estimate_name,study_name,source_name,publication_date,source_type,estimate_grade,study_type,country,state,city,study_inclusion_criteria,study_exclusion_criteria,sampling_start_date,sampling_end_date,population_group,sex,age,age_min,age_max,subgroup_var,subgroup_specific_category,denominator_value,serum_pos_prevalence,seroprev_95_ci_lower,seroprev_95_ci_upper,dashboard_primary_estimate,test_adj,pop_adj,clustering_adjustment,academic_primary_estimate,sampling_method,test_name,test_manufacturer,test_type,specimen_type,isotypes,antibody_target,test_validation,sensitivity,specificity,overall_risk_of_bias,jbi_1,jbi_2,jbi_3,jbi_4,jbi_5,jbi_6,jbi_7,jbi_8,jbi_9,first_author,lead_institution,is_unity_aligned,url,date_created,last_modified_time,data_quality_status,zotero_citation_key,alpha_3_code
200801_Afghanistan_AfghanistanMinistryofPublicHealth,200801_Afghanistan_AfghanistanMinistryofPublicHealth,"Prevalence of COVID-19 and its Related Deaths in Afghanistan: A Nationwide, Population-Based Seroepidemiological Study July 202",2020-08-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Afghanistan,,,"Blood samples are collected from two household member randomly (one from 5 to 17 years
and another from equal and above 18 years of age) ","Due to shortage of time and to have valid
data, insecure and inaccessible Enumerated Areas are not included in the study.",2020-06-01,2020-06-15,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,Overall national gen pop,9514,0.315,,,True,,True,,True,Stratified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Sayed Ataullah Saeedzai,Afghanistan Ministry of Public Health ,Not Unity-Aligned,https://moph.gov.af/sites/default/files/2020-08/Final%20COVID-19%20Survey%20English%20Report.pdf,2021-05-19,2022-12-08,Verified,sayed_ataullah_prevalence_2020,AFG
200801_Afghanistan_AfghanistanMinistryofPublicHealthage5-17,200801_Afghanistan_AfghanistanMinistryofPublicHealth,"Prevalence of COVID-19 and its Related Deaths in Afghanistan: A Nationwide, Population-Based Seroepidemiological Study July 202",2020-08-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Afghanistan,,,"Blood samples are collected from two household member randomly (one from 5 to 17 years
and another from equal and above 18 years of age) ","Due to shortage of time and to have valid
data, insecure and inaccessible Enumerated Areas are not included in the study.",2020-06-01,2020-06-15,Household and community samples,All,Children and Youth (0-17 years),5.0,17.0,Age,age 5-17,4346,0.35100000000000003,0.31,0.395,,,True,,,Stratified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Sayed Ataullah Saeedzai,Afghanistan Ministry of Public Health ,Not Unity-Aligned,https://moph.gov.af/sites/default/files/2020-08/Final%20COVID-19%20Survey%20English%20Report.pdf,2021-06-10,2022-07-16,Verified,sayed_ataullah_prevalence_2020,AFG
200801_Afghanistan_AfghanistanMinistryofPublicHealthage18+,200801_Afghanistan_AfghanistanMinistryofPublicHealth,"Prevalence of COVID-19 and its Related Deaths in Afghanistan: A Nationwide, Population-Based Seroepidemiological Study July 202",2020-08-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Afghanistan,,,"Blood samples are collected from two household member randomly (one from 5 to 17 years
and another from equal and above 18 years of age) ","Due to shortage of time and to have valid
data, insecure and inaccessible Enumerated Areas are not included in the study.",2020-06-01,2020-06-15,Household and community samples,All,Multiple groups,18.0,,Age,age 18+,5168,0.253,0.20500000000000002,0.308,,,True,,,Stratified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Sayed Ataullah Saeedzai,Afghanistan Ministry of Public Health ,Not Unity-Aligned,https://moph.gov.af/sites/default/files/2020-08/Final%20COVID-19%20Survey%20English%20Report.pdf,2021-06-10,2022-07-16,Verified,sayed_ataullah_prevalence_2020,AFG
201220_Afghanistan_UnitedStatesAirForce,201220_Afghanistan_UnitedStatesAirForce,Using serosurveillance for SARS-CoV-2 to conserve PCR tests in a resource constrained combat environment,2020-12-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Afghanistan,,,"High risk populations included: those leaving quarantine, base defense guards, isolation unit guards, medical personnel, dining facility workers, and those who interact with local populations. ",,2020-04-17,2020-06-01,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,1957,0.019,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,Brian White,United States Air Force,Not Unity-Aligned,http://dx.doi.org/10.1093/ofid/ofaa439.666,2021-05-02,2022-12-08,Verified,white_473_2020,AFG
220725_TiranaAndBerat_AcademyOfSciencesOfAlbania_Overall,220725_TiranaAndBerat_AcademyOfSciencesOfAlbania,Estimating the seroprevalence of SARS-CoV-2 antibodies: Understanding population-level immunity in Albania at the end of the Alpha variant wave.,2022-07-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Albania,,"Tirana, Berat","""We measured the anti-S1 antibodies of the SARS-CoV-2 virus spike protein in a sample of urban population individuals aged 18 to 70 years, randomly selected from Tirana and Berat’s primary health centres’ electronic registers from June to July 2021.""",,2021-06-15,2021-07-15,Household and community samples,All,Multiple groups,18.0,70.0,Primary Estimate,,1527,0.7334999999999999,,,True,,,,True,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Fabian Cenko,Academy of Sciences of Albania,Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.03054,2022-08-11,2024-03-15,Verified,cenko_estimating_2022,ALB
220725_TiranaAndBerat_AcademyOfSciencesOfAlbania_Age60+,220725_TiranaAndBerat_AcademyOfSciencesOfAlbania,Estimating the seroprevalence of SARS-CoV-2 antibodies: Understanding population-level immunity in Albania at the end of the Alpha variant wave.,2022-07-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Albania,,"Tirana, Berat","""We measured the anti-S1 antibodies of the SARS-CoV-2 virus spike protein in a sample of urban population individuals aged 18 to 70 years, randomly selected from Tirana and Berat’s primary health centres’ electronic registers from June to July 2021.""",,2021-06-15,2021-07-15,Household and community samples,All,Seniors (65+ years),60.0,70.0,Age,Age: ≥60 years,530,0.8170000000000001,,,,,,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Fabian Cenko,Academy of Sciences of Albania,Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.03054,2022-08-11,2024-03-15,Verified,cenko_estimating_2022,ALB
220725_TiranaAndBerat_AcademyOfSciencesOfAlbania_SexFemale,220725_TiranaAndBerat_AcademyOfSciencesOfAlbania,Estimating the seroprevalence of SARS-CoV-2 antibodies: Understanding population-level immunity in Albania at the end of the Alpha variant wave.,2022-07-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Albania,,"Tirana, Berat","""We measured the anti-S1 antibodies of the SARS-CoV-2 virus spike protein in a sample of urban population individuals aged 18 to 70 years, randomly selected from Tirana and Berat’s primary health centres’ electronic registers from June to July 2021.""",,2021-06-15,2021-07-15,Household and community samples,Female,Multiple groups,18.0,70.0,Sex/Gender,,1002,0.7525000000000001,,,,,,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Fabian Cenko,Academy of Sciences of Albania,Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.03054,2022-08-11,2024-03-15,Verified,cenko_estimating_2022,ALB
220725_TiranaAndBerat_AcademyOfSciencesOfAlbania_Age18-59,220725_TiranaAndBerat_AcademyOfSciencesOfAlbania,Estimating the seroprevalence of SARS-CoV-2 antibodies: Understanding population-level immunity in Albania at the end of the Alpha variant wave.,2022-07-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Albania,,"Tirana, Berat","""We measured the anti-S1 antibodies of the SARS-CoV-2 virus spike protein in a sample of urban population individuals aged 18 to 70 years, randomly selected from Tirana and Berat’s primary health centres’ electronic registers from June to July 2021.""",,2021-06-15,2021-07-15,Household and community samples,All,Adults (18-64 years),18.0,59.0,Age,Age: 18-59 years,996,0.6888,,,,,,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Fabian Cenko,Academy of Sciences of Albania,Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.03054,2022-08-11,2024-03-15,Verified,cenko_estimating_2022,ALB
220725_TiranaAndBerat_AcademyOfSciencesOfAlbania_Vaccinated,220725_TiranaAndBerat_AcademyOfSciencesOfAlbania,Estimating the seroprevalence of SARS-CoV-2 antibodies: Understanding population-level immunity in Albania at the end of the Alpha variant wave.,2022-07-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Albania,,"Tirana, Berat","""We measured the anti-S1 antibodies of the SARS-CoV-2 virus spike protein in a sample of urban population individuals aged 18 to 70 years, randomly selected from Tirana and Berat’s primary health centres’ electronic registers from June to July 2021.""",,2021-06-15,2021-07-15,Household and community samples,All,Multiple groups,18.0,70.0,COVID-19 vaccination status,,638,0.9013,,,,,,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Fabian Cenko,Academy of Sciences of Albania,Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.03054,2022-08-11,2024-03-15,Verified,cenko_estimating_2022,ALB
220725_TiranaAndBerat_AcademyOfSciencesOfAlbania_Unvaccinated,220725_TiranaAndBerat_AcademyOfSciencesOfAlbania,Estimating the seroprevalence of SARS-CoV-2 antibodies: Understanding population-level immunity in Albania at the end of the Alpha variant wave.,2022-07-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Albania,,"Tirana, Berat","""We measured the anti-S1 antibodies of the SARS-CoV-2 virus spike protein in a sample of urban population individuals aged 18 to 70 years, randomly selected from Tirana and Berat’s primary health centres’ electronic registers from June to July 2021.""",,2021-06-15,2021-07-15,Household and community samples,All,Multiple groups,18.0,70.0,COVID-19 vaccination status,,889,0.613,,,,,,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Fabian Cenko,Academy of Sciences of Albania,Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.03054,2022-08-11,2024-03-15,Verified,cenko_estimating_2022,ALB
220725_TiranaAndBerat_AcademyOfSciencesOfAlbania_SexMale,220725_TiranaAndBerat_AcademyOfSciencesOfAlbania,Estimating the seroprevalence of SARS-CoV-2 antibodies: Understanding population-level immunity in Albania at the end of the Alpha variant wave.,2022-07-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Albania,,"Tirana, Berat","""We measured the anti-S1 antibodies of the SARS-CoV-2 virus spike protein in a sample of urban population individuals aged 18 to 70 years, randomly selected from Tirana and Berat’s primary health centres’ electronic registers from June to July 2021.""",,2021-06-15,2021-07-15,Household and community samples,Male,Multiple groups,18.0,70.0,Sex/Gender,,525,0.6970999999999999,,,,,,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Fabian Cenko,Academy of Sciences of Albania,Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.03054,2022-08-11,2024-03-15,Verified,cenko_estimating_2022,ALB
230227_Albania_WorldHealthOrganization,230227_Albania_WorldHealthOrganization,Factors associated with receipt of COVID-19 vaccination and SARS-CoV-2 seropositivity among healthcare workers in Albania (February 2021-June 2022): secondary analysis of a prospective cohort study.,2023-02-27,Journal Article (Peer-Reviewed),Local,Prospective cohort,Albania,,,"""in early 2021, all employees at three publicly funded
hospitals in Albania (Durres, Fier, and Tirana) who were
eligible for vaccination were invited to participate in the
study, regardless of their intention to receive COVID-19
vaccine or known previous infections.""",,2021-02-19,2021-05-07,Health care workers and caregivers,All,Multiple groups,22.0,71.0,Primary Estimate,,1452,0.718,,,True,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"IgG, IgM, IgA",Spike,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Pernille Jorgensen,World Health Organization,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanepe.2023.100584,2023-05-03,2024-03-01,Unverified,jorgensen_factors_2023,ALB
230802_TiranaAndBeratCity_GeorgeMasonUniversity_2021_AntiS,230802_TiranaAndBeratCity_GeorgeMasonUniversity_2021,Dynamics of Anti-SARS-CoV-2 Antibodies in the Albanian Population: Impact of Infection and Vaccine-Induced Immunity during the COVID-19 Pandemic Year from August 2021 to August 2022,2023-08-02,Preprint,Local,Repeated cross-sectional study,Albania,,"Tirana, Berat City","Two independent samples from the Albanian general population, comprising all age groups, were studied in July-August of 2021 and 2022 to assess seroprevalence in the Albanian general population.",,2021-07-15,2021-08-15,Multiple populations,All,Multiple groups,4.0,97.0,Primary Estimate,Anti-S,1716,0.7179,,,True,,,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.944,0.996,['High'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Genc Sulcebe,George Mason University,Not Unity-Aligned,https://doi.org/10.20944/preprints202308.0151.v1,2023-09-22,2024-03-01,Unverified,sulcebe_dynamics_2023,ALB
230802_TiranaAndBeratCity_GeorgeMasonUniversity_2022_AntiS,230802_TiranaAndBeratCity_GeorgeMasonUniversity_2022,Dynamics of Anti-SARS-CoV-2 Antibodies in the Albanian Population: Impact of Infection and Vaccine-Induced Immunity during the COVID-19 Pandemic Year from August 2021 to August 2022,2023-08-02,Preprint,Local,Repeated cross-sectional study,Albania,,"Tirana, Berat City","Two independent samples from the Albanian general population, comprising all age groups, were studied in July-August of 2021 and 2022 to assess seroprevalence in the Albanian general population.",,2022-07-15,2022-08-15,Multiple populations,All,Multiple groups,1.0,87.0,Primary Estimate,Anti-S,1899,0.9115,,,True,,,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.944,0.996,['High'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Genc Sulcebe,George Mason University,Not Unity-Aligned,https://doi.org/10.20944/preprints202308.0151.v1,2023-09-22,2024-03-01,Unverified,sulcebe_dynamics_2023,ALB
230826_Tirana_CatholicUniversityOurLadyOfGoodCounsel_Dec,230826_Tirana_CatholicUniversityOurLadyOfGoodCounsel_Dec,Rapid increase of SARS-CoV-2 seroprevalence during the second half of the COVID-19 pandemic year 2020 in the adult urban Albanian population.,2023-08-26,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Albania,,Tirana,"This study aims to fill this gap by providing data on the changes in COVID-19 seroprevalence among the adult urban population of Albania between July and December 2020, using two independent, randomly selected samples of individuals aged 20–70 years who reside in Metropolitan Tirana, which represents approximately one-third of Albania’s urban population [9].",,2020-12-21,2020-12-28,Household and community samples,All,Adults (18-64 years),20.0,70.0,Primary Estimate,"Round 2 (Dec 21 - Dec 28, 2020)",815,0.482,0.448,0.517,True,,,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.944,0.996,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Genc Sulcebe,"Catholic University ""Our Lady of Good Counsel""",Unity-Aligned,https://dx.doi.org/10.1016/j.heliyon.2023.e19547,2023-10-10,2024-04-24,Verified,sulcebe_rapid_2023,ALB
230826_Tirana_CatholicUniversityOurLadyOfGoodCounsel_Jul,230826_Tirana_CatholicUniversityOurLadyOfGoodCounsel_Jul,Rapid increase of SARS-CoV-2 seroprevalence during the second half of the COVID-19 pandemic year 2020 in the adult urban Albanian population.,2023-08-26,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Albania,,Tirana,"This study aims to fill this gap by providing data on the changes in COVID-19 seroprevalence among the adult urban population of Albania between July and December 2020, using two independent, randomly selected samples of individuals aged 20–70 years who reside in Metropolitan Tirana, which represents approximately one-third of Albania’s urban population [9].",,2020-06-27,2020-07-03,Household and community samples,All,Adults (18-64 years),20.0,70.0,Primary Estimate,"Round 1 (June 27 - July 3, 2020)",266,0.075,0.043,0.107,True,,,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.944,0.996,['Moderate'],Yes,Yes,No,Yes,Unclear,Yes,Yes,Yes,Yes,Genc Sulcebe,"Catholic University ""Our Lady of Good Counsel""",Unity-Aligned,https://dx.doi.org/10.1016/j.heliyon.2023.e19547,2023-10-10,2024-04-24,Verified,sulcebe_rapid_2023,ALB
230607_Oran_UniversityofOran_Overall,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Algeria,"Oran
",,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Multiple groups,,,Primary Estimate,,1185,0.356,0.3294,0.3838,True,,,,True,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9049999999999997,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023-06-29,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_EsSenia,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Es Senia,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Multiple groups,,,Geographical area,Es Senia,77,0.247,0.164,0.3535,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023-06-29,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Benfreha,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Benfreha,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Multiple groups,,,Geographical area,Benfreha,21,0.857,0.6537,0.9502,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023-06-29,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_HassiMefsoukh,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Hassi Mefsoukh,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Multiple groups,,,Geographical area,Hassi Mefsoukh,12,0.75,0.4677,0.9111,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023-06-29,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Age70-79,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Algeria,"Oran
",,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Seniors (65+ years),70.0,79.0,Age,70-79,65,0.4,,,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9049999999999997,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2024-04-30,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_MersEIKebir,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Mers EI Kebir,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Multiple groups,,,Geographical area,Mers EI Kebir,12,0.5,0.2538,0.7462,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023-06-29,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Age10-19,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Algeria,"Oran
",,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,217,0.2765,,,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9049999999999997,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2024-04-30,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Misserghin,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Misserghin,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Multiple groups,,,Geographical area,Misserghin,23,0.174,0.0698,0.3714,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023-06-29,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Tafraoui,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Tafraoui,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Multiple groups,,,Geographical area,Tafraoui,10,0.1,0.0179,0.4041,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023-06-29,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_MersEIHedjaj,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Mers EI Hedjaj,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Multiple groups,,,Geographical area,Mers EI Hedjaj,12,0.917,0.6461,0.9851,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023-06-29,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_SidiChahmi,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Sidi Chahmi,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Multiple groups,,,Geographical area,Sidi Chahmi,118,0.331,0.2522,0.4195,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023-06-29,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_EIKerma,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",EI Kerma,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Multiple groups,,,Geographical area,EI Kerma,26,0.0,0.0,0.1287,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023-06-29,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Bousfer,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Bousfer,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Multiple groups,,,Geographical area,Bousfer,17,0.353,0.1731,0.587,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023-06-29,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_OuedTlelat,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Oued Tlelat,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Multiple groups,,,Geographical area,Oued Tlelat,15,0.333,0.1518,0.5829,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023-06-29,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_AinEITurk,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Ain EI Turk,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Multiple groups,,,Geographical area,Ain EI Turk,29,0.448,0.2841,0.6245,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023-06-29,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_AinEIBia,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Ain EI Bia,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Multiple groups,,,Geographical area,Ain EI Bia,24,0.708,0.5083,0.8508,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023-06-29,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_SidiBenyebkra,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Sidi Benyebkra,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Multiple groups,,,Geographical area,Sidi Benyebkra,6,0.833,0.4365,0.9699,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023-06-29,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_HassiBenOkba,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Hassi Ben Okba,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Multiple groups,,,Geographical area,Hassi Ben Okba,12,0.5,0.2538,0.7462,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023-06-29,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Age50-59,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Algeria,"Oran
",,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,183,0.3825,,,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9049999999999997,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2024-04-30,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_EIOngor,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",EI Ongor,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Multiple groups,,,Geographical area,EI Ongor,10,0.3,0.1078,0.6032,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023-06-29,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_EIBraya,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",EI Braya,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Multiple groups,,,Geographical area,EI Braya,6,0.333,0.0968,0.7,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023-06-29,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Age40-49,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Algeria,"Oran
",,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,189,0.381,,,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9049999999999997,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2024-04-30,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Gdyel,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Gdyel,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Multiple groups,,,Geographical area,Gdyel,30,0.733,0.5555,0.8582,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023-06-29,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Arzew,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Arzew,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Multiple groups,,,Geographical area,Arzew,64,0.672,0.55,0.7743,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023-06-29,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Age20-29,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Algeria,"Oran
",,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,119,0.3361,,,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9049999999999997,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2024-04-30,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Age30-39,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Algeria,"Oran
",,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,162,0.3827,,,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9049999999999997,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2024-04-30,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Oran,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Oran,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Multiple groups,,,Geographical area,Oran,308,0.338,0.2871,0.3922,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023-06-29,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Age80+,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Algeria,"Oran
",,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Seniors (65+ years),80.0,,Age,80+,35,0.3143,,,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9049999999999997,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2024-04-30,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Boufatis,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Boufatis,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Multiple groups,,,Geographical area,Boufatis,8,0.75,0.4093,0.9285,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023-06-29,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_BirEIDjir,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Bir EI Djir,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Multiple groups,,,Geographical area,Bir EI Djir,257,0.105,0.0732,0.1485,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023-06-29,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_AinEIKerma,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Ain EI Kerma,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Multiple groups,,,Geographical area,Ain EI Kerma,5,0.0,0.0,0.4345,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9049999999999998,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023-06-29,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Boutlelis,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Boutlelis,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Multiple groups,,,Geographical area,Boutlelis,19,0.263,0.1181,0.4879,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023-06-29,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_HassiBounif,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Hassi Bounif,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Multiple groups,,,Geographical area,Hassi Bounif,53,0.774,0.6447,0.8654,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023-06-29,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Bethioua,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Bethioua,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Multiple groups,,,Geographical area,Bethioua,11,0.909,0.6227,0.9838,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023-06-29,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Age<10,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Algeria,"Oran
",,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Children and Youth (0-17 years),,9.0,Age,<10,86,0.3488,,,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9049999999999997,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2024-04-30,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Age60-69,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023-06-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Algeria,"Oran
",,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021-01-07,2021-01-20,Household and community samples,All,Multiple groups,60.0,69.0,Age,60-69,129,0.3953,,,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9049999999999997,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2024-04-30,2024-04-30,Verified,dali-ali_seroprevalence_2023,DZA
210521_Andorra_ISGlobal_Overall,210521_Andorra_ISGlobal,"Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra",2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Andorra,,,"We conducted a two-phase screening study on the entire popula-tion in Andorra above the age of 2 who voluntarily signed theinformed consent. Beyond Andorran citizens, we also included regis-tered cross-border workers.", The only exclusion criterion was therefusal to provide the signed informed consent,2020-05-04,2020-05-28,Household and community samples,All,Multiple groups,2.0,,Primary Estimate,overall,72964,0.11,,,True,,,,True,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.92,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Cristina Royo Cebrecos,ISGlobal,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S266677622100096X,2021-07-29,2024-03-01,Verified,royo-cebrecos_mass_2021,AND
210521_Andorra_ISGlobal_40-49,210521_Andorra_ISGlobal,"Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra",2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Andorra,,,"We conducted a two-phase screening study on the entire popula-tion in Andorra above the age of 2 who voluntarily signed theinformed consent. Beyond Andorran citizens, we also included regis-tered cross-border workers.", The only exclusion criterion was therefusal to provide the signed informed consent,2020-05-04,2020-05-28,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,10985,0.11699999999999999,,,,,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.92,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Cristina Royo Cebrecos,ISGlobal,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S266677622100096X,2021-07-29,2024-03-01,Verified,royo-cebrecos_mass_2021,AND
210521_Andorra_ISGlobal_80-89,210521_Andorra_ISGlobal,"Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra",2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Andorra,,,"We conducted a two-phase screening study on the entire popula-tion in Andorra above the age of 2 who voluntarily signed theinformed consent. Beyond Andorran citizens, we also included regis-tered cross-border workers.", The only exclusion criterion was therefusal to provide the signed informed consent,2020-05-04,2020-05-28,Household and community samples,All,Seniors (65+ years),80.0,89.0,Age,80-89,1093,0.14800000000000002,,,,,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.92,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Cristina Royo Cebrecos,ISGlobal,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S266677622100096X,2021-07-29,2024-03-01,Verified,royo-cebrecos_mass_2021,AND
210521_Andorra_ISGlobal_Female,210521_Andorra_ISGlobal,"Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra",2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Andorra,,,"We conducted a two-phase screening study on the entire popula-tion in Andorra above the age of 2 who voluntarily signed theinformed consent. Beyond Andorran citizens, we also included regis-tered cross-border workers.", The only exclusion criterion was therefusal to provide the signed informed consent,2020-05-04,2020-05-28,Household and community samples,Female,Multiple groups,2.0,,Sex/Gender,female,27858,0.125,,,,,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.92,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Cristina Royo Cebrecos,ISGlobal,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S266677622100096X,2021-07-29,2024-03-01,Verified,royo-cebrecos_mass_2021,AND
210521_Andorra_ISGlobal_70-79,210521_Andorra_ISGlobal,"Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra",2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Andorra,,,"We conducted a two-phase screening study on the entire popula-tion in Andorra above the age of 2 who voluntarily signed theinformed consent. Beyond Andorran citizens, we also included regis-tered cross-border workers.", The only exclusion criterion was therefusal to provide the signed informed consent,2020-05-04,2020-05-28,Household and community samples,All,Seniors (65+ years),70.0,79.0,Age,70-79,2776,0.13699999999999998,,,,,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.92,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Cristina Royo Cebrecos,ISGlobal,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S266677622100096X,2021-07-29,2024-03-01,Verified,royo-cebrecos_mass_2021,AND
210521_Andorra_ISGlobal_60-69,210521_Andorra_ISGlobal,"Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra",2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Andorra,,,"We conducted a two-phase screening study on the entire popula-tion in Andorra above the age of 2 who voluntarily signed theinformed consent. Beyond Andorran citizens, we also included regis-tered cross-border workers.", The only exclusion criterion was therefusal to provide the signed informed consent,2020-05-04,2020-05-28,Household and community samples,All,Adults (18-64 years),60.0,69.0,Age,60-69,5655,0.136,,,,,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.92,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Cristina Royo Cebrecos,ISGlobal,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S266677622100096X,2021-07-29,2024-03-01,Verified,royo-cebrecos_mass_2021,AND
210521_Andorra_ISGlobal_2-9,210521_Andorra_ISGlobal,"Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra",2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Andorra,,,"We conducted a two-phase screening study on the entire popula-tion in Andorra above the age of 2 who voluntarily signed theinformed consent. Beyond Andorran citizens, we also included regis-tered cross-border workers.", The only exclusion criterion was therefusal to provide the signed informed consent,2020-05-04,2020-05-28,Household and community samples,All,Children and Youth (0-17 years),2.0,9.0,Age,0-9,3899,0.115,,,,,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.92,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Cristina Royo Cebrecos,ISGlobal,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S266677622100096X,2021-07-29,2024-03-01,Verified,royo-cebrecos_mass_2021,AND
210521_Andorra_ISGlobal_90+,210521_Andorra_ISGlobal,"Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra",2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Andorra,,,"We conducted a two-phase screening study on the entire popula-tion in Andorra above the age of 2 who voluntarily signed theinformed consent. Beyond Andorran citizens, we also included regis-tered cross-border workers.", The only exclusion criterion was therefusal to provide the signed informed consent,2020-05-04,2020-05-28,Household and community samples,All,Seniors (65+ years),90.0,,Age,90+,226,0.17300000000000001,,,,,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.92,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Cristina Royo Cebrecos,ISGlobal,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S266677622100096X,2021-07-29,2024-03-01,Verified,royo-cebrecos_mass_2021,AND
210521_Andorra_ISGlobal_50-59,210521_Andorra_ISGlobal,"Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra",2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Andorra,,,"We conducted a two-phase screening study on the entire popula-tion in Andorra above the age of 2 who voluntarily signed theinformed consent. Beyond Andorran citizens, we also included regis-tered cross-border workers.", The only exclusion criterion was therefusal to provide the signed informed consent,2020-05-04,2020-05-28,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,9560,0.146,,,,,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.92,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Cristina Royo Cebrecos,ISGlobal,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S266677622100096X,2021-07-29,2024-03-01,Verified,royo-cebrecos_mass_2021,AND
210521_Andorra_ISGlobal_Male,210521_Andorra_ISGlobal,"Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra",2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Andorra,,,"We conducted a two-phase screening study on the entire popula-tion in Andorra above the age of 2 who voluntarily signed theinformed consent. Beyond Andorran citizens, we also included regis-tered cross-border workers.", The only exclusion criterion was therefusal to provide the signed informed consent,2020-05-04,2020-05-28,Household and community samples,Male,Multiple groups,2.0,,Sex/Gender,male,28301,0.12400000000000001,,,,,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.92,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Cristina Royo Cebrecos,ISGlobal,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S266677622100096X,2021-07-29,2024-03-01,Verified,royo-cebrecos_mass_2021,AND
210521_Andorra_ISGlobal_20-29,210521_Andorra_ISGlobal,"Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra",2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Andorra,,,"We conducted a two-phase screening study on the entire popula-tion in Andorra above the age of 2 who voluntarily signed theinformed consent. Beyond Andorran citizens, we also included regis-tered cross-border workers.", The only exclusion criterion was therefusal to provide the signed informed consent,2020-05-04,2020-05-28,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,6305,0.107,,,,,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.92,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Cristina Royo Cebrecos,ISGlobal,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S266677622100096X,2021-07-29,2024-03-01,Verified,royo-cebrecos_mass_2021,AND
210521_Andorra_ISGlobal_30-39,210521_Andorra_ISGlobal,"Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra",2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Andorra,,,"We conducted a two-phase screening study on the entire popula-tion in Andorra above the age of 2 who voluntarily signed theinformed consent. Beyond Andorran citizens, we also included regis-tered cross-border workers.", The only exclusion criterion was therefusal to provide the signed informed consent,2020-05-04,2020-05-28,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,8587,0.105,,,,,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.92,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Cristina Royo Cebrecos,ISGlobal,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S266677622100096X,2021-07-29,2024-03-01,Verified,royo-cebrecos_mass_2021,AND
210521_Andorra_ISGlobal_10-19,210521_Andorra_ISGlobal,"Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra",2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Andorra,,,"We conducted a two-phase screening study on the entire popula-tion in Andorra above the age of 2 who voluntarily signed theinformed consent. Beyond Andorran citizens, we also included regis-tered cross-border workers.", The only exclusion criterion was therefusal to provide the signed informed consent,2020-05-04,2020-05-28,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,6196,0.14300000000000002,,,,,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.92,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Cristina Royo Cebrecos,ISGlobal,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S266677622100096X,2021-07-29,2024-03-01,Verified,royo-cebrecos_mass_2021,AND
210921_Andorra_HospitalNostraSenyoradeMeritxell_November,210921_Andorra_HospitalNostraSenyoradeMeritxell_November,1601P SARS-CoV-2 serological response in cancer patients in the Principality of Andorra (COVONCO study),2021-09-21,Presentation or Conference,Local,Prospective cohort,Andorra,,,All adult patients with cancer diagnosis within 5 years (2016-April 2020) who accepted participation were included since May 2020.,,2020-11-01,2020-11-30,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),,,Primary Estimate,,156,0.0641,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,No,,Unclear,Yes,No,,C Royo-Cebrecos,Hospital Nostra Senyora de Meritxell,Not Unity-Aligned,http://dx.doi.org/10.1016/j.annonc.2021.08.1594,2021-09-28,2022-07-16,Unverified,royo-cebrecos_1601p_2021,AND
220412_Andorra_HospitalNostraSenyoradeMeritxell_Primary,220412_Andorra_HospitalNostraSenyoradeMeritxell,Seroprevalence study prior and post vaccination in Cancer patients in Principality of Andorra (COVONCO study),2022-04-12,Preprint,National,Cross-sectional survey ,Andorra,,,"This study included all patients ≥ 18 years of age with a
diagnosis of solid tumour or haematological malignancy in the last 5 years (from January 2016-May 2020) who participated in the nation-wide SARS-CoV-2 population screening in May 202015 with means
of serological testing and who provided informed oral consent","Patients who failed to provide informed oral consent, had been cancer-free for the last 5 years or deceased before the start of the study from a
non-COVID-19 related death were excluded. Anonymized use of data was collected as per standard of care.",2020-05-15,2021-06-15,Representative patient population,All,Multiple groups,18.0,,Primary Estimate,overall seroprevalence ,373,0.182,,,True,,,,True,Convenience,"2019-nCoV IgG/IgM Antibody Detection Kit,Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)","Zhuhai Livzon Diagnostics Inc,Roche Diagnostics",Multiple Types,Plasma,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristina Royo-Cebrecos,Hospital Nostra Senyora de Meritxell,Not Unity-Aligned,10.21203/rs.3.rs-1538781/v1,2022-04-21,2024-03-01,Unverified,royo-cebrecos_mass_2021_1,AND
210506_Luanda_InstitutoNacionaldeInvestigaçãoemSaúde_IgG,210506_Luanda_InstitutoNacionaldeInvestigaçãoemSaúde,"Serological identification of past and recent SARS-CoV-2 infection through antibody screening in Luanda, Angola.",2021-05-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Angola,Luanda Province,Luanda,"Individuals seeking health services at Instituto Nacional de Investigação em Saúde (INIS), located in Luanda, the capital city of Angola",,2020-07-15,2020-09-15,Residual sera,All,Multiple groups,12.0,67.0,Primary Estimate,Overall,660,0.011000000000000001,,,True,,,,True,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,Other,Serum,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Cruz Sebastiao,Instituto Nacional de Investigação em Saúde,Not Unity-Aligned,https://dx.doi.org/10.1002/hsr2.280,2021-05-30,2024-03-01,Verified,sebastiao_serological_2021,AGO
210506_Luanda_InstitutoNacionaldeInvestigaçãoemSaúde_IgG_UrbanArea,210506_Luanda_InstitutoNacionaldeInvestigaçãoemSaúde,"Serological identification of past and recent SARS-CoV-2 infection through antibody screening in Luanda, Angola.",2021-05-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Angola,Luanda Province,Luanda,"Individuals seeking health services at Instituto Nacional de Investigação em Saúde (INIS), located in Luanda, the capital city of Angola",,2020-07-15,2020-09-15,Residual sera,All,Multiple groups,12.0,67.0,Geographical area,,335,0.015,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,Other,Serum,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Cruz Sebastiao,Instituto Nacional de Investigação em Saúde,Not Unity-Aligned,https://dx.doi.org/10.1002/hsr2.280,2021-07-22,2024-03-01,Verified,sebastiao_serological_2021,AGO
210506_Luanda_InstitutoNacionaldeInvestigaçãoemSaúde_IgG_<40,210506_Luanda_InstitutoNacionaldeInvestigaçãoemSaúde,"Serological identification of past and recent SARS-CoV-2 infection through antibody screening in Luanda, Angola.",2021-05-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Angola,Luanda Province,Luanda,"Individuals seeking health services at Instituto Nacional de Investigação em Saúde (INIS), located in Luanda, the capital city of Angola",,2020-07-15,2020-09-15,Residual sera,All,Adults (18-64 years),12.0,39.0,Age,,331,0.009000000000000001,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,Other,Serum,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Cruz Sebastiao,Instituto Nacional de Investigação em Saúde,Not Unity-Aligned,https://dx.doi.org/10.1002/hsr2.280,2021-07-22,2024-03-01,Verified,sebastiao_serological_2021,AGO
210506_Luanda_InstitutoNacionaldeInvestigaçãoemSaúde_IgG_Luanda,210506_Luanda_InstitutoNacionaldeInvestigaçãoemSaúde,"Serological identification of past and recent SARS-CoV-2 infection through antibody screening in Luanda, Angola.",2021-05-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Angola,Luanda Province,Luanda,"Individuals seeking health services at Instituto Nacional de Investigação em Saúde (INIS), located in Luanda, the capital city of Angola",,2020-07-15,2020-09-15,Residual sera,All,Multiple groups,12.0,67.0,Geographical area,,659,0.011000000000000001,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,Other,Serum,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Cruz Sebastiao,Instituto Nacional de Investigação em Saúde,Not Unity-Aligned,https://dx.doi.org/10.1002/hsr2.280,2021-07-22,2024-03-01,Verified,sebastiao_serological_2021,AGO
210506_Luanda_InstitutoNacionaldeInvestigaçãoemSaúde_IgG_Outside Luanda,210506_Luanda_InstitutoNacionaldeInvestigaçãoemSaúde,"Serological identification of past and recent SARS-CoV-2 infection through antibody screening in Luanda, Angola.",2021-05-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Angola,Luanda Province,Luanda,"Individuals seeking health services at Instituto Nacional de Investigação em Saúde (INIS), located in Luanda, the capital city of Angola",,2020-07-15,2020-09-15,Residual sera,All,Multiple groups,12.0,67.0,Geographical area,,1,0.0,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,Other,Serum,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Cruz Sebastiao,Instituto Nacional de Investigação em Saúde,Not Unity-Aligned,https://dx.doi.org/10.1002/hsr2.280,2021-07-22,2024-03-01,Verified,sebastiao_serological_2021,AGO
210506_Luanda_InstitutoNacionaldeInvestigaçãoemSaúde_IgG_Male,210506_Luanda_InstitutoNacionaldeInvestigaçãoemSaúde,"Serological identification of past and recent SARS-CoV-2 infection through antibody screening in Luanda, Angola.",2021-05-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Angola,Luanda Province,Luanda,"Individuals seeking health services at Instituto Nacional de Investigação em Saúde (INIS), located in Luanda, the capital city of Angola",,2020-07-15,2020-09-15,Residual sera,Male,Multiple groups,12.0,67.0,Sex/Gender,Male,572,0.012,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,Other,Serum,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Cruz Sebastiao,Instituto Nacional de Investigação em Saúde,Not Unity-Aligned,https://dx.doi.org/10.1002/hsr2.280,2021-07-22,2024-03-01,Verified,sebastiao_serological_2021,AGO
210506_Luanda_InstitutoNacionaldeInvestigaçãoemSaúde_IgG_Female,210506_Luanda_InstitutoNacionaldeInvestigaçãoemSaúde,"Serological identification of past and recent SARS-CoV-2 infection through antibody screening in Luanda, Angola.",2021-05-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Angola,Luanda Province,Luanda,"Individuals seeking health services at Instituto Nacional de Investigação em Saúde (INIS), located in Luanda, the capital city of Angola",,2020-07-15,2020-09-15,Residual sera,Female,Multiple groups,12.0,67.0,Sex/Gender,Female,88,0.0,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,Other,Serum,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Cruz Sebastiao,Instituto Nacional de Investigação em Saúde,Not Unity-Aligned,https://dx.doi.org/10.1002/hsr2.280,2021-07-22,2024-03-01,Verified,sebastiao_serological_2021,AGO
210506_Luanda_InstitutoNacionaldeInvestigaçãoemSaúde_IgG_RuralArea,210506_Luanda_InstitutoNacionaldeInvestigaçãoemSaúde,"Serological identification of past and recent SARS-CoV-2 infection through antibody screening in Luanda, Angola.",2021-05-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Angola,Luanda Province,Luanda,"Individuals seeking health services at Instituto Nacional de Investigação em Saúde (INIS), located in Luanda, the capital city of Angola",,2020-07-15,2020-09-15,Residual sera,All,Multiple groups,12.0,67.0,Geographical area,,352,0.006,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,Other,Serum,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Cruz Sebastiao,Instituto Nacional de Investigação em Saúde,Not Unity-Aligned,https://dx.doi.org/10.1002/hsr2.280,2021-07-22,2024-03-01,Verified,sebastiao_serological_2021,AGO
210506_Luanda_InstitutoNacionaldeInvestigaçãoemSaúde_IgG_40+,210506_Luanda_InstitutoNacionaldeInvestigaçãoemSaúde,"Serological identification of past and recent SARS-CoV-2 infection through antibody screening in Luanda, Angola.",2021-05-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Angola,Luanda Province,Luanda,"Individuals seeking health services at Instituto Nacional de Investigação em Saúde (INIS), located in Luanda, the capital city of Angola",,2020-07-15,2020-09-15,Residual sera,All,Multiple groups,40.0,67.0,Age,,329,0.012,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,Other,Serum,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Cruz Sebastiao,Instituto Nacional de Investigação em Saúde,Not Unity-Aligned,https://dx.doi.org/10.1002/hsr2.280,2021-07-22,2024-03-01,Verified,sebastiao_serological_2021,AGO
211102_Luanda_UniversidadeAgostinhoNeto_Primary,211102_Luanda_UniversidadeAgostinhoNeto,"Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola.",2021-11-02,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Angola,Luanda,Luanda,"Included subjects who were apparently healthy for donation at the Instituto Nacional de Sangue and Clínica Girassol, both in Luanda, the capital city of Angola, between December 2019 to February 2020 and between July to September 2020","NR
",2019-12-15,2020-09-15,Blood donors,All,Adults (18-64 years),18.0,61.0,Primary Estimate,,343,0.047,,,True,,,,True,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,ELISA,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Cruz Sebastiao,Instituto Nacional de Investigação em Saúde,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06814-0,2021-11-10,2024-03-01,Verified,sebastiao_seroprevalence_2021,AGO
211102_Luanda_UniversidadeAgostinhoNeto_20-40,211102_Luanda_UniversidadeAgostinhoNeto,"Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola.",2021-11-02,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Angola,,Luanda,"Included subjects who were apparently healthy for donation at the Instituto Nacional de Sangue and Clínica Girassol, both in Luanda, the capital city of Angola, between December 2019 to February 2020 and between July to September 2020","NR
",2019-12-15,2020-09-15,Blood donors,All,Adults (18-64 years),20.0,40.0,Age,20-40 years-old,279,0.047,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,ELISA,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Cruz Sebastiao,Instituto Nacional de Investigação em Saúde,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06814-0,2021-11-10,2024-03-01,Verified,sebastiao_seroprevalence_2021,AGO
211102_Luanda_UniversidadeAgostinhoNeto_Feb2020,211102_Luanda_UniversidadeAgostinhoNeto,"Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola.",2021-11-02,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Angola,,Luanda,"Included subjects who were apparently healthy for donation at the Instituto Nacional de Sangue and Clínica Girassol, both in Luanda, the capital city of Angola, between December 2019 to February 2020 and between July to September 2020","NR
",2020-02-01,2020-02-29,Blood donors,All,Adults (18-64 years),18.0,61.0,Time frame,February 2020 ,42,0.0,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,ELISA,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Cruz Sebastiao,Instituto Nacional de Investigação em Saúde,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06814-0,2021-11-10,2024-03-01,Verified,sebastiao_seroprevalence_2021,AGO
211102_Luanda_UniversidadeAgostinhoNeto_Sep2020,211102_Luanda_UniversidadeAgostinhoNeto,"Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola.",2021-11-02,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Angola,,Luanda,"Included subjects who were apparently healthy for donation at the Instituto Nacional de Sangue and Clínica Girassol, both in Luanda, the capital city of Angola, between December 2019 to February 2020 and between July to September 2020","NR
",2020-09-01,2020-09-30,Blood donors,All,Adults (18-64 years),18.0,61.0,Time frame,September 2020 ,55,0.2,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,ELISA,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Cruz Sebastiao,Instituto Nacional de Investigação em Saúde,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06814-0,2021-11-10,2024-03-01,Verified,sebastiao_seroprevalence_2021,AGO
211102_Luanda_UniversidadeAgostinhoNeto_Dec2019,211102_Luanda_UniversidadeAgostinhoNeto,"Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola.",2021-11-02,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Angola,,Luanda,"Included subjects who were apparently healthy for donation at the Instituto Nacional de Sangue and Clínica Girassol, both in Luanda, the capital city of Angola, between December 2019 to February 2020 and between July to September 2020","NR
",2019-12-01,2019-12-31,Blood donors,All,Adults (18-64 years),18.0,61.0,Time frame,December 2019 ,25,0.0,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,ELISA,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Cruz Sebastiao,Instituto Nacional de Investigação em Saúde,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06814-0,2021-11-10,2024-03-01,Verified,sebastiao_seroprevalence_2021,AGO
211102_Luanda_UniversidadeAgostinhoNeto_Aug2020,211102_Luanda_UniversidadeAgostinhoNeto,"Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola.",2021-11-02,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Angola,,Luanda,"Included subjects who were apparently healthy for donation at the Instituto Nacional de Sangue and Clínica Girassol, both in Luanda, the capital city of Angola, between December 2019 to February 2020 and between July to September 2020","NR
",2020-08-01,2020-08-31,Blood donors,All,Adults (18-64 years),18.0,61.0,Time frame,August 2020 ,24,0.125,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,ELISA,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Cruz Sebastiao,Instituto Nacional de Investigação em Saúde,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06814-0,2021-11-10,2024-03-01,Verified,sebastiao_seroprevalence_2021,AGO
211102_Luanda_UniversidadeAgostinhoNeto_Female,211102_Luanda_UniversidadeAgostinhoNeto,"Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola.",2021-11-02,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Angola,,Luanda,"Included subjects who were apparently healthy for donation at the Instituto Nacional de Sangue and Clínica Girassol, both in Luanda, the capital city of Angola, between December 2019 to February 2020 and between July to September 2020","NR
",2019-12-15,2020-09-15,Blood donors,Female,Adults (18-64 years),18.0,61.0,Sex/Gender,,24,0.0,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,ELISA,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Cruz Sebastiao,Instituto Nacional de Investigação em Saúde,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06814-0,2021-11-10,2024-03-01,Verified,sebastiao_seroprevalence_2021,AGO
211102_Luanda_UniversidadeAgostinhoNeto_Jul2020,211102_Luanda_UniversidadeAgostinhoNeto,"Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola.",2021-11-02,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Angola,,Luanda,"Included subjects who were apparently healthy for donation at the Instituto Nacional de Sangue and Clínica Girassol, both in Luanda, the capital city of Angola, between December 2019 to February 2020 and between July to September 2020","NR
",2020-07-01,2020-07-31,Blood donors,All,Adults (18-64 years),18.0,61.0,Time frame,July 2020 ,52,0.019,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,ELISA,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Cruz Sebastiao,Instituto Nacional de Investigação em Saúde,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06814-0,2021-11-10,2024-03-01,Verified,sebastiao_seroprevalence_2021,AGO
211102_Luanda_UniversidadeAgostinhoNeto_Jan2020,211102_Luanda_UniversidadeAgostinhoNeto,"Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola.",2021-11-02,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Angola,,Luanda,"Included subjects who were apparently healthy for donation at the Instituto Nacional de Sangue and Clínica Girassol, both in Luanda, the capital city of Angola, between December 2019 to February 2020 and between July to September 2020","NR
",2020-01-01,2020-01-31,Blood donors,All,Adults (18-64 years),18.0,61.0,Time frame,January 2020 ,145,0.006999999999999999,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,ELISA,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Cruz Sebastiao,Instituto Nacional de Investigação em Saúde,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06814-0,2021-11-10,2024-03-01,Verified,sebastiao_seroprevalence_2021,AGO
211102_Luanda_UniversidadeAgostinhoNeto_<20,211102_Luanda_UniversidadeAgostinhoNeto,"Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola.",2021-11-02,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Angola,,Luanda,"Included subjects who were apparently healthy for donation at the Instituto Nacional de Sangue and Clínica Girassol, both in Luanda, the capital city of Angola, between December 2019 to February 2020 and between July to September 2020","NR
",2019-12-15,2020-09-15,Blood donors,All,Adults (18-64 years),18.0,19.0,Age,<20 years-old,7,0.14300000000000002,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,ELISA,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Cruz Sebastiao,Instituto Nacional de Investigação em Saúde,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06814-0,2021-11-10,2024-03-01,Verified,sebastiao_seroprevalence_2021,AGO
211102_Luanda_UniversidadeAgostinhoNeto_Male,211102_Luanda_UniversidadeAgostinhoNeto,"Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola.",2021-11-02,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Angola,,Luanda,"Included subjects who were apparently healthy for donation at the Instituto Nacional de Sangue and Clínica Girassol, both in Luanda, the capital city of Angola, between December 2019 to February 2020 and between July to September 2020","NR
",2019-12-15,2020-09-15,Blood donors,Male,Adults (18-64 years),18.0,61.0,Sex/Gender,,319,0.05,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,ELISA,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Cruz Sebastiao,Instituto Nacional de Investigação em Saúde,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06814-0,2021-11-10,2024-03-01,Verified,sebastiao_seroprevalence_2021,AGO
211102_Luanda_UniversidadeAgostinhoNeto_>40,211102_Luanda_UniversidadeAgostinhoNeto,"Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola.",2021-11-02,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Angola,,Luanda,"Included subjects who were apparently healthy for donation at the Instituto Nacional de Sangue and Clínica Girassol, both in Luanda, the capital city of Angola, between December 2019 to February 2020 and between July to September 2020","NR
",2019-12-15,2020-09-15,Blood donors,All,Adults (18-64 years),41.0,61.0,Age,>40 years-old,57,0.035,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,ELISA,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Cruz Sebastiao,Instituto Nacional de Investigação em Saúde,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06814-0,2021-11-10,2024-03-01,Verified,sebastiao_seroprevalence_2021,AGO
"200718_BuenosAires_MinisterofHealth,BuenosAiresCity_Homeless",200718_BuenosAires_MinisterofHealthBuenosAiresCity_2_Homeless,"Community-level SARS-CoV-2 Seroprevalence Survey in urban slum dwellers of Buenos Aires City, Argentina: a participatory research.",2020-07-18,Preprint,Local,Cross-sectional survey ,Argentina,Buenos Aires,Buenos Aires,"A sample for convenience of 60 homeless people in the “Comedor del Fondo”, a popular dining room managed by a non-governmental organization. This sample is not part of the overall prevalence estimate, it was done as a first step. ",,2020-06-10,2020-07-01,Persons experiencing homelessness,All,Multiple groups,14.0,,Primary Estimate,,60,0.36,,,True,,,,True,Convenience,COVIDAR IgM and IgG ELISA,CONICET,ELISA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['High'],Yes,No,No,No,Unclear,Unclear,Yes,Yes,,Silvana Figar,"Minister of Health, Buenos Aires City",Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.14.20153858v1,2020-07-17,2022-07-16,Verified,figar_community-level_2020,ARG
200828_VillaAzul_MinisterioDeSaludDeLaProvinciaDeBuenosAires_overall,200828_VillaAzul_MinisterioDeSaludDeLaProvinciaDeBuenosAires,"Surveillance and Seroprevalence: Evaluation of IgG antibodies for SARS-Cov2 by ELISA in the popular neighborhood Villa Azul, Quilmes, province of Buenos Aires, Argentina",2020-08-28,Preprint,Local,Cross-sectional survey ,Argentina,Buenos Aires,Quilmes,Residents of Villa Azul who were over 19 years of age,,2020-07-15,2020-07-16,Household and community samples,All,Multiple groups,20.0,,Primary Estimate,,284,0.14800000000000002,0.111,0.195,True,,,,True,Stratified non-probability,SEROKIT-ELISA COVIDAR IgG,COVIDAR,ELISA,Serum,IgG,,Validated by manufacturers,0.9500000000000001,1.0,['High'],Yes,No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Laura Munoz,Ministerio de Salud de la Provincia de Buenos Aires,Unity-Aligned,https://preprints.scielo.org/index.php/scielo/preprint/view/1147,2021-04-21,2022-07-16,Verified,munoz_surveillance_2020,ARG
200828_VillaAzul_MinisterioDeSaludDeLaProvinciaDeBuenosAires_male,200828_VillaAzul_MinisterioDeSaludDeLaProvinciaDeBuenosAires,"Surveillance and Seroprevalence: Evaluation of IgG antibodies for SARS-Cov2 by ELISA in the popular neighborhood Villa Azul, Quilmes, province of Buenos Aires, Argentina",2020-08-28,Preprint,Local,Cross-sectional survey ,Argentina,Buenos Aires,Quilmes,Residents of Villa Azul who were over 19 years of age,,2020-07-15,2020-07-16,Household and community samples,Male,Multiple groups,20.0,,Sex/Gender,male,110,0.127,0.077,0.204,,,,,,Stratified non-probability,SEROKIT-ELISA COVIDAR IgG,COVIDAR,ELISA,Serum,IgG,,Validated by manufacturers,0.9500000000000001,1.0,['High'],Yes,No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Laura Munoz,Ministerio de Salud de la Provincia de Buenos Aires,Unity-Aligned,https://preprints.scielo.org/index.php/scielo/preprint/view/1147,2021-04-21,2022-07-16,Verified,munoz_surveillance_2020,ARG
200828_VillaAzul_MinisterioDeSaludDeLaProvinciaDeBuenosAires_female,200828_VillaAzul_MinisterioDeSaludDeLaProvinciaDeBuenosAires,"Surveillance and Seroprevalence: Evaluation of IgG antibodies for SARS-Cov2 by ELISA in the popular neighborhood Villa Azul, Quilmes, province of Buenos Aires, Argentina",2020-08-28,Preprint,Local,Cross-sectional survey ,Argentina,Buenos Aires,Quilmes,Residents of Villa Azul who were over 19 years of age,,2020-07-15,2020-07-16,Household and community samples,Female,Multiple groups,20.0,,Sex/Gender,female,173,0.162,0.114,0.225,,,,,,Stratified non-probability,SEROKIT-ELISA COVIDAR IgG,COVIDAR,ELISA,Serum,IgG,,Validated by manufacturers,0.9500000000000001,1.0,['High'],Yes,No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Laura Munoz,Ministerio de Salud de la Provincia de Buenos Aires,Unity-Aligned,https://preprints.scielo.org/index.php/scielo/preprint/view/1147,2021-04-21,2022-07-16,Verified,munoz_surveillance_2020,ARG
200909_BuenosAires_InstitutoNacionalDeEpidemiologia_Overall,200909_BuenosAires_InstitutoNacionalDeEpidemiologia,"Seroprevalence of the SARS-CoV-2 infection in health workers of the Sanitary Region VIII, at province of Buenos Aires",2020-09-09,Preprint,Local,Cross-sectional survey ,Argentina,Buenos Aires,Buenos Aires,HCWs from public facilities from the RS VIII from Buenos Aires province during June 2020. ,,2020-06-03,2020-07-06,Health care workers and caregivers,All,Multiple groups,19.0,73.0,Primary Estimate,,738,0.0075,0.0,0.08130000000000001,True,,True,,True,Stratified probability,COVIDAR IgM and IgG ELISA,CONICET,ELISA,Plasma,"['IgG', 'IgM']",Spike,,,,['Moderate'],Yes,Yes,Yes,No,Yes,Unclear,Yes,No,Yes,Andrea Silva,Instituto Nacional de Epidemiologia,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.07.20189050v1,2020-11-10,2022-07-16,Verified,silva_seroprevalence_2020,ARG
201201_BuenosAires_HospitalGeneraldeNiñosPedrodeElizalde_overall,201201_BuenosAires_HospitalGeneraldeNiñosPedrodeElizalde,Seroprevalence of SARS-CoV-2 antibodies among physicians from a children's hospital,2020-12-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Argentina,Province of Buenos Aires,Autonomous City of Buenos Aires,"Staff physicians and residents from Hospital General de Niños Pedro de Elizalde (HGNPE) who worked at the hospital by April 30th, 2020",,2020-06-08,2020-06-09,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Physicians and residents overall,116,0.009000000000000001,0.001,0.055,True,,,,True,Simplified probability,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.956,0.96,['High'],Yes,Yes,No,No,Unclear,Yes,Yes,No,Unclear,Claudia Insua,Hospital General de Niños Pedro de Elizalde,Not Unity-Aligned,https://dx.doi.org/10.5546/aap.2020.eng.381,2021-01-25,2024-03-01,Verified,insua_seroprevalence_2020,ARG
201230_ArgentinaHurlingham_UniversidadNacionalHurlingham,201230_Hurlingham_UniversidadNacionalHurlingham,Se presentaron los resultados del estudio de seroprevalencia de COVID-19 que realizó la Universidad en el Municipio de Hurlingham,2020-12-30,Institutional Report,Local,Cross-sectional survey ,Argentina,Buenos Aires,Buenos Aires,The tests were carried out using a drop of blood taken from people's homes,,2020-12-01,2020-12-30,Household and community samples,All,Multiple groups,18.0,90.0,Primary Estimate,,1182,0.121,0.1,0.142,True,,,,True,Stratified probability,SEROKIT-ELISA COVIDAR IgG,COVIDAR,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,Universidad Nacional De Hurlingham,Universidad Nacional De Hurlingham,Not Unity-Aligned,http://www.unahur.edu.ar/es/se-presentaron-los-resultados-del-estudio-de-seroprevalencia-de-covid-19-que-realizo-la-universidad,2021-05-21,2022-07-16,Verified,universidad_nacional_de_hurlingham_se_2020,ARG
210107_BuenosAires_UniversityOfBuenosAires_Primary,210107_BuenosAires_UniversityOfBuenosAires,Assesment of SARS-CoV-2 infection-in dentists and supporting staff at a university dental hospital in Argentina,2021-01-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Argentina,,Buenos Aires,"The sample consisted of 358 FOUBA workers from clinical and nonclinical areas, male and female, over 21 years old, who provided essential services during the first 180 days of the COVID-19 pandemic during the PMSIs.",,2020-03-01,2020-10-31,Health care workers and caregivers,All,Adults (18-64 years),21.0,59.0,Primary Estimate,ELISA test,317,0.03,0.02,0.05,True,,,,True,Stratified non-probability,Not reported/ Unable to specify,,ELISA,,,,Validated by manufacturers,0.85,0.9500000000000001,['High'],Yes,No,No,Yes,Unclear,Unclear,Yes,No,Yes,Puia Sebastian ,University of Buenos Aires,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jobcr.2021.01.006,2021-02-18,2022-07-16,Verified,sebastian_assesment_2021,ARG
210121_BarrioMugica_MinistryOfHealthOfTheCityOfBuenosAires,210121_BarrioMugica_MinistryOfHealthOfTheCityOfBuenosAires,SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SEROEPIDEMIOLOGY STUDY IN ARGENTINIAN SLUM ,2021-01-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Argentina,Buenos Aires,Buenos Aires,Men and women 14 years of age or older who are inhabitants of Barrio Murgica in Buenos Aires City,,2020-06-10,2020-06-26,Persons living in slums,All,Multiple groups,14.0,,Primary Estimate,,873,0.534,0.528,0.541,True,,True,,True,Simplified probability,COVIDAR IgM and IgG ELISA,CONICET,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9,1.0,['Low'],Yes,Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Silvana Figar,Ministry of Health of the City of Buenos Aires,Unity-Aligned,https://www.medicinabuenosaires.com/revistas/vol81-21/destacado/original_7453.pdf,2021-04-21,2022-07-16,Verified,figar_severe_2021,ARG
210121_BarrioMugica_MinistryOfHealthOfTheCityOfBuenosAires_male,210121_BarrioMugica_MinistryOfHealthOfTheCityOfBuenosAires,SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SEROEPIDEMIOLOGY STUDY IN ARGENTINIAN SLUM ,2021-01-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Argentina,Buenos Aires,Buenos Aires,Men and women 14 years of age or older who are inhabitants of Barrio Murgica in Buenos Aires City,,2020-06-10,2020-06-26,Persons living in slums,Male,Multiple groups,14.0,,Sex/Gender,male,374,0.515,0.506,0.524,,,True,,,Simplified probability,COVIDAR IgM and IgG ELISA,CONICET,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9,1.0,['Low'],Yes,Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Silvana Figar,Ministry of Health of the City of Buenos Aires,Unity-Aligned,https://www.medicinabuenosaires.com/revistas/vol81-21/destacado/original_7453.pdf,2021-04-21,2022-07-16,Verified,figar_severe_2021,ARG
210121_BarrioMugica_MinistryOfHealthOfTheCityOfBuenosAires_Female,210121_BarrioMugica_MinistryOfHealthOfTheCityOfBuenosAires,SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SEROEPIDEMIOLOGY STUDY IN ARGENTINIAN SLUM ,2021-01-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Argentina,Buenos Aires,Buenos Aires,Men and women 14 years of age or older who are inhabitants of Barrio Murgica in Buenos Aires City,,2020-06-10,2020-06-26,Persons living in slums,Female,Multiple groups,14.0,,Sex/Gender,female,499,0.5529999999999999,0.544,0.562,,,True,,,Simplified probability,COVIDAR IgM and IgG ELISA,CONICET,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9,1.0,['Low'],Yes,Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Silvana Figar,Ministry of Health of the City of Buenos Aires,Unity-Aligned,https://www.medicinabuenosaires.com/revistas/vol81-21/destacado/original_7453.pdf,2021-04-21,2022-07-16,Verified,figar_severe_2021,ARG
210122_BuenosAires_GovernmentOfTheProvinceOfBuenosAires,210122_BuenosAiresCity_GovernmentOfTheProvinceOfBuenosAires,"ONLY 13 PERCENT OF THE
  NEIGHBOURS OF 30 PEOPLE'S NEIGHBOURHOODS OF THE AMBA HAD CORONAVIRUS",2021-01-22,News and Media,Local,Cross-sectional survey ,Argentina,Buenos Aires,Metropolitan Area of Buenos Aires,,,2020-07-15,2020-12-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,9000,0.13,,,True,,,,True,Unclear,Not reported/ Unable to specify,,ELISA,Whole Blood,,,,,,['High'],,Unclear,Yes,No,,Unclear,Yes,No,,Government of the Province of Buenos Aires,Government of the Province of Buenos Aires,Not Unity-Aligned,https://www.gba.gob.ar/saludprovincia/noticias/s%C3%B3lo_el_13_por_ciento_de_los_vecinos_y_vecinas_de_30_barrios_populares_del,2021-05-17,2022-07-16,Unverified,government_of_the_province_of_buenos_aires_only_2021,ARG
210615_SantaFe_UniversidadNacionalDelLitoral_genpop_overall,210615_SantaFe_UniversidadNacionalDelLitoral,Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina.,2021-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Argentina,,Santa Fe,"""Volunteers over 18 years of age, of both sexes, residents from the different districts of the city were included""","""Individuals previously diagnosed with COVID-19 clinically and/or
by laboratory tests (RT-PCR, antigen detection, or antibodies
test) were excluded according to the criteria of suspected cases
throughout the study period., we We also excluded people who
had been in close contact with confirmed or suspected cases 20 days before taking the sample, if they developed symptoms
attributable to COVID-19.""",2020-07-01,2020-11-30,Multiple general populations,All,Multiple groups,18.0,,Primary Estimate,,3000,0.0883,,,True,,,,True,Convenience,SEROKIT-ELISA COVIDAR IgG,COVIDAR,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,1.0,['Moderate'],,No,Yes,No,,Unclear,Yes,Yes,,Luz Maria Rodeles,Universidad Nacional del Litoral,Not Unity-Aligned,https://dx.doi.org/10.26633/RPSP.2021.66,2021-07-05,2022-07-16,Unverified,rodeles_seroprevalence_2021-1,ARG
210615_SantaFe_UniversidadNacionalDelLitoral_genpop_age18-45,210615_SantaFe_UniversidadNacionalDelLitoral,Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina.,2021-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Argentina,,Santa Fe,"""Volunteers over 18 years of age, of both sexes, residents from the different districts of the city were included""","""Individuals previously diagnosed with COVID-19 clinically and/or
by laboratory tests (RT-PCR, antigen detection, or antibodies
test) were excluded according to the criteria of suspected cases
throughout the study period., we We also excluded people who
had been in close contact with confirmed or suspected cases 20 days before taking the sample, if they developed symptoms
attributable to COVID-19.""",2020-07-01,2020-11-30,Multiple general populations,All,Adults (18-64 years),18.0,45.0,Age,18-45,2118,0.08199999999999999,,,,,True,,,Convenience,SEROKIT-ELISA COVIDAR IgG,COVIDAR,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,1.0,['Moderate'],,No,Yes,No,,Unclear,Yes,Yes,,Luz Maria Rodeles,Universidad Nacional del Litoral,Not Unity-Aligned,https://dx.doi.org/10.26633/RPSP.2021.66,2021-07-05,2022-07-16,Unverified,rodeles_seroprevalence_2021-1,ARG
210615_SantaFe_UniversidadNacionalDelLitoral_genpop_age65+,210615_SantaFe_UniversidadNacionalDelLitoral,Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina.,2021-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Argentina,,Santa Fe,"""Volunteers over 18 years of age, of both sexes, residents from the different districts of the city were included""","""Individuals previously diagnosed with COVID-19 clinically and/or
by laboratory tests (RT-PCR, antigen detection, or antibodies
test) were excluded according to the criteria of suspected cases
throughout the study period., we We also excluded people who
had been in close contact with confirmed or suspected cases 20 days before taking the sample, if they developed symptoms
attributable to COVID-19.""",2020-07-01,2020-11-30,Multiple general populations,All,Seniors (65+ years),65.0,,Age,>65,133,0.109,,,,,True,,,Convenience,SEROKIT-ELISA COVIDAR IgG,COVIDAR,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,1.0,['Moderate'],,No,Yes,No,,Unclear,Yes,Yes,,Luz Maria Rodeles,Universidad Nacional del Litoral,Not Unity-Aligned,https://dx.doi.org/10.26633/RPSP.2021.66,2021-07-05,2022-07-16,Unverified,rodeles_seroprevalence_2021-1,ARG
210615_SantaFe_UniversidadNacionalDelLitoral_genpop_age46-65,210615_SantaFe_UniversidadNacionalDelLitoral,Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina.,2021-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Argentina,,Santa Fe,"""Volunteers over 18 years of age, of both sexes, residents from the different districts of the city were included""","""Individuals previously diagnosed with COVID-19 clinically and/or
by laboratory tests (RT-PCR, antigen detection, or antibodies
test) were excluded according to the criteria of suspected cases
throughout the study period., we We also excluded people who
had been in close contact with confirmed or suspected cases 20 days before taking the sample, if they developed symptoms
attributable to COVID-19.""",2020-07-01,2020-11-30,Multiple general populations,All,Multiple groups,46.0,65.0,Age,46-65,749,0.099,,,,,True,,,Convenience,SEROKIT-ELISA COVIDAR IgG,COVIDAR,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,1.0,['Moderate'],,No,Yes,No,,Unclear,Yes,Yes,,Luz Maria Rodeles,Universidad Nacional del Litoral,Not Unity-Aligned,https://dx.doi.org/10.26633/RPSP.2021.66,2021-07-05,2022-07-16,Unverified,rodeles_seroprevalence_2021-1,ARG
220314_PuertoMadryn_UniversidadAustral_Overall,220314_PuertoMadryn_UniversidadAustral,SARS-CoV-2 seroprevalence in the city of Puerto Madryn: Underdiagnosis and relevance of children in the pandemic.,2022-03-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Argentina,Chubut,Puerto Madryn,The target population of the study were subjects of different age groups residing in the city of Puerto Madryn.,"We excluded from the study subjects who refused to give their informed written consent, those in whom digital blood puncture was contraindicated, subjects with acute symptoms potentially related to COVID-19 infection, subjects who received COVID-19 vaccination, and subjects with mental disorders or unable to make decisions that are not accompanied by their legal representative.",2021-03-03,2021-04-17,Household and community samples,All,Multiple groups,,,Primary Estimate,,987,0.3921,0.36200000000000004,0.423,True,,,,True,Stratified probability,SEROKIT-ELISA COVIDAR IgG,COVIDAR,,Serum,IgG,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Daniel Schonfeld,Universidad Austra,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0263679,2022-03-22,2022-07-16,Unverified,schonfeld_sars-cov-2_2022,ARG
220314_PuertoMadryn_UniversidadAustral_Age40-64,220314_PuertoMadryn_UniversidadAustral,SARS-CoV-2 seroprevalence in the city of Puerto Madryn: Underdiagnosis and relevance of children in the pandemic.,2022-03-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Argentina,Chubut,Puerto Madryn,The target population of the study were subjects of different age groups residing in the city of Puerto Madryn.,"We excluded from the study subjects who refused to give their informed written consent, those in whom digital blood puncture was contraindicated, subjects with acute symptoms potentially related to COVID-19 infection, subjects who received COVID-19 vaccination, and subjects with mental disorders or unable to make decisions that are not accompanied by their legal representative.",2021-03-03,2021-04-17,Household and community samples,All,Adults (18-64 years),40.0,64.0,Age,40-64,337,0.38280000000000003,0.33299999999999996,0.435,,,,,,Stratified probability,SEROKIT-ELISA COVIDAR IgG,COVIDAR,,Serum,IgG,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Daniel Schonfeld,Universidad Austra,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0263679,2022-03-22,2022-07-16,Unverified,schonfeld_sars-cov-2_2022,ARG
220314_PuertoMadryn_UniversidadAustral_SexMale,220314_PuertoMadryn_UniversidadAustral,SARS-CoV-2 seroprevalence in the city of Puerto Madryn: Underdiagnosis and relevance of children in the pandemic.,2022-03-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Argentina,Chubut,Puerto Madryn,The target population of the study were subjects of different age groups residing in the city of Puerto Madryn.,"We excluded from the study subjects who refused to give their informed written consent, those in whom digital blood puncture was contraindicated, subjects with acute symptoms potentially related to COVID-19 infection, subjects who received COVID-19 vaccination, and subjects with mental disorders or unable to make decisions that are not accompanied by their legal representative.",2021-03-03,2021-04-17,Household and community samples,Male,Multiple groups,,,Sex/Gender,,360,0.39170000000000005,0.341,0.44200000000000006,,,,,,Stratified probability,SEROKIT-ELISA COVIDAR IgG,COVIDAR,,Serum,IgG,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Daniel Schonfeld,Universidad Austra,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0263679,2022-03-22,2022-07-16,Unverified,schonfeld_sars-cov-2_2022,ARG
220314_PuertoMadryn_UniversidadAustral_Age65+,220314_PuertoMadryn_UniversidadAustral,SARS-CoV-2 seroprevalence in the city of Puerto Madryn: Underdiagnosis and relevance of children in the pandemic.,2022-03-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Argentina,Chubut,Puerto Madryn,The target population of the study were subjects of different age groups residing in the city of Puerto Madryn.,"We excluded from the study subjects who refused to give their informed written consent, those in whom digital blood puncture was contraindicated, subjects with acute symptoms potentially related to COVID-19 infection, subjects who received COVID-19 vaccination, and subjects with mental disorders or unable to make decisions that are not accompanied by their legal representative.",2021-03-03,2021-04-17,Household and community samples,All,Seniors (65+ years),65.0,,Age,,81,0.3951,0.289,0.502,,,,,,Stratified probability,SEROKIT-ELISA COVIDAR IgG,COVIDAR,,Serum,IgG,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Daniel Schonfeld,Universidad Austra,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0263679,2022-03-22,2022-07-16,Unverified,schonfeld_sars-cov-2_2022,ARG
220314_PuertoMadryn_UniversidadAustral_Age15-39,220314_PuertoMadryn_UniversidadAustral,SARS-CoV-2 seroprevalence in the city of Puerto Madryn: Underdiagnosis and relevance of children in the pandemic.,2022-03-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Argentina,Chubut,Puerto Madryn,The target population of the study were subjects of different age groups residing in the city of Puerto Madryn.,"We excluded from the study subjects who refused to give their informed written consent, those in whom digital blood puncture was contraindicated, subjects with acute symptoms potentially related to COVID-19 infection, subjects who received COVID-19 vaccination, and subjects with mental disorders or unable to make decisions that are not accompanied by their legal representative.",2021-03-03,2021-04-17,Household and community samples,All,Adults (18-64 years),15.0,39.0,Age,15-39,342,0.348,0.297,0.39799999999999996,,,,,,Stratified probability,SEROKIT-ELISA COVIDAR IgG,COVIDAR,,Serum,IgG,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Daniel Schonfeld,Universidad Austra,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0263679,2022-03-22,2022-07-16,Unverified,schonfeld_sars-cov-2_2022,ARG
220314_PuertoMadryn_UniversidadAustral_Age<10,220314_PuertoMadryn_UniversidadAustral,SARS-CoV-2 seroprevalence in the city of Puerto Madryn: Underdiagnosis and relevance of children in the pandemic.,2022-03-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Argentina,Chubut,Puerto Madryn,The target population of the study were subjects of different age groups residing in the city of Puerto Madryn.,"We excluded from the study subjects who refused to give their informed written consent, those in whom digital blood puncture was contraindicated, subjects with acute symptoms potentially related to COVID-19 infection, subjects who received COVID-19 vaccination, and subjects with mental disorders or unable to make decisions that are not accompanied by their legal representative.",2021-03-03,2021-04-17,Household and community samples,All,Children and Youth (0-17 years),,9.0,Age,<10,114,0.42979999999999996,0.332,0.521,,,,,,Stratified probability,SEROKIT-ELISA COVIDAR IgG,COVIDAR,,Serum,IgG,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Daniel Schonfeld,Universidad Austra,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0263679,2022-03-22,2022-07-16,Unverified,schonfeld_sars-cov-2_2022,ARG
220314_PuertoMadryn_UniversidadAustral_Age10-14,220314_PuertoMadryn_UniversidadAustral,SARS-CoV-2 seroprevalence in the city of Puerto Madryn: Underdiagnosis and relevance of children in the pandemic.,2022-03-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Argentina,Chubut,Puerto Madryn,The target population of the study were subjects of different age groups residing in the city of Puerto Madryn.,"We excluded from the study subjects who refused to give their informed written consent, those in whom digital blood puncture was contraindicated, subjects with acute symptoms potentially related to COVID-19 infection, subjects who received COVID-19 vaccination, and subjects with mental disorders or unable to make decisions that are not accompanied by their legal representative.",2021-03-03,2021-04-17,Household and community samples,All,Children and Youth (0-17 years),10.0,14.0,Age,10-14,113,0.5133,0.42100000000000004,0.605,,,,,,Stratified probability,SEROKIT-ELISA COVIDAR IgG,COVIDAR,,Serum,IgG,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Daniel Schonfeld,Universidad Austra,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0263679,2022-03-22,2022-07-16,Unverified,schonfeld_sars-cov-2_2022,ARG
220314_PuertoMadryn_UniversidadAustral_SexFemale,220314_PuertoMadryn_UniversidadAustral,SARS-CoV-2 seroprevalence in the city of Puerto Madryn: Underdiagnosis and relevance of children in the pandemic.,2022-03-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Argentina,Chubut,Puerto Madryn,The target population of the study were subjects of different age groups residing in the city of Puerto Madryn.,"We excluded from the study subjects who refused to give their informed written consent, those in whom digital blood puncture was contraindicated, subjects with acute symptoms potentially related to COVID-19 infection, subjects who received COVID-19 vaccination, and subjects with mental disorders or unable to make decisions that are not accompanied by their legal representative.",2021-03-03,2021-04-17,Household and community samples,Female,Multiple groups,,,Sex/Gender,,627,0.3923,0.354,0.43100000000000005,,,,,,Stratified probability,SEROKIT-ELISA COVIDAR IgG,COVIDAR,,Serum,IgG,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Daniel Schonfeld,Universidad Austra,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0263679,2022-03-22,2022-07-16,Unverified,schonfeld_sars-cov-2_2022,ARG
220520_Córdoba_MinistryOfHealth_Overall,220520_Córdoba_MinistryOfHealth,"A population-based study on seroprevalence and factors associated with SARS-CoV-2 infection in Cordoba, Argentina",2022-05-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Argentina,Córdoba,Córdoba,"""To participate in the study, the inclusion criteria were defined as being a resident of the city of Córdoba and over two years of age, regardless of having previously suffered from COVID-19.""","People who were experiencing the disease and/or were in close contact at the time of blood sampling were excluded, as well as those who had been vaccinated against COVID-19 with at least one dose.",2020-12-15,2021-01-15,Household and community samples,All,Multiple groups,2.0,,Primary Estimate,,3225,0.1668,0.15410000000000001,0.1801,True,,,,True,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Laura Aballay,Ministry of Health of the Province of Córdoba,Unity-Aligned,https://dx.doi.org/10.1590/0102-311XES219821,2022-06-01,2024-03-22,Verified,aballay_estudio_2022,ARG
220520_Córdoba_MinistryOfHealth_Female,220520_Córdoba_MinistryOfHealth,"A population-based study on seroprevalence and factors associated with SARS-CoV-2 infection in Cordoba, Argentina",2022-05-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Argentina,Córdoba,Córdoba,"""To participate in the study, the inclusion criteria were defined as being a resident of the city of Córdoba and over two years of age, regardless of having previously suffered from COVID-19.""","People who were experiencing the disease and/or were in close contact at the time of blood sampling were excluded, as well as those who had been vaccinated against COVID-19 with at least one dose.",2020-12-15,2021-01-15,Household and community samples,Female,Multiple groups,2.0,,Sex/Gender,Female,1823,0.17690000000000003,0.15960000000000002,0.19510000000000002,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Laura Aballay,Ministry of Health of the Province of Córdoba,Unity-Aligned,https://dx.doi.org/10.1590/0102-311XES219821,2022-06-01,2024-03-22,Verified,aballay_estudio_2022,ARG
220520_Córdoba_MinistryOfHealth_Male,220520_Córdoba_MinistryOfHealth,"A population-based study on seroprevalence and factors associated with SARS-CoV-2 infection in Cordoba, Argentina",2022-05-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Argentina,Córdoba,Córdoba,"""To participate in the study, the inclusion criteria were defined as being a resident of the city of Córdoba and over two years of age, regardless of having previously suffered from COVID-19.""","People who were experiencing the disease and/or were in close contact at the time of blood sampling were excluded, as well as those who had been vaccinated against COVID-19 with at least one dose.",2020-12-15,2021-01-15,Household and community samples,Male,Multiple groups,2.0,,Sex/Gender,Male,1395,0.1537,0.1351,0.1736,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Laura Aballay,Ministry of Health of the Province of Córdoba,Unity-Aligned,https://dx.doi.org/10.1590/0102-311XES219821,2022-06-01,2024-03-22,Verified,aballay_estudio_2022,ARG
220520_Córdoba_MinistryOfHealth_Age65+,220520_Córdoba_MinistryOfHealth,"A population-based study on seroprevalence and factors associated with SARS-CoV-2 infection in Cordoba, Argentina",2022-05-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Argentina,Córdoba,Córdoba,"""To participate in the study, the inclusion criteria were defined as being a resident of the city of Córdoba and over two years of age, regardless of having previously suffered from COVID-19.""","People who were experiencing the disease and/or were in close contact at the time of blood sampling were excluded, as well as those who had been vaccinated against COVID-19 with at least one dose.",2020-12-15,2021-01-15,Household and community samples,All,Seniors (65+ years),65.0,,Age,>64,383,0.14880000000000002,0.11470000000000001,0.1884,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Laura Aballay,Ministry of Health of the Province of Córdoba,Unity-Aligned,https://dx.doi.org/10.1590/0102-311XES219821,2022-06-01,2024-03-22,Verified,aballay_estudio_2022,ARG
220520_Córdoba_MinistryOfHealth_Age2-18,220520_Córdoba_MinistryOfHealth,"A population-based study on seroprevalence and factors associated with SARS-CoV-2 infection in Cordoba, Argentina",2022-05-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Argentina,Córdoba,Córdoba,"""To participate in the study, the inclusion criteria were defined as being a resident of the city of Córdoba and over two years of age, regardless of having previously suffered from COVID-19.""","People who were experiencing the disease and/or were in close contact at the time of blood sampling were excluded, as well as those who had been vaccinated against COVID-19 with at least one dose.",2020-12-15,2021-01-15,Household and community samples,All,Multiple groups,2.0,,Age,2-18,712,0.2177,0.18789999999999998,0.24980000000000002,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Laura Aballay,Ministry of Health of the Province of Córdoba,Unity-Aligned,https://dx.doi.org/10.1590/0102-311XES219821,2022-06-01,2024-03-22,Verified,aballay_estudio_2022,ARG
220520_Córdoba_MinistryOfHealth_Age19-49,220520_Córdoba_MinistryOfHealth,"A population-based study on seroprevalence and factors associated with SARS-CoV-2 infection in Cordoba, Argentina",2022-05-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Argentina,Córdoba,Córdoba,"""To participate in the study, the inclusion criteria were defined as being a resident of the city of Córdoba and over two years of age, regardless of having previously suffered from COVID-19.""","People who were experiencing the disease and/or were in close contact at the time of blood sampling were excluded, as well as those who had been vaccinated against COVID-19 with at least one dose.",2020-12-15,2021-01-15,Household and community samples,All,Adults (18-64 years),19.0,,Age,19-49,1612,0.1514,0.1342,0.1698,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Laura Aballay,Ministry of Health of the Province of Córdoba,Unity-Aligned,https://dx.doi.org/10.1590/0102-311XES219821,2022-06-01,2024-03-22,Verified,aballay_estudio_2022,ARG
220520_Córdoba_MinistryOfHealth_Age50-64,220520_Córdoba_MinistryOfHealth,"A population-based study on seroprevalence and factors associated with SARS-CoV-2 infection in Cordoba, Argentina",2022-05-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Argentina,Córdoba,Córdoba,"""To participate in the study, the inclusion criteria were defined as being a resident of the city of Córdoba and over two years of age, regardless of having previously suffered from COVID-19.""","People who were experiencing the disease and/or were in close contact at the time of blood sampling were excluded, as well as those who had been vaccinated against COVID-19 with at least one dose.",2020-12-15,2021-01-15,Household and community samples,All,Adults (18-64 years),50.0,,Age,50-64,518,0.1583,0.12789999999999999,0.19260000000000002,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Laura Aballay,Ministry of Health of the Province of Córdoba,Unity-Aligned,https://dx.doi.org/10.1590/0102-311XES219821,2022-06-01,2024-03-22,Verified,aballay_estudio_2022,ARG
220613_SantaFe_UniversidadNacionaldelLitoral,220613_SantaFe_UniversidadNacionaldelLitoral,"Preceding anti-spike IgG levels predicted risk and severity of COVID-19 during the Omicron-dominant wave in Santa Fe city, Argentina",2022-06-13,Preprint,Regional,Cross-sectional survey ,Argentina,Santa Fe province,Santa Fe,Randomly selected households in Santa Fe,,2021-11-01,2021-12-23,Household and community samples,All,Multiple groups,,95.0,Primary Estimate,,1455,0.887,,,True,,,,True,Convenience,SEROKIT-ELISA COVIDAR IgG,COVIDAR,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Ayelen Eberhardt,Universidad Nacional del Litoral,Not Unity-Aligned,https://dx.doi.org/10.1101/2022.05.18.22275138,2022-09-13,2022-09-21,Unverified,eberhardt_preceding_2022,ARG
220613_SantaFe_UniversidadNacionaldelLitoral_Age_13-20,220613_SantaFe_UniversidadNacionaldelLitoral,"Preceding anti-spike IgG levels predicted risk and severity of COVID-19 during the Omicron-dominant wave in Santa Fe city, Argentina",2022-06-13,Preprint,Regional,Cross-sectional survey ,Argentina,Santa Fe province,Santa Fe,Randomly selected households in Santa Fe,,2021-11-01,2021-12-23,Household and community samples,All,Multiple groups,13.0,20.0,Age,13-20,87,0.91,,,,,,,,Convenience,SEROKIT-ELISA COVIDAR IgG,COVIDAR,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Ayelen Eberhardt,Universidad Nacional del Litoral,Not Unity-Aligned,https://dx.doi.org/10.1101/2022.05.18.22275138,2022-09-13,2022-09-21,Unverified,eberhardt_preceding_2022,ARG
220613_SantaFe_UniversidadNacionaldelLitoral_Age_>60,220613_SantaFe_UniversidadNacionaldelLitoral,"Preceding anti-spike IgG levels predicted risk and severity of COVID-19 during the Omicron-dominant wave in Santa Fe city, Argentina",2022-06-13,Preprint,Regional,Cross-sectional survey ,Argentina,Santa Fe province,Santa Fe,Randomly selected households in Santa Fe,,2021-11-01,2021-12-23,Household and community samples,All,Seniors (65+ years),61.0,,Age,,311,0.941,,,,,,,,Convenience,SEROKIT-ELISA COVIDAR IgG,COVIDAR,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Ayelen Eberhardt,Universidad Nacional del Litoral,Not Unity-Aligned,https://dx.doi.org/10.1101/2022.05.18.22275138,2022-09-13,2022-09-21,Unverified,eberhardt_preceding_2022,ARG
220613_SantaFe_UniversidadNacionaldelLitoral_Age_0-12,220613_SantaFe_UniversidadNacionaldelLitoral,"Preceding anti-spike IgG levels predicted risk and severity of COVID-19 during the Omicron-dominant wave in Santa Fe city, Argentina",2022-06-13,Preprint,Regional,Cross-sectional survey ,Argentina,Santa Fe province,Santa Fe,Randomly selected households in Santa Fe,,2021-11-01,2021-12-23,Household and community samples,All,Children and Youth (0-17 years),0.0,12.0,Age,0-12,84,0.5660000000000001,,,,,,,,Convenience,SEROKIT-ELISA COVIDAR IgG,COVIDAR,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Ayelen Eberhardt,Universidad Nacional del Litoral,Not Unity-Aligned,https://dx.doi.org/10.1101/2022.05.18.22275138,2022-09-13,2022-09-21,Unverified,eberhardt_preceding_2022,ARG
220613_SantaFe_UniversidadNacionaldelLitoral_Age_21-40,220613_SantaFe_UniversidadNacionaldelLitoral,"Preceding anti-spike IgG levels predicted risk and severity of COVID-19 during the Omicron-dominant wave in Santa Fe city, Argentina",2022-06-13,Preprint,Regional,Cross-sectional survey ,Argentina,Santa Fe province,Santa Fe,Randomly selected households in Santa Fe,,2021-11-01,2021-12-23,Household and community samples,All,Adults (18-64 years),21.0,40.0,Age,21-40,535,0.878,,,,,,,,Convenience,SEROKIT-ELISA COVIDAR IgG,COVIDAR,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Ayelen Eberhardt,Universidad Nacional del Litoral,Not Unity-Aligned,https://dx.doi.org/10.1101/2022.05.18.22275138,2022-09-13,2022-09-21,Unverified,eberhardt_preceding_2022,ARG
220613_SantaFe_UniversidadNacionaldelLitoral_Age_41-60,220613_SantaFe_UniversidadNacionaldelLitoral,"Preceding anti-spike IgG levels predicted risk and severity of COVID-19 during the Omicron-dominant wave in Santa Fe city, Argentina",2022-06-13,Preprint,Regional,Cross-sectional survey ,Argentina,Santa Fe province,Santa Fe,Randomly selected households in Santa Fe,,2021-11-01,2021-12-23,Household and community samples,All,Adults (18-64 years),41.0,60.0,Age,41-60,438,0.905,,,,,,,,Convenience,SEROKIT-ELISA COVIDAR IgG,COVIDAR,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Ayelen Eberhardt,Universidad Nacional del Litoral,Not Unity-Aligned,https://dx.doi.org/10.1101/2022.05.18.22275138,2022-09-13,2022-09-21,Unverified,eberhardt_preceding_2022,ARG
200630_Yerevan_ArmeniaMinistryofHealth_HCWs,200630_Yerevan_ArmeniaMinistryofHealth,Antibodies found in Armenia's 61 medical workers from 380 examinations: testing continues,2020-06-30,News and Media,Local,Cross-sectional survey ,Armenia,Yerevan,Yerevan,Health care workers in Yerevan's polyclinics,,,2020-06-29,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,380,0.1605,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,1.0,0.998,['High'],Yes,No,No,No,Unclear,Unclear,Yes,Yes,Unclear,Anna Grigoryan,Ministry of Health of the Republic of Armenia,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://armenpress.am/eng/news/1020040/&ct=ga&cd=CAEYFioTMTc0ODAyMDA0NzI0ODEyNTQxODIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNHN-cSj3u7JgQAyBjN07fSTGAdlgA,2020-08-01,2022-07-16,Verified,grigoryan_antibodies_2020,ARM
211021_Armenia_EcoSenseDiagnosticCenter,211021_Armenia_EcoSenseDiagnosticCenter,Serological investigation of covid 19 antibodies in Armenia,2021-10-21,Presentation or Conference,National,Cross-sectional survey ,Armenia,,,The cross-sectional study with convenience sampling of individuals who turned to “EcoSense” laboratories to be testedfor COVID 19 IgG were examined.,,2020-03-15,2020-12-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,837,0.25329999999999997,,,True,,,,True,Self-referral,NovaLisa® SARS-CoV-2 IgG/IgM,NovaTec Immundiagnostics GmbH,ELISA,Serum,IgG,,,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,I Nazaryan,EcoSense Diagnostic Center,Not Unity-Aligned,http://dx.doi.org/10.1515/cclm-2021-5027,2021-12-14,2024-03-01,Unverified,nazaryan_w051_2021,ARM
230401_Armenia_FederalServiceforSupervisionofConsumerRightsProtectionandHumanWelfare,230401_Armenia_FederalServiceforSupervisionofConsumerRightsProtectionandHumanWelfare,SARS-CoV-2 COLLECTIVE IMMUNITY AMONG THE POPULATION OF THE REPUBLIC OF ARMENIA,2023-04-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Armenia,,,,"""Grounds for non-inclusion in the study were: a refusal of subsequent laboratory testing; or the pres- ence of manifest COVID-19 at the moment of ques- tionnaire completion.""",2022-04-12,2022-04-16,Household and community samples,All,Multiple groups,1.0,,Primary Estimate,,6057,0.986,0.981,0.987,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,Plasma,,Spike,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Anna Yu Popova,Federal Service for Supervision of Consumer Rights Protection and Human Welfare,Not Unity-Aligned,https://dx.doi.org/10.15789/2220-7619-SCI-2450,2023-05-31,2023-06-01,Unverified,popovaSARSCoV2CollectiveImmunity2023,ARM
200803_NewSouthWales_UniversityOfSydney_IndividualsInEducationalSetting,200803_NewSouthWales_UniversityOfSydney,Transmission of SARS-CoV-2 in Australian educational settings: a prospective cohort study,2020-08-03,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Australia,New South Wales,,Close contacts of children and adults that are asymptomatic,,2020-01-25,2020-04-10,Contacts of COVID patients,All,Multiple groups,1.0,64.0,Primary Estimate,,173,0.023119999999999998,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,Other,Whole Blood,"['IgA', 'IgG', 'IgM']",,Validated by developers,0.913,0.9890000000000001,['High'],Yes,No,No,No,Yes,Unclear,Yes,Yes,Unclear,Kristine Macartney,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1016/S2352-4642(20)30251-0,2020-10-16,2022-07-16,Verified,macartney_transmission_2020,AUS
210109_Australia_AustralianNationalUniversity_overall_adj,210109_Australia_AustralianNationalUniversity,Prevalence of asymptomatic SARS‐CoV‐2 infection in elective surgical patients in Australia: a prospective surveillance study,2021-01-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,"New South Wales, South Australia, Victoria and Western Australia",,"""patients admitted for elective surgery at each of the participating hospitals were approached during a six‐week period (2 June to 17 July 2020; Fig. 1), if they were adult (≥18 years) admitted for elective surgery under general anaesthesia""","""Exclusion criteria included symptoms or signs of SARS‐CoV‐2 or any other respiratory tract infection, or recent COVID‐19 contact.""",2020-06-02,2020-07-17,Residual sera,All,Multiple groups,15.0,95.0,Primary Estimate,Surgical Patients,2991,0.0016,0.0,0.0047,True,True,,,,Sequential,Author designed (ELISA) - MULTIPLEXED,,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,No,Yes,Unclear,Yes,Yes,Yes,Nicholas Coatsworth ,Australian National University,Unity-Aligned,https://onlinelibrary.wiley.com/doi/full/10.1111/ans.16564,2021-03-19,2022-07-16,Verified,coatsworth_prevalence_2021,AUS
210109_Australia_AustralianNationalUniversity_overall_unadj,210109_Australia_AustralianNationalUniversity,Prevalence of asymptomatic SARS‐CoV‐2 infection in elective surgical patients in Australia: a prospective surveillance study,2021-01-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,,,"""patients admitted for elective surgery at each of the participating hospitals were approached during a six‐week period (2 June to 17 July 2020; Fig. 1), if they were adult (≥18 years) admitted for elective surgery under general anaesthesia""","""Exclusion criteria included symptoms or signs of SARS‐CoV‐2 or any other respiratory tract infection, or recent COVID‐19 contact.""",2020-06-02,2020-07-17,Residual sera,All,Multiple groups,15.0,95.0,Analysis,Surgical Patients,2991,0.00167,,,,,,,True,Sequential,Author designed (ELISA) - MULTIPLEXED,,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,No,Yes,Unclear,Yes,Yes,Yes,Nicholas Coatsworth ,Australian National University,Unity-Aligned,https://onlinelibrary.wiley.com/doi/full/10.1111/ans.16564,2021-03-19,2022-07-16,Verified,coatsworth_prevalence_2021,AUS
210203_Sydney_Children'sHospitalAtWestmead_AntenatalScreening_overall_TestAdj,210203_Sydney_Children'sHospitalAtWestmead_AntenatalScreening,Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,New South Wales,Sydney,"pregnant women aged 20–39 years who had undergone routine antenatal screening from three large pri- vate pathology services (Douglass Hanly Moir Pathology, 4Cyte Pathology, Laverty Pathology)",,2020-05-04,2020-05-23,Pregnant or parturient women,Female,Adults (18-64 years),20.0,39.0,Primary Estimate,,560,0.0079,0.0004,0.0188,True,True,,,,Stratified probability,Author designed (IFA) - MULTIPLEXED,,IFA,,IgG,,Validated by independent authors/third party/non-developers,0.907,0.993,['Moderate'],,Yes,No,No,,Unclear,Yes,Yes,,Heather F Gidding,Children's Hospital at Westmead,Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.5694/mja2.50940,2021-03-19,2022-07-16,Unverified,gidding_seroprevalence_2021,AUS
210203_Sydney_Children'sHospitalAtWestmead_AntenatalScreening_overall_Unadj,210203_Sydney_Children'sHospitalAtWestmead_AntenatalScreening,Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,New South Wales,Sydney,"pregnant women aged 20–39 years who had undergone routine antenatal screening from three large pri- vate pathology services (Douglass Hanly Moir Pathology, 4Cyte Pathology, Laverty Pathology)",,2020-05-04,2020-05-23,Pregnant or parturient women,Female,Adults (18-64 years),20.0,39.0,Analysis,Unadjusted,560,0.01,,,,,,,True,Stratified probability,Author designed (IFA) - MULTIPLEXED,,IFA,,IgG,,Validated by independent authors/third party/non-developers,0.907,0.993,['Moderate'],,Yes,No,No,,Unclear,Yes,Yes,,Heather F Gidding,Children's Hospital at Westmead,Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.5694/mja2.50940,2021-03-19,2022-07-16,Unverified,gidding_seroprevalence_2021,AUS
210203_Sydney_Children'sHospitalAtWestmead_AntenatalScreening_overall_age30-39,210203_Sydney_Children'sHospitalAtWestmead_AntenatalScreening,Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,New South Wales,Sydney,"pregnant women aged 20–39 years who had undergone routine antenatal screening from three large pri- vate pathology services (Douglass Hanly Moir Pathology, 4Cyte Pathology, Laverty Pathology)",,2020-05-04,2020-05-23,Pregnant or parturient women,Female,Adults (18-64 years),30.0,39.0,Age,30-39,336,0.011899999999999999,,,,,,,,Stratified probability,Author designed (IFA) - MULTIPLEXED,,IFA,,IgG,,Validated by independent authors/third party/non-developers,0.907,0.993,['Moderate'],,Yes,No,No,,Unclear,Yes,Yes,,Heather F Gidding,Children's Hospital at Westmead,Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.5694/mja2.50940,2021-03-19,2022-07-16,Unverified,gidding_seroprevalence_2021,AUS
210203_Sydney_Children'sHospitalAtWestmead_AntenatalScreening_overall_age20-29,210203_Sydney_Children'sHospitalAtWestmead_AntenatalScreening,Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,New South Wales,Sydney,"pregnant women aged 20–39 years who had undergone routine antenatal screening from three large pri- vate pathology services (Douglass Hanly Moir Pathology, 4Cyte Pathology, Laverty Pathology)",,2020-05-04,2020-05-23,Pregnant or parturient women,Female,Adults (18-64 years),20.0,29.0,Age,20-29,224,0.013300000000000001,,,,,,,,Stratified probability,Author designed (IFA) - MULTIPLEXED,,IFA,,IgG,,Validated by independent authors/third party/non-developers,0.907,0.993,['Moderate'],,Yes,No,No,,Unclear,Yes,Yes,,Heather F Gidding,Children's Hospital at Westmead,Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.5694/mja2.50940,2021-03-19,2022-07-16,Unverified,gidding_seroprevalence_2021,AUS
210203_Sydney_Children'sHospitalAtWestmead_AntenatalScreening_overall_Neutralizationassay,210203_Sydney_Children'sHospitalAtWestmead_AntenatalScreening,Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,New South Wales,Sydney,"pregnant women aged 20–39 years who had undergone routine antenatal screening from three large pri- vate pathology services (Douglass Hanly Moir Pathology, 4Cyte Pathology, Laverty Pathology)",,2020-05-04,2020-05-23,Pregnant or parturient women,Female,Adults (18-64 years),20.0,39.0,Test used,Neutralization assay,7,0.71,,,,,,,,Stratified probability,Author designed (Neutralization Assay),,Neutralization,,TotalAntibody,,,,,['Moderate'],,Yes,No,No,,Unclear,Yes,Yes,,Heather F Gidding,Children's Hospital at Westmead,Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.5694/mja2.50940,2021-03-19,2022-07-16,Unverified,gidding_seroprevalence_2021,AUS
210203_Sydney_Children'sHospitalAtWestmead_GeneralPathology_overall_TestAdj,210203_Sydney_Children'sHospitalAtWestmead_GeneralPathology,Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,New South Wales,Sydney,"people of all ages who had provided blood for testing at se- lected diagnostic pathology services from six NSW Health pathology laboratories across Sydney and three large pri- vate pathology services (Douglass Hanly Moir Pathology, 4Cyte Pathology, Laverty Pathology)",General pathology specimens were excluded if they were collected from hospital inpatients (to exclude people possibly admitted with COVID-19) or if SARS- CoV-2 antibody testing had been specifically requested during collection (to reduce selection bias),2020-04-20,2020-05-22,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,3231,0.0015,0.0004,0.0040999999999999995,True,True,,,,Stratified probability,Author designed (IFA) - Unknown,,IFA,,IgG,,Validated by independent authors/third party/non-developers,0.907,0.993,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Heather F Gidding,Children's Hospital at Westmead,Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.5694/mja2.50940,2021-03-18,2022-07-16,Unverified,gidding_seroprevalence_2021,AUS
210203_Sydney_Children'sHospitalAtWestmead_GeneralPathology_age20-39_Test_Adj,210203_Sydney_Children'sHospitalAtWestmead_GeneralPathology,Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,New South Wales,Sydney,"people of all ages who had provided blood for testing at se- lected diagnostic pathology services from six NSW Health pathology laboratories across Sydney and three large pri- vate pathology services (Douglass Hanly Moir Pathology, 4Cyte Pathology, Laverty Pathology)",General pathology specimens were excluded if they were collected from hospital inpatients (to exclude people possibly admitted with COVID-19) or if SARS- CoV-2 antibody testing had been specifically requested during collection (to reduce selection bias),2020-04-20,2020-05-22,Residual sera,All,Adults (18-64 years),20.0,39.0,Age,20-39,701,0.0024,0.0004,0.008,,True,,,,Stratified probability,Author designed (IFA) - Unknown,,IFA,,IgG,,Validated by independent authors/third party/non-developers,0.907,0.993,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Heather F Gidding,Children's Hospital at Westmead,Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.5694/mja2.50940,2021-03-19,2022-07-16,Unverified,gidding_seroprevalence_2021,AUS
210203_Sydney_Children'sHospitalAtWestmead_GeneralPathology_overall_Unadj,210203_Sydney_Children'sHospitalAtWestmead_GeneralPathology,Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,New South Wales,Sydney,"people of all ages who had provided blood for testing at se- lected diagnostic pathology services from six NSW Health pathology laboratories across Sydney and three large pri- vate pathology services (Douglass Hanly Moir Pathology, 4Cyte Pathology, Laverty Pathology)",General pathology specimens were excluded if they were collected from hospital inpatients (to exclude people possibly admitted with COVID-19) or if SARS- CoV-2 antibody testing had been specifically requested during collection (to reduce selection bias),2020-04-20,2020-05-22,Residual sera,All,Multiple groups,0.0,,Analysis,Unadjusted estimate,3231,0.006,,,,,,,True,Stratified probability,Author designed (IFA) - Unknown,,IFA,,IgG,,Validated by independent authors/third party/non-developers,0.907,0.993,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Heather F Gidding,Children's Hospital at Westmead,Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.5694/mja2.50940,2021-03-18,2022-07-16,Unverified,gidding_seroprevalence_2021,AUS
210203_Sydney_Children'sHospitalAtWestmead_GeneralPathology_age20-69_TestAdj,210203_Sydney_Children'sHospitalAtWestmead_GeneralPathology,Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,New South Wales,Sydney,"people of all ages who had provided blood for testing at se- lected diagnostic pathology services from six NSW Health pathology laboratories across Sydney and three large pri- vate pathology services (Douglass Hanly Moir Pathology, 4Cyte Pathology, Laverty Pathology)",General pathology specimens were excluded if they were collected from hospital inpatients (to exclude people possibly admitted with COVID-19) or if SARS- CoV-2 antibody testing had been specifically requested during collection (to reduce selection bias),2020-04-20,2020-05-22,Residual sera,All,Adults (18-64 years),20.0,69.0,Age,20-69,1774,0.0025,0.0004,0.0068000000000000005,,True,,,,Stratified probability,Author designed (IFA) - Unknown,,IFA,,IgG,,Validated by independent authors/third party/non-developers,0.907,0.993,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Heather F Gidding,Children's Hospital at Westmead,Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.5694/mja2.50940,2021-03-19,2022-07-16,Unverified,gidding_seroprevalence_2021,AUS
210203_Sydney_Children'sHospitalAtWestmead_GeneralPathology_age0-9,210203_Sydney_Children'sHospitalAtWestmead_GeneralPathology,Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,New South Wales,Sydney,"people of all ages who had provided blood for testing at se- lected diagnostic pathology services from six NSW Health pathology laboratories across Sydney and three large pri- vate pathology services (Douglass Hanly Moir Pathology, 4Cyte Pathology, Laverty Pathology)",General pathology specimens were excluded if they were collected from hospital inpatients (to exclude people possibly admitted with COVID-19) or if SARS- CoV-2 antibody testing had been specifically requested during collection (to reduce selection bias),2020-04-20,2020-05-22,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,0-9,201,0.0,,,,,,,,Stratified probability,Author designed (IFA) - Unknown,,IFA,,IgG,,Validated by independent authors/third party/non-developers,0.907,0.993,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Heather F Gidding,Children's Hospital at Westmead,Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.5694/mja2.50940,2021-03-18,2022-07-16,Unverified,gidding_seroprevalence_2021,AUS
210203_Sydney_Children'sHospitalAtWestmead_GeneralPathology_age80+,210203_Sydney_Children'sHospitalAtWestmead_GeneralPathology,Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,New South Wales,Sydney,"people of all ages who had provided blood for testing at se- lected diagnostic pathology services from six NSW Health pathology laboratories across Sydney and three large pri- vate pathology services (Douglass Hanly Moir Pathology, 4Cyte Pathology, Laverty Pathology)",General pathology specimens were excluded if they were collected from hospital inpatients (to exclude people possibly admitted with COVID-19) or if SARS- CoV-2 antibody testing had been specifically requested during collection (to reduce selection bias),2020-04-20,2020-05-22,Residual sera,All,Seniors (65+ years),80.0,,Age,80+,437,0.0046,,,,,,,,Stratified probability,Author designed (IFA) - Unknown,,IFA,,IgG,,Validated by independent authors/third party/non-developers,0.907,0.993,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Heather F Gidding,Children's Hospital at Westmead,Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.5694/mja2.50940,2021-03-18,2022-07-16,Unverified,gidding_seroprevalence_2021,AUS
210203_Sydney_Children'sHospitalAtWestmead_GeneralPathology_Neutralization,210203_Sydney_Children'sHospitalAtWestmead_GeneralPathology,Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,New South Wales,Sydney,"people of all ages who had provided blood for testing at se- lected diagnostic pathology services from six NSW Health pathology laboratories across Sydney and three large pri- vate pathology services (Douglass Hanly Moir Pathology, 4Cyte Pathology, Laverty Pathology)",General pathology specimens were excluded if they were collected from hospital inpatients (to exclude people possibly admitted with COVID-19) or if SARS- CoV-2 antibody testing had been specifically requested during collection (to reduce selection bias),2020-04-20,2020-05-22,Residual sera,All,Multiple groups,0.0,,Test used,Neutralization assay,19,0.42,,,,,,,,Stratified probability,Author designed (Neutralization Assay),,Neutralization,,TotalAntibody,,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Heather F Gidding,Children's Hospital at Westmead,Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.5694/mja2.50940,2021-03-18,2022-07-16,Unverified,gidding_seroprevalence_2021,AUS
210203_Sydney_Children'sHospitalAtWestmead_GeneralPathology_age50-59,210203_Sydney_Children'sHospitalAtWestmead_GeneralPathology,Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,New South Wales,Sydney,"people of all ages who had provided blood for testing at se- lected diagnostic pathology services from six NSW Health pathology laboratories across Sydney and three large pri- vate pathology services (Douglass Hanly Moir Pathology, 4Cyte Pathology, Laverty Pathology)",General pathology specimens were excluded if they were collected from hospital inpatients (to exclude people possibly admitted with COVID-19) or if SARS- CoV-2 antibody testing had been specifically requested during collection (to reduce selection bias),2020-04-20,2020-05-22,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,367,0.0054,,,,,,,,Stratified probability,Author designed (IFA) - Unknown,,IFA,,IgG,,Validated by independent authors/third party/non-developers,0.907,0.993,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Heather F Gidding,Children's Hospital at Westmead,Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.5694/mja2.50940,2021-03-18,2022-07-16,Unverified,gidding_seroprevalence_2021,AUS
210203_Sydney_Children'sHospitalAtWestmead_GeneralPathology_age20-29,210203_Sydney_Children'sHospitalAtWestmead_GeneralPathology,Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,New South Wales,Sydney,"people of all ages who had provided blood for testing at se- lected diagnostic pathology services from six NSW Health pathology laboratories across Sydney and three large pri- vate pathology services (Douglass Hanly Moir Pathology, 4Cyte Pathology, Laverty Pathology)",General pathology specimens were excluded if they were collected from hospital inpatients (to exclude people possibly admitted with COVID-19) or if SARS- CoV-2 antibody testing had been specifically requested during collection (to reduce selection bias),2020-04-20,2020-05-22,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29,419,0.0072,,,,,,,,Stratified probability,Author designed (IFA) - Unknown,,IFA,,IgG,,Validated by independent authors/third party/non-developers,0.907,0.993,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Heather F Gidding,Children's Hospital at Westmead,Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.5694/mja2.50940,2021-03-18,2022-07-16,Unverified,gidding_seroprevalence_2021,AUS
210203_Sydney_Children'sHospitalAtWestmead_GeneralPathology_male,210203_Sydney_Children'sHospitalAtWestmead_GeneralPathology,Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,New South Wales,Sydney,"people of all ages who had provided blood for testing at se- lected diagnostic pathology services from six NSW Health pathology laboratories across Sydney and three large pri- vate pathology services (Douglass Hanly Moir Pathology, 4Cyte Pathology, Laverty Pathology)",General pathology specimens were excluded if they were collected from hospital inpatients (to exclude people possibly admitted with COVID-19) or if SARS- CoV-2 antibody testing had been specifically requested during collection (to reduce selection bias),2020-04-20,2020-05-22,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,male,1518,0.006600000000000001,,,,,,,,Stratified probability,Author designed (IFA) - Unknown,,IFA,,IgG,,Validated by independent authors/third party/non-developers,0.907,0.993,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Heather F Gidding,Children's Hospital at Westmead,Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.5694/mja2.50940,2021-03-18,2022-07-16,Unverified,gidding_seroprevalence_2021,AUS
210203_Sydney_Children'sHospitalAtWestmead_GeneralPathology_female,210203_Sydney_Children'sHospitalAtWestmead_GeneralPathology,Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,New South Wales,Sydney,"people of all ages who had provided blood for testing at se- lected diagnostic pathology services from six NSW Health pathology laboratories across Sydney and three large pri- vate pathology services (Douglass Hanly Moir Pathology, 4Cyte Pathology, Laverty Pathology)",General pathology specimens were excluded if they were collected from hospital inpatients (to exclude people possibly admitted with COVID-19) or if SARS- CoV-2 antibody testing had been specifically requested during collection (to reduce selection bias),2020-04-20,2020-05-22,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,female,1713,0.00525,,,,,,,,Stratified probability,Author designed (IFA) - Unknown,,IFA,,IgG,,Validated by independent authors/third party/non-developers,0.907,0.993,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Heather F Gidding,Children's Hospital at Westmead,Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.5694/mja2.50940,2021-03-18,2022-07-16,Unverified,gidding_seroprevalence_2021,AUS
210203_Sydney_Children'sHospitalAtWestmead_GeneralPathology_age70-79,210203_Sydney_Children'sHospitalAtWestmead_GeneralPathology,Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,New South Wales,Sydney,"people of all ages who had provided blood for testing at se- lected diagnostic pathology services from six NSW Health pathology laboratories across Sydney and three large pri- vate pathology services (Douglass Hanly Moir Pathology, 4Cyte Pathology, Laverty Pathology)",General pathology specimens were excluded if they were collected from hospital inpatients (to exclude people possibly admitted with COVID-19) or if SARS- CoV-2 antibody testing had been specifically requested during collection (to reduce selection bias),2020-04-20,2020-05-22,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,350,0.0086,,,,,,,,Stratified probability,Author designed (IFA) - Unknown,,IFA,,IgG,,Validated by independent authors/third party/non-developers,0.907,0.993,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Heather F Gidding,Children's Hospital at Westmead,Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.5694/mja2.50940,2021-03-18,2022-07-16,Unverified,gidding_seroprevalence_2021,AUS
210203_Sydney_Children'sHospitalAtWestmead_GeneralPathology_age40-49,210203_Sydney_Children'sHospitalAtWestmead_GeneralPathology,Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,New South Wales,Sydney,"people of all ages who had provided blood for testing at se- lected diagnostic pathology services from six NSW Health pathology laboratories across Sydney and three large pri- vate pathology services (Douglass Hanly Moir Pathology, 4Cyte Pathology, Laverty Pathology)",General pathology specimens were excluded if they were collected from hospital inpatients (to exclude people possibly admitted with COVID-19) or if SARS- CoV-2 antibody testing had been specifically requested during collection (to reduce selection bias),2020-04-20,2020-05-22,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,357,0.0084,,,,,,,,Stratified probability,Author designed (IFA) - Unknown,,IFA,,IgG,,Validated by independent authors/third party/non-developers,0.907,0.993,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Heather F Gidding,Children's Hospital at Westmead,Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.5694/mja2.50940,2021-03-18,2022-07-16,Unverified,gidding_seroprevalence_2021,AUS
210203_Sydney_Children'sHospitalAtWestmead_GeneralPathology_age10-19,210203_Sydney_Children'sHospitalAtWestmead_GeneralPathology,Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,New South Wales,Sydney,"people of all ages who had provided blood for testing at se- lected diagnostic pathology services from six NSW Health pathology laboratories across Sydney and three large pri- vate pathology services (Douglass Hanly Moir Pathology, 4Cyte Pathology, Laverty Pathology)",General pathology specimens were excluded if they were collected from hospital inpatients (to exclude people possibly admitted with COVID-19) or if SARS- CoV-2 antibody testing had been specifically requested during collection (to reduce selection bias),2020-04-20,2020-05-22,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,469,0.0043,,,,,,,,Stratified probability,Author designed (IFA) - Unknown,,IFA,,IgG,,Validated by independent authors/third party/non-developers,0.907,0.993,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Heather F Gidding,Children's Hospital at Westmead,Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.5694/mja2.50940,2021-03-18,2022-07-16,Unverified,gidding_seroprevalence_2021,AUS
210203_Sydney_Children'sHospitalAtWestmead_GeneralPathology_age60-69,210203_Sydney_Children'sHospitalAtWestmead_GeneralPathology,Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,New South Wales,Sydney,"people of all ages who had provided blood for testing at se- lected diagnostic pathology services from six NSW Health pathology laboratories across Sydney and three large pri- vate pathology services (Douglass Hanly Moir Pathology, 4Cyte Pathology, Laverty Pathology)",General pathology specimens were excluded if they were collected from hospital inpatients (to exclude people possibly admitted with COVID-19) or if SARS- CoV-2 antibody testing had been specifically requested during collection (to reduce selection bias),2020-04-20,2020-05-22,Residual sera,All,Adults (18-64 years),60.0,69.0,Age,60-69,349,0.0143,,,,,,,,Stratified probability,Author designed (IFA) - Unknown,,IFA,,IgG,,Validated by independent authors/third party/non-developers,0.907,0.993,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Heather F Gidding,Children's Hospital at Westmead,Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.5694/mja2.50940,2021-03-18,2022-07-16,Unverified,gidding_seroprevalence_2021,AUS
210203_Sydney_Children'sHospitalAtWestmead_GeneralPathology_age30-39,210203_Sydney_Children'sHospitalAtWestmead_GeneralPathology,Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,New South Wales,Sydney,"people of all ages who had provided blood for testing at se- lected diagnostic pathology services from six NSW Health pathology laboratories across Sydney and three large pri- vate pathology services (Douglass Hanly Moir Pathology, 4Cyte Pathology, Laverty Pathology)",General pathology specimens were excluded if they were collected from hospital inpatients (to exclude people possibly admitted with COVID-19) or if SARS- CoV-2 antibody testing had been specifically requested during collection (to reduce selection bias),2020-04-20,2020-05-22,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,282,0.0,,,,,,,,Stratified probability,Author designed (IFA) - Unknown,,IFA,,IgG,,Validated by independent authors/third party/non-developers,0.907,0.993,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Heather F Gidding,Children's Hospital at Westmead,Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.5694/mja2.50940,2021-03-18,2022-07-16,Unverified,gidding_seroprevalence_2021,AUS
210203_Sydney_Children'sHospitalAtWestmead_PlasmapheresisDonors_overall_TestAdj,210203_Sydney_Children'sHospitalAtWestmead_PlasmapheresisDonors,Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,New South Wales,Sydney," Australian Red Cross Lifeblood plasmapheresis donors, a healthy adult population aged 20–69 years.",Samples from blood donors actively recruited to donate convalescent plasma after diagnosis with COVID-19 were also excluded,2020-05-05,2020-06-02,Blood donors,All,Adults (18-64 years),20.0,69.0,Primary Estimate,,1548,0.0029,0.0004,0.0075,True,True,,,,Stratified probability,Author designed (IFA) - Unknown,,Other,,IgG,,Validated by independent authors/third party/non-developers,0.907,0.993,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Heather F Gidding,Children's Hospital at Westmead,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.5694/mja2.50940,2021-03-19,2022-07-16,Unverified,gidding_seroprevalence_2021,AUS
210203_Sydney_Children'sHospitalAtWestmead_PlasmapheresisDonors_age20-39_TestAdj,210203_Sydney_Children'sHospitalAtWestmead_PlasmapheresisDonors,Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,New South Wales,Sydney," Australian Red Cross Lifeblood plasmapheresis donors, a healthy adult population aged 20–69 years.",Samples from blood donors actively recruited to donate convalescent plasma after diagnosis with COVID-19 were also excluded,2020-05-05,2020-06-02,Blood donors,All,Adults (18-64 years),20.0,39.0,Age,20-39,753,0.0069,0.0004,0.0159,,True,,,,Stratified probability,Author designed (IFA) - Unknown,,Other,,IgG,,Validated by independent authors/third party/non-developers,0.907,0.993,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Heather F Gidding,Children's Hospital at Westmead,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.5694/mja2.50940,2021-03-19,2022-07-16,Unverified,gidding_seroprevalence_2021,AUS
210203_Sydney_Children'sHospitalAtWestmead_PlasmapheresisDonors_overall_Unadj,210203_Sydney_Children'sHospitalAtWestmead_PlasmapheresisDonors,Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,New South Wales,Sydney," Australian Red Cross Lifeblood plasmapheresis donors, a healthy adult population aged 20–69 years.",Samples from blood donors actively recruited to donate convalescent plasma after diagnosis with COVID-19 were also excluded,2020-05-05,2020-06-02,Blood donors,All,Adults (18-64 years),20.0,69.0,Analysis,Unadjusted,1548,0.008,,,,,,,True,Stratified probability,Author designed (IFA) - Unknown,,Other,,IgG,,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Heather F Gidding,Children's Hospital at Westmead,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.5694/mja2.50940,2021-03-19,2022-07-16,Unverified,gidding_seroprevalence_2021,AUS
210203_Sydney_Children'sHospitalAtWestmead_PlasmapheresisDonors_female,210203_Sydney_Children'sHospitalAtWestmead_PlasmapheresisDonors,Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,New South Wales,Sydney," Australian Red Cross Lifeblood plasmapheresis donors, a healthy adult population aged 20–69 years.",Samples from blood donors actively recruited to donate convalescent plasma after diagnosis with COVID-19 were also excluded,2020-05-05,2020-06-02,Blood donors,Female,Adults (18-64 years),20.0,69.0,Sex/Gender,female,807,0.0087,,,,,,,,Stratified probability,Author designed (IFA) - Unknown,,Other,,IgG,,Validated by independent authors/third party/non-developers,0.907,0.993,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Heather F Gidding,Children's Hospital at Westmead,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.5694/mja2.50940,2021-03-19,2022-07-16,Unverified,gidding_seroprevalence_2021,AUS
210203_Sydney_Children'sHospitalAtWestmead_PlasmapheresisDonors_age20-69_TestAdj,210203_Sydney_Children'sHospitalAtWestmead_PlasmapheresisDonors,Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,New South Wales,Sydney," Australian Red Cross Lifeblood plasmapheresis donors, a healthy adult population aged 20–69 years.",Samples from blood donors actively recruited to donate convalescent plasma after diagnosis with COVID-19 were also excluded,2020-05-05,2020-06-02,Blood donors,All,Adults (18-64 years),20.0,69.0,Age,20-69,1548,0.0029,0.0004,0.0075,,True,,,,Stratified probability,Author designed (IFA) - Unknown,,Other,,IgG,,Validated by independent authors/third party/non-developers,0.907,0.993,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Heather F Gidding,Children's Hospital at Westmead,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.5694/mja2.50940,2021-03-19,2022-07-16,Unverified,gidding_seroprevalence_2021,AUS
210203_Sydney_Children'sHospitalAtWestmead_PlasmapheresisDonors_age60-69,210203_Sydney_Children'sHospitalAtWestmead_PlasmapheresisDonors,Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,New South Wales,Sydney," Australian Red Cross Lifeblood plasmapheresis donors, a healthy adult population aged 20–69 years.",Samples from blood donors actively recruited to donate convalescent plasma after diagnosis with COVID-19 were also excluded,2020-05-05,2020-06-02,Blood donors,All,Adults (18-64 years),60.0,69.0,Age,60-69,191,0.0,,,,,,,,Stratified probability,Author designed (IFA) - Unknown,,Other,,IgG,,Validated by independent authors/third party/non-developers,0.907,0.993,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Heather F Gidding,Children's Hospital at Westmead,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.5694/mja2.50940,2021-03-19,2022-07-16,Unverified,gidding_seroprevalence_2021,AUS
210203_Sydney_Children'sHospitalAtWestmead_PlasmapheresisDonors_age30-39,210203_Sydney_Children'sHospitalAtWestmead_PlasmapheresisDonors,Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,New South Wales,Sydney," Australian Red Cross Lifeblood plasmapheresis donors, a healthy adult population aged 20–69 years.",Samples from blood donors actively recruited to donate convalescent plasma after diagnosis with COVID-19 were also excluded,2020-05-05,2020-06-02,Blood donors,All,Adults (18-64 years),30.0,39.0,Age,30-39,389,0.0026000000000000003,,,,,,,,Stratified probability,Author designed (IFA) - Unknown,,Other,,IgG,,Validated by independent authors/third party/non-developers,0.907,0.993,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Heather F Gidding,Children's Hospital at Westmead,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.5694/mja2.50940,2021-03-19,2022-07-16,Unverified,gidding_seroprevalence_2021,AUS
210203_Sydney_Children'sHospitalAtWestmead_PlasmapheresisDonors_age50-59,210203_Sydney_Children'sHospitalAtWestmead_PlasmapheresisDonors,Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,New South Wales,Sydney," Australian Red Cross Lifeblood plasmapheresis donors, a healthy adult population aged 20–69 years.",Samples from blood donors actively recruited to donate convalescent plasma after diagnosis with COVID-19 were also excluded,2020-05-05,2020-06-02,Blood donors,All,Adults (18-64 years),50.0,59.0,Age,50-59,287,0.0,,,,,,,,Stratified probability,Author designed (IFA) - Unknown,,Other,,IgG,,Validated by independent authors/third party/non-developers,0.907,0.993,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Heather F Gidding,Children's Hospital at Westmead,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.5694/mja2.50940,2021-03-19,2022-07-16,Unverified,gidding_seroprevalence_2021,AUS
210203_Sydney_Children'sHospitalAtWestmead_PlasmapheresisDonors_age40-49,210203_Sydney_Children'sHospitalAtWestmead_PlasmapheresisDonors,Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,New South Wales,Sydney," Australian Red Cross Lifeblood plasmapheresis donors, a healthy adult population aged 20–69 years.",Samples from blood donors actively recruited to donate convalescent plasma after diagnosis with COVID-19 were also excluded,2020-05-05,2020-06-02,Blood donors,All,Adults (18-64 years),40.0,49.0,Age,40-49,317,0.0095,,,,,,,,Stratified probability,Author designed (IFA) - Unknown,,Other,,IgG,,Validated by independent authors/third party/non-developers,0.907,0.993,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Heather F Gidding,Children's Hospital at Westmead,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.5694/mja2.50940,2021-03-19,2022-07-16,Unverified,gidding_seroprevalence_2021,AUS
210203_Sydney_Children'sHospitalAtWestmead_PlasmapheresisDonors_age20-29,210203_Sydney_Children'sHospitalAtWestmead_PlasmapheresisDonors,Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,New South Wales,Sydney," Australian Red Cross Lifeblood plasmapheresis donors, a healthy adult population aged 20–69 years.",Samples from blood donors actively recruited to donate convalescent plasma after diagnosis with COVID-19 were also excluded,2020-05-05,2020-06-02,Blood donors,All,Adults (18-64 years),20.0,29.0,Age,20-29,364,0.022000000000000002,,,,,,,,Stratified probability,Author designed (IFA) - Unknown,,Other,,IgG,,Validated by independent authors/third party/non-developers,0.907,0.993,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Heather F Gidding,Children's Hospital at Westmead,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.5694/mja2.50940,2021-03-19,2022-07-16,Unverified,gidding_seroprevalence_2021,AUS
210203_Sydney_Children'sHospitalAtWestmead_PlasmapheresisDonors_male,210203_Sydney_Children'sHospitalAtWestmead_PlasmapheresisDonors,Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,New South Wales,Sydney," Australian Red Cross Lifeblood plasmapheresis donors, a healthy adult population aged 20–69 years.",Samples from blood donors actively recruited to donate convalescent plasma after diagnosis with COVID-19 were also excluded,2020-05-05,2020-06-02,Blood donors,Male,Adults (18-64 years),20.0,69.0,Sex/Gender,male,741,0.0067,,,,,,,,Stratified probability,Author designed (IFA) - Unknown,,Other,,IgG,,Validated by independent authors/third party/non-developers,0.907,0.993,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Heather F Gidding,Children's Hospital at Westmead,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.5694/mja2.50940,2021-03-19,2022-07-16,Unverified,gidding_seroprevalence_2021,AUS
210703_Melbourne_RoyalChildrensHospital_Primary,210703_Melbourne_RoyalChildrensHospital,Seroprevalence of SARS-CoV-2 antibodies in health-care workers at a tertiary paediatric hospital.,2021-07-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,,Melbourne,All RCH HCWs at the Royal Children's Hospital were invited to participate between 21 and 30 October 2020.,NR ,2020-10-21,2020-10-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,318,0.0,,,True,,,,True,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,Anti-SARS-CoV-2 ELISA IgG,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Anti-SARS-CoV-2 ELISA IgA","DiaSorin,EUROIMMUN,GenScript,Beijing Wantai Biological",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,No,Unclear,Jane Tuckerman,Royal Children's Hospital,Not Unity-Aligned,https://dx.doi.org/10.1111/jpc.15585,2021-07-12,2024-03-01,Verified,tuckerman_seroprevalence_2021,AUS
210413_Melbourne_EasternHealth_OverallHCW,210413_Melbourne_EasternHealth,"SARS-CoV-2 seroprevalence in healthcare workers in a tertiary healthcare network in Victoria, Australia.",2021-08-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,Victoria,Melbourne,"any employee within EH, including subcontracted services such as cleaning and catering.",,2020-11-09,2020-12-04,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,Overall HCW,736,0.0217,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Author designed (Neutralization Assay),Author designed (ELISA) - Unknown","Roche Diagnostics,NA",Multiple Types,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Jillian SY Lau,Eastern Health,Not Unity-Aligned,https://dx.doi.org/10.1016/j.idh.2021.03.004,2021-05-19,2024-03-01,Verified,lau_sars-cov-2_2021,AUS
210413_Melbourne_EasternHealth_Age30Minus,210413_Melbourne_EasternHealth,"SARS-CoV-2 seroprevalence in healthcare workers in a tertiary healthcare network in Victoria, Australia.",2021-08-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,Victoria,Melbourne,"any employee within EH, including subcontracted services such as cleaning and catering.",,2020-11-09,2020-12-04,Health care workers and caregivers,All,Adults (18-64 years),,,Age,<30,152,0.0395,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Author designed (Neutralization Assay),Author designed (ELISA) - Unknown","Roche Diagnostics,NA",Multiple Types,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Jillian SY Lau,Eastern Health,Not Unity-Aligned,https://dx.doi.org/10.1016/j.idh.2021.03.004,2021-07-30,2024-03-01,Verified,lau_sars-cov-2_2021,AUS
210413_Melbourne_EasternHealth_Age3140,210413_Melbourne_EasternHealth,"SARS-CoV-2 seroprevalence in healthcare workers in a tertiary healthcare network in Victoria, Australia.",2021-08-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,Victoria,Melbourne,"any employee within EH, including subcontracted services such as cleaning and catering.",,2020-11-09,2020-12-04,Health care workers and caregivers,All,Adults (18-64 years),,,Age,3140,143,0.021,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Author designed (Neutralization Assay),Author designed (ELISA) - Unknown","Roche Diagnostics,NA",Multiple Types,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Jillian SY Lau,Eastern Health,Not Unity-Aligned,https://dx.doi.org/10.1016/j.idh.2021.03.004,2021-07-30,2024-03-01,Verified,lau_sars-cov-2_2021,AUS
210413_Melbourne_EasternHealth_Age60plus,210413_Melbourne_EasternHealth,"SARS-CoV-2 seroprevalence in healthcare workers in a tertiary healthcare network in Victoria, Australia.",2021-08-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,Victoria,Melbourne,"any employee within EH, including subcontracted services such as cleaning and catering.",,2020-11-09,2020-12-04,Health care workers and caregivers,All,Seniors (65+ years),,,Age,>60,90,0.0,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Author designed (Neutralization Assay),Author designed (ELISA) - Unknown","Roche Diagnostics,NA",Multiple Types,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Jillian SY Lau,Eastern Health,Not Unity-Aligned,https://dx.doi.org/10.1016/j.idh.2021.03.004,2021-07-30,2024-03-01,Verified,lau_sars-cov-2_2021,AUS
210413_Melbourne_EasternHealth_Age5160,210413_Melbourne_EasternHealth,"SARS-CoV-2 seroprevalence in healthcare workers in a tertiary healthcare network in Victoria, Australia.",2021-08-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,Victoria,Melbourne,"any employee within EH, including subcontracted services such as cleaning and catering.",,2020-11-09,2020-12-04,Health care workers and caregivers,All,Adults (18-64 years),,,Age,5160,186,0.0108,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Author designed (Neutralization Assay),Author designed (ELISA) - Unknown","Roche Diagnostics,NA",Multiple Types,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Jillian SY Lau,Eastern Health,Not Unity-Aligned,https://dx.doi.org/10.1016/j.idh.2021.03.004,2021-07-30,2024-03-01,Verified,lau_sars-cov-2_2021,AUS
210413_Melbourne_EasternHealth_Age4150,210413_Melbourne_EasternHealth,"SARS-CoV-2 seroprevalence in healthcare workers in a tertiary healthcare network in Victoria, Australia.",2021-08-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,Victoria,Melbourne,"any employee within EH, including subcontracted services such as cleaning and catering.",,2020-11-09,2020-12-04,Health care workers and caregivers,All,Adults (18-64 years),,,Age,4150,164,0.0305,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Author designed (Neutralization Assay),Author designed (ELISA) - Unknown","Roche Diagnostics,NA",Multiple Types,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Jillian SY Lau,Eastern Health,Not Unity-Aligned,https://dx.doi.org/10.1016/j.idh.2021.03.004,2021-07-30,2024-03-01,Verified,lau_sars-cov-2_2021,AUS
211111_Australia_NSWWestmeadHospital_Primary,211111_Australia_NSWWestmeadHospital,The utility of SARS-CoV-2-specific serology in COVID-19 diagnosis.,2021-11-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,"Australia (Western Australia, South Australia, Tasmania, Victoria
and the Australian Capital Territory) and countries (New Zealand)",,"individuals with clinical suspicion of recent or past COVID-19 throughout New South Wales as well as other states and territories (Western Australia, South Australia, Tasmania, Victoria and the Australian Capital Territory) and countries (New Zealand)

Serology was performed for the following reasons: a) highrisk
populations such as healthcare workers (HCW); b) close contacts of confirmed cases; c) international travel history; d) illness
without a clear alternate diagnosis or falsenegative NAT suspected; e) public health investigations to identify source of infection; f) identification of historical or asymptomatic cases; g) provide an estimate for the timing of infection in confirmed cases",,2020-01-24,2020-07-31,Multiple populations,All,Multiple groups,,,Primary Estimate,,10595,0.098,,,True,,,,True,Sequential,Author designed (IFA) - Unknown,,IFA,Serum,"['IgA', 'IgG', 'IgM']",,Validated by developers,0.913,0.9890000000000001,['High'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Tasnim Hasan,New South Wales Westmead Hospital,Not Unity-Aligned,https://dx.doi.org/10.1111/1753-6405.13155,2021-11-18,2022-07-16,Verified,hasan_utility_2021,AUS
220131_Australia_UniversityOfSydney_Antenatal_Overall_TestAdjustment,220131_Australia_UniversityOfSydney_Antenatal,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,,,"Specimens submitted for antenatal testing from pregnant females regardless of stage of pregnancy

Ages 20-39 were eligible",Nil,2020-06-19,2020-08-06,Pregnant or parturient women,Female,Adults (18-64 years),20.0,39.0,Primary Estimate,Test adjusted,2972,0.0023,0.0004,0.0054,True,True,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2023-08-15,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_Antenatal_AreaNT,220131_Australia_UniversityOfSydney_Antenatal,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Australia,Northern Territory,,"Specimens submitted for antenatal testing from pregnant females regardless of stage of pregnancy

Ages 20-39 were eligible",Nil,2020-06-19,2020-08-06,Pregnant or parturient women,Female,Adults (18-64 years),20.0,39.0,Geographical area,Northern Territory,134,0.0075,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_Antenatal_Age20to<30,220131_Australia_UniversityOfSydney_Antenatal,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,,,"Specimens submitted for antenatal testing from pregnant females regardless of stage of pregnancy

Ages 20-39 were eligible",Nil,2020-06-19,2020-08-06,Pregnant or parturient women,Female,Adults (18-64 years),20.0,29.0,Age,20-29,1434,0.0034999999999999996,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_Antenatal_AreaTAS,220131_Australia_UniversityOfSydney_Antenatal,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Australia,Tasmania,,"Specimens submitted for antenatal testing from pregnant females regardless of stage of pregnancy

Ages 20-39 were eligible",Nil,2020-06-19,2020-08-06,Pregnant or parturient women,Female,Adults (18-64 years),20.0,39.0,Geographical area,Tasmania,287,0.0034999999999999996,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_Antenatal_AreaVIC,220131_Australia_UniversityOfSydney_Antenatal,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Australia,Victoria,,"Specimens submitted for antenatal testing from pregnant females regardless of stage of pregnancy

Ages 20-39 were eligible",Nil,2020-06-19,2020-08-06,Pregnant or parturient women,Female,Adults (18-64 years),20.0,39.0,Geographical area,Victoria,389,0.0051,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_Antenatal_Overall_Crude,220131_Australia_UniversityOfSydney_Antenatal,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,,,"Specimens submitted for antenatal testing from pregnant females regardless of stage of pregnancy

Ages 20-39 were eligible",Nil,2020-06-19,2020-08-06,Pregnant or parturient women,Female,Adults (18-64 years),20.0,39.0,Analysis,Crude,2972,0.005,,,,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_Antenatal_Age30to<40,220131_Australia_UniversityOfSydney_Antenatal,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,,,"Specimens submitted for antenatal testing from pregnant females regardless of stage of pregnancy

Ages 20-39 were eligible",Nil,2020-06-19,2020-08-06,Pregnant or parturient women,Female,Adults (18-64 years),30.0,39.0,Age,,1538,0.006500000000000001,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_Antenatal_AreaQLD,220131_Australia_UniversityOfSydney_Antenatal,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Australia,Queensland,,"Specimens submitted for antenatal testing from pregnant females regardless of stage of pregnancy

Ages 20-39 were eligible",Nil,2020-06-19,2020-08-06,Pregnant or parturient women,Female,Adults (18-64 years),20.0,39.0,Geographical area,Queensland,397,0.005,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_Antenatal_AreaACT,220131_Australia_UniversityOfSydney_Antenatal,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Australia,Australian Capital Territory,,"Specimens submitted for antenatal testing from pregnant females regardless of stage of pregnancy

Ages 20-39 were eligible",Nil,2020-06-19,2020-08-06,Pregnant or parturient women,Female,Adults (18-64 years),20.0,39.0,Geographical area,Australian Capital Territory,311,0.0032,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_Antenatal_AreaWA,220131_Australia_UniversityOfSydney_Antenatal,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Australia,Western Australia,,"Specimens submitted for antenatal testing from pregnant females regardless of stage of pregnancy

Ages 20-39 were eligible",Nil,2020-06-19,2020-08-06,Pregnant or parturient women,Female,Adults (18-64 years),20.0,39.0,Geographical area,Western Australia,370,0.0,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_Antenatal_AreaNSW,220131_Australia_UniversityOfSydney_Antenatal,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Australia,New South Wales,,"Specimens submitted for antenatal testing from pregnant females regardless of stage of pregnancy

Ages 20-39 were eligible",Nil,2020-06-19,2020-08-06,Pregnant or parturient women,Female,Adults (18-64 years),20.0,39.0,Geographical area,New South Wales,732,0.010900000000000002,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_Antenatal_AreaSA,220131_Australia_UniversityOfSydney_Antenatal,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Australia,South Australia,,"Specimens submitted for antenatal testing from pregnant females regardless of stage of pregnancy

Ages 20-39 were eligible",Nil,2020-06-19,2020-08-06,Pregnant or parturient women,Female,Adults (18-64 years),20.0,39.0,Geographical area,South Australia,352,0.0,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_BloodDonors_Overall_TestAdjustment,220131_Australia_UniversityOfSydney_BloodDonors,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,,,"Specimens from blood donors

Ages 20-69 were eligible","Specimens from donors with a previous, self-reported COVID-19 infection who enrolled to donate for the first time after recovery from COVID-19 (ie, may have been recruited for convalescent plasma)",2020-06-19,2020-08-06,Blood donors,All,Multiple groups,20.0,69.0,Primary Estimate,Test adjusted,3213,0.0047,0.0004,0.0089,True,True,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2023-08-15,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_BloodDonors_Age60to<70,220131_Australia_UniversityOfSydney_BloodDonors,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,,,"Specimens from blood donors

Ages 20-69 were eligible","Specimens from donors with a previous, self-reported COVID-19 infection who enrolled to donate for the first time after recovery from COVID-19 (ie, may have been recruited for convalescent plasma)",2020-06-19,2020-08-06,Blood donors,All,Seniors (65+ years),60.0,69.0,Age,,630,0.0079,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_BloodDonors_SexFemale,220131_Australia_UniversityOfSydney_BloodDonors,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,,,"Specimens from blood donors

Ages 20-69 were eligible","Specimens from donors with a previous, self-reported COVID-19 infection who enrolled to donate for the first time after recovery from COVID-19 (ie, may have been recruited for convalescent plasma)",2020-06-19,2020-08-06,Blood donors,Female,Multiple groups,20.0,69.0,Sex/Gender,,1576,0.0095,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_BloodDonors_Age40to<50,220131_Australia_UniversityOfSydney_BloodDonors,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,,,"Specimens from blood donors

Ages 20-69 were eligible","Specimens from donors with a previous, self-reported COVID-19 infection who enrolled to donate for the first time after recovery from COVID-19 (ie, may have been recruited for convalescent plasma)",2020-06-19,2020-08-06,Blood donors,All,Adults (18-64 years),40.0,49.0,Age,,643,0.010900000000000002,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_BloodDonors_AreaTAS,220131_Australia_UniversityOfSydney_BloodDonors,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Australia,Tasmania,,"Specimens from blood donors

Ages 20-69 were eligible","Specimens from donors with a previous, self-reported COVID-19 infection who enrolled to donate for the first time after recovery from COVID-19 (ie, may have been recruited for convalescent plasma)",2020-06-19,2020-08-06,Blood donors,All,Multiple groups,20.0,69.0,Geographical area,Tasmania,334,0.009000000000000001,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_BloodDonors_SexMale,220131_Australia_UniversityOfSydney_BloodDonors,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,,,"Specimens from blood donors

Ages 20-69 were eligible","Specimens from donors with a previous, self-reported COVID-19 infection who enrolled to donate for the first time after recovery from COVID-19 (ie, may have been recruited for convalescent plasma)",2020-06-19,2020-08-06,Blood donors,Male,Multiple groups,20.0,69.0,Sex/Gender,,1637,0.0073,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_BloodDonors_Age20to<30,220131_Australia_UniversityOfSydney_BloodDonors,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,,,"Specimens from blood donors

Ages 20-69 were eligible","Specimens from donors with a previous, self-reported COVID-19 infection who enrolled to donate for the first time after recovery from COVID-19 (ie, may have been recruited for convalescent plasma)",2020-06-19,2020-08-06,Blood donors,All,Adults (18-64 years),20.0,29.0,Age,20-29,643,0.0078000000000000005,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_BloodDonors_Age50to<60,220131_Australia_UniversityOfSydney_BloodDonors,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,,,"Specimens from blood donors

Ages 20-69 were eligible","Specimens from donors with a previous, self-reported COVID-19 infection who enrolled to donate for the first time after recovery from COVID-19 (ie, may have been recruited for convalescent plasma)",2020-06-19,2020-08-06,Blood donors,All,Adults (18-64 years),50.0,59.0,Age,,639,0.0094,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_BloodDonors_Age30to<40,220131_Australia_UniversityOfSydney_BloodDonors,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,,,"Specimens from blood donors

Ages 20-69 were eligible","Specimens from donors with a previous, self-reported COVID-19 infection who enrolled to donate for the first time after recovery from COVID-19 (ie, may have been recruited for convalescent plasma)",2020-06-19,2020-08-06,Blood donors,All,Adults (18-64 years),30.0,39.0,Age,,658,0.0061,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_BloodDonors_AreaVIC,220131_Australia_UniversityOfSydney_BloodDonors,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Australia,Victoria,,"Specimens from blood donors

Ages 20-69 were eligible","Specimens from donors with a previous, self-reported COVID-19 infection who enrolled to donate for the first time after recovery from COVID-19 (ie, may have been recruited for convalescent plasma)",2020-06-19,2020-08-06,Blood donors,All,Multiple groups,20.0,69.0,Geographical area,Victoria,503,0.006,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_BloodDonors_AreaWA,220131_Australia_UniversityOfSydney_BloodDonors,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Australia,Western Australia,,"Specimens from blood donors

Ages 20-69 were eligible","Specimens from donors with a previous, self-reported COVID-19 infection who enrolled to donate for the first time after recovery from COVID-19 (ie, may have been recruited for convalescent plasma)",2020-06-19,2020-08-06,Blood donors,All,Multiple groups,20.0,69.0,Geographical area,Western Australia,347,0.0144,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_BloodDonors_AreaNT,220131_Australia_UniversityOfSydney_BloodDonors,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Australia,Northern Territory,,"Specimens from blood donors

Ages 20-69 were eligible","Specimens from donors with a previous, self-reported COVID-19 infection who enrolled to donate for the first time after recovery from COVID-19 (ie, may have been recruited for convalescent plasma)",2020-06-19,2020-08-06,Blood donors,All,Multiple groups,20.0,69.0,Geographical area,Northern Territory,368,0.0054,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_BloodDonors_Overall_Crude,220131_Australia_UniversityOfSydney_BloodDonors,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,,,"Specimens from blood donors

Ages 20-69 were eligible","Specimens from donors with a previous, self-reported COVID-19 infection who enrolled to donate for the first time after recovery from COVID-19 (ie, may have been recruited for convalescent plasma)",2020-06-19,2020-08-06,Blood donors,All,Multiple groups,20.0,69.0,Analysis,Crude,3213,0.0084,,,,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_BloodDonors_AreaNSW,220131_Australia_UniversityOfSydney_BloodDonors,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Australia,New South Wales,,"Specimens from blood donors

Ages 20-69 were eligible","Specimens from donors with a previous, self-reported COVID-19 infection who enrolled to donate for the first time after recovery from COVID-19 (ie, may have been recruited for convalescent plasma)",2020-06-19,2020-08-06,Blood donors,All,Multiple groups,20.0,69.0,Geographical area,New South Wales,581,0.0103,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_BloodDonors_AreaACT,220131_Australia_UniversityOfSydney_BloodDonors,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Australia,Australian Capital Territory,,"Specimens from blood donors

Ages 20-69 were eligible","Specimens from donors with a previous, self-reported COVID-19 infection who enrolled to donate for the first time after recovery from COVID-19 (ie, may have been recruited for convalescent plasma)",2020-06-19,2020-08-06,Blood donors,All,Multiple groups,20.0,69.0,Geographical area,Australian Capital Territory,351,0.011399999999999999,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_BloodDonors_AreaSA,220131_Australia_UniversityOfSydney_BloodDonors,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Australia,South Australia,,"Specimens from blood donors

Ages 20-69 were eligible","Specimens from donors with a previous, self-reported COVID-19 infection who enrolled to donate for the first time after recovery from COVID-19 (ie, may have been recruited for convalescent plasma)",2020-06-19,2020-08-06,Blood donors,All,Multiple groups,20.0,69.0,Geographical area,South Australia,343,0.0,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_BloodDonors_AreaQLD,220131_Australia_UniversityOfSydney_BloodDonors,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Australia,Queensland,,"Specimens from blood donors

Ages 20-69 were eligible","Specimens from donors with a previous, self-reported COVID-19 infection who enrolled to donate for the first time after recovery from COVID-19 (ie, may have been recruited for convalescent plasma)",2020-06-19,2020-08-06,Blood donors,All,Multiple groups,20.0,69.0,Geographical area,Queensland,386,0.010400000000000001,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_GeneralPathology_Overall_TestAdjustment,220131_Australia_UniversityOfSydney_GeneralPathology,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,,,"Specimens collected for routine pathology testing at public and private laboratories (including hospital outpatient and emergency departments)

All ages were eligible",Specimens from hospital inpatients and specimens submitted for a SARS-CoV-2 antibody diagnostic test,2020-06-19,2020-08-06,Residual sera,All,Multiple groups,,,Primary Estimate,Test adjusted,5132,0.0025,0.0003,0.0054,True,True,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2023-08-15,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_GeneralPathology_Age0to<5,220131_Australia_UniversityOfSydney_GeneralPathology,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,,,"Specimens collected for routine pathology testing at public and private laboratories (including hospital outpatient and emergency departments)

All ages were eligible",Specimens from hospital inpatients and specimens submitted for a SARS-CoV-2 antibody diagnostic test,2020-06-19,2020-08-06,Residual sera,All,Children and Youth (0-17 years),0.0,4.0,Age,0-4,424,0.0047,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_GeneralPathology_AreaACT,220131_Australia_UniversityOfSydney_GeneralPathology,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Australia,Australian Capital Territory,,"Specimens collected for routine pathology testing at public and private laboratories (including hospital outpatient and emergency departments)

All ages were eligible",Specimens from hospital inpatients and specimens submitted for a SARS-CoV-2 antibody diagnostic test,2020-06-19,2020-08-06,Residual sera,All,Multiple groups,,,Geographical area,Australian Capital Territory,439,0.0023,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_GeneralPathology_Age80+,220131_Australia_UniversityOfSydney_GeneralPathology,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,,,"Specimens collected for routine pathology testing at public and private laboratories (including hospital outpatient and emergency departments)

All ages were eligible",Specimens from hospital inpatients and specimens submitted for a SARS-CoV-2 antibody diagnostic test,2020-06-19,2020-08-06,Residual sera,All,Seniors (65+ years),80.0,,Age,80+,378,0.0053,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_GeneralPathology_AreaTAS,220131_Australia_UniversityOfSydney_GeneralPathology,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Australia,Tasmania,,"Specimens collected for routine pathology testing at public and private laboratories (including hospital outpatient and emergency departments)

All ages were eligible",Specimens from hospital inpatients and specimens submitted for a SARS-CoV-2 antibody diagnostic test,2020-06-19,2020-08-06,Residual sera,All,Multiple groups,,,Geographical area,Tasmania,426,0.0047,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_GeneralPathology_AreaWA,220131_Australia_UniversityOfSydney_GeneralPathology,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Australia,Western Australia,,"Specimens collected for routine pathology testing at public and private laboratories (including hospital outpatient and emergency departments)

All ages were eligible",Specimens from hospital inpatients and specimens submitted for a SARS-CoV-2 antibody diagnostic test,2020-06-19,2020-08-06,Residual sera,All,Multiple groups,,,Geographical area,Western Australia,368,0.008199999999999999,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_GeneralPathology_Overall_Crude,220131_Australia_UniversityOfSydney_GeneralPathology,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,,,"Specimens collected for routine pathology testing at public and private laboratories (including hospital outpatient and emergency departments)

All ages were eligible",Specimens from hospital inpatients and specimens submitted for a SARS-CoV-2 antibody diagnostic test,2020-06-19,2020-08-06,Residual sera,All,Multiple groups,,,Analysis,Crude,5132,0.005699999999999999,,,,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_GeneralPathology_Age40to<50,220131_Australia_UniversityOfSydney_GeneralPathology,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,,,"Specimens collected for routine pathology testing at public and private laboratories (including hospital outpatient and emergency departments)

All ages were eligible",Specimens from hospital inpatients and specimens submitted for a SARS-CoV-2 antibody diagnostic test,2020-06-19,2020-08-06,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,,571,0.0053,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_GeneralPathology_SexMale,220131_Australia_UniversityOfSydney_GeneralPathology,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,,,"Specimens collected for routine pathology testing at public and private laboratories (including hospital outpatient and emergency departments)

All ages were eligible",Specimens from hospital inpatients and specimens submitted for a SARS-CoV-2 antibody diagnostic test,2020-06-19,2020-08-06,Residual sera,Male,Multiple groups,,,Sex/Gender,,2345,0.006,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_GeneralPathology_Age20to<30,220131_Australia_UniversityOfSydney_GeneralPathology,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,,,"Specimens collected for routine pathology testing at public and private laboratories (including hospital outpatient and emergency departments)

All ages were eligible",Specimens from hospital inpatients and specimens submitted for a SARS-CoV-2 antibody diagnostic test,2020-06-19,2020-08-06,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29,598,0.0067,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_GeneralPathology_Age10to<20,220131_Australia_UniversityOfSydney_GeneralPathology,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,,,"Specimens collected for routine pathology testing at public and private laboratories (including hospital outpatient and emergency departments)

All ages were eligible",Specimens from hospital inpatients and specimens submitted for a SARS-CoV-2 antibody diagnostic test,2020-06-19,2020-08-06,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,584,0.0068000000000000005,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_GeneralPathology_Age30to<40,220131_Australia_UniversityOfSydney_GeneralPathology,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,,,"Specimens collected for routine pathology testing at public and private laboratories (including hospital outpatient and emergency departments)

All ages were eligible",Specimens from hospital inpatients and specimens submitted for a SARS-CoV-2 antibody diagnostic test,2020-06-19,2020-08-06,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,,609,0.0049,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_GeneralPathology_Age5to<10,220131_Australia_UniversityOfSydney_GeneralPathology,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,,,"Specimens collected for routine pathology testing at public and private laboratories (including hospital outpatient and emergency departments)

All ages were eligible",Specimens from hospital inpatients and specimens submitted for a SARS-CoV-2 antibody diagnostic test,2020-06-19,2020-08-06,Residual sera,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,423,0.0047,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_GeneralPathology_SexFemale,220131_Australia_UniversityOfSydney_GeneralPathology,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,,,"Specimens collected for routine pathology testing at public and private laboratories (including hospital outpatient and emergency departments)

All ages were eligible",Specimens from hospital inpatients and specimens submitted for a SARS-CoV-2 antibody diagnostic test,2020-06-19,2020-08-06,Residual sera,Female,Multiple groups,,,Sex/Gender,,2787,0.0054,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_GeneralPathology_AreaSA,220131_Australia_UniversityOfSydney_GeneralPathology,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Australia,South Australia,,"Specimens collected for routine pathology testing at public and private laboratories (including hospital outpatient and emergency departments)

All ages were eligible",Specimens from hospital inpatients and specimens submitted for a SARS-CoV-2 antibody diagnostic test,2020-06-19,2020-08-06,Residual sera,All,Multiple groups,,,Geographical area,South Australia,354,0.0028000000000000004,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_GeneralPathology_Age50to<60,220131_Australia_UniversityOfSydney_GeneralPathology,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,,,"Specimens collected for routine pathology testing at public and private laboratories (including hospital outpatient and emergency departments)

All ages were eligible",Specimens from hospital inpatients and specimens submitted for a SARS-CoV-2 antibody diagnostic test,2020-06-19,2020-08-06,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,,552,0.0072,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_GeneralPathology_Age70to<80,220131_Australia_UniversityOfSydney_GeneralPathology,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,,,"Specimens collected for routine pathology testing at public and private laboratories (including hospital outpatient and emergency departments)

All ages were eligible",Specimens from hospital inpatients and specimens submitted for a SARS-CoV-2 antibody diagnostic test,2020-06-19,2020-08-06,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,467,0.0086,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_GeneralPathology_AreaNT,220131_Australia_UniversityOfSydney_GeneralPathology,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Australia,Northern Territory,,"Specimens collected for routine pathology testing at public and private laboratories (including hospital outpatient and emergency departments)

All ages were eligible",Specimens from hospital inpatients and specimens submitted for a SARS-CoV-2 antibody diagnostic test,2020-06-19,2020-08-06,Residual sera,All,Multiple groups,,,Geographical area,Northern Territory,319,0.015700000000000002,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_GeneralPathology_AreaNSW,220131_Australia_UniversityOfSydney_GeneralPathology,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Australia,New South Wales,,"Specimens collected for routine pathology testing at public and private laboratories (including hospital outpatient and emergency departments)

All ages were eligible",Specimens from hospital inpatients and specimens submitted for a SARS-CoV-2 antibody diagnostic test,2020-06-19,2020-08-06,Residual sera,All,Multiple groups,,,Geographical area,New South Wales,1285,0.006999999999999999,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_GeneralPathology_Age60to<70,220131_Australia_UniversityOfSydney_GeneralPathology,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,,,"Specimens collected for routine pathology testing at public and private laboratories (including hospital outpatient and emergency departments)

All ages were eligible",Specimens from hospital inpatients and specimens submitted for a SARS-CoV-2 antibody diagnostic test,2020-06-19,2020-08-06,Residual sera,All,Seniors (65+ years),60.0,69.0,Age,,526,0.0019,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_GeneralPathology_AreaVIC,220131_Australia_UniversityOfSydney_GeneralPathology,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Australia,Victoria,,"Specimens collected for routine pathology testing at public and private laboratories (including hospital outpatient and emergency departments)

All ages were eligible",Specimens from hospital inpatients and specimens submitted for a SARS-CoV-2 antibody diagnostic test,2020-06-19,2020-08-06,Residual sera,All,Multiple groups,,,Geographical area,Victoria,1070,0.0047,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220131_Australia_UniversityOfSydney_GeneralPathology_AreaQLD,220131_Australia_UniversityOfSydney_GeneralPathology,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.,2022-01-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Australia,Queensland,,"Specimens collected for routine pathology testing at public and private laboratories (including hospital outpatient and emergency departments)

All ages were eligible",Specimens from hospital inpatients and specimens submitted for a SARS-CoV-2 antibody diagnostic test,2020-06-19,2020-08-06,Residual sera,All,Multiple groups,,,Geographical area,Queensland,871,0.0034000000000000002,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kaitlyn Vette,University of Sydney,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac002,2022-02-22,2024-03-01,Verified,vette_seroprevalence_2022,AUS
220313_Melbourne_UniversityofNewSouthWales_OverallPopTestAdjust,220313_Melbourne_UniversityofNewSouthWales,"Serological testing of blood donors to characterise the impact of COVID-19 in Melbourne, Australia, 2020",2022-03-13,Preprint,Local,Cross-sectional survey ,Australia,Victoria,Metropolitan Melbourne,residual specimens provided by blood donors from three groups of Melbourne metropolitan postcodes of residence defined by COVID-19 case notification data from the start of the pandemic to 28 October 2020 [8].,,2020-11-23,2020-12-17,Blood donors,All,Adults (18-64 years),20.0,69.0,Primary Estimate,,4799,0.009000000000000001,,,True,True,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Dorothy Machalek,University of New South Wales,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.11.22272185v1.full-text,2022-03-21,2023-08-15,Verified,machalek_serological_2022,AUS
220313_Melbourne_UniversityofNewSouthWales_SexFemale,220313_Melbourne_UniversityofNewSouthWales,"Serological testing of blood donors to characterise the impact of COVID-19 in Melbourne, Australia, 2020",2022-03-13,Preprint,Local,Cross-sectional survey ,Australia,Victoria,Metropolitan Melbourne,residual specimens provided by blood donors from three groups of Melbourne metropolitan postcodes of residence defined by COVID-19 case notification data from the start of the pandemic to 28 October 2020 [8].,,2020-11-23,2020-12-17,Blood donors,Female,Adults (18-64 years),20.0,69.0,Sex/Gender,,2400,0.0146,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Dorothy Machalek,University of New South Wales,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.11.22272185v1.full-text,2022-03-21,2024-03-01,Verified,machalek_serological_2022,AUS
220313_Melbourne_UniversityofNewSouthWales_Age50-59,220313_Melbourne_UniversityofNewSouthWales,"Serological testing of blood donors to characterise the impact of COVID-19 in Melbourne, Australia, 2020",2022-03-13,Preprint,Local,Cross-sectional survey ,Australia,Victoria,Metropolitan Melbourne,residual specimens provided by blood donors from three groups of Melbourne metropolitan postcodes of residence defined by COVID-19 case notification data from the start of the pandemic to 28 October 2020 [8].,,2020-11-23,2020-12-17,Blood donors,All,Adults (18-64 years),50.0,59.0,Age,,760,0.014499999999999999,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Dorothy Machalek,University of New South Wales,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.11.22272185v1.full-text,2022-03-21,2024-03-01,Verified,machalek_serological_2022,AUS
220313_Melbourne_UniversityofNewSouthWales_Age60-69,220313_Melbourne_UniversityofNewSouthWales,"Serological testing of blood donors to characterise the impact of COVID-19 in Melbourne, Australia, 2020",2022-03-13,Preprint,Local,Cross-sectional survey ,Australia,Victoria,Metropolitan Melbourne,residual specimens provided by blood donors from three groups of Melbourne metropolitan postcodes of residence defined by COVID-19 case notification data from the start of the pandemic to 28 October 2020 [8].,,2020-11-23,2020-12-17,Blood donors,All,Adults (18-64 years),60.0,69.0,Age,,512,0.0195,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Dorothy Machalek,University of New South Wales,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.11.22272185v1.full-text,2022-03-21,2024-03-01,Verified,machalek_serological_2022,AUS
220313_Melbourne_UniversityofNewSouthWales_SexMale,220313_Melbourne_UniversityofNewSouthWales,"Serological testing of blood donors to characterise the impact of COVID-19 in Melbourne, Australia, 2020",2022-03-13,Preprint,Local,Cross-sectional survey ,Australia,Victoria,Metropolitan Melbourne,residual specimens provided by blood donors from three groups of Melbourne metropolitan postcodes of residence defined by COVID-19 case notification data from the start of the pandemic to 28 October 2020 [8].,,2020-11-23,2020-12-17,Blood donors,Male,Adults (18-64 years),20.0,69.0,Sex/Gender,,2399,0.0175,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Dorothy Machalek,University of New South Wales,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.11.22272185v1.full-text,2022-03-21,2024-03-01,Verified,machalek_serological_2022,AUS
220313_Melbourne_UniversityofNewSouthWales_OverallCrude,220313_Melbourne_UniversityofNewSouthWales,"Serological testing of blood donors to characterise the impact of COVID-19 in Melbourne, Australia, 2020",2022-03-13,Preprint,Local,Cross-sectional survey ,Australia,Victoria,Metropolitan Melbourne,residual specimens provided by blood donors from three groups of Melbourne metropolitan postcodes of residence defined by COVID-19 case notification data from the start of the pandemic to 28 October 2020 [8].,,2020-11-23,2020-12-17,Blood donors,All,Adults (18-64 years),20.0,69.0,Analysis,,4799,0.016,,,,,,,True,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Dorothy Machalek,University of New South Wales,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.11.22272185v1.full-text,2022-03-21,2024-03-01,Verified,machalek_serological_2022,AUS
220313_Melbourne_UniversityofNewSouthWales_Age40-49,220313_Melbourne_UniversityofNewSouthWales,"Serological testing of blood donors to characterise the impact of COVID-19 in Melbourne, Australia, 2020",2022-03-13,Preprint,Local,Cross-sectional survey ,Australia,Victoria,Metropolitan Melbourne,residual specimens provided by blood donors from three groups of Melbourne metropolitan postcodes of residence defined by COVID-19 case notification data from the start of the pandemic to 28 October 2020 [8].,,2020-11-23,2020-12-17,Blood donors,All,Adults (18-64 years),40.0,49.0,Age,,916,0.010900000000000002,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Dorothy Machalek,University of New South Wales,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.11.22272185v1.full-text,2022-03-21,2024-03-01,Verified,machalek_serological_2022,AUS
220313_Melbourne_UniversityofNewSouthWales_Age30-39,220313_Melbourne_UniversityofNewSouthWales,"Serological testing of blood donors to characterise the impact of COVID-19 in Melbourne, Australia, 2020",2022-03-13,Preprint,Local,Cross-sectional survey ,Australia,Victoria,Metropolitan Melbourne,residual specimens provided by blood donors from three groups of Melbourne metropolitan postcodes of residence defined by COVID-19 case notification data from the start of the pandemic to 28 October 2020 [8].,,2020-11-23,2020-12-17,Blood donors,All,Adults (18-64 years),30.0,39.0,Age,,1309,0.016,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Dorothy Machalek,University of New South Wales,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.11.22272185v1.full-text,2022-03-21,2024-03-01,Verified,machalek_serological_2022,AUS
220313_Melbourne_UniversityofNewSouthWales_Age20-29,220313_Melbourne_UniversityofNewSouthWales,"Serological testing of blood donors to characterise the impact of COVID-19 in Melbourne, Australia, 2020",2022-03-13,Preprint,Local,Cross-sectional survey ,Australia,Victoria,Metropolitan Melbourne,residual specimens provided by blood donors from three groups of Melbourne metropolitan postcodes of residence defined by COVID-19 case notification data from the start of the pandemic to 28 October 2020 [8].,,2020-11-23,2020-12-17,Blood donors,All,Adults (18-64 years),20.0,29.0,Age,20-29,1302,0.0192,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Dorothy Machalek,University of New South Wales,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.11.22272185v1.full-text,2022-03-21,2024-03-01,Verified,machalek_serological_2022,AUS
220416_NewSouthWales_DouglassHanlyMoirPathology,220416_NewSouthWales_DouglassHanlyMoirPathology,"SARS-CoV-2 IgM testing for travellers: a private pathology perspective from New South Wales and the Australian Capital Territory, Australia.",2022-04-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,New South Wales and the Australian Capital Territory,,"""We undertook a retrospective audit of all serology performed in our two laboratories between 9 July 2020 and19 September 2021 with a particular focus on those requiring evaluation prior to travel.""",,2020-07-09,2021-09-19,Residual sera,All,Multiple groups,,,Primary Estimate,,545,0.084,,,True,,,,True,Sequential,"Elecsys® Anti‐SARS‐CoV‐2 (S),Architect Anti-SARS-CoV-2 IgM","Roche Diagnostics,Abbott Laboratories",CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Unclear,No,No,,Michael Wehrhahn,Douglass Hanly Moir Pathology,Not Unity-Aligned,https://dx.doi.org/10.1016/j.pathol.2022.03.001,2022-04-29,2024-03-01,Unverified,wehrhahn_sars-cov-2_2022,AUS
220521_Australia_UniversityOfSydney_ELISA_TestAdj_Overall,220521_Australia_UniversityOfSydney,"The seroprevalence of SARS-CoV-2-specific antibodies in children, Australia, November 2020 - March 2021.",2022-05-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,Queensland; New South Wales; Victoria; South Australia; Western Australia.,Brisbane; Sydney; Melbourne; Adelaide; Perth.,"""We assessed the seroprevalence of SARS- CoV-2specific antibodies in children aged 0–19 years in blood opportunistically collected during anaesthesia from patients undergoing elective surgery at seven hospitals in the Paediatric Active Enhanced Disease Surveillance network""","""Four of 1689 blood specimens were excluded because the children lived outside the five states included in our study.""",2020-11-03,2021-03-12,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Primary Estimate,Test adjusted,1685,0.0023,0.0006,0.005699999999999999,True,True,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Archana Koirala,University of Sydney,Unity-Aligned,https://dx.doi.org/10.5694/mja2.51542,2022-06-04,2024-03-22,Verified,koirala_seroprevalence_2022,AUS
220521_Australia_UniversityOfSydney_ELISA_Crude_NewSouthWales_Sydney,220521_Australia_UniversityOfSydney,"The seroprevalence of SARS-CoV-2-specific antibodies in children, Australia, November 2020 - March 2021.",2022-05-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,New South Wales,Sydney,"""We assessed the seroprevalence of SARS- CoV-2specific antibodies in children aged 0–19 years in blood opportunistically collected during anaesthesia from patients undergoing elective surgery at seven hospitals in the Paediatric Active Enhanced Disease Surveillance network""","""Four of 1689 blood specimens were excluded because the children lived outside the five states included in our study.""",2020-11-03,2021-03-12,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Geographical area,State: New South Wales,462,0.006500000000000001,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Archana Koirala,University of Sydney,Unity-Aligned,https://dx.doi.org/10.5694/mja2.51542,2022-06-04,2024-03-22,Verified,koirala_seroprevalence_2022,AUS
220521_Australia_UniversityOfSydney_ELISA_Crude_Age_5-9,220521_Australia_UniversityOfSydney,"The seroprevalence of SARS-CoV-2-specific antibodies in children, Australia, November 2020 - March 2021.",2022-05-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,Queensland; New South Wales; Victoria; South Australia; Western Australia.,Brisbane; Sydney; Melbourne; Adelaide; Perth.,"""We assessed the seroprevalence of SARS- CoV-2specific antibodies in children aged 0–19 years in blood opportunistically collected during anaesthesia from patients undergoing elective surgery at seven hospitals in the Paediatric Active Enhanced Disease Surveillance network""","""Four of 1689 blood specimens were excluded because the children lived outside the five states included in our study.""",2020-11-03,2021-03-12,Residual sera,All,Children and Youth (0-17 years),5.0,9.0,Age,Age: 5-9,494,0.002,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Archana Koirala,University of Sydney,Unity-Aligned,https://dx.doi.org/10.5694/mja2.51542,2022-06-04,2024-03-22,Verified,koirala_seroprevalence_2022,AUS
220521_Australia_UniversityOfSydney_ELISA_Crude_WesternAustralia_Perth,220521_Australia_UniversityOfSydney,"The seroprevalence of SARS-CoV-2-specific antibodies in children, Australia, November 2020 - March 2021.",2022-05-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,Western Australia,Perth,"""We assessed the seroprevalence of SARS- CoV-2specific antibodies in children aged 0–19 years in blood opportunistically collected during anaesthesia from patients undergoing elective surgery at seven hospitals in the Paediatric Active Enhanced Disease Surveillance network""","""Four of 1689 blood specimens were excluded because the children lived outside the five states included in our study.""",2020-11-03,2021-03-12,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Geographical area,State: Western Australia,97,0.0,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Archana Koirala,University of Sydney,Unity-Aligned,https://dx.doi.org/10.5694/mja2.51542,2022-06-04,2024-03-22,Verified,koirala_seroprevalence_2022,AUS
220521_Australia_UniversityOfSydney_ELISAandIFA_Crude_Overall,220521_Australia_UniversityOfSydney,"The seroprevalence of SARS-CoV-2-specific antibodies in children, Australia, November 2020 - March 2021.",2022-05-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,Queensland; New South Wales; Victoria; South Australia; Western Australia.,Brisbane; Sydney; Melbourne; Adelaide; Perth.,"""We assessed the seroprevalence of SARS- CoV-2specific antibodies in children aged 0–19 years in blood opportunistically collected during anaesthesia from patients undergoing elective surgery at seven hospitals in the Paediatric Active Enhanced Disease Surveillance network""","""Four of 1689 blood specimens were excluded because the children lived outside the five states included in our study.""",2020-11-03,2021-03-12,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Test used,"Test used: ELISA, then Immunofluorescent antibody",1685,0.0018,,,,,,,,Convenience,"Wantai SARS-CoV-2 Total Ab ELISA,Author designed (IFA) - Unknown","Beijing Wantai Biological,NA",Multiple Types,Serum,TotalAntibody,,Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Archana Koirala,University of Sydney,Unity-Aligned,https://dx.doi.org/10.5694/mja2.51542,2022-06-04,2024-03-22,Verified,koirala_seroprevalence_2022,AUS
220521_Australia_UniversityOfSydney_ELISAandMicroneutralisation_Crude_Overall,220521_Australia_UniversityOfSydney,"The seroprevalence of SARS-CoV-2-specific antibodies in children, Australia, November 2020 - March 2021.",2022-05-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,Queensland; New South Wales; Victoria; South Australia; Western Australia.,Brisbane; Sydney; Melbourne; Adelaide; Perth.,"""We assessed the seroprevalence of SARS- CoV-2specific antibodies in children aged 0–19 years in blood opportunistically collected during anaesthesia from patients undergoing elective surgery at seven hospitals in the Paediatric Active Enhanced Disease Surveillance network""","""Four of 1689 blood specimens were excluded because the children lived outside the five states included in our study.""",2020-11-03,2021-03-12,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Test used,"Test used: ELISA, then Microneutralisation",1685,0.0018,,,,,,,,Convenience,"Wantai SARS-CoV-2 Total Ab ELISA,Author designed (Neutralization Assay)","Beijing Wantai Biological,NA",Multiple Types,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Archana Koirala,University of Sydney,Unity-Aligned,https://dx.doi.org/10.5694/mja2.51542,2022-06-04,2024-03-22,Verified,koirala_seroprevalence_2022,AUS
220521_Australia_UniversityOfSydney_ELISA_Crude_Overall,220521_Australia_UniversityOfSydney,"The seroprevalence of SARS-CoV-2-specific antibodies in children, Australia, November 2020 - March 2021.",2022-05-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,Queensland; New South Wales; Victoria; South Australia; Western Australia.,Brisbane; Sydney; Melbourne; Adelaide; Perth.,"""We assessed the seroprevalence of SARS- CoV-2specific antibodies in children aged 0–19 years in blood opportunistically collected during anaesthesia from patients undergoing elective surgery at seven hospitals in the Paediatric Active Enhanced Disease Surveillance network""","""Four of 1689 blood specimens were excluded because the children lived outside the five states included in our study.""",2020-11-03,2021-03-12,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Analysis,Crude,1685,0.0042,,,,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Archana Koirala,University of Sydney,Unity-Aligned,https://dx.doi.org/10.5694/mja2.51542,2022-06-04,2024-03-22,Verified,koirala_seroprevalence_2022,AUS
220521_Australia_UniversityOfSydney_ELISA_Crude_Queensland_Brisbane,220521_Australia_UniversityOfSydney,"The seroprevalence of SARS-CoV-2-specific antibodies in children, Australia, November 2020 - March 2021.",2022-05-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,Queensland,Brisbane,"""We assessed the seroprevalence of SARS- CoV-2specific antibodies in children aged 0–19 years in blood opportunistically collected during anaesthesia from patients undergoing elective surgery at seven hospitals in the Paediatric Active Enhanced Disease Surveillance network""","""Four of 1689 blood specimens were excluded because the children lived outside the five states included in our study.""",2020-11-03,2021-03-12,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Geographical area,State: Queensland,323,0.0031,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Archana Koirala,University of Sydney,Unity-Aligned,https://dx.doi.org/10.5694/mja2.51542,2022-06-04,2024-03-22,Verified,koirala_seroprevalence_2022,AUS
220521_Australia_UniversityOfSydney_ELISA_Crude_Age_0-4,220521_Australia_UniversityOfSydney,"The seroprevalence of SARS-CoV-2-specific antibodies in children, Australia, November 2020 - March 2021.",2022-05-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,Queensland; New South Wales; Victoria; South Australia; Western Australia.,Brisbane; Sydney; Melbourne; Adelaide; Perth.,"""We assessed the seroprevalence of SARS- CoV-2specific antibodies in children aged 0–19 years in blood opportunistically collected during anaesthesia from patients undergoing elective surgery at seven hospitals in the Paediatric Active Enhanced Disease Surveillance network""","""Four of 1689 blood specimens were excluded because the children lived outside the five states included in our study.""",2020-11-03,2021-03-12,Residual sera,All,Children and Youth (0-17 years),0.0,4.0,Age,Age: 0-4,630,0.0,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Archana Koirala,University of Sydney,Unity-Aligned,https://dx.doi.org/10.5694/mja2.51542,2022-06-04,2024-03-22,Verified,koirala_seroprevalence_2022,AUS
220521_Australia_UniversityOfSydney_ELISA_Crude_Sex_Boys,220521_Australia_UniversityOfSydney,"The seroprevalence of SARS-CoV-2-specific antibodies in children, Australia, November 2020 - March 2021.",2022-05-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,Queensland; New South Wales; Victoria; South Australia; Western Australia.,Brisbane; Sydney; Melbourne; Adelaide; Perth.,"""We assessed the seroprevalence of SARS- CoV-2specific antibodies in children aged 0–19 years in blood opportunistically collected during anaesthesia from patients undergoing elective surgery at seven hospitals in the Paediatric Active Enhanced Disease Surveillance network""","""Four of 1689 blood specimens were excluded because the children lived outside the five states included in our study.""",2020-11-03,2021-03-12,Residual sera,Male,Children and Youth (0-17 years),0.0,19.0,Sex/Gender,,1023,0.0059,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Archana Koirala,University of Sydney,Unity-Aligned,https://dx.doi.org/10.5694/mja2.51542,2022-06-04,2024-03-22,Verified,koirala_seroprevalence_2022,AUS
220521_Australia_UniversityOfSydney_ELISA_Crude_Age_10-19,220521_Australia_UniversityOfSydney,"The seroprevalence of SARS-CoV-2-specific antibodies in children, Australia, November 2020 - March 2021.",2022-05-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,Queensland; New South Wales; Victoria; South Australia; Western Australia.,Brisbane; Sydney; Melbourne; Adelaide; Perth.,"""We assessed the seroprevalence of SARS- CoV-2specific antibodies in children aged 0–19 years in blood opportunistically collected during anaesthesia from patients undergoing elective surgery at seven hospitals in the Paediatric Active Enhanced Disease Surveillance network""","""Four of 1689 blood specimens were excluded because the children lived outside the five states included in our study.""",2020-11-03,2021-03-12,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,Age: 10-19,561,0.010700000000000001,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Archana Koirala,University of Sydney,Unity-Aligned,https://dx.doi.org/10.5694/mja2.51542,2022-06-04,2024-03-22,Verified,koirala_seroprevalence_2022,AUS
220521_Australia_UniversityOfSydney_ELISA_Crude_Victoria_Melbourne,220521_Australia_UniversityOfSydney,"The seroprevalence of SARS-CoV-2-specific antibodies in children, Australia, November 2020 - March 2021.",2022-05-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,Victoria,Melbourne,"""We assessed the seroprevalence of SARS- CoV-2specific antibodies in children aged 0–19 years in blood opportunistically collected during anaesthesia from patients undergoing elective surgery at seven hospitals in the Paediatric Active Enhanced Disease Surveillance network""","""Four of 1689 blood specimens were excluded because the children lived outside the five states included in our study.""",2020-11-03,2021-03-12,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Geographical area,State: Victoria,455,0.006600000000000001,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Archana Koirala,University of Sydney,Unity-Aligned,https://dx.doi.org/10.5694/mja2.51542,2022-06-04,2024-03-22,Verified,koirala_seroprevalence_2022,AUS
220521_Australia_UniversityOfSydney_ELISA_Crude_Sex_Girls,220521_Australia_UniversityOfSydney,"The seroprevalence of SARS-CoV-2-specific antibodies in children, Australia, November 2020 - March 2021.",2022-05-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Australia,Queensland; New South Wales; Victoria; South Australia; Western Australia.,Brisbane; Sydney; Melbourne; Adelaide; Perth.,"""We assessed the seroprevalence of SARS- CoV-2specific antibodies in children aged 0–19 years in blood opportunistically collected during anaesthesia from patients undergoing elective surgery at seven hospitals in the Paediatric Active Enhanced Disease Surveillance network""","""Four of 1689 blood specimens were excluded because the children lived outside the five states included in our study.""",2020-11-03,2021-03-12,Residual sera,Female,Children and Youth (0-17 years),0.0,19.0,Sex/Gender,,662,0.0015,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Archana Koirala,University of Sydney,Unity-Aligned,https://dx.doi.org/10.5694/mja2.51542,2022-06-04,2024-03-22,Verified,koirala_seroprevalence_2022,AUS
220521_Australia_UniversityOfSydney_ELISA_Crude_SouthAustralia_Adelaide,220521_Australia_UniversityOfSydney,"The seroprevalence of SARS-CoV-2-specific antibodies in children, Australia, November 2020 - March 2021.",2022-05-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,South Australia,Adelaide,"""We assessed the seroprevalence of SARS- CoV-2specific antibodies in children aged 0–19 years in blood opportunistically collected during anaesthesia from patients undergoing elective surgery at seven hospitals in the Paediatric Active Enhanced Disease Surveillance network""","""Four of 1689 blood specimens were excluded because the children lived outside the five states included in our study.""",2020-11-03,2021-03-12,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Geographical area,State: South Australia,348,0.0,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.951,0.996,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Archana Koirala,University of Sydney,Unity-Aligned,https://dx.doi.org/10.5694/mja2.51542,2022-06-04,2024-03-22,Verified,koirala_seroprevalence_2022,AUS
220603_Australia_KirbyInstitute_antiS,220603_ Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, February–March 2022",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Australia,,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-02-23,2022-03-03,Blood donors,All,Multiple groups,18.0,83.0,Primary Estimate,anti-S overall,5185,0.981,0.9770000000000001,0.985,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-february-march,2022-08-04,2024-03-01,Unverified,kirby-institute_seroprevalence_2022,AUS
220603_Australia_KirbyInstitute_antiS_Age70to89,220603_ Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, February–March 2022",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Australia,,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-02-23,2022-03-03,Blood donors,All,Seniors (65+ years),70.0,89.0,Age,"anti-S overall, age: 70-89",313,0.9870000000000001,0.968,0.997,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-february-march,2022-08-04,2024-03-01,Unverified,kirby-institute_seroprevalence_2022,AUS
220603_Australia_KirbyInstitute_antiS_Male,220603_ Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, February–March 2022",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Australia,,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-02-23,2022-03-03,Blood donors,Male,Multiple groups,70.0,89.0,Sex/Gender,anti-S overall,3017,0.9790000000000001,0.9740000000000001,0.9840000000000001,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-february-march,2022-08-04,2024-03-01,Unverified,kirby-institute_seroprevalence_2022,AUS
220603_Australia_KirbyInstitute_antiS_ACT,220603_ Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, February–March 2022",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Australia,Australian Capital Territory,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-02-23,2022-03-03,Blood donors,All,Multiple groups,18.0,83.0,Geographical area,anti-S ACT Jurisdition,177,1.0,0.9790000000000001,1.0,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-february-march,2022-08-04,2024-03-01,Unverified,kirby-institute_seroprevalence_2022,AUS
220603_Australia_KirbyInstitute_antiS_Age60to69,220603_ Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, February–March 2022",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Australia,,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-02-23,2022-03-03,Blood donors,All,Multiple groups,60.0,69.0,Age,"anti-S overall, age: 60-69",852,0.9840000000000001,0.973,0.991,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-february-march,2022-08-04,2024-03-01,Unverified,kirby-institute_seroprevalence_2022,AUS
220603_Australia_KirbyInstitute_antiS_WA,220603_ Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, February–March 2022",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Australia,Western Australia,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-02-23,2022-03-03,Blood donors,All,Multiple groups,18.0,83.0,Geographical area,anti-S WA Jurisdition,999,0.9840000000000001,0.9740000000000001,0.991,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-february-march,2022-08-04,2024-03-01,Unverified,kirby-institute_seroprevalence_2022,AUS
220603_Australia_KirbyInstitute_antiN,220603_ Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, February–March 2022",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Australia,,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-02-23,2022-03-03,Blood donors,All,Multiple groups,18.0,83.0,Test used,anti-N overall,5185,0.17,0.16,0.18,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Multiple Types,,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-february-march,2022-08-04,2024-03-01,Unverified,kirby-institute_seroprevalence_2022,AUS
220603_Australia_KirbyInstitute_antiS_Age50to59,220603_ Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, February–March 2022",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Australia,,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-02-23,2022-03-03,Blood donors,All,Adults (18-64 years),50.0,59.0,Age,"anti-S overall, age: 50-59",972,0.978,0.9670000000000001,0.9870000000000001,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-february-march,2022-08-04,2024-03-01,Unverified,kirby-institute_seroprevalence_2022,AUS
220603_Australia_KirbyInstitute_antiS_Age30to39,220603_ Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, February–March 2022",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Australia,,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-02-23,2022-03-03,Blood donors,All,Adults (18-64 years),30.0,39.0,Age,"anti-S overall, age: 30-39",993,0.98,0.9690000000000001,0.988,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-february-march,2022-08-04,2024-03-01,Unverified,kirby-institute_seroprevalence_2022,AUS
220603_Australia_KirbyInstitute_antiS_Age40to49,220603_ Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, February–March 2022",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Australia,,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-02-23,2022-03-03,Blood donors,All,Adults (18-64 years),40.0,49.0,Age,"anti-S overall, age: 40-49",895,0.973,0.96,0.983,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-february-march,2022-08-04,2024-03-01,Unverified,kirby-institute_seroprevalence_2022,AUS
220603_Australia_KirbyInstitute_antiS_SA,220603_ Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, February–March 2022",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Australia,South Australia,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-02-23,2022-03-03,Blood donors,All,Multiple groups,18.0,83.0,Geographical area,anti-S SA Jurisdition,205,0.985,0.958,0.997,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-february-march,2022-08-04,2024-03-01,Unverified,kirby-institute_seroprevalence_2022,AUS
220603_Australia_KirbyInstitute_antiS_NT,220603_ Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, February–March 2022",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Australia,Northern Territory,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-02-23,2022-03-03,Blood donors,All,Multiple groups,18.0,83.0,Geographical area,anti-S NT Jurisdition,199,0.985,0.9570000000000001,0.997,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-february-march,2022-08-04,2024-03-01,Unverified,kirby-institute_seroprevalence_2022,AUS
220603_Australia_KirbyInstitute_antiS_Age18to29,220603_ Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, February–March 2022",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Australia,,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-02-23,2022-03-03,Blood donors,All,Adults (18-64 years),18.0,29.0,Age,"anti-S overall, age: 18-29",1160,0.9890000000000001,0.981,0.9940000000000001,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-february-march,2022-08-04,2024-03-01,Unverified,kirby-institute_seroprevalence_2022,AUS
220603_Australia_KirbyInstitute_antiS_Tasmania,220603_ Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, February–March 2022",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Australia,Tasmania,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-02-23,2022-03-03,Blood donors,All,Multiple groups,18.0,83.0,Geographical area,anti-S Tasmania Jurisdition,216,0.991,0.9670000000000001,0.9990000000000001,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-february-march,2022-08-04,2024-03-01,Unverified,kirby-institute_seroprevalence_2022,AUS
220603_Australia_KirbyInstitute_antiS_NSW,220603_ Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, February–March 2022",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Australia,New South Wales,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-02-23,2022-03-03,Blood donors,All,Multiple groups,18.0,83.0,Geographical area,anti-S NSW Jurisdition,1155,0.9840000000000001,0.9740000000000001,0.99,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-february-march,2022-08-04,2024-03-01,Unverified,kirby-institute_seroprevalence_2022,AUS
220603_Australia_KirbyInstitute_antiS_Victoria,220603_ Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, February–March 2022",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Australia,Victoria,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-02-23,2022-03-03,Blood donors,All,Multiple groups,18.0,83.0,Geographical area,anti-S Victoria Jurisdition,1099,0.988,0.98,0.9940000000000001,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-february-march,2022-08-04,2024-03-01,Unverified,kirby-institute_seroprevalence_2022,AUS
220603_Australia_KirbyInstitute_antiS_Female,220603_ Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, February–March 2022",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Australia,,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-02-23,2022-03-03,Blood donors,Female,Multiple groups,70.0,89.0,Sex/Gender,anti-S overall,2168,0.9840000000000001,0.978,0.9890000000000001,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-february-march,2022-08-04,2024-03-01,Unverified,kirby-institute_seroprevalence_2022,AUS
220603_Australia_KirbyInstitute_antiS_Queensland,220603_ Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, February–March 2022",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Australia,Queensland,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-02-23,2022-03-03,Blood donors,All,Multiple groups,18.0,83.0,Geographical area,anti-S Queensland Jurisdition,1135,0.965,0.9520000000000001,0.975,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-february-march,2022-08-04,2024-03-01,Unverified,kirby-institute_seroprevalence_2022,AUS
220726_Australia_KirbyInstitute_antiS,220726_Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, May–June 2022",2022-07-26,Institutional Report,National,Repeated cross-sectional study,Australia,,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-06-09,2022-06-18,Blood donors,All,Multiple groups,18.0,83.0,Primary Estimate,anti-S overall,5138,0.99,0.9870000000000001,0.9920000000000001,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-may-june-2022,2022-08-04,2024-04-06,Verified,kirby-institute_seroprevalence_2022-1,AUS
220726_Australia_KirbyInstitute_antiN,220726_Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, May–June 2022",2022-07-26,Institutional Report,National,Repeated cross-sectional study,Australia,,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-06-09,2022-06-18,Blood donors,All,Multiple groups,18.0,83.0,Test used,anti-N overall,5138,0.462,0.44799999999999995,0.47600000000000003,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Multiple Types,,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-may-june-2022,2022-08-04,2024-04-06,Verified,kirby-institute_seroprevalence_2022-1,AUS
220726_Australia_KirbyInstitute_antiS_Age40to49,220726_Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, May–June 2022",2022-07-26,Institutional Report,National,Repeated cross-sectional study,Australia,,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-06-09,2022-06-18,Blood donors,All,Adults (18-64 years),40.0,49.0,Age,"anti-S overall, age: 40-49",914,0.988,0.9790000000000001,0.994,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-may-june-2022,2022-08-04,2024-04-06,Verified,kirby-institute_seroprevalence_2022-1,AUS
220726_Australia_KirbyInstitute_antiS_NSW,220726_Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, May–June 2022",2022-07-26,Institutional Report,Regional,Repeated cross-sectional study,Australia,New South Wales,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-06-09,2022-06-18,Blood donors,All,Multiple groups,18.0,83.0,Geographical area,anti-S NSW Jurisdition,1226,0.99,0.983,0.995,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-may-june-2022,2022-08-04,2024-04-06,Verified,kirby-institute_seroprevalence_2022-1,AUS
220726_Australia_KirbyInstitute_antiS_Age60to69,220726_Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, May–June 2022",2022-07-26,Institutional Report,National,Repeated cross-sectional study,Australia,,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-06-09,2022-06-18,Blood donors,All,Multiple groups,60.0,69.0,Age,"anti-S overall, age: 60-69",781,0.988,0.978,0.995,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-may-june-2022,2022-08-04,2024-04-06,Verified,kirby-institute_seroprevalence_2022-1,AUS
220726_Australia_KirbyInstitute_antiS_WA,220726_Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, May–June 2022",2022-07-26,Institutional Report,Regional,Repeated cross-sectional study,Australia,Western Australia,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-06-09,2022-06-18,Blood donors,All,Multiple groups,18.0,83.0,Geographical area,anti-S WA Jurisdition,982,0.9890000000000001,0.98,0.9940000000000001,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-may-june-2022,2022-08-04,2024-04-06,Verified,kirby-institute_seroprevalence_2022-1,AUS
220726_Australia_KirbyInstitute_antiS_Age70to89,220726_Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, May–June 2022",2022-07-26,Institutional Report,National,Repeated cross-sectional study,Australia,,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-06-09,2022-06-18,Blood donors,All,Seniors (65+ years),70.0,89.0,Age,"anti-S overall, age: 70-89",268,0.9740000000000001,0.9470000000000001,0.9890000000000001,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-may-june-2022,2022-08-04,2024-04-06,Verified,kirby-institute_seroprevalence_2022-1,AUS
220726_Australia_KirbyInstitute_antiS_Age30to39,220726_Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, May–June 2022",2022-07-26,Institutional Report,National,Repeated cross-sectional study,Australia,,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-06-09,2022-06-18,Blood donors,All,Adults (18-64 years),30.0,39.0,Age,"anti-S overall, age: 30-39",1056,0.991,0.983,0.995,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-may-june-2022,2022-08-04,2024-04-06,Verified,kirby-institute_seroprevalence_2022-1,AUS
220726_Australia_KirbyInstitute_antiS_Age50to59,220726_Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, May–June 2022",2022-07-26,Institutional Report,National,Repeated cross-sectional study,Australia,,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-06-09,2022-06-18,Blood donors,All,Adults (18-64 years),50.0,59.0,Age,"anti-S overall, age: 50-59",993,0.9890000000000001,0.98,0.9940000000000001,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-may-june-2022,2022-08-04,2024-04-06,Verified,kirby-institute_seroprevalence_2022-1,AUS
220726_Australia_KirbyInstitute_antiS_Tasmania,220726_Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, May–June 2022",2022-07-26,Institutional Report,Regional,Repeated cross-sectional study,Australia,Tasmania,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-06-09,2022-06-18,Blood donors,All,Multiple groups,18.0,83.0,Geographical area,anti-S Tasmania Jurisdition,203,0.98,0.9500000000000001,0.995,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-may-june-2022,2022-08-04,2024-04-06,Verified,kirby-institute_seroprevalence_2022-1,AUS
220726_Australia_KirbyInstitute_antiS_Age18to29,220726_Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, May–June 2022",2022-07-26,Institutional Report,National,Repeated cross-sectional study,Australia,,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-06-09,2022-06-18,Blood donors,All,Adults (18-64 years),18.0,29.0,Age,"anti-S overall, age: 18-29",1127,0.996,0.99,0.9990000000000001,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-may-june-2022,2022-08-04,2024-04-06,Verified,kirby-institute_seroprevalence_2022-1,AUS
220726_Australia_KirbyInstitute_antiS_Victoria,220726_Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, May–June 2022",2022-07-26,Institutional Report,Regional,Repeated cross-sectional study,Australia,Victoria,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-06-09,2022-06-18,Blood donors,All,Multiple groups,18.0,83.0,Geographical area,anti-S Victoria Jurisdition,1035,0.993,0.986,0.997,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-may-june-2022,2022-08-04,2024-04-06,Verified,kirby-institute_seroprevalence_2022-1,AUS
220726_Australia_KirbyInstitute_antiS_ACT,220726_Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, May–June 2022",2022-07-26,Institutional Report,Regional,Repeated cross-sectional study,Australia,Australian Capital Territory,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-06-09,2022-06-18,Blood donors,All,Multiple groups,18.0,83.0,Geographical area,anti-S ACT Jurisdition,164,1.0,0.978,1.0,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-may-june-2022,2022-08-04,2024-04-06,Verified,kirby-institute_seroprevalence_2022-1,AUS
220726_Australia_KirbyInstitute_antiS_Queensland,220726_Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, May–June 2022",2022-07-26,Institutional Report,Regional,Repeated cross-sectional study,Australia,Queensland,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-06-09,2022-06-18,Blood donors,All,Multiple groups,18.0,83.0,Geographical area,anti-S Queensland Jurisdition,1145,0.985,0.976,0.991,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-may-june-2022,2022-08-04,2024-04-06,Verified,kirby-institute_seroprevalence_2022-1,AUS
220726_Australia_KirbyInstitute_antiS_Female,220726_Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, May–June 2022",2022-07-26,Institutional Report,National,Repeated cross-sectional study,Australia,,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-06-09,2022-06-18,Blood donors,Female,Multiple groups,18.0,89.0,Sex/Gender,anti-S overall; Female,2263,0.993,0.9890000000000001,0.996,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-may-june-2022,2022-08-04,2024-04-06,Verified,kirby-institute_seroprevalence_2022-1,AUS
220726_Australia_KirbyInstitute_antiS_Male,220726_Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, May–June 2022",2022-07-26,Institutional Report,National,Repeated cross-sectional study,Australia,,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-06-09,2022-06-18,Blood donors,Male,Multiple groups,18.0,89.0,Sex/Gender,anti-S overall; Male,2876,0.9870000000000001,0.9820000000000001,0.991,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-may-june-2022,2022-08-04,2024-04-06,Verified,kirby-institute_seroprevalence_2022-1,AUS
220726_Australia_KirbyInstitute_antiS_NT,220726_Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, May–June 2022",2022-07-26,Institutional Report,Regional,Repeated cross-sectional study,Australia,Northern Territory,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-06-09,2022-06-18,Blood donors,All,Multiple groups,18.0,83.0,Geographical area,anti-S NT Jurisdition,174,0.9940000000000001,0.968,1.0,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-may-june-2022,2022-08-04,2024-04-06,Verified,kirby-institute_seroprevalence_2022-1,AUS
220726_Australia_KirbyInstitute_antiS_SA,220726_Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, May–June 2022",2022-07-26,Institutional Report,Regional,Repeated cross-sectional study,Australia,South Australia,,"Residual blood donation samples were collected from four Lifeblood processing centres located in NSW, Victoria, Queensland, and WA from any blood donations (plasmapheresis or whole blood) following routine screening prior to discarding. Donors aged 18 years or over who met routine donor eligibility criteria, as per the Australia Red Cross Lifeblood (https://www.lifeblood.com.au/blood/eligibility), were eligible for inclusion. Data on age, sex, and residential postcode were collected for each specimen.",,2022-06-09,2022-06-18,Blood donors,All,Multiple groups,18.0,83.0,Geographical area,anti-S SA Jurisdition,210,0.995,0.9740000000000001,1.0,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/report/seroprevalence-sars-cov-2-specific-antibodies-among-australian-blood-donors-may-june-2022,2022-08-04,2024-04-06,Verified,kirby-institute_seroprevalence_2022-1,AUS
220916_Australia_AustralianRedCrossLifeblood_antiS,220916_Australia_AustralianRedCrossLifeblood,Seroprevalence of Sars-Cov-2 Antibodies Among Australian Blood Donors Following the Arrival of the Omicron Variant,2022-09-16,Presentation or Conference,National,Cross-sectional survey ,Australia,,,blood donor samples (age>18) from the 4 national Australian Red Cross Life- blood processing centres,,2022-02-23,2022-03-03,Blood donors,All,Multiple groups,18.0,,Primary Estimate,anti-S overall,5177,0.981,0.9770000000000001,0.985,True,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,,Spike,,,,['Moderate'],No,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Rena Hirani,Australian Red Cross Lifeblood,Unity-Aligned,https://dx.doi.org/10.1111/trf.17058,2022-11-09,2024-04-12,Verified,hirani_seroprevalence_2022,AUS
210921_Australia_HarryPerkinsInstituteOfMedicalResearch,210921_Australia_HarryPerkinsInstituteOfMedicalResearch,COVID-19 Serosurvey of Frontline Healthcare Workers in Western Australia.,2022-09-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Australia,,,"The study was advertised through email and posters in mid-May 2020 to frontline healthcare workers (Emergency Department, Intensive Care Unit, Respiratory Ward, Anaesthetics) at Fiona Stanley Hospital (FSH) and Royal Perth Hospital (RPH), two large tertiary hospitals in Western Australia.",,2020-06-01,2020-08-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,799,0.0038,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Herbert Ludewick,Harry Perkins Institute of Medical Research,Not Unity-Aligned,https://dx.doi.org/10.1007/s44197-022-00065-1,2022-10-20,2022-10-20,Unverified,ludewick_covid-19_2022,AUS
221103_Australia_PAEDS_Overall,221103_Australia_PAEDS,"Paediatric SARS-CoV-2 serosurvey 2022, Australia
Summary report",2022-11-03,Institutional Report,National,Cross-sectional survey ,Australia,"New South Wales, Victoria, South Australia, Western Australia, Northern Territory, Queensland","Westmead, Sydney, Melbourne, Adelaide, Perth, Darwin, Brisbane","""Children [aged 0-19] undergoing an anaesthetic procedure (e.g. for day surgery, trauma or other reason) were recruited for this study through eight paediatric hospitals of the Paediatric Active Enhanced Disease Surveillance (PAEDS) network across Australia.""","""Children who were immunosuppressed or receiving intravenous immunoglobulin were excluded due to the possibility that they may not have a strong antibody response to infection or they may have had donor antibody from the blood product donation, respectively.""",2022-06-08,2022-08-31,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Primary Estimate,Anti-S,2045,0.8963,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Paediatric Active Enhanced Disease Surveillance (PAEDS),Paediatric Active Enhanced Disease Surveillance (PAEDS),Unity-Aligned,https://paeds.org.au/sites/default/files/2022-11/PAEDS%20NCIRS_COVID-19%20Paediatric%20Serosurvey%202022%20Report_3-11-2022_Final_1.pdf,2022-11-17,2024-04-17,Verified,paediatric_active_enhanced_disease_surveillance_paeds_paediatric_2022,AUS
221103_Australia_PAEDS_Age_5-11,221103_Australia_PAEDS,"Paediatric SARS-CoV-2 serosurvey 2022, Australia
Summary report",2022-11-03,Institutional Report,National,Cross-sectional survey ,Australia,"New South Wales, Victoria, South Australia, Western Australia, Northern Territory, Queensland","Westmead, Sydney, Melbourne, Adelaide, Perth, Darwin, Brisbane","""Children [aged 0-19] undergoing an anaesthetic procedure (e.g. for day surgery, trauma or other reason) were recruited for this study through eight paediatric hospitals of the Paediatric Active Enhanced Disease Surveillance (PAEDS) network across Australia.""","""Children who were immunosuppressed or receiving intravenous immunoglobulin were excluded due to the possibility that they may not have a strong antibody response to infection or they may have had donor antibody from the blood product donation, respectively.""",2022-06-08,2022-08-31,Residual sera,All,Children and Youth (0-17 years),5.0,11.0,Age,5-11,696,0.9339000000000001,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Paediatric Active Enhanced Disease Surveillance (PAEDS),Paediatric Active Enhanced Disease Surveillance (PAEDS),Unity-Aligned,https://paeds.org.au/sites/default/files/2022-11/PAEDS%20NCIRS_COVID-19%20Paediatric%20Serosurvey%202022%20Report_3-11-2022_Final_1.pdf,2022-11-17,2024-04-17,Verified,paediatric_active_enhanced_disease_surveillance_paeds_paediatric_2022,AUS
221103_Australia_PAEDS_Age_12-15,221103_Australia_PAEDS,"Paediatric SARS-CoV-2 serosurvey 2022, Australia
Summary report",2022-11-03,Institutional Report,National,Cross-sectional survey ,Australia,"New South Wales, Victoria, South Australia, Western Australia, Northern Territory, Queensland","Westmead, Sydney, Melbourne, Adelaide, Perth, Darwin, Brisbane","""Children [aged 0-19] undergoing an anaesthetic procedure (e.g. for day surgery, trauma or other reason) were recruited for this study through eight paediatric hospitals of the Paediatric Active Enhanced Disease Surveillance (PAEDS) network across Australia.""","""Children who were immunosuppressed or receiving intravenous immunoglobulin were excluded due to the possibility that they may not have a strong antibody response to infection or they may have had donor antibody from the blood product donation, respectively.""",2022-06-08,2022-08-31,Residual sera,All,Children and Youth (0-17 years),12.0,15.0,Age,12-15,397,0.9924,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Paediatric Active Enhanced Disease Surveillance (PAEDS),Paediatric Active Enhanced Disease Surveillance (PAEDS),Unity-Aligned,https://paeds.org.au/sites/default/files/2022-11/PAEDS%20NCIRS_COVID-19%20Paediatric%20Serosurvey%202022%20Report_3-11-2022_Final_1.pdf,2022-11-17,2024-04-17,Verified,paediatric_active_enhanced_disease_surveillance_paeds_paediatric_2022,AUS
221103_Australia_PAEDS_Vaccinated,221103_Australia_PAEDS,"Paediatric SARS-CoV-2 serosurvey 2022, Australia
Summary report",2022-11-03,Institutional Report,National,Cross-sectional survey ,Australia,"New South Wales, Victoria, South Australia, Western Australia, Northern Territory, Queensland","Westmead, Sydney, Melbourne, Adelaide, Perth, Darwin, Brisbane","""Children [aged 0-19] undergoing an anaesthetic procedure (e.g. for day surgery, trauma or other reason) were recruited for this study through eight paediatric hospitals of the Paediatric Active Enhanced Disease Surveillance (PAEDS) network across Australia.""","""Children who were immunosuppressed or receiving intravenous immunoglobulin were excluded due to the possibility that they may not have a strong antibody response to infection or they may have had donor antibody from the blood product donation, respectively.""",2022-06-08,2022-08-31,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,COVID-19 vaccination status,Vaccinated,861,1.0,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Paediatric Active Enhanced Disease Surveillance (PAEDS),Paediatric Active Enhanced Disease Surveillance (PAEDS),Unity-Aligned,https://paeds.org.au/sites/default/files/2022-11/PAEDS%20NCIRS_COVID-19%20Paediatric%20Serosurvey%202022%20Report_3-11-2022_Final_1.pdf,2022-11-17,2024-04-17,Verified,paediatric_active_enhanced_disease_surveillance_paeds_paediatric_2022,AUS
221103_Australia_PAEDS_Age_16-19,221103_Australia_PAEDS,"Paediatric SARS-CoV-2 serosurvey 2022, Australia
Summary report",2022-11-03,Institutional Report,National,Cross-sectional survey ,Australia,"New South Wales, Victoria, South Australia, Western Australia, Northern Territory, Queensland","Westmead, Sydney, Melbourne, Adelaide, Perth, Darwin, Brisbane","""Children [aged 0-19] undergoing an anaesthetic procedure (e.g. for day surgery, trauma or other reason) were recruited for this study through eight paediatric hospitals of the Paediatric Active Enhanced Disease Surveillance (PAEDS) network across Australia.""","""Children who were immunosuppressed or receiving intravenous immunoglobulin were excluded due to the possibility that they may not have a strong antibody response to infection or they may have had donor antibody from the blood product donation, respectively.""",2022-06-08,2022-08-31,Residual sera,All,Children and Youth (0-17 years),16.0,19.0,Age,16-19,137,0.9927,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Paediatric Active Enhanced Disease Surveillance (PAEDS),Paediatric Active Enhanced Disease Surveillance (PAEDS),Unity-Aligned,https://paeds.org.au/sites/default/files/2022-11/PAEDS%20NCIRS_COVID-19%20Paediatric%20Serosurvey%202022%20Report_3-11-2022_Final_1.pdf,2022-11-17,2024-04-17,Verified,paediatric_active_enhanced_disease_surveillance_paeds_paediatric_2022,AUS
221103_Australia_PAEDS_Sex_Female,221103_Australia_PAEDS,"Paediatric SARS-CoV-2 serosurvey 2022, Australia
Summary report",2022-11-03,Institutional Report,National,Cross-sectional survey ,Australia,"New South Wales, Victoria, South Australia, Western Australia, Northern Territory, Queensland","Westmead, Sydney, Melbourne, Adelaide, Perth, Darwin, Brisbane","""Children [aged 0-19] undergoing an anaesthetic procedure (e.g. for day surgery, trauma or other reason) were recruited for this study through eight paediatric hospitals of the Paediatric Active Enhanced Disease Surveillance (PAEDS) network across Australia.""","""Children who were immunosuppressed or receiving intravenous immunoglobulin were excluded due to the possibility that they may not have a strong antibody response to infection or they may have had donor antibody from the blood product donation, respectively.""",2022-06-08,2022-08-31,Residual sera,Female,Children and Youth (0-17 years),0.0,19.0,Sex/Gender,Female,872,0.9083,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Paediatric Active Enhanced Disease Surveillance (PAEDS),Paediatric Active Enhanced Disease Surveillance (PAEDS),Unity-Aligned,https://paeds.org.au/sites/default/files/2022-11/PAEDS%20NCIRS_COVID-19%20Paediatric%20Serosurvey%202022%20Report_3-11-2022_Final_1.pdf,2022-11-17,2024-04-17,Verified,paediatric_active_enhanced_disease_surveillance_paeds_paediatric_2022,AUS
221103_Australia_PAEDS_Region_NewSouthWales,221103_Australia_PAEDS,"Paediatric SARS-CoV-2 serosurvey 2022, Australia
Summary report",2022-11-03,Institutional Report,Local,Cross-sectional survey ,Australia,New South Wales,"Westmead, Sydney","""Children [aged 0-19] undergoing an anaesthetic procedure (e.g. for day surgery, trauma or other reason) were recruited for this study through eight paediatric hospitals of the Paediatric Active Enhanced Disease Surveillance (PAEDS) network across Australia.""","""Children who were immunosuppressed or receiving intravenous immunoglobulin were excluded due to the possibility that they may not have a strong antibody response to infection or they may have had donor antibody from the blood product donation, respectively.""",2022-06-08,2022-08-31,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Geographical area,New South Wales,511,0.9217000000000001,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Paediatric Active Enhanced Disease Surveillance (PAEDS),Paediatric Active Enhanced Disease Surveillance (PAEDS),Unity-Aligned,https://paeds.org.au/sites/default/files/2022-11/PAEDS%20NCIRS_COVID-19%20Paediatric%20Serosurvey%202022%20Report_3-11-2022_Final_1.pdf,2022-11-17,2024-04-17,Verified,paediatric_active_enhanced_disease_surveillance_paeds_paediatric_2022,AUS
221103_Australia_PAEDS_Sex_Male,221103_Australia_PAEDS,"Paediatric SARS-CoV-2 serosurvey 2022, Australia
Summary report",2022-11-03,Institutional Report,National,Cross-sectional survey ,Australia,"New South Wales, Victoria, South Australia, Western Australia, Northern Territory, Queensland","Westmead, Sydney, Melbourne, Adelaide, Perth, Darwin, Brisbane","""Children [aged 0-19] undergoing an anaesthetic procedure (e.g. for day surgery, trauma or other reason) were recruited for this study through eight paediatric hospitals of the Paediatric Active Enhanced Disease Surveillance (PAEDS) network across Australia.""","""Children who were immunosuppressed or receiving intravenous immunoglobulin were excluded due to the possibility that they may not have a strong antibody response to infection or they may have had donor antibody from the blood product donation, respectively.""",2022-06-08,2022-08-31,Residual sera,Male,Children and Youth (0-17 years),0.0,19.0,Sex/Gender,Male,1171,0.8873000000000001,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Paediatric Active Enhanced Disease Surveillance (PAEDS),Paediatric Active Enhanced Disease Surveillance (PAEDS),Unity-Aligned,https://paeds.org.au/sites/default/files/2022-11/PAEDS%20NCIRS_COVID-19%20Paediatric%20Serosurvey%202022%20Report_3-11-2022_Final_1.pdf,2022-11-17,2024-04-17,Verified,paediatric_active_enhanced_disease_surveillance_paeds_paediatric_2022,AUS
221103_Australia_PAEDS_Region_NorthernTerritory,221103_Australia_PAEDS,"Paediatric SARS-CoV-2 serosurvey 2022, Australia
Summary report",2022-11-03,Institutional Report,Local,Cross-sectional survey ,Australia,Northern Territory,Darwin,"""Children [aged 0-19] undergoing an anaesthetic procedure (e.g. for day surgery, trauma or other reason) were recruited for this study through eight paediatric hospitals of the Paediatric Active Enhanced Disease Surveillance (PAEDS) network across Australia.""","""Children who were immunosuppressed or receiving intravenous immunoglobulin were excluded due to the possibility that they may not have a strong antibody response to infection or they may have had donor antibody from the blood product donation, respectively.""",2022-06-08,2022-08-31,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Geographical area,Northern Territory,102,0.8235,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Paediatric Active Enhanced Disease Surveillance (PAEDS),Paediatric Active Enhanced Disease Surveillance (PAEDS),Unity-Aligned,https://paeds.org.au/sites/default/files/2022-11/PAEDS%20NCIRS_COVID-19%20Paediatric%20Serosurvey%202022%20Report_3-11-2022_Final_1.pdf,2022-11-17,2024-04-17,Verified,paediatric_active_enhanced_disease_surveillance_paeds_paediatric_2022,AUS
221103_Australia_PAEDS_Region_Victoria,221103_Australia_PAEDS,"Paediatric SARS-CoV-2 serosurvey 2022, Australia
Summary report",2022-11-03,Institutional Report,Local,Cross-sectional survey ,Australia,Victoria,Melbourne,"""Children [aged 0-19] undergoing an anaesthetic procedure (e.g. for day surgery, trauma or other reason) were recruited for this study through eight paediatric hospitals of the Paediatric Active Enhanced Disease Surveillance (PAEDS) network across Australia.""","""Children who were immunosuppressed or receiving intravenous immunoglobulin were excluded due to the possibility that they may not have a strong antibody response to infection or they may have had donor antibody from the blood product donation, respectively.""",2022-06-08,2022-08-31,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Geographical area,Victoria,400,0.9175,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Paediatric Active Enhanced Disease Surveillance (PAEDS),Paediatric Active Enhanced Disease Surveillance (PAEDS),Unity-Aligned,https://paeds.org.au/sites/default/files/2022-11/PAEDS%20NCIRS_COVID-19%20Paediatric%20Serosurvey%202022%20Report_3-11-2022_Final_1.pdf,2022-11-17,2024-04-17,Verified,paediatric_active_enhanced_disease_surveillance_paeds_paediatric_2022,AUS
221103_Australia_PAEDS_AntiN,221103_Australia_PAEDS,"Paediatric SARS-CoV-2 serosurvey 2022, Australia
Summary report",2022-11-03,Institutional Report,National,Cross-sectional survey ,Australia,"New South Wales, Victoria, South Australia, Western Australia, Northern Territory, Queensland","Westmead, Sydney, Melbourne, Adelaide, Perth, Darwin, Brisbane","""Children [aged 0-19] undergoing an anaesthetic procedure (e.g. for day surgery, trauma or other reason) were recruited for this study through eight paediatric hospitals of the Paediatric Active Enhanced Disease Surveillance (PAEDS) network across Australia.""","""Children who were immunosuppressed or receiving intravenous immunoglobulin were excluded due to the possibility that they may not have a strong antibody response to infection or they may have had donor antibody from the blood product donation, respectively.""",2022-06-08,2022-08-31,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Test used,Anti-N,2046,0.6398,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Paediatric Active Enhanced Disease Surveillance (PAEDS),Paediatric Active Enhanced Disease Surveillance (PAEDS),Unity-Aligned,https://paeds.org.au/sites/default/files/2022-11/PAEDS%20NCIRS_COVID-19%20Paediatric%20Serosurvey%202022%20Report_3-11-2022_Final_1.pdf,2022-11-17,2024-04-17,Verified,paediatric_active_enhanced_disease_surveillance_paeds_paediatric_2022,AUS
221103_Australia_PAEDS_Region_Queensland,221103_Australia_PAEDS,"Paediatric SARS-CoV-2 serosurvey 2022, Australia
Summary report",2022-11-03,Institutional Report,Local,Cross-sectional survey ,Australia,Queensland,Brisbane,"""Children [aged 0-19] undergoing an anaesthetic procedure (e.g. for day surgery, trauma or other reason) were recruited for this study through eight paediatric hospitals of the Paediatric Active Enhanced Disease Surveillance (PAEDS) network across Australia.""","""Children who were immunosuppressed or receiving intravenous immunoglobulin were excluded due to the possibility that they may not have a strong antibody response to infection or they may have had donor antibody from the blood product donation, respectively.""",2022-06-08,2022-08-31,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Geographical area,Queensland,352,0.8976999999999999,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Paediatric Active Enhanced Disease Surveillance (PAEDS),Paediatric Active Enhanced Disease Surveillance (PAEDS),Unity-Aligned,https://paeds.org.au/sites/default/files/2022-11/PAEDS%20NCIRS_COVID-19%20Paediatric%20Serosurvey%202022%20Report_3-11-2022_Final_1.pdf,2022-11-17,2024-04-17,Verified,paediatric_active_enhanced_disease_surveillance_paeds_paediatric_2022,AUS
221103_Australia_PAEDS_Region_SouthAustralia,221103_Australia_PAEDS,"Paediatric SARS-CoV-2 serosurvey 2022, Australia
Summary report",2022-11-03,Institutional Report,Local,Cross-sectional survey ,Australia,South Australia,Adelaide,"""Children [aged 0-19] undergoing an anaesthetic procedure (e.g. for day surgery, trauma or other reason) were recruited for this study through eight paediatric hospitals of the Paediatric Active Enhanced Disease Surveillance (PAEDS) network across Australia.""","""Children who were immunosuppressed or receiving intravenous immunoglobulin were excluded due to the possibility that they may not have a strong antibody response to infection or they may have had donor antibody from the blood product donation, respectively.""",2022-06-08,2022-08-31,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Geographical area,South Australia,399,0.9198000000000001,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Paediatric Active Enhanced Disease Surveillance (PAEDS),Paediatric Active Enhanced Disease Surveillance (PAEDS),Unity-Aligned,https://paeds.org.au/sites/default/files/2022-11/PAEDS%20NCIRS_COVID-19%20Paediatric%20Serosurvey%202022%20Report_3-11-2022_Final_1.pdf,2022-11-17,2024-04-17,Verified,paediatric_active_enhanced_disease_surveillance_paeds_paediatric_2022,AUS
221103_Australia_PAEDS_Age_0-1,221103_Australia_PAEDS,"Paediatric SARS-CoV-2 serosurvey 2022, Australia
Summary report",2022-11-03,Institutional Report,National,Cross-sectional survey ,Australia,"New South Wales, Victoria, South Australia, Western Australia, Northern Territory, Queensland","Westmead, Sydney, Melbourne, Adelaide, Perth, Darwin, Brisbane","""Children [aged 0-19] undergoing an anaesthetic procedure (e.g. for day surgery, trauma or other reason) were recruited for this study through eight paediatric hospitals of the Paediatric Active Enhanced Disease Surveillance (PAEDS) network across Australia.""","""Children who were immunosuppressed or receiving intravenous immunoglobulin were excluded due to the possibility that they may not have a strong antibody response to infection or they may have had donor antibody from the blood product donation, respectively.""",2022-06-08,2022-08-31,Residual sera,All,Children and Youth (0-17 years),0.0,1.0,Age,0-1,144,0.8611,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Paediatric Active Enhanced Disease Surveillance (PAEDS),Paediatric Active Enhanced Disease Surveillance (PAEDS),Unity-Aligned,https://paeds.org.au/sites/default/files/2022-11/PAEDS%20NCIRS_COVID-19%20Paediatric%20Serosurvey%202022%20Report_3-11-2022_Final_1.pdf,2022-11-17,2024-04-17,Verified,paediatric_active_enhanced_disease_surveillance_paeds_paediatric_2022,AUS
221103_Australia_PAEDS_Sex_Others,221103_Australia_PAEDS,"Paediatric SARS-CoV-2 serosurvey 2022, Australia
Summary report",2022-11-03,Institutional Report,National,Cross-sectional survey ,Australia,"New South Wales, Victoria, South Australia, Western Australia, Northern Territory, Queensland","Westmead, Sydney, Melbourne, Adelaide, Perth, Darwin, Brisbane","""Children [aged 0-19] undergoing an anaesthetic procedure (e.g. for day surgery, trauma or other reason) were recruited for this study through eight paediatric hospitals of the Paediatric Active Enhanced Disease Surveillance (PAEDS) network across Australia.""","""Children who were immunosuppressed or receiving intravenous immunoglobulin were excluded due to the possibility that they may not have a strong antibody response to infection or they may have had donor antibody from the blood product donation, respectively.""",2022-06-08,2022-08-31,Residual sera,Other,Children and Youth (0-17 years),0.0,19.0,Sex/Gender,Other,2,1.0,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Paediatric Active Enhanced Disease Surveillance (PAEDS),Paediatric Active Enhanced Disease Surveillance (PAEDS),Unity-Aligned,https://paeds.org.au/sites/default/files/2022-11/PAEDS%20NCIRS_COVID-19%20Paediatric%20Serosurvey%202022%20Report_3-11-2022_Final_1.pdf,2022-11-17,2024-04-17,Verified,paediatric_active_enhanced_disease_surveillance_paeds_paediatric_2022,AUS
221103_Australia_PAEDS_Age_1-4,221103_Australia_PAEDS,"Paediatric SARS-CoV-2 serosurvey 2022, Australia
Summary report",2022-11-03,Institutional Report,National,Cross-sectional survey ,Australia,"New South Wales, Victoria, South Australia, Western Australia, Northern Territory, Queensland","Westmead, Sydney, Melbourne, Adelaide, Perth, Darwin, Brisbane","""Children [aged 0-19] undergoing an anaesthetic procedure (e.g. for day surgery, trauma or other reason) were recruited for this study through eight paediatric hospitals of the Paediatric Active Enhanced Disease Surveillance (PAEDS) network across Australia.""","""Children who were immunosuppressed or receiving intravenous immunoglobulin were excluded due to the possibility that they may not have a strong antibody response to infection or they may have had donor antibody from the blood product donation, respectively.""",2022-06-08,2022-08-31,Residual sera,All,Children and Youth (0-17 years),1.0,4.0,Age,1-4,671,0.7884000000000001,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Paediatric Active Enhanced Disease Surveillance (PAEDS),Paediatric Active Enhanced Disease Surveillance (PAEDS),Unity-Aligned,https://paeds.org.au/sites/default/files/2022-11/PAEDS%20NCIRS_COVID-19%20Paediatric%20Serosurvey%202022%20Report_3-11-2022_Final_1.pdf,2022-11-17,2024-04-17,Verified,paediatric_active_enhanced_disease_surveillance_paeds_paediatric_2022,AUS
221103_Australia_PAEDS_Unvaccinated,221103_Australia_PAEDS,"Paediatric SARS-CoV-2 serosurvey 2022, Australia
Summary report",2022-11-03,Institutional Report,National,Cross-sectional survey ,Australia,"New South Wales, Victoria, South Australia, Western Australia, Northern Territory, Queensland","Westmead, Sydney, Melbourne, Adelaide, Perth, Darwin, Brisbane","""Children [aged 0-19] undergoing an anaesthetic procedure (e.g. for day surgery, trauma or other reason) were recruited for this study through eight paediatric hospitals of the Paediatric Active Enhanced Disease Surveillance (PAEDS) network across Australia.""","""Children who were immunosuppressed or receiving intravenous immunoglobulin were excluded due to the possibility that they may not have a strong antibody response to infection or they may have had donor antibody from the blood product donation, respectively.""",2022-06-08,2022-08-31,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,COVID-19 vaccination status,Unvaccinated,1170,0.8214,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Paediatric Active Enhanced Disease Surveillance (PAEDS),Paediatric Active Enhanced Disease Surveillance (PAEDS),Unity-Aligned,https://paeds.org.au/sites/default/files/2022-11/PAEDS%20NCIRS_COVID-19%20Paediatric%20Serosurvey%202022%20Report_3-11-2022_Final_1.pdf,2022-11-17,2024-04-17,Verified,paediatric_active_enhanced_disease_surveillance_paeds_paediatric_2022,AUS
221103_Australia_PAEDS_Region_WesternAustralia,221103_Australia_PAEDS,"Paediatric SARS-CoV-2 serosurvey 2022, Australia
Summary report",2022-11-03,Institutional Report,Local,Cross-sectional survey ,Australia,Western Australia,Perth,"""Children [aged 0-19] undergoing an anaesthetic procedure (e.g. for day surgery, trauma or other reason) were recruited for this study through eight paediatric hospitals of the Paediatric Active Enhanced Disease Surveillance (PAEDS) network across Australia.""","""Children who were immunosuppressed or receiving intravenous immunoglobulin were excluded due to the possibility that they may not have a strong antibody response to infection or they may have had donor antibody from the blood product donation, respectively.""",2022-06-08,2022-08-31,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Geographical area,Western Australia,281,0.8114,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Paediatric Active Enhanced Disease Surveillance (PAEDS),Paediatric Active Enhanced Disease Surveillance (PAEDS),Unity-Aligned,https://paeds.org.au/sites/default/files/2022-11/PAEDS%20NCIRS_COVID-19%20Paediatric%20Serosurvey%202022%20Report_3-11-2022_Final_1.pdf,2022-11-17,2024-04-17,Verified,paediatric_active_enhanced_disease_surveillance_paeds_paediatric_2022,AUS
221103_Australia_KirbyInstitute_antiS,221103_Australia_KirbyInstitute,Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors: Round 3 update,2022-11-03,Institutional Report,National,Repeated cross-sectional study,Australia,,,The Australian COVID-19 Serosurveillance Network is conducting regular serological surveys among Australian blood donors (aged 18 years and older) to study prevalence of antibodies to SARS-CoV-2 in Australia.,,2022-08-23,2022-09-02,Blood donors,All,Multiple groups,18.0,84.0,Primary Estimate,anti-S overall,5005,0.996,0.993,0.997,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/project/serosurveillance-sars-cov-2-infection-inform-public-health-responses,2022-11-14,2024-04-17,Verified,kirby_institute_seroprevalence_2022,AUS
221103_Australia_KirbyInstitute_antiS_Queensland,221103_Australia_KirbyInstitute,Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors: Round 3 update,2022-11-03,Institutional Report,Regional,Repeated cross-sectional study,Australia,Queensland,,The Australian COVID-19 Serosurveillance Network is conducting regular serological surveys among Australian blood donors (aged 18 years and older) to study prevalence of antibodies to SARS-CoV-2 in Australia.,,2022-08-23,2022-09-02,Blood donors,All,Multiple groups,18.0,84.0,Geographical area,anti-S Queensland Jurisdition,960,0.998,0.996,0.9990000000000001,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/project/serosurveillance-sars-cov-2-infection-inform-public-health-responses,2022-11-14,2024-04-17,Verified,kirby_institute_seroprevalence_2022,AUS
221103_Australia_KirbyInstitute_antiS_Male,221103_Australia_KirbyInstitute,Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors: Round 3 update,2022-11-03,Institutional Report,National,Repeated cross-sectional study,Australia,,,The Australian COVID-19 Serosurveillance Network is conducting regular serological surveys among Australian blood donors (aged 18 years and older) to study prevalence of antibodies to SARS-CoV-2 in Australia.,,2022-08-23,2022-09-02,Blood donors,Male,Multiple groups,18.0,89.0,Sex/Gender,"anti-S overall, male",2796,0.996,0.993,0.998,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/project/serosurveillance-sars-cov-2-infection-inform-public-health-responses,2022-11-14,2024-04-17,Verified,kirby_institute_seroprevalence_2022,AUS
221103_Australia_KirbyInstitute_antiS_NSW,221103_Australia_KirbyInstitute,Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors: Round 3 update,2022-11-03,Institutional Report,Regional,Repeated cross-sectional study,Australia,New South Wales,,The Australian COVID-19 Serosurveillance Network is conducting regular serological surveys among Australian blood donors (aged 18 years and older) to study prevalence of antibodies to SARS-CoV-2 in Australia.,,2022-08-23,2022-09-02,Blood donors,All,Multiple groups,18.0,84.0,Geographical area,anti-S NSW Jurisdition,1185,0.996,0.99,0.998,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/project/serosurveillance-sars-cov-2-infection-inform-public-health-responses,2022-11-14,2024-04-17,Verified,kirby_institute_seroprevalence_2022,AUS
221103_Australia_KirbyInstitute_antiS_Age18to29,221103_Australia_KirbyInstitute,Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors: Round 3 update,2022-11-03,Institutional Report,National,Repeated cross-sectional study,Australia,,,The Australian COVID-19 Serosurveillance Network is conducting regular serological surveys among Australian blood donors (aged 18 years and older) to study prevalence of antibodies to SARS-CoV-2 in Australia.,,2022-08-23,2022-09-02,Blood donors,All,Adults (18-64 years),18.0,29.0,Age,"anti-S overall, age: 18-29",911,1.0,0.996,1.0,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/project/serosurveillance-sars-cov-2-infection-inform-public-health-responses,2022-11-14,2024-04-17,Verified,kirby_institute_seroprevalence_2022,AUS
221103_Australia_KirbyInstitute_antiS_Age50to59,221103_Australia_KirbyInstitute,Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors: Round 3 update,2022-11-03,Institutional Report,National,Repeated cross-sectional study,Australia,,,The Australian COVID-19 Serosurveillance Network is conducting regular serological surveys among Australian blood donors (aged 18 years and older) to study prevalence of antibodies to SARS-CoV-2 in Australia.,,2022-08-23,2022-09-02,Blood donors,All,Adults (18-64 years),50.0,59.0,Age,"anti-S overall, age: 50-59",1097,0.993,0.986,0.996,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/project/serosurveillance-sars-cov-2-infection-inform-public-health-responses,2022-11-14,2024-04-17,Verified,kirby_institute_seroprevalence_2022,AUS
221103_Australia_KirbyInstitute_antiN,221103_Australia_KirbyInstitute,Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors: Round 3 update,2022-11-03,Institutional Report,National,Repeated cross-sectional study,Australia,,,The Australian COVID-19 Serosurveillance Network is conducting regular serological surveys among Australian blood donors (aged 18 years and older) to study prevalence of antibodies to SARS-CoV-2 in Australia.,,2022-08-23,2022-09-02,Blood donors,All,Multiple groups,18.0,84.0,Test used,anti-N overall,5005,0.652,0.639,0.665,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Multiple Types,,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.84,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/project/serosurveillance-sars-cov-2-infection-inform-public-health-responses,2022-11-14,2024-04-17,Verified,kirby_institute_seroprevalence_2022,AUS
221103_Australia_KirbyInstitute_antiS_Female,221103_Australia_KirbyInstitute,Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors: Round 3 update,2022-11-03,Institutional Report,National,Repeated cross-sectional study,Australia,,,The Australian COVID-19 Serosurveillance Network is conducting regular serological surveys among Australian blood donors (aged 18 years and older) to study prevalence of antibodies to SARS-CoV-2 in Australia.,,2022-08-23,2022-09-02,Blood donors,Female,Multiple groups,18.0,89.0,Sex/Gender,"anti-S overall, female",2209,0.996,0.9920000000000001,0.998,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/project/serosurveillance-sars-cov-2-infection-inform-public-health-responses,2022-11-14,2024-04-17,Verified,kirby_institute_seroprevalence_2022,AUS
221103_Australia_KirbyInstitute_antiS_Age70to89,221103_Australia_KirbyInstitute,Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors: Round 3 update,2022-11-03,Institutional Report,National,Repeated cross-sectional study,Australia,,,The Australian COVID-19 Serosurveillance Network is conducting regular serological surveys among Australian blood donors (aged 18 years and older) to study prevalence of antibodies to SARS-CoV-2 in Australia.,,2022-08-23,2022-09-02,Blood donors,All,Seniors (65+ years),70.0,89.0,Age,"anti-S overall, age: 70-89",284,0.986,0.963,0.995,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/project/serosurveillance-sars-cov-2-infection-inform-public-health-responses,2022-11-14,2024-04-17,Verified,kirby_institute_seroprevalence_2022,AUS
221103_Australia_KirbyInstitute_antiS_Age40to49,221103_Australia_KirbyInstitute,Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors: Round 3 update,2022-11-03,Institutional Report,National,Repeated cross-sectional study,Australia,,,The Australian COVID-19 Serosurveillance Network is conducting regular serological surveys among Australian blood donors (aged 18 years and older) to study prevalence of antibodies to SARS-CoV-2 in Australia.,,2022-08-23,2022-09-02,Blood donors,All,Adults (18-64 years),40.0,49.0,Age,"anti-S overall, age: 40-49",970,0.993,0.985,0.997,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/project/serosurveillance-sars-cov-2-infection-inform-public-health-responses,2022-11-14,2024-04-17,Verified,kirby_institute_seroprevalence_2022,AUS
221103_Australia_KirbyInstitute_antiS_Age30to39,221103_Australia_KirbyInstitute,Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors: Round 3 update,2022-11-03,Institutional Report,National,Repeated cross-sectional study,Australia,,,The Australian COVID-19 Serosurveillance Network is conducting regular serological surveys among Australian blood donors (aged 18 years and older) to study prevalence of antibodies to SARS-CoV-2 in Australia.,,2022-08-23,2022-09-02,Blood donors,All,Adults (18-64 years),30.0,39.0,Age,"anti-S overall, age: 30-39",904,0.9990000000000001,0.9920000000000001,1.0,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/project/serosurveillance-sars-cov-2-infection-inform-public-health-responses,2022-11-14,2024-04-17,Verified,kirby_institute_seroprevalence_2022,AUS
221103_Australia_KirbyInstitute_antiS_Age60to69,221103_Australia_KirbyInstitute,Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors: Round 3 update,2022-11-03,Institutional Report,National,Repeated cross-sectional study,Australia,,,The Australian COVID-19 Serosurveillance Network is conducting regular serological surveys among Australian blood donors (aged 18 years and older) to study prevalence of antibodies to SARS-CoV-2 in Australia.,,2022-08-23,2022-09-02,Blood donors,All,Adults (18-64 years),60.0,69.0,Age,"anti-S overall, age: 60-69",839,0.998,0.991,0.9990000000000001,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/project/serosurveillance-sars-cov-2-infection-inform-public-health-responses,2022-11-14,2024-04-17,Verified,kirby_institute_seroprevalence_2022,AUS
221103_Australia_KirbyInstitute_antiS_Tasmania,221103_Australia_KirbyInstitute,Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors: Round 3 update,2022-11-03,Institutional Report,Regional,Repeated cross-sectional study,Australia,Tasmania,,The Australian COVID-19 Serosurveillance Network is conducting regular serological surveys among Australian blood donors (aged 18 years and older) to study prevalence of antibodies to SARS-CoV-2 in Australia.,,2022-08-23,2022-09-02,Blood donors,All,Multiple groups,18.0,84.0,Geographical area,anti-S Tasmania Jurisdition,202,0.99,0.961,0.998,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/project/serosurveillance-sars-cov-2-infection-inform-public-health-responses,2022-11-14,2024-04-17,Verified,kirby_institute_seroprevalence_2022,AUS
221103_Australia_KirbyInstitute_antiS_NT,221103_Australia_KirbyInstitute,Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors: Round 3 update,2022-11-03,Institutional Report,Regional,Repeated cross-sectional study,Australia,Northern Territory,,The Australian COVID-19 Serosurveillance Network is conducting regular serological surveys among Australian blood donors (aged 18 years and older) to study prevalence of antibodies to SARS-CoV-2 in Australia.,,2022-08-23,2022-09-02,Blood donors,All,Multiple groups,18.0,84.0,Geographical area,anti-S NT Jurisdition,186,1.0,0.98,1.0,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/project/serosurveillance-sars-cov-2-infection-inform-public-health-responses,2022-11-14,2024-04-17,Verified,kirby_institute_seroprevalence_2022,AUS
221103_Australia_KirbyInstitute_antiS_WA,221103_Australia_KirbyInstitute,Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors: Round 3 update,2022-11-03,Institutional Report,Regional,Repeated cross-sectional study,Australia,Western Australia,,The Australian COVID-19 Serosurveillance Network is conducting regular serological surveys among Australian blood donors (aged 18 years and older) to study prevalence of antibodies to SARS-CoV-2 in Australia.,,2022-08-23,2022-09-02,Blood donors,All,Multiple groups,18.0,84.0,Geographical area,anti-S WA Jurisdition,996,0.993,0.985,0.997,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/project/serosurveillance-sars-cov-2-infection-inform-public-health-responses,2022-11-14,2024-04-17,Verified,kirby_institute_seroprevalence_2022,AUS
221103_Australia_KirbyInstitute_antiS_Victoria,221103_Australia_KirbyInstitute,Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors: Round 3 update,2022-11-03,Institutional Report,Regional,Repeated cross-sectional study,Australia,Victoria,,The Australian COVID-19 Serosurveillance Network is conducting regular serological surveys among Australian blood donors (aged 18 years and older) to study prevalence of antibodies to SARS-CoV-2 in Australia.,,2022-08-23,2022-09-02,Blood donors,All,Multiple groups,18.0,84.0,Geographical area,anti-S Victoria Jurisdition,1105,0.997,0.9920000000000001,0.9990000000000001,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/project/serosurveillance-sars-cov-2-infection-inform-public-health-responses,2022-11-14,2024-04-17,Verified,kirby_institute_seroprevalence_2022,AUS
221103_Australia_KirbyInstitute_antiS_ACT,221103_Australia_KirbyInstitute,Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors: Round 3 update,2022-11-03,Institutional Report,Regional,Repeated cross-sectional study,Australia,Australian Capital Territory,,The Australian COVID-19 Serosurveillance Network is conducting regular serological surveys among Australian blood donors (aged 18 years and older) to study prevalence of antibodies to SARS-CoV-2 in Australia.,,2022-08-23,2022-09-02,Blood donors,All,Multiple groups,18.0,84.0,Geographical area,anti-S ACT Jurisdition,165,1.0,0.978,1.0,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/project/serosurveillance-sars-cov-2-infection-inform-public-health-responses,2022-11-14,2024-04-17,Verified,kirby_institute_seroprevalence_2022,AUS
221103_Australia_KirbyInstitute_antiS_SA,221103_Australia_KirbyInstitute,Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors: Round 3 update,2022-11-03,Institutional Report,Regional,Repeated cross-sectional study,Australia,South Australia,,The Australian COVID-19 Serosurveillance Network is conducting regular serological surveys among Australian blood donors (aged 18 years and older) to study prevalence of antibodies to SARS-CoV-2 in Australia.,,2022-08-23,2022-09-02,Blood donors,All,Multiple groups,18.0,84.0,Geographical area,anti-S SA Jurisdition,206,0.995,0.966,0.9990000000000001,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/project/serosurveillance-sars-cov-2-infection-inform-public-health-responses,2022-11-14,2024-04-17,Verified,kirby_institute_seroprevalence_2022,AUS
230119_Australia_UniversityofNewSouthWales,230119_Australia_UniversityofNewSouthWales,SARS-CoV-2 Seroprevalence in a Cohort of International Travellers Returning to Rural Australia: Enablers and Barriers to Containment of COVID-19,2023-01-19,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Australia,,,"""All international travellers 18 years of age and over who had returned to Australia between 1 January and 31 March and who received SARS-CoV-2 nucleic acid testing (NAT) through Albury Wodonga Health Service were approached for inclusion in this study. ""","""People were excluded from the study if they were younger than 18 years of age, died prior to the collection of sera for SARS-CoV-2 serology, did not travel internationally or did not receive SARS-CoV-2 NAT.""",2021-01-01,2021-03-31,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,99,0.0808,,,True,,,,True,Convenience,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgA', 'IgG', 'IgM', 'TotalAntibody']",,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Justin Jackson,University of New South Wales,Not Unity-Aligned,https://dx.doi.org/10.1016/j.anzjph.2022.100003,2023-02-09,2023-03-19,Unverified,jacksonSARSCoV2SeroprevalenceCohort2023,AUS
230119_Burnie_DepartmentofHealthTasmania_Round1_Overall,230119_Burnie_DepartmentofHealthTasmania_Round1,"Serology study of healthcare workers following a hospital-based outbreak of COVID-19 in North West Tasmania, Australia, 2020",2023-01-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,Tasmani,Burnie,clinical and non-clinical workers who worked on the implicated health campus between 20 March and 13 April 2020.,,2020-07-06,2020-08-14,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,261,0.146,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Michelle McPherson,"Public Health Services, Department of Health, Tasmania, Australia",Not Unity-Aligned,https://dx.doi.org/10.33321/cdi.2023.47.6,2023-02-09,2024-03-01,Unverified,mcpherson_serology_2023,AUS
230119_Burnie_DepartmentofHealthTasmania_Round2_Overall,230119_Burnie_DepartmentofHealthTasmania_Round2,"Serology study of healthcare workers following a hospital-based outbreak of COVID-19 in North West Tasmania, Australia, 2020",2023-01-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Australia,Tasmani,Burnie,clinical and non-clinical workers who worked on the implicated health campus between 20 March and 13 April 2020.,,2020-12-07,2020-12-24,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,129,0.11599999999999999,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Michelle McPherson,"Public Health Services, Department of Health, Tasmania, Australia",Not Unity-Aligned,https://dx.doi.org/10.33321/cdi.2023.47.6,2023-02-09,2024-03-01,Unverified,mcpherson_serology_2023,AUS
230208_Australia_KirbyInstitute_AntiS,230208_Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among
Australian blood donors: Round 4 update",2023-02-08,Institutional Report,National,Repeated cross-sectional study,Australia,,,"In Round 4, 4,996 de-identified specimens from all Australian states and territories were tested for the presence of 2 types of antibodies to SARS-CoV-2 using commercially available Roche assays.",,2022-11-29,2022-12-13,Blood donors,All,Multiple groups,18.0,89.0,Primary Estimate,anti-S overall,4996,0.996,0.994,0.997,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/project/serosurveillance-sars-cov-2-infection-inform-public-health-responses,2023-03-31,2024-04-12,Verified,kirby_institute_seroprevalence_2023,AUS
230208_Australia_KirbyInstitute_40-49_AntiS,230208_Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among
Australian blood donors: Round 4 update",2023-02-08,Institutional Report,National,Repeated cross-sectional study,Australia,,,"In Round 4, 4,996 de-identified specimens from all Australian states and territories were tested for the presence of 2 types of antibodies to SARS-CoV-2 using commercially available Roche assays.",,2022-11-29,2022-12-13,Blood donors,All,Adults (18-64 years),40.0,49.0,Age,40-49,912,0.996,0.988,0.998,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/project/serosurveillance-sars-cov-2-infection-inform-public-health-responses,2024-04-12,2024-04-12,Verified,kirby_institute_seroprevalence_2023,AUS
230208_Australia_KirbyInstitute_Victoria_AntiS,230208_Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among
Australian blood donors: Round 4 update",2023-02-08,Institutional Report,Regional,Repeated cross-sectional study,Australia,Victoria,,"In Round 4, 4,996 de-identified specimens from all Australian states and territories were tested for the presence of 2 types of antibodies to SARS-CoV-2 using commercially available Roche assays.",,2022-11-29,2022-12-13,Blood donors,All,Multiple groups,18.0,89.0,Geographical area,,1090,0.998,0.993,1.0,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/project/serosurveillance-sars-cov-2-infection-inform-public-health-responses,2023-03-31,2024-04-12,Verified,kirby_institute_seroprevalence_2023,AUS
230208_Australia_KirbyInstitute_30-39_AntiS,230208_Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among
Australian blood donors: Round 4 update",2023-02-08,Institutional Report,National,Repeated cross-sectional study,Australia,,,"In Round 4, 4,996 de-identified specimens from all Australian states and territories were tested for the presence of 2 types of antibodies to SARS-CoV-2 using commercially available Roche assays.",,2022-11-29,2022-12-13,Blood donors,All,Adults (18-64 years),30.0,39.0,Age,30-39,944,0.996,0.989,0.998,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/project/serosurveillance-sars-cov-2-infection-inform-public-health-responses,2024-04-12,2024-04-12,Verified,kirby_institute_seroprevalence_2023,AUS
230208_Australia_KirbyInstitute_WA_AntiS,230208_Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among
Australian blood donors: Round 4 update",2023-02-08,Institutional Report,Regional,Repeated cross-sectional study,Australia,WA,,"In Round 4, 4,996 de-identified specimens from all Australian states and territories were tested for the presence of 2 types of antibodies to SARS-CoV-2 using commercially available Roche assays.",,2022-11-29,2022-12-13,Blood donors,All,Multiple groups,18.0,89.0,Geographical area,,989,0.993,0.985,0.997,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/project/serosurveillance-sars-cov-2-infection-inform-public-health-responses,2023-03-31,2024-04-12,Verified,kirby_institute_seroprevalence_2023,AUS
230208_Australia_KirbyInstitute_Queensland_AntiS,230208_Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among
Australian blood donors: Round 4 update",2023-02-08,Institutional Report,Regional,Repeated cross-sectional study,Australia,Queensland,,"In Round 4, 4,996 de-identified specimens from all Australian states and territories were tested for the presence of 2 types of antibodies to SARS-CoV-2 using commercially available Roche assays.",,2022-11-29,2022-12-13,Blood donors,All,Multiple groups,18.0,89.0,Geographical area,,992,0.992,0.984,0.996,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/project/serosurveillance-sars-cov-2-infection-inform-public-health-responses,2023-03-31,2024-04-12,Verified,kirby_institute_seroprevalence_2023,AUS
230208_Australia_KirbyInstitute_AntiN,230208_Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among
Australian blood donors: Round 4 update",2023-02-08,Institutional Report,National,Repeated cross-sectional study,Australia,,,"In Round 4, 4,996 de-identified specimens from all Australian states and territories were tested for the presence of 2 types of antibodies to SARS-CoV-2 using commercially available Roche assays.",,2022-11-29,2022-12-13,Blood donors,All,Multiple groups,18.0,89.0,Test used,anti-N overall,4996,0.708,0.695,0.72,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/project/serosurveillance-sars-cov-2-infection-inform-public-health-responses,2023-03-31,2024-04-12,Verified,kirby_institute_seroprevalence_2023,AUS
230208_Australia_KirbyInstitute_60-69_AntiS,230208_Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among
Australian blood donors: Round 4 update",2023-02-08,Institutional Report,National,Repeated cross-sectional study,Australia,,,"In Round 4, 4,996 de-identified specimens from all Australian states and territories were tested for the presence of 2 types of antibodies to SARS-CoV-2 using commercially available Roche assays.",,2022-11-29,2022-12-13,Blood donors,All,Multiple groups,60.0,69.0,Age,60-69,915,0.997,0.99,0.999,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/project/serosurveillance-sars-cov-2-infection-inform-public-health-responses,2024-04-12,2024-04-12,Verified,kirby_institute_seroprevalence_2023,AUS
230208_Australia_KirbyInstitute_70-89_AntiS,230208_Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among
Australian blood donors: Round 4 update",2023-02-08,Institutional Report,National,Repeated cross-sectional study,Australia,,,"In Round 4, 4,996 de-identified specimens from all Australian states and territories were tested for the presence of 2 types of antibodies to SARS-CoV-2 using commercially available Roche assays.",,2022-11-29,2022-12-13,Blood donors,All,Seniors (65+ years),70.0,89.0,Age,70-89,323,0.994,0.976,0.999,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/project/serosurveillance-sars-cov-2-infection-inform-public-health-responses,2024-04-12,2024-04-12,Verified,kirby_institute_seroprevalence_2023,AUS
230208_Australia_KirbyInstitute_18-29_AntiS,230208_Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among
Australian blood donors: Round 4 update",2023-02-08,Institutional Report,National,Repeated cross-sectional study,Australia,,,"In Round 4, 4,996 de-identified specimens from all Australian states and territories were tested for the presence of 2 types of antibodies to SARS-CoV-2 using commercially available Roche assays.",,2022-11-29,2022-12-13,Blood donors,All,Adults (18-64 years),18.0,29.0,Age,18-29,849,0.998,0.991,0.999,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/project/serosurveillance-sars-cov-2-infection-inform-public-health-responses,2024-04-12,2024-04-12,Verified,kirby_institute_seroprevalence_2023,AUS
230208_Australia_KirbyInstitute_NSW_AntiS,230208_Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among
Australian blood donors: Round 4 update",2023-02-08,Institutional Report,Regional,Repeated cross-sectional study,Australia,NSW,,"In Round 4, 4,996 de-identified specimens from all Australian states and territories were tested for the presence of 2 types of antibodies to SARS-CoV-2 using commercially available Roche assays.",,2022-11-29,2022-12-13,Blood donors,All,Multiple groups,18.0,89.0,Geographical area,,1171,0.997,0.992,0.999,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/project/serosurveillance-sars-cov-2-infection-inform-public-health-responses,2023-03-31,2024-04-12,Verified,kirby_institute_seroprevalence_2023,AUS
230208_Australia_KirbyInstitute_Tasmania_AntiS,230208_Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among
Australian blood donors: Round 4 update",2023-02-08,Institutional Report,Regional,Repeated cross-sectional study,Australia,Tasmania,,"In Round 4, 4,996 de-identified specimens from all Australian states and territories were tested for the presence of 2 types of antibodies to SARS-CoV-2 using commercially available Roche assays.",,2022-11-29,2022-12-13,Blood donors,All,Multiple groups,18.0,89.0,Geographical area,,199,1.0,0.982,1.0,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/project/serosurveillance-sars-cov-2-infection-inform-public-health-responses,2023-03-31,2024-04-12,Verified,kirby_institute_seroprevalence_2023,AUS
230208_Australia_KirbyInstitute_SA_AntiS,230208_Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among
Australian blood donors: Round 4 update",2023-02-08,Institutional Report,Regional,Repeated cross-sectional study,Australia,SA,,"In Round 4, 4,996 de-identified specimens from all Australian states and territories were tested for the presence of 2 types of antibodies to SARS-CoV-2 using commercially available Roche assays.",,2022-11-29,2022-12-13,Blood donors,All,Multiple groups,18.0,89.0,Geographical area,,203,0.995,0.966,0.999,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/project/serosurveillance-sars-cov-2-infection-inform-public-health-responses,2023-03-31,2024-04-12,Verified,kirby_institute_seroprevalence_2023,AUS
230208_Australia_KirbyInstitute_50-59_AntiS,230208_Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among
Australian blood donors: Round 4 update",2023-02-08,Institutional Report,National,Repeated cross-sectional study,Australia,,,"In Round 4, 4,996 de-identified specimens from all Australian states and territories were tested for the presence of 2 types of antibodies to SARS-CoV-2 using commercially available Roche assays.",,2022-11-29,2022-12-13,Blood donors,All,Adults (18-64 years),50.0,59.0,Age,50-59,1053,0.994,0.987,0.997,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/project/serosurveillance-sars-cov-2-infection-inform-public-health-responses,2024-04-12,2024-04-12,Verified,kirby_institute_seroprevalence_2023,AUS
230208_Australia_KirbyInstitute_ACT_AntiS,230208_Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among
Australian blood donors: Round 4 update",2023-02-08,Institutional Report,Regional,Repeated cross-sectional study,Australia,ACT,,"In Round 4, 4,996 de-identified specimens from all Australian states and territories were tested for the presence of 2 types of antibodies to SARS-CoV-2 using commercially available Roche assays.",,2022-11-29,2022-12-13,Blood donors,All,Multiple groups,18.0,89.0,Geographical area,,168,1.0,0.978,1.0,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/project/serosurveillance-sars-cov-2-infection-inform-public-health-responses,2023-03-31,2024-04-12,Verified,kirby_institute_seroprevalence_2023,AUS
230208_Australia_KirbyInstitute_NT_AntiS,230208_Australia_KirbyInstitute,"Seroprevalence of SARS-CoV-2-specific antibodies among
Australian blood donors: Round 4 update",2023-02-08,Institutional Report,Regional,Repeated cross-sectional study,Australia,NT,,"In Round 4, 4,996 de-identified specimens from all Australian states and territories were tested for the presence of 2 types of antibodies to SARS-CoV-2 using commercially available Roche assays.",,2022-11-29,2022-12-13,Blood donors,All,Multiple groups,18.0,89.0,Geographical area,,184,1.0,0.98,1.0,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Multiple Types,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,The Australian COVID-19 Serosurveillance Network,The Kirby Institute,Unity-Aligned,https://kirby.unsw.edu.au/project/serosurveillance-sars-cov-2-infection-inform-public-health-responses,2023-03-31,2024-04-12,Verified,kirby_institute_seroprevalence_2023,AUS
200720_Tyrol_InnsbruckClinicalMicrobiologyLaboratory_Physicians_IgG,200720_Tyrol_InnsbruckClinicalMicrobiologyLaboratory,Antibody kinetics in primary- and secondary-care physicians with mild to moderate SARS-CoV-2 infection,2020-07-20,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Austria,Tyrol,,"377 individuals (201male, 176 female; median age: 51 years, median number of patient contacts 38 per day) had either a negative
or no PCR test and only a minority reported symptoms
compatible with a SARS-CoV-2 infection. ",,2020-03-20,2020-03-27,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,377,0.003,0.0001,0.015,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,,Validated by manufacturers,,,['High'],Yes,No,No,Yes,No,Yes,Yes,Yes,Unclear,Dorothea Orth-Holler,Innsbruck Clinical Microbiology Laboratory,Not Unity-Aligned,https://www.tandfonline.com/doi/pdf/10.1080/22221751.2020.1793690,2020-08-01,2024-03-01,Verified,orth-holler_antibody_2020,AUT
200819_Autria_UniversityHospitalKrems_hcw_ELISA_IgGIgM,200819_Austria_UniversityHospitalKrems,Diagnostic accuracy of two commercially available rapid assays for detection of IgG and IgM antibodies to SARS-CoV-2 compared to ELISA in a low-prevalence population,2020-08-19,Preprint,Local,Cross-sectional survey ,Austria,,,"All participants were recruited at the University Hospital Krems, Austria, in April 2020. The participants belonged to hospital staff (e.g. medical doctors, nurses, biomedical analysts, and physiotherapists), with known close contact to COVID-19 patients without wearing personal protective equipment, mainly due to
a primarily negative (but repeated and subsequently positive) RT-PCR-result and/or lack of symptoms of the patients.",,2020-04-01,2020-04-30,Health care workers and caregivers,All,Adults (18-64 years),19.0,64.0,Primary Estimate,,130,0.023,,,True,,,,True,Convenience,EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit,"Epitope Diagnostics, Inc.",ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Klaus Hackner,Karl Landsteiner University of Health Sciences,Not Unity-Aligned,https://www.researchsquare.com/article/rs-50887/v1,2020-10-18,2024-03-01,Verified,hackner_diagnostic_2020,AUT
200808_Vienna_MedicalUniversityOfVienna_HCP,200808_Vienna_MedicalUniversityOfVienna_HCP,SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic.,2020-09-02,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Austria,Vienna,Vienna,Oncological HCPs were included.,,2020-04-01,2020-06-04,Health care workers and caregivers,All,Adults (18-64 years),23.0,59.0,Primary Estimate,Healthcare professionals,62,0.032,0.004,0.11199999999999999,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,No,Unclear,Thorsten Fuereder,Medical University of Vienna,Not Unity-Aligned,https://dx.doi.org/10.1136/esmoopen-2020-000889,2020-11-05,2024-03-01,Verified,fuereder_sars-cov-2_2020,AUT
200808_Vienna_MedicalUniversityOfVienna_Patients,200808_Vienna_MedicalUniversityofVienna_Patients,SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic.,2020-09-02,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Austria,Vienna,Vienna,"all patients, who consented to participate in our biobanking programme and were both routinely tested for SARS-CoV-2 and for whom archival serum was available in our biobank facility between 21 March and 4 June 2020 at the Division of Oncology, Medical University of Vienna, Vienna",,2020-03-21,2020-06-04,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,86.0,Primary Estimate,Oncology patients,84,0.024,0.003,0.083,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,No,Unclear,Thorsten Fuereder,Medical University of Vienna,Not Unity-Aligned,https://dx.doi.org/10.1136/esmoopen-2020-000889,2020-11-05,2024-03-01,Verified,fuereder_sars-cov-2_2020,AUT
201211_Austria_StatistikAustria_overall_PopAdj,201211_Austria_StatistikAustria,COVID-19 Prävalenz und Seroprävalenz,2020-12-11,Institutional Report,National,Cross-sectional survey ,Austria,,,Individuals aged 16 and over in private households in Austria,,2020-11-12,2020-11-14,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,,2229,0.047,0.038,0.055999999999999994,True,,True,,True,Simplified probability,Author designed (Neutralization Assay),,Multiple Types,Serum,,,,,,['Moderate'],,Yes,Yes,No,,Unclear,Yes,No,,Statistik Austria,StatistikAustria,Not Unity-Aligned,http://www.statistik.at/wcm/idc/idcplg?IdcService=GET_PDF_FILE&dDocName=124957,2021-05-21,2022-07-16,Unverified,noauthor_covid-19_2020,AUT
201212_Europe_UniversityOfGlasgow_Austria3,201212_Europe_UniversityOfGlasgow_Austria3,SARS-Cov-2 viral and serological screening of staff in 31 European fertility units.,2020-12-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Austria,,"Klagenfurt, Vienna and Wels","all staff members recommencing work at the Fertility Partnership, including clinical and head office staf",,2020-04-15,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,72,0.0278,0.0077,0.0958,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,,Scott M Nelson,University of Glasgow,Not Unity-Aligned,https://dx.doi.org/10.1093/hropen/hoaa056,2021-06-07,2024-03-01,Verified,nelson_sars-cov-2_2020,AUT
201222_Vienna_MedicalUniversityofVienna_Overall,201222_Vienna_MedicalUniversityofVienna,A longitudinal seroprevalence study in a large cohort of working adults reveals that neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independent of the severity of symptoms,2020-12-22,Preprint,Local,Prospective cohort,Austria,Vienna,Vienna,We included 1655 serum samples of employees working for a large company in Vienna ,,2020-04-02,2020-04-17,Non-essential workers and unemployed persons,All,Adults (18-64 years),16.0,65.0,Primary Estimate,,1655,0.1015,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA",EUROIMMUN,ELISA,Serum,"['IgA', 'IgG']",Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,Unclear,Angelika Wagner,Medical University of Vienna,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.12.22.20248604v1,2021-01-23,2024-03-01,Verified,wagner_longitudinal_2020,AUT
210108_Linz_OrdensklinikumLinzBarmherzigeSchwestern_OverallHCW,210108_Linz_OrdensklinikumLinzBarmherzigeSchwestern,"Prevalence of SARS-CoV-2 antibodies in health care personnel of two acute care hospitals in Linz, Austria",2021-01-08,Journal Article (Peer-Reviewed),Local,Prospective cohort,Austria,Upper Austria,Linz,anti-SARS-CoV-2 testing was offered to all employees of both hospitals between 15th of June 2020 and 15th of July 2020 on a voluntary basis.,,2020-06-15,2020-07-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Overall hcws,1757,0.02,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Margot Egger,Ordensklinikum Linz Barmherzige Schwestern and Konventhospital Barmherzige Brueder Linz  ,Not Unity-Aligned,https://dx.doi.org/10.1515/cclm-2020-1681,2021-03-19,2024-03-01,Verified,egger_prevalence_2021,AUT
210107_Austria_UniversityCollegeLondon_PaediatricHCW,210107_Austria_UniversityCollegeLondon,Cross Sectional Prevalence of SARS-CoV-2 antibodies in Health Care Workers in Paediatric Facilities in Eight Countries,2021-01-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Austria,,Vienna,"This was part of a larger study undertaken in HCWs in paediatric facilities in seven European sites and one South African site. Staff of all categories in each healthcare setting were invited to join the study, irrespective of symptoms or whether they suspected they had previously had COVID-19. ",,2020-07-17,2020-07-24,Health care workers and caregivers,All,Adults (18-64 years),22.0,65.0,Primary Estimate,,196,0.0,0.0,0.0192,True,,,,True,Convenience,"EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit,Meso Scale Discovery multiplex assay","Epitope Diagnostics, Inc.,Meso Scale Discovery",ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],,No,No,No,,Yes,Yes,No,,D Goldblatt,University College London,Not Unity-Aligned,http://dx.doi.org/10.1016/j.jhin.2020.12.019,2021-03-13,2024-03-01,Unverified,goldblatt_cross-sectional_2021,AUT
210129_Vienna_MedicalUniversityOfVienna_Overall,210129_Vienna_MedicalUniversityOfVienna,Lessons from low seroprevalence of SARS-CoV-2 antibodies in schoolchildren: a cross-sectional study,2021-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Austria,Vienna,Vienna,Schoolchildren in Vienna,Symptomatic children and adolescents were excluded at date of visit.,2020-05-18,2020-07-02,Students and Daycares,All,Children and Youth (0-17 years),5.0,21.0,Primary Estimate,,2042,0.012700000000000001,,,True,,,,True,Convenience,"Wantai SARS-CoV-2 Total Ab ELISA,Author designed (Neutralization Assay),Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)","Beijing Wantai Biological,NA,EUROIMMUN",Multiple Types,Serum,"['IgG', 'Neutralizing', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Unclear,Zsolt Szepfalusi,Medical University of Vienna,Not Unity-Aligned,https://dx.doi.org/10.1111/pai.13459,2021-02-16,2024-03-01,Unverified,szepfalusi_lessons_2021,AUT
210129_Vienna_MedicalUniversityOfVienna_Age_7,210129_Vienna_MedicalUniversityOfVienna,Lessons from low seroprevalence of SARS-CoV-2 antibodies in schoolchildren: a cross-sectional study,2021-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Austria,Vienna,Vienna,Schoolchildren in Vienna,Symptomatic children and adolescents were excluded at date of visit.,2020-05-18,2020-07-02,Students and Daycares,All,Children and Youth (0-17 years),7.0,7.0,Age,Age = 7,132,0.0152,,,,,,,,Convenience,"Wantai SARS-CoV-2 Total Ab ELISA,Author designed (Neutralization Assay),Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)","Beijing Wantai Biological,NA,EUROIMMUN",Multiple Types,Serum,"['IgG', 'Neutralizing', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Unclear,Zsolt Szepfalusi,Medical University of Vienna,Not Unity-Aligned,https://dx.doi.org/10.1111/pai.13459,2022-02-19,2024-03-01,Unverified,szepfalusi_lessons_2021,AUT
210129_Vienna_MedicalUniversityOfVienna_Age_5,210129_Vienna_MedicalUniversityOfVienna,Lessons from low seroprevalence of SARS-CoV-2 antibodies in schoolchildren: a cross-sectional study,2021-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Austria,Vienna,Vienna,Schoolchildren in Vienna,Symptomatic children and adolescents were excluded at date of visit.,2020-05-18,2020-07-02,Students and Daycares,All,Children and Youth (0-17 years),5.0,5.0,Age,Age = 5,1,0.0,,,,,,,,Convenience,"Wantai SARS-CoV-2 Total Ab ELISA,Author designed (Neutralization Assay),Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)","Beijing Wantai Biological,NA,EUROIMMUN",Multiple Types,Serum,"['IgG', 'Neutralizing', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Unclear,Zsolt Szepfalusi,Medical University of Vienna,Not Unity-Aligned,https://dx.doi.org/10.1111/pai.13459,2022-02-19,2024-03-01,Unverified,szepfalusi_lessons_2021,AUT
210129_Vienna_MedicalUniversityOfVienna_Age_19,210129_Vienna_MedicalUniversityOfVienna,Lessons from low seroprevalence of SARS-CoV-2 antibodies in schoolchildren: a cross-sectional study,2021-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Austria,Vienna,Vienna,Schoolchildren in Vienna,Symptomatic children and adolescents were excluded at date of visit.,2020-05-18,2020-07-02,Students and Daycares,All,Children and Youth (0-17 years),19.0,19.0,Age,Age = 19,6,0.0,,,,,,,,Convenience,"Wantai SARS-CoV-2 Total Ab ELISA,Author designed (Neutralization Assay),Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)","Beijing Wantai Biological,NA,EUROIMMUN",Multiple Types,Serum,"['IgG', 'Neutralizing', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Unclear,Zsolt Szepfalusi,Medical University of Vienna,Not Unity-Aligned,https://dx.doi.org/10.1111/pai.13459,2022-02-19,2024-03-01,Unverified,szepfalusi_lessons_2021,AUT
210129_Vienna_MedicalUniversityOfVienna_Age_20,210129_Vienna_MedicalUniversityOfVienna,Lessons from low seroprevalence of SARS-CoV-2 antibodies in schoolchildren: a cross-sectional study,2021-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Austria,Vienna,Vienna,Schoolchildren in Vienna,Symptomatic children and adolescents were excluded at date of visit.,2020-05-18,2020-07-02,Students and Daycares,All,Children and Youth (0-17 years),20.0,20.0,Age,Age = 20,1,0.0,,,,,,,,Convenience,"Wantai SARS-CoV-2 Total Ab ELISA,Author designed (Neutralization Assay),Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)","Beijing Wantai Biological,NA,EUROIMMUN",Multiple Types,Serum,"['IgG', 'Neutralizing', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Unclear,Zsolt Szepfalusi,Medical University of Vienna,Not Unity-Aligned,https://dx.doi.org/10.1111/pai.13459,2022-02-19,2024-03-01,Unverified,szepfalusi_lessons_2021,AUT
210129_Vienna_MedicalUniversityOfVienna_Age_12,210129_Vienna_MedicalUniversityOfVienna,Lessons from low seroprevalence of SARS-CoV-2 antibodies in schoolchildren: a cross-sectional study,2021-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Austria,Vienna,Vienna,Schoolchildren in Vienna,Symptomatic children and adolescents were excluded at date of visit.,2020-05-18,2020-07-02,Students and Daycares,All,Children and Youth (0-17 years),12.0,12.0,Age,Age = 12,205,0.0098,,,,,,,,Convenience,"Wantai SARS-CoV-2 Total Ab ELISA,Author designed (Neutralization Assay),Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)","Beijing Wantai Biological,NA,EUROIMMUN",Multiple Types,Serum,"['IgG', 'Neutralizing', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Unclear,Zsolt Szepfalusi,Medical University of Vienna,Not Unity-Aligned,https://dx.doi.org/10.1111/pai.13459,2022-02-19,2024-03-01,Unverified,szepfalusi_lessons_2021,AUT
210129_Vienna_MedicalUniversityOfVienna_Age_13,210129_Vienna_MedicalUniversityOfVienna,Lessons from low seroprevalence of SARS-CoV-2 antibodies in schoolchildren: a cross-sectional study,2021-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Austria,Vienna,Vienna,Schoolchildren in Vienna,Symptomatic children and adolescents were excluded at date of visit.,2020-05-18,2020-07-02,Students and Daycares,All,Children and Youth (0-17 years),13.0,13.0,Age,Age = 13,231,0.0563,,,,,,,,Convenience,"Wantai SARS-CoV-2 Total Ab ELISA,Author designed (Neutralization Assay),Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)","Beijing Wantai Biological,NA,EUROIMMUN",Multiple Types,Serum,"['IgG', 'Neutralizing', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Unclear,Zsolt Szepfalusi,Medical University of Vienna,Not Unity-Aligned,https://dx.doi.org/10.1111/pai.13459,2022-02-19,2024-03-01,Unverified,szepfalusi_lessons_2021,AUT
210129_Vienna_MedicalUniversityOfVienna_Age_9,210129_Vienna_MedicalUniversityOfVienna,Lessons from low seroprevalence of SARS-CoV-2 antibodies in schoolchildren: a cross-sectional study,2021-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Austria,Vienna,Vienna,Schoolchildren in Vienna,Symptomatic children and adolescents were excluded at date of visit.,2020-05-18,2020-07-02,Students and Daycares,All,Children and Youth (0-17 years),9.0,9.0,Age,Age = 9,150,0.0,,,,,,,,Convenience,"Wantai SARS-CoV-2 Total Ab ELISA,Author designed (Neutralization Assay),Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)","Beijing Wantai Biological,NA,EUROIMMUN",Multiple Types,Serum,"['IgG', 'Neutralizing', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Unclear,Zsolt Szepfalusi,Medical University of Vienna,Not Unity-Aligned,https://dx.doi.org/10.1111/pai.13459,2022-02-19,2024-03-01,Unverified,szepfalusi_lessons_2021,AUT
210129_Vienna_MedicalUniversityOfVienna_Age_18,210129_Vienna_MedicalUniversityOfVienna,Lessons from low seroprevalence of SARS-CoV-2 antibodies in schoolchildren: a cross-sectional study,2021-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Austria,Vienna,Vienna,Schoolchildren in Vienna,Symptomatic children and adolescents were excluded at date of visit.,2020-05-18,2020-07-02,Students and Daycares,All,Children and Youth (0-17 years),18.0,18.0,Age,Age = 18,38,0.0,,,,,,,,Convenience,"Wantai SARS-CoV-2 Total Ab ELISA,Author designed (Neutralization Assay),Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)","Beijing Wantai Biological,NA,EUROIMMUN",Multiple Types,Serum,"['IgG', 'Neutralizing', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Unclear,Zsolt Szepfalusi,Medical University of Vienna,Not Unity-Aligned,https://dx.doi.org/10.1111/pai.13459,2022-02-19,2024-03-01,Unverified,szepfalusi_lessons_2021,AUT
210129_Vienna_MedicalUniversityOfVienna_Age_21,210129_Vienna_MedicalUniversityOfVienna,Lessons from low seroprevalence of SARS-CoV-2 antibodies in schoolchildren: a cross-sectional study,2021-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Austria,Vienna,Vienna,Schoolchildren in Vienna,Symptomatic children and adolescents were excluded at date of visit.,2020-05-18,2020-07-02,Students and Daycares,All,Children and Youth (0-17 years),21.0,21.0,Age,Age = 21,1,0.0,,,,,,,,Convenience,"Wantai SARS-CoV-2 Total Ab ELISA,Author designed (Neutralization Assay),Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)","Beijing Wantai Biological,NA,EUROIMMUN",Multiple Types,Serum,"['IgG', 'Neutralizing', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Unclear,Zsolt Szepfalusi,Medical University of Vienna,Not Unity-Aligned,https://dx.doi.org/10.1111/pai.13459,2022-02-19,2024-03-01,Unverified,szepfalusi_lessons_2021,AUT
210129_Vienna_MedicalUniversityOfVienna_Age_14,210129_Vienna_MedicalUniversityOfVienna,Lessons from low seroprevalence of SARS-CoV-2 antibodies in schoolchildren: a cross-sectional study,2021-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Austria,Vienna,Vienna,Schoolchildren in Vienna,Symptomatic children and adolescents were excluded at date of visit.,2020-05-18,2020-07-02,Students and Daycares,All,Children and Youth (0-17 years),14.0,14.0,Age,Age = 14,185,0.0054,,,,,,,,Convenience,"Wantai SARS-CoV-2 Total Ab ELISA,Author designed (Neutralization Assay),Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)","Beijing Wantai Biological,NA,EUROIMMUN",Multiple Types,Serum,"['IgG', 'Neutralizing', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Unclear,Zsolt Szepfalusi,Medical University of Vienna,Not Unity-Aligned,https://dx.doi.org/10.1111/pai.13459,2022-02-19,2024-03-01,Unverified,szepfalusi_lessons_2021,AUT
210129_Vienna_MedicalUniversityOfVienna_Age_17,210129_Vienna_MedicalUniversityOfVienna,Lessons from low seroprevalence of SARS-CoV-2 antibodies in schoolchildren: a cross-sectional study,2021-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Austria,Vienna,Vienna,Schoolchildren in Vienna,Symptomatic children and adolescents were excluded at date of visit.,2020-05-18,2020-07-02,Students and Daycares,All,Children and Youth (0-17 years),17.0,17.0,Age,Age = 17,200,0.01,,,,,,,,Convenience,"Wantai SARS-CoV-2 Total Ab ELISA,Author designed (Neutralization Assay),Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)","Beijing Wantai Biological,NA,EUROIMMUN",Multiple Types,Serum,"['IgG', 'Neutralizing', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Unclear,Zsolt Szepfalusi,Medical University of Vienna,Not Unity-Aligned,https://dx.doi.org/10.1111/pai.13459,2022-02-19,2024-03-01,Unverified,szepfalusi_lessons_2021,AUT
210129_Vienna_MedicalUniversityOfVienna_Age_10,210129_Vienna_MedicalUniversityOfVienna,Lessons from low seroprevalence of SARS-CoV-2 antibodies in schoolchildren: a cross-sectional study,2021-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Austria,Vienna,Vienna,Schoolchildren in Vienna,Symptomatic children and adolescents were excluded at date of visit.,2020-05-18,2020-07-02,Students and Daycares,All,Children and Youth (0-17 years),10.0,10.0,Age,Age = 10,157,0.0064,,,,,,,,Convenience,"Wantai SARS-CoV-2 Total Ab ELISA,Author designed (Neutralization Assay),Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)","Beijing Wantai Biological,NA,EUROIMMUN",Multiple Types,Serum,"['IgG', 'Neutralizing', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Unclear,Zsolt Szepfalusi,Medical University of Vienna,Not Unity-Aligned,https://dx.doi.org/10.1111/pai.13459,2022-02-19,2024-03-01,Unverified,szepfalusi_lessons_2021,AUT
210129_Vienna_MedicalUniversityOfVienna_Age_16,210129_Vienna_MedicalUniversityOfVienna,Lessons from low seroprevalence of SARS-CoV-2 antibodies in schoolchildren: a cross-sectional study,2021-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Austria,Vienna,Vienna,Schoolchildren in Vienna,Symptomatic children and adolescents were excluded at date of visit.,2020-05-18,2020-07-02,Students and Daycares,All,Children and Youth (0-17 years),16.0,16.0,Age,Age = 16,210,0.0095,,,,,,,,Convenience,"Wantai SARS-CoV-2 Total Ab ELISA,Author designed (Neutralization Assay),Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)","Beijing Wantai Biological,NA,EUROIMMUN",Multiple Types,Serum,"['IgG', 'Neutralizing', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Unclear,Zsolt Szepfalusi,Medical University of Vienna,Not Unity-Aligned,https://dx.doi.org/10.1111/pai.13459,2022-02-19,2024-03-01,Unverified,szepfalusi_lessons_2021,AUT
210129_Vienna_MedicalUniversityOfVienna_Age_15,210129_Vienna_MedicalUniversityOfVienna,Lessons from low seroprevalence of SARS-CoV-2 antibodies in schoolchildren: a cross-sectional study,2021-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Austria,Vienna,Vienna,Schoolchildren in Vienna,Symptomatic children and adolescents were excluded at date of visit.,2020-05-18,2020-07-02,Students and Daycares,All,Children and Youth (0-17 years),15.0,15.0,Age,Age = 15,185,0.0054,,,,,,,,Convenience,"Wantai SARS-CoV-2 Total Ab ELISA,Author designed (Neutralization Assay),Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)","Beijing Wantai Biological,NA,EUROIMMUN",Multiple Types,Serum,"['IgG', 'Neutralizing', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Unclear,Zsolt Szepfalusi,Medical University of Vienna,Not Unity-Aligned,https://dx.doi.org/10.1111/pai.13459,2022-02-19,2024-03-01,Unverified,szepfalusi_lessons_2021,AUT
210129_Vienna_MedicalUniversityOfVienna_Age_6,210129_Vienna_MedicalUniversityOfVienna,Lessons from low seroprevalence of SARS-CoV-2 antibodies in schoolchildren: a cross-sectional study,2021-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Austria,Vienna,Vienna,Schoolchildren in Vienna,Symptomatic children and adolescents were excluded at date of visit.,2020-05-18,2020-07-02,Students and Daycares,All,Children and Youth (0-17 years),6.0,6.0,Age,Age = 6,34,0.0,,,,,,,,Convenience,"Wantai SARS-CoV-2 Total Ab ELISA,Author designed (Neutralization Assay),Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)","Beijing Wantai Biological,NA,EUROIMMUN",Multiple Types,Serum,"['IgG', 'Neutralizing', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Unclear,Zsolt Szepfalusi,Medical University of Vienna,Not Unity-Aligned,https://dx.doi.org/10.1111/pai.13459,2022-02-19,2024-03-01,Unverified,szepfalusi_lessons_2021,AUT
210129_Vienna_MedicalUniversityOfVienna_Age_11,210129_Vienna_MedicalUniversityOfVienna,Lessons from low seroprevalence of SARS-CoV-2 antibodies in schoolchildren: a cross-sectional study,2021-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Austria,Vienna,Vienna,Schoolchildren in Vienna,Symptomatic children and adolescents were excluded at date of visit.,2020-05-18,2020-07-02,Students and Daycares,All,Children and Youth (0-17 years),11.0,11.0,Age,Age = 11,198,0.0101,,,,,,,,Convenience,"Wantai SARS-CoV-2 Total Ab ELISA,Author designed (Neutralization Assay),Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)","Beijing Wantai Biological,NA,EUROIMMUN",Multiple Types,Serum,"['IgG', 'Neutralizing', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Unclear,Zsolt Szepfalusi,Medical University of Vienna,Not Unity-Aligned,https://dx.doi.org/10.1111/pai.13459,2022-02-19,2024-03-01,Unverified,szepfalusi_lessons_2021,AUT
210129_Vienna_MedicalUniversityOfVienna_Age_8,210129_Vienna_MedicalUniversityOfVienna,Lessons from low seroprevalence of SARS-CoV-2 antibodies in schoolchildren: a cross-sectional study,2021-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Austria,Vienna,Vienna,Schoolchildren in Vienna,Symptomatic children and adolescents were excluded at date of visit.,2020-05-18,2020-07-02,Students and Daycares,All,Children and Youth (0-17 years),8.0,8.0,Age,Age = 8,108,0.0,,,,,,,,Convenience,"Wantai SARS-CoV-2 Total Ab ELISA,Author designed (Neutralization Assay),Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)","Beijing Wantai Biological,NA,EUROIMMUN",Multiple Types,Serum,"['IgG', 'Neutralizing', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Unclear,Zsolt Szepfalusi,Medical University of Vienna,Not Unity-Aligned,https://dx.doi.org/10.1111/pai.13459,2022-02-19,2024-03-01,Unverified,szepfalusi_lessons_2021,AUT
210203_Austria_MedicalUniversityOfVienna_Overall,210203_Austria_MedicalUniversityOfVienna,Antibody seroprevalence and rate of asymptomatic infections with SARS-CoV-2 in Austrian hospital personnel,2021-02-03,Preprint,National,Cross-sectional survey ,Austria,,,,,2020-05-11,2020-12-21,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,3301,0.0051,,,True,,,,True,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","DiaSorin,Roche Diagnostics",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,Unclear,Iris Leister,Medical University of Vienna,Not Unity-Aligned,10.1101/2021.02.01.21250898,2021-02-17,2024-03-01,Verified,leister_antibody_2021,AUT
210212_Ischgl_MedicalUniversityofInnsbruck_overall,210212_Ischgl_MedicalUniversityofInnsbruck,"Estimating seroprevalence of SARS-CoV-2 antibodies using three self-reported symptoms: Development of a prediction model based on data from Ischgl, Austria",2021-02-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Austria,Tyrol,Ischgl,"All residents in Ischgl were invited via a letter to participate in the study and visit the study centre (a recreational centre in Ischgl).Participants who were not able to visit the study centre (e.g.due to quarantine) were visited at home by their generalpractitioner. Participants were included in the analysis if they provided a blood sample, returned the completed questionnaire and were above 18 years of age. ","Participants were excluded if they were below 18 years of age (n= 216), had incomplete biosamples (n= 61), or did not return the completed questionnaire (n= 806). ",2020-04-21,2020-04-27,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,General population,451,0.43700000000000006,,,True,,,,True,Entire sample,"Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgA,Anti-SARS-CoV-2 ELISA IgG,Author designed (Neutralization Assay)","Abbott Laboratories,EUROIMMUN,NA",Multiple Types,Serum,"['IgA', 'IgG']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,Yes,No,Yes,Unclear,Yes,Yes,No,No,Jens Lehmann, Medical University of Innsbruck,Unity-Aligned,https://dx.doi.org/10.1017/S0950268821000418,2021-03-27,2024-03-01,Verified,lehmann_estimating_2021,AUT
210409_Vienna_MedicalUniversityofVienna,210409_Vienna_MedicalUniversityofVienna,COVID-19 serology in nephrology healthcare workers,2021-04-09,Journal Article (Peer-Reviewed),Local,Prospective cohort,Austria,Vienna,Vienna,"The COVID-19 serology in nephrology healthcare
workers (CONEC, ClinicalTrials.gov no. NCT04347694)
study is a longitudinal study examining the antibody
response to SARS-CoV-2 among staff members of the
Division of Nephrology and Dialysis, Department of
Medicine. We enrolled nurses, doctors, researchers
administrators, cleaners and other staff.",,2020-03-22,2020-03-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,235,0.255,0.204,0.315,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,Serum,"['IgG', 'IgM']",,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Thomas Reiter,Medical University of Vienna,Not Unity-Aligned,https://dx.doi.org/10.1007/s00508-021-01848-5,2021-04-23,2022-07-16,Unverified,reiter_covid-19_2021,AUT
210404_Vienna_MedicalUniversityofVienna_Overall_2months,210404_Vienna_MedicalUniversityofVienna,A longitudinal seroprevalence study evaluating infection control and prevention strategies at a large tertiary care center with low covid-19 incidence,2021-04-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,Austria,Vienna,Vienna,"Nurses, physicians, physiotherapists, as well as administrative staff greater 18 years of age were invited in person or by email to participate in our study. ",,2020-04-01,2020-06-01,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,Healthcare workers,553,0.015,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,Other,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Lorenz Schubert,Medical University of Vienna,Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph18084201,2021-05-17,2024-03-01,Verified,schubert_longitudinal_2021,AUT
210428_Austria_HanuschHospital,210428_Austria_HanuschHospital,Screening and Confirmatory Testing for SARS-CoV-2 Antibodies: Comparison of Health and Non-Health Workers in a Nationwide Healthcare Organization in Central Europe.,2021-04-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Austria,,,"Employees of the Austrian Health Insurance fund - Subjects who were at least 18 years of age were eligible for inclusion in the study. Healthcare workers included physicians,
nurses, nursing assistants, phlebotomists, radiology technicians, dietitian, dental health
professionals, and physical/occupational therapists at a 400-bed tertiary referral hospital,
five large multi-specialty outpatient clinics, and nearly a hundred primary care services
across Austria.",,2020-07-01,2020-07-31,Non-essential workers and unemployed persons,All,Adults (18-64 years),18.0,,Primary Estimate,Overall ,7858,0.011200000000000002,0.009000000000000001,0.0138,True,,,,True,Convenience,"Panbio COVID-19 IgG/IgM rapid test device,Author designed (Neutralization Assay)","Abbott Laboratories,NA",Multiple Types,Multiple Types,"['IgG', 'Neutralizing']",Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,No,Yes,Johann Bartko,Hanusch Hospital,Not Unity-Aligned,https://dx.doi.org/10.3390/jcm10091909,2021-05-21,2024-03-01,Verified,bartko_screening_2021,AUT
210512_Vienna_LudwigBoltzmannInstituteForLungHealth_overall,210512_Vienna_LudwigBoltzmannInstituteForLungHealth,Low SARS-CoV-2 seroprevalence in the Austrian capital after an early governmental lockdown.,2021-05-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Austria,,Vienna,"Individuals in the LEAD study cohort and their household members.
(The LEAD study cohort is a general population cohort providing a representative sample of the general Viennese population in terms of age, sex, smoking habits, and place of residence.)",,2020-04-20,2020-05-20,Household and community samples,All,Multiple groups,6.0,,Primary Estimate,,12419,0.0131,,,True,,,,True,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (S),Anti-SARS-CoV-2 ELISA IgG,Author designed (Neutralization Assay)","Roche Diagnostics,EUROIMMUN,NA",Multiple Types,Serum,"['IgG', 'Neutralizing']",Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Marie Kathrin Breyer,Ludwig Boltzmann Institute for Lung Health,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89711-5,2021-05-28,2024-03-01,Verified,breyer_low_2021,AUT
210524_Weibenkirchen_DanubePrivateUniversity_Overall,210524_Weibenkirchen_DanubePrivateUniversity,SARS-CoV-2-Specific Antibody Prevalence and Symptoms in a Local Austrian Population,2021-05-24,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Austria,Lower Austria,Weißenkirchen,,,2020-06-01,2020-06-30,Household and community samples,All,Multiple groups,7.0,89.0,Primary Estimate,,835,0.085,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Dennis Ladage,Danube Private University,Unity-Aligned,http://dx.doi.org/10.3389/fmed.2021.632942,2021-06-19,2024-03-01,Verified,ladage_sars-cov-2-specific_2021,AUT
210524_Weibenkirchen_DanubePrivateUniversity_Female,210524_Weibenkirchen_DanubePrivateUniversity,SARS-CoV-2-Specific Antibody Prevalence and Symptoms in a Local Austrian Population,2021-05-24,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Austria,Lower Austria,Weißenkirchen,,,2020-06-01,2020-06-30,Household and community samples,Female,Multiple groups,7.0,89.0,Sex/Gender,,431,0.0766,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Dennis Ladage,Danube Private University,Unity-Aligned,http://dx.doi.org/10.3389/fmed.2021.632942,2021-08-12,2024-03-01,Verified,ladage_sars-cov-2-specific_2021,AUT
210524_Weibenkirchen_DanubePrivateUniversity_Male,210524_Weibenkirchen_DanubePrivateUniversity,SARS-CoV-2-Specific Antibody Prevalence and Symptoms in a Local Austrian Population,2021-05-24,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Austria,Lower Austria,Weißenkirchen,,,2020-06-01,2020-06-30,Household and community samples,Male,Multiple groups,7.0,89.0,Sex/Gender,,404,0.0941,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Dennis Ladage,Danube Private University,Unity-Aligned,http://dx.doi.org/10.3389/fmed.2021.632942,2021-08-12,2024-03-01,Verified,ladage_sars-cov-2-specific_2021,AUT
210616_Austria_UniversityHospitalOfSalzburg_Overall,210616_Austria_UniversityHospitalOfSalzburg_Overall,Seroprevalence of anti-SARS-CoV-2 total antibody is higher in younger Austrian blood donors.,2021-06-16,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Austria,,,"Before donating blood, all donors had a brief health screening and had to complete a written questionnaire, including an informed consent on pathogen screening as a standard part of the blood donation process. Therefore, only individuals that appeared fit to donate at the time of the blood donation and had not reported symptoms of a common cold within the last two weeks or other health issues within a relevant time span before the donation were included.

No further preselection (e.g. according to a putative previous SARS-CoV-2 infection) of sample material was done",,2020-06-05,2020-12-04,Blood donors,All,Multiple groups,18.0,72.0,Primary Estimate,,20228,0.025,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981000000000001,['High'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,,Lisa Weidner, University Hospital of Salzburg,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01639-0,2021-09-08,2024-03-01,Verified,weidner_seroprevalence_2021,AUT
210616_Austria_UniversityHospitalOfSalzburg_Date_November,210616_Austria_UniversityHospitalOfSalzburg_Overall,Seroprevalence of anti-SARS-CoV-2 total antibody is higher in younger Austrian blood donors.,2021-06-16,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Austria,,,"Before donating blood, all donors had a brief health screening and had to complete a written questionnaire, including an informed consent on pathogen screening as a standard part of the blood donation process. Therefore, only individuals that appeared fit to donate at the time of the blood donation and had not reported symptoms of a common cold within the last two weeks or other health issues within a relevant time span before the donation were included.

No further preselection (e.g. according to a putative previous SARS-CoV-2 infection) of sample material was done",,2020-11-05,2020-12-04,Blood donors,All,Multiple groups,18.0,72.0,Time frame,November,3311,0.054000000000000006,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981000000000001,['High'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,,Lisa Weidner, University Hospital of Salzburg,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01639-0,2021-09-08,2024-03-01,Verified,weidner_seroprevalence_2021,AUT
210616_Austria_UniversityHospitalOfSalzburg_Age_36to45,210616_Austria_UniversityHospitalOfSalzburg_Overall,Seroprevalence of anti-SARS-CoV-2 total antibody is higher in younger Austrian blood donors.,2021-06-16,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Austria,,,"Before donating blood, all donors had a brief health screening and had to complete a written questionnaire, including an informed consent on pathogen screening as a standard part of the blood donation process. Therefore, only individuals that appeared fit to donate at the time of the blood donation and had not reported symptoms of a common cold within the last two weeks or other health issues within a relevant time span before the donation were included.

No further preselection (e.g. according to a putative previous SARS-CoV-2 infection) of sample material was done",,2020-06-05,2020-12-04,Blood donors,All,Adults (18-64 years),36.0,45.0,Age,36-45,3556,0.02,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981000000000001,['High'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,,Lisa Weidner, University Hospital of Salzburg,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01639-0,2021-09-08,2024-03-01,Verified,weidner_seroprevalence_2021,AUT
210616_Austria_UniversityHospitalOfSalzburg_Date_September,210616_Austria_UniversityHospitalOfSalzburg_Overall,Seroprevalence of anti-SARS-CoV-2 total antibody is higher in younger Austrian blood donors.,2021-06-16,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Austria,,,"Before donating blood, all donors had a brief health screening and had to complete a written questionnaire, including an informed consent on pathogen screening as a standard part of the blood donation process. Therefore, only individuals that appeared fit to donate at the time of the blood donation and had not reported symptoms of a common cold within the last two weeks or other health issues within a relevant time span before the donation were included.

No further preselection (e.g. according to a putative previous SARS-CoV-2 infection) of sample material was done",,2020-09-05,2020-10-04,Blood donors,All,Multiple groups,18.0,72.0,Time frame,September,2569,0.024,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981000000000001,['High'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,,Lisa Weidner, University Hospital of Salzburg,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01639-0,2021-09-08,2024-03-01,Verified,weidner_seroprevalence_2021,AUT
210616_Austria_UniversityHospitalOfSalzburg_District_Salzburg,210616_Austria_UniversityHospitalOfSalzburg_Overall,Seroprevalence of anti-SARS-CoV-2 total antibody is higher in younger Austrian blood donors.,2021-06-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Austria,Salzburg,,"Before donating blood, all donors had a brief health screening and had to complete a written questionnaire, including an informed consent on pathogen screening as a standard part of the blood donation process. Therefore, only individuals that appeared fit to donate at the time of the blood donation and had not reported symptoms of a common cold within the last two weeks or other health issues within a relevant time span before the donation were included.

No further preselection (e.g. according to a putative previous SARS-CoV-2 infection) of sample material was done",,2020-06-05,2020-12-04,Blood donors,All,Multiple groups,18.0,72.0,Geographical area,Salzburg,13364,0.027000000000000003,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981000000000001,['High'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,,Lisa Weidner, University Hospital of Salzburg,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01639-0,2021-09-08,2024-03-01,Verified,weidner_seroprevalence_2021,AUT
210616_Austria_UniversityHospitalOfSalzburg_Female,210616_Austria_UniversityHospitalOfSalzburg_Overall,Seroprevalence of anti-SARS-CoV-2 total antibody is higher in younger Austrian blood donors.,2021-06-16,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Austria,,,"Before donating blood, all donors had a brief health screening and had to complete a written questionnaire, including an informed consent on pathogen screening as a standard part of the blood donation process. Therefore, only individuals that appeared fit to donate at the time of the blood donation and had not reported symptoms of a common cold within the last two weeks or other health issues within a relevant time span before the donation were included.

No further preselection (e.g. according to a putative previous SARS-CoV-2 infection) of sample material was done",,2020-06-05,2020-12-04,Blood donors,Female,Multiple groups,18.0,72.0,Sex/Gender,,7968,0.024,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981000000000001,['High'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,,Lisa Weidner, University Hospital of Salzburg,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01639-0,2021-09-08,2024-03-01,Verified,weidner_seroprevalence_2021,AUT
210616_Austria_UniversityHospitalOfSalzburg_Age_56to65,210616_Austria_UniversityHospitalOfSalzburg_Overall,Seroprevalence of anti-SARS-CoV-2 total antibody is higher in younger Austrian blood donors.,2021-06-16,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Austria,,,"Before donating blood, all donors had a brief health screening and had to complete a written questionnaire, including an informed consent on pathogen screening as a standard part of the blood donation process. Therefore, only individuals that appeared fit to donate at the time of the blood donation and had not reported symptoms of a common cold within the last two weeks or other health issues within a relevant time span before the donation were included.

No further preselection (e.g. according to a putative previous SARS-CoV-2 infection) of sample material was done",,2020-06-05,2020-12-04,Blood donors,All,Adults (18-64 years),56.0,65.0,Age,56-65,3616,0.022000000000000002,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981000000000001,['High'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,,Lisa Weidner, University Hospital of Salzburg,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01639-0,2021-09-08,2024-03-01,Verified,weidner_seroprevalence_2021,AUT
210616_Austria_UniversityHospitalOfSalzburg_District_LowerAustria,210616_Austria_UniversityHospitalOfSalzburg_Overall,Seroprevalence of anti-SARS-CoV-2 total antibody is higher in younger Austrian blood donors.,2021-06-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Austria,Lower Austria,,"Before donating blood, all donors had a brief health screening and had to complete a written questionnaire, including an informed consent on pathogen screening as a standard part of the blood donation process. Therefore, only individuals that appeared fit to donate at the time of the blood donation and had not reported symptoms of a common cold within the last two weeks or other health issues within a relevant time span before the donation were included.

No further preselection (e.g. according to a putative previous SARS-CoV-2 infection) of sample material was done",,2020-06-05,2020-12-04,Blood donors,All,Multiple groups,18.0,72.0,Geographical area,Lower Austria,3292,0.023,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981000000000001,['High'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,,Lisa Weidner, University Hospital of Salzburg,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01639-0,2021-09-08,2024-03-01,Verified,weidner_seroprevalence_2021,AUT
210616_Austria_UniversityHospitalOfSalzburg_Date_July,210616_Austria_UniversityHospitalOfSalzburg_Overall,Seroprevalence of anti-SARS-CoV-2 total antibody is higher in younger Austrian blood donors.,2021-06-16,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Austria,,,"Before donating blood, all donors had a brief health screening and had to complete a written questionnaire, including an informed consent on pathogen screening as a standard part of the blood donation process. Therefore, only individuals that appeared fit to donate at the time of the blood donation and had not reported symptoms of a common cold within the last two weeks or other health issues within a relevant time span before the donation were included.

No further preselection (e.g. according to a putative previous SARS-CoV-2 infection) of sample material was done",,2020-07-05,2020-08-04,Blood donors,All,Multiple groups,18.0,72.0,Time frame,July,6782,0.012,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981000000000001,['High'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,,Lisa Weidner, University Hospital of Salzburg,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01639-0,2021-09-08,2024-03-01,Verified,weidner_seroprevalence_2021,AUT
210616_Austria_UniversityHospitalOfSalzburg_Age_18to25,210616_Austria_UniversityHospitalOfSalzburg_Overall,Seroprevalence of anti-SARS-CoV-2 total antibody is higher in younger Austrian blood donors.,2021-06-16,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Austria,,,"Before donating blood, all donors had a brief health screening and had to complete a written questionnaire, including an informed consent on pathogen screening as a standard part of the blood donation process. Therefore, only individuals that appeared fit to donate at the time of the blood donation and had not reported symptoms of a common cold within the last two weeks or other health issues within a relevant time span before the donation were included.

No further preselection (e.g. according to a putative previous SARS-CoV-2 infection) of sample material was done",,2020-06-05,2020-12-04,Blood donors,All,Adults (18-64 years),18.0,25.0,Age,18-25,3744,0.032,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981000000000001,['High'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,,Lisa Weidner, University Hospital of Salzburg,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01639-0,2021-09-08,2024-03-01,Verified,weidner_seroprevalence_2021,AUT
210616_Austria_UniversityHospitalOfSalzburg_Date_October,210616_Austria_UniversityHospitalOfSalzburg_Overall,Seroprevalence of anti-SARS-CoV-2 total antibody is higher in younger Austrian blood donors.,2021-06-16,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Austria,,,"Before donating blood, all donors had a brief health screening and had to complete a written questionnaire, including an informed consent on pathogen screening as a standard part of the blood donation process. Therefore, only individuals that appeared fit to donate at the time of the blood donation and had not reported symptoms of a common cold within the last two weeks or other health issues within a relevant time span before the donation were included.

No further preselection (e.g. according to a putative previous SARS-CoV-2 infection) of sample material was done",,2020-10-05,2020-11-04,Blood donors,All,Multiple groups,18.0,72.0,Time frame,October,2513,0.03,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981000000000001,['High'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,,Lisa Weidner, University Hospital of Salzburg,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01639-0,2021-09-08,2024-03-01,Verified,weidner_seroprevalence_2021,AUT
210616_Austria_UniversityHospitalOfSalzburg_Date_June,210616_Austria_UniversityHospitalOfSalzburg_Overall,Seroprevalence of anti-SARS-CoV-2 total antibody is higher in younger Austrian blood donors.,2021-06-16,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Austria,,,"Before donating blood, all donors had a brief health screening and had to complete a written questionnaire, including an informed consent on pathogen screening as a standard part of the blood donation process. Therefore, only individuals that appeared fit to donate at the time of the blood donation and had not reported symptoms of a common cold within the last two weeks or other health issues within a relevant time span before the donation were included.

No further preselection (e.g. according to a putative previous SARS-CoV-2 infection) of sample material was done",,2020-06-05,2020-07-04,Blood donors,All,Multiple groups,18.0,72.0,Time frame,June ,1678,0.018000000000000002,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981000000000001,['High'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,,Lisa Weidner, University Hospital of Salzburg,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01639-0,2021-09-08,2024-03-01,Verified,weidner_seroprevalence_2021,AUT
210616_Austria_UniversityHospitalOfSalzburg_Age_46to55,210616_Austria_UniversityHospitalOfSalzburg_Overall,Seroprevalence of anti-SARS-CoV-2 total antibody is higher in younger Austrian blood donors.,2021-06-16,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Austria,,,"Before donating blood, all donors had a brief health screening and had to complete a written questionnaire, including an informed consent on pathogen screening as a standard part of the blood donation process. Therefore, only individuals that appeared fit to donate at the time of the blood donation and had not reported symptoms of a common cold within the last two weeks or other health issues within a relevant time span before the donation were included.

No further preselection (e.g. according to a putative previous SARS-CoV-2 infection) of sample material was done",,2020-06-05,2020-12-04,Blood donors,All,Adults (18-64 years),46.0,55.0,Age,46-55,4734,0.027999999999999997,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981000000000001,['High'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,,Lisa Weidner, University Hospital of Salzburg,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01639-0,2021-09-08,2024-03-01,Verified,weidner_seroprevalence_2021,AUT
210616_Austria_UniversityHospitalOfSalzburg_District_Burgenland,210616_Austria_UniversityHospitalOfSalzburg_Overall,Seroprevalence of anti-SARS-CoV-2 total antibody is higher in younger Austrian blood donors.,2021-06-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Austria,Burgenland,,"Before donating blood, all donors had a brief health screening and had to complete a written questionnaire, including an informed consent on pathogen screening as a standard part of the blood donation process. Therefore, only individuals that appeared fit to donate at the time of the blood donation and had not reported symptoms of a common cold within the last two weeks or other health issues within a relevant time span before the donation were included.

No further preselection (e.g. according to a putative previous SARS-CoV-2 infection) of sample material was done",,2020-06-05,2020-12-04,Blood donors,All,Multiple groups,18.0,72.0,Geographical area,Burgenland,852,0.004,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981000000000001,['High'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,,Lisa Weidner, University Hospital of Salzburg,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01639-0,2021-09-08,2024-03-01,Verified,weidner_seroprevalence_2021,AUT
210616_Austria_UniversityHospitalOfSalzburg_Age_26to35,210616_Austria_UniversityHospitalOfSalzburg_Overall,Seroprevalence of anti-SARS-CoV-2 total antibody is higher in younger Austrian blood donors.,2021-06-16,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Austria,,,"Before donating blood, all donors had a brief health screening and had to complete a written questionnaire, including an informed consent on pathogen screening as a standard part of the blood donation process. Therefore, only individuals that appeared fit to donate at the time of the blood donation and had not reported symptoms of a common cold within the last two weeks or other health issues within a relevant time span before the donation were included.

No further preselection (e.g. according to a putative previous SARS-CoV-2 infection) of sample material was done",,2020-06-05,2020-12-04,Blood donors,All,Adults (18-64 years),26.0,35.0,Age,26-35,3983,0.022000000000000002,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981000000000001,['High'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,,Lisa Weidner, University Hospital of Salzburg,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01639-0,2021-09-08,2024-03-01,Verified,weidner_seroprevalence_2021,AUT
210616_Austria_UniversityHospitalOfSalzburg_District_Vienna,210616_Austria_UniversityHospitalOfSalzburg_Overall,Seroprevalence of anti-SARS-CoV-2 total antibody is higher in younger Austrian blood donors.,2021-06-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Austria,Vienna,,"Before donating blood, all donors had a brief health screening and had to complete a written questionnaire, including an informed consent on pathogen screening as a standard part of the blood donation process. Therefore, only individuals that appeared fit to donate at the time of the blood donation and had not reported symptoms of a common cold within the last two weeks or other health issues within a relevant time span before the donation were included.

No further preselection (e.g. according to a putative previous SARS-CoV-2 infection) of sample material was done",,2020-06-05,2020-12-04,Blood donors,All,Multiple groups,18.0,72.0,Geographical area,Vienna,2720,0.021,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981000000000001,['High'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,,Lisa Weidner, University Hospital of Salzburg,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01639-0,2021-09-08,2024-03-01,Verified,weidner_seroprevalence_2021,AUT
210616_Austria_UniversityHospitalOfSalzburg_Sex_Male,210616_Austria_UniversityHospitalOfSalzburg_Overall,Seroprevalence of anti-SARS-CoV-2 total antibody is higher in younger Austrian blood donors.,2021-06-16,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Austria,,,"Before donating blood, all donors had a brief health screening and had to complete a written questionnaire, including an informed consent on pathogen screening as a standard part of the blood donation process. Therefore, only individuals that appeared fit to donate at the time of the blood donation and had not reported symptoms of a common cold within the last two weeks or other health issues within a relevant time span before the donation were included.

No further preselection (e.g. according to a putative previous SARS-CoV-2 infection) of sample material was done",,2020-06-05,2020-12-04,Blood donors,Male,Multiple groups,18.0,72.0,Sex/Gender,,12260,0.025,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981000000000001,['High'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,,Lisa Weidner, University Hospital of Salzburg,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01639-0,2021-09-08,2024-03-01,Verified,weidner_seroprevalence_2021,AUT
210616_Austria_UniversityHospitalOfSalzburg_Age_>65,210616_Austria_UniversityHospitalOfSalzburg_Overall,Seroprevalence of anti-SARS-CoV-2 total antibody is higher in younger Austrian blood donors.,2021-06-16,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Austria,,,"Before donating blood, all donors had a brief health screening and had to complete a written questionnaire, including an informed consent on pathogen screening as a standard part of the blood donation process. Therefore, only individuals that appeared fit to donate at the time of the blood donation and had not reported symptoms of a common cold within the last two weeks or other health issues within a relevant time span before the donation were included.

No further preselection (e.g. according to a putative previous SARS-CoV-2 infection) of sample material was done",,2020-06-05,2020-12-04,Blood donors,All,Seniors (65+ years),65.0,,Age,>65,595,0.008,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981000000000001,['High'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,,Lisa Weidner, University Hospital of Salzburg,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01639-0,2021-09-08,2024-03-01,Verified,weidner_seroprevalence_2021,AUT
210616_Austria_UniversityHospitalOfSalzburg_Date_August,210616_Austria_UniversityHospitalOfSalzburg_Overall,Seroprevalence of anti-SARS-CoV-2 total antibody is higher in younger Austrian blood donors.,2021-06-16,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Austria,,,"Before donating blood, all donors had a brief health screening and had to complete a written questionnaire, including an informed consent on pathogen screening as a standard part of the blood donation process. Therefore, only individuals that appeared fit to donate at the time of the blood donation and had not reported symptoms of a common cold within the last two weeks or other health issues within a relevant time span before the donation were included.

No further preselection (e.g. according to a putative previous SARS-CoV-2 infection) of sample material was done",,2020-08-05,2020-09-04,Blood donors,All,Multiple groups,18.0,72.0,Time frame,August,3375,0.02,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981000000000001,['High'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,,Lisa Weidner, University Hospital of Salzburg,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01639-0,2021-09-08,2024-03-01,Verified,weidner_seroprevalence_2021,AUT
210630_Ischgl_MedicalUniversityOfInnsbruck_Primary,210630_Ischgl_MedicalUniversityOfInnsbruck,High SARS-CoV-2 seroprevalence in children and adults in the Austrian ski resort of Ischgl,2021-06-30,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Austria,Tyrol,Ischgl,"This cross-sectional epidemiological survey targeted all
residents of Ischgl/Tyrol irrespective of age and gender","""After exclusion of 61 study participants (due to missing of one of the biosamples, i.e., blood sampling was not possible in 2 children and 59 adults refused swab sampling), 1473 (79% of the Ischgl population) were included in our statistical
analysis.""

Missing of one of the biosamples, i.e., blood sampling was
not possible in 2 children and 59 adults refused swab sampling",2020-04-21,2020-04-27,Household and community samples,All,Multiple groups,,,Primary Estimate,,1473,0.424,0.39799999999999996,0.44700000000000006,True,,,,True,Self-referral,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA,Abbott Architect SARS-CoV-2 IgG,Author designed (Neutralization Assay)","EUROIMMUN,Abbott Laboratories,NA",Multiple Types,Serum,"['IgA', 'IgG']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,No,Yes,Ludwig Knabl,Medical University Of Innsbruck,Not Unity-Aligned,https://www.nature.com/articles/s43856-021-00007-1?error=cookies_not_supported&code=8b72864e-3eb4-4c31-bdd1-924a657e6b28,2021-09-01,2024-03-01,Verified,knablHighSARSCoV2Seroprevalence2021,AUT
210630_Ischgl_MedicalUniversityOfInnsbruck_Male,210630_Ischgl_MedicalUniversityOfInnsbruck,High SARS-CoV-2 seroprevalence in children and adults in the Austrian ski resort of Ischgl,2021-06-30,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Austria,Tyrol,Ischgl,"This cross-sectional epidemiological survey targeted all
residents of Ischgl/Tyrol irrespective of age and gender","""After exclusion of 61 study participants (due to missing of one of the biosamples, i.e., blood sampling was not possible in 2 children and 59 adults refused swab sampling), 1473 (79% of the Ischgl population) were included in our statistical
analysis.""

Missing of one of the biosamples, i.e., blood sampling was
not possible in 2 children and 59 adults refused swab sampling",2020-04-21,2020-04-27,Household and community samples,Male,Multiple groups,,,Sex/Gender,>=18,712,0.435,,,,,,,,Self-referral,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA,Abbott Architect SARS-CoV-2 IgG,Author designed (Neutralization Assay)","EUROIMMUN,Abbott Laboratories,NA",Multiple Types,Serum,"['IgA', 'IgG']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,No,Yes,Ludwig Knabl,Medical University Of Innsbruck,Not Unity-Aligned,https://www.nature.com/articles/s43856-021-00007-1?error=cookies_not_supported&code=8b72864e-3eb4-4c31-bdd1-924a657e6b28,2021-09-08,2024-03-01,Verified,knablHighSARSCoV2Seroprevalence2021,AUT
210630_Ischgl_MedicalUniversityOfInnsbruck_Adult,210630_Ischgl_MedicalUniversityOfInnsbruck,High SARS-CoV-2 seroprevalence in children and adults in the Austrian ski resort of Ischgl,2021-06-30,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Austria,Tyrol,Ischgl,"This cross-sectional epidemiological survey targeted all
residents of Ischgl/Tyrol irrespective of age and gender","""After exclusion of 61 study participants (due to missing of one of the biosamples, i.e., blood sampling was not possible in 2 children and 59 adults refused swab sampling), 1473 (79% of the Ischgl population) were included in our statistical
analysis.""

Missing of one of the biosamples, i.e., blood sampling was
not possible in 2 children and 59 adults refused swab sampling",2020-04-21,2020-04-27,Household and community samples,All,Multiple groups,18.0,,Age,>=18,1259,0.45,0.42200000000000004,0.47700000000000004,,,,,,Self-referral,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA,Abbott Architect SARS-CoV-2 IgG,Author designed (Neutralization Assay)","EUROIMMUN,Abbott Laboratories,NA",Multiple Types,Serum,"['IgA', 'IgG']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,No,Yes,Ludwig Knabl,Medical University Of Innsbruck,Not Unity-Aligned,https://www.nature.com/articles/s43856-021-00007-1?error=cookies_not_supported&code=8b72864e-3eb4-4c31-bdd1-924a657e6b28,2021-09-08,2024-03-01,Verified,knablHighSARSCoV2Seroprevalence2021,AUT
210630_Ischgl_MedicalUniversityOfInnsbruck_Female,210630_Ischgl_MedicalUniversityOfInnsbruck,High SARS-CoV-2 seroprevalence in children and adults in the Austrian ski resort of Ischgl,2021-06-30,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Austria,Tyrol,Ischgl,"This cross-sectional epidemiological survey targeted all
residents of Ischgl/Tyrol irrespective of age and gender","""After exclusion of 61 study participants (due to missing of one of the biosamples, i.e., blood sampling was not possible in 2 children and 59 adults refused swab sampling), 1473 (79% of the Ischgl population) were included in our statistical
analysis.""

Missing of one of the biosamples, i.e., blood sampling was
not possible in 2 children and 59 adults refused swab sampling",2020-04-21,2020-04-27,Household and community samples,Female,Multiple groups,,,Sex/Gender,>=18,759,0.41200000000000003,,,,,,,,Self-referral,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA,Abbott Architect SARS-CoV-2 IgG,Author designed (Neutralization Assay)","EUROIMMUN,Abbott Laboratories,NA",Multiple Types,Serum,"['IgA', 'IgG']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,No,Yes,Ludwig Knabl,Medical University Of Innsbruck,Not Unity-Aligned,https://www.nature.com/articles/s43856-021-00007-1?error=cookies_not_supported&code=8b72864e-3eb4-4c31-bdd1-924a657e6b28,2021-09-08,2024-03-01,Verified,knablHighSARSCoV2Seroprevalence2021,AUT
210630_Ischgl_MedicalUniversityOfInnsbruck_Children,210630_Ischgl_MedicalUniversityOfInnsbruck,High SARS-CoV-2 seroprevalence in children and adults in the Austrian ski resort of Ischgl,2021-06-30,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Austria,Tyrol,Ischgl,"This cross-sectional epidemiological survey targeted all
residents of Ischgl/Tyrol irrespective of age and gender","""After exclusion of 61 study participants (due to missing of one of the biosamples, i.e., blood sampling was not possible in 2 children and 59 adults refused swab sampling), 1473 (79% of the Ischgl population) were included in our statistical
analysis.""

Missing of one of the biosamples, i.e., blood sampling was
not possible in 2 children and 59 adults refused swab sampling",2020-04-21,2020-04-27,Household and community samples,All,Children and Youth (0-17 years),,17.0,Age,<18,214,0.271,0.21300000000000002,0.336,,,,,,Self-referral,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA,Abbott Architect SARS-CoV-2 IgG,Author designed (Neutralization Assay)","EUROIMMUN,Abbott Laboratories,NA",Multiple Types,Serum,"['IgA', 'IgG']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,No,Yes,Ludwig Knabl,Medical University Of Innsbruck,Not Unity-Aligned,https://www.nature.com/articles/s43856-021-00007-1?error=cookies_not_supported&code=8b72864e-3eb4-4c31-bdd1-924a657e6b28,2021-09-08,2024-03-01,Verified,knablHighSARSCoV2Seroprevalence2021,AUT
210714_Vienna_MedicalUniversityofVienna_Overall,210714_Vienna_MedicalUniversityofVienna,Neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independently of symptoms in adults.,2021-07-14,Journal Article (Peer-Reviewed),Local,Prospective cohort,Austria,Vienna,Vienna,We included 1655 serum samples of employees working for a large company in Vienna ,,2020-04-02,2020-04-17,Non-essential workers and unemployed persons,All,Adults (18-64 years),16.0,65.0,Primary Estimate,,1655,0.1015,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA",EUROIMMUN,ELISA,Serum,"['IgA', 'IgG']",Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,No,,Angelika Wagner,Medical University of Vienna,Not Unity-Aligned,https://dx.doi.org/10.1038/s43856-021-00012-4,2022-06-02,2024-03-01,Unverified,wagner_neutralising_2021,AUT
210811_Ischgl_MedicalUniversityOfInnsbruck,210811_Ischgl_MedicalUniversityOfInnsbruck,Persistence of immunity to SARS-CoV-2 over time in the ski resort Ischgl,2021-08-01,Journal Article (Peer-Reviewed),Local,Prospective cohort,Austria,Tyrol,Ischgl,Adults in ski resort Ischgl in Austria,,2020-11-02,2020-11-08,Household and community samples,All,Adults (18-64 years),18.0,,Primary Estimate,,801,0.454,0.42,0.49,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgA,Anti-SARS-CoV-2 ELISA IgG,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N),Author designed (Neutralization Assay)","EUROIMMUN,Abbott Laboratories,Roche Diagnostics,NA",Multiple Types,Multiple Types,"['IgA', 'IgG']",Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Wegene Borena,Medical University Of Innsbruck,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103534,2021-08-28,2024-03-01,Verified,borenaPersistenceImmunitySARSCoV22021,AUT
211026_Tyrol_TirolKlinikenGmbH_Abbott_Primary,211026_Tyrol_TirolKlinikenGmbH,"Prevalence of SARS-CoV-2 antibodies in healthy blood donors from the state of Tyrol, Austria, in summer 2020.",2021-10-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Austria,"Tyrol
",,"(i) meet the general requirements for a blood donation; (ii) be living in Tyrol; (iii) be in a healthy state (for instance, free of malignant diseases, autoimmune diseases or infectious diseases); and (iv) be asymptomatic for at least 28 days in case they had had a PCR-confirmed or suspected SARS-CoV-2 infection",Excluded individuals with specific comorbidities which are known to influence severity and disease progression of COVID19,2020-06-08,2020-09-04,Blood donors,All,Multiple groups,18.0,71.0,Primary Estimate,,5345,0.031000000000000003,0.026000000000000002,0.036000000000000004,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Anita Siller,Tirol Kliniken GmbH,Not Unity-Aligned,https://dx.doi.org/10.1007/s00508-021-01963-3,2021-11-03,2024-03-01,Unverified,siller_prevalence_2021,AUT
211026_Tyrol_TirolKlinikenGmbH_25-34,211026_Tyrol_TirolKlinikenGmbH,"Prevalence of SARS-CoV-2 antibodies in healthy blood donors from the state of Tyrol, Austria, in summer 2020.",2021-10-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Austria,Tyrol,,"(i) meet the general requirements for a blood donation; (ii) be living in Tyrol; (iii) be in a healthy state (for instance, free of malignant diseases, autoimmune diseases or infectious diseases); and (iv) be asymptomatic for at least 28 days in case they had had a PCR-confirmed or suspected SARS-CoV-2 infection",Excluded individuals with specific comorbidities which are known to influence severity and disease progression of COVID19,2020-06-08,2020-09-04,Blood donors,All,Adults (18-64 years),25.0,34.0,Age,25-34 years-old,992,0.027000000000000003,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Anita Siller,Tirol Kliniken GmbH,Not Unity-Aligned,https://dx.doi.org/10.1007/s00508-021-01963-3,2021-11-03,2024-03-01,Unverified,siller_prevalence_2021,AUT
211026_Tyrol_TirolKlinikenGmbH_35-44,211026_Tyrol_TirolKlinikenGmbH,"Prevalence of SARS-CoV-2 antibodies in healthy blood donors from the state of Tyrol, Austria, in summer 2020.",2021-10-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Austria,Tyrol,,"(i) meet the general requirements for a blood donation; (ii) be living in Tyrol; (iii) be in a healthy state (for instance, free of malignant diseases, autoimmune diseases or infectious diseases); and (iv) be asymptomatic for at least 28 days in case they had had a PCR-confirmed or suspected SARS-CoV-2 infection",Excluded individuals with specific comorbidities which are known to influence severity and disease progression of COVID19,2020-06-08,2020-09-04,Blood donors,All,Adults (18-64 years),35.0,44.0,Age,35-44 years-old,982,0.033,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Anita Siller,Tirol Kliniken GmbH,Not Unity-Aligned,https://dx.doi.org/10.1007/s00508-021-01963-3,2021-11-03,2024-03-01,Unverified,siller_prevalence_2021,AUT
211026_Tyrol_TirolKlinikenGmbH_<25,211026_Tyrol_TirolKlinikenGmbH,"Prevalence of SARS-CoV-2 antibodies in healthy blood donors from the state of Tyrol, Austria, in summer 2020.",2021-10-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Austria,Tyrol,,"(i) meet the general requirements for a blood donation; (ii) be living in Tyrol; (iii) be in a healthy state (for instance, free of malignant diseases, autoimmune diseases or infectious diseases); and (iv) be asymptomatic for at least 28 days in case they had had a PCR-confirmed or suspected SARS-CoV-2 infection",Excluded individuals with specific comorbidities which are known to influence severity and disease progression of COVID19,2020-06-08,2020-09-04,Blood donors,All,Adults (18-64 years),18.0,24.0,Age,< 25 years-old,688,0.047,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Anita Siller,Tirol Kliniken GmbH,Not Unity-Aligned,https://dx.doi.org/10.1007/s00508-021-01963-3,2021-11-03,2024-03-01,Unverified,siller_prevalence_2021,AUT
211026_Tyrol_TirolKlinikenGmbH_45-54,211026_Tyrol_TirolKlinikenGmbH,"Prevalence of SARS-CoV-2 antibodies in healthy blood donors from the state of Tyrol, Austria, in summer 2020.",2021-10-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Austria,Tyrol,,"(i) meet the general requirements for a blood donation; (ii) be living in Tyrol; (iii) be in a healthy state (for instance, free of malignant diseases, autoimmune diseases or infectious diseases); and (iv) be asymptomatic for at least 28 days in case they had had a PCR-confirmed or suspected SARS-CoV-2 infection",Excluded individuals with specific comorbidities which are known to influence severity and disease progression of COVID19,2020-06-08,2020-09-04,Blood donors,All,Adults (18-64 years),45.0,54.0,Age,45-54 years-old,1439,0.028999999999999998,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Anita Siller,Tirol Kliniken GmbH,Not Unity-Aligned,https://dx.doi.org/10.1007/s00508-021-01963-3,2021-11-03,2024-03-01,Unverified,siller_prevalence_2021,AUT
211026_Tyrol_TirolKlinikenGmbH_55-64,211026_Tyrol_TirolKlinikenGmbH,"Prevalence of SARS-CoV-2 antibodies in healthy blood donors from the state of Tyrol, Austria, in summer 2020.",2021-10-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Austria,Tyrol,,"(i) meet the general requirements for a blood donation; (ii) be living in Tyrol; (iii) be in a healthy state (for instance, free of malignant diseases, autoimmune diseases or infectious diseases); and (iv) be asymptomatic for at least 28 days in case they had had a PCR-confirmed or suspected SARS-CoV-2 infection",Excluded individuals with specific comorbidities which are known to influence severity and disease progression of COVID19,2020-06-08,2020-09-04,Blood donors,All,Adults (18-64 years),55.0,64.0,Age,55-64 years-old,1104,0.025,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Anita Siller,Tirol Kliniken GmbH,Not Unity-Aligned,https://dx.doi.org/10.1007/s00508-021-01963-3,2021-11-03,2024-03-01,Unverified,siller_prevalence_2021,AUT
211026_Tyrol_TirolKlinikenGmbH_Male,211026_Tyrol_TirolKlinikenGmbH,"Prevalence of SARS-CoV-2 antibodies in healthy blood donors from the state of Tyrol, Austria, in summer 2020.",2021-10-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Austria,Tyrol,,"(i) meet the general requirements for a blood donation; (ii) be living in Tyrol; (iii) be in a healthy state (for instance, free of malignant diseases, autoimmune diseases or infectious diseases); and (iv) be asymptomatic for at least 28 days in case they had had a PCR-confirmed or suspected SARS-CoV-2 infection",Excluded individuals with specific comorbidities which are known to influence severity and disease progression of COVID19,2020-06-08,2020-09-04,Blood donors,Male,Multiple groups,18.0,71.0,Sex/Gender,,2848,0.031000000000000003,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Anita Siller,Tirol Kliniken GmbH,Not Unity-Aligned,https://dx.doi.org/10.1007/s00508-021-01963-3,2021-11-03,2024-03-01,Unverified,siller_prevalence_2021,AUT
211026_Tyrol_TirolKlinikenGmbH_>=65,211026_Tyrol_TirolKlinikenGmbH,"Prevalence of SARS-CoV-2 antibodies in healthy blood donors from the state of Tyrol, Austria, in summer 2020.",2021-10-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Austria,Tyrol,,"(i) meet the general requirements for a blood donation; (ii) be living in Tyrol; (iii) be in a healthy state (for instance, free of malignant diseases, autoimmune diseases or infectious diseases); and (iv) be asymptomatic for at least 28 days in case they had had a PCR-confirmed or suspected SARS-CoV-2 infection",Excluded individuals with specific comorbidities which are known to influence severity and disease progression of COVID19,2020-06-08,2020-09-04,Blood donors,All,Seniors (65+ years),65.0,71.0,Age,>= 65 years-old,140,0.028999999999999998,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Anita Siller,Tirol Kliniken GmbH,Not Unity-Aligned,https://dx.doi.org/10.1007/s00508-021-01963-3,2021-11-03,2024-03-01,Unverified,siller_prevalence_2021,AUT
211026_Tyrol_TirolKlinikenGmbH_Wantai,211026_Tyrol_TirolKlinikenGmbH,"Prevalence of SARS-CoV-2 antibodies in healthy blood donors from the state of Tyrol, Austria, in summer 2020.",2021-10-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Austria,Tyrol,,"(i) meet the general requirements for a blood donation; (ii) be living in Tyrol; (iii) be in a healthy state (for instance, free of malignant diseases, autoimmune diseases or infectious diseases); and (iv) be asymptomatic for at least 28 days in case they had had a PCR-confirmed or suspected SARS-CoV-2 infection",Excluded individuals with specific comorbidities which are known to influence severity and disease progression of COVID19,2020-06-08,2020-09-04,Blood donors,All,Multiple groups,18.0,71.0,Test used,,5345,0.025,0.021,0.03,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Wantai SARS-CoV-2 Total Ab ELISA","Abbott Laboratories,Beijing Wantai Biological",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Anita Siller,Tirol Kliniken GmbH,Not Unity-Aligned,https://dx.doi.org/10.1007/s00508-021-01963-3,2021-11-03,2024-03-01,Unverified,siller_prevalence_2021,AUT
211026_Tyrol_TirolKlinikenGmbH_Female,211026_Tyrol_TirolKlinikenGmbH,"Prevalence of SARS-CoV-2 antibodies in healthy blood donors from the state of Tyrol, Austria, in summer 2020.",2021-10-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Austria,Tyrol,,"(i) meet the general requirements for a blood donation; (ii) be living in Tyrol; (iii) be in a healthy state (for instance, free of malignant diseases, autoimmune diseases or infectious diseases); and (iv) be asymptomatic for at least 28 days in case they had had a PCR-confirmed or suspected SARS-CoV-2 infection",Excluded individuals with specific comorbidities which are known to influence severity and disease progression of COVID19,2020-06-08,2020-09-04,Blood donors,Female,Multiple groups,18.0,71.0,Sex/Gender,,2497,0.03,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Anita Siller,Tirol Kliniken GmbH,Not Unity-Aligned,https://dx.doi.org/10.1007/s00508-021-01963-3,2021-11-03,2024-03-01,Unverified,siller_prevalence_2021,AUT
211215_Austria_UniversityofAppliedScienceWienerNeustadt_NonVac,211215_Austria_UniversityofAppliedScienceWienerNeustadt,Prevalence of asymptomatic SARS-CoV-2 infection in an Austrian cohort,2021-12-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Austria,,Wiener Neustadt,336 volunteers from the university’s environment (University of Applied Science Wiener Neustadt),,2021-02-15,2021-03-03,Multiple populations,All,Adults (18-64 years),,,Primary Estimate,seropositivity in non-vaccinated individuals,311,0.113,,,True,,,,True,Self-referral,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,No,No,,Unclear,Yes,No,,Elisabeth Mara,University of Applied Science Wiener Neustadt,Not Unity-Aligned,https://dx.doi.org/10.1016/j.clicom.2021.08.002,2023-03-31,2023-04-12,Unverified,mara_prevalence_2023,AUT
220228_UpperAustria_JohannesKeplerUniversity,220228_UpperAustria_JohannesKeplerUniversity,Low-entry-barrier point-of-care testing of anti-SARS-CoV-2 IgG in the population of Upper Austria from December 2020 until April 2021-a feasible surveillance strategy for post-pandemic monitoring?.,2022-02-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Austria,Upper Austria,,self-referred individuals to the respective test sites,,2020-12-18,2021-04-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,7554,0.31,,,,,,,,Self-referral,GENSPEED COVID-19 IgG xPOC,Genspeed Biotech GmbH,CLIA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.93,['High'],,No,Yes,No,,Unclear,Yes,No,,Christian Doppler,Johannes Kepler University,Not Unity-Aligned,https://dx.doi.org/10.1007/s00216-022-03966-z,2022-03-08,2022-07-16,Unverified,doppler_low-entry-barrier_2022,AUT
220309_Tyrol_MedicalUniversityofInnsbruck_Overall_UnAdj,220309_Tyrol_MedicalUniversityofInnsbruck,"Seroprevalence, Waning and Correlates of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Large-Scale Study of 35,193 Blood Donors Conducted between June 2020 and September 2021",2022-03-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Austria,Tyrol,,"Individuals were eligible for inclusion if they (i) were aged between 18 and 70 years; (ii) were permanent residents in Tyrol; (iii) and fulfilled the general requirements for donating blood, including being in a healthy state (e.g., free of malignant disease, auto-immune disease, or infectious diseases).",After excluding individuals without a laboratory result (n = 17) and without information on their vaccination status (n = 4),2021-03-19,2021-09-30,Blood donors,All,Multiple groups,18.0,70.0,Primary Estimate,,19792,0.6324000000000001,,,True,,,,True,Sequential,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9934999999999999,0.996,['High'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,,Anita Siller,Medical University of Innsbruck ,Unity-Aligned,https://dx.doi.org/10.3390/v14030568,2022-04-07,2024-03-01,Verified,siller_seroprevalence_2022,AUT
220309_Tyrol_MedicalUniversityofInnsbruck_Unvaccinated ,220309_Tyrol_MedicalUniversityofInnsbruck,"Seroprevalence, Waning and Correlates of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Large-Scale Study of 35,193 Blood Donors Conducted between June 2020 and September 2021",2022-03-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Austria,Tyrol,,"Individuals were eligible for inclusion if they (i) were aged between 18 and 70 years; (ii) were permanent residents in Tyrol; (iii) and fulfilled the general requirements for donating blood, including being in a healthy state (e.g., free of malignant disease, auto-immune disease, or infectious diseases).",After excluding individuals without a laboratory result (n = 17) and without information on their vaccination status (n = 4),2021-03-19,2021-09-30,Blood donors,All,Multiple groups,18.0,70.0,COVID-19 vaccination status,,9096,0.2607,,,,,,,,Sequential,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9934999999999999,0.996,['High'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,,Anita Siller,Medical University of Innsbruck ,Unity-Aligned,https://dx.doi.org/10.3390/v14030568,2022-04-07,2024-03-01,Verified,siller_seroprevalence_2022,AUT
220309_Tyrol_MedicalUniversityofInnsbruck_Vaccinated,220309_Tyrol_MedicalUniversityofInnsbruck,"Seroprevalence, Waning and Correlates of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Large-Scale Study of 35,193 Blood Donors Conducted between June 2020 and September 2021",2022-03-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Austria,Tyrol,,"Individuals were eligible for inclusion if they (i) were aged between 18 and 70 years; (ii) were permanent residents in Tyrol; (iii) and fulfilled the general requirements for donating blood, including being in a healthy state (e.g., free of malignant disease, auto-immune disease, or infectious diseases).",After excluding individuals without a laboratory result (n = 17) and without information on their vaccination status (n = 4),2021-03-19,2021-09-30,Blood donors,All,Multiple groups,18.0,70.0,COVID-19 vaccination status,,10696,0.9486,,,,,,,,Sequential,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9934999999999999,0.996,['High'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,,Anita Siller,Medical University of Innsbruck ,Unity-Aligned,https://dx.doi.org/10.3390/v14030568,2022-04-07,2024-03-01,Verified,siller_seroprevalence_2022,AUT
220411_Austria_LKHHochsteiermarkLeobenVordernbergerstr_Primary,220411_Austria_LKHHochsteiermarkLeobenVordernbergerstr,[SARS-CoV-2 seroprevalence in Austria. The situation before the omicron wave].,2022-04-21,Presentation or Conference,Local,Cross-sectional survey ,Austria,,Vienna,"additional blood and serum samples were taken as part of the blood tests that were carried out anyway and subsequently analyzed at the Center for Virology in Vienna. Samples were obtained in 3 different settings:

Partner institutions of the Center for Virology within the Sentinel network for surveillance of respiratory viruses,

examination for military service,

Departments for paediatrics and youth medicine in Austrian hospitals.

In addition, some resident paediatricians took part.",,2021-11-30,2022-01-13,Multiple populations,All,Multiple groups,,,Primary Estimate,,1217,0.217,0.17600000000000002,0.254,True,,True,,True,Unclear,SARS-CoV-2 ViraChip IgG,Viramed Biotech AG,IFA,Multiple Types,IgG,,,,,['High'],,Unclear,Yes,No,,Yes,Yes,Yes,,Reinhold Kerbl,LKH Hochsteiermark Leoben Vordernbergerstr,Not Unity-Aligned,https://dx.doi.org/10.1007/s00112-022-01491-y,2022-05-02,2024-03-01,Verified,kerbl_sars-cov-2_2022,AUT
220411_Austria_LKHHochsteiermarkLeobenVordernbergerstr_Adults,220411_Austria_LKHHochsteiermarkLeobenVordernbergerstr,[SARS-CoV-2 seroprevalence in Austria. The situation before the omicron wave].,2022-04-21,Presentation or Conference,Local,Cross-sectional survey ,Austria,,Vienna,"additional blood and serum samples were taken as part of the blood tests that were carried out anyway and subsequently analyzed at the Center for Virology in Vienna. Samples were obtained in 3 different settings:

Partner institutions of the Center for Virology within the Sentinel network for surveillance of respiratory viruses,

examination for military service,

Departments for paediatrics and youth medicine in Austrian hospitals.

In addition, some resident paediatricians took part.",,2021-11-30,2022-01-13,Multiple populations,All,Adults (18-64 years),19.0,,Age,> 18 years,550,0.203,0.15,0.262,,,True,,,Unclear,SARS-CoV-2 ViraChip IgG,Viramed Biotech AG,IFA,Multiple Types,IgG,,,,,['High'],,Unclear,Yes,No,,Yes,Yes,Yes,,Reinhold Kerbl,LKH Hochsteiermark Leoben Vordernbergerstr,Not Unity-Aligned,https://dx.doi.org/10.1007/s00112-022-01491-y,2022-06-05,2024-03-01,Verified,kerbl_sars-cov-2_2022,AUT
220411_Austria_LKHHochsteiermarkLeobenVordernbergerstr_Children,220411_Austria_LKHHochsteiermarkLeobenVordernbergerstr,[SARS-CoV-2 seroprevalence in Austria. The situation before the omicron wave].,2022-04-21,Presentation or Conference,Local,Cross-sectional survey ,Austria,,Vienna,"additional blood and serum samples were taken as part of the blood tests that were carried out anyway and subsequently analyzed at the Center for Virology in Vienna. Samples were obtained in 3 different settings:

Partner institutions of the Center for Virology within the Sentinel network for surveillance of respiratory viruses,

examination for military service,

Departments for paediatrics and youth medicine in Austrian hospitals.

In addition, some resident paediatricians took part.",,2021-11-30,2022-01-13,Residual sera,All,Children and Youth (0-17 years),,18.0,Age,<= 18 years,667,0.23199999999999998,0.168,0.281,,,True,,,Convenience,SARS-CoV-2 ViraChip IgG,Viramed Biotech AG,IFA,Multiple Types,IgG,,,,,['High'],,Unclear,Yes,No,,Yes,Yes,Yes,,Reinhold Kerbl,LKH Hochsteiermark Leoben Vordernbergerstr,Not Unity-Aligned,https://dx.doi.org/10.1007/s00112-022-01491-y,2022-06-05,2024-03-01,Verified,kerbl_sars-cov-2_2022,AUT
220524_Vorarlberg_VIVIT_t1,220524_Vorarlberg_VIVIT,SARS-CoV-2 RBD-specific and NP-specific antibody response of healthcare workers in the westernmost Austrian state Vorarlberg: a prospective cohort study.,2022-05-24,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Austria,Vorarlberg,,"working as HCW in Vorarlberg, the westernmost federal state of Austria. All participants are employed by one of the state hospitals and 174 (44%) at a COVID-19- specialised
hospital.",,2020-06-26,2020-08-19,Health care workers and caregivers,All,Adults (18-64 years),18.0,64.0,Primary Estimate,t1: Jun 26 - Aug 19 2020,395,0.061,,,True,,,,True,Self-referral,5600100 TECHNOZYM anti SARS-CoV-2 RBD IgG ELISA 96T,Technoclone,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,No,Yes,No,,Michele Atzl,Vorarlberg Institute for Vascular Investigation and Treatment,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-052130,2022-06-05,2024-03-01,Unverified,atzl_sars-cov-2_2022,AUT
220727_Weißenkirchen_DanubePrivateUniversity_Overall,220727_Weißenkirchen_DanubePrivateUniversity,Longitudinal monitoring of SARS-CoV-2 spike protein-specific antibody responses in Lower Austria.,2022-07-27,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Austria,,Weißenkirchen,"Research subjects had to be inhabitants of Weißenkirchen, Austria, to be eligible for enrollment. The cohort consisted of non-infected participants, and formerly infected but recovered cases. We cannot exclude, that cases were also included with asymptomatic infections at the time point of sample collection.",,2021-02-13,2021-02-13,Household and community samples,All,Multiple groups,,,Primary Estimate,,552,0.25,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Heike Rebholz,Danube Private University,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0271382,2022-08-03,2024-03-01,Verified,rebholz_longitudinal_2022,AUT
220825_Tyrol_MedicalUniversityOfInnsbruck_Overall,220825_Tyrol_MedicalUniversityOfInnsbruck,"Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Updated Analysis Involving 22,607 Blood Donors Covering the Period October 2021 to April 2022",2022-08-25,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Austria,"Tyrol
",,"(i) were aged between 18 and 70 years; (ii) were permanent residents in Tyrol; (iii) and fulfilled the general requirements for donating blood, including being in a healthy state.","exclusion of children, adolescents, and individuals aged ≥70 years",2021-10-01,2022-04-28,Blood donors,All,Multiple groups,18.0,69.0,Primary Estimate,,22607,0.919,,,True,,True,,True,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by developers,0.9934999999999999,0.996,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Lisa Seekircher,Medical University of Innsbruck,Unity-Aligned,https://doi.org/10.3390/v14091877,2024-04-16,2024-04-16,Unverified,seekircher_seroprevalence_2022-1,AUT
220825_Tyrol_MedicalUniversityOfInnsbruck_April,220825_Tyrol_MedicalUniversityOfInnsbruck,"Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Updated Analysis Involving 22,607 Blood Donors Covering the Period October 2021 to April 2022",2022-08-25,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Austria,"Tyrol
",,"(i) were aged between 18 and 70 years; (ii) were permanent residents in Tyrol; (iii) and fulfilled the general requirements for donating blood, including being in a healthy state.","exclusion of children, adolescents, and individuals aged ≥70 years",2022-04-01,2022-04-28,Blood donors,All,Multiple groups,18.0,69.0,Time frame,Apr 2022,2756,0.958,0.9490000000000001,0.9640000000000001,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by developers,0.9934999999999999,0.996,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Lisa Seekircher,Medical University of Innsbruck,Unity-Aligned,https://doi.org/10.3390/v14091877,2024-04-16,2024-04-16,Unverified,seekircher_seroprevalence_2022-1,AUT
220825_Tyrol_MedicalUniversityOfInnsbruck_January,220825_Tyrol_MedicalUniversityOfInnsbruck,"Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Updated Analysis Involving 22,607 Blood Donors Covering the Period October 2021 to April 2022",2022-08-25,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Austria,"Tyrol
",,"(i) were aged between 18 and 70 years; (ii) were permanent residents in Tyrol; (iii) and fulfilled the general requirements for donating blood, including being in a healthy state.","exclusion of children, adolescents, and individuals aged ≥70 years",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,18.0,69.0,Time frame,Jan 2022,4567,0.935,0.9279999999999999,0.9420000000000001,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by developers,0.9934999999999999,0.996,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Lisa Seekircher,Medical University of Innsbruck,Unity-Aligned,https://doi.org/10.3390/v14091877,2024-04-16,2024-04-16,Unverified,seekircher_seroprevalence_2022-1,AUT
220825_Tyrol_MedicalUniversityOfInnsbruck_February,220825_Tyrol_MedicalUniversityOfInnsbruck,"Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Updated Analysis Involving 22,607 Blood Donors Covering the Period October 2021 to April 2022",2022-08-25,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Austria,"Tyrol
",,"(i) were aged between 18 and 70 years; (ii) were permanent residents in Tyrol; (iii) and fulfilled the general requirements for donating blood, including being in a healthy state.","exclusion of children, adolescents, and individuals aged ≥70 years",2022-02-01,2022-02-28,Blood donors,All,Multiple groups,18.0,69.0,Time frame,Feb 2022,3059,0.953,0.9450000000000001,0.96,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by developers,0.9934999999999999,0.996,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Lisa Seekircher,Medical University of Innsbruck,Unity-Aligned,https://doi.org/10.3390/v14091877,2024-04-16,2024-04-16,Unverified,seekircher_seroprevalence_2022-1,AUT
220825_Tyrol_MedicalUniversityOfInnsbruck_November,220825_Tyrol_MedicalUniversityOfInnsbruck,"Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Updated Analysis Involving 22,607 Blood Donors Covering the Period October 2021 to April 2022",2022-08-25,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Austria,"Tyrol
",,"(i) were aged between 18 and 70 years; (ii) were permanent residents in Tyrol; (iii) and fulfilled the general requirements for donating blood, including being in a healthy state.","exclusion of children, adolescents, and individuals aged ≥70 years",2021-11-01,2021-11-30,Blood donors,All,Multiple groups,18.0,69.0,Time frame,Nov 2021,3833,0.887,0.876,0.8959999999999999,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by developers,0.9934999999999999,0.996,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Lisa Seekircher,Medical University of Innsbruck,Unity-Aligned,https://doi.org/10.3390/v14091877,2024-04-16,2024-04-16,Unverified,seekircher_seroprevalence_2022-1,AUT
220825_Tyrol_MedicalUniversityOfInnsbruck_December,220825_Tyrol_MedicalUniversityOfInnsbruck,"Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Updated Analysis Involving 22,607 Blood Donors Covering the Period October 2021 to April 2022",2022-08-25,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Austria,"Tyrol
",,"(i) were aged between 18 and 70 years; (ii) were permanent residents in Tyrol; (iii) and fulfilled the general requirements for donating blood, including being in a healthy state.","exclusion of children, adolescents, and individuals aged ≥70 years",2021-12-01,2021-12-31,Blood donors,All,Multiple groups,18.0,69.0,Time frame,Dec 2021,3363,0.91,0.903,0.923,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by developers,0.9934999999999999,0.996,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Lisa Seekircher,Medical University of Innsbruck,Unity-Aligned,https://doi.org/10.3390/v14091877,2024-04-16,2024-04-16,Unverified,seekircher_seroprevalence_2022-1,AUT
220825_Tyrol_MedicalUniversityOfInnsbruck_March,220825_Tyrol_MedicalUniversityOfInnsbruck,"Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Updated Analysis Involving 22,607 Blood Donors Covering the Period October 2021 to April 2022",2022-08-25,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Austria,"Tyrol
",,"(i) were aged between 18 and 70 years; (ii) were permanent residents in Tyrol; (iii) and fulfilled the general requirements for donating blood, including being in a healthy state.","exclusion of children, adolescents, and individuals aged ≥70 years",2022-03-01,2022-03-31,Blood donors,All,Multiple groups,18.0,69.0,Time frame,Mar 2022,3753,0.9590000000000001,0.9520000000000001,0.965,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by developers,0.9934999999999999,0.996,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Lisa Seekircher,Medical University of Innsbruck,Unity-Aligned,https://doi.org/10.3390/v14091877,2024-04-16,2024-04-16,Unverified,seekircher_seroprevalence_2022-1,AUT
220825_Tyrol_MedicalUniversityOfInnsbruck_October,220825_Tyrol_MedicalUniversityOfInnsbruck,"Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Updated Analysis Involving 22,607 Blood Donors Covering the Period October 2021 to April 2022",2022-08-25,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Austria,"Tyrol
",,"(i) were aged between 18 and 70 years; (ii) were permanent residents in Tyrol; (iii) and fulfilled the general requirements for donating blood, including being in a healthy state.","exclusion of children, adolescents, and individuals aged ≥70 years",2021-10-15,2021-10-30,Blood donors,All,Multiple groups,18.0,69.0,Time frame,Oct 2021,4230,0.8490000000000001,0.838,0.86,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by developers,0.9934999999999999,0.996,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Lisa Seekircher,Medical University of Innsbruck,Unity-Aligned,https://doi.org/10.3390/v14091877,2024-04-16,2024-04-16,Unverified,seekircher_seroprevalence_2022-1,AUT
220909_Tyrol_MedicalUniversityOfInnsbruck_AntiS,220909_Tyrol_MedicalUniversityOfInnsbruck,Seroprevalence of SARS-CoV-2 infection in the Tyrolean district of Schwaz at the time of the rapid mass vaccination in March 2021 following B.1.351-variant outbreak.,2022-09-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Austria,Tyrol,Schwaz,"All adult residents of the district Schwaz in Tyrol, aged 18 years and above",,2021-03-01,2021-03-31,Household and community samples,All,Multiple groups,18.0,89.0,Primary Estimate,anti-S IgG postive,2474,0.514,,,True,,,,True,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,Multiple Types,Plasma,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Peter Willeit,Medical University of Innsbruck ,Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.989337,2022-10-04,2024-03-01,Unverified,willeit_seroprevalence_2022,AUT
220909_Tyrol_MedicalUniversityOfInnsbruck_Neutralizing,220909_Tyrol_MedicalUniversityOfInnsbruck,Seroprevalence of SARS-CoV-2 infection in the Tyrolean district of Schwaz at the time of the rapid mass vaccination in March 2021 following B.1.351-variant outbreak.,2022-09-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Austria,Tyrol,Schwaz,"All adult residents of the district Schwaz in Tyrol, aged 18 years and above",,2021-03-01,2021-03-31,Household and community samples,All,Multiple groups,18.0,89.0,Test used,% of reference population including previously documented cases**,2474,0.306,,,,,,,,Convenience,"SARS-CoV-2 IgG II Quant ,Elecsys® Anti‐SARS‐CoV‐2 (N),Author designed (Neutralization Assay)","Abbott Laboratories,Roche Diagnostics,NA",Multiple Types,Plasma,,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Peter Willeit,Medical University of Innsbruck ,Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.989337,2022-10-04,2024-03-01,Unverified,willeit_seroprevalence_2022,AUT
220909_Tyrol_MedicalUniversityOfInnsbruck_AntiN,220909_Tyrol_MedicalUniversityOfInnsbruck,Seroprevalence of SARS-CoV-2 infection in the Tyrolean district of Schwaz at the time of the rapid mass vaccination in March 2021 following B.1.351-variant outbreak.,2022-09-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Austria,Tyrol,Schwaz,"All adult residents of the district Schwaz in Tyrol, aged 18 years and above",,2021-03-01,2021-03-31,Household and community samples,All,Multiple groups,18.0,89.0,Test used,Anti-N Ig positive,2474,0.34299999999999997,,,,,,,,Convenience,"SARS-CoV-2 IgG II Quant ,Elecsys® Anti‐SARS‐CoV‐2 (N),Author designed (Neutralization Assay)","Abbott Laboratories,Roche Diagnostics,NA",Multiple Types,Plasma,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Peter Willeit,Medical University of Innsbruck ,Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.989337,2022-10-04,2024-03-01,Unverified,willeit_seroprevalence_2022,AUT
221019_Tyrol_MedicalUniversityOfInnsbruck_Overall,221019_Tyrol_MedicalUniversityOfInnsbruck,High Prevalence of Undocumented SARS-CoV-2 Infections in the Pediatric Population of the Tyrolean District of Schwaz.,2022-10-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Austria,Tyrolean District,Schwaz,Study participants were eligible for enrollment if they met the following inclusion criteria: Participants at the time of enrollment had to be at least 2 years old and no older than 15 years. Participants had to be permanent residents of the district of Schwaz and could not have received any vaccine against SARS-CoV-2 at the time of enrollment to be eligible.,"Children who did not meet the eligibility criteria or failed to provide questionnaire data and/or blood samples were excluded from the study. Participants with a positive PCR or antigen test within the last 300 days
prior to enrollment in the original study in March",2021-05-01,2021-08-30,Blood donors,All,Children and Youth (0-17 years),2.0,15.0,Primary Estimate,,369,0.35700000000000004,,,True,,,,True,Convenience,"SARS-CoV-2 IgG II Quant ,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",CLIA,Plasma,IgG,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,No,,Teresa Harthaller,Medical University of Innsbruck,Not Unity-Aligned,https://dx.doi.org/10.3390/v14102294,2022-11-01,2024-03-01,Unverified,harthaller_high_2022,AUT
230118_Vienna_MedicalUniversityOfVienna_HCWs_Overall,230118_Vienna_MedicalUniversityOfVienna_HCWs,Comparison of the prevalence of SARS-CoV-2 nucleoprotein antibodies in healthcare workers and an unselected adult and paediatric all-comer patient population: insights from a longitudinal study of healthcare workers and concurrent serial cross-sectional studies of patients at an academic medical centre in Austria,2023-01-18,Journal Article (Peer-Reviewed),Local,Prospective cohort,Austria,,Vienna,"""The Vienna-versus-Virus study (ClinicalTrials.gov Identifier: NCT04407429) was designed as a prospective, observational study to assess the seroprevalence of SARS-CoV-2 antibodies in healthcare workers and an all-comer patient population at Vienna General Hospital and the Medical University of Vienna.""

""Eligible healthcare workers were physicians, nursing staff, midwives, medical-technical assistants (ie, medical, therapeutic and diagnostic healthcare staff, and medical and nursing assistants) and administrative personnel with patient contact.""",,2020-08-24,2021-11-23,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,over the entire study period,812,0.121,0.1,0.145,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,"CLIA, CMIA",Serum,"IgG, IgM, IgA",Nucleocapsid (N-protein),Validated by manufacturers,0.99,0.99,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Martin Riesenhuber,Medical University of Vienna,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2022-063760,2023-02-10,2024-03-01,Unverified,riesenhuber_comparison_2023,AUT
230118_Vienna_MedicalUniversityOfVienna_Patients_Overall,230118_Vienna_MedicalUniversityOfVienna_Patients,Comparison of the prevalence of SARS-CoV-2 nucleoprotein antibodies in healthcare workers and an unselected adult and paediatric all-comer patient population: insights from a longitudinal study of healthcare workers and concurrent serial cross-sectional studies of patients at an academic medical centre in Austria,2023-01-18,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Austria,,Vienna,"""All patients who received medical care at Vienna General Hospital and the Medical University of Vienna with available residual serum samples (which were collected based on the clinical indication by the patients’ treating physician) were included"".

""Vienna General Hospital was contracted to provide care for non-COVID-19 related emergencies ... patients admitted to the ward were typically required to have no signs of active SARS-CoV-2 infection and a negative SARS-CoV-2 PCR test.""",,2020-08-24,2021-11-23,Residual sera,All,Multiple groups,,,Primary Estimate,over the entire study period,8451,0.0779,,,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,"CLIA, CMIA",Serum,"IgG, IgM, IgA",Nucleocapsid (N-protein),Validated by manufacturers,0.99,0.99,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Martin Riesenhuber,Medical University of Vienna,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2022-063760,2023-02-10,2024-03-01,Unverified,riesenhuber_comparison_2023,AUT
230118_Vienna_MedicalUniversityOfVienna_Patients_PeriodB,230118_Vienna_MedicalUniversityOfVienna_Patients,Comparison of the prevalence of SARS-CoV-2 nucleoprotein antibodies in healthcare workers and an unselected adult and paediatric all-comer patient population: insights from a longitudinal study of healthcare workers and concurrent serial cross-sectional studies of patients at an academic medical centre in Austria,2023-01-18,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Austria,,Vienna,"""All patients who received medical care at Vienna General Hospital and the Medical University of Vienna with available residual serum samples (which were collected based on the clinical indication by the patients’ treating physician) were included"".

""Vienna General Hospital was contracted to provide care for non-COVID-19 related emergencies ... patients admitted to the ward were typically required to have no signs of active SARS-CoV-2 infection and a negative SARS-CoV-2 PCR test.""",,2021-02-08,2021-02-22,Residual sera,All,Multiple groups,,,Time frame,Period B,3082,0.09300000000000001,0.084,0.10400000000000001,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,"CLIA, CMIA",Serum,"IgG, IgM, IgA",Nucleocapsid (N-protein),Validated by manufacturers,0.99,0.99,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Martin Riesenhuber,Medical University of Vienna,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2022-063760,2023-02-10,2024-03-01,Unverified,riesenhuber_comparison_2023,AUT
230118_Vienna_MedicalUniversityOfVienna_Patients_PeriodA,230118_Vienna_MedicalUniversityOfVienna_Patients,Comparison of the prevalence of SARS-CoV-2 nucleoprotein antibodies in healthcare workers and an unselected adult and paediatric all-comer patient population: insights from a longitudinal study of healthcare workers and concurrent serial cross-sectional studies of patients at an academic medical centre in Austria,2023-01-18,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Austria,,Vienna,"""All patients who received medical care at Vienna General Hospital and the Medical University of Vienna with available residual serum samples (which were collected based on the clinical indication by the patients’ treating physician) were included"".

""Vienna General Hospital was contracted to provide care for non-COVID-19 related emergencies ... patients admitted to the ward were typically required to have no signs of active SARS-CoV-2 infection and a negative SARS-CoV-2 PCR test.""",,2020-08-24,2020-09-07,Residual sera,All,Multiple groups,,,Time frame,Period A,3010,0.02,0.016,0.026000000000000002,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,"CLIA, CMIA",Serum,"IgG, IgM, IgA",Nucleocapsid (N-protein),Validated by manufacturers,0.99,0.99,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Martin Riesenhuber,Medical University of Vienna,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2022-063760,2023-02-10,2024-03-01,Unverified,riesenhuber_comparison_2023,AUT
230118_Vienna_MedicalUniversityOfVienna_Patients_PeriodC,230118_Vienna_MedicalUniversityOfVienna_Patients,Comparison of the prevalence of SARS-CoV-2 nucleoprotein antibodies in healthcare workers and an unselected adult and paediatric all-comer patient population: insights from a longitudinal study of healthcare workers and concurrent serial cross-sectional studies of patients at an academic medical centre in Austria,2023-01-18,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Austria,,Vienna,"""All patients who received medical care at Vienna General Hospital and the Medical University of Vienna with available residual serum samples (which were collected based on the clinical indication by the patients’ treating physician) were included"".

""Vienna General Hospital was contracted to provide care for non-COVID-19 related emergencies ... patients admitted to the ward were typically required to have no signs of active SARS-CoV-2 infection and a negative SARS-CoV-2 PCR test.""",,2021-11-09,2021-11-23,Residual sera,All,Multiple groups,,,Time frame,Period C,3184,0.128,0.11699999999999999,0.14,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,"CLIA, CMIA",Serum,"IgG, IgM, IgA",Nucleocapsid (N-protein),Validated by manufacturers,0.99,0.99,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Martin Riesenhuber,Medical University of Vienna,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2022-063760,2023-02-10,2024-03-01,Unverified,riesenhuber_comparison_2023,AUT
230602_Vienna_MedicalUniversityofVienna,230602_Vienna_MedicalUniversityofVienna,"SARS-CoV-2 infections in ""less visible"" hospital staff: The roles and safety of environmental services and allied health professionals.",2023-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Austria,,Vienna,"• Age ≥ 18 years.
• Hospital staff with the following functions were included.
• Environmental Services (cleaning/service staff, patient trans- portation).
• Allied health professionals (physiotherapists, occupational therapists, nutritionists, nurse assistants, biomedical analysts, radiology technicians).
• Participants speaking German, English, Bulgarian, Croatian, or Serbian were included, based on the language skills of the re- searchers staff.","• Inability to read or sign the informed consent.
• Limiting language barriers.",2020-05-15,2021-03-15,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,221,0.077,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,IgG,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Sebastian Jensen,Medical University of Vienna,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jiph.2023.05.041,2023-08-01,2023-08-15,Unverified,jensenSARSCoV2InfectionsLess2023,AUT
220115_Azerbaijan_WorldHealthOrganization_Overall,220115_Azerbaijan_WorldHealthOrganization,"The effectiveness of primary series CoronaVac vaccine in preventing COVID-19 illness: a prospective cohort study among health workers in Azerbaijan, May-November, 2021",2023-01-15,Preprint,Local,Prospective cohort,Azerbaijan,,Buka,"we enrolled HCWs at seven hospitals in the Baku United Hospital network in Baku, the capital city of Azerbaijan, into a prospective cohort.",Three participants were excluded because no follow-up data were obtained after enrolment,2021-05-03,2021-07-11,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,1582,0.9,,,True,,,,True,Convenience,"Platelia SARS-CoV-2 Total Ab assay,Wantai SARS-CoV-2 Total Ab ELISA","Bio-rad,Beijing Wantai Biological",ELISA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,No,Yes,No,,Mark Katz,World Health Organization,Not Unity-Aligned,http://doi.org/10.22541/au.167394784.44174107/v1,2023-02-10,2024-03-01,Unverified,katz_effectiveness_2023,AZE
210905_Razarbag_BRACUniversity_GroupII_Overall,210905_Razarbag_BRACUniversity,Assessment of a rapid pan-antibody dot test for detection of antibodies against SARS-CoV-2,2021-09-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bangladesh,Dhaka District,Dhaka,"Using the quota sampling technique, 509 patient
samples were collected from the Fever clinic of
BSMMU and Central Police Hospital, Razarbag,
Dhaka. Among the 509 patients, both blood samples
and nasopharyngeal swabs were collected from 300
symptomatic suspected COVID-19 infections and
109 convalescent patients from mid-May to mid-
June 2020. An additional 100 serum samples from
archived pre-pandemic specimens collected between
the years of 2017 to 2018 were used as control.",,2020-05-15,2020-06-15,Residual sera,All,Multiple groups,,,Primary Estimate,Group II patients: RT-PCR negative patients for SARS-CoV-2 (n=100),100,0.2,,,True,,,,True,Stratified non-probability,Author designed (type unknown),,LFIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,0.96,['High'],No,No,No,No,Unclear,Unclear,Yes,No,Unclear,Md Ahsanul Haq,BRAC University,Not Unity-Aligned,http://dx.doi.org/10.3329/BJMS.V20I5.55407,2021-10-12,2022-07-16,Verified,haq_assessment_2021,BGD
220110_SitakundaSubdistrict_icddrb_Overall_PopTestClusterAdj,220110_SitakundaSubdistrict_icddrb,"SARS-CoV-2 Seroprevalence before Delta Variant Surge, Chattogram, Bangladesh, March-June 2021.",2022-01-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bangladesh,,Sitakunda subdistrict,"Households in Chattogram.

""We attempted to enroll all persons ≥1 year of age in each [randomly selected] household.""",,2021-03-27,2021-06-13,Household and community samples,All,Multiple groups,1.0,97.0,Primary Estimate,"Adjusted for sex, age, household clustering, and test performance",2307,0.6409999999999999,0.6,0.6809999999999999,True,True,True,True,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.877,0.991,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Taufiqur Bhuiyan,"icddr,b [International Centre for Diarrhoeal Disease Research, Bangladesh]",Unity-Aligned,https://dx.doi.org/10.3201/eid2802.211689,2022-02-02,2023-08-15,Verified,bhuiyan_sars-cov-2_2022,BGD
220110_SitakundaSubdistrict_icddrb_Age_45-54,220110_SitakundaSubdistrict_icddrb,"SARS-CoV-2 Seroprevalence before Delta Variant Surge, Chattogram, Bangladesh, March-June 2021.",2022-01-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bangladesh,,Sitakunda subdistrict,"Households in Chattogram.

""We attempted to enroll all persons ≥1 year of age in each [randomly selected] household.""",,2021-03-27,2021-06-13,Household and community samples,All,Adults (18-64 years),45.0,54.0,Age,Age: 45-54,250,0.72,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.877,0.991,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Taufiqur Bhuiyan,"icddr,b [International Centre for Diarrhoeal Disease Research, Bangladesh]",Unity-Aligned,https://dx.doi.org/10.3201/eid2802.211689,2022-05-31,2024-03-01,Verified,bhuiyan_sars-cov-2_2022,BGD
220110_SitakundaSubdistrict_icddrb_Age_1-4,220110_SitakundaSubdistrict_icddrb,"SARS-CoV-2 Seroprevalence before Delta Variant Surge, Chattogram, Bangladesh, March-June 2021.",2022-01-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bangladesh,,Sitakunda subdistrict,"Households in Chattogram.

""We attempted to enroll all persons ≥1 year of age in each [randomly selected] household.""",,2021-03-27,2021-06-13,Household and community samples,All,Children and Youth (0-17 years),1.0,4.0,Age,Age: 1-4,90,0.4111,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.877,0.991,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Taufiqur Bhuiyan,"icddr,b [International Centre for Diarrhoeal Disease Research, Bangladesh]",Unity-Aligned,https://dx.doi.org/10.3201/eid2802.211689,2022-05-31,2024-03-01,Verified,bhuiyan_sars-cov-2_2022,BGD
220110_SitakundaSubdistrict_icddrb_Sex_Female,220110_SitakundaSubdistrict_icddrb,"SARS-CoV-2 Seroprevalence before Delta Variant Surge, Chattogram, Bangladesh, March-June 2021.",2022-01-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bangladesh,,Sitakunda subdistrict,"Households in Chattogram.

""We attempted to enroll all persons ≥1 year of age in each [randomly selected] household.""",,2021-03-27,2021-06-13,Household and community samples,Female,Multiple groups,1.0,97.0,Sex/Gender,,1235,0.6097,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.877,0.991,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Taufiqur Bhuiyan,"icddr,b [International Centre for Diarrhoeal Disease Research, Bangladesh]",Unity-Aligned,https://dx.doi.org/10.3201/eid2802.211689,2022-05-31,2024-03-01,Verified,bhuiyan_sars-cov-2_2022,BGD
220110_SitakundaSubdistrict_icddrb_Sex_Male,220110_SitakundaSubdistrict_icddrb,"SARS-CoV-2 Seroprevalence before Delta Variant Surge, Chattogram, Bangladesh, March-June 2021.",2022-01-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bangladesh,,Sitakunda subdistrict,"Households in Chattogram.

""We attempted to enroll all persons ≥1 year of age in each [randomly selected] household.""",,2021-03-27,2021-06-13,Household and community samples,Male,Multiple groups,1.0,97.0,Sex/Gender,,1072,0.6437,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.877,0.991,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Taufiqur Bhuiyan,"icddr,b [International Centre for Diarrhoeal Disease Research, Bangladesh]",Unity-Aligned,https://dx.doi.org/10.3201/eid2802.211689,2022-05-31,2024-03-01,Verified,bhuiyan_sars-cov-2_2022,BGD
220110_SitakundaSubdistrict_icddrb_Age_25-34,220110_SitakundaSubdistrict_icddrb,"SARS-CoV-2 Seroprevalence before Delta Variant Surge, Chattogram, Bangladesh, March-June 2021.",2022-01-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bangladesh,,Sitakunda subdistrict,"Households in Chattogram.

""We attempted to enroll all persons ≥1 year of age in each [randomly selected] household.""",,2021-03-27,2021-06-13,Household and community samples,All,Adults (18-64 years),25.0,34.0,Age,Age: 25-34,381,0.6772,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.877,0.991,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Taufiqur Bhuiyan,"icddr,b [International Centre for Diarrhoeal Disease Research, Bangladesh]",Unity-Aligned,https://dx.doi.org/10.3201/eid2802.211689,2022-05-31,2024-03-01,Verified,bhuiyan_sars-cov-2_2022,BGD
220110_SitakundaSubdistrict_icddrb_Age_55-64,220110_SitakundaSubdistrict_icddrb,"SARS-CoV-2 Seroprevalence before Delta Variant Surge, Chattogram, Bangladesh, March-June 2021.",2022-01-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bangladesh,,Sitakunda subdistrict,"Households in Chattogram.

""We attempted to enroll all persons ≥1 year of age in each [randomly selected] household.""",,2021-03-27,2021-06-13,Household and community samples,All,Adults (18-64 years),55.0,64.0,Age,Age: 55-64,208,0.6346,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.877,0.991,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Taufiqur Bhuiyan,"icddr,b [International Centre for Diarrhoeal Disease Research, Bangladesh]",Unity-Aligned,https://dx.doi.org/10.3201/eid2802.211689,2022-05-31,2024-03-01,Verified,bhuiyan_sars-cov-2_2022,BGD
220110_SitakundaSubdistrict_icddrb_Vaccinated,220110_SitakundaSubdistrict_icddrb,"SARS-CoV-2 Seroprevalence before Delta Variant Surge, Chattogram, Bangladesh, March-June 2021.",2022-01-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bangladesh,,Sitakunda subdistrict,"Households in Chattogram.

""We attempted to enroll all persons ≥1 year of age in each [randomly selected] household.""",,2021-03-27,2021-06-13,Household and community samples,All,Multiple groups,1.0,97.0,COVID-19 vaccination status,,125,0.976,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.877,0.991,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Taufiqur Bhuiyan,"icddr,b [International Centre for Diarrhoeal Disease Research, Bangladesh]",Unity-Aligned,https://dx.doi.org/10.3201/eid2802.211689,2022-05-31,2024-03-01,Verified,bhuiyan_sars-cov-2_2022,BGD
220110_SitakundaSubdistrict_icddrb_Age_5-9,220110_SitakundaSubdistrict_icddrb,"SARS-CoV-2 Seroprevalence before Delta Variant Surge, Chattogram, Bangladesh, March-June 2021.",2022-01-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bangladesh,,Sitakunda subdistrict,"Households in Chattogram.

""We attempted to enroll all persons ≥1 year of age in each [randomly selected] household.""",,2021-03-27,2021-06-13,Household and community samples,All,Children and Youth (0-17 years),5.0,9.0,Age,Age: 5-9,174,0.408,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.877,0.991,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Taufiqur Bhuiyan,"icddr,b [International Centre for Diarrhoeal Disease Research, Bangladesh]",Unity-Aligned,https://dx.doi.org/10.3201/eid2802.211689,2022-05-31,2024-03-01,Verified,bhuiyan_sars-cov-2_2022,BGD
220110_SitakundaSubdistrict_icddrb_Age_35-44,220110_SitakundaSubdistrict_icddrb,"SARS-CoV-2 Seroprevalence before Delta Variant Surge, Chattogram, Bangladesh, March-June 2021.",2022-01-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bangladesh,,Sitakunda subdistrict,"Households in Chattogram.

""We attempted to enroll all persons ≥1 year of age in each [randomly selected] household.""",,2021-03-27,2021-06-13,Household and community samples,All,Adults (18-64 years),35.0,44.0,Age,Age: 35-44,325,0.6923,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.877,0.991,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Taufiqur Bhuiyan,"icddr,b [International Centre for Diarrhoeal Disease Research, Bangladesh]",Unity-Aligned,https://dx.doi.org/10.3201/eid2802.211689,2022-05-31,2024-03-01,Verified,bhuiyan_sars-cov-2_2022,BGD
220110_SitakundaSubdistrict_icddrb_Age_>=65,220110_SitakundaSubdistrict_icddrb,"SARS-CoV-2 Seroprevalence before Delta Variant Surge, Chattogram, Bangladesh, March-June 2021.",2022-01-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bangladesh,,Sitakunda subdistrict,"Households in Chattogram.

""We attempted to enroll all persons ≥1 year of age in each [randomly selected] household.""",,2021-03-27,2021-06-13,Household and community samples,All,Seniors (65+ years),65.0,97.0,Age,Age: ≥65,139,0.6835,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.877,0.991,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Taufiqur Bhuiyan,"icddr,b [International Centre for Diarrhoeal Disease Research, Bangladesh]",Unity-Aligned,https://dx.doi.org/10.3201/eid2802.211689,2022-05-31,2024-03-01,Verified,bhuiyan_sars-cov-2_2022,BGD
220110_SitakundaSubdistrict_icddrb_Age_10-14,220110_SitakundaSubdistrict_icddrb,"SARS-CoV-2 Seroprevalence before Delta Variant Surge, Chattogram, Bangladesh, March-June 2021.",2022-01-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bangladesh,,Sitakunda subdistrict,"Households in Chattogram.

""We attempted to enroll all persons ≥1 year of age in each [randomly selected] household.""",,2021-03-27,2021-06-13,Household and community samples,All,Children and Youth (0-17 years),10.0,14.0,Age,Age: 10-14,258,0.5426,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.877,0.991,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Taufiqur Bhuiyan,"icddr,b [International Centre for Diarrhoeal Disease Research, Bangladesh]",Unity-Aligned,https://dx.doi.org/10.3201/eid2802.211689,2022-05-31,2024-03-01,Verified,bhuiyan_sars-cov-2_2022,BGD
220110_SitakundaSubdistrict_icddrb_Age_15-24,220110_SitakundaSubdistrict_icddrb,"SARS-CoV-2 Seroprevalence before Delta Variant Surge, Chattogram, Bangladesh, March-June 2021.",2022-01-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bangladesh,,Sitakunda subdistrict,"Households in Chattogram.

""We attempted to enroll all persons ≥1 year of age in each [randomly selected] household.""",,2021-03-27,2021-06-13,Household and community samples,All,Adults (18-64 years),15.0,24.0,Age,Age: 15-24,482,0.6328,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.877,0.991,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Taufiqur Bhuiyan,"icddr,b [International Centre for Diarrhoeal Disease Research, Bangladesh]",Unity-Aligned,https://dx.doi.org/10.3201/eid2802.211689,2022-05-31,2024-03-01,Verified,bhuiyan_sars-cov-2_2022,BGD
220110_SitakundaSubdistrict_icddrb_Overall_Unadj,220110_SitakundaSubdistrict_icddrb,"SARS-CoV-2 Seroprevalence before Delta Variant Surge, Chattogram, Bangladesh, March-June 2021.",2022-01-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bangladesh,,Sitakunda subdistrict,"Households in Chattogram.

""We attempted to enroll all persons ≥1 year of age in each [randomly selected] household.""",,2021-03-27,2021-06-13,Household and community samples,All,Multiple groups,1.0,97.0,Analysis,Unadjusted,2307,0.6255,,,,,,,True,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.877,0.991,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Taufiqur Bhuiyan,"icddr,b [International Centre for Diarrhoeal Disease Research, Bangladesh]",Unity-Aligned,https://dx.doi.org/10.3201/eid2802.211689,2022-02-03,2024-03-01,Verified,bhuiyan_sars-cov-2_2022,BGD
220110_SitakundaSubdistrict_icddrb_Unvaccinated,220110_SitakundaSubdistrict_icddrb,"SARS-CoV-2 Seroprevalence before Delta Variant Surge, Chattogram, Bangladesh, March-June 2021.",2022-01-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bangladesh,,Sitakunda subdistrict,"Households in Chattogram.

""We attempted to enroll all persons ≥1 year of age in each [randomly selected] household.""",,2021-03-27,2021-06-13,Household and community samples,All,Multiple groups,1.0,97.0,COVID-19 vaccination status,,2181,0.6052000000000001,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.877,0.991,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Taufiqur Bhuiyan,"icddr,b [International Centre for Diarrhoeal Disease Research, Bangladesh]",Unity-Aligned,https://dx.doi.org/10.3201/eid2802.211689,2022-05-31,2024-03-01,Verified,bhuiyan_sars-cov-2_2022,BGD
220127_Dhaka_BRiCM,220127_Dhaka_BRiCM,Seropositivity of SARS-CoV-2 IgG Antibody among People in Dhaka City during the Prevaccination Period.,2022-01-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bangladesh,,Dhaka,"""We enrolled volunteers, mostly from Dhaka, with or without
symptoms of COVID-19 infection between October 2020
and February 2021.""",,2020-10-15,2021-02-15,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,,239,0.42200000000000004,,,True,,,,True,Convenience,ErbaLisa® COVID-19 IgG semi quantitative kit,Erba Manneim,ELISA,Serum,IgG,,,0.983,0.981,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,,Zabed Ahmed,Bangladesh Reference Institute for Chemical Measurements ,Unity-Aligned,https://dx.doi.org/10.1155/2022/4451144,2022-02-08,2024-03-01,Verified,ahmed_seropositivity_2022,BGD
220202_Bangladesh_InternationalCentreforDiarrhoealDiseaseResearch,220202_Bangladesh_InternationalCentreforDiarrhoealDiseaseResearch,Seroprevalence of SARS-CoV-2 antibodies in Bangladesh related to novel coronavirus infection,2022-02-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Bangladesh,,,general population from urban and slum areas of Dhaka and outside of Dhaka,,2020-04-15,2020-10-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,2582,0.304,0.24,0.37,True,,True,True,True,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,0.98,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Taufiqur Bhuiyan,International Centre for Diarrhoeal Disease Research,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809641/,2022-06-30,2024-01-20,Verified,bhuiyan_seroprevalence_2022,BGD
220202_Bangladesh_InternationalCentreforDiarrhoealDiseaseResearch_Age_10-14,220202_Bangladesh_InternationalCentreforDiarrhoealDiseaseResearch,Seroprevalence of SARS-CoV-2 antibodies in Bangladesh related to novel coronavirus infection,2022-02-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Bangladesh,,,general population from urban and slum areas of Dhaka and outside of Dhaka,,2020-04-15,2020-10-15,Household and community samples,All,Multiple groups,,,Age,10-14,181,0.153,0.02,0.29,,,True,True,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,0.98,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Taufiqur Bhuiyan,International Centre for Diarrhoeal Disease Research,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809641/,2022-06-30,2022-07-16,Unverified,bhuiyan_seroprevalence_2022,BGD
220202_Bangladesh_InternationalCentreforDiarrhoealDiseaseResearch_Sex_Female,220202_Bangladesh_InternationalCentreforDiarrhoealDiseaseResearch,Seroprevalence of SARS-CoV-2 antibodies in Bangladesh related to novel coronavirus infection,2022-02-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Bangladesh,,,general population from urban and slum areas of Dhaka and outside of Dhaka,,2020-04-15,2020-10-15,Household and community samples,Female,Multiple groups,,,Sex/Gender,,1327,0.334,0.26,0.41000000000000003,,,True,True,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,0.98,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Taufiqur Bhuiyan,International Centre for Diarrhoeal Disease Research,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809641/,2022-06-30,2022-07-16,Unverified,bhuiyan_seroprevalence_2022,BGD
220202_Bangladesh_InternationalCentreforDiarrhoealDiseaseResearch_Age_20-39,220202_Bangladesh_InternationalCentreforDiarrhoealDiseaseResearch,Seroprevalence of SARS-CoV-2 antibodies in Bangladesh related to novel coronavirus infection,2022-02-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Bangladesh,,,general population from urban and slum areas of Dhaka and outside of Dhaka,,2020-04-15,2020-10-15,Household and community samples,All,Multiple groups,,,Age,20-39,1069,0.326,0.25,0.4,,,True,True,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,0.98,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Taufiqur Bhuiyan,International Centre for Diarrhoeal Disease Research,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809641/,2022-06-30,2022-07-16,Unverified,bhuiyan_seroprevalence_2022,BGD
220202_Bangladesh_InternationalCentreforDiarrhoealDiseaseResearch_Age_>=60,220202_Bangladesh_InternationalCentreforDiarrhoealDiseaseResearch,Seroprevalence of SARS-CoV-2 antibodies in Bangladesh related to novel coronavirus infection,2022-02-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Bangladesh,,,general population from urban and slum areas of Dhaka and outside of Dhaka,,2020-04-15,2020-10-15,Household and community samples,All,Multiple groups,,,Age,>=60,268,0.318,0.24,0.4,,,True,True,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,0.98,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Taufiqur Bhuiyan,International Centre for Diarrhoeal Disease Research,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809641/,2022-06-30,2022-07-16,Unverified,bhuiyan_seroprevalence_2022,BGD
220202_Bangladesh_InternationalCentreforDiarrhoealDiseaseResearch_Age_15-19,220202_Bangladesh_InternationalCentreforDiarrhoealDiseaseResearch,Seroprevalence of SARS-CoV-2 antibodies in Bangladesh related to novel coronavirus infection,2022-02-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Bangladesh,,,general population from urban and slum areas of Dhaka and outside of Dhaka,,2020-04-15,2020-10-15,Household and community samples,All,Multiple groups,,,Age,15-19,261,0.23800000000000002,0.14,0.34,,,True,True,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,0.98,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Taufiqur Bhuiyan,International Centre for Diarrhoeal Disease Research,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809641/,2022-06-30,2022-07-16,Unverified,bhuiyan_seroprevalence_2022,BGD
220202_Bangladesh_InternationalCentreforDiarrhoealDiseaseResearch_Age_40-59,220202_Bangladesh_InternationalCentreforDiarrhoealDiseaseResearch,Seroprevalence of SARS-CoV-2 antibodies in Bangladesh related to novel coronavirus infection,2022-02-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Bangladesh,,,general population from urban and slum areas of Dhaka and outside of Dhaka,,2020-04-15,2020-10-15,Household and community samples,All,Multiple groups,,,Age,40-59,728,0.355,0.25,0.46,,,True,True,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,0.98,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Taufiqur Bhuiyan,International Centre for Diarrhoeal Disease Research,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809641/,2022-06-30,2022-07-16,Unverified,bhuiyan_seroprevalence_2022,BGD
220202_Bangladesh_InternationalCentreforDiarrhoealDiseaseResearch_Age_<10,220202_Bangladesh_InternationalCentreforDiarrhoealDiseaseResearch,Seroprevalence of SARS-CoV-2 antibodies in Bangladesh related to novel coronavirus infection,2022-02-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Bangladesh,"
",,general population from urban and slum areas of Dhaka and outside of Dhaka,,2020-04-15,2020-10-15,Household and community samples,All,Multiple groups,,,Age,,75,0.08199999999999999,0.0,0.19,,,True,True,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,0.98,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Taufiqur Bhuiyan,International Centre for Diarrhoeal Disease Research,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809641/,2022-06-30,2022-07-16,Unverified,bhuiyan_seroprevalence_2022,BGD
220202_Bangladesh_InternationalCentreforDiarrhoealDiseaseResearch_Sex_Male,220202_Bangladesh_InternationalCentreforDiarrhoealDiseaseResearch,Seroprevalence of SARS-CoV-2 antibodies in Bangladesh related to novel coronavirus infection,2022-02-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Bangladesh,,,general population from urban and slum areas of Dhaka and outside of Dhaka,,2020-04-15,2020-10-15,Household and community samples,Male,Multiple groups,,,Sex/Gender,,1255,0.278,0.21,0.35000000000000003,,,True,True,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,0.98,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Taufiqur Bhuiyan,International Centre for Diarrhoeal Disease Research,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809641/,2022-06-30,2022-07-16,Unverified,bhuiyan_seroprevalence_2022,BGD
220209_Chattogram_ChattogramVeterinaryandAnimalSciencesUniversity_Overall_TestAdjusted,220209_Chattogram_ChattogramVeterinaryandAnimalSciencesUniversity,"Sero-prevalence of anti-SARS-CoV-2 antibodies in Chattogram Metropolitan Area, Bangladesh",2022-02-09,Preprint,Local,Cross-sectional survey ,Bangladesh,Chittagong Division,Chattogram,"""we conducted a cross-sectional population-based study among HCWs (e.g., doctors, nurses, hospital staff, ward boy, and cleaner), garment workers, and indoor and outdoor patients (non-COVID-19) of six government and private hospitals each, and two garment factories in CMA.""

Inclusion criteria

Asymptomatic: Only an asymptomatic group was included to ensure the presence of antibodies. Participants had no COVID-19 related clinical signs, e.g., fever, coughing, runny nose, sore throat, dyspnea, shortness of breath, aches and pain at the time of sample collection

In case of having past confirmed COVID-19 status (by Rt PCR):

Participants who had already passed at least 28 days after a negative Rt-PCR test.

Participants who did not take a repeated test to ensure negativity had passed at least 42 days after the first COVID-19 test.","persons under 18 were excluded, as were those with an incomplete questionnaire.",2021-02-15,2021-09-15,Multiple populations,All,Multiple groups,19.0,84.0,Primary Estimate,Test Adjusted,748,0.6698999999999999,0.634,0.7040000000000001,True,True,,,,Stratified probability,COVID-19 IgG Antibody ELISA Test Kit,Kewei Diagnostic,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.938,0.973,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Jahan Ara,Chattogram Veterinary and Animal Sciences University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.09.22270717v1.full-text,2022-02-18,2023-08-15,Unverified,ara_sero-prevalence_2022,BGD
220209_Chattogram_ChattogramVeterinaryandAnimalSciencesUniversity_Age45to84,220209_Chattogram_ChattogramVeterinaryandAnimalSciencesUniversity,"Sero-prevalence of anti-SARS-CoV-2 antibodies in Chattogram Metropolitan Area, Bangladesh",2022-02-09,Preprint,Local,Cross-sectional survey ,Bangladesh,Chittagong Division,Chattogram,"""we conducted a cross-sectional population-based study among HCWs (e.g., doctors, nurses, hospital staff, ward boy, and cleaner), garment workers, and indoor and outdoor patients (non-COVID-19) of six government and private hospitals each, and two garment factories in CMA.""

Inclusion criteria

Asymptomatic: Only an asymptomatic group was included to ensure the presence of antibodies. Participants had no COVID-19 related clinical signs, e.g., fever, coughing, runny nose, sore throat, dyspnea, shortness of breath, aches and pain at the time of sample collection

In case of having past confirmed COVID-19 status (by Rt PCR):

Participants who had already passed at least 28 days after a negative Rt-PCR test.

Participants who did not take a repeated test to ensure negativity had passed at least 42 days after the first COVID-19 test.","persons under 18 were excluded, as were those with an incomplete questionnaire.",2021-02-15,2021-09-15,Multiple populations,All,Multiple groups,45.0,84.0,Age,45-84,182,0.7308,,,,,,,,Stratified probability,COVID-19 IgG Antibody ELISA Test Kit,Kewei Diagnostic,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.938,0.973,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Jahan Ara,Chattogram Veterinary and Animal Sciences University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.09.22270717v1.full-text,2022-02-18,2024-03-01,Unverified,ara_sero-prevalence_2022,BGD
220209_Chattogram_ChattogramVeterinaryandAnimalSciencesUniversity_Age30to35,220209_Chattogram_ChattogramVeterinaryandAnimalSciencesUniversity,"Sero-prevalence of anti-SARS-CoV-2 antibodies in Chattogram Metropolitan Area, Bangladesh",2022-02-09,Preprint,Local,Cross-sectional survey ,Bangladesh,Chittagong Division,Chattogram,"""we conducted a cross-sectional population-based study among HCWs (e.g., doctors, nurses, hospital staff, ward boy, and cleaner), garment workers, and indoor and outdoor patients (non-COVID-19) of six government and private hospitals each, and two garment factories in CMA.""

Inclusion criteria

Asymptomatic: Only an asymptomatic group was included to ensure the presence of antibodies. Participants had no COVID-19 related clinical signs, e.g., fever, coughing, runny nose, sore throat, dyspnea, shortness of breath, aches and pain at the time of sample collection

In case of having past confirmed COVID-19 status (by Rt PCR):

Participants who had already passed at least 28 days after a negative Rt-PCR test.

Participants who did not take a repeated test to ensure negativity had passed at least 42 days after the first COVID-19 test.","persons under 18 were excluded, as were those with an incomplete questionnaire.",2021-02-15,2021-09-15,Multiple populations,All,Adults (18-64 years),30.0,35.0,Age,30-35,184,0.6467,,,,,,,,Stratified probability,COVID-19 IgG Antibody ELISA Test Kit,Kewei Diagnostic,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.938,0.973,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Jahan Ara,Chattogram Veterinary and Animal Sciences University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.09.22270717v1.full-text,2022-02-18,2024-03-01,Unverified,ara_sero-prevalence_2022,BGD
220209_Chattogram_ChattogramVeterinaryandAnimalSciencesUniversity_Age36to44,220209_Chattogram_ChattogramVeterinaryandAnimalSciencesUniversity,"Sero-prevalence of anti-SARS-CoV-2 antibodies in Chattogram Metropolitan Area, Bangladesh",2022-02-09,Preprint,Local,Cross-sectional survey ,Bangladesh,Chittagong Division,Chattogram,"""we conducted a cross-sectional population-based study among HCWs (e.g., doctors, nurses, hospital staff, ward boy, and cleaner), garment workers, and indoor and outdoor patients (non-COVID-19) of six government and private hospitals each, and two garment factories in CMA.""

Inclusion criteria

Asymptomatic: Only an asymptomatic group was included to ensure the presence of antibodies. Participants had no COVID-19 related clinical signs, e.g., fever, coughing, runny nose, sore throat, dyspnea, shortness of breath, aches and pain at the time of sample collection

In case of having past confirmed COVID-19 status (by Rt PCR):

Participants who had already passed at least 28 days after a negative Rt-PCR test.

Participants who did not take a repeated test to ensure negativity had passed at least 42 days after the first COVID-19 test.","persons under 18 were excluded, as were those with an incomplete questionnaire.",2021-02-15,2021-09-15,Multiple populations,All,Adults (18-64 years),36.0,44.0,Age,36-44,180,0.7333,,,,,,,,Stratified probability,COVID-19 IgG Antibody ELISA Test Kit,Kewei Diagnostic,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.938,0.973,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Jahan Ara,Chattogram Veterinary and Animal Sciences University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.09.22270717v1.full-text,2022-02-18,2024-03-01,Unverified,ara_sero-prevalence_2022,BGD
220209_Chattogram_ChattogramVeterinaryandAnimalSciencesUniversity_Age19to29,220209_Chattogram_ChattogramVeterinaryandAnimalSciencesUniversity,"Sero-prevalence of anti-SARS-CoV-2 antibodies in Chattogram Metropolitan Area, Bangladesh",2022-02-09,Preprint,Local,Cross-sectional survey ,Bangladesh,Chittagong Division,Chattogram,"""we conducted a cross-sectional population-based study among HCWs (e.g., doctors, nurses, hospital staff, ward boy, and cleaner), garment workers, and indoor and outdoor patients (non-COVID-19) of six government and private hospitals each, and two garment factories in CMA.""

Inclusion criteria

Asymptomatic: Only an asymptomatic group was included to ensure the presence of antibodies. Participants had no COVID-19 related clinical signs, e.g., fever, coughing, runny nose, sore throat, dyspnea, shortness of breath, aches and pain at the time of sample collection

In case of having past confirmed COVID-19 status (by Rt PCR):

Participants who had already passed at least 28 days after a negative Rt-PCR test.

Participants who did not take a repeated test to ensure negativity had passed at least 42 days after the first COVID-19 test.","persons under 18 were excluded, as were those with an incomplete questionnaire.",2021-02-15,2021-09-15,Multiple populations,All,Adults (18-64 years),19.0,29.0,Age,19-29,201,0.5672,,,,,,,,Stratified probability,COVID-19 IgG Antibody ELISA Test Kit,Kewei Diagnostic,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.938,0.973,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Jahan Ara,Chattogram Veterinary and Animal Sciences University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.09.22270717v1.full-text,2022-02-18,2024-03-01,Unverified,ara_sero-prevalence_2022,BGD
220325_Dhaka_icddrb_Day1_HighDensity_IgG,220325_Dhaka_icddrb_Day1_HighDensity,"Transmission of SARS-CoV-2 in the Population Living in High-and Low-Density Gradient Areas in Dhaka, Bangladesh",2022-03-25,Journal Article (Peer-Reviewed),Local,Prospective cohort,Bangladesh,,Dhaka,"""We considered an individual as a contact who experienced any of the following exposures during the 2 days before and the 14 days after the onset of symptoms of a laboratory-confirmed COVID-19 case: (1) face-to-face contact with a confirmed case within 1 m and for more than 15 min (including travel, gossips, tea stall) or (2) direct physical contact with a confirmed COVID-19 case.""

""High-density areas are slums which are horizontally shared spaces with more than 5 people living in a 9–12 feet by 6–8 feet room.""",,2020-06-27,2020-09-26,Contacts of COVID patients,All,Multiple groups,,,Primary Estimate,IgG,442,0.6312,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,,,['High'],,No,No,No,,Unclear,Yes,No,,Syed Moinuddin Satter,"International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)",Not Unity-Aligned,https://dx.doi.org/10.3390/tropicalmed7040053,2022-04-25,2022-07-16,Unverified,satter_transmission_2022,BGD
220325_Dhaka_icddrb_Day1_LowDensity_IgG,220325_Dhaka_icddrb_Day1_LowDensity,"Transmission of SARS-CoV-2 in the Population Living in High-and Low-Density Gradient Areas in Dhaka, Bangladesh",2022-03-25,Journal Article (Peer-Reviewed),Local,Prospective cohort,Bangladesh,,Dhaka,"""We considered an individual as a contact who experienced any of the following exposures during the 2 days before and the 14 days after the onset of symptoms of a laboratory-confirmed COVID-19 case: (1) face-to-face contact with a confirmed case within 1 m and for more than 15 min (including travel, gossips, tea stall) or (2) direct physical contact with a confirmed COVID-19 case.""

""Low-density areas are non-slum wards, which have high-rise buildings and apartments.""",,2020-06-27,2020-09-26,Contacts of COVID patients,All,Multiple groups,,,Primary Estimate,IgG,118,0.6102000000000001,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,,,['High'],,No,No,No,,Unclear,Yes,No,,Syed Moinuddin Satter,"International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)",Not Unity-Aligned,https://dx.doi.org/10.3390/tropicalmed7040053,2022-05-02,2022-07-16,Unverified,satter_transmission_2022,BGD
220325_Dhaka_icddrb_Day28_HighDensity_IgG,220325_Dhaka_icddrb_Day28_HighDensity,"Transmission of SARS-CoV-2 in the Population Living in High-and Low-Density Gradient Areas in Dhaka, Bangladesh",2022-03-25,Journal Article (Peer-Reviewed),Local,Prospective cohort,Bangladesh,,Dhaka,"""We considered an individual as a contact who experienced any of the following exposures during the 2 days before and the 14 days after the onset of symptoms of a laboratory-confirmed COVID-19 case: (1) face-to-face contact with a confirmed case within 1 m and for more than 15 min (including travel, gossips, tea stall) or (2) direct physical contact with a confirmed COVID-19 case.""

""High-density areas are slums which are horizontally shared spaces with more than 5 people living in a 9–12 feet by 6–8 feet room.""",,2020-06-27,2020-09-26,Contacts of COVID patients,All,Multiple groups,,,Primary Estimate,IgG,442,0.6335000000000001,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,,,['High'],,No,No,No,,Unclear,Yes,No,,Syed Moinuddin Satter,"International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)",Not Unity-Aligned,https://dx.doi.org/10.3390/tropicalmed7040053,2022-05-02,2022-07-16,Unverified,satter_transmission_2022,BGD
220325_Dhaka_icddrb_Day28_LowDensity_IgG,220325_Dhaka_icddrb_Day28_LowDensity,"Transmission of SARS-CoV-2 in the Population Living in High-and Low-Density Gradient Areas in Dhaka, Bangladesh",2022-03-25,Journal Article (Peer-Reviewed),Local,Prospective cohort,Bangladesh,,Dhaka,"""We considered an individual as a contact who experienced any of the following exposures during the 2 days before and the 14 days after the onset of symptoms of a laboratory-confirmed COVID-19 case: (1) face-to-face contact with a confirmed case within 1 m and for more than 15 min (including travel, gossips, tea stall) or (2) direct physical contact with a confirmed COVID-19 case.""

""Low-density areas are non-slum wards, which have high-rise buildings and apartments.""",,2020-06-27,2020-09-26,Contacts of COVID patients,All,Multiple groups,,,Primary Estimate,IgG,118,0.6525,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,,,['High'],,No,No,No,,Unclear,Yes,No,,Syed Moinuddin Satter,"International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)",Not Unity-Aligned,https://dx.doi.org/10.3390/tropicalmed7040053,2022-05-02,2022-07-16,Unverified,satter_transmission_2022,BGD
220523_Bangladesh_icddrb_Overall,220523_Bangladesh_icddrb,Seroprevalence of SARS-CoV-2 infection and associated factors among Bangladeshi slum and non-slum dwellers in pre-COVID-19 vaccination era: October 2020 to February 2021.,2022-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Bangladesh,,"Dhaka, Chattogram","Samples were collected from 2118 slum inhabitants and 1102 from non-slums in a 2:1 ratio. After household selection, all the eligible members aged >=10 years, were invited to participate. In the early phase of the pandemic, susceptibility to COVID-19 was rare in <10 years old children and existing reports on adolescents (10–19 years) were controversial [31]. Therefore, adolescents, who can give assent and donate blood were enrolled in this study to determine seroprevalence of SARS-CoV-2 in this age group along with the adults. ",The exclusion criteria included refusal to give time to respond to all questions and give blood.,2020-10-15,2021-02-15,Household and community samples,All,Multiple groups,10.0,,Primary Estimate,,3220,0.6729999999999999,0.652,0.693,True,,True,True,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Plasma,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.933,1.0,['Moderate'],No,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Rubhana Raqib,icddrb,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0268093,2022-06-01,2024-03-29,Verified,raqib_seroprevalence_2022,BGD
220523_Bangladesh_icddrb_31-50,220523_Bangladesh_icddrb,Seroprevalence of SARS-CoV-2 infection and associated factors among Bangladeshi slum and non-slum dwellers in pre-COVID-19 vaccination era: October 2020 to February 2021.,2022-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Bangladesh,,"Dhaka, Chattogram","Samples were collected from 2118 slum inhabitants and 1102 from non-slums in a 2:1 ratio. After household selection, all the eligible members aged >=10 years, were invited to participate. In the early phase of the pandemic, susceptibility to COVID-19 was rare in <10 years old children and existing reports on adolescents (10–19 years) were controversial [31]. Therefore, adolescents, who can give assent and donate blood were enrolled in this study to determine seroprevalence of SARS-CoV-2 in this age group along with the adults. ",The exclusion criteria included refusal to give time to respond to all questions and give blood.,2020-10-15,2021-02-15,Household and community samples,All,Adults (18-64 years),31.0,50.0,Age,31-50,1015,0.6970000000000001,0.6609999999999999,0.731,,,True,True,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Plasma,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.933,1.0,['Moderate'],No,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Rubhana Raqib,icddrb,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0268093,2022-06-01,2024-03-29,Verified,raqib_seroprevalence_2022,BGD
220523_Bangladesh_icddrb_10-17,220523_Bangladesh_icddrb,Seroprevalence of SARS-CoV-2 infection and associated factors among Bangladeshi slum and non-slum dwellers in pre-COVID-19 vaccination era: October 2020 to February 2021.,2022-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Bangladesh,,"Dhaka, Chattogram","Samples were collected from 2118 slum inhabitants and 1102 from non-slums in a 2:1 ratio. After household selection, all the eligible members aged >=10 years, were invited to participate. In the early phase of the pandemic, susceptibility to COVID-19 was rare in <10 years old children and existing reports on adolescents (10–19 years) were controversial [31]. Therefore, adolescents, who can give assent and donate blood were enrolled in this study to determine seroprevalence of SARS-CoV-2 in this age group along with the adults. ",The exclusion criteria included refusal to give time to respond to all questions and give blood.,2020-10-15,2021-02-15,Household and community samples,All,Children and Youth (0-17 years),10.0,17.0,Age,10-17,776,0.628,0.585,0.669,,,True,True,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Plasma,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.933,1.0,['Moderate'],No,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Rubhana Raqib,icddrb,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0268093,2022-06-01,2024-03-29,Verified,raqib_seroprevalence_2022,BGD
220523_Bangladesh_icddrb_Chattogram,220523_Bangladesh_icddrb,Seroprevalence of SARS-CoV-2 infection and associated factors among Bangladeshi slum and non-slum dwellers in pre-COVID-19 vaccination era: October 2020 to February 2021.,2022-05-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bangladesh,,Chattogram,"Samples were collected from 2118 slum inhabitants and 1102 from non-slums in a 2:1 ratio. After household selection, all the eligible members aged >=10 years, were invited to participate. In the early phase of the pandemic, susceptibility to COVID-19 was rare in <10 years old children and existing reports on adolescents (10–19 years) were controversial [31]. Therefore, adolescents, who can give assent and donate blood were enrolled in this study to determine seroprevalence of SARS-CoV-2 in this age group along with the adults. ",The exclusion criteria included refusal to give time to respond to all questions and give blood.,2020-10-15,2021-02-15,Household and community samples,All,Multiple groups,10.0,,Geographical area,Chattogram,606,0.542,0.501,0.583,,,True,True,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Plasma,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.933,1.0,['Moderate'],No,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Rubhana Raqib,icddrb,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0268093,2022-06-01,2024-03-29,Verified,raqib_seroprevalence_2022,BGD
220523_Bangladesh_icddrb_Female,220523_Bangladesh_icddrb,Seroprevalence of SARS-CoV-2 infection and associated factors among Bangladeshi slum and non-slum dwellers in pre-COVID-19 vaccination era: October 2020 to February 2021.,2022-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Bangladesh,,"Dhaka, Chattogram","Samples were collected from 2118 slum inhabitants and 1102 from non-slums in a 2:1 ratio. After household selection, all the eligible members aged >=10 years, were invited to participate. In the early phase of the pandemic, susceptibility to COVID-19 was rare in <10 years old children and existing reports on adolescents (10–19 years) were controversial [31]. Therefore, adolescents, who can give assent and donate blood were enrolled in this study to determine seroprevalence of SARS-CoV-2 in this age group along with the adults. ",The exclusion criteria included refusal to give time to respond to all questions and give blood.,2020-10-15,2021-02-15,Household and community samples,Female,Multiple groups,10.0,,Sex/Gender,Female,1828,0.693,0.667,0.7190000000000001,,,True,True,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Plasma,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.933,1.0,['Moderate'],No,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Rubhana Raqib,icddrb,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0268093,2022-06-01,2024-03-29,Verified,raqib_seroprevalence_2022,BGD
220523_Bangladesh_icddrb_18-30,220523_Bangladesh_icddrb,Seroprevalence of SARS-CoV-2 infection and associated factors among Bangladeshi slum and non-slum dwellers in pre-COVID-19 vaccination era: October 2020 to February 2021.,2022-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Bangladesh,,"Dhaka, Chattogram","Samples were collected from 2118 slum inhabitants and 1102 from non-slums in a 2:1 ratio. After household selection, all the eligible members aged >=10 years, were invited to participate. In the early phase of the pandemic, susceptibility to COVID-19 was rare in <10 years old children and existing reports on adolescents (10–19 years) were controversial [31]. Therefore, adolescents, who can give assent and donate blood were enrolled in this study to determine seroprevalence of SARS-CoV-2 in this age group along with the adults. ",The exclusion criteria included refusal to give time to respond to all questions and give blood.,2020-10-15,2021-02-15,Household and community samples,All,Adults (18-64 years),18.0,30.0,Age,18-30,945,0.68,0.642,0.716,,,True,True,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Plasma,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.933,1.0,['Moderate'],No,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Rubhana Raqib,icddrb,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0268093,2022-06-01,2024-03-29,Verified,raqib_seroprevalence_2022,BGD
220523_Bangladesh_icddrb_Dhaka,220523_Bangladesh_icddrb,Seroprevalence of SARS-CoV-2 infection and associated factors among Bangladeshi slum and non-slum dwellers in pre-COVID-19 vaccination era: October 2020 to February 2021.,2022-05-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bangladesh,,Dhaka,"Samples were collected from 2118 slum inhabitants and 1102 from non-slums in a 2:1 ratio. After household selection, all the eligible members aged >=10 years, were invited to participate. In the early phase of the pandemic, susceptibility to COVID-19 was rare in <10 years old children and existing reports on adolescents (10–19 years) were controversial [31]. Therefore, adolescents, who can give assent and donate blood were enrolled in this study to determine seroprevalence of SARS-CoV-2 in this age group along with the adults. ",The exclusion criteria included refusal to give time to respond to all questions and give blood.,2020-10-15,2021-02-15,Household and community samples,All,Multiple groups,10.0,,Geographical area,Dhaka,2614,0.7290000000000001,0.706,0.751,,,True,True,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Plasma,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.933,1.0,['Moderate'],No,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Rubhana Raqib,icddrb,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0268093,2022-06-01,2024-03-29,Verified,raqib_seroprevalence_2022,BGD
220523_Bangladesh_icddrb_>50,220523_Bangladesh_icddrb,Seroprevalence of SARS-CoV-2 infection and associated factors among Bangladeshi slum and non-slum dwellers in pre-COVID-19 vaccination era: October 2020 to February 2021.,2022-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Bangladesh,,"Dhaka, Chattogram","Samples were collected from 2118 slum inhabitants and 1102 from non-slums in a 2:1 ratio. After household selection, all the eligible members aged >=10 years, were invited to participate. In the early phase of the pandemic, susceptibility to COVID-19 was rare in <10 years old children and existing reports on adolescents (10–19 years) were controversial [31]. Therefore, adolescents, who can give assent and donate blood were enrolled in this study to determine seroprevalence of SARS-CoV-2 in this age group along with the adults. ",The exclusion criteria included refusal to give time to respond to all questions and give blood.,2020-10-15,2021-02-15,Household and community samples,All,Multiple groups,51.0,,Age,>50,484,0.684,0.629,0.7340000000000001,,,True,True,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Plasma,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.933,1.0,['Moderate'],No,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Rubhana Raqib,icddrb,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0268093,2022-06-01,2024-03-29,Verified,raqib_seroprevalence_2022,BGD
220523_Bangladesh_icddrb_Male,220523_Bangladesh_icddrb,Seroprevalence of SARS-CoV-2 infection and associated factors among Bangladeshi slum and non-slum dwellers in pre-COVID-19 vaccination era: October 2020 to February 2021.,2022-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Bangladesh,,"Dhaka, Chattogram","Samples were collected from 2118 slum inhabitants and 1102 from non-slums in a 2:1 ratio. After household selection, all the eligible members aged >=10 years, were invited to participate. In the early phase of the pandemic, susceptibility to COVID-19 was rare in <10 years old children and existing reports on adolescents (10–19 years) were controversial [31]. Therefore, adolescents, who can give assent and donate blood were enrolled in this study to determine seroprevalence of SARS-CoV-2 in this age group along with the adults. ",The exclusion criteria included refusal to give time to respond to all questions and give blood.,2020-10-15,2021-02-15,Household and community samples,Male,Multiple groups,10.0,,Sex/Gender,Male,1392,0.6459999999999999,0.614,0.6759999999999999,,,True,True,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Plasma,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.933,1.0,['Moderate'],No,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Rubhana Raqib,icddrb,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0268093,2022-06-01,2024-03-29,Verified,raqib_seroprevalence_2022,BGD
220723_Bangladesh_JohnsHopkins_Mothers,220723_Bangladesh_JohnsHopkins_Mothers,Sero-prevalence and risk factors for Severe Acute Respiratory Syndrome Coronavirus 2 infection in women and children in a rural district of Bangladesh: A cohort study.,2022-07-23,Journal Article (Peer-Reviewed),Local,Prospective cohort,Bangladesh,Sylhet Division,Zakiganj Upazila,Mothers and their children participating in the Bangladesh site of the multi-country Alliance for Maternal and Newborn Health Improvement (AMANHI) biorepository study,,2021-03-01,2021-07-31,Perinatal,Female,Adults (18-64 years),,,Age,>30 and <= 30,2041,0.358,0.337,0.379,True,,,,True,Unclear,Not reported/ Unable to specify,,,Whole Blood,,,Validated by manufacturers,0.995,0.998,['Missing'],,Unclear,No,No,,Unclear,Yes,No,,Rasheda Khanam,Johns Hopkins,Not Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.05030,2022-08-08,2024-02-01,Unverified,khanam_sero-prevalence_2022,BGD
221101_Cox'sBazar_InstituteOfEpidemiologyDiseaseControlAndResearch_PopTestAdj,221101_Cox'sBazar_InstituteOfEpidemiologyDiseaseControlAndResearch,"Seroprevalence of SARS-CoV-2 antibodies among Forcibly Displaced Myanmar Nationals in Cox's Bazar, Bangladesh 2020: a population-based cross-sectional study.",2022-11-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bangladesh,Chittagong Division,Cox's Bazar,The study was done on household members of the FDMN (forcible displaced Myanmar nationals) population,,2020-12-01,2020-12-31,Persons living in slums,All,Multiple groups,1.0,94.0,Primary Estimate,,3446,0.483,0.453,0.514,True,True,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by developers,0.978,0.998,[{'error': '#ERROR!'}],Yes,No,Yes,Yes,Unclear,Unclear,Yes,{'error': '#ERROR!'},Yes,Mahbubur Rahman,Institute of Epidemiology Disease Control and Research,{'error': '#ERROR!'},https://dx.doi.org/10.1136/bmjopen-2022-066653,2022-12-15,2024-03-24,Verified,rahman_seroprevalence_2022,BGD
221101_Cox'sBazar_InstituteOfEpidemiologyDiseaseControlAndResearch_Unadj,221101_Cox'sBazar_InstituteOfEpidemiologyDiseaseControlAndResearch,"Seroprevalence of SARS-CoV-2 antibodies among Forcibly Displaced Myanmar Nationals in Cox's Bazar, Bangladesh 2020: a population-based cross-sectional study.",2022-11-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bangladesh,Chittagong Division,Cox's Bazar,The study was done on household members of the FDMN (forcible displaced Myanmar nationals) population,,2020-12-01,2020-12-31,Persons living in slums,All,Multiple groups,1.0,94.0,Primary Estimate,Unadjusted,3446,0.607,0.59,0.623,,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by developers,0.978,0.998,[{'error': '#ERROR!'}],Yes,No,Yes,Yes,Unclear,Unclear,Yes,{'error': '#ERROR!'},Yes,Mahbubur Rahman,Institute of Epidemiology Disease Control and Research,{'error': '#ERROR!'},https://dx.doi.org/10.1136/bmjopen-2022-066653,2024-03-24,2024-03-24,Verified,rahman_seroprevalence_2022,BGD
221101_Cox'sBazar_InstituteOfEpidemiologyDiseaseControlAndResearch_18-94,221101_Cox'sBazar_InstituteOfEpidemiologyDiseaseControlAndResearch,"Seroprevalence of SARS-CoV-2 antibodies among Forcibly Displaced Myanmar Nationals in Cox's Bazar, Bangladesh 2020: a population-based cross-sectional study.",2022-11-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bangladesh,Chittagong Division,Cox's Bazar,The study was done on household members of the FDMN (forcible displaced Myanmar nationals) population,,2020-12-01,2020-12-31,Persons living in slums,All,Adults (18-64 years),18.0,94.0,Age,28-94,2392,0.645,0.626,0.664,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by developers,0.978,0.998,[{'error': '#ERROR!'}],Yes,No,Yes,Yes,Unclear,Unclear,Yes,{'error': '#ERROR!'},Yes,Mahbubur Rahman,Institute of Epidemiology Disease Control and Research,{'error': '#ERROR!'},https://dx.doi.org/10.1136/bmjopen-2022-066653,2024-03-24,2024-03-24,Verified,rahman_seroprevalence_2022,BGD
221101_Cox'sBazar_InstituteOfEpidemiologyDiseaseControlAndResearch_1-17,221101_Cox'sBazar_InstituteOfEpidemiologyDiseaseControlAndResearch,"Seroprevalence of SARS-CoV-2 antibodies among Forcibly Displaced Myanmar Nationals in Cox's Bazar, Bangladesh 2020: a population-based cross-sectional study.",2022-11-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bangladesh,Chittagong Division,Cox's Bazar,The study was done on household members of the FDMN (forcible displaced Myanmar nationals) population,,2020-12-01,2020-12-31,Persons living in slums,All,Children and Youth (0-17 years),1.0,17.0,Age,1-17,1054,0.519,0.488,0.55,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by developers,0.978,0.998,[{'error': '#ERROR!'}],Yes,No,Yes,Yes,Unclear,Unclear,Yes,{'error': '#ERROR!'},Yes,Mahbubur Rahman,Institute of Epidemiology Disease Control and Research,{'error': '#ERROR!'},https://dx.doi.org/10.1136/bmjopen-2022-066653,2024-03-24,2024-03-24,Verified,rahman_seroprevalence_2022,BGD
221107_Bangladesh_QuestBangladesh_overall,221107_Bangladesh_QuestBangladesh,Sero-surveillance of SARS-CoV-2 specific antibody (IgG) among garment workers in Bangladesh,2022-11-07,Preprint,Local,Cross-sectional survey ,Bangladesh,,Dhaka,""" Both male and female unvaccinated workers, non-pregnant,
working for at least 2 years without interruption, both asymptomatic healthy workers and workers, history of suffering
covid-19 infection and the workers who were willing to participate in the study workers were included.""",,2021-07-15,2021-12-15,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,402,0.81,,,True,,,,True,Convenience,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Abu Syed Mosa,Quest Bangladesh,Not Unity-Aligned, https://doi.org/10.21203/rs.3.rs-2238518/v1,2022-11-17,2024-03-01,Unverified,mosaSerosurveillanceSARSCoV2Specific2022,BGD
221121_Dhaka_BangladeshMedicalCollegeHospital,221121_Dhaka_BangladeshMedicalCollegeHospital,SARS-CoV-2 antibodies and the association with vitamin D among nonvaccinated health service providers in Dhaka city of Bangladesh,2022-11-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bangladesh,Dhaka Division,Dhaka,"""inclusion criteria were a healthcare service provider who never got any SARS-CoV-2 vaccine and never tested positive for SARS-CoV-2 through the RT-PCR or Rapid Antigen Test.""",,2021-07-15,2021-08-15,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,251,0.171,,,True,,,,True,Unclear,Not reported/ Unable to specify,,ELISA,Plasma,IgG,,,,,['High'],,Unclear,Yes,Yes,,Unclear,Yes,No,,Tarek Alam,Shomman Foundation,Not Unity-Aligned,https://dx.doi.org/10.4103/ecdt.ecdt_7_22,2023-01-25,2023-03-19,Unverified,alam_sars-cov-2_2022,BGD
221212_USA_RTIInternational_Bangladesh,221212_USA_RTIInternational_Bangladesh,"COVID-19 Antibody Positivity Over Time and Pregnancy Outcomes in Seven Low-and-Middle-Income Countries: A Prospective, Observational Study of the Global Network for Women's and Children's Health Research.",2022-12-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Bangladesh,,,"""The COVID-19 antibody study, embedded within the MNHR, included a sub-set of women who were approached at delivery and enrolled. We collected a serum sample at or near delivery for each mother who was approached and consented.""", Women who did not consent to give blood for testing. Indeterminate results are excluded. ,2020-11-01,2020-11-30,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,2049,0.225,,,True,,,,True,Convenience,ELISA SARS-CoV-2 IgG Test System,Zeus,ELISA,Serum,IgG,"Nucleocapsid (N-protein), Spike",,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Robert L. Goldenberg,RTI International,Unity-Aligned,https://dx.doi.org/10.1111/1471-0528.17366,2022-12-24,2024-03-01,Unverified,goldenberg_covid-19_2022,BGD
230417_Bangladesh_UniversityOfDhaka,230417_Bangladesh_UniversityOfDhaka,Evaluating the seroprevalence of SARS-CoV-2 IgG in five different districts of Bangladesh. A seroepidemiological study.,2023-04-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Bangladesh,,,"Bangladeshi individuals were enrolled in the present study from five different geographical locations (Bogra, Dhaka, Dinajpur, Jhenaidah, Rajshahi) of the country covering Northern, Southern and central parts",,2021-08-25,2021-10-01,Household and community samples,All,Multiple groups,,,Primary Estimate,,753,0.583,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Abdullah Al Saba,University Of Dhaka,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jiph.2023.04.013,2023-05-16,2023-06-03,Unverified,saba_evaluating_2023,BGD
230720_Bangladesh_JawaharlalNehruMedicalCollege_Overall,230720_Bangladesh_JawaharlalNehruMedicalCollege,COVID-19 symptoms and antibody positivity among unvaccinated pregnant women: An observational study in seven countries from the Global Network,2023-07-20,Journal Article (Peer-Reviewed),National,Prospective cohort,Bangladesh,,,staff (registry administrators [RAs]) identified pregnant women in their respective clusters,vaccinated pregnant women,2020-10-01,2022-06-30,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,2976,0.356,,,True,,,,True,Stratified non-probability,Not reported/ Unable to specify,,,Serum,,,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Avinash Kavi,Jawaharlal Nehru Medical College,Not Unity-Aligned,https://dx.doi.org/10.1111/1471-0528.17604,2023-08-22,2023-08-23,Unverified,kavi_covid-19_2023,BGD
211031_Belarus_StPetersburgPasteurInstitute_Overall,211031_Belarus_StPetersburgPasteurInstitute,HERD IMMUNITY to SARS-CoV-2 among the POPULATION of the REPUBLIC of BELARUS AMID the COVID-19 PANDEMIC,2021-10-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Belarus,,,People from all regions in Belarus were eligible,,2021-05-14,2021-05-19,Household and community samples,All,Multiple groups,1.0,,Primary Estimate,,12926,0.384,0.376,0.455,True,,,,True,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anna Popova,St. Petersburg Pasteur Institute,Not Unity-Aligned,https://dx.doi.org/10.15789/2220-7619-HIT-1798,2022-01-13,2022-07-16,Unverified,popova_herd_2021-1,BLR
211031_Belarus_StPetersburgPasteurInstitute_Age18-29,211031_Belarus_StPetersburgPasteurInstitute,HERD IMMUNITY to SARS-CoV-2 among the POPULATION of the REPUBLIC of BELARUS AMID the COVID-19 PANDEMIC,2021-10-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Belarus,,,People from all regions in Belarus were eligible,,2021-05-14,2021-05-19,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,18-29,1761,0.278,0.217,0.3,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anna Popova,St. Petersburg Pasteur Institute,Not Unity-Aligned,https://dx.doi.org/10.15789/2220-7619-HIT-1798,2022-01-13,2022-07-16,Unverified,popova_herd_2021-1,BLR
211031_Belarus_StPetersburgPasteurInstitute_Age40-49,211031_Belarus_StPetersburgPasteurInstitute,HERD IMMUNITY to SARS-CoV-2 among the POPULATION of the REPUBLIC of BELARUS AMID the COVID-19 PANDEMIC,2021-10-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Belarus,,,People from all regions in Belarus were eligible,,2021-05-14,2021-05-19,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,,1900,0.368,0.344,0.39,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anna Popova,St. Petersburg Pasteur Institute,Not Unity-Aligned,https://dx.doi.org/10.15789/2220-7619-HIT-1798,2022-01-13,2022-07-16,Unverified,popova_herd_2021-1,BLR
211031_Belarus_StPetersburgPasteurInstitute_Unvaccinated,211031_Belarus_StPetersburgPasteurInstitute,HERD IMMUNITY to SARS-CoV-2 among the POPULATION of the REPUBLIC of BELARUS AMID the COVID-19 PANDEMIC,2021-10-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Belarus,,,People from all regions in Belarus were eligible,,2021-05-14,2021-05-19,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,,11217,0.401,,,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anna Popova,St. Petersburg Pasteur Institute,Not Unity-Aligned,https://dx.doi.org/10.15789/2220-7619-HIT-1798,2022-01-13,2022-07-16,Unverified,popova_herd_2021-1,BLR
211031_Belarus_StPetersburgPasteurInstitute_Vaccinated,211031_Belarus_StPetersburgPasteurInstitute,HERD IMMUNITY to SARS-CoV-2 among the POPULATION of the REPUBLIC of BELARUS AMID the COVID-19 PANDEMIC,2021-10-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Belarus,,,People from all regions in Belarus were eligible,,2021-05-14,2021-05-19,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,,1709,0.273,0.252,0.295,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anna Popova,St. Petersburg Pasteur Institute,Not Unity-Aligned,https://dx.doi.org/10.15789/2220-7619-HIT-1798,2022-01-13,2022-07-16,Unverified,popova_herd_2021-1,BLR
211031_Belarus_StPetersburgPasteurInstitute_Female,211031_Belarus_StPetersburgPasteurInstitute,HERD IMMUNITY to SARS-CoV-2 among the POPULATION of the REPUBLIC of BELARUS AMID the COVID-19 PANDEMIC,2021-10-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Belarus,,,People from all regions in Belarus were eligible,,2021-05-14,2021-05-19,Household and community samples,Female,Multiple groups,1.0,,Sex/Gender,,8551,0.378,0.368,0.38799999999999996,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anna Popova,St. Petersburg Pasteur Institute,Not Unity-Aligned,https://dx.doi.org/10.15789/2220-7619-HIT-1798,2022-01-13,2022-07-16,Unverified,popova_herd_2021-1,BLR
211031_Belarus_StPetersburgPasteurInstitute_Age70+,211031_Belarus_StPetersburgPasteurInstitute,HERD IMMUNITY to SARS-CoV-2 among the POPULATION of the REPUBLIC of BELARUS AMID the COVID-19 PANDEMIC,2021-10-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Belarus,,,People from all regions in Belarus were eligible,,2021-05-14,2021-05-19,Household and community samples,All,Seniors (65+ years),70.0,,Age,,1807,0.43100000000000005,0.384,0.454,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anna Popova,St. Petersburg Pasteur Institute,Not Unity-Aligned,https://dx.doi.org/10.15789/2220-7619-HIT-1798,2022-01-13,2022-07-16,Unverified,popova_herd_2021-1,BLR
211031_Belarus_StPetersburgPasteurInstitute_Age7-13,211031_Belarus_StPetersburgPasteurInstitute,HERD IMMUNITY to SARS-CoV-2 among the POPULATION of the REPUBLIC of BELARUS AMID the COVID-19 PANDEMIC,2021-10-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Belarus,,,People from all regions in Belarus were eligible,,2021-05-14,2021-05-19,Household and community samples,All,Children and Youth (0-17 years),7.0,13.0,Age,7-13,803,0.42200000000000004,0.38799999999999996,0.457,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anna Popova,St. Petersburg Pasteur Institute,Not Unity-Aligned,https://dx.doi.org/10.15789/2220-7619-HIT-1798,2022-01-13,2022-07-16,Unverified,popova_herd_2021-1,BLR
211031_Belarus_StPetersburgPasteurInstitute_Age14-17,211031_Belarus_StPetersburgPasteurInstitute,HERD IMMUNITY to SARS-CoV-2 among the POPULATION of the REPUBLIC of BELARUS AMID the COVID-19 PANDEMIC,2021-10-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Belarus,,,People from all regions in Belarus were eligible,,2021-05-14,2021-05-19,Household and community samples,All,Children and Youth (0-17 years),14.0,17.0,Age,14-17,725,0.385,0.349,0.42100000000000004,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anna Popova,St. Petersburg Pasteur Institute,Not Unity-Aligned,https://dx.doi.org/10.15789/2220-7619-HIT-1798,2022-01-13,2022-07-16,Unverified,popova_herd_2021-1,BLR
211031_Belarus_StPetersburgPasteurInstitute_Age1-6,211031_Belarus_StPetersburgPasteurInstitute,HERD IMMUNITY to SARS-CoV-2 among the POPULATION of the REPUBLIC of BELARUS AMID the COVID-19 PANDEMIC,2021-10-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Belarus,,,People from all regions in Belarus were eligible,,2021-05-14,2021-05-19,Household and community samples,All,Children and Youth (0-17 years),1.0,6.0,Age,1-6,199,0.29600000000000004,0.23399999999999999,0.365,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anna Popova,St. Petersburg Pasteur Institute,Not Unity-Aligned,https://dx.doi.org/10.15789/2220-7619-HIT-1798,2022-01-13,2022-07-16,Unverified,popova_herd_2021-1,BLR
211031_Belarus_StPetersburgPasteurInstitute_Age30-39,211031_Belarus_StPetersburgPasteurInstitute,HERD IMMUNITY to SARS-CoV-2 among the POPULATION of the REPUBLIC of BELARUS AMID the COVID-19 PANDEMIC,2021-10-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Belarus,,,People from all regions in Belarus were eligible,,2021-05-14,2021-05-19,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,,1862,0.294,0.256,0.314,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anna Popova,St. Petersburg Pasteur Institute,Not Unity-Aligned,https://dx.doi.org/10.15789/2220-7619-HIT-1798,2022-01-13,2022-07-16,Unverified,popova_herd_2021-1,BLR
211031_Belarus_StPetersburgPasteurInstitute_Male,211031_Belarus_StPetersburgPasteurInstitute,HERD IMMUNITY to SARS-CoV-2 among the POPULATION of the REPUBLIC of BELARUS AMID the COVID-19 PANDEMIC,2021-10-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Belarus,,,People from all regions in Belarus were eligible,,2021-05-14,2021-05-19,Household and community samples,Male,Multiple groups,1.0,,Sex/Gender,,4375,0.397,0.383,0.41200000000000003,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anna Popova,St. Petersburg Pasteur Institute,Not Unity-Aligned,https://dx.doi.org/10.15789/2220-7619-HIT-1798,2022-01-13,2022-07-16,Unverified,popova_herd_2021-1,BLR
211031_Belarus_StPetersburgPasteurInstitute_Age50-59,211031_Belarus_StPetersburgPasteurInstitute,HERD IMMUNITY to SARS-CoV-2 among the POPULATION of the REPUBLIC of BELARUS AMID the COVID-19 PANDEMIC,2021-10-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Belarus,,,People from all regions in Belarus were eligible,,2021-05-14,2021-05-19,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,,1958,0.47100000000000003,0.446,0.513,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anna Popova,St. Petersburg Pasteur Institute,Not Unity-Aligned,https://dx.doi.org/10.15789/2220-7619-HIT-1798,2022-01-13,2022-07-16,Unverified,popova_herd_2021-1,BLR
211031_Belarus_StPetersburgPasteurInstitute_Age60-69,211031_Belarus_StPetersburgPasteurInstitute,HERD IMMUNITY to SARS-CoV-2 among the POPULATION of the REPUBLIC of BELARUS AMID the COVID-19 PANDEMIC,2021-10-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Belarus,,,People from all regions in Belarus were eligible,,2021-05-14,2021-05-19,Household and community samples,All,Seniors (65+ years),60.0,69.0,Age,,1911,0.446,0.41700000000000004,0.469,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anna Popova,St. Petersburg Pasteur Institute,Not Unity-Aligned,https://dx.doi.org/10.15789/2220-7619-HIT-1798,2022-01-13,2022-07-16,Unverified,popova_herd_2021-1,BLR
200529_Belgium_BelgianInstituteofHealth_blooddonors_march_primary,200529_Belgium_BelgianInstituteofHealth_blooddonors_March,COVID-19 – WEKELIJKS EPIDEMIOLOGISCH BULLETIN VAN 29 MEI 2020,2020-05-29,Institutional Report,National,Repeated cross-sectional study,Belgium,,,"The blood donors
represent the Belgian population between 18 and 75 years who are healthy at the
time of donation.","Individuals with previously confirmed or possible COVID-19 infection
or with close contact with a confirmed case, may be allowed for 28 days after the
disappearance of the symptoms or do not donate blood after contact and are therefore
excluded from the study at this time.",2020-03-30,2020-03-30,Blood donors,All,Multiple groups,18.0,75.0,Primary Estimate,,584,0.013000000000000001,,,True,,True,,True,Convenience,Not reported/ Unable to specify,,,Serum,,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Belgian Institute of Health,Belgian Institute of Health ,Not Unity-Aligned,https://covid-19.sciensano.be/sites/default/files/Covid19/COVID-19_Weekly%20report_20200529%20-%20NL_0.pdf,2021-09-14,2022-07-16,Unverified,sciensano_covid-19_2020,BEL
200615_Belgium_ZiekenhuisOost-Limburg_HealthCareWorkers,200615_Belgium_ZiekenhuisOost-Limburg,Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a Tertiary Center in Belgium,2020-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Belgium,Limburg,Genk,"All persons
who worked at Hospital East-Limburg (including clinical and
nonclinical staff and volunteers) were invited for serologic
testing.","Staff with active symptoms were quarantined and
not tested.",2020-04-22,2020-04-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,3056,0.064,0.055,0.073,True,,,,True,Convenience,COVID-19 IgG/IgM Ab Test Cassette (Whole Blood/Serum/Plasma),Multi-G B.V.,LFIA,,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.97,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,Yes,Deborah Steensels,ZiekenhuisOost-Limburg,Not Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2767382,2020-06-18,2024-03-01,Verified,steensels_hospital-wide_2020,BEL
200625_Brussels_UniversitéLibredeBruxelles_OverallHCW,200625_Brussels_UniversiteLibredeBruxelles,Dynamics of SARS-CoV-2 RT-PCR positivity and seroprevalence among high-risk health care workers and hospital staff,2020-06-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Belgium,Brussels,City of Brussels,Presence of symptoms was not an exclusion criterion,staff members working in these Covid-19 highly exposed Units,2020-04-15,2020-05-18,Health care workers and caregivers,All,Adults (18-64 years),21.0,66.0,Primary Estimate,,326,0.11,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Multiple Types,IgG,Spike,,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,No,Charlotte Martin,Université Libre de Bruxelles,Not Unity-Aligned,https://www.journalofhospitalinfection.com/article/S0195-6701(20)30313-3/fulltext,2020-07-21,2024-03-01,Verified,martin_dynamics_2020,BEL
200730_Belgium_IrisHospitalsSouth_HCW_UnAdj,200730_Belgium_IrisHospitalsSouth,"Large-scale, molecular and serological SARS-CoV-2 screening of healthcare workers in a 4-site public hospital in Belgium after COVID-19 outbreak.",2020-07-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Belgium,Brussels,City of Brussels,"All staff members (n = 3145), regardless of their status and function in the network of Iris hospitals South. Participation was voluntary and regardless of whether the HCW had already contracted the disease or not.",,2020-05-25,2020-06-19,Health care workers and caregivers,All,Multiple groups,21.6,72.0,Primary Estimate,,1485,0.14612,,,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,1.0,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Laurent Blairon,Iris Hospitals South,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2020.07.033,2020-10-05,2024-03-01,Verified,blairon_large-scale_2020,BEL
200811_Belgium_universitairesSaint-Luc_Overall,200811_Belgium_universitairesSaint-Luc,SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis,2020-08-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Belgium,,City of Brussels,"CF patients followed in the CF reference center of the Cliniques universitaires Saint-Luc (Brussels), were recruited prospectively by receiving a letter containing an empty tube to test IgM and IgG against SARS-CoV-2. Between April 16, 2020 and May 19, 2020, sera were collected from 149 patients (first case in Belgium on February 4, 2020, peak of the epidemy on April 10, 2020, lock- down for CF patients since March 12, 2020).",,2020-04-16,2020-05-19,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,149,0.027000000000000003,,,True,,,,True,Convenience,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Multiple Types,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.956,0.96,['High'],Yes,No,No,Yes,Yes,Yes,Yes,No,Unclear,Silvia Berardis,Cliniques universitaires Saint-Luc,Not Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S1569199320308213,2020-10-24,2024-03-01,Verified,berardis_sars-cov-2_2020,BEL
201018_Belgium_UniversityHospitalsLeuven_Overall_unadj,201018_Belgium_UniversityHospitalsLeuven,Added value of anti-SARS-CoV-2 antibody testing in a Flemish nursing home during an acute COVID-19 outbreak in April 2020,2020-10-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Belgium,Limburg,Lanaken,Residents and staff of nursing home,,2020-04-14,2020-04-16,Multiple populations,All,Multiple groups,,,Primary Estimate,,188,0.18600000000000003,,,True,,,,True,Convenience,COVID-19 antibody rapid test,SureScreen Diagnostics,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.747,0.951,['High'],Yes,No,No,No,No,Yes,Yes,No,Yes,Frank Buntinx,University of Leuven,Not Unity-Aligned,http://dx.doi.org/10.1080/17843286.2020.1834285,2021-01-16,2024-03-01,Verified,buntinx_added_2020,BEL
210120_Antwerp_UniversityofAntwerp_primary,210120_Antwerp_UniversityofAntwerp,Hospital-wide SARS-CoV-2 antibody screening of staff in a university psychiatric centre in Belgium,2021-01-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Belgium,,Antwerp,"both clinical and non-clinical staff at the UPC
Duffel and associated long-stay facilities (PVT Schorshaegen) were
invited for serological testin","Staff with active symptoms who
were currently on sick leave could not be included. ",2020-06-03,2020-06-17,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,431,0.032,0.019,0.054000000000000006,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.8,0.985,['High'],Yes,No,No,Yes,Yes,Unclear,Yes,No,,Kawtar El Abdellati,University of Antwerp,Not Unity-Aligned,https://dx.doi.org/10.1192/bjo.2020.172,2021-02-06,2023-07-04,Verified,el_abdellati_hospital-wide_2021,BEL
210227_Belgium_AntwerpUniversityHospital_AdultCancer_DiaSorin,210227_Belgium_AntwerpUniversityHospital_Adult_Cancer_Patients,Immunoglobin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests,2021-02-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Belgium,,,"All (cancer) patients having a routine blood sampling
and HCW consenting to participate in the study in the
Multidisciplinary Oncology unit of the Antwerp University
Hospital, and the AZ Maria Middelares Hospital,
Ghent.","Critically ill patients or volunteers in which the consenting
procedure of taking additional blood samples is
not ethically and/or clinically acceptable.",2020-03-24,2020-05-31,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,DiaSorin CLIA,827,0.062000000000000006,,,True,,,,True,Sequential,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Peter van Dam,Antwerp University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ejca.2021.02.024,2021-05-24,2024-03-01,Verified,van_dam_immunoglobin_2021,BEL
210227_Belgium_AntwerpUniversityHospital_Adult_nonCancer_DiaSorin,210227_Belgium_AntwerpUniversityHospital_Adult_Noncancer,Immunoglobin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests,2021-02-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Belgium,,,"All patients, having a
routine blood sampling, whose parents or guardian
consented to participate in the study in the Antwerp
University Hospital at time points 0, 1, 2 and 3 months.","Critically ill patients or volunteers in which the consenting
procedure of taking additional blood samples is
not ethically and/or clinically acceptable.",2020-03-24,2020-05-31,Residual sera,All,Multiple groups,,,Primary Estimate,DiaSorin CLIA,90,0.055999999999999994,,,True,,,,True,Sequential,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['High'],No,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Peter van Dam,Antwerp University Hospital,Unity-Aligned,https://dx.doi.org/10.1016/j.ejca.2021.02.024,2021-05-24,2024-03-01,Verified,van_dam_immunoglobin_2021,BEL
210227_Belgium_AntwerpUniversityHospital_Adult_nonCancer_Roche,210227_Belgium_AntwerpUniversityHospital_Adult_Noncancer,Immunoglobin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests,2021-02-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Belgium,,,"All patients, having a
routine blood sampling, whose parents or guardian
consented to participate in the study in the Antwerp
University Hospital at time points 0, 1, 2 and 3 months.","Critically ill patients or volunteers in which the consenting
procedure of taking additional blood samples is
not ethically and/or clinically acceptable.",2020-03-24,2020-05-31,Residual sera,All,Multiple groups,,,Test used,Roche CLIA,87,0.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['High'],No,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Peter van Dam,Antwerp University Hospital,Unity-Aligned,https://dx.doi.org/10.1016/j.ejca.2021.02.024,2021-08-12,2024-03-01,Verified,van_dam_immunoglobin_2021,BEL
210227_Belgium_AntwerpUniversityHospital_Adult_nonCancer_Abbott,210227_Belgium_AntwerpUniversityHospital_Adult_Noncancer,Immunoglobin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests,2021-02-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Belgium,,,"All patients, having a
routine blood sampling, whose parents or guardian
consented to participate in the study in the Antwerp
University Hospital at time points 0, 1, 2 and 3 months.","Critically ill patients or volunteers in which the consenting
procedure of taking additional blood samples is
not ethically and/or clinically acceptable.",2020-03-24,2020-05-31,Residual sera,All,Multiple groups,,,Test used,Abbott CLIA,90,0.011000000000000001,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Peter van Dam,Antwerp University Hospital,Unity-Aligned,https://dx.doi.org/10.1016/j.ejca.2021.02.024,2021-08-12,2024-03-01,Verified,van_dam_immunoglobin_2021,BEL
210227_Belgium_AntwerpUniversityHospital_HCW_DiaSorin,210227_Belgium_AntwerpUniversityHospital_HCW,Immunoglobin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests,2021-02-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Belgium,,,"All HCW consenting to participate in the study in the
Multidisciplinary Oncology unit of the Antwerp University
Hospital, and the AZ Maria Middelares Hospital,
Ghent. ",,2020-03-24,2020-05-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,DiaSorin CLIA,92,0.12,,,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['High'],No,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Peter van Dam,Antwerp University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ejca.2021.02.024,2021-04-21,2024-03-01,Verified,van_dam_immunoglobin_2021,BEL
210227_Belgium_AntwerpUniversityHospital_PediatricCancer_DiaSorin,210227_Belgium_AntwerpUniversityHospital_Pediatric_Cancer,Immunoglobin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests,2021-02-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Belgium,,,"All paediatric cancer patients, having a
routine blood sampling, whose parents or guardian
consented to participate in the study in the Antwerp
University Hospital at time points 0, 1, 2 and 3 months.","Critically ill patients or volunteers in which the consenting
procedure of taking additional blood samples is
not ethically and/or clinically acceptable.",2020-03-24,2020-05-31,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),,,Primary Estimate,DiaSorin CLIA,11,0.091,,,True,,,,True,Sequential,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['High'],No,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Peter van Dam,Antwerp University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ejca.2021.02.024,2021-04-21,2024-03-01,Verified,van_dam_immunoglobin_2021,BEL
210415_Belgium_UniversiteCatholiquedeLouvain_T4_overall,210415_Belgium_UniversiteCatholiquedeLouvain_T4,"A longitudinal, 3-month serologic assessment of sars-cov-2 infections in a belgian hemodialysis facility",2021-04-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,Belgium,Brussels,Brussels,"We included all patients on in-center maintenance HD at Cliniques Universitaires Saint-Luc, Brussels, Belgium.",,2020-07-07,2020-07-08,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,Hemodialysis patients,96,0.0833,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,No,Yes,Laura Labriola,University Catholique de Louvain,Not Unity-Aligned,http://dx.doi.org/10.2215/CJN.12490720,2021-05-18,2024-03-01,Verified,labriola_longitudinal_2021,BEL
210505_Brussels_CliniquesUniversitairesSaint-Luc,210505_Brussels_CliniquesUniversitairesSaint-Luc,Seroprevalence of SARS-CoV-2 infection in health care workers of a teaching hospital in Belgium: self-reported occupational and household risk factors for seropositivity,2021-05-05,Journal Article (Peer-Reviewed),Local,Prospective cohort,Belgium,Brussels-Capital,City of Brussels,All HCWs including administrative staff were invited to participate to this prospective study in a voluntary basis.,,2020-06-19,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,3255,0.078,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9500000000000001,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Anais Scohy,Cliniques universitaires Saint-Luc,Not Unity-Aligned,http://dx.doi.org/10.1016/j.diagmicrobio.2021.115414,2021-06-16,2024-03-01,Unverified,anaisscohySeroprevalenceSARSCoV2Infection2021,BEL
210629_Belgium_Sciensano_Baseline,210629_Belgium_Sciensano_Baseline,Prevalence and incidence of anti-SARS-CoV-2 antibodies among healthcare workers in Belgian hospitals before vaccination: a prospective cohort study.,2021-06-29,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Belgium,,,"To be eligible, HCW had to have an employment contract with the hospital covering at least the length of the study and they had to have contact with patients, be it in COVID-19-dedicated or other wards.","If a selected HCW did not want to participate, he/she was replaced by the next person on the list.",2020-04-25,2020-05-25,Health care workers and caregivers,All,Adults (18-64 years),20.0,67.0,Primary Estimate,,850,0.085,,,True,,,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Laure Mortgat,Sciensano,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-050824,2021-07-05,2024-03-01,Unverified,mortgat_prevalence_2021,BEL
210705_UniversitairZiekenhuisBrussel_Brussels_hcw,210705_UZBrussel_UZBrussel_Phase1,SARS-COV-2 seroprevalence among employees of a University Hospital in Belgium during the 2020 COVID-19 outbreak (COVEMUZ-study).,2021-07-05,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Belgium,,Brussels,"After signing a written informed consent, participants were recruited for blood sampling and
completion of a pseudonymized questionnaire",Staff not active during the inclusion period were excluded.,2020-05-19,2020-06-12,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,2662,0.07400000000000001,0.064,0.084,True,,,,True,Convenience,Not reported/ Unable to specify,,,Serum,IgG,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,, Deborah De Geyter,Universitair Ziekenhuis Brussel,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268821001540,2021-07-13,2022-07-16,Unverified,de_geyter_sars-cov-2_2021,BEL
210719_Brussels_UniversitéLibredeBruxelles,210719_Brussels_UniversitéLibredeBruxelles,Anti-SARS-CoV-2 antibodies in new-onset type 1 diabetes in children during pandemic in Belgium.,2021-07-19,Journal Article (Peer-Reviewed),Local,Prospective cohort,Belgium,,Brussels,Inclusion criteria were all patients admitted with new-onset type 1diabetes to the Diabetes Clinic of the Queen Fabiola Uni-versity  Children's  Hospital  between  March  2020  andFebruary 2021.,,2020-03-15,2021-02-15,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),0.0,16.0,Primary Estimate,overall,75,0.2,,,True,,,,True,Sequential,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Anissa Messaaoui,Université Libre de Bruxelles,Not Unity-Aligned,https://dx.doi.org/10.1515/jpem-2021-0289,2021-07-29,2022-07-16,Unverified,messaaoui_anti-sars-cov-2_2021,BEL
210722_Belgium_UniversityOfNamur_overall,210722_Belgium_UniversityOfNamur,Antibody titres decline 3-month post-vaccination with BNT162b2,2021-07-22,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Belgium,,,"HCWs in three medical centers in Belgium were enrolled 

(from ref: https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(21)00224-X/pdf) ",,2021-01-16,2021-02-15,Health care workers and caregivers,All,Multiple groups,23.0,66.0,Primary Estimate,,200,0.29,,,True,,,,True,Unclear,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,Unclear,No,Yes,Unclear,Yes,Yes,No,Unclear,Julien Favresse,University of Namur,Not Unity-Aligned,http://dx.doi.org/10.1080/22221751.2021.1953403,2021-08-01,2024-03-01,Verified,favresse_antibody_2021,BEL
210810_Antwerp_UniversityOfAntwerp,210810_Antwerp_UniversityOfAntwerp,SARS-CoV-2 seroprevalence survey among health care providers in a Belgian public multiple-site hospital.,2021-08-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Belgium,Antwerp Province,Antwerp,"HCPs included all hospital staff (nurses, doctors, paramedics, administrative and maintenance staff ).",,2020-06-09,2020-06-29,Health care workers and caregivers,All,Multiple groups,17.0,73.0,Primary Estimate,,5233,0.076,0.069,0.083,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,ELISA,,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9500000000000001,0.99,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Reinout Naesens,University Of Antwerp,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268821001497,2021-08-17,2024-03-01,Unverified,reinoutnaesensSARSCoV2SeroprevalenceSurvey2021,BEL
210827_Flanders_UniversityofAntwerp_December,210827_Flanders_UniversityofAntwerp_December,"Prospective SARS-CoV-2 cohort study among primary health care providers during the second COVID-19 wave in Flanders, Belgium.",2021-08-27,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Belgium,Flanders,,Primary health care practitioners that are currently working in a general practice and physically manage patients/clients in Flanders. ,,2020-12-01,2020-12-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,698,0.134,0.10800000000000001,0.16399999999999998,True,,,,True,Convenience,Author designed (Luminex),,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,0.99,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Joachim Marien,University of Antwerp,Not Unity-Aligned,https://dx.doi.org/10.1093/fampra/cmab094,2021-09-15,2022-07-16,Unverified,marien_prospective_2021-1,BEL
210827_Flanders_UniversityofAntwerp_June,210827_Flanders_UniversityofAntwerp_June,"Prospective SARS-CoV-2 cohort study among primary health care providers during the second COVID-19 wave in Flanders, Belgium.",2021-08-27,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Belgium,Flanders,,Primary health care practitioners that are currently working in a general practice and physically manage patients/clients in Flanders. ,,2020-06-01,2020-07-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,698,0.046,,,True,,,,True,Convenience,Author designed (Luminex),,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,0.99,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Joachim Marien,University of Antwerp,Not Unity-Aligned,https://dx.doi.org/10.1093/fampra/cmab094,2021-09-15,2022-07-16,Unverified,marien_prospective_2021-1,BEL
210827_Flanders_UniversityofAntwerp_October,210827_Flanders_UniversityofAntwerp_October,"Prospective SARS-CoV-2 cohort study among primary health care providers during the second COVID-19 wave in Flanders, Belgium.",2021-08-27,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Belgium,Flanders,,Primary health care practitioners that are currently working in a general practice and physically manage patients/clients in Flanders. ,,2020-10-01,2020-10-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,698,0.081,,,True,,,,True,Convenience,Author designed (Luminex),,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,0.99,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Joachim Marien,University of Antwerp,Not Unity-Aligned,https://dx.doi.org/10.1093/fampra/cmab094,2021-09-15,2022-07-16,Unverified,marien_prospective_2021-1,BEL
210827_Flanders_UniversityofAntwerp_September,210827_Flanders_UniversityofAntwerp_September,"Prospective SARS-CoV-2 cohort study among primary health care providers during the second COVID-19 wave in Flanders, Belgium.",2021-08-27,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Belgium,Flanders,,Primary health care practitioners that are currently working in a general practice and physically manage patients/clients in Flanders. ,,2020-09-01,2020-09-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,698,0.05,,,True,,,,True,Convenience,Author designed (Luminex),,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,0.99,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Joachim Marien,University of Antwerp,Not Unity-Aligned,https://dx.doi.org/10.1093/fampra/cmab094,2021-09-15,2022-07-16,Unverified,marien_prospective_2021-1,BEL
210827_Belgium_UniversityofLiegeHospital_Overall,210827_Belgium_UniversityofLiegeHospital,Systematic screening for SARS-CoV-2 S1/S2 antibodies helps to better assess the real incidence of COVID-19 in kidney transplant recipients,2021-08-27,Presentation or Conference,National,Prospective cohort,Belgium,,,Kidney transplant recipients (KTRs) in Belgium during first wave (from 1 March to 30 Sep 2020).,,2020-03-01,2020-09-30,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,525,0.0267,,,True,,,,True,Unclear,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,,IgG,Spike,,,,['High'],,Unclear,No,No,,Yes,Yes,Yes,,Louis Firket,University of Liege Hospital,Not Unity-Aligned,http://dx.doi.org/10.1111/tri.13944,2021-09-21,2024-03-01,Unverified,firket_abstracts_2021,BEL
210828_Belgium_KatholiekeUniversiteitLeuven_Overall,210828_Belgium_KatholiekeUniversiteitLeuven,Age-dependent seroprevalence of SARS-CoV-2 antibodies in school-aged children from areas with low and high community transmission.,2021-08-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Belgium,Limburg Province,"Pelt Municipality, Alken Municipality",Primary (6 – 12 years) and lower secondary (12 – 15 years) schoolchildren in two Belgian municipalities,,2020-09-21,2020-10-06,Students and Daycares,All,Children and Youth (0-17 years),6.0,15.0,Primary Estimate,Overall,362,0.094,0.057,0.131,True,,,,True,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,0.996,['Moderate'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Lisa Boey,Katholieke Universiteit Leuven,Not Unity-Aligned,https://dx.doi.org/10.1007/s00431-021-04222-9,2021-05-23,2024-03-01,Verified,boey_age-dependent_2021-1,BEL
210828_Belgium_KatholiekeUniversiteitLeuven_PrimarySchool_Age_6-12,210828_Belgium_KatholiekeUniversiteitLeuven,Age-dependent seroprevalence of SARS-CoV-2 antibodies in school-aged children from areas with low and high community transmission.,2021-08-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Belgium,Limburg Province,"Pelt Municipality, Alken Municipality",Primary (6 – 12 years) and lower secondary (12 – 15 years) schoolchildren in two Belgian municipalities,,2020-09-21,2020-10-06,Students and Daycares,All,Children and Youth (0-17 years),6.0,12.0,Age,Age: 6-12,181,0.066,0.012,0.121,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,0.996,['Moderate'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Lisa Boey,Katholieke Universiteit Leuven,Not Unity-Aligned,https://dx.doi.org/10.1007/s00431-021-04222-9,2022-02-17,2024-03-01,Unverified,boey_age-dependent_2021-1,BEL
210828_Belgium_KatholiekeUniversiteitLeuven_SecondarySchool_Age_12-15,210828_Belgium_KatholiekeUniversiteitLeuven,Age-dependent seroprevalence of SARS-CoV-2 antibodies in school-aged children from areas with low and high community transmission.,2021-08-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Belgium,Limburg Province,"Pelt Municipality, Alken Municipality",Primary (6 – 12 years) and lower secondary (12 – 15 years) schoolchildren in two Belgian municipalities,,2020-09-21,2020-10-06,Students and Daycares,All,Children and Youth (0-17 years),11.0,15.0,Age,Age: 12-15,181,0.122,0.07200000000000001,0.171,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,0.996,['Moderate'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Lisa Boey,Katholieke Universiteit Leuven,Not Unity-Aligned,https://dx.doi.org/10.1007/s00431-021-04222-9,2022-02-17,2024-03-01,Unverified,boey_age-dependent_2021-1,BEL
210922_Flanders_GhentUniversity_residents,210922_Flanders_GhentUniversity_residents,Comparison of Dried Blood Spots and Venous Blood for the Detection of SARS-CoV-2 Antibodies in a Population of Nursing Home Residents.,2021-09-22,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Belgium,Flanders,"Wingene, Liedekerke, Assenede, Wetteren","Residents from four NHs (Amphora, Wingene; Sint-Rafaël, Liedekerke; Sint-Jozef, Assenede; Sint-Jozef, Wetteren) in Flanders, Belgium that had experienced a SARS-CoV-2 outbreak in the period of March to July 2020. All interested residents were eligible to participate in the study.",Residents with severe dementia,2020-08-01,2020-08-31,Assisted living and long-term care facilities,All,Seniors (65+ years),,,Primary Estimate,,199,0.3015,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,Other,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,No,,Yes,Yes,Yes,,Eline Meyers,Ghent University,Not Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00178-21,2021-09-28,2024-03-01,Unverified,meyers_comparison_2021,BEL
210922_Flanders_GhentUniversity_staff,210922_Flanders_GhentUniversity_staff,Comparison of Dried Blood Spots and Venous Blood for the Detection of SARS-CoV-2 Antibodies in a Population of Nursing Home Residents.,2021-09-22,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Belgium,Flanders,"Wingene, Liedekerke, Assenede, Wetteren","Staff from four NHs (Amphora, Wingene; Sint-Rafaël, Liedekerke; Sint-Jozef, Assenede; Sint-Jozef, Wetteren) in Flanders, Belgium that had experienced a SARS-CoV-2 outbreak in the period of March to July 2020. All interested staff were eligible to participate in the study.",,2020-08-01,2020-08-31,Assisted living and long-term care facilities,All,Adults (18-64 years),,,Primary Estimate,,241,0.2863,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,Other,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,No,,Yes,Yes,Yes,,Eline Meyers,Ghent University,Not Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00178-21,2021-09-28,2024-03-01,Unverified,meyers_comparison_2021,BEL
211022_Belgium_UniversitéLibreDeBruxelles,211022_Belgium_UniversitéLibreDeBruxelles,"SARS-CoV-2 seroprevalence in children and their family members, July-October 2020, Brussels.",2021-10-22,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Belgium,,,"All patients requiring a blood sample between 1 July 2020 and 31 October 2020 in our institution were invited to participate. Their parents and siblings could also participate to estimate familial transmission and the congruence between serological statuses.

Children aged between 6 months and 16 years at the time of recruitment who needed a blood sample for any reason were eligible to participate. Informed consent was obtained, and assent was given by children 9 years or older. If the informed consent was given for the child, we offered parents living with the child and any siblings to be included as well. ",Participants were free to decline/withdraw consent at any time without providing a reason and without being subject to any resulting detriment.,2020-07-01,2020-10-31,Students and Daycares,All,Children and Youth (0-17 years),,,Primary Estimate,,112,0.125,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Lorraine Dethioux,Université Libre de Bruxelles,Not Unity-Aligned,https://dx.doi.org/10.1007/s00431-021-04284-9,2021-11-05,2024-03-01,Unverified,dethiouxSARSCoV2SeroprevalenceChildren2021,BEL
211111_UZBrussel_UZBrussel_Phase2,211111_UZBrussel_UZBrussel_Phase2,"Fear for CoViD-19 and reluctance to work among health care workers during the epidemic, a prospective monocentric cohort study.",2021-11-11,Journal Article (Peer-Reviewed),Local,Prospective cohort,Belgium,,Brussels," All employees of the UZ Brussel, working partially or full-time, between April and October, were eligible for study inclusion and were considered as the study frame.

Both health-care workers, exercising a medical or paramedical profession, as well as non-medical employees were included.

Participation in phase 2 of the study was restricted to employees who participated to phase 1.",Employees not working at the time of participants’ recruitment were excluded.,2020-10-01,2020-10-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,2336,0.0792,,,True,,,,True,Convenience,Not reported/ Unable to specify,,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Marco Moretti,University Hospital Brussels,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ajic.2021.10.042,2021-11-25,2022-07-16,Unverified,moretti_fear_2021,BEL
211118_Belgium_CliniqueNotreDamedeGrace,211118_Belgium_CliniqueNotreDamedeGrace,SARS-CoV-2 seroprevalence in high-risk health care workers in a Belgian general hospital: evolution from the first wave to the second.,2021-11-18,Journal Article (Peer-Reviewed),Local,Prospective cohort,Belgium,,Gosselies,"""Subjects were selected based on volunteer participa-tion of HCWs from various professional activities who worked in at least one COVID-19-dedicated ward at any point of the pandemic at the Clinique Notre- Dame-de-Grâce (Gosselies, Belgium)""",,2021-01-18,2021-02-08,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,189,0.418,,,True,,,,True,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,Anti-SARS-CoV-2 ELISA IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","DiaSorin,EUROIMMUN,Siemens",CLIA,Serum,"['IgG', 'TotalAntibody']",,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Loris Wauthier,Clinique Notre-Dame de Grâce,Not Unity-Aligned,https://dx.doi.org/10.1080/17843286.2021.2004349,2021-11-24,2024-03-01,Unverified,wauthier_sars-cov-2_2021,BEL
211227_Ghent_GhentUniversityHospital_Overall,211227_Ghent_GhentUniversityHospital,Comparison of the positivity rate of anti-spike and anti-nucleocapsid SARS-CoV-2 IgG in asymptomatic pregnant women.,2021-12-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Belgium,East Flanders,Ghent,Asymptomatic pregnant women in their third trimester of pregnancy.,,2020-01-15,2020-11-15,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,265,0.015,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit","EUROIMMUN,Epitope Diagnostics, Inc.",ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,No,Unclear,Yes,Yes,No,Unclear,Laura Heireman,Ghent University Hospital,Unity-Aligned,https://dx.doi.org/10.1080/01443615.2021.1997960,2022-01-13,2024-03-01,Verified,heireman_comparison_2021,BEL
211227_Ghent_GhentUniversityHospital_AntiS,211227_Ghent_GhentUniversityHospital,Comparison of the positivity rate of anti-spike and anti-nucleocapsid SARS-CoV-2 IgG in asymptomatic pregnant women.,2021-12-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Belgium,East Flanders,Ghent,Asymptomatic pregnant women in their third trimester of pregnancy.,,2020-01-15,2020-11-15,Pregnant or parturient women,Female,Adults (18-64 years),,,Test used,EUROIMMUN anti-SARS-CoV-2 IgG ELISA,265,0.015,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,No,No,Unclear,Yes,Yes,No,Unclear,Laura Heireman,Ghent University Hospital,Unity-Aligned,https://dx.doi.org/10.1080/01443615.2021.1997960,2022-01-13,2024-03-01,Verified,heireman_comparison_2021,BEL
211227_Ghent_GhentUniversityHospital_AntiN,211227_Ghent_GhentUniversityHospital,Comparison of the positivity rate of anti-spike and anti-nucleocapsid SARS-CoV-2 IgG in asymptomatic pregnant women.,2021-12-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Belgium,East Flanders,Ghent,Asymptomatic pregnant women in their third trimester of pregnancy.,,2020-01-15,2020-11-15,Pregnant or parturient women,Female,Adults (18-64 years),,,Test used,EDITM anti-SARS-CoV-2 IgG ELISA,265,0.0,,,,,,,,Convenience,EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit,"Epitope Diagnostics, Inc.",ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,No,No,Unclear,Yes,Yes,No,Unclear,Laura Heireman,Ghent University Hospital,Unity-Aligned,https://dx.doi.org/10.1080/01443615.2021.1997960,2022-01-13,2024-03-01,Verified,heireman_comparison_2021,BEL
220121_Leuven_UniversityOfOxford,220121_Leuven_UniversityOfOxford,"Trans-continental analysis of over, 2000 inflammatory bowel disease patients implicates geography, disease type, and exposure to immunosuppression as drivers of SARS-CoV-2 seroprevalence: Data from the ICARUS-IBD consortium",2022-01-21,Presentation or Conference,Local,Cross-sectional survey ,Belgium,,Leuven,IBD patients prior to vaccination,,2020-05-26,2021-09-24,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,862,0.056799999999999996,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Atellica® IM SARS-CoV-2 Total (COV2T)","Roche Diagnostics,Siemens",,Serum,TotalAntibody,Spike,,,,['High'],,No,Yes,No,,Unclear,No,No,,S Y Wong,University of Oxford,Not Unity-Aligned,https://dx.doi.org/10.1093/ecco-jcc/jjab232.469,2022-03-08,2024-03-01,Unverified,wong_p342_2022,BEL
220127_Belgium_Sciensano_PHCPs_13-26Dec2021,220127_Belgium_Sciensano_PHCPs_13-26Dec2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG and/or IgM) among primary healthcare workers in Belgium,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Any Belgian general practitioner (GP) (including those in professional training) currently
working in primary care and any other primary health care providers (PHCPs) from the same
GP practice who physically manage (examine, test, treat) patients/clients (frontline PHCP),
are able to comply with the study protocol and provided informed consent to participate in
the study (see Appendix 2 and 3 for the information and consent form, respectively). Also
PHCPs having been diagnosed with COVID-19 are included.","- Staff hired on a temporary (interim) basis will be excluded as follow-up over time will be
compromised.
- Administrative staff or technical staff without any contact with patients/clients will also be
excluded.
- PHCPs who were not active during the inclusion period will automatically be excluded.",2021-12-13,2021-12-26,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,2498,0.9390000000000001,,,True,,True,True,True,Convenience,"COVID-19 IgG/IgM Rapid Test,Elecsys® Anti‐SARS‐CoV‐2 (S),Atellica® IM SARS-CoV-2 Total (COV2T),Liaison SARS-CoV-2 S1/S2 IgG","Zhejiang Orient Gene Biotech,Roche Diagnostics,Siemens,DiaSorin",Multiple Types,Multiple Types,"['IgA', 'IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-17,2024-03-01,Unverified,sciensano_prevalence_2022-4,BEL
220127_Belgium_Sciensano_PHCPs_13-26Sep2021,220127_Belgium_Sciensano_PHCPs_13-26Sep2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG and/or IgM) among primary healthcare workers in Belgium,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Any Belgian general practitioner (GP) (including those in professional training) currently
working in primary care and any other primary health care providers (PHCPs) from the same
GP practice who physically manage (examine, test, treat) patients/clients (frontline PHCP),
are able to comply with the study protocol and provided informed consent to participate in
the study (see Appendix 2 and 3 for the information and consent form, respectively). Also
PHCPs having been diagnosed with COVID-19 are included.","- Staff hired on a temporary (interim) basis will be excluded as follow-up over time will be
compromised.
- Administrative staff or technical staff without any contact with patients/clients will also be
excluded.
- PHCPs who were not active during the inclusion period will automatically be excluded.",2021-09-13,2021-09-26,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,2730,0.701,0.684,0.72,True,,True,True,True,Convenience,"COVID-19 IgG/IgM Rapid Test,Elecsys® Anti‐SARS‐CoV‐2 (S),Atellica® IM SARS-CoV-2 Total (COV2T),Liaison SARS-CoV-2 S1/S2 IgG","Zhejiang Orient Gene Biotech,Roche Diagnostics,Siemens,DiaSorin",Multiple Types,Multiple Types,"['IgA', 'IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-17,2024-03-01,Unverified,sciensano_prevalence_2022-4,BEL
220127_Belgium_Sciensano_PHCPs_14-27Jun2021,220127_Belgium_Sciensano_PHCPs_14-27Jun2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG and/or IgM) among primary healthcare workers in Belgium,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Any Belgian general practitioner (GP) (including those in professional training) currently
working in primary care and any other primary health care providers (PHCPs) from the same
GP practice who physically manage (examine, test, treat) patients/clients (frontline PHCP),
are able to comply with the study protocol and provided informed consent to participate in
the study (see Appendix 2 and 3 for the information and consent form, respectively). Also
PHCPs having been diagnosed with COVID-19 are included.","- Staff hired on a temporary (interim) basis will be excluded as follow-up over time will be
compromised.
- Administrative staff or technical staff without any contact with patients/clients will also be
excluded.
- PHCPs who were not active during the inclusion period will automatically be excluded.",2021-06-14,2021-06-27,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,2725,0.816,0.8,0.831,True,,True,True,True,Convenience,"COVID-19 IgG/IgM Rapid Test,Elecsys® Anti‐SARS‐CoV‐2 (S),Atellica® IM SARS-CoV-2 Total (COV2T),Liaison SARS-CoV-2 S1/S2 IgG","Zhejiang Orient Gene Biotech,Roche Diagnostics,Siemens,DiaSorin",Multiple Types,Multiple Types,"['IgA', 'IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-17,2024-03-01,Unverified,sciensano_prevalence_2022-4,BEL
220127_Belgium_Sciensano_PHCPs_19-28Apr2021,220127_Belgium_Sciensano_PHCPs_19-28Apr2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG and/or IgM) among primary healthcare workers in Belgium,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Any Belgian general practitioner (GP) (including those in professional training) currently
working in primary care and any other primary health care providers (PHCPs) from the same
GP practice who physically manage (examine, test, treat) patients/clients (frontline PHCP),
are able to comply with the study protocol and provided informed consent to participate in
the study (see Appendix 2 and 3 for the information and consent form, respectively). Also
PHCPs having been diagnosed with COVID-19 are included.","- Staff hired on a temporary (interim) basis will be excluded as follow-up over time will be
compromised.
- Administrative staff or technical staff without any contact with patients/clients will also be
excluded.
- PHCPs who were not active during the inclusion period will automatically be excluded.",2021-04-19,2021-04-28,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,2859,0.841,0.8270000000000001,0.855,True,,True,True,True,Convenience,"COVID-19 IgG/IgM Rapid Test,Elecsys® Anti‐SARS‐CoV‐2 (S),Atellica® IM SARS-CoV-2 Total (COV2T),Liaison SARS-CoV-2 S1/S2 IgG","Zhejiang Orient Gene Biotech,Roche Diagnostics,Siemens,DiaSorin",Multiple Types,Multiple Types,"['IgA', 'IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-17,2024-03-01,Unverified,sciensano_prevalence_2022-4,BEL
220127_Belgium_Sciensano_PHCPs_22-28Feb2021,220127_Belgium_Sciensano_PHCPs_22-28Feb2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG and/or IgM) among primary healthcare workers in Belgium,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Any Belgian general practitioner (GP) (including those in professional training) currently
working in primary care and any other primary health care providers (PHCPs) from the same
GP practice who physically manage (examine, test, treat) patients/clients (frontline PHCP),
are able to comply with the study protocol and provided informed consent to participate in
the study (see Appendix 2 and 3 for the information and consent form, respectively). Also
PHCPs having been diagnosed with COVID-19 are included.","- Staff hired on a temporary (interim) basis will be excluded as follow-up over time will be
compromised.
- Administrative staff or technical staff without any contact with patients/clients will also be
excluded.
- PHCPs who were not active during the inclusion period will automatically be excluded.",2021-02-22,2021-02-28,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,2967,0.757,0.74,0.774,True,,True,True,True,Convenience,"COVID-19 IgG/IgM Rapid Test,Elecsys® Anti‐SARS‐CoV‐2 (S),Atellica® IM SARS-CoV-2 Total (COV2T),Liaison SARS-CoV-2 S1/S2 IgG","Zhejiang Orient Gene Biotech,Roche Diagnostics,Siemens,DiaSorin",Multiple Types,Multiple Types,"['IgA', 'IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-17,2024-03-01,Unverified,sciensano_prevalence_2022-4,BEL
220127_Belgium_Sciensano_PHCPs_22-31Mar2021,220127_Belgium_Sciensano_PHCPs_22-31Mar2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG and/or IgM) among primary healthcare workers in Belgium,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Any Belgian general practitioner (GP) (including those in professional training) currently
working in primary care and any other primary health care providers (PHCPs) from the same
GP practice who physically manage (examine, test, treat) patients/clients (frontline PHCP),
are able to comply with the study protocol and provided informed consent to participate in
the study (see Appendix 2 and 3 for the information and consent form, respectively). Also
PHCPs having been diagnosed with COVID-19 are included.","- Staff hired on a temporary (interim) basis will be excluded as follow-up over time will be
compromised.
- Administrative staff or technical staff without any contact with patients/clients will also be
excluded.
- PHCPs who were not active during the inclusion period will automatically be excluded.",2021-03-22,2021-03-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,2980,0.8420000000000001,0.8290000000000001,0.855,True,,True,True,True,Convenience,"COVID-19 IgG/IgM Rapid Test,Elecsys® Anti‐SARS‐CoV‐2 (S),Atellica® IM SARS-CoV-2 Total (COV2T),Liaison SARS-CoV-2 S1/S2 IgG","Zhejiang Orient Gene Biotech,Roche Diagnostics,Siemens,DiaSorin",Multiple Types,Multiple Types,"['IgA', 'IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-17,2024-03-01,Unverified,sciensano_prevalence_2022-4,BEL
220127_Belgium_Sciensano_PHCPs_24Dec-8Jan2021,220127_Belgium_Sciensano_PHCPs_24Dec-8Jan2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG and/or IgM) among primary healthcare workers in Belgium,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Any Belgian general practitioner (GP) (including those in professional training) currently
working in primary care and any other primary health care providers (PHCPs) from the same
GP practice who physically manage (examine, test, treat) patients/clients (frontline PHCP),
are able to comply with the study protocol and provided informed consent to participate in
the study (see Appendix 2 and 3 for the information and consent form, respectively). Also
PHCPs having been diagnosed with COVID-19 are included.","- Staff hired on a temporary (interim) basis will be excluded as follow-up over time will be
compromised.
- Administrative staff or technical staff without any contact with patients/clients will also be
excluded.
- PHCPs who were not active during the inclusion period will automatically be excluded.",2020-12-24,2021-01-08,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,2629,0.151,0.135,0.166,True,,True,True,True,Convenience,"COVID-19 IgG/IgM Rapid Test,Elecsys® Anti‐SARS‐CoV‐2 (S),Atellica® IM SARS-CoV-2 Total (COV2T),Liaison SARS-CoV-2 S1/S2 IgG","Zhejiang Orient Gene Biotech,Roche Diagnostics,Siemens,DiaSorin",Multiple Types,Multiple Types,"['IgA', 'IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-17,2024-03-01,Unverified,sciensano_prevalence_2022-4,BEL
220127_Belgium_Sciensano_PHCPs_25-31Jan2021,220127_Belgium_Sciensano_PHCPs_25-31Jan2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG and/or IgM) among primary healthcare workers in Belgium,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Any Belgian general practitioner (GP) (including those in professional training) currently
working in primary care and any other primary health care providers (PHCPs) from the same
GP practice who physically manage (examine, test, treat) patients/clients (frontline PHCP),
are able to comply with the study protocol and provided informed consent to participate in
the study (see Appendix 2 and 3 for the information and consent form, respectively). Also
PHCPs having been diagnosed with COVID-19 are included.","- Staff hired on a temporary (interim) basis will be excluded as follow-up over time will be
compromised.
- Administrative staff or technical staff without any contact with patients/clients will also be
excluded.
- PHCPs who were not active during the inclusion period will automatically be excluded.",2021-01-25,2021-01-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,2995,0.254,0.23800000000000002,0.271,True,,True,True,True,Convenience,"COVID-19 IgG/IgM Rapid Test,Elecsys® Anti‐SARS‐CoV‐2 (S),Atellica® IM SARS-CoV-2 Total (COV2T),Liaison SARS-CoV-2 S1/S2 IgG","Zhejiang Orient Gene Biotech,Roche Diagnostics,Siemens,DiaSorin",Multiple Types,Multiple Types,"['IgA', 'IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-17,2024-03-01,Unverified,sciensano_prevalence_2022-4,BEL
220127_Belgium_Sciensano_NursingHomeResidents_1Feb-24Mar2021,220127_Belgium_Sciensano_NursingHomeResidents_1Feb-24Mar2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG and/or IgM) among residents and staff in Belgian nursing homes,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Both residents/staff that did
experience COVID-19(-like) symptoms or had a positive COVID-19 test before, as well as
residents/staff that did not experience COVID-19(-like) symptoms can participate in this study
- Participants can be included if they are ≥ 18 years old, have been informed (orally and by means
of a written information form) on the goal of the study and the procedures of the study and have
agreed to participate in the study by means of a signature on the informed consent form. In
some cases, NH residents can give oral consent to their legal representative or caregiver, who
will confirm this oral consent by their signature","- Service flat residents are not considered as
target population in this study and are therefore excluded.
- Temporary staff, employed for a
period of less than 1 year starting from baseline collection, will also be excluded.
- Participants who are unable to provide a capillary blood sample for the point-of-care (POC) test will also be excluded.",2021-02-01,2021-03-24,Assisted living and long-term care facilities,All,Seniors (65+ years),,,Primary Estimate,,1624,0.6900000000000001,0.63,0.74,True,,,True,True,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.929,0.963,['Moderate'],,Yes,Yes,No,,Yes,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-17,2024-03-01,Unverified,sciensano_prevalence_2022-5,BEL
220127_Belgium_Sciensano_NursingHomeResidents_25May-22Jun2022,220127_Belgium_Sciensano_NursingHomeResidents_25May-22Jun2022,Prevalence of anti-SARS-CoV-2 antibodies (IgG and/or IgM) among residents and staff in Belgian nursing homes,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Both residents/staff that did
experience COVID-19(-like) symptoms or had a positive COVID-19 test before, as well as
residents/staff that did not experience COVID-19(-like) symptoms can participate in this study
- Participants can be included if they are ≥ 18 years old, have been informed (orally and by means
of a written information form) on the goal of the study and the procedures of the study and have
agreed to participate in the study by means of a signature on the informed consent form. In
some cases, NH residents can give oral consent to their legal representative or caregiver, who
will confirm this oral consent by their signature","- Service flat residents are not considered as
target population in this study and are therefore excluded.
- Temporary staff, employed for a
period of less than 1 year starting from baseline collection, will also be excluded.
- Participants who are unable to provide a capillary blood sample for the point-of-care (POC) test will also be excluded.",2022-05-25,2022-06-22,Assisted living and long-term care facilities,All,Seniors (65+ years),,,Primary Estimate,,428,0.996,,,True,,,True,True,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.929,0.963,['High'],,Yes,No,No,,Yes,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-08-10,2024-03-01,Unverified,sciensano_prevalence_2022-5,BEL
220127_Belgium_Sciensano_NursingHomeResidents_26Nov-27Dec2021,220127_Belgium_Sciensano_NursingHomeResidents_26Nov-27Dec2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG and/or IgM) among residents and staff in Belgian nursing homes,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Both residents/staff that did
experience COVID-19(-like) symptoms or had a positive COVID-19 test before, as well as
residents/staff that did not experience COVID-19(-like) symptoms can participate in this study
- Participants can be included if they are ≥ 18 years old, have been informed (orally and by means
of a written information form) on the goal of the study and the procedures of the study and have
agreed to participate in the study by means of a signature on the informed consent form. In
some cases, NH residents can give oral consent to their legal representative or caregiver, who
will confirm this oral consent by their signature","- Service flat residents are not considered as
target population in this study and are therefore excluded.
- Temporary staff, employed for a
period of less than 1 year starting from baseline collection, will also be excluded.
- Participants who are unable to provide a capillary blood sample for the point-of-care (POC) test will also be excluded.",2021-11-26,2021-12-27,Assisted living and long-term care facilities,All,Seniors (65+ years),,,Primary Estimate,,1199,0.9770000000000001,,,True,,,True,True,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.929,0.963,['Moderate'],,Yes,Yes,No,,Yes,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-06-22,2024-03-01,Unverified,sciensano_prevalence_2022-5,BEL
220127_Belgium_Sciensano_NursingHomeResidents_27Sep-28Oct2021,220127_Belgium_Sciensano_NursingHomeResidents_27Sep-28Oct2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG and/or IgM) among residents and staff in Belgian nursing homes,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Both residents/staff that did
experience COVID-19(-like) symptoms or had a positive COVID-19 test before, as well as
residents/staff that did not experience COVID-19(-like) symptoms can participate in this study
- Participants can be included if they are ≥ 18 years old, have been informed (orally and by means
of a written information form) on the goal of the study and the procedures of the study and have
agreed to participate in the study by means of a signature on the informed consent form. In
some cases, NH residents can give oral consent to their legal representative or caregiver, who
will confirm this oral consent by their signature","- Service flat residents are not considered as
target population in this study and are therefore excluded.
- Temporary staff, employed for a
period of less than 1 year starting from baseline collection, will also be excluded.
- Participants who are unable to provide a capillary blood sample for the point-of-care (POC) test will also be excluded.",2021-09-27,2021-10-28,Assisted living and long-term care facilities,All,Seniors (65+ years),,,Primary Estimate,,1347,0.6900000000000001,,,True,,,True,True,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.929,0.963,['Moderate'],,Yes,Yes,No,,Yes,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-17,2024-03-01,Unverified,sciensano_prevalence_2022-5,BEL
220127_Belgium_Sciensano_NursingHomeResidents_28Feb-22Mar2022,220127_Belgium_Sciensano_NursingHomeResidents_28Feb-24Mar2022,Prevalence of anti-SARS-CoV-2 antibodies (IgG and/or IgM) among residents and staff in Belgian nursing homes,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Both residents/staff that did
experience COVID-19(-like) symptoms or had a positive COVID-19 test before, as well as
residents/staff that did not experience COVID-19(-like) symptoms can participate in this study
- Participants can be included if they are ≥ 18 years old, have been informed (orally and by means
of a written information form) on the goal of the study and the procedures of the study and have
agreed to participate in the study by means of a signature on the informed consent form. In
some cases, NH residents can give oral consent to their legal representative or caregiver, who
will confirm this oral consent by their signature","- Service flat residents are not considered as
target population in this study and are therefore excluded.
- Temporary staff, employed for a
period of less than 1 year starting from baseline collection, will also be excluded.
- Participants who are unable to provide a capillary blood sample for the point-of-care (POC) test will also be excluded.",2022-02-28,2022-03-24,Assisted living and long-term care facilities,All,Seniors (65+ years),,,Primary Estimate,,472,0.996,,,True,,,True,True,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.929,0.963,['High'],,Yes,No,No,,Yes,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-06-22,2024-03-01,Unverified,sciensano_prevalence_2022-5,BEL
220127_Belgium_Sciensano_NursingHomeResidents_29Jul-31Aug2021,220127_Belgium_Sciensano_NursingHomeResidents_29Jul-31Aug2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG and/or IgM) among residents and staff in Belgian nursing homes,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Both residents/staff that did
experience COVID-19(-like) symptoms or had a positive COVID-19 test before, as well as
residents/staff that did not experience COVID-19(-like) symptoms can participate in this study
- Participants can be included if they are ≥ 18 years old, have been informed (orally and by means
of a written information form) on the goal of the study and the procedures of the study and have
agreed to participate in the study by means of a signature on the informed consent form. In
some cases, NH residents can give oral consent to their legal representative or caregiver, who
will confirm this oral consent by their signature","- Service flat residents are not considered as
target population in this study and are therefore excluded.
- Temporary staff, employed for a
period of less than 1 year starting from baseline collection, will also be excluded.
- Participants who are unable to provide a capillary blood sample for the point-of-care (POC) test will also be excluded.",2021-07-29,2021-08-31,Assisted living and long-term care facilities,All,Seniors (65+ years),,,Primary Estimate,,1385,0.68,0.64,0.72,True,,,True,True,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.929,0.963,['Moderate'],,Yes,Yes,No,,Yes,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-17,2024-03-01,Unverified,sciensano_prevalence_2022-5,BEL
220127_Belgium_Sciensano_NursingHomeResidents_30May-30Jun2021,220127_Belgium_Sciensano_NursingHomeResidents_30May-30Jun2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG and/or IgM) among residents and staff in Belgian nursing homes,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Both residents/staff that did
experience COVID-19(-like) symptoms or had a positive COVID-19 test before, as well as
residents/staff that did not experience COVID-19(-like) symptoms can participate in this study
- Participants can be included if they are ≥ 18 years old, have been informed (orally and by means
of a written information form) on the goal of the study and the procedures of the study and have
agreed to participate in the study by means of a signature on the informed consent form. In
some cases, NH residents can give oral consent to their legal representative or caregiver, who
will confirm this oral consent by their signature","- Service flat residents are not considered as
target population in this study and are therefore excluded.
- Temporary staff, employed for a
period of less than 1 year starting from baseline collection, will also be excluded.
- Participants who are unable to provide a capillary blood sample for the point-of-care (POC) test will also be excluded.",2021-05-30,2021-06-30,Assisted living and long-term care facilities,All,Seniors (65+ years),,,Primary Estimate,,1480,0.86,0.8300000000000001,0.88,True,,,True,True,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.929,0.963,['Moderate'],,Yes,Yes,No,,Yes,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-17,2024-03-01,Unverified,sciensano_prevalence_2022-5,BEL
220127_Belgium_Sciensano_NursingHomeResidents_31Mar-1May2021,220127_Belgium_Sciensano_NursingHomeResidents_31Mar-1May2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG and/or IgM) among residents and staff in Belgian nursing homes,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Both residents/staff that did
experience COVID-19(-like) symptoms or had a positive COVID-19 test before, as well as
residents/staff that did not experience COVID-19(-like) symptoms can participate in this study
- Participants can be included if they are ≥ 18 years old, have been informed (orally and by means
of a written information form) on the goal of the study and the procedures of the study and have
agreed to participate in the study by means of a signature on the informed consent form. In
some cases, NH residents can give oral consent to their legal representative or caregiver, who
will confirm this oral consent by their signature","- Service flat residents are not considered as
target population in this study and are therefore excluded.
- Temporary staff, employed for a
period of less than 1 year starting from baseline collection, will also be excluded.
- Participants who are unable to provide a capillary blood sample for the point-of-care (POC) test will also be excluded.",2021-03-31,2021-05-01,Assisted living and long-term care facilities,All,Seniors (65+ years),,,Primary Estimate,,1553,0.9,0.87,0.92,True,,,True,True,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.929,0.963,['Moderate'],,Yes,Yes,No,,Yes,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-17,2024-03-01,Unverified,sciensano_prevalence_2022-5,BEL
220127_Belgium_Sciensano_NursingHomeStaff_1Feb-24Mar2021,220127_Belgium_Sciensano_NursingHomeStaff_1Feb-24Mar2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG and/or IgM) among residents and staff in Belgian nursing homes,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Both residents/staff that did
experience COVID-19(-like) symptoms or had a positive COVID-19 test before, as well as
residents/staff that did not experience COVID-19(-like) symptoms can participate in this study
- Participants can be included if they are ≥ 18 years old, have been informed (orally and by means
of a written information form) on the goal of the study and the procedures of the study and have
agreed to participate in the study by means of a signature on the informed consent form. In
some cases, NH residents can give oral consent to their legal representative or caregiver, who
will confirm this oral consent by their signature","- Service flat residents are not considered as
target population in this study and are therefore excluded.
- Temporary staff, employed for a
period of less than 1 year starting from baseline collection, will also be excluded.
- Participants who are unable to provide a capillary blood sample for the point-of-care (POC) test will also be excluded.",2021-02-01,2021-03-24,Assisted living and long-term care facilities,All,Adults (18-64 years),,,Primary Estimate,,1337,0.8,0.76,0.8300000000000001,True,,,True,True,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.929,0.963,['Moderate'],,Yes,Yes,No,,Yes,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-17,2024-03-01,Unverified,sciensano_prevalence_2022-5,BEL
220127_Belgium_Sciensano_NursingHomeStaff_26Nov-27Dec2021,220127_Belgium_Sciensano_NursingHomeStaff_26Nov-27Dec2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG and/or IgM) among residents and staff in Belgian nursing homes,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Both residents/staff that did
experience COVID-19(-like) symptoms or had a positive COVID-19 test before, as well as
residents/staff that did not experience COVID-19(-like) symptoms can participate in this study
- Participants can be included if they are ≥ 18 years old, have been informed (orally and by means
of a written information form) on the goal of the study and the procedures of the study and have
agreed to participate in the study by means of a signature on the informed consent form. In
some cases, NH residents can give oral consent to their legal representative or caregiver, who
will confirm this oral consent by their signature","- Service flat residents are not considered as
target population in this study and are therefore excluded.
- Temporary staff, employed for a
period of less than 1 year starting from baseline collection, will also be excluded.
- Participants who are unable to provide a capillary blood sample for the point-of-care (POC) test will also be excluded.",2021-11-26,2021-12-27,Assisted living and long-term care facilities,All,Adults (18-64 years),,,Primary Estimate,,876,0.881,,,True,,,True,True,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.929,0.963,['Moderate'],,Yes,Yes,No,,Yes,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-06-22,2024-03-01,Unverified,sciensano_prevalence_2022-5,BEL
220127_Belgium_Sciensano_NursingHomeStaff_27Sep-28Oct2021,220127_Belgium_Sciensano_NursingHomeStaff_27Sep-28Oct2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG and/or IgM) among residents and staff in Belgian nursing homes,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Both residents/staff that did
experience COVID-19(-like) symptoms or had a positive COVID-19 test before, as well as
residents/staff that did not experience COVID-19(-like) symptoms can participate in this study
- Participants can be included if they are ≥ 18 years old, have been informed (orally and by means
of a written information form) on the goal of the study and the procedures of the study and have
agreed to participate in the study by means of a signature on the informed consent form. In
some cases, NH residents can give oral consent to their legal representative or caregiver, who
will confirm this oral consent by their signature","- Service flat residents are not considered as
target population in this study and are therefore excluded.
- Temporary staff, employed for a
period of less than 1 year starting from baseline collection, will also be excluded.
- Participants who are unable to provide a capillary blood sample for the point-of-care (POC) test will also be excluded.",2021-09-27,2021-10-28,Assisted living and long-term care facilities,All,Adults (18-64 years),,,Primary Estimate,,1012,0.8,,,True,,,True,True,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.929,0.963,['Moderate'],,Yes,Yes,No,,Yes,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-17,2024-03-01,Unverified,sciensano_prevalence_2022-5,BEL
220127_Belgium_Sciensano_NursingHomeStaff_29Jul-31Aug2021,220127_Belgium_Sciensano_NursingHomeStaff_29Jul-31Aug2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG and/or IgM) among residents and staff in Belgian nursing homes,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Both residents/staff that did
experience COVID-19(-like) symptoms or had a positive COVID-19 test before, as well as
residents/staff that did not experience COVID-19(-like) symptoms can participate in this study
- Participants can be included if they are ≥ 18 years old, have been informed (orally and by means
of a written information form) on the goal of the study and the procedures of the study and have
agreed to participate in the study by means of a signature on the informed consent form. In
some cases, NH residents can give oral consent to their legal representative or caregiver, who
will confirm this oral consent by their signature","- Service flat residents are not considered as
target population in this study and are therefore excluded.
- Temporary staff, employed for a
period of less than 1 year starting from baseline collection, will also be excluded.
- Participants who are unable to provide a capillary blood sample for the point-of-care (POC) test will also be excluded.",2021-07-29,2021-08-31,Assisted living and long-term care facilities,All,Adults (18-64 years),,,Primary Estimate,,1012,0.86,0.8300000000000001,0.89,True,,,True,True,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.929,0.963,['Moderate'],,Yes,Yes,No,,Yes,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-17,2024-03-01,Unverified,sciensano_prevalence_2022-5,BEL
220127_Belgium_Sciensano_NursingHomeStaff_30May-30Jun2021,220127_Belgium_Sciensano_NursingHomeStaff_30May-30Jun2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG and/or IgM) among residents and staff in Belgian nursing homes,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Both residents/staff that did
experience COVID-19(-like) symptoms or had a positive COVID-19 test before, as well as
residents/staff that did not experience COVID-19(-like) symptoms can participate in this study
- Participants can be included if they are ≥ 18 years old, have been informed (orally and by means
of a written information form) on the goal of the study and the procedures of the study and have
agreed to participate in the study by means of a signature on the informed consent form. In
some cases, NH residents can give oral consent to their legal representative or caregiver, who
will confirm this oral consent by their signature","- Service flat residents are not considered as
target population in this study and are therefore excluded.
- Temporary staff, employed for a
period of less than 1 year starting from baseline collection, will also be excluded.
- Participants who are unable to provide a capillary blood sample for the point-of-care (POC) test will also be excluded.",2021-05-30,2021-06-30,Assisted living and long-term care facilities,All,Adults (18-64 years),,,Primary Estimate,,1184,0.9400000000000001,0.92,0.9500000000000001,True,,,True,True,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.929,0.963,['Moderate'],,Yes,Yes,No,,Yes,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-17,2024-03-01,Unverified,sciensano_prevalence_2022-5,BEL
220127_Belgium_Sciensano_NursingHomeStaff_31Mar-1May2021,220127_Belgium_Sciensano_NursingHomeStaff_31Mar-1May2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG and/or IgM) among residents and staff in Belgian nursing homes,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Both residents/staff that did
experience COVID-19(-like) symptoms or had a positive COVID-19 test before, as well as
residents/staff that did not experience COVID-19(-like) symptoms can participate in this study
- Participants can be included if they are ≥ 18 years old, have been informed (orally and by means
of a written information form) on the goal of the study and the procedures of the study and have
agreed to participate in the study by means of a signature on the informed consent form. In
some cases, NH residents can give oral consent to their legal representative or caregiver, who
will confirm this oral consent by their signature","- Service flat residents are not considered as
target population in this study and are therefore excluded.
- Temporary staff, employed for a
period of less than 1 year starting from baseline collection, will also be excluded.
- Participants who are unable to provide a capillary blood sample for the point-of-care (POC) test will also be excluded.",2021-03-31,2021-05-01,Assisted living and long-term care facilities,All,Adults (18-64 years),,,Primary Estimate,,1290,0.92,0.9,0.9400000000000001,True,,,True,True,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.929,0.963,['Moderate'],,Yes,Yes,No,,Yes,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-17,2024-03-01,Unverified,sciensano_prevalence_2022-5,BEL
220127_Belgium_Sciensano_Primary_1-26Mar2021_Overall,220127_Belgium_Sciensano_Primary_1-26Mar2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG) among children and school staff in Belgium,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"any pupil from the 3rd grade (or from the 2nd grade if not enough participants from 3rd grade are available in the selected school) who regularly attend school and is
present at school at the first testing period. Prior known SARS-CoV-2 infection does not exclude participation.","- Pupils or staff who refuse to have the saliva sample taken
- For children: being a sibling of a study participant
- A close family member included in the study: only one member per nuclear family will be included in the study
- No informed consent form signed (by parent of legal caregiver) available at the recruitment",2021-03-01,2021-03-26,Students and Daycares,All,Children and Youth (0-17 years),7.0,9.0,Primary Estimate,,648,0.171,0.133,0.219,True,,True,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Saliva,IgG,Spike,Validated by independent authors/third party/non-developers,0.9590000000000001,0.986,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2024-03-01,Unverified,sciensano_prevalence_2022-2,BEL
220127_Belgium_Sciensano_Primary_17May-11Jun2021,220127_Belgium_Sciensano_Primary_17May-11Jun2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG) among children and school staff in Belgium,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"any pupil from the 3rd grade (or from the 2nd grade if not enough participants from 3rd grade are available in the selected school) who regularly attend school and is
present at school at the first testing period. Prior known SARS-CoV-2 infection does not exclude participation.","- Pupils or staff who refuse to have the saliva sample taken
- For children: being a sibling of a study participant
- A close family member included in the study: only one member per nuclear family will be included in the study
- No informed consent form signed (by parent of legal caregiver) available at the recruitment",2021-05-17,2021-06-11,Students and Daycares,All,Children and Youth (0-17 years),7.0,9.0,Primary Estimate,,664,0.154,0.122,0.196,True,,True,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Saliva,IgG,Spike,Validated by independent authors/third party/non-developers,0.9590000000000001,0.986,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2024-03-01,Unverified,sciensano_prevalence_2022-2,BEL
220127_Belgium_Sciensano_Primary_20Sep-8Oct2021,220127_Belgium_Sciensano_Primary_20Sep-8Oct2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG) among children and school staff in Belgium,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"any pupil from the 3rd grade (or from the 2nd grade if not enough participants from 3rd grade are available in the selected school) who regularly attend school and is
present at school at the first testing period. Prior known SARS-CoV-2 infection does not exclude participation.","- Pupils or staff who refuse to have the saliva sample taken
- For children: being a sibling of a study participant
- A close family member included in the study: only one member per nuclear family will be included in the study
- No informed consent form signed (by parent of legal caregiver) available at the recruitment",2021-09-20,2021-10-08,Students and Daycares,All,Children and Youth (0-17 years),7.0,9.0,Primary Estimate,,478,0.266,0.215,0.32799999999999996,True,,True,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Saliva,IgG,Spike,Validated by independent authors/third party/non-developers,0.9590000000000001,0.986,['Moderate'],,Yes,No,No,,Yes,Yes,Yes,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2024-03-01,Unverified,sciensano_prevalence_2022-2,BEL
220127_Belgium_Sciensano_Primary_3Dec2020-28Jan2021_Overall,220127_Belgium_Sciensano_Primary_3Dec2020-28Jan2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG) among children and school staff in Belgium,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"any pupil from the 3rd grade (or from the 2nd grade if not enough participants from 3rd grade are available in the selected school) who regularly attend school and is
present at school at the first testing period. Prior known SARS-CoV-2 infection does not exclude participation.","- Pupils or staff who refuse to have the saliva sample taken
- For children: being a sibling of a study participant
- A close family member included in the study: only one member per nuclear family will be included in the study
- No informed consent form signed (by parent of legal caregiver) available at the recruitment",2020-12-03,2021-01-28,Students and Daycares,All,Children and Youth (0-17 years),7.0,9.0,Primary Estimate,,479,0.11,0.076,0.159,True,,True,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Saliva,IgG,Spike,Validated by independent authors/third party/non-developers,0.9590000000000001,0.986,['Moderate'],,Yes,No,No,,Yes,Yes,Yes,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2024-03-01,Unverified,sciensano_prevalence_2022-2,BEL
220127_Belgium_Sciensano_Primary_6-17Dec2021_Overall,220127_Belgium_Sciensano_Primary_6-17Dec2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG) among children and school staff in Belgium,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"any pupil from the 3rd grade (or from the 2nd grade if not enough participants from 3rd grade are available in the selected school) who regularly attend school and is
present at school at the first testing period. Prior known SARS-CoV-2 infection does not exclude participation.","- Pupils or staff who refuse to have the saliva sample taken
- For children: being a sibling of a study participant
- A close family member included in the study: only one member per nuclear family will be included in the study
- No informed consent form signed (by parent of legal caregiver) available at the recruitment",2021-12-06,2021-12-17,Students and Daycares,All,Children and Youth (0-17 years),7.0,9.0,Primary Estimate,,432,0.509,,,True,,True,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Saliva,IgG,Spike,Validated by independent authors/third party/non-developers,0.9590000000000001,0.986,['Moderate'],,Yes,No,No,,Yes,Yes,Yes,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2024-03-01,Unverified,sciensano_prevalence_2022-2,BEL
220127_Belgium_Sciensano_SchoolStaff_1-26Mar2021,220127_Belgium_Sciensano_SchoolStaff_1-26Mar2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG) among children and school staff in Belgium,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"1) Staff primary schools: any teaching or supporting/none-teaching staff (e.g. administrative staff) having contact with pupils and is present at school at the first testing period
2) Staff secondary schools: any teaching staff teaching at least also in the 1st or 2nd grade of the
secondary school and is present at school at the first testing period","- staff who refuse to have the saliva sample taken
- A close family member included in the study: only one member per nuclear family will be included in the study",2021-03-01,2021-03-26,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,691,0.19,0.161,0.223,True,,True,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Saliva,IgG,Spike,Validated by independent authors/third party/non-developers,0.9590000000000001,0.986,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2024-03-01,Unverified,sciensano_prevalence_2022-2,BEL
220127_Belgium_Sciensano_SchoolStaff_17May-11Jun2021,220127_Belgium_Sciensano_SchoolStaff_17May-11Jun2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG) among children and school staff in Belgium,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"1) Staff primary schools: any teaching or supporting/none-teaching staff (e.g. administrative staff) having contact with pupils and is present at school at the first testing period
2) Staff secondary schools: any teaching staff teaching at least also in the 1st or 2nd grade of the
secondary school and is present at school at the first testing period","- staff who refuse to have the saliva sample taken
- A close family member included in the study: only one member per nuclear family will be included in the study",2021-05-17,2021-06-11,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,643,0.38,0.334,0.433,True,,True,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Saliva,IgG,Spike,Validated by independent authors/third party/non-developers,0.9590000000000001,0.986,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2024-03-01,Unverified,sciensano_prevalence_2022-2,BEL
220127_Belgium_Sciensano_SchoolStaff_3Dec2020-28Jan2021,220127_Belgium_Sciensano_SchoolStaff_3Dec2020-28Jan2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG) among children and school staff in Belgium,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"1) Staff primary schools: any teaching or supporting/none-teaching staff (e.g. administrative staff) having contact with pupils and is present at school at the first testing period
2) Staff secondary schools: any teaching staff teaching at least also in the 1st or 2nd grade of the
secondary school and is present at school at the first testing period","- staff who refuse to have the saliva sample taken
- A close family member included in the study: only one member per nuclear family will be included in the study",2020-12-03,2021-01-28,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,629,0.14800000000000002,0.122,0.18,True,,True,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Saliva,IgG,Spike,Validated by independent authors/third party/non-developers,0.9590000000000001,0.986,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2024-03-01,Unverified,sciensano_prevalence_2022-2,BEL
220127_Belgium_Sciensano_Secondary_1-26Mar2021,220127_Belgium_Sciensano_Secondary_1-26Mar2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG) among children and school staff in Belgium,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,any pupil from 2nd grade (of secondary school) who regularly attend school and is present at school at the first testing period. Prior known SARS-CoV-2 infection does not exclude participation,"- Pupils or staff who refuse to have the saliva sample taken
- For children: being a sibling of a study participant
- A close family member included in the study: only one member per nuclear family will be included in the study
- No informed consent form signed (by parent of legal caregiver) available at the recruitment",2021-03-01,2021-03-26,Students and Daycares,All,Children and Youth (0-17 years),13.0,14.0,Primary Estimate,,515,0.18,0.136,0.23800000000000002,True,,True,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Saliva,IgG,Spike,Validated by independent authors/third party/non-developers,0.9590000000000001,0.986,['Moderate'],,Yes,No,No,,Yes,Yes,Yes,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2024-03-01,Unverified,sciensano_prevalence_2022-2,BEL
220127_Belgium_Sciensano_Secondary_17May-11Jun2021,220127_Belgium_Sciensano_Secondary_17May-11Jun2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG) among children and school staff in Belgium,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,any pupil from 2nd grade (of secondary school) who regularly attend school and is present at school at the first testing period. Prior known SARS-CoV-2 infection does not exclude participation,"- Pupils or staff who refuse to have the saliva sample taken
- For children: being a sibling of a study participant
- A close family member included in the study: only one member per nuclear family will be included in the study
- No informed consent form signed (by parent of legal caregiver) available at the recruitment",2021-05-17,2021-06-11,Students and Daycares,All,Children and Youth (0-17 years),13.0,14.0,Primary Estimate,,525,0.172,0.131,0.227,True,,True,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Saliva,IgG,Spike,Validated by independent authors/third party/non-developers,0.9590000000000001,0.986,['Moderate'],,Yes,No,No,,Yes,Yes,Yes,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2024-03-01,Unverified,sciensano_prevalence_2022-2,BEL
220127_Belgium_Sciensano_Secondary_3Dec2020-28Jan2021,220127_Belgium_Sciensano_Secondary_3Dec2020-28Jan2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG) among children and school staff in Belgium,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,any pupil from 2nd grade (of secondary school) who regularly attend school and is present at school at the first testing period. Prior known SARS-CoV-2 infection does not exclude participation,"- Pupils or staff who refuse to have the saliva sample taken
- For children: being a sibling of a study participant
- A close family member included in the study: only one member per nuclear family will be included in the study
- No informed consent form signed (by parent of legal caregiver) available at the recruitment",2020-12-03,2021-01-28,Students and Daycares,All,Children and Youth (0-17 years),13.0,14.0,Primary Estimate,,451,0.136,0.099,0.185,True,,True,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Saliva,IgG,Spike,Validated by independent authors/third party/non-developers,0.9590000000000001,0.986,['Moderate'],,Yes,No,No,,Yes,Yes,Yes,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2024-03-01,Unverified,sciensano_prevalence_2022-2,BEL
220127_Belgium_Sciensano_HCWs_19-24May2020,220127_Belgium_Sciensano_HCWs_19-24May2020,Prevalence of anti-SARS-CoV-2 antibodies (IgG) among healthcare workers in Belgian hospitals,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Any permanent medical and paramedical staff working in the hospital who provided a signed informed consent to participate in the study.
- Participants must have a social security insurance (mandatory in Belgium).
- This study only include adults (18 years and older)","- Staff hired on a temporary (interim) basis will be excluded as follow-up over time will be compromised.
- Administrative staff or technical staff will also be excluded.
- HCW who were not active during the inclusion period will automatically be excluded.",2020-05-19,2020-05-24,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,834,0.08800000000000001,0.057999999999999996,0.13,True,,,True,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-17,2024-03-01,Unverified,sciensano_prevalence_2022-1,BEL
220127_Belgium_Sciensano_HCWs_21-24Dec2020,220127_Belgium_Sciensano_HCWs_21-24Dec2020,Prevalence of anti-SARS-CoV-2 antibodies (IgG) among healthcare workers in Belgian hospitals,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Any permanent medical and paramedical staff working in the hospital who provided a signed informed consent to participate in the study.
- Participants must have a social security insurance (mandatory in Belgium).
- This study only include adults (18 years and older)","- Staff hired on a temporary (interim) basis will be excluded as follow-up over time will be compromised.
- Administrative staff or technical staff will also be excluded.
- HCW who were not active during the inclusion period will automatically be excluded.",2020-12-21,2020-12-24,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,308,0.197,0.11699999999999999,0.312,True,,,True,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-17,2024-03-01,Unverified,sciensano_prevalence_2022-1,BEL
220127_Belgium_Sciensano_HCWs_21-25Apr2021,220127_Belgium_Sciensano_HCWs_21-25Apr2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG) among healthcare workers in Belgian hospitals,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Any permanent medical and paramedical staff working in the hospital who provided a signed informed consent to participate in the study.
- Participants must have a social security insurance (mandatory in Belgium).
- This study only include adults (18 years and older)","- Staff hired on a temporary (interim) basis will be excluded as follow-up over time will be compromised.
- Administrative staff or technical staff will also be excluded.
- HCW who were not active during the inclusion period will automatically be excluded.",2021-04-21,2021-04-25,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,304,0.9670000000000001,0.934,0.9840000000000001,True,,,True,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-17,2024-03-01,Unverified,sciensano_prevalence_2022-1,BEL
220127_Belgium_Sciensano_HCWs_21-25Oct2020,220127_Belgium_Sciensano_HCWs_21-25Oct2020,Prevalence of anti-SARS-CoV-2 antibodies (IgG) among healthcare workers in Belgian hospitals,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Any permanent medical and paramedical staff working in the hospital who provided a signed informed consent to participate in the study.
- Participants must have a social security insurance (mandatory in Belgium).
- This study only include adults (18 years and older)","- Staff hired on a temporary (interim) basis will be excluded as follow-up over time will be compromised.
- Administrative staff or technical staff will also be excluded.
- HCW who were not active during the inclusion period will automatically be excluded.",2020-10-21,2020-10-25,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,341,0.10800000000000001,0.059000000000000004,0.189,True,,,True,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-17,2024-03-01,Unverified,sciensano_prevalence_2022-1,BEL
220127_Belgium_Sciensano_HCWs_22-26Apr2020,220127_Belgium_Sciensano_HCWs_22-26Apr2020,Prevalence of anti-SARS-CoV-2 antibodies (IgG) among healthcare workers in Belgian hospitals,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Any permanent medical and paramedical staff working in the hospital who provided a signed informed consent to participate in the study.
- Participants must have a social security insurance (mandatory in Belgium).
- This study only include adults (18 years and older)","- Staff hired on a temporary (interim) basis will be excluded as follow-up over time will be compromised.
- Administrative staff or technical staff will also be excluded.
- HCW who were not active during the inclusion period will automatically be excluded.",2020-04-22,2020-04-26,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,699,0.077,0.047,0.122,True,,,True,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-17,2024-03-01,Unverified,sciensano_prevalence_2022-1,BEL
220127_Belgium_Sciensano_HCWs_22-26Jul2020,220127_Belgium_Sciensano_HCWs_22-26Jul2020,Prevalence of anti-SARS-CoV-2 antibodies (IgG) among healthcare workers in Belgian hospitals,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Any permanent medical and paramedical staff working in the hospital who provided a signed informed consent to participate in the study.
- Participants must have a social security insurance (mandatory in Belgium).
- This study only include adults (18 years and older)","- Staff hired on a temporary (interim) basis will be excluded as follow-up over time will be compromised.
- Administrative staff or technical staff will also be excluded.
- HCW who were not active during the inclusion period will automatically be excluded.",2020-07-22,2020-07-26,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,651,0.084,0.052000000000000005,0.134,True,,,True,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-17,2024-03-01,Unverified,sciensano_prevalence_2022-1,BEL
220127_Belgium_Sciensano_HCWs_23-27Sep2020,220127_Belgium_Sciensano_HCWs_23-27Sep2020,Prevalence of anti-SARS-CoV-2 antibodies (IgG) among healthcare workers in Belgian hospitals,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Any permanent medical and paramedical staff working in the hospital who provided a signed informed consent to participate in the study.
- Participants must have a social security insurance (mandatory in Belgium).
- This study only include adults (18 years and older)","- Staff hired on a temporary (interim) basis will be excluded as follow-up over time will be compromised.
- Administrative staff or technical staff will also be excluded.
- HCW who were not active during the inclusion period will automatically be excluded.",2020-09-23,2020-09-27,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,673,0.08199999999999999,0.057,0.11599999999999999,True,,,True,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-17,2024-03-01,Unverified,sciensano_prevalence_2022-1,BEL
220127_Belgium_Sciensano_HCWs_24-28Feb2021,220127_Belgium_Sciensano_HCWs_24-28Feb2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG) among healthcare workers in Belgian hospitals,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Any permanent medical and paramedical staff working in the hospital who provided a signed informed consent to participate in the study.
- Participants must have a social security insurance (mandatory in Belgium).
- This study only include adults (18 years and older)","- Staff hired on a temporary (interim) basis will be excluded as follow-up over time will be compromised.
- Administrative staff or technical staff will also be excluded.
- HCW who were not active during the inclusion period will automatically be excluded.",2021-02-24,2021-02-28,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,343,0.637,0.498,0.757,True,,,True,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-17,2024-03-01,Unverified,sciensano_prevalence_2022-1,BEL
220127_Belgium_Sciensano_HCWs_24-28Jun2020,220127_Belgium_Sciensano_HCWs_24-28Jun2020,Prevalence of anti-SARS-CoV-2 antibodies (IgG) among healthcare workers in Belgian hospitals,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Any permanent medical and paramedical staff working in the hospital who provided a signed informed consent to participate in the study.
- Participants must have a social security insurance (mandatory in Belgium).
- This study only include adults (18 years and older)","- Staff hired on a temporary (interim) basis will be excluded as follow-up over time will be compromised.
- Administrative staff or technical staff will also be excluded.
- HCW who were not active during the inclusion period will automatically be excluded.",2020-06-24,2020-06-28,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,779,0.094,0.065,0.134,True,,,True,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-17,2024-03-01,Unverified,sciensano_prevalence_2022-1,BEL
220127_Belgium_Sciensano_HCWs_24-28Mar2021,220127_Belgium_Sciensano_HCWs_24-28Mar2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG) among healthcare workers in Belgian hospitals,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Any permanent medical and paramedical staff working in the hospital who provided a signed informed consent to participate in the study.
- Participants must have a social security insurance (mandatory in Belgium).
- This study only include adults (18 years and older)","- Staff hired on a temporary (interim) basis will be excluded as follow-up over time will be compromised.
- Administrative staff or technical staff will also be excluded.
- HCW who were not active during the inclusion period will automatically be excluded.",2021-03-24,2021-03-28,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,332,0.946,0.912,0.9670000000000001,True,,,True,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-17,2024-03-01,Unverified,sciensano_prevalence_2022-1,BEL
220127_Belgium_Sciensano_HCWs_25-29Nov2020,220127_Belgium_Sciensano_HCWs_25-29Nov2020,Prevalence of anti-SARS-CoV-2 antibodies (IgG) among healthcare workers in Belgian hospitals,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Any permanent medical and paramedical staff working in the hospital who provided a signed informed consent to participate in the study.
- Participants must have a social security insurance (mandatory in Belgium).
- This study only include adults (18 years and older)","- Staff hired on a temporary (interim) basis will be excluded as follow-up over time will be compromised.
- Administrative staff or technical staff will also be excluded.
- HCW who were not active during the inclusion period will automatically be excluded.",2020-11-25,2020-11-29,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,363,0.174,0.099,0.287,True,,,True,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-17,2024-03-01,Unverified,sciensano_prevalence_2022-1,BEL
220127_Belgium_Sciensano_HCWs_26-30Aug2020,220127_Belgium_Sciensano_HCWs_26-30Aug2020,Prevalence of anti-SARS-CoV-2 antibodies (IgG) among healthcare workers in Belgian hospitals,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Any permanent medical and paramedical staff working in the hospital who provided a signed informed consent to participate in the study.
- Participants must have a social security insurance (mandatory in Belgium).
- This study only include adults (18 years and older)","- Staff hired on a temporary (interim) basis will be excluded as follow-up over time will be compromised.
- Administrative staff or technical staff will also be excluded.
- HCW who were not active during the inclusion period will automatically be excluded.",2020-08-26,2020-08-30,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,640,0.078,0.051,0.11900000000000001,True,,,True,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-17,2024-03-01,Unverified,sciensano_prevalence_2022-1,BEL
220127_Belgium_Sciensano_HCWs_27-31Jan2021,220127_Belgium_Sciensano_HCWs_27-31Jan2021,Prevalence of anti-SARS-CoV-2 antibodies (IgG) among healthcare workers in Belgian hospitals,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Any permanent medical and paramedical staff working in the hospital who provided a signed informed consent to participate in the study.
- Participants must have a social security insurance (mandatory in Belgium).
- This study only include adults (18 years and older)","- Staff hired on a temporary (interim) basis will be excluded as follow-up over time will be compromised.
- Administrative staff or technical staff will also be excluded.
- HCW who were not active during the inclusion period will automatically be excluded.",2021-01-27,2021-01-31,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,347,0.24100000000000002,0.149,0.364,True,,,True,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-17,2024-03-01,Unverified,sciensano_prevalence_2022-1,BEL
220127_Belgium_Sciensano_HCWs_6-10May2020,220127_Belgium_Sciensano_HCWs_6-10May2020,Prevalence of anti-SARS-CoV-2 antibodies (IgG) among healthcare workers in Belgian hospitals,2022-01-27,Institutional Report,National,Prospective cohort,Belgium,,,"- Any permanent medical and paramedical staff working in the hospital who provided a signed informed consent to participate in the study.
- Participants must have a social security insurance (mandatory in Belgium).
- This study only include adults (18 years and older)","- Staff hired on a temporary (interim) basis will be excluded as follow-up over time will be compromised.
- Administrative staff or technical staff will also be excluded.
- HCW who were not active during the inclusion period will automatically be excluded.",2020-05-06,2020-05-10,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,785,0.078,0.05,0.11900000000000001,True,,,True,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-17,2024-03-01,Unverified,sciensano_prevalence_2022-1,BEL
220127_Belgium_Sciensano_06-08Dec2021,220127_Belgium_Sciensano_06-08Dec2021,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Belgium,2022-01-27,Institutional Report,National,Cross-sectional survey ,Belgium,,,"Blood donors from the Red Cross in Flanders, Belgium and blood donors from the Blood Services of the Red Cross in Wallonia and Brussels, Belgium. Blood donors are 18 to 75 years old in good health.",People with a possible/confirmed COVID-19 infection or who were in direct contact with a confirmed case are not allowed to donate blood for 28 days after symptoms resolve or after contact.,2021-12-06,2021-12-08,Blood donors,All,Multiple groups,18.0,75.0,Primary Estimate,,1122,1.0,,,True,,True,,True,Convenience,Not reported/ Unable to specify,,,,TotalAntibody,,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-05-16,2022-07-16,Unverified,sciensano_prevalence_2022,BEL
220127_Belgium_Sciensano_1-2Feb2021,220127_Belgium_Sciensano_1-2Feb2021,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Belgium,2022-01-27,Institutional Report,National,Cross-sectional survey ,Belgium,,,"Blood donors from the Red Cross in Flanders, Belgium and blood donors from the Blood Services of the Red Cross in Wallonia and Brussels, Belgium. Blood donors are 18 to 75 years old in good health.",People with a possible/confirmed COVID-19 infection or who were in direct contact with a confirmed case are not allowed to donate blood for 28 days after symptoms resolve or after contact.,2021-02-01,2021-02-02,Blood donors,All,Multiple groups,18.0,75.0,Primary Estimate,,1135,0.203,0.17500000000000002,0.233,True,,True,,True,Convenience,,,,,TotalAntibody,,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2022-02-16,Unverified,sciensano_prevalence_2022,BEL
220127_Belgium_Sciensano_1-2Mar2021,220127_Belgium_Sciensano_1-2Mar2021,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Belgium,2022-01-27,Institutional Report,National,Cross-sectional survey ,Belgium,,,"Blood donors from the Red Cross in Flanders, Belgium and blood donors from the Blood Services of the Red Cross in Wallonia and Brussels, Belgium. Blood donors are 18 to 75 years old in good health.",People with a possible/confirmed COVID-19 infection or who were in direct contact with a confirmed case are not allowed to donate blood for 28 days after symptoms resolve or after contact.,2021-03-01,2021-03-02,Blood donors,All,Multiple groups,18.0,75.0,Primary Estimate,,1175,0.256,0.214,0.299,True,,True,,True,Convenience,,,,,TotalAntibody,,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2022-02-16,Unverified,sciensano_prevalence_2022,BEL
220127_Belgium_Sciensano_10-11Oct2021,220127_Belgium_Sciensano_10-11Oct2021,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Belgium,2022-01-27,Institutional Report,National,Cross-sectional survey ,Belgium,,,"Blood donors from the Red Cross in Flanders, Belgium and blood donors from the Blood Services of the Red Cross in Wallonia and Brussels, Belgium. Blood donors are 18 to 75 years old in good health.",People with a possible/confirmed COVID-19 infection or who were in direct contact with a confirmed case are not allowed to donate blood for 28 days after symptoms resolve or after contact.,2021-10-10,2021-10-11,Blood donors,All,Multiple groups,18.0,75.0,Primary Estimate,,1192,0.99,,,True,,True,,True,Convenience,Not reported/ Unable to specify,,,,TotalAntibody,,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-05-16,2022-07-16,Unverified,sciensano_prevalence_2022,BEL
220127_Belgium_Sciensano_11-13May2020,220127_Belgium_Sciensano_11-13May2020,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Belgium,2022-01-27,Institutional Report,National,Cross-sectional survey ,Belgium,,,"Blood donors from the Red Cross in Flanders, Belgium and blood donors from the Blood Services of the Red Cross in Wallonia and Brussels, Belgium. Blood donors are 18 to 75 years old in good health.",People with a possible/confirmed COVID-19 infection or who were in direct contact with a confirmed case are not allowed to donate blood for 28 days after symptoms resolve or after contact.,2020-05-11,2020-05-13,Blood donors,All,Multiple groups,18.0,75.0,Primary Estimate,,900,0.053,0.036000000000000004,0.07200000000000001,True,,True,,True,Convenience,,,,,TotalAntibody,,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2022-02-16,Unverified,sciensano_prevalence_2022,BEL
220127_Belgium_Sciensano_12-14Oct2020,220127_Belgium_Sciensano_12-14Oct2020,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Belgium,2022-01-27,Institutional Report,National,Cross-sectional survey ,Belgium,,,"Blood donors from the Red Cross in Flanders, Belgium and blood donors from the Blood Services of the Red Cross in Wallonia and Brussels, Belgium. Blood donors are 18 to 75 years old in good health.",People with a possible/confirmed COVID-19 infection or who were in direct contact with a confirmed case are not allowed to donate blood for 28 days after symptoms resolve or after contact.,2020-10-12,2020-10-14,Blood donors,All,Multiple groups,18.0,75.0,Primary Estimate,,900,0.057,0.038,0.077,True,,True,,True,Convenience,,,,,TotalAntibody,,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2022-02-16,Unverified,sciensano_prevalence_2022,BEL
220127_Belgium_Sciensano_14-16Apr2020,220127_Belgium_Sciensano_14-16Apr2020,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Belgium,2022-01-27,Institutional Report,National,Cross-sectional survey ,Belgium,,,"Blood donors from the Red Cross in Flanders, Belgium and blood donors from the Blood Services of the Red Cross in Wallonia and Brussels, Belgium. Blood donors are 18 to 75 years old in good health.",People with a possible/confirmed COVID-19 infection or who were in direct contact with a confirmed case are not allowed to donate blood for 28 days after symptoms resolve or after contact.,2020-04-14,2020-04-16,Blood donors,All,Multiple groups,18.0,75.0,Primary Estimate,,900,0.053,0.035,0.066,True,,True,,True,Convenience,,,,,TotalAntibody,,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2022-02-16,Unverified,sciensano_prevalence_2022,BEL
220127_Belgium_Sciensano_14-16Sep2020,220127_Belgium_Sciensano_14-16Sep2020,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Belgium,2022-01-27,Institutional Report,National,Cross-sectional survey ,Belgium,,,"Blood donors from the Red Cross in Flanders, Belgium and blood donors from the Blood Services of the Red Cross in Wallonia and Brussels, Belgium. Blood donors are 18 to 75 years old in good health.",People with a possible/confirmed COVID-19 infection or who were in direct contact with a confirmed case are not allowed to donate blood for 28 days after symptoms resolve or after contact.,2020-09-14,2020-09-16,Blood donors,All,Multiple groups,18.0,75.0,Primary Estimate,,900,0.044000000000000004,0.027999999999999997,0.062000000000000006,True,,True,,True,Convenience,,,,,TotalAntibody,,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2022-02-16,Unverified,sciensano_prevalence_2022,BEL
220127_Belgium_Sciensano_17-19Aug2020,220127_Belgium_Sciensano_17-19Aug2020,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Belgium,2022-01-27,Institutional Report,National,Cross-sectional survey ,Belgium,,,"Blood donors from the Red Cross in Flanders, Belgium and blood donors from the Blood Services of the Red Cross in Wallonia and Brussels, Belgium. Blood donors are 18 to 75 years old in good health.",People with a possible/confirmed COVID-19 infection or who were in direct contact with a confirmed case are not allowed to donate blood for 28 days after symptoms resolve or after contact.,2020-08-17,2020-08-19,Blood donors,All,Multiple groups,18.0,75.0,Primary Estimate,,900,0.06,0.042,0.079,True,,True,,True,Convenience,,,,,TotalAntibody,,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2022-02-16,Unverified,sciensano_prevalence_2022,BEL
220127_Belgium_Sciensano_18-20Jan2021,220127_Belgium_Sciensano_18-20Jan2021,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Belgium,2022-01-27,Institutional Report,National,Cross-sectional survey ,Belgium,,,"Blood donors from the Red Cross in Flanders, Belgium and blood donors from the Blood Services of the Red Cross in Wallonia and Brussels, Belgium. Blood donors are 18 to 75 years old in good health.",People with a possible/confirmed COVID-19 infection or who were in direct contact with a confirmed case are not allowed to donate blood for 28 days after symptoms resolve or after contact.,2021-01-18,2021-01-20,Blood donors,All,Multiple groups,18.0,75.0,Primary Estimate,,900,0.19399999999999998,0.16,0.228,True,,True,,True,Convenience,,,,,TotalAntibody,,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2022-02-16,Unverified,sciensano_prevalence_2022,BEL
220127_Belgium_Sciensano_19-20Jul2021,220127_Belgium_Sciensano_19-20Jul2021,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Belgium,2022-01-27,Institutional Report,National,Cross-sectional survey ,Belgium,,,"Blood donors from the Red Cross in Flanders, Belgium and blood donors from the Blood Services of the Red Cross in Wallonia and Brussels, Belgium. Blood donors are 18 to 75 years old in good health.",People with a possible/confirmed COVID-19 infection or who were in direct contact with a confirmed case are not allowed to donate blood for 28 days after symptoms resolve or after contact.,2021-07-19,2021-07-20,Blood donors,All,Multiple groups,18.0,75.0,Primary Estimate,,1185,0.98,,,True,,True,,True,Convenience,,,,,TotalAntibody,,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2022-02-16,Unverified,sciensano_prevalence_2022,BEL
220127_Belgium_Sciensano_20-23Jul2020,220127_Belgium_Sciensano_20-23Jul2020,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Belgium,2022-01-27,Institutional Report,National,Cross-sectional survey ,Belgium,,,"Blood donors from the Red Cross in Flanders, Belgium and blood donors from the Blood Services of the Red Cross in Wallonia and Brussels, Belgium. Blood donors are 18 to 75 years old in good health.",People with a possible/confirmed COVID-19 infection or who were in direct contact with a confirmed case are not allowed to donate blood for 28 days after symptoms resolve or after contact.,2020-07-20,2020-07-23,Blood donors,All,Multiple groups,18.0,75.0,Primary Estimate,,900,0.052000000000000005,0.035,0.069,True,,True,,True,Convenience,,,,,TotalAntibody,,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2022-02-16,Unverified,sciensano_prevalence_2022,BEL
220127_Belgium_Sciensano_21-22Jun2021,220127_Belgium_Sciensano_21-22Jun2021,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Belgium,2022-01-27,Institutional Report,National,Cross-sectional survey ,Belgium,,,"Blood donors from the Red Cross in Flanders, Belgium and blood donors from the Blood Services of the Red Cross in Wallonia and Brussels, Belgium. Blood donors are 18 to 75 years old in good health.",People with a possible/confirmed COVID-19 infection or who were in direct contact with a confirmed case are not allowed to donate blood for 28 days after symptoms resolve or after contact.,2021-06-21,2021-06-22,Blood donors,All,Multiple groups,18.0,75.0,Primary Estimate,,1199,0.787,0.7590000000000001,0.8150000000000001,True,,True,,True,Convenience,,,,,TotalAntibody,,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2022-02-16,Unverified,sciensano_prevalence_2022,BEL
220127_Belgium_Sciensano_21Dec2020,220127_Belgium_Sciensano_21Dec2020,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Belgium,2022-01-27,Institutional Report,National,Cross-sectional survey ,Belgium,,,"Blood donors from the Red Cross in Flanders, Belgium and blood donors from the Blood Services of the Red Cross in Wallonia and Brussels, Belgium. Blood donors are 18 to 75 years old in good health.",People with a possible/confirmed COVID-19 infection or who were in direct contact with a confirmed case are not allowed to donate blood for 28 days after symptoms resolve or after contact.,2020-12-21,2020-12-21,Blood donors,All,Multiple groups,18.0,75.0,Primary Estimate,,900,0.196,0.155,0.245,True,,True,,True,Convenience,,,,,TotalAntibody,,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2022-02-16,Unverified,sciensano_prevalence_2022,BEL
220127_Belgium_Sciensano_22-24Jun2020,220127_Belgium_Sciensano_22-24Jun2020,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Belgium,2022-01-27,Institutional Report,National,Cross-sectional survey ,Belgium,,,"Blood donors from the Red Cross in Flanders, Belgium and blood donors from the Blood Services of the Red Cross in Wallonia and Brussels, Belgium. Blood donors are 18 to 75 years old in good health.",People with a possible/confirmed COVID-19 infection or who were in direct contact with a confirmed case are not allowed to donate blood for 28 days after symptoms resolve or after contact.,2020-06-22,2020-06-24,Blood donors,All,Multiple groups,18.0,75.0,Primary Estimate,,900,0.059000000000000004,0.043,0.078,True,,True,,True,Convenience,,,,,TotalAntibody,,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2022-02-16,Unverified,sciensano_prevalence_2022,BEL
220127_Belgium_Sciensano_23-25Nov2020,220127_Belgium_Sciensano_23-25Nov2020,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Belgium,2022-01-27,Institutional Report,National,Cross-sectional survey ,Belgium,,,"Blood donors from the Red Cross in Flanders, Belgium and blood donors from the Blood Services of the Red Cross in Wallonia and Brussels, Belgium. Blood donors are 18 to 75 years old in good health.",People with a possible/confirmed COVID-19 infection or who were in direct contact with a confirmed case are not allowed to donate blood for 28 days after symptoms resolve or after contact.,2020-11-23,2020-11-25,Blood donors,All,Multiple groups,18.0,75.0,Primary Estimate,,900,0.16399999999999998,0.131,0.203,True,,True,,True,Convenience,,,,,TotalAntibody,,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2022-02-16,Unverified,sciensano_prevalence_2022,BEL
220127_Belgium_Sciensano_24-25May2021,220127_Belgium_Sciensano_24-25May2021,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Belgium,2022-01-27,Institutional Report,National,Cross-sectional survey ,Belgium,,,"Blood donors from the Red Cross in Flanders, Belgium and blood donors from the Blood Services of the Red Cross in Wallonia and Brussels, Belgium. Blood donors are 18 to 75 years old in good health.",People with a possible/confirmed COVID-19 infection or who were in direct contact with a confirmed case are not allowed to donate blood for 28 days after symptoms resolve or after contact.,2021-05-24,2021-05-25,Blood donors,All,Multiple groups,18.0,75.0,Primary Estimate,,1186,0.611,0.5750000000000001,0.6509999999999999,True,,True,,True,Convenience,,,,,TotalAntibody,,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2022-02-16,Unverified,sciensano_prevalence_2022,BEL
220127_Belgium_Sciensano_25-27May2020,220127_Belgium_Sciensano_25-27May2020,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Belgium,2022-01-27,Institutional Report,National,Cross-sectional survey ,Belgium,,,"Blood donors from the Red Cross in Flanders, Belgium and blood donors from the Blood Services of the Red Cross in Wallonia and Brussels, Belgium. Blood donors are 18 to 75 years old in good health.",People with a possible/confirmed COVID-19 infection or who were in direct contact with a confirmed case are not allowed to donate blood for 28 days after symptoms resolve or after contact.,2020-05-25,2020-05-27,Blood donors,All,Multiple groups,18.0,75.0,Primary Estimate,,900,0.055,0.038,0.07400000000000001,True,,True,,True,Convenience,,,,,TotalAntibody,,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2022-02-16,Unverified,sciensano_prevalence_2022,BEL
220127_Belgium_Sciensano_26-27Apr2021,220127_Belgium_Sciensano_26-27Apr2021,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Belgium,2022-01-27,Institutional Report,National,Cross-sectional survey ,Belgium,,,"Blood donors from the Red Cross in Flanders, Belgium and blood donors from the Blood Services of the Red Cross in Wallonia and Brussels, Belgium. Blood donors are 18 to 75 years old in good health.",People with a possible/confirmed COVID-19 infection or who were in direct contact with a confirmed case are not allowed to donate blood for 28 days after symptoms resolve or after contact.,2021-04-26,2021-04-27,Blood donors,All,Multiple groups,18.0,75.0,Primary Estimate,,1200,0.456,0.41200000000000003,0.503,True,,True,,True,Convenience,,,,,TotalAntibody,,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2022-02-16,Unverified,sciensano_prevalence_2022,BEL
220127_Belgium_Sciensano_26-28Oct2020,220127_Belgium_Sciensano_26-28Oct2020,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Belgium,2022-01-27,Institutional Report,National,Cross-sectional survey ,Belgium,,,"Blood donors from the Red Cross in Flanders, Belgium and blood donors from the Blood Services of the Red Cross in Wallonia and Brussels, Belgium. Blood donors are 18 to 75 years old in good health.",People with a possible/confirmed COVID-19 infection or who were in direct contact with a confirmed case are not allowed to donate blood for 28 days after symptoms resolve or after contact.,2020-10-26,2020-10-28,Blood donors,All,Multiple groups,18.0,75.0,Primary Estimate,,900,0.092,0.068,0.12,True,,True,,True,Convenience,,,,,TotalAntibody,,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2022-02-16,Unverified,sciensano_prevalence_2022,BEL
220127_Belgium_Sciensano_27-29Apr2020,220127_Belgium_Sciensano_27-29Apr2020,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Belgium,2022-01-27,Institutional Report,National,Cross-sectional survey ,Belgium,,,"Blood donors from the Red Cross in Flanders, Belgium and blood donors from the Blood Services of the Red Cross in Wallonia and Brussels, Belgium. Blood donors are 18 to 75 years old in good health.",People with a possible/confirmed COVID-19 infection or who were in direct contact with a confirmed case are not allowed to donate blood for 28 days after symptoms resolve or after contact.,2020-04-27,2020-04-29,Blood donors,All,Multiple groups,18.0,75.0,Primary Estimate,,900,0.05,0.034,0.067,True,,True,,True,Convenience,,,,,TotalAntibody,,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2022-02-16,Unverified,sciensano_prevalence_2022,BEL
220127_Belgium_Sciensano_28-30Sep2020,220127_Belgium_Sciensano_28-30Sep2020,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Belgium,2022-01-27,Institutional Report,National,Cross-sectional survey ,Belgium,,,"Blood donors from the Red Cross in Flanders, Belgium and blood donors from the Blood Services of the Red Cross in Wallonia and Brussels, Belgium. Blood donors are 18 to 75 years old in good health.",People with a possible/confirmed COVID-19 infection or who were in direct contact with a confirmed case are not allowed to donate blood for 28 days after symptoms resolve or after contact.,2020-09-28,2020-09-30,Blood donors,All,Multiple groups,18.0,75.0,Primary Estimate,,900,0.048,0.03,0.069,True,,True,,True,Convenience,,,,,TotalAntibody,,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2022-02-16,Unverified,sciensano_prevalence_2022,BEL
220127_Belgium_Sciensano_29-30Mar2021,220127_Belgium_Sciensano_29-30Mar2021,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Belgium,2022-01-27,Institutional Report,National,Cross-sectional survey ,Belgium,,,"Blood donors from the Red Cross in Flanders, Belgium and blood donors from the Blood Services of the Red Cross in Wallonia and Brussels, Belgium. Blood donors are 18 to 75 years old in good health.",People with a possible/confirmed COVID-19 infection or who were in direct contact with a confirmed case are not allowed to donate blood for 28 days after symptoms resolve or after contact.,2021-03-29,2021-03-30,Blood donors,All,Multiple groups,18.0,75.0,Primary Estimate,,1200,0.315,0.273,0.35600000000000004,True,,True,,True,Convenience,,,,,TotalAntibody,,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2022-02-16,Unverified,sciensano_prevalence_2022,BEL
220127_Belgium_Sciensano_3-5Aug2020,220127_Belgium_Sciensano_3-5Aug2020,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Belgium,2022-01-27,Institutional Report,National,Cross-sectional survey ,Belgium,,,"Blood donors from the Red Cross in Flanders, Belgium and blood donors from the Blood Services of the Red Cross in Wallonia and Brussels, Belgium. Blood donors are 18 to 75 years old in good health.",People with a possible/confirmed COVID-19 infection or who were in direct contact with a confirmed case are not allowed to donate blood for 28 days after symptoms resolve or after contact.,2020-08-03,2020-08-05,Blood donors,All,Multiple groups,18.0,75.0,Primary Estimate,,869,0.048,0.031000000000000003,0.066,True,,True,,True,Convenience,,,,,TotalAntibody,,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2022-02-16,Unverified,sciensano_prevalence_2022,BEL
220127_Belgium_Sciensano_31Aug-2Sep2020,220127_Belgium_Sciensano_31Aug-2Sep2020,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Belgium,2022-01-27,Institutional Report,National,Cross-sectional survey ,Belgium,,,"Blood donors from the Red Cross in Flanders, Belgium and blood donors from the Blood Services of the Red Cross in Wallonia and Brussels, Belgium. Blood donors are 18 to 75 years old in good health.",People with a possible/confirmed COVID-19 infection or who were in direct contact with a confirmed case are not allowed to donate blood for 28 days after symptoms resolve or after contact.,2020-08-31,2020-09-02,Blood donors,All,Multiple groups,18.0,75.0,Primary Estimate,,900,0.049,0.03,0.069,True,,True,,True,Convenience,,,,,TotalAntibody,,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2022-02-16,Unverified,sciensano_prevalence_2022,BEL
220127_Belgium_Sciensano_4-6Jan2021,220127_Belgium_Sciensano_4-6Jan2021,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Belgium,2022-01-27,Institutional Report,National,Cross-sectional survey ,Belgium,,,"Blood donors from the Red Cross in Flanders, Belgium and blood donors from the Blood Services of the Red Cross in Wallonia and Brussels, Belgium. Blood donors are 18 to 75 years old in good health.",People with a possible/confirmed COVID-19 infection or who were in direct contact with a confirmed case are not allowed to donate blood for 28 days after symptoms resolve or after contact.,2021-01-04,2021-01-06,Blood donors,All,Multiple groups,18.0,75.0,Primary Estimate,,1011,0.187,0.156,0.217,True,,True,,True,Convenience,,,,,TotalAntibody,,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2022-02-16,Unverified,sciensano_prevalence_2022,BEL
220127_Belgium_Sciensano_6-7Jul2020,220127_Belgium_Sciensano_6-7Jul2020,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Belgium,2022-01-27,Institutional Report,National,Cross-sectional survey ,Belgium,,,"Blood donors from the Red Cross in Flanders, Belgium and blood donors from the Blood Services of the Red Cross in Wallonia and Brussels, Belgium. Blood donors are 18 to 75 years old in good health.",People with a possible/confirmed COVID-19 infection or who were in direct contact with a confirmed case are not allowed to donate blood for 28 days after symptoms resolve or after contact.,2020-07-06,2020-07-07,Blood donors,All,Multiple groups,18.0,75.0,Primary Estimate,,900,0.057999999999999996,0.04,0.078,True,,True,,True,Convenience,,,,,TotalAntibody,,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2022-02-16,Unverified,sciensano_prevalence_2022,BEL
220127_Belgium_Sciensano_7-9Dec2020,220127_Belgium_Sciensano_7-9Dec2020,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Belgium,2022-01-27,Institutional Report,National,Cross-sectional survey ,Belgium,,,"Blood donors from the Red Cross in Flanders, Belgium and blood donors from the Blood Services of the Red Cross in Wallonia and Brussels, Belgium. Blood donors are 18 to 75 years old in good health.",People with a possible/confirmed COVID-19 infection or who were in direct contact with a confirmed case are not allowed to donate blood for 28 days after symptoms resolve or after contact.,2020-12-07,2020-12-09,Blood donors,All,Multiple groups,18.0,75.0,Primary Estimate,,900,0.187,0.149,0.228,True,,True,,True,Convenience,,,,,TotalAntibody,,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2022-02-16,Unverified,sciensano_prevalence_2022,BEL
220127_Belgium_Sciensano_8-10Jun2020,220127_Belgium_Sciensano_8-10Jun2020,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Belgium,2022-01-27,Institutional Report,National,Cross-sectional survey ,Belgium,,,"Blood donors from the Red Cross in Flanders, Belgium and blood donors from the Blood Services of the Red Cross in Wallonia and Brussels, Belgium. Blood donors are 18 to 75 years old in good health.",People with a possible/confirmed COVID-19 infection or who were in direct contact with a confirmed case are not allowed to donate blood for 28 days after symptoms resolve or after contact.,2020-06-08,2020-06-10,Blood donors,All,Multiple groups,18.0,75.0,Primary Estimate,,900,0.045,0.03,0.061,True,,True,,True,Convenience,,,,,TotalAntibody,,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2022-02-16,Unverified,sciensano_prevalence_2022,BEL
220127_Belgium_Sciensano_9-11Nov2020,220127_Belgium_Sciensano_9-11Nov2020,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Belgium,2022-01-27,Institutional Report,National,Cross-sectional survey ,Belgium,,,"Blood donors from the Red Cross in Flanders, Belgium and blood donors from the Blood Services of the Red Cross in Wallonia and Brussels, Belgium. Blood donors are 18 to 75 years old in good health.",People with a possible/confirmed COVID-19 infection or who were in direct contact with a confirmed case are not allowed to donate blood for 28 days after symptoms resolve or after contact.,2020-11-09,2020-11-11,Blood donors,All,Multiple groups,18.0,75.0,Primary Estimate,,900,0.136,0.106,0.167,True,,True,,True,Convenience,,,,,TotalAntibody,,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2022-02-16,Unverified,sciensano_prevalence_2022,BEL
220127_Flanders_Sciensano_30Mar2020,220127_Flanders_Sciensano_30Mar2020,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Belgium,2022-01-27,Institutional Report,Regional,Cross-sectional survey ,Belgium,Flanders (Flemish region),,"Blood donors from the Red Cross in Flanders, Belgium. 
Blood donors are 18 to 75 years old in good health.",People with a possible/confirmed COVID-19 infection or who were in direct contact with a confirmed case are not allowed to donate blood for 28 days after symptoms resolve or after contact.,2020-03-30,2020-03-30,Blood donors,All,Multiple groups,18.0,75.0,Primary Estimate,,584,0.02,0.006,0.035,True,,True,,True,Convenience,,,,,TotalAntibody,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Sciensano,Sciensano,Not Unity-Aligned,https://datastudio.google.com/embed/u/0/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB,2022-02-16,2022-02-16,Unverified,sciensano_prevalence_2022,BEL
220302_Flanders_GhentUniversity_Residents,220302_Flanders_GhentUniversity_Residents,Pre-vaccination SARS-CoV-2 seroprevalence among staff and residents of nursing homes in Flanders (Belgium) in fall 2020.,2022-03-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Belgium,Region of Flanders,,Residents and staff of nursing homes in Flanders,"""For the residents, those living in assisted living facilities were excluded.""",2020-10-19,2020-11-13,Assisted living and long-term care facilities,All,Seniors (65+ years),,,Primary Estimate,,615,0.189,0.159,0.222,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Heidi Janssens,Ghent University,Not Unity-Aligned,https://dx.doi.org/10.1017/S095026882200036X,2022-03-09,2024-03-01,Unverified,janssens_pre-vaccination_2022,BEL
220302_Flanders_GhentUniversity_Staff,220302_Flanders_GhentUniversity_Staff,Pre-vaccination SARS-CoV-2 seroprevalence among staff and residents of nursing homes in Flanders (Belgium) in fall 2020.,2022-03-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Belgium,Region of Flanders,,Residents and staff of nursing homes in Flanders,"""For the staff members, there were no exclusion criteria.""",2020-10-19,2020-11-13,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,478,0.149,0.11900000000000001,0.184,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Heidi Janssens,Ghent University,Not Unity-Aligned,https://dx.doi.org/10.1017/S095026882200036X,2022-03-09,2024-03-01,Unverified,janssens_pre-vaccination_2022,BEL
220306_Belgium_UniversityofAntwerp_c1_OverallPopAdj,220306_Belgium_UniversityofAntwerp_c1,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-03-30,2020-04-05,Residual sera,All,Multiple groups,0.0,101.0,Primary Estimate,,3910,0.0183,0.01,0.026099999999999998,True,True,True,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c1_Age20-29,220306_Belgium_UniversityofAntwerp_c1,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-03-30,2020-04-05,Residual sera,All,Adults (18-64 years),20.0,30.0,Age,20-29,436,0.0058,0.0003,0.02,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c1_Age30-39,220306_Belgium_UniversityofAntwerp_c1,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-03-30,2020-04-05,Residual sera,All,Adults (18-64 years),30.0,40.0,Age,30-39,461,0.018000000000000002,0.0045000000000000005,0.0369,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c1_Age0-9,220306_Belgium_UniversityofAntwerp_c1,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-03-30,2020-04-05,Residual sera,All,Children and Youth (0-17 years),0.0,10.0,Age,0-9,39,0.058600000000000006,0.0175,0.12150000000000001,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c1_Age90+,220306_Belgium_UniversityofAntwerp_c1,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-03-30,2020-04-05,Residual sera,All,Seniors (65+ years),90.0,101.0,Age,90+,211,0.023799999999999998,0.0009,0.0978,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c1_Age60-69,220306_Belgium_UniversityofAntwerp_c1,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-03-30,2020-04-05,Residual sera,All,Seniors (65+ years),60.0,70.0,Age,,507,0.0191,0.0048,0.0391,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c1_Age70-79,220306_Belgium_UniversityofAntwerp_c1,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-03-30,2020-04-05,Residual sera,All,Seniors (65+ years),70.0,80.0,Age,70-79,506,0.0209,0.0043,0.0455,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c1_SexMale,220306_Belgium_UniversityofAntwerp_c1,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-03-30,2020-04-05,Residual sera,Male,Multiple groups,0.0,101.0,Sex/Gender,,1799,0.0219,0.0125,0.0322,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c1_Age50-59,220306_Belgium_UniversityofAntwerp_c1,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-03-30,2020-04-05,Residual sera,All,Adults (18-64 years),50.0,60.0,Age,,498,0.037200000000000004,0.02,0.05940000000000001,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c1_Age40-49,220306_Belgium_UniversityofAntwerp_c1,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-03-30,2020-04-05,Residual sera,All,Adults (18-64 years),40.0,50.0,Age,,468,0.0216,0.0072,0.0412,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c1_Age80-89,220306_Belgium_UniversityofAntwerp_c1,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-03-30,2020-04-05,Residual sera,All,Seniors (65+ years),80.0,90.0,Age,80-89,493,0.015300000000000001,0.0012,0.0447,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c1_SexFemale,220306_Belgium_UniversityofAntwerp_c1,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-03-30,2020-04-05,Residual sera,Female,Multiple groups,0.0,101.0,Sex/Gender,,2111,0.0159,0.0069,0.025400000000000002,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c1_Age10-19,220306_Belgium_UniversityofAntwerp_c1,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-03-30,2020-04-05,Residual sera,All,Children and Youth (0-17 years),10.0,20.0,Age,10-19,294,0.016200000000000003,0.0025,0.037000000000000005,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c2_OverallPopAdj,220306_Belgium_UniversityofAntwerp_c2,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-04-20,2020-04-26,Residual sera,All,Multiple groups,0.0,101.0,Primary Estimate,,3397,0.0525,0.0422,0.0635,True,True,True,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c2_SexFemale,220306_Belgium_UniversityofAntwerp_c2,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-04-20,2020-04-26,Residual sera,Female,Multiple groups,0.0,101.0,Sex/Gender,,1798,0.0402,0.0286,0.05280000000000001,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c2_Age70-79,220306_Belgium_UniversityofAntwerp_c2,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-04-20,2020-04-26,Residual sera,All,Seniors (65+ years),70.0,80.0,Age,70-79,316,0.0379,0.0141,0.07150000000000001,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c2_Age40-49,220306_Belgium_UniversityofAntwerp_c2,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-04-20,2020-04-26,Residual sera,All,Adults (18-64 years),40.0,50.0,Age,,406,0.057800000000000004,0.0349,0.0868,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c2_Age50-59,220306_Belgium_UniversityofAntwerp_c2,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-04-20,2020-04-26,Residual sera,All,Adults (18-64 years),50.0,60.0,Age,,430,0.0667,0.042699999999999995,0.09570000000000001,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c2_Age0-9,220306_Belgium_UniversityofAntwerp_c2,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-04-20,2020-04-26,Residual sera,All,Children and Youth (0-17 years),0.0,10.0,Age,0-9,85,0.0466,0.0195,0.08410000000000001,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c2_Age60-69,220306_Belgium_UniversityofAntwerp_c2,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-04-20,2020-04-26,Residual sera,All,Seniors (65+ years),60.0,70.0,Age,,426,0.0313,0.012700000000000001,0.056600000000000004,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c2_Age80-89,220306_Belgium_UniversityofAntwerp_c2,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-04-20,2020-04-26,Residual sera,All,Seniors (65+ years),80.0,90.0,Age,80-89,315,0.08470000000000001,0.0429,0.1416,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c2_Age20-29,220306_Belgium_UniversityofAntwerp_c2,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-04-20,2020-04-26,Residual sera,All,Adults (18-64 years),20.0,30.0,Age,20-29,375,0.0714,0.044500000000000005,0.10490000000000001,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c2_Age10-19,220306_Belgium_UniversityofAntwerp_c2,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-04-20,2020-04-26,Residual sera,All,Children and Youth (0-17 years),10.0,20.0,Age,10-19,442,0.045899999999999996,0.023700000000000002,0.0748,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c2_Age90+,220306_Belgium_UniversityofAntwerp_c2,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-04-20,2020-04-26,Residual sera,All,Seniors (65+ years),90.0,101.0,Age,90+,195,0.1552,0.0564,0.3024,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c2_SexMale,220306_Belgium_UniversityofAntwerp_c2,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-04-20,2020-04-26,Residual sera,Male,Multiple groups,0.0,101.0,Sex/Gender,,1599,0.0661,0.0518,0.08130000000000001,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c2_Age30-39,220306_Belgium_UniversityofAntwerp_c2,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-04-20,2020-04-26,Residual sera,All,Adults (18-64 years),30.0,40.0,Age,30-39,407,0.0495,0.0279,0.0762,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c3_OverallPopAdj,220306_Belgium_UniversityofAntwerp_c3,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-05-18,2020-05-25,Residual sera,All,Multiple groups,0.0,101.0,Primary Estimate,,3242,0.062000000000000006,0.050499999999999996,0.0731,True,True,True,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c3_Age50-59,220306_Belgium_UniversityofAntwerp_c3,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-05-18,2020-05-25,Residual sera,All,Adults (18-64 years),50.0,60.0,Age,,419,0.051500000000000004,0.0296,0.0795,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c3_Age80-89,220306_Belgium_UniversityofAntwerp_c3,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-05-18,2020-05-25,Residual sera,All,Seniors (65+ years),80.0,90.0,Age,80-89,163,0.0717,0.0311,0.12810000000000002,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c3_Age70-79,220306_Belgium_UniversityofAntwerp_c3,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-05-18,2020-05-25,Residual sera,All,Seniors (65+ years),70.0,80.0,Age,70-79,236,0.0313,0.009000000000000001,0.0646,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c3_Age20-29,220306_Belgium_UniversityofAntwerp_c3,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-05-18,2020-05-25,Residual sera,All,Adults (18-64 years),20.0,30.0,Age,20-29,414,0.0844,0.0553,0.1199,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c3_SexFemale,220306_Belgium_UniversityofAntwerp_c3,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-05-18,2020-05-25,Residual sera,Female,Multiple groups,0.0,101.0,Sex/Gender,,1655,0.0641,0.049800000000000004,0.0791,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c3_Age40-49,220306_Belgium_UniversityofAntwerp_c3,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-05-18,2020-05-25,Residual sera,All,Adults (18-64 years),40.0,50.0,Age,,411,0.0801,0.0534,0.1131,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c3_SexMale,220306_Belgium_UniversityofAntwerp_c3,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-05-18,2020-05-25,Residual sera,Male,Multiple groups,0.0,101.0,Sex/Gender,,1587,0.0605,0.0468,0.0757,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c3_Age10-19,220306_Belgium_UniversityofAntwerp_c3,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-05-18,2020-05-25,Residual sera,All,Children and Youth (0-17 years),10.0,20.0,Age,10-19,431,0.049800000000000004,0.025099999999999997,0.0818,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c3_Age0-9,220306_Belgium_UniversityofAntwerp_c3,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-05-18,2020-05-25,Residual sera,All,Children and Youth (0-17 years),0.0,10.0,Age,0-9,174,0.107,0.0722,0.1493,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c3_Age30-39,220306_Belgium_UniversityofAntwerp_c3,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-05-18,2020-05-25,Residual sera,All,Adults (18-64 years),30.0,40.0,Age,30-39,424,0.0626,0.0371,0.0943,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c3_Age90+,220306_Belgium_UniversityofAntwerp_c3,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-05-18,2020-05-25,Residual sera,All,Seniors (65+ years),90.0,101.0,Age,90+,153,0.1187,0.030699999999999998,0.267,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c3_Age60-69,220306_Belgium_UniversityofAntwerp_c3,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-05-18,2020-05-25,Residual sera,All,Seniors (65+ years),60.0,70.0,Age,,417,0.0329,0.0129,0.0605,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c4_OverallPopAdj,220306_Belgium_UniversityofAntwerp_c4,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-06-08,2020-06-13,Residual sera,All,Multiple groups,0.0,101.0,Primary Estimate,,2960,0.047400000000000005,0.0365,0.058499999999999996,True,True,True,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c4_Age60-69,220306_Belgium_UniversityofAntwerp_c4,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-06-08,2020-06-13,Residual sera,All,Seniors (65+ years),60.0,70.0,Age,,399,0.0468,0.0222,0.0786,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c4_Age70-79,220306_Belgium_UniversityofAntwerp_c4,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-06-08,2020-06-13,Residual sera,All,Seniors (65+ years),70.0,80.0,Age,70-79,201,0.013600000000000001,0.001,0.0418,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c4_SexMale,220306_Belgium_UniversityofAntwerp_c4,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-06-08,2020-06-13,Residual sera,Male,Multiple groups,0.0,101.0,Sex/Gender,,1425,0.055099999999999996,0.0412,0.0708,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c4_Age30-39,220306_Belgium_UniversityofAntwerp_c4,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-06-08,2020-06-13,Residual sera,All,Adults (18-64 years),30.0,40.0,Age,30-39,395,0.0441,0.022000000000000002,0.0726,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c4_Age50-59,220306_Belgium_UniversityofAntwerp_c4,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-06-08,2020-06-13,Residual sera,All,Adults (18-64 years),50.0,60.0,Age,,393,0.061500000000000006,0.0366,0.09330000000000001,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c4_Age0-9,220306_Belgium_UniversityofAntwerp_c4,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-06-08,2020-06-13,Residual sera,All,Children and Youth (0-17 years),0.0,10.0,Age,0-9,124,0.028900000000000002,0.0088,0.0582,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c4_Age20-29,220306_Belgium_UniversityofAntwerp_c4,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-06-08,2020-06-13,Residual sera,All,Adults (18-64 years),20.0,30.0,Age,20-29,383,0.0707,0.0431,0.1057,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c4_Age10-19,220306_Belgium_UniversityofAntwerp_c4,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-06-08,2020-06-13,Residual sera,All,Children and Youth (0-17 years),10.0,20.0,Age,10-19,375,0.0709,0.042699999999999995,0.1091,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c4_Age90+,220306_Belgium_UniversityofAntwerp_c4,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-06-08,2020-06-13,Residual sera,All,Seniors (65+ years),90.0,101.0,Age,90+,130,0.0844,0.0113,0.22920000000000001,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c4_SexFemale,220306_Belgium_UniversityofAntwerp_c4,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-06-08,2020-06-13,Residual sera,Female,Multiple groups,0.0,101.0,Sex/Gender,,1535,0.0409,0.0286,0.0546,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c4_Age40-49,220306_Belgium_UniversityofAntwerp_c4,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-06-08,2020-06-13,Residual sera,All,Adults (18-64 years),40.0,50.0,Age,,394,0.0581,0.033,0.08960000000000001,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c4_Age80-89,220306_Belgium_UniversityofAntwerp_c4,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-06-08,2020-06-13,Residual sera,All,Seniors (65+ years),80.0,90.0,Age,80-89,166,0.022000000000000002,0.0019,0.0658,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c5_OverallPopAdj,220306_Belgium_UniversityofAntwerp_c5,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-06-29,2020-07-04,Residual sera,All,Multiple groups,0.0,101.0,Primary Estimate,,3023,0.0366,0.026400000000000003,0.047,True,True,True,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c5_Age90+,220306_Belgium_UniversityofAntwerp_c5,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-06-29,2020-07-04,Residual sera,All,Seniors (65+ years),90.0,101.0,Age,90+,140,0.0723,0.0078000000000000005,0.2059,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c5_Age30-39,220306_Belgium_UniversityofAntwerp_c5,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-06-29,2020-07-04,Residual sera,All,Adults (18-64 years),30.0,40.0,Age,30-39,396,0.0509,0.027700000000000002,0.0817,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c5_Age10-19,220306_Belgium_UniversityofAntwerp_c5,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-06-29,2020-07-04,Residual sera,All,Children and Youth (0-17 years),10.0,20.0,Age,10-19,413,0.0858,0.054400000000000004,0.1241,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c5_SexFemale,220306_Belgium_UniversityofAntwerp_c5,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-06-29,2020-07-04,Residual sera,Female,Multiple groups,0.0,101.0,Sex/Gender,,1552,0.028900000000000002,0.0176,0.040999999999999995,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c5_Age20-29,220306_Belgium_UniversityofAntwerp_c5,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-06-29,2020-07-04,Residual sera,All,Adults (18-64 years),20.0,30.0,Age,20-29,394,0.06559999999999999,0.037700000000000004,0.10070000000000001,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c5_SexMale,220306_Belgium_UniversityofAntwerp_c5,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-06-29,2020-07-04,Residual sera,Male,Multiple groups,0.0,101.0,Sex/Gender,,1471,0.045599999999999995,0.033,0.060300000000000006,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c5_Age50-59,220306_Belgium_UniversityofAntwerp_c5,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-06-29,2020-07-04,Residual sera,All,Adults (18-64 years),50.0,60.0,Age,,400,0.03,0.0117,0.055400000000000005,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c5_Age70-79,220306_Belgium_UniversityofAntwerp_c5,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-06-29,2020-07-04,Residual sera,All,Seniors (65+ years),70.0,80.0,Age,70-79,204,0.0196,0.0023,0.050499999999999996,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c5_Age60-69,220306_Belgium_UniversityofAntwerp_c5,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-06-29,2020-07-04,Residual sera,All,Seniors (65+ years),60.0,70.0,Age,,403,0.0124,0.0011,0.034300000000000004,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c5_Age40-49,220306_Belgium_UniversityofAntwerp_c5,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-06-29,2020-07-04,Residual sera,All,Adults (18-64 years),40.0,50.0,Age,,403,0.0189,0.0043,0.0421,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c5_Age80-89,220306_Belgium_UniversityofAntwerp_c5,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-06-29,2020-07-04,Residual sera,All,Seniors (65+ years),80.0,90.0,Age,80-89,160,0.0258,0.0031,0.0699,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c5_Age0-9,220306_Belgium_UniversityofAntwerp_c5,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-06-29,2020-07-04,Residual sera,All,Children and Youth (0-17 years),0.0,10.0,Age,0-9,110,0.0311,0.0098,0.0616,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c6_OverallPopAdj,220306_Belgium_UniversityofAntwerp_c6,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-09-07,2020-09-12,Residual sera,All,Multiple groups,0.0,101.0,Primary Estimate,,3047,0.032799999999999996,0.0229,0.0432,True,True,True,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c6_Age60-69,220306_Belgium_UniversityofAntwerp_c6,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-09-07,2020-09-12,Residual sera,All,Seniors (65+ years),60.0,70.0,Age,,403,0.024900000000000002,0.0070999999999999995,0.049100000000000005,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c6_Age80-89,220306_Belgium_UniversityofAntwerp_c6,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-09-07,2020-09-12,Residual sera,All,Seniors (65+ years),80.0,90.0,Age,80-89,167,0.015,0.0009,0.0519,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c6_Age10-19,220306_Belgium_UniversityofAntwerp_c6,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-09-07,2020-09-12,Residual sera,All,Children and Youth (0-17 years),10.0,20.0,Age,10-19,432,0.0229,0.005200000000000001,0.04820000000000001,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c6_Age0-9,220306_Belgium_UniversityofAntwerp_c6,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-09-07,2020-09-12,Residual sera,All,Children and Youth (0-17 years),0.0,10.0,Age,0-9,68,0.0608,0.0268,0.1076,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c6_SexMale,220306_Belgium_UniversityofAntwerp_c6,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-09-07,2020-09-12,Residual sera,Male,Multiple groups,0.0,101.0,Sex/Gender,,1500,0.0305,0.0191,0.0434,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c6_SexFemale,220306_Belgium_UniversityofAntwerp_c6,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-09-07,2020-09-12,Residual sera,Female,Multiple groups,0.0,101.0,Sex/Gender,,1547,0.0365,0.0244,0.0493,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c6_Age40-49,220306_Belgium_UniversityofAntwerp_c6,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-09-07,2020-09-12,Residual sera,All,Adults (18-64 years),40.0,50.0,Age,,399,0.0644,0.0391,0.0959,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c6_Age50-59,220306_Belgium_UniversityofAntwerp_c6,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-09-07,2020-09-12,Residual sera,All,Adults (18-64 years),50.0,60.0,Age,,402,0.029300000000000003,0.0116,0.0534,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c6_Age20-29,220306_Belgium_UniversityofAntwerp_c6,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-09-07,2020-09-12,Residual sera,All,Adults (18-64 years),20.0,30.0,Age,20-29,406,0.0646,0.038700000000000005,0.0986,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c6_Age90+,220306_Belgium_UniversityofAntwerp_c6,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-09-07,2020-09-12,Residual sera,All,Seniors (65+ years),90.0,101.0,Age,90+,162,0.084,0.0134,0.2181,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c6_Age70-79,220306_Belgium_UniversityofAntwerp_c6,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-09-07,2020-09-12,Residual sera,All,Seniors (65+ years),70.0,80.0,Age,70-79,212,0.011200000000000002,0.0006,0.036000000000000004,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c6_Age30-39,220306_Belgium_UniversityofAntwerp_c6,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-09-07,2020-09-12,Residual sera,All,Adults (18-64 years),30.0,40.0,Age,30-39,396,0.0166,0.0028000000000000004,0.038700000000000005,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c7_OverallPopAdj,220306_Belgium_UniversityofAntwerp_c7,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-10-12,2020-10-17,Residual sera,All,Multiple groups,0.0,101.0,Primary Estimate,,2966,0.0418,0.031200000000000002,0.052000000000000005,True,True,True,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c7_Age40-49,220306_Belgium_UniversityofAntwerp_c7,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-10-12,2020-10-17,Residual sera,All,Adults (18-64 years),40.0,50.0,Age,,397,0.0422,0.0215,0.07110000000000001,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c7_Age90+,220306_Belgium_UniversityofAntwerp_c7,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-10-12,2020-10-17,Residual sera,All,Seniors (65+ years),90.0,101.0,Age,90+,127,0.09820000000000001,0.0166,0.24300000000000002,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c7_Age10-19,220306_Belgium_UniversityofAntwerp_c7,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-10-12,2020-10-17,Residual sera,All,Children and Youth (0-17 years),10.0,20.0,Age,10-19,405,0.0396,0.0177,0.0701,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c7_Age70-79,220306_Belgium_UniversityofAntwerp_c7,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-10-12,2020-10-17,Residual sera,All,Seniors (65+ years),70.0,80.0,Age,70-79,204,0.0336,0.0101,0.067,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c7_Age60-69,220306_Belgium_UniversityofAntwerp_c7,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-10-12,2020-10-17,Residual sera,All,Seniors (65+ years),60.0,70.0,Age,,406,0.0095,0.0006,0.029900000000000003,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c7_Age0-9,220306_Belgium_UniversityofAntwerp_c7,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-10-12,2020-10-17,Residual sera,All,Children and Youth (0-17 years),0.0,10.0,Age,0-9,68,0.0625,0.0285,0.1103,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c7_Age80-89,220306_Belgium_UniversityofAntwerp_c7,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-10-12,2020-10-17,Residual sera,All,Seniors (65+ years),80.0,90.0,Age,80-89,160,0.0246,0.0021,0.06910000000000001,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c7_SexMale,220306_Belgium_UniversityofAntwerp_c7,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-10-12,2020-10-17,Residual sera,Male,Multiple groups,0.0,101.0,Sex/Gender,,1377,0.0351,0.0226,0.04820000000000001,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c7_Age50-59,220306_Belgium_UniversityofAntwerp_c7,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-10-12,2020-10-17,Residual sera,All,Adults (18-64 years),50.0,60.0,Age,,400,0.0404,0.0189,0.0676,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c7_Age30-39,220306_Belgium_UniversityofAntwerp_c7,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-10-12,2020-10-17,Residual sera,All,Adults (18-64 years),30.0,40.0,Age,30-39,397,0.05740000000000001,0.0329,0.0888,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c7_SexFemale,220306_Belgium_UniversityofAntwerp_c7,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-10-12,2020-10-17,Residual sera,Female,Multiple groups,0.0,101.0,Sex/Gender,,1589,0.049100000000000005,0.0357,0.06420000000000001,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220306_Belgium_UniversityofAntwerp_c7_Age20-29,220306_Belgium_UniversityofAntwerp_c7,"Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020",2022-03-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Belgium,,,"Residual samples in this study originated from ambulatory patients (including people living in nursing homes) visiting their doctor (mainly general practitioners) for any reason including primary care, routine check-up or follow-up of pathology at several large laboratories accross the country.","To avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19, samples originating from hospitals and triage centers were excluded from the study",2020-10-12,2020-10-17,Residual sera,All,Adults (18-64 years),20.0,30.0,Age,20-29,402,0.0776,0.0493,0.1127,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.9870000000000001,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Sereina Herzog,University of Antwerp,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419,2022-03-22,2023-08-15,Unverified,herzog_seroprevalence_2022,BEL
220325_Liege_CHUofLiege_Phase2,220325_Liege_CHUofLiege_Phase2,Long-term longitudinal evaluation of the prevalence of SARS-CoV-2 antibodies in healthcare and university workers.,2022-03-25,Journal Article (Peer-Reviewed),Local,Prospective cohort,Belgium,,Liege,"Workers of the University Hospital Center (CHU) of Liège across all
sites and of the University of Liège (ULiège) on the Sart-Tilman site were invited to participate","When
suspected of COVID-19 within 14 days before testing",2020-05-21,2020-06-21,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,3187,0.099,,,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by manufacturers,,0.993,['High'],,No,Yes,No,,Yes,Yes,Yes,,Pascale Huynen,CHU of Liege,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09215-8,2022-04-04,2024-03-01,Unverified,huynen_long-term_2022,BEL
220325_Liege_CHUofLiege_Phase3,220325_Liege_CHUofLiege_Phase3,Long-term longitudinal evaluation of the prevalence of SARS-CoV-2 antibodies in healthcare and university workers.,2022-03-25,Journal Article (Peer-Reviewed),Local,Prospective cohort,Belgium,,Liege,"Workers of the University Hospital Center (CHU) of Liège across all
sites and of the University of Liège (ULiège) on the Sart-Tilman site were invited to participate","When
suspected of COVID-19 within 14 days before testing",2020-07-05,2020-08-05,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,2498,0.115,,,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by manufacturers,,0.993,['High'],,No,Yes,No,,Yes,Yes,Yes,,Pascale Huynen,CHU of Liege,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09215-8,2022-04-04,2024-03-01,Unverified,huynen_long-term_2022,BEL
220401_Belgium_UniversityHospitalsLeuven_antiN/S,220401_Belgium_UniversityHospitalsLeuven,"Liver or Kidney Transplantation After SARS-CoV-2 Infection: Prevalence, Short-term Outcome, and Kinetics of Serum IgG Antibodies",2022-04-01,Journal Article (Peer-Reviewed),Local,Prospective cohort,Belgium,Flemish Brabant,Leuven,"All patients receiving a liver or kidney transplantation at University Hospitals Leuven between May 1, 2020, and March 18, 2021, were included in this study",,2020-05-01,2021-03-18,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,168,0.054000000000000006,,,True,,,,True,Entire sample,"SARS-CoV-2 IgG II Quant ,Abbott Architect SARS-CoV-2 IgG",Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Missing'],,Yes,No,No,,Yes,Yes,No,,Jef Verbeek,University Hospitals Leuven,Not Unity-Aligned,https://journals.lww.com/transplantjournal/Fulltext/2022/04000/Liver_or_Kidney_Transplantation_After_SARS_CoV_2.29.aspx,2022-04-11,2024-03-01,Unverified,verbeek_liver_2022,BEL
220613_Liege_CHUofLiege_Phase1_Overall,220613_Liege_CHUofLiege_Phase1,Predictive factors for the presence and long-term persistence of SARS-CoV-2 antibodies in healthcare and university workers,2022-06-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Belgium,,Liege,"Based on another article of the same study (https://airtable.com/appFfYIupTrVQ0HJx/tbl9ldV2170ox2BWJ/viwebfDZuM4u8mSwH/recoCT3RvB4Y0eAKx?blocks=hide):

""Workers of the University Hospital Center (CHU) of Liège across all
sites and of the University of Liège (ULiège) on the Sart-Tilman site were invited to participate.""","Based on another article of the same study (https://airtable.com/appFfYIupTrVQ0HJx/tbl9ldV2170ox2BWJ/viwebfDZuM4u8mSwH/recoCT3RvB4Y0eAKx?blocks=hide):

""When suspected of COVID-19 within 14 days before testing"".",2020-04-06,2020-05-05,Multiple populations,All,Multiple groups,20.1,81.3,Primary Estimate,,3776,0.08900000000000001,,,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,1.0,0.9790000000000001,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Celine Gregoire,CHU of Liege,Not Unity-Aligned,https://doi.org/10.1038/s41598-022-13450-4,2022-06-20,2024-03-01,Unverified,gregoire_predictive_2022,BEL
220713_Belgium_UCLouvain_Children,220713_Belgium_UCLouvain_Children,SARS-CoV-2 antibody seroprevalence in children and workers from Belgian French-speaking primary schools,2022-07-13,Preprint,Regional,Cross-sectional survey ,Belgium,Wallonia and Brussels-Capital Regions,Angleur; Berchem-Ste Agathe; Jette; Koekelberg; Herve; Seraing; Beauraing; Châtelineau; La Hulpe; Farciennes,"School children (6-12 years) ""in primary schools of the Federation Wallonia Brussels in Belgium.""

""Participants were enrolled into the study if the consent was signed by both parents and the child or by the school staff.""","""Among the 8 schools initially selected, 2 schools were excluded from the study because of a refusal from the school principal in one and a high refusal rate of children and parents (up to 40%) in the other one. Five additional schools were then proposed, leading to 11 schools enrolled in the study (among the 13 invited schools).""",2021-01-14,2021-05-18,Students and Daycares,All,Children and Youth (0-17 years),6.0,12.0,Primary Estimate,,922,0.2126,,,True,,,,True,Stratified non-probability,Novel Coronavirus (2019-nCov) Antibody IgG/IgM Assay Kit (Colloidal Gold),"Avioq Bio-Tech, Shandong, China",LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.688,0.958,['High'],,No,Yes,No,,Unclear,Yes,No,,Kelly Cremer,Université catholique de Louvain (UCLouvain),Not Unity-Aligned,https://doi.org/10.21203/rs.3.rs-1781857/v1,2022-07-18,2022-07-19,Unverified,cremer_sars-cov-2_2022,BEL
220713_Belgium_UCLouvain_SchoolStaff,220713_Belgium_UCLouvain_SchoolStaff,SARS-CoV-2 antibody seroprevalence in children and workers from Belgian French-speaking primary schools,2022-07-13,Preprint,Regional,Cross-sectional survey ,Belgium,Wallonia and Brussels-Capital Regions,Angleur; Berchem-Ste Agathe; Jette; Koekelberg; Herve; Seraing; Beauraing; Châtelineau; La Hulpe; Farciennes,"School staff ""in primary schools of the Federation Wallonia Brussels in Belgium.""

""Participants were enrolled into the study if the consent was signed by both parents and the child or by the school staff.""","""Among the 8 schools initially selected, 2 schools were excluded from the study because of a refusal from the school principal in one and a high refusal rate of children and parents (up to 40%) in the other one. Five additional schools were then proposed, leading to 11 schools enrolled in the study (among the 13 invited schools).""",2021-01-14,2021-05-18,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,240,0.2833,,,True,,,,True,Stratified non-probability,Novel Coronavirus (2019-nCov) Antibody IgG/IgM Assay Kit (Colloidal Gold),"Avioq Bio-Tech, Shandong, China",LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.688,0.958,['High'],,No,No,No,,Unclear,Yes,No,,Kelly Cremer,Université catholique de Louvain (UCLouvain),Not Unity-Aligned,https://doi.org/10.21203/rs.3.rs-1781857/v1,2022-07-18,2022-07-19,Unverified,cremer_sars-cov-2_2022,BEL
220714_Charleroi_GrandHopitalDeCharleroi_Summer2020_Overall,220714_Charleroi_GrandHopitalDeCharleroi_Summer2020,SARS-CoV-2 Seroprevalence among Healthcare Workers after the First and Second Pandemic Waves.,2022-07-14,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Belgium,Walloon Region,Charleroi,"""all HCWs at the Grand Hôpital de Charleroi were invited to participate in this monocentric cross-sectional study.""

""After having given their consent, all participants were asked to fill out a questionnaire"".",,2020-06-20,2020-08-11,Health care workers and caregivers,All,Multiple groups,18.0,79.0,Primary Estimate,,2817,0.1072,0.09630000000000001,0.1192,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Nathalie de Visscher,Grand Hôpital de Charleroi,Not Unity-Aligned,https://dx.doi.org/10.3390/v14071535,2022-08-03,2024-03-01,Unverified,de_visscher_sars-cov-2_2022,BEL
220714_Charleroi_GrandHopitalDeCharleroi_Winter2021_Overall,220714_Charleroi_GrandHopitalDeCharleroi_Winter2021,SARS-CoV-2 Seroprevalence among Healthcare Workers after the First and Second Pandemic Waves.,2022-07-14,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Belgium,Walloon Region,Charleroi,"""all HCWs at the Grand Hôpital de Charleroi were invited to participate in this monocentric cross-sectional study.""

""After having given their consent, all participants were asked to fill out a questionnaire"".",,2021-02-06,2021-03-31,Health care workers and caregivers,All,Multiple groups,18.0,79.0,Primary Estimate,,1191,0.3392,0.3129,0.3666,True,,,,True,Convenience,LIAISON® SARS-CoV-2 TrimericS IgG,DiaSorin,,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Nathalie de Visscher,Grand Hôpital de Charleroi,Not Unity-Aligned,https://dx.doi.org/10.3390/v14071535,2022-08-03,2024-03-01,Unverified,de_visscher_sars-cov-2_2022,BEL
220808_Liege_UniversityOfLiegeHospital_Period1_Primary,220808_Liege_UniversityOfLiegeHospital_Period1,The prospective screening for SARS-CoV-2 S1/S2 antibodies delineates the factual incidence of COVID-19 and shows a sustained serological response post COVID-19 in kidney transplant recipients.,2022-08-08,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Belgium,Wallonia,Liege,"All KTRs followed at our center were invited to participate in this study during their outpatient
appointment",,2020-03-01,2020-09-30,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,,Primary Estimate,,525,0.0286,,,True,,,,True,Sequential,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.89,0.978,['High'],,No,No,No,,Yes,Yes,No,,Louis Firket,University of Liege Hospital,Not Unity-Aligned,https://dx.doi.org/10.1080/17843286.2022.2108978,2022-08-17,2024-03-01,Unverified,firket_prospective_2022,BEL
220808_Liege_UniversityOfLiegeHospital_Period2_Primary,220808_Liege_UniversityOfLiegeHospital_Period2,The prospective screening for SARS-CoV-2 S1/S2 antibodies delineates the factual incidence of COVID-19 and shows a sustained serological response post COVID-19 in kidney transplant recipients.,2022-08-08,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Belgium,Wallonia,Liege,"All KTRs followed at our center were invited to participate in this study during their outpatient
appointment",,2020-10-01,2021-05-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,,Primary Estimate,,471,0.0467,,,True,,,,True,Sequential,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.89,0.978,['High'],,No,No,No,,Yes,Yes,No,,Louis Firket,University of Liege Hospital,Not Unity-Aligned,https://dx.doi.org/10.1080/17843286.2022.2108978,2022-08-17,2024-03-01,Unverified,firket_prospective_2022,BEL
220817_UniversiteLibredeBruxelles_Brussels_Overall,220817_UniversiteLibredeBruxelles_Brussels,Relapse rate in children with nephrotic syndrome during the SARS-CoV-2 pandemic,2022-08-17,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Belgium,,Brussels,"All children aged up to 18 years with a diagnosis of INS followed at
Hôpital Universitaire des Enfants Reine Fabiola (HUDERF)
in Brussels, Belgium. INS was defined as a nephrotic
range proteinuria that has a urinary protein:creatinine ratio
(uPr/uCr)>2 g/g associated with hypoalbuminemia (serum
albumin<25 g/l) and edema.","Genetic and steroid-resistant forms
of NS were not included. Steroid resistance was defined as
a lack of response to 6 weeks of oral steroid treatment followed by 3 high-dose boluses of intravenous steroid and
by another 2 weeks of oral steroid.",2020-09-15,2020-12-31,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),,18.0,Primary Estimate,,42,0.31,,,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,,IgG,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Benedetta Chiodini,Vrije Universiteit Brussel,Not Unity-Aligned,https://dx.doi.org/10.1007/s00467-022-05702-2,2022-08-31,2022-09-23,Unverified,chiodini_relapse_2022,BEL
230330_Belgium_UniversityOfAntwerp,230330_Belgium_UniversityOfAntwerp,Validation of a rapid SARS-CoV-2 antibody test in general practice.,2023-03-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Belgium,,,"Participants Any general practitioner (GP) working in primary care in Belgium and any other PHCP from the same GP practice who physically manages patients were eligible in the seroprevalence study. For the validation study, all participants who tested positive (376) on the RST at the first testing timepoint (T1) and a random sample of those who tested negative (790) and unclear (24) were included.",,2020-12-24,2021-12-26,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1073,0.249,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Atellica® IM SARS-CoV-2 Total (COV2T),Liason SARS-CoV-2 IgM test","Roche Diagnostics,Siemens,DiaSorin",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']",Spike,,,,[{'error': '#ERROR!'}],,No,Yes,No,,{'error': '#ERROR!'},Yes,{'error': '#ERROR!'},,Julie Domen,University of Antwerp,{'error': '#ERROR!'},https://dx.doi.org/10.1136/bmjopen-2022-069997,2023-06-02,2024-03-01,Unverified,domen_validation_2023,BEL
230418_Belgium_Sciensano_2021Jun14-Jul11,230418_Belgium_Sciensano_2021Jun14-Jul11,Prevalence of SARS-CoV-2 antibodies and associated factors in the adult population of Belgium: a general population cohort study between March 2021 and April 2022,2023-04-18,Preprint,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Belgium,,,"In brief, this is a prospective cohort study in a random sample of adults selected from the Belgian National Register of residents. A strati¦ed clustered sampling method was used, with private households as primary sampling unit. Within a selected household, all participants aged 18 years and older were eligible for participation.",,2021-06-14,2021-07-11,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,780,0.69,0.633,0.746,True,,True,,True,Stratified probability,Wantai SARS-CoV-2 IgG ELISA,Beijing Wantai Biological,ELISA,Saliva,IgG,Spike,Validated by independent authors/third party/non-developers,0.951,0.967,['Moderate'],,Yes,Yes,No,,No,Yes,No,,Johan Van der Heyden,Sciensano,Not Unity-Aligned,http://doi.org/10.21203/rs.3.rs-2802349/v1,2023-05-08,2024-03-01,Unverified,heyden_prevalence_2023,BEL
230418_Belgium_Sciensano_2021Mar29-Apr11,230418_Belgium_Sciensano_2021Mar29-Apr11,Prevalence of SARS-CoV-2 antibodies and associated factors in the adult population of Belgium: a general population cohort study between March 2021 and April 2022,2023-04-18,Preprint,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Belgium,,,"In brief, this is a prospective cohort study in a random sample of adults selected from the Belgian National Register of residents. A strati¦ed clustered sampling method was used, with private households as primary sampling unit. Within a selected household, all participants aged 18 years and older were eligible for participation.",,2021-03-29,2021-04-11,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,284,0.251,0.187,0.316,True,,True,,True,Stratified probability,Wantai SARS-CoV-2 IgG ELISA,Beijing Wantai Biological,ELISA,Saliva,IgG,Spike,Validated by independent authors/third party/non-developers,0.951,0.967,['High'],,Yes,No,No,,No,Yes,No,,Johan Van der Heyden,Sciensano,Not Unity-Aligned,http://doi.org/10.21203/rs.3.rs-2802349/v1,2023-05-08,2024-03-01,Unverified,heyden_prevalence_2023,BEL
230418_Belgium_Sciensano_2021May17-Jun13,230418_Belgium_Sciensano_2021May17-Jun13,Prevalence of SARS-CoV-2 antibodies and associated factors in the adult population of Belgium: a general population cohort study between March 2021 and April 2022,2023-04-18,Preprint,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Belgium,,,"In brief, this is a prospective cohort study in a random sample of adults selected from the Belgian National Register of residents. A strati¦ed clustered sampling method was used, with private households as primary sampling unit. Within a selected household, all participants aged 18 years and older were eligible for participation.",,2021-05-17,2021-06-13,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,1111,0.478,0.441,0.515,True,,True,,True,Stratified probability,Wantai SARS-CoV-2 IgG ELISA,Beijing Wantai Biological,ELISA,Saliva,IgG,Spike,Validated by independent authors/third party/non-developers,0.951,0.967,['Moderate'],,Yes,Yes,No,,No,Yes,No,,Johan Van der Heyden,Sciensano,Not Unity-Aligned,http://doi.org/10.21203/rs.3.rs-2802349/v1,2023-05-08,2024-03-01,Unverified,heyden_prevalence_2023,BEL
230418_Belgium_Sciensano_2021Oct25-Nov21,230418_Belgium_Sciensano_2021Oct25-Nov21,Prevalence of SARS-CoV-2 antibodies and associated factors in the adult population of Belgium: a general population cohort study between March 2021 and April 2022,2023-04-18,Preprint,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Belgium,,,"In brief, this is a prospective cohort study in a random sample of adults selected from the Belgian National Register of residents. A strati¦ed clustered sampling method was used, with private households as primary sampling unit. Within a selected household, all participants aged 18 years and older were eligible for participation.",,2021-10-25,2021-11-21,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,713,0.891,0.849,0.932,True,,True,,True,Stratified probability,Wantai SARS-CoV-2 IgG ELISA,Beijing Wantai Biological,ELISA,Saliva,IgG,Spike,Validated by independent authors/third party/non-developers,0.951,0.967,['Moderate'],,Yes,Yes,No,,No,Yes,No,,Johan Van der Heyden,Sciensano,Not Unity-Aligned,http://doi.org/10.21203/rs.3.rs-2802349/v1,2023-05-08,2024-03-01,Unverified,heyden_prevalence_2023,BEL
230418_Belgium_Sciensano_2021Sep27-Oct24,230418_Belgium_Sciensano_2021Sep27-Oct24,Prevalence of SARS-CoV-2 antibodies and associated factors in the adult population of Belgium: a general population cohort study between March 2021 and April 2022,2023-04-18,Preprint,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Belgium,,,"In brief, this is a prospective cohort study in a random sample of adults selected from the Belgian National Register of residents. A strati¦ed clustered sampling method was used, with private households as primary sampling unit. Within a selected household, all participants aged 18 years and older were eligible for participation.",,2021-09-27,2021-10-24,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,841,0.845,0.793,0.896,True,,True,,True,Stratified probability,Wantai SARS-CoV-2 IgG ELISA,Beijing Wantai Biological,ELISA,Saliva,IgG,Spike,Validated by independent authors/third party/non-developers,0.951,0.967,['Moderate'],,Yes,Yes,No,,No,Yes,No,,Johan Van der Heyden,Sciensano,Not Unity-Aligned,http://doi.org/10.21203/rs.3.rs-2802349/v1,2023-05-08,2024-03-01,Unverified,heyden_prevalence_2023,BEL
230418_Belgium_Sciensano_2022Feb21-Mar20,230418_Belgium_Sciensano_2022Feb21-Mar20,Prevalence of SARS-CoV-2 antibodies and associated factors in the adult population of Belgium: a general population cohort study between March 2021 and April 2022,2023-04-18,Preprint,National,Prospective cohort,Belgium,,,"In brief, this is a prospective cohort study in a random sample of adults selected from the Belgian National Register of residents. A strati¦ed clustered sampling method was used, with private households as primary sampling unit. Within a selected household, all participants aged 18 years and older were eligible for participation.",,2022-02-21,2022-03-20,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,242,0.923,0.868,0.979,True,,True,,True,Stratified probability,Wantai SARS-CoV-2 IgG ELISA,Beijing Wantai Biological,ELISA,Saliva,IgG,Spike,Validated by independent authors/third party/non-developers,0.951,0.967,['High'],,Yes,No,No,,No,Yes,No,,Johan Van der Heyden,Sciensano,Not Unity-Aligned,http://doi.org/10.21203/rs.3.rs-2802349/v1,2023-05-08,2024-03-01,Unverified,heyden_prevalence_2023,BEL
230418_Belgium_Sciensano_2022Jan24-Feb20,230418_Belgium_Sciensano_2022Jan24-Feb20,Prevalence of SARS-CoV-2 antibodies and associated factors in the adult population of Belgium: a general population cohort study between March 2021 and April 2022,2023-04-18,Preprint,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Belgium,,,"In brief, this is a prospective cohort study in a random sample of adults selected from the Belgian National Register of residents. A strati¦ed clustered sampling method was used, with private households as primary sampling unit. Within a selected household, all participants aged 18 years and older were eligible for participation.",,2022-01-24,2022-02-20,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,1076,0.913,0.871,0.955,True,,True,,True,Stratified probability,Wantai SARS-CoV-2 IgG ELISA,Beijing Wantai Biological,ELISA,Saliva,IgG,Spike,Validated by independent authors/third party/non-developers,0.951,0.967,['Moderate'],,Yes,Yes,No,,No,Yes,No,,Johan Van der Heyden,Sciensano,Not Unity-Aligned,http://doi.org/10.21203/rs.3.rs-2802349/v1,2023-05-08,2024-03-01,Unverified,heyden_prevalence_2023,BEL
230624_Belgium_MountSinai,230624_Belgium_MountSinai,Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium,2023-06-24,Journal Article (Peer-Reviewed),National,Prospective cohort,Belgium,,,"Our initial core objective was to include all adult patients with IBD who entered the infusion center for vedolizumab or infliximab (originator or biosimilars), as well as intravenous ustekinumab induction, regardless of history of known COVID-19 infection, and without any exclusion criteria.",None,2020-05-15,2021-12-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,862,0.0673,,,True,,,,True,Convenience,SARS-CoV-2 Rapid Antibody Test,Roche Diagnostics,LFIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Serre-Yu Wong,Mount Sinai,Not Unity-Aligned,https://dx.doi.org/10.1093/ibd/izad097,2023-08-02,2024-03-01,Unverified,wong_geography_2023,BEL
230807_Belgium_GhentUniversityHospital_Overall,230807_Belgium_GhentUniversityHospital,Comparison of SARS-CoV-2 seroconversion in children with chronic diseases with healthy children and adults during the first waves of the COVID-19 pandemic,2023-08-07,Journal Article (Peer-Reviewed),Local,Prospective cohort,Belgium,East Flanders province,Ghent,"Children (0–18 years of age) with chronic diseases that require regular follow-ups in the Princess Elisabeth Children’s Hospital (Ghent University Hospital, Belgium) were eligible for inclusion.",,2020-11-01,2021-09-30,Residual sera,All,Children and Youth (0-17 years),0.0,18.0,Primary Estimate,"Nov 1, 2020 - Sept 30, 2021",525,0.097,0.075,0.126,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,Levi Hoste,Ghent University Hospital,Unity-Aligned,https://dx.doi.org/10.3389/fped.2023.1210181,2023-09-15,2024-03-01,Unverified,hoste_comparison_2023,BEL
230807_Belgium_GhentUniversityHospital_JulSept2021,230807_Belgium_GhentUniversityHospital,Comparison of SARS-CoV-2 seroconversion in children with chronic diseases with healthy children and adults during the first waves of the COVID-19 pandemic,2023-08-07,Journal Article (Peer-Reviewed),Local,Prospective cohort,Belgium,East Flanders province,Ghent,"Children (0–18 years of age) with chronic diseases that require regular follow-ups in the Princess Elisabeth Children’s Hospital (Ghent University Hospital, Belgium) were eligible for inclusion.",,2021-07-01,2021-09-30,Residual sera,All,Children and Youth (0-17 years),0.0,18.0,Time frame,Jul - Sept 2021,37,0.216,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,Levi Hoste,Ghent University Hospital,Unity-Aligned,https://dx.doi.org/10.3389/fped.2023.1210181,2023-09-15,2024-03-01,Unverified,hoste_comparison_2023,BEL
230807_Belgium_GhentUniversityHospital_JanFeb2021,230807_Belgium_GhentUniversityHospital,Comparison of SARS-CoV-2 seroconversion in children with chronic diseases with healthy children and adults during the first waves of the COVID-19 pandemic,2023-08-07,Journal Article (Peer-Reviewed),Local,Prospective cohort,Belgium,East Flanders province,Ghent,"Children (0–18 years of age) with chronic diseases that require regular follow-ups in the Princess Elisabeth Children’s Hospital (Ghent University Hospital, Belgium) were eligible for inclusion.",,2021-01-01,2021-02-28,Residual sera,All,Children and Youth (0-17 years),0.0,18.0,Time frame,Jan - Feb 2021,158,0.108,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,Levi Hoste,Ghent University Hospital,Unity-Aligned,https://dx.doi.org/10.3389/fped.2023.1210181,2023-09-15,2024-03-01,Unverified,hoste_comparison_2023,BEL
230807_Belgium_GhentUniversityHospital_MarApr2021,230807_Belgium_GhentUniversityHospital,Comparison of SARS-CoV-2 seroconversion in children with chronic diseases with healthy children and adults during the first waves of the COVID-19 pandemic,2023-08-07,Journal Article (Peer-Reviewed),Local,Prospective cohort,Belgium,East Flanders province,Ghent,"Children (0–18 years of age) with chronic diseases that require regular follow-ups in the Princess Elisabeth Children’s Hospital (Ghent University Hospital, Belgium) were eligible for inclusion.",,2021-03-01,2021-04-30,Residual sera,All,Children and Youth (0-17 years),0.0,18.0,Time frame,Mar - Apr 2021,57,0.123,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,Levi Hoste,Ghent University Hospital,Unity-Aligned,https://dx.doi.org/10.3389/fped.2023.1210181,2023-09-15,2024-03-01,Unverified,hoste_comparison_2023,BEL
230807_Belgium_GhentUniversityHospital_MayJun2021,230807_Belgium_GhentUniversityHospital,Comparison of SARS-CoV-2 seroconversion in children with chronic diseases with healthy children and adults during the first waves of the COVID-19 pandemic,2023-08-07,Journal Article (Peer-Reviewed),Local,Prospective cohort,Belgium,East Flanders province,Ghent,"Children (0–18 years of age) with chronic diseases that require regular follow-ups in the Princess Elisabeth Children’s Hospital (Ghent University Hospital, Belgium) were eligible for inclusion.",,2021-05-01,2021-06-30,Residual sera,All,Children and Youth (0-17 years),0.0,18.0,Time frame,May - Jun 2021,66,0.106,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,Levi Hoste,Ghent University Hospital,Unity-Aligned,https://dx.doi.org/10.3389/fped.2023.1210181,2023-09-15,2024-03-01,Unverified,hoste_comparison_2023,BEL
230807_Belgium_GhentUniversityHospital_NovDec2020,230807_Belgium_GhentUniversityHospital,Comparison of SARS-CoV-2 seroconversion in children with chronic diseases with healthy children and adults during the first waves of the COVID-19 pandemic,2023-08-07,Journal Article (Peer-Reviewed),Local,Prospective cohort,Belgium,East Flanders province,Ghent,"Children (0–18 years of age) with chronic diseases that require regular follow-ups in the Princess Elisabeth Children’s Hospital (Ghent University Hospital, Belgium) were eligible for inclusion.",,2020-11-01,2020-12-31,Residual sera,All,Children and Youth (0-17 years),0.0,18.0,Time frame,Nov - Dec 2020,207,0.058,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,Levi Hoste,Ghent University Hospital,Unity-Aligned,https://dx.doi.org/10.3389/fped.2023.1210181,2023-09-15,2024-03-01,Unverified,hoste_comparison_2023,BEL
230527_Cotonou_UniversiteDeParisCite_Survey1,230527_Cotonou_UniversiteDeParisCite_Survey1,Interest of seroprevalence surveys for the epidemiological surveillance of the SARS-CoV-2 pandemic in African populations: Insights from the ARIACOV project in Benin.,2023-05-27,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Benin,,Cotonou,"In order to balance the age groups in the study sample to be able to compare the two surveys by age groups, in half of the households all the residents were invited to participate in the study, and in the remaining 50%, only the residents aged 40 years and older were invited to participate.",,2021-03-03,2021-03-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,1405,0.2977,0.2312,0.3741,True,,True,,True,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,0.997,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Parfait Houngbegnon,Université de Paris Cité,Unity-Aligned,https://dx.doi.org/10.1111/tmi.13895,2023-06-28,2024-04-30,Verified,houngbegnon_interest_2023,BEN
230527_Cotonou_UniversiteDeParisCite_Survey1_Age18-39,230527_Cotonou_UniversiteDeParisCite_Survey1,Interest of seroprevalence surveys for the epidemiological surveillance of the SARS-CoV-2 pandemic in African populations: Insights from the ARIACOV project in Benin.,2023-05-27,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Benin,,Cotonou,"In order to balance the age groups in the study sample to be able to compare the two surveys by age groups, in half of the households all the residents were invited to participate in the study, and in the remaining 50%, only the residents aged 40 years and older were invited to participate.",,2021-03-03,2021-03-15,Household and community samples,All,Adults (18-64 years),18.0,39.0,Age,18-39,466,0.2653,,,,,,,,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,0.997,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Parfait Houngbegnon,Université de Paris Cité,Unity-Aligned,https://dx.doi.org/10.1111/tmi.13895,2024-04-30,2024-04-30,Verified,houngbegnon_interest_2023,BEN
230527_Cotonou_UniversiteDeParisCite_Survey1_Age60+,230527_Cotonou_UniversiteDeParisCite_Survey1,Interest of seroprevalence surveys for the epidemiological surveillance of the SARS-CoV-2 pandemic in African populations: Insights from the ARIACOV project in Benin.,2023-05-27,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Benin,,Cotonou,"In order to balance the age groups in the study sample to be able to compare the two surveys by age groups, in half of the households all the residents were invited to participate in the study, and in the remaining 50%, only the residents aged 40 years and older were invited to participate.",,2021-03-03,2021-03-15,Household and community samples,All,Seniors (65+ years),60.0,,Age,60+,253,0.3354,,,,,,,,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,0.997,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Parfait Houngbegnon,Université de Paris Cité,Unity-Aligned,https://dx.doi.org/10.1111/tmi.13895,2024-04-30,2024-04-30,Verified,houngbegnon_interest_2023,BEN
230527_Cotonou_UniversiteDeParisCite_Survey1_Age<18,230527_Cotonou_UniversiteDeParisCite_Survey1,Interest of seroprevalence surveys for the epidemiological surveillance of the SARS-CoV-2 pandemic in African populations: Insights from the ARIACOV project in Benin.,2023-05-27,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Benin,,Cotonou,"In order to balance the age groups in the study sample to be able to compare the two surveys by age groups, in half of the households all the residents were invited to participate in the study, and in the remaining 50%, only the residents aged 40 years and older were invited to participate.",,2021-03-03,2021-03-15,Household and community samples,All,Children and Youth (0-17 years),,17.0,Age,<18,199,0.2341,,,,,,,,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,0.997,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Parfait Houngbegnon,Université de Paris Cité,Unity-Aligned,https://dx.doi.org/10.1111/tmi.13895,2024-04-30,2024-04-30,Verified,houngbegnon_interest_2023,BEN
230527_Cotonou_UniversiteDeParisCite_Survey1_Age40-59,230527_Cotonou_UniversiteDeParisCite_Survey1,Interest of seroprevalence surveys for the epidemiological surveillance of the SARS-CoV-2 pandemic in African populations: Insights from the ARIACOV project in Benin.,2023-05-27,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Benin,,Cotonou,"In order to balance the age groups in the study sample to be able to compare the two surveys by age groups, in half of the households all the residents were invited to participate in the study, and in the remaining 50%, only the residents aged 40 years and older were invited to participate.",,2021-03-03,2021-03-15,Household and community samples,All,Adults (18-64 years),40.0,59.0,Age,40-59,487,0.4181,,,,,,,,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,0.997,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Parfait Houngbegnon,Université de Paris Cité,Unity-Aligned,https://dx.doi.org/10.1111/tmi.13895,2024-04-30,2024-04-30,Verified,houngbegnon_interest_2023,BEN
230527_Cotonou_UniversiteDeParisCite_Survey2,230527_Cotonou_UniversiteDeParisCite_Survey2,Interest of seroprevalence surveys for the epidemiological surveillance of the SARS-CoV-2 pandemic in African populations: Insights from the ARIACOV project in Benin.,2023-05-27,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Benin,,Cotonou,"In order to balance the age groups in the study sample to be able to compare the two surveys by age groups, in half of the households all the residents were invited to participate in the study, and in the remaining 50%, only the residents aged 40 years and older were invited to participate.",,2021-05-27,2021-06-08,Household and community samples,All,Multiple groups,,,Primary Estimate,,1460,0.3486,0.3157,0.383,True,,True,,True,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,0.997,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Parfait Houngbegnon,Université de Paris Cité,Unity-Aligned,https://dx.doi.org/10.1111/tmi.13895,2023-06-28,2024-04-30,Verified,houngbegnon_interest_2023,BEN
230527_Cotonou_UniversiteDeParisCite_Survey2_Age<18,230527_Cotonou_UniversiteDeParisCite_Survey2,Interest of seroprevalence surveys for the epidemiological surveillance of the SARS-CoV-2 pandemic in African populations: Insights from the ARIACOV project in Benin.,2023-05-27,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Benin,,Cotonou,"In order to balance the age groups in the study sample to be able to compare the two surveys by age groups, in half of the households all the residents were invited to participate in the study, and in the remaining 50%, only the residents aged 40 years and older were invited to participate.",,2021-05-27,2021-06-08,Household and community samples,All,Children and Youth (0-17 years),,17.0,Age,<18,379,0.3245,,,,,,,,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,0.997,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Parfait Houngbegnon,Université de Paris Cité,Unity-Aligned,https://dx.doi.org/10.1111/tmi.13895,2024-04-30,2024-04-30,Verified,houngbegnon_interest_2023,BEN
230527_Cotonou_UniversiteDeParisCite_Survey2_Age40-59,230527_Cotonou_UniversiteDeParisCite_Survey2,Interest of seroprevalence surveys for the epidemiological surveillance of the SARS-CoV-2 pandemic in African populations: Insights from the ARIACOV project in Benin.,2023-05-27,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Benin,,Cotonou,"In order to balance the age groups in the study sample to be able to compare the two surveys by age groups, in half of the households all the residents were invited to participate in the study, and in the remaining 50%, only the residents aged 40 years and older were invited to participate.",,2021-05-27,2021-06-08,Household and community samples,All,Adults (18-64 years),40.0,59.0,Age,40-59,438,0.347,,,,,,,,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,0.997,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Parfait Houngbegnon,Université de Paris Cité,Unity-Aligned,https://dx.doi.org/10.1111/tmi.13895,2024-04-30,2024-04-30,Verified,houngbegnon_interest_2023,BEN
230527_Cotonou_UniversiteDeParisCite_Survey2_Age60+,230527_Cotonou_UniversiteDeParisCite_Survey2,Interest of seroprevalence surveys for the epidemiological surveillance of the SARS-CoV-2 pandemic in African populations: Insights from the ARIACOV project in Benin.,2023-05-27,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Benin,,Cotonou,"In order to balance the age groups in the study sample to be able to compare the two surveys by age groups, in half of the households all the residents were invited to participate in the study, and in the remaining 50%, only the residents aged 40 years and older were invited to participate.",,2021-05-27,2021-06-08,Household and community samples,All,Seniors (65+ years),60.0,,Age,60+,215,0.3116,,,,,,,,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,0.997,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Parfait Houngbegnon,Université de Paris Cité,Unity-Aligned,https://dx.doi.org/10.1111/tmi.13895,2024-04-30,2024-04-30,Verified,houngbegnon_interest_2023,BEN
230527_Cotonou_UniversiteDeParisCite_Survey2_Age18-39,230527_Cotonou_UniversiteDeParisCite_Survey2,Interest of seroprevalence surveys for the epidemiological surveillance of the SARS-CoV-2 pandemic in African populations: Insights from the ARIACOV project in Benin.,2023-05-27,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Benin,,Cotonou,"In order to balance the age groups in the study sample to be able to compare the two surveys by age groups, in half of the households all the residents were invited to participate in the study, and in the remaining 50%, only the residents aged 40 years and older were invited to participate.",,2021-05-27,2021-06-08,Household and community samples,All,Adults (18-64 years),18.0,39.0,Age,18-39,428,0.4149,,,,,,,,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,0.997,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Parfait Houngbegnon,Université de Paris Cité,Unity-Aligned,https://dx.doi.org/10.1111/tmi.13895,2024-04-30,2024-04-30,Verified,houngbegnon_interest_2023,BEN
230527_Natitingou_UniversiteDeParisCite,230527_Natitingou_UniversiteDeParisCite,Interest of seroprevalence surveys for the epidemiological surveillance of the SARS-CoV-2 pandemic in African populations: Insights from the ARIACOV project in Benin.,2023-05-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Benin,,Natitingou,"In Natitingou, all the residents of any household were invited to participate in the study.",,2021-08-20,2021-08-26,Household and community samples,All,Multiple groups,,,Primary Estimate,,735,0.3334,0.2775,0.3944,True,,True,,True,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,0.997,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Parfait Houngbegnon,Université de Paris Cité,Unity-Aligned,https://dx.doi.org/10.1111/tmi.13895,2023-06-28,2024-04-30,Verified,houngbegnon_interest_2023,BEN
230527_Natitingou_UniversiteDeParisCite_Age60+,230527_Natitingou_UniversiteDeParisCite,Interest of seroprevalence surveys for the epidemiological surveillance of the SARS-CoV-2 pandemic in African populations: Insights from the ARIACOV project in Benin.,2023-05-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Benin,,Natitingou,"In Natitingou, all the residents of any household were invited to participate in the study.",,2021-08-20,2021-08-26,Household and community samples,All,Seniors (65+ years),60.0,,Age,60+,47,0.4958,,,,,,,,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,0.997,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Parfait Houngbegnon,Université de Paris Cité,Unity-Aligned,https://dx.doi.org/10.1111/tmi.13895,2024-04-30,2024-04-30,Verified,houngbegnon_interest_2023,BEN
230527_Natitingou_UniversiteDeParisCite_Age<18,230527_Natitingou_UniversiteDeParisCite,Interest of seroprevalence surveys for the epidemiological surveillance of the SARS-CoV-2 pandemic in African populations: Insights from the ARIACOV project in Benin.,2023-05-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Benin,,Natitingou,"In Natitingou, all the residents of any household were invited to participate in the study.",,2021-08-20,2021-08-26,Household and community samples,All,Children and Youth (0-17 years),,17.0,Age,<18,309,0.3373,,,,,,,,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,0.997,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Parfait Houngbegnon,Université de Paris Cité,Unity-Aligned,https://dx.doi.org/10.1111/tmi.13895,2024-04-30,2024-04-30,Verified,houngbegnon_interest_2023,BEN
230527_Natitingou_UniversiteDeParisCite_Age18-39,230527_Natitingou_UniversiteDeParisCite,Interest of seroprevalence surveys for the epidemiological surveillance of the SARS-CoV-2 pandemic in African populations: Insights from the ARIACOV project in Benin.,2023-05-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Benin,,Natitingou,"In Natitingou, all the residents of any household were invited to participate in the study.",,2021-08-20,2021-08-26,Household and community samples,All,Adults (18-64 years),18.0,39.0,Age,18-39,259,0.2806,,,,,,,,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,0.997,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Parfait Houngbegnon,Université de Paris Cité,Unity-Aligned,https://dx.doi.org/10.1111/tmi.13895,2024-04-30,2024-04-30,Verified,houngbegnon_interest_2023,BEN
230527_Natitingou_UniversiteDeParisCite_Age40-59,230527_Natitingou_UniversiteDeParisCite,Interest of seroprevalence surveys for the epidemiological surveillance of the SARS-CoV-2 pandemic in African populations: Insights from the ARIACOV project in Benin.,2023-05-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Benin,,Natitingou,"In Natitingou, all the residents of any household were invited to participate in the study.",,2021-08-20,2021-08-26,Household and community samples,All,Adults (18-64 years),40.0,59.0,Age,40-59,120,0.3689,,,,,,,,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,0.997,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Parfait Houngbegnon,Université de Paris Cité,Unity-Aligned,https://dx.doi.org/10.1111/tmi.13895,2024-04-30,2024-04-30,Verified,houngbegnon_interest_2023,BEN
220125_Cochabamba_Aix-MarseilleUniversity_Overall,220125_Cochabamba_Aix-MarseilleUniversity,"High SARS-CoV-2 Prevalence among Healthcare Workers in Cochabamba, Bolivia",2022-01-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bolivia (Plurinational State of),,Cochabamba,"Participants were included from: (i) the main and largest public tertiary-care hospitals
admitting COVID-19 patients, (ii) two
private tertiary care clinics, (iii) Central Diagnostic Laboratory, Germán Urquidi Maternity
Hospital, and Cochabamba Clinic. All participants were included, irrespective of whether they had had COVID-19
symptoms or not.",,2021-01-01,2021-01-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,783,0.434,0.38799999999999996,0.48,True,,,,True,Convenience,"Access SARS-CoV-2 IgG Reagent Antibody Test,Anti-SARS-CoV-2 ELISA IgG,Author designed (Neutralization Assay)","Beckman Coulter,EUROIMMUN,NA",Multiple Types,Multiple Types,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Paola Villarroel,Aix-Marseille University,Not Unity-Aligned,https://dx.doi.org/10.3390/v14020232,2022-02-09,2024-03-01,Unverified,saba_villarroel_high_2022,BOL
210318_Sarajevo_InternationalBurchUniversity_DrAbdulahNakasGeneralHospital1_overall,210318_Sarajevo_InternationalBurchUniversity_DrAbdulahNakasGeneralHospital1,Serological testing for SARS-CoV-2 in Bosnia and Herzegovina: first report.,2021-03-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bosnia and Herzegovina,,Sarajevo,Patients triaged at the Dr. Abdulah Nakaš General Hospital,,2020-04-15,2020-05-15,Residual sera,All,Multiple groups,,,Primary Estimate,,1720,0.034100000000000005,,,True,,,,True,Convenience,One Step Novel Coronavirus (COVID-19) IgM/IgG Antibody Test,Artron Laboratories Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,,Adna Asic,International Burch University,Unity-Aligned,https://dx.doi.org/10.5114/aoms/134143,2021-05-29,2024-03-01,Verified,asic_serological_2021,BIH
210318_Sarajevo_InternationalBurchUniversity_EurofarmCentreLaboratory2_overall,210318_Sarajevo_InternationalBurchUniversity_EurofarmCentreLaboratory2,Serological testing for SARS-CoV-2 in Bosnia and Herzegovina: first report.,2021-03-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bosnia and Herzegovina,,Sarajevo,All samples were collected as a part of the hospital triage procedure. Blood samples were collected in a tube containing an anticoagulant and were tested immediately.,,2020-04-21,2020-07-17,Residual sera,All,Multiple groups,,,Primary Estimate,,1121,0.042800000000000005,,,True,,,,True,Convenience,2019-nCoV IgG/IgM Rapid Test,Dynamiker Biotechnology (Tianjin) Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Adna Asic,International Burch University,Unity-Aligned,https://dx.doi.org/10.5114/aoms/134143,2021-05-29,2024-03-01,Verified,asic_serological_2021,BIH
210604_RepublicOfSrpska_InstituteforTransfusionMedicine_Primary,210604_RepublicOfSrpska_InstituteforTransfusionMedicine,Anti-SARS-CoV-2 IgG seroprevalence study among blood donors in the Republic of Srpska: A 30-day survey,2021-06-04,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Bosnia and Herzegovina,Republic of Srpska,,"blood samples from apparently healthy blood donors, aged 18–64",,2020-06-17,2020-07-16,Blood donors,All,Adults (18-64 years),18.0,64.0,Primary Estimate,,807,0.027000000000000003,,,True,,,,True,Unclear,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,Other,,IgG,,,,,['High'],No,Unclear,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Gordana Guzijan,Institute for Transfusion Medicine of the Republic of Srpska,Not Unity-Aligned,http://dx.doi.org/10.2298/VSP200122059G,2021-07-18,2024-03-01,Verified,guzijan_anti-sars-cov-2_2021,BIH
210604_RepublicOfSrpska_InstituteforTransfusionMedicine_Male,210604_RepublicOfSrpska_InstituteforTransfusionMedicine,Anti-SARS-CoV-2 IgG seroprevalence study among blood donors in the Republic of Srpska: A 30-day survey,2021-06-04,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Bosnia and Herzegovina,Republic of Srpska,,"blood samples from apparently healthy blood donors, aged 18–64",,2020-06-17,2020-07-16,Blood donors,Male,Adults (18-64 years),18.0,64.0,Sex/Gender,,643,0.025,,,,,,,,Unclear,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,Other,,IgG,,,,,['High'],No,Unclear,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Gordana Guzijan,Institute for Transfusion Medicine of the Republic of Srpska,Not Unity-Aligned,http://dx.doi.org/10.2298/VSP200122059G,2021-07-18,2024-03-01,Verified,guzijan_anti-sars-cov-2_2021,BIH
210604_RepublicOfSrpska_InstituteforTransfusionMedicine_3150,210604_RepublicOfSrpska_InstituteforTransfusionMedicine,Anti-SARS-CoV-2 IgG seroprevalence study among blood donors in the Republic of Srpska: A 30-day survey,2021-06-04,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Bosnia and Herzegovina,Republic of Srpska,,"blood samples from apparently healthy blood donors, aged 18–64",,2020-06-17,2020-07-16,Blood donors,All,Adults (18-64 years),31.0,50.0,Age,31-50,427,0.013999999999999999,,,,,,,,Unclear,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,Other,,IgG,,,,,['High'],No,Unclear,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Gordana Guzijan,Institute for Transfusion Medicine of the Republic of Srpska,Not Unity-Aligned,http://dx.doi.org/10.2298/VSP200122059G,2021-07-18,2024-03-01,Verified,guzijan_anti-sars-cov-2_2021,BIH
210604_RepublicOfSrpska_InstituteforTransfusionMedicine_1830,210604_RepublicOfSrpska_InstituteforTransfusionMedicine,Anti-SARS-CoV-2 IgG seroprevalence study among blood donors in the Republic of Srpska: A 30-day survey,2021-06-04,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Bosnia and Herzegovina,Republic of Srpska,,"blood samples from apparently healthy blood donors, aged 18–64",,2020-06-17,2020-07-16,Blood donors,All,Adults (18-64 years),18.0,30.0,Age,18-30,296,0.051,,,,,,,,Unclear,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,Other,,IgG,,,,,['High'],No,Unclear,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Gordana Guzijan,Institute for Transfusion Medicine of the Republic of Srpska,Not Unity-Aligned,http://dx.doi.org/10.2298/VSP200122059G,2021-07-18,2024-03-01,Verified,guzijan_anti-sars-cov-2_2021,BIH
210604_RepublicOfSrpska_InstituteforTransfusionMedicine_5164,210604_RepublicOfSrpska_InstituteforTransfusionMedicine,Anti-SARS-CoV-2 IgG seroprevalence study among blood donors in the Republic of Srpska: A 30-day survey,2021-06-04,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Bosnia and Herzegovina,Republic of Srpska,,"blood samples from apparently healthy blood donors, aged 18–64",,2020-06-17,2020-07-16,Blood donors,All,Adults (18-64 years),51.0,64.0,Age,51-64,84,0.012,,,,,,,,Unclear,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,Other,,IgG,,,,,['High'],No,Unclear,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Gordana Guzijan,Institute for Transfusion Medicine of the Republic of Srpska,Not Unity-Aligned,http://dx.doi.org/10.2298/VSP200122059G,2021-07-18,2024-03-01,Verified,guzijan_anti-sars-cov-2_2021,BIH
210604_RepublicOfSrpska_InstituteforTransfusionMedicine_Female,210604_RepublicOfSrpska_InstituteforTransfusionMedicine,Anti-SARS-CoV-2 IgG seroprevalence study among blood donors in the Republic of Srpska: A 30-day survey,2021-06-04,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Bosnia and Herzegovina,Republic of Srpska,,"blood samples from apparently healthy blood donors, aged 18–64",,2020-06-17,2020-07-16,Blood donors,Female,Adults (18-64 years),18.0,64.0,Sex/Gender,,164,0.037000000000000005,,,,,,,,Unclear,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,Other,,IgG,,,,,['High'],No,Unclear,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Gordana Guzijan,Institute for Transfusion Medicine of the Republic of Srpska,Not Unity-Aligned,http://dx.doi.org/10.2298/VSP200122059G,2021-07-18,2024-03-01,Verified,guzijan_anti-sars-cov-2_2021,BIH
211013_SarajevoCanton_PublicHealthInstitute_Overall,211013_SarajevoCanton_PublicHealthInstitute,Study of SARS-CoV-2 Seroprevalence in Canton Sarajevo,2021-10-13,Institutional Report,Local,Cross-sectional survey ,Bosnia and Herzegovina,,Sarajevo Canton,"The criteria included in the study were:
• Residents of Sarajevo Canton, based on age and gender structure in Sarajevo Canton;
• Risk groups (health workers, members of the Ministry of the Interior, traders, public transport workers, taxi drivers, educators);
• Share of respondents in relation to age and gender structure in Sarajevo Canton;
• Healthcare workers who were PCR confirmed cases more than 30 days ago.","Exclusion criteria were:
· People with acute SARS-CoV-2 disease
· People who have been confirmed by the case (PCR confirmed the presence of SARS-CoV-2 virus) in the past 90 days.",2021-01-05,2021-03-20,Multiple populations,All,Multiple groups,,,Primary Estimate,,3650,0.2726027397,,,True,,,,True,Convenience,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Serum,IgG,,,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Anes Joguncic,Public Health Institute,Not Unity-Aligned,,2021-10-31,2024-03-01,Unverified,anes_joguncic_study_2021,BIH
211013_SarajevoCanton_PublicHealthInstitute_Age_41-65,211013_SarajevoCanton_PublicHealthInstitute,Study of SARS-CoV-2 Seroprevalence in Canton Sarajevo,2021-10-13,Institutional Report,Local,Cross-sectional survey ,Bosnia and Herzegovina,,Sarajevo Canton,"The criteria included in the study were:
• Residents of Sarajevo Canton, based on age and gender structure in Sarajevo Canton;
• Risk groups (health workers, members of the Ministry of the Interior, traders, public transport workers, taxi drivers, educators);
• Share of respondents in relation to age and gender structure in Sarajevo Canton;
• Healthcare workers who were PCR confirmed cases more than 30 days ago.","Exclusion criteria were:
· People with acute SARS-CoV-2 disease
· People who have been confirmed by the case (PCR confirmed the presence of SARS-CoV-2 virus) in the past 90 days.",2021-01-05,2021-03-20,Multiple populations,All,Adults (18-64 years),41.0,65.0,Age,41-65,1917,0.3015127804,,,,,,,,Convenience,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Serum,IgG,,,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Anes Joguncic,Public Health Institute,Not Unity-Aligned,,2021-10-31,2024-03-01,Unverified,anes_joguncic_study_2021,BIH
211013_SarajevoCanton_PublicHealthInstitute_Age_Unknown,211013_SarajevoCanton_PublicHealthInstitute,Study of SARS-CoV-2 Seroprevalence in Canton Sarajevo,2021-10-13,Institutional Report,Local,Cross-sectional survey ,Bosnia and Herzegovina,,Sarajevo Canton,"The criteria included in the study were:
• Residents of Sarajevo Canton, based on age and gender structure in Sarajevo Canton;
• Risk groups (health workers, members of the Ministry of the Interior, traders, public transport workers, taxi drivers, educators);
• Share of respondents in relation to age and gender structure in Sarajevo Canton;
• Healthcare workers who were PCR confirmed cases more than 30 days ago.","Exclusion criteria were:
· People with acute SARS-CoV-2 disease
· People who have been confirmed by the case (PCR confirmed the presence of SARS-CoV-2 virus) in the past 90 days.",2021-01-05,2021-03-20,Multiple populations,All,Multiple groups,,,Age,Unknown,132,0.3106,,,,,,,,Convenience,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Serum,IgG,,,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Anes Joguncic,Public Health Institute,Not Unity-Aligned,,2021-10-31,2024-03-01,Unverified,anes_joguncic_study_2021,BIH
211013_SarajevoCanton_PublicHealthInstitute_Age_19-40,211013_SarajevoCanton_PublicHealthInstitute,Study of SARS-CoV-2 Seroprevalence in Canton Sarajevo,2021-10-13,Institutional Report,Local,Cross-sectional survey ,Bosnia and Herzegovina,,Sarajevo Canton,"The criteria included in the study were:
• Residents of Sarajevo Canton, based on age and gender structure in Sarajevo Canton;
• Risk groups (health workers, members of the Ministry of the Interior, traders, public transport workers, taxi drivers, educators);
• Share of respondents in relation to age and gender structure in Sarajevo Canton;
• Healthcare workers who were PCR confirmed cases more than 30 days ago.","Exclusion criteria were:
· People with acute SARS-CoV-2 disease
· People who have been confirmed by the case (PCR confirmed the presence of SARS-CoV-2 virus) in the past 90 days.",2021-01-05,2021-03-20,Multiple populations,All,Adults (18-64 years),19.0,40.0,Age,19-40,1255,0.219123506,,,,,,,,Convenience,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Serum,IgG,,,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Anes Joguncic,Public Health Institute,Not Unity-Aligned,,2021-10-31,2024-03-01,Unverified,anes_joguncic_study_2021,BIH
211013_SarajevoCanton_PublicHealthInstitute_Age_<18,211013_SarajevoCanton_PublicHealthInstitute,Study of SARS-CoV-2 Seroprevalence in Canton Sarajevo,2021-10-13,Institutional Report,Local,Cross-sectional survey ,Bosnia and Herzegovina,,Sarajevo Canton,"The criteria included in the study were:
• Residents of Sarajevo Canton, based on age and gender structure in Sarajevo Canton;
• Risk groups (health workers, members of the Ministry of the Interior, traders, public transport workers, taxi drivers, educators);
• Share of respondents in relation to age and gender structure in Sarajevo Canton;
• Healthcare workers who were PCR confirmed cases more than 30 days ago.","Exclusion criteria were:
· People with acute SARS-CoV-2 disease
· People who have been confirmed by the case (PCR confirmed the presence of SARS-CoV-2 virus) in the past 90 days.",2021-01-05,2021-03-20,Multiple populations,All,Children and Youth (0-17 years),,18.0,Age,<18,220,0.2909090909,,,,,,,,Convenience,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Serum,IgG,,,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Anes Joguncic,Public Health Institute,Not Unity-Aligned,,2021-10-31,2024-03-01,Unverified,anes_joguncic_study_2021,BIH
211013_SarajevoCanton_PublicHealthInstitute_Age_66+,211013_SarajevoCanton_PublicHealthInstitute,Study of SARS-CoV-2 Seroprevalence in Canton Sarajevo,2021-10-13,Institutional Report,Local,Cross-sectional survey ,Bosnia and Herzegovina,,Sarajevo Canton,"The criteria included in the study were:
• Residents of Sarajevo Canton, based on age and gender structure in Sarajevo Canton;
• Risk groups (health workers, members of the Ministry of the Interior, traders, public transport workers, taxi drivers, educators);
• Share of respondents in relation to age and gender structure in Sarajevo Canton;
• Healthcare workers who were PCR confirmed cases more than 30 days ago.","Exclusion criteria were:
· People with acute SARS-CoV-2 disease
· People who have been confirmed by the case (PCR confirmed the presence of SARS-CoV-2 virus) in the past 90 days.",2021-01-05,2021-03-20,Multiple populations,All,Seniors (65+ years),66.0,,Age,66+,126,0.46825396830000005,,,,,,,,Convenience,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Serum,IgG,,,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Anes Joguncic,Public Health Institute,Not Unity-Aligned,,2021-10-31,2024-03-01,Unverified,anes_joguncic_study_2021,BIH
220128_RepublicOfSrpska_UniversityOfBanjaLuka_Overall,220128_RepublicOfSrpska_UniversityOfBanjaLuka,"Seroprevalence of SARS-CoV-2 antibodies and knowledge, attitude and practice toward COVID-19 in the Republic of Srpska-Bosnia & Herzegovina: A population-based study",2022-01-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Bosnia and Herzegovina,Republic of Srpska,"""a total of 64 municipalities""",,"""The study did not include persons accommodated in student dormitories, boarding schools for children and youth with disabilities, nursing homes, prisons, monasteries and convents.""

""Participants who refused to participate were not included in the study, nor were the members of their families.""",2020-12-01,2021-01-15,Household and community samples,All,Multiple groups,1.0,88.0,Primary Estimate,Overall,1855,0.40270000000000006,,,True,,,,True,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9436,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Biljana Mijovic,University of Banja Luka,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0262738,2022-02-08,2024-03-01,Verified,mijovic_seroprevalence_2022,BIH
220128_RepublicOfSrpska_UniversityOfBanjaLuka_Age_20–34,220128_RepublicOfSrpska_UniversityOfBanjaLuka,"Seroprevalence of SARS-CoV-2 antibodies and knowledge, attitude and practice toward COVID-19 in the Republic of Srpska-Bosnia & Herzegovina: A population-based study",2022-01-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Bosnia and Herzegovina,Republic of Srpska,"""a total of 64 municipalities""",,"""The study did not include persons accommodated in student dormitories, boarding schools for children and youth with disabilities, nursing homes, prisons, monasteries and convents.""

""Participants who refused to participate were not included in the study, nor were the members of their families.""",2020-12-01,2021-01-15,Household and community samples,All,Adults (18-64 years),20.0,34.0,Age,Age: 20–34,314,0.47450000000000003,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9436,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Biljana Mijovic,University of Banja Luka,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0262738,2022-02-09,2024-03-01,Verified,mijovic_seroprevalence_2022,BIH
220128_RepublicOfSrpska_UniversityOfBanjaLuka_Age_50–64,220128_RepublicOfSrpska_UniversityOfBanjaLuka,"Seroprevalence of SARS-CoV-2 antibodies and knowledge, attitude and practice toward COVID-19 in the Republic of Srpska-Bosnia & Herzegovina: A population-based study",2022-01-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Bosnia and Herzegovina,Republic of Srpska,"""a total of 64 municipalities""",,"""The study did not include persons accommodated in student dormitories, boarding schools for children and youth with disabilities, nursing homes, prisons, monasteries and convents.""

""Participants who refused to participate were not included in the study, nor were the members of their families.""",2020-12-01,2021-01-15,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,Age: 50–64,512,0.4121,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9436,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Biljana Mijovic,University of Banja Luka,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0262738,2022-02-09,2024-03-01,Verified,mijovic_seroprevalence_2022,BIH
220128_RepublicOfSrpska_UniversityOfBanjaLuka_Age_10–19,220128_RepublicOfSrpska_UniversityOfBanjaLuka,"Seroprevalence of SARS-CoV-2 antibodies and knowledge, attitude and practice toward COVID-19 in the Republic of Srpska-Bosnia & Herzegovina: A population-based study",2022-01-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Bosnia and Herzegovina,Republic of Srpska,"""a total of 64 municipalities""",,"""The study did not include persons accommodated in student dormitories, boarding schools for children and youth with disabilities, nursing homes, prisons, monasteries and convents.""

""Participants who refused to participate were not included in the study, nor were the members of their families.""",2020-12-01,2021-01-15,Household and community samples,All,Multiple groups,10.0,19.0,Age,Age: 10–19,244,0.4098,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9436,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Biljana Mijovic,University of Banja Luka,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0262738,2022-02-09,2024-03-01,Verified,mijovic_seroprevalence_2022,BIH
220128_RepublicOfSrpska_UniversityOfBanjaLuka_Age_65andAbove,220128_RepublicOfSrpska_UniversityOfBanjaLuka,"Seroprevalence of SARS-CoV-2 antibodies and knowledge, attitude and practice toward COVID-19 in the Republic of Srpska-Bosnia & Herzegovina: A population-based study",2022-01-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Bosnia and Herzegovina,Republic of Srpska,"""a total of 64 municipalities""",,"""The study did not include persons accommodated in student dormitories, boarding schools for children and youth with disabilities, nursing homes, prisons, monasteries and convents.""

""Participants who refused to participate were not included in the study, nor were the members of their families.""",2020-12-01,2021-01-15,Household and community samples,All,Seniors (65+ years),65.0,88.0,Age,Age: ≥ 65,189,0.2593,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9436,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Biljana Mijovic,University of Banja Luka,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0262738,2022-02-09,2024-03-01,Verified,mijovic_seroprevalence_2022,BIH
220128_RepublicOfSrpska_UniversityOfBanjaLuka_Age_35–49,220128_RepublicOfSrpska_UniversityOfBanjaLuka,"Seroprevalence of SARS-CoV-2 antibodies and knowledge, attitude and practice toward COVID-19 in the Republic of Srpska-Bosnia & Herzegovina: A population-based study",2022-01-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Bosnia and Herzegovina,Republic of Srpska,"""a total of 64 municipalities""",,"""The study did not include persons accommodated in student dormitories, boarding schools for children and youth with disabilities, nursing homes, prisons, monasteries and convents.""

""Participants who refused to participate were not included in the study, nor were the members of their families.""",2020-12-01,2021-01-15,Household and community samples,All,Adults (18-64 years),35.0,49.0,Age,Age: 35–49,534,0.4045,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9436,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Biljana Mijovic,University of Banja Luka,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0262738,2022-02-09,2024-03-01,Verified,mijovic_seroprevalence_2022,BIH
220128_RepublicOfSrpska_UniversityOfBanjaLuka_Age_0–9,220128_RepublicOfSrpska_UniversityOfBanjaLuka,"Seroprevalence of SARS-CoV-2 antibodies and knowledge, attitude and practice toward COVID-19 in the Republic of Srpska-Bosnia & Herzegovina: A population-based study",2022-01-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Bosnia and Herzegovina,Republic of Srpska,"""a total of 64 municipalities""",,"""The study did not include persons accommodated in student dormitories, boarding schools for children and youth with disabilities, nursing homes, prisons, monasteries and convents.""

""Participants who refused to participate were not included in the study, nor were the members of their families.""",2020-12-01,2021-01-15,Household and community samples,All,Children and Youth (0-17 years),1.0,9.0,Age,Age: 0–9,62,0.35479999999999995,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9436,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Biljana Mijovic,University of Banja Luka,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0262738,2022-02-09,2024-03-01,Verified,mijovic_seroprevalence_2022,BIH
220128_RepublicOfSrpska_UniversityOfBanjaLuka_Sex_Male,220128_RepublicOfSrpska_UniversityOfBanjaLuka,"Seroprevalence of SARS-CoV-2 antibodies and knowledge, attitude and practice toward COVID-19 in the Republic of Srpska-Bosnia & Herzegovina: A population-based study",2022-01-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Bosnia and Herzegovina,Republic of Srpska,"""a total of 64 municipalities""",,"""The study did not include persons accommodated in student dormitories, boarding schools for children and youth with disabilities, nursing homes, prisons, monasteries and convents.""

""Participants who refused to participate were not included in the study, nor were the members of their families.""",2020-12-01,2021-01-15,Household and community samples,Male,Multiple groups,1.0,88.0,Sex/Gender,Sex: Male,809,0.4215,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9436,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Biljana Mijovic,University of Banja Luka,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0262738,2022-02-09,2024-03-01,Verified,mijovic_seroprevalence_2022,BIH
220128_RepublicOfSrpska_UniversityOfBanjaLuka_Sex_Female,220128_RepublicOfSrpska_UniversityOfBanjaLuka,"Seroprevalence of SARS-CoV-2 antibodies and knowledge, attitude and practice toward COVID-19 in the Republic of Srpska-Bosnia & Herzegovina: A population-based study",2022-01-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Bosnia and Herzegovina,Republic of Srpska,"""a total of 64 municipalities""",,"""The study did not include persons accommodated in student dormitories, boarding schools for children and youth with disabilities, nursing homes, prisons, monasteries and convents.""

""Participants who refused to participate were not included in the study, nor were the members of their families.""",2020-12-01,2021-01-15,Household and community samples,Female,Multiple groups,1.0,88.0,Sex/Gender,Sex: Female,1046,0.38810000000000006,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9436,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Biljana Mijovic,University of Banja Luka,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0262738,2022-02-09,2024-03-01,Verified,mijovic_seroprevalence_2022,BIH
220214_RepublicofSrpska_UniversityofBanjaLuka_Overall,220214_RepublicofSrpska_UniversityofBanjaLuka,"Seroprevalence of SARS-CoV-2 antibodies among primary healthcare workers in the Republic of Srpska, Bosnia & Herzegovina: A cross-sectional study.",2022-02-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Bosnia and Herzegovina,Republic of Srpska,,HCWs at the selected primary healthcare centres,,2021-03-19,2021-04-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1023,0.6950000000000001,,,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,Serum,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Darija Knezevic,University of Banja Luka,Not Unity-Aligned,https://akjournals.com/view/journals/030/aop/article-10.1556-030.2022.01706/article-10.1556-030.2022.01706.xml,2022-03-09,2022-07-16,Unverified,knezevic_seroprevalence_2022,BIH
220331_CantonSarajevo_InternationalBurchUniversity_Overall,220331_CantonSarajevo_InternationalBurchUniversity,"Antibody seroprevalence against SARS-CoV-2 within the Canton of Sarajevo, Bosnia and Herzegovina-One year later",2022-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bosnia and Herzegovina,,,"""We collected the blood samples from all the patients who came for serological testing"".
""The research was conducted at Eurofarm Central Laboratory.""",,2020-09-15,2021-05-15,Household and community samples,All,Multiple groups,0.0,93.0,Primary Estimate,,18066,0.2992,,,True,,,,True,Self-referral,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,,0.998,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Jasminka Prguda-Mujic,International Burch University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0265431,2022-04-13,2024-03-01,Unverified,prguda-mujic_antibody_2022,BIH
220331_CantonSarajevo_InternationalBurchUniversity_Time_Apr2021,220331_CantonSarajevo_InternationalBurchUniversity,"Antibody seroprevalence against SARS-CoV-2 within the Canton of Sarajevo, Bosnia and Herzegovina-One year later",2022-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bosnia and Herzegovina,,,"""We collected the blood samples from all the patients who came for serological testing"".
""The research was conducted at Eurofarm Central Laboratory.""",,2020-09-15,2021-05-15,Household and community samples,All,Multiple groups,,,Time frame,Time frame: April 2021,1734,0.6038,,,,,,,,Self-referral,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,,0.998,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Jasminka Prguda-Mujic,International Burch University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0265431,2022-04-14,2024-03-01,Unverified,prguda-mujic_antibody_2022,BIH
220331_CantonSarajevo_InternationalBurchUniversity_Time_Feb2021,220331_CantonSarajevo_InternationalBurchUniversity,"Antibody seroprevalence against SARS-CoV-2 within the Canton of Sarajevo, Bosnia and Herzegovina-One year later",2022-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bosnia and Herzegovina,,,"""We collected the blood samples from all the patients who came for serological testing"".
""The research was conducted at Eurofarm Central Laboratory.""",,2020-09-15,2021-05-15,Household and community samples,All,Multiple groups,,,Time frame,Time frame: February 2021,1223,0.3851,,,,,,,,Self-referral,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,,0.998,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Jasminka Prguda-Mujic,International Burch University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0265431,2022-04-14,2024-03-01,Unverified,prguda-mujic_antibody_2022,BIH
220331_CantonSarajevo_InternationalBurchUniversity_Age_Above50,220331_CantonSarajevo_InternationalBurchUniversity,"Antibody seroprevalence against SARS-CoV-2 within the Canton of Sarajevo, Bosnia and Herzegovina-One year later",2022-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bosnia and Herzegovina,,,"""We collected the blood samples from all the patients who came for serological testing"".
""The research was conducted at Eurofarm Central Laboratory.""",,2020-09-15,2021-05-15,Household and community samples,All,Multiple groups,51.0,93.0,Age,Age: > 50 years,5297,0.31620000000000004,,,,,,,,Self-referral,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,,0.998,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Jasminka Prguda-Mujic,International Burch University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0265431,2022-04-14,2024-03-01,Unverified,prguda-mujic_antibody_2022,BIH
220331_CantonSarajevo_InternationalBurchUniversity_Time_Sep2020,220331_CantonSarajevo_InternationalBurchUniversity,"Antibody seroprevalence against SARS-CoV-2 within the Canton of Sarajevo, Bosnia and Herzegovina-One year later",2022-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bosnia and Herzegovina,,,"""We collected the blood samples from all the patients who came for serological testing"".
""The research was conducted at Eurofarm Central Laboratory.""",,2020-09-15,2021-05-15,Household and community samples,All,Multiple groups,,,Time frame,Time frame: September 2020,2376,0.0375,,,,,,,,Self-referral,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,,0.998,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Jasminka Prguda-Mujic,International Burch University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0265431,2022-04-14,2024-03-01,Unverified,prguda-mujic_antibody_2022,BIH
220331_CantonSarajevo_InternationalBurchUniversity_Time_Jan2021,220331_CantonSarajevo_InternationalBurchUniversity,"Antibody seroprevalence against SARS-CoV-2 within the Canton of Sarajevo, Bosnia and Herzegovina-One year later",2022-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bosnia and Herzegovina,,,"""We collected the blood samples from all the patients who came for serological testing"".
""The research was conducted at Eurofarm Central Laboratory.""",,2020-09-15,2021-05-15,Household and community samples,All,Multiple groups,,,Time frame,Time frame: January 2021,1693,0.3136,,,,,,,,Self-referral,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,,0.998,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Jasminka Prguda-Mujic,International Burch University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0265431,2022-04-14,2024-03-01,Unverified,prguda-mujic_antibody_2022,BIH
220331_CantonSarajevo_InternationalBurchUniversity_Sex_Female,220331_CantonSarajevo_InternationalBurchUniversity,"Antibody seroprevalence against SARS-CoV-2 within the Canton of Sarajevo, Bosnia and Herzegovina-One year later",2022-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bosnia and Herzegovina,,,"""We collected the blood samples from all the patients who came for serological testing"".
""The research was conducted at Eurofarm Central Laboratory.""",,2020-09-15,2021-05-15,Household and community samples,Female,Multiple groups,,,Sex/Gender,,8266,0.3056,,,,,,,,Self-referral,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,,0.998,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Jasminka Prguda-Mujic,International Burch University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0265431,2022-04-14,2024-03-01,Unverified,prguda-mujic_antibody_2022,BIH
220331_CantonSarajevo_InternationalBurchUniversity_Sex_Male,220331_CantonSarajevo_InternationalBurchUniversity,"Antibody seroprevalence against SARS-CoV-2 within the Canton of Sarajevo, Bosnia and Herzegovina-One year later",2022-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bosnia and Herzegovina,,,"""We collected the blood samples from all the patients who came for serological testing"".
""The research was conducted at Eurofarm Central Laboratory.""",,2020-09-15,2021-05-15,Household and community samples,Male,Multiple groups,,,Sex/Gender,,9797,0.294,,,,,,,,Self-referral,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,,0.998,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Jasminka Prguda-Mujic,International Burch University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0265431,2022-04-14,2024-03-01,Unverified,prguda-mujic_antibody_2022,BIH
220331_CantonSarajevo_InternationalBurchUniversity_Time_May2021,220331_CantonSarajevo_InternationalBurchUniversity,"Antibody seroprevalence against SARS-CoV-2 within the Canton of Sarajevo, Bosnia and Herzegovina-One year later",2022-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bosnia and Herzegovina,,,"""We collected the blood samples from all the patients who came for serological testing"".
""The research was conducted at Eurofarm Central Laboratory.""",,2020-09-15,2021-05-15,Household and community samples,All,Multiple groups,,,Time frame,Time frame: May 2021,1391,0.17329999999999998,,,,,,,,Self-referral,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,,0.998,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Jasminka Prguda-Mujic,International Burch University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0265431,2022-04-14,2024-03-01,Unverified,prguda-mujic_antibody_2022,BIH
220331_CantonSarajevo_InternationalBurchUniversity_Time_Dec2020,220331_CantonSarajevo_InternationalBurchUniversity,"Antibody seroprevalence against SARS-CoV-2 within the Canton of Sarajevo, Bosnia and Herzegovina-One year later",2022-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bosnia and Herzegovina,,,"""We collected the blood samples from all the patients who came for serological testing"".
""The research was conducted at Eurofarm Central Laboratory.""",,2020-09-15,2021-05-15,Household and community samples,All,Multiple groups,,,Time frame,Time frame: December 2020,1878,0.3876,,,,,,,,Self-referral,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,,0.998,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Jasminka Prguda-Mujic,International Burch University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0265431,2022-04-14,2024-03-01,Unverified,prguda-mujic_antibody_2022,BIH
220331_CantonSarajevo_InternationalBurchUniversity_Time_Oct2020,220331_CantonSarajevo_InternationalBurchUniversity,"Antibody seroprevalence against SARS-CoV-2 within the Canton of Sarajevo, Bosnia and Herzegovina-One year later",2022-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bosnia and Herzegovina,,,"""We collected the blood samples from all the patients who came for serological testing"".
""The research was conducted at Eurofarm Central Laboratory.""",,2020-09-15,2021-05-15,Household and community samples,All,Multiple groups,,,Time frame,Time frame: October 2020,1509,0.055700000000000006,,,,,,,,Self-referral,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,,0.998,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Jasminka Prguda-Mujic,International Burch University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0265431,2022-04-14,2024-03-01,Unverified,prguda-mujic_antibody_2022,BIH
220331_CantonSarajevo_InternationalBurchUniversity_Time_Mar2021,220331_CantonSarajevo_InternationalBurchUniversity,"Antibody seroprevalence against SARS-CoV-2 within the Canton of Sarajevo, Bosnia and Herzegovina-One year later",2022-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bosnia and Herzegovina,,,"""We collected the blood samples from all the patients who came for serological testing"".
""The research was conducted at Eurofarm Central Laboratory.""",,2020-09-15,2021-05-15,Household and community samples,All,Multiple groups,,,Time frame,Time frame: March 2021,2801,0.4988,,,,,,,,Self-referral,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,,0.998,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Jasminka Prguda-Mujic,International Burch University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0265431,2022-04-14,2024-03-01,Unverified,prguda-mujic_antibody_2022,BIH
220331_CantonSarajevo_InternationalBurchUniversity_Time_Nov2020,220331_CantonSarajevo_InternationalBurchUniversity,"Antibody seroprevalence against SARS-CoV-2 within the Canton of Sarajevo, Bosnia and Herzegovina-One year later",2022-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bosnia and Herzegovina,,,"""We collected the blood samples from all the patients who came for serological testing"".
""The research was conducted at Eurofarm Central Laboratory.""",,2020-09-15,2021-05-15,Household and community samples,All,Multiple groups,,,Time frame,Time frame: November 2020,3461,0.2366,,,,,,,,Self-referral,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,,0.998,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Jasminka Prguda-Mujic,International Burch University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0265431,2022-04-14,2024-03-01,Unverified,prguda-mujic_antibody_2022,BIH
220331_CantonSarajevo_InternationalBurchUniversity_Age_Below50,220331_CantonSarajevo_InternationalBurchUniversity,"Antibody seroprevalence against SARS-CoV-2 within the Canton of Sarajevo, Bosnia and Herzegovina-One year later",2022-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bosnia and Herzegovina,,,"""We collected the blood samples from all the patients who came for serological testing"".
""The research was conducted at Eurofarm Central Laboratory.""",,2020-09-15,2021-05-15,Household and community samples,All,Multiple groups,0.0,50.0,Age,Age: ≤ 50 years,12766,0.2923,,,,,,,,Self-referral,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,,0.998,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Jasminka Prguda-Mujic,International Burch University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0265431,2022-04-14,2024-03-01,Unverified,prguda-mujic_antibody_2022,BIH
20220915_BosniaandHerzegovina_InstituteforHealthandFoodSafety_Overall,20220915_BosniaandHerzegovina_InstituteforHealthandFoodSafety,"Detection of anti-SARS-CoV-2 antibodies and its seroprevalence in Zavidovici municipality of Zenica-Doboj Canton, Bosnia and Herzegovina.",2022-09-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bosnia and Herzegovina,Zenica-Doboj Canton,Zavidovići municipality,"consecutive, nonduplicate serum samples were collected from participants who were not vaccinated with inactivated SARS-CoV-2 vaccine in Health Center of Zavidovići.",,2021-03-15,2021-04-15,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,256,0.40625,,,True,,,,True,Sequential,Tigsun COVID-19 Combo IgM/IgG Rapid test,"Tigsun, Beijing",LFIA,Serum,"['IgG', 'IgM']",,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Amir Ibrahimagic,Institute for Health and Food Safety,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/36101851/,2022-09-21,2022-09-21,Unverified,ibrahimagic_detection_2022,BIH
20220915_BosniaandHerzegovina_InstituteforHealthandFoodSafety_Female,20220915_BosniaandHerzegovina_InstituteforHealthandFoodSafety,"Detection of anti-SARS-CoV-2 antibodies and its seroprevalence in Zavidovici municipality of Zenica-Doboj Canton, Bosnia and Herzegovina.",2022-09-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bosnia and Herzegovina,Zenica-Doboj Canton,Zavidovići municipality,"consecutive, nonduplicate serum samples were collected from participants who were not vaccinated with inactivated SARS-CoV-2 vaccine in Health Center of Zavidovići.",,2021-03-15,2021-04-15,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,187,0.43850267379999996,,,,,,,,Sequential,Tigsun COVID-19 Combo IgM/IgG Rapid test,"Tigsun, Beijing",LFIA,Serum,"['IgG', 'IgM']",,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Amir Ibrahimagic,Institute for Health and Food Safety,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/36101851/,2022-09-21,2022-09-21,Unverified,ibrahimagic_detection_2022,BIH
20220915_BosniaandHerzegovina_InstituteforHealthandFoodSafety_Age25to50,20220915_BosniaandHerzegovina_InstituteforHealthandFoodSafety,"Detection of anti-SARS-CoV-2 antibodies and its seroprevalence in Zavidovici municipality of Zenica-Doboj Canton, Bosnia and Herzegovina.",2022-09-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bosnia and Herzegovina,Zenica-Doboj Canton,Zavidovići municipality,"consecutive, nonduplicate serum samples were collected from participants who were not vaccinated with inactivated SARS-CoV-2 vaccine in Health Center of Zavidovići.",,2021-03-15,2021-04-15,Residual sera,All,Adults (18-64 years),25.0,50.0,Age,age: 25-50,147,0.41496598640000004,,,,,,,,Sequential,Tigsun COVID-19 Combo IgM/IgG Rapid test,"Tigsun, Beijing",LFIA,Serum,"['IgG', 'IgM']",,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Amir Ibrahimagic,Institute for Health and Food Safety,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/36101851/,2022-09-21,2022-09-21,Unverified,ibrahimagic_detection_2022,BIH
20220915_BosniaandHerzegovina_InstituteforHealthandFoodSafety_AgeOver65,20220915_BosniaandHerzegovina_InstituteforHealthandFoodSafety,"Detection of anti-SARS-CoV-2 antibodies and its seroprevalence in Zavidovici municipality of Zenica-Doboj Canton, Bosnia and Herzegovina.",2022-09-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bosnia and Herzegovina,Zenica-Doboj Canton,Zavidovići municipality,"consecutive, nonduplicate serum samples were collected from participants who were not vaccinated with inactivated SARS-CoV-2 vaccine in Health Center of Zavidovići.",,2021-03-15,2021-04-15,Residual sera,All,Seniors (65+ years),65.0,,Age,age: >= 65,107,0.45794392520000005,,,,,,,,Sequential,Tigsun COVID-19 Combo IgM/IgG Rapid test,"Tigsun, Beijing",LFIA,Serum,"['IgG', 'IgM']",,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Amir Ibrahimagic,Institute for Health and Food Safety,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/36101851/,2022-09-21,2022-09-21,Unverified,ibrahimagic_detection_2022,BIH
20220915_BosniaandHerzegovina_InstituteforHealthandFoodSafety_Age51to64,20220915_BosniaandHerzegovina_InstituteforHealthandFoodSafety,"Detection of anti-SARS-CoV-2 antibodies and its seroprevalence in Zavidovici municipality of Zenica-Doboj Canton, Bosnia and Herzegovina.",2022-09-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bosnia and Herzegovina,Zenica-Doboj Canton,Zavidovići municipality,"consecutive, nonduplicate serum samples were collected from participants who were not vaccinated with inactivated SARS-CoV-2 vaccine in Health Center of Zavidovići.",,2021-03-15,2021-04-15,Residual sera,All,Adults (18-64 years),51.0,64.0,Age,age: 51-64,131,0.4351145038,,,,,,,,Sequential,Tigsun COVID-19 Combo IgM/IgG Rapid test,"Tigsun, Beijing",LFIA,Serum,"['IgG', 'IgM']",,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Amir Ibrahimagic,Institute for Health and Food Safety,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/36101851/,2022-09-21,2022-09-21,Unverified,ibrahimagic_detection_2022,BIH
20220915_BosniaandHerzegovina_InstituteforHealthandFoodSafety_Age0to14,20220915_BosniaandHerzegovina_InstituteforHealthandFoodSafety,"Detection of anti-SARS-CoV-2 antibodies and its seroprevalence in Zavidovici municipality of Zenica-Doboj Canton, Bosnia and Herzegovina.",2022-09-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bosnia and Herzegovina,Zenica-Doboj Canton,Zavidovići municipality,"consecutive, nonduplicate serum samples were collected from participants who were not vaccinated with inactivated SARS-CoV-2 vaccine in Health Center of Zavidovići.",,2021-03-15,2021-04-15,Residual sera,All,Children and Youth (0-17 years),0.0,14.0,Age,age: 0-14,29,0.5172413793,,,,,,,,Sequential,Tigsun COVID-19 Combo IgM/IgG Rapid test,"Tigsun, Beijing",LFIA,Serum,"['IgG', 'IgM']",,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Amir Ibrahimagic,Institute for Health and Food Safety,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/36101851/,2022-09-21,2022-09-21,Unverified,ibrahimagic_detection_2022,BIH
20220915_BosniaandHerzegovina_InstituteforHealthandFoodSafety_Male,20220915_BosniaandHerzegovina_InstituteforHealthandFoodSafety,"Detection of anti-SARS-CoV-2 antibodies and its seroprevalence in Zavidovici municipality of Zenica-Doboj Canton, Bosnia and Herzegovina.",2022-09-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bosnia and Herzegovina,Zenica-Doboj Canton,Zavidovići municipality,"consecutive, nonduplicate serum samples were collected from participants who were not vaccinated with inactivated SARS-CoV-2 vaccine in Health Center of Zavidovići.",,2021-03-15,2021-04-15,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,443,0.41986455980000004,,,,,,,,Sequential,Tigsun COVID-19 Combo IgM/IgG Rapid test,"Tigsun, Beijing",LFIA,Serum,"['IgG', 'IgM']",,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Amir Ibrahimagic,Institute for Health and Food Safety,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/36101851/,2022-09-21,2022-09-21,Unverified,ibrahimagic_detection_2022,BIH
20220915_BosniaandHerzegovina_InstituteforHealthandFoodSafety_Age15to24,20220915_BosniaandHerzegovina_InstituteforHealthandFoodSafety,"Detection of anti-SARS-CoV-2 antibodies and its seroprevalence in Zavidovici municipality of Zenica-Doboj Canton, Bosnia and Herzegovina.",2022-09-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bosnia and Herzegovina,Zenica-Doboj Canton,Zavidovići municipality,"consecutive, nonduplicate serum samples were collected from participants who were not vaccinated with inactivated SARS-CoV-2 vaccine in Health Center of Zavidovići.",,2021-03-15,2021-04-15,Residual sera,All,Multiple groups,15.0,24.0,Age,age: 15-24,29,0.1379310345,,,,,,,,Sequential,Tigsun COVID-19 Combo IgM/IgG Rapid test,"Tigsun, Beijing",LFIA,Serum,"['IgG', 'IgM']",,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Amir Ibrahimagic,Institute for Health and Food Safety,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/36101851/,2022-09-21,2022-09-21,Unverified,ibrahimagic_detection_2022,BIH
230611_Sarajevo_AcademyofSciencesandArtsofBosniaandHerzegovina_Overall,230611_Sarajevo_AcademyofSciencesandArtsofBosniaandHerzegovina,"COVID-19 Seroprevalence in Children during Pandemic Waves in Sarajevo, a Single Center Experience.",2023-06-11,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Bosnia and Herzegovina,,Sarajevo,"""A total of 762 children were tested in the period between September 2020 and May 2021""",,2020-09-15,2021-05-15,Residual sera,All,Children and Youth (0-17 years),0.0,18.0,Primary Estimate,,762,0.245,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM', 'TotalAntibody']",Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Senka Mesihovic-Dinarevic,Academy of Sciences and Arts of Bosnia and Herzegovina,Unity-Aligned,https://dx.doi.org/10.5644/ama2006-124.403,2023-08-01,2024-04-29,Verified,mesihović-dinarevićCOVID19SeroprevalenceChildren2023,BIH
230611_Sarajevo_AcademyofSciencesandArtsofBosniaandHerzegovina_Age_6-13,230611_Sarajevo_AcademyofSciencesandArtsofBosniaandHerzegovina,"COVID-19 Seroprevalence in Children during Pandemic Waves in Sarajevo, a Single Center Experience.",2023-06-11,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Bosnia and Herzegovina,,Sarajevo,"""A total of 762 children were tested in the period between September 2020 and May 2021""",,2020-09-15,2021-05-15,Residual sera,All,Children and Youth (0-17 years),6.0,13.0,Age,6-13 years,373,0.444,,,,True,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM', 'TotalAntibody']",Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Senka Mesihovic-Dinarevic,Academy of Sciences and Arts of Bosnia and Herzegovina,Unity-Aligned,https://dx.doi.org/10.5644/ama2006-124.403,2024-04-29,2024-04-29,Verified,mesihović-dinarevićCOVID19SeroprevalenceChildren2023,BIH
230611_Sarajevo_AcademyofSciencesandArtsofBosniaandHerzegovina_Age_0-5,230611_Sarajevo_AcademyofSciencesandArtsofBosniaandHerzegovina,"COVID-19 Seroprevalence in Children during Pandemic Waves in Sarajevo, a Single Center Experience.",2023-06-11,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Bosnia and Herzegovina,,Sarajevo,"""A total of 762 children were tested in the period between September 2020 and May 2021""",,2020-09-15,2021-05-15,Residual sera,All,Children and Youth (0-17 years),0.0,5.0,Age,0-5 years,73,0.101,,,,True,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM', 'TotalAntibody']",Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Senka Mesihovic-Dinarevic,Academy of Sciences and Arts of Bosnia and Herzegovina,Unity-Aligned,https://dx.doi.org/10.5644/ama2006-124.403,2024-04-29,2024-04-29,Verified,mesihović-dinarevićCOVID19SeroprevalenceChildren2023,BIH
230611_Sarajevo_AcademyofSciencesandArtsofBosniaandHerzegovina_Age_14-18,230611_Sarajevo_AcademyofSciencesandArtsofBosniaandHerzegovina,"COVID-19 Seroprevalence in Children during Pandemic Waves in Sarajevo, a Single Center Experience.",2023-06-11,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Bosnia and Herzegovina,,Sarajevo,"""A total of 762 children were tested in the period between September 2020 and May 2021""",,2020-09-15,2021-05-15,Residual sera,All,Children and Youth (0-17 years),14.0,18.0,Age,14-18 years,316,0.455,,,,True,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM', 'TotalAntibody']",Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Senka Mesihovic-Dinarevic,Academy of Sciences and Arts of Bosnia and Herzegovina,Unity-Aligned,https://dx.doi.org/10.5644/ama2006-124.403,2024-04-29,2024-04-29,Verified,mesihović-dinarevićCOVID19SeroprevalenceChildren2023,BIH
230822_SarajevoCanton_WorldHealthOrganizationRegionalOfficeForEurope_NovDec2020,230822_SarajevoCanton_WorldHealthOrganizationRegionalOfficeForEurope_NovDec2020,"Evolution of seroprevalence to SARS-CoV-2 in blood donors in Sarajevo Canton, Federation of Bosnia and Herzegovina: Cross-sectional and longitudinal studies.",2023-08-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Bosnia and Herzegovina,Sarajevo Canton,,"We conducted repeated cross-sectional analyses among blood donors aged 18 to 65 years who attended the Institute of Transfusion Medicine of the FBiH at end of 2020 (Phase 1) and end of 2021 (Phase 2) to estimate the seroprevalence of anti-SARS-CoV-2 antibodies in Sarajevo Canton. We aligned methods with WHO standardized protocol under the Unity Studies initiative. 10 In the cross-sectional analyses, blood donors were invited to participate in the study, irrespective of prior SARS-CoV-2 infection (Figure 1).","Nonresidents of Sarajevo Canton and those experiencing COVID-19 symptoms, or who reported contact with a confirmed COVID-19 case within 14 days prior, were excluded.

Participants were excluded due to refusal to participate or residence outside Sarajevo Canton.",2020-11-02,2020-12-11,Blood donors,All,Adults (18-64 years),18.0,65.0,Primary Estimate,Age-adj anti-N,1015,0.177,0.154,0.202,True,,True,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Sanjin Musa,World Health Organization Regional Office for Europe,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.13182,2023-09-22,2024-03-01,Unverified,musa_evolution_2023,BIH
230822_SarajevoCanton_WorldHealthOrganizationRegionalOfficeForEurope_NovDec2021,230822_SarajevoCanton_WorldHealthOrganizationRegionalOfficeForEurope_NovDec2021,"Evolution of seroprevalence to SARS-CoV-2 in blood donors in Sarajevo Canton, Federation of Bosnia and Herzegovina: Cross-sectional and longitudinal studies.",2023-08-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Bosnia and Herzegovina,Sarajevo Canton,,"We conducted repeated cross-sectional analyses among blood donors aged 18 to 65 years who attended the Institute of Transfusion Medicine of the FBiH at end of 2020 (Phase 1) and end of 2021 (Phase 2) to estimate the seroprevalence of anti-SARS-CoV-2 antibodies in Sarajevo Canton. We aligned methods with WHO standardized protocol under the Unity Studies initiative. 10 In the cross-sectional analyses, blood donors were invited to participate in the study, irrespective of prior SARS-CoV-2 infection (Figure 1).","Nonresidents of Sarajevo Canton and those experiencing COVID-19 symptoms, or who reported contact with a confirmed COVID-19 case within 14 days prior, were excluded.

Participants were excluded due to refusal to participate or residence outside Sarajevo Canton.",2021-11-07,2021-12-31,Blood donors,All,Adults (18-64 years),18.0,65.0,Primary Estimate,Age-adj anti-S,1152,0.916,0.87,0.965,True,,True,,True,Sequential,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Sanjin Musa,World Health Organization Regional Office for Europe,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.13182,2023-09-22,2024-03-01,Unverified,musa_evolution_2023,BIH
200517_SaoPaolo_GrupoFleury_GenPop,200517_SaoPaolo_GrupoFleury,"In the neighborhoods of São Paulo most affected by Covid-19, only 5% had contact with the virus",2020-05-17,News and Media,Local,Cross-sectional survey ,Brazil,São Paulo,São Paulo,"Randomly selected 1,152 houses in the neighborhoods in question, then randomly chosen residents of 296 selected houses and 224 other people who also lived in these homes.

Focus on the neighborhoods of Morumbi, Jardim Paulistano and Bela Vista - the three with the highest number of cases per 100 thousand inhabitants in the city - and Água Rasa, Belém and Pari - which have the highest number of deaths per 100 thousand inhabitants.",,2020-05-04,2020-05-12,Household and community samples,All,Multiple groups,,,Primary Estimate,,520,0.0519,,,True,,,,True,Stratified probability,Not reported/ Unable to specify,,,,,,,0.9,,['High'],Yes,Yes,No,No,Unclear,Unclear,Yes,No,Unclear,Phillippe Watanabe,Grupo Fleury,Not Unity-Aligned,https://www1.folha.uol.com.br/equilibrioesaude/2020/05/nos-bairros-de-sp-mais-afetados-pela-covid-19-so-5-tiveram-contato-com-o-virus.shtml,2020-06-02,2022-07-16,Verified,watanabe_neighborhoods_2020,BRA
200527_RioGrandeDoSul_FederalUniversityOfPelotas_overall,200527_RioGrandeDoSul_FederalUniversityOfPelotas,"Fourth stage of research shows
  stability in the total number of coronavirus ",2020-05-27,News and Media,Regional,Repeated cross-sectional study,Brazil,Rio Grande do Sul,,inhabitants of Rio Grande do Sul,,2020-05-23,2020-05-25,Household and community samples,All,Multiple groups,,,Primary Estimate,,4500,0.0018,0.0008,0.0034999999999999996,True,,,,True,Unclear,Not reported/ Unable to specify,,LFIA,Whole Blood,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,Governo do Estato do Rio Grande do Sul,Governo do Estato do Rio Grande do Sul,Not Unity-Aligned,https://estado.rs.gov.br/quarta-etapa-de-pesquisa-aponta-estabilidade-no-total-de-infectados-por-coronavirus-no-rs,2021-05-03,2022-07-16,Verified,governo_do_estado_rio_grande_do_sul_quarta_2020,BRA
200602_Biguacu_SecretariaMunicipaldeSaude_primary,200602_Biguacu_SecretariaMunicipaldeSaude,Check out a study on the Covid-19 pandemic in Biguaçu in graphs ,2020-06-02,News and Media,Local,Cross-sectional survey ,Brazil,,Biguacu,,,2020-05-30,2020-05-30,Household and community samples,All,Multiple groups,,,Primary Estimate,,217,0.004,,,True,,,,True,Stratified probability,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,Yes,No,Yes,Yes,Unclear,Yes,No,Unclear,Ozias Alves Jr,Secretaria Municipal de Saude,Not Unity-Aligned,http://jbfoco.com.br/2020/06/confira-um-estudo-sobre-a-pandemia-de-covid-19-em-biguacu-em-graficos/,2021-04-23,2022-07-16,Verified,noauthor_confira_2020,BRA
200604_Goiania_CityOfGoiania_overall,200604_Goiania_CityOfGoiania,"Survey shows that 1% of the
  population has already had Covid-19 in Goiânia",2020-06-04,News and Media,Local,Cross-sectional survey ,Brazil,Goiás,Goiania,Individuals in Goiania,,2020-05-30,2020-05-30,Household and community samples,All,Multiple groups,,,Primary Estimate,,2400,0.0075,,,True,,,,True,Simplified probability,Not reported/ Unable to specify,,,,,,,,,['Moderate'],Yes,Yes,Yes,No,Yes,Unclear,Yes,No,Unclear,Mauro Junio,City of Goiania,Not Unity-Aligned,https://www.goiania.go.gov.br/inquerito-aponta-que-1-das-pessoas-ja-tiveram-covid-19-em-goiania/,2021-04-29,2022-07-16,Verified,junio_inquerito_2020,BRA
200616_Brazil_SecretariadeEstadodaSaúdedoEspíritoSanto_GenPopUrban,200616_Brazil_SecretariadeEstadodaSaúdedoEspíritoSanto_1_Urban,"A population-based study of the prevalence of COVID-19 infection in Espírito Santo, Brazil: methodology and results of the first stage",2020-06-16,Preprint,Regional,Cross-sectional survey ,Brazil,Espírito Santo,,"The included individuals were older than two years. The legal guardian answered the questions for those younger than 16. The ‘prevalence study’ comprises the sampling of each reference municipality, added by the four most populous in the metropolitan region and one elected municipality in the region lacking a reference. Therefore, there are 11 municipalities allocated to the prevalence study.",,2020-05-13,2020-05-15,Household and community samples,All,Multiple groups,2.0,,Primary Estimate,,4612,0.021,0.0167,0.0252,True,,,,True,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.8640000000000001,0.9763,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Cristiana Gomes,Secretaria de Estado da Saúde do Espírito Santo,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.06.13.20130559v1.full.pdf,2020-06-18,2024-03-01,Verified,costa_gomes_population-based_2020,BRA
200616_Brazil_SecretariadeEstadodaSaúdedoEspíritoSanto_WhiteUrban,200616_Brazil_SecretariadeEstadodaSaúdedoEspíritoSanto_1_Urban,"A population-based study of the prevalence of COVID-19 infection in Espírito Santo, Brazil: methodology and results of the first stage",2020-06-16,Preprint,Regional,Cross-sectional survey ,Brazil,Espírito Santo,,"The included individuals were older than two years. The legal guardian answered the questions for those younger than 16. The ‘prevalence study’ comprises the sampling of each reference municipality, added by the four most populous in the metropolitan region and one elected municipality in the region lacking a reference. Therefore, there are 11 municipalities allocated to the prevalence study.",,2020-05-13,2020-05-15,Household and community samples,All,Multiple groups,2.0,,Race,White,1795,0.015600000000000001,,,,,,,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.8640000000000001,0.9763,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Cristiana Gomes,Secretaria de Estado da Saúde do Espírito Santo,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.06.13.20130559v1.full.pdf,2020-07-17,2024-03-01,Verified,costa_gomes_population-based_2020,BRA
200616_Brazil_SecretariadeEstadodaSaúdedoEspíritoSanto_IndianUrban,200616_Brazil_SecretariadeEstadodaSaúdedoEspíritoSanto_1_Urban,"A population-based study of the prevalence of COVID-19 infection in Espírito Santo, Brazil: methodology and results of the first stage",2020-06-16,Preprint,Regional,Cross-sectional survey ,Brazil,Espírito Santo,,"The included individuals were older than two years. The legal guardian answered the questions for those younger than 16. The ‘prevalence study’ comprises the sampling of each reference municipality, added by the four most populous in the metropolitan region and one elected municipality in the region lacking a reference. Therefore, there are 11 municipalities allocated to the prevalence study.",,2020-05-13,2020-05-15,Household and community samples,All,Multiple groups,2.0,,Race,Indian,12,0.0,,,,,,,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.8640000000000001,0.9763,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Cristiana Gomes,Secretaria de Estado da Saúde do Espírito Santo,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.06.13.20130559v1.full.pdf,2020-07-17,2024-03-01,Verified,costa_gomes_population-based_2020,BRA
200616_Brazil_SecretariadeEstadodaSaúdedoEspíritoSanto_>=81yrsUrban,200616_Brazil_SecretariadeEstadodaSaúdedoEspíritoSanto_1_Urban,"A population-based study of the prevalence of COVID-19 infection in Espírito Santo, Brazil: methodology and results of the first stage",2020-06-16,Preprint,Regional,Cross-sectional survey ,Brazil,Espírito Santo,,"The included individuals were older than two years. The legal guardian answered the questions for those younger than 16. The ‘prevalence study’ comprises the sampling of each reference municipality, added by the four most populous in the metropolitan region and one elected municipality in the region lacking a reference. Therefore, there are 11 municipalities allocated to the prevalence study.",,2020-05-13,2020-05-15,Household and community samples,All,Seniors (65+ years),81.0,,Age,>=81,143,0.0,,,,,,,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.8640000000000001,0.9763,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Cristiana Gomes,Secretaria de Estado da Saúde do Espírito Santo,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.06.13.20130559v1.full.pdf,2020-07-17,2024-03-01,Verified,costa_gomes_population-based_2020,BRA
200616_Brazil_SecretariadeEstadodaSaúdedoEspíritoSanto_MaleUrban,200616_Brazil_SecretariadeEstadodaSaúdedoEspíritoSanto_1_Urban,"A population-based study of the prevalence of COVID-19 infection in Espírito Santo, Brazil: methodology and results of the first stage",2020-06-16,Preprint,Regional,Cross-sectional survey ,Brazil,Espírito Santo,,"The included individuals were older than two years. The legal guardian answered the questions for those younger than 16. The ‘prevalence study’ comprises the sampling of each reference municipality, added by the four most populous in the metropolitan region and one elected municipality in the region lacking a reference. Therefore, there are 11 municipalities allocated to the prevalence study.",,2020-05-13,2020-05-15,Household and community samples,Male,Multiple groups,2.0,,Sex/Gender,Male,1799,0.014450000000000001,,,,,,,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.8640000000000001,0.9763,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Cristiana Gomes,Secretaria de Estado da Saúde do Espírito Santo,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.06.13.20130559v1.full.pdf,2020-07-17,2024-03-01,Verified,costa_gomes_population-based_2020,BRA
200616_Brazil_SecretariadeEstadodaSaúdedoEspíritoSanto_BlackUrban,200616_Brazil_SecretariadeEstadodaSaúdedoEspíritoSanto_1_Urban,"A population-based study of the prevalence of COVID-19 infection in Espírito Santo, Brazil: methodology and results of the first stage",2020-06-16,Preprint,Regional,Cross-sectional survey ,Brazil,Espírito Santo,,"The included individuals were older than two years. The legal guardian answered the questions for those younger than 16. The ‘prevalence study’ comprises the sampling of each reference municipality, added by the four most populous in the metropolitan region and one elected municipality in the region lacking a reference. Therefore, there are 11 municipalities allocated to the prevalence study.",,2020-05-13,2020-05-15,Household and community samples,All,Multiple groups,2.0,,Race,Black,710,0.031000000000000003,,,,,,,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.8640000000000001,0.9763,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Cristiana Gomes,Secretaria de Estado da Saúde do Espírito Santo,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.06.13.20130559v1.full.pdf,2020-07-17,2024-03-01,Verified,costa_gomes_population-based_2020,BRA
200616_Brazil_SecretariadeEstadodaSaúdedoEspíritoSanto_21-40yrsUrban,200616_Brazil_SecretariadeEstadodaSaúdedoEspíritoSanto_1_Urban,"A population-based study of the prevalence of COVID-19 infection in Espírito Santo, Brazil: methodology and results of the first stage",2020-06-16,Preprint,Regional,Cross-sectional survey ,Brazil,Espírito Santo,,"The included individuals were older than two years. The legal guardian answered the questions for those younger than 16. The ‘prevalence study’ comprises the sampling of each reference municipality, added by the four most populous in the metropolitan region and one elected municipality in the region lacking a reference. Therefore, there are 11 municipalities allocated to the prevalence study.",,2020-05-13,2020-05-15,Household and community samples,All,Adults (18-64 years),21.0,40.0,Age,21-40,1367,0.0263,,,,,,,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.8640000000000001,0.9763,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Cristiana Gomes,Secretaria de Estado da Saúde do Espírito Santo,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.06.13.20130559v1.full.pdf,2020-07-17,2024-03-01,Verified,costa_gomes_population-based_2020,BRA
200616_Brazil_SecretariadeEstadodaSaúdedoEspíritoSanto_FemaleUrban,200616_Brazil_SecretariadeEstadodaSaúdedoEspíritoSanto_1_Urban,"A population-based study of the prevalence of COVID-19 infection in Espírito Santo, Brazil: methodology and results of the first stage",2020-06-16,Preprint,Regional,Cross-sectional survey ,Brazil,Espírito Santo,,"The included individuals were older than two years. The legal guardian answered the questions for those younger than 16. The ‘prevalence study’ comprises the sampling of each reference municipality, added by the four most populous in the metropolitan region and one elected municipality in the region lacking a reference. Therefore, there are 11 municipalities allocated to the prevalence study.",,2020-05-13,2020-05-15,Household and community samples,Female,Multiple groups,2.0,,Sex/Gender,Female,2809,0.0253,,,,,,,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.8640000000000001,0.9763,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Cristiana Gomes,Secretaria de Estado da Saúde do Espírito Santo,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.06.13.20130559v1.full.pdf,2020-07-17,2024-03-01,Verified,costa_gomes_population-based_2020,BRA
200616_Brazil_SecretariadeEstadodaSaúdedoEspíritoSanto_Until20yrs,200616_Brazil_SecretariadeEstadodaSaúdedoEspíritoSanto_1_Urban,"A population-based study of the prevalence of COVID-19 infection in Espírito Santo, Brazil: methodology and results of the first stage",2020-06-16,Preprint,Regional,Cross-sectional survey ,Brazil,Espírito Santo,,"The included individuals were older than two years. The legal guardian answered the questions for those younger than 16. The ‘prevalence study’ comprises the sampling of each reference municipality, added by the four most populous in the metropolitan region and one elected municipality in the region lacking a reference. Therefore, there are 11 municipalities allocated to the prevalence study.",,2020-05-13,2020-05-15,Household and community samples,All,Children and Youth (0-17 years),2.0,20.0,Age,<20,434,0.0276,,,,,,,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.8640000000000001,0.9763,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Cristiana Gomes,Secretaria de Estado da Saúde do Espírito Santo,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.06.13.20130559v1.full.pdf,2020-07-17,2024-03-01,Verified,costa_gomes_population-based_2020,BRA
200616_Brazil_SecretariadeEstadodaSaúdedoEspíritoSanto_41-60yrsUrban,200616_Brazil_SecretariadeEstadodaSaúdedoEspíritoSanto_1_Urban,"A population-based study of the prevalence of COVID-19 infection in Espírito Santo, Brazil: methodology and results of the first stage",2020-06-16,Preprint,Regional,Cross-sectional survey ,Brazil,Espírito Santo,,"The included individuals were older than two years. The legal guardian answered the questions for those younger than 16. The ‘prevalence study’ comprises the sampling of each reference municipality, added by the four most populous in the metropolitan region and one elected municipality in the region lacking a reference. Therefore, there are 11 municipalities allocated to the prevalence study.",,2020-05-13,2020-05-15,Household and community samples,All,Adults (18-64 years),41.0,60.0,Age,41-60,1583,0.0158,,,,,,,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.8640000000000001,0.9763,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Cristiana Gomes,Secretaria de Estado da Saúde do Espírito Santo,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.06.13.20130559v1.full.pdf,2020-07-17,2024-03-01,Verified,costa_gomes_population-based_2020,BRA
"200616_Brazil_SecretariadeEstadodaSaúdedoEspíritoSanto_""Yellow""Urban",200616_Brazil_SecretariadeEstadodaSaúdedoEspíritoSanto_1_Urban,"A population-based study of the prevalence of COVID-19 infection in Espírito Santo, Brazil: methodology and results of the first stage",2020-06-16,Preprint,Regional,Cross-sectional survey ,Brazil,Espírito Santo,,"The included individuals were older than two years. The legal guardian answered the questions for those younger than 16. The ‘prevalence study’ comprises the sampling of each reference municipality, added by the four most populous in the metropolitan region and one elected municipality in the region lacking a reference. Therefore, there are 11 municipalities allocated to the prevalence study.",,2020-05-13,2020-05-15,Household and community samples,All,Multiple groups,2.0,,Race,Yellow (term reported in review),46,0.0217,,,,,,,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.8640000000000001,0.9763,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Cristiana Gomes,Secretaria de Estado da Saúde do Espírito Santo,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.06.13.20130559v1.full.pdf,2020-07-17,2024-03-01,Verified,costa_gomes_population-based_2020,BRA
200616_Brazil_SecretariadeEstadodaSaúdedoEspíritoSanto_MixedRaceUrban,200616_Brazil_SecretariadeEstadodaSaúdedoEspíritoSanto_1_Urban,"A population-based study of the prevalence of COVID-19 infection in Espírito Santo, Brazil: methodology and results of the first stage",2020-06-16,Preprint,Regional,Cross-sectional survey ,Brazil,Espírito Santo,,"The included individuals were older than two years. The legal guardian answered the questions for those younger than 16. The ‘prevalence study’ comprises the sampling of each reference municipality, added by the four most populous in the metropolitan region and one elected municipality in the region lacking a reference. Therefore, there are 11 municipalities allocated to the prevalence study.",,2020-05-13,2020-05-15,Household and community samples,All,Multiple groups,2.0,,Race,Mixed,2026,0.0222,,,,,,,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.8640000000000001,0.9763,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Cristiana Gomes,Secretaria de Estado da Saúde do Espírito Santo,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.06.13.20130559v1.full.pdf,2020-07-17,2024-03-01,Verified,costa_gomes_population-based_2020,BRA
200616_Brazil_SecretariadeEstadodaSaúdedoEspíritoSanto_61-80yrsUrban,200616_Brazil_SecretariadeEstadodaSaúdedoEspíritoSanto_1_Urban,"A population-based study of the prevalence of COVID-19 infection in Espírito Santo, Brazil: methodology and results of the first stage",2020-06-16,Preprint,Regional,Cross-sectional survey ,Brazil,Espírito Santo,,"The included individuals were older than two years. The legal guardian answered the questions for those younger than 16. The ‘prevalence study’ comprises the sampling of each reference municipality, added by the four most populous in the metropolitan region and one elected municipality in the region lacking a reference. Therefore, there are 11 municipalities allocated to the prevalence study.",,2020-05-13,2020-05-15,Household and community samples,All,Seniors (65+ years),61.0,80.0,Age,61-80,1081,0.0222,,,,,,,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.8640000000000001,0.9763,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Cristiana Gomes,Secretaria de Estado da Saúde do Espírito Santo,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.06.13.20130559v1.full.pdf,2020-07-17,2024-03-01,Verified,costa_gomes_population-based_2020,BRA
200616_Brazil_SecretariadeEstadodaSaúdedoEspíritoSanto_GenPop2Sub-urban,200616_Brazil_SecretariadeEstadodaSaúdedoEspíritoSanto_2_Suburban,"A population-based study of the prevalence of COVID-19 infection in Espírito Santo, Brazil: methodology and results of the first stage",2020-06-16,Preprint,Regional,Cross-sectional survey ,Brazil,Espírito Santo,,"The included individuals were older than two years. The legal guardian answered the questions for those younger than 16. The step called ‘extension study’ comprises the sampling on 16 lesser populous
municipalities, being two in each one of the eight regions. The urban population of these
municipalities varies from approximately 14,000 to about 100,000 inhabitants each, but
only three of them have more than 30,000 inhabitants.",,2020-05-13,2020-05-15,Household and community samples,All,Multiple groups,2.0,,Primary Estimate,,1163,0.0026000000000000003,0.0005,0.0075,True,,,,True,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.8640000000000001,0.9763,['Moderate'],,Yes,Yes,No,,No,Yes,No,,Cristiana Gomes,Secretaria de Estado da Saúde do Espírito Santo,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.06.13.20130559v1.full.pdf,2020-06-18,2024-03-01,Verified,costa_gomes_population-based_2020,BRA
200626_BomJesus_InstitutoPiaunienseDeOpiniaoPubilca_overall,200626_BomJesus_InstitutoPiaunienseDeOpiniaoPubilca,Pesquisa Sobre Status Sorológico da População Quanto a Infecção por SARS‐COV‐2 em Situação de Pandemia,2020-06-26,Institutional Report,Local,Cross-sectional survey ,Brazil,Piauí,Bom Jesus,People residing in the urban area of ​​the municipality of Bom Jesus,,2020-06-24,2020-06-26,Household and community samples,All,Multiple groups,,,Primary Estimate,,200,0.08,,,True,,,,True,Simplified probability,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],Yes,Yes,No,Yes,Yes,Unclear,Yes,No,Unclear,Instituto Piauniense de Opiniao Publica,Instituto Piauniense de Opinião Pública,Not Unity-Aligned,https://portalpontox.com/wp-content/uploads/2020/06/PESQUISA-BOM-JESUS-COVID-24a26-06.2020.pdf,2021-05-05,2022-07-16,Verified,instituto_piauniense_de_opiniao_publica_pesquisa_2020,BRA
200626_BomJesus_InstitutoPiaunienseDeOpiniaoPubilca_Age_30-39,200626_BomJesus_InstitutoPiaunienseDeOpiniaoPubilca,Pesquisa Sobre Status Sorológico da População Quanto a Infecção por SARS‐COV‐2 em Situação de Pandemia,2020-06-26,Institutional Report,Local,Cross-sectional survey ,Brazil,Piauí,Bom Jesus,People residing in the urban area of ​​the municipality of Bom Jesus,,2020-06-24,2020-06-26,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,36,0.0278,,,,,,,,Simplified probability,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],Yes,Yes,No,Yes,Yes,Unclear,Yes,No,Unclear,Instituto Piauniense de Opiniao Publica,Instituto Piauniense de Opinião Pública,Not Unity-Aligned,https://portalpontox.com/wp-content/uploads/2020/06/PESQUISA-BOM-JESUS-COVID-24a26-06.2020.pdf,2021-05-05,2022-07-16,Verified,instituto_piauniense_de_opiniao_publica_pesquisa_2020,BRA
200626_BomJesus_InstitutoPiaunienseDeOpiniaoPubilca_Age_60-69,200626_BomJesus_InstitutoPiaunienseDeOpiniaoPubilca,Pesquisa Sobre Status Sorológico da População Quanto a Infecção por SARS‐COV‐2 em Situação de Pandemia,2020-06-26,Institutional Report,Local,Cross-sectional survey ,Brazil,Piauí,Bom Jesus,People residing in the urban area of ​​the municipality of Bom Jesus,,2020-06-24,2020-06-26,Household and community samples,All,Multiple groups,60.0,69.0,Age,60-69,18,0.11109999999999999,,,,,,,,Simplified probability,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],Yes,Yes,No,Yes,Yes,Unclear,Yes,No,Unclear,Instituto Piauniense de Opiniao Publica,Instituto Piauniense de Opinião Pública,Not Unity-Aligned,https://portalpontox.com/wp-content/uploads/2020/06/PESQUISA-BOM-JESUS-COVID-24a26-06.2020.pdf,2021-05-05,2022-07-16,Verified,instituto_piauniense_de_opiniao_publica_pesquisa_2020,BRA
200626_BomJesus_InstitutoPiaunienseDeOpiniaoPubilca_Age_20-24,200626_BomJesus_InstitutoPiaunienseDeOpiniaoPubilca,Pesquisa Sobre Status Sorológico da População Quanto a Infecção por SARS‐COV‐2 em Situação de Pandemia,2020-06-26,Institutional Report,Local,Cross-sectional survey ,Brazil,Piauí,Bom Jesus,People residing in the urban area of ​​the municipality of Bom Jesus,,2020-06-24,2020-06-26,Household and community samples,All,Adults (18-64 years),20.0,24.0,Age,20-24,19,0.0,,,,,,,,Simplified probability,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],Yes,Yes,No,Yes,Yes,Unclear,Yes,No,Unclear,Instituto Piauniense de Opiniao Publica,Instituto Piauniense de Opinião Pública,Not Unity-Aligned,https://portalpontox.com/wp-content/uploads/2020/06/PESQUISA-BOM-JESUS-COVID-24a26-06.2020.pdf,2021-05-05,2022-07-16,Verified,instituto_piauniense_de_opiniao_publica_pesquisa_2020,BRA
200626_BomJesus_InstitutoPiaunienseDeOpiniaoPubilca_Female,200626_BomJesus_InstitutoPiaunienseDeOpiniaoPubilca,Pesquisa Sobre Status Sorológico da População Quanto a Infecção por SARS‐COV‐2 em Situação de Pandemia,2020-06-26,Institutional Report,Local,Cross-sectional survey ,Brazil,Piauí,Bom Jesus,People residing in the urban area of ​​the municipality of Bom Jesus,,2020-06-24,2020-06-26,Household and community samples,Female,Multiple groups,,,Sex/Gender,female,130,0.08460000000000001,,,,,,,,Simplified probability,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],Yes,Yes,No,Yes,Yes,Unclear,Yes,No,Unclear,Instituto Piauniense de Opiniao Publica,Instituto Piauniense de Opinião Pública,Not Unity-Aligned,https://portalpontox.com/wp-content/uploads/2020/06/PESQUISA-BOM-JESUS-COVID-24a26-06.2020.pdf,2021-05-05,2022-07-16,Verified,instituto_piauniense_de_opiniao_publica_pesquisa_2020,BRA
200626_BomJesus_InstitutoPiaunienseDeOpiniaoPubilca_Age_70+,200626_BomJesus_InstitutoPiaunienseDeOpiniaoPubilca,Pesquisa Sobre Status Sorológico da População Quanto a Infecção por SARS‐COV‐2 em Situação de Pandemia,2020-06-26,Institutional Report,Local,Cross-sectional survey ,Brazil,Piauí,Bom Jesus,People residing in the urban area of ​​the municipality of Bom Jesus,,2020-06-24,2020-06-26,Household and community samples,All,Seniors (65+ years),70.0,,Age,70+,26,0.07690000000000001,,,,,,,,Simplified probability,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],Yes,Yes,No,Yes,Yes,Unclear,Yes,No,Unclear,Instituto Piauniense de Opiniao Publica,Instituto Piauniense de Opinião Pública,Not Unity-Aligned,https://portalpontox.com/wp-content/uploads/2020/06/PESQUISA-BOM-JESUS-COVID-24a26-06.2020.pdf,2021-05-05,2022-07-16,Verified,instituto_piauniense_de_opiniao_publica_pesquisa_2020,BRA
200626_BomJesus_InstitutoPiaunienseDeOpiniaoPubilca_Age_25-29,200626_BomJesus_InstitutoPiaunienseDeOpiniaoPubilca,Pesquisa Sobre Status Sorológico da População Quanto a Infecção por SARS‐COV‐2 em Situação de Pandemia,2020-06-26,Institutional Report,Local,Cross-sectional survey ,Brazil,Piauí,Bom Jesus,People residing in the urban area of ​​the municipality of Bom Jesus,,2020-06-24,2020-06-26,Household and community samples,All,Adults (18-64 years),25.0,29.0,Age,25-29,21,0.1429,,,,,,,,Simplified probability,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],Yes,Yes,No,Yes,Yes,Unclear,Yes,No,Unclear,Instituto Piauniense de Opiniao Publica,Instituto Piauniense de Opinião Pública,Not Unity-Aligned,https://portalpontox.com/wp-content/uploads/2020/06/PESQUISA-BOM-JESUS-COVID-24a26-06.2020.pdf,2021-05-05,2022-07-16,Verified,instituto_piauniense_de_opiniao_publica_pesquisa_2020,BRA
200626_BomJesus_InstitutoPiaunienseDeOpiniaoPubilca_Age_15-19,200626_BomJesus_InstitutoPiaunienseDeOpiniaoPubilca,Pesquisa Sobre Status Sorológico da População Quanto a Infecção por SARS‐COV‐2 em Situação de Pandemia,2020-06-26,Institutional Report,Local,Cross-sectional survey ,Brazil,Piauí,Bom Jesus,People residing in the urban area of ​​the municipality of Bom Jesus,,2020-06-24,2020-06-26,Household and community samples,All,Children and Youth (0-17 years),15.0,19.0,Age,15-19,12,0.0,,,,,,,,Simplified probability,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],Yes,Yes,No,Yes,Yes,Unclear,Yes,No,Unclear,Instituto Piauniense de Opiniao Publica,Instituto Piauniense de Opinião Pública,Not Unity-Aligned,https://portalpontox.com/wp-content/uploads/2020/06/PESQUISA-BOM-JESUS-COVID-24a26-06.2020.pdf,2021-05-05,2022-07-16,Verified,instituto_piauniense_de_opiniao_publica_pesquisa_2020,BRA
200626_BomJesus_InstitutoPiaunienseDeOpiniaoPubilca_Age_40-49,200626_BomJesus_InstitutoPiaunienseDeOpiniaoPubilca,Pesquisa Sobre Status Sorológico da População Quanto a Infecção por SARS‐COV‐2 em Situação de Pandemia,2020-06-26,Institutional Report,Local,Cross-sectional survey ,Brazil,Piauí,Bom Jesus,People residing in the urban area of ​​the municipality of Bom Jesus,,2020-06-24,2020-06-26,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,31,0.1935,,,,,,,,Simplified probability,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],Yes,Yes,No,Yes,Yes,Unclear,Yes,No,Unclear,Instituto Piauniense de Opiniao Publica,Instituto Piauniense de Opinião Pública,Not Unity-Aligned,https://portalpontox.com/wp-content/uploads/2020/06/PESQUISA-BOM-JESUS-COVID-24a26-06.2020.pdf,2021-05-05,2022-07-16,Verified,instituto_piauniense_de_opiniao_publica_pesquisa_2020,BRA
200626_BomJesus_InstitutoPiaunienseDeOpiniaoPubilca_Age_0-4,200626_BomJesus_InstitutoPiaunienseDeOpiniaoPubilca,Pesquisa Sobre Status Sorológico da População Quanto a Infecção por SARS‐COV‐2 em Situação de Pandemia,2020-06-26,Institutional Report,Local,Cross-sectional survey ,Brazil,Piauí,Bom Jesus,People residing in the urban area of ​​the municipality of Bom Jesus,,2020-06-24,2020-06-26,Household and community samples,All,Children and Youth (0-17 years),0.0,4.0,Age,0-14,2,0.5,,,,,,,,Simplified probability,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],Yes,Yes,No,Yes,Yes,Unclear,Yes,No,Unclear,Instituto Piauniense de Opiniao Publica,Instituto Piauniense de Opinião Pública,Not Unity-Aligned,https://portalpontox.com/wp-content/uploads/2020/06/PESQUISA-BOM-JESUS-COVID-24a26-06.2020.pdf,2021-05-05,2022-07-16,Verified,instituto_piauniense_de_opiniao_publica_pesquisa_2020,BRA
200626_BomJesus_InstitutoPiaunienseDeOpiniaoPubilca_Male,200626_BomJesus_InstitutoPiaunienseDeOpiniaoPubilca,Pesquisa Sobre Status Sorológico da População Quanto a Infecção por SARS‐COV‐2 em Situação de Pandemia,2020-06-26,Institutional Report,Local,Cross-sectional survey ,Brazil,Piauí,Bom Jesus,People residing in the urban area of ​​the municipality of Bom Jesus,,2020-06-24,2020-06-26,Household and community samples,Male,Multiple groups,,,Sex/Gender,male,70,0.0714,,,,,,,,Simplified probability,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],Yes,Yes,No,Yes,Yes,Unclear,Yes,No,Unclear,Instituto Piauniense de Opiniao Publica,Instituto Piauniense de Opinião Pública,Not Unity-Aligned,https://portalpontox.com/wp-content/uploads/2020/06/PESQUISA-BOM-JESUS-COVID-24a26-06.2020.pdf,2021-05-05,2022-07-16,Verified,instituto_piauniense_de_opiniao_publica_pesquisa_2020,BRA
200626_BomJesus_InstitutoPiaunienseDeOpiniaoPubilca_Age_50-59,200626_BomJesus_InstitutoPiaunienseDeOpiniaoPubilca,Pesquisa Sobre Status Sorológico da População Quanto a Infecção por SARS‐COV‐2 em Situação de Pandemia,2020-06-26,Institutional Report,Local,Cross-sectional survey ,Brazil,Piauí,Bom Jesus,People residing in the urban area of ​​the municipality of Bom Jesus,,2020-06-24,2020-06-26,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,31,0.0323,,,,,,,,Simplified probability,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],Yes,Yes,No,Yes,Yes,Unclear,Yes,No,Unclear,Instituto Piauniense de Opiniao Publica,Instituto Piauniense de Opinião Pública,Not Unity-Aligned,https://portalpontox.com/wp-content/uploads/2020/06/PESQUISA-BOM-JESUS-COVID-24a26-06.2020.pdf,2021-05-05,2022-07-16,Verified,instituto_piauniense_de_opiniao_publica_pesquisa_2020,BRA
200626_BomJesus_InstitutoPiaunienseDeOpiniaoPubilca_Age_10-14,200626_BomJesus_InstitutoPiaunienseDeOpiniaoPubilca,Pesquisa Sobre Status Sorológico da População Quanto a Infecção por SARS‐COV‐2 em Situação de Pandemia,2020-06-26,Institutional Report,Local,Cross-sectional survey ,Brazil,Piauí,Bom Jesus,People residing in the urban area of ​​the municipality of Bom Jesus,,2020-06-24,2020-06-26,Household and community samples,All,Children and Youth (0-17 years),10.0,14.0,Age, 10-14,4,0.0,,,,,,,,Simplified probability,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],Yes,Yes,No,Yes,Yes,Unclear,Yes,No,Unclear,Instituto Piauniense de Opiniao Publica,Instituto Piauniense de Opinião Pública,Not Unity-Aligned,https://portalpontox.com/wp-content/uploads/2020/06/PESQUISA-BOM-JESUS-COVID-24a26-06.2020.pdf,2021-05-05,2022-07-16,Verified,instituto_piauniense_de_opiniao_publica_pesquisa_2020,BRA
200629_Goiania_CityOfGoiania_overall,200629_Goiania_CityOfGoiania,"Research shows that 31,838,000
  people have already been infected with COVID-19 in Goiânia",2020-06-29,News and Media,Local,Repeated cross-sectional study,Brazil,Goiás,Goiania,Residents of Goiania,,2020-06-10,2020-06-10,Household and community samples,All,Multiple groups,,,Primary Estimate,,2628,0.021,,,True,,,,True,Simplified probability,Not reported/ Unable to specify,,,,,,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,City of Goiania,Municipal Health Department of the City of Goiania,Not Unity-Aligned,https://www.goiania.go.gov.br/pesquisa-aponta-que-31-838-mil-pessoas-ja-foram-infectadas-por-covid-19-em-goiania/,2021-05-03,2022-07-16,Verified,prefeitura_de_goiania_pesquisa_2020,BRA
200703_Teresina_CentrodeOperaçõesdeEmergênciasemSaúdePública_Apr26,200703_Teresina_ CentrodeOperaçõesdeEmergênciasemSaúdePública_2_Apr26,Sequential serological surveys in the early stages of the coronavirus disease epidemic: limitations and  perspectives,2020-07-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Piaui,Teresina,Individuals in Teresina,,2020-04-26,2020-04-26,Household and community samples,All,Multiple groups,,,Primary Estimate,,900,0.0089,0.0039000000000000003,0.0175,True,,,,True,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.86,0.99,['Moderate'],Yes,Yes,Yes,No,Unclear,No,Yes,No,Unclear,Marcelo Vieira, Centro de Operações de Emergências em Saúde Pública,Not Unity-Aligned,https://dx.doi.org/10.1590/0037-8682-0351-2020,2020-07-30,2024-03-01,Verified,vieira_sequential_2020,BRA
200703_Teresina_CentrodeOperaçõesdeEmergênciasemSaúdePública_May3,200703_Teresina_ CentrodeOperaçõesdeEmergênciasemSaúdePública_3_May3,Sequential serological surveys in the early stages of the coronavirus disease epidemic: limitations and  perspectives,2020-07-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Piaui,Teresina,Individuals in Teresina,,2020-05-03,2020-05-03,Household and community samples,All,Multiple groups,,,Primary Estimate,,900,0.0144,0.0077,0.0245,True,,,,True,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.86,0.99,['Moderate'],Yes,Yes,Yes,No,Unclear,No,Yes,No,Unclear,Marcelo Vieira, Centro de Operações de Emergências em Saúde Pública,Not Unity-Aligned,https://dx.doi.org/10.1590/0037-8682-0351-2020,2020-07-30,2024-03-01,Verified,vieira_sequential_2020,BRA
200703_Teresina_CentrodeOperaçõesdeEmergênciasemSaúdePública_May10,200703_Teresina_ CentrodeOperaçõesdeEmergênciasemSaúdePública_4_May10,Sequential serological surveys in the early stages of the coronavirus disease epidemic: limitations and  perspectives,2020-07-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Piaui,Teresina,Individuals in Teresina,,2020-05-10,2020-05-10,Household and community samples,All,Multiple groups,,,Primary Estimate,,900,0.02,0.011899999999999999,0.031400000000000004,True,,,,True,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.86,0.99,['Moderate'],Yes,Yes,Yes,No,Unclear,No,Yes,No,Unclear,Marcelo Vieira, Centro de Operações de Emergências em Saúde Pública,Not Unity-Aligned,https://dx.doi.org/10.1590/0037-8682-0351-2020,2020-07-30,2024-03-01,Verified,vieira_sequential_2020,BRA
200703_Teresina_CentrodeOperaçõesdeEmergênciasemSaúdePública_May17,200703_Teresina_ CentrodeOperaçõesdeEmergênciasemSaúdePública_5_May17,Sequential serological surveys in the early stages of the coronavirus disease epidemic: limitations and  perspectives,2020-07-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Piaui,Teresina,Individuals in Teresina,,2020-05-17,2020-05-17,Household and community samples,All,Multiple groups,,,Primary Estimate,,900,0.0378,0.0263,0.0524,True,,,,True,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.86,0.99,['Moderate'],Yes,Yes,Yes,No,Unclear,No,Yes,No,Unclear,Marcelo Vieira, Centro de Operações de Emergências em Saúde Pública,Not Unity-Aligned,https://dx.doi.org/10.1590/0037-8682-0351-2020,2020-07-30,2024-03-01,Verified,vieira_sequential_2020,BRA
200703_Teresina_CentrodeOperaçõesdeEmergênciasemSaúdePública_May24,200703_Teresina_ CentrodeOperaçõesdeEmergênciasemSaúdePública_6_May24,Sequential serological surveys in the early stages of the coronavirus disease epidemic: limitations and  perspectives,2020-07-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Piaui,Teresina,Individuals in Teresina,,2020-05-24,2020-05-24,Household and community samples,All,Multiple groups,,,Primary Estimate,,900,0.057800000000000004,0.043,0.073,True,,,,True,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.86,0.99,['Moderate'],Yes,Yes,Yes,No,Unclear,No,Yes,No,Unclear,Marcelo Vieira, Centro de Operações de Emergências em Saúde Pública,Not Unity-Aligned,https://dx.doi.org/10.1590/0037-8682-0351-2020,2020-07-30,2024-03-01,Verified,vieira_sequential_2020,BRA
200703_Teresina_CentrodeOperaçõesdeEmergênciasemSaúdePública_May31,200703_Teresina_ CentrodeOperaçõesdeEmergênciasemSaúdePública_7_May31,Sequential serological surveys in the early stages of the coronavirus disease epidemic: limitations and  perspectives,2020-07-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Piaui,Teresina,Individuals in Teresina,,2020-05-31,2020-05-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,900,0.0833,0.0661,0.1033,True,,,,True,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.86,0.99,['Moderate'],Yes,Yes,Yes,No,Unclear,No,Yes,No,Unclear,Marcelo Vieira, Centro de Operações de Emergências em Saúde Pública,Not Unity-Aligned,https://dx.doi.org/10.1590/0037-8682-0351-2020,2020-07-30,2024-03-01,Verified,vieira_sequential_2020,BRA
200703_Teresina_CentrodeOperaçõesdeEmergênciasemSaúdePública_Apr19,200703_Teresina_CentrodeOperaçõesdeEmergênciasemSaúdePública_1_Apr19,Sequential serological surveys in the early stages of the coronavirus disease epidemic: limitations and  perspectives,2020-07-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Piaui,Teresina,Individuals in Teresina,,2020-04-19,2020-04-19,Household and community samples,All,Multiple groups,,,Primary Estimate,,900,0.005600000000000001,0.0018,0.013000000000000001,True,,,,True,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.86,0.99,['Moderate'],Yes,Yes,Yes,No,Unclear,No,Yes,No,Unclear,Marcelo Vieira, Centro de Operações de Emergências em Saúde Pública,Not Unity-Aligned,https://dx.doi.org/10.1590/0037-8682-0351-2020,2020-07-30,2024-03-01,Verified,vieira_sequential_2020,BRA
200706_RiodeJaneiro_UniversidadedoEstadodoRiodeJaneiro_BloodDonors_OverallAdj,200706_RiodeJaneiro_UniversidadedoEstadodoRiodeJaneiro,"Seroprevalence of anti-SARS-CoV-2 among blood donors in Rio de Janeiro, Brazil",2020-07-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Rio de Janeiro,Rio de Janeiro,candidates had to comply with donation eligiblity criteria and criteria regarding covid-19 ,rejected if candidates presented covid-19 related symptoms,2020-04-14,2020-04-27,Blood donors,All,Adults (18-64 years),18.0,69.0,Primary Estimate,"Adjusted: population, test",2857,0.033,0.026000000000000002,0.040999999999999995,True,True,True,,,Sequential,MedTest Coronavirus 2019-nCoV IgG/IgM,MedLevensohn,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.85,0.99,['Moderate'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Yes,Amorim Filho,Universidade do Estado do Rio de Janeiro,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334006/,2020-07-10,2022-07-16,Verified,filho_seroprevalence_nodate,BRA
200706_RiodeJaneiro_UniversidadedoEstadodoRiodeJaneiro_BloodDonors_FemaleAdj,200706_RiodeJaneiro_UniversidadedoEstadodoRiodeJaneiro,"Seroprevalence of anti-SARS-CoV-2 among blood donors in Rio de Janeiro, Brazil",2020-07-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Rio de Janeiro,candidates had to comply with donation eligiblity criteria and criteria regarding covid-19 ,rejected if candidates presented covid-19 related symptoms,2020-04-14,2020-04-27,Blood donors,Female,Adults (18-64 years),18.0,69.0,Sex/Gender,Female,1470,0.035,,,,,True,,,Sequential,MedTest Coronavirus 2019-nCoV IgG/IgM,MedLevensohn,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.85,0.99,['Moderate'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Yes,Amorim Filho,Universidade do Estado do Rio de Janeiro,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334006/,2020-07-10,2022-07-16,Verified,filho_seroprevalence_nodate,BRA
200706_RiodeJaneiro_UniversidadedoEstadodoRiodeJaneiro_BloodDonors_18-29_Adj,200706_RiodeJaneiro_UniversidadedoEstadodoRiodeJaneiro,"Seroprevalence of anti-SARS-CoV-2 among blood donors in Rio de Janeiro, Brazil",2020-07-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Rio de Janeiro,candidates had to comply with donation eligiblity criteria and criteria regarding covid-19 ,rejected if candidates presented covid-19 related symptoms,2020-04-14,2020-04-27,Blood donors,All,Adults (18-64 years),18.0,29.0,Age,18-29,718,0.053,,,,,True,,,Sequential,MedTest Coronavirus 2019-nCoV IgG/IgM,MedLevensohn,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.85,0.99,['Moderate'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Yes,Amorim Filho,Universidade do Estado do Rio de Janeiro,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334006/,2020-07-10,2022-07-16,Verified,filho_seroprevalence_nodate,BRA
200706_RiodeJaneiro_UniversidadedoEstadodoRiodeJaneiro_BloodDonors_50-69_Adj,200706_RiodeJaneiro_UniversidadedoEstadodoRiodeJaneiro,"Seroprevalence of anti-SARS-CoV-2 among blood donors in Rio de Janeiro, Brazil",2020-07-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Rio de Janeiro,candidates had to comply with donation eligiblity criteria and criteria regarding covid-19 ,rejected if candidates presented covid-19 related symptoms,2020-04-14,2020-04-27,Blood donors,All,Adults (18-64 years),50.0,69.0,Age,50-69,940,0.028999999999999998,,,,,True,,,Sequential,MedTest Coronavirus 2019-nCoV IgG/IgM,MedLevensohn,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.85,0.99,['Moderate'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Yes,Amorim Filho,Universidade do Estado do Rio de Janeiro,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334006/,2020-07-10,2022-07-16,Verified,filho_seroprevalence_nodate,BRA
200706_RiodeJaneiro_UniversidadedoEstadodoRiodeJaneiro_BloodDonors_MaleAdj,200706_RiodeJaneiro_UniversidadedoEstadodoRiodeJaneiro,"Seroprevalence of anti-SARS-CoV-2 among blood donors in Rio de Janeiro, Brazil",2020-07-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Rio de Janeiro,candidates had to comply with donation eligiblity criteria and criteria regarding covid-19 ,rejected if candidates presented covid-19 related symptoms,2020-04-14,2020-04-27,Blood donors,Male,Adults (18-64 years),18.0,69.0,Sex/Gender,Male,1387,0.040999999999999995,,,,,True,,,Sequential,MedTest Coronavirus 2019-nCoV IgG/IgM,MedLevensohn,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.85,0.99,['Moderate'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Yes,Amorim Filho,Universidade do Estado do Rio de Janeiro,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334006/,2020-07-10,2022-07-16,Verified,filho_seroprevalence_nodate,BRA
200706_RiodeJaneiro_UniversidadedoEstadodoRiodeJaneiro_30-49_AdjHemorio,200706_RiodeJaneiro_UniversidadedoEstadodoRiodeJaneiro,"Seroprevalence of anti-SARS-CoV-2 among blood donors in Rio de Janeiro, Brazil",2020-07-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Rio de Janeiro,candidates had to comply with donation eligiblity criteria and criteria regarding covid-19 ,rejected if candidates presented covid-19 related symptoms,2020-04-14,2020-04-27,Blood donors,All,Adults (18-64 years),30.0,49.0,Age,30-49,1199,0.036000000000000004,,,,,True,,,Sequential,MedTest Coronavirus 2019-nCoV IgG/IgM,MedLevensohn,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.85,0.99,['Moderate'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Yes,Amorim Filho,Universidade do Estado do Rio de Janeiro,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334006/,2020-07-10,2022-07-16,Verified,filho_seroprevalence_nodate,BRA
200706_RiodeJaneiro_UniversidadedoEstadodoRiodeJaneiro_BloodDonors_UnAdj,200706_RiodeJaneiro_UniversidadedoEstadodoRiodeJaneiro,"Seroprevalence of anti-SARS-CoV-2 among blood donors in Rio de Janeiro, Brazil",2020-07-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Rio de Janeiro,Rio de Janeiro,candidates had to comply with donation eligiblity criteria and criteria regarding covid-19 ,rejected if candidates presented covid-19 related symptoms,2020-04-14,2020-04-27,Blood donors,All,Adults (18-64 years),18.0,69.0,Analysis,,2857,0.04,0.033,0.047,,,,,True,Sequential,MedTest Coronavirus 2019-nCoV IgG/IgM,MedLevensohn,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.85,0.99,['Moderate'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Yes,Amorim Filho,Universidade do Estado do Rio de Janeiro,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334006/,2020-07-10,2022-07-16,Verified,filho_seroprevalence_nodate,BRA
200812_Cajamar_MunicipalSecretariatOfCajamar_overall,200812_Cajamar_MunicipalSecretariatOfCajamar,"Department of Health releases
  balance sheet of active search for antibodies to Sars-Cov-2",2020-08-12,News and Media,Local,Cross-sectional survey ,Brazil,São Paulo,Municipality of Cajamar,people who were present at open-air markets and shopping centers in the municipality.,,2020-07-21,2020-07-27,Household and community samples,All,Multiple groups,0.0,86.0,Primary Estimate,,1015,0.04,,,True,,,,True,Convenience,Not reported/ Unable to specify,,LFIA,Whole Blood,,,,,,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,Unclear,Municipal Secretariat of Cajamar,Municipal Secretariat of Cajamar,Not Unity-Aligned,https://cajamar.sp.gov.br/noticias/2020/08/12/secretaria-de-saude-divulga-balanco-da-pesquisa-de-busca-ativa-de-anticorpos-para-sars-cov-2/,2021-05-06,2022-07-16,Verified,noauthor_secretaria_2020,BRA
200821_Campinas_CampinasMunicipalHealthDepartment,200821_Campinas_CampinasMunicipalHealthDepartment,"Campinas City Hall presents
  second Covid-19 Serological Survey",2020-08-21,News and Media,Local,Cross-sectional survey ,Brazil,Sao Paulo,Campinas,,,2020-08-03,2020-08-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,1876,0.0368,,,True,,,,True,Simplified probability,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,Campinas City Hall,Campinas Municipal Health Department,Not Unity-Aligned,https://covid-19.campinas.sp.gov.br/prefeitura-de-campinas-apresenta-segundo-inqu-rito-sorol-gico-da-covid-19,2021-05-20,2022-07-16,Verified,campinas_municipal_health_department_campinas_2020,BRA
200831_Limeira_LimeriaCityHall_overall,200831_Limeira_LimeriaCityHall,"Study suggests that almost
  36,000 residents of Limeira had covid-19",2020-08-31,News and Media,Local,Cross-sectional survey ,Brazil,São Paulo,Limeira,Residents of Limeira 15 and older,,2020-08-24,2020-08-29,Household and community samples,All,Multiple groups,15.0,,Primary Estimate,,1291,0.146,0.11900000000000001,0.17300000000000001,True,,,,True,Simplified probability,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,Redacao Educadora,Limeira City Hall,Not Unity-Aligned,https://elimeira.com.br/noticias/limeira/estudo-sugere-que-quase-36-mil-moradores-de-limeira-tiveram-covid-19/,2021-05-11,2022-07-16,Verified,redacao_educadora_estudo_2020,BRA
200901_Petrópolis_CentrodeTerapiaOncológica_HCW_IGGorIGM,200901_Petrópolis_CentrodeTerapiaOncológica,Universal screening of SARS-CoV-2 of oncology healthcare workers - a Brazilian experience,2020-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Rio de Janeiro,Petrópolis,"Centro de Terapia Oncológica (CTO) HCW at an Oncology clinic in Petrópolis, countryside of Rio de Janeiro, Brazil",,2020-04-09,2020-04-29,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,IgG and/or IgM,61,0.049100000000000005,,,True,,,,True,Convenience,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,Unclear,Yes,No,Unclear,P Ismael Amaral Silva,Centro de Terapia Oncológica,Not Unity-Aligned,http://dx.doi.org/10.1016/j.annonc.2020.08.1825,2021-01-04,2022-07-16,Verified,ismael_amaral_silva_1761p_2020,BRA
200916_Lajeado_UniversidadedoValedodoTaquari_Survey1,200916_Lajeado_UniversidadedoValedoTaquari_Study1,"Coronavirus Disease 2019 Population-based Prevalence, Risk Factors, Hospitalization, and Fatality Rates in Southern Brazil",2020-09-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Rio Grande do Sul,Lajeado,"The target population was the 64,000 adults residing in Lajeado. The study population was the non-institutionalized adults of the target population.",Individuals <18 years were not eligible. Participants who refused or withdrew consent were excluded.,2020-05-30,2020-06-04,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,First survey conducted May 30 to Jun 4,1450,0.0403,0.0308,0.0518,True,True,True,,,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.7624,0.9956999999999999,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Rafael Picon,Universidade do Vale do Taquari,Not Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2020.09.028,2020-11-12,2023-07-04,Verified,picon_coronavirus_2020,BRA
200916_Lajeado_UniversidadedoValedodoTaquari_Survey1_60+age,200916_Lajeado_UniversidadedoValedoTaquari_Study1,"Coronavirus Disease 2019 Population-based Prevalence, Risk Factors, Hospitalization, and Fatality Rates in Southern Brazil",2020-09-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Rio Grande do Sul,Lajeado,"The target population was the 64,000 adults residing in Lajeado. The study population was the non-institutionalized adults of the target population.",Individuals <18 years were not eligible. Participants who refused or withdrew consent were excluded.,2020-05-30,2020-06-17,Household and community samples,All,Seniors (65+ years),60.0,,Age,60+ ,431,0.0371,,,,,,,,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.7624,0.9956999999999999,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Rafael Picon,Universidade do Vale do Taquari,Not Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2020.09.028,2021-02-06,2024-03-01,Verified,picon_coronavirus_2020,BRA
200916_Lajeado_UniversidadedoValedodoTaquari_Survey1_testunadj,200916_Lajeado_UniversidadedoValedoTaquari_Study1,"Coronavirus Disease 2019 Population-based Prevalence, Risk Factors, Hospitalization, and Fatality Rates in Southern Brazil",2020-09-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Rio Grande do Sul,Lajeado,"The target population was the 64,000 adults residing in Lajeado. The study population was the non-institutionalized adults of the target population.",Individuals <18 years were not eligible. Participants who refused or withdrew consent were excluded.,2020-05-30,2020-06-04,Household and community samples,All,Multiple groups,18.0,,Analysis,No test adjustment ,1450,0.0317,0.0222,0.0452,,,True,,True,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.7624,0.9956999999999999,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Rafael Picon,Universidade do Vale do Taquari,Not Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2020.09.028,2021-02-06,2024-03-01,Verified,picon_coronavirus_2020,BRA
200916_Lajeado_UniversidadedoValedodoTaquari_Survey1_20to59,200916_Lajeado_UniversidadedoValedoTaquari_Study1,"Coronavirus Disease 2019 Population-based Prevalence, Risk Factors, Hospitalization, and Fatality Rates in Southern Brazil",2020-09-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Rio Grande do Sul,Lajeado,"The target population was the 64,000 adults residing in Lajeado. The study population was the non-institutionalized adults of the target population.",Individuals <18 years were not eligible. Participants who refused or withdrew consent were excluded.,2020-05-30,2020-06-17,Household and community samples,All,Adults (18-64 years),20.0,39.0,Age,20-39 ,970,0.0433,,,,,,,,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.7624,0.9956999999999999,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Rafael Picon,Universidade do Vale do Taquari,Not Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2020.09.028,2021-02-06,2024-03-01,Verified,picon_coronavirus_2020,BRA
200916_Lajeado_UniversidadedoValedodoTaquari_Survey2,200916_Lajeado_UniversidadedoValedoTaquari_Study2,"Coronavirus Disease 2019 Population-based Prevalence, Risk Factors, Hospitalization, and Fatality Rates in Southern Brazil",2020-09-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Rio Grande do Sul,Lajeado,"The target population was the 64,000 adults residing in Lajeado. The study population was the non-institutionalized adults of the target population.",Individuals <18 years were not eligible. Participants who refused or withdrew consent were excluded.,2020-06-13,2020-06-17,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,Second survey conducted Jun 13 to Jun 17,1127,0.0259,0.0175,0.037000000000000005,True,True,True,,,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.7624,0.9956999999999999,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Rafael Picon,Universidade do Vale do Taquari,Not Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2020.09.028,2020-11-12,2023-07-04,Verified,picon_coronavirus_2020,BRA
200916_Lajeado_UniversidadedoValedodoTaquari_Survey2_60+age,200916_Lajeado_UniversidadedoValedoTaquari_Study2,"Coronavirus Disease 2019 Population-based Prevalence, Risk Factors, Hospitalization, and Fatality Rates in Southern Brazil",2020-09-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Rio Grande do Sul,Lajeado,"The target population was the 64,000 adults residing in Lajeado. The study population was the non-institutionalized adults of the target population.",Individuals <18 years were not eligible. Participants who refused or withdrew consent were excluded.,2020-06-13,2020-06-17,Household and community samples,All,Seniors (65+ years),60.0,,Age,60+ ,341,0.0088,,,,,,,,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.7624,0.9956999999999999,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Rafael Picon,Universidade do Vale do Taquari,Not Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2020.09.028,2021-02-06,2024-03-01,Verified,picon_coronavirus_2020,BRA
200916_Lajeado_UniversidadedoValedodoTaquari_Survey2_20to59,200916_Lajeado_UniversidadedoValedoTaquari_Study2,"Coronavirus Disease 2019 Population-based Prevalence, Risk Factors, Hospitalization, and Fatality Rates in Southern Brazil",2020-09-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Rio Grande do Sul,Lajeado,"The target population was the 64,000 adults residing in Lajeado. The study population was the non-institutionalized adults of the target population.",Individuals <18 years were not eligible. Participants who refused or withdrew consent were excluded.,2020-06-13,2020-06-17,Household and community samples,All,Adults (18-64 years),20.0,39.0,Age,20-39 ,750,0.0333,,,,,,,,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.7624,0.9956999999999999,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Rafael Picon,Universidade do Vale do Taquari,Not Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2020.09.028,2021-02-06,2024-03-01,Verified,picon_coronavirus_2020,BRA
200916_Lajeado_UniversidadedoValedodoTaquari_Survey2_testunadj,200916_Lajeado_UniversidadedoValedoTaquari_Study2,"Coronavirus Disease 2019 Population-based Prevalence, Risk Factors, Hospitalization, and Fatality Rates in Southern Brazil",2020-09-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Rio Grande do Sul,Lajeado,"The target population was the 64,000 adults residing in Lajeado. The study population was the non-institutionalized adults of the target population.",Individuals <18 years were not eligible. Participants who refused or withdrew consent were excluded.,2020-06-13,2020-06-17,Household and community samples,All,Multiple groups,18.0,,Analysis,No test adjustment ,1127,0.0204,0.0123,0.0335,,,True,,True,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.7624,0.9956999999999999,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Rafael Picon,Universidade do Vale do Taquari,Not Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2020.09.028,2021-02-06,2024-03-01,Verified,picon_coronavirus_2020,BRA
200928_BaixadaSantistaMetropolitanRegion_UniversidadeSantaCecília_overall_Phase 1,200928_BaixadaSantistaMetropolitanRegion_UniversidadeSantaCecília_Phase 1,COVID-19 at a metropolitan region: public polices and social vulnerability within an iniquity context,2020-09-28,Preprint,Local,Repeated cross-sectional study,Brazil,São Paulo state,Baixada Santista,inhabitants of Baixada Santista Metropolitan Region ,,2020-04-29,2020-05-01,Household and community samples,All,Multiple groups,,,Primary Estimate,,2314,0.013999999999999999,,,True,,,,True,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,TotalAntibody,,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Arthur Chioro,Baixada Santista Metropolitan Region ,Not Unity-Aligned,https://preprints.scielo.org/index.php/scielo/preprint/view/1270,2021-04-26,2024-03-01,Verified,chioro_covid-19_2020,BRA
200928_BaixadaSantistaMetropolitanRegion_UniversidadeSantaCecília_overall_Phase 2,200928_BaixadaSantistaMetropolitanRegion_UniversidadeSantaCecília_Phase 2,COVID-19 at a metropolitan region: public polices and social vulnerability within an iniquity context,2020-09-28,Preprint,Local,Repeated cross-sectional study,Brazil,São Paulo state,Baixada Santista,inhabitants of Baixada Santista Metropolitan Region ,,2020-05-13,2020-05-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,2415,0.022000000000000002,,,True,,,,True,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,TotalAntibody,,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,No,Yes,No,Unclear,Arthur Chioro,Baixada Santista Metropolitan Region ,Not Unity-Aligned,https://preprints.scielo.org/index.php/scielo/preprint/view/1270,2021-04-27,2024-03-01,Verified,chioro_covid-19_2020,BRA
200930_Sergipe_FederalUniversityofSergipe_OverallIgG,200930_Sergipe_FederalUniversityofSergipe,"Anti-SARS-CoV-2 IgM and IgG antibodies in health workers in Sergipe, Brazil",2020-09-30,Preprint,Regional,Cross-sectional survey ,Brazil,Sergipe,,"Health professionals working on the front line to combat COVID-19 in six hospital units in the state of Sergipe, Brazil",,2020-06-01,2020-06-30,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,"Overall estimate, IgG+",471,0.1359,,,True,,,,True,Convenience,Ichroma COVID-19 Ab Test,Boditech Med Inc.,Other,Serum,IgG,,Validated by independent authors/third party/non-developers,0.958,0.97,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Monica de Melo,Federal University of Sergipe,Not Unity-Aligned,https://www.medrxiv.org/content/medrxiv/early/2020/09/30/2020.09.24.20200873.full.pdf,2020-11-23,2024-03-01,Verified,de_melo_anti-sars-cov-2_2020,BRA
211006_Goiânia_MunicipalityofGoiâniaHealthDepartment,211006_Goiânia_MunicipalityofGoiâniaHealthDepartment,Population Survey helps identify areas of higher concentration of Covid-19,2020-10-06,News and Media,Local,Repeated cross-sectional study,Brazil,Goiás,,,,2020-09-19,2020-09-19,Household and community samples,All,Multiple groups,,,Primary Estimate,,2436,0.13957307060755336,,,True,,,,True,Unclear,Not reported/ Unable to specify,,CLIA,,IgG,,,,,['High'],Yes,Unclear,Yes,No,No,Unclear,Yes,No,Unclear,Prefeitura De Goiania,Health Department of the Municipality of Goiânia ,Not Unity-Aligned,https://www.goiania.go.gov.br/inquerito-populacional-ajuda-identificar-areas-de-maior-concentracao-da-covid-19/,2021-05-13,2022-07-16,Verified,prefeitura_de_goiania_inquerito_2020,BRA
201006_Brazil_FederalUniversityofSergipe_genpop_IgG,201006_Brazil_FederalUniversityofSergipe,"Seroprevalence of SARS-CoV-2 IgM and IgG antibodies in an asymptomatic population in Sergipe, Brazil",2020-10-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Sergipe,"Aracaju, Simão Dias, Itabaiana, Itabaianinha, Nossa Senhora do, São Cristóvão, Estância, Lagarto, Tobias Barreto, Nossa Senhora da Glória","Asymptomatic residents at the main wet-market of
each city at the time of the study were enrolled in the study after
giving their informed consent. ","Symptomatic individuals (cough, fever, body aches, and shortness of breath) were excluded from the sample, as were health workers.",2020-05-02,2020-05-09,Household and community samples,All,Multiple groups,,,Primary Estimate,,2635,0.083,0.07200000000000001,0.094,True,,,,True,Convenience,Ichroma COVID-19 Ab Test,Boditech Med Inc.,LFIA,Serum,IgG,,Validated by independent authors/third party/non-developers,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Lysandro Pinto Borges,Federal University of Sergipe ,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541966/,2020-12-20,2024-03-01,Verified,borges_seroprevalence_2020,BRA
201006_Brazil_FederalUniversityofSergipe_genpop_female_Igg,201006_Brazil_FederalUniversityofSergipe,"Seroprevalence of SARS-CoV-2 IgM and IgG antibodies in an asymptomatic population in Sergipe, Brazil",2020-10-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Sergipe,"Aracaju, Simão Dias, Itabaiana, Itabaianinha, Nossa Senhora do, São Cristóvão, Estância, Lagarto, Tobias Barreto, Nossa Senhora da Glória","Asymptomatic residents at the main wet-market of
each city at the time of the study were enrolled in the study after
giving their informed consent. ","Symptomatic individuals (cough, fever, body aches, and shortness of breath) were excluded from the sample, as were health workers.",2020-05-02,2020-05-09,Household and community samples,Female,Multiple groups,,,Sex/Gender,Female,1327,0.08800000000000001,0.073,0.105,,,,,,Convenience,Ichroma COVID-19 Ab Test,Boditech Med Inc.,LFIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.958,0.97,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Lysandro Pinto Borges,Federal University of Sergipe ,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541966/,2020-12-20,2024-03-01,Verified,borges_seroprevalence_2020,BRA
201006_Brazil_FederalUniversityofSergipe_genpop_60,201006_Brazil_FederalUniversityofSergipe,"Seroprevalence of SARS-CoV-2 IgM and IgG antibodies in an asymptomatic population in Sergipe, Brazil",2020-10-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Sergipe,"Aracaju, Simão Dias, Itabaiana, Itabaianinha, Nossa Senhora do, São Cristóvão, Estância, Lagarto, Tobias Barreto, Nossa Senhora da Glória","Asymptomatic residents at the main wet-market of
each city at the time of the study were enrolled in the study after
giving their informed consent. ","Symptomatic individuals (cough, fever, body aches, and shortness of breath) were excluded from the sample, as were health workers.",2020-05-02,2020-05-09,Household and community samples,All,Seniors (65+ years),60.0,,Age,60 and over,357,0.11480000000000001,,,,,,,,Convenience,Ichroma COVID-19 Ab Test,Boditech Med Inc.,LFIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.958,0.97,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Lysandro Pinto Borges,Federal University of Sergipe ,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541966/,2020-12-20,2024-03-01,Verified,borges_seroprevalence_2020,BRA
201006_Brazil_FederalUniversityofSergipe_genpop_20-39,201006_Brazil_FederalUniversityofSergipe,"Seroprevalence of SARS-CoV-2 IgM and IgG antibodies in an asymptomatic population in Sergipe, Brazil",2020-10-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Sergipe,"Aracaju, Simão Dias, Itabaiana, Itabaianinha, Nossa Senhora do, São Cristóvão, Estância, Lagarto, Tobias Barreto, Nossa Senhora da Glória","Asymptomatic residents at the main wet-market of
each city at the time of the study were enrolled in the study after
giving their informed consent. ","Symptomatic individuals (cough, fever, body aches, and shortness of breath) were excluded from the sample, as were health workers.",2020-05-02,2020-05-09,Household and community samples,All,Adults (18-64 years),20.0,39.0,Age,20 to 39 years,1097,0.0747,,,,,,,,Convenience,Ichroma COVID-19 Ab Test,Boditech Med Inc.,LFIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.958,0.97,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Lysandro Pinto Borges,Federal University of Sergipe ,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541966/,2020-12-20,2024-03-01,Verified,borges_seroprevalence_2020,BRA
201006_Brazil_FederalUniversityofSergipe_genpop_male,201006_Brazil_FederalUniversityofSergipe,"Seroprevalence of SARS-CoV-2 IgM and IgG antibodies in an asymptomatic population in Sergipe, Brazil",2020-10-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Sergipe,"Aracaju, Simão Dias, Itabaiana, Itabaianinha, Nossa Senhora do, São Cristóvão, Estância, Lagarto, Tobias Barreto, Nossa Senhora da Glória","Asymptomatic residents at the main wet-market of
each city at the time of the study were enrolled in the study after
giving their informed consent. ","Symptomatic individuals (cough, fever, body aches, and shortness of breath) were excluded from the sample, as were health workers.",2020-05-02,2020-05-09,Household and community samples,Male,Multiple groups,,,Sex/Gender,IgG,1308,0.077,0.063,0.09300000000000001,,,,,,Convenience,Ichroma COVID-19 Ab Test,Boditech Med Inc.,LFIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.958,0.97,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Lysandro Pinto Borges,Federal University of Sergipe ,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541966/,2020-12-20,2024-03-01,Verified,borges_seroprevalence_2020,BRA
201006_Brazil_FederalUniversityofSergipe_genpop_40-59,201006_Brazil_FederalUniversityofSergipe,"Seroprevalence of SARS-CoV-2 IgM and IgG antibodies in an asymptomatic population in Sergipe, Brazil",2020-10-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Sergipe,"Aracaju, Simão Dias, Itabaiana, Itabaianinha, Nossa Senhora do, São Cristóvão, Estância, Lagarto, Tobias Barreto, Nossa Senhora da Glória","Asymptomatic residents at the main wet-market of
each city at the time of the study were enrolled in the study after
giving their informed consent. ","Symptomatic individuals (cough, fever, body aches, and shortness of breath) were excluded from the sample, as were health workers.",2020-05-02,2020-05-09,Household and community samples,All,Adults (18-64 years),40.0,59.0,Age,40 to 59,869,0.0886,,,,,,,,Convenience,Ichroma COVID-19 Ab Test,Boditech Med Inc.,LFIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.958,0.97,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Lysandro Pinto Borges,Federal University of Sergipe ,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541966/,2020-12-20,2024-03-01,Verified,borges_seroprevalence_2020,BRA
201006_Brazil_FederalUniversityofSergipe_genpop_0-19,201006_Brazil_FederalUniversityofSergipe,"Seroprevalence of SARS-CoV-2 IgM and IgG antibodies in an asymptomatic population in Sergipe, Brazil",2020-10-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Sergipe,"Aracaju, Simão Dias, Itabaiana, Itabaianinha, Nossa Senhora do, São Cristóvão, Estância, Lagarto, Tobias Barreto, Nossa Senhora da Glória","Asymptomatic residents at the main wet-market of
each city at the time of the study were enrolled in the study after
giving their informed consent. ","Symptomatic individuals (cough, fever, body aches, and shortness of breath) were excluded from the sample, as were health workers.",2020-05-02,2020-05-09,Household and community samples,All,Children and Youth (0-17 years),0.0,19.0,Age,0 to 19,312,0.057699999999999994,,,,,,,,Convenience,Ichroma COVID-19 Ab Test,Boditech Med Inc.,LFIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.958,0.97,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Lysandro Pinto Borges,Federal University of Sergipe ,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541966/,2020-12-20,2024-03-01,Verified,borges_seroprevalence_2020,BRA
201021_SaoPaulo_AdolfoLutzCentralInstitute,201021_SaoPaulo_AdolfoLutzCentralInstitute,"Prevalence of antibodies against sars-cov-2 in professionals of a public health laboratory at Sao Paulo, sp, Brazil",2020-10-21,Preprint,Local,Cross-sectional survey ,Brazil,State of Sao Paulo,Sao Paulo,Professionals of Adolfo Lutz Institute in Sao Paulo and administrative personnel of the Secretary of Health that share common work buildings.,,2020-06-05,2020-07-31,Multiple populations,All,Multiple groups,,,Primary Estimate,"Workers at the Adolfo Lutz Institute in Sao Paulo, Brazil and personnel of the Secretary of Health that who work in the same building ",406,0.086,,,True,,,,True,Convenience,"Finecare SARS-CoV-2 Antibody test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Guangzhou Wondfo Biotech Co. Ltd,Roche Diagnostics",Multiple Types,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),,,,['High'],No,No,No,Yes,Unclear,No,Yes,No,Unclear,Valeria Oliveira Silva,Adolfo Lutz Central Institute,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.19.20213421v1,2021-01-17,2024-03-01,Verified,silva_prevalence_2020,BRA
201027_FernandoNoronha_UniversidadeFederaldoCeará,201027_FernandoNoronha_UniversidadeFederaldoCeará,Fernando de Noronha: how an island controlled the community transmission of COVID-19 in Brazil,2020-10-27,Preprint,Local,Cross-sectional survey ,Brazil,State of Pernambuco,Fernando de Noronha,All individuals residing on the island of any age were eligible to be included in the study. Names and addresses were drawn at random from a current list of all residents.,Residents were excluded if not found at home after a second visit and replaced with another randomly selected.,2020-05-22,2020-05-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,904,0.043,0.032,0.059000000000000004,True,,,,True,Simplified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Unclear,Mozart Julio Tabosa Sales,Universidade Federal do Ceará,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.22.20216010v1.full-text,2021-04-27,2024-03-01,Verified,sales_fernando_2020,BRA
201110_Maranhao_UniversidadeFederaldoMaranhao_Phase2_OverallPopAdj,201110_Maranhao_UniversidadeFederaldoMaranhao_Phase2,"Prevalência de infecção pelo vírus SARS-CoV-2 no Maranhão, Brasil Relatório Final de Pesquisa Fase II",2020-11-10,Institutional Report,Regional,Prospective cohort,Brazil,Maranhão,,Residents age 1 year or older of households in 5 strata of the state of Maranhão,,2020-10-19,2020-10-30,Household and community samples,All,Multiple groups,1.0,,Primary Estimate,,4563,0.381,0.348,0.414,True,,True,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Antonio da Silva,Universidade Federal do Maranhao,Unity-Aligned,https://www.saude.ma.gov.br/wp-content/uploads/2020/11/Inquerito-Sorologico-Maranhao-Fase-2.pdf,2021-05-20,2024-03-01,Verified,da_silva_prevalencia_2020-1,BRA
201110_Maranhao_UniversidadeFederaldoMaranhao_Phase2_age70+,201110_Maranhao_UniversidadeFederaldoMaranhao_Phase2,"Prevalência de infecção pelo vírus SARS-CoV-2 no Maranhão, Brasil Relatório Final de Pesquisa Fase II",2020-11-10,Institutional Report,Regional,Prospective cohort,Brazil,Maranhão,,Residents age 1 year or older of households in 5 strata of the state of Maranhão,,2020-10-19,2020-10-30,Household and community samples,All,Seniors (65+ years),70.0,,Age,age 70 +,566,0.359,0.299,0.419,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Antonio da Silva,Universidade Federal do Maranhao,Unity-Aligned,https://www.saude.ma.gov.br/wp-content/uploads/2020/11/Inquerito-Sorologico-Maranhao-Fase-2.pdf,2021-07-22,2024-03-01,Verified,da_silva_prevalencia_2020-1,BRA
201110_Maranhao_UniversidadeFederaldoMaranhao_Phase2_age1to9,201110_Maranhao_UniversidadeFederaldoMaranhao_Phase2,"Prevalência de infecção pelo vírus SARS-CoV-2 no Maranhão, Brasil Relatório Final de Pesquisa Fase II",2020-11-10,Institutional Report,Regional,Prospective cohort,Brazil,Maranhão,,Residents age 1 year or older of households in 5 strata of the state of Maranhão,,2020-10-19,2020-10-30,Household and community samples,All,Children and Youth (0-17 years),1.0,9.0,Age,age 1 to 9,119,0.292,0.215,0.369,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Antonio da Silva,Universidade Federal do Maranhao,Unity-Aligned,https://www.saude.ma.gov.br/wp-content/uploads/2020/11/Inquerito-Sorologico-Maranhao-Fase-2.pdf,2021-07-22,2024-03-01,Verified,da_silva_prevalencia_2020-1,BRA
201110_Maranhao_UniversidadeFederaldoMaranhao_Phase2_age20to29,201110_Maranhao_UniversidadeFederaldoMaranhao_Phase2,"Prevalência de infecção pelo vírus SARS-CoV-2 no Maranhão, Brasil Relatório Final de Pesquisa Fase II",2020-11-10,Institutional Report,Regional,Prospective cohort,Brazil,Maranhão,,Residents age 1 year or older of households in 5 strata of the state of Maranhão,,2020-10-19,2020-10-30,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,age 20 to 29,630,0.41700000000000004,0.34600000000000003,0.488,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Antonio da Silva,Universidade Federal do Maranhao,Unity-Aligned,https://www.saude.ma.gov.br/wp-content/uploads/2020/11/Inquerito-Sorologico-Maranhao-Fase-2.pdf,2021-07-22,2024-03-01,Verified,da_silva_prevalencia_2020-1,BRA
201110_Maranhao_UniversidadeFederaldoMaranhao_Phase2_age50to59,201110_Maranhao_UniversidadeFederaldoMaranhao_Phase2,"Prevalência de infecção pelo vírus SARS-CoV-2 no Maranhão, Brasil Relatório Final de Pesquisa Fase II",2020-11-10,Institutional Report,Regional,Prospective cohort,Brazil,Maranhão,,Residents age 1 year or older of households in 5 strata of the state of Maranhão,,2020-10-19,2020-10-30,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,age 50 to 59,724,0.4,0.342,0.459,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Antonio da Silva,Universidade Federal do Maranhao,Unity-Aligned,https://www.saude.ma.gov.br/wp-content/uploads/2020/11/Inquerito-Sorologico-Maranhao-Fase-2.pdf,2021-07-22,2024-03-01,Verified,da_silva_prevalencia_2020-1,BRA
201110_Maranhao_UniversidadeFederaldoMaranhao_Phase2_age60to69,201110_Maranhao_UniversidadeFederaldoMaranhao_Phase2,"Prevalência de infecção pelo vírus SARS-CoV-2 no Maranhão, Brasil Relatório Final de Pesquisa Fase II",2020-11-10,Institutional Report,Regional,Prospective cohort,Brazil,Maranhão,,Residents age 1 year or older of households in 5 strata of the state of Maranhão,,2020-10-19,2020-10-30,Household and community samples,All,Adults (18-64 years),60.0,69.0,Age,age 60 to 69,651,0.34,0.273,0.40700000000000003,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Antonio da Silva,Universidade Federal do Maranhao,Unity-Aligned,https://www.saude.ma.gov.br/wp-content/uploads/2020/11/Inquerito-Sorologico-Maranhao-Fase-2.pdf,2021-07-22,2024-03-01,Verified,da_silva_prevalencia_2020-1,BRA
201110_Maranhao_UniversidadeFederaldoMaranhao_Phase2_age40to49,201110_Maranhao_UniversidadeFederaldoMaranhao_Phase2,"Prevalência de infecção pelo vírus SARS-CoV-2 no Maranhão, Brasil Relatório Final de Pesquisa Fase II",2020-11-10,Institutional Report,Regional,Prospective cohort,Brazil,Maranhão,,Residents age 1 year or older of households in 5 strata of the state of Maranhão,,2020-10-19,2020-10-30,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,age 40 to 49,714,0.376,0.309,0.443,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Antonio da Silva,Universidade Federal do Maranhao,Unity-Aligned,https://www.saude.ma.gov.br/wp-content/uploads/2020/11/Inquerito-Sorologico-Maranhao-Fase-2.pdf,2021-07-22,2024-03-01,Verified,da_silva_prevalencia_2020-1,BRA
201110_Maranhao_UniversidadeFederaldoMaranhao_Phase2_female,201110_Maranhao_UniversidadeFederaldoMaranhao_Phase2,"Prevalência de infecção pelo vírus SARS-CoV-2 no Maranhão, Brasil Relatório Final de Pesquisa Fase II",2020-11-10,Institutional Report,Regional,Prospective cohort,Brazil,Maranhão,,Residents age 1 year or older of households in 5 strata of the state of Maranhão,,2020-10-19,2020-10-30,Household and community samples,Female,Multiple groups,1.0,,Sex/Gender,,2959,0.394,0.355,0.433,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Antonio da Silva,Universidade Federal do Maranhao,Unity-Aligned,https://www.saude.ma.gov.br/wp-content/uploads/2020/11/Inquerito-Sorologico-Maranhao-Fase-2.pdf,2021-07-22,2024-03-01,Verified,da_silva_prevalencia_2020-1,BRA
201110_Maranhao_UniversidadeFederaldoMaranhao_Phase2_age10to19,201110_Maranhao_UniversidadeFederaldoMaranhao_Phase2,"Prevalência de infecção pelo vírus SARS-CoV-2 no Maranhão, Brasil Relatório Final de Pesquisa Fase II",2020-11-10,Institutional Report,Regional,Prospective cohort,Brazil,Maranhão,,Residents age 1 year or older of households in 5 strata of the state of Maranhão,,2020-10-19,2020-10-30,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,age 10 to 19,416,0.392,0.32799999999999996,0.456,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Antonio da Silva,Universidade Federal do Maranhao,Unity-Aligned,https://www.saude.ma.gov.br/wp-content/uploads/2020/11/Inquerito-Sorologico-Maranhao-Fase-2.pdf,2021-07-22,2024-03-01,Verified,da_silva_prevalencia_2020-1,BRA
201110_Maranhao_UniversidadeFederaldoMaranhao_Phase2_male,201110_Maranhao_UniversidadeFederaldoMaranhao_Phase2,"Prevalência de infecção pelo vírus SARS-CoV-2 no Maranhão, Brasil Relatório Final de Pesquisa Fase II",2020-11-10,Institutional Report,Regional,Prospective cohort,Brazil,Maranhão,,Residents age 1 year or older of households in 5 strata of the state of Maranhão,,2020-10-19,2020-10-30,Household and community samples,Male,Multiple groups,1.0,,Sex/Gender,,1604,0.355,0.316,0.395,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Antonio da Silva,Universidade Federal do Maranhao,Unity-Aligned,https://www.saude.ma.gov.br/wp-content/uploads/2020/11/Inquerito-Sorologico-Maranhao-Fase-2.pdf,2021-07-22,2024-03-01,Verified,da_silva_prevalencia_2020-1,BRA
201110_Maranhao_UniversidadeFederaldoMaranhao_Phase2_age30to39,201110_Maranhao_UniversidadeFederaldoMaranhao_Phase2,"Prevalência de infecção pelo vírus SARS-CoV-2 no Maranhão, Brasil Relatório Final de Pesquisa Fase II",2020-11-10,Institutional Report,Regional,Prospective cohort,Brazil,Maranhão,,Residents age 1 year or older of households in 5 strata of the state of Maranhão,,2020-10-19,2020-10-30,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,age 30 to 39,743,0.39299999999999996,0.33799999999999997,0.44799999999999995,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Antonio da Silva,Universidade Federal do Maranhao,Unity-Aligned,https://www.saude.ma.gov.br/wp-content/uploads/2020/11/Inquerito-Sorologico-Maranhao-Fase-2.pdf,2021-07-22,2024-03-01,Verified,da_silva_prevalencia_2020-1,BRA
201113_SaoPaulo_UniversidadeSaoPaulo_primary,201113_SaoPaulo_UniversidadedeSãoPaulo,"Prevalence of anti-SARS-CoV-2 antibodies in outpatients of a large public university hospital in Sao Paulo, Brazil",2020-11-13,Journal Article (Peer-Reviewed),Local,Prospective cohort,Brazil,State of Sao Paulo,Sao Paulo,adult patients followed-up at various outpatient services of the hospital ,,2020-06-30,2020-08-04,Residual sera,All,Multiple groups,18.0,,Primary Estimate,Outpatients overall,439,0.139,,,True,,,,True,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","DiaSorin,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Luanda Mara da Silva Oliveira,Universidade de São Paulo,Unity-Aligned,https://dx.doi.org/10.1590/S1678-9946202062091,2021-01-23,2024-03-01,Verified,oliveira_prevalence_2020,BRA
201119_SaoPaulo_ClinicaDeReumatologia_RheumaticPatients,201119_SaoPaulo_ClínicaDeReumatologia,"Seroconversion for SARS-CoV-2 in rheumatic patients on synthetic and biologics Disease Modifying Anti-Rheumatic Drugs in Sao Paulo, Brazil",2020-11-19,Preprint,Local,Prospective cohort,Brazil,State of Sao Paulo,Sao Paulo,"One hundred patients (>=18yrs) with a diagnosis of rheumatic diseases followed by five rheumatologists (members of this research team: FMS, MOP, JBL, JFC, CPF) were enrolled in this prospective study",patients not found or who refused to participate,2020-03-15,2020-08-15,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),18.0,,Primary Estimate,IgG and/or IgM overall,100,0.21,,,True,,,,True,Convenience,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Felipe Santana,Clínica de Reumatologia,Not Unity-Aligned,https://www.researchsquare.com/article/rs-97191/v1,2021-01-23,2024-03-01,Verified,santena_seroconversion_2020,BRA
201130_Sergipe_FederalUniversityofSergipe_residualsera_primary,201130_Sergipe_FederalUniversityofSergipe,SARS-CoV-2 has been circulating in northeastern Brazil since February 2019: evidence for antibody detection in asymptomatic patients,2020-11-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Sergipe,Aracaju,patients undergoing laboratory tests for routine examinations and health checks for causes unrelated to COVID-19.,,2020-01-15,2020-04-15,Residual sera,All,Multiple groups,,,Primary Estimate,,987,0.016,,,True,,,,True,Sequential,"Not reported/ Unable to specify,Ichroma COVID-19 Ab Test","NA,Boditech Med Inc.",LFIA,Serum,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Ricardo Queiroz Gurgel,Federal University of Sergipe,Unity-Aligned,http://dx.doi.org/10.1016/j.jinf.2020.11.037,2021-01-29,2024-03-01,Verified,gurgel_sars-cov-2_2020,BRA
201130_Sergipe_FederalUniversityofSergipe_residualsera_sex_male,201130_Sergipe_FederalUniversityofSergipe,SARS-CoV-2 has been circulating in northeastern Brazil since February 2019: evidence for antibody detection in asymptomatic patients,2020-11-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Sergipe,Aracaju,patients undergoing laboratory tests for routine examinations and health checks for causes unrelated to COVID-19.,,2020-01-15,2020-04-15,Residual sera,Male,Multiple groups,,,Sex/Gender,,304,0.0098,,,,,,,,Sequential,"Not reported/ Unable to specify,Ichroma COVID-19 Ab Test","NA,Boditech Med Inc.",LFIA,Serum,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Ricardo Queiroz Gurgel,Federal University of Sergipe,Unity-Aligned,http://dx.doi.org/10.1016/j.jinf.2020.11.037,2021-01-29,2024-03-01,Verified,gurgel_sars-cov-2_2020,BRA
201130_Sergipe_FederalUniversityofSergipe_residualsera_sex_female,201130_Sergipe_FederalUniversityofSergipe,SARS-CoV-2 has been circulating in northeastern Brazil since February 2019: evidence for antibody detection in asymptomatic patients,2020-11-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Sergipe,Aracaju,patients undergoing laboratory tests for routine examinations and health checks for causes unrelated to COVID-19.,,2020-01-15,2020-04-15,Residual sera,Female,Multiple groups,,,Sex/Gender,Female,683,0.019,,,,,,,,Sequential,"Not reported/ Unable to specify,Ichroma COVID-19 Ab Test","NA,Boditech Med Inc.",LFIA,Serum,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Ricardo Queiroz Gurgel,Federal University of Sergipe,Unity-Aligned,http://dx.doi.org/10.1016/j.jinf.2020.11.037,2021-01-29,2024-03-01,Verified,gurgel_sars-cov-2_2020,BRA
201211_Pitangueiras_PrefeituraMunicipaldePitangueiras_firstfase_primary,201211_Pitangueiras_PrefeituraMunicipaldePitangueiras_firstfase,Avaliação da prevalência de marcadores virológicos e sorológicos da infecção pelo SARS-CoV-2 na população de Pitangueiras-SP: inquérito epidemiológico populacional,2020-12-11,Institutional Report,Local,Prospective cohort,Brazil,,Pitangueiras,population of Pitangueiras,,2020-08-24,2020-08-29,Household and community samples,All,Multiple groups,15.0,,Primary Estimate,,150,0.0172,0.0051,0.029300000000000003,True,,True,,True,Stratified probability,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],,Yes,No,Yes,,Unclear,Yes,No,,Ana Celeste Crotti Peixoto,Prefeitura Municipal de Pitangueiras  ,Not Unity-Aligned,https://pitangueiras.sp.gov.br/wp-content/uploads/2020/12/Relatorio-Inquerito-COVID-19-Final.pdf,2021-05-22,2022-07-16,Unverified,crotti_peixoto_avaliacao_2020,BRA
201211_Pitangueiras_PrefeituraMunicipaldePitangueiras_secondfase_primary,201211_Pitangueiras_PrefeituraMunicipaldePitangueiras_secondfase,Avaliação da prevalência de marcadores virológicos e sorológicos da infecção pelo SARS-CoV-2 na população de Pitangueiras-SP: inquérito epidemiológico populacional,2020-12-11,Institutional Report,Local,Prospective cohort,Brazil,,Pitangueiras,population of Pitangueiras,,2020-09-24,2020-09-29,Household and community samples,All,Multiple groups,15.0,,Primary Estimate,,125,0.08,,,True,,,,True,Stratified probability,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],,Yes,No,No,,Unclear,Yes,No,,Ana Celeste Crotti Peixoto,Prefeitura Municipal de Pitangueiras  ,Not Unity-Aligned,https://pitangueiras.sp.gov.br/wp-content/uploads/2020/12/Relatorio-Inquerito-COVID-19-Final.pdf,2021-05-22,2022-07-16,Unverified,crotti_peixoto_avaliacao_2020,BRA
201213_SaoPaulo_ FaculdadeDeMedicinaDaUniversidade_Overall,201213_SaoPaulo_ FaculdadeDeMedicinaDaUniversidade,SARS-CoV-2 seroprevalence and risk factors among oligo/asymptomatic healthcare workers(HCW): estimating the impact of community transmission,2020-12-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,São Paulo State,São Paulo ,HCWs in the Central and the Outpatient Institutes of HC.,,2020-05-14,2020-05-28,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Overall,4987,0.141,0.131,0.15,True,,,,True,Convenience,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,No,Yes,Yes,Unclear,No,Yes,No,Yes,Silvia Costa,Faculdade De Medicina da Universidade,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1845,2021-01-23,2024-03-01,Verified,costa_sars-cov-2_2020,BRA
201210_MatoGrosso_StateUniversityOfMatoGrosso,201210_MatoGrosso_StateUniversityOfMatoGrosso,"Unemat coordinates study on
  health conditions of MT population during pandemic",2020-12-20,News and Media,Regional,Cross-sectional survey ,Brazil,Mato Grosso,"Água Boa, Alta Floresta, Barra do Garças, Cáceres, Cuiabá, Juína, Rondonópolis, Sinop, Tangará da Serra and Várzea Grande",,,2020-09-16,2020-10-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,4206,0.125,,,True,,,,True,Simplified probability,Not reported/ Unable to specify,,CLIA,Serum,IgG,Spike,,,,['High'],,Yes,Yes,No,,Unclear,Yes,No,,Lygia Lima,State University of Mato Gross,Not Unity-Aligned,http://www.mt.gov.br/-/16042707-unemat-coordena-estudo-sobre-condicoes-de-saude-da-populacao-de-mt-durante-pandemia,2021-05-17,2022-07-16,Unverified,lygia_lima_unemat_2020,BRA
210106_EspiritoSanto_SecretariadeEstadodaSaúdedoEspíritoSanto_primary,210106_EspiritoSanto_SecretariadeEstadodaSaúdedoEspíritoSanto,Covert cases of Severe Acute Respiratory Syndrome Coronavirus 2: An obscure but present danger in regions endemic for Dengue and Chikungunya viruses,2021-01-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Espírito Santo,,"samples from subjects with clinical symptoms compatible with Dengue and/or Chikungunya infection, 2) residents of the state of Espírito Santo, and 3) subjects with no prior history of COVID-19 diagnosis.",,2019-12-01,2020-06-30,Representative patient population,All,Multiple groups,,,Primary Estimate,Patients with Dengue or Chikunguya clinical symptoms,7370,0.0285,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Lorenzzo Lyrio Stringari,Secretaria de Estado da Saúde do Espírito Santo,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0244937,2021-01-30,2024-03-01,Verified,stringari_covert_2021,BRA
210113_SaoPaulo_CidadeDeSaoPaolo_2021_Phase1_overall,210113_SaoPaulo_CityOfSaoPaolo_2021_Phase1,Novo inquérito sorológico 2021 - fase 1,2021-01-13,Institutional Report,Local,Repeated cross-sectional study,Brazil,Sao Paulo,Sao Paulo,,,2021-01-05,2021-01-07,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,1960,0.141,0.11699999999999999,0.168,True,,,,True,Simplified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",,,0.9787,,['Moderate'],Yes,Yes,Yes,No,No,No,Yes,No,Unclear,City of Sao Paulo,Cidade de São Paulo,Not Unity-Aligned,http://www.capital.sp.gov.br/arquivos/pdf/2021/coletiva_saude_14-01.pdf,2021-05-21,2024-03-01,Verified,cidade_de_sao_paulo_novo_2021,BRA
210116_SaoPaulo_UniversityOfSãoPaulo_overall_IgG,210116_SaoPaulo_UniversityOfSãoPaulo,"The ""false-positive"" conundrum: IgA reference level overestimates the seroprevalence of antibodies to SARS-CoV-2",2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Sao Paulo,Sao Paulo,"members from an upper-class social and sports club in São Paulo, Brazil.","Patients with fever, dyspnea, cough, or other symptoms related to active disease were not authorized by the club board to come and are not represented in this group",2020-05-20,2020-05-22,Multiple populations,All,Multiple groups,,,Primary Estimate,overall IgG,938,0.057999999999999996,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Bruno Caramelli,University of São Paulo,Not Unity-Aligned,https://dx.doi.org/10.7189/jogh.11.05001,2021-03-27,2024-03-01,Verified,caramelli_false-positive_2021,BRA
210116_SaoPaulo_UniversityOfSãoPaulo_overall_age<60_IgG,210116_SaoPaulo_UniversityOfSãoPaulo,"The ""false-positive"" conundrum: IgA reference level overestimates the seroprevalence of antibodies to SARS-CoV-2",2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Sao Paulo,"members from an upper-class social and sports club in São Paulo, Brazil.","Patients with fever, dyspnea, cough, or other symptoms related to active disease were not authorized by the club board to come and are not represented in this group",2020-05-20,2020-05-22,Multiple populations,All,Multiple groups,,59.0,Age,age < 60 IgG,603,0.059699999999999996,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Bruno Caramelli,University of São Paulo,Not Unity-Aligned,https://dx.doi.org/10.7189/jogh.11.05001,2021-03-27,2024-03-01,Verified,caramelli_false-positive_2021,BRA
210116_SaoPaulo_UniversityOfSãoPaulo_overall_age60+_IgG,210116_SaoPaulo_UniversityOfSãoPaulo,"The ""false-positive"" conundrum: IgA reference level overestimates the seroprevalence of antibodies to SARS-CoV-2",2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Sao Paulo,"members from an upper-class social and sports club in São Paulo, Brazil.","Patients with fever, dyspnea, cough, or other symptoms related to active disease were not authorized by the club board to come and are not represented in this group",2020-05-20,2020-05-22,Multiple populations,All,Seniors (65+ years),60.0,,Age,age 60+ IgG,335,0.053700000000000005,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Bruno Caramelli,University of São Paulo,Not Unity-Aligned,https://dx.doi.org/10.7189/jogh.11.05001,2021-03-27,2024-03-01,Verified,caramelli_false-positive_2021,BRA
210115_Manaus_UniversidadedeSãoPaulo_Apr_PopTestAdj,210115_Manaus_UniversidadedeSãoPaulo_Apr,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Amazonas,Manaus,"routine blood
donations made at the Fundação
Hospitalar de Hematologia e Hemoterapia
do Amazonas (HEMOAM) in Manaus.",Excluding extreme negative values,2020-04-06,2020-04-17,Blood donors,All,Multiple groups,,,Primary Estimate,Pop/test adjusted,829,0.05,0.028999999999999998,0.07400000000000001,True,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2023-07-04,Verified,buss_three-quarters_2021,BRA
210115_Manaus_UniversidadedeSãoPaulo_Apr_PopAdj,210115_Manaus_UniversidadedeSãoPaulo_Apr,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Amazonas,Manaus,"routine blood
donations made at the Fundação
Hospitalar de Hematologia e Hemoterapia
do Amazonas (HEMOAM) in Manaus.",Excluding extreme negative values,2020-04-06,2020-04-17,Blood donors,All,Multiple groups,,,Analysis,Pop adjusted,829,0.077,0.059000000000000004,0.099,,,True,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2024-03-01,Verified,buss_three-quarters_2021,BRA
210115_Manaus_UniversidadedeSãoPaulo_Aug_PopTestAdj,210115_Manaus_UniversidadedeSãoPaulo_Aug,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Amazonas,Manaus,"routine blood
donations made at the Fundação
Hospitalar de Hematologia e Hemoterapia
do Amazonas (HEMOAM) in Manaus.",,2020-08-08,2020-08-19,Blood donors,All,Multiple groups,,,Primary Estimate,Pop/test adj,881,0.456,0.41100000000000003,0.501,True,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2023-07-04,Verified,buss_three-quarters_2021,BRA
210115_Manaus_UniversidadedeSãoPaulo_Aug_PopAdj,210115_Manaus_UniversidadedeSãoPaulo_Aug,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Amazonas,Manaus,"routine blood
donations made at the Fundação
Hospitalar de Hematologia e Hemoterapia
do Amazonas (HEMOAM) in Manaus.",,2020-08-08,2020-08-19,Blood donors,All,Multiple groups,,,Analysis,Pop adj,881,0.44,0.4,0.48,,,True,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2024-03-01,Verified,buss_three-quarters_2021,BRA
210115_Manaus_UniversidadedeSãoPaulo_Feb_PopTestAdj,210115_Manaus_UniversidadedeSãoPaulo_Feb,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Amazonas,Manaus,"routine blood
donations made at the Fundação
Hospitalar de Hematologia e Hemoterapia
do Amazonas (HEMOAM) in Manaus.",Excluding extreme negative values,2020-02-07,2020-02-13,Blood donors,All,Multiple groups,,,Primary Estimate,Pop/test adj,821,0.004,0.0,0.033,True,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2023-07-04,Verified,buss_three-quarters_2021,BRA
210115_Manaus_UniversidadedeSãoPaulo_Feb_PopAdj,210115_Manaus_UniversidadedeSãoPaulo_Feb,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Amazonas,Manaus,"routine blood
donations made at the Fundação
Hospitalar de Hematologia e Hemoterapia
do Amazonas (HEMOAM) in Manaus.",Excluding extreme negative values,2020-02-07,2020-02-13,Blood donors,All,Multiple groups,,,Analysis,Pop adj,821,0.036000000000000004,0.02,0.063,,,True,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2024-03-01,Verified,buss_three-quarters_2021,BRA
210115_Manaus_UniversidadedeSãoPaulo_Jul_PopTestAdj,210115_Manaus_UniversidadedeSãoPaulo_Jul,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Amazonas,Manaus,"routine blood
donations made at the Fundação
Hospitalar de Hematologia e Hemoterapia
do Amazonas (HEMOAM) in Manaus.",Excluding extreme negative values,2020-07-06,2020-07-15,Blood donors,All,Multiple groups,,,Primary Estimate,Pop/test adj,1147,0.49,0.44200000000000006,0.536,True,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2023-07-04,Verified,buss_three-quarters_2021,BRA
210115_Manaus_UniversidadedeSãoPaulo_Jul_PopAdj,210115_Manaus_UniversidadedeSãoPaulo_Jul,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Amazonas,Manaus,"routine blood
donations made at the Fundação
Hospitalar de Hematologia e Hemoterapia
do Amazonas (HEMOAM) in Manaus.",Excluding extreme negative values,2020-07-06,2020-07-15,Blood donors,All,Multiple groups,,,Analysis,Pop adj,1147,0.469,0.42700000000000005,0.511,,,True,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2024-03-01,Verified,buss_three-quarters_2021,BRA
210115_Manaus_UniversidadedeSãoPaulo_Jun_PopTestAdj,210115_Manaus_UniversidadedeSãoPaulo_Jun,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Amazonas,Manaus,"routine blood
donations made at the Fundação
Hospitalar de Hematologia e Hemoterapia
do Amazonas (HEMOAM) in Manaus.",Excluding extreme negative values,2020-06-05,2020-06-15,Blood donors,All,Multiple groups,,,Primary Estimate,Pop/test adj,911,0.554,0.507,0.601,True,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2023-07-04,Verified,buss_three-quarters_2021,BRA
210115_Manaus_UniversidadedeSãoPaulo_Jun_PopAdj,210115_Manaus_UniversidadedeSãoPaulo_Jun,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Amazonas,Manaus,"routine blood
donations made at the Fundação
Hospitalar de Hematologia e Hemoterapia
do Amazonas (HEMOAM) in Manaus.",Excluding extreme negative values,2020-06-05,2020-06-15,Blood donors,All,Multiple groups,,,Analysis,Pop adj,911,0.527,0.485,0.569,,,True,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2024-03-01,Verified,buss_three-quarters_2021,BRA
210115_Manaus_UniversidadedeSãoPaulo_Mar_PopTestAdj,210115_Manaus_UniversidadedeSãoPaulo_Mar,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Amazonas,Manaus,"routine blood
donations made at the Fundação
Hospitalar de Hematologia e Hemoterapia
do Amazonas (HEMOAM) in Manaus.",Excluding extreme negative values,2020-03-06,2020-03-12,Blood donors,All,Multiple groups,,,Primary Estimate,Pop/test adj,832,0.0,0.0,0.008,True,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2023-07-04,Verified,buss_three-quarters_2021,BRA
210115_Manaus_UniversidadedeSãoPaulo_Mar_PopAdj,210115_Manaus_UniversidadedeSãoPaulo_Mar,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Amazonas,Manaus,"routine blood
donations made at the Fundação
Hospitalar de Hematologia e Hemoterapia
do Amazonas (HEMOAM) in Manaus.",Excluding extreme negative values,2020-03-06,2020-03-12,Blood donors,All,Multiple groups,,,Analysis,Pop adj,832,0.026000000000000002,0.016,0.040999999999999995,,,True,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2024-03-01,Verified,buss_three-quarters_2021,BRA
210115_Manaus_UniversidadedeSãoPaulo_May_PopTestAdj,210115_Manaus_UniversidadedeSãoPaulo_May,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Amazonas,Manaus," routine blood
donations made at the Fundação
Hospitalar de Hematologia e Hemoterapia
do Amazonas (HEMOAM) in Manaus.",Excluding extreme negative values,2020-05-05,2020-05-14,Blood donors,All,Multiple groups,,,Primary Estimate,Pop/test adj,901,0.434,0.384,0.48600000000000004,True,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2023-07-04,Verified,buss_three-quarters_2021,BRA
210115_Manaus_UniversidadedeSãoPaulo_May_PopAdj,210115_Manaus_UniversidadedeSãoPaulo_May,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Amazonas,Manaus," routine blood
donations made at the Fundação
Hospitalar de Hematologia e Hemoterapia
do Amazonas (HEMOAM) in Manaus.",Excluding extreme negative values,2020-05-05,2020-05-14,Blood donors,All,Multiple groups,,,Analysis,pop adj,901,0.42100000000000004,0.375,0.467,,,True,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2024-03-01,Verified,buss_three-quarters_2021,BRA
210115_Manaus_UniversidadedeSãoPaulo_Oct_PopTestAdj,210115_Manaus_UniversidadedeSãoPaulo_Oct,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Amazonas,Manaus,"routine blood
donations made at the Fundação
Hospitalar de Hematologia e Hemoterapia
do Amazonas (HEMOAM) in Manaus.",Excluding extreme negative values,2020-10-10,2020-10-17,Blood donors,All,Multiple groups,,,Primary Estimate,Pop/test adj,882,0.446,0.39299999999999996,0.5,True,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2023-07-04,Verified,buss_three-quarters_2021,BRA
210115_Manaus_UniversidadedeSãoPaulo_Oct_PopAdj,210115_Manaus_UniversidadedeSãoPaulo_Oct,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Amazonas,Manaus,"routine blood
donations made at the Fundação
Hospitalar de Hematologia e Hemoterapia
do Amazonas (HEMOAM) in Manaus.",Excluding extreme negative values,2020-10-10,2020-10-17,Blood donors,All,Multiple groups,,,Analysis,pop adj,882,0.43100000000000005,0.383,0.479,,,True,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2024-03-01,Verified,buss_three-quarters_2021,BRA
210115_Manaus_UniversidadedeSãoPaulo_Sept_PopTestAdj,210115_Manaus_UniversidadedeSãoPaulo_Sept,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Amazonas,Manaus,"routine blood
donations made at the Fundação
Hospitalar de Hematologia e Hemoterapia
do Amazonas (HEMOAM) in Manaus.",Excluding extreme negative values,2020-09-05,2020-09-14,Blood donors,All,Multiple groups,,,Primary Estimate,Pop/test adj,868,0.473,0.42100000000000004,0.525,True,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2023-07-04,Verified,buss_three-quarters_2021,BRA
210115_Manaus_UniversidadedeSãoPaulo_Sept_PopAdj,210115_Manaus_UniversidadedeSãoPaulo_Sept,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Amazonas,Manaus,"routine blood
donations made at the Fundação
Hospitalar de Hematologia e Hemoterapia
do Amazonas (HEMOAM) in Manaus.",Excluding extreme negative values,2020-09-05,2020-09-14,Blood donors,All,Multiple groups,,,Analysis,pop adj,868,0.454,0.408,0.501,,,True,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2024-03-01,Verified,buss_three-quarters_2021,BRA
210115_SaoPaulo_UniversidadedeSãoPaulo_Apr_PopTestAdj,210115_SaoPaulo_UniversidadedeSãoPaulo_Apr,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Sao Paulo State,Sao Paulo,"routine blood
donations made at the Fundação Pró-Sangue
blood bank in São Paulo .",Excluding extreme negative values,2020-04-08,2020-04-30,Blood donors,All,Multiple groups,,,Primary Estimate,Pop/test adj,900,0.04,0.018000000000000002,0.066,True,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2023-07-04,Verified,buss_three-quarters_2021,BRA
210115_SaoPaulo_UniversidadedeSãoPaulo_Apr_PopAdj,210115_SaoPaulo_UniversidadedeSãoPaulo_Apr,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Sao Paulo State,Sao Paulo,"routine blood
donations made at the Fundação Pró-Sangue
blood bank in São Paulo .",Excluding extreme negative values,2020-04-08,2020-04-30,Blood donors,All,Multiple groups,,,Analysis,pop adj,900,0.068,0.049,0.091,,,True,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2024-03-01,Verified,buss_three-quarters_2021,BRA
210115_SaoPaulo_UniversidadedeSãoPaulo_Aug_PopTestAdj,210115_SaoPaulo_UniversidadedeSãoPaulo_Aug,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Sao Paulo State,Sao Paulo,"routine blood
donations made at the Fundação Pró-Sangue
blood bank in São Paulo .",Excluding extreme negative values,2020-08-10,2020-08-29,Blood donors,All,Multiple groups,,,Primary Estimate,Pop/test adj,906,0.155,0.12300000000000001,0.182,True,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2023-07-04,Verified,buss_three-quarters_2021,BRA
210115_SaoPaulo_UniversidadedeSãoPaulo_Aug_PopAdj,210115_SaoPaulo_UniversidadedeSãoPaulo_Aug,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Sao Paulo State,Sao Paulo,"routine blood
donations made at the Fundação Pró-Sangue
blood bank in São Paulo .",Excluding extreme negative values,2020-08-10,2020-08-29,Blood donors,All,Multiple groups,,,Analysis,pop adj,906,0.172,0.145,0.201,,,True,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2024-03-01,Verified,buss_three-quarters_2021,BRA
210115_SaoPaulo_UniversidadedeSãoPaulo_DonorsTestOverall,210115_SaoPaulo_UniversidadedeSãoPaulo_DonorsTest,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Sao Paulo State,Sao Paulo,Blood donations given in Sao Paulo in July 2020,Excluding extreme negative values,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,,,Primary Estimate,Overall Abbott + Roche test,1000,0.133,,,True,,,,,Unclear,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",CLIA,Serum,IgG,Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],No,Unclear,Yes,No,Unclear,Unclear,No,No,Unclear,Lewis Buss,Universidade de Sao Paulo,Not Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2024-03-01,Verified,buss_three-quarters_2021,BRA
210115_SaoPaulo_UniversidadedeSãoPaulo_DonorsTestRoche,210115_SaoPaulo_UniversidadedeSãoPaulo_DonorsTest,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Sao Paulo State,Sao Paulo,Blood donations given in Sao Paulo in July 2020,Excluding extreme negative values,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,,,Test used,Roche test,1000,0.133,,,,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,,0.99,['High'],No,Unclear,Yes,No,Unclear,Unclear,No,No,Unclear,Lewis Buss,Universidade de Sao Paulo,Not Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2024-03-01,Verified,buss_three-quarters_2021,BRA
210115_SaoPaulo_UniversidadedeSãoPaulo_DonorsTestAbbott,210115_SaoPaulo_UniversidadedeSãoPaulo_DonorsTest,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Sao Paulo State,Sao Paulo,Blood donations given in Sao Paulo in July 2020,Excluding extreme negative values,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,,,Test used,Abbott test,1000,0.10300000000000001,,,,,,,True,Unclear,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['High'],No,Unclear,Yes,No,Unclear,Unclear,No,No,Unclear,Lewis Buss,Universidade de Sao Paulo,Not Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2024-03-01,Verified,buss_three-quarters_2021,BRA
210115_SaoPaulo_UniversidadedeSãoPaulo_Feb_PopTestAdj,210115_SaoPaulo_UniversidadedeSãoPaulo_Feb,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Sao Paulo State,Sao Paulo,"routine blood
donations made at the Fundação Pró-Sangue
blood bank in São Paulo .",Excluding extreme negative values,2020-02-08,2020-02-29,Blood donors,All,Multiple groups,,,Primary Estimate,Pop/test adj,799,0.01,0.0,0.028999999999999998,True,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2023-07-04,Verified,buss_three-quarters_2021,BRA
210115_SaoPaulo_UniversidadedeSãoPaulo_Feb_PopAdj,210115_SaoPaulo_UniversidadedeSãoPaulo_Feb,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Sao Paulo State,Sao Paulo,"routine blood
donations made at the Fundação Pró-Sangue
blood bank in São Paulo .",Excluding extreme negative values,2020-02-08,2020-02-29,Blood donors,All,Multiple groups,,,Analysis,pop adj,799,0.042,0.028999999999999998,0.06,,,True,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2024-03-01,Verified,buss_three-quarters_2021,BRA
210115_SaoPaulo_UniversidadedeSãoPaulo_Jul_PopTestAdj,210115_SaoPaulo_UniversidadedeSãoPaulo_Jul,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Sao Paulo State,Sao Paulo,"routine blood
donations made at the Fundação Pró-Sangue
blood bank in São Paulo .",Excluding extreme negative values,2020-07-13,2020-07-25,Blood donors,All,Multiple groups,,,Primary Estimate,Pop/test adj,879,0.106,0.081,0.135,True,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2023-07-04,Verified,buss_three-quarters_2021,BRA
210115_SaoPaulo_UniversidadedeSãoPaulo_Jul_PopAdj,210115_SaoPaulo_UniversidadedeSãoPaulo_Jul,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Sao Paulo State,Sao Paulo,"routine blood
donations made at the Fundação Pró-Sangue
blood bank in São Paulo .",Excluding extreme negative values,2020-07-13,2020-07-25,Blood donors,All,Multiple groups,,,Analysis,pop adj,879,0.128,0.105,0.153,,,True,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2024-03-01,Verified,buss_three-quarters_2021,BRA
210115_SaoPaulo_UniversidadedeSãoPaulo_Jun_PopTestAdj,210115_SaoPaulo_UniversidadedeSãoPaulo_Jun,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Sao Paulo State,Sao Paulo,"routine blood
donations made at the Fundação Pró-Sangue
blood bank in São Paulo .",Excluding extreme negative values,2020-06-08,2020-06-20,Blood donors,All,Multiple groups,,,Primary Estimate,Pop/test adj,880,0.131,0.10300000000000001,0.163,True,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2023-07-04,Verified,buss_three-quarters_2021,BRA
210115_SaoPaulo_UniversidadedeSãoPaulo_Jun_PopAdj,210115_SaoPaulo_UniversidadedeSãoPaulo_Jun,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Sao Paulo State,Sao Paulo,"routine blood
donations made at the Fundação Pró-Sangue
blood bank in São Paulo .",Excluding extreme negative values,2020-06-08,2020-06-20,Blood donors,All,Multiple groups,,,Analysis,pop adj,880,0.15,0.125,0.17800000000000002,,,True,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2024-03-01,Verified,buss_three-quarters_2021,BRA
210115_SaoPaulo_UniversidadedeSãoPaulo_Mar_PopTestAdj,210115_SaoPaulo_UniversidadedeSãoPaulo_Mar,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Sao Paulo State,Sao Paulo,"routine blood
donations made at the Fundação Pró-Sangue
blood bank in São Paulo .",Excluding extreme negative values,2020-03-09,2020-03-21,Blood donors,All,Multiple groups,,,Primary Estimate,Pop/test adj,2454,0.027999999999999997,0.018000000000000002,0.039,True,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2023-07-04,Verified,buss_three-quarters_2021,BRA
210115_SaoPaulo_UniversidadedeSãoPaulo_Mar_PopAdj,210115_SaoPaulo_UniversidadedeSãoPaulo_Mar,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Sao Paulo State,Sao Paulo,"routine blood
donations made at the Fundação Pró-Sangue
blood bank in São Paulo .",Excluding extreme negative values,2020-03-09,2020-03-21,Blood donors,All,Multiple groups,,,Analysis,pop adj,2454,0.057999999999999996,0.049,0.068,,,True,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2024-03-01,Verified,buss_three-quarters_2021,BRA
210115_SaoPaulo_UniversidadedeSãoPaulo_May_PopTestAdj,210115_SaoPaulo_UniversidadedeSãoPaulo_May,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Sao Paulo State,Sao Paulo,"routine blood
donations made at the Fundação Pró-Sangue
blood bank in São Paulo .",Excluding extreme negative values,2020-05-08,2020-05-21,Blood donors,All,Multiple groups,,,Primary Estimate,Pop/test adj,826,0.047,0.026000000000000002,0.073,True,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2023-07-04,Verified,buss_three-quarters_2021,BRA
210115_SaoPaulo_UniversidadedeSãoPaulo_May_PopAdj,210115_SaoPaulo_UniversidadedeSãoPaulo_May,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Sao Paulo State,Sao Paulo,"routine blood
donations made at the Fundação Pró-Sangue
blood bank in São Paulo .",Excluding extreme negative values,2020-05-08,2020-05-21,Blood donors,All,Multiple groups,,,Analysis,pop adj,826,0.075,0.055999999999999994,0.098,,,True,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2024-03-01,Verified,buss_three-quarters_2021,BRA
210115_SaoPaulo_UniversidadedeSãoPaulo_Oct_PopTestAdj,210115_SaoPaulo_UniversidadedeSãoPaulo_Oct,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Sao Paulo State,Sao Paulo,"routine blood
donations made at the Fundação Pró-Sangue
blood bank in São Paulo .",Excluding extreme negative values,2020-10-12,2020-10-24,Blood donors,All,Multiple groups,,,Primary Estimate,Pop/test adj,877,0.182,0.15,0.217,True,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2023-07-04,Verified,buss_three-quarters_2021,BRA
210115_SaoPaulo_UniversidadedeSãoPaulo_Oct_PopAdj,210115_SaoPaulo_UniversidadedeSãoPaulo_Oct,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Sao Paulo State,Sao Paulo,"routine blood
donations made at the Fundação Pró-Sangue
blood bank in São Paulo .",Excluding extreme negative values,2020-10-12,2020-10-24,Blood donors,All,Multiple groups,,,Analysis,pop adj,877,0.195,0.166,0.227,,,True,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2024-03-01,Verified,buss_three-quarters_2021,BRA
210115_SaoPaulo_UniversidadedeSãoPaulo_Sept_PopTestAdj,210115_SaoPaulo_UniversidadedeSãoPaulo_Sept,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Sao Paulo State,Sao Paulo,"routine blood
donations made at the Fundação Pró-Sangue
blood bank in São Paulo .",Excluding extreme negative values,2020-09-07,2020-09-29,Blood donors,All,Multiple groups,,,Primary Estimate,Pop/test adj,933,0.151,0.12300000000000001,0.182,True,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2023-07-04,Verified,buss_three-quarters_2021,BRA
210115_SaoPaulo_UniversidadedeSãoPaulo_Sept_PopAdj,210115_SaoPaulo_UniversidadedeSãoPaulo_Sept,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,2021-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Sao Paulo State,Sao Paulo,"routine blood
donations made at the Fundação Pró-Sangue
blood bank in São Paulo .",Excluding extreme negative values,2020-09-07,2020-09-29,Blood donors,All,Multiple groups,,,Analysis,pop adj,933,0.167,0.142,0.195,,,True,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.922,0.961,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Lewis Buss,Universidade de Sao Paulo,Unity-Aligned,https://science.sciencemag.org/content/371/6526/288,2021-04-07,2024-03-01,Verified,buss_three-quarters_2021,BRA
210118_SaoPaulo_ProvinciaFranciscanadaImaculadaConceicaodoBrasil_Overall,210118_SaoPaulo_ProvinciaFranciscanadaImaculadaConceicaodoBrasil,COVID-19 among workers assisting homeless and socially vulnerable people.,2021-01-18,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Brazil,,Sao Paulo,"Serviço Franciscano de Solidariedade (SEFRAS) is a
not-for-profit social organization providing care to more
than 3,000 people on a daily basis, including children,
youngsters, older adults, homeless and immigrants.
Since March 2020, SEFRAS acts primarily in provision
of food to homeless and socially vulnerable people. Data were collected from professionals and
volunteers working at SEFRAS.",,2020-05-20,2020-06-02,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,173,0.266,,,True,,,,True,Convenience,Author designed (LFIA),,LFIA,Whole Blood,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Nidia Horie,Província Franciscana da Imaculada Conceição do Brasil,Not Unity-Aligned,https://dx.doi.org/10.31744/einstein_journal/2022AO6237,2022-03-21,2022-07-16,Unverified,horie_covid-19_2022,BRA
210128_XikrinofBacaja_InstitutodeCiênciasBiológicasdaUniversidadeFederaldoPará_overall,210128_XikrinofBacaja_InstitutodeCiênciasBiológicasdaUniversidadeFederaldoPará,High prevalence of anti-SARS-CoV-2 IgG antibody in the Xikrin of Bacaja (Kayapo) indigenous population in the brazilian Amazon,2021-01-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Pará,Xikrin of Bacaja Villages,"individuals from the Kenkrô, Bacajá, Pykatum, Moinorô, Mrotidjam, and Pytako villages",,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,2.0,82.0,Primary Estimate,,100,0.73,,,True,,,,True,Unclear,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,,IgG,Spike,,,,['High'],Yes,Unclear,No,Yes,Yes,Yes,Yes,Yes,Unclear,Eliene Putira Sacuema Rodrigues,Instituto de Ciências Biológicas da Universidade Federal do Pará,Not Unity-Aligned,https://dx.doi.org/10.1186/s12939-021-01392-8,2021-03-09,2024-03-01,Verified,rodrigues_high_2021,BRA
0128_XikrinofBacaja_InstitutodeCiênciasBiológicasdaUniversidadeFederaldoPará_Pytako,210128_XikrinofBacaja_InstitutodeCiênciasBiológicasdaUniversidadeFederaldoPará,High prevalence of anti-SARS-CoV-2 IgG antibody in the Xikrin of Bacaja (Kayapo) indigenous population in the brazilian Amazon,2021-01-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Pytako villages,"individuals from the Kenkrô, Bacajá, Pykatum, Moinorô, Mrotidjam, and Pytako villages",,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,2.0,82.0,Geographical area,Pytako villages,19,1.0,,,,,,,,Unclear,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,,IgG,Spike,,,,['High'],Yes,Unclear,No,Yes,Yes,Yes,Yes,Yes,Unclear,Eliene Putira Sacuema Rodrigues,Instituto de Ciências Biológicas da Universidade Federal do Pará,Not Unity-Aligned,https://dx.doi.org/10.1186/s12939-021-01392-8,2021-03-09,2024-03-01,Verified,rodrigues_high_2021,BRA
0128_XikrinofBacaja_InstitutodeCiênciasBiológicasdaUniversidadeFederaldoPará_Mrotid-jam,210128_XikrinofBacaja_InstitutodeCiênciasBiológicasdaUniversidadeFederaldoPará,High prevalence of anti-SARS-CoV-2 IgG antibody in the Xikrin of Bacaja (Kayapo) indigenous population in the brazilian Amazon,2021-01-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Mrotid-jam villages,"individuals from the Kenkrô, Bacajá, Pykatum, Moinorô, Mrotidjam, and Pytako villages",,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,2.0,82.0,Geographical area,Mrotid-jam villages,1,1.0,,,,,,,,Unclear,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,,IgG,Spike,,,,['High'],Yes,Unclear,No,Yes,Yes,Yes,Yes,Yes,Unclear,Eliene Putira Sacuema Rodrigues,Instituto de Ciências Biológicas da Universidade Federal do Pará,Not Unity-Aligned,https://dx.doi.org/10.1186/s12939-021-01392-8,2021-03-09,2024-03-01,Verified,rodrigues_high_2021,BRA
0128_XikrinofBacaja_InstitutodeCiênciasBiológicasdaUniversidadeFederaldoPará_Kenkro,210128_XikrinofBacaja_InstitutodeCiênciasBiológicasdaUniversidadeFederaldoPará,High prevalence of anti-SARS-CoV-2 IgG antibody in the Xikrin of Bacaja (Kayapo) indigenous population in the brazilian Amazon,2021-01-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Kenkro village,"individuals from the Kenkrô, Bacajá, Pykatum, Moinorô, Mrotidjam, and Pytako villages",,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,2.0,82.0,Geographical area,Kenkro village,41,0.902,,,,,,,,Unclear,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,,IgG,Spike,,,,['High'],Yes,Unclear,No,Yes,Yes,Yes,Yes,Yes,Unclear,Eliene Putira Sacuema Rodrigues,Instituto de Ciências Biológicas da Universidade Federal do Pará,Not Unity-Aligned,https://dx.doi.org/10.1186/s12939-021-01392-8,2021-03-09,2024-03-01,Verified,rodrigues_high_2021,BRA
0128_XikrinofBacaja_InstitutodeCiênciasBiológicasdaUniversidadeFederaldoPará_Moinoro,210128_XikrinofBacaja_InstitutodeCiênciasBiológicasdaUniversidadeFederaldoPará,High prevalence of anti-SARS-CoV-2 IgG antibody in the Xikrin of Bacaja (Kayapo) indigenous population in the brazilian Amazon,2021-01-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Moinoro villages,"individuals from the Kenkrô, Bacajá, Pykatum, Moinorô, Mrotidjam, and Pytako villages",,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,2.0,82.0,Geographical area,Moinoro villages,13,1.0,,,,,,,,Unclear,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,,IgG,Spike,,,,['High'],Yes,Unclear,No,Yes,Yes,Yes,Yes,Yes,Unclear,Eliene Putira Sacuema Rodrigues,Instituto de Ciências Biológicas da Universidade Federal do Pará,Not Unity-Aligned,https://dx.doi.org/10.1186/s12939-021-01392-8,2021-03-09,2024-03-01,Verified,rodrigues_high_2021,BRA
0128_XikrinofBacaja_InstitutodeCiênciasBiológicasdaUniversidadeFederaldoPará_Bacaja,210128_XikrinofBacaja_InstitutodeCiênciasBiológicasdaUniversidadeFederaldoPará,High prevalence of anti-SARS-CoV-2 IgG antibody in the Xikrin of Bacaja (Kayapo) indigenous population in the brazilian Amazon,2021-01-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Bacaja village,"individuals from the Kenkrô, Bacajá, Pykatum, Moinorô, Mrotidjam, and Pytako villages",,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,2.0,82.0,Geographical area,Bacaja village,23,0.304,,,,,,,,Unclear,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,,IgG,Spike,,,,['High'],Yes,Unclear,No,Yes,Yes,Yes,Yes,Yes,Unclear,Eliene Putira Sacuema Rodrigues,Instituto de Ciências Biológicas da Universidade Federal do Pará,Not Unity-Aligned,https://dx.doi.org/10.1186/s12939-021-01392-8,2021-03-09,2024-03-01,Verified,rodrigues_high_2021,BRA
0128_XikrinofBacaja_InstitutodeCiênciasBiológicasdaUniversidadeFederaldoPará_overall_rapid,210128_XikrinofBacaja_InstitutodeCiênciasBiológicasdaUniversidadeFederaldoPará,High prevalence of anti-SARS-CoV-2 IgG antibody in the Xikrin of Bacaja (Kayapo) indigenous population in the brazilian Amazon,2021-01-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Xikrin of Bacaja Villages,"individuals from the Kenkrô, Bacajá, Pykatum, Moinorô, Mrotidjam, and Pytako villages",,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,2.0,82.0,Test used,Rapid test,100,0.58,,,,,,,,Unclear,Wondfo SARS-CoV-2 Antibody Test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,,IgG,,,,,['High'],Yes,Unclear,No,Yes,Yes,Yes,Yes,Yes,Unclear,Eliene Putira Sacuema Rodrigues,Instituto de Ciências Biológicas da Universidade Federal do Pará,Not Unity-Aligned,https://dx.doi.org/10.1186/s12939-021-01392-8,2021-03-28,2024-03-01,Verified,rodrigues_high_2021,BRA
0128_XikrinofBacaja_InstitutodeCiênciasBiológicasdaUniversidadeFederaldoPará_Pykatum,210128_XikrinofBacaja_InstitutodeCiênciasBiológicasdaUniversidadeFederaldoPará,High prevalence of anti-SARS-CoV-2 IgG antibody in the Xikrin of Bacaja (Kayapo) indigenous population in the brazilian Amazon,2021-01-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Pykatum village,"individuals from the Kenkrô, Bacajá, Pykatum, Moinorô, Mrotidjam, and Pytako villages",,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,2.0,82.0,Geographical area,Pykatum village,4,0.0,,,,,,,,Unclear,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,,IgG,Spike,,,,['High'],Yes,Unclear,No,Yes,Yes,Yes,Yes,Yes,Unclear,Eliene Putira Sacuema Rodrigues,Instituto de Ciências Biológicas da Universidade Federal do Pará,Not Unity-Aligned,https://dx.doi.org/10.1186/s12939-021-01392-8,2021-03-09,2024-03-01,Verified,rodrigues_high_2021,BRA
210129_Botuacato_InstitutoButantan_Primary,210129_Botuacato_InstitutoButantan,COVID-19 in long-term care facilities in Brazil: serological survey in a post-outbreak setting,2021-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Sao Paolo,Botucato,Residents of LTCF with COVID-19 outbreaks,,2020-06-22,2020-07-08,Assisted living and long-term care facilities,All,Multiple groups,50.0,106.0,Primary Estimate,Long term care facilities,209,0.115,0.071,0.166,True,,,,True,Convenience,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.8640000000000001,0.996,['High'],Yes,No,No,Yes,Yes,No,Yes,No,Yes,Eliana Nogueira Castro de Barros,Instituto Butantan,Not Unity-Aligned,https://dx.doi.org/10.1590/S1678-9946202163010,2021-03-18,2024-03-01,Verified,barros_covid-19_2021,BRA
210204_SaoPaulo_CityOfSaoPaulo_2021_Phase2,210204_SaoPaulo_CityOfSaoPaulo_2021_Phase2,inquérito sorológico adultos (>18) para sars-cov-2 evolução da prevalência da infecção no msp 2021 - resultado da fase 2 de 2021,2021-02-04,Institutional Report,Local,Cross-sectional survey ,Brazil,Sao Paulo,Sao Paulo,Adults aged 18+,,2021-01-07,2021-01-21,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,1841,0.139,0.11699999999999999,0.16399999999999998,True,,,,True,Simplified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",,,0.9787,,['Moderate'],Yes,Yes,Yes,No,No,No,Yes,No,Unclear,City of Sao Paulo,City of Sao Paulo,Not Unity-Aligned,http://www.capital.sp.gov.br/arquivos/pdf/2021/inquerito_fase-02_2021.pdf/view,2021-05-21,2024-03-01,Verified,city_of_sao_paulo_inquerito_2021,BRA
210209_Sergipe_FederalUniversityofSergipe,210209_Sergipe_FederalUniversityofSergipe,Seroprevalence of SARS-CoV-2 antibodies in low-income university students,2021-02-09,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Sergipe,"Aracaji, Itabaiana, Lagarto, Larangeiras, Nossa Senhora da Gloria, Sao Cristovao"," included students registered with the Programa de Auxílio Moradia e Residência Universitária (PAMRU - the Housing and University Residency Assistance
Program) at the Federal University of Sergipe (UFS), Sergipe State, Northeast Brazil",,2020-09-15,2020-10-06,Students and Daycares,All,Adults (18-64 years),,,Primary Estimate,Overall,276,0.225,0.179,0.277,True,,,,True,Convenience,"Ichroma COVID-19 Ab Test,KOVID Ab (COVID-19 IgG / IgM) kit","Boditech Med Inc.,Kovalent",LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.958,0.97,['High'],Yes,No,No,Yes,Yes,Unclear,Yes,Yes,No,Adriano Antunes de Souza Araujo,Federal University of Sergipe,Not Unity-Aligned,https://dx.doi.org/10.17179/excli2021-3459,2021-03-27,2024-03-01,Verified,araujo_seroprevalence_2021,BRA
210210_Joinville_CityHallofJoinville_PopAdj,210210_Joinville_CityHallofJoinville,"Population-Based Study of anti-SARS-CoV-2, Social Distancing and Government Responses in Joinville, Brazil",2021-02-10,Preprint,Local,Repeated cross-sectional study,Brazil,Santa Catarina,Joinville,"households in Joinville, Brazil",younger than 18 months old,2020-06-15,2020-08-07,Household and community samples,All,Multiple groups,1.0,,Primary Estimate,Adjusted for age,4403,0.0484,,,True,,True,,True,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8643000000000001,0.9956999999999999,['Moderate'],Yes,Yes,Yes,No,Unclear,No,Yes,No,Unclear,Henrique Diegoli,City Hall of Joinville,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.08.21251009v1.full,2021-05-13,2024-03-01,Verified,diegoli_population-based_2021,BRA
210210_Joinville_CityHallofJoinville_Unadj,210210_Joinville_CityHallofJoinville,"Population-Based Study of anti-SARS-CoV-2, Social Distancing and Government Responses in Joinville, Brazil",2021-02-10,Preprint,Local,Repeated cross-sectional study,Brazil,Santa Catarina,Joinville,"households in Joinville, Brazil",younger than 18 months old,2020-06-15,2020-08-07,Household and community samples,All,Multiple groups,1.0,,Analysis,Unadjusted,4403,0.044500000000000005,,,,,,,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8643000000000001,0.9956999999999999,['Moderate'],Yes,Yes,Yes,No,Unclear,No,Yes,No,Unclear,Henrique Diegoli,City Hall of Joinville,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.08.21251009v1.full,2021-05-13,2024-03-01,Verified,diegoli_population-based_2021,BRA
210312_SaoPaulo_CityOfSaoPaulo_2021_Phase4_overall,210312_SaoPaulo_CityOfSaoPaulo_2021_Phase4,inquérito sorológico adultos (>18)para sars-cov-2 - resultado da fase 4 de 2021,2021-03-12,Institutional Report,Local,Repeated cross-sectional study,Brazil,São Paulo,São Paulo,São Paulo residents 18+,,2021-02-16,2021-02-18,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,1793,0.25,0.217,0.287,True,,,,True,Simplified probability,"Finecare SARS-CoV-2 Antibody test,Anti-SARS-CoV-2 ELISA IgG","Guangzhou Wondfo Biotech Co. Ltd,EUROIMMUN",Multiple Types,Multiple Types,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,No,No,Yes,Yes,No,,City of Sao Paulo,City of São Paulo,Unity-Aligned,http://www.capital.sp.gov.br/arquivos/pdf/2021/inquerito_fase-04_2021.pdf/,2021-07-20,2024-03-01,Verified,cidade_de_sao_paulo_inquerito_2021,BRA
210312_SaoPaulo_CityOfSaoPaulo_2021_Phase4_RapidTest,210312_SaoPaulo_CityOfSaoPaulo_2021_Phase4,inquérito sorológico adultos (>18)para sars-cov-2 - resultado da fase 4 de 2021,2021-03-12,Institutional Report,Local,Repeated cross-sectional study,Brazil,São Paulo,São Paulo,São Paulo residents 18+,,2021-02-16,2021-02-18,Household and community samples,All,Multiple groups,18.0,,Test used,Positive on Wondfo Rapid test,1793,0.146,,,,,,,,Simplified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,No,No,Yes,Yes,No,,City of Sao Paulo,City of São Paulo,Unity-Aligned,http://www.capital.sp.gov.br/arquivos/pdf/2021/inquerito_fase-04_2021.pdf/,2021-07-20,2024-03-01,Verified,cidade_de_sao_paulo_inquerito_2021,BRA
210312_SaoPaulo_CityOfSaoPaulo_2021_Phase4_ELISA,210312_SaoPaulo_CityOfSaoPaulo_2021_Phase4,inquérito sorológico adultos (>18)para sars-cov-2 - resultado da fase 4 de 2021,2021-03-12,Institutional Report,Local,Repeated cross-sectional study,Brazil,São Paulo,São Paulo,São Paulo residents 18+,,2021-02-16,2021-02-18,Household and community samples,All,Multiple groups,18.0,,Test used,Positive on Euroimmun ELISA,1793,0.237,,,,,,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,No,No,Yes,Yes,No,,City of Sao Paulo,City of São Paulo,Unity-Aligned,http://www.capital.sp.gov.br/arquivos/pdf/2021/inquerito_fase-04_2021.pdf/,2021-07-20,2024-03-01,Verified,cidade_de_sao_paulo_inquerito_2021,BRA
210324_SaoPaulo_UniversityofSaoPaulo_overall,210324_SaoPaulo_UniversityofSaoPaulo,SARS-Cov-2 seroprevalence and risk factors among Health Care Workers: estimating the risk of COVID-19 dedicated units,2021-03-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Sao Paulo,Sao Paulo,"Any professional who worked at the Hospital Sírio-Libanês between March and July, 2020, was invited to participate. HCW were defined as any worker working within the hospital, including hospital and auxiliary services.

the second step was to invite all HCW of“COVID-19 units”(estimated 1,200 employees); then we randomly choose units dedicated for care of non-COVID patients and some administrative areas (estimated 2,300). Wards (12 units) and ICUs (3 units) dedicated to non-COVID-19 patients are allocated on different floors and we chose some randomly.","Thus, when planning for inviting employees, we first excluded those at home office, medical leave or vacation(estimated 2,500). ",2020-06-17,2020-07-08,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1996,0.05511,,,True,,,,True,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,,IgG,,Validated by manufacturers,0.9500000000000001,1.0,['High'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Maura Salaroli de Oliveira,University of São Paulo,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ajic.2021.03.010,2021-04-18,2022-07-16,Verified,oliveira_sars-cov-2_2021,BRA
210326_RiodeJaneiro_InstitutoD’OrdePesquisaeEnsino,210326_RiodeJaneiro_InstitutoD’OrdePesquisaeEnsino,Screening of COVID-19 in outpatient children with cancer or solid organ transplantation: preliminary report,2021-03-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Rio de Janeiro,Rio de Janeiro,"immunosuppressed patients, from 0 to 18 years old, in a tertiary hospital in Rio de Janeiro, Brazil",,2020-06-30,2020-08-28,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),0.0,18.0,Primary Estimate,"Kidney transplantation, liver transplantation or cancer (children)",114,0.307,,,True,,,,True,Sequential,Leccurate SARS-CoV-2 Antibody Rapid Test Kit (Colloidal Gold Immunochromatography),Beijing Lepu Medical Technology,Other,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.66,0.97,['High'],,No,No,No,,Yes,Yes,No,,Thais Cleto Yamane,Instituto D’Or de Pesquisa e Ensino,Not Unity-Aligned,https://dx.doi.org/10.1007/s00431-021-04044-9,2021-04-23,2024-03-01,Unverified,cleto-yamane_screening_2021,BRA
210329_PortoAlegre_UniversidadeFederaldeCienciasdaSaudedePortoAlegre_HCW_August,210329_PortoAlegre_UniversidadeFederaldeCienciasdaSaudedePortoAlegre_august,"Prevalence of COVID-19 in healthcare professionals working in hospital emergencies during first wave peak in 2020, Porto Alegre - Brazil",2021-03-29,Journal Article (Peer-Reviewed),Local,Prospective cohort,Brazil,Rio Grande do Sul,Porto Alegre,"healthcare professionals working in the emergency departments of five large tertiary hospitals located in Porto Alegre, Southern Brazil

Jobs were nursing assistants (43.5%), physicians (23.0%), nurses (15.0%), administrative workers (12.9%), and cleaners (3.6%).",,2020-08-10,2020-08-14,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,August 10-14 ,911,0.055999999999999994,,,,,,,,Unclear,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.943,0.951,['High'],Yes,Unclear,Yes,No,Unclear,No,Yes,No,Unclear,Ana Dubiela,Universidade Federal de Ciencias da Saude de Porto Alegre,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2021.139,2021-04-17,2024-03-01,Verified,dubiela_prevalence_2021,BRA
210329_PortoAlegre_UniversidadeFederaldeCienciasdaSaudedePortoAlegre_HCW_July,210329_PortoAlegre_UniversidadeFederaldeCienciasdaSaudedePortoAlegre_july,"Prevalence of COVID-19 in healthcare professionals working in hospital emergencies during first wave peak in 2020, Porto Alegre - Brazil",2021-03-29,Journal Article (Peer-Reviewed),Local,Prospective cohort,Brazil,Rio Grande do Sul,Porto Alegre,"healthcare professionals working in the emergency departments of five large tertiary hospitals located in Porto Alegre, Southern Brazil

Jobs were nursing assistants (43.5%), physicians (23.0%), nurses (15.0%), administrative workers (12.9%), and cleaners (3.6%).",,2020-07-20,2020-07-24,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,July 20-24 (baseline),1163,0.055,,,True,,,,True,Unclear,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.943,0.951,['High'],Yes,Unclear,Yes,No,Unclear,No,Yes,No,Unclear,Ana Dubiela,Universidade Federal de Ciencias da Saude de Porto Alegre,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2021.139,2021-04-17,2024-03-01,Verified,dubiela_prevalence_2021,BRA
210416_Itabaianinha_FederalUniversityofSergipe_ControlCohort2,210416_Itabaianinha_FederalUniversityofSergipe_ControlCohort2,Individuals with isolated congenital GH deficiency due to a GHRH receptor gene mutation appear to cope better with SARS-CoV-2 infection than controls.,2021-04-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Sergipe,Itabaianinha,"Inclusion criteria for IGHD were homozygosity for the c.57+1G→A GHRHR mutation, while homozygosity for the wild-type GHRHR allele was required for the control group.","Exclusion criteria were age less than 12 years, GH treatment in the past ten years, and current signs and symptoms of COVID 19, namely cough, sore throat, fever, muscle or joint pain, fatigue, or headache",2020-10-01,2020-10-03,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,12.0,,Primary Estimate,Control Group,27,0.185,,,True,,,,True,Convenience,Ichroma COVID-19 Ab Test,Boditech Med Inc.,ELISA,Serum,"['IgG', 'IgM']",,,0.958,0.97,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Manuela A Melo,"Federal University of Sergipe, Aracaju",Not Unity-Aligned,https://dx.doi.org/10.1007/s12020-021-02728-8,2021-05-22,2024-03-01,Verified,manuelaa.meloIndividualsIsolatedCongenital2021,BRA
210416_Itabaianinha_FederalUniversityofSergipe_IGHDCohort1,210416_Itabaianinha_FederalUniversityofSergipe_IGHDCohort1,Individuals with isolated congenital GH deficiency due to a GHRH receptor gene mutation appear to cope better with SARS-CoV-2 infection than controls.,2021-04-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Sergipe,Itabaianinha,"Inclusion criteria for IGHD were homozygosity for the c.57+1G→A GHRHR mutation, while homozygosity for the wild-type GHRHR allele was required for the control group.","Exclusion criteria were age less than 12 years, GH treatment in the past ten years, and current signs and symptoms of COVID 19, namely cough, sore throat, fever, muscle or joint pain, fatigue, or headache",2020-10-01,2020-10-03,Household and community samples,All,Multiple groups,12.0,,Primary Estimate,IGHD Cohort,27,0.222,,,True,,,,True,Convenience,Ichroma COVID-19 Ab Test,Boditech Med Inc.,ELISA,,"['IgG', 'IgM']",,,0.958,0.97,['High'],,No,No,Yes,,Yes,Yes,Yes,,Manuela A Melo,"Federal University of Sergipe, Aracaju",Not Unity-Aligned,https://dx.doi.org/10.1007/s12020-021-02728-8,2021-05-22,2024-03-01,Unverified,manuelaa.meloIndividualsIsolatedCongenital2021,BRA
210419_Sergipe_UniversidadeFederalDeSergipe_Stage2_overall_unadj copy,210419_Sergipe_UniversidadeFederalDeSergipe_Stage2,Evolução da Prevalência de Infecção por SARS-CoV-2 em Sergipe. Resultados da Terceira Fase: 18 de fevereiro a 30 de março de 2021.,2021-04-19,Institutional Report,Regional,Repeated cross-sectional study,Brazil,Sergipe,,Residents of 15 municipalities of Sergipe,,2020-08-11,2020-11-17,Household and community samples,All,Multiple groups,,,Primary Estimate,,5405,0.079,0.068,0.091,True,,,,True,Stratified probability,"KOVID Ab (COVID-19 IgG / IgM) kit,Ichroma COVID-19 Ab Test","Kovalent,Boditech Med Inc.",Multiple Types,Multiple Types,"['IgG', 'IgM']",,,,,['Moderate'],,Yes,Yes,No,,Unclear,Yes,No,,Adriano Araujo,The Federal Univeristy of Sergipe,Not Unity-Aligned,https://www.researchgate.net/publication/350976274_Evolucao_da_Prevalencia_de_Infeccao_por_SARS-CoV-2_em_Sergipe_Resultados_da_Terceira_Fase_18_de_fevereiro_a_30_de_marco_de_2021,2021-05-19,2024-03-01,Unverified,araujo_evolucao_2021,BRA
210419_Sergipe_UniversidadeFederalDeSergipe_Stage3_overall_unadj copy,210419_Sergipe_UniversidadeFederalDeSergipe_Stage3,Evolução da Prevalência de Infecção por SARS-CoV-2 em Sergipe. Resultados da Terceira Fase: 18 de fevereiro a 30 de março de 2021.,2021-04-19,Institutional Report,Regional,Repeated cross-sectional study,Brazil,Sergipe,,Residents of 15 municipalities of Sergipe,,2021-02-18,2021-03-30,Household and community samples,All,Multiple groups,,,Primary Estimate,,5527,0.154,0.145,0.16399999999999998,True,,,,True,Stratified probability,"KOVID Ab (COVID-19 IgG / IgM) kit,Ichroma COVID-19 Ab Test","Kovalent,Boditech Med Inc.",Multiple Types,Multiple Types,"['IgG', 'IgM']",,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Adriano Araujo,The Federal Univeristy of Sergipe,Not Unity-Aligned,https://www.researchgate.net/publication/350976274_Evolucao_da_Prevalencia_de_Infeccao_por_SARS-CoV-2_em_Sergipe_Resultados_da_Terceira_Fase_18_de_fevereiro_a_30_de_marco_de_2021,2021-05-19,2024-03-01,Unverified,araujo_evolucao_2021,BRA
210422_RioGrandeDoSul_SantaCasaDeMisericordiaDePortoAlegre_police,210422_RioGrandeDoSul_SantaCasaDeMisericordiaDePortoAlegre,"COVID-19 seroprevalence in military police force, Southern Brazil",2021-04-22,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Rio Grande do Sul State,"Porto Alegre, Caxias do Sul, Canoas, Pelotas, Santa Maria, Passo Fundo, Uruguaiana, Santa Cruz do Sul, Ijui, and Lajeado ","This was a cross-sectional study involving military police in ten cities of Rio Grande do Sul:
Porto Alegre, Caxias do Sul, Canoas, Pelotas, Santa Maria, Passo Fundo, Uruguaiana, Santa
Cruz do Sul, Ijui, and Lajeado.","Forty-five individuals were excluded from the seroprevalence study because of previously
confirmed COVID-19. Smaller cities and rural areas were not included",2020-07-23,2020-07-25,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,Military police,1592,0.033,,,True,,,,True,Stratified probability,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA",EUROIMMUN,ELISA,,"['IgA', 'IgG']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Alessandro Pasqualotto,Molecular Biology Laboratory at Santa Casa de Misericordia de Porto Alegre,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0249672,2021-05-17,2024-03-01,Verified,pasqualotto_covid-19_2021,BRA
210429_Fortaleza_StateUniversityofCearáCampusdoItaperi_Overall,210501_Fortaleza_StateUniversityofCearaCampusdoItaperi,"Prevalence of COVID-19 in children, adolescents, and adults in remote education situation in the city of Fortaleza - Brazil.",2021-05-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Ceará,Fortaleza,"Children, adolescents and adults (school employees - teachers and administrative professionals) attending schools belonging to each of the city’s six educational districts. ","Children, adolescents and adults were excluded if they had any medical condition that prevented or hindered their school attendance. ",2020-11-09,2020-12-09,Multiple populations,All,Multiple groups,,,Primary Estimate,,1559,0.267,,,True,,,,True,Simplified probability,Leccurate SARS-CoV-2 Antibody Rapid Test Kit (Colloidal Gold Immunochromatography),Beijing Lepu Medical Technology,Other,,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.9890000000000001,0.976,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Valdester Cavalcante Pinto Junior,"State University of Ceará, Campus do Itaperi",Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.04.086,2021-05-27,2024-03-01,Verified,valdestercavalcantepintojunioretal.PrevalenceCOVID19Children2021,BRA
210429_Fortaleza_StateUniversityofCearáCampusdoItaperi_>19,210501_Fortaleza_StateUniversityofCearaCampusdoItaperi,"Prevalence of COVID-19 in children, adolescents, and adults in remote education situation in the city of Fortaleza - Brazil.",2021-05-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Ceará,Fortaleza,"Children, adolescents and adults (school employees - teachers and administrative professionals) attending schools belonging to each of the city’s six educational districts. ","Children, adolescents and adults were excluded if they had any medical condition that prevented or hindered their school attendance. ",2020-11-09,2020-12-09,Essential non-healthcare workers,All,Adults (18-64 years),,,Age,>19,282,0.209,,,,,,,,Simplified probability,Leccurate SARS-CoV-2 Antibody Rapid Test Kit (Colloidal Gold Immunochromatography),Beijing Lepu Medical Technology,Other,,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.9890000000000001,0.976,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Valdester Cavalcante Pinto Junior,"State University of Ceará, Campus do Itaperi",Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.04.086,2021-09-03,2024-03-01,Verified,valdestercavalcantepintojunioretal.PrevalenceCOVID19Children2021,BRA
210429_Fortaleza_StateUniversityofCearáCampusdoItaperi_10-19,210501_Fortaleza_StateUniversityofCearaCampusdoItaperi,"Prevalence of COVID-19 in children, adolescents, and adults in remote education situation in the city of Fortaleza - Brazil.",2021-05-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Ceará,Fortaleza,"Children, adolescents and adults (school employees - teachers and administrative professionals) attending schools belonging to each of the city’s six educational districts. ","Children, adolescents and adults were excluded if they had any medical condition that prevented or hindered their school attendance. ",2020-11-09,2020-12-09,Students and Daycares,All,Children and Youth (0-17 years),,,Age,10-19,854,0.29300000000000004,,,,,,,,Simplified probability,Leccurate SARS-CoV-2 Antibody Rapid Test Kit (Colloidal Gold Immunochromatography),Beijing Lepu Medical Technology,Other,,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.9890000000000001,0.976,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Valdester Cavalcante Pinto Junior,"State University of Ceará, Campus do Itaperi",Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.04.086,2021-09-03,2024-03-01,Verified,valdestercavalcantepintojunioretal.PrevalenceCOVID19Children2021,BRA
210429_Fortaleza_StateUniversityofCearáCampusdoItaperi_<=9,210501_Fortaleza_StateUniversityofCearaCampusdoItaperi,"Prevalence of COVID-19 in children, adolescents, and adults in remote education situation in the city of Fortaleza - Brazil.",2021-05-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Ceará,Fortaleza,"Children, adolescents and adults (school employees - teachers and administrative professionals) attending schools belonging to each of the city’s six educational districts. ","Children, adolescents and adults were excluded if they had any medical condition that prevented or hindered their school attendance. ",2020-11-09,2020-12-09,Students and Daycares,All,Children and Youth (0-17 years),,,Age,<=9,423,0.253,,,,,,,,Simplified probability,Leccurate SARS-CoV-2 Antibody Rapid Test Kit (Colloidal Gold Immunochromatography),Beijing Lepu Medical Technology,Other,,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.9890000000000001,0.976,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Valdester Cavalcante Pinto Junior,"State University of Ceará, Campus do Itaperi",Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.04.086,2021-09-03,2024-03-01,Verified,valdestercavalcantepintojunioretal.PrevalenceCOVID19Children2021,BRA
210501_SãoPaulo_Ipec_overall_Unadj,210501_SãoPaulo_Ipec,"SoroEpi MSP – Inquéritos soroepidemiológicos seriados para monitorar a prevalência da  infecção por SARS-CoV-2 no Município de São Paulo, SP, Brasil: Fase 6",2021-05-01,Institutional Report,Local,Cross-sectional survey ,Brazil,São Paulo,São Paulo,Inhabitants of the municipality of São Paulo over the age of 18,,2021-04-22,2021-05-01,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,1187,0.41600000000000004,,,True,,,,True,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,No,Unclear,Beatriz Tess,Inteligência em Pesquisa e Consultoria,Unity-Aligned,https://www.monitoramentocovid19.org/resultados,2021-05-22,2024-03-01,Verified,tess_soroepi_2020,BRA
210518_Sergipe_FederalUniversityofSergipe_overall,210518_Sergipe_FederalUniversityofSergipe,Seroprevalence of SARS-CoV-2 antibodies in the poorest region of Brazil: results from a population-based study.,2021-05-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Sergipe,," individuals not previously tested for SARS-CoV-2 residing in Sergipe state, Northeast Brazil",,2020-07-01,2020-07-31,Household and community samples,All,Multiple groups,,,Primary Estimate,Sergipe state overall,5615,0.0926,0.085,0.10099999999999999,True,,,,True,Stratified probability,"Finecare SARS-CoV-2 Antibody test,Ichroma COVID-19 Ab Test","Guangzhou Wondfo Biotech Co. Ltd,Boditech Med Inc.",Multiple Types,Whole Blood,"['IgG', 'IgM']",Spike,Validated by manufacturers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Unclear,Adriano Antunes de Souza Araújo,Federal University of Sergipe,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268821001163,2021-05-30,2024-03-01,Verified,de_souza_araujo_seroprevalence_2021,BRA
210518_Sergipe_FederalUniversityofSergipe_female,210518_Sergipe_FederalUniversityofSergipe,Seroprevalence of SARS-CoV-2 antibodies in the poorest region of Brazil: results from a population-based study.,2021-05-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Sergipe,," individuals not previously tested for SARS-CoV-2 residing in Sergipe state, Northeast Brazil",,2020-07-01,2020-07-31,Household and community samples,Female,Multiple groups,,,Sex/Gender,,3353,0.102,0.092,0.113,,,,,,Stratified probability,"Finecare SARS-CoV-2 Antibody test,Ichroma COVID-19 Ab Test","Guangzhou Wondfo Biotech Co. Ltd,Boditech Med Inc.",Multiple Types,Whole Blood,"['IgG', 'IgM']",Spike,Validated by manufacturers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Unclear,Adriano Antunes de Souza Araújo,Federal University of Sergipe,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268821001163,2021-06-25,2024-03-01,Verified,de_souza_araujo_seroprevalence_2021,BRA
210518_Sergipe_FederalUniversityofSergipe_male,210518_Sergipe_FederalUniversityofSergipe,Seroprevalence of SARS-CoV-2 antibodies in the poorest region of Brazil: results from a population-based study.,2021-05-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Sergipe,," individuals not previously tested for SARS-CoV-2 residing in Sergipe state, Northeast Brazil",,2020-07-01,2020-07-31,Household and community samples,Male,Multiple groups,,,Sex/Gender,,2262,0.079,0.068,0.091,,,,,,Stratified probability,"Finecare SARS-CoV-2 Antibody test,Ichroma COVID-19 Ab Test","Guangzhou Wondfo Biotech Co. Ltd,Boditech Med Inc.",Multiple Types,Whole Blood,"['IgG', 'IgM']",Spike,Validated by manufacturers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Unclear,Adriano Antunes de Souza Araújo,Federal University of Sergipe,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268821001163,2021-06-25,2024-03-01,Verified,de_souza_araujo_seroprevalence_2021,BRA
210518_Sergipe_FederalUniversityofSergipe_NonmetropolitanResidence,210518_Sergipe_FederalUniversityofSergipe,Seroprevalence of SARS-CoV-2 antibodies in the poorest region of Brazil: results from a population-based study.,2021-05-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Sergipe,," individuals not previously tested for SARS-CoV-2 residing in Sergipe state, Northeast Brazil",,2020-07-01,2020-07-31,Household and community samples,All,Multiple groups,,,Geographical area,People residing in nonmetropolitan areas,3706,0.08,0.07200000000000001,0.08900000000000001,,,,,,Stratified probability,"Finecare SARS-CoV-2 Antibody test,Ichroma COVID-19 Ab Test","Guangzhou Wondfo Biotech Co. Ltd,Boditech Med Inc.",Multiple Types,Whole Blood,"['IgG', 'IgM']",Spike,Validated by manufacturers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Unclear,Adriano Antunes de Souza Araújo,Federal University of Sergipe,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268821001163,2021-06-25,2024-03-01,Verified,de_souza_araujo_seroprevalence_2021,BRA
210518_Sergipe_FederalUniversityofSergipe_MetropolitanResidence,210518_Sergipe_FederalUniversityofSergipe,Seroprevalence of SARS-CoV-2 antibodies in the poorest region of Brazil: results from a population-based study.,2021-05-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Sergipe,," individuals not previously tested for SARS-CoV-2 residing in Sergipe state, Northeast Brazil",,2020-07-01,2020-07-31,Household and community samples,All,Multiple groups,,,Geographical area,People residing in metropolitan areas,1909,0.11699999999999999,0.10300000000000001,0.132,,,,,,Stratified probability,"Finecare SARS-CoV-2 Antibody test,Ichroma COVID-19 Ab Test","Guangzhou Wondfo Biotech Co. Ltd,Boditech Med Inc.",Multiple Types,Whole Blood,"['IgG', 'IgM']",Spike,Validated by manufacturers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Unclear,Adriano Antunes de Souza Araújo,Federal University of Sergipe,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268821001163,2021-06-25,2024-03-01,Verified,de_souza_araujo_seroprevalence_2021,BRA
210609_SouthBrazil_UniversidadeFederaldoParaná,210609_SouthBrazil_UniversidadeFederaldoParaná ,SARS-CoV-2 in asymptomatic pregnant women in South Brazil: RT-PCR and serological detection.,2021-06-09,Preprint,Regional,Prospective cohort,Brazil,Mato Grosso do Sul,Curitiba,"The inclusion criteria were: pregnancy at any gestational age and the absence of COVID-19 symptoms as fever, sore throat, cough, coryza, headache, diarrhea, anosmia and ageusia. ",The exclusion criteria were the previous diagnosis of COVID-19 and the patient’s refusal to participate.,2020-09-15,2020-10-15,Pregnant or parturient women,All,Adults (18-64 years),,,Primary Estimate,Pregnant women,195,0.087,,,True,,,,True,Convenience,Not reported/ Unable to specify,,LFIA,Serum,"['IgG', 'IgM']",,,,,['High'],,No,No,No,,Unclear,Yes,No,,Jullie Anne Chiste,Complexo Hospital de Clínicas da Universidade Federal do Paraná ,Not Unity-Aligned,https://dx.doi.org/10.1515/jpm-2021-0173,2021-06-17,2022-07-16,Unverified,jullieannechisteSARSCoV2AsymptomaticPregnant2021,BRA
210617_Campinas_UniversityOfCampinas,210617_Campinas_UniversityOfCampinas,Low SARS-CoV-2 seroprevalence in a cohort of Brazilian sickle cell disease patients: Possible effects of emphasis on social isolation for a population initially considered to be at very high risk,2021-06-17,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Brazil,Sao Paulo,Campinas,"Patients with any genotypic presentation (HbSS, Sβ-thalassemia, or HbSC) and above 18 years of age were included",,2020-08-15,2021-01-15,Representative patient population,All,Multiple groups,19.0,74.0,Primary Estimate,,135,0.11,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Architect Anti-SARS-CoV-2 IgM",Abbott Laboratories,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,No,Yes,Yes,Unclear,No,No,Unclear,Luiza Francisco Trafane,University of Campinas,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.1002/jha2.254,2021-09-08,2024-03-01,Verified,trafane_low_2021,BRA
210618_Brazil_UniversidadeFederaldePelotas_primary,210618_Brazil_UniversidadeFederaldePelotas,COVID-19 and social distancing among children and adolescents in Brazil.,2021-06-18,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,,general population,,2020-05-14,2020-06-23,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,89362,0.023,,,True,,,,True,Stratified probability,Wondfo SARS-CoV-2 Antibody Test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,,,Validated by independent authors/third party/non-developers,0.848,0.99,['Moderate'],Yes,Yes,Yes,No,Yes,No,Yes,No,Yes,Fernando C Barros,Universidade Federal de Pelotas,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225319/,2021-07-21,2024-03-01,Verified,barros_covid-19_2021-1,BRA
210618_Brazil_UniversidadeFederaldePelotas_age_0-9,210618_Brazil_UniversidadeFederaldePelotas,COVID-19 and social distancing among children and adolescents in Brazil.,2021-06-18,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,,general population,,2020-05-14,2020-06-23,Household and community samples,All,Children and Youth (0-17 years),0.0,9.0,Age,,4263,0.023,0.018000000000000002,0.027000000000000003,,,,,,Stratified probability,Wondfo SARS-CoV-2 Antibody Test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,,,Validated by independent authors/third party/non-developers,0.848,0.99,['Moderate'],Yes,Yes,Yes,No,Yes,No,Yes,No,Yes,Fernando C Barros,Universidade Federal de Pelotas,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225319/,2021-07-21,2024-03-01,Verified,barros_covid-19_2021-1,BRA
210618_Brazil_UniversidadeFederaldePelotas_age_10-19,210618_Brazil_UniversidadeFederaldePelotas,COVID-19 and social distancing among children and adolescents in Brazil.,2021-06-18,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,,general population,,2020-05-14,2020-06-23,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,,8024,0.018000000000000002,0.015,0.021,,,,,,Stratified probability,Wondfo SARS-CoV-2 Antibody Test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,,,Validated by independent authors/third party/non-developers,0.848,0.99,['Moderate'],Yes,Yes,Yes,No,Yes,No,Yes,No,Yes,Fernando C Barros,Universidade Federal de Pelotas,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225319/,2021-07-21,2024-03-01,Verified,barros_covid-19_2021-1,BRA
210618_Brazil_UniversidadeFederaldePelotas_age_20+,210618_Brazil_UniversidadeFederaldePelotas,COVID-19 and social distancing among children and adolescents in Brazil.,2021-06-18,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,,general population,,2020-05-14,2020-06-23,Household and community samples,All,Adults (18-64 years),20.0,,Age,,77075,0.024,0.022000000000000002,0.025,,,,,,Stratified probability,Wondfo SARS-CoV-2 Antibody Test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,,,Validated by independent authors/third party/non-developers,0.848,0.99,['Moderate'],Yes,Yes,Yes,No,Yes,No,Yes,No,Yes,Fernando C Barros,Universidade Federal de Pelotas,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225319/,2021-07-21,2024-03-01,Verified,barros_covid-19_2021-1,BRA
210624_Brazil_UniversidadeFederalDePelotas_overall,210624_Brazil_UniversidadeFederalDePelotas,High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2.,2021-06-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Brazil,,,Individuals living in the 133 sentinel cities of Brazil,"Previous diagnosis of COVID-19, those with missing information on symptoms, or those with symptoms. ",2020-06-21,2020-06-24,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,31869,0.027000000000000003,,,True,,,,True,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.9995,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Yes,Ana M. B. Menezes,Universidade Federal de Pelotas,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-92775-y,2021-07-06,2024-03-01,Verified,menezes_high_2021,BRA
210624_Brazil_UniversidadeFederalDePelotas_age20-29,210624_Brazil_UniversidadeFederalDePelotas,High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2.,2021-06-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Brazil,,,Individuals living in the 133 sentinel cities of Brazil,"Previous diagnosis of COVID-19, those with missing information on symptoms, or those with symptoms. ",2020-06-21,2020-06-24,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,4965,0.024,,,,,,,,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.9995,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Yes,Ana M. B. Menezes,Universidade Federal de Pelotas,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-92775-y,2021-07-06,2024-03-01,Verified,menezes_high_2021,BRA
210624_Brazil_UniversidadeFederalDePelotas_male,210624_Brazil_UniversidadeFederalDePelotas,High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2.,2021-06-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Brazil,,,Individuals living in the 133 sentinel cities of Brazil,"Previous diagnosis of COVID-19, those with missing information on symptoms, or those with symptoms. ",2020-06-21,2020-06-24,Household and community samples,Male,Multiple groups,0.0,,Sex/Gender,,13223,0.027000000000000003,,,,,,,,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.9995,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Yes,Ana M. B. Menezes,Universidade Federal de Pelotas,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-92775-y,2021-07-06,2024-03-01,Verified,menezes_high_2021,BRA
210624_Brazil_UniversidadeFederalDePelotas_age10-19,210624_Brazil_UniversidadeFederalDePelotas,High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2.,2021-06-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Brazil,,,Individuals living in the 133 sentinel cities of Brazil,"Previous diagnosis of COVID-19, those with missing information on symptoms, or those with symptoms. ",2020-06-21,2020-06-24,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,2789,0.019,,,,,,,,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.9995,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Yes,Ana M. B. Menezes,Universidade Federal de Pelotas,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-92775-y,2021-07-06,2024-03-01,Verified,menezes_high_2021,BRA
210624_Brazil_UniversidadeFederalDePelotas_age50-59,210624_Brazil_UniversidadeFederalDePelotas,High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2.,2021-06-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Brazil,,,Individuals living in the 133 sentinel cities of Brazil,"Previous diagnosis of COVID-19, those with missing information on symptoms, or those with symptoms. ",2020-06-21,2020-06-24,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,5032,0.03,,,,,,,,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.9995,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Yes,Ana M. B. Menezes,Universidade Federal de Pelotas,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-92775-y,2021-07-06,2024-03-01,Verified,menezes_high_2021,BRA
210624_Brazil_UniversidadeFederalDePelotas_age70+,210624_Brazil_UniversidadeFederalDePelotas,High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2.,2021-06-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Brazil,,,Individuals living in the 133 sentinel cities of Brazil,"Previous diagnosis of COVID-19, those with missing information on symptoms, or those with symptoms. ",2020-06-21,2020-06-24,Household and community samples,All,Seniors (65+ years),70.0,,Age,70+,3273,0.021,,,,,,,,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.9995,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Yes,Ana M. B. Menezes,Universidade Federal de Pelotas,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-92775-y,2021-07-06,2024-03-01,Verified,menezes_high_2021,BRA
210624_Brazil_UniversidadeFederalDePelotas_age0-4,210624_Brazil_UniversidadeFederalDePelotas,High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2.,2021-06-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Brazil,,,Individuals living in the 133 sentinel cities of Brazil,"Previous diagnosis of COVID-19, those with missing information on symptoms, or those with symptoms. ",2020-06-21,2020-06-24,Household and community samples,All,Children and Youth (0-17 years),0.0,4.0,Age,0-4,637,0.046,,,,,,,,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.9995,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Yes,Ana M. B. Menezes,Universidade Federal de Pelotas,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-92775-y,2021-07-06,2024-03-01,Verified,menezes_high_2021,BRA
210624_Brazil_UniversidadeFederalDePelotas_age30-39,210624_Brazil_UniversidadeFederalDePelotas,High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2.,2021-06-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Brazil,,,Individuals living in the 133 sentinel cities of Brazil,"Previous diagnosis of COVID-19, those with missing information on symptoms, or those with symptoms. ",2020-06-21,2020-06-24,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,4999,0.03,,,,,,,,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.9995,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Yes,Ana M. B. Menezes,Universidade Federal de Pelotas,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-92775-y,2021-07-06,2024-03-01,Verified,menezes_high_2021,BRA
210624_Brazil_UniversidadeFederalDePelotas_age40-49,210624_Brazil_UniversidadeFederalDePelotas,High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2.,2021-06-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Brazil,,,Individuals living in the 133 sentinel cities of Brazil,"Previous diagnosis of COVID-19, those with missing information on symptoms, or those with symptoms. ",2020-06-21,2020-06-24,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,5078,0.027999999999999997,,,,,,,,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.9995,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Yes,Ana M. B. Menezes,Universidade Federal de Pelotas,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-92775-y,2021-07-06,2024-03-01,Verified,menezes_high_2021,BRA
210624_Brazil_UniversidadeFederalDePelotas_age5-9,210624_Brazil_UniversidadeFederalDePelotas,High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2.,2021-06-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Brazil,,,Individuals living in the 133 sentinel cities of Brazil,"Previous diagnosis of COVID-19, those with missing information on symptoms, or those with symptoms. ",2020-06-21,2020-06-24,Household and community samples,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,862,0.027000000000000003,,,,,,,,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.9995,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Yes,Ana M. B. Menezes,Universidade Federal de Pelotas,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-92775-y,2021-07-06,2024-03-01,Verified,menezes_high_2021,BRA
210624_Brazil_UniversidadeFederalDePelotas_female,210624_Brazil_UniversidadeFederalDePelotas,High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2.,2021-06-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Brazil,,,Individuals living in the 133 sentinel cities of Brazil,"Previous diagnosis of COVID-19, those with missing information on symptoms, or those with symptoms. ",2020-06-21,2020-06-24,Household and community samples,Female,Multiple groups,0.0,,Sex/Gender,,18646,0.026000000000000002,,,,,,,,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.9995,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Yes,Ana M. B. Menezes,Universidade Federal de Pelotas,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-92775-y,2021-07-06,2024-03-01,Verified,menezes_high_2021,BRA
210624_Brazil_UniversidadeFederalDePelotas_age60-69,210624_Brazil_UniversidadeFederalDePelotas,High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2.,2021-06-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Brazil,,,Individuals living in the 133 sentinel cities of Brazil,"Previous diagnosis of COVID-19, those with missing information on symptoms, or those with symptoms. ",2020-06-21,2020-06-24,Household and community samples,All,Multiple groups,60.0,69.0,Age,60-69,4234,0.026000000000000002,,,,,,,,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.9995,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Yes,Ana M. B. Menezes,Universidade Federal de Pelotas,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-92775-y,2021-07-06,2024-03-01,Verified,menezes_high_2021,BRA
210629_RioGrandedoSul_UniversidadeFederaldePelotas_Primary,210629_RioGrandedoSul_UniversidadeFederaldePelotas,Slow Spread of SARS-CoV-2 in Southern Brazil Over a 6-Month Period: Report on 8 Sequential Statewide Serological Surveys Including 35611 Participants.,2021-06-29,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Rio Grande do Sul,,General population in 8 municipalities,,2020-04-11,2020-09-06,Household and community samples,All,Multiple groups,,,Primary Estimate,,35611,0.0058,,,True,,,,True,Stratified probability,Wondfo SARS-CoV-2 Antibody Test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,,,Validated by independent authors/third party/non-developers,0.848,0.9995,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Yes,Pedro C. Hallal ,Universidade Federal de Pelotas ,Unity-Aligned,https://dx.doi.org/10.2105/AJPH.2021.306351,2021-09-09,2024-03-01,Verified,hallal_slow_2021,BRA
210629_RioGrandedoSul_UniversidadeFederaldePelotas_round6,210629_RioGrandedoSul_UniversidadeFederaldePelotas,Slow Spread of SARS-CoV-2 in Southern Brazil Over a 6-Month Period: Report on 8 Sequential Statewide Serological Surveys Including 35611 Participants.,2021-06-29,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Rio Grande do Sul,,General population in 8 municipalities,,2020-07-24,2020-07-26,Household and community samples,All,Multiple groups,,,Time frame,,4500,0.010700000000000001,0.0075,0.0148,,True,,True,,Stratified probability,Wondfo SARS-CoV-2 Antibody Test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,,,Validated by independent authors/third party/non-developers,0.848,0.9995,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Yes,Pedro C. Hallal ,Universidade Federal de Pelotas ,Unity-Aligned,https://dx.doi.org/10.2105/AJPH.2021.306351,2021-07-06,2023-08-15,Verified,hallal_slow_2021,BRA
210629_RioGrandedoSul_UniversidadeFederaldePelotas_round5,210629_RioGrandedoSul_UniversidadeFederaldePelotas,Slow Spread of SARS-CoV-2 in Southern Brazil Over a 6-Month Period: Report on 8 Sequential Statewide Serological Surveys Including 35611 Participants.,2021-06-29,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Rio Grande do Sul,,General population in 8 municipalities,,2020-06-26,2020-06-28,Household and community samples,All,Multiple groups,,,Time frame,,4500,0.0049,0.0027,0.0083,,True,,True,,Stratified probability,Wondfo SARS-CoV-2 Antibody Test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,,,Validated by independent authors/third party/non-developers,0.848,0.9995,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Yes,Pedro C. Hallal ,Universidade Federal de Pelotas ,Unity-Aligned,https://dx.doi.org/10.2105/AJPH.2021.306351,2021-07-06,2023-08-15,Verified,hallal_slow_2021,BRA
210629_RioGrandedoSul_UniversidadeFederaldePelotas_round1,210629_RioGrandedoSul_UniversidadeFederaldePelotas,Slow Spread of SARS-CoV-2 in Southern Brazil Over a 6-Month Period: Report on 8 Sequential Statewide Serological Surveys Including 35611 Participants.,2021-06-29,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Rio Grande do Sul,,General population in 8 municipalities,,2020-04-11,2020-04-13,Household and community samples,All,Multiple groups,,,Time frame,,4151,0.0003,0.0,0.0034000000000000002,,True,,True,,Stratified probability,Wondfo SARS-CoV-2 Antibody Test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,,,Validated by independent authors/third party/non-developers,0.848,0.9995,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Yes,Pedro C. Hallal ,Universidade Federal de Pelotas ,Unity-Aligned,https://dx.doi.org/10.2105/AJPH.2021.306351,2021-07-06,2023-08-15,Verified,hallal_slow_2021,BRA
210629_RioGrandedoSul_UniversidadeFederaldePelotas_round2,210629_RioGrandedoSul_UniversidadeFederaldePelotas,Slow Spread of SARS-CoV-2 in Southern Brazil Over a 6-Month Period: Report on 8 Sequential Statewide Serological Surveys Including 35611 Participants.,2021-06-29,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Rio Grande do Sul,,General population in 8 municipalities,,2020-04-25,2020-04-27,Household and community samples,All,Multiple groups,,,Time frame,,4660,0.001,0.0001,0.0038,,True,,True,,Stratified probability,Wondfo SARS-CoV-2 Antibody Test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,,,Validated by independent authors/third party/non-developers,0.848,0.9995,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Yes,Pedro C. Hallal ,Universidade Federal de Pelotas ,Unity-Aligned,https://dx.doi.org/10.2105/AJPH.2021.306351,2021-07-06,2023-08-15,Verified,hallal_slow_2021,BRA
210629_RioGrandedoSul_UniversidadeFederaldePelotas_Age20-39,210629_RioGrandedoSul_UniversidadeFederaldePelotas,Slow Spread of SARS-CoV-2 in Southern Brazil Over a 6-Month Period: Report on 8 Sequential Statewide Serological Surveys Including 35611 Participants.,2021-06-29,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Rio Grande do Sul,,General population in 8 municipalities,,2020-04-11,2020-09-06,Household and community samples,All,Adults (18-64 years),20.0,39.0,Age,20-39,9850,0.0061,0.0046,0.0079,,,,,,Stratified probability,Wondfo SARS-CoV-2 Antibody Test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,,,Validated by independent authors/third party/non-developers,0.848,0.9995,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Yes,Pedro C. Hallal ,Universidade Federal de Pelotas ,Unity-Aligned,https://dx.doi.org/10.2105/AJPH.2021.306351,2021-09-09,2024-03-01,Verified,hallal_slow_2021,BRA
210629_RioGrandedoSul_UniversidadeFederaldePelotas_Male,210629_RioGrandedoSul_UniversidadeFederaldePelotas,Slow Spread of SARS-CoV-2 in Southern Brazil Over a 6-Month Period: Report on 8 Sequential Statewide Serological Surveys Including 35611 Participants.,2021-06-29,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Rio Grande do Sul,,General population in 8 municipalities,,2020-04-11,2020-09-06,Household and community samples,Male,Multiple groups,,,Sex/Gender,,21278,0.0054,0.0043,0.0067,,,,,,Stratified probability,Wondfo SARS-CoV-2 Antibody Test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,,,Validated by independent authors/third party/non-developers,0.848,0.9995,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Yes,Pedro C. Hallal ,Universidade Federal de Pelotas ,Unity-Aligned,https://dx.doi.org/10.2105/AJPH.2021.306351,2021-09-09,2024-03-01,Verified,hallal_slow_2021,BRA
210629_RioGrandedoSul_UniversidadeFederaldePelotas_round4,210629_RioGrandedoSul_UniversidadeFederaldePelotas,Slow Spread of SARS-CoV-2 in Southern Brazil Over a 6-Month Period: Report on 8 Sequential Statewide Serological Surveys Including 35611 Participants.,2021-06-29,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Rio Grande do Sul,,General population in 8 municipalities,,2020-05-23,2020-05-25,Household and community samples,All,Multiple groups,,,Time frame,,4500,0.0015,0.0003,0.0044,,True,,True,,Stratified probability,Wondfo SARS-CoV-2 Antibody Test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,,,Validated by independent authors/third party/non-developers,0.848,0.9995,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Yes,Pedro C. Hallal ,Universidade Federal de Pelotas ,Unity-Aligned,https://dx.doi.org/10.2105/AJPH.2021.306351,2021-07-06,2023-08-15,Verified,hallal_slow_2021,BRA
210629_RioGrandedoSul_UniversidadeFederaldePelotas_round7,210629_RioGrandedoSul_UniversidadeFederaldePelotas,Slow Spread of SARS-CoV-2 in Southern Brazil Over a 6-Month Period: Report on 8 Sequential Statewide Serological Surveys Including 35611 Participants.,2021-06-29,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Rio Grande do Sul,,General population in 8 municipalities,,2020-08-14,2020-08-16,Household and community samples,All,Multiple groups,,,Time frame,,4500,0.0139,0.0101,0.018500000000000003,,True,,True,,Stratified probability,Wondfo SARS-CoV-2 Antibody Test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,,,Validated by independent authors/third party/non-developers,0.848,0.9995,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Yes,Pedro C. Hallal ,Universidade Federal de Pelotas ,Unity-Aligned,https://dx.doi.org/10.2105/AJPH.2021.306351,2021-07-06,2023-08-15,Verified,hallal_slow_2021,BRA
210629_RioGrandedoSul_UniversidadeFederaldePelotas_round3,210629_RioGrandedoSul_UniversidadeFederaldePelotas,Slow Spread of SARS-CoV-2 in Southern Brazil Over a 6-Month Period: Report on 8 Sequential Statewide Serological Surveys Including 35611 Participants.,2021-06-29,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Rio Grande do Sul,,General population in 8 municipalities,,2020-05-09,2020-05-11,Household and community samples,All,Multiple groups,,,Time frame,,4500,0.0021,0.0006,0.0049,,True,,True,,Stratified probability,Wondfo SARS-CoV-2 Antibody Test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,,,Validated by independent authors/third party/non-developers,0.848,0.9995,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Yes,Pedro C. Hallal ,Universidade Federal de Pelotas ,Unity-Aligned,https://dx.doi.org/10.2105/AJPH.2021.306351,2021-07-06,2023-08-15,Verified,hallal_slow_2021,BRA
210629_RioGrandedoSul_UniversidadeFederaldePelotas_Female,210629_RioGrandedoSul_UniversidadeFederaldePelotas,Slow Spread of SARS-CoV-2 in Southern Brazil Over a 6-Month Period: Report on 8 Sequential Statewide Serological Surveys Including 35611 Participants.,2021-06-29,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Rio Grande do Sul,,General population in 8 municipalities,,2020-04-11,2020-09-06,Household and community samples,Female,Multiple groups,,,Sex/Gender,,14333,0.0061,0.0051,0.0073,,,,,,Stratified probability,Wondfo SARS-CoV-2 Antibody Test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,,,Validated by independent authors/third party/non-developers,0.848,0.9995,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Yes,Pedro C. Hallal ,Universidade Federal de Pelotas ,Unity-Aligned,https://dx.doi.org/10.2105/AJPH.2021.306351,2021-09-09,2024-03-01,Verified,hallal_slow_2021,BRA
210629_RioGrandedoSul_UniversidadeFederaldePelotas_Age40-59,210629_RioGrandedoSul_UniversidadeFederaldePelotas,Slow Spread of SARS-CoV-2 in Southern Brazil Over a 6-Month Period: Report on 8 Sequential Statewide Serological Surveys Including 35611 Participants.,2021-06-29,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Rio Grande do Sul,,General population in 8 municipalities,,2020-04-11,2020-09-06,Household and community samples,All,Adults (18-64 years),40.0,59.0,Age,40-59,11158,0.006999999999999999,0.005600000000000001,0.0087,,,,,,Stratified probability,Wondfo SARS-CoV-2 Antibody Test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,,,Validated by independent authors/third party/non-developers,0.848,0.9995,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Yes,Pedro C. Hallal ,Universidade Federal de Pelotas ,Unity-Aligned,https://dx.doi.org/10.2105/AJPH.2021.306351,2021-09-09,2024-03-01,Verified,hallal_slow_2021,BRA
210629_RioGrandedoSul_UniversidadeFederaldePelotas_Age60+,210629_RioGrandedoSul_UniversidadeFederaldePelotas,Slow Spread of SARS-CoV-2 in Southern Brazil Over a 6-Month Period: Report on 8 Sequential Statewide Serological Surveys Including 35611 Participants.,2021-06-29,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Rio Grande do Sul,,General population in 8 municipalities,,2020-04-11,2020-09-06,Household and community samples,All,Seniors (65+ years),60.0,,Age,,10582,0.0040999999999999995,0.003,0.0055000000000000005,,,,,,Stratified probability,Wondfo SARS-CoV-2 Antibody Test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,,,Validated by independent authors/third party/non-developers,0.848,0.9995,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Yes,Pedro C. Hallal ,Universidade Federal de Pelotas ,Unity-Aligned,https://dx.doi.org/10.2105/AJPH.2021.306351,2021-09-09,2024-03-01,Verified,hallal_slow_2021,BRA
210629_RioGrandedoSul_UniversidadeFederaldePelotas_round8,210629_RioGrandedoSul_UniversidadeFederaldePelotas,Slow Spread of SARS-CoV-2 in Southern Brazil Over a 6-Month Period: Report on 8 Sequential Statewide Serological Surveys Including 35611 Participants.,2021-06-29,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Rio Grande do Sul,,General population in 8 municipalities,,2020-09-04,2020-09-06,Household and community samples,All,Multiple groups,,,Time frame,,4500,0.015700000000000002,0.0117,0.0206,,True,,True,,Stratified probability,Wondfo SARS-CoV-2 Antibody Test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,,,Validated by independent authors/third party/non-developers,0.848,0.9995,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Yes,Pedro C. Hallal ,Universidade Federal de Pelotas ,Unity-Aligned,https://dx.doi.org/10.2105/AJPH.2021.306351,2021-07-06,2023-08-15,Verified,hallal_slow_2021,BRA
210629_RioGrandedoSul_UniversidadeFederaldePelotas_Age0-19,210629_RioGrandedoSul_UniversidadeFederaldePelotas,Slow Spread of SARS-CoV-2 in Southern Brazil Over a 6-Month Period: Report on 8 Sequential Statewide Serological Surveys Including 35611 Participants.,2021-06-29,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Rio Grande do Sul,,General population in 8 municipalities,,2020-04-11,2020-09-06,Household and community samples,All,Children and Youth (0-17 years),0.0,19.0,Age,0-19,2862,0.0063,0.0038,0.0099,,,,,,Stratified probability,Wondfo SARS-CoV-2 Antibody Test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,,,Validated by independent authors/third party/non-developers,0.848,0.9995,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Yes,Pedro C. Hallal ,Universidade Federal de Pelotas ,Unity-Aligned,https://dx.doi.org/10.2105/AJPH.2021.306351,2021-09-09,2024-03-01,Verified,hallal_slow_2021,BRA
210630_RioDeJaneiro_HospitalFederaldosServidoresdoEstado,210630_RioDeJaneiro_HospitalFederaldosServidoresdoEstado,Maternal and Neonatal Outcomes of SARS-CoV-2 Infection in a Cohort of Pregnant Women with Comorbid Disorders.,2021-06-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Rio de Janeiro,"The inclusion criteria were:  admission to the maternity unit during gestation,≥18 years of age, willingness to have nasopharyngeal swabs and blood samples collected for diagnosis of SARS-CoV-2 infection, and provided signed informed consent"," The exclusion criteria were women not willing to participate and subsequent admissions in the same pregnancy during the study period. Sampling was not longitudinal as most patients received prenatal care at other health institutions, delivered at our hospital,and post-natal follow-up occurred elsewhere.",2020-04-13,2020-06-17,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,115,0.23500000000000001,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,,,['High'],No,No,No,No,Yes,Unclear,Yes,No,Yes,Maria de Lourdes Benamor Teixeira,Hospital Federaldo dos Servidores do Estado,Not Unity-Aligned,https://dx.doi.org/10.3390/v13071277,2021-07-12,2022-07-16,Verified,teixeira_maternal_2021,BRA
210701_RioDeJaneiro_OswaldoCruzFoundation_Primarysam,210701_RioDeJaneiro_OswaldoCruzFoundation,SARS-CoV-2 infection dynamics in children and household contacts in a slum in Rio de Janeiro,2021-07-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Rio de Janeiro,"Rio de Janeiro
","children aged <14 years who visited a primary health care facility for any reason (eg, immunization, routine consultation, emergency care, accompanying relatives to the clinic, etc) and additional children who shared the same residential address along with adult household contacts",Consent not provided,2020-05-18,2020-09-24,Multiple general populations,All,Multiple groups,,,Primary Estimate,,515,0.29300000000000004,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,Yes,Pamella Lugon,Oswaldo Cruz Foundation,Unity-Aligned,https://europepmc.org/article/MED/33863845,2021-07-14,2024-03-01,Verified,lugon_sars-cov-2_2021,BRA
210701_RioDeJaneiro_OswaldoCruzFoundation_Age0-14,210701_RioDeJaneiro_OswaldoCruzFoundation,SARS-CoV-2 infection dynamics in children and household contacts in a slum in Rio de Janeiro,2021-07-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Rio de Janeiro,"Rio de Janeiro
","children aged <14 years who visited a primary health care facility for any reason (eg, immunization, routine consultation, emergency care, accompanying relatives to the clinic, etc) and additional children who shared the same residential address along with adult household contacts",Consent not provided,2020-05-18,2020-09-24,Multiple general populations,All,Children and Youth (0-17 years),0.0,14.0,Age,,243,0.325,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,Yes,Pamella Lugon,Oswaldo Cruz Foundation,Unity-Aligned,https://europepmc.org/article/MED/33863845,2021-07-14,2024-03-01,Verified,lugon_sars-cov-2_2021,BRA
210701_RioDeJaneiro_OswaldoCruzFoundation_Age15+,210701_RioDeJaneiro_OswaldoCruzFoundation,SARS-CoV-2 infection dynamics in children and household contacts in a slum in Rio de Janeiro,2021-07-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Rio de Janeiro,"Rio de Janeiro
","children aged <14 years who visited a primary health care facility for any reason (eg, immunization, routine consultation, emergency care, accompanying relatives to the clinic, etc) and additional children who shared the same residential address along with adult household contacts",Consent not provided,2020-05-18,2020-09-24,Household and community samples,All,Adults (18-64 years),15.0,,Age,15+,272,0.319,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,Yes,Pamella Lugon,Oswaldo Cruz Foundation,Unity-Aligned,https://europepmc.org/article/MED/33863845,2021-07-14,2024-03-01,Verified,lugon_sars-cov-2_2021,BRA
210702_RibeiraoPreto_UniversidadedeSãoPaulo_Followup,210702_RibeiraoPreto_UniversidadedeSãoPaulo_June11-14,"Prevalence of virological and serological markers of SARS-CoV-2 infection in the population of Ribeirao Preto, Southeast Brazil: an epidemiological survey.",2021-07-02,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Brazil,São Paulo,Ribeirão Preto (RP),"The survey included participants of both sexes and any age living in RP, except neonates, who agreed to participate and signed written informed consent forms.",People living in rural areas were excluded.,2020-06-11,2020-06-14,Household and community samples,All,Multiple groups,,,Primary Estimate,,646,0.0279,,,True,,,,True,Stratified probability,Wondfo SARS-CoV-2 Antibody Test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Serum,,,Validated by manufacturers,0.8640000000000001,0.996,['Moderate'],Yes,Yes,Yes,No,Yes,No,Yes,No,Unclear,Edson Zangiacomi Martinez,Universidade de São Paulo,Unity-Aligned,https://dx.doi.org/10.1590/0037-8682-0210-2021,2021-07-14,2024-03-01,Verified,martinez_prevalence_2021-1,BRA
210702_RibeiraoPreto_UniversidadedeSãoPaulo_Baseline,210702_RibeiraoPreto_UniversidadedeSãoPaulo_May1-3,"Prevalence of virological and serological markers of SARS-CoV-2 infection in the population of Ribeirao Preto, Southeast Brazil: an epidemiological survey.",2021-07-02,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Brazil,São Paulo,Ribeirão Preto (RP),"The survey included participants of both sexes and any age living in RP, except neonates, who agreed to participate and signed written informed consent forms.",People living in rural areas were excluded.,2020-05-01,2020-05-03,Household and community samples,All,Multiple groups,0.0,99.0,Primary Estimate,,709,0.012700000000000001,,,True,,,,True,Stratified probability,Wondfo SARS-CoV-2 Antibody Test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Serum,,,Validated by manufacturers,0.8640000000000001,0.996,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Unclear,Edson Zangiacomi Martinez,Universidade de São Paulo,Unity-Aligned,https://dx.doi.org/10.1590/0037-8682-0210-2021,2021-07-14,2024-03-01,Verified,martinez_prevalence_2021-1,BRA
210702_RibeiraoPreto_UniversidadedeSãoPaulo_Age50-59,210702_RibeiraoPreto_UniversidadedeSãoPaulo_May1-3,"Prevalence of virological and serological markers of SARS-CoV-2 infection in the population of Ribeirao Preto, Southeast Brazil: an epidemiological survey.",2021-07-02,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Brazil,São Paulo,Ribeirão Preto (RP),"The survey included participants of both sexes and any age living in RP, except neonates, who agreed to participate and signed written informed consent forms.",People living in rural areas were excluded.,2020-05-01,2020-05-03,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,,116,0.017,,,,,,,,Stratified probability,Wondfo SARS-CoV-2 Antibody Test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Serum,,,Validated by manufacturers,0.8640000000000001,0.996,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Unclear,Edson Zangiacomi Martinez,Universidade de São Paulo,Unity-Aligned,https://dx.doi.org/10.1590/0037-8682-0210-2021,2021-08-05,2024-03-01,Verified,martinez_prevalence_2021-1,BRA
210702_RibeiraoPreto_UniversidadedeSãoPaulo_Age40-49,210702_RibeiraoPreto_UniversidadedeSãoPaulo_May1-3,"Prevalence of virological and serological markers of SARS-CoV-2 infection in the population of Ribeirao Preto, Southeast Brazil: an epidemiological survey.",2021-07-02,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Brazil,São Paulo,Ribeirão Preto (RP),"The survey included participants of both sexes and any age living in RP, except neonates, who agreed to participate and signed written informed consent forms.",People living in rural areas were excluded.,2020-05-01,2020-05-03,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,,114,0.027000000000000003,,,,,,,,Stratified probability,Wondfo SARS-CoV-2 Antibody Test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Serum,,,Validated by manufacturers,0.8640000000000001,0.996,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Unclear,Edson Zangiacomi Martinez,Universidade de São Paulo,Unity-Aligned,https://dx.doi.org/10.1590/0037-8682-0210-2021,2021-08-05,2024-03-01,Verified,martinez_prevalence_2021-1,BRA
210702_RibeiraoPreto_UniversidadedeSãoPaulo_Age60-69,210702_RibeiraoPreto_UniversidadedeSãoPaulo_May1-3,"Prevalence of virological and serological markers of SARS-CoV-2 infection in the population of Ribeirao Preto, Southeast Brazil: an epidemiological survey.",2021-07-02,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Brazil,São Paulo,Ribeirão Preto (RP),"The survey included participants of both sexes and any age living in RP, except neonates, who agreed to participate and signed written informed consent forms.",People living in rural areas were excluded.,2020-05-01,2020-05-03,Household and community samples,All,Seniors (65+ years),60.0,69.0,Age,,124,0.016,,,,,,,,Stratified probability,Wondfo SARS-CoV-2 Antibody Test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Serum,,,Validated by manufacturers,0.8640000000000001,0.996,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Unclear,Edson Zangiacomi Martinez,Universidade de São Paulo,Unity-Aligned,https://dx.doi.org/10.1590/0037-8682-0210-2021,2021-08-05,2024-03-01,Verified,martinez_prevalence_2021-1,BRA
210702_RibeiraoPreto_UniversidadedeSãoPaulo_Age0-39,210702_RibeiraoPreto_UniversidadedeSãoPaulo_May1-3,"Prevalence of virological and serological markers of SARS-CoV-2 infection in the population of Ribeirao Preto, Southeast Brazil: an epidemiological survey.",2021-07-02,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Brazil,São Paulo,Ribeirão Preto (RP),"The survey included participants of both sexes and any age living in RP, except neonates, who agreed to participate and signed written informed consent forms.",People living in rural areas were excluded.,2020-05-01,2020-05-03,Household and community samples,All,Multiple groups,0.0,39.0,Age,0-39,241,0.004,,,,,,,,Stratified probability,Wondfo SARS-CoV-2 Antibody Test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Serum,,,Validated by manufacturers,0.8640000000000001,0.996,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Unclear,Edson Zangiacomi Martinez,Universidade de São Paulo,Unity-Aligned,https://dx.doi.org/10.1590/0037-8682-0210-2021,2021-08-05,2024-03-01,Verified,martinez_prevalence_2021-1,BRA
210702_RibeiraoPreto_UniversidadedeSãoPaulo_Male,210702_RibeiraoPreto_UniversidadedeSãoPaulo_May1-3,"Prevalence of virological and serological markers of SARS-CoV-2 infection in the population of Ribeirao Preto, Southeast Brazil: an epidemiological survey.",2021-07-02,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Brazil,São Paulo,Ribeirão Preto (RP),"The survey included participants of both sexes and any age living in RP, except neonates, who agreed to participate and signed written informed consent forms.",People living in rural areas were excluded.,2020-05-01,2020-05-03,Household and community samples,Male,Multiple groups,0.0,99.0,Sex/Gender,,310,0.01,,,,,,,,Stratified probability,Wondfo SARS-CoV-2 Antibody Test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Serum,,,Validated by manufacturers,0.8640000000000001,0.996,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Unclear,Edson Zangiacomi Martinez,Universidade de São Paulo,Unity-Aligned,https://dx.doi.org/10.1590/0037-8682-0210-2021,2021-08-05,2024-03-01,Verified,martinez_prevalence_2021-1,BRA
210702_RibeiraoPreto_UniversidadedeSãoPaulo_Age70-79,210702_RibeiraoPreto_UniversidadedeSãoPaulo_May1-3,"Prevalence of virological and serological markers of SARS-CoV-2 infection in the population of Ribeirao Preto, Southeast Brazil: an epidemiological survey.",2021-07-02,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Brazil,São Paulo,Ribeirão Preto (RP),"The survey included participants of both sexes and any age living in RP, except neonates, who agreed to participate and signed written informed consent forms.",People living in rural areas were excluded.,2020-05-01,2020-05-03,Household and community samples,All,Seniors (65+ years),70.0,79.0,Age,70-79,79,0.013000000000000001,,,,,,,,Stratified probability,Wondfo SARS-CoV-2 Antibody Test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Serum,,,Validated by manufacturers,0.8640000000000001,0.996,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Unclear,Edson Zangiacomi Martinez,Universidade de São Paulo,Unity-Aligned,https://dx.doi.org/10.1590/0037-8682-0210-2021,2021-08-05,2024-03-01,Verified,martinez_prevalence_2021-1,BRA
210702_RibeiraoPreto_UniversidadedeSãoPaulo_Age80-99,210702_RibeiraoPreto_UniversidadedeSãoPaulo_May1-3,"Prevalence of virological and serological markers of SARS-CoV-2 infection in the population of Ribeirao Preto, Southeast Brazil: an epidemiological survey.",2021-07-02,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Brazil,São Paulo,Ribeirão Preto (RP),"The survey included participants of both sexes and any age living in RP, except neonates, who agreed to participate and signed written informed consent forms.",People living in rural areas were excluded.,2020-05-01,2020-05-03,Household and community samples,All,Seniors (65+ years),80.0,99.0,Age,80-99,35,0.0,,,,,,,,Stratified probability,Wondfo SARS-CoV-2 Antibody Test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Serum,,,Validated by manufacturers,0.8640000000000001,0.996,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Unclear,Edson Zangiacomi Martinez,Universidade de São Paulo,Unity-Aligned,https://dx.doi.org/10.1590/0037-8682-0210-2021,2021-08-05,2024-03-01,Verified,martinez_prevalence_2021-1,BRA
210702_RibeiraoPreto_UniversidadedeSãoPaulo_Female,210702_RibeiraoPreto_UniversidadedeSãoPaulo_May1-3,"Prevalence of virological and serological markers of SARS-CoV-2 infection in the population of Ribeirao Preto, Southeast Brazil: an epidemiological survey.",2021-07-02,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Brazil,São Paulo,Ribeirão Preto (RP),"The survey included participants of both sexes and any age living in RP, except neonates, who agreed to participate and signed written informed consent forms.",People living in rural areas were excluded.,2020-05-01,2020-05-03,Household and community samples,Female,Multiple groups,0.0,99.0,Sex/Gender,,399,0.015,,,,,,,,Stratified probability,Wondfo SARS-CoV-2 Antibody Test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Serum,,,Validated by manufacturers,0.8640000000000001,0.996,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Unclear,Edson Zangiacomi Martinez,Universidade de São Paulo,Unity-Aligned,https://dx.doi.org/10.1590/0037-8682-0210-2021,2021-08-05,2024-03-01,Verified,martinez_prevalence_2021-1,BRA
210719_RioGrandeDoSul_UniversidadeFederalDeSantaMaria_Overall,210719_RioGrandeDoSul_UniversidadeFederalDeSantaMaria,COVID-19 in otolaryngologists: a cross-sectional multicenter study,2021-07-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Rio Grande Do Sul,,"Otolaryngologists were included if they (1) were duly reg-istered with the Brazilian Federal Medical Council at thetime of the survey, (2) were actively practicing in the statethrough the Brazilian Unified Health System or privately(including patient appointments and/or surgical procedures)prior to the pandemic declaration on March 11, 2020, (3)returned a signed form consenting to participate in thestudy and to individually provided a sample for a rapidIgM-IgG combined antibody test for SARS-CoV-2 infectiondiagnosis, and (4) returned a completed questionnaire","Oto-laryngologists who (1) were inactive or practicing outsidethe state in the period immediately prior to the World HealthOrganization (WHO) pandemic declaration, (2) could not becontacted for invitation and/or explanations, (3) were nolonger living in the state, (4) did not return the question-naire or returned an incomplete questionnaire, or (5) failedto meet the deadline for serological testing for SARS-CoV-2antibodies were excluded",2020-08-01,2020-09-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,358,0.064,,,,,,,True,Convenience,COVID-19 IgG/IgM ECO Test,ECO Diagnostica LTDA,Other,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9451,0.9573999999999999,['High'],,No,No,Yes,,Yes,Yes,No,,Fabricio Scapini,Universidade Federal de Santa Maria,Not Unity-Aligned,https://dx.doi.org/10.1016/j.bjorl.2021.06.007,2021-08-16,2024-03-01,Unverified,scapini_covid-19_2021-1,BRA
210726_Chapecó_CommunityUniversityOfChapecóRegion_Primary,210726_Chapecó_CommunityUniversityOfChapecóRegion,Seroprevalence of SARS-CoV-2 infection in a municipality in southern Brazil,2021-07-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Santa Catarina,Chapecó,"The sample was calculated from the population estimate of the municipality of Chapecó for the year 2020. The EpInfo application was used, with 95% reliability, a margin of error of 2% and a greater heterogeneity scenario, taking into consideration the proportionality regarding gender and age groups","All  those  who  refused  to  participate  or  those  who  did  not  allow  the  recording  of  verbal  consent  from  the  IC  were excluded. In addition, after three consecutive  attempts to contact  each other on different shifts, those who did not answer the call were excluded and replaced by subsequent ones. Also excluded were those who did not have updated telephone contact or those who no longer lived in the municipality of Chapecó-SC.",2020-06-15,2020-08-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,2179,0.0064,,,True,,,,True,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,,0.86,0.99,['Moderate'],Yes,Yes,Yes,No,Unclear,No,Yes,No,Yes,Maria Silva,Community University of Chapecó Region,Not Unity-Aligned,https://rsdjournal.org/index.php/rsd/article/view/17996/16175,2021-08-03,2024-03-01,Verified,silvaSeroprevalenceSARSCoV2Infection2021,BRA
210726_Chapecó_CommunityUniversityOfChapecóRegion_Female,210726_Chapecó_CommunityUniversityOfChapecóRegion,Seroprevalence of SARS-CoV-2 infection in a municipality in southern Brazil,2021-07-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Santa Catarina,Chapecó,"The sample was calculated from the population estimate of the municipality of Chapecó for the year 2020. The EpInfo application was used, with 95% reliability, a margin of error of 2% and a greater heterogeneity scenario, taking into consideration the proportionality regarding gender and age groups","All  those  who  refused  to  participate  or  those  who  did  not  allow  the  recording  of  verbal  consent  from  the  IC  were excluded. In addition, after three consecutive  attempts to contact  each other on different shifts, those who did not answer the call were excluded and replaced by subsequent ones. Also excluded were those who did not have updated telephone contact or those who no longer lived in the municipality of Chapecó-SC.",2020-06-15,2020-08-15,Household and community samples,Female,Multiple groups,,,Sex/Gender,,1053,0.006600000000000001,,,,,,,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,,0.86,0.99,['Moderate'],Yes,Yes,Yes,No,Unclear,No,Yes,No,Yes,Maria Silva,Community University of Chapecó Region,Not Unity-Aligned,https://rsdjournal.org/index.php/rsd/article/view/17996/16175,2021-08-03,2024-03-01,Verified,silvaSeroprevalenceSARSCoV2Infection2021,BRA
210726_Chapecó_CommunityUniversityOfChapecóRegion_Male,210726_Chapecó_CommunityUniversityOfChapecóRegion,Seroprevalence of SARS-CoV-2 infection in a municipality in southern Brazil,2021-07-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Santa Catarina,Chapecó,"The sample was calculated from the population estimate of the municipality of Chapecó for the year 2020. The EpInfo application was used, with 95% reliability, a margin of error of 2% and a greater heterogeneity scenario, taking into consideration the proportionality regarding gender and age groups","All  those  who  refused  to  participate  or  those  who  did  not  allow  the  recording  of  verbal  consent  from  the  IC  were excluded. In addition, after three consecutive  attempts to contact  each other on different shifts, those who did not answer the call were excluded and replaced by subsequent ones. Also excluded were those who did not have updated telephone contact or those who no longer lived in the municipality of Chapecó-SC.",2020-06-15,2020-08-15,Household and community samples,Male,Multiple groups,,,Sex/Gender,,1126,0.0062,,,,,,,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,,0.86,0.99,['Moderate'],Yes,Yes,Yes,No,Unclear,No,Yes,No,Yes,Maria Silva,Community University of Chapecó Region,Not Unity-Aligned,https://rsdjournal.org/index.php/rsd/article/view/17996/16175,2021-08-03,2024-03-01,Verified,silvaSeroprevalenceSARSCoV2Infection2021,BRA
210729_SãoPaulo_HospitalIsraelitaAlbertEinstein_Adj,210729_SãoPaulo_HospitalIsraelitaAlbertEinstein,"A seroprevalence survey of anti-SARS-CoV-2 antibodies among individuals 18 years of age or older living in a vulnerable region of the city of São Paulo, Brazil",2021-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,"São Paulo State
",São Paulo,"The source population was composed by approximately 41 thousand individuals, 18 years of age or older, registered at one of three public primary health care (PHC) units serving the neighborhood of Paraisópolis, an area recognized as especially vulnerable in the Vila Andrade district at the city of São Paulo, Brazil.",,2020-09-15,2020-12-15,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,272,0.452,0.394,0.51,True,,True,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,,,,['Moderate'],Yes,Yes,No,Yes,No,Yes,Yes,Yes,Yes,Joao Luiz Miraglia ,Hospital Israelita Albert Einstein,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0255412,2021-08-17,2024-03-01,Verified,miragliaSeroprevalenceSurveyAntiSARSCoV22021,BRA
210729_SãoPaulo_HospitalIsraelitaAlbertEinstein_Female,210729_SãoPaulo_HospitalIsraelitaAlbertEinstein,"A seroprevalence survey of anti-SARS-CoV-2 antibodies among individuals 18 years of age or older living in a vulnerable region of the city of São Paulo, Brazil",2021-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,"São Paulo State
",São Paulo,"The source population was composed by approximately 41 thousand individuals, 18 years of age or older, registered at one of three public primary health care (PHC) units serving the neighborhood of Paraisópolis, an area recognized as especially vulnerable in the Vila Andrade district at the city of São Paulo, Brazil.",,2020-09-15,2020-12-15,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,181,0.446,0.38,0.51,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,,,,['Moderate'],Yes,Yes,No,Yes,No,Yes,Yes,Yes,Yes,Joao Luiz Miraglia ,Hospital Israelita Albert Einstein,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0255412,2021-09-08,2024-03-01,Verified,miragliaSeroprevalenceSurveyAntiSARSCoV22021,BRA
210729_SãoPaulo_HospitalIsraelitaAlbertEinstein_30-49yrs,210729_SãoPaulo_HospitalIsraelitaAlbertEinstein,"A seroprevalence survey of anti-SARS-CoV-2 antibodies among individuals 18 years of age or older living in a vulnerable region of the city of São Paulo, Brazil",2021-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,"São Paulo State
",São Paulo,"The source population was composed by approximately 41 thousand individuals, 18 years of age or older, registered at one of three public primary health care (PHC) units serving the neighborhood of Paraisópolis, an area recognized as especially vulnerable in the Vila Andrade district at the city of São Paulo, Brazil.",,2020-09-15,2020-12-15,Household and community samples,All,Adults (18-64 years),30.0,49.0,Age,30-49 years,125,0.484,0.397,0.5700000000000001,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,,,,['Moderate'],Yes,Yes,No,Yes,No,Yes,Yes,Yes,Yes,Joao Luiz Miraglia ,Hospital Israelita Albert Einstein,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0255412,2021-09-08,2024-03-01,Unverified,miragliaSeroprevalenceSurveyAntiSARSCoV22021,BRA
210729_SãoPaulo_HospitalIsraelitaAlbertEinstein_18-29yrs,210729_SãoPaulo_HospitalIsraelitaAlbertEinstein,"A seroprevalence survey of anti-SARS-CoV-2 antibodies among individuals 18 years of age or older living in a vulnerable region of the city of São Paulo, Brazil",2021-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,"São Paulo State
",São Paulo,"The source population was composed by approximately 41 thousand individuals, 18 years of age or older, registered at one of three public primary health care (PHC) units serving the neighborhood of Paraisópolis, an area recognized as especially vulnerable in the Vila Andrade district at the city of São Paulo, Brazil.",,2020-09-15,2020-12-15,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,18-29 years,71,0.423,0.311,0.52,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,,,,['Moderate'],Yes,Yes,No,Yes,No,Yes,Yes,Yes,Yes,Joao Luiz Miraglia ,Hospital Israelita Albert Einstein,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0255412,2021-09-08,2024-03-01,Verified,miragliaSeroprevalenceSurveyAntiSARSCoV22021,BRA
210729_SãoPaulo_HospitalIsraelitaAlbertEinstein_Male,210729_SãoPaulo_HospitalIsraelitaAlbertEinstein,"A seroprevalence survey of anti-SARS-CoV-2 antibodies among individuals 18 years of age or older living in a vulnerable region of the city of São Paulo, Brazil",2021-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,"São Paulo State
",São Paulo,"The source population was composed by approximately 41 thousand individuals, 18 years of age or older, registered at one of three public primary health care (PHC) units serving the neighborhood of Paraisópolis, an area recognized as especially vulnerable in the Vila Andrade district at the city of São Paulo, Brazil.",,2020-09-15,2020-12-15,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,91,0.44,0.34500000000000003,0.54,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,,,,['Moderate'],Yes,Yes,No,Yes,No,Yes,Yes,Yes,Yes,Joao Luiz Miraglia ,Hospital Israelita Albert Einstein,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0255412,2021-09-08,2024-03-01,Verified,miragliaSeroprevalenceSurveyAntiSARSCoV22021,BRA
210729_SãoPaulo_HospitalIsraelitaAlbertEinstein_>50yrs,210729_SãoPaulo_HospitalIsraelitaAlbertEinstein,"A seroprevalence survey of anti-SARS-CoV-2 antibodies among individuals 18 years of age or older living in a vulnerable region of the city of São Paulo, Brazil",2021-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,"São Paulo State
",São Paulo,"The source population was composed by approximately 41 thousand individuals, 18 years of age or older, registered at one of three public primary health care (PHC) units serving the neighborhood of Paraisópolis, an area recognized as especially vulnerable in the Vila Andrade district at the city of São Paulo, Brazil.",,2020-09-15,2020-12-15,Household and community samples,All,Multiple groups,50.0,,Age,>50 years,76,0.41500000000000004,0.317,0.52,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,,,,['Moderate'],Yes,Yes,No,Yes,No,Yes,Yes,Yes,Yes,Joao Luiz Miraglia ,Hospital Israelita Albert Einstein,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0255412,2021-09-08,2024-03-01,Verified,miragliaSeroprevalenceSurveyAntiSARSCoV22021,BRA
210729_SãoPaulo_HospitalIsraelitaAlbertEinstein_Unadj,210729_SãoPaulo_HospitalIsraelitaAlbertEinstein,"A seroprevalence survey of anti-SARS-CoV-2 antibodies among individuals 18 years of age or older living in a vulnerable region of the city of São Paulo, Brazil",2021-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,"São Paulo State
",São Paulo,"The source population was composed by approximately 41 thousand individuals, 18 years of age or older, registered at one of three public primary health care (PHC) units serving the neighborhood of Paraisópolis, an area recognized as especially vulnerable in the Vila Andrade district at the city of São Paulo, Brazil.",,2020-09-15,2020-12-15,Household and community samples,All,Multiple groups,18.0,,Analysis,Unadjusted estimate,272,0.438,0.37700000000000006,0.5,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,,,,['Moderate'],Yes,Yes,No,Yes,No,Yes,Yes,Yes,Yes,Joao Luiz Miraglia ,Hospital Israelita Albert Einstein,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0255412,2021-08-17,2024-03-01,Verified,miragliaSeroprevalenceSurveyAntiSARSCoV22021,BRA
210729_Mariana+OuroPreto_FederalUniversityOfOuro,210729_Mariana+OuroPreto_FederalUniversityOfOuro,COVID-Inconfidentes - SARS-CoV-2 seroprevalence in two Brazilian urban areas during the pandemic first wave: study protocol and initial results,2021-07-29,Preprint,Local,Cross-sectional survey ,Brazil,Minas Gerais,"Mariana, OuroPreto","Residents  in  permanent  households  in  the  urban  areas  of  the  cities  of  Ouro  Preto  and Mariana, aged 18 years or older, were considered eligible for this",,2020-10-15,2020-12-15,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,Overall,1762,0.055,,,True,,,,True,Convenience,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by manufacturers,0.8643000000000001,0.9956999999999999,['High'],,No,Yes,Yes,,No,Yes,No,,Adriana Lucia Meireles,Federal University of Ouro,Not Unity-Aligned,https://preprints.scielo.org/index.php/scielo/preprint/view/2720,2021-08-10,2024-03-01,Unverified,meirelesCOVIDInconfidentesSARSCoV2Seroprevalence2021,BRA
210629_SaoPaulo_UniversidadeFederaldeSãoPaulo_Overall,210629_SaoPaulo_UniversidadeFederaldeSãoPaulo,"Lower seroprevalence for SARS-CoV-2-specific antibodies among kidney transplant recipients compared to the general population in the city of Sao Paulo, Brazil.",2021-07-29,Preprint,Local,Cross-sectional survey ,Brazil,,Sao Paulo,"Eligible patients were all kidney transplant recipients of any age currently living in Sao Paulo, with at least one outpatient visit within the last year (n=2,636). Due to mobility restrictions, only those patients with a scheduled face-to-face appointment were screened.",Enrolled in COVID-19  vaccine  clinical  trials  or  have  undergone  vaccination  prior  to  antibody measurement.,2020-09-01,2020-09-25,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,,Primary Estimate,,416,0.08199999999999999,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Marina P Cristelli,Universidade Federal de São Paulo,Not Unity-Aligned,https://dx.doi.org/10.1111/tid.13706,2021-08-02,2024-03-01,Unverified,cristelli_lower_2021,BRA
210801_Aracuja_FederalUniversityofSergipe_Overall_IgG,210801_Aracuja_FederalUniversityofSergipe,Estimated SARS-CoV-2 infection and seroprevalence in firefighters from a Northeastern Brazilian state: A cross-sectional study,2021-08-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Sergipe,Aracuja,"The sample population was comprised of 123 military firefighters, representatives of the fire brigade of Aracaju, capital of the state of Sergipe, Brazil.",,2021-01-01,2021-01-31,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,123,0.26,,,True,,,,True,Convenience,Ichroma COVID-19 Ab Test,Boditech Med Inc.,LFIA,Serum,IgG,,,0.958,0.97,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Lysandro Borges,"Federal University of Sergipe
",Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph18158148,2021-08-13,2024-03-01,Verified,borges_estimated_2021,BRA
210801_Aracuja_FederalUniversityofSergipe_Age_>40,210801_Aracuja_FederalUniversityofSergipe,Estimated SARS-CoV-2 infection and seroprevalence in firefighters from a Northeastern Brazilian state: A cross-sectional study,2021-08-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Sergipe,Aracuja,"The sample population was comprised of 123 military firefighters, representatives of the fire brigade of Aracaju, capital of the state of Sergipe, Brazil.",,2021-01-01,2021-01-31,Essential non-healthcare workers,All,Adults (18-64 years),40.0,,Age,>40 years old,81,0.222,,,,,,,,Convenience,Ichroma COVID-19 Ab Test,Boditech Med Inc.,LFIA,Serum,IgG,,,0.958,0.97,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Lysandro Borges,"Federal University of Sergipe
",Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph18158148,2021-08-19,2024-03-01,Verified,borges_estimated_2021,BRA
210801_Aracuja_FederalUniversityofSergipe_Age_<40,210801_Aracuja_FederalUniversityofSergipe,Estimated SARS-CoV-2 infection and seroprevalence in firefighters from a Northeastern Brazilian state: A cross-sectional study,2021-08-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Sergipe,Aracuja,"The sample population was comprised of 123 military firefighters, representatives of the fire brigade of Aracaju, capital of the state of Sergipe, Brazil.",,2021-01-01,2021-01-31,Essential non-healthcare workers,All,Adults (18-64 years),,40.0,Age,<=40 years old,42,0.33299999999999996,,,,,,,,Convenience,Ichroma COVID-19 Ab Test,Boditech Med Inc.,LFIA,Serum,IgG,,,0.958,0.97,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Lysandro Borges,"Federal University of Sergipe
",Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph18158148,2021-08-19,2024-03-01,Verified,borges_estimated_2021,BRA
210810_SaoPaulo_UniversidadedeSaoPaulo_Primary,210810_SaoPaulo_UniversidadedeSaoPaulo,"Assessment of initial SARS-CoV-2 seroprevalence in the most affected districts in the municipality of Sao Paulo, Brazil",2021-08-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,,Sao Paulo,"""The target population was individuals aged 18 years or older on the date of the study visit, residing in permanent private households, located within six administrative districts in the municipality of Sao Paulo. The districts were selected based on official data on the number of confirmed COVID-19 cases and suspected or confirmed COVID-19 deaths, released on April 17, 2020, by the Municipal Department of Health. The three districts with the highest number of confirmed cases per 100,000inhabitants (Morumbi, Bela Vista, and Jardim Paulista) and the three districts with the highest number of suspected or confirmed deaths per 100,000 inhabitants (Pari, Belem, and Agua Rasa) were included in the study.""

""All residents aged 18 years or older who could understand the information provided by the research teams were eligible to participate.""",,2020-05-04,2020-05-12,Multiple general populations,All,Multiple groups,18.0,89.0,Primary Estimate,,463,0.06,0.039,0.083,True,,True,,True,Stratified non-probability,"MAGLUMI 2019-nCoV IgM/IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),Roche Diagnostics",Multiple Types,Serum,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,No,Unclear,Beatriz Tess,Universidade de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.bjid.2021.101604,2021-08-29,2024-03-01,Verified,tess_assessment_2021,BRA
210810_SaoPaulo_UniversidadedeSaoPaulo_>=60,210810_SaoPaulo_UniversidadedeSaoPaulo,"Assessment of initial SARS-CoV-2 seroprevalence in the most affected districts in the municipality of Sao Paulo, Brazil",2021-08-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,,Sao Paulo,"""The target population was individuals aged 18 years or older on the date of the study visit, residing in permanent private households, located within six administrative districts in the municipality of Sao Paulo. The districts were selected based on official data on the number of confirmed COVID-19 cases and suspected or confirmed COVID-19 deaths, released on April 17, 2020, by the Municipal Department of Health. The three districts with the highest number of confirmed cases per 100,000inhabitants (Morumbi, Bela Vista, and Jardim Paulista) and the three districts with the highest number of suspected or confirmed deaths per 100,000 inhabitants (Pari, Belem, and Agua Rasa) were included in the study.""

""All residents aged 18 years or older who could understand the information provided by the research teams were eligible to participate.""",,2020-05-04,2020-05-12,Multiple general populations,All,Multiple groups,60.0,89.0,Age,>=60,113,0.035,0.002,0.069,,,True,,,Stratified non-probability,"MAGLUMI 2019-nCoV IgM/IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),Roche Diagnostics",Multiple Types,Serum,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,No,Unclear,Beatriz Tess,Universidade de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.bjid.2021.101604,2021-08-29,2024-03-01,Verified,tess_assessment_2021,BRA
210810_SaoPaulo_UniversidadedeSaoPaulo_Male,210810_SaoPaulo_UniversidadedeSaoPaulo,"Assessment of initial SARS-CoV-2 seroprevalence in the most affected districts in the municipality of Sao Paulo, Brazil",2021-08-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,,Sao Paulo,"""The target population was individuals aged 18 years or older on the date of the study visit, residing in permanent private households, located within six administrative districts in the municipality of Sao Paulo. The districts were selected based on official data on the number of confirmed COVID-19 cases and suspected or confirmed COVID-19 deaths, released on April 17, 2020, by the Municipal Department of Health. The three districts with the highest number of confirmed cases per 100,000inhabitants (Morumbi, Bela Vista, and Jardim Paulista) and the three districts with the highest number of suspected or confirmed deaths per 100,000 inhabitants (Pari, Belem, and Agua Rasa) were included in the study.""

""All residents aged 18 years or older who could understand the information provided by the research teams were eligible to participate.""",,2020-05-04,2020-05-12,Multiple general populations,Male,Multiple groups,18.0,89.0,Sex/Gender,,214,0.07400000000000001,0.037000000000000005,0.111,,,True,,,Stratified non-probability,"MAGLUMI 2019-nCoV IgM/IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),Roche Diagnostics",Multiple Types,Serum,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,No,Unclear,Beatriz Tess,Universidade de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.bjid.2021.101604,2021-08-29,2024-03-01,Verified,tess_assessment_2021,BRA
210810_SaoPaulo_UniversidadedeSaoPaulo_<40,210810_SaoPaulo_UniversidadedeSaoPaulo,"Assessment of initial SARS-CoV-2 seroprevalence in the most affected districts in the municipality of Sao Paulo, Brazil",2021-08-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,,Sao Paulo,"""The target population was individuals aged 18 years or older on the date of the study visit, residing in permanent private households, located within six administrative districts in the municipality of Sao Paulo. The districts were selected based on official data on the number of confirmed COVID-19 cases and suspected or confirmed COVID-19 deaths, released on April 17, 2020, by the Municipal Department of Health. The three districts with the highest number of confirmed cases per 100,000inhabitants (Morumbi, Bela Vista, and Jardim Paulista) and the three districts with the highest number of suspected or confirmed deaths per 100,000 inhabitants (Pari, Belem, and Agua Rasa) were included in the study.""

""All residents aged 18 years or older who could understand the information provided by the research teams were eligible to participate.""",,2020-05-04,2020-05-12,Multiple general populations,All,Adults (18-64 years),18.0,40.0,Age,<40,195,0.084,0.039,0.13,,,True,,,Stratified non-probability,"MAGLUMI 2019-nCoV IgM/IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),Roche Diagnostics",Multiple Types,Serum,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,No,Unclear,Beatriz Tess,Universidade de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.bjid.2021.101604,2021-08-29,2024-03-01,Verified,tess_assessment_2021,BRA
210810_SaoPaulo_UniversidadedeSaoPaulo_Female,210810_SaoPaulo_UniversidadedeSaoPaulo,"Assessment of initial SARS-CoV-2 seroprevalence in the most affected districts in the municipality of Sao Paulo, Brazil",2021-08-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,,Sao Paulo,"""The target population was individuals aged 18 years or older on the date of the study visit, residing in permanent private households, located within six administrative districts in the municipality of Sao Paulo. The districts were selected based on official data on the number of confirmed COVID-19 cases and suspected or confirmed COVID-19 deaths, released on April 17, 2020, by the Municipal Department of Health. The three districts with the highest number of confirmed cases per 100,000inhabitants (Morumbi, Bela Vista, and Jardim Paulista) and the three districts with the highest number of suspected or confirmed deaths per 100,000 inhabitants (Pari, Belem, and Agua Rasa) were included in the study.""

""All residents aged 18 years or older who could understand the information provided by the research teams were eligible to participate.""",,2020-05-04,2020-05-12,Multiple general populations,Female,Multiple groups,18.0,89.0,Sex/Gender,,249,0.05,0.022000000000000002,0.077,,,True,,,Stratified non-probability,"MAGLUMI 2019-nCoV IgM/IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),Roche Diagnostics",Multiple Types,Serum,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,No,Unclear,Beatriz Tess,Universidade de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.bjid.2021.101604,2021-08-29,2024-03-01,Verified,tess_assessment_2021,BRA
210810_SaoPaulo_UniversidadedeSaoPaulo_40-59,210810_SaoPaulo_UniversidadedeSaoPaulo,"Assessment of initial SARS-CoV-2 seroprevalence in the most affected districts in the municipality of Sao Paulo, Brazil",2021-08-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,,Sao Paulo,"""The target population was individuals aged 18 years or older on the date of the study visit, residing in permanent private households, located within six administrative districts in the municipality of Sao Paulo. The districts were selected based on official data on the number of confirmed COVID-19 cases and suspected or confirmed COVID-19 deaths, released on April 17, 2020, by the Municipal Department of Health. The three districts with the highest number of confirmed cases per 100,000inhabitants (Morumbi, Bela Vista, and Jardim Paulista) and the three districts with the highest number of suspected or confirmed deaths per 100,000 inhabitants (Pari, Belem, and Agua Rasa) were included in the study.""

""All residents aged 18 years or older who could understand the information provided by the research teams were eligible to participate.""",,2020-05-04,2020-05-12,Multiple general populations,All,Adults (18-64 years),41.0,59.0,Age,41-59,155,0.055,0.021,0.08900000000000001,,,True,,,Stratified non-probability,"MAGLUMI 2019-nCoV IgM/IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),Roche Diagnostics",Multiple Types,Serum,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,No,Unclear,Beatriz Tess,Universidade de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.bjid.2021.101604,2021-08-29,2024-03-01,Verified,tess_assessment_2021,BRA
210813_Brazil_FederalUniversityofOuroPreto_Town1,210813_Brazil_FederalUniversityofOuroPreto_Town1,Logistics workers are a key factor for SARS-CoV-2 spread in Brazilian small towns: case-control study.,2021-08-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Minas Gerais,Nepomuceno,Residents of Nepomuceno,,2020-05-30,2020-05-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,400,0.005,0.0013000000000000002,0.018000000000000002,True,,,,True,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,No,No,Yes,Yes,Unclear,Breno Bernardes-Souza,Federal University of Ouro Preto,Unity-Aligned,https://dx.doi.org/10.2196/30406,2021-08-24,2024-03-01,Verified,bernardes-souza_logistics_2021,BRA
210813_Brazil_FederalUniversityofOuroPreto_Town2,210813_Brazil_FederalUniversityofOuroPreto_Town2,Logistics workers are a key factor for SARS-CoV-2 spread in Brazilian small towns: case-control study.,2021-08-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Minas Gerais,Carmópolis,Residents of Carmópolis,,2020-06-27,2020-06-28,Household and community samples,All,Multiple groups,,,Primary Estimate,,400,0.0175,0.0085,0.0357,True,,,,True,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],,Yes,Yes,Yes,,No,Yes,Yes,,Breno Bernardes-Souza,Federal University of Ouro Preto,Unity-Aligned,https://dx.doi.org/10.2196/30406,2021-08-24,2024-03-01,Verified,bernardes-souza_logistics_2021,BRA
210901_Petropolis_SociedadeFrancoBrasileiradeOncologia_baseline,210901_Petropolis_SociedadeFrancoBrasileiradeOncologia_baseline,1603P SARS-CoV-2 seroconversion among oncology healthcare workers in Brazil,2021-09-01,Presentation or Conference,Local,Prospective cohort,Brazil,,Petropolis,Oncology HCWs from Centro de Terapia Oncológica (CTO),,2020-04-09,2020-04-29,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,60,0.05,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Carla Ismael,Sociedade Franco Brasileira de Oncologia (SFBO),Not Unity-Aligned,http://dx.doi.org/10.1016/j.annonc.2021.08.1596,2021-09-28,2022-07-16,Unverified,ismael_1603p_2021,BRA
210901_Petropolis_SociedadeFrancoBrasileiradeOncologia_followup,210901_Petropolis_SociedadeFrancoBrasileiradeOncologia_followup,1603P SARS-CoV-2 seroconversion among oncology healthcare workers in Brazil,2021-09-01,Presentation or Conference,Local,Prospective cohort,Brazil,,Petropolis,"Oncology HCWs from Centro de Terapia Oncológica (CTO) who had been tested at baseline (April 9 -29, 2020)",,2020-11-05,2020-12-28,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,60,0.1,,,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Carla Ismael,Sociedade Franco Brasileira de Oncologia (SFBO),Not Unity-Aligned,http://dx.doi.org/10.1016/j.annonc.2021.08.1596,2021-09-28,2024-03-01,Unverified,ismael_1603p_2021,BRA
210902_Manaus_InstitutoNacionaldePesquisasdaAmazônia_overall,210902_Manaus_InstitutoNacionaldePesquisasdaAmazônia,Increased vulnerability to SARS-CoV-2 infection among indigenous people living in the urban area of Manaus.,2021-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Amazonas,Manaus,"Indigenous residents in the community of Parque das Tribos, the biggest multiethnic urban indigenous community in Manaus.",Excluded (n=50) withdrew from participating in the study or did not allow new sample collection,2020-10-10,2020-11-14,Household and community samples,All,Multiple groups,1.0,83.0,Primary Estimate,,280,0.6464,0.5901,0.7028,True,,,,True,Sequential,"Anti-SARS-CoV-2 ELISA IgA,Anti-SARS-CoV-2 ELISA IgG",EUROIMMUN,ELISA,Serum,"['IgA', 'IgG']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],Yes,No,No,Yes,Yes,Yes,Yes,No,Unclear,Gemilson Soares Pontes,Instituto Nacional de Pesquisas da Amazônia,Unity-Aligned,https://www.nature.com/articles/s41598-021-96843-1,2021-09-14,2024-03-01,Verified,pontes_increased_2021-1,BRA
210902_Manaus_InstitutoNacionaldePesquisasdaAmazônia_13-19,210902_Manaus_InstitutoNacionaldePesquisasdaAmazônia,Increased vulnerability to SARS-CoV-2 infection among indigenous people living in the urban area of Manaus.,2021-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Amazonas,Manaus,"Indigenous residents in the community of Parque das Tribos, the biggest multiethnic urban indigenous community in Manaus.",Excluded (n=50) withdrew from participating in the study or did not allow new sample collection,2020-10-10,2020-11-14,Household and community samples,All,Multiple groups,13.0,19.0,Age,13-19,36,0.6940000000000001,,,,,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgA,Anti-SARS-CoV-2 ELISA IgG",EUROIMMUN,ELISA,Serum,"['IgA', 'IgG']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],Yes,No,No,Yes,Yes,Yes,Yes,No,Unclear,Gemilson Soares Pontes,Instituto Nacional de Pesquisas da Amazônia,Unity-Aligned,https://www.nature.com/articles/s41598-021-96843-1,2021-09-14,2024-03-01,Verified,pontes_increased_2021-1,BRA
210902_Manaus_InstitutoNacionaldePesquisasdaAmazônia_30-39,210902_Manaus_InstitutoNacionaldePesquisasdaAmazônia,Increased vulnerability to SARS-CoV-2 infection among indigenous people living in the urban area of Manaus.,2021-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Amazonas,Manaus,"Indigenous residents in the community of Parque das Tribos, the biggest multiethnic urban indigenous community in Manaus.",Excluded (n=50) withdrew from participating in the study or did not allow new sample collection,2020-10-10,2020-11-14,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,48,0.521,,,,,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgA,Anti-SARS-CoV-2 ELISA IgG",EUROIMMUN,ELISA,Serum,"['IgA', 'IgG']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],Yes,No,No,Yes,Yes,Yes,Yes,No,Unclear,Gemilson Soares Pontes,Instituto Nacional de Pesquisas da Amazônia,Unity-Aligned,https://www.nature.com/articles/s41598-021-96843-1,2021-09-14,2024-03-01,Verified,pontes_increased_2021-1,BRA
210902_Manaus_InstitutoNacionaldePesquisasdaAmazônia_1-12,210902_Manaus_InstitutoNacionaldePesquisasdaAmazônia,Increased vulnerability to SARS-CoV-2 infection among indigenous people living in the urban area of Manaus.,2021-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Amazonas,Manaus,"Indigenous residents in the community of Parque das Tribos, the biggest multiethnic urban indigenous community in Manaus.",Excluded (n=50) withdrew from participating in the study or did not allow new sample collection,2020-10-10,2020-11-14,Household and community samples,All,Children and Youth (0-17 years),1.0,12.0,Age,1-12,39,0.615,,,,,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgA,Anti-SARS-CoV-2 ELISA IgG",EUROIMMUN,ELISA,Serum,"['IgA', 'IgG']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],Yes,No,No,Yes,Yes,Yes,Yes,No,Unclear,Gemilson Soares Pontes,Instituto Nacional de Pesquisas da Amazônia,Unity-Aligned,https://www.nature.com/articles/s41598-021-96843-1,2021-09-14,2024-03-01,Verified,pontes_increased_2021-1,BRA
210902_Manaus_InstitutoNacionaldePesquisasdaAmazônia_≥60,210902_Manaus_InstitutoNacionaldePesquisasdaAmazônia,Increased vulnerability to SARS-CoV-2 infection among indigenous people living in the urban area of Manaus.,2021-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Amazonas,Manaus,"Indigenous residents in the community of Parque das Tribos, the biggest multiethnic urban indigenous community in Manaus.",Excluded (n=50) withdrew from participating in the study or did not allow new sample collection,2020-10-10,2020-11-14,Household and community samples,All,Multiple groups,60.0,83.0,Age,≥60,34,0.559,,,,,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgA,Anti-SARS-CoV-2 ELISA IgG",EUROIMMUN,ELISA,Serum,"['IgA', 'IgG']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],Yes,No,No,Yes,Yes,Yes,Yes,No,Unclear,Gemilson Soares Pontes,Instituto Nacional de Pesquisas da Amazônia,Unity-Aligned,https://www.nature.com/articles/s41598-021-96843-1,2021-09-14,2024-03-01,Verified,pontes_increased_2021-1,BRA
210902_Manaus_InstitutoNacionaldePesquisasdaAmazônia_40-49,210902_Manaus_InstitutoNacionaldePesquisasdaAmazônia,Increased vulnerability to SARS-CoV-2 infection among indigenous people living in the urban area of Manaus.,2021-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Amazonas,Manaus,"Indigenous residents in the community of Parque das Tribos, the biggest multiethnic urban indigenous community in Manaus.",Excluded (n=50) withdrew from participating in the study or did not allow new sample collection,2020-10-10,2020-11-14,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,48,0.7290000000000001,,,,,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgA,Anti-SARS-CoV-2 ELISA IgG",EUROIMMUN,ELISA,Serum,"['IgA', 'IgG']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],Yes,No,No,Yes,Yes,Yes,Yes,No,Unclear,Gemilson Soares Pontes,Instituto Nacional de Pesquisas da Amazônia,Unity-Aligned,https://www.nature.com/articles/s41598-021-96843-1,2021-09-14,2024-03-01,Verified,pontes_increased_2021-1,BRA
210902_Manaus_InstitutoNacionaldePesquisasdaAmazônia_male,210902_Manaus_InstitutoNacionaldePesquisasdaAmazônia,Increased vulnerability to SARS-CoV-2 infection among indigenous people living in the urban area of Manaus.,2021-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Amazonas,Manaus,"Indigenous residents in the community of Parque das Tribos, the biggest multiethnic urban indigenous community in Manaus.",Excluded (n=50) withdrew from participating in the study or did not allow new sample collection,2020-10-10,2020-11-14,Household and community samples,Male,Multiple groups,1.0,83.0,Sex/Gender,Male,118,0.6779999999999999,,,,,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgA,Anti-SARS-CoV-2 ELISA IgG",EUROIMMUN,ELISA,Serum,"['IgA', 'IgG']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],Yes,No,No,Yes,Yes,Yes,Yes,No,Unclear,Gemilson Soares Pontes,Instituto Nacional de Pesquisas da Amazônia,Unity-Aligned,https://www.nature.com/articles/s41598-021-96843-1,2021-09-14,2024-03-01,Verified,pontes_increased_2021-1,BRA
210902_Manaus_InstitutoNacionaldePesquisasdaAmazônia_20-29,210902_Manaus_InstitutoNacionaldePesquisasdaAmazônia,Increased vulnerability to SARS-CoV-2 infection among indigenous people living in the urban area of Manaus.,2021-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Amazonas,Manaus,"Indigenous residents in the community of Parque das Tribos, the biggest multiethnic urban indigenous community in Manaus.",Excluded (n=50) withdrew from participating in the study or did not allow new sample collection,2020-10-10,2020-11-14,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,39,0.6920000000000001,,,,,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgA,Anti-SARS-CoV-2 ELISA IgG",EUROIMMUN,ELISA,Serum,"['IgA', 'IgG']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],Yes,No,No,Yes,Yes,Yes,Yes,No,Unclear,Gemilson Soares Pontes,Instituto Nacional de Pesquisas da Amazônia,Unity-Aligned,https://www.nature.com/articles/s41598-021-96843-1,2021-09-14,2024-03-01,Verified,pontes_increased_2021-1,BRA
210902_Manaus_InstitutoNacionaldePesquisasdaAmazônia_50-59,210902_Manaus_InstitutoNacionaldePesquisasdaAmazônia,Increased vulnerability to SARS-CoV-2 infection among indigenous people living in the urban area of Manaus.,2021-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Amazonas,Manaus,"Indigenous residents in the community of Parque das Tribos, the biggest multiethnic urban indigenous community in Manaus.",Excluded (n=50) withdrew from participating in the study or did not allow new sample collection,2020-10-10,2020-11-14,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,36,0.7220000000000001,,,,,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgA,Anti-SARS-CoV-2 ELISA IgG",EUROIMMUN,ELISA,Serum,"['IgA', 'IgG']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],Yes,No,No,Yes,Yes,Yes,Yes,No,Unclear,Gemilson Soares Pontes,Instituto Nacional de Pesquisas da Amazônia,Unity-Aligned,https://www.nature.com/articles/s41598-021-96843-1,2021-09-14,2024-03-01,Verified,pontes_increased_2021-1,BRA
210902_Manaus_InstitutoNacionaldePesquisasdaAmazônia_female,210902_Manaus_InstitutoNacionaldePesquisasdaAmazônia,Increased vulnerability to SARS-CoV-2 infection among indigenous people living in the urban area of Manaus.,2021-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Amazonas,Manaus,"Indigenous residents in the community of Parque das Tribos, the biggest multiethnic urban indigenous community in Manaus.",Excluded (n=50) withdrew from participating in the study or did not allow new sample collection,2020-10-10,2020-11-14,Household and community samples,Female,Multiple groups,1.0,83.0,Sex/Gender,Female,162,0.623,,,,,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgA,Anti-SARS-CoV-2 ELISA IgG",EUROIMMUN,ELISA,Serum,"['IgA', 'IgG']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],Yes,No,No,Yes,Yes,Yes,Yes,No,Unclear,Gemilson Soares Pontes,Instituto Nacional de Pesquisas da Amazônia,Unity-Aligned,https://www.nature.com/articles/s41598-021-96843-1,2021-09-14,2024-03-01,Verified,pontes_increased_2021-1,BRA
210913_Belém_UniversidadeFederaldoPará,210913_Belém_UniversidadeFederaldoPará,"Migration in times of pandemic: SARS-CoV-2 infection among the Warao indigenous refugees in Belem, Para, Amazonia, Brazil.",2021-09-13,Journal Article (Peer-Reviewed),Local,Prospective cohort,Brazil,Pará State,Belém,"After the explanation of the project’s objectives and
the approval of its development by the leaders and the
families, all the adults (i.e. 18 years or older) were invited to participate.",,2020-09-15,2021-01-15,Household and community samples,All,Multiple groups,18.0,77.0,Primary Estimate,,101,0.8320000000000001,,,True,,,,True,Entire sample,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,No,Yes,Unclear,Yes,Yes,Yes,No,Hilton Pereira da Silva,Universidade Federal do Pará,Unity-Aligned,https://dx.doi.org/10.1186/s12889-021-11696-7,2021-09-21,2024-03-01,Unverified,da_silva_migration_2021,BRA
210913_Belém_UniversidadeFederaldoPará_male,210913_Belém_UniversidadeFederaldoPará,"Migration in times of pandemic: SARS-CoV-2 infection among the Warao indigenous refugees in Belem, Para, Amazonia, Brazil.",2021-09-13,Journal Article (Peer-Reviewed),Local,Prospective cohort,Brazil,Pará State,Belém,"After the explanation of the project’s objectives and
the approval of its development by the leaders and the
families, all the adults (i.e. 18 years or older) were invited to participate.",,2020-09-15,2021-01-15,Household and community samples,Male,Multiple groups,,,Sex/Gender,,43,0.907,,,,,,,,Entire sample,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,No,Yes,Unclear,Yes,Yes,Yes,No,Hilton Pereira da Silva,Universidade Federal do Pará,Unity-Aligned,https://dx.doi.org/10.1186/s12889-021-11696-7,2021-09-24,2024-03-01,Verified,da_silva_migration_2021,BRA
210913_Belém_UniversidadeFederaldoPará_female,210913_Belém_UniversidadeFederaldoPará,"Migration in times of pandemic: SARS-CoV-2 infection among the Warao indigenous refugees in Belem, Para, Amazonia, Brazil.",2021-09-13,Journal Article (Peer-Reviewed),Local,Prospective cohort,Brazil,Pará State,Belém,"After the explanation of the project’s objectives and
the approval of its development by the leaders and the
families, all the adults (i.e. 18 years or older) were invited to participate.",,2020-09-15,2021-01-15,Household and community samples,Female,Multiple groups,,,Sex/Gender,,58,0.7759999999999999,,,,,,,,Entire sample,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,No,Yes,Unclear,Yes,Yes,Yes,No,Hilton Pereira da Silva,Universidade Federal do Pará,Unity-Aligned,https://dx.doi.org/10.1186/s12889-021-11696-7,2021-09-24,2024-03-01,Verified,da_silva_migration_2021,BRA
210922_EspiritoSanto_LaboratoriodeEpidemiologia_Overall,210922_EspiritoSanto_LaboratoriodeEpidemiologia,"COVID-19 in children, adolescents and young adults: a cross-sectional study in Espirito Santo, Brazil, 2020.",2021-09-22,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Espirito Santo,"Colatina, Linhares, São Mateus, Afonso Cláudio, Nova Venécia, Cachoeiro de Itapemirim, Alegre, Vila Velha, Cariacica, Serra, Vitória","Municipalities in the State of Espirito Santo, Brazil, with the largest populations (Colatina; Linhares; São Mateus; Afonso Cláudio; Nova Venécia; Cachoeiro de Itapemirim; Alegre) as well as the four municipalities that comprise the metropolitan region of Greater Vitória (Vila Velha; Cariacica; Serra; and the state capital, Vitória) were selected for the study. The study included individuals aged 2 to 22 years chosen at random from each selected household (study unit was one inhabitant per household).",No exclusion criteria were established.,2020-05-10,2020-06-21,Household and community samples,All,Children and Youth (0-17 years),2.0,22.0,Primary Estimate,,1693,0.061,,,True,,,,True,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8640000000000001,0.996,['Moderate'],Yes,Yes,Yes,Yes,No,No,Yes,No,Unclear,Ethel Leonor Noia Maciel,Laboratorio de Epidemiologia,Unity-Aligned,https://dx.doi.org/10.1590/S1679-49742021000400001,2021-10-05,2024-03-01,Verified,maciel_covid-19_2021,BRA
210922_EspiritoSanto_LaboratoriodeEpidemiologia_Age1_15-18,210922_EspiritoSanto_LaboratoriodeEpidemiologia,"COVID-19 in children, adolescents and young adults: a cross-sectional study in Espirito Santo, Brazil, 2020.",2021-09-22,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Espirito Santo,"Colatina, Linhares, São Mateus, Afonso Cláudio, Nova Venécia, Cachoeiro de Itapemirim, Alegre, Vila Velha, Cariacica, Serra, Vitória","Municipalities in the State of Espirito Santo, Brazil, with the largest populations (Colatina; Linhares; São Mateus; Afonso Cláudio; Nova Venécia; Cachoeiro de Itapemirim; Alegre) as well as the four municipalities that comprise the metropolitan region of Greater Vitória (Vila Velha; Cariacica; Serra; and the state capital, Vitória) were selected for the study. The study included individuals aged 2 to 22 years chosen at random from each selected household (study unit was one inhabitant per household).",No exclusion criteria were established.,2020-05-10,2020-06-21,Household and community samples,All,Children and Youth (0-17 years),15.0,18.0,Age,Age categorization #1: 15-18,361,0.064,,,,,,,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8640000000000001,0.996,['Moderate'],Yes,Yes,Yes,Yes,No,No,Yes,No,Unclear,Ethel Leonor Noia Maciel,Laboratorio de Epidemiologia,Unity-Aligned,https://dx.doi.org/10.1590/S1679-49742021000400001,2021-10-05,2024-03-01,Verified,maciel_covid-19_2021,BRA
210922_EspiritoSanto_LaboratoriodeEpidemiologia_Male,210922_EspiritoSanto_LaboratoriodeEpidemiologia,"COVID-19 in children, adolescents and young adults: a cross-sectional study in Espirito Santo, Brazil, 2020.",2021-09-22,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Espirito Santo,"Colatina, Linhares, São Mateus, Afonso Cláudio, Nova Venécia, Cachoeiro de Itapemirim, Alegre, Vila Velha, Cariacica, Serra, Vitória","Municipalities in the State of Espirito Santo, Brazil, with the largest populations (Colatina; Linhares; São Mateus; Afonso Cláudio; Nova Venécia; Cachoeiro de Itapemirim; Alegre) as well as the four municipalities that comprise the metropolitan region of Greater Vitória (Vila Velha; Cariacica; Serra; and the state capital, Vitória) were selected for the study. The study included individuals aged 2 to 22 years chosen at random from each selected household (study unit was one inhabitant per household).",No exclusion criteria were established.,2020-05-10,2020-06-21,Household and community samples,Male,Children and Youth (0-17 years),2.0,22.0,Sex/Gender,,735,0.055999999999999994,,,,,,,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8640000000000001,0.996,['Moderate'],Yes,Yes,Yes,Yes,No,No,Yes,No,Unclear,Ethel Leonor Noia Maciel,Laboratorio de Epidemiologia,Unity-Aligned,https://dx.doi.org/10.1590/S1679-49742021000400001,2021-10-05,2024-03-01,Verified,maciel_covid-19_2021,BRA
210922_EspiritoSanto_LaboratoriodeEpidemiologia_Age2_11-18,210922_EspiritoSanto_LaboratoriodeEpidemiologia,"COVID-19 in children, adolescents and young adults: a cross-sectional study in Espirito Santo, Brazil, 2020.",2021-09-22,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Espirito Santo,"Colatina, Linhares, São Mateus, Afonso Cláudio, Nova Venécia, Cachoeiro de Itapemirim, Alegre, Vila Velha, Cariacica, Serra, Vitória","Municipalities in the State of Espirito Santo, Brazil, with the largest populations (Colatina; Linhares; São Mateus; Afonso Cláudio; Nova Venécia; Cachoeiro de Itapemirim; Alegre) as well as the four municipalities that comprise the metropolitan region of Greater Vitória (Vila Velha; Cariacica; Serra; and the state capital, Vitória) were selected for the study. The study included individuals aged 2 to 22 years chosen at random from each selected household (study unit was one inhabitant per household).",No exclusion criteria were established.,2020-05-10,2020-06-21,Household and community samples,All,Children and Youth (0-17 years),11.0,18.0,Age,Age categorization #2: 11-18,629,0.0541,,,,,,,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8640000000000001,0.996,['Moderate'],Yes,Yes,Yes,Yes,No,No,Yes,No,Unclear,Ethel Leonor Noia Maciel,Laboratorio de Epidemiologia,Unity-Aligned,https://dx.doi.org/10.1590/S1679-49742021000400001,2021-10-05,2024-03-01,Verified,maciel_covid-19_2021,BRA
210922_EspiritoSanto_LaboratoriodeEpidemiologia_Age1_≤5,210922_EspiritoSanto_LaboratoriodeEpidemiologia,"COVID-19 in children, adolescents and young adults: a cross-sectional study in Espirito Santo, Brazil, 2020.",2021-09-22,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Espirito Santo,"Colatina, Linhares, São Mateus, Afonso Cláudio, Nova Venécia, Cachoeiro de Itapemirim, Alegre, Vila Velha, Cariacica, Serra, Vitória","Municipalities in the State of Espirito Santo, Brazil, with the largest populations (Colatina; Linhares; São Mateus; Afonso Cláudio; Nova Venécia; Cachoeiro de Itapemirim; Alegre) as well as the four municipalities that comprise the metropolitan region of Greater Vitória (Vila Velha; Cariacica; Serra; and the state capital, Vitória) were selected for the study. The study included individuals aged 2 to 22 years chosen at random from each selected household (study unit was one inhabitant per household).",No exclusion criteria were established.,2020-05-10,2020-06-21,Household and community samples,All,Children and Youth (0-17 years),2.0,5.0,Age,Age categorization #1: ≤5,136,0.066,,,,,,,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8640000000000001,0.996,['Moderate'],Yes,Yes,Yes,Yes,No,No,Yes,No,Unclear,Ethel Leonor Noia Maciel,Laboratorio de Epidemiologia,Unity-Aligned,https://dx.doi.org/10.1590/S1679-49742021000400001,2021-10-05,2024-03-01,Verified,maciel_covid-19_2021,BRA
210922_EspiritoSanto_LaboratoriodeEpidemiologia_Age2_2-10,210922_EspiritoSanto_LaboratoriodeEpidemiologia,"COVID-19 in children, adolescents and young adults: a cross-sectional study in Espirito Santo, Brazil, 2020.",2021-09-22,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Espirito Santo,"Colatina, Linhares, São Mateus, Afonso Cláudio, Nova Venécia, Cachoeiro de Itapemirim, Alegre, Vila Velha, Cariacica, Serra, Vitória","Municipalities in the State of Espirito Santo, Brazil, with the largest populations (Colatina; Linhares; São Mateus; Afonso Cláudio; Nova Venécia; Cachoeiro de Itapemirim; Alegre) as well as the four municipalities that comprise the metropolitan region of Greater Vitória (Vila Velha; Cariacica; Serra; and the state capital, Vitória) were selected for the study. The study included individuals aged 2 to 22 years chosen at random from each selected household (study unit was one inhabitant per household).",No exclusion criteria were established.,2020-05-10,2020-06-21,Household and community samples,All,Children and Youth (0-17 years),2.0,10.0,Age,Age categorization #2: 2-10,348,0.0488,,,,,,,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8640000000000001,0.996,['Moderate'],Yes,Yes,Yes,Yes,No,No,Yes,No,Unclear,Ethel Leonor Noia Maciel,Laboratorio de Epidemiologia,Unity-Aligned,https://dx.doi.org/10.1590/S1679-49742021000400001,2021-10-05,2024-03-01,Verified,maciel_covid-19_2021,BRA
210922_EspiritoSanto_LaboratoriodeEpidemiologia_Age1_11-14,210922_EspiritoSanto_LaboratoriodeEpidemiologia,"COVID-19 in children, adolescents and young adults: a cross-sectional study in Espirito Santo, Brazil, 2020.",2021-09-22,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Espirito Santo,"Colatina, Linhares, São Mateus, Afonso Cláudio, Nova Venécia, Cachoeiro de Itapemirim, Alegre, Vila Velha, Cariacica, Serra, Vitória","Municipalities in the State of Espirito Santo, Brazil, with the largest populations (Colatina; Linhares; São Mateus; Afonso Cláudio; Nova Venécia; Cachoeiro de Itapemirim; Alegre) as well as the four municipalities that comprise the metropolitan region of Greater Vitória (Vila Velha; Cariacica; Serra; and the state capital, Vitória) were selected for the study. The study included individuals aged 2 to 22 years chosen at random from each selected household (study unit was one inhabitant per household).",No exclusion criteria were established.,2020-05-10,2020-06-21,Household and community samples,All,Children and Youth (0-17 years),11.0,14.0,Age,Age categorization #1: 11-14,268,0.040999999999999995,,,,,,,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8640000000000001,0.996,['Moderate'],Yes,Yes,Yes,Yes,No,No,Yes,No,Unclear,Ethel Leonor Noia Maciel,Laboratorio de Epidemiologia,Unity-Aligned,https://dx.doi.org/10.1590/S1679-49742021000400001,2021-10-05,2024-03-01,Verified,maciel_covid-19_2021,BRA
210922_EspiritoSanto_LaboratoriodeEpidemiologia_Female,210922_EspiritoSanto_LaboratoriodeEpidemiologia,"COVID-19 in children, adolescents and young adults: a cross-sectional study in Espirito Santo, Brazil, 2020.",2021-09-22,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Espirito Santo,"Colatina, Linhares, São Mateus, Afonso Cláudio, Nova Venécia, Cachoeiro de Itapemirim, Alegre, Vila Velha, Cariacica, Serra, Vitória","Municipalities in the State of Espirito Santo, Brazil, with the largest populations (Colatina; Linhares; São Mateus; Afonso Cláudio; Nova Venécia; Cachoeiro de Itapemirim; Alegre) as well as the four municipalities that comprise the metropolitan region of Greater Vitória (Vila Velha; Cariacica; Serra; and the state capital, Vitória) were selected for the study. The study included individuals aged 2 to 22 years chosen at random from each selected household (study unit was one inhabitant per household).",No exclusion criteria were established.,2020-05-10,2020-06-21,Household and community samples,Female,Children and Youth (0-17 years),2.0,22.0,Sex/Gender,,958,0.066,,,,,,,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8640000000000001,0.996,['Moderate'],Yes,Yes,Yes,Yes,No,No,Yes,No,Unclear,Ethel Leonor Noia Maciel,Laboratorio de Epidemiologia,Unity-Aligned,https://dx.doi.org/10.1590/S1679-49742021000400001,2021-10-05,2024-03-01,Verified,maciel_covid-19_2021,BRA
210922_EspiritoSanto_LaboratoriodeEpidemiologia_Age1_6-10,210922_EspiritoSanto_LaboratoriodeEpidemiologia,"COVID-19 in children, adolescents and young adults: a cross-sectional study in Espirito Santo, Brazil, 2020.",2021-09-22,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Espirito Santo,"Colatina, Linhares, São Mateus, Afonso Cláudio, Nova Venécia, Cachoeiro de Itapemirim, Alegre, Vila Velha, Cariacica, Serra, Vitória","Municipalities in the State of Espirito Santo, Brazil, with the largest populations (Colatina; Linhares; São Mateus; Afonso Cláudio; Nova Venécia; Cachoeiro de Itapemirim; Alegre) as well as the four municipalities that comprise the metropolitan region of Greater Vitória (Vila Velha; Cariacica; Serra; and the state capital, Vitória) were selected for the study. The study included individuals aged 2 to 22 years chosen at random from each selected household (study unit was one inhabitant per household).",No exclusion criteria were established.,2020-05-10,2020-06-21,Household and community samples,All,Children and Youth (0-17 years),6.0,10.0,Age,Age categorization #1: 6-10,212,0.038,,,,,,,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8640000000000001,0.996,['Moderate'],Yes,Yes,Yes,Yes,No,No,Yes,No,Unclear,Ethel Leonor Noia Maciel,Laboratorio de Epidemiologia,Unity-Aligned,https://dx.doi.org/10.1590/S1679-49742021000400001,2021-10-05,2024-03-01,Verified,maciel_covid-19_2021,BRA
210922_EspiritoSanto_LaboratoriodeEpidemiologia_Age1_19-22,210922_EspiritoSanto_LaboratoriodeEpidemiologia,"COVID-19 in children, adolescents and young adults: a cross-sectional study in Espirito Santo, Brazil, 2020.",2021-09-22,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Espirito Santo,"Colatina, Linhares, São Mateus, Afonso Cláudio, Nova Venécia, Cachoeiro de Itapemirim, Alegre, Vila Velha, Cariacica, Serra, Vitória","Municipalities in the State of Espirito Santo, Brazil, with the largest populations (Colatina; Linhares; São Mateus; Afonso Cláudio; Nova Venécia; Cachoeiro de Itapemirim; Alegre) as well as the four municipalities that comprise the metropolitan region of Greater Vitória (Vila Velha; Cariacica; Serra; and the state capital, Vitória) were selected for the study. The study included individuals aged 2 to 22 years chosen at random from each selected household (study unit was one inhabitant per household).",No exclusion criteria were established.,2020-05-10,2020-06-21,Household and community samples,All,Adults (18-64 years),19.0,22.0,Age,Age categorization #1: 19-22,716,0.07400000000000001,,,,,,,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8640000000000001,0.996,['Moderate'],Yes,Yes,Yes,Yes,No,No,Yes,No,Unclear,Ethel Leonor Noia Maciel,Laboratorio de Epidemiologia,Unity-Aligned,https://dx.doi.org/10.1590/S1679-49742021000400001,2021-10-05,2024-03-01,Verified,maciel_covid-19_2021,BRA
210926_RiodeJaneiro_OswaldoCruzFoundation_Primary,210926_RiodeJaneiro_OswaldoCruzFoundation,P-87 HIGH PREVALENCE OF SARS-COV-2 ANTIBODIES IN PREGNANT WOMEN INFECTED WITH VIRAL HEPATITIS IN BRAZIL,2021-09-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Rio de Janeiro,Rio de Janeiro,"pregnant women from Rio de Janeiro, Brazil with viral hepatitis",,2020-01-07,2021-01-11,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,31,0.1935,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,,,,,['High'],Unclear,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Alanna Calheiros Santos,Oswaldo Cruz Foundation,Unity-Aligned,http://dx.doi.org/10.1016/j.aohep.2021.100450,2021-10-04,2024-03-01,Verified,calheiros_santos_p-87_2021,BRA
210926_RiodeJaneiro_OswaldoCruzFoundation_>=35,210926_RiodeJaneiro_OswaldoCruzFoundation,P-87 HIGH PREVALENCE OF SARS-COV-2 ANTIBODIES IN PREGNANT WOMEN INFECTED WITH VIRAL HEPATITIS IN BRAZIL,2021-09-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Rio de Janeiro,Rio de Janeiro,"pregnant women from Rio de Janeiro, Brazil with viral hepatitis",,2020-01-07,2021-01-11,Pregnant or parturient women,Female,Adults (18-64 years),,,Age,≥35,11,0.1818,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,,,,,['High'],Unclear,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Alanna Calheiros Santos,Oswaldo Cruz Foundation,Unity-Aligned,http://dx.doi.org/10.1016/j.aohep.2021.100450,2021-10-04,2024-03-01,Verified,calheiros_santos_p-87_2021,BRA
210926_RiodeJaneiro_OswaldoCruzFoundation_<35,210926_RiodeJaneiro_OswaldoCruzFoundation,P-87 HIGH PREVALENCE OF SARS-COV-2 ANTIBODIES IN PREGNANT WOMEN INFECTED WITH VIRAL HEPATITIS IN BRAZIL,2021-09-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Rio de Janeiro,Rio de Janeiro,"pregnant women from Rio de Janeiro, Brazil with viral hepatitis",,2020-01-07,2021-01-11,Pregnant or parturient women,Female,Adults (18-64 years),,,Age,<35,20,0.2,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,,,,,['High'],Unclear,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Alanna Calheiros Santos,Oswaldo Cruz Foundation,Unity-Aligned,http://dx.doi.org/10.1016/j.aohep.2021.100450,2021-10-04,2024-03-01,Verified,calheiros_santos_p-87_2021,BRA
211019_SãoPaulo_FederalUniversityofParaná_homeless_overall,211019_SãoPaulo_FederalUniversityofParaná_homeless,"High SARS-CoV-2 seroprevalence in persons experiencing homelessness and shelter workers from a day-shelter in Sao Paulo, Brazil",2021-10-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,São Paulo State,São Paulo,"People who are homeless that accessed the Community Center of São Martinho de Lima from August 25th-27th

""To be included in the study, participants needed to have answered the questionnaire and collected both blood and swab samples.""",,2020-08-25,2020-08-27,Persons experiencing homelessness,All,Multiple groups,18.0,,Primary Estimate,,203,0.547,0.478,0.615,True,,,,True,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Anahi Chechia do Couto,Federal University of Paraná,Not Unity-Aligned,https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0009754,2021-11-17,2022-07-16,Unverified,couto_high_2021,BRA
211019_SãoPaulo_FederalUniversityofParaná_workers_overall,211019_SãoPaulo_FederalUniversityofParaná_workers,"High SARS-CoV-2 seroprevalence in persons experiencing homelessness and shelter workers from a day-shelter in Sao Paulo, Brazil",2021-10-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,São Paulo State,São Paulo,"These shelter workers were healthcare and assistance professionals (e.g., nurses, social workers, administrative personnel, cooks, cleaning, and maintenance professionals) providing care to people who were homeless. 
...
To be included in the study, participants needed to have answered the questionnaire and collected both blood and swab samples.",,2020-08-25,2020-08-27,Essential non-healthcare workers,All,Multiple groups,18.0,,Primary Estimate,,87,0.4943,,,True,,,,True,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Anahi Chechia do Couto,Federal University of Paraná,Not Unity-Aligned,https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0009754,2021-11-17,2022-07-16,Unverified,couto_high_2021,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase1,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase1,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2020-06-29,2020-07-02,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2481,0.09699999999999999,0.079,0.11800000000000001,True,,True,True,True,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase1_Age65+,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase1,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2020-06-29,2020-07-02,Household and community samples,All,Seniors (65+ years),65.0,,Age,65+,489,0.051,0.027000000000000003,0.095,,,True,True,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase1_Women,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase1,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2020-06-29,2020-07-02,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,1583,0.10099999999999999,0.076,0.133,,,True,True,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase1_Age50-64,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase1,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2020-06-29,2020-07-02,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50-64,617,0.12400000000000001,0.08900000000000001,0.171,,,True,True,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase1_Age18-34,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase1,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2020-06-29,2020-07-02,Household and community samples,All,Adults (18-64 years),18.0,34.0,Age,18-34,622,0.1,0.073,0.135,,,True,True,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase1_Men,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase1,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2020-06-29,2020-07-02,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,892,0.086,0.066,0.111,,,True,True,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase1_Age35-49,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase1,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2020-06-29,2020-07-02,Household and community samples,All,Adults (18-64 years),35.0,49.0,Age,35-49,753,0.096,0.059000000000000004,0.153,,,True,True,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase10,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase10,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2021-02-02,2021-02-04,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,1742,0.16,0.131,0.193,True,,True,True,True,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.99,['Moderate'],Yes,Yes,Yes,No,Yes,No,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase11,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase11,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2021-02-16,2021-02-18,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,1780,0.25,0.217,0.287,True,,True,True,True,Stratified probability,"One Step COVID-19 Test,Anti-SARS-CoV-2 ELISA IgG","Celer Technologies Inc.,EUROIMMUN",Multiple Types,Serum,"['IgG', 'IgM']","['Notreported', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Not Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase11_Women,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase11,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2021-02-16,2021-02-18,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,609,0.273,0.227,0.326,,,True,True,,Stratified probability,"One Step COVID-19 Test,Anti-SARS-CoV-2 ELISA IgG","Celer Technologies Inc.,EUROIMMUN",Multiple Types,Serum,"['IgG', 'IgM']","['Notreported', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Not Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase11_Age18-34,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase11,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2021-02-16,2021-02-18,Household and community samples,All,Adults (18-64 years),18.0,34.0,Age,18-34,411,0.294,0.239,0.35600000000000004,,,True,True,,Stratified probability,"One Step COVID-19 Test,Anti-SARS-CoV-2 ELISA IgG","Celer Technologies Inc.,EUROIMMUN",Multiple Types,Serum,"['IgG', 'IgM']","['Notreported', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Not Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase11_Age35-49,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase11,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2021-02-16,2021-02-18,Household and community samples,All,Adults (18-64 years),35.0,49.0,Age,35-49,489,0.21300000000000002,0.16,0.277,,,True,True,,Stratified probability,"One Step COVID-19 Test,Anti-SARS-CoV-2 ELISA IgG","Celer Technologies Inc.,EUROIMMUN",Multiple Types,Serum,"['IgG', 'IgM']","['Notreported', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Not Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase11_Age50-64,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase11,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2021-02-16,2021-02-18,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50-64,491,0.27,0.195,0.36,,,True,True,,Stratified probability,"One Step COVID-19 Test,Anti-SARS-CoV-2 ELISA IgG","Celer Technologies Inc.,EUROIMMUN",Multiple Types,Serum,"['IgG', 'IgM']","['Notreported', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Not Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase11_Men,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase11,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2021-02-16,2021-02-18,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,1184,0.207,0.171,0.24800000000000003,,,True,True,,Stratified probability,"One Step COVID-19 Test,Anti-SARS-CoV-2 ELISA IgG","Celer Technologies Inc.,EUROIMMUN",Multiple Types,Serum,"['IgG', 'IgM']","['Notreported', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Not Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase11_Age65+,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase11,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2021-02-16,2021-02-18,Household and community samples,All,Seniors (65+ years),65.0,,Age,65+,402,0.214,0.17,0.265,,,True,True,,Stratified probability,"One Step COVID-19 Test,Anti-SARS-CoV-2 ELISA IgG","Celer Technologies Inc.,EUROIMMUN",Multiple Types,Serum,"['IgG', 'IgM']","['Notreported', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Not Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase2,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase2,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2020-07-13,2020-07-16,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2323,0.111,0.096,0.129,True,,True,True,True,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.99,['Moderate'],Yes,Yes,Yes,No,Yes,No,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase3,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase3,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2020-07-28,2020-07-30,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2529,0.109,0.092,0.129,True,,True,True,True,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.99,['Moderate'],Yes,Yes,Yes,No,Yes,No,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase4,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase4,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2020-08-11,2020-08-13,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2447,0.11,0.09,0.133,True,,True,True,True,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase4_Age35-49,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase4,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2020-08-11,2020-08-13,Household and community samples,All,Adults (18-64 years),35.0,49.0,Age,35-49,680,0.12,0.081,0.17600000000000002,,,True,True,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase4_Age65+,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase4,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2020-08-11,2020-08-13,Household and community samples,All,Seniors (65+ years),65.0,,Age,65+,499,0.09300000000000001,0.061,0.14,,,True,True,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase4_Age50-64,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase4,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2020-08-11,2020-08-13,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50-64,597,0.081,0.055,0.11599999999999999,,,True,True,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase4_Age18-34,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase4,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2020-08-11,2020-08-13,Household and community samples,All,Adults (18-64 years),18.0,34.0,Age,18-34,672,0.131,0.095,0.179,,,True,True,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase4_Women,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase4,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2020-08-11,2020-08-13,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,1567,0.12,0.095,0.151,,,True,True,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase4_Men,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase4,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2020-08-11,2020-08-13,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,881,0.094,0.065,0.134,,,True,True,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase5,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase5,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2020-08-25,2020-08-27,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2225,0.139,0.11800000000000001,0.162,True,,True,True,True,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.99,['Moderate'],Yes,Yes,Yes,No,Yes,No,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase6,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase6,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2020-09-08,2020-09-10,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2125,0.11900000000000001,0.1,0.141,True,,True,True,True,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.99,['Moderate'],Yes,Yes,Yes,No,Yes,No,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase7,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase7,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2020-09-22,2020-09-24,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2012,0.136,0.11599999999999999,0.158,True,,True,True,True,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase7_Men,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase7,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2020-09-22,2020-09-24,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,703,0.135,0.10400000000000001,0.174,,,True,True,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase7_Age50-64,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase7,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2020-09-22,2020-09-24,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50-64,518,0.14400000000000002,0.11,0.185,,,True,True,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase7_Age18-34,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase7,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2020-09-22,2020-09-24,Household and community samples,All,Adults (18-64 years),18.0,34.0,Age,18-34,540,0.10800000000000001,0.073,0.157,,,True,True,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase7_Age65+,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase7,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2020-09-22,2020-09-24,Household and community samples,All,Seniors (65+ years),65.0,,Age,65+,441,0.092,0.059000000000000004,0.14300000000000002,,,True,True,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase7_Age35-49,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase7,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2020-09-22,2020-09-24,Household and community samples,All,Adults (18-64 years),35.0,49.0,Age,35-49,547,0.19100000000000003,0.14800000000000002,0.244,,,True,True,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase7_Women,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase7,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2020-09-22,2020-09-24,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,1313,0.136,0.11199999999999999,0.165,,,True,True,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase8,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase8,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2021-01-05,2021-01-07,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,1908,0.141,0.11699999999999999,0.168,True,,True,True,True,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.99,['Moderate'],Yes,Yes,Yes,No,Yes,No,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase9,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Phase9,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2021-01-19,2021-01-21,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,1795,0.139,0.11699999999999999,0.16399999999999998,True,,True,True,True,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.99,['Moderate'],Yes,Yes,Yes,No,Yes,No,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Pilot,211022_SaoPaulo_SecretariaMunicipalDeSaudeDeSaoPaulo_Pilot,"Prevalence evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021.",2021-10-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Greater São Paulo,,"""18 years or over, residing in the five regions""

""Data were analyzed considering five regions of the city: Central-West; East; North; Southeast; and South. ""

This is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method.",,2020-06-10,2020-06-17,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2645,0.095,0.079,0.114,True,,True,True,True,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.848,0.99,['Moderate'],Yes,Yes,Yes,No,Yes,No,Yes,No,No,José Olimpio Moura de Albuquerque,Secretaria Municipal de Saude de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2021055003970,2021-11-03,2024-03-01,Verified,albuquerque_prevalence_2021-1,BRA
211022_MinasGerais_FundacaoHemominas_Overall,211022_MinasGerais_FundacaoHemominas,SOROPREVALENCIA DE IGG ANTI-SARS-COV-2 EM DOADORES DE SANGUE DE MINAS GERAIS,2021-10-22,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Minas Gerais,,"Blood donors from blood centers in Belo Horizonte (HBH), Governador Valadares (GOV), Juiz
de Fora (JFO), Montes Claros (MOC), Pouso Alegre (PAL), Uberaba (URA) and Uberlandia (UDI)",,2020-03-15,2020-12-15,Blood donors,All,Multiple groups,,,Primary Estimate,,7837,0.055999999999999994,,,True,,,,True,Convenience,Author designed (CLIA),,CLIA,Serum,IgG,,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,IR Oliveira,Fundacao Hemominas,Not Unity-Aligned,https://dx.doi.org/10.1016/j.htct.2021.10.912,2022-06-02,2022-07-16,Unverified,oliveira_soroprevalencia_2021,BRA
211029_Vitória_UniversidadeFederalDoEspíritoSanto_AGNSN,211029_Vitória_UniversidadeFederalDoEspíritoSanto_AGNSN,"Living conditions, seroprevalence and symptoms of COVID-19 in slums in the Metropolitan Region of Vitoria (Espirito Santo).",2021-10-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Espírito Santo,Vitória,"In each municipality, census tracts were drawn and divided into two groups: AGSN and 
AGNSN, proportional to the size of the population in these municipalities. The draw took 
place in census sectors with urban population, with less than 100 hectares of area and more 
than 200 households, according to IBGE data for the 2020 Census. A random selection of 
households was carried out in the sectors, being only one resident selected at random. 
Each sector had 40 households.
Only individuals aged over 2 years were included to answer the questionnaire and blood 
sample collection for antibody detection test against SARS-CoV-2. To answer the interview, 
the resident should be over 16 years old or supervised by a responsible person",,2020-06-22,2020-06-26,Persons living in slums,All,Multiple groups,,81.0,Primary Estimate,,733,0.1023,0.0797,0.125,True,,,,True,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,,"['IgG', 'IgM']",,,0.8640000000000001,0.9763,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Ethel Leonor Noia Maciel,Universidade Federal do Espírito Santo,Not Unity-Aligned,https://dx.doi.org/10.1590/1980-549720210048,2021-11-11,2024-03-01,Unverified,macielLivingConditionsSeroprevalence2021,BRA
211029_Vitória_UniversidadeFederalDoEspíritoSanto_AGSN,211029_Vitória_UniversidadeFederalDoEspíritoSanto_AGSN,"Living conditions, seroprevalence and symptoms of COVID-19 in slums in the Metropolitan Region of Vitoria (Espirito Santo).",2021-10-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Espírito Santo,Vitória,"In each municipality, census tracts were drawn and divided into two groups: AGSN and 
AGNSN, proportional to the size of the population in these municipalities. The draw took 
place in census sectors with urban population, with less than 100 hectares of area and more 
than 200 households, according to IBGE data for the 2020 Census. A random selection of 
households was carried out in the sectors, being only one resident selected at random. 
Each sector had 40 households.
Only individuals aged over 2 years were included to answer the questionnaire and blood 
sample collection for antibody detection test against SARS-CoV-2. To answer the interview, 
the resident should be over 16 years old or supervised by a responsible person",,2020-06-22,2020-06-26,Household and community samples,All,Multiple groups,,81.0,Primary Estimate,,714,0.12050000000000001,0.0959,0.145,True,,,,True,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,,"['IgG', 'IgM']",,,0.8640000000000001,0.9763,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Ethel Leonor Noia Maciel,Universidade Federal do Espírito Santo,Not Unity-Aligned,https://dx.doi.org/10.1590/1980-549720210048,2021-11-11,2024-03-01,Unverified,macielLivingConditionsSeroprevalence2021,BRA
211101_Manaus_UniversidadeFederaldoAmazona_Primary,211101_Manaus_UniversidadeFederaldoAmazona,"High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behaviour measures: results from the prospective DETECTCoV-19 cohort.",2021-11-01,Journal Article (Peer-Reviewed),Local,Prospective cohort,Brazil,Amazonas,Manaus,""" we    included    participants    in    the    DETECTCoV-19  study  who  had  at  least  two  study  visits  with  serum  sample  collections  separated  by  at  least  4 weeks"" >1819 August, 2020

","""We excluded individuals who reported having a COVID-19 diagnosis before the first study visit (either by PCR, serology, radiology, or clinical diagnosis); who had no data or did not answer questions regarding COVID-19 diagnosis before the first visit; and who were positive for anti-SARS-CoV-2 nucleocapsid IgG antibodies (based on the ELISA described below) at visit 1.""",2020-08-20,2020-11-20,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,1631,0.1306,0.1152,0.1479,True,True,,,True,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by developers,0.9428000000000001,0.9703,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Pritesh Lalwani,Universidade Federal do Amazonas,Not Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(21)00355-7,2021-11-05,2022-07-16,Verified,lalwani_high_2021,BRA
211101_Manaus_UniversidadeFederaldoAmazona_AgeOver60,211101_Manaus_UniversidadeFederaldoAmazona,"High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behaviour measures: results from the prospective DETECTCoV-19 cohort.",2021-11-01,Journal Article (Peer-Reviewed),Local,Prospective cohort,Brazil,Amazonas,Manaus,""" we    included    participants    in    the    DETECTCoV-19  study  who  had  at  least  two  study  visits  with  serum  sample  collections  separated  by  at  least  4 weeks"" >1819 August, 2020

","""We excluded individuals who reported having a COVID-19 diagnosis before the first study visit (either by PCR, serology, radiology, or clinical diagnosis); who had no data or did not answer questions regarding COVID-19 diagnosis before the first visit; and who were positive for anti-SARS-CoV-2 nucleocapsid IgG antibodies (based on the ELISA described below) at visit 1.""",2020-08-20,2020-11-20,Household and community samples,All,Seniors (65+ years),60.0,69.0,Age,age: over 60,200,0.11,,,,,,,,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by developers,0.9428000000000001,0.9703,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Pritesh Lalwani,Universidade Federal do Amazonas,Not Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(21)00355-7,2021-11-05,2022-07-16,Verified,lalwani_high_2021,BRA
211101_Manaus_UniversidadeFederaldoAmazona_Age4049,211101_Manaus_UniversidadeFederaldoAmazona,"High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behaviour measures: results from the prospective DETECTCoV-19 cohort.",2021-11-01,Journal Article (Peer-Reviewed),Local,Prospective cohort,Brazil,Amazonas,Manaus,""" we    included    participants    in    the    DETECTCoV-19  study  who  had  at  least  two  study  visits  with  serum  sample  collections  separated  by  at  least  4 weeks"" >1819 August, 2020

","""We excluded individuals who reported having a COVID-19 diagnosis before the first study visit (either by PCR, serology, radiology, or clinical diagnosis); who had no data or did not answer questions regarding COVID-19 diagnosis before the first visit; and who were positive for anti-SARS-CoV-2 nucleocapsid IgG antibodies (based on the ELISA described below) at visit 1.""",2020-08-20,2020-11-20,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,age: 40-49,354,0.1356,,,,,,,,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by developers,0.9428000000000001,0.9703,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Pritesh Lalwani,Universidade Federal do Amazonas,Not Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(21)00355-7,2021-11-05,2022-07-16,Verified,lalwani_high_2021,BRA
211101_Manaus_UniversidadeFederaldoAmazona_Age5059,211101_Manaus_UniversidadeFederaldoAmazona,"High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behaviour measures: results from the prospective DETECTCoV-19 cohort.",2021-11-01,Journal Article (Peer-Reviewed),Local,Prospective cohort,Brazil,Amazonas,Manaus,""" we    included    participants    in    the    DETECTCoV-19  study  who  had  at  least  two  study  visits  with  serum  sample  collections  separated  by  at  least  4 weeks"" >1819 August, 2020

","""We excluded individuals who reported having a COVID-19 diagnosis before the first study visit (either by PCR, serology, radiology, or clinical diagnosis); who had no data or did not answer questions regarding COVID-19 diagnosis before the first visit; and who were positive for anti-SARS-CoV-2 nucleocapsid IgG antibodies (based on the ELISA described below) at visit 1.""",2020-08-20,2020-11-20,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,age: 50-59,292,0.13699999999999998,,,,,,,,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by developers,0.9428000000000001,0.9703,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Pritesh Lalwani,Universidade Federal do Amazonas,Not Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(21)00355-7,2021-11-05,2022-07-16,Verified,lalwani_high_2021,BRA
211101_Manaus_UniversidadeFederaldoAmazona_Age3039,211101_Manaus_UniversidadeFederaldoAmazona,"High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behaviour measures: results from the prospective DETECTCoV-19 cohort.",2021-11-01,Journal Article (Peer-Reviewed),Local,Prospective cohort,Brazil,Amazonas,Manaus,""" we    included    participants    in    the    DETECTCoV-19  study  who  had  at  least  two  study  visits  with  serum  sample  collections  separated  by  at  least  4 weeks"" >1819 August, 2020

","""We excluded individuals who reported having a COVID-19 diagnosis before the first study visit (either by PCR, serology, radiology, or clinical diagnosis); who had no data or did not answer questions regarding COVID-19 diagnosis before the first visit; and who were positive for anti-SARS-CoV-2 nucleocapsid IgG antibodies (based on the ELISA described below) at visit 1.""",2020-08-20,2020-11-20,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,age: 30-39,420,0.1333,,,,,,,,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by developers,0.9428000000000001,0.9703,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Pritesh Lalwani,Universidade Federal do Amazonas,Not Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(21)00355-7,2021-11-05,2022-07-16,Verified,lalwani_high_2021,BRA
211101_Manaus_UniversidadeFederaldoAmazona_Age1829,211101_Manaus_UniversidadeFederaldoAmazona,"High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behaviour measures: results from the prospective DETECTCoV-19 cohort.",2021-11-01,Journal Article (Peer-Reviewed),Local,Prospective cohort,Brazil,Amazonas,Manaus,""" we    included    participants    in    the    DETECTCoV-19  study  who  had  at  least  two  study  visits  with  serum  sample  collections  separated  by  at  least  4 weeks"" >1819 August, 2020

","""We excluded individuals who reported having a COVID-19 diagnosis before the first study visit (either by PCR, serology, radiology, or clinical diagnosis); who had no data or did not answer questions regarding COVID-19 diagnosis before the first visit; and who were positive for anti-SARS-CoV-2 nucleocapsid IgG antibodies (based on the ELISA described below) at visit 1.""",2020-08-20,2020-11-20,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,age: 18-29,372,0.129,,,,,,,,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by developers,0.9428000000000001,0.9703,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Pritesh Lalwani,Universidade Federal do Amazonas,Not Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(21)00355-7,2021-11-05,2022-07-16,Verified,lalwani_high_2021,BRA
211101_Manaus_UniversidadeFederaldoAmazona_Female,211101_Manaus_UniversidadeFederaldoAmazona,"High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behaviour measures: results from the prospective DETECTCoV-19 cohort.",2021-11-01,Journal Article (Peer-Reviewed),Local,Prospective cohort,Brazil,Amazonas,Manaus,""" we    included    participants    in    the    DETECTCoV-19  study  who  had  at  least  two  study  visits  with  serum  sample  collections  separated  by  at  least  4 weeks"" >1819 August, 2020

","""We excluded individuals who reported having a COVID-19 diagnosis before the first study visit (either by PCR, serology, radiology, or clinical diagnosis); who had no data or did not answer questions regarding COVID-19 diagnosis before the first visit; and who were positive for anti-SARS-CoV-2 nucleocapsid IgG antibodies (based on the ELISA described below) at visit 1.""",2020-08-20,2020-11-20,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,1031,0.1261,,,,,,,,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by developers,0.9428000000000001,0.9703,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Pritesh Lalwani,Universidade Federal do Amazonas,Not Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(21)00355-7,2021-11-05,2022-07-16,Verified,lalwani_high_2021,BRA
211101_Manaus_UniversidadeFederaldoAmazona_Visit1,211101_Manaus_UniversidadeFederaldoAmazona,"High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behaviour measures: results from the prospective DETECTCoV-19 cohort.",2021-11-01,Journal Article (Peer-Reviewed),Local,Prospective cohort,Brazil,Amazonas,Manaus,""" we    included    participants    in    the    DETECTCoV-19  study  who  had  at  least  two  study  visits  with  serum  sample  collections  separated  by  at  least  4 weeks"" >1819 August, 2020

","""We excluded individuals who reported having a COVID-19 diagnosis before the first study visit (either by PCR, serology, radiology, or clinical diagnosis); who had no data or did not answer questions regarding COVID-19 diagnosis before the first visit; and who were positive for anti-SARS-CoV-2 nucleocapsid IgG antibodies (based on the ELISA described below) at visit 1.""",2020-08-20,2020-11-20,Household and community samples,All,Multiple groups,18.0,,Time frame,visit 1 between aug 19 and oct 2,2496,0.0817,,,,,,,,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by developers,0.9428000000000001,0.9703,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Pritesh Lalwani,Universidade Federal do Amazonas,Not Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(21)00355-7,2021-11-05,2022-07-16,Verified,lalwani_high_2021,BRA
211101_Manaus_UniversidadeFederaldoAmazona_Male,211101_Manaus_UniversidadeFederaldoAmazona,"High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behaviour measures: results from the prospective DETECTCoV-19 cohort.",2021-11-01,Journal Article (Peer-Reviewed),Local,Prospective cohort,Brazil,Amazonas,Manaus,""" we    included    participants    in    the    DETECTCoV-19  study  who  had  at  least  two  study  visits  with  serum  sample  collections  separated  by  at  least  4 weeks"" >1819 August, 2020

","""We excluded individuals who reported having a COVID-19 diagnosis before the first study visit (either by PCR, serology, radiology, or clinical diagnosis); who had no data or did not answer questions regarding COVID-19 diagnosis before the first visit; and who were positive for anti-SARS-CoV-2 nucleocapsid IgG antibodies (based on the ELISA described below) at visit 1.""",2020-08-20,2020-11-20,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,607,0.1384,,,,,,,,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by developers,0.9428000000000001,0.9703,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Pritesh Lalwani,Universidade Federal do Amazonas,Not Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(21)00355-7,2021-11-05,2022-07-16,Verified,lalwani_high_2021,BRA
211105_Sergipe_FederalUniversityofSergipe_Phase1_Overall,211105_Sergipe_FederalUniversityofSergipe_Phase1,Does In-Person Visiting Affect the Number of COVID-19 Cases in Prisons?.,2021-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Sergipe,,"In the first phase of this study (when in-person visiting was suspended), inmates from seven prisons in the state of Sergipe, Brazil were sampled. Inmates presenting symptoms compatible with an acute respiratory infection were also included.",,2020-08-31,2020-09-09,Persons who are incarcerated,All,Multiple groups,,,Primary Estimate,,778,0.32,,,True,,,,True,Simplified probability,EGENS COVID-19 IgG/IgM Rapid Test Kit,Nantong Egens Biotechnology,LFIA,,"['IgG', 'IgM']",,Validated by developers,0.97,0.99,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Lysandro Pinto Borges,Federal University of Sergipe,Not Unity-Aligned,https://dx.doi.org/10.3390/life11111184,2021-12-09,2022-07-16,Unverified,borges_does_2021,BRA
211105_Sergipe_FederalUniversityofSergipe_Phase2,211105_Sergipe_FederalUniversityofSergipe_Phase2,Does In-Person Visiting Affect the Number of COVID-19 Cases in Prisons?.,2021-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Sergipe,,"In the second phase of this study (when in-person visiting was allowed), inmates from seven prisons in the state of Sergipe, Brazil were sampled. Inmates presenting symptoms compatible with an acute respiratory infection were also included. Inmates who had tested negative for SARS-CoV-2 antigens and for IgM and IgG antibodies in the first phase were included.",Individuals who had tested positive for SARS-CoV-2 antigens and/or IgM and/or IgG antibodies in the first phase and those who were not at the prison facility at the time of testing were excluded from this phase.,2020-10-05,2020-10-09,Persons who are incarcerated,All,Multiple groups,,,Primary Estimate,,453,0.196,,,True,,,,True,Simplified probability,EGENS COVID-19 IgG/IgM Rapid Test Kit,Nantong Egens Biotechnology,LFIA,,"['IgG', 'IgM']",,Validated by developers,0.97,0.99,['Moderate'],,Yes,No,Yes,,Unclear,Yes,Yes,,Lysandro Pinto Borges,Federal University of Sergipe,Not Unity-Aligned,https://dx.doi.org/10.3390/life11111184,2021-12-09,2022-07-16,Unverified,borges_does_2021,BRA
211111_Brazil_UniversidadedeSantaCruzdoSul_Primary,211111_Brazil_UniversidadedeSantaCruzdoSul,"[Social distancing as protection factor against COVID-19 in a non-metropolitan area in the State of Rio Grande do Sul, BrazilLas medidas de distanciamiento social como factor de proteccion contra la COVID-19 en el interior de Rio Grande do Sul, Brasil].",2021-11-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Vale do Rio Pardo,,"Multilevel sampling approach

”When approaching the selected household, all residents
were listed, but only one was selected, too. by lot, to be tested.","In case of refusal, one second resident was drawn. Faced with a new refusal, the domicile was excluded from the sample and the interviewers were directed to the next home on the right. Likewise, if the residents were absent, the next home on the right was
selected.",2020-08-01,2020-10-17,Household and community samples,All,Multiple groups,0.0,100.0,Primary Estimate,Steps 1-4,4252,0.028999999999999998,,,True,,,,True,Stratified probability,Leccurate SARS-CoV-2 Antibody Rapid Test Kit (Colloidal Gold Immunochromatography),Beijing Lepu Medical Technology,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.968,0.976,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Ana Schneider,Universidade de Santa Cruz do Sul,Unity-Aligned,https://dx.doi.org/10.26633/RPSP.2021.145,2021-12-08,2024-03-01,Verified,schneider_social_2021,BRA
211111_Brazil_UniversidadedeSantaCruzdoSul_Step1to3,211111_Brazil_UniversidadedeSantaCruzdoSul,"[Social distancing as protection factor against COVID-19 in a non-metropolitan area in the State of Rio Grande do Sul, BrazilLas medidas de distanciamiento social como factor de proteccion contra la COVID-19 en el interior de Rio Grande do Sul, Brasil].",2021-11-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Vale do Rio Pardo,,"Multilevel sampling approach

”When approaching the selected household, all residents
were listed, but only one was selected, too. by lot, to be tested.","In case of refusal, one second resident was drawn. Faced with a new refusal, the domicile was excluded from the sample and the interviewers were directed to the next home on the right. Likewise, if the residents were absent, the next home on the right was
selected.",2020-08-01,2020-08-15,Household and community samples,All,Multiple groups,0.0,100.0,Time frame,August 1-15,3189,0.027999999999999997,,,,,,,,Stratified probability,Leccurate SARS-CoV-2 Antibody Rapid Test Kit (Colloidal Gold Immunochromatography),Beijing Lepu Medical Technology,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.968,0.976,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Ana Schneider,Universidade de Santa Cruz do Sul,Unity-Aligned,https://dx.doi.org/10.26633/RPSP.2021.145,2021-12-08,2024-03-01,Verified,schneider_social_2021,BRA
211111_Brazil_UniversidadedeSantaCruzdoSul_Step4,211111_Brazil_UniversidadedeSantaCruzdoSul,"[Social distancing as protection factor against COVID-19 in a non-metropolitan area in the State of Rio Grande do Sul, BrazilLas medidas de distanciamiento social como factor de proteccion contra la COVID-19 en el interior de Rio Grande do Sul, Brasil].",2021-11-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Vale do Rio Pardo,,"Multilevel sampling approach

”When approaching the selected household, all residents
were listed, but only one was selected, too. by lot, to be tested.","In case of refusal, one second resident was drawn. Faced with a new refusal, the domicile was excluded from the sample and the interviewers were directed to the next home on the right. Likewise, if the residents were absent, the next home on the right was
selected.",2020-10-04,2020-10-17,Household and community samples,All,Multiple groups,0.0,100.0,Time frame,October 4-17,1063,0.034,,,,,,,,Stratified probability,Leccurate SARS-CoV-2 Antibody Rapid Test Kit (Colloidal Gold Immunochromatography),Beijing Lepu Medical Technology,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.968,0.976,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Ana Schneider,Universidade de Santa Cruz do Sul,Unity-Aligned,https://dx.doi.org/10.26633/RPSP.2021.145,2021-12-08,2024-03-01,Verified,schneider_social_2021,BRA
211116_RioGrandedoSul_UniversidadeFederaldoRioGrandedoSul_August_Overall,211116_RioGrandedoSul_UniversidadeFederaldoRioGrandedoSul_August,Prospective study on COVID-19 seroprevalence and behavioural patterns in military personnel from the Southern Brazil.,2021-11-16,Preprint,Regional,Cross-sectional survey ,Brazil,Rio Grande do Sul,,"Military staff from various barracks and among ranks within Rio Grande do Sul, Brazil.",,2020-08-01,2020-08-31,Essential non-healthcare workers,All,Multiple groups,,,Primary Estimate,,46,0.023,0.003,0.147,True,,,,True,Stratified non-probability,Acro Biotech COVID-19 IgM/IgG Rapid POC test,ACRO Biotech Inc,LFIA,,,,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Sergio Renato da Rosa Decker,Universidade Federal do Rio Grande do Sul,Not Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.1995039,2021-11-23,2024-03-01,Unverified,decker_prospective_2021,BRA
211116_RioGrandedoSul_UniversidadeFederaldoRioGrandedoSul_July_Overall,211116_RioGrandedoSul_UniversidadeFederaldoRioGrandedoSul_July,Prospective study on COVID-19 seroprevalence and behavioural patterns in military personnel from the Southern Brazil.,2021-11-16,Preprint,Regional,Cross-sectional survey ,Brazil,Rio Grande do Sul,,"Military staff from various barracks and among ranks within Rio Grande do Sul, Brazil. ",,2020-07-01,2020-07-31,Essential non-healthcare workers,All,Multiple groups,,,Primary Estimate,,48,0.061,0.019,0.177,True,,,,True,Stratified non-probability,Acro Biotech COVID-19 IgM/IgG Rapid POC test,ACRO Biotech Inc,LFIA,,,,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Sergio Renato da Rosa Decker,Universidade Federal do Rio Grande do Sul,Not Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.1995039,2021-11-23,2024-03-01,Unverified,decker_prospective_2021,BRA
211119_RiodeJaneiro_FundaçãoOswaldoCruz_Primary,211119_RiodeJaneiro_FundaçãoOswaldoCruz,"Anti-SARS-CoV-2 antibodies seroprevalence among patients submitted to treatment for tuberculosis in Rio de Janeiro, Brazil: a cross-sectional study",2021-11-19,Preprint,Local,Cross-sectional survey ,Brazil,,Rio de Janeiro,"Patients under medical care at the Centro de Referência Professor Hélio Fraga (CRPHF) undergoing treatment for TB or TB-DR, aged 18 years old or more",,2020-09-01,2021-02-28,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,19.0,,Primary Estimate,,83,0.265,0.17,0.36,True,,,,True,Convenience,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karen Gomes,Fundação Oswaldo Cruz,Not Unity-Aligned,10.1101/2021.11.17.21266274,2021-11-30,2022-07-16,Unverified,gomes_anti-sars-cov-2_2021,BRA
211122_RioGrandedoSul_UniversidadeFederaldePelotas_Round10_Overall,211122_RioGrandedoSul_UniversidadeFederaldePelotas_Round10,"Population-level seropositivity trend for SARS-Cov-2 in Rio Grande do Sul, Brazil.",2021-11-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Rio Grande do Sul,,General population in nine sentinel cities.,,2021-04-09,2021-04-11,Household and community samples,All,Multiple groups,,,Primary Estimate,,4499,0.1816,0.16899999999999998,0.1949,True,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.9500000000000001,0.986,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Aluisio Barros,Universidade Federal de Pelotas,Unity-Aligned,https://www.scielosp.org/article/rsp/2021.v55/78/,2021-12-02,2022-07-16,Verified,barros_population-level_2021,BRA
211122_RioGrandedoSul_UniversidadeFederaldePelotas_Round9_Overall,211122_RioGrandedoSul_UniversidadeFederaldePelotas_Round9,"Population-level seropositivity trend for SARS-Cov-2 in Rio Grande do Sul, Brazil.",2021-11-22,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,Rio Grande do Sul,,General population in nine sentinel cities.,,2021-02-05,2021-02-07,Household and community samples,All,Multiple groups,,,Primary Estimate,,4501,0.09970000000000001,0.0906,0.1095,True,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.9500000000000001,0.986,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Aluisio Barros,Universidade Federal de Pelotas,Unity-Aligned,https://www.scielosp.org/article/rsp/2021.v55/78/,2021-12-02,2022-07-16,Verified,barros_population-level_2021,BRA
211122_Ipojuca_UniversidadedePernambuco,211122_Ipojuca_UniversidadedePernambuco,Viral symptoms in children and SARS-COV-2: information for pediatric dentists for the control of transmission,2021-11-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Pernambuco,,Children seen for dental emergency care,"Children excluded from the sample had some health conditions that prevented examination, such as blood dyscrasias and behavioral changes such as attention deficit hyperactivity disorder",2020-03-15,2020-07-15,Residual sera,All,Children and Youth (0-17 years),6.0,9.0,Primary Estimate,,54,0.167,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Thaysa Santos,Universidade de Pernambuco,Not Unity-Aligned,https://dx.doi.org/10.1590/1807-3107bor-2022.vol36.0029,2022-03-18,2022-07-16,Unverified,santos_viral_2022,BRA
211210_EspíritoSanto_UniversidadeFederaldoEspíritoSanto_HCW_Primary,211210_EspíritoSanto_UniversidadeFederaldoEspíritoSanto_HCW,Prevalence of COVID-19 infection in the prison system in Espirito Santo/Brazil: persons deprived of liberty and justice workers.,2021-12-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Espírito Santo,,"Of note, the study population comprised the prison population without distinction of gender or sentence regime, in addition to professionals who work directly in the prison health system, including prison officers.","the staff on vacation or on leave due to several reasons, as well as refusals during the performance of the epidemiological survey",2020-08-31,2020-09-04,Health care workers and caregivers,All,Adults (18-64 years),21.0,60.0,Primary Estimate,,311,0.1189,0.08140000000000001,0.15660000000000002,True,,,,True,Stratified probability,MedTest Coronavirus 2019-nCoV IgG/IgM,MedLevensohn,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9740000000000001,0.993,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Adriana Ilha da Silva,Universidade Federal do Espírito Santo,Not Unity-Aligned,https://dx.doi.org/10.1590/1980-549720210053,2021-12-15,2022-07-16,Unverified,silva_prevalence_2021,BRA
211210_EspíritoSanto_UniversidadeFederaldoEspíritoSanto_PDL_Primary,211210_EspíritoSanto_UniversidadeFederaldoEspíritoSanto_PDL,Prevalence of COVID-19 infection in the prison system in Espirito Santo/Brazil: persons deprived of liberty and justice workers.,2021-12-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Espírito Santo,,"Of note, the study population comprised the prison population without distinction of gender or sentence regime, in addition to professionals who work directly in the prison health system, including prison officers.","the staff on vacation or on leave due to several reasons, as well as refusals during the performance of the epidemiological survey",2020-08-31,2020-09-04,Persons who are incarcerated,All,Adults (18-64 years),,60.0,Primary Estimate,,884,0.3164,0.28440000000000004,0.3483,True,,,,True,Stratified probability,MedTest Coronavirus 2019-nCoV IgG/IgM,MedLevensohn,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9740000000000001,0.993,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Adriana Ilha da Silva,Universidade Federal do Espírito Santo,Not Unity-Aligned,https://dx.doi.org/10.1590/1980-549720210053,2021-12-15,2022-07-16,Unverified,silva_prevalence_2021,BRA
211210_EspíritoSanto_UniversidadeFederaldoEspíritoSanto_PrisonOfficer_Primary,211210_EspíritoSanto_UniversidadeFederaldoEspíritoSanto_PrisonOfficer,Prevalence of COVID-19 infection in the prison system in Espirito Santo/Brazil: persons deprived of liberty and justice workers.,2021-12-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Espírito Santo,,"Of note, the study population comprised the prison population without distinction of gender or sentence regime, in addition to professionals who work directly in the prison health system, including prison officers.","the staff on vacation or on leave due to several reasons, as well as refusals during the performance of the epidemiological survey",2020-08-31,2020-09-04,Essential non-healthcare workers,All,Adults (18-64 years),,60.0,Primary Estimate,,675,0.2207,0.1887,0.2528,True,,,,True,Stratified probability,MedTest Coronavirus 2019-nCoV IgG/IgM,MedLevensohn,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9740000000000001,0.993,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Adriana Ilha da Silva,Universidade Federal do Espírito Santo,Not Unity-Aligned,https://dx.doi.org/10.1590/1980-549720210053,2021-12-15,2022-07-16,Unverified,silva_prevalence_2021,BRA
211228_MâncioLima_UniversityofSãoPaulo_AprtoMay2021,211228_MâncioLima_UniversityofSãoPaulo_AprtoMay2021,"Epidemiology of COVID-19 after Emergence of SARS-CoV-2 Gamma Variant, Brazilian Amazon, 2020-2021.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Brazil,Acre,Mâncio Lima,Mâncio Lima cohort in the Brazilian Amazon (https://www.niaid.nih.gov/research/amazonian-international-center-excellence-malaria-research),Vaccinated individuals,2021-04-15,2021-05-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,1215,0.542,0.513,0.5710000000000001,True,True,,,True,Unclear,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Whole Blood,IgG,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],,Unclear,Yes,No,,Yes,Yes,Yes,,Vanessa Nicolete,University of São Paulo,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2803.211993,2022-01-08,2023-08-15,Unverified,nicolete_epidemiology_2022,BRA
211228_MâncioLima_UniversityofSãoPaulo_OcttoNov2020,211228_MâncioLima_UniversityofSãoPaulo_OcttoNov2020,"Epidemiology of COVID-19 after Emergence of SARS-CoV-2 Gamma Variant, Brazilian Amazon, 2020-2021.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Brazil,Acre,Mâncio Lima,Mâncio Lima cohort in the Brazilian Amazon (https://www.niaid.nih.gov/research/amazonian-international-center-excellence-malaria-research),Vaccinated individuals,2020-10-15,2020-11-15,Household and community samples,All,Multiple groups,0.0,93.0,Primary Estimate,,1215,0.335,0.332,0.44799999999999995,True,True,,,True,Unclear,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Whole Blood,IgG,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],,Unclear,Yes,No,,Yes,Yes,Yes,,Vanessa Nicolete,University of São Paulo,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2803.211993,2022-01-08,2023-08-15,Unverified,nicolete_epidemiology_2022,BRA
211231_RiodeJaneiro_NationalInstituteofHealthforWomenChildrenandAdolescentsFernandesFigueira,211231_RiodeJaneiro_NationalInstituteofHealthforWomenChildrenandAdolescentsFernandesFigueira,"SARS-CoV-2 seroprevalence and social inequalities in different subgroups of healthcare workers in Rio de Janeiro, Brazil.",2021-12-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Rio de Janeiro,"healthcare
professionals and support workers from a public hospital in Rio de Janeiro","Symptomatic workers were on sick leave and did not participate in the
study. ",2020-06-01,2020-07-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1141,0.3,,,True,,,,True,Convenience,Anti-SARS-CoV-2 NCP ELISA (IgG),EUROIMMUN,ELISA,Serum,IgG,,Validated by manufacturers,0.9940000000000001,0.996,['High'],,No,Yes,No,,Yes,Yes,Yes,,Roberta Correia,"National Institute of Health for Women, Children and Adolescents Fernandes Figueira",Not Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2021.100170,2022-01-18,2024-03-01,Unverified,correia_sars-cov-2_2022,BRA
220101_Maracana_UniversidadeFederaldoPará,220101_Maracana_UniversidadeFederaldoPará,"AVALIACAO CLINICO-EPIDEMIOLOGICA DA INFECCAO PELO SARS-COV-2 EM MORADORES DO MUNICIPIO DE MARACANA, NO ESTADO DO PARA",2022-01-01,Presentation or Conference,Local,Cross-sectional survey ,Brazil,Rio de Janeiro,Rio de Janeiro,individuals residing in the municipality of Maracanã,,2021-05-01,2021-05-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,117,0.423,,,True,,,,True,Unclear,Not reported/ Unable to specify,,ELISA,,IgG,,,,,['High'],,Unclear,No,Yes,,Unclear,Yes,No,,Aline Lima,Universidade Federal do Pará,Not Unity-Aligned,https://dx.doi.org/10.1016/j.bjid.2021.102011,2022-02-25,2022-07-16,Unverified,de_lima_avaliacao_2022,BRA
220101_DivonopolisUniversidade FederaldeSaoJoaoDelRei_Wave1,220101_DivonopolisUniversidade FederaldeSaoJoaoDelRei_Wave1,PREVALENCIA DE INFECCAO POR SARS-COV-2 NA POPULACAO DE DIVINOPOLIS/MG EM TRES MOMENTOS DISTINTOS DA PANDEMIA,2022-01-01,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Minas Gerais,"Divinopolis
","""among resident individuals and users of all
basic health units in Divinopolis""",,2020-11-15,2020-12-15,Multiple general populations,All,Multiple groups,2.0,,Primary Estimate,,616,0.065,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],,Unclear,Yes,No,,Unclear,Yes,No,,Gustavo Rocha,Universidade Federal de Sao Joao Del-Rei,Not Unity-Aligned,https://dx.doi.org/10.1016/j.bjid.2021.102059,2022-02-22,2022-07-16,Unverified,rocha_prevalencia_2022,BRA
220101_DivonopolisUniversidade FederaldeSaoJoaoDelRei_Wave2,220101_DivonopolisUniversidade FederaldeSaoJoaoDelRei_Wave2,PREVALENCIA DE INFECCAO POR SARS-COV-2 NA POPULACAO DE DIVINOPOLIS/MG EM TRES MOMENTOS DISTINTOS DA PANDEMIA,2022-01-01,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Minas Gerais,"Divinopolis
","""among resident individuals and users of all
basic health units in Divinopolis""",,2021-01-15,2021-02-15,Multiple general populations,All,Multiple groups,2.0,,Primary Estimate,,671,0.07200000000000001,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],,Unclear,Yes,No,,Unclear,Yes,No,,Gustavo Rocha,Universidade Federal de Sao Joao Del-Rei,Not Unity-Aligned,https://dx.doi.org/10.1016/j.bjid.2021.102059,2022-02-22,2022-07-16,Unverified,rocha_prevalencia_2022,BRA
220101_DivonopolisUniversidade FederaldeSaoJoaoDelRei_Wave3,220101_DivonopolisUniversidade FederaldeSaoJoaoDelRei_Wave3,PREVALENCIA DE INFECCAO POR SARS-COV-2 NA POPULACAO DE DIVINOPOLIS/MG EM TRES MOMENTOS DISTINTOS DA PANDEMIA,2022-01-01,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Minas Gerais,"Divinopolis
","""among resident individuals and users of all
basic health units in Divinopolis""",,2021-05-15,2021-07-15,Multiple general populations,All,Multiple groups,2.0,,Primary Estimate,,619,0.133,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],,Unclear,Yes,No,,Unclear,Yes,No,,Gustavo Rocha,Universidade Federal de Sao Joao Del-Rei,Not Unity-Aligned,https://dx.doi.org/10.1016/j.bjid.2021.102059,2022-02-22,2022-07-16,Unverified,rocha_prevalencia_2022,BRA
220112_Sergipe_FederalUniversityofSergipe_Overall,220112_Sergipe_FederalUniversityofSergipe,Seroprevalence of SARS-CoV-2 antibodies in radio and television workers.,2022-01-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Sergipe,,Professionals from the three largest media companies (radio and TV workers) in Sergipe state were included in this study,,2020-12-01,2020-12-20,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,113,0.24800000000000003,0.177,0.335,True,,,,True,Convenience,Ichroma COVID-19 Ab Test,Boditech Med Inc.,IFA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.958,0.97,['High'],,No,No,Yes,,Yes,Yes,Yes,,Paulo Ricardo Martins-Filho,Federal University of Sergipe,Not Unity-Aligned,https://dx.doi.org/10.17179/excli2021-4545,2022-03-07,2024-03-01,Unverified,martins-filho_seroprevalence_2022,BRA
220207_Betim_UniversidadeFederaldeMinasGerais,220207_Betim_UniversidadeFederaldeMinasGerais,"Seroprevalence, Prevalence, and Genomic Surveillance: Monitoring the Initial Phases of the SARS-CoV-2 Pandemic in Betim, Brazil.",2022-02-07,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Minas Gerais,Betim,General population of all populated areas in the Betim ,,2020-06-03,2020-07-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,3239,0.012,,,True,,,,True,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8643000000000001,0.9956999999999999,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Unclear,Ana Silva,Universidade Federal de Minas Gerais,Unity-Aligned,https://dx.doi.org/10.3389/fmicb.2022.799713,2022-03-07,2024-03-01,Verified,silva_seroprevalence_2022,BRA
220207_Betim_UniversidadeFederaldeMinasGerais,220207_Betim_UniversidadeFederaldeMinasGerais,"Seroprevalence, Prevalence, and Genomic Surveillance: Monitoring the Initial Phases of the SARS-CoV-2 Pandemic in Betim, Brazil.",2022-02-07,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Minas Gerais,Betim,General population of all populated areas in the Betim ,,2020-06-03,2020-06-05,Household and community samples,All,Multiple groups,,,Time frame,First survey,1079,0.003,,,,,,,,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8643000000000001,0.9956999999999999,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Unclear,Ana Silva,Universidade Federal de Minas Gerais,Unity-Aligned,https://dx.doi.org/10.3389/fmicb.2022.799713,2022-05-23,2024-03-01,Verified,silva_seroprevalence_2022,BRA
220207_Betim_UniversidadeFederaldeMinasGerais,220207_Betim_UniversidadeFederaldeMinasGerais,"Seroprevalence, Prevalence, and Genomic Surveillance: Monitoring the Initial Phases of the SARS-CoV-2 Pandemic in Betim, Brazil.",2022-02-07,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Minas Gerais,Betim,General population of all populated areas in the Betim ,,2020-07-13,2020-07-15,Household and community samples,All,Multiple groups,,,Time frame,Third survey,1080,0.026000000000000002,,,,,,,,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8643000000000001,0.9956999999999999,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Unclear,Ana Silva,Universidade Federal de Minas Gerais,Unity-Aligned,https://dx.doi.org/10.3389/fmicb.2022.799713,2022-05-23,2024-03-01,Verified,silva_seroprevalence_2022,BRA
220207_Betim_UniversidadeFederaldeMinasGerais,220207_Betim_UniversidadeFederaldeMinasGerais,"Seroprevalence, Prevalence, and Genomic Surveillance: Monitoring the Initial Phases of the SARS-CoV-2 Pandemic in Betim, Brazil.",2022-02-07,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Minas Gerais,Betim,General population of all populated areas in the Betim ,,2020-06-23,2020-06-25,Household and community samples,All,Multiple groups,,,Time frame,Second survey,1080,0.006999999999999999,,,,,,,,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8643000000000001,0.9956999999999999,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Unclear,Ana Silva,Universidade Federal de Minas Gerais,Unity-Aligned,https://dx.doi.org/10.3389/fmicb.2022.799713,2022-05-23,2024-03-01,Verified,silva_seroprevalence_2022,BRA
220210_Cameta_UniversidadeFederaldoPara_Overall,220210_Cameta_UniversidadeFederaldoPara,"PREVALENCIA DO CORONAVIRUS 2 DA SINDROME RESPIRATORIA AGUDA GRAVE (SARS-COV-2) EM COMUNIDADES QUILOMBOLAS DO MUNICIPIO DE CAMETA, PARA",2022-02-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Para,,"individuals belonging to five communities: Arimandeua, Aripijo, Bacuri, Cabanagem and Sao Benedito",,2021-04-01,2021-04-30,Household and community samples,All,Multiple groups,,,Primary Estimate,,140,0.521,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Plasma,IgG,,,,,['High'],Unclear,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Keise Pereira,Universidade Federal do Para,Unity-Aligned,https://dx.doi.org/10.1016/j.bjid.2021.102060,2022-02-21,2024-03-01,Verified,pereira_prevalencia_2022,BRA
220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020June_Overall,220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020June,"Increasing rate of anti-SARS-CoV-2 antibodies between the first and second waves of COVID-19 in Sao Paulo, Brazil: A cross-sectional blood donors-based study",2022-02-18,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,São Paulo,Sao Paulo city (Campo Limpo in the south and Tatuape in the east regions of the city); Sao Bernardo do Campo; Sorocaba.,"blood samples from sera banks in Sao Paulo, Brazil.

""all blood donors must have been free of respiratory symptoms for at least 30 days before the donation.""

""all subjects were healthy at the time of donation and had no reported health issues in the 4-weeks before donation.""",,2020-06-01,2020-06-30,Blood donors,All,Adults (18-64 years),16.0,69.0,Primary Estimate,,926,0.114,,,True,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Nayara Vale,Universidade Federal de São Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.clinsp.2022.100016,2022-03-29,2024-03-01,Verified,moya_rios_do_vale_increasing_2022,BRA
220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020June_Age30-39,220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020June,"Increasing rate of anti-SARS-CoV-2 antibodies between the first and second waves of COVID-19 in Sao Paulo, Brazil: A cross-sectional blood donors-based study",2022-02-18,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,São Paulo,Sao Paulo city (Campo Limpo in the south and Tatuape in the east regions of the city); Sao Bernardo do Campo; Sorocaba.,"blood samples from sera banks in Sao Paulo, Brazil.

""all blood donors must have been free of respiratory symptoms for at least 30 days before the donation.""

""all subjects were healthy at the time of donation and had no reported health issues in the 4-weeks before donation.""",,2020-06-01,2020-06-30,Blood donors,All,Adults (18-64 years),30.0,39.0,Age,30-39,261,0.107,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Nayara Vale,Universidade Federal de São Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.clinsp.2022.100016,2022-03-30,2024-03-01,Verified,moya_rios_do_vale_increasing_2022,BRA
220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020June_Sex_Male,220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020June,"Increasing rate of anti-SARS-CoV-2 antibodies between the first and second waves of COVID-19 in Sao Paulo, Brazil: A cross-sectional blood donors-based study",2022-02-18,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,São Paulo,Sao Paulo city (Campo Limpo in the south and Tatuape in the east regions of the city); Sao Bernardo do Campo; Sorocaba.,"blood samples from sera banks in Sao Paulo, Brazil.

""all blood donors must have been free of respiratory symptoms for at least 30 days before the donation.""

""all subjects were healthy at the time of donation and had no reported health issues in the 4-weeks before donation.""",,2020-06-01,2020-06-30,Blood donors,Male,Adults (18-64 years),,,Sex/Gender,,496,0.121,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Nayara Vale,Universidade Federal de São Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.clinsp.2022.100016,2022-05-31,2024-03-01,Verified,moya_rios_do_vale_increasing_2022,BRA
220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020June_Capital_SaoPauloCity,220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020June,"Increasing rate of anti-SARS-CoV-2 antibodies between the first and second waves of COVID-19 in Sao Paulo, Brazil: A cross-sectional blood donors-based study",2022-02-18,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,São Paulo,Sao Paulo city (Campo Limpo in the south and Tatuape in the east regions of the city),"blood samples from sera banks in Sao Paulo, Brazil.

""all blood donors must have been free of respiratory symptoms for at least 30 days before the donation.""

""all subjects were healthy at the time of donation and had no reported health issues in the 4-weeks before donation.""",,2020-06-01,2020-06-30,Blood donors,All,Adults (18-64 years),,,Geographical area,Location: Sao Paulo city,447,0.18100000000000002,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Nayara Vale,Universidade Federal de São Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.clinsp.2022.100016,2022-05-31,2024-03-01,Verified,moya_rios_do_vale_increasing_2022,BRA
220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020June_Metropolitan_SaoBernardoDoCampo,220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020June,"Increasing rate of anti-SARS-CoV-2 antibodies between the first and second waves of COVID-19 in Sao Paulo, Brazil: A cross-sectional blood donors-based study",2022-02-18,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,São Paulo,Sao Bernardo do Campo,"blood samples from sera banks in Sao Paulo, Brazil.

""all blood donors must have been free of respiratory symptoms for at least 30 days before the donation.""

""all subjects were healthy at the time of donation and had no reported health issues in the 4-weeks before donation.""",,2020-06-01,2020-06-30,Blood donors,All,Adults (18-64 years),,,Geographical area,Location: Sao Bernardo do Campo,255,0.08199999999999999,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Nayara Vale,Universidade Federal de São Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.clinsp.2022.100016,2022-05-31,2024-03-01,Verified,moya_rios_do_vale_increasing_2022,BRA
220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020June_Countryside_Sorocaba,220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020June,"Increasing rate of anti-SARS-CoV-2 antibodies between the first and second waves of COVID-19 in Sao Paulo, Brazil: A cross-sectional blood donors-based study",2022-02-18,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,São Paulo,Sorocaba,"blood samples from sera banks in Sao Paulo, Brazil.

""all blood donors must have been free of respiratory symptoms for at least 30 days before the donation.""

""all subjects were healthy at the time of donation and had no reported health issues in the 4-weeks before donation.""",,2020-06-01,2020-06-30,Blood donors,All,Adults (18-64 years),,,Geographical area,Location: Sorocaba,224,0.018000000000000002,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Nayara Vale,Universidade Federal de São Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.clinsp.2022.100016,2022-05-31,2024-03-01,Verified,moya_rios_do_vale_increasing_2022,BRA
220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020June_Age40-49,220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020June,"Increasing rate of anti-SARS-CoV-2 antibodies between the first and second waves of COVID-19 in Sao Paulo, Brazil: A cross-sectional blood donors-based study",2022-02-18,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,São Paulo,Sao Paulo city (Campo Limpo in the south and Tatuape in the east regions of the city); Sao Bernardo do Campo; Sorocaba.,"blood samples from sera banks in Sao Paulo, Brazil.

""all blood donors must have been free of respiratory symptoms for at least 30 days before the donation.""

""all subjects were healthy at the time of donation and had no reported health issues in the 4-weeks before donation.""",,2020-06-01,2020-06-30,Blood donors,All,Adults (18-64 years),40.0,49.0,Age,40-49,214,0.14,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Nayara Vale,Universidade Federal de São Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.clinsp.2022.100016,2022-03-30,2024-03-01,Verified,moya_rios_do_vale_increasing_2022,BRA
220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020June_Age16-29,220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020June,"Increasing rate of anti-SARS-CoV-2 antibodies between the first and second waves of COVID-19 in Sao Paulo, Brazil: A cross-sectional blood donors-based study",2022-02-18,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,São Paulo,Sao Paulo city (Campo Limpo in the south and Tatuape in the east regions of the city); Sao Bernardo do Campo; Sorocaba.,"blood samples from sera banks in Sao Paulo, Brazil.

""all blood donors must have been free of respiratory symptoms for at least 30 days before the donation.""

""all subjects were healthy at the time of donation and had no reported health issues in the 4-weeks before donation.""",,2020-06-01,2020-06-30,Blood donors,All,Adults (18-64 years),16.0,29.0,Age,16-29,279,0.14,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Nayara Vale,Universidade Federal de São Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.clinsp.2022.100016,2022-03-30,2024-03-01,Verified,moya_rios_do_vale_increasing_2022,BRA
220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020June_Age>=50,220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020June,"Increasing rate of anti-SARS-CoV-2 antibodies between the first and second waves of COVID-19 in Sao Paulo, Brazil: A cross-sectional blood donors-based study",2022-02-18,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,São Paulo,Sao Paulo city (Campo Limpo in the south and Tatuape in the east regions of the city); Sao Bernardo do Campo; Sorocaba.,"blood samples from sera banks in Sao Paulo, Brazil.

""all blood donors must have been free of respiratory symptoms for at least 30 days before the donation.""

""all subjects were healthy at the time of donation and had no reported health issues in the 4-weeks before donation.""",,2020-06-01,2020-06-30,Blood donors,All,Adults (18-64 years),50.0,69.0,Age,≥50,172,0.052000000000000005,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Nayara Vale,Universidade Federal de São Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.clinsp.2022.100016,2022-03-30,2024-03-01,Verified,moya_rios_do_vale_increasing_2022,BRA
220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020June_Sex_Female,220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020June,"Increasing rate of anti-SARS-CoV-2 antibodies between the first and second waves of COVID-19 in Sao Paulo, Brazil: A cross-sectional blood donors-based study",2022-02-18,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,São Paulo,Sao Paulo city (Campo Limpo in the south and Tatuape in the east regions of the city); Sao Bernardo do Campo; Sorocaba.,"blood samples from sera banks in Sao Paulo, Brazil.

""all blood donors must have been free of respiratory symptoms for at least 30 days before the donation.""

""all subjects were healthy at the time of donation and had no reported health issues in the 4-weeks before donation.""",,2020-06-01,2020-06-30,Blood donors,Female,Adults (18-64 years),,,Sex/Gender,,430,0.107,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Nayara Vale,Universidade Federal de São Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.clinsp.2022.100016,2022-05-31,2024-03-01,Verified,moya_rios_do_vale_increasing_2022,BRA
220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020October_Overall,220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020October,"Increasing rate of anti-SARS-CoV-2 antibodies between the first and second waves of COVID-19 in Sao Paulo, Brazil: A cross-sectional blood donors-based study",2022-02-18,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,São Paulo,Sao Paulo city (Campo Limpo in the south and Tatuape in the east regions of the city); Sao Bernardo do Campo; Sorocaba.,"blood samples from sera banks in Sao Paulo, Brazil.

""all blood donors must have been free of respiratory symptoms for at least 30 days before the donation.""

""all subjects were healthy at the time of donation and had no reported health issues in the 4-weeks before donation.""",,2020-10-01,2020-10-31,Blood donors,All,Adults (18-64 years),16.0,69.0,Primary Estimate,,940,0.22,,,True,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Nayara Vale,Universidade Federal de São Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.clinsp.2022.100016,2022-03-29,2024-03-01,Verified,moya_rios_do_vale_increasing_2022,BRA
220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020October_Age16-29,220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020October,"Increasing rate of anti-SARS-CoV-2 antibodies between the first and second waves of COVID-19 in Sao Paulo, Brazil: A cross-sectional blood donors-based study",2022-02-18,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,São Paulo,Sao Paulo city (Campo Limpo in the south and Tatuape in the east regions of the city); Sao Bernardo do Campo; Sorocaba.,"blood samples from sera banks in Sao Paulo, Brazil.

""all blood donors must have been free of respiratory symptoms for at least 30 days before the donation.""

""all subjects were healthy at the time of donation and had no reported health issues in the 4-weeks before donation.""",,2020-10-01,2020-10-31,Blood donors,All,Adults (18-64 years),16.0,29.0,Age,16-29,277,0.242,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Nayara Vale,Universidade Federal de São Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.clinsp.2022.100016,2022-03-30,2024-03-01,Verified,moya_rios_do_vale_increasing_2022,BRA
220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020October_Age>=50,220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020October,"Increasing rate of anti-SARS-CoV-2 antibodies between the first and second waves of COVID-19 in Sao Paulo, Brazil: A cross-sectional blood donors-based study",2022-02-18,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,São Paulo,Sao Paulo city (Campo Limpo in the south and Tatuape in the east regions of the city); Sao Bernardo do Campo; Sorocaba.,"blood samples from sera banks in Sao Paulo, Brazil.

""all blood donors must have been free of respiratory symptoms for at least 30 days before the donation.""

""all subjects were healthy at the time of donation and had no reported health issues in the 4-weeks before donation.""",,2020-10-01,2020-10-31,Blood donors,All,Adults (18-64 years),50.0,69.0,Age,≥50,171,0.17,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Nayara Vale,Universidade Federal de São Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.clinsp.2022.100016,2022-03-30,2024-03-01,Verified,moya_rios_do_vale_increasing_2022,BRA
220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020October_Age40-49,220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020October,"Increasing rate of anti-SARS-CoV-2 antibodies between the first and second waves of COVID-19 in Sao Paulo, Brazil: A cross-sectional blood donors-based study",2022-02-18,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,São Paulo,Sao Paulo city (Campo Limpo in the south and Tatuape in the east regions of the city); Sao Bernardo do Campo; Sorocaba.,"blood samples from sera banks in Sao Paulo, Brazil.

""all blood donors must have been free of respiratory symptoms for at least 30 days before the donation.""

""all subjects were healthy at the time of donation and had no reported health issues in the 4-weeks before donation.""",,2020-10-01,2020-10-31,Blood donors,All,Adults (18-64 years),40.0,49.0,Age,40-49,224,0.228,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Nayara Vale,Universidade Federal de São Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.clinsp.2022.100016,2022-03-30,2024-03-01,Verified,moya_rios_do_vale_increasing_2022,BRA
220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020October_Metropolitan_SaoBernardoDoCampo,220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020October,"Increasing rate of anti-SARS-CoV-2 antibodies between the first and second waves of COVID-19 in Sao Paulo, Brazil: A cross-sectional blood donors-based study",2022-02-18,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,São Paulo,Sao Bernardo do Campo,"blood samples from sera banks in Sao Paulo, Brazil.

""all blood donors must have been free of respiratory symptoms for at least 30 days before the donation.""

""all subjects were healthy at the time of donation and had no reported health issues in the 4-weeks before donation.""",,2020-10-01,2020-10-31,Blood donors,All,Adults (18-64 years),,,Geographical area,Location: Sao Bernardo do Campo,230,0.21300000000000002,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Nayara Vale,Universidade Federal de São Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.clinsp.2022.100016,2022-05-31,2024-03-01,Verified,moya_rios_do_vale_increasing_2022,BRA
220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020October_Capital_SaoPauloCity,220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020October,"Increasing rate of anti-SARS-CoV-2 antibodies between the first and second waves of COVID-19 in Sao Paulo, Brazil: A cross-sectional blood donors-based study",2022-02-18,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,São Paulo,Sao Paulo city (Campo Limpo in the south and Tatuape in the east regions of the city),"blood samples from sera banks in Sao Paulo, Brazil.

""all blood donors must have been free of respiratory symptoms for at least 30 days before the donation.""

""all subjects were healthy at the time of donation and had no reported health issues in the 4-weeks before donation.""",,2020-10-01,2020-10-31,Blood donors,All,Adults (18-64 years),,,Geographical area,Location: Sao Paulo city,480,0.273,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Nayara Vale,Universidade Federal de São Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.clinsp.2022.100016,2022-05-31,2024-03-01,Verified,moya_rios_do_vale_increasing_2022,BRA
220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020October_Sex_Female,220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020October,"Increasing rate of anti-SARS-CoV-2 antibodies between the first and second waves of COVID-19 in Sao Paulo, Brazil: A cross-sectional blood donors-based study",2022-02-18,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,São Paulo,Sao Paulo city (Campo Limpo in the south and Tatuape in the east regions of the city); Sao Bernardo do Campo; Sorocaba.,"blood samples from sera banks in Sao Paulo, Brazil.

""all blood donors must have been free of respiratory symptoms for at least 30 days before the donation.""

""all subjects were healthy at the time of donation and had no reported health issues in the 4-weeks before donation.""",,2020-10-01,2020-10-31,Blood donors,Female,Adults (18-64 years),,,Sex/Gender,,459,0.2,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Nayara Vale,Universidade Federal de São Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.clinsp.2022.100016,2022-05-31,2024-03-01,Verified,moya_rios_do_vale_increasing_2022,BRA
220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020October_Age30-39,220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020October,"Increasing rate of anti-SARS-CoV-2 antibodies between the first and second waves of COVID-19 in Sao Paulo, Brazil: A cross-sectional blood donors-based study",2022-02-18,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,São Paulo,Sao Paulo city (Campo Limpo in the south and Tatuape in the east regions of the city); Sao Bernardo do Campo; Sorocaba.,"blood samples from sera banks in Sao Paulo, Brazil.

""all blood donors must have been free of respiratory symptoms for at least 30 days before the donation.""

""all subjects were healthy at the time of donation and had no reported health issues in the 4-weeks before donation.""",,2020-10-01,2020-10-31,Blood donors,All,Adults (18-64 years),30.0,39.0,Age,30-39,268,0.22399999999999998,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Nayara Vale,Universidade Federal de São Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.clinsp.2022.100016,2022-03-30,2024-03-01,Verified,moya_rios_do_vale_increasing_2022,BRA
220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020October_Countryside_Sorocaba,220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020October,"Increasing rate of anti-SARS-CoV-2 antibodies between the first and second waves of COVID-19 in Sao Paulo, Brazil: A cross-sectional blood donors-based study",2022-02-18,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,São Paulo,Sorocaba,"blood samples from sera banks in Sao Paulo, Brazil.

""all blood donors must have been free of respiratory symptoms for at least 30 days before the donation.""

""all subjects were healthy at the time of donation and had no reported health issues in the 4-weeks before donation.""",,2020-10-01,2020-10-31,Blood donors,All,Adults (18-64 years),,,Geographical area,Location: Sorocaba,230,0.11699999999999999,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Nayara Vale,Universidade Federal de São Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.clinsp.2022.100016,2022-05-31,2024-03-01,Verified,moya_rios_do_vale_increasing_2022,BRA
220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020October_Sex_Male,220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2020October,"Increasing rate of anti-SARS-CoV-2 antibodies between the first and second waves of COVID-19 in Sao Paulo, Brazil: A cross-sectional blood donors-based study",2022-02-18,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,São Paulo,Sao Paulo city (Campo Limpo in the south and Tatuape in the east regions of the city); Sao Bernardo do Campo; Sorocaba.,"blood samples from sera banks in Sao Paulo, Brazil.

""all blood donors must have been free of respiratory symptoms for at least 30 days before the donation.""

""all subjects were healthy at the time of donation and had no reported health issues in the 4-weeks before donation.""",,2020-10-01,2020-10-31,Blood donors,Male,Adults (18-64 years),,,Sex/Gender,,481,0.239,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Nayara Vale,Universidade Federal de São Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.clinsp.2022.100016,2022-05-31,2024-03-01,Verified,moya_rios_do_vale_increasing_2022,BRA
220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2021February_Overall,220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2021February,"Increasing rate of anti-SARS-CoV-2 antibodies between the first and second waves of COVID-19 in Sao Paulo, Brazil: A cross-sectional blood donors-based study",2022-02-18,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,São Paulo,Sao Paulo city (Campo Limpo in the south and Tatuape in the east regions of the city); Sao Bernardo do Campo; Sorocaba.,"blood samples from sera banks in Sao Paulo, Brazil.

""all blood donors must have been free of respiratory symptoms for at least 30 days before the donation.""

""all subjects were healthy at the time of donation and had no reported health issues in the 4-weeks before donation.""","""A total of 10 samples of the February group were not eligible for this study due to previous vaccination.""",2021-02-01,2021-02-28,Blood donors,All,Adults (18-64 years),16.0,69.0,Primary Estimate,,940,0.309,,,True,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Nayara Vale,Universidade Federal de São Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.clinsp.2022.100016,2022-03-29,2024-03-01,Verified,moya_rios_do_vale_increasing_2022,BRA
220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2021February_Metropolitan_SaoBernardoDoCampo,220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2021February,"Increasing rate of anti-SARS-CoV-2 antibodies between the first and second waves of COVID-19 in Sao Paulo, Brazil: A cross-sectional blood donors-based study",2022-02-18,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,São Paulo,Sao Bernardo do Campo,"blood samples from sera banks in Sao Paulo, Brazil.

""all blood donors must have been free of respiratory symptoms for at least 30 days before the donation.""

""all subjects were healthy at the time of donation and had no reported health issues in the 4-weeks before donation.""","""A total of 10 samples of the February group were not eligible for this study due to previous vaccination.""",2021-02-01,2021-02-28,Blood donors,All,Adults (18-64 years),,,Geographical area,Location: Sao Bernardo do Campo,230,0.313,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Nayara Vale,Universidade Federal de São Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.clinsp.2022.100016,2022-05-31,2024-03-01,Verified,moya_rios_do_vale_increasing_2022,BRA
220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2021February_Age40-49,220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2021February,"Increasing rate of anti-SARS-CoV-2 antibodies between the first and second waves of COVID-19 in Sao Paulo, Brazil: A cross-sectional blood donors-based study",2022-02-18,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,São Paulo,Sao Paulo city (Campo Limpo in the south and Tatuape in the east regions of the city); Sao Bernardo do Campo; Sorocaba.,"blood samples from sera banks in Sao Paulo, Brazil.

""all blood donors must have been free of respiratory symptoms for at least 30 days before the donation.""

""all subjects were healthy at the time of donation and had no reported health issues in the 4-weeks before donation.""","""A total of 10 samples of the February group were not eligible for this study due to previous vaccination.""",2021-02-01,2021-02-28,Blood donors,All,Adults (18-64 years),40.0,49.0,Age,40-49,248,0.262,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Nayara Vale,Universidade Federal de São Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.clinsp.2022.100016,2022-03-30,2024-03-01,Verified,moya_rios_do_vale_increasing_2022,BRA
220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2021February_Age30-39,220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2021February,"Increasing rate of anti-SARS-CoV-2 antibodies between the first and second waves of COVID-19 in Sao Paulo, Brazil: A cross-sectional blood donors-based study",2022-02-18,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,São Paulo,Sao Paulo city (Campo Limpo in the south and Tatuape in the east regions of the city); Sao Bernardo do Campo; Sorocaba.,"blood samples from sera banks in Sao Paulo, Brazil.

""all blood donors must have been free of respiratory symptoms for at least 30 days before the donation.""

""all subjects were healthy at the time of donation and had no reported health issues in the 4-weeks before donation.""","""A total of 10 samples of the February group were not eligible for this study due to previous vaccination.""",2021-02-01,2021-02-28,Blood donors,All,Adults (18-64 years),30.0,39.0,Age,30-39,245,0.4,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Nayara Vale,Universidade Federal de São Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.clinsp.2022.100016,2022-03-30,2024-03-01,Verified,moya_rios_do_vale_increasing_2022,BRA
220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2021February_Age16-29,220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2021February,"Increasing rate of anti-SARS-CoV-2 antibodies between the first and second waves of COVID-19 in Sao Paulo, Brazil: A cross-sectional blood donors-based study",2022-02-18,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,São Paulo,Sao Paulo city (Campo Limpo in the south and Tatuape in the east regions of the city); Sao Bernardo do Campo; Sorocaba.,"blood samples from sera banks in Sao Paulo, Brazil.

""all blood donors must have been free of respiratory symptoms for at least 30 days before the donation.""

""all subjects were healthy at the time of donation and had no reported health issues in the 4-weeks before donation.""","""A total of 10 samples of the February group were not eligible for this study due to previous vaccination.""",2021-02-01,2021-02-28,Blood donors,All,Adults (18-64 years),16.0,29.0,Age,16-29,271,0.31,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Nayara Vale,Universidade Federal de São Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.clinsp.2022.100016,2022-03-30,2024-03-01,Verified,moya_rios_do_vale_increasing_2022,BRA
220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2021February_Sex_Male,220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2021February,"Increasing rate of anti-SARS-CoV-2 antibodies between the first and second waves of COVID-19 in Sao Paulo, Brazil: A cross-sectional blood donors-based study",2022-02-18,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,São Paulo,Sao Paulo city (Campo Limpo in the south and Tatuape in the east regions of the city); Sao Bernardo do Campo; Sorocaba.,"blood samples from sera banks in Sao Paulo, Brazil.

""all blood donors must have been free of respiratory symptoms for at least 30 days before the donation.""

""all subjects were healthy at the time of donation and had no reported health issues in the 4-weeks before donation.""","""A total of 10 samples of the February group were not eligible for this study due to previous vaccination.""",2021-02-01,2021-02-28,Blood donors,Male,Adults (18-64 years),,,Sex/Gender,,515,0.315,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Nayara Vale,Universidade Federal de São Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.clinsp.2022.100016,2022-05-31,2024-03-01,Verified,moya_rios_do_vale_increasing_2022,BRA
220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2021February_Capital_SaoPauloCity,220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2021February,"Increasing rate of anti-SARS-CoV-2 antibodies between the first and second waves of COVID-19 in Sao Paulo, Brazil: A cross-sectional blood donors-based study",2022-02-18,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,São Paulo,Sao Paulo city (Campo Limpo in the south and Tatuape in the east regions of the city),"blood samples from sera banks in Sao Paulo, Brazil.

""all blood donors must have been free of respiratory symptoms for at least 30 days before the donation.""

""all subjects were healthy at the time of donation and had no reported health issues in the 4-weeks before donation.""","""A total of 10 samples of the February group were not eligible for this study due to previous vaccination.""",2021-02-01,2021-02-28,Blood donors,All,Adults (18-64 years),,,Geographical area,Location: Sao Paulo city,480,0.363,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Nayara Vale,Universidade Federal de São Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.clinsp.2022.100016,2022-05-31,2024-03-01,Verified,moya_rios_do_vale_increasing_2022,BRA
220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2021February_Age>=50,220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2021February,"Increasing rate of anti-SARS-CoV-2 antibodies between the first and second waves of COVID-19 in Sao Paulo, Brazil: A cross-sectional blood donors-based study",2022-02-18,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,São Paulo,Sao Paulo city (Campo Limpo in the south and Tatuape in the east regions of the city); Sao Bernardo do Campo; Sorocaba.,"blood samples from sera banks in Sao Paulo, Brazil.

""all blood donors must have been free of respiratory symptoms for at least 30 days before the donation.""

""all subjects were healthy at the time of donation and had no reported health issues in the 4-weeks before donation.""","""A total of 10 samples of the February group were not eligible for this study due to previous vaccination.""",2021-02-01,2021-02-28,Blood donors,All,Adults (18-64 years),50.0,69.0,Age,≥50,176,0.25,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Nayara Vale,Universidade Federal de São Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.clinsp.2022.100016,2022-03-30,2024-03-01,Verified,moya_rios_do_vale_increasing_2022,BRA
220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2021February_Countryside_Sorocaba,220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2021February,"Increasing rate of anti-SARS-CoV-2 antibodies between the first and second waves of COVID-19 in Sao Paulo, Brazil: A cross-sectional blood donors-based study",2022-02-18,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,São Paulo,Sorocaba,"blood samples from sera banks in Sao Paulo, Brazil.

""all blood donors must have been free of respiratory symptoms for at least 30 days before the donation.""

""all subjects were healthy at the time of donation and had no reported health issues in the 4-weeks before donation.""","""A total of 10 samples of the February group were not eligible for this study due to previous vaccination.""",2021-02-01,2021-02-28,Blood donors,All,Adults (18-64 years),,,Geographical area,Location: Sorocaba,230,0.19100000000000003,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Nayara Vale,Universidade Federal de São Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.clinsp.2022.100016,2022-05-31,2024-03-01,Verified,moya_rios_do_vale_increasing_2022,BRA
220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2021February_Sex_Female,220218_SaoPaulo_UniversidadeFederaldeSaoPaulo_2021February,"Increasing rate of anti-SARS-CoV-2 antibodies between the first and second waves of COVID-19 in Sao Paulo, Brazil: A cross-sectional blood donors-based study",2022-02-18,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,São Paulo,Sao Paulo city (Campo Limpo in the south and Tatuape in the east regions of the city); Sao Bernardo do Campo; Sorocaba.,"blood samples from sera banks in Sao Paulo, Brazil.

""all blood donors must have been free of respiratory symptoms for at least 30 days before the donation.""

""all subjects were healthy at the time of donation and had no reported health issues in the 4-weeks before donation.""","""A total of 10 samples of the February group were not eligible for this study due to previous vaccination.""",2021-02-01,2021-02-28,Blood donors,Female,Adults (18-64 years),,,Sex/Gender,,425,0.30100000000000005,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Nayara Vale,Universidade Federal de São Paulo,Unity-Aligned,https://dx.doi.org/10.1016/j.clinsp.2022.100016,2022-05-31,2024-03-01,Verified,moya_rios_do_vale_increasing_2022,BRA
220218_MinasGerais_FundacaoHemominas_Overall_TestAdj,220218_MinasGerais_FundacaoHemominas,"SARS-CoV-2 IgG Seroprevalence among Blood Donors as a Monitor of the COVID-19 Epidemic, Brazil",2022-02-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Minas Gerais,"Belo Horizonte, Governador Valadares, Juiz de Fora, Montes Claros, Pouso Alegre, Uberaba, and Uberlândia","blood donors at 7 blood donation centers (Fundação HEMOMINAS) in Minas Gerais, Brazil (in Brazil, populations who cannot donate blood include persons <16 and >70 years of age and residents of nursing homes and prisons; excluded asymptomatic candidates who had contact with infected persons <30 days before going to a donation center; those donors had to wait 14 days from the date they were first seen at the blood center before they could donate; also excluded potential blood donors who had a COVID-19 diagnosis until >30 days after their symptoms disappeared)",excluded samples from the same donors that were previously IgG positive,2020-03-01,2020-12-31,Blood donors,All,Multiple groups,,,Primary Estimate,,7837,0.052000000000000005,0.047,0.057999999999999996,True,True,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9,0.99,['Moderate'],No,Yes,Yes,Yes,No,Yes,Yes,Yes,,Daniel Chaves,Fundacao Hemominas,Unity-Aligned,https://dx.doi.org/10.3201/eid2804.211961,2022-02-28,2023-08-15,Verified,goncalves_chaves_sars-cov-2_2022,BRA
220218_MinasGerais_FundacaoHemominas_Female,220218_MinasGerais_FundacaoHemominas,"SARS-CoV-2 IgG Seroprevalence among Blood Donors as a Monitor of the COVID-19 Epidemic, Brazil",2022-02-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Minas Gerais,"Belo Horizonte, Governador Valadares, Juiz de Fora, Montes Claros, Pouso Alegre, Uberaba, and Uberlândia","blood donors at 7 blood donation centers (Fundação HEMOMINAS) in Minas Gerais, Brazil (in Brazil, populations who cannot donate blood include persons <16 and >70 years of age and residents of nursing homes and prisons; excluded asymptomatic candidates who had contact with infected persons <30 days before going to a donation center; those donors had to wait 14 days from the date they were first seen at the blood center before they could donate; also excluded potential blood donors who had a COVID-19 diagnosis until >30 days after their symptoms disappeared)",excluded samples from the same donors that were previously IgG positive,2020-03-01,2020-12-31,Blood donors,Female,Multiple groups,,,Sex/Gender,,3553,0.04730000000000001,0.040999999999999995,0.055,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9,0.99,['Moderate'],No,Yes,Yes,Yes,No,Yes,Yes,Yes,,Daniel Chaves,Fundacao Hemominas,Unity-Aligned,https://dx.doi.org/10.3201/eid2804.211961,2022-02-28,2024-03-01,Verified,goncalves_chaves_sars-cov-2_2022,BRA
220218_MinasGerais_FundacaoHemominas_16-30,220218_MinasGerais_FundacaoHemominas,"SARS-CoV-2 IgG Seroprevalence among Blood Donors as a Monitor of the COVID-19 Epidemic, Brazil",2022-02-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Minas Gerais,"Belo Horizonte, Governador Valadares, Juiz de Fora, Montes Claros, Pouso Alegre, Uberaba, and Uberlândia","blood donors at 7 blood donation centers (Fundação HEMOMINAS) in Minas Gerais, Brazil (in Brazil, populations who cannot donate blood include persons <16 and >70 years of age and residents of nursing homes and prisons; excluded asymptomatic candidates who had contact with infected persons <30 days before going to a donation center; those donors had to wait 14 days from the date they were first seen at the blood center before they could donate; also excluded potential blood donors who had a COVID-19 diagnosis until >30 days after their symptoms disappeared)",excluded samples from the same donors that were previously IgG positive,2020-03-01,2020-12-31,Blood donors,All,Multiple groups,,,Age,16-30,2895,0.05280000000000001,0.045,0.062000000000000006,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9,0.99,['Moderate'],No,Yes,Yes,Yes,No,Yes,Yes,Yes,,Daniel Chaves,Fundacao Hemominas,Unity-Aligned,https://dx.doi.org/10.3201/eid2804.211961,2022-02-28,2024-03-01,Verified,goncalves_chaves_sars-cov-2_2022,BRA
220218_MinasGerais_FundacaoHemominas_31-40,220218_MinasGerais_FundacaoHemominas,"SARS-CoV-2 IgG Seroprevalence among Blood Donors as a Monitor of the COVID-19 Epidemic, Brazil",2022-02-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Minas Gerais,"Belo Horizonte, Governador Valadares, Juiz de Fora, Montes Claros, Pouso Alegre, Uberaba, and Uberlândia","blood donors at 7 blood donation centers (Fundação HEMOMINAS) in Minas Gerais, Brazil (in Brazil, populations who cannot donate blood include persons <16 and >70 years of age and residents of nursing homes and prisons; excluded asymptomatic candidates who had contact with infected persons <30 days before going to a donation center; those donors had to wait 14 days from the date they were first seen at the blood center before they could donate; also excluded potential blood donors who had a COVID-19 diagnosis until >30 days after their symptoms disappeared)",excluded samples from the same donors that were previously IgG positive,2020-03-01,2020-12-31,Blood donors,All,Adults (18-64 years),,,Age,31-40,2330,0.0579,0.049,0.068,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9,0.99,['Moderate'],No,Yes,Yes,Yes,No,Yes,Yes,Yes,,Daniel Chaves,Fundacao Hemominas,Unity-Aligned,https://dx.doi.org/10.3201/eid2804.211961,2022-02-28,2024-03-01,Verified,goncalves_chaves_sars-cov-2_2022,BRA
220218_MinasGerais_FundacaoHemominas_Overall_Unadj,220218_MinasGerais_FundacaoHemominas,"SARS-CoV-2 IgG Seroprevalence among Blood Donors as a Monitor of the COVID-19 Epidemic, Brazil",2022-02-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Minas Gerais,"Belo Horizonte, Governador Valadares, Juiz de Fora, Montes Claros, Pouso Alegre, Uberaba, and Uberlândia","blood donors at 7 blood donation centers (Fundação HEMOMINAS) in Minas Gerais, Brazil (in Brazil, populations who cannot donate blood include persons <16 and >70 years of age and residents of nursing homes and prisons; excluded asymptomatic candidates who had contact with infected persons <30 days before going to a donation center; those donors had to wait 14 days from the date they were first seen at the blood center before they could donate; also excluded potential blood donors who had a COVID-19 diagnosis until >30 days after their symptoms disappeared)",excluded samples from the same donors that were previously IgG positive,2020-03-01,2020-12-31,Blood donors,All,Multiple groups,,,Analysis,,7837,0.0563,0.051,0.062000000000000006,,,,,True,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9,0.99,['Moderate'],No,Yes,Yes,Yes,No,Yes,Yes,Yes,,Daniel Chaves,Fundacao Hemominas,Unity-Aligned,https://dx.doi.org/10.3201/eid2804.211961,2022-02-28,2024-03-01,Verified,goncalves_chaves_sars-cov-2_2022,BRA
220218_MinasGerais_FundacaoHemominas_51-60,220218_MinasGerais_FundacaoHemominas,"SARS-CoV-2 IgG Seroprevalence among Blood Donors as a Monitor of the COVID-19 Epidemic, Brazil",2022-02-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Minas Gerais,"Belo Horizonte, Governador Valadares, Juiz de Fora, Montes Claros, Pouso Alegre, Uberaba, and Uberlândia","blood donors at 7 blood donation centers (Fundação HEMOMINAS) in Minas Gerais, Brazil (in Brazil, populations who cannot donate blood include persons <16 and >70 years of age and residents of nursing homes and prisons; excluded asymptomatic candidates who had contact with infected persons <30 days before going to a donation center; those donors had to wait 14 days from the date they were first seen at the blood center before they could donate; also excluded potential blood donors who had a COVID-19 diagnosis until >30 days after their symptoms disappeared)",excluded samples from the same donors that were previously IgG positive,2020-03-01,2020-12-31,Blood donors,All,Adults (18-64 years),,,Age,51-60,829,0.0386,0.027999999999999997,0.054000000000000006,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9,0.99,['Moderate'],No,Yes,Yes,Yes,No,Yes,Yes,Yes,,Daniel Chaves,Fundacao Hemominas,Unity-Aligned,https://dx.doi.org/10.3201/eid2804.211961,2022-02-28,2024-03-01,Verified,goncalves_chaves_sars-cov-2_2022,BRA
220218_MinasGerais_FundacaoHemominas_Male,220218_MinasGerais_FundacaoHemominas,"SARS-CoV-2 IgG Seroprevalence among Blood Donors as a Monitor of the COVID-19 Epidemic, Brazil",2022-02-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Minas Gerais,"Belo Horizonte, Governador Valadares, Juiz de Fora, Montes Claros, Pouso Alegre, Uberaba, and Uberlândia","blood donors at 7 blood donation centers (Fundação HEMOMINAS) in Minas Gerais, Brazil (in Brazil, populations who cannot donate blood include persons <16 and >70 years of age and residents of nursing homes and prisons; excluded asymptomatic candidates who had contact with infected persons <30 days before going to a donation center; those donors had to wait 14 days from the date they were first seen at the blood center before they could donate; also excluded potential blood donors who had a COVID-19 diagnosis until >30 days after their symptoms disappeared)",excluded samples from the same donors that were previously IgG positive,2020-03-01,2020-12-31,Blood donors,Male,Multiple groups,,,Sex/Gender,,4284,0.0637,0.057,0.071,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9,0.99,['Moderate'],No,Yes,Yes,Yes,No,Yes,Yes,Yes,,Daniel Chaves,Fundacao Hemominas,Unity-Aligned,https://dx.doi.org/10.3201/eid2804.211961,2022-02-28,2024-03-01,Verified,goncalves_chaves_sars-cov-2_2022,BRA
220218_MinasGerais_FundacaoHemominas_61-70,220218_MinasGerais_FundacaoHemominas,"SARS-CoV-2 IgG Seroprevalence among Blood Donors as a Monitor of the COVID-19 Epidemic, Brazil",2022-02-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Minas Gerais,"Belo Horizonte, Governador Valadares, Juiz de Fora, Montes Claros, Pouso Alegre, Uberaba, and Uberlândia","blood donors at 7 blood donation centers (Fundação HEMOMINAS) in Minas Gerais, Brazil (in Brazil, populations who cannot donate blood include persons <16 and >70 years of age and residents of nursing homes and prisons; excluded asymptomatic candidates who had contact with infected persons <30 days before going to a donation center; those donors had to wait 14 days from the date they were first seen at the blood center before they could donate; also excluded potential blood donors who had a COVID-19 diagnosis until >30 days after their symptoms disappeared)",excluded samples from the same donors that were previously IgG positive,2020-03-01,2020-12-31,Blood donors,All,Multiple groups,,,Age,61-70,82,0.0732,0.034,0.151,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9,0.99,['Moderate'],No,Yes,Yes,Yes,No,Yes,Yes,Yes,,Daniel Chaves,Fundacao Hemominas,Unity-Aligned,https://dx.doi.org/10.3201/eid2804.211961,2022-02-28,2024-03-01,Verified,goncalves_chaves_sars-cov-2_2022,BRA
220218_MinasGerais_FundacaoHemominas_41-50,220218_MinasGerais_FundacaoHemominas,"SARS-CoV-2 IgG Seroprevalence among Blood Donors as a Monitor of the COVID-19 Epidemic, Brazil",2022-02-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Minas Gerais,"Belo Horizonte, Governador Valadares, Juiz de Fora, Montes Claros, Pouso Alegre, Uberaba, and Uberlândia","blood donors at 7 blood donation centers (Fundação HEMOMINAS) in Minas Gerais, Brazil (in Brazil, populations who cannot donate blood include persons <16 and >70 years of age and residents of nursing homes and prisons; excluded asymptomatic candidates who had contact with infected persons <30 days before going to a donation center; those donors had to wait 14 days from the date they were first seen at the blood center before they could donate; also excluded potential blood donors who had a COVID-19 diagnosis until >30 days after their symptoms disappeared)",excluded samples from the same donors that were previously IgG positive,2020-03-01,2020-12-31,Blood donors,All,Adults (18-64 years),,,Age,41-50,1701,0.0676,0.057,0.081,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9,0.99,['Moderate'],No,Yes,Yes,Yes,No,Yes,Yes,Yes,,Daniel Chaves,Fundacao Hemominas,Unity-Aligned,https://dx.doi.org/10.3201/eid2804.211961,2022-02-28,2024-03-01,Verified,goncalves_chaves_sars-cov-2_2022,BRA
220222_Brasilia_MinisteriodaSaudeBrazil_Overall,220222_Brasilia_MinisteriodaSaudeBrazil,"SARS CoV-2 seroprevalence and diagnostic accuracy during a COVID-19 outbreak in a major penitentiary complex in Brazil, June to July 2020",2022-02-22,Journal Article (Peer-Reviewed),Local,Prospective cohort,Brazil,Federal District,Brasilia,"Prisoners representative of the population from the
penitentiary complex. Unit I houses prisoners under pretrial detention, Unit II houses persons
under a semi-open regime and Units III and IV house convicted prisoners","Not including prisoners who had recently been transferred to the
prison complex and were under quarantine in a separate unit",2020-06-17,2020-07-22,Persons who are incarcerated,Male,Adults (18-64 years),,,Primary Estimate,,455,0.8109999999999999,0.7440000000000001,0.878,True,,,,True,Stratified probability,"Architect Anti-SARS-CoV-2 IgM,Abbott Architect SARS-CoV-2 IgG",Abbott Laboratories,CLIA,Serum,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,,,['High'],,Yes,No,No,,No,Yes,No,,Fernando Gouvea-Reis,Universidade de Brasilia,Not Unity-Aligned,10.1108/IJPH-08-2021-0083,2022-03-15,2024-03-01,Unverified,gouvea-reis_sars_2022,BRA
220228_EspíritoSanto_DiretoriaDeSaúdeDoSistemaPenal_HealthcareProfessional,220228_EspíritoSanto_DiretoriaDeSaúdeDoSistemaPenal_HealthProfessional,"Serological prevalence of SARS-CoV-2 infection among prison system workers in the state of Espirito Santo, Brazil, 2020",2022-02-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Espírito Santo,,population professionals working in the 34 prisons in Espírito Santo state (healthcare professionals),,2020-08-31,2020-09-04,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,311,0.11900000000000001,0.081,0.157,True,,,,True,Simplified probability,MedTest Coronavirus 2019-nCoV IgG/IgM,MedLevensohn,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],,Yes,No,Yes,,Unclear,Yes,No,,Camila Leal Cravo Duque,Diretoria de Saúde do Sistema Penal,Not Unity-Aligned,https://dx.doi.org/10.1590/S1679-49742022000100008,2022-03-17,2022-07-16,Unverified,duque_prevalencia_2022,BRA
220228_EspíritoSanto_DiretoriaDeSaúdeDoSistemaPenal_PrisonOfficers,220228_EspíritoSanto_DiretoriaDeSaúdeDoSistemaPenal_PrisonOfficers,"Serological prevalence of SARS-CoV-2 infection among prison system workers in the state of Espirito Santo, Brazil, 2020",2022-02-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Espírito Santo,,population professionals working in the 34 prisons in Espírito Santo state (healthcare professionals),,2020-08-31,2020-09-04,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,675,0.22100000000000003,0.188,0.253,True,,,,True,Simplified probability,MedTest Coronavirus 2019-nCoV IgG/IgM,MedLevensohn,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Camila Leal Cravo Duque,Diretoria de Saúde do Sistema Penal,Not Unity-Aligned,https://dx.doi.org/10.1590/S1679-49742022000100008,2022-03-17,2022-07-16,Unverified,duque_prevalencia_2022,BRA
220311_Vitoria_FederalUniversityofEspiritoSanto,220311_Vitoria_FederalUniversityofEspiritoSanto,SARS-CoV-2 infection in pregnant women assisted in a high-risk maternity hospital in Brazil: Clinical aspects and obstetric outcomes.,2022-03-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Espírito Santo,Victória,"""This was a cross-sectional study conducted with pregnant women who were assisted at the HUCAM high-risk maternity unit from July to October 2020.""

""All patients admitted for delivery or miscarriage care were tested for SARS-CoV-2 using polymerase chain reaction (PCR) and for immunoglobulin (I)gM, and/or IgG by immunochromatography.""",,2020-07-15,2020-10-15,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,261,0.272,,,True,,,,True,Sequential,COVID-19 IgG/IgM ECO Test,ECO Diagnostica LTDA,CLIA,Whole Blood,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,,,['High'],No,No,No,No,No,Yes,Yes,Yes,,Carolina Ferrugini,Federal University of Espírito Santo,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0264901,2022-03-23,2024-03-01,Verified,ferrugini_sars-cov-2_2022,BRA
220312_Brazil_FederalUniversityofParaná,220312_Brazil_FederalUniversityofParaná,SARS-CoV-2 seroconversion in response to infection and vaccination: A time series local study in Brazil,2022-03-12,Preprint,Regional,Cross-sectional survey ,Brazil,Paraná,Matinhos ,,,2021-01-15,2021-12-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,1384,0.111,0.096,0.126,True,,,,True,Self-referral,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Nucleocapsid(N-protein),,0.9500000000000001,0.995,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Luciano Huergo,Federal University of Paraná,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.10.22271805v1.full-text,2022-03-22,2022-07-16,Unverified,huergo_sars-cov-2_2022,BRA
220314_FederalDistrict_UniversidadedeBrasilia,220314_FederalDistrict_UniversidadedeBrasilia,SARS-CoV-2 infection among Brazilian dentists: a seroprevalence study.,2022-03-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Federal District,,"""Professionally active dentists registered with the Regional Council of Dentistry of the Federal District"" from Federal District of Brazil",,2020-10-15,2020-11-15,Health care workers and caregivers,All,Multiple groups,21.0,71.0,Primary Estimate,,324,0.19100000000000003,,,True,,,,True,Stratified non-probability,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",,,0.971,0.978,['High'],,No,No,Yes,,Yes,Yes,Yes,,Jaiane Ribeiro,Universidade de Brasília,Not Unity-Aligned,https://dx.doi.org/10.1590/1807-3107bor-2022.vol36.0035,2022-03-23,2024-03-01,Unverified,ribeiro_sars-cov-2_2022,BRA
220414_DantePazzaneseInstituteofCardiology_DantePazzaneseInstituteofCardiology_Coronavac,220414_DantePazzaneseInstituteofCardiology_DantePazzaneseInstituteofCardiology_Coronavac,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers.,2022-04-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,São Paulo,"""All healthcare workers, administrative and support staff working at our hospital, and those who agreed to receive anti-SARS-CoV-2 vaccines were eligible for this study""","People who did not have blood samples collected at all three time point: before the first dose (T1), before the second dose (T2), and 30 days after the second dose (T3).",2021-01-15,2021-02-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,750,0.3347,,,True,,,,True,Unclear,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,Validated by developers,0.9400000000000001,,['High'],,Unclear,Yes,No,,Unclear,Yes,No,,Hui Lin-Wang,Dante Pazzanese Institute of Cardiology,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27782,2022-04-22,2022-07-16,Unverified,lin-wang_sequential_2022,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-04_Overall,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-04,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-04-01,2020-04-30,Residual sera,All,Multiple groups,0.0,100.0,Primary Estimate,,202,0.05940000000000001,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-04_Age40-49,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-04,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-04-01,2020-04-30,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,,44,0.0227,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-04_Age60-69,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-04,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-04-01,2020-04-30,Residual sera,All,Seniors (65+ years),60.0,69.0,Age,,30,0.0333,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-04_SexMale,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-04,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-04-01,2020-04-30,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,90,0.0444,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-04_SexFemale,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-04,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-04-01,2020-04-30,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,112,0.0714,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-04_Age70-79,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-04,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-04-01,2020-04-30,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,8,0.25,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-04_Age30-39,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-04,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-04-01,2020-04-30,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,,56,0.0893,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-04_Age50-59,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-04,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-04-01,2020-04-30,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,,32,0.0313,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-04_Age20-29,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-04,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-04-01,2020-04-30,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,,15,0.0667,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-04_Age0-9,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-04,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-04-01,2020-04-30,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,,8,0.0,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-04_Age10-19,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-04,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-04-01,2020-04-30,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,,9,0.11109999999999999,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-05_Overall,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-05,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-05-01,2020-05-31,Residual sera,All,Multiple groups,0.0,100.0,Primary Estimate,,496,0.0484,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-05_Age80-89,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-05,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-05-01,2020-05-31,Residual sera,All,Seniors (65+ years),80.0,89.0,Age,80-79,2,0.0,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-05_Age70-79,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-05,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-05-01,2020-05-31,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,12,0.0,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-05_SexFemale,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-05,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-05-01,2020-05-31,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,296,0.043899999999999995,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-05_Age30-39,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-05,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-05-01,2020-05-31,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,,142,0.042300000000000004,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-05_Age0-9,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-05,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-05-01,2020-05-31,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,,14,0.0,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-05_Age40-49,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-05,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-05-01,2020-05-31,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,,130,0.046200000000000005,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-05_Age60-69,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-05,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-05-01,2020-05-31,Residual sera,All,Seniors (65+ years),60.0,69.0,Age,,54,0.0556,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-05_Age10-19,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-05,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-05-01,2020-05-31,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,,26,0.0,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-05_Age50-59,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-05,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-05-01,2020-05-31,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,,60,0.1,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-05_Age20-29,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-05,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-05-01,2020-05-31,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,,56,0.0536,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-05_SexMale,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-05,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-05-01,2020-05-31,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,200,0.055,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-06_Overall,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-06,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-06-01,2020-06-30,Residual sera,All,Multiple groups,0.0,100.0,Primary Estimate,,1446,0.1487,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-06_Age60-69,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-06,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-06-01,2020-06-30,Residual sera,All,Seniors (65+ years),60.0,69.0,Age,,158,0.1392,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-06_Age40-49,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-06,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-06-01,2020-06-30,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,,356,0.16010000000000002,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-06_Age30-39,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-06,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-06-01,2020-06-30,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,,404,0.1436,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-06_Age50-59,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-06,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-06-01,2020-06-30,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,,212,0.1887,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-06_Age70-79,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-06,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-06-01,2020-06-30,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,50,0.08,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-06_Age0-9,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-06,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-06-01,2020-06-30,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,,48,0.125,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-06_Age10-19,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-06,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-06-01,2020-06-30,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,,56,0.125,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-06_Age80-89,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-06,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-06-01,2020-06-30,Residual sera,All,Seniors (65+ years),80.0,89.0,Age,80-79,16,0.25,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-06_SexMale,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-06,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-06-01,2020-06-30,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,578,0.1592,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-06_Age20-29,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-06,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-06-01,2020-06-30,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,,146,0.1164,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-06_SexFemale,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-06,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-06-01,2020-06-30,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,868,0.1417,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-07_Overall,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-07,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-07-01,2020-07-31,Residual sera,All,Multiple groups,0.0,100.0,Primary Estimate,,4221,0.27030000000000004,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-07_SexMale,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-07,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-07-01,2020-07-31,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,1684,0.2779,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-07_SexFemale,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-07,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-07-01,2020-07-31,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,2537,0.26530000000000004,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-07_Age30-39,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-07,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-07-01,2020-07-31,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,,955,0.23870000000000002,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-07_Age50-59,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-07,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-07-01,2020-07-31,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,,771,0.275,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-07_Age60-69,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-07,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-07-01,2020-07-31,Residual sera,All,Seniors (65+ years),60.0,69.0,Age,,506,0.3103,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-07_Age20-29,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-07,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-07-01,2020-07-31,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,,566,0.2261,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-07_Age40-49,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-07,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-07-01,2020-07-31,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,,936,0.2895,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-07_Age10-19,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-07,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-07-01,2020-07-31,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,,130,0.2231,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-07_Age80-89,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-07,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-07-01,2020-07-31,Residual sera,All,Seniors (65+ years),80.0,89.0,Age,80-79,56,0.2857,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-07_Age70-79,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-07,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-07-01,2020-07-31,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,203,0.3744,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-07_Age0-9,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-07,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-07-01,2020-07-31,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,,98,0.24489999999999998,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-08_Overall,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-08,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-08-01,2020-08-31,Residual sera,All,Multiple groups,0.0,100.0,Primary Estimate,,1224,0.3105,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-08_SexFemale,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-08,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-08-01,2020-08-31,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,711,0.2813,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-08_Age50-59,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-08,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-08-01,2020-08-31,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,,225,0.3333,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-08_Age90-100,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-08,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-08-01,2020-08-31,Residual sera,All,Seniors (65+ years),90.0,100.0,Age,90-100,8,0.25,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-08_Age40-49,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-08,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-08-01,2020-08-31,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,,261,0.2912,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-08_SexMale,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-08,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-08-01,2020-08-31,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,513,0.35090000000000005,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-08_Age80-89,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-08,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-08-01,2020-08-31,Residual sera,All,Seniors (65+ years),80.0,89.0,Age,80-79,32,0.1875,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-08_Age10-19,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-08,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-08-01,2020-08-31,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,,46,0.39130000000000004,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-08_Age0-9,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-08,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-08-01,2020-08-31,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,,46,0.39130000000000004,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-08_Age20-29,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-08,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-08-01,2020-08-31,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,,116,0.25,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-08_Age30-39,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-08,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-08-01,2020-08-31,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,,261,0.272,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-08_Age70-79,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-08,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-08-01,2020-08-31,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,53,0.5094,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-08_Age60-69,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-08,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-08-01,2020-08-31,Residual sera,All,Seniors (65+ years),60.0,69.0,Age,,176,0.3295,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-09_Overall,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-09,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-09-01,2020-09-30,Residual sera,All,Multiple groups,0.0,100.0,Primary Estimate,,402,0.2164,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-09_Age50-59,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-09,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-09-01,2020-09-30,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,,76,0.2237,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-09_Age0-9,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-09,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-09-01,2020-09-30,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,,15,0.2,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-09_SexFemale,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-09,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-09-01,2020-09-30,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,209,0.21050000000000002,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-09_Age90-100,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-09,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-09-01,2020-09-30,Residual sera,All,Seniors (65+ years),90.0,100.0,Age,90-100,3,0.0,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-09_Age20-29,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-09,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-09-01,2020-09-30,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,,38,0.21050000000000002,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-09_SexMale,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-09,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-09-01,2020-09-30,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,193,0.22280000000000003,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-09_Age70-79,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-09,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-09-01,2020-09-30,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,16,0.25,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-09_Age10-19,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-09,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-09-01,2020-09-30,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,,16,0.25,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-09_Age60-69,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-09,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-09-01,2020-09-30,Residual sera,All,Seniors (65+ years),60.0,69.0,Age,,58,0.2414,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-09_Age80-89,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-09,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-09-01,2020-09-30,Residual sera,All,Seniors (65+ years),80.0,89.0,Age,80-79,17,0.29410000000000003,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-09_Age30-39,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-09,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-09-01,2020-09-30,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,,76,0.1711,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-09_Age40-49,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-09,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-09-01,2020-09-30,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,,87,0.2184,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-10_Overall,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-10,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-10-01,2020-10-31,Residual sera,All,Multiple groups,0.0,100.0,Primary Estimate,,330,0.1576,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-10_Age50-59,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-10,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-10-01,2020-10-31,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,,67,0.1493,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-10_Age70-79,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-10,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-10-01,2020-10-31,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,26,0.07690000000000001,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-10_SexMale,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-10,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-10-01,2020-10-31,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,141,0.1773,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-10_Age0-9,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-10,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-10-01,2020-10-31,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,,5,0.4,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-10_Age60-69,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-10,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-10-01,2020-10-31,Residual sera,All,Seniors (65+ years),60.0,69.0,Age,,54,0.1852,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-10_Age30-39,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-10,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-10-01,2020-10-31,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,,60,0.1833,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-10_Age20-29,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-10,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-10-01,2020-10-31,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,,24,0.25,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-10_Age10-19,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-10,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-10-01,2020-10-31,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,,9,0.11109999999999999,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-10_SexFemale,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-10,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-10-01,2020-10-31,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,189,0.1429,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-10_Age40-49,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-10,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-10-01,2020-10-31,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,,77,0.12990000000000002,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-10_Age90-100,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-10,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-10-01,2020-10-31,Residual sera,All,Seniors (65+ years),90.0,100.0,Age,90-100,1,0.0,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-10_Age80-89,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-10,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-10-01,2020-10-31,Residual sera,All,Seniors (65+ years),80.0,89.0,Age,80-79,7,0.0,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-11_Overall,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-11,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-11-01,2020-11-30,Residual sera,All,Multiple groups,0.0,100.0,Primary Estimate,,184,0.1359,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-11_Age30-39,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-11,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-11-01,2020-11-30,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,,31,0.0645,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-11_Age70-79,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-11,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-11-01,2020-11-30,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,5,0.0,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-11_SexMale,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-11,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-11-01,2020-11-30,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,70,0.1143,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-11_Age60-69,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-11,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-11-01,2020-11-30,Residual sera,All,Seniors (65+ years),60.0,69.0,Age,,36,0.25,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-11_Age50-59,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-11,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-11-01,2020-11-30,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,,30,0.1333,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-11_Age80-89,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-11,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-11-01,2020-11-30,Residual sera,All,Seniors (65+ years),80.0,89.0,Age,80-79,2,1.0,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-11_Age90-100,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-11,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-11-01,2020-11-30,Residual sera,All,Seniors (65+ years),90.0,100.0,Age,90-100,1,0.0,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-11_Age10-19,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-11,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-11-01,2020-11-30,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,,8,0.125,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-11_Age20-29,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-11,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-11-01,2020-11-30,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,,22,0.0455,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-11_Age40-49,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-11,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-11-01,2020-11-30,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,,43,0.13949999999999999,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-11_Age0-9,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-11,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-11-01,2020-11-30,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,,6,0.0,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-11_SexFemale,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-11,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-11-01,2020-11-30,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,114,0.1491,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-12_Overall,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-12,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-12-01,2020-12-31,Residual sera,All,Multiple groups,0.0,100.0,Primary Estimate,,379,0.1504,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-12_Age30-39,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-12,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-12-01,2020-12-31,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,,76,0.1184,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-12_Age90-100,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-12,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-12-01,2020-12-31,Residual sera,All,Seniors (65+ years),90.0,100.0,Age,90-100,1,0.0,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-12_Age50-59,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-12,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-12-01,2020-12-31,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,,67,0.1791,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-12_Age60-69,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-12,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-12-01,2020-12-31,Residual sera,All,Seniors (65+ years),60.0,69.0,Age,,53,0.1887,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-12_SexFemale,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-12,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-12-01,2020-12-31,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,222,0.1577,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-12_Age80-89,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-12,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-12-01,2020-12-31,Residual sera,All,Seniors (65+ years),80.0,89.0,Age,80-79,9,0.11109999999999999,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-12_Age0-9,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-12,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-12-01,2020-12-31,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,,10,0.1,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-12_Age40-49,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-12,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-12-01,2020-12-31,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,,86,0.2093,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-12_Age20-29,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-12,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-12-01,2020-12-31,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,,37,0.1081,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-12_SexMale,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-12,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-12-01,2020-12-31,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,157,0.1401,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-12_Age70-79,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-12,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-12-01,2020-12-31,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,24,0.0833,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-12_Age10-19,220415_Cuiaba_UniversidadeFederaldeMatoGrosso_2020-12,Prevalence of molecular and serological tests of the new coronavirus (SARS-CoV-2) in Carlos Chagas laboratory - Sabin group in Cuiaba.,2022-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Brazil,Mato Grosso,Cuiabá,"samples from the secondary database of Carlos Chagas Laboratory – Sabin Group, in Cuiabá – MT, collected between April and July 2020. To verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2.",Rapid IgG or IgM test data were excluded from the study.,2020-12-01,2020-12-31,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,,16,0.0,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristiane Paula,Universidade Federal de Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20210769,2022-04-26,2022-07-16,Unverified,paula_prevalence_2022-1,BRA
220429_Brazil_UniversidadeFederaldoCeará_Overall,220429_Brazil_UniversidadeFederaldoCeará,Seroprevalence and factors associated with SARS-CoV-2 infection among education workers after the first wave: the first cross-sectional study in Brazil.,2022-04-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Ceará,Fortaleza,"private school teachers and staff in Fortaleza, Brazil from pre-schools to universities of higher education were invited.
",No participant ID,2020-10-15,2020-11-15,Essential non-healthcare workers,All,Multiple groups,,,Primary Estimate,,1901,0.08,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9440000000000001,1.0,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Pamela Franca,Universidade Federal do Ceará,Not Unity-Aligned,https://dx.doi.org/10.1590/0037-8682-0606-2021,2022-05-16,2024-03-01,Unverified,franca_seroprevalence_2022,BRA
220429_Brazil_UniversidadeFederaldoCeará_Age46+,220429_Brazil_UniversidadeFederaldoCeará,Seroprevalence and factors associated with SARS-CoV-2 infection among education workers after the first wave: the first cross-sectional study in Brazil.,2022-04-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Ceará,Fortaleza,"private school teachers and staff in Fortaleza, Brazil from pre-schools to universities of higher education were invited.
",No participant ID,2020-10-15,2020-11-15,Essential non-healthcare workers,All,Multiple groups,46.0,,Age,46+,422,0.12560000000000002,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9440000000000001,1.0,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Pamela Franca,Universidade Federal do Ceará,Not Unity-Aligned,https://dx.doi.org/10.1590/0037-8682-0606-2021,2022-05-16,2024-03-01,Unverified,franca_seroprevalence_2022,BRA
220429_Brazil_UniversidadeFederaldoCeará_Age31to45,220429_Brazil_UniversidadeFederaldoCeará,Seroprevalence and factors associated with SARS-CoV-2 infection among education workers after the first wave: the first cross-sectional study in Brazil.,2022-04-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Ceará,Fortaleza,"private school teachers and staff in Fortaleza, Brazil from pre-schools to universities of higher education were invited.
",No participant ID,2020-10-15,2020-11-15,Essential non-healthcare workers,All,Adults (18-64 years),31.0,45.0,Age,31-45,896,0.0647,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9440000000000001,1.0,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Pamela Franca,Universidade Federal do Ceará,Not Unity-Aligned,https://dx.doi.org/10.1590/0037-8682-0606-2021,2022-05-16,2024-03-01,Unverified,franca_seroprevalence_2022,BRA
220429_Brazil_UniversidadeFederaldoCeará_Age<=30,220429_Brazil_UniversidadeFederaldoCeará,Seroprevalence and factors associated with SARS-CoV-2 infection among education workers after the first wave: the first cross-sectional study in Brazil.,2022-04-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Ceará,Fortaleza,"private school teachers and staff in Fortaleza, Brazil from pre-schools to universities of higher education were invited.
",No participant ID,2020-10-15,2020-11-15,Essential non-healthcare workers,All,Multiple groups,0.0,30.0,Age,<=30,563,0.0728,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9440000000000001,1.0,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Pamela Franca,Universidade Federal do Ceará,Not Unity-Aligned,https://dx.doi.org/10.1590/0037-8682-0606-2021,2022-05-16,2024-03-01,Unverified,franca_seroprevalence_2022,BRA
220510_BeloHorizonte_UniversidadeFederalDeMinasGerais,220510_BeloHorizonte_UniversidadeFederalDeMinasGerais,Biosafety in Dental Health Care During the COVID-19 Pandemic: A Longitudinal Study.,2022-05-10,Journal Article (Peer-Reviewed),Local,Prospective cohort,Brazil,Minas Gerais,Belo Horizonte,"A longitudinal study with convenience sampling was performed
at the Clinic of Emergence at the School of Dentistry of UFMG,
from 11th January to 12th March 2021

In the first and last week of the study, whole blood samples
were collected from the DHCPs (teachers, dental students, and
dental assistants) to detect anti-SARS-CoV-2 IgM and IgG
antibodies using serological tests",,2021-01-11,2021-03-12,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,99,0.162,,,True,,,,True,Convenience,"Author designed (LFIA),Author designed (CLIA),Author designed (IFA) - Unknown,Author designed (ELISA) - Unknown",,Multiple Types,Whole Blood,"['IgG', 'IgM']",,,,,['High'],,No,No,No,,Unclear,Yes,No,,Lucyene Miguita,Universidade Federal de Minas Gerais,Not Unity-Aligned,https://dx.doi.org/10.3389/froh.2022.871107,2022-06-07,2022-07-16,Unverified,miguita_biosafety_2022,BRA
220520_Belem_FederalUniversityofPara_Overall,220520_Belem_FederalUniversityofPara,Seroprevalence and risk factors for COVID-19 in the metropolis of the Brazilian Amazon.,2022-05-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,"Para
",Belem,Volunteers living in the city of Belém,"Individuals already vaccinated with one or two doses against SARS-CoV-2, those who did not complete the epidemiological questionnaire, those who did not sign the informed consent form and those younger than 7 years
were excluded from the study",2020-10-15,2021-02-15,Household and community samples,All,Multiple groups,7.0,,Primary Estimate,,704,0.391,,,True,,,,True,Unclear,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,,0.996,['High'],,Unclear,Yes,No,,Yes,Yes,Yes,,Maria Torres,Federal University of Pará ,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-12629-z,2022-06-02,2024-03-01,Unverified,da_silva_torres_seroprevalence_2022,BRA
220520_Belem_FederalUniversityofPara_60-69,220520_Belem_FederalUniversityofPara,Seroprevalence and risk factors for COVID-19 in the metropolis of the Brazilian Amazon.,2022-05-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,"Para
",Belem,Volunteers living in the city of Belém,"Individuals already vaccinated with one or two doses against SARS-CoV-2, those who did not complete the epidemiological questionnaire, those who did not sign the informed consent form and those younger than 7 years
were excluded from the study",2020-10-15,2021-02-15,Household and community samples,All,Adults (18-64 years),60.0,69.0,Age,60-69,100,0.37,,,,,,,,Unclear,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,,0.996,['High'],,Unclear,Yes,No,,Yes,Yes,Yes,,Maria Torres,Federal University of Pará ,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-12629-z,2022-06-02,2024-03-01,Unverified,da_silva_torres_seroprevalence_2022,BRA
220520_Belem_FederalUniversityofPara_19-29,220520_Belem_FederalUniversityofPara,Seroprevalence and risk factors for COVID-19 in the metropolis of the Brazilian Amazon.,2022-05-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,"Para
",Belem,Volunteers living in the city of Belém,"Individuals already vaccinated with one or two doses against SARS-CoV-2, those who did not complete the epidemiological questionnaire, those who did not sign the informed consent form and those younger than 7 years
were excluded from the study",2020-10-15,2021-02-15,Household and community samples,All,Adults (18-64 years),19.0,29.0,Age,19-29,130,0.423,,,,,,,,Unclear,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,,0.996,['High'],,Unclear,Yes,No,,Yes,Yes,Yes,,Maria Torres,Federal University of Pará ,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-12629-z,2022-06-02,2024-03-01,Unverified,da_silva_torres_seroprevalence_2022,BRA
220520_Belem_FederalUniversityofPara_>=70,220520_Belem_FederalUniversityofPara,Seroprevalence and risk factors for COVID-19 in the metropolis of the Brazilian Amazon.,2022-05-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,"Para
",Belem,Volunteers living in the city of Belém,"Individuals already vaccinated with one or two doses against SARS-CoV-2, those who did not complete the epidemiological questionnaire, those who did not sign the informed consent form and those younger than 7 years
were excluded from the study",2020-10-15,2021-02-15,Household and community samples,All,Seniors (65+ years),70.0,,Age,>=70,63,0.47600000000000003,,,,,,,,Unclear,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,,0.996,['High'],,Unclear,Yes,No,,Yes,Yes,Yes,,Maria Torres,Federal University of Pará ,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-12629-z,2022-06-02,2024-03-01,Unverified,da_silva_torres_seroprevalence_2022,BRA
220520_Belem_FederalUniversityofPara_<=18,220520_Belem_FederalUniversityofPara,Seroprevalence and risk factors for COVID-19 in the metropolis of the Brazilian Amazon.,2022-05-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,"Para
",Belem,Volunteers living in the city of Belém,"Individuals already vaccinated with one or two doses against SARS-CoV-2, those who did not complete the epidemiological questionnaire, those who did not sign the informed consent form and those younger than 7 years
were excluded from the study",2020-10-15,2021-02-15,Household and community samples,All,Children and Youth (0-17 years),7.0,18.0,Age,<=18,67,0.269,,,,,,,,Unclear,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,,0.996,['High'],,Unclear,Yes,No,,Yes,Yes,Yes,,Maria Torres,Federal University of Pará ,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-12629-z,2022-06-02,2024-03-01,Unverified,da_silva_torres_seroprevalence_2022,BRA
220520_Belem_FederalUniversityofPara_50-59,220520_Belem_FederalUniversityofPara,Seroprevalence and risk factors for COVID-19 in the metropolis of the Brazilian Amazon.,2022-05-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,"Para
",Belem,Volunteers living in the city of Belém,"Individuals already vaccinated with one or two doses against SARS-CoV-2, those who did not complete the epidemiological questionnaire, those who did not sign the informed consent form and those younger than 7 years
were excluded from the study",2020-10-15,2021-02-15,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,124,0.44700000000000006,,,,,,,,Unclear,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,,0.996,['High'],,Unclear,Yes,No,,Yes,Yes,Yes,,Maria Torres,Federal University of Pará ,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-12629-z,2022-06-02,2024-03-01,Unverified,da_silva_torres_seroprevalence_2022,BRA
220520_Belem_FederalUniversityofPara_30-39,220520_Belem_FederalUniversityofPara,Seroprevalence and risk factors for COVID-19 in the metropolis of the Brazilian Amazon.,2022-05-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,"Para
",Belem,Volunteers living in the city of Belém,"Individuals already vaccinated with one or two doses against SARS-CoV-2, those who did not complete the epidemiological questionnaire, those who did not sign the informed consent form and those younger than 7 years
were excluded from the study",2020-10-15,2021-02-15,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,91,0.319,,,,,,,,Unclear,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,,0.996,['High'],,Unclear,Yes,No,,Yes,Yes,Yes,,Maria Torres,Federal University of Pará ,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-12629-z,2022-06-02,2024-03-01,Unverified,da_silva_torres_seroprevalence_2022,BRA
220520_Belem_FederalUniversityofPara_40-49,220520_Belem_FederalUniversityofPara,Seroprevalence and risk factors for COVID-19 in the metropolis of the Brazilian Amazon.,2022-05-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,"Para
",Belem,Volunteers living in the city of Belém,"Individuals already vaccinated with one or two doses against SARS-CoV-2, those who did not complete the epidemiological questionnaire, those who did not sign the informed consent form and those younger than 7 years
were excluded from the study",2020-10-15,2021-02-15,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,125,0.384,,,,,,,,Unclear,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,,0.996,['High'],,Unclear,Yes,No,,Yes,Yes,Yes,,Maria Torres,Federal University of Pará ,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-12629-z,2022-06-02,2024-03-01,Unverified,da_silva_torres_seroprevalence_2022,BRA
220526_RioDeJaneiro_OswaldoCruzFoundation,220526_RioDeJaneiro_OswaldoCruzFoundation,"Incidence of SARS-CoV-2 over four epidemic waves in a low-resource community in Rio de Janeiro, Brazil: A prospective cohort study.",2022-05-26,Journal Article (Peer-Reviewed),Local,Prospective cohort,Brazil,Rio de Janeiro,Rio de Janeiro,We offered study participation to all household contacts of children aged 13 and under who were seen at a primary health care centre for any reason including routine vaccinations and preventative care,,2020-05-15,2021-11-14,Household and community samples,All,Multiple groups,,,Primary Estimate,,2501,0.5913,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Marilia Sa Carvalho,Oswaldo Cruz Foundation,Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2022.100283,2022-06-16,2024-03-23,Verified,carvalho_incidence_2022,BRA
220602_SaoPaulo_UniversityOfSaoPaulo,220602_SaoPaulo_UniversityOfSaoPaulo,"Validation of Serological Methods for COVID-19 and Retrospective Screening of Health Employees and Visitors to the Sao Paulo University Hospital, Brazil.",2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Sao Paulo,Sao Paulo,"""a cohort of health employees and visitors to the University Hospital of the University of São Paulo.""",,2020-03-15,2020-07-15,Multiple populations,All,Multiple groups,,,Primary Estimate,,1119,0.1153,,,True,,,,True,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9692000000000001,0.9878,['High'],,Unclear,Yes,No,,Yes,Yes,Yes,,Robert Andreata-Santos,University of São Paulo,Not Unity-Aligned,https://dx.doi.org/10.3389/fcimb.2022.787411,2022-06-29,2024-03-01,Unverified,andreata-santos_validation_2022,BRA
220606_Brazil_FederalUniversityOfParana_HCWs_Primary,220606_Brazil_FederalUniversityOfParana_HCWs,"SARS-CoV-2 in saliva, viremia and seroprevalence for COVID-19 surveillance at a single hematopoietic stem cell transplantation center: a prospective cohort study.",2022-06-06,Journal Article (Peer-Reviewed),Local,Prospective cohort,Brazil,Parana,Curitiba,nurses and dentists,"NR
",2020-06-15,2020-10-15,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,50,0.08,,,True,,,,True,Convenience,Not reported/ Unable to specify,,Other,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Rafael Mobile,Federal University of Parana,Not Unity-Aligned,https://dx.doi.org/10.1590/S1678-9946202264039,2022-06-20,2022-07-16,Unverified,mobile_sars-cov-2_2022,BRA
220606_Brazil_FederalUniversityOfParana_Patients_Primary,220606_Brazil_FederalUniversityOfParana_Patients,"SARS-CoV-2 in saliva, viremia and seroprevalence for COVID-19 surveillance at a single hematopoietic stem cell transplantation center: a prospective cohort study.",2022-06-06,Journal Article (Peer-Reviewed),Local,Prospective cohort,Brazil,Parana,Curitiba,"patients undergoing allo-HSCT (hematopoietic stem cell transplantation, day -7 to day +180 after HSCT)","NR
",2020-06-15,2020-12-15,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),18.0,,Primary Estimate,,29,0.069,,,True,,,,True,Convenience,Not reported/ Unable to specify,,Other,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Rafael Mobile,Federal University of Parana,Not Unity-Aligned,https://dx.doi.org/10.1590/S1678-9946202264039,2022-06-20,2022-07-16,Unverified,mobile_sars-cov-2_2022,BRA
220608_MatoGrosso_FederalUniversityOfMatoGrosso_Overall,220608_MatoGrosso_FederalUniversityOfMatoGrosso,"[Prevalence of SARS-CoV-2 antibodies in the State of Mato Grosso, Brazil: a population-based survey].",2022-06-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Mato Grosso,,"A seroepidemiological survey was carried out in important municipalities in the health macro-regions of Mato Grosso, established by state resolution for the articulation and management of health care related to COVID-19.",,2020-09-16,2020-10-15,Household and community samples,All,Adults (18-64 years),18.0,,Primary Estimate,,4306,0.125,0.105,0.147,True,,,,True,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9740000000000001,0.985,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Elaine Oliveira,Federal University of Mato Grosso,Unity-Aligned,https://dx.doi.org/10.1590/0102-311XPT093021,2022-06-27,2024-03-24,Verified,elaine_cristina_de_oliveira_prevalence_2022,BRA
220706_ SaoPaulo_UniversityofSaoPaulo,220706_ SaoPaulo_UniversityofSaoPaulo,PREVALENCE AND PREDICTIVE FACTORS ASSOCIATED WITH POSITIVITY OF SARS-COV-2 SEROLOGICAL MARKERS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AT AN IBD REFERRAL CENTER.,2022-07-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Sao Paulo,"""All patients specifically denied symptoms suggestive of COVID-19, such as fever, cough, sore throat, runny nose, nasal congestion, dyspnea, anosmia, headache, and dysgeusia.""","""Patients with previous polymerase chain reaction by reverse transcriptase (RT-PCR) positivity were excluded from the study""",2020-05-26,2020-09-30,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),,,Primary Estimate,,233,0.11199999999999999,,,True,,,,True,Convenience,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Serum,TotalAntibody,,,0.998,1.0,['High'],,No,No,Yes,,Yes,Yes,Yes,,Sandro da Costa Ferreira,University of Sao Paulo,Not Unity-Aligned,https://dx.doi.org/10.1590/S0004-2803.202202000-32,2022-07-21,2024-03-01,Unverified,ferreira_prevalence_2022,BRA
220718_CruzeirodoSul_UniversityofSaoPaulo_Overall,220718_CruzeirodoSul_UniversityofSaoPaulo,SARS-CoV-2 seropositivity and COVID-19 among 5 years-old Amazonian children and their association with poverty and food insecurity.,2022-07-18,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Brazil,Acre State,Cruzeiro do Sul,"Children of the 5-year follow-up to the Maternal and Child Health and Nutrition in Acre, Brazil (MINA-Brazil) study",,2021-01-15,2021-07-04,Perinatal,All,Children and Youth (0-17 years),,,Primary Estimate,,660,0.45,0.41200000000000003,0.489,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9720000000000001,0.998,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Marcelo Ferreira,University of Sao Paulo,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0010580,2022-07-26,2024-03-01,Unverified,ferreira_sars-cov-2_2022,BRA
220721_Salvador_UniversidadeFederaldaBahia_Overall,220721_Salvador_UniversidadeFederaldaBahia,"SARS-CoV-2 Incidence, signs and symptoms and main risk factors for COVID-19 infection in Health Care Workers: A hospital-wide survey in Salvador, Brazil.",2022-07-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Salvador,"All HCWs over 18 years of age were
invited to participate",,2020-05-15,2020-09-15,Health care workers and caregivers,All,Adults (18-64 years),19.0,,Primary Estimate,,2083,0.13,,,True,,,,True,Convenience,"COVID-19 IgG/IgM ECO Test,Author designed (ELISA) - Unknown","ECO Diagnostica LTDA,NA",Multiple Types,Plasma,IgG,,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Iris Montano-Castellon,Universidade Federal da Bahia,Not Unity-Aligned,https://dx.doi.org/10.1016/j.bjid.2022.102387,2022-08-08,2024-03-01,Unverified,montano-castellon_sars-cov-2_2022,BRA
220722_MatoGrosso_UniversidadedeSaoPaulo_Overall,220722_MatoGrosso_UniversidadedeSaoPaulo,Factors associated with suicidal ideation during the COVID-19 pandemic in a population in the Brazilian Legal Amazon.,2022-07-22,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Mato Grosso,"Cuiabá, Várzea
Grande, Cáceres, Rondonópolis, Barra do Garças,
Tangará da Serra, Alta Floresta, Água Boa, Juína and Sinop",Residents over the age of 18 from permanent households,"Municipalities with less than 25,000 inhabitants, census sectors that encompassed rural areas and indigenous reserves and unconscious bedridden
residents.",2020-09-15,2020-10-15,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,4203,0.138,,,True,,,,True,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9740000000000001,0.985,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Ana Trettel,Universidade de Sao Paulo,Unity-Aligned,https://dx.doi.org/10.1590/1413-81232022278.04972022,2022-08-03,2024-04-01,Verified,trettel_factors_2022,BRA
220729_RiodeJaneiro_FIOCRUZ_AntiS,220729_RiodeJaneiro_FIOCRUZ,Prevalence and predictors of anti-SARS-CoV-2 serology in a highly vulnerable population of Rio de Janeiro: A population-based serosurvey,2022-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Rio de Janeiro,"Individuals aged 1 year or older, registered in one of the two primary health care clinics (CFVV or CSEGSF) composed the sampling unit that was taken as eligible for the study.

As of July 2020, 38,883 individuals were registered at one of the two above-mentioned primary health clin- ics. We aimed to enrol 6000 individuals aged ≥ 1 year old to be enrolled over 8 weeks, assuming an enroll- ment rate of 750 individuals per week.","Reasons for inclusion failure:
-	No one answered the door after 2 attempts (including one attempt over the weekend) (N= 4,302)
-	Individuals moved/changed address (N=2,168)
-	Individuals or their representative declined participation (N= 1,191)
-	Addresses were not found (N=646)
-	Ineligible (younger than 1 year old or adults who lack capacity to consent) (N= 137)
-	Deceased (N=92)
-	Blood samples were not collected (N=4)
-	Individuals without any documents to check identity (N=1)
",2020-09-15,2021-02-10,Household and community samples,All,Multiple groups,1.0,,Primary Estimate,IgG anti-S overall,4033,0.4897,0.468,0.512,True,,,,True,Stratified probability,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9937,0.9954999999999999,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Lara E. Coelho,FIOCRUZ,Unity-Aligned,https://doi.org/10.1016/j.lana.2022.100338,2022-08-09,2024-04-18,Verified,coelho_prevalence_2022,BRA
220729_RiodeJaneiro_FIOCRUZ_AntiS_Age5to9,220729_RiodeJaneiro_FIOCRUZ,Prevalence and predictors of anti-SARS-CoV-2 serology in a highly vulnerable population of Rio de Janeiro: A population-based serosurvey,2022-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Rio de Janeiro,"Individuals aged 1 year or older, registered in one of the two primary health care clinics (CFVV or CSEGSF) composed the sampling unit that was taken as eligible for the study.

As of July 2020, 38,883 individuals were registered at one of the two above-mentioned primary health clin- ics. We aimed to enrol 6000 individuals aged ≥ 1 year old to be enrolled over 8 weeks, assuming an enroll- ment rate of 750 individuals per week.","Reasons for inclusion failure:
-	No one answered the door after 2 attempts (including one attempt over the weekend) (N= 4,302)
-	Individuals moved/changed address (N=2,168)
-	Individuals or their representative declined participation (N= 1,191)
-	Addresses were not found (N=646)
-	Ineligible (younger than 1 year old or adults who lack capacity to consent) (N= 137)
-	Deceased (N=92)
-	Blood samples were not collected (N=4)
-	Individuals without any documents to check identity (N=1)
",2020-09-15,2021-02-10,Household and community samples,All,Children and Youth (0-17 years),5.0,9.0,Age,IgG anti-S Age: 5-9,194,0.4485,,,,,,,,Stratified probability,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9937,0.9954999999999999,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Lara E. Coelho,FIOCRUZ,Unity-Aligned,https://doi.org/10.1016/j.lana.2022.100338,2022-08-09,2024-04-18,Verified,coelho_prevalence_2022,BRA
220729_RiodeJaneiro_FIOCRUZ_AntiS_Age60to69,220729_RiodeJaneiro_FIOCRUZ,Prevalence and predictors of anti-SARS-CoV-2 serology in a highly vulnerable population of Rio de Janeiro: A population-based serosurvey,2022-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Rio de Janeiro,"Individuals aged 1 year or older, registered in one of the two primary health care clinics (CFVV or CSEGSF) composed the sampling unit that was taken as eligible for the study.

As of July 2020, 38,883 individuals were registered at one of the two above-mentioned primary health clin- ics. We aimed to enrol 6000 individuals aged ≥ 1 year old to be enrolled over 8 weeks, assuming an enroll- ment rate of 750 individuals per week.","Reasons for inclusion failure:
-	No one answered the door after 2 attempts (including one attempt over the weekend) (N= 4,302)
-	Individuals moved/changed address (N=2,168)
-	Individuals or their representative declined participation (N= 1,191)
-	Addresses were not found (N=646)
-	Ineligible (younger than 1 year old or adults who lack capacity to consent) (N= 137)
-	Deceased (N=92)
-	Blood samples were not collected (N=4)
-	Individuals without any documents to check identity (N=1)
",2020-09-15,2021-02-10,Household and community samples,All,Seniors (65+ years),60.0,69.0,Age,IgG anti-S Age: 60-69,531,0.435,,,,,,,,Stratified probability,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9937,0.9954999999999999,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Lara E. Coelho,FIOCRUZ,Unity-Aligned,https://doi.org/10.1016/j.lana.2022.100338,2022-08-09,2024-04-18,Verified,coelho_prevalence_2022,BRA
220729_RiodeJaneiro_FIOCRUZ_AntiS_Male,220729_RiodeJaneiro_FIOCRUZ,Prevalence and predictors of anti-SARS-CoV-2 serology in a highly vulnerable population of Rio de Janeiro: A population-based serosurvey,2022-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Rio de Janeiro,"Individuals aged 1 year or older, registered in one of the two primary health care clinics (CFVV or CSEGSF) composed the sampling unit that was taken as eligible for the study.

As of July 2020, 38,883 individuals were registered at one of the two above-mentioned primary health clin- ics. We aimed to enrol 6000 individuals aged ≥ 1 year old to be enrolled over 8 weeks, assuming an enroll- ment rate of 750 individuals per week.","Reasons for inclusion failure:
-	No one answered the door after 2 attempts (including one attempt over the weekend) (N= 4,302)
-	Individuals moved/changed address (N=2,168)
-	Individuals or their representative declined participation (N= 1,191)
-	Addresses were not found (N=646)
-	Ineligible (younger than 1 year old or adults who lack capacity to consent) (N= 137)
-	Deceased (N=92)
-	Blood samples were not collected (N=4)
-	Individuals without any documents to check identity (N=1)
",2020-09-15,2021-02-10,Household and community samples,Male,Multiple groups,1.0,,Sex/Gender,Male,1584,0.5,,,,,,,,Stratified probability,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9937,0.9954999999999999,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Lara E. Coelho,FIOCRUZ,Unity-Aligned,https://doi.org/10.1016/j.lana.2022.100338,2022-08-09,2024-04-18,Verified,coelho_prevalence_2022,BRA
220729_RiodeJaneiro_FIOCRUZ_AntiN,220729_RiodeJaneiro_FIOCRUZ,Prevalence and predictors of anti-SARS-CoV-2 serology in a highly vulnerable population of Rio de Janeiro: A population-based serosurvey,2022-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Rio de Janeiro,"Individuals aged 1 year or older, registered in one of the two primary health care clinics (CFVV or CSEGSF) composed the sampling unit that was taken as eligible for the study.

As of July 2020, 38,883 individuals were registered at one of the two above-mentioned primary health clin- ics. We aimed to enrol 6000 individuals aged ≥ 1 year old to be enrolled over 8 weeks, assuming an enroll- ment rate of 750 individuals per week.","Reasons for inclusion failure:
-	No one answered the door after 2 attempts (including one attempt over the weekend) (N= 4,302)
-	Individuals moved/changed address (N=2,168)
-	Individuals or their representative declined participation (N= 1,191)
-	Addresses were not found (N=646)
-	Ineligible (younger than 1 year old or adults who lack capacity to consent) (N= 137)
-	Deceased (N=92)
-	Blood samples were not collected (N=4)
-	Individuals without any documents to check identity (N=1)
",2020-09-15,2021-02-10,Household and community samples,All,Multiple groups,1.0,,Test used,IgG anti-N overall,4033,0.1736,0.161,0.187,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Lara E. Coelho,FIOCRUZ,Unity-Aligned,https://doi.org/10.1016/j.lana.2022.100338,2022-08-09,2024-04-18,Verified,coelho_prevalence_2022,BRA
220729_RiodeJaneiro_FIOCRUZ_AntiS_Age20to29,220729_RiodeJaneiro_FIOCRUZ,Prevalence and predictors of anti-SARS-CoV-2 serology in a highly vulnerable population of Rio de Janeiro: A population-based serosurvey,2022-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Rio de Janeiro,"Individuals aged 1 year or older, registered in one of the two primary health care clinics (CFVV or CSEGSF) composed the sampling unit that was taken as eligible for the study.

As of July 2020, 38,883 individuals were registered at one of the two above-mentioned primary health clin- ics. We aimed to enrol 6000 individuals aged ≥ 1 year old to be enrolled over 8 weeks, assuming an enroll- ment rate of 750 individuals per week.","Reasons for inclusion failure:
-	No one answered the door after 2 attempts (including one attempt over the weekend) (N= 4,302)
-	Individuals moved/changed address (N=2,168)
-	Individuals or their representative declined participation (N= 1,191)
-	Addresses were not found (N=646)
-	Ineligible (younger than 1 year old or adults who lack capacity to consent) (N= 137)
-	Deceased (N=92)
-	Blood samples were not collected (N=4)
-	Individuals without any documents to check identity (N=1)
",2020-09-15,2021-02-10,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,IgG anti-S Age: 20-29,600,0.5683,,,,,,,,Stratified probability,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9937,0.9954999999999999,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Lara E. Coelho,FIOCRUZ,Unity-Aligned,https://doi.org/10.1016/j.lana.2022.100338,2022-08-09,2024-04-18,Verified,coelho_prevalence_2022,BRA
220729_RiodeJaneiro_FIOCRUZ_AntiS_Female,220729_RiodeJaneiro_FIOCRUZ,Prevalence and predictors of anti-SARS-CoV-2 serology in a highly vulnerable population of Rio de Janeiro: A population-based serosurvey,2022-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Rio de Janeiro,"Individuals aged 1 year or older, registered in one of the two primary health care clinics (CFVV or CSEGSF) composed the sampling unit that was taken as eligible for the study.

As of July 2020, 38,883 individuals were registered at one of the two above-mentioned primary health clin- ics. We aimed to enrol 6000 individuals aged ≥ 1 year old to be enrolled over 8 weeks, assuming an enroll- ment rate of 750 individuals per week.","Reasons for inclusion failure:
-	No one answered the door after 2 attempts (including one attempt over the weekend) (N= 4,302)
-	Individuals moved/changed address (N=2,168)
-	Individuals or their representative declined participation (N= 1,191)
-	Addresses were not found (N=646)
-	Ineligible (younger than 1 year old or adults who lack capacity to consent) (N= 137)
-	Deceased (N=92)
-	Blood samples were not collected (N=4)
-	Individuals without any documents to check identity (N=1)
",2020-09-15,2021-02-10,Household and community samples,Female,Multiple groups,1.0,,Sex/Gender,Female,2449,0.48310000000000003,,,,,,,,Stratified probability,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9937,0.9954999999999999,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Lara E. Coelho,FIOCRUZ,Unity-Aligned,https://doi.org/10.1016/j.lana.2022.100338,2022-08-09,2024-04-18,Verified,coelho_prevalence_2022,BRA
220729_RiodeJaneiro_FIOCRUZ_AntiS_Age10to19,220729_RiodeJaneiro_FIOCRUZ,Prevalence and predictors of anti-SARS-CoV-2 serology in a highly vulnerable population of Rio de Janeiro: A population-based serosurvey,2022-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Rio de Janeiro,"Individuals aged 1 year or older, registered in one of the two primary health care clinics (CFVV or CSEGSF) composed the sampling unit that was taken as eligible for the study.

As of July 2020, 38,883 individuals were registered at one of the two above-mentioned primary health clin- ics. We aimed to enrol 6000 individuals aged ≥ 1 year old to be enrolled over 8 weeks, assuming an enroll- ment rate of 750 individuals per week.","Reasons for inclusion failure:
-	No one answered the door after 2 attempts (including one attempt over the weekend) (N= 4,302)
-	Individuals moved/changed address (N=2,168)
-	Individuals or their representative declined participation (N= 1,191)
-	Addresses were not found (N=646)
-	Ineligible (younger than 1 year old or adults who lack capacity to consent) (N= 137)
-	Deceased (N=92)
-	Blood samples were not collected (N=4)
-	Individuals without any documents to check identity (N=1)
",2020-09-15,2021-02-10,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,IgG anti-S Age: 10-19,582,0.5309,,,,,,,,Stratified probability,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9937,0.9954999999999999,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Lara E. Coelho,FIOCRUZ,Unity-Aligned,https://doi.org/10.1016/j.lana.2022.100338,2022-08-09,2024-04-18,Verified,coelho_prevalence_2022,BRA
220729_RiodeJaneiro_FIOCRUZ_AntiS_Age30to39,220729_RiodeJaneiro_FIOCRUZ,Prevalence and predictors of anti-SARS-CoV-2 serology in a highly vulnerable population of Rio de Janeiro: A population-based serosurvey,2022-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Rio de Janeiro,"Individuals aged 1 year or older, registered in one of the two primary health care clinics (CFVV or CSEGSF) composed the sampling unit that was taken as eligible for the study.

As of July 2020, 38,883 individuals were registered at one of the two above-mentioned primary health clin- ics. We aimed to enrol 6000 individuals aged ≥ 1 year old to be enrolled over 8 weeks, assuming an enroll- ment rate of 750 individuals per week.","Reasons for inclusion failure:
-	No one answered the door after 2 attempts (including one attempt over the weekend) (N= 4,302)
-	Individuals moved/changed address (N=2,168)
-	Individuals or their representative declined participation (N= 1,191)
-	Addresses were not found (N=646)
-	Ineligible (younger than 1 year old or adults who lack capacity to consent) (N= 137)
-	Deceased (N=92)
-	Blood samples were not collected (N=4)
-	Individuals without any documents to check identity (N=1)
",2020-09-15,2021-02-10,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,IgG anti-S Age: 30-39,547,0.5375,,,,,,,,Stratified probability,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9937,0.9954999999999999,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Lara E. Coelho,FIOCRUZ,Unity-Aligned,https://doi.org/10.1016/j.lana.2022.100338,2022-08-09,2024-04-18,Verified,coelho_prevalence_2022,BRA
220729_RiodeJaneiro_FIOCRUZ_AntiS_Age50to59,220729_RiodeJaneiro_FIOCRUZ,Prevalence and predictors of anti-SARS-CoV-2 serology in a highly vulnerable population of Rio de Janeiro: A population-based serosurvey,2022-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Rio de Janeiro,"Individuals aged 1 year or older, registered in one of the two primary health care clinics (CFVV or CSEGSF) composed the sampling unit that was taken as eligible for the study.

As of July 2020, 38,883 individuals were registered at one of the two above-mentioned primary health clin- ics. We aimed to enrol 6000 individuals aged ≥ 1 year old to be enrolled over 8 weeks, assuming an enroll- ment rate of 750 individuals per week.","Reasons for inclusion failure:
-	No one answered the door after 2 attempts (including one attempt over the weekend) (N= 4,302)
-	Individuals moved/changed address (N=2,168)
-	Individuals or their representative declined participation (N= 1,191)
-	Addresses were not found (N=646)
-	Ineligible (younger than 1 year old or adults who lack capacity to consent) (N= 137)
-	Deceased (N=92)
-	Blood samples were not collected (N=4)
-	Individuals without any documents to check identity (N=1)
",2020-09-15,2021-02-10,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,IgG anti-S Age: 50-59,566,0.4717,,,,,,,,Stratified probability,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9937,0.9954999999999999,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Lara E. Coelho,FIOCRUZ,Unity-Aligned,https://doi.org/10.1016/j.lana.2022.100338,2022-08-09,2024-04-18,Verified,coelho_prevalence_2022,BRA
220729_RiodeJaneiro_FIOCRUZ_AntiS_Age1to4,220729_RiodeJaneiro_FIOCRUZ,Prevalence and predictors of anti-SARS-CoV-2 serology in a highly vulnerable population of Rio de Janeiro: A population-based serosurvey,2022-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Rio de Janeiro,"Individuals aged 1 year or older, registered in one of the two primary health care clinics (CFVV or CSEGSF) composed the sampling unit that was taken as eligible for the study.

As of July 2020, 38,883 individuals were registered at one of the two above-mentioned primary health clin- ics. We aimed to enrol 6000 individuals aged ≥ 1 year old to be enrolled over 8 weeks, assuming an enroll- ment rate of 750 individuals per week.","Reasons for inclusion failure:
-	No one answered the door after 2 attempts (including one attempt over the weekend) (N= 4,302)
-	Individuals moved/changed address (N=2,168)
-	Individuals or their representative declined participation (N= 1,191)
-	Addresses were not found (N=646)
-	Ineligible (younger than 1 year old or adults who lack capacity to consent) (N= 137)
-	Deceased (N=92)
-	Blood samples were not collected (N=4)
-	Individuals without any documents to check identity (N=1)
",2020-09-15,2021-02-10,Household and community samples,All,Children and Youth (0-17 years),1.0,4.0,Age,IgG anti-S Age: 1-4,113,0.34509999999999996,,,,,,,,Stratified probability,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9937,0.9954999999999999,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Lara E. Coelho,FIOCRUZ,Unity-Aligned,https://doi.org/10.1016/j.lana.2022.100338,2022-08-09,2024-04-18,Verified,coelho_prevalence_2022,BRA
220729_RiodeJaneiro_FIOCRUZ_AntiS_AgeOver80,220729_RiodeJaneiro_FIOCRUZ,Prevalence and predictors of anti-SARS-CoV-2 serology in a highly vulnerable population of Rio de Janeiro: A population-based serosurvey,2022-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Rio de Janeiro,"Individuals aged 1 year or older, registered in one of the two primary health care clinics (CFVV or CSEGSF) composed the sampling unit that was taken as eligible for the study.

As of July 2020, 38,883 individuals were registered at one of the two above-mentioned primary health clin- ics. We aimed to enrol 6000 individuals aged ≥ 1 year old to be enrolled over 8 weeks, assuming an enroll- ment rate of 750 individuals per week.","Reasons for inclusion failure:
-	No one answered the door after 2 attempts (including one attempt over the weekend) (N= 4,302)
-	Individuals moved/changed address (N=2,168)
-	Individuals or their representative declined participation (N= 1,191)
-	Addresses were not found (N=646)
-	Ineligible (younger than 1 year old or adults who lack capacity to consent) (N= 137)
-	Deceased (N=92)
-	Blood samples were not collected (N=4)
-	Individuals without any documents to check identity (N=1)
",2020-09-15,2021-02-10,Household and community samples,All,Seniors (65+ years),80.0,,Age,IgG anti-S Age: >= 80,85,0.36469999999999997,,,,,,,,Stratified probability,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9937,0.9954999999999999,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Lara E. Coelho,FIOCRUZ,Unity-Aligned,https://doi.org/10.1016/j.lana.2022.100338,2022-08-09,2024-04-18,Verified,coelho_prevalence_2022,BRA
220729_RiodeJaneiro_FIOCRUZ_AntiS_Age70to79,220729_RiodeJaneiro_FIOCRUZ,Prevalence and predictors of anti-SARS-CoV-2 serology in a highly vulnerable population of Rio de Janeiro: A population-based serosurvey,2022-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Rio de Janeiro,"Individuals aged 1 year or older, registered in one of the two primary health care clinics (CFVV or CSEGSF) composed the sampling unit that was taken as eligible for the study.

As of July 2020, 38,883 individuals were registered at one of the two above-mentioned primary health clin- ics. We aimed to enrol 6000 individuals aged ≥ 1 year old to be enrolled over 8 weeks, assuming an enroll- ment rate of 750 individuals per week.","Reasons for inclusion failure:
-	No one answered the door after 2 attempts (including one attempt over the weekend) (N= 4,302)
-	Individuals moved/changed address (N=2,168)
-	Individuals or their representative declined participation (N= 1,191)
-	Addresses were not found (N=646)
-	Ineligible (younger than 1 year old or adults who lack capacity to consent) (N= 137)
-	Deceased (N=92)
-	Blood samples were not collected (N=4)
-	Individuals without any documents to check identity (N=1)
",2020-09-15,2021-02-10,Household and community samples,All,Seniors (65+ years),70.0,79.0,Age,IgG anti-S Age: 70-79,258,0.3643,,,,,,,,Stratified probability,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9937,0.9954999999999999,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Lara E. Coelho,FIOCRUZ,Unity-Aligned,https://doi.org/10.1016/j.lana.2022.100338,2022-08-09,2024-04-18,Verified,coelho_prevalence_2022,BRA
220729_RiodeJaneiro_FIOCRUZ_AntiS_Age40to49,220729_RiodeJaneiro_FIOCRUZ,Prevalence and predictors of anti-SARS-CoV-2 serology in a highly vulnerable population of Rio de Janeiro: A population-based serosurvey,2022-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Rio de Janeiro,"Individuals aged 1 year or older, registered in one of the two primary health care clinics (CFVV or CSEGSF) composed the sampling unit that was taken as eligible for the study.

As of July 2020, 38,883 individuals were registered at one of the two above-mentioned primary health clin- ics. We aimed to enrol 6000 individuals aged ≥ 1 year old to be enrolled over 8 weeks, assuming an enroll- ment rate of 750 individuals per week.","Reasons for inclusion failure:
-	No one answered the door after 2 attempts (including one attempt over the weekend) (N= 4,302)
-	Individuals moved/changed address (N=2,168)
-	Individuals or their representative declined participation (N= 1,191)
-	Addresses were not found (N=646)
-	Ineligible (younger than 1 year old or adults who lack capacity to consent) (N= 137)
-	Deceased (N=92)
-	Blood samples were not collected (N=4)
-	Individuals without any documents to check identity (N=1)
",2020-09-15,2021-02-10,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,IgG anti-S Age: 40-49,557,0.5063000000000001,,,,,,,,Stratified probability,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9937,0.9954999999999999,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Lara E. Coelho,FIOCRUZ,Unity-Aligned,https://doi.org/10.1016/j.lana.2022.100338,2022-08-09,2024-04-18,Verified,coelho_prevalence_2022,BRA
220801_Brazil_UniversidadeFederaldeUberlândia_Mothers,220801_Brazil_UniversidadeFederaldeUberlândia_Mothers,Serological survey for IgG antibodies against SARS-CoV-2 from newborns and their mothers.,2022-08-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Minas Gerais,,"""All neonates aged up to seven days who attended public primary health care clinics for newborn screening accompanied by their mothers were selected to participate in the serological survey. Mothers provided verbal consent to participate with their neonates.""","""We excluded dyads when mothers did not answer the clinical and sociodemographic questionnaire for any reason (n = 31) or were
vaccinated for SARS-CoV-2 during pregnancy (n = 13). Samples not satisfactory to be tested were also excluded (n = 17)."" ",2021-04-15,2021-08-15,Perinatal,Female,Adults (18-64 years),,,Primary Estimate,,1609,0.131,,,True,,,,True,Convenience,Allserum EIA COVID-19 IgG-Dried Blood Spot,MBiolog Diagnosticos,ELISA,Dried Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.8,0.97,['High'],,No,Yes,No,,Unclear,Yes,No,,Gabriela Soutto Mayor Assumpcao Pinheiro,Universidade Federal de Uberlândia,Not Unity-Aligned,https://dx.doi.org/10.1590/0102-311XEN021022,2022-09-21,2024-02-18,Unverified,pinheiro_serological_2022,BRA
220801_Brazil_UniversidadeFederaldeUberlândia_Neonates,220801_Brazil_UniversidadeFederaldeUberlândia_Neonates,Serological survey for IgG antibodies against SARS-CoV-2 from newborns and their mothers.,2022-08-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Minas Gerais,,"""All neonates aged up to seven days who attended public primary health care clinics for newborn screening accompanied by their mothers were selected to participate in the serological survey. Mothers provided verbal consent to participate with their neonates.""","""We excluded dyads when mothers did not answer the clinical and sociodemographic questionnaire for any reason (n = 31) or were
vaccinated for SARS-CoV-2 during pregnancy (n = 13). Samples not satisfactory to be tested were also excluded (n = 17)."" ",2021-04-15,2021-08-15,Perinatal,All,Children and Youth (0-17 years),,,Primary Estimate,,1901,0.147,,,True,,,,True,Convenience,Allserum EIA COVID-19 IgG-Dried Blood Spot,MBiolog Diagnosticos,ELISA,Dried Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.8,0.97,['High'],,No,Yes,No,,Unclear,Yes,No,,Gabriela Soutto Mayor Assumpcao Pinheiro,Universidade Federal de Uberlândia,Not Unity-Aligned,https://dx.doi.org/10.1590/0102-311XEN021022,2022-09-21,2024-01-11,Unverified,pinheiro_serological_2022,BRA
220805_RibeiraoPreto_FundacaoOswaldoCruz_Phase1,220805_RibeiraoPreto_FundacaoOswaldoCruz_Phase1,"COVID-19 seroepidemiological survey among healthcare workers in the City of Ribeirao Preto, Sao Paulo, Brazil.",2022-08-05,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Brazil,Sao Paulo,Ribeirao Preto,"Healthcare professionals and support staff who work in basic care
units, emergency care units, psychosocial care centers, family
health units, and hospitals could participate in the study. The main inclusion criterion was working for at least
4 consecutive hours in healthcare units or hospitalization of
patients with confirmed COVID-19.",,2020-06-29,2020-08-26,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,10172,0.127,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Patricia Evora,Fundacao Oswaldo Cruz,Not Unity-Aligned,https://dx.doi.org/10.1590/0037-8682-0088-2022,2022-08-18,2024-03-01,Unverified,martinez_evora_covid-19_2022,BRA
220805_RibeiraoPreto_FundacaoOswaldoCruz_Phase2,220805_RibeiraoPreto_FundacaoOswaldoCruz_Phase2,"COVID-19 seroepidemiological survey among healthcare workers in the City of Ribeirao Preto, Sao Paulo, Brazil.",2022-08-05,Journal Article (Peer-Reviewed),Local,Prospective cohort,Brazil,Sao Paulo,Ribeirao Preto,"Healthcare professionals and support staff who work in basic care
units, emergency care units, psychosocial care centers, family
health units, and hospitals could participate in the study. The main inclusion criterion was working for at least
4 consecutive hours in healthcare units or hospitalization of
patients with confirmed COVID-19.",,2020-10-02,2020-11-03,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,2129,0.121,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Patricia Evora,Fundacao Oswaldo Cruz,Not Unity-Aligned,https://dx.doi.org/10.1590/0037-8682-0088-2022,2022-08-18,2024-03-01,Unverified,martinez_evora_covid-19_2022,BRA
220808_MatoGrosso_UniversidadedoEstadodeMatoGrosso,220808_MatoGrosso_UniversidadedoEstadodeMatoGrosso,Self-reported symptoms and seroprevalence against SARS-CoV-2 in the population of Mato Grosso: a household-based survey in 2020.,2022-08-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Mato Grosso,,Resident >18,,2020-09-16,2020-10-15,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,4206,0.125,0.105,0.147,True,,,,True,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9740000000000001,0.985,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Ana Cláudia Pereira Tercas-Trettel,Universidade do Estado de Mato Grosso,Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20220078,2022-08-22,2024-03-12,Verified,tercas-trettel_self-reported_2022,BRA
220812_Brazil_HospitalSirioLibanes,220812_Brazil_HospitalSirioLibanes,"Seroprevalence of SARS-CoV-2 in Emergency Department Healthcare Workers at Sirio-Libanes Hospital, Brazil",2022-08-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Sao Paulo,"""Medical professionals, nurses, and nursing technicians who had been caring for patients with flu-like illnesses since Feb- ruary 25, 2020 and were working in the emergency room of S ́ırio-Libaneˆs Hospital were asked to participate.""","""Three participants did not complete the flu-like symptoms form, which included previous infection reporting, and were, therefore, excluded from the flu-like symptoms analysis.""",2020-05-28,2020-06-26,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,164,0.268,,,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Ricardo Madureira,Sirio-Libanes Hospital ,Not Unity-Aligned,https://dx.doi.org/10.1089/hs.2022.0045,2022-08-23,2022-08-26,Unverified,madureiraSeroprevalenceSARSCoV2Emergency2022,BRA
220829_EspiritoSanto_SubsecretariadeEstadodeVigilânciaemSaúde_Overall,220829_EspiritoSanto_SubsecretariadeEstadodeVigilânciaemSaúde,"SARS-CoV-2 infection prevalence and associated factors: a serial population-based study in Espirito Santo, Brazil, May to June 2020.",2022-08-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,"Espírito Santo, Greater Vitória, and interior region of the state",,"""11 municipalities were surveyed, and the results are presented according to three clusters: the whole of Espírito Santo state; the Greater Vitória Metropolitan Region; and municipalities in the interior region of the state.""

""Census tracts were used as territorial units, taking urban census tracts according to the census tract grid established in 2010, whereby the inclusion criteria were tract size of less than 100 hectares and more than 200 households in the tract.""

""The households were selected systematically, by selecting one household in five, starting from a randomly generated point. ""

""individuals above 2 years of age were included in the study""",,2020-05-10,2020-06-27,Household and community samples,All,Multiple groups,2.0,,Primary Estimate,,18786,0.061,,,True,,,,True,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8640000000000001,0.976,['Moderate'],Yes,Yes,Yes,Yes,No,No,Yes,No,Unclear,Orlei Amaral Cardoso,Subsecretaria de Estado de Vigilância em Saúde,Unity-Aligned,https://doi.org/10.1590/S1679-49742022000200023,2022-09-07,2024-04-09,Verified,cardosoSARSCoV2InfectionPrevalence2022,BRA
220829_EspiritoSanto_SubsecretariadeEstadodeVigilânciaemSaúde_61to80,220829_EspiritoSanto_SubsecretariadeEstadodeVigilânciaemSaúde,"SARS-CoV-2 infection prevalence and associated factors: a serial population-based study in Espirito Santo, Brazil, May to June 2020.",2022-08-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,"Espírito Santo, Greater Vitória, and interior region of the state",,"""11 municipalities were surveyed, and the results are presented according to three clusters: the whole of Espírito Santo state; the Greater Vitória Metropolitan Region; and municipalities in the interior region of the state.""

""Census tracts were used as territorial units, taking urban census tracts according to the census tract grid established in 2010, whereby the inclusion criteria were tract size of less than 100 hectares and more than 200 households in the tract.""

""The households were selected systematically, by selecting one household in five, starting from a randomly generated point. ""

""individuals above 2 years of age were included in the study""",,2020-05-10,2020-06-27,Household and community samples,All,Seniors (65+ years),61.0,80.0,Age,61-80,4648,0.053,,,,,,,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8640000000000001,0.976,['Moderate'],Yes,Yes,Yes,Yes,No,No,Yes,No,Unclear,Orlei Amaral Cardoso,Subsecretaria de Estado de Vigilância em Saúde,Unity-Aligned,https://doi.org/10.1590/S1679-49742022000200023,2022-09-07,2024-04-09,Verified,cardosoSARSCoV2InfectionPrevalence2022,BRA
220829_EspiritoSanto_SubsecretariadeEstadodeVigilânciaemSaúde_41to60,220829_EspiritoSanto_SubsecretariadeEstadodeVigilânciaemSaúde,"SARS-CoV-2 infection prevalence and associated factors: a serial population-based study in Espirito Santo, Brazil, May to June 2020.",2022-08-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,"Espírito Santo, Greater Vitória, and interior region of the state",,"""11 municipalities were surveyed, and the results are presented according to three clusters: the whole of Espírito Santo state; the Greater Vitória Metropolitan Region; and municipalities in the interior region of the state.""

""Census tracts were used as territorial units, taking urban census tracts according to the census tract grid established in 2010, whereby the inclusion criteria were tract size of less than 100 hectares and more than 200 households in the tract.""

""The households were selected systematically, by selecting one household in five, starting from a randomly generated point. ""

""individuals above 2 years of age were included in the study""",,2020-05-10,2020-06-27,Household and community samples,All,Adults (18-64 years),41.0,60.0,Age,41-60,6598,0.064,,,,,,,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8640000000000001,0.976,['Moderate'],Yes,Yes,Yes,Yes,No,No,Yes,No,Unclear,Orlei Amaral Cardoso,Subsecretaria de Estado de Vigilância em Saúde,Unity-Aligned,https://doi.org/10.1590/S1679-49742022000200023,2022-09-07,2024-04-09,Verified,cardosoSARSCoV2InfectionPrevalence2022,BRA
220829_EspiritoSanto_SubsecretariadeEstadodeVigilânciaemSaúde_81plus,220829_EspiritoSanto_SubsecretariadeEstadodeVigilânciaemSaúde,"SARS-CoV-2 infection prevalence and associated factors: a serial population-based study in Espirito Santo, Brazil, May to June 2020.",2022-08-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,"Espírito Santo, Greater Vitória, and interior region of the state",,"""11 municipalities were surveyed, and the results are presented according to three clusters: the whole of Espírito Santo state; the Greater Vitória Metropolitan Region; and municipalities in the interior region of the state.""

""Census tracts were used as territorial units, taking urban census tracts according to the census tract grid established in 2010, whereby the inclusion criteria were tract size of less than 100 hectares and more than 200 households in the tract.""

""The households were selected systematically, by selecting one household in five, starting from a randomly generated point. ""

""individuals above 2 years of age were included in the study""",,2020-05-10,2020-06-27,Household and community samples,All,Seniors (65+ years),81.0,,Age,81+,604,0.048,,,,,,,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8640000000000001,0.976,['Moderate'],Yes,Yes,Yes,Yes,No,No,Yes,No,Unclear,Orlei Amaral Cardoso,Subsecretaria de Estado de Vigilância em Saúde,Unity-Aligned,https://doi.org/10.1590/S1679-49742022000200023,2022-09-07,2024-04-09,Verified,cardosoSARSCoV2InfectionPrevalence2022,BRA
220829_EspiritoSanto_SubsecretariadeEstadodeVigilânciaemSaúde_Female,220829_EspiritoSanto_SubsecretariadeEstadodeVigilânciaemSaúde,"SARS-CoV-2 infection prevalence and associated factors: a serial population-based study in Espirito Santo, Brazil, May to June 2020.",2022-08-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,"Espírito Santo, Greater Vitória, and interior region of the state",,"""11 municipalities were surveyed, and the results are presented according to three clusters: the whole of Espírito Santo state; the Greater Vitória Metropolitan Region; and municipalities in the interior region of the state.""

""Census tracts were used as territorial units, taking urban census tracts according to the census tract grid established in 2010, whereby the inclusion criteria were tract size of less than 100 hectares and more than 200 households in the tract.""

""The households were selected systematically, by selecting one household in five, starting from a randomly generated point. ""

""individuals above 2 years of age were included in the study""",,2020-05-10,2020-06-27,Household and community samples,Female,Multiple groups,2.0,,Sex/Gender,Female,11715,0.065,,,,,,,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8640000000000001,0.976,['Moderate'],Yes,Yes,Yes,Yes,No,No,Yes,No,Unclear,Orlei Amaral Cardoso,Subsecretaria de Estado de Vigilância em Saúde,Unity-Aligned,https://doi.org/10.1590/S1679-49742022000200023,2022-09-07,2024-04-09,Verified,cardosoSARSCoV2InfectionPrevalence2022,BRA
220829_EspiritoSanto_SubsecretariadeEstadodeVigilânciaemSaúde_21to40,220829_EspiritoSanto_SubsecretariadeEstadodeVigilânciaemSaúde,"SARS-CoV-2 infection prevalence and associated factors: a serial population-based study in Espirito Santo, Brazil, May to June 2020.",2022-08-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,"Espírito Santo, Greater Vitória, and interior region of the state",,"""11 municipalities were surveyed, and the results are presented according to three clusters: the whole of Espírito Santo state; the Greater Vitória Metropolitan Region; and municipalities in the interior region of the state.""

""Census tracts were used as territorial units, taking urban census tracts according to the census tract grid established in 2010, whereby the inclusion criteria were tract size of less than 100 hectares and more than 200 households in the tract.""

""The households were selected systematically, by selecting one household in five, starting from a randomly generated point. ""

""individuals above 2 years of age were included in the study""",,2020-05-10,2020-06-27,Household and community samples,All,Adults (18-64 years),21.0,40.0,Age,21-40,5638,0.066,,,,,,,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8640000000000001,0.976,['Moderate'],Yes,Yes,Yes,Yes,No,No,Yes,No,Unclear,Orlei Amaral Cardoso,Subsecretaria de Estado de Vigilância em Saúde,Unity-Aligned,https://doi.org/10.1590/S1679-49742022000200023,2022-09-07,2024-04-09,Verified,cardosoSARSCoV2InfectionPrevalence2022,BRA
220829_EspiritoSanto_SubsecretariadeEstadodeVigilânciaemSaúde_lessthan20,220829_EspiritoSanto_SubsecretariadeEstadodeVigilânciaemSaúde,"SARS-CoV-2 infection prevalence and associated factors: a serial population-based study in Espirito Santo, Brazil, May to June 2020.",2022-08-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,"Espírito Santo, Greater Vitória, and interior region of the state",,"""11 municipalities were surveyed, and the results are presented according to three clusters: the whole of Espírito Santo state; the Greater Vitória Metropolitan Region; and municipalities in the interior region of the state.""

""Census tracts were used as territorial units, taking urban census tracts according to the census tract grid established in 2010, whereby the inclusion criteria were tract size of less than 100 hectares and more than 200 households in the tract.""

""The households were selected systematically, by selecting one household in five, starting from a randomly generated point. ""

""individuals above 2 years of age were included in the study""",,2020-05-10,2020-06-27,Household and community samples,All,Children and Youth (0-17 years),2.0,20.0,Age,2-20,1298,0.057999999999999996,,,,,,,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8640000000000001,0.976,['Moderate'],Yes,Yes,Yes,Yes,No,No,Yes,No,Unclear,Orlei Amaral Cardoso,Subsecretaria de Estado de Vigilância em Saúde,Unity-Aligned,https://doi.org/10.1590/S1679-49742022000200023,2022-09-07,2024-04-09,Verified,cardosoSARSCoV2InfectionPrevalence2022,BRA
220829_EspiritoSanto_SubsecretariadeEstadodeVigilânciaemSaúde_Male,220829_EspiritoSanto_SubsecretariadeEstadodeVigilânciaemSaúde,"SARS-CoV-2 infection prevalence and associated factors: a serial population-based study in Espirito Santo, Brazil, May to June 2020.",2022-08-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,"Espírito Santo, Greater Vitória, and interior region of the state",,"""11 municipalities were surveyed, and the results are presented according to three clusters: the whole of Espírito Santo state; the Greater Vitória Metropolitan Region; and municipalities in the interior region of the state.""

""Census tracts were used as territorial units, taking urban census tracts according to the census tract grid established in 2010, whereby the inclusion criteria were tract size of less than 100 hectares and more than 200 households in the tract.""

""The households were selected systematically, by selecting one household in five, starting from a randomly generated point. ""

""individuals above 2 years of age were included in the study""",,2020-05-10,2020-06-27,Household and community samples,Male,Multiple groups,2.0,,Sex/Gender,Male,7071,0.055,,,,,,,,Stratified probability,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8640000000000001,0.976,['Moderate'],Yes,Yes,Yes,Yes,No,No,Yes,No,Unclear,Orlei Amaral Cardoso,Subsecretaria de Estado de Vigilância em Saúde,Unity-Aligned,https://doi.org/10.1590/S1679-49742022000200023,2022-09-07,2024-04-09,Verified,cardosoSARSCoV2InfectionPrevalence2022,BRA
220908_Salvador_YaleSchoolofPublicHealth_TestPopAdjusted_Overall,220908_Salvador_YaleSchoolofPublicHealth,"Structural factors associated with SARS-CoV-2 infection risk in an urban slum setting in Salvador, Brazil: A cross-sectional survey.",2022-09-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Bahia,Salvador,"""Study teams canvas households located within the study area and perform a census (number of residents, age, and gender of residents) in households where at least 1 adult resident is present at the time of the study visit and is able to provide such information. Individuals who meet eligibility criteria (sleeping 3 nights or more per week within the study area, aged 2 years or more) and who provide written informed consent (parental consent for minors <18 years of age) are recruited for participation in household and serological surveys, which have been conducted annually or semiannually since 2002.""","""Participants with missing values for independent variables were excluded from the relevant analyses (pairwise deletion).""",2020-11-18,2021-02-26,Persons living in slums,All,Multiple groups,2.0,,Primary Estimate,,2041,0.4793,0.4422,0.521,True,True,True,True,,Entire sample,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.911,1.0,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Mariam Fofana,Yale School of Public Health,Unity-Aligned,https://dx.doi.org/10.1371/journal.pmed.1004093,2022-09-14,2024-04-15,Verified,fofana_structural_2022-1,BRA
220908_Salvador_YaleSchoolofPublicHealth_Test/PopAdjusted_Adults18+,220908_Salvador_YaleSchoolofPublicHealth,"Structural factors associated with SARS-CoV-2 infection risk in an urban slum setting in Salvador, Brazil: A cross-sectional survey.",2022-09-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Bahia,Salvador,"""Study teams canvas households located within the study area and perform a census (number of residents, age, and gender of residents) in households where at least 1 adult resident is present at the time of the study visit and is able to provide such information. Individuals who meet eligibility criteria (sleeping 3 nights or more per week within the study area, aged 2 years or more) and who provide written informed consent (parental consent for minors <18 years of age) are recruited for participation in household and serological surveys, which have been conducted annually or semiannually since 2002.""","""Participants with missing values for independent variables were excluded from the relevant analyses (pairwise deletion).""",2020-11-18,2021-02-26,Persons living in slums,All,Multiple groups,18.0,,Age,Ages 18+,1460,0.4537,0.4149,0.4972,,True,True,True,,Entire sample,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.911,1.0,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Mariam Fofana,Yale School of Public Health,Unity-Aligned,https://dx.doi.org/10.1371/journal.pmed.1004093,2022-09-16,2024-04-15,Verified,fofana_structural_2022-1,BRA
220908_Salvador_YaleSchoolofPublicHealth_Test/PopAdjusted_Children<18,220908_Salvador_YaleSchoolofPublicHealth,"Structural factors associated with SARS-CoV-2 infection risk in an urban slum setting in Salvador, Brazil: A cross-sectional survey.",2022-09-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Bahia,Salvador,"""Study teams canvas households located within the study area and perform a census (number of residents, age, and gender of residents) in households where at least 1 adult resident is present at the time of the study visit and is able to provide such information. Individuals who meet eligibility criteria (sleeping 3 nights or more per week within the study area, aged 2 years or more) and who provide written informed consent (parental consent for minors <18 years of age) are recruited for participation in household and serological surveys, which have been conducted annually or semiannually since 2002.""","""Participants with missing values for independent variables were excluded from the relevant analyses (pairwise deletion).""",2020-11-18,2021-02-26,Persons living in slums,All,Children and Youth (0-17 years),2.0,17.0,Age,Age <18,581,0.5438,0.4957,0.5929,,True,True,True,,Entire sample,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.911,1.0,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Mariam Fofana,Yale School of Public Health,Unity-Aligned,https://dx.doi.org/10.1371/journal.pmed.1004093,2022-09-16,2024-04-15,Verified,fofana_structural_2022-1,BRA
220908_Salvador_YaleSchoolofPublicHealth_Unadjusted_Children<18,220908_Salvador_YaleSchoolofPublicHealth,"Structural factors associated with SARS-CoV-2 infection risk in an urban slum setting in Salvador, Brazil: A cross-sectional survey.",2022-09-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Bahia,Salvador,"""Study teams canvas households located within the study area and perform a census (number of residents, age, and gender of residents) in households where at least 1 adult resident is present at the time of the study visit and is able to provide such information. Individuals who meet eligibility criteria (sleeping 3 nights or more per week within the study area, aged 2 years or more) and who provide written informed consent (parental consent for minors <18 years of age) are recruited for participation in household and serological surveys, which have been conducted annually or semiannually since 2002.""","""Participants with missing values for independent variables were excluded from the relevant analyses (pairwise deletion).""",2020-11-18,2021-02-26,Persons living in slums,All,Children and Youth (0-17 years),2.0,17.0,Age,Age <18,581,0.573,0.532,0.614,,,,,,Entire sample,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.911,1.0,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Mariam Fofana,Yale School of Public Health,Unity-Aligned,https://dx.doi.org/10.1371/journal.pmed.1004093,2022-09-16,2024-04-15,Verified,fofana_structural_2022-1,BRA
220908_Salvador_YaleSchoolofPublicHealth_Test/PopAdjusted_Male,220908_Salvador_YaleSchoolofPublicHealth,"Structural factors associated with SARS-CoV-2 infection risk in an urban slum setting in Salvador, Brazil: A cross-sectional survey.",2022-09-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Bahia,Salvador,"""Study teams canvas households located within the study area and perform a census (number of residents, age, and gender of residents) in households where at least 1 adult resident is present at the time of the study visit and is able to provide such information. Individuals who meet eligibility criteria (sleeping 3 nights or more per week within the study area, aged 2 years or more) and who provide written informed consent (parental consent for minors <18 years of age) are recruited for participation in household and serological surveys, which have been conducted annually or semiannually since 2002.""","""Participants with missing values for independent variables were excluded from the relevant analyses (pairwise deletion).""",2020-11-18,2021-02-26,Persons living in slums,Male,Multiple groups,2.0,,Sex/Gender,Male,848,0.4462,0.4013,0.4944,,True,True,True,,Entire sample,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.911,1.0,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Mariam Fofana,Yale School of Public Health,Unity-Aligned,https://dx.doi.org/10.1371/journal.pmed.1004093,2022-09-16,2024-04-15,Verified,fofana_structural_2022-1,BRA
220908_Salvador_YaleSchoolofPublicHealth_Unadjusted_Female,220908_Salvador_YaleSchoolofPublicHealth,"Structural factors associated with SARS-CoV-2 infection risk in an urban slum setting in Salvador, Brazil: A cross-sectional survey.",2022-09-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Bahia,Salvador,"""Study teams canvas households located within the study area and perform a census (number of residents, age, and gender of residents) in households where at least 1 adult resident is present at the time of the study visit and is able to provide such information. Individuals who meet eligibility criteria (sleeping 3 nights or more per week within the study area, aged 2 years or more) and who provide written informed consent (parental consent for minors <18 years of age) are recruited for participation in household and serological surveys, which have been conducted annually or semiannually since 2002.""","""Participants with missing values for independent variables were excluded from the relevant analyses (pairwise deletion).""",2020-11-18,2021-02-26,Persons living in slums,Female,Multiple groups,2.0,,Sex/Gender,Female,1193,0.501,0.473,0.53,,,,,,Entire sample,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.911,1.0,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Mariam Fofana,Yale School of Public Health,Unity-Aligned,https://dx.doi.org/10.1371/journal.pmed.1004093,2022-09-16,2024-04-15,Verified,fofana_structural_2022-1,BRA
220908_Salvador_YaleSchoolofPublicHealth_Unadjusted_Ages30-44,220908_Salvador_YaleSchoolofPublicHealth,"Structural factors associated with SARS-CoV-2 infection risk in an urban slum setting in Salvador, Brazil: A cross-sectional survey.",2022-09-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Bahia,Salvador,"""Study teams canvas households located within the study area and perform a census (number of residents, age, and gender of residents) in households where at least 1 adult resident is present at the time of the study visit and is able to provide such information. Individuals who meet eligibility criteria (sleeping 3 nights or more per week within the study area, aged 2 years or more) and who provide written informed consent (parental consent for minors <18 years of age) are recruited for participation in household and serological surveys, which have been conducted annually or semiannually since 2002.""","""Participants with missing values for independent variables were excluded from the relevant analyses (pairwise deletion).""",2020-11-18,2021-02-26,Persons living in slums,All,Adults (18-64 years),30.0,44.0,Age,Ages 30-44,516,0.44,0.39,0.48,,,,,,Entire sample,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.911,1.0,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Mariam Fofana,Yale School of Public Health,Unity-Aligned,https://dx.doi.org/10.1371/journal.pmed.1004093,2022-09-16,2024-04-15,Verified,fofana_structural_2022-1,BRA
220908_Salvador_YaleSchoolofPublicHealth_Unadjusted_Male,220908_Salvador_YaleSchoolofPublicHealth,"Structural factors associated with SARS-CoV-2 infection risk in an urban slum setting in Salvador, Brazil: A cross-sectional survey.",2022-09-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Bahia,Salvador,"""Study teams canvas households located within the study area and perform a census (number of residents, age, and gender of residents) in households where at least 1 adult resident is present at the time of the study visit and is able to provide such information. Individuals who meet eligibility criteria (sleeping 3 nights or more per week within the study area, aged 2 years or more) and who provide written informed consent (parental consent for minors <18 years of age) are recruited for participation in household and serological surveys, which have been conducted annually or semiannually since 2002.""","""Participants with missing values for independent variables were excluded from the relevant analyses (pairwise deletion).""",2020-11-18,2021-02-26,Persons living in slums,Male,Multiple groups,2.0,,Sex/Gender,Male,848,0.45299999999999996,0.419,0.48,,,,,,Entire sample,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.911,1.0,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Mariam Fofana,Yale School of Public Health,Unity-Aligned,https://dx.doi.org/10.1371/journal.pmed.1004093,2022-09-16,2024-04-15,Verified,fofana_structural_2022-1,BRA
220908_Salvador_YaleSchoolofPublicHealth_Unadjusted_Ages45-59,220908_Salvador_YaleSchoolofPublicHealth,"Structural factors associated with SARS-CoV-2 infection risk in an urban slum setting in Salvador, Brazil: A cross-sectional survey.",2022-09-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Bahia,Salvador,"""Study teams canvas households located within the study area and perform a census (number of residents, age, and gender of residents) in households where at least 1 adult resident is present at the time of the study visit and is able to provide such information. Individuals who meet eligibility criteria (sleeping 3 nights or more per week within the study area, aged 2 years or more) and who provide written informed consent (parental consent for minors <18 years of age) are recruited for participation in household and serological surveys, which have been conducted annually or semiannually since 2002.""","""Participants with missing values for independent variables were excluded from the relevant analyses (pairwise deletion).""",2020-11-18,2021-02-26,Persons living in slums,All,Adults (18-64 years),45.0,59.0,Age,Ages 45-59,332,0.392,0.33899999999999997,0.44700000000000006,,,,,,Entire sample,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.911,1.0,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Mariam Fofana,Yale School of Public Health,Unity-Aligned,https://dx.doi.org/10.1371/journal.pmed.1004093,2022-09-16,2024-04-15,Verified,fofana_structural_2022-1,BRA
220908_Salvador_YaleSchoolofPublicHealth_Test/PopAdjusted_Female,220908_Salvador_YaleSchoolofPublicHealth,"Structural factors associated with SARS-CoV-2 infection risk in an urban slum setting in Salvador, Brazil: A cross-sectional survey.",2022-09-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Bahia,Salvador,"""Study teams canvas households located within the study area and perform a census (number of residents, age, and gender of residents) in households where at least 1 adult resident is present at the time of the study visit and is able to provide such information. Individuals who meet eligibility criteria (sleeping 3 nights or more per week within the study area, aged 2 years or more) and who provide written informed consent (parental consent for minors <18 years of age) are recruited for participation in household and serological surveys, which have been conducted annually or semiannually since 2002.""","""Participants with missing values for independent variables were excluded from the relevant analyses (pairwise deletion).""",2020-11-18,2021-02-26,Persons living in slums,Female,Multiple groups,2.0,,Sex/Gender,Female,1193,0.5029,0.4632,0.5482,,True,True,True,,Entire sample,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.911,1.0,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Mariam Fofana,Yale School of Public Health,Unity-Aligned,https://dx.doi.org/10.1371/journal.pmed.1004093,2022-09-16,2024-04-15,Verified,fofana_structural_2022-1,BRA
220908_Salvador_YaleSchoolofPublicHealth_Unadjusted_Ages60+,220908_Salvador_YaleSchoolofPublicHealth,"Structural factors associated with SARS-CoV-2 infection risk in an urban slum setting in Salvador, Brazil: A cross-sectional survey.",2022-09-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Bahia,Salvador,"""Study teams canvas households located within the study area and perform a census (number of residents, age, and gender of residents) in households where at least 1 adult resident is present at the time of the study visit and is able to provide such information. Individuals who meet eligibility criteria (sleeping 3 nights or more per week within the study area, aged 2 years or more) and who provide written informed consent (parental consent for minors <18 years of age) are recruited for participation in household and serological surveys, which have been conducted annually or semiannually since 2002.""","""Participants with missing values for independent variables were excluded from the relevant analyses (pairwise deletion).""",2020-11-18,2021-02-26,Persons living in slums,All,Seniors (65+ years),60.0,,Age,Ages 60+,162,0.43200000000000005,0.355,0.512,,,,,,Entire sample,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.911,1.0,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Mariam Fofana,Yale School of Public Health,Unity-Aligned,https://dx.doi.org/10.1371/journal.pmed.1004093,2022-09-16,2024-04-15,Verified,fofana_structural_2022-1,BRA
220908_Salvador_YaleSchoolofPublicHealth_Unadjusted_Ages18-29,220908_Salvador_YaleSchoolofPublicHealth,"Structural factors associated with SARS-CoV-2 infection risk in an urban slum setting in Salvador, Brazil: A cross-sectional survey.",2022-09-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Bahia,Salvador,"""Study teams canvas households located within the study area and perform a census (number of residents, age, and gender of residents) in households where at least 1 adult resident is present at the time of the study visit and is able to provide such information. Individuals who meet eligibility criteria (sleeping 3 nights or more per week within the study area, aged 2 years or more) and who provide written informed consent (parental consent for minors <18 years of age) are recruited for participation in household and serological surveys, which have been conducted annually or semiannually since 2002.""","""Participants with missing values for independent variables were excluded from the relevant analyses (pairwise deletion).""",2020-11-18,2021-02-26,Persons living in slums,All,Adults (18-64 years),18.0,29.0,Age,18-29,450,0.493,0.446,0.54,,,,,,Entire sample,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.911,1.0,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Mariam Fofana,Yale School of Public Health,Unity-Aligned,https://dx.doi.org/10.1371/journal.pmed.1004093,2022-09-16,2024-04-15,Verified,fofana_structural_2022-1,BRA
220908_Salvador_YaleSchoolofPublicHealth_Unadjusted_Overall,220908_Salvador_YaleSchoolofPublicHealth,"Structural factors associated with SARS-CoV-2 infection risk in an urban slum setting in Salvador, Brazil: A cross-sectional survey.",2022-09-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Bahia,Salvador,"""Study teams canvas households located within the study area and perform a census (number of residents, age, and gender of residents) in households where at least 1 adult resident is present at the time of the study visit and is able to provide such information. Individuals who meet eligibility criteria (sleeping 3 nights or more per week within the study area, aged 2 years or more) and who provide written informed consent (parental consent for minors <18 years of age) are recruited for participation in household and serological surveys, which have been conducted annually or semiannually since 2002.""","""Participants with missing values for independent variables were excluded from the relevant analyses (pairwise deletion).""",2020-11-18,2021-02-26,Persons living in slums,All,Multiple groups,2.0,,Analysis,,2041,0.48100000000000004,0.459,0.503,,,,,True,Entire sample,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.911,1.0,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Mariam Fofana,Yale School of Public Health,Unity-Aligned,https://dx.doi.org/10.1371/journal.pmed.1004093,2022-09-16,2024-04-15,Verified,fofana_structural_2022-1,BRA
220909_Brazil_UniversidadedeSãoPaulo_overall,220909_Brazil_UniversidadedeSãoPaulo,AVALIACAO DO EFEITO POTENCIAL DO USO CONTINUO DE MEDICAMENTOS ANTIRRETROVIRAIS SOBRE A INFECCAO POR SARS-COV-2,2022-09-09,Journal Article (Peer-Reviewed),National,Retrospective cohort,Brazil,,,PLHIV on ARV treatment and close contacts without a diagnosis of HIV infection,,2020-04-15,2021-01-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,442,0.167,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,IgG,,,,,['High'],No,Unclear,No,No,No,Unclear,Yes,No,,Lucas Chaves Netto,Universidade de São Paulo,Not Unity-Aligned,https://dx.doi.org/10.1016/j.bjid.2022.102496,2022-09-27,2022-10-21,Unverified,nettoAVALIAÇÃOEFEITOPOTENCIAL2022,BRA
220909_Jundiai_JundiaiMedicalSchool,220909_Jundiai_JundiaiMedicalSchool,"Seroepidemiological investigation of COVID-19: A cross-sectional study in Jundiai, Sao Paulo, Brazil.",2022-09-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Sao Paolo,Jundiai,"""Inclusion criteria for both phases (UBS and households) were individuals who were residents in Jundiaı´, signing the free informed consent form, having more than 18 years old. Having no symptoms at moment of the study.""","""The exclusion criteria were subjects under the
influence of alcohol and/or toxic substances that prevented them from completing the questionnaire were excluded.""",2020-06-01,2020-06-19,Multiple populations,All,Multiple groups,18.0,,Primary Estimate,,2431,0.174,,,True,,,,True,Convenience,Vyttra Smart Test,Vyttra Diagnosticos,Other,Whole Blood,"['IgG', 'IgM']",,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Marília Jesus Batista,Jundiai Medical School,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0000460,2023-05-03,2023-05-09,Unverified,batista_seroepidemiological_2022,BRA
220912_Brazil_FederalUniversityofSergipe_Phase1_overall,220912_Brazil_FederalUniversityofSergipe_Phase1,Dynamics of SARS-CoV-2 seroprevalence during the first year of the COVID-19 pandemic in the Northeast region of Brazil.,2022-09-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,"Sergipe
",,"""In each municipality, households were randomly selected from a sampling frame developed from a census list. At the beginning of the visit, all house-hold members were listed, and one individual was randomly selected for data collection. There was no overlapping population in the different phases of the study.""","""Fully or partially vaccinated people were not included as the vaccination campaign against COVID-19 in the state started on 19 January 2021""

",2020-07-01,2020-07-30,Household and community samples,All,Multiple groups,,,Primary Estimate,,5619,0.09300000000000001,,,True,,,,True,Simplified probability,"The BioSys Plus COVID-19 IgM/IgG Rapid Test,KOVID Ab (COVID-19 IgG / IgM) kit,Ichroma COVID-19 Ab Test,Finecare SARS-CoV-2 Antibody test,COVID-19 IgG/IgM ECO Test","BioSys Laboratories,Kovalent,Boditech Med Inc.,Guangzhou Wondfo Biotech Co. Ltd,ECO Diagnostica LTDA",Multiple Types,Whole Blood,"['IgA', 'IgM']",,,,,['Moderate'],,Yes,Yes,No,,Unclear,Yes,No,,Adriano Antunes de Souza Araujo,Federal University of Sergipe,Not Unity-Aligned,https://dx.doi.org/10.1080/20477724.2022.2121366,2022-09-18,2024-03-01,Unverified,desouzaaraújoDynamicsSARSCoV2Seroprevalence2022,BRA
220912_Brazil_FederalUniversityofSergipe_Phase1_0to19,220912_Brazil_FederalUniversityofSergipe_Phase1,Dynamics of SARS-CoV-2 seroprevalence during the first year of the COVID-19 pandemic in the Northeast region of Brazil.,2022-09-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,"Sergipe
",,"""In each municipality, households were randomly selected from a sampling frame developed from a census list. At the beginning of the visit, all house-hold members were listed, and one individual was randomly selected for data collection. There was no overlapping population in the different phases of the study.""","""Fully or partially vaccinated people were not included as the vaccination campaign against COVID-19 in the state started on 19 January 2021""

",2020-07-01,2020-07-30,Household and community samples,All,Children and Youth (0-17 years),0.0,19.0,Age,0-19,606,0.099,,,,,,,,Simplified probability,"The BioSys Plus COVID-19 IgM/IgG Rapid Test,KOVID Ab (COVID-19 IgG / IgM) kit,Ichroma COVID-19 Ab Test,Finecare SARS-CoV-2 Antibody test,COVID-19 IgG/IgM ECO Test","BioSys Laboratories,Kovalent,Boditech Med Inc.,Guangzhou Wondfo Biotech Co. Ltd,ECO Diagnostica LTDA",Multiple Types,Whole Blood,"['IgA', 'IgM']",,,,,['Moderate'],,Yes,Yes,No,,Unclear,Yes,No,,Adriano Antunes de Souza Araujo,Federal University of Sergipe,Not Unity-Aligned,https://dx.doi.org/10.1080/20477724.2022.2121366,2022-09-18,2024-03-01,Unverified,desouzaaraújoDynamicsSARSCoV2Seroprevalence2022,BRA
220912_Brazil_FederalUniversityofSergipe_Phase1_60plus,220912_Brazil_FederalUniversityofSergipe_Phase1,Dynamics of SARS-CoV-2 seroprevalence during the first year of the COVID-19 pandemic in the Northeast region of Brazil.,2022-09-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,"Sergipe
",,"""In each municipality, households were randomly selected from a sampling frame developed from a census list. At the beginning of the visit, all house-hold members were listed, and one individual was randomly selected for data collection. There was no overlapping population in the different phases of the study.""","""Fully or partially vaccinated people were not included as the vaccination campaign against COVID-19 in the state started on 19 January 2021""

",2020-07-01,2020-07-30,Household and community samples,All,Seniors (65+ years),60.0,,Age,60+,1167,0.09,,,,,,,,Simplified probability,"The BioSys Plus COVID-19 IgM/IgG Rapid Test,KOVID Ab (COVID-19 IgG / IgM) kit,Ichroma COVID-19 Ab Test,Finecare SARS-CoV-2 Antibody test,COVID-19 IgG/IgM ECO Test","BioSys Laboratories,Kovalent,Boditech Med Inc.,Guangzhou Wondfo Biotech Co. Ltd,ECO Diagnostica LTDA",Multiple Types,Whole Blood,"['IgA', 'IgM']",,,,,['Moderate'],,Yes,Yes,No,,Unclear,Yes,No,,Adriano Antunes de Souza Araujo,Federal University of Sergipe,Not Unity-Aligned,https://dx.doi.org/10.1080/20477724.2022.2121366,2022-09-18,2024-03-01,Unverified,desouzaaraújoDynamicsSARSCoV2Seroprevalence2022,BRA
220912_Brazil_FederalUniversityofSergipe_Phase1_20to59,220912_Brazil_FederalUniversityofSergipe_Phase1,Dynamics of SARS-CoV-2 seroprevalence during the first year of the COVID-19 pandemic in the Northeast region of Brazil.,2022-09-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,"Sergipe
",,"""In each municipality, households were randomly selected from a sampling frame developed from a census list. At the beginning of the visit, all house-hold members were listed, and one individual was randomly selected for data collection. There was no overlapping population in the different phases of the study.""","""Fully or partially vaccinated people were not included as the vaccination campaign against COVID-19 in the state started on 19 January 2021""

",2020-07-01,2020-07-30,Household and community samples,All,Adults (18-64 years),20.0,59.0,Age,20-59,3796,0.09300000000000001,,,,,,,,Simplified probability,"The BioSys Plus COVID-19 IgM/IgG Rapid Test,KOVID Ab (COVID-19 IgG / IgM) kit,Ichroma COVID-19 Ab Test,Finecare SARS-CoV-2 Antibody test,COVID-19 IgG/IgM ECO Test","BioSys Laboratories,Kovalent,Boditech Med Inc.,Guangzhou Wondfo Biotech Co. Ltd,ECO Diagnostica LTDA",Multiple Types,Whole Blood,"['IgA', 'IgM']",,,,,['Moderate'],,Yes,Yes,No,,Unclear,Yes,No,,Adriano Antunes de Souza Araujo,Federal University of Sergipe,Not Unity-Aligned,https://dx.doi.org/10.1080/20477724.2022.2121366,2022-09-18,2024-03-01,Unverified,desouzaaraújoDynamicsSARSCoV2Seroprevalence2022,BRA
220912_Brazil_FederalUniversityofSergipe_Phase1_male,220912_Brazil_FederalUniversityofSergipe_Phase1,Dynamics of SARS-CoV-2 seroprevalence during the first year of the COVID-19 pandemic in the Northeast region of Brazil.,2022-09-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,"Sergipe
",,"""In each municipality, households were randomly selected from a sampling frame developed from a census list. At the beginning of the visit, all house-hold members were listed, and one individual was randomly selected for data collection. There was no overlapping population in the different phases of the study.""","""Fully or partially vaccinated people were not included as the vaccination campaign against COVID-19 in the state started on 19 January 2021""

",2020-07-01,2020-07-30,Household and community samples,Male,Multiple groups,,,Sex/Gender,3,2266,0.079,,,,,,,,Simplified probability,"The BioSys Plus COVID-19 IgM/IgG Rapid Test,KOVID Ab (COVID-19 IgG / IgM) kit,Ichroma COVID-19 Ab Test,Finecare SARS-CoV-2 Antibody test,COVID-19 IgG/IgM ECO Test","BioSys Laboratories,Kovalent,Boditech Med Inc.,Guangzhou Wondfo Biotech Co. Ltd,ECO Diagnostica LTDA",Multiple Types,Whole Blood,"['IgA', 'IgM']",,,,,['Moderate'],,Yes,Yes,No,,Unclear,Yes,No,,Adriano Antunes de Souza Araujo,Federal University of Sergipe,Not Unity-Aligned,https://dx.doi.org/10.1080/20477724.2022.2121366,2022-09-18,2024-03-01,Unverified,desouzaaraújoDynamicsSARSCoV2Seroprevalence2022,BRA
220912_Brazil_FederalUniversityofSergipe_Phase1_female,220912_Brazil_FederalUniversityofSergipe_Phase1,Dynamics of SARS-CoV-2 seroprevalence during the first year of the COVID-19 pandemic in the Northeast region of Brazil.,2022-09-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,"Sergipe
",,"""In each municipality, households were randomly selected from a sampling frame developed from a census list. At the beginning of the visit, all house-hold members were listed, and one individual was randomly selected for data collection. There was no overlapping population in the different phases of the study.""","""Fully or partially vaccinated people were not included as the vaccination campaign against COVID-19 in the state started on 19 January 2021""

",2020-07-01,2020-07-30,Household and community samples,Female,Multiple groups,,,Sex/Gender,,3353,0.102,,,,,,,,Simplified probability,"The BioSys Plus COVID-19 IgM/IgG Rapid Test,KOVID Ab (COVID-19 IgG / IgM) kit,Ichroma COVID-19 Ab Test,Finecare SARS-CoV-2 Antibody test,COVID-19 IgG/IgM ECO Test","BioSys Laboratories,Kovalent,Boditech Med Inc.,Guangzhou Wondfo Biotech Co. Ltd,ECO Diagnostica LTDA",Multiple Types,Whole Blood,"['IgA', 'IgM']",,,,,['Moderate'],,Yes,Yes,No,,Unclear,Yes,No,,Adriano Antunes de Souza Araujo,Federal University of Sergipe,Not Unity-Aligned,https://dx.doi.org/10.1080/20477724.2022.2121366,2022-09-18,2024-03-01,Unverified,desouzaaraújoDynamicsSARSCoV2Seroprevalence2022,BRA
220912_Brazil_FederalUniversityofSergipe_Phase2_overall,220912_Brazil_FederalUniversityofSergipe_Phase2,Dynamics of SARS-CoV-2 seroprevalence during the first year of the COVID-19 pandemic in the Northeast region of Brazil.,2022-09-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,"Sergipe
",,"""In each municipality, households were randomly selected from a sampling frame developed from a census list. At the beginning of the visit, all house-hold members were listed, and one individual was randomly selected for data collection. There was no overlapping population in the different phases of the study.""","""Fully or partially vaccinated people were not included as the vaccination campaign against COVID-19 in the state started on 19 January 2021""",2020-08-11,2020-11-17,Household and community samples,All,Multiple groups,,,Primary Estimate,,5400,0.12,,,True,,,,True,Simplified probability,"The BioSys Plus COVID-19 IgM/IgG Rapid Test,KOVID Ab (COVID-19 IgG / IgM) kit,Ichroma COVID-19 Ab Test,Finecare SARS-CoV-2 Antibody test,COVID-19 IgG/IgM ECO Test","BioSys Laboratories,Kovalent,Boditech Med Inc.,Guangzhou Wondfo Biotech Co. Ltd,ECO Diagnostica LTDA",Multiple Types,Whole Blood,"['IgA', 'IgM']",,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Adriano Antunes de Souza Araujo,Federal University of Sergipe,Not Unity-Aligned,https://dx.doi.org/10.1080/20477724.2022.2121366,2022-09-18,2024-03-01,Unverified,desouzaaraújoDynamicsSARSCoV2Seroprevalence2022,BRA
220912_Brazil_FederalUniversityofSergipe_Phase2_male,220912_Brazil_FederalUniversityofSergipe_Phase2,Dynamics of SARS-CoV-2 seroprevalence during the first year of the COVID-19 pandemic in the Northeast region of Brazil.,2022-09-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,"Sergipe
",,"""In each municipality, households were randomly selected from a sampling frame developed from a census list. At the beginning of the visit, all house-hold members were listed, and one individual was randomly selected for data collection. There was no overlapping population in the different phases of the study.""","""Fully or partially vaccinated people were not included as the vaccination campaign against COVID-19 in the state started on 19 January 2021""",2020-08-11,2020-11-17,Household and community samples,Male,Multiple groups,,,Sex/Gender,,1991,0.10800000000000001,,,,,,,,Simplified probability,"The BioSys Plus COVID-19 IgM/IgG Rapid Test,KOVID Ab (COVID-19 IgG / IgM) kit,Ichroma COVID-19 Ab Test,Finecare SARS-CoV-2 Antibody test,COVID-19 IgG/IgM ECO Test","BioSys Laboratories,Kovalent,Boditech Med Inc.,Guangzhou Wondfo Biotech Co. Ltd,ECO Diagnostica LTDA",Multiple Types,Whole Blood,"['IgA', 'IgM']",,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Adriano Antunes de Souza Araujo,Federal University of Sergipe,Not Unity-Aligned,https://dx.doi.org/10.1080/20477724.2022.2121366,2022-09-18,2024-03-01,Unverified,desouzaaraújoDynamicsSARSCoV2Seroprevalence2022,BRA
220912_Brazil_FederalUniversityofSergipe_Phase2_20to59,220912_Brazil_FederalUniversityofSergipe_Phase2,Dynamics of SARS-CoV-2 seroprevalence during the first year of the COVID-19 pandemic in the Northeast region of Brazil.,2022-09-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,"Sergipe
",,"""In each municipality, households were randomly selected from a sampling frame developed from a census list. At the beginning of the visit, all house-hold members were listed, and one individual was randomly selected for data collection. There was no overlapping population in the different phases of the study.""","""Fully or partially vaccinated people were not included as the vaccination campaign against COVID-19 in the state started on 19 January 2021""",2020-08-11,2020-11-17,Household and community samples,All,Adults (18-64 years),20.0,59.0,Age,20-59,3780,0.12300000000000001,,,,,,,,Simplified probability,"The BioSys Plus COVID-19 IgM/IgG Rapid Test,KOVID Ab (COVID-19 IgG / IgM) kit,Ichroma COVID-19 Ab Test,Finecare SARS-CoV-2 Antibody test,COVID-19 IgG/IgM ECO Test","BioSys Laboratories,Kovalent,Boditech Med Inc.,Guangzhou Wondfo Biotech Co. Ltd,ECO Diagnostica LTDA",Multiple Types,Whole Blood,"['IgA', 'IgM']",,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Adriano Antunes de Souza Araujo,Federal University of Sergipe,Not Unity-Aligned,https://dx.doi.org/10.1080/20477724.2022.2121366,2022-09-18,2024-03-01,Unverified,desouzaaraújoDynamicsSARSCoV2Seroprevalence2022,BRA
220912_Brazil_FederalUniversityofSergipe_Phase2_60plus,220912_Brazil_FederalUniversityofSergipe_Phase2,Dynamics of SARS-CoV-2 seroprevalence during the first year of the COVID-19 pandemic in the Northeast region of Brazil.,2022-09-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,"Sergipe
",,"""In each municipality, households were randomly selected from a sampling frame developed from a census list. At the beginning of the visit, all house-hold members were listed, and one individual was randomly selected for data collection. There was no overlapping population in the different phases of the study.""","""Fully or partially vaccinated people were not included as the vaccination campaign against COVID-19 in the state started on 19 January 2021""",2020-08-11,2020-11-17,Household and community samples,All,Seniors (65+ years),60.0,,Age,60+,991,0.109,,,,,,,,Simplified probability,"The BioSys Plus COVID-19 IgM/IgG Rapid Test,KOVID Ab (COVID-19 IgG / IgM) kit,Ichroma COVID-19 Ab Test,Finecare SARS-CoV-2 Antibody test,COVID-19 IgG/IgM ECO Test","BioSys Laboratories,Kovalent,Boditech Med Inc.,Guangzhou Wondfo Biotech Co. Ltd,ECO Diagnostica LTDA",Multiple Types,Whole Blood,"['IgA', 'IgM']",,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Adriano Antunes de Souza Araujo,Federal University of Sergipe,Not Unity-Aligned,https://dx.doi.org/10.1080/20477724.2022.2121366,2022-09-18,2024-03-01,Unverified,desouzaaraújoDynamicsSARSCoV2Seroprevalence2022,BRA
220912_Brazil_FederalUniversityofSergipe_Phase2_female,220912_Brazil_FederalUniversityofSergipe_Phase2,Dynamics of SARS-CoV-2 seroprevalence during the first year of the COVID-19 pandemic in the Northeast region of Brazil.,2022-09-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,"Sergipe
",,"""In each municipality, households were randomly selected from a sampling frame developed from a census list. At the beginning of the visit, all house-hold members were listed, and one individual was randomly selected for data collection. There was no overlapping population in the different phases of the study.""","""Fully or partially vaccinated people were not included as the vaccination campaign against COVID-19 in the state started on 19 January 2021""",2020-08-11,2020-11-17,Household and community samples,Female,Multiple groups,,,Sex/Gender,,3409,0.127,,,,,,,,Simplified probability,"The BioSys Plus COVID-19 IgM/IgG Rapid Test,KOVID Ab (COVID-19 IgG / IgM) kit,Ichroma COVID-19 Ab Test,Finecare SARS-CoV-2 Antibody test,COVID-19 IgG/IgM ECO Test","BioSys Laboratories,Kovalent,Boditech Med Inc.,Guangzhou Wondfo Biotech Co. Ltd,ECO Diagnostica LTDA",Multiple Types,Whole Blood,"['IgA', 'IgM']",,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Adriano Antunes de Souza Araujo,Federal University of Sergipe,Not Unity-Aligned,https://dx.doi.org/10.1080/20477724.2022.2121366,2022-09-18,2024-03-01,Unverified,desouzaaraújoDynamicsSARSCoV2Seroprevalence2022,BRA
220912_Brazil_FederalUniversityofSergipe_Phase2_0to19,220912_Brazil_FederalUniversityofSergipe_Phase2,Dynamics of SARS-CoV-2 seroprevalence during the first year of the COVID-19 pandemic in the Northeast region of Brazil.,2022-09-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,"Sergipe
",,"""In each municipality, households were randomly selected from a sampling frame developed from a census list. At the beginning of the visit, all house-hold members were listed, and one individual was randomly selected for data collection. There was no overlapping population in the different phases of the study.""","""Fully or partially vaccinated people were not included as the vaccination campaign against COVID-19 in the state started on 19 January 2021""",2020-08-11,2020-11-17,Household and community samples,All,Children and Youth (0-17 years),0.0,19.0,Age,0-19,616,0.11199999999999999,,,,,,,,Simplified probability,"The BioSys Plus COVID-19 IgM/IgG Rapid Test,KOVID Ab (COVID-19 IgG / IgM) kit,Ichroma COVID-19 Ab Test,Finecare SARS-CoV-2 Antibody test,COVID-19 IgG/IgM ECO Test","BioSys Laboratories,Kovalent,Boditech Med Inc.,Guangzhou Wondfo Biotech Co. Ltd,ECO Diagnostica LTDA",Multiple Types,Whole Blood,"['IgA', 'IgM']",,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Adriano Antunes de Souza Araujo,Federal University of Sergipe,Not Unity-Aligned,https://dx.doi.org/10.1080/20477724.2022.2121366,2022-09-18,2024-03-01,Unverified,desouzaaraújoDynamicsSARSCoV2Seroprevalence2022,BRA
220912_Brazil_FederalUniversityofSergipe_Phase3_overall,220912_Brazil_FederalUniversityofSergipe_Phase3,Dynamics of SARS-CoV-2 seroprevalence during the first year of the COVID-19 pandemic in the Northeast region of Brazil.,2022-09-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,"Sergipe
",,"""In each municipality, households were randomly selected from a sampling frame developed from a census list. At the beginning of the visit, all house-hold members were listed, and one individual was randomly selected for data collection. There was no overlapping population in the different phases of the study.""","""Fully or partially vaccinated people were not included as the vaccination campaign against COVID-19 in the state started on 19 January 2021""",2021-02-18,2021-03-30,Household and community samples,All,Multiple groups,,,Primary Estimate,,5525,0.154,,,True,,,,True,Simplified probability,"The BioSys Plus COVID-19 IgM/IgG Rapid Test,KOVID Ab (COVID-19 IgG / IgM) kit,Ichroma COVID-19 Ab Test,Finecare SARS-CoV-2 Antibody test,COVID-19 IgG/IgM ECO Test","BioSys Laboratories,Kovalent,Boditech Med Inc.,Guangzhou Wondfo Biotech Co. Ltd,ECO Diagnostica LTDA",Multiple Types,Whole Blood,"['IgA', 'IgM']",,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Adriano Antunes de Souza Araujo,Federal University of Sergipe,Not Unity-Aligned,https://dx.doi.org/10.1080/20477724.2022.2121366,2022-09-18,2024-03-01,Unverified,desouzaaraújoDynamicsSARSCoV2Seroprevalence2022,BRA
220912_Brazil_FederalUniversityofSergipe_Phase3_female,220912_Brazil_FederalUniversityofSergipe_Phase3,Dynamics of SARS-CoV-2 seroprevalence during the first year of the COVID-19 pandemic in the Northeast region of Brazil.,2022-09-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,"Sergipe
",,"""In each municipality, households were randomly selected from a sampling frame developed from a census list. At the beginning of the visit, all house-hold members were listed, and one individual was randomly selected for data collection. There was no overlapping population in the different phases of the study.""","""Fully or partially vaccinated people were not included as the vaccination campaign against COVID-19 in the state started on 19 January 2021""",2021-02-18,2021-03-30,Household and community samples,Female,Multiple groups,,,Sex/Gender,,3606,0.17,,,,,,,,Simplified probability,"The BioSys Plus COVID-19 IgM/IgG Rapid Test,KOVID Ab (COVID-19 IgG / IgM) kit,Ichroma COVID-19 Ab Test,Finecare SARS-CoV-2 Antibody test,COVID-19 IgG/IgM ECO Test","BioSys Laboratories,Kovalent,Boditech Med Inc.,Guangzhou Wondfo Biotech Co. Ltd,ECO Diagnostica LTDA",Multiple Types,Whole Blood,"['IgA', 'IgM']",,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Adriano Antunes de Souza Araujo,Federal University of Sergipe,Not Unity-Aligned,https://dx.doi.org/10.1080/20477724.2022.2121366,2022-09-18,2024-03-01,Unverified,desouzaaraújoDynamicsSARSCoV2Seroprevalence2022,BRA
220912_Brazil_FederalUniversityofSergipe_Phase3_male,220912_Brazil_FederalUniversityofSergipe_Phase3,Dynamics of SARS-CoV-2 seroprevalence during the first year of the COVID-19 pandemic in the Northeast region of Brazil.,2022-09-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,"Sergipe
",,"""In each municipality, households were randomly selected from a sampling frame developed from a census list. At the beginning of the visit, all house-hold members were listed, and one individual was randomly selected for data collection. There was no overlapping population in the different phases of the study.""","""Fully or partially vaccinated people were not included as the vaccination campaign against COVID-19 in the state started on 19 January 2021""",2021-02-18,2021-03-30,Household and community samples,Male,Multiple groups,,,Sex/Gender,,1919,0.12400000000000001,,,,,,,,Simplified probability,"The BioSys Plus COVID-19 IgM/IgG Rapid Test,KOVID Ab (COVID-19 IgG / IgM) kit,Ichroma COVID-19 Ab Test,Finecare SARS-CoV-2 Antibody test,COVID-19 IgG/IgM ECO Test","BioSys Laboratories,Kovalent,Boditech Med Inc.,Guangzhou Wondfo Biotech Co. Ltd,ECO Diagnostica LTDA",Multiple Types,Whole Blood,"['IgA', 'IgM']",,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Adriano Antunes de Souza Araujo,Federal University of Sergipe,Not Unity-Aligned,https://dx.doi.org/10.1080/20477724.2022.2121366,2022-09-18,2024-03-01,Unverified,desouzaaraújoDynamicsSARSCoV2Seroprevalence2022,BRA
220912_Brazil_FederalUniversityofSergipe_Phase3_60plus,220912_Brazil_FederalUniversityofSergipe_Phase3,Dynamics of SARS-CoV-2 seroprevalence during the first year of the COVID-19 pandemic in the Northeast region of Brazil.,2022-09-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,"Sergipe
",,"""In each municipality, households were randomly selected from a sampling frame developed from a census list. At the beginning of the visit, all house-hold members were listed, and one individual was randomly selected for data collection. There was no overlapping population in the different phases of the study.""","""Fully or partially vaccinated people were not included as the vaccination campaign against COVID-19 in the state started on 19 January 2021""",2021-02-18,2021-03-30,Household and community samples,All,Seniors (65+ years),60.0,,Age,60+,814,0.188,,,,,,,,Simplified probability,"The BioSys Plus COVID-19 IgM/IgG Rapid Test,KOVID Ab (COVID-19 IgG / IgM) kit,Ichroma COVID-19 Ab Test,Finecare SARS-CoV-2 Antibody test,COVID-19 IgG/IgM ECO Test","BioSys Laboratories,Kovalent,Boditech Med Inc.,Guangzhou Wondfo Biotech Co. Ltd,ECO Diagnostica LTDA",Multiple Types,Whole Blood,"['IgA', 'IgM']",,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Adriano Antunes de Souza Araujo,Federal University of Sergipe,Not Unity-Aligned,https://dx.doi.org/10.1080/20477724.2022.2121366,2022-09-18,2024-03-01,Unverified,desouzaaraújoDynamicsSARSCoV2Seroprevalence2022,BRA
220912_Brazil_FederalUniversityofSergipe_Phase3_0to19,220912_Brazil_FederalUniversityofSergipe_Phase3,Dynamics of SARS-CoV-2 seroprevalence during the first year of the COVID-19 pandemic in the Northeast region of Brazil.,2022-09-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,"Sergipe
",,"""In each municipality, households were randomly selected from a sampling frame developed from a census list. At the beginning of the visit, all house-hold members were listed, and one individual was randomly selected for data collection. There was no overlapping population in the different phases of the study.""","""Fully or partially vaccinated people were not included as the vaccination campaign against COVID-19 in the state started on 19 January 2021""",2021-02-18,2021-03-30,Household and community samples,All,Children and Youth (0-17 years),0.0,19.0,Age,0-19,655,0.084,,,,,,,,Simplified probability,"The BioSys Plus COVID-19 IgM/IgG Rapid Test,KOVID Ab (COVID-19 IgG / IgM) kit,Ichroma COVID-19 Ab Test,Finecare SARS-CoV-2 Antibody test,COVID-19 IgG/IgM ECO Test","BioSys Laboratories,Kovalent,Boditech Med Inc.,Guangzhou Wondfo Biotech Co. Ltd,ECO Diagnostica LTDA",Multiple Types,Whole Blood,"['IgA', 'IgM']",,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Adriano Antunes de Souza Araujo,Federal University of Sergipe,Not Unity-Aligned,https://dx.doi.org/10.1080/20477724.2022.2121366,2022-09-18,2024-03-01,Unverified,desouzaaraújoDynamicsSARSCoV2Seroprevalence2022,BRA
220912_Brazil_FederalUniversityofSergipe_Phase3_20to59,220912_Brazil_FederalUniversityofSergipe_Phase3,Dynamics of SARS-CoV-2 seroprevalence during the first year of the COVID-19 pandemic in the Northeast region of Brazil.,2022-09-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Brazil,"Sergipe
",,"""In each municipality, households were randomly selected from a sampling frame developed from a census list. At the beginning of the visit, all house-hold members were listed, and one individual was randomly selected for data collection. There was no overlapping population in the different phases of the study.""","""Fully or partially vaccinated people were not included as the vaccination campaign against COVID-19 in the state started on 19 January 2021""",2021-02-18,2021-03-30,Household and community samples,All,Adults (18-64 years),20.0,59.0,Age,20-59,3761,0.163,,,,,,,,Simplified probability,"The BioSys Plus COVID-19 IgM/IgG Rapid Test,KOVID Ab (COVID-19 IgG / IgM) kit,Ichroma COVID-19 Ab Test,Finecare SARS-CoV-2 Antibody test,COVID-19 IgG/IgM ECO Test","BioSys Laboratories,Kovalent,Boditech Med Inc.,Guangzhou Wondfo Biotech Co. Ltd,ECO Diagnostica LTDA",Multiple Types,Whole Blood,"['IgA', 'IgM']",,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Adriano Antunes de Souza Araujo,Federal University of Sergipe,Not Unity-Aligned,https://dx.doi.org/10.1080/20477724.2022.2121366,2022-09-18,2024-03-01,Unverified,desouzaaraújoDynamicsSARSCoV2Seroprevalence2022,BRA
220912_Brazil_UniversidadedeSaoPaulo_overall,220912_Brazil_UniversidadedeSaoPaulo,Seroconversion in asymptomatic COVID-19 pediatric patients with rheumatic diseases of one tertiary referral hospital.,2022-09-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,São Paulo estado ,Sao Paulo,"""The study included subjects between one to 18 years old who did not have a previous diagnosis of COVID-19 by Reverse Transcription Polymerase Chain Reaction (RT-PCR) or serology over the last year and did not present signs or symptoms of COVID-19 strong enough to alert them for the possibility of the disease or to led them to seek for medical attention ...""","""Children under one year of age were excluded due to the possibility of having circulating maternal antibodies, and above 19 years old, who are already considered adults according to the World Health Organization (WHO) criteria. People who had shown warning signs for COVID-19 or who had been diagnosed with the disease in the previous year were excluded, as well as subjects who had signs of active infection on the day of sample collection. Patients who received Rituximab (RTX) or Intravenous Immunoglobulin (IVIG) in the six months prior to the study were also excluded ...""",2021-03-01,2021-03-31,Residual sera,All,Children and Youth (0-17 years),4.0,19.0,Primary Estimate,,122,0.197,,,True,,,,True,Sequential,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.8643000000000001,0.9956999999999999,['High'],,No,No,Yes,,No,Yes,No,,Juliana Simon,Universidade de Sao Paulo,Not Unity-Aligned,https://dx.doi.org/10.1016/j.clinsp.2022.100110,2022-10-14,2024-03-01,Unverified,simon_seroconversion_2022,BRA
220916_Belem_Federal UniversityofPara_overall,220916_Belem_Federal UniversityofPara,Changes in the seroprevalence and risk factors between the first and second waves of COVID-19 in a metropolis in the Brazilian Amazon.,2022-09-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,State of Para,Belem,""" individuals residing in the city of Belém during two major periods: after the first wave of COVID-19 (October 2020 to February 2021, 736 individuals) and after the second wave of COVID-19 (March 2021 to December 2021, 601 individuals).""","""Individuals already vaccinated with one or two doses against SARS-CoV-2, those who did not respond to the epidemiological questionnaire, those who did not sign the informed consent form, and those under 7 years of age were excluded from the research. There was no overlap of the individuals analyzed in the two study periods.""",2020-10-15,2021-12-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,1262,0.443,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Plasma,IgG,Spike,,0.9,1.0,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Maria Karoliny da Silva Torres,Federal University of Para,Not Unity-Aligned,https://dx.doi.org/10.3389/fcimb.2022.932563,2022-10-12,2024-03-01,Unverified,dasilvatorresChangesSeroprevalenceRisk2022,BRA
220916_Belem_Federal UniversityofPara_wave2,220916_Belem_Federal UniversityofPara,Changes in the seroprevalence and risk factors between the first and second waves of COVID-19 in a metropolis in the Brazilian Amazon.,2022-09-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,State of Para,Belem,""" individuals residing in the city of Belém during two major periods: after the first wave of COVID-19 (October 2020 to February 2021, 736 individuals) and after the second wave of COVID-19 (March 2021 to December 2021, 601 individuals).""","""Individuals already vaccinated with one or two doses against SARS-CoV-2, those who did not respond to the epidemiological questionnaire, those who did not sign the informed consent form, and those under 7 years of age were excluded from the research. There was no overlap of the individuals analyzed in the two study periods.""",2021-03-15,2021-12-15,Household and community samples,All,Multiple groups,,,Time frame,,558,0.5089,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Plasma,IgG,Spike,,0.9,1.0,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Maria Karoliny da Silva Torres,Federal University of Para,Not Unity-Aligned,https://dx.doi.org/10.3389/fcimb.2022.932563,2022-10-12,2024-03-01,Unverified,dasilvatorresChangesSeroprevalenceRisk2022,BRA
220916_Belem_Federal UniversityofPara_wave1,220916_Belem_Federal UniversityofPara,Changes in the seroprevalence and risk factors between the first and second waves of COVID-19 in a metropolis in the Brazilian Amazon.,2022-09-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,State of Para,Belem,""" individuals residing in the city of Belém during two major periods: after the first wave of COVID-19 (October 2020 to February 2021, 736 individuals) and after the second wave of COVID-19 (March 2021 to December 2021, 601 individuals).""","""Individuals already vaccinated with one or two doses against SARS-CoV-2, those who did not respond to the epidemiological questionnaire, those who did not sign the informed consent form, and those under 7 years of age were excluded from the research. There was no overlap of the individuals analyzed in the two study periods.""",2020-10-15,2021-02-15,Household and community samples,All,Multiple groups,,,Time frame,,704,0.391,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Plasma,IgG,Spike,,0.9,1.0,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Maria Karoliny da Silva Torres,Federal University of Para,Not Unity-Aligned,https://dx.doi.org/10.3389/fcimb.2022.932563,2022-10-12,2024-03-01,Unverified,dasilvatorresChangesSeroprevalenceRisk2022,BRA
220922_Brazil_UniversityofSãoPaulo_overall,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-03-15,2021-03-15,Blood donors,All,Adults (18-64 years),16.0,64.0,Primary Estimate,,98640,0.2022,,,True,,,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint39,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-10-20,2020-10-27,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,557,0.2837,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint45,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-11-29,2020-12-06,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,1611,0.24710000000000001,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_sexunknown,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-03-15,2021-03-15,Blood donors,Female,Adults (18-64 years),16.0,64.0,Sex/Gender,,791,0.3578,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint22,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-06-06,2020-06-13,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,530,0.24530000000000002,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint41,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-10-28,2020-11-04,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,1116,0.267,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint53,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2021-02-01,2021-02-08,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,1341,0.1991,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint44,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-11-21,2020-11-28,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,721,0.2469,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint17,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-04-27,2020-05-04,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,937,0.0352,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint81,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2021-09-13,2021-09-20,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,14,0.7857,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint12,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-03-18,2020-03-25,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,2548,0.0314,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint82,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2021-09-21,2021-09-28,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,6,0.6667000000000001,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint54,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2021-02-09,2021-02-16,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,3515,0.2262,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint52,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2021-01-24,2021-01-31,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,716,0.2332,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint64,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2021-04-30,2021-05-07,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,1366,0.2775,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint13,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-03-26,2020-04-02,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,1028,0.0204,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint63,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2021-04-22,2021-04-29,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,3580,0.3011,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint66,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2021-05-16,2021-05-23,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,48,0.2917,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint16,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-04-19,2020-04-26,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,1963,0.0438,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_male,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-03-15,2021-03-15,Blood donors,Male,Adults (18-64 years),16.0,64.0,Sex/Gender,,56201,0.2233,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint47,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-12-15,2020-12-22,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,1940,0.2237,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint25,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-06-30,2020-07-07,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,1800,0.19,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint31,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-08-17,2020-08-24,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,360,0.175,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint48,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-12-23,2020-12-30,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,568,0.2183,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint19,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-05-13,2020-05-20,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,2409,0.1631,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint72,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2021-07-03,2021-07-10,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,19,0.5263,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint73,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2021-07-11,2021-07-18,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,2,0.5,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint43,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-11-13,2020-11-20,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,1962,0.2385,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint37,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-10-04,2020-10-11,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,4357,0.2385,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint46,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-12-07,2020-12-14,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,3588,0.204,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint32,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-08-25,2020-09-01,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,1500,0.272,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint78,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2021-08-20,2021-08-27,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,3,1.0,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint65,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2021-05-08,2021-05-15,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,441,0.2358,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint26,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-07-08,2020-07-15,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,457,0.2254,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint34,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-09-10,2020-09-17,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,1897,0.2599,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint68,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2021-06-01,2021-06-08,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,155,0.3419,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint21,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-05-29,2020-06-05,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,1238,0.1583,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint10,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-03-02,2020-03-09,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,1646,0.0231,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint38,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-10-12,2020-10-19,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,1952,0.2418,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint23,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-06-14,2020-06-21,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,1525,0.2407,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint42,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-11-05,2020-11-12,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,3807,0.2262,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint29,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-08-01,2020-08-08,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,3094,0.1917,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint28,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-07-24,2020-07-31,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,2227,0.2932,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint58,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2021-03-13,2021-03-20,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,1422,0.2567,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint55,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2021-02-17,2021-02-24,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,2227,0.2667,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint33,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-09-02,2020-09-09,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,3740,0.2479,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint27,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-07-16,2020-07-23,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,186,0.4892,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint20,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-05-21,2020-05-28,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,3064,0.1361,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint11,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-03-10,2020-03-17,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,3306,0.0306,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint36,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-09-26,2020-10-03,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,1083,0.277,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint14,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-04-03,2020-04-10,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,123,0.0569,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint24,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-06-22,2020-06-29,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,3332,0.2287,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint71,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2021-06-25,2021-07-02,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,31,0.4194,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint56,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2021-02-25,2021-03-04,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,621,0.1852,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint59,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2021-03-21,2021-03-28,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,3979,0.2586,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint69,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2021-06-09,2021-06-16,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,271,0.3469,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint70,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2021-06-17,2021-06-24,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,33,0.2727,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint67,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2021-05-24,2021-05-31,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,153,0.281,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint15,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-04-11,2020-04-18,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,3589,0.0318,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint30,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-08-09,2020-08-16,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,1437,0.2234,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_female,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-03-15,2021-03-15,Blood donors,Female,Adults (18-64 years),16.0,64.0,Sex/Gender,,41648,0.17070000000000002,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint60,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2021-03-29,2021-04-05,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,1873,0.2653,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint57,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2021-03-05,2021-03-12,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,185,0.227,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint35,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-09-18,2020-09-25,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,788,0.2627,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint18,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-05-05,2020-05-12,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,299,0.056900000000000006,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint49,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2020-12-31,2021-01-07,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,1115,0.2108,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint51,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2021-01-16,2021-01-23,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,1726,0.2074,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint62,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2021-04-14,2021-04-21,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,1224,0.3105,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint50,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2021-01-08,2021-01-15,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,3981,0.2336,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
220922_Brazil_UniversityofSãoPaulo_timepoint61,220922_Brazil_UniversityofSãoPaulo,SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study,2022-09-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Brazil,,"Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo","""we analyse the divergent epidemic SARS-CoV-2 dynamics in eight of the biggest Brazilian cities (Belo Horizonte, Curitiba, Fortaleza, Manaus, Recife, Rio de Janeiro, Salvador, and São Paulo). We estimate the seroprevalence over time for these cities disaggregated by age and sex using repeated cross-sectional convenience samples of routine blood donors collected from March 2020 to March 2021. ""","""From 453,211 available blood samples collected in all 8 cities except Manaus, 72,783 had a missing or invalid residential postal code, and 198,199 were from individuals living in regions not included in this study, thus 182,229 samples were eligible for selection.""",2021-04-06,2021-04-13,Blood donors,All,Adults (18-64 years),16.0,64.0,Time frame,,308,0.2435,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9059999999999999,0.975,['High'],,No,Yes,No,,Yes,Yes,Yes,,Carlos Prete Jr,University of São Paulo,Unity-Aligned,https://doi.org/10.7554/eLife.78233,2022-10-20,2024-04-14,Verified,preteSARSCoV2AntibodyDynamics2022,BRA
221015_PortoAlegre_UniversidadeFederalDoRioGrandeDoSul,221015_PortoAlegre_UniversidadeFederalDoRioGrandeDoSul,FREQUENCIA DE TESTES RAPIDOS POSITIVOS PARA SARS-COV-2 ENTRE DOADORES DE SANGUE,2022-10-15,Presentation or Conference,Local,Cross-sectional survey ,Brazil,Rio Grande do Sul,Porto Alegre,"Google translated:
""A retrospective cross-sectional study was carried out with serum samples from blood donors, who donated between January and March 2021 at the Blood Bank of Hospital de Clínicas de Porto Alegre.""",,2021-01-15,2021-03-15,Blood donors,All,Multiple groups,,,Primary Estimate,,1837,0.133,,,True,,,,True,Sequential,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Serum,"IgG, IgM",Spike,,,,['High'],,No,Yes,No,,No,Yes,No,,MB Silva,Universidade Federal do Rio Grande do Sul ,Not Unity-Aligned,https://dx.doi.org/10.1016/j.htct.2022.09.1146,2023-01-11,2024-03-01,Unverified,silva_frequencia_2022,BRA
221015_RibeiraoPreto_FundacaoHemocentroDeRibeiraoPreto,221015_RibeiraoPreto_FundacaoHemocentroDeRibeiraoPreto,O IMPACTO DO SARS-COV-2 NA MEDICINA TRANSFUSIONAL: AVALIACAO DA SOROPREVALENCIA E DETECCAO MOLECULAR DE SARS-COV-2 EM DOADORES DE SANGUE,2022-10-15,Presentation or Conference,Local,Cross-sectional survey ,Brazil,,Ribeirao Preto,"Google translated:
""blood donors from the Hemocenter of Ribeirão Preto"" in the year 2020.",,2020-01-15,2020-12-15,Blood donors,All,Multiple groups,,,Primary Estimate,,646,0.0487,,,True,,,,True,Sequential,Not reported/ Unable to specify,,,Plasma,IgG,,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,M Evaristo,Fundação Hemocentro de Ribeirão Preto,Not Unity-Aligned,https://dx.doi.org/10.1016/j.htct.2022.09.1139,2023-01-10,2023-03-19,Unverified,evaristo_o_2022,BRA
221104_Sergipe_UniversityofSaoPaulo_SchoolWorkers_Overall,221104_Sergipe_UniversityofSaoPaulo_SchoolWorkers,Cross-sectional analysis of students and school workers reveals a high number of asymptomatic SARS-CoV-2 infections during school reopening in Brazilian cities.,2022-11-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Sergipe,,We only included in our study high school (teenagers) and adult high school students. Participants came from 28 cities in all seven administrative health regions of Sergipe (Figure 2). Municipality selection was based on including at least three cities for each administrative health region having the largest number of school communities. ,Fifty-three individuals were excluded because their PCR results were inconclusive or had missing additional information.,2020-11-17,2021-01-21,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,1120,0.22321000000000002,,,True,,,,True,Unclear,EGENS COVID-19 IgG/IgM Rapid Test Kit,Nantong Egens Biotechnology,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.968,0.9652,['High'],,Unclear,Yes,Yes,,Unclear,Yes,No,,Lysandro Borges,University of Sao Paulo,Not Unity-Aligned,https://dx.doi.org/10.1016/j.heliyon.2022.e11368,2022-11-17,2022-11-17,Unverified,borges_cross-sectional_2022,BRA
221104_Sergipe_UniversityofSaoPaulo_Students_Overall,221104_Sergipe_UniversityofSaoPaulo_Students,Cross-sectional analysis of students and school workers reveals a high number of asymptomatic SARS-CoV-2 infections during school reopening in Brazilian cities.,2022-11-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Sergipe,,We only included in our study high school (teenagers) and adult high school students. Participants came from 28 cities in all seven administrative health regions of Sergipe (Figure 2). Municipality selection was based on including at least three cities for each administrative health region having the largest number of school communities. ,Fifty-three individuals were excluded because their PCR results were inconclusive or had missing additional information.,2020-11-17,2021-01-21,Students and Daycares,All,Children and Youth (0-17 years),,,Primary Estimate,,1139,0.16417,,,True,,,,True,Unclear,EGENS COVID-19 IgG/IgM Rapid Test Kit,Nantong Egens Biotechnology,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.968,0.9652,['High'],,Unclear,Yes,Yes,,Unclear,Yes,No,,Lysandro Borges,University of Sao Paulo,Not Unity-Aligned,https://dx.doi.org/10.1016/j.heliyon.2022.e11368,2022-11-17,2022-11-17,Unverified,borges_cross-sectional_2022,BRA
221114_Brazil_RiodeJaneiroCityGovernment_Primary,221114_Brazil_RiodeJaneiroCityGovernment,Seroepidemiology of SARS-CoV-2 on a partially vaccinated island in Brazil: Determinants of infection and vaccine response,2022-11-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Rio de Janeiro city,"""All residents of Paquetá Island were eligible for the study.""","""we excluded participants with vaccination inconsistencies (duplicity of doses; more than one on the same day; second doses without first dose) and those with missing variables information.""",2021-06-16,2021-06-19,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,3016,0.536,0.51,0.563,True,,,,True,Self-referral,"SARS-CoV-2 IgG II Quant ,Fastep lateral-flow rapid test","Abbott Laboratories,Azure Tech. Co., Ltd.—Hangzhou, Zhejiang, China",Multiple Types,Multiple Types,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,No,No,,Jose Cerbino-Neto,Rio de Janeiro City Government,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.1017337,2022-12-24,2024-03-01,Unverified,cerbino-neto_seroepidemiology_2022,BRA
221114_Brazil_RiodeJaneiroCityGovernment_Age12to17,221114_Brazil_RiodeJaneiroCityGovernment,Seroepidemiology of SARS-CoV-2 on a partially vaccinated island in Brazil: Determinants of infection and vaccine response,2022-11-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Rio de Janeiro city,"""All residents of Paquetá Island were eligible for the study.""","""we excluded participants with vaccination inconsistencies (duplicity of doses; more than one on the same day; second doses without first dose) and those with missing variables information.""",2021-06-16,2021-06-19,Household and community samples,All,Children and Youth (0-17 years),12.0,17.0,Age,age: 12-17 (regardless of vaccination status),326,0.18100000000000002,0.138,0.233,,,,,,Self-referral,Fastep lateral-flow rapid test,"Azure Tech. Co., Ltd.—Hangzhou, Zhejiang, China",LFIA,,"IgG, IgM","Nucleocapsid (N-protein), Spike",Validated by manufacturers,,,['High'],,No,Yes,Yes,,Unclear,No,No,,Jose Cerbino-Neto,Rio de Janeiro City Government,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.1017337,2022-12-24,2024-03-01,Unverified,cerbino-neto_seroepidemiology_2022,BRA
221114_Brazil_RiodeJaneiroCityGovernment_Age0to11,221114_Brazil_RiodeJaneiroCityGovernment,Seroepidemiology of SARS-CoV-2 on a partially vaccinated island in Brazil: Determinants of infection and vaccine response,2022-11-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Rio de Janeiro city,"""All residents of Paquetá Island were eligible for the study.""","""we excluded participants with vaccination inconsistencies (duplicity of doses; more than one on the same day; second doses without first dose) and those with missing variables information.""",2021-06-16,2021-06-19,Household and community samples,All,Children and Youth (0-17 years),0.0,11.0,Age,age: 0-11 (regardless of vaccination status),292,0.249,0.19899999999999998,0.308,,,,,,Self-referral,Fastep lateral-flow rapid test,"Azure Tech. Co., Ltd.—Hangzhou, Zhejiang, China",LFIA,,"IgG, IgM","Nucleocapsid (N-protein), Spike",Validated by manufacturers,,,['High'],,No,Yes,Yes,,Unclear,No,No,,Jose Cerbino-Neto,Rio de Janeiro City Government,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.1017337,2022-12-24,2024-03-01,Unverified,cerbino-neto_seroepidemiology_2022,BRA
221114_Brazil_RiodeJaneiroCityGovernment_AgeOver60,221114_Brazil_RiodeJaneiroCityGovernment,Seroepidemiology of SARS-CoV-2 on a partially vaccinated island in Brazil: Determinants of infection and vaccine response,2022-11-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Rio de Janeiro city,"""All residents of Paquetá Island were eligible for the study.""","""we excluded participants with vaccination inconsistencies (duplicity of doses; more than one on the same day; second doses without first dose) and those with missing variables information.""",2021-06-16,2021-06-19,Household and community samples,All,Seniors (65+ years),60.0,,Age,age: >= 60 (regardless of vaccination status),643,0.938,0.866,1.0,,,,,,Self-referral,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,"CLIA, CMIA",,IgG,Spike,Validated by manufacturers,,,['High'],,No,Yes,Yes,,Unclear,No,No,,Jose Cerbino-Neto,Rio de Janeiro City Government,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.1017337,2022-12-24,2024-03-01,Unverified,cerbino-neto_seroepidemiology_2022,BRA
221114_Brazil_RiodeJaneiroCityGovernment_Male,221114_Brazil_RiodeJaneiroCityGovernment,Seroepidemiology of SARS-CoV-2 on a partially vaccinated island in Brazil: Determinants of infection and vaccine response,2022-11-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Rio de Janeiro city,"""All residents of Paquetá Island were eligible for the study.""","""we excluded participants with vaccination inconsistencies (duplicity of doses; more than one on the same day; second doses without first dose) and those with missing variables information.""",2021-06-16,2021-06-19,Household and community samples,Male,Multiple groups,0.0,,Sex/Gender,Male (regardless of vaccination status),1324,0.489,,,,,,,,Self-referral,"SARS-CoV-2 IgG II Quant ,Fastep lateral-flow rapid test","Abbott Laboratories,Azure Tech. Co., Ltd.—Hangzhou, Zhejiang, China",Multiple Types,Multiple Types,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,No,No,,Jose Cerbino-Neto,Rio de Janeiro City Government,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.1017337,2022-12-24,2024-03-01,Unverified,cerbino-neto_seroepidemiology_2022,BRA
221114_Brazil_RiodeJaneiroCityGovernment_Age18to59,221114_Brazil_RiodeJaneiroCityGovernment,Seroepidemiology of SARS-CoV-2 on a partially vaccinated island in Brazil: Determinants of infection and vaccine response,2022-11-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Rio de Janeiro city,"""All residents of Paquetá Island were eligible for the study.""","""we excluded participants with vaccination inconsistencies (duplicity of doses; more than one on the same day; second doses without first dose) and those with missing variables information.""",2021-06-16,2021-06-19,Household and community samples,All,Adults (18-64 years),18.0,59.0,Age,age: 18-59 (regardless of vaccination status),1658,0.503,0.47000000000000003,0.539,,,,,,Self-referral,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,"CLIA, CMIA",,IgG,Spike,Validated by manufacturers,,,['High'],,No,Yes,Yes,,Unclear,No,No,,Jose Cerbino-Neto,Rio de Janeiro City Government,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.1017337,2022-12-24,2024-03-01,Unverified,cerbino-neto_seroepidemiology_2022,BRA
221114_Brazil_RiodeJaneiroCityGovernment_Female,221114_Brazil_RiodeJaneiroCityGovernment,Seroepidemiology of SARS-CoV-2 on a partially vaccinated island in Brazil: Determinants of infection and vaccine response,2022-11-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Rio de Janeiro city,"""All residents of Paquetá Island were eligible for the study.""","""we excluded participants with vaccination inconsistencies (duplicity of doses; more than one on the same day; second doses without first dose) and those with missing variables information.""",2021-06-16,2021-06-19,Household and community samples,Female,Multiple groups,0.0,,Sex/Gender,Female (regardless of vaccination status),1595,0.564,,,,,,,,Self-referral,"SARS-CoV-2 IgG II Quant ,Fastep lateral-flow rapid test","Abbott Laboratories,Azure Tech. Co., Ltd.—Hangzhou, Zhejiang, China",Multiple Types,Multiple Types,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,No,No,,Jose Cerbino-Neto,Rio de Janeiro City Government,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.1017337,2022-12-24,2024-03-01,Unverified,cerbino-neto_seroepidemiology_2022,BRA
230105_SaoPaulo_LondonSchoolofHygieneTropicalMedicine_Overall,230105_SaoPaulo_LondonSchoolofHygieneTropicalMedicine,Monitoring SARS-CoV-2 seroprevalence over time among pregnant women admitted to delivery units: Suitability for surveillance,2023-01-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Sao Paulo,"consecutive pregnant women admitted for delivery at the L&D unit at Hospital Universita´rio from July 20th 2020 to February 21st 2021, were invited to participate. Those pregnant women of all ages who provided signed written informed consent to participate in the study were eligible
and included.",pregnant women were admitted at night or during weekends; pregnant women refused to participate,2020-07-20,2021-02-21,Pregnant or parturient women,Female,Adults (18-64 years),18.0,,Primary Estimate,,763,0.29,,,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Mariana Yumi Miyadahira,London School of Hygiene & Tropical Medicine,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0280109,2023-02-09,2024-03-27,Verified,miyadahira_monitoring_2023,BRA
230105_SaoPaulo_LondonSchoolofHygieneTropicalMedicine_>29,230105_SaoPaulo_LondonSchoolofHygieneTropicalMedicine,Monitoring SARS-CoV-2 seroprevalence over time among pregnant women admitted to delivery units: Suitability for surveillance,2023-01-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Sao Paulo,"consecutive pregnant women admitted for delivery at the L&D unit at Hospital Universita´rio from July 20th 2020 to February 21st 2021, were invited to participate. Those pregnant women of all ages who provided signed written informed consent to participate in the study were eligible
and included.",pregnant women were admitted at night or during weekends; pregnant women refused to participate,2020-07-20,2021-02-21,Pregnant or parturient women,Female,Adults (18-64 years),30.0,,Age,>29,354,0.2599,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Mariana Yumi Miyadahira,London School of Hygiene & Tropical Medicine,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0280109,2024-03-26,2024-03-27,Verified,miyadahira_monitoring_2023,BRA
230105_SaoPaulo_LondonSchoolofHygieneTropicalMedicine_<30,230105_SaoPaulo_LondonSchoolofHygieneTropicalMedicine,Monitoring SARS-CoV-2 seroprevalence over time among pregnant women admitted to delivery units: Suitability for surveillance,2023-01-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,Sao Paulo,"consecutive pregnant women admitted for delivery at the L&D unit at Hospital Universita´rio from July 20th 2020 to February 21st 2021, were invited to participate. Those pregnant women of all ages who provided signed written informed consent to participate in the study were eligible
and included.",pregnant women were admitted at night or during weekends; pregnant women refused to participate,2020-07-20,2021-02-21,Pregnant or parturient women,Female,Adults (18-64 years),18.0,29.0,Age,<30,409,0.3154,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Mariana Yumi Miyadahira,London School of Hygiene & Tropical Medicine,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0280109,2024-03-26,2024-03-27,Verified,miyadahira_monitoring_2023,BRA
230403_Brazil_UniversityofSão Paulo,230403_Brazil_UniversityofSão Paulo,Serological Evaluation for Sars-cov-2 in Pediatric Heart Transplant Recipients and Patients on Pediatric Heart Transplant Waiting List in a Quaternary Hospital,2023-04-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Brazil,,,"""A cross-sectional cohort was performed in children and adults with heart disease, before and after heart transplant. """,,2022-01-15,2022-08-15,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),,,Primary Estimate,,144,0.4722,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],,No,No,No,,Unclear,Yes,No,,C.A. Villari,University of São Paulo,Not Unity-Aligned,https://dx.doi.org/10.1016/j.healun.2023.02.434,2023-05-05,2023-05-09,Unverified,villariSerologicalEvaluationSarscov22023,BRA
230413_MinasGerais_UniversidadeFederalDeAlfenas_Overall,230413_MinasGerais_UniversidadeFederalDeAlfenas,Seroprevalence of SARS-CoV-2 in hospital workers in the southern region of Minas Gerais state in Brazil: An analysis of the pre-vaccine period.,2023-04-13,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Minas Gerais state,,"Professionals directly and indirectly involved in COVID-19 combat strategies were invited to participate. The following inclusion criteria were used for sample collection: a) all health professionals directly involved
with suspected or confirmed individuals with COVID-19. b) professionals who worked in other sectors of the hospitals.",,2020-08-15,2020-12-15,Health care workers and caregivers,All,Multiple groups,18.0,72.0,Primary Estimate,,859,0.216,,,True,,,,True,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by developers,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Duillio Alves Caixeta,Universidade Federal de Alfenas,Not Unity-Aligned,https://dx.doi.org/10.1007/s42770-023-00966-8,2023-05-08,2023-05-09,Unverified,caixeta_seroprevalence_2023,BRA
230428_SãoSebastião_HospitalUniversitáriodeBrasília_Overall,230428_SãoSebastião_HospitalUniversitáriodeBrasília,"Seroprevalence of SARS-CoV-2 and Vaccination Coverage among Residents of a Lower-Middle-Class Population in the Federal District, Brazil",2023-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Federal District,São Sebastião,Residents of lower-middle class ,,2021-09-24,2021-12-19,Household and community samples,All,Multiple groups,,,Primary Estimate,,733,0.2415,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],Unclear,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Raissa Nogueira de Brito,Hospital Universitário de Brasília,Unity-Aligned,https://dx.doi.org/10.3390/vaccines11050916,2023-06-28,2024-04-25,Verified,nogueira_de_brito_seroprevalence_2023,BRA
230508_Mato Grosso_UniversidadeFederalDoMatoGrosso,230508_Mato Grosso_UniversidadeFederalDoMatoGrosso,Prevalence of Ivermectin use to prevent COVID-19 during the pandemic in Mato Grosso: cross-sectional home-based study.,2023-05-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Brazil,Mato Grosso,,,,2020-09-15,2020-10-15,Household and community samples,All,Adults (18-64 years),18.0,,Primary Estimate,,4206,0.125,,,True,,,,True,Stratified probability,Not reported/ Unable to specify,,,,,,,,,['High'],,Yes,Yes,No,,Unclear,Yes,No,,Nathalia Beatriz Lobo da Silva,Universidade Federal do Mato Grosso,Not Unity-Aligned,https://dx.doi.org/10.1590/1980-549720230026,2023-06-02,2023-06-03,Unverified,silva_prevalence_2023,BRA
230511_SãoPaulo_ CoordenadoriadeVigilânciaemSaúde_overall,230511_SãoPaulo_ CoordenadoriadeVigilânciaemSaúde,"Seroprevalence of SARS-CoV-2 antibodies in schoolchildren in the city of Sao Paulo, 2020.",2023-05-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,São Paulo,"""Sample participants were students registered on the database of public (municipal and state) and private school systems of the Municipal and State Education Secretariats of São Paulo, considering the following inclusion criteria: children aged 4 to 14 years old, living in the city of São Paulo.""",,2020-09-01,2020-09-16,Students and Daycares,All,Children and Youth (0-17 years),4.0,14.0,Primary Estimate,,4198,0.166,0.154,0.178,True,,True,,True,Stratified probability,Wondfo SARS-CoV-2 Antibody Test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.864,0.996,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Gabriela Akemi Kamioka, Coordenadoria de Vigilância em Saúde,Not Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2023057004782,2023-06-29,2024-03-01,Unverified,kamiokaSoroprevalenciaAnticorposVirus2023,BRA
230606_SãoPaulo_UniversidadedeSãoPaulo_Inmate_Overall,230606_SãoPaulo_UniversidadedeSãoPaulo_Inmate,Overview of SARS-COV-2 infection at the Butantan Penitentiary Progression Center.,2023-06-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,São Paulo,Inmates of the facility,Potential participants who show no interest in participating in the study.,2020-06-24,2020-08-20,Persons who are incarcerated,Female,Multiple groups,,,Primary Estimate,inmate overall,879,0.061,0.047,0.077,True,,,,True,Entire sample,Not reported/ Unable to specify,,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9811,0.9972,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Soraya Gomes de Amorim Andrade,Universidade de São Paulo,Not Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2023057004717,2023-06-22,2023-07-04,Unverified,andrade_panorama_2023,BRA
230606_SãoPaulo_UniversidadedeSãoPaulo_Servant_Overall,230606_SãoPaulo_UniversidadedeSãoPaulo_Servant,Overview of SARS-COV-2 infection at the Butantan Penitentiary Progression Center.,2023-06-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,,São Paulo,"employees of the CPP of Butantan in the health (nursing technicians, nurses, psychologists, social and medical workers); be administrative employees or correctional officers, regardless of age, who showed interest in participating in the study by signing the term of free and informed consent (TCLE).",Potential participants who show no interest in participating in the study.,2020-06-24,2020-08-20,Essential non-healthcare workers,All,Multiple groups,,,Primary Estimate,servant overall,159,0.075,0.04,0.128,True,,,,True,Entire sample,Not reported/ Unable to specify,,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9811,0.9972,['Moderate'],,Yes,No,Yes,,Unclear,Yes,Yes,,Soraya Gomes de Amorim Andrade,Universidade de São Paulo,Not Unity-Aligned,https://dx.doi.org/10.11606/s1518-8787.2023057004717,2023-06-22,2023-07-04,Unverified,andrade_panorama_2023,BRA
230918_Alvorada_UniversidadeFederalDoRioGrandeDoSul,230918_Alvorada_UniversidadeFederalDoRioGrandeDoSul,Severe acute respiratory syndrome coronavirus 2 seroprevalence among patients with pulmonary tuberculosis.,2023-09-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Brazil,Rio Grande do Sul,Alvorada,"We conducted a cross-sectional study, from October to December 2020, with prospective data collection in an outpatient TB clinic in Alvorada, RS, Brazil.

Outpatients aged>18 years with active pulmonary tuberculosis, no prior history of coronavirus disease 2019, and no suspected coronavirus disease 2019 were included in the study.

Pulmonary TB was diagnosed according to the Brazilian Guidelines for Tuberculosis.",Patients with extrapulmonary TB were excluded from this study.,2020-10-15,2020-12-15,Residual sera,All,Multiple groups,,,Primary Estimate,,52,0.3077,,,True,,,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Whole Blood,TotalAntibody,,Validated by manufacturers,0.794,0.991,['High'],,No,No,Yes,,Yes,Yes,No,,Natan José Dutra Dias,Universidade Federal do Rio Grande do Sul,Not Unity-Aligned,https://dx.doi.org/10.1590/1806-9282.20230661,2023-10-11,2024-03-01,Unverified,dias_severe_2023,BRA
200527_Varna_MedicalDiagnosticLaboratory_IgG/IgM,200527_Varna_MedicalDiagnosticLaboratory,SARS-CoV-2: seroepidemiological pattern in northeastern Bulgaria,2020-05-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bulgaria,Varna, Varna,"Outpatients (general population, policemen, medical workers) in Varna city, Bulgaria",,2020-03-26,2020-04-20,Residual sera,All,Multiple groups,3.0,92.0,Primary Estimate,,586,0.048,0.032,0.068,True,,,,True,Convenience,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Denitsa Tsaneva-Damyanova,"Medical Diagnostic Laboratory ""STATUS"" ",Unity-Aligned,https://www.tandfonline.com/doi/pdf/10.1080/13102818.2020.1772105?needAccess=true,2020-07-20,2024-03-01,Verified,tsaneva-damyanova_sars-cov-2_2020,BGR
200527_Varna_MedicalDiagnosticLaboratory_Age61-70,200527_Varna_MedicalDiagnosticLaboratory,SARS-CoV-2: seroepidemiological pattern in northeastern Bulgaria,2020-05-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bulgaria,Varna, Varna,"Outpatients (general population, policemen, medical workers) in Varna city, Bulgaria",,2020-03-26,2020-04-20,Residual sera,All,Adults (18-64 years),61.0,70.0,Age,61-70 ,74,0.0405,,,,,,,,Convenience,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Denitsa Tsaneva-Damyanova,"Medical Diagnostic Laboratory ""STATUS"" ",Unity-Aligned,https://www.tandfonline.com/doi/pdf/10.1080/13102818.2020.1772105?needAccess=true,2020-07-23,2024-03-01,Verified,tsaneva-damyanova_sars-cov-2_2020,BGR
200527_Varna_MedicalDiagnosticLaboratory_Male ,200527_Varna_MedicalDiagnosticLaboratory,SARS-CoV-2: seroepidemiological pattern in northeastern Bulgaria,2020-05-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bulgaria,Varna, Varna,"Outpatients (general population, policemen, medical workers) in Varna city, Bulgaria",,2020-03-26,2020-04-20,Residual sera,Male,Multiple groups,3.0,92.0,Sex/Gender,Male ,257,0.038900000000000004,,,,,,,,Convenience,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Denitsa Tsaneva-Damyanova,"Medical Diagnostic Laboratory ""STATUS"" ",Unity-Aligned,https://www.tandfonline.com/doi/pdf/10.1080/13102818.2020.1772105?needAccess=true,2020-07-20,2024-03-01,Verified,tsaneva-damyanova_sars-cov-2_2020,BGR
200527_Varna_MedicalDiagnosticLaboratory_Age41-50,200527_Varna_MedicalDiagnosticLaboratory,SARS-CoV-2: seroepidemiological pattern in northeastern Bulgaria,2020-05-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bulgaria,Varna, Varna,"Outpatients (general population, policemen, medical workers) in Varna city, Bulgaria",,2020-03-26,2020-04-20,Residual sera,All,Adults (18-64 years),41.0,50.0,Age,41-50,157,0.0255,,,,,,,,Convenience,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Denitsa Tsaneva-Damyanova,"Medical Diagnostic Laboratory ""STATUS"" ",Unity-Aligned,https://www.tandfonline.com/doi/pdf/10.1080/13102818.2020.1772105?needAccess=true,2020-07-23,2024-03-01,Verified,tsaneva-damyanova_sars-cov-2_2020,BGR
200527_Varna_MedicalDiagnosticLaboratory_Age71-92,200527_Varna_MedicalDiagnosticLaboratory,SARS-CoV-2: seroepidemiological pattern in northeastern Bulgaria,2020-05-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bulgaria,Varna, Varna,"Outpatients (general population, policemen, medical workers) in Varna city, Bulgaria",,2020-03-26,2020-04-20,Residual sera,All,Seniors (65+ years),71.0,92.0,Age,70-92,17,0.0,,,,,,,,Convenience,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Denitsa Tsaneva-Damyanova,"Medical Diagnostic Laboratory ""STATUS"" ",Unity-Aligned,https://www.tandfonline.com/doi/pdf/10.1080/13102818.2020.1772105?needAccess=true,2020-07-23,2024-03-01,Verified,tsaneva-damyanova_sars-cov-2_2020,BGR
200527_Varna_MedicalDiagnosticLaboratory_Age21-30,200527_Varna_MedicalDiagnosticLaboratory,SARS-CoV-2: seroepidemiological pattern in northeastern Bulgaria,2020-05-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bulgaria,Varna, Varna,"Outpatients (general population, policemen, medical workers) in Varna city, Bulgaria",,2020-03-26,2020-04-20,Residual sera,All,Adults (18-64 years),21.0,30.0,Age,21-30,67,0.059699999999999996,,,,,,,,Convenience,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Denitsa Tsaneva-Damyanova,"Medical Diagnostic Laboratory ""STATUS"" ",Unity-Aligned,https://www.tandfonline.com/doi/pdf/10.1080/13102818.2020.1772105?needAccess=true,2020-07-23,2024-03-01,Verified,tsaneva-damyanova_sars-cov-2_2020,BGR
200527_Varna_MedicalDiagnosticLaboratory_Female,200527_Varna_MedicalDiagnosticLaboratory,SARS-CoV-2: seroepidemiological pattern in northeastern Bulgaria,2020-05-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bulgaria,Varna, Varna,"Outpatients (general population, policemen, medical workers) in Varna city, Bulgaria",,2020-03-26,2020-04-20,Residual sera,Female,Multiple groups,3.0,92.0,Sex/Gender,Female,329,0.0547,,,,,,,,Convenience,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Denitsa Tsaneva-Damyanova,"Medical Diagnostic Laboratory ""STATUS"" ",Unity-Aligned,https://www.tandfonline.com/doi/pdf/10.1080/13102818.2020.1772105?needAccess=true,2020-07-20,2024-03-01,Verified,tsaneva-damyanova_sars-cov-2_2020,BGR
200527_Varna_MedicalDiagnosticLaboratory_Age51-60,200527_Varna_MedicalDiagnosticLaboratory,SARS-CoV-2: seroepidemiological pattern in northeastern Bulgaria,2020-05-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bulgaria,Varna, Varna,"Outpatients (general population, policemen, medical workers) in Varna city, Bulgaria",,2020-03-26,2020-04-20,Residual sera,All,Adults (18-64 years),51.0,60.0,Age,51-60,137,0.0584,,,,,,,,Convenience,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Denitsa Tsaneva-Damyanova,"Medical Diagnostic Laboratory ""STATUS"" ",Unity-Aligned,https://www.tandfonline.com/doi/pdf/10.1080/13102818.2020.1772105?needAccess=true,2020-07-23,2024-03-01,Verified,tsaneva-damyanova_sars-cov-2_2020,BGR
200527_Varna_MedicalDiagnosticLaboratory_Age3-20,200527_Varna_MedicalDiagnosticLaboratory,SARS-CoV-2: seroepidemiological pattern in northeastern Bulgaria,2020-05-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bulgaria,Varna, Varna,"Outpatients (general population, policemen, medical workers) in Varna city, Bulgaria",,2020-03-26,2020-04-20,Residual sera,All,Children and Youth (0-17 years),3.0,20.0,Age,3-20,13,0.0,,,,,,,,Convenience,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Denitsa Tsaneva-Damyanova,"Medical Diagnostic Laboratory ""STATUS"" ",Unity-Aligned,https://www.tandfonline.com/doi/pdf/10.1080/13102818.2020.1772105?needAccess=true,2020-07-23,2024-03-01,Verified,tsaneva-damyanova_sars-cov-2_2020,BGR
200527_Varna_MedicalDiagnosticLaboratory_Age31-40,200527_Varna_MedicalDiagnosticLaboratory,SARS-CoV-2: seroepidemiological pattern in northeastern Bulgaria,2020-05-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bulgaria,Varna, Varna,"Outpatients (general population, policemen, medical workers) in Varna city, Bulgaria",,2020-03-26,2020-04-20,Residual sera,All,Adults (18-64 years),31.0,40.0,Age,31-40,121,0.07440000000000001,,,,,,,,Convenience,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Denitsa Tsaneva-Damyanova,"Medical Diagnostic Laboratory ""STATUS"" ",Unity-Aligned,https://www.tandfonline.com/doi/pdf/10.1080/13102818.2020.1772105?needAccess=true,2020-07-23,2024-03-01,Verified,tsaneva-damyanova_sars-cov-2_2020,BGR
230914_Sofia_NationalCenterofInfectiousandParasiticDiseases_GenPop2021,230914_Sofia_NationalCenterofInfectiousandParasiticDiseases_GenPop_2021,A study of anti-SARS-CoV-2 antibodies among healthcare personnel and the general population,2023-09-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bulgaria,,Sofia,"""Serum  samples  from  the  general  pop-ulation  were  collected  randomly  from  persons  visiting  laboratories  in  primary  healthcare  centers  for  routine  prophylactic   check-ups   in   Sofia. ""","""Individuals  who  refused  to  give  informed  consent  or  had  contraindications  to  venipuncture  were  excluded  from  the  study.""",2021-12-01,2022-01-01,Household and community samples,All,Multiple groups,,,Primary Estimate,,124,0.7,0.62,0.78,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA,Anti-SARS-CoV-2 NCP ELISA (IgG),cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit","EUROIMMUN,GenScript",Multiple Types,Serum,"['IgA', 'IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Unclear,Yes,No,,Iva Trifonova,National Center of Infectious and Parasitic Diseases,Not Unity-Aligned,10.1080/13102818.2023.2256417,2024-03-09,2024-03-09,Unverified,trifonova_study_2023,BGR
230914_Sofia_NationalCenterofInfectiousandParasiticDiseases_GenPop2023,230914_Sofia_NationalCenterofInfectiousandParasiticDiseases_GenPop_2023,A study of anti-SARS-CoV-2 antibodies among healthcare personnel and the general population,2023-09-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bulgaria,,Sofia,"""Serum  samples  from  the  general  pop-ulation  were  collected  randomly  from  persons  visiting  laboratories  in  primary  healthcare  centers  for  routine  prophylactic   check-ups   in   Sofia. ""","""Individuals  who  refused  to  give  informed  consent  or  had  contraindications  to  venipuncture  were  excluded  from  the  study.""",2023-02-01,2023-03-01,Household and community samples,All,Multiple groups,,,Primary Estimate,,113,0.78,0.7,0.85,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA,Anti-SARS-CoV-2 NCP ELISA (IgG),cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit","EUROIMMUN,GenScript",Multiple Types,Serum,"['IgA', 'IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Unclear,Yes,No,,Iva Trifonova,National Center of Infectious and Parasitic Diseases,Not Unity-Aligned,10.1080/13102818.2023.2256417,2024-03-09,2024-03-09,Unverified,trifonova_study_2023,BGR
230914_Sofia_NationalCenterofInfectiousandParasiticDiseases_HCW,230914_Sofia_NationalCenterofInfectiousandParasiticDiseases_HCW,A study of anti-SARS-CoV-2 antibodies among healthcare personnel and the general population,2023-09-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Bulgaria,,Sofia,"""The  eligibility  requirements  included  the  capacity    of    HCWs    to    provide    informed    consent.""","""Individuals  who  refused  to  give  informed  consent  or  had  contraindications  to  venipuncture  were  excluded  from  the  study.""",2023-02-01,2023-03-01,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,104,0.99,0.97,1.0,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA,Anti-SARS-CoV-2 NCP ELISA (IgG),cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit","EUROIMMUN,GenScript",Multiple Types,Serum,"['IgA', 'IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Iva Trifonova,National Center of Infectious and Parasitic Diseases,Not Unity-Aligned,10.1080/13102818.2023.2256417,2024-03-09,2024-03-09,Unverified,trifonova_study_2023,BGR
220525_BurkinaFaso_CentredeRechercheBiomoleculairePietroAnnigoni_Overall_TestAdj,220525_BurkinaFaso_CentredeRechercheBiomoleculairePietroAnnigoni,Enigma of the high prevalence of anti-SARS-CoV-2 antibodies in HIV-positive people with no symptoms of COVID-19 in Burkina Faso.,2022-05-25,Journal Article (Peer-Reviewed),Local,Prospective cohort,Burkina Faso,,,"Inclusion criteria: PLHIV regardless of age or sex and with no symptoms of COVID-19 according to national investigation tools (fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, diarrhea). Considering that vulnerable individuals, including those infected with HIV, accounted for a large proportion of all admissions to COVID-19, the group of PLHIV was targeted for this study.",,2020-11-02,2020-11-30,Representative patient population,All,Multiple groups,4.0,87.0,Primary Estimate,,200,0.1872,,,True,True,,,,Convenience,Standard Q COVID-19 IgM/IgG Combo,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,,0.818,0.9670000000000001,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,Unclear,Tani Sagna,Centre de Recherche Biomoléculaire Pietro Annigoni,Unity-Aligned,https://dx.doi.org/10.4081/jphia.2022.1778,2022-06-30,2024-02-19,Unverified,sagna_enigma_2022,BFA
220525_BurkinaFaso_CentredeRechercheBiomoleculairePietroAnnigoni_Overall_Unadj,220525_BurkinaFaso_CentredeRechercheBiomoleculairePietroAnnigoni,Enigma of the high prevalence of anti-SARS-CoV-2 antibodies in HIV-positive people with no symptoms of COVID-19 in Burkina Faso.,2022-05-25,Journal Article (Peer-Reviewed),Local,Prospective cohort,Burkina Faso,,,"Inclusion criteria: PLHIV regardless of age or sex and with no symptoms of COVID-19 according to national investigation tools (fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, diarrhea). Considering that vulnerable individuals, including those infected with HIV, accounted for a large proportion of all admissions to COVID-19, the group of PLHIV was targeted for this study.",,2020-11-02,2020-11-30,Representative patient population,All,Multiple groups,4.0,87.0,Analysis,,200,0.18,,,,,,,True,Convenience,Standard Q COVID-19 IgM/IgG Combo,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,,0.818,0.9670000000000001,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,Unclear,Tani Sagna,Centre de Recherche Biomoléculaire Pietro Annigoni,Unity-Aligned,https://dx.doi.org/10.4081/jphia.2022.1778,2022-06-29,2022-07-16,Unverified,sagna_enigma_2022,BFA
220905_Germany_BernhardNochtInsituteForTropicalMedicine_Bobo‐Dioulasso_Adj,220905_Germany_BernhardNochtInsituteForTropicalMedicine_Bobo‐Dioulasso,"High seroprevalence of SARS-CoV-2 in Burkina-Faso, Ghana and Madagascar in 2021: a population-based study.",2022-09-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Burkina Faso,Houet Province,Bobo‐Dioulasso,A minimum age of 10 years and a requirement of no existing health problems contraindicating blood sample collection were applied.,Households were excluded from analysis in the case of ID mismatches,2021-02-03,2021-03-11,Household and community samples,All,Multiple groups,10.0,,Primary Estimate,test and pop adjusted,627,0.557,0.49,0.682,True,True,True,,,Stratified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Nicole S. Struck,Bernhard Nocht Insitute for Tropical Medicine,Not Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13918-y,2022-09-12,2022-09-23,Unverified,struck_high_2022,BFA
220905_Germany_BernhardNochtInsituteForTropicalMedicine_Bobo‐Dioulasso_Crude,220905_Germany_BernhardNochtInsituteForTropicalMedicine_Bobo‐Dioulasso,"High seroprevalence of SARS-CoV-2 in Burkina-Faso, Ghana and Madagascar in 2021: a population-based study.",2022-09-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Burkina Faso,Houet Province,Bobo‐Dioulasso,A minimum age of 10 years and a requirement of no existing health problems contraindicating blood sample collection were applied.,Households were excluded from analysis in the case of ID mismatches,2021-02-03,2021-03-11,Household and community samples,All,Multiple groups,10.0,,Analysis,,627,0.506,,,,,,,True,Stratified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Nicole S. Struck,Bernhard Nocht Insitute for Tropical Medicine,Not Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13918-y,2022-09-12,2022-09-12,Unverified,struck_high_2022,BFA
220905_Germany_BernhardNochtInsituteForTropicalMedicine_Ouagadougou_Adj,220905_Germany_BernhardNochtInsituteForTropicalMedicine_Ouagadougou,"High seroprevalence of SARS-CoV-2 in Burkina-Faso, Ghana and Madagascar in 2021: a population-based study.",2022-09-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Burkina Faso,Kadiogo Province,Ouagadougou,A minimum age of 10 years and a requirement of no existing health problems contraindicating blood sample collection were applied.,Households were excluded from analysis in the case of ID mismatches,2021-02-02,2021-03-13,Household and community samples,All,Multiple groups,10.0,,Primary Estimate,test and pop adjusted,522,0.374,0.313,0.435,True,True,True,,,Stratified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Nicole S. Struck,Bernhard Nocht Insitute for Tropical Medicine,Not Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13918-y,2022-09-12,2022-09-12,Unverified,struck_high_2022,BFA
220905_Germany_BernhardNochtInsituteForTropicalMedicine_Ouagadougou_Crude,220905_Germany_BernhardNochtInsituteForTropicalMedicine_Ouagadougou,"High seroprevalence of SARS-CoV-2 in Burkina-Faso, Ghana and Madagascar in 2021: a population-based study.",2022-09-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Burkina Faso,Kadiogo Province,Ouagadougou,A minimum age of 10 years and a requirement of no existing health problems contraindicating blood sample collection were applied.,Households were excluded from analysis in the case of ID mismatches,2021-02-02,2021-03-13,Household and community samples,All,Multiple groups,10.0,,Analysis,,522,0.326,,,,,,,True,Stratified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Nicole S. Struck,Bernhard Nocht Insitute for Tropical Medicine,Not Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13918-y,2022-09-12,2022-09-12,Unverified,struck_high_2022,BFA
220924_BurkinaFaso_RobertKochInstitut_Overall,220924_BurkinaFaso_RobertKochInstitut,"Multicountry study of SARS-CoV-2 and associated risk factors among healthcare workers in Cote d'Ivoire, Burkina Faso and South Africa.",2022-09-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Burkina Faso,,Bobo Dioulasso,"""HCW participants were recruited on a voluntary basis. All staff, irrespective of symptoms or suspicion of previous COVID-19 infection, were invited to par- ticipate by their hospital administration through internal facility announcements. HCWs > 16 y of age and working during the period of the COVID-19 pandemic at the selected hospitals were eligible for inclusion. ""","""borderline or positive samples were excluded due to poor quality and quantity of the sample""",2021-02-25,2021-03-12,Health care workers and caregivers,All,Adults (18-64 years),16.0,,Primary Estimate,adjusted overall,221,0.47200000000000003,0.40399999999999997,0.542,True,True,,,True,Self-referral,"Anti-SARS-CoV-2 ELISA IgG,Wantai SARS-CoV-2 Total Ab ELISA,Author designed (Neutralization Assay)","EUROIMMUN,Beijing Wantai Biological,NA",Multiple Types,Serum,"['IgG', 'TotalAntibody']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,Yes,,Sarah Kribi,Robert Koch Institut,Not Unity-Aligned,https://dx.doi.org/10.1093/trstmh/trac089,2022-10-04,2023-08-15,Unverified,kirbi_multicountry_2022,BFA
221211_BurkinaFaso_IPBLN-CSIC_Overall,221211_BurkinaFaso_IPBLN-CSIC,Prevalence of SARS-CoV-2 and co-infection with malaria during the first wave of the pandemic (the Burkina Faso case).,2022-12-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Burkina Faso,,,The study was conducted in 11 villages from different rural and urban areas in the south of Burkina Faso,,2020-08-22,2020-11-19,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,,998,0.032,0.021,0.043,True,,,,True,Unclear,INgezim COVID 19 DR,Eurofins Ingenasa,LFIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.9450000000000001,0.993,['High'],Yes,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Diana Lopez-Farfan,Consejo Superior de Investigaciones Científicas,Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.1048404,2023-01-13,2024-04-19,Verified,lopez-farfan_prevalence_2022-1,BFA
221211_BurkinaFaso_IPBLN-CSIC_Female,221211_BurkinaFaso_IPBLN-CSIC,Prevalence of SARS-CoV-2 and co-infection with malaria during the first wave of the pandemic (the Burkina Faso case).,2022-12-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Burkina Faso,,,The study was conducted in 11 villages from different rural and urban areas in the south of Burkina Faso,,2020-08-22,2020-11-19,Household and community samples,Female,Multiple groups,5.0,,Sex/Gender,Female,549,0.031000000000000003,,,,,,,,Unclear,INgezim COVID 19 DR,Eurofins Ingenasa,LFIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.9450000000000001,0.993,['High'],Yes,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Diana Lopez-Farfan,Consejo Superior de Investigaciones Científicas,Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.1048404,2023-01-13,2024-04-19,Verified,lopez-farfan_prevalence_2022-1,BFA
221211_BurkinaFaso_IPBLN-CSIC_Age13-20,221211_BurkinaFaso_IPBLN-CSIC,Prevalence of SARS-CoV-2 and co-infection with malaria during the first wave of the pandemic (the Burkina Faso case).,2022-12-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Burkina Faso,,,The study was conducted in 11 villages from different rural and urban areas in the south of Burkina Faso,,2020-08-22,2020-11-19,Household and community samples,All,Children and Youth (0-17 years),13.0,20.0,Age,13-20,249,0.0281,,,,,,,,Unclear,INgezim COVID 19 DR,Eurofins Ingenasa,LFIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.9450000000000001,0.993,['High'],Yes,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Diana Lopez-Farfan,Consejo Superior de Investigaciones Científicas,Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.1048404,2023-01-13,2024-04-19,Verified,lopez-farfan_prevalence_2022-1,BFA
221211_BurkinaFaso_IPBLN-CSIC_Age5-12,221211_BurkinaFaso_IPBLN-CSIC,Prevalence of SARS-CoV-2 and co-infection with malaria during the first wave of the pandemic (the Burkina Faso case).,2022-12-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Burkina Faso,,,The study was conducted in 11 villages from different rural and urban areas in the south of Burkina Faso,,2020-08-22,2020-11-19,Household and community samples,All,Children and Youth (0-17 years),5.0,12.0,Age,5-12,251,0.0239,,,,,,,,Unclear,INgezim COVID 19 DR,Eurofins Ingenasa,LFIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.9450000000000001,0.993,['High'],Yes,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Diana Lopez-Farfan,Consejo Superior de Investigaciones Científicas,Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.1048404,2023-01-13,2024-04-19,Verified,lopez-farfan_prevalence_2022-1,BFA
221211_BurkinaFaso_IPBLN-CSIC_Age40+,221211_BurkinaFaso_IPBLN-CSIC,Prevalence of SARS-CoV-2 and co-infection with malaria during the first wave of the pandemic (the Burkina Faso case).,2022-12-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Burkina Faso,,,The study was conducted in 11 villages from different rural and urban areas in the south of Burkina Faso,,2020-08-22,2020-11-19,Household and community samples,All,Multiple groups,41.0,,Age,>40,247,0.0688,,,,,,,,Unclear,INgezim COVID 19 DR,Eurofins Ingenasa,LFIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.9450000000000001,0.993,['High'],Yes,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Diana Lopez-Farfan,Consejo Superior de Investigaciones Científicas,Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.1048404,2023-01-13,2024-04-19,Verified,lopez-farfan_prevalence_2022-1,BFA
221211_BurkinaFaso_IPBLN-CSIC_Age21-40,221211_BurkinaFaso_IPBLN-CSIC,Prevalence of SARS-CoV-2 and co-infection with malaria during the first wave of the pandemic (the Burkina Faso case).,2022-12-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Burkina Faso,,,The study was conducted in 11 villages from different rural and urban areas in the south of Burkina Faso,,2020-08-22,2020-11-19,Household and community samples,All,Adults (18-64 years),21.0,40.0,Age,21-40,251,0.008,,,,,,,,Unclear,INgezim COVID 19 DR,Eurofins Ingenasa,LFIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.9450000000000001,0.993,['High'],Yes,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Diana Lopez-Farfan,Consejo Superior de Investigaciones Científicas,Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.1048404,2023-01-13,2024-04-19,Verified,lopez-farfan_prevalence_2022-1,BFA
221211_BurkinaFaso_IPBLN-CSIC_Male,221211_BurkinaFaso_IPBLN-CSIC,Prevalence of SARS-CoV-2 and co-infection with malaria during the first wave of the pandemic (the Burkina Faso case).,2022-12-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Burkina Faso,,,The study was conducted in 11 villages from different rural and urban areas in the south of Burkina Faso,,2020-08-22,2020-11-19,Household and community samples,Male,Multiple groups,5.0,,Sex/Gender,Male,449,0.0334,,,,,,,,Unclear,INgezim COVID 19 DR,Eurofins Ingenasa,LFIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.9450000000000001,0.993,['High'],Yes,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Diana Lopez-Farfan,Consejo Superior de Investigaciones Científicas,Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.1048404,2023-01-13,2024-04-19,Verified,lopez-farfan_prevalence_2022-1,BFA
230614_BurkinaFaso_SouroSanouUniversityHospital,230614_BurkinaFaso_SouroSanouUniversityHospital,"Seroprevalence of SARS-CoV-2 IgG and associated factors among people living with HIV over the first 12 months following the outbreak of COVID-19 in Burkina Faso, a sub-Saharan African country.",2023-06-14,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Burkina Faso,,, specimens collected for routine plasma HIV-RNA viral load measurements,,2020-03-09,2021-03-08,Residual sera,All,Multiple groups,18.0,,Primary Estimate,,419,0.31,0.262,0.357,True,,,,True,Sequential,Author designed (ELISA) - Unknown,,ELISA,Plasma,IgG,Spike,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Odilon Kabore,Souro Sanou University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0286665,2023-06-30,2023-07-04,Unverified,kaboréSeroprevalenceSARSCoV2IgG2023,BFA
210108_CapeVerde_MestreEmSaúdeEDesenvolvimento_overall,210108_CapeVerde_MestreEmSaúdeEDesenvolvimento,Sero-Epidemiological Survey and Profile of SARS-CoV-2 Infection in Cape Verde,2021-01-08,Preprint,National,Cross-sectional survey ,Cabo Verde,,,"As an inclusion criterion, individuals aged 10 to 80 years (including extremes) and residing in Cape Verde were considered.","The following exclusion criteria were defined: individuals present in the household who were not part of the household or who refused to give informed consent (IC) (supplement document I), or who had contraindications for the collection of a biological sample, or who had physical and / or health limitations that make it impossible to understand the IC.",2020-06-26,2020-07-04,Household and community samples,All,Multiple groups,10.0,80.0,Primary Estimate,,5348,0.004,,,True,,,,True,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.8643000000000001,0.9956999999999999,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Yes,Lara Ferrero Gomez,Mestre em Saúde e Desenvolvimento,Not Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3762489,2021-04-29,2024-03-01,Verified,gomez_sero-epidemiological_2021,CPV
210108_CapeVerde_MestreEmSaúdeEDesenvolvimento_male,210108_CapeVerde_MestreEmSaúdeEDesenvolvimento,Sero-Epidemiological Survey and Profile of SARS-CoV-2 Infection in Cape Verde,2021-01-08,Preprint,National,Cross-sectional survey ,Cabo Verde,,,"As an inclusion criterion, individuals aged 10 to 80 years (including extremes) and residing in Cape Verde were considered.","The following exclusion criteria were defined: individuals present in the household who were not part of the household or who refused to give informed consent (IC) (supplement document I), or who had contraindications for the collection of a biological sample, or who had physical and / or health limitations that make it impossible to understand the IC.",2020-06-26,2020-07-04,Household and community samples,Male,Multiple groups,10.0,80.0,Sex/Gender,male,2300,0.0013000000000000002,,,,,,,,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.8643000000000001,0.9956999999999999,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Yes,Lara Ferrero Gomez,Mestre em Saúde e Desenvolvimento,Not Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3762489,2021-04-29,2024-03-01,Verified,gomez_sero-epidemiological_2021,CPV
210108_CapeVerde_MestreEmSaúdeEDesenvolvimento_female,210108_CapeVerde_MestreEmSaúdeEDesenvolvimento,Sero-Epidemiological Survey and Profile of SARS-CoV-2 Infection in Cape Verde,2021-01-08,Preprint,National,Cross-sectional survey ,Cabo Verde,,,"As an inclusion criterion, individuals aged 10 to 80 years (including extremes) and residing in Cape Verde were considered.","The following exclusion criteria were defined: individuals present in the household who were not part of the household or who refused to give informed consent (IC) (supplement document I), or who had contraindications for the collection of a biological sample, or who had physical and / or health limitations that make it impossible to understand the IC.",2020-06-26,2020-07-04,Household and community samples,Female,Multiple groups,10.0,80.0,Sex/Gender,female,3048,0.0059,,,,,,,,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.8643000000000001,0.9956999999999999,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Yes,Lara Ferrero Gomez,Mestre em Saúde e Desenvolvimento,Not Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3762489,2021-04-29,2024-03-01,Verified,gomez_sero-epidemiological_2021,CPV
210530_Cameroon_UniversityofYaoundé_primary,210530_Cameroon_UniversityofYaoundé,Serologic Response to SARS-CoV-2 in an African Population.,2021-05-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Cameroon,,,"Individuals aged 21 years or older who presented to any of the sites for voluntary screening (hereafter, non-hospitalized) and symptomatic inpatients admitted to one of the six treatment centers for the management of COVID-19 (hereafter, hospitalized) were included.",,2020-06-15,2020-08-15,Multiple populations,All,Multiple groups,,,Primary Estimate,,999,0.32,0.27,0.35000000000000003,True,,,,True,Convenience,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",,,,,['High'],,No,Yes,No,,No,Yes,No,,Karl Njuwa Fai,University of Yaoundé,Not Unity-Aligned,https://dx.doi.org/10.1016/j.sciaf.2021.e00802,2021-06-16,2024-03-01,Unverified,fai_serologic_2021,CMR
211006_Yaoundé_HopitalCentraldeYaounde_PopTestAdj_Overall,211006_Yaoundé_HopitalCentraldeYaounde,SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon.,2021-10-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Cameroon,Centre,Yaoundé,"In each household, all individuals between five and 80 years of age were included if they (a) had been present in the household for at least 14 days prior to the survey, and (b) could give written informed consent (or had an adult guardian who could give consent).",,2020-10-14,2020-11-26,Household and community samples,All,Multiple groups,5.0,80.0,Primary Estimate,Overall pop test adj,971,0.292,0.23800000000000002,0.349,True,True,True,,,Simplified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.915,0.935,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Kene Nwosu,Hopital Central de Yaounde,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-25946-0,2021-10-13,2023-08-15,Verified,nwosu_sars-cov-2_2021-1,CMR
211006_Yaoundé_HopitalCentraldeYaounde_PopAdj_15-29,211006_Yaoundé_HopitalCentraldeYaounde,SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon.,2021-10-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Cameroon,Centre,Yaoundé,"In each household, all individuals between five and 80 years of age were included if they (a) had been present in the household for at least 14 days prior to the survey, and (b) could give written informed consent (or had an adult guardian who could give consent).",,2020-10-14,2020-11-26,Household and community samples,All,Multiple groups,15.0,29.0,Age,15-29,325,0.307,0.258,0.36,,,True,,,Simplified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.915,0.935,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Kene Nwosu,Hopital Central de Yaounde,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-25946-0,2021-10-13,2024-03-01,Verified,nwosu_sars-cov-2_2021-1,CMR
211006_Yaoundé_HopitalCentraldeYaounde_PopAdj_5-14,211006_Yaoundé_HopitalCentraldeYaounde,SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon.,2021-10-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Cameroon,Centre,Yaoundé,"In each household, all individuals between five and 80 years of age were included if they (a) had been present in the household for at least 14 days prior to the survey, and (b) could give written informed consent (or had an adult guardian who could give consent).",,2020-10-14,2020-11-26,Household and community samples,All,Children and Youth (0-17 years),5.0,14.0,Age,5-14,241,0.287,0.223,0.36,,,True,,,Simplified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.915,0.935,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Kene Nwosu,Hopital Central de Yaounde,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-25946-0,2021-10-13,2024-03-01,Verified,nwosu_sars-cov-2_2021-1,CMR
211006_Yaoundé_HopitalCentraldeYaounde_PopAdj_45-64,211006_Yaoundé_HopitalCentraldeYaounde,SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon.,2021-10-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Cameroon,Centre,Yaoundé,"In each household, all individuals between five and 80 years of age were included if they (a) had been present in the household for at least 14 days prior to the survey, and (b) could give written informed consent (or had an adult guardian who could give consent).",,2020-10-14,2020-11-26,Household and community samples,All,Adults (18-64 years),45.0,64.0,Age,45-64,153,0.341,0.271,0.418,,,True,,,Simplified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.915,0.935,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Kene Nwosu,Hopital Central de Yaounde,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-25946-0,2021-10-13,2024-03-01,Verified,nwosu_sars-cov-2_2021-1,CMR
211006_Yaoundé_HopitalCentraldeYaounde_PopAdj_30-44,211006_Yaoundé_HopitalCentraldeYaounde,SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon.,2021-10-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Cameroon,Centre,Yaoundé,"In each household, all individuals between five and 80 years of age were included if they (a) had been present in the household for at least 14 days prior to the survey, and (b) could give written informed consent (or had an adult guardian who could give consent).",,2020-10-14,2020-11-26,Household and community samples,All,Adults (18-64 years),30.0,44.0,Age,30-44,212,0.327,0.262,0.399,,,True,,,Simplified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.915,0.935,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Kene Nwosu,Hopital Central de Yaounde,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-25946-0,2021-10-13,2024-03-01,Verified,nwosu_sars-cov-2_2021-1,CMR
211006_Yaoundé_HopitalCentraldeYaounde_PopAdj_Female,211006_Yaoundé_HopitalCentraldeYaounde,SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon.,2021-10-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Cameroon,Centre,Yaoundé,"In each household, all individuals between five and 80 years of age were included if they (a) had been present in the household for at least 14 days prior to the survey, and (b) could give written informed consent (or had an adult guardian who could give consent).",,2020-10-14,2020-11-26,Household and community samples,Female,Multiple groups,5.0,80.0,Sex/Gender,,549,0.28,0.23600000000000002,0.329,,,True,,,Simplified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.915,0.935,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Kene Nwosu,Hopital Central de Yaounde,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-25946-0,2021-10-13,2024-03-01,Verified,nwosu_sars-cov-2_2021-1,CMR
211006_Yaoundé_HopitalCentraldeYaounde_PopAdj_Male,211006_Yaoundé_HopitalCentraldeYaounde,SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon.,2021-10-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Cameroon,Centre,Yaoundé,"In each household, all individuals between five and 80 years of age were included if they (a) had been present in the household for at least 14 days prior to the survey, and (b) could give written informed consent (or had an adult guardian who could give consent).",,2020-10-14,2020-11-26,Household and community samples,Male,Multiple groups,5.0,80.0,Sex/Gender,,422,0.34600000000000003,0.299,0.397,,,True,,,Simplified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.915,0.935,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Kene Nwosu,Hopital Central de Yaounde,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-25946-0,2021-10-13,2024-03-01,Verified,nwosu_sars-cov-2_2021-1,CMR
211006_Yaoundé_HopitalCentraldeYaounde_PopAdj_Overall,211006_Yaoundé_HopitalCentraldeYaounde,SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon.,2021-10-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Cameroon,Centre,Yaoundé,"In each household, all individuals between five and 80 years of age were included if they (a) had been present in the household for at least 14 days prior to the survey, and (b) could give written informed consent (or had an adult guardian who could give consent).",,2020-10-14,2020-11-26,Household and community samples,All,Multiple groups,5.0,80.0,Analysis,Overall pop adj,971,0.313,0.27899999999999997,0.349,,,True,,True,Simplified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.915,0.935,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Kene Nwosu,Hopital Central de Yaounde,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-25946-0,2021-10-13,2024-03-01,Verified,nwosu_sars-cov-2_2021-1,CMR
211006_Yaoundé_HopitalCentraldeYaounde_PopAdj_65+,211006_Yaoundé_HopitalCentraldeYaounde,SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon.,2021-10-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Cameroon,Centre,Yaoundé,"In each household, all individuals between five and 80 years of age were included if they (a) had been present in the household for at least 14 days prior to the survey, and (b) could give written informed consent (or had an adult guardian who could give consent).",,2020-10-14,2020-11-26,Household and community samples,All,Seniors (65+ years),65.0,80.0,Age,65+,40,0.394,0.244,0.5660000000000001,,,True,,,Simplified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.915,0.935,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Kene Nwosu,Hopital Central de Yaounde,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-25946-0,2021-10-13,2024-03-01,Verified,nwosu_sars-cov-2_2021-1,CMR
220426_Yaoundé_MinistryOfPublicHealthOfCameroon_1_Overall,220426_Yaoundé_MinistryOfPublicHealthOfCameroon_1,"Rapid Increase of Community SARS-CoV-2 Seroprevalence during Second Wave of COVID-19, Yaoundé, Cameroon",2022-04-26,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Cameroon,,Yaoundé,"""We randomly selected households in 6 of the 7 health districts in Yaoundé... in  50%  of  house-holds, we invited all residents to participate; among the  remaining  50%,  we  invited  only  residents  >40 years of age""
""All  persons  be-longing to the selected household were eligible""",,2021-01-27,2021-02-06,Household and community samples,All,Multiple groups,,,Primary Estimate,,722,0.186,0.157,0.217,True,,True,,True,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,,Plasma,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,0.997,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Francis Ndongo,Ministry of Public Health of Cameroon,Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/35470795/,2023-06-30,2024-03-21,Verified,ndongoRapidIncreaseCommunity2022,CMR
220426_Yaoundé_MinistryOfPublilcHealthOfCameroon_1_20-39,220426_Yaoundé_MinistryOfPublicHealthOfCameroon_1,"Rapid Increase of Community SARS-CoV-2 Seroprevalence during Second Wave of COVID-19, Yaoundé, Cameroon",2022-04-26,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Cameroon,,Yaoundé,"""We randomly selected households in 6 of the 7 health districts in Yaoundé... in  50%  of  house-holds, we invited all residents to participate; among the  remaining  50%,  we  invited  only  residents  >40 years of age""
""All  persons  be-longing to the selected household were eligible""",,2021-01-27,2021-02-06,Household and community samples,All,Adults (18-64 years),20.0,39.0,Age,20-39,276,0.257,0.208,0.314,,,,,,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,,Plasma,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,0.997,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Francis Ndongo,Ministry of Public Health of Cameroon,Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/35470795/,2024-03-20,2024-03-21,Verified,ndongoRapidIncreaseCommunity2022,CMR
220426_Yaoundé_MinistryOfPublicHealthOfCameroon_1_>39,220426_Yaoundé_MinistryOfPublicHealthOfCameroon_1,"Rapid Increase of Community SARS-CoV-2 Seroprevalence during Second Wave of COVID-19, Yaoundé, Cameroon",2022-04-26,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Cameroon,,Yaoundé,"""We randomly selected households in 6 of the 7 health districts in Yaoundé... in  50%  of  house-holds, we invited all residents to participate; among the  remaining  50%,  we  invited  only  residents  >40 years of age""
""All  persons  be-longing to the selected household were eligible""",,2021-01-27,2021-02-06,Household and community samples,All,Adults (18-64 years),40.0,,Age,>39,210,0.229,0.175,0.292,,,,,,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,,Plasma,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,0.997,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Francis Ndongo,Ministry of Public Health of Cameroon,Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/35470795/,2024-03-20,2024-03-21,Verified,ndongoRapidIncreaseCommunity2022,CMR
220426_Yaoundé_MinistryOfPublicHealthOfCameroon_1_0-19,220426_Yaoundé_MinistryOfPublicHealthOfCameroon_1,"Rapid Increase of Community SARS-CoV-2 Seroprevalence during Second Wave of COVID-19, Yaoundé, Cameroon",2022-04-26,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Cameroon,,Yaoundé,"""We randomly selected households in 6 of the 7 health districts in Yaoundé... in  50%  of  house-holds, we invited all residents to participate; among the  remaining  50%,  we  invited  only  residents  >40 years of age""
""All  persons  be-longing to the selected household were eligible""",,2021-01-27,2021-02-06,Household and community samples,All,Multiple groups,,19.0,Age,0-19,236,0.131,0.093,0.183,,,,,,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,,Plasma,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,0.997,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Francis Ndongo,Ministry of Public Health of Cameroon,Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/35470795/,2024-03-20,2024-03-21,Verified,ndongoRapidIncreaseCommunity2022,CMR
220426_Yaoundé_MinistryOfPublicHealthOfCameroon_2_Overall,220426_Yaoundé_MinistryOfPublicHealthOfCameroon_2,"Rapid Increase of Community SARS-CoV-2 Seroprevalence during Second Wave of COVID-19, Yaoundé, Cameroon",2022-04-26,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Cameroon,,Yaoundé,"""We randomly selected households in 6 of the 7 health districts in Yaoundé... In  50%  of  house-holds, we invited all residents to participate; among the  remaining  50%,  we  invited  only  residents  >40 years of age""
""All  persons  be-longing to the selected household were eligible""",,2021-04-24,2021-05-19,Household and community samples,All,Multiple groups,,,Primary Estimate,,1228,0.513042,0.483,0.542,True,,True,,True,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,,Plasma,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,0.997,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Francis Ndongo,Ministry of Public Health of Cameroon,Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/35470795/,2023-06-30,2024-03-21,Verified,ndongoRapidIncreaseCommunity2022,CMR
220426_Yaoundé_MinistryOfPublicHealthOfCameroon_2_20-39,220426_Yaoundé_MinistryOfPublicHealthOfCameroon_2,"Rapid Increase of Community SARS-CoV-2 Seroprevalence during Second Wave of COVID-19, Yaoundé, Cameroon",2022-04-26,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Cameroon,,Yaoundé,"""We randomly selected households in 6 of the 7 health districts in Yaoundé... In  50%  of  house-holds, we invited all residents to participate; among the  remaining  50%,  we  invited  only  residents  >40 years of age""
""All  persons  be-longing to the selected household were eligible""",,2021-04-24,2021-05-19,Household and community samples,All,Adults (18-64 years),20.0,39.0,Age,20-39,440,0.598,0.55,0.644,,,,,,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,,Plasma,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,0.997,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Francis Ndongo,Ministry of Public Health of Cameroon,Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/35470795/,2024-03-20,2024-03-21,Verified,ndongoRapidIncreaseCommunity2022,CMR
220426_Yaoundé_MinistryOfPublicHealthOfCameroon_2_40AndOver,220426_Yaoundé_MinistryOfPublicHealthOfCameroon_2,"Rapid Increase of Community SARS-CoV-2 Seroprevalence during Second Wave of COVID-19, Yaoundé, Cameroon",2022-04-26,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Cameroon,,Yaoundé,"""We randomly selected households in 6 of the 7 health districts in Yaoundé... In  50%  of  house-holds, we invited all residents to participate; among the  remaining  50%,  we  invited  only  residents  >40 years of age""
""All  persons  be-longing to the selected household were eligible""",,2021-04-24,2021-05-19,Household and community samples,All,Adults (18-64 years),40.0,,Age,>39,320,0.628,0.573,0.68,,,,,,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,,Plasma,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,0.997,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Francis Ndongo,Ministry of Public Health of Cameroon,Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/35470795/,2024-03-20,2024-03-21,Verified,ndongoRapidIncreaseCommunity2022,CMR
220426_Yaoundé_MinistryOfPublicHealthOfCameroon_2_0-19,220426_Yaoundé_MinistryOfPublicHealthOfCameroon_2,"Rapid Increase of Community SARS-CoV-2 Seroprevalence during Second Wave of COVID-19, Yaoundé, Cameroon",2022-04-26,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Cameroon,,Yaoundé,"""We randomly selected households in 6 of the 7 health districts in Yaoundé... In  50%  of  house-holds, we invited all residents to participate; among the  remaining  50%,  we  invited  only  residents  >40 years of age""
""All  persons  be-longing to the selected household were eligible""",,2021-04-24,2021-05-19,Household and community samples,All,Multiple groups,,19.0,Age,0-19,468,0.427,0.383,0.473,,,,,,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,,Plasma,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,0.997,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Francis Ndongo,Ministry of Public Health of Cameroon,Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/35470795/,2024-03-20,2024-03-21,Verified,ndongoRapidIncreaseCommunity2022,CMR
230127_Cameroon_UniversityofRomeTorVergata,230127_Cameroon_UniversityofRomeTorVergata,The COVID-19 wave was already here: High seroprevalence of SARS-CoV-2 antibodies among staff and students in a Cameroon University,2023-01-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Cameroon,Bandjoun,,"""This study took place at the UEC campus at two different periods, Staff as well as students, were included""","""the remaining 07 samples were excluded because the quality and quantity did not meet the requirements of the kit""",2020-12-15,2021-12-15,Multiple populations,All,Adults (18-64 years),,,Primary Estimate,,106,0.919,0.847,0.964,True,,,,True,Convenience,COVID19 RAPID TEST,Phamatech,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by manufacturers,0.982,0.997,['High'],,No,No,Yes,,No,Yes,Yes,,Andrillene Laure Deutou Wondeu,University of Rome Tor Vergata,Not Unity-Aligned,https://dx.doi.org/10.4081/jphia.2023.2242,2023-03-06,2024-03-01,Unverified,wondeuCOVID19WaveWas2023,CMR
230420_Yaounde_CentralHospitalofYaounde_PopAdj,230420_Yaounde_CentralHospitalofYaounde,"Large Diffusion of Severe Acute Respiratory Syndrome Coronavirus 2 After the Successive Epidemiological Waves, Including Omicron, in Guinea and Cameroon: Implications for Vaccine Strategies.",2023-04-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Cameroon,,Yaounde,All persons belonging to the selected household were eligible. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9155890/),,2022-05-01,2022-05-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,1425,0.7471,0.7199,0.7725,True,,True,,True,Simplified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Mamadou Diallo,Central Hospital of Yaounde,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofad216,2023-06-02,2024-04-27,Verified,diallo_large_2023,CMR
230420_Yaounde_CentralHospitalofYaounde_Age20-39,230420_Yaounde_CentralHospitalofYaounde,"Large Diffusion of Severe Acute Respiratory Syndrome Coronavirus 2 After the Successive Epidemiological Waves, Including Omicron, in Guinea and Cameroon: Implications for Vaccine Strategies.",2023-04-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Cameroon,,Yaounde,All persons belonging to the selected household were eligible. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9155890/),,2022-05-01,2022-05-31,Household and community samples,All,Adults (18-64 years),20.0,39.0,Age,20-39,601,0.8253,,,,,,,,Simplified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Mamadou Diallo,Central Hospital of Yaounde,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofad216,2024-04-27,2024-04-27,Verified,diallo_large_2023,CMR
230420_Yaounde_CentralHospitalofYaoundeAge40+,230420_Yaounde_CentralHospitalofYaounde,"Large Diffusion of Severe Acute Respiratory Syndrome Coronavirus 2 After the Successive Epidemiological Waves, Including Omicron, in Guinea and Cameroon: Implications for Vaccine Strategies.",2023-04-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Cameroon,,Yaounde,All persons belonging to the selected household were eligible. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9155890/),,2022-05-01,2022-05-31,Household and community samples,All,Multiple groups,40.0,,Age,40+,381,0.8451,,,,,,,,Simplified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Mamadou Diallo,Central Hospital of Yaounde,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofad216,2024-04-27,2024-04-27,Verified,diallo_large_2023,CMR
230420_Yaounde_CentralHospitalofYaounde_Age0-19,230420_Yaounde_CentralHospitalofYaounde,"Large Diffusion of Severe Acute Respiratory Syndrome Coronavirus 2 After the Successive Epidemiological Waves, Including Omicron, in Guinea and Cameroon: Implications for Vaccine Strategies.",2023-04-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Cameroon,,Yaounde,All persons belonging to the selected household were eligible. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9155890/),,2022-05-01,2022-05-31,Household and community samples,All,Children and Youth (0-17 years),0.0,19.0,Age,0-19,443,0.6704,,,,,,,,Simplified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Mamadou Diallo,Central Hospital of Yaounde,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofad216,2024-04-27,2024-04-27,Verified,diallo_large_2023,CMR
230502_Cameroon_ CentrePasteurduCameroun_round1_poptestadj,230502_Cameroon_ CentrePasteurduCameroun_round1,Spread of SARS-CoV-2 Infection in Adult Populations in Cameroon: A Repeated Cross-Sectional Study Among Blood Donors in the Cities of Yaounde and Douala.,2023-05-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Cameroon,,Yaoundé and Douala,"""It was a consecutive and observational sample, where all healthy individuals aged from 18 to 55 years at all sites were included in the study after consent provision.""","NR
",2021-01-25,2021-02-15,Blood donors,All,Adults (18-64 years),18.0,55.0,Analysis,population and test adjusted estimate,742,0.663,0.611,0.713,True,True,True,,,Convenience,Wantai SARS-CoV-2 IgG ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.967,0.975,['High'],No,No,Yes,Yes,Yes,No,Yes,Yes,,Arsene Brunelle Sandie, Centre Pasteur du Cameroun,Unity-Aligned,https://dx.doi.org/10.1007/s44197-023-00102-7,2023-06-01,2024-04-30,Verified,sandieSpreadSARSCoV2Infection2023,CMR
230502_Cameroon_ CentrePasteurduCameroun_round1_Age35-55,230502_Cameroon_ CentrePasteurduCameroun_round1,Spread of SARS-CoV-2 Infection in Adult Populations in Cameroon: A Repeated Cross-Sectional Study Among Blood Donors in the Cities of Yaounde and Douala.,2023-05-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Cameroon,,Yaoundé and Douala,"""It was a consecutive and observational sample, where all healthy individuals aged from 18 to 55 years at all sites were included in the study after consent provision.""","NR
",2021-01-25,2021-02-15,Blood donors,All,Adults (18-64 years),35.0,55.0,Age,35-5,174,0.655,,,,,,,,Convenience,Wantai SARS-CoV-2 IgG ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.967,0.975,['High'],No,No,Yes,Yes,Yes,No,Yes,Yes,,Arsene Brunelle Sandie, Centre Pasteur du Cameroun,Unity-Aligned,https://dx.doi.org/10.1007/s44197-023-00102-7,2024-04-30,2024-04-30,Verified,sandieSpreadSARSCoV2Infection2023,CMR
230502_Cameroon_ CentrePasteurduCameroun_round1_unadj,230502_Cameroon_ CentrePasteurduCameroun_round1,Spread of SARS-CoV-2 Infection in Adult Populations in Cameroon: A Repeated Cross-Sectional Study Among Blood Donors in the Cities of Yaounde and Douala.,2023-05-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Cameroon,,Yaoundé and Douala,"""It was a consecutive and observational sample, where all healthy individuals aged from 18 to 55 years at all sites were included in the study after consent provision.""","NR
",2021-01-25,2021-02-15,Blood donors,All,Adults (18-64 years),18.0,55.0,Primary Estimate,crude estimate,742,0.6401617251,,,,,,,,Convenience,Wantai SARS-CoV-2 IgG ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.967,0.975,['High'],No,No,Yes,Yes,Yes,No,Yes,Yes,,Arsene Brunelle Sandie, Centre Pasteur du Cameroun,Unity-Aligned,https://dx.doi.org/10.1007/s44197-023-00102-7,2023-06-01,2024-04-30,Verified,sandieSpreadSARSCoV2Infection2023,CMR
230502_Cameroon_ CentrePasteurduCameroun_round1_Age18-34,230502_Cameroon_ CentrePasteurduCameroun_round1,Spread of SARS-CoV-2 Infection in Adult Populations in Cameroon: A Repeated Cross-Sectional Study Among Blood Donors in the Cities of Yaounde and Douala.,2023-05-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Cameroon,,Yaoundé and Douala,"""It was a consecutive and observational sample, where all healthy individuals aged from 18 to 55 years at all sites were included in the study after consent provision.""","NR
",2021-01-25,2021-02-15,Blood donors,All,Adults (18-64 years),18.0,34.0,Age,18-34,568,0.6356,,,,,,,,Convenience,Wantai SARS-CoV-2 IgG ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.967,0.975,['High'],No,No,Yes,Yes,Yes,No,Yes,Yes,,Arsene Brunelle Sandie, Centre Pasteur du Cameroun,Unity-Aligned,https://dx.doi.org/10.1007/s44197-023-00102-7,2024-04-30,2024-04-30,Verified,sandieSpreadSARSCoV2Infection2023,CMR
230502_Cameroon_ CentrePasteurduCameroun_round1_popadj,230502_Cameroon_ CentrePasteurduCameroun_round1,Spread of SARS-CoV-2 Infection in Adult Populations in Cameroon: A Repeated Cross-Sectional Study Among Blood Donors in the Cities of Yaounde and Douala.,2023-05-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Cameroon,,Yaoundé and Douala,"""It was a consecutive and observational sample, where all healthy individuals aged from 18 to 55 years at all sites were included in the study after consent provision.""","NR
",2021-01-25,2021-02-15,Blood donors,All,Adults (18-64 years),18.0,55.0,Analysis,population adjusted estimate,742,0.64,0.603,0.697,,,True,,True,Convenience,Wantai SARS-CoV-2 IgG ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.967,0.975,['High'],No,No,Yes,Yes,Yes,No,Yes,Yes,,Arsene Brunelle Sandie, Centre Pasteur du Cameroun,Unity-Aligned,https://dx.doi.org/10.1007/s44197-023-00102-7,2023-06-01,2024-04-30,Verified,sandieSpreadSARSCoV2Infection2023,CMR
230502_Cameroon_ CentrePasteurduCameroun_round2_poptestadj,230502_Cameroon_ CentrePasteurduCameroun_round2,Spread of SARS-CoV-2 Infection in Adult Populations in Cameroon: A Repeated Cross-Sectional Study Among Blood Donors in the Cities of Yaounde and Douala.,2023-05-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Cameroon,,Yaoundé and Douala,"""It was a consecutive and observational sample, where all healthy individuals aged from 18 to 55 years at all sites were included in the study after consent provision.""","NR
",2021-05-03,2021-05-28,Blood donors,All,Adults (18-64 years),18.0,55.0,Analysis,population and test adjusted estimate,1201,0.872,0.84,0.9,True,True,True,,,Convenience,Wantai SARS-CoV-2 IgG ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.967,0.975,['High'],No,No,Yes,Yes,Yes,No,Yes,Yes,,Arsene Brunelle Sandie, Centre Pasteur du Cameroun,Unity-Aligned,https://dx.doi.org/10.1007/s44197-023-00102-7,2023-06-01,2024-04-30,Verified,sandieSpreadSARSCoV2Infection2023,CMR
230502_Cameroon_ CentrePasteurduCameroun_round2_Age18-34,230502_Cameroon_ CentrePasteurduCameroun_round2,Spread of SARS-CoV-2 Infection in Adult Populations in Cameroon: A Repeated Cross-Sectional Study Among Blood Donors in the Cities of Yaounde and Douala.,2023-05-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Cameroon,,Yaoundé and Douala,"""It was a consecutive and observational sample, where all healthy individuals aged from 18 to 55 years at all sites were included in the study after consent provision.""","NR
",2021-05-03,2021-05-28,Blood donors,All,Adults (18-64 years),18.0,34.0,Age,18-34,929,0.8321,,,,,,,,Convenience,Wantai SARS-CoV-2 IgG ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.967,0.975,['High'],No,No,Yes,Yes,Yes,No,Yes,Yes,,Arsene Brunelle Sandie, Centre Pasteur du Cameroun,Unity-Aligned,https://dx.doi.org/10.1007/s44197-023-00102-7,2024-04-30,2024-04-30,Verified,sandieSpreadSARSCoV2Infection2023,CMR
230502_Cameroon_ CentrePasteurduCameroun_round2_unadj,230502_Cameroon_ CentrePasteurduCameroun_round2,Spread of SARS-CoV-2 Infection in Adult Populations in Cameroon: A Repeated Cross-Sectional Study Among Blood Donors in the Cities of Yaounde and Douala.,2023-05-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Cameroon,,Yaoundé and Douala,"""It was a consecutive and observational sample, where all healthy individuals aged from 18 to 55 years at all sites were included in the study after consent provision.""","NR
",2021-05-03,2021-05-28,Blood donors,All,Adults (18-64 years),18.0,55.0,Primary Estimate,crude estimate,1201,0.836,,,,,,,,Convenience,Wantai SARS-CoV-2 IgG ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.967,0.975,['High'],No,No,Yes,Yes,Yes,No,Yes,Yes,,Arsene Brunelle Sandie, Centre Pasteur du Cameroun,Unity-Aligned,https://dx.doi.org/10.1007/s44197-023-00102-7,2023-06-01,2024-04-30,Verified,sandieSpreadSARSCoV2Infection2023,CMR
230502_Cameroon_ CentrePasteurduCameroun_round2_Age35-55,230502_Cameroon_ CentrePasteurduCameroun_round2,Spread of SARS-CoV-2 Infection in Adult Populations in Cameroon: A Repeated Cross-Sectional Study Among Blood Donors in the Cities of Yaounde and Douala.,2023-05-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Cameroon,,Yaoundé and Douala,"""It was a consecutive and observational sample, where all healthy individuals aged from 18 to 55 years at all sites were included in the study after consent provision.""","NR
",2021-05-03,2021-05-28,Blood donors,All,Adults (18-64 years),35.0,55.0,Age,35-55,272,0.8493,,,,,,,,Convenience,Wantai SARS-CoV-2 IgG ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.967,0.975,['High'],No,No,Yes,Yes,Yes,No,Yes,Yes,,Arsene Brunelle Sandie, Centre Pasteur du Cameroun,Unity-Aligned,https://dx.doi.org/10.1007/s44197-023-00102-7,2024-04-30,2024-04-30,Verified,sandieSpreadSARSCoV2Infection2023,CMR
230502_Cameroon_ CentrePasteurduCameroun_round2_popadj,230502_Cameroon_ CentrePasteurduCameroun_round2,Spread of SARS-CoV-2 Infection in Adult Populations in Cameroon: A Repeated Cross-Sectional Study Among Blood Donors in the Cities of Yaounde and Douala.,2023-05-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Cameroon,,Yaoundé and Douala,"""It was a consecutive and observational sample, where all healthy individuals aged from 18 to 55 years at all sites were included in the study after consent provision.""","NR
",2021-05-03,2021-05-28,Blood donors,All,Adults (18-64 years),18.0,55.0,Analysis,population adjusted estimate,1201,0.847,0.822,0.873,,,True,,True,Convenience,Wantai SARS-CoV-2 IgG ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.967,0.975,['High'],No,No,Yes,Yes,Yes,No,Yes,Yes,,Arsene Brunelle Sandie, Centre Pasteur du Cameroun,Unity-Aligned,https://dx.doi.org/10.1007/s44197-023-00102-7,2023-06-01,2024-04-30,Verified,sandieSpreadSARSCoV2Infection2023,CMR
230502_Cameroon_ CentrePasteurduCameroun_round3_poptestadj,230502_Cameroon_ CentrePasteurduCameroun_round3,Spread of SARS-CoV-2 Infection in Adult Populations in Cameroon: A Repeated Cross-Sectional Study Among Blood Donors in the Cities of Yaounde and Douala.,2023-05-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Cameroon,,Yaoundé and Douala,"""It was a consecutive and observational sample, where all healthy individuals aged from 18 to 55 years at all sites were included in the study after consent provision.""","NR
",2021-11-29,2021-12-31,Blood donors,All,Adults (18-64 years),18.0,55.0,Analysis,population and test adjusted estimate,1500,0.984,0.968,0.997,True,True,True,,,Convenience,Wantai SARS-CoV-2 IgG ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.967,0.975,['High'],No,No,Yes,Yes,Yes,No,Yes,Yes,,Arsene Brunelle Sandie, Centre Pasteur du Cameroun,Unity-Aligned,https://dx.doi.org/10.1007/s44197-023-00102-7,2023-06-01,2024-04-30,Verified,sandieSpreadSARSCoV2Infection2023,CMR
230502_Cameroon_ CentrePasteurduCameroun_round3_popadj,230502_Cameroon_ CentrePasteurduCameroun_round3,Spread of SARS-CoV-2 Infection in Adult Populations in Cameroon: A Repeated Cross-Sectional Study Among Blood Donors in the Cities of Yaounde and Douala.,2023-05-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Cameroon,,Yaoundé and Douala,"""It was a consecutive and observational sample, where all healthy individuals aged from 18 to 55 years at all sites were included in the study after consent provision.""","NR
",2021-11-29,2021-12-31,Blood donors,All,Adults (18-64 years),18.0,55.0,Analysis,population adjusted estimate,1500,0.953,0.94,0.967,,,True,,True,Convenience,Wantai SARS-CoV-2 IgG ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.967,0.975,['High'],No,No,Yes,Yes,Yes,No,Yes,Yes,,Arsene Brunelle Sandie, Centre Pasteur du Cameroun,Unity-Aligned,https://dx.doi.org/10.1007/s44197-023-00102-7,2023-06-01,2024-04-30,Verified,sandieSpreadSARSCoV2Infection2023,CMR
230502_Cameroon_ CentrePasteurduCameroun_round3_Age35-55,230502_Cameroon_ CentrePasteurduCameroun_round3,Spread of SARS-CoV-2 Infection in Adult Populations in Cameroon: A Repeated Cross-Sectional Study Among Blood Donors in the Cities of Yaounde and Douala.,2023-05-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Cameroon,,Yaoundé and Douala,"""It was a consecutive and observational sample, where all healthy individuals aged from 18 to 55 years at all sites were included in the study after consent provision.""","NR
",2021-11-29,2021-12-31,Blood donors,All,Adults (18-64 years),35.0,55.0,Age,35-55,317,0.9432,,,,,,,,Convenience,Wantai SARS-CoV-2 IgG ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.967,0.975,['High'],No,No,Yes,Yes,Yes,No,Yes,Yes,,Arsene Brunelle Sandie, Centre Pasteur du Cameroun,Unity-Aligned,https://dx.doi.org/10.1007/s44197-023-00102-7,2024-04-30,2024-04-30,Verified,sandieSpreadSARSCoV2Infection2023,CMR
230502_Cameroon_ CentrePasteurduCameroun_round3_Age18-34,230502_Cameroon_ CentrePasteurduCameroun_round3,Spread of SARS-CoV-2 Infection in Adult Populations in Cameroon: A Repeated Cross-Sectional Study Among Blood Donors in the Cities of Yaounde and Douala.,2023-05-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Cameroon,,Yaoundé and Douala,"""It was a consecutive and observational sample, where all healthy individuals aged from 18 to 55 years at all sites were included in the study after consent provision.""","NR
",2021-11-29,2021-12-31,Blood donors,All,Adults (18-64 years),18.0,34.0,Age,18-34,1183,0.9518,,,,,,,,Convenience,Wantai SARS-CoV-2 IgG ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.967,0.975,['High'],No,No,Yes,Yes,Yes,No,Yes,Yes,,Arsene Brunelle Sandie, Centre Pasteur du Cameroun,Unity-Aligned,https://dx.doi.org/10.1007/s44197-023-00102-7,2024-04-30,2024-04-30,Verified,sandieSpreadSARSCoV2Infection2023,CMR
230502_Cameroon_ CentrePasteurduCameroun_round3_unadj,230502_Cameroon_ CentrePasteurduCameroun_round3,Spread of SARS-CoV-2 Infection in Adult Populations in Cameroon: A Repeated Cross-Sectional Study Among Blood Donors in the Cities of Yaounde and Douala.,2023-05-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Cameroon,,Yaoundé and Douala,"""It was a consecutive and observational sample, where all healthy individuals aged from 18 to 55 years at all sites were included in the study after consent provision.""","NR
",2021-11-29,2021-12-31,Blood donors,All,Adults (18-64 years),18.0,55.0,Primary Estimate,crude estimate,1500,0.95,,,,,,,,Convenience,Wantai SARS-CoV-2 IgG ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.967,0.975,['High'],No,No,Yes,Yes,Yes,No,Yes,Yes,,Arsene Brunelle Sandie, Centre Pasteur du Cameroun,Unity-Aligned,https://dx.doi.org/10.1007/s44197-023-00102-7,2023-06-01,2024-04-30,Verified,sandieSpreadSARSCoV2Infection2023,CMR
230504_Cameroon_ColumbiaUniversity,230504_Cameroon_ColumbiaUniversity,"Seroprevalence of SARS-CoV-2 in 10 Regional Capitals of Cameroon, October-December 2020",2023-05-04,Preprint,National,Cross-sectional survey ,Cameroon,,,">5, from community sites in each regional capital","""Children < 5 years were excluded due to the difficulty in obtaining blood from young children, especially in such public settings.""",2020-10-16,2020-12-15,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,,9332,0.105,0.091,0.12,True,,True,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Wantai SARS-CoV-2 Total Ab ELISA","Abbott Laboratories,Beijing Wantai Biological",Multiple Types,Plasma,"['IgG', 'IgG, IgM, IgA']","['Nucleocapsid (N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Karampreet Sachathep,Columbia University,Not Unity-Aligned,10.22541/au.168319263.36814253/v1,2023-06-01,2024-03-01,Unverified,sachathep_seroprevalence_2023,CMR
230825_Cameroon_TheUniversityofDouala_IgG,230825_Cameroon_TheUniversityofDouala,Serological surveillance reveals a high exposure to SARS-CoV-2 and altered immune response among COVID-19 unvaccinated Cameroonian individuals,2023-08-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Cameroon,,,"We included all Cameroonian patients of both sexes, aged > 18 years old, settled in Douala, and having signed an informed consent form.","we excluded from this study: i) foreigners, ii) patients who were not willing to participate, iii) those who refused to sign an informed consent form, iv) those admitted to intensive care units; and v) those for whom blood collection was impossible",2022-01-01,2022-09-30,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,,Primary Estimate,,342,0.889,,,True,,,,True,Convenience,VIDAS® SARS-COV-2 IgG,BioMérieux,,Serum,IgG,,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Arlette Flore Moguem Soubgui,The University of Douala,Not Unity-Aligned,10.1101/2023.08.24.23294559,2023-09-20,2024-03-01,Unverified,soubgui_serological_2023,CMR
200715_GreaterVancouverArea_BC-Centre-For-Disease-Control_MarchSnapshot_OverallPopAdj,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_March,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-03-05,2020-03-13,Residual sera,All,Multiple groups,,,Primary Estimate,,869,0.0028000000000000004,0.0003,0.0095,True,,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Author designed (Neutralization Assay),ADVIA Centaur Immunoassay System","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,NA,Siemens",CLIA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-07-16,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-For-Disease-Control_MarchSnapshot_AbbottCLIA_Age<10,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_March,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-03-05,2020-03-13,Residual sera,All,Children and Youth (0-17 years),0.0,10.0,Age,<10 ,96,0.0,,,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9390000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-For-Disease-Control_MarchSnapshot_AbbottCLIA_Age60to69,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_March,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-03-05,2020-03-13,Residual sera,All,Adults (18-64 years),60.0,69.0,Age,60-69,100,0.0,,,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9390000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-For-Disease-Control_MarchSnapshot_OrthoClinicalCLIA_Age<10,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_March,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-03-05,2020-03-13,Residual sera,All,Children and Youth (0-17 years),0.0,10.0,Age,<10 ,96,0.0,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.85,0.995,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-For-Disease-Control_MarchSnapshot_OverallUnadj,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_March,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-03-05,2020-03-13,Residual sera,All,Multiple groups,,,Analysis,Unadjusted,869,0.0023,0.0003,0.0083,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,ADVIA Centaur Immunoassay System","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Siemens",CLIA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-07-16,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-For-Disease-Control_MarchSnapshot_AbbottCLIA_Age50to59,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_March,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-03-05,2020-03-13,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,99,0.0,,,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9390000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-For-Disease-Control_MarchSnapshot_AbbottCLIA,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_March,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-03-05,2020-03-13,Residual sera,All,Multiple groups,,,Test used,Abbott ARCHITECT ,869,0.0046,0.0013000000000000002,0.0117,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9390000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-07-16,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-For-Disease-Control_MarchSnapshot_AbbottCLIA_Age20to29,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_March,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-03-05,2020-03-13,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29,98,0.01,0.0003,0.055999999999999994,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9390000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-For-Disease-Control_MarchSnapshot_OrthoClinicalCLIA,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_March,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-03-05,2020-03-13,Residual sera,All,Multiple groups,,,Test used,Ortho-clinical diagnostics CLIA,870,0.008,0.0032,0.0165,,,,,True,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.85,0.995,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-07-16,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-For-Disease-Control_MarchSnapshot_AbbottCLIA_Age70to79,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_March,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-03-05,2020-03-13,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,100,0.01,0.0003,0.055,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9390000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-For-Disease-Control_MarchSnapshot_OrthoClinicalCLIA_Age20to29,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_March,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-03-05,2020-03-13,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29,98,0.0,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.85,0.995,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-For-Disease-Control_MarchSnapshot_AbbottCLIA_Age10to19,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_March,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-03-05,2020-03-13,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,83,0.0,,,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9390000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-For-Disease-Control_MarchSnapshot_AbbottCLIA_Age40to49,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_March,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-03-05,2020-03-13,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,100,0.0,,,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9390000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-For-Disease-Control_MarchSnapshot_OrthoClinicalCLIA_Age40to49,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_March,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-03-05,2020-03-13,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,100,0.01,0.0003,0.055,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.85,0.995,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-For-Disease-Control_MarchSnapshot_OrthoClinicalCLIA_Age80+,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_March,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-03-05,2020-03-13,Residual sera,All,Seniors (65+ years),80.0,,Age,80 and over,97,0.021,0.0025,0.073,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.85,0.995,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-For-Disease-Control_MarchSnapshot_OrthoClinicalCLIA_Age10to19,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_March,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-03-05,2020-03-13,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,83,0.0,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.85,0.995,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-For-Disease-Control_MarchSnapshot_OrthoClinicalCLIA_Age50to59,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_March,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-03-05,2020-03-13,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,99,0.02,0.0025,0.071,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.85,0.995,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-For-Disease-Control_MarchSnapshot_OrthoClinicalCLIA_Age60to69,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_March,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-03-05,2020-03-13,Residual sera,All,Adults (18-64 years),60.0,69.0,Age,60-69,100,0.01,0.0003,0.055,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.85,0.995,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-For-Disease-Control_MarchSnapshot_AbbottCLIA_Age30to39,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_March,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-03-05,2020-03-13,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,97,0.0,,,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9390000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-For-Disease-Control_MarchSnapshot_OrthoClinicalCLIA_Age30to39,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_March,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-03-05,2020-03-13,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,97,0.0,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.85,0.995,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-For-Disease-Control_MarchSnapshot_OrthoClinicalCLIA_Age70to79,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_March,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-03-05,2020-03-13,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,100,0.01,0.0003,0.055,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.85,0.995,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-For-Disease-Control_MarchSnapshot_AbbottCLIA_Age80+,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_March,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-03-05,2020-03-13,Residual sera,All,Seniors (65+ years),80.0,,Age,80 and over,97,0.021,0.0025,0.073,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9390000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-for-Disease-Control_MaySnapshot_OverallPopAdj,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_May,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-05-15,2020-05-27,Residual sera,All,Multiple groups,,,Primary Estimate,,885,0.0055000000000000005,0.0015,0.013700000000000002,True,,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-07-16,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-for-Disease-Control_MaySnapshot_OrthoDiagnosticsCLIA_Age70to79,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_May,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-05-15,2020-05-27,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,100,0.01,0.0003,0.055,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.85,0.995,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-for-Disease-Control_MaySnapshot_OrthoDiagnosticsCLIA_Age60to69,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_May,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-05-15,2020-05-27,Residual sera,All,Adults (18-64 years),60.0,69.0,Age,60-69,100,0.0,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.85,0.995,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-for-Disease-Control_MaySnapshot_AbbottCLIA_Age20to29,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_May,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-05-15,2020-05-27,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29,98,0.0,,,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9390000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-for-Disease-Control_MaySnapshot_OrthoDiagnosticsCLIA_Age20to29,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_May,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-05-15,2020-05-27,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29,98,0.0,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.85,0.995,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-for-Disease-Control_MaySnapshot_AbbottCLIA_Age70to79,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_May,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-05-15,2020-05-27,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,100,0.01,0.0003,0.055,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9390000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-for-Disease-Control_MaySnapshot_AbbottCLIA_Age<10,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_May,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-05-15,2020-05-27,Residual sera,All,Children and Youth (0-17 years),0.0,10.0,Age,<10 ,102,0.0,,,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9390000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-for-Disease-Control_MaySnapshot_OrthoDiagnosticsCLIA_Age30to39,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_May,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-05-15,2020-05-27,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,100,0.01,0.0003,0.055,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.85,0.995,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-for-Disease-Control_MaySnapshot_OrthoDiagnosticsCLIA_Age50to59,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_May,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-05-15,2020-05-27,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,98,0.031000000000000003,0.0064,0.087,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.85,0.995,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-for-Disease-Control_MaySnapshot_OrthoDiagnosticsCLIA_Age40to49,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_May,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-05-15,2020-05-27,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,99,0.0,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.85,0.995,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-for-Disease-Control_MaySnapshot_AbbottCLIA_Age30to39,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_May,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-05-15,2020-05-27,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,100,0.01,0.0003,0.055,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9390000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-for-Disease-Control_MaySnapshot_OrthoDiagnosticsCLIA_Age<10,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_May,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-05-15,2020-05-27,Residual sera,All,Children and Youth (0-17 years),0.0,10.0,Age,<10 ,102,0.0,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.85,0.995,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-for-Disease-Control_MaySnapshot_AbbottCLIA_Age50to59,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_May,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-05-15,2020-05-27,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,98,0.031000000000000003,0.0064,0.087,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9390000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-for-Disease-Control_MaySnapshot_AbbottCLIA_Age80+,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_May,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-05-15,2020-05-27,Residual sera,All,Seniors (65+ years),80.0,,Age,80 and over,98,0.01,0.0003,0.057,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9390000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-for-Disease-Control_MaySnapshot_AbbottCLIA_Age40to49,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_May,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-05-15,2020-05-27,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,99,0.0,,,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9390000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-for-Disease-Control_MaySnapshot_OrthoDiagnosticsCLIA_Age80+,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_May,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-05-15,2020-05-27,Residual sera,All,Seniors (65+ years),80.0,,Age,80 and over,98,0.0,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.85,0.995,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-for-Disease-Control_MaySnapshot_AbbottCLIA,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_May,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-05-15,2020-05-27,Residual sera,All,Multiple groups,,,Test used,Abbott ARCHITECT ,885,0.0079,0.0032,0.016200000000000003,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9390000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-07-16,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-for-Disease-Control_MaySnapshot_AbbottCLIA_Age10to19,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_May,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-05-15,2020-05-27,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,94,0.011000000000000001,0.0003,0.059000000000000004,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9390000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-for-Disease-Control_MaySnapshot_OverallUnadj,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_May,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-05-15,2020-05-27,Residual sera,All,Multiple groups,,,Analysis,Unadjusted,885,0.0045000000000000005,0.0012,0.0115,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,ADVIA Centaur Immunoassay System","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Siemens",CLIA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-07-16,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-for-Disease-Control_MaySnapshot_OrthoDiagnosticsCLIA,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_May,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-05-15,2020-05-27,Residual sera,All,Multiple groups,,,Test used,Ortho-clinical diagnostics CLIA,870,0.008,0.0032,0.0165,,,,,True,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.85,0.995,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-07-16,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-for-Disease-Control_MaySnapshot_AbbottCLIA_Age60to69,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_May,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-05-15,2020-05-27,Residual sera,All,Adults (18-64 years),60.0,69.0,Age,60-69,100,0.0,,,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9390000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
200715_GreaterVancouverArea_BC-Centre-for-Disease-Control_MaySnapshot_OrthoDiagnosticsCLIA_Age10to19,200715_GreaterVancouverArea_BCCentreForDiseaseControl_1_May,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",2020-07-15,Preprint,Regional,Cross-sectional survey ,Canada,British Columbia,,"Patients attending one of 80 diagnostic service centres of outpatient laboratory networks in Lower Mainland, BC.

Sera was obtained from 100 patients within each WHO-age group, only if 200uL of residual sera was remaining after testing. ",,2020-05-15,2020-05-27,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,94,0.011000000000000001,0.0003,0.057999999999999996,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.85,0.995,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Danuta Skowronski,British Columbia Centre for Disease Control,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.13.20153148v1,2020-10-29,2024-03-01,Verified,skowronski_low_2020,CAN
201017_Vancouver_UniversityofBritishColumbia_LTCF_overall,201017_Vancouver_UniversityofBritishColumbia,"Serological survey following SARS-COV-2 outbreaks at long-term care facilities in metro Vancouver, British Columbia: Implications for outbreak management and infection control policies",2020-10-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,British Columbia,Vancouver,"Residents and staff members at 2 adult
LTC facilities located in the Metro Vancouver area, British Columbia.",,2020-05-04,2020-05-14,Assisted living and long-term care facilities,All,Multiple groups,,,Primary Estimate,Both staff and residents,291,0.39,,,True,,,,True,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,ADVIA Centaur Immunoassay System","DiaSorin,Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Siemens",,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,No,Yes,Yes,Unclear,Yes,No,No,Rohit Vijh,University of British Columbia,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ajic.2020.10.009,2020-12-18,2024-03-01,Verified,vijh_serological_2020,CAN
201027_Montreal_ShrinersHospital_accompanying_unadj,201027_Montreal_ShrinersHospital_AccompanyingPersons,Prevalence of SARS-CoV-2 Infections in a Pediatric Orthopedic Hospital,2020-10-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Québec,Montreal,Individuals accompanying patients,,2020-06-10,2020-07-27,Hospital visitors,All,Adults (18-64 years),,,Primary Estimate,Accompanying persons,61,0.11480000000000001,,,True,,,,True,Convenience,Omega diagnostics COVID-19 IgG ELISA,Generic Diagnostics Ltd,ELISA,Serum,IgG,,,,0.97,['High'],Yes,No,No,No,No,Unclear,Yes,No,Unclear,Ghalib Bardai,Shriners Hospital for Children,Not Unity-Aligned,https://doi.org/10.1111/pan.14047,2020-12-18,2024-03-01,Verified,bardai_prevalence_2021,CAN
201027_Montreal_ShrinersHospital_employees_unadj,201027_Montreal_ShrinersHospital_HCW,Prevalence of SARS-CoV-2 Infections in a Pediatric Orthopedic Hospital,2020-10-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Québec,Montreal,employees (100 employees—approximately one third of the full‐time staff,,2020-06-10,2020-07-27,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Hospital employees,99,0.12,,,True,,,,True,Convenience,Omega diagnostics COVID-19 IgG ELISA,Generic Diagnostics Ltd,ELISA,Serum,IgG,,,,0.97,['High'],Yes,No,No,No,No,Unclear,Yes,No,Unclear,Ghalib Bardai,Shriners Hospital for Children,Not Unity-Aligned,https://doi.org/10.1111/pan.14047,2020-12-18,2024-03-01,Verified,bardai_prevalence_2021,CAN
201027_Montreal_ShrinersHospital_children_unadj,201027_Montreal_ShrinersHospital_Patients,Prevalence of SARS-CoV-2 Infections in a Pediatric Orthopedic Hospital,2020-10-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Québec,Montreal,Patients at the hospital,,2020-06-10,2020-07-27,Residual sera,All,Children and Youth (0-17 years),,,Primary Estimate,Patients,39,0.08,,,True,,,,True,Convenience,Omega diagnostics COVID-19 IgG ELISA,Generic Diagnostics Ltd,ELISA,Serum,IgG,,,,0.97,['High'],Yes,No,No,No,No,Unclear,Yes,No,Unclear,Ghalib Bardai,Shriners Hospital for Children,Not Unity-Aligned,https://doi.org/10.1111/pan.14047,2020-12-18,2024-03-01,Verified,bardai_prevalence_2021,CAN
201203_Edmonton_UniversityofAlberta_Children,201203_Edmonton_UniversityofAlberta,Increased Mask Use and Fewer Gatherings Associated with Lower SARS-CoV-2 Seropositivity Among Young School-Age Children,2020-12-03,Preprint,Local,Cross-sectional survey ,Canada,Alberta,Edmonton,"We invited 8-13-year-old children in Edmonton, Alberta, Canada to participate in a longitudinal SARS-CoV-2 seroprevalence study. Participants were identified from the Edmonton Canadian Health Infant Longitudinal Development (CHILD) and Edmonton Alberta Pregnant Outcomes and Nutrition (APrON) cohorts, their friends, similar-aged cousins living in different households, and families responding to earned media. Only one child per household was recruited for this study. The CHILD cohort study, recruiting participants between 2008 and 2012, is a prospective longitudinal birth cohort study of over 3000 children from four centres in Canada (Vancouver, Edmonton, Manitoba, Toronto). The Edmonton CHILD cohort has more than 700 participants. The primary objective is to examine genetic and early childhood environment exposures associated with atopic disease including allergy and asthma. The APrON prospective longitudinal birth cohort study, started in 2009, recruited participants from Calgary and Edmonton. There are approximately 200 Edmonton APrON participants. The APrON cohort was designed to understand the impact of pregnancy and early childhood nutrition and parental mental health on child’s neurodevelopment and mental health. ",There were no exclusion criteria for this SARS-CoV-2 study.,2020-08-14,2020-10-23,Household and community samples,All,Children and Youth (0-17 years),8.0,13.0,Primary Estimate,Overall children,565,0.016,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.8420000000000001,1.0,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,No,Unclear,Emilie Manny,University of Alberta,Unity-Aligned,https://poseidon01.ssrn.com/delivery.php?ID=579098091025087124113094013092119126025046084059055038121105001063029013061117127066089088099029120125126127122027092067006090071077064116068026070083111035094021057114045098065076072116064007032059100097072054064094007027094015098095104082088098074069111094090004070124099079094007105068078&EXT=pdf&INDEX=TRUE,2021-01-31,2024-03-01,Verified,manny_increased_2020,CAN
201203_Edmonton_UniversityofAlberta_Male,201203_Edmonton_UniversityofAlberta,Increased Mask Use and Fewer Gatherings Associated with Lower SARS-CoV-2 Seropositivity Among Young School-Age Children,2020-12-03,Preprint,Local,Cross-sectional survey ,Canada,Alberta,Edmonton,"We invited 8-13-year-old children in Edmonton, Alberta, Canada to participate in a longitudinal SARS-CoV-2 seroprevalence study. Participants were identified from the Edmonton Canadian Health Infant Longitudinal Development (CHILD) and Edmonton Alberta Pregnant Outcomes and Nutrition (APrON) cohorts, their friends, similar-aged cousins living in different households, and families responding to earned media. Only one child per household was recruited for this study. The CHILD cohort study, recruiting participants between 2008 and 2012, is a prospective longitudinal birth cohort study of over 3000 children from four centres in Canada (Vancouver, Edmonton, Manitoba, Toronto). The Edmonton CHILD cohort has more than 700 participants. The primary objective is to examine genetic and early childhood environment exposures associated with atopic disease including allergy and asthma. The APrON prospective longitudinal birth cohort study, started in 2009, recruited participants from Calgary and Edmonton. There are approximately 200 Edmonton APrON participants. The APrON cohort was designed to understand the impact of pregnancy and early childhood nutrition and parental mental health on child’s neurodevelopment and mental health. ",There were no exclusion criteria for this SARS-CoV-2 study.,2020-08-14,2020-10-23,Household and community samples,Male,Children and Youth (0-17 years),8.0,13.0,Sex/Gender,Male,260,0.015,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.8420000000000001,1.0,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,No,Unclear,Emilie Manny,University of Alberta,Unity-Aligned,https://poseidon01.ssrn.com/delivery.php?ID=579098091025087124113094013092119126025046084059055038121105001063029013061117127066089088099029120125126127122027092067006090071077064116068026070083111035094021057114045098065076072116064007032059100097072054064094007027094015098095104082088098074069111094090004070124099079094007105068078&EXT=pdf&INDEX=TRUE,2021-02-27,2024-03-01,Verified,manny_increased_2020,CAN
201203_Edmonton_UniversityofAlberta_Female,201203_Edmonton_UniversityofAlberta,Increased Mask Use and Fewer Gatherings Associated with Lower SARS-CoV-2 Seropositivity Among Young School-Age Children,2020-12-03,Preprint,Local,Cross-sectional survey ,Canada,Alberta,Edmonton,"We invited 8-13-year-old children in Edmonton, Alberta, Canada to participate in a longitudinal SARS-CoV-2 seroprevalence study. Participants were identified from the Edmonton Canadian Health Infant Longitudinal Development (CHILD) and Edmonton Alberta Pregnant Outcomes and Nutrition (APrON) cohorts, their friends, similar-aged cousins living in different households, and families responding to earned media. Only one child per household was recruited for this study. The CHILD cohort study, recruiting participants between 2008 and 2012, is a prospective longitudinal birth cohort study of over 3000 children from four centres in Canada (Vancouver, Edmonton, Manitoba, Toronto). The Edmonton CHILD cohort has more than 700 participants. The primary objective is to examine genetic and early childhood environment exposures associated with atopic disease including allergy and asthma. The APrON prospective longitudinal birth cohort study, started in 2009, recruited participants from Calgary and Edmonton. There are approximately 200 Edmonton APrON participants. The APrON cohort was designed to understand the impact of pregnancy and early childhood nutrition and parental mental health on child’s neurodevelopment and mental health. ",There were no exclusion criteria for this SARS-CoV-2 study.,2020-08-14,2020-10-23,Household and community samples,Female,Children and Youth (0-17 years),8.0,13.0,Sex/Gender,Female,278,0.018000000000000002,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.8420000000000001,1.0,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,No,Unclear,Emilie Manny,University of Alberta,Unity-Aligned,https://poseidon01.ssrn.com/delivery.php?ID=579098091025087124113094013092119126025046084059055038121105001063029013061117127066089088099029120125126127122027092067006090071077064116068026070083111035094021057114045098065076072116064007032059100097072054064094007027094015098095104082088098074069111094090004070124099079094007105068078&EXT=pdf&INDEX=TRUE,2021-02-27,2024-03-01,Verified,manny_increased_2020,CAN
201218_Canada_CBS_BloodDonors_Overall_PopTestAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,16811,0.0088,0.0073,0.010400000000000001,True,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Age_40-59_UnAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 years,6446,0.0105,0.008199999999999999,0.0134,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Vancouver_UnAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,207,0.014499999999999999,0.003,0.0418,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Overall_UnAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Analysis,,16811,0.0092,0.0078000000000000005,0.010700000000000001,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Calgary_UnAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,371,0.0108,0.0029,0.027400000000000004,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Ethnicity_Indigenous_UnAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Race,Indigenous,157,0.0,0.0,0.0232,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Saskatchewan_PopAdjTestAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,286,0.0017000000000000001,0.0,0.0059,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_BritishColumbia_UnAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,607,0.0115,0.0046,0.0236,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Alberta_UnAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,1028,0.0088,0.004,0.0166,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Ottawa_PopAdjTestAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1154,0.009300000000000001,0.002,0.0166,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Sex_Male_UnAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,9553,0.01,0.008100000000000001,0.0123,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Ethnicity_Others_PopAdjTestAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Race,Others,1536,0.0189,0.0115,0.0263,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Calgary_PopAdjTestAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,371,0.0099,0.003,0.0172,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Age_60+_UnAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ years,4339,0.006500000000000001,0.0043,0.009300000000000001,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_NovaScotia_UnAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1083,0.0092,0.0044,0.0169,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Ottawa_UnAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1154,0.0095,0.0048,0.017,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Sex_Female_UnAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female ,7258,0.0074,0.005600000000000001,0.0097,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Ethnicity_Asian_PopAdjTestAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Race,Asian,598,0.0159,0.0055000000000000005,0.0262,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Age_25-39_PopAdjTestAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 years,4535,0.0097,0.006500000000000001,0.013000000000000001,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Edmonton_PopAdjTestAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,445,0.0069,0.001,0.0124,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Age_17-24_PopAdjTestAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 years,1491,0.010400000000000001,0.005600000000000001,0.0151,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_NewfoundlandLabrador_PopAdjTestAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,441,0.0006,0.0,0.005200000000000001,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Winnipeg_PopAdjTestAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,131,0.0075,0.0,0.0171,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Alberta_PopAdjTestAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,1028,0.0076,0.0038,0.011399999999999999,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Age_25-39_UnAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 years,4535,0.0086,0.0061,0.0117,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Manitoba_PopAdjTestAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,257,0.0296,0.017,0.042300000000000004,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_BritishColumbia_PopAdjTestAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,607,0.0086,0.005,0.0123,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Manitoba_UnAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,257,0.027200000000000002,0.011000000000000001,0.0553,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Ontario_PopAdjTestAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,11808,0.0087,0.006500000000000001,0.0108,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_NewBrunswick_UnAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,994,0.003,0.0006,0.0088,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Vancouver_PopAdjTestAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,207,0.011899999999999999,0.005,0.0192,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Ethnicity_White_PopAdjTestAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Race,White,12893,0.0067,0.0051,0.0083,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Ethnicity_Indigenous_PopAdjTestAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Race,Indigenous,157,0.0,0.0,0.0,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_NewfoundlandLabrador_UnAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,441,0.0023,0.0001,0.0126,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Age_17-24_UnAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 years,1491,0.0101,0.005600000000000001,0.0165,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Saskatchewan_UnAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,286,0.0034999999999999996,0.0001,0.0193,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_PrinceEdwardIsland_PopAdjTestAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,307,0.0,0.0,0.0,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Age_60+_PopAdjTestAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ years,4339,0.006,0.0034999999999999996,0.0084,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Toronto_UnAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,3940,0.0122,0.009000000000000001,0.0161,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Toronto_PopAdjTestAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,3940,0.0116,0.006999999999999999,0.0159,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Ethnicity_White_UnAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Race,White,12893,0.0075,0.0061,0.0092,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Ontario_UnAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,11808,0.0095,0.0078000000000000005,0.011399999999999999,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Ethnicity_Others_UnAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Race,Others,1536,0.0182,0.0121,0.0262,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Winnipeg_UnAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,131,0.0076,0.0002,0.0418,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_NewBrunswick_PopAdjTestAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,994,0.0017000000000000001,0.0,0.0059,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Overall_PopAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Analysis,,16811,0.0086,0.006999999999999999,0.0101,,,True,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Age_40-59_PopAdjTestAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 years,6446,0.0099,0.0070999999999999995,0.012700000000000001,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Sex_Male_PopAdjTestAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,9553,0.010900000000000002,0.0084,0.013300000000000001,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_NovaScotia_PopAdjTestAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1083,0.0098,0.0011,0.018500000000000003,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Ethnicity_Asian_UnAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Race,Asian,598,0.0167,0.008,0.0305,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Sex_Female_PopAdjTestAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female ,7258,0.0069,0.0049,0.0088,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_PrinceEdwardIsland_UnAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,307,0.0,0.0,0.011899999999999999,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
201218_Canada_CBS_BloodDonors_Edmonton_UnAdj,201218_Canada_CBS,"COVID-19 Seroprevalence Report December 18, 2020 Report #3: October 2020 Survey",2020-12-18,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-10-12,2020-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,445,0.009000000000000001,0.0025,0.0229,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-01-21,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Overall_PopAdjTestAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,17049,0.0151,0.0131,0.0171,True,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Calgary_UnAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,527,0.022799999999999997,0.0118,0.0394,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Alberta_PopAdjTestAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,1297,0.0179,0.0124,0.0234,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Edmonton_UnAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,529,0.020800000000000003,0.010400000000000001,0.0369,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Saskatchewan_PopAdjTestAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,290,0.0417,0.0257,0.057699999999999994,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_NewfoundlandLabrador_PopAdjTestAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,427,0.0095,0.0,0.0209,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_NovaScotia_UnAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,890,0.0034000000000000002,0.0007000000000000001,0.0098,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_NewBrunswick_UnAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,988,0.0061,0.0022,0.013200000000000002,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Sex_Male_UnAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,9598,0.0108,0.0089,0.0131,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Toronto_PopAdjTestAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,3425,0.0098,0.006,0.0141,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Sex_Female_UnAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female ,7451,0.0102,0.008,0.0128,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Ontario_PopAdjTestAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,11662,0.0077,0.005600000000000001,0.0097,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Ottawa_UnAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1101,0.008199999999999999,0.0037,0.015500000000000002,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Manitoba_UnAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,380,0.07110000000000001,0.04730000000000001,0.1017,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Overall_PopAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Analysis,,17049,0.015,0.013200000000000002,0.017,,,True,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-21,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Ethnicity_Indigenous_PopAdjTestAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Race,Indigenous,174,0.0359,0.0088,0.063,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Ottawa_PopAdjTestAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1101,0.0088,0.002,0.016,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Alberta_UnAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,1297,0.0177,0.0113,0.0265,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Ethnicity_Others_UnAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Race,Others,1800,0.015,0.0099,0.0217,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Ethnicity_Asian_PopAdjTestAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Race,Asian,527,0.024300000000000002,0.0111,0.0375,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Calgary_PopAdjTestAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,527,0.0222,0.013000000000000001,0.0318,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_BritishColumbia_PopAdjTestAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,914,0.0151,0.010400000000000001,0.0197,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_BritishColumbia_UnAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,Regional,Repeated cross-sectional study,Canada,"British Columbia
",,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,914,0.014199999999999999,0.0076,0.0242,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Ontario_UnAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,11662,0.0078000000000000005,0.0063,0.0096,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Age_40-59_UnAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 years,6382,0.0091,0.0069,0.0117,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_PrinceEdwardIsland_PopAdjTestAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,201,0.0,,,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Toronto_UnAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,3425,0.0096,0.006600000000000001,0.013500000000000002,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_NovaScotia_PopAdjTestAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,890,0.0019,0.0,0.006500000000000001,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Saskatchewan_UnAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,290,0.0414,0.0216,0.0712,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Ethnicity_White_PopAdjTestAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Race,White,12806,0.013500000000000002,0.0113,0.015700000000000002,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Age_17-24_PopAdjTestAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 years,1631,0.029700000000000004,0.022000000000000002,0.0373,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Age_25-39_UnAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 years,4644,0.0108,0.008,0.014199999999999999,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Ethnicity_Indigenous_UnAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Race,Indigenous,174,0.0172,0.0036,0.0496,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Sex_Male_PopAdjTestAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,9598,0.0151,0.0123,0.018000000000000002,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_PrinceEdwardIsland_UnAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,201,0.0,0.0,0.0182,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Ethnicity_White_UnAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Race,White,12806,0.0095,0.0079,0.011399999999999999,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Overall_UnAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Analysis,,17049,0.0106,0.0091,0.0122,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-21,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Manitoba_PopAdjTestAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,380,0.08560000000000001,0.0651,0.10619999999999999,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Ethnicity_Others_PopAdjTestAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Race,Others,1800,0.0182,0.012,0.0244,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Sex_Female_PopAdjTestAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female ,7451,0.0151,0.0124,0.0178,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Edmonton_PopAdjTestAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,529,0.0223,0.013000000000000001,0.0318,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Age_17-24_UnAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 years,1631,0.0202,0.013999999999999999,0.028300000000000002,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Winnipeg_UnAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,288,0.0382,0.0192,0.06730000000000001,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Age_60+_PopAdjTestAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ years,4392,0.013300000000000001,0.0098,0.0168,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Age_40-59_PopAdjTestAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 years,6382,0.010900000000000002,0.008,0.0138,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Vancouver_PopAdjTestAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,677,0.014199999999999999,0.009000000000000001,0.0196,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Winnipeg_PopAdjTestAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,288,0.0509,0.032,0.0694,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_NewBrunswick_PopAdjTestAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,988,0.0049,0.0,0.012,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Age_60+_UnAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ years,4392,0.0089,0.0063,0.0121,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Ethnicity_Asian_UnAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Race,Asian,527,0.019,0.0091,0.0346,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Vancouver_UnAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,677,0.013300000000000001,0.0061,0.025099999999999997,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_Age_25-39_PopAdjTestAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 years,4644,0.0158,0.0117,0.0199,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210112_Canada_CBS_BloodDonors_NewfoundlandLabrador_UnAdj,210112_Canada_CBS,"COVID-19 Seroprevalence Report January 12, 2021 Report #4: November 2020 Survey",2021-01-12,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2020-11-07,2020-11-25,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,427,0.0117,0.0038,0.0271,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,https://slack-files.com/files-pri-safe/T011KSPAYPR-F01K401T9J9/covid-19_report_november_2020_final_12jan2021-1.pdf?c=1611144789-a5afc223a057856a,2021-01-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210201_Canada_CanadianBloodServices_Overall_adj,210201_Canada_CBS,SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada,2021-02-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Canada,"Yukon, Northwest Territories, Nunavut, British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick, Nove Scotia, Prince Edward Island, Newfoundland and Labrador",,Whole blood donors donating at all Canadian Blood Services locations (fixed and mobile sites in all larger cities and most urban areas from all provinces except Quebec). Donors must meet numerous selection criteria to ensure that they are in good health and at low risk of infectious disease.,"Beginning in March 2020, donors were deferred for 2 weeks if they were diagnosed with SARS-CoV-2 infection or if they were in contact with a known case. Donors were assessed at the door of the collection site and not permitted to enter if they had COVID-19 risk factors and symptoms by questionnaire (n = 234) or elevated temperature (n = 967) or refusing to wear a mask (n = 71). Although there is no evidence that SARS-CoV-2 is transmissible by blood transfusion, these extra steps were put in place to enhance safety for donors and staff.9 ",2020-05-09,2020-07-21,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,74642,0.006999999999999999,0.0063,0.0076,True,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Sahar Saeed,Canadian Blood Services,Unity-Aligned,http://dx.doi.org/10.1111/trf.16296,2021-03-21,2023-07-04,Verified,saeed_sarscov2_2021,CAN
210201_Canada_CanadianBloodServices_55-64,210201_Canada_CBS,SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada,2021-02-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Canada,"Yukon, Northwest Territories, Nunavut, British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick, Nove Scotia, Prince Edward Island, Newfoundland and Labrador",,Whole blood donors donating at all Canadian Blood Services locations (fixed and mobile sites in all larger cities and most urban areas from all provinces except Quebec). Donors must meet numerous selection criteria to ensure that they are in good health and at low risk of infectious disease.,"Beginning in March 2020, donors were deferred for 2 weeks if they were diagnosed with SARS-CoV-2 infection or if they were in contact with a known case. Donors were assessed at the door of the collection site and not permitted to enter if they had COVID-19 risk factors and symptoms by questionnaire (n = 234) or elevated temperature (n = 967) or refusing to wear a mask (n = 71). Although there is no evidence that SARS-CoV-2 is transmissible by blood transfusion, these extra steps were put in place to enhance safety for donors and staff.9 ",2020-05-09,2020-07-21,Blood donors,All,Adults (18-64 years),55.0,64.0,Age,55-64,16753,0.006999999999999999,0.0058,0.0084,,,True,,,Entire sample,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Sahar Saeed,Canadian Blood Services,Unity-Aligned,http://dx.doi.org/10.1111/trf.16296,2021-08-27,2024-03-01,Verified,saeed_sarscov2_2021,CAN
210201_Canada_CanadianBloodServices_Female,210201_Canada_CBS,SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada,2021-02-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Canada,"Yukon, Northwest Territories, Nunavut, British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick, Nove Scotia, Prince Edward Island, Newfoundland and Labrador",,Whole blood donors donating at all Canadian Blood Services locations (fixed and mobile sites in all larger cities and most urban areas from all provinces except Quebec). Donors must meet numerous selection criteria to ensure that they are in good health and at low risk of infectious disease.,"Beginning in March 2020, donors were deferred for 2 weeks if they were diagnosed with SARS-CoV-2 infection or if they were in contact with a known case. Donors were assessed at the door of the collection site and not permitted to enter if they had COVID-19 risk factors and symptoms by questionnaire (n = 234) or elevated temperature (n = 967) or refusing to wear a mask (n = 71). Although there is no evidence that SARS-CoV-2 is transmissible by blood transfusion, these extra steps were put in place to enhance safety for donors and staff.9 ",2020-05-09,2020-07-21,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,,35547,0.0072,0.0063,0.008100000000000001,,,True,,,Entire sample,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Sahar Saeed,Canadian Blood Services,Unity-Aligned,http://dx.doi.org/10.1111/trf.16296,2021-03-21,2024-03-01,Verified,saeed_sarscov2_2021,CAN
210201_Canada_CanadianBloodServices_Male,210201_Canada_CBS,SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada,2021-02-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Canada,"Yukon, Northwest Territories, Nunavut, British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick, Nove Scotia, Prince Edward Island, Newfoundland and Labrador",,Whole blood donors donating at all Canadian Blood Services locations (fixed and mobile sites in all larger cities and most urban areas from all provinces except Quebec). Donors must meet numerous selection criteria to ensure that they are in good health and at low risk of infectious disease.,"Beginning in March 2020, donors were deferred for 2 weeks if they were diagnosed with SARS-CoV-2 infection or if they were in contact with a known case. Donors were assessed at the door of the collection site and not permitted to enter if they had COVID-19 risk factors and symptoms by questionnaire (n = 234) or elevated temperature (n = 967) or refusing to wear a mask (n = 71). Although there is no evidence that SARS-CoV-2 is transmissible by blood transfusion, these extra steps were put in place to enhance safety for donors and staff.9 ",2020-05-09,2020-07-21,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,,39095,0.0078000000000000005,0.0069,0.0088,,,True,,,Entire sample,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Sahar Saeed,Canadian Blood Services,Unity-Aligned,http://dx.doi.org/10.1111/trf.16296,2021-03-21,2024-03-01,Verified,saeed_sarscov2_2021,CAN
210201_Canada_CanadianBloodServices_17-24,210201_Canada_CBS,SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada,2021-02-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Canada,"Yukon, Northwest Territories, Nunavut, British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick, Nove Scotia, Prince Edward Island, Newfoundland and Labrador",,Whole blood donors donating at all Canadian Blood Services locations (fixed and mobile sites in all larger cities and most urban areas from all provinces except Quebec). Donors must meet numerous selection criteria to ensure that they are in good health and at low risk of infectious disease.,"Beginning in March 2020, donors were deferred for 2 weeks if they were diagnosed with SARS-CoV-2 infection or if they were in contact with a known case. Donors were assessed at the door of the collection site and not permitted to enter if they had COVID-19 risk factors and symptoms by questionnaire (n = 234) or elevated temperature (n = 967) or refusing to wear a mask (n = 71). Although there is no evidence that SARS-CoV-2 is transmissible by blood transfusion, these extra steps were put in place to enhance safety for donors and staff.9 ",2020-05-09,2020-07-21,Blood donors,All,Multiple groups,17.0,24.0,Age,17-24,7165,0.008100000000000001,0.0064,0.0101,,,True,,,Entire sample,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Sahar Saeed,Canadian Blood Services,Unity-Aligned,http://dx.doi.org/10.1111/trf.16296,2021-08-27,2024-03-01,Verified,saeed_sarscov2_2021,CAN
210201_Canada_CanadianBloodServices_35-44,210201_Canada_CBS,SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada,2021-02-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Canada,"Yukon, Northwest Territories, Nunavut, British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick, Nove Scotia, Prince Edward Island, Newfoundland and Labrador",,Whole blood donors donating at all Canadian Blood Services locations (fixed and mobile sites in all larger cities and most urban areas from all provinces except Quebec). Donors must meet numerous selection criteria to ensure that they are in good health and at low risk of infectious disease.,"Beginning in March 2020, donors were deferred for 2 weeks if they were diagnosed with SARS-CoV-2 infection or if they were in contact with a known case. Donors were assessed at the door of the collection site and not permitted to enter if they had COVID-19 risk factors and symptoms by questionnaire (n = 234) or elevated temperature (n = 967) or refusing to wear a mask (n = 71). Although there is no evidence that SARS-CoV-2 is transmissible by blood transfusion, these extra steps were put in place to enhance safety for donors and staff.9 ",2020-05-09,2020-07-21,Blood donors,All,Adults (18-64 years),35.0,44.0,Age,35-44,12286,0.0062,0.0048,0.0079,,,True,,,Entire sample,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Sahar Saeed,Canadian Blood Services,Unity-Aligned,http://dx.doi.org/10.1111/trf.16296,2021-08-27,2024-03-01,Verified,saeed_sarscov2_2021,CAN
210201_Canada_CanadianBloodServices_Female_adj,210201_Canada_CBS,SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada,2021-02-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Canada,"Yukon, Northwest Territories, Nunavut, British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick, Nove Scotia, Prince Edward Island, Newfoundland and Labrador",,Whole blood donors donating at all Canadian Blood Services locations (fixed and mobile sites in all larger cities and most urban areas from all provinces except Quebec). Donors must meet numerous selection criteria to ensure that they are in good health and at low risk of infectious disease.,"Beginning in March 2020, donors were deferred for 2 weeks if they were diagnosed with SARS-CoV-2 infection or if they were in contact with a known case. Donors were assessed at the door of the collection site and not permitted to enter if they had COVID-19 risk factors and symptoms by questionnaire (n = 234) or elevated temperature (n = 967) or refusing to wear a mask (n = 71). Although there is no evidence that SARS-CoV-2 is transmissible by blood transfusion, these extra steps were put in place to enhance safety for donors and staff.9 ",2020-05-09,2020-07-21,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,,35547,0.0067,0.0058,0.0075,,True,True,,,Entire sample,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Sahar Saeed,Canadian Blood Services,Unity-Aligned,http://dx.doi.org/10.1111/trf.16296,2021-03-21,2023-07-04,Verified,saeed_sarscov2_2021,CAN
210201_Canada_CanadianBloodServices_Male_adj,210201_Canada_CBS,SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada,2021-02-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Canada,"Yukon, Northwest Territories, Nunavut, British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick, Nove Scotia, Prince Edward Island, Newfoundland and Labrador",,Whole blood donors donating at all Canadian Blood Services locations (fixed and mobile sites in all larger cities and most urban areas from all provinces except Quebec). Donors must meet numerous selection criteria to ensure that they are in good health and at low risk of infectious disease.,"Beginning in March 2020, donors were deferred for 2 weeks if they were diagnosed with SARS-CoV-2 infection or if they were in contact with a known case. Donors were assessed at the door of the collection site and not permitted to enter if they had COVID-19 risk factors and symptoms by questionnaire (n = 234) or elevated temperature (n = 967) or refusing to wear a mask (n = 71). Although there is no evidence that SARS-CoV-2 is transmissible by blood transfusion, these extra steps were put in place to enhance safety for donors and staff.9 ",2020-05-09,2020-07-21,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,,39095,0.0073,0.0064,0.0083,,True,True,,,Entire sample,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Sahar Saeed,Canadian Blood Services,Unity-Aligned,http://dx.doi.org/10.1111/trf.16296,2021-03-21,2023-07-04,Verified,saeed_sarscov2_2021,CAN
210201_Canada_CanadianBloodServices_45-54,210201_Canada_CBS,SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada,2021-02-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Canada,"Yukon, Northwest Territories, Nunavut, British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick, Nove Scotia, Prince Edward Island, Newfoundland and Labrador",,Whole blood donors donating at all Canadian Blood Services locations (fixed and mobile sites in all larger cities and most urban areas from all provinces except Quebec). Donors must meet numerous selection criteria to ensure that they are in good health and at low risk of infectious disease.,"Beginning in March 2020, donors were deferred for 2 weeks if they were diagnosed with SARS-CoV-2 infection or if they were in contact with a known case. Donors were assessed at the door of the collection site and not permitted to enter if they had COVID-19 risk factors and symptoms by questionnaire (n = 234) or elevated temperature (n = 967) or refusing to wear a mask (n = 71). Although there is no evidence that SARS-CoV-2 is transmissible by blood transfusion, these extra steps were put in place to enhance safety for donors and staff.9 ",2020-05-09,2020-07-21,Blood donors,All,Adults (18-64 years),45.0,54.0,Age,45-54,13339,0.0073,0.0059,0.0089,,,True,,,Entire sample,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Sahar Saeed,Canadian Blood Services,Unity-Aligned,http://dx.doi.org/10.1111/trf.16296,2021-08-27,2024-03-01,Verified,saeed_sarscov2_2021,CAN
210201_Canada_CanadianBloodServices_Overall_unadj,210201_Canada_CBS,SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada,2021-02-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Canada,"Yukon, Northwest Territories, Nunavut, British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick, Nove Scotia, Prince Edward Island, Newfoundland and Labrador",,Whole blood donors donating at all Canadian Blood Services locations (fixed and mobile sites in all larger cities and most urban areas from all provinces except Quebec). Donors must meet numerous selection criteria to ensure that they are in good health and at low risk of infectious disease.,"Beginning in March 2020, donors were deferred for 2 weeks if they were diagnosed with SARS-CoV-2 infection or if they were in contact with a known case. Donors were assessed at the door of the collection site and not permitted to enter if they had COVID-19 risk factors and symptoms by questionnaire (n = 234) or elevated temperature (n = 967) or refusing to wear a mask (n = 71). Although there is no evidence that SARS-CoV-2 is transmissible by blood transfusion, these extra steps were put in place to enhance safety for donors and staff.9 ",2020-05-09,2020-07-21,Blood donors,All,Multiple groups,17.0,,Analysis,,74642,0.0074,0.0068000000000000005,0.008,,,,,True,Entire sample,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Sahar Saeed,Canadian Blood Services,Unity-Aligned,http://dx.doi.org/10.1111/trf.16296,2021-03-21,2024-03-01,Verified,saeed_sarscov2_2021,CAN
210201_Canada_CanadianBloodServices_65+,210201_Canada_CBS,SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada,2021-02-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Canada,"Yukon, Northwest Territories, Nunavut, British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick, Nove Scotia, Prince Edward Island, Newfoundland and Labrador",,Whole blood donors donating at all Canadian Blood Services locations (fixed and mobile sites in all larger cities and most urban areas from all provinces except Quebec). Donors must meet numerous selection criteria to ensure that they are in good health and at low risk of infectious disease.,"Beginning in March 2020, donors were deferred for 2 weeks if they were diagnosed with SARS-CoV-2 infection or if they were in contact with a known case. Donors were assessed at the door of the collection site and not permitted to enter if they had COVID-19 risk factors and symptoms by questionnaire (n = 234) or elevated temperature (n = 967) or refusing to wear a mask (n = 71). Although there is no evidence that SARS-CoV-2 is transmissible by blood transfusion, these extra steps were put in place to enhance safety for donors and staff.9 ",2020-05-09,2020-07-21,Blood donors,All,Seniors (65+ years),65.0,,Age,65+,9845,0.008100000000000001,0.006600000000000001,0.0099,,,True,,,Entire sample,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Sahar Saeed,Canadian Blood Services,Unity-Aligned,http://dx.doi.org/10.1111/trf.16296,2021-08-27,2024-03-01,Verified,saeed_sarscov2_2021,CAN
210201_Canada_CanadianBloodServices_25-34,210201_Canada_CBS,SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada,2021-02-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Canada,"Yukon, Northwest Territories, Nunavut, British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick, Nove Scotia, Prince Edward Island, Newfoundland and Labrador",,Whole blood donors donating at all Canadian Blood Services locations (fixed and mobile sites in all larger cities and most urban areas from all provinces except Quebec). Donors must meet numerous selection criteria to ensure that they are in good health and at low risk of infectious disease.,"Beginning in March 2020, donors were deferred for 2 weeks if they were diagnosed with SARS-CoV-2 infection or if they were in contact with a known case. Donors were assessed at the door of the collection site and not permitted to enter if they had COVID-19 risk factors and symptoms by questionnaire (n = 234) or elevated temperature (n = 967) or refusing to wear a mask (n = 71). Although there is no evidence that SARS-CoV-2 is transmissible by blood transfusion, these extra steps were put in place to enhance safety for donors and staff.9 ",2020-05-09,2020-07-21,Blood donors,All,Adults (18-64 years),25.0,34.0,Age,25-34,15254,0.0085,0.006999999999999999,0.0103,,,True,,,Entire sample,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Sahar Saeed,Canadian Blood Services,Unity-Aligned,http://dx.doi.org/10.1111/trf.16296,2021-08-27,2024-03-01,Verified,saeed_sarscov2_2021,CAN
210205_Ontario_PublicHealthOntario_August_Abbott,210205_Ontario_PublicHealthOntario_August,SARS-CoV-2 seroprevalence survey estimates are affected by anti-nucleocapsid antibody decline,2021-02-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Ontario,,"Residual sera, plasma, and blood specimens remaining after routine clinical testing at the Public Health Ontario laboratory. Specimens were selected to represent both sexes, all age
groups and all geographic regions in Ontario.",,2020-08-01,2020-08-21,Residual sera,All,Multiple groups,,,Test used,,5764,0.015600000000000001,,,True,,,,True,Stratified non-probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.8420000000000001,1.0,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiaa796,2020-12-07,2024-03-01,Verified,bolotin_sars-cov-2_2020,CAN
210205_Ontario_PublicHealthOntario_August_Primary,210205_Ontario_PublicHealthOntario_August,SARS-CoV-2 seroprevalence survey estimates are affected by anti-nucleocapsid antibody decline,2021-02-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Ontario,,"Residual sera, plasma, and blood specimens remaining after routine clinical testing at the Public Health Ontario laboratory. Specimens were selected to represent both sexes, all age
groups and all geographic regions in Ontario.",,2020-08-01,2020-08-21,Residual sera,All,Multiple groups,,,Primary Estimate,Abbott and ortho,5764,0.011000000000000001,0.008,0.013999999999999999,,,,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiaa796,2020-12-07,2024-03-01,Verified,bolotin_sars-cov-2_2020,CAN
210205_Ontario_PublicHealthOntario_July_Abbott,210205_Ontario_PublicHealthOntario_July,SARS-CoV-2 seroprevalence survey estimates are affected by anti-nucleocapsid antibody decline,2021-02-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Ontario,,"Residual sera, plasma, and blood specimens remaining after routine clinical testing at the Public Health Ontario laboratory. Specimens were selected to represent both sexes, all age
groups and all geographic regions in Ontario.",,2020-07-04,2020-07-31,Residual sera,All,Multiple groups,,,Test used,,7001,0.0139,,,True,,,,True,Stratified non-probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.8420000000000001,1.0,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiaa796,2020-12-07,2024-03-01,Verified,bolotin_sars-cov-2_2020,CAN
210205_Ontario_PublicHealthOntario_July_Primary,210205_Ontario_PublicHealthOntario_July,SARS-CoV-2 seroprevalence survey estimates are affected by anti-nucleocapsid antibody decline,2021-02-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Ontario,,"Residual sera, plasma, and blood specimens remaining after routine clinical testing at the Public Health Ontario laboratory. Specimens were selected to represent both sexes, all age
groups and all geographic regions in Ontario.",,2020-07-04,2020-07-31,Residual sera,All,Multiple groups,,,Primary Estimate,Abbott and ortho,7001,0.01,0.008,0.012,,,,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiaa796,2020-12-07,2024-03-01,Verified,bolotin_sars-cov-2_2020,CAN
210208_Canada_CBS_BloodDonors_Overall_PopTestAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,16961,0.013700000000000002,0.0118,0.015600000000000001,True,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-19,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Ethnicity_Indigenous_PopAdjTestAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,209,0.0351,0.0068000000000000005,0.0635,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_NovaScotia_UnAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,845,0.0059,0.0019,0.0138,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Manitoba_PopAdjTestAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1247,0.0302,0.0175,0.0429,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Winnipeg_PopAdjTestAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,809,0.0187,0.006,0.0313,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Age_17-24_PopAdjTestAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 years,1551,0.0275,0.0201,0.0349,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-19,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Overall_UnAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Analysis,,16961,0.0151,0.013300000000000001,0.017,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-19,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Age_25-39_UnAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 years,4618,0.0149,0.0116,0.0189,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_NewBrunswick_PopAdjTestAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,395,0.0097,0.0001,0.0193,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Saskatchewan_UnAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1324,0.0189,0.0123,0.027700000000000002,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Saskatchewan_PopAdjTestAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1324,0.0196,0.0083,0.0308,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_BritishColumbia_PopAdjTestAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,3263,0.0105,0.006500000000000001,0.014499999999999999,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Sex_Female_UnAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female ,7308,0.0134,0.010900000000000002,0.0163,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Winnipeg_UnAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,809,0.0198,0.0113,0.0319,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Sex_Male_PopAdjTestAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,9653,0.016399999999999998,0.013500000000000002,0.0194,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-19,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Age_17-24_UnAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 years,1551,0.0271,0.0196,0.0364,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Ethnicity_Others_PopAdjTestAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,Others,1490,0.027400000000000004,0.0187,0.0361,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Ethnicity_Others_UnAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,Others,1490,0.0235,0.016399999999999998,0.0325,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Ethnicity_White_PopAdjTestAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,12751,0.011399999999999999,0.0094,0.0134,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Edmonton_UnAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1339,0.0269,0.0189,0.037000000000000005,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Age_60+_PopAdjTestAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ years,4262,0.0096,0.006600000000000001,0.012700000000000001,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-19,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Ontario_PopAdjTestAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,5543,0.0117,0.0092,0.014199999999999999,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Vancouver_UnAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,1820,0.013200000000000002,0.0085,0.0196,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_NewfoundlandLabrador_PopAdjTestAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,3263,0.0024,0.0,0.0088,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_PrinceEdwardIsland_UnAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,170,0.0,0.0,0.0215,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_PrinceEdwardIsland_PopAdjTestAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,170,0.0,,,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_NovaScotia_PopAdjTestAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,845,0.006500000000000001,0.0,0.013700000000000002,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Overall_PopAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Analysis,,16961,0.013700000000000002,0.012,0.015500000000000002,,,True,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-19,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Ethnicity_Asian_PopAdjTestAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,680,0.0117,0.0028000000000000004,0.0206,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Age_60+_UnAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ years,4262,0.011000000000000001,0.008100000000000001,0.0146,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Toronto_UnAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,1429,0.021,0.014199999999999999,0.0298,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Calgary_UnAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,1430,0.0147,0.0091,0.022400000000000003,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Age_40-59_PopAdjTestAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 years,6530,0.0124,0.009300000000000001,0.0154,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-19,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Sex_Male_UnAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,9653,0.016399999999999998,0.0139,0.0191,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Age_40-59_UnAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 years,6530,0.015,0.0122,0.0183,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Manitoba_UnAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1247,0.029700000000000004,0.021,0.04070000000000001,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Ottawa_PopAdjTestAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,664,0.0059,0.001,0.0113,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Age_25-39_PopAdjTestAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 years,4618,0.013300000000000001,0.0095,0.0171,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-19,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Ethnicity_Indigenous_UnAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,209,0.0144,0.003,0.0414,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_NewBrunswick_UnAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,395,0.0076,0.0016,0.022000000000000002,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Calgary_PopAdjTestAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,1430,0.013500000000000002,0.005,0.0216,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Vancouver_PopAdjTestAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,1820,0.0126,0.006999999999999999,0.018500000000000003,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Sex_Female_PopAdjTestAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female ,7308,0.011200000000000002,0.0088,0.013600000000000001,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-19,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Edmonton_PopAdjTestAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1339,0.0285,0.017,0.0404,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_NewfoundlandLabrador_UnAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,3263,0.0047,0.0001,0.026099999999999998,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_BritishColumbia_UnAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,3263,0.0113,0.008,0.015600000000000001,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Alberta_UnAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,3963,0.021400000000000002,0.0172,0.0265,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Alberta_PopAdjTestAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,3963,0.0221,0.016,0.0282,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Ethnicity_Asian_UnAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,680,0.016200000000000003,0.008100000000000001,0.0288,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Ottawa_UnAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,664,0.0075,0.0024,0.0175,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Toronto_PopAdjTestAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,1429,0.0259,0.019,0.033,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2023-07-04,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Ontario_UnAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,5543,0.011399999999999999,0.0087,0.014499999999999999,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210208_Canada_CBS_BloodDonors_Ethnicity_White_UnAdj,210208_Canada_CBS,"COVID-19 Seroprevalence Report February 8, 2021 Report #5: December 2020 Survey",2021-02-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate. Repeat tested samples were excluded from the present analysis.",2020-12-10,2020-12-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,12751,0.013300000000000001,0.0113,0.0154,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-02-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021,CAN
210216_Toronto_UniversityHealthNetwork_Euroimmun+Microarray,210216_Toronto_UniversityHealthNetwork,Prospective observational study and serosurvey of SARS-CoV-2 infection in asymptomatic healthcare workers at a Canadian tertiary care center,2021-02-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Ontario,Toronto,"HCWs were required to be asymptomatic and not have a previous diagnosis of COVID-19. Additional HCWs, whether asymptomatic or symptomatic, who sought voluntary screening through OHS during the same six-week period, were also included as a separate cohort",symptomatic HCWs and those with a known previous diagnosis of COVID were excluded from our study,2020-04-17,2020-05-29,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Euroimmun anti-S test confirmed by microarray assay,996,0.005,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Author designed (Multiplex)","EUROIMMUN,NA",Multiple Types,Serum,IgG,Spike,Validated by manufacturers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Victor Ferreira,University Health Network,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0247258,2021-03-22,2024-03-01,Verified,ferreira_prospective_2021,CAN
210315_Vancouver_BCChildren’sHospitalResearchInstitute_OverallPrimary,210315_Vancouver_BCChildren’sHospitalResearchInstitute,A majority of uninfected adults show pre-existing antibody reactivity against SARS-CoV-2,2021-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,British Columbia,Vancouver,"Adults over 18 years of age from the greater Vancouver metropolitan area were included if they did not have active COVID-19, did not require self-isolation as per BC provincial public measures, or had recovered from COVID-19 at least 14 days prior to the study visit and blood collection.  all adults who responded to the invitation email and returned their signed consent form were enrolled ","Excluded if if they had active COVID-19, required self-isolation as per BC provincial public measures, or had not yet recovered from COVID-19 at least 14 days prior to the study visit and blood collection",2020-05-17,2020-06-19,Household and community samples,All,Adults (18-64 years),18.0,,Primary Estimate,"Overall, test adjusted",276,0.006,0.0,0.0271,True,True,,,,Convenience,"Meso Scale Discovery multiplex assay,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total","Meso Scale Discovery,Ortho Clinical Diagnostics Inc.",Multiple Types,,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,,Abdelilah Majdoubi,BC Children’s Hospital Research Institute,Not Unity-Aligned,https://dx.doi.org/10.1172/jci.insight.146316,2021-04-11,2023-08-15,Verified,majdoubi_majority_2021,CAN
210315_Vancouver_BCChildren’sHospitalResearchInstitute_female,210315_Vancouver_BCChildren’sHospitalResearchInstitute,A majority of uninfected adults show pre-existing antibody reactivity against SARS-CoV-2,2021-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,British Columbia,Vancouver,"Adults over 18 years of age from the greater Vancouver metropolitan area were included if they did not have active COVID-19, did not require self-isolation as per BC provincial public measures, or had recovered from COVID-19 at least 14 days prior to the study visit and blood collection.  all adults who responded to the invitation email and returned their signed consent form were enrolled ","Excluded if if they had active COVID-19, required self-isolation as per BC provincial public measures, or had not yet recovered from COVID-19 at least 14 days prior to the study visit and blood collection",2020-05-17,2020-06-19,Household and community samples,Female,Adults (18-64 years),18.0,,Sex/Gender,,186,0.0108,,,,,,,,Convenience,"Meso Scale Discovery multiplex assay,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total","Meso Scale Discovery,Ortho Clinical Diagnostics Inc.",Multiple Types,,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,,Abdelilah Majdoubi,BC Children’s Hospital Research Institute,Not Unity-Aligned,https://dx.doi.org/10.1172/jci.insight.146316,2021-04-11,2024-03-01,Verified,majdoubi_majority_2021,CAN
210315_Vancouver_BCChildren’sHospitalResearchInstitute_male,210315_Vancouver_BCChildren’sHospitalResearchInstitute,A majority of uninfected adults show pre-existing antibody reactivity against SARS-CoV-2,2021-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,British Columbia,Vancouver,"Adults over 18 years of age from the greater Vancouver metropolitan area were included if they did not have active COVID-19, did not require self-isolation as per BC provincial public measures, or had recovered from COVID-19 at least 14 days prior to the study visit and blood collection.  all adults who responded to the invitation email and returned their signed consent form were enrolled ","Excluded if if they had active COVID-19, required self-isolation as per BC provincial public measures, or had not yet recovered from COVID-19 at least 14 days prior to the study visit and blood collection",2020-05-17,2020-06-19,Household and community samples,Male,Adults (18-64 years),18.0,,Sex/Gender,,90,0.011000000000000001,,,,,,,,Convenience,"Meso Scale Discovery multiplex assay,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total","Meso Scale Discovery,Ortho Clinical Diagnostics Inc.",Multiple Types,,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,,Abdelilah Majdoubi,BC Children’s Hospital Research Institute,Not Unity-Aligned,https://dx.doi.org/10.1172/jci.insight.146316,2021-04-11,2024-03-01,Verified,majdoubi_majority_2021,CAN
210315_Vancouver_BCChildren’sHospitalResearchInstitute_Analysis,210315_Vancouver_BCChildren’sHospitalResearchInstitute,A majority of uninfected adults show pre-existing antibody reactivity against SARS-CoV-2,2021-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,British Columbia,Vancouver,"Adults over 18 years of age from the greater Vancouver metropolitan area were included if they did not have active COVID-19, did not require self-isolation as per BC provincial public measures, or had recovered from COVID-19 at least 14 days prior to the study visit and blood collection.  all adults who responded to the invitation email and returned their signed consent form were enrolled ","Excluded if if they had active COVID-19, required self-isolation as per BC provincial public measures, or had not yet recovered from COVID-19 at least 14 days prior to the study visit and blood collection",2020-05-17,2020-06-19,Household and community samples,All,Adults (18-64 years),18.0,,Analysis,,276,0.011000000000000001,,,,,,,True,Convenience,"Meso Scale Discovery multiplex assay,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total","Meso Scale Discovery,Ortho Clinical Diagnostics Inc.",Multiple Types,,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,,Abdelilah Majdoubi,BC Children’s Hospital Research Institute,Not Unity-Aligned,https://dx.doi.org/10.1172/jci.insight.146316,2021-08-26,2024-03-01,Verified,majdoubi_majority_2021,CAN
210510_Canada_CBS_BloodDonors_RocheS_Overall_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,33400,0.0278,0.0258,0.029700000000000004,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Geographical Area_Manitoba_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1798,0.053700000000000005,0.0421,0.0652,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Age_40-59_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,12280,0.02801302932,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,1316,0.03571428571,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Geographical Area_Ontario_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,13616,0.02129847239,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Geographical Area_Winnipeg_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1079,0.02780352178,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Geographical Area_Toronto_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4119,0.030299999999999997,0.0252,0.0355,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Geographical Area_New Brunswick_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,1080,0.0018,0.0,0.0058,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Geographical Area_Edmonton_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,2300,0.03739130435,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Age_60+_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9093,0.0097,0.0073,0.0121,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24857,0.02989097638,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Geographical Area_Ontario_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,13616,0.022799999999999997,0.0203,0.0252,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Geographical Area_Vancouver_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,3545,0.022002820870000002,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Overall_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Test used,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay PopTest Adj,33400,0.022400000000000003,0.020800000000000003,0.024100000000000003,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Geographical Area_Winnipeg_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1079,0.022799999999999997,0.0126,0.0329,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Geographical Area_Alberta_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6880,0.0509,0.044500000000000005,0.05740000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Age_60+_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9093,0.0103,0.008100000000000001,0.0126,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Geographical Area_Newfoundland and Labrador_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,474,0.00210970464,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24857,0.0194,0.0176,0.0212,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,397,0.01763224181,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Sex_Male_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,19028,0.02590918646,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Geographical Area_Manitoba_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1798,0.055617352610000004,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Geographical Area_Saskatchewan_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1711,0.03331385155,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Geographical Area_Nova Scotia_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1348,0.01112759644,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Age_40-59_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,12280,0.02166123779,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Geographical Area_Winnipeg_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1079,0.0246,0.013500000000000002,0.0356,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Geographical Area_British Columbia_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,6192,0.020499999999999997,0.0165,0.0245,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Geographical Area_Newfoundland and Labrador_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,474,0.01476793249,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Geographical Area_Ottawa_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1295,0.011200000000000002,0.0055000000000000005,0.0169,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,1316,0.028900000000000002,0.0194,0.0383,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210318_Canada_CBS_BloodDonors_Abbott_Overall_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Test used,Abbott Architect SARS-CoV-2 IgG assay,34921,0.0199,0.0184,0.0215,,True,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Geographical Area_New Brunswick_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,1080,0.008,0.0009,0.0152,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Geographical Area_Saskatchewan_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1711,0.0347,0.0245,0.0449,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,1316,0.0308,0.0207,0.040999999999999995,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Geographical Area_Alberta_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6880,0.050581395349999995,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Sex_Male_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,19028,0.0262,0.0235,0.0288,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,3015,0.042300000000000004,0.0349,0.0497,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Geographical Area_Ontario_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,13616,0.0192,0.017,0.021400000000000002,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Geographical Area_Prince Edward Island_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,301,0.0,0.0,0.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Geographical Area_Manitoba_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1798,0.055999999999999994,0.043899999999999995,0.068,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Geographical Area_Ottawa_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1295,0.016399999999999998,0.0092,0.0236,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Geographical Area_Ontario_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,13616,0.02665981199,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,397,0.0201511335,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Overall_PopAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Analysis,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay Pop Adj,33400,0.024300000000000002,0.0227,0.026000000000000002,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Age_25-39_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,9432,0.031000000000000003,0.0271,0.0349,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Age_40-59_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,12280,0.0225,0.0195,0.0255,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Geographical Area_Alberta_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6880,0.039244186050000004,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Geographical Area_Vancouver_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,3545,0.027000000000000003,0.021,0.033,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Geographical Area_Edmonton_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,2300,0.0363,0.027000000000000003,0.0455,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Overall_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Analysis,,33400,0.0326,0.0308,0.0346,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Geographical Area_New Brunswick_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,1080,0.01111111111,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24857,0.022207024180000003,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,1316,0.030395136780000002,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,3015,0.04311774461,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Geographical Area_Calgary_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2478,0.02865213882,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Age_60+_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9093,0.012867040580000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Geographical Area_Newfoundland and Labrador_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,474,0.0088,0.0,0.0176,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Geographical Area_Saskatchewan_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1711,0.046200000000000005,0.0342,0.058300000000000005,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Geographical Area_British Columbia_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,6192,0.01841085271,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Geographical Area_Prince Edward Island_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,301,0.0337,0.0053,0.0621,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Geographical Area_New Brunswick_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,1080,0.00277777778,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Sex_Female_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,14372,0.02379627053,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,3015,0.0484,0.0403,0.0565,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Age_17-24_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2595,0.06088631985,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Geographical Area_Calgary_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2478,0.0406,0.0308,0.050300000000000004,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Geographical Area_Nova Scotia_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1348,0.0039000000000000003,0.0,0.008199999999999999,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Geographical Area_Edmonton_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,2300,0.04652173913,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Sex_Female_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,14372,0.029300000000000003,0.0265,0.032,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Age_17-24_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2595,0.0525,0.0454,0.059699999999999996,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,397,0.0151,0.0021,0.027999999999999997,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Geographical Area_Calgary_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2478,0.028900000000000002,0.020800000000000003,0.037000000000000005,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Geographical Area_Nova Scotia_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1348,0.0059,0.0,0.0118,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Geographical Area_Newfoundland and Labrador_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,474,0.0,0.0,0.0028000000000000004,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Age_25-39_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,9432,0.04360000000000001,0.038900000000000004,0.04820000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Geographical Area_Winnipeg_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1079,0.024096385539999998,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Geographical Area_Calgary_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2478,0.04075867635,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Geographical Area_Vancouver_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,3545,0.03018335684,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Geographical Area_Nova Scotia_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1348,0.00519287834,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Geographical Area_Ottawa_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1295,0.018532818529999998,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,3015,0.051741293529999996,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Age_25-39_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,9432,0.048452078030000005,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Sex_Male_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,19028,0.02879966365,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Age_17-24_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2595,0.045899999999999996,0.0394,0.0525,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Sex_Female_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,14372,0.0377122182,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Age_60+_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9093,0.01440668646,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Age_25-39_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,9432,0.03360899067,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Geographical Area_Prince Edward Island_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,301,0.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Sex_Female_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,14372,0.0198,0.0176,0.022000000000000002,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Geographical Area_British Columbia_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,6192,0.0163,0.0128,0.0197,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Geographical Area_Alberta_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6880,0.0402,0.0346,0.0458,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Age_17-24_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2595,0.05202312139,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Geographical Area_Toronto_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4119,0.03326050012,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Geographical Area_Toronto_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4119,0.02840495266,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Geographical Area_Ottawa_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1295,0.012355212360000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Geographical Area_British Columbia_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,6192,0.02487080103,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Overall_PopAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Analysis,,33400,0.0318,0.029900000000000003,0.0337,,,True,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Sex_Male_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,19028,0.0252,0.0227,0.0278,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Geographical Area_Edmonton_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,2300,0.0443,0.0338,0.0547,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24857,0.0248,0.0227,0.0269,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Geographical Area_Manitoba_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1798,0.05172413793,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Age_40-59_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,12280,0.0178,0.015300000000000001,0.0204,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Geographical Area_Vancouver_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,3545,0.020499999999999997,0.0154,0.0255,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Geographical Area_Saskatchewan_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1711,0.045587375799999996,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,397,0.0151,0.0012,0.0291,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheS_Geographical Area_Prince Edward Island_UnAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,301,0.04318936877,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-06-08,2024-03-01,Verified,canadian_blood_services_covid-19_2021-2,CAN
210510_Canada_CBS_BloodDonors_RocheN_Geographical Area_Toronto_PopTestAdj,210510_Canada_CBS,"COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey",2021-05-10,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-01-01,2021-01-27,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4119,0.027000000000000003,0.0223,0.0317,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-07-05,2023-08-15,Verified,canadian_blood_services_covid-19_2021-2,CAN
210512_Canada_UniversityofAlberta_April1,210512_Canada_UniversityofAlberta_April1,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence: Navigating the absence of a gold standard,2021-05-12,Preprint,National,Cross-sectional survey ,Canada,,,This serial cross-sectional study was conducted using plasma samples from healthy blood donors between April-September 2020,,2020-04-01,2020-04-30,Blood donors,All,Adults (18-64 years),,,Primary Estimate,,8999,0.030699999999999998,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,,0.891,,['High'],,No,Yes,No,,Unclear,Yes,No,,Sahar Saeed,University of Alberta,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.05.11.21256992v1.full-text#T1,2021-06-04,2022-07-16,Unverified,saharsaeedSevereAcuteRespiratory2021,CAN
210512_Canada_UniversityofAlberta_September2,210512_Canada_UniversityofAlberta_September2,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence: Navigating the absence of a gold standard,2021-05-12,Preprint,National,Prospective cohort,Canada,,,This serial cross-sectional study was conducted using plasma samples from healthy blood donors between April-September 2020,,2020-09-01,2020-09-30,Blood donors,All,Adults (18-64 years),,,Primary Estimate,,8999,0.0267,,,True,,,,True,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,,0.891,0.9820000000000001,['Moderate'],,Yes,Yes,No,,Unclear,Yes,No,,Sahar Saeed,University of Alberta,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.05.11.21256992v1.full-text#T1,2021-06-04,2022-07-16,Unverified,saharsaeedSevereAcuteRespiratory2021,CAN
210517_Quebec_Héma-Québec_PopAdj,210517_Quebec_Héma-Québec,"SARS-CoV-2 seroprevalence among blood donors in Quebec, and analysis of symptoms associated with seropositivity: a nested case-control study.",2021-05-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Québec,,Prospective donors included in the study had to be free of COVID-19 symptoms in the preceding 14 days and otherwise eligible to donate according to standard criteria,,2020-05-25,2020-07-09,Blood donors,All,Adults (18-64 years),,,Primary Estimate,"Population adjusted for population size, age, and sex",7691,0.0223,0.019,0.0256,True,,True,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['High'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,Yes,Hema-Quebec,Héma-Québec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-021-00531-6,2021-06-03,2022-07-16,Verified,lewin_sars-cov-2_2021,CAN
210517_Quebec_Héma-Québec_Unadj,210517_Quebec_Héma-Québec,"SARS-CoV-2 seroprevalence among blood donors in Quebec, and analysis of symptoms associated with seropositivity: a nested case-control study.",2021-05-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Québec,,Prospective donors included in the study had to be free of COVID-19 symptoms in the preceding 14 days and otherwise eligible to donate according to standard criteria,,2020-05-25,2020-07-09,Blood donors,All,Adults (18-64 years),,,Analysis,Crude estimate,7691,0.0225,0.0193,0.026099999999999998,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['High'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,Yes,Hema-Quebec,Héma-Québec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-021-00531-6,2021-09-05,2022-07-16,Verified,lewin_sars-cov-2_2021,CAN
210609_Canada_CBS_BloodDonors_RocheS_Overall_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,16873,0.0985,0.09390000000000001,0.10310000000000001,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Age_40-59_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,6255,0.028300000000000002,0.0239,0.0327,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Age_17-24_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1410,0.07375886525,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,1588,0.1183879093,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Age_25-39_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,4582,0.046,0.0395,0.0526,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Geographical Area_Saskatchewan_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,671,0.053651266770000004,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,201,0.09452736317999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Age_17-24_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1410,0.0637,0.053099999999999994,0.07440000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Sex_Male_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,9906,0.0751,0.0692,0.081,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,1588,0.1144,0.0986,0.1302,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Geographical Area_Ontario_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,8015,0.02919525889,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Geographical Area_British Columbia_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,2547,0.08362779741000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Geographical Area_Manitoba_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,807,0.0675,0.0493,0.08560000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Age_17-24_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1410,0.1375886525,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Geographical Area_Newfoundland and Labrador_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,322,0.001,0.0,0.0069,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Geographical Area_New Brunswick_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,556,0.0,0.0,0.003,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Geographical Area_Toronto_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,2734,0.11480000000000001,0.0993,0.1236,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,12584,0.03035600763,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Geographical Area_Ottawa_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,712,0.0702247191,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Geographical Area_British Columbia_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,2547,0.0211,0.015700000000000002,0.0265,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Geographical Area_Ontario_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,8015,0.10619999999999999,0.09949999999999999,0.113,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Geographical Area_Alberta_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,3191,0.06173613287,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Age_40-59_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,6255,0.08569144683999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Sex_Female_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,6967,0.127745084,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Sex_Female_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,6967,0.03373044352,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Geographical Area_Ontario_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,8015,0.0278,0.024100000000000003,0.031400000000000004,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,783,0.04086845466,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Geographical Area_New Brunswick_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,556,0.0017985611500000002,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,12584,0.0947,0.0894,0.1,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Geographical Area_Edmonton_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,948,0.05063291139000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Geographical Area_Ottawa_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,712,0.015700000000000002,0.006500000000000001,0.0263,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,783,0.1277,0.105,0.15050000000000002,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Geographical Area_Calgary_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,1183,0.03127641589,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Geographical Area_Vancouver_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,1353,0.09090909091,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Geographical Area_Edmonton_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,948,0.0936,0.0681,0.1051,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Age_60+_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,4626,0.0121,0.0088,0.015500000000000002,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Age_60+_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,4626,0.054474708170000004,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Geographical Area_Ontario_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,8015,0.1051777916,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,1588,0.059000000000000004,0.047400000000000005,0.0706,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Geographical Area_Ottawa_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,712,0.0658,0.0477,0.0859,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Geographical Area_Manitoba_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,807,0.06815365551000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Overall_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Test used,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay PopTest Adj,16873,0.0325,0.029700000000000004,0.0352,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Geographical Area_NewfoundlandandLabrador_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,322,0.0031055900600000003,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,783,0.1379310345,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Geographical Area_Alberta_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,3191,0.10278909430000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Geographical Area_British Columbia_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,2547,0.0227718885,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Geographical Area_Newfoundland and Labrador_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,322,0.02795031056,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Geographical Area_Vancouver_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,1353,0.0288248337,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Geographical Area_Vancouver_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,1353,0.09550000000000002,0.0723,0.1034,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Age_40-59_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,6255,0.03149480416,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Geographical Area_Winnipeg_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,526,0.027999999999999997,0.010900000000000002,0.0386,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Age_25-39_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,4582,0.14650000000000002,0.1355,0.1575,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Sex_Male_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,9906,0.0358,0.0316,0.039900000000000005,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Geographical Area_Prince Edward Island_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,150,0.06666666667,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Overall_PopAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Analysis,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay Pop Adj,16873,0.034300000000000004,0.0316,0.0371,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Geographical Area_Winnipeg_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,526,0.026615969580000003,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Geographical Area_Saskatchewan_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,671,0.1034,0.0796,0.1272,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Geographical Area_Edmonton_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,948,0.08966244726,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Geographical Area_Prince Edward Island_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,150,0.0,,,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,201,0.028999999999999998,0.0044,0.0535,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,783,0.037200000000000004,0.0242,0.0501,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,201,0.02487562189,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Geographical Area_New Brunswick_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,556,0.04676258993,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Geographical Area_Alberta_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,3191,0.109,0.09640000000000001,0.12150000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,201,0.1027,0.058600000000000006,0.1468,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Geographical Area_Edmonton_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,948,0.0527,0.0349,0.063,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Geographical Area_Calgary_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,1183,0.0665,0.0489,0.07780000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Geographical Area_Nova Scotia_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,614,0.0,0.0,0.0029,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Geographical Area_Calgary_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,1183,0.0296,0.0195,0.0395,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Geographical Area_Prince Edward Island_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,150,0.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Geographical Area_Newfoundland and Labrador_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,322,0.0225,0.0049,0.0401,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Geographical Area_Manitoba_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,807,0.1375464684,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Geographical Area_Calgary_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,1183,0.06677937447,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Geographical Area_Winnipeg_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,526,0.0987,0.0632,0.11320000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Geographical Area_New Brunswick_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,556,0.048,0.0276,0.0683,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Age_25-39_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,4582,0.04714098647,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Geographical Area_Toronto_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,2734,0.0382,0.032799999999999996,0.0479,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,1588,0.06108312343,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Geographical Area_Vancouver_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,1353,0.0262,0.018000000000000002,0.036000000000000004,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Geographical Area_Ottawa_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,712,0.018258426969999998,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,12584,0.09130642085,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Geographical Area_Winnipeg_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,526,0.09125475285000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Age_40-59_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,6255,0.0883,0.0808,0.09570000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Geographical Area_Saskatchewan_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,671,0.1043219076,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Geographical Area_Toronto_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,2734,0.1141185077,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Age_25-39_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,4582,0.14142295940000002,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Geographical Area_Nova Scotia_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,614,0.0016286644999999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Sex_Male_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,9906,0.035130224110000004,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Sex_Female_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,6967,0.0294,0.0257,0.033,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Age_60+_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,4626,0.014267185469999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Geographical Area_Nova Scotia_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,614,0.0325732899,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Sex_Male_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,9906,0.07470220069,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Overall_PopAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Analysis,,16873,0.1014,0.0968,0.106,,,True,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Geographical Area_Saskatchewan_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,671,0.0536,0.0361,0.07110000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Geographical Area_Alberta_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,3191,0.0653,0.055400000000000005,0.0751,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Geographical Area_Prince Edward Island_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,150,0.0633,0.011000000000000001,0.1155,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Age_60+_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,4626,0.0587,0.0517,0.06570000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Geographical Area_British Columbia_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,2547,0.0874,0.077,0.0978,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Age_17-24_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1410,0.12300000000000001,0.1086,0.1374,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Sex_Female_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,6967,0.12050000000000001,0.1135,0.1276,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Overall_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Analysis,,16873,0.0966,0.0922,0.1012,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Geographical Area_Manitoba_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,807,0.1429,0.1174,0.1684,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,12584,0.028399999999999998,0.025400000000000002,0.031400000000000004,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheS_Geographical Area_Nova Scotia_PopTestAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,614,0.025400000000000002,0.0115,0.0393,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-3,CAN
210609_Canada_CBS_BloodDonors_RocheN_Geographical Area_Toronto_UnAdj,210609_Canada_CBS,"COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-02-27,2021-03-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,2734,0.04206291149,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-3,CAN
210618_Vancouver_UniversityOfBritishColumbia_BloodDonors_TestAdj,210618_Vancouver_UniversityOfBritishColumbia_BloodDonors,"SARS-CoV-2 seroprevalence among Vancouver public school staff in British Columbia, Canada",2021-06-18,Preprint,Local,Cross-sectional survey ,Canada,British Columbia,Vancouver,," People were ineligible to donate blood if they had a recent COVID-19 infection two weeks after symptoms resolved, or were hospitalized within 3 weeks before",2021-01-01,2021-01-31,Blood donors,All,Adults (18-64 years),,,Primary Estimate,,2502,0.023,0.017,0.03,True,True,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],,No,Yes,No,,Unclear,No,Yes,,David Goldfarb,University of British Columbia,Not Unity-Aligned,10.1101/2021.06.16.21258861,2021-06-30,2023-08-15,Unverified,goldfarb_sars-cov-2_2021,CAN
210618_Vancouver_UniversityOfBritishColumbia_BloodDonors_Unadj,210618_Vancouver_UniversityOfBritishColumbia_BloodDonors,"SARS-CoV-2 seroprevalence among Vancouver public school staff in British Columbia, Canada",2021-06-18,Preprint,Local,Cross-sectional survey ,Canada,British Columbia,Vancouver,," People were ineligible to donate blood if they had a recent COVID-19 infection two weeks after symptoms resolved, or were hospitalized within 3 weeks before",2021-01-01,2021-01-31,Blood donors,All,Adults (18-64 years),,,Analysis,,2502,0.02,0.015,0.027000000000000003,,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],,No,Yes,No,,Unclear,No,Yes,,David Goldfarb,University of British Columbia,Not Unity-Aligned,10.1101/2021.06.16.21258861,2021-06-30,2024-03-01,Unverified,goldfarb_sars-cov-2_2021,CAN
210618_Vancouver_UniversityOfBritishColumbia_TestAdj,210618_Vancouver_UniversityOfBritishColumbia_SchoolStaff,"SARS-CoV-2 seroprevalence among Vancouver public school staff in British Columbia, Canada",2021-06-18,Preprint,Local,Cross-sectional survey ,Canada,British Columbia,Vancouver,"Staff were included if they were a current, full or part-time staff member (confirmed by District email address).","Staff who reported being temporary staff, on-leave, or on-call with no reported classroom time were excluded",2021-02-10,2021-05-15,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,1556,0.023,0.016,0.032,True,True,,,,Self-referral,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,No,Yes,,David Goldfarb,University of British Columbia,Not Unity-Aligned,10.1101/2021.06.16.21258861,2021-06-30,2023-08-15,Unverified,goldfarb_sars-cov-2_2021,CAN
210630_Canada_CBS_BloodDonors_RocheS_Overall_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,16931,0.26920000000000005,0.26239999999999997,0.276,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Overall_PopAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Analysis,,16931,0.2693,0.2626,0.276,,,True,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Geographical Area_NewfoundlandandLabrador_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,432,0.0088,0.0,0.0198,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Geographical Area_NewfoundlandandLabrador_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,432,0.1712962963,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Geographical Area_Saskatchewan_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,850,0.0334,0.0193,0.0475,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,209,0.0059,0.0,0.0179,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Geographical Area_Ottawa_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,719,0.20723226700000003,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Overall_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Analysis,,16931,0.2589,0.2523,0.2655,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Geographical Area_Calgary_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,1302,0.04070660522,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Geographical Area_Ontario_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,7777,0.03510351035,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Geographical Area_Prince Edward Island_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,211,0.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Geographical Area_Nova Scotia_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,796,0.0043,0.0,0.0108,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Age_60+_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,4440,0.018500000000000003,0.0144,0.0225,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Geographical Area_Winnipeg_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,533,0.0178,0.0048,0.030699999999999998,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Geographical Area_Prince Edward Island_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,211,0.17550000000000002,0.0958,0.2552,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Age_17-24_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1407,0.05756929638,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Sex_Male_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,9330,0.217,0.2079,0.226,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Geographical Area_Alberta_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,3138,0.2716,0.2539,0.2892,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Geographical Area_Manitoba_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,883,0.22530000000000003,0.1949,0.25579999999999997,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Geographical Area_Toronto_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,2639,0.277756726,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Geographical Area_Ottawa_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,719,0.021400000000000002,0.0106,0.0323,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Sex_Female_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,7601,0.034074463890000004,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,1744,0.2196100917,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,12765,0.0281,0.025099999999999997,0.0311,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Geographical Area_Winnipeg_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,533,0.018761726080000003,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Geographical Area_Toronto_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,2639,0.04190000000000001,0.0352,0.048499999999999995,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Sex_Male_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,9330,0.032799999999999996,0.0288,0.0368,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Geographical Area_Vancouver_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,1315,0.26996197720000004,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Geographical Area_Ontario_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,7777,0.2751703742,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Geographical Area_Alberta_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,3138,0.047482472910000004,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Overall_PopAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Analysis,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay Pop Adj,16931,0.034100000000000005,0.0315,0.037000000000000005,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Age_17-24_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1407,0.0535,0.04360000000000001,0.0633,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Geographical Area_NewfoundlandandLabrador_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,432,0.006944444440000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Geographical Area_Edmonton_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1174,0.051,0.037000000000000005,0.065,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,717,0.2404,0.20989999999999998,0.27090000000000003,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Geographical Area_Edmonton_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1174,0.2842,0.2557,0.3128,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Geographical Area_BritishColumbia_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,2285,0.02800875274,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Geographical Area_Alberta_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,3138,0.28234544300000003,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,209,0.2727272727,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,717,0.23570432360000002,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Geographical Area_New Brunswick_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,559,0.00178890877,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Age_17-24_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1407,0.17768301350000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,12765,0.2661966314,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Geographical Area_Ottawa_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,719,0.21850000000000003,0.1884,0.2486,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Geographical Area_Manitoba_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,883,0.041600000000000005,0.0269,0.0563,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Geographical Area_Nova Scotia_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,796,0.135678392,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Geographical Area_Toronto_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,2639,0.04622963244,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,1744,0.22460000000000002,0.20550000000000002,0.2438,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,1744,0.06422018349,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Age_25-39_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,4790,0.0415,0.0353,0.0478,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Geographical Area_BritishColumbia_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,2285,0.255,0.23920000000000002,0.2708,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Age_40-59_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,6294,0.18700349540000002,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Geographical Area_Manitoba_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,883,0.22989807469999998,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Geographical Area_Edmonton_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1174,0.047700170359999995,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Geographical Area_Ontario_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,7777,0.034,0.03,0.038,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Geographical Area_Prince Edward Island_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,211,0.0,0.0,0.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Geographical Area_Winnipeg_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,533,0.2251407129,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Geographical Area_Ontario_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,7777,0.2926,0.2827,0.3024,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Sex_Female_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,7601,0.3185,0.3086,0.3284,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Geographical Area_BritishColumbia_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,2285,0.24814004380000002,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,717,0.04463040446,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Age_40-59_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,6294,0.19760000000000003,0.1872,0.2079,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Geographical Area_Saskatchewan_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,850,0.03529411765,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Geographical Area_Toronto_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,2639,0.3084,0.2932,0.3236,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Geographical Area_Vancouver_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,1315,0.04182509506,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Sex_Female_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,7601,0.29522431260000004,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Geographical Area_Prince Edward Island_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,211,0.1753554502,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Geographical Area_NewfoundlandandLabrador_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,432,0.1796,0.1379,0.2213,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Geographical Area_Vancouver_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,1315,0.27890000000000004,0.2571,0.3006,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Sex_Male_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,9330,0.03236870311,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Age_25-39_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,4790,0.2123173278,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,12765,0.028985507250000004,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Geographical Area_BritishColumbia_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,2285,0.024,0.0183,0.0296,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,209,0.00956937799,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Age_60+_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,4440,0.4485,0.43420000000000003,0.46280000000000004,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Geographical Area_Calgary_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,1302,0.2665,0.2364,0.2965,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Sex_Female_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,7601,0.0319,0.0281,0.0357,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Geographical Area_Ottawa_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,719,0.022253129349999998,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Age_60+_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,4440,0.4367117117,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Geographical Area_New Brunswick_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,559,0.20879999999999999,0.172,0.2457,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Overall_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Test used,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay PopTest Adj,16931,0.0323,0.0296,0.0351,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Geographical Area_Winnipeg_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,533,0.2139,0.1753,0.2525,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Geographical Area_New Brunswick_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,559,0.2057245081,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Geographical Area_Calgary_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,1302,0.0443,0.0302,0.0584,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Geographical Area_Calgary_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,1302,0.2741935484,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Age_25-39_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,4790,0.217,0.20420000000000002,0.2298,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,717,0.0391,0.025099999999999997,0.053099999999999994,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Geographical Area_Edmonton_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1174,0.2998296422,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,1744,0.0636,0.0524,0.07490000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Geographical Area_Nova Scotia_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,796,0.1302,0.10220000000000001,0.1582,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,12765,0.2788,0.27090000000000003,0.2868,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Geographical Area_Saskatchewan_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,850,0.3,0.2646,0.33530000000000004,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Geographical Area_Alberta_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,3138,0.051100000000000007,0.042300000000000004,0.0599,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Age_17-24_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1407,0.1655,0.1493,0.18170000000000003,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,209,0.271,0.2097,0.3322,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Geographical Area_Nova Scotia_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,796,0.00628140704,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Age_60+_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,4440,0.01981981982,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Geographical Area_Manitoba_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,883,0.04077010193,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Geographical Area_Saskatchewan_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,850,0.29764705880000003,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Age_25-39_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,4790,0.04091858038,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Geographical Area_Vancouver_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,1315,0.0379,0.0286,0.04730000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Age_40-59_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,6294,0.0296,0.0252,0.034100000000000005,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Geographical Area_New Brunswick_PopTestAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,559,0.0,0.0,0.0022,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheS_Sex_Male_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,9330,0.2292604502,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210630_Canada_CBS_BloodDonors_RocheN_Age_40-59_UnAdj,210630_Canada_CBS,"COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking seroprevalence in the vaccine era",2021-06-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-04-13,2021-04-30,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,6294,0.03114076899,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-4,CAN
210706_Canada_StatisticsCanada_Overall,210706_Canada_StatisticsCanada,Study reveals children and youth had highest rates of SARS-CoV-2 infection in Canada before third wave,2021-07-06,News and Media,National,Cross-sectional survey ,Canada,,,"Canadians, 1 year of age and older from across Canada ","The observed population excludes: persons living in the three territories outside of the capitals; persons living on reserves and other Aboriginal settlements in the provinces; full-time members of the Canadian Forces; the institutionalized population and residents of certain remote regions.

(taken from: https://www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&SDDS=5339#a1)",2020-11-15,2021-04-15,Household and community samples,All,Multiple groups,1.0,,Primary Estimate,Overal,11124,0.036000000000000004,0.026000000000000002,0.042,True,,True,,True,Stratified probability,Author designed (type unknown),,,Dried Blood,,,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,No,Statistics Canada,Statistics Canada,Not Unity-Aligned,https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310081801,2021-07-31,2022-07-16,Verified,statistics_canada_study_2021,CAN
210727_Canada_CBS_BloodDonors_RocheS_Overall_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,17001,0.639,0.6317,0.6464,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,219,0.6757990868,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1058,0.058601134220000003,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,678,0.4675516224,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,2700,0.0317,0.0253,0.0382,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,843,0.6346381969,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,2606,0.6834228702999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_Age_60+_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,4501,0.02355032215,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_Sex_Female_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,7217,0.04032146321,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,258,0.00775193798,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_Age_25-39_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,4702,0.4304551255,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,3207,0.06049267228,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_Age_25-39_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,4702,0.05082943428,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_Age_60+_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,4501,0.891579649,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_Age_17-24_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1423,0.3369,0.3165,0.35740000000000005,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,627,0.0434,0.0276,0.0593,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,765,0.5998,0.5635,0.6361,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1058,0.7268431002,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,1282,0.6691,0.6377,0.7006,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_Age_60+_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,4501,0.0215,0.0172,0.0258,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,3207,0.687246648,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,829,0.05548854041,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_Sex_Male_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,9784,0.04272281276,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,678,0.48850000000000005,0.44780000000000003,0.5292,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,136,0.4632352941,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,136,0.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_Age_40-59_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,6375,0.0391,0.034,0.0442,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,843,0.053700000000000005,0.0375,0.0699,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,136,0.4275,0.32439999999999997,0.5306000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,627,0.7198000000000001,0.6849,0.7547,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,829,0.5392038601,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,843,0.6125,0.5776,0.6474,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,678,0.00884955752,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,219,0.03652968037,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,843,0.053380782919999994,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,1455,0.0447,0.0344,0.055099999999999996,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,12464,0.6513,0.6426999999999999,0.6598999999999999,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,8026,0.6559999999999999,0.6456999999999999,0.6663,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,3207,0.06420000000000001,0.054400000000000004,0.0739,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,829,0.0543,0.0391,0.0695,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_Age_40-59_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,6375,0.6505098039000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_Overall_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Analysis,,17001,0.627,0.6196,0.6342,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,829,0.5516,0.5185000000000001,0.5848,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,1455,0.6178694158,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_Sex_Female_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,7217,0.0369,0.032799999999999996,0.040999999999999995,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,765,0.0339869281,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,1282,0.054602184090000006,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,2700,0.6236,0.606,0.6412000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,589,0.04,0.0232,0.056799999999999996,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_Overall_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Test used,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay PopTest Adj,17001,0.0401,0.0371,0.0432,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,3207,0.6784,0.6598,0.6970999999999999,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,1878,0.548455804,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,219,0.6840999999999999,0.6225,0.7456,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_Overall_PopAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Analysis,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay Pop Adj,17001,0.04190000000000001,0.038900000000000004,0.045,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,589,0.614,0.5725,0.6554000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,1455,0.6368,0.6127,0.6607999999999999,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,627,0.7368421053,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,526,0.5171102662,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_Age_40-59_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,6375,0.668,0.6558,0.6803,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_Sex_Female_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,7217,0.6746,0.6646,0.6847,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_Sex_Female_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,7217,0.6408479978,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1058,0.7112999999999999,0.6808,0.7418000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,258,0.005,0.0,0.0141,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,12464,0.03393774069,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,526,0.5132,0.46740000000000004,0.559,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_Age_17-24_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1423,0.07,0.0589,0.081,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_Age_60+_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,4501,0.9072,0.8984000000000001,0.9159,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,8026,0.040999999999999995,0.0366,0.0453,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,12464,0.6379172015000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,8026,0.042611512580000004,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,258,0.4496124031,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,2700,0.0337037037,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,2700,0.6051851852,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,765,0.585620915,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,2606,0.05333844973,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,219,0.030699999999999998,0.0076,0.0538,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_Sex_Male_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,9784,0.6013000000000001,0.5906,0.6121,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_Age_25-39_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,4702,0.048,0.041299999999999996,0.0546,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_Age_17-24_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1423,0.07238229093000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_Age_17-24_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1423,0.3338018271,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,1878,0.5526,0.53,0.5752,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_Sex_Male_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,9784,0.04360000000000001,0.0391,0.0481,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,589,0.6349745331,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,8026,0.6299526539,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,1878,0.09158679446000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1058,0.059699999999999996,0.0438,0.0755,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,1282,0.6762870515,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,136,0.0,0.0,0.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,678,0.0075,0.0,0.0152,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_Overall_PopAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Analysis,,17001,0.633,0.6255,0.6402,,,True,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,1878,0.08810000000000001,0.0753,0.10099999999999999,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,765,0.0333,0.0199,0.0468,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_Age_25-39_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,4702,0.44170000000000004,0.4264,0.457,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,1282,0.0529,0.0379,0.0678,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,258,0.4525,0.39799999999999996,0.5071,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,2606,0.0496,0.042300000000000004,0.057,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,1455,0.04536082474,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,589,0.04244482173,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_Sex_Male_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,9784,0.6167211774,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,627,0.04625199362,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,2606,0.7066,0.6912,0.7220000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,526,0.0,0.0,0.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,526,0.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_Age_40-59_UnAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,6375,0.04094117647,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2024-03-01,Verified,canadian_blood_services_covid-19_2021-5,CAN
210727_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_PopTestAdj,210727_Canada_CBS,"COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking seroprevalence in the vaccine era",2021-07-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-05-08,2021-06-04,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,12464,0.0325,0.0292,0.0357,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-08-18,2023-08-15,Verified,canadian_blood_services_covid-19_2021-5,CAN
210802_Calgary_UniversityofCalgary,210802_Calgary_UniversityofCalgary,Antibody response to SARS-CoV-2 among individuals with IBD diminishes over time: a serosurveillance cohort study.,2021-08-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Alberta,Calgary,"""Individuals with IBD from Calgary, Canada, were recruited from October 2020 to April 2021 and stratified into two cohorts: (1) serosurveillance (n=279) defined as those who were not previously diagnosed with COVID-19; and (2) COVID-19 recovered (n=45), defined as those with a molecular-confirmed diagnosis of SARS-CoV-2 infection via PCR"" -  listed here is only the first cohort. ",None,2020-10-15,2021-04-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,IBD patients overall,279,0.0108,0.0022,0.0311,True,,,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9500000000000001,0.99,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Gilaad Kaplan,University of Calgary,Not Unity-Aligned,https://dx.doi.org/10.1136/gutjnl-2021-325238,2021-08-11,2024-03-01,Verified,kaplan_antibody_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_1_June_Overall_PopAdj,210818_Alberta_AlbertaPrecisionLaboratories_1_June,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-06-01,2020-06-05,Residual sera,All,Multiple groups,0.0,,Primary Estimate,PopAdj,8442,0.0092,0.0091,0.009290000000000001,True,,True,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_1_June_Sex_Female,210818_Alberta_AlbertaPrecisionLaboratories_1_June,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-06-01,2020-06-05,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,Female,4735,0.008239999999999999,0.005659999999999999,0.01081,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_1_June_Geography_Lethbridge,210818_Alberta_AlbertaPrecisionLaboratories_1_June,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Lethbridge,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-06-01,2020-06-05,Residual sera,All,Multiple groups,0.0,,Geographical area,Lethbridge,198,0.0,0.0,0.0,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_1_June_Geography_Edmonton,210818_Alberta_AlbertaPrecisionLaboratories_1_June,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Edmonton,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-06-01,2020-06-05,Residual sera,All,Multiple groups,0.0,,Geographical area,Edmonton,2988,0.00167,0.00021,0.00314,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_1_June_Age_70-79,210818_Alberta_AlbertaPrecisionLaboratories_1_June,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-06-01,2020-06-05,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,1405,0.00783,0.00322,0.01244,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_1_June_Age_0-9,210818_Alberta_AlbertaPrecisionLaboratories_1_June,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-06-01,2020-06-05,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,0-9,96,0.0,0.0,0.0,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_1_June_Age_60-69,210818_Alberta_AlbertaPrecisionLaboratories_1_June,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-06-01,2020-06-05,Residual sera,All,Adults (18-64 years),60.0,69.0,Age,60-69,1706,0.00528,0.00184,0.00871,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_1_June_Age_80+,210818_Alberta_AlbertaPrecisionLaboratories_1_June,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-06-01,2020-06-05,Residual sera,All,Seniors (65+ years),80.0,,Age,80+,897,0.00892,0.0027700000000000003,0.01507,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_1_June_Age_10-19,210818_Alberta_AlbertaPrecisionLaboratories_1_June,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-06-01,2020-06-05,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,245,0.008159999999999999,0.0,0.01943,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_1_June_Geography_Calgary,210818_Alberta_AlbertaPrecisionLaboratories_1_June,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Calgary,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-06-01,2020-06-05,Residual sera,All,Multiple groups,0.0,,Geographical area,Calgary,737,0.03528,0.021960000000000004,0.048600000000000004,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_1_June_Geography_Brooks,210818_Alberta_AlbertaPrecisionLaboratories_1_June,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Brooks,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-06-01,2020-06-05,Residual sera,All,Multiple groups,0.0,,Geographical area,Brooks,86,0.1977,0.1135,0.2818,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_1_June_Overall_UnAdj,210818_Alberta_AlbertaPrecisionLaboratories_1_June,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-06-01,2020-06-05,Residual sera,All,Multiple groups,0.0,,Analysis,UnAdj,8442,0.00924,0.0072,0.011279999999999998,,,,,True,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_1_June_Age_20-29,210818_Alberta_AlbertaPrecisionLaboratories_1_June,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-06-01,2020-06-05,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29,696,0.008620000000000001,0.0017499999999999998,0.01549,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_1_June_Geography_RedDeer,210818_Alberta_AlbertaPrecisionLaboratories_1_June,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Red Deer,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-06-01,2020-06-05,Residual sera,All,Multiple groups,0.0,,Geographical area,Red Deer,341,0.00587,0.0,0.01397,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_1_June_Geography_GrandePrairie,210818_Alberta_AlbertaPrecisionLaboratories_1_June,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Grande Prairie,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-06-01,2020-06-05,Residual sera,All,Multiple groups,0.0,,Geographical area,Grande Prairie,448,0.0067,0.0,0.01425,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_1_June_Age_30-39,210818_Alberta_AlbertaPrecisionLaboratories_1_June,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-06-01,2020-06-05,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,1073,0.014910000000000001,0.00766,0.022160000000000003,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_1_June_Age_50-59,210818_Alberta_AlbertaPrecisionLaboratories_1_June,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-06-01,2020-06-05,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,1347,0.00817,0.00336,0.012969999999999999,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_1_June_Geography_MedicineHat,210818_Alberta_AlbertaPrecisionLaboratories_1_June,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Medicine Hat,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-06-01,2020-06-05,Residual sera,All,Multiple groups,0.0,,Geographical area,Medicine Hat,607,0.00494,0.0,0.01052,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_1_June_Sex_Male,210818_Alberta_AlbertaPrecisionLaboratories_1_June,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-06-01,2020-06-05,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,Male,3707,0.01052,0.00724,0.013810000000000001,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_1_June_Geography_Other,210818_Alberta_AlbertaPrecisionLaboratories_1_June,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Other,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-06-01,2020-06-05,Residual sera,All,Multiple groups,0.0,,Geographical area,Other,1806,0.00443,0.0013700000000000001,0.00749,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_1_June_Age_40-49,210818_Alberta_AlbertaPrecisionLaboratories_1_June,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-06-01,2020-06-05,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,977,0.015349999999999999,0.00764,0.02306,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_2_July_Overall_PopAdj,210818_Alberta_AlbertaPrecisionLaboratories_2_July,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-07-06,2020-07-10,Residual sera,All,Multiple groups,0.0,,Primary Estimate,PopAdj,13175,0.00859,0.00851,0.00868,True,,True,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_2_July_Sex_Male,210818_Alberta_AlbertaPrecisionLaboratories_2_July,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-07-06,2020-07-10,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,Male,5749,0.0059099999999999995,0.0039000000000000003,0.0079,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_2_July_Age_40-49,210818_Alberta_AlbertaPrecisionLaboratories_2_July,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-07-06,2020-07-10,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,1669,0.009000000000000001,0.00446,0.01352,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_2_July_Age_60-69,210818_Alberta_AlbertaPrecisionLaboratories_2_July,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-07-06,2020-07-10,Residual sera,All,Adults (18-64 years),60.0,69.0,Age,60-69,2716,0.00184,0.00023,0.00345,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_2_July_Age_80+,210818_Alberta_AlbertaPrecisionLaboratories_2_July,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-07-06,2020-07-10,Residual sera,All,Seniors (65+ years),80.0,,Age,80+,1252,0.0008,0.0,0.00236,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_2_July_Sex_Female,210818_Alberta_AlbertaPrecisionLaboratories_2_July,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-07-06,2020-07-10,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,Female,7426,0.00458,0.00304,0.00611,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_2_July_Geography_Other,210818_Alberta_AlbertaPrecisionLaboratories_2_July,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Other,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-07-06,2020-07-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Other,2577,0.00233,0.00047,0.00419,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_2_July_Geography_RedDeer,210818_Alberta_AlbertaPrecisionLaboratories_2_July,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Red Deer,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-07-06,2020-07-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Red Deer,326,0.00307,0.0,0.00907,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_2_July_Geography_GrandePrairie,210818_Alberta_AlbertaPrecisionLaboratories_2_July,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Grande Prairie,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-07-06,2020-07-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Grande Prairie,445,0.0,0.0,0.0,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_2_July_Geography_MedicineHat,210818_Alberta_AlbertaPrecisionLaboratories_2_July,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Medicine Hat,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-07-06,2020-07-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Medicine Hat,594,0.0,0.0,0.0,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_2_July_Age_30-39,210818_Alberta_AlbertaPrecisionLaboratories_2_July,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-07-06,2020-07-10,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,1687,0.006520000000000001,0.00268,0.010360000000000001,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_2_July_Age_70-79,210818_Alberta_AlbertaPrecisionLaboratories_2_July,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-07-06,2020-07-10,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,2157,0.0027800000000000004,0.0005600000000000001,0.005,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_2_July_Geography_Edmonton,210818_Alberta_AlbertaPrecisionLaboratories_2_July,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Edmonton,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-07-06,2020-07-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Edmonton,2768,0.0028899999999999998,0.00089,0.00489,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_2_July_Age_20-29,210818_Alberta_AlbertaPrecisionLaboratories_2_July,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-07-06,2020-07-10,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29,976,0.01127,0.0046500000000000005,0.01789,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_2_July_Age_50-59,210818_Alberta_AlbertaPrecisionLaboratories_2_July,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-07-06,2020-07-10,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,2140,0.00607,0.0027800000000000004,0.009370000000000002,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_2_July_Age_10-19,210818_Alberta_AlbertaPrecisionLaboratories_2_July,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-07-06,2020-07-10,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,449,0.0089,0.0002,0.0176,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_2_July_Geography_Lethbridge,210818_Alberta_AlbertaPrecisionLaboratories_2_July,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Lethbridge,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-07-06,2020-07-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Lethbridge,601,0.0,0.0,0.0,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_2_July_Age_0-9,210818_Alberta_AlbertaPrecisionLaboratories_2_July,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-07-06,2020-07-10,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,0-9,139,0.015500000000000002,0.0,0.03682,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_2_July_Geography_Calgary,210818_Alberta_AlbertaPrecisionLaboratories_2_July,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Calgary,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-07-06,2020-07-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Calgary,3795,0.0058,0.00338,0.00821,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_2_July_Overall_UnAdj,210818_Alberta_AlbertaPrecisionLaboratories_2_July,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-07-06,2020-07-10,Residual sera,All,Multiple groups,0.0,,Analysis,UnAdj,13175,0.0051600000000000005,0.00394,0.00639,,,,,True,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_2_July_Geography_Brooks,210818_Alberta_AlbertaPrecisionLaboratories_2_July,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Brooks,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-07-06,2020-07-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Brooks,179,0.13970000000000002,0.08888,0.1905,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_3_August_Overall_PopAdj,210818_Alberta_AlbertaPrecisionLaboratories_3_August,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-08-04,2020-08-11,Residual sera,All,Multiple groups,0.0,,Primary Estimate,PopAdj,12284,0.012350000000000002,0.01225,0.01246,True,,True,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_3_August_Geography_Other,210818_Alberta_AlbertaPrecisionLaboratories_3_August,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Other,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-08-04,2020-08-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Other,2305,0.00217,0.00027,0.00407,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_3_August_Age_50-59,210818_Alberta_AlbertaPrecisionLaboratories_3_August,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-08-04,2020-08-11,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,1959,0.011200000000000002,0.006600000000000001,0.0159,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_3_August_Geography_MedicineHat,210818_Alberta_AlbertaPrecisionLaboratories_3_August,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Medicine Hat,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-08-04,2020-08-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Medicine Hat,521,0.0057599999999999995,0.0,0.01226,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_3_August_Age_30-39,210818_Alberta_AlbertaPrecisionLaboratories_3_August,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-08-04,2020-08-11,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,1577,0.008199999999999999,0.0038,0.012700000000000001,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_3_August_Age_60-69,210818_Alberta_AlbertaPrecisionLaboratories_3_August,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-08-04,2020-08-11,Residual sera,All,Adults (18-64 years),60.0,69.0,Age,60-69,2523,0.00396,0.0015,0.0064,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_3_August_Geography_RedDeer,210818_Alberta_AlbertaPrecisionLaboratories_3_August,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Red Deer,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-08-04,2020-08-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Red Deer,375,0.0,0.0,0.0,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_3_August_Overall_UnAdj,210818_Alberta_AlbertaPrecisionLaboratories_3_August,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-08-04,2020-08-11,Residual sera,All,Multiple groups,0.0,,Analysis,UnAdj,12284,0.00749,0.00596,0.00901,,,,,True,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_3_August_Age_80+,210818_Alberta_AlbertaPrecisionLaboratories_3_August,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-08-04,2020-08-11,Residual sera,All,Seniors (65+ years),80.0,,Age,80+,1311,0.006860000000000001,0.0024,0.01133,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_3_August_Geography_Edmonton,210818_Alberta_AlbertaPrecisionLaboratories_3_August,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Edmonton,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-08-04,2020-08-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Edmonton,2833,0.00318,0.0011,0.00525,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_3_August_Age_0-9,210818_Alberta_AlbertaPrecisionLaboratories_3_August,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-08-04,2020-08-11,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,0-9,121,0.033100000000000004,0.0012,0.06491,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_3_August_Age_70-79,210818_Alberta_AlbertaPrecisionLaboratories_3_August,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-08-04,2020-08-11,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,1979,0.004,0.0013000000000000002,0.0068000000000000005,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_3_August_Sex_Female,210818_Alberta_AlbertaPrecisionLaboratories_3_August,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-08-04,2020-08-11,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,Female,7070,0.0074,0.0054,0.00935,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_3_August_Geography_Calgary,210818_Alberta_AlbertaPrecisionLaboratories_3_August,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Calgary,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-08-04,2020-08-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Calgary,3362,0.00833,0.00526,0.011399999999999999,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_3_August_Sex_Male,210818_Alberta_AlbertaPrecisionLaboratories_3_August,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-08-04,2020-08-11,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,Male,5214,0.007670000000000001,0.0053,0.01004,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_3_August_Age_10-19,210818_Alberta_AlbertaPrecisionLaboratories_3_August,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-08-04,2020-08-11,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,390,0.00513,0.0,0.01222,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_3_August_Age_40-49,210818_Alberta_AlbertaPrecisionLaboratories_3_August,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-08-04,2020-08-11,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,1478,0.011014999999999999,0.005,0.015300000000000001,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_3_August_Geography_GrandePrairie,210818_Alberta_AlbertaPrecisionLaboratories_3_August,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Grande Prairie,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-08-04,2020-08-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Grande Prairie,318,0.0062900000000000005,0.0,0.01498,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_3_August_Age_20-29,210818_Alberta_AlbertaPrecisionLaboratories_3_August,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-08-04,2020-08-11,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29,946,0.0095,0.0033000000000000004,0.015700000000000002,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_3_August_Geography_Lethbridge,210818_Alberta_AlbertaPrecisionLaboratories_3_August,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Lethbridge,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-08-04,2020-08-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Lethbridge,625,0.0032,0.0,0.0076300000000000005,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_3_August_Geography_Brooks,210818_Alberta_AlbertaPrecisionLaboratories_3_August,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Brooks,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-08-04,2020-08-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Brooks,143,0.1608,0.10060000000000001,0.2211,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_4_September_Overall_PopAdj,210818_Alberta_AlbertaPrecisionLaboratories_4_September,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-09-07,2020-09-11,Residual sera,All,Multiple groups,0.0,,Primary Estimate,PopAdj,12006,0.0102,0.01005,0.01024,True,,True,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_4_September_Age_70-79,210818_Alberta_AlbertaPrecisionLaboratories_4_September,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-09-07,2020-09-11,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,2027,0.0069,0.0033000000000000004,0.0105,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_4_September_Age_60-69,210818_Alberta_AlbertaPrecisionLaboratories_4_September,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-09-07,2020-09-11,Residual sera,All,Adults (18-64 years),60.0,69.0,Age,60-69,2552,0.0102,0.0063,0.0141,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_4_September_Age_40-49,210818_Alberta_AlbertaPrecisionLaboratories_4_September,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-09-07,2020-09-11,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,1472,0.0102,0.0051,0.015300000000000001,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_4_September_Geography_Lethbridge,210818_Alberta_AlbertaPrecisionLaboratories_4_September,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Lethbridge,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-09-07,2020-09-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Lethbridge,632,0.00475,0.0,0.01011,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_4_September_Sex_Female,210818_Alberta_AlbertaPrecisionLaboratories_4_September,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-09-07,2020-09-11,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,Female,6857,0.0095,0.0072,0.0118,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_4_September_Geography_MedicineHat,210818_Alberta_AlbertaPrecisionLaboratories_4_September,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Medicine Hat,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-09-07,2020-09-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Medicine Hat,600,0.00167,0.0,0.00493,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_4_September_Geography_Brooks,210818_Alberta_AlbertaPrecisionLaboratories_4_September,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Brooks,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-09-07,2020-09-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Brooks,162,0.0679,0.02916,0.1066,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_4_September_Age_0-9,210818_Alberta_AlbertaPrecisionLaboratories_4_September,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-09-07,2020-09-11,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,0-9,86,0.0116,0.0,0.034300000000000004,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_4_September_Age_50-59,210818_Alberta_AlbertaPrecisionLaboratories_4_September,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-09-07,2020-09-11,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,1898,0.01,0.0055000000000000005,0.014499999999999999,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_4_September_Age_10-19,210818_Alberta_AlbertaPrecisionLaboratories_4_September,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-09-07,2020-09-11,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,285,0.0105,0.0,0.022400000000000003,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_4_September_Geography_RedDeer,210818_Alberta_AlbertaPrecisionLaboratories_4_September,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Red Deer,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-09-07,2020-09-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Red Deer,244,0.0,0.0,0.0,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_4_September_Age_20-29,210818_Alberta_AlbertaPrecisionLaboratories_4_September,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-09-07,2020-09-11,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29,865,0.012700000000000001,0.0053,0.0202,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_4_September_Geography_Calgary,210818_Alberta_AlbertaPrecisionLaboratories_4_September,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Calgary,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-09-07,2020-09-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Calgary,3626,0.00634,0.00376,0.00893,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_4_September_Geography_Other,210818_Alberta_AlbertaPrecisionLaboratories_4_September,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Other,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-09-07,2020-09-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Other,2113,0.00426,0.00148,0.007039999999999999,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_4_September_Overall_UnAdj,210818_Alberta_AlbertaPrecisionLaboratories_4_September,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-09-07,2020-09-11,Residual sera,All,Multiple groups,0.0,,Analysis,UnAdj,12006,0.00958,0.00784,0.011319999999999998,,,,,True,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_4_September_Geography_GrandePrairie,210818_Alberta_AlbertaPrecisionLaboratories_4_September,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Grande Prairie,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-09-07,2020-09-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Grande Prairie,381,0.00787,0.0,0.01675,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_4_September_Age_30-39,210818_Alberta_AlbertaPrecisionLaboratories_4_September,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-09-07,2020-09-11,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,1482,0.0088,0.004,0.013500000000000002,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_4_September_Sex_Male,210818_Alberta_AlbertaPrecisionLaboratories_4_September,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-09-07,2020-09-11,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,Male,5149,0.0097,0.006999999999999999,0.0124,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_4_September_Age_80+,210818_Alberta_AlbertaPrecisionLaboratories_4_September,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-09-07,2020-09-11,Residual sera,All,Seniors (65+ years),80.0,,Age,80+,1339,0.0097,0.0045000000000000005,0.014960000000000001,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_4_September_Geography_Edmonton,210818_Alberta_AlbertaPrecisionLaboratories_4_September,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Edmonton,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-09-07,2020-09-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Edmonton,2508,0.01077,0.006730000000000001,0.0148,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_5_October_Overall_PopAdj,210818_Alberta_AlbertaPrecisionLaboratories_5_October,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-10-05,2020-10-09,Residual sera,All,Multiple groups,0.0,,Primary Estimate,PopAdj,13490,0.01162,0.011519999999999999,0.01172,True,,True,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_5_October_Geography_Calgary,210818_Alberta_AlbertaPrecisionLaboratories_5_October,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Calgary,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-10-05,2020-10-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Calgary,3603,0.007216208710000001,0.00445,0.009980000000000001,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_5_October_Age_70-79,210818_Alberta_AlbertaPrecisionLaboratories_5_October,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-10-05,2020-10-09,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,2128,0.00376,0.00116,0.00636,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_5_October_Age_40-49,210818_Alberta_AlbertaPrecisionLaboratories_5_October,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-10-05,2020-10-09,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,1769,0.01018,0.0055000000000000005,0.014850000000000002,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_5_October_Age_60-69,210818_Alberta_AlbertaPrecisionLaboratories_5_October,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-10-05,2020-10-09,Residual sera,All,Adults (18-64 years),60.0,69.0,Age,60-69,2839,0.00634,0.0034200000000000003,0.009260000000000001,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_5_October_Age_80+,210818_Alberta_AlbertaPrecisionLaboratories_5_October,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-10-05,2020-10-09,Residual sera,All,Seniors (65+ years),80.0,,Age,80+,1186,0.00506,0.0010199999999999999,0.0091,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_5_October_Age_50-59,210818_Alberta_AlbertaPrecisionLaboratories_5_October,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-10-05,2020-10-09,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,2249,0.01467,0.0097,0.01964,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_5_October_Geography_Brooks,210818_Alberta_AlbertaPrecisionLaboratories_5_October,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Brooks,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-10-05,2020-10-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Brooks,169,0.1065088757,0.06,0.153,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_5_October_Sex_Male,210818_Alberta_AlbertaPrecisionLaboratories_5_October,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-10-05,2020-10-09,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,Male,5860,0.007850000000000001,0.00559,0.01011,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_5_October_Age_30-39,210818_Alberta_AlbertaPrecisionLaboratories_5_October,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-10-05,2020-10-09,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,1784,0.00953,0.00502,0.014039999999999999,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_5_October_Geography_Edmonton,210818_Alberta_AlbertaPrecisionLaboratories_5_October,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Edmonton,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-10-05,2020-10-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Edmonton,3083,0.0064871878000000004,0.00365,0.00932,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_5_October_Age_0-9,210818_Alberta_AlbertaPrecisionLaboratories_5_October,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-10-05,2020-10-09,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,0-9,130,0.02308,0.0,0.04889,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_5_October_Geography_MedicineHat,210818_Alberta_AlbertaPrecisionLaboratories_5_October,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Medicine Hat,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-10-05,2020-10-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Medicine Hat,658,0.0,0.0,0.0,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_5_October_Geography_Lethbridge,210818_Alberta_AlbertaPrecisionLaboratories_5_October,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Lethbridge,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-10-05,2020-10-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Lethbridge,571,0.00350262697,0.0,0.00835,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_5_October_Age_20-29,210818_Alberta_AlbertaPrecisionLaboratories_5_October,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-10-05,2020-10-09,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29,1029,0.01069,0.00441,0.016970000000000002,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_5_October_Sex_Female,210818_Alberta_AlbertaPrecisionLaboratories_5_October,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-10-05,2020-10-09,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,Female,7631,0.00957,0.00738,0.01175,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_5_October_Age_10-19,210818_Alberta_AlbertaPrecisionLaboratories_5_October,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-10-05,2020-10-09,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,377,0.013260000000000001,0.0017100000000000001,0.02481,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_5_October_Geography_GrandePrairie,210818_Alberta_AlbertaPrecisionLaboratories_5_October,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Grande Prairie,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-10-05,2020-10-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Grande Prairie,480,0.00208333333,0.0,0.00616,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_5_October_Geography_Other,210818_Alberta_AlbertaPrecisionLaboratories_5_October,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Other,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-10-05,2020-10-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Other,2571,0.00233372229,0.0005,0.0042,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_5_October_Overall_UnAdj,210818_Alberta_AlbertaPrecisionLaboratories_5_October,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-10-05,2020-10-09,Residual sera,All,Multiple groups,0.0,,Analysis,UnAdj,13490,0.00882,0.00724,0.010400000000000001,,,,,True,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_5_October_Geography_RedDeer,210818_Alberta_AlbertaPrecisionLaboratories_5_October,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Red Deer,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-10-05,2020-10-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Red Deer,286,0.0034965035,0.0,0.01034,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_6_November_Overall_PopAdj,210818_Alberta_AlbertaPrecisionLaboratories_6_November,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-11-09,2020-11-13,Residual sera,All,Multiple groups,0.0,,Primary Estimate,PopAdj,11471,0.01607,0.01595,0.01619,True,,True,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_6_November_Geography_Brooks,210818_Alberta_AlbertaPrecisionLaboratories_6_November,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Brooks,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-11-09,2020-11-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Brooks,134,0.08208955224,0.03561,0.1286,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_6_November_Age_70-79,210818_Alberta_AlbertaPrecisionLaboratories_6_November,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-11-09,2020-11-13,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,1729,0.0069299999999999995,0.003,0.010900000000000002,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_6_November_Age_50-59,210818_Alberta_AlbertaPrecisionLaboratories_6_November,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-11-09,2020-11-13,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,1879,0.01064,0.006,0.01528,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_6_November_Geography_Other,210818_Alberta_AlbertaPrecisionLaboratories_6_November,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Other,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-11-09,2020-11-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Other,2212,0.0054249547899999995,0.00236,0.00849,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_6_November_Sex_Male,210818_Alberta_AlbertaPrecisionLaboratories_6_November,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-11-09,2020-11-13,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,Male,5054,0.01345,0.010280000000000001,0.01663,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_6_November_Age_10-19,210818_Alberta_AlbertaPrecisionLaboratories_6_November,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-11-09,2020-11-13,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,337,0.01484,0.00193,0.02774,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_6_November_Geography_Lethbridge,210818_Alberta_AlbertaPrecisionLaboratories_6_November,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Lethbridge,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-11-09,2020-11-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Lethbridge,576,0.008680555559999999,0.0011,0.01626,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_6_November_Age_80+,210818_Alberta_AlbertaPrecisionLaboratories_6_November,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-11-09,2020-11-13,Residual sera,All,Seniors (65+ years),80.0,,Age,80+,1000,0.01,0.0038,0.01617,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_6_November_Age_40-49,210818_Alberta_AlbertaPrecisionLaboratories_6_November,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-11-09,2020-11-13,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,1574,0.01525,0.00919,0.0213,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_6_November_Geography_GrandePrairie,210818_Alberta_AlbertaPrecisionLaboratories_6_November,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Grande Prairie,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-11-09,2020-11-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Grande Prairie,169,0.00591715976,0.0,0.01748,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_6_November_Age_30-39,210818_Alberta_AlbertaPrecisionLaboratories_6_November,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-11-09,2020-11-13,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,1567,0.01085,0.005719999999999999,0.01598,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_6_November_Geography_RedDeer,210818_Alberta_AlbertaPrecisionLaboratories_6_November,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Red Deer,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-11-09,2020-11-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Red Deer,298,0.0,0.0,0.0,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_6_November_Age_0-9,210818_Alberta_AlbertaPrecisionLaboratories_6_November,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-11-09,2020-11-13,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,0-9,107,0.037380000000000004,0.0014399999999999999,0.07333,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_6_November_Geography_Calgary,210818_Alberta_AlbertaPrecisionLaboratories_6_November,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Calgary,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-11-09,2020-11-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Calgary,3481,0.00459638035,0.00235,0.006840000000000001,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_6_November_Age_20-29,210818_Alberta_AlbertaPrecisionLaboratories_6_November,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-11-09,2020-11-13,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29,895,0.020110000000000003,0.01091,0.029310000000000003,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_6_November_Geography_MedicineHat,210818_Alberta_AlbertaPrecisionLaboratories_6_November,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Medicine Hat,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-11-09,2020-11-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Medicine Hat,426,0.0,0.0,0.0,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_6_November_Overall_UnAdj,210818_Alberta_AlbertaPrecisionLaboratories_6_November,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-11-09,2020-11-13,Residual sera,All,Multiple groups,0.0,,Analysis,UnAdj,11471,0.011510000000000001,0.009559999999999999,0.013460000000000001,,,,,True,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_6_November_Age_60-69,210818_Alberta_AlbertaPrecisionLaboratories_6_November,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-11-09,2020-11-13,Residual sera,All,Adults (18-64 years),60.0,69.0,Age,60-69,2383,0.00923,0.005390000000000001,0.01307,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_6_November_Sex_Female,210818_Alberta_AlbertaPrecisionLaboratories_6_November,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-11-09,2020-11-13,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,Female,6416,0.009980000000000001,0.00754,0.012410000000000001,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_6_November_Geography_Edmonton,210818_Alberta_AlbertaPrecisionLaboratories_6_November,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Edmonton,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-11-09,2020-11-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Edmonton,2737,0.01863354037,0.01357,0.023700000000000002,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_7_December_Overall_PopAdj,210818_Alberta_AlbertaPrecisionLaboratories_7_December,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-12-07,2020-12-10,Residual sera,All,Multiple groups,0.0,,Primary Estimate,PopAdj,12076,0.024700000000000003,0.0246,0.024900000000000002,True,,True,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_7_December_Age_20-29,210818_Alberta_AlbertaPrecisionLaboratories_7_December,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-12-07,2020-12-10,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29,917,0.03380588877,0.022109999999999998,0.0455,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_7_December_Geography_MedicineHat,210818_Alberta_AlbertaPrecisionLaboratories_7_December,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Medicine Hat,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-12-07,2020-12-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Medicine Hat,504,0.00198412698,0.0,0.00587,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_7_December_Age_40-49,210818_Alberta_AlbertaPrecisionLaboratories_7_December,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-12-07,2020-12-10,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,1663,0.021647624770000002,0.014650000000000002,0.02864,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_7_December_Age_80+,210818_Alberta_AlbertaPrecisionLaboratories_7_December,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-12-07,2020-12-10,Residual sera,All,Seniors (65+ years),80.0,,Age,80+,1059,0.007554296510000001,0.00234,0.01277,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_7_December_Sex_Male,210818_Alberta_AlbertaPrecisionLaboratories_7_December,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-12-07,2020-12-10,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,Male,5418,0.0227,0.018740000000000003,0.02667,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_7_December_Age_50-59,210818_Alberta_AlbertaPrecisionLaboratories_7_December,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-12-07,2020-12-10,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,2009,0.02140368342,0.01508,0.02773,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_7_December_Geography_RedDeer,210818_Alberta_AlbertaPrecisionLaboratories_7_December,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Red Deer,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-12-07,2020-12-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Red Deer,279,0.00358422939,0.0,0.0106,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_7_December_Geography_Edmonton,210818_Alberta_AlbertaPrecisionLaboratories_7_December,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Edmonton,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-12-07,2020-12-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Edmonton,2904,0.03305785124,0.02656,0.03956,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_7_December_Age_0-9,210818_Alberta_AlbertaPrecisionLaboratories_7_December,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-12-07,2020-12-10,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,0-9,119,0.025210084030000003,0.0,0.053380000000000004,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_7_December_Geography_Lethbridge,210818_Alberta_AlbertaPrecisionLaboratories_7_December,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Lethbridge,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-12-07,2020-12-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Lethbridge,278,0.01079136691,0.0,0.022940000000000002,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_7_December_Age_30-39,210818_Alberta_AlbertaPrecisionLaboratories_7_December,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-12-07,2020-12-10,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,1655,0.0332326284,0.02459,0.041870000000000004,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_7_December_Overall_UnAdj,210818_Alberta_AlbertaPrecisionLaboratories_7_December,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-12-07,2020-12-10,Residual sera,All,Multiple groups,0.0,,Analysis,UnAdj,12076,0.019960000000000002,0.0176,0.0226,,,,,True,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_7_December_Age_70-79,210818_Alberta_AlbertaPrecisionLaboratories_7_December,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-12-07,2020-12-10,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,1761,0.011925042589999999,0.006860000000000001,0.01699,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_7_December_Geography_Other,210818_Alberta_AlbertaPrecisionLaboratories_7_December,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Other,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-12-07,2020-12-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Other,2474,0.0109135004,0.0068200000000000005,0.015009999999999999,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_7_December_Geography_Brooks,210818_Alberta_AlbertaPrecisionLaboratories_7_December,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Brooks,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-12-07,2020-12-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Brooks,151,0.05298013245,0.01725,0.08871000000000001,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_7_December_Geography_GrandePrairie,210818_Alberta_AlbertaPrecisionLaboratories_7_December,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Grande Prairie,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-12-07,2020-12-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Grande Prairie,277,0.00722021661,0.0,0.01719,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_7_December_Sex_Female,210818_Alberta_AlbertaPrecisionLaboratories_7_December,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-12-07,2020-12-10,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,Female,6657,0.01773,0.01456,0.0209,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_7_December_Age_10-19,210818_Alberta_AlbertaPrecisionLaboratories_7_December,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-12-07,2020-12-10,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,374,0.018716577539999998,0.00498,0.03245,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_7_December_Geography_Calgary,210818_Alberta_AlbertaPrecisionLaboratories_7_December,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Calgary,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-12-07,2020-12-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Calgary,3511,0.01566505269,0.011559999999999999,0.019770000000000003,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_7_December_Age_60-69,210818_Alberta_AlbertaPrecisionLaboratories_7_December,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2020-12-07,2020-12-10,Residual sera,All,Adults (18-64 years),60.0,69.0,Age,60-69,2519,0.0146883684,0.0099,0.01939,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_8_January_Overall_PopAdj,210818_Alberta_AlbertaPrecisionLaboratories_8_January,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2021-01-11,2021-01-14,Residual sera,All,Multiple groups,0.0,,Primary Estimate,PopAdj,11094,0.04622,0.046020000000000005,0.04641,True,,True,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_8_January_Overall_UnAdj,210818_Alberta_AlbertaPrecisionLaboratories_8_January,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2021-01-11,2021-01-14,Residual sera,All,Multiple groups,0.0,,Analysis,UnAdj,11049,0.0362,0.03272,0.039689999999999996,,,,,True,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_8_January_Age_20-29,210818_Alberta_AlbertaPrecisionLaboratories_8_January,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2021-01-11,2021-01-14,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29,909,0.04730473047,0.0335,0.0611,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_8_January_Age_10-19,210818_Alberta_AlbertaPrecisionLaboratories_8_January,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2021-01-11,2021-01-14,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,329,0.04863221884,0.025390000000000003,0.07187,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_8_January_Age_40-49,210818_Alberta_AlbertaPrecisionLaboratories_8_January,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2021-01-11,2021-01-14,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,1559,0.04105195638,0.031200000000000002,0.0509,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_8_January_Age_50-59,210818_Alberta_AlbertaPrecisionLaboratories_8_January,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2021-01-11,2021-01-14,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,1859,0.03765465304,0.028999999999999998,0.046310000000000004,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_8_January_Sex_Male,210818_Alberta_AlbertaPrecisionLaboratories_8_January,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2021-01-11,2021-01-14,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,Male,4984,0.03451043339,0.02944,0.039580000000000004,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_8_January_Age_80+,210818_Alberta_AlbertaPrecisionLaboratories_8_January,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2021-01-11,2021-01-14,Residual sera,All,Seniors (65+ years),80.0,,Age,80+,901,0.0166481687,0.00829,0.02501,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_8_January_Geography_RedDeer,210818_Alberta_AlbertaPrecisionLaboratories_8_January,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Red Deer,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2021-01-11,2021-01-14,Residual sera,All,Multiple groups,0.0,,Geographical area,Red Deer,322,0.03416149068,0.01432,0.054000000000000006,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_8_January_Age_60-69,210818_Alberta_AlbertaPrecisionLaboratories_8_January,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2021-01-11,2021-01-14,Residual sera,All,Adults (18-64 years),60.0,69.0,Age,60-69,2301,0.03172533681,0.02456,0.03889,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_8_January_Geography_Other,210818_Alberta_AlbertaPrecisionLaboratories_8_January,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Other,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2021-01-11,2021-01-14,Residual sera,All,Multiple groups,0.0,,Geographical area,Other,2072,0.02268339768,0.01627,0.029089999999999998,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Unverified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_8_January_Geography_Edmonton,210818_Alberta_AlbertaPrecisionLaboratories_8_January,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Edmonton,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2021-01-11,2021-01-14,Residual sera,All,Multiple groups,0.0,,Geographical area,Edmonton,2439,0.059450594509999996,0.05006,0.06884,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_8_January_Age_70-79,210818_Alberta_AlbertaPrecisionLaboratories_8_January,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2021-01-11,2021-01-14,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,1614,0.022924411400000004,0.01562,0.030230000000000003,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_8_January_Geography_Lethbridge,210818_Alberta_AlbertaPrecisionLaboratories_8_January,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Lethbridge,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2021-01-11,2021-01-14,Residual sera,All,Multiple groups,0.0,,Geographical area,Lethbridge,621,0.008051529790000001,0.0010199999999999999,0.01508,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_8_January_Geography_MedicineHat,210818_Alberta_AlbertaPrecisionLaboratories_8_January,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Medicine Hat,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2021-01-11,2021-01-14,Residual sera,All,Multiple groups,0.0,,Geographical area,Medicine Hat,503,0.0059642147099999996,0.0,0.01269,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_8_January_Geography_Calgary,210818_Alberta_AlbertaPrecisionLaboratories_8_January,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Calgary,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2021-01-11,2021-01-14,Residual sera,All,Multiple groups,0.0,,Geographical area,Calgary,3364,0.0338882283,0.027770000000000003,0.04,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_8_January_Geography_GrandePrairie,210818_Alberta_AlbertaPrecisionLaboratories_8_January,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Grande Prairie,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2021-01-11,2021-01-14,Residual sera,All,Multiple groups,0.0,,Geographical area,Grande Prairie,101,0.0,0.0,0.0,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_8_January_Sex_Female,210818_Alberta_AlbertaPrecisionLaboratories_8_January,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2021-01-11,2021-01-14,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,Female,6066,0.03758654797,0.032799999999999996,0.042370000000000005,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_8_January_Age_30-39,210818_Alberta_AlbertaPrecisionLaboratories_8_January,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2021-01-11,2021-01-14,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,1480,0.050675675680000004,0.0395,0.061849999999999995,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_8_January_Age_0-9,210818_Alberta_AlbertaPrecisionLaboratories_8_January,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2021-01-11,2021-01-14,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,0-9,97,0.07216494845,0.02067,0.12366,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210818_Alberta_AlbertaPrecisionLaboratories_8_January_Geography_Brooks,210818_Alberta_AlbertaPrecisionLaboratories_8_January,"Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.",2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Alberta,Brooks,"Residual blood specimens (serum, plasma, and heparinized plasma) were gathered monthly from clinical testing laboratories across Alberta and sent to the Public Health Laboratory (ProvLab) for SARS-CoV-2 serology testing. These samples were collected by phlebotomy from community patients for test requests unrelated to COVID-19 serology. Geographical areas of laboratories: Calgary, Edmonton, Grande Prairie, Red Deer, Lethbridge, Brooks, and Medicine Hat.",Excluded duplicate specimens from the same survey period. Any patients who had received a vaccine prior to specimen collection were excluded from the analysis.,2021-01-11,2021-01-14,Residual sera,All,Multiple groups,0.0,,Geographical area,Brooks,146,0.07534246575,0.03253,0.1182,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Carmen Charlton,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00291-21,2021-09-03,2024-03-01,Verified,charlton_pre-vaccine_2021,CAN
210830_Canada_CBS_BloodDonors_RocheS_Overall_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,16884,0.9078,0.9032,0.9125,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_Age_60+_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,4478,0.025011165700000004,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,625,0.055700000000000006,0.034300000000000004,0.0771,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,3591,0.8833194096,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,1754,0.09699999999999999,0.0833,0.11080000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,638,0.0015673981200000002,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_Sex_Female_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,7341,0.9174,0.9112,0.9236,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_Overall_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Analysis,,16884,0.8942,0.8895000000000001,0.8987999999999999,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,1339,0.0481,0.0373,0.0589,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,3591,0.08109999999999999,0.07,0.0922,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_Sex_Female_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,7341,0.0358,0.0318,0.039900000000000005,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,178,0.8484999999999999,0.7703,0.9267000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,3591,0.07713728766,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,638,0.0001,0.0,0.0039000000000000003,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_Age_40-59_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,6341,0.8948115439000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,883,0.9147,0.8916,0.9379000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_Age_17-24_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1477,0.8493,0.8333,0.8653000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,1754,0.8916761688,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,178,0.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_Overall_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Test used,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay PopTest Adj,16884,0.0451,0.04190000000000001,0.0483,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_Overall_PopAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Analysis,,16884,0.8974,0.8926999999999999,0.902,,,True,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_Sex_Female_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,7341,0.04195613677,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,6983,0.0446,0.0402,0.049100000000000005,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_Age_60+_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,4478,0.9370254577999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,1339,0.9301,0.9164,0.9438,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_Sex_Male_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,9543,0.054900000000000004,0.0499,0.06,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,625,0.9087999999999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_Age_25-39_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,4588,0.05906713165,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1213,0.9248000000000001,0.9056000000000001,0.9440000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,1268,0.9261,0.9063,0.946,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_Sex_Male_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,9543,0.8926962171,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,12602,0.04054911919,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,690,0.00434782609,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,1754,0.897,0.8822,0.9118,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,12602,0.8945405491,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,625,0.055999999999999994,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_Age_60+_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,4478,0.023,0.018500000000000003,0.027400000000000004,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,625,0.9170999999999999,0.8901000000000001,0.9440999999999999,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1008,0.06646825397,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,211,0.9024,0.8592000000000001,0.9455,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1213,0.056059356969999995,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,178,0.0,0.0,0.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,3591,0.8892,0.8759,0.9024,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,690,0.8941,0.8673000000000001,0.9209999999999999,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_Overall_PopAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Analysis,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay Pop Adj,16884,0.0468,0.0437,0.0501,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_Sex_Female_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,7341,0.8961994279,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,638,0.9090909091,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,2335,0.9359000000000001,0.927,0.9448000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,814,0.05282555283,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_Age_40-59_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,6341,0.0384,0.0334,0.0435,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,814,0.0497,0.0348,0.0646,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,475,0.04,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,6983,0.04654160103,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,883,0.04643261608,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,2670,0.0318,0.0252,0.0383,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,6983,0.8951739940000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1213,0.0555,0.0398,0.0713,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,690,0.884057971,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,2670,0.929,0.9189,0.9392,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,475,0.9170999999999999,0.8911,0.9431999999999999,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_Sex_Male_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,9543,0.8976999999999999,0.8906999999999999,0.9047000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,814,0.9324324324,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,2670,0.03483146067,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,475,0.9010526316,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,2335,0.06509635974,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,178,0.8258426966000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,1268,0.9195583596,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,6983,0.9098999999999999,0.9035,0.9163,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1008,0.8703000000000001,0.8451000000000001,0.8955,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,243,0.00411522634,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,1754,0.09749144812,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_Age_17-24_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1477,0.836831415,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,12602,0.037200000000000004,0.0338,0.0406,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_Age_25-39_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,4588,0.8700959024,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_Sex_Male_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,9543,0.05239442523,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,2670,0.9183520599000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,1339,0.9238237491,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_Age_40-59_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,6341,0.04336855386,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1008,0.0679,0.0496,0.0862,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,1268,0.0722,0.053700000000000005,0.0907,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,211,0.048499999999999995,0.018500000000000003,0.0786,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,211,0.04265402844,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,1268,0.06388012618000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,243,0.9077,0.8737,0.9417,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_Age_60+_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,4478,0.9570000000000001,0.9505,0.9634999999999999,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_Age_25-39_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,4588,0.8809,0.8704999999999999,0.8913,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,12602,0.9081,0.9027,0.9135,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,2335,0.9220556745,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,2335,0.059699999999999996,0.0517,0.0677,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,243,0.0006,0.0,0.0062,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,1339,0.053024645259999996,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,690,0.0027,0.0,0.0084,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_Age_17-24_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1477,0.1015572106,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1213,0.9150865622000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,883,0.0492,0.032100000000000004,0.0663,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_Age_25-39_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,4588,0.055999999999999994,0.0489,0.0632,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_Age_17-24_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1477,0.09300000000000001,0.0804,0.1057,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,211,0.8767772512,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,638,0.9115000000000001,0.8840000000000001,0.9390999999999999,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,243,0.8806584362,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,475,0.0354,0.018600000000000002,0.0521,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,814,0.9517,0.9356,0.9678,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,883,0.906002265,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_Age_40-59_PopTestAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,6341,0.9076000000000001,0.8997,0.9155,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2023-08-15,Verified,canadian_blood_services_covid-19_2021-6,CAN
210830_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_UnAdj,210830_Canada_CBS,"COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking seroprevalence in the vaccine era",2021-08-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,Canadian blood donors that are in good health and do not have risk factors for infections that may be transmitted to blood recipients.,"Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear (3 weeks if hospitalized). Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.",2021-06-14,2021-06-29,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1008,0.8650793650999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services,Unity-Aligned,,2021-09-16,2024-03-01,Verified,canadian_blood_services_covid-19_2021-6,CAN
211012_Ontario_TheHospitalforSickChildren_Primary,211012_Ontario_TheHospitalforSickChildren,SARS-CoV-2 antibodies in Ontario health care workers during and after the first wave of the pandemic: a cohort study.,2021-10-12,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Canada,Ontario,,"Health care workers invited to participate included health care professionals, defined as physicians, nurses and nurse practitioners; allied health workers, defined as phlebotomists, respiratory therapists, social workers, dieticians, diagnostic imaging staff, physiotherapists, occupational therapists and
dentistry staff; and auxiliary health care workers (as defined by the World Health Organization as workers who may have had contact with patients, their body fluids or their environments), including environmental services, patient transport and laboratory personnel, and ward clerical workers. In addition, we specifically recruited health care workers who worked in emergency departments, COVID-19 wards or units and intensive care units, and those involved with aerosol-generating medical procedures (e.g., anesthesia and respiratory therapy).",Excluded (lack of completion of demographic or clinical information),2020-04-01,2020-11-13,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1062,0.053700000000000005,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9,0.98,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Michelle Science,The Hospital for Sick Children ,Not Unity-Aligned,https://dx.doi.org/10.9778/cmajo.20210044,2021-10-19,2024-03-01,Unverified,science_sars-cov-2_2021,CAN
211013_Canada_CBS_BloodDonors_RocheS_Overall_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,8457,0.9469,0.9416,0.9522,True,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-10-20,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,602,0.9352,0.9095000000000001,0.9609000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,579,0.00690846287,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,453,0.9580573951,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_Age_25-39_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,2384,0.9216,0.9091,0.9340999999999999,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_Age_60+_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,2476,0.0182,0.0125,0.023799999999999998,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_Age_25-39_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,2384,0.056627516780000005,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,176,0.00568181818,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,639,0.043818466349999995,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,876,0.9440639269000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,426,0.056338028170000005,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,579,0.0034999999999999996,0.0,0.0118,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,602,0.9285714286,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_Overall_PopAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Analysis,,8457,0.9359000000000001,0.9305,0.941,,,True,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-10-20,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,701,0.9492,0.9246,0.9737000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,88,0.9772727273,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,1746,0.9089,0.8919,0.9259000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_Age_17-24_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1092,0.9496,0.9348000000000001,0.9644,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,1746,0.8997709049,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-10-26,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,6328,0.03824273072,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,453,0.9686,0.943,0.9941,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_Age_40-59_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,2505,0.0379241517,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_Age_25-39_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,2384,0.9089765101,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-10-26,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,6328,0.9325221239,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-10-26,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,88,0.0,0.0,0.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,836,0.06459330144,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_Age_60+_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,2476,0.9604200323000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-10-26,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,591,0.0761,0.0509,0.10130000000000002,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,6328,0.0333,0.028700000000000003,0.0378,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,639,0.0388,0.0175,0.06,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,701,0.940085592,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-10-26,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,1601,0.9477,0.9352,0.9601000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,836,0.9568000000000001,0.9406,0.973,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_Overall_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Test used,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay PopTest Adj,8457,0.0408,0.0365,0.0451,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_Sex_Female_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,3722,0.9509000000000001,0.9437000000000001,0.9581000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,639,0.9311424100000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-10-26,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_Sex_Male_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,4735,0.044139387540000005,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,639,0.9440999999999999,0.9169,0.9712000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,2500,0.041600000000000005,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,176,0.9820000000000001,0.9558,1.0082,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,701,0.0286,0.0113,0.045899999999999996,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_Overall_PopAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Analysis,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay Pop Adj,8457,0.0425,0.0383,0.047,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,427,0.006,0.0,0.0173,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_Age_40-59_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,2505,0.9396,0.9302,0.9490000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,883,0.9176000000000001,0.8987,0.9364,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,591,0.9508,0.9281,0.9734,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,124,0.040322580649999995,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,579,0.9274611399,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,426,0.9671361502000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-10-26,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,6328,0.9504000000000001,0.9444,0.9564,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_Age_60+_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,2476,0.023828756059999998,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,883,0.0906002265,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_Sex_Female_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,3722,0.9344438474000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-10-26,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_Sex_Male_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,4735,0.9290390707,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-10-26,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,209,0.02392344498,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,1601,0.9369144285000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-10-26,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,1601,0.04497189257,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,427,0.9344262295,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,579,0.9425,0.9134000000000001,0.9715,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,836,0.9461722488,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,883,0.9161947905,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-10-26,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,209,0.9718000000000001,0.9527,0.991,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,591,0.9373942470000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,426,0.9851000000000001,0.97,1.0003,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_Age_17-24_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1092,0.07875457875000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,2500,0.9564,0.9494,0.9634,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,836,0.0589,0.042,0.0758,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_Age_25-39_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,2384,0.0571,0.046900000000000004,0.06730000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,2500,0.0376,0.0317,0.04360000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,1746,0.08018327606,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,427,0.948,0.917,0.9791,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_Sex_Male_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,4735,0.04360000000000001,0.037200000000000004,0.0501,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_Age_60+_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,2476,0.9767,0.9692000000000001,0.9842000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,602,0.05481727575,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_Age_17-24_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1092,0.0671,0.0517,0.0825,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,1746,0.0781,0.063,0.0932,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,124,0.9032258065000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-10-26,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,602,0.0525,0.030699999999999998,0.0743,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_Sex_Female_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,3722,0.0381,0.0322,0.043899999999999995,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,88,0.0,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,209,0.016,0.0031,0.028900000000000002,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,176,0.9659090909,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_Sex_Female_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,3722,0.044599677590000004,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_Age_40-59_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,2505,0.0383,0.031200000000000002,0.0454,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,876,0.06050228311,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,176,0.0154,0.0,0.0354,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,209,0.961722488,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,1601,0.0393,0.0292,0.0493,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,124,0.0647,0.018500000000000003,0.1109,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,701,0.03281027104,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,453,0.0197,0.0016,0.0379,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,427,0.0070257611200000005,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,591,0.07783417936,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,426,0.0504,0.029700000000000004,0.07110000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,883,0.08460000000000001,0.0666,0.1027,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,2500,0.9440000000000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-10-26,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,453,0.024282560709999998,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,876,0.9539,0.9422,0.9656,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,876,0.0546,0.0432,0.0661,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_Sex_Male_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,4735,0.9427,0.9348000000000001,0.9505,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_Age_17-24_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1092,0.9267399267,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-10-26,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,88,0.9873999999999999,0.9420999999999999,1.0327,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_PopTestAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,124,0.9235,0.8706,0.9764,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-11-12,2023-08-15,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_Overall_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Multiple groups,17.0,,Analysis,,8457,0.9314,0.9258,0.9367000000000001,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-10-26,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211013_Canada_CBS_BloodDonors_RocheS_Age_40-59_UnAdj,211013_Canada_CBS,"COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era",2021-10-13,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-07-14,2021-07-23,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,2505,0.9261477046000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-10-26,2024-03-01,Verified,canadian_blood_services_covid-19_2021-7,CAN
211022_Canada_UniversityofAlberta,211022_Canada_UniversityofAlberta,COVID-19 infection and mental wellness in a Canadian cohort study of healthcare workers,2021-10-22,Presentation or Conference,National,Prospective cohort,Canada,"British Columbia, Alberta, Ontario, Québec",,"HCWs from British Columbia, Alberta, Ontario, and Quebec",,2020-03-19,2020-09-22,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,5135,0.0019,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],,Unclear,Yes,No,,Unclear,Yes,No,,Nicola Cherry,University of Alberta,Not Unity-Aligned,http://dx.doi.org/10.1136/OEM-2021-EPI.34,2021-12-14,2022-07-16,Unverified,cherry_o-168_2021,CAN
211027_Canada_CBS_BloodDonors_RocheS_Overall_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,9109,0.9609000000000001,0.9562999999999999,0.9654,True,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,121,0.9749,0.9216,1.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_Sex_Female_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,3515,0.9450924609000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,121,0.9583,0.9179,0.9987,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,2049,0.9338,0.9194,0.9481,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_Age_17-24_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1070,0.0844,0.068,0.1009,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,755,0.04900662252,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,3155,0.9648000000000001,0.9586,0.971,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,135,0.0,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_Age_25-39_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,2310,0.938961039,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,1515,0.048844884490000004,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,121,0.958677686,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_Age_60+_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,2719,0.0161,0.010900000000000002,0.0212,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_Overall_PopAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Analysis,,9109,0.9496,0.9449,0.9540000000000001,,,True,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,755,0.9541,0.9335,0.9747,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,408,1.0,0.9909,1.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,121,0.0043,0.0,0.026400000000000003,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,874,0.06407322654,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_Sex_Male_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,5594,0.9578,0.951,0.9645,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,670,0.9358208955,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,302,1.0,0.9906,1.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,455,0.0021978022,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,302,0.027000000000000003,0.0103,0.0437,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,408,0.0536,0.0322,0.075,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,444,0.9853000000000001,0.9662999999999999,1.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,6898,0.9460713250000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_Sex_Male_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,5594,0.0512,0.044500000000000005,0.057800000000000004,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,455,0.9828,0.9619,1.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_Age_40-59_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,3010,0.044518272430000005,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,611,0.0279,0.0103,0.045599999999999995,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,302,0.9867549669000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,755,0.9456953642000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,1515,0.9584158415999999,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,2049,0.9258174719000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,121,0.9256198347,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,670,0.9511000000000001,0.9278000000000001,0.9744,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,121,0.00826446281,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,6898,0.033,0.0286,0.0374,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,3155,0.9492868463,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_Sex_Female_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,3515,0.0378,0.032100000000000004,0.0434,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,135,0.0,0.0,0.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_Sex_Female_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,3515,0.04068278805,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_Overall_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Analysis,,9109,0.9453,0.9405,0.9499,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,121,0.03305785124,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,3155,0.04360000000000001,0.0375,0.0497,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,755,0.0504,0.0308,0.0699,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_Age_40-59_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,3010,0.9571,0.9492,0.9651000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,408,0.9901960784000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_Overall_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Analysis,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay UnAdj,9109,0.045599999999999995,0.0414,0.05,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-01-25,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_Sex_Female_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,3515,0.9638,0.9576000000000001,0.97,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,962,0.06964656965,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,858,0.11140000000000001,0.09140000000000001,0.1315,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,1515,0.0441,0.0339,0.0543,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,858,0.9393939394,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,962,0.0689,0.056900000000000006,0.0809,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,962,0.9688149688000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,693,0.9509379509,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,455,0.9714285714,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_Age_60+_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,2719,0.020963589549999998,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_Sex_Male_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,5594,0.048623525210000004,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_Age_17-24_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1070,0.9345794393,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,611,0.9132569558,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,962,0.9804,0.9721,0.9886,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,444,0.0458,0.020800000000000003,0.0709,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,398,0.9824120603000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,2049,0.0669,0.0534,0.0804,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,874,0.9576659039000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_Age_40-59_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,3010,0.041100000000000005,0.034100000000000005,0.04820000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,874,0.9695999999999999,0.9565000000000001,0.9827,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,858,0.09790209790000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,444,0.04954954955,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,3155,0.04278922345,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_Age_40-59_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,3010,0.942192691,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_Age_25-39_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,2310,0.05627705628,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_Age_60+_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,2719,0.9769,0.9697,0.9841,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,408,0.0612745098,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_Overall_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Test used,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay PopTest Adj,9109,0.0443,0.039900000000000005,0.048600000000000004,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,2049,0.06393362616,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,693,0.0637,0.0409,0.08650000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,858,0.9531999999999999,0.9381999999999999,0.9682,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_Age_25-39_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,2310,0.0608,0.0507,0.0709,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,1515,0.9699,0.9601000000000001,0.9798000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_Age_17-24_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1070,0.9537000000000001,0.9399,0.9675,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,121,0.0446,0.006999999999999999,0.0821,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,6898,0.036967236880000004,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_Sex_Male_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,5594,0.9454772971000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,693,0.062049062050000006,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,670,0.08059701493,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_Age_25-39_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,2310,0.9512999999999999,0.9413,0.9612999999999999,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,670,0.07540000000000001,0.0496,0.10130000000000002,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,398,0.0025,0.0,0.01,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,611,0.9186,0.8884000000000001,0.9489000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,455,0.0009,0.0,0.0075,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,135,1.0011,0.9856999999999999,1.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,693,0.9614,0.9411,0.9816,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,874,0.059500000000000004,0.044000000000000004,0.075,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,302,0.02649006623,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,135,0.9851851852,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_Age_60+_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,2719,0.9584406032,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,6898,0.9612999999999999,0.9561000000000001,0.9666,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,398,0.00502512563,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_Age_17-24_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1070,0.08785046729,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_Overall_PopAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Analysis,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay Pop Adj,9109,0.046,0.0418,0.050499999999999996,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_PopTestAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,398,0.9924,0.9771,1.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,444,0.9752252252,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211027_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_UnAdj,211027_Canada_CBS,"COVID-19 Seroprevalence Report October 27, 2021 Report #13: August 2021 Survey Tracking seroprevalence in the vaccine era",2021-10-27,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-08-15,2021-08-26,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,611,0.02782324059,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-8,CAN
211106_Calgary_UniversityofCalgary_Ambulatory_Overall,211106_Calgary_UniversityofCalgary_Ambulatory,SARS-CoV-2 seroprevalence and seroconversion in a systemic lupus erythematosus cohort and comparison to general population controls,2021-11-06,Presentation or Conference,Local,Cross-sectional survey ,Canada,Alberta,,"ambulatory patients in Calgary, Alberta",,2020-03-15,2021-01-31,Residual sera,All,Multiple groups,,,Primary Estimate,,148,0.0338,,,True,,,,True,Sequential,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay","EUROIMMUN,Luminex Corporation",ELISA,Serum,"['IgA', 'IgG']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Unclear,Yes,No,,Hannah Mathew,University of Calgary,Not Unity-Aligned,https://acrabstracts.org/abstract/sars-cov-2-seroprevalence-and-seroconversion-in-a-systemic-lupus-erythematosus-cohort-and-comparison-to-general-population-controls/,2022-03-09,2024-03-01,Unverified,hannah_matthew_sars-cov-2_2021,CAN
211106_Calgary_UniversityofCalgary_Ambulatory_EuroimmunIgG,211106_Calgary_UniversityofCalgary_Ambulatory,SARS-CoV-2 seroprevalence and seroconversion in a systemic lupus erythematosus cohort and comparison to general population controls,2021-11-06,Presentation or Conference,Local,Cross-sectional survey ,Canada,Alberta,,"ambulatory patients in Calgary, Alberta",,2020-03-15,2021-01-31,Residual sera,All,Multiple groups,,,Test used,Euroimmun IgG,148,0.0338,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],,No,No,No,,Unclear,Yes,No,,Hannah Mathew,University of Calgary,Not Unity-Aligned,https://acrabstracts.org/abstract/sars-cov-2-seroprevalence-and-seroconversion-in-a-systemic-lupus-erythematosus-cohort-and-comparison-to-general-population-controls/,2022-03-09,2024-03-01,Unverified,hannah_matthew_sars-cov-2_2021,CAN
211106_Calgary_UniversityofCalgary_Ambulatory_Xmap,211106_Calgary_UniversityofCalgary_Ambulatory,SARS-CoV-2 seroprevalence and seroconversion in a systemic lupus erythematosus cohort and comparison to general population controls,2021-11-06,Presentation or Conference,Local,Cross-sectional survey ,Canada,Alberta,,"ambulatory patients in Calgary, Alberta",,2020-03-15,2021-01-31,Residual sera,All,Multiple groups,,,Test used,Xmap,148,0.0203,,,,,,,,Sequential,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Unclear,Yes,No,,Hannah Mathew,University of Calgary,Not Unity-Aligned,https://acrabstracts.org/abstract/sars-cov-2-seroprevalence-and-seroconversion-in-a-systemic-lupus-erythematosus-cohort-and-comparison-to-general-population-controls/,2022-03-09,2024-03-01,Unverified,hannah_matthew_sars-cov-2_2021,CAN
211106_Calgary_UniversityofCalgary_Ambulatory_EuroimmunIgA,211106_Calgary_UniversityofCalgary_Ambulatory,SARS-CoV-2 seroprevalence and seroconversion in a systemic lupus erythematosus cohort and comparison to general population controls,2021-11-06,Presentation or Conference,Local,Cross-sectional survey ,Canada,Alberta,,"ambulatory patients in Calgary, Alberta",,2020-03-15,2021-01-31,Residual sera,All,Multiple groups,,,Test used,Euroimmun IgA,148,0.0203,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgA,EUROIMMUN,ELISA,Serum,IgA,Spike,,,,['High'],,No,No,No,,Unclear,Yes,No,,Hannah Mathew,University of Calgary,Not Unity-Aligned,https://acrabstracts.org/abstract/sars-cov-2-seroprevalence-and-seroconversion-in-a-systemic-lupus-erythematosus-cohort-and-comparison-to-general-population-controls/,2022-03-09,2024-03-01,Unverified,hannah_matthew_sars-cov-2_2021,CAN
211106_Calgary_UniversityofCalgary_SLE_Overall,211106_Calgary_UniversityofCalgary_SLE,SARS-CoV-2 seroprevalence and seroconversion in a systemic lupus erythematosus cohort and comparison to general population controls,2021-11-06,Presentation or Conference,Local,Cross-sectional survey ,Canada,Alberta,,"Systemic Lupus Erythematosus patients in Calgary, Alberta",,2020-03-15,2021-01-31,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,173,0.0347,,,True,,,,True,Sequential,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay","EUROIMMUN,Luminex Corporation",ELISA,Serum,"['IgA', 'IgG']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Hannah Mathew,University of Calgary,Not Unity-Aligned,https://acrabstracts.org/abstract/sars-cov-2-seroprevalence-and-seroconversion-in-a-systemic-lupus-erythematosus-cohort-and-comparison-to-general-population-controls/,2022-03-09,2024-03-01,Unverified,hannah_matthew_sars-cov-2_2021,CAN
211122_Montreal_UniversityOfMontreal_10-14,211122_Montreal_UniversityOfMontreal,"Seroprevalence of SARS-CoV-2 Antibodies Among Children in School and Day Care in Montreal, Canada.",2021-11-23,Journal Article (Peer-Reviewed),Local,Prospective cohort,Canada,Québec,Montreal,"Participants were eligible for enrollment if they attended 1 of the participating schools or day cares, if they were between the ages of 2 and 17 years, and if their parent or legal guardian gave informed
consent to participate and the child gave their assent. Multiple children per household were eligible, as long as they all attended a participating school or day care. Parental consent and their child’s assent were provided online, which was followed by an online questionnaire. ",,2020-10-22,2021-03-22,Students and Daycares,All,Children and Youth (0-17 years),10.0,14.0,Age,10-14,529,0.068,0.042,0.094,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,,IgG,Spike,Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Kate Zinszer,University of Montreal,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.35975,2022-02-06,2022-07-16,Unverified,zinszerSeroprevalenceSARSCoV2Antibodies2021,CAN
211122_Montreal_UniversityOfMontreal_2-4,211122_Montreal_UniversityOfMontreal,"Seroprevalence of SARS-CoV-2 Antibodies Among Children in School and Day Care in Montreal, Canada.",2021-11-23,Journal Article (Peer-Reviewed),Local,Prospective cohort,Canada,Québec,Montreal,"Participants were eligible for enrollment if they attended 1 of the participating schools or day cares, if they were between the ages of 2 and 17 years, and if their parent or legal guardian gave informed
consent to participate and the child gave their assent. Multiple children per household were eligible, as long as they all attended a participating school or day care. Parental consent and their child’s assent were provided online, which was followed by an online questionnaire. ",,2020-10-22,2021-03-22,Students and Daycares,All,Children and Youth (0-17 years),2.0,4.0,Age,2-4,332,0.048,0.028999999999999998,0.067,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,,IgG,Spike,Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Kate Zinszer,University of Montreal,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.35975,2022-02-06,2022-07-16,Unverified,zinszerSeroprevalenceSARSCoV2Antibodies2021,CAN
211122_Montreal_UniversityOfMontreal_5-9,211122_Montreal_UniversityOfMontreal,"Seroprevalence of SARS-CoV-2 Antibodies Among Children in School and Day Care in Montreal, Canada.",2021-11-23,Journal Article (Peer-Reviewed),Local,Prospective cohort,Canada,Québec,Montreal,"Participants were eligible for enrollment if they attended 1 of the participating schools or day cares, if they were between the ages of 2 and 17 years, and if their parent or legal guardian gave informed
consent to participate and the child gave their assent. Multiple children per household were eligible, as long as they all attended a participating school or day care. Parental consent and their child’s assent were provided online, which was followed by an online questionnaire. ",,2020-10-22,2021-03-22,Students and Daycares,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,542,0.05,0.034,0.066,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,,IgG,Spike,Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Kate Zinszer,University of Montreal,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.35975,2022-02-06,2022-07-16,Unverified,zinszerSeroprevalenceSARSCoV2Antibodies2021,CAN
211122_Montreal_UniversityOfMontreal,211122_Montreal_UniversityOfMontreal,"Seroprevalence of SARS-CoV-2 Antibodies Among Children in School and Day Care in Montreal, Canada.",2021-11-23,Journal Article (Peer-Reviewed),Local,Prospective cohort,Canada,Québec,Montreal,"Participants were eligible for enrollment if they attended 1 of the participating schools or day cares, if they were between the ages of 2 and 17 years, and if their parent or legal guardian gave informed
consent to participate and the child gave their assent. Multiple children per household were eligible, as long as they all attended a participating school or day care. Parental consent and their child’s assent were provided online, which was followed by an online questionnaire. ",,2020-10-22,2021-03-22,Students and Daycares,All,Children and Youth (0-17 years),2.0,17.0,Primary Estimate,,1632,0.057999999999999996,0.049,0.07,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,,IgG,Spike,Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Kate Zinszer,University of Montreal,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.35975,2021-12-01,2022-07-16,Unverified,zinszerSeroprevalenceSARSCoV2Antibodies2021,CAN
211122_Montreal_UniversityOfMontreal_15-17,211122_Montreal_UniversityOfMontreal,"Seroprevalence of SARS-CoV-2 Antibodies Among Children in School and Day Care in Montreal, Canada.",2021-11-23,Journal Article (Peer-Reviewed),Local,Prospective cohort,Canada,Québec,Montreal,"Participants were eligible for enrollment if they attended 1 of the participating schools or day cares, if they were between the ages of 2 and 17 years, and if their parent or legal guardian gave informed
consent to participate and the child gave their assent. Multiple children per household were eligible, as long as they all attended a participating school or day care. Parental consent and their child’s assent were provided online, which was followed by an online questionnaire. ",,2020-10-22,2021-03-22,Students and Daycares,All,Children and Youth (0-17 years),15.0,17.0,Age,15-17,221,0.07200000000000001,0.034,0.11,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,,IgG,Spike,Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['Moderate'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Kate Zinszer,University of Montreal,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.35975,2022-02-06,2022-07-16,Unverified,zinszerSeroprevalenceSARSCoV2Antibodies2021,CAN
211130_Calgary_UniversityofCalgary_Visit1_Spike,211130_Calgary_UniversityofCalgary_Visit1,"Alberta Childhood COVID-19 Cohort (AB3C) Aim 3: Longitudinal Sero-Epidemiology Study Interim Report November 30, 2021",2021-11-30,Institutional Report,Local,Prospective cohort,Canada,Alberta,Calgary,"All study participants were children under the age of 18 years, residing primarily in the Calgary Zone served by Alberta Health Services. Children in this group may have had a negative PCR test for COVID-19, or may have never been tested during 2020.",,2020-07-30,2020-11-18,Household and community samples,All,Children and Youth (0-17 years),,17.0,Primary Estimate,Abbott test - spike,902,0.0067,,,True,,,,True,Self-referral,Not reported/ Unable to specify,,,Serum,,Spike,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,James Kellner,University of Calgary,Not Unity-Aligned,,2022-02-16,2023-01-03,Unverified,kellner_alberta_2021-1,CAN
211130_Calgary_UniversityofCalgary_Visit1_NCP,211130_Calgary_UniversityofCalgary_Visit1,"Alberta Childhood COVID-19 Cohort (AB3C) Aim 3: Longitudinal Sero-Epidemiology Study Interim Report November 30, 2021",2021-11-30,Institutional Report,Local,Prospective cohort,Canada,Alberta,Calgary,"All study participants were children under the age of 18 years, residing primarily in the Calgary Zone served by Alberta Health Services. Children in this group may have had a negative PCR test for COVID-19, or may have never been tested during 2020.",,2020-07-30,2020-11-18,Household and community samples,All,Children and Youth (0-17 years),,17.0,Test used,Abbott test - nucleocapsid,909,0.0011,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,Unclear,Yes,No,,James Kellner,University of Calgary,Not Unity-Aligned,,2022-02-17,2024-03-01,Unverified,kellner_alberta_2021-1,CAN
211130_Calgary_UniversityofCalgary_Visit2_Spike,211130_Calgary_UniversityofCalgary_Visit2,"Alberta Childhood COVID-19 Cohort (AB3C) Aim 3: Longitudinal Sero-Epidemiology Study Interim Report November 30, 2021",2021-11-30,Institutional Report,Local,Prospective cohort,Canada,Alberta,Calgary,"All study participants were children under the age of 18 years, residing primarily in the Calgary Zone served by Alberta Health Services. Children in this group may have had a negative PCR test for COVID-19, or may have never been tested during 2020.",,2021-02-10,2021-04-15,Household and community samples,All,Children and Youth (0-17 years),,17.0,Primary Estimate,Abbott test - spike,840,0.032100000000000004,,,True,,,,True,Self-referral,Not reported/ Unable to specify,,,Serum,,Spike,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,James Kellner,University of Calgary,Not Unity-Aligned,,2022-02-16,2023-01-03,Unverified,kellner_alberta_2021-1,CAN
211130_Calgary_UniversityofCalgary_Visit2_NCP,211130_Calgary_UniversityofCalgary_Visit2,"Alberta Childhood COVID-19 Cohort (AB3C) Aim 3: Longitudinal Sero-Epidemiology Study Interim Report November 30, 2021",2021-11-30,Institutional Report,Local,Prospective cohort,Canada,Alberta,Calgary,"All study participants were children under the age of 18 years, residing primarily in the Calgary Zone served by Alberta Health Services. Children in this group may have had a negative PCR test for COVID-19, or may have never been tested during 2020.",,2021-02-10,2021-04-15,Household and community samples,All,Children and Youth (0-17 years),,17.0,Test used,Abbott test - nucleocapsid,842,0.0202,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,Unclear,Yes,No,,James Kellner,University of Calgary,Not Unity-Aligned,,2022-02-17,2024-03-01,Unverified,kellner_alberta_2021-1,CAN
211130_Calgary_UniversityofCalgary_Visit3_Spike,211130_Calgary_UniversityofCalgary_Visit3,"Alberta Childhood COVID-19 Cohort (AB3C) Aim 3: Longitudinal Sero-Epidemiology Study Interim Report November 30, 2021",2021-11-30,Institutional Report,Local,Prospective cohort,Canada,Alberta,Calgary,"All study participants were children under the age of 18 years, residing primarily in the Calgary Zone served by Alberta Health Services. Children in this group may have had a negative PCR test for COVID-19, or may have never been tested during 2020.",,2021-08-11,2021-10-22,Household and community samples,All,Children and Youth (0-17 years),,17.0,Primary Estimate,Abbott test - spike,783,0.4828,,,True,,,,True,Self-referral,Not reported/ Unable to specify,,,Serum,,Spike,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,James Kellner,University of Calgary,Not Unity-Aligned,,2022-02-16,2023-01-03,Unverified,kellner_alberta_2021-1,CAN
211130_Calgary_UniversityofCalgary_Visit3_NCP,211130_Calgary_UniversityofCalgary_Visit3,"Alberta Childhood COVID-19 Cohort (AB3C) Aim 3: Longitudinal Sero-Epidemiology Study Interim Report November 30, 2021",2021-11-30,Institutional Report,Local,Prospective cohort,Canada,Alberta,Calgary,"All study participants were children under the age of 18 years, residing primarily in the Calgary Zone served by Alberta Health Services. Children in this group may have had a negative PCR test for COVID-19, or may have never been tested during 2020.",,2020-07-30,2020-11-18,Household and community samples,All,Children and Youth (0-17 years),,17.0,Test used,Abbott test - nucleocapsid,784,0.048499999999999995,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,Unclear,Yes,No,,James Kellner,University of Calgary,Not Unity-Aligned,,2022-02-17,2024-03-01,Unverified,kellner_alberta_2021-1,CAN
211130_Canada_CBS_BloodDonors_RocheS_Overall_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,9363,0.9703,0.9662000000000001,0.9744,True,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,2100,0.0828,0.0681,0.0974,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,704,0.9573863636000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_Age_40-59_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,3195,0.0379,0.031200000000000002,0.0447,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,261,0.9808429119000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,309,0.0077,0.0,0.0194,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,1037,0.045323047250000005,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,805,0.9849,0.9736,0.9962000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_Age_25-39_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,2290,0.05283842795,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,1626,0.9661746617,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_Age_25-39_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,2290,0.0489,0.0398,0.0579,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,2100,0.9475,0.9346,0.9605,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,447,0.049400000000000006,0.0239,0.07490000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,320,0.975,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,805,0.9701863354,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,7205,0.9698000000000001,0.9651000000000001,0.9745,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,261,0.9945,0.9804,1.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_Age_60+_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,2800,0.9854,0.9792000000000001,0.9916,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,711,0.9634999999999999,0.9440999999999999,0.983,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_Age_60+_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,2800,0.028214285710000002,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_Sex_Female_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,3772,0.04904559915,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,309,0.9756999999999999,0.9531000000000001,0.9983,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,625,0.9604,0.9376000000000001,0.9831000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_Age_17-24_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1078,0.9655,0.9531999999999999,0.9777,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_Overall_PopAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Analysis,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay Pop Adj,9363,0.0455,0.0414,0.0499,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,309,0.00970873786,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_Sex_Male_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,5591,0.9520658201000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_Age_25-39_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,2290,0.9484716156999999,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,1626,0.9793000000000001,0.9707,0.9879000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,661,0.9561270802,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,499,0.9715,0.9500000000000001,0.9929000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_Sex_Male_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,5591,0.045599999999999995,0.0394,0.0518,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_Age_60+_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,2800,0.9714285714,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,625,0.062400000000000004,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,805,0.061,0.0442,0.07780000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,116,0.981,0.9327,1.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,2100,0.07904761905,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,704,0.053977272730000005,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_Age_17-24_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1078,0.087,0.0706,0.1034,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,711,0.065,0.0425,0.08750000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,711,0.06047819972,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_Sex_Male_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,5591,0.9639,0.9577,0.9702,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,320,0.9847,0.961,1.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,403,0.057699999999999994,0.0361,0.07940000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_Age_25-39_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,2290,0.9614,0.9523999999999999,0.9705,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,661,0.9701000000000001,0.9509000000000001,0.9893000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,1037,0.0454,0.0359,0.055,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_Age_60+_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,2800,0.0278,0.0213,0.034300000000000004,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,711,0.9535864979,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,109,0.9742000000000001,0.9374,1.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,403,0.9974,0.9864,1.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_Age_40-59_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,3195,0.966,0.9587000000000001,0.9732,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,261,0.0178,0.0029,0.0327,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,704,0.0558,0.0347,0.0768,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_Overall_PopAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Analysis,,9363,0.9589,0.9547,0.9628,,,True,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,116,0.9655172414000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,403,0.04962779156,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,661,0.05446293495,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,1626,0.0455104551,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,499,0.9619238477000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,499,0.00801603206,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,625,0.9488,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,320,0.0,0.0,0.0001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,3107,0.9607338268,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_Sex_Female_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,3772,0.0422,0.0364,0.048,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_Overall_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Analysis,,9363,0.956,0.9516,0.9601000000000001,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,7205,0.040111034,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_Overall_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Analysis,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay Pop Adj,9363,0.0468,0.0426,0.0513,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2022-01-25,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,3107,0.9737000000000001,0.9681000000000001,0.9792000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_Age_40-59_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,3195,0.9499217527,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,2100,0.9376190475999999,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,844,0.9549763033,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,1037,0.9672131147999999,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,309,0.9611650485,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,116,0.0,0.0,0.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,1626,0.042300000000000004,0.032400000000000005,0.052300000000000006,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,805,0.06335403727,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_Age_17-24_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1078,0.09276437848,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,447,0.04921700224,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_Age_40-59_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,3195,0.04319248826,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,3107,0.0376,0.0319,0.0432,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,844,0.0919,0.073,0.11080000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,116,0.0,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,3107,0.03733504989,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,261,0.0153256705,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,499,0.0043,0.0,0.0129,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,447,0.9843400447,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,844,0.9708,0.9578,0.9837,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,447,0.9994,0.9864,1.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,109,0.027522935780000004,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,109,0.0182,0.0,0.0451,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_Sex_Female_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,3772,0.9763,0.971,0.9816,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,625,0.05940000000000001,0.0349,0.084,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_Overall_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Test used,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay PopTest Adj,9363,0.0438,0.0396,0.0481,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,109,0.9724770642,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_Sex_Female_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,3772,0.9618239661,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_Sex_Male_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,5591,0.04525129673,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,661,0.055400000000000005,0.0332,0.0776,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,7205,0.0365,0.032,0.040999999999999995,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,7205,0.9561415684000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,403,0.982630273,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,844,0.10189573460000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,704,0.9703,0.9521,0.9884000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,320,0.0,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_PopTestAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,1037,0.9789,0.9708,0.9870000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2023-08-15,Verified,canadian_blood_services_covid-19_2021-9,CAN
211130_Canada_CBS_BloodDonors_RocheS_Age_17-24_UnAdj,211130_Canada_CBS,"COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking seroprevalence in the vaccine era",2021-11-30,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-09-14,2021-09-24,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1078,0.9499072356000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/antibody-wane-being-observed-yet-breakthrough-infections-rare-latest-canadian-blood-services-report/,2021-12-23,2024-03-01,Verified,canadian_blood_services_covid-19_2021-9,CAN
211207_Calgary_CummingSchoolofMedicine,211207_Calgary_CummingSchoolofMedicine,"SARS-CoV-2 seroprevalence, seroconversion and neutralizing antibodies in a systemic lupus erythematosus cohort and comparison to controls.",2021-12-07,Journal Article (Peer-Reviewed),Local,Prospective cohort,Canada,Alberta,Calgary,Patients diagnosed with systemic lupus erythematosus (SLE) ,,2020-01-01,2021-01-31,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,173,0.035,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay","EUROIMMUN,Luminex Corporation",Multiple Types,Serum,"['IgA', 'IgG']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Hanna Mathew,"Cumming School of Medicine, University of Calgary",Not Unity-Aligned,https://dx.doi.org/10.1177/09612033211063793,2021-12-14,2024-03-01,Unverified,mathew_sars-cov-2_2021,CAN
211216_Ontario_PublicHealthOntario_June_Overall_PopTestAdj,211216_Ontario_PublicHealthOntario_June,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-06-05,2020-06-30,Residual sera,All,Multiple groups,0.0,,Primary Estimate,"Adjusted: population, test",7014,0.011000000000000001,0.008,0.013000000000000001,True,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-05,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_June_Region_Northern_PopTestAdj,211216_Ontario_PublicHealthOntario_June,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Northern Ontario,422,0.003,8.999999999999999e-05,0.019,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_June_Region_Central West_UnAdj,211216_Ontario_PublicHealthOntario_June,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,,1236,0.008,0.003,0.013000000000000001,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_June_Region_South West_UnAdj,211216_Ontario_PublicHealthOntario_June,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,,446,0.004,0.0005,0.016,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_June_Region_Toronto_UnAdj,211216_Ontario_PublicHealthOntario_June,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,,1837,0.013999999999999999,0.009000000000000001,0.02,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_June_Age_0–19_PopTestAdj,211216_Ontario_PublicHealthOntario_June,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Age,,978,0.008,0.003,0.013999999999999999,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_June_Age_0–19_UnAdj,211216_Ontario_PublicHealthOntario_June,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Age,,978,0.009000000000000001,0.003,0.015,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_June_Sex_Female_PopTestAdj,211216_Ontario_PublicHealthOntario_June,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,3591,0.01,0.006999999999999999,0.013000000000000001,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_June_Age_ ≥ 60_PopTestAdj,211216_Ontario_PublicHealthOntario_June,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,60.0,,Age,,2040,0.016,0.011000000000000001,0.021,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_June_Region_Central East_UnAdj,211216_Ontario_PublicHealthOntario_June,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,,2446,0.016,0.011000000000000001,0.02,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_June_Region_South West_PopTestAdj,211216_Ontario_PublicHealthOntario_June,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,South West Ontario,446,0.004,0.0005,0.015,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_June_Region_Eastern_PopTestAdj,211216_Ontario_PublicHealthOntario_June,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Eastern Ontario,627,0.003,0.0004,0.011000000000000001,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_June_Age_20–59_UnAdj,211216_Ontario_PublicHealthOntario_June,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Adults (18-64 years),20.0,59.0,Age,,3996,0.009000000000000001,0.006,0.012,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_June_Sex_Male_PopTestAdj,211216_Ontario_PublicHealthOntario_June,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,3423,0.012,0.009000000000000001,0.016,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_June_Age_20–59_PopTestAdj,211216_Ontario_PublicHealthOntario_June,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Adults (18-64 years),20.0,59.0,Age,,3996,0.01,0.006999999999999999,0.013000000000000001,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_June_Sex_Male_UnAdj,211216_Ontario_PublicHealthOntario_June,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,3423,0.013000000000000001,0.009000000000000001,0.017,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_June_Overall_UnAdj,211216_Ontario_PublicHealthOntario_June,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-06-05,2020-06-30,Residual sera,All,Multiple groups,0.0,,Analysis,,7014,0.011000000000000001,0.009000000000000001,0.013999999999999999,,,,,True,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_June_Sex_Female_UnAdj,211216_Ontario_PublicHealthOntario_June,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,3591,0.009000000000000001,0.006,0.013000000000000001,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_June_Region_Central East_PopTestAdj,211216_Ontario_PublicHealthOntario_June,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Central East Ontario,2446,0.015,0.01,0.02,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_June_Region_Eastern_UnAdj,211216_Ontario_PublicHealthOntario_June,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,,627,0.003,0.0004,0.011000000000000001,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_June_Region_Central West_PopTestAdj,211216_Ontario_PublicHealthOntario_June,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Central West Ontario,1236,0.011000000000000001,0.004,0.017,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_June_Region_Northern_UnAdj,211216_Ontario_PublicHealthOntario_June,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,,422,0.002,6e-05,0.013000000000000001,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_June_Region_Toronto_PopTestAdj,211216_Ontario_PublicHealthOntario_June,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Toronto,1837,0.015,0.009000000000000001,0.021,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_June_Age_ ≥ 60_UnAdj,211216_Ontario_PublicHealthOntario_June,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,60.0,,Age,,2040,0.017,0.011000000000000001,0.022000000000000002,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_March_Overall_PopTestAdj,211216_Ontario_PublicHealthOntario_March,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Primary Estimate,"Adjusted: population, test",827,0.005,0.001,0.015,True,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-05,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_March_Region_CentralEast_UnAdj,211216_Ontario_PublicHealthOntario_March,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,,205,0.005,0.0001,0.027000000000000003,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_March_Age_ ≥ 60_UnAdj,211216_Ontario_PublicHealthOntario_March,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,60.0,,Age,,142,0.013999999999999999,0.002,0.05,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_March_Sex_Male_UnAdj,211216_Ontario_PublicHealthOntario_March,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,337,0.009000000000000001,0.002,0.026000000000000002,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_March_Region_CentralEast_PopTestAdj,211216_Ontario_PublicHealthOntario_March,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Central East Ontario,205,0.008,0.0002,0.042,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_March_Sex_Female_UnAdj,211216_Ontario_PublicHealthOntario_March,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,490,0.0,0.0,0.008,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_March_Sex_Female_PopTestAdj,211216_Ontario_PublicHealthOntario_March,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,490,0.0,0.0,0.008,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_March_Overall_UnAdj,211216_Ontario_PublicHealthOntario_March,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Analysis,,827,0.004,0.0007000000000000001,0.011000000000000001,,,,,True,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_March_Region_Northern_UnAdj,211216_Ontario_PublicHealthOntario_March,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,,238,0.0,0.0,0.015,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_March_Region_Eastern_UnAdj,211216_Ontario_PublicHealthOntario_March,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,,47,0.0,0.0,0.075,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_March_Region_SouthWest_UnAdj,211216_Ontario_PublicHealthOntario_March,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,,30,0.0,0.0,0.11599999999999999,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_March_Region_Toronto_UnAdj,211216_Ontario_PublicHealthOntario_March,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,,259,0.008,0.001,0.027999999999999997,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_March_Age_20–59_UnAdj,211216_Ontario_PublicHealthOntario_March,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Adults (18-64 years),20.0,59.0,Age,,503,0.002,5e-05,0.011000000000000001,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_March_Age_0–19_PopTestAdj,211216_Ontario_PublicHealthOntario_March,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Age,,182,0.0,0.0,0.022000000000000002,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_March_Age_0–19_UnAdj,211216_Ontario_PublicHealthOntario_March,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Age,,182,0.0,0.0,0.02,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_March_Sex_Male_PopTestAdj,211216_Ontario_PublicHealthOntario_March,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,337,0.011000000000000001,0.002,0.031000000000000003,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_March_Region_CentralWest_PopTestAdj,211216_Ontario_PublicHealthOntario_March,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Central West Ontario,48,0.0,0.0,0.08199999999999999,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_March_Age_20–59_PopTestAdj,211216_Ontario_PublicHealthOntario_March,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Adults (18-64 years),20.0,59.0,Age,,503,0.004,0.0001,0.021,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_March_Region_Toronto_PopTestAdj,211216_Ontario_PublicHealthOntario_March,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Toronto,259,0.009000000000000001,0.001,0.031000000000000003,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_March_Region_CentralWest_UnAdj,211216_Ontario_PublicHealthOntario_March,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,,48,0.0,0.0,0.07400000000000001,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_March_Region_Northern_PopTestAdj,211216_Ontario_PublicHealthOntario_March,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Northern Ontario,238,0.0,0.0,0.017,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_March_Region_Eastern_PopTestAdj,211216_Ontario_PublicHealthOntario_March,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Eastern Ontario,47,0.0,0.0,0.084,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_March_Region_SouthWest_PopTestAdj,211216_Ontario_PublicHealthOntario_March,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,South West Ontario,30,0.0,0.0,0.128,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_March_Age_ ≥ 60_PopTestAdj,211216_Ontario_PublicHealthOntario_March,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,60.0,,Age,,142,0.013000000000000001,0.002,0.046,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_May_Overall_PopTestAdj,211216_Ontario_PublicHealthOntario_May,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-05-26,2020-05-31,Residual sera,All,Multiple groups,0.0,,Primary Estimate,"Adjusted: population, test",1061,0.015,0.006999999999999999,0.022000000000000002,True,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-05,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_May_Region_Toronto_UnAdj,211216_Ontario_PublicHealthOntario_May,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,,275,0.028999999999999998,0.009000000000000001,0.049,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_May_Region_Northern_PopTestAdj,211216_Ontario_PublicHealthOntario_May,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Northern Ontario,74,0.013000000000000001,0.0003,0.07200000000000001,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_May_Region_Central West_UnAdj,211216_Ontario_PublicHealthOntario_May,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,,191,0.016,0.003,0.045,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_May_Region_Northern_UnAdj,211216_Ontario_PublicHealthOntario_May,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,,74,0.013999999999999999,0.0003,0.073,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_May_Overall_UnAdj,211216_Ontario_PublicHealthOntario_May,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-05-26,2020-05-31,Residual sera,All,Multiple groups,0.0,,Analysis,,1061,0.013999999999999999,0.006999999999999999,0.021,,,,,True,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_May_Region_South West_PopTestAdj,211216_Ontario_PublicHealthOntario_May,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,South West Ontario,93,0.009000000000000001,0.0002,0.051,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_May_Region_Eastern_PopTestAdj,211216_Ontario_PublicHealthOntario_May,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Eastern Ontario,29,0.0,0.0,0.132,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_May_Region_Central East_UnAdj,211216_Ontario_PublicHealthOntario_May,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,,399,0.005,0.0006,0.018000000000000002,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_May_Age_ ≥ 60_UnAdj,211216_Ontario_PublicHealthOntario_May,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,60.0,,Age,,322,0.009000000000000001,0.002,0.027000000000000003,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_May_Region_Central West_PopTestAdj,211216_Ontario_PublicHealthOntario_May,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Central West Ontario,191,0.018000000000000002,0.004,0.052000000000000005,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_May_Age_20–59_UnAdj,211216_Ontario_PublicHealthOntario_May,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Adults (18-64 years),20.0,59.0,Age,,521,0.019,0.006999999999999999,0.031000000000000003,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_May_Age_ ≥ 60_PopTestAdj,211216_Ontario_PublicHealthOntario_May,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,60.0,,Age,,322,0.008,0.002,0.024,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_May_Age_0–19_PopTestAdj,211216_Ontario_PublicHealthOntario_May,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Age,,218,0.006999999999999999,0.0008,0.024,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_May_Age_0–19_UnAdj,211216_Ontario_PublicHealthOntario_May,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Age,,218,0.009000000000000001,0.001,0.033,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_May_Sex_Male_PopTestAdj,211216_Ontario_PublicHealthOntario_May,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,525,0.011000000000000001,0.002,0.021,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_May_Sex_Male_UnAdj,211216_Ontario_PublicHealthOntario_May,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,525,0.011000000000000001,0.002,0.021,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_May_Region_Toronto_PopTestAdj,211216_Ontario_PublicHealthOntario_May,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Toronto,275,0.032,0.01,0.053,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_May_Region_Eastern_UnAdj,211216_Ontario_PublicHealthOntario_May,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,,29,0.0,0.0,0.11900000000000001,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_May_Age_20–59_PopTestAdj,211216_Ontario_PublicHealthOntario_May,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Adults (18-64 years),20.0,59.0,Age,,521,0.021,0.008,0.034,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_May_Region_South West_UnAdj,211216_Ontario_PublicHealthOntario_May,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,,93,0.011000000000000001,0.0003,0.057999999999999996,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_May_Region_Central East_PopTestAdj,211216_Ontario_PublicHealthOntario_May,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Central East Ontario,399,0.006999999999999999,0.0008,0.024,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_May_Sex_Female_PopTestAdj,211216_Ontario_PublicHealthOntario_May,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,536,0.018000000000000002,0.006,0.03,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2023-08-15,Verified,bolotin_assessment_2021,CAN
211216_Ontario_PublicHealthOntario_May_Sex_Female_UnAdj,211216_Ontario_PublicHealthOntario_May,"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.",2021-12-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Ontario,,"We used residual sera, plasma and blood specimens left over after routine clinical testing at the PHO laboratory. The PHO laboratory is Ontario’s public health reference laboratory and is the largest public health laboratory in Canada, conducting over 6 million tests on a variety of sample types annually. The samples selected for this study were initially submitted for various diagnostic (March–June samples), and occupational and prenatal tests (June samples only), ensuring an adequate diversity of samples from all ages and Ontario regions.","We excluded samples with missing information on age group, sex or geographical region of residence, samples without sufficient quantity, and those where the sample integrity was compromised.",2020-03-27,2020-04-30,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,536,0.017,0.006,0.027999999999999997,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Shelly Bolotin,Public Health Ontario,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2001559,2022-05-06,2024-03-01,Verified,bolotin_assessment_2021,CAN
220103_Canada_CBS_BloodDonors_RocheS_Overall_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,9627,0.9801000000000001,0.9765,0.9836,True,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_Age_60+_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,2843,0.023214913820000002,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_Overall_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Test used,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay PopTest Adj,9627,0.0453,0.030699999999999998,0.06,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,440,0.03863636364,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,783,0.9770114943,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,1576,0.05139593909,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,440,0.0378,0.0147,0.061,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,3200,0.9656250000000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_Age_25-39_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,2388,0.055276381910000005,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,163,1.0,0.9973000000000001,1.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_Sex_Female_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,3855,0.05058365759,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_Sex_Female_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,3855,0.986,0.9815,0.9905,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,163,0.9938650307000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,454,0.9845814978,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,1048,0.9892000000000001,0.9823000000000001,0.9962000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_Age_40-59_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,3187,0.9607781613,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_Age_25-39_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,2388,0.9681742044000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,163,0.0,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,835,0.08539999999999999,0.0665,0.1043,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,454,0.9997,0.9895999999999999,1.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,923,0.9901000000000001,0.981,0.9993000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_Age_17-24_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1209,0.08602150538,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,3200,0.035937500000000004,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_Sex_Male_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,5772,0.9738,0.9682,0.9793000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,454,0.03524229075,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,440,0.9795454545,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_Age_17-24_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1209,0.9758,0.9651000000000001,0.9865,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_Age_25-39_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,2388,0.9817,0.9747,0.9887,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,7397,0.0385,0.034,0.0431,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,530,0.9904000000000001,0.9745999999999999,1.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,2245,0.08285077951,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,7397,0.9819,0.978,0.9859000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,530,0.010700000000000001,0.0,0.022799999999999997,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,119,0.04201680672,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,695,0.056115107909999996,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,759,0.0667,0.043899999999999995,0.08960000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_Overall_PopAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Analysis,,9627,0.9684999999999999,0.9648000000000001,0.9719,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_Age_17-24_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1209,0.075,0.059800000000000006,0.0901,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,835,0.9760479042,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_Age_40-59_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,3187,0.04957640414,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_Overall_PopAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Analysis,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay Pop Adj,9627,0.0426,0.0385,0.0468,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_Age_25-39_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,2388,0.053,0.0437,0.0622,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,329,0.0269,0.0131,0.04070000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,530,0.9735849057,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_Age_17-24_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1209,0.9669148056000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_Overall_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Analysis,,9627,0.9658,0.9620000000000001,0.9694,,,,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,783,0.061302681989999996,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,1576,0.9777918782,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,119,0.031400000000000004,0.0,0.06480000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,159,0.0,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,329,0.9922,0.9806999999999999,1.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,695,0.9590000000000001,0.938,0.98,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,454,0.0256,0.0108,0.0405,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_Sex_Female_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,3855,0.04070000000000001,0.035,0.0463,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,2245,0.08650000000000001,0.0717,0.10130000000000002,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,835,0.08742514970000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,329,0.02431610942,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,370,0.01081081081,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,7397,0.044477490870000004,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,370,0.0063,0.0,0.0171,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,329,0.9787234042999999,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,3200,0.0333,0.027999999999999997,0.0385,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_Age_60+_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,2843,0.9856999999999999,0.9795999999999999,0.9918000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,7397,0.9679599838,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,2245,0.9550111359000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,759,0.9670619236000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_Age_60+_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,2843,0.9690467816,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_Age_40-59_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,3187,0.0446,0.0374,0.0517,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,923,0.9783315276000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,159,0.0,0.0,0.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,119,0.938,0.8890000000000001,0.9869,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,759,0.9777,0.9612,0.9942000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,2245,0.9661000000000001,0.9551000000000001,0.9771,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_Sex_Female_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,3855,0.9709468223000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_Sex_Male_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,5772,0.04591129591,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,159,0.9902,0.9501000000000001,1.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,695,0.054900000000000004,0.0333,0.0765,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,923,0.052300000000000006,0.0382,0.0663,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,783,0.0652,0.0429,0.0874,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,689,0.9651669086,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,695,0.9496402878000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,163,0.0,0.0,0.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,689,0.9747,0.9555,0.9939,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_Sex_Male_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,5772,0.9624047124,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,1576,0.9884000000000001,0.9811,0.9956,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,1576,0.0468,0.0366,0.057,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,1048,0.9751908397,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_Sex_Male_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,5772,0.0447,0.0386,0.0507,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,530,0.00943396226,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,783,0.9889,0.9754,1.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_Age_60+_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,2843,0.017,0.0118,0.0221,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,370,1.0,0.9901000000000001,1.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,370,0.9891891892,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,689,0.0443,0.023100000000000002,0.0655,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,119,0.9075630252000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,159,0.9685534591,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,759,0.06587615283,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,923,0.056338028170000005,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,689,0.043541364299999996,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,3200,0.9805,0.9756,0.9855,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,835,0.9871,0.9766,0.9976,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_UnAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,1048,0.035305343510000003,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2024-03-01,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,1048,0.030699999999999998,0.022400000000000003,0.038900000000000004,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_Age_40-59_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,3187,0.9759000000000001,0.9695,0.9823000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_PopTestAdj,220103_Canada_CBS,"COVID-19 Seroprevalence Report January 3rd, 2022 Report #15: October 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-10-14,2021-10-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,440,0.9915,0.9745999999999999,1.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-data-reveal-evidence-of-antibody-wane-among-adult-population/,2022-01-14,2023-08-15,Verified,canadian_blood_services_covid-19_2022,CAN
220103_BritishColumbia_UniversityofBritishColumbia_Dec2020_Overall,220103_BritishColumbia_UniversityofBritishColumbia_Dec2020,Persistence of Anti-SARS-CoV-2 Antibodies in Long Term Care Residents Over Seven Months After Two COVID-19 Outbreaks.,2022-01-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,,venous blood specimens were collected from residents in a long term care facility in BC,,,2020-12-22,Assisted living and long-term care facilities,All,Seniors (65+ years),,,Primary Estimate,,45,0.444,,,True,,,,True,Convenience,"ADVIA Centaur Immunoassay System,Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total","Siemens,Abbott Laboratories,Ortho Clinical Diagnostics Inc.",CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Guadalein Tanunliong,University of British Columbia,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2021.775420,2022-01-27,2024-03-01,Unverified,tanunliong_persistence_2022,CAN
220103_BritishColumbia_UniversityofBritishColumbia_May2020_Overall,220103_BritishColumbia_UniversityofBritishColumbia_May2020,Persistence of Anti-SARS-CoV-2 Antibodies in Long Term Care Residents Over Seven Months After Two COVID-19 Outbreaks.,2022-01-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,,venous blood specimens were collected from residents in a long term care facility in BC,,2020-05-04,2020-05-14,Assisted living and long-term care facilities,All,Seniors (65+ years),,,Primary Estimate,,87,0.402,,,True,,,,True,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Abbott Architect SARS-CoV-2 IgG,ADVIA Centaur Immunoassay System","DiaSorin,Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Guadalein Tanunliong,University of British Columbia,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2021.775420,2022-01-27,2024-03-01,Unverified,tanunliong_persistence_2022,CAN
220117_Quebec_ McGillUniversityHealthCentre,220117_Quebec_ McGillUniversityHealthCentre,"Seroprevalence and Risk Factors for Severe Acute Respiratory Syndrome Coronavirus 2 among Incarcerated Adult Men in Quebec, Canada, 2021",2022-01-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"""We included individuals aged 18 years who were incarcerated for more than 24 hours and able to consent to study participation in either English or French. ""","""We excluded individuals who were both in isolation with active SARS-CoV-2 or under investigation for COVID-19 as a close contact of a diagnosed case as the research team was denied access to these individuals and those who posed a security risk to the research team.""",2021-01-20,2021-09-20,Persons who are incarcerated,Male,Multiple groups,18.0,,Primary Estimate,,1100,0.22,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Nadine Kronfli, McGill University Health Centre,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac031,2023-01-23,2024-03-01,Unverified,kronfliSeroprevalenceRiskFactors2022,CAN
220117_Quebec_McGillUniversity_EDM,220117_Quebec_McGillUniversity_EDM1,"Seroprevalence and risk factors for SARS-CoV-2 among incarcerated adult men in Quebec, Canada (2021).",2022-01-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Québec,Montreal,"""We included individuals aged 18 years or older who were incarcerated for more than 24 hours and able to consent to study participation in either English or French.""

Men incarcerated in l’Établissement de détention de Montréal (EDM).","""We excluded individuals who were both in isolation with active SARS-CoV-2 or under investigation for COVID-19 as a close contact of a diagnosed case as the research team was denied access to these individuals, and those who posed a security risk to the research team.""

Also, females were excluded.",2021-01-19,2021-07-20,Persons who are incarcerated,Male,Adults (18-64 years),18.0,,Primary Estimate,,600,0.2733,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,No,Nadine Kronfli,McGill University,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac031,2022-01-26,2024-03-01,Verified,kronfli_seroprevalence_2022,CAN
220117_Quebec_McGillUniversity_EDRDP,220117_Quebec_McGillUniversity_EDRDP2,"Seroprevalence and risk factors for SARS-CoV-2 among incarcerated adult men in Quebec, Canada (2021).",2022-01-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Québec,Montreal,"""We included individuals aged 18 years or older who were incarcerated for more than 24 hours and able to consent to study participation in either English or French.""

Men incarcerated in l’Établissement de détention de Rivière-des-Prairies (EDRDP).","""We excluded individuals who were both in isolation with active SARS-CoV-2 or under investigation for COVID-19 as a close contact of a diagnosed case as the research team was denied access to these individuals, and those who posed a security risk to the research team.""

Also, females were excluded.",2021-02-03,2021-03-24,Persons who are incarcerated,Male,Adults (18-64 years),18.0,,Primary Estimate,,300,0.1467,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,No,No,Yes,Yes,Yes,Yes,Unclear,Nadine Kronfli,McGill University,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac031,2022-01-26,2024-03-01,Verified,kronfli_seroprevalence_2022,CAN
220117_Quebec_McGillUniversity_EDSJ,220117_Quebec_McGillUniversity_EDSJ3,"Seroprevalence and risk factors for SARS-CoV-2 among incarcerated adult men in Quebec, Canada (2021).",2022-01-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Québec,Saint-Jérôme,"""We included individuals aged 18 years or older who were incarcerated for more than 24 hours and able to consent to study participation in either English or French.""

Men incarcerated in l’Établissement de détention de S Jérôme (EDSJ).","""We excluded individuals who were both in isolation with active SARS-CoV-2 or under investigation for COVID-19 as a close contact of a diagnosed case as the research team was denied access to these individuals, and those who posed a security risk to the research team.""

Also, females were excluded.",2021-03-30,2021-09-15,Persons who are incarcerated,Male,Adults (18-64 years),18.0,,Primary Estimate,,200,0.19,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,No,No,Yes,Yes,Yes,Yes,Unclear,Nadine Kronfli,McGill University,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac031,2022-01-26,2024-03-01,Verified,kronfli_seroprevalence_2022,CAN
220121_Toronto_UniversityOfOxford,220121_Toronto_UniversityOfOxford,"Trans-continental analysis of over, 2000 inflammatory bowel disease patients implicates geography, disease type, and exposure to immunosuppression as drivers of SARS-CoV-2 seroprevalence: Data from the ICARUS-IBD consortium",2022-01-21,Presentation or Conference,Local,Cross-sectional survey ,Canada,,Toronto,IBD patients prior to vaccination,,2020-05-26,2021-09-24,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,28,0.0357,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Atellica® IM SARS-CoV-2 Total (COV2T)","Roche Diagnostics,Siemens",,Serum,TotalAntibody,Spike,,,,['High'],,No,No,No,,Unclear,No,No,,S Y Wong,University of Oxford,Not Unity-Aligned,https://dx.doi.org/10.1093/ecco-jcc/jjab232.469,2022-03-08,2024-03-01,Unverified,wong_p342_2022,CAN
220125_Canada_CBS_BloodDonors_RocheS_Overall_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,9018,0.9852,0.9818000000000001,0.9886,True,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,842,0.0541,0.04360000000000001,0.0646,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,537,0.00931098696,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,6989,0.045599999999999995,0.0405,0.0507,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,2048,0.9682617188000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,124,0.0527,0.0122,0.0932,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,768,0.0703125,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_Sex_Female_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,3489,0.9921,0.9881000000000001,0.9962000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,537,0.9925512104,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_Age_40-59_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,2922,0.9681724846,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,120,0.9916666667,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_Age_25-39_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,2238,0.062109025920000005,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,374,0.9703,0.9454000000000001,0.9952,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,816,0.1032,0.083,0.1233,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_Age_60+_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,2737,0.9873000000000001,0.9812000000000001,0.9934000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,2835,0.040917107579999994,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,661,0.083,0.053899999999999997,0.11199999999999999,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,309,0.01941747573,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_Age_60+_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,2737,0.9711362806,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,2048,0.09521484375,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_Overall_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Analysis,,9018,0.9701000000000001,0.9662999999999999,0.9734999999999999,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,852,0.970657277,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,721,0.9927,0.983,1.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,2835,0.986,0.9813,0.9906999999999999,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,790,0.9620253165,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,374,0.01336898396,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,816,0.9681372549,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,1421,0.05277973258,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,470,0.9765957447,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_Age_60+_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,2737,0.0286,0.0219,0.0353,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,661,0.9515885023,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,852,0.9821,0.9679000000000001,0.9963,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,337,0.04451038576,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,6989,0.9866,0.9828,0.9904000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,721,0.06518723994,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_Age_40-59_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,2922,0.05441478439,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,721,0.0591,0.0424,0.0757,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_Sex_Female_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,3489,0.05760963027,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,816,0.1090686275,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,768,0.0696,0.0471,0.0922,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,337,0.9910979228,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,232,0.9984000000000001,0.9812000000000001,1.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,309,0.015300000000000001,0.0021,0.0286,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,120,0.0163,0.0,0.0541,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,470,0.9894,0.9705,1.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,124,0.9758064516,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_Sex_Female_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,3489,0.044800000000000006,0.038700000000000005,0.0509,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,790,0.9734999999999999,0.9547,0.9923000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,120,0.01666666667,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_Age_17-24_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1121,0.9918000000000001,0.9834,1.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,1421,0.9767769177,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,721,0.9778085992,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,790,0.08860759494,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,1421,0.9909,0.9838,0.998,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_Sex_Male_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,5529,0.05823837945,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,768,0.9791666667,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,661,0.08018154312,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,842,0.9809976247000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,232,0.9870689655,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_Overall_PopAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Analysis,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay Pop Adj,9018,0.052000000000000005,0.0475,0.056799999999999996,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,470,0.046808510639999995,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,768,0.9899,0.9770000000000001,1.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,374,0.9625668449,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,337,0.0454,0.0242,0.0666,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_Age_17-24_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1121,0.9768064228000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_Age_17-24_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1121,0.1141837645,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_Sex_Female_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,3489,0.977357409,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,842,0.05819477435,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,537,0.005699999999999999,0.0,0.015300000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,124,0.9944,0.9709000000000001,1.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,816,0.9844,0.9736,0.9952,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_Overall_PopAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Analysis,,9018,0.9734999999999999,0.97,0.9767,,,True,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_Overall_Unadj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Analysis,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay Unadj,9018,0.057999999999999996,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-05-27,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_Overall_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Test used,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay PopTest Adj,9018,0.0504,0.0458,0.055,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,337,0.9966,0.9843000000000001,1.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,1421,0.0463,0.0359,0.056799999999999996,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,374,0.017,0.0001,0.034,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,309,1.0,0.9895,1.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_Sex_Male_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,5529,0.0563,0.0493,0.0632,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_Age_25-39_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,2238,0.9834,0.9764,0.9904000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_Age_40-59_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,2922,0.04730000000000001,0.039700000000000006,0.054900000000000004,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_Age_60+_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,2737,0.035440263060000005,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,2835,0.0404,0.0345,0.0463,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_Sex_Male_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,5529,0.9654548743,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_Age_25-39_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,2238,0.9678284182,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_Sex_Male_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,5529,0.9779000000000001,0.9725,0.9833,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,232,0.00862068966,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,2048,0.9812000000000001,0.9719,0.9906,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,6989,0.9713836028,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,537,0.9998,0.9877,1.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,309,0.9902912621000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_Age_17-24_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1121,0.0935,0.0762,0.1107,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,2048,0.0925,0.0767,0.1082,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,6989,0.05322649878,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,842,0.9953000000000001,0.9894,1.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,852,0.0706,0.049100000000000005,0.09210000000000002,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,232,0.0063,0.0,0.0197,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,852,0.07394366197,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,790,0.0883,0.0604,0.1161,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,470,0.045599999999999995,0.018600000000000002,0.0725,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_Age_40-59_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,2922,0.9825,0.9765,0.9884000000000001,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_Age_25-39_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,2238,0.0581,0.0481,0.068,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,661,0.9601000000000001,0.9368000000000001,0.9833,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,2835,0.9689594356000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_UnAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,124,0.06451612903000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-1,CAN
220125_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_PopTestAdj,220125_Canada_CBS,"COVID-19 Seroprevalence Report January 25th, 2022 Report #16: November 2021 Survey Tracking seroprevalence in the vaccine era",2022-01-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-11-13,2021-11-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,120,0.9688,0.9133,1.0,,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-reflect-uptick-in-infections-prior-to-omicron-surge/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-1,CAN
220209_Canada_CBS_BloodDonors_RocheS_Overall_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,16816,0.9858,0.9834,0.9882,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,2891,0.9789000346000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,521,0.021113243759999997,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,134,0.9850746269,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,7178,0.0543,0.049400000000000006,0.0592,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,649,0.0046224961500000005,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,882,0.9905,0.9794,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,807,0.9665427509,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,196,0.0612244898,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_Age_60+_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,4302,0.9737331474,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_Age_25-39_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,4418,0.08669081031999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,3390,0.9775811209,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_Overall_PopAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Analysis,,16816,0.9741,0.9716,0.9765,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,649,0.9830508475,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,12432,0.9865,0.9837,0.9893000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,984,0.9898,0.9788,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,984,0.0759,0.055999999999999994,0.0958,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,3455,0.1294,0.1162,0.1427,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,185,0.9949,0.9825,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,807,0.07558859975,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,521,0.9920000000000001,0.9812000000000001,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,521,0.9827255278,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,136,0.01470588235,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_Age_40-59_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,6520,0.9713190184,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,1203,0.09119999999999999,0.0717,0.1106,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_Overall_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Test used,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay PopTest Adj,16816,0.0639,0.0601,0.0676,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,807,0.9777,0.9647,0.9906,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2022,0.9703264095,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,3455,0.9779000000000001,0.9707,0.985,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2022,0.1300692384,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2022,0.1258,0.1112,0.1405,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_Age_60+_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,4302,0.0358,0.0304,0.041299999999999996,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,7178,0.05600445807,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,185,0.01081081081,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,1821,0.9851729819,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,931,0.9881847476000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,196,0.9495,0.9155,0.9834999999999999,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,136,0.0096,0.0,0.0212,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,649,0.0025,0.0,0.0079,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_Age_60+_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,4302,0.04184100418,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2022,0.9812000000000001,0.9736,0.9888,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_Age_40-59_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,6520,0.06518404908,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,7178,0.9735302312999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_Age_60+_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,4302,0.9866,0.9820000000000001,0.9911,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,931,0.0681,0.051500000000000004,0.08470000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,136,1.0,0.9895,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_Overall_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Analysis,,16816,0.973,0.9704,0.9754,,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,12432,0.06040862291,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,535,0.9831775701,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,3455,0.9649782923,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,521,0.0227,0.0108,0.0346,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_Sex_Female_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,6997,0.06917250250000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_Age_17-24_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1576,0.1294416244,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,1203,0.9870000000000001,0.9765,0.9975,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,931,0.9986,0.9911,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_Age_40-59_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,6520,0.9844,0.9801000000000001,0.9886,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_Sex_Male_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,9819,0.9858,0.9823000000000001,0.9893000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,7178,0.9849,0.9814,0.9884000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_Age_17-24_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1576,0.9841370558,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_Overall_PopAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Test used,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay Pop Adj,16816,0.0654,0.0617,0.0693,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,1821,0.07303679297,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,1203,0.9733998337,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,2891,0.9887,0.9837,0.9937,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_Sex_Male_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,9819,0.07210510235,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,535,0.0634,0.04190000000000001,0.085,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,535,0.05981308411,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,2891,0.07780000000000001,0.069,0.0867,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,134,0.0,,,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_Age_25-39_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,4418,0.0804,0.07200000000000001,0.0888,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,3390,0.058300000000000005,0.049800000000000004,0.0669,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,984,0.07520325203,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_Age_17-24_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1576,0.1137,0.0999,0.1275,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_Sex_Female_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,6997,0.9858,0.9823999999999999,0.9892000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,134,0.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,3390,0.06135693215,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,984,0.9756097561,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_Sex_Female_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,6997,0.9735600972,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_Age_25-39_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,4418,0.9821,0.9768000000000001,0.9873999999999999,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_Sex_Male_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,9819,0.0689,0.0633,0.0745,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_Age_25-39_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Adults (18-64 years),25.0,49.0,Age,25-39 Years,4418,0.9708012675000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,185,0.0045000000000000005,0.0,0.0122,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,882,0.07,0.050300000000000004,0.0898,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_Age_40-59_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Adults (18-64 years),40.0,60.0,Age,40-59 Years,6520,0.0572,0.051100000000000007,0.0633,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,931,0.06337271751000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,882,0.07256235828,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,136,0.9926470587999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,649,0.9969,0.9869,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_Sex_Female_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,6997,0.0591,0.0541,0.06420000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,3455,0.13024602030000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,1821,0.997,0.9909,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,185,0.9783783784000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,807,0.0818,0.0621,0.1014,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,535,0.9968000000000001,0.986,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,1821,0.07200000000000001,0.059000000000000004,0.085,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_Age_17-24_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1576,0.9954000000000001,0.9899,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_Sex_Male_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,9819,0.9726041348,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,3390,0.9899,0.9845999999999999,0.9952,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,882,0.9750566893,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,196,0.0484,0.0179,0.0789,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,1203,0.09310058187999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,12432,0.9734555985000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,12432,0.0521,0.0481,0.056100000000000004,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,196,0.9387755102,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_UnAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,2891,0.08094085092,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2024-03-01,Verified,canadian_blood_services_covid-19_2022-2,CAN
220209_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_PopTestAdj,220209_Canada_CBS,"COVID-19 Seroprevalence Report February 9th, 2022 Report #17: December 2021 Survey The advance of Omicron",2022-02-09,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2021-12-14,2021-12-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,134,0.9991,0.9755,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,https://www.covid19immunitytaskforce.ca/canadian-blood-services-december-report-the-advance-of-omicron/,2022-03-08,2023-08-15,Verified,canadian_blood_services_covid-19_2022-2,CAN
220216_Canada_UniversityofToronto_Phase1_Overall_PopAdj,220216_Canada_UniversityofToronto_Phase1,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island, British Columbia, some Yukon Territory, Alberta, Saskatchewan, Manitoba, some Northwest Territories, Ontario, Quebec",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results,2020-05-01,2020-09-30,Household and community samples,All,Multiple groups,,,Primary Estimate,Population adjusted (age and education level),8967,0.019,,,True,,True,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.98,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,No,Xuyang Tang,University of Toronto,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-23,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase1_Unadj_Ontario,220216_Canada_UniversityofToronto_Phase1,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,Ontario,,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results,2020-05-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Ontario,3906,0.026600000000000002,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.98,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,No,Xuyang Tang,University of Toronto,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase1_Unadj_BritishColumbia,220216_Canada_UniversityofToronto_Phase1,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"British Columbia, some Yukon Territory",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results,2020-05-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,British Columbia (some Yukon Territory),1579,0.013300000000000001,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.98,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,No,Xuyang Tang,University of Toronto,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase1_Unadj_60-69,220216_Canada_UniversityofToronto_Phase1,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island, British Columbia, some Yukon Territory, Alberta, Saskatchewan, Manitoba, some Northwest Territories, Ontario, Quebec",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results,2020-05-01,2020-09-30,Household and community samples,All,Multiple groups,,,Age,60-69,2149,0.0195,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.98,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,No,Xuyang Tang,University of Toronto,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase1_Unadj_Atlantic,220216_Canada_UniversityofToronto_Phase1,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results,2020-05-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,"Atlantic provinces (New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island)",563,0.0124,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.98,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,No,Xuyang Tang,University of Toronto,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase1_PopAdj_40-59,220216_Canada_UniversityofToronto_Phase1,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island, British Columbia, some Yukon Territory, Alberta, Saskatchewan, Manitoba, some Northwest Territories, Ontario, Quebec",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results,2020-05-01,2020-09-30,Household and community samples,All,Adults (18-64 years),,,Age,40-59,3027,0.018000000000000002,,,,,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.98,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,No,Xuyang Tang,University of Toronto,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase1_PopAdj_BritishColumbia,220216_Canada_UniversityofToronto_Phase1,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"British Columbia, some Yukon Territory",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results,2020-05-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,British Columbia (some Yukon Territory),1579,0.013000000000000001,,,,,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.98,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,No,Xuyang Tang,University of Toronto,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase1_PopAdj_Ontario,220216_Canada_UniversityofToronto_Phase1,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,Ontario,,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results,2020-05-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Ontario,3906,0.026000000000000002,,,,,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.98,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,No,Xuyang Tang,University of Toronto,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase1_Unadj_Male,220216_Canada_UniversityofToronto_Phase1,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island, British Columbia, some Yukon Territory, Alberta, Saskatchewan, Manitoba, some Northwest Territories, Ontario, Quebec",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results,2020-05-01,2020-09-30,Household and community samples,Male,Multiple groups,,,Sex/Gender,,3694,0.0173,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.98,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,No,Xuyang Tang,University of Toronto,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase1_PopAdj_≥70,220216_Canada_UniversityofToronto_Phase1,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island, British Columbia, some Yukon Territory, Alberta, Saskatchewan, Manitoba, some Northwest Territories, Ontario, Quebec",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results,2020-05-01,2020-09-30,Household and community samples,All,Seniors (65+ years),,,Age,≥70,1029,0.006999999999999999,,,,,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.98,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,No,Xuyang Tang,University of Toronto,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase1_Unadj_≥70,220216_Canada_UniversityofToronto_Phase1,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island, British Columbia, some Yukon Territory, Alberta, Saskatchewan, Manitoba, some Northwest Territories, Ontario, Quebec",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results,2020-05-01,2020-09-30,Household and community samples,All,Seniors (65+ years),,,Age,≥70,1029,0.0068000000000000005,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.98,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,No,Xuyang Tang,University of Toronto,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase1_Unadj_40-59,220216_Canada_UniversityofToronto_Phase1,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island, British Columbia, some Yukon Territory, Alberta, Saskatchewan, Manitoba, some Northwest Territories, Ontario, Quebec",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results,2020-05-01,2020-09-30,Household and community samples,All,Adults (18-64 years),,,Age,40-59,3027,0.0172,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.98,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,No,Xuyang Tang,University of Toronto,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase1_Overall_PopUnadj,220216_Canada_UniversityofToronto_Phase1,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island, British Columbia, some Yukon Territory, Alberta, Saskatchewan, Manitoba, some Northwest Territories, Ontario, Quebec",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results,2020-05-01,2020-09-30,Household and community samples,All,Multiple groups,,,Analysis,,8967,0.0187,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.98,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,No,Xuyang Tang,University of Toronto,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase1_PopAdj_Male,220216_Canada_UniversityofToronto_Phase1,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island, British Columbia, some Yukon Territory, Alberta, Saskatchewan, Manitoba, some Northwest Territories, Ontario, Quebec",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results,2020-05-01,2020-09-30,Household and community samples,Male,Multiple groups,,,Sex/Gender,,3694,0.018000000000000002,,,,,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.98,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,No,Xuyang Tang,University of Toronto,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase1_PopAdj_18-39,220216_Canada_UniversityofToronto_Phase1,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island, British Columbia, some Yukon Territory, Alberta, Saskatchewan, Manitoba, some Northwest Territories, Ontario, Quebec",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results,2020-05-01,2020-09-30,Household and community samples,All,Adults (18-64 years),,,Age,18-39,2762,0.024,,,,,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.98,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,No,Xuyang Tang,University of Toronto,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase1_Unadj_Prairies,220216_Canada_UniversityofToronto_Phase1,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"Alberta, Saskatchewan, Manitoba, some Northwest Territories",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results,2020-05-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,"Prairies (some Northwest Territories; Alberta, Saskatchewan, Manitoba)",1540,0.0117,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.98,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,No,Xuyang Tang,University of Toronto,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase1_PopAdj_Quebec,220216_Canada_UniversityofToronto_Phase1,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,Quebec,,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results,2020-05-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Quebec,1378,0.013999999999999999,,,,,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.98,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,No,Xuyang Tang,University of Toronto,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase1_PopAdj_60-69,220216_Canada_UniversityofToronto_Phase1,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island, British Columbia, some Yukon Territory, Alberta, Saskatchewan, Manitoba, some Northwest Territories, Ontario, Quebec",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results,2020-05-01,2020-09-30,Household and community samples,All,Multiple groups,,,Age,60-69,2149,0.019,,,,,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.98,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,No,Xuyang Tang,University of Toronto,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase1_Unadj_18-39,220216_Canada_UniversityofToronto_Phase1,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island, British Columbia, some Yukon Territory, Alberta, Saskatchewan, Manitoba, some Northwest Territories, Ontario, Quebec",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results,2020-05-01,2020-09-30,Household and community samples,All,Adults (18-64 years),,,Age,18-39,2762,0.024300000000000002,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.98,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,No,Xuyang Tang,University of Toronto,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase1_PopAdj_Prairies,220216_Canada_UniversityofToronto_Phase1,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"Alberta, Saskatchewan, Manitoba, some Northwest Territories",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results,2020-05-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,"Prairies (some Northwest Territories; Alberta, Saskatchewan, Manitoba)",1540,0.012,,,,,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.98,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,No,Xuyang Tang,University of Toronto,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase1_PopAdj_Atlantic,220216_Canada_UniversityofToronto_Phase1,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results,2020-05-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,"Atlantic provinces (New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island)",563,0.013000000000000001,,,,,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.98,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,No,Xuyang Tang,University of Toronto,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase1_PopAdj_Female,220216_Canada_UniversityofToronto_Phase1,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island, British Columbia, some Yukon Territory, Alberta, Saskatchewan, Manitoba, some Northwest Territories, Ontario, Quebec",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results,2020-05-01,2020-09-30,Household and community samples,Female,Multiple groups,,,Sex/Gender,,5226,0.019,,,,,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.98,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,No,Xuyang Tang,University of Toronto,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase1_Unadj_Female,220216_Canada_UniversityofToronto_Phase1,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island, British Columbia, some Yukon Territory, Alberta, Saskatchewan, Manitoba, some Northwest Territories, Ontario, Quebec",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results,2020-05-01,2020-09-30,Household and community samples,Female,Multiple groups,,,Sex/Gender,,5226,0.0197,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.98,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,No,Xuyang Tang,University of Toronto,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase1_Unadj_Quebec,220216_Canada_UniversityofToronto_Phase1,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,Quebec,,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results,2020-05-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Quebec,1378,0.0131,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.98,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,No,Xuyang Tang,University of Toronto,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase2_Overall_PopAdj,220216_Canada_UniversityofToronto_Phase2,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island, British Columbia, some Yukon Territory, Alberta, Saskatchewan, Manitoba, some Northwest Territories, Ontario, Quebec",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results; Participants who had received a vaccine,2020-12-01,2021-03-31,Household and community samples,All,Multiple groups,,,Primary Estimate,Population adjusted (age and education level),6955,0.065,,,True,,,,True,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,No,Xuyang Tang,University of Toronto,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-23,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase2_Unadj_40-59,220216_Canada_UniversityofToronto_Phase2,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island, British Columbia, some Yukon Territory, Alberta, Saskatchewan, Manitoba, some Northwest Territories, Ontario, Quebec",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results; Participants who had received a vaccine,2020-12-01,2021-03-31,Household and community samples,All,Adults (18-64 years),,,Age,40-59,2400,0.0617,,,,,,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,No,Xuyang Tang,University of Toronto,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase2_Unadj_≥70,220216_Canada_UniversityofToronto_Phase2,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island, British Columbia, some Yukon Territory, Alberta, Saskatchewan, Manitoba, some Northwest Territories, Ontario, Quebec",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results; Participants who had received a vaccine,2020-12-01,2021-03-31,Household and community samples,All,Seniors (65+ years),,,Age,≥70,880,0.061399999999999996,,,,,,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,No,Xuyang Tang,University of Toronto,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase2_PopAdj_60-69,220216_Canada_UniversityofToronto_Phase2,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island, British Columbia, some Yukon Territory, Alberta, Saskatchewan, Manitoba, some Northwest Territories, Ontario, Quebec",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results; Participants who had received a vaccine,2020-12-01,2021-03-31,Household and community samples,All,Multiple groups,,,Age,60-69,1798,0.069,,,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,No,Xuyang Tang,University of Toronto,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase2_Unadj_18-39,220216_Canada_UniversityofToronto_Phase2,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island, British Columbia, some Yukon Territory, Alberta, Saskatchewan, Manitoba, some Northwest Territories, Ontario, Quebec",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results; Participants who had received a vaccine,2020-12-01,2021-03-31,Household and community samples,All,Adults (18-64 years),,,Age,18-39,1877,0.0671,,,,,,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,No,Xuyang Tang,University of Toronto,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase2_PopAdj_Male,220216_Canada_UniversityofToronto_Phase2,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island, British Columbia, some Yukon Territory, Alberta, Saskatchewan, Manitoba, some Northwest Territories, Ontario, Quebec",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results; Participants who had received a vaccine,2020-12-01,2021-03-31,Household and community samples,Male,Multiple groups,,,Sex/Gender,,2843,0.064,,,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,No,Xuyang Tang,University of Toronto,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase2_PopAdj_BritishColumbia,220216_Canada_UniversityofToronto_Phase2,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"British Columbia, some Yukon Territory",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results; Participants who had received a vaccine,2020-12-01,2021-03-31,Household and community samples,All,Seniors (65+ years),,,Geographical area,British Columbia (some Yukon Territory),1286,0.064,,,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,No,Xuyang Tang,University of Toronto,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase2_PopAdj_≥70,220216_Canada_UniversityofToronto_Phase2,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island, British Columbia, some Yukon Territory, Alberta, Saskatchewan, Manitoba, some Northwest Territories, Ontario, Quebec",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results; Participants who had received a vaccine,2020-12-01,2021-03-31,Household and community samples,All,Seniors (65+ years),,,Age,≥70,880,0.061,,,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,No,Xuyang Tang,University of Toronto,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase2_Unadj_Male,220216_Canada_UniversityofToronto_Phase2,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island, British Columbia, some Yukon Territory, Alberta, Saskatchewan, Manitoba, some Northwest Territories, Ontario, Quebec",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results; Participants who had received a vaccine,2020-12-01,2021-03-31,Household and community samples,Male,Multiple groups,,,Sex/Gender,,2843,0.0644,,,,,,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,No,Xuyang Tang,University of Toronto,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase2_PopAdj_40-59,220216_Canada_UniversityofToronto_Phase2,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island, British Columbia, some Yukon Territory, Alberta, Saskatchewan, Manitoba, some Northwest Territories, Ontario, Quebec",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results; Participants who had received a vaccine,2020-12-01,2021-03-31,Household and community samples,All,Adults (18-64 years),,,Age,40-59,2400,0.061,,,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,No,Xuyang Tang,University of Toronto,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase2_PopAdj_Quebec,220216_Canada_UniversityofToronto_Phase2,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,Quebec,,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results; Participants who had received a vaccine,2020-12-01,2021-03-31,Household and community samples,All,Seniors (65+ years),,,Geographical area,Quebec,1080,0.064,,,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,No,Xuyang Tang,University of Toronto,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase2_Unadj_BritishColumbia,220216_Canada_UniversityofToronto_Phase2,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"British Columbia, some Yukon Territory",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results; Participants who had received a vaccine,2020-12-01,2021-03-31,Household and community samples,All,Multiple groups,,,Geographical area,British Columbia (some Yukon Territory),1286,0.0653,,,,,,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,No,Xuyang Tang,University of Toronto,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase2_Overall_PopUnadj,220216_Canada_UniversityofToronto_Phase2,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island, British Columbia, some Yukon Territory, Alberta, Saskatchewan, Manitoba, some Northwest Territories, Ontario, Quebec",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results; Participants who had received a vaccine,2020-12-01,2021-03-31,Household and community samples,All,Multiple groups,,,Analysis,,6955,0.0654,,,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,No,Xuyang Tang,University of Toronto,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase2_PopAdj_Prairies,220216_Canada_UniversityofToronto_Phase2,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"Alberta, Saskatchewan, Manitoba, some Northwest Territories",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results; Participants who had received a vaccine,2020-12-01,2021-03-31,Household and community samples,All,Seniors (65+ years),,,Geographical area,"Prairies (some Northwest Territories; Alberta, Saskatchewan, Manitoba)",1229,0.07,,,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,No,Xuyang Tang,University of Toronto,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase2_Unadj_Atlantic,220216_Canada_UniversityofToronto_Phase2,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results; Participants who had received a vaccine,2020-12-01,2021-03-31,Household and community samples,All,Multiple groups,,,Geographical area,"Atlantic provinces (New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island)",396,0.0354,,,,,,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,No,Xuyang Tang,University of Toronto,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase2_PopAdj_18-39,220216_Canada_UniversityofToronto_Phase2,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island, British Columbia, some Yukon Territory, Alberta, Saskatchewan, Manitoba, some Northwest Territories, Ontario, Quebec",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results; Participants who had received a vaccine,2020-12-01,2021-03-31,Household and community samples,All,Adults (18-64 years),,,Age,18-39,1877,0.067,,,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,No,Xuyang Tang,University of Toronto,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase2_Unadj_Female,220216_Canada_UniversityofToronto_Phase2,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island, British Columbia, some Yukon Territory, Alberta, Saskatchewan, Manitoba, some Northwest Territories, Ontario, Quebec",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results; Participants who had received a vaccine,2020-12-01,2021-03-31,Household and community samples,Female,Multiple groups,,,Sex/Gender,,4077,0.0665,,,,,,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,No,Xuyang Tang,University of Toronto,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase2_Unadj_Ontario,220216_Canada_UniversityofToronto_Phase2,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,Ontario,,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results; Participants who had received a vaccine,2020-12-01,2021-03-31,Household and community samples,All,Multiple groups,,,Geographical area,Ontario,2964,0.06820000000000001,,,,,,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,No,Xuyang Tang,University of Toronto,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase2_Unadj_60-69,220216_Canada_UniversityofToronto_Phase2,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island, British Columbia, some Yukon Territory, Alberta, Saskatchewan, Manitoba, some Northwest Territories, Ontario, Quebec",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results; Participants who had received a vaccine,2020-12-01,2021-03-31,Household and community samples,All,Multiple groups,,,Age,60-69,1798,0.0706,,,,,,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,No,Xuyang Tang,University of Toronto,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase2_PopAdj_Female,220216_Canada_UniversityofToronto_Phase2,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island, British Columbia, some Yukon Territory, Alberta, Saskatchewan, Manitoba, some Northwest Territories, Ontario, Quebec",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results; Participants who had received a vaccine,2020-12-01,2021-03-31,Household and community samples,Female,Seniors (65+ years),,,Sex/Gender,,4077,0.066,,,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,No,Xuyang Tang,University of Toronto,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase2_Unadj_Prairies,220216_Canada_UniversityofToronto_Phase2,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"Alberta, Saskatchewan, Manitoba, some Northwest Territories",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results; Participants who had received a vaccine,2020-12-01,2021-03-31,Household and community samples,All,Multiple groups,,,Geographical area,"Prairies (some Northwest Territories; Alberta, Saskatchewan, Manitoba)",1229,0.07,,,,,,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,No,Xuyang Tang,University of Toronto,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase2_PopAdj_Atlantic,220216_Canada_UniversityofToronto_Phase2,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,"New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island",,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results; Participants who had received a vaccine,2020-12-01,2021-03-31,Household and community samples,All,Seniors (65+ years),,,Geographical area,"Atlantic provinces (New Brunswick, Newfoundland, Nova Scotia, and Prince Edward Island)",396,0.033,,,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,No,Xuyang Tang,University of Toronto,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase2_Unadj_Quebec,220216_Canada_UniversityofToronto_Phase2,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,Quebec,,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results; Participants who had received a vaccine,2020-12-01,2021-03-31,Household and community samples,All,Multiple groups,,,Geographical area,Quebec,1080,0.0639,,,,,,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,No,Xuyang Tang,University of Toronto,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220216_Canada_UniversityofToronto_Phase2_PopAdj_Ontario,220216_Canada_UniversityofToronto_Phase2,Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.,2022-02-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,Ontario,,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),Incomplete test results; Participants who had received a vaccine,2020-12-01,2021-03-31,Household and community samples,All,Seniors (65+ years),,,Geographical area,Ontario,2964,0.067,,,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,No,Xuyang Tang,University of Toronto,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.46798,2022-02-24,2022-07-16,Verified,tang_assessment_2022,CAN
220217_Ontario_SinaiHealthSystem_Overall,220217_Ontario_SinaiHealthSystem,Study of the epidemiology of COVID-19 in Ontario elementary and secondary school education workers: an interim analysis following the first school year.,2022-02-17,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Canada,Ontario,,"""The study is open to all education workers (teachers, educational assistants, school office staff, custodians, librarians, early childhood educators, etc.) aged 18–74 years, employed in any capacity in an Ontario school or school board, working an average of ≥ 8 h/ week (remote or in person) during the 2020–2021 school year, and planning to continue working for at least 3 months after enrolment. To permit dried blood spot (DBS) self-collection, eligibility was restricted to those who did not have a bleeding disorder, had not received chemotherapy in the previous 4 weeks, and had not had a bilateral mastectomy.""",,2021-02-18,2021-07-17,Essential non-healthcare workers,All,Multiple groups,18.0,74.0,Primary Estimate,,1252,0.0184,,,True,,,,True,Convenience,BioPlex 2200 SARS-CoV-2 IgG Panel,Bio-rad,,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Brenda Coleman,Sinai Health System,Not Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00613-z,2022-02-23,2024-03-01,Unverified,coleman_study_2022,CAN
220223_Canada_CanadianBloodServices_OverallAND,220223_Canada_CanadianBloodServices,"Estimating SARS-CoV-2 Seroprevalence in Canadian Blood Donors, April 2020 to March 2021: Improving Accuracy with Multiple Assays.",2022-02-23,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Canada,,,"Canadian Blood Services has blood
collection sites concentrated in large and small cities in all Canadian provinces except Quebec. Blood
donors must meet the following criteria: be at least 17 years of age; pass health selection criteria screening
and pass infectious diseases screening protocols for blood donations that are then used to manufacture
products for transfusion.",,2020-04-15,2021-03-15,Blood donors,All,Multiple groups,,,Primary Estimate,Apr 2020 - Mar 2021; two or more assays represent a true positive case,17999,0.021,0.019,0.023,True,True,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Author designed (ELISA) - Nucleocapsid,Author designed (ELISA) -Spike","Abbott Laboratories,NA",Multiple Types,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Ashleigh Tuite,Canadian Blood Services,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.02563-21,2022-03-09,2023-08-15,Verified,tuite_estimating_2022,CAN
220223_Canada_CanadianBloodServices_OverallOR,220223_Canada_CanadianBloodServices,"Estimating SARS-CoV-2 Seroprevalence in Canadian Blood Donors, April 2020 to March 2021: Improving Accuracy with Multiple Assays.",2022-02-23,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Canada,,,"Canadian Blood Services has blood
collection sites concentrated in large and small cities in all Canadian provinces except Quebec. Blood
donors must meet the following criteria: be at least 17 years of age; pass health selection criteria screening
and pass infectious diseases screening protocols for blood donations that are then used to manufacture
products for transfusion.",,2020-04-15,2021-03-15,Blood donors,All,Multiple groups,,,Test used,Apr 2020 - Mar 2021; single assay represents a true positive case,17999,0.052000000000000005,,,,True,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Author designed (ELISA) - Nucleocapsid,Author designed (ELISA) -Spike","Abbott Laboratories,NA",Multiple Types,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Ashleigh Tuite,Canadian Blood Services,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.02563-21,2022-03-09,2023-08-15,Verified,tuite_estimating_2022,CAN
220301_Quebec_McGillUniversity,220301_Quebec_McGillUniversity,Seroprevalence and risk factors for SARS-CoV-2 among incarcerated adult men in Quebec,2022-03-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,Incarcerated adult men in Quebec,,2021-01-19,2021-09-15,Persons who are incarcerated,All,Adults (18-64 years),,,Primary Estimate,,1100,0.2236,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],,Unclear,Yes,No,,Unclear,Yes,No,,Nadine Kronfli,McGill University,Not Unity-Aligned,https://www.iasusa.org/tam/march-2022/,2022-06-17,2022-07-16,Unverified,kronfli_seroprevalence_2022-1,CAN
220307_Quebec_InstitutnationaldesantépubliqueduQuébec_Overall,220307_Quebec_InstitutnationaldesantépubliqueduQuébec,"Séroprévalence du SRAS-CoV-2 chez les travailleurs de la santé de 10 hôpitaux du Québec, au Canada: étude transversale",2022-03-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"Healthcare workers from 10 acute care hospitals that accepted COVID-19 patients. Healthcare workers included physicians, nurses, auxiliary staff, administrative staff, maintenance staff.
At least 18 years of age.",,2020-07-06,2020-09-24,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,2056,0.11720000000000001,,,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8200000000000001,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Nicholas Brousseau,Institut national de santé publique du Québec,Not Unity-Aligned,https://dx.doi.org/10.1503/cmaj.202783-f,2022-04-12,2024-03-01,Unverified,brousseau_seroprevalence_2022,CAN
220307_Quebec_InstitutnationaldesantépubliqueduQuébec_Age60+,220307_Quebec_InstitutnationaldesantépubliqueduQuébec,"Séroprévalence du SRAS-CoV-2 chez les travailleurs de la santé de 10 hôpitaux du Québec, au Canada: étude transversale",2022-03-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"Healthcare workers from 10 acute care hospitals that accepted COVID-19 patients. Healthcare workers included physicians, nurses, auxiliary staff, administrative staff, maintenance staff.
At least 18 years of age.",,2020-07-06,2020-09-24,Health care workers and caregivers,All,Adults (18-64 years),60.0,,Age,60+,83,0.1084,,,,,,,,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8200000000000001,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Nicholas Brousseau,Institut national de santé publique du Québec,Not Unity-Aligned,https://dx.doi.org/10.1503/cmaj.202783-f,2022-04-12,2024-03-01,Unverified,brousseau_seroprevalence_2022,CAN
220307_Quebec_InstitutnationaldesantépubliqueduQuébec_Age30-39,220307_Quebec_InstitutnationaldesantépubliqueduQuébec,"Séroprévalence du SRAS-CoV-2 chez les travailleurs de la santé de 10 hôpitaux du Québec, au Canada: étude transversale",2022-03-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"Healthcare workers from 10 acute care hospitals that accepted COVID-19 patients. Healthcare workers included physicians, nurses, auxiliary staff, administrative staff, maintenance staff.
At least 18 years of age.",,2020-07-06,2020-09-24,Health care workers and caregivers,All,Adults (18-64 years),30.0,39.0,Age,,643,0.1213,,,,,,,,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8200000000000001,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Nicholas Brousseau,Institut national de santé publique du Québec,Not Unity-Aligned,https://dx.doi.org/10.1503/cmaj.202783-f,2022-04-12,2024-03-01,Unverified,brousseau_seroprevalence_2022,CAN
220307_Quebec_InstitutnationaldesantépubliqueduQuébec_Age50-59,220307_Quebec_InstitutnationaldesantépubliqueduQuébec,"Séroprévalence du SRAS-CoV-2 chez les travailleurs de la santé de 10 hôpitaux du Québec, au Canada: étude transversale",2022-03-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"Healthcare workers from 10 acute care hospitals that accepted COVID-19 patients. Healthcare workers included physicians, nurses, auxiliary staff, administrative staff, maintenance staff.
At least 18 years of age.",,2020-07-06,2020-09-24,Health care workers and caregivers,All,Adults (18-64 years),50.0,59.0,Age,,356,0.1208,,,,,,,,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8200000000000001,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Nicholas Brousseau,Institut national de santé publique du Québec,Not Unity-Aligned,https://dx.doi.org/10.1503/cmaj.202783-f,2022-04-12,2024-03-01,Unverified,brousseau_seroprevalence_2022,CAN
220307_Quebec_InstitutnationaldesantépubliqueduQuébec_Age40-49,220307_Quebec_InstitutnationaldesantépubliqueduQuébec,"Séroprévalence du SRAS-CoV-2 chez les travailleurs de la santé de 10 hôpitaux du Québec, au Canada: étude transversale",2022-03-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"Healthcare workers from 10 acute care hospitals that accepted COVID-19 patients. Healthcare workers included physicians, nurses, auxiliary staff, administrative staff, maintenance staff.
At least 18 years of age.",,2020-07-06,2020-09-24,Health care workers and caregivers,All,Adults (18-64 years),40.0,49.0,Age,,547,0.128,,,,,,,,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8200000000000001,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Nicholas Brousseau,Institut national de santé publique du Québec,Not Unity-Aligned,https://dx.doi.org/10.1503/cmaj.202783-f,2022-04-12,2024-03-01,Unverified,brousseau_seroprevalence_2022,CAN
220307_Quebec_InstitutnationaldesantépubliqueduQuébec_Age18-29,220307_Quebec_InstitutnationaldesantépubliqueduQuébec,"Séroprévalence du SRAS-CoV-2 chez les travailleurs de la santé de 10 hôpitaux du Québec, au Canada: étude transversale",2022-03-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"Healthcare workers from 10 acute care hospitals that accepted COVID-19 patients. Healthcare workers included physicians, nurses, auxiliary staff, administrative staff, maintenance staff.
At least 18 years of age.",,2020-07-06,2020-09-24,Health care workers and caregivers,All,Adults (18-64 years),18.0,29.0,Age,18-29,427,0.096,,,,,,,,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8200000000000001,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Nicholas Brousseau,Institut national de santé publique du Québec,Not Unity-Aligned,https://dx.doi.org/10.1503/cmaj.202783-f,2022-04-12,2024-03-01,Unverified,brousseau_seroprevalence_2022,CAN
220311_Canada_CBS_BloodDonors_RocheS_Overall_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,32505,0.9889,0.9873000000000001,0.9906,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,1192,0.023489932890000002,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,400,0.0152,0.0,0.0345,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_Age_25-39_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8856,0.9755,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6741,0.1678,0.1572,0.1784,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_Sex_Male_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18593,0.9854,0.9828,0.9879000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1712,0.04439252336,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_Overall_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Test used,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay PopTest Adj,32505,0.12119999999999999,0.1176,0.12480000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_Overall_PopAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Analysis,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay Pop Adj,32505,0.1223,0.11880000000000002,0.1259,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,3024,0.9940000000000001,0.9895999999999999,0.9984000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,3199,0.212566427,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_Age_40-59_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11876,0.97499,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,440,0.08636363636000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,2280,0.1391,0.1222,0.156,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2501,0.9788100000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1328,0.98193,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,2280,0.9873999999999999,0.9798000000000001,0.995,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6741,0.9803000000000001,0.9753000000000001,0.9852,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,2001,0.98,0.9709000000000001,0.9890000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,3199,0.98124,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,1484,1.0,0.9995999999999999,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1328,0.1054216867,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1553,0.97682,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,440,0.9861,0.971,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_Age_60+_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9361,0.063,0.0579,0.068,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,3672,0.1642156863,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,13085,0.11417653800000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_Age_25-39_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8856,0.1542,0.1462,0.16219999999999998,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_Overall_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Analysis,,32505,0.9767,0.975,0.9784,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,400,0.9944,0.9748000000000001,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24932,0.10183699660000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1712,1.0,0.9940000000000001,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_Sex_Male_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18593,0.9740800000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,2001,0.9705100000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_Age_60+_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9361,0.9915,0.9884999999999999,0.9944,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,2001,0.1504247876,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5305,0.9883,0.9843000000000001,0.9923000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,13085,0.9908,0.9886,0.9931000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2501,0.1597,0.1412,0.1782,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,2001,0.16260000000000002,0.1436,0.1816,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_Age_17-24_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2412,0.9825900000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,1484,0.1212938005,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,516,0.99225,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_Age_40-59_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11876,0.9866,0.9837,0.9895,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1608,0.0761,0.060300000000000006,0.09179999999999999,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,1484,0.99124,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,1192,0.9790300000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,1484,0.12890000000000001,0.1125,0.1452,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5305,0.1182,0.1097,0.1266,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,1192,0.024300000000000002,0.0138,0.0347,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,516,1.0,0.993,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,3672,0.9978,0.9949,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_Age_60+_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9361,0.06163871381,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,440,0.08800000000000001,0.0611,0.115,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,516,0.021,0.009300000000000001,0.0326,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,3672,0.9844799999999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,516,0.02325581395,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,3672,0.16329999999999997,0.1542,0.1723,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,2280,0.1307017544,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,2280,0.97588,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1608,1.0,0.9994,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2501,0.9920000000000001,0.9849,0.9991,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_Age_60+_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9361,0.97863,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1712,0.9900700000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,400,0.015,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_Age_17-24_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2412,0.22014925370000002,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_Age_17-24_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2412,0.22219999999999998,0.2093,0.23510000000000003,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_Age_17-24_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2412,0.9945999999999999,0.9905,0.9987,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_Age_25-39_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8856,0.1489385727,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2501,0.15273890440000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1608,0.07835820896000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_Age_25-39_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8856,0.9865,0.983,0.99,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_Sex_Female_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13912,0.1131,0.1082,0.11789999999999999,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1553,0.1153,0.0975,0.133,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,440,0.97273,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,3024,0.14830000000000002,0.1365,0.16,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5305,0.97719,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_Sex_Male_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18593,0.1298,0.1245,0.1351,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24932,0.9765,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5305,0.11065032990000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,1192,0.9913,0.9819,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_Overall_PopAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Analysis,,32505,0.9772,0.9755,0.9788,,,True,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1553,0.9876,0.9791,0.9962000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6741,0.97063,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1553,0.1075338055,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,3024,0.144510582,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6741,0.15576323990000002,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1608,0.9944,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_Sex_Female_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13912,0.9803000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,3199,0.9947,0.9903000000000001,0.9990000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,3024,0.9808199999999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_Sex_Female_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13912,0.11048016100000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1712,0.038,0.026600000000000002,0.0495,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_Age_40-59_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11876,0.10895924550000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,3199,0.22030000000000002,0.2064,0.2341,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_Sex_Male_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18593,0.1174635616,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_Sex_Female_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13912,0.9923000000000001,0.9902,0.9944,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_Age_40-59_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11876,0.1091,0.1033,0.1149,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,400,0.9925,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1328,0.993,0.9838,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24932,0.9883,0.9864,0.9902,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1328,0.1079,0.087,0.1288,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24932,0.1073,0.1034,0.1112,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_PopTestAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,13085,0.1213,0.1162,0.1264,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2023-08-15,Verified,canadian_blood_services_covid-19_2022-4,CAN
220311_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_UnAdj,220311_Canada_CBS,"COVID-19 Seroprevalence Report March 11th, 2022 Report #18: January 2022 Survey The advance of Omicron",2022-03-11,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-01-01,2022-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,13085,0.97761,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-03-21,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-4,CAN
220323_BC_UniversityOfBritishColumbia_Spike,220323_BC_UniversityOfBritishColumbia,"Age-Associated Seroprevalence of Coronavirus Antibodies: Population-Based Serosurveys in 2013 and 2020, British Columbia, Canada",2022-03-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,British Columbia,,"""Remaining archived specimens were included in the study if at least 200 µL were available.""",,2020-03-15,2020-05-31,Residual sera,All,Multiple groups,0.0,99.0,Primary Estimate,Antibody target: Spike,488,0.0184,,,True,,,,True,Stratified probability,Meso Scale Discovery multiplex assay,Meso Scale Discovery,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,Yes,No,Yes,Unclear,Unclear,Yes,Yes,Unclear,Guadalein Tanunliong,University of British Columbia,Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2022.836449,2022-04-22,2023-06-22,Verified,tanunliong_age-associated_2022,CAN
220323_BC_UniversityOfBritishColumbia_Nucleocapsid,220323_BC_UniversityOfBritishColumbia,"Age-Associated Seroprevalence of Coronavirus Antibodies: Population-Based Serosurveys in 2013 and 2020, British Columbia, Canada",2022-03-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,British Columbia,,"""Remaining archived specimens were included in the study if at least 200 µL were available.""",,2020-03-15,2020-05-31,Residual sera,All,Multiple groups,0.0,99.0,Test used,Antibody target: Nucleocapsid,488,0.026600000000000002,,,,,,,,Stratified probability,Meso Scale Discovery multiplex assay,Meso Scale Discovery,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.988,['High'],No,Yes,No,Yes,Unclear,Unclear,Yes,Yes,Unclear,Guadalein Tanunliong,University of British Columbia,Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2022.836449,2022-04-22,2023-06-22,Verified,tanunliong_age-associated_2022,CAN
220323_BC_UniversityOfBritishColumbia_RBD,220323_BC_UniversityOfBritishColumbia,"Age-Associated Seroprevalence of Coronavirus Antibodies: Population-Based Serosurveys in 2013 and 2020, British Columbia, Canada",2022-03-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,British Columbia,,"""Remaining archived specimens were included in the study if at least 200 µL were available.""",,2020-03-15,2020-05-31,Residual sera,All,Multiple groups,0.0,99.0,Test used,Antibody target: RBD,488,0.1865,,,,,,,,Stratified probability,Meso Scale Discovery multiplex assay,Meso Scale Discovery,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,1.0,0.9420000000000001,['High'],No,Yes,No,Yes,Unclear,Unclear,Yes,Yes,Unclear,Guadalein Tanunliong,University of British Columbia,Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2022.836449,2022-04-22,2023-06-22,Verified,tanunliong_age-associated_2022,CAN
220323_BC_UniversityOfBritishColumbia_DualPositivity,220323_BC_UniversityOfBritishColumbia,"Age-Associated Seroprevalence of Coronavirus Antibodies: Population-Based Serosurveys in 2013 and 2020, British Columbia, Canada",2022-03-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,British Columbia,,"""Remaining archived specimens were included in the study if at least 200 µL were available.""",,2020-03-15,2020-05-31,Residual sera,All,Multiple groups,0.0,99.0,Test used,"Antibody target: Positive for at least two of three SARS-CoV-2 targets (S1 RBD and/or nucleocapsid, and/or spike)",488,0.016399999999999998,,,,,,,,Stratified probability,Meso Scale Discovery multiplex assay,Meso Scale Discovery,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.988,['High'],No,Yes,No,Yes,Unclear,Unclear,Yes,Yes,Unclear,Guadalein Tanunliong,University of British Columbia,Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2022.836449,2022-04-22,2023-06-22,Verified,tanunliong_age-associated_2022,CAN
220401_Ontario_McMasterUniversity_Overall_Pop_Adj,220401_Ontario_McMasterUniversity,What factors converged to create a COVID-19 hot-spot? Lessons from the South Asian community in Ontario,2022-04-01,Preprint,Regional,Cross-sectional survey ,Canada,Ontario,,"Adults ≥ 18 years of age and South Asian were eligible. South Asian ethnicity was self-reported and defined by parental South Asian ancestry from the Indian subcontinent, Africa, Caribbean, and Guyana.",,2021-04-14,2021-07-28,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,"Overall, population adjusted",916,0.231,0.22899999999999998,0.23399999999999999,True,,True,,True,Convenience,Author Designed (ELISA) - Spike and Nucleocapsid,,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sonia Anand,McMaster University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.04.01.22273252v1.full-text,2022-04-25,2022-07-16,Unverified,anand_what_2022,CAN
220401_Ontario_McMasterUniversity_Male_Pop_Adj,220401_Ontario_McMasterUniversity,What factors converged to create a COVID-19 hot-spot? Lessons from the South Asian community in Ontario,2022-04-01,Preprint,Regional,Cross-sectional survey ,Canada,Ontario,,"Adults ≥ 18 years of age and South Asian were eligible. South Asian ethnicity was self-reported and defined by parental South Asian ancestry from the Indian subcontinent, Africa, Caribbean, and Guyana.",,2021-04-14,2021-07-28,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,male,462,0.249,0.245,0.253,,,True,,,Convenience,Author Designed (ELISA) - Spike and Nucleocapsid,,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sonia Anand,McMaster University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.04.01.22273252v1.full-text,2022-04-25,2022-07-16,Unverified,anand_what_2022,CAN
220401_Ontario_McMasterUniversity_Vaccinated_Antii-N_Pop_Adj,220401_Ontario_McMasterUniversity,What factors converged to create a COVID-19 hot-spot? Lessons from the South Asian community in Ontario,2022-04-01,Preprint,Regional,Cross-sectional survey ,Canada,Ontario,,"Adults ≥ 18 years of age and South Asian were eligible. South Asian ethnicity was self-reported and defined by parental South Asian ancestry from the Indian subcontinent, Africa, Caribbean, and Guyana.",,2021-04-14,2021-07-28,Household and community samples,All,Multiple groups,18.0,,COVID-19 vaccination status,,458,0.23399999999999999,0.23,0.237,,,True,,,Convenience,Author Designed (ELISA) - Spike and Nucleocapsid,,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sonia Anand,McMaster University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.04.01.22273252v1.full-text,2022-04-25,2022-07-16,Unverified,anand_what_2022,CAN
220401_Ontario_McMasterUniversity_Age_25-34_Pop_Adj,220401_Ontario_McMasterUniversity,What factors converged to create a COVID-19 hot-spot? Lessons from the South Asian community in Ontario,2022-04-01,Preprint,Regional,Cross-sectional survey ,Canada,Ontario,,"Adults ≥ 18 years of age and South Asian were eligible. South Asian ethnicity was self-reported and defined by parental South Asian ancestry from the Indian subcontinent, Africa, Caribbean, and Guyana.",,2021-04-14,2021-07-28,Household and community samples,All,Adults (18-64 years),25.0,34.0,Age,25-34,233,0.21,0.20500000000000002,0.21600000000000003,,,True,,,Convenience,Author Designed (ELISA) - Spike and Nucleocapsid,,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sonia Anand,McMaster University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.04.01.22273252v1.full-text,2022-04-25,2022-07-16,Unverified,anand_what_2022,CAN
220401_Ontario_McMasterUniversity_Caledon_Pop_Adj,220401_Ontario_McMasterUniversity,What factors converged to create a COVID-19 hot-spot? Lessons from the South Asian community in Ontario,2022-04-01,Preprint,Local,Cross-sectional survey ,Canada,Ontario,Caledron,"Adults ≥ 18 years of age and South Asian were eligible. South Asian ethnicity was self-reported and defined by parental South Asian ancestry from the Indian subcontinent, Africa, Caribbean, and Guyana.",,2021-04-14,2021-07-28,Household and community samples,All,Multiple groups,18.0,,Geographical area,Celdon,39,0.179,0.167,0.192,,,True,,,Convenience,Author Designed (ELISA) - Spike and Nucleocapsid,,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sonia Anand,McMaster University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.04.01.22273252v1.full-text,2022-04-25,2022-07-16,Unverified,anand_what_2022,CAN
220401_Ontario_McMasterUniversity_Brampton_Pop_Adj,220401_Ontario_McMasterUniversity,What factors converged to create a COVID-19 hot-spot? Lessons from the South Asian community in Ontario,2022-04-01,Preprint,Local,Cross-sectional survey ,Canada,Ontario,Brampton,"Adults ≥ 18 years of age and South Asian were eligible. South Asian ethnicity was self-reported and defined by parental South Asian ancestry from the Indian subcontinent, Africa, Caribbean, and Guyana.",,2021-04-14,2021-07-28,Household and community samples,All,Multiple groups,18.0,,Geographical area,Brampton,742,0.24,0.237,0.24300000000000002,,,True,,,Convenience,Author Designed (ELISA) - Spike and Nucleocapsid,,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sonia Anand,McMaster University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.04.01.22273252v1.full-text,2022-04-25,2022-07-16,Unverified,anand_what_2022,CAN
220401_Ontario_McMasterUniversity_Mississauga_Pop_Adj,220401_Ontario_McMasterUniversity,What factors converged to create a COVID-19 hot-spot? Lessons from the South Asian community in Ontario,2022-04-01,Preprint,Local,Cross-sectional survey ,Canada,Ontario,Mississauga,"Adults ≥ 18 years of age and South Asian were eligible. South Asian ethnicity was self-reported and defined by parental South Asian ancestry from the Indian subcontinent, Africa, Caribbean, and Guyana.",,2021-04-14,2021-07-28,Household and community samples,All,Multiple groups,18.0,,Geographical area,Mississauga,49,0.184,0.17300000000000001,0.195,,,True,,,Convenience,Author Designed (ELISA) - Spike and Nucleocapsid,,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sonia Anand,McMaster University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.04.01.22273252v1.full-text,2022-04-25,2022-07-16,Unverified,anand_what_2022,CAN
220401_Ontario_McMasterUniversity_Age_65+_Pop_Adj,220401_Ontario_McMasterUniversity,What factors converged to create a COVID-19 hot-spot? Lessons from the South Asian community in Ontario,2022-04-01,Preprint,Regional,Cross-sectional survey ,Canada,Ontario,,"Adults ≥ 18 years of age and South Asian were eligible. South Asian ethnicity was self-reported and defined by parental South Asian ancestry from the Indian subcontinent, Africa, Caribbean, and Guyana.",,2021-04-14,2021-07-28,Household and community samples,All,Seniors (65+ years),65.0,,Age,65+,80,0.275,0.265,0.28500000000000003,,,True,,,Convenience,Author Designed (ELISA) - Spike and Nucleocapsid,,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sonia Anand,McMaster University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.04.01.22273252v1.full-text,2022-04-25,2022-07-16,Unverified,anand_what_2022,CAN
220401_Ontario_McMasterUniversity_Age_35-44_Pop_Adj,220401_Ontario_McMasterUniversity,What factors converged to create a COVID-19 hot-spot? Lessons from the South Asian community in Ontario,2022-04-01,Preprint,Regional,Cross-sectional survey ,Canada,Ontario,,"Adults ≥ 18 years of age and South Asian were eligible. South Asian ethnicity was self-reported and defined by parental South Asian ancestry from the Indian subcontinent, Africa, Caribbean, and Guyana.",,2021-04-14,2021-07-28,Household and community samples,All,Adults (18-64 years),35.0,44.0,Age,35-44,247,0.219,0.21300000000000002,0.22399999999999998,,,True,,,Convenience,Author Designed (ELISA) - Spike and Nucleocapsid,,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sonia Anand,McMaster University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.04.01.22273252v1.full-text,2022-04-25,2022-07-16,Unverified,anand_what_2022,CAN
220401_Ontario_McMasterUniversity_Peel_Pop_Adj,220401_Ontario_McMasterUniversity,What factors converged to create a COVID-19 hot-spot? Lessons from the South Asian community in Ontario,2022-04-01,Preprint,Local,Cross-sectional survey ,Canada,Ontario,,"Adults ≥ 18 years of age and South Asian were eligible. South Asian ethnicity was self-reported and defined by parental South Asian ancestry from the Indian subcontinent, Africa, Caribbean, and Guyana.",,2021-04-14,2021-07-28,Household and community samples,All,Multiple groups,18.0,,Geographical area,Peel region,830,0.23399999999999999,0.231,0.237,,,True,,,Convenience,Author Designed (ELISA) - Spike and Nucleocapsid,,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sonia Anand,McMaster University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.04.01.22273252v1.full-text,2022-04-25,2022-07-16,Unverified,anand_what_2022,CAN
220401_Ontario_McMasterUniversity_Female_Pop_Adj,220401_Ontario_McMasterUniversity,What factors converged to create a COVID-19 hot-spot? Lessons from the South Asian community in Ontario,2022-04-01,Preprint,Regional,Cross-sectional survey ,Canada,Ontario,,"Adults ≥ 18 years of age and South Asian were eligible. South Asian ethnicity was self-reported and defined by parental South Asian ancestry from the Indian subcontinent, Africa, Caribbean, and Guyana.",,2021-04-14,2021-07-28,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,female,451,0.21300000000000002,0.209,0.217,,,True,,,Convenience,Author Designed (ELISA) - Spike and Nucleocapsid,,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sonia Anand,McMaster University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.04.01.22273252v1.full-text,2022-04-25,2022-07-16,Unverified,anand_what_2022,CAN
220401_Ontario_McMasterUniversity_Age_18-24_Pop_Adj,220401_Ontario_McMasterUniversity,What factors converged to create a COVID-19 hot-spot? Lessons from the South Asian community in Ontario,2022-04-01,Preprint,Regional,Cross-sectional survey ,Canada,Ontario,,"Adults ≥ 18 years of age and South Asian were eligible. South Asian ethnicity was self-reported and defined by parental South Asian ancestry from the Indian subcontinent, Africa, Caribbean, and Guyana.",,2021-04-14,2021-07-28,Household and community samples,All,Adults (18-64 years),18.0,24.0,Age,18-24,95,0.23199999999999998,0.223,0.24,,,True,,,Convenience,Author Designed (ELISA) - Spike and Nucleocapsid,,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sonia Anand,McMaster University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.04.01.22273252v1.full-text,2022-04-25,2022-07-16,Unverified,anand_what_2022,CAN
220401_Ontario_McMasterUniversity_Age_45-54_Pop_Adj,220401_Ontario_McMasterUniversity,What factors converged to create a COVID-19 hot-spot? Lessons from the South Asian community in Ontario,2022-04-01,Preprint,Regional,Cross-sectional survey ,Canada,Ontario,,"Adults ≥ 18 years of age and South Asian were eligible. South Asian ethnicity was self-reported and defined by parental South Asian ancestry from the Indian subcontinent, Africa, Caribbean, and Guyana.",,2021-04-14,2021-07-28,Household and community samples,All,Adults (18-64 years),45.0,54.0,Age,45-54,157,0.22899999999999998,0.223,0.23600000000000002,,,True,,,Convenience,Author Designed (ELISA) - Spike and Nucleocapsid,,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sonia Anand,McMaster University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.04.01.22273252v1.full-text,2022-04-25,2022-07-16,Unverified,anand_what_2022,CAN
220401_Ontario_McMasterUniversity_Age_55-64_Pop_Adj,220401_Ontario_McMasterUniversity,What factors converged to create a COVID-19 hot-spot? Lessons from the South Asian community in Ontario,2022-04-01,Preprint,Regional,Cross-sectional survey ,Canada,Ontario,,"Adults ≥ 18 years of age and South Asian were eligible. South Asian ethnicity was self-reported and defined by parental South Asian ancestry from the Indian subcontinent, Africa, Caribbean, and Guyana.",,2021-04-14,2021-07-28,Household and community samples,All,Adults (18-64 years),55.0,64.0,Age,55-64,94,0.298,0.289,0.307,,,True,,,Convenience,Author Designed (ELISA) - Spike and Nucleocapsid,,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sonia Anand,McMaster University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.04.01.22273252v1.full-text,2022-04-25,2022-07-16,Unverified,anand_what_2022,CAN
220401_Ontario_McMasterUniversity_UnVaccinated_Pop_Adj,220401_Ontario_McMasterUniversity,What factors converged to create a COVID-19 hot-spot? Lessons from the South Asian community in Ontario,2022-04-01,Preprint,Regional,Cross-sectional survey ,Canada,Ontario,,"Adults ≥ 18 years of age and South Asian were eligible. South Asian ethnicity was self-reported and defined by parental South Asian ancestry from the Indian subcontinent, Africa, Caribbean, and Guyana.",,2021-04-14,2021-07-28,Household and community samples,All,Multiple groups,18.0,,COVID-19 vaccination status,,458,0.22899999999999998,0.225,0.233,,,True,,,Convenience,Author Designed (ELISA) - Spike and Nucleocapsid,,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sonia Anand,McMaster University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.04.01.22273252v1.full-text,2022-04-25,2022-07-16,Unverified,anand_what_2022,CAN
220504_Vancouver_UniversityOfBritishColumbia_BloodDonors2,220504_Vancouver_UniversityOfBritishColumbia_BloodDonors2,"SARS-CoV-2 seroprevalence among Vancouver public school staff in British Columbia, Canada: a cross-sectional study.",2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,British Columbia,Vancouver,,"People were ineligible to donate blood if they had a recent COVID-19 infection 2 weeks after symptoms resolved, or were hospitalised within 3 weeks before. ",2021-01-01,2021-05-31,Blood donors,All,Adults (18-64 years),,,Primary Estimate,,5417,0.026000000000000002,0.022000000000000002,0.031000000000000003,True,True,True,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.988,0.996,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,David Goldfarb,University of British Colombia,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-057846,2022-05-01,2023-08-15,Verified,goldfarb_sars-cov-2_2022,CAN
220504_Vancouver_UniversityOfBritishColumbia_SchoolStaff1_PopAdj,220504_Vancouver_UniversityOfBritishColumbia_SchoolStaff1,"SARS-CoV-2 seroprevalence among Vancouver public school staff in British Columbia, Canada: a cross-sectional study.",2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,British Columbia,Vancouver,"Staff were included if they were a current, full or part-time staff member (confirmed by District email address).","Staff who reported being temporary staff, on-leave or on-call with no classroom time, or working exclusively in an adult education setting were ineligible",2021-02-10,2021-05-15,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,Pop Adj,1556,0.026000000000000002,0.019,0.036000000000000004,True,,True,,True,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,No,David Goldfarb,University of British Colombia,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-057846,2022-05-01,2024-03-01,Verified,goldfarb_sars-cov-2_2022,CAN
220405_Quebec_HemaQuebec_Race_American Indian_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Race,American Indian,15,0.0181,0.0,0.10890000000000001,,,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Sex_Male_UnAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,Male,Multiple groups,18.0,,Sex/Gender,,4248,0.1259416196,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Sex_Female_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,Female,Multiple groups,18.0,,Sex/Gender,,3676,0.16940000000000002,0.1558,0.18300000000000002,,,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Other regions_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,Other Quebec regions ,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Other regions,4777,0.1431,0.1303,0.156,,,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Abitibi-Témiscamingue_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,Abitibi-Témiscamingue,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Abitibi-Témiscamingue,394,0.239,0.15990000000000001,0.3182,,,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Saguenay,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,Saguenay–Lac-Saint-Jean,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Saguenay–Lac-Saint-Jean,406,0.10591133,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Montréal-Laval_UnAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,Montréal-Laval,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Montréal-Laval,1657,0.1713940857,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Lanaudière_UnAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,Lanaudière,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Lanaudière,501,0.1357285429,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Age_25-39_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39,1793,0.167,0.1478,0.1862,,,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Race_Asian_UnAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Race,Asian,89,0.1797752809,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Abitibi-Témiscamingue_UnAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,Abitibi-Témiscamingue,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Abitibi-Témiscamingue,394,0.2893401015,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Outaouais_UnAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,Outaouais,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Outaouais,461,0.1193058568,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Sex_Female_UnAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,Female,Multiple groups,18.0,,Sex/Gender,,3676,0.1784548422,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Montréal-Laval_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,Montréal-Laval,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Montréal-Laval,1657,0.1705,0.1529,0.1881,,,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Mauricie et Centre-du-Québec_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,Mauricie et Centre-du-Québec,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Mauricie et Centre-du-Québec,450,0.1582,0.1081,0.2084,,,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Race_Indian_UnAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Race,Indian,16,0.125,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Sex_Male_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,Male,Multiple groups,18.0,,Sex/Gender,,4248,0.1247,0.1126,0.1368,,,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Capitale-Nationale_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,Capitale-Nationale,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Capitale-Nationale,425,0.1323,0.1039,0.1607,,,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Outaouais_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,Outaouais,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Outaouais,461,0.1302,0.0913,0.16920000000000002,,,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Race_White_UnAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Race,White,7343,0.14517227289999998,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Estrie_UnAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,Estrie,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Estrie,524,0.1011450382,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Age_40-59_UnAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59,2713,0.1374861777,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Age_70+_UnAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Seniors (65+ years),70.0,,Age,70+,587,0.1550255537,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Capitale-Nationale_UnAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,Capitale-Nationale,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Capitale-Nationale,425,0.1317647059,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Race_Hispanic_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Ethnicity,Hispanic,110,0.2231,0.1487,0.2974,,,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Surrounding Montréal-Laval urban areas_UnAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Surrounding Montréal-Laval urban areas,1490,0.1234899329,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Age_60-69_UnAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,60.0,69.0,Age,60-69,1911,0.1177394035,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Unvaccinated_UnAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,COVID-19 vaccination status,Unvaccinated,7304,0.09789156627000001,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Race_Other_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Race,Other,110,0.171,0.09480000000000001,0.2472,,,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Laval_UnAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,Laval,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Laval,394,0.17512690360000002,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Race_Arab_UnAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Race,Arab,146,0.20547945210000002,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Laurentides_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,Laurentides,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Laurentides,593,0.1354,0.1032,0.16760000000000003,,,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Race_Black_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Race,Black,91,0.36590000000000006,0.2695,0.46240000000000003,,,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Bas-Saint-Laurent_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,Bas-Saint-Laurent,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Bas-Saint-Laurent,532,0.1043,0.0562,0.1525,,,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Bas-Saint-Laurent_UnAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,Bas-Saint-Laurent,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Bas-Saint-Laurent,532,0.09774436090000001,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Laval_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,Laval,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Laval,394,0.18539999999999998,0.1416,0.22920000000000001,,,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Saguenay–Lac-Saint-Jean_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,Saguenay–Lac-Saint-Jean,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Saguenay–Lac-Saint-Jean,406,0.1399,0.09330000000000001,0.1864,,,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Race_American Indian_UnAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Race,American Indian,15,0.06666666667,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Montréal_UnAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,Montréal,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Montréal,1263,0.170229612,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Age_18-24_UnAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Adults (18-64 years),18.0,24.0,Age,18-24,920,0.2043478261,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Age_18-24_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Adults (18-64 years),18.0,24.0,Age,18-24,920,0.19,0.165,0.2151,,,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Race_Black_UnAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Race,Black,91,0.3516483516,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Overall_UnAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Analysis,,7924,0.1503,,,,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Race_Other_UnAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Race,Other,110,0.1909090909,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Race_White_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Race,White,7343,0.1391,0.1297,0.1485,,,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Chaudière-Appalaches_UnAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,Chaudière-Appalaches,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Chaudière-Appalaches,464,0.1465517241,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Other regions_UnAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,Other Quebec regions ,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Other regions,4777,0.1513502198,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Montérégie_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,Montérégie,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Montérégie,1117,0.12789999999999999,0.10830000000000001,0.1476,,,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Race_Hispanic_UnAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Ethnicity,Hispanic,110,0.2,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Overall_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Primary Estimate,Population adjustment (weighting),7924,0.1472,0.1381,0.15630000000000002,,True,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Gaspésie–Îles-de-la-Madeleine_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,Gaspésie–Îles-de-la-Madeleine,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Gaspésie–Îles-de-la-Madeleine,398,0.2776,0.1752,0.38,,,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Age_60-69_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,60.0,69.0,Age,60-69,1911,0.09789999999999999,0.0793,0.1164,,,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Age_40-59_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59,2713,0.1436,0.12890000000000001,0.1583,,,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Montérégie_UnAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,Montérégie,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Montérégie,1117,0.1190689346,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Estrie_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,Estrie,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Estrie,524,0.096,0.058499999999999996,0.1334,,,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Gaspésie,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,Gaspésie–Îles-de-la-Madeleine,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Gaspésie–Îles-de-la-Madeleine,398,0.29899497490000004,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Côte-Nord_UnAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,Côte-Nord,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Côte-Nord,2,0.0,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Unvaccinated_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,COVID-19 vaccination status,Unvaccinated,7304,0.1052,0.0971,0.1133,,,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Age_70+_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Seniors (65+ years),70.0,,Age,70+,587,0.0947,0.0576,0.1317,,,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Race_Arab_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Race,Arab,146,0.2243,0.1574,0.2912,,,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Côte-Nord_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,Côte-Nord,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Côte-Nord,2,0.0,0.0,0.0,,,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Surrounding Montréal-Laval urban areas_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Surrounding Montréal-Laval urban areas,1490,0.1234,0.10490000000000001,0.1419,,,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Age_25-39_UnAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39,1793,0.17512548800000002,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Chaudière-Appalaches_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,Chaudière-Appalaches,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Chaudière-Appalaches,464,0.156,0.1158,0.1961,,,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Race_Indian_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Race,Indian,16,0.114,0.0,0.26,,,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Laurentides_UnAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,Laurentides,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Laurentides,593,0.1349072513,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Lanaudière_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,Lanaudière,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Lanaudière,501,0.1373,0.102,0.17260000000000003,,,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Montréal_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,Montréal,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Montréal,1263,0.1674,0.1481,0.18660000000000002,,,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Race_Asian_PopAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Race,Asian,89,0.1536,0.0815,0.2256,,,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220405_Quebec_HemaQuebec_Region_Mauricie et Centre-du-Québec_UnAdj,220405_Quebec_HemaQuebec,Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Quebec,Mauricie et Centre-du-Québec,"regular blood donors were included if they met the following criteria: (1) donated blood between January 25, 2021 and March 11, 2021—a pe- riod characterized by the vaccination of priority groups, in- cluding older persons and health care workers; (2) resided in Québec; (3) were free of COVID-19 symptoms in the preced- ing 14 days; and (4) met standard blood donation criteria.",symptomatic donors were excluded from this study,2021-01-25,2021-03-11,Blood donors,All,Multiple groups,18.0,,Geographical area,Mauricie et Centre-du-Québec,450,0.1466666667,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9890000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Antoine Lewin,Hema Quebec,Unity-Aligned,https://dx.doi.org/10.17269/s41997-022-00622-y,2022-05-05,2022-07-16,Verified,lewin_seroprevalence_2022,CAN
220410_Canada_CBS_BloodDonors_RocheS_Overall_PopTestAdj,220410_Canada_CBS,"COVID-19 Seroprevalence Report April 10th, 2022 Report #19: February 2022 Survey The advance of Omicron",2022-04-10,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-02-01,2022-02-28,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,28616,0.996,0.9945,0.9975,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-05-24,2023-08-15,Verified,canadian_blood_services_covid-19_2022-7,CAN
20220420_Canada_StatisticsCanada_OverallUnadj,20220420_Canada_StatisticsCanada,COVID-19 infection in the Canadian household population.,2022-04-20,Institutional Report,National,Cross-sectional survey ,Canada,10 provinces and 3 territories,,"The Canadian COVID-19 Antibody and Health Survey (CCAHS) is cross-sectional. It used a direct sampling frame for people aged 1 to 24 years and a multi-stage sampling frame for those aged 25 or older to select a sample of 47,900 people living in private households across the 10 provinces and the three territorial capitals. ","The present analysis excluded 206 respondents who were seropositive for vaccination or who reported being vaccinated. The final analytical sample included 10,820 respondents of",2020-11-15,2021-04-15,Household and community samples,All,Multiple groups,1.0,,Primary Estimate,,10820,0.019,,,True,,,,True,Stratified probability,Author designed (ELISA) -Unknown,,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Tracey Bushnik,Statistics Canada,Not Unity-Aligned,https://dx.doi.org/10.25318/82-003-x202200400003-eng,2022-04-26,2022-07-16,Unverified,bushnik_covid-19_2022,CAN
20220420_Canada_StatisticsCanada_Male,20220420_Canada_StatisticsCanada,COVID-19 infection in the Canadian household population.,2022-04-20,Institutional Report,National,Cross-sectional survey ,Canada,10 provinces and 3 territories,,"The Canadian COVID-19 Antibody and Health Survey (CCAHS) is cross-sectional. It used a direct sampling frame for people aged 1 to 24 years and a multi-stage sampling frame for those aged 25 or older to select a sample of 47,900 people living in private households across the 10 provinces and the three territorial capitals. ","The present analysis excluded 206 respondents who were seropositive for vaccination or who reported being vaccinated. The final analytical sample included 10,820 respondents of",2020-11-15,2021-04-15,Household and community samples,Male,Multiple groups,1.0,,Sex/Gender,,4810,0.028999999999999998,0.022000000000000002,0.037000000000000005,,,True,,,Stratified probability,Author designed (ELISA) -Unknown,,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Tracey Bushnik,Statistics Canada,Not Unity-Aligned,https://dx.doi.org/10.25318/82-003-x202200400003-eng,2022-04-26,2022-07-16,Unverified,bushnik_covid-19_2022,CAN
20220420_Canada_StatisticsCanada_AgeOver60,20220420_Canada_StatisticsCanada,COVID-19 infection in the Canadian household population.,2022-04-20,Institutional Report,National,Cross-sectional survey ,Canada,10 provinces and 3 territories,,"The Canadian COVID-19 Antibody and Health Survey (CCAHS) is cross-sectional. It used a direct sampling frame for people aged 1 to 24 years and a multi-stage sampling frame for those aged 25 or older to select a sample of 47,900 people living in private households across the 10 provinces and the three territorial capitals. ","The present analysis excluded 206 respondents who were seropositive for vaccination or who reported being vaccinated. The final analytical sample included 10,820 respondents of",2020-11-15,2021-04-15,Household and community samples,All,Seniors (65+ years),60.0,,Age,age: >= 60,3200,0.013999999999999999,0.009000000000000001,0.022000000000000002,,,True,,,Stratified probability,Author designed (ELISA) -Unknown,,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Tracey Bushnik,Statistics Canada,Not Unity-Aligned,https://dx.doi.org/10.25318/82-003-x202200400003-eng,2022-04-26,2022-07-16,Unverified,bushnik_covid-19_2022,CAN
20220420_Canada_StatisticsCanada_Age20to59,20220420_Canada_StatisticsCanada,COVID-19 infection in the Canadian household population.,2022-04-20,Institutional Report,National,Cross-sectional survey ,Canada,10 provinces and 3 territories,,"The Canadian COVID-19 Antibody and Health Survey (CCAHS) is cross-sectional. It used a direct sampling frame for people aged 1 to 24 years and a multi-stage sampling frame for those aged 25 or older to select a sample of 47,900 people living in private households across the 10 provinces and the three territorial capitals. ","The present analysis excluded 206 respondents who were seropositive for vaccination or who reported being vaccinated. The final analytical sample included 10,820 respondents of",2020-11-15,2021-04-15,Household and community samples,All,Adults (18-64 years),20.0,59.0,Age,age: 20 to 59,5615,0.028999999999999998,0.022000000000000002,0.039,,,True,,,Stratified probability,Author designed (ELISA) -Unknown,,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Tracey Bushnik,Statistics Canada,Not Unity-Aligned,https://dx.doi.org/10.25318/82-003-x202200400003-eng,2022-04-26,2022-07-16,Unverified,bushnik_covid-19_2022,CAN
20220420_Canada_StatisticsCanada_Age1to19,20220420_Canada_StatisticsCanada,COVID-19 infection in the Canadian household population.,2022-04-20,Institutional Report,National,Cross-sectional survey ,Canada,10 provinces and 3 territories,,"The Canadian COVID-19 Antibody and Health Survey (CCAHS) is cross-sectional. It used a direct sampling frame for people aged 1 to 24 years and a multi-stage sampling frame for those aged 25 or older to select a sample of 47,900 people living in private households across the 10 provinces and the three territorial capitals. ","The present analysis excluded 206 respondents who were seropositive for vaccination or who reported being vaccinated. The final analytical sample included 10,820 respondents of",2020-11-15,2021-04-15,Household and community samples,All,Children and Youth (0-17 years),1.0,19.0,Age,age: 1 to 19,2005,0.033,0.024,0.046,,,True,,,Simplified probability,Author designed (ELISA) -Unknown,,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Tracey Bushnik,Statistics Canada,Not Unity-Aligned,https://dx.doi.org/10.25318/82-003-x202200400003-eng,2022-04-26,2022-07-16,Unverified,bushnik_covid-19_2022,CAN
20220420_Canada_StatisticsCanada_Female,20220420_Canada_StatisticsCanada,COVID-19 infection in the Canadian household population.,2022-04-20,Institutional Report,National,Cross-sectional survey ,Canada,10 provinces and 3 territories,,"The Canadian COVID-19 Antibody and Health Survey (CCAHS) is cross-sectional. It used a direct sampling frame for people aged 1 to 24 years and a multi-stage sampling frame for those aged 25 or older to select a sample of 47,900 people living in private households across the 10 provinces and the three territorial capitals. ","The present analysis excluded 206 respondents who were seropositive for vaccination or who reported being vaccinated. The final analytical sample included 10,820 respondents of",2020-11-15,2021-04-15,Household and community samples,Female,Multiple groups,1.0,,Sex/Gender,,5975,0.024,0.018000000000000002,0.033,,,True,,,Stratified probability,Author designed (ELISA) -Unknown,,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Tracey Bushnik,Statistics Canada,Not Unity-Aligned,https://dx.doi.org/10.25318/82-003-x202200400003-eng,2022-04-26,2022-07-16,Unverified,bushnik_covid-19_2022,CAN
220501_Ottawa_OttawaHospitalResearchInstitute,220501_Ottawa_OttawaHospitalResearchInstitute,"Universal SARS-CoV-2 Testing Among Obstetrical Patients (UNIVERSE-OB) in Ottawa, Canada",2022-05-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Ontario,Ottawa,"""From October 19th to November 27th, 2020, pregnant individuals admitted to triage assessment units at The Ottawa Hospital (TOH) were consented for SARS-CoV-2 testing.""",,2020-10-19,2020-11-27,Pregnant or parturient women,All,Adults (18-64 years),,,Primary Estimate,,353,0.045,,,True,,,,True,Sequential,Not reported/ Unable to specify,,,,IgG,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Kameela Alibhai,Ottawa Hospital Research Institute,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jogc.2022.02.017,2022-09-07,2022-09-23,Unverified,alibhaiUniversalSARSCoV2Testing2022,CAN
220506_Canada_CBS_BloodDonors_RocheS_Overall_PopTestAdj,220506_Canada_CBS,"COVID-19 Seroprevalence Report May 6th, 2022 Report #20: March 2022 Survey The advance of Omicron",2022-05-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-03-01,2022-03-31,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,26026,0.9956999999999999,0.9942000000000001,0.9973000000000001,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-05-24,2023-08-15,Verified,canadian_blood_services_covid-19_2022-8,CAN
220517_Canada_CBS_BloodDonors_RocheS_Overall_Unadj,220517_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #21A: April 1-15, 2022, Survey",2022-05-17,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-15,Blood donors,All,Multiple groups,17.0,,Primary Estimate,Roche S overall,14341,0.998,0.996,0.9999,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Service,Canadian Blood Services ,Unity-Aligned,,2022-05-24,2024-03-01,Verified,canadian_blood_services_covid-19_2022-9,CAN
220517_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_UnAdj,220517_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #21A: April 1-15, 2022, Survey",2022-05-17,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,443,0.34537246050000003,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Service,Canadian Blood Services ,Unity-Aligned,,2022-05-24,2024-03-01,Verified,canadian_blood_services_covid-19_2022-9,CAN
220517_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_UnAdj,220517_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #21A: April 1-15, 2022, Survey",2022-05-17,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-15,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,176,0.39772727269999997,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Service,Canadian Blood Services ,Unity-Aligned,,2022-05-24,2024-03-01,Verified,canadian_blood_services_covid-19_2022-9,CAN
220517_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_UnAdj,220517_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #21A: April 1-15, 2022, Survey",2022-05-17,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,6699,0.3209434244,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Service,Canadian Blood Services ,Unity-Aligned,,2022-05-24,2024-03-01,Verified,canadian_blood_services_covid-19_2022-9,CAN
220517_Canada_CBS_BloodDonors_RocheN_Sex_Female_UnAdj,220517_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #21A: April 1-15, 2022, Survey",2022-05-17,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-15,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,5963,0.33338923360000006,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Service,Canadian Blood Services ,Unity-Aligned,,2022-05-24,2024-03-01,Verified,canadian_blood_services_covid-19_2022-9,CAN
220517_Canada_CBS_BloodDonors_RocheN_Overall_Apr8-15_Unadj,220517_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #21A: April 1-15, 2022, Survey",2022-05-17,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-08,2022-04-15,Blood donors,All,Multiple groups,17.0,,Test used,Apr 8-15,7908,0.3528,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Service,Canadian Blood Services ,Unity-Aligned,,2022-06-03,2024-03-01,Verified,canadian_blood_services_covid-19_2022-9,CAN
220517_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_UnAdj,220517_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #21A: April 1-15, 2022, Survey",2022-05-17,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-15,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,2308,0.32668977470000005,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Service,Canadian Blood Services ,Unity-Aligned,,2022-05-24,2024-03-01,Verified,canadian_blood_services_covid-19_2022-9,CAN
220517_Canada_CBS_BloodDonors_RocheN_Age_40-59_UnAdj,220517_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #21A: April 1-15, 2022, Survey",2022-05-17,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-15,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,5324,0.3480465815,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Service,Canadian Blood Services ,Unity-Aligned,,2022-05-24,2024-03-01,Verified,canadian_blood_services_covid-19_2022-9,CAN
220517_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_UnAdj,220517_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #21A: April 1-15, 2022, Survey",2022-05-17,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-15,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,10776,0.32191907940000003,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Service,Canadian Blood Services ,Unity-Aligned,,2022-05-24,2024-03-01,Verified,canadian_blood_services_covid-19_2022-9,CAN
220517_Canada_CBS_BloodDonors_RocheN_Age_25-39_UnAdj,220517_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #21A: April 1-15, 2022, Survey",2022-05-17,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-15,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,3832,0.4368475992,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Service,Canadian Blood Services ,Unity-Aligned,,2022-05-24,2024-03-01,Verified,canadian_blood_services_covid-19_2022-9,CAN
220517_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_UnAdj,220517_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #21A: April 1-15, 2022, Survey",2022-05-17,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-15,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,778,0.3277634961,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Service,Canadian Blood Services ,Unity-Aligned,,2022-05-24,2024-03-01,Verified,canadian_blood_services_covid-19_2022-9,CAN
220517_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_UnAdj,220517_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #21A: April 1-15, 2022, Survey",2022-05-17,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-15,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,224,0.3258928571,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Service,Canadian Blood Services ,Unity-Aligned,,2022-05-24,2024-03-01,Verified,canadian_blood_services_covid-19_2022-9,CAN
220517_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_UnAdj,220517_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #21A: April 1-15, 2022, Survey",2022-05-17,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,2328,0.3492268041,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Service,Canadian Blood Services ,Unity-Aligned,,2022-05-24,2024-03-01,Verified,canadian_blood_services_covid-19_2022-9,CAN
220517_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_UnAdj,220517_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #21A: April 1-15, 2022, Survey",2022-05-17,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,1247,0.3648757017,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Service,Canadian Blood Services ,Unity-Aligned,,2022-05-24,2024-03-01,Verified,canadian_blood_services_covid-19_2022-9,CAN
220517_Canada_CBS_BloodDonors_RocheN_Overall_UnAdj,220517_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #21A: April 1-15, 2022, Survey",2022-05-17,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-15,Blood donors,All,Multiple groups,17.0,,Test used,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay UnAdj,14341,0.33888850150000005,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Service,Canadian Blood Services ,Unity-Aligned,,2022-05-24,2024-03-01,Verified,canadian_blood_services_covid-19_2022-9,CAN
220517_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_UnAdj,220517_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #21A: April 1-15, 2022, Survey",2022-05-17,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,95,0.1789473684,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Service,Canadian Blood Services ,Unity-Aligned,,2022-05-24,2024-03-01,Verified,canadian_blood_services_covid-19_2022-9,CAN
220517_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_UnAdj,220517_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #21A: April 1-15, 2022, Survey",2022-05-17,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,1058,0.3979206049,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Service,Canadian Blood Services ,Unity-Aligned,,2022-05-24,2024-03-01,Verified,canadian_blood_services_covid-19_2022-9,CAN
220517_Canada_CBS_BloodDonors_RocheN_Overall_Apr8-15_PopTestAdj,220517_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #21A: April 1-15, 2022, Survey",2022-05-17,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-08,2022-04-15,Blood donors,All,Multiple groups,17.0,,Analysis,Apr 8-15,7908,0.35259999999999997,0.3419,0.3632,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Service,Canadian Blood Services ,Unity-Aligned,,2022-06-03,2024-03-01,Verified,canadian_blood_services_covid-19_2022-9,CAN
220517_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_UnAdj,220517_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #21A: April 1-15, 2022, Survey",2022-05-17,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,215,0.2418604651,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Service,Canadian Blood Services ,Unity-Aligned,,2022-05-24,2024-03-01,Verified,canadian_blood_services_covid-19_2022-9,CAN
220517_Canada_CBS_BloodDonors_RocheN_Age_60+_UnAdj,220517_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #21A: April 1-15, 2022, Survey",2022-05-17,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-15,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,4106,0.1841207988,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Service,Canadian Blood Services ,Unity-Aligned,,2022-05-24,2024-03-01,Verified,canadian_blood_services_covid-19_2022-9,CAN
220517_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_UnAdj,220517_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #21A: April 1-15, 2022, Survey",2022-05-17,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,3019,0.41073203049999996,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Service,Canadian Blood Services ,Unity-Aligned,,2022-05-24,2024-03-01,Verified,canadian_blood_services_covid-19_2022-9,CAN
220517_Canada_CBS_BloodDonors_RocheN_Sex_Male_UnAdj,220517_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #21A: April 1-15, 2022, Survey",2022-05-17,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-15,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,8378,0.34280257820000004,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Service,Canadian Blood Services ,Unity-Aligned,,2022-05-24,2024-03-01,Verified,canadian_blood_services_covid-19_2022-9,CAN
220517_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_UnAdj,220517_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #21A: April 1-15, 2022, Survey",2022-05-17,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,752,0.2167553191,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Service,Canadian Blood Services ,Unity-Aligned,,2022-05-24,2024-03-01,Verified,canadian_blood_services_covid-19_2022-9,CAN
220517_Canada_CBS_BloodDonors_RocheN_Overall_Apr1-7_Unadj,220517_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #21A: April 1-15, 2022, Survey",2022-05-17,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-07,Blood donors,All,Multiple groups,17.0,,Test used,Apr 1-7,6433,0.32180000000000003,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Service,Canadian Blood Services ,Unity-Aligned,,2022-06-03,2024-03-01,Verified,canadian_blood_services_covid-19_2022-9,CAN
220517_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_UnAdj,220517_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #21A: April 1-15, 2022, Survey",2022-05-17,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,520,0.2019230769,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Service,Canadian Blood Services ,Unity-Aligned,,2022-05-24,2024-03-01,Verified,canadian_blood_services_covid-19_2022-9,CAN
220517_Canada_CBS_BloodDonors_RocheN_Age_17-24_UnAdj,220517_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #21A: April 1-15, 2022, Survey",2022-05-17,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-15,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1079,0.5347544022,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Service,Canadian Blood Services ,Unity-Aligned,,2022-05-24,2024-03-01,Verified,canadian_blood_services_covid-19_2022-9,CAN
220517_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_UnAdj,220517_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #21A: April 1-15, 2022, Survey",2022-05-17,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,653,0.37825421130000003,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Service,Canadian Blood Services ,Unity-Aligned,,2022-05-24,2024-03-01,Verified,canadian_blood_services_covid-19_2022-9,CAN
220517_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_UnAdj,220517_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #21A: April 1-15, 2022, Survey",2022-05-17,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-15,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,1615,0.4656346749,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Service,Canadian Blood Services ,Unity-Aligned,,2022-05-24,2024-03-01,Verified,canadian_blood_services_covid-19_2022-9,CAN
220517_Canada_CBS_BloodDonors_RocheN_Overall_Apr1-7_PopTestAdj,220517_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #21A: April 1-15, 2022, Survey",2022-05-17,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-07,Blood donors,All,Multiple groups,17.0,,Analysis,Apr 1-7,6433,0.3259,0.3144,0.3373,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Service,Canadian Blood Services ,Unity-Aligned,,2022-06-03,2024-03-01,Verified,canadian_blood_services_covid-19_2022-9,CAN
220517_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_UnAdj,220517_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #21A: April 1-15, 2022, Survey",2022-05-17,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,608,0.36513157890000003,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Service,Canadian Blood Services ,Unity-Aligned,,2022-05-24,2024-03-01,Verified,canadian_blood_services_covid-19_2022-9,CAN
220517_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_UnAdj,220517_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #21A: April 1-15, 2022, Survey",2022-05-17,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #20: March 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1019,0.3523061825,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Canadian Blood Service,Canadian Blood Services ,Unity-Aligned,,2022-05-24,2024-03-01,Verified,canadian_blood_services_covid-19_2022-9,CAN
220518_Canada_UnityHealthToronto_Phase3_Overall_UnAdj,220518_Canada_UnityHealthToronto_Phase3,Omicron BA.1/1.1 SARS-CoV-2 Infection among Vaccinated Canadian Adults,2022-05-18,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,,,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),,2021-08-15,2021-10-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,5155,0.11080000000000001,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.9,0.9,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Patrick Brown,Unity Health Toronto,Not Unity-Aligned,https://doi.org/10.1056/NEJMc2202879,2022-06-06,2022-07-16,Unverified,brown_omicron_2022,CAN
220518_Canada_UnityHealthToronto_Phase4_Overall_UnAdj,220518_Canada_UnityHealthToronto_Phase4,Omicron BA.1/1.1 SARS-CoV-2 Infection among Vaccinated Canadian Adults,2022-05-18,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,,,members of the Angus Reid Forum (nationwide polling panel of Canadian adults 18 years and older),,2022-01-24,2022-03-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,5031,0.3715,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.9,0.9,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Patrick Brown,Unity Health Toronto,Not Unity-Aligned,https://doi.org/10.1056/NEJMc2202879,2022-06-06,2022-07-16,Unverified,brown_omicron_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_April_Overall_Adj,220531_Alberta_AlbertaPrecisionLaboratories_April,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-09,2021-04-16,Residual sera,All,Multiple groups,,,Primary Estimate,Overall Pop Adjusted,12123,0.11900000000000001,0.11900000000000001,0.12,True,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_April_UnvacAge70to79_Adj,220531_Alberta_AlbertaPrecisionLaboratories_April,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-09,2021-04-16,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,Unvaccinated Age 70-79 Pop Adjusted,360,0.07200000000000001,0.046,0.099,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_April_UnvacMale_Adj,220531_Alberta_AlbertaPrecisionLaboratories_April,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-09,2021-04-16,Residual sera,Male,Multiple groups,,,Sex/Gender,Unvaccinated Male Pop Adjusted,2872,0.1,0.08900000000000001,0.111,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_April_UnvacAgeOver80_Adj,220531_Alberta_AlbertaPrecisionLaboratories_April,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-09,2021-04-16,Residual sera,All,Seniors (65+ years),80.0,,Age,Unvaccinated Age Over 80 Pop Adjusted,125,0.11199999999999999,0.057,0.167,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_April_UnvacAge60to69_Adj,220531_Alberta_AlbertaPrecisionLaboratories_April,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-09,2021-04-16,Residual sera,All,Multiple groups,60.0,69.0,Age,Unvaccinated Age 60-69 Pop Adjusted,949,0.085,0.068,0.10300000000000001,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_April_Overall_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_April,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-09,2021-04-16,Residual sera,All,Multiple groups,,,Analysis,Overall Pop Unadjusted,12123,0.10300000000000001,0.098,0.10800000000000001,,,,,True,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_April_UnvacAge20to29_Adj,220531_Alberta_AlbertaPrecisionLaboratories_April,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-09,2021-04-16,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,Unvaccinated Age 20-29 Pop Adjusted,876,0.114,0.09300000000000001,0.135,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_April_UnvacCalgary_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_April,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-09,2021-04-16,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Calgary Pop Unadjusted,1968,0.092,0.079,0.105,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_April_Unvac_Adj,220531_Alberta_AlbertaPrecisionLaboratories_April,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-09,2021-04-16,Residual sera,All,Multiple groups,,,COVID-19 vaccination status,Unvaccinated Pop Unadjusted,7174,0.111,0.111,0.111,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_April_UnvacRural_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_April,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-09,2021-04-16,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Rural Pop Unadjusted,803,0.131,0.107,0.154,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_April_UnvacAge40to49_Adj,220531_Alberta_AlbertaPrecisionLaboratories_April,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-09,2021-04-16,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,Unvaccinated Age 40-49 Pop Adjusted,1452,0.105,0.08900000000000001,0.12,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_April_UnvacGrandePrairie_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_April,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Alberta,Grande Prairie,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-09,2021-04-16,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Grand Prairie Pop Unadjusted,9,0.111,0.0,0.316,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_April_UnvacLethbridge_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_April,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Alberta,Lethbridge,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-09,2021-04-16,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Lethbridge Pop Unadjusted,249,0.032,0.01,0.054000000000000006,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_April_UnvacRedDeer_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_April,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Alberta,Red Deer,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-09,2021-04-16,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Red Deer Pop Unadjusted,270,0.085,0.052000000000000005,0.11900000000000001,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_April_UnvacAge10to19_Adj,220531_Alberta_AlbertaPrecisionLaboratories_April,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-09,2021-04-16,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,Unvaccinated Age 10-19 Pop Adjusted,410,0.132,0.099,0.16399999999999998,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_April_UnvacFemale_Adj,220531_Alberta_AlbertaPrecisionLaboratories_April,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-09,2021-04-16,Residual sera,Female,Multiple groups,,,Sex/Gender,Unvaccinated Female Pop Adjusted,4300,0.106,0.09699999999999999,0.115,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_April_UnvacAge30to39_Adj,220531_Alberta_AlbertaPrecisionLaboratories_April,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-09,2021-04-16,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,Unvaccinated Age 30-39 Pop Adjusted,1454,0.111,0.095,0.128,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_April_Unvac_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_April,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-09,2021-04-16,Residual sera,All,Multiple groups,,,Analysis,Unvaccinated Pop Adjusted,7174,0.10300000000000001,0.096,0.11,,,,,True,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_April_UnvacMedicineHat_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_April,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Alberta,Medicine Hat,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-09,2021-04-16,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Medicine Hat Pop Unadjusted,164,0.061,0.024,0.098,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_April_UnvacAge0to9_Adj,220531_Alberta_AlbertaPrecisionLaboratories_April,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-09,2021-04-16,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,Unvaccinated Age 0-9 Pop Adjusted,120,0.17500000000000002,0.107,0.24300000000000002,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_April_UnvacAge50to59_Adj,220531_Alberta_AlbertaPrecisionLaboratories_April,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-09,2021-04-16,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,Unvaccinated Age 50-59 Pop Adjusted,1428,0.092,0.077,0.107,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_April_UnvacEdmonton_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_April,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Alberta,Edmondon,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-09,2021-04-16,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Edmonton Pop Unadjusted,2087,0.129,0.115,0.14400000000000002,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_July_OverallAdj,220531_Alberta_AlbertaPrecisionLaboratories_July,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-07-02,2021-07-09,Residual sera,All,Multiple groups,,,Primary Estimate,Overall Pop Adjusted,12539,0.7020000000000001,0.7020000000000001,0.703,True,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_July_UnvacLethbridge_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_July,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Alberta,Lethbridge,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-07-02,2021-07-09,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Lethbridge Pop Unadjusted,139,0.122,0.068,0.177,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_July_Unvac_Adj,220531_Alberta_AlbertaPrecisionLaboratories_July,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-07-02,2021-07-09,Residual sera,All,Multiple groups,,,COVID-19 vaccination status,Unvaccinated Pop Unadjusted,2502,0.20199999999999999,0.201,0.20199999999999999,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_July_UnvacEdmonton_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_July,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Alberta,Edmondon,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-07-02,2021-07-09,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Edmonton Pop Unadjusted,608,0.227,0.19399999999999998,0.26,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_July_UnvacMedicineHat_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_July,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Alberta,Medicine Hat,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-07-02,2021-07-09,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Medicine Hat Pop Unadjusted,55,0.109,0.027000000000000003,0.192,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_July_UnvacFemale_Adj,220531_Alberta_AlbertaPrecisionLaboratories_July,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-07-02,2021-07-09,Residual sera,Female,Multiple groups,,,Sex/Gender,Unvaccinated Female Pop Adjusted,1471,0.201,0.18100000000000002,0.222,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_July_UnvacAge70to79_Adj,220531_Alberta_AlbertaPrecisionLaboratories_July,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-07-02,2021-07-09,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,Unvaccinated Age 70-79 Pop Adjusted,208,0.20199999999999999,0.147,0.257,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_July_UnvacMale_Adj,220531_Alberta_AlbertaPrecisionLaboratories_July,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-07-02,2021-07-09,Residual sera,Male,Multiple groups,,,Sex/Gender,Unvaccinated Male Pop Adjusted,1031,0.21300000000000002,0.188,0.23800000000000002,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_July_UnvacAge30to39_Adj,220531_Alberta_AlbertaPrecisionLaboratories_July,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-07-02,2021-07-09,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,Unvaccinated Age 30-39 Pop Adjusted,470,0.19399999999999998,0.158,0.22899999999999998,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_July_UnvacAge40to49_Adj,220531_Alberta_AlbertaPrecisionLaboratories_July,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-07-02,2021-07-09,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,Unvaccinated Age 40-49 Pop Adjusted,365,0.203,0.162,0.242,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_July_UnvacRural_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_July,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-07-02,2021-07-09,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Rural Pop Unadjusted,479,0.23800000000000002,0.2,0.276,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_July_UnvacGrandePrairie_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_July,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Alberta,Grande Prairie,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-07-02,2021-07-09,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Grand Prairie Pop Unadjusted,100,0.24,0.156,0.324,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_July_OverallUnAdj,220531_Alberta_AlbertaPrecisionLaboratories_July,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-07-02,2021-07-09,Residual sera,All,Multiple groups,,,Analysis,Overall Pop Unadjusted,12539,0.805,0.799,0.813,,,,,True,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_July_UnvacCalgary_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_July,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-07-02,2021-07-09,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Calgary Pop Unadjusted,484,0.215,0.17800000000000002,0.252,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_July_UnvacAgeOver80_Adj,220531_Alberta_AlbertaPrecisionLaboratories_July,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-07-02,2021-07-09,Residual sera,All,Seniors (65+ years),80.0,,Age,Unvaccinated Age Over 80 Pop Adjusted,92,0.12,0.053,0.18600000000000003,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_July_UnvacAge10to19_Adj,220531_Alberta_AlbertaPrecisionLaboratories_July,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-07-02,2021-07-09,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,Unvaccinated Age 10-19 Pop Adjusted,156,0.22399999999999998,0.159,0.29,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_July_UnvacAge60to69_Adj,220531_Alberta_AlbertaPrecisionLaboratories_July,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-07-02,2021-07-09,Residual sera,All,Multiple groups,60.0,69.0,Age,Unvaccinated Age 60-69 Pop Adjusted,349,0.189,0.14800000000000002,0.23,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_July_Unvac_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_July,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-07-02,2021-07-09,Residual sera,All,Multiple groups,,,Analysis,Unvaccinated Pop Adjusted,2502,0.209,0.193,0.226,,,,,True,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_July_UnvacAge50to59_Adj,220531_Alberta_AlbertaPrecisionLaboratories_July,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-07-02,2021-07-09,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,Unvaccinated Age 50-59 Pop Adjusted,392,0.23199999999999998,0.19,0.27399999999999997,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_July_UnvacAge20to29_Adj,220531_Alberta_AlbertaPrecisionLaboratories_July,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-07-02,2021-07-09,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,Unvaccinated Age 20-29 Pop Adjusted,331,0.242,0.196,0.28800000000000003,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_July_UnvacRedDeer_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_July,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Alberta,Red Deer,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-07-02,2021-07-09,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Red Deer Pop Unadjusted,83,0.145,0.069,0.22,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_July_UnvacAge0to9_Adj,220531_Alberta_AlbertaPrecisionLaboratories_July,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-07-02,2021-07-09,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,Unvaccinated Age 0-9 Pop Adjusted,139,0.187,0.122,0.252,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_June_OverallAdj,220531_Alberta_AlbertaPrecisionLaboratories_June,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-06-03,2021-06-11,Residual sera,All,Multiple groups,,,Primary Estimate,Overall Pop Adjusted,11894,0.624,0.624,0.625,True,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_June_UnvacRedDeer_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_June,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Alberta,Red Deer,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-06-03,2021-06-11,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Red Deer Pop Unadjusted,4,0.25,0.0,0.674,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_June_UnvacAge20to29_Adj,220531_Alberta_AlbertaPrecisionLaboratories_June,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-06-03,2021-06-11,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,Unvaccinated Age 20-29 Pop Adjusted,366,0.22100000000000003,0.179,0.264,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_June_UnvacAge70to79_Adj,220531_Alberta_AlbertaPrecisionLaboratories_June,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-06-03,2021-06-11,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,Unvaccinated Age 70-79 Pop Adjusted,196,0.219,0.162,0.277,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_June_UnvacAge50to59_Adj,220531_Alberta_AlbertaPrecisionLaboratories_June,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-06-03,2021-06-11,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,Unvaccinated Age 50-59 Pop Adjusted,398,0.20600000000000002,0.166,0.24600000000000002,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_June_UnvacAge60to69_Adj,220531_Alberta_AlbertaPrecisionLaboratories_June,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-06-03,2021-06-11,Residual sera,All,Multiple groups,60.0,69.0,Age,Unvaccinated Age 60-69 Pop Adjusted,371,0.17500000000000002,0.13699999999999998,0.214,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_June_UnvacLethbridge_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_June,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Alberta,Lethbridge,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-06-03,2021-06-11,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Lethbridge Pop Unadjusted,145,0.076,0.033,0.11900000000000001,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_June_UnvacRural_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_June,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-06-03,2021-06-11,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Rural Pop Unadjusted,470,0.219,0.182,0.257,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_June_Unvac_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_June,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-06-03,2021-06-11,Residual sera,All,Multiple groups,,,Analysis,Unvaccinated Pop Adjusted,2752,0.20199999999999999,0.187,0.217,,,,,True,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_June_UnvacFemale_Adj,220531_Alberta_AlbertaPrecisionLaboratories_June,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-06-03,2021-06-11,Residual sera,Female,Multiple groups,,,Sex/Gender,Unvaccinated Female Pop Adjusted,1665,0.182,0.163,0.201,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_June_UnvacAge0to9_Adj,220531_Alberta_AlbertaPrecisionLaboratories_June,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-06-03,2021-06-11,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,Unvaccinated Age 0-9 Pop Adjusted,134,0.20199999999999999,0.134,0.269,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_June_UnvacAge30to39_Adj,220531_Alberta_AlbertaPrecisionLaboratories_June,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-06-03,2021-06-11,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,Unvaccinated Age 30-39 Pop Adjusted,583,0.201,0.168,0.233,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_June_Unvac_Adj,220531_Alberta_AlbertaPrecisionLaboratories_June,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-06-03,2021-06-11,Residual sera,All,Multiple groups,,,COVID-19 vaccination status,Unvaccinated Pop Unadjusted,2752,0.201,0.2,0.201,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_June_UnvacGrandePrairie_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_June,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Alberta,Grande Prairie,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-06-03,2021-06-11,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Grand Prairie Pop Unadjusted,108,0.21300000000000002,0.136,0.29,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_June_OverallUnAdj,220531_Alberta_AlbertaPrecisionLaboratories_June,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-06-03,2021-06-11,Residual sera,All,Multiple groups,,,Analysis,Overall Pop Unadjusted,11894,0.7270000000000001,0.7190000000000001,0.735,,,,,True,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_June_UnvacAge10to19_Adj,220531_Alberta_AlbertaPrecisionLaboratories_June,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-06-03,2021-06-11,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,Unvaccinated Age 10-19 Pop Adjusted,168,0.19100000000000003,0.131,0.25,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_June_UnvacMale_Adj,220531_Alberta_AlbertaPrecisionLaboratories_June,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-06-03,2021-06-11,Residual sera,Male,Multiple groups,,,Sex/Gender,Unvaccinated Male Pop Adjusted,1086,0.22899999999999998,0.204,0.254,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_June_UnvacCalgary_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_June,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-06-03,2021-06-11,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Calgary Pop Unadjusted,612,0.18300000000000002,0.152,0.214,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_June_UnvacMedicineHat_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_June,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Alberta,Medicine Hat,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-06-03,2021-06-11,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Medicine Hat Pop Unadjusted,100,0.19,0.113,0.267,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_June_UnvacAgeOver80_Adj,220531_Alberta_AlbertaPrecisionLaboratories_June,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-06-03,2021-06-11,Residual sera,All,Seniors (65+ years),80.0,,Age,Unvaccinated Age Over 80 Pop Adjusted,83,0.048,0.002,0.094,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_June_UnvacEdmonton_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_June,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Alberta,Edmondon,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-06-03,2021-06-11,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Edmonton Pop Unadjusted,657,0.237,0.20500000000000002,0.27,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_June_UnvacAge40to49_Adj,220531_Alberta_AlbertaPrecisionLaboratories_June,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-06-03,2021-06-11,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,Unvaccinated Age 40-49 Pop Adjusted,452,0.22399999999999998,0.185,0.262,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_March_OverallAdj,220531_Alberta_AlbertaPrecisionLaboratories_March,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-02-26,2021-03-04,Residual sera,All,Multiple groups,,,Primary Estimate,Overall Pop Adjusted,12490,0.11900000000000001,0.11900000000000001,0.12,True,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_March_UnvacAge70to79_Adj,220531_Alberta_AlbertaPrecisionLaboratories_March,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-02-26,2021-03-04,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,Unvaccinated Age 70-79 Pop Adjusted,1706,0.039,0.03,0.048,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_March_UnvacMale_Adj,220531_Alberta_AlbertaPrecisionLaboratories_March,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-02-26,2021-03-04,Residual sera,Male,Multiple groups,,,Sex/Gender,Unvaccinated Male Pop Adjusted,5129,0.065,0.057999999999999996,0.07200000000000001,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_March_UnvacAge30to39_Adj,220531_Alberta_AlbertaPrecisionLaboratories_March,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-02-26,2021-03-04,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,Unvaccinated Age 30-39 Pop Adjusted,1642,0.095,0.081,0.109,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_March_UnvacGrandePrairie_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_March,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Alberta,Grande Prairie,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-02-26,2021-03-04,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Grand Prairie Pop Unadjusted,291,0.034,0.013000000000000001,0.055,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_March_UnvacLethbridge_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_March,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Alberta,Lethbridge,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-02-26,2021-03-04,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Lethbridge Pop Unadjusted,532,0.019,0.0007000000000000001,0.03,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_March_UnvacMedicineHat_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_March,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Alberta,Medicine Hat,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-02-26,2021-03-04,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Medicine Hat Pop Unadjusted,268,0.049,0.023,0.07400000000000001,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_March_UnvacRedDeer_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_March,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Alberta,Red Deer,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-02-26,2021-03-04,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Red Deer Pop Unadjusted,458,0.031000000000000003,0.015,0.046,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_March_Unvac_Adj,220531_Alberta_AlbertaPrecisionLaboratories_March,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-02-26,2021-03-04,Residual sera,All,Multiple groups,,,COVID-19 vaccination status,Unvaccinated Pop Unadjusted,11458,0.094,0.09300000000000001,0.094,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_March_OverallUnAdj,220531_Alberta_AlbertaPrecisionLaboratories_March,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-02-26,2021-03-04,Residual sera,All,Multiple groups,,,Analysis,Overall Pop Unadjusted,12490,0.10300000000000001,0.098,0.10800000000000001,,,,,True,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_March_UnvacAge10to19_Adj,220531_Alberta_AlbertaPrecisionLaboratories_March,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-02-26,2021-03-04,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,Unvaccinated Age 10-19 Pop Adjusted,398,0.083,0.055999999999999994,0.11,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_March_UnvacAgeOver80_Adj,220531_Alberta_AlbertaPrecisionLaboratories_March,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-02-26,2021-03-04,Residual sera,All,Seniors (65+ years),80.0,,Age,Unvaccinated Age Over 80 Pop Adjusted,767,0.033,0.02,0.045,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_March_UnvacEdmonton_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_March,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Alberta,Edmondon,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-02-26,2021-03-04,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Edmonton Pop Unadjusted,2772,0.08800000000000001,0.077,0.098,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_March_UnvacAge60to69_Adj,220531_Alberta_AlbertaPrecisionLaboratories_March,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-02-26,2021-03-04,Residual sera,All,Multiple groups,60.0,69.0,Age,Unvaccinated Age 60-69 Pop Adjusted,2476,0.035,0.027999999999999997,0.042,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_March_Unvac_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_March,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-02-26,2021-03-04,Residual sera,All,Multiple groups,,,Analysis,Unvaccinated Pop Adjusted,11458,0.065,0.061,0.07,,,,,True,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_March_UnvacAge20to29_Adj,220531_Alberta_AlbertaPrecisionLaboratories_March,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-02-26,2021-03-04,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,Unvaccinated Age 20-29 Pop Adjusted,880,0.098,0.078,0.11699999999999999,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_March_UnvacRural_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_March,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-02-26,2021-03-04,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Rural Pop Unadjusted,1476,0.081,0.067,0.095,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_March_UnvacAge50to59_Adj,220531_Alberta_AlbertaPrecisionLaboratories_March,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-02-26,2021-03-04,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,Unvaccinated Age 50-59 Pop Adjusted,1904,0.069,0.057999999999999996,0.081,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_March_UnvacAge40to49_Adj,220531_Alberta_AlbertaPrecisionLaboratories_March,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-02-26,2021-03-04,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,Unvaccinated Age 40-49 Pop Adjusted,1566,0.091,0.077,0.105,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_March_UnvacCalgary_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_March,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-02-26,2021-03-04,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Calgary Pop Unadjusted,3213,0.061,0.053,0.069,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_March_UnvacFemale_Adj,220531_Alberta_AlbertaPrecisionLaboratories_March,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-02-26,2021-03-04,Residual sera,Female,Multiple groups,,,Sex/Gender,Unvaccinated Female Pop Adjusted,6328,0.066,0.06,0.07200000000000001,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_March_UnvacAge0to9_Adj,220531_Alberta_AlbertaPrecisionLaboratories_March,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-02-26,2021-03-04,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,Unvaccinated Age 0-9 Pop Adjusted,118,0.17800000000000002,0.109,0.247,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_May_OverallAdj,220531_Alberta_AlbertaPrecisionLaboratories_May,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-30,2021-05-07,Residual sera,All,Multiple groups,,,Primary Estimate,Overall Pop Adjusted,11586,0.34600000000000003,0.34500000000000003,0.34600000000000003,True,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_May_UnvacCalgary_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_May,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-30,2021-05-07,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Calgary Pop Unadjusted,1584,0.12300000000000001,0.106,0.139,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_May_UnvacEdmonton_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_May,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Alberta,Edmondon,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-30,2021-05-07,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Edmonton Pop Unadjusted,1358,0.16399999999999998,0.14400000000000002,0.18300000000000002,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_May_UnvacAge30to39_Adj,220531_Alberta_AlbertaPrecisionLaboratories_May,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-30,2021-05-07,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,Unvaccinated Age 30-39 Pop Adjusted,1116,0.138,0.11800000000000001,0.158,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_May_UnvacAge50to59_Adj,220531_Alberta_AlbertaPrecisionLaboratories_May,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-30,2021-05-07,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,Unvaccinated Age 50-59 Pop Adjusted,787,0.122,0.099,0.145,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_May_UnvacAge70to79_Adj,220531_Alberta_AlbertaPrecisionLaboratories_May,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-30,2021-05-07,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,Unvaccinated Age 70-79 Pop Adjusted,231,0.134,0.09,0.17800000000000002,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_May_Unvac_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_May,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-30,2021-05-07,Residual sera,All,Multiple groups,,,Analysis,Unvaccinated Pop Adjusted,4870,0.133,0.12300000000000001,0.142,,,,,True,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_May_UnvacGrandePrairie_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_May,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Alberta,Grande Prairie,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-30,2021-05-07,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Grand Prairie Pop Unadjusted,64,0.156,0.067,0.245,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_May_UnvacMedicineHat_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_May,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Alberta,Medicine Hat,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-30,2021-05-07,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Medicine Hat Pop Unadjusted,101,0.109,0.048,0.17,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_May_UnvacRedDeer_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_May,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Alberta,Red Deer,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-30,2021-05-07,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Red Deer Pop Unadjusted,130,0.069,0.025,0.113,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_May_UnvacAge0to9_Adj,220531_Alberta_AlbertaPrecisionLaboratories_May,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-30,2021-05-07,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,Unvaccinated Age 0-9 Pop Adjusted,119,0.11800000000000001,0.06,0.17600000000000002,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_May_Unvac_Adj,220531_Alberta_AlbertaPrecisionLaboratories_May,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-30,2021-05-07,Residual sera,All,Multiple groups,,,COVID-19 vaccination status,Unvaccinated Pop Unadjusted,4870,0.131,0.131,0.131,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_May_UnvacAge20to29_Adj,220531_Alberta_AlbertaPrecisionLaboratories_May,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-30,2021-05-07,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,Unvaccinated Age 20-29 Pop Adjusted,735,0.14800000000000002,0.12300000000000001,0.174,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_May_UnvacAge40to49_Adj,220531_Alberta_AlbertaPrecisionLaboratories_May,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-30,2021-05-07,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,Unvaccinated Age 40-49 Pop Adjusted,822,0.139,0.115,0.162,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_May_UnvacAge60to69_Adj,220531_Alberta_AlbertaPrecisionLaboratories_May,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-30,2021-05-07,Residual sera,All,Multiple groups,60.0,69.0,Age,Unvaccinated Age 60-69 Pop Adjusted,554,0.126,0.099,0.154,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_May_UnvacRural_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_May,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-30,2021-05-07,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Rural Pop Unadjusted,509,0.134,0.10400000000000001,0.163,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_May_OverallUnAdj,220531_Alberta_AlbertaPrecisionLaboratories_May,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-30,2021-05-07,Residual sera,All,Multiple groups,,,Analysis,Overall Pop Unadjusted,11586,0.48100000000000004,0.47200000000000003,0.49,,,,,True,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_May_UnvacAgeOver80_Adj,220531_Alberta_AlbertaPrecisionLaboratories_May,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-30,2021-05-07,Residual sera,All,Seniors (65+ years),80.0,,Age,Unvaccinated Age Over 80 Pop Adjusted,103,0.078,0.026000000000000002,0.129,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_May_UnvacFemale_Adj,220531_Alberta_AlbertaPrecisionLaboratories_May,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-30,2021-05-07,Residual sera,Female,Multiple groups,,,Sex/Gender,Unvaccinated Female Pop Adjusted,2955,0.136,0.12300000000000001,0.14800000000000002,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_May_UnvacAge10to19_Adj,220531_Alberta_AlbertaPrecisionLaboratories_May,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-30,2021-05-07,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,Unvaccinated Age 10-19 Pop Adjusted,403,0.127,0.094,0.159,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_May_UnvacLethbridge_UnAdj,220531_Alberta_AlbertaPrecisionLaboratories_May,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,Alberta,Lethbridge,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-30,2021-05-07,Residual sera,All,Multiple groups,,,Geographical area,Unvaccinated Lethbridge Pop Unadjusted,84,0.071,0.016,0.127,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220531_Alberta_AlbertaPrecisionLaboratories_May_UnvacMale_Adj,220531_Alberta_AlbertaPrecisionLaboratories_May,"Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).",2022-05-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"residual blood samples (serum, plasma, and heparinised plasma), originally collected for other indications. Specimens were procured from two major metropolitan (Calgary and Edmonton) and four large regional laboratories (Grande Prairie, Red Deer, Lethbridge, and Medicine Hat).","3942 patients (6.5%) excluded as they were first vaccinated less than 14 days. Vaccination status not available for 709/60,632 (1.2%) individuals and therefore not included either.",2021-04-30,2021-05-07,Residual sera,Male,Multiple groups,,,Sex/Gender,Unvaccinated Male Pop Adjusted,1915,0.129,0.114,0.14300000000000002,,,True,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jamil N. Kanji,Alberta Precision Laboratories,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2080250,2022-06-07,2024-05-01,Verified,kanji_seropositivity_2022,CAN
220603_Canada_CBS_BloodDonors_RocheS_Overall_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,29786,0.9974,0.996,0.9988,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_Age_17-24_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2248,0.9942000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_Overall_PopAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Analysis,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay Pop Adj,29787,0.3665,0.361,0.372,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,379,0.4222,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,510,0.27899999999999997,0.2425,0.3156,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_Age_25-39_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,7996,0.9999,0.9973000000000001,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,22334,0.9968000000000001,0.9952,0.9984999999999999,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1899,0.9995,0.9941,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1899,0.4133,0.38939999999999997,0.43710000000000004,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_Age_40-59_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11150,0.3736,0.3643,0.383,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1403,0.3849,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,5074,0.9864,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_Age_25-39_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,7996,0.459,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2614,0.39530000000000004,0.378,0.41259999999999997,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,5074,0.9977,0.9949,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2614,0.9836,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_Sex_Male_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,17159,0.0368,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1403,0.9872,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1403,0.40399999999999997,0.37670000000000003,0.4292,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1287,1.0,0.9952,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,710,0.3423,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_Overall_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Analysis,,29786,0.9849,0.9835,0.9863,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1501,0.2532,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_Age_40-59_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11150,0.983,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,22335,0.3478,0.34149999999999997,0.3542,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_Age_25-39_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,7996,0.46390000000000003,0.4523,0.4754,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1287,0.2078,0.1829,0.2327,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,3374,0.49060000000000004,0.4742,0.507,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1317,0.3997,0.3714,0.428,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,4662,0.996,0.9926,0.9994,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,4662,0.3632,0.35009999999999997,0.3762,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,1641,0.3778,0.3557,0.39990000000000003,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2614,0.39630000000000004,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_Age_60+_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,8392,0.9819,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,931,0.37070000000000003,0.33899999999999997,0.4025,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1501,1.0,0.9976,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1316,0.9988,0.9922,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2614,0.9949,0.9902,0.9995,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,3374,0.9890000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,5592,0.9972,0.9936,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_Age_17-24_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2248,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,5074,0.3653,0.35380000000000006,0.3768,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,4662,0.35950000000000004,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,510,1.0,0.9969,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1899,0.9863,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,5074,0.36869999999999997,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1501,0.9940000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_Sex_Male_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,17159,0.3859,0.3779,0.39380000000000004,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1403,0.9995999999999999,0.9937,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,931,0.3577,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14103,0.3489,0.3412,0.3566,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,710,1.0,0.9945,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_Age_60+_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,8392,0.9942000000000001,0.9913,0.997,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_Sex_Female_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,12627,0.9989,0.9971,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,1996,0.4394,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,1996,1.0,0.9945,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,1996,0.4554,0.4292,0.4816,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1316,0.9863,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1287,0.2036,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_Age_17-24_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2248,0.5537,0.5376,0.5699000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,931,1.0,0.9951000000000001,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,510,0.2725,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1287,0.9915,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_Age_25-39_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,7996,0.9881000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,3374,1.0,0.9977,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_Age_40-59_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11150,0.9948,0.9922,0.9973000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14103,0.9963,0.9942000000000001,0.9983,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,1641,0.365,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,203,0.20199999999999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,931,0.9903000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14103,0.9838,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,5592,0.4644,0.4496,0.47909999999999997,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,4662,0.9837,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,510,0.9941,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,5592,0.4487,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_Sex_Female_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,12628,0.3494,0.3418,0.35700000000000004,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_Age_60+_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,8392,0.20510000000000003,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_Overall_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Test used,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay PopTest Adj,29787,0.36710000000000004,0.3616,0.3726,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,1641,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_Sex_Male_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,17159,0.9958,0.9937,0.9979000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_Age_17-24_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2248,0.5543,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,3374,0.48340000000000005,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14103,0.34840000000000004,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,203,0.9951000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,203,0.9978,0.9794,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,710,0.3536,0.3199,0.3873,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,1641,0.9956999999999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_Sex_Female_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,12628,0.3594,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_Sex_Female_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,12627,0.9873999999999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_Age_40-59_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11150,0.3779,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,22335,0.3483,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,379,0.9967,0.9843000000000001,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,22334,0.9845,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1317,0.4009,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1899,0.40490000000000004,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_Sex_Male_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,17159,0.9831000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_Age_60+_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,8392,0.19260000000000002,0.1841,0.2011,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,710,0.9901000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,1996,0.988,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,203,0.371,0.2956,0.4464,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,379,0.4275,0.378,0.47700000000000004,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_Overall_PopAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Analysis,,29786,0.9856,0.9841,0.9869,,,True,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,379,0.9868000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_PopTestAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1501,0.2656,0.23850000000000002,0.2927,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220603_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_UnAdj,220603_Canada_CBS,"COVID-19 Seroprevalence Report June 3rd, 2022 Report #21: April 2022 Survey - The advance of Omicron",2022-06-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-04-01,2022-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,5592,0.9845999999999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-05-06,Verified,canadian_blood_services_covid-19_2022-13,CAN
220623_Canada_CBS_BloodDonors_RocheS_Overall_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,31764,1.0,1.0,1.0,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,424,1.0,0.9978,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,1305,0.9923371648,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2731,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_Age_40-59_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11725,0.47869999999999996,0.4693,0.488,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1651,0.4930345245,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,1305,1.0,0.9961,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1256,0.36340000000000006,0.33409999999999995,0.39270000000000005,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,422,0.32701421799999997,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,23698,0.44310000000000005,0.43670000000000003,0.4495,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1349,1.0,0.9938,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_Sex_Male_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18001,0.9999,0.9982,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_Age_17-24_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2464,0.6497564935,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,1305,0.4233,0.39049999999999996,0.4561,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_Overall_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Test used,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay PopTest Adj,31764,0.4632,0.45770000000000005,0.4687,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1388,0.34510086459999995,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_Sex_Male_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18001,0.4606,0.4533,0.46799999999999997,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1933,1.0,0.9992000000000001,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4869,0.4667,0.455,0.4783,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2253,0.5317354638,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2731,0.4990845844,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,1795,0.9944289694,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1256,0.997611465,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,424,0.9976415094,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_Overall_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Analysis,,31764,0.9894,0.9882,0.9905,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,1305,0.41072796930000005,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,23698,0.9888176217000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_Age_25-39_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8515,0.5510275984,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1036,1.0,0.9998,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1933,0.5157,0.4908,0.5406000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_Sex_Female_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13763,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1388,0.9942363112,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,1795,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_Age_40-59_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11725,1.0,0.9984999999999999,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6020,0.538372093,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,1795,0.46030000000000004,0.4388,0.4818,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2731,0.9930428415,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_Age_25-39_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8515,0.5574,0.5463,0.5685,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_Sex_Male_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18001,0.4594189212,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14137,0.9885407088,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1388,1.0,0.9992000000000001,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_Sex_Female_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13763,0.46280000000000004,0.4545,0.4712,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1651,0.9866747426000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4869,0.9907578558000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_Age_60+_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9060,0.2832,0.27390000000000003,0.2926,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1349,0.9881393625,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2731,0.4939,0.4764,0.5113000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_Age_25-39_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8515,0.9916617732999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2253,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,23698,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,196,0.9964000000000001,0.9767,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1933,0.4992240041,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5296,1.0,0.9989,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1388,0.34520000000000006,0.3171,0.37320000000000003,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_Sex_Male_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18001,0.9873895895,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1256,0.3678343949,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1349,0.4833209785,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_Age_17-24_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2464,0.9975649351,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,23698,0.44231580719999997,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6020,0.9895348837000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,196,0.306122449,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1349,0.5003,0.4723,0.5282,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2253,0.993786063,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,422,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,424,0.5335,0.4854,0.5815,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_Age_40-59_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11725,0.47991471220000004,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1651,0.5096,0.48360000000000003,0.5356000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,196,0.9948979592000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,1795,0.4690807799,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14137,0.4487515031,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,3571,0.9952394287,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4869,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_Sex_Female_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13763,0.4615999419,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14137,0.4485,0.44079999999999997,0.45630000000000004,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_Age_60+_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9060,0.9857615894,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_Age_17-24_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2464,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1036,0.455,0.4219,0.488,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1933,0.9922400414000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6020,1.0,0.9992000000000001,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,422,0.9976303317999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_Age_40-59_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11725,0.9887420043,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5296,0.4543,0.4412,0.46740000000000004,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,3571,0.5898,0.5740999999999999,0.6055,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_Age_60+_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9060,0.29834437090000004,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,3571,0.5779893587,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5296,0.4454305136,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,3571,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_Overall_PopAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Analysis,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay Pop Adj,31764,0.462,0.4565,0.4675,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_Age_25-39_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8515,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_Sex_Female_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13763,0.9919348979,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6020,0.5579,0.5436,0.5722,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1036,0.9951737452,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_Age_17-24_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2464,0.6447,0.6296,0.6598,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1651,0.9990000000000001,0.9931000000000001,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,424,0.5353773585,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2253,0.5487,0.5236,0.5738000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14137,1.0,0.9998,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1036,0.44691119690000003,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5296,0.9896148036,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_Age_60+_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9060,0.9976,0.9951000000000001,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1256,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,422,0.33,0.2929,0.36710000000000004,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_UnAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4869,0.4789484494,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheS_Overall_PopAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Analysis,,31764,0.9901000000000001,0.9890000000000001,0.9912000000000001,,,True,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220623_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_PopTestAdj,220623_Canada_CBS,"COVID-19 Seroprevalence Report June 23rd, 2022 - Report #22: May 2022 Survey The advance of Omicron",2022-06-23,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-05-01,2022-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,196,0.3178,0.2429,0.39270000000000005,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-04-23,Verified,canadian_blood_services_covid-19_2022-11,CAN
220705_Ontario_McMasterUniversity_Overall_Pop_Adj,220705_Ontario_McMasterUniversity,Seropositivity and risk factors for SARS-CoV-2 infection in a South Asian community in Ontario: a cross-sectional analysis of a prospective cohort study,2022-07-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Ontario,,"Adults >= 18 of South Asian ethnicity living in the Peel Region. ""South Asian ethnicity was self-reported and defined by parental South Asian ancestry from the Indian subcontinent, Africa, Caribbean, and Guyana."" ",,2021-04-14,2021-07-28,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,"Overall, population adjusted",916,0.22899999999999998,0.201,0.261,True,,True,,True,Convenience,Author Designed (ELISA) - Spike and Nucleocapsid,,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sonia Anand,McMaster University,Not Unity-Aligned,https://doi.org/10.9778/cmajo.20220031,2022-07-15,2022-07-16,Unverified,anand_seropositivity_2022,CAN
220705_Ontario_McMasterUniversity_Male_Pop_Adj,220705_Ontario_McMasterUniversity,Seropositivity and risk factors for SARS-CoV-2 infection in a South Asian community in Ontario: a cross-sectional analysis of a prospective cohort study,2022-07-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Ontario,,"Adults >= 18 of South Asian ethnicity living in the Peel Region. ""South Asian ethnicity was self-reported and defined by parental South Asian ancestry from the Indian subcontinent, Africa, Caribbean, and Guyana."" ",,2021-04-14,2021-07-28,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,Male,462,0.249,0.209,0.28800000000000003,,,True,,,Convenience,Author Designed (ELISA) - Spike and Nucleocapsid,,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sonia Anand,McMaster University,Not Unity-Aligned,https://doi.org/10.9778/cmajo.20220031,2022-07-15,2022-07-16,Unverified,anand_seropositivity_2022,CAN
220705_Ontario_McMasterUniversity_18-24_Pop_Adj,220705_Ontario_McMasterUniversity,Seropositivity and risk factors for SARS-CoV-2 infection in a South Asian community in Ontario: a cross-sectional analysis of a prospective cohort study,2022-07-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Ontario,,"Adults >= 18 of South Asian ethnicity living in the Peel Region. ""South Asian ethnicity was self-reported and defined by parental South Asian ancestry from the Indian subcontinent, Africa, Caribbean, and Guyana."" ",,2021-04-14,2021-07-28,Household and community samples,All,Adults (18-64 years),18.0,24.0,Age,18-24,95,0.226,0.14800000000000002,0.32799999999999996,,,True,,,Convenience,Author Designed (ELISA) - Spike and Nucleocapsid,,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sonia Anand,McMaster University,Not Unity-Aligned,https://doi.org/10.9778/cmajo.20220031,2022-07-15,2022-07-16,Unverified,anand_seropositivity_2022,CAN
220705_Ontario_McMasterUniversity_65+_Pop_Adj,220705_Ontario_McMasterUniversity,Seropositivity and risk factors for SARS-CoV-2 infection in a South Asian community in Ontario: a cross-sectional analysis of a prospective cohort study,2022-07-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Ontario,,"Adults >= 18 of South Asian ethnicity living in the Peel Region. ""South Asian ethnicity was self-reported and defined by parental South Asian ancestry from the Indian subcontinent, Africa, Caribbean, and Guyana."" ",,2021-04-14,2021-07-28,Household and community samples,All,Seniors (65+ years),65.0,,Age,65+,80,0.281,0.185,0.401,,,True,,,Convenience,Author Designed (ELISA) - Spike and Nucleocapsid,,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sonia Anand,McMaster University,Not Unity-Aligned,https://doi.org/10.9778/cmajo.20220031,2022-07-15,2022-07-16,Unverified,anand_seropositivity_2022,CAN
220705_Ontario_McMasterUniversity_45-54_Pop_Adj,220705_Ontario_McMasterUniversity,Seropositivity and risk factors for SARS-CoV-2 infection in a South Asian community in Ontario: a cross-sectional analysis of a prospective cohort study,2022-07-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Ontario,,"Adults >= 18 of South Asian ethnicity living in the Peel Region. ""South Asian ethnicity was self-reported and defined by parental South Asian ancestry from the Indian subcontinent, Africa, Caribbean, and Guyana."" ",,2021-04-14,2021-07-28,Household and community samples,All,Adults (18-64 years),45.0,54.0,Age,45-54,157,0.23199999999999998,0.168,0.31,,,True,,,Convenience,Author Designed (ELISA) - Spike and Nucleocapsid,,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sonia Anand,McMaster University,Not Unity-Aligned,https://doi.org/10.9778/cmajo.20220031,2022-07-15,2022-07-16,Unverified,anand_seropositivity_2022,CAN
220705_Ontario_McMasterUniversity_55-64_Pop_Adj,220705_Ontario_McMasterUniversity,Seropositivity and risk factors for SARS-CoV-2 infection in a South Asian community in Ontario: a cross-sectional analysis of a prospective cohort study,2022-07-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Ontario,,"Adults >= 18 of South Asian ethnicity living in the Peel Region. ""South Asian ethnicity was self-reported and defined by parental South Asian ancestry from the Indian subcontinent, Africa, Caribbean, and Guyana."" ",,2021-04-14,2021-07-28,Household and community samples,All,Adults (18-64 years),55.0,64.0,Age,55-64,94,0.29600000000000004,0.20600000000000002,0.405,,,True,,,Convenience,Author Designed (ELISA) - Spike and Nucleocapsid,,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sonia Anand,McMaster University,Not Unity-Aligned,https://doi.org/10.9778/cmajo.20220031,2022-07-15,2022-07-16,Unverified,anand_seropositivity_2022,CAN
220705_Ontario_McMasterUniversity_35-44_Pop_Adj,220705_Ontario_McMasterUniversity,Seropositivity and risk factors for SARS-CoV-2 infection in a South Asian community in Ontario: a cross-sectional analysis of a prospective cohort study,2022-07-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Ontario,,"Adults >= 18 of South Asian ethnicity living in the Peel Region. ""South Asian ethnicity was self-reported and defined by parental South Asian ancestry from the Indian subcontinent, Africa, Caribbean, and Guyana."" ",,2021-04-14,2021-07-28,Household and community samples,All,Adults (18-64 years),35.0,44.0,Age,35-44,247,0.215,0.165,0.276,,,True,,,Convenience,Author Designed (ELISA) - Spike and Nucleocapsid,,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sonia Anand,McMaster University,Not Unity-Aligned,https://doi.org/10.9778/cmajo.20220031,2022-07-15,2022-07-16,Unverified,anand_seropositivity_2022,CAN
220705_Ontario_McMasterUniversity_Female_Pop_Adj,220705_Ontario_McMasterUniversity,Seropositivity and risk factors for SARS-CoV-2 infection in a South Asian community in Ontario: a cross-sectional analysis of a prospective cohort study,2022-07-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Ontario,,"Adults >= 18 of South Asian ethnicity living in the Peel Region. ""South Asian ethnicity was self-reported and defined by parental South Asian ancestry from the Indian subcontinent, Africa, Caribbean, and Guyana."" ",,2021-04-14,2021-07-28,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,Female,451,0.21,0.17300000000000001,0.254,,,True,,,Convenience,Author Designed (ELISA) - Spike and Nucleocapsid,,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sonia Anand,McMaster University,Not Unity-Aligned,https://doi.org/10.9778/cmajo.20220031,2022-07-15,2022-07-16,Unverified,anand_seropositivity_2022,CAN
220705_Ontario_McMasterUniversity_25-34_Pop_Adj,220705_Ontario_McMasterUniversity,Seropositivity and risk factors for SARS-CoV-2 infection in a South Asian community in Ontario: a cross-sectional analysis of a prospective cohort study,2022-07-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Ontario,,"Adults >= 18 of South Asian ethnicity living in the Peel Region. ""South Asian ethnicity was self-reported and defined by parental South Asian ancestry from the Indian subcontinent, Africa, Caribbean, and Guyana."" ",,2021-04-14,2021-07-28,Household and community samples,All,Adults (18-64 years),25.0,34.0,Age,25-34,233,0.209,0.158,0.271,,,True,,,Convenience,Author Designed (ELISA) - Spike and Nucleocapsid,,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sonia Anand,McMaster University,Not Unity-Aligned,https://doi.org/10.9778/cmajo.20220031,2022-07-15,2022-07-16,Unverified,anand_seropositivity_2022,CAN
220712_Ottawa_OMNIResearchGroup_Primary,220712_Ottawa_OMNIResearchGroup,"Prevalence of SARS-CoV-2 infection among obstetric patients in Ottawa, Canada: a descriptive study.",2022-07-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Ontario,"Ottawa
","Participants were pregnant individuals who were admitted to 1 of 2 obstetric triage units (generally ≥ 20 weeks’ gestation, unless the circumstances are exceptional). Patients with or without symptoms of COVID-19 were eligible to participate.","We excluded individuals who did not speak English or French, were younger than 18 years, were enrolled in conflicting research studies or were admitted for a pregnancy termination. Given the necessity of having research staff available to collect consent, individuals who presented to triage units overnight (i.e., between the hours of 11:31 pm and 7:29 am) were not eligible to participate.",2020-10-19,2020-11-27,Pregnant or parturient women,Female,Adults (18-64 years),18.0,,Primary Estimate,,352,0.185,,,True,,,,True,Convenience,Author designed (ELISA) - MULTIPLEXED,,ELISA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Unclear,Yes,No,,Romina Fakhraei,OMNI Research Group,Not Unity-Aligned,https://dx.doi.org/10.9778/cmajo.20210228,2022-07-18,2022-07-18,Unverified,fakhraei_prevalence_2022,CAN
220803_Canada_CBS_BloodDonors_RocheS_Overall_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,32121,1.0,1.0,1.0,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-02-22,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_Overall_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Test used,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay PopTest Adj,32121,0.507,0.5015,0.5126,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,804,0.44530000000000003,0.41270000000000007,0.478,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_Sex_Male_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,17628,0.4988087134,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2743,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,403,0.5654,0.5162,0.6145,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14562,0.472943277,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,192,0.4924,0.41659999999999997,0.5682,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1730,0.9953757225,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1276,1.0,0.9993000000000001,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_Overall_PopAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Analysis,,32121,0.9906,0.9895,0.9917,,,True,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-01,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5202,0.5054,0.49229999999999996,0.5186,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,1708,0.5134660422,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14562,0.9892185139,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_Age_17-24_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2354,0.6665250637,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1995,0.5528822055,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1096,0.5285,0.49460000000000004,0.5624,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2743,0.5368,0.5196000000000001,0.5539000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24321,0.9908309691,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24321,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1730,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5202,0.485774702,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_Overall_PopAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Analysis,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay Pop Adj,32121,0.5055,0.5,0.511,,,True,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,3470,0.9919308357,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,385,1.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4499,0.9899977773,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24321,0.4901,0.48380000000000006,0.4965,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_Age_60+_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9436,0.3373,0.3275,0.3471,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_Sex_Female_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,14493,0.9916511419,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_Age_17-24_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2354,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_Sex_Female_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,14493,0.4961,0.48850000000000005,0.5038,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,385,0.4572,0.4178,0.4966,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_Age_40-59_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,12169,0.9896458213,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_Age_60+_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9436,0.9986,0.9962000000000001,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6415,0.5878409977,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2743,0.9930732774000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,192,0.9976,0.9797,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5202,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,3470,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_Sex_Male_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,17628,0.9892784206999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,192,0.9947916667,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_Overall_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Analysis,,32121,0.9903000000000001,0.9892000000000001,0.9914000000000001,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1096,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1995,1.0,0.9993000000000001,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,804,0.9925373134000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1730,0.5473988439,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_Age_40-59_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,12169,1.0,0.9994,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14562,0.4814,0.4737,0.4892,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1995,0.9919799499,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6415,1.0,0.9991,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_Age_60+_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9436,0.9865409072,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1588,0.3987,0.3697,0.4278,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_Age_25-39_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8162,0.6013232051,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_Age_60+_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9436,0.3460152607,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,385,0.4753246753,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_Sex_Female_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,14493,0.5029324501,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2390,0.5957,0.5706,0.6208,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14562,1.0,0.9995999999999999,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2390,0.5824267782,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1276,0.41490000000000005,0.3858,0.444,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1588,0.9968513854,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2743,0.5311702515000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,192,0.47395833330000003,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_Age_25-39_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8162,0.9937515315000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,3470,0.6083573487,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,804,1.0,0.9967,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6415,0.6086,0.5945,0.6226,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1730,0.5627000000000001,0.537,0.5885,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,1708,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6415,0.9897116134,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,403,0.9875930520999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,1708,0.4993,0.4769,0.5216,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,403,0.5533498759,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1555,0.5286173633,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1555,0.9897106109000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,804,0.43283582090000006,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,385,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1276,0.9937304075000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5202,0.9907727797,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2390,0.9895397490000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,3470,0.6232,0.6078,0.6386999999999999,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_Age_17-24_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2354,0.6629,0.6481,0.6777,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_Age_25-39_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8162,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1555,0.9995999999999999,0.9934000000000001,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1276,0.3965517241,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_Age_40-59_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,12169,0.5199,0.5106,0.5292,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1588,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2390,1.0,0.9956,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4499,0.5032229384,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1588,0.39483627200000004,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4499,0.5037,0.4917,0.5156000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_Age_40-59_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,12169,0.5209959734,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1995,0.5770000000000001,0.5525,0.6016,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1096,0.996350365,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_Age_17-24_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2354,0.997451147,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,1708,0.9959016393000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_Sex_Female_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,14493,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1555,0.5545,0.5266,0.5822999999999999,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_Sex_Male_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,17628,1.0,0.9999,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24321,0.48472513470000006,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4499,1.0,0.9992000000000001,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_Age_25-39_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8162,0.6062,0.5953,0.6171,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,403,0.9990000000000001,0.9877,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_UnAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1096,0.5200729927,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220803_Canada_CBS_BloodDonors_RocheN_Sex_Male_PopTestAdj,220803_Canada_CBS,"COVID-19 Seroprevalence Report August 3rd, 2022 - Report #23: June 2022 Survey The advance of Omicron",2022-08-03,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-06-01,2022-06-30,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,17628,0.5186,0.5107,0.5265,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-26,2024-03-29,Verified,canadian_blood_services_covid-19_2022-12,CAN
220825_Canada_CBS_BloodDonors_RocheS_Overall_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,31275,1.0,1.0,1.0,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1781,0.5826,0.5590999999999999,0.606,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_Age_40-59_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11754,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,3472,0.9925,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_Sex_Female_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13225,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1392,0.9921,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1504,1.0,0.9997,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_Age_60+_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9045,0.37570000000000003,0.36560000000000004,0.3859,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_Age_40-59_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11754,0.5463,0.5369,0.5557,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,304,0.9934000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1504,0.9947,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4819,0.9921,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_Sex_Male_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18050,0.9904000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,5637,0.6078,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2501,0.579,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2501,0.9932,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_Age_25-39_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8287,0.9925,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2178,0.6364,0.6117,0.6609999999999999,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,3472,0.6711,0.6557,0.6864,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_Age_60+_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9045,1.0,0.9982,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2501,0.5834,0.5660000000000001,0.6008,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,1650,0.9976,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14936,0.9912000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1016,1.0,0.9954000000000001,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,304,0.48360000000000003,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_Overall_PopAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Analysis,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay Pop Adj,31275,0.5401,0.5345000000000001,0.5456000000000001,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1564,0.555,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,856,0.48130000000000006,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,1650,0.5303,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_Sex_Female_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13225,0.9934999999999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_Sex_Female_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13225,0.5277000000000001,0.52,0.5355,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,427,0.9906,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1472,0.4413,0.4112,0.47130000000000005,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1564,1.0,0.9959,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,1650,0.5297999999999999,0.5069,0.5527000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_Age_25-39_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8287,0.6258,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,856,1.0,0.9975,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1016,0.5335,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_Age_40-59_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11754,0.9914000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14936,0.5086,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_Overall_PopAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Analysis,,31275,1.0,1.0,1.0,,,True,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1504,0.43729999999999997,0.40770000000000006,0.467,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_Age_25-39_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8287,0.634,0.6231,0.6448999999999999,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,5637,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_Age_17-24_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2189,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1472,0.9945999999999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2178,0.623,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1392,1.0,0.9953000000000001,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,3472,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,4670,0.9914000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1472,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,23718,0.5147,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,412,0.9951000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2178,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1472,0.4375,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1016,0.5442,0.5105,0.5778,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4819,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,4670,0.5519,0.5387,0.5652,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1781,0.9927,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_Age_25-39_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8287,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,5637,0.9922,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1016,0.9921,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1781,1.0,0.9997,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4819,0.5437,0.5316,0.5557,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1564,0.5695,0.5433,0.5956,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,23718,0.9915,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_Overall_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Test used,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay PopTest Adj,31275,0.5401,0.5345000000000001,0.5456000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,412,1.0,0.9989,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_Age_17-24_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2189,0.9986,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_Sex_Female_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13225,0.5301,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14936,0.5168,0.5089,0.5246000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1781,0.5755,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_Age_17-24_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2189,0.7058,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_Overall_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Analysis,,31275,0.9917,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4819,0.5455,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_Sex_Male_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18050,0.5317000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,4670,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,1650,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,427,1.0,0.99,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,427,0.5831000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1392,0.5709000000000001,0.5428000000000001,0.599,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,304,0.48950000000000005,0.4128,0.5662,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,3472,0.6478,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,304,0.9944,0.9745,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_Age_17-24_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2189,0.7115,0.6970999999999999,0.7259000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1504,0.44079999999999997,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,23718,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2501,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_Age_60+_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9045,0.9895999999999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_Sex_Male_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18050,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2178,0.9959,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,856,0.993,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_Sex_Male_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18050,0.5531,0.5452,0.5611,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_Age_40-59_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11754,0.5468999999999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_Age_60+_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9045,0.3814,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1392,0.5445000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,427,0.6106,0.5646,0.6565000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,412,0.5243,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,4670,0.5403,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,856,0.49600000000000005,0.46270000000000006,0.5293,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_UnAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1564,0.9904000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2024-03-01,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,412,0.5429,0.503,0.5828,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,23718,0.5201,0.5136999999999999,0.5266,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,5637,0.6232,0.6091,0.6373,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220825_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_PopTestAdj,220825_Canada_CBS,"COVID-19 Seroprevalence Report August 25th, 2022 Report #24: July 2022 - Survey The advance of Omicron",2022-08-25,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-07-01,2022-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14936,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-08-30,2023-08-15,Unverified,canadian_blood_services_covid-19_2022-14,CAN
220829_BritishColumbia_UniversityofBritishColumbia,220829_BritishColumbia_UniversityofBritishColumbia,"Seropositivity of SARS-CoV-2 in an unvaccinated cohort in British Columbia, Canada: a cross-sectional survey with dried blood spot samples.",2022-08-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,British Columbia,,"""Participants were recruited from existing large research
cohorts in BC, comprised of individuals who had provided
consent to be contacted for future research, in addition to
general public recruitment through social media, patient
research networks, as well as stakeholder and community
websites (index participants). Eligible participants were
those 25–69 years of age who were current residents of
BC.""",,2020-11-15,2021-06-15,Household and community samples,All,Multiple groups,25.0,69.0,Primary Estimate,,4048,0.028999999999999998,,,True,,,,True,Convenience,Meso Scale Discovery multiplex assay,Meso Scale Discovery,CLIA,Dried Blood,IgG,Spike,,0.79,0.97,['High'],,No,Yes,Yes,,Unclear,Yes,No,,C Sarai Racey,The University of British Columbia,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2022-062567,2022-09-10,2023-06-22,Unverified,racey_seropositivity_2022,CAN
220829_BritishColumbia_UniversityofBritishColumbia_Sex_Female,220829_BritishColumbia_UniversityofBritishColumbia,"Seropositivity of SARS-CoV-2 in an unvaccinated cohort in British Columbia, Canada: a cross-sectional survey with dried blood spot samples.",2022-08-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,British Columbia,,"""Participants were recruited from existing large research
cohorts in BC, comprised of individuals who had provided
consent to be contacted for future research, in addition to
general public recruitment through social media, patient
research networks, as well as stakeholder and community
websites (index participants). Eligible participants were
those 25–69 years of age who were current residents of
BC.""",,2020-11-15,2021-06-15,Household and community samples,Female,Multiple groups,,,Sex/Gender,,3563,0.028999999999999998,,,,,,,,Convenience,Meso Scale Discovery multiplex assay,Meso Scale Discovery,CLIA,Dried Blood,IgG,Spike,,0.79,0.97,['High'],,No,Yes,Yes,,Unclear,Yes,No,,C Sarai Racey,The University of British Columbia,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2022-062567,2022-09-12,2023-06-22,Unverified,racey_seropositivity_2022,CAN
220829_BritishColumbia_UniversityofBritishColumbia_Age_50-59,220829_BritishColumbia_UniversityofBritishColumbia,"Seropositivity of SARS-CoV-2 in an unvaccinated cohort in British Columbia, Canada: a cross-sectional survey with dried blood spot samples.",2022-08-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,British Columbia,,"""Participants were recruited from existing large research
cohorts in BC, comprised of individuals who had provided
consent to be contacted for future research, in addition to
general public recruitment through social media, patient
research networks, as well as stakeholder and community
websites (index participants). Eligible participants were
those 25–69 years of age who were current residents of
BC.""",,2020-11-15,2021-06-15,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,,1116,0.018000000000000002,,,,,,,,Convenience,Meso Scale Discovery multiplex assay,Meso Scale Discovery,CLIA,Dried Blood,IgG,Spike,,0.79,0.97,['High'],,No,Yes,Yes,,Unclear,Yes,No,,C Sarai Racey,The University of British Columbia,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2022-062567,2022-09-12,2023-06-22,Unverified,racey_seropositivity_2022,CAN
220829_BritishColumbia_UniversityofBritishColumbia_Sex_Missing,220829_BritishColumbia_UniversityofBritishColumbia,"Seropositivity of SARS-CoV-2 in an unvaccinated cohort in British Columbia, Canada: a cross-sectional survey with dried blood spot samples.",2022-08-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,British Columbia,,"""Participants were recruited from existing large research
cohorts in BC, comprised of individuals who had provided
consent to be contacted for future research, in addition to
general public recruitment through social media, patient
research networks, as well as stakeholder and community
websites (index participants). Eligible participants were
those 25–69 years of age who were current residents of
BC.""",,2020-11-15,2021-06-15,Household and community samples,Other,Multiple groups,,,Sex/Gender,,5,0.2,,,,,,,,Convenience,Meso Scale Discovery multiplex assay,Meso Scale Discovery,CLIA,Dried Blood,IgG,Spike,,0.79,0.97,['High'],,No,Yes,Yes,,Unclear,Yes,No,,C Sarai Racey,The University of British Columbia,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2022-062567,2022-09-12,2023-06-22,Unverified,racey_seropositivity_2022,CAN
220829_BritishColumbia_UniversityofBritishColumbia_Age_60-70,220829_BritishColumbia_UniversityofBritishColumbia,"Seropositivity of SARS-CoV-2 in an unvaccinated cohort in British Columbia, Canada: a cross-sectional survey with dried blood spot samples.",2022-08-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,British Columbia,,"""Participants were recruited from existing large research
cohorts in BC, comprised of individuals who had provided
consent to be contacted for future research, in addition to
general public recruitment through social media, patient
research networks, as well as stakeholder and community
websites (index participants). Eligible participants were
those 25–69 years of age who were current residents of
BC.""",,2020-11-15,2021-06-15,Household and community samples,All,Multiple groups,60.0,70.0,Age,,1055,0.03,,,,,,,,Convenience,Meso Scale Discovery multiplex assay,Meso Scale Discovery,CLIA,Dried Blood,IgG,Spike,,0.79,0.97,['High'],,No,Yes,Yes,,Unclear,Yes,No,,C Sarai Racey,The University of British Columbia,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2022-062567,2022-09-12,2023-06-22,Unverified,racey_seropositivity_2022,CAN
220829_BritishColumbia_UniversityofBritishColumbia_Age_40-49,220829_BritishColumbia_UniversityofBritishColumbia,"Seropositivity of SARS-CoV-2 in an unvaccinated cohort in British Columbia, Canada: a cross-sectional survey with dried blood spot samples.",2022-08-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,British Columbia,,"""Participants were recruited from existing large research
cohorts in BC, comprised of individuals who had provided
consent to be contacted for future research, in addition to
general public recruitment through social media, patient
research networks, as well as stakeholder and community
websites (index participants). Eligible participants were
those 25–69 years of age who were current residents of
BC.""",,2020-11-15,2021-06-15,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,,961,0.032,,,,,,,,Convenience,Meso Scale Discovery multiplex assay,Meso Scale Discovery,CLIA,Dried Blood,IgG,Spike,,0.79,0.97,['High'],,No,Yes,Yes,,Unclear,Yes,No,,C Sarai Racey,The University of British Columbia,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2022-062567,2022-09-12,2023-06-22,Unverified,racey_seropositivity_2022,CAN
220829_BritishColumbia_UniversityofBritishColumbia_Age_30-39,220829_BritishColumbia_UniversityofBritishColumbia,"Seropositivity of SARS-CoV-2 in an unvaccinated cohort in British Columbia, Canada: a cross-sectional survey with dried blood spot samples.",2022-08-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,British Columbia,,"""Participants were recruited from existing large research
cohorts in BC, comprised of individuals who had provided
consent to be contacted for future research, in addition to
general public recruitment through social media, patient
research networks, as well as stakeholder and community
websites (index participants). Eligible participants were
those 25–69 years of age who were current residents of
BC.""",,2020-11-15,2021-06-15,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,,693,0.036000000000000004,,,,,,,,Convenience,Meso Scale Discovery multiplex assay,Meso Scale Discovery,CLIA,Dried Blood,IgG,Spike,,0.79,0.97,['High'],,No,Yes,Yes,,Unclear,Yes,No,,C Sarai Racey,The University of British Columbia,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2022-062567,2022-09-12,2023-06-22,Unverified,racey_seropositivity_2022,CAN
220829_BritishColumbia_UniversityofBritishColumbia_Sex_Male,220829_BritishColumbia_UniversityofBritishColumbia,"Seropositivity of SARS-CoV-2 in an unvaccinated cohort in British Columbia, Canada: a cross-sectional survey with dried blood spot samples.",2022-08-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,British Columbia,,"""Participants were recruited from existing large research
cohorts in BC, comprised of individuals who had provided
consent to be contacted for future research, in addition to
general public recruitment through social media, patient
research networks, as well as stakeholder and community
websites (index participants). Eligible participants were
those 25–69 years of age who were current residents of
BC.""",,2020-11-15,2021-06-15,Household and community samples,Male,Multiple groups,,,Sex/Gender,,480,0.028999999999999998,,,,,,,,Convenience,Meso Scale Discovery multiplex assay,Meso Scale Discovery,CLIA,Dried Blood,IgG,Spike,,0.79,0.97,['High'],,No,Yes,Yes,,Unclear,Yes,No,,C Sarai Racey,The University of British Columbia,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2022-062567,2022-09-12,2023-06-22,Unverified,racey_seropositivity_2022,CAN
220829_BritishColumbia_UniversityofBritishColumbia_Age_25-29,220829_BritishColumbia_UniversityofBritishColumbia,"Seropositivity of SARS-CoV-2 in an unvaccinated cohort in British Columbia, Canada: a cross-sectional survey with dried blood spot samples.",2022-08-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,British Columbia,,"""Participants were recruited from existing large research
cohorts in BC, comprised of individuals who had provided
consent to be contacted for future research, in addition to
general public recruitment through social media, patient
research networks, as well as stakeholder and community
websites (index participants). Eligible participants were
those 25–69 years of age who were current residents of
BC.""",,2020-11-15,2021-06-15,Household and community samples,All,Adults (18-64 years),25.0,29.0,Age,25-29,223,0.045,,,,,,,,Convenience,Meso Scale Discovery multiplex assay,Meso Scale Discovery,CLIA,Dried Blood,IgG,Spike,,0.79,0.97,['High'],,No,Yes,Yes,,Unclear,Yes,No,,C Sarai Racey,The University of British Columbia,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2022-062567,2022-09-12,2023-06-22,Unverified,racey_seropositivity_2022,CAN
220929_Canada_CBS_BloodDonors_RocheS_Overall_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,35118,1.0,1.0,1.0,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,271,1.0,0.9876,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,15961,0.9923563686,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,3811,0.6898451849999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_Age_40-59_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,12876,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_Overall_PopAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Analysis,,35118,0.9933,0.9924,0.9941,,,True,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,271,0.5461254613,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,3121,0.6224000000000001,0.6052000000000001,0.6395000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_Age_60+_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,10103,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1510,0.9933774834000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_Overall_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Analysis,,35118,0.9928,0.9918000000000001,0.9936,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_Age_60+_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,10104,0.4106,0.4008,0.4203,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,444,0.9954954954999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1859,0.9983862292000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,26851,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,481,0.6271,0.5907,0.6636,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,3121,0.62,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1510,0.5937,0.5675,0.6199,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_Sex_Male_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,19054,0.9911304713,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2463,0.9935038571,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1518,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1518,0.49802371540000007,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_Sex_Male_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,19056,0.5982000000000001,0.5908,0.6056,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,481,0.9979209979,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,5167,0.5893,0.5758,0.6028,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1738,0.6087456847,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_Sex_Female_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,16065,0.5761329681,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2463,0.6824,0.6639,0.701,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1993,0.9919719017,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_Age_17-24_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2643,0.7461218313000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_Sex_Male_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,19054,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,6102,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_Overall_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Test used,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay PopTest Adj,35121,0.5855,0.5803,0.5907,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,1060,1.0,0.9964000000000001,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_Sex_Female_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,16064,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,15962,0.5512,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1168,0.5753424658,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_Age_25-39_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,9497,0.6665,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,1811,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1859,0.5164066703000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1510,1.0,0.9995999999999999,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,444,1.0,0.9911,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_Overall_PopAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Analysis,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay Pop Adj,35121,0.5834,0.5782,0.5885,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,5167,0.5872,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,481,0.6257796258,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1738,0.995972382,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1993,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1993,0.5957,0.574,0.6175,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6477,0.991045237,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1993,0.5935775213000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,1812,0.6082,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,3811,0.9929152453000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_Age_40-59_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,12877,0.6049,0.5962,0.6136,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1738,0.6262,0.6023,0.65,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,15961,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_Age_40-59_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,12876,0.9917676297,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,1060,0.9924528302000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2463,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,3811,0.7095999999999999,0.6955,0.7237,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_Age_40-59_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,12877,0.6009,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_Age_25-39_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,9496,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_Age_25-39_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,9496,0.9959983151,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2463,0.6796589525000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,26853,0.5663,0.5602,0.5723,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1859,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,271,1.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,5166,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,1812,0.6113000000000001,0.5899,0.6327,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,3120,0.9955128205,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_Age_60+_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,10103,0.9893101059,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,1060,0.5603773585,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_Age_25-39_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,9497,0.6756000000000001,0.6656000000000001,0.6856,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1510,0.5682119205,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_Age_17-24_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2643,0.7506,0.7377,0.7636000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,6104,0.5915,0.5792,0.6038,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,3120,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,271,0.5479,0.47619999999999996,0.6196,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1738,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_Sex_Female_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,16065,0.5734,0.5662,0.5807,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,1811,0.9961347322,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_Age_17-24_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2643,0.9992432841000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1168,0.9991438356000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1168,0.5774,0.5488000000000001,0.6059,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,1060,0.5722,0.5413,0.6031000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,6102,0.9934447722,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,3811,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,15962,0.5604,0.5529999999999999,0.5678,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,444,0.6418918919,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1518,0.9947299078,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_Sex_Female_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,16064,0.9947086653,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6477,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1518,0.5086,0.4804,0.5367000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6477,0.6642,0.6513,0.6770999999999999,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,444,0.6468,0.6034,0.6903,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1859,0.518,0.49520000000000003,0.5409,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,481,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,5166,0.9943863724,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,26851,0.9927749432,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,6104,0.5755,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_Age_60+_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,10104,0.416213006,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1168,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheS_Age_17-24_PopTestAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2643,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6477,0.6510730276,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,26853,0.5593,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
220929_Canada_CBS_BloodDonors_RocheN_Sex_Male_UnAdj,220929_Canada_CBS,"COVID-19 Seroprevalence Report September 29th, 2022, Report #25: August 2022 Survey The advance of Omicron",2022-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-08-01,2022-08-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,19056,0.5767292957,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-10-20,2024-04-23,Verified,canadian_blood_services_covid-19_2022-15,CAN
221030_Montreal_UniversityofMontreal_Round1_Primary,221030_Montreal_UniversityofMontreal_Round1,"Seroprevalence, seroconversion, and seroreversion of infection-induced SARS-CoV-2 antibodies among a cohort of children and adolescents in Montreal, Canada",2022-10-30,Preprint,Regional,Repeated cross-sectional study,Canada,Québec,Québec,"Between ages 2-17, attending one of schools or daycares selected by the study in Montreal. ",,2020-10-20,2021-03-15,Students and Daycares,All,Children and Youth (0-17 years),2.0,17.0,Primary Estimate,,1632,0.057999999999999996,0.048,0.071,True,,True,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Kate Zinszer,University of Montreal,Not Unity-Aligned,10.1101/2022.10.28.22281660,2022-11-10,2023-03-19,Unverified,zinszer_seroprevalence_2022,CAN
221030_Montreal_UniversityofMontreal_Round1_Age_2-4,221030_Montreal_UniversityofMontreal_Round1,"Seroprevalence, seroconversion, and seroreversion of infection-induced SARS-CoV-2 antibodies among a cohort of children and adolescents in Montreal, Canada",2022-10-30,Preprint,Regional,Repeated cross-sectional study,Canada,Québec,Montreal,"Between ages 2-17, attending one of schools or daycares selected by the study in Montreal. ",,2020-10-20,2021-03-15,Students and Daycares,All,Children and Youth (0-17 years),2.0,4.0,Age,2-4,328,0.049,0.03,0.078,,,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Kate Zinszer,University of Montreal,Not Unity-Aligned,10.1101/2022.10.28.22281660,2022-11-10,2023-03-19,Unverified,zinszer_seroprevalence_2022,CAN
221030_Montreal_UniversityofMontreal_Round1_Age_12-18,221030_Montreal_UniversityofMontreal_Round1,"Seroprevalence, seroconversion, and seroreversion of infection-induced SARS-CoV-2 antibodies among a cohort of children and adolescents in Montreal, Canada",2022-10-30,Preprint,Regional,Repeated cross-sectional study,Canada,Québec,Montreal,"Between ages 2-17, attending one of schools or daycares selected by the study in Montreal. ",,2020-10-20,2021-03-15,Students and Daycares,All,Children and Youth (0-17 years),12.0,18.0,Age,12-18,577,0.066,0.048,0.08900000000000001,,,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Kate Zinszer,University of Montreal,Not Unity-Aligned,10.1101/2022.10.28.22281660,2022-11-10,2023-03-19,Unverified,zinszer_seroprevalence_2022,CAN
221030_Montreal_UniversityofMontreal_Round1_Age_5-11,221030_Montreal_UniversityofMontreal_Round1,"Seroprevalence, seroconversion, and seroreversion of infection-induced SARS-CoV-2 antibodies among a cohort of children and adolescents in Montreal, Canada",2022-10-30,Preprint,Regional,Repeated cross-sectional study,Canada,Québec,Montreal,"Between ages 2-17, attending one of schools or daycares selected by the study in Montreal. ",,2020-10-20,2021-03-15,Students and Daycares,All,Children and Youth (0-17 years),5.0,11.0,Age,5-11,727,0.055999999999999994,0.042,0.076,,,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Kate Zinszer,University of Montreal,Not Unity-Aligned,10.1101/2022.10.28.22281660,2022-11-10,2023-03-19,Unverified,zinszer_seroprevalence_2022,CAN
221030_Montreal_UniversityofMontreal_Round2_Primary,221030_Montreal_UniversityofMontreal_Round2,"Seroprevalence, seroconversion, and seroreversion of infection-induced SARS-CoV-2 antibodies among a cohort of children and adolescents in Montreal, Canada",2022-10-30,Preprint,Regional,Repeated cross-sectional study,Canada,Québec,Montreal,"Between ages 2-17, attending one of schools or daycares selected by the study in Montreal. ",,2021-05-18,2021-07-21,Students and Daycares,All,Children and Youth (0-17 years),,,Primary Estimate,,936,0.105,0.086,0.127,True,,True,,True,Convenience,"Author designed (ELISA) - Nucleocapsid,Author designed (ELISA) -Spike",,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Kate Zinszer,University of Montreal,Not Unity-Aligned,10.1101/2022.10.28.22281660,2023-01-04,2023-03-19,Unverified,zinszer_seroprevalence_2022,CAN
221030_Montreal_UniversityofMontreal_Round2_Age_12-18,221030_Montreal_UniversityofMontreal_Round2,"Seroprevalence, seroconversion, and seroreversion of infection-induced SARS-CoV-2 antibodies among a cohort of children and adolescents in Montreal, Canada",2022-10-30,Preprint,Regional,Repeated cross-sectional study,Canada,Québec,Montreal,"Between ages 2-17, attending one of schools or daycares selected by the study in Montreal. ",,2021-05-18,2021-07-21,Students and Daycares,All,Children and Youth (0-17 years),12.0,18.0,Age,12-18,338,0.083,0.057,0.12,,,True,,,Convenience,"Author designed (ELISA) - Nucleocapsid,Author designed (ELISA) -Spike",,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Kate Zinszer,University of Montreal,Not Unity-Aligned,10.1101/2022.10.28.22281660,2023-01-04,2023-03-19,Unverified,zinszer_seroprevalence_2022,CAN
221030_Montreal_UniversityofMontreal_Round2_Age_5-11,221030_Montreal_UniversityofMontreal_Round2,"Seroprevalence, seroconversion, and seroreversion of infection-induced SARS-CoV-2 antibodies among a cohort of children and adolescents in Montreal, Canada",2022-10-30,Preprint,Regional,Repeated cross-sectional study,Canada,Québec,Montreal,"Between ages 2-17, attending one of schools or daycares selected by the study in Montreal. ",,2021-05-18,2021-07-21,Students and Daycares,All,Children and Youth (0-17 years),5.0,11.0,Age,5-11,448,0.129,0.1,0.165,,,True,,,Convenience,"Author designed (ELISA) - Nucleocapsid,Author designed (ELISA) -Spike",,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Kate Zinszer,University of Montreal,Not Unity-Aligned,10.1101/2022.10.28.22281660,2023-01-04,2023-03-19,Unverified,zinszer_seroprevalence_2022,CAN
221030_Montreal_UniversityofMontreal_Round2_Age_2-4,221030_Montreal_UniversityofMontreal_Round2,"Seroprevalence, seroconversion, and seroreversion of infection-induced SARS-CoV-2 antibodies among a cohort of children and adolescents in Montreal, Canada",2022-10-30,Preprint,Regional,Repeated cross-sectional study,Canada,Québec,Montreal,"Between ages 2-17, attending one of schools or daycares selected by the study in Montreal. ",,2021-05-18,2021-07-21,Students and Daycares,All,Children and Youth (0-17 years),2.0,4.0,Age,2-4,150,0.084,0.049,0.14,,,True,,,Convenience,"Author designed (ELISA) - Nucleocapsid,Author designed (ELISA) -Spike",,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Kate Zinszer,University of Montreal,Not Unity-Aligned,10.1101/2022.10.28.22281660,2023-01-04,2023-03-19,Unverified,zinszer_seroprevalence_2022,CAN
221030_Montreal_UniversityofMontreal_Round3_Primary,221030_Montreal_UniversityofMontreal_Round3,"Seroprevalence, seroconversion, and seroreversion of infection-induced SARS-CoV-2 antibodies among a cohort of children and adolescents in Montreal, Canada",2022-10-30,Preprint,Regional,Repeated cross-sectional study,Canada,Québec,Montreal,"Between ages 2-17, attending one of schools or daycares selected by the study in Montreal. ",,2021-11-18,2022-01-20,Students and Daycares,All,Children and Youth (0-17 years),,,Primary Estimate,,723,0.109,0.08800000000000001,0.135,True,,True,,True,Convenience,"Author designed (ELISA) - Nucleocapsid,Author designed (ELISA) -Spike",,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Kate Zinszer,University of Montreal,Not Unity-Aligned,10.1101/2022.10.28.22281660,2023-01-04,2023-03-19,Unverified,zinszer_seroprevalence_2022,CAN
221030_Montreal_UniversityofMontreal_Round3_Age_2-4,221030_Montreal_UniversityofMontreal_Round3,"Seroprevalence, seroconversion, and seroreversion of infection-induced SARS-CoV-2 antibodies among a cohort of children and adolescents in Montreal, Canada",2022-10-30,Preprint,Regional,Repeated cross-sectional study,Canada,Québec,Montreal,"Between ages 2-17, attending one of schools or daycares selected by the study in Montreal. ",,2021-11-18,2022-01-20,Students and Daycares,All,Children and Youth (0-17 years),2.0,4.0,Age,2-4,88,0.063,0.027999999999999997,0.135,,,True,,,Convenience,"Author designed (ELISA) - Nucleocapsid,Author designed (ELISA) -Spike",,ELISA,Dried Blood,IgG,[],Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Kate Zinszer,University of Montreal,Not Unity-Aligned,10.1101/2022.10.28.22281660,2023-01-04,2023-03-19,Unverified,zinszer_seroprevalence_2022,CAN
221030_Montreal_UniversityofMontreal_Round3_Age_5-11,221030_Montreal_UniversityofMontreal_Round3,"Seroprevalence, seroconversion, and seroreversion of infection-induced SARS-CoV-2 antibodies among a cohort of children and adolescents in Montreal, Canada",2022-10-30,Preprint,Regional,Repeated cross-sectional study,Canada,Québec,Montreal,"Between ages 2-17, attending one of schools or daycares selected by the study in Montreal. ",,2021-11-18,2022-01-20,Students and Daycares,All,Children and Youth (0-17 years),5.0,11.0,Age,5-11,346,0.138,0.105,0.18,,,True,,,Convenience,"Author designed (ELISA) - Nucleocapsid,Author designed (ELISA) -Spike",,ELISA,Dried Blood,IgG,[],Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Kate Zinszer,University of Montreal,Not Unity-Aligned,10.1101/2022.10.28.22281660,2023-01-04,2023-03-19,Unverified,zinszer_seroprevalence_2022,CAN
221030_Montreal_UniversityofMontreal_Round3_Age_12-18,221030_Montreal_UniversityofMontreal_Round3,"Seroprevalence, seroconversion, and seroreversion of infection-induced SARS-CoV-2 antibodies among a cohort of children and adolescents in Montreal, Canada",2022-10-30,Preprint,Regional,Repeated cross-sectional study,Canada,Québec,Montreal,"Between ages 2-17, attending one of schools or daycares selected by the study in Montreal. ",,2021-11-18,2022-01-20,Students and Daycares,All,Children and Youth (0-17 years),12.0,18.0,Age,12-18,289,0.09,0.061,0.13,,,True,,,Convenience,"Author designed (ELISA) - Nucleocapsid,Author designed (ELISA) -Spike",,ELISA,Dried Blood,IgG,[],Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Kate Zinszer,University of Montreal,Not Unity-Aligned,10.1101/2022.10.28.22281660,2023-01-04,2023-03-19,Unverified,zinszer_seroprevalence_2022,CAN
221105_Calgary_UniversityofCalgary_visit1,221105_Calgary_UniversityofCalgary_visit1,"A Longitudinal Seroepidemiology Study to Evaluate Antibody Response to SARS-CoV-2 Virus and Vaccination in Children in Calgary, Canada from July 2020 to April 2022",2022-11-05,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,Alberta,Calgary,"All study participants were under 18 years of age, residing in the Calgary area. Two study groups were enrolled. Group 1 included children with confirmed or probable COVID-19 infection prior to enrollment and Group 2 included children not diagnosed with COVID- 19 infections prior to enrollment.",,2020-07-15,2020-11-15,Household and community samples,All,Children and Youth (0-17 years),5.0,13.0,Primary Estimate,,1012,0.095,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Spike,,0.99,1.0,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Emily J Doucette,University of Calgary,Not Unity-Aligned,https://doi.org/10.1101/2022.11.02.22281665,2022-11-10,2024-03-01,Unverified,doucetteLongitudinalSeroepidemiologyStudy2022,CAN
221105_Calgary_UniversityofCalgary_visit2,221105_Calgary_UniversityofCalgary_visit2,"A Longitudinal Seroepidemiology Study to Evaluate Antibody Response to SARS-CoV-2 Virus and Vaccination in Children in Calgary, Canada from July 2020 to April 2022",2022-11-05,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,Alberta,Calgary,"All study participants were under 18 years of age, residing in the Calgary area. Two study groups were enrolled. Group 1 included children with confirmed or probable COVID-19 infection prior to enrollment and Group 2 included children not diagnosed with COVID- 19 infections prior to enrollment.",,2021-02-15,2021-04-15,Household and community samples,All,Children and Youth (0-17 years),,,Primary Estimate,,950,0.129,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Spike,,0.99,1.0,['High'],,No,Yes,No,,Yes,Yes,Yes,,Emily J Doucette,University of Calgary,Not Unity-Aligned,https://doi.org/10.1101/2022.11.02.22281665,2022-11-10,2024-03-01,Unverified,doucetteLongitudinalSeroepidemiologyStudy2022,CAN
221105_Calgary_UniversityofCalgary_visit3,221105_Calgary_UniversityofCalgary_visit3,"A Longitudinal Seroepidemiology Study to Evaluate Antibody Response to SARS-CoV-2 Virus and Vaccination in Children in Calgary, Canada from July 2020 to April 2022",2022-11-05,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,Alberta,Calgary,"All study participants were under 18 years of age, residing in the Calgary area. Two study groups were enrolled. Group 1 included children with confirmed or probable COVID-19 infection prior to enrollment and Group 2 included children not diagnosed with COVID- 19 infections prior to enrollment.",,2021-08-15,2021-10-15,Household and community samples,All,Children and Youth (0-17 years),,,Primary Estimate,,923,0.519,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Spike,,0.99,1.0,['High'],,No,Yes,No,,Yes,Yes,Yes,,Emily J Doucette,University of Calgary,Not Unity-Aligned,https://doi.org/10.1101/2022.11.02.22281665,2022-11-10,2024-03-01,Unverified,doucetteLongitudinalSeroepidemiologyStudy2022,CAN
221105_Calgary_UniversityofCalgary_visit4,221105_Calgary_UniversityofCalgary_visit4,"A Longitudinal Seroepidemiology Study to Evaluate Antibody Response to SARS-CoV-2 Virus and Vaccination in Children in Calgary, Canada from July 2020 to April 2022",2022-11-05,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Canada,Alberta,Calgary,"All study participants were under 18 years of age, residing in the Calgary area. Two study groups were enrolled. Group 1 included children with confirmed or probable COVID-19 infection prior to enrollment and Group 2 included children not diagnosed with COVID- 19 infections prior to enrollment.",,2022-02-15,2022-04-15,Household and community samples,All,Children and Youth (0-17 years),,,Primary Estimate,,865,0.903,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Spike,,0.99,1.0,['High'],,No,Yes,No,,Yes,Yes,Yes,,Emily J Doucette,University of Calgary,Not Unity-Aligned,https://doi.org/10.1101/2022.11.02.22281665,2022-11-10,2024-03-01,Unverified,doucetteLongitudinalSeroepidemiologyStudy2022,CAN
221107_Canada_CBS_BloodDonors_RocheS_Overall_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,31606,1.0,1.0,1.0,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1396,0.5582,0.5285,0.5879,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1396,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1269,0.5794,0.5554,0.6034,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_Age_25-39_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8322,0.7240000000000001,0.7140000000000001,0.7341,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1396,0.9964183380999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1492,0.9886058981,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1269,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_Age_17-24_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2342,0.7852263023,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2304,1.0,0.9987,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_Overall_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Test used,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay PopTest Adj,31606,0.6323,0.6269,0.6377,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24105,0.6175482265000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,940,0.6308510638,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2980,0.6743000000000001,0.6577,0.6909000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_Overall_PopAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Analysis,,31606,0.9933,0.9923000000000001,0.9942000000000001,,,True,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,1651,0.6527,0.631,0.6745,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1492,0.6456999999999999,0.6186,0.6729,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_Overall_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Analysis,,31606,0.9929000000000001,0.9920000000000001,0.9938,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_Age_25-39_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8322,0.7207402066999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6084,0.9926035503,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,464,0.6400862069000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,464,0.6327,0.5943,0.6709999999999999,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2304,0.7238,0.7007,0.7469,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,966,0.6329,0.6009000000000001,0.665,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1492,0.6380697051,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1779,0.6866,0.6633,0.7099,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_Sex_Female_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13986,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,121,0.6402,0.5665,0.7138,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24105,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_Age_17-24_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2342,0.9978650725999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2980,0.994966443,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24105,0.9931134618999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,384,0.7083333333,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,940,1.0,0.9971,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1779,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4644,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,384,0.9947916667,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_Sex_Male_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,17620,0.9924517594,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2304,0.7044270833,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_Sex_Male_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,17620,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_Overall_PopAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Analysis,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay Pop Adj,31606,0.6299,0.6245,0.6352000000000001,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,13910,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_Age_60+_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,8778,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,1651,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,3458,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1666,0.6691,0.6443000000000001,0.6938,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_Age_60+_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,8778,0.4768740032,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_Age_25-39_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8322,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4644,0.6199397071,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_Sex_Female_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13986,0.9935649936000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_Age_40-59_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,12164,0.6502795133,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,464,1.0,0.9993000000000001,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,13910,0.608,0.6004,0.6156,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1269,0.9984239559,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5507,0.6277465044,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1779,0.6767847105,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_Age_17-24_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2342,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2304,0.9926215278,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4644,0.6202000000000001,0.6084,0.632,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1779,0.9960652052000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,1651,0.9945487583000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_Age_40-59_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,12164,0.6481,0.6391,0.657,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_Sex_Female_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13986,0.6271,0.6196,0.6346,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5507,0.9936444525,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,13910,0.6058950395,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5507,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,966,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_Age_60+_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,8778,0.4673,0.4569,0.4778,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_Sex_Female_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13986,0.6357071357,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,966,0.6231884058,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_Sex_Male_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,17620,0.6266742338000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_Overall_Unadj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Analysis,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay Pop Adj,31606,0.6307,0.6253,0.636,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-04-17,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,1651,0.6656571775000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4644,0.9937553833,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_Sex_Male_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,17620,0.6378,0.6302000000000001,0.6455,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6084,0.7133,0.7001000000000001,0.7265,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2980,0.6697986577,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,3458,0.7283,0.7138,0.7428,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,464,0.9956896552000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2980,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_Age_40-59_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,12164,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1269,0.5862884161,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5507,0.6373,0.6245,0.6501,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,3458,0.9945054945,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,121,0.6115702479,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1492,0.9999,0.9937,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,384,0.6818000000000001,0.6351,0.7284999999999999,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,3458,0.7165991903,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6084,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,13910,0.9928828181,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24105,0.6176,0.6113000000000001,0.6238,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,940,0.9946808511,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_Age_25-39_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8322,0.9953136265000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,121,0.9963,0.9773000000000001,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,384,1.0,0.9909,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1666,0.9915966387,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1396,0.5565902579,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_Age_40-59_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,12164,0.9925189083,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1666,0.6554621849000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_Age_17-24_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2342,0.7825,0.7694,0.7956000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,940,0.642,0.6082,0.6758,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6084,0.6992110454,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,966,0.9948240166,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,121,0.9917355372000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_Age_60+_UnAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,8778,0.9899749373000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221107_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_PopTestAdj,221107_Canada_CBS,"COVID-19 Seroprevalence Report November 7th, 2022 Report #26: September 2022 Survey The advance of Omicron",2022-11-07,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-09-01,2022-09-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1666,1.0,0.9951000000000001,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-11-14,2024-04-17,Verified,canadian_blood_services_covid-19_2022-17,CAN
221109_Quebec_McGillUniversityHealthCentre_Overall,221109_Quebec_McGillUniversityHealthCentre,"Importance of occupation for SARS-CoV-2 seroprevalence and COVID-19 vaccination among correctional workers in Quebec, Canada: A cross-sectional study",2022-11-09,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,Correctional workers over the age of 18 and who were able to consent in either English or French were invited to participate in this study.,Those who were in isolation with COVID-19 or quarantined at home as a contact of a positive case were excluded.,2021-07-14,2021-11-15,Essential non-healthcare workers,All,Adults (18-64 years),18.0,,Primary Estimate,overall seroprevalence,600,0.18,,,True,,,,True,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,"CLIA, CMIA",,"IgG, IgM, IgA",Nucleocapsid (N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Nadine Kronfli,McGill University Health Centre,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.1021871,2022-12-13,2024-03-01,Unverified,kronfli_importance_2022,CAN
221109_Quebec_McGillUniversityHealthCentre_Age50Over,221109_Quebec_McGillUniversityHealthCentre,"Importance of occupation for SARS-CoV-2 seroprevalence and COVID-19 vaccination among correctional workers in Quebec, Canada: A cross-sectional study",2022-11-09,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,Correctional workers over the age of 18 and who were able to consent in either English or French were invited to participate in this study.,Those who were in isolation with COVID-19 or quarantined at home as a contact of a positive case were excluded.,2021-07-14,2021-11-15,Essential non-healthcare workers,All,Adults (18-64 years),50.0,,Age,age: >= 50,180,0.14400000000000002,,,,,,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,"CLIA, CMIA",,"IgG, IgM, IgA",Nucleocapsid (N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Nadine Kronfli,McGill University Health Centre,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.1021871,2022-12-14,2024-03-01,Unverified,kronfli_importance_2022,CAN
221109_Quebec_McGillUniversityHealthCentre_Age40to49,221109_Quebec_McGillUniversityHealthCentre,"Importance of occupation for SARS-CoV-2 seroprevalence and COVID-19 vaccination among correctional workers in Quebec, Canada: A cross-sectional study",2022-11-09,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,Correctional workers over the age of 18 and who were able to consent in either English or French were invited to participate in this study.,Those who were in isolation with COVID-19 or quarantined at home as a contact of a positive case were excluded.,2021-07-14,2021-11-15,Essential non-healthcare workers,All,Adults (18-64 years),40.0,49.0,Age,age: 40-49,189,0.17500000000000002,,,,,,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,"CLIA, CMIA",,"IgG, IgM, IgA",Nucleocapsid (N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Nadine Kronfli,McGill University Health Centre,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.1021871,2022-12-14,2024-03-01,Unverified,kronfli_importance_2022,CAN
221109_Quebec_McGillUniversityHealthCentre_Age30to39,221109_Quebec_McGillUniversityHealthCentre,"Importance of occupation for SARS-CoV-2 seroprevalence and COVID-19 vaccination among correctional workers in Quebec, Canada: A cross-sectional study",2022-11-09,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,Correctional workers over the age of 18 and who were able to consent in either English or French were invited to participate in this study.,Those who were in isolation with COVID-19 or quarantined at home as a contact of a positive case were excluded.,2021-07-14,2021-11-15,Essential non-healthcare workers,All,Adults (18-64 years),30.0,39.0,Age,age: 30-39,142,0.218,,,,,,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,"CLIA, CMIA",,"IgG, IgM, IgA",Nucleocapsid (N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Nadine Kronfli,McGill University Health Centre,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.1021871,2022-12-14,2024-03-01,Unverified,kronfli_importance_2022,CAN
221109_Quebec_McGillUniversityHealthCentre_Age18to29,221109_Quebec_McGillUniversityHealthCentre,"Importance of occupation for SARS-CoV-2 seroprevalence and COVID-19 vaccination among correctional workers in Quebec, Canada: A cross-sectional study",2022-11-09,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,Quebec,,Correctional workers over the age of 18 and who were able to consent in either English or French were invited to participate in this study.,Those who were in isolation with COVID-19 or quarantined at home as a contact of a positive case were excluded.,2021-07-14,2021-11-15,Essential non-healthcare workers,All,Adults (18-64 years),18.0,29.0,Age,age: 18-29,86,0.163,,,,,,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,"CLIA, CMIA",,"IgG, IgM, IgA",Nucleocapsid (N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Nadine Kronfli,McGill University Health Centre,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.1021871,2022-12-14,2024-03-01,Unverified,kronfli_importance_2022,CAN
221202_Canada_CBS_BloodDonors_RocheS_Overall_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,31451,1.0,1.0,1.0,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1198,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2235,0.7518000000000001,0.7339,0.7696,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_Sex_Male_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18070,0.6809000000000001,0.6735,0.6884,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,386,0.7046632124,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,386,0.9896373057,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,5961,0.7365,0.7236,0.7494,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1203,0.6417290108,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,478,1.0,0.9986,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_Sex_Male_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18070,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1198,0.6210350584,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1920,0.9932291667,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14704,0.6559,0.6485,0.6634000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_Overall_PopAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Analysis,,31451,0.9934999999999999,0.9926,0.9944,,,True,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1554,0.685,0.6607,0.7093,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,326,0.9969325153,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1554,0.9935649936000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2705,0.712754159,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3115,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5200,0.6717307692,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_Sex_Male_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18070,0.9920863309000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,386,0.7143,0.6691,0.7594,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_Age_17-24_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2432,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1203,0.6288,0.5997,0.6579,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,5365,0.6788,0.6677,0.6900000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3115,0.7574,0.7427,0.7721,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,326,0.6519,0.579,0.7248,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1920,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1285,0.6953,0.6692,0.7212999999999999,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14704,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_Overall_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Test used,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay PopTest Adj,31451,0.6729999999999999,0.6678000000000001,0.6783,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,478,0.9958158996,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1285,0.9945525292,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_Age_60+_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,8955,0.9901730877,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,928,0.6498,0.6173,0.6824,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24513,0.6521845551,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,5961,0.9929542023000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,326,0.6441717791000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1554,0.6737451737000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24513,0.6533,0.6473000000000001,0.6594,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_Age_25-39_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8233,0.7517,0.7419,0.7615000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1285,1.0,0.9998,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1198,0.9949916528,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1285,0.6848249027,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_Age_40-59_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11831,0.9923083425,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_Age_17-24_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2432,0.9979440789,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2705,1.0,0.9999,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,740,0.9972972973,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2211,0.736318408,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2705,0.708,0.6919,0.7241,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_Age_60+_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,8955,1.0,0.9997,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,5365,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2705,0.993715342,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1920,0.7051000000000001,0.6826000000000001,0.7276,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2211,0.9963817277,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,928,0.6379310345,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_Age_25-39_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8233,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,928,1.0,0.9987,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24513,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,740,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5200,0.9923076923,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_Sex_Female_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13381,0.6713997459,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,928,0.9956896552000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_Age_25-39_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8233,0.9959917406,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_Sex_Male_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18070,0.6684006641000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1198,0.632,0.6054,0.6587000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2211,0.7551000000000001,0.7329000000000001,0.7772,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3115,0.9974317816999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_Overall_Unadj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Analysis,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay Pop Adj,31451,0.6697,0.6644,0.6749,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-04-18,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_Sex_Female_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13381,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14704,0.6499591948,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_Overall_PopAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Analysis,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay Pop Adj,31451,0.6703,0.6651,0.6755,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1203,0.9966749792,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,478,0.6736401674,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24513,0.9929017256,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_Overall_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Analysis,,31451,0.9931000000000001,0.9921,0.9940000000000001,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2235,0.7494407158999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,326,0.9983,0.9806,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2211,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_Age_60+_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,8955,0.5181,0.5075999999999999,0.5285,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,740,0.6297297297000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1920,0.6895833333,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_Age_25-39_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8233,0.7490586663000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,386,0.9975,0.9856,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,740,0.6424,0.6106,0.6742,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,5961,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_Age_40-59_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11831,0.6902206069000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2235,1.0,0.9984000000000001,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_Sex_Female_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13381,0.6656000000000001,0.6581999999999999,0.6729,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1203,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14704,0.9925870511,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_Age_40-59_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11831,0.6920000000000001,0.6833,0.7007,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,5961,0.7238718336,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_Age_60+_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,8955,0.5280848687999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_Age_17-24_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2432,0.8223684211,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_Sex_Female_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13381,0.9944697706,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1554,1.0,0.9995999999999999,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3115,0.7505617978,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5200,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,5365,0.6762348555,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_Age_40-59_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11831,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2235,0.9910514541000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_UnAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,5365,0.9955265609999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,478,0.6708,0.6335000000000001,0.7081000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_Age_17-24_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2432,0.8175,0.8052,0.8298000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_PopTestAdj,221202_Canada_CBS,"COVID-19 Seroprevalence Report December 2, 2022 Report #27: October 2022 Survey The advance of Omicron",2022-12-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-10-01,2022-10-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5200,0.6759999999999999,0.6635,0.6884,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2022-12-16,2024-04-18,Verified,canadian_blood_services_covid-19_2022-20,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round1_Adj,221205_Vancouver_BCCentreforDiseaseControl_Round1,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-03-05,2020-03-13,Residual sera,All,Multiple groups,0.0,,Primary Estimate,test and pop adjusted estimate,895,0.003,0.0007000000000000001,0.008,True,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round1_Age60to69,221205_Vancouver_BCCentreforDiseaseControl_Round1,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-03-05,2020-03-13,Residual sera,All,Multiple groups,60.0,69.0,Age,"age: 60-69, test and pop adjusted estimate",100,0.003,0.0004,0.009000000000000001,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9950000000000003,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round1_Age0to4,221205_Vancouver_BCCentreforDiseaseControl_Round1,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-03-05,2020-03-13,Residual sera,All,Children and Youth (0-17 years),0.0,4.0,Age,"age: 0-4, test and pop adjusted estimate",38,0.003,0.00046,0.009000000000000001,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round1_Age10to19,221205_Vancouver_BCCentreforDiseaseControl_Round1,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-03-05,2020-03-13,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,"age: 10-19, test and pop adjusted estimate",89,0.003,0.00045,0.009000000000000001,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round1_Age70to79,221205_Vancouver_BCCentreforDiseaseControl_Round1,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-03-05,2020-03-13,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,"age: 70-79, test and pop adjusted estimate",100,0.003,0.00046,0.009000000000000001,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9950000000000003,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round1_TestUsed_Siemens-S1-RBD,221205_Vancouver_BCCentreforDiseaseControl_Round1,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-03-05,2020-03-13,Residual sera,All,Multiple groups,0.0,,Test used,Siemens-S1-RBD,10,0.2,0.0252,0.556,,,,,,Stratified non-probability,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,1.0,0.9950000000000004,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2024-05-01,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round1_Age5to9,221205_Vancouver_BCCentreforDiseaseControl_Round1,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-03-05,2020-03-13,Residual sera,All,Children and Youth (0-17 years),5.0,9.0,Age,"age: 5-9, test and pop adjusted estimate",76,0.003,0.0004,0.01,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round1_Age50to59,221205_Vancouver_BCCentreforDiseaseControl_Round1,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-03-05,2020-03-13,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,"age: 50-59, test and pop adjusted estimate",98,0.004,0.001,0.011000000000000001,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9950000000000002,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round1_TestUsed_Ortho-S1,221205_Vancouver_BCCentreforDiseaseControl_Round1,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-03-05,2020-03-13,Residual sera,All,Multiple groups,0.0,,Test used,Ortho-S1,897,0.007,0.003,0.0145,,,,,,Stratified non-probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,1.0,0.9950000000000004,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2024-05-01,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round1_TestUsed_Abbott-NP,221205_Vancouver_BCCentreforDiseaseControl_Round1,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-03-05,2020-03-13,Residual sera,All,Multiple groups,0.0,,Test used,Abbott-NP,896,0.0045,0.001,0.011,,,,,,Stratified non-probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9950000000000004,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2024-05-01,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round1_Age40to49,221205_Vancouver_BCCentreforDiseaseControl_Round1,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-03-05,2020-03-13,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,"age: 40-49, test and pop adjusted estimate",100,0.004,0.001,0.011000000000000001,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round1_Age30to39,221205_Vancouver_BCCentreforDiseaseControl_Round1,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-03-05,2020-03-13,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,"age: 30-39, test and pop adjusted estimate",98,0.003,0.00046,0.009000000000000001,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round1_Age20to29,221205_Vancouver_BCCentreforDiseaseControl_Round1,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-03-05,2020-03-13,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,"age: 20-29, test and pop adjusted estimate",99,0.003,0.001,0.009000000000000001,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round1_Male,221205_Vancouver_BCCentreforDiseaseControl_Round1,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-03-05,2020-03-13,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,test and pop adjusted estimate,443,0.004,0.0006,0.008,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round1_UnAdj,221205_Vancouver_BCCentreforDiseaseControl_Round1,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-03-05,2020-03-13,Residual sera,All,Multiple groups,0.0,,Analysis,crude estimate,895,0.002,0.0003,0.008,,,,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round1_AgeOver80,221205_Vancouver_BCCentreforDiseaseControl_Round1,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-03-05,2020-03-13,Residual sera,All,Seniors (65+ years),80.0,,Age,"age: >= 80, test and pop adjusted estimate",97,0.003,0.001,0.009000000000000001,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9950000000000004,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round1_Female,221205_Vancouver_BCCentreforDiseaseControl_Round1,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-03-05,2020-03-13,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,test and pop adjusted estimate,452,0.003,0.0006,0.008,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round2_Adj,221205_Vancouver_BCCentreforDiseaseControl_Round2,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-05-08,2020-05-27,Residual sera,All,Multiple groups,0.0,,Primary Estimate,test and pop adjusted estimate,890,0.006,0.002,0.011000000000000001,True,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round2_Age30to39,221205_Vancouver_BCCentreforDiseaseControl_Round2,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-05-08,2020-05-27,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,"age: 30-39, test and pop adjusted estimate",100,0.006,0.002,0.013000000000000001,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round2_Age50to59,221205_Vancouver_BCCentreforDiseaseControl_Round2,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-05-08,2020-05-27,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,"age: 50-59, test and pop adjusted estimate",98,0.006,0.002,0.017,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9950000000000002,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round2_Age40to49,221205_Vancouver_BCCentreforDiseaseControl_Round2,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-05-08,2020-05-27,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,"age: 40-49, test and pop adjusted estimate",99,0.0053,0.001,0.012,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round2_Age0to4,221205_Vancouver_BCCentreforDiseaseControl_Round2,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-05-08,2020-05-27,Residual sera,All,Children and Youth (0-17 years),0.0,4.0,Age,"age: 0-4, test and pop adjusted estimate",16,0.006,0.001,0.013999999999999999,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round2_Age60to69,221205_Vancouver_BCCentreforDiseaseControl_Round2,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-05-08,2020-05-27,Residual sera,All,Multiple groups,60.0,69.0,Age,"age: 60-69, test and pop adjusted estimate",100,0.0053,0.001,0.012,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9950000000000003,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round2_TestUsed_Siemens-S1-RBD,221205_Vancouver_BCCentreforDiseaseControl_Round2,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-05-08,2020-05-27,Residual sera,All,Multiple groups,0.0,,Test used,Siemens-S1-RBD,9,0.444,0.137,0.788,,,,,,Stratified non-probability,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,1.0,0.9950000000000004,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2024-05-01,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round2_TestUsed_Abbott-NP,221205_Vancouver_BCCentreforDiseaseControl_Round2,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-05-08,2020-05-27,Residual sera,All,Multiple groups,0.0,,Test used,Abbott-NP,890,0.008,0.003,0.016,,,,,,Stratified non-probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9950000000000004,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2024-05-01,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round2_AgeOver80,221205_Vancouver_BCCentreforDiseaseControl_Round2,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-05-08,2020-05-27,Residual sera,All,Seniors (65+ years),80.0,,Age,"age: >= 80, test and pop adjusted estimate",96,0.0053,0.001,0.012,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9950000000000004,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round2_Male,221205_Vancouver_BCCentreforDiseaseControl_Round2,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-05-08,2020-05-27,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,test and pop adjusted estimate,440,0.006,0.002,0.013000000000000001,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round2_Age20to29,221205_Vancouver_BCCentreforDiseaseControl_Round2,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-05-08,2020-05-27,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,"age: 20-29, test and pop adjusted estimate",98,0.0054,0.001,0.012,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round2_Female,221205_Vancouver_BCCentreforDiseaseControl_Round2,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-05-08,2020-05-27,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,test and pop adjusted estimate,450,0.0053,0.002,0.011000000000000001,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round2_TestUsed_Ortho-S1,221205_Vancouver_BCCentreforDiseaseControl_Round2,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-05-08,2020-05-27,Residual sera,All,Multiple groups,0.0,,Test used,Ortho-S1,894,0.007,0.003,0.0146,,,,,,Stratified non-probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,1.0,0.9950000000000004,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2024-05-01,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round2_Age10to19,221205_Vancouver_BCCentreforDiseaseControl_Round2,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-05-08,2020-05-27,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,"age: 10-19, test and pop adjusted estimate",95,0.006,0.002,0.0152,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round2_Age5to9,221205_Vancouver_BCCentreforDiseaseControl_Round2,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-05-08,2020-05-27,Residual sera,All,Children and Youth (0-17 years),5.0,9.0,Age,"age: 5-9, test and pop adjusted estimate",89,0.0053,0.001,0.013000000000000001,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round2_Age70to79,221205_Vancouver_BCCentreforDiseaseControl_Round2,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-05-08,2020-05-27,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,"age: 70-79, test and pop adjusted estimate",99,0.0053,0.001,0.012,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9950000000000003,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round2_UnAdj,221205_Vancouver_BCCentreforDiseaseControl_Round2,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-05-08,2020-05-27,Residual sera,All,Multiple groups,0.0,,Analysis,crude estimate,890,0.0045000000000000005,0.001,0.012,,,,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round3_Adj,221205_Vancouver_BCCentreforDiseaseControl_Round3,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-09-17,2020-09-29,Residual sera,All,Multiple groups,0.0,,Primary Estimate,test and pop adjusted estimate,2000,0.01,0.006,0.0152,True,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round3_Male,221205_Vancouver_BCCentreforDiseaseControl_Round3,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-09-17,2020-09-29,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,test and pop adjusted estimate,1000,0.01,0.006,0.0154,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round3_Age20to29,221205_Vancouver_BCCentreforDiseaseControl_Round3,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-09-17,2020-09-29,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,"age: 20-29, test and pop adjusted estimate",200,0.01,0.006,0.018000000000000002,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round3_Age5to9,221205_Vancouver_BCCentreforDiseaseControl_Round3,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-09-17,2020-09-29,Residual sera,All,Children and Youth (0-17 years),5.0,9.0,Age,"age: 5-9, test and pop adjusted estimate",200,0.01,0.0048,0.016,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round3_Age40to49,221205_Vancouver_BCCentreforDiseaseControl_Round3,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-09-17,2020-09-29,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,"age: 40-49, test and pop adjusted estimate",200,0.009000000000000001,0.004,0.0154,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round3_Age10to19,221205_Vancouver_BCCentreforDiseaseControl_Round3,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-09-17,2020-09-29,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,"age: 10-19, test and pop adjusted estimate",200,0.011000000000000001,0.006,0.018000000000000002,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round3_Female,221205_Vancouver_BCCentreforDiseaseControl_Round3,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-09-17,2020-09-29,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,test and pop adjusted estimate,1000,0.01,0.006,0.016,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round3_UnAdj,221205_Vancouver_BCCentreforDiseaseControl_Round3,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-09-17,2020-09-29,Residual sera,All,Multiple groups,0.0,,Analysis,crude estimate,2000,0.01,0.006,0.0148,,,,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round3_Age70to79,221205_Vancouver_BCCentreforDiseaseControl_Round3,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-09-17,2020-09-29,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,"age: 70-79, test and pop adjusted estimate",200,0.01,0.0048,0.016,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9950000000000003,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round3_AgeOver80,221205_Vancouver_BCCentreforDiseaseControl_Round3,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-09-17,2020-09-29,Residual sera,All,Seniors (65+ years),80.0,,Age,"age: >= 80, test and pop adjusted estimate",200,0.009000000000000001,0.004,0.015300000000000001,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9950000000000004,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round3_Age0to4,221205_Vancouver_BCCentreforDiseaseControl_Round3,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-09-17,2020-09-29,Residual sera,All,Children and Youth (0-17 years),0.0,4.0,Age,"age: 0-4, test and pop adjusted estimate",200,0.01,0.005200000000000001,0.017,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round3_TestUsed_Siemens-S1-RBD,221205_Vancouver_BCCentreforDiseaseControl_Round3,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-09-17,2020-09-29,Residual sera,All,Multiple groups,0.0,,Test used,Siemens-S1-RBD,28,0.679,0.477,0.841,,,,,,Stratified non-probability,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,1.0,0.9950000000000004,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2024-05-01,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round3_Age60to69,221205_Vancouver_BCCentreforDiseaseControl_Round3,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-09-17,2020-09-29,Residual sera,All,Multiple groups,60.0,69.0,Age,"age: 60-69, test and pop adjusted estimate",200,0.01,0.0049,0.016,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9950000000000003,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round3_TestUsed_Ortho-S1,221205_Vancouver_BCCentreforDiseaseControl_Round3,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-09-17,2020-09-29,Residual sera,All,Multiple groups,0.0,,Test used,Ortho-S1,2000,0.011,0.007,0.016,,,,,,Stratified non-probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,1.0,0.9950000000000004,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2024-05-01,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round3_TestUsed_Abbott-NP,221205_Vancouver_BCCentreforDiseaseControl_Round3,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-09-17,2020-09-29,Residual sera,All,Multiple groups,0.0,,Test used,Abbott-NP,2000,0.01,0.006,0.0154,,,,,,Stratified non-probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9950000000000004,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2024-05-01,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round3_Age30to39,221205_Vancouver_BCCentreforDiseaseControl_Round3,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-09-17,2020-09-29,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,"age: 30-39, test and pop adjusted estimate",200,0.011000000000000001,0.006,0.021,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round3_Age50to59,221205_Vancouver_BCCentreforDiseaseControl_Round3,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2020-09-17,2020-09-29,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,"age: 50-59, test and pop adjusted estimate",200,0.01,0.006,0.018000000000000002,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9950000000000002,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round4_Adj,221205_Vancouver_BCCentreforDiseaseControl_Round4,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-01-16,2021-01-27,Residual sera,All,Multiple groups,0.0,,Primary Estimate,test and pop adjusted estimate,1999,0.0348,0.027000000000000003,0.044000000000000004,True,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round4_UnAdj,221205_Vancouver_BCCentreforDiseaseControl_Round4,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-01-16,2021-01-27,Residual sera,All,Multiple groups,0.0,,Analysis,crude estimate,1999,0.038,0.03,0.047,,,,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round4_TestUsed_Ortho-S1,221205_Vancouver_BCCentreforDiseaseControl_Round4,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-01-16,2021-01-27,Residual sera,All,Multiple groups,0.0,,Test used,Ortho-S1,2000,0.048,0.039,0.058,,,,,,Stratified non-probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,1.0,0.9950000000000004,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2024-05-01,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round4_TestUsed_Abbott-NP,221205_Vancouver_BCCentreforDiseaseControl_Round4,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-01-16,2021-01-27,Residual sera,All,Multiple groups,0.0,,Test used,Abbott-NP,2000,0.042,0.034,0.052,,,,,,Stratified non-probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9950000000000004,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2024-05-01,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round4_TestUsed_Siemens-S1-RBD,221205_Vancouver_BCCentreforDiseaseControl_Round4,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-01-16,2021-01-27,Residual sera,All,Multiple groups,0.0,,Test used,Siemens-S1-RBD,97,0.773,0.677,0.852,,,,,,Stratified non-probability,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,1.0,0.9950000000000004,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2024-05-01,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round4_Age60to69,221205_Vancouver_BCCentreforDiseaseControl_Round4,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-01-16,2021-01-27,Residual sera,All,Multiple groups,60.0,69.0,Age,"age: 60-69, test and pop adjusted estimate",200,0.027999999999999997,0.013999999999999999,0.046,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9950000000000003,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round4_Male,221205_Vancouver_BCCentreforDiseaseControl_Round4,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-01-16,2021-01-27,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,test and pop adjusted estimate,1000,0.037000000000000005,0.027000000000000003,0.048,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round4_Age50to59,221205_Vancouver_BCCentreforDiseaseControl_Round4,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-01-16,2021-01-27,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,"age: 50-59, test and pop adjusted estimate",200,0.027999999999999997,0.013999999999999999,0.0455,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9950000000000002,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round4_AgeOver80,221205_Vancouver_BCCentreforDiseaseControl_Round4,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-01-16,2021-01-27,Residual sera,All,Seniors (65+ years),80.0,,Age,"age: >= 80, test and pop adjusted estimate",200,0.037000000000000005,0.021,0.059000000000000004,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9950000000000004,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round4_TestUsed_Roche-NP,221205_Vancouver_BCCentreforDiseaseControl_Round4,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-01-16,2021-01-27,Residual sera,All,Multiple groups,0.0,,Test used,Roche-NP,74,0.743,0.628,0.838,,,,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9950000000000004,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2024-05-01,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round4_Female,221205_Vancouver_BCCentreforDiseaseControl_Round4,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-01-16,2021-01-27,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,test and pop adjusted estimate,999,0.033,0.024,0.043,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round4_Age5to9,221205_Vancouver_BCCentreforDiseaseControl_Round4,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-01-16,2021-01-27,Residual sera,All,Children and Youth (0-17 years),5.0,9.0,Age,"age: 5-9, test and pop adjusted estimate",200,0.0552,0.0347,0.084,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round4_Age40to49,221205_Vancouver_BCCentreforDiseaseControl_Round4,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-01-16,2021-01-27,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,"age: 40-49, test and pop adjusted estimate",200,0.037000000000000005,0.022000000000000002,0.057999999999999996,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round4_Age0to4,221205_Vancouver_BCCentreforDiseaseControl_Round4,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-01-16,2021-01-27,Residual sera,All,Children and Youth (0-17 years),0.0,4.0,Age,"age: 0-4, test and pop adjusted estimate",199,0.059000000000000004,0.036000000000000004,0.08800000000000001,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round4_Age70to79,221205_Vancouver_BCCentreforDiseaseControl_Round4,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-01-16,2021-01-27,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,"age: 70-79, test and pop adjusted estimate",200,0.031000000000000003,0.017,0.048,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9950000000000003,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round4_TestUsed_Abbott-NP/Roche-NP,221205_Vancouver_BCCentreforDiseaseControl_Round4,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-01-16,2021-01-27,Residual sera,All,Multiple groups,0.0,,Test used,Abbott-NP or Roche-NP,2000,0.045,0.036,0.055,,,,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",Multiple Types,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9950000000000004,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2024-05-01,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round4_Age20to29,221205_Vancouver_BCCentreforDiseaseControl_Round4,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-01-16,2021-01-27,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,"age: 20-29, test and pop adjusted estimate",200,0.043,0.024700000000000003,0.067,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round4_Age10to19,221205_Vancouver_BCCentreforDiseaseControl_Round4,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-01-16,2021-01-27,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,"age: 10-19, test and pop adjusted estimate",200,0.027000000000000003,0.013999999999999999,0.044000000000000004,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round4_Age30to39,221205_Vancouver_BCCentreforDiseaseControl_Round4,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-01-16,2021-01-27,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,"age: 30-39, test and pop adjusted estimate",200,0.031000000000000003,0.016,0.049,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round5_Adj,221205_Vancouver_BCCentreforDiseaseControl_Round5,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-05-30,2021-06-11,Residual sera,All,Multiple groups,0.0,,Primary Estimate,test and pop adjusted estimate,1991,0.10099999999999999,0.08800000000000001,0.11599999999999999,True,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round5_TestUsed_Abbott-NP/Roche-NP,221205_Vancouver_BCCentreforDiseaseControl_Round5,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-05-30,2021-06-11,Residual sera,All,Multiple groups,0.0,,Test used,Abbott-NP or Roche-NP,1999,0.109,0.096,0.124,,,,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",Multiple Types,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9950000000000004,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2024-05-01,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round5_AgeOver80,221205_Vancouver_BCCentreforDiseaseControl_Round5,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-05-30,2021-06-11,Residual sera,All,Seniors (65+ years),80.0,,Age,"age: >= 80, test and pop adjusted estimate",199,0.076,0.048,0.107,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9950000000000004,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round5_Age10to19,221205_Vancouver_BCCentreforDiseaseControl_Round5,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-05-30,2021-06-11,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,"age: 10-19, test and pop adjusted estimate",200,0.11800000000000001,0.086,0.156,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round5_Age0to4,221205_Vancouver_BCCentreforDiseaseControl_Round5,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-05-30,2021-06-11,Residual sera,All,Children and Youth (0-17 years),0.0,4.0,Age,"age: 0-4, test and pop adjusted estimate",201,0.134,0.099,0.1746,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round5_Age70to79,221205_Vancouver_BCCentreforDiseaseControl_Round5,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-05-30,2021-06-11,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,"age: 70-79, test and pop adjusted estimate",196,0.102,0.073,0.13460000000000003,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9950000000000003,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round5_Male,221205_Vancouver_BCCentreforDiseaseControl_Round5,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-05-30,2021-06-11,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,test and pop adjusted estimate,994,0.102,0.086,0.121,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round5_Age20to29,221205_Vancouver_BCCentreforDiseaseControl_Round5,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-05-30,2021-06-11,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,"age: 20-29, test and pop adjusted estimate",200,0.11900000000000001,0.086,0.15539999999999998,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round5_Age50to59,221205_Vancouver_BCCentreforDiseaseControl_Round5,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-05-30,2021-06-11,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,"age: 50-59, test and pop adjusted estimate",200,0.076,0.048,0.107,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9950000000000002,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round5_Age60to69,221205_Vancouver_BCCentreforDiseaseControl_Round5,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-05-30,2021-06-11,Residual sera,All,Multiple groups,60.0,69.0,Age,"age: 60-69, test and pop adjusted estimate",199,0.087,0.059000000000000004,0.11900000000000001,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9950000000000003,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round5_Age30to39,221205_Vancouver_BCCentreforDiseaseControl_Round5,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-05-30,2021-06-11,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,"age: 30-39, test and pop adjusted estimate",199,0.0951,0.066,0.129,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round5_Age40to49,221205_Vancouver_BCCentreforDiseaseControl_Round5,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-05-30,2021-06-11,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,"age: 40-49, test and pop adjusted estimate",200,0.09699999999999999,0.069,0.129,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round5_TestUsed_Abbott-NP,221205_Vancouver_BCCentreforDiseaseControl_Round5,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-05-30,2021-06-11,Residual sera,All,Multiple groups,0.0,,Test used,Abbott-NP,1999,0.08,0.069,0.093,,,,,,Stratified non-probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9950000000000004,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2024-05-01,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round5_TestUsed_Roche-NP,221205_Vancouver_BCCentreforDiseaseControl_Round5,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-05-30,2021-06-11,Residual sera,All,Multiple groups,0.0,,Test used,Roche-NP,1160,0.166,0.1454,0.189,,,,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9950000000000004,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2024-05-01,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round5_Age5to9,221205_Vancouver_BCCentreforDiseaseControl_Round5,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-05-30,2021-06-11,Residual sera,All,Children and Youth (0-17 years),5.0,9.0,Age,"age: 5-9, test and pop adjusted estimate",197,0.13699999999999998,0.10099999999999999,0.17800000000000002,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round5_Female,221205_Vancouver_BCCentreforDiseaseControl_Round5,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-05-30,2021-06-11,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,test and pop adjusted estimate,997,0.1,0.083,0.11699999999999999,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round5_UnAdj,221205_Vancouver_BCCentreforDiseaseControl_Round5,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-05-30,2021-06-11,Residual sera,All,Multiple groups,0.0,,Analysis,crude estimate,1991,0.10800000000000001,0.094,0.122,,,,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.995,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round5_TestUsed_Ortho-S1,221205_Vancouver_BCCentreforDiseaseControl_Round5,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-05-30,2021-06-11,Residual sera,All,Multiple groups,0.0,,Test used,Ortho-S1,1999,0.589,0.567,0.611,,,,,,Stratified non-probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,1.0,0.9950000000000004,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2024-05-01,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round5_TestUsed_Siemens-S1-RBD,221205_Vancouver_BCCentreforDiseaseControl_Round5,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-05-30,2021-06-11,Residual sera,All,Multiple groups,0.0,,Test used,Siemens-S1-RBD,1163,0.899,0.881,0.916,,,,,,Stratified non-probability,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,1.0,0.9950000000000004,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2024-05-01,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round6_Adj,221205_Vancouver_BCCentreforDiseaseControl_Round6,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-09-26,2021-10-08,Residual sera,All,Multiple groups,0.0,,Primary Estimate,test and pop adjusted estimate,1990,0.094,0.081,0.10800000000000001,True,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round6_Male,221205_Vancouver_BCCentreforDiseaseControl_Round6,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-09-26,2021-10-08,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,test and pop adjusted estimate,996,0.1,0.08199999999999999,0.11800000000000001,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round6_TestUsed_Siemens-S1-RBD,221205_Vancouver_BCCentreforDiseaseControl_Round6,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-09-26,2021-10-08,Residual sera,All,Multiple groups,0.0,,Test used,Siemens-S1-RBD,1990,0.754,0.7347,0.773,,,,,,Stratified non-probability,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2024-05-01,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round6_AgeOver80,221205_Vancouver_BCCentreforDiseaseControl_Round6,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-09-26,2021-10-08,Residual sera,All,Seniors (65+ years),80.0,,Age,"age: >= 80, test and pop adjusted estimate",198,0.055999999999999994,0.032,0.086,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round6_Age40to49,221205_Vancouver_BCCentreforDiseaseControl_Round6,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-09-26,2021-10-08,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,"age: 40-49, test and pop adjusted estimate",199,0.10099999999999999,0.071,0.13699999999999998,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round6_Female,221205_Vancouver_BCCentreforDiseaseControl_Round6,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-09-26,2021-10-08,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,test and pop adjusted estimate,994,0.08800000000000001,0.071,0.1051,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round6_Age30to39,221205_Vancouver_BCCentreforDiseaseControl_Round6,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-09-26,2021-10-08,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,"age: 30-39, test and pop adjusted estimate",200,0.105,0.07400000000000001,0.142,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round6_TestUsed_Roche-NP,221205_Vancouver_BCCentreforDiseaseControl_Round6,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-09-26,2021-10-08,Residual sera,All,Multiple groups,0.0,,Test used,Roche-NP,1991,0.097,0.084,0.111,,,,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2024-05-01,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round6_Age60to69,221205_Vancouver_BCCentreforDiseaseControl_Round6,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-09-26,2021-10-08,Residual sera,All,Multiple groups,60.0,69.0,Age,"age: 60-69, test and pop adjusted estimate",200,0.057999999999999996,0.034,0.087,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round6_Age70to79,221205_Vancouver_BCCentreforDiseaseControl_Round6,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-09-26,2021-10-08,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,"age: 70-79, test and pop adjusted estimate",200,0.08199999999999999,0.055,0.1134,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round6_Age20to29,221205_Vancouver_BCCentreforDiseaseControl_Round6,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-09-26,2021-10-08,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,"age: 20-29, test and pop adjusted estimate",199,0.08900000000000001,0.061,0.122,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round6_UnAdj,221205_Vancouver_BCCentreforDiseaseControl_Round6,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-09-26,2021-10-08,Residual sera,All,Multiple groups,0.0,,Analysis,crude estimate,1990,0.09699999999999999,0.084,0.111,,,,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round6_Age0to4,221205_Vancouver_BCCentreforDiseaseControl_Round6,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-09-26,2021-10-08,Residual sera,All,Children and Youth (0-17 years),0.0,4.0,Age,"age: 0-4, test and pop adjusted estimate",195,0.133,0.098,0.174,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round6_TestUsed_Ortho-S1,221205_Vancouver_BCCentreforDiseaseControl_Round6,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-09-26,2021-10-08,Residual sera,All,Multiple groups,0.0,,Test used,Ortho-S1,1989,0.768,0.749,0.787,,,,,,Stratified non-probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2024-05-01,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round6_Age50to59,221205_Vancouver_BCCentreforDiseaseControl_Round6,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-09-26,2021-10-08,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,"age: 50-59, test and pop adjusted estimate",199,0.092,0.064,0.1251,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round6_Age10to19,221205_Vancouver_BCCentreforDiseaseControl_Round6,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-09-26,2021-10-08,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,"age: 10-19, test and pop adjusted estimate",200,0.113,0.081,0.15,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round6_Age5to9,221205_Vancouver_BCCentreforDiseaseControl_Round6,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2021-09-26,2021-10-08,Residual sera,All,Children and Youth (0-17 years),5.0,9.0,Age,"age: 5-9, test and pop adjusted estimate",200,0.113,0.081,0.15,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round7_Adj,221205_Vancouver_BCCentreforDiseaseControl_Round7,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",ndividuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2022-03-13,2022-03-24,Residual sera,All,Multiple groups,0.0,,Primary Estimate,test and pop adjusted estimate,2000,0.42479999999999996,0.402,0.449,True,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round7_Age30to39,221205_Vancouver_BCCentreforDiseaseControl_Round7,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",ndividuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2022-03-13,2022-03-24,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,"age: 30-39, test and pop adjusted estimate",200,0.544,0.48200000000000004,0.608,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round7_TestUsed_Siemens-S1-RBD,221205_Vancouver_BCCentreforDiseaseControl_Round7,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",ndividuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2022-03-13,2022-03-24,Residual sera,All,Multiple groups,0.0,,Test used,Siemens-S1-RBD,1999,0.92,0.907,0.931,,,,,,Stratified non-probability,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2024-05-01,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round7_TestUsed_Roche-NP,221205_Vancouver_BCCentreforDiseaseControl_Round7,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",ndividuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2022-03-13,2022-03-24,Residual sera,All,Multiple groups,0.0,,Test used,Roche-NP,2000,0.426,0.404,0.448,,,,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2024-05-01,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round7_AgeOver80,221205_Vancouver_BCCentreforDiseaseControl_Round7,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",ndividuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2022-03-13,2022-03-24,Residual sera,All,Seniors (65+ years),80.0,,Age,"age: >= 80, test and pop adjusted estimate",200,0.154,0.111,0.204,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round7_Female,221205_Vancouver_BCCentreforDiseaseControl_Round7,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",ndividuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2022-03-13,2022-03-24,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,test and pop adjusted estimate,1000,0.424,0.39299999999999996,0.456,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round7_Age50to59,221205_Vancouver_BCCentreforDiseaseControl_Round7,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",ndividuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2022-03-13,2022-03-24,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,"age: 50-59, test and pop adjusted estimate",200,0.327,0.267,0.39,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round7_Age60to69,221205_Vancouver_BCCentreforDiseaseControl_Round7,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",ndividuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2022-03-13,2022-03-24,Residual sera,All,Multiple groups,60.0,69.0,Age,"age: 60-69, test and pop adjusted estimate",200,0.249,0.1955,0.306,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round7_Age10to19,221205_Vancouver_BCCentreforDiseaseControl_Round7,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",ndividuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2022-03-13,2022-03-24,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,"age: 10-19, test and pop adjusted estimate",200,0.56,0.4954,0.624,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round7_UnAdj,221205_Vancouver_BCCentreforDiseaseControl_Round7,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",ndividuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2022-03-13,2022-03-24,Residual sera,All,Multiple groups,0.0,,Analysis,crude estimate,2000,0.425,0.40299999999999997,0.44700000000000006,,,,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round7_TestUsed_Ortho-S1,221205_Vancouver_BCCentreforDiseaseControl_Round7,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",ndividuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2022-03-13,2022-03-24,Residual sera,All,Multiple groups,0.0,,Test used,Ortho-S1,2000,0.939,0.928,0.949,,,,,,Stratified non-probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2024-05-01,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round7_Age40to49,221205_Vancouver_BCCentreforDiseaseControl_Round7,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",ndividuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2022-03-13,2022-03-24,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,"age: 40-49, test and pop adjusted estimate",200,0.4451,0.381,0.513,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round7_Age70to79,221205_Vancouver_BCCentreforDiseaseControl_Round7,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",ndividuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2022-03-13,2022-03-24,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,"age: 70-79, test and pop adjusted estimate",200,0.14300000000000002,0.098,0.193,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round7_Age20to29,221205_Vancouver_BCCentreforDiseaseControl_Round7,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",ndividuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2022-03-13,2022-03-24,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,"age: 20-29, test and pop adjusted estimate",200,0.49700000000000005,0.43,0.5660000000000001,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round7_Age5to9,221205_Vancouver_BCCentreforDiseaseControl_Round7,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",ndividuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2022-03-13,2022-03-24,Residual sera,All,Children and Youth (0-17 years),5.0,9.0,Age,"age: 5-9, test and pop adjusted estimate",200,0.659,0.593,0.7220000000000001,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round7_Male,221205_Vancouver_BCCentreforDiseaseControl_Round7,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",ndividuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2022-03-13,2022-03-24,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,test and pop adjusted estimate,1000,0.4253,0.394,0.456,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round7_Age0to4,221205_Vancouver_BCCentreforDiseaseControl_Round7,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",ndividuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2022-03-13,2022-03-24,Residual sera,All,Children and Youth (0-17 years),0.0,4.0,Age,"age: 0-4, test and pop adjusted estimate",200,0.629,0.5579999999999999,0.6946,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Siemens,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round8_Adj,221205_Vancouver_BCCentreforDiseaseControl_Round8,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2022-07-31,2022-08-11,Residual sera,All,Multiple groups,0.0,,Primary Estimate,test and pop adjusted estimate,2000,0.611,0.588,0.634,True,True,True,,,Stratified non-probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG","Siemens,Roche Diagnostics,Abbott Laboratories",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round8_Age40to49,221205_Vancouver_BCCentreforDiseaseControl_Round8,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2022-07-31,2022-08-11,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,"age: 40-49, test and pop adjusted estimate",200,0.6409999999999999,0.5760000000000001,0.7051000000000001,,True,True,,,Stratified non-probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG","Siemens,Roche Diagnostics,Abbott Laboratories",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round8_Age0to4,221205_Vancouver_BCCentreforDiseaseControl_Round8,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2022-07-31,2022-08-11,Residual sera,All,Children and Youth (0-17 years),0.0,4.0,Age,"age: 0-4, test and pop adjusted estimate",200,0.726,0.6559999999999999,0.792,,True,True,,,Stratified non-probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG","Siemens,Roche Diagnostics,Abbott Laboratories",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round8_Age60to69,221205_Vancouver_BCCentreforDiseaseControl_Round8,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2022-07-31,2022-08-11,Residual sera,All,Multiple groups,60.0,69.0,Age,"age: 60-69, test and pop adjusted estimate",200,0.423,0.36,0.48600000000000004,,True,True,,,Stratified non-probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG","Siemens,Roche Diagnostics,Abbott Laboratories",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round8_Age5to9,221205_Vancouver_BCCentreforDiseaseControl_Round8,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2022-07-31,2022-08-11,Residual sera,All,Children and Youth (0-17 years),5.0,9.0,Age,"age: 5-9, test and pop adjusted estimate",200,0.7046,0.6459999999999999,0.763,,True,True,,,Stratified non-probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG","Siemens,Roche Diagnostics,Abbott Laboratories",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round8_Female,221205_Vancouver_BCCentreforDiseaseControl_Round8,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2022-07-31,2022-08-11,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,test and pop adjusted estimate,1000,0.5920000000000001,0.56,0.624,,True,True,,,Stratified non-probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG","Siemens,Roche Diagnostics,Abbott Laboratories",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round8_TestUsed_Roche-NP,221205_Vancouver_BCCentreforDiseaseControl_Round8,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2022-07-31,2022-08-11,Residual sera,All,Multiple groups,0.0,,Test used,Roche-NP,2000,0.623,0.601,0.644,,,,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2024-05-01,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round8_TestUsed_Siemens-S1-RBD,221205_Vancouver_BCCentreforDiseaseControl_Round8,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2022-07-31,2022-08-11,Residual sera,All,Multiple groups,0.0,,Test used,Siemens-S1-RBD,2000,0.976,0.968,0.982,,,,,,Stratified non-probability,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2024-05-01,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round8_Age30to39,221205_Vancouver_BCCentreforDiseaseControl_Round8,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2022-07-31,2022-08-11,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,"age: 30-39, test and pop adjusted estimate",200,0.6459999999999999,0.5760000000000001,0.7120000000000001,,True,True,,,Stratified non-probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG","Siemens,Roche Diagnostics,Abbott Laboratories",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round8_Age10to19,221205_Vancouver_BCCentreforDiseaseControl_Round8,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2022-07-31,2022-08-11,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,"age: 10-19, test and pop adjusted estimate",200,0.76,0.7046,0.8140000000000001,,True,True,,,Stratified non-probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG","Siemens,Roche Diagnostics,Abbott Laboratories",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round8_Age50to59,221205_Vancouver_BCCentreforDiseaseControl_Round8,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2022-07-31,2022-08-11,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,"age: 50-59, test and pop adjusted estimate",200,0.596,0.53,0.663,,True,True,,,Stratified non-probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG","Siemens,Roche Diagnostics,Abbott Laboratories",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round8_TestUsed_Abbott-NP,221205_Vancouver_BCCentreforDiseaseControl_Round8,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2022-07-31,2022-08-11,Residual sera,All,Multiple groups,0.0,,Test used,Abbott-NP,2000,0.948,0.937,0.957,,,,,,Stratified non-probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2024-05-01,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round8_Age70to79,221205_Vancouver_BCCentreforDiseaseControl_Round8,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2022-07-31,2022-08-11,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,"age: 70-79, test and pop adjusted estimate",200,0.43100000000000005,0.3655,0.49700000000000005,,True,True,,,Stratified non-probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG","Siemens,Roche Diagnostics,Abbott Laboratories",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round8_AgeOver80,221205_Vancouver_BCCentreforDiseaseControl_Round8,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2022-07-31,2022-08-11,Residual sera,All,Seniors (65+ years),80.0,,Age,"age: >= 80, test and pop adjusted estimate",200,0.379,0.317,0.443,,True,True,,,Stratified non-probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG","Siemens,Roche Diagnostics,Abbott Laboratories",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round8_Age20to29,221205_Vancouver_BCCentreforDiseaseControl_Round8,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2022-07-31,2022-08-11,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,"age: 20-29, test and pop adjusted estimate",200,0.6951,0.633,0.7540000000000001,,True,True,,,Stratified non-probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG","Siemens,Roche Diagnostics,Abbott Laboratories",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round8_Male,221205_Vancouver_BCCentreforDiseaseControl_Round8,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2022-07-31,2022-08-11,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,test and pop adjusted estimate,1000,0.631,0.599,0.662,,True,True,,,Stratified non-probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG","Siemens,Roche Diagnostics,Abbott Laboratories",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
221205_Vancouver_BCCentreforDiseaseControl_Round8_UnAdj,221205_Vancouver_BCCentreforDiseaseControl_Round8,"Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada",2022-12-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Residual sera were sampled from the Lower Mainland, BC with eligible municipalities affiliated with two health authorities",Individuals presenting for SARS-CoV-2 antibody testing and those residing in care or correctional facilities were excluded.,2022-07-31,2022-08-11,Residual sera,All,Multiple groups,0.0,,Analysis,crude estimate,2000,0.618,0.596,0.639,,,,,True,Stratified non-probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG","Siemens,Roche Diagnostics,Abbott Laboratories",Multiple Types,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Danuta Skowronski,BC Centre for Disease Control,Unity-Aligned,https://doi.org/10.1503/cmaj.221335,2022-09-19,2024-05-01,Verified,skowronski_serial_2022,CAN
230106_Canada_CBS_BloodDonors_RocheS_Overall_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,31080,1.0,1.0,1.0,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2101,0.9952403617000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1112,1.0,0.995,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1610,1.0,0.9971,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14761,0.6874872976,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_Sex_Female_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13191,0.9957546812,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,304,0.9934210526,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_Age_17-24_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2483,0.8352799033,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1609,0.7217,0.698,0.7454000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4411,0.9950124687999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1112,0.993705036,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24887,0.6858,0.6799,0.6917,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1682,0.6714,0.6428,0.7000000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,912,0.6809210526,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_Age_60+_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,8940,0.5660000000000001,0.5555,0.5764,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_Sex_Male_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,17888,0.7148000000000001,0.7075,0.7221,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1902,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14761,0.6972,0.6899,0.7044,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2129,0.9962423673,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_Sex_Male_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,17889,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1238,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1111,0.7053,0.6738,0.7369,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_Overall_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Analysis,,31080,0.9947,0.9938,0.9954000000000001,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1238,0.9959612278000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_Age_25-39_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,7986,0.7784000000000001,0.7689,0.7879,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24887,0.6800337526,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1902,0.9963196635,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1221,0.9967239967000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4411,0.6957605984999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3198,0.792057536,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3198,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,912,0.684,0.6529,0.7151000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_Age_40-59_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11670,0.7222793488000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,5640,0.7628,0.7503000000000001,0.7752,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2101,0.778,0.7605,0.7956000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1682,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_Age_40-59_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11670,0.7242000000000001,0.7156999999999999,0.7327,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4411,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,5640,0.7491134752,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_Age_25-39_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,7986,0.7714750814,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,912,0.9978070175000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2101,0.769157544,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1221,0.7190827191,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,304,0.6868000000000001,0.6153000000000001,0.7584000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_Age_60+_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,8940,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1610,0.9925465839000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,5640,0.9946808511,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,449,1.0,0.998,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3198,0.9981238274,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5042,0.9936533122000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2674,0.9951383695,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_Age_17-24_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2483,0.9987917840999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2129,0.7656176609,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_Age_17-24_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2483,0.8455,0.8339,0.8571,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,352,0.9971590909,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1238,0.6373182553000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3198,0.7945000000000001,0.7812000000000001,0.8079000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_Overall_PopAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Analysis,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay Pop Adj,31079,0.7049,0.6998000000000001,0.71,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,5640,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,352,0.6884,0.6513,0.7254,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1682,0.6581450654,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4411,0.7018000000000001,0.6909000000000001,0.7128,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14761,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_Age_17-24_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2483,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_Age_60+_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,8940,0.9925055928000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_Sex_Female_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13191,0.7012999999999999,0.6940999999999999,0.7084999999999999,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_Age_40-59_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11671,0.9943449576000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2129,0.7734000000000001,0.752,0.7948000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5042,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_Age_60+_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,8940,0.5703579418000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_Sex_Male_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,17888,0.7010845259,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1609,0.703542573,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14761,0.9947158052,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1221,0.7281000000000001,0.7027,0.7535,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24888,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,449,0.7750556793,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_Age_40-59_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11671,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_Age_25-39_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,7986,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2129,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,912,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5042,0.6985323284,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1902,0.7445,0.7227,0.7662000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2101,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_Sex_Female_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13191,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_Overall_PopAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Analysis,,31080,0.9948,0.9940000000000001,0.9956,,,True,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1221,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1902,0.7329127234,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,304,0.9953000000000001,0.9756999999999999,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,352,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2674,0.7387,0.7229000000000001,0.7545000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2674,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_Overall_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Test used,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay PopTest Adj,31079,0.7078,0.7027,0.713,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,449,0.9977728285,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,304,0.6809210526,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_Age_25-39_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,7986,0.996243426,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2674,0.7397157816000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1238,0.6421,0.6131000000000001,0.6712,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_Sex_Female_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13191,0.6991130316,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_Sex_Male_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,17889,0.9938509699,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1111,0.6885688569,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24888,0.9942140791,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1682,0.9976218787000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_UnAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,352,0.6846590909,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,449,0.7864,0.7490000000000001,0.8238,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230106_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_PopTestAdj,230106_Canada_CBS,"COVID-19 Seroprevalence Report January 6, 2023 Report #28: November 2022 Survey The advance of Omicron",2023-01-06,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-11-01,2022-11-30,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5042,0.7040000000000001,0.6917,0.7162000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-01-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023,CAN
230112_BritishColumbia_UniversityOfBritishColumbia_Phase2_antiS,230112_BritishColumbia_UniversityOfBritishColumbia_Phase2,Canadian antenatal COVID-19 seroprevalence study; population mapping of the COVID-19 pandemic utilizing stored antenatal sera,2023-01-12,Presentation or Conference,Regional,Retrospective cohort,Canada,British Columbia,,"""The Canadian Antenatal Serological Survey assessed SARS-CoV-2 seroprevalence across Canada at various pandemic stages using residual antenatal sera as a representative sample of reproductive age females.""",,2021-11-15,2021-12-03,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,Overall anti-S,3369,0.881,,,True,,,,True,Sequential,Not reported/ Unable to specify,,,Serum,,Spike,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,A Atkinson,University of British Columbia,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ajog.2022.11.132,2023-02-07,2023-03-19,Unverified,atkinson_canadian_2023,CAN
230117_Canada_CBS_BloodDonors_RocheS_Overall_PopTestAdj,230117_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #29A: December 1 - December 15, 2022, Survey",2023-01-17,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-15,Blood donors,All,Multiple groups,17.0,,Primary Estimate,Roche S overall,17053,1.0,1.0,1.0,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-03-29,Verified,canadian_blood_services_covid-19_2023-1,CAN
230117_Canada_CBS_BloodDonors_RocheN_Time_Dec8-15_Unadj,230117_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #29A: December 1 - December 15, 2022, Survey",2023-01-17,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-15,Blood donors,All,Multiple groups,17.0,,Test used,Dec 8-15,10013,0.7233596325000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-03-29,Verified,canadian_blood_services_covid-19_2023-1,CAN
230117_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_UnAdj,230117_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #29A: December 1 - December 15, 2022, Survey",2023-01-17,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,481,0.7422037422,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-03-29,Verified,canadian_blood_services_covid-19_2023-1,CAN
230117_Canada_CBS_BloodDonors_RocheN_Overall_UnAdj,230117_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #29A: December 1 - December 15, 2022, Survey",2023-01-17,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-15,Blood donors,All,Multiple groups,17.0,,Test used,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay UnAdj,17053,0.7184659591000001,,,,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-03-29,Verified,canadian_blood_services_covid-19_2023-1,CAN
230117_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_UnAdj,230117_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #29A: December 1 - December 15, 2022, Survey",2023-01-17,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,987,0.7608915907,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-03-29,Verified,canadian_blood_services_covid-19_2023-1,CAN
230117_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_UnAdj,230117_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #29A: December 1 - December 15, 2022, Survey",2023-01-17,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,828,0.672705314,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-03-29,Verified,canadian_blood_services_covid-19_2023-1,CAN
230117_Canada_CBS_BloodDonors_RocheN_Age_17-24_UnAdj,230117_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #29A: December 1 - December 15, 2022, Survey",2023-01-17,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-15,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1389,0.8711303096,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-03-29,Verified,canadian_blood_services_covid-19_2023-1,CAN
230117_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_UnAdj,230117_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #29A: December 1 - December 15, 2022, Survey",2023-01-17,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,1415,0.7512367491,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-03-29,Verified,canadian_blood_services_covid-19_2023-1,CAN
230117_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_UnAdj,230117_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #29A: December 1 - December 15, 2022, Survey",2023-01-17,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,681,0.7386196769,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-03-29,Verified,canadian_blood_services_covid-19_2023-1,CAN
230117_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_UnAdj,230117_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #29A: December 1 - December 15, 2022, Survey",2023-01-17,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,317,0.7097791798,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-03-29,Verified,canadian_blood_services_covid-19_2023-1,CAN
230117_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_UnAdj,230117_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #29A: December 1 - December 15, 2022, Survey",2023-01-17,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,3227,0.7824604896,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-03-29,Verified,canadian_blood_services_covid-19_2023-1,CAN
230117_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_UnAdj,230117_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #29A: December 1 - December 15, 2022, Survey",2023-01-17,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-15,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,1148,0.781358885,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-03-29,Verified,canadian_blood_services_covid-19_2023-1,CAN
230117_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_UnAdj,230117_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #29A: December 1 - December 15, 2022, Survey",2023-01-17,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-15,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,14002,0.7043279531000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-03-29,Verified,canadian_blood_services_covid-19_2023-1,CAN
230117_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_UnAdj,230117_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #29A: December 1 - December 15, 2022, Survey",2023-01-17,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,779,0.7573812580000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-03-29,Verified,canadian_blood_services_covid-19_2023-1,CAN
230117_Canada_CBS_BloodDonors_RocheN_Sex_Male_UnAdj,230117_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #29A: December 1 - December 15, 2022, Survey",2023-01-17,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-15,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,9770,0.7136131013000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-03-29,Verified,canadian_blood_services_covid-19_2023-1,CAN
230117_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_UnAdj,230117_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #29A: December 1 - December 15, 2022, Survey",2023-01-17,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,8269,0.6997218527,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-03-29,Verified,canadian_blood_services_covid-19_2023-1,CAN
230117_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_UnAdj,230117_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #29A: December 1 - December 15, 2022, Survey",2023-01-17,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,601,0.6222961730000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-03-29,Verified,canadian_blood_services_covid-19_2023-1,CAN
230117_Canada_CBS_BloodDonors_RocheN_Time_Dec1-7_Unadj,230117_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #29A: December 1 - December 15, 2022, Survey",2023-01-17,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-15,Blood donors,All,Multiple groups,17.0,,Test used,Dec 1-7,7040,0.7115056818,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-03-29,Verified,canadian_blood_services_covid-19_2023-1,CAN
230117_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_UnAdj,230117_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #29A: December 1 - December 15, 2022, Survey",2023-01-17,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,128,0.7265625,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-03-29,Verified,canadian_blood_services_covid-19_2023-1,CAN
230117_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_UnAdj,230117_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #29A: December 1 - December 15, 2022, Survey",2023-01-17,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,1105,0.7764705882,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-03-29,Verified,canadian_blood_services_covid-19_2023-1,CAN
230117_Canada_CBS_BloodDonors_RocheN_Age_25-39_UnAdj,230117_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #29A: December 1 - December 15, 2022, Survey",2023-01-17,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-15,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,4133,0.7965158481000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-03-29,Verified,canadian_blood_services_covid-19_2023-1,CAN
230117_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_UnAdj,230117_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #29A: December 1 - December 15, 2022, Survey",2023-01-17,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-15,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,208,0.7403846154,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-03-29,Verified,canadian_blood_services_covid-19_2023-1,CAN
230117_Canada_CBS_BloodDonors_RocheN_Age_60+_UnAdj,230117_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #29A: December 1 - December 15, 2022, Survey",2023-01-17,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-15,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,5181,0.5958309207,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-03-29,Verified,canadian_blood_services_covid-19_2023-1,CAN
230117_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_UnAdj,230117_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #29A: December 1 - December 15, 2022, Survey",2023-01-17,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-15,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,1436,0.8001392758,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-03-29,Verified,canadian_blood_services_covid-19_2023-1,CAN
230117_Canada_CBS_BloodDonors_RocheN_Sex_Female_UnAdj,230117_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #29A: December 1 - December 15, 2022, Survey",2023-01-17,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-15,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,7283,0.7249759714,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-03-29,Verified,canadian_blood_services_covid-19_2023-1,CAN
230117_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_UnAdj,230117_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #29A: December 1 - December 15, 2022, Survey",2023-01-17,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,2365,0.7310782241,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-03-29,Verified,canadian_blood_services_covid-19_2023-1,CAN
230117_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_UnAdj,230117_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #29A: December 1 - December 15, 2022, Survey",2023-01-17,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-15,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,232,0.6724137931,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-03-29,Verified,canadian_blood_services_covid-19_2023-1,CAN
230117_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_UnAdj,230117_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #29A: December 1 - December 15, 2022, Survey",2023-01-17,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-15,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,2819,0.7094714437999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-03-29,Verified,canadian_blood_services_covid-19_2023-1,CAN
230117_Canada_CBS_BloodDonors_RocheN_Age_40-59_UnAdj,230117_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #29A: December 1 - December 15, 2022, Survey",2023-01-17,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #28: November 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-15,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,6350,0.7343307087,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-03-29,Verified,canadian_blood_services_covid-19_2023-1,CAN
230202_Canada_CBS_BloodDonors_RocheS_Overall_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,32720,1.0,1.0,1.0,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,26498,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5190,0.7241,0.7125,0.7356999999999999,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_Sex_Female_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13984,0.7243,0.7175,0.7312000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1297,0.9961449499,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,26478,0.7197,0.7141,0.7252,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5189,0.9963384082000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1660,0.6936,0.6663,0.7209000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2275,0.7963,0.7803,0.8124,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,2064,0.9946705426,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5190,0.7165703276000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_Age_17-24_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2681,0.9992540097,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1154,0.7658,0.7373000000000001,0.7942,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1581,0.7717,0.7484000000000001,0.7948999999999999,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1154,0.7521663778000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_Age_17-24_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2680,0.8676,0.8570000000000001,0.8782,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_Age_25-39_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8139,0.809,0.8002,0.8177,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1668,0.9982014388,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,495,0.9979797979999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1582,0.9974715550000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14903,0.7158,0.7088,0.7228,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_Sex_Male_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18736,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,613,0.7308319739,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3017,0.7981438515000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,495,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1154,0.9982668977,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1581,0.7533206831,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_Overall_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Test used,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay PopTest Adj,32698,0.735,0.7301000000000001,0.7398,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2750,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,2064,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_Age_17-24_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2680,0.8679104477999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_Overall_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Analysis,,32720,0.9947,0.9938,0.9954000000000001,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_Age_25-39_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8139,0.8009583487,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14925,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2751,0.752090149,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3017,0.7959999999999999,0.7822,0.8097,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_Sex_Female_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13984,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2383,0.9970625262,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2383,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,408,0.7895000000000001,0.7488,0.8301999999999999,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_Age_25-39_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8143,0.9963158541,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1582,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,408,0.7794117647000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_Age_40-59_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,12591,0.7448177269,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1776,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_Sex_Male_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18736,0.9934884714000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4232,0.9955103970000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4232,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3017,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_Age_17-24_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2681,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_Sex_Female_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13984,0.9970680778000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_Sex_Male_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18714,0.7283317303,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,408,1.0,0.9947,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_Age_25-39_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8143,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_Age_40-59_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,12591,0.741,0.7329000000000001,0.7492000000000001,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,253,1.0,0.9859000000000001,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_Overall_PopAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Analysis,,32720,0.9956,0.9948,0.9963,,,True,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1297,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3017,0.9973483593000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1297,0.6708,0.6432,0.6985,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2275,0.7907692308000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,26498,0.9948297985000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,613,0.9967373573,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6590,0.8002,0.7889,0.8116,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2277,0.9947299078,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,495,0.7373737374,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_Age_60+_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9288,0.6077734711,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2277,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6590,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_Age_60+_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9292,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2751,0.7502,0.7358,0.7646,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,2064,0.7582364341000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_Age_40-59_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,12604,0.9952396065000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,26478,0.7160284009,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2383,0.8119,0.792,0.8317,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1660,0.6831325301,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4224,0.7336647727000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,613,0.7267,0.6973999999999999,0.756,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1668,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2750,0.9967272726999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_Age_60+_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9288,0.6048,0.5948,0.6149,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1154,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1297,0.6676946800000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,408,0.9950980392,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2383,0.7960553924,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,613,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_Sex_Male_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18714,0.7462000000000001,0.7394,0.7531,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1776,0.7846,0.7635,0.8057,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14903,0.7074414547000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6590,0.9939301973000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1776,0.9971846847000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_Overall_PopAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Analysis,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay Pop Adj,32698,0.7318000000000001,0.7270000000000001,0.7366,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4224,0.7276,0.7171,0.7382,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14925,0.9941708543000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_Age_60+_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9292,0.9923590185000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6590,0.7874051593,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,495,0.7609,0.7275,0.7942,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,253,0.7447,0.6794,0.8099,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5189,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_Age_40-59_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,12604,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1776,0.7668918919,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,253,1.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,253,0.7312252964,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_Sex_Female_UnAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13984,0.7321224256000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230202_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_PopTestAdj,230202_Canada_CBS,"COVID-19 Seroprevalence Report February 2, 2023
Report #28: December 2022 Survey The advance of Omicron",2023-02-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2022-12-01,2022-12-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,2064,0.775,0.7548,0.7951,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-02-09,2024-04-21,Verified,canadian_blood_services_covid-19_2023-2,CAN
230215_Canada_CBS_BloodDonors_RocheS_Overall_PopTestAdj,230215_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #30A: January 1 - January 15, 2023, Survey",2023-02-15,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-15,Blood donors,All,Multiple groups,17.0,,Primary Estimate,Roche S overall,16293,1.0,1.0,1.0,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-06,Verified,canadian_blood_services_covid-19_2023-3,CAN
230215_Canada_CBS_BloodDonors_RocheN_Age_60+_UnAdj,230215_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #30A: January 1 - January 15, 2023, Survey",2023-02-15,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-15,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,5249,0.6498380644,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-06,Verified,canadian_blood_services_covid-19_2023-3,CAN
230215_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_UnAdj,230215_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #30A: January 1 - January 15, 2023, Survey",2023-02-15,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,93,0.6666666667,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-06,Verified,canadian_blood_services_covid-19_2023-3,CAN
230215_Canada_CBS_BloodDonors_RocheN_Time_Jan1-7_Unadj,230215_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #30A: January 1 - January 15, 2023, Survey",2023-02-15,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-15,Blood donors,All,Multiple groups,17.0,,Test used,Jan 1-7,8277,0.748822037,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-06,Verified,canadian_blood_services_covid-19_2023-3,CAN
230215_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_UnAdj,230215_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #30A: January 1 - January 15, 2023, Survey",2023-02-15,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,563,0.7371225577,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-06,Verified,canadian_blood_services_covid-19_2023-3,CAN
230215_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_UnAdj,230215_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #30A: January 1 - January 15, 2023, Survey",2023-02-15,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,7260,0.7436639118,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-06,Verified,canadian_blood_services_covid-19_2023-3,CAN
230215_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_UnAdj,230215_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #30A: January 1 - January 15, 2023, Survey",2023-02-15,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-15,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,1284,0.8060747664,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-06,Verified,canadian_blood_services_covid-19_2023-3,CAN
230215_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_UnAdj,230215_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #30A: January 1 - January 15, 2023, Survey",2023-02-15,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,1678,0.7502979738,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-06,Verified,canadian_blood_services_covid-19_2023-3,CAN
230215_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_UnAdj,230215_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #30A: January 1 - January 15, 2023, Survey",2023-02-15,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,694,0.7622478386,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-06,Verified,canadian_blood_services_covid-19_2023-3,CAN
230215_Canada_CBS_BloodDonors_RocheN_Age_17-24_UnAdj,230215_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #30A: January 1 - January 15, 2023, Survey",2023-02-15,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-15,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1003,0.8713858425,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-06,Verified,canadian_blood_services_covid-19_2023-3,CAN
230215_Canada_CBS_BloodDonors_RocheN_Age_40-59_UnAdj,230215_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #30A: January 1 - January 15, 2023, Survey",2023-02-15,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-15,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,5978,0.7768484443,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-06,Verified,canadian_blood_services_covid-19_2023-3,CAN
230215_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_UnAdj,230215_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #30A: January 1 - January 15, 2023, Survey",2023-02-15,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-15,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,1128,0.7969858156,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-06,Verified,canadian_blood_services_covid-19_2023-3,CAN
230215_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_UnAdj,230215_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #30A: January 1 - January 15, 2023, Survey",2023-02-15,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-15,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,13349,0.7409543786,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-06,Verified,canadian_blood_services_covid-19_2023-3,CAN
230215_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_UnAdj,230215_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #30A: January 1 - January 15, 2023, Survey",2023-02-15,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,892,0.7051569507,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-06,Verified,canadian_blood_services_covid-19_2023-3,CAN
230215_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_UnAdj,230215_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #30A: January 1 - January 15, 2023, Survey",2023-02-15,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,459,0.7516339869,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-06,Verified,canadian_blood_services_covid-19_2023-3,CAN
230215_Canada_CBS_BloodDonors_RocheN_Time_Jan8-15_Unadj,230215_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #30A: January 1 - January 15, 2023, Survey",2023-02-15,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-15,Blood donors,All,Multiple groups,17.0,,Test used,Jan 8-15,8016,0.7518712575,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-06,Verified,canadian_blood_services_covid-19_2023-3,CAN
230215_Canada_CBS_BloodDonors_RocheN_Age_25-39_UnAdj,230215_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #30A: January 1 - January 15, 2023, Survey",2023-02-15,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-15,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,4063,0.8112232341,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-06,Verified,canadian_blood_services_covid-19_2023-3,CAN
230215_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_UnAdj,230215_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #30A: January 1 - January 15, 2023, Survey",2023-02-15,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-15,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,3065,0.7243066884,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-06,Verified,canadian_blood_services_covid-19_2023-3,CAN
230215_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_UnAdj,230215_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #30A: January 1 - January 15, 2023, Survey",2023-02-15,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,962,0.7702702703,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-06,Verified,canadian_blood_services_covid-19_2023-3,CAN
230215_Canada_CBS_BloodDonors_RocheN_Sex_Male_UnAdj,230215_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #30A: January 1 - January 15, 2023, Survey",2023-02-15,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-15,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,9178,0.7464589235,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-06,Verified,canadian_blood_services_covid-19_2023-3,CAN
230215_Canada_CBS_BloodDonors_RocheN_Overall_UnAdj,230215_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #30A: January 1 - January 15, 2023, Survey",2023-02-15,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-15,Blood donors,All,Multiple groups,17.0,,Test used,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay UnAdj,16293,0.7503222243,,,,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-06,Verified,canadian_blood_services_covid-19_2023-3,CAN
230215_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_UnAdj,230215_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #30A: January 1 - January 15, 2023, Survey",2023-02-15,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,1133,0.7890556046,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-06,Verified,canadian_blood_services_covid-19_2023-3,CAN
230215_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_UnAdj,230215_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #30A: January 1 - January 15, 2023, Survey",2023-02-15,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,772,0.7707253886,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-06,Verified,canadian_blood_services_covid-19_2023-3,CAN
230215_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_UnAdj,230215_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #30A: January 1 - January 15, 2023, Survey",2023-02-15,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,1884,0.7569002123,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-06,Verified,canadian_blood_services_covid-19_2023-3,CAN
230215_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_UnAdj,230215_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #30A: January 1 - January 15, 2023, Survey",2023-02-15,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,180,0.7388888889,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-06,Verified,canadian_blood_services_covid-19_2023-3,CAN
230215_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_UnAdj,230215_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #30A: January 1 - January 15, 2023, Survey",2023-02-15,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-15,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,3182,0.7859836581,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-06,Verified,canadian_blood_services_covid-19_2023-3,CAN
230215_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_UnAdj,230215_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #30A: January 1 - January 15, 2023, Survey",2023-02-15,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-15,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,245,0.7591836735,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-06,Verified,canadian_blood_services_covid-19_2023-3,CAN
230215_Canada_CBS_BloodDonors_RocheN_Sex_Female_UnAdj,230215_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #30A: January 1 - January 15, 2023, Survey",2023-02-15,Institutional Report,National,Repeated cross-sectional study,Canada,,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-15,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,7115,0.7553056922,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-06,Verified,canadian_blood_services_covid-19_2023-3,CAN
230215_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_UnAdj,230215_Canada_CBS,"COVID-19 Seroprevalence Brief Report Report #30A: January 1 - January 15, 2023, Survey",2023-02-15,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","Full details on methods, data management and analysis, and ethical issues can be found in the previous Report, #29: December 2022.

""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-15,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,484,0.7665289256,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-06,Verified,canadian_blood_services_covid-19_2023-3,CAN
230302_Canada_CBS_BloodDonors_RocheS_Overall_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,32062,1.0,1.0,1.0,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2494,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_Age_40-59_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11748,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2224,0.8129496403,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,491,0.7739307536,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4248,0.7657721281,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1086,0.9953959484,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14008,0.7504283267,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,2039,0.792,0.7722,0.8118,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,153,1.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1561,0.7008327995,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2494,0.8195,0.7994,0.8395,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,153,0.7385620915,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1436,0.7618384401,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_Sex_Female_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13794,0.9963752356,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_Age_17-24_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2175,0.8655,0.8546,0.8763,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2494,0.8047313553,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14008,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1086,0.7208,0.6938,0.7478,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_Age_60+_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9855,0.9935058346,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1569,0.7947,0.7734,0.816,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,891,1.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,2039,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14008,0.9959308966,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,2779,0.8229,0.8092,0.8366,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,6128,0.7287859008,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_Sex_Male_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18268,0.7668,0.7601,0.7735,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,491,0.9938900204,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,3243,0.7644,0.7496,0.7792,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_Overall_PopAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Analysis,,32062,0.996,0.9952,0.9966,,,True,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_Age_25-39_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8284,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,891,0.7676767677,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2224,0.8226,0.8071,0.8381,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1569,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6519,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,830,0.7821,0.7535,0.8107,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,830,0.9987951807,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,2039,0.7866601275,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2224,0.9959532374,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_Sex_Male_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18268,0.9952923144,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_Age_25-39_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8284,0.8227909223,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,153,0.7641,0.6989,0.8293,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1436,1.0,0.9998,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,2779,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1086,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_Age_40-59_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11748,0.9956588355,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_Age_40-59_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11748,0.7808,0.773,0.7885,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6519,0.8139,0.8026,0.8253,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,830,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_Overall_PopAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Analysis,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay Pop Adj,32062,0.7638,0.7591,0.7684,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,3243,0.9947579402,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,333,0.996996997,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_Age_60+_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9855,0.6539,0.644,0.6637,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,2779,0.9982007917,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,333,0.7598,0.7255,0.794,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,830,0.765060241,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_Age_17-24_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2175,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1569,0.7864882091,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_Age_60+_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9855,0.6527650939,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1561,0.998078155,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_Age_25-39_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8284,0.9980685659,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2494,0.9979951885,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1561,0.705,0.6777,0.7323,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2224,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,3243,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14008,0.7626,0.756,0.7691,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,891,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_Sex_Female_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13794,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,2779,0.8136020151,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,6128,0.9933093995,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,153,1.0,0.9846,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_Age_25-39_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8284,0.8298,0.8213,0.8383,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_Age_60+_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9855,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,491,0.7836,0.7467,0.8204,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,26000,0.7468076923,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_Age_40-59_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11748,0.7808137555,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,2039,0.998038254,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1569,0.9974506055,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6519,0.9972388403,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_Age_17-24_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2175,0.8694252874,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1086,0.7182320442,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,26000,0.7544,0.7491,0.7598,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,6128,0.7403,0.7286,0.752,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_Overall_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Test used,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay PopTest Adj,32062,0.7672,0.7625,0.7719,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_Sex_Female_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13794,0.7672901261,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,26000,0.9955769231,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_Age_17-24_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2175,0.9977011494,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4248,0.9964689266,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_Sex_Female_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13794,0.7675,0.761,0.7741,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1436,0.7772,0.7536,0.8009,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,3243,0.7628738822,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,6128,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_Sex_Male_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18268,0.7515327348,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6519,0.8024236846,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_Overall_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Analysis,,32062,0.9958,0.995,0.9964,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4248,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4248,0.7715,0.7617,0.7813,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,26000,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1436,0.9937325905,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_Sex_Male_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18268,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,891,0.776,0.7467,0.8052,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,333,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1561,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_UnAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,333,0.7447447447,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230302_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_PopTestAdj,230302_Canada_CBS,"COVID-19 Seroprevalence Report March 2, 2023 Report #30: January 2023 Survey The advance of Omicron",2023-03-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-01-01,2023-01-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,491,1.0,0.9945,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-03-10,2024-04-21,Verified,canadian_blood_services_covid-19_2023-4,CAN
230322_Montreal_UniversityofMontreal_Round1,230322_Montreal_UniversityofMontreal_Round1,"Pre-Omicron seroprevalence, seroconversion, and seroreversion of infection-induced SARS-CoV-2 antibodies among a cohort of children and teenagers in Montreal, Canada.",2023-03-22,Journal Article (Peer-Reviewed),Local,Prospective cohort,Canada,Quebec,Montreal,"Participants were initially recruited through selected day cares and schools in four different neighborhoods to reflect diversity in terms of geography, cumulative COVID-19 cases, and neighbor- hood socioeconomic status. The populations living in the West Is- land and Plateau-Mont-Royal are more affluent and highly edu- cated, whereas Montréal North is one of the city’s poorest and most racially and ethnically diverse neighborhoods, and Mercier- Hochelaga-Maisonneuve (HOMA) is a working-class neighborhood with nearly one-third of the population living below the poverty line",,2020-10-15,2021-04-15,Students and Daycares,All,Children and Youth (0-17 years),2.0,17.0,Primary Estimate,,1632,0.058,0.048,0.071,True,,,,True,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Dried Blood,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.95,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Kate Zinszer,University of Montreal,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2023.03.036,2023-05-09,2023-05-09,Unverified,zinszer_pre-omicron_2023,CAN
230322_Montreal_UniversityofMontreal_Round2,230322_Montreal_UniversityofMontreal_Round2,"Pre-Omicron seroprevalence, seroconversion, and seroreversion of infection-induced SARS-CoV-2 antibodies among a cohort of children and teenagers in Montreal, Canada.",2023-03-22,Journal Article (Peer-Reviewed),Local,Prospective cohort,Canada,Quebec,Montreal,"Participants were initially recruited through selected day cares and schools in four different neighborhoods to reflect diversity in terms of geography, cumulative COVID-19 cases, and neighbor- hood socioeconomic status. The populations living in the West Is- land and Plateau-Mont-Royal are more affluent and highly edu- cated, whereas Montréal North is one of the city’s poorest and most racially and ethnically diverse neighborhoods, and Mercier- Hochelaga-Maisonneuve (HOMA) is a working-class neighborhood with nearly one-third of the population living below the poverty line",,2021-05-15,2021-09-15,Students and Daycares,All,Children and Youth (0-17 years),2.0,17.0,Primary Estimate,,936,0.105,0.086,0.127,True,,,,True,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Dried Blood,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.95,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Kate Zinszer,University of Montreal,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2023.03.036,2023-05-09,2023-05-09,Unverified,zinszer_pre-omicron_2023,CAN
230322_Montreal_UniversityofMontreal_Round3,230322_Montreal_UniversityofMontreal_Round3,"Pre-Omicron seroprevalence, seroconversion, and seroreversion of infection-induced SARS-CoV-2 antibodies among a cohort of children and teenagers in Montreal, Canada.",2023-03-22,Journal Article (Peer-Reviewed),Local,Prospective cohort,Canada,Quebec,Montreal,"Participants were initially recruited through selected day cares and schools in four different neighborhoods to reflect diversity in terms of geography, cumulative COVID-19 cases, and neighbor- hood socioeconomic status. The populations living in the West Is- land and Plateau-Mont-Royal are more affluent and highly edu- cated, whereas Montréal North is one of the city’s poorest and most racially and ethnically diverse neighborhoods, and Mercier- Hochelaga-Maisonneuve (HOMA) is a working-class neighborhood with nearly one-third of the population living below the poverty line",,2021-11-15,2022-03-15,Students and Daycares,All,Children and Youth (0-17 years),2.0,17.0,Primary Estimate,,723,0.11,0.088,0.135,True,,,,True,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Dried Blood,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Kate Zinszer,University of Montreal,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2023.03.036,2023-05-09,2023-05-09,Unverified,zinszer_pre-omicron_2023,CAN
230404_Canada_UniversityofBritishColumbia_PeriodB_AB,230404_Canada_UniversityofBritishColumbia_PeriodB_AB,Canadian SARS-CoV-2 serological survey using antenatal serum samples: a retrospective seroprevalence study,2023-04-04,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Alberta,,"stored antenatal samples from 5 sampling periods between Feb. 3, 2020, and Dec. 3, 2021, as follows. Period A: Feb. 3 to Feb. 21, 2020, before the WHO declared the COVID-19 outbreak to be a pandemic and nationwide restrictions were implemented, with testing for SARS-CoV-2 limited to high-risk travellers. Period B: Aug. 24 to Sept. 11, 2020, which corresponds to seropreva- lence after the first wave of infection. Period C: Nov. 16 to Dec. 4, 2020, corresponding to the start of the second period of SARS-CoV-2 infection and before vaccine introduction. Period D: Nov. 15 to Dec. 3, 2021, corresponding to the beginning of the Omicron wave in Canada. Finally, we carried out a provincial BC longitudinal analysis, sampling weekly batches from Nov. 15, 2021, to June 11, 2022, which spanned the period in which the SARS-CoV-2 B.1.1.529 (Omicron) variant was predominant.",,2020-08-24,2020-09-11,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,3497,0.0157,0.0116,0.0208,True,,,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,"CLIA, CMIA",,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,Unclear,Andrea Atkinson,University of British Columbia,Unity-Aligned,https://dx.doi.org/10.9778/cmajo.20220045,2023-05-09,2024-03-01,Unverified,atkinson_canadian_2023-1,CAN
230404_Canada_UniversityofBritishColumbia_PeriodB_BC,230404_Canada_UniversityofBritishColumbia_PeriodB_BC,Canadian SARS-CoV-2 serological survey using antenatal serum samples: a retrospective seroprevalence study,2023-04-04,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,British Columbia,,"stored antenatal samples from 5 sampling periods between Feb. 3, 2020, and Dec. 3, 2021, as follows. Period A: Feb. 3 to Feb. 21, 2020, before the WHO declared the COVID-19 outbreak to be a pandemic and nationwide restrictions were implemented, with testing for SARS-CoV-2 limited to high-risk travellers. Period B: Aug. 24 to Sept. 11, 2020, which corresponds to seropreva- lence after the first wave of infection. Period C: Nov. 16 to Dec. 4, 2020, corresponding to the start of the second period of SARS-CoV-2 infection and before vaccine introduction. Period D: Nov. 15 to Dec. 3, 2021, corresponding to the beginning of the Omicron wave in Canada. Finally, we carried out a provincial BC longitudinal analysis, sampling weekly batches from Nov. 15, 2021, to June 11, 2022, which spanned the period in which the SARS-CoV-2 B.1.1.529 (Omicron) variant was predominant.",,2020-08-24,2020-09-11,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,2427,0.0034,0.0012,0.0073,True,,,,True,Sequential,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,,TotalAntibody,Spike,,,,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,Unclear,Andrea Atkinson,University of British Columbia,Unity-Aligned,https://dx.doi.org/10.9778/cmajo.20220045,2023-05-09,2024-03-01,Unverified,atkinson_canadian_2023-1,CAN
230404_Canada_UniversityofBritishColumbia_PeriodB_NL,230404_Canada_UniversityofBritishColumbia_PeriodB_NL,Canadian SARS-CoV-2 serological survey using antenatal serum samples: a retrospective seroprevalence study,2023-04-04,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"stored antenatal samples from 5 sampling periods between Feb. 3, 2020, and Dec. 3, 2021, as follows. Period A: Feb. 3 to Feb. 21, 2020, before the WHO declared the COVID-19 outbreak to be a pandemic and nationwide restrictions were implemented, with testing for SARS-CoV-2 limited to high-risk travellers. Period B: Aug. 24 to Sept. 11, 2020, which corresponds to seropreva- lence after the first wave of infection. Period C: Nov. 16 to Dec. 4, 2020, corresponding to the start of the second period of SARS-CoV-2 infection and before vaccine introduction. Period D: Nov. 15 to Dec. 3, 2021, corresponding to the beginning of the Omicron wave in Canada. Finally, we carried out a provincial BC longitudinal analysis, sampling weekly batches from Nov. 15, 2021, to June 11, 2022, which spanned the period in which the SARS-CoV-2 B.1.1.529 (Omicron) variant was predominant.",,2020-08-24,2020-09-11,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,33,0.0,,,True,,,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,,IgG,Spike,,,,['High'],Yes,No,No,No,Yes,Yes,Yes,Yes,Unclear,Andrea Atkinson,University of British Columbia,Unity-Aligned,https://dx.doi.org/10.9778/cmajo.20220045,2023-05-09,2024-03-01,Unverified,atkinson_canadian_2023-1,CAN
230404_Canada_UniversityofBritishColumbia_PeriodB_NS,230404_Canada_UniversityofBritishColumbia_PeriodB_NS,Canadian SARS-CoV-2 serological survey using antenatal serum samples: a retrospective seroprevalence study,2023-04-04,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"stored antenatal samples from 5 sampling periods between Feb. 3, 2020, and Dec. 3, 2021, as follows. Period A: Feb. 3 to Feb. 21, 2020, before the WHO declared the COVID-19 outbreak to be a pandemic and nationwide restrictions were implemented, with testing for SARS-CoV-2 limited to high-risk travellers. Period B: Aug. 24 to Sept. 11, 2020, which corresponds to seropreva- lence after the first wave of infection. Period C: Nov. 16 to Dec. 4, 2020, corresponding to the start of the second period of SARS-CoV-2 infection and before vaccine introduction. Period D: Nov. 15 to Dec. 3, 2021, corresponding to the beginning of the Omicron wave in Canada. Finally, we carried out a provincial BC longitudinal analysis, sampling weekly batches from Nov. 15, 2021, to June 11, 2022, which spanned the period in which the SARS-CoV-2 B.1.1.529 (Omicron) variant was predominant.",,2020-08-24,2020-09-11,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,489,0.0041,0.0005,0.0147,True,,,,True,Sequential,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,,TotalAntibody,Spike,,,,['High'],Yes,No,No,No,Yes,Yes,Yes,Yes,Unclear,Andrea Atkinson,University of British Columbia,Unity-Aligned,https://dx.doi.org/10.9778/cmajo.20220045,2023-05-09,2024-03-01,Unverified,atkinson_canadian_2023-1,CAN
230404_Canada_UniversityofBritishColumbia_PeriodB_SK,230404_Canada_UniversityofBritishColumbia_PeriodB_SK,Canadian SARS-CoV-2 serological survey using antenatal serum samples: a retrospective seroprevalence study,2023-04-04,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"stored antenatal samples from 5 sampling periods between Feb. 3, 2020, and Dec. 3, 2021, as follows. Period A: Feb. 3 to Feb. 21, 2020, before the WHO declared the COVID-19 outbreak to be a pandemic and nationwide restrictions were implemented, with testing for SARS-CoV-2 limited to high-risk travellers. Period B: Aug. 24 to Sept. 11, 2020, which corresponds to seropreva- lence after the first wave of infection. Period C: Nov. 16 to Dec. 4, 2020, corresponding to the start of the second period of SARS-CoV-2 infection and before vaccine introduction. Period D: Nov. 15 to Dec. 3, 2021, corresponding to the beginning of the Omicron wave in Canada. Finally, we carried out a provincial BC longitudinal analysis, sampling weekly batches from Nov. 15, 2021, to June 11, 2022, which spanned the period in which the SARS-CoV-2 B.1.1.529 (Omicron) variant was predominant.",,2020-08-24,2020-09-11,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,2427,0.0066,0.0018,0.0168,True,,,,True,Sequential,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,,TotalAntibody,Spike,,,,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,Unclear,Andrea Atkinson,University of British Columbia,Unity-Aligned,https://dx.doi.org/10.9778/cmajo.20220045,2023-05-09,2024-03-01,Unverified,atkinson_canadian_2023-1,CAN
230405_Canada_CBS_BloodDonors_RocheS_Overall_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,31755,1.0,1.0,1.0,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,436,0.9975,0.9862,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,440,0.9993031359,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1435,0.9993,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_Sex_Female_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,12865,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_Sex_Male_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18890,0.9944944415,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,5878,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5201,0.7601,0.7488,0.7714,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_Age_25-39_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8206,0.8325615403,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2137,0.9967355822,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_Overall_PopAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Analysis,,31755,0.9955,0.9947,0.9962,,,True,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,436,0.9908,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,5878,0.8086,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1435,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2137,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_Age_60+_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9120,0.6492,0.6393,0.6592,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,25242,0.7537,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1298,0.7386,0.7126,0.7646,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14702,0.9952,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1435,0.7376,0.711,0.7642,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1470,0.7993,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3045,0.8427,0.8303,0.855,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_Age_40-59_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11990,0.7899916597,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1891,0.9968,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2409,0.9938,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1298,0.9977,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_Sex_Male_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18889,0.78,0.7734,0.7866,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1435,0.724,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,440,0.7916,0.7593,0.8239,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1470,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,25242,0.7592,0.7538,0.7646,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,1300,1.0,0.9995,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,919,0.7769,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5201,0.7474,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1891,0.7959,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4658,0.7915,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2409,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3045,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_Overall_PopAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Analysis,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay Pop Adj,31755,0.7725,0.7678,0.7771,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2137,0.8247,0.8051,0.8444,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,1300,0.772,0.7443,0.7997,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,919,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1470,0.9973,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4659,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_Age_40-59_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11991,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4658,0.7908,0.781,0.8007,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,440,0.7841,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_Sex_Female_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,12865,0.9964244073,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,25243,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_Age_17-24_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2438,0.8761279737,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,440,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1320,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4659,0.9948,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2409,0.8351,0.8205,0.8498,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,5878,0.8246,0.8136,0.8356,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_Sex_Female_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,12865,0.772,0.7655,0.7785,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,146,0.7603,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1320,0.7621,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_Overall_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Test used,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay PopTest Adj,31755,0.7759,0.7713,0.7806,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,146,0.8019,0.7412,0.8627,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,436,0.7773,0.7381,0.8165,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_Sex_Female_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,12865,0.7733385154,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,1300,0.9946,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_Sex_Male_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18889,0.7636719784,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,919,0.9967,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,146,0.9973,0.9791,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_Age_25-39_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8206,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_Age_40-59_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11990,0.7948,0.7872,0.8024,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1891,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_Age_25-39_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8206,0.9979283451,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,25243,0.9952,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_Age_17-24_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2438,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2661,0.7836,0.769,0.7981,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_Age_25-39_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8206,0.8402,0.8319,0.8485,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1891,0.8113,0.7922,0.8303,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,146,0.9932,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_Age_17-24_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2438,0.884,0.8738,0.8942,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_Age_40-59_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11991,0.9953298307,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_Sex_Male_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18890,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3045,0.8322,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,919,0.7757,0.748,0.8034,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1320,0.9985,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,436,0.7706,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_Age_60+_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9120,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1298,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1320,0.7775,0.7541,0.8009,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2409,0.8244,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14701,0.7579,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14702,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3045,0.999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_Overall_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Analysis,,31755,0.9953,0.9945,0.996,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5201,0.9937,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_Age_60+_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9120,0.9918859649,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2661,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2137,0.8147,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_Age_60+_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9120,0.6506578947,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2661,0.9966,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_Age_17-24_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2438,0.9987694832,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,1300,0.7592,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5201,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14701,0.767,0.7604,0.7737,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1298,0.7458,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2661,0.7775,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_UnAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,5878,0.9951,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230405_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_PopTestAdj,230405_Canada_CBS,"COVID-19 Seroprevalence Report April 5, 2023 Report #31: February 2023 Survey",2023-04-05,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-02-01,2023-02-28,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1470,0.796,0.775,0.817,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-04-12,2024-04-21,Verified,canadian_blood_services_covid-19_2023-6,CAN
230406_Calgary_UniversityofCalgary_Visit1_Anti-S,230406_Calgary_UniversityofCalgary_Visit1,"A longitudinal seroepidemiology study to evaluate antibody response to SARS-CoV-2 virus infection and vaccination in children in Calgary, Canada from July 2020 to April 2022: Alberta COVID-19 Childhood Cohort (AB3C) Study.",2023-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Alberta,Calgary,"All study participants were under 18 years of age, residing in the Calgary area. Two study groups were enrolled. Group 2 included children not diagnosed with COVID-19 infections prior to enrolment, and whose families expressed interest in the study through responding to a study announcement posted on social media. Children in this group either had a prior negative PCR test for SARS-CoV-2 or were never tested.

",Children with prior PCR infection,2020-07-15,2020-11-15,Household and community samples,All,Children and Youth (0-17 years),,18.0,Primary Estimate,,902,0.007,0.002,0.01,True,,,,True,Convenience,AdviseDX SARS-CoV-2 anti-IgG II assay,Abbott Laboratories,,Serum,IgG,Spike,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Emily Doucette,University of Calgary,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0284046,2023-05-09,2024-03-01,Unverified,doucette_longitudinal_2023,CAN
230406_Calgary_UniversityofCalgary_Visit1_Anti-N,230406_Calgary_UniversityofCalgary_Visit1,"A longitudinal seroepidemiology study to evaluate antibody response to SARS-CoV-2 virus infection and vaccination in children in Calgary, Canada from July 2020 to April 2022: Alberta COVID-19 Childhood Cohort (AB3C) Study.",2023-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Alberta,Calgary,"All study participants were under 18 years of age, residing in the Calgary area. Two study groups were enrolled. Group 2 included children not diagnosed with COVID-19 infections prior to enrolment, and whose families expressed interest in the study through responding to a study announcement posted on social media. Children in this group either had a prior negative PCR test for SARS-CoV-2 or were never tested.

",Children with prior PCR infection,2020-07-15,2020-11-15,Household and community samples,All,Children and Youth (0-17 years),,18.0,Test used,,909,0.001,0.0,0.006,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Emily Doucette,University of Calgary,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0284046,2023-05-09,2024-03-01,Unverified,doucette_longitudinal_2023,CAN
230406_Calgary_UniversityofCalgary_Visit2_Anti-S,230406_Calgary_UniversityofCalgary_Visit2,"A longitudinal seroepidemiology study to evaluate antibody response to SARS-CoV-2 virus infection and vaccination in children in Calgary, Canada from July 2020 to April 2022: Alberta COVID-19 Childhood Cohort (AB3C) Study.",2023-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Alberta,Calgary,"All study participants were under 18 years of age, residing in the Calgary area. Two study groups were enrolled. Group 2 included children not diagnosed with COVID-19 infections prior to enrolment, and whose families expressed interest in the study through responding to a study announcement posted on social media. Children in this group either had a prior negative PCR test for SARS-CoV-2 or were never tested.

",Children with prior PCR infection,2021-02-15,2021-04-15,Household and community samples,All,Children and Youth (0-17 years),,18.0,Primary Estimate,,840,0.032,0.021,0.046,True,,,,True,Convenience,AdviseDX SARS-CoV-2 anti-IgG II assay,Abbott Laboratories,,Serum,IgG,Spike,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Emily Doucette,University of Calgary,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0284046,2023-05-09,2024-03-01,Unverified,doucette_longitudinal_2023,CAN
230406_Calgary_UniversityofCalgary_Visit2_Anti-N,230406_Calgary_UniversityofCalgary_Visit2,"A longitudinal seroepidemiology study to evaluate antibody response to SARS-CoV-2 virus infection and vaccination in children in Calgary, Canada from July 2020 to April 2022: Alberta COVID-19 Childhood Cohort (AB3C) Study.",2023-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Alberta,Calgary,"All study participants were under 18 years of age, residing in the Calgary area. Two study groups were enrolled. Group 2 included children not diagnosed with COVID-19 infections prior to enrolment, and whose families expressed interest in the study through responding to a study announcement posted on social media. Children in this group either had a prior negative PCR test for SARS-CoV-2 or were never tested.

",Children with prior PCR infection,2021-02-15,2021-04-15,Household and community samples,All,Children and Youth (0-17 years),,18.0,Test used,,842,0.002,0.001,0.003,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Emily Doucette,University of Calgary,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0284046,2023-05-09,2024-03-01,Unverified,doucette_longitudinal_2023,CAN
230406_Calgary_UniversityofCalgary_Visit3_Anti-S,230406_Calgary_UniversityofCalgary_Visit3,"A longitudinal seroepidemiology study to evaluate antibody response to SARS-CoV-2 virus infection and vaccination in children in Calgary, Canada from July 2020 to April 2022: Alberta COVID-19 Childhood Cohort (AB3C) Study.",2023-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Alberta,Calgary,"All study participants were under 18 years of age, residing in the Calgary area. Two study groups were enrolled. Group 2 included children not diagnosed with COVID-19 infections prior to enrolment, and whose families expressed interest in the study through responding to a study announcement posted on social media. Children in this group either had a prior negative PCR test for SARS-CoV-2 or were never tested.

",Children with prior PCR infection,2021-08-15,2021-10-15,Household and community samples,All,Children and Youth (0-17 years),,18.0,Primary Estimate,,822,0.474,0.44,0.509,True,,,,True,Convenience,AdviseDX SARS-CoV-2 anti-IgG II assay,Abbott Laboratories,,Serum,IgG,Spike,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Emily Doucette,University of Calgary,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0284046,2023-05-09,2024-03-01,Unverified,doucette_longitudinal_2023,CAN
230406_Calgary_UniversityofCalgary_Visit3_Anti-N,230406_Calgary_UniversityofCalgary_Visit3,"A longitudinal seroepidemiology study to evaluate antibody response to SARS-CoV-2 virus infection and vaccination in children in Calgary, Canada from July 2020 to April 2022: Alberta COVID-19 Childhood Cohort (AB3C) Study.",2023-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Alberta,Calgary,"All study participants were under 18 years of age, residing in the Calgary area. Two study groups were enrolled. Group 2 included children not diagnosed with COVID-19 infections prior to enrolment, and whose families expressed interest in the study through responding to a study announcement posted on social media. Children in this group either had a prior negative PCR test for SARS-CoV-2 or were never tested.

",Children with prior PCR infection,2021-08-15,2021-10-15,Household and community samples,All,Children and Youth (0-17 years),,18.0,Test used,,823,0.047,0.034,0.064,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Emily Doucette,University of Calgary,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0284046,2023-05-09,2024-03-01,Unverified,doucette_longitudinal_2023,CAN
230406_Calgary_UniversityofCalgary_Visit4_Anti-S,230406_Calgary_UniversityofCalgary_Visit4,"A longitudinal seroepidemiology study to evaluate antibody response to SARS-CoV-2 virus infection and vaccination in children in Calgary, Canada from July 2020 to April 2022: Alberta COVID-19 Childhood Cohort (AB3C) Study.",2023-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Alberta,Calgary,"All study participants were under 18 years of age, residing in the Calgary area. Two study groups were enrolled. Group 2 included children not diagnosed with COVID-19 infections prior to enrolment, and whose families expressed interest in the study through responding to a study announcement posted on social media. Children in this group either had a prior negative PCR test for SARS-CoV-2 or were never tested.

",Children with prior PCR infection,2022-02-15,2022-04-15,Household and community samples,All,Children and Youth (0-17 years),,18.0,Primary Estimate,,770,0.894,0.869,0.914,True,,,,True,Convenience,AdviseDX SARS-CoV-2 anti-IgG II assay,Abbott Laboratories,,Serum,IgG,Spike,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Emily Doucette,University of Calgary,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0284046,2023-05-09,2024-03-01,Unverified,doucette_longitudinal_2023,CAN
230406_Calgary_UniversityofCalgary_Visit4_Anti-N,230406_Calgary_UniversityofCalgary_Visit4,"A longitudinal seroepidemiology study to evaluate antibody response to SARS-CoV-2 virus infection and vaccination in children in Calgary, Canada from July 2020 to April 2022: Alberta COVID-19 Childhood Cohort (AB3C) Study.",2023-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Alberta,Calgary,"All study participants were under 18 years of age, residing in the Calgary area. Two study groups were enrolled. Group 2 included children not diagnosed with COVID-19 infections prior to enrolment, and whose families expressed interest in the study through responding to a study announcement posted on social media. Children in this group either had a prior negative PCR test for SARS-CoV-2 or were never tested.

",Children with prior PCR infection,2022-02-15,2022-04-15,Household and community samples,All,Children and Youth (0-17 years),,18.0,Test used,,770,0.348,0.314,0.383,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Emily Doucette,University of Calgary,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0284046,2023-05-09,2024-03-01,Unverified,doucette_longitudinal_2023,CAN
230601_Vancouver_UBC_Ad,230601_Vancouver_UBC,"SARS-CoV-2 cross-sectional seroprevalence study among public school staff in Metro Vancouver after the first Omicron wave in British Columbia, Canada.",2023-06-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,British Columbia,Vancouver,"The study included current, full or part-time district staff members recruited from a prospective longitudinal study conducted from February to June 2021","The study excluded staff who were: temporary, on-leave, or on-call with no classroom time, or working exclusively in adult education.",2022-01-26,2022-04-08,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,Cluster + Pop + Test-adjusted,1620,0.265,0.239,0.29300000000000004,True,True,True,True,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,,,Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Allison W Watts,University of British Columbia,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2022-071228,2022-09-13,2023-08-15,Unverified,watts_sars-cov-2_2023,CAN
230602_Canada_CBS_BloodDonors_RocheS_Overall_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,30792,1.0,1.0,1.0,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1344,1.0,0.9962,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6366,0.9957587182,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1923,1.0,0.9986,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,2754,0.8458,0.833,0.8586,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,815,1.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1744,0.7399,0.7133,0.7666,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4295,0.8003,0.7905,0.8101,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_Age_60+_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9968,0.6741573034,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4294,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_Age_60+_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9968,0.674,0.664,0.6839,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2832,0.7828,0.7683,0.7973,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_Overall_PopAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Analysis,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay Pop Adj,30793,0.7832,0.7785,0.7878,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14596,0.7835,0.7769,0.7901,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2225,0.8346067416,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2226,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,747,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2832,0.7733050847,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_Sex_Male_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18677,0.9957701986,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_Age_40-59_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11533,0.7973640857,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24648,0.7597370983,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,627,0.9968102073,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_Age_17-24_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2197,0.8916704597,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2225,0.8475,0.8327,0.8622,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6366,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,815,0.7521472393,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,555,0.7747747748,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24646,0.9963077173,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14596,0.9963688682,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_Age_17-24_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2197,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2321,0.8005170185,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,403,0.7717121588,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,63,0.9066,0.8609,0.9523,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1744,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1744,0.7327981651,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_Age_40-59_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11533,0.7992,0.7915,0.8068,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,2754,0.8347857662,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1923,0.8155,0.7962,0.8349,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14596,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2832,0.9971751412,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,627,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24646,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,627,0.7192982456,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2321,0.9969840586,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,2754,0.9989106754,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_Sex_Male_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18677,0.7825,0.7758,0.7892,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,747,0.7847,0.7571,0.8123,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_Overall_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Analysis,,30792,0.9965,0.9957,0.9971,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_Sex_Female_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,12115,0.9975237309,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_Overall_PopAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Analysis,,30792,0.997,0.9964,0.9976,,,True,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,815,0.7852,0.7569,0.8136,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24648,0.7717,0.7663,0.7771,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_Age_25-39_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,7095,0.8456,0.8373,0.8539,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1155,1.0,0.9954,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1344,0.7693452381,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6366,0.8097706566,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,63,1.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1344,0.8038,0.7828,0.8248,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,555,0.7855,0.7524,0.8187,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_Age_25-39_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,7096,0.998167982,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6366,0.8253,0.8141,0.8365,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,2754,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_Age_25-39_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,7095,0.8343904158,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14596,0.7723348863,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,403,0.7984,0.7586,0.8382,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5339,0.9964412811,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,63,0.746031746,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1923,0.997399896,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2321,0.8145,0.7941,0.8349,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1344,0.9985119048,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2832,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_Age_25-39_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,7096,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,815,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_Sex_Female_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,12116,0.7857378673,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5340,0.7402621723,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,403,1.0,0.9895,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1155,0.8037,0.7809,0.8264,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1744,0.9994266055,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4294,0.9960409874,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,747,1.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1155,0.7645021645,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_Age_60+_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9967,0.9948831143,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,403,1.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,63,0.9892,0.9573,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_Sex_Female_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,12115,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_Age_40-59_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11532,0.9960978148,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_Age_60+_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9967,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,555,1.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1155,0.9948051948,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,747,0.7617135207,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_Age_17-24_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2197,0.8917,0.8817,0.9018,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_Sex_Male_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18677,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,627,0.7457,0.7195,0.772,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4295,0.7953434226,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,555,1.0,0.9966,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_Sex_Female_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,12116,0.7906,0.7842,0.797,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1923,0.7997919917,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_Age_17-24_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2197,1.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5340,0.76,0.7485,0.7714,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_Age_40-59_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11532,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_Overall_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Test used,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay PopTest Adj,30793,0.7867,0.7821,0.7913,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheN_Sex_Male_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18677,0.7643090432,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2321,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_PopTestAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5339,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230602_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_UnAdj,230602_Canada_CBS,"COVID-19 Seroprevalence Report June 2, 2023 Report #32: March 2023 Survey",2023-06-02,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-03-01,2023-03-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2226,0.995507637,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-8,CAN
230608_Canada_CBS_BloodDonors_RocheS_Overall_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,31978,1.0,1.0,1.0,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,1965,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2633,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,431,0.8312,0.7956,0.8669,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3187,0.8475,0.8353,0.8597,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1340,0.839,0.818,0.86,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1772,0.9971783296,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5009,0.9952086245,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,82,1.0,0.9845,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_Age_25-39_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,7858,0.8302367015,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1395,0.9964157706,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,25524,0.7737423601,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_Age_17-24_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2251,0.8924922257,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,5575,0.8326,0.8216,0.8437,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_Sex_Female_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13057,0.9970130964,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_Sex_Male_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18921,0.9950848264,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,911,0.9989023052,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,1035,0.9961352657,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,5276,0.996777862,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1340,0.9985074627,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,5575,0.8143497758,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5009,0.7718107407,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1358,0.9985272459,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1395,0.7899641577,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_Age_60+_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9843,0.9941074876,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,1965,0.996437659,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,15182,0.7827,0.7763,0.789,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,15182,0.7771044658,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_Age_40-59_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,12027,0.995759541,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,1965,0.810178117,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,431,0.9953596288,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1358,0.7532,0.7272,0.7791,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2156,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_Age_25-39_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,7858,0.9972003054,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,82,1.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,1965,0.8252,0.8054,0.8451,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1712,0.9976635514,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,15181,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_Sex_Male_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18921,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2633,0.9984808204,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1358,0.7444771723,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,911,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_Age_60+_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9843,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1712,0.7453271028,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_Overall_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Test used,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay PopTest Adj,31979,0.7941,0.7896,0.7986,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,911,0.803,0.7768,0.8291,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_Age_40-59_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,12027,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1772,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,5276,0.7956,0.7859,0.8054,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5009,0.7845,0.7735,0.7955,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_Overall_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Analysis,,31978,0.9959,0.9951,0.9965,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,5575,0.9947982063,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2156,0.8172541744,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5009,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,1035,0.7980676329,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1395,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_Overall_PopAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Analysis,,31978,0.9961,0.9954,0.9968,,,True,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2633,0.8136,0.7998,0.8273,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_Sex_Female_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13057,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_Age_25-39_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,7858,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_Sex_Female_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13058,0.7933067851,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,15181,0.9957842039,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1395,0.808,0.7872,0.8287,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,911,0.7848518112,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_Age_17-24_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2250,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,649,1.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,25523,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_Age_60+_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9843,0.6913542619,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,649,0.8104776579,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1358,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2633,0.8040258261,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1340,0.8089552239,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_Age_60+_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9843,0.6903,0.6807,0.6999,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3187,0.9993724506,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_Age_40-59_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,12027,0.8101771015,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,1035,0.8125,0.7864,0.8386,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2156,0.829,0.8134,0.8447,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1772,0.8086907449,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_Age_40-59_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,12027,0.8115,0.8041,0.8188,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,649,0.8182,0.7871,0.8492,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,1035,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,649,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,5276,0.793404094,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1772,0.8241,0.8052,0.843,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,5575,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,82,0.7804878049,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_Sex_Male_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18921,0.7925,0.7861,0.799,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_Sex_Male_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18921,0.77813012,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_Age_17-24_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2251,0.8942,0.8844,0.9041,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1712,0.7544,0.7286,0.7802,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,25524,0.7821,0.7769,0.7873,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,431,0.8120649652,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_Age_25-39_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,7858,0.8396,0.8313,0.8479,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1712,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1340,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,5276,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,82,0.8245,0.7658,0.8832,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_Sex_Female_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,13058,0.7956,0.7894,0.8019,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2156,0.995825603,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,431,0.9967,0.9851,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,25523,0.9954158994,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_PopTestAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3187,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_Overall_PopAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Analysis,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay Pop Adj,31979,0.7906,0.7861,0.795,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3187,0.8377784751,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230608_Canada_CBS_BloodDonors_RocheS_Age_17-24_UnAdj,230608_Canada_CBS,"COVID-19 Seroprevalence Report June 8, 2023 Report #33: April 2023 Survey",2023-06-08,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-04-01,2023-04-30,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2250,0.9995555556,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-9,CAN
230624_Canada_MountSinai,230624_Canada_MountSinai,Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium,2023-06-24,Journal Article (Peer-Reviewed),National,Prospective cohort,Canada,,,"Our initial core objective was to include all adult patients with IBD who entered the infusion center for vedolizumab or infliximab (originator or biosimilars), as well as intravenous ustekinumab induction, regardless of history of known COVID-19 infection, and without any exclusion criteria.",None,2020-05-15,2021-12-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,13,0.0,,,True,,,,True,Convenience,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Yes,Yes,Yes,,Serre-Yu Wong,Mount Sinai,Not Unity-Aligned,https://dx.doi.org/10.1093/ibd/izad097,2023-08-02,2024-03-01,Unverified,wong_geography_2023,CAN
230628_Canada_CBS_BloodDonors_RocheS_Overall_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,31708,1.0,1.0,1.0,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3236,0.999381953,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,2081,0.7948101874,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_Overall_PopAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Analysis,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay Pop Adj,31711,0.7928,0.7883,0.7973,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1663,0.9963920625,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_Age_40-59_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11697,0.8014020689,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_Sex_Female_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,12749,0.7971,0.7908,0.8033,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14183,0.784883311,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1025,0.9990243902,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5953,0.7643205107,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_Age_17-24_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2332,1.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,2081,0.8064,0.7868,0.826,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_Sex_Male_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18959,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_Age_60+_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9671,0.7025126667,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4838,0.9971062422,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3236,0.8453,0.8332,0.8573,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,107,0.7836,0.72,0.8471,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1413,0.8333,0.812,0.8546,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5953,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14181,0.9962626049,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2384,0.8267,0.8071,0.8463,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,3123,0.9971181556,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,3123,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,467,0.9996,0.9893,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6267,0.824,0.8128,0.8353,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,107,1.0,0.9843,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4839,0.8016119033,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1025,0.737,0.7105,0.7635,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,263,0.9961977186,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,467,0.9935760171,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1063,0.9962370649,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1025,0.7317073171,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,107,0.7663551402,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1663,0.8155,0.795,0.836,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,837,0.7670250896,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1063,0.8005644403,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1481,0.77,0.745,0.795,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6267,0.8099569172,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24843,0.7807,0.7754,0.7859,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_Age_60+_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9671,0.7021,0.6925,0.7117,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,263,0.8164,0.7849,0.8479,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1413,0.9950460014,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24843,0.7713239142,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1413,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_Age_40-59_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11695,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1663,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_Age_25-39_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8011,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_Age_40-59_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11695,0.9961522018,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_Age_17-24_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2332,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3236,0.837144623,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6266,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_Sex_Female_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,12749,0.7955133736,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_Age_60+_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9670,0.9944157187,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1663,0.8027660854,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2357,0.9953330505,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_Age_17-24_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2332,0.897084048,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4838,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14181,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5953,0.7828,0.7718,0.7939,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2384,0.8137583893,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_Overall_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Analysis,,31708,0.9962,0.9955,0.9969,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_Overall_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Test used,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay PopTest Adj,31711,0.7964,0.7919,0.8009,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,467,0.8372591006,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14183,0.7926,0.7863,0.7989,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,837,0.9988052569,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1025,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2357,0.8504,0.8363,0.8646,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_Sex_Male_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18962,0.7791899589,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2384,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_Sex_Male_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18962,0.7957,0.7893,0.8022,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_Age_25-39_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8011,0.8309823992,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_Overall_PopAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Analysis,,31708,0.9966,0.9959,0.9972,,,True,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_Sex_Male_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18959,0.9955693866,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6266,0.9966485796,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,3123,0.7987,0.7848,0.8127,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2384,0.9983221477,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_Sex_Female_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,12749,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,837,0.7903,0.7631,0.8176,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,467,0.8385,0.804,0.873,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,837,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2357,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,3123,0.7838616715,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,2080,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3236,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1413,0.804670913,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1063,0.8093,0.782,0.8365,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24840,0.9959742351,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24840,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,4839,0.8007,0.7914,0.81,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,263,0.8098859316,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,2080,0.9951923077,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1063,1.0,0.9995,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_Age_25-39_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8011,0.8393,0.831,0.8476,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1481,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_Sex_Female_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,12749,0.9972546866,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,263,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1481,0.9986495611,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5953,0.9951285066,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_Age_25-39_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8011,0.9975034328,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_Age_60+_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9670,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_Age_40-59_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11697,0.8062,0.7988,0.8137,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1481,0.7589466577,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2357,0.8370810352,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheN_Age_17-24_PopTestAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2332,0.8989,0.8892,0.9085,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230628_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_UnAdj,230628_Canada_CBS,"COVID-19 Seroprevalence Report June 28, 2023 Report #34: May 2023 Survey",2023-06-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-05-01,2023-05-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,107,1.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-06-30,2024-04-25,Verified,canadian_blood_services_covid-19_2023-10,CAN
230720_Canada_UniversityofOttawa,230720_Canada_UniversityofOttawa,Cross-sectional Characterization of SARS-CoV-2 Antibody Levels and Decay Rates Following Infection of Unvaccinated Elderly Individuals.,2023-07-20,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Canada,,,"""Residual serum/plasma samples were collected from individuals undergoing routine SARS-CoV-2 polymerase chain reaction testing in a community laboratory in Canada. The samples were collected in 2020, before vaccines became available. ""","""Nine samples were excluded due to low sample volume""",2020-04-28,2020-09-20,Residual sera,All,Multiple groups,21.0,105.0,Primary Estimate,,739,0.631,,,True,,,,True,Sequential,Not reported/ Unable to specify,,ELISA,Multiple Types,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Marilyn Whelan,University of Ottawa,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofad384,2023-08-23,2023-08-25,Unverified,whelanCrosssectionalCharacterizationSARSCoV22023,CAN
230728_Canada_CBS_BloodDonors_RocheS_Overall_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,31790,1.0,1.0,1.0,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24867,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2186,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_Sex_Male_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,19327,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,426,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_Sex_Female_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,12463,0.7968386424,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1431,0.9972,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1431,0.7876,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1047,0.9962,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,15463,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_Age_40-59_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11991,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,97,0.7835,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_Age_60+_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9659,0.7033,0.6937,0.7128,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1543,0.8354,0.8159,0.8548,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,531,0.7934,0.7666,0.8203,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1431,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_Overall_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Test used,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay PopTest Adj,31790,0.8,0.7955,0.8044,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_Age_60+_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9659,0.7011077751,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5450,0.7849,0.774,0.7958,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,3000,0.8147,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,15463,0.9972,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_Age_40-59_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11991,0.9959969977,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,917,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_Age_25-39_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8047,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2341,0.8618,0.8479,0.8757,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,3000,0.9977,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1047,0.7423,0.7161,0.7685,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,15463,0.7828,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_Age_40-59_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11991,0.8123,0.8049,0.8196,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,531,1.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3356,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_Sex_Female_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,12463,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,917,0.8236,0.7975,0.8497,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_Age_25-39_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8047,0.842,0.8338,0.8502,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2186,0.8123,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,111,0.8037,0.772,0.8354,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3356,0.8445,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1047,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_Overall_PopAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Analysis,,31790,1.0,1.0,1.0,,,True,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2341,0.8458,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,531,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_Age_17-24_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2093,0.9022,0.8927,0.9117,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2341,0.994,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1543,0.9968,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,3000,0.8178,0.8044,0.8311,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_Sex_Female_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,12463,0.8008,0.7946,0.807,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,531,0.7834,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,917,0.8081,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,5293,0.8056,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,97,1.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24867,0.9968,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3356,0.8562,0.8445,0.8679,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1230,0.7374,0.7147,0.7601,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_Age_40-59_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11991,0.8088566425,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,426,0.8216,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_Sex_Male_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,19327,0.7991,0.7927,0.8055,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,97,1.0,0.9849,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_Age_17-24_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2093,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_Age_17-24_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2093,0.8996655518,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,5293,0.9974,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,111,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,426,0.8296,0.7942,0.865,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6117,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1047,0.7354,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2186,0.9973,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2186,0.8312,0.8117,0.8506,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,111,1.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_Age_25-39_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8047,0.8355909034,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24867,0.775,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1431,0.81,0.7878,0.8322,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,3000,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1973,0.9959,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1973,0.8314,0.8128,0.8501,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,97,0.8022,0.7413,0.8631,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6117,0.8366,0.8259,0.8474,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5450,0.7758,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_Age_17-24_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2093,0.9990444338,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,111,0.7748,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_Age_60+_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9659,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_Age_25-39_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8047,0.998508761,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_Overall_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Analysis,,31790,0.9968,0.9961,0.9974,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2341,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,917,0.9989,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_Sex_Female_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,12463,0.9975928749,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_Sex_Male_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,19327,0.9963263828,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1230,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24867,0.7838,0.7786,0.789,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6117,0.8179,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,426,1.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_Overall_PopAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Analysis,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay Pop Adj,31790,0.7964,0.7919,0.8008,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5450,0.9965,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1543,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,5293,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3356,1.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1230,0.9984,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1230,0.7341,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,5293,0.8139,0.8045,0.8233,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1973,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1973,0.815,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1543,0.8211,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_Age_60+_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9659,0.9959623149,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_Sex_Male_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,19327,0.7837222538,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,15463,0.7947,0.7883,0.801,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_PopTestAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5450,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230728_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_UnAdj,230728_Canada_CBS,"COVID-19 Seroprevalence Report July 28, 2023 Report #35: June 2023 Survey",2023-07-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-06-01,2023-06-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,6117,0.9959,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-08-03,2024-04-25,Verified,canadian_blood_services_covid-19_2023-11,CAN
230806_Toronto_TheHospitalForSickChildren,230806_Toronto_TheHospitalForSickChildren,SARS-CoV-2 serology in pediatrics: Seroprevalence studies in unvaccinated children and humoral antibody response post vaccination.,2023-08-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Canada,Ontario,Toronto,Pediatric specimen from The Hospital for Sick Children,,2022-07-15,2022-09-15,Residual sera,All,Children and Youth (0-17 years),,5.0,Primary Estimate,,2662,0.73,,,True,,,,True,Sequential,"AdviseDX SARS-CoV-2 anti-IgG II assay,LIAISON® SARS-CoV-2 TrimericS IgG","Abbott Laboratories,DiaSorin",CLIA,,IgG,Spike,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Mary Kathryn Bohn,The Hospital for Sick Children,Not Unity-Aligned,https://dx.doi.org/10.1016/j.clinbiochem.2023.110630,2023-08-24,2024-03-01,Unverified,bohn_sars-cov-2_2023,CAN
230828_Canada_CBS_BloodDonors_RocheS_Overall_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,31977,1.0,1.0,1.0,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3565,0.8406732118,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_Age_25-39_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8123,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1393,0.9978463747,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1838,0.9972796518,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3565,0.8499,0.8385,0.8612,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,468,0.9957264957,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_Overall_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Analysis,,31977,0.9968102073,0.9961,0.9974,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,5397,0.9966648138,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_Sex_Female_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,12796,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1393,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,670,0.7713,0.7431,0.7994,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_Sex_Female_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,12796,0.7947796186,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,670,0.7447761194,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_Sex_Female_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,12796,0.9978899656,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,15380,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_Age_17-24_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1982,1.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3564,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2411,0.9966818747,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1393,0.7487437186,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_Age_17-24_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1982,0.8990918264,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,468,1.0,0.9987,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1184,0.7991,0.7717,0.8266,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_Sex_Male_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,19181,0.9960898806,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1766,0.7921857305,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_Age_40-59_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,12083,0.7986427212,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_Sex_Male_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,19182,0.7777082682,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2411,0.8484,0.8343,0.8625,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,670,0.9985074627,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,5659,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_Age_60+_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9790,0.9960163432,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1766,0.9977349943,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,180,0.819,0.7601,0.8778,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1018,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2142,0.8118580766,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,15380,0.7985,0.7922,0.8048,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_Sex_Male_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,19181,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_Age_40-59_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,12082,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2411,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,3091,0.7958589453,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1393,0.7648,0.7392,0.7904,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,180,1.0,0.985,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,3090,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2411,0.8320199088,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5672,0.785,0.7742,0.7959,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,258,1.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_Overall_PopAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Analysis,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay Pop Adj,31978,0.7958,0.7914,0.8002,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1018,0.7455,0.7193,0.7716,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1375,0.7890909091,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1018,1.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24711,0.7701833192,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,5397,0.8126,0.8037,0.8215,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1184,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_Overall_PopAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Analysis,,31977,0.9973,0.9967,0.9979,,,True,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24711,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,468,0.8192,0.7841,0.8544,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,5397,0.8082267927,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2142,0.9985994398,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1375,0.9941818182,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_Sex_Male_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,19182,0.7952,0.7888,0.8017,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5671,0.9968259566,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,5659,0.8294,0.8185,0.8403,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24711,0.784,0.7788,0.7893,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,3091,0.8051,0.7915,0.8186,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,670,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_Age_40-59_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,12082,0.9960271478,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_Age_17-24_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1982,0.9,0.8905,0.9096,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,5659,0.9964658067,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,3090,0.9971,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1375,0.8086,0.7864,0.8308,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1766,0.8013,0.7805,0.8221,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1018,0.7367387033,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_Age_60+_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9790,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_Age_17-24_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,1982,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,15380,0.7841352406,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_Sex_Female_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,12796,0.8034,0.7972,0.8096,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,15380,0.9966840052,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1766,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,180,0.8,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_Age_25-39_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8123,0.839,0.8308,0.8473,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,5659,0.810567238,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_Overall_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Test used,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay PopTest Adj,31978,0.7994,0.795,0.8039,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,258,0.7945736434,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_Age_60+_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9790,0.7091930541,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2142,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,258,0.8334,0.8036,0.8631,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1375,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2142,0.8282,0.809,0.8475,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1838,0.8079434168,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,468,0.8141025641,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1838,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5672,0.7685119887,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,180,1.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1838,0.8253,0.8069,0.8436,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,258,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1184,0.7905405405,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,5397,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3564,0.9988776655,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_Age_25-39_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8123,0.8264188108,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_Age_60+_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9790,0.711,0.7015,0.7204,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24711,0.9966007041,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5671,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheN_Age_40-59_PopTestAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,12083,0.8074,0.8,0.8148,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_Age_25-39_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8123,0.9981533916,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
230828_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_UnAdj,230828_Canada_CBS,"COVID-19 Seroprevalence Report August 28, 2023 Report #36: July 2023 Survey",2023-08-28,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-07-01,2023-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1184,0.9991554054,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2023-09-25,2024-04-25,Verified,canadian_blood_services_covid-19_2023-12,CAN
240923_Canada_CBS_BloodDonors_RocheS_Overall_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,31651,1.0,1.0,1.0,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_Age_40-59_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11763,0.7896795035,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,5362,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,5964,0.8066733736,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1374,0.8002,0.7777,0.8227,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1946,0.8004,0.7806,0.8202,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2910,0.9972508591,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3476,0.999136939,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,442,0.8213,0.7855,0.8571,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,5362,0.8002610966,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_Sex_Male_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18981,0.79,0.7835,0.7965,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1303,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_Ethnicity_Asian_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3476,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1647,0.9975713418,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1641,0.8039,0.7832,0.8247,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24515,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2375,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5366,0.9960864704,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ottawa_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1647,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2910,0.8047,0.7914,0.8181,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,633,0.9968404423,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,356,0.8323,0.8025,0.8621,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2130,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,144,1.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Vancouver_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2910,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_Age_25-39_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8160,0.9992647059,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_GeographicalArea_BritishColumbia_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5366,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1045,0.7963,0.7696,0.8229,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Winnipeg_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1045,0.7799043062,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_Sex_Male_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18865,0.995600318,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_Age_17-24_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2101,0.8787,0.8683,0.8891,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14977,0.7677772585,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewfoundlandandLabrador_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,356,0.808988764,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1045,0.9990430622,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,442,0.9954751131,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_Age_25-39_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8160,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Edmonton_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1946,0.7903391572,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_Age_17-24_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2101,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1304,0.7505,0.7248,0.7761,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_Age_60+_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9652,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_Overall_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Analysis,,31651,0.9963,0.9956,0.997,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Saskatchewan_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1374,0.7823871907,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1374,0.9963609898,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_Ethnicity_Indigenous_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,442,0.8122171946,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14938,0.9961172848,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Alberta_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,5964,0.8222,0.8111,0.8333,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Winnipeg_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Manitoba,Winnipeg,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Winnipeg,1045,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,153,0.7516339869,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5367,0.7814,0.7705,0.7923,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_Age_60+_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9745,0.6946126219,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_GeographicalArea_PrinceEdwardIsland_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,144,1.0,0.9841,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_Age_60+_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9652,0.9935764608,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3481,0.8474576271,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_Age_40-59_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11738,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_Sex_Female_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,12795,0.7834310277,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_Sex_Female_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,12795,0.7906,0.7843,0.7969,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_Age_40-59_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11763,0.7953,0.7877,0.8029,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2158,0.8317,0.8125,0.8509,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_Age_17-24_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2101,0.8752974774,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_Sex_Female_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,12786,0.9974190521,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1911,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,5896,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1648,0.7368,0.7104,0.7632,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_Ethnicity_Indigenous_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Indigenous,442,1.0,0.9976,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_GeographicalArea_PrinceEdwardIsland_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Prince Edward Island,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Prince Edward Island,153,0.7613,0.6964,0.8261,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,640,0.7765625,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Alberta_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Alberta,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Alberta,5896,0.9957598372,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1641,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewBrunswick_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,633,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24629,0.7604856064,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_Ethnicity_Other_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2375,0.9928421053,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Toronto_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,5362,0.9979485267,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Ontario_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14938,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_Age_25-39_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8167,0.8299253092,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ottawa_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Ottawa,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ottawa,1648,0.7245145631,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2381,0.8357,0.821,0.8504,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Ontario_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Ontario,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Ontario,14977,0.7831,0.7767,0.7896,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_Overall_PopAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Analysis,,31651,0.9968,0.9961,0.9974,,,True,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Manitoba_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1641,0.7879341865,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Toronto_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Ontario,Toronto,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Toronto,5362,0.8065,0.7972,0.8159,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_Overall_PopAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Analysis,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay Pop Adj,31776,0.7868,0.7822,0.7913,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Edmonton_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Edmonton,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Edmonton,1911,0.9994767138,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_Ethnicity_White_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24629,0.7728,0.7675,0.7782,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_Age_17-24_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Adults (18-64 years),17.0,24.0,Age,17-24 Years,2101,1.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_Ethnicity_Asian_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Asian,3481,0.8541,0.8429,0.8654,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NovaScotia_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1303,0.9992325403,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,356,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NewBrunswick_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,New Brunswick,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,New Brunswick,640,0.796,0.7694,0.8226,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_Sex_Female_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,Female,12786,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_Sex_Male_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18981,0.7718771403,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_Overall_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Test used,Roche Elecsys ® Anti-SARS-CoV-2 N immunoassay PopTest Adj,31776,0.7903,0.7858,0.7949,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_Sex_Male_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,Male,18865,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_Age_40-59_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 Years,11738,0.9959107173,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_GeographicalArea_NewfoundlandandLabrador_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Newfoundland and Labrador,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Newfoundland and Labrador,356,1.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_Age_25-39_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39 Years,8167,0.843,0.8347,0.8512,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Manitoba_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Manitoba,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Manitoba,1641,0.9975624619,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_GeographicalArea_BritishColumbia_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,British Columbia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,British Columbia,5367,0.7685858021,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Saskatchewan_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Saskatchewan,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Saskatchewan,1374,1.0,1.0,1.0,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_Age_60+_PopTestAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Seniors (65+ years),60.0,,Age,60+ Years,9745,0.6997,0.6901,0.7093,,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_Ethnicity_White_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,White,24515,0.9963287783,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_Ethnicity_Other_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,National,Repeated cross-sectional study,Canada,,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Ethnicity,Other,2381,0.8185636287,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Vancouver_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,British Columbia,Vancouver,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Vancouver,2910,0.8020618557,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheS_GeographicalArea_Calgary_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2130,0.996713615,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.988,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_GeographicalArea_NovaScotia_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Regional,Repeated cross-sectional study,Canada,Nova Scotia,,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Nova Scotia,1304,0.745398773,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
240923_Canada_CBS_BloodDonors_RocheN_GeographicalArea_Calgary_UnAdj,240923_Canada_CBS,"COVID-19 Seroprevalence Report September 29, 2023 Report #37: August 2023 Survey",2023-09-29,Institutional Report,Local,Repeated cross-sectional study,Canada,Alberta,Calgary,"""Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients.""","""Donors are deferred if they have been in contact with someone who was infected or if they have had the infection for 2 weeks after symptoms disappear (3 weeks if hospitalized)""",2023-08-01,2023-08-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Calgary,2158,0.813253012,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Canadian Blood Services,Canadian Blood Services ,Unity-Aligned,,2024-03-09,2024-04-26,Verified,canadian_blood_services_covid-19_2023-13,CAN
231020_LowerMainland_BritishColumbiaCovid19Cohort_AntiN,231020_LowerMainland_BritishColumbiaCovid19Cohort_Survey10,"Risk of hospital admission and death from first-ever SARS-CoV-2 infection by age group during the Delta and Omicron periods in British Columbia, Canada",2023-10-20,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Canada,British Columbia,,"Between March 2020 and August 2022, the British Columbia Centre for Disease Control (BCCDC) conducted 8 cross-sectional, population-based SARS-CoV-2 serosurveys using a longstanding protocol that was first developed for emerging and pandemic influenza risk assessment.9–15 Sampling included people of both sexes and all age groups (< 5 yr to > 80 yr) residing in the Lower Mainland, BC. ",,2022-07-16,2022-07-25,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,2000,0.79,0.771,0.808,True,,True,,True,Unclear,"SARS-CoV-2 IgG II Quant ,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,Unclear,Yes,No,,Unclear,Yes,No,,Danuta M. Skowronski,British Columbia Centre for Disease Control (BCCDC),Not Unity-Aligned,https://dx.doi.org/10.1503/cmaj.230721,2024-03-09,2024-03-09,Unverified,skowronski_risk_2023,CAN
211121_Bengui_UniversityofBangui,211121_Bengui_UniversityofBangui,"Very high relative seroprevalence of anti-SARS-CoV-2 antibodies among communities in Bangui, Central African Republic",2021-11-21,Preprint,Local,Cross-sectional survey ,Central African Republic,,Bangui,"Residency in the city of Bangui, Central African Republic",,2021-07-12,2021-08-20,Household and community samples,All,Multiple groups,1.0,75.0,Primary Estimate,,799,0.741,,,True,,,,True,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,,0.9940000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Alexandre Manirakiza,University of Bangui,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.18.21266496v1.full-text,2021-11-30,2024-03-01,Unverified,manirakiza_very_2021,CAF
211121_Bengui_UniversityofBangui_Age_>=60,211121_Bengui_UniversityofBangui,"Very high relative seroprevalence of anti-SARS-CoV-2 antibodies among communities in Bangui, Central African Republic",2021-11-21,Preprint,Local,Cross-sectional survey ,Central African Republic,,Bangui,"Residency in the city of Bangui, Central African Republic",,2021-07-12,2021-08-20,Household and community samples,All,Multiple groups,60.0,75.0,Age,>=60,18,0.833,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,,0.9940000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Alexandre Manirakiza,University of Bangui,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.18.21266496v1.full-text,2021-11-30,2024-03-01,Unverified,manirakiza_very_2021,CAF
211121_Bengui_UniversityofBangui_Sex_Male,211121_Bengui_UniversityofBangui,"Very high relative seroprevalence of anti-SARS-CoV-2 antibodies among communities in Bangui, Central African Republic",2021-11-21,Preprint,Local,Cross-sectional survey ,Central African Republic,,Bangui,"Residency in the city of Bangui, Central African Republic",,2021-07-12,2021-08-20,Household and community samples,Male,Multiple groups,1.0,75.0,Sex/Gender,,366,0.76,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,,0.9940000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Alexandre Manirakiza,University of Bangui,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.18.21266496v1.full-text,2021-11-30,2024-03-01,Unverified,manirakiza_very_2021,CAF
211121_Bengui_UniversityofBangui_Sex_Female,211121_Bengui_UniversityofBangui,"Very high relative seroprevalence of anti-SARS-CoV-2 antibodies among communities in Bangui, Central African Republic",2021-11-21,Preprint,Local,Cross-sectional survey ,Central African Republic,,Bangui,"Residency in the city of Bangui, Central African Republic",,2021-07-12,2021-08-20,Household and community samples,Female,Multiple groups,1.0,75.0,Sex/Gender,,433,0.751,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,,0.9940000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Alexandre Manirakiza,University of Bangui,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.18.21266496v1.full-text,2021-11-30,2024-03-01,Unverified,manirakiza_very_2021,CAF
211121_Bengui_UniversityofBangui_Age_<=20,211121_Bengui_UniversityofBangui,"Very high relative seroprevalence of anti-SARS-CoV-2 antibodies among communities in Bangui, Central African Republic",2021-11-21,Preprint,Local,Cross-sectional survey ,Central African Republic,,Bangui,"Residency in the city of Bangui, Central African Republic",,2021-07-12,2021-08-20,Household and community samples,All,Multiple groups,1.0,20.0,Age,<=20,307,0.6609999999999999,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,,0.9940000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Alexandre Manirakiza,University of Bangui,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.18.21266496v1.full-text,2021-11-30,2024-03-01,Unverified,manirakiza_very_2021,CAF
211121_Bengui_UniversityofBangui_Age_21-40,211121_Bengui_UniversityofBangui,"Very high relative seroprevalence of anti-SARS-CoV-2 antibodies among communities in Bangui, Central African Republic",2021-11-21,Preprint,Local,Cross-sectional survey ,Central African Republic,,Bangui,"Residency in the city of Bangui, Central African Republic",,2021-07-12,2021-08-20,Household and community samples,All,Adults (18-64 years),21.0,40.0,Age,21-40,358,0.818,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,,0.9940000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Alexandre Manirakiza,University of Bangui,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.18.21266496v1.full-text,2021-11-30,2024-03-01,Unverified,manirakiza_very_2021,CAF
211121_Bengui_UniversityofBangui_Age_41-60,211121_Bengui_UniversityofBangui,"Very high relative seroprevalence of anti-SARS-CoV-2 antibodies among communities in Bangui, Central African Republic",2021-11-21,Preprint,Local,Cross-sectional survey ,Central African Republic,,Bangui,"Residency in the city of Bangui, Central African Republic",,2021-07-12,2021-08-20,Household and community samples,All,Adults (18-64 years),41.0,60.0,Age,41-60,116,0.793,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,,0.9940000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Alexandre Manirakiza,University of Bangui,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.18.21266496v1.full-text,2021-11-30,2024-03-01,Unverified,manirakiza_very_2021,CAF
221226_Bangui_InstitutPasteurofBangui_survey1_overall,221226_Bangui_InstitutPasteurofBangui_survey1,"Seroprevalence of anti-SARS-CoV-2 antibodies before and after implementation of anti-COVID-19 vaccination among hospital staff in Bangui, Central African Republic",2022-12-26,Preprint,Regional,Repeated cross-sectional study,Central African Republic,"Bangui
",,"""Our study population consisted of healthcare workers (HCWs) in hospital departments. Included were all staff administering health care to patients and support staff in the healthcare departments in the hospitals. All staff were eligible for this survey, and an informed consent form signed by each staff member was required before including them in the survey. """,,2021-04-01,2021-04-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,179,0.36310000000000003,,,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,,"['IgG', 'IgM']",,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Alexandre Manirakiza,Institut Pasteur of Bangui,Not Unity-Aligned,10.1101/2022.12.22.22283871,2023-01-10,2023-03-19,Unverified,manirakizaSeroprevalenceAntiSARSCoV2Antibodies2022,CAF
221226_Bangui_InstitutPasteurofBangui_survey1_31to40,221226_Bangui_InstitutPasteurofBangui_survey1,"Seroprevalence of anti-SARS-CoV-2 antibodies before and after implementation of anti-COVID-19 vaccination among hospital staff in Bangui, Central African Republic",2022-12-26,Preprint,Regional,Repeated cross-sectional study,Central African Republic,"Bangui
",,"""Our study population consisted of healthcare workers (HCWs) in hospital departments. Included were all staff administering health care to patients and support staff in the healthcare departments in the hospitals. All staff were eligible for this survey, and an informed consent form signed by each staff member was required before including them in the survey. """,,2021-04-01,2021-04-30,Health care workers and caregivers,All,Adults (18-64 years),,,Age,31-40,53,0.585,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,,"['IgG', 'IgM']",,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Alexandre Manirakiza,Institut Pasteur of Bangui,Not Unity-Aligned,10.1101/2022.12.22.22283871,2023-01-10,2023-03-22,Unverified,manirakizaSeroprevalenceAntiSARSCoV2Antibodies2022,CAF
221226_Bangui_InstitutPasteurofBangui_survey1_lessthan30,221226_Bangui_InstitutPasteurofBangui_survey1,"Seroprevalence of anti-SARS-CoV-2 antibodies before and after implementation of anti-COVID-19 vaccination among hospital staff in Bangui, Central African Republic",2022-12-26,Preprint,Regional,Repeated cross-sectional study,Central African Republic,"Bangui
",,"""Our study population consisted of healthcare workers (HCWs) in hospital departments. Included were all staff administering health care to patients and support staff in the healthcare departments in the hospitals. All staff were eligible for this survey, and an informed consent form signed by each staff member was required before including them in the survey. """,,2021-04-01,2021-04-30,Health care workers and caregivers,All,Adults (18-64 years),,,Age,<30,20,0.7000000000000001,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,,"['IgG', 'IgM']",,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Alexandre Manirakiza,Institut Pasteur of Bangui,Not Unity-Aligned,10.1101/2022.12.22.22283871,2023-01-10,2023-03-19,Unverified,manirakizaSeroprevalenceAntiSARSCoV2Antibodies2022,CAF
221226_Bangui_InstitutPasteurofBangui_survey1_41to50,221226_Bangui_InstitutPasteurofBangui_survey1,"Seroprevalence of anti-SARS-CoV-2 antibodies before and after implementation of anti-COVID-19 vaccination among hospital staff in Bangui, Central African Republic",2022-12-26,Preprint,Regional,Repeated cross-sectional study,Central African Republic,"Bangui
",,"""Our study population consisted of healthcare workers (HCWs) in hospital departments. Included were all staff administering health care to patients and support staff in the healthcare departments in the hospitals. All staff were eligible for this survey, and an informed consent form signed by each staff member was required before including them in the survey. """,,2021-04-01,2021-04-30,Health care workers and caregivers,All,Adults (18-64 years),,,Age,41-50,57,0.667,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,,"['IgG', 'IgM']",,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Alexandre Manirakiza,Institut Pasteur of Bangui,Not Unity-Aligned,10.1101/2022.12.22.22283871,2023-01-10,2023-03-19,Unverified,manirakizaSeroprevalenceAntiSARSCoV2Antibodies2022,CAF
221226_Bangui_InstitutPasteurofBangui_survey1_50plus ,221226_Bangui_InstitutPasteurofBangui_survey1,"Seroprevalence of anti-SARS-CoV-2 antibodies before and after implementation of anti-COVID-19 vaccination among hospital staff in Bangui, Central African Republic",2022-12-26,Preprint,Regional,Repeated cross-sectional study,Central African Republic,"Bangui
",,"""Our study population consisted of healthcare workers (HCWs) in hospital departments. Included were all staff administering health care to patients and support staff in the healthcare departments in the hospitals. All staff were eligible for this survey, and an informed consent form signed by each staff member was required before including them in the survey. """,,2021-04-01,2021-04-30,Health care workers and caregivers,All,Adults (18-64 years),,,Age,50+,49,0.633,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,,"['IgG', 'IgM']",,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Alexandre Manirakiza,Institut Pasteur of Bangui,Not Unity-Aligned,10.1101/2022.12.22.22283871,2023-01-10,2023-03-19,Unverified,manirakizaSeroprevalenceAntiSARSCoV2Antibodies2022,CAF
221226_Bangui_InstitutPasteurofBangui_survey2_overall,221226_Bangui_InstitutPasteurofBangui_survey2,"Seroprevalence of anti-SARS-CoV-2 antibodies before and after implementation of anti-COVID-19 vaccination among hospital staff in Bangui, Central African Republic",2022-12-26,Preprint,Regional,Repeated cross-sectional study,Central African Republic,"Bangui
",,"""Our study population consisted of healthcare workers (HCWs) in hospital departments. Included were all staff administering health care to patients and support staff in the healthcare departments in the hospitals. All staff were eligible for this survey, and an informed consent form signed by each staff member was required before including them in the survey. """,,2022-05-01,2022-05-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,141,0.9573999999999999,,,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,,"['IgG', 'IgM']",,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Alexandre Manirakiza,Institut Pasteur of Bangui,Not Unity-Aligned,10.1101/2022.12.22.22283871,2023-01-10,2023-03-19,Unverified,manirakizaSeroprevalenceAntiSARSCoV2Antibodies2022,CAF
221226_Bangui_InstitutPasteurofBangui_survey2_lessthan30,221226_Bangui_InstitutPasteurofBangui_survey2,"Seroprevalence of anti-SARS-CoV-2 antibodies before and after implementation of anti-COVID-19 vaccination among hospital staff in Bangui, Central African Republic",2022-12-26,Preprint,Regional,Repeated cross-sectional study,Central African Republic,"Bangui
",,"""Our study population consisted of healthcare workers (HCWs) in hospital departments. Included were all staff administering health care to patients and support staff in the healthcare departments in the hospitals. All staff were eligible for this survey, and an informed consent form signed by each staff member was required before including them in the survey. """,,2022-05-01,2022-05-31,Health care workers and caregivers,All,Adults (18-64 years),,,Age,<30,23,0.9109999999999999,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,,"['IgG', 'IgM']",,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Alexandre Manirakiza,Institut Pasteur of Bangui,Not Unity-Aligned,10.1101/2022.12.22.22283871,2023-01-10,2023-03-19,Unverified,manirakizaSeroprevalenceAntiSARSCoV2Antibodies2022,CAF
221226_Bangui_InstitutPasteurofBangui_survey2_50plus ,221226_Bangui_InstitutPasteurofBangui_survey2,"Seroprevalence of anti-SARS-CoV-2 antibodies before and after implementation of anti-COVID-19 vaccination among hospital staff in Bangui, Central African Republic",2022-12-26,Preprint,Regional,Repeated cross-sectional study,Central African Republic,"Bangui
",,"""Our study population consisted of healthcare workers (HCWs) in hospital departments. Included were all staff administering health care to patients and support staff in the healthcare departments in the hospitals. All staff were eligible for this survey, and an informed consent form signed by each staff member was required before including them in the survey. """,,2022-05-01,2022-05-31,Health care workers and caregivers,All,Adults (18-64 years),,,Age,50+,28,1.0,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,,"['IgG', 'IgM']",,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Alexandre Manirakiza,Institut Pasteur of Bangui,Not Unity-Aligned,10.1101/2022.12.22.22283871,2023-01-10,2023-03-19,Unverified,manirakizaSeroprevalenceAntiSARSCoV2Antibodies2022,CAF
221226_Bangui_InstitutPasteurofBangui_survey2_31to40,221226_Bangui_InstitutPasteurofBangui_survey2,"Seroprevalence of anti-SARS-CoV-2 antibodies before and after implementation of anti-COVID-19 vaccination among hospital staff in Bangui, Central African Republic",2022-12-26,Preprint,Regional,Repeated cross-sectional study,Central African Republic,"Bangui
",,"""Our study population consisted of healthcare workers (HCWs) in hospital departments. Included were all staff administering health care to patients and support staff in the healthcare departments in the hospitals. All staff were eligible for this survey, and an informed consent form signed by each staff member was required before including them in the survey. """,,2022-05-01,2022-05-31,Health care workers and caregivers,All,Adults (18-64 years),,,Age,31-40,38,0.9470000000000001,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,,"['IgG', 'IgM']",,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Alexandre Manirakiza,Institut Pasteur of Bangui,Not Unity-Aligned,10.1101/2022.12.22.22283871,2023-01-10,2023-03-19,Unverified,manirakizaSeroprevalenceAntiSARSCoV2Antibodies2022,CAF
221226_Bangui_InstitutPasteurofBangui_survey2_41to50,221226_Bangui_InstitutPasteurofBangui_survey2,"Seroprevalence of anti-SARS-CoV-2 antibodies before and after implementation of anti-COVID-19 vaccination among hospital staff in Bangui, Central African Republic",2022-12-26,Preprint,Regional,Repeated cross-sectional study,Central African Republic,"Bangui
",,"""Our study population consisted of healthcare workers (HCWs) in hospital departments. Included were all staff administering health care to patients and support staff in the healthcare departments in the hospitals. All staff were eligible for this survey, and an informed consent form signed by each staff member was required before including them in the survey. """,,2022-05-01,2022-05-31,Health care workers and caregivers,All,Adults (18-64 years),,,Age,41-50,52,0.9620000000000001,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,,"['IgG', 'IgM']",,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Alexandre Manirakiza,Institut Pasteur of Bangui,Not Unity-Aligned,10.1101/2022.12.22.22283871,2023-01-10,2023-03-19,Unverified,manirakizaSeroprevalenceAntiSARSCoV2Antibodies2022,CAF
230111_Chad_GoodSamaritanUniversityHospitalCentre_AntiN,230111_Chad_GoodSamaritanUniversityHospitalCentre,High seroprevalence of anti-SARS-CoV-2 antibodies in the capital of Chad,2023-01-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Chad,Ndjamena,Ndjamena,"2,700 samples from voluntary donors who came for routine consultations in 11 healthcare facilities in the city of Ndjamena and referred to the laboratory for blood sampling were included in the study",Homolysed blood was excluded.,2021-08-12,2021-10-26,Blood donors,All,Multiple groups,,,Primary Estimate,overall anti-N,2700,0.6950000000000001,0.677,0.713,True,,,,True,Self-referral,Indirect ELISA,"Diatheva SRL, Cartaceto, Italy",ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by developers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Andrillene Laure Deutou Wondeu,Good Samaritan University Hospital Centre,Not Unity-Aligned,https://dx.doi.org/10.4081/jphia.2022.2255,2023-02-06,2024-03-01,Unverified,wondeu_high_2023,TCD
200710_Santiago_UniversidadDeChile_AllStudents,200710_Santiago_UniversidadDeChile_1_Students,SARS-CoV-2 antibody prevalence in blood in a large school community subject to a Covid-19 outbreak: a cross-sectional study.,2020-07-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Chile,Santiago,Vitacura,"Staff or students at the identified large school community in Santiago, Chile ",,2020-05-04,2020-05-19,Students and Daycares,All,Children and Youth (0-17 years),4.0,18.0,Primary Estimate,,1009,0.099,0.086,0.115,True,,,,True,Stratified probability,Novel Coronavirus IgG/IgM test kit,Genrui Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9101,0.9537000000000001,['Moderate'],No,Yes,Yes,Yes,Yes,No,Yes,No,Yes,Juan Pablo Torres,Universidade de Chile,Not Unity-Aligned,https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa955/5869860,2020-07-26,2024-03-01,Verified,torres_severe_2020,CHL
200710_Santiago_UniversidadDeChile_HighSchoolStudents,200710_Santiago_UniversidadDeChile_1_Students,SARS-CoV-2 antibody prevalence in blood in a large school community subject to a Covid-19 outbreak: a cross-sectional study.,2020-07-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Chile,Santiago,Vitacura,"Staff or students at the identified large school community in Santiago, Chile ",,2020-05-04,2020-05-19,Students and Daycares,All,Children and Youth (0-17 years),15.0,18.0,Age,Students from preschool to highschool,281,0.057,0.036000000000000004,0.08900000000000001,,,,,,Stratified probability,Novel Coronavirus IgG/IgM test kit,Genrui Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9101,0.9537000000000001,['Moderate'],No,Yes,Yes,Yes,Yes,No,Yes,No,Yes,Juan Pablo Torres,Universidade de Chile,Not Unity-Aligned,https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa955/5869860,2020-07-16,2024-03-01,Verified,torres_severe_2020,CHL
200710_Santiago_UniversidadDeChile_ElementaryStudents,200710_Santiago_UniversidadDeChile_1_Students,SARS-CoV-2 antibody prevalence in blood in a large school community subject to a Covid-19 outbreak: a cross-sectional study.,2020-07-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Chile,Santiago,Vitacura,"Staff or students at the identified large school community in Santiago, Chile ",,2020-05-04,2020-05-19,Students and Daycares,All,Children and Youth (0-17 years),7.0,12.0,Age,Elementary school student,286,0.10800000000000001,0.078,0.147,,,,,,Stratified probability,Novel Coronavirus IgG/IgM test kit,Genrui Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9101,0.9537000000000001,['Moderate'],No,Yes,Yes,Yes,Yes,No,Yes,No,Yes,Juan Pablo Torres,Universidade de Chile,Not Unity-Aligned,https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa955/5869860,2020-07-16,2024-03-01,Verified,torres_severe_2020,CHL
200710_Santiago_UniversidadDeChile_MiddleSchoolStudents,200710_Santiago_UniversidadDeChile_1_Students,SARS-CoV-2 antibody prevalence in blood in a large school community subject to a Covid-19 outbreak: a cross-sectional study.,2020-07-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Chile,Santiago,Vitacura,"Staff or students at the identified large school community in Santiago, Chile ",,2020-05-04,2020-05-19,Students and Daycares,All,Children and Youth (0-17 years),12.0,14.0,Age,Middle school student,295,0.11900000000000001,0.08800000000000001,0.159,,,,,,Stratified probability,Novel Coronavirus IgG/IgM test kit,Genrui Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9101,0.9537000000000001,['Moderate'],No,Yes,Yes,Yes,Yes,No,Yes,No,Yes,Juan Pablo Torres,Universidade de Chile,Not Unity-Aligned,https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa955/5869860,2020-07-16,2024-03-01,Verified,torres_severe_2020,CHL
200710_Santiago_UniversidadDeChile_PreschoolStudents,200710_Santiago_UniversidadDeChile_1_Students,SARS-CoV-2 antibody prevalence in blood in a large school community subject to a Covid-19 outbreak: a cross-sectional study.,2020-07-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Chile,Santiago,Vitacura,"Staff or students at the identified large school community in Santiago, Chile ",,2020-05-04,2020-05-19,Students and Daycares,All,Children and Youth (0-17 years),4.0,6.0,Age,Preschool student,147,0.12300000000000001,0.078,0.18600000000000003,,,,,,Stratified probability,Novel Coronavirus IgG/IgM test kit,Genrui Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9101,0.9537000000000001,['Moderate'],No,Yes,Yes,Yes,Yes,No,Yes,No,Yes,Juan Pablo Torres,Universidade de Chile,Not Unity-Aligned,https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa955/5869860,2020-07-16,2024-03-01,Verified,torres_severe_2020,CHL
200710_Santiago_UniversidadDeChile_AllStaff,200710_Santiago_UniversidadDeChile_2_Staff,SARS-CoV-2 antibody prevalence in blood in a large school community subject to a Covid-19 outbreak: a cross-sectional study.,2020-07-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Chile,Santiago,Vitacura,"Staff or students at the identified large school community in Santiago, Chile ",,2020-05-04,2020-05-19,Essential non-healthcare workers,All,Adults (18-64 years),26.0,57.0,Primary Estimate,,235,0.166,0.121,0.219,True,,,,True,Stratified probability,Novel Coronavirus IgG/IgM test kit,Genrui Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9101,0.9537000000000001,['High'],No,Yes,No,Yes,Yes,No,Yes,No,Yes,Juan Pablo Torres,Universidade de Chile,Not Unity-Aligned,https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa955/5869860,2020-07-26,2024-03-01,Verified,torres_severe_2020,CHL
210215_Chile_UniversityOfChile_HCW,210215_Chile_UniversityOfChile,"SARS-CoV-2 Antibody Prevalence Among 85,529 Healthcare Workers Following the First Wave of COVID-19 in Chile",2021-02-15,Preprint,National,Cross-sectional survey ,Chile,,,"Workers, including clinical, administrative and support staff, were identified using national registries as of June 30, 2020 (sources: Division of Human Resources Ministry of Health for Hospital Workers, Secondary Health Care; Division of
Primary Care for Workers within the Municipal Primary Health Care System)","The only exclusion criteria was the presence of symptoms compatible with COVID-19 at the time of consultation, in which case the subject was referred for RT-PCR testing for SARS-Cov-2.",2020-09-11,2020-10-24,Health care workers and caregivers,All,Multiple groups,18.0,,Primary Estimate,,85528,0.07200000000000001,,,True,,,,True,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.958,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Marcela Zuniga,Universidad de Chile,Not Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3785998,2021-05-22,2024-03-01,Verified,zuniga_sars-cov-2_2021,CHL
210526_Chile_UniversidadDelDesarrollo_Baseline1_Overall,210526_Chile_UniversidadDelDesarrollo_Baseline1,Longitudinal assessment of SARS-CoV-2 IgG seroconversionamong front-line healthcare workers during the first wave of the Covid-19 pandemic at a tertiary-care hospital in Chile.,2021-05-26,Journal Article (Peer-Reviewed),Local,Prospective cohort,Chile,Santiago,Santiago,"All front-line HCWs serving in clinical areas exclusively dedicated to Covid-19 patients (medical wards, intensive care units [ICUs],
step down units, and respiratory ER) were invited to participate
as “high-risk” group. In addition, HCWs from
selected areas without direct contact with Covid-19 patients
(i.e.,cardiothoracic ICU) were offered to participate
as part of a “low-risk” group.",HCWs with active symptoms or on quarantine as per national regulations were only enrolled once the mandatory isolation period was completed.,2020-04-27,2020-04-27,Health care workers and caregivers,All,Multiple groups,20.0,,Primary Estimate,,446,0.096,,,True,,,,True,Convenience,"COVID-19 ELISA IgG,Anti-SARS-CoV-2 ELISA IgG","Vircell S.L.,EUROIMMUN",ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,Yes,No,No,Yes,No,Unclear,Mirentxu Iruretagoyena,Universidad del Desarrollo,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06208-2,2021-06-06,2024-03-01,Verified,iruretagoyena_longitudinal_2021,CHL
210526_Chile_UniversidadDelDesarrollo_Overall2_Overall,210526_Chile_UniversidadDelDesarrollo_Overall2,Longitudinal assessment of SARS-CoV-2 IgG seroconversionamong front-line healthcare workers during the first wave of the Covid-19 pandemic at a tertiary-care hospital in Chile.,2021-05-26,Journal Article (Peer-Reviewed),Local,Prospective cohort,Chile,Santiago,Santiago,"All front-line HCWs serving in clinical areas exclusively dedicated to Covid-19 patients (medical wards, intensive care units [ICUs],
step down units, and respiratory ER) were invited to participate
as “high-risk” group. In addition, HCWs from
selected areas without direct contact with Covid-19 patients
(i.e.,cardiothoracic ICU) were offered to participate
as part of a “low-risk” group.",HCWs with active symptoms or on quarantine as per national regulations were only enrolled once the mandatory isolation period was completed.,2020-04-27,2020-07-31,Health care workers and caregivers,All,Multiple groups,20.0,,Primary Estimate,,446,0.24,0.20199999999999999,0.28300000000000003,True,,,,True,Convenience,"COVID-19 ELISA IgG,Anti-SARS-CoV-2 ELISA IgG","Vircell S.L.,EUROIMMUN",ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,Yes,No,No,Yes,No,Unclear,Mirentxu Iruretagoyena,Universidad del Desarrollo,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06208-2,2021-06-06,2024-03-01,Verified,iruretagoyena_longitudinal_2021,CHL
210526_Chile_UniversidadDelDesarrollo_Overall2_Age_65+,210526_Chile_UniversidadDelDesarrollo_Overall2,Longitudinal assessment of SARS-CoV-2 IgG seroconversionamong front-line healthcare workers during the first wave of the Covid-19 pandemic at a tertiary-care hospital in Chile.,2021-05-26,Journal Article (Peer-Reviewed),Local,Prospective cohort,Chile,Santiago,Santiago,"All front-line HCWs serving in clinical areas exclusively dedicated to Covid-19 patients (medical wards, intensive care units [ICUs],
step down units, and respiratory ER) were invited to participate
as “high-risk” group. In addition, HCWs from
selected areas without direct contact with Covid-19 patients
(i.e.,cardiothoracic ICU) were offered to participate
as part of a “low-risk” group.",HCWs with active symptoms or on quarantine as per national regulations were only enrolled once the mandatory isolation period was completed.,2020-04-27,2020-07-31,Health care workers and caregivers,All,Multiple groups,65.0,,Age,65+,4,0.0,0.0,0.49,,,,,,Convenience,"COVID-19 ELISA IgG,Anti-SARS-CoV-2 ELISA IgG","Vircell S.L.,EUROIMMUN",ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,Yes,No,No,Yes,No,Unclear,Mirentxu Iruretagoyena,Universidad del Desarrollo,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06208-2,2021-07-31,2024-03-01,Verified,iruretagoyena_longitudinal_2021,CHL
210526_Chile_UniversidadDelDesarrollo_Overall2_Age_50-65,210526_Chile_UniversidadDelDesarrollo_Overall2,Longitudinal assessment of SARS-CoV-2 IgG seroconversionamong front-line healthcare workers during the first wave of the Covid-19 pandemic at a tertiary-care hospital in Chile.,2021-05-26,Journal Article (Peer-Reviewed),Local,Prospective cohort,Chile,Santiago,Santiago,"All front-line HCWs serving in clinical areas exclusively dedicated to Covid-19 patients (medical wards, intensive care units [ICUs],
step down units, and respiratory ER) were invited to participate
as “high-risk” group. In addition, HCWs from
selected areas without direct contact with Covid-19 patients
(i.e.,cardiothoracic ICU) were offered to participate
as part of a “low-risk” group.",HCWs with active symptoms or on quarantine as per national regulations were only enrolled once the mandatory isolation period was completed.,2020-04-27,2020-07-31,Health care workers and caregivers,All,Adults (18-64 years),50.0,65.0,Age,50-65,67,0.209,0.132,0.318,,,,,,Convenience,"COVID-19 ELISA IgG,Anti-SARS-CoV-2 ELISA IgG","Vircell S.L.,EUROIMMUN",ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,Yes,No,No,Yes,No,Unclear,Mirentxu Iruretagoyena,Universidad del Desarrollo,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06208-2,2021-06-06,2024-03-01,Verified,iruretagoyena_longitudinal_2021,CHL
210526_Chile_UniversidadDelDesarrollo_Overall2_Age_35-49,210526_Chile_UniversidadDelDesarrollo_Overall2,Longitudinal assessment of SARS-CoV-2 IgG seroconversionamong front-line healthcare workers during the first wave of the Covid-19 pandemic at a tertiary-care hospital in Chile.,2021-05-26,Journal Article (Peer-Reviewed),Local,Prospective cohort,Chile,Santiago,Santiago,"All front-line HCWs serving in clinical areas exclusively dedicated to Covid-19 patients (medical wards, intensive care units [ICUs],
step down units, and respiratory ER) were invited to participate
as “high-risk” group. In addition, HCWs from
selected areas without direct contact with Covid-19 patients
(i.e.,cardiothoracic ICU) were offered to participate
as part of a “low-risk” group.",HCWs with active symptoms or on quarantine as per national regulations were only enrolled once the mandatory isolation period was completed.,2020-04-27,2020-07-31,Health care workers and caregivers,All,Adults (18-64 years),35.0,49.0,Age,35-49,201,0.22399999999999998,0.171,0.292,,,,,,Convenience,"COVID-19 ELISA IgG,Anti-SARS-CoV-2 ELISA IgG","Vircell S.L.,EUROIMMUN",ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,Yes,No,No,Yes,No,Unclear,Mirentxu Iruretagoyena,Universidad del Desarrollo,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06208-2,2021-06-06,2024-03-01,Verified,iruretagoyena_longitudinal_2021,CHL
210526_Chile_UniversidadDelDesarrollo_Overall2_Age_20-34,210526_Chile_UniversidadDelDesarrollo_Overall2,Longitudinal assessment of SARS-CoV-2 IgG seroconversionamong front-line healthcare workers during the first wave of the Covid-19 pandemic at a tertiary-care hospital in Chile.,2021-05-26,Journal Article (Peer-Reviewed),Local,Prospective cohort,Chile,Santiago,Santiago,"All front-line HCWs serving in clinical areas exclusively dedicated to Covid-19 patients (medical wards, intensive care units [ICUs],
step down units, and respiratory ER) were invited to participate
as “high-risk” group. In addition, HCWs from
selected areas without direct contact with Covid-19 patients
(i.e.,cardiothoracic ICU) were offered to participate
as part of a “low-risk” group.",HCWs with active symptoms or on quarantine as per national regulations were only enrolled once the mandatory isolation period was completed.,2020-04-27,2020-07-31,Health care workers and caregivers,All,Adults (18-64 years),20.0,34.0,Age,20-34,174,0.276,0.223,0.349,,,,,,Convenience,"COVID-19 ELISA IgG,Anti-SARS-CoV-2 ELISA IgG","Vircell S.L.,EUROIMMUN",ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,Yes,No,No,Yes,No,Unclear,Mirentxu Iruretagoyena,Universidad del Desarrollo,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06208-2,2021-06-06,2024-03-01,Verified,iruretagoyena_longitudinal_2021,CHL
210909_Chile_UniversidaddeChile,210909_Chile_UniversidaddeChile,Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.,2021-09-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Chile,,,Individuals voluntarily approaching the testing stations were invited to do a lateral flow test by finger prick.,"Individuals were excluded from the analysis if they were younger than 18 years, had no declared gender, had an invalid IgG test result, had previously tested positive for SARS-CoV-2 infection on PCR, could not recall their vaccination status, or had been immunised against COVID-19 with vaccines other than CoronaVac or BNT162b2. Here, we report data collected up to July 2, 2021.",2021-03-12,2021-07-02,Household and community samples,All,Multiple groups,,,Primary Estimate,,54261,0.5284089862,,,True,,,,True,Convenience,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Denis Saure,Universidad de Chile,Not Unity-Aligned,https://dx.doi.org/10.1016/S1473-3099(21)00479-5,2021-09-23,2024-03-01,Unverified,saure_dynamic_2021,CHL
210909_Chile_UniversidaddeChile_Week12,210909_Chile_UniversidaddeChile,Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.,2021-09-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Chile,,,Individuals voluntarily approaching the testing stations were invited to do a lateral flow test by finger prick.,"Individuals were excluded from the analysis if they were younger than 18 years, had no declared gender, had an invalid IgG test result, had previously tested positive for SARS-CoV-2 infection on PCR, could not recall their vaccination status, or had been immunised against COVID-19 with vaccines other than CoronaVac or BNT162b2. Here, we report data collected up to July 2, 2021.",2021-05-28,2021-06-04,Household and community samples,All,Multiple groups,,,Time frame,,4085,0.5638000000000001,,,,,,,,Convenience,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Denis Saure,Universidad de Chile,Not Unity-Aligned,https://dx.doi.org/10.1016/S1473-3099(21)00479-5,2022-02-12,2024-03-01,Unverified,saure_dynamic_2021,CHL
210909_Chile_UniversidaddeChile_Week10,210909_Chile_UniversidaddeChile,Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.,2021-09-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Chile,,,Individuals voluntarily approaching the testing stations were invited to do a lateral flow test by finger prick.,"Individuals were excluded from the analysis if they were younger than 18 years, had no declared gender, had an invalid IgG test result, had previously tested positive for SARS-CoV-2 infection on PCR, could not recall their vaccination status, or had been immunised against COVID-19 with vaccines other than CoronaVac or BNT162b2. Here, we report data collected up to July 2, 2021.",2021-05-14,2021-05-21,Household and community samples,All,Multiple groups,,,Time frame,,2644,0.5692,,,,,,,,Convenience,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Denis Saure,Universidad de Chile,Not Unity-Aligned,https://dx.doi.org/10.1016/S1473-3099(21)00479-5,2022-02-12,2024-03-01,Unverified,saure_dynamic_2021,CHL
210909_Chile_UniversidaddeChile_Week1,210909_Chile_UniversidaddeChile,Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.,2021-09-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Chile,,,Individuals voluntarily approaching the testing stations were invited to do a lateral flow test by finger prick.,"Individuals were excluded from the analysis if they were younger than 18 years, had no declared gender, had an invalid IgG test result, had previously tested positive for SARS-CoV-2 infection on PCR, could not recall their vaccination status, or had been immunised against COVID-19 with vaccines other than CoronaVac or BNT162b2. Here, we report data collected up to July 2, 2021.",2021-03-12,2021-03-19,Household and community samples,All,Multiple groups,,,Time frame,,876,0.1084,,,,,,,,Convenience,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Denis Saure,Universidad de Chile,Not Unity-Aligned,https://dx.doi.org/10.1016/S1473-3099(21)00479-5,2022-02-12,2024-03-01,Unverified,saure_dynamic_2021,CHL
210909_Chile_UniversidaddeChile_Week13,210909_Chile_UniversidaddeChile,Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.,2021-09-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Chile,,,Individuals voluntarily approaching the testing stations were invited to do a lateral flow test by finger prick.,"Individuals were excluded from the analysis if they were younger than 18 years, had no declared gender, had an invalid IgG test result, had previously tested positive for SARS-CoV-2 infection on PCR, could not recall their vaccination status, or had been immunised against COVID-19 with vaccines other than CoronaVac or BNT162b2. Here, we report data collected up to July 2, 2021.",2021-06-04,2021-06-11,Household and community samples,All,Multiple groups,,,Time frame,,4634,0.5647,,,,,,,,Convenience,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Denis Saure,Universidad de Chile,Not Unity-Aligned,https://dx.doi.org/10.1016/S1473-3099(21)00479-5,2022-02-12,2024-03-01,Unverified,saure_dynamic_2021,CHL
210909_Chile_UniversidaddeChile_Week5,210909_Chile_UniversidaddeChile,Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.,2021-09-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Chile,,,Individuals voluntarily approaching the testing stations were invited to do a lateral flow test by finger prick.,"Individuals were excluded from the analysis if they were younger than 18 years, had no declared gender, had an invalid IgG test result, had previously tested positive for SARS-CoV-2 infection on PCR, could not recall their vaccination status, or had been immunised against COVID-19 with vaccines other than CoronaVac or BNT162b2. Here, we report data collected up to July 2, 2021.",2021-04-09,2021-04-16,Household and community samples,All,Multiple groups,,,Time frame,,4582,0.4978,,,,,,,,Convenience,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Denis Saure,Universidad de Chile,Not Unity-Aligned,https://dx.doi.org/10.1016/S1473-3099(21)00479-5,2022-02-12,2024-03-01,Unverified,saure_dynamic_2021,CHL
210909_Chile_UniversidaddeChile_Week2,210909_Chile_UniversidaddeChile,Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.,2021-09-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Chile,,,Individuals voluntarily approaching the testing stations were invited to do a lateral flow test by finger prick.,"Individuals were excluded from the analysis if they were younger than 18 years, had no declared gender, had an invalid IgG test result, had previously tested positive for SARS-CoV-2 infection on PCR, could not recall their vaccination status, or had been immunised against COVID-19 with vaccines other than CoronaVac or BNT162b2. Here, we report data collected up to July 2, 2021.",2021-03-19,2021-03-26,Household and community samples,All,Multiple groups,,,Time frame,,2423,0.2443,,,,,,,,Convenience,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Denis Saure,Universidad de Chile,Not Unity-Aligned,https://dx.doi.org/10.1016/S1473-3099(21)00479-5,2022-02-12,2024-03-01,Unverified,saure_dynamic_2021,CHL
210909_Chile_UniversidaddeChile_Week6,210909_Chile_UniversidaddeChile,Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.,2021-09-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Chile,,,Individuals voluntarily approaching the testing stations were invited to do a lateral flow test by finger prick.,"Individuals were excluded from the analysis if they were younger than 18 years, had no declared gender, had an invalid IgG test result, had previously tested positive for SARS-CoV-2 infection on PCR, could not recall their vaccination status, or had been immunised against COVID-19 with vaccines other than CoronaVac or BNT162b2. Here, we report data collected up to July 2, 2021.",2021-04-16,2021-04-23,Household and community samples,All,Multiple groups,,,Time frame,,4764,0.4658,,,,,,,,Convenience,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Denis Saure,Universidad de Chile,Not Unity-Aligned,https://dx.doi.org/10.1016/S1473-3099(21)00479-5,2022-02-12,2024-03-01,Unverified,saure_dynamic_2021,CHL
210909_Chile_UniversidaddeChile_Week11,210909_Chile_UniversidaddeChile,Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.,2021-09-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Chile,,,Individuals voluntarily approaching the testing stations were invited to do a lateral flow test by finger prick.,"Individuals were excluded from the analysis if they were younger than 18 years, had no declared gender, had an invalid IgG test result, had previously tested positive for SARS-CoV-2 infection on PCR, could not recall their vaccination status, or had been immunised against COVID-19 with vaccines other than CoronaVac or BNT162b2. Here, we report data collected up to July 2, 2021.",2021-05-21,2021-05-28,Household and community samples,All,Multiple groups,,,Time frame,,3265,0.5513,,,,,,,,Convenience,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Denis Saure,Universidad de Chile,Not Unity-Aligned,https://dx.doi.org/10.1016/S1473-3099(21)00479-5,2022-02-12,2024-03-01,Unverified,saure_dynamic_2021,CHL
210909_Chile_UniversidaddeChile_Week7,210909_Chile_UniversidaddeChile,Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.,2021-09-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Chile,,,Individuals voluntarily approaching the testing stations were invited to do a lateral flow test by finger prick.,"Individuals were excluded from the analysis if they were younger than 18 years, had no declared gender, had an invalid IgG test result, had previously tested positive for SARS-CoV-2 infection on PCR, could not recall their vaccination status, or had been immunised against COVID-19 with vaccines other than CoronaVac or BNT162b2. Here, we report data collected up to July 2, 2021.",2021-04-23,2021-04-30,Household and community samples,All,Multiple groups,,,Time frame,,4442,0.5356000000000001,,,,,,,,Convenience,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Denis Saure,Universidad de Chile,Not Unity-Aligned,https://dx.doi.org/10.1016/S1473-3099(21)00479-5,2022-02-12,2024-03-01,Unverified,saure_dynamic_2021,CHL
210909_Chile_UniversidaddeChile_Week14,210909_Chile_UniversidaddeChile,Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.,2021-09-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Chile,,,Individuals voluntarily approaching the testing stations were invited to do a lateral flow test by finger prick.,"Individuals were excluded from the analysis if they were younger than 18 years, had no declared gender, had an invalid IgG test result, had previously tested positive for SARS-CoV-2 infection on PCR, could not recall their vaccination status, or had been immunised against COVID-19 with vaccines other than CoronaVac or BNT162b2. Here, we report data collected up to July 2, 2021.",2021-06-11,2021-06-18,Household and community samples,All,Multiple groups,,,Time frame,,4209,0.5811000000000001,,,,,,,,Convenience,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Denis Saure,Universidad de Chile,Not Unity-Aligned,https://dx.doi.org/10.1016/S1473-3099(21)00479-5,2022-02-12,2024-03-01,Unverified,saure_dynamic_2021,CHL
210909_Chile_UniversidaddeChile_Week3,210909_Chile_UniversidaddeChile,Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.,2021-09-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Chile,,,Individuals voluntarily approaching the testing stations were invited to do a lateral flow test by finger prick.,"Individuals were excluded from the analysis if they were younger than 18 years, had no declared gender, had an invalid IgG test result, had previously tested positive for SARS-CoV-2 infection on PCR, could not recall their vaccination status, or had been immunised against COVID-19 with vaccines other than CoronaVac or BNT162b2. Here, we report data collected up to July 2, 2021.",2021-03-26,2021-04-02,Household and community samples,All,Multiple groups,,,Time frame,,2298,0.2707,,,,,,,,Convenience,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Denis Saure,Universidad de Chile,Not Unity-Aligned,https://dx.doi.org/10.1016/S1473-3099(21)00479-5,2022-02-12,2024-03-01,Unverified,saure_dynamic_2021,CHL
210909_Chile_UniversidaddeChile_Week9,210909_Chile_UniversidaddeChile,Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.,2021-09-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Chile,,,Individuals voluntarily approaching the testing stations were invited to do a lateral flow test by finger prick.,"Individuals were excluded from the analysis if they were younger than 18 years, had no declared gender, had an invalid IgG test result, had previously tested positive for SARS-CoV-2 infection on PCR, could not recall their vaccination status, or had been immunised against COVID-19 with vaccines other than CoronaVac or BNT162b2. Here, we report data collected up to July 2, 2021.",2021-05-07,2021-05-14,Household and community samples,All,Multiple groups,,,Time frame,,4475,0.5421,,,,,,,,Convenience,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Denis Saure,Universidad de Chile,Not Unity-Aligned,https://dx.doi.org/10.1016/S1473-3099(21)00479-5,2022-02-12,2024-03-01,Unverified,saure_dynamic_2021,CHL
210909_Chile_UniversidaddeChile_Week8,210909_Chile_UniversidaddeChile,Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.,2021-09-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Chile,,,Individuals voluntarily approaching the testing stations were invited to do a lateral flow test by finger prick.,"Individuals were excluded from the analysis if they were younger than 18 years, had no declared gender, had an invalid IgG test result, had previously tested positive for SARS-CoV-2 infection on PCR, could not recall their vaccination status, or had been immunised against COVID-19 with vaccines other than CoronaVac or BNT162b2. Here, we report data collected up to July 2, 2021.",2021-04-30,2021-05-07,Household and community samples,All,Multiple groups,,,Time frame,,4430,0.5424,,,,,,,,Convenience,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Denis Saure,Universidad de Chile,Not Unity-Aligned,https://dx.doi.org/10.1016/S1473-3099(21)00479-5,2022-02-12,2024-03-01,Unverified,saure_dynamic_2021,CHL
210909_Chile_UniversidaddeChile_Week16,210909_Chile_UniversidaddeChile,Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.,2021-09-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Chile,,,Individuals voluntarily approaching the testing stations were invited to do a lateral flow test by finger prick.,"Individuals were excluded from the analysis if they were younger than 18 years, had no declared gender, had an invalid IgG test result, had previously tested positive for SARS-CoV-2 infection on PCR, could not recall their vaccination status, or had been immunised against COVID-19 with vaccines other than CoronaVac or BNT162b2. Here, we report data collected up to July 2, 2021.",2021-06-25,2021-07-02,Household and community samples,All,Multiple groups,,,Time frame,,2718,0.613,,,,,,,,Convenience,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Denis Saure,Universidad de Chile,Not Unity-Aligned,https://dx.doi.org/10.1016/S1473-3099(21)00479-5,2022-02-12,2024-03-01,Unverified,saure_dynamic_2021,CHL
210909_Chile_UniversidaddeChile_Week15,210909_Chile_UniversidaddeChile,Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.,2021-09-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Chile,,,Individuals voluntarily approaching the testing stations were invited to do a lateral flow test by finger prick.,"Individuals were excluded from the analysis if they were younger than 18 years, had no declared gender, had an invalid IgG test result, had previously tested positive for SARS-CoV-2 infection on PCR, could not recall their vaccination status, or had been immunised against COVID-19 with vaccines other than CoronaVac or BNT162b2. Here, we report data collected up to July 2, 2021.",2021-06-18,2021-06-25,Household and community samples,All,Multiple groups,,,Time frame,,3470,0.662,,,,,,,,Convenience,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Denis Saure,Universidad de Chile,Not Unity-Aligned,https://dx.doi.org/10.1016/S1473-3099(21)00479-5,2022-02-12,2024-03-01,Unverified,saure_dynamic_2021,CHL
210909_Chile_UniversidaddeChile_Week4,210909_Chile_UniversidaddeChile,Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.,2021-09-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Chile,,,Individuals voluntarily approaching the testing stations were invited to do a lateral flow test by finger prick.,"Individuals were excluded from the analysis if they were younger than 18 years, had no declared gender, had an invalid IgG test result, had previously tested positive for SARS-CoV-2 infection on PCR, could not recall their vaccination status, or had been immunised against COVID-19 with vaccines other than CoronaVac or BNT162b2. Here, we report data collected up to July 2, 2021.",2021-04-02,2021-04-09,Household and community samples,All,Multiple groups,,,Time frame,,2946,0.3469,,,,,,,,Convenience,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Denis Saure,Universidad de Chile,Not Unity-Aligned,https://dx.doi.org/10.1016/S1473-3099(21)00479-5,2022-02-12,2024-03-01,Unverified,saure_dynamic_2021,CHL
211226_Chile_UniversidaddeChile_Overall,211226_Chile_UniversidaddeChile,A cross sectional study found differential risks for COVID-19 seropositivity amongst health care professionals in Chile.,2021-12-26,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Chile,,," all HCWs in the Chilean public health care system, which comprises 42.6% of the total healthcare workforce in the country",presence of symptoms compatible with COVID-19 at the time of consultation,2020-09-11,2020-10-24,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,85529,0.071776,,,True,,,,True,Convenience,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.958,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Marcela Zuniga,Universidad de Chile,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jclinepi.2021.12.026,2022-01-12,2024-03-01,Unverified,zuniga_cross_2021,CHL
220128_Chile_UniversidaddelDesarrollo_Overall_PopAdj,220128_Chile_UniversidaddelDesarrollo,"Seroprevalence, spatial distribution, and social determinants of SARS-CoV-2 in three urban centers of Chile.",2022-01-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Chile,"Coquimbo, Talca, Santiago",,"Residents (aged 7 years and older) of 3 urban areas in the center zone of Chile (Greater Santiago, Coquimbo-La Serena, Talca)",,2020-09-25,2020-11-25,Household and community samples,All,Multiple groups,7.0,94.0,Primary Estimate,Overall pop adj,2493,0.10400000000000001,0.078,0.13699999999999998,True,,True,,True,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (S),2019-nCoV IgG/IgM Antibody Detection Kit","Roche Diagnostics,Zhuhai Livzon Diagnostics Inc",Multiple Types,Multiple Types,"['IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Pablo Vial,Universidad del Desarrollo,Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07045-7,2022-02-08,2024-03-01,Verified,vial_seroprevalence_2022,CHL
220128_Chile_UniversidaddelDesarrollo_40-59_PopAdj,220128_Chile_UniversidaddelDesarrollo,"Seroprevalence, spatial distribution, and social determinants of SARS-CoV-2 in three urban centers of Chile.",2022-01-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Chile,"Coquimbo, Talca, Santiago",,"Residents (aged 7 years and older) of 3 urban areas in the center zone of Chile (Greater Santiago, Coquimbo-La Serena, Talca)",,2020-09-25,2020-11-25,Household and community samples,All,Adults (18-64 years),40.0,59.0,Age,40-59,813,0.121,0.078,0.18300000000000002,,,True,,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (S),2019-nCoV IgG/IgM Antibody Detection Kit","Roche Diagnostics,Zhuhai Livzon Diagnostics Inc",Multiple Types,Multiple Types,"['IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Pablo Vial,Universidad del Desarrollo,Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07045-7,2022-02-08,2024-03-01,Verified,vial_seroprevalence_2022,CHL
220128_Chile_UniversidaddelDesarrollo_60+_PopAdj,220128_Chile_UniversidaddelDesarrollo,"Seroprevalence, spatial distribution, and social determinants of SARS-CoV-2 in three urban centers of Chile.",2022-01-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Chile,"Coquimbo, Talca, Santiago",,"Residents (aged 7 years and older) of 3 urban areas in the center zone of Chile (Greater Santiago, Coquimbo-La Serena, Talca)",,2020-09-25,2020-11-25,Household and community samples,All,Multiple groups,60.0,94.0,Age,≥60,495,0.067,0.034,0.129,,,True,,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (S),2019-nCoV IgG/IgM Antibody Detection Kit","Roche Diagnostics,Zhuhai Livzon Diagnostics Inc",Multiple Types,Multiple Types,"['IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Pablo Vial,Universidad del Desarrollo,Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07045-7,2022-02-08,2024-03-01,Verified,vial_seroprevalence_2022,CHL
220128_Chile_UniversidaddelDesarrollo_Santiago_PopAdj,220128_Chile_UniversidaddelDesarrollo,"Seroprevalence, spatial distribution, and social determinants of SARS-CoV-2 in three urban centers of Chile.",2022-01-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Chile,Santiago,Talca,"Residents (aged 7 years and older) of 3 urban areas in the center zone of Chile (Greater Santiago, Coquimbo-La Serena, Talca)",,2020-09-25,2020-11-25,Household and community samples,All,Multiple groups,,,Geographical area,Santiago,1441,0.11,0.08199999999999999,0.147,,,True,,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (S),2019-nCoV IgG/IgM Antibody Detection Kit","Roche Diagnostics,Zhuhai Livzon Diagnostics Inc",Multiple Types,Multiple Types,"['IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Pablo Vial,Universidad del Desarrollo,Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07045-7,2022-02-08,2024-03-01,Verified,vial_seroprevalence_2022,CHL
220128_Chile_UniversidaddelDesarrollo_15-24_PopAdj,220128_Chile_UniversidaddelDesarrollo,"Seroprevalence, spatial distribution, and social determinants of SARS-CoV-2 in three urban centers of Chile.",2022-01-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Chile,"Coquimbo, Talca, Santiago",,"Residents (aged 7 years and older) of 3 urban areas in the center zone of Chile (Greater Santiago, Coquimbo-La Serena, Talca)",,2020-09-25,2020-11-25,Household and community samples,All,Multiple groups,15.0,24.0,Age,15-24,360,0.09,0.052000000000000005,0.153,,,True,,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (S),2019-nCoV IgG/IgM Antibody Detection Kit","Roche Diagnostics,Zhuhai Livzon Diagnostics Inc",Multiple Types,Multiple Types,"['IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Pablo Vial,Universidad del Desarrollo,Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07045-7,2022-02-08,2024-03-01,Verified,vial_seroprevalence_2022,CHL
220128_Chile_UniversidaddelDesarrollo_Talca_PopAdj,220128_Chile_UniversidaddelDesarrollo,"Seroprevalence, spatial distribution, and social determinants of SARS-CoV-2 in three urban centers of Chile.",2022-01-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Chile,Talca,Talca,"Residents (aged 7 years and older) of 3 urban areas in the center zone of Chile (Greater Santiago, Coquimbo-La Serena, Talca)",,2020-09-25,2020-11-25,Household and community samples,All,Multiple groups,,,Geographical area,Talca,574,0.02,0.008,0.047,,,True,,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (S),2019-nCoV IgG/IgM Antibody Detection Kit","Roche Diagnostics,Zhuhai Livzon Diagnostics Inc",Multiple Types,Multiple Types,"['IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Pablo Vial,Universidad del Desarrollo,Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07045-7,2022-02-08,2024-03-01,Verified,vial_seroprevalence_2022,CHL
220128_Chile_UniversidaddelDesarrollo_Female_PopAdj,220128_Chile_UniversidaddelDesarrollo,"Seroprevalence, spatial distribution, and social determinants of SARS-CoV-2 in three urban centers of Chile.",2022-01-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Chile,"Coquimbo, Talca, Santiago",,"Residents (aged 7 years and older) of 3 urban areas in the center zone of Chile (Greater Santiago, Coquimbo-La Serena, Talca)",,2020-09-25,2020-11-25,Household and community samples,Female,Multiple groups,,,Sex/Gender,,1503,0.087,0.062000000000000006,0.12,,,True,,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (S),2019-nCoV IgG/IgM Antibody Detection Kit","Roche Diagnostics,Zhuhai Livzon Diagnostics Inc",Multiple Types,Multiple Types,"['IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Pablo Vial,Universidad del Desarrollo,Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07045-7,2022-02-08,2024-03-01,Verified,vial_seroprevalence_2022,CHL
220128_Chile_UniversidaddelDesarrollo_25-39_PopAdj,220128_Chile_UniversidaddelDesarrollo,"Seroprevalence, spatial distribution, and social determinants of SARS-CoV-2 in three urban centers of Chile.",2022-01-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Chile,"Coquimbo, Talca, Santiago",,"Residents (aged 7 years and older) of 3 urban areas in the center zone of Chile (Greater Santiago, Coquimbo-La Serena, Talca)",,2020-09-25,2020-11-25,Household and community samples,All,Adults (18-64 years),25.0,39.0,Age,25-39,649,0.10400000000000001,0.065,0.162,,,True,,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (S),2019-nCoV IgG/IgM Antibody Detection Kit","Roche Diagnostics,Zhuhai Livzon Diagnostics Inc",Multiple Types,Multiple Types,"['IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Pablo Vial,Universidad del Desarrollo,Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07045-7,2022-02-08,2024-03-01,Verified,vial_seroprevalence_2022,CHL
220128_Chile_UniversidaddelDesarrollo_LaSerenaCoquimbo_PopAdj,220128_Chile_UniversidaddelDesarrollo,"Seroprevalence, spatial distribution, and social determinants of SARS-CoV-2 in three urban centers of Chile.",2022-01-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Chile,Coquimbo,Coquimbo,"Residents (aged 7 years and older) of 3 urban areas in the center zone of Chile (Greater Santiago, Coquimbo-La Serena, Talca)",,2020-09-25,2020-11-25,Household and community samples,All,Multiple groups,,,Geographical area,La Serena-Coquimbo,478,0.055999999999999994,0.033,0.095,,,True,,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (S),2019-nCoV IgG/IgM Antibody Detection Kit","Roche Diagnostics,Zhuhai Livzon Diagnostics Inc",Multiple Types,Multiple Types,"['IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Pablo Vial,Universidad del Desarrollo,Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07045-7,2022-02-08,2024-03-01,Verified,vial_seroprevalence_2022,CHL
220128_Chile_UniversidaddelDesarrollo_7-14_PopAdj,220128_Chile_UniversidaddelDesarrollo,"Seroprevalence, spatial distribution, and social determinants of SARS-CoV-2 in three urban centers of Chile.",2022-01-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Chile,"Coquimbo, Talca, Santiago",,"Residents (aged 7 years and older) of 3 urban areas in the center zone of Chile (Greater Santiago, Coquimbo-La Serena, Talca)",,2020-09-25,2020-11-25,Household and community samples,All,Children and Youth (0-17 years),7.0,14.0,Age,7-14,176,0.125,0.061,0.23800000000000002,,,True,,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (S),2019-nCoV IgG/IgM Antibody Detection Kit","Roche Diagnostics,Zhuhai Livzon Diagnostics Inc",Multiple Types,Multiple Types,"['IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Pablo Vial,Universidad del Desarrollo,Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07045-7,2022-02-08,2024-03-01,Verified,vial_seroprevalence_2022,CHL
220128_Chile_UniversidaddelDesarrollo_Male_PopAdj,220128_Chile_UniversidaddelDesarrollo,"Seroprevalence, spatial distribution, and social determinants of SARS-CoV-2 in three urban centers of Chile.",2022-01-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Chile,"Coquimbo, Talca, Santiago",,"Residents (aged 7 years and older) of 3 urban areas in the center zone of Chile (Greater Santiago, Coquimbo-La Serena, Talca)",,2020-09-25,2020-11-25,Household and community samples,Male,Multiple groups,,,Sex/Gender,,990,0.122,0.083,0.17500000000000002,,,True,,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (S),2019-nCoV IgG/IgM Antibody Detection Kit","Roche Diagnostics,Zhuhai Livzon Diagnostics Inc",Multiple Types,Multiple Types,"['IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Pablo Vial,Universidad del Desarrollo,Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07045-7,2022-02-08,2024-03-01,Verified,vial_seroprevalence_2022,CHL
220407_Chile_ClinicaAlemanaUniversidaddelDesarrollo_TestAdj,220407_Chile_ClinicaAlemanaUniversidaddelDesarrollo,Seroprevalence and estimation of the impact of SARS-CoV-2 infection in older adults residing in Long-term Care Facilities in Chile.,2022-04-07,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Chile,Valparaiso; Metropolitan; O'Higgins,,"Older adults residing in 105 public LTCFs in the three central regions of Chile (Valparaiso, Metropolitan and O'Higgins). Participation could be authorized by the resident, by a responsible family member if the resident presented cognitive impairment, or by the director of the LTCF.",,2020-09-15,2020-11-15,Assisted living and long-term care facilities,All,Seniors (65+ years),,,Primary Estimate,,2088,0.162,0.146,0.179,True,True,,,,Convenience,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.903,1.0,['Moderate'],,No,Yes,Yes,,No,Yes,Yes,,Paola Rubilar,Fundacion Chile,Not Unity-Aligned,https://dx.doi.org/10.5867/medwave.2022.03.002553,2022-04-28,2023-08-15,Unverified,rubilar_seroprevalence_2022,CHL
220413_Chile_UniversidadDelDesarrollo_Overall,220413_Chile_UniversidadDelDesarrollo,Immunization and SARS-CoV-2 antibodies seroprevalence in a country with high vaccination coverage: Lessons from Chile,2022-04-13,Preprint,Regional,Cross-sectional survey ,Chile,Center zone,Santiago; Coquimbo/La Serena; Talca.,"""We perform a population-based cross-sectional serosurvey based on a previous study of a representative sample of the cities of Santiago, Coquimbo/La Serena, and Talca"".",,2021-10-05,2021-11-25,Household and community samples,All,Multiple groups,7.0,93.0,Primary Estimate,,2198,0.9732,,,True,,,,True,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,COVID-19 IgG/IgM Rapid Test Cassette","Beijing Wantai Biological,Cellex Inc.",Multiple Types,Serum,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,Ximena Aguilera,Universidad del Desarrollo,Not Unity-Aligned,https://doi.org/10.21203/rs.3.rs-1548211/v1,2022-04-23,2024-03-01,Unverified,aguilera_immunization_2022,CHL
220413_Chile_UniversidadDelDesarrollo_Age_50-59,220413_Chile_UniversidadDelDesarrollo,Immunization and SARS-CoV-2 antibodies seroprevalence in a country with high vaccination coverage: Lessons from Chile,2022-04-13,Preprint,Regional,Cross-sectional survey ,Chile,Center zone,Santiago; Coquimbo/La Serena; Talca.,"""We perform a population-based cross-sectional serosurvey based on a previous study of a representative sample of the cities of Santiago, Coquimbo/La Serena, and Talca"".",,2021-10-05,2021-11-25,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,Age: 50-59 years,367,0.9782,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,COVID-19 IgG/IgM Rapid Test Cassette","Beijing Wantai Biological,Cellex Inc.",Multiple Types,Serum,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,Ximena Aguilera,Universidad del Desarrollo,Not Unity-Aligned,https://doi.org/10.21203/rs.3.rs-1548211/v1,2022-04-23,2024-03-01,Unverified,aguilera_immunization_2022,CHL
220413_Chile_UniversidadDelDesarrollo_city_Coquimbo-LaSerena,220413_Chile_UniversidadDelDesarrollo,Immunization and SARS-CoV-2 antibodies seroprevalence in a country with high vaccination coverage: Lessons from Chile,2022-04-13,Preprint,Local,Cross-sectional survey ,Chile,,Coquimbo/La Serena,"""We perform a population-based cross-sectional serosurvey based on a previous study of a representative sample of the cities of Santiago, Coquimbo/La Serena, and Talca"".",,2021-10-05,2021-11-25,Household and community samples,All,Multiple groups,7.0,93.0,Geographical area,City: Coquimbo - La Serena,536,0.9384,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,COVID-19 IgG/IgM Rapid Test Cassette","Beijing Wantai Biological,Cellex Inc.",Multiple Types,Serum,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,Ximena Aguilera,Universidad del Desarrollo,Not Unity-Aligned,https://doi.org/10.21203/rs.3.rs-1548211/v1,2022-04-23,2024-03-01,Unverified,aguilera_immunization_2022,CHL
220413_Chile_UniversidadDelDesarrollo_Age_70-93,220413_Chile_UniversidadDelDesarrollo,Immunization and SARS-CoV-2 antibodies seroprevalence in a country with high vaccination coverage: Lessons from Chile,2022-04-13,Preprint,Regional,Cross-sectional survey ,Chile,Center zone,Santiago; Coquimbo/La Serena; Talca.,"""We perform a population-based cross-sectional serosurvey based on a previous study of a representative sample of the cities of Santiago, Coquimbo/La Serena, and Talca"".",,2021-10-05,2021-11-25,Household and community samples,All,Seniors (65+ years),70.0,93.0,Age,Age: 70 or more,199,0.9799,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,COVID-19 IgG/IgM Rapid Test Cassette","Beijing Wantai Biological,Cellex Inc.",Multiple Types,Serum,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,Ximena Aguilera,Universidad del Desarrollo,Not Unity-Aligned,https://doi.org/10.21203/rs.3.rs-1548211/v1,2022-04-23,2024-03-01,Unverified,aguilera_immunization_2022,CHL
220413_Chile_UniversidadDelDesarrollo_city_Talca,220413_Chile_UniversidadDelDesarrollo,Immunization and SARS-CoV-2 antibodies seroprevalence in a country with high vaccination coverage: Lessons from Chile,2022-04-13,Preprint,Local,Cross-sectional survey ,Chile,,Talca,"""We perform a population-based cross-sectional serosurvey based on a previous study of a representative sample of the cities of Santiago, Coquimbo/La Serena, and Talca"".",,2021-10-05,2021-11-25,Household and community samples,All,Multiple groups,7.0,93.0,Geographical area,City: Talca,458,0.9847,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,COVID-19 IgG/IgM Rapid Test Cassette","Beijing Wantai Biological,Cellex Inc.",Multiple Types,Serum,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,Ximena Aguilera,Universidad del Desarrollo,Not Unity-Aligned,https://doi.org/10.21203/rs.3.rs-1548211/v1,2022-04-23,2024-03-01,Unverified,aguilera_immunization_2022,CHL
220413_Chile_UniversidadDelDesarrollo_Age_60-69,220413_Chile_UniversidadDelDesarrollo,Immunization and SARS-CoV-2 antibodies seroprevalence in a country with high vaccination coverage: Lessons from Chile,2022-04-13,Preprint,Regional,Cross-sectional survey ,Chile,Center zone,Santiago; Coquimbo/La Serena; Talca.,"""We perform a population-based cross-sectional serosurvey based on a previous study of a representative sample of the cities of Santiago, Coquimbo/La Serena, and Talca"".",,2021-10-05,2021-11-25,Household and community samples,All,Seniors (65+ years),60.0,69.0,Age,Age: 60-69 years,309,0.9806,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,COVID-19 IgG/IgM Rapid Test Cassette","Beijing Wantai Biological,Cellex Inc.",Multiple Types,Serum,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,Ximena Aguilera,Universidad del Desarrollo,Not Unity-Aligned,https://doi.org/10.21203/rs.3.rs-1548211/v1,2022-04-23,2024-03-01,Unverified,aguilera_immunization_2022,CHL
220413_Chile_UniversidadDelDesarrollo_Age_20-29,220413_Chile_UniversidadDelDesarrollo,Immunization and SARS-CoV-2 antibodies seroprevalence in a country with high vaccination coverage: Lessons from Chile,2022-04-13,Preprint,Regional,Cross-sectional survey ,Chile,Center zone,Santiago; Coquimbo/La Serena; Talca.,"""We perform a population-based cross-sectional serosurvey based on a previous study of a representative sample of the cities of Santiago, Coquimbo/La Serena, and Talca"".",,2021-10-05,2021-11-25,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,Age: 20-29 years,321,0.9813,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,COVID-19 IgG/IgM Rapid Test Cassette","Beijing Wantai Biological,Cellex Inc.",Multiple Types,Serum,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,Ximena Aguilera,Universidad del Desarrollo,Not Unity-Aligned,https://doi.org/10.21203/rs.3.rs-1548211/v1,2022-04-23,2024-03-01,Unverified,aguilera_immunization_2022,CHL
220413_Chile_UniversidadDelDesarrollo_Age_40-49,220413_Chile_UniversidadDelDesarrollo,Immunization and SARS-CoV-2 antibodies seroprevalence in a country with high vaccination coverage: Lessons from Chile,2022-04-13,Preprint,Regional,Cross-sectional survey ,Chile,Center zone,Santiago; Coquimbo/La Serena; Talca.,"""We perform a population-based cross-sectional serosurvey based on a previous study of a representative sample of the cities of Santiago, Coquimbo/La Serena, and Talca"".",,2021-10-05,2021-11-25,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,Age: 40-49 years,370,0.9811,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,COVID-19 IgG/IgM Rapid Test Cassette","Beijing Wantai Biological,Cellex Inc.",Multiple Types,Serum,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,Ximena Aguilera,Universidad del Desarrollo,Not Unity-Aligned,https://doi.org/10.21203/rs.3.rs-1548211/v1,2022-04-23,2024-03-01,Unverified,aguilera_immunization_2022,CHL
220413_Chile_UniversidadDelDesarrollo_UnVaccinated,220413_Chile_UniversidadDelDesarrollo,Immunization and SARS-CoV-2 antibodies seroprevalence in a country with high vaccination coverage: Lessons from Chile,2022-04-13,Preprint,Regional,Cross-sectional survey ,Chile,Center zone,Santiago; Coquimbo/La Serena; Talca.,"""We perform a population-based cross-sectional serosurvey based on a previous study of a representative sample of the cities of Santiago, Coquimbo/La Serena, and Talca"".",,2021-10-05,2021-11-25,Household and community samples,All,Multiple groups,7.0,93.0,COVID-19 vaccination status,Unvaccinated,66,0.40909999999999996,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,COVID-19 IgG/IgM Rapid Test Cassette","Beijing Wantai Biological,Cellex Inc.",Multiple Types,Serum,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,Ximena Aguilera,Universidad del Desarrollo,Not Unity-Aligned,https://doi.org/10.21203/rs.3.rs-1548211/v1,2022-04-23,2024-03-01,Unverified,aguilera_immunization_2022,CHL
220413_Chile_UniversidadDelDesarrollo_Vaccinated_2doses,220413_Chile_UniversidadDelDesarrollo,Immunization and SARS-CoV-2 antibodies seroprevalence in a country with high vaccination coverage: Lessons from Chile,2022-04-13,Preprint,Regional,Cross-sectional survey ,Chile,Center zone,Santiago; Coquimbo/La Serena; Talca.,"""We perform a population-based cross-sectional serosurvey based on a previous study of a representative sample of the cities of Santiago, Coquimbo/La Serena, and Talca"".",,2021-10-05,2021-11-25,Household and community samples,All,Multiple groups,7.0,93.0,COVID-19 vaccination status,Vaccinated: two doses or complete basal schedule,1129,0.9903000000000001,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,COVID-19 IgG/IgM Rapid Test Cassette","Beijing Wantai Biological,Cellex Inc.",Multiple Types,Serum,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,Ximena Aguilera,Universidad del Desarrollo,Not Unity-Aligned,https://doi.org/10.21203/rs.3.rs-1548211/v1,2022-04-23,2024-03-01,Unverified,aguilera_immunization_2022,CHL
220413_Chile_UniversidadDelDesarrollo_Age_7-9,220413_Chile_UniversidadDelDesarrollo,Immunization and SARS-CoV-2 antibodies seroprevalence in a country with high vaccination coverage: Lessons from Chile,2022-04-13,Preprint,Regional,Cross-sectional survey ,Chile,Center zone,Santiago; Coquimbo/La Serena; Talca.,"""We perform a population-based cross-sectional serosurvey based on a previous study of a representative sample of the cities of Santiago, Coquimbo/La Serena, and Talca"".",,2021-10-05,2021-11-25,Household and community samples,All,Children and Youth (0-17 years),7.0,9.0,Age,Age: Less than 10 years,32,0.6875,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,COVID-19 IgG/IgM Rapid Test Cassette","Beijing Wantai Biological,Cellex Inc.",Multiple Types,Serum,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,Ximena Aguilera,Universidad del Desarrollo,Not Unity-Aligned,https://doi.org/10.21203/rs.3.rs-1548211/v1,2022-04-23,2024-03-01,Unverified,aguilera_immunization_2022,CHL
220413_Chile_UniversidadDelDesarrollo_Age_30-39,220413_Chile_UniversidadDelDesarrollo,Immunization and SARS-CoV-2 antibodies seroprevalence in a country with high vaccination coverage: Lessons from Chile,2022-04-13,Preprint,Regional,Cross-sectional survey ,Chile,Center zone,Santiago; Coquimbo/La Serena; Talca.,"""We perform a population-based cross-sectional serosurvey based on a previous study of a representative sample of the cities of Santiago, Coquimbo/La Serena, and Talca"".",,2021-10-05,2021-11-25,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,Age: 30-39 years,358,0.9972,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,COVID-19 IgG/IgM Rapid Test Cassette","Beijing Wantai Biological,Cellex Inc.",Multiple Types,Serum,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,Ximena Aguilera,Universidad del Desarrollo,Not Unity-Aligned,https://doi.org/10.21203/rs.3.rs-1548211/v1,2022-04-23,2024-03-01,Unverified,aguilera_immunization_2022,CHL
220413_Chile_UniversidadDelDesarrollo_Vaccinated_Booster,220413_Chile_UniversidadDelDesarrollo,Immunization and SARS-CoV-2 antibodies seroprevalence in a country with high vaccination coverage: Lessons from Chile,2022-04-13,Preprint,Regional,Cross-sectional survey ,Chile,Center zone,Santiago; Coquimbo/La Serena; Talca.,"""We perform a population-based cross-sectional serosurvey based on a previous study of a representative sample of the cities of Santiago, Coquimbo/La Serena, and Talca"".",,2021-10-05,2021-11-25,Household and community samples,All,Multiple groups,7.0,93.0,COVID-19 vaccination status,Vaccinated: complete basal plus booster,936,0.9979000000000001,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,COVID-19 IgG/IgM Rapid Test Cassette","Beijing Wantai Biological,Cellex Inc.",Multiple Types,Serum,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,Ximena Aguilera,Universidad del Desarrollo,Not Unity-Aligned,https://doi.org/10.21203/rs.3.rs-1548211/v1,2022-04-23,2024-03-01,Unverified,aguilera_immunization_2022,CHL
220413_Chile_UniversidadDelDesarrollo_Vaccinated_1dose,220413_Chile_UniversidadDelDesarrollo,Immunization and SARS-CoV-2 antibodies seroprevalence in a country with high vaccination coverage: Lessons from Chile,2022-04-13,Preprint,Regional,Cross-sectional survey ,Chile,Center zone,Santiago; Coquimbo/La Serena; Talca.,"""We perform a population-based cross-sectional serosurvey based on a previous study of a representative sample of the cities of Santiago, Coquimbo/La Serena, and Talca"".",,2021-10-05,2021-11-25,Household and community samples,All,Multiple groups,7.0,93.0,COVID-19 vaccination status,Vaccinated: one dose,67,0.8955,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,COVID-19 IgG/IgM Rapid Test Cassette","Beijing Wantai Biological,Cellex Inc.",Multiple Types,Serum,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,Ximena Aguilera,Universidad del Desarrollo,Not Unity-Aligned,https://doi.org/10.21203/rs.3.rs-1548211/v1,2022-04-23,2024-03-01,Unverified,aguilera_immunization_2022,CHL
220413_Chile_UniversidadDelDesarrollo_Age_10-19,220413_Chile_UniversidadDelDesarrollo,Immunization and SARS-CoV-2 antibodies seroprevalence in a country with high vaccination coverage: Lessons from Chile,2022-04-13,Preprint,Regional,Cross-sectional survey ,Chile,Center zone,Santiago; Coquimbo/La Serena; Talca.,"""We perform a population-based cross-sectional serosurvey based on a previous study of a representative sample of the cities of Santiago, Coquimbo/La Serena, and Talca"".",,2021-10-05,2021-11-25,Household and community samples,All,Multiple groups,10.0,19.0,Age,Age: 10-19 years,242,0.9298000000000001,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,COVID-19 IgG/IgM Rapid Test Cassette","Beijing Wantai Biological,Cellex Inc.",Multiple Types,Serum,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,Ximena Aguilera,Universidad del Desarrollo,Not Unity-Aligned,https://doi.org/10.21203/rs.3.rs-1548211/v1,2022-04-23,2024-03-01,Unverified,aguilera_immunization_2022,CHL
220413_Chile_UniversidadDelDesarrollo_Sex_Male,220413_Chile_UniversidadDelDesarrollo,Immunization and SARS-CoV-2 antibodies seroprevalence in a country with high vaccination coverage: Lessons from Chile,2022-04-13,Preprint,Regional,Cross-sectional survey ,Chile,Center zone,Santiago; Coquimbo/La Serena; Talca.,"""We perform a population-based cross-sectional serosurvey based on a previous study of a representative sample of the cities of Santiago, Coquimbo/La Serena, and Talca"".",,2021-10-05,2021-11-25,Household and community samples,Male,Multiple groups,7.0,93.0,Sex/Gender,,833,0.9664,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,COVID-19 IgG/IgM Rapid Test Cassette","Beijing Wantai Biological,Cellex Inc.",Multiple Types,Serum,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,Ximena Aguilera,Universidad del Desarrollo,Not Unity-Aligned,https://doi.org/10.21203/rs.3.rs-1548211/v1,2022-04-23,2024-03-01,Unverified,aguilera_immunization_2022,CHL
220413_Chile_UniversidadDelDesarrollo_city_Santiago,220413_Chile_UniversidadDelDesarrollo,Immunization and SARS-CoV-2 antibodies seroprevalence in a country with high vaccination coverage: Lessons from Chile,2022-04-13,Preprint,Local,Cross-sectional survey ,Chile,,Santiago,"""We perform a population-based cross-sectional serosurvey based on a previous study of a representative sample of the cities of Santiago, Coquimbo/La Serena, and Talca"".",,2021-10-05,2021-11-25,Household and community samples,All,Multiple groups,7.0,93.0,Geographical area,City: Santiago,1204,0.9842000000000001,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,COVID-19 IgG/IgM Rapid Test Cassette","Beijing Wantai Biological,Cellex Inc.",Multiple Types,Serum,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,Ximena Aguilera,Universidad del Desarrollo,Not Unity-Aligned,https://doi.org/10.21203/rs.3.rs-1548211/v1,2022-04-23,2024-03-01,Unverified,aguilera_immunization_2022,CHL
220413_Chile_UniversidadDelDesarrollo_Sex_Female,220413_Chile_UniversidadDelDesarrollo,Immunization and SARS-CoV-2 antibodies seroprevalence in a country with high vaccination coverage: Lessons from Chile,2022-04-13,Preprint,Regional,Cross-sectional survey ,Chile,Center zone,Santiago; Coquimbo/La Serena; Talca.,"""We perform a population-based cross-sectional serosurvey based on a previous study of a representative sample of the cities of Santiago, Coquimbo/La Serena, and Talca"".",,2021-10-05,2021-11-25,Household and community samples,Female,Multiple groups,7.0,93.0,Sex/Gender,,1365,0.9773000000000001,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,COVID-19 IgG/IgM Rapid Test Cassette","Beijing Wantai Biological,Cellex Inc.",Multiple Types,Serum,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,Ximena Aguilera,Universidad del Desarrollo,Not Unity-Aligned,https://doi.org/10.21203/rs.3.rs-1548211/v1,2022-04-23,2024-03-01,Unverified,aguilera_immunization_2022,CHL
220423_Chile_UniversidadDeChile_Primary,220423_Chile_UniversidadDeChile,SARS-COV-2 IgG positivity in vaccinated and non-vaccinated Chilean children: a national cross-sectional study in Schools.,2022-04-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Chile,,,all parent/children pairs were invited to participate through a letter sent by school authorities.,,,2021-12-24,Students and Daycares,All,Children and Youth (0-17 years),6.0,18.0,Primary Estimate,,2302,0.8570000000000001,0.843,0.871,True,,,,True,Convenience,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Dried Blood,IgG,,Validated by manufacturers,0.9670000000000001,0.981,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Juan Torres,Universidad de Chile,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2022.04.039,2022-05-05,2024-03-01,Unverified,torres_sars-cov-2_2022,CHL
220423_Chile_UniversidadDeChile_Age12-18,220423_Chile_UniversidadDeChile,SARS-COV-2 IgG positivity in vaccinated and non-vaccinated Chilean children: a national cross-sectional study in Schools.,2022-04-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Chile,,,all parent/children pairs were invited to participate through a letter sent by school authorities.,,,2021-12-24,Students and Daycares,All,Children and Youth (0-17 years),12.0,18.0,Age,12-18,1269,0.895,0.878,0.912,,,,,,Convenience,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Dried Blood,IgG,,Validated by manufacturers,0.9670000000000001,0.981,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Juan Torres,Universidad de Chile,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2022.04.039,2022-05-05,2024-03-01,Unverified,torres_sars-cov-2_2022,CHL
220423_Chile_UniversidadDeChile_Age6-11,220423_Chile_UniversidadDeChile,SARS-COV-2 IgG positivity in vaccinated and non-vaccinated Chilean children: a national cross-sectional study in Schools.,2022-04-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Chile,,,all parent/children pairs were invited to participate through a letter sent by school authorities.,,,2021-12-24,Students and Daycares,All,Children and Youth (0-17 years),6.0,11.0,Age,6-11,1033,0.81,0.7859999999999999,0.8340000000000001,,,,,,Convenience,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Dried Blood,IgG,,Validated by manufacturers,0.9670000000000001,0.981,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Juan Torres,Universidad de Chile,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2022.04.039,2022-05-05,2024-03-01,Unverified,torres_sars-cov-2_2022,CHL
220713_Santiago_ UniversidadDelDesarrollo_Age_60+,220713_Santiago_ UniversidadDelDesarrollo,"First wave of SARS-CoV-2 in Santiago Chile: Seroprevalence, asymptomatic infection and infection fatality rate",2022-07-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Chile,Santiago Province,Santiago,"We performed a cross-sectional, population-based study to estimate the seroprevalence of SARS-CoV-2 antibodies in Santiago, a city with seven million inhabitants (National Institute of Statistics Government of Chile, 2018) distributed in 34 urban municipalities, located at −33.437, −70.6501 degrees of latitude and longitude. To this end, we used a random sample of non-institutional dwellings from a long-standing panel survey representative of Santiago, conducted by the Universidad del Desarrollo School of Government since 2017",,2020-04-24,2020-06-21,Household and community samples,All,Seniors (65+ years),60.0,,Age,,209,0.081,0.051,0.127,True,,,,True,Simplified probability,"Acro Biotech COVID-19 IgM/IgG Rapid POC test,COVID-19 IgG/IgM Rapid Test Cassette,2019-nCoV IgG/IgM Rapid Test,2019-nCoV IgG/IgM Antibody Detection Kit","ACRO Biotech Inc,Cellex Inc.,Dynamiker Biotechnology (Tianjin) Co. Ltd,Zhuhai Livzon Diagnostics Inc",Multiple Types,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,,,['Moderate'],,Yes,Yes,No,,Unclear,Yes,No,,Pablo A. Vial,Universidad del Desarrollo,Not Unity-Aligned,https://dx.doi.org/10.1016/j.epidem.2022.100606,2022-08-11,2024-03-01,Unverified,vial_first_2022,CHL
220713_Santiago_ UniversidadDelDesarrollo_Overall,220713_Santiago_ UniversidadDelDesarrollo,"First wave of SARS-CoV-2 in Santiago Chile: Seroprevalence, asymptomatic infection and infection fatality rate",2022-07-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Chile,Santiago Province,Santiago,"We performed a cross-sectional, population-based study to estimate the seroprevalence of SARS-CoV-2 antibodies in Santiago, a city with seven million inhabitants (National Institute of Statistics Government of Chile, 2018) distributed in 34 urban municipalities, located at −33.437, −70.6501 degrees of latitude and longitude. To this end, we used a random sample of non-institutional dwellings from a long-standing panel survey representative of Santiago, conducted by the Universidad del Desarrollo School of Government since 2017",,2020-04-24,2020-06-21,Household and community samples,All,Multiple groups,,,Primary Estimate,,1368,0.0679,0.0558,0.08259999999999999,True,,,,True,Simplified probability,"Acro Biotech COVID-19 IgM/IgG Rapid POC test,COVID-19 IgG/IgM Rapid Test Cassette,2019-nCoV IgG/IgM Rapid Test,2019-nCoV IgG/IgM Antibody Detection Kit","ACRO Biotech Inc,Cellex Inc.,Dynamiker Biotechnology (Tianjin) Co. Ltd,Zhuhai Livzon Diagnostics Inc",Multiple Types,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,,,['Moderate'],,Yes,Yes,No,,Unclear,Yes,No,,Pablo A. Vial,Universidad del Desarrollo,Not Unity-Aligned,https://dx.doi.org/10.1016/j.epidem.2022.100606,2022-08-10,2024-03-01,Unverified,vial_first_2022,CHL
220713_Santiago_ UniversidadDelDesarrollo_Sex_Male,220713_Santiago_ UniversidadDelDesarrollo,"First wave of SARS-CoV-2 in Santiago Chile: Seroprevalence, asymptomatic infection and infection fatality rate",2022-07-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Chile,Santiago Province,Santiago,"We performed a cross-sectional, population-based study to estimate the seroprevalence of SARS-CoV-2 antibodies in Santiago, a city with seven million inhabitants (National Institute of Statistics Government of Chile, 2018) distributed in 34 urban municipalities, located at −33.437, −70.6501 degrees of latitude and longitude. To this end, we used a random sample of non-institutional dwellings from a long-standing panel survey representative of Santiago, conducted by the Universidad del Desarrollo School of Government since 2017",,2020-04-24,2020-06-21,Household and community samples,Male,Multiple groups,,,Sex/Gender,,590,0.073,0.054000000000000006,0.09699999999999999,True,,,,True,Simplified probability,"Acro Biotech COVID-19 IgM/IgG Rapid POC test,COVID-19 IgG/IgM Rapid Test Cassette,2019-nCoV IgG/IgM Rapid Test,2019-nCoV IgG/IgM Antibody Detection Kit","ACRO Biotech Inc,Cellex Inc.,Dynamiker Biotechnology (Tianjin) Co. Ltd,Zhuhai Livzon Diagnostics Inc",Multiple Types,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,,,['Moderate'],,Yes,Yes,No,,Unclear,Yes,No,,Pablo A. Vial,Universidad del Desarrollo,Not Unity-Aligned,https://dx.doi.org/10.1016/j.epidem.2022.100606,2022-08-11,2024-03-01,Unverified,vial_first_2022,CHL
220713_Santiago_ UniversidadDelDesarrollo_Age_25-39,220713_Santiago_ UniversidadDelDesarrollo,"First wave of SARS-CoV-2 in Santiago Chile: Seroprevalence, asymptomatic infection and infection fatality rate",2022-07-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Chile,Santiago Province,Santiago,"We performed a cross-sectional, population-based study to estimate the seroprevalence of SARS-CoV-2 antibodies in Santiago, a city with seven million inhabitants (National Institute of Statistics Government of Chile, 2018) distributed in 34 urban municipalities, located at −33.437, −70.6501 degrees of latitude and longitude. To this end, we used a random sample of non-institutional dwellings from a long-standing panel survey representative of Santiago, conducted by the Universidad del Desarrollo School of Government since 2017",,2020-04-24,2020-06-21,Household and community samples,All,Adults (18-64 years),25.0,39.0,Age,,455,0.057,0.039,0.083,True,,,,True,Simplified probability,"Acro Biotech COVID-19 IgM/IgG Rapid POC test,COVID-19 IgG/IgM Rapid Test Cassette,2019-nCoV IgG/IgM Rapid Test,2019-nCoV IgG/IgM Antibody Detection Kit","ACRO Biotech Inc,Cellex Inc.,Dynamiker Biotechnology (Tianjin) Co. Ltd,Zhuhai Livzon Diagnostics Inc",Multiple Types,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,,,['Moderate'],,Yes,Yes,No,,Unclear,Yes,No,,Pablo A. Vial,Universidad del Desarrollo,Not Unity-Aligned,https://dx.doi.org/10.1016/j.epidem.2022.100606,2022-08-11,2024-03-01,Unverified,vial_first_2022,CHL
220713_Santiago_ UniversidadDelDesarrollo_Age_7-14,220713_Santiago_ UniversidadDelDesarrollo,"First wave of SARS-CoV-2 in Santiago Chile: Seroprevalence, asymptomatic infection and infection fatality rate",2022-07-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Chile,Santiago Province,Santiago,"We performed a cross-sectional, population-based study to estimate the seroprevalence of SARS-CoV-2 antibodies in Santiago, a city with seven million inhabitants (National Institute of Statistics Government of Chile, 2018) distributed in 34 urban municipalities, located at −33.437, −70.6501 degrees of latitude and longitude. To this end, we used a random sample of non-institutional dwellings from a long-standing panel survey representative of Santiago, conducted by the Universidad del Desarrollo School of Government since 2017",,2020-04-24,2020-06-21,Household and community samples,All,Children and Youth (0-17 years),7.0,14.0,Age,,67,0.10400000000000001,0.051,0.203,True,,,,True,Simplified probability,"Acro Biotech COVID-19 IgM/IgG Rapid POC test,COVID-19 IgG/IgM Rapid Test Cassette,2019-nCoV IgG/IgM Rapid Test,2019-nCoV IgG/IgM Antibody Detection Kit","ACRO Biotech Inc,Cellex Inc.,Dynamiker Biotechnology (Tianjin) Co. Ltd,Zhuhai Livzon Diagnostics Inc",Multiple Types,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,,,['Moderate'],,Yes,Yes,No,,Unclear,Yes,No,,Pablo A. Vial,Universidad del Desarrollo,Not Unity-Aligned,https://dx.doi.org/10.1016/j.epidem.2022.100606,2022-08-11,2024-03-01,Unverified,vial_first_2022,CHL
220713_Santiago_ UniversidadDelDesarrollo_Age_40-59,220713_Santiago_ UniversidadDelDesarrollo,"First wave of SARS-CoV-2 in Santiago Chile: Seroprevalence, asymptomatic infection and infection fatality rate",2022-07-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Chile,Santiago Province,Santiago,"We performed a cross-sectional, population-based study to estimate the seroprevalence of SARS-CoV-2 antibodies in Santiago, a city with seven million inhabitants (National Institute of Statistics Government of Chile, 2018) distributed in 34 urban municipalities, located at −33.437, −70.6501 degrees of latitude and longitude. To this end, we used a random sample of non-institutional dwellings from a long-standing panel survey representative of Santiago, conducted by the Universidad del Desarrollo School of Government since 2017",,2020-04-24,2020-06-21,Household and community samples,All,Adults (18-64 years),40.0,59.0,Age,,470,0.07400000000000001,0.054000000000000006,0.102,True,,,,True,Simplified probability,"Acro Biotech COVID-19 IgM/IgG Rapid POC test,COVID-19 IgG/IgM Rapid Test Cassette,2019-nCoV IgG/IgM Rapid Test,2019-nCoV IgG/IgM Antibody Detection Kit","ACRO Biotech Inc,Cellex Inc.,Dynamiker Biotechnology (Tianjin) Co. Ltd,Zhuhai Livzon Diagnostics Inc",Multiple Types,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,,,['Moderate'],,Yes,Yes,No,,Unclear,Yes,No,,Pablo A. Vial,Universidad del Desarrollo,Not Unity-Aligned,https://dx.doi.org/10.1016/j.epidem.2022.100606,2022-08-11,2024-03-01,Unverified,vial_first_2022,CHL
220713_Santiago_ UniversidadDelDesarrollo_Age_15-24,220713_Santiago_ UniversidadDelDesarrollo,"First wave of SARS-CoV-2 in Santiago Chile: Seroprevalence, asymptomatic infection and infection fatality rate",2022-07-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Chile,Santiago Province,Santiago,"We performed a cross-sectional, population-based study to estimate the seroprevalence of SARS-CoV-2 antibodies in Santiago, a city with seven million inhabitants (National Institute of Statistics Government of Chile, 2018) distributed in 34 urban municipalities, located at −33.437, −70.6501 degrees of latitude and longitude. To this end, we used a random sample of non-institutional dwellings from a long-standing panel survey representative of Santiago, conducted by the Universidad del Desarrollo School of Government since 2017",,2020-04-24,2020-06-21,Household and community samples,All,Multiple groups,15.0,24.0,Age,,167,0.048,0.024,0.09300000000000001,True,,,,True,Simplified probability,"Acro Biotech COVID-19 IgM/IgG Rapid POC test,COVID-19 IgG/IgM Rapid Test Cassette,2019-nCoV IgG/IgM Rapid Test,2019-nCoV IgG/IgM Antibody Detection Kit","ACRO Biotech Inc,Cellex Inc.,Dynamiker Biotechnology (Tianjin) Co. Ltd,Zhuhai Livzon Diagnostics Inc",Multiple Types,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,,,['Moderate'],,Yes,Yes,No,,Unclear,Yes,No,,Pablo A. Vial,Universidad del Desarrollo,Not Unity-Aligned,https://dx.doi.org/10.1016/j.epidem.2022.100606,2022-08-11,2024-03-01,Unverified,vial_first_2022,CHL
220713_Santiago_ UniversidadDelDesarrollo_Sex_Female,220713_Santiago_ UniversidadDelDesarrollo,"First wave of SARS-CoV-2 in Santiago Chile: Seroprevalence, asymptomatic infection and infection fatality rate",2022-07-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Chile,Santiago Province,Santiago,"We performed a cross-sectional, population-based study to estimate the seroprevalence of SARS-CoV-2 antibodies in Santiago, a city with seven million inhabitants (National Institute of Statistics Government of Chile, 2018) distributed in 34 urban municipalities, located at −33.437, −70.6501 degrees of latitude and longitude. To this end, we used a random sample of non-institutional dwellings from a long-standing panel survey representative of Santiago, conducted by the Universidad del Desarrollo School of Government since 2017",,2020-04-24,2020-06-21,Household and community samples,Female,Multiple groups,,,Sex/Gender,,778,0.064,0.049,0.084,True,,,,True,Simplified probability,"Acro Biotech COVID-19 IgM/IgG Rapid POC test,COVID-19 IgG/IgM Rapid Test Cassette,2019-nCoV IgG/IgM Rapid Test,2019-nCoV IgG/IgM Antibody Detection Kit","ACRO Biotech Inc,Cellex Inc.,Dynamiker Biotechnology (Tianjin) Co. Ltd,Zhuhai Livzon Diagnostics Inc",Multiple Types,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,,,['Moderate'],,Yes,Yes,No,,Unclear,Yes,No,,Pablo A. Vial,Universidad del Desarrollo,Not Unity-Aligned,https://dx.doi.org/10.1016/j.epidem.2022.100606,2022-08-11,2024-03-01,Unverified,vial_first_2022,CHL
220803_Santiago_UniversidadDelDesarrollo_Overall,220803_Santiago_UniversidadDelDesarrollo,"Immune response against SARS-CoV-2 of primary healthcare personnel in a commune of Santiago, Chile: follow-up at 6 months",2022-08-03,Preprint,Local,Cross-sectional survey ,Chile,,Santiago,"""primary healthcare personnel from the commune of La Pintana"".

""all staff members were invited to participate.""",,2020-11-01,2020-11-30,Health care workers and caregivers,All,Multiple groups,18.0,83.0,Primary Estimate,,463,0.2225,,,True,,,,True,Convenience,COVID-19 ELISA IgG,Vircell S.L.,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.8570000000000001,0.985,['High'],,No,No,Yes,,No,Yes,No,,Andrea Olea,Universidad del Desarrollo,Not Unity-Aligned,http://doi.org/10.1101/2022.08.03.22278369,2022-08-18,2024-03-01,Unverified,olea_immune_2022,CHL
221124_Santiago_UniversidadDelDesarrollo_Overall,221124_Santiago_UniversidadDelDesarrollo,"Immune response to SARS-CoV-2 in Primary Health Care personnel from a commune of Santiago, Chile",2022-11-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Chile,,Santiago,"From Google translated doc: ""Cross-sectional study of personnel working in PHC in the commune of La Pintana, a sector of high social vulnerability13, located in the southern zone of the Metropolitan Region, Chile.""",,2020-11-01,2020-11-30,Health care workers and caregivers,All,Multiple groups,18.0,83.0,Primary Estimate,,463,0.222,,,True,,,,True,Convenience,COVID-19 ELISA IgG,Vircell S.L.,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.8570000000000001,0.985,['High'],,No,No,Yes,,No,Yes,No,,Andrea Olea,Universidad del Desarrollo,Not Unity-Aligned,https://dx.doi.org/10.4067/s0716-10182022000400382,2022-12-09,2024-03-01,Unverified,olea_respuesta_2022,CHL
230110_Chile_UniversidadDelDesarrollo_Round1,230110_Chile_UniversidadDelDesarrollo_Round1,"Seroprevalence of Natural and Acquired Immunity against the SARS-CoV-2 Virus in a Population Cohort from Two Chilean Cities, 2020-2022",2023-01-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Chile,,"La Serena-Coquimbo, Talca",All population samples were randomly selected and were representative of both cities.,NR   ,2020-09-15,2020-11-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,14,0.036000000000000004,,,True,,,,True,Stratified probability,Qualitative Elecsys Anti-SARS-CoV-2 Probe,Roche Diagnostics,CLIA,Serum,IgG,,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Loreto Nunez Franz,Universidad del Desarrollo,Not Unity-Aligned,https://dx.doi.org/10.3390/v15010201,2023-02-09,2023-03-19,Unverified,nunez-franz_seroprevalence_2023,CHL
230110_Chile_UniversidadDelDesarrollo_Round2,230110_Chile_UniversidadDelDesarrollo_Round2,"Seroprevalence of Natural and Acquired Immunity against the SARS-CoV-2 Virus in a Population Cohort from Two Chilean Cities, 2020-2022",2023-01-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Chile,,"La Serena-Coquimbo, Talca",All population samples were randomly selected and were representative of both cities.,NR   ,2021-10-15,2021-11-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,374,0.9690000000000001,,,True,,,,True,Stratified probability,Wantai SARS-CoV-2 IgG ELISA,Beijing Wantai Biological,ELISA,Serum,IgG,,,,,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Loreto Nunez Franz,Universidad del Desarrollo,Unity-Aligned,https://dx.doi.org/10.3390/v15010201,2023-02-10,2024-03-01,Unverified,nunez-franz_seroprevalence_2023,CHL
230110_Chile_UniversidadDelDesarrollo_Round3,230110_Chile_UniversidadDelDesarrollo_Round3,"Seroprevalence of Natural and Acquired Immunity against the SARS-CoV-2 Virus in a Population Cohort from Two Chilean Cities, 2020-2022",2023-01-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Chile,,"La Serena-Coquimbo, Talca",All population samples were randomly selected and were representative of both cities.,NR   ,2022-04-15,2022-09-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,381,0.9870000000000001,,,True,,,,True,Stratified probability,Author designed (ELISA) -Unknown,,ELISA,Serum,IgG,,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Loreto Nunez Franz,Universidad del Desarrollo,Not Unity-Aligned,https://dx.doi.org/10.3390/v15010201,2023-02-10,2023-03-19,Unverified,nunez-franz_seroprevalence_2023,CHL
230215_Valdivia_HospitalBaseDeValdivia_3tests,230215_Valdivia_HospitalBaseDeValdivia,No seroconversion among healthcare workers exposed to SARS-CoV-2 during the early phase of the pandemic,2023-02-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,Chile,Los Ríos,Valdivia,"HCW who attended or cared COVID-19 patients in an outpatient or inpatient basis.

Prospective study of a HCW cohort from the Hospital Base de Valdivia in Los Ríos Region in southern Chile, who were exposed during care or attention of patients affected by SARS-CoV-2.

For this study we included HCW of the Respiratory Emergency Unit, the outpatient unit for HCW with respiratory symptoms (enabled during the pandemic), the outpatient clinic for community patients with respiratory symptoms (enabled during the pandemic), general wards designated for the hospitalization of COVID- 19 patients, Intensive Care Units, the Molecular Biology Laboratory and 4 infectious disease physicians. All HCW from these units were invited to participate in the study with their respective informed consent.",,2020-04-12,2020-07-25,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Tests used: 2 ELISA techniques were applied successively with a final neutralization assay.,179,0.0056,,,True,,,,True,Convenience,"COVID-19 ELISA IgG,SERION ELISA agile SARS-CoV-2,Neutralizing Antibodies Detection Kit","Vircell S.L.,Institut Virion/Serion,AdipoGen LifeSciences",ELISA,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Unclear,Yes,No,,Alberto Fica,Hospital Base de Valdivia,Not Unity-Aligned,https://dx.doi.org/10.4067/S0034-98872023000100023,2023-10-10,2024-03-01,Unverified,fica_no_2023,CHL
200420_Wuhan_CR&WISCOGeneralHospital_HospitalizedPatients,200420_Wuhan_WuhanUniversity_1_HospitalizedPatients,"Serological tests facilitate identification of asymptomatic SARS-CoV-2 infection in Wuhan, China",2020-04-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"Hospitalized patients, at a hospital in Qinshan District, Wuhan. ",,2020-04-03,2020-04-15,Residual sera,All,Multiple groups,,,Primary Estimate,,381,0.10490000000000001,,,True,,,,True,Unclear,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,,0.873,1.0,['High'],Yes,Unclear,No,No,Unclear,No,Yes,No,Unclear,Xiaodong Wu,Wuhan University,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.25904,2020-07-19,2024-03-01,Verified,wu_x_serological_2020,CHN
200420_Wuhan_CR&WISCOGeneralHospital_PeopleSeekingReturntoWork,200420_Wuhan_WuhanUniversity_2_ReturingWorkers,"Serological tests facilitate identification of asymptomatic SARS-CoV-2 infection in Wuhan, China",2020-04-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"Individuals who are either applying for permission of resume at a hospital in Qinshan District, Wuhan. ",,2020-04-03,2020-04-15,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,1021,0.096,,,True,,,,True,Unclear,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,,0.873,1.0,['High'],No,Unclear,Yes,No,Unclear,No,Yes,No,Unclear,Xiaodong Wu,Wuhan University,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.25904,2020-07-19,2024-03-01,Verified,wu_x_serological_2020,CHN
200605_China_NationalClinicalResearchCentre_CommunitySetting,200605_China_NationalClinicalResearchCenter_Community1,Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China,2020-06-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,China,"Hubei, Sichuan, Guangdong","Wuhan, Guangzhou, Chengdu","We enrolled individuals from different
populations in seven cities in Huibei Province (Wuhan, Honghu and Jingzhou),
Guangdong Province (Guangzhou and Foshan), Sichuan Province (Chengdu) and
Chongqing in China. A total of 17,368 individuals, including 2,535 patients, 4,384
healthcare workers, 219 family members of healthcare workers, 346 staff members
from hotels designated for accommodation of healthcare workers responsible for
COVID-19 management, 442 factory workers and 9,442 community residents,
were enrolled. Healthcare workers, family members, outpatients and community
residents were recruited by voluntary participation by a public call. Patients
undergoing hemodialysis, hotel staff members and factory workers were required
to take the serological test at the participant centers after implementation of
regulations for COVID-19 surveillance of these populations during the epidemic
in China.",,2020-03-09,2020-04-10,Multiple populations,All,Adults (18-64 years),,,Primary Estimate,,10449,0.008,,,True,,,,True,Self-referral,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,0.993,['High'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Xin Xu,National Clinical Research Centre for Kidney Disease,Not Unity-Aligned,https://www.nature.com/articles/s41591-020-0949-6,2020-06-06,2022-07-16,Verified,xu_seroprevalence_2020,CHN
200605_China_NationalClinicalResearchCentre_CommunityResidentChengdu,200605_China_NationalClinicalResearchCenter_Community1,Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China,2020-06-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Sichuan,Chengdu,"We enrolled individuals from different
populations in seven cities in Huibei Province (Wuhan, Honghu and Jingzhou),
Guangdong Province (Guangzhou and Foshan), Sichuan Province (Chengdu) and
Chongqing in China. A total of 17,368 individuals, including 2,535 patients, 4,384
healthcare workers, 219 family members of healthcare workers, 346 staff members
from hotels designated for accommodation of healthcare workers responsible for
COVID-19 management, 442 factory workers and 9,442 community residents,
were enrolled. Healthcare workers, family members, outpatients and community
residents were recruited by voluntary participation by a public call. Patients
undergoing hemodialysis, hotel staff members and factory workers were required
to take the serological test at the participant centers after implementation of
regulations for COVID-19 surveillance of these populations during the epidemic
in China.",,2020-03-09,2020-04-10,Household and community samples,All,Adults (18-64 years),,,Geographical area,Chengdu - Community residents,9442,0.0058,0.0045000000000000005,0.0076,,,,,,Self-referral,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,0.993,['High'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Xin Xu,National Clinical Research Centre for Kidney Disease,Not Unity-Aligned,https://www.nature.com/articles/s41591-020-0949-6,2020-11-09,2022-07-16,Verified,xu_seroprevalence_2020,CHN
200605_China_NationalClinicalResearchCentre_HospitalSetting,200605_China_NationalClinicalResearchCenter_Healthcare2,Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China,2020-06-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,China,"Hubei, Sichuan, Guangdong","Wuhan, Guangzhou, Jinzhou, Honghu, Chongqing, Chengdu, Foshan","We enrolled individuals from different
populations in seven cities in Huibei Province (Wuhan, Honghu and Jingzhou),
Guangdong Province (Guangzhou and Foshan), Sichuan Province (Chengdu) and
Chongqing in China. A total of 17,368 individuals, including 2,535 patients, 4,384
healthcare workers, 219 family members of healthcare workers, 346 staff members
from hotels designated for accommodation of healthcare workers responsible for
COVID-19 management, 442 factory workers and 9,442 community residents,
were enrolled. Healthcare workers, family members, outpatients and community
residents were recruited by voluntary participation by a public call. Patients
undergoing hemodialysis, hotel staff members and factory workers were required
to take the serological test at the participant centers after implementation of
regulations for COVID-19 surveillance of these populations during the epidemic
in China.",,2020-03-09,2020-04-10,Multiple populations,All,Adults (18-64 years),,,Primary Estimate,,6919,0.024569999999999998,,,True,,,,True,Self-referral,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,0.993,['High'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Xin Xu,National Clinical Research Centre for Kidney Disease,Not Unity-Aligned,https://www.nature.com/articles/s41591-020-0949-6,2020-07-25,2022-07-16,Verified,xu_seroprevalence_2020,CHN
200605_China_NationalClinicalResearchCentre_OutpatientChongqing,200605_China_NationalClinicalResearchCenter_Healthcare2,Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China,2020-06-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,,Chongqing,"We enrolled individuals from different
populations in seven cities in Huibei Province (Wuhan, Honghu and Jingzhou),
Guangdong Province (Guangzhou and Foshan), Sichuan Province (Chengdu) and
Chongqing in China. A total of 17,368 individuals, including 2,535 patients, 4,384
healthcare workers, 219 family members of healthcare workers, 346 staff members
from hotels designated for accommodation of healthcare workers responsible for
COVID-19 management, 442 factory workers and 9,442 community residents,
were enrolled. Healthcare workers, family members, outpatients and community
residents were recruited by voluntary participation by a public call. Patients
undergoing hemodialysis, hotel staff members and factory workers were required
to take the serological test at the participant centers after implementation of
regulations for COVID-19 surveillance of these populations during the epidemic
in China.",,2020-03-09,2020-04-10,Residual sera,All,Adults (18-64 years),,,Geographical area,Chongqing - outpatients,993,0.038,0.027999999999999997,0.052000000000000005,,,,,,Self-referral,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,0.993,['High'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Xin Xu,National Clinical Research Centre for Kidney Disease,Not Unity-Aligned,https://www.nature.com/articles/s41591-020-0949-6,2020-11-09,2022-07-16,Verified,xu_seroprevalence_2020,CHN
200602_Wuhan_SunYat-senUniversity_HCW_IgG,200610_Wuhan_SunYat-senUniversity,"Use of personal protective equipment against coronavirus disease 2019 by healthcare professionals in Wuhan, China: cross sectional study",2020-06-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"Healthcare professionals from the First Affiliated Hospital and Sun Yat-sen Memorial Hospital (both of Sun Yat-sen University), and Nanfang Hospital of Southern Medical University who were deployed to Wuhan from 24 January to 7 April 2020.

420 healthcare professionals consisted of doctors and nurses, and 67.6% were from departments other than intensive care, respiratory medicine, and infectious diseases.

Healthcare professionals who were involved in the direct care of patients with covid-19 were equipped with standardised personal protective equipment, including protective suits, masks, gloves, goggles, face shields, and gowns.",,2020-02-07,2020-04-21,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,420,0.0,,,True,,,,True,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.978,0.9790000000000001,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,Unclear,Min Liu,Sun Yat-sen University,Not Unity-Aligned,https://www.bmj.com/content/369/bmj.m2195,2020-06-12,2023-07-04,Verified,liu_use_2020,CHN
200720_Guangzhou_NanfangHospital_Primary,200720_Guangzhou_NanfangHospital,Personnel protection strategy for healthcare workers in Wuhan during the COVID-19 epidemic,2020-07-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"Enrolled a total of 8529 healthcare workers, including
medical teams aiding Hubei, local healthcare workers
in Wuhan and Jingzhou of Hubei Province. Employees
in the participating hospitals, including those without
direct patient care responsibilities, were invited to take a serological test for antibodies against SARS-CoV-2",,2020-03-20,2020-04-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,943,0.0,,,True,,,,True,Entire sample,Not reported/ Unable to specify,,,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.873,0.995,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Fan Fan Hou,Nanfang Hospital,Not Unity-Aligned,https://dx.doi.org/10.1093/PCMEDI/PBAA024,2022-01-08,2022-07-16,Unverified,hou_personnel_2020,CHN
200720_Wuhan_NanfangHospital_Primary,200720_Wuhan_NanfangHospital,Personnel protection strategy for healthcare workers in Wuhan during the COVID-19 epidemic,2020-07-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"Enrolled a total of 8529 healthcare workers, including
medical teams aiding Hubei, local healthcare workers
in Wuhan and Jingzhou of Hubei Province. Employees
in the participating hospitals, including those without
direct patient care responsibilities, were invited to take a serological test for antibodies against SARS-CoV-2",,2020-03-20,2020-04-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,7586,0.032,,,True,,,,True,Entire sample,Not reported/ Unable to specify,,,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.873,0.995,['Missing'],,Yes,Yes,Yes,,Unclear,Yes,No,,Fan Fan Hou,Nanfang Hospital,Not Unity-Aligned,https://dx.doi.org/10.1093/PCMEDI/PBAA024,2022-01-08,2022-07-16,Unverified,hou_personnel_2020,CHN
200720_Guangzhou_GuangzhouMedicalUniversity_OverallIgG/IgM,200720_Guangzhou1_GuangzhouMedicalUniversity,Serosurvey of SARS-CoV-2 among hospital visitors in China,2020-07-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Guangdong,Guangzhou,Hospital visitors (inpatients and their healthy companions) from the First Affiliated Hospital of Guangzhou Medical University in Guangzhou,,2020-01-20,2020-04-30,Multiple populations,All,Multiple groups,0.0,99.0,Primary Estimate,,8782,0.0059,,,True,,,,True,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,1.0,['Moderate'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,No,Yes,Wenhua Liang,The First Affiliated Hospital of Guangzhou Medical University,Not Unity-Aligned,https://dx.doi.org/10.1038/s41422-020-0371-0,2020-08-01,2022-07-16,Verified,liang_serosurvey_2020,CHN
200720_Wuhan_GuangzhouMedicalUniversity_OverallIgG/IgM,200720_Wuhan2_GuangzhouMedicalUniversity,Serosurvey of SARS-CoV-2 among hospital visitors in China,2020-07-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,Hospital visitors (inpatients and their healthy companions) from Hubei Cancer Hospital in Wuhan,,2020-01-19,2020-04-30,Multiple populations,All,Multiple groups,0.0,89.0,Primary Estimate,,8272,0.021400000000000002,,,True,,,,True,Convenience,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.873,1.0,['Moderate'],Yes,No,Yes,Yes,Unclear,No,Yes,No,Yes,Wenhua Liang,The First Affiliated Hospital of Guangzhou Medical University,Not Unity-Aligned,https://dx.doi.org/10.1038/s41422-020-0371-0,2020-08-01,2024-03-01,Verified,liang_serosurvey_2020,CHN
200811_Wuhan_HuazhongUniversityofScienceandTechnologyIgG,200811_Wuhan_HuazhongUniversityofScienceandTechnology,Prevention of COVID-19 infection in a pediatric oncology ward in Wuhan,2020-08-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"Patients with established hematologic malignancies admitted for chemotherapy in the Department of Pediatric Hematology of Tongji Hospital from Jan- uary 23 to March 27, 2020",,2020-01-23,2020-03-27,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),1.0,15.0,Primary Estimate,Pediatric cancer patients (admitted to oncology ward),44,0.0,,,True,,,,True,Sequential,Not reported/ Unable to specify,,CLIA,Serum,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,Yes,Unclear,Yes,No,Unclear,Ai Zhang,Huazhong University of Science and Technology,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/full/10.1002/pbc.28424,2020-10-09,2022-07-16,Verified,zhang_prevention_nodate,CHN
200819_Guangzhou_InstituteofBloodTransfusion_BloodDonors_TotalAnti,200819_Guangzhou_InstituteofBloodTransfusion,"Low prevalence of antibodies against SARS-CoV-2 among voluntary blood donors in Guangzhou, China",2020-08-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Guangdong,Guangzhou,"Before donation, the BDs were required to meet the defined criteria of whole blood and platelet apheresis donation. During the COVID‐19 outbreak, BDs were required to answer an additional questionnaire on whether in the past 28 days they (a) had close contact with confirmed or suspected cases of COVID‐19; (b) had traveled in areas with active COVID‐19 epidemic; (c) had such symptoms as fever, cough, fatigue, sore throat, muscle pain or diarrhea. For BDs who were positive for SARS‐CoV‐2 nucleic acid or antibody testing, an epidemiological survey was conducted, and their family members and close contacts were given the same tests.",,2020-03-23,2020-04-02,Blood donors,All,Adults (18-64 years),18.0,59.0,Primary Estimate,IgG and/or IgATo,2199,0.0032,,,True,,,,True,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Whole Blood,"['IgA', 'IgG']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,Yes,Yes,Yes,No,Yes,Yes,Yes,,Ru Xu,Institute of Blood Transfusion,Unity-Aligned,http://dx.doi.org/10.1002/jmv.26445,2020-10-18,2024-03-01,Verified,xu_low_nodate,CHN
200820_Hubei_NanjingUniversity_hcw_IgG,200820_Hubei_NanjingUniversity,Surveillance of SARS-CoV-2 infection among frontline health care workers in Wuhan during COVID-19 outbreak.,2020-08-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"In China, a large number of HCWs from various
provinces in China went to Wuhan city for support.
In Nanjing Drum Tower Hospital, a tertiary hospital
in Nanjing city of China, a total of 222 medical staff,
including 63 doctors and 159 nurses stayed in three
medical centers in Wuhan City, respectively. To further identify any possible infection of SARSCoV‐
2, the seroprevalence, nucleic acid assay, and chest
computed tomography (CT) of SARS‐CoV‐2 among 222
HCWs were performed when they were back to Nanjing.",,2020-05-12,2020-05-15,Health care workers and caregivers,All,Adults (18-64 years),24.0,58.0,Primary Estimate,,191,0.0,,,True,,,,True,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,,,,,['High'],Yes,No,No,Yes,No,Unclear,Yes,No,Unclear,Xin Tong,Nanjing University Medical School,Not Unity-Aligned,https://dx.doi.org/10.1002/iid3.340,2020-10-13,2023-07-04,Verified,tong_surveillance_2020,CHN
200824_Wuhan_WuhanUniversity_IgG_T2,200824_Wuhan_WuhanUniversity,"Positive Rate of Serology and RT-PCR for COVID-19 among Healthcare Workers during Different Periods in Wuhan, China",2020-08-24,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,China,Hubei,Wuhan,,,2020-05-13,2020-06-10,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,May 13 to June 10,1059,0.09300000000000001,,,True,,,,True,Convenience,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,IgG,,,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Lu He,Wuhan University,Not Unity-Aligned,http://dx.doi.org/10.1016/j.jinf.2020.08.027,2020-10-19,2024-03-01,Verified,he_positive_2020-1,CHN
200825_Wuhan_ChineseCenterforDiseaseControlandPrevention_primary,200825_Wuhan_ChineseCenterforDiseaseControlandPrevention,"Seroprevalence and epidemiological characteristics of immunoglobulin M and G antibodies against SARS-CoV-2 in asymptomatic people in Wuhan, China: a cross-sectional study",2020-08-25,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,"All ages with no fever, headache or other symptoms of
COVID-19 in whom specific IgG and IgM antibodies against SARS-CoV-2 were detected",No specific test for SARS-CoV-2 antibodies was completed or clinical data was incomplete. ,2020-03-25,2020-04-28,Household and community samples,All,Multiple groups,4.0,81.0,Primary Estimate,,18712,0.0327,0.0302,0.0352,True,,True,,True,Self-referral,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.895,0.99,['High'],Yes,No,Yes,Yes,Yes,No,Yes,No,Unclear,Ruijie Ling,Chinese Center for Disease Control and Prevention,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.06.16.20132423v3,2021-04-08,2024-03-01,Verified,ling_seroprevalence_2020-1,CHN
200825_Wuhan_ChineseCenterforDiseaseControlandPrevention_genpop_IgG_Qiaokou,200825_Wuhan_ChineseCenterforDiseaseControlandPrevention,"Seroprevalence and epidemiological characteristics of immunoglobulin M and G antibodies against SARS-CoV-2 in asymptomatic people in Wuhan, China: a cross-sectional study",2020-08-25,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,"All ages with no fever, headache or other symptoms of
COVID-19 in whom specific IgG and IgM antibodies against SARS-CoV-2 were detected",No specific test for SARS-CoV-2 antibodies was completed or clinical data was incomplete. ,2020-03-25,2020-04-28,Household and community samples,All,Multiple groups,4.0,81.0,Geographical area,,974,0.013300000000000001,0.0126,0.013999999999999999,,,,,,Self-referral,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,Serum,IgG,,Validated by manufacturers,0.867,0.98,['High'],Yes,No,Yes,Yes,Yes,No,Yes,No,Unclear,Ruijie Ling,Chinese Center for Disease Control and Prevention,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.06.16.20132423v3,2021-04-08,2024-03-01,Verified,ling_seroprevalence_2020-1,CHN
200825_Wuhan_ChineseCenterforDiseaseControlandPrevention_genpop_unadj,200825_Wuhan_ChineseCenterforDiseaseControlandPrevention,"Seroprevalence and epidemiological characteristics of immunoglobulin M and G antibodies against SARS-CoV-2 in asymptomatic people in Wuhan, China: a cross-sectional study",2020-08-25,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,"All ages with no fever, headache or other symptoms of
COVID-19 in whom specific IgG and IgM antibodies against SARS-CoV-2 were detected",No specific test for SARS-CoV-2 antibodies was completed or clinical data was incomplete. ,2020-03-25,2020-04-28,Household and community samples,All,Multiple groups,4.0,81.0,Analysis,Unadjusted,18712,0.0351,0.0325,0.037700000000000004,,,,,,Self-referral,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.895,0.99,['High'],Yes,No,Yes,Yes,Yes,No,Yes,No,Unclear,Ruijie Ling,Chinese Center for Disease Control and Prevention,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.06.16.20132423v3,2021-04-08,2024-03-01,Verified,ling_seroprevalence_2020-1,CHN
200825_Wuhan_ChineseCenterforDiseaseControlandPrevention_genpop_IgG_Hanyang,200825_Wuhan_ChineseCenterforDiseaseControlandPrevention,"Seroprevalence and epidemiological characteristics of immunoglobulin M and G antibodies against SARS-CoV-2 in asymptomatic people in Wuhan, China: a cross-sectional study",2020-08-25,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,"All ages with no fever, headache or other symptoms of
COVID-19 in whom specific IgG and IgM antibodies against SARS-CoV-2 were detected",No specific test for SARS-CoV-2 antibodies was completed or clinical data was incomplete. ,2020-03-25,2020-04-28,Household and community samples,All,Multiple groups,4.0,81.0,Geographical area,,1515,0.0257,0.0177,0.0337,,,,,,Self-referral,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,Serum,IgG,,Validated by manufacturers,0.867,0.98,['High'],Yes,No,Yes,Yes,Yes,No,Yes,No,Unclear,Ruijie Ling,Chinese Center for Disease Control and Prevention,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.06.16.20132423v3,2021-04-08,2024-03-01,Verified,ling_seroprevalence_2020-1,CHN
200825_Wuhan_ChineseCenterforDiseaseControlandPrevention_male_popadj,200825_Wuhan_ChineseCenterforDiseaseControlandPrevention,"Seroprevalence and epidemiological characteristics of immunoglobulin M and G antibodies against SARS-CoV-2 in asymptomatic people in Wuhan, China: a cross-sectional study",2020-08-25,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,"All ages with no fever, headache or other symptoms of
COVID-19 in whom specific IgG and IgM antibodies against SARS-CoV-2 were detected",No specific test for SARS-CoV-2 antibodies was completed or clinical data was incomplete. ,2020-03-25,2020-04-28,Household and community samples,Male,Multiple groups,4.0,81.0,Sex/Gender,Male,11391,0.0267,0.023700000000000002,0.029700000000000004,,,True,,,Self-referral,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.895,0.99,['High'],Yes,No,Yes,Yes,Yes,No,Yes,No,Unclear,Ruijie Ling,Chinese Center for Disease Control and Prevention,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.06.16.20132423v3,2021-04-08,2024-03-01,Verified,ling_seroprevalence_2020-1,CHN
200825_Wuhan_ChineseCenterforDiseaseControlandPrevention_genpop_IgG_Jianghan,200825_Wuhan_ChineseCenterforDiseaseControlandPrevention,"Seroprevalence and epidemiological characteristics of immunoglobulin M and G antibodies against SARS-CoV-2 in asymptomatic people in Wuhan, China: a cross-sectional study",2020-08-25,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,"All ages with no fever, headache or other symptoms of
COVID-19 in whom specific IgG and IgM antibodies against SARS-CoV-2 were detected",No specific test for SARS-CoV-2 antibodies was completed or clinical data was incomplete. ,2020-03-25,2020-04-28,Household and community samples,All,Multiple groups,4.0,81.0,Geographical area,,10667,0.039700000000000006,0.036000000000000004,0.0434,,,,,,Self-referral,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,Serum,IgG,,Validated by manufacturers,0.867,0.98,['High'],Yes,No,Yes,Yes,Yes,No,Yes,No,Unclear,Ruijie Ling,Chinese Center for Disease Control and Prevention,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.06.16.20132423v3,2021-04-08,2024-03-01,Verified,ling_seroprevalence_2020-1,CHN
200825_Wuhan_ChineseCenterforDiseaseControlandPrevention_genpop_IgG_Huangpi,200825_Wuhan_ChineseCenterforDiseaseControlandPrevention,"Seroprevalence and epidemiological characteristics of immunoglobulin M and G antibodies against SARS-CoV-2 in asymptomatic people in Wuhan, China: a cross-sectional study",2020-08-25,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,"All ages with no fever, headache or other symptoms of
COVID-19 in whom specific IgG and IgM antibodies against SARS-CoV-2 were detected",No specific test for SARS-CoV-2 antibodies was completed or clinical data was incomplete. ,2020-03-25,2020-04-28,Household and community samples,All,Multiple groups,4.0,81.0,Geographical area,,1808,0.0216,0.0149,0.028300000000000002,,,,,,Self-referral,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,Serum,IgG,,Validated by manufacturers,0.867,0.98,['High'],Yes,No,Yes,Yes,Yes,No,Yes,No,Unclear,Ruijie Ling,Chinese Center for Disease Control and Prevention,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.06.16.20132423v3,2021-04-08,2024-03-01,Verified,ling_seroprevalence_2020-1,CHN
200825_Wuhan_ChineseCenterforDiseaseControlandPrevention_genpop_IgG_Dongxihu,200825_Wuhan_ChineseCenterforDiseaseControlandPrevention,"Seroprevalence and epidemiological characteristics of immunoglobulin M and G antibodies against SARS-CoV-2 in asymptomatic people in Wuhan, China: a cross-sectional study",2020-08-25,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,"All ages with no fever, headache or other symptoms of
COVID-19 in whom specific IgG and IgM antibodies against SARS-CoV-2 were detected",No specific test for SARS-CoV-2 antibodies was completed or clinical data was incomplete. ,2020-03-25,2020-04-28,Household and community samples,All,Multiple groups,4.0,81.0,Geographical area,,172,0.0233,0.0008,0.0458,,,,,,Self-referral,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,Serum,IgG,,Validated by manufacturers,0.867,0.98,['High'],Yes,No,Yes,Yes,Yes,No,Yes,No,Unclear,Ruijie Ling,Chinese Center for Disease Control and Prevention,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.06.16.20132423v3,2021-04-08,2024-03-01,Verified,ling_seroprevalence_2020-1,CHN
200825_Wuhan_ChineseCenterforDiseaseControlandPrevention_genpop_IgG_Wuchang,200825_Wuhan_ChineseCenterforDiseaseControlandPrevention,"Seroprevalence and epidemiological characteristics of immunoglobulin M and G antibodies against SARS-CoV-2 in asymptomatic people in Wuhan, China: a cross-sectional study",2020-08-25,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,"All ages with no fever, headache or other symptoms of
COVID-19 in whom specific IgG and IgM antibodies against SARS-CoV-2 were detected",No specific test for SARS-CoV-2 antibodies was completed or clinical data was incomplete. ,2020-03-25,2020-04-28,Household and community samples,All,Multiple groups,4.0,81.0,Geographical area,wuchang,884,0.04190000000000001,0.028700000000000003,0.055099999999999996,,,,,,Self-referral,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,Serum,IgG,,Validated by manufacturers,0.867,0.98,['High'],Yes,No,Yes,Yes,Yes,No,Yes,No,Unclear,Ruijie Ling,Chinese Center for Disease Control and Prevention,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.06.16.20132423v3,2021-04-08,2024-03-01,Verified,ling_seroprevalence_2020-1,CHN
200825_Wuhan_ChineseCenterforDiseaseControlandPrevention_genpop_IgG_Caidian+Others,200825_Wuhan_ChineseCenterforDiseaseControlandPrevention,"Seroprevalence and epidemiological characteristics of immunoglobulin M and G antibodies against SARS-CoV-2 in asymptomatic people in Wuhan, China: a cross-sectional study",2020-08-25,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,"All ages with no fever, headache or other symptoms of
COVID-19 in whom specific IgG and IgM antibodies against SARS-CoV-2 were detected",No specific test for SARS-CoV-2 antibodies was completed or clinical data was incomplete. ,2020-03-25,2020-04-28,Household and community samples,All,Multiple groups,4.0,81.0,Geographical area,,87,0.046,0.002,0.09,,,,,,Self-referral,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,Serum,IgG,,Validated by manufacturers,0.867,0.98,['High'],Yes,No,Yes,Yes,Yes,No,Yes,No,Unclear,Ruijie Ling,Chinese Center for Disease Control and Prevention,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.06.16.20132423v3,2021-04-08,2024-03-01,Verified,ling_seroprevalence_2020-1,CHN
200825_Wuhan_ChineseCenterforDiseaseControlandPrevention_female_popadj,200825_Wuhan_ChineseCenterforDiseaseControlandPrevention,"Seroprevalence and epidemiological characteristics of immunoglobulin M and G antibodies against SARS-CoV-2 in asymptomatic people in Wuhan, China: a cross-sectional study",2020-08-25,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,"All ages with no fever, headache or other symptoms of
COVID-19 in whom specific IgG and IgM antibodies against SARS-CoV-2 were detected",No specific test for SARS-CoV-2 antibodies was completed or clinical data was incomplete. ,2020-03-25,2020-04-28,Household and community samples,Female,Multiple groups,4.0,81.0,Sex/Gender,Female,7321,0.038900000000000004,0.0345,0.0433,,,True,,,Self-referral,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.895,0.99,['High'],Yes,No,Yes,Yes,Yes,No,Yes,No,Unclear,Ruijie Ling,Chinese Center for Disease Control and Prevention,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.06.16.20132423v3,2021-04-08,2024-03-01,Verified,ling_seroprevalence_2020-1,CHN
200825_Wuhan_ChineseCenterforDiseaseControlandPrevention_genpop_IgG_Hongshan,200825_Wuhan_ChineseCenterforDiseaseControlandPrevention,"Seroprevalence and epidemiological characteristics of immunoglobulin M and G antibodies against SARS-CoV-2 in asymptomatic people in Wuhan, China: a cross-sectional study",2020-08-25,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,"All ages with no fever, headache or other symptoms of
COVID-19 in whom specific IgG and IgM antibodies against SARS-CoV-2 were detected",No specific test for SARS-CoV-2 antibodies was completed or clinical data was incomplete. ,2020-03-25,2020-04-28,Household and community samples,All,Multiple groups,4.0,81.0,Geographical area,,565,0.0248,0.012,0.0376,,,,,,Self-referral,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,Serum,IgG,,Validated by manufacturers,0.867,0.98,['High'],Yes,No,Yes,Yes,Yes,No,Yes,No,Unclear,Ruijie Ling,Chinese Center for Disease Control and Prevention,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.06.16.20132423v3,2021-04-08,2024-03-01,Verified,ling_seroprevalence_2020-1,CHN
200825_Wuhan_ChineseCenterforDiseaseControlandPrevention_genpop_IgG_Jiangan,200825_Wuhan_ChineseCenterforDiseaseControlandPrevention,"Seroprevalence and epidemiological characteristics of immunoglobulin M and G antibodies against SARS-CoV-2 in asymptomatic people in Wuhan, China: a cross-sectional study",2020-08-25,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,"All ages with no fever, headache or other symptoms of
COVID-19 in whom specific IgG and IgM antibodies against SARS-CoV-2 were detected",No specific test for SARS-CoV-2 antibodies was completed or clinical data was incomplete. ,2020-03-25,2020-04-28,Household and community samples,All,Multiple groups,4.0,81.0,Geographical area,,1468,0.027200000000000002,0.0189,0.0355,,,,,,Self-referral,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,Serum,IgG,,Validated by manufacturers,0.867,0.98,['High'],Yes,No,Yes,Yes,Yes,No,Yes,No,Unclear,Ruijie Ling,Chinese Center for Disease Control and Prevention,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.06.16.20132423v3,2021-04-08,2024-03-01,Verified,ling_seroprevalence_2020-1,CHN
200829_Hubei_HuazhongUniversity_HospitalizedChildren,200829_Hubei_HuazhongUniversity,"Screening of SARS-CoV-2 in 299 Hospitalized Children with Hemato-oncological Diseases: A Multicenter Survey in Hubei, China",2020-08-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,"Wuhan, Xiangyang",children aged 2 months to 16 years old,,2020-01-23,2020-04-24,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),0.0,16.0,Primary Estimate,,299,0.0,,,True,,,,True,Unclear,Not reported/ Unable to specify,,CLIA,Serum,"['IgG', 'IgM']",,,,,['High'],Yes,Unclear,No,Yes,Yes,Unclear,Yes,No,Unclear,Song mi Want,Huazhong University of Science and Technology,Not Unity-Aligned,https://link.springer.com/article/10.1007/s11596-020-2228-7,2020-10-04,2022-07-16,Verified,wang_screening_nodate,CHN
200901_Wuhan_ZhongnanHospitalofWuhanUniversity_IgGTotal,200901_Wuhan_ZhongnanHospitalofWuhanUniversity,Tracing asymptomatic SARS-CoV-2 carriers among 3674 hospital staff:a cross-sectional survey,2020-09-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,Hospital staff without clinical symptoms related to COVID-19,hospital staff who had been infected with SARS-CoV-2,2020-03-16,2020-03-25,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,Overall IgM-/IgG+,3674,0.017,,,True,,,,True,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Fuling Zhou,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,http://dx.doi.org/10.1016/j.eclinm.2020.100510,2020-10-29,2023-07-04,Verified,zhou_tracing_2020,CHN
200901_Wuhan_ZhongnanHospitalofWuhanUniversity_IgM_18-30,200901_Wuhan_ZhongnanHospitalofWuhanUniversity,Tracing asymptomatic SARS-CoV-2 carriers among 3674 hospital staff:a cross-sectional survey,2020-09-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,Hospital staff without clinical symptoms related to COVID-19,hospital staff who had been infected with SARS-CoV-2,2020-03-16,2020-03-25,Health care workers and caregivers,All,Adults (18-64 years),18.0,30.0,Age,"18-30 years old, IgM+/IgG-",1378,0.0022,,,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgM,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Fuling Zhou,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,http://dx.doi.org/10.1016/j.eclinm.2020.100510,2020-10-29,2023-07-04,Verified,zhou_tracing_2020,CHN
200901_Wuhan_ZhongnanHospitalofWuhanUniversity_IgG_31-50,200901_Wuhan_ZhongnanHospitalofWuhanUniversity,Tracing asymptomatic SARS-CoV-2 carriers among 3674 hospital staff:a cross-sectional survey,2020-09-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,Hospital staff without clinical symptoms related to COVID-19,hospital staff who had been infected with SARS-CoV-2,2020-03-16,2020-03-25,Health care workers and caregivers,All,Adults (18-64 years),31.0,50.0,Age,"31-50 years old, IgM-/IgG+",1656,0.014499999999999999,,,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Fuling Zhou,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,http://dx.doi.org/10.1016/j.eclinm.2020.100510,2020-10-29,2023-07-04,Verified,zhou_tracing_2020,CHN
200901_Wuhan_ZhongnanHospitalofWuhanUniversity_IgGandIgM_31-50,200901_Wuhan_ZhongnanHospitalofWuhanUniversity,Tracing asymptomatic SARS-CoV-2 carriers among 3674 hospital staff:a cross-sectional survey,2020-09-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,Hospital staff without clinical symptoms related to COVID-19,hospital staff who had been infected with SARS-CoV-2,2020-03-16,2020-03-25,Health care workers and caregivers,All,Adults (18-64 years),31.0,50.0,Age,"31-50 years old, IgM+/IgG+",1656,0.0024,,,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Fuling Zhou,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,http://dx.doi.org/10.1016/j.eclinm.2020.100510,2020-10-29,2022-07-16,Verified,zhou_tracing_2020,CHN
200901_Wuhan_ZhongnanHospitalofWuhanUniversity_IgGandIgM_18-30,200901_Wuhan_ZhongnanHospitalofWuhanUniversity,Tracing asymptomatic SARS-CoV-2 carriers among 3674 hospital staff:a cross-sectional survey,2020-09-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,Hospital staff without clinical symptoms related to COVID-19,hospital staff who had been infected with SARS-CoV-2,2020-03-16,2020-03-25,Health care workers and caregivers,All,Adults (18-64 years),18.0,30.0,Age,"18-30 years old, IgM+/IgG+",1378,0.0015,,,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Fuling Zhou,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,http://dx.doi.org/10.1016/j.eclinm.2020.100510,2020-10-29,2022-07-16,Verified,zhou_tracing_2020,CHN
200901_Wuhan_ZhongnanHospitalofWuhanUniversity_IgG_18-30,200901_Wuhan_ZhongnanHospitalofWuhanUniversity,Tracing asymptomatic SARS-CoV-2 carriers among 3674 hospital staff:a cross-sectional survey,2020-09-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,Hospital staff without clinical symptoms related to COVID-19,hospital staff who had been infected with SARS-CoV-2,2020-03-16,2020-03-25,Health care workers and caregivers,All,Adults (18-64 years),18.0,30.0,Age,"18-30 years old, IgM-/IgG+",1378,0.016,,,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Fuling Zhou,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,http://dx.doi.org/10.1016/j.eclinm.2020.100510,2020-10-29,2023-07-04,Verified,zhou_tracing_2020,CHN
200901_Wuhan_ZhongnanHospitalofWuhanUniversity_IgG_Over50,200901_Wuhan_ZhongnanHospitalofWuhanUniversity,Tracing asymptomatic SARS-CoV-2 carriers among 3674 hospital staff:a cross-sectional survey,2020-09-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,Hospital staff without clinical symptoms related to COVID-19,hospital staff who had been infected with SARS-CoV-2,2020-03-16,2020-03-25,Health care workers and caregivers,All,Adults (18-64 years),51.0,,Age,">50 years old, IgM-/IgG+",640,0.026600000000000002,,,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Fuling Zhou,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,http://dx.doi.org/10.1016/j.eclinm.2020.100510,2020-10-29,2023-07-04,Verified,zhou_tracing_2020,CHN
200901_Wuhan_ZhongnanHospitalofWuhanUniversity_IgM_31-50,200901_Wuhan_ZhongnanHospitalofWuhanUniversity,Tracing asymptomatic SARS-CoV-2 carriers among 3674 hospital staff:a cross-sectional survey,2020-09-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,Hospital staff without clinical symptoms related to COVID-19,hospital staff who had been infected with SARS-CoV-2,2020-03-16,2020-03-25,Health care workers and caregivers,All,Adults (18-64 years),31.0,50.0,Age,"31-50 years old, IgM+/IgG-",1656,0.0054,,,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgM,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Fuling Zhou,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,http://dx.doi.org/10.1016/j.eclinm.2020.100510,2020-10-29,2023-07-04,Verified,zhou_tracing_2020,CHN
200901_Wuhan_ZhongnanHospitalofWuhanUniversity_IgGandIgM_Over50,200901_Wuhan_ZhongnanHospitalofWuhanUniversity,Tracing asymptomatic SARS-CoV-2 carriers among 3674 hospital staff:a cross-sectional survey,2020-09-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,Hospital staff without clinical symptoms related to COVID-19,hospital staff who had been infected with SARS-CoV-2,2020-03-16,2020-03-25,Health care workers and caregivers,All,Adults (18-64 years),51.0,,Age,">50 years old, IgM+/IgG+",640,0.0063,,,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Fuling Zhou,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,http://dx.doi.org/10.1016/j.eclinm.2020.100510,2020-10-29,2022-07-16,Verified,zhou_tracing_2020,CHN
200901_Wuhan_ZhongnanHospitalofWuhanUniversity_IgM_Over50,200901_Wuhan_ZhongnanHospitalofWuhanUniversity,Tracing asymptomatic SARS-CoV-2 carriers among 3674 hospital staff:a cross-sectional survey,2020-09-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,Hospital staff without clinical symptoms related to COVID-19,hospital staff who had been infected with SARS-CoV-2,2020-03-16,2020-03-25,Health care workers and caregivers,All,Adults (18-64 years),51.0,,Age,">50 years old, IgM+/IgG-",640,0.0063,,,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgM,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Fuling Zhou,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,http://dx.doi.org/10.1016/j.eclinm.2020.100510,2020-10-29,2023-07-04,Verified,zhou_tracing_2020,CHN
200921_Wuhan_TongjiMedicalCollege_Overall,200921_Wuhan_TongjiMedicalCollege,Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections.,2020-09-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"Epidemiologically suspect individuals at the Tongji Hospital, Wuhan: Close contacts of confirmed cases, close social distance during cluster investigation, close social distance during tracing infectious sources, screening personnel returning to work. ",,2020-02-17,2020-04-28,Multiple populations,All,Multiple groups,,,Primary Estimate,,11766,0.005,,,True,,,,True,Sequential,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,0.667,0.995,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,Unclear,Qing Lei, Tongji Medical College,Not Unity-Aligned,https://dx.doi.org/10.1111/all.14622,2020-11-25,2022-07-16,Verified,lei_antibody_2020,CHN
200923_Beijing_PekingUniversity_Overall,200923_Beijing_PekingUniversity,"A population-based seroprevalence survey of severe acute respiratory syndrome coronavirus 2 infection in Beijing, China",2020-09-23,Preprint,Local,Cross-sectional survey ,China,Hebei,Beijing,"Residents who aged > 1-year-old, lived in Beijing for at least 14 days in between of January and March 2020 were eligible for participation.",,2020-04-15,2020-04-18,Household and community samples,All,Multiple groups,2.0,,Primary Estimate,Primary estimate,2184,0.0017000000000000001,,,True,,True,,True,Stratified probability,"2019-nCoV IgG Rapid Test,Finecare SARS-CoV-2 Antibody test","Innovita Biological Technology Co. Ltd,Guangzhou Wondfo Biotech Co. Ltd",Multiple Types,Multiple Types,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Xiaoli Wang,Peking University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.23.20197756v1,2020-11-22,2024-03-01,Verified,wang_population-based_2020,CHN
200923_Beijing_PekingUniversity_Overallunadj,200923_Beijing_PekingUniversity,"A population-based seroprevalence survey of severe acute respiratory syndrome coronavirus 2 infection in Beijing, China",2020-09-23,Preprint,Local,Cross-sectional survey ,China,,Beijing,"Residents who aged > 1-year-old, lived in Beijing for at least 14 days in between of January and March 2020 were eligible for participation.",,2020-04-15,2020-04-18,Household and community samples,All,Multiple groups,2.0,,Analysis,unadjusted,2184,0.0059499999999999996,,,,,,,,Stratified probability,"2019-nCoV IgG Rapid Test,Finecare SARS-CoV-2 Antibody test","Innovita Biological Technology Co. Ltd,Guangzhou Wondfo Biotech Co. Ltd",LFIA,Multiple Types,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Xiaoli Wang,Peking University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.23.20197756v1,2020-11-22,2024-03-01,Verified,wang_population-based_2020,CHN
200923_Beijing_PekingUniversity_Female,200923_Beijing_PekingUniversity,"A population-based seroprevalence survey of severe acute respiratory syndrome coronavirus 2 infection in Beijing, China",2020-09-23,Preprint,Local,Cross-sectional survey ,China,,Beijing,"Residents who aged > 1-year-old, lived in Beijing for at least 14 days in between of January and March 2020 were eligible for participation.",,2020-04-15,2020-04-18,Household and community samples,Female,Multiple groups,2.0,,Sex/Gender,Female,1187,0.00505,,,,,,,,Stratified probability,"2019-nCoV IgG Rapid Test,Finecare SARS-CoV-2 Antibody test","Innovita Biological Technology Co. Ltd,Guangzhou Wondfo Biotech Co. Ltd",LFIA,Multiple Types,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Xiaoli Wang,Peking University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.23.20197756v1,2020-11-22,2024-03-01,Verified,wang_population-based_2020,CHN
200923_Beijing_PekingUniversity_Male,200923_Beijing_PekingUniversity,"A population-based seroprevalence survey of severe acute respiratory syndrome coronavirus 2 infection in Beijing, China",2020-09-23,Preprint,Local,Cross-sectional survey ,China,,Beijing,"Residents who aged > 1-year-old, lived in Beijing for at least 14 days in between of January and March 2020 were eligible for participation.",,2020-04-15,2020-04-18,Household and community samples,Male,Multiple groups,2.0,,Sex/Gender,Male,997,0.007019999999999999,,,,,,,,Stratified probability,"2019-nCoV IgG Rapid Test,Finecare SARS-CoV-2 Antibody test","Innovita Biological Technology Co. Ltd,Guangzhou Wondfo Biotech Co. Ltd",LFIA,Multiple Types,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Xiaoli Wang,Peking University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.23.20197756v1,2020-11-22,2024-03-01,Verified,wang_population-based_2020,CHN
200923_Wuhan_NationalCenterforMedicalServiceAdministration_Overall,200923_Wuhan_NationalCenterforMedicalServiceAdministration,Highlighted prospects of an IgM/IgG antibodies test in identifying individuals with asymptomatic SARS CoV-2 infection,2020-09-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"389 individuals with close contacts in Huangpi People's Hospital of Jianghan University (Wuhan, Hubei, China) from 10 February 2020 to 22 March 2020",severe or critical cases of COVID-19 excluded,2020-02-10,2020-03-22,Contacts of COVID patients,All,Multiple groups,,,Primary Estimate,Overall estimate of PCR negative participants,300,0.4767,,,True,,,,True,Convenience,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.971,0.953,['High'],Unclear,No,No,No,Unclear,No,Yes,No,Unclear,Yaqing Li,National Center for Medical Service Administration,Not Unity-Aligned,https://dx.doi.org/10.5858/arpa.2020-0310-SA,2020-11-19,2024-03-01,Verified,li_highlighted_2021,CHN
200922_Wuhan_WuhanUniversity_IgM/IgG,200922_Wuhan_WuhanUniversity,"Seroprevalence of SARS-CoV-2 immunoglobulin antibodies in Wuhan, China: part of the city-wide massive testing campaign",2020-10-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"residents in Wuchang District, Wuhan",". Hospitalized patients, including confirmed patients with COVID-19 and other diseases, and individuals under quarantine, were excluded.",2020-05-15,2020-05-26,Household and community samples,All,Multiple groups,0.0,101.0,Primary Estimate,,61437,0.0239,0.0227,0.0252,True,,,,True,Stratified probability,2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,Nanjing Vazyme Medical Technology Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.9154000000000001,0.9702,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,Yes,Unclear,Yunbao Pan,Wuhan University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.09.044,2020-12-08,2024-02-20,Verified,pan_seroprevalence_2020,CHN
200922_Wuhan_WuhanUniversity_IgM/IgG_40-49,200922_Wuhan_WuhanUniversity,"Seroprevalence of SARS-CoV-2 immunoglobulin antibodies in Wuhan, China: part of the city-wide massive testing campaign",2020-10-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"residents in Wuchang District, Wuhan",". Hospitalized patients, including confirmed patients with COVID-19 and other diseases, and individuals under quarantine, were excluded.",2020-05-15,2020-05-26,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49 yrs,8951,0.0219,0.019,0.0252,,,,,,Stratified probability,2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,Nanjing Vazyme Medical Technology Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.9154000000000001,0.9702,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,Yes,Unclear,Yunbao Pan,Wuhan University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.09.044,2020-12-08,2024-02-29,Verified,pan_seroprevalence_2020,CHN
200922_Wuhan_WuhanUniversity_IgM/IgG_<9,200922_Wuhan_WuhanUniversity,"Seroprevalence of SARS-CoV-2 immunoglobulin antibodies in Wuhan, China: part of the city-wide massive testing campaign",2020-10-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"residents in Wuchang District, Wuhan",". Hospitalized patients, including confirmed patients with COVID-19 and other diseases, and individuals under quarantine, were excluded.",2020-05-15,2020-05-26,Household and community samples,All,Children and Youth (0-17 years),0.0,9.0,Age,<=9,1601,0.015,0.0098,0.0226,,,,,,Stratified probability,2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,Nanjing Vazyme Medical Technology Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.9154000000000001,0.9702,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,Yes,Unclear,Yunbao Pan,Wuhan University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.09.044,2020-12-08,2024-03-01,Verified,pan_seroprevalence_2020,CHN
200922_Wuhan_WuhanUniversity_IgM/IgG_50-59,200922_Wuhan_WuhanUniversity,"Seroprevalence of SARS-CoV-2 immunoglobulin antibodies in Wuhan, China: part of the city-wide massive testing campaign",2020-10-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"residents in Wuchang District, Wuhan",". Hospitalized patients, including confirmed patients with COVID-19 and other diseases, and individuals under quarantine, were excluded.",2020-05-15,2020-05-26,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59 yrs,10230,0.0291,0.026000000000000002,0.0326,,,,,,Stratified probability,2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,Nanjing Vazyme Medical Technology Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.9154000000000001,0.9702,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,Yes,Unclear,Yunbao Pan,Wuhan University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.09.044,2020-12-08,2024-03-01,Verified,pan_seroprevalence_2020,CHN
200922_Wuhan_WuhanUniversity_IgM/IgG_70-79,200922_Wuhan_WuhanUniversity,"Seroprevalence of SARS-CoV-2 immunoglobulin antibodies in Wuhan, China: part of the city-wide massive testing campaign",2020-10-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"residents in Wuchang District, Wuhan",". Hospitalized patients, including confirmed patients with COVID-19 and other diseases, and individuals under quarantine, were excluded.",2020-05-15,2020-05-26,Household and community samples,All,Seniors (65+ years),70.0,79.0,Age,70-79 yrs,5672,0.039,0.034100000000000005,0.0444,,,,,,Stratified probability,2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,Nanjing Vazyme Medical Technology Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.9154000000000001,0.9702,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,Yes,Unclear,Yunbao Pan,Wuhan University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.09.044,2020-12-08,2024-02-27,Verified,pan_seroprevalence_2020,CHN
200922_Wuhan_WuhanUniversity_IgM/IgG_20-29,200922_Wuhan_WuhanUniversity,"Seroprevalence of SARS-CoV-2 immunoglobulin antibodies in Wuhan, China: part of the city-wide massive testing campaign",2020-10-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"residents in Wuchang District, Wuhan",". Hospitalized patients, including confirmed patients with COVID-19 and other diseases, and individuals under quarantine, were excluded.",2020-05-15,2020-05-26,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29 yrs,7566,0.0086,0.0067,0.011000000000000001,,,,,,Stratified probability,2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,Nanjing Vazyme Medical Technology Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.9154000000000001,0.9702,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,Yes,Unclear,Yunbao Pan,Wuhan University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.09.044,2020-12-08,2024-03-01,Verified,pan_seroprevalence_2020,CHN
200922_Wuhan_WuhanUniversity_IgM/IgG_90+,200922_Wuhan_WuhanUniversity,"Seroprevalence of SARS-CoV-2 immunoglobulin antibodies in Wuhan, China: part of the city-wide massive testing campaign",2020-10-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"residents in Wuchang District, Wuhan",". Hospitalized patients, including confirmed patients with COVID-19 and other diseases, and individuals under quarantine, were excluded.",2020-05-15,2020-05-26,Household and community samples,All,Seniors (65+ years),90.0,101.0,Age,90+ years,381,0.0184,0.008100000000000001,0.0392,,,,,,Stratified probability,2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,Nanjing Vazyme Medical Technology Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.9154000000000001,0.9702,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,Yes,Unclear,Yunbao Pan,Wuhan University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.09.044,2020-12-08,2024-03-01,Verified,pan_seroprevalence_2020,CHN
200922_Wuhan_WuhanUniversity_IgM/IgG_10-19,200922_Wuhan_WuhanUniversity,"Seroprevalence of SARS-CoV-2 immunoglobulin antibodies in Wuhan, China: part of the city-wide massive testing campaign",2020-10-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"residents in Wuchang District, Wuhan",". Hospitalized patients, including confirmed patients with COVID-19 and other diseases, and individuals under quarantine, were excluded.",2020-05-15,2020-05-26,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19 years,3593,0.0122,0.009000000000000001,0.0166,,,,,,Stratified probability,2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,Nanjing Vazyme Medical Technology Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.9154000000000001,0.9702,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,Yes,Unclear,Yunbao Pan,Wuhan University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.09.044,2020-12-08,2024-03-01,Verified,pan_seroprevalence_2020,CHN
200922_Wuhan_WuhanUniversity_IgM/IgG_60-69,200922_Wuhan_WuhanUniversity,"Seroprevalence of SARS-CoV-2 immunoglobulin antibodies in Wuhan, China: part of the city-wide massive testing campaign",2020-10-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"residents in Wuchang District, Wuhan",". Hospitalized patients, including confirmed patients with COVID-19 and other diseases, and individuals under quarantine, were excluded.",2020-05-15,2020-05-26,Household and community samples,All,Adults (18-64 years),60.0,69.0,Age,60-69 yrs,10089,0.0368,0.0332,0.04070000000000001,,,,,,Stratified probability,2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,Nanjing Vazyme Medical Technology Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.9154000000000001,0.9702,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,Yes,Unclear,Yunbao Pan,Wuhan University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.09.044,2020-12-08,2024-02-29,Verified,pan_seroprevalence_2020,CHN
200922_Wuhan_WuhanUniversity_IgM/IgG_Male,200922_Wuhan_WuhanUniversity,"Seroprevalence of SARS-CoV-2 immunoglobulin antibodies in Wuhan, China: part of the city-wide massive testing campaign",2020-10-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"residents in Wuchang District, Wuhan",". Hospitalized patients, including confirmed patients with COVID-19 and other diseases, and individuals under quarantine, were excluded.",2020-05-15,2020-05-26,Household and community samples,Male,Multiple groups,0.0,101.0,Sex/Gender,,30032,0.020499999999999997,0.0189,0.0222,,,,,,Stratified probability,2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,Nanjing Vazyme Medical Technology Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.9154000000000001,0.9702,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,Yes,Unclear,Yunbao Pan,Wuhan University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.09.044,2020-12-08,2024-03-01,Verified,pan_seroprevalence_2020,CHN
200922_Wuhan_WuhanUniversity_IgM/IgG_30-39,200922_Wuhan_WuhanUniversity,"Seroprevalence of SARS-CoV-2 immunoglobulin antibodies in Wuhan, China: part of the city-wide massive testing campaign",2020-10-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"residents in Wuchang District, Wuhan",". Hospitalized patients, including confirmed patients with COVID-19 and other diseases, and individuals under quarantine, were excluded.",2020-05-15,2020-05-26,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39 yrs,10237,0.0152,0.013000000000000001,0.0179,,,,,,Stratified probability,2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,Nanjing Vazyme Medical Technology Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.9154000000000001,0.9702,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,Yes,Unclear,Yunbao Pan,Wuhan University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.09.044,2020-12-08,2024-02-20,Verified,pan_seroprevalence_2020,CHN
200922_Wuhan_WuhanUniversity_IgM/IgG_80-89,200922_Wuhan_WuhanUniversity,"Seroprevalence of SARS-CoV-2 immunoglobulin antibodies in Wuhan, China: part of the city-wide massive testing campaign",2020-10-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"residents in Wuchang District, Wuhan",". Hospitalized patients, including confirmed patients with COVID-19 and other diseases, and individuals under quarantine, were excluded.",2020-05-15,2020-05-26,Household and community samples,All,Seniors (65+ years),80.0,89.0,Age,80-89 yrs,3117,0.0282,0.022799999999999997,0.0348,,,,,,Stratified probability,2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,Nanjing Vazyme Medical Technology Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.9154000000000001,0.9702,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,Yes,Unclear,Yunbao Pan,Wuhan University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.09.044,2020-12-08,2024-02-20,Verified,pan_seroprevalence_2020,CHN
200922_Wuhan_WuhanUniversity_IgM/IgG_Female,200922_Wuhan_WuhanUniversity,"Seroprevalence of SARS-CoV-2 immunoglobulin antibodies in Wuhan, China: part of the city-wide massive testing campaign",2020-10-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"residents in Wuchang District, Wuhan",". Hospitalized patients, including confirmed patients with COVID-19 and other diseases, and individuals under quarantine, were excluded.",2020-05-15,2020-05-26,Household and community samples,Female,Multiple groups,0.0,101.0,Sex/Gender,Female,31405,0.027200000000000002,0.0255,0.0291,,,,,,Stratified probability,2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,Nanjing Vazyme Medical Technology Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.9154000000000001,0.9702,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,Yes,Unclear,Yunbao Pan,Wuhan University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.09.044,2020-12-08,2024-02-20,Verified,pan_seroprevalence_2020,CHN
201010_Taipei_TaipeiVeteransGeneralHospital_popadj,201010_Taipei_TaipeiVeteransGeneralHospital,"Seroprevalence of COVID-19 in Taiwan revealed by testing anti-SARS-CoV-2 serological antibodies on 14,765 hospital patients.",2020-10-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,,Taipei,"The residual specimens obtained from routine laboratory blood tests for outpatient and emergency department patients visiting Taipei Veterans General Hospital, Taipei, Taiwan",,2020-05-25,2020-07-08,Residual sera,All,Multiple groups,20.0,,Primary Estimate,,14765,0.0005,0.0002,0.001,True,,True,,,Sequential,"Academia Sinica ELISA assay,Elecsys® Anti‐SARS‐CoV‐2 (N)","Academia Sinica,Roche Diagnostics",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Hsiang-Ling Ho,Taipei Veterans General Hospital,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2020.100041,2021-07-07,2024-03-01,Verified,ho_seroprevalence_2020,CHN
201010_Taipei_TaipeiVeteransGeneralHospital_40-49,201010_Taipei_TaipeiVeteransGeneralHospital,"Seroprevalence of COVID-19 in Taiwan revealed by testing anti-SARS-CoV-2 serological antibodies on 14,765 hospital patients.",2020-10-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,,Taipei,"The residual specimens obtained from routine laboratory blood tests for outpatient and emergency department patients visiting Taipei Veterans General Hospital, Taipei, Taiwan",,2020-05-25,2020-07-08,Residual sera,All,Multiple groups,40.0,49.0,Age,age 40-49,1536,0.0007000000000000001,0.0,0.0036,,,,,,Sequential,"Academia Sinica ELISA assay,Elecsys® Anti‐SARS‐CoV‐2 (N)","Academia Sinica,Roche Diagnostics",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Hsiang-Ling Ho,Taipei Veterans General Hospital,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2020.100041,2021-07-16,2024-03-01,Verified,ho_seroprevalence_2020,CHN
201010_Taipei_TaipeiVeteransGeneralHospital_50-59,201010_Taipei_TaipeiVeteransGeneralHospital,"Seroprevalence of COVID-19 in Taiwan revealed by testing anti-SARS-CoV-2 serological antibodies on 14,765 hospital patients.",2020-10-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,,Taipei,"The residual specimens obtained from routine laboratory blood tests for outpatient and emergency department patients visiting Taipei Veterans General Hospital, Taipei, Taiwan",,2020-05-25,2020-07-08,Residual sera,All,Multiple groups,50.0,59.0,Age,age 50-59,2762,0.0004,0.0,0.002,,,,,,Sequential,"Academia Sinica ELISA assay,Elecsys® Anti‐SARS‐CoV‐2 (N)","Academia Sinica,Roche Diagnostics",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Hsiang-Ling Ho,Taipei Veterans General Hospital,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2020.100041,2021-07-16,2024-03-01,Verified,ho_seroprevalence_2020,CHN
201010_Taipei_TaipeiVeteransGeneralHospital_male,201010_Taipei_TaipeiVeteransGeneralHospital,"Seroprevalence of COVID-19 in Taiwan revealed by testing anti-SARS-CoV-2 serological antibodies on 14,765 hospital patients.",2020-10-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,,Taipei,"The residual specimens obtained from routine laboratory blood tests for outpatient and emergency department patients visiting Taipei Veterans General Hospital, Taipei, Taiwan",,2020-05-25,2020-07-08,Residual sera,Male,Multiple groups,20.0,,Sex/Gender,,7290,0.001,0.0004,0.002,,,,,,Sequential,"Academia Sinica ELISA assay,Elecsys® Anti‐SARS‐CoV‐2 (N)","Academia Sinica,Roche Diagnostics",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Hsiang-Ling Ho,Taipei Veterans General Hospital,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2020.100041,2021-07-16,2024-03-01,Verified,ho_seroprevalence_2020,CHN
201010_Taipei_TaipeiVeteransGeneralHospital_Elecsys,201010_Taipei_TaipeiVeteransGeneralHospital,"Seroprevalence of COVID-19 in Taiwan revealed by testing anti-SARS-CoV-2 serological antibodies on 14,765 hospital patients.",2020-10-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,,Taipei,"The residual specimens obtained from routine laboratory blood tests for outpatient and emergency department patients visiting Taipei Veterans General Hospital, Taipei, Taiwan",,2020-05-25,2020-07-08,Residual sera,All,Multiple groups,20.0,,Test used,Elecsys assay only,14765,0.0017000000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,,0.998,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Hsiang-Ling Ho,Taipei Veterans General Hospital,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2020.100041,2021-07-16,2024-03-01,Verified,ho_seroprevalence_2020,CHN
201010_Taipei_TaipeiVeteransGeneralHospital_90+,201010_Taipei_TaipeiVeteransGeneralHospital,"Seroprevalence of COVID-19 in Taiwan revealed by testing anti-SARS-CoV-2 serological antibodies on 14,765 hospital patients.",2020-10-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,,Taipei,"The residual specimens obtained from routine laboratory blood tests for outpatient and emergency department patients visiting Taipei Veterans General Hospital, Taipei, Taiwan",,2020-05-25,2020-07-08,Residual sera,All,Multiple groups,90.0,,Age,age 90+,564,0.0034999999999999996,0.0004,0.012700000000000001,,,,,,Sequential,"Academia Sinica ELISA assay,Elecsys® Anti‐SARS‐CoV‐2 (N)","Academia Sinica,Roche Diagnostics",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Hsiang-Ling Ho,Taipei Veterans General Hospital,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2020.100041,2021-07-16,2024-03-01,Verified,ho_seroprevalence_2020,CHN
201010_Taipei_TaipeiVeteransGeneralHospital_age30-39,201010_Taipei_TaipeiVeteransGeneralHospital,"Seroprevalence of COVID-19 in Taiwan revealed by testing anti-SARS-CoV-2 serological antibodies on 14,765 hospital patients.",2020-10-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,,Taipei,"The residual specimens obtained from routine laboratory blood tests for outpatient and emergency department patients visiting Taipei Veterans General Hospital, Taipei, Taiwan",,2020-05-25,2020-07-08,Residual sera,All,Multiple groups,30.0,39.0,Age,age 30-39,1070,0.0009,0.0,0.005200000000000001,,,,,,Sequential,"Academia Sinica ELISA assay,Elecsys® Anti‐SARS‐CoV‐2 (N)","Academia Sinica,Roche Diagnostics",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Hsiang-Ling Ho,Taipei Veterans General Hospital,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2020.100041,2021-07-16,2024-03-01,Verified,ho_seroprevalence_2020,CHN
201010_Taipei_TaipeiVeteransGeneralHospital_period1,201010_Taipei_TaipeiVeteransGeneralHospital,"Seroprevalence of COVID-19 in Taiwan revealed by testing anti-SARS-CoV-2 serological antibodies on 14,765 hospital patients.",2020-10-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,,Taipei,"The residual specimens obtained from routine laboratory blood tests for outpatient and emergency department patients visiting Taipei Veterans General Hospital, Taipei, Taiwan",,2020-05-25,2020-05-30,Residual sera,All,Multiple groups,20.0,,Time frame,Study period 1,9777,0.0007000000000000001,0.0003,0.0015,,,,,,Sequential,"Academia Sinica ELISA assay,Elecsys® Anti‐SARS‐CoV‐2 (N)","Academia Sinica,Roche Diagnostics",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Hsiang-Ling Ho,Taipei Veterans General Hospital,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2020.100041,2021-07-16,2024-03-01,Verified,ho_seroprevalence_2020,CHN
201010_Taipei_TaipeiVeteransGeneralHospital_80-89,201010_Taipei_TaipeiVeteransGeneralHospital,"Seroprevalence of COVID-19 in Taiwan revealed by testing anti-SARS-CoV-2 serological antibodies on 14,765 hospital patients.",2020-10-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,,Taipei,"The residual specimens obtained from routine laboratory blood tests for outpatient and emergency department patients visiting Taipei Veterans General Hospital, Taipei, Taiwan",,2020-05-25,2020-07-08,Residual sera,All,Multiple groups,80.0,89.0,Age,age 80-89,1546,0.0006,0.0,0.0036,,,,,,Sequential,"Academia Sinica ELISA assay,Elecsys® Anti‐SARS‐CoV‐2 (N)","Academia Sinica,Roche Diagnostics",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Hsiang-Ling Ho,Taipei Veterans General Hospital,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2020.100041,2021-07-16,2024-03-01,Verified,ho_seroprevalence_2020,CHN
201010_Taipei_TaipeiVeteransGeneralHospital_60-69,201010_Taipei_TaipeiVeteransGeneralHospital,"Seroprevalence of COVID-19 in Taiwan revealed by testing anti-SARS-CoV-2 serological antibodies on 14,765 hospital patients.",2020-10-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,,Taipei,"The residual specimens obtained from routine laboratory blood tests for outpatient and emergency department patients visiting Taipei Veterans General Hospital, Taipei, Taiwan",,2020-05-25,2020-07-08,Residual sera,All,Multiple groups,60.0,69.0,Age,age 60-69,3847,0.001,0.0003,0.0027,,,,,,Sequential,"Academia Sinica ELISA assay,Elecsys® Anti‐SARS‐CoV‐2 (N)","Academia Sinica,Roche Diagnostics",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Hsiang-Ling Ho,Taipei Veterans General Hospital,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2020.100041,2021-07-16,2024-03-01,Verified,ho_seroprevalence_2020,CHN
201010_Taipei_TaipeiVeteransGeneralHospital_period2,201010_Taipei_TaipeiVeteransGeneralHospital,"Seroprevalence of COVID-19 in Taiwan revealed by testing anti-SARS-CoV-2 serological antibodies on 14,765 hospital patients.",2020-10-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,,Taipei,"The residual specimens obtained from routine laboratory blood tests for outpatient and emergency department patients visiting Taipei Veterans General Hospital, Taipei, Taiwan",,2020-07-06,2020-07-08,Residual sera,All,Multiple groups,20.0,,Time frame,Study period 2,4988,0.0008,0.0002,0.002,,,,,,Sequential,"Academia Sinica ELISA assay,Elecsys® Anti‐SARS‐CoV‐2 (N)","Academia Sinica,Roche Diagnostics",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Hsiang-Ling Ho,Taipei Veterans General Hospital,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2020.100041,2021-07-16,2024-03-01,Verified,ho_seroprevalence_2020,CHN
201010_Taipei_TaipeiVeteransGeneralHospital_unadj,201010_Taipei_TaipeiVeteransGeneralHospital,"Seroprevalence of COVID-19 in Taiwan revealed by testing anti-SARS-CoV-2 serological antibodies on 14,765 hospital patients.",2020-10-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,,Taipei,"The residual specimens obtained from routine laboratory blood tests for outpatient and emergency department patients visiting Taipei Veterans General Hospital, Taipei, Taiwan",,2020-05-25,2020-07-08,Residual sera,All,Multiple groups,20.0,,Analysis,,14765,0.0007000000000000001,0.0004,0.0013000000000000002,,,,,True,Sequential,"Academia Sinica ELISA assay,Elecsys® Anti‐SARS‐CoV‐2 (N)","Academia Sinica,Roche Diagnostics",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Hsiang-Ling Ho,Taipei Veterans General Hospital,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2020.100041,2021-07-07,2024-03-01,Verified,ho_seroprevalence_2020,CHN
201010_Taipei_TaipeiVeteransGeneralHospital_70-79,201010_Taipei_TaipeiVeteransGeneralHospital,"Seroprevalence of COVID-19 in Taiwan revealed by testing anti-SARS-CoV-2 serological antibodies on 14,765 hospital patients.",2020-10-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,,Taipei,"The residual specimens obtained from routine laboratory blood tests for outpatient and emergency department patients visiting Taipei Veterans General Hospital, Taipei, Taiwan",,2020-05-25,2020-07-08,Residual sera,All,Multiple groups,70.0,79.0,Age,age 70-79,2823,0.0004,0.0,0.002,,,,,,Sequential,"Academia Sinica ELISA assay,Elecsys® Anti‐SARS‐CoV‐2 (N)","Academia Sinica,Roche Diagnostics",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Hsiang-Ling Ho,Taipei Veterans General Hospital,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2020.100041,2021-07-16,2024-03-01,Verified,ho_seroprevalence_2020,CHN
201010_Taipei_TaipeiVeteransGeneralHospital_female,201010_Taipei_TaipeiVeteransGeneralHospital,"Seroprevalence of COVID-19 in Taiwan revealed by testing anti-SARS-CoV-2 serological antibodies on 14,765 hospital patients.",2020-10-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,,Taipei,"The residual specimens obtained from routine laboratory blood tests for outpatient and emergency department patients visiting Taipei Veterans General Hospital, Taipei, Taiwan",,2020-05-25,2020-07-08,Residual sera,Female,Multiple groups,20.0,,Sex/Gender,,7475,0.0005,0.0001,0.0014000000000000002,,,,,,Sequential,"Academia Sinica ELISA assay,Elecsys® Anti‐SARS‐CoV‐2 (N)","Academia Sinica,Roche Diagnostics",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Hsiang-Ling Ho,Taipei Veterans General Hospital,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2020.100041,2021-07-16,2024-03-01,Verified,ho_seroprevalence_2020,CHN
201010_Taipei_TaipeiVeteransGeneralHospital_age20-29,201010_Taipei_TaipeiVeteransGeneralHospital,"Seroprevalence of COVID-19 in Taiwan revealed by testing anti-SARS-CoV-2 serological antibodies on 14,765 hospital patients.",2020-10-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,,Taipei,"The residual specimens obtained from routine laboratory blood tests for outpatient and emergency department patients visiting Taipei Veterans General Hospital, Taipei, Taiwan",,2020-05-25,2020-07-08,Residual sera,All,Multiple groups,20.0,29.0,Age,age 20-29,617,0.0,0.0,0.006,,,,,,Sequential,"Academia Sinica ELISA assay,Elecsys® Anti‐SARS‐CoV‐2 (N)","Academia Sinica,Roche Diagnostics",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Hsiang-Ling Ho,Taipei Veterans General Hospital,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2020.100041,2021-07-16,2024-03-01,Verified,ho_seroprevalence_2020,CHN
201023_Wuhan_HuazhongUniversityofScienceandTechnology_Overall_unadj,201023_Wuhan_HuazhongUniversityofScienceandTechnology,"Seropositive Prevalence of Antibodies Against SARS-CoV-2 in Wuhan, China",2020-10-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"Healthy community residents and employees who underwent SARS-CoV-2 nucleic acid test of nasal swabs, CT scan and SARS-CoV-2 specific serological tests. None of the participants had a history of COVID-19.",,2020-03-27,2020-05-26,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,primary estimate,35040,0.039,0.037000000000000005,0.040999999999999995,True,,,,True,Unclear,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],Yes,Unclear,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anding Liu,Huazhong University of Science and Technology,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2020.25717,2021-01-23,2023-07-04,Verified,liu_seropositive_2020,CHN
201023_Wuhan_HuazhongUniversityofScienceandTechnology_Female_unadj,201023_Wuhan_HuazhongUniversityofScienceandTechnology,"Seropositive Prevalence of Antibodies Against SARS-CoV-2 in Wuhan, China",2020-10-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"Healthy community residents and employees who underwent SARS-CoV-2 nucleic acid test of nasal swabs, CT scan and SARS-CoV-2 specific serological tests. None of the participants had a history of COVID-19.",,2020-03-27,2020-05-26,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,Female,17771,0.044000000000000004,0.040999999999999995,0.046,,,,,,Unclear,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],Yes,Unclear,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anding Liu,Huazhong University of Science and Technology,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2020.25717,2021-01-23,2023-07-04,Verified,liu_seropositive_2020,CHN
201023_Wuhan_HuazhongUniversityofScienceandTechnology_Male_unadj,201023_Wuhan_HuazhongUniversityofScienceandTechnology,"Seropositive Prevalence of Antibodies Against SARS-CoV-2 in Wuhan, China",2020-10-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"Healthy community residents and employees who underwent SARS-CoV-2 nucleic acid test of nasal swabs, CT scan and SARS-CoV-2 specific serological tests. None of the participants had a history of COVID-19.",,2020-03-27,2020-05-26,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,17269,0.033,0.031000000000000003,0.036000000000000004,,,,,,Unclear,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],Yes,Unclear,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anding Liu,Huazhong University of Science and Technology,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2020.25717,2021-01-23,2023-07-04,Verified,liu_seropositive_2020,CHN
201023_Wuhan_HuazhongUniversityofScienceandTechnology_40-49_unadj,201023_Wuhan_HuazhongUniversityofScienceandTechnology,"Seropositive Prevalence of Antibodies Against SARS-CoV-2 in Wuhan, China",2020-10-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"Healthy community residents and employees who underwent SARS-CoV-2 nucleic acid test of nasal swabs, CT scan and SARS-CoV-2 specific serological tests. None of the participants had a history of COVID-19.",,2020-03-27,2020-05-26,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,7713,0.040999999999999995,0.036000000000000004,0.045,,,,,,Unclear,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],Yes,Unclear,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anding Liu,Huazhong University of Science and Technology,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2020.25717,2021-01-23,2023-07-04,Verified,liu_seropositive_2020,CHN
201023_Wuhan_HuazhongUniversityofScienceandTechnology_>60_unadj,201023_Wuhan_HuazhongUniversityofScienceandTechnology,"Seropositive Prevalence of Antibodies Against SARS-CoV-2 in Wuhan, China",2020-10-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"Healthy community residents and employees who underwent SARS-CoV-2 nucleic acid test of nasal swabs, CT scan and SARS-CoV-2 specific serological tests. None of the participants had a history of COVID-19.",,2020-03-27,2020-05-26,Household and community samples,All,Seniors (65+ years),61.0,,Age,>60 ,761,0.092,0.071,0.113,,,,,,Unclear,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],Yes,Unclear,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anding Liu,Huazhong University of Science and Technology,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2020.25717,2021-01-23,2023-07-04,Verified,liu_seropositive_2020,CHN
201023_Wuhan_HuazhongUniversityofScienceandTechnology_50-59_unadj,201023_Wuhan_HuazhongUniversityofScienceandTechnology,"Seropositive Prevalence of Antibodies Against SARS-CoV-2 in Wuhan, China",2020-10-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"Healthy community residents and employees who underwent SARS-CoV-2 nucleic acid test of nasal swabs, CT scan and SARS-CoV-2 specific serological tests. None of the participants had a history of COVID-19.",,2020-03-27,2020-05-26,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,4932,0.045,0.039,0.051,,,,,,Unclear,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],Yes,Unclear,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anding Liu,Huazhong University of Science and Technology,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2020.25717,2021-01-23,2023-07-04,Verified,liu_seropositive_2020,CHN
201023_Wuhan_HuazhongUniversityofScienceandTechnology_18-29_unadj,201023_Wuhan_HuazhongUniversityofScienceandTechnology,"Seropositive Prevalence of Antibodies Against SARS-CoV-2 in Wuhan, China",2020-10-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"Healthy community residents and employees who underwent SARS-CoV-2 nucleic acid test of nasal swabs, CT scan and SARS-CoV-2 specific serological tests. None of the participants had a history of COVID-19.",,2020-03-27,2020-05-26,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,18-29 ,8163,0.027999999999999997,0.025,0.032,,,,,,Unclear,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],Yes,Unclear,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anding Liu,Huazhong University of Science and Technology,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2020.25717,2021-01-23,2023-07-04,Verified,liu_seropositive_2020,CHN
201023_Wuhan_HuazhongUniversityofScienceandTechnology_30-39_unadj,201023_Wuhan_HuazhongUniversityofScienceandTechnology,"Seropositive Prevalence of Antibodies Against SARS-CoV-2 in Wuhan, China",2020-10-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"Healthy community residents and employees who underwent SARS-CoV-2 nucleic acid test of nasal swabs, CT scan and SARS-CoV-2 specific serological tests. None of the participants had a history of COVID-19.",,2020-03-27,2020-05-26,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,13471,0.039,0.036000000000000004,0.042,,,,,,Unclear,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],Yes,Unclear,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anding Liu,Huazhong University of Science and Technology,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2020.25717,2021-01-23,2023-07-04,Verified,liu_seropositive_2020,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_HealthCareWorkers_IgG,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_1_HCW,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,"Healthcare providers (doctors, nurses, and nursing workers) without a confirmed COVID-19 diagnosis working in Zhongnan Hospital of Wuhan University who received these tests before resuming normal clinical services for patients without COVID-19",,2020-02-29,2020-04-29,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,3832,0.04,0.034,0.047,True,,,,True,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-06-18,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_HealthCareWorkers_IgG_Age50to59,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_1_HCW,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,"Healthcare providers (doctors, nurses, and nursing workers) without a confirmed COVID-19 diagnosis working in Zhongnan Hospital of Wuhan University who received these tests before resuming normal clinical services for patients without COVID-19",,2020-02-29,2020-04-29,Health care workers and caregivers,All,Adults (18-64 years),50.0,59.0,Age,50-59,600,0.055,0.037000000000000005,0.073,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-29,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_HealthCareWorkers_IgM_Age40to49,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_1_HCW,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,"Healthcare providers (doctors, nurses, and nursing workers) without a confirmed COVID-19 diagnosis working in Zhongnan Hospital of Wuhan University who received these tests before resuming normal clinical services for patients without COVID-19",,2020-02-29,2020-04-29,Health care workers and caregivers,All,Adults (18-64 years),40.0,49.0,Age,40-49,607,0.021,0.01,0.033,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgM,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_HealthCareWorkers_IgM_Age60to69,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_1_HCW,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,"Healthcare providers (doctors, nurses, and nursing workers) without a confirmed COVID-19 diagnosis working in Zhongnan Hospital of Wuhan University who received these tests before resuming normal clinical services for patients without COVID-19",,2020-02-29,2020-04-29,Health care workers and caregivers,All,Adults (18-64 years),60.0,69.0,Age,60-69,114,0.026000000000000002,0.0,0.055999999999999994,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgM,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_HealthCareWorkers_IgG_AgeLess30,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_1_HCW,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,"Healthcare providers (doctors, nurses, and nursing workers) without a confirmed COVID-19 diagnosis working in Zhongnan Hospital of Wuhan University who received these tests before resuming normal clinical services for patients without COVID-19",,2020-02-29,2020-04-29,Health care workers and caregivers,All,Adults (18-64 years),,30.0,Age,<30,1236,0.027999999999999997,0.019,0.038,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-29,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_HealthCareWorkers_IgG_Age70orMore,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_1_HCW,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,"Healthcare providers (doctors, nurses, and nursing workers) without a confirmed COVID-19 diagnosis working in Zhongnan Hospital of Wuhan University who received these tests before resuming normal clinical services for patients without COVID-19",,2020-02-29,2020-04-29,Health care workers and caregivers,All,Seniors (65+ years),70.0,,Age,>=70,10,0.1,0.0,0.326,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-29,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_HealthCareWorkers_IgM_Age50to59,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_1_HCW,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,"Healthcare providers (doctors, nurses, and nursing workers) without a confirmed COVID-19 diagnosis working in Zhongnan Hospital of Wuhan University who received these tests before resuming normal clinical services for patients without COVID-19",,2020-02-29,2020-04-29,Health care workers and caregivers,All,Adults (18-64 years),50.0,59.0,Age,50-59,600,0.02,0.009000000000000001,0.031000000000000003,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgM,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_HealthCareWorkers_IgG_Age40to49,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_1_HCW,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,"Healthcare providers (doctors, nurses, and nursing workers) without a confirmed COVID-19 diagnosis working in Zhongnan Hospital of Wuhan University who received these tests before resuming normal clinical services for patients without COVID-19",,2020-02-29,2020-04-29,Health care workers and caregivers,All,Adults (18-64 years),40.0,49.0,Age,40-49,607,0.044000000000000004,0.027999999999999997,0.061,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-29,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_HealthCareWorkers_IgM_Age30to39,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_1_HCW,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,"Healthcare providers (doctors, nurses, and nursing workers) without a confirmed COVID-19 diagnosis working in Zhongnan Hospital of Wuhan University who received these tests before resuming normal clinical services for patients without COVID-19",,2020-02-29,2020-04-29,Health care workers and caregivers,All,Adults (18-64 years),30.0,39.0,Age,30-39,1265,0.012,0.006,0.018000000000000002,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgM,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_HealthCareWorkers_IgG_Age30to39,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_1_HCW,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,"Healthcare providers (doctors, nurses, and nursing workers) without a confirmed COVID-19 diagnosis working in Zhongnan Hospital of Wuhan University who received these tests before resuming normal clinical services for patients without COVID-19",,2020-02-29,2020-04-29,Health care workers and caregivers,All,Adults (18-64 years),30.0,39.0,Age,30-39,1265,0.038,0.027000000000000003,0.048,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-29,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_HealthCareWorkers_IgM_AgeLess30,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_1_HCW,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,"Healthcare providers (doctors, nurses, and nursing workers) without a confirmed COVID-19 diagnosis working in Zhongnan Hospital of Wuhan University who received these tests before resuming normal clinical services for patients without COVID-19",,2020-02-29,2020-04-29,Health care workers and caregivers,All,Adults (18-64 years),,30.0,Age,<30,1236,0.011000000000000001,0.005,0.016,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgM,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_HealthCareWorkers_IgG_Age60to69,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_1_HCW,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,"Healthcare providers (doctors, nurses, and nursing workers) without a confirmed COVID-19 diagnosis working in Zhongnan Hospital of Wuhan University who received these tests before resuming normal clinical services for patients without COVID-19",,2020-02-29,2020-04-29,Health care workers and caregivers,All,Adults (18-64 years),60.0,69.0,Age,60-69,114,0.096,0.040999999999999995,0.152,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-29,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_HealthCareWorkers_IgM_Age70orMore,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_1_HCW,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,"Healthcare providers (doctors, nurses, and nursing workers) without a confirmed COVID-19 diagnosis working in Zhongnan Hospital of Wuhan University who received these tests before resuming normal clinical services for patients without COVID-19",,2020-02-29,2020-04-29,Health care workers and caregivers,All,Seniors (65+ years),70.0,,Age,>=70,10,0.0,0.0,0.0,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgM,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_GenPopWorkers_IgG,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_2_Genpop,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,General workers in Wuhan before returning to work,Without a confirmed diagnosis of COVID-19,2020-02-29,2020-04-29,Household and community samples,All,Multiple groups,,,Primary Estimate,,19555,0.046,0.043,0.049,True,,,,True,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-06-18,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_GenPopWorkers_IgG_Age50to59,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_2_Genpop,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,General workers in Wuhan before returning to work,Without a confirmed diagnosis of COVID-19,2020-02-29,2020-04-29,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,4031,0.048,0.040999999999999995,0.054000000000000006,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_GenPopWorkers_IgM_Age30to39,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_2_Genpop,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,General workers in Wuhan before returning to work,Without a confirmed diagnosis of COVID-19,2020-02-29,2020-04-29,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,6068,0.01,0.006999999999999999,0.012,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgM,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_GenPopWorkers_IgG_AgeLess30,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_2_Genpop,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,General workers in Wuhan before returning to work,Without a confirmed diagnosis of COVID-19,2020-02-29,2020-04-29,Household and community samples,All,Adults (18-64 years),,30.0,Age,<30,3960,0.035,0.028999999999999998,0.040999999999999995,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_GenPopWorkers_IgG_Female,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_2_Genpop,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,General workers in Wuhan before returning to work,Without a confirmed diagnosis of COVID-19,2020-02-29,2020-04-29,Household and community samples,Female,Multiple groups,,,Sex/Gender,Female ,9735,0.05,0.045,0.054000000000000006,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_GenPopWorkers_IgG_Age30to39,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_2_Genpop,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,General workers in Wuhan before returning to work,Without a confirmed diagnosis of COVID-19,2020-02-29,2020-04-29,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,6068,0.047,0.042,0.053,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_GenPopWorkers_IgG_Age60to69,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_2_Genpop,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,General workers in Wuhan before returning to work,Without a confirmed diagnosis of COVID-19,2020-02-29,2020-04-29,Household and community samples,All,Adults (18-64 years),60.0,69.0,Age,60-69,1315,0.068,0.054000000000000006,0.081,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_GenPopWorkers_IgM_Age70ormore,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_2_Genpop,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,General workers in Wuhan before returning to work,Without a confirmed diagnosis of COVID-19,2020-02-29,2020-04-29,Household and community samples,All,Seniors (65+ years),70.0,,Age,>=70,493,0.024,0.011000000000000001,0.038,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgM,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_GenPopWorkers_IgG_Age70ormore,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_2_Genpop,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,General workers in Wuhan before returning to work,Without a confirmed diagnosis of COVID-19,2020-02-29,2020-04-29,Household and community samples,All,Seniors (65+ years),70.0,,Age,>=70,493,0.059000000000000004,0.038,0.08,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_GenPopWorkers_IgM_Male,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_2_Genpop,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,General workers in Wuhan before returning to work,Without a confirmed diagnosis of COVID-19,2020-02-29,2020-04-29,Household and community samples,Male,Multiple groups,,,Sex/Gender,Male,9820,0.009000000000000001,0.006999999999999999,0.011000000000000001,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgM,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_GenPopWorkers_IgG_Age40to49,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_2_Genpop,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,General workers in Wuhan before returning to work,Without a confirmed diagnosis of COVID-19,2020-02-29,2020-04-29,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,3688,0.046,0.039,0.053,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_GenPopWorkers_IgM_AgeLess30,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_2_Genpop,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,General workers in Wuhan before returning to work,Without a confirmed diagnosis of COVID-19,2020-02-29,2020-04-29,Household and community samples,All,Adults (18-64 years),,30.0,Age,<30,3960,0.006999999999999999,0.004,0.01,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgM,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_GenPopWorkers_IgM_Female,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_2_Genpop,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,General workers in Wuhan before returning to work,Without a confirmed diagnosis of COVID-19,2020-02-29,2020-04-29,Household and community samples,Female,Multiple groups,,,Sex/Gender,Female ,9735,0.017,0.013999999999999999,0.019,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgM,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_GenPopWorkers_IgM_Age60to69,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_2_Genpop,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,General workers in Wuhan before returning to work,Without a confirmed diagnosis of COVID-19,2020-02-29,2020-04-29,Household and community samples,All,Adults (18-64 years),60.0,69.0,Age,60-69,1315,0.017,0.01,0.025,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgM,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_GenPopWorkers_IgM_Age50to59,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_2_Genpop,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,General workers in Wuhan before returning to work,Without a confirmed diagnosis of COVID-19,2020-02-29,2020-04-29,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,4031,0.017,0.013000000000000001,0.021,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgM,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_GenPopWorkers_IgG_Male,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_2_Genpop,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,General workers in Wuhan before returning to work,Without a confirmed diagnosis of COVID-19,2020-02-29,2020-04-29,Household and community samples,Male,Multiple groups,,,Sex/Gender,Male,9820,0.043,0.039,0.047,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_GenPopWorkers_IgM_Age40to49,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_2_Genpop,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,General workers in Wuhan before returning to work,Without a confirmed diagnosis of COVID-19,2020-02-29,2020-04-29,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,3688,0.017,0.013000000000000001,0.021,,,,,,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgM,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_NonCOVIDPatients_IgG,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_3_patients,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,Patients without a confirmed COVID-19 diagnosis who received these screening tests before being admitted to Zhongnan Hospital of Wuhan University.,Excluded 133 patients with COVID-19 whose IgM/IgG tests were less than 21 days after symptom onset to allow enough time for IgG antibodies against SARS-CoV-2 to develop.,2020-02-29,2020-04-29,Residual sera,All,Multiple groups,,,Primary Estimate,,1616,0.01,0.005,0.015,True,,,,True,Sequential,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-06-18,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_NonCOVIDPatients_IgG_Age70tomore,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_3_patients,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,Patients without a confirmed COVID-19 diagnosis who received these screening tests before being admitted to Zhongnan Hospital of Wuhan University.,Excluded 133 patients with COVID-19 whose IgM/IgG tests were less than 21 days after symptom onset to allow enough time for IgG antibodies against SARS-CoV-2 to develop.,2020-02-29,2020-04-29,Residual sera,All,Seniors (65+ years),70.0,,Age,>=70,241,0.021,0.003,0.039,,,,,,Sequential,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_NonCOVIDPatients_IgG_Age30orless,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_3_patients,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,Patients without a confirmed COVID-19 diagnosis who received these screening tests before being admitted to Zhongnan Hospital of Wuhan University.,Excluded 133 patients with COVID-19 whose IgM/IgG tests were less than 21 days after symptom onset to allow enough time for IgG antibodies against SARS-CoV-2 to develop.,2020-02-29,2020-04-29,Residual sera,All,Adults (18-64 years),,30.0,Age,<30,154,0.0,0.0,0.0,,,,,,Sequential,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_NonCOVIDPatients_IgG_Female,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_3_patients,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,Patients without a confirmed COVID-19 diagnosis who received these screening tests before being admitted to Zhongnan Hospital of Wuhan University.,Excluded 133 patients with COVID-19 whose IgM/IgG tests were less than 21 days after symptom onset to allow enough time for IgG antibodies against SARS-CoV-2 to develop.,2020-02-29,2020-04-29,Residual sera,Female,Multiple groups,,,Sex/Gender,Female ,708,0.01,0.003,0.017,,,,,,Sequential,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_NonCOVIDPatients_IgM_Male,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_3_patients,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,Patients without a confirmed COVID-19 diagnosis who received these screening tests before being admitted to Zhongnan Hospital of Wuhan University.,Excluded 133 patients with COVID-19 whose IgM/IgG tests were less than 21 days after symptom onset to allow enough time for IgG antibodies against SARS-CoV-2 to develop.,2020-02-29,2020-04-29,Residual sera,Male,Multiple groups,,,Sex/Gender,Male,908,0.002,0.0,0.005,,,,,,Sequential,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgM,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_NonCOVIDPatients_IgM_Age70tomore,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_3_patients,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,Patients without a confirmed COVID-19 diagnosis who received these screening tests before being admitted to Zhongnan Hospital of Wuhan University.,Excluded 133 patients with COVID-19 whose IgM/IgG tests were less than 21 days after symptom onset to allow enough time for IgG antibodies against SARS-CoV-2 to develop.,2020-02-29,2020-04-29,Residual sera,All,Seniors (65+ years),70.0,,Age,>=70,241,0.0,0.0,0.0,,,,,,Sequential,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgM,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_NonCOVIDPatients_IgM_Age30orless,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_3_patients,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,Patients without a confirmed COVID-19 diagnosis who received these screening tests before being admitted to Zhongnan Hospital of Wuhan University.,Excluded 133 patients with COVID-19 whose IgM/IgG tests were less than 21 days after symptom onset to allow enough time for IgG antibodies against SARS-CoV-2 to develop.,2020-02-29,2020-04-29,Residual sera,All,Adults (18-64 years),,30.0,Age,<30,154,0.0,0.0,0.0,,,,,,Sequential,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgM,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_NonCOVIDPatients_IgM_Age40to49,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_3_patients,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,Patients without a confirmed COVID-19 diagnosis who received these screening tests before being admitted to Zhongnan Hospital of Wuhan University.,Excluded 133 patients with COVID-19 whose IgM/IgG tests were less than 21 days after symptom onset to allow enough time for IgG antibodies against SARS-CoV-2 to develop.,2020-02-29,2020-04-29,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,239,0.004,0.0,0.012,,,,,,Sequential,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgM,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_NonCOVIDPatients_IgG_Age50to59,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_3_patients,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,Patients without a confirmed COVID-19 diagnosis who received these screening tests before being admitted to Zhongnan Hospital of Wuhan University.,Excluded 133 patients with COVID-19 whose IgM/IgG tests were less than 21 days after symptom onset to allow enough time for IgG antibodies against SARS-CoV-2 to develop.,2020-02-29,2020-04-29,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,459,0.006999999999999999,0.0,0.013999999999999999,,,,,,Sequential,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_NonCOVIDPatients_IgG_Age40to49,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_3_patients,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,Patients without a confirmed COVID-19 diagnosis who received these screening tests before being admitted to Zhongnan Hospital of Wuhan University.,Excluded 133 patients with COVID-19 whose IgM/IgG tests were less than 21 days after symptom onset to allow enough time for IgG antibodies against SARS-CoV-2 to develop.,2020-02-29,2020-04-29,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,239,0.013000000000000001,0.0,0.027000000000000003,,,,,,Sequential,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_NonCOVIDPatients_IgG_Age60to69,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_3_patients,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,Patients without a confirmed COVID-19 diagnosis who received these screening tests before being admitted to Zhongnan Hospital of Wuhan University.,Excluded 133 patients with COVID-19 whose IgM/IgG tests were less than 21 days after symptom onset to allow enough time for IgG antibodies against SARS-CoV-2 to develop.,2020-02-29,2020-04-29,Residual sera,All,Adults (18-64 years),60.0,69.0,Age,60-69,357,0.011000000000000001,0.0,0.022000000000000002,,,,,,Sequential,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_NonCOVIDPatients_IgM_Age60to69,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_3_patients,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,Patients without a confirmed COVID-19 diagnosis who received these screening tests before being admitted to Zhongnan Hospital of Wuhan University.,Excluded 133 patients with COVID-19 whose IgM/IgG tests were less than 21 days after symptom onset to allow enough time for IgG antibodies against SARS-CoV-2 to develop.,2020-02-29,2020-04-29,Residual sera,All,Adults (18-64 years),60.0,69.0,Age,60-69,357,0.006,0.0,0.013000000000000001,,,,,,Sequential,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgM,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_NonCOVIDPatients_IgM_Age30to39,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_3_patients,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,Patients without a confirmed COVID-19 diagnosis who received these screening tests before being admitted to Zhongnan Hospital of Wuhan University.,Excluded 133 patients with COVID-19 whose IgM/IgG tests were less than 21 days after symptom onset to allow enough time for IgG antibodies against SARS-CoV-2 to develop.,2020-02-29,2020-04-29,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,166,0.0,0.0,0.0,,,,,,Sequential,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgM,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_NonCOVIDPatients_IgM_Age50to59,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_3_patients,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,Patients without a confirmed COVID-19 diagnosis who received these screening tests before being admitted to Zhongnan Hospital of Wuhan University.,Excluded 133 patients with COVID-19 whose IgM/IgG tests were less than 21 days after symptom onset to allow enough time for IgG antibodies against SARS-CoV-2 to develop.,2020-02-29,2020-04-29,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,459,0.0,0.0,0.0,,,,,,Sequential,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgM,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_NonCOVIDPatients_IgG_Age30to39,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_3_patients,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,Patients without a confirmed COVID-19 diagnosis who received these screening tests before being admitted to Zhongnan Hospital of Wuhan University.,Excluded 133 patients with COVID-19 whose IgM/IgG tests were less than 21 days after symptom onset to allow enough time for IgG antibodies against SARS-CoV-2 to develop.,2020-02-29,2020-04-29,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,166,0.006,0.0,0.018000000000000002,,,,,,Sequential,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_NonCOVIDPatients_IgG_Male,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_3_patients,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,Patients without a confirmed COVID-19 diagnosis who received these screening tests before being admitted to Zhongnan Hospital of Wuhan University.,Excluded 133 patients with COVID-19 whose IgM/IgG tests were less than 21 days after symptom onset to allow enough time for IgG antibodies against SARS-CoV-2 to develop.,2020-02-29,2020-04-29,Residual sera,Male,Multiple groups,,,Sex/Gender,Male,908,0.01,0.003,0.016,,,,,,Sequential,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
200616_Wuhan_ZhongnanHospitalofWuhanUniversity_NonCOVIDPatients_IgM_Female,200616_Wuhan_ZhongnanHospitalofWuhanUniversity_3_patients,"Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan, Implications for the Longevity of Antibodies Against SARS-CoV-2",2020-11-02,Preprint,Local,Cross-sectional survey ,China,Hubei,Wuhan,Patients without a confirmed COVID-19 diagnosis who received these screening tests before being admitted to Zhongnan Hospital of Wuhan University.,Excluded 133 patients with COVID-19 whose IgM/IgG tests were less than 21 days after symptom onset to allow enough time for IgG antibodies against SARS-CoV-2 to develop.,2020-02-29,2020-04-29,Residual sera,Female,Multiple groups,,,Sex/Gender,Female ,708,0.001,0.0,0.004,,,,,,Sequential,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgM,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.978,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Tao Liu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-99748/v1,2020-07-30,2023-07-04,Verified,liu_prevalence_2020-1,CHN
201119_Shanghai_FudanUniversity_Overall,201119_Shanghai_FudanUniversity,Seroprevalence of antibodies to SARS-CoV-2 is particularly high in patient population with ocular surface diseases,2020-11-19,Preprint,Local,Cross-sectional survey ,China,Shanghai Municipality,Shanghai,This study included individuals with various ocular diseases in the Eye and ENT Hospital of Fudan University (Fenyang branch and Pujiang branch) from May to October 2020,,2020-05-15,2020-10-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,"All patients included in study, IgG OR IgM",6414,0.0031,,,True,,,,True,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,No,Unclear,Unclear,Yes,No,Unclear,Shengjie Li,Fudan University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.22.20198465v2,2020-11-30,2023-07-04,Verified,li_seroprevalence_2020-1,CHN
201225_Wuhan_RenminHospitalofWuhanUniversity_Community,201225_Wuhan_RenminHospitalofWuhanUniversity_Community,"Positive Rate of Serology and RT-PCR for COVID-19 between Community Residents and Healthcare Workers in Wuhan, China.",2020-12-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,Community residents of Wuhan,,2020-05-15,2020-05-29,Household and community samples,All,Multiple groups,,,Primary Estimate,Overall estimate IG,4454,0.028999999999999998,,,True,,,,True,Convenience,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,IgG,,,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Lu He,Renmin Hospital of Wuhan University,Unity-Aligned,https://dx.doi.org/10.7883/yoken.JJID.2020.691,2021-01-28,2024-03-01,Verified,he_positive_2020,CHN
201225_Wuhan_RenminHopsitalofWuhanUniversity_HCW,201225_Wuhan_RenminHospitalofWuhanUniversity_HCW,"Positive Rate of Serology and RT-PCR for COVID-19 between Community Residents and Healthcare Workers in Wuhan, China.",2020-12-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,Health care workers in a tertiary care hospital in Wuhan,,2020-05-15,2020-05-29,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Overall estimate IgG,4614,0.033,,,True,,,,True,Convenience,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,IgG,,,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Lu He,Renmin Hospital of Wuhan University,Not Unity-Aligned,https://dx.doi.org/10.7883/yoken.JJID.2020.691,2021-01-28,2024-03-01,Verified,he_positive_2020,CHN
201228_Beijing_CapitalMedicalUniversity_IgG,201228_Beijing_CapitalMedicalUniversity,Seroprevalence of SARS-CoV-2 infections among children visiting a hospital,2020-12-28,Journal Article (Peer-Reviewed),Local,Retrospective cohort,China,,Beijing,"To further implement the requirements of the Joint Prevention and Control Mechanism for COVID-19, Beijing Children’s Hospital has carried out SARS-CoV-2 nucleic acid and serum antibody tests for children who have a fever or require hospitalization. In this study, we retrospectively analyzed the anti-SARS-CoV-2 antibody results of these children",,2020-01-01,2020-08-31,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,,19797,0.0006,,,True,,,,True,Sequential,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,Yes,No,Yes,No,,Ran Wang,Capital Medical University ,Not Unity-Aligned,https://dx.doi.org/10.1002/ped4.12231,2021-01-31,2024-03-01,Verified,wang_seroprevalence_2020,CHN
210107_China_WuhanUniversity,210107_China_WuhanUniversity,Seroprevalence and asymptomatic carrier status of SARS-CoV-2 in Wuhan City and other places of China,2021-01-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,China,Hubei,,healthy individuals returning to work for a medical examination,,2020-03-06,2020-05-03,Essential non-healthcare workers,All,Multiple groups,,,Primary Estimate,workers,63107,0.0074,,,True,,,,True,Unclear,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,,"['IgG', 'IgM']",,,,,['High'],,Unclear,Yes,Yes,,No,Yes,No,,Shuhui Duan,Wuhan University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0008975,2021-02-07,2024-03-01,Unverified,duan_seroprevalence_2021,CHN
210107_China_WuhanUniversity_21-30years,210107_China_WuhanUniversity,Seroprevalence and asymptomatic carrier status of SARS-CoV-2 in Wuhan City and other places of China,2021-01-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,China,Hubei,,healthy individuals returning to work for a medical examination,,2020-03-06,2020-05-03,Essential non-healthcare workers,All,Adults (18-64 years),21.0,30.0,Age,workers,29428,0.0053,,,,,,,,Unclear,2019-nCoV IgG Rapid Test,Innovita Biological Technology Co. Ltd,LFIA,,IgG,,,,,['High'],,Unclear,Yes,Yes,,No,Yes,No,,Shuhui Duan,Wuhan University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0008975,2021-02-07,2023-07-04,Unverified,duan_seroprevalence_2021,CHN
210107_China_WuhanUniversity_20years,210107_China_WuhanUniversity,Seroprevalence and asymptomatic carrier status of SARS-CoV-2 in Wuhan City and other places of China,2021-01-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,China,Hubei,,healthy individuals returning to work for a medical examination,,2020-03-06,2020-05-03,Essential non-healthcare workers,All,Children and Youth (0-17 years),,20.0,Age,workers,2499,0.0036,,,,,,,,Unclear,2019-nCoV IgG Rapid Test,Innovita Biological Technology Co. Ltd,LFIA,,IgG,,,,,['High'],,Unclear,Yes,Yes,,No,Yes,No,,Shuhui Duan,Wuhan University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0008975,2021-02-07,2023-07-04,Unverified,duan_seroprevalence_2021,CHN
210107_China_WuhanUniversity_31-40years,210107_China_WuhanUniversity,Seroprevalence and asymptomatic carrier status of SARS-CoV-2 in Wuhan City and other places of China,2021-01-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,China,Hubei,,healthy individuals returning to work for a medical examination,,2020-03-06,2020-05-03,Essential non-healthcare workers,All,Adults (18-64 years),31.0,40.0,Age,workers,23099,0.0067,,,,,,,,Unclear,2019-nCoV IgG Rapid Test,Innovita Biological Technology Co. Ltd,LFIA,,IgG,,,,,['High'],,Unclear,Yes,Yes,,No,Yes,No,,Shuhui Duan,Wuhan University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0008975,2021-02-07,2023-07-04,Unverified,duan_seroprevalence_2021,CHN
210107_China_WuhanUniversity_41-50years,210107_China_WuhanUniversity,Seroprevalence and asymptomatic carrier status of SARS-CoV-2 in Wuhan City and other places of China,2021-01-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,China,Hubei,,healthy individuals returning to work for a medical examination,,2020-03-06,2020-05-03,Essential non-healthcare workers,All,Adults (18-64 years),41.0,50.0,Age,workers,5111,0.01,,,,,,,,Unclear,2019-nCoV IgG Rapid Test,Innovita Biological Technology Co. Ltd,LFIA,,IgG,,,,,['High'],,Unclear,Yes,Yes,,No,Yes,No,,Shuhui Duan,Wuhan University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0008975,2021-02-07,2023-07-04,Unverified,duan_seroprevalence_2021,CHN
210107_China_WuhanUniversity_50years,210107_China_WuhanUniversity,Seroprevalence and asymptomatic carrier status of SARS-CoV-2 in Wuhan City and other places of China,2021-01-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,China,Hubei,,healthy individuals returning to work for a medical examination,,2020-03-06,2020-05-03,Essential non-healthcare workers,All,Multiple groups,50.0,,Age,workers,2970,0.0209,,,,,,,,Unclear,2019-nCoV IgG Rapid Test,Innovita Biological Technology Co. Ltd,LFIA,,IgG,,,,,['High'],,Unclear,Yes,Yes,,No,Yes,No,,Shuhui Duan,Wuhan University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0008975,2021-02-07,2023-07-04,Unverified,duan_seroprevalence_2021,CHN
210109_Taiwan_NationalTaiwanUniversityHospital_HCW_Overall,210109_Taiwan_NationalTaiwanUniversityHospital,A cross-sectional seroprevalence for COVID-19 among healthcare workers in a tertially care hospital in Taiwan,2021-01-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Taiwan,Taipei,"HCWs of National Taiwan University Hospital who have been working at the COVID-19 ward, providing care for suspected and/or confirmed COVID-19 patients, or HCWs who regards himself/herself had  risk  for  COVID-19  exposure  were  encouraged  to participate in the study.",,2020-07-01,2020-08-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Primary,194,0.0,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,recomLine SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Mikrogen GmbH,Roche Diagnostics",Multiple Types,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,No,No,Unclear,Unclear,Yes,No,Unclear,Sung Ching Pan,National Taiwan University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jfma.2021.01.002,2021-03-14,2024-03-01,Unverified,pan_cross-sectional_2021,CHN
210118_Hangzhou_ZhejiangUniversitySchoolofMedicine_Overall,210118_Hangzhou_ZhejiangUniversitySchoolofMedicine,"Mass SARS-CoV-2 molecular and serological screening of medical staff and patients in Hangzhou, China: no evidence of RNA detection, low seroprevalence, and limited exposure risk in the hospital setting.",2021-01-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Zhejiang,Hangzhou,"hospital staff, inpatients, inpatient chaperones, outpatients, and fever clinic patients of Sir Run Run Shaw Hospital between April and May 2020",,2020-04-24,2020-05-08,Multiple populations,All,Multiple groups,,,Primary Estimate,,16043,0.0046,,,True,,,,True,Convenience,"2019-nCoV IgG/IgM Antibody Detection Kit,2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit","Zhuhai Livzon Diagnostics Inc,Nanjing Vazyme Medical Technology Co. Ltd",LFIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Unclear,No,Yes,No,Unclear,Jun Huang,Zhejiang University School of Medicine,Not Unity-Aligned,https://dx.doi.org/10.21037/atm-20-7163,2021-05-28,2024-03-01,Verified,huang_mass_2021,CHN
210119_Shenzen_ShenzhenCenterforDiseaseControlandPrevention_NeighbourhoodNoCases_TotalAb_TestAdj,210119_Shenzen_ShenzhenCenterforDiseaseControlandPrevention_NeighbourhoodNoCases,Insight into the practical performance of RT-PCR testing for SARS-CoV-2 using serological data: a cohort study,2021-01-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,,Shenzen,"we did a serosurvey of 350 volunteers from neighbourhoods where no cases were reported (in two districts, Luohu and Longgang)",,2020-04-17,2020-04-23,Household and community samples,All,Multiple groups,,,Primary Estimate,General pop,350,0.0,0.0,0.011000000000000001,True,True,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.98,0.99,['High'],Yes,No,No,No,No,Yes,Yes,Yes,Unclear,Zhen Zhang,Shenzhen Center for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1016/S2666-5247(20)30200-7,2021-02-24,2023-07-04,Verified,zhang_insight_2021,CHN
210119_Shenzen_ShenzhenCenterforDiseaseControlandPrevention_NeighbourhoodNoCases_TotalAb_Unadj,210119_Shenzen_ShenzhenCenterforDiseaseControlandPrevention_NeighbourhoodNoCases,Insight into the practical performance of RT-PCR testing for SARS-CoV-2 using serological data: a cohort study,2021-01-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,,Shenzen,"we did a serosurvey of 350 volunteers from neighbourhoods where no cases were reported (in two districts, Luohu and Longgang)",,2020-04-17,2020-04-23,Household and community samples,All,Multiple groups,,,Analysis,,350,0.003,0.0,0.016,,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.98,0.99,['High'],Yes,No,No,No,No,Yes,Yes,Yes,Unclear,Zhen Zhang,Shenzhen Center for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1016/S2666-5247(20)30200-7,2021-02-24,2024-03-01,Verified,zhang_insight_2021,CHN
210119_Shenzen_ShenzhenCenterforDiseaseControlandPrevention_NeighbourhoodReportedCases_TotalAb_TestAdj,210119_Shenzen_ShenzhenCenterforDiseaseControlandPrevention_NeighbourhoodReportedCases,Insight into the practical performance of RT-PCR testing for SARS-CoV-2 using serological data: a cohort study,2021-01-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,,Shenzen,we did a serosurvey of 50 volunteers from neighbourhoods with reported cases (in Luohu; three RT-PCR-confirmed cases within case neighbourhoods; 1·2 cases per 10 000 population),,2020-04-17,2020-04-23,Household and community samples,All,Multiple groups,,,Primary Estimate,,50,0.0,0.0,0.068,True,True,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.98,0.99,['High'],Yes,No,No,No,No,Yes,Yes,Yes,Unclear,Zhen Zhang,Shenzhen Center for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1016/S2666-5247(20)30200-7,2021-02-24,2023-07-04,Verified,zhang_insight_2021,CHN
210119_Shenzen_ShenzhenCenterforDiseaseControlandPrevention_NeighbourhoodReportedCases_TotalAb_Unadj,210119_Shenzen_ShenzhenCenterforDiseaseControlandPrevention_NeighbourhoodReportedCases,Insight into the practical performance of RT-PCR testing for SARS-CoV-2 using serological data: a cohort study,2021-01-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,,Shenzen,we did a serosurvey of 50 volunteers from neighbourhoods with reported cases (in Luohu; three RT-PCR-confirmed cases within case neighbourhoods; 1·2 cases per 10 000 population),,2020-04-17,2020-04-23,Household and community samples,All,Multiple groups,,,Analysis,,50,0.0,0.0,0.011000000000000001,,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.98,0.99,['High'],Yes,No,No,No,No,Yes,Yes,Yes,Unclear,Zhen Zhang,Shenzhen Center for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1016/S2666-5247(20)30200-7,2021-02-24,2024-03-01,Verified,zhang_insight_2021,CHN
210119_Shenzen_ShenzhenCenterforDiseaseControlandPrevention_contacts_TotalAb_TestAdj,210119_Shenzen_ShenzhenCenterforDiseaseControlandPrevention_contacts,Insight into the practical performance of RT-PCR testing for SARS-CoV-2 using serological data: a cohort study,2021-01-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,,Shenzen,"Contact tracing was used to identify close contacts of confirmed cases of SARS-CoV-2, defined as those who lived in the same residence as, or shared a meal, travelled, or socially interacted with, an index case within 2 days before symptom onset. Between April 12 and May 4, 2020, we attempted to recruit by telephone all RT-PCR-negative close contacts of all confirmed SARS-CoV-2 cases in Shenzhen for serological testing."," Non-local residents who left Shenzhen after quarantine, those without contact tracing records, individuals whose last exposure to the index case was within 2 weeks of the sampling date.",2020-04-12,2020-05-04,Contacts of COVID patients,All,Multiple groups,,,Primary Estimate,Contacts,880,0.040999999999999995,0.028999999999999998,0.057,True,True,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.98,0.99,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Zhen Zhang,Shenzhen Center for Disease Control and Prevention,Not Unity-Aligned,https://dx.doi.org/10.1016/S2666-5247(20)30200-7,2021-02-24,2023-07-04,Verified,zhang_insight_2021,CHN
210206_China_ChineseCenterforDiseaseControlandPrevention_Overall,210206_China_ChineseCenterforDiseaseControlandPrevention,"Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China",2021-02-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,China,,,Eligible participants were over one year old who lived in the surveyed areas for at least 14 days during the epidemic period (December 2019 to March 2020),,2020-04-10,2020-04-18,Household and community samples,All,Multiple groups,1.0,,Primary Estimate,Overall,34857,0.0123,,,True,,,,True,Stratified probability,"Finecare SARS-CoV-2 Antibody test,2019-nCoV IgG Rapid Test,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Author designed (Neutralization Assay)","Guangzhou Wondfo Biotech Co. Ltd,Innovita Biological Technology Co. Ltd,Bioscience Diagnostics,NA",Multiple Types,Serum,"['IgG', 'IgM', 'Neutralizing', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Zhongjie Li ,Chinese Center for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2021.100094,2021-03-24,2024-03-01,Verified,li_antibody_2021,CHN
210206_China_ChineseCenterforDiseaseControlandPrevention_OtherProvinces,210206_China_ChineseCenterforDiseaseControlandPrevention,"Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China",2021-02-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,China,"Beijing, Shanghai, Guangdong, Jiangsu, Sichuan, Liaoning",,Eligible participants were over one year old who lived in the surveyed areas for at least 14 days during the epidemic period (December 2019 to March 2020),,2020-04-10,2020-04-18,Household and community samples,All,Multiple groups,1.0,,Geographical area,Other (6 provinces/cities),12872,0.001,,,,,True,,,Stratified probability,"Finecare SARS-CoV-2 Antibody test,2019-nCoV IgG Rapid Test,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Author designed (Neutralization Assay)","Guangzhou Wondfo Biotech Co. Ltd,Innovita Biological Technology Co. Ltd,Bioscience Diagnostics,NA",Multiple Types,Serum,"['IgG', 'IgM', 'Neutralizing', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Zhongjie Li ,Chinese Center for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2021.100094,2021-03-24,2024-03-01,Verified,li_antibody_2021,CHN
210206_China_ChineseCenterforDiseaseControlandPrevention_40-59,210206_China_ChineseCenterforDiseaseControlandPrevention,"Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China",2021-02-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,China,,,Eligible participants were over one year old who lived in the surveyed areas for at least 14 days during the epidemic period (December 2019 to March 2020),,2020-04-10,2020-04-18,Household and community samples,All,Adults (18-64 years),40.0,59.0,Age,40-59,11547,0.015,,,,,,,,Stratified probability,"Finecare SARS-CoV-2 Antibody test,2019-nCoV IgG Rapid Test,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Author designed (Neutralization Assay)","Guangzhou Wondfo Biotech Co. Ltd,Innovita Biological Technology Co. Ltd,Bioscience Diagnostics,NA",Multiple Types,Serum,"['IgG', 'IgM', 'Neutralizing', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Zhongjie Li ,Chinese Center for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2021.100094,2021-03-24,2024-03-01,Verified,li_antibody_2021,CHN
210206_China_ChineseCenterforDiseaseControlandPrevention_Hubei,210206_China_ChineseCenterforDiseaseControlandPrevention,"Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China",2021-02-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,China,Hubei,,Eligible participants were over one year old who lived in the surveyed areas for at least 14 days during the epidemic period (December 2019 to March 2020),,2020-04-10,2020-04-18,Household and community samples,All,Multiple groups,1.0,,Geographical area,Hubei excluding Wuhan,10632,0.0044,0.0026000000000000003,0.0076,,,True,,,Stratified probability,"Finecare SARS-CoV-2 Antibody test,2019-nCoV IgG Rapid Test,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Author designed (Neutralization Assay)","Guangzhou Wondfo Biotech Co. Ltd,Innovita Biological Technology Co. Ltd,Bioscience Diagnostics,NA",Multiple Types,Serum,"['IgG', 'IgM', 'Neutralizing', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Zhongjie Li ,Chinese Center for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2021.100094,2021-03-24,2024-03-01,Verified,li_antibody_2021,CHN
210206_China_ChineseCenterforDiseaseControlandPrevention_60+,210206_China_ChineseCenterforDiseaseControlandPrevention,"Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China",2021-02-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,China,,,Eligible participants were over one year old who lived in the surveyed areas for at least 14 days during the epidemic period (December 2019 to March 2020),,2020-04-10,2020-04-18,Household and community samples,All,Seniors (65+ years),60.0,,Age,60+,6957,0.0128,,,,,,,,Stratified probability,"Finecare SARS-CoV-2 Antibody test,2019-nCoV IgG Rapid Test,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Author designed (Neutralization Assay)","Guangzhou Wondfo Biotech Co. Ltd,Innovita Biological Technology Co. Ltd,Bioscience Diagnostics,NA",Multiple Types,Serum,"['IgG', 'IgM', 'Neutralizing', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Zhongjie Li ,Chinese Center for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2021.100094,2021-03-24,2024-03-01,Verified,li_antibody_2021,CHN
210206_China_ChineseCenterforDiseaseControlandPrevention_Wuhan,210206_China_ChineseCenterforDiseaseControlandPrevention,"Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China",2021-02-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,Eligible participants were over one year old who lived in the surveyed areas for at least 14 days during the epidemic period (December 2019 to March 2020),,2020-04-10,2020-04-18,Household and community samples,All,Multiple groups,1.0,,Geographical area,Wuhan,11353,0.0443,0.0348,0.0562,,,True,,,Stratified probability,"Finecare SARS-CoV-2 Antibody test,2019-nCoV IgG Rapid Test,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Author designed (Neutralization Assay)","Guangzhou Wondfo Biotech Co. Ltd,Innovita Biological Technology Co. Ltd,Bioscience Diagnostics,NA",Multiple Types,Serum,"['IgG', 'IgM', 'Neutralizing', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Zhongjie Li ,Chinese Center for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2021.100094,2021-03-24,2024-03-01,Verified,li_antibody_2021,CHN
210206_China_ChineseCenterforDiseaseControlandPrevention_20-39,210206_China_ChineseCenterforDiseaseControlandPrevention,"Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China",2021-02-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,China,,,Eligible participants were over one year old who lived in the surveyed areas for at least 14 days during the epidemic period (December 2019 to March 2020),,2020-04-10,2020-04-18,Household and community samples,All,Adults (18-64 years),20.0,39.0,Age,20-39,9701,0.011899999999999999,,,,,,,,Stratified probability,"Finecare SARS-CoV-2 Antibody test,2019-nCoV IgG Rapid Test,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Author designed (Neutralization Assay)","Guangzhou Wondfo Biotech Co. Ltd,Innovita Biological Technology Co. Ltd,Bioscience Diagnostics,NA",Multiple Types,Serum,"['IgG', 'IgM', 'Neutralizing', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Zhongjie Li ,Chinese Center for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2021.100094,2021-03-24,2024-03-01,Verified,li_antibody_2021,CHN
210206_China_ChineseCenterforDiseaseControlandPrevention_Male,210206_China_ChineseCenterforDiseaseControlandPrevention,"Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China",2021-02-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,China,,,Eligible participants were over one year old who lived in the surveyed areas for at least 14 days during the epidemic period (December 2019 to March 2020),,2020-04-10,2020-04-18,Household and community samples,Male,Multiple groups,1.0,,Sex/Gender,,16962,0.01,,,,,,,,Stratified probability,"Finecare SARS-CoV-2 Antibody test,2019-nCoV IgG Rapid Test,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Author designed (Neutralization Assay)","Guangzhou Wondfo Biotech Co. Ltd,Innovita Biological Technology Co. Ltd,Bioscience Diagnostics,NA",Multiple Types,Serum,"['IgG', 'IgM', 'Neutralizing', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Zhongjie Li ,Chinese Center for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2021.100094,2021-03-24,2024-03-01,Verified,li_antibody_2021,CHN
210206_China_ChineseCenterforDiseaseControlandPrevention_2xLFIA+CLIA,210206_China_ChineseCenterforDiseaseControlandPrevention,"Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China",2021-02-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,China,,,Eligible participants were over one year old who lived in the surveyed areas for at least 14 days during the epidemic period (December 2019 to March 2020),,2020-04-10,2020-04-18,Household and community samples,All,Multiple groups,1.0,,Test used,Only LFIA test,34857,0.033,,,,,,,,Stratified probability,"Finecare SARS-CoV-2 Antibody test,2019-nCoV IgG Rapid Test,Magnetic Chemiluminescence Enzyme Immunoassay Kit","Guangzhou Wondfo Biotech Co. Ltd,Innovita Biological Technology Co. Ltd,Bioscience Diagnostics",Multiple Types,Serum,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Zhongjie Li ,Chinese Center for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2021.100094,2021-03-24,2024-03-01,Verified,li_antibody_2021,CHN
210206_China_ChineseCenterforDiseaseControlandPrevention_1-9,210206_China_ChineseCenterforDiseaseControlandPrevention,"Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China",2021-02-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,China,,,Eligible participants were over one year old who lived in the surveyed areas for at least 14 days during the epidemic period (December 2019 to March 2020),,2020-04-10,2020-04-18,Household and community samples,All,Children and Youth (0-17 years),1.0,9.0,Age,1-9,3264,0.0067,,,,,,,,Stratified probability,"Finecare SARS-CoV-2 Antibody test,2019-nCoV IgG Rapid Test,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Author designed (Neutralization Assay)","Guangzhou Wondfo Biotech Co. Ltd,Innovita Biological Technology Co. Ltd,Bioscience Diagnostics,NA",Multiple Types,Serum,"['IgG', 'IgM', 'Neutralizing', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Zhongjie Li ,Chinese Center for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2021.100094,2021-03-24,2024-03-01,Verified,li_antibody_2021,CHN
210206_China_ChineseCenterforDiseaseControlandPrevention_Female,210206_China_ChineseCenterforDiseaseControlandPrevention,"Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China",2021-02-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,China,,,Eligible participants were over one year old who lived in the surveyed areas for at least 14 days during the epidemic period (December 2019 to March 2020),,2020-04-10,2020-04-18,Household and community samples,Female,Multiple groups,1.0,,Sex/Gender,,17895,0.0141,,,,,,,,Stratified probability,"Finecare SARS-CoV-2 Antibody test,2019-nCoV IgG Rapid Test,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Author designed (Neutralization Assay)","Guangzhou Wondfo Biotech Co. Ltd,Innovita Biological Technology Co. Ltd,Bioscience Diagnostics,NA",Multiple Types,Serum,"['IgG', 'IgM', 'Neutralizing', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Zhongjie Li ,Chinese Center for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2021.100094,2021-03-24,2024-03-01,Verified,li_antibody_2021,CHN
210206_China_ChineseCenterforDiseaseControlandPrevention_10-19,210206_China_ChineseCenterforDiseaseControlandPrevention,"Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China",2021-02-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,China,,,Eligible participants were over one year old who lived in the surveyed areas for at least 14 days during the epidemic period (December 2019 to March 2020),,2020-04-10,2020-04-18,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,3388,0.0083,,,,,,,,Stratified probability,"Finecare SARS-CoV-2 Antibody test,2019-nCoV IgG Rapid Test,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Author designed (Neutralization Assay)","Guangzhou Wondfo Biotech Co. Ltd,Innovita Biological Technology Co. Ltd,Bioscience Diagnostics,NA",Multiple Types,Serum,"['IgG', 'IgM', 'Neutralizing', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Zhongjie Li ,Chinese Center for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2021.100094,2021-03-24,2024-03-01,Verified,li_antibody_2021,CHN
210302_Shenzhen_ChineseAcademyofMedicalSciences2_overall_adj,210302_Shenzhen_ChineseAcademyofMedicalSciences2,The prevalence of antibodies to SARS-CoV-2 among blood donors in China,2021-03-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,,Shenzhen,Blood donors donated in the 3 blood centers during the study period.,,2020-01-15,2020-04-15,Blood donors,All,Multiple groups,18.0,65.0,Primary Estimate,,6810,0.00033,2.9e-05,0.00267,True,,True,,,Convenience,Author designed (Neutralization Assay),,Neutralization,,"['IgG', 'IgM', 'TotalAntibody']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Le Chang,Chinese Academy of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-21503-x,2021-04-12,2022-07-16,Unverified,le_chang_prevalence_2020,CHN
210302_Shenzhen_ChineseAcademyofMedicalSciences2_overall_unadj,210302_Shenzhen_ChineseAcademyofMedicalSciences2,The prevalence of antibodies to SARS-CoV-2 among blood donors in China,2021-03-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,,Shenzhen,Blood donors donated in the 3 blood centers during the study period.,,2020-01-15,2020-04-15,Blood donors,All,Multiple groups,18.0,65.0,Analysis,,6810,0.00029,8.1e-05,0.0011,,,,,True,Convenience,Author designed (Neutralization Assay),,Neutralization,,"['IgG', 'IgM', 'TotalAntibody']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Le Chang,Chinese Academy of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-21503-x,2021-04-12,2022-07-16,Unverified,le_chang_prevalence_2020,CHN
210302_Shijiazhuang_ChineseAcademyofMedicalSciences3_overall_adj,210302_Shijiazhuang_ChineseAcademyofMedicalSciences3,The prevalence of antibodies to SARS-CoV-2 among blood donors in China,2021-03-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hebei Province,Shijiazhuang,Blood donors donated in the 3 blood centers during the study period.,,2020-01-15,2020-04-15,Blood donors,All,Adults (18-64 years),18.0,60.0,Primary Estimate,,13540,2.8e-05,1.0000000000000002e-06,0.00158,True,,True,,,Convenience,Author designed (Neutralization Assay),,Neutralization,,"['IgG', 'IgM', 'TotalAntibody']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Le Chang,Chinese Academy of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-21503-x,2021-04-12,2022-07-16,Verified,le_chang_prevalence_2020,CHN
210302_Shijiazhuang_ChineseAcademyofMedicalSciences3_overall_unadj,210302_Shijiazhuang_ChineseAcademyofMedicalSciences3,The prevalence of antibodies to SARS-CoV-2 among blood donors in China,2021-03-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hebei Province,Shijiazhuang,Blood donors donated in the 3 blood centers during the study period.,,2020-01-15,2020-04-15,Blood donors,All,Adults (18-64 years),18.0,60.0,Analysis,,13540,7.400000000000001e-05,1.3e-05,0.00042,,,,,True,Convenience,Author designed (Neutralization Assay),,Neutralization,,"['IgG', 'IgM', 'TotalAntibody']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Le Chang,Chinese Academy of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-21503-x,2021-04-12,2022-07-16,Verified,le_chang_prevalence_2020,CHN
210302_Wuhan_ChineseAcademyofMedicalSciences1_overall_adj,210302_Wuhan_ChineseAcademyofMedicalSciences1,The prevalence of antibodies to SARS-CoV-2 among blood donors in China,2021-03-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei Province,Wuhan,Blood donors donated in the 3 blood centers during the study period.,,2020-01-15,2020-04-15,Blood donors,All,Adults (18-64 years),18.0,60.0,Primary Estimate,,17794,0.026600000000000002,0.022400000000000003,0.030699999999999998,True,,True,,,Convenience,Author designed (Neutralization Assay),,Neutralization,,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Le Chang,Chinese Academy of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-21503-x,2021-04-12,2022-07-16,Verified,le_chang_prevalence_2020,CHN
210302_Wuhan_ChineseAcademyofMedicalSciences1_overall_unadj,210302_Wuhan_ChineseAcademyofMedicalSciences1,The prevalence of antibodies to SARS-CoV-2 among blood donors in China,2021-03-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei Province,Wuhan,Blood donors donated in the 3 blood centers during the study period.,,2020-01-15,2020-04-15,Blood donors,All,Adults (18-64 years),18.0,60.0,Analysis,,17794,0.0222,0.0201,0.0245,,,,,True,Convenience,Author designed (Neutralization Assay),,Neutralization,,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Le Chang,Chinese Academy of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-21503-x,2021-04-12,2022-07-16,Verified,le_chang_prevalence_2020,CHN
210308_ZhongnanHospital_Wuhan,210308_ZhongnanHospital_Wuhan,"Safety and Effectiveness of Orthopaedic Medical Staff in Providing Support in Combating the COVID-19 Pandemic: A Retrospective Investigation from Wuhan, China",2021-03-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"The orthopaedic medical staff from Zhongnan Hospital of Wuhan University were included in this study as the participants. Only the staff who fulfilled the following criteria was permitted to participate in the support work against COVID‐19: (i) those who were 50 years old or younger without comorbidities such as cardiovascular diseases and diabetes; (ii) non‐pregnant women; (iii) those who had completed the training and simulation exercises and passed the exam; (iv) those with normal body temperature, with negative findings on chest CT scans, and without respiratory symptoms; and (v) those who were willing to participate in the work.",,2020-01-01,2020-04-08,Health care workers and caregivers,All,Adults (18-64 years),,50.0,Primary Estimate,Orthopaedic staff (surgeons and nurses),112,0.0,,,True,,,,True,Entire sample,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],No,Yes,No,Yes,No,Unclear,Yes,No,Yes,Yin-xian Wen,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://dx.doi.org/10.1111/os.12898,2021-04-19,2022-07-16,Verified,wen_safety_2021,CHN
210320_Wuhan_ChineseAcademyOfMedicalSciences_overall_Roche,210320_Wuhan_ChineseAcademyOfMedicalSciences,"Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study",2021-03-20,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,China,Wuhan,,"eligible individuals were those who had lived in Wuhan for at least 14 days since Dec 1, 2019","Individuals who experienced serious disease other than COVID-19, including but not limited to advanced cancers and people with severe mental illness, were excluded. We further excluded those who refused to participate and who were not able to finish sample collection.",2020-04-14,2020-04-15,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,Overall pop adj,9542,0.0692,0.0641,0.0743,True,,True,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,1.0,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Zhenyu He,Chinese Academy of Medical Sciences & Peking Union Medical College,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00238-5/fulltext?dgcid=raven_jbs_etoc_email,2021-03-24,2024-03-01,Verified,he_seroprevalence_2021,CHN
210320_Wuhan_ChineseAcademyOfMedicalSciences_age6-11,210320_Wuhan_ChineseAcademyOfMedicalSciences,"Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study",2021-03-20,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,China,Wuhan,,"eligible individuals were those who had lived in Wuhan for at least 14 days since Dec 1, 2019","Individuals who experienced serious disease other than COVID-19, including but not limited to advanced cancers and people with severe mental illness, were excluded. We further excluded those who refused to participate and who were not able to finish sample collection.",2020-04-14,2020-04-15,Household and community samples,All,Children and Youth (0-17 years),6.0,11.0,Age,age 6-11,682,0.0472,0.0313,0.0631,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,1.0,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Zhenyu He,Chinese Academy of Medical Sciences & Peking Union Medical College,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00238-5/fulltext?dgcid=raven_jbs_etoc_email,2021-03-24,2024-03-01,Verified,he_seroprevalence_2021,CHN
210320_Wuhan_ChineseAcademyOfMedicalSciences_age45-65,210320_Wuhan_ChineseAcademyOfMedicalSciences,"Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study",2021-03-20,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,China,Wuhan,,"eligible individuals were those who had lived in Wuhan for at least 14 days since Dec 1, 2019","Individuals who experienced serious disease other than COVID-19, including but not limited to advanced cancers and people with severe mental illness, were excluded. We further excluded those who refused to participate and who were not able to finish sample collection.",2020-04-14,2020-04-15,Household and community samples,All,Adults (18-64 years),45.0,65.0,Age,age 45-65,3340,0.0771,0.0681,0.0861,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,1.0,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Zhenyu He,Chinese Academy of Medical Sciences & Peking Union Medical College,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00238-5/fulltext?dgcid=raven_jbs_etoc_email,2021-03-24,2024-03-01,Verified,he_seroprevalence_2021,CHN
210320_Wuhan_ChineseAcademyOfMedicalSciences_female,210320_Wuhan_ChineseAcademyOfMedicalSciences,"Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study",2021-03-20,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,China,Wuhan,,"eligible individuals were those who had lived in Wuhan for at least 14 days since Dec 1, 2019","Individuals who experienced serious disease other than COVID-19, including but not limited to advanced cancers and people with severe mental illness, were excluded. We further excluded those who refused to participate and who were not able to finish sample collection.",2020-04-14,2020-04-15,Household and community samples,Female,Multiple groups,0.0,,Sex/Gender,female,4884,0.077,0.0695,0.08449999999999999,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,1.0,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Zhenyu He,Chinese Academy of Medical Sciences & Peking Union Medical College,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00238-5/fulltext?dgcid=raven_jbs_etoc_email,2021-03-24,2024-03-01,Verified,he_seroprevalence_2021,CHN
210320_Wuhan_ChineseAcademyOfMedicalSciences_age18-44,210320_Wuhan_ChineseAcademyOfMedicalSciences,"Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study",2021-03-20,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,China,Wuhan,,"eligible individuals were those who had lived in Wuhan for at least 14 days since Dec 1, 2019","Individuals who experienced serious disease other than COVID-19, including but not limited to advanced cancers and people with severe mental illness, were excluded. We further excluded those who refused to participate and who were not able to finish sample collection.",2020-04-14,2020-04-15,Household and community samples,All,Adults (18-64 years),18.0,44.0,Age,age 18-44,3905,0.0665,0.0587,0.0743,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,1.0,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Zhenyu He,Chinese Academy of Medical Sciences & Peking Union Medical College,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00238-5/fulltext?dgcid=raven_jbs_etoc_email,2021-03-24,2024-03-01,Verified,he_seroprevalence_2021,CHN
210320_Wuhan_ChineseAcademyOfMedicalSciences_age66+,210320_Wuhan_ChineseAcademyOfMedicalSciences,"Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study",2021-03-20,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,China,Wuhan,,"eligible individuals were those who had lived in Wuhan for at least 14 days since Dec 1, 2019","Individuals who experienced serious disease other than COVID-19, including but not limited to advanced cancers and people with severe mental illness, were excluded. We further excluded those who refused to participate and who were not able to finish sample collection.",2020-04-14,2020-04-15,Household and community samples,All,Seniors (65+ years),66.0,,Age,age 66+,827,0.0951,0.0751,0.1151,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,1.0,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Zhenyu He,Chinese Academy of Medical Sciences & Peking Union Medical College,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00238-5/fulltext?dgcid=raven_jbs_etoc_email,2021-03-24,2024-03-01,Verified,he_seroprevalence_2021,CHN
210320_Wuhan_ChineseAcademyOfMedicalSciences_age12-17,210320_Wuhan_ChineseAcademyOfMedicalSciences,"Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study",2021-03-20,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,China,Wuhan,,"eligible individuals were those who had lived in Wuhan for at least 14 days since Dec 1, 2019","Individuals who experienced serious disease other than COVID-19, including but not limited to advanced cancers and people with severe mental illness, were excluded. We further excluded those who refused to participate and who were not able to finish sample collection.",2020-04-14,2020-04-15,Household and community samples,All,Children and Youth (0-17 years),12.0,17.0,Age,age 12-17,485,0.0322,0.0165,0.0479,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,1.0,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Zhenyu He,Chinese Academy of Medical Sciences & Peking Union Medical College,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00238-5/fulltext?dgcid=raven_jbs_etoc_email,2021-03-24,2024-03-01,Verified,he_seroprevalence_2021,CHN
210320_Wuhan_ChineseAcademyOfMedicalSciences_age0-5,210320_Wuhan_ChineseAcademyOfMedicalSciences,"Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study",2021-03-20,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,China,Wuhan,,"eligible individuals were those who had lived in Wuhan for at least 14 days since Dec 1, 2019","Individuals who experienced serious disease other than COVID-19, including but not limited to advanced cancers and people with severe mental illness, were excluded. We further excluded those who refused to participate and who were not able to finish sample collection.",2020-04-14,2020-04-15,Household and community samples,All,Children and Youth (0-17 years),0.0,5.0,Age,age 0-5,303,0.0533,0.027999999999999997,0.0786,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,1.0,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Zhenyu He,Chinese Academy of Medical Sciences & Peking Union Medical College,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00238-5/fulltext?dgcid=raven_jbs_etoc_email,2021-03-24,2024-03-01,Verified,he_seroprevalence_2021,CHN
210320_Wuhan_ChineseAcademyOfMedicalSciences_male,210320_Wuhan_ChineseAcademyOfMedicalSciences,"Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study",2021-03-20,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,China,Wuhan,,"eligible individuals were those who had lived in Wuhan for at least 14 days since Dec 1, 2019","Individuals who experienced serious disease other than COVID-19, including but not limited to advanced cancers and people with severe mental illness, were excluded. We further excluded those who refused to participate and who were not able to finish sample collection.",2020-04-14,2020-04-15,Household and community samples,Male,Multiple groups,0.0,,Sex/Gender,male,4658,0.0622,0.0553,0.06910000000000001,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,1.0,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Zhenyu He,Chinese Academy of Medical Sciences & Peking Union Medical College,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00238-5/fulltext?dgcid=raven_jbs_etoc_email,2021-03-24,2024-03-01,Verified,he_seroprevalence_2021,CHN
210408_Taiwan_NationalChengKungUniversityHospital_overall,210408_Taiwan_NationalChengKungUniversityHospital,A seroprevalence study of COVID-19 at a campus in southern Taiwan,2021-04-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,China,Taiwan,,We utilized residual serum samples of the students visiting the hospital for routine health check-up between August and early September in 2020.,,2020-08-15,2020-09-13,Residual sera,All,Adults (18-64 years),,,Primary Estimate,Taiwanese college students,969,0.0,,,True,,,,True,Convenience," ASK COVID-19 IgG/IgM Rapid Test,Finecare SARS-CoV-2 Antibody test,Elecsys® Anti‐SARS‐CoV‐2 (N)","TONYAR Biotech Inc., Taiwan,Guangzhou Wondfo Biotech Co. Ltd,Roche Diagnostics",CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Ming Chi Li,National Cheng Kung University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jmii.2021.03.018,2021-05-19,2024-03-01,Unverified,li_seroprevalence_2021,CHN
210419_Wuhan_ChineseAcademyofSciences,210419_Wuhan_ChineseAcademyofSciences,Serological investigation of asymptomatic cases of SARS-CoV-2 infection reveals weak and declining antibody responses.,2021-04-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,healthy food workers from the Wuchang district ,,2020-05-30,2020-06-12,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,Overall food workers,508,0.0591,,,True,,,,True,Unclear,Author designed (ELISA) - MULTIPLEXED,,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,Unclear,No,No,Unclear,Unclear,Yes,No,Unclear,Yong Yang,Chinese Academy of Sciences,Not Unity-Aligned,https://dx.doi.org/10.1080/22221751.2021.1919032,2021-05-19,2022-07-16,Verified,yang_serological_2021,CHN
210421_Wuhan_WuhanUniversity_overall,210421_Wuhan_WuhanUniversity,"SARS-CoV-2
  Antibody Seroprevalence in Wuhan, China, from 23 April to 24 May 2020",2021-04-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,"Wuhan
","We recruited 35,326 residents (17,610 males and 17,716 females greater than 4 years old) from four communities (Dushuyuan, Huatijie, Pengliuyang, and Xichangkou) in Wuhan from
23 April 2020 to 24 May 2020. All participants had not previously tested positive for COVID-19 before
providing serum samples for this study.",,2020-04-23,2020-05-24,Household and community samples,All,Multiple groups,4.0,,Primary Estimate,,35326,0.037700000000000004,0.0358,0.039700000000000006,True,,,,True,Convenience,"2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,iFlash-SARS-CoV-2 IgM/IgG","Nanjing Vazyme Medical Technology Co. Ltd,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,"['IgG', 'IgM']",,,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Huan Han,Wuhan University,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/33883260/,2021-05-22,2024-02-27,Verified,han_sars-cov-2_2021,CHN
210421_Wuhan_WuhanUniversity_21-30,210421_Wuhan_WuhanUniversity,"SARS-CoV-2
  Antibody Seroprevalence in Wuhan, China, from 23 April to 24 May 2020",2021-04-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,"Wuhan
","We recruited 35,326 residents (17,610 males and 17,716 females greater than 4 years old) from four communities (Dushuyuan, Huatijie, Pengliuyang, and Xichangkou) in Wuhan from
23 April 2020 to 24 May 2020. All participants had not previously tested positive for COVID-19 before
providing serum samples for this study.",,2020-04-23,2020-05-24,Household and community samples,All,Adults (18-64 years),21.0,30.0,Age,21-30,5333,0.0189,,,,,,,,Convenience,"2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,iFlash-SARS-CoV-2 IgM/IgG","Nanjing Vazyme Medical Technology Co. Ltd,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,"['IgG', 'IgM']",,,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Huan Han,Wuhan University,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/33883260/,2021-09-02,2024-02-28,Verified,han_sars-cov-2_2021,CHN
210421_Wuhan_WuhanUniversity_Female,210421_Wuhan_WuhanUniversity,"SARS-CoV-2
  Antibody Seroprevalence in Wuhan, China, from 23 April to 24 May 2020",2021-04-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,"Wuhan
","We recruited 35,326 residents (17,610 males and 17,716 females greater than 4 years old) from four communities (Dushuyuan, Huatijie, Pengliuyang, and Xichangkou) in Wuhan from
23 April 2020 to 24 May 2020. All participants had not previously tested positive for COVID-19 before
providing serum samples for this study.",,2020-04-23,2020-05-24,Household and community samples,Female,Multiple groups,4.0,,Sex/Gender,,17716,0.0452,0.0422,0.0483,,,,,,Convenience,"2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,iFlash-SARS-CoV-2 IgM/IgG","Nanjing Vazyme Medical Technology Co. Ltd,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,"['IgG', 'IgM']",,,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Huan Han,Wuhan University,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/33883260/,2021-09-02,2024-02-29,Verified,han_sars-cov-2_2021,CHN
210421_Wuhan_WuhanUniversity_11-20,210421_Wuhan_WuhanUniversity,"SARS-CoV-2
  Antibody Seroprevalence in Wuhan, China, from 23 April to 24 May 2020",2021-04-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,"Wuhan
","We recruited 35,326 residents (17,610 males and 17,716 females greater than 4 years old) from four communities (Dushuyuan, Huatijie, Pengliuyang, and Xichangkou) in Wuhan from
23 April 2020 to 24 May 2020. All participants had not previously tested positive for COVID-19 before
providing serum samples for this study.",,2020-04-23,2020-05-24,Household and community samples,All,Children and Youth (0-17 years),11.0,20.0,Age,11-20,1512,0.0192,,,,,,,,Convenience,"2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,iFlash-SARS-CoV-2 IgM/IgG","Nanjing Vazyme Medical Technology Co. Ltd,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,"['IgG', 'IgM']",,,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Huan Han,Wuhan University,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/33883260/,2021-09-02,2024-03-01,Verified,han_sars-cov-2_2021,CHN
210421_Wuhan_WuhanUniversity_31-40,210421_Wuhan_WuhanUniversity,"SARS-CoV-2
  Antibody Seroprevalence in Wuhan, China, from 23 April to 24 May 2020",2021-04-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,"Wuhan
","We recruited 35,326 residents (17,610 males and 17,716 females greater than 4 years old) from four communities (Dushuyuan, Huatijie, Pengliuyang, and Xichangkou) in Wuhan from
23 April 2020 to 24 May 2020. All participants had not previously tested positive for COVID-19 before
providing serum samples for this study.",,2020-04-23,2020-05-24,Household and community samples,All,Adults (18-64 years),31.0,40.0,Age,31-40,6674,0.0265,,,,,,,,Convenience,"2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,iFlash-SARS-CoV-2 IgM/IgG","Nanjing Vazyme Medical Technology Co. Ltd,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,"['IgG', 'IgM']",,,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Huan Han,Wuhan University,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/33883260/,2021-09-02,2024-03-01,Verified,han_sars-cov-2_2021,CHN
210421_Wuhan_WuhanUniversity_51-60,210421_Wuhan_WuhanUniversity,"SARS-CoV-2
  Antibody Seroprevalence in Wuhan, China, from 23 April to 24 May 2020",2021-04-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,"Wuhan
","We recruited 35,326 residents (17,610 males and 17,716 females greater than 4 years old) from four communities (Dushuyuan, Huatijie, Pengliuyang, and Xichangkou) in Wuhan from
23 April 2020 to 24 May 2020. All participants had not previously tested positive for COVID-19 before
providing serum samples for this study.",,2020-04-23,2020-05-24,Household and community samples,All,Adults (18-64 years),51.0,60.0,Age,51-60,7076,0.0488,,,,,,,,Convenience,"2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,iFlash-SARS-CoV-2 IgM/IgG","Nanjing Vazyme Medical Technology Co. Ltd,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,"['IgG', 'IgM']",,,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Huan Han,Wuhan University,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/33883260/,2021-09-02,2024-02-29,Verified,han_sars-cov-2_2021,CHN
210421_Wuhan_WuhanUniversity_Male,210421_Wuhan_WuhanUniversity,"SARS-CoV-2
  Antibody Seroprevalence in Wuhan, China, from 23 April to 24 May 2020",2021-04-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,"Wuhan
","We recruited 35,326 residents (17,610 males and 17,716 females greater than 4 years old) from four communities (Dushuyuan, Huatijie, Pengliuyang, and Xichangkou) in Wuhan from
23 April 2020 to 24 May 2020. All participants had not previously tested positive for COVID-19 before
providing serum samples for this study.",,2020-04-23,2020-05-24,Household and community samples,Male,Multiple groups,4.0,,Sex/Gender,,17610,0.0302,0.027700000000000002,0.0327,,,,,,Convenience,"2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,iFlash-SARS-CoV-2 IgM/IgG","Nanjing Vazyme Medical Technology Co. Ltd,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,"['IgG', 'IgM']",,,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Huan Han,Wuhan University,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/33883260/,2021-09-02,2024-03-01,Verified,han_sars-cov-2_2021,CHN
210421_Wuhan_WuhanUniversity_61-70,210421_Wuhan_WuhanUniversity,"SARS-CoV-2
  Antibody Seroprevalence in Wuhan, China, from 23 April to 24 May 2020",2021-04-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,"Wuhan
","We recruited 35,326 residents (17,610 males and 17,716 females greater than 4 years old) from four communities (Dushuyuan, Huatijie, Pengliuyang, and Xichangkou) in Wuhan from
23 April 2020 to 24 May 2020. All participants had not previously tested positive for COVID-19 before
providing serum samples for this study.",,2020-04-23,2020-05-24,Household and community samples,All,Seniors (65+ years),61.0,70.0,Age,61-70,5106,0.0562,,,,,,,,Convenience,"2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,iFlash-SARS-CoV-2 IgM/IgG","Nanjing Vazyme Medical Technology Co. Ltd,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,"['IgG', 'IgM']",,,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Huan Han,Wuhan University,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/33883260/,2021-09-02,2024-02-20,Verified,han_sars-cov-2_2021,CHN
210421_Wuhan_WuhanUniversity_<=10,210421_Wuhan_WuhanUniversity,"SARS-CoV-2
  Antibody Seroprevalence in Wuhan, China, from 23 April to 24 May 2020",2021-04-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,"Wuhan
","We recruited 35,326 residents (17,610 males and 17,716 females greater than 4 years old) from four communities (Dushuyuan, Huatijie, Pengliuyang, and Xichangkou) in Wuhan from
23 April 2020 to 24 May 2020. All participants had not previously tested positive for COVID-19 before
providing serum samples for this study.",,2020-04-23,2020-05-24,Household and community samples,All,Children and Youth (0-17 years),4.0,10.0,Age,<=10,697,0.0201,,,,,,,,Convenience,"2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,iFlash-SARS-CoV-2 IgM/IgG","Nanjing Vazyme Medical Technology Co. Ltd,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,"['IgG', 'IgM']",,,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Huan Han,Wuhan University,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/33883260/,2021-09-02,2024-03-01,Verified,han_sars-cov-2_2021,CHN
210421_Wuhan_WuhanUniversity_41-50,210421_Wuhan_WuhanUniversity,"SARS-CoV-2
  Antibody Seroprevalence in Wuhan, China, from 23 April to 24 May 2020",2021-04-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,"Wuhan
","We recruited 35,326 residents (17,610 males and 17,716 females greater than 4 years old) from four communities (Dushuyuan, Huatijie, Pengliuyang, and Xichangkou) in Wuhan from
23 April 2020 to 24 May 2020. All participants had not previously tested positive for COVID-19 before
providing serum samples for this study.",,2020-04-23,2020-05-24,Household and community samples,All,Adults (18-64 years),41.0,50.0,Age,41-50,6115,0.0371,,,,,,,,Convenience,"2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,iFlash-SARS-CoV-2 IgM/IgG","Nanjing Vazyme Medical Technology Co. Ltd,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,"['IgG', 'IgM']",,,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Huan Han,Wuhan University,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/33883260/,2021-09-02,2024-03-01,Verified,han_sars-cov-2_2021,CHN
210421_Wuhan_WuhanUniversity_>=71,210421_Wuhan_WuhanUniversity,"SARS-CoV-2
  Antibody Seroprevalence in Wuhan, China, from 23 April to 24 May 2020",2021-04-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,"Wuhan
","We recruited 35,326 residents (17,610 males and 17,716 females greater than 4 years old) from four communities (Dushuyuan, Huatijie, Pengliuyang, and Xichangkou) in Wuhan from
23 April 2020 to 24 May 2020. All participants had not previously tested positive for COVID-19 before
providing serum samples for this study.",,2020-04-23,2020-05-24,Household and community samples,All,Seniors (65+ years),70.0,,Age,>=71,2813,0.054000000000000006,,,,,,,,Convenience,"2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,iFlash-SARS-CoV-2 IgM/IgG","Nanjing Vazyme Medical Technology Co. Ltd,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,"['IgG', 'IgM']",,,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Huan Han,Wuhan University,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/33883260/,2021-09-02,2024-02-20,Verified,han_sars-cov-2_2021,CHN
210518_Taiwan_NationalTaiwanUniversity_GroupC2,210518_Taiwan_NationalTaiwanUniversity_GroupC2,Seroprevalence Surveys for Anti-SARS-CoV-2 Antibody in Different Populations in Taiwan With Low Incidence of COVID-19 in 2020 and Severe Outbreaks of SARS in 2003.,2021-05-18,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,China,Taiwan,"Taipei, Zhubei",Healthy adult citizens.,"Individuals who had previously confirmed SARS-CoV-2 infection, failed to be contacted, refused to participate, or did not show up during the study period were excluded.",2020-06-25,2020-07-29,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Healthcare workers,1142,0.0009,0.0,0.0049,True,,,,True,Convenience,Not reported/ Unable to specify,,Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Wen Pin Tseng,Researchers at the National Taiwan University studied symptomatic patients with frontline healthcare workers (n=464) and found a stringently judged seroprevalence of 0%.,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2021.626609,2021-06-16,2023-08-15,Unverified,wenpintsengSeroprevalenceSurveysAntiSARSCoV22021,CHN
210518_Taiwan_NationalTaiwanUniversity_GroupH1,210518_Taiwan_NationalTaiwanUniversity_GroupH1,Seroprevalence Surveys for Anti-SARS-CoV-2 Antibody in Different Populations in Taiwan With Low Incidence of COVID-19 in 2020 and Severe Outbreaks of SARS in 2003.,2021-05-18,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,China,Taiwan,"Taipei, Zhubei",Frontline healthcare workers,"Individuals who had previously confirmed SARS-CoV-2 infection, failed to be contacted, refused to participate, or did not show up during the study period were excluded.",2020-06-25,2020-07-29,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Healthcare workers,464,0.0,0.0,0.0079,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (S),recomWell SARS-CoV-2 IgG ELISA","Abbott Laboratories,Roche Diagnostics,Mikrogen GmbH",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Wen Pin Tseng,National Taiwan University,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2021.626609,2021-06-15,2024-03-01,Unverified,wenpintsengSeroprevalenceSurveysAntiSARSCoV22021,CHN
210722_Wuhan_HospitalofHubeiProvince_HCW_primary,210722_Wuhan_HospitalofHubeiProvince_HCW,"Humoral immune durability of IgG for anti-SARS-CoV-2 in the normal pregnant women in Wuhan, China.",2021-07-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,all medical staff (385 members) in the department of obstetrics in our hospital underwent throat swab test and serological screening ,,2020-04-01,2020-04-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,385,0.018000000000000002,,,True,,,,True,Entire sample,Not reported/ Unable to specify,,LFIA,,"['IgG', 'IgM']",,,,,['High'],No,Yes,No,No,Unclear,Unclear,Yes,No,Unclear,Hongwen Ma,Hospital of Hubei Province,Not Unity-Aligned,https://dx.doi.org/10.1007/s12026-021-09213-4,2021-07-27,2022-07-16,Verified,ma_humoral_2021,CHN
210722_Wuhan_HospitalofHubeiProvince_partners_primary,210722_Wuhan_HospitalofHubeiProvince_partners,"Humoral immune durability of IgG for anti-SARS-CoV-2 in the normal pregnant women in Wuhan, China.",2021-07-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"all pregnant women and their accompanying members (≤ 2 per person, including husband) on admission in our hospital",,2020-04-01,2020-12-30,Multiple general populations,All,Adults (18-64 years),,,Primary Estimate,,15671,0.0073,,,True,,,,True,Entire sample,Not reported/ Unable to specify,,LFIA,,"['IgG', 'IgM']",,,,,['Moderate'],No,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,Hongwen Ma,Hospital of Hubei Province,Not Unity-Aligned,https://dx.doi.org/10.1007/s12026-021-09213-4,2021-07-27,2022-07-16,Verified,ma_humoral_2021,CHN
210722_Wuhan_HospitalofHubeiProvince_pregnant_primary,210722_Wuhan_HospitalofHubeiProvince_pregnant,"Humoral immune durability of IgG for anti-SARS-CoV-2 in the normal pregnant women in Wuhan, China.",2021-07-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"all pregnant women and their accompanying members (≤ 2 per person, including husband) on admission in our hospital",,2020-04-01,2020-12-30,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,15953,0.006600000000000001,,,True,,,,True,Entire sample,Not reported/ Unable to specify,,LFIA,,"['IgG', 'IgM']",,,,,['Moderate'],No,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,Hongwen Ma,Hospital of Hubei Province,Not Unity-Aligned,https://dx.doi.org/10.1007/s12026-021-09213-4,2021-07-27,2022-07-16,Verified,ma_humoral_2021,CHN
210806_China_FudanUniversity_NoOcularDisease_Overall,210806_China_FudanUniversity_NoOcularDisease,Association of Ocular Surface Diseases With SARS-CoV-2 Infection in Six Districts of China: An Observational Cohort Study.,2021-08-06,Journal Article (Peer-Reviewed),National,Prospective cohort,China,,,"""In this study, all the participants were RT-PCR negative for SARS-CoV-2 from throat swabs.""","""The subjects who have been vaccinated against SARS-CoV-2 were excluded from this study (n=81).""",2020-05-15,2021-03-15,Residual sera,All,Multiple groups,,,Primary Estimate,,5852,0.0092,,,True,,,,True,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Shengjie Li,Shanghai Engineering Research Center of Laser and Autostereoscopic 3D for Vision Care,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2021.695428,2021-09-01,2022-07-16,Unverified,li_association_2021,CHN
210806_China_FudanUniversity_NoOcularDisease_Sex_Female,210806_China_FudanUniversity_NoOcularDisease,Association of Ocular Surface Diseases With SARS-CoV-2 Infection in Six Districts of China: An Observational Cohort Study.,2021-08-06,Journal Article (Peer-Reviewed),National,Prospective cohort,China,,,"""In this study, all the participants were RT-PCR negative for SARS-CoV-2 from throat swabs.""","""The subjects who have been vaccinated against SARS-CoV-2 were excluded from this study (n=81).""",2020-05-15,2021-03-15,Residual sera,Female,Multiple groups,,,Sex/Gender,,3100,0.011000000000000001,,,,,,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Shengjie Li,Shanghai Engineering Research Center of Laser and Autostereoscopic 3D for Vision Care,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2021.695428,2021-09-01,2022-07-16,Unverified,li_association_2021,CHN
210806_China_FudanUniversity_NoOcularDisease_Province_Henan,210806_China_FudanUniversity_NoOcularDisease,Association of Ocular Surface Diseases With SARS-CoV-2 Infection in Six Districts of China: An Observational Cohort Study.,2021-08-06,Journal Article (Peer-Reviewed),Regional,Prospective cohort,China,Henan,,"""In this study, all the participants were RT-PCR negative for SARS-CoV-2 from throat swabs.""","""The subjects who have been vaccinated against SARS-CoV-2 were excluded from this study (n=81).""",2020-05-15,2021-03-15,Residual sera,All,Multiple groups,,,Geographical area,Henan,609,0.008199999999999999,,,,,,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Shengjie Li,Shanghai Engineering Research Center of Laser and Autostereoscopic 3D for Vision Care,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2021.695428,2021-09-01,2022-07-16,Unverified,li_association_2021,CHN
210806_China_FudanUniversity_NoOcularDisease_Province_Shanghai,210806_China_FudanUniversity_NoOcularDisease,Association of Ocular Surface Diseases With SARS-CoV-2 Infection in Six Districts of China: An Observational Cohort Study.,2021-08-06,Journal Article (Peer-Reviewed),Regional,Prospective cohort,China,Shanghai,,"""In this study, all the participants were RT-PCR negative for SARS-CoV-2 from throat swabs.""","""The subjects who have been vaccinated against SARS-CoV-2 were excluded from this study (n=81).""",2020-05-15,2021-03-15,Residual sera,All,Multiple groups,,,Geographical area,Shanghai ,1035,0.0087,,,,,,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Shengjie Li,Shanghai Engineering Research Center of Laser and Autostereoscopic 3D for Vision Care,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2021.695428,2021-09-01,2022-07-16,Unverified,li_association_2021,CHN
210806_China_FudanUniversity_NoOcularDisease_Province_Jiangxi,210806_China_FudanUniversity_NoOcularDisease,Association of Ocular Surface Diseases With SARS-CoV-2 Infection in Six Districts of China: An Observational Cohort Study.,2021-08-06,Journal Article (Peer-Reviewed),Regional,Prospective cohort,China,Jiangxi,,"""In this study, all the participants were RT-PCR negative for SARS-CoV-2 from throat swabs.""","""The subjects who have been vaccinated against SARS-CoV-2 were excluded from this study (n=81).""",2020-05-15,2021-03-15,Residual sera,All,Multiple groups,,,Geographical area,Jiangxi,685,0.0102,,,,,,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Shengjie Li,Shanghai Engineering Research Center of Laser and Autostereoscopic 3D for Vision Care,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2021.695428,2021-09-01,2022-07-16,Unverified,li_association_2021,CHN
210806_China_FudanUniversity_NoOcularDisease_Province_Jiangsu,210806_China_FudanUniversity_NoOcularDisease,Association of Ocular Surface Diseases With SARS-CoV-2 Infection in Six Districts of China: An Observational Cohort Study.,2021-08-06,Journal Article (Peer-Reviewed),Regional,Prospective cohort,China,Jiangsu,,"""In this study, all the participants were RT-PCR negative for SARS-CoV-2 from throat swabs.""","""The subjects who have been vaccinated against SARS-CoV-2 were excluded from this study (n=81).""",2020-05-15,2021-03-15,Residual sera,All,Multiple groups,,,Geographical area,Jiangsu,1239,0.008100000000000001,,,,,,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Shengjie Li,Shanghai Engineering Research Center of Laser and Autostereoscopic 3D for Vision Care,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2021.695428,2021-09-01,2022-07-16,Unverified,li_association_2021,CHN
210806_China_FudanUniversity_NoOcularDisease_Sex_Male,210806_China_FudanUniversity_NoOcularDisease,Association of Ocular Surface Diseases With SARS-CoV-2 Infection in Six Districts of China: An Observational Cohort Study.,2021-08-06,Journal Article (Peer-Reviewed),National,Prospective cohort,China,,,"""In this study, all the participants were RT-PCR negative for SARS-CoV-2 from throat swabs.""","""The subjects who have been vaccinated against SARS-CoV-2 were excluded from this study (n=81).""",2020-05-15,2021-03-15,Residual sera,Male,Multiple groups,,,Sex/Gender,,2752,0.0073,,,,,,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Shengjie Li,Shanghai Engineering Research Center of Laser and Autostereoscopic 3D for Vision Care,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2021.695428,2021-09-01,2022-07-16,Unverified,li_association_2021,CHN
210806_China_FudanUniversity_NoOcularDisease_Province_Zhejiang,210806_China_FudanUniversity_NoOcularDisease,Association of Ocular Surface Diseases With SARS-CoV-2 Infection in Six Districts of China: An Observational Cohort Study.,2021-08-06,Journal Article (Peer-Reviewed),Regional,Prospective cohort,China,Zhejiang,,"""In this study, all the participants were RT-PCR negative for SARS-CoV-2 from throat swabs.""","""The subjects who have been vaccinated against SARS-CoV-2 were excluded from this study (n=81).""",2020-05-15,2021-03-15,Residual sera,All,Multiple groups,,,Geographical area,Zhejiang,1455,0.011000000000000001,,,,,,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Shengjie Li,Shanghai Engineering Research Center of Laser and Autostereoscopic 3D for Vision Care,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2021.695428,2021-09-01,2022-07-16,Unverified,li_association_2021,CHN
210806_China_FudanUniversity_NoOcularDisease_Province_Anhui,210806_China_FudanUniversity_NoOcularDisease,Association of Ocular Surface Diseases With SARS-CoV-2 Infection in Six Districts of China: An Observational Cohort Study.,2021-08-06,Journal Article (Peer-Reviewed),Regional,Prospective cohort,China,Anhui,,"""In this study, all the participants were RT-PCR negative for SARS-CoV-2 from throat swabs.""","""The subjects who have been vaccinated against SARS-CoV-2 were excluded from this study (n=81).""",2020-05-15,2021-03-15,Residual sera,All,Multiple groups,,,Geographical area,Anhui,829,0.0084,,,,,,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Shengjie Li,Shanghai Engineering Research Center of Laser and Autostereoscopic 3D for Vision Care,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2021.695428,2021-09-01,2022-07-16,Unverified,li_association_2021,CHN
210806_China_FudanUniversity_NoOcularSurfaceDisease_Overall,210806_China_FudanUniversity_NoOcularSurfaceDisease,Association of Ocular Surface Diseases With SARS-CoV-2 Infection in Six Districts of China: An Observational Cohort Study.,2021-08-06,Journal Article (Peer-Reviewed),National,Prospective cohort,China,,,"""In this study, all the participants were RT-PCR negative for SARS-CoV-2 from throat swabs.""","""The subjects who have been vaccinated against SARS-CoV-2 were excluded from this study (n=81).""",2020-05-15,2021-03-15,Representative patient population,All,Multiple groups,,,Primary Estimate,,12550,0.006999999999999999,,,True,,,,True,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Shengjie Li,Shanghai Engineering Research Center of Laser and Autostereoscopic 3D for Vision Care,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2021.695428,2021-09-01,2022-07-16,Unverified,li_association_2021,CHN
210806_China_FudanUniversity_OcularSurfaceDisease_Overall,210806_China_FudanUniversity_OcularSurfaceDisease_Sex_Female,Association of Ocular Surface Diseases With SARS-CoV-2 Infection in Six Districts of China: An Observational Cohort Study.,2021-08-06,Journal Article (Peer-Reviewed),National,Prospective cohort,China,,,"""In this study, all the participants were RT-PCR negative for SARS-CoV-2 from throat swabs.""","""The subjects who have been vaccinated against SARS-CoV-2 were excluded from this study (n=81).""",2020-05-15,2021-03-15,Representative patient population,All,Multiple groups,,,Primary Estimate,Ocular Surface Diseases,1755,0.022799999999999997,,,True,,,,True,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Shengjie Li,Shanghai Engineering Research Center of Laser and Autostereoscopic 3D for Vision Care,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2021.695428,2021-08-31,2022-07-16,Unverified,li_association_2021,CHN
210915_Wuhan_HubeiProvincialHospital_AgeSexAdj,210915_Wuhan_HubeiProvincialHospital,Seroprevalence of IgM and IgG Antibodies against SARS-CoV-2 in Asymptomatic People in Wuhan: Data from a General Hospital Near South China Seafood Wholesale Market during March to April in 2020.,2021-09-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"18,712 asymptomatic participants from 154 work units in Wuhan in a general hospital near the Huanan Seafood Wholesale Market",,2020-03-25,2020-04-28,Multiple populations,All,Multiple groups,4.0,81.0,Primary Estimate,,18712,0.0315,0.028999999999999998,0.034,True,,True,,True,Convenience,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,No,No,Yes,No,,LING Rui Jie,Hubei Provincial Hospital,Not Unity-Aligned,https://dx.doi.org/10.3967/bes2021.103,2021-09-28,2024-03-01,Verified,jie_seroprevalence_2021,CHN
211115_HongKong_TheChineseUniversityofHongKong_Overall_PopAdjusted,211115_HongKong_TheChineseUniversityofHongKong,Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves.,2021-11-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,China,,,"Adults 18 years or older were invited through various public channels, including posters, e-mails, and social media.",Individuals with COVID-19 confirmed in Hong Kong or elsewhere were excluded.,2020-04-21,2021-04-18,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,4198,0.0015,0.0006,0.0032,True,,True,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Author designed (ELISA) -Spike","Roche Diagnostics,NA",Multiple Types,Plasma,"['IgG', 'Notreported']",Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Siaw Boon,The Chinese University of Hong Kong,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.32923,2021-11-22,2024-03-01,Unverified,boon_seroprevalence_2021,CHN
211115_HongKong_TheChineseUniversityofHongKong_Recruitment2,211115_HongKong_TheChineseUniversityofHongKong,Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves.,2021-11-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,China,,,"Adults 18 years or older were invited through various public channels, including posters, e-mails, and social media.",Individuals with COVID-19 confirmed in Hong Kong or elsewhere were excluded.,2020-09-29,2020-11-23,Household and community samples,All,Multiple groups,18.0,,Time frame,20200929-20201123,1046,0.001,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Author designed (ELISA) -Spike","Roche Diagnostics,NA",Multiple Types,Plasma,"['IgG', 'Notreported']",Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Siaw Boon,The Chinese University of Hong Kong,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.32923,2021-11-22,2024-03-01,Unverified,boon_seroprevalence_2021,CHN
211115_HongKong_TheChineseUniversityofHongKong_Recruitment1,211115_HongKong_TheChineseUniversityofHongKong,Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves.,2021-11-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,China,,,"Adults 18 years or older were invited through various public channels, including posters, e-mails, and social media.",Individuals with COVID-19 confirmed in Hong Kong or elsewhere were excluded.,2020-04-21,2020-07-07,Household and community samples,All,Multiple groups,18.0,,Time frame,20200421-20200707,903,0.0022,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Author designed (ELISA) -Spike","Roche Diagnostics,NA",Multiple Types,Plasma,"['IgG', 'Notreported']",Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Siaw Boon,The Chinese University of Hong Kong,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.32923,2021-11-22,2024-03-01,Unverified,boon_seroprevalence_2021,CHN
211115_HongKong_TheChineseUniversityofHongKong_Recruitment3,211115_HongKong_TheChineseUniversityofHongKong,Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves.,2021-11-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,China,,,"Adults 18 years or older were invited through various public channels, including posters, e-mails, and social media.",Individuals with COVID-19 confirmed in Hong Kong or elsewhere were excluded.,2021-01-15,2021-04-18,Household and community samples,All,Multiple groups,18.0,,Time frame,20210115-20210418,2249,0.0013000000000000002,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Author designed (ELISA) -Spike","Roche Diagnostics,NA",Multiple Types,Plasma,"['IgG', 'Notreported']",Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Siaw Boon,The Chinese University of Hong Kong,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.32923,2021-11-22,2024-03-01,Unverified,boon_seroprevalence_2021,CHN
211115_HongKong_TheChineseUniversityofHongKong_Overall_Unadjusted,211115_HongKong_TheChineseUniversityofHongKong,Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves.,2021-11-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,China,,,"Adults 18 years or older were invited through various public channels, including posters, e-mails, and social media.",Individuals with COVID-19 confirmed in Hong Kong or elsewhere were excluded.,2020-04-21,2021-04-18,Household and community samples,All,Multiple groups,18.0,,Analysis,,4198,0.0014000000000000002,0.0005,0.0031,,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Author designed (ELISA) -Spike","Roche Diagnostics,NA",Multiple Types,Plasma,"['IgG', 'Notreported']",Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Siaw Boon,The Chinese University of Hong Kong,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.32923,2021-11-22,2024-03-01,Unverified,boon_seroprevalence_2021,CHN
211118_Guangdong_GuangzhouMedicalUniversity_OverallPopAdjust,211118_Guangdong_GuangzhouMedicalUniversity,"Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020.",2021-11-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,China,Guangdong,"Chaozhou,Heyuan,Jiangmen,Jieyang,Maoming,Meizhou,Qingyuan,Shantou,Shanwei,Shaoguan,Yangjiang,Yunfu,Zhanjiang,Zhaoqing,Dongguan,Foshan,Guangzhou,Huizhou,Shenzhen,Zhongshan,Zhuhai",We selected sera submitted for blood chemistry tests,excluded those that were submitted for autoimmune or cancer screening.,2020-03-11,2020-06-24,Residual sera,All,Multiple groups,,,Primary Estimate,Population adjusted,14629,0.0015,0.0006,0.0024,True,,True,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.8959999999999999,0.9920000000000001,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Cheng Xiao,Guangzhou Medical University,Not Unity-Aligned,https://www.mdpi.com/2076-0817/10/11/1505/htm,2021-12-08,2022-07-16,Unverified,xiao_seroprevalence_2021,CHN
211118_Guangdong_GuangzhouMedicalUniversity_RegionDongguan,211118_Guangdong_GuangzhouMedicalUniversity,"Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020.",2021-11-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Guangdong,Dongguan,We selected sera submitted for blood chemistry tests,excluded those that were submitted for autoimmune or cancer screening.,2020-03-11,2020-06-24,Residual sera,All,Multiple groups,,,Geographical area,Dongguan,1235,0.0,,,,,,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.8959999999999999,0.9920000000000001,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Cheng Xiao,Guangzhou Medical University,Not Unity-Aligned,https://www.mdpi.com/2076-0817/10/11/1505/htm,2021-12-08,2022-07-16,Unverified,xiao_seroprevalence_2021,CHN
211118_Guangdong_GuangzhouMedicalUniversity_RegionShaoguan,211118_Guangdong_GuangzhouMedicalUniversity,"Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020.",2021-11-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Guangdong,Shaoguan,We selected sera submitted for blood chemistry tests,excluded those that were submitted for autoimmune or cancer screening.,2020-03-11,2020-06-24,Residual sera,All,Multiple groups,,,Geographical area,Shaoguan,346,0.0,,,,,,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.8959999999999999,0.9920000000000001,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Cheng Xiao,Guangzhou Medical University,Not Unity-Aligned,https://www.mdpi.com/2076-0817/10/11/1505/htm,2021-12-08,2022-07-16,Unverified,xiao_seroprevalence_2021,CHN
211118_Guangdong_GuangzhouMedicalUniversity_RegionMaoming,211118_Guangdong_GuangzhouMedicalUniversity,"Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020.",2021-11-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Guangdong,Maoming,We selected sera submitted for blood chemistry tests,excluded those that were submitted for autoimmune or cancer screening.,2020-03-11,2020-06-24,Residual sera,All,Multiple groups,,,Geographical area,Maoming,886,0.0,,,,,,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.8959999999999999,0.9920000000000001,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Cheng Xiao,Guangzhou Medical University,Not Unity-Aligned,https://www.mdpi.com/2076-0817/10/11/1505/htm,2021-12-08,2022-07-16,Unverified,xiao_seroprevalence_2021,CHN
211118_Guangdong_GuangzhouMedicalUniversity_RegionZhaoqing,211118_Guangdong_GuangzhouMedicalUniversity,"Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020.",2021-11-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Guangdong,Zhaoqing,We selected sera submitted for blood chemistry tests,excluded those that were submitted for autoimmune or cancer screening.,2020-03-11,2020-06-24,Residual sera,All,Multiple groups,,,Geographical area,Zhaoqing,237,0.0,,,,,,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.8959999999999999,0.9920000000000001,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Cheng Xiao,Guangzhou Medical University,Not Unity-Aligned,https://www.mdpi.com/2076-0817/10/11/1505/htm,2021-12-08,2022-07-16,Unverified,xiao_seroprevalence_2021,CHN
211118_Guangdong_GuangzhouMedicalUniversity_Age10-19,211118_Guangdong_GuangzhouMedicalUniversity,"Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020.",2021-11-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,China,Guangdong,"Chaozhou,Heyuan,Jiangmen,Jieyang,Maoming,Meizhou,Qingyuan,Shantou,Shanwei,Shaoguan,Yangjiang,Yunfu,Zhanjiang,Zhaoqing,Dongguan,Foshan,Guangzhou,Huizhou,Shenzhen,Zhongshan,Zhuhai",We selected sera submitted for blood chemistry tests,excluded those that were submitted for autoimmune or cancer screening.,2020-03-11,2020-06-24,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,915,0.0022,0.0003,0.0079,,,,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.8959999999999999,0.9920000000000001,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Cheng Xiao,Guangzhou Medical University,Not Unity-Aligned,https://www.mdpi.com/2076-0817/10/11/1505/htm,2021-12-08,2022-07-16,Unverified,xiao_seroprevalence_2021,CHN
211118_Guangdong_GuangzhouMedicalUniversity_RegionChaozhou,211118_Guangdong_GuangzhouMedicalUniversity,"Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020.",2021-11-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Guangdong,Chaozhou,We selected sera submitted for blood chemistry tests,excluded those that were submitted for autoimmune or cancer screening.,2020-03-11,2020-06-24,Residual sera,All,Multiple groups,,,Geographical area,Chaozhou,195,0.0,,,,,,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.8959999999999999,0.9920000000000001,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Cheng Xiao,Guangzhou Medical University,Not Unity-Aligned,https://www.mdpi.com/2076-0817/10/11/1505/htm,2021-12-08,2022-07-16,Unverified,xiao_seroprevalence_2021,CHN
211118_Guangdong_GuangzhouMedicalUniversity_RegionGuangzhou,211118_Guangdong_GuangzhouMedicalUniversity,"Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020.",2021-11-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Guangdong,Guangzhou,We selected sera submitted for blood chemistry tests,excluded those that were submitted for autoimmune or cancer screening.,2020-03-11,2020-06-24,Residual sera,All,Multiple groups,,,Geographical area,Guangzhou,2520,0.0008,,,,,,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.8959999999999999,0.9920000000000001,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Cheng Xiao,Guangzhou Medical University,Not Unity-Aligned,https://www.mdpi.com/2076-0817/10/11/1505/htm,2021-12-08,2022-07-16,Unverified,xiao_seroprevalence_2021,CHN
211118_Guangdong_GuangzhouMedicalUniversity_RegionHeyuan,211118_Guangdong_GuangzhouMedicalUniversity,"Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020.",2021-11-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Guangdong,Heyuan,We selected sera submitted for blood chemistry tests,excluded those that were submitted for autoimmune or cancer screening.,2020-03-11,2020-06-24,Residual sera,All,Multiple groups,,,Geographical area,Heyuan,90,0.0,,,,,,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.8959999999999999,0.9920000000000001,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Cheng Xiao,Guangzhou Medical University,Not Unity-Aligned,https://www.mdpi.com/2076-0817/10/11/1505/htm,2021-12-08,2022-07-16,Unverified,xiao_seroprevalence_2021,CHN
211118_Guangdong_GuangzhouMedicalUniversity_RegionShanwei,211118_Guangdong_GuangzhouMedicalUniversity,"Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020.",2021-11-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Guangdong,Shanwei,We selected sera submitted for blood chemistry tests,excluded those that were submitted for autoimmune or cancer screening.,2020-03-11,2020-06-24,Residual sera,All,Multiple groups,,,Geographical area,Shanwei,533,0.0,,,,,,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.8959999999999999,0.9920000000000001,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Cheng Xiao,Guangzhou Medical University,Not Unity-Aligned,https://www.mdpi.com/2076-0817/10/11/1505/htm,2021-12-08,2022-07-16,Unverified,xiao_seroprevalence_2021,CHN
211118_Guangdong_GuangzhouMedicalUniversity_RegionShenzhen,211118_Guangdong_GuangzhouMedicalUniversity,"Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020.",2021-11-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Guangdong,Shenzhen,We selected sera submitted for blood chemistry tests,excluded those that were submitted for autoimmune or cancer screening.,2020-03-11,2020-06-24,Residual sera,All,Multiple groups,,,Geographical area,Shenzhen,2231,0.0022,,,,,,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.8959999999999999,0.9920000000000001,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Cheng Xiao,Guangzhou Medical University,Not Unity-Aligned,https://www.mdpi.com/2076-0817/10/11/1505/htm,2021-12-08,2022-07-16,Unverified,xiao_seroprevalence_2021,CHN
211118_Guangdong_GuangzhouMedicalUniversity_Age40-59,211118_Guangdong_GuangzhouMedicalUniversity,"Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020.",2021-11-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,China,Guangdong,"Chaozhou,Heyuan,Jiangmen,Jieyang,Maoming,Meizhou,Qingyuan,Shantou,Shanwei,Shaoguan,Yangjiang,Yunfu,Zhanjiang,Zhaoqing,Dongguan,Foshan,Guangzhou,Huizhou,Shenzhen,Zhongshan,Zhuhai",We selected sera submitted for blood chemistry tests,excluded those that were submitted for autoimmune or cancer screening.,2020-03-11,2020-06-24,Residual sera,All,Adults (18-64 years),40.0,59.0,Age,40-59,3128,0.0013000000000000002,0.0004,0.0033000000000000004,,,,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.8959999999999999,0.9920000000000001,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Cheng Xiao,Guangzhou Medical University,Not Unity-Aligned,https://www.mdpi.com/2076-0817/10/11/1505/htm,2021-12-08,2022-07-16,Unverified,xiao_seroprevalence_2021,CHN
211118_Guangdong_GuangzhouMedicalUniversity_RegionJieyang,211118_Guangdong_GuangzhouMedicalUniversity,"Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020.",2021-11-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Guangdong,Jieyang,We selected sera submitted for blood chemistry tests,excluded those that were submitted for autoimmune or cancer screening.,2020-03-11,2020-06-24,Residual sera,All,Multiple groups,,,Geographical area,Jieyang,435,0.0,,,,,,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.8959999999999999,0.9920000000000001,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Cheng Xiao,Guangzhou Medical University,Not Unity-Aligned,https://www.mdpi.com/2076-0817/10/11/1505/htm,2021-12-08,2022-07-16,Unverified,xiao_seroprevalence_2021,CHN
211118_Guangdong_GuangzhouMedicalUniversity_RegionYunfu,211118_Guangdong_GuangzhouMedicalUniversity,"Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020.",2021-11-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Guangdong,Yunfu,We selected sera submitted for blood chemistry tests,excluded those that were submitted for autoimmune or cancer screening.,2020-03-11,2020-06-24,Residual sera,All,Multiple groups,,,Geographical area,Yunfu,161,0.0,,,,,,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.8959999999999999,0.9920000000000001,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Cheng Xiao,Guangzhou Medical University,Not Unity-Aligned,https://www.mdpi.com/2076-0817/10/11/1505/htm,2021-12-08,2022-07-16,Unverified,xiao_seroprevalence_2021,CHN
211118_Guangdong_GuangzhouMedicalUniversity_RegionShantou,211118_Guangdong_GuangzhouMedicalUniversity,"Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020.",2021-11-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Guangdong,Shantou,We selected sera submitted for blood chemistry tests,excluded those that were submitted for autoimmune or cancer screening.,2020-03-11,2020-06-24,Residual sera,All,Multiple groups,,,Geographical area,Shantou,497,0.006,,,,,,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.8959999999999999,0.9920000000000001,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Cheng Xiao,Guangzhou Medical University,Not Unity-Aligned,https://www.mdpi.com/2076-0817/10/11/1505/htm,2021-12-08,2022-07-16,Unverified,xiao_seroprevalence_2021,CHN
211118_Guangdong_GuangzhouMedicalUniversity_RegionYangjiang,211118_Guangdong_GuangzhouMedicalUniversity,"Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020.",2021-11-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Guangdong,Yangjiang,We selected sera submitted for blood chemistry tests,excluded those that were submitted for autoimmune or cancer screening.,2020-03-11,2020-06-24,Residual sera,All,Multiple groups,,,Geographical area,Yangjiang,281,0.0,,,,,,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.8959999999999999,0.9920000000000001,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Cheng Xiao,Guangzhou Medical University,Not Unity-Aligned,https://www.mdpi.com/2076-0817/10/11/1505/htm,2021-12-08,2022-07-16,Unverified,xiao_seroprevalence_2021,CHN
211118_Guangdong_GuangzhouMedicalUniversity_Age20-39,211118_Guangdong_GuangzhouMedicalUniversity,"Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020.",2021-11-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,China,Guangdong,"Chaozhou,Heyuan,Jiangmen,Jieyang,Maoming,Meizhou,Qingyuan,Shantou,Shanwei,Shaoguan,Yangjiang,Yunfu,Zhanjiang,Zhaoqing,Dongguan,Foshan,Guangzhou,Huizhou,Shenzhen,Zhongshan,Zhuhai",We selected sera submitted for blood chemistry tests,excluded those that were submitted for autoimmune or cancer screening.,2020-03-11,2020-06-24,Residual sera,All,Adults (18-64 years),20.0,39.0,Age,20-39,4317,0.0016,0.0007000000000000001,0.0033000000000000004,,,,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.8959999999999999,0.9920000000000001,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Cheng Xiao,Guangzhou Medical University,Not Unity-Aligned,https://www.mdpi.com/2076-0817/10/11/1505/htm,2021-12-08,2022-07-16,Unverified,xiao_seroprevalence_2021,CHN
211118_Guangdong_GuangzhouMedicalUniversity_RegionZhuhai,211118_Guangdong_GuangzhouMedicalUniversity,"Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020.",2021-11-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Guangdong,Zhuhai,We selected sera submitted for blood chemistry tests,excluded those that were submitted for autoimmune or cancer screening.,2020-03-11,2020-06-24,Residual sera,All,Multiple groups,,,Geographical area,Zhuhai,706,0.0042,,,,,,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.8959999999999999,0.9920000000000001,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Cheng Xiao,Guangzhou Medical University,Not Unity-Aligned,https://www.mdpi.com/2076-0817/10/11/1505/htm,2021-12-08,2022-07-16,Unverified,xiao_seroprevalence_2021,CHN
211118_Guangdong_GuangzhouMedicalUniversity_RegionMeizhou,211118_Guangdong_GuangzhouMedicalUniversity,"Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020.",2021-11-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Guangdong,Meizhou,We selected sera submitted for blood chemistry tests,excluded those that were submitted for autoimmune or cancer screening.,2020-03-11,2020-06-24,Residual sera,All,Multiple groups,,,Geographical area,Meizhou,119,0.0,,,,,,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.8959999999999999,0.9920000000000001,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Cheng Xiao,Guangzhou Medical University,Not Unity-Aligned,https://www.mdpi.com/2076-0817/10/11/1505/htm,2021-12-08,2022-07-16,Unverified,xiao_seroprevalence_2021,CHN
211118_Guangdong_GuangzhouMedicalUniversity_RegionHuizhou,211118_Guangdong_GuangzhouMedicalUniversity,"Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020.",2021-11-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Guangdong,Huizhou,We selected sera submitted for blood chemistry tests,excluded those that were submitted for autoimmune or cancer screening.,2020-03-11,2020-06-24,Residual sera,All,Multiple groups,,,Geographical area,Huizhou,933,0.0011,,,,,,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.8959999999999999,0.9920000000000001,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Cheng Xiao,Guangzhou Medical University,Not Unity-Aligned,https://www.mdpi.com/2076-0817/10/11/1505/htm,2021-12-08,2022-07-16,Unverified,xiao_seroprevalence_2021,CHN
211118_Guangdong_GuangzhouMedicalUniversity_Age0-9,211118_Guangdong_GuangzhouMedicalUniversity,"Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020.",2021-11-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,China,Guangdong,"Chaozhou,Heyuan,Jiangmen,Jieyang,Maoming,Meizhou,Qingyuan,Shantou,Shanwei,Shaoguan,Yangjiang,Yunfu,Zhanjiang,Zhaoqing,Dongguan,Foshan,Guangzhou,Huizhou,Shenzhen,Zhongshan,Zhuhai",We selected sera submitted for blood chemistry tests,excluded those that were submitted for autoimmune or cancer screening.,2020-03-11,2020-06-24,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,0-9,2969,0.0007000000000000001,0.0001,0.0024,,,,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.8959999999999999,0.9920000000000001,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Cheng Xiao,Guangzhou Medical University,Not Unity-Aligned,https://www.mdpi.com/2076-0817/10/11/1505/htm,2021-12-08,2022-07-16,Unverified,xiao_seroprevalence_2021,CHN
211118_Guangdong_GuangzhouMedicalUniversity_RegionJiangmen,211118_Guangdong_GuangzhouMedicalUniversity,"Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020.",2021-11-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Guangdong,Jiangmen,We selected sera submitted for blood chemistry tests,excluded those that were submitted for autoimmune or cancer screening.,2020-03-11,2020-06-24,Residual sera,All,Multiple groups,,,Geographical area,Jiangmen,200,0.005,,,,,,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.8959999999999999,0.9920000000000001,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Cheng Xiao,Guangzhou Medical University,Not Unity-Aligned,https://www.mdpi.com/2076-0817/10/11/1505/htm,2021-12-08,2022-07-16,Unverified,xiao_seroprevalence_2021,CHN
211118_Guangdong_GuangzhouMedicalUniversity_RegionZhanjiang,211118_Guangdong_GuangzhouMedicalUniversity,"Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020.",2021-11-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Guangdong,Zhanjiang,We selected sera submitted for blood chemistry tests,excluded those that were submitted for autoimmune or cancer screening.,2020-03-11,2020-06-24,Residual sera,All,Multiple groups,,,Geographical area,Zhanjiang,158,0.0,,,,,,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.8959999999999999,0.9920000000000001,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Cheng Xiao,Guangzhou Medical University,Not Unity-Aligned,https://www.mdpi.com/2076-0817/10/11/1505/htm,2021-12-08,2022-07-16,Unverified,xiao_seroprevalence_2021,CHN
211118_Guangdong_GuangzhouMedicalUniversity_Age60+,211118_Guangdong_GuangzhouMedicalUniversity,"Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020.",2021-11-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,China,Guangdong,"Chaozhou,Heyuan,Jiangmen,Jieyang,Maoming,Meizhou,Qingyuan,Shantou,Shanwei,Shaoguan,Yangjiang,Yunfu,Zhanjiang,Zhaoqing,Dongguan,Foshan,Guangzhou,Huizhou,Shenzhen,Zhongshan,Zhuhai",We selected sera submitted for blood chemistry tests,excluded those that were submitted for autoimmune or cancer screening.,2020-03-11,2020-06-24,Residual sera,All,Seniors (65+ years),60.0,,Age,60+,3300,0.0018,0.0007000000000000001,0.004,,,,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.8959999999999999,0.9920000000000001,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Cheng Xiao,Guangzhou Medical University,Not Unity-Aligned,https://www.mdpi.com/2076-0817/10/11/1505/htm,2021-12-08,2022-07-16,Unverified,xiao_seroprevalence_2021,CHN
211118_Guangdong_GuangzhouMedicalUniversity_RegionZhongshan,211118_Guangdong_GuangzhouMedicalUniversity,"Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020.",2021-11-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Guangdong,Zhongshan,We selected sera submitted for blood chemistry tests,excluded those that were submitted for autoimmune or cancer screening.,2020-03-11,2020-06-24,Residual sera,All,Multiple groups,,,Geographical area,Zhongshan,450,0.0044,,,,,,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.8959999999999999,0.9920000000000001,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Cheng Xiao,Guangzhou Medical University,Not Unity-Aligned,https://www.mdpi.com/2076-0817/10/11/1505/htm,2021-12-08,2022-07-16,Unverified,xiao_seroprevalence_2021,CHN
211118_Guangdong_GuangzhouMedicalUniversity_RegionQingyuan,211118_Guangdong_GuangzhouMedicalUniversity,"Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020.",2021-11-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Guangdong,Qingyuan,We selected sera submitted for blood chemistry tests,excluded those that were submitted for autoimmune or cancer screening.,2020-03-11,2020-06-24,Residual sera,All,Multiple groups,,,Geographical area,Qingyuan,1126,0.0009,,,,,,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.8959999999999999,0.9920000000000001,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Cheng Xiao,Guangzhou Medical University,Not Unity-Aligned,https://www.mdpi.com/2076-0817/10/11/1505/htm,2021-12-08,2022-07-16,Unverified,xiao_seroprevalence_2021,CHN
211118_Guangdong_GuangzhouMedicalUniversity_RegionFoshan,211118_Guangdong_GuangzhouMedicalUniversity,"Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020.",2021-11-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Guangdong,Foshan,We selected sera submitted for blood chemistry tests,excluded those that were submitted for autoimmune or cancer screening.,2020-03-11,2020-06-24,Residual sera,All,Multiple groups,,,Geographical area,Foshan,1290,0.0023,,,,,,,,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.8959999999999999,0.9920000000000001,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Cheng Xiao,Guangzhou Medical University,Not Unity-Aligned,https://www.mdpi.com/2076-0817/10/11/1505/htm,2021-12-08,2022-07-16,Unverified,xiao_seroprevalence_2021,CHN
211118_Guangdong_GuangzhouMedicalUniversity_OverallCrude,211118_Guangdong_GuangzhouMedicalUniversity,"Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020.",2021-11-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,China,Guangdong,"Chaozhou,Heyuan,Jiangmen,Jieyang,Maoming,Meizhou,Qingyuan,Shantou,Shanwei,Shaoguan,Yangjiang,Yunfu,Zhanjiang,Zhaoqing,Dongguan,Foshan,Guangzhou,Huizhou,Shenzhen,Zhongshan,Zhuhai",We selected sera submitted for blood chemistry tests,excluded those that were submitted for autoimmune or cancer screening.,2020-03-11,2020-06-24,Residual sera,All,Multiple groups,,,Analysis,Crude,14629,0.0014000000000000002,,,,,,,True,Convenience,Magnetic Chemiluminescence Enzyme Immunoassay Kit,Bioscience Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.8959999999999999,0.9920000000000001,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Cheng Xiao,Guangzhou Medical University,Not Unity-Aligned,https://www.mdpi.com/2076-0817/10/11/1505/htm,2021-12-08,2022-07-16,Unverified,xiao_seroprevalence_2021,CHN
211201_Wuhan_ZhongnanHospitalUniversityOfWuhan_IgG,211201_Wuhan_ZhongnanHospitalUniversityOfWuhan,"Public screening for COVID-19 in Wuhan, China and beware of the antibody positive in women and tumor patients.",2021-12-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"state-funded COVID-19 screening, screening before factories and companies reopened, and pre-hospital screening for patients and their escorts.",Refused to provide consent,2020-03-01,2020-06-30,Multiple populations,All,Multiple groups,,,Primary Estimate,,21398,0.045700000000000005,0.043,0.048600000000000004,True,,,,True,Convenience,"iFlash-SARS-CoV-2 IgM/IgG,Author designed (LFIA)","Shenzhen Yhlo Biotech Co. Ltd,NA",Multiple Types,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,No,,Unclear,No,No,,Yufeng Shang,University of Wuhan Zhongnan Hospital,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27483,2021-12-09,2022-07-16,Unverified,shang_public_2021,CHN
220104_Wuhan_ZhongnanHospitalOfWuhanUniversity_IgG,220104_Wuhan_ZhongnanHospitalOfWuhanUniversity,Surveillance of SARS-CoV-2 antibodies of patients in the local affected area during Wuhan lockdown.,2022-01-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"Blood samples were collected from a total of 3062
outpatients, including 2597 ordinary patients (outpatients
without COVID-19 confirmed history or symptoms related to COVID-19) for COVID-19 screening",,2020-03-21,2020-05-21,Residual sera,All,Multiple groups,,,Primary Estimate,,3062,0.0751,,,True,,,,True,Convenience,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.89,0.98,['High'],,No,Yes,Yes,,No,Yes,No,,Yueting Tang,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-07010-w,2022-01-09,2024-03-01,Unverified,tang_surveillance_2022,CHN
220104_Wuhan_ZhongnanHospitalOfWuhanUniversity_IgGAge41to60,220104_Wuhan_ZhongnanHospitalOfWuhanUniversity,Surveillance of SARS-CoV-2 antibodies of patients in the local affected area during Wuhan lockdown.,2022-01-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"Blood samples were collected from a total of 3062
outpatients, including 2597 ordinary patients (outpatients
without COVID-19 confirmed history or symptoms related to COVID-19) for COVID-19 screening",,2020-03-21,2020-05-21,Residual sera,All,Adults (18-64 years),41.0,60.0,Age,age: 41-60,1262,0.0824,0.0681,0.0993,,,,,,Convenience,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.89,0.98,['High'],,No,Yes,Yes,,No,Yes,No,,Yueting Tang,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-07010-w,2022-01-09,2024-03-01,Unverified,tang_surveillance_2022,CHN
220104_Wuhan_ZhongnanHospitalOfWuhanUniversity_IgGAgeOver60,220104_Wuhan_ZhongnanHospitalOfWuhanUniversity,Surveillance of SARS-CoV-2 antibodies of patients in the local affected area during Wuhan lockdown.,2022-01-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"Blood samples were collected from a total of 3062
outpatients, including 2597 ordinary patients (outpatients
without COVID-19 confirmed history or symptoms related to COVID-19) for COVID-19 screening",,2020-03-21,2020-05-21,Residual sera,All,Seniors (65+ years),60.0,,Age,age: >=60,685,0.0861,0.0667,0.1103,,,,,,Convenience,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.89,0.98,['High'],,No,Yes,Yes,,No,Yes,No,,Yueting Tang,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-07010-w,2022-01-09,2024-03-01,Unverified,tang_surveillance_2022,CHN
220104_Wuhan_ZhongnanHospitalOfWuhanUniversity_IgGMale,220104_Wuhan_ZhongnanHospitalOfWuhanUniversity,Surveillance of SARS-CoV-2 antibodies of patients in the local affected area during Wuhan lockdown.,2022-01-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"Blood samples were collected from a total of 3062
outpatients, including 2597 ordinary patients (outpatients
without COVID-19 confirmed history or symptoms related to COVID-19) for COVID-19 screening",,2020-03-21,2020-05-21,Residual sera,Male,Multiple groups,,,Sex/Gender,,1652,0.063,0.052000000000000005,0.076,,,,,,Convenience,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.89,0.98,['High'],,No,Yes,Yes,,No,Yes,No,,Yueting Tang,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-07010-w,2022-01-09,2024-03-01,Unverified,tang_surveillance_2022,CHN
220104_Wuhan_ZhongnanHospitalOfWuhanUniversity_IgGAge21to40,220104_Wuhan_ZhongnanHospitalOfWuhanUniversity,Surveillance of SARS-CoV-2 antibodies of patients in the local affected area during Wuhan lockdown.,2022-01-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"Blood samples were collected from a total of 3062
outpatients, including 2597 ordinary patients (outpatients
without COVID-19 confirmed history or symptoms related to COVID-19) for COVID-19 screening",,2020-03-21,2020-05-21,Residual sera,All,Adults (18-64 years),21.0,40.0,Age,age: 21-40,1059,0.061399999999999996,0.048,0.078,,,,,,Convenience,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.89,0.98,['High'],,No,Yes,Yes,,No,Yes,No,,Yueting Tang,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-07010-w,2022-01-09,2024-03-01,Unverified,tang_surveillance_2022,CHN
220104_Wuhan_ZhongnanHospitalOfWuhanUniversity_IgGAge20,220104_Wuhan_ZhongnanHospitalOfWuhanUniversity,Surveillance of SARS-CoV-2 antibodies of patients in the local affected area during Wuhan lockdown.,2022-01-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"Blood samples were collected from a total of 3062
outpatients, including 2597 ordinary patients (outpatients
without COVID-19 confirmed history or symptoms related to COVID-19) for COVID-19 screening",,2020-03-21,2020-05-21,Residual sera,All,Children and Youth (0-17 years),,20.0,Age,age: <= 20,56,0.0357,0.0062,0.1338,,,,,,Convenience,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.89,0.98,['High'],,No,Yes,Yes,,No,Yes,No,,Yueting Tang,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-07010-w,2022-01-09,2024-03-01,Unverified,tang_surveillance_2022,CHN
220104_Wuhan_ZhongnanHospitalOfWuhanUniversity_IgGFemale,220104_Wuhan_ZhongnanHospitalOfWuhanUniversity,Surveillance of SARS-CoV-2 antibodies of patients in the local affected area during Wuhan lockdown.,2022-01-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"Blood samples were collected from a total of 3062
outpatients, including 2597 ordinary patients (outpatients
without COVID-19 confirmed history or symptoms related to COVID-19) for COVID-19 screening",,2020-03-21,2020-05-21,Residual sera,Female,Multiple groups,,,Sex/Gender,,1401,0.0894,0.0752,0.1058,,,,,,Convenience,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.89,0.98,['High'],,No,Yes,Yes,,No,Yes,No,,Yueting Tang,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-07010-w,2022-01-09,2024-03-01,Unverified,tang_surveillance_2022,CHN
220110_Chongqing_ArmyMedicalUniversity_GenPop,220110_Chongqing_ArmyMedicalUniversity_GenPop,"SARS-CoV-2 seroprevalence among blood donors, Chongqing, China, January 1 to May 31, 2020.",2022-01-10,Journal Article (Peer-Reviewed),Local,Retrospective cohort,China,,Chongqing,250 donors from the general population,,2020-01-01,2020-03-31,Blood donors,All,Adults (18-64 years),,,Primary Estimate,,250,0.0,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,Plasma,"['IgG', 'IgM']",,,,,['High'],,Unclear,No,Yes,,Unclear,Yes,No,,Shichun Wang,Army Medical University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jfma.2022.01.004,2022-01-25,2022-07-16,Unverified,wang_sars-cov-2_2022,CHN
220110_Chongqing_ArmyMedicalUniversity_HCW,220110_Chongqing_ArmyMedicalUniversity_HCW,"SARS-CoV-2 seroprevalence among blood donors, Chongqing, China, January 1 to May 31, 2020.",2022-01-10,Journal Article (Peer-Reviewed),Local,Retrospective cohort,China,,Chongqing,blood donors who were medical personnel,,2020-01-01,2020-03-31,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,,248,0.0,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,Plasma,"['IgG', 'IgM']",,,,,['High'],,Unclear,No,Yes,,Unclear,Yes,No,,Shichun Wang,Army Medical University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jfma.2022.01.004,2022-01-25,2022-07-16,Unverified,wang_sars-cov-2_2022,CHN
220121_HongKong_UniversityOfOxford,220121_HongKong_UniversityOfOxford,"Trans-continental analysis of over, 2000 inflammatory bowel disease patients implicates geography, disease type, and exposure to immunosuppression as drivers of SARS-CoV-2 seroprevalence: Data from the ICARUS-IBD consortium",2022-01-21,Presentation or Conference,Local,Cross-sectional survey ,China,,Hong Kong,IBD patients prior to vaccination,,2020-05-26,2021-09-24,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,72,0.0,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Atellica® IM SARS-CoV-2 Total (COV2T)","Roche Diagnostics,Siemens",,Serum,TotalAntibody,Spike,,,,['High'],,No,No,No,,Unclear,No,No,,S Y Wong,University of Oxford,Not Unity-Aligned,https://dx.doi.org/10.1093/ecco-jcc/jjab232.469,2022-03-08,2024-03-01,Unverified,wong_p342_2022,CHN
220128_HongKong_TheChineseUniversityofHongKong,220128_HongKong_TheChineseUniversityofHongKong,Effects of strict public health measures on seroprevalence of anti-SARS-CoV-2 antibodies during pregnancy.,2022-01-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,China,Hong Kong,Hong Kong,"""This prospective cohort study included pregnant women who presented for routine DSS and underwent routine blood sample collection at 11 to 13 weeks of gestation between November 2019 and October 2020. All participants delivered at Kwong Wah Hospital or Prince of Wales Hospital, Hong Kong; the last delivery occurred in March 2021. Eligibility criteria included consent to serum storage for future research purposes and intention to deliver at the booking hospital.""","Women who delivered elsewhere, experienced pregnancy termination or miscarriage, or received a diagnosis of COVID-19 before the study were excluded.",2019-11-15,2020-10-15,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,1830,0.0034000000000000002,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),High-sensitive SARS-CoV-2 S1 IgG ELISA Kit,SARS-CoV-2 S1 IgM ELISA Kit","Roche Diagnostics,ImmunoDiagnostics",Multiple Types,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Hillary Leung,The Chinese University of Hong Kong,Not Unity-Aligned,https://dx.doi.org/10.12809/hkmj219653,2022-02-09,2024-03-01,Unverified,leung_effects_2022,CHN
220128_HongKong_TheChineseUniversityofHongKong_AND,220128_HongKong_TheChineseUniversityofHongKong,Effects of strict public health measures on seroprevalence of anti-SARS-CoV-2 antibodies during pregnancy.,2022-01-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,China,Hong Kong,Hong Kong,"""This prospective cohort study included pregnant women who presented for routine DSS and underwent routine blood sample collection at 11 to 13 weeks of gestation between November 2019 and October 2020. All participants delivered at Kwong Wah Hospital or Prince of Wales Hospital, Hong Kong; the last delivery occurred in March 2021. Eligibility criteria included consent to serum storage for future research purposes and intention to deliver at the booking hospital.""","Women who delivered elsewhere, experienced pregnancy termination or miscarriage, or received a diagnosis of COVID-19 before the study were excluded.",2019-11-15,2020-10-15,Pregnant or parturient women,Female,Adults (18-64 years),,,Test used,,1830,0.0005,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),High-sensitive SARS-CoV-2 S1 IgG ELISA Kit,SARS-CoV-2 S1 IgM ELISA Kit","Roche Diagnostics,ImmunoDiagnostics",Multiple Types,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Hillary Leung,The Chinese University of Hong Kong,Not Unity-Aligned,https://dx.doi.org/10.12809/hkmj219653,2022-02-09,2024-03-01,Unverified,leung_effects_2022,CHN
220128_HongKong_TheChineseUniversityofHongKong_IgG,220128_HongKong_TheChineseUniversityofHongKong,Effects of strict public health measures on seroprevalence of anti-SARS-CoV-2 antibodies during pregnancy.,2022-01-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,China,Hong Kong,Hong Kong,"""This prospective cohort study included pregnant women who presented for routine DSS and underwent routine blood sample collection at 11 to 13 weeks of gestation between November 2019 and October 2020. All participants delivered at Kwong Wah Hospital or Prince of Wales Hospital, Hong Kong; the last delivery occurred in March 2021. Eligibility criteria included consent to serum storage for future research purposes and intention to deliver at the booking hospital.""","Women who delivered elsewhere, experienced pregnancy termination or miscarriage, or received a diagnosis of COVID-19 before the study were excluded.",2019-11-15,2020-10-15,Pregnant or parturient women,Female,Adults (18-64 years),,,Test used,,1830,0.0034000000000000002,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),High-sensitive SARS-CoV-2 S1 IgG ELISA Kit","Roche Diagnostics,ImmunoDiagnostics",Multiple Types,Serum,IgG,Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Hillary Leung,The Chinese University of Hong Kong,Not Unity-Aligned,https://dx.doi.org/10.12809/hkmj219653,2022-02-09,2024-03-01,Unverified,leung_effects_2022,CHN
220128_HongKong_TheChineseUniversityofHongKong_IgM,220128_HongKong_TheChineseUniversityofHongKong,Effects of strict public health measures on seroprevalence of anti-SARS-CoV-2 antibodies during pregnancy.,2022-01-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,China,Hong Kong,Hong Kong,"""This prospective cohort study included pregnant women who presented for routine DSS and underwent routine blood sample collection at 11 to 13 weeks of gestation between November 2019 and October 2020. All participants delivered at Kwong Wah Hospital or Prince of Wales Hospital, Hong Kong; the last delivery occurred in March 2021. Eligibility criteria included consent to serum storage for future research purposes and intention to deliver at the booking hospital.""","Women who delivered elsewhere, experienced pregnancy termination or miscarriage, or received a diagnosis of COVID-19 before the study were excluded.",2019-11-15,2020-10-15,Pregnant or parturient women,Female,Adults (18-64 years),,,Test used,,1830,0.0005,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),SARS-CoV-2 S1 IgM ELISA Kit","Roche Diagnostics,ImmunoDiagnostics",Multiple Types,Serum,IgM,Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Hillary Leung,The Chinese University of Hong Kong,Not Unity-Aligned,https://dx.doi.org/10.12809/hkmj219653,2022-02-09,2024-03-01,Unverified,leung_effects_2022,CHN
220407_HongKong_UniversityofHongKong_Overall,220407_HongKong_UniversityofHongKong,Contribution of low population immunity to the severe Omicron BA.2 outbreak in Hong Kong,2022-04-07,Preprint,Regional,Cross-sectional survey ,China,Hong Kong,,Anonymised archived serum samples from the clinical biochemistry laboratory of Queen Mary Hospital in Hong Kong were used,Specimens were excluded if there was an insufficient volume of serum.,2021-01-15,2021-12-15,Residual sera,All,Multiple groups,,,Primary Estimate,,1800,0.147,,,True,,,,True,Convenience,iFlash-SARS-CoV-2 S1 IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,Neutralizing,Spike,,,,['Moderate'],Yes,No,Yes,No,No,Yes,Yes,Yes,,Lin-Lei Chen,The University of Hong Kong,Unity-Aligned,https://www.researchsquare.com/article/rs-1512533/v1,2022-04-14,2024-03-01,Verified,chen_contribution_2022,CHN
220407_HongKong_UniversityofHongKong_Time6NovDec,220407_HongKong_UniversityofHongKong,Contribution of low population immunity to the severe Omicron BA.2 outbreak in Hong Kong,2022-04-07,Preprint,Regional,Cross-sectional survey ,China,Hong Kong,,Anonymised archived serum samples from the clinical biochemistry laboratory of Queen Mary Hospital in Hong Kong were used,Specimens were excluded if there was an insufficient volume of serum.,2021-11-15,2021-12-15,Residual sera,All,Multiple groups,,,Time frame,November-December,300,0.303,,,,,,,,Convenience,iFlash-SARS-CoV-2 S1 IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,Neutralizing,Spike,,,,['Moderate'],Yes,No,Yes,No,No,Yes,Yes,Yes,,Lin-Lei Chen,The University of Hong Kong,Unity-Aligned,https://www.researchsquare.com/article/rs-1512533/v1,2022-04-14,2024-03-01,Verified,chen_contribution_2022,CHN
220407_HongKong_UniversityofHongKong_cVNT_OmicronBA.2,220407_HongKong_UniversityofHongKong,Contribution of low population immunity to the severe Omicron BA.2 outbreak in Hong Kong,2022-04-07,Preprint,Regional,Cross-sectional survey ,China,Hong Kong,,Anonymised archived serum samples from the clinical biochemistry laboratory of Queen Mary Hospital in Hong Kong were used,Specimens were excluded if there was an insufficient volume of serum.,2021-11-15,2021-12-15,Residual sera,All,Multiple groups,,,Test used,Conventional live virus neutralization test (cVNT) for the Omicron sublineage BA.2,300,0.073,,,,,,,,Convenience,"Author designed (Neutralization Assay),iFlash-SARS-CoV-2 S1 IgG","NA,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,Neutralizing,Whole-virusantigen,,,,['Moderate'],Yes,No,Yes,No,No,Yes,Yes,Yes,,Lin-Lei Chen,The University of Hong Kong,Unity-Aligned,https://www.researchsquare.com/article/rs-1512533/v1,2022-04-14,2024-03-01,Verified,chen_contribution_2022,CHN
220407_HongKong_UniversityofHongKong_Time2MarApr,220407_HongKong_UniversityofHongKong,Contribution of low population immunity to the severe Omicron BA.2 outbreak in Hong Kong,2022-04-07,Preprint,Regional,Cross-sectional survey ,China,Hong Kong,,Anonymised archived serum samples from the clinical biochemistry laboratory of Queen Mary Hospital in Hong Kong were used,Specimens were excluded if there was an insufficient volume of serum.,2021-03-15,2021-04-15,Residual sera,All,Multiple groups,,,Time frame,March-April,300,0.017,,,,,,,,Convenience,iFlash-SARS-CoV-2 S1 IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,Neutralizing,Spike,,,,['Moderate'],Yes,No,Yes,No,No,Yes,Yes,Yes,,Lin-Lei Chen,The University of Hong Kong,Unity-Aligned,https://www.researchsquare.com/article/rs-1512533/v1,2022-04-14,2024-03-01,Verified,chen_contribution_2022,CHN
220407_HongKong_UniversityofHongKong_cVNT_OmicronBA.1,220407_HongKong_UniversityofHongKong,Contribution of low population immunity to the severe Omicron BA.2 outbreak in Hong Kong,2022-04-07,Preprint,Regional,Cross-sectional survey ,China,Hong Kong,,Anonymised archived serum samples from the clinical biochemistry laboratory of Queen Mary Hospital in Hong Kong were used,Specimens were excluded if there was an insufficient volume of serum.,2021-11-15,2021-12-15,Residual sera,All,Multiple groups,,,Test used,Conventional live virus neutralization test (cVNT) for the Omicron sublineage BA.1,300,0.023,,,,,,,,Convenience,"Author designed (Neutralization Assay),iFlash-SARS-CoV-2 S1 IgG","NA,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,Neutralizing,Whole-virusantigen,,,,['Moderate'],Yes,No,Yes,No,No,Yes,Yes,Yes,,Lin-Lei Chen,The University of Hong Kong,Unity-Aligned,https://www.researchsquare.com/article/rs-1512533/v1,2022-04-14,2024-03-01,Verified,chen_contribution_2022,CHN
220407_HongKong_UniversityofHongKong_Time5SepOct,220407_HongKong_UniversityofHongKong,Contribution of low population immunity to the severe Omicron BA.2 outbreak in Hong Kong,2022-04-07,Preprint,Regional,Cross-sectional survey ,China,Hong Kong,,Anonymised archived serum samples from the clinical biochemistry laboratory of Queen Mary Hospital in Hong Kong were used,Specimens were excluded if there was an insufficient volume of serum.,2021-09-15,2021-10-15,Residual sera,All,Multiple groups,,,Time frame,September-October,300,0.34299999999999997,,,,,,,,Convenience,iFlash-SARS-CoV-2 S1 IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,Neutralizing,Spike,,,,['Moderate'],Yes,No,Yes,No,No,Yes,Yes,Yes,,Lin-Lei Chen,The University of Hong Kong,Unity-Aligned,https://www.researchsquare.com/article/rs-1512533/v1,2022-04-14,2024-03-01,Verified,chen_contribution_2022,CHN
220429_Wuhan_ZhongnanHospitalofWuhanUniversity_HIVnegative_Overall,220429_Wuhan_ZhongnanHospitalofWuhanUniversity_HIVnegative,"Risk of SARS-CoV-2 Infection Among People Living With HIV in Wuhan, China.",2022-04-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,HIV-negative individuals aged 18 years and above who had lived in the Wuchang district for at least 1 month during the COVID-19 onset (from 1 December 2019 to 8 April 2020).,,2020-05-01,2020-05-30,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,,Primary Estimate,,1048,0.0601,,,True,,,,True,Simplified probability,Author designed (LFIA),,LFIA,Serum,"['IgG', 'IgM']",,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Mengmeng Wu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.833783,2022-05-24,2022-07-16,Unverified,wu_risk_2022,CHN
220429_Wuhan_ZhongnanHospitalofWuhanUniversity_HIVpositive_Overall,220429_Wuhan_ZhongnanHospitalofWuhanUniversity_HIVpositive,"Risk of SARS-CoV-2 Infection Among People Living With HIV in Wuhan, China.",2022-04-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"People living with HIV

individuals aged 18 years and above who had lived in the Wuchang district for at least 1 month during the COVID-19 onset (from 1 December 2019 to 8 April 2020).",,2020-05-01,2020-05-30,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,857,0.0047,,,True,,,,True,Simplified probability,Author designed (LFIA),,LFIA,Serum,"['IgG', 'IgM']",,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Mengmeng Wu,Zhongnan Hospital of Wuhan University,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.833783,2022-05-24,2022-07-16,Unverified,wu_risk_2022,CHN
220524_Wuhan_ChineseAcademyOfMedicalSciences_Overall_Total-Ig-nAb,220524_Wuhan_ChineseAcademyOfMedicalSciences,"Serosurvey for SARS-CoV-2 among blood donors in Wuhan, China from September to December 2019.",2022-05-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"""Blood donation samples donated from 1 September to 31 December 2019 in Wuhan Blood Center were all enrolled in the study.""","""samples with volume of <300 μL (considering the minimum volume for antibody testing and the loss of transfer process), fibrin clot, severe hemolysis were unincluded for further testing.""",2019-09-01,2019-12-31,Blood donors,All,Multiple groups,18.0,,Primary Estimate,,43850,0.0,,,True,,,,True,Sequential,"Wantai SARS-CoV-2 Total Ab ELISA,Author designed (Neutralization Assay)","Beijing Wantai Biological,NA","ELISA,Neutralization Assay",Plasma,"IgG, IgM, IgA",Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Le Chang,Chinese Academy of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/procel/pwac013,2023-03-09,2024-03-01,Unverified,chang_serosurvey_2022,CHN
220524_Wuhan_ChineseAcademyOfMedicalSciences_Total-Ig-nAb_Dec,220524_Wuhan_ChineseAcademyOfMedicalSciences,"Serosurvey for SARS-CoV-2 among blood donors in Wuhan, China from September to December 2019.",2022-05-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"""Blood donation samples donated from 1 September to 31 December 2019 in Wuhan Blood Center were all enrolled in the study.""","""samples with volume of <300 μL (considering the minimum volume for antibody testing and the loss of transfer process), fibrin clot, severe hemolysis were unincluded for further testing.""",2019-12-01,2019-12-31,Blood donors,All,Multiple groups,18.0,,Time frame,,13809,0.0,,,,,,,,Sequential,"Wantai SARS-CoV-2 Total Ab ELISA,Author designed (Neutralization Assay)","Beijing Wantai Biological,NA","ELISA,Neutralization Assay",Plasma,"IgG, IgM, IgA",Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Le Chang,Chinese Academy of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/procel/pwac013,2023-03-10,2024-03-01,Unverified,chang_serosurvey_2022,CHN
220524_Wuhan_ChineseAcademyOfMedicalSciences_Total-Ig-nAb_Nov,220524_Wuhan_ChineseAcademyOfMedicalSciences,"Serosurvey for SARS-CoV-2 among blood donors in Wuhan, China from September to December 2019.",2022-05-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"""Blood donation samples donated from 1 September to 31 December 2019 in Wuhan Blood Center were all enrolled in the study.""","""samples with volume of <300 μL (considering the minimum volume for antibody testing and the loss of transfer process), fibrin clot, severe hemolysis were unincluded for further testing.""",2019-11-01,2019-11-30,Blood donors,All,Multiple groups,18.0,,Time frame,,9338,0.0,,,,,,,,Sequential,"Wantai SARS-CoV-2 Total Ab ELISA,Author designed (Neutralization Assay)","Beijing Wantai Biological,NA","ELISA,Neutralization Assay",Plasma,"IgG, IgM, IgA",Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Le Chang,Chinese Academy of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/procel/pwac013,2023-03-10,2024-03-01,Unverified,chang_serosurvey_2022,CHN
220524_Wuhan_ChineseAcademyOfMedicalSciences_TestUsed_Total-Ig-IgG-IgM,220524_Wuhan_ChineseAcademyOfMedicalSciences,"Serosurvey for SARS-CoV-2 among blood donors in Wuhan, China from September to December 2019.",2022-05-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"""Blood donation samples donated from 1 September to 31 December 2019 in Wuhan Blood Center were all enrolled in the study.""","""samples with volume of <300 μL (considering the minimum volume for antibody testing and the loss of transfer process), fibrin clot, severe hemolysis were unincluded for further testing.""",2019-09-01,2019-12-31,Blood donors,All,Multiple groups,18.0,,Test used,,43850,0.0012,,,,,,,,Sequential,"Wantai SARS-CoV-2 Total Ab ELISA,Wantai SARS-CoV-2 IgG ELISA,Wantai SARS-CoV-2 IgM ELISA",Beijing Wantai Biological,"ELISA,ELISA,ELISA",Plasma,"['IgG', 'IgG, IgM, IgA', 'IgM']",Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Le Chang,Chinese Academy of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/procel/pwac013,2023-03-10,2024-03-01,Unverified,chang_serosurvey_2022,CHN
220524_Wuhan_ChineseAcademyOfMedicalSciences_Total-Ig-nAb_Sep,220524_Wuhan_ChineseAcademyOfMedicalSciences,"Serosurvey for SARS-CoV-2 among blood donors in Wuhan, China from September to December 2019.",2022-05-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"""Blood donation samples donated from 1 September to 31 December 2019 in Wuhan Blood Center were all enrolled in the study.""","""samples with volume of <300 μL (considering the minimum volume for antibody testing and the loss of transfer process), fibrin clot, severe hemolysis were unincluded for further testing.""",2019-09-01,2019-09-30,Blood donors,All,Multiple groups,18.0,,Time frame,,9732,0.0,,,,,,,,Sequential,"Wantai SARS-CoV-2 Total Ab ELISA,Author designed (Neutralization Assay)","Beijing Wantai Biological,NA","ELISA,Neutralization Assay",Plasma,"IgG, IgM, IgA",Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Le Chang,Chinese Academy of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/procel/pwac013,2023-03-10,2024-03-01,Unverified,chang_serosurvey_2022,CHN
220524_Wuhan_ChineseAcademyOfMedicalSciences_TestUsed_Total-Ig,220524_Wuhan_ChineseAcademyOfMedicalSciences,"Serosurvey for SARS-CoV-2 among blood donors in Wuhan, China from September to December 2019.",2022-05-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"""Blood donation samples donated from 1 September to 31 December 2019 in Wuhan Blood Center were all enrolled in the study.""","""samples with volume of <300 μL (considering the minimum volume for antibody testing and the loss of transfer process), fibrin clot, severe hemolysis were unincluded for further testing.""",2019-09-01,2019-12-31,Blood donors,All,Multiple groups,18.0,,Test used,,43850,0.00602,,,,,,,,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,"IgG, IgM, IgA",Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Le Chang,Chinese Academy of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/procel/pwac013,2023-03-10,2024-03-01,Unverified,chang_serosurvey_2022,CHN
220524_Wuhan_ChineseAcademyOfMedicalSciences_Total-Ig-nAb_Oct,220524_Wuhan_ChineseAcademyOfMedicalSciences,"Serosurvey for SARS-CoV-2 among blood donors in Wuhan, China from September to December 2019.",2022-05-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,Hubei,Wuhan,"""Blood donation samples donated from 1 September to 31 December 2019 in Wuhan Blood Center were all enrolled in the study.""","""samples with volume of <300 μL (considering the minimum volume for antibody testing and the loss of transfer process), fibrin clot, severe hemolysis were unincluded for further testing.""",2019-10-01,2019-10-31,Blood donors,All,Multiple groups,18.0,,Time frame,,10971,0.0,,,,,,,,Sequential,"Wantai SARS-CoV-2 Total Ab ELISA,Author designed (Neutralization Assay)","Beijing Wantai Biological,NA","ELISA,Neutralization Assay",Plasma,"IgG, IgM, IgA",Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Le Chang,Chinese Academy of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/procel/pwac013,2023-03-10,2024-03-01,Unverified,chang_serosurvey_2022,CHN
220715_Wuhan_UnionMedicalCollege_overall,220715_Wuhan_UnionMedicalCollege,Seroprevalence and dynamics of anti-SARS-CoV-2 antibodies: a longitudinal study based on patients with underlying diseases in Wuhan,2022-07-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,,Wuhan,"""We selected 100 communities in Wuhan using the probability-proportional-to-size sampling method. From these 100 communities, we randomly selected households according to a list provided by the local government. Individuals who have lived in Wuhan for at least 14 days since December 2019 and were ≥ 40 years old were included.""","""Individuals who could not be obtained or refused to participate were excluded.""",2020-04-09,2020-04-13,Household and community samples,All,Multiple groups,40.0,,Primary Estimate,,5067,0.0618,,,True,,,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,1.0,0.995,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Jin Yang,Union Medical College,Unity-Aligned,https://dx.doi.org/10.1186/s12931-022-02096-5,2022-07-27,2024-03-31,Verified,yangSeroprevalenceDynamicsAntiSARSCoV22022,CHN
220715_Wuhan_UnionMedicalCollege_male,220715_Wuhan_UnionMedicalCollege,Seroprevalence and dynamics of anti-SARS-CoV-2 antibodies: a longitudinal study based on patients with underlying diseases in Wuhan,2022-07-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,,Wuhan,"""We selected 100 communities in Wuhan using the probability-proportional-to-size sampling method. From these 100 communities, we randomly selected households according to a list provided by the local government. Individuals who have lived in Wuhan for at least 14 days since December 2019 and were ≥ 40 years old were included.""","""Individuals who could not be obtained or refused to participate were excluded.""",2020-04-09,2020-04-13,Household and community samples,Male,Multiple groups,40.0,,Sex/Gender,,2492,0.049800000000000004,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,1.0,0.995,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Jin Yang,Union Medical College,Unity-Aligned,https://dx.doi.org/10.1186/s12931-022-02096-5,2022-07-27,2024-03-31,Verified,yangSeroprevalenceDynamicsAntiSARSCoV22022,CHN
220715_Wuhan_UnionMedicalCollege_66plus,220715_Wuhan_UnionMedicalCollege,Seroprevalence and dynamics of anti-SARS-CoV-2 antibodies: a longitudinal study based on patients with underlying diseases in Wuhan,2022-07-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,,Wuhan,"""We selected 100 communities in Wuhan using the probability-proportional-to-size sampling method. From these 100 communities, we randomly selected households according to a list provided by the local government. Individuals who have lived in Wuhan for at least 14 days since December 2019 and were ≥ 40 years old were included.""","""Individuals who could not be obtained or refused to participate were excluded.""",2020-04-09,2020-04-13,Household and community samples,All,Seniors (65+ years),66.0,,Age,66+,827,0.0762,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,1.0,0.995,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Jin Yang,Union Medical College,Unity-Aligned,https://dx.doi.org/10.1186/s12931-022-02096-5,2022-07-27,2024-03-31,Verified,yangSeroprevalenceDynamicsAntiSARSCoV22022,CHN
220715_Wuhan_UnionMedicalCollege_female,220715_Wuhan_UnionMedicalCollege,Seroprevalence and dynamics of anti-SARS-CoV-2 antibodies: a longitudinal study based on patients with underlying diseases in Wuhan,2022-07-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,,Wuhan,"""We selected 100 communities in Wuhan using the probability-proportional-to-size sampling method. From these 100 communities, we randomly selected households according to a list provided by the local government. Individuals who have lived in Wuhan for at least 14 days since December 2019 and were ≥ 40 years old were included.""","""Individuals who could not be obtained or refused to participate were excluded.""",2020-04-09,2020-04-13,Household and community samples,Female,Multiple groups,40.0,,Sex/Gender,,2575,0.0734,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,1.0,0.995,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Jin Yang,Union Medical College,Unity-Aligned,https://dx.doi.org/10.1186/s12931-022-02096-5,2022-07-27,2024-03-31,Verified,yangSeroprevalenceDynamicsAntiSARSCoV22022,CHN
220715_Wuhan_UnionMedicalCollege_61to65,220715_Wuhan_UnionMedicalCollege,Seroprevalence and dynamics of anti-SARS-CoV-2 antibodies: a longitudinal study based on patients with underlying diseases in Wuhan,2022-07-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,,Wuhan,"""We selected 100 communities in Wuhan using the probability-proportional-to-size sampling method. From these 100 communities, we randomly selected households according to a list provided by the local government. Individuals who have lived in Wuhan for at least 14 days since December 2019 and were ≥ 40 years old were included.""","""Individuals who could not be obtained or refused to participate were excluded.""",2020-04-09,2020-04-13,Household and community samples,All,Adults (18-64 years),60.0,65.0,Age,61-65,740,0.05,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,1.0,0.995,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Jin Yang,Union Medical College,Unity-Aligned,https://dx.doi.org/10.1186/s12931-022-02096-5,2022-07-27,2024-03-31,Verified,yangSeroprevalenceDynamicsAntiSARSCoV22022,CHN
220715_Wuhan_UnionMedicalCollege_46to50,220715_Wuhan_UnionMedicalCollege,Seroprevalence and dynamics of anti-SARS-CoV-2 antibodies: a longitudinal study based on patients with underlying diseases in Wuhan,2022-07-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,,Wuhan,"""We selected 100 communities in Wuhan using the probability-proportional-to-size sampling method. From these 100 communities, we randomly selected households according to a list provided by the local government. Individuals who have lived in Wuhan for at least 14 days since December 2019 and were ≥ 40 years old were included.""","""Individuals who could not be obtained or refused to participate were excluded.""",2020-04-09,2020-04-13,Household and community samples,All,Adults (18-64 years),46.0,50.0,Age,46-50,924,0.0519,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,1.0,0.995,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Jin Yang,Union Medical College,Unity-Aligned,https://dx.doi.org/10.1186/s12931-022-02096-5,2022-07-27,2024-03-31,Verified,yangSeroprevalenceDynamicsAntiSARSCoV22022,CHN
220715_Wuhan_UnionMedicalCollege_56to60,220715_Wuhan_UnionMedicalCollege,Seroprevalence and dynamics of anti-SARS-CoV-2 antibodies: a longitudinal study based on patients with underlying diseases in Wuhan,2022-07-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,,Wuhan,"""We selected 100 communities in Wuhan using the probability-proportional-to-size sampling method. From these 100 communities, we randomly selected households according to a list provided by the local government. Individuals who have lived in Wuhan for at least 14 days since December 2019 and were ≥ 40 years old were included.""","""Individuals who could not be obtained or refused to participate were excluded.""",2020-04-09,2020-04-13,Household and community samples,All,Adults (18-64 years),56.0,60.0,Age,56-60,767,0.0821,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,1.0,0.995,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Jin Yang,Union Medical College,Unity-Aligned,https://dx.doi.org/10.1186/s12931-022-02096-5,2022-07-27,2024-03-31,Verified,yangSeroprevalenceDynamicsAntiSARSCoV22022,CHN
220715_Wuhan_UnionMedicalCollege_40to45,220715_Wuhan_UnionMedicalCollege,Seroprevalence and dynamics of anti-SARS-CoV-2 antibodies: a longitudinal study based on patients with underlying diseases in Wuhan,2022-07-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,,Wuhan,"""We selected 100 communities in Wuhan using the probability-proportional-to-size sampling method. From these 100 communities, we randomly selected households according to a list provided by the local government. Individuals who have lived in Wuhan for at least 14 days since December 2019 and were ≥ 40 years old were included.""","""Individuals who could not be obtained or refused to participate were excluded.""",2020-04-09,2020-04-13,Household and community samples,All,Adults (18-64 years),40.0,45.0,Age,40-45,1072,0.053200000000000004,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,1.0,0.995,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Jin Yang,Union Medical College,Unity-Aligned,https://dx.doi.org/10.1186/s12931-022-02096-5,2022-07-27,2024-03-31,Verified,yangSeroprevalenceDynamicsAntiSARSCoV22022,CHN
220715_Wuhan_UnionMedicalCollege_51to55,220715_Wuhan_UnionMedicalCollege,Seroprevalence and dynamics of anti-SARS-CoV-2 antibodies: a longitudinal study based on patients with underlying diseases in Wuhan,2022-07-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,China,,Wuhan,"""We selected 100 communities in Wuhan using the probability-proportional-to-size sampling method. From these 100 communities, we randomly selected households according to a list provided by the local government. Individuals who have lived in Wuhan for at least 14 days since December 2019 and were ≥ 40 years old were included.""","""Individuals who could not be obtained or refused to participate were excluded.""",2020-04-09,2020-04-13,Household and community samples,All,Adults (18-64 years),50.0,44.0,Age,51-55,737,0.0611,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,1.0,0.995,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Jin Yang,Union Medical College,Unity-Aligned,https://dx.doi.org/10.1186/s12931-022-02096-5,2022-07-27,2024-03-31,Verified,yangSeroprevalenceDynamicsAntiSARSCoV22022,CHN
20220726_HongKong_QueenMaryHospital_Dec2021_RBD,20220726_HongKong_QueenMaryHospital_Dec2021,SARS-CoV-2 IgG seropositivity after the severe Omicron wave of COVID-19 in Hong Kong.,2022-07-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,China,Hong Kong,Hong Kong,anonymized archived serum or plasma specimens,Blood specimens were excluded if the volume was insufficient for anti-RBD IgG testing,2021-12-01,2021-12-31,Residual sera,All,Multiple groups,,,Primary Estimate,"Anti S-RBD test, all",423,0.522,,,True,,,,True,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,,Multiple Types,IgG,Spike,,,,['High'],,No,No,No,,Yes,Yes,Yes,,Rosana Wing-Shan Poon,Queen Mary Hospital,Unity-Aligned,https://dx.doi.org/10.1080/22221751.2022.2106899,2022-08-03,2024-03-01,Verified,poon_sars-cov-2_2022,CHN
20220726_HongKong_QueenMaryHospital_Dec2021_RBD_Age0to9,20220726_HongKong_QueenMaryHospital_Dec2021,SARS-CoV-2 IgG seropositivity after the severe Omicron wave of COVID-19 in Hong Kong.,2022-07-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,China,Hong Kong,Hong Kong,anonymized archived serum or plasma specimens,Blood specimens were excluded if the volume was insufficient for anti-RBD IgG testing,2021-12-01,2021-12-31,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,"Anti S-RBD test, age: 0-9",19,0.0,,,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,,Multiple Types,IgG,Spike,,,,['High'],,No,No,No,,Yes,Yes,Yes,,Rosana Wing-Shan Poon,Queen Mary Hospital,Unity-Aligned,https://dx.doi.org/10.1080/22221751.2022.2106899,2022-08-03,2024-03-01,Verified,poon_sars-cov-2_2022,CHN
20220726_HongKong_QueenMaryHospital_Dec2021_RBD_Age20to29,20220726_HongKong_QueenMaryHospital_Dec2021,SARS-CoV-2 IgG seropositivity after the severe Omicron wave of COVID-19 in Hong Kong.,2022-07-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,China,Hong Kong,Hong Kong,anonymized archived serum or plasma specimens,Blood specimens were excluded if the volume was insufficient for anti-RBD IgG testing,2021-12-01,2021-12-31,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,"Anti S-RBD test, age: 20-29",52,0.75,,,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,,Multiple Types,IgG,Spike,,,,['High'],,No,No,No,,Yes,Yes,Yes,,Rosana Wing-Shan Poon,Queen Mary Hospital,Unity-Aligned,https://dx.doi.org/10.1080/22221751.2022.2106899,2022-08-03,2024-03-01,Verified,poon_sars-cov-2_2022,CHN
20220726_HongKong_QueenMaryHospital_Dec2021_Ntest,20220726_HongKong_QueenMaryHospital_Dec2021,SARS-CoV-2 IgG seropositivity after the severe Omicron wave of COVID-19 in Hong Kong.,2022-07-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,China,Hong Kong,Hong Kong,anonymized archived serum or plasma specimens,Blood specimens were excluded if the volume was insufficient for anti-RBD IgG testing,2021-12-01,2021-12-31,Residual sera,All,Multiple groups,,,Test used,"Anti N test, all",412,0.017,,,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,,Multiple Types,IgG,Spike,,,,['High'],,No,No,No,,Yes,Yes,Yes,,Rosana Wing-Shan Poon,Queen Mary Hospital,Unity-Aligned,https://dx.doi.org/10.1080/22221751.2022.2106899,2022-08-03,2024-03-01,Verified,poon_sars-cov-2_2022,CHN
20220726_HongKong_QueenMaryHospital_May2022_RBD,20220726_HongKong_QueenMaryHospital_May2022,SARS-CoV-2 IgG seropositivity after the severe Omicron wave of COVID-19 in Hong Kong.,2022-07-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,China,Hong Kong,Hong Kong,anonymized archived serum or plasma specimens,Blood specimens were excluded if the volume was insufficient for anti-RBD IgG testing,2022-05-01,2022-05-31,Residual sera,All,Multiple groups,,,Primary Estimate,"Anti S-RBD test, all",450,0.893,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Multiple Types,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,No,,Yes,Yes,Yes,,Rosana Wing-Shan Poon,Queen Mary Hospital,Unity-Aligned,https://dx.doi.org/10.1080/22221751.2022.2106899,2022-08-03,2024-03-01,Verified,poon_sars-cov-2_2022,CHN
20220726_HongKong_QueenMaryHospital_May2022_Ntest,20220726_HongKong_QueenMaryHospital_May2022,SARS-CoV-2 IgG seropositivity after the severe Omicron wave of COVID-19 in Hong Kong.,2022-07-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,China,Hong Kong,Hong Kong,anonymized archived serum or plasma specimens,Blood specimens were excluded if the volume was insufficient for anti-RBD IgG testing,2022-05-01,2022-05-31,Residual sera,All,Multiple groups,,,Test used,"Anti N test, all",398,0.43200000000000005,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Multiple Types,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,No,,Yes,Yes,Yes,,Rosana Wing-Shan Poon,Queen Mary Hospital,Unity-Aligned,https://dx.doi.org/10.1080/22221751.2022.2106899,2022-08-03,2024-03-01,Verified,poon_sars-cov-2_2022,CHN
20220726_HongKong_QueenMaryHospital_May2022_RBD_Age0to9,20220726_HongKong_QueenMaryHospital_May2022,SARS-CoV-2 IgG seropositivity after the severe Omicron wave of COVID-19 in Hong Kong.,2022-07-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,China,Hong Kong,Hong Kong,anonymized archived serum or plasma specimens,Blood specimens were excluded if the volume was insufficient for anti-RBD IgG testing,2022-05-01,2022-05-31,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,"Anti S-RBD test, age: 0-9",50,0.7000000000000001,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Multiple Types,IgG,Spike,,,,['High'],,No,No,No,,Yes,Yes,Yes,,Rosana Wing-Shan Poon,Queen Mary Hospital,Unity-Aligned,https://dx.doi.org/10.1080/22221751.2022.2106899,2022-08-03,2024-03-01,Verified,poon_sars-cov-2_2022,CHN
20220726_HongKong_QueenMaryHospital_May2022_RBD_Age20to29,20220726_HongKong_QueenMaryHospital_May2022,SARS-CoV-2 IgG seropositivity after the severe Omicron wave of COVID-19 in Hong Kong.,2022-07-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,China,Hong Kong,Hong Kong,anonymized archived serum or plasma specimens,Blood specimens were excluded if the volume was insufficient for anti-RBD IgG testing,2022-05-01,2022-05-31,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,"Anti S-RBD test, age: 20-29",50,1.0,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Multiple Types,IgG,Spike,,,,['High'],,No,No,No,,Yes,Yes,Yes,,Rosana Wing-Shan Poon,Queen Mary Hospital,Unity-Aligned,https://dx.doi.org/10.1080/22221751.2022.2106899,2022-08-03,2024-03-01,Verified,poon_sars-cov-2_2022,CHN
220916_Taiwan_TaiwanBloodServicesFoundation,220916_Taiwan_TaiwanBloodServicesFoundation,Surveillance of Sars-Cov-2 Virus and Its Corresponding Antibody in Blood Donors after a Nosocomial Infection in Taiwan,2022-09-16,Presentation or Conference,Regional,Cross-sectional survey ,China,Taiwan,,Blood donors in Taiwan,,2021-01-01,2021-02-28,Blood donors,All,Multiple groups,,,Primary Estimate,,10000,0.0002,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Min-Hui Yang,Taiwan Blood Services Foundation,Not Unity-Aligned,https://dx.doi.org/10.1111/trf.17058,2022-11-10,2024-03-01,Unverified,yang_surveillance_2022,CHN
221107_Beijing_CapitalInstituteofPediatrics,221107_Beijing_CapitalInstituteofPediatrics,"Post-vaccination SARS-CoV-2 seroprevalence in children aged 3-11 years and the positivity in unvaccinated children: A retrospective, single-center study",2022-11-07,Journal Article (Peer-Reviewed),Local,Retrospective cohort,China,,Beijing,"""Data of SARS-CoV-2 immunoglobulin M (IgM) and IgG
serological assays collected from children who were admitted to
the Children’s Hospital, Capital Institute of Pediatrics (a 400-bed
tertiary pediatric hospital in China with an average of 30,000
admissions per year) from January 2022 to July 2022 were
retrospectively analyzed"" ","""Considering the hematological products transfusion may affect seropositive rates in the vaccinated individuals, children with autoimmune
diseases or hematological system diseases were excluded""",2022-01-15,2022-07-15,Residual sera,All,Children and Youth (0-17 years),0.0,11.0,Primary Estimate,,5309,0.02,,,True,,,,True,Sequential,SARS CoV-2 IgM/IgG Antibody Assay Colloidal Gold Complex test,Maccura Biotechnology Ltd,LFIA,Serum,"IgG, IgM","Spike, Nucleocapsid (N-protein)",,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Jing Li,Capital Institute of Pediatrics,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2022.1030238,2023-04-03,2023-04-12,Unverified,li_post-vaccination_2022,CHN
230624_HongKong_MountSinai,230624_HongKong_MountSinai,Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium,2023-06-24,Journal Article (Peer-Reviewed),National,Prospective cohort,China,,,"Our initial core objective was to include all adult patients with IBD who entered the infusion center for vedolizumab or infliximab (originator or biosimilars), as well as intravenous ustekinumab induction, regardless of history of known COVID-19 infection, and without any exclusion criteria.",None,2020-05-15,2021-12-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,72,0.0,,,True,,,,True,Convenience,SARS-CoV-2 Rapid Antibody Test,Roche Diagnostics,LFIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Yes,Yes,Yes,,Serre-Yu Wong,Mount Sinai,Not Unity-Aligned,https://dx.doi.org/10.1093/ibd/izad097,2023-08-02,2024-03-01,Unverified,wong_geography_2023,CHN
231108_Jiangsu_YixingSecondPeoplesHospital_Overall,231108_Jiangsu_YixingSecondPeoplesHospital,"Incidence of SARS-CoV-2 infection in children shortly after ending zero-COVID-19 policy in China on December 7, 2022: a cross-sectional, multicenter, seroepidemiological study",2023-11-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,China,Jiangsu,,"we collected 1,065 serum or plasma samples from 1,065 children aged 8 months to 12 years at the collaborating hospitals. Accompanied by parents or guardians, these children visited hospitals for various reasons and required necessary blood tests by venipunctur",,2023-02-10,2023-03-10,Residual sera,All,Children and Youth (0-17 years),0.0,12.0,Primary Estimate,,1065,0.928,0.912,0.943,True,,,,True,Sequential,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Yi-Hua Zhou,Yixing Second People's Hospital,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2023.1283158,2024-03-08,2024-03-08,Unverified,zhou_incidence_2023,CHN
231108_Jiangsu_YixingSecondPeoplesHospital_Male,231108_Jiangsu_YixingSecondPeoplesHospital,"Incidence of SARS-CoV-2 infection in children shortly after ending zero-COVID-19 policy in China on December 7, 2022: a cross-sectional, multicenter, seroepidemiological study",2023-11-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,China,Jiangsu,,"we collected 1,065 serum or plasma samples from 1,065 children aged 8 months to 12 years at the collaborating hospitals. Accompanied by parents or guardians, these children visited hospitals for various reasons and required necessary blood tests by venipunctur",,2023-02-10,2023-03-10,Residual sera,Male,Children and Youth (0-17 years),0.0,12.0,Sex/Gender,,596,0.914,0.892,0.937,,,,,,Sequential,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Yi-Hua Zhou,Yixing Second People's Hospital,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2023.1283158,2024-03-08,2024-03-08,Unverified,zhou_incidence_2023,CHN
231108_Jiangsu_YixingSecondPeoplesHospital_3-5yrs,231108_Jiangsu_YixingSecondPeoplesHospital,"Incidence of SARS-CoV-2 infection in children shortly after ending zero-COVID-19 policy in China on December 7, 2022: a cross-sectional, multicenter, seroepidemiological study",2023-11-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,China,Jiangsu,,"we collected 1,065 serum or plasma samples from 1,065 children aged 8 months to 12 years at the collaborating hospitals. Accompanied by parents or guardians, these children visited hospitals for various reasons and required necessary blood tests by venipunctur",,2023-02-10,2023-03-10,Residual sera,All,Children and Youth (0-17 years),3.0,5.0,Age,3-5 years,338,0.885,0.85,0.903,,,,,,Sequential,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Yi-Hua Zhou,Yixing Second People's Hospital,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2023.1283158,2024-03-08,2024-03-08,Unverified,zhou_incidence_2023,CHN
231108_Jiangsu_YixingSecondPeoplesHospital_Female,231108_Jiangsu_YixingSecondPeoplesHospital,"Incidence of SARS-CoV-2 infection in children shortly after ending zero-COVID-19 policy in China on December 7, 2022: a cross-sectional, multicenter, seroepidemiological study",2023-11-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,China,Jiangsu,,"we collected 1,065 serum or plasma samples from 1,065 children aged 8 months to 12 years at the collaborating hospitals. Accompanied by parents or guardians, these children visited hospitals for various reasons and required necessary blood tests by venipunctur",,2023-02-10,2023-03-10,Residual sera,Female,Children and Youth (0-17 years),0.0,12.0,Sex/Gender,,469,0.945,0.924,0.965,,,,,,Sequential,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Yi-Hua Zhou,Yixing Second People's Hospital,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2023.1283158,2024-03-08,2024-03-08,Unverified,zhou_incidence_2023,CHN
231108_Jiangsu_YixingSecondPeoplesHospital_6-12yrs,231108_Jiangsu_YixingSecondPeoplesHospital,"Incidence of SARS-CoV-2 infection in children shortly after ending zero-COVID-19 policy in China on December 7, 2022: a cross-sectional, multicenter, seroepidemiological study",2023-11-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,China,Jiangsu,,"we collected 1,065 serum or plasma samples from 1,065 children aged 8 months to 12 years at the collaborating hospitals. Accompanied by parents or guardians, these children visited hospitals for various reasons and required necessary blood tests by venipunctur",,2023-02-10,2023-03-10,Residual sera,All,Children and Youth (0-17 years),6.0,12.0,Age,6-12 years,403,0.983,0.97,0.995,,,,,,Sequential,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Yi-Hua Zhou,Yixing Second People's Hospital,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2023.1283158,2024-03-08,2024-03-08,Unverified,zhou_incidence_2023,CHN
231108_Jiangsu_YixingSecondPeoplesHospital_0-2yrs,231108_Jiangsu_YixingSecondPeoplesHospital,"Incidence of SARS-CoV-2 infection in children shortly after ending zero-COVID-19 policy in China on December 7, 2022: a cross-sectional, multicenter, seroepidemiological study",2023-11-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,China,Jiangsu,,"we collected 1,065 serum or plasma samples from 1,065 children aged 8 months to 12 years at the collaborating hospitals. Accompanied by parents or guardians, these children visited hospitals for various reasons and required necessary blood tests by venipunctur",,2023-02-10,2023-03-10,Residual sera,All,Children and Youth (0-17 years),0.0,2.0,Age,8 months to 2 years,324,0.904,0.872,0.937,,,,,,Sequential,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Yi-Hua Zhou,Yixing Second People's Hospital,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2023.1283158,2024-03-08,2024-03-08,Unverified,zhou_incidence_2023,CHN
201030_Colombia_UniversidadIndustrialdeSantander_primary,201030_Colombia_UniversidadIndustrialdeSantander,Performance of rapid IgM-IgG combined antibody tests in the occupational surveillance of COVID-19 in Colombian enterprises.,2020-10-30,Journal Article (Peer-Reviewed),National,Prospective cohort,Colombia,,,Workers with in person activities in different businesses that participated in periodic testing. ,,2020-04-17,2020-07-14,Essential non-healthcare workers,All,Multiple groups,,,Primary Estimate,Workers in general,4234,0.04,,,True,,,,True,Unclear,Not reported/ Unable to specify,,LFIA,,"['IgG', 'IgM']",,,,,['High'],No,Unclear,Yes,No,No,Unclear,Yes,No,No,Alvaro J Idrovo,Universidad Industrial de Santander,Not Unity-Aligned,https://dx.doi.org/10.7705/biomedica.5829,2021-01-23,2022-07-16,Verified,idrovo_desempeno_2020,COL
201112_Monteria_UniversidaddeCórdoba_GenPopAdj,201112_Monteria_UniversidaddeCórdoba,"Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among Adults in a Tropical City of the Caribbean Area, Colombia: Are We Much Closer to Herd Immunity Than Developed Countries?",2020-11-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Colombia,Caribbean Region,Monteria,"Residents of Monteria, Colombia",,2020-08-04,2020-09-01,Household and community samples,All,Multiple groups,,,Primary Estimate,Overall,1368,0.5529999999999999,0.525,0.578,True,,True,,True,Stratified probability,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.92,1.0,['Low'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Salim Mattar,Universidad de Córdoba,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofaa550,2021-02-05,2024-03-01,Verified,mattar_severe_2020,COL
201112_Monteria_UniversidaddeCórdoba_Male,201112_Monteria_UniversidaddeCórdoba,"Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among Adults in a Tropical City of the Caribbean Area, Colombia: Are We Much Closer to Herd Immunity Than Developed Countries?",2020-11-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Colombia,Caribbean Region,Monteria,"Residents of Monteria, Colombia",,2020-08-04,2020-09-01,Household and community samples,Male,Multiple groups,,,Sex/Gender,,577,0.5720000000000001,0.531,0.613,,,,,,Stratified probability,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.92,1.0,['Low'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Salim Mattar,Universidad de Córdoba,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofaa550,2021-02-05,2024-03-01,Verified,mattar_severe_2020,COL
201112_Monteria_UniversidaddeCórdoba_GenPopUnadj,201112_Monteria_UniversidaddeCórdoba,"Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among Adults in a Tropical City of the Caribbean Area, Colombia: Are We Much Closer to Herd Immunity Than Developed Countries?",2020-11-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Colombia,Caribbean Region,Monteria,"Residents of Monteria, Colombia",,2020-08-04,2020-09-01,Household and community samples,All,Multiple groups,,,Analysis,Overall unadjusted,1368,0.413,,,,,,,,Stratified probability,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.92,1.0,['Low'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Salim Mattar,Universidad de Córdoba,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofaa550,2021-02-05,2024-03-01,Verified,mattar_severe_2020,COL
201112_Monteria_UniversidaddeCórdoba_Female,201112_Monteria_UniversidaddeCórdoba,"Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among Adults in a Tropical City of the Caribbean Area, Colombia: Are We Much Closer to Herd Immunity Than Developed Countries?",2020-11-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Colombia,Caribbean Region,Monteria,"Residents of Monteria, Colombia",,2020-08-04,2020-09-01,Household and community samples,Female,Multiple groups,,,Sex/Gender,Female,791,0.544,0.508,0.58,,,,,,Stratified probability,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.92,1.0,['Low'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Salim Mattar,Universidad de Córdoba,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofaa550,2021-02-05,2024-03-01,Verified,mattar_severe_2020,COL
200918_Bogota_PontificiaUniversidadJaveriana_HCW_FinalEndpoint_UnAdj,210103_Bogota_PontificiaUniversidadJaveriana,"Seroprevalence and seroconversion rates to SARS-CoV-2 in interns, residents, and medical doctors in a University Hospital in Bogota, Colombia",2021-01-03,Journal Article (Peer-Reviewed),Local,Prospective cohort,Colombia,Capital District Cundinamarca,Bogotá,Medical doctors and trainees at Hospital Universitario San Ignacio in Bogota.,"Potential participants who were not attending patients at HUSI in June and July and who were taking immunosuppressive drugs (chloroquine, corticosteroids, etc.) were excluded from the study.",2020-06-25,2020-08-10,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,351,0.08259999999999999,0.0581,0.1161,True,,,,True,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,1.0,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,No,Beatriz Ariza,Pontificia Universidad Javeriana,Not Unity-Aligned,http://www.revistainfectio.org/index.php/infectio/article/view/938,2020-10-06,2024-03-01,Verified,ariza_seroprevalence_2021,COL
210122_Bogota_InstitutoNacionaldeSalud_OverallTestAdj,210122_Bogota_InstitutoNacionaldeSalud,"Seroprevalence and seroconversions for SARS-CoV-2 infections in workers at Bogota Airport, Colombia, 2020",2021-01-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Colombia,Capital District Cundinamarca,Bogota,We included airport workers between 18 and 60 years old with a direct contract from the airport., The study excluded workers who were at home–office work modality and workers with chronic diseases.,2020-06-01,2020-09-30,Essential non-healthcare workers,All,Adults (18-64 years),18.0,60.0,Primary Estimate,Overall test adj,212,0.16030000000000003,0.1043,0.2162,True,True,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Whole Blood,TotalAntibody,,Validated by independent authors/third party/non-developers,0.855,0.973,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Jeadran Malagon Rojas,Instituto Nacional de Salud,Not Unity-Aligned,https://academic.oup.com/jtm/advance-article/doi/10.1093/jtm/taab006/6106252?searchresult=1,2021-03-13,2023-08-15,Verified,malagon-rojas_seroprevalence_2021,COL
210317_UniversidadDeLosAndes_UniversidadDeLosAndes_overall,210317_UniversidadDeLosAndes_UniversidadDeLosAndes,Seroreactivity to SARS-CoV-2 in individuals attending a university campus in Bogotá Colombia,2021-03-17,Preprint,Local,Cross-sectional survey ,Colombia,Capital District Cundinamarca,Bogotá,"Volunteers of this study were working at the campus during city lockdown, when teaching was mostly remote.",,2020-11-23,2020-12-06,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,237,0.135,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,John M Gonzalez,Universidad de Los Andes,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.15.21253609v1,2021-03-29,2024-03-01,Verified,gonzalez_seroreactivity_2021,COL
210425_Bucaramanga_FundaciónCardiovascularDeColombia_overall_popadj_testadj,210425_Bucaramanga_FundaciónCardiovascularDeColombia,"Seroprevalence of sars-cov-2 infection among occupational groups from the bucaramanga metropolitan area, Colombia",2021-04-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Colombia,,Bucaramanga,"Adults (> 18 years old) who were formally employed in any of the following occupational groups: health, construction, public transportation (bus, taxi drivers), public force (army, police, transit officers) or bike delivery messen- gers, were independent workers o were part of informal commerce (including shop- keepers in grocery stores), and were residents of Bucaramanga or its metropolitan area since August 2020 were invited to participate.",,2020-09-28,2020-12-24,Essential non-healthcare workers,All,Adults (18-64 years),18.0,,Primary Estimate,,7045,0.195,0.18600000000000003,0.204,True,True,True,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,Multiple Types,Whole Blood,"['IgG', 'IgM']",,,0.8520000000000001,0.973,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,Unclear,Claudia Colmenares-Mejia ,Fundación Cardiovascular de Colombia,Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph18084172,2021-05-22,2023-08-15,Verified,colmenares-mejia_seroprevalence_2021-1,COL
210611_Cordoba_UniversidadNacionaldeColombia_Primary,210611_Cordoba_UniversidadNacionaldeColombia,Using serological studies to assess COVID-19 infection fatality rate in developing countries. A case study from one Colombian department.,2021-06-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Colombia,Cordoba,,>9 years old,,2020-03-15,2020-10-02,Household and community samples,All,Multiple groups,10.0,,Primary Estimate,,2447,0.408,,,True,,,,True,Stratified probability,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.93,0.9500000000000001,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,No,Unclear,Nelson Alvis Guzma,Universidad de Cordoba,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.06.018,2021-06-20,2024-03-01,Verified,guzman_using_2021,COL
210611_Cordoba_UniversidadNacionaldeColombia_>=70,210611_Cordoba_UniversidadNacionaldeColombia,Using serological studies to assess COVID-19 infection fatality rate in developing countries. A case study from one Colombian department.,2021-06-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Colombia,Cordoba,,>9 years old,,2020-03-15,2020-10-02,Household and community samples,All,Seniors (65+ years),70.0,,Age,>=70 years-old,164,0.36600000000000005,,,,,,,,Stratified probability,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.93,0.9500000000000001,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,No,Unclear,Nelson Alvis Guzma,Universidad de Cordoba,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.06.018,2021-10-24,2024-03-01,Verified,guzman_using_2021,COL
210611_Cordoba_UniversidadNacionaldeColombia_60-69,210611_Cordoba_UniversidadNacionaldeColombia,Using serological studies to assess COVID-19 infection fatality rate in developing countries. A case study from one Colombian department.,2021-06-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Colombia,Cordoba,,>9 years old,,2020-03-15,2020-10-02,Household and community samples,All,Adults (18-64 years),60.0,69.0,Age,60-69 years-old,297,0.441,,,,,,,,Stratified probability,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.93,0.9500000000000001,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,No,Unclear,Nelson Alvis Guzma,Universidad de Cordoba,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.06.018,2021-10-24,2024-03-01,Verified,guzman_using_2021,COL
210611_Cordoba_UniversidadNacionaldeColombia_15-19,210611_Cordoba_UniversidadNacionaldeColombia,Using serological studies to assess COVID-19 infection fatality rate in developing countries. A case study from one Colombian department.,2021-06-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Colombia,"Cordoba
",,>9 years old,,2020-03-15,2020-10-02,Household and community samples,All,Children and Youth (0-17 years),15.0,19.0,Age,15-19 years-old,100,0.47000000000000003,,,,,,,,Stratified probability,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.93,0.9500000000000001,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,No,Unclear,Nelson Alvis Guzma,Universidad de Cordoba,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.06.018,2021-10-24,2024-03-01,Verified,guzman_using_2021,COL
210611_Cordoba_UniversidadNacionaldeColombia_40-49,210611_Cordoba_UniversidadNacionaldeColombia,Using serological studies to assess COVID-19 infection fatality rate in developing countries. A case study from one Colombian department.,2021-06-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Colombia,Cordoba,,>9 years old,,2020-03-15,2020-10-02,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49 years-old,463,0.436,,,,,,,,Stratified probability,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.93,0.9500000000000001,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,No,Unclear,Nelson Alvis Guzma,Universidad de Cordoba,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.06.018,2021-10-24,2024-03-01,Verified,guzman_using_2021,COL
210611_Cordoba_UniversidadNacionaldeColombia_20-29,210611_Cordoba_UniversidadNacionaldeColombia,Using serological studies to assess COVID-19 infection fatality rate in developing countries. A case study from one Colombian department.,2021-06-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Colombia,Cordoba,,>9 years old,,2020-03-15,2020-10-02,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29 years-old,424,0.41000000000000003,,,,,,,,Stratified probability,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.93,0.9500000000000001,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,No,Unclear,Nelson Alvis Guzma,Universidad de Cordoba,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.06.018,2021-10-24,2024-03-01,Verified,guzman_using_2021,COL
210611_Cordoba_UniversidadNacionaldeColombia_30-39,210611_Cordoba_UniversidadNacionaldeColombia,Using serological studies to assess COVID-19 infection fatality rate in developing countries. A case study from one Colombian department.,2021-06-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Colombia,Cordoba,,>9 years old,,2020-03-15,2020-10-02,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39 years-old,523,0.392,,,,,,,,Stratified probability,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.93,0.9500000000000001,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,No,Unclear,Nelson Alvis Guzma,Universidad de Cordoba,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.06.018,2021-10-24,2024-03-01,Verified,guzman_using_2021,COL
210611_Cordoba_UniversidadNacionaldeColombia_50-59,210611_Cordoba_UniversidadNacionaldeColombia,Using serological studies to assess COVID-19 infection fatality rate in developing countries. A case study from one Colombian department.,2021-06-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Colombia,Cordoba,,>9 years old,,2020-03-15,2020-10-02,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59 years-old,428,0.355,,,,,,,,Stratified probability,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.93,0.9500000000000001,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,No,Unclear,Nelson Alvis Guzma,Universidad de Cordoba,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.06.018,2021-10-24,2024-03-01,Verified,guzman_using_2021,COL
210611_Cordoba_UniversidadNacionaldeColombia_10-14,210611_Cordoba_UniversidadNacionaldeColombia,Using serological studies to assess COVID-19 infection fatality rate in developing countries. A case study from one Colombian department.,2021-06-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Colombia,"Cordoba
",,>9 years old,,2020-03-15,2020-10-02,Household and community samples,All,Children and Youth (0-17 years),10.0,14.0,Age,10-14 years-old,45,0.556,,,,,,,,Stratified probability,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.93,0.9500000000000001,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,No,Unclear,Nelson Alvis Guzma,Universidad de Cordoba,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.06.018,2021-10-24,2024-03-01,Verified,guzman_using_2021,COL
210629_Cordoba_ColombiaUniversidadDeCordoba_Overall,210629_Cordoba_ColombiaUniversidadDeCordoba,"SARS-CoV-2 in eight municipalities of the Colombian tropics: high immunity, clinical and sociodemographic outcomes.",2021-06-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Colombia,Cordoba Department,,Eight municipalities with the largest populations were chosen between July and November 2020; blood samples were taken from people distributed proportionally from the total population of the eight selected municipalities,,2020-07-15,2020-11-15,Household and community samples,All,Multiple groups,2.0,98.0,Primary Estimate,Overall,2564,0.408,,,True,,,,True,Stratified non-probability,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by developers,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,,Evelin Garay,Colombia-Universidad de Cordoba,Unity-Aligned,https://dx.doi.org/10.1093/trstmh/trab094,2021-07-06,2024-03-01,Verified,10.1093/trstmh/trab094,COL
210629_Cordoba_ColombiaUniversidadDeCordoba_40-49,210629_Cordoba_ColombiaUniversidadDeCordoba,"SARS-CoV-2 in eight municipalities of the Colombian tropics: high immunity, clinical and sociodemographic outcomes.",2021-06-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Colombia,Cordoba Department,,Eight municipalities with the largest populations were chosen between July and November 2020; blood samples were taken from people distributed proportionally from the total population of the eight selected municipalities,,2020-07-15,2020-11-15,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,463,0.43,,,,,,,,Stratified non-probability,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by developers,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,,Evelin Garay,Colombia-Universidad de Cordoba,Unity-Aligned,https://dx.doi.org/10.1093/trstmh/trab094,2021-07-06,2024-03-01,Verified,10.1093/trstmh/trab094,COL
210629_Cordoba_ColombiaUniversidadDeCordoba_Female,210629_Cordoba_ColombiaUniversidadDeCordoba,"SARS-CoV-2 in eight municipalities of the Colombian tropics: high immunity, clinical and sociodemographic outcomes.",2021-06-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Colombia,Cordoba Department,,Eight municipalities with the largest populations were chosen between July and November 2020; blood samples were taken from people distributed proportionally from the total population of the eight selected municipalities,,2020-07-15,2020-11-15,Household and community samples,Female,Multiple groups,2.0,98.0,Sex/Gender,Female,1415,0.406,,,,,,,,Stratified non-probability,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by developers,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,,Evelin Garay,Colombia-Universidad de Cordoba,Unity-Aligned,https://dx.doi.org/10.1093/trstmh/trab094,2021-07-06,2024-03-01,Verified,10.1093/trstmh/trab094,COL
210629_Cordoba_ColombiaUniversidadDeCordoba_70+,210629_Cordoba_ColombiaUniversidadDeCordoba,"SARS-CoV-2 in eight municipalities of the Colombian tropics: high immunity, clinical and sociodemographic outcomes.",2021-06-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Colombia,Cordoba Department,,Eight municipalities with the largest populations were chosen between July and November 2020; blood samples were taken from people distributed proportionally from the total population of the eight selected municipalities,,2020-07-15,2020-11-15,Household and community samples,All,Seniors (65+ years),70.0,,Age,70+,165,0.37200000000000005,,,,,,,,Stratified non-probability,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by developers,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,,Evelin Garay,Colombia-Universidad de Cordoba,Unity-Aligned,https://dx.doi.org/10.1093/trstmh/trab094,2021-07-06,2024-03-01,Verified,10.1093/trstmh/trab094,COL
210629_Cordoba_ColombiaUniversidadDeCordoba_50-59,210629_Cordoba_ColombiaUniversidadDeCordoba,"SARS-CoV-2 in eight municipalities of the Colombian tropics: high immunity, clinical and sociodemographic outcomes.",2021-06-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Colombia,Cordoba Department,,Eight municipalities with the largest populations were chosen between July and November 2020; blood samples were taken from people distributed proportionally from the total population of the eight selected municipalities,,2020-07-15,2020-11-15,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,428,0.364,,,,,,,,Stratified non-probability,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by developers,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,,Evelin Garay,Colombia-Universidad de Cordoba,Unity-Aligned,https://dx.doi.org/10.1093/trstmh/trab094,2021-07-06,2024-03-01,Verified,10.1093/trstmh/trab094,COL
210629_Cordoba_ColombiaUniversidadDeCordoba_60-69,210629_Cordoba_ColombiaUniversidadDeCordoba,"SARS-CoV-2 in eight municipalities of the Colombian tropics: high immunity, clinical and sociodemographic outcomes.",2021-06-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Colombia,Cordoba Department,,Eight municipalities with the largest populations were chosen between July and November 2020; blood samples were taken from people distributed proportionally from the total population of the eight selected municipalities,,2020-07-15,2020-11-15,Household and community samples,All,Multiple groups,60.0,69.0,Age,60-69,197,0.44,,,,,,,,Stratified non-probability,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by developers,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,,Evelin Garay,Colombia-Universidad de Cordoba,Unity-Aligned,https://dx.doi.org/10.1093/trstmh/trab094,2021-07-06,2024-03-01,Verified,10.1093/trstmh/trab094,COL
210629_Cordoba_ColombiaUniversidadDeCordoba_30-39,210629_Cordoba_ColombiaUniversidadDeCordoba,"SARS-CoV-2 in eight municipalities of the Colombian tropics: high immunity, clinical and sociodemographic outcomes.",2021-06-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Colombia,Cordoba Department,,Eight municipalities with the largest populations were chosen between July and November 2020; blood samples were taken from people distributed proportionally from the total population of the eight selected municipalities,,2020-07-15,2020-11-15,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,523,0.41000000000000003,,,,,,,,Stratified non-probability,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by developers,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,,Evelin Garay,Colombia-Universidad de Cordoba,Unity-Aligned,https://dx.doi.org/10.1093/trstmh/trab094,2021-07-06,2024-03-01,Verified,10.1093/trstmh/trab094,COL
210629_Cordoba_ColombiaUniversidadDeCordoba_15-19,210629_Cordoba_ColombiaUniversidadDeCordoba,"SARS-CoV-2 in eight municipalities of the Colombian tropics: high immunity, clinical and sociodemographic outcomes.",2021-06-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Colombia,Cordoba Department,,Eight municipalities with the largest populations were chosen between July and November 2020; blood samples were taken from people distributed proportionally from the total population of the eight selected municipalities,,2020-07-15,2020-11-15,Household and community samples,All,Children and Youth (0-17 years),15.0,19.0,Age,15-19,100,0.46,,,,,,,,Stratified non-probability,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by developers,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,,Evelin Garay,Colombia-Universidad de Cordoba,Unity-Aligned,https://dx.doi.org/10.1093/trstmh/trab094,2021-07-06,2024-03-01,Verified,10.1093/trstmh/trab094,COL
210629_Cordoba_ColombiaUniversidadDeCordoba_10-14,210629_Cordoba_ColombiaUniversidadDeCordoba,"SARS-CoV-2 in eight municipalities of the Colombian tropics: high immunity, clinical and sociodemographic outcomes.",2021-06-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Colombia,Cordoba Department,,Eight municipalities with the largest populations were chosen between July and November 2020; blood samples were taken from people distributed proportionally from the total population of the eight selected municipalities,,2020-07-15,2020-11-15,Household and community samples,All,Children and Youth (0-17 years),10.0,14.0,Age,10-14,45,0.53,,,,,,,,Stratified non-probability,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by developers,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,,Evelin Garay,Colombia-Universidad de Cordoba,Unity-Aligned,https://dx.doi.org/10.1093/trstmh/trab094,2021-07-06,2024-03-01,Verified,10.1093/trstmh/trab094,COL
210629_Cordoba_ColombiaUniversidadDeCordoba_Male,210629_Cordoba_ColombiaUniversidadDeCordoba,"SARS-CoV-2 in eight municipalities of the Colombian tropics: high immunity, clinical and sociodemographic outcomes.",2021-06-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Colombia,Cordoba Department,,Eight municipalities with the largest populations were chosen between July and November 2020; blood samples were taken from people distributed proportionally from the total population of the eight selected municipalities,,2020-07-15,2020-11-15,Household and community samples,Male,Multiple groups,2.0,98.0,Sex/Gender,Male,1149,0.41000000000000003,,,,,,,,Stratified non-probability,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by developers,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,,Evelin Garay,Colombia-Universidad de Cordoba,Unity-Aligned,https://dx.doi.org/10.1093/trstmh/trab094,2021-07-06,2024-03-01,Verified,10.1093/trstmh/trab094,COL
210629_Cordoba_ColombiaUniversidadDeCordoba_20-29,210629_Cordoba_ColombiaUniversidadDeCordoba,"SARS-CoV-2 in eight municipalities of the Colombian tropics: high immunity, clinical and sociodemographic outcomes.",2021-06-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Colombia,Cordoba Department,,Eight municipalities with the largest populations were chosen between July and November 2020; blood samples were taken from people distributed proportionally from the total population of the eight selected municipalities,,2020-07-15,2020-11-15,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,424,0.41000000000000003,,,,,,,,Stratified non-probability,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by developers,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,,Evelin Garay,Colombia-Universidad de Cordoba,Unity-Aligned,https://dx.doi.org/10.1093/trstmh/trab094,2021-07-06,2024-03-01,Verified,10.1093/trstmh/trab094,COL
211001_Colombia_MedicalMissionInstitute_Overall,211001_Colombia_MedicalMissionInstitute,Direct and indirect proof of sars-cov-2 infections in indigenous wiwa communities in north-eastern colombia-a cross-sectional assessment providing preliminary surveillance data,2021-10-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Colombia,"Department of Cesar, Department of La Guajira","San Juan, Sabana de Higuieron, Piñoncito, Ahuyamal, Surimena, Tezhumake, Valledupar, La Junta, Atanquez, Los Corazones, Patillal, Siminke and Vereda Platanal.","People in the north-eastern Colombian territories inhabited by the indigenous population of the Wiwas, as well as in San Juan as an urban centre. The individuals had not been vaccinated against SARS-CoV-2 previously and participated on a voluntary basis",,2021-03-28,2021-04-26,Household and community samples,All,Multiple groups,,,Primary Estimate,,452,0.277,,,True,,,,True,Convenience,BELTEST-IT COV-2 Rapid Test,PharmACT,LFIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,1.0,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Gustavo Concha,Medical Mission Institute,Unity-Aligned,http://dx.doi.org/10.3390/vaccines9101120,2021-10-13,2024-03-01,Verified,concha_direct_2021,COL
211027_Amazon_UniversidaddeCórdoba_Primary,211027_Amazon_UniversidaddeCórdoba,High prevalence of SARS-CoV-2 in an indigenous community of the Colombian amazon region,2021-10-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Colombia,Columbian Amazon,Mitú,"A population of indigenous ancestry from the municipality of Mitú, Vaupés, Colombian Amazon.",,2020-12-01,2020-12-31,Household and community samples,All,Multiple groups,10.0,,Primary Estimate,,589,0.5760000000000001,,,True,,,,True,Convenience,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9009999999999999,0.9920000000000001,['High'],Unclear,No,No,Yes,Yes,Yes,Yes,Yes,Yes,Hector Serrano-Coll,Universidad de Córdoba,Unity-Aligned,http://dx.doi.org/10.3390/tropicalmed6040191,2021-11-09,2024-03-01,Verified,serrano-coll_high_2021-1,COL
211027_Amazon_UniversidaddeCórdoba_Age_20–29,211027_Amazon_UniversidaddeCórdoba,High prevalence of SARS-CoV-2 in an indigenous community of the Colombian amazon region,2021-10-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Colombia,Columbian Amazon,Mitú,"A population of indigenous ancestry from the municipality of Mitú, Vaupés, Colombian Amazon.",,2020-12-01,2020-12-31,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,153,0.5947712418,,,,,,,,Convenience,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9009999999999999,0.9920000000000001,['High'],Unclear,No,No,Yes,Yes,Yes,Yes,Yes,Yes,Hector Serrano-Coll,Universidad de Córdoba,Unity-Aligned,http://dx.doi.org/10.3390/tropicalmed6040191,2021-11-09,2024-03-01,Verified,serrano-coll_high_2021-1,COL
211027_Amazon_UniversidaddeCórdoba_Age_>=70,211027_Amazon_UniversidaddeCórdoba,High prevalence of SARS-CoV-2 in an indigenous community of the Colombian amazon region,2021-10-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Colombia,Columbian Amazon,Mitú,"A population of indigenous ancestry from the municipality of Mitú, Vaupés, Colombian Amazon.",,2020-12-01,2020-12-31,Household and community samples,All,Seniors (65+ years),70.0,,Age,>=70,31,0.4838709677,,,,,,,,Convenience,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9009999999999999,0.9920000000000001,['High'],Unclear,No,No,Yes,Yes,Yes,Yes,Yes,Yes,Hector Serrano-Coll,Universidad de Córdoba,Unity-Aligned,http://dx.doi.org/10.3390/tropicalmed6040191,2021-11-09,2024-03-01,Verified,serrano-coll_high_2021-1,COL
211027_Amazon_UniversidaddeCórdoba_Age_40–49,211027_Amazon_UniversidaddeCórdoba,High prevalence of SARS-CoV-2 in an indigenous community of the Colombian amazon region,2021-10-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Colombia,Columbian Amazon,Mitú,"A population of indigenous ancestry from the municipality of Mitú, Vaupés, Colombian Amazon.",,2020-12-01,2020-12-31,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,63,0.5396825397,,,,,,,,Convenience,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9009999999999999,0.9920000000000001,['High'],Unclear,No,No,Yes,Yes,Yes,Yes,Yes,Yes,Hector Serrano-Coll,Universidad de Córdoba,Unity-Aligned,http://dx.doi.org/10.3390/tropicalmed6040191,2021-11-09,2024-03-01,Verified,serrano-coll_high_2021-1,COL
211027_Amazon_UniversidaddeCórdoba_Age_30–39,211027_Amazon_UniversidaddeCórdoba,High prevalence of SARS-CoV-2 in an indigenous community of the Colombian amazon region,2021-10-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Colombia,Columbian Amazon,Mitú,"A population of indigenous ancestry from the municipality of Mitú, Vaupés, Colombian Amazon.",,2020-12-01,2020-12-31,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,131,0.5954198473000001,,,,,,,,Convenience,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9009999999999999,0.9920000000000001,['High'],Unclear,No,No,Yes,Yes,Yes,Yes,Yes,Yes,Hector Serrano-Coll,Universidad de Córdoba,Unity-Aligned,http://dx.doi.org/10.3390/tropicalmed6040191,2021-11-09,2024-03-01,Verified,serrano-coll_high_2021-1,COL
211027_Amazon_UniversidaddeCórdoba_Age_10–14,211027_Amazon_UniversidaddeCórdoba,High prevalence of SARS-CoV-2 in an indigenous community of the Colombian amazon region,2021-10-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Colombia,Columbian Amazon,Mitú,"A population of indigenous ancestry from the municipality of Mitú, Vaupés, Colombian Amazon.",,2020-12-01,2020-12-31,Household and community samples,All,Children and Youth (0-17 years),10.0,14.0,Age,10-14,7,0.5714285714,,,,,,,,Convenience,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9009999999999999,0.9920000000000001,['High'],Unclear,No,No,Yes,Yes,Yes,Yes,Yes,Yes,Hector Serrano-Coll,Universidad de Córdoba,Unity-Aligned,http://dx.doi.org/10.3390/tropicalmed6040191,2021-11-09,2024-03-01,Verified,serrano-coll_high_2021-1,COL
211027_Amazon_UniversidaddeCórdoba_Age_60–69,211027_Amazon_UniversidaddeCórdoba,High prevalence of SARS-CoV-2 in an indigenous community of the Colombian amazon region,2021-10-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Colombia,Columbian Amazon,Mitú,"A population of indigenous ancestry from the municipality of Mitú, Vaupés, Colombian Amazon.",,2020-12-01,2020-12-31,Household and community samples,All,Seniors (65+ years),60.0,69.0,Age,60-69,61,0.5245901639,,,,,,,,Convenience,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9009999999999999,0.9920000000000001,['High'],Unclear,No,No,Yes,Yes,Yes,Yes,Yes,Yes,Hector Serrano-Coll,Universidad de Córdoba,Unity-Aligned,http://dx.doi.org/10.3390/tropicalmed6040191,2021-11-09,2024-03-01,Verified,serrano-coll_high_2021-1,COL
211027_Amazon_UniversidaddeCórdoba_Age_15–19,211027_Amazon_UniversidaddeCórdoba,High prevalence of SARS-CoV-2 in an indigenous community of the Colombian amazon region,2021-10-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Colombia,Columbian Amazon,Mitú,"A population of indigenous ancestry from the municipality of Mitú, Vaupés, Colombian Amazon.",,2020-12-01,2020-12-31,Household and community samples,All,Multiple groups,15.0,19.0,Age,15-19,50,0.68,,,,,,,,Convenience,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9009999999999999,0.9920000000000001,['High'],Unclear,No,No,Yes,Yes,Yes,Yes,Yes,Yes,Hector Serrano-Coll,Universidad de Córdoba,Unity-Aligned,http://dx.doi.org/10.3390/tropicalmed6040191,2021-11-09,2024-03-01,Verified,serrano-coll_high_2021-1,COL
211027_Amazon_UniversidaddeCórdoba_Sex_Female,211027_Amazon_UniversidaddeCórdoba,High prevalence of SARS-CoV-2 in an indigenous community of the Colombian amazon region,2021-10-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Colombia,Columbian Amazon,Mitú,"A population of indigenous ancestry from the municipality of Mitú, Vaupés, Colombian Amazon.",,2020-12-01,2020-12-31,Household and community samples,Female,Multiple groups,10.0,,Sex/Gender,,333,0.588588589,,,,,,,,Convenience,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9009999999999999,0.9920000000000001,['High'],Unclear,No,No,Yes,Yes,Yes,Yes,Yes,Yes,Hector Serrano-Coll,Universidad de Córdoba,Unity-Aligned,http://dx.doi.org/10.3390/tropicalmed6040191,2021-11-09,2024-03-01,Verified,serrano-coll_high_2021-1,COL
211027_Amazon_UniversidaddeCórdoba_Age_50–59,211027_Amazon_UniversidaddeCórdoba,High prevalence of SARS-CoV-2 in an indigenous community of the Colombian amazon region,2021-10-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Colombia,Columbian Amazon,Mitú,"A population of indigenous ancestry from the municipality of Mitú, Vaupés, Colombian Amazon.",,2020-12-01,2020-12-31,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,69,0.5072463768000001,,,,,,,,Convenience,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9009999999999999,0.9920000000000001,['High'],Unclear,No,No,Yes,Yes,Yes,Yes,Yes,Yes,Hector Serrano-Coll,Universidad de Córdoba,Unity-Aligned,http://dx.doi.org/10.3390/tropicalmed6040191,2021-11-09,2024-03-01,Verified,serrano-coll_high_2021-1,COL
211027_Amazon_UniversidaddeCórdoba_Sex_Male,211027_Amazon_UniversidaddeCórdoba,High prevalence of SARS-CoV-2 in an indigenous community of the Colombian amazon region,2021-10-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Colombia,Columbian Amazon,Mitú,"A population of indigenous ancestry from the municipality of Mitú, Vaupés, Colombian Amazon.",,2020-12-01,2020-12-31,Household and community samples,Male,Multiple groups,10.0,,Sex/Gender,,254,0.559055118,,,,,,,,Convenience,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9009999999999999,0.9920000000000001,['High'],Unclear,No,No,Yes,Yes,Yes,Yes,Yes,Yes,Hector Serrano-Coll,Universidad de Córdoba,Unity-Aligned,http://dx.doi.org/10.3390/tropicalmed6040191,2021-11-09,2024-03-01,Verified,serrano-coll_high_2021-1,COL
211105_Colombia_InstitutoNacionaldeSalud_TestAdj,211105_Colombia_InstitutoNacionaldeSalud,Seroprevalence of the SARS-CoV-2 antibody in healthcare workers: a multicentre cross-sectional study in 10 Colombian cities.,2021-11-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Colombia,,"Bogotá, Barranquilla, Bucaramanga, Cali, Cúcuta, Medellín, Villavicencio, Leticia, Ipiales, Guapi","Health workers from public and private hospitals in
10 cities in Colombia. We included personnel either directly or indirectly involved in the healthcare attention: doctors, nurses, pharmacists, physiotherapists, respiratory therapists, bacteriologists, healthcare technicians, admission assistants, general
services (catering and cleaning staff), and security personnel.",,2020-09-15,2020-11-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Test adjusted,3296,0.35000000000000003,0.33,0.37,True,True,,,,Convenience,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.86,0.99,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Jeadran Nevardo Malagon-Rojas,Instituto Nacional de Salud,Not Unity-Aligned,https://dx.doi.org/10.1136/oemed-2021-107487,2021-11-17,2023-08-15,Unverified,malagon-rojas_seroprevalence_2021-1,COL
20220223_Colombia_InstitutoNacionaldeSalud_Analysis,220222_Colombia_InstitutoNacionaldeSalud,"Seroprevalence of anti-SARS-CoV-2 antibodies in Colombia, 2020: A population-based study.",2022-02-22,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Colombia,,"Bogota, Medellin, Cali, Barranquilla, Cucuta,
Bucaramanga and Villavicencio Leticia, Ipiales and Guapi","Seven of the ten most populated cities in Colombia (Bogot a, Medell ın, Cali, Barranquilla, Cucuta, Bucaramanga and Villavicencio) as well as cities in key border regions (Leticia, Ipiales and Guapi) were involved. Individuals in the selected households were invited to participate.",,2020-09-21,2020-12-11,Household and community samples,All,Multiple groups,5.0,80.0,Primary Estimate,,17863,0.32530000000000003,0.32,0.33,True,,,,True,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.86,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Marcela Mercado-Reye,Instituto Nacional de Salud,Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2022.100195,2022-02-23,2024-03-01,Verified,mercado-reyes_seroprevalence_2022,COL
220222_Colombia_InstitutoNacionaldeSalud_AreaCali,220222_Colombia_InstitutoNacionaldeSalud,"Seroprevalence of anti-SARS-CoV-2 antibodies in Colombia, 2020: A population-based study.",2022-02-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Colombia,,Cali,"Seven of the ten most populated cities in Colombia (Bogot a, Medell ın, Cali, Barranquilla, Cucuta, Bucaramanga and Villavicencio) as well as cities in key border regions (Leticia, Ipiales and Guapi) were involved. Individuals in the selected households were invited to participate.",,2020-09-21,2020-12-11,Household and community samples,All,Multiple groups,5.0,80.0,Geographical area,Cali,1983,0.26420000000000005,0.226,0.30100000000000005,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.86,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Marcela Mercado-Reye,Instituto Nacional de Salud,Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2022.100195,2022-05-18,2024-03-01,Verified,mercado-reyes_seroprevalence_2022,COL
220222_Colombia_InstitutoNacionaldeSalud_AreaVillavicencio,220222_Colombia_InstitutoNacionaldeSalud,"Seroprevalence of anti-SARS-CoV-2 antibodies in Colombia, 2020: A population-based study.",2022-02-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Colombia,,Villavicencio,"Seven of the ten most populated cities in Colombia (Bogot a, Medell ın, Cali, Barranquilla, Cucuta, Bucaramanga and Villavicencio) as well as cities in key border regions (Leticia, Ipiales and Guapi) were involved. Individuals in the selected households were invited to participate.",,2020-09-21,2020-12-11,Household and community samples,All,Multiple groups,5.0,80.0,Geographical area,Villavicencio,1470,0.2993,0.256,0.342,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.86,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Marcela Mercado-Reye,Instituto Nacional de Salud,Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2022.100195,2022-05-18,2024-03-01,Verified,mercado-reyes_seroprevalence_2022,COL
20220223_Colombia_InstitutoNacionaldeSalud_Age19to40,220222_Colombia_InstitutoNacionaldeSalud,"Seroprevalence of anti-SARS-CoV-2 antibodies in Colombia, 2020: A population-based study.",2022-02-22,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Colombia,,"Bogot a, Medell ın, Cali, Barranquilla, Cucuta,
Bucaramanga and Villavicencio Leticia, Ipiales and Guapi","Seven of the ten most populated cities in Colombia (Bogot a, Medell ın, Cali, Barranquilla, Cucuta, Bucaramanga and Villavicencio) as well as cities in key border regions (Leticia, Ipiales and Guapi) were involved. Individuals in the selected households were invited to participate.",,2020-09-21,2020-12-11,Household and community samples,All,Adults (18-64 years),19.0,40.0,Age,age: 19-40,6365,0.3456,0.33,0.36,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.86,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Marcela Mercado-Reye,Instituto Nacional de Salud,Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2022.100195,2022-02-23,2024-03-01,Verified,mercado-reyes_seroprevalence_2022,COL
20220223_Colombia_InstitutoNacionaldeSalud_Age5to10,220222_Colombia_InstitutoNacionaldeSalud,"Seroprevalence of anti-SARS-CoV-2 antibodies in Colombia, 2020: A population-based study.",2022-02-22,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Colombia,,"Bogot a, Medell ın, Cali, Barranquilla, Cucuta,
Bucaramanga and Villavicencio Leticia, Ipiales and Guapi","Seven of the ten most populated cities in Colombia (Bogot a, Medell ın, Cali, Barranquilla, Cucuta, Bucaramanga and Villavicencio) as well as cities in key border regions (Leticia, Ipiales and Guapi) were involved. Individuals in the selected households were invited to participate.",,2020-09-21,2020-12-11,Household and community samples,All,Children and Youth (0-17 years),5.0,10.0,Age,age: 5-10,1150,0.36350000000000005,0.34,0.39,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.86,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Marcela Mercado-Reye,Instituto Nacional de Salud,Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2022.100195,2022-02-23,2024-03-01,Verified,mercado-reyes_seroprevalence_2022,COL
220222_Colombia_InstitutoNacionaldeSalud_AreaLeticia,220222_Colombia_InstitutoNacionaldeSalud,"Seroprevalence of anti-SARS-CoV-2 antibodies in Colombia, 2020: A population-based study.",2022-02-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Colombia,,Leticia,"Seven of the ten most populated cities in Colombia (Bogot a, Medell ın, Cali, Barranquilla, Cucuta, Bucaramanga and Villavicencio) as well as cities in key border regions (Leticia, Ipiales and Guapi) were involved. Individuals in the selected households were invited to participate.",,2020-09-21,2020-12-11,Household and community samples,All,Multiple groups,5.0,80.0,Geographical area,Leticia,1417,0.5124000000000001,0.47500000000000003,0.5479999999999999,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.86,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Marcela Mercado-Reye,Instituto Nacional de Salud,Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2022.100195,2022-05-18,2024-03-01,Verified,mercado-reyes_seroprevalence_2022,COL
220222_Colombia_InstitutoNacionaldeSalud_AreaCúcuta,220222_Colombia_InstitutoNacionaldeSalud,"Seroprevalence of anti-SARS-CoV-2 antibodies in Colombia, 2020: A population-based study.",2022-02-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Colombia,,Cúcuta,"Seven of the ten most populated cities in Colombia (Bogot a, Medell ın, Cali, Barranquilla, Cucuta, Bucaramanga and Villavicencio) as well as cities in key border regions (Leticia, Ipiales and Guapi) were involved. Individuals in the selected households were invited to participate.",,2020-09-21,2020-12-11,Household and community samples,All,Multiple groups,5.0,80.0,Geographical area,Cúcuta,1454,0.3494,0.307,0.39,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.86,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Marcela Mercado-Reye,Instituto Nacional de Salud,Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2022.100195,2022-05-18,2024-03-01,Verified,mercado-reyes_seroprevalence_2022,COL
220222_Colombia_InstitutoNacionaldeSalud_AreaIpiales,220222_Colombia_InstitutoNacionaldeSalud,"Seroprevalence of anti-SARS-CoV-2 antibodies in Colombia, 2020: A population-based study.",2022-02-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Colombia,,Ipiales,"Seven of the ten most populated cities in Colombia (Bogot a, Medell ın, Cali, Barranquilla, Cucuta, Bucaramanga and Villavicencio) as well as cities in key border regions (Leticia, Ipiales and Guapi) were involved. Individuals in the selected households were invited to participate.",,2020-09-21,2020-12-11,Household and community samples,All,Multiple groups,5.0,80.0,Geographical area,Ipiales,1465,0.3038,0.261,0.34600000000000003,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.86,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Marcela Mercado-Reye,Instituto Nacional de Salud,Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2022.100195,2022-05-18,2024-03-01,Verified,mercado-reyes_seroprevalence_2022,COL
20220223_Colombia_InstitutoNacionaldeSalud_Age11to18,220222_Colombia_InstitutoNacionaldeSalud,"Seroprevalence of anti-SARS-CoV-2 antibodies in Colombia, 2020: A population-based study.",2022-02-22,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Colombia,,"Bogot a, Medell ın, Cali, Barranquilla, Cucuta,
Bucaramanga and Villavicencio Leticia, Ipiales and Guapi","Seven of the ten most populated cities in Colombia (Bogot a, Medell ın, Cali, Barranquilla, Cucuta, Bucaramanga and Villavicencio) as well as cities in key border regions (Leticia, Ipiales and Guapi) were involved. Individuals in the selected households were invited to participate.",,2020-09-21,2020-12-11,Household and community samples,All,Children and Youth (0-17 years),11.0,18.0,Age,age: 11-18,2267,0.37979999999999997,0.36,0.4,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.86,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Marcela Mercado-Reye,Instituto Nacional de Salud,Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2022.100195,2022-02-23,2024-03-01,Verified,mercado-reyes_seroprevalence_2022,COL
20220223_Colombia_InstitutoNacionaldeSalud_Female,220222_Colombia_InstitutoNacionaldeSalud,"Seroprevalence of anti-SARS-CoV-2 antibodies in Colombia, 2020: A population-based study.",2022-02-22,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Colombia,,"Bogot a, Medell ın, Cali, Barranquilla, Cucuta,
Bucaramanga and Villavicencio Leticia, Ipiales and Guapi","Seven of the ten most populated cities in Colombia (Bogot a, Medell ın, Cali, Barranquilla, Cucuta, Bucaramanga and Villavicencio) as well as cities in key border regions (Leticia, Ipiales and Guapi) were involved. Individuals in the selected households were invited to participate.",,2020-09-21,2020-12-11,Household and community samples,Female,Multiple groups,5.0,80.0,Sex/Gender,,10980,0.32920000000000005,0.32,0.34,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.86,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Marcela Mercado-Reye,Instituto Nacional de Salud,Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2022.100195,2022-02-23,2024-03-01,Verified,mercado-reyes_seroprevalence_2022,COL
220222_Colombia_InstitutoNacionaldeSalud_AreaBogotá,220222_Colombia_InstitutoNacionaldeSalud,"Seroprevalence of anti-SARS-CoV-2 antibodies in Colombia, 2020: A population-based study.",2022-02-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Colombia,,Bogotá,"Seven of the ten most populated cities in Colombia (Bogot a, Medell ın, Cali, Barranquilla, Cucuta, Bucaramanga and Villavicencio) as well as cities in key border regions (Leticia, Ipiales and Guapi) were involved. Individuals in the selected households were invited to participate.",,2020-09-21,2020-12-11,Household and community samples,All,Multiple groups,5.0,80.0,Geographical area,Bogotá,4515,0.2627,0.237,0.287,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.86,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Marcela Mercado-Reye,Instituto Nacional de Salud,Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2022.100195,2022-05-18,2024-03-01,Verified,mercado-reyes_seroprevalence_2022,COL
220222_Colombia_InstitutoNacionaldeSalud_AreaGuapi,220222_Colombia_InstitutoNacionaldeSalud,"Seroprevalence of anti-SARS-CoV-2 antibodies in Colombia, 2020: A population-based study.",2022-02-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Colombia,,Guapi,"Seven of the ten most populated cities in Colombia (Bogot a, Medell ın, Cali, Barranquilla, Cucuta, Bucaramanga and Villavicencio) as well as cities in key border regions (Leticia, Ipiales and Guapi) were involved. Individuals in the selected households were invited to participate.",,2020-09-21,2020-12-11,Household and community samples,All,Multiple groups,5.0,80.0,Geographical area,Guapi,721,0.5867,0.539,0.633,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.86,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Marcela Mercado-Reye,Instituto Nacional de Salud,Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2022.100195,2022-05-18,2024-03-01,Verified,mercado-reyes_seroprevalence_2022,COL
20220223_Colombia_InstitutoNacionaldeSalud_Age41to60,220222_Colombia_InstitutoNacionaldeSalud,"Seroprevalence of anti-SARS-CoV-2 antibodies in Colombia, 2020: A population-based study.",2022-02-22,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Colombia,,"Bogot a, Medell ın, Cali, Barranquilla, Cucuta,
Bucaramanga and Villavicencio Leticia, Ipiales and Guapi","Seven of the ten most populated cities in Colombia (Bogot a, Medell ın, Cali, Barranquilla, Cucuta, Bucaramanga and Villavicencio) as well as cities in key border regions (Leticia, Ipiales and Guapi) were involved. Individuals in the selected households were invited to participate.",,2020-09-21,2020-12-11,Household and community samples,All,Adults (18-64 years),41.0,60.0,Age,age: 41-60,4982,0.3171,0.3,0.33,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.86,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Marcela Mercado-Reye,Instituto Nacional de Salud,Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2022.100195,2022-02-23,2024-03-01,Verified,mercado-reyes_seroprevalence_2022,COL
20220223_Colombia_InstitutoNacionaldeSalud_Male,220222_Colombia_InstitutoNacionaldeSalud,"Seroprevalence of anti-SARS-CoV-2 antibodies in Colombia, 2020: A population-based study.",2022-02-22,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Colombia,,"Bogot a, Medell ın, Cali, Barranquilla, Cucuta,
Bucaramanga and Villavicencio Leticia, Ipiales and Guapi","Seven of the ten most populated cities in Colombia (Bogot a, Medell ın, Cali, Barranquilla, Cucuta, Bucaramanga and Villavicencio) as well as cities in key border regions (Leticia, Ipiales and Guapi) were involved. Individuals in the selected households were invited to participate.",,2020-09-21,2020-12-11,Household and community samples,Male,Multiple groups,5.0,80.0,Sex/Gender,,6880,0.3188,0.31,0.33,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.86,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Marcela Mercado-Reye,Instituto Nacional de Salud,Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2022.100195,2022-02-23,2024-03-01,Verified,mercado-reyes_seroprevalence_2022,COL
220222_Colombia_InstitutoNacionaldeSalud_AreaBucaramanga,220222_Colombia_InstitutoNacionaldeSalud,"Seroprevalence of anti-SARS-CoV-2 antibodies in Colombia, 2020: A population-based study.",2022-02-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Colombia,,Bucaramanga,"Seven of the ten most populated cities in Colombia (Bogot a, Medell ın, Cali, Barranquilla, Cucuta, Bucaramanga and Villavicencio) as well as cities in key border regions (Leticia, Ipiales and Guapi) were involved. Individuals in the selected households were invited to participate.",,2020-09-21,2020-12-11,Household and community samples,All,Multiple groups,5.0,80.0,Geographical area,Bucaramanga,1425,0.2793,0.23500000000000001,0.32299999999999995,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.86,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Marcela Mercado-Reye,Instituto Nacional de Salud,Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2022.100195,2022-05-18,2024-03-01,Verified,mercado-reyes_seroprevalence_2022,COL
220222_Colombia_InstitutoNacionaldeSalud_AreaBarranquilla,220222_Colombia_InstitutoNacionaldeSalud,"Seroprevalence of anti-SARS-CoV-2 antibodies in Colombia, 2020: A population-based study.",2022-02-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Colombia,,Barranquilla,"Seven of the ten most populated cities in Colombia (Bogot a, Medell ın, Cali, Barranquilla, Cucuta, Bucaramanga and Villavicencio) as well as cities in key border regions (Leticia, Ipiales and Guapi) were involved. Individuals in the selected households were invited to participate.",,2020-09-21,2020-12-11,Household and community samples,All,Multiple groups,5.0,80.0,Geographical area,Barranquilla,1426,0.4888,0.451,0.525,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.86,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Marcela Mercado-Reye,Instituto Nacional de Salud,Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2022.100195,2022-05-18,2024-03-01,Verified,mercado-reyes_seroprevalence_2022,COL
220222_Colombia_InstitutoNacionaldeSalud_AreaMedellín,220222_Colombia_InstitutoNacionaldeSalud,"Seroprevalence of anti-SARS-CoV-2 antibodies in Colombia, 2020: A population-based study.",2022-02-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Colombia,,Medellín,"Seven of the ten most populated cities in Colombia (Bogot a, Medell ın, Cali, Barranquilla, Cucuta, Bucaramanga and Villavicencio) as well as cities in key border regions (Leticia, Ipiales and Guapi) were involved. Individuals in the selected households were invited to participate.",,2020-09-21,2020-12-11,Household and community samples,All,Multiple groups,5.0,80.0,Geographical area,Medellín,1987,0.2335,0.195,0.272,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.86,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Marcela Mercado-Reye,Instituto Nacional de Salud,Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2022.100195,2022-05-18,2024-03-01,Verified,mercado-reyes_seroprevalence_2022,COL
20220223_Colombia_InstitutoNacionaldeSalud_Age61to100,220222_Colombia_InstitutoNacionaldeSalud,"Seroprevalence of anti-SARS-CoV-2 antibodies in Colombia, 2020: A population-based study.",2022-02-22,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Colombia,,"Bogot a, Medell ın, Cali, Barranquilla, Cucuta,
Bucaramanga and Villavicencio Leticia, Ipiales and Guapi","Seven of the ten most populated cities in Colombia (Bogot a, Medell ın, Cali, Barranquilla, Cucuta, Bucaramanga and Villavicencio) as well as cities in key border regions (Leticia, Ipiales and Guapi) were involved. Individuals in the selected households were invited to participate.",,2020-09-21,2020-12-11,Household and community samples,All,Seniors (65+ years),61.0,100.0,Age,age: 61-100,2964,0.2389,0.22,0.25,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.86,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Marcela Mercado-Reye,Instituto Nacional de Salud,Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2022.100195,2022-02-23,2024-03-01,Verified,mercado-reyes_seroprevalence_2022,COL
220323_Colombia_FundacionSantaFedeBogota_Overall,220323_Colombia_FundacionSantaFedeBogota,Prevalence of SARS-CoV-2 infection and SARS-CoV-2-specific antibody detection among healthcare workers and hospital staff of a university hospital in Colombia.,2022-03-23,Journal Article (Peer-Reviewed),Local,Prospective cohort,Colombia,Bogotá,Bogotá,The inclusion criteria included: 1) women and men older than 18 years; and 2) active hospital workers.,Participants with contraindications for collecting nasopharyngeal and blood samples were excluded.,2020-06-25,2020-10-30,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,420,0.231,,,True,,,,True,Convenience,"Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,2019-nCoV IgG/IgM Rapid Test","Qingdao Hightop Biotech Co. Ltd ,Dynamiker Biotechnology (Tianjin) Co. Ltd",,Serum,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,No,No,,Nohemí Caballero,Fundación Santa Fe de Bogotá,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942465/,2022-06-29,2024-03-01,Unverified,caballero_prevalence_2022,COL
220901_Colombia_IPSSanPabloApóstol_overall,220901_Colombia_IPSSanPabloApóstol,"Seroprevalence of antibodies against to SARS-CoV 2 in umbilical cord blood in two hospital centers in Cordoba and Sucre, Colombia.",2022-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Colombia,,,""" Two hospitals from the departments of Córdoba and Sucre, located in the Caribbean area in the Northwest of Colombia, participated""

",,2021-03-15,2021-06-15,Perinatal,Female,Adults (18-64 years),15.0,42.0,Primary Estimate,,360,0.294,,,True,,,,True,Convenience,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,0.925,0.9920000000000001,['High'],,No,No,No,,Yes,Yes,Yes,,Jose Berrocal,IPS San Pablo Apóstol,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jiph.2022.08.017,2022-09-27,2024-03-01,Unverified,berrocalSeroprevalenceAntibodiesSARSCoV2022,COL
220905_Colombia_UniversidadDeLaSalle_Overall_TestAdj,220905_Colombia_UniversidadDeLaSalle,Seroprevalence of IgM and IgG anti-SARS-COV-2 and associated factors among agricultural workers in Colombia.,2022-09-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Colombia,,,"""Inclusion criteria: inhabitants of rural and urban areas, who are adults and workers, as well as family members linked to the selected production chains.""","""Exclusion criteria: people vaccinated with one or two doses of COVID-19.""",2021-03-15,2021-06-15,Multiple populations,All,Multiple groups,,,Primary Estimate,"""Adjusted for the COV2T test sensitivity and specificity""",1225,0.392,,,True,True,,,,Convenience,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,1.0,0.998,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Martha Rodríguez,Universidad de La Salle,Not Unity-Aligned,https://dx.doi.org/10.1016/j.nmni.2022.101026,2022-09-19,2023-08-15,Unverified,rodriguez_seroprevalence_2022,COL
220919_Bogota_PontificiaUniversidadJaveriana_Overall,220919_Bogota_PontificiaUniversidadJaveriana,"Cumulative incidence, prevalence, seroconversion, and associated factors for SARS-CoV-2 infection among healthcare workers of a University Hospital in Bogota, Colombia.",2022-09-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Colombia,,Bogota,"All HCWs employed by HUSI, including administrative staff, were invited to participate by an institutional e-mail.",,2020-11-17,2021-02-12,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,2597,0.215,,,True,,,,True,Self-referral,"Author designed (type unknown),Abbott Architect SARS-CoV-2 IgG,Author designed (ELISA) -Spike,VIDAS® SARS-COV-2 IgM","NA,Abbott Laboratories,BioMérieux",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sandra Liliana Valderrama-Beltran,Pontificia Universidad Javeriana,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0274484,2022-09-26,2024-03-01,Unverified,valderrama-beltrán_cumulative_2022,COL
221215_Medellin_InstituciónUniversitariaColegioMayordeAntioquia,221215_Medellin_InstituciónUniversitariaColegioMayordeAntioquia,"Comparison of capillary blood and plasma samples for the evaluation of seroprevalence to SARS-CoV-2 antibodies by lateral flow immunoassay in a university population in Medellin, Colombia, 2020.",2022-12-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Colombia,,Medellin,"""Eligible participants (N = 280) were aged ≥18 years, and
were able to read and sign informed consent documents""",,2020-11-15,2021-01-15,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,260,0.11199999999999999,,,True,,,,True,Convenience,Wondfo SARS-CoV-2 Antibody Test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Multiple Types,"IgG, IgM",[],,,,['High'],,No,No,No,,No,Yes,No,,Miguel Octavio Perez Navarro,Institución Universitaria Colegio Mayor de Antioquia,Not Unity-Aligned,https://dx.doi.org/10.1016/j.puhip.2022.100347,2023-01-13,2024-03-01,Unverified,navarro_comparison_2023,COL
230131_Bogota_FundaciónCardioinfantil-InstitutodeCardiología,230131_Bogota_FundaciónCardioinfantil-InstitutodeCardiología,SARS-CoV-2 seroprevalence in workers from a Colombian University Hospital.,2023-01-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Colombia,,Bogota,"""We conducted a cross-sectional study of medical and non-medical workers of a third level university hospital. Those who had at least one viral identification test for SARS-CoV-2 in- fection (RT–PCR or antigen test) between March 2020 and March 2021 and voluntarily participated in the study were eligible for inclusion.""",did not perform the Ab test,2021-04-19,2021-05-13,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1021,0.3448,,,True,,,,True,Convenience,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.978,0.928,['High'],,No,Yes,No,,No,Yes,No,,Karen Moreno-Medina,Fundación Cardioinfantil-Instituto de Cardiología,Not Unity-Aligned,https://dx.doi.org/10.1093/occmed/kqad003,2023-03-05,2024-03-01,Unverified,moreno-medina_sars-cov-2_2023,COL
230215_Colombia_GlobalInstituteOfClinicalExcellence_IgG,230215_Colombia_GlobalInstituteOfClinicalExcellence,Prevention and control of COVID-19 outbreak in a hemodialysis center,2023-02-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,Colombia,,Bogota,"All adult patients with stage 5 CKD on HD therapy between March 1, 2020, and January 28, 2021", Patients with acute kidney disease requiring in-center hemodialysis were excluded. ,2020-03-01,2021-01-28,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,,Primary Estimate,IgG,162,0.25,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,IgG,,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Camilo Alberto González González,Global Institute of Clinical Excellence,Not Unity-Aligned,https://dx.doi.org/10.4067/S0034-98872023000100072,2023-10-02,2023-10-03,Unverified,gonzalez-gonzalez_prevention_2023,COL
201222_Brazzaville_FondationCongolaisePourLaRechercheMédicale_GenPop_Overall,201222_Brazzaville_FondationCongolaisePourLaRechercheMédicale,"High SARS-COV2 IgG/IGM seroprevalence in asymptomatic Congolese in Brazzaville, the Republic of Congo",2020-12-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Congo,,Brazzaville,"Only individuals without any disease symptom, aged more than 18 years old and giving a written consent were enrolled. The participants were resident of all the districts of Brazzaville",,2020-04-01,2020-07-31,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,,754,0.197,,,True,,,,True,Self-referral,"UNSCIENCE COVID-19 IgG/IgM antibody Rapid Test Kit,Sienna-Clarity COVIBLOCK COVID-19 IgG/IgM Rapid Test Cassette","Wuhan UNscience Biotechnology Co. Ltd,Salofa Oy",LFIA,Serum,"['IgG', 'IgM']",,,,,['High'],Unclear,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear, Armel Batchi Bouyou,Fondation Congolaise pour la Recherche Médicale,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2020.12.065,2021-01-30,2024-03-01,Verified,batchi-bouyou_high_2020,COG
220315_Bomassa_FCRM_IgGIgM,220315_Bomassa_FCRM,"Seroprevalence of anti-SARS-CoV-2 antibodies in a population living in Bomassa village, Republic of Congo",2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Congo,,"Bomassa
","In total, 304 Congolese residents aged from 18 to 60 years old, and with no known COVID-19 symptoms, were randomly recruited across all of Bo- massa village",,2021-05-20,2021-06-02,Household and community samples,All,Adults (18-64 years),18.0,60.0,Primary Estimate,IgG/IgM,304,0.36,,,True,,,,True,Simplified probability,"SARS-CoV-2 IgG ELISA,SARS-CoV-2 IgM ELISA",VIROTECH,ELISA,Plasma,"['IgG', 'IgM']",,,,,['High'],Yes,Yes,No,Yes,Yes,No,Yes,No,Unclear,LineLobaloba Ingoba,Fondation Congolaise pour la Recherche Médicale,Not Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S2772707622000066?via%3Dihub,2022-04-27,2024-03-01,Unverified,lobaloba-ingoba_seroprevalence_2022,COG
220315_Bomassa_FCRM_NeutralizingAb,220315_Bomassa_FCRM,"Seroprevalence of anti-SARS-CoV-2 antibodies in a population living in Bomassa village, Republic of Congo",2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Congo,,"Bomassa
","In total, 304 Congolese residents aged from 18 to 60 years old, and with no known COVID-19 symptoms, were randomly recruited across all of Bo- massa village",,2021-05-20,2021-06-02,Household and community samples,All,Adults (18-64 years),18.0,60.0,Test used,Neutralizing Ab,304,0.16,,,,,,,,Simplified probability,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,GenScript,ELISA,Plasma,Neutralizing,Spike,,,,['High'],Yes,Yes,No,Yes,Yes,No,Yes,No,Unclear,LineLobaloba Ingoba,Fondation Congolaise pour la Recherche Médicale,Not Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S2772707622000066?via%3Dihub,2022-04-27,2024-03-01,Unverified,lobaloba-ingoba_seroprevalence_2022,COG
220315_Bomassa_FCRM_Age35to44,220315_Bomassa_FCRM,"Seroprevalence of anti-SARS-CoV-2 antibodies in a population living in Bomassa village, Republic of Congo",2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Congo,,"Bomassa
","In total, 304 Congolese residents aged from 18 to 60 years old, and with no known COVID-19 symptoms, were randomly recruited across all of Bo- massa village",,2021-05-20,2021-06-02,Household and community samples,All,Adults (18-64 years),35.0,44.0,Age,"Age: 35-44, IgG",41,0.37,,,,,,,,Simplified probability,SARS-CoV-2 IgG ELISA,VIROTECH,ELISA,Plasma,IgG,,,,,['High'],Yes,Yes,No,Yes,Yes,No,Yes,No,Unclear,LineLobaloba Ingoba,Fondation Congolaise pour la Recherche Médicale,Not Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S2772707622000066?via%3Dihub,2022-04-27,2024-03-01,Unverified,lobaloba-ingoba_seroprevalence_2022,COG
220315_Bomassa_FCRM_Age45to60,220315_Bomassa_FCRM,"Seroprevalence of anti-SARS-CoV-2 antibodies in a population living in Bomassa village, Republic of Congo",2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Congo,,"Bomassa
","In total, 304 Congolese residents aged from 18 to 60 years old, and with no known COVID-19 symptoms, were randomly recruited across all of Bo- massa village",,2021-05-20,2021-06-02,Household and community samples,All,Adults (18-64 years),45.0,60.0,Age,"Age: 45-60, IgG",42,0.38,,,,,,,,Simplified probability,SARS-CoV-2 IgG ELISA,VIROTECH,ELISA,Plasma,IgG,,,,,['High'],Yes,Yes,No,Yes,Yes,No,Yes,No,Unclear,LineLobaloba Ingoba,Fondation Congolaise pour la Recherche Médicale,Not Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S2772707622000066?via%3Dihub,2022-04-27,2024-03-01,Unverified,lobaloba-ingoba_seroprevalence_2022,COG
220315_Bomassa_FCRM_Age18to24,220315_Bomassa_FCRM,"Seroprevalence of anti-SARS-CoV-2 antibodies in a population living in Bomassa village, Republic of Congo",2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Congo,,"Bomassa
","In total, 304 Congolese residents aged from 18 to 60 years old, and with no known COVID-19 symptoms, were randomly recruited across all of Bo- massa village",,2021-05-20,2021-06-02,Household and community samples,All,Adults (18-64 years),18.0,24.0,Age,"Age: 18-24, IgG",71,0.28,,,,,,,,Simplified probability,SARS-CoV-2 IgG ELISA,VIROTECH,ELISA,Plasma,IgG,,,,,['High'],Yes,Yes,No,Yes,Yes,No,Yes,No,Unclear,LineLobaloba Ingoba,Fondation Congolaise pour la Recherche Médicale,Not Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S2772707622000066?via%3Dihub,2022-04-27,2024-03-01,Unverified,lobaloba-ingoba_seroprevalence_2022,COG
220315_Bomassa_FCRM_Age25to34,220315_Bomassa_FCRM,"Seroprevalence of anti-SARS-CoV-2 antibodies in a population living in Bomassa village, Republic of Congo",2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Congo,,"Bomassa
","In total, 304 Congolese residents aged from 18 to 60 years old, and with no known COVID-19 symptoms, were randomly recruited across all of Bo- massa village",,2021-05-20,2021-06-02,Household and community samples,All,Adults (18-64 years),25.0,34.0,Age,"Age: 25-34, IgG",87,0.25,,,,,,,,Simplified probability,SARS-CoV-2 IgG ELISA,VIROTECH,ELISA,Plasma,IgG,,,,,['High'],Yes,Yes,No,Yes,Yes,No,Yes,No,Unclear,LineLobaloba Ingoba,Fondation Congolaise pour la Recherche Médicale,Not Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S2772707622000066?via%3Dihub,2022-04-27,2024-03-01,Unverified,lobaloba-ingoba_seroprevalence_2022,COG
221006_RepublicOfCongo_NationalLaboratoryOfPublicHealth_Overall,221006_RepublicOfCongo_NationalLaboratoryOfPublicHealth,SARS-CoV-2 antibodies prevalence in the Republic of Congo in mid-2021.,2022-10-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Congo,,"Brazzaville, Pointe-Noire, a rural site in Ouesso.","""The study participants were recruited in the general population, and inclusion criteria were: being aged ≥15 years and provide a written informed-consent.""","""Being vaccinated for the COVID-19 was an exclusion criterion.""",2021-06-15,2021-07-15,Household and community samples,All,Multiple groups,15.0,,Primary Estimate,,1669,0.318,0.295,0.34,True,,,,True,Convenience,Biosynex COVID-19 BSS assay,Biosynex,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9500000000000001,0.98,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Fabien Niama,National Laboratory of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijregi.2022.09.012,2022-10-19,2024-03-01,Unverified,niama_sars-cov-2_2022,COG
221006_RepublicOfCongo_NationalLaboratoryOfPublicHealth_Age25-54,221006_RepublicOfCongo_NationalLaboratoryOfPublicHealth,SARS-CoV-2 antibodies prevalence in the Republic of Congo in mid-2021.,2022-10-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Congo,,"Brazzaville, Pointe-Noire, a rural site in Ouesso.","""The study participants were recruited in the general population, and inclusion criteria were: being aged ≥15 years and provide a written informed-consent.""","""Being vaccinated for the COVID-19 was an exclusion criterion.""",2021-06-15,2021-07-15,Household and community samples,All,Adults (18-64 years),25.0,54.0,Age,Age group: 25-54 years,1158,0.321,0.294,0.349,,,,,,Convenience,Biosynex COVID-19 BSS assay,Biosynex,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9500000000000001,0.98,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Fabien Niama,National Laboratory of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijregi.2022.09.012,2022-10-19,2024-03-01,Unverified,niama_sars-cov-2_2022,COG
221006_RepublicOfCongo_NationalLaboratoryOfPublicHealth_AgeAbove65,221006_RepublicOfCongo_NationalLaboratoryOfPublicHealth,SARS-CoV-2 antibodies prevalence in the Republic of Congo in mid-2021.,2022-10-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Congo,,"Brazzaville, Pointe-Noire, a rural site in Ouesso.","""The study participants were recruited in the general population, and inclusion criteria were: being aged ≥15 years and provide a written informed-consent.""","""Being vaccinated for the COVID-19 was an exclusion criterion.""",2021-06-15,2021-07-15,Household and community samples,All,Seniors (65+ years),65.0,,Age,Age group: ≥65 years,48,0.375,0.24,0.526,,,,,,Convenience,Biosynex COVID-19 BSS assay,Biosynex,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9500000000000001,0.98,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Fabien Niama,National Laboratory of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijregi.2022.09.012,2022-10-19,2024-03-01,Unverified,niama_sars-cov-2_2022,COG
221006_RepublicOfCongo_NationalLaboratoryOfPublicHealth_Age15-24,221006_RepublicOfCongo_NationalLaboratoryOfPublicHealth,SARS-CoV-2 antibodies prevalence in the Republic of Congo in mid-2021.,2022-10-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Congo,,"Brazzaville, Pointe-Noire, a rural site in Ouesso.","""The study participants were recruited in the general population, and inclusion criteria were: being aged ≥15 years and provide a written informed-consent.""","""Being vaccinated for the COVID-19 was an exclusion criterion.""",2021-06-15,2021-07-15,Household and community samples,All,Adults (18-64 years),15.0,24.0,Age,Age group: 15-24 years,324,0.225,0.18100000000000002,0.275,,,,,,Convenience,Biosynex COVID-19 BSS assay,Biosynex,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9500000000000001,0.98,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Fabien Niama,National Laboratory of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijregi.2022.09.012,2022-10-19,2024-03-01,Unverified,niama_sars-cov-2_2022,COG
221006_RepublicOfCongo_NationalLaboratoryOfPublicHealth_Age55-64,221006_RepublicOfCongo_NationalLaboratoryOfPublicHealth,SARS-CoV-2 antibodies prevalence in the Republic of Congo in mid-2021.,2022-10-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Congo,,"Brazzaville, Pointe-Noire, a rural site in Ouesso.","""The study participants were recruited in the general population, and inclusion criteria were: being aged ≥15 years and provide a written informed-consent.""","""Being vaccinated for the COVID-19 was an exclusion criterion.""",2021-06-15,2021-07-15,Household and community samples,All,Adults (18-64 years),55.0,64.0,Age,Age group: 55-64 years,140,0.479,0.39299999999999996,0.5650000000000001,,,,,,Convenience,Biosynex COVID-19 BSS assay,Biosynex,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9500000000000001,0.98,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Fabien Niama,National Laboratory of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijregi.2022.09.012,2022-10-19,2024-03-01,Unverified,niama_sars-cov-2_2022,COG
200515_Croatia_UniversityofSplit_IndustryWorkers_Overall,200515_Croatia_UniversityofSplit,"SARS-CoV-2 antibody seroprevalence in industry workers in Split-Dalmatia and Sibenik-Knin County, Croatia",2020-05-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Croatia,,,Adult employees of DIV group in Split and Knin,,2020-04-23,2020-04-28,Essential non-healthcare workers,All,Multiple groups,19.0,79.0,Primary Estimate,,1494,0.012700000000000001,0.0077,0.0198,True,,,,True,Convenience,AMP Rapid Test SARS-CoV-2 IgG/IgM,AMEDA Labordiagnostik GmbH,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.918,0.9640000000000001,['High'],Yes,No,Yes,Yes,No,Yes,Yes,No,Unclear,Ivan Jerkovic,University of Split,Not Unity-Aligned,https://journals.lww.com/joem/Abstract/9000/SARS_CoV_2_Antibody_Seroprevalence_in_Industry.98091.aspx,2020-07-17,2024-03-01,Verified,jerkovic_sars-cov-2_2020,HRV
200826_Croatia_UniversityofZagreb_HCWsIgG,200826_Croatia_UniversityofZagreb,"Severe acute respiratory syndrome coronavirus 2 seroprevalence among personnel in the healthcare facilities of Croatia, 2020.",2020-08-26,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Croatia,,,"Sampled from several health care centres accross Croatia. The study group included: a) healthcare professionals working in different hospital/emergency wards; b) laboratory personnel included in the phlebotomy and SARS-CoV-2 diagnostic units; c) patient transporters; d) cleaning personnel; and e) others (social workers, physical therapists, and administrative workers). ",,2020-04-25,2020-05-24,Health care workers and caregivers,All,Adults (18-64 years),20.0,65.0,Primary Estimate,IgG,592,0.027000000000000003,,,True,,,,True,Convenience,COVID-19 ELISA IgG,Vircell S.L.,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,No,No,Yes,No,Yes,No,Unclear,Tatjana Vilibic Cavlek,University of Zagreb,Not Unity-Aligned,https://dx.doi.org/10.1590/0037-8682-0458-2020,2020-10-17,2024-03-01,Verified,vilibic-cavlek_severe_2020,HRV
201104_Croatia_CroatianFootballFederation_FootballPlayers&ClubStaff,201104_Croatia_CroatianFootballFederation,"SARS-CoV-2 Seroprevalence in a Cohort of Asymptomatic, RT-PCR Negative Croatian First League Football Players",2020-11-04,Preprint,Local,Prospective cohort,Croatia,,,"A total of 350 participants including all registered football players and club staff members of the Croatian First Football National League participated in this study, all of whom were male aged from 17 to 71 years. All participants were enrolled at the primary club setting. The participants strictly followed the Croatian Football Federation protocol that included limited social contact and training in small groups. None of the participants presented with fever or any respiratory symptoms at the time of testing. An epidemiological questionnaire was filled out at the beginning of the study. One participant was excluded from the study for not completing the questionnaire.
At the time of the third sampling 44 participants were lost to follow-up.",,2020-05-29,2020-07-31,Non-essential workers and unemployed persons,Male,Adults (18-64 years),17.0,71.0,Primary Estimate,Overall,305,0.2,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG),Anti-SARS-CoV-2 ELISA IgA",EUROIMMUN,ELISA,Serum,"['IgA', 'IgG']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,No,No,Unclear,Unclear,Yes,No,Yes,Adriana Vince,Croatian Football Federation,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.30.20223230v1,2021-02-06,2024-03-01,Verified,vince_sars-cov-2_2020,HRV
201231_Zagreb_ZagrebUniversity_overall,201231_Zagreb_ZagrebUniversity,The reliability of SARS-CoV-2 IgG antibody testing - a pilot study in asymptomatic health care workers in a Croatian university hospital,2020-12-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Croatia,,Zagreb,"The study enrolled 1678 asymptomatic HCW (median age, 43 years) who were actively involved in patient care and associated hospital activities from mid-March to the end of April 2020.",All asymptomatic HCW with previously con- firmed COVID-19 were excluded from this part of the study,2020-05-01,2020-05-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1678,0.006,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Ivana Lapic,Zagreb University,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/33410294/,2021-02-01,2024-03-01,Verified,lapic_reliability_2020,HRV
210415_Croatia_ChildrensHospitalZagreb_timepoint1_primary,210415_Croatia_ChildrensHospitalZagreb_timepoint1,Seroprevalence of SARS-CoV-2 infection among children in Children's Hospital Zagreb during the initial and second wave of COVID-19 pandemic in Croatia,2021-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Croatia,,Zagreb,All blood samples of children which arrived at the Department of Laboratory Diagnostics of CHZ that met the residual criterion volume (> 350 µL) after the routine laboratory analysis were included in the study at two time points of COVID-19 pandemic.,,2020-05-13,2020-05-29,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Primary Estimate,Children in hospital,240,0.028999999999999998,,,True,,,,True,Convenience,"COVID-19 ELISA IgG,COVID-19 ELISA IgM/IgA,Author designed (Neutralization Assay)","Vircell S.L.,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,No,Unclear,Jasna Lenicek Krleza,Children's Hospital Zagreb,Unity-Aligned,https://dx.doi.org/10.11613/BM.2021.020706,2021-05-20,2024-03-01,Verified,lenicek_krleza_seroprevalence_2021,HRV
210415_Croatia_ChildrensHospitalZagreb_timepoint1_ELISA,210415_Croatia_ChildrensHospitalZagreb_timepoint1,Seroprevalence of SARS-CoV-2 infection among children in Children's Hospital Zagreb during the initial and second wave of COVID-19 pandemic in Croatia,2021-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Croatia,,Zagreb,All blood samples of children which arrived at the Department of Laboratory Diagnostics of CHZ that met the residual criterion volume (> 350 µL) after the routine laboratory analysis were included in the study at two time points of COVID-19 pandemic.,,2020-05-13,2020-05-29,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Test used,ELISA tests only,240,0.038,,,,,,,,Convenience,"COVID-19 ELISA IgG,COVID-19 ELISA IgM/IgA",Vircell S.L.,ELISA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,0.9920000000000001,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,No,Unclear,Jasna Lenicek Krleza,Children's Hospital Zagreb,Unity-Aligned,https://dx.doi.org/10.11613/BM.2021.020706,2021-06-25,2024-03-01,Verified,lenicek_krleza_seroprevalence_2021,HRV
210415_Croatia_ChildrensHospitalZagreb_timepoint1_age1-10,210415_Croatia_ChildrensHospitalZagreb_timepoint1,Seroprevalence of SARS-CoV-2 infection among children in Children's Hospital Zagreb during the initial and second wave of COVID-19 pandemic in Croatia,2021-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Croatia,,Zagreb,All blood samples of children which arrived at the Department of Laboratory Diagnostics of CHZ that met the residual criterion volume (> 350 µL) after the routine laboratory analysis were included in the study at two time points of COVID-19 pandemic.,,2020-05-13,2020-05-29,Residual sera,All,Children and Youth (0-17 years),1.0,10.0,Age,Children in hospital,124,0.032,,,,,,,,Convenience,"COVID-19 ELISA IgG,COVID-19 ELISA IgM/IgA,Author designed (Neutralization Assay)","Vircell S.L.,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,No,Unclear,Jasna Lenicek Krleza,Children's Hospital Zagreb,Unity-Aligned,https://dx.doi.org/10.11613/BM.2021.020706,2021-06-25,2024-03-01,Verified,lenicek_krleza_seroprevalence_2021,HRV
210415_Croatia_ChildrensHospitalZagreb_timepoint1_age<1,210415_Croatia_ChildrensHospitalZagreb_timepoint1,Seroprevalence of SARS-CoV-2 infection among children in Children's Hospital Zagreb during the initial and second wave of COVID-19 pandemic in Croatia,2021-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Croatia,,Zagreb,All blood samples of children which arrived at the Department of Laboratory Diagnostics of CHZ that met the residual criterion volume (> 350 µL) after the routine laboratory analysis were included in the study at two time points of COVID-19 pandemic.,,2020-05-13,2020-05-29,Residual sera,All,Children and Youth (0-17 years),0.0,1.0,Age,Children in hospital,21,0.05,,,,,,,,Convenience,"COVID-19 ELISA IgG,COVID-19 ELISA IgM/IgA,Author designed (Neutralization Assay)","Vircell S.L.,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,No,Unclear,Jasna Lenicek Krleza,Children's Hospital Zagreb,Unity-Aligned,https://dx.doi.org/10.11613/BM.2021.020706,2021-06-25,2024-03-01,Verified,lenicek_krleza_seroprevalence_2021,HRV
210415_Croatia_ChildrensHospitalZagreb_timepoint1_age11-19,210415_Croatia_ChildrensHospitalZagreb_timepoint1,Seroprevalence of SARS-CoV-2 infection among children in Children's Hospital Zagreb during the initial and second wave of COVID-19 pandemic in Croatia,2021-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Croatia,,Zagreb,All blood samples of children which arrived at the Department of Laboratory Diagnostics of CHZ that met the residual criterion volume (> 350 µL) after the routine laboratory analysis were included in the study at two time points of COVID-19 pandemic.,,2020-05-13,2020-05-29,Residual sera,All,Children and Youth (0-17 years),11.0,19.0,Age,Children in hospital,95,0.021,,,,,,,,Convenience,"COVID-19 ELISA IgG,COVID-19 ELISA IgM/IgA,Author designed (Neutralization Assay)","Vircell S.L.,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,No,Unclear,Jasna Lenicek Krleza,Children's Hospital Zagreb,Unity-Aligned,https://dx.doi.org/10.11613/BM.2021.020706,2021-06-25,2024-03-01,Verified,lenicek_krleza_seroprevalence_2021,HRV
210415_Croatia_ChildrensHospitalZagreb_timepoint2_primary,210415_Croatia_ChildrensHospitalZagreb_timepoint2,Seroprevalence of SARS-CoV-2 infection among children in Children's Hospital Zagreb during the initial and second wave of COVID-19 pandemic in Croatia,2021-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Croatia,,Zagreb,All blood samples of children which arrived at the Department of Laboratory Diagnostics of CHZ that met the residual criterion volume (> 350 µL) after the routine laboratory analysis were included in the study at two time points of COVID-19 pandemic.,,2020-10-24,2020-11-23,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Primary Estimate,Children in hospital,308,0.084,,,True,,,,True,Convenience,"Author designed (Neutralization Assay),Elecsys® Anti‐SARS‐CoV‐2 (N)","NA,Roche Diagnostics",Multiple Types,Serum,"['IgG', 'IgM', 'Neutralizing']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['High'],Yes,No,No,Yes,Unclear,Unclear,Yes,No,,Jasna Lenicek Krleza,Children's Hospital Zagreb,Not Unity-Aligned,https://dx.doi.org/10.11613/BM.2021.020706,2021-05-20,2024-03-01,Verified,lenicek_krleza_seroprevalence_2021,HRV
210415_Croatia_ChildrensHospitalZagreb_timepoint2_age1-10,210415_Croatia_ChildrensHospitalZagreb_timepoint2,Seroprevalence of SARS-CoV-2 infection among children in Children's Hospital Zagreb during the initial and second wave of COVID-19 pandemic in Croatia,2021-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Croatia,,Zagreb,All blood samples of children which arrived at the Department of Laboratory Diagnostics of CHZ that met the residual criterion volume (> 350 µL) after the routine laboratory analysis were included in the study at two time points of COVID-19 pandemic.,,2020-10-24,2020-11-23,Residual sera,All,Children and Youth (0-17 years),1.0,10.0,Age,Children in hospital,167,0.054000000000000006,,,,,,,,Convenience,"Author designed (Neutralization Assay),Elecsys® Anti‐SARS‐CoV‐2 (N)","NA,Roche Diagnostics",Multiple Types,Serum,"['IgG', 'IgM', 'Neutralizing']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['High'],Yes,No,No,Yes,Unclear,Unclear,Yes,No,,Jasna Lenicek Krleza,Children's Hospital Zagreb,Not Unity-Aligned,https://dx.doi.org/10.11613/BM.2021.020706,2021-06-25,2024-03-01,Verified,lenicek_krleza_seroprevalence_2021,HRV
210415_Croatia_ChildrensHospitalZagreb_timepoint2_age<1,210415_Croatia_ChildrensHospitalZagreb_timepoint2,Seroprevalence of SARS-CoV-2 infection among children in Children's Hospital Zagreb during the initial and second wave of COVID-19 pandemic in Croatia,2021-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Croatia,,Zagreb,All blood samples of children which arrived at the Department of Laboratory Diagnostics of CHZ that met the residual criterion volume (> 350 µL) after the routine laboratory analysis were included in the study at two time points of COVID-19 pandemic.,,2020-10-24,2020-11-23,Residual sera,All,Children and Youth (0-17 years),0.0,1.0,Age,Children in hospital,27,0.07,,,,,,,,Convenience,"Author designed (Neutralization Assay),Elecsys® Anti‐SARS‐CoV‐2 (N)","NA,Roche Diagnostics",Multiple Types,Serum,"['IgG', 'IgM', 'Neutralizing']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['High'],Yes,No,No,Yes,Unclear,Unclear,Yes,No,,Jasna Lenicek Krleza,Children's Hospital Zagreb,Not Unity-Aligned,https://dx.doi.org/10.11613/BM.2021.020706,2021-06-25,2024-03-01,Verified,lenicek_krleza_seroprevalence_2021,HRV
210415_Croatia_ChildrensHospitalZagreb_timepoint2_age11-19,210415_Croatia_ChildrensHospitalZagreb_timepoint2,Seroprevalence of SARS-CoV-2 infection among children in Children's Hospital Zagreb during the initial and second wave of COVID-19 pandemic in Croatia,2021-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Croatia,,Zagreb,All blood samples of children which arrived at the Department of Laboratory Diagnostics of CHZ that met the residual criterion volume (> 350 µL) after the routine laboratory analysis were included in the study at two time points of COVID-19 pandemic.,,2020-10-24,2020-11-23,Residual sera,All,Children and Youth (0-17 years),11.0,19.0,Age,Children in hospital,114,0.132,,,,,,,,Convenience,"Author designed (Neutralization Assay),Elecsys® Anti‐SARS‐CoV‐2 (N)","NA,Roche Diagnostics",Multiple Types,Serum,"['IgG', 'IgM', 'Neutralizing']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['High'],Yes,No,No,Yes,Unclear,Unclear,Yes,No,,Jasna Lenicek Krleza,Children's Hospital Zagreb,Not Unity-Aligned,https://dx.doi.org/10.11613/BM.2021.020706,2021-06-25,2024-03-01,Verified,lenicek_krleza_seroprevalence_2021,HRV
210415_Croatia_ChildrensHospitalZagreb_timepoint2_CLIA,210415_Croatia_ChildrensHospitalZagreb_timepoint2,Seroprevalence of SARS-CoV-2 infection among children in Children's Hospital Zagreb during the initial and second wave of COVID-19 pandemic in Croatia,2021-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Croatia,,Zagreb,All blood samples of children which arrived at the Department of Laboratory Diagnostics of CHZ that met the residual criterion volume (> 350 µL) after the routine laboratory analysis were included in the study at two time points of COVID-19 pandemic.,,2020-10-24,2020-11-23,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Test used,Single CLIA test,308,0.08800000000000001,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,0.997,['High'],Yes,No,No,Yes,Unclear,Unclear,Yes,No,,Jasna Lenicek Krleza,Children's Hospital Zagreb,Not Unity-Aligned,https://dx.doi.org/10.11613/BM.2021.020706,2021-06-25,2024-03-01,Verified,lenicek_krleza_seroprevalence_2021,HRV
210602_Croatia_UniversityofZagreb,210602_Croatia_UniversityofZagreb,Seroprevalence of SARS-CoV-2 in Croatian solid-organ transplant recipients.,2021-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Croatia,,,"Adult patients. All transplanted patients who had an appointment in the transplant outpatient clinic during the sampling period and signed
the informed consent were included in the study. They all happened to be asymptomatic. ",,2020-09-07,2020-11-27,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,83.0,Primary Estimate,,512,0.201,0.16399999999999998,0.263,True,,,,True,Entire sample,COVID-19 ELISA IgG,Vircell S.L.,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,Yes,No,Yes,,No,Yes,No,,Anna Mrzljak,University of Zagreb,Not Unity-Aligned,https://dx.doi.org/10.11613/BM.2021.030901,2021-10-24,2024-03-01,Unverified,stevanovic_seroprevalence_2021,HRV
210620_Croatia_CroatianInstituteOfPublicHealth_FirstWave_Overall,210620_Croatia_CroatianInstituteOfPublicHealth_FirstWave,SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia.,2021-06-20,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Croatia,,,,,2020-05-15,2020-07-15,Multiple general populations,All,Multiple groups,,,Primary Estimate,,1088,0.022000000000000002,0.013999999999999999,0.033,True,,,,True,Convenience,"COVID-19 ELISA IgG,Author designed (Neutralization Assay)","Vircell S.L.,NA",Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Tatjana Vilibic-Cavlek,Croatian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/pathogens10060774,2021-07-13,2024-03-01,Verified,vilibic-cavlek_sars-cov-2_2021,HRV
210620_Croatia_CroatianInstituteOfPublicHealth_FirstWave_age20-29,210620_Croatia_CroatianInstituteOfPublicHealth_FirstWave,SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia.,2021-06-20,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Croatia,,,,,2020-05-15,2020-07-15,Multiple general populations,All,Adults (18-64 years),,,Age,20-29,117,0.0,,,,,,,,Convenience,"COVID-19 ELISA IgG,Author designed (Neutralization Assay)","Vircell S.L.,NA",Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Tatjana Vilibic-Cavlek,Croatian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/pathogens10060774,2021-07-13,2024-03-01,Verified,vilibic-cavlek_sars-cov-2_2021,HRV
210620_Croatia_CroatianInstituteOfPublicHealth_FirstWave_age30-39,210620_Croatia_CroatianInstituteOfPublicHealth_FirstWave,SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia.,2021-06-20,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Croatia,,,,,2020-05-15,2020-07-15,Multiple general populations,All,Adults (18-64 years),,,Age,30-39,241,0.012,0.003,0.036000000000000004,,,,,,Convenience,"COVID-19 ELISA IgG,Author designed (Neutralization Assay)","Vircell S.L.,NA",Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Tatjana Vilibic-Cavlek,Croatian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/pathogens10060774,2021-07-13,2024-03-01,Verified,vilibic-cavlek_sars-cov-2_2021,HRV
210620_Croatia_CroatianInstituteOfPublicHealth_FirstWave_age50-59,210620_Croatia_CroatianInstituteOfPublicHealth_FirstWave,SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia.,2021-06-20,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Croatia,,,,,2020-05-15,2020-07-15,Multiple general populations,All,Adults (18-64 years),,,Age,50-59,114,0.017,0.002,0.062000000000000006,,,,,,Convenience,"COVID-19 ELISA IgG,Author designed (Neutralization Assay)","Vircell S.L.,NA",Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Tatjana Vilibic-Cavlek,Croatian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/pathogens10060774,2021-07-13,2024-03-01,Verified,vilibic-cavlek_sars-cov-2_2021,HRV
210620_Croatia_CroatianInstituteOfPublicHealth_FirstWave_age40-49,210620_Croatia_CroatianInstituteOfPublicHealth_FirstWave,SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia.,2021-06-20,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Croatia,,,,,2020-05-15,2020-07-15,Multiple general populations,All,Adults (18-64 years),,,Age,40-49,130,0.038,0.013000000000000001,0.08800000000000001,,,,,,Convenience,"COVID-19 ELISA IgG,Author designed (Neutralization Assay)","Vircell S.L.,NA",Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Tatjana Vilibic-Cavlek,Croatian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/pathogens10060774,2021-07-13,2024-03-01,Verified,vilibic-cavlek_sars-cov-2_2021,HRV
210620_Croatia_CroatianInstituteOfPublicHealth_FirstWave_female,210620_Croatia_CroatianInstituteOfPublicHealth_FirstWave,SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia.,2021-06-20,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Croatia,,,,,2020-05-15,2020-07-15,Multiple general populations,Female,Multiple groups,,,Sex/Gender,,717,0.017,0.009000000000000001,0.028999999999999998,,,,,,Convenience,"COVID-19 ELISA IgG,Author designed (Neutralization Assay)","Vircell S.L.,NA",Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Tatjana Vilibic-Cavlek,Croatian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/pathogens10060774,2021-07-13,2024-03-01,Verified,vilibic-cavlek_sars-cov-2_2021,HRV
210620_Croatia_CroatianInstituteOfPublicHealth_FirstWave_age60-69,210620_Croatia_CroatianInstituteOfPublicHealth_FirstWave,SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia.,2021-06-20,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Croatia,,,,,2020-05-15,2020-07-15,Multiple general populations,All,Multiple groups,,,Age,60-69 ,125,0.016,0.002,0.057,,,,,,Convenience,"COVID-19 ELISA IgG,Author designed (Neutralization Assay)","Vircell S.L.,NA",Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Tatjana Vilibic-Cavlek,Croatian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/pathogens10060774,2021-07-13,2024-03-01,Verified,vilibic-cavlek_sars-cov-2_2021,HRV
210620_Croatia_CroatianInstituteOfPublicHealth_FirstWave_age<10,210620_Croatia_CroatianInstituteOfPublicHealth_FirstWave,SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia.,2021-06-20,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Croatia,,,,,2020-05-15,2020-07-15,Multiple general populations,All,Children and Youth (0-17 years),,,Age,<10,146,0.034,0.011000000000000001,0.078,,,,,,Convenience,"COVID-19 ELISA IgG,Author designed (Neutralization Assay)","Vircell S.L.,NA",Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Tatjana Vilibic-Cavlek,Croatian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/pathogens10060774,2021-07-13,2024-03-01,Verified,vilibic-cavlek_sars-cov-2_2021,HRV
210620_Croatia_CroatianInstituteOfPublicHealth_FirstWave_age>70,210620_Croatia_CroatianInstituteOfPublicHealth_FirstWave,SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia.,2021-06-20,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Croatia,,,,,2020-05-15,2020-07-15,Multiple general populations,All,Seniors (65+ years),,,Age,>70,96,0.042,0.011000000000000001,0.10300000000000001,,,,,,Convenience,"COVID-19 ELISA IgG,Author designed (Neutralization Assay)","Vircell S.L.,NA",Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Tatjana Vilibic-Cavlek,Croatian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/pathogens10060774,2021-07-13,2024-03-01,Verified,vilibic-cavlek_sars-cov-2_2021,HRV
210620_Croatia_CroatianInstituteOfPublicHealth_FirstWave_male,210620_Croatia_CroatianInstituteOfPublicHealth_FirstWave,SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia.,2021-06-20,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Croatia,,,,,2020-05-15,2020-07-15,Multiple general populations,Male,Multiple groups,,,Sex/Gender,,371,0.032,0.017,0.055999999999999994,,,,,,Convenience,"COVID-19 ELISA IgG,Author designed (Neutralization Assay)","Vircell S.L.,NA",Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Tatjana Vilibic-Cavlek,Croatian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/pathogens10060774,2021-07-13,2024-03-01,Verified,vilibic-cavlek_sars-cov-2_2021,HRV
210620_Croatia_CroatianInstituteOfPublicHealth_FirstWave_age10-19,210620_Croatia_CroatianInstituteOfPublicHealth_FirstWave,SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia.,2021-06-20,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Croatia,,,,,2020-05-15,2020-07-15,Multiple general populations,All,Multiple groups,,,Age,10-19,119,0.025,0.005,0.07200000000000001,,,,,,Convenience,"COVID-19 ELISA IgG,Author designed (Neutralization Assay)","Vircell S.L.,NA",Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Tatjana Vilibic-Cavlek,Croatian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/pathogens10060774,2021-07-13,2024-03-01,Verified,vilibic-cavlek_sars-cov-2_2021,HRV
210620_Croatia_CroatianInstituteOfPublicHealth_SecondWave_Overall,210620_Croatia_CroatianInstituteOfPublicHealth_SecondWave,SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia.,2021-06-20,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Croatia,,,,,2020-12-15,2021-02-15,Multiple general populations,All,Multiple groups,,,Primary Estimate,,1436,0.251,0.228,0.27399999999999997,True,,,,True,Convenience,"COVID-19 ELISA IgG,Author designed (Neutralization Assay)","Vircell S.L.,NA",Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Tatjana Vilibic-Cavlek,Croatian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/pathogens10060774,2021-07-13,2024-03-01,Verified,vilibic-cavlek_sars-cov-2_2021,HRV
210620_Croatia_CroatianInstituteOfPublicHealth_SecondWave_Age30-39,210620_Croatia_CroatianInstituteOfPublicHealth_SecondWave,SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia.,2021-06-20,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Croatia,,,,,2020-12-15,2021-02-15,Multiple general populations,All,Adults (18-64 years),,,Age,30-39,220,0.24600000000000002,0.18600000000000003,0.303,,,,,,Convenience,"COVID-19 ELISA IgG,Author designed (Neutralization Assay)","Vircell S.L.,NA",Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Tatjana Vilibic-Cavlek,Croatian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/pathogens10060774,2021-07-13,2024-03-01,Verified,vilibic-cavlek_sars-cov-2_2021,HRV
210620_Croatia_CroatianInstituteOfPublicHealth_SecondWave_Zagreb&ZagrebCounty,210620_Croatia_CroatianInstituteOfPublicHealth_SecondWave,SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia.,2021-06-20,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Croatia,"Croatia Proper
",Zagreb,,,2020-12-15,2021-02-15,Multiple general populations,All,Multiple groups,,,Geographical area,,460,0.204,0.168,0.244,,,,,,Convenience,"COVID-19 ELISA IgG,Author designed (Neutralization Assay)","Vircell S.L.,NA",Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Tatjana Vilibic-Cavlek,Croatian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/pathogens10060774,2021-07-14,2024-03-01,Verified,vilibic-cavlek_sars-cov-2_2021,HRV
210620_Croatia_CroatianInstituteOfPublicHealth_SecondWave_Age50-59,210620_Croatia_CroatianInstituteOfPublicHealth_SecondWave,SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia.,2021-06-20,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Croatia,,,,,2020-12-15,2021-02-15,Multiple general populations,All,Adults (18-64 years),,,Age,50-59,207,0.262,0.20199999999999999,0.326,,,,,,Convenience,"COVID-19 ELISA IgG,Author designed (Neutralization Assay)","Vircell S.L.,NA",Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Tatjana Vilibic-Cavlek,Croatian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/pathogens10060774,2021-07-13,2024-03-01,Verified,vilibic-cavlek_sars-cov-2_2021,HRV
210620_Croatia_CroatianInstituteOfPublicHealth_SecondWave_Male,210620_Croatia_CroatianInstituteOfPublicHealth_SecondWave,SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia.,2021-06-20,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Croatia,,,,,2020-12-15,2021-02-15,Multiple general populations,Male,Multiple groups,,,Sex/Gender,,622,0.251,0.217,0.287,,,,,,Convenience,"COVID-19 ELISA IgG,Author designed (Neutralization Assay)","Vircell S.L.,NA",Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Tatjana Vilibic-Cavlek,Croatian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/pathogens10060774,2021-07-13,2024-03-01,Verified,vilibic-cavlek_sars-cov-2_2021,HRV
210620_Croatia_CroatianInstituteOfPublicHealth_SecondWave_IstriaCounty,210620_Croatia_CroatianInstituteOfPublicHealth_SecondWave,SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia.,2021-06-20,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Croatia,Istria,,,,2020-12-15,2021-02-15,Multiple general populations,All,Multiple groups,,,Geographical area,,178,0.163,0.11199999999999999,0.225,,,,,,Convenience,"COVID-19 ELISA IgG,Author designed (Neutralization Assay)","Vircell S.L.,NA",Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Tatjana Vilibic-Cavlek,Croatian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/pathogens10060774,2021-07-14,2024-03-01,Verified,vilibic-cavlek_sars-cov-2_2021,HRV
210620_Croatia_CroatianInstituteOfPublicHealth_SecondWave_Osijek-BaranjaCounty,210620_Croatia_CroatianInstituteOfPublicHealth_SecondWave,SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia.,2021-06-20,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Croatia,Slavonia,,,,2020-12-15,2021-02-15,Multiple general populations,All,Multiple groups,,,Geographical area,,225,0.32,0.259,0.385,,,,,,Convenience,"COVID-19 ELISA IgG,Author designed (Neutralization Assay)","Vircell S.L.,NA",Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Tatjana Vilibic-Cavlek,Croatian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/pathogens10060774,2021-07-14,2024-03-01,Verified,vilibic-cavlek_sars-cov-2_2021,HRV
210620_Croatia_CroatianInstituteOfPublicHealth_SecondWave_VarazdinCounty,210620_Croatia_CroatianInstituteOfPublicHealth_SecondWave,SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia.,2021-06-20,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Croatia,Croatia Proper,,,,2020-12-15,2021-02-15,Multiple general populations,All,Multiple groups,,,Geographical area,,97,0.36100000000000004,0.266,0.465,,,,,,Convenience,"COVID-19 ELISA IgG,Author designed (Neutralization Assay)","Vircell S.L.,NA",Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Tatjana Vilibic-Cavlek,Croatian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/pathogens10060774,2021-07-14,2024-03-01,Verified,vilibic-cavlek_sars-cov-2_2021,HRV
210620_Croatia_CroatianInstituteOfPublicHealth_SecondWave_Female,210620_Croatia_CroatianInstituteOfPublicHealth_SecondWave,SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia.,2021-06-20,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Croatia,,,,,2020-12-15,2021-02-15,Multiple general populations,Female,Multiple groups,,,Sex/Gender,,814,0.251,0.22,0.281,,,,,,Convenience,"COVID-19 ELISA IgG,Author designed (Neutralization Assay)","Vircell S.L.,NA",Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Tatjana Vilibic-Cavlek,Croatian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/pathogens10060774,2021-07-13,2024-03-01,Verified,vilibic-cavlek_sars-cov-2_2021,HRV
210620_Croatia_CroatianInstituteOfPublicHealth_SecondWave_Age20-29,210620_Croatia_CroatianInstituteOfPublicHealth_SecondWave,SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia.,2021-06-20,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Croatia,,,,,2020-12-15,2021-02-15,Multiple general populations,All,Adults (18-64 years),,,Age,20-29,146,0.289,0.21600000000000003,0.368,,,,,,Convenience,"COVID-19 ELISA IgG,Author designed (Neutralization Assay)","Vircell S.L.,NA",Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Tatjana Vilibic-Cavlek,Croatian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/pathogens10060774,2021-07-13,2024-03-01,Verified,vilibic-cavlek_sars-cov-2_2021,HRV
210620_Croatia_CroatianInstituteOfPublicHealth_SecondWave_Age>70,210620_Croatia_CroatianInstituteOfPublicHealth_SecondWave,SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia.,2021-06-20,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Croatia,,,,,2020-12-15,2021-02-15,Multiple general populations,All,Seniors (65+ years),,,Age,>70,94,0.1702,0.1,0.262,,,,,,Convenience,"COVID-19 ELISA IgG,Author designed (Neutralization Assay)","Vircell S.L.,NA",Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Tatjana Vilibic-Cavlek,Croatian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/pathogens10060774,2021-07-13,2024-03-01,Verified,vilibic-cavlek_sars-cov-2_2021,HRV
210620_Croatia_CroatianInstituteOfPublicHealth_SecondWave_Age40-49,210620_Croatia_CroatianInstituteOfPublicHealth_SecondWave,SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia.,2021-06-20,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Croatia,,,,,2020-12-15,2021-02-15,Multiple general populations,All,Adults (18-64 years),,,Age,40-49,238,0.27399999999999997,0.217,0.334,,,,,,Convenience,"COVID-19 ELISA IgG,Author designed (Neutralization Assay)","Vircell S.L.,NA",Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Tatjana Vilibic-Cavlek,Croatian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/pathogens10060774,2021-07-13,2024-03-01,Verified,vilibic-cavlek_sars-cov-2_2021,HRV
210620_Croatia_CroatianInstituteOfPublicHealth_SecondWave_Age<10,210620_Croatia_CroatianInstituteOfPublicHealth_SecondWave,SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia.,2021-06-20,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Croatia,,,,,2020-12-15,2021-02-15,Multiple general populations,All,Children and Youth (0-17 years),,,Age,<10,174,0.19,0.135,0.257,,,,,,Convenience,"COVID-19 ELISA IgG,Author designed (Neutralization Assay)","Vircell S.L.,NA",Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Tatjana Vilibic-Cavlek,Croatian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/pathogens10060774,2021-07-13,2024-03-01,Verified,vilibic-cavlek_sars-cov-2_2021,HRV
210620_Croatia_CroatianInstituteOfPublicHealth_SecondWave_Split-DalmatiaCounty,210620_Croatia_CroatianInstituteOfPublicHealth_SecondWave,SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia.,2021-06-20,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Croatia,"Dalmatia
",,,,2020-12-15,2021-02-15,Multiple general populations,All,Multiple groups,,,Geographical area,,265,0.287,0.233,0.34500000000000003,,,,,,Convenience,"COVID-19 ELISA IgG,Author designed (Neutralization Assay)","Vircell S.L.,NA",Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Tatjana Vilibic-Cavlek,Croatian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/pathogens10060774,2021-07-14,2024-03-01,Verified,vilibic-cavlek_sars-cov-2_2021,HRV
210620_Croatia_CroatianInstituteOfPublicHealth_SecondWave_Age60-69,210620_Croatia_CroatianInstituteOfPublicHealth_SecondWave,SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia.,2021-06-20,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Croatia,,,,,2020-12-15,2021-02-15,Multiple general populations,All,Multiple groups,,,Age,60-69 ,162,0.28600000000000003,0.21600000000000003,0.36,,,,,,Convenience,"COVID-19 ELISA IgG,Author designed (Neutralization Assay)","Vircell S.L.,NA",Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Tatjana Vilibic-Cavlek,Croatian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/pathogens10060774,2021-07-13,2024-03-01,Verified,vilibic-cavlek_sars-cov-2_2021,HRV
210620_Croatia_CroatianInstituteOfPublicHealth_SecondWave_Age10-19,210620_Croatia_CroatianInstituteOfPublicHealth_SecondWave,SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia.,2021-06-20,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Croatia,,,,,2020-12-15,2021-02-15,Multiple general populations,All,Multiple groups,,,Age,10-19,195,0.258,0.197,0.324,,,,,,Convenience,"COVID-19 ELISA IgG,Author designed (Neutralization Assay)","Vircell S.L.,NA",Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Tatjana Vilibic-Cavlek,Croatian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/pathogens10060774,2021-07-13,2024-03-01,Verified,vilibic-cavlek_sars-cov-2_2021,HRV
200802_AguadadePasajeros_UniversityofMedicalSciencesofCienfuegos,200802_AguadadePasajeros_UniversityofMedicalSciencesofCienfuegos,"Surveillance and control actions before notification of confirmed cases to COVID-19. Aguada de Pasajeros, Cienfuegos. Cuba",2020-08-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Cuba,Cienfuegos,Aguada de Pasajeros,Household and non-household contacts of an index case of COVID-19 in the community- a seven-month-old female patient,,2020-03-23,2020-04-06,Contacts of COVID patients,All,Multiple groups,,,Primary Estimate,Overall estimate,200,0.0,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],No,No,No,No,Unclear,Unclear,Yes,No,Unclear,Alain Morejon Giraldoni,University of Medical Sciences of Cienfuegos,Not Unity-Aligned,http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1727-897X2020000400721,2021-01-07,2022-07-16,Verified,morejon_giraldoni_acciones_2020,CUB
211231_Cyprus_CyprusSchoolofMolecularMedicine_AntiS1RBD_TestAdjusted,211231_Cyprus_CyprusSchoolofMolecularMedicine,Characterization of IgG Antibody Response against SARS-CoV-2 (COVID-19) in the Cypriot Population,2021-12-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Cyprus,,,"""The study inclusion criteria were >18 years of age, with ... negative SARS-CoV-2 RT-PCR detection test.""",Positive PCR test,2020-10-15,2021-05-15,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,Test Adjusted,194,0.0661,,,True,,,,,Convenience,SARS-CoV-2 S1RBD IgG ELISA Kit,ImmunoDiagnostics,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.925,0.9329999999999999,['High'],,No,No,Yes,,Yes,Yes,No,,George Krashias,Cyprus School of Molecular Medicine,Not Unity-Aligned,https://www.mdpi.com/2076-2607/10/1/85,2022-02-07,2024-03-01,Unverified,krashias_characterization_2022,CYP
211231_Cyprus_CyprusSchoolofMolecularMedicine_AntiNP,211231_Cyprus_CyprusSchoolofMolecularMedicine,Characterization of IgG Antibody Response against SARS-CoV-2 (COVID-19) in the Cypriot Population,2021-12-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Cyprus,,,"""The study inclusion criteria were >18 years of age, with ... negative SARS-CoV-2 RT-PCR detection test.""",Positive PCR test,2020-10-15,2021-05-15,Household and community samples,All,Multiple groups,18.0,,Test used,NP,194,0.12890000000000001,,,,,,,,Convenience,SARS-CoV-2 NP IgG/IgM ELISA Kit,ImmunoDiagnostics,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.97,0.99,['High'],,No,No,Yes,,Yes,Yes,No,,George Krashias,Cyprus School of Molecular Medicine,Not Unity-Aligned,https://www.mdpi.com/2076-2607/10/1/85,2022-02-07,2024-03-01,Unverified,krashias_characterization_2022,CYP
211231_Cyprus_CyprusSchoolofMolecularMedicine_AntiS1RBD_Unadjusted,211231_Cyprus_CyprusSchoolofMolecularMedicine,Characterization of IgG Antibody Response against SARS-CoV-2 (COVID-19) in the Cypriot Population,2021-12-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Cyprus,,,"""The study inclusion criteria were >18 years of age, with ... negative SARS-CoV-2 RT-PCR detection test.""",Positive PCR test,2020-10-15,2021-05-15,Household and community samples,All,Multiple groups,18.0,,Analysis,Unadjusted,194,0.12369999999999999,,,,,,,True,Convenience,SARS-CoV-2 S1RBD IgG ELISA Kit,ImmunoDiagnostics,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.925,0.9329999999999999,['High'],,No,No,Yes,,Yes,Yes,No,,George Krashias,Cyprus School of Molecular Medicine,Not Unity-Aligned,https://www.mdpi.com/2076-2607/10/1/85,2022-02-07,2024-03-01,Unverified,krashias_characterization_2022,CYP
220101_NorthernCyprus_NearEastUniversity,220101_NorthernCyprus_NearEastUniversity,The pediatric asymptomatic SARS-CoV-2 IgG seropositivity in the Turkish Republic of Northern Cyprus.,2022-01-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Cyprus,Northern Cyprus,North Nicosia,"children who were admitted to Near
East University Hospital for routine control or
with complaints other than those associated
with COVID-19 between September 2020
and January 2021 were included in the study.",,2020-09-15,2021-01-15,Residual sera,All,Children and Youth (0-17 years),2.0,15.0,Primary Estimate,,80,0.0125,,,True,,,,True,Convenience,COVID-19 IgG – ELISA,Diagnostic Bioprobes,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.922,0.84,['High'],,No,No,Yes,,Unclear,Yes,No,,Umut Gazi,Near East University,Not Unity-Aligned,https://dx.doi.org/10.24953/turkjped.2021.1330,2022-03-25,2022-07-16,Unverified,gazi_pediatric_2022,CYP
200506_CzechRepublic_MinistryofHealthoftheCzechRepublic_Brno/South Moravian Region,200506_CzechRepublic_MinistryofHealthoftheCzechRepublic_Brno/South Moravian Region,Studie SARS-CoV-2-CZ-Preval,2020-05-06,Presentation or Conference,Regional,Cross-sectional survey ,Czechia,Brno / South Moravian,,"Age from 18 to 89 years
Age from 8 to 17 years (only areas of the capital city of Prague and Brno and its surroundings)
No acute health problems typical of COVID-19
No elevated temperature
No confirmed diagnosis of COVID-19
Permanent / temporary residence in the Czech Republic",,2020-04-23,2020-05-01,Household and community samples,All,Multiple groups,10.0,89.0,Primary Estimate,,5049,0.0008,0.0001,0.0015300000000000001,True,,True,,True,Stratified non-probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,,,Validated by manufacturers,0.9500000000000001,1.0,['Moderate'],,No,Yes,No,,Unclear,Yes,Yes,,Ladislav Dušek,Ministry o fHealth of the Czech Republic,Not Unity-Aligned,https://covid-imunita.uzis.cz/res/file/prezentace/20200506-dusek.pdf,2021-06-08,2022-07-16,Unverified,ladislav_dusek_studie_2020,CZE
200506_CzechRepublic_MinistryofHealthoftheCzechRepublic_Litomerice,200506_CzechRepublic_MinistryofHealthoftheCzechRepublic_Litomerice,Studie SARS-CoV-2-CZ-Preval,2020-05-06,Presentation or Conference,Local,Cross-sectional survey ,Czechia,,Litomerice,"Age from 18 to 89 years
Age from 8 to 17 years (only areas of the capital city of Prague and Brno and its surroundings)
No acute health problems typical of COVID-19
No elevated temperature
No confirmed diagnosis of COVID-19
Permanent / temporary residence in the Czech Republic",,2020-04-23,2020-05-01,Household and community samples,All,Multiple groups,10.0,89.0,Primary Estimate,,3106,0.00244,0.0007099999999999999,0.00418,True,,True,,True,Stratified non-probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,,,Validated by manufacturers,0.9500000000000001,1.0,['Moderate'],,No,Yes,No,,Unclear,Yes,Yes,,Ladislav Dušek,Ministry o fHealth of the Czech Republic,Not Unity-Aligned,https://covid-imunita.uzis.cz/res/file/prezentace/20200506-dusek.pdf,2021-06-08,2022-07-16,Unverified,ladislav_dusek_studie_2020,CZE
200506_CzechRepublic_MinistryofHealthoftheCzechRepublic_Litovel_Unicov,200506_CzechRepublic_MinistryofHealthoftheCzechRepublic_Litovel_Unicov,Studie SARS-CoV-2-CZ-Preval,2020-05-06,Presentation or Conference,Local,Cross-sectional survey ,Czechia,,"Litovel, Unicov","Age from 18 to 89 years
Age from 8 to 17 years (only areas of the capital city of Prague and Brno and its surroundings)
No acute health problems typical of COVID-19
No elevated temperature
No confirmed diagnosis of COVID-19
Permanent / temporary residence in the Czech Republic",,2020-04-23,2020-05-01,Household and community samples,All,Multiple groups,10.0,89.0,Primary Estimate,,2409,0.0179,0.01242,0.02335,True,,True,,True,Stratified non-probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,,,Validated by manufacturers,0.9500000000000001,1.0,['Moderate'],,No,Yes,No,,Unclear,Yes,Yes,,Ladislav Dušek,Ministry o fHealth of the Czech Republic,Not Unity-Aligned,https://covid-imunita.uzis.cz/res/file/prezentace/20200506-dusek.pdf,2021-06-08,2022-07-16,Unverified,ladislav_dusek_studie_2020,CZE
200506_CzechRepublic_MinistryofHealthoftheCzechRepublic_Olomouc/Olomouckykraj,200506_CzechRepublic_MinistryofHealthoftheCzechRepublic_Olomouc/Olomouckykraj,Studie SARS-CoV-2-CZ-Preval,2020-05-06,Presentation or Conference,Regional,Cross-sectional survey ,Czechia,Olomouc / Olomouc ,,"Age from 18 to 89 years
Age from 8 to 17 years (only areas of the capital city of Prague and Brno and its surroundings)
No acute health problems typical of COVID-19
No elevated temperature
No confirmed diagnosis of COVID-19
Permanent / temporary residence in the Czech Republic",,2020-04-23,2020-05-01,Household and community samples,All,Multiple groups,10.0,89.0,Primary Estimate,,6686,0.0069,0.00484,0.00905,True,,True,,True,Stratified non-probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,,,Validated by manufacturers,0.9500000000000001,1.0,['Moderate'],,No,Yes,No,,Unclear,Yes,Yes,,Ladislav Dušek,Ministry o fHealth of the Czech Republic,Not Unity-Aligned,https://covid-imunita.uzis.cz/res/file/prezentace/20200506-dusek.pdf,2021-06-08,2022-07-16,Unverified,ladislav_dusek_studie_2020,CZE
200506_CzechRepublic_MinistryofHealthoftheCzechRepublic_Prague,200506_CzechRepublic_MinistryofHealthoftheCzechRepublic_Prague,Studie SARS-CoV-2-CZ-Preval,2020-05-06,Presentation or Conference,Local,Cross-sectional survey ,Czechia,,Prague,"Age from 18 to 89 years
Age from 8 to 17 years (only areas of the capital city of Prague and Brno and its surroundings)
No acute health problems typical of COVID-19
No elevated temperature
No confirmed diagnosis of COVID-19
Permanent / temporary residence in the Czech Republic",,2020-04-23,2020-05-01,Household and community samples,All,Multiple groups,10.0,89.0,Primary Estimate,,5021,0.0016500000000000002,0.0005,0.0028000000000000004,True,,True,,True,Stratified non-probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,,,Validated by manufacturers,0.9500000000000001,1.0,['Moderate'],,No,Yes,No,,Unclear,Yes,Yes,,Ladislav Dušek,Ministry o fHealth of the Czech Republic,Not Unity-Aligned,https://covid-imunita.uzis.cz/res/file/prezentace/20200506-dusek.pdf,2021-06-08,2022-07-16,Unverified,ladislav_dusek_studie_2020,CZE
200714_CzechRepublic_ResearchCenterIBD_HCW,200714_CzechRepublic_ResearchCenterIBD,Anti-SARS-CoV-2 antibody testing in IBD healthcare professionals: are we currently able to provide COVID-free IBD clinics?,2020-07-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Czechia,Central Bohemian,Prague,"We have attempted to identify staff who (1) have no signs of infection and are healthy; (2) have had the infection, recovered, and are now healthy and protected; and (3) are infected and have the disease either asymptomatically or symptomatically",,,2020-04-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,92,0.0217,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,,,['High'],Yes,No,No,Yes,Yes,Yes,Yes,Yes,Unclear, Karin Malickova,Clinical and Research Center for Inflammatory Bowel Disease,Not Unity-Aligned,https://dx.doi.org/10.1080/00365521.2020.1791244,2020-08-02,2024-03-01,Verified,malickova_anti-sars-cov-2_2020-1,CZE
201112_Prague_CharlesUniversityandThomayer'sHospital_Roche,201112_Prague_CharlesUniversityandThomayer’sHospital,Searching for COVID-19 Antibodies in Czech Children-A Needle in the Haystack,2020-11-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Czechia,Prague,Prague,"patients aged 0–18 years, who were examined between July 3rd and August 19th, 2020, in the Department of Pediatrics in Thomayer’s hospital in Prague, Czech Republic, for various general pediatric reasons", residency outside of the Czech Republic and known primary antibody deficiency,2020-07-03,2020-08-19,Residual sera,All,Children and Youth (0-17 years),0.0,18.0,Primary Estimate,Roche CLIA test,200,0.0,0.0,0.005,True,True,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.995,0.998,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Marketa Bloomfield,Charles University and Thomayer’s Hospital,Unity-Aligned,http://dx.doi.org/10.3389/fped.2020.597736,2021-01-23,2023-07-04,Verified,bloomfield_searching_2020,CZE
201112_Prague_CharlesUniversityandThomayer'sHospital_Roche copy,201112_Prague_CharlesUniversityandThomayer’sHospital,Searching for COVID-19 Antibodies in Czech Children-A Needle in the Haystack,2020-11-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Czechia,Prague,Prague,"patients aged 0–18 years, who were examined between July 3rd and August 19th, 2020, in the Department of Pediatrics in Thomayer’s hospital in Prague, Czech Republic, for various general pediatric reasons", residency outside of the Czech Republic and known primary antibody deficiency,2020-07-03,2020-08-19,Residual sera,All,Children and Youth (0-17 years),0.0,18.0,Analysis,Roche CLIA test,200,0.0,,,,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.995,0.998,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Marketa Bloomfield,Charles University and Thomayer’s Hospital,Unity-Aligned,http://dx.doi.org/10.3389/fped.2020.597736,2021-02-26,2024-03-01,Verified,bloomfield_searching_2020,CZE
201112_Prague_CharlesUniversityandThomayer'sHospital_Euroimmun,201112_Prague_CharlesUniversityandThomayer’sHospital,Searching for COVID-19 Antibodies in Czech Children-A Needle in the Haystack,2020-11-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Czechia,Prague,Prague,"patients aged 0–18 years, who were examined between July 3rd and August 19th, 2020, in the Department of Pediatrics in Thomayer’s hospital in Prague, Czech Republic, for various general pediatric reasons", residency outside of the Czech Republic and known primary antibody deficiency,2020-07-03,2020-08-19,Residual sera,All,Children and Youth (0-17 years),0.0,18.0,Test used,Euroimmun ELISA,200,0.0,,,,,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA",EUROIMMUN,ELISA,Serum,"['IgA', 'IgG']",Spike,Validated by independent authors/third party/non-developers,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Marketa Bloomfield,Charles University and Thomayer’s Hospital,Unity-Aligned,http://dx.doi.org/10.3389/fped.2020.597736,2021-01-23,2024-03-01,Verified,bloomfield_searching_2020,CZE
210701_Prague_InstituteForClinicalAndExperimentalMedicine_HCWs,210701_Prague_InstituteForClinicalAndExperimentalMedicine_HCWs,Humoral Response To SARS-CoV-2 Is Well-Preserved And Symptom-Dependent In Kidney Transplant Recipients.,2021-07-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Czechia,,Prague,Serologic testing was offered to all KTR with regular out-patient visits and HCW regardless of previous symptoms or SARS-CoV-2 PCR positivity. All KTR who accepted the invitation were eligible to participate in the study.,nr ,2020-10-01,2020-11-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,512,0.11900000000000001,,,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,,IgG,Spike,Validated by independent authors/third party/non-developers,0.912,0.902,['High'],,No,No,Yes,,Yes,Yes,No,,Maria Magicova,Institute for Clinical and Experimental Medicine,Not Unity-Aligned,https://dx.doi.org/10.1111/ajt.16746,2021-07-12,2024-03-01,Unverified,magicova_humoral_nodate,CZE
210701_Prague_InstituteForClinicalAndExperimentalMedicine_Patients,210701_Prague_InstituteForClinicalAndExperimentalMedicine_Patients,Humoral Response To SARS-CoV-2 Is Well-Preserved And Symptom-Dependent In Kidney Transplant Recipients.,2021-07-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Czechia,,Prague,Serologic testing was offered to all KTR with regular out-patient visits and HCW regardless of previous symptoms or SARS-CoV-2 PCR positivity. All KTR who accepted the invitation were eligible to participate in the study.,nr ,2020-10-01,2020-11-30,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,1002,0.068,,,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,,IgG,Spike,Validated by independent authors/third party/non-developers,0.912,0.902,['High'],,No,Yes,Yes,,Yes,Yes,No,,Maria Magicova,Institute for Clinical and Experimental Medicine,Not Unity-Aligned,https://dx.doi.org/10.1111/ajt.16746,2021-07-12,2024-03-01,Unverified,magicova_humoral_nodate,CZE
210728_HavlickuvBrod_CharlesUniversity_Overall,210728_HavlickuvBrod_CharlesUniversity,What is the immunity of high school students to coronavirus?.,2021-07-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Czechia,Vysočina,Havlíčkův Brod,"Students of the Havlickuv Grammar School in Havlickuv Brod, Czech Republic, belonging to one of 9 classes across 3 high school grades (excluding the last graduating year).",excluded students who had 1st dose of vaccine,2021-06-08,2021-06-21,Students and Daycares,All,Children and Youth (0-17 years),15.0,19.0,Primary Estimate,,196,0.459,0.38799999999999996,0.532,True,,,,True,Convenience,AdviseDX SARS-CoV-2 anti-IgG II assay,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.981,0.996,['High'],,No,No,Yes,,Yes,Yes,Yes,,Vaclav Fejt,Charles University (Univerzity Karlovy),Not Unity-Aligned,https://www.prolekare.cz/en/journals/journal-of-czech-physicians/2021-4-5/what-is-the-immunity-of-high-school-students-to-coronavirus-127893,2021-08-31,2024-03-01,Unverified,fejt_what_2021,CZE
210815_ Czechia_GENNETImmunologyLaboratory_Primary,210815_ Czechia_GENNETImmunologyLaboratory,COVID-19-free workplace: Measuring the level of antibodies against coronavirus as a basis for testing strategy in companies.,2021-08-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Czechia,,Prague,"All employees who are included in the project were included
employed at clinics GENNET Archa, Kostelní and Liberec
in the main employment relationship or on a performance agreement work or an agreement on work activities and come to the workplace.

This list included a total of 297 people, of which 101 were
employed at Clinic A (GENNET Archa), 153 at Clinic
B (GENNET Kostelní) and 43 at clinic C (GENNET Liberec). A total of 115 (38.6%) employees were vaccinated",,2020-03-28,2021-03-28,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,182,0.35700000000000004,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)","EUROIMMUN,Abbott Laboratories",Multiple Types,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],,No,No,No,,Unclear,Yes,No,,Zuzana Kratka,GENNET Immunology Laboratory,Not Unity-Aligned,https://www.prolekare.cz/casopisy/casopis-lekaru-ceskych/2021-4-5/download?hl=cs,2021-08-30,2024-03-01,Unverified,kratka_covid-19-free_2021,CZE
220105_Prague_ThomayerUniversityHospital_IgG,220105_Prague_ThomayerUniversityHospital,Prevalence of SARS-COV-2 antibodies in the Thomayer University Hospital staff after the first wave of COVID-19.,2022-01-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Czechia,,Prague,Our goal was to map the occurrence of antibodies against SARS-CoV-2 in all employees of Thomayer University Hospital (FTN) in Prague after the first wave of covid-19 disease.,,2020-06-30,2020-09-07,Health care workers and caregivers,All,Multiple groups,20.0,76.0,Primary Estimate,IgG,808,0.018600000000000002,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Anti-SARS-CoV-2 ELISA IgG","Roche Diagnostics,EUROIMMUN",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],,No,Yes,Yes,,Yes,Yes,No,,Marketa Ibrahimova,Thomayer University Hospital,Not Unity-Aligned,https://www.prolekare.cz/en/journals/epidemiology-microbiology-immunology/2022-1-21/prevalence-of-sars-cov-2-antibodies-in-the-thomayer-university-hospital-staff-after-the-first-wave-of-covid-19-130625,2022-05-04,2024-03-01,Unverified,ibrahimova_prevalence_2022,CZE
220105_Prague_ThomayerUniversityHospital_Age_Below30,220105_Prague_ThomayerUniversityHospital,Prevalence of SARS-COV-2 antibodies in the Thomayer University Hospital staff after the first wave of COVID-19.,2022-01-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Czechia,,Prague,Our goal was to map the occurrence of antibodies against SARS-CoV-2 in all employees of Thomayer University Hospital (FTN) in Prague after the first wave of covid-19 disease.,,2020-06-30,2020-09-07,Health care workers and caregivers,All,Adults (18-64 years),20.0,30.0,Age,IgG; Age: <30 years,74,0.0405,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Anti-SARS-CoV-2 ELISA IgG","Roche Diagnostics,EUROIMMUN",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],,No,Yes,Yes,,Yes,Yes,No,,Marketa Ibrahimova,Thomayer University Hospital,Not Unity-Aligned,https://www.prolekare.cz/en/journals/epidemiology-microbiology-immunology/2022-1-21/prevalence-of-sars-cov-2-antibodies-in-the-thomayer-university-hospital-staff-after-the-first-wave-of-covid-19-130625,2022-05-05,2024-03-01,Unverified,ibrahimova_prevalence_2022,CZE
220105_Prague_ThomayerUniversityHospital_Age_30-65,220105_Prague_ThomayerUniversityHospital,Prevalence of SARS-COV-2 antibodies in the Thomayer University Hospital staff after the first wave of COVID-19.,2022-01-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Czechia,,Prague,Our goal was to map the occurrence of antibodies against SARS-CoV-2 in all employees of Thomayer University Hospital (FTN) in Prague after the first wave of covid-19 disease.,,2020-06-30,2020-09-07,Health care workers and caregivers,All,Multiple groups,30.0,65.0,Age,IgG; Age: 30-65 years,681,0.016200000000000003,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Anti-SARS-CoV-2 ELISA IgG","Roche Diagnostics,EUROIMMUN",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],,No,Yes,Yes,,Yes,Yes,No,,Marketa Ibrahimova,Thomayer University Hospital,Not Unity-Aligned,https://www.prolekare.cz/en/journals/epidemiology-microbiology-immunology/2022-1-21/prevalence-of-sars-cov-2-antibodies-in-the-thomayer-university-hospital-staff-after-the-first-wave-of-covid-19-130625,2022-05-05,2024-03-01,Unverified,ibrahimova_prevalence_2022,CZE
220105_Prague_ThomayerUniversityHospital_Age_Above65,220105_Prague_ThomayerUniversityHospital,Prevalence of SARS-COV-2 antibodies in the Thomayer University Hospital staff after the first wave of COVID-19.,2022-01-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Czechia,,Prague,Our goal was to map the occurrence of antibodies against SARS-CoV-2 in all employees of Thomayer University Hospital (FTN) in Prague after the first wave of covid-19 disease.,,2020-06-30,2020-09-07,Health care workers and caregivers,All,Multiple groups,65.0,76.0,Age,IgG; Age: >65 years,53,0.0189,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Anti-SARS-CoV-2 ELISA IgG","Roche Diagnostics,EUROIMMUN",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],,No,Yes,Yes,,Yes,Yes,No,,Marketa Ibrahimova,Thomayer University Hospital,Not Unity-Aligned,https://www.prolekare.cz/en/journals/epidemiology-microbiology-immunology/2022-1-21/prevalence-of-sars-cov-2-antibodies-in-the-thomayer-university-hospital-staff-after-the-first-wave-of-covid-19-130625,2022-05-05,2024-03-01,Unverified,ibrahimova_prevalence_2022,CZE
220301_CzechRepublic_MasarykUniversity_1Oct2020Nov2020_OverallAdjusted,220301_CzechRepublic_MasarykUniversity_1Oct2020Nov2020,Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population,2022-03-01,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Czechia,,,All clients of the second-largest health insurance company in the Czech Republic were sent a written invitation to participate in the study.,The presence of COVID-19 symptoms on the day of study enrolment was used as the sole exclusion criterion.,2020-10-01,2020-11-30,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,Population Adjusted,3626,0.27899999999999997,0.261,0.297,True,,True,,,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,SARS-CoV-2 IgG II Quant ","DiaSorin,Abbott Laboratories",CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Pavel Piler,Masaryk University,Unity-Aligned,https://doi.org/10.1038/s43856-022-00080-0,2022-03-16,2024-03-01,Verified,piler_nationwide_2022,CZE
220301_CzechRepublic_MasarykUniversity_1Oct2020Nov2020_Age50-59,220301_CzechRepublic_MasarykUniversity_1Oct2020Nov2020,Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population,2022-03-01,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Czechia,,,All clients of the second-largest health insurance company in the Czech Republic were sent a written invitation to participate in the study.,The presence of COVID-19 symptoms on the day of study enrolment was used as the sole exclusion criterion.,2020-10-01,2020-11-30,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,,842,0.31,,,,,,,,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,SARS-CoV-2 IgG II Quant ","DiaSorin,Abbott Laboratories",CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Pavel Piler,Masaryk University,Unity-Aligned,https://doi.org/10.1038/s43856-022-00080-0,2022-03-16,2024-03-01,Verified,piler_nationwide_2022,CZE
220301_CzechRepublic_MasarykUniversity_1Oct2020Nov2020_OverallCrude,220301_CzechRepublic_MasarykUniversity_1Oct2020Nov2020,Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population,2022-03-01,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Czechia,,,All clients of the second-largest health insurance company in the Czech Republic were sent a written invitation to participate in the study.,The presence of COVID-19 symptoms on the day of study enrolment was used as the sole exclusion criterion.,2020-10-01,2020-11-30,Household and community samples,All,Multiple groups,18.0,,Analysis,Crude,3626,0.28300000000000003,,,,,,,True,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,SARS-CoV-2 IgG II Quant ","DiaSorin,Abbott Laboratories",CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Pavel Piler,Masaryk University,Unity-Aligned,https://doi.org/10.1038/s43856-022-00080-0,2022-03-16,2024-03-01,Verified,piler_nationwide_2022,CZE
220301_CzechRepublic_MasarykUniversity_1Oct2020Nov2020_Age18-29,220301_CzechRepublic_MasarykUniversity_1Oct2020Nov2020,Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population,2022-03-01,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Czechia,,,All clients of the second-largest health insurance company in the Czech Republic were sent a written invitation to participate in the study.,The presence of COVID-19 symptoms on the day of study enrolment was used as the sole exclusion criterion.,2020-10-01,2020-11-30,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,18-29,318,0.311,,,,,,,,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,SARS-CoV-2 IgG II Quant ","DiaSorin,Abbott Laboratories",CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Pavel Piler,Masaryk University,Unity-Aligned,https://doi.org/10.1038/s43856-022-00080-0,2022-03-16,2024-03-01,Verified,piler_nationwide_2022,CZE
220301_CzechRepublic_MasarykUniversity_1Oct2020Nov2020_SexMale,220301_CzechRepublic_MasarykUniversity_1Oct2020Nov2020,Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population,2022-03-01,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Czechia,,,All clients of the second-largest health insurance company in the Czech Republic were sent a written invitation to participate in the study.,The presence of COVID-19 symptoms on the day of study enrolment was used as the sole exclusion criterion.,2020-10-01,2020-11-30,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,1424,0.277,,,,,,,,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,SARS-CoV-2 IgG II Quant ","DiaSorin,Abbott Laboratories",CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Pavel Piler,Masaryk University,Unity-Aligned,https://doi.org/10.1038/s43856-022-00080-0,2022-03-16,2024-03-01,Verified,piler_nationwide_2022,CZE
220301_CzechRepublic_MasarykUniversity_1Oct2020Nov2020_Age40-49,220301_CzechRepublic_MasarykUniversity_1Oct2020Nov2020,Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population,2022-03-01,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Czechia,,,All clients of the second-largest health insurance company in the Czech Republic were sent a written invitation to participate in the study.,The presence of COVID-19 symptoms on the day of study enrolment was used as the sole exclusion criterion.,2020-10-01,2020-11-30,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,,1354,0.29300000000000004,,,,,,,,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,SARS-CoV-2 IgG II Quant ","DiaSorin,Abbott Laboratories",CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Pavel Piler,Masaryk University,Unity-Aligned,https://doi.org/10.1038/s43856-022-00080-0,2022-03-16,2024-03-01,Verified,piler_nationwide_2022,CZE
220301_CzechRepublic_MasarykUniversity_1Oct2020Nov2020_SexFemale,220301_CzechRepublic_MasarykUniversity_1Oct2020Nov2020,Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population,2022-03-01,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Czechia,,,All clients of the second-largest health insurance company in the Czech Republic were sent a written invitation to participate in the study.,The presence of COVID-19 symptoms on the day of study enrolment was used as the sole exclusion criterion.,2020-10-01,2020-11-30,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,2202,0.287,,,,,,,,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,SARS-CoV-2 IgG II Quant ","DiaSorin,Abbott Laboratories",CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Pavel Piler,Masaryk University,Unity-Aligned,https://doi.org/10.1038/s43856-022-00080-0,2022-03-16,2024-03-01,Verified,piler_nationwide_2022,CZE
220301_CzechRepublic_MasarykUniversity_1Oct2020Nov2020_Age60+,220301_CzechRepublic_MasarykUniversity_1Oct2020Nov2020,Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population,2022-03-01,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Czechia,,,All clients of the second-largest health insurance company in the Czech Republic were sent a written invitation to participate in the study.,The presence of COVID-19 symptoms on the day of study enrolment was used as the sole exclusion criterion.,2020-10-01,2020-11-30,Household and community samples,All,Seniors (65+ years),60.0,,Age,,450,0.262,,,,,,,,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,SARS-CoV-2 IgG II Quant ","DiaSorin,Abbott Laboratories",CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Pavel Piler,Masaryk University,Unity-Aligned,https://doi.org/10.1038/s43856-022-00080-0,2022-03-16,2024-03-01,Verified,piler_nationwide_2022,CZE
220301_CzechRepublic_MasarykUniversity_1Oct2020Nov2020_Age30-39,220301_CzechRepublic_MasarykUniversity_1Oct2020Nov2020,Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population,2022-03-01,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Czechia,,,All clients of the second-largest health insurance company in the Czech Republic were sent a written invitation to participate in the study.,The presence of COVID-19 symptoms on the day of study enrolment was used as the sole exclusion criterion.,2020-10-01,2020-11-30,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,,662,0.24800000000000003,,,,,,,,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,SARS-CoV-2 IgG II Quant ","DiaSorin,Abbott Laboratories",CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Pavel Piler,Masaryk University,Unity-Aligned,https://doi.org/10.1038/s43856-022-00080-0,2022-03-16,2024-03-01,Verified,piler_nationwide_2022,CZE
220301_CzechRepublic_MasarykUniversity_2Dec2020Jan2021_OverallAdjusted,220301_CzechRepublic_MasarykUniversity_2Dec2020Jan2021,Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population,2022-03-01,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Czechia,,,All clients of the second-largest health insurance company in the Czech Republic were sent a written invitation to participate in the study.,The presence of COVID-19 symptoms on the day of study enrolment was used as the sole exclusion criterion.,2020-12-01,2021-01-31,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,Population Adjusted,6880,0.42200000000000004,0.408,0.435,True,,True,,,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,SARS-CoV-2 IgG II Quant ","DiaSorin,Abbott Laboratories",CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Pavel Piler,Masaryk University,Unity-Aligned,https://doi.org/10.1038/s43856-022-00080-0,2022-03-16,2024-03-01,Verified,piler_nationwide_2022,CZE
220301_CzechRepublic_MasarykUniversity_2Dec2020Jan2021_Age50-59,220301_CzechRepublic_MasarykUniversity_2Dec2020Jan2021,Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population,2022-03-01,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Czechia,,,All clients of the second-largest health insurance company in the Czech Republic were sent a written invitation to participate in the study.,The presence of COVID-19 symptoms on the day of study enrolment was used as the sole exclusion criterion.,2020-12-01,2021-01-31,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,,1845,0.47500000000000003,,,,,,,,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,SARS-CoV-2 IgG II Quant ","DiaSorin,Abbott Laboratories",CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Pavel Piler,Masaryk University,Unity-Aligned,https://doi.org/10.1038/s43856-022-00080-0,2022-03-16,2024-03-01,Verified,piler_nationwide_2022,CZE
220301_CzechRepublic_MasarykUniversity_2Dec2020Jan2021_Age18-29,220301_CzechRepublic_MasarykUniversity_2Dec2020Jan2021,Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population,2022-03-01,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Czechia,,,All clients of the second-largest health insurance company in the Czech Republic were sent a written invitation to participate in the study.,The presence of COVID-19 symptoms on the day of study enrolment was used as the sole exclusion criterion.,2020-12-01,2021-01-31,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,18-29,582,0.43100000000000005,,,,,,,,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,SARS-CoV-2 IgG II Quant ","DiaSorin,Abbott Laboratories",CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Pavel Piler,Masaryk University,Unity-Aligned,https://doi.org/10.1038/s43856-022-00080-0,2022-03-16,2024-03-01,Verified,piler_nationwide_2022,CZE
220301_CzechRepublic_MasarykUniversity_2Dec2020Jan2021_Age60+,220301_CzechRepublic_MasarykUniversity_2Dec2020Jan2021,Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population,2022-03-01,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Czechia,,,All clients of the second-largest health insurance company in the Czech Republic were sent a written invitation to participate in the study.,The presence of COVID-19 symptoms on the day of study enrolment was used as the sole exclusion criterion.,2020-12-01,2021-01-31,Household and community samples,All,Seniors (65+ years),60.0,,Age,,1215,0.41600000000000004,,,,,,,,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,SARS-CoV-2 IgG II Quant ","DiaSorin,Abbott Laboratories",CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Pavel Piler,Masaryk University,Unity-Aligned,https://doi.org/10.1038/s43856-022-00080-0,2022-03-16,2024-03-01,Verified,piler_nationwide_2022,CZE
220301_CzechRepublic_MasarykUniversity_2Dec2020Jan2021_Age40-49,220301_CzechRepublic_MasarykUniversity_2Dec2020Jan2021,Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population,2022-03-01,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Czechia,,,All clients of the second-largest health insurance company in the Czech Republic were sent a written invitation to participate in the study.,The presence of COVID-19 symptoms on the day of study enrolment was used as the sole exclusion criterion.,2020-12-01,2021-01-31,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,,2262,0.438,,,,,,,,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,SARS-CoV-2 IgG II Quant ","DiaSorin,Abbott Laboratories",CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Pavel Piler,Masaryk University,Unity-Aligned,https://doi.org/10.1038/s43856-022-00080-0,2022-03-16,2024-03-01,Verified,piler_nationwide_2022,CZE
220301_CzechRepublic_MasarykUniversity_2Dec2020Jan2021_Age30-39,220301_CzechRepublic_MasarykUniversity_2Dec2020Jan2021,Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population,2022-03-01,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Czechia,,,All clients of the second-largest health insurance company in the Czech Republic were sent a written invitation to participate in the study.,The presence of COVID-19 symptoms on the day of study enrolment was used as the sole exclusion criterion.,2020-12-01,2021-01-31,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,,976,0.369,,,,,,,,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,SARS-CoV-2 IgG II Quant ","DiaSorin,Abbott Laboratories",CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Pavel Piler,Masaryk University,Unity-Aligned,https://doi.org/10.1038/s43856-022-00080-0,2022-03-16,2024-03-01,Verified,piler_nationwide_2022,CZE
220301_CzechRepublic_MasarykUniversity_2Dec2020Jan2021_SexMale,220301_CzechRepublic_MasarykUniversity_2Dec2020Jan2021,Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population,2022-03-01,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Czechia,,,All clients of the second-largest health insurance company in the Czech Republic were sent a written invitation to participate in the study.,The presence of COVID-19 symptoms on the day of study enrolment was used as the sole exclusion criterion.,2020-12-01,2021-01-31,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,2756,0.418,,,,,,,,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,SARS-CoV-2 IgG II Quant ","DiaSorin,Abbott Laboratories",CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Pavel Piler,Masaryk University,Unity-Aligned,https://doi.org/10.1038/s43856-022-00080-0,2022-03-16,2024-03-01,Verified,piler_nationwide_2022,CZE
220301_CzechRepublic_MasarykUniversity_2Dec2020Jan2021_OverallCrude,220301_CzechRepublic_MasarykUniversity_2Dec2020Jan2021,Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population,2022-03-01,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Czechia,,,All clients of the second-largest health insurance company in the Czech Republic were sent a written invitation to participate in the study.,The presence of COVID-19 symptoms on the day of study enrolment was used as the sole exclusion criterion.,2020-12-01,2021-01-31,Household and community samples,All,Multiple groups,18.0,,Analysis,Crude,6880,0.434,,,,,,,True,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,SARS-CoV-2 IgG II Quant ","DiaSorin,Abbott Laboratories",CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Pavel Piler,Masaryk University,Unity-Aligned,https://doi.org/10.1038/s43856-022-00080-0,2022-03-16,2024-03-01,Verified,piler_nationwide_2022,CZE
220301_CzechRepublic_MasarykUniversity_2Dec2020Jan2021_SexFemale,220301_CzechRepublic_MasarykUniversity_2Dec2020Jan2021,Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population,2022-03-01,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Czechia,,,All clients of the second-largest health insurance company in the Czech Republic were sent a written invitation to participate in the study.,The presence of COVID-19 symptoms on the day of study enrolment was used as the sole exclusion criterion.,2020-12-01,2021-01-31,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,4124,0.444,,,,,,,,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,SARS-CoV-2 IgG II Quant ","DiaSorin,Abbott Laboratories",CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Pavel Piler,Masaryk University,Unity-Aligned,https://doi.org/10.1038/s43856-022-00080-0,2022-03-16,2024-03-01,Verified,piler_nationwide_2022,CZE
220301_CzechRepublic_MasarykUniversity_3Feb2021Mar2021_OverallAdjusted,220301_CzechRepublic_MasarykUniversity_3Feb2021Mar2021,Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population,2022-03-01,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Czechia,,,All clients of the second-largest health insurance company in the Czech Republic were sent a written invitation to participate in the study.,The presence of COVID-19 symptoms on the day of study enrolment was used as the sole exclusion criterion.,2021-02-01,2021-03-31,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,Population Adjusted,19548,0.51,0.503,0.518,True,,True,,,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,SARS-CoV-2 IgG II Quant ","DiaSorin,Abbott Laboratories",CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Pavel Piler,Masaryk University,Unity-Aligned,https://doi.org/10.1038/s43856-022-00080-0,2022-03-16,2024-03-01,Verified,piler_nationwide_2022,CZE
220301_CzechRepublic_MasarykUniversity_3Feb2021Mar2021_Age40-49,220301_CzechRepublic_MasarykUniversity_3Feb2021Mar2021,Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population,2022-03-01,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Czechia,,,All clients of the second-largest health insurance company in the Czech Republic were sent a written invitation to participate in the study.,The presence of COVID-19 symptoms on the day of study enrolment was used as the sole exclusion criterion.,2021-02-01,2021-03-31,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,,5515,0.514,,,,,,,,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,SARS-CoV-2 IgG II Quant ","DiaSorin,Abbott Laboratories",CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Pavel Piler,Masaryk University,Unity-Aligned,https://doi.org/10.1038/s43856-022-00080-0,2022-03-16,2024-03-01,Verified,piler_nationwide_2022,CZE
220301_CzechRepublic_MasarykUniversity_3Feb2021Mar2021_Age30-39,220301_CzechRepublic_MasarykUniversity_3Feb2021Mar2021,Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population,2022-03-01,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Czechia,,,All clients of the second-largest health insurance company in the Czech Republic were sent a written invitation to participate in the study.,The presence of COVID-19 symptoms on the day of study enrolment was used as the sole exclusion criterion.,2021-02-01,2021-03-31,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,,2621,0.479,,,,,,,,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,SARS-CoV-2 IgG II Quant ","DiaSorin,Abbott Laboratories",CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Pavel Piler,Masaryk University,Unity-Aligned,https://doi.org/10.1038/s43856-022-00080-0,2022-03-16,2024-03-01,Verified,piler_nationwide_2022,CZE
220301_CzechRepublic_MasarykUniversity_3Feb2021Mar2021_OverallCrude,220301_CzechRepublic_MasarykUniversity_3Feb2021Mar2021,Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population,2022-03-01,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Czechia,,,All clients of the second-largest health insurance company in the Czech Republic were sent a written invitation to participate in the study.,The presence of COVID-19 symptoms on the day of study enrolment was used as the sole exclusion criterion.,2021-02-01,2021-03-31,Household and community samples,All,Multiple groups,18.0,,Analysis,Crude,19548,0.514,,,,,,,True,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,SARS-CoV-2 IgG II Quant ","DiaSorin,Abbott Laboratories",CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Pavel Piler,Masaryk University,Unity-Aligned,https://doi.org/10.1038/s43856-022-00080-0,2022-03-16,2024-03-01,Verified,piler_nationwide_2022,CZE
220301_CzechRepublic_MasarykUniversity_3Feb2021Mar2021_SexMale,220301_CzechRepublic_MasarykUniversity_3Feb2021Mar2021,Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population,2022-03-01,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Czechia,,,All clients of the second-largest health insurance company in the Czech Republic were sent a written invitation to participate in the study.,The presence of COVID-19 symptoms on the day of study enrolment was used as the sole exclusion criterion.,2021-02-01,2021-03-31,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,7612,0.511,,,,,,,,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,SARS-CoV-2 IgG II Quant ","DiaSorin,Abbott Laboratories",CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Pavel Piler,Masaryk University,Unity-Aligned,https://doi.org/10.1038/s43856-022-00080-0,2022-03-16,2024-03-01,Verified,piler_nationwide_2022,CZE
220301_CzechRepublic_MasarykUniversity_3Feb2021Mar2021_Age18-29,220301_CzechRepublic_MasarykUniversity_3Feb2021Mar2021,Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population,2022-03-01,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Czechia,,,All clients of the second-largest health insurance company in the Czech Republic were sent a written invitation to participate in the study.,The presence of COVID-19 symptoms on the day of study enrolment was used as the sole exclusion criterion.,2021-02-01,2021-03-31,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,18-29,1660,0.525,,,,,,,,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,SARS-CoV-2 IgG II Quant ","DiaSorin,Abbott Laboratories",CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Pavel Piler,Masaryk University,Unity-Aligned,https://doi.org/10.1038/s43856-022-00080-0,2022-03-16,2024-03-01,Verified,piler_nationwide_2022,CZE
220301_CzechRepublic_MasarykUniversity_3Feb2021Mar2021_SexFemale,220301_CzechRepublic_MasarykUniversity_3Feb2021Mar2021,Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population,2022-03-01,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Czechia,,,All clients of the second-largest health insurance company in the Czech Republic were sent a written invitation to participate in the study.,The presence of COVID-19 symptoms on the day of study enrolment was used as the sole exclusion criterion.,2021-02-01,2021-03-31,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,11936,0.517,,,,,,,,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,SARS-CoV-2 IgG II Quant ","DiaSorin,Abbott Laboratories",CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Pavel Piler,Masaryk University,Unity-Aligned,https://doi.org/10.1038/s43856-022-00080-0,2022-03-16,2024-03-01,Verified,piler_nationwide_2022,CZE
220301_CzechRepublic_MasarykUniversity_3Feb2021Mar2021_Age50-59,220301_CzechRepublic_MasarykUniversity_3Feb2021Mar2021,Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population,2022-03-01,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Czechia,,,All clients of the second-largest health insurance company in the Czech Republic were sent a written invitation to participate in the study.,The presence of COVID-19 symptoms on the day of study enrolment was used as the sole exclusion criterion.,2021-02-01,2021-03-31,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,,5020,0.537,,,,,,,,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,SARS-CoV-2 IgG II Quant ","DiaSorin,Abbott Laboratories",CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Pavel Piler,Masaryk University,Unity-Aligned,https://doi.org/10.1038/s43856-022-00080-0,2022-03-16,2024-03-01,Verified,piler_nationwide_2022,CZE
220301_CzechRepublic_MasarykUniversity_3Feb2021Mar2021_Age60+,220301_CzechRepublic_MasarykUniversity_3Feb2021Mar2021,Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population,2022-03-01,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Czechia,,,All clients of the second-largest health insurance company in the Czech Republic were sent a written invitation to participate in the study.,The presence of COVID-19 symptoms on the day of study enrolment was used as the sole exclusion criterion.,2021-02-01,2021-03-31,Household and community samples,All,Seniors (65+ years),60.0,,Age,,4732,0.506,,,,,,,,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,SARS-CoV-2 IgG II Quant ","DiaSorin,Abbott Laboratories",CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Pavel Piler,Masaryk University,Unity-Aligned,https://doi.org/10.1038/s43856-022-00080-0,2022-03-16,2024-03-01,Verified,piler_nationwide_2022,CZE
210318_IvoryCoast_CentreHospitalierRegionald’Orleans_Overall,210318_IvoryCoast_CentreHospitalierRegionald’Orleans,SARS-CoV-2 Infection in Ivory Coast: A Serosurveillance Survey among Gold Mine Workers,2021-03-18,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Côte d'Ivoire,,,"Gold mine workers at two sites and Abidjan headquarters. All employees were informed about the objectives of the
campaign and were invited to participate. No clinical criteria
were required to be tested.",,2020-07-15,2020-10-13,Essential non-healthcare workers,All,Adults (18-64 years),18.0,66.0,Primary Estimate,,1687,0.251,,,True,,,,True,Convenience,COVID-PRESTO®,AAZ LMB,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,1.0,1.0,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Jean Milleliri,Centre Hospitalier Regional d’Orleans,Not Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.21-0081,2021-04-15,2024-03-01,Unverified,milleliri_sars-cov-2_2021,CIV
220924_CoteDIvoire_RobertKochInstitut_Overall,220924_CoteDIvoire_RobertKochInstitut,"Multicountry study of SARS-CoV-2 and associated risk factors among healthcare workers in Cote d'Ivoire, Burkina Faso and South Africa.",2022-09-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Côte d'Ivoire,,Bouaké,"""HCW participants were recruited on a voluntary basis. All staff, irrespective of symptoms or suspicion of previous COVID-19 infection, were invited to par- ticipate by their hospital administration through internal facility announcements. HCWs > 16 y of age and working during the period of the COVID-19 pandemic at the selected hospitals were eligible for inclusion. ""","""borderline or positive samples were excluded due to poor quality and quantity of the sample""",2021-02-09,2021-02-19,Health care workers and caregivers,All,Adults (18-64 years),16.0,,Primary Estimate,adjusted overall,286,0.13699999999999998,0.1,0.184,True,True,,,True,Self-referral,"Anti-SARS-CoV-2 ELISA IgG,Wantai SARS-CoV-2 Total Ab ELISA,Author designed (Neutralization Assay)","EUROIMMUN,Beijing Wantai Biological,NA",Multiple Types,Serum,"['IgG', 'TotalAntibody']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,Yes,,Sarah Kribi,Robert Koch Institut,Not Unity-Aligned,https://dx.doi.org/10.1093/trstmh/trac089,2022-10-04,2023-08-15,Unverified,kirbi_multicountry_2022,CIV
230608_Abidjan_Epicentre,230608_Abidjan_Epicentre,"Seroprevalence of SARS-CoV-2 antibodies and retrospective mortality in two African settings: Lubumbashi, Democratic Republic of the Congo and Abidjan, Cote d'Ivoire.",2023-06-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Côte d'Ivoire,,,"We conducted two cross-sectional household-based surveys in the cities of Lubumbashi (DRC) and Abidjan (Côte d’Ivoire). The survey in Lubumbashi took place in the health zones Lubumbashi (stratum 1) and Kampemba/Tshamilemba (stratum 2), which were chosen based on COVID incidence in the initial months and increased reporting of deaths through cemetery surveillance, respectively. In Abidjan, the survey was implemented in the communes of Marcory (stratum 1) and Yopougon (stratum 2). These urban areas were chosen because, while the prevalence of poverty is higher in Yopougon than Marcory [7], Yopougon had a much lower COVID-19 attack rate than Marcory according to available surveillance data [8].",,2021-07-15,2021-11-10,Household and community samples,All,Multiple groups,,,Primary Estimate,,1471,0.388,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Spike,,0.988,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Erica Simons,Epicentre,Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0001457,2023-06-30,2023-07-04,Unverified,simonsSeroprevalenceSARSCoV2Antibodies2023,CIV
210127_Bukavu_CliniqueSaint-LucDeBukavu_Overall,210127_Bukavu_CliniqueSaint-LucDeBukavu,"Seroprevalence of SARS-CoV-2 antibodies among travellers and workers screened at the saint luc clinic in Bukavu, a city in eastern democratic Republic of the Congo, from may to august 2020",2021-01-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,,Bukavu,"Any subject, regardless of age, sex and origin was eligible for voluntary serological screening for SARS-CoV-2.",,2020-05-15,2020-08-30,Multiple populations,All,Multiple groups,,,Primary Estimate,Poitive for IgG and/or IgM,684,0.4079,,,True,,,,True,Self-referral,COVID-19 IgG/IgM Rapid Test Cassette,Cellex Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.938,0.96,['High'],No,No,Yes,Yes,Yes,No,Yes,No,Unclear,Philippe Bianga Katchunga,Clinique Saint-Luc de Bukavu,Not Unity-Aligned,https://www.panafrican-med-journal.com/content/article/38/93/full/,2021-04-15,2024-03-01,Verified,katchunga_seroprevalence_2021,COD
210216_Bukavu_UniversitéLibredeBruxelles_OverallELISA,210216_Bukavu_UniversitéLibredeBruxelles,"High SARS-CoV-2 Seroprevalence in Healthcare Workers in Bukavu, Eastern Democratic Republic of Congo",2021-02-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,South-Kivu,Bukavu,"All staff members working in Panzi General Referral Hospital located in Bukavu, DRC, were invited to participate in a seroprevalence study on a voluntary basis.",,2020-07-02,2020-08-19,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,359,0.41200000000000003,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,,IgG,,,0.617,0.986,['High'],No,No,No,Yes,Unclear,Yes,Yes,No,Yes,Denis Mukwege ,Université Libre de Bruxelles (ULB),Not Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.20-1526,2021-03-14,2024-03-01,Verified,mukwege_high_2021,COD
210217_Kinhasa_InstitutNationaldeRechercheBiomedicale_EUROIMMUN,210217_Kinhasa_InstitutNationaldeRechercheBiomedicale,Challenges in interpreting SARS-CoV-2 serological results in African countries,2021-02-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,Kinhasa,Kinhasa,"We preselected five health zones across
the city, from which we included one
hospital, two health-care centres,
and one COVID-19 response team.
Within each facility, health-care
workers and other service staff from
different departments were randomly
selected. ",No consent,2020-07-17,2020-08-13,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,EUROIMMUN IgG,562,0.36,,,True,,,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.946,0.998,['Moderate'],Yes,Yes,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Antoine Nkuba Ndaye,Institut National de Recherche Biomedicale,Not Unity-Aligned,https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(21)00060-7/fulltext,2021-03-21,2024-03-01,Verified,nkuba_ndaye_challenges_2021,COD
210605_Kinshasa_InstitutNationaldeRechercheBiomédicale_primary,210605_Kinshasa_InstitutNationaldeRechercheBiomédicale,"High prevalence of anti-SARS-CoV-2 antibodies after the first wave of COVID-19 in Kinshasa, Democratic Republic of the Congo: results of a cross-sectional household-based survey.",2021-06-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,,Kinshasa,"all the residents were invited to participate in the study in 50% of households and among the
remaining 50%, only the residents aged 18 years and older were invited to participate",,2020-10-22,2020-11-08,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,1080,0.166,0.14,0.195,True,,True,,True,Stratified probability,Author designed (Luminex),,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,0.997,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Antoine Nkuba,Institut National de Recherche Biomédicale,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab515,2021-06-17,2022-07-16,Verified,nkuba_high_2021,COD
210605_Kinshasa_InstitutNationaldeRechercheBiomédicale_0-17,210605_Kinshasa_InstitutNationaldeRechercheBiomédicale,"High prevalence of anti-SARS-CoV-2 antibodies after the first wave of COVID-19 in Kinshasa, Democratic Republic of the Congo: results of a cross-sectional household-based survey.",2021-06-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,,Kinshasa,"all the residents were invited to participate in the study in 50% of households and among the
remaining 50%, only the residents aged 18 years and older were invited to participate",,2020-10-22,2020-11-08,Household and community samples,All,Children and Youth (0-17 years),0.0,17.0,Age,0-17,281,0.149,0.10400000000000001,0.20800000000000002,,,True,,,Stratified probability,Author designed (Luminex),,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,0.997,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Antoine Nkuba,Institut National de Recherche Biomédicale,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab515,2021-08-12,2022-07-16,Verified,nkuba_high_2021,COD
210605_Kinshasa_InstitutNationaldeRechercheBiomédicale_18-39,210605_Kinshasa_InstitutNationaldeRechercheBiomédicale,"High prevalence of anti-SARS-CoV-2 antibodies after the first wave of COVID-19 in Kinshasa, Democratic Republic of the Congo: results of a cross-sectional household-based survey.",2021-06-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,,Kinshasa,"all the residents were invited to participate in the study in 50% of households and among the
remaining 50%, only the residents aged 18 years and older were invited to participate",,2020-10-22,2020-11-08,Household and community samples,All,Adults (18-64 years),18.0,39.0,Age,18-39,428,0.13699999999999998,0.10099999999999999,0.18300000000000002,,,True,,,Stratified probability,Author designed (Luminex),,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,0.997,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Antoine Nkuba,Institut National de Recherche Biomédicale,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab515,2021-08-12,2022-07-16,Verified,nkuba_high_2021,COD
210605_Kinshasa_InstitutNationaldeRechercheBiomédicale_Female,210605_Kinshasa_InstitutNationaldeRechercheBiomédicale,"High prevalence of anti-SARS-CoV-2 antibodies after the first wave of COVID-19 in Kinshasa, Democratic Republic of the Congo: results of a cross-sectional household-based survey.",2021-06-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,,Kinshasa,"all the residents were invited to participate in the study in 50% of households and among the
remaining 50%, only the residents aged 18 years and older were invited to participate",,2020-10-22,2020-11-08,Household and community samples,Female,Multiple groups,0.0,,Sex/Gender,,663,0.177,0.139,0.209,,,True,,,Stratified probability,Author designed (Luminex),,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,0.997,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Antoine Nkuba,Institut National de Recherche Biomédicale,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab515,2021-08-12,2022-07-16,Verified,nkuba_high_2021,COD
210605_Kinshasa_InstitutNationaldeRechercheBiomédicale_>40,210605_Kinshasa_InstitutNationaldeRechercheBiomédicale,"High prevalence of anti-SARS-CoV-2 antibodies after the first wave of COVID-19 in Kinshasa, Democratic Republic of the Congo: results of a cross-sectional household-based survey.",2021-06-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,,Kinshasa,"all the residents were invited to participate in the study in 50% of households and among the
remaining 50%, only the residents aged 18 years and older were invited to participate",,2020-10-22,2020-11-08,Household and community samples,All,Multiple groups,40.0,,Age,>=40,371,0.212,0.166,0.267,,,True,,,Stratified probability,Author designed (Luminex),,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,0.997,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Antoine Nkuba,Institut National de Recherche Biomédicale,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab515,2021-08-12,2022-07-16,Verified,nkuba_high_2021,COD
210605_Kinshasa_InstitutNationaldeRechercheBiomédicale_Male,210605_Kinshasa_InstitutNationaldeRechercheBiomédicale,"High prevalence of anti-SARS-CoV-2 antibodies after the first wave of COVID-19 in Kinshasa, Democratic Republic of the Congo: results of a cross-sectional household-based survey.",2021-06-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,,Kinshasa,"all the residents were invited to participate in the study in 50% of households and among the
remaining 50%, only the residents aged 18 years and older were invited to participate",,2020-10-22,2020-11-08,Household and community samples,Male,Multiple groups,0.0,,Sex/Gender,,417,0.157,0.11800000000000001,0.207,,,True,,,Stratified probability,Author designed (Luminex),,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,0.997,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Antoine Nkuba,Institut National de Recherche Biomédicale,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab515,2021-08-12,2022-07-16,Verified,nkuba_high_2021,COD
221212_USA_RTIInternational_DRC,221212_USA_RTIInternational_DRC,"COVID-19 Antibody Positivity Over Time and Pregnancy Outcomes in Seven Low-and-Middle-Income Countries: A Prospective, Observational Study of the Global Network for Women's and Children's Health Research.",2022-12-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Democratic Republic of the Congo,,,"""The COVID-19 antibody study, embedded within the MNHR, included a sub-set of women who were approached at delivery and enrolled. We collected a serum sample at or near delivery for each mother who was approached and consented.""", Women who did not consent to give blood for testing. Indeterminate results are excluded. ,2020-11-01,2020-11-30,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,1816,0.29100000000000004,,,True,,,,True,Convenience,ELISA SARS-CoV-2 IgG Test System,Zeus,ELISA,Serum,IgG,"Nucleocapsid (N-protein), Spike",,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Robert L. Goldenberg,RTI International,Unity-Aligned,https://dx.doi.org/10.1111/1471-0528.17366,2022-12-24,2024-03-01,Unverified,goldenberg_covid-19_2022,COD
221218_Kinshasa_HokkaidoUniversity,221218_Kinshasa_HokkaidoUniversity,"High SARS-CoV-2 Seroprevalence after Second COVID-19 Wave (October 2020-April 2021), Democratic Republic of the Congo.",2022-12-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,,Kinshasa,"""We determined eligible participants as persons of all ages who stayed
in Kinshasa 2 weeks before the survey and had no contraindications to venipuncture. We obtained written informed consent from adults (participants
≥18 years of age) and emancipated minors, parental consent for participants <18 years, and assent for participants 10–17 years of age.""",,2021-03-06,2021-03-14,Household and community samples,All,Multiple groups,,,Primary Estimate,,2476,0.7220000000000001,0.698,0.7440000000000001,True,,True,,True,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"IgG, IgM, IgA",Spike,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yannick Munyeku-Bazitama,Hokkaido University,Unity-Aligned,https://dx.doi.org/10.3201/eid2901.221009,2023-01-11,2024-04-11,Verified,munyeku-bazitama_high_nodate,COD
221218_Kinshasa_HokkaidoUniversity_Age_30-39,221218_Kinshasa_HokkaidoUniversity,"High SARS-CoV-2 Seroprevalence after Second COVID-19 Wave (October 2020-April 2021), Democratic Republic of the Congo.",2022-12-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,,Kinshasa,"""We determined eligible participants as persons of all ages who stayed
in Kinshasa 2 weeks before the survey and had no contraindications to venipuncture. We obtained written informed consent from adults (participants
≥18 years of age) and emancipated minors, parental consent for participants <18 years, and assent for participants 10–17 years of age.""",,2021-03-06,2021-03-14,Household and community samples,All,Adults (18-64 years),,,Age,30-39,393,0.7506,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"IgG, IgM, IgA",Spike,,0.944,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yannick Munyeku-Bazitama,Hokkaido University,Unity-Aligned,https://dx.doi.org/10.3201/eid2901.221009,2023-01-11,2024-04-11,Verified,munyeku-bazitama_high_nodate,COD
221218_Kinshasa_HokkaidoUniversity_Age_5-9,221218_Kinshasa_HokkaidoUniversity,"High SARS-CoV-2 Seroprevalence after Second COVID-19 Wave (October 2020-April 2021), Democratic Republic of the Congo.",2022-12-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,,Kinshasa,"""We determined eligible participants as persons of all ages who stayed
in Kinshasa 2 weeks before the survey and had no contraindications to venipuncture. We obtained written informed consent from adults (participants
≥18 years of age) and emancipated minors, parental consent for participants <18 years, and assent for participants 10–17 years of age.""",,2021-03-06,2021-03-14,Household and community samples,All,Children and Youth (0-17 years),,,Age,5-9,165,0.5939,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"IgG, IgM, IgA",Spike,,0.944,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yannick Munyeku-Bazitama,Hokkaido University,Unity-Aligned,https://dx.doi.org/10.3201/eid2901.221009,2023-01-11,2024-04-11,Verified,munyeku-bazitama_high_nodate,COD
221218_Kinshasa_HokkaidoUniversity_Sex_Male,221218_Kinshasa_HokkaidoUniversity,"High SARS-CoV-2 Seroprevalence after Second COVID-19 Wave (October 2020-April 2021), Democratic Republic of the Congo.",2022-12-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,,Kinshasa,"""We determined eligible participants as persons of all ages who stayed
in Kinshasa 2 weeks before the survey and had no contraindications to venipuncture. We obtained written informed consent from adults (participants
≥18 years of age) and emancipated minors, parental consent for participants <18 years, and assent for participants 10–17 years of age.""",,2021-03-06,2021-03-14,Household and community samples,Male,Multiple groups,,,Sex/Gender,Male,1107,0.7046,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"IgG, IgM, IgA",Spike,,0.944,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yannick Munyeku-Bazitama,Hokkaido University,Unity-Aligned,https://dx.doi.org/10.3201/eid2901.221009,2023-01-11,2024-04-11,Verified,munyeku-bazitama_high_nodate,COD
221218_Kinshasa_HokkaidoUniversity_Age_0-4,221218_Kinshasa_HokkaidoUniversity,"High SARS-CoV-2 Seroprevalence after Second COVID-19 Wave (October 2020-April 2021), Democratic Republic of the Congo.",2022-12-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,,Kinshasa,"""We determined eligible participants as persons of all ages who stayed
in Kinshasa 2 weeks before the survey and had no contraindications to venipuncture. We obtained written informed consent from adults (participants
≥18 years of age) and emancipated minors, parental consent for participants <18 years, and assent for participants 10–17 years of age.""",,2021-03-06,2021-03-14,Household and community samples,All,Children and Youth (0-17 years),,,Age,0-4,32,0.6875,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"IgG, IgM, IgA",Spike,,0.944,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yannick Munyeku-Bazitama,Hokkaido University,Unity-Aligned,https://dx.doi.org/10.3201/eid2901.221009,2023-01-11,2024-04-11,Verified,munyeku-bazitama_high_nodate,COD
221218_Kinshasa_HokkaidoUniversity_Age_40-49,221218_Kinshasa_HokkaidoUniversity,"High SARS-CoV-2 Seroprevalence after Second COVID-19 Wave (October 2020-April 2021), Democratic Republic of the Congo.",2022-12-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,,Kinshasa,"""We determined eligible participants as persons of all ages who stayed
in Kinshasa 2 weeks before the survey and had no contraindications to venipuncture. We obtained written informed consent from adults (participants
≥18 years of age) and emancipated minors, parental consent for participants <18 years, and assent for participants 10–17 years of age.""",,2021-03-06,2021-03-14,Household and community samples,All,Adults (18-64 years),,,Age,40-49,349,0.7794,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"IgG, IgM, IgA",Spike,,0.944,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yannick Munyeku-Bazitama,Hokkaido University,Unity-Aligned,https://dx.doi.org/10.3201/eid2901.221009,2023-01-11,2024-04-11,Verified,munyeku-bazitama_high_nodate,COD
221218_Kinshasa_HokkaidoUniversity_Age_50-59,221218_Kinshasa_HokkaidoUniversity,"High SARS-CoV-2 Seroprevalence after Second COVID-19 Wave (October 2020-April 2021), Democratic Republic of the Congo.",2022-12-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,,Kinshasa,"""We determined eligible participants as persons of all ages who stayed
in Kinshasa 2 weeks before the survey and had no contraindications to venipuncture. We obtained written informed consent from adults (participants
≥18 years of age) and emancipated minors, parental consent for participants <18 years, and assent for participants 10–17 years of age.""",,2021-03-06,2021-03-14,Household and community samples,All,Adults (18-64 years),,,Age,50-59,265,0.7321,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"IgG, IgM, IgA",Spike,,0.944,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yannick Munyeku-Bazitama,Hokkaido University,Unity-Aligned,https://dx.doi.org/10.3201/eid2901.221009,2023-01-11,2024-04-11,Verified,munyeku-bazitama_high_nodate,COD
221218_Kinshasa_HokkaidoUniversity_Age_60-69,221218_Kinshasa_HokkaidoUniversity,"High SARS-CoV-2 Seroprevalence after Second COVID-19 Wave (October 2020-April 2021), Democratic Republic of the Congo.",2022-12-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,,Kinshasa,"""We determined eligible participants as persons of all ages who stayed
in Kinshasa 2 weeks before the survey and had no contraindications to venipuncture. We obtained written informed consent from adults (participants
≥18 years of age) and emancipated minors, parental consent for participants <18 years, and assent for participants 10–17 years of age.""",,2021-03-06,2021-03-14,Household and community samples,All,Multiple groups,,,Age,60-69,179,0.7318,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"IgG, IgM, IgA",Spike,,0.944,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yannick Munyeku-Bazitama,Hokkaido University,Unity-Aligned,https://dx.doi.org/10.3201/eid2901.221009,2023-01-11,2024-04-11,Verified,munyeku-bazitama_high_nodate,COD
221218_Kinshasa_HokkaidoUniversity_Age_15-19,221218_Kinshasa_HokkaidoUniversity,"High SARS-CoV-2 Seroprevalence after Second COVID-19 Wave (October 2020-April 2021), Democratic Republic of the Congo.",2022-12-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,,Kinshasa,"""We determined eligible participants as persons of all ages who stayed
in Kinshasa 2 weeks before the survey and had no contraindications to venipuncture. We obtained written informed consent from adults (participants
≥18 years of age) and emancipated minors, parental consent for participants <18 years, and assent for participants 10–17 years of age.""",,2021-03-06,2021-03-14,Household and community samples,All,Children and Youth (0-17 years),,,Age,15-19,258,0.7248,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"IgG, IgM, IgA",Spike,,0.944,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yannick Munyeku-Bazitama,Hokkaido University,Unity-Aligned,https://dx.doi.org/10.3201/eid2901.221009,2023-01-11,2024-04-11,Verified,munyeku-bazitama_high_nodate,COD
221218_Kinshasa_HokkaidoUniversity_Age_10-14,221218_Kinshasa_HokkaidoUniversity,"High SARS-CoV-2 Seroprevalence after Second COVID-19 Wave (October 2020-April 2021), Democratic Republic of the Congo.",2022-12-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,,Kinshasa,"""We determined eligible participants as persons of all ages who stayed
in Kinshasa 2 weeks before the survey and had no contraindications to venipuncture. We obtained written informed consent from adults (participants
≥18 years of age) and emancipated minors, parental consent for participants <18 years, and assent for participants 10–17 years of age.""",,2021-03-06,2021-03-14,Household and community samples,All,Children and Youth (0-17 years),,,Age,10-14,255,0.6392,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"IgG, IgM, IgA",Spike,,0.944,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yannick Munyeku-Bazitama,Hokkaido University,Unity-Aligned,https://dx.doi.org/10.3201/eid2901.221009,2023-01-11,2024-04-11,Verified,munyeku-bazitama_high_nodate,COD
221218_Kinshasa_HokkaidoUniversity_Age_20-29,221218_Kinshasa_HokkaidoUniversity,"High SARS-CoV-2 Seroprevalence after Second COVID-19 Wave (October 2020-April 2021), Democratic Republic of the Congo.",2022-12-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,,Kinshasa,"""We determined eligible participants as persons of all ages who stayed
in Kinshasa 2 weeks before the survey and had no contraindications to venipuncture. We obtained written informed consent from adults (participants
≥18 years of age) and emancipated minors, parental consent for participants <18 years, and assent for participants 10–17 years of age.""",,2021-03-06,2021-03-14,Household and community samples,All,Adults (18-64 years),,,Age,20-29,497,0.7324,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"IgG, IgM, IgA",Spike,,0.944,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yannick Munyeku-Bazitama,Hokkaido University,Unity-Aligned,https://dx.doi.org/10.3201/eid2901.221009,2023-01-11,2024-04-11,Verified,munyeku-bazitama_high_nodate,COD
221218_Kinshasa_HokkaidoUniversity_Age_>=80,221218_Kinshasa_HokkaidoUniversity,"High SARS-CoV-2 Seroprevalence after Second COVID-19 Wave (October 2020-April 2021), Democratic Republic of the Congo.",2022-12-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,,Kinshasa,"""We determined eligible participants as persons of all ages who stayed
in Kinshasa 2 weeks before the survey and had no contraindications to venipuncture. We obtained written informed consent from adults (participants
≥18 years of age) and emancipated minors, parental consent for participants <18 years, and assent for participants 10–17 years of age.""",,2021-03-06,2021-03-14,Household and community samples,All,Seniors (65+ years),,,Age,>=80,14,0.5714,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"IgG, IgM, IgA",Spike,,0.944,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yannick Munyeku-Bazitama,Hokkaido University,Unity-Aligned,https://dx.doi.org/10.3201/eid2901.221009,2023-01-11,2024-04-11,Verified,munyeku-bazitama_high_nodate,COD
221218_Kinshasa_HokkaidoUniversity_Age_70-79,221218_Kinshasa_HokkaidoUniversity,"High SARS-CoV-2 Seroprevalence after Second COVID-19 Wave (October 2020-April 2021), Democratic Republic of the Congo.",2022-12-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,,Kinshasa,"""We determined eligible participants as persons of all ages who stayed
in Kinshasa 2 weeks before the survey and had no contraindications to venipuncture. We obtained written informed consent from adults (participants
≥18 years of age) and emancipated minors, parental consent for participants <18 years, and assent for participants 10–17 years of age.""",,2021-03-06,2021-03-14,Household and community samples,All,Seniors (65+ years),,,Age,70-79,69,0.739,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"IgG, IgM, IgA",Spike,,0.944,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yannick Munyeku-Bazitama,Hokkaido University,Unity-Aligned,https://dx.doi.org/10.3201/eid2901.221009,2023-01-11,2024-04-11,Verified,munyeku-bazitama_high_nodate,COD
221218_Kinshasa_HokkaidoUniversity_Sex_Female,221218_Kinshasa_HokkaidoUniversity,"High SARS-CoV-2 Seroprevalence after Second COVID-19 Wave (October 2020-April 2021), Democratic Republic of the Congo.",2022-12-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,,Kinshasa,"""We determined eligible participants as persons of all ages who stayed
in Kinshasa 2 weeks before the survey and had no contraindications to venipuncture. We obtained written informed consent from adults (participants
≥18 years of age) and emancipated minors, parental consent for participants <18 years, and assent for participants 10–17 years of age.""",,2021-03-06,2021-03-14,Household and community samples,Female,Multiple groups,,,Sex/Gender,Female,1369,0.734,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"IgG, IgM, IgA",Spike,,0.944,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yannick Munyeku-Bazitama,Hokkaido University,Unity-Aligned,https://dx.doi.org/10.3201/eid2901.221009,2023-01-11,2024-04-11,Verified,munyeku-bazitama_high_nodate,COD
230118_Matadi_InstitutNationalDeRechercheBiomedicale_Overall_TestAdj,230118_Matadi_InstitutNationalDeRechercheBiomedicale,"High Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Prevalence After the Third Epidemic Wave (May–October 2021) in Matadi, Democratic Republic of the Congo",2023-01-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,Kongo Central,Matadi,"""Individuals at least 5 years of age who stayed in Matadi >2 weeks before the survey and had no contraindications to venipuncture were eligible for the study. To avoid oversampling participants <18 years old, residents aged 18 years and older were invited to participate in all households, whereas residents aged 5–17 years were invited to participate in only 50% of households.""","From Figure 1:
- not agreeing to participate;
- Being absent on the survey dates.",2021-10-16,2021-10-24,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,,2197,0.881,0.862,0.901,True,True,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"IgG, IgM, IgA",Spike,Validated by manufacturers,0.944,1.0,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Yannick Munyeku-Bazitama,Institut National de Recherche Biomédicale,Unity-Aligned,https://doi.org/10.1093/ofid/ofad023,2023-03-09,2024-03-27,Verified,munyeku-bazitama_high_2023,COD
230118_Matadi_InstitutNationalDeRechercheBiomedicale_>79,230118_Matadi_InstitutNationalDeRechercheBiomedicale,"High Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Prevalence After the Third Epidemic Wave (May–October 2021) in Matadi, Democratic Republic of the Congo",2023-01-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,Kongo Central,Matadi,"""Individuals at least 5 years of age who stayed in Matadi >2 weeks before the survey and had no contraindications to venipuncture were eligible for the study. To avoid oversampling participants <18 years old, residents aged 18 years and older were invited to participate in all households, whereas residents aged 5–17 years were invited to participate in only 50% of households.""","From Figure 1:
- not agreeing to participate;
- Being absent on the survey dates.",2021-10-16,2021-10-24,Household and community samples,All,Seniors (65+ years),80.0,,Age,>79,21,0.667,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"IgG, IgM, IgA",Spike,Validated by manufacturers,0.944,1.0,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Yannick Munyeku-Bazitama,Institut National de Recherche Biomédicale,Unity-Aligned,https://doi.org/10.1093/ofid/ofad023,2024-03-27,2024-03-27,Verified,munyeku-bazitama_high_2023,COD
230118_Matadi_InstitutNationalDeRechercheBiomedicale_5-9,230118_Matadi_InstitutNationalDeRechercheBiomedicale,"High Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Prevalence After the Third Epidemic Wave (May–October 2021) in Matadi, Democratic Republic of the Congo",2023-01-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,Kongo Central,Matadi,"""Individuals at least 5 years of age who stayed in Matadi >2 weeks before the survey and had no contraindications to venipuncture were eligible for the study. To avoid oversampling participants <18 years old, residents aged 18 years and older were invited to participate in all households, whereas residents aged 5–17 years were invited to participate in only 50% of households.""","From Figure 1:
- not agreeing to participate;
- Being absent on the survey dates.",2021-10-16,2021-10-24,Household and community samples,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,212,0.599,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"IgG, IgM, IgA",Spike,Validated by manufacturers,0.944,1.0,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Yannick Munyeku-Bazitama,Institut National de Recherche Biomédicale,Unity-Aligned,https://doi.org/10.1093/ofid/ofad023,2024-03-27,2024-03-27,Verified,munyeku-bazitama_high_2023,COD
230118_Matadi_InstitutNationalDeRechercheBiomedicale_20-29,230118_Matadi_InstitutNationalDeRechercheBiomedicale,"High Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Prevalence After the Third Epidemic Wave (May–October 2021) in Matadi, Democratic Republic of the Congo",2023-01-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,Kongo Central,Matadi,"""Individuals at least 5 years of age who stayed in Matadi >2 weeks before the survey and had no contraindications to venipuncture were eligible for the study. To avoid oversampling participants <18 years old, residents aged 18 years and older were invited to participate in all households, whereas residents aged 5–17 years were invited to participate in only 50% of households.""","From Figure 1:
- not agreeing to participate;
- Being absent on the survey dates.",2021-10-16,2021-10-24,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,447,0.875,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"IgG, IgM, IgA",Spike,Validated by manufacturers,0.944,1.0,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Yannick Munyeku-Bazitama,Institut National de Recherche Biomédicale,Unity-Aligned,https://doi.org/10.1093/ofid/ofad023,2024-03-27,2024-03-27,Verified,munyeku-bazitama_high_2023,COD
230118_Matadi_InstitutNationalDeRechercheBiomedicale_Overall_UnAdj,230118_Matadi_InstitutNationalDeRechercheBiomedicale,"High Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Prevalence After the Third Epidemic Wave (May–October 2021) in Matadi, Democratic Republic of the Congo",2023-01-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,Kongo Central,Matadi,"""Individuals at least 5 years of age who stayed in Matadi >2 weeks before the survey and had no contraindications to venipuncture were eligible for the study. To avoid oversampling participants <18 years old, residents aged 18 years and older were invited to participate in all households, whereas residents aged 5–17 years were invited to participate in only 50% of households.""","From Figure 1:
- not agreeing to participate;
- Being absent on the survey dates.",2021-10-16,2021-10-24,Household and community samples,All,Multiple groups,5.0,,Analysis,,2197,0.823,,,,,,,True,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"IgG, IgM, IgA",Spike,Validated by manufacturers,0.944,1.0,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Yannick Munyeku-Bazitama,Institut National de Recherche Biomédicale,Unity-Aligned,https://doi.org/10.1093/ofid/ofad023,2023-03-09,2024-03-27,Verified,munyeku-bazitama_high_2023,COD
230118_Matadi_InstitutNationalDeRechercheBiomedicale_10-14,230118_Matadi_InstitutNationalDeRechercheBiomedicale,"High Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Prevalence After the Third Epidemic Wave (May–October 2021) in Matadi, Democratic Republic of the Congo",2023-01-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,Kongo Central,Matadi,"""Individuals at least 5 years of age who stayed in Matadi >2 weeks before the survey and had no contraindications to venipuncture were eligible for the study. To avoid oversampling participants <18 years old, residents aged 18 years and older were invited to participate in all households, whereas residents aged 5–17 years were invited to participate in only 50% of households.""","From Figure 1:
- not agreeing to participate;
- Being absent on the survey dates.",2021-10-16,2021-10-24,Household and community samples,All,Children and Youth (0-17 years),10.0,14.0,Age,10-14,244,0.783,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"IgG, IgM, IgA",Spike,Validated by manufacturers,0.944,1.0,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Yannick Munyeku-Bazitama,Institut National de Recherche Biomédicale,Unity-Aligned,https://doi.org/10.1093/ofid/ofad023,2024-03-27,2024-03-27,Verified,munyeku-bazitama_high_2023,COD
230118_Matadi_InstitutNationalDeRechercheBiomedicale_40-49,230118_Matadi_InstitutNationalDeRechercheBiomedicale,"High Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Prevalence After the Third Epidemic Wave (May–October 2021) in Matadi, Democratic Republic of the Congo",2023-01-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,Kongo Central,Matadi,"""Individuals at least 5 years of age who stayed in Matadi >2 weeks before the survey and had no contraindications to venipuncture were eligible for the study. To avoid oversampling participants <18 years old, residents aged 18 years and older were invited to participate in all households, whereas residents aged 5–17 years were invited to participate in only 50% of households.""","From Figure 1:
- not agreeing to participate;
- Being absent on the survey dates.",2021-10-16,2021-10-24,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,256,0.883,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"IgG, IgM, IgA",Spike,Validated by manufacturers,0.944,1.0,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Yannick Munyeku-Bazitama,Institut National de Recherche Biomédicale,Unity-Aligned,https://doi.org/10.1093/ofid/ofad023,2024-03-27,2024-03-27,Verified,munyeku-bazitama_high_2023,COD
230118_Matadi_InstitutNationalDeRechercheBiomedicale_15-19,230118_Matadi_InstitutNationalDeRechercheBiomedicale,"High Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Prevalence After the Third Epidemic Wave (May–October 2021) in Matadi, Democratic Republic of the Congo",2023-01-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,Kongo Central,Matadi,"""Individuals at least 5 years of age who stayed in Matadi >2 weeks before the survey and had no contraindications to venipuncture were eligible for the study. To avoid oversampling participants <18 years old, residents aged 18 years and older were invited to participate in all households, whereas residents aged 5–17 years were invited to participate in only 50% of households.""","From Figure 1:
- not agreeing to participate;
- Being absent on the survey dates.",2021-10-16,2021-10-24,Household and community samples,All,Children and Youth (0-17 years),15.0,19.0,Age,15-19,291,0.832,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"IgG, IgM, IgA",Spike,Validated by manufacturers,0.944,1.0,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Yannick Munyeku-Bazitama,Institut National de Recherche Biomédicale,Unity-Aligned,https://doi.org/10.1093/ofid/ofad023,2024-03-27,2024-03-27,Verified,munyeku-bazitama_high_2023,COD
230118_Matadi_InstitutNationalDeRechercheBiomedicale_30-39,230118_Matadi_InstitutNationalDeRechercheBiomedicale,"High Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Prevalence After the Third Epidemic Wave (May–October 2021) in Matadi, Democratic Republic of the Congo",2023-01-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,Kongo Central,Matadi,"""Individuals at least 5 years of age who stayed in Matadi >2 weeks before the survey and had no contraindications to venipuncture were eligible for the study. To avoid oversampling participants <18 years old, residents aged 18 years and older were invited to participate in all households, whereas residents aged 5–17 years were invited to participate in only 50% of households.""","From Figure 1:
- not agreeing to participate;
- Being absent on the survey dates.",2021-10-16,2021-10-24,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,316,0.851,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"IgG, IgM, IgA",Spike,Validated by manufacturers,0.944,1.0,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Yannick Munyeku-Bazitama,Institut National de Recherche Biomédicale,Unity-Aligned,https://doi.org/10.1093/ofid/ofad023,2024-03-27,2024-03-27,Verified,munyeku-bazitama_high_2023,COD
230118_Matadi_InstitutNationalDeRechercheBiomedicale_60-69,230118_Matadi_InstitutNationalDeRechercheBiomedicale,"High Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Prevalence After the Third Epidemic Wave (May–October 2021) in Matadi, Democratic Republic of the Congo",2023-01-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,Kongo Central,Matadi,"""Individuals at least 5 years of age who stayed in Matadi >2 weeks before the survey and had no contraindications to venipuncture were eligible for the study. To avoid oversampling participants <18 years old, residents aged 18 years and older were invited to participate in all households, whereas residents aged 5–17 years were invited to participate in only 50% of households.""","From Figure 1:
- not agreeing to participate;
- Being absent on the survey dates.",2021-10-16,2021-10-24,Household and community samples,All,Adults (18-64 years),60.0,69.0,Age,60-69,143,0.846,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"IgG, IgM, IgA",Spike,Validated by manufacturers,0.944,1.0,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Yannick Munyeku-Bazitama,Institut National de Recherche Biomédicale,Unity-Aligned,https://doi.org/10.1093/ofid/ofad023,2024-03-27,2024-03-27,Verified,munyeku-bazitama_high_2023,COD
230118_Matadi_InstitutNationalDeRechercheBiomedicale_50-59,230118_Matadi_InstitutNationalDeRechercheBiomedicale,"High Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Prevalence After the Third Epidemic Wave (May–October 2021) in Matadi, Democratic Republic of the Congo",2023-01-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,Kongo Central,Matadi,"""Individuals at least 5 years of age who stayed in Matadi >2 weeks before the survey and had no contraindications to venipuncture were eligible for the study. To avoid oversampling participants <18 years old, residents aged 18 years and older were invited to participate in all households, whereas residents aged 5–17 years were invited to participate in only 50% of households.""","From Figure 1:
- not agreeing to participate;
- Being absent on the survey dates.",2021-10-16,2021-10-24,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,209,0.837,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"IgG, IgM, IgA",Spike,Validated by manufacturers,0.944,1.0,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Yannick Munyeku-Bazitama,Institut National de Recherche Biomédicale,Unity-Aligned,https://doi.org/10.1093/ofid/ofad023,2024-03-27,2024-03-27,Verified,munyeku-bazitama_high_2023,COD
230118_Matadi_InstitutNationalDeRechercheBiomedicale_70-79,230118_Matadi_InstitutNationalDeRechercheBiomedicale,"High Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Prevalence After the Third Epidemic Wave (May–October 2021) in Matadi, Democratic Republic of the Congo",2023-01-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,Kongo Central,Matadi,"""Individuals at least 5 years of age who stayed in Matadi >2 weeks before the survey and had no contraindications to venipuncture were eligible for the study. To avoid oversampling participants <18 years old, residents aged 18 years and older were invited to participate in all households, whereas residents aged 5–17 years were invited to participate in only 50% of households.""","From Figure 1:
- not agreeing to participate;
- Being absent on the survey dates.",2021-10-16,2021-10-24,Household and community samples,All,Seniors (65+ years),70.0,79.0,Age,70-79,58,0.897,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"IgG, IgM, IgA",Spike,Validated by manufacturers,0.944,1.0,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Yannick Munyeku-Bazitama,Institut National de Recherche Biomédicale,Unity-Aligned,https://doi.org/10.1093/ofid/ofad023,2024-03-27,2024-03-27,Verified,munyeku-bazitama_high_2023,COD
230201_Bukavu_UniversiteCatholiqueDeLouvain_Overall_TestAdj,230201_Bukavu_UniversiteCatholiqueDeLouvain,Seroprevalence of COVID-19 infection in a densely populated district in the eastern Democratic Republic of Congo.,2023-02-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,South Kivu,Bukavu,"The inclusion criteria were i) the continuous presence of the household in the neighborhood since February 14th , 2020 the day when the first COVID-19 case was recorded on the African continent [19], and ii) the lack of any record of vaccination against SARS-CoV-2.",,2021-06-24,2021-09-15,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,Overall; test-adjusted,507,0.84,0.762,0.924,True,True,,,,Stratified probability,QuickZen® COVID-19 IgM/IgG kit,"ZenTech, Angleur, Belgium",LFIA,Whole Blood,"IgG, IgM",Spike,Validated by independent authors/third party/non-developers,0.711,1.0,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Leonid Irenge,Université catholique de Louvain,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268823000158,2023-03-10,2023-03-19,Unverified,irenge_seroprevalence_2023,COD
230201_Bukavu_UniversiteCatholiqueDeLouvain_Overall_UnAdj,230201_Bukavu_UniversiteCatholiqueDeLouvain,Seroprevalence of COVID-19 infection in a densely populated district in the eastern Democratic Republic of Congo.,2023-02-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,South Kivu,Bukavu,"The inclusion criteria were i) the continuous presence of the household in the neighborhood since February 14th , 2020 the day when the first COVID-19 case was recorded on the African continent [19], and ii) the lack of any record of vaccination against SARS-CoV-2.",,2021-06-24,2021-09-15,Household and community samples,All,Multiple groups,0.0,,Analysis,,507,0.5970000000000001,0.554,0.639,,,,,True,Stratified probability,QuickZen® COVID-19 IgM/IgG kit,"ZenTech, Angleur, Belgium",LFIA,Whole Blood,"IgG, IgM",Spike,Validated by independent authors/third party/non-developers,0.711,1.0,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Leonid Irenge,Université catholique de Louvain,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268823000158,2023-03-10,2024-03-01,Unverified,irenge_seroprevalence_2023,COD
230329_Goma_InstituteNationalResearchBiomedical_D0_Overall,230329_Goma_InstituteNationalResearchBiomedical_D0,"Prevalence of immunoglobulin G and M to SARS-CoV-2 and other human coronaviruses in The Democratic Republic of Congo, Sierra Leone, and Uganda: A longitudinal study",2023-03-29,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Democratic Republic of the Congo,,Goma,"""staff working within primary healthcare facilities"".",,2021-02-01,2021-02-28,Health care workers and caregivers,All,Multiple groups,15.0,76.0,Primary Estimate,RBD or NP; IgG or IgM,196,0.704,,,True,,,,True,Convenience,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Bolarinde Lawal,Institute National Research biomedical,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2023.03.049,2023-03-31,2024-03-01,Unverified,lawal_prevalence_2023-1,COD
230329_Goma_InstituteNationalResearchBiomedical_M2_Overall,230329_Goma_InstituteNationalResearchBiomedical_M2,"Prevalence of immunoglobulin G and M to SARS-CoV-2 and other human coronaviruses in The Democratic Republic of Congo, Sierra Leone, and Uganda: A longitudinal study",2023-03-29,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Democratic Republic of the Congo,,Goma,"""staff working within primary healthcare facilities"".",,2021-04-01,2021-04-30,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,RBD or NP; IgG or IgM,189,0.804,,,True,,,,True,Convenience,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],,No,No,No,,Yes,Yes,Yes,,Bolarinde Lawal,Institute National Research biomedical,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2023.03.049,2023-03-31,2024-03-01,Unverified,lawal_prevalence_2023-1,COD
230329_Goma_InstituteNationalResearchBiomedical_M4_Overall,230329_Goma_InstituteNationalResearchBiomedical_M4,"Prevalence of immunoglobulin G and M to SARS-CoV-2 and other human coronaviruses in The Democratic Republic of Congo, Sierra Leone, and Uganda: A longitudinal study",2023-03-29,Journal Article (Peer-Reviewed),Local,Prospective cohort,Democratic Republic of the Congo,,Goma,"""staff working within primary healthcare facilities"".",,2021-06-01,2021-06-30,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,RBD or NP; IgG or IgM,189,0.831,,,True,,,,True,Convenience,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],,No,No,No,,Yes,Yes,Yes,,Bolarinde Lawal,Institute National Research biomedical,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2023.03.049,2023-03-31,2024-03-01,Unverified,lawal_prevalence_2023-1,COD
230608_Lumbashi_Epicentre,230608_Lumbashi_Epicentre,"Seroprevalence of SARS-CoV-2 antibodies and retrospective mortality in two African settings: Lubumbashi, Democratic Republic of the Congo and Abidjan, Cote d'Ivoire.",2023-06-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,,Lumbashi,"The survey in Lubumbashi took place in the health zones Lubumbashi (stratum 1) and Kampemba/Tshamilemba (stratum 2), which were chosen based on COVID incidence in the initial months and increased reporting of deaths through cemetery surveillance, respectively",,2021-04-15,2021-05-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,1897,0.432,0.4,0.464,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,,IgG,Spike,,0.9,1.0,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Erica Simons,Epicentre,Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0001457,2023-06-30,2024-03-01,Unverified,simonsSeroprevalenceSARSCoV2Antibodies2023,COD
230720_Congo_JawaharlalNehruMedicalCollege_Overall,230720_Congo_JawaharlalNehruMedicalCollege,COVID-19 symptoms and antibody positivity among unvaccinated pregnant women: An observational study in seven countries from the Global Network,2023-07-20,Journal Article (Peer-Reviewed),National,Prospective cohort,Democratic Republic of the Congo,,,staff (registry administrators [RAs]) identified pregnant women in their respective clusters,vaccinated pregnant women,2020-10-01,2022-06-30,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,2898,0.376,,,True,,,,True,Stratified non-probability,Not reported/ Unable to specify,,,Serum,,,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Avinash Kavi,Jawaharlal Nehru Medical College,Not Unity-Aligned,https://dx.doi.org/10.1111/1471-0528.17604,2023-08-22,2023-08-23,Unverified,kavi_covid-19_2023,COD
230919_DRC_UCLouvain_Customers_nonAdj,230919_DRC_UCLouvain_Customers,Prevalence of anti-SARS-CoV-2 antibodies in people attending the two main Goma markets in the eastern Democratic Republic of the Congo.,2023-09-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Democratic Republic of the Congo,,Goma,"""a sample of vendors, and customers in the Kituku and Virunga markets of Goma, DRC.""",,2021-09-01,2021-11-08,Household and community samples,All,Multiple groups,,,Analysis,,342,0.702,,,True,,,,True,Convenience,QuickZen® COVID-19 IgM/IgG kit,"ZenTech, Angleur, Belgium",LFIA,Dried Blood,"['IgG', 'IgM']",Spike,,,,['Missing'],,Unclear,No,Yes,,Unclear,Yes,No,,Prudence Ndeba Mitangala,Université catholique de Louvain,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268823001498,2023-03-06,2024-03-01,Unverified,mitangala_prevalence_2023,COD
200625_Denmark_GeneralPopTestAdj,200625_Denmark_CopenhagenUniversityHospital,Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors,2020-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Denmark,,,"Blood donors are healthy and must comply with strict
blood bank eligibility criteria. ","Currently, donors must self-defer for two weeks if they develop fever with upper
respiratory symptoms. ",2020-04-06,2020-05-03,Blood donors,All,Adults (18-64 years),17.0,69.0,Analysis,Adjusted: test,20640,0.019,0.008,0.023,True,True,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8258,0.9954000000000001,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Christian Erikstrup,Copenhagen University Hospital,Unity-Aligned,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa849/5862661,2020-06-26,2023-07-04,Verified,erikstrup_estimation_2020,DNK
200625_Denmark_50-59,200625_Denmark_CopenhagenUniversityHospital,Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors,2020-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Denmark,,,"Blood donors are healthy and must comply with strict
blood bank eligibility criteria. ","Currently, donors must self-defer for two weeks if they develop fever with upper
respiratory symptoms. ",2020-04-06,2020-05-03,Blood donors,All,Adults (18-64 years),50.0,59.0,Age,50-59 ,4501,0.017,,,,,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8258,0.9954000000000001,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Christian Erikstrup,Copenhagen University Hospital,Unity-Aligned,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa849/5862661,2020-07-19,2024-03-01,Verified,erikstrup_estimation_2020,DNK
200625_Denmark_40-49,200625_Denmark_CopenhagenUniversityHospital,Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors,2020-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Denmark,,,"Blood donors are healthy and must comply with strict
blood bank eligibility criteria. ","Currently, donors must self-defer for two weeks if they develop fever with upper
respiratory symptoms. ",2020-04-06,2020-05-03,Blood donors,All,Adults (18-64 years),40.0,49.0,Age,40-49,4841,0.02,,,,,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8258,0.9954000000000001,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Christian Erikstrup,Copenhagen University Hospital,Unity-Aligned,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa849/5862661,2020-07-19,2024-03-01,Verified,erikstrup_estimation_2020,DNK
200625_Denmark_females,200625_Denmark_CopenhagenUniversityHospital,Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors,2020-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Denmark,,,"Blood donors are healthy and must comply with strict
blood bank eligibility criteria. ","Currently, donors must self-defer for two weeks if they develop fever with upper
respiratory symptoms. ",2020-04-06,2020-05-03,Blood donors,Female,Adults (18-64 years),17.0,69.0,Sex/Gender,Female,10443,0.019,,0.023,,,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8258,0.9954000000000001,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Christian Erikstrup,Copenhagen University Hospital,Unity-Aligned,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa849/5862661,2020-07-19,2024-03-01,Verified,erikstrup_estimation_2020,DNK
200625_Denmark_males,200625_Denmark_CopenhagenUniversityHospital,Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors,2020-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Denmark,,,"Blood donors are healthy and must comply with strict
blood bank eligibility criteria. ","Currently, donors must self-defer for two weeks if they develop fever with upper
respiratory symptoms. ",2020-04-06,2020-05-03,Blood donors,Male,Adults (18-64 years),17.0,69.0,Sex/Gender,Male,10217,0.021,,0.023,,,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8258,0.9954000000000001,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Christian Erikstrup,Copenhagen University Hospital,Unity-Aligned,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa849/5862661,2020-07-19,2024-03-01,Verified,erikstrup_estimation_2020,DNK
200625_Denmark_genpop_SouthDkZealand_testadj,200625_Denmark_CopenhagenUniversityHospital,Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors,2020-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Denmark,,,"Blood donors are healthy and must comply with strict
blood bank eligibility criteria. ","Currently, donors must self-defer for two weeks if they develop fever with upper
respiratory symptoms. ",2020-04-06,2020-05-03,Blood donors,All,Adults (18-64 years),17.0,69.0,Geographical area,South DK Zealand,7886,0.013999999999999999,0.003,0.02,,True,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8258,0.9954000000000001,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Christian Erikstrup,Copenhagen University Hospital,Unity-Aligned,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa849/5862661,2020-07-19,2023-07-04,Verified,erikstrup_estimation_2020,DNK
200625_Denmark_genpop_SouthDkZealand,200625_Denmark_CopenhagenUniversityHospital,Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors,2020-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Denmark,,,"Blood donors are healthy and must comply with strict
blood bank eligibility criteria. ","Currently, donors must self-defer for two weeks if they develop fever with upper
respiratory symptoms. ",2020-04-06,2020-05-03,Blood donors,All,Adults (18-64 years),17.0,69.0,Geographical area,South DK Zealand,7886,0.016,0.013999999999999999,0.02,,,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8258,0.9954000000000001,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Christian Erikstrup,Copenhagen University Hospital,Unity-Aligned,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa849/5862661,2020-07-19,2024-03-01,Verified,erikstrup_estimation_2020,DNK
200625_Denmark_genpop_CentralDKNorthDK_testadj,200625_Denmark_CopenhagenUniversityHospital,Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors,2020-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Denmark,,,"Blood donors are healthy and must comply with strict
blood bank eligibility criteria. ","Currently, donors must self-defer for two weeks if they develop fever with upper
respiratory symptoms. ",2020-04-06,2020-05-03,Blood donors,All,Adults (18-64 years),17.0,69.0,Geographical area,Central DK North DK,6226,0.01,0.0,0.015,,True,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8258,0.9954000000000001,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Christian Erikstrup,Copenhagen University Hospital,Unity-Aligned,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa849/5862661,2020-07-19,2023-07-04,Verified,erikstrup_estimation_2020,DNK
200625_Denmark_60-69,200625_Denmark_CopenhagenUniversityHospital,Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors,2020-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Denmark,,,"Blood donors are healthy and must comply with strict
blood bank eligibility criteria. ","Currently, donors must self-defer for two weeks if they develop fever with upper
respiratory symptoms. ",2020-04-06,2020-05-03,Blood donors,All,Adults (18-64 years),60.0,69.0,Age,60-69,2191,0.025,,,,,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8258,0.9954000000000001,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Christian Erikstrup,Copenhagen University Hospital,Unity-Aligned,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa849/5862661,2020-07-19,2024-03-01,Verified,erikstrup_estimation_2020,DNK
200625_Denmark_GeneralPopTestUnadj_IgGIgM,200625_Denmark_CopenhagenUniversityHospital,Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors,2020-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Denmark,,,"Blood donors are healthy and must comply with strict
blood bank eligibility criteria. ","Currently, donors must self-defer for two weeks if they develop fever with upper
respiratory symptoms. ",2020-04-06,2020-05-03,Blood donors,All,Adults (18-64 years),17.0,69.0,Primary Estimate,,20640,0.02,0.018000000000000002,0.022000000000000002,,,,,True,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8258,0.9954000000000001,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Christian Erikstrup,Copenhagen University Hospital,Unity-Aligned,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa849/5862661,2020-06-26,2024-03-01,Verified,erikstrup_estimation_2020,DNK
200625_Denmark_genpop_capitalregion,200625_Denmark_CopenhagenUniversityHospital,Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors,2020-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Denmark,,,"Blood donors are healthy and must comply with strict
blood bank eligibility criteria. ","Currently, donors must self-defer for two weeks if they develop fever with upper
respiratory symptoms. ",2020-04-06,2020-05-03,Blood donors,All,Adults (18-64 years),17.0,69.0,Geographical area,Capital region,6528,0.031000000000000003,0.027000000000000003,0.036000000000000004,,,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8258,0.9954000000000001,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Christian Erikstrup,Copenhagen University Hospital,Unity-Aligned,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa849/5862661,2020-07-19,2024-03-01,Verified,erikstrup_estimation_2020,DNK
200625_Denmark_genpop_capitalregion_testadj,200625_Denmark_CopenhagenUniversityHospital,Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors,2020-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Denmark,,,"Blood donors are healthy and must comply with strict
blood bank eligibility criteria. ","Currently, donors must self-defer for two weeks if they develop fever with upper
respiratory symptoms. ",2020-04-06,2020-05-03,Blood donors,All,Adults (18-64 years),17.0,69.0,Geographical area,Capital region,6528,0.032,0.021,0.039,,True,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8258,0.9954000000000001,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Christian Erikstrup,Copenhagen University Hospital,Unity-Aligned,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa849/5862661,2020-07-19,2023-07-04,Verified,erikstrup_estimation_2020,DNK
200625_Denmark_genpop_CentralDKNorthDK,200625_Denmark_CopenhagenUniversityHospital,Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors,2020-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Denmark,,,"Blood donors are healthy and must comply with strict
blood bank eligibility criteria. ","Currently, donors must self-defer for two weeks if they develop fever with upper
respiratory symptoms. ",2020-04-06,2020-05-03,Blood donors,All,Adults (18-64 years),17.0,69.0,Geographical area,Central DK North DK,6226,0.013000000000000001,0.01,0.016,,,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8258,0.9954000000000001,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Christian Erikstrup,Copenhagen University Hospital,Unity-Aligned,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa849/5862661,2020-07-19,2024-03-01,Verified,erikstrup_estimation_2020,DNK
200625_Denmark_17-29,200625_Denmark_CopenhagenUniversityHospital,Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors,2020-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Denmark,,,"Blood donors are healthy and must comply with strict
blood bank eligibility criteria. ","Currently, donors must self-defer for two weeks if they develop fever with upper
respiratory symptoms. ",2020-04-06,2020-05-03,Blood donors,All,Adults (18-64 years),17.0,29.0,Age,17-29,5068,0.025,,,,,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8258,0.9954000000000001,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Christian Erikstrup,Copenhagen University Hospital,Unity-Aligned,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa849/5862661,2020-07-19,2024-03-01,Verified,erikstrup_estimation_2020,DNK
200625_Denmark_30-39,200625_Denmark_CopenhagenUniversityHospital,Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors,2020-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Denmark,,,"Blood donors are healthy and must comply with strict
blood bank eligibility criteria. ","Currently, donors must self-defer for two weeks if they develop fever with upper
respiratory symptoms. ",2020-04-06,2020-05-03,Blood donors,All,Adults (18-64 years),30.0,39.0,Age,30-39,4039,0.013999999999999999,,,,,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8258,0.9954000000000001,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Christian Erikstrup,Copenhagen University Hospital,Unity-Aligned,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa849/5862661,2020-07-19,2024-03-01,Verified,erikstrup_estimation_2020,DNK
200803_CapitalRegionDenmark_UniversityofCopenhagen_hcw_IgG_ANDOR_IgM_adj,200803_CapitalRegionDenmark_UniversityofCopenhagen_1_HCW,Risk of COVID-19 in health-care workers in Denmark: an observational cohort study,2020-08-03,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Capital Region of Denmark,,"• >18 years old
• Consent to participation
• Employed at a Hospital in the Capital Region of Denmark",,2020-04-15,2020-04-22,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Health care worker,28792,0.04360000000000001,0.0409,0.04650000000000001,True,True,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.7340000000000001,0.9990000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Kasper Iversen,University of Copenhagen,Not Unity-Aligned,https://dx.doi.org/10.1016/S1473-3099(20)30589-2,2020-09-30,2023-07-04,Verified,iversen_risk_2020,DNK
200803_CapitalRegionDenmark_UniversityofCopenhagen_blooddonors_IgG_ANDOR_IgM,200803_CapitalRegionDenmark_UniversityofCopenhagen_2_blood,Risk of COVID-19 in health-care workers in Denmark: an observational cohort study,2020-08-03,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Capital Region of Denmark,,"• >18 years old
• Consent to participation
• Employed at a Hospital in the Capital Region of Denmark",,2020-04-15,2020-04-22,Blood donors,All,Adults (18-64 years),,,Primary Estimate,Blood donor,4672,0.0304,0.0258,0.0357,True,True,,,True,Sequential,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.7340000000000001,0.9990000000000001,['Moderate'],No,No,Yes,No,Unclear,Yes,Yes,Yes,,Kasper Iversen,University of Copenhagen,Unity-Aligned,https://dx.doi.org/10.1016/S1473-3099(20)30589-2,2020-10-01,2023-07-04,Verified,iversen_risk_2020,DNK
201003_Denmark_AarhusUniversity_HCW_testadj,201003_Denmark_AarhusUniversityHospital_HCW1,"Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Survey Among 17 971 Healthcare and Administrative Personnel at Hospitals, Prehospital Services, and Specialist Practitioners in the Central Denmark Region ",2020-10-03,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Central Denmark Region,,"All healthcare and administrative personnel at hospitals, prehospital services, and specialist practitioners in the Central Denmark Region were invited by email to be tested for antibodies against SARS-CoV-2. Healthcare workers at the hospitals were grouped according to their geographical location: (1) Herning and Holstebro Regional Hospitals serving the western part of the region, Regional Hospital West Jutland (RHWJ); (2) Viborg and Silkeborg Regional Hospitals serving the central part, Regional Hospital Central Jutland (RHCJ); and (3) Randers Regional Hospital, Horsens Regional Hospital, and Aarhus University Hospital servicing the eastern part (East). ",,2020-05-18,2020-06-19,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,17948,0.0336,0.023799999999999998,0.0382,True,True,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Senne Jespersen,Aarhus University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1471,2020-12-19,2023-07-04,Verified,jespersen_severe_2020,DNK
201003_Denmark_AarhusUniversity_HCW_<29,201003_Denmark_AarhusUniversityHospital_HCW1,"Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Survey Among 17 971 Healthcare and Administrative Personnel at Hospitals, Prehospital Services, and Specialist Practitioners in the Central Denmark Region ",2020-10-03,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Central Denmark Region,,"All healthcare and administrative personnel at hospitals, prehospital services, and specialist practitioners in the Central Denmark Region were invited by email to be tested for antibodies against SARS-CoV-2. Healthcare workers at the hospitals were grouped according to their geographical location: (1) Herning and Holstebro Regional Hospitals serving the western part of the region, Regional Hospital West Jutland (RHWJ); (2) Viborg and Silkeborg Regional Hospitals serving the central part, Regional Hospital Central Jutland (RHCJ); and (3) Randers Regional Hospital, Horsens Regional Hospital, and Aarhus University Hospital servicing the eastern part (East). ",,2020-05-18,2020-06-19,Health care workers and caregivers,All,Adults (18-64 years),,28.0,Age,<29,2032,0.0571,0.0478,0.068,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Senne Jespersen,Aarhus University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1471,2020-12-20,2024-03-01,Verified,jespersen_severe_2020,DNK
201003_Denmark_AarhusUniversity_HCW_>=60,201003_Denmark_AarhusUniversityHospital_HCW1,"Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Survey Among 17 971 Healthcare and Administrative Personnel at Hospitals, Prehospital Services, and Specialist Practitioners in the Central Denmark Region ",2020-10-03,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Central Denmark Region,,"All healthcare and administrative personnel at hospitals, prehospital services, and specialist practitioners in the Central Denmark Region were invited by email to be tested for antibodies against SARS-CoV-2. Healthcare workers at the hospitals were grouped according to their geographical location: (1) Herning and Holstebro Regional Hospitals serving the western part of the region, Regional Hospital West Jutland (RHWJ); (2) Viborg and Silkeborg Regional Hospitals serving the central part, Regional Hospital Central Jutland (RHCJ); and (3) Randers Regional Hospital, Horsens Regional Hospital, and Aarhus University Hospital servicing the eastern part (East). ",,2020-05-18,2020-06-19,Health care workers and caregivers,All,Seniors (65+ years),60.0,,Age,>=60,2577,0.0279,0.0223,0.035,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Senne Jespersen,Aarhus University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1471,2020-12-20,2024-03-01,Verified,jespersen_severe_2020,DNK
201003_Denmark_AarhusUniversity_HCW_40-49,201003_Denmark_AarhusUniversityHospital_HCW1,"Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Survey Among 17 971 Healthcare and Administrative Personnel at Hospitals, Prehospital Services, and Specialist Practitioners in the Central Denmark Region ",2020-10-03,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Central Denmark Region,,"All healthcare and administrative personnel at hospitals, prehospital services, and specialist practitioners in the Central Denmark Region were invited by email to be tested for antibodies against SARS-CoV-2. Healthcare workers at the hospitals were grouped according to their geographical location: (1) Herning and Holstebro Regional Hospitals serving the western part of the region, Regional Hospital West Jutland (RHWJ); (2) Viborg and Silkeborg Regional Hospitals serving the central part, Regional Hospital Central Jutland (RHCJ); and (3) Randers Regional Hospital, Horsens Regional Hospital, and Aarhus University Hospital servicing the eastern part (East). ",,2020-05-18,2020-06-19,Health care workers and caregivers,Male,Adults (18-64 years),40.0,49.0,Age,40-49,4735,0.037000000000000005,0.032,0.042699999999999995,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Senne Jespersen,Aarhus University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1471,2020-12-20,2024-03-01,Verified,jespersen_severe_2020,DNK
201003_Denmark_AarhusUniversity_HCW_50-59,201003_Denmark_AarhusUniversityHospital_HCW1,"Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Survey Among 17 971 Healthcare and Administrative Personnel at Hospitals, Prehospital Services, and Specialist Practitioners in the Central Denmark Region ",2020-10-03,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Central Denmark Region,,"All healthcare and administrative personnel at hospitals, prehospital services, and specialist practitioners in the Central Denmark Region were invited by email to be tested for antibodies against SARS-CoV-2. Healthcare workers at the hospitals were grouped according to their geographical location: (1) Herning and Holstebro Regional Hospitals serving the western part of the region, Regional Hospital West Jutland (RHWJ); (2) Viborg and Silkeborg Regional Hospitals serving the central part, Regional Hospital Central Jutland (RHCJ); and (3) Randers Regional Hospital, Horsens Regional Hospital, and Aarhus University Hospital servicing the eastern part (East). ",,2020-05-18,2020-06-19,Health care workers and caregivers,Male,Adults (18-64 years),50.0,59.0,Age,50-59,4666,0.0345,0.0296,0.0401,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Senne Jespersen,Aarhus University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1471,2020-12-20,2024-03-01,Verified,jespersen_severe_2020,DNK
201003_Denmark_AarhusUniversity_HCW_30-39,201003_Denmark_AarhusUniversityHospital_HCW1,"Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Survey Among 17 971 Healthcare and Administrative Personnel at Hospitals, Prehospital Services, and Specialist Practitioners in the Central Denmark Region ",2020-10-03,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Central Denmark Region,,"All healthcare and administrative personnel at hospitals, prehospital services, and specialist practitioners in the Central Denmark Region were invited by email to be tested for antibodies against SARS-CoV-2. Healthcare workers at the hospitals were grouped according to their geographical location: (1) Herning and Holstebro Regional Hospitals serving the western part of the region, Regional Hospital West Jutland (RHWJ); (2) Viborg and Silkeborg Regional Hospitals serving the central part, Regional Hospital Central Jutland (RHCJ); and (3) Randers Regional Hospital, Horsens Regional Hospital, and Aarhus University Hospital servicing the eastern part (East). ",,2020-05-18,2020-06-19,Health care workers and caregivers,Male,Adults (18-64 years),30.0,39.0,Age,30-39,3938,0.0366,0.0311,0.0429,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Senne Jespersen,Aarhus University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1471,2020-12-20,2024-03-01,Verified,jespersen_severe_2020,DNK
201003_EastCentralDenmark_AarhusUniversityHospital_BloodDonors3,201003_EastCentralDenmark_AarhusUniversityHospital_BloodDonors3,"Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Survey Among 17 971 Healthcare and Administrative Personnel at Hospitals, Prehospital Services, and Specialist Practitioners in the Central Denmark Region ",2020-10-03,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Eastern Central Denmark Region,,"tested 360 anonymous blood donor samples from Central Denmark region, an area of 13,000 square kilometers, 180 of which were from the Eastern part of the Central Denmark ",missing blood sample or poor sample quality,2020-06-17,2020-06-30,Blood donors,All,Adults (18-64 years),,,Primary Estimate,,180,0.006,0.0,0.035,,True,,,True,Convenience,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['High'],No,No,No,No,Unclear,Yes,Yes,Yes,,Senne Jespersen,Aarhus University Hospital,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1471,2021-04-21,2023-07-04,Verified,jespersen_severe_2020,DNK
201003_WestCentralDenmark_AarhusUniversityHospital_BloodDonors2,201003_WestCentralDenmark_AarhusUniversityHospital_BloodDonors2,"Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Survey Among 17 971 Healthcare and Administrative Personnel at Hospitals, Prehospital Services, and Specialist Practitioners in the Central Denmark Region ",2020-10-03,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Western Central Denmark Region,,"tested 360 anonymous blood donor samples from Central Denmark region, an area of 13,000 square kilometers, 180 of which were from the Western part of the Central Denmark region
",missing blood sample or poor sample quality,2020-06-17,2020-06-30,Blood donors,All,Adults (18-64 years),,,Primary Estimate,,180,0.012,0.0,0.044000000000000004,,True,,,True,Convenience,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['High'],No,No,No,No,Unclear,Yes,Yes,Yes,,Senne Jespersen,Aarhus University Hospital,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1471,2021-04-21,2023-07-04,Verified,jespersen_severe_2020,DNK
201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_Active_adj,201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_Active2,SARS-CoV-2 infection fatality rate among elderly retired Danish blood donors - A cross-sectional study,2020-10-26,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Denmark,,,active blood donors (aged 17–69 years) who had given blood between 1 and 12 June 2020 in the Central Denmark Region and between 22 and 26 June 2020 in the Zealand and Capital Regions,,2020-06-01,2020-06-26,Blood donors,All,Adults (18-64 years),17.0,69.0,Primary Estimate,,1110,0.025,0.013000000000000001,0.038,True,True,True,,,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,,Ole Birger Pedersen,Copenhagen University Hospital Rigshospitalet,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1627,2021-01-12,2023-07-04,Verified,pedersen_severe_2020,DNK
201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_Active_zealand_unadj ,201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_Active2,SARS-CoV-2 infection fatality rate among elderly retired Danish blood donors - A cross-sectional study,2020-10-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Zealand,,active blood donors (aged 17–69 years) who had given blood between 1 and 12 June 2020 in the Central Denmark Region and between 22 and 26 June 2020 in the Zealand and Capital Regions,,2020-06-01,2020-06-26,Blood donors,All,Adults (18-64 years),17.0,69.0,Geographical area,,250,0.027999999999999997,0.011000000000000001,0.057,,,,,,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,,Ole Birger Pedersen,Copenhagen University Hospital Rigshospitalet,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1627,2021-01-12,2024-03-01,Verified,pedersen_severe_2020,DNK
201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_Active_zealand_adj ,201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_Active2,SARS-CoV-2 infection fatality rate among elderly retired Danish blood donors - A cross-sectional study,2020-10-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Zealand,,active blood donors (aged 17–69 years) who had given blood between 1 and 12 June 2020 in the Central Denmark Region and between 22 and 26 June 2020 in the Zealand and Capital Regions,,2020-06-01,2020-06-26,Blood donors,All,Adults (18-64 years),17.0,69.0,Geographical area,,250,0.025,0.006,0.053,,True,True,,,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,,Ole Birger Pedersen,Copenhagen University Hospital Rigshospitalet,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1627,2021-01-12,2023-07-04,Verified,pedersen_severe_2020,DNK
201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_Active_capital_unadj ,201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_Active2,SARS-CoV-2 infection fatality rate among elderly retired Danish blood donors - A cross-sectional study,2020-10-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Capital Region of Denmark,,active blood donors (aged 17–69 years) who had given blood between 1 and 12 June 2020 in the Central Denmark Region and between 22 and 26 June 2020 in the Zealand and Capital Regions,,2020-06-01,2020-06-26,Blood donors,All,Adults (18-64 years),17.0,69.0,Geographical area,,500,0.042,0.026000000000000002,0.063,,,,,,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,,Ole Birger Pedersen,Copenhagen University Hospital Rigshospitalet,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1627,2021-01-12,2024-03-01,Verified,pedersen_severe_2020,DNK
201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_Active_unadj,201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_Active2,SARS-CoV-2 infection fatality rate among elderly retired Danish blood donors - A cross-sectional study,2020-10-26,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Denmark,,,active blood donors (aged 17–69 years) who had given blood between 1 and 12 June 2020 in the Central Denmark Region and between 22 and 26 June 2020 in the Zealand and Capital Regions,,2020-06-01,2020-06-26,Blood donors,All,Adults (18-64 years),17.0,69.0,Analysis,,1110,0.03,0.021,0.040999999999999995,,,,,True,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,,Ole Birger Pedersen,Copenhagen University Hospital Rigshospitalet,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1627,2021-01-12,2024-03-01,Verified,pedersen_severe_2020,DNK
201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_Active_capital_adj,201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_Active2,SARS-CoV-2 infection fatality rate among elderly retired Danish blood donors - A cross-sectional study,2020-10-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Capital Region of Denmark,,active blood donors (aged 17–69 years) who had given blood between 1 and 12 June 2020 in the Central Denmark Region and between 22 and 26 June 2020 in the Zealand and Capital Regions,,2020-06-01,2020-06-26,Blood donors,All,Adults (18-64 years),17.0,69.0,Geographical area,,500,0.039,0.021,0.06,,True,True,,,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,,Ole Birger Pedersen,Copenhagen University Hospital Rigshospitalet,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1627,2021-01-12,2023-07-04,Verified,pedersen_severe_2020,DNK
201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_Active_CentralDenmark_unadj  ,201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_Active2,SARS-CoV-2 infection fatality rate among elderly retired Danish blood donors - A cross-sectional study,2020-10-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Central Denmark Region,,active blood donors (aged 17–69 years) who had given blood between 1 and 12 June 2020 in the Central Denmark Region and between 22 and 26 June 2020 in the Zealand and Capital Regions,,2020-06-01,2020-06-26,Blood donors,All,Adults (18-64 years),17.0,69.0,Geographical area,,360,0.013999999999999999,0.005,0.032,,,,,,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,,Ole Birger Pedersen,Copenhagen University Hospital Rigshospitalet,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1627,2021-01-12,2024-03-01,Verified,pedersen_severe_2020,DNK
201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_Active_CentralDenmark_adj,201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_Active2,SARS-CoV-2 infection fatality rate among elderly retired Danish blood donors - A cross-sectional study,2020-10-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Central Denmark Region,,active blood donors (aged 17–69 years) who had given blood between 1 and 12 June 2020 in the Central Denmark Region and between 22 and 26 June 2020 in the Zealand and Capital Regions,,2020-06-01,2020-06-26,Blood donors,All,Adults (18-64 years),17.0,69.0,Geographical area,,360,0.011000000000000001,0.0,0.027999999999999997,,True,True,,,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,,Ole Birger Pedersen,Copenhagen University Hospital Rigshospitalet,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1627,2021-01-12,2023-07-04,Verified,pedersen_severe_2020,DNK
201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_retired_adj,201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_Retired1,SARS-CoV-2 infection fatality rate among elderly retired Danish blood donors - A cross-sectional study,2020-10-26,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Denmark,,," retired blood donors in 3 out of the 5 Danish administrative regions (the Danish Capital Region, the Zealand Region, and the Central Denmark Region",Persons without an ebook address or persons living too far from a blood donation center (from fig 1),2020-06-02,2020-06-19,Blood donors,All,Seniors (65+ years),70.0,,Primary Estimate,,1200,0.013999999999999999,0.003,0.025,True,True,True,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Ole Birger Pedersen,Copenhagen University Hospital Rigshospitalet,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1627,2021-01-10,2023-07-04,Verified,pedersen_severe_2020,DNK
201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_retired_capital_adj,201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_Retired1,SARS-CoV-2 infection fatality rate among elderly retired Danish blood donors - A cross-sectional study,2020-10-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Capital Region of Denmark,," retired blood donors in 3 out of the 5 Danish administrative regions (the Danish Capital Region, the Zealand Region, and the Central Denmark Region",Persons without an ebook address or persons living too far from a blood donation center (from fig 1),2020-06-02,2020-06-19,Blood donors,All,Seniors (65+ years),70.0,,Geographical area,,449,0.022000000000000002,0.006,0.040999999999999995,,True,True,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Ole Birger Pedersen,Copenhagen University Hospital Rigshospitalet,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1627,2021-01-12,2023-07-04,Verified,pedersen_severe_2020,DNK
201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_retired_unadj ,201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_Retired1,SARS-CoV-2 infection fatality rate among elderly retired Danish blood donors - A cross-sectional study,2020-10-26,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Denmark,,," retired blood donors in 3 out of the 5 Danish administrative regions (the Danish Capital Region, the Zealand Region, and the Central Denmark Region",Persons without an ebook address or persons living too far from a blood donation center (from fig 1),2020-06-02,2020-06-19,Blood donors,All,Seniors (65+ years),70.0,,Analysis,,1200,0.018000000000000002,0.012,0.027999999999999997,,,,,True,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Ole Birger Pedersen,Copenhagen University Hospital Rigshospitalet,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1627,2021-01-12,2024-03-01,Verified,pedersen_severe_2020,DNK
201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_retired_capital_unadj,201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_Retired1,SARS-CoV-2 infection fatality rate among elderly retired Danish blood donors - A cross-sectional study,2020-10-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Capital Region of Denmark,," retired blood donors in 3 out of the 5 Danish administrative regions (the Danish Capital Region, the Zealand Region, and the Central Denmark Region",Persons without an ebook address or persons living too far from a blood donation center (from fig 1),2020-06-02,2020-06-19,Blood donors,All,Seniors (65+ years),70.0,,Geographical area,,449,0.022000000000000002,0.011000000000000001,0.040999999999999995,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Ole Birger Pedersen,Copenhagen University Hospital Rigshospitalet,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1627,2021-01-12,2024-03-01,Verified,pedersen_severe_2020,DNK
201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_retired_Central_Denmark_unadj,201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_Retired1,SARS-CoV-2 infection fatality rate among elderly retired Danish blood donors - A cross-sectional study,2020-10-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Capital Region of Denmark,," retired blood donors in 3 out of the 5 Danish administrative regions (the Danish Capital Region, the Zealand Region, and the Central Denmark Region",Persons without an ebook address or persons living too far from a blood donation center (from fig 1),2020-06-02,2020-06-19,Blood donors,All,Seniors (65+ years),70.0,,Geographical area,,291,0.01,0.002,0.03,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Ole Birger Pedersen,Copenhagen University Hospital Rigshospitalet,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1627,2021-01-12,2024-03-01,Verified,pedersen_severe_2020,DNK
201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_retired_zealand_adj ,201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_Retired1,SARS-CoV-2 infection fatality rate among elderly retired Danish blood donors - A cross-sectional study,2020-10-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Zealand,," retired blood donors in 3 out of the 5 Danish administrative regions (the Danish Capital Region, the Zealand Region, and the Central Denmark Region",Persons without an ebook address or persons living too far from a blood donation center (from fig 1),2020-06-02,2020-06-19,Blood donors,All,Seniors (65+ years),70.0,,Geographical area,,461,0.019,0.004,0.037000000000000005,,True,True,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Ole Birger Pedersen,Copenhagen University Hospital Rigshospitalet,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1627,2021-01-12,2023-07-04,Verified,pedersen_severe_2020,DNK
201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_retired_Female_unadj,201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_Retired1,SARS-CoV-2 infection fatality rate among elderly retired Danish blood donors - A cross-sectional study,2020-10-26,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Denmark,,," retired blood donors in 3 out of the 5 Danish administrative regions (the Danish Capital Region, the Zealand Region, and the Central Denmark Region",Persons without an ebook address or persons living too far from a blood donation center (from fig 1),2020-06-02,2020-06-19,Blood donors,Female,Seniors (65+ years),70.0,,Sex/Gender,Female,516,0.02131,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Ole Birger Pedersen,Copenhagen University Hospital Rigshospitalet,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1627,2021-02-19,2024-03-01,Verified,pedersen_severe_2020,DNK
201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_retired_Male_Unadj,201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_Retired1,SARS-CoV-2 infection fatality rate among elderly retired Danish blood donors - A cross-sectional study,2020-10-26,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Denmark,,," retired blood donors in 3 out of the 5 Danish administrative regions (the Danish Capital Region, the Zealand Region, and the Central Denmark Region",Persons without an ebook address or persons living too far from a blood donation center (from fig 1),2020-06-02,2020-06-19,Blood donors,Male,Seniors (65+ years),70.0,,Sex/Gender,,684,0.01608,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Ole Birger Pedersen,Copenhagen University Hospital Rigshospitalet,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1627,2021-02-19,2024-03-01,Verified,pedersen_severe_2020,DNK
201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_retired_CentralDenmark_adj ,201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_Retired1,SARS-CoV-2 infection fatality rate among elderly retired Danish blood donors - A cross-sectional study,2020-10-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Central Denmark Region,," retired blood donors in 3 out of the 5 Danish administrative regions (the Danish Capital Region, the Zealand Region, and the Central Denmark Region",Persons without an ebook address or persons living too far from a blood donation center (from fig 1),2020-06-02,2020-06-19,Blood donors,All,Seniors (65+ years),70.0,,Geographical area,,291,0.006999999999999999,0.0,0.03,,True,True,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Ole Birger Pedersen,Copenhagen University Hospital Rigshospitalet,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1627,2021-01-12,2023-07-04,Verified,pedersen_severe_2020,DNK
201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_retired_zealand_unadj ,201026_Denmark_CopenhagenUniversityHospitalRigshospitalet_Retired1,SARS-CoV-2 infection fatality rate among elderly retired Danish blood donors - A cross-sectional study,2020-10-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Zealand,," retired blood donors in 3 out of the 5 Danish administrative regions (the Danish Capital Region, the Zealand Region, and the Central Denmark Region",Persons without an ebook address or persons living too far from a blood donation center (from fig 1),2020-06-02,2020-06-19,Blood donors,All,Seniors (65+ years),70.0,,Geographical area,,461,0.02,0.009000000000000001,0.037000000000000005,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Low'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Ole Birger Pedersen,Copenhagen University Hospital Rigshospitalet,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1627,2021-01-12,2024-03-01,Verified,pedersen_severe_2020,DNK
201027_Copenhagen_CopenhagenUniversityHospitalHvidovre_Newborns,201027_Copenhagen_CopenhagenUniversityHospitalHvidovre_Newborns,"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies at Delivery in Women, Partners, and Newborns",2020-10-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Denmark,Capital Region of Denmark,Copenhagen ,"From April 4, 2020, to July 3, 2020 (3 months), during the first epidemic wave in Denmark, all women giving birth at the department and their partners were approached and invited to participate in the study, along with their newborns.",,2020-04-04,2020-07-03,Perinatal,All,Children and Youth (0-17 years),,,Primary Estimate,,1206,0.013999999999999999,,,True,,,,True,Sequential,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9400000000000001,0.993,['Moderate'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,,Pia Egerup,Copenhagen University Hospital Hvidovre,Not Unity-Aligned,https://dx.doi.org/10.1097/AOG.0000000000004199,2021-01-10,2022-07-16,Verified,egerup_severe_2021,DNK
201027_Copenhagen_CopenhagenUniversityHospitalHvidovre_PartnersofParturientWomen_TestAdj,201027_Copenhagen_CopenhagenUniversityHospitalHvidovre_PartnersofParturientWomen,"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies at Delivery in Women, Partners, and Newborns",2020-10-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Denmark,Capital Region of Denmark,Copenhagen ,"From April 4, 2020, to July 3, 2020 (3 months), during the first epidemic wave in Denmark, all women giving birth at the department and their partners were approached and invited to participate in the study, along with their newborns.",,2020-04-04,2020-07-03,Hospital visitors,All,Adults (18-64 years),,,Primary Estimate,Partners of parturient women,1188,0.035,0.023,0.051,True,True,,,,Sequential,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9400000000000001,0.993,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,Yes,Pia Egerup,Copenhagen University Hospital Hvidovre,Not Unity-Aligned,https://dx.doi.org/10.1097/AOG.0000000000004199,2021-01-09,2022-07-16,Verified,egerup_severe_2021,DNK
201027_Copenhagen_CopenhagenUniversityHospitalHvidovre_ParturientWomen_TestAdj,201027_Copenhagen_CopenhagenUniversityHospitalHvidovre_ParturientWomen,"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies at Delivery in Women, Partners, and Newborns",2020-10-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Denmark,Capital Region of Denmark,Copenhagen,"From April 4, 2020, to July 3, 2020 (3 months), during the first epidemic wave in Denmark, all women giving birth at the department and their partners were approached and invited to participate in the study, along with their newborns.",,2020-04-04,2020-07-03,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,Primary estimate,1313,0.026000000000000002,0.017,0.04,True,True,,,,Sequential,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9400000000000001,0.993,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,Yes,Pia Egerup,Copenhagen University Hospital Hvidovre,Unity-Aligned,https://dx.doi.org/10.1097/AOG.0000000000004199,2021-01-09,2022-07-16,Verified,egerup_severe_2021,DNK
201027_Copenhagen_CopenhagenUniversityHospitalHvidovre_ParturientWomen_Unadj,201027_Copenhagen_CopenhagenUniversityHospitalHvidovre_ParturientWomen,"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies at Delivery in Women, Partners, and Newborns",2020-10-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Denmark,Capital Region of Denmark,Copenhagen,"From April 4, 2020, to July 3, 2020 (3 months), during the first epidemic wave in Denmark, all women giving birth at the department and their partners were approached and invited to participate in the study, along with their newborns.",,2020-04-04,2020-07-03,Pregnant or parturient women,Female,Adults (18-64 years),,,Analysis,Parturient women estimate unadjusted for test sn/sp,1313,0.021,,,,,,,True,Sequential,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9400000000000001,0.993,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,Yes,Pia Egerup,Copenhagen University Hospital Hvidovre,Unity-Aligned,https://dx.doi.org/10.1097/AOG.0000000000004199,2021-01-09,2022-07-16,Verified,egerup_severe_2021,DNK
201027_Aarhus_AarhusDepartmentofPublicHealth_IgGorIgM,201027_Aarhus_AarhusDepartmentofPublicHealth,First wave of COVID-19 did not reach the homeless population in Aarhus.,2020-11-20,Journal Article (Peer-Reviewed),Local,Prospective cohort,Denmark,Central Denmark Region,Aarhus,"Homeless individuals presenting at drop- in centres, injection rooms and homeless shelters",,2020-06-01,2020-06-04,Persons experiencing homelessness,All,Adults (18-64 years),42.0,61.0,Primary Estimate,Overall,129,0.047,0.021,0.098,True,,,,True,Convenience,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9890000000000001,0.976,['High'],Yes,No,No,Yes,No,Unclear,Yes,Yes,Unclear,Signe Storgaard,Aarhus Department of Public Health ,Not Unity-Aligned,"https://pubmed.ncbi.nlm.nih.gov/33269697/#:~:text=Conclusions%3A%20Despite%20their%20vulnerable%20profile,funded%20by%20Aarhus%20University%20Hospital.",2021-01-23,2022-07-16,Verified,storgaard_first_2020,DNK
201212_Europe_UniversityOfGlasgow_Denmark4,201212_Europe_UniversityOfGlasgow_Denmark4,SARS-Cov-2 viral and serological screening of staff in 31 European fertility units.,2020-12-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Denmark,,Aarhus and Copenhagen,"all staff members recommencing work at the Fertility Partnership, including clinical and head office staf",,2020-04-15,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,34,0.0294,0.005200000000000001,0.1491,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,,Scott M Nelson,University of Glasgow,Not Unity-Aligned,https://dx.doi.org/10.1093/hropen/hoaa056,2021-06-07,2024-03-01,Verified,nelson_sars-cov-2_2020,DNK
201227_Denmark_CopenhagenUniversityHospital_PregnancyLoss2_Overall,201227_Denmark_CopenhagenUniversityHospital_PregnancyLoss2,SARS-CoV-2 in first trimester pregnancy: a cohort study,2020-12-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Denmark,Copenhagen,Copenhagen,"From 14 April to 21 May 2020, women referred with a pregnancy loss before the time of the double test were also invited to participate.","non-pregnant women, did not have first trimester scan",2020-04-14,2020-05-21,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,36,0.0,,,True,,,,True,Self-referral,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,"['IgG', 'IgM']",,,,,['High'],No,No,No,No,No,Unclear,Yes,No,Yes, ‪Nina Freiesleben,Copenhagen University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1093/humrep/deaa311,2021-01-15,2022-07-16,Verified,la_cour_freiesleben_sars-cov-2_2020-1,DNK
201227_Denmark_CopenhagenUniversityHospital_Pregnant1_Overall,201227_Denmark_CopenhagenUniversityHospital_Pregnant1,SARS-CoV-2 in first trimester pregnancy: a cohort study,2020-12-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Denmark,Copenhagen,Copenhagen,"All pregnant women, who had a double test performed at Hvidovre Hospital from 17 February 2020 to 23 April 2020","non-pregnant women, did not have first trimester scan",2020-02-17,2020-04-17,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,1019,0.018000000000000002,,,True,,,,True,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,No,No,Unclear,Yes,No,Yes, ‪Nina Freiesleben,Copenhagen University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1093/humrep/deaa311,2021-02-13,2022-07-16,Verified,la_cour_freiesleben_sars-cov-2_2020-1,DNK
210121_Denmark_CopenhagenUniversityHospital_Denmark,210121_Denmark_CopenhagenUniversityHospital,Prevalence of SARS-CoV-2 IgG/IgM antibodies among Danish and Swedish Falck emergency and non-emergency healthcare workers,2021-01-21,Journal Article (Peer-Reviewed),National,Prospective cohort,Denmark,,,Participants were included on account of being Falck employees.,,2020-06-22,2020-08-10,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,2024,0.027999999999999997,,,True,,,,True,Convenience,"2019-nCoV IgG/IgM Antibody Detection Kit,Finecare SARS-CoV-2 Antibody test,Wondfo SARS-CoV-2 Antibody Test","Zhuhai Livzon Diagnostics Inc,Guangzhou Wondfo Biotech Co. Ltd",LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Jannie Laursen,Copenhagen University Hospital,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph18030923,2021-02-25,2024-03-01,Verified,laursen_prevalence_2021,DNK
210121_Denmark_CopenhagenUniversityHospital_Denmark_<40yo,210121_Denmark_CopenhagenUniversityHospital,Prevalence of SARS-CoV-2 IgG/IgM antibodies among Danish and Swedish Falck emergency and non-emergency healthcare workers,2021-01-21,Journal Article (Peer-Reviewed),National,Prospective cohort,Denmark,,,Participants were included on account of being Falck employees.,,2020-06-22,2020-08-10,Health care workers and caregivers,All,Adults (18-64 years),,39.0,Age,<40,542,0.03,,,,,,,,Convenience,"2019-nCoV IgG/IgM Antibody Detection Kit,Finecare SARS-CoV-2 Antibody test,Wondfo SARS-CoV-2 Antibody Test","Zhuhai Livzon Diagnostics Inc,Guangzhou Wondfo Biotech Co. Ltd",LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Jannie Laursen,Copenhagen University Hospital,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph18030923,2021-02-25,2024-03-01,Verified,laursen_prevalence_2021,DNK
210121_Denmark_CopenhagenUniversityHospital_Denmark_40-60,210121_Denmark_CopenhagenUniversityHospital,Prevalence of SARS-CoV-2 IgG/IgM antibodies among Danish and Swedish Falck emergency and non-emergency healthcare workers,2021-01-21,Journal Article (Peer-Reviewed),National,Prospective cohort,Denmark,,,Participants were included on account of being Falck employees.,,2020-06-22,2020-08-10,Health care workers and caregivers,All,Adults (18-64 years),40.0,60.0,Age,40-60yo,1045,0.028999999999999998,,,,,,,,Convenience,"2019-nCoV IgG/IgM Antibody Detection Kit,Finecare SARS-CoV-2 Antibody test,Wondfo SARS-CoV-2 Antibody Test","Zhuhai Livzon Diagnostics Inc,Guangzhou Wondfo Biotech Co. Ltd",LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Jannie Laursen,Copenhagen University Hospital,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph18030923,2021-02-25,2024-03-01,Verified,laursen_prevalence_2021,DNK
210121_Denmark_CopenhagenUniversityHospital_Denmark_60+,210121_Denmark_CopenhagenUniversityHospital,Prevalence of SARS-CoV-2 IgG/IgM antibodies among Danish and Swedish Falck emergency and non-emergency healthcare workers,2021-01-21,Journal Article (Peer-Reviewed),National,Prospective cohort,Denmark,,,Participants were included on account of being Falck employees.,,2020-06-22,2020-08-10,Health care workers and caregivers,All,Seniors (65+ years),60.0,,Age,60+ yo,437,0.023,,,,,,,,Convenience,"2019-nCoV IgG/IgM Antibody Detection Kit,Finecare SARS-CoV-2 Antibody test,Wondfo SARS-CoV-2 Antibody Test","Zhuhai Livzon Diagnostics Inc,Guangzhou Wondfo Biotech Co. Ltd",LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Jannie Laursen,Copenhagen University Hospital,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph18030923,2021-02-25,2024-03-01,Verified,laursen_prevalence_2021,DNK
210212_Copenhagen_Herlev-GentofteHospital_Overall,210212_Copenhagen_Herlev-GentofteHospital,Anti-SARS-CoV-2 seropositivity among medical students in Copenhagen,2021-02-12,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Denmark,Capital Region,Copenhagen,"All medical students who were enrolled at UCPH (n=3673)11, were offered the possibility to participate in this observational cohort study",,2020-10-19,2020-10-26,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Overall; medical students,1096,0.3458,0.3182,0.37450000000000006,True,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgA', 'IgG', 'IgM']",,Validated by manufacturers,0.97,0.995,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Johannes R Madsen,Herlev-Gentofte Hospital,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.09.21251421v1,2021-03-18,2024-03-01,Verified,madsen_anti-sars-cov-2_2021,DNK
210401_Denmark_SlagelseSygehus_blooddonors_primary,210401_Denmark_SlagelseSygehus_blooddonors,Prevalence of SARS-CoV-2-Antibodies in Danish Children and Adults,2021-04-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Capital Region and Region Zealand,,blood donors living in the same regions as children,,2020-06-22,2020-07-03,Blood donors,All,Adults (18-64 years),,,Primary Estimate,,750,0.02,0.011000000000000001,0.033,True,,,,True,Simplified probability,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.93,0.98,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,Yes,Maren J H Rytter,Slagelse Sygehus,Unity-Aligned,http://dx.doi.org/10.1097/INF.0000000000003048,2021-05-19,2024-03-01,Verified,rytter_prevalence_2021,DNK
210401_Denmark_SlagelseSygehus_children_primary,210401_Denmark_SlagelseSygehus_children,Prevalence of SARS-CoV-2-Antibodies in Danish Children and Adults,2021-04-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Capital Region and Region Zealand,,"We invited children 0–17 years of age visiting a pediatric department for any reason (eg, acute illness, surgery and out-patient visit) to participate by convenience sampling in a cross-sectional study.",Exclusion criteria were treatment with chemotherapy and inability to cooperate with blood sampling,2020-06-22,2020-07-03,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,,1033,0.016,0.01,0.026000000000000002,True,,,,True,Convenience,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.93,0.98,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Maren J H Rytter,Slagelse Sygehus,Unity-Aligned,http://dx.doi.org/10.1097/INF.0000000000003048,2021-05-19,2024-03-01,Verified,rytter_prevalence_2021,DNK
210401_Denmark_SlagelseSygehus_children_0-4,210401_Denmark_SlagelseSygehus_children,Prevalence of SARS-CoV-2-Antibodies in Danish Children and Adults,2021-04-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Capital Region and Region Zealand,,"We invited children 0–17 years of age visiting a pediatric department for any reason (eg, acute illness, surgery and out-patient visit) to participate by convenience sampling in a cross-sectional study.",Exclusion criteria were treatment with chemotherapy and inability to cooperate with blood sampling,2020-06-22,2020-07-03,Residual sera,All,Children and Youth (0-17 years),0.0,4.0,Age,0-4 years of age,225,0.013000000000000001,,,,,,,,Convenience,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.93,0.98,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Maren J H Rytter,Slagelse Sygehus,Unity-Aligned,http://dx.doi.org/10.1097/INF.0000000000003048,2021-07-27,2024-03-01,Verified,rytter_prevalence_2021,DNK
210401_Denmark_SlagelseSygehus_children_5-9,210401_Denmark_SlagelseSygehus_children,Prevalence of SARS-CoV-2-Antibodies in Danish Children and Adults,2021-04-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Capital Region and Region Zealand,,"We invited children 0–17 years of age visiting a pediatric department for any reason (eg, acute illness, surgery and out-patient visit) to participate by convenience sampling in a cross-sectional study.",Exclusion criteria were treatment with chemotherapy and inability to cooperate with blood sampling,2020-06-22,2020-07-03,Residual sera,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9 years of age,241,0.017,,,,,,,,Convenience,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.93,0.98,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Maren J H Rytter,Slagelse Sygehus,Unity-Aligned,http://dx.doi.org/10.1097/INF.0000000000003048,2021-07-27,2024-03-01,Verified,rytter_prevalence_2021,DNK
210401_Denmark_SlagelseSygehus_children_females,210401_Denmark_SlagelseSygehus_children,Prevalence of SARS-CoV-2-Antibodies in Danish Children and Adults,2021-04-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Capital Region and Region Zealand,,"We invited children 0–17 years of age visiting a pediatric department for any reason (eg, acute illness, surgery and out-patient visit) to participate by convenience sampling in a cross-sectional study.",Exclusion criteria were treatment with chemotherapy and inability to cooperate with blood sampling,2020-06-22,2020-07-03,Residual sera,Female,Children and Youth (0-17 years),0.0,17.0,Sex/Gender,females,490,0.022000000000000002,,,,,,,,Convenience,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.93,0.98,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Maren J H Rytter,Slagelse Sygehus,Unity-Aligned,http://dx.doi.org/10.1097/INF.0000000000003048,2021-07-27,2024-03-01,Verified,rytter_prevalence_2021,DNK
210401_Denmark_SlagelseSygehus_children_10-14,210401_Denmark_SlagelseSygehus_children,Prevalence of SARS-CoV-2-Antibodies in Danish Children and Adults,2021-04-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Capital Region and Region Zealand,,"We invited children 0–17 years of age visiting a pediatric department for any reason (eg, acute illness, surgery and out-patient visit) to participate by convenience sampling in a cross-sectional study.",Exclusion criteria were treatment with chemotherapy and inability to cooperate with blood sampling,2020-06-22,2020-07-03,Residual sera,All,Children and Youth (0-17 years),10.0,14.0,Age,10-14 years of age,339,0.021,,,,,,,,Convenience,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.93,0.98,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Maren J H Rytter,Slagelse Sygehus,Unity-Aligned,http://dx.doi.org/10.1097/INF.0000000000003048,2021-07-27,2024-03-01,Verified,rytter_prevalence_2021,DNK
210401_Denmark_SlagelseSygehus_children_males,210401_Denmark_SlagelseSygehus_children,Prevalence of SARS-CoV-2-Antibodies in Danish Children and Adults,2021-04-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Capital Region and Region Zealand,,"We invited children 0–17 years of age visiting a pediatric department for any reason (eg, acute illness, surgery and out-patient visit) to participate by convenience sampling in a cross-sectional study.",Exclusion criteria were treatment with chemotherapy and inability to cooperate with blood sampling,2020-06-22,2020-07-03,Residual sera,Male,Children and Youth (0-17 years),0.0,17.0,Sex/Gender,males,543,0.011000000000000001,,,,,,,,Convenience,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.93,0.98,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Maren J H Rytter,Slagelse Sygehus,Unity-Aligned,http://dx.doi.org/10.1097/INF.0000000000003048,2021-07-27,2024-03-01,Verified,rytter_prevalence_2021,DNK
210401_Denmark_SlagelseSygehus_children_15-17,210401_Denmark_SlagelseSygehus_children,Prevalence of SARS-CoV-2-Antibodies in Danish Children and Adults,2021-04-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Capital Region and Region Zealand,,"We invited children 0–17 years of age visiting a pediatric department for any reason (eg, acute illness, surgery and out-patient visit) to participate by convenience sampling in a cross-sectional study.",Exclusion criteria were treatment with chemotherapy and inability to cooperate with blood sampling,2020-06-22,2020-07-03,Residual sera,All,Children and Youth (0-17 years),15.0,17.0,Age,15-17 years of age,228,0.013000000000000001,,,,,,,,Convenience,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.93,0.98,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Maren J H Rytter,Slagelse Sygehus,Unity-Aligned,http://dx.doi.org/10.1097/INF.0000000000003048,2021-07-27,2024-03-01,Verified,rytter_prevalence_2021,DNK
210510_Denmark_CopenhagenUniversityHospital_BloodDonorsOverall,210510_Denmark_CopenhagenUniversityHospital_BloodDonors1,Seroprevalence of SARS-CoV-2 antibodies in social housing areas in Denmark,2021-05-10,Preprint,National,Cross-sectional survey ,Denmark,,,all Danish blood donations,,2021-01-08,2021-01-31,Blood donors,All,Multiple groups,,,Primary Estimate,Overall blood donors,22677,0.057999999999999996,,,True,,,,True,Entire sample,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,,,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kamille Fogh,Copenhagen University Hospital,Unity-Aligned,https://doi.org/10.1101/2021.05.07.21256725,2021-05-30,2024-03-01,Verified,fogh_seroprevalence_2021,DNK
210510_Denmark_CopenhagenUniversityHospital_SHOverall,210510_Denmark_CopenhagenUniversityHospital_SH2,Seroprevalence of SARS-CoV-2 antibodies in social housing areas in Denmark,2021-05-10,Preprint,National,Cross-sectional survey ,Denmark,,"Copenhagen, Aarhus, Odense, Hoeje Taastrup, Helsingoer and Slagelse ","We recruited participants from 13 different Social housing areas in Denmark (see appendix, Figure 1). Persons more than 15 years of age were invited to participate",,2021-01-08,2021-01-31,Household and community samples,All,Multiple groups,15.0,,Primary Estimate,Overall social housing ,13279,0.17300000000000001,,,True,,,,True,Stratified non-probability,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9,1.0,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Kamille Fogh,Copenhagen University Hospital,Not Unity-Aligned,https://doi.org/10.1101/2021.05.07.21256725,2021-05-30,2024-03-01,Verified,fogh_seroprevalence_2021,DNK
210510_Denmark_CopenhagenUniversityHospital_SH_Male,210510_Denmark_CopenhagenUniversityHospital_SH2,Seroprevalence of SARS-CoV-2 antibodies in social housing areas in Denmark,2021-05-10,Preprint,National,Cross-sectional survey ,Denmark,,"Copenhagen, Aarhus, Odense, Hoeje Taastrup, Helsingoer and Slagelse ","We recruited participants from 13 different Social housing areas in Denmark (see appendix, Figure 1). Persons more than 15 years of age were invited to participate",,2021-01-08,2021-01-31,Household and community samples,Male,Multiple groups,15.0,,Sex/Gender,Males in social housing,6612,0.18100000000000002,,,,,,,,Stratified non-probability,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9,1.0,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Kamille Fogh,Copenhagen University Hospital,Not Unity-Aligned,https://doi.org/10.1101/2021.05.07.21256725,2021-08-12,2024-03-01,Verified,fogh_seroprevalence_2021,DNK
210510_Denmark_CopenhagenUniversityHospital_SH_Female,210510_Denmark_CopenhagenUniversityHospital_SH2,Seroprevalence of SARS-CoV-2 antibodies in social housing areas in Denmark,2021-05-10,Preprint,National,Cross-sectional survey ,Denmark,,"Copenhagen, Aarhus, Odense, Hoeje Taastrup, Helsingoer and Slagelse ","We recruited participants from 13 different Social housing areas in Denmark (see appendix, Figure 1). Persons more than 15 years of age were invited to participate",,2021-01-08,2021-01-31,Household and community samples,Female,Multiple groups,15.0,,Sex/Gender,females in social housing,6667,0.165,,,,,,,,Stratified non-probability,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9,1.0,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Kamille Fogh,Copenhagen University Hospital,Not Unity-Aligned,https://doi.org/10.1101/2021.05.07.21256725,2021-08-12,2024-03-01,Verified,fogh_seroprevalence_2021,DNK
210512_Denmark_CopenhagenUniversityHospital_PEH1_Overall,210512_Denmark_CopenhagenUniversityHospital_PEH1,"SARS-CoV-2 antibody prevalence among homeless people, sex workers and shelter workers in Denmark: a nationwide cross-sectional study",2021-05-12,Preprint,National,Cross-sectional survey ,Denmark,"Central, North, Capital, South"," Copenhagen, Aarhus, Aalborg and Odense","participants (people experiencing homelessness and shelter workers) from 21 sites in the four biggest cities in Denmark; Copenhagen, Aarhus, Aalborg and Odense. The recruitment sites were shelters, supervised sites for intravenous drug abusers, food distribution sites, meeting places and day/night cafés.",,2020-11-02,2020-11-20,Persons experiencing homelessness,All,Adults (18-64 years),,,Primary Estimate,people experiencing homelessness,628,0.068,,,True,,,,True,Convenience,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",,,0.9686,0.9939,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Alexandra R Rothlin Eriksen,Copenhagen University Hospital,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.05.07.21256388v2,2021-05-25,2024-03-01,Verified,rothlin_eriksen_sars-cov-2_2021,DNK
210512_Denmark_CopenhagenUniversityHospital_ShelterWorkers2_Overall,210512_Denmark_CopenhagenUniversityHospital_ShelterWorkers2,"SARS-CoV-2 antibody prevalence among homeless people, sex workers and shelter workers in Denmark: a nationwide cross-sectional study",2021-05-12,Preprint,National,Cross-sectional survey ,Denmark,"Central, North, Capital, South"," Copenhagen, Aarhus, Aalborg and Odense","participants (people experiencing homelessness and shelter workers) from 21 sites in the four biggest cities in Denmark; Copenhagen, Aarhus, Aalborg and Odense. The recruitment sites were shelters, supervised sites for intravenous drug abusers, food distribution sites, meeting places and day/night cafés.",,2020-11-02,2020-11-20,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,shelter workers,191,0.063,,,True,,,,True,Convenience,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9686,0.9939,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Alexandra R Rothlin Eriksen,Copenhagen University Hospital,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.05.07.21256388v2,2021-05-25,2024-03-01,Verified,rothlin_eriksen_sars-cov-2_2021,DNK
210531_Denmark_AarhusUniversity_BloodDonors2,210531_Denmark_AarhusUniversity_BloodDonors2,"Isolation, behavioral changes and low seroprevalence of SARS-CoV-2 antibodies in patients with Systemic Lupus Erythematosus or Rheumatoid arthritis.",2021-05-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Denmark,,,This study aimed to assess the seroprevalence of blood SARS-CoV-2 total antibodies in patients with CRDs and blood donors (BDs) during the first wave of the pandemic.,,2020-06-08,2020-06-19,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,Blood Donors,513,0.019,,,True,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['High'],,No,No,Yes,,Yes,Yes,Yes,,Christian Ammitzboll,Aarhus University,Not Unity-Aligned,https://dx.doi.org/10.1002/acr.24716,2021-06-07,2024-03-01,Unverified,christianammitzbollIsolationBehavioralChanges2021,DNK
210531_Denmark_AarhusUniversity_CRDPatients1,210531_Denmark_AarhusUniversity_CRDPatients1,"Isolation, behavioral changes and low seroprevalence of SARS-CoV-2 antibodies in patients with Systemic Lupus Erythematosus or Rheumatoid arthritis.",2021-05-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Denmark,,,This study aimed to assess the seroprevalence of blood SARS-CoV-2 total antibodies in patients with CRDs and blood donors (BDs) during the first wave of the pandemic.,,2020-06-08,2020-06-19,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,CRD Patients,365,0.003,,,True,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['High'],,No,No,No,,Yes,Yes,Yes,,Christian Ammitzboll,Aarhus University,Not Unity-Aligned,https://dx.doi.org/10.1002/acr.24716,2021-06-07,2024-03-01,Unverified,christianammitzbollIsolationBehavioralChanges2021,DNK
210609_CentralDenmarkRegion_AarhusUniversity,210609_CentralDenmarkRegion_AarhusUniversity,Symptoms reported by SARS-CoV-2 seropositive and seronegative healthcare and administrative employees in Denmark from May to August 2020.,2021-06-09,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Central Denmark Region,,"healthcare and administrative personnel at hospitals, prehospital services and specialist practitioners in Central Denmark Region",,2020-05-18,2020-06-19,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,11138,0.04,,,True,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Kathrine Agergard Kaspersen,Aarhus University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.06.017,2021-06-21,2024-03-01,Unverified,kaspersen_symptoms_2021,DNK
210813_Denmark_CopenhagenUniversityHospital_Primary,210813_Denmark_CopenhagenUniversityHospital,Testing Denmark: A Danish nationwide surveillance study of COVID-19,2021-08-13,Preprint,National,Cross-sectional survey ,Denmark,,,"1.3 million Danish citizens >15 years (22% of the population) were randomly drawn from the Civil Registration System and invited to participate via the governmental, personal, password protected digital mailbox system (e-Boks) from September 25, 2020.",,2020-10-02,2020-10-11,Household and community samples,All,Multiple groups,15.0,,Primary Estimate,,318552,0.0079,,,True,,,,True,Simplified probability,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9329999999999999,0.9820000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Kamille Fogh,Copenhagen University Hospital,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.10.21261777v1,2021-08-23,2024-03-01,Verified,fogh_testing_2021,DNK
210813_Denmark_CopenhagenUniversityHospital_Male,210813_Denmark_CopenhagenUniversityHospital,Testing Denmark: A Danish nationwide surveillance study of COVID-19,2021-08-13,Preprint,National,Cross-sectional survey ,Denmark,,,"1.3 million Danish citizens >15 years (22% of the population) were randomly drawn from the Civil Registration System and invited to participate via the governmental, personal, password protected digital mailbox system (e-Boks) from September 25, 2020.",,2020-10-02,2020-10-11,Household and community samples,Male,Multiple groups,15.0,,Sex/Gender,,134424,0.0075,,,,,,,,Simplified probability,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9329999999999999,0.9820000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Kamille Fogh,Copenhagen University Hospital,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.10.21261777v1,2021-08-23,2024-03-01,Verified,fogh_testing_2021,DNK
210813_Denmark_CopenhagenUniversityHospital_Age61-75,210813_Denmark_CopenhagenUniversityHospital,Testing Denmark: A Danish nationwide surveillance study of COVID-19,2021-08-13,Preprint,National,Cross-sectional survey ,Denmark,,,"1.3 million Danish citizens >15 years (22% of the population) were randomly drawn from the Civil Registration System and invited to participate via the governmental, personal, password protected digital mailbox system (e-Boks) from September 25, 2020.",,2020-10-02,2020-10-11,Household and community samples,All,Multiple groups,61.0,75.0,Age,61-75,85847,0.0018,,,,,,,,Simplified probability,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9329999999999999,0.9820000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Kamille Fogh,Copenhagen University Hospital,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.10.21261777v1,2021-08-23,2024-03-01,Verified,fogh_testing_2021,DNK
210813_Denmark_CopenhagenUniversityHospital_AgeOver75,210813_Denmark_CopenhagenUniversityHospital,Testing Denmark: A Danish nationwide surveillance study of COVID-19,2021-08-13,Preprint,National,Cross-sectional survey ,Denmark,,,"1.3 million Danish citizens >15 years (22% of the population) were randomly drawn from the Civil Registration System and invited to participate via the governmental, personal, password protected digital mailbox system (e-Boks) from September 25, 2020.",,2020-10-02,2020-10-11,Household and community samples,All,Seniors (65+ years),75.0,,Age,>75,15193,0.0028000000000000004,,,,,,,,Simplified probability,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9329999999999999,0.9820000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Kamille Fogh,Copenhagen University Hospital,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.10.21261777v1,2021-08-23,2024-03-01,Verified,fogh_testing_2021,DNK
210813_Denmark_CopenhagenUniversityHospital_Age31-45,210813_Denmark_CopenhagenUniversityHospital,Testing Denmark: A Danish nationwide surveillance study of COVID-19,2021-08-13,Preprint,National,Cross-sectional survey ,Denmark,,,"1.3 million Danish citizens >15 years (22% of the population) were randomly drawn from the Civil Registration System and invited to participate via the governmental, personal, password protected digital mailbox system (e-Boks) from September 25, 2020.",,2020-10-02,2020-10-11,Household and community samples,All,Adults (18-64 years),31.0,45.0,Age,31-45,66313,0.0018,,,,,,,,Simplified probability,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9329999999999999,0.9820000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Kamille Fogh,Copenhagen University Hospital,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.10.21261777v1,2021-08-23,2024-03-01,Verified,fogh_testing_2021,DNK
210813_Denmark_CopenhagenUniversityHospital_Age15-30,210813_Denmark_CopenhagenUniversityHospital,Testing Denmark: A Danish nationwide surveillance study of COVID-19,2021-08-13,Preprint,National,Cross-sectional survey ,Denmark,,,"1.3 million Danish citizens >15 years (22% of the population) were randomly drawn from the Civil Registration System and invited to participate via the governmental, personal, password protected digital mailbox system (e-Boks) from September 25, 2020.",,2020-10-02,2020-10-11,Household and community samples,All,Multiple groups,15.0,30.0,Age,15-30,47953,0.0014000000000000002,,,,,,,,Simplified probability,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9329999999999999,0.9820000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Kamille Fogh,Copenhagen University Hospital,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.10.21261777v1,2021-08-23,2024-03-01,Verified,fogh_testing_2021,DNK
210813_Denmark_CopenhagenUniversityHospital_Age46-60,210813_Denmark_CopenhagenUniversityHospital,Testing Denmark: A Danish nationwide surveillance study of COVID-19,2021-08-13,Preprint,National,Cross-sectional survey ,Denmark,,,"1.3 million Danish citizens >15 years (22% of the population) were randomly drawn from the Civil Registration System and invited to participate via the governmental, personal, password protected digital mailbox system (e-Boks) from September 25, 2020.",,2020-10-02,2020-10-11,Household and community samples,All,Adults (18-64 years),46.0,60.0,Age,46-60,103246,0.002,,,,,,,,Simplified probability,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9329999999999999,0.9820000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Kamille Fogh,Copenhagen University Hospital,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.10.21261777v1,2021-08-23,2024-03-01,Verified,fogh_testing_2021,DNK
210813_Denmark_CopenhagenUniversityHospital_Female,210813_Denmark_CopenhagenUniversityHospital,Testing Denmark: A Danish nationwide surveillance study of COVID-19,2021-08-13,Preprint,National,Cross-sectional survey ,Denmark,,,"1.3 million Danish citizens >15 years (22% of the population) were randomly drawn from the Civil Registration System and invited to participate via the governmental, personal, password protected digital mailbox system (e-Boks) from September 25, 2020.",,2020-10-02,2020-10-11,Household and community samples,Female,Multiple groups,15.0,,Sex/Gender,,184128,0.008199999999999999,,,,,,,,Simplified probability,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9329999999999999,0.9820000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Kamille Fogh,Copenhagen University Hospital,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.10.21261777v1,2021-08-23,2024-03-01,Verified,fogh_testing_2021,DNK
210822_Denmark_StatensSerumInstitut_August_testadj,210822_Denmark_StatensSerumInstitut_August,"Prevalence of SARS-CoV-2 antibodies in Denmark: nationwide, population-based seroepidemiological study.",2021-08-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Denmark,,,"For DSS-I, adults aged 18 years and older with an address in one of 30 municipalities which had a test facility (see below) at that time (n = 5), or were neighbouring a municipality with a test facility (n = 25) were eligible (approximately 45% of the population of Denmark). For DSS-II and DSS-III, people aged 12 years or older were selected by random sampling, with no restriction on municipality (n = 98). To make it a safe experience for children and motivate participation, parents living on the same address as invited children 12–17 years old, were also invited to have an antibody test. Parents’ antibody test results were not included in the seroprevalence calculation.",,2020-08-15,2020-09-30,Household and community samples,All,Multiple groups,12.0,,Primary Estimate,,11478,0.02,0.017,0.024,True,True,True,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Laura Espenhain,Statens Serum Institut,Unity-Aligned,https://dx.doi.org/10.1007/s10654-021-00796-8,2021-08-31,2023-08-15,Verified,espenhain_prevalence_2021-1,DNK
210822_Denmark_StatensSerumInstitut_August_unadj,210822_Denmark_StatensSerumInstitut_August,"Prevalence of SARS-CoV-2 antibodies in Denmark: nationwide, population-based seroepidemiological study.",2021-08-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Denmark,,,"For DSS-I, adults aged 18 years and older with an address in one of 30 municipalities which had a test facility (see below) at that time (n = 5), or were neighbouring a municipality with a test facility (n = 25) were eligible (approximately 45% of the population of Denmark). For DSS-II and DSS-III, people aged 12 years or older were selected by random sampling, with no restriction on municipality (n = 98). To make it a safe experience for children and motivate participation, parents living on the same address as invited children 12–17 years old, were also invited to have an antibody test. Parents’ antibody test results were not included in the seroprevalence calculation.",,2020-08-15,2020-09-30,Household and community samples,All,Multiple groups,12.0,,Analysis,,11478,0.021,0.013000000000000001,0.026000000000000002,,,,,True,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Laura Espenhain,Statens Serum Institut,Unity-Aligned,https://dx.doi.org/10.1007/s10654-021-00796-8,2021-08-31,2024-03-01,Verified,espenhain_prevalence_2021-1,DNK
210822_Denmark_StatensSerumInstitut_December_testadj,210822_Denmark_StatensSerumInstitut_December,"Prevalence of SARS-CoV-2 antibodies in Denmark: nationwide, population-based seroepidemiological study.",2021-08-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Denmark,,,"For DSS-I, adults aged 18 years and older with an address in one of 30 municipalities which had a test facility (see below) at that time (n = 5), or were neighbouring a municipality with a test facility (n = 25) were eligible (approximately 45% of the population of Denmark). For DSS-II and DSS-III, people aged 12 years or older were selected by random sampling, with no restriction on municipality (n = 98). To make it a safe experience for children and motivate participation, parents living on the same address as invited children 12–17 years old, were also invited to have an antibody test. Parents’ antibody test results were not included in the seroprevalence calculation.",,2020-12-01,2020-12-31,Household and community samples,All,Multiple groups,12.0,,Primary Estimate,,4044,0.043,0.034,0.051,True,True,True,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Laura Espenhain,Statens Serum Institut,Unity-Aligned,https://dx.doi.org/10.1007/s10654-021-00796-8,2021-08-31,2023-08-15,Verified,espenhain_prevalence_2021-1,DNK
210822_Denmark_StatensSerumInstitut_December_unadj,210822_Denmark_StatensSerumInstitut_December,"Prevalence of SARS-CoV-2 antibodies in Denmark: nationwide, population-based seroepidemiological study.",2021-08-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Denmark,,,"For DSS-I, adults aged 18 years and older with an address in one of 30 municipalities which had a test facility (see below) at that time (n = 5), or were neighbouring a municipality with a test facility (n = 25) were eligible (approximately 45% of the population of Denmark). For DSS-II and DSS-III, people aged 12 years or older were selected by random sampling, with no restriction on municipality (n = 98). To make it a safe experience for children and motivate participation, parents living on the same address as invited children 12–17 years old, were also invited to have an antibody test. Parents’ antibody test results were not included in the seroprevalence calculation.",,2020-12-01,2020-12-31,Household and community samples,All,Multiple groups,12.0,,Analysis,,4044,0.040999999999999995,0.031000000000000003,0.049,,,,,True,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Laura Espenhain,Statens Serum Institut,Unity-Aligned,https://dx.doi.org/10.1007/s10654-021-00796-8,2021-08-31,2024-03-01,Verified,espenhain_prevalence_2021-1,DNK
210822_Denmark_StatensSerumInstitut_May_testadj,210822_Denmark_StatensSerumInstitut_May,"Prevalence of SARS-CoV-2 antibodies in Denmark: nationwide, population-based seroepidemiological study.",2021-08-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Denmark,,,"For DSS-I, adults aged 18 years and older with an address in one of 30 municipalities which had a test facility (see below) at that time (n = 5), or were neighbouring a municipality with a test facility (n = 25) were eligible",,2020-05-05,2020-05-15,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2512,0.015,0.009000000000000001,0.021,True,True,True,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,No,Laura Espenhain,Statens Serum Institut,Unity-Aligned,https://dx.doi.org/10.1007/s10654-021-00796-8,2021-08-31,2023-08-15,Verified,espenhain_prevalence_2021-1,DNK
210822_Denmark_StatensSerumInstitut_May_unadj,210822_Denmark_StatensSerumInstitut_May,"Prevalence of SARS-CoV-2 antibodies in Denmark: nationwide, population-based seroepidemiological study.",2021-08-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Denmark,,,"For DSS-I, adults aged 18 years and older with an address in one of 30 municipalities which had a test facility (see below) at that time (n = 5), or were neighbouring a municipality with a test facility (n = 25) were eligible",,2020-05-05,2020-05-15,Household and community samples,All,Multiple groups,18.0,,Analysis,,2512,0.012,0.003,0.019,,,,,True,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,No,Laura Espenhain,Statens Serum Institut,Unity-Aligned,https://dx.doi.org/10.1007/s10654-021-00796-8,2021-08-31,2024-03-01,Verified,espenhain_prevalence_2021-1,DNK
210822_Denmark_StatensSerumInstitut_October_testadj,210822_Denmark_StatensSerumInstitut_October,"Prevalence of SARS-CoV-2 antibodies in Denmark: nationwide, population-based seroepidemiological study.",2021-08-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Denmark,,,"For DSS-I, adults aged 18 years and older with an address in one of 30 municipalities which had a test facility (see below) at that time (n = 5), or were neighbouring a municipality with a test facility (n = 25) were eligible (approximately 45% of the population of Denmark). For DSS-II and DSS-III, people aged 12 years or older were selected by random sampling, with no restriction on municipality (n = 98). To make it a safe experience for children and motivate participation, parents living on the same address as invited children 12–17 years old, were also invited to have an antibody test. Parents’ antibody test results were not included in the seroprevalence calculation.",,2020-10-01,2020-11-30,Household and community samples,All,Multiple groups,12.0,,Primary Estimate,,9654,0.024,0.019,0.027999999999999997,True,True,True,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Laura Espenhain,Statens Serum Institut,Unity-Aligned,https://dx.doi.org/10.1007/s10654-021-00796-8,2021-08-31,2023-08-15,Verified,espenhain_prevalence_2021-1,DNK
210822_Denmark_StatensSerumInstitut_October_unadj,210822_Denmark_StatensSerumInstitut_October,"Prevalence of SARS-CoV-2 antibodies in Denmark: nationwide, population-based seroepidemiological study.",2021-08-22,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Denmark,,,"For DSS-I, adults aged 18 years and older with an address in one of 30 municipalities which had a test facility (see below) at that time (n = 5), or were neighbouring a municipality with a test facility (n = 25) were eligible (approximately 45% of the population of Denmark). For DSS-II and DSS-III, people aged 12 years or older were selected by random sampling, with no restriction on municipality (n = 98). To make it a safe experience for children and motivate participation, parents living on the same address as invited children 12–17 years old, were also invited to have an antibody test. Parents’ antibody test results were not included in the seroprevalence calculation.",,2020-10-01,2020-11-30,Household and community samples,All,Multiple groups,12.0,,Analysis,,9654,0.022000000000000002,0.015,0.028999999999999998,,,,,True,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Laura Espenhain,Statens Serum Institut,Unity-Aligned,https://dx.doi.org/10.1007/s10654-021-00796-8,2021-08-31,2024-03-01,Verified,espenhain_prevalence_2021-1,DNK
210914_Denmark_OdenseUniversityTestAdj,210914_Denmark_OdenseUniversity,"SARS-CoV-2 seroprevalence among 7,950 health-care workers in the Region of Southern Denmark. (THEIJID-D-21-01420R1).",2021-09-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Region of Southern Denmark,,"""HCWs and administrative staf fin the Region of Southern Denmark (N=30,490 at the present time) were invited to participate on a voluntary basis.""","""Only individuals with both serological and questionnaire data were included in the study.""",2020-05-01,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),18.0,76.0,Primary Estimate,,7950,0.013999999999999999,0.01,0.018000000000000002,True,True,,,,Convenience,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Plasma,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.78,0.993,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Sebastian von Huth,Odense University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.09.023,2021-09-28,2023-08-15,Unverified,huth_sars-cov-2_2021,DNK
210917_DenmarkCapitalRegion_UniversityofCopenhagen_Round1,210917_DenmarkCapitalRegion_UniversityofCopenhagen_Round1,Seroprevalence of SARS-CoV-2 antibodies and reduced risk of reinfection through 6 months: a Danish observational cohort study of 44 000 healthcare workers,2021-09-17,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Denmark,Capital Region of Denmark,,"All staff at somatic, psychiatric, prehospital and specialized healthcare institutions, as well as administrative and technical staff employed in the healthcare organization in the Capital Region of Denmark, were offered screening. Further, doctors and other staff working in the primary healthcare sector, as well as students working in the healthcare system, were invited to participate.",,2020-04-15,2020-05-07,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,37452,0.0401,,,True,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Kasper Iversen,University of Copenhagen,Not Unity-Aligned,http://dx.doi.org/10.1016/j.cmi.2021.09.005,2021-10-20,2024-03-01,Unverified,iversen_seroprevalence_2021,DNK
210917_DenmarkCapitalRegion_UniversityofCopenhagen_Round2,210917_DenmarkCapitalRegion_UniversityofCopenhagen_Round2,Seroprevalence of SARS-CoV-2 antibodies and reduced risk of reinfection through 6 months: a Danish observational cohort study of 44 000 healthcare workers,2021-09-17,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Denmark,Capital Region of Denmark,,"All staff at somatic, psychiatric, prehospital and specialized healthcare institutions, as well as administrative and technical staff employed in the healthcare organization in the Capital Region of Denmark, were offered screening. Further, doctors and other staff working in the primary healthcare sector, as well as students working in the healthcare system, were invited to participate.",,2020-06-02,2020-06-10,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,29862,0.057699999999999994,,,True,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Kasper Iversen,University of Copenhagen,Not Unity-Aligned,http://dx.doi.org/10.1016/j.cmi.2021.09.005,2021-10-20,2024-03-01,Unverified,iversen_seroprevalence_2021,DNK
210917_DenmarkCapitalRegion_UniversityofCopenhagen_Round3_Overall,210917_DenmarkCapitalRegion_UniversityofCopenhagen_Round3,Seroprevalence of SARS-CoV-2 antibodies and reduced risk of reinfection through 6 months: a Danish observational cohort study of 44 000 healthcare workers,2021-09-17,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Denmark,Capital Region of Denmark,,"All staff at somatic, psychiatric, prehospital and specialized healthcare institutions, as well as administrative and technical staff employed in the healthcare organization in the Capital Region of Denmark, were offered screening. Further, doctors and other staff working in the primary healthcare sector, as well as students working in the healthcare system, were invited to participate.",,2020-09-30,2020-10-07,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,27457,0.0736,,,True,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Kasper Iversen,University of Copenhagen,Not Unity-Aligned,http://dx.doi.org/10.1016/j.cmi.2021.09.005,2021-10-20,2024-03-01,Unverified,iversen_seroprevalence_2021,DNK
211112_Denmark_AarhusUniversity_2020Weeks41to44_TestAdjusted,211112_Denmark_AarhusUniversity_2020Weeks41to44,Estimation of SARS-CoV-2 infection fatality rate by age and comorbidity status using antibody screening of blood donors during the COVID-19 epidemic in Denmark.,2021-11-12,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Denmark,,,Blood donors in Denmark,"Convalescent 
plasma donors and donations, and SARS-CoV-2 vaccinated donors were not included. ",2020-10-05,2020-11-01,Blood donors,All,Adults (18-64 years),17.0,69.0,Primary Estimate,Test adjusted,22690,0.020800000000000003,0.0117,0.024700000000000003,True,True,,,,Entire sample,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Kathrine Kaspersen,Aarhus University,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab566,2021-11-21,2023-08-15,Verified,kaspersen_estimation_2021,DNK
211112_Denmark_AarhusUniversity_2020Weeks41to44_Age51-60,211112_Denmark_AarhusUniversity_2020Weeks41to44,Estimation of SARS-CoV-2 infection fatality rate by age and comorbidity status using antibody screening of blood donors during the COVID-19 epidemic in Denmark.,2021-11-12,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Denmark,,,Blood donors in Denmark,"Convalescent 
plasma donors and donations, and SARS-CoV-2 vaccinated donors were not included. ",2020-10-05,2020-11-01,Blood donors,All,Adults (18-64 years),51.0,60.0,Age,51-60,4762,0.0233,,,,,,,,Entire sample,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Kathrine Kaspersen,Aarhus University,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab566,2021-11-21,2024-03-01,Verified,kaspersen_estimation_2021,DNK
211112_Denmark_AarhusUniversity_2020Weeks41to44_Unadjusted,211112_Denmark_AarhusUniversity_2020Weeks41to44,Estimation of SARS-CoV-2 infection fatality rate by age and comorbidity status using antibody screening of blood donors during the COVID-19 epidemic in Denmark.,2021-11-12,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Denmark,,,Blood donors in Denmark,"Convalescent 
plasma donors and donations, and SARS-CoV-2 vaccinated donors were not included. ",2020-10-05,2020-11-01,Blood donors,All,Adults (18-64 years),17.0,69.0,Analysis,Unadjusted,22690,0.0246,,,,,,,True,Entire sample,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Kathrine Kaspersen,Aarhus University,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab566,2021-11-21,2024-03-01,Verified,kaspersen_estimation_2021,DNK
211112_Denmark_AarhusUniversity_2020Weeks41to44_RegionSouthDenmark,211112_Denmark_AarhusUniversity_2020Weeks41to44,Estimation of SARS-CoV-2 infection fatality rate by age and comorbidity status using antibody screening of blood donors during the COVID-19 epidemic in Denmark.,2021-11-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Denmark,South Denmark,,Blood donors in Denmark,"Convalescent 
plasma donors and donations, and SARS-CoV-2 vaccinated donors were not included. ",2020-10-05,2020-11-01,Blood donors,All,Adults (18-64 years),17.0,69.0,Geographical area,South Denmark,4994,0.0178,,,,,,,,Entire sample,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Kathrine Kaspersen,Aarhus University,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab566,2021-11-21,2024-03-01,Verified,kaspersen_estimation_2021,DNK
211112_Denmark_AarhusUniversity_2020Weeks41to44_RegionCapital,211112_Denmark_AarhusUniversity_2020Weeks41to44,Estimation of SARS-CoV-2 infection fatality rate by age and comorbidity status using antibody screening of blood donors during the COVID-19 epidemic in Denmark.,2021-11-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Denmark,Capital Region,,Blood donors in Denmark,"Convalescent 
plasma donors and donations, and SARS-CoV-2 vaccinated donors were not included. ",2020-10-05,2020-11-01,Blood donors,All,Adults (18-64 years),17.0,69.0,Geographical area,Capital Region,6707,0.0429,,,,,,,,Entire sample,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Kathrine Kaspersen,Aarhus University,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab566,2021-11-21,2024-03-01,Verified,kaspersen_estimation_2021,DNK
211112_Denmark_AarhusUniversity_2020Weeks41to44_Age61-69,211112_Denmark_AarhusUniversity_2020Weeks41to44,Estimation of SARS-CoV-2 infection fatality rate by age and comorbidity status using antibody screening of blood donors during the COVID-19 epidemic in Denmark.,2021-11-12,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Denmark,,,Blood donors in Denmark,"Convalescent 
plasma donors and donations, and SARS-CoV-2 vaccinated donors were not included. ",2020-10-05,2020-11-01,Blood donors,All,Adults (18-64 years),61.0,69.0,Age,61-69,2324,0.0138,,,,,,,,Entire sample,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Kathrine Kaspersen,Aarhus University,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab566,2021-11-21,2024-03-01,Verified,kaspersen_estimation_2021,DNK
211112_Denmark_AarhusUniversity_2020Weeks41to44_RegionNorthDenmark,211112_Denmark_AarhusUniversity_2020Weeks41to44,Estimation of SARS-CoV-2 infection fatality rate by age and comorbidity status using antibody screening of blood donors during the COVID-19 epidemic in Denmark.,2021-11-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Denmark,North Denmark,,Blood donors in Denmark,"Convalescent 
plasma donors and donations, and SARS-CoV-2 vaccinated donors were not included. ",2020-10-05,2020-11-01,Blood donors,All,Adults (18-64 years),17.0,69.0,Geographical area,North Denmark,2390,0.0121,,,,,,,,Entire sample,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Kathrine Kaspersen,Aarhus University,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab566,2021-11-21,2024-03-01,Verified,kaspersen_estimation_2021,DNK
211112_Denmark_AarhusUniversity_2020Weeks41to44_RegionCentralDenmark,211112_Denmark_AarhusUniversity_2020Weeks41to44,Estimation of SARS-CoV-2 infection fatality rate by age and comorbidity status using antibody screening of blood donors during the COVID-19 epidemic in Denmark.,2021-11-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Denmark,Central Denmark,,Blood donors in Denmark,"Convalescent 
plasma donors and donations, and SARS-CoV-2 vaccinated donors were not included. ",2020-10-05,2020-11-01,Blood donors,All,Adults (18-64 years),17.0,69.0,Geographical area,Central Denmark,5354,0.018500000000000003,,,,,,,,Entire sample,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Kathrine Kaspersen,Aarhus University,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab566,2021-11-21,2024-03-01,Verified,kaspersen_estimation_2021,DNK
211112_Denmark_AarhusUniversity_2020Weeks41to44_Age17-35,211112_Denmark_AarhusUniversity_2020Weeks41to44,Estimation of SARS-CoV-2 infection fatality rate by age and comorbidity status using antibody screening of blood donors during the COVID-19 epidemic in Denmark.,2021-11-12,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Denmark,,,Blood donors in Denmark,"Convalescent 
plasma donors and donations, and SARS-CoV-2 vaccinated donors were not included. ",2020-10-05,2020-11-01,Blood donors,All,Adults (18-64 years),17.0,35.0,Age,17-35,8472,0.0301,,,,,,,,Entire sample,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Kathrine Kaspersen,Aarhus University,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab566,2021-11-21,2024-03-01,Verified,kaspersen_estimation_2021,DNK
211112_Denmark_AarhusUniversity_2020Weeks41to44_Age36-50,211112_Denmark_AarhusUniversity_2020Weeks41to44,Estimation of SARS-CoV-2 infection fatality rate by age and comorbidity status using antibody screening of blood donors during the COVID-19 epidemic in Denmark.,2021-11-12,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Denmark,,,Blood donors in Denmark,"Convalescent 
plasma donors and donations, and SARS-CoV-2 vaccinated donors were not included. ",2020-10-05,2020-11-01,Blood donors,All,Adults (18-64 years),36.0,50.0,Age,36-50,7132,0.0226,,,,,,,,Entire sample,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Kathrine Kaspersen,Aarhus University,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab566,2021-11-21,2024-03-01,Verified,kaspersen_estimation_2021,DNK
211112_Denmark_AarhusUniversity_2020Weeks41to44_RegionZealand,211112_Denmark_AarhusUniversity_2020Weeks41to44,Estimation of SARS-CoV-2 infection fatality rate by age and comorbidity status using antibody screening of blood donors during the COVID-19 epidemic in Denmark.,2021-11-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Denmark,Zealand,,Blood donors in Denmark,"Convalescent 
plasma donors and donations, and SARS-CoV-2 vaccinated donors were not included. ",2020-10-05,2020-11-01,Blood donors,All,Adults (18-64 years),17.0,69.0,Geographical area,Zealand,3245,0.0166,,,,,,,,Entire sample,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Kathrine Kaspersen,Aarhus University,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab566,2021-11-21,2024-03-01,Verified,kaspersen_estimation_2021,DNK
211112_Denmark_AarhusUniversity_2021Weeks5to8_Unadjusted,211112_Denmark_AarhusUniversity_2021Weeks5to8,Estimation of SARS-CoV-2 infection fatality rate by age and comorbidity status using antibody screening of blood donors during the COVID-19 epidemic in Denmark.,2021-11-12,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Denmark,,,Blood donors in Denmark,"Convalescent 
plasma donors and donations, and SARS-CoV-2 vaccinated donors were not included. ",2021-02-01,2021-02-28,Blood donors,All,Adults (18-64 years),17.0,69.0,Analysis,Unadjusted,20398,0.07400000000000001,,,True,,,,,Entire sample,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Kathrine Kaspersen,Aarhus University,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab566,2021-11-21,2024-03-01,Verified,kaspersen_estimation_2021,DNK
211112_Denmark_AarhusUniversity_2021Weeks5to8_Age61-69,211112_Denmark_AarhusUniversity_2021Weeks5to8,Estimation of SARS-CoV-2 infection fatality rate by age and comorbidity status using antibody screening of blood donors during the COVID-19 epidemic in Denmark.,2021-11-12,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Denmark,,,Blood donors in Denmark,"Convalescent 
plasma donors and donations, and SARS-CoV-2 vaccinated donors were not included. ",2021-02-01,2021-02-28,Blood donors,All,Adults (18-64 years),61.0,69.0,Age,61-69,2078,0.045700000000000005,,,,,,,,Entire sample,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Kathrine Kaspersen,Aarhus University,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab566,2021-11-21,2024-03-01,Verified,kaspersen_estimation_2021,DNK
211112_Denmark_AarhusUniversity_2021Weeks5to8_RegionSouthDenmark,211112_Denmark_AarhusUniversity_2021Weeks5to8,Estimation of SARS-CoV-2 infection fatality rate by age and comorbidity status using antibody screening of blood donors during the COVID-19 epidemic in Denmark.,2021-11-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Denmark,South Denmark,,Blood donors in Denmark,"Convalescent 
plasma donors and donations, and SARS-CoV-2 vaccinated donors were not included. ",2021-02-01,2021-02-28,Blood donors,All,Adults (18-64 years),17.0,69.0,Geographical area,South Denmark,3986,0.0404,,,,,,,,Entire sample,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Kathrine Kaspersen,Aarhus University,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab566,2021-11-21,2024-03-01,Verified,kaspersen_estimation_2021,DNK
211112_Denmark_AarhusUniversity_2021Weeks5to8_TestAdjusted,211112_Denmark_AarhusUniversity_2021Weeks5to8,Estimation of SARS-CoV-2 infection fatality rate by age and comorbidity status using antibody screening of blood donors during the COVID-19 epidemic in Denmark.,2021-11-12,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Denmark,,,Blood donors in Denmark,"Convalescent 
plasma donors and donations, and SARS-CoV-2 vaccinated donors were not included. ",2021-02-01,2021-02-28,Blood donors,All,Adults (18-64 years),17.0,69.0,Primary Estimate,Test adjusted,20398,0.0721,0.063,0.07780000000000001,,True,,,,Entire sample,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Kathrine Kaspersen,Aarhus University,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab566,2021-11-21,2023-08-15,Verified,kaspersen_estimation_2021,DNK
211112_Denmark_AarhusUniversity_2021Weeks5to8_Age17-35,211112_Denmark_AarhusUniversity_2021Weeks5to8,Estimation of SARS-CoV-2 infection fatality rate by age and comorbidity status using antibody screening of blood donors during the COVID-19 epidemic in Denmark.,2021-11-12,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Denmark,,,Blood donors in Denmark,"Convalescent 
plasma donors and donations, and SARS-CoV-2 vaccinated donors were not included. ",2021-02-01,2021-02-28,Blood donors,All,Adults (18-64 years),17.0,35.0,Age,17-35,7801,0.0942,,,,,,,,Entire sample,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Kathrine Kaspersen,Aarhus University,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab566,2021-11-21,2024-03-01,Verified,kaspersen_estimation_2021,DNK
211112_Denmark_AarhusUniversity_2021Weeks5to8_Age51-60,211112_Denmark_AarhusUniversity_2021Weeks5to8,Estimation of SARS-CoV-2 infection fatality rate by age and comorbidity status using antibody screening of blood donors during the COVID-19 epidemic in Denmark.,2021-11-12,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Denmark,,,Blood donors in Denmark,"Convalescent 
plasma donors and donations, and SARS-CoV-2 vaccinated donors were not included. ",2021-02-01,2021-02-28,Blood donors,All,Adults (18-64 years),51.0,60.0,Age,51-60,4251,0.0605,,,,,,,,Entire sample,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Kathrine Kaspersen,Aarhus University,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab566,2021-11-21,2024-03-01,Verified,kaspersen_estimation_2021,DNK
211112_Denmark_AarhusUniversity_2021Weeks5to8_Age36-50,211112_Denmark_AarhusUniversity_2021Weeks5to8,Estimation of SARS-CoV-2 infection fatality rate by age and comorbidity status using antibody screening of blood donors during the COVID-19 epidemic in Denmark.,2021-11-12,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Denmark,,,Blood donors in Denmark,"Convalescent 
plasma donors and donations, and SARS-CoV-2 vaccinated donors were not included. ",2021-02-01,2021-02-28,Blood donors,All,Adults (18-64 years),36.0,50.0,Age,36-50,6268,0.06730000000000001,,,,,,,,Entire sample,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Kathrine Kaspersen,Aarhus University,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab566,2021-11-21,2024-03-01,Verified,kaspersen_estimation_2021,DNK
211112_Denmark_AarhusUniversity_2021Weeks5to8_RegionZealand,211112_Denmark_AarhusUniversity_2021Weeks5to8,Estimation of SARS-CoV-2 infection fatality rate by age and comorbidity status using antibody screening of blood donors during the COVID-19 epidemic in Denmark.,2021-11-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Denmark,Zealand,,Blood donors in Denmark,"Convalescent 
plasma donors and donations, and SARS-CoV-2 vaccinated donors were not included. ",2021-02-01,2021-02-28,Blood donors,All,Adults (18-64 years),17.0,69.0,Geographical area,Zealand,2966,0.0698,,,,,,,,Entire sample,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Kathrine Kaspersen,Aarhus University,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab566,2021-11-21,2024-03-01,Verified,kaspersen_estimation_2021,DNK
211112_Denmark_AarhusUniversity_2021Weeks5to8_RegionCentralDenmark,211112_Denmark_AarhusUniversity_2021Weeks5to8,Estimation of SARS-CoV-2 infection fatality rate by age and comorbidity status using antibody screening of blood donors during the COVID-19 epidemic in Denmark.,2021-11-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Denmark,Central Denmark,,Blood donors in Denmark,"Convalescent 
plasma donors and donations, and SARS-CoV-2 vaccinated donors were not included. ",2021-02-01,2021-02-28,Blood donors,All,Adults (18-64 years),17.0,69.0,Geographical area,Central Denmark,5236,0.0605,,,,,,,,Entire sample,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Kathrine Kaspersen,Aarhus University,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab566,2021-11-21,2024-03-01,Verified,kaspersen_estimation_2021,DNK
211112_Denmark_AarhusUniversity_2021Weeks5to8_RegionCapital,211112_Denmark_AarhusUniversity_2021Weeks5to8,Estimation of SARS-CoV-2 infection fatality rate by age and comorbidity status using antibody screening of blood donors during the COVID-19 epidemic in Denmark.,2021-11-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Denmark,Capital Region,,Blood donors in Denmark,"Convalescent 
plasma donors and donations, and SARS-CoV-2 vaccinated donors were not included. ",2021-02-01,2021-02-28,Blood donors,All,Adults (18-64 years),17.0,69.0,Geographical area,Capital Region,6101,0.11570000000000001,,,,,,,True,Entire sample,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Kathrine Kaspersen,Aarhus University,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab566,2021-11-21,2024-03-01,Verified,kaspersen_estimation_2021,DNK
211112_Denmark_AarhusUniversity_2021Weeks5to8_RegionNorthDenmark,211112_Denmark_AarhusUniversity_2021Weeks5to8,Estimation of SARS-CoV-2 infection fatality rate by age and comorbidity status using antibody screening of blood donors during the COVID-19 epidemic in Denmark.,2021-11-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Denmark,North Denmark,,Blood donors in Denmark,"Convalescent 
plasma donors and donations, and SARS-CoV-2 vaccinated donors were not included. ",2021-02-01,2021-02-28,Blood donors,All,Adults (18-64 years),17.0,69.0,Geographical area,North Denmark,2109,0.055999999999999994,,,,,,,,Entire sample,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Kathrine Kaspersen,Aarhus University,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab566,2021-11-21,2024-03-01,Verified,kaspersen_estimation_2021,DNK
220301_CapitalRegionofDenmark_UniversityofCopenhagen_BloodDonors_Overall_TestAdj,220301_CapitalRegionofDenmark_UniversityofCopenhagen_BloodDonors,SARS-CoV-2 seroprevalence among patients with severe mental illness: A cross-sectional study.,2022-03-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Capital Region of Denmark,,unvaccinated blood donors in the Capital Region of Denmark,,2021-01-18,2021-02-19,Blood donors,All,Adults (18-64 years),,,Primary Estimate,,6088,0.12240000000000001,0.11410000000000001,0.1311,True,True,,,,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.9450000000000001,1.0,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Marie Reeberg Sass,University of Copenhagen,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0264325,2022-03-07,2023-08-15,Unverified,sass_sars-cov-2_2022,DNK
220301_CapitalRegionofDenmark_UniversityofCopenhagen_BloodDonors_Female,220301_CapitalRegionofDenmark_UniversityofCopenhagen_BloodDonors,SARS-CoV-2 seroprevalence among patients with severe mental illness: A cross-sectional study.,2022-03-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Capital Region of Denmark,,unvaccinated blood donors in the Capital Region of Denmark,,2021-01-18,2021-02-19,Blood donors,Female,Adults (18-64 years),,,Sex/Gender,,3044,0.1302,0.1184,0.1431,,True,,,,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.9450000000000001,1.0,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Marie Reeberg Sass,University of Copenhagen,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0264325,2022-03-07,2023-08-15,Unverified,sass_sars-cov-2_2022,DNK
220301_CapitalRegionofDenmark_UniversityofCopenhagen_BloodDonors_Male,220301_CapitalRegionofDenmark_UniversityofCopenhagen_BloodDonors,SARS-CoV-2 seroprevalence among patients with severe mental illness: A cross-sectional study.,2022-03-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Capital Region of Denmark,,unvaccinated blood donors in the Capital Region of Denmark,,2021-01-18,2021-02-19,Blood donors,Male,Adults (18-64 years),,,Sex/Gender,,3044,0.11449999999999999,0.1033,0.1267,,True,,,,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.9450000000000001,1.0,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Marie Reeberg Sass,University of Copenhagen,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0264325,2022-03-07,2023-08-15,Unverified,sass_sars-cov-2_2022,DNK
220301_CapitalRegionofDenmark_UniversityofCopenhagen_BloodDonors_Overall_Unadj,220301_CapitalRegionofDenmark_UniversityofCopenhagen_BloodDonors,SARS-CoV-2 seroprevalence among patients with severe mental illness: A cross-sectional study.,2022-03-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Capital Region of Denmark,,unvaccinated blood donors in the Capital Region of Denmark,,2021-01-18,2021-02-19,Blood donors,All,Adults (18-64 years),,,Analysis,,6088,0.11560000000000001,,,,,,,True,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.9450000000000001,1.0,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Marie Reeberg Sass,University of Copenhagen,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0264325,2022-03-07,2024-03-01,Unverified,sass_sars-cov-2_2022,DNK
220301_CapitalRegionofDenmark_UniversityofCopenhagen_SMIPatients_Overall_TestAdj,220301_CapitalRegionofDenmark_UniversityofCopenhagen_SMIPatients,SARS-CoV-2 seroprevalence among patients with severe mental illness: A cross-sectional study.,2022-03-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Denmark,Capital Region of Denmark,,"Eligible patients were adults aged 18 or above, diagnosed with SMI i.e. schizophrenia, schizoaffective disorder, or bipolar affective disorder according to the criteria of the International Classification of Diseases, World Health Organization (WHO), and treated in the Capital Region of Denmark (one of 7 psychiatric centres).","Patients who were found too vulnerable for participation by their treating psychiatrists were excluded.
Inconclusive test results and results from study participants and blood donors who had received at least one dose of any vaccine against SARS-CoV-2 were excluded from the statistical analysis.",2021-01-18,2021-02-19,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,1258,0.0496,0.038700000000000005,,True,True,,,,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.9450000000000001,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Marie Reeberg Sass,University of Copenhagen,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0264325,2022-03-07,2023-08-15,Unverified,sass_sars-cov-2_2022,DNK
220407_Denmark_UniversityOfCopenhagen,220407_Denmark_UniversityOfCopenhagen,Prevalence and duration of anti-SARS-CoV-2 antibodies in healthcare workers,2022-04-07,Journal Article (Peer-Reviewed),National,Prospective cohort,Denmark,,,"Healthcare workers at Nordsjællands Hospital and Nykøbing Falster Sygehus, in Denmark",,2020-03-30,2020-06-29,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,379,0.053,,,True,,,,True,Sequential,"Author designed (ELISA) -Spike,Author designed (Neutralization Assay)",,Multiple Types,Serum,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],,No,No,Yes,,Unclear,No,No,,Caroline Klint Johannesen,University of Copenhagen,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/35485785/,2022-05-10,2022-07-16,Unverified,johannesen_prevalence_2022,DNK
220627_Denmark_CopenhagenUniversityHospital_BloodDonors_Adj,220627_Denmark_CopenhagenUniversityHospital_BloodDonors,SARS-CoV-2 antibody prevalence among homeless people and shelter workers in Denmark: a nationwide cross-sectional study.,2022-06-27,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Denmark,,,All Danish blood donors,,2020-11-01,2020-11-22,Blood donors,All,Multiple groups,17.0,69.0,Primary Estimate,,18505,0.025,0.0226,0.0276,True,True,,,,Entire sample,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,,"['IgG', 'IgM']",,Validated by manufacturers,0.9670000000000001,0.995,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Alexandra Eriksen,Copenhagen University Hospital,Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13642-7,2022-07-12,2023-08-15,Unverified,eriksen_sars-cov-2_2022,DNK
220627_Denmark_CopenhagenUniversityHospital_BloodDonors_UnAdj,220627_Denmark_CopenhagenUniversityHospital_BloodDonors,SARS-CoV-2 antibody prevalence among homeless people and shelter workers in Denmark: a nationwide cross-sectional study.,2022-06-27,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Denmark,,,All Danish blood donors,,2020-11-01,2020-11-22,Blood donors,All,Multiple groups,17.0,69.0,Analysis,,18505,0.028999999999999998,,,,True,,,True,Entire sample,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,,"['IgG', 'IgM']",,Validated by manufacturers,0.9670000000000001,0.995,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Alexandra Eriksen,Copenhagen University Hospital,Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13642-7,2022-07-29,2023-08-15,Unverified,eriksen_sars-cov-2_2022,DNK
220627_Denmark_CopenhagenUniversityHospital_Overall,220627_Denmark_CopenhagenUniversityHospital_PeopleExperiencingHomelessnessandShelterWorkers,SARS-CoV-2 antibody prevalence among homeless people and shelter workers in Denmark: a nationwide cross-sectional study.,2022-06-27,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Denmark,,,PEH (people experiencing homelessness) and shelter workers from 21 assessed sites all over Denmark,,2020-11-02,2020-11-20,Multiple populations,All,Multiple groups,,,Primary Estimate,,819,0.067,,,True,,,,True,Convenience,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9686,0.9939,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Alexandra Eriksen,Copenhagen University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13642-7,2022-07-12,2024-03-01,Unverified,eriksen_sars-cov-2_2022,DNK
220805_Denmark_AarhusUniversityHospital_NovemberBaseline_Primary,220805_Denmark_AarhusUniversityHospital_NovemberBaseline,Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in Denmark: A nationwide serosurveillance study,2022-08-05,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Denmark,"Capital Region of Denmark, Region Zealand, Region of Southern Denmark, Central Denmark Region, North Denmark Region",,"""blood samples from blood donors from each of the five administrative regions in Denmark""","""All data sets were restricted to people aged 17−72 years""",2021-10-26,2021-11-30,Blood donors,All,Multiple groups,17.0,72.0,Primary Estimate,,8701,0.012,0.01,0.015,True,True,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Christian Erikstrup,University of Copenhagen,Unity-Aligned,10.1016/j.lanepe.2022.100479,2022-10-16,2024-04-16,Verified,erikstrup_seroprevalence_2022,DNK
220805_Denmark_AarhusUniversityHospital_NovemberBaseline_61-72,220805_Denmark_AarhusUniversityHospital_NovemberBaseline,Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in Denmark: A nationwide serosurveillance study,2022-08-05,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Denmark,"Capital Region of Denmark, Region Zealand, Region of Southern Denmark, Central Denmark Region, North Denmark Region",,"""blood samples from blood donors from each of the five administrative regions in Denmark""","""All data sets were restricted to people aged 17−72 years""",2021-10-26,2021-11-30,Blood donors,All,Seniors (65+ years),61.0,72.0,Age,61-72,1121,0.01,0.005,0.018000000000000002,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Christian Erikstrup,University of Copenhagen,Unity-Aligned,10.1016/j.lanepe.2022.100479,2022-10-16,2024-04-16,Verified,erikstrup_seroprevalence_2022,DNK
220805_Denmark_AarhusUniversityHospital_NovemberBaseline_17-35,220805_Denmark_AarhusUniversityHospital_NovemberBaseline,Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in Denmark: A nationwide serosurveillance study,2022-08-05,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Denmark,"Capital Region of Denmark, Region Zealand, Region of Southern Denmark, Central Denmark Region, North Denmark Region",,"""blood samples from blood donors from each of the five administrative regions in Denmark""","""All data sets were restricted to people aged 17−72 years""",2021-10-26,2021-11-30,Blood donors,All,Adults (18-64 years),17.0,35.0,Age,17-35,2767,0.013999999999999999,0.01,0.019,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Christian Erikstrup,University of Copenhagen,Unity-Aligned,10.1016/j.lanepe.2022.100479,2022-10-16,2024-04-16,Verified,erikstrup_seroprevalence_2022,DNK
220805_Denmark_AarhusUniversityHospital_NovemberBaseline_Males,220805_Denmark_AarhusUniversityHospital_NovemberBaseline,Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in Denmark: A nationwide serosurveillance study,2022-08-05,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Denmark,"Capital Region of Denmark, Region Zealand, Region of Southern Denmark, Central Denmark Region, North Denmark Region",,"""blood samples from blood donors from each of the five administrative regions in Denmark""","""All data sets were restricted to people aged 17−72 years""",2021-10-26,2021-11-30,Blood donors,Male,Multiple groups,17.0,72.0,Sex/Gender,Male,4812,0.011000000000000001,0.008,0.013999999999999999,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Christian Erikstrup,University of Copenhagen,Unity-Aligned,10.1016/j.lanepe.2022.100479,2022-10-16,2024-04-16,Verified,erikstrup_seroprevalence_2022,DNK
220805_Denmark_AarhusUniversityHospital_NovemberBaseline_NorthDenmarkRegion,220805_Denmark_AarhusUniversityHospital_NovemberBaseline,Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in Denmark: A nationwide serosurveillance study,2022-08-05,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Denmark,Central Denmark Region,,"""blood samples from blood donors from each of the five administrative regions in Denmark""","""All data sets were restricted to people aged 17−72 years""",2021-10-26,2021-11-30,Blood donors,All,Multiple groups,61.0,72.0,Geographical area,North Denmark Region,1142,0.02,0.013000000000000001,0.03,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Christian Erikstrup,University of Copenhagen,Unity-Aligned,10.1016/j.lanepe.2022.100479,2022-10-16,2024-04-16,Verified,erikstrup_seroprevalence_2022,DNK
220805_Denmark_AarhusUniversityHospital_NovemberBaseline_CentralDenmarkRegion,220805_Denmark_AarhusUniversityHospital_NovemberBaseline,Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in Denmark: A nationwide serosurveillance study,2022-08-05,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Denmark,Central Denmark Region,,"""blood samples from blood donors from each of the five administrative regions in Denmark""","""All data sets were restricted to people aged 17−72 years""",2021-10-26,2021-11-30,Blood donors,All,Multiple groups,61.0,72.0,Geographical area,Central Denmark Region,1532,0.01,0.006,0.016,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Christian Erikstrup,University of Copenhagen,Unity-Aligned,10.1016/j.lanepe.2022.100479,2022-10-16,2024-04-16,Verified,erikstrup_seroprevalence_2022,DNK
220805_Denmark_AarhusUniversityHospital_NovemberBaseline_CapitalRegion,220805_Denmark_AarhusUniversityHospital_NovemberBaseline,Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in Denmark: A nationwide serosurveillance study,2022-08-05,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Denmark,Capital Region of Denmark,,"""blood samples from blood donors from each of the five administrative regions in Denmark""","""All data sets were restricted to people aged 17−72 years""",2021-10-26,2021-11-30,Blood donors,All,Multiple groups,61.0,72.0,Geographical area,Capital region,1795,0.017,0.012,0.025,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Christian Erikstrup,University of Copenhagen,Unity-Aligned,10.1016/j.lanepe.2022.100479,2022-10-16,2024-04-16,Verified,erikstrup_seroprevalence_2022,DNK
220805_Denmark_AarhusUniversityHospital_NovemberBaseline_Unadjusted,220805_Denmark_AarhusUniversityHospital_NovemberBaseline,Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in Denmark: A nationwide serosurveillance study,2022-08-05,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Denmark,"Capital Region of Denmark, Region Zealand, Region of Southern Denmark, Central Denmark Region, North Denmark Region",,"""blood samples from blood donors from each of the five administrative regions in Denmark""","""All data sets were restricted to people aged 17−72 years""",2021-10-26,2021-11-30,Blood donors,All,Multiple groups,17.0,72.0,Analysis,Unadjusted,8701,0.012,0.01,0.013999999999999999,,,,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Christian Erikstrup,University of Copenhagen,Unity-Aligned,10.1016/j.lanepe.2022.100479,2022-10-16,2024-04-16,Verified,erikstrup_seroprevalence_2022,DNK
220805_Denmark_AarhusUniversityHospital_NovemberBaseline_RegionofSouthernDenmark,220805_Denmark_AarhusUniversityHospital_NovemberBaseline,Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in Denmark: A nationwide serosurveillance study,2022-08-05,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Denmark,Region of Southern Denmark,,"""blood samples from blood donors from each of the five administrative regions in Denmark""","""All data sets were restricted to people aged 17−72 years""",2021-10-26,2021-11-30,Blood donors,All,Multiple groups,61.0,72.0,Geographical area,Region of Southern Denmark,2686,0.01,0.006999999999999999,0.013999999999999999,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Christian Erikstrup,University of Copenhagen,Unity-Aligned,10.1016/j.lanepe.2022.100479,2022-10-16,2024-04-16,Verified,erikstrup_seroprevalence_2022,DNK
220805_Denmark_AarhusUniversityHospital_NovemberBaseline_RegionZealand,220805_Denmark_AarhusUniversityHospital_NovemberBaseline,Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in Denmark: A nationwide serosurveillance study,2022-08-05,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Denmark,Region Zealand,,"""blood samples from blood donors from each of the five administrative regions in Denmark""","""All data sets were restricted to people aged 17−72 years""",2021-10-26,2021-11-30,Blood donors,All,Multiple groups,61.0,72.0,Geographical area,Region Zealand,1546,0.005,0.003,0.01,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Christian Erikstrup,University of Copenhagen,Unity-Aligned,10.1016/j.lanepe.2022.100479,2022-10-16,2024-04-16,Verified,erikstrup_seroprevalence_2022,DNK
220805_Denmark_AarhusUniversityHospital_NovemberBaseline_Females,220805_Denmark_AarhusUniversityHospital_NovemberBaseline,Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in Denmark: A nationwide serosurveillance study,2022-08-05,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Denmark,"Capital Region of Denmark, Region Zealand, Region of Southern Denmark, Central Denmark Region, North Denmark Region",,"""blood samples from blood donors from each of the five administrative regions in Denmark""","""All data sets were restricted to people aged 17−72 years""",2021-10-26,2021-11-30,Blood donors,Female,Multiple groups,17.0,72.0,Sex/Gender,Female,3889,0.013000000000000001,0.01,0.017,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Christian Erikstrup,University of Copenhagen,Unity-Aligned,10.1016/j.lanepe.2022.100479,2022-10-16,2024-04-16,Verified,erikstrup_seroprevalence_2022,DNK
220805_Denmark_AarhusUniversityHospital_NovemberBaseline_36-50,220805_Denmark_AarhusUniversityHospital_NovemberBaseline,Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in Denmark: A nationwide serosurveillance study,2022-08-05,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Denmark,"Capital Region of Denmark, Region Zealand, Region of Southern Denmark, Central Denmark Region, North Denmark Region",,"""blood samples from blood donors from each of the five administrative regions in Denmark""","""All data sets were restricted to people aged 17−72 years""",2021-10-26,2021-11-30,Blood donors,All,Adults (18-64 years),36.0,50.0,Age,36-50,2719,0.009000000000000001,0.006,0.013999999999999999,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Christian Erikstrup,University of Copenhagen,Unity-Aligned,10.1016/j.lanepe.2022.100479,2022-10-16,2024-04-16,Verified,erikstrup_seroprevalence_2022,DNK
220805_Denmark_AarhusUniversityHospital_NovemberBaseline_51-60,220805_Denmark_AarhusUniversityHospital_NovemberBaseline,Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in Denmark: A nationwide serosurveillance study,2022-08-05,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Denmark,"Capital Region of Denmark, Region Zealand, Region of Southern Denmark, Central Denmark Region, North Denmark Region",,"""blood samples from blood donors from each of the five administrative regions in Denmark""","""All data sets were restricted to people aged 17−72 years""",2021-10-26,2021-11-30,Blood donors,All,Adults (18-64 years),51.0,60.0,Age,51-60,2094,0.013000000000000001,0.009000000000000001,0.019,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Christian Erikstrup,University of Copenhagen,Unity-Aligned,10.1016/j.lanepe.2022.100479,2022-10-16,2024-04-16,Verified,erikstrup_seroprevalence_2022,DNK
220805_Denmark_AarhusUniversityHospital_Week11_Primary,220805_Denmark_AarhusUniversityHospital_Week11,Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in Denmark: A nationwide serosurveillance study,2022-08-05,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Denmark,"Capital Region of Denmark, Region Zealand, Region of Southern Denmark, Central Denmark Region, North Denmark Region",,"""blood samples from blood donors from each of the five administrative regions in Denmark""","""All data sets were restricted to people aged 17−72 years""",2022-03-15,2022-03-21,Blood donors,All,Multiple groups,17.0,72.0,Primary Estimate,,6132,0.5,0.49,0.52,True,,,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Christian Erikstrup,University of Copenhagen,Unity-Aligned,10.1016/j.lanepe.2022.100479,2022-10-16,2024-04-16,Verified,erikstrup_seroprevalence_2022,DNK
220805_Denmark_AarhusUniversityHospital_Week13_Primary,220805_Denmark_AarhusUniversityHospital_Week13,Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in Denmark: A nationwide serosurveillance study,2022-08-05,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Denmark,"Capital Region of Denmark, Region Zealand, Region of Southern Denmark, Central Denmark Region, North Denmark Region",,"""blood samples from blood donors from each of the five administrative regions in Denmark""","""All data sets were restricted to people aged 17−72 years""",2022-03-29,2022-04-03,Blood donors,All,Multiple groups,17.0,72.0,Primary Estimate,,6604,0.51,0.49,0.53,True,,,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Christian Erikstrup,University of Copenhagen,Unity-Aligned,10.1016/j.lanepe.2022.100479,2022-10-16,2024-04-16,Verified,erikstrup_seroprevalence_2022,DNK
220805_Denmark_AarhusUniversityHospital_Week3_Primary,220805_Denmark_AarhusUniversityHospital_Week3,Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in Denmark: A nationwide serosurveillance study,2022-08-05,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Denmark,"Capital Region of Denmark, Region Zealand, Region of Southern Denmark, Central Denmark Region, North Denmark Region",,"""blood samples from blood donors from each of the five administrative regions in Denmark""","""All data sets were restricted to people aged 17−72 years""",2022-01-18,2022-01-24,Blood donors,All,Multiple groups,17.0,72.0,Primary Estimate,,4722,0.12,0.11,0.13,True,,,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Christian Erikstrup,University of Copenhagen,Unity-Aligned,10.1016/j.lanepe.2022.100479,2022-10-16,2024-04-16,Verified,erikstrup_seroprevalence_2022,DNK
220805_Denmark_AarhusUniversityHospital_Week5_Primary,220805_Denmark_AarhusUniversityHospital_Week5,Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in Denmark: A nationwide serosurveillance study,2022-08-05,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Denmark,"Capital Region of Denmark, Region Zealand, Region of Southern Denmark, Central Denmark Region, North Denmark Region",,"""blood samples from blood donors from each of the five administrative regions in Denmark""","""All data sets were restricted to people aged 17−72 years""",2022-02-01,2022-02-07,Blood donors,All,Multiple groups,17.0,72.0,Primary Estimate,,5847,0.18,0.17,0.19,True,,,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Christian Erikstrup,University of Copenhagen,Unity-Aligned,10.1016/j.lanepe.2022.100479,2022-10-16,2024-04-16,Verified,erikstrup_seroprevalence_2022,DNK
220805_Denmark_AarhusUniversityHospital_Week7_Primary,220805_Denmark_AarhusUniversityHospital_Week7,Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in Denmark: A nationwide serosurveillance study,2022-08-05,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Denmark,"Capital Region of Denmark, Region Zealand, Region of Southern Denmark, Central Denmark Region, North Denmark Region",,"""blood samples from blood donors from each of the five administrative regions in Denmark""","""All data sets were restricted to people aged 17−72 years""",2022-02-15,2022-02-21,Blood donors,All,Multiple groups,17.0,72.0,Primary Estimate,,5310,0.31,0.29,0.32,True,,,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Christian Erikstrup,University of Copenhagen,Unity-Aligned,10.1016/j.lanepe.2022.100479,2022-10-16,2024-04-16,Verified,erikstrup_seroprevalence_2022,DNK
220805_Denmark_AarhusUniversityHospital_Week9_Primary,220805_Denmark_AarhusUniversityHospital_Week9,Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in Denmark: A nationwide serosurveillance study,2022-08-05,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Denmark,"Capital Region of Denmark, Region Zealand, Region of Southern Denmark, Central Denmark Region, North Denmark Region",,"""blood samples from blood donors from each of the five administrative regions in Denmark""","""All data sets were restricted to people aged 17−72 years""",2022-03-01,2022-03-07,Blood donors,All,Multiple groups,17.0,72.0,Primary Estimate,,5771,0.46,0.44,0.48,True,,,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Christian Erikstrup,University of Copenhagen,Unity-Aligned,10.1016/j.lanepe.2022.100479,2022-10-16,2024-04-16,Verified,erikstrup_seroprevalence_2022,DNK
221109_Denmark_CopenhagenUniversityHospital_Overall,221109_Denmark_CopenhagenUniversityHospital,Self-Reported Long COVID and Its Association with the Presence of SARS-CoV-2 Antibodies in a Danish Cohort up to 12 Months after Infection.,2022-11-09,Journal Article (Peer-Reviewed),National,Retrospective cohort,Denmark,,,"all 8,000 members of the social media group Facebook “Covidramte med senfølger” (“long COVID sufferers'') above the age of 17 years and living in Denmark were invited to participate in a short electronic questionnaire about long COVID,",,2020-02-10,2021-03-11,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,341,0.6803519062,,,True,,,,True,Self-referral,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,,0.998,['High'],,No,No,Yes,,Yes,Yes,Yes,,Kamille Fogh,Copenhagen University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1128/spectrum.02537-22,2022-11-17,2024-03-01,Unverified,fogh_self-reported_2022,DNK
221109_Denmark_CopenhagenUniversityHospital_Male,221109_Denmark_CopenhagenUniversityHospital,Self-Reported Long COVID and Its Association with the Presence of SARS-CoV-2 Antibodies in a Danish Cohort up to 12 Months after Infection.,2022-11-09,Journal Article (Peer-Reviewed),National,Retrospective cohort,Denmark,,,"all 8,000 members of the social media group Facebook “Covidramte med senfølger” (“long COVID sufferers'') above the age of 17 years and living in Denmark were invited to participate in a short electronic questionnaire about long COVID,",,2020-02-10,2021-03-11,Blood donors,Male,Multiple groups,17.0,,Sex/Gender,,309,0.6763754045,,,,,,,,Self-referral,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,,0.998,['High'],,No,No,Yes,,Yes,Yes,Yes,,Kamille Fogh,Copenhagen University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1128/spectrum.02537-22,2022-11-17,2024-03-01,Unverified,fogh_self-reported_2022,DNK
221109_Denmark_CopenhagenUniversityHospital_NotVaccinated,221109_Denmark_CopenhagenUniversityHospital,Self-Reported Long COVID and Its Association with the Presence of SARS-CoV-2 Antibodies in a Danish Cohort up to 12 Months after Infection.,2022-11-09,Journal Article (Peer-Reviewed),National,Retrospective cohort,Denmark,,,"all 8,000 members of the social media group Facebook “Covidramte med senfølger” (“long COVID sufferers'') above the age of 17 years and living in Denmark were invited to participate in a short electronic questionnaire about long COVID,",,2020-02-10,2021-03-11,Blood donors,All,Multiple groups,17.0,,COVID-19 vaccination status,,315,0.673015873,,,,,,,,Self-referral,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,,0.998,['High'],,No,No,Yes,,Yes,Yes,Yes,,Kamille Fogh,Copenhagen University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1128/spectrum.02537-22,2022-11-17,2024-03-01,Unverified,fogh_self-reported_2022,DNK
221109_Denmark_CopenhagenUniversityHospital_Female,221109_Denmark_CopenhagenUniversityHospital,Self-Reported Long COVID and Its Association with the Presence of SARS-CoV-2 Antibodies in a Danish Cohort up to 12 Months after Infection.,2022-11-09,Journal Article (Peer-Reviewed),National,Retrospective cohort,Denmark,,,"all 8,000 members of the social media group Facebook “Covidramte med senfølger” (“long COVID sufferers'') above the age of 17 years and living in Denmark were invited to participate in a short electronic questionnaire about long COVID,",,2020-02-10,2021-03-11,Blood donors,Female,Multiple groups,17.0,,Sex/Gender,,32,0.71875,,,,,,,,Self-referral,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,,0.998,['High'],,No,No,Yes,,Yes,Yes,Yes,,Kamille Fogh,Copenhagen University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1128/spectrum.02537-22,2022-11-17,2024-03-01,Unverified,fogh_self-reported_2022,DNK
221109_Denmark_CopenhagenUniversityHospital_Vaccinated,221109_Denmark_CopenhagenUniversityHospital,Self-Reported Long COVID and Its Association with the Presence of SARS-CoV-2 Antibodies in a Danish Cohort up to 12 Months after Infection.,2022-11-09,Journal Article (Peer-Reviewed),National,Retrospective cohort,Denmark,,,"all 8,000 members of the social media group Facebook “Covidramte med senfølger” (“long COVID sufferers'') above the age of 17 years and living in Denmark were invited to participate in a short electronic questionnaire about long COVID,",,2020-02-10,2021-03-11,Blood donors,All,Multiple groups,17.0,,COVID-19 vaccination status,,26,0.7692307692,,,,,,,,Self-referral,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,,0.998,['High'],,No,No,Yes,,Yes,Yes,Yes,,Kamille Fogh,Copenhagen University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1128/spectrum.02537-22,2022-11-17,2024-03-01,Unverified,fogh_self-reported_2022,DNK
221222_Denmark_CopenhagenUniversityHospital_Overall,221222_Denmark_CopenhagenUniversityHospital,A Cross-Sectional Study of SARS-CoV-2 Antibodies and Risk Factors for Seropositivity in Staff in Day Care Facilities and Preschools in Denmark,2022-12-22,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Denmark,,, union members and employees over the age of 15 years at day care facilities and pre schools,,2021-02-15,2021-03-15,Essential non-healthcare workers,All,Adults (18-64 years),15.0,,Primary Estimate,,20267,0.092,,,True,,,,True,Convenience,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.9,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Kamille Fogh,Copenhagen University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1128/spectrum.04174-22,2023-01-12,2024-03-01,Unverified,fogh_cross-sectional_2022,DNK
230115_Denmark_StatensSerumInstitut_Round5,230115_Denmark_StatensSerumInstitut,"Seroprevalence of SARS-CoV-2 Antibodies in Denmark: Results of Two Nationwide Population-Based Surveys, February and May 2021",2023-01-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Denmark,,,"""In the last week of February and the first week of May, random samples of 125,000 residents of Denmark ≥12 years old were
retrieved from the CRS"" Civil Registration System",Persons already vaccinated with at least one vaccine dose against COVID-19 were removed from the list,2021-05-10,2021-05-31,Household and community samples,All,Multiple groups,12.0,,Time frame,May 2021,5139,0.086,0.076,0.095,True,True,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"IgG, IgM, IgA",Spike,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Lene Wulff Krogsgaard,Statens Serum Institut,Not Unity-Aligned,https://dx.doi.org/10.2147/IDR.S383491,2023-02-09,2023-03-19,Unverified,krogsgaard_seroprevalence_2023,DNK
230115_Denmark_StatensSerumInstitut_Round4,230115_Denmark_StatensSerumInstitut,"Seroprevalence of SARS-CoV-2 Antibodies in Denmark: Results of Two Nationwide Population-Based Surveys, February and May 2021",2023-01-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Denmark,,,"""In the last week of February and the first week of May, random samples of 125,000 residents of Denmark ≥12 years old were
retrieved from the CRS"" Civil Registration System",Persons already vaccinated with at least one vaccine dose against COVID-19 were removed from the list,2021-03-01,2021-03-22,Household and community samples,All,Multiple groups,12.0,,Primary Estimate,,11275,0.07200000000000001,0.066,0.076,True,True,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"IgG, IgM, IgA",Spike,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Lene Wulff Krogsgaard,Statens Serum Institut,Not Unity-Aligned,https://dx.doi.org/10.2147/IDR.S383491,2023-02-09,2023-03-19,Unverified,krogsgaard_seroprevalence_2023,DNK
230406_Denmark_CopenhagenUniversityHospital_12mo_overall,230406_Denmark_CopenhagenUniversityHospital_12mo,SARS-CoV-2 antibody dynamics over time and risk factors associated with infection and long COVID-19 symptoms in large working environments.,2023-04-06,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Denmark,,,"""All employees and their household members (>18 years) were invited to participate in a baseline (June–August 2020), 6- month follow-up (December 2020–January 2021), and 12-month follow-up (August 2021) sampling."""," excluded due to incomplete questionnaire (n=350)
",2021-08-01,2021-08-31,Residual sera,All,Adults (18-64 years),18.0,,Primary Estimate,,7358,0.944,,,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.97,0.98,['Missing'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cecilie Bo Hansen,Copenhagen University,Unity-Aligned,https://dx.doi.org/10.1111/joim.13637,2023-05-07,2024-04-22,Verified,hansen_sarscov2_2023,DNK
230406_Denmark_CopenhagenUniversityHospital_6mo_overall,230406_Denmark_CopenhagenUniversityHospital_6mo,SARS-CoV-2 antibody dynamics over time and risk factors associated with infection and long COVID-19 symptoms in large working environments.,2023-04-06,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Denmark,,,"""All employees and their household members (>18 years) were invited to participate in a baseline (June–August 2020), 6- month follow-up (December 2020–January 2021), and 12-month follow-up (August 2021) sampling."""," excluded due to incomplete questionnaire (n=378) and due to vaccination (n=9)
",2020-12-01,2021-01-31,Residual sera,All,Adults (18-64 years),18.0,,Primary Estimate,,11354,0.091,,,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.97,0.98,['Missing'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cecilie Bo Hansen,Copenhagen University,Unity-Aligned,https://dx.doi.org/10.1111/joim.13637,2023-05-07,2024-04-22,Verified,hansen_sarscov2_2023,DNK
230406_Denmark_CopenhagenUniversityHospital_6mo_dec20,230406_Denmark_CopenhagenUniversityHospital_6mo,SARS-CoV-2 antibody dynamics over time and risk factors associated with infection and long COVID-19 symptoms in large working environments.,2023-04-06,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Denmark,,,"""All employees and their household members (>18 years) were invited to participate in a baseline (June–August 2020), 6- month follow-up (December 2020–January 2021), and 12-month follow-up (August 2021) sampling."""," excluded due to incomplete questionnaire (n=378) and due to vaccination (n=9)
",2020-12-01,2020-12-31,Residual sera,All,Adults (18-64 years),18.0,,Time frame,Dec 2020,9755,0.076,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.97,0.98,['Missing'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cecilie Bo Hansen,Copenhagen University,Unity-Aligned,https://dx.doi.org/10.1111/joim.13637,2023-05-07,2024-04-22,Verified,hansen_sarscov2_2023,DNK
230406_Denmark_CopenhagenUniversityHospital_6mo_jan21,230406_Denmark_CopenhagenUniversityHospital_6mo,SARS-CoV-2 antibody dynamics over time and risk factors associated with infection and long COVID-19 symptoms in large working environments.,2023-04-06,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Denmark,,,"""All employees and their household members (>18 years) were invited to participate in a baseline (June–August 2020), 6- month follow-up (December 2020–January 2021), and 12-month follow-up (August 2021) sampling."""," excluded due to incomplete questionnaire (n=378) and due to vaccination (n=9)
",2021-01-01,2021-01-31,Residual sera,All,Adults (18-64 years),18.0,,Time frame,Jan 2021,1599,0.179,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.97,0.98,['Missing'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cecilie Bo Hansen,Copenhagen University,Unity-Aligned,https://dx.doi.org/10.1111/joim.13637,2023-05-07,2024-04-22,Verified,hansen_sarscov2_2023,DNK
230406_Denmark_CopenhagenUniversityHospital_baseline_overall,230406_Denmark_CopenhagenUniversityHospital_baseline,SARS-CoV-2 antibody dynamics over time and risk factors associated with infection and long COVID-19 symptoms in large working environments.,2023-04-06,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Denmark,,,"""All employees and their household members (>18 years) were invited to participate in a baseline (June–August 2020), 6- month follow-up (December 2020–January 2021), and 12-month follow-up (August 2021) sampling."""," excluded due to incomplete questionnaire (n=129)
",2020-06-01,2020-08-31,Residual sera,All,Adults (18-64 years),18.0,,Primary Estimate,,14895,0.039,,,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.97,0.98,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Cecilie Bo Hansen,Copenhagen University,Unity-Aligned,https://dx.doi.org/10.1111/joim.13637,2023-05-07,2024-04-22,Verified,hansen_sarscov2_2023,DNK
230406_Denmark_CopenhagenUniversityHospital_baseline_junejuly20,230406_Denmark_CopenhagenUniversityHospital_baseline,SARS-CoV-2 antibody dynamics over time and risk factors associated with infection and long COVID-19 symptoms in large working environments.,2023-04-06,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Denmark,,,"""All employees and their household members (>18 years) were invited to participate in a baseline (June–August 2020), 6- month follow-up (December 2020–January 2021), and 12-month follow-up (August 2021) sampling."""," excluded due to incomplete questionnaire (n=129)
",2020-06-01,2020-07-31,Residual sera,All,Adults (18-64 years),18.0,,Time frame,June/ July 2020,12429,0.038,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.97,0.98,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Cecilie Bo Hansen,Copenhagen University,Unity-Aligned,https://dx.doi.org/10.1111/joim.13637,2023-05-07,2024-04-22,Verified,hansen_sarscov2_2023,DNK
230406_Denmark_CopenhagenUniversityHospital_baseline_aug20,230406_Denmark_CopenhagenUniversityHospital_baseline,SARS-CoV-2 antibody dynamics over time and risk factors associated with infection and long COVID-19 symptoms in large working environments.,2023-04-06,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Denmark,,,"""All employees and their household members (>18 years) were invited to participate in a baseline (June–August 2020), 6- month follow-up (December 2020–January 2021), and 12-month follow-up (August 2021) sampling."""," excluded due to incomplete questionnaire (n=129)
",2020-08-01,2020-08-31,Residual sera,All,Adults (18-64 years),18.0,,Time frame,Aug 2020,2466,0.04,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.97,0.98,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Cecilie Bo Hansen,Copenhagen University,Unity-Aligned,https://dx.doi.org/10.1111/joim.13637,2023-05-07,2024-04-22,Verified,hansen_sarscov2_2023,DNK
230705_Denmark_UniversityHospitalofSouthernDenmark,230705_Denmark_UniversityHospitalofSouthernDenmark,Comparatively low rates of COVID-19 in women admitted in labor and their newborns prior to routine vaccination of pregnant women: insights from Denmark.,2023-07-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Denmark,,,"""From April 23 to November 15, 2020, all women admit- ted in labor at two Danish hospitals were invited""",,2020-04-23,2020-11-15,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,1042,0.016,,,True,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,,"['IgA', 'IgG', 'IgM']",Spike,Validated by manufacturers,0.967,0.995,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Stine Yde Nielsen,University Hospital of Southern Denmark,Unity-Aligned,https://dx.doi.org/10.1080/14767058.2023.2229933,2023-08-01,2024-04-30,Verified,nielsenComparativelyLowRates2023,DNK
201202_DominicanRepublic_UniversidadIberoamericana_genpop_IgG,201202_DominicanRepublic_UniversidadIberoamericana,Seroprevalence of Specific Antibodies against SARS-CoV-2 from Hotspot Communities in the Dominican Republic,2020-12-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Dominican Republic,,,We contacted individuals randomly in communities identified as emerging hotspots for SARS-CoV-2 by Ministry of Health reports and invited members of households to participate in the seroprevalence study.,,2020-04-15,2020-06-15,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,12897,0.055,,,True,,,,True,Simplified probability,GenBody COVID-19 IgM/IgG,GenBody Inc.,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.5670000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Robert Paulino Ramirez,Universidad Iberoamericana,Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.20-0907,2021-01-12,2024-03-01,Verified,paulino-ramirez_seroprevalence_2020,DOM
201202_DominicanRepublic_UniversidadIberoamericana_DistritoNacional_IgM_,201202_DominicanRepublic_UniversidadIberoamericana,Seroprevalence of Specific Antibodies against SARS-CoV-2 from Hotspot Communities in the Dominican Republic,2020-12-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Dominican Republic,Distrito Nacional,,We contacted individuals randomly in communities identified as emerging hotspots for SARS-CoV-2 by Ministry of Health reports and invited members of households to participate in the seroprevalence study.,,2020-04-15,2020-06-15,Household and community samples,All,Multiple groups,0.0,,Geographical area,Distrito Nacional,8174,0.01076584292,,,,,,,,Simplified probability,GenBody COVID-19 IgM/IgG,GenBody Inc.,LFIA,Whole Blood,IgM,Spike,Validated by independent authors/third party/non-developers,0.4,0.988,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Robert Paulino Ramirez,Universidad Iberoamericana,Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.20-0907,2021-01-14,2024-03-01,Verified,paulino-ramirez_seroprevalence_2020,DOM
201202_DominicanRepublic_UniversidadIberoamericana_Duarte_IgM_,201202_DominicanRepublic_UniversidadIberoamericana,Seroprevalence of Specific Antibodies against SARS-CoV-2 from Hotspot Communities in the Dominican Republic,2020-12-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Dominican Republic,Duarte,,We contacted individuals randomly in communities identified as emerging hotspots for SARS-CoV-2 by Ministry of Health reports and invited members of households to participate in the seroprevalence study.,,2020-04-15,2020-06-15,Household and community samples,All,Multiple groups,0.0,,Geographical area,Duarte,876,0.08675799087,,,,,,,,Simplified probability,GenBody COVID-19 IgM/IgG,GenBody Inc.,LFIA,Whole Blood,IgM,Spike,Validated by independent authors/third party/non-developers,0.4,0.988,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Robert Paulino Ramirez,Universidad Iberoamericana,Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.20-0907,2021-01-14,2024-03-01,Verified,paulino-ramirez_seroprevalence_2020,DOM
201202_DominicanRepublic_UniversidadIberoamericana_SanCristobal_IgM,201202_DominicanRepublic_UniversidadIberoamericana,Seroprevalence of Specific Antibodies against SARS-CoV-2 from Hotspot Communities in the Dominican Republic,2020-12-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Dominican Republic,Duarte,,We contacted individuals randomly in communities identified as emerging hotspots for SARS-CoV-2 by Ministry of Health reports and invited members of households to participate in the seroprevalence study.,,2020-04-15,2020-06-15,Household and community samples,All,Multiple groups,0.0,,Geographical area,Duarte,1863,0.030600000000000002,,,,,,,,Simplified probability,GenBody COVID-19 IgM/IgG,GenBody Inc.,LFIA,Whole Blood,IgM,Spike,Validated by independent authors/third party/non-developers,0.4,0.988,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Robert Paulino Ramirez,Universidad Iberoamericana,Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.20-0907,2021-01-14,2024-03-01,Verified,paulino-ramirez_seroprevalence_2020,DOM
201202_DominicanRepublic_UniversidadIberoamericana_PuertoPlata_IgM,201202_DominicanRepublic_UniversidadIberoamericana,Seroprevalence of Specific Antibodies against SARS-CoV-2 from Hotspot Communities in the Dominican Republic,2020-12-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Dominican Republic,Puerto Plata,,We contacted individuals randomly in communities identified as emerging hotspots for SARS-CoV-2 by Ministry of Health reports and invited members of households to participate in the seroprevalence study.,,2020-04-15,2020-06-15,Household and community samples,All,Multiple groups,0.0,,Geographical area,Puerto Plata,479,0.0063,,,,,,,,Simplified probability,GenBody COVID-19 IgM/IgG,GenBody Inc.,LFIA,Whole Blood,IgM,Spike,Validated by independent authors/third party/non-developers,0.4,0.988,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Robert Paulino Ramirez,Universidad Iberoamericana,Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.20-0907,2021-01-14,2024-03-01,Verified,paulino-ramirez_seroprevalence_2020,DOM
201202_DominicanRepublic_UniversidadIberoamericana_LaRomana _IgG,201202_DominicanRepublic_UniversidadIberoamericana,Seroprevalence of Specific Antibodies against SARS-CoV-2 from Hotspot Communities in the Dominican Republic,2020-12-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Dominican Republic,La Romana ,,We contacted individuals randomly in communities identified as emerging hotspots for SARS-CoV-2 by Ministry of Health reports and invited members of households to participate in the seroprevalence study.,,2020-04-15,2020-06-15,Household and community samples,All,Multiple groups,0.0,,Geographical area,La Romana ,834,0.0168,,,,,,,,Simplified probability,GenBody COVID-19 IgM/IgG,GenBody Inc.,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.5670000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Robert Paulino Ramirez,Universidad Iberoamericana,Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.20-0907,2021-01-14,2024-03-01,Verified,paulino-ramirez_seroprevalence_2020,DOM
201202_DominicanRepublic_UniversidadIberoamericana_SanJosedeOcoa_IgM,201202_DominicanRepublic_UniversidadIberoamericana,Seroprevalence of Specific Antibodies against SARS-CoV-2 from Hotspot Communities in the Dominican Republic,2020-12-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Dominican Republic,San Jose de Ocoa,,We contacted individuals randomly in communities identified as emerging hotspots for SARS-CoV-2 by Ministry of Health reports and invited members of households to participate in the seroprevalence study.,,2020-04-15,2020-06-15,Household and community samples,All,Multiple groups,0.0,,Geographical area,San Jose de Ocoa,67,0.029900000000000003,,,,,,,,Simplified probability,GenBody COVID-19 IgM/IgG,GenBody Inc.,LFIA,Whole Blood,IgM,Spike,Validated by independent authors/third party/non-developers,0.4,0.988,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Robert Paulino Ramirez,Universidad Iberoamericana,Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.20-0907,2021-01-14,2024-03-01,Verified,paulino-ramirez_seroprevalence_2020,DOM
201202_DominicanRepublic_UniversidadIberoamericana_LaVega_IgG,201202_DominicanRepublic_UniversidadIberoamericana,Seroprevalence of Specific Antibodies against SARS-CoV-2 from Hotspot Communities in the Dominican Republic,2020-12-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Dominican Republic,La Vega,,We contacted individuals randomly in communities identified as emerging hotspots for SARS-CoV-2 by Ministry of Health reports and invited members of households to participate in the seroprevalence study.,,2020-04-15,2020-06-15,Household and community samples,All,Multiple groups,0.0,,Geographical area,La Vega,1297,0.02,,,,,,,,Simplified probability,GenBody COVID-19 IgM/IgG,GenBody Inc.,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.5670000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Robert Paulino Ramirez,Universidad Iberoamericana,Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.20-0907,2021-01-14,2024-03-01,Verified,paulino-ramirez_seroprevalence_2020,DOM
201202_DominicanRepublic_UniversidadIberoamericana_Santiago_IgG,201202_DominicanRepublic_UniversidadIberoamericana,Seroprevalence of Specific Antibodies against SARS-CoV-2 from Hotspot Communities in the Dominican Republic,2020-12-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Dominican Republic,Santiago,,We contacted individuals randomly in communities identified as emerging hotspots for SARS-CoV-2 by Ministry of Health reports and invited members of households to participate in the seroprevalence study.,,2020-04-15,2020-06-15,Household and community samples,All,Multiple groups,0.0,,Geographical area,Santiago,2249,0.0507,,,,,,,,Simplified probability,GenBody COVID-19 IgM/IgG,GenBody Inc.,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.5670000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Robert Paulino Ramirez,Universidad Iberoamericana,Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.20-0907,2021-01-14,2024-03-01,Verified,paulino-ramirez_seroprevalence_2020,DOM
201202_DominicanRepublic_UniversidadIberoamericana_LaAtlagracia_IgM_,201202_DominicanRepublic_UniversidadIberoamericana,Seroprevalence of Specific Antibodies against SARS-CoV-2 from Hotspot Communities in the Dominican Republic,2020-12-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Dominican Republic,La Atlagracia,,We contacted individuals randomly in communities identified as emerging hotspots for SARS-CoV-2 by Ministry of Health reports and invited members of households to participate in the seroprevalence study.,,2020-04-15,2020-06-15,Household and community samples,All,Multiple groups,0.0,,Geographical area,La Atlagracia,788,0.0444,,,,,,,,Simplified probability,GenBody COVID-19 IgM/IgG,GenBody Inc.,LFIA,Whole Blood,IgM,Spike,Validated by independent authors/third party/non-developers,0.4,0.988,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Robert Paulino Ramirez,Universidad Iberoamericana,Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.20-0907,2021-01-14,2024-03-01,Verified,paulino-ramirez_seroprevalence_2020,DOM
201202_DominicanRepublic_UniversidadIberoamericana_SantoDomingo_IgG,201202_DominicanRepublic_UniversidadIberoamericana,Seroprevalence of Specific Antibodies against SARS-CoV-2 from Hotspot Communities in the Dominican Republic,2020-12-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Dominican Republic,Duarte,,We contacted individuals randomly in communities identified as emerging hotspots for SARS-CoV-2 by Ministry of Health reports and invited members of households to participate in the seroprevalence study.,,2020-04-15,2020-06-15,Household and community samples,All,Multiple groups,0.0,,Geographical area,Duarte,9448,0.0184,,,,,,,,Simplified probability,GenBody COVID-19 IgM/IgG,GenBody Inc.,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.5670000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Robert Paulino Ramirez,Universidad Iberoamericana,Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.20-0907,2021-01-14,2024-03-01,Verified,paulino-ramirez_seroprevalence_2020,DOM
201202_DominicanRepublic_UniversidadIberoamericana_Duarte_IgG,201202_DominicanRepublic_UniversidadIberoamericana,Seroprevalence of Specific Antibodies against SARS-CoV-2 from Hotspot Communities in the Dominican Republic,2020-12-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Dominican Republic,Duarte,,We contacted individuals randomly in communities identified as emerging hotspots for SARS-CoV-2 by Ministry of Health reports and invited members of households to participate in the seroprevalence study.,,2020-04-15,2020-06-15,Household and community samples,All,Multiple groups,0.0,,Geographical area,Duarte,876,0.1747,,,,,,,,Simplified probability,GenBody COVID-19 IgM/IgG,GenBody Inc.,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.5670000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Robert Paulino Ramirez,Universidad Iberoamericana,Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.20-0907,2021-01-14,2024-03-01,Verified,paulino-ramirez_seroprevalence_2020,DOM
201202_DominicanRepublic_UniversidadIberoamericana_LaRomana _IgM_,201202_DominicanRepublic_UniversidadIberoamericana,Seroprevalence of Specific Antibodies against SARS-CoV-2 from Hotspot Communities in the Dominican Republic,2020-12-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Dominican Republic,La Romana ,,We contacted individuals randomly in communities identified as emerging hotspots for SARS-CoV-2 by Ministry of Health reports and invited members of households to participate in the seroprevalence study.,,2020-04-15,2020-06-15,Household and community samples,All,Multiple groups,0.0,,Geographical area,La Romana ,834,0.0048,,,,,,,,Simplified probability,GenBody COVID-19 IgM/IgG,GenBody Inc.,LFIA,Whole Blood,IgM,Spike,Validated by independent authors/third party/non-developers,0.4,0.988,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Robert Paulino Ramirez,Universidad Iberoamericana,Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.20-0907,2021-01-14,2024-03-01,Verified,paulino-ramirez_seroprevalence_2020,DOM
201202_DominicanRepublic_UniversidadIberoamericana_SanCristobal_IgG,201202_DominicanRepublic_UniversidadIberoamericana,Seroprevalence of Specific Antibodies against SARS-CoV-2 from Hotspot Communities in the Dominican Republic,2020-12-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Dominican Republic,San Cristobal,,We contacted individuals randomly in communities identified as emerging hotspots for SARS-CoV-2 by Ministry of Health reports and invited members of households to participate in the seroprevalence study.,,2020-04-15,2020-06-15,Household and community samples,All,Multiple groups,0.0,,Geographical area,San Cristobal,1863,0.028999999999999998,,,,,,,,Simplified probability,GenBody COVID-19 IgM/IgG,GenBody Inc.,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.5670000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Robert Paulino Ramirez,Universidad Iberoamericana,Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.20-0907,2021-01-14,2024-03-01,Verified,paulino-ramirez_seroprevalence_2020,DOM
201202_DominicanRepublic_UniversidadIberoamericana_LaAtlagracia_IgG,201202_DominicanRepublic_UniversidadIberoamericana,Seroprevalence of Specific Antibodies against SARS-CoV-2 from Hotspot Communities in the Dominican Republic,2020-12-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Dominican Republic,La Atlagracia,,We contacted individuals randomly in communities identified as emerging hotspots for SARS-CoV-2 by Ministry of Health reports and invited members of households to participate in the seroprevalence study.,,2020-04-15,2020-06-15,Household and community samples,All,Multiple groups,0.0,,Geographical area,La Atlagracia,788,0.04820000000000001,,,,,,,,Simplified probability,GenBody COVID-19 IgM/IgG,GenBody Inc.,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.5670000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Robert Paulino Ramirez,Universidad Iberoamericana,Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.20-0907,2021-01-14,2024-03-01,Verified,paulino-ramirez_seroprevalence_2020,DOM
201202_DominicanRepublic_UniversidadIberoamericana_SantoDomingo_IgM,201202_DominicanRepublic_UniversidadIberoamericana,Seroprevalence of Specific Antibodies against SARS-CoV-2 from Hotspot Communities in the Dominican Republic,2020-12-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Dominican Republic,Santo Domingo,,We contacted individuals randomly in communities identified as emerging hotspots for SARS-CoV-2 by Ministry of Health reports and invited members of households to participate in the seroprevalence study.,,2020-04-15,2020-06-15,Household and community samples,All,Multiple groups,0.0,,Geographical area,Santo Domingo,9448,0.0167,,,,,,,,Simplified probability,GenBody COVID-19 IgM/IgG,GenBody Inc.,LFIA,Whole Blood,IgM,Spike,Validated by independent authors/third party/non-developers,0.4,0.988,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Robert Paulino Ramirez,Universidad Iberoamericana,Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.20-0907,2021-01-14,2024-03-01,Verified,paulino-ramirez_seroprevalence_2020,DOM
201202_DominicanRepublic_UniversidadIberoamericana_SanJosedeOcoa_IgG,201202_DominicanRepublic_UniversidadIberoamericana,Seroprevalence of Specific Antibodies against SARS-CoV-2 from Hotspot Communities in the Dominican Republic,2020-12-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Dominican Republic,San Jose de Ocoa,,We contacted individuals randomly in communities identified as emerging hotspots for SARS-CoV-2 by Ministry of Health reports and invited members of households to participate in the seroprevalence study.,,2020-04-15,2020-06-15,Household and community samples,All,Multiple groups,0.0,,Geographical area,San Jose de Ocoa,67,0.029900000000000003,,,,,,,,Simplified probability,GenBody COVID-19 IgM/IgG,GenBody Inc.,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.5670000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Robert Paulino Ramirez,Universidad Iberoamericana,Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.20-0907,2021-01-14,2024-03-01,Verified,paulino-ramirez_seroprevalence_2020,DOM
201202_DominicanRepublic_UniversidadIberoamericana_PuertoPlata_IgG ,201202_DominicanRepublic_UniversidadIberoamericana,Seroprevalence of Specific Antibodies against SARS-CoV-2 from Hotspot Communities in the Dominican Republic,2020-12-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Dominican Republic,Puerto Plata,,We contacted individuals randomly in communities identified as emerging hotspots for SARS-CoV-2 by Ministry of Health reports and invited members of households to participate in the seroprevalence study.,,2020-04-15,2020-06-15,Household and community samples,All,Multiple groups,0.0,,Geographical area,Puerto Plata,479,0.010400000000000001,,,,,,,,Simplified probability,GenBody COVID-19 IgM/IgG,GenBody Inc.,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.5670000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Robert Paulino Ramirez,Universidad Iberoamericana,Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.20-0907,2021-01-14,2024-03-01,Verified,paulino-ramirez_seroprevalence_2020,DOM
201202_DominicanRepublic_UniversidadIberoamericana_LaVega_IgM,201202_DominicanRepublic_UniversidadIberoamericana,Seroprevalence of Specific Antibodies against SARS-CoV-2 from Hotspot Communities in the Dominican Republic,2020-12-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Dominican Republic,La Vega,,We contacted individuals randomly in communities identified as emerging hotspots for SARS-CoV-2 by Ministry of Health reports and invited members of households to participate in the seroprevalence study.,,2020-04-15,2020-06-15,Household and community samples,All,Multiple groups,0.0,,Geographical area,La Vega,1297,0.0116,,,,,,,,Simplified probability,GenBody COVID-19 IgM/IgG,GenBody Inc.,LFIA,Whole Blood,IgM,Spike,Validated by independent authors/third party/non-developers,0.4,0.988,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Robert Paulino Ramirez,Universidad Iberoamericana,Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.20-0907,2021-01-14,2024-03-01,Verified,paulino-ramirez_seroprevalence_2020,DOM
201202_DominicanRepublic_UniversidadIberoamericana_DistritoNacional_IgG,201202_DominicanRepublic_UniversidadIberoamericana,Seroprevalence of Specific Antibodies against SARS-CoV-2 from Hotspot Communities in the Dominican Republic,2020-12-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Dominican Republic,Distrito Nacional,,We contacted individuals randomly in communities identified as emerging hotspots for SARS-CoV-2 by Ministry of Health reports and invited members of households to participate in the seroprevalence study.,,2020-04-15,2020-06-15,Household and community samples,All,Multiple groups,0.0,,Geographical area,Distrito Nacional,8174,0.015,,,,,,,,Simplified probability,GenBody COVID-19 IgM/IgG,GenBody Inc.,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.5670000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Robert Paulino Ramirez,Universidad Iberoamericana,Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.20-0907,2021-01-14,2024-03-01,Verified,paulino-ramirez_seroprevalence_2020,DOM
201202_DominicanRepublic_UniversidadIberoamericana_Santiago_IgM,201202_DominicanRepublic_UniversidadIberoamericana,Seroprevalence of Specific Antibodies against SARS-CoV-2 from Hotspot Communities in the Dominican Republic,2020-12-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Dominican Republic,Santiago,,We contacted individuals randomly in communities identified as emerging hotspots for SARS-CoV-2 by Ministry of Health reports and invited members of households to participate in the seroprevalence study.,,2020-04-15,2020-06-15,Household and community samples,All,Multiple groups,0.0,,Geographical area,Santiago,2249,0.0236,,,,,,,,Simplified probability,GenBody COVID-19 IgM/IgG,GenBody Inc.,LFIA,Whole Blood,IgM,Spike,Validated by independent authors/third party/non-developers,0.4,0.988,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Robert Paulino Ramirez,Universidad Iberoamericana,Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.20-0907,2021-01-14,2024-03-01,Verified,paulino-ramirez_seroprevalence_2020,DOM
221108_DominicanRepublic_UniversityofQueensland_Overall_PopAdj,221108_DominicanRepublic_UniversityofQueensland,"SARS-CoV-2 seroprevalence, cumulative infections, and immunity to symptomatic infection - A multistage national household survey and modelling study, Dominican Republic, June-October 2021.",2022-11-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Dominican Republic,,,"""Household members aged ≥5 years old present in the home at the time of the serosurvey were invited to participate.""","""0- to 4-year age group were not enrolled in this study"".",2021-06-30,2021-10-12,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,Overall pop-adjusted anti-S,6683,0.85,0.821,0.88,True,,True,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,"CLIA, CMIA",,"IgG, IgM, IgA",Spike,Validated by independent authors/third party/non-developers,0.9820000000000001,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Eric Nilles,University of Queensland,Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2022.100390,2022-12-16,2024-03-01,Unverified,nilles_sars-cov-2_2022,DOM
221108_DominicanRepublic_UniversityofQueensland_SexOther,221108_DominicanRepublic_UniversityofQueensland,"SARS-CoV-2 seroprevalence, cumulative infections, and immunity to symptomatic infection - A multistage national household survey and modelling study, Dominican Republic, June-October 2021.",2022-11-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Dominican Republic,,,"""Household members aged ≥5 years old present in the home at the time of the serosurvey were invited to participate.""","""0- to 4-year age group were not enrolled in this study"".",2021-06-30,2021-10-12,Household and community samples,Other,Multiple groups,5.0,,Sex/Gender,Other,45,0.875,0.639,0.965,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,"CLIA, CMIA",,"IgG, IgM, IgA",Spike,Validated by independent authors/third party/non-developers,0.9820000000000001,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Eric Nilles,University of Queensland,Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2022.100390,2022-12-16,2024-03-01,Unverified,nilles_sars-cov-2_2022,DOM
221108_DominicanRepublic_UniversityofQueensland_Age55-64,221108_DominicanRepublic_UniversityofQueensland,"SARS-CoV-2 seroprevalence, cumulative infections, and immunity to symptomatic infection - A multistage national household survey and modelling study, Dominican Republic, June-October 2021.",2022-11-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Dominican Republic,,,"""Household members aged ≥5 years old present in the home at the time of the serosurvey were invited to participate.""","""0- to 4-year age group were not enrolled in this study"".",2021-06-30,2021-10-12,Household and community samples,All,Adults (18-64 years),55.0,64.0,Age,55-64 years,913,0.9359999999999999,0.902,0.9590000000000001,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,"CLIA, CMIA",,"IgG, IgM, IgA",Spike,Validated by independent authors/third party/non-developers,0.9820000000000001,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Eric Nilles,University of Queensland,Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2022.100390,2022-12-16,2024-03-01,Unverified,nilles_sars-cov-2_2022,DOM
221108_DominicanRepublic_UniversityofQueensland_Age45-54,221108_DominicanRepublic_UniversityofQueensland,"SARS-CoV-2 seroprevalence, cumulative infections, and immunity to symptomatic infection - A multistage national household survey and modelling study, Dominican Republic, June-October 2021.",2022-11-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Dominican Republic,,,"""Household members aged ≥5 years old present in the home at the time of the serosurvey were invited to participate.""","""0- to 4-year age group were not enrolled in this study"".",2021-06-30,2021-10-12,Household and community samples,All,Adults (18-64 years),45.0,54.0,Age,45-54 years,953,0.913,0.88,0.938,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,"CLIA, CMIA",,"IgG, IgM, IgA",Spike,Validated by independent authors/third party/non-developers,0.9820000000000001,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Eric Nilles,University of Queensland,Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2022.100390,2022-12-16,2024-03-01,Unverified,nilles_sars-cov-2_2022,DOM
221108_DominicanRepublic_UniversityofQueensland_Age25-34,221108_DominicanRepublic_UniversityofQueensland,"SARS-CoV-2 seroprevalence, cumulative infections, and immunity to symptomatic infection - A multistage national household survey and modelling study, Dominican Republic, June-October 2021.",2022-11-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Dominican Republic,,,"""Household members aged ≥5 years old present in the home at the time of the serosurvey were invited to participate.""","""0- to 4-year age group were not enrolled in this study"".",2021-06-30,2021-10-12,Household and community samples,All,Adults (18-64 years),25.0,34.0,Age,25-34 years,1010,0.8959999999999999,0.809,0.946,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,"CLIA, CMIA",,"IgG, IgM, IgA",Spike,Validated by independent authors/third party/non-developers,0.9820000000000001,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Eric Nilles,University of Queensland,Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2022.100390,2022-12-16,2024-03-01,Unverified,nilles_sars-cov-2_2022,DOM
221108_DominicanRepublic_UniversityofQueensland_Age35-44,221108_DominicanRepublic_UniversityofQueensland,"SARS-CoV-2 seroprevalence, cumulative infections, and immunity to symptomatic infection - A multistage national household survey and modelling study, Dominican Republic, June-October 2021.",2022-11-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Dominican Republic,,,"""Household members aged ≥5 years old present in the home at the time of the serosurvey were invited to participate.""","""0- to 4-year age group were not enrolled in this study"".",2021-06-30,2021-10-12,Household and community samples,All,Adults (18-64 years),35.0,44.0,Age,35-44 years,950,0.923,0.8640000000000001,0.9570000000000001,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,"CLIA, CMIA",,"IgG, IgM, IgA",Spike,Validated by independent authors/third party/non-developers,0.9820000000000001,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Eric Nilles,University of Queensland,Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2022.100390,2022-12-16,2024-03-01,Unverified,nilles_sars-cov-2_2022,DOM
221108_DominicanRepublic_UniversityofQueensland_Age65-74,221108_DominicanRepublic_UniversityofQueensland,"SARS-CoV-2 seroprevalence, cumulative infections, and immunity to symptomatic infection - A multistage national household survey and modelling study, Dominican Republic, June-October 2021.",2022-11-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Dominican Republic,,,"""Household members aged ≥5 years old present in the home at the time of the serosurvey were invited to participate.""","""0- to 4-year age group were not enrolled in this study"".",2021-06-30,2021-10-12,Household and community samples,All,Seniors (65+ years),65.0,74.0,Age,65-74 years,673,0.935,0.902,0.958,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,"CLIA, CMIA",,"IgG, IgM, IgA",Spike,Validated by independent authors/third party/non-developers,0.9820000000000001,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Eric Nilles,University of Queensland,Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2022.100390,2022-12-16,2024-03-01,Unverified,nilles_sars-cov-2_2022,DOM
221108_DominicanRepublic_UniversityofQueensland_Age15-24,221108_DominicanRepublic_UniversityofQueensland,"SARS-CoV-2 seroprevalence, cumulative infections, and immunity to symptomatic infection - A multistage national household survey and modelling study, Dominican Republic, June-October 2021.",2022-11-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Dominican Republic,,,"""Household members aged ≥5 years old present in the home at the time of the serosurvey were invited to participate.""","""0- to 4-year age group were not enrolled in this study"".",2021-06-30,2021-10-12,Household and community samples,All,Adults (18-64 years),15.0,24.0,Age,15-24 years,1133,0.865,0.805,0.909,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,"CLIA, CMIA",,"IgG, IgM, IgA",Spike,Validated by independent authors/third party/non-developers,0.9820000000000001,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Eric Nilles,University of Queensland,Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2022.100390,2022-12-16,2024-03-01,Unverified,nilles_sars-cov-2_2022,DOM
221108_DominicanRepublic_UniversityofQueensland_SexMale,221108_DominicanRepublic_UniversityofQueensland,"SARS-CoV-2 seroprevalence, cumulative infections, and immunity to symptomatic infection - A multistage national household survey and modelling study, Dominican Republic, June-October 2021.",2022-11-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Dominican Republic,,,"""Household members aged ≥5 years old present in the home at the time of the serosurvey were invited to participate.""","""0- to 4-year age group were not enrolled in this study"".",2021-06-30,2021-10-12,Household and community samples,Male,Multiple groups,5.0,,Sex/Gender,Male,2494,0.84,0.8079999999999999,0.868,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,"CLIA, CMIA",,"IgG, IgM, IgA",Spike,Validated by independent authors/third party/non-developers,0.9820000000000001,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Eric Nilles,University of Queensland,Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2022.100390,2022-12-16,2024-03-01,Unverified,nilles_sars-cov-2_2022,DOM
221108_DominicanRepublic_UniversityofQueensland_SexFemale,221108_DominicanRepublic_UniversityofQueensland,"SARS-CoV-2 seroprevalence, cumulative infections, and immunity to symptomatic infection - A multistage national household survey and modelling study, Dominican Republic, June-October 2021.",2022-11-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Dominican Republic,,,"""Household members aged ≥5 years old present in the home at the time of the serosurvey were invited to participate.""","""0- to 4-year age group were not enrolled in this study"".",2021-06-30,2021-10-12,Household and community samples,Female,Multiple groups,5.0,,Sex/Gender,Female,4144,0.86,0.8170000000000001,0.8940000000000001,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,"CLIA, CMIA",,"IgG, IgM, IgA",Spike,Validated by independent authors/third party/non-developers,0.9820000000000001,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Eric Nilles,University of Queensland,Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2022.100390,2022-12-16,2024-03-01,Unverified,nilles_sars-cov-2_2022,DOM
221108_DominicanRepublic_UniversityofQueensland_Overall_UnAdjusted,221108_DominicanRepublic_UniversityofQueensland,"SARS-CoV-2 seroprevalence, cumulative infections, and immunity to symptomatic infection - A multistage national household survey and modelling study, Dominican Republic, June-October 2021.",2022-11-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Dominican Republic,,,"""Household members aged ≥5 years old present in the home at the time of the serosurvey were invited to participate.""","""0- to 4-year age group were not enrolled in this study"".",2021-06-30,2021-10-12,Household and community samples,All,Multiple groups,5.0,,Analysis,Overall unadjusted anti-S,6683,0.892,0.8840000000000001,0.899,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,"CLIA, CMIA",,"IgG, IgM, IgA",Spike,Validated by independent authors/third party/non-developers,0.9820000000000001,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Eric Nilles,University of Queensland,Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2022.100390,2022-12-16,2024-03-01,Unverified,nilles_sars-cov-2_2022,DOM
221108_DominicanRepublic_UniversityofQueensland_Age75+,221108_DominicanRepublic_UniversityofQueensland,"SARS-CoV-2 seroprevalence, cumulative infections, and immunity to symptomatic infection - A multistage national household survey and modelling study, Dominican Republic, June-October 2021.",2022-11-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Dominican Republic,,,"""Household members aged ≥5 years old present in the home at the time of the serosurvey were invited to participate.""","""0- to 4-year age group were not enrolled in this study"".",2021-06-30,2021-10-12,Household and community samples,All,Seniors (65+ years),75.0,,Age,≥75 years,390,0.9420000000000001,0.86,0.978,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,"CLIA, CMIA",,"IgG, IgM, IgA",Spike,Validated by independent authors/third party/non-developers,0.9820000000000001,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Eric Nilles,University of Queensland,Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2022.100390,2022-12-16,2024-03-01,Unverified,nilles_sars-cov-2_2022,DOM
221108_DominicanRepublic_UniversityofQueensland_Age5-14,221108_DominicanRepublic_UniversityofQueensland,"SARS-CoV-2 seroprevalence, cumulative infections, and immunity to symptomatic infection - A multistage national household survey and modelling study, Dominican Republic, June-October 2021.",2022-11-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Dominican Republic,,,"""Household members aged ≥5 years old present in the home at the time of the serosurvey were invited to participate.""","""0- to 4-year age group were not enrolled in this study"".",2021-06-30,2021-10-12,Household and community samples,All,Children and Youth (0-17 years),5.0,14.0,Age,5-14 years,661,0.667,0.5970000000000001,0.73,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,"CLIA, CMIA",,"IgG, IgM, IgA",Spike,Validated by independent authors/third party/non-developers,0.9820000000000001,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Eric Nilles,University of Queensland,Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2022.100390,2022-12-16,2024-03-01,Unverified,nilles_sars-cov-2_2022,DOM
221108_DominicanRepublic_UniversityofQueensland_TestUsed_AntiN,221108_DominicanRepublic_UniversityofQueensland,"SARS-CoV-2 seroprevalence, cumulative infections, and immunity to symptomatic infection - A multistage national household survey and modelling study, Dominican Republic, June-October 2021.",2022-11-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Dominican Republic,,,"""Household members aged ≥5 years old present in the home at the time of the serosurvey were invited to participate.""","""0- to 4-year age group were not enrolled in this study"".",2021-06-30,2021-10-12,Household and community samples,All,Multiple groups,5.0,,Test used,Overall pop-adjusted anti-N,6683,0.743,0.7020000000000001,0.78,,True,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,"CLIA, CMIA",,"IgG, IgM, IgA",Nucleocapsid (N-protein),Validated by independent authors/third party/non-developers,0.908,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Eric Nilles,University of Queensland,Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2022.100390,2022-12-16,2023-03-19,Unverified,nilles_sars-cov-2_2022,DOM
200727_Atahualpa_UniversidadPeruanaCayetanoHeredia_RuralOver40_Overall,200727_Atahualpa_UniversidadPeruanaCayetanoHeredia,SARS-CoV-2 in rural Latin America. A population-based study in coastal Ecuador,2020-07-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ecuador,El Oro,,"Members of the Atahualpa cohort project, ongoing since 2012 - adults over 40 years old and reside in the village of Atahualpa, Ecuador",,2020-05-01,2020-05-25,Household and community samples,All,Multiple groups,40.0,,Primary Estimate,,673,0.45,,,True,,,,True,Convenience,BIOHIT SARS-CoV-2 antibody test,Biohit Health Care Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,No,Yes,Yes,Yes,No,Yes,No,Yes,Oscar Del Brutto,Universidad Peruana Cayetano Heredia,Unity-Aligned,http://dx.doi.org/10.1093/cid/ciaa1055,2020-10-02,2024-03-01,Verified,del_brutto_sars-cov-2_2020,ECU
200727_Atahualpa_UniversidadPeruanaCayetanoHeredia_RuralOver40_Women,200727_Atahualpa_UniversidadPeruanaCayetanoHeredia,SARS-CoV-2 in rural Latin America. A population-based study in coastal Ecuador,2020-07-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ecuador,,,"Members of the Atahualpa cohort project, ongoing since 2012 - adults over 40 years old and reside in the village of Atahualpa, Ecuador",,2020-05-01,2020-05-25,Household and community samples,Female,Multiple groups,40.0,,Sex/Gender,Female,381,0.451,,,,,,,,Convenience,BIOHIT SARS-CoV-2 antibody test,Biohit Health Care Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,No,Yes,Yes,Yes,No,Yes,No,Yes,Oscar Del Brutto,Universidad Peruana Cayetano Heredia,Unity-Aligned,http://dx.doi.org/10.1093/cid/ciaa1055,2020-10-02,2024-03-01,Verified,del_brutto_sars-cov-2_2020,ECU
200727_Atahualpa_UniversidadPeruanaCayetanoHeredia_RuralOver40_OpenLatrines,200727_Atahualpa_UniversidadPeruanaCayetanoHeredia,SARS-CoV-2 in rural Latin America. A population-based study in coastal Ecuador,2020-07-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ecuador,,,"Members of the Atahualpa cohort project, ongoing since 2012 - adults over 40 years old and reside in the village of Atahualpa, Ecuador",,2020-05-01,2020-05-25,Household and community samples,All,Multiple groups,40.0,,Analysis,Use of open latrines,137,0.54,,,,,,,,Convenience,BIOHIT SARS-CoV-2 antibody test,Biohit Health Care Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,No,Yes,Yes,Yes,No,Yes,No,Yes,Oscar Del Brutto,Universidad Peruana Cayetano Heredia,Unity-Aligned,http://dx.doi.org/10.1093/cid/ciaa1055,2020-10-02,2024-03-01,Verified,del_brutto_sars-cov-2_2020,ECU
200923_Ecuador_UniversidadCatólicaDelEcuador_Patients,200923_Ecuador_UniversidadCatólicaDelEcuador,Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies in Ecuadorian Population,2020-09-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ecuador,,Quito,"11,540 patients came to the laboratory to perform the antibody test in a clinical laboratory in Quito city. Written informed consent was signed by each patient",,2020-05-12,2020-07-20,Household and community samples,All,Multiple groups,,,Primary Estimate,,11540,0.19,,,True,,,,True,Self-referral,NovaLisa® SARS-CoV-2 IgG/IgM,NovaTec Immundiagnostics GmbH,ELISA,Serum,IgG,,,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,,Camilo Zurita Salinas,Universidad Católica Del Ecuador,Not Unity-Aligned,https://www.researchgate.net/publication/344477310_SEROPREVALENCE_OF_ANTI-SARS-COV-2_IGG_ANTIBODIES_IN_ECUADORIAN_POPULATION,2021-05-02,2024-03-01,Verified,zurita_seroprevalence_2020,ECU
200929_Atahualpa_UniversidadPeruanaCayetanoHeredia_overall,200929_Atahualpa_UniversidadPeruanaCayetanoHeredia,Late incidence of SARS-CoV-2 infection in a highly-endemic remote rural village. A prospective population-based cohort study,2020-09-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ecuador,,Atahualpa,Indviduals residing in Atahualpa who were seronegative in a cross-sectional serosurvey conducted in May 2020,,2020-06-25,2020-06-30,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,,362,0.077,,,True,,,,True,Simplified probability,BIOHIT SARS-CoV-2 antibody test,Biohit Health Care Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],No,Yes,No,Yes,Yes,No,Yes,No,Yes,Oscar H Del Brutto,Universidad Peruana Cayetano Heredia,Not Unity-Aligned,https://www.tandfonline.com/doi/full/10.1080/20477724.2020.1826152,2021-04-26,2024-03-01,Verified,brutto_late_2020,ECU
210319_Ecuador_ InstitutoEcuatorianodeEnfermedadesDigestivas,210319_Ecuador_InstitutoEcuatorianodeEnfermedadesDigestivas,Rapid covid-19 antibodies screening testing combined with clinical evaluation for resuming activities in the endoscopy unit: A single-center experience,2021-03-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ecuador,Guayas,Guayaquil,"Patients were screened via telemedicine consult by a pulmonologist for a history of acute symptoms, close contacts, or exposure to COVID-19. Serological screening within 24-hours prior to endoscopic procedures was performed and combined with clinical interpretation. ",,2020-04-15,2020-05-22,Residual sera,All,Adults (18-64 years),,,Primary Estimate,,127,0.0709,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,IgM,,,,,['High'],No,No,No,No,Unclear,Unclear,Yes,No,Unclear,C Robles Medranda,Instituto Ecuatoriano de Enfermedades Digestivas,Not Unity-Aligned,http://dx.doi.org/10.1055/s-0041-1724977,2021-06-06,2022-07-16,Verified,Robles-Medranda_rapid_2021,ECU
210427_Cuenca_UniversityOfAntwerp_overall_UnAdj,210427_Cuenca_UniversityOfAntwerp,"Seroprevalence of SARS-CoV-2 Infection and Adherence to Preventive Measures in Cuenca, Ecuador, October 2020, a Cross-Sectional Study",2021-04-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ecuador,Azuay,,Individuals living in rural or urban areas of Cuenca,,2020-08-11,2020-11-01,Household and community samples,All,Multiple groups,,,Primary Estimate,,2457,0.132,,,True,,,,True,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.8790000000000001,0.943,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Unclear,David Acurio Paez,University of Antwerp,Unity-Aligned,https://www.mdpi.com/1660-4601/18/9/4657,2021-05-21,2024-03-01,Verified,acurio-paez_seroprevalence_2021,ECU
210427_Cuenca_UniversityOfAntwerp_Age20to34,210427_Cuenca_UniversityOfAntwerp,"Seroprevalence of SARS-CoV-2 Infection and Adherence to Preventive Measures in Cuenca, Ecuador, October 2020, a Cross-Sectional Study",2021-04-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ecuador,Azuay,,Individuals living in rural or urban areas of Cuenca,,2020-08-11,2020-11-01,Household and community samples,All,Adults (18-64 years),20.0,34.0,Age,20-34,675,0.11699999999999999,0.094,0.14300000000000002,,,,,,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.8790000000000001,0.943,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Unclear,David Acurio Paez,University of Antwerp,Unity-Aligned,https://www.mdpi.com/1660-4601/18/9/4657,2021-08-12,2024-03-01,Verified,acurio-paez_seroprevalence_2021,ECU
210427_Cuenca_UniversityOfAntwerp_Age50to64,210427_Cuenca_UniversityOfAntwerp,"Seroprevalence of SARS-CoV-2 Infection and Adherence to Preventive Measures in Cuenca, Ecuador, October 2020, a Cross-Sectional Study",2021-04-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ecuador,Azuay,,Individuals living in rural or urban areas of Cuenca,,2020-08-11,2020-11-01,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50-64,461,0.13699999999999998,0.107,0.172,,,,,,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.8790000000000001,0.943,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Unclear,David Acurio Paez,University of Antwerp,Unity-Aligned,https://www.mdpi.com/1660-4601/18/9/4657,2021-08-12,2024-03-01,Verified,acurio-paez_seroprevalence_2021,ECU
210427_Cuenca_UniversityOfAntwerp_AgeOver65,210427_Cuenca_UniversityOfAntwerp,"Seroprevalence of SARS-CoV-2 Infection and Adherence to Preventive Measures in Cuenca, Ecuador, October 2020, a Cross-Sectional Study",2021-04-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ecuador,Azuay,,Individuals living in rural or urban areas of Cuenca,,2020-08-11,2020-11-01,Household and community samples,All,Seniors (65+ years),65.0,,Age,>=65,295,0.13,0.09300000000000001,0.174,,,,,,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.8790000000000001,0.943,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Unclear,David Acurio Paez,University of Antwerp,Unity-Aligned,https://www.mdpi.com/1660-4601/18/9/4657,2021-08-12,2024-03-01,Verified,acurio-paez_seroprevalence_2021,ECU
210427_Cuenca_UniversityOfAntwerp_Age0to19,210427_Cuenca_UniversityOfAntwerp,"Seroprevalence of SARS-CoV-2 Infection and Adherence to Preventive Measures in Cuenca, Ecuador, October 2020, a Cross-Sectional Study",2021-04-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ecuador,Azuay,,Individuals living in rural or urban areas of Cuenca,,2020-08-11,2020-11-01,Household and community samples,All,Children and Youth (0-17 years),0.0,19.0,Age,0-19,402,0.11199999999999999,0.084,0.14800000000000002,,,,,,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.8790000000000001,0.943,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Unclear,David Acurio Paez,University of Antwerp,Unity-Aligned,https://www.mdpi.com/1660-4601/18/9/4657,2021-08-12,2024-03-01,Verified,acurio-paez_seroprevalence_2021,ECU
210427_Cuenca_UniversityOfAntwerp_Age35to49,210427_Cuenca_UniversityOfAntwerp,"Seroprevalence of SARS-CoV-2 Infection and Adherence to Preventive Measures in Cuenca, Ecuador, October 2020, a Cross-Sectional Study",2021-04-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ecuador,Azuay,,Individuals living in rural or urban areas of Cuenca,,2020-08-11,2020-11-01,Household and community samples,All,Adults (18-64 years),35.0,49.0,Age,35-49,624,0.16,0.133,0.192,,,,,,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.8790000000000001,0.943,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Unclear,David Acurio Paez,University of Antwerp,Unity-Aligned,https://www.mdpi.com/1660-4601/18/9/4657,2021-08-12,2024-03-01,Verified,acurio-paez_seroprevalence_2021,ECU
210427_Cuenca_UniversityOfAntwerp_Female,210427_Cuenca_UniversityOfAntwerp,"Seroprevalence of SARS-CoV-2 Infection and Adherence to Preventive Measures in Cuenca, Ecuador, October 2020, a Cross-Sectional Study",2021-04-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ecuador,Azuay,,Individuals living in rural or urban areas of Cuenca,,2020-08-11,2020-11-01,Household and community samples,Female,Multiple groups,,,Sex/Gender,,1460,0.142,0.125,0.161,,,,,,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.8790000000000001,0.943,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Unclear,David Acurio Paez,University of Antwerp,Unity-Aligned,https://www.mdpi.com/1660-4601/18/9/4657,2021-08-12,2024-03-01,Verified,acurio-paez_seroprevalence_2021,ECU
210427_Cuenca_UniversityOfAntwerp_Male,210427_Cuenca_UniversityOfAntwerp,"Seroprevalence of SARS-CoV-2 Infection and Adherence to Preventive Measures in Cuenca, Ecuador, October 2020, a Cross-Sectional Study",2021-04-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ecuador,Azuay,,Individuals living in rural or urban areas of Cuenca,,2020-08-11,2020-11-01,Household and community samples,Male,Multiple groups,,,Sex/Gender,,997,0.12,0.1,0.14,,,,,,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.8790000000000001,0.943,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Unclear,David Acurio Paez,University of Antwerp,Unity-Aligned,https://www.mdpi.com/1660-4601/18/9/4657,2021-08-12,2024-03-01,Verified,acurio-paez_seroprevalence_2021,ECU
210929_Atahualpa_StonyBrookUniversity_April2020_primary,210929_Atahualpa_StonyBrookUniversity_1April2020,Body Composition in Community-Dwelling Older Adults Before and After SARS-CoV-2 Infection: A Longitudinal Prospective Study in a Rural Village Struck by the Pandemic.,2021-09-29,Journal Article (Peer-Reviewed),Local,Prospective cohort,Ecuador,,Atahualpa,"non-disabled, community-dwellers aged ≥60 years registered in the Atahualpa Project cohort that received baseline clinical evaluations and body composition determinations 3 months before the onset of the SARS-CoV-2 pandemic in the village (January 2020)",,2020-04-01,2020-04-30,Household and community samples,All,Multiple groups,60.0,,Primary Estimate,,277,0.43700000000000006,,,True,,,,True,Unclear,BIOHIT SARS-CoV-2 antibody test,Biohit Health Care Ltd,LFIA,,"['IgG', 'IgM']",,,,,['High'],,Unclear,No,Yes,No,No,Yes,No,Unclear,Oscar Del Brutto,Stony Brook University,Not Unity-Aligned,https://dx.doi.org/10.1177/21501327211047781,2021-10-06,2024-03-01,Verified,del_brutto_body_2021,ECU
210929_Atahualpa_StonyBrookUniversity_June2020_primary,210929_Atahualpa_StonyBrookUniversity_2June2020,Body Composition in Community-Dwelling Older Adults Before and After SARS-CoV-2 Infection: A Longitudinal Prospective Study in a Rural Village Struck by the Pandemic.,2021-09-29,Journal Article (Peer-Reviewed),Local,Prospective cohort,Ecuador,,Atahualpa,"non-disabled, community-dwellers aged ≥60 years registered in the Atahualpa Project cohort that received baseline clinical evaluations and body composition determinations 3 months before the onset of the SARS-CoV-2 pandemic in the village (January 2020)",,2020-06-01,2020-06-30,Household and community samples,All,Multiple groups,60.0,,Primary Estimate,,277,0.469,,,True,,,,True,Unclear,BIOHIT SARS-CoV-2 antibody test,Biohit Health Care Ltd,LFIA,,"['IgG', 'IgM']",,,,,['High'],,Unclear,No,Yes,No,No,Yes,No,Unclear,Oscar Del Brutto,Stony Brook University,Not Unity-Aligned,https://dx.doi.org/10.1177/21501327211047781,2021-10-06,2024-03-01,Verified,del_brutto_body_2021,ECU
210929_Atahualpa_StonyBrookUniversity_Sep2020_primary,210929_Atahualpa_StonyBrookUniversity_3Sep2020,Body Composition in Community-Dwelling Older Adults Before and After SARS-CoV-2 Infection: A Longitudinal Prospective Study in a Rural Village Struck by the Pandemic.,2021-09-29,Journal Article (Peer-Reviewed),Local,Prospective cohort,Ecuador,,Atahualpa,"non-disabled, community-dwellers aged ≥60 years registered in the Atahualpa Project cohort that received baseline clinical evaluations and body composition determinations 3 months before the onset of the SARS-CoV-2 pandemic in the village (January 2020)",,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,60.0,,Primary Estimate,,277,0.513,,,True,,,,True,Unclear,BIOHIT SARS-CoV-2 antibody test,Biohit Health Care Ltd,LFIA,,"['IgG', 'IgM']",,,,,['High'],,Unclear,No,Yes,No,No,Yes,No,Unclear,Oscar Del Brutto,Stony Brook University,Not Unity-Aligned,https://dx.doi.org/10.1177/21501327211047781,2021-10-06,2024-03-01,Verified,del_brutto_body_2021,ECU
210929_Atahualpa_StonyBrookUniversity_Jan2021_primary,210929_Atahualpa_StonyBrookUniversity_4Jan2021,Body Composition in Community-Dwelling Older Adults Before and After SARS-CoV-2 Infection: A Longitudinal Prospective Study in a Rural Village Struck by the Pandemic.,2021-09-29,Journal Article (Peer-Reviewed),Local,Prospective cohort,Ecuador,,Atahualpa,"non-disabled, community-dwellers aged ≥60 years registered in the Atahualpa Project cohort that received baseline clinical evaluations and body composition determinations 3 months before the onset of the SARS-CoV-2 pandemic in the village (January 2020)",,2021-01-01,2021-01-30,Household and community samples,All,Multiple groups,60.0,,Primary Estimate,,277,0.596,,,True,,,,True,Unclear,BIOHIT SARS-CoV-2 antibody test,Biohit Health Care Ltd,LFIA,,"['IgG', 'IgM']",,,,,['High'],,Unclear,No,Yes,No,No,Yes,No,Unclear,Oscar Del Brutto,Stony Brook University,Not Unity-Aligned,https://dx.doi.org/10.1177/21501327211047781,2021-10-06,2024-03-01,Verified,del_brutto_body_2021,ECU
210929_Atahualpa_StonyBrookUniversity_April2021_primary,210929_Atahualpa_StonyBrookUniversity_5April2021,Body Composition in Community-Dwelling Older Adults Before and After SARS-CoV-2 Infection: A Longitudinal Prospective Study in a Rural Village Struck by the Pandemic.,2021-09-29,Journal Article (Peer-Reviewed),Local,Prospective cohort,Ecuador,,Atahualpa,"non-disabled, community-dwellers aged ≥60 years registered in the Atahualpa Project cohort that received baseline clinical evaluations and body composition determinations 3 months before the onset of the SARS-CoV-2 pandemic in the village (January 2020)",,2021-04-01,2021-04-30,Household and community samples,All,Multiple groups,60.0,,Primary Estimate,,277,0.632,,,True,,,,True,Unclear,BIOHIT SARS-CoV-2 antibody test,Biohit Health Care Ltd,LFIA,,"['IgG', 'IgM']",,,,,['High'],,Unclear,No,Yes,No,No,Yes,No,Unclear,Oscar Del Brutto,Stony Brook University,Not Unity-Aligned,https://dx.doi.org/10.1177/21501327211047781,2021-10-06,2024-03-01,Verified,del_brutto_body_2021,ECU
211006_Babahoyo_WayneStateUniversity,211006_Babahoyo_WayneStateUniversity,Seroprevalence of SARS-CoV-2 immunoglobulins in pregnant women and neonatal cord blood from a highly impacted region.,2021-10-06,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Ecuador,Los Ríos,Babahoyo,""" This was retrospective study done with samples sent for tests that were originally not related to this study.
...
The study included 100 serum samples collected from pregnant women at the time of delivery along with corresponding neonatal cord blood. Serum samples were collected for routine screening and blood typing. Neonatal cord blood samples were collected only for blood typing.""",,2020-09-03,2021-01-31,Pregnant or parturient women,Female,Multiple groups,16.0,41.0,Primary Estimate,,100,0.32,,,True,,,,True,Unclear,Not reported/ Unable to specify,,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,Unclear,No,No,,Unclear,Yes,No,,Hector Zambrano,Wayne State University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.placenta.2021.10.001,2021-10-19,2022-07-16,Unverified,zambrano_seroprevalence_2021,ECU
211029_Ecuador_UniversidadEspirituSanto,211029_Ecuador_UniversidadEspirituSanto,Factors Associated With a Persistent Seronegative Status 1 Year After a SARS-CoV-2 Massive Infection Outbreak in Community Dwellers Living in Rural Ecuador: A Prospective Population-based Study.,2021-10-29,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Ecuador,Santa Elena Province,Atahualpa,"""Those who granted consent for anti-body determinations were included in this study.""",,2020-05-01,2021-04-30,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,,673,0.637,,,True,,,,True,Convenience,BIOHIT SARS-CoV-2 antibody test,Biohit Health Care Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.975,1.0,['High'],No,No,Yes,Yes,Unclear,No,Yes,Yes,Yes,Oscar Del Brutto,Universidad Espíritu Santo,Unity-Aligned,https://dx.doi.org/10.1177/21501327211054989,2021-11-11,2024-03-01,Verified,del_brutto_factors_2021,ECU
220122_Atahualpa_UniversidadEspirituSanto_Overall,220122_Atahualpa_UniversidadEspirituSanto,Risk for Subsequent SARS-CoV-2 Infection and Severe COVID-19 Among Community-Dwellers With Pre-Existing Cervicocephalic Atherosclerosis: A Population-Based Study.,2022-01-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ecuador,,,"Following a population-based prospective longitudinal study
design, all individuals actively enrolled in the Atahualpa
Project Cohort as of May 2020, who previously had assessments of intracranial and extracranial carotid artery atherosclerosis biomarkers, were eligible for this study. Those who
also signed an informed consent for determination of SARSCoV-2 IgM and IgG antibodies were enrolled.",,2020-05-15,2021-04-15,Household and community samples,All,Adults (18-64 years),40.0,,Primary Estimate,,519,0.63,,,True,,,,True,Convenience,BIOHIT SARS-CoV-2 antibody test,Biohit Health Care Ltd,,,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,Unclear,No,Yes,No,Yes,Oscar Del Brutto,Stony Brook University,Unity-Aligned,https://dx.doi.org/10.1177/21501319211070685,2022-01-31,2024-03-01,Unverified,del_brutto_risk_2022,ECU
220818_Ecuador_UniversidadDeLasAmericas_Overall,220818_Ecuador_UniversidadDeLasAmericas,Sustained COVID-19 community transmission and potential super spreading events at neglected afro-ecuadorian communities assessed by massive RT-qPCR and serological testing of community dwelling population.,2022-08-18,Journal Article (Peer-Reviewed),National,Retrospective cohort,Ecuador,"Atacames, Quininde, Esmeraldas, Muisne, Río Verde",,"All samples were taken from community-dwelling asymptomatic or mild symptomatic individuals at the communities visited from 12th to 19th October 2020 in five out of seven cantons of Esmeraldas province: Esmeraldas, Atacames, Muisne, and Quinindé y Rio Verde",Two cantons were not included in the study (San Lorenzo and Eloy Alfaro),2020-10-12,2020-10-19,Blood donors,All,Multiple groups,0.0,,Primary Estimate,,1259,0.1168,0.0998,0.1362,True,,,,True,Convenience,2019-nCoV IgG Rapid Test,Innovita Biological Technology Co. Ltd,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,0.795,1.0,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,No,,Alexander Paolo Vallejo-Janeta,Universidad de Las Americas,Unity-Aligned,https://dx.doi.org/10.3389/fmed.2022.933260,2022-09-12,2024-04-21,Unverified,vallejo-janeta_sustained_2022,ECU
220818_Ecuador_UniversidadDeLasAmericas_Muisne,220818_Ecuador_UniversidadDeLasAmericas,Sustained COVID-19 community transmission and potential super spreading events at neglected afro-ecuadorian communities assessed by massive RT-qPCR and serological testing of community dwelling population.,2022-08-18,Journal Article (Peer-Reviewed),Regional,Retrospective cohort,Ecuador,Muisne Province,,"All samples were taken from community-dwelling asymptomatic or mild symptomatic individuals at the communities visited from 12th to 19th October 2020 in five out of seven cantons of Esmeraldas province: Esmeraldas, Atacames, Muisne, and Quinindé y Rio Verde",Two cantons were not included in the study (San Lorenzo and Eloy Alfaro),2020-10-12,2020-10-19,Blood donors,All,Multiple groups,0.0,,Geographical area,Muisne Province,59,0.0678,0.0219,0.1727,,,,,,Convenience,2019-nCoV IgG Rapid Test,Innovita Biological Technology Co. Ltd,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,0.795,1.0,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,No,,Alexander Paolo Vallejo-Janeta,Universidad de Las Americas,Unity-Aligned,https://dx.doi.org/10.3389/fmed.2022.933260,2022-09-12,2022-09-12,Unverified,vallejo-janeta_sustained_2022,ECU
220818_Ecuador_UniversidadDeLasAmericas_Quininde,220818_Ecuador_UniversidadDeLasAmericas,Sustained COVID-19 community transmission and potential super spreading events at neglected afro-ecuadorian communities assessed by massive RT-qPCR and serological testing of community dwelling population.,2022-08-18,Journal Article (Peer-Reviewed),Regional,Retrospective cohort,Ecuador,Quininde Province,,"All samples were taken from community-dwelling asymptomatic or mild symptomatic individuals at the communities visited from 12th to 19th October 2020 in five out of seven cantons of Esmeraldas province: Esmeraldas, Atacames, Muisne, and Quinindé y Rio Verde",Two cantons were not included in the study (San Lorenzo and Eloy Alfaro),2020-10-12,2020-10-19,Blood donors,All,Multiple groups,0.0,,Geographical area,Quininde Province,262,0.12210000000000001,0.0862,0.16949999999999998,,,,,,Convenience,2019-nCoV IgG Rapid Test,Innovita Biological Technology Co. Ltd,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,0.795,1.0,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,No,,Alexander Paolo Vallejo-Janeta,Universidad de Las Americas,Unity-Aligned,https://dx.doi.org/10.3389/fmed.2022.933260,2022-09-12,2022-09-12,Unverified,vallejo-janeta_sustained_2022,ECU
220818_Ecuador_UniversidadDeLasAmericas_Female,220818_Ecuador_UniversidadDeLasAmericas,Sustained COVID-19 community transmission and potential super spreading events at neglected afro-ecuadorian communities assessed by massive RT-qPCR and serological testing of community dwelling population.,2022-08-18,Journal Article (Peer-Reviewed),National,Retrospective cohort,Ecuador,"Atacames, Quininde, Esmeraldas, Muisne, Río Verde",,"All samples were taken from community-dwelling asymptomatic or mild symptomatic individuals at the communities visited from 12th to 19th October 2020 in five out of seven cantons of Esmeraldas province: Esmeraldas, Atacames, Muisne, and Quinindé y Rio Verde",Two cantons were not included in the study (San Lorenzo and Eloy Alfaro),2020-10-12,2020-10-19,Blood donors,Female,Multiple groups,0.0,,Sex/Gender,,642,0.1371,0.1119,0.16670000000000001,,,,,,Convenience,2019-nCoV IgG Rapid Test,Innovita Biological Technology Co. Ltd,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,0.795,1.0,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,No,,Alexander Paolo Vallejo-Janeta,Universidad de Las Americas,Unity-Aligned,https://dx.doi.org/10.3389/fmed.2022.933260,2022-09-12,2022-09-12,Unverified,vallejo-janeta_sustained_2022,ECU
220818_Ecuador_UniversidadDeLasAmericas_Male,220818_Ecuador_UniversidadDeLasAmericas,Sustained COVID-19 community transmission and potential super spreading events at neglected afro-ecuadorian communities assessed by massive RT-qPCR and serological testing of community dwelling population.,2022-08-18,Journal Article (Peer-Reviewed),National,Retrospective cohort,Ecuador,"Atacames, Quininde, Esmeraldas, Muisne, Río Verde",,"All samples were taken from community-dwelling asymptomatic or mild symptomatic individuals at the communities visited from 12th to 19th October 2020 in five out of seven cantons of Esmeraldas province: Esmeraldas, Atacames, Muisne, and Quinindé y Rio Verde",Two cantons were not included in the study (San Lorenzo and Eloy Alfaro),2020-10-12,2020-10-19,Blood donors,Male,Multiple groups,0.0,,Sex/Gender,,608,0.0953,0.0738,0.1223,,,,,,Convenience,2019-nCoV IgG Rapid Test,Innovita Biological Technology Co. Ltd,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,0.795,1.0,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,No,,Alexander Paolo Vallejo-Janeta,Universidad de Las Americas,Unity-Aligned,https://dx.doi.org/10.3389/fmed.2022.933260,2022-09-12,2022-09-12,Unverified,vallejo-janeta_sustained_2022,ECU
220818_Ecuador_UniversidadDeLasAmericas_RíoVerde,220818_Ecuador_UniversidadDeLasAmericas,Sustained COVID-19 community transmission and potential super spreading events at neglected afro-ecuadorian communities assessed by massive RT-qPCR and serological testing of community dwelling population.,2022-08-18,Journal Article (Peer-Reviewed),Regional,Retrospective cohort,Ecuador,Río Verde Province,,"All samples were taken from community-dwelling asymptomatic or mild symptomatic individuals at the communities visited from 12th to 19th October 2020 in five out of seven cantons of Esmeraldas province: Esmeraldas, Atacames, Muisne, and Quinindé y Rio Verde",Two cantons were not included in the study (San Lorenzo and Eloy Alfaro),2020-10-12,2020-10-19,Blood donors,All,Multiple groups,0.0,,Geographical area,Río Verde Province,60,0.0167,0.0009,0.1014,,,,,,Convenience,2019-nCoV IgG Rapid Test,Innovita Biological Technology Co. Ltd,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,0.795,1.0,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,No,,Alexander Paolo Vallejo-Janeta,Universidad de Las Americas,Unity-Aligned,https://dx.doi.org/10.3389/fmed.2022.933260,2022-09-12,2022-09-12,Unverified,vallejo-janeta_sustained_2022,ECU
220818_Ecuador_UniversidadDeLasAmericas_AgeOver60,220818_Ecuador_UniversidadDeLasAmericas,Sustained COVID-19 community transmission and potential super spreading events at neglected afro-ecuadorian communities assessed by massive RT-qPCR and serological testing of community dwelling population.,2022-08-18,Journal Article (Peer-Reviewed),National,Retrospective cohort,Ecuador,"Atacames, Quininde, Esmeraldas, Muisne, Río Verde",,"All samples were taken from community-dwelling asymptomatic or mild symptomatic individuals at the communities visited from 12th to 19th October 2020 in five out of seven cantons of Esmeraldas province: Esmeraldas, Atacames, Muisne, and Quinindé y Rio Verde",Two cantons were not included in the study (San Lorenzo and Eloy Alfaro),2020-10-12,2020-10-19,Blood donors,All,Seniors (65+ years),60.0,,Age,age: >= 60,196,0.184,0.1335,0.2466,,,,,,Convenience,2019-nCoV IgG Rapid Test,Innovita Biological Technology Co. Ltd,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,0.795,1.0,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,No,,Alexander Paolo Vallejo-Janeta,Universidad de Las Americas,Unity-Aligned,https://dx.doi.org/10.3389/fmed.2022.933260,2022-09-12,2022-09-12,Unverified,vallejo-janeta_sustained_2022,ECU
220818_Ecuador_UniversidadDeLasAmericas_Age0to14,220818_Ecuador_UniversidadDeLasAmericas,Sustained COVID-19 community transmission and potential super spreading events at neglected afro-ecuadorian communities assessed by massive RT-qPCR and serological testing of community dwelling population.,2022-08-18,Journal Article (Peer-Reviewed),National,Retrospective cohort,Ecuador,"Atacames, Quininde, Esmeraldas, Muisne, Río Verde",,"All samples were taken from community-dwelling asymptomatic or mild symptomatic individuals at the communities visited from 12th to 19th October 2020 in five out of seven cantons of Esmeraldas province: Esmeraldas, Atacames, Muisne, and Quinindé y Rio Verde",Two cantons were not included in the study (San Lorenzo and Eloy Alfaro),2020-10-12,2020-10-19,Blood donors,All,Children and Youth (0-17 years),0.0,14.0,Age,age: 0-14,70,0.18600000000000003,0.10640000000000001,0.3002,,,,,,Convenience,2019-nCoV IgG Rapid Test,Innovita Biological Technology Co. Ltd,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,0.795,1.0,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,No,,Alexander Paolo Vallejo-Janeta,Universidad de Las Americas,Unity-Aligned,https://dx.doi.org/10.3389/fmed.2022.933260,2022-09-12,2022-09-12,Unverified,vallejo-janeta_sustained_2022,ECU
220818_Ecuador_UniversidadDeLasAmericas_Esmeraldas,220818_Ecuador_UniversidadDeLasAmericas,Sustained COVID-19 community transmission and potential super spreading events at neglected afro-ecuadorian communities assessed by massive RT-qPCR and serological testing of community dwelling population.,2022-08-18,Journal Article (Peer-Reviewed),Regional,Retrospective cohort,Ecuador,Esmeraldas Province,,"All samples were taken from community-dwelling asymptomatic or mild symptomatic individuals at the communities visited from 12th to 19th October 2020 in five out of seven cantons of Esmeraldas province: Esmeraldas, Atacames, Muisne, and Quinindé y Rio Verde",Two cantons were not included in the study (San Lorenzo and Eloy Alfaro),2020-10-12,2020-10-19,Blood donors,All,Multiple groups,0.0,,Geographical area,Esmeraldas Province,775,0.111,0.0902,0.13570000000000002,,,,,,Convenience,2019-nCoV IgG Rapid Test,Innovita Biological Technology Co. Ltd,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,0.795,1.0,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,No,,Alexander Paolo Vallejo-Janeta,Universidad de Las Americas,Unity-Aligned,https://dx.doi.org/10.3389/fmed.2022.933260,2022-09-12,2022-09-12,Unverified,vallejo-janeta_sustained_2022,ECU
220818_Ecuador_UniversidadDeLasAmericas_Atacames,220818_Ecuador_UniversidadDeLasAmericas,Sustained COVID-19 community transmission and potential super spreading events at neglected afro-ecuadorian communities assessed by massive RT-qPCR and serological testing of community dwelling population.,2022-08-18,Journal Article (Peer-Reviewed),Regional,Retrospective cohort,Ecuador,Atacames Province,,"All samples were taken from community-dwelling asymptomatic or mild symptomatic individuals at the communities visited from 12th to 19th October 2020 in five out of seven cantons of Esmeraldas province: Esmeraldas, Atacames, Muisne, and Quinindé y Rio Verde",Two cantons were not included in the study (San Lorenzo and Eloy Alfaro),2020-10-12,2020-10-19,Blood donors,All,Multiple groups,0.0,,Geographical area,Atacames Province,94,0.2447,0.16440000000000002,0.3461,,,,,,Convenience,2019-nCoV IgG Rapid Test,Innovita Biological Technology Co. Ltd,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,0.795,1.0,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,No,,Alexander Paolo Vallejo-Janeta,Universidad de Las Americas,Unity-Aligned,https://dx.doi.org/10.3389/fmed.2022.933260,2022-09-12,2022-09-12,Unverified,vallejo-janeta_sustained_2022,ECU
220818_Ecuador_UniversidadDeLasAmericas_Age40to59,220818_Ecuador_UniversidadDeLasAmericas,Sustained COVID-19 community transmission and potential super spreading events at neglected afro-ecuadorian communities assessed by massive RT-qPCR and serological testing of community dwelling population.,2022-08-18,Journal Article (Peer-Reviewed),National,Retrospective cohort,Ecuador,"Atacames, Quininde, Esmeraldas, Muisne, Río Verde",,"All samples were taken from community-dwelling asymptomatic or mild symptomatic individuals at the communities visited from 12th to 19th October 2020 in five out of seven cantons of Esmeraldas province: Esmeraldas, Atacames, Muisne, and Quinindé y Rio Verde",Two cantons were not included in the study (San Lorenzo and Eloy Alfaro),2020-10-12,2020-10-19,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,age: 40-59,431,0.132,0.10250000000000001,0.1688,,,,,,Convenience,2019-nCoV IgG Rapid Test,Innovita Biological Technology Co. Ltd,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,0.795,1.0,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,No,,Alexander Paolo Vallejo-Janeta,Universidad de Las Americas,Unity-Aligned,https://dx.doi.org/10.3389/fmed.2022.933260,2022-09-12,2022-09-12,Unverified,vallejo-janeta_sustained_2022,ECU
220818_Ecuador_UniversidadDeLasAmericas_Age15to39,220818_Ecuador_UniversidadDeLasAmericas,Sustained COVID-19 community transmission and potential super spreading events at neglected afro-ecuadorian communities assessed by massive RT-qPCR and serological testing of community dwelling population.,2022-08-18,Journal Article (Peer-Reviewed),National,Retrospective cohort,Ecuador,"Atacames, Quininde, Esmeraldas, Muisne, Río Verde",,"All samples were taken from community-dwelling asymptomatic or mild symptomatic individuals at the communities visited from 12th to 19th October 2020 in five out of seven cantons of Esmeraldas province: Esmeraldas, Atacames, Muisne, and Quinindé y Rio Verde",Two cantons were not included in the study (San Lorenzo and Eloy Alfaro),2020-10-12,2020-10-19,Blood donors,All,Multiple groups,15.0,39.0,Age,age: 15-39,553,0.07200000000000001,0.05280000000000001,0.098,,,,,,Convenience,2019-nCoV IgG Rapid Test,Innovita Biological Technology Co. Ltd,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,0.795,1.0,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,No,,Alexander Paolo Vallejo-Janeta,Universidad de Las Americas,Unity-Aligned,https://dx.doi.org/10.3389/fmed.2022.933260,2022-09-12,2022-09-12,Unverified,vallejo-janeta_sustained_2022,ECU
200721_Egypt_CairoUniversity_TotalHCW_Overall,200721_Egypt_CairoUniversity,SARS-CoV-2 infection among healthcare workers of a gastroenterological service in a tertiary care facility,2020-07-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Egypt,,Cairo,"All 138 healthcare workers employed in the gastroenterology service of Al-Manial University Hospital, Cairo University were invited to participate in the study according to the eligibility criteria: active clinical work in the department, no involvement in COVID-19 wards.  Presence of isolated other minor symptoms, however, was not an exclusion criterion in order not to underestimate the extent of infection in the studied population","Patients with a combination of major symptoms (fever, new persistent cough) were considered suspicious of COVID-19 and were temporarily excluded from work and were not entitled to enter the study. Presence of isolated other minor symptoms, however, was not an exclusion criterion in order not to underestimate the extent of infection in the studied population",2020-06-01,2020-06-14,Health care workers and caregivers,All,Adults (18-64 years),23.0,48.0,Primary Estimate,IgG and/or IgM ,74,0.122,,,True,,,,True,Convenience,One Step Novel Coronavirus (COVID-19) IgM/IgG Antibody Test,Artron Laboratories Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.934,0.9770000000000001,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,No,Abdel Meguid Kassem,Cairo University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ajg.2020.07.005,2020-09-29,2024-03-01,Verified,kassem_sars-cov-2_2020,EGY
201023_Egypt_AinShamsUniversity_Overall,201023_Egypt_AinShamsUniversity,Universal COVID-19 screening of 4040 health care workers in a resource-limited setting: an Egyptian pilot model in a university with 12 public hospitals and medical centers.,2020-10-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Egypt,Cairo Governorate,Cairo,"Baseline screening at ASU hospitals was piloted between 22 April and 14 May 2020. It consisted of a cross-sectional study that included an online survey to identify HCWs’ epidemiologicaland clinical characteristics, plus laboratory sampling and testing to assess HCWs’ SARS-CoV-2 infection status. Screening targeted all hospital staff on the job (approximately 6000), who provided clinical or non-clinical care to patients—including asymptomatic HCWs—and in all hospital areas (no units/wards were prioritized for screening).","There were no exclusion criteria, i.e. screening targeted all hospital staff on the job (approximately 6000), who provided clinical or non-clinical care to patients—including asymptomatic HCWs—and in all hospital areas (no units/wards were prioritized for screening).",2020-04-22,2020-05-14,Health care workers and caregivers,All,Multiple groups,18.0,,Primary Estimate,,4040,0.0131,,,True,,,,True,Convenience,One Step Novel Coronavirus (COVID-19) IgM/IgG Antibody Test,Artron Laboratories Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.833,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Unclear,Aya Mostafa,Ain Shams University,Not Unity-Aligned,https://academic.oup.com/ije/advance-article/doi/10.1093/ije/dyaa173/5936053,2021-01-23,2024-03-01,Verified,mostafa_universal_2020,EGY
210115_Cairo_CairoUniversity,210115_Cairo_CairoUniversity,SARS-CoV-2 infection among asymptomatic healthcare workers of the emergency department in a tertiary care facility,2021-01-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Egypt,,Cairo,"HCWs including physicians, nurses, workers, technicians, and clerks.","symptoms suggestive of COVID-19, and/or tested positive for SARSCoV-2 by RT-PCR.",2020-06-01,2020-06-14,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Asymptomatic healthcare workers at a large tertiary care center,203,0.182,,,True,,,,True,Convenience,One Step Novel Coronavirus (COVID-19) IgM/IgG Antibody Test,Artron Laboratories Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.934,0.9770000000000001,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,No,Reham Abdelmoniem,Cairo University ,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcv.2020.104710,2021-01-23,2024-03-01,Verified,abdelmoniem_sars-cov-2_2021,EGY
210311_Egypt_CenterofScientificExcellenceforInfluenzaViruses_April1,210311_Egypt_CenterofScientificExcellenceforInfluenzaViruses_April1,"Incidence, household transmission, and neutralizing antibody seroprevalence of Coronavirus Disease 2019 in Egypt: Results of a community-based cohort.",2021-03-11,Journal Article (Peer-Reviewed),National,Prospective cohort,Egypt,"Sharkiyah Governorate, Gharbiyah Governorate, Kafr El Sheikh Governorate, Qalyubiyah Governorate, Fayyoum Governorate",,"households raising backyard poultry were selected from five villages in four Nile Delta governorates (Sharkiyah, Gharbiyah, Kafr El Sheikh, and Qalyubiyah) and Fayyoum governorate starting August 2015. All individuals within the household who were older than two years were invited to participate.
The study protocol was amended in April 2020, to allow COVID-19 incidence and seroprevalence studies in four study sites (Fayyoum, Gharbiyah, Kafr El Sheikh, and Qalyubiyah) comprising 290 households.

This cohort was initially intended to study the household transmission of zoonotic influenza viruses in a cohort of Egyptian poultry growers.",,2020-04-01,2020-04-30,Household and community samples,All,Multiple groups,2.0,,Primary Estimate,,212,0.0,,,True,,,,True,Simplified probability,Author designed (ELISA) -Spike,,Neutralization,Serum,Neutralizing,,,,,['High'],No,Yes,No,No,Unclear,Unclear,Yes,No,Unclear,Mokhtar R Gomaa,Center of Scientific Excellence for Influenza Viruses ,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.ppat.1009413,2021-05-10,2022-07-16,Verified,gomaa_incidence_2021,EGY
210311_Egypt_CenterofScientificExcellenceforInfluenzaViruses_July2,210311_Egypt_CenterofScientificExcellenceforInfluenzaViruses_July2,"Incidence, household transmission, and neutralizing antibody seroprevalence of Coronavirus Disease 2019 in Egypt: Results of a community-based cohort.",2021-03-11,Journal Article (Peer-Reviewed),National,Prospective cohort,Egypt,"Sharkiyah Governorate, Gharbiyah Governorate, Kafr El Sheikh Governorate, Qalyubiyah Governorate, Fayyoum Governorate",,"households raising backyard poultry were selected from five villages in four Nile Delta governorates (Sharkiyah, Gharbiyah, Kafr El Sheikh, and Qalyubiyah) and Fayyoum governorate starting August 2015. All individuals within the household who were older than two years were invited to participate.
The study protocol was amended in April 2020, to allow COVID-19 incidence and seroprevalence studies in four study sites (Fayyoum, Gharbiyah, Kafr El Sheikh, and Qalyubiyah) comprising 290 households.

This cohort was initially intended to study the household transmission of zoonotic influenza viruses in a cohort of Egyptian poultry growers.",,2020-07-01,2020-07-31,Household and community samples,All,Multiple groups,2.0,,Primary Estimate,,1244,0.2,,,,,,,,Simplified probability,Author designed (ELISA) -Spike,,Neutralization,Serum,Neutralizing,,,,,['High'],No,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,Mokhtar R Gomaa,Center of Scientific Excellence for Influenza Viruses ,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.ppat.1009413,2021-05-10,2022-07-16,Verified,gomaa_incidence_2021,EGY
210311_Egypt_CenterofScientificExcellenceforInfluenzaViruses_October3,210311_Egypt_CenterofScientificExcellenceforInfluenzaViruses_October3,"Incidence, household transmission, and neutralizing antibody seroprevalence of Coronavirus Disease 2019 in Egypt: Results of a community-based cohort.",2021-03-11,Journal Article (Peer-Reviewed),National,Prospective cohort,Egypt,"Sharkiyah Governorate, Gharbiyah Governorate, Kafr El Sheikh Governorate, Qalyubiyah Governorate, Fayyoum Governorate",,"households raising backyard poultry were selected from five villages in four Nile Delta governorates (Sharkiyah, Gharbiyah, Kafr El Sheikh, and Qalyubiyah) and Fayyoum governorate starting August 2015. All individuals within the household who were older than two years were invited to participate.
The study protocol was amended in April 2020, to allow COVID-19 incidence and seroprevalence studies in four study sites (Fayyoum, Gharbiyah, Kafr El Sheikh, and Qalyubiyah) comprising 290 households.

This cohort was initially intended to study the household transmission of zoonotic influenza viruses in a cohort of Egyptian poultry growers.",,2020-10-01,2020-10-31,Household and community samples,All,Multiple groups,2.0,,Primary Estimate,,1260,0.348,,,True,,,,True,Simplified probability,Author designed (Neutralization Assay),,Neutralization,Serum,Neutralizing,,,,,['Moderate'],No,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,Mokhtar R Gomaa,Center of Scientific Excellence for Influenza Viruses ,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.ppat.1009413,2021-05-10,2022-07-16,Verified,gomaa_incidence_2021,EGY
210402_Cairo_CairoUniversity_HCW,210402_Cairo_CairoUniversity,Asymptomatic SARS-CoV-2 infection among healthcare workers in a non-COVID-19 Teaching University Hospital,2021-04-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Egypt,,,"The researchers defined the study population as those HCWs who deliver care and services to patients ,including physicians and nurses. Inclusion criteria included being an adult (>18 years) working at Cairo University Hospital. 

All participants had worked at Cairo University Hospital for at least one month before study enrollment and were asymptomatic at the point of study recruitment.","Exclusion criteria included: a) absenteeism from the workplace in the last 30 days, retirement, or end-of-contract, and working in a COVID hospital.

HCWs who were previously diagnosed with COVID-19 were excluded from the study",2020-05-05,2020-06-11,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,455,0.079,0.057999999999999996,0.10800000000000001,True,,,,True,Convenience,"Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,iFlash-SARS-CoV-2 IgM/IgG","SD Biosensor,Shenzhen Yhlo Biotech Co. Ltd",Multiple Types,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],No,No,No,Yes,Unclear,Unclear,Yes,No,Yes,Ahmed Mukhtar,Cairo University,Not Unity-Aligned,https://dx.doi.org/10.4081/jphr.2021.2102,2021-04-18,2024-03-01,Verified,mukhtar_asymptomatic_2021,EGY
210610_Cairo_CairoUniversity_GenPop2_overall_TotalAbCLIA,210610_Cairo_CairoUniversity_GenPop2,Prevalence of SARS-CoV-2 infection and dynamics of antibodies response among previously undiagnosed healthcare workers in a university hospital: A prospective cohort study.,2021-06-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Egypt,,Cairo,Non-healthcare workers (NHCWs) were recruited randomly as volunteers not affiliated to any healthcare facility,Individuals previously tested positive for SARS-CoV-2 via RT-PCR or those self-isolating at home due to symptoms typical of COVID-19 during the last 14 days were excluded from the study.,2020-06-01,2020-06-14,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,"Overall, total Ab CLIA",725,0.294,,,True,,,,True,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Sherief Musa,Cairo University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jiph.2021.06.001,2021-07-06,2024-03-01,Verified,musa_prevalence_2021,EGY
210610_Cairo_CairoUniversity_GenPop2_overall_IgGCLIA,210610_Cairo_CairoUniversity_GenPop2,Prevalence of SARS-CoV-2 infection and dynamics of antibodies response among previously undiagnosed healthcare workers in a university hospital: A prospective cohort study.,2021-06-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Egypt,,Cairo,Non-healthcare workers (NHCWs) were recruited randomly as volunteers not affiliated to any healthcare facility,Individuals previously tested positive for SARS-CoV-2 via RT-PCR or those self-isolating at home due to symptoms typical of COVID-19 during the last 14 days were excluded from the study.,2020-06-01,2020-06-14,Household and community samples,All,Adults (18-64 years),,,Test used,"Overall, IgG CLIA",725,0.276,,,,,,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,IgG,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Sherief Musa,Cairo University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jiph.2021.06.001,2021-07-06,2024-03-01,Verified,musa_prevalence_2021,EGY
210610_Cairo_CairoUniversity_GenPop2_RST,210610_Cairo_CairoUniversity_GenPop2,Prevalence of SARS-CoV-2 infection and dynamics of antibodies response among previously undiagnosed healthcare workers in a university hospital: A prospective cohort study.,2021-06-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Egypt,,Cairo,Non-healthcare workers (NHCWs) were recruited randomly as volunteers not affiliated to any healthcare facility,Individuals previously tested positive for SARS-CoV-2 via RT-PCR or those self-isolating at home due to symptoms typical of COVID-19 during the last 14 days were excluded from the study.,2020-06-01,2020-06-14,Household and community samples,All,Adults (18-64 years),,,Test used,"Overall, RDT",725,0.062000000000000006,,,,,,,,Simplified probability,One Step Novel Coronavirus (COVID-19) IgM/IgG Antibody Test,Artron Laboratories Inc.,LFIA,Serum,IgM,,Validated by manufacturers,0.934,0.9770000000000001,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Sherief Musa,Cairo University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jiph.2021.06.001,2021-07-06,2024-03-01,Verified,musa_prevalence_2021,EGY
210610_Cairo_CairoUniversity_HCW1_overall,210610_Cairo_CairoUniversity_HCW1,Prevalence of SARS-CoV-2 infection and dynamics of antibodies response among previously undiagnosed healthcare workers in a university hospital: A prospective cohort study.,2021-06-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Egypt,,Cairo,"Eligible HCWs were defined as those who deliver healthcare services to patients in Kasr Al-Aini University Hospital at the time of the study, either directly as physicians or nurses, or indirectly as administrative officers, transporters, or cleaners.",Individuals previously tested positive for SARS-CoV-2 via RT-PCR or those self-isolating at home due to symptoms typical of COVID-19 during the last 14 days were excluded from the study.,2020-06-01,2020-06-14,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,386,0.158,,,True,,,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.9,1.0,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Sherief Musa,Cairo University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jiph.2021.06.001,2021-07-06,2024-03-01,Verified,musa_prevalence_2021,EGY
210715_Egypt_NationalResearchCentre_Primary,210715_Egypt_NationalResearchCentre,Determinants of having severe acute respiratory syndrome coronavirus 2 neutralizing antibodies in Egypt.,2021-07-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Egypt,,Cairo,"The study population was employees of a major research institution in
Egypt located in Greater Cairo, totaling around 7000.9 In the period
August–October 2020, study personnel visited all departments of the
institution on two different days and invited all individuals present at
the time of the visit and who never had a laboratory-confirmed SARSCoV-2 infection to participate.",Research institution employees who have had a laboratory-confirmed SARSCoV-2 infection.,2020-08-15,2020-10-15,Multiple general populations,All,Multiple groups,,,Primary Estimate,,888,0.3,,,True,,,,True,Convenience,Author designed (Neutralization Assay),,Neutralization,Serum,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Amira S. El Rifay,National Research Centre,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.12889,2021-07-19,2022-07-16,Unverified,rifay_determinants_2021,EGY
210715_Egypt_NationalResearchCentre_4150,210715_Egypt_NationalResearchCentre,Determinants of having severe acute respiratory syndrome coronavirus 2 neutralizing antibodies in Egypt.,2021-07-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Egypt,,Cairo,"The study population was employees of a major research institution in
Egypt located in Greater Cairo, totaling around 7000.9 In the period
August–October 2020, study personnel visited all departments of the
institution on two different days and invited all individuals present at
the time of the visit and who never had a laboratory-confirmed SARSCoV-2 infection to participate.",Research institution employees who have had a laboratory-confirmed SARSCoV-2 infection.,2020-08-15,2020-10-15,Multiple general populations,All,Adults (18-64 years),,,Age,,223,0.35000000000000003,,,,,,,,Convenience,Author designed (Neutralization Assay),,Neutralization,Serum,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Amira S. El Rifay,National Research Centre,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.12889,2021-07-19,2022-07-16,Unverified,rifay_determinants_2021,EGY
210715_Egypt_NationalResearchCentre_5160,210715_Egypt_NationalResearchCentre,Determinants of having severe acute respiratory syndrome coronavirus 2 neutralizing antibodies in Egypt.,2021-07-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Egypt,,Cairo,"The study population was employees of a major research institution in
Egypt located in Greater Cairo, totaling around 7000.9 In the period
August–October 2020, study personnel visited all departments of the
institution on two different days and invited all individuals present at
the time of the visit and who never had a laboratory-confirmed SARSCoV-2 infection to participate.",Research institution employees who have had a laboratory-confirmed SARSCoV-2 infection.,2020-08-15,2020-10-15,Multiple general populations,All,Adults (18-64 years),,,Age,,264,0.322,,,,,,,,Convenience,Author designed (Neutralization Assay),,Neutralization,Serum,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Amira S. El Rifay,National Research Centre,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.12889,2021-07-19,2022-07-16,Unverified,rifay_determinants_2021,EGY
210715_Egypt_NationalResearchCentre_6170,210715_Egypt_NationalResearchCentre,Determinants of having severe acute respiratory syndrome coronavirus 2 neutralizing antibodies in Egypt.,2021-07-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Egypt,,Cairo,"The study population was employees of a major research institution in
Egypt located in Greater Cairo, totaling around 7000.9 In the period
August–October 2020, study personnel visited all departments of the
institution on two different days and invited all individuals present at
the time of the visit and who never had a laboratory-confirmed SARSCoV-2 infection to participate.",Research institution employees who have had a laboratory-confirmed SARSCoV-2 infection.,2020-08-15,2020-10-15,Multiple general populations,All,Multiple groups,,,Age,,51,0.294,,,,,,,,Convenience,Author designed (Neutralization Assay),,Neutralization,Serum,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Amira S. El Rifay,National Research Centre,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.12889,2021-07-19,2022-07-16,Unverified,rifay_determinants_2021,EGY
210715_Egypt_NationalResearchCentre_30minus,210715_Egypt_NationalResearchCentre,Determinants of having severe acute respiratory syndrome coronavirus 2 neutralizing antibodies in Egypt.,2021-07-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Egypt,,Cairo,"The study population was employees of a major research institution in
Egypt located in Greater Cairo, totaling around 7000.9 In the period
August–October 2020, study personnel visited all departments of the
institution on two different days and invited all individuals present at
the time of the visit and who never had a laboratory-confirmed SARSCoV-2 infection to participate.",Research institution employees who have had a laboratory-confirmed SARSCoV-2 infection.,2020-08-15,2020-10-15,Multiple general populations,All,Adults (18-64 years),,,Age,younger than 30,86,0.233,,,,,,,,Convenience,Author designed (Neutralization Assay),,Neutralization,Serum,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Amira S. El Rifay,National Research Centre,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.12889,2021-07-19,2022-07-16,Unverified,rifay_determinants_2021,EGY
210715_Egypt_NationalResearchCentre_3140,210715_Egypt_NationalResearchCentre,Determinants of having severe acute respiratory syndrome coronavirus 2 neutralizing antibodies in Egypt.,2021-07-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Egypt,,Cairo,"The study population was employees of a major research institution in
Egypt located in Greater Cairo, totaling around 7000.9 In the period
August–October 2020, study personnel visited all departments of the
institution on two different days and invited all individuals present at
the time of the visit and who never had a laboratory-confirmed SARSCoV-2 infection to participate.",Research institution employees who have had a laboratory-confirmed SARSCoV-2 infection.,2020-08-15,2020-10-15,Multiple general populations,All,Adults (18-64 years),,,Age,,251,0.271,,,,,,,,Convenience,Author designed (Neutralization Assay),,Neutralization,Serum,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Amira S. El Rifay,National Research Centre,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.12889,2021-07-19,2022-07-16,Unverified,rifay_determinants_2021,EGY
210715_Egypt_NationalResearchCentre_70plus,210715_Egypt_NationalResearchCentre,Determinants of having severe acute respiratory syndrome coronavirus 2 neutralizing antibodies in Egypt.,2021-07-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Egypt,,Cairo,"The study population was employees of a major research institution in
Egypt located in Greater Cairo, totaling around 7000.9 In the period
August–October 2020, study personnel visited all departments of the
institution on two different days and invited all individuals present at
the time of the visit and who never had a laboratory-confirmed SARSCoV-2 infection to participate.",Research institution employees who have had a laboratory-confirmed SARSCoV-2 infection.,2020-08-15,2020-10-15,Multiple general populations,All,Seniors (65+ years),,,Age,over 70,13,0.0,,,,,,,,Convenience,Author designed (Neutralization Assay),,Neutralization,Serum,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Amira S. El Rifay,National Research Centre,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.12889,2021-07-19,2022-07-16,Unverified,rifay_determinants_2021,EGY
210715_Cairo_Ain-ShamsUniversity_TestAdj,210715_Cairo_Ain-ShamsUniversity,SARS-CoV-2 PCR positivity rate and seroprevalence of related antibodies among a sample of patients in Cairo: Pre-wave 2 results of a screening program in a university hospital,2021-07-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Egypt,Cairo Governate,Cairo,All patients needing admission to ASU hospitals were eligible for the study,,2020-05-05,2020-10-31,Residual sera,All,Multiple groups,,,Primary Estimate,Test adj,2927,0.2982,0.2816,0.31510000000000005,True,True,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Samia Girgis,Ain-Shams University,Unity-Aligned,http://dx.doi.org/10.1371/journal.pone.0254581,2021-08-03,2023-08-15,Unverified,girgis_sars-cov-2_2021,EGY
210715_Cairo_Ain-ShamsUniversity_Unadj,210715_Cairo_Ain-ShamsUniversity,SARS-CoV-2 PCR positivity rate and seroprevalence of related antibodies among a sample of patients in Cairo: Pre-wave 2 results of a screening program in a university hospital,2021-07-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Egypt,Cairo Governate,Cairo,All patients needing admission to ASU hospitals were eligible for the study,,2020-05-05,2020-10-31,Residual sera,All,Multiple groups,,,Analysis,Unadj,2927,0.29960000000000003,0.2831,0.3166,,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Samia Girgis,Ain-Shams University,Unity-Aligned,http://dx.doi.org/10.1371/journal.pone.0254581,2021-08-03,2024-03-01,Unverified,girgis_sars-cov-2_2021,EGY
210911_Egypt_AinShamsUniversity_Primary,210911_Egypt_AinShamsUniversity,Comparative evaluation of sars-cov-2 rapid immunochromatographic test assays with chemiluminescent immunoassay for the diagnosis of covid-19,2021-09-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Egypt,Cairo Governate,Cairo,"In total, 49 attendees of the outpatient clinic
at the Reference Laboratory of Egyptian university
hospitals (RLEUH) were enrolled in this study. One serum sample was collected as per each participant. ",,2021-04-15,2021-05-15,Residual sera,All,Multiple groups,13.0,60.0,Primary Estimate,CLIA testing results,49,0.7347,,,,,,,,Convenience,Mindray CL-900i anti-SARS-CoV-2 IgG/IgM,Shenzhen Mindray Bio-Medical Electronics Co.,CLIA,Serum,"['IgG', 'IgM']",,,,,['High'],Unclear,No,No,Yes,Unclear,Unclear,Yes,No,,Ghada Ismail,Ain Shams University,Not Unity-Aligned,http://dx.doi.org/10.3889/oamjms.2021.7076,2021-10-19,2022-08-24,Verified,ismail_comparative_2021,EGY
210920_Egypt_AssiutUniversity_Overall,210920_Egypt_AssiutUniversity,Sero-prevalence of anti-SARS-CoV-2 antibodies among healthcare workers: A multicenter study from Egypt.,2021-09-20,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Egypt,"Ash Sharqiyah, Asyut","Zagazig, Assiut","""HCWs who were working in SARS-CoV-2 Isolation Hospitals either in Zagazig and Assiut Universities during the period from April to June 2020.""",,2020-10-15,2020-12-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,82,0.46299999999999997,,,True,,,,True,Unclear,Not reported/ Unable to specify,,ELISA,Serum,"['IgG', 'IgM']",Spike,,,,['High'],,Unclear,No,Yes,,Unclear,Yes,No,,Rehab El-Sokkary,Assiut University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jiph.2021.09.011,2021-10-05,2022-07-16,Unverified,el-sokkary_sero-prevalence_2021,EGY
211029_Cairo_AinShamsUniversity,211029_Cairo_AinShamsUniversity,Seropositive coronavirus disease 2019 detection among apparently healthy voluntary blood donors: a preliminary step to catch asymptomatic cases as a potential viral spread route,2021-10-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Egypt,,Cairo,Blood Donors at Ain-Shams University Hospitals from September 2020 to October 2020. ,,2020-09-06,2020-10-31,Blood donors,All,Adults (18-64 years),,,Primary Estimate,,100,0.38,,,True,,,,True,Simplified probability,AMP Rapid Test SARS-CoV-2 IgG/IgM,AMEDA Labordiagnostik GmbH,LFIA,Serum,"['IgG', 'IgM']",Spike,,,,['High'],No,Yes,No,No,Unclear,Yes,Yes,Yes,,Sahar Abdelmaksoud,Ain-Shams University,Unity-Aligned,https://www.ehj.eg.net/article.asp?issn=1110-1067;year=2021;volume=46;issue=2;spage=65;epage=69;aulast=Abdelmaksoud,2021-12-14,2024-03-01,Verified,abdelmaksoud_seropositive_2021,EGY
220429_Egypt_AssiutUniversity_Baby_TotalAb,220429_Egypt_AssiutUniversity_Baby,The rate of SARS-CoV-2 among asymptomatic non-immunised low-risk parturient women between the two waves.,2022-04-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Egypt,,Assiut,"""All non-immunised parturient women with no history of SARS CoV-2 or direct exposure were included in our study. We included women who were pregnant between 28 and 42 weeks and accepted to participate in the study.""","""We did exclude women who were not in labour or admitted but not
scheduled for childbirth. Women with known current or previous diagnosis with COVID-19 by PCR or had a history of direct exposure had been also excluded.""",2020-07-01,2020-09-30,Perinatal,All,Children and Youth (0-17 years),,,Primary Estimate,"neonates - Total ab (i.e., IgG, no IgM detected)",171,0.281,,,True,,,,True,Sequential,"One Step Novel Coronavirus (COVID-19) IgM/IgG Antibody Test,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Abbott Architect SARS-CoV-2 IgG","Artron Laboratories Inc.,Roche Diagnostics,Abbott Laboratories",Multiple Types,Serum,IgG,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Tarek Al-Hussaini,Assiut University,Not Unity-Aligned,https://dx.doi.org/10.1080/01443615.2022.2049720,2022-05-10,2024-03-01,Unverified,al-hussaini_risk_2022,EGY
220429_Egypt_AssiutUniversity_Mother_TotalAb,220429_Egypt_AssiutUniversity_Mother,The rate of SARS-CoV-2 among asymptomatic non-immunised low-risk parturient women between the two waves.,2022-04-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Egypt,,Assiut,"""All non-immunised parturient women with no history of SARS CoV-2 or direct exposure were included in our study. We included women who were pregnant between 28 and 42 weeks and accepted to participate in the study.""","""We did exclude women who were not in labour or admitted but not
scheduled for childbirth. Women with known current or previous diagnosis with COVID-19 by PCR or had a history of direct exposure had been also excluded.""",2020-07-01,2020-09-30,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,parturient women - total ab,171,0.322,,,True,,,,True,Sequential,"One Step Novel Coronavirus (COVID-19) IgM/IgG Antibody Test,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Abbott Architect SARS-CoV-2 IgG","Artron Laboratories Inc.,Roche Diagnostics,Abbott Laboratories",Multiple Types,Serum,"['IgG', 'IgM']",,,,,['High'],,No,Yes,No,,Yes,Yes,No,,Tarek Al-Hussaini,Assiut University,Not Unity-Aligned,https://dx.doi.org/10.1080/01443615.2022.2049720,2022-05-10,2024-03-01,Unverified,al-hussaini_risk_2022,EGY
220506_Asyut_AssiutUniversityHospitals,220506_Asyut_AssiutUniversityHospitals,"Prevalence of SARS-CoV-2 Antibodies in Laboratory Healthcare Workers at Assiut University Hospital, Egypt.",2022-05-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Egypt,,Asyut,"""We recruited a total of 199 asymptomaticLHCWs from different laboratory areas including molecular biology, microbiology, parasitology, and outpatient laboratories in addition to LHCWs working in automation, phlebotomy, rotating physicians, and those working in the sample receiving area.""","""Symptomatic or suspected COVID-19 LHCWs and lab workers who refuse to share were excluded.""",2020-04-15,2020-06-15,Health care workers and caregivers,All,Adults (18-64 years),22.0,59.0,Primary Estimate,,199,0.24600000000000002,,,True,,,,True,Convenience,"One Step Novel Coronavirus (COVID-19) IgM/IgG Antibody Test,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Abbott Architect SARS-CoV-2 IgG","Artron Laboratories Inc.,Roche Diagnostics,Abbott Laboratories",Multiple Types,Serum,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Azza Eldin,Assiut University Hospitals,Not Unity-Aligned,https://dx.doi.org/10.1155/2022/7833623,2022-06-05,2024-03-01,Unverified,ezz_eldin_prevalence_2022,EGY
220512_Egypt_CairoUniversity_Group1,220512_Egypt_CairoUniversity_Group1,SARS-CoV-2 antibody seroprevalence rates among Egyptian blood donors around the third wave: Cross-sectional study.,2022-05-12,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Egypt,,Cairo,The study subjects included all eligible donors who attended CUBB for blood donation at the time in which the kits for SARS-Cov-2 antibody testing are available.,"donors could not have had flu-like symptoms within the 30 days before donation nor had close contact with suspected or confirmed COVID-19 cases or traveled abroad in the past 30 days. Candidates presenting with fever (forehead temperature > 37.8°C) on the donation date were also deferred. Thus, individuals included in the study had no symptoms of COVID-19 and were healthy and asymptomatic individuals.",2021-03-20,2021-03-30,Blood donors,All,Adults (18-64 years),18.0,59.0,Primary Estimate,,954,0.13210000000000002,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,Yes,No,No,Yes,Yes,Yes,,Nermeen Eldesoukey,Cairo University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.634,2022-06-03,2024-03-01,Unverified,eldesoukey_sars-cov-2_2022,EGY
220512_Egypt_CairoUniversity_Group2,220512_Egypt_CairoUniversity_Group2,SARS-CoV-2 antibody seroprevalence rates among Egyptian blood donors around the third wave: Cross-sectional study.,2022-05-12,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Egypt,,Cairo,The study subjects included all eligible donors who attended CUBB for blood donation at the time in which the kits for SARS-Cov-2 antibody testing are available.,"donors could not have had flu-like symptoms within the 30 days before donation nor had close contact with suspected or confirmed COVID-19 cases or traveled abroad in the past 30 days. Candidates presenting with fever (forehead temperature > 37.8°C) on the donation date were also deferred. Thus, individuals included in the study had no symptoms of COVID-19 and were healthy and asymptomatic individuals.",2021-06-03,2021-06-10,Blood donors,All,Adults (18-64 years),18.0,59.0,Primary Estimate,,990,0.19190000000000002,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,Yes,No,No,Yes,Yes,Yes,,Nermeen Eldesoukey,Cairo University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.634,2022-06-03,2024-03-01,Unverified,eldesoukey_sars-cov-2_2022,EGY
220512_Egypt_CairoUniversity_Group3,220512_Egypt_CairoUniversity_Group3,SARS-CoV-2 antibody seroprevalence rates among Egyptian blood donors around the third wave: Cross-sectional study.,2022-05-12,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Egypt,,Cairo,The study subjects included all eligible donors who attended CUBB for blood donation at the time in which the kits for SARS-Cov-2 antibody testing are available.,"donors could not have had flu-like symptoms within the 30 days before donation nor had close contact with suspected or confirmed COVID-19 cases or traveled abroad in the past 30 days. Candidates presenting with fever (forehead temperature > 37.8°C) on the donation date were also deferred. Thus, individuals included in the study had no symptoms of COVID-19 and were healthy and asymptomatic individuals.",2021-07-20,2021-07-30,Blood donors,All,Adults (18-64 years),18.0,59.0,Primary Estimate,,1114,0.6616,,,True,,,,True,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,,Plasma,"['IgG', 'Neutralizing']",Spike,,,,['High'],No,No,Yes,No,No,Yes,Yes,Yes,,Nermeen Eldesoukey,Cairo University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.634,2022-06-03,2024-03-01,Unverified,eldesoukey_sars-cov-2_2022,EGY
220604_Egypt_AlexandriaUniversity_Primary,220604_Egypt_AlexandriaUniversity,Prevalence of severe acute respiratory syndrome coronavirus 2 spike antibodies in some healthcare settings in Egypt.,2022-06-04,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Egypt,"Giza, Alexandria, Menoufeya, Cairo, Kafr El-Sheikh",,"The HCWs included physicians, nurses, technicians, pharmacists, employees, office personnel, personal care workers, and faculty members were selected from 39 hospitals.",HCWs who declined to participate (via either blood sampling or questionnaire interview) were excluded from the study.,2021-01-15,2021-06-15,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,559,0.59,,,True,True,,,,Stratified non-probability,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Engy Mohamed El-Ghitany,Alexandria University,Not Unity-Aligned,https://dx.doi.org/10.1186/s42506-022-00106-4,2022-06-15,2023-08-15,Unverified,el-ghitany_prevalence_2022,EGY
220810_Egypt_AlexandriaUniversity_TestAdjusted,220810_Egypt_AlexandriaUniversity,A pre-vaccine exploratory survey of SARS-CoV-2 humoral immunity among Egyptian general population.,2022-08-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Egypt,,,"""All ages were included regardless of their history of
previous COVID-19 infection and there were no exclu-
sion criteria""",,2021-01-15,2021-06-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,2360,0.46299999999999997,0.44200000000000006,0.483,True,True,,,,Convenience,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Serum,IgG,Spike,,0.932,0.998,[{'error': '#ERROR!'}],Yes,No,Yes,Yes,Yes,{'error': '#ERROR!'},Yes,{'error': '#ERROR!'},Unclear,Engy Mohamed El‑Ghitany,Alexandria University,{'error': '#ERROR!'},https://dx.doi.org/10.1186/s41182-022-00448-x,2022-08-25,2024-03-12,Verified,el-ghitany_pre-vaccine_2022,EGY
220810_Egypt_AlexandriaUniversity_Age_15-29,220810_Egypt_AlexandriaUniversity,A pre-vaccine exploratory survey of SARS-CoV-2 humoral immunity among Egyptian general population.,2022-08-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Egypt,,,"""All ages were included regardless of their history of
previous COVID-19 infection and there were no exclu-
sion criteria""",,2021-01-15,2021-06-15,Household and community samples,All,Multiple groups,,,Age,15-29,432,0.4236,,,,,,,,Convenience,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Serum,IgG,Spike,,0.932,0.998,[{'error': '#ERROR!'}],Yes,No,Yes,Yes,Yes,{'error': '#ERROR!'},Yes,{'error': '#ERROR!'},Unclear,Engy Mohamed El‑Ghitany,Alexandria University,{'error': '#ERROR!'},https://dx.doi.org/10.1186/s41182-022-00448-x,2022-08-25,2024-03-13,Verified,el-ghitany_pre-vaccine_2022,EGY
220810_Egypt_AlexandriaUniversity_Age_30-39,220810_Egypt_AlexandriaUniversity,A pre-vaccine exploratory survey of SARS-CoV-2 humoral immunity among Egyptian general population.,2022-08-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Egypt,,,"""All ages were included regardless of their history of
previous COVID-19 infection and there were no exclu-
sion criteria""",,2021-01-15,2021-06-15,Household and community samples,All,Adults (18-64 years),,,Age,,415,0.4193,,,,,,,,Convenience,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Serum,IgG,Spike,,0.932,0.998,[{'error': '#ERROR!'}],Yes,No,Yes,Yes,Yes,{'error': '#ERROR!'},Yes,{'error': '#ERROR!'},Unclear,Engy Mohamed El‑Ghitany,Alexandria University,{'error': '#ERROR!'},https://dx.doi.org/10.1186/s41182-022-00448-x,2022-08-25,2024-03-13,Verified,el-ghitany_pre-vaccine_2022,EGY
220810_Egypt_AlexandriaUniversity_Age_60+,220810_Egypt_AlexandriaUniversity,A pre-vaccine exploratory survey of SARS-CoV-2 humoral immunity among Egyptian general population.,2022-08-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Egypt,,,"""All ages were included regardless of their history of
previous COVID-19 infection and there were no exclu-
sion criteria""",,2021-01-15,2021-06-15,Household and community samples,All,Multiple groups,,,Age,60+,286,0.4231,,,,,,,,Convenience,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Serum,IgG,Spike,,0.932,0.998,[{'error': '#ERROR!'}],Yes,No,Yes,Yes,Yes,{'error': '#ERROR!'},Yes,{'error': '#ERROR!'},Unclear,Engy Mohamed El‑Ghitany,Alexandria University,{'error': '#ERROR!'},https://dx.doi.org/10.1186/s41182-022-00448-x,2022-08-25,2024-03-13,Verified,el-ghitany_pre-vaccine_2022,EGY
220810_Egypt_AlexandriaUniversity_Unadjusted,220810_Egypt_AlexandriaUniversity,A pre-vaccine exploratory survey of SARS-CoV-2 humoral immunity among Egyptian general population.,2022-08-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Egypt,,,"""All ages were included regardless of their history of
previous COVID-19 infection and there were no exclu-
sion criteria""",,2021-01-15,2021-06-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,2360,0.43200000000000005,,,,,,,True,Convenience,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Serum,IgG,Spike,,0.932,0.998,[{'error': '#ERROR!'}],Yes,No,Yes,Yes,Yes,{'error': '#ERROR!'},Yes,{'error': '#ERROR!'},Unclear,Engy Mohamed El‑Ghitany,Alexandria University,{'error': '#ERROR!'},https://dx.doi.org/10.1186/s41182-022-00448-x,2022-08-25,2024-03-12,Verified,el-ghitany_pre-vaccine_2022,EGY
220810_Egypt_AlexandriaUniversity_Sex_Female,220810_Egypt_AlexandriaUniversity,A pre-vaccine exploratory survey of SARS-CoV-2 humoral immunity among Egyptian general population.,2022-08-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Egypt,,,"""All ages were included regardless of their history of
previous COVID-19 infection and there were no exclu-
sion criteria""",,2021-01-15,2021-06-15,Household and community samples,Female,Multiple groups,,,Sex/Gender,,1264,0.4684,,,,,,,,Convenience,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Serum,IgG,Spike,,0.932,0.998,[{'error': '#ERROR!'}],Yes,No,Yes,Yes,Yes,{'error': '#ERROR!'},Yes,{'error': '#ERROR!'},Unclear,Engy Mohamed El‑Ghitany,Alexandria University,{'error': '#ERROR!'},https://dx.doi.org/10.1186/s41182-022-00448-x,2022-08-25,2024-03-13,Verified,el-ghitany_pre-vaccine_2022,EGY
220810_Egypt_AlexandriaUniversity_Sex_Male,220810_Egypt_AlexandriaUniversity,A pre-vaccine exploratory survey of SARS-CoV-2 humoral immunity among Egyptian general population.,2022-08-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Egypt,,,"""All ages were included regardless of their history of
previous COVID-19 infection and there were no exclu-
sion criteria""",,2021-01-15,2021-06-15,Household and community samples,Male,Multiple groups,,,Sex/Gender,,1096,0.3905,,,,,,,,Convenience,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Serum,IgG,Spike,,0.932,0.998,[{'error': '#ERROR!'}],Yes,No,Yes,Yes,Yes,{'error': '#ERROR!'},Yes,{'error': '#ERROR!'},Unclear,Engy Mohamed El‑Ghitany,Alexandria University,{'error': '#ERROR!'},https://dx.doi.org/10.1186/s41182-022-00448-x,2022-08-25,2024-03-13,Verified,el-ghitany_pre-vaccine_2022,EGY
220810_Egypt_AlexandriaUniversity_Age_40-59,220810_Egypt_AlexandriaUniversity,A pre-vaccine exploratory survey of SARS-CoV-2 humoral immunity among Egyptian general population.,2022-08-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Egypt,,,"""All ages were included regardless of their history of
previous COVID-19 infection and there were no exclu-
sion criteria""",,2021-01-15,2021-06-15,Household and community samples,All,Adults (18-64 years),,,Age,40-59,770,0.4338,,,,,,,,Convenience,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Serum,IgG,Spike,,0.932,0.998,[{'error': '#ERROR!'}],Yes,No,Yes,Yes,Yes,{'error': '#ERROR!'},Yes,{'error': '#ERROR!'},Unclear,Engy Mohamed El‑Ghitany,Alexandria University,{'error': '#ERROR!'},https://dx.doi.org/10.1186/s41182-022-00448-x,2022-08-25,2024-03-13,Verified,el-ghitany_pre-vaccine_2022,EGY
220810_Egypt_AlexandriaUniversity_Age_<15,220810_Egypt_AlexandriaUniversity,A pre-vaccine exploratory survey of SARS-CoV-2 humoral immunity among Egyptian general population.,2022-08-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Egypt,,,"""All ages were included regardless of their history of
previous COVID-19 infection and there were no exclu-
sion criteria""",,2021-01-15,2021-06-15,Household and community samples,All,Children and Youth (0-17 years),,,Age,,457,0.4551,,,,,,,,Convenience,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Serum,IgG,Spike,,0.932,0.998,[{'error': '#ERROR!'}],Yes,No,Yes,Yes,Yes,{'error': '#ERROR!'},Yes,{'error': '#ERROR!'},Unclear,Engy Mohamed El‑Ghitany,Alexandria University,{'error': '#ERROR!'},https://dx.doi.org/10.1186/s41182-022-00448-x,2022-08-25,2024-03-13,Verified,el-ghitany_pre-vaccine_2022,EGY
230115_Egypt_SohagUniversity_Overall,230115_Egypt_SohagUniversity,"Estimation of immune response (IgG) to SARS-COV2 (COVID-19) after the third COVID-19 wave in Egypt, A cross-sectional Study",2023-01-15,Presentation or Conference,National,Cross-sectional survey ,Egypt,,,tudy was conducted in August 2021 after the third wave of COVID-19. The study included 287 participants,,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,,,Primary Estimate,positive IgG response to COVID-19,287,0.5,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,IgG,,,,,['High'],,Unclear,No,No,,Unclear,Yes,No,,Mona M Abdelrahmans,Sohag University,Not Unity-Aligned,https://doi.org/10.55133/eji.300104,2023-02-10,2023-03-22,Unverified,abdelrahmans_estimation_2023,EGY
230505_Fayoum_FayoumUniversity_Overall,230505_Fayoum_FayoumUniversity,"Seroprevalence of SARS-CoV-2 immunoglobulin G antibody during COVID-19 pandemic in Fayoum District, Egypt: a community-based pilot survey",2023-05-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Egypt,Fayoum Governorate,Fayoum,"Fayoum governorate includes six administrative districts (Fayoum, Sinnuris, Tamiya, Etsa, Abshoay, and Youssef Sadiek). Within the randomly selected Fayoum district, a village was randomly chosen that was recorded in census data. Within the selected village a street was chosen at random with the decision to proceed in one direction. Then, each first and fourth house on the street was randomly chosen.",,2021-02-15,2021-07-15,Household and community samples,All,Multiple groups,9.0,84.0,Primary Estimate,,155,0.606,,,True,,,,True,Simplified probability,RADIM SARS-CoV-2,DIALAB,ELISA,Serum,IgG,Spike,,,,['High'],No,Yes,No,Yes,No,Yes,Yes,Yes,Unclear,Salwa Bakr,Fayoum University,Unity-Aligned,https://dx.doi.org/10.11604/pamj.2023.45.22.36513,2023-08-03,2024-04-23,Verified,bakr_seroprevalence_2023,EGY
220207_SanSalvador_OsakaCityUniversity_HCW_Overall,220207_SanSalvador_OsakaCityUniversity,"Cumulative seroprevalence among healthcare workers after the first wave of the COVID-19 pandemic in El Salvador, Central America",2022-02-07,Preprint,Local,Cross-sectional survey ,El Salvador,,San Salvador,"HCWs from the National Clinical Laboratory and the National Rosales Hospital, El Salvador, were recruited to participate. ",,2021-01-18,2021-02-14,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,973,0.526,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),SARS-CoV-2 IgG II Quant ","Roche Diagnostics,Abbott Laboratories",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Yu Nakagama,Osaka City University,Not Unity-Aligned,10.1101/2022.02.06.22270565,2022-02-17,2024-03-01,Unverified,nakagama_cumulative_2022,SLV
200924_Estonia_UniversityofTartu_overall,200924_Estonia_UniversityofTartu,Seroprevalence of SARS‐CoV‐2 antibodies among pregnant women in Estonia: A call for epidemiological studies,2020-09-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Estonia,,,Pregnant women in their first trimester in all regions of Estonia,,2020-05-04,2020-06-10,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,pregnant women in their first trimester in all parts of Estonia,433,0.0046,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,,,,['High'],No,No,No,No,Unclear,Yes,Yes,Yes,,Piret Veerus,University of Tartu,Unity-Aligned,https://obgyn.onlinelibrary.wiley.com/doi/full/10.1111/aogs.13995,2021-03-20,2024-03-01,Verified,veerus_seroprevalence_2020,EST
210107_Estonia_UniversityCollegeLondon_PaediatricHCW,210107_Estonia_UniversityCollegeLondon,Cross Sectional Prevalence of SARS-CoV-2 antibodies in Health Care Workers in Paediatric Facilities in Eight Countries,2021-01-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Estonia,,,"This was part of a larger study undertaken in HCWs in paediatric facilities in seven European sites and one South African site. Staff of all categories in each healthcare setting were invited to join the study, irrespective of symptoms or whether they suspected they had previously had COVID-19. ",,2020-06-10,2020-06-12,Health care workers and caregivers,All,Adults (18-64 years),19.0,71.0,Primary Estimate,,130,0.0,0.0,0.028700000000000003,True,,,,True,Convenience,"EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit,Meso Scale Discovery multiplex assay","Epitope Diagnostics, Inc.,Meso Scale Discovery",ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,No,No,Unclear,Yes,Yes,No,Unclear,D Goldblatt,University College London,Not Unity-Aligned,http://dx.doi.org/10.1016/j.jhin.2020.12.019,2021-03-13,2024-03-01,Verified,goldblatt_cross-sectional_2021,EST
210805_Estonia_TartuUniversityHospital_Saaremaa_overall_testadj,210805_Estonia_TartuUniversityHospital_Saaremaa,Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study).,2021-09-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Estonia,,Saaremaa,"""Strata were formed by classifying patients from each GP into 10-year age groups, except the age group of 80 years or older due to their small number. From each stratum individuals were randomly identified by Estonian Health Insurance Fund with the aim to include at least 110 participants per age group from both GP practices to achieve desirable precision for the seroprevalence estimates.""",,2020-05-08,2020-07-31,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,0.0,100.0,Primary Estimate,,954,0.067,0.05,0.084,True,True,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Author designed (Neutralization Assay),Author designed (CLIA)","Abbott Laboratories,DiaSorin,SD Biosensor,NA",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Piia Jogi,University of Tartu,Not Unity-Aligned,https://dx.doi.org/10.1016/j.vaccine.2021.07.093,2021-08-25,2023-08-15,Verified,jogi_prevalence_2021,EST
210805_Estonia_TartuUniversityHospital_Saaremaa_50-59,210805_Estonia_TartuUniversityHospital_Saaremaa,Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study).,2021-09-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Estonia,,Saaremaa,"""Strata were formed by classifying patients from each GP into 10-year age groups, except the age group of 80 years or older due to their small number. From each stratum individuals were randomly identified by Estonian Health Insurance Fund with the aim to include at least 110 participants per age group from both GP practices to achieve desirable precision for the seroprevalence estimates.""",,2020-05-08,2020-07-31,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),50.0,59.0,Age,50-59,113,0.071,0.031000000000000003,0.135,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Author designed (Neutralization Assay),Author designed (CLIA)","Abbott Laboratories,DiaSorin,SD Biosensor,NA",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Piia Jogi,University of Tartu,Not Unity-Aligned,https://dx.doi.org/10.1016/j.vaccine.2021.07.093,2021-08-25,2023-08-15,Verified,jogi_prevalence_2021,EST
210805_Estonia_TartuUniversityHospital_Saaremaa_20-29,210805_Estonia_TartuUniversityHospital_Saaremaa,Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study).,2021-09-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Estonia,,Saaremaa,"""Strata were formed by classifying patients from each GP into 10-year age groups, except the age group of 80 years or older due to their small number. From each stratum individuals were randomly identified by Estonian Health Insurance Fund with the aim to include at least 110 participants per age group from both GP practices to achieve desirable precision for the seroprevalence estimates.""",,2020-05-08,2020-07-31,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),20.0,29.0,Age,20-29,104,0.057999999999999996,0.021,0.121,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Author designed (Neutralization Assay),Author designed (CLIA)","Abbott Laboratories,DiaSorin,SD Biosensor,NA",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Piia Jogi,University of Tartu,Not Unity-Aligned,https://dx.doi.org/10.1016/j.vaccine.2021.07.093,2021-08-25,2023-08-15,Verified,jogi_prevalence_2021,EST
210805_Estonia_TartuUniversityHospital_Saaremaa_40-49,210805_Estonia_TartuUniversityHospital_Saaremaa,Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study).,2021-09-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Estonia,,Saaremaa,"""Strata were formed by classifying patients from each GP into 10-year age groups, except the age group of 80 years or older due to their small number. From each stratum individuals were randomly identified by Estonian Health Insurance Fund with the aim to include at least 110 participants per age group from both GP practices to achieve desirable precision for the seroprevalence estimates.""",,2020-05-08,2020-07-31,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),40.0,49.0,Age,40-49,114,0.07,0.031000000000000003,0.134,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Author designed (Neutralization Assay),Author designed (CLIA)","Abbott Laboratories,DiaSorin,SD Biosensor,NA",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Piia Jogi,University of Tartu,Not Unity-Aligned,https://dx.doi.org/10.1016/j.vaccine.2021.07.093,2021-08-25,2023-08-15,Verified,jogi_prevalence_2021,EST
210805_Estonia_TartuUniversityHospital_Saaremaa_60-69,210805_Estonia_TartuUniversityHospital_Saaremaa,Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study).,2021-09-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Estonia,,Saaremaa,"""Strata were formed by classifying patients from each GP into 10-year age groups, except the age group of 80 years or older due to their small number. From each stratum individuals were randomly identified by Estonian Health Insurance Fund with the aim to include at least 110 participants per age group from both GP practices to achieve desirable precision for the seroprevalence estimates.""",,2020-05-08,2020-07-31,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,60.0,69.0,Age,60-69,112,0.054000000000000006,0.02,0.113,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Author designed (Neutralization Assay),Author designed (CLIA)","Abbott Laboratories,DiaSorin,SD Biosensor,NA",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Piia Jogi,University of Tartu,Not Unity-Aligned,https://dx.doi.org/10.1016/j.vaccine.2021.07.093,2021-08-25,2023-08-15,Verified,jogi_prevalence_2021,EST
210805_Estonia_TartuUniversityHospital_Saaremaa_0-9,210805_Estonia_TartuUniversityHospital_Saaremaa,Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study).,2021-09-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Estonia,,Saaremaa,"""Strata were formed by classifying patients from each GP into 10-year age groups, except the age group of 80 years or older due to their small number. From each stratum individuals were randomly identified by Estonian Health Insurance Fund with the aim to include at least 110 participants per age group from both GP practices to achieve desirable precision for the seroprevalence estimates.""",,2020-05-08,2020-07-31,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),0.0,9.0,Age,0-9,101,0.059000000000000004,0.022000000000000002,0.125,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Author designed (Neutralization Assay),Author designed (CLIA)","Abbott Laboratories,DiaSorin,SD Biosensor,NA",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Piia Jogi,University of Tartu,Not Unity-Aligned,https://dx.doi.org/10.1016/j.vaccine.2021.07.093,2021-08-25,2023-08-15,Verified,jogi_prevalence_2021,EST
210805_Estonia_TartuUniversityHospital_Saaremaa_80-100,210805_Estonia_TartuUniversityHospital_Saaremaa,Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study).,2021-09-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Estonia,,Saaremaa,"""Strata were formed by classifying patients from each GP into 10-year age groups, except the age group of 80 years or older due to their small number. From each stratum individuals were randomly identified by Estonian Health Insurance Fund with the aim to include at least 110 participants per age group from both GP practices to achieve desirable precision for the seroprevalence estimates.""",,2020-05-08,2020-07-31,Patients seeking care for non-COVID-19 reasons,All,Seniors (65+ years),80.0,100.0,Age,80-100,67,0.09,0.034,0.185,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Author designed (Neutralization Assay),Author designed (CLIA)","Abbott Laboratories,DiaSorin,SD Biosensor,NA",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Piia Jogi,University of Tartu,Not Unity-Aligned,https://dx.doi.org/10.1016/j.vaccine.2021.07.093,2021-08-25,2023-08-15,Verified,jogi_prevalence_2021,EST
210805_Estonia_TartuUniversityHospital_Saaremaa_70-79,210805_Estonia_TartuUniversityHospital_Saaremaa,Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study).,2021-09-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Estonia,,Saaremaa,"""Strata were formed by classifying patients from each GP into 10-year age groups, except the age group of 80 years or older due to their small number. From each stratum individuals were randomly identified by Estonian Health Insurance Fund with the aim to include at least 110 participants per age group from both GP practices to achieve desirable precision for the seroprevalence estimates.""",,2020-05-08,2020-07-31,Patients seeking care for non-COVID-19 reasons,All,Seniors (65+ years),70.0,79.0,Age,70-79,112,0.036000000000000004,0.01,0.08900000000000001,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Author designed (Neutralization Assay),Author designed (CLIA)","Abbott Laboratories,DiaSorin,SD Biosensor,NA",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Piia Jogi,University of Tartu,Not Unity-Aligned,https://dx.doi.org/10.1016/j.vaccine.2021.07.093,2021-08-25,2023-08-15,Verified,jogi_prevalence_2021,EST
210805_Estonia_TartuUniversityHospital_Saaremaa_10-19,210805_Estonia_TartuUniversityHospital_Saaremaa,Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study).,2021-09-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Estonia,,Saaremaa,"""Strata were formed by classifying patients from each GP into 10-year age groups, except the age group of 80 years or older due to their small number. From each stratum individuals were randomly identified by Estonian Health Insurance Fund with the aim to include at least 110 participants per age group from both GP practices to achieve desirable precision for the seroprevalence estimates.""",,2020-05-08,2020-07-31,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,110,0.055,0.02,0.115,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Author designed (Neutralization Assay),Author designed (CLIA)","Abbott Laboratories,DiaSorin,SD Biosensor,NA",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Piia Jogi,University of Tartu,Not Unity-Aligned,https://dx.doi.org/10.1016/j.vaccine.2021.07.093,2021-08-25,2023-08-15,Verified,jogi_prevalence_2021,EST
210805_Estonia_TartuUniversityHospital_Saaremaa_30-39,210805_Estonia_TartuUniversityHospital_Saaremaa,Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study).,2021-09-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Estonia,,Saaremaa,"""Strata were formed by classifying patients from each GP into 10-year age groups, except the age group of 80 years or older due to their small number. From each stratum individuals were randomly identified by Estonian Health Insurance Fund with the aim to include at least 110 participants per age group from both GP practices to achieve desirable precision for the seroprevalence estimates.""",,2020-05-08,2020-07-31,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),30.0,39.0,Age,30-39,121,0.07400000000000001,0.035,0.13699999999999998,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Author designed (Neutralization Assay),Author designed (CLIA)","Abbott Laboratories,DiaSorin,SD Biosensor,NA",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Piia Jogi,University of Tartu,Not Unity-Aligned,https://dx.doi.org/10.1016/j.vaccine.2021.07.093,2021-08-25,2023-08-15,Verified,jogi_prevalence_2021,EST
210805_Estonia_TartuUniversityHospital_Tallinn_overall_testadj,210805_Estonia_TartuUniversityHospital_Tallinn,Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study).,2021-09-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Estonia,,Tallinn,"""Strata were formed by classifying patients from each GP into 10-year age groups, except the age group of 80 years or older due to their small number. From each stratum individuals were randomly identified by Estonian Health Insurance Fund with the aim to include at least 110 participants per age group from both GP practices to achieve desirable precision for the seroprevalence estimates.""",,2020-05-08,2020-07-31,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,0.0,100.0,Primary Estimate,,1006,0.015,0.006,0.024,True,True,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Author designed (Neutralization Assay),Author designed (CLIA)","Abbott Laboratories,DiaSorin,SD Biosensor,NA",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Piia Jogi,University of Tartu,Not Unity-Aligned,https://dx.doi.org/10.1016/j.vaccine.2021.07.093,2021-08-25,2023-08-15,Verified,jogi_prevalence_2021,EST
210805_Estonia_TartuUniversityHospital_Tallinn_80-100,210805_Estonia_TartuUniversityHospital_Tallinn,Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study).,2021-09-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Estonia,,Tallinn,"""Strata were formed by classifying patients from each GP into 10-year age groups, except the age group of 80 years or older due to their small number. From each stratum individuals were randomly identified by Estonian Health Insurance Fund with the aim to include at least 110 participants per age group from both GP practices to achieve desirable precision for the seroprevalence estimates.""",,2020-05-08,2020-07-31,Patients seeking care for non-COVID-19 reasons,All,Seniors (65+ years),80.0,100.0,Age,80-100,98,0.01,0.0,0.055999999999999994,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Author designed (Neutralization Assay),Author designed (CLIA)","Abbott Laboratories,DiaSorin,SD Biosensor,NA",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Piia Jogi,University of Tartu,Not Unity-Aligned,https://dx.doi.org/10.1016/j.vaccine.2021.07.093,2021-08-25,2023-08-15,Verified,jogi_prevalence_2021,EST
210805_Estonia_TartuUniversityHospital_Tallinn_50-59,210805_Estonia_TartuUniversityHospital_Tallinn,Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study).,2021-09-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Estonia,,Tallinn,"""Strata were formed by classifying patients from each GP into 10-year age groups, except the age group of 80 years or older due to their small number. From each stratum individuals were randomly identified by Estonian Health Insurance Fund with the aim to include at least 110 participants per age group from both GP practices to achieve desirable precision for the seroprevalence estimates.""",,2020-05-08,2020-07-31,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),50.0,59.0,Age,50-59,117,0.017,0.002,0.06,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Author designed (Neutralization Assay),Author designed (CLIA)","Abbott Laboratories,DiaSorin,SD Biosensor,NA",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Piia Jogi,University of Tartu,Not Unity-Aligned,https://dx.doi.org/10.1016/j.vaccine.2021.07.093,2021-08-25,2023-08-15,Verified,jogi_prevalence_2021,EST
210805_Estonia_TartuUniversityHospital_Tallinn_40-49,210805_Estonia_TartuUniversityHospital_Tallinn,Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study).,2021-09-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Estonia,,Tallinn,"""Strata were formed by classifying patients from each GP into 10-year age groups, except the age group of 80 years or older due to their small number. From each stratum individuals were randomly identified by Estonian Health Insurance Fund with the aim to include at least 110 participants per age group from both GP practices to achieve desirable precision for the seroprevalence estimates.""",,2020-05-08,2020-07-31,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),40.0,49.0,Age,40-49,120,0.017,0.002,0.059000000000000004,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Author designed (Neutralization Assay),Author designed (CLIA)","Abbott Laboratories,DiaSorin,SD Biosensor,NA",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Piia Jogi,University of Tartu,Not Unity-Aligned,https://dx.doi.org/10.1016/j.vaccine.2021.07.093,2021-08-25,2023-08-15,Verified,jogi_prevalence_2021,EST
210805_Estonia_TartuUniversityHospital_Tallinn_70-79,210805_Estonia_TartuUniversityHospital_Tallinn,Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study).,2021-09-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Estonia,,Tallinn,"""Strata were formed by classifying patients from each GP into 10-year age groups, except the age group of 80 years or older due to their small number. From each stratum individuals were randomly identified by Estonian Health Insurance Fund with the aim to include at least 110 participants per age group from both GP practices to achieve desirable precision for the seroprevalence estimates.""",,2020-05-08,2020-07-31,Patients seeking care for non-COVID-19 reasons,All,Seniors (65+ years),70.0,79.0,Age,70-79,114,0.0,0.0,0.032,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Author designed (Neutralization Assay),Author designed (CLIA)","Abbott Laboratories,DiaSorin,SD Biosensor,NA",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Piia Jogi,University of Tartu,Not Unity-Aligned,https://dx.doi.org/10.1016/j.vaccine.2021.07.093,2021-08-25,2023-08-15,Verified,jogi_prevalence_2021,EST
210805_Estonia_TartuUniversityHospital_Tallinn_60-69,210805_Estonia_TartuUniversityHospital_Tallinn,Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study).,2021-09-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Estonia,,Tallinn,"""Strata were formed by classifying patients from each GP into 10-year age groups, except the age group of 80 years or older due to their small number. From each stratum individuals were randomly identified by Estonian Health Insurance Fund with the aim to include at least 110 participants per age group from both GP practices to achieve desirable precision for the seroprevalence estimates.""",,2020-05-08,2020-07-31,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,60.0,69.0,Age,60-69,116,0.026000000000000002,0.005,0.07400000000000001,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Author designed (Neutralization Assay),Author designed (CLIA)","Abbott Laboratories,DiaSorin,SD Biosensor,NA",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Piia Jogi,University of Tartu,Not Unity-Aligned,https://dx.doi.org/10.1016/j.vaccine.2021.07.093,2021-08-25,2023-08-15,Verified,jogi_prevalence_2021,EST
210805_Estonia_TartuUniversityHospital_Tallinn_0-9,210805_Estonia_TartuUniversityHospital_Tallinn,Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study).,2021-09-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Estonia,,Tallinn,"""Strata were formed by classifying patients from each GP into 10-year age groups, except the age group of 80 years or older due to their small number. From each stratum individuals were randomly identified by Estonian Health Insurance Fund with the aim to include at least 110 participants per age group from both GP practices to achieve desirable precision for the seroprevalence estimates.""",,2020-05-08,2020-07-31,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),0.0,9.0,Age,0-9,106,0.038,0.01,0.094,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Author designed (Neutralization Assay),Author designed (CLIA)","Abbott Laboratories,DiaSorin,SD Biosensor,NA",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Piia Jogi,University of Tartu,Not Unity-Aligned,https://dx.doi.org/10.1016/j.vaccine.2021.07.093,2021-08-25,2023-08-15,Verified,jogi_prevalence_2021,EST
210805_Estonia_TartuUniversityHospital_Tallinn_10-19,210805_Estonia_TartuUniversityHospital_Tallinn,Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study).,2021-09-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Estonia,,Tallinn,"""Strata were formed by classifying patients from each GP into 10-year age groups, except the age group of 80 years or older due to their small number. From each stratum individuals were randomly identified by Estonian Health Insurance Fund with the aim to include at least 110 participants per age group from both GP practices to achieve desirable precision for the seroprevalence estimates.""",,2020-05-08,2020-07-31,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,107,0.0,0.0,0.034,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Author designed (Neutralization Assay),Author designed (CLIA)","Abbott Laboratories,DiaSorin,SD Biosensor,NA",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Piia Jogi,University of Tartu,Not Unity-Aligned,https://dx.doi.org/10.1016/j.vaccine.2021.07.093,2021-08-25,2023-08-15,Verified,jogi_prevalence_2021,EST
210805_Estonia_TartuUniversityHospital_Tallinn_20-29,210805_Estonia_TartuUniversityHospital_Tallinn,Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study).,2021-09-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Estonia,,Tallinn,"""Strata were formed by classifying patients from each GP into 10-year age groups, except the age group of 80 years or older due to their small number. From each stratum individuals were randomly identified by Estonian Health Insurance Fund with the aim to include at least 110 participants per age group from both GP practices to achieve desirable precision for the seroprevalence estimates.""",,2020-05-08,2020-07-31,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),20.0,29.0,Age,20-29,111,0.009000000000000001,0.0,0.049,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Author designed (Neutralization Assay),Author designed (CLIA)","Abbott Laboratories,DiaSorin,SD Biosensor,NA",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Piia Jogi,University of Tartu,Not Unity-Aligned,https://dx.doi.org/10.1016/j.vaccine.2021.07.093,2021-08-25,2023-08-15,Verified,jogi_prevalence_2021,EST
210805_Estonia_TartuUniversityHospital_Tallinn_30-39,210805_Estonia_TartuUniversityHospital_Tallinn,Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study).,2021-09-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Estonia,,Tallinn,"""Strata were formed by classifying patients from each GP into 10-year age groups, except the age group of 80 years or older due to their small number. From each stratum individuals were randomly identified by Estonian Health Insurance Fund with the aim to include at least 110 participants per age group from both GP practices to achieve desirable precision for the seroprevalence estimates.""",,2020-05-08,2020-07-31,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),30.0,39.0,Age,30-39,117,0.009000000000000001,0.0,0.047,,True,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Author designed (Neutralization Assay),Author designed (CLIA)","Abbott Laboratories,DiaSorin,SD Biosensor,NA",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Piia Jogi,University of Tartu,Not Unity-Aligned,https://dx.doi.org/10.1016/j.vaccine.2021.07.093,2021-08-25,2023-08-15,Verified,jogi_prevalence_2021,EST
210914_Estonia_UniversityofTartu_overall,210914_Estonia_UniversityofTartu,Seroprevalence and levels of IgG antibodies after COVID-19 infection or vaccination.,2021-09-14,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Estonia,,,"Leftover blood samples were selected by SYNLAB Estonia from samples sent by general practitioners for routine clinical testing from all fifteen counties and age groups (0–9, 10–19, 20–59, 60–69, 70–79, 80–100 years) proportionally to the whole Estonian population.",,2021-02-08,2021-03-25,Residual sera,All,Multiple groups,,,Primary Estimate,,2517,0.201,0.185,0.217,True,,,,True,Stratified non-probability,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Hiie Soeorg,University of Tartu,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.1974540,2021-09-21,2024-03-01,Verified,soeorg_seroprevalence_2021,EST
210914_Estonia_UniversityofTartu_Vaccinated,210914_Estonia_UniversityofTartu,Seroprevalence and levels of IgG antibodies after COVID-19 infection or vaccination.,2021-09-14,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Estonia,,,"Leftover blood samples were selected by SYNLAB Estonia from samples sent by general practitioners for routine clinical testing from all fifteen counties and age groups (0–9, 10–19, 20–59, 60–69, 70–79, 80–100 years) proportionally to the whole Estonian population.",,2021-02-08,2021-03-25,Residual sera,All,Multiple groups,,,COVID-19 vaccination status,vaccinated with one dose at least 14 days prior to sampling or with 2 doses,119,0.9159999999999999,,,,,,,,Stratified non-probability,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Hiie Soeorg,University of Tartu,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.1974540,2021-09-22,2024-03-01,Verified,soeorg_seroprevalence_2021,EST
210914_Estonia_UniversityofTartu_age70-79,210914_Estonia_UniversityofTartu,Seroprevalence and levels of IgG antibodies after COVID-19 infection or vaccination.,2021-09-14,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Estonia,,,"Leftover blood samples were selected by SYNLAB Estonia from samples sent by general practitioners for routine clinical testing from all fifteen counties and age groups (0–9, 10–19, 20–59, 60–69, 70–79, 80–100 years) proportionally to the whole Estonian population.",,2021-02-08,2021-03-25,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,age 70-79,225,0.17800000000000002,0.13,0.23399999999999999,,,,,,Stratified non-probability,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Hiie Soeorg,University of Tartu,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.1974540,2021-09-22,2024-03-01,Verified,soeorg_seroprevalence_2021,EST
210914_Estonia_UniversityofTartu_age60-69,210914_Estonia_UniversityofTartu,Seroprevalence and levels of IgG antibodies after COVID-19 infection or vaccination.,2021-09-14,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Estonia,,,"Leftover blood samples were selected by SYNLAB Estonia from samples sent by general practitioners for routine clinical testing from all fifteen counties and age groups (0–9, 10–19, 20–59, 60–69, 70–79, 80–100 years) proportionally to the whole Estonian population.",,2021-02-08,2021-03-25,Residual sera,All,Adults (18-64 years),60.0,69.0,Age,age 60-69,336,0.193,0.153,0.24,,,,,,Stratified non-probability,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Hiie Soeorg,University of Tartu,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.1974540,2021-09-22,2024-03-01,Verified,soeorg_seroprevalence_2021,EST
210914_Estonia_UniversityofTartu_age0-9,210914_Estonia_UniversityofTartu,Seroprevalence and levels of IgG antibodies after COVID-19 infection or vaccination.,2021-09-14,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Estonia,,,"Leftover blood samples were selected by SYNLAB Estonia from samples sent by general practitioners for routine clinical testing from all fifteen counties and age groups (0–9, 10–19, 20–59, 60–69, 70–79, 80–100 years) proportionally to the whole Estonian population.",,2021-02-08,2021-03-25,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,age 0-9,205,0.195,0.14300000000000002,0.256,,,,,,Stratified non-probability,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Hiie Soeorg,University of Tartu,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.1974540,2021-09-22,2024-03-01,Verified,soeorg_seroprevalence_2021,EST
210914_Estonia_UniversityofTartu_age80+,210914_Estonia_UniversityofTartu,Seroprevalence and levels of IgG antibodies after COVID-19 infection or vaccination.,2021-09-14,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Estonia,,,"Leftover blood samples were selected by SYNLAB Estonia from samples sent by general practitioners for routine clinical testing from all fifteen counties and age groups (0–9, 10–19, 20–59, 60–69, 70–79, 80–100 years) proportionally to the whole Estonian population.",,2021-02-08,2021-03-25,Residual sera,All,Seniors (65+ years),80.0,,Age,age 80+,156,0.269,0.201,0.34600000000000003,,,,,,Stratified non-probability,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Hiie Soeorg,University of Tartu,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.1974540,2021-09-22,2024-03-01,Verified,soeorg_seroprevalence_2021,EST
210914_Estonia_UniversityofTartu_age20-59,210914_Estonia_UniversityofTartu,Seroprevalence and levels of IgG antibodies after COVID-19 infection or vaccination.,2021-09-14,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Estonia,,,"Leftover blood samples were selected by SYNLAB Estonia from samples sent by general practitioners for routine clinical testing from all fifteen counties and age groups (0–9, 10–19, 20–59, 60–69, 70–79, 80–100 years) proportionally to the whole Estonian population.",,2021-02-08,2021-03-25,Residual sera,All,Adults (18-64 years),20.0,59.0,Age,age 20-59,1333,0.20199999999999999,0.18100000000000002,0.22399999999999998,,,,,,Stratified non-probability,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Hiie Soeorg,University of Tartu,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.1974540,2021-09-22,2024-03-01,Verified,soeorg_seroprevalence_2021,EST
210914_Estonia_UniversityofTartu_age10-19,210914_Estonia_UniversityofTartu,Seroprevalence and levels of IgG antibodies after COVID-19 infection or vaccination.,2021-09-14,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Estonia,,,"Leftover blood samples were selected by SYNLAB Estonia from samples sent by general practitioners for routine clinical testing from all fifteen counties and age groups (0–9, 10–19, 20–59, 60–69, 70–79, 80–100 years) proportionally to the whole Estonian population.",,2021-02-08,2021-03-25,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,age 10-19,262,0.19100000000000003,0.145,0.244,,,,,,Stratified non-probability,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Hiie Soeorg,University of Tartu,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.1974540,2021-09-22,2024-03-01,Verified,soeorg_seroprevalence_2021,EST
210914_Estonia_UniversityofTartu_NotVaccinated ,210914_Estonia_UniversityofTartu,Seroprevalence and levels of IgG antibodies after COVID-19 infection or vaccination.,2021-09-14,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Estonia,,,"Leftover blood samples were selected by SYNLAB Estonia from samples sent by general practitioners for routine clinical testing from all fifteen counties and age groups (0–9, 10–19, 20–59, 60–69, 70–79, 80–100 years) proportionally to the whole Estonian population.",,2021-02-08,2021-03-25,Residual sera,All,Multiple groups,,,COVID-19 vaccination status,Vaccinated no,2398,0.166,,,,,,,,Stratified non-probability,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Hiie Soeorg,University of Tartu,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.1974540,2021-09-22,2024-03-01,Verified,soeorg_seroprevalence_2021,EST
210226_Estonia_UniversityOfTartu_Stage14_Overall,210226_Estonia_UniversityofTartu_Stage14,The study on the prevalence of the coronavirus in Estonia,2023-01-30,Institutional Report,National,Repeated cross-sectional study,Estonia,,,Men and women 18 and over will be included in the study. People from 17 regions of Estonia will be included in the sample of the study: from every county and separately from Tallinn and Tartu.,The study will not include people who cannot or do not wish to participate in it.,2021-02-11,2021-02-22,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2626,0.1149,0.10289999999999999,0.1277,True,,True,,True,Stratified probability,Quantitative IgG antibody test for coronavirus,Synlab,CLIA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,University of Tartu,University of Tartu,Not Unity-Aligned,https://ut.ee/et/sisu/koroonaviiruse-levimuse-seireuuringu-antikehade-analuusi-tulemused,2021-02-26,2022-09-23,Verified,university_of_tartu_study_2020,EST
210323_Estonia_UniversityOfTartu_Stage15_Overall,210323_Estonia_UniversityOfTartu_Stage15,The study on the prevalence of the coronavirus in Estonia,2023-01-30,Institutional Report,National,Repeated cross-sectional study,Estonia,,,Men and women 18 and over will be included in the study. People from 17 regions of Estonia will be included in the sample of the study: from every county and separately from Tallinn and Tartu.,The study will not include people who cannot or do not wish to participate in it.,2021-03-11,2021-03-22,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2382,0.2141,0.1978,0.2311,True,,True,,True,Stratified probability,Quantitative IgG antibody test for coronavirus,Synlab,CLIA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,University of Tartu,Univeristy of Tartu,Not Unity-Aligned,https://ut.ee/et/sisu/koroonaviiruse-levimuse-seireuuringu-antikehade-analuusi-tulemused,2021-03-25,2022-09-23,Verified,university_of_tartu_study_2020,EST
210420_Estonia_UniversityOfTartu_Stage16_Overall,210420_Estonia_UniversityOfTartu_Stage16N parti,The study on the prevalence of the coronavirus in Estonia,2023-01-30,Institutional Report,National,Repeated cross-sectional study,Estonia,,,Men and women 18 and over will be included in the study. People from 17 regions of Estonia will be included in the sample of the study: from every county and separately from Tallinn and Tartu.,The study will not include people who cannot or do not wish to participate in it.,2021-04-08,2021-04-19,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2491,0.35869999999999996,0.3397,0.3779,True,,True,,True,Stratified probability,Quantitative IgG antibody test for coronavirus,Synlab,CLIA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,University of Tartu,Univeristy of Tartu,Not Unity-Aligned,https://ut.ee/et/sisu/koroonaviiruse-levimuse-seireuuringu-antikehade-analuusi-tulemused,2021-04-21,2022-09-23,Verified,university_of_tartu_study_2020,EST
210527_Estonia_UniversityOfTartu_Stage17_Overall,210527_Estonia_UniversityOfTartu_Stage17,The study on the prevalence of the coronavirus in Estonia,2023-01-30,Institutional Report,National,Repeated cross-sectional study,Estonia,,,Men and women 18 and over will be included in the study. People from 17 regions of Estonia will be included in the sample of the study: from every county and separately from Tallinn and Tartu.,The study will not include people who cannot or do not wish to participate in it.,2021-05-13,2021-05-24,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2290,0.49520000000000003,0.47450000000000003,0.5159,True,,True,,True,Stratified probability,Quantitative IgG antibody test for coronavirus,Synlab,CLIA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,University of Tartu,Univeristy of Tartu,Not Unity-Aligned,https://ut.ee/et/sisu/koroonaviiruse-levimuse-seireuuringu-antikehade-analuusi-tulemused,2021-05-29,2022-10-20,Verified,university_of_tartu_study_2020,EST
210622_Estonia_UniversityOfTartu_Stage18_Overall,210622_Estonia_UniversityOfTartu_Stage18,The study on the prevalence of the coronavirus in Estonia,2023-01-30,Institutional Report,National,Repeated cross-sectional study,Estonia,,,Men and women 18 and over will be included in the study. People from 17 regions of Estonia will be included in the sample of the study: from every county and separately from Tallinn and Tartu.,The study will not include people who cannot or do not wish to participate in it.,2021-06-10,2021-06-21,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2330,0.679,0.6596,0.6979000000000001,True,,True,,True,Stratified probability,Quantitative IgG antibody test for coronavirus,Synlab,CLIA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,University of Tartu,Univeristy of Tartu,Not Unity-Aligned,https://ut.ee/et/sisu/koroonaviiruse-levimuse-seireuuringu-antikehade-analuusi-tulemused,2021-06-28,2022-11-18,Verified,university_of_tartu_study_2020,EST
211001_Estonia_UniversityOfTartu_Stage20_Overall,211001_Estonia_UniversityOfTartu_Stage20,The study on the prevalence of the coronavirus in Estonia,2023-01-30,Institutional Report,National,Repeated cross-sectional study,Estonia,,,Men and women 18 and over will be included in the study. People from 17 regions of Estonia will be included in the sample of the study: from every county and separately from Tallinn and Tartu.,The study will not include people who cannot or do not wish to participate in it.,2021-09-15,2021-09-27,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2302,0.767,0.7491,0.784,True,,True,,True,Stratified probability,Quantitative IgG antibody test for coronavirus,Synlab,CLIA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,University of Tartu,Univeristy of Tartu,Not Unity-Aligned,https://ut.ee/et/sisu/koroonaviiruse-levimuse-seireuuringu-antikehade-analuusi-tulemused,2021-10-13,2022-09-08,Verified,university_of_tartu_study_2020,EST
211025_Estonia_UniversityOfTartu_Stage21_Overall,211025_Estonia_UniversityOfTartu_Stage21,The study on the prevalence of the coronavirus in Estonia,2023-01-30,Institutional Report,National,Repeated cross-sectional study,Estonia,,,Men and women 18 and over will be included in the study. People from 17 regions of Estonia will be included in the sample of the study: from every county and separately from Tallinn and Tartu.,The study will not include people who cannot or do not wish to participate in it.,2021-10-13,2021-10-25,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2312,0.7640000000000001,0.743,0.784,True,,True,,True,Stratified probability,Quantitative IgG antibody test for coronavirus,Synlab,CLIA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,University of Tartu,Univeristy of Tartu,Not Unity-Aligned,https://ut.ee/et/sisu/koroonaviiruse-levimuse-seireuuringu-antikehade-analuusi-tulemused,2021-11-03,2022-09-08,Verified,university_of_tartu_study_2020,EST
211213_Estonia_UniversityOfTartu_Stage22_Overall,211213_Estonia_UniversityOfTartu_Stage22,The study on the prevalence of the coronavirus in Estonia,2023-01-30,Institutional Report,National,Repeated cross-sectional study,Estonia,,,Men and women 18 and over will be included in the study. People from 17 regions of Estonia will be included in the sample of the study: from every county and separately from Tallinn and Tartu.,The study will not include people who cannot or do not wish to participate in it.,2021-12-01,2021-12-13,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2290,0.8150000000000001,0.7809999999999999,0.848,True,,True,,True,Stratified probability,Quantitative IgG antibody test for coronavirus,Synlab,CLIA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,University of Tartu,Univeristy of Tartu,Not Unity-Aligned,https://ut.ee/et/sisu/koroonaviiruse-levimuse-seireuuringu-antikehade-analuusi-tulemused,2022-01-10,2022-09-08,Verified,university_of_tartu_study_2020,EST
220124_Estonia_UniversityOfTartu_Stage23_Overall,220124_Estonia_UniversityOfTartu_Stage23,The study on the prevalence of the coronavirus in Estonia,2023-01-30,Institutional Report,National,Repeated cross-sectional study,Estonia,,,Men and women 18 and over will be included in the study. People from 17 regions of Estonia will be included in the sample of the study: from every county and separately from Tallinn and Tartu.,The study will not include people who cannot or do not wish to participate in it.,2022-01-11,2022-01-24,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2301,0.828,0.8,0.8540000000000001,True,,True,,True,Stratified probability,Quantitative IgG antibody test for coronavirus,Synlab,CLIA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,University of Tartu,Univeristy of Tartu,Not Unity-Aligned,https://ut.ee/et/sisu/koroonaviiruse-levimuse-seireuuringu-antikehade-analuusi-tulemused,2022-02-03,2022-09-08,Verified,university_of_tartu_study_2020,EST
220321_Estonia_UniversityOfTartu_Stage24_Overall,220321_Estonia_UniversityOfTartu_Stage24,The study on the prevalence of the coronavirus in Estonia,2023-01-30,Institutional Report,National,Repeated cross-sectional study,Estonia,,,Men and women 18 and over will be included in the study. People from 17 regions of Estonia will be included in the sample of the study: from every county and separately from Tallinn and Tartu.,The study will not include people who cannot or do not wish to participate in it.,2022-03-09,2022-03-21,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2308,0.891,0.8740000000000001,0.908,True,,True,,True,Stratified probability,Quantitative IgG antibody test for coronavirus,Synlab,CLIA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,University of Tartu,Univeristy of Tartu,Not Unity-Aligned,https://ut.ee/et/sisu/koroonaviiruse-levimuse-seireuuringu-antikehade-analuusi-tulemused,2022-03-31,2022-09-08,Unverified,university_of_tartu_study_2020,EST
220411_Estonia_UniversityOfTartu_Stage25,220411_Estonia_UniversityOfTartu_Stage25,The study on the prevalence of the coronavirus in Estonia,2023-01-30,Institutional Report,National,Repeated cross-sectional study,Estonia,,,Men and women 18 and over will be included in the study. People from 17 regions of Estonia will be included in the sample of the study: from every county and separately from Tallinn and Tartu.,The study will not include people who cannot or do not wish to participate in it.,2022-03-30,2022-04-11,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2304,0.871,0.8470000000000001,0.8940000000000001,True,,True,,True,Stratified probability,Quantitative IgG antibody test for coronavirus,Synlab,CLIA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,University of Tartu,Univeristy of Tartu,Not Unity-Aligned,https://ut.ee/et/sisu/koroonaviiruse-levimuse-seireuuringu-antikehade-analuusi-tulemused,2022-04-24,2022-09-08,Unverified,university_of_tartu_study_2020,EST
220509_Estonia_UniversityOfTartu_Stage26,220509_Estonia_UniversityOfTartu_Stage26,The study on the prevalence of the coronavirus in Estonia,2023-01-30,Institutional Report,National,Repeated cross-sectional study,Estonia,,,Men and women 18 and over will be included in the study. People from 17 regions of Estonia will be included in the sample of the study: from every county and separately from Tallinn and Tartu.,The study will not include people who cannot or do not wish to participate in it.,2022-04-27,2022-05-09,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2228,0.865,0.8320000000000001,0.8959999999999999,True,,True,,True,Stratified probability,Quantitative IgG antibody test for coronavirus,Synlab,CLIA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,University of Tartu,Univeristy of Tartu,Not Unity-Aligned,https://ut.ee/et/sisu/koroonaviiruse-levimuse-seireuuringu-antikehade-analuusi-tulemused,2022-05-18,2022-09-08,Unverified,university_of_tartu_study_2020,EST
220613_Estonia_UniversityOfTartu_Stage27,220613_Estonia_UniversityOfTartu_Stage27,The study on the prevalence of the coronavirus in Estonia,2023-01-30,Institutional Report,National,Repeated cross-sectional study,Estonia,,,Men and women 18 and over will be included in the study. People from 17 regions of Estonia will be included in the sample of the study: from every county and separately from Tallinn and Tartu.,The study will not include people who cannot or do not wish to participate in it.,2022-06-01,2022-06-13,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2439,0.875,0.8490000000000001,0.899,True,,True,,True,Stratified probability,Quantitative IgG antibody test for coronavirus,Synlab,CLIA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,University of Tartu,University of Tartu,Not Unity-Aligned,https://ut.ee/et/sisu/koroonaviiruse-levimuse-seireuuringu-antikehade-analuusi-tulemused,2022-06-29,2022-09-08,Unverified,university_of_tartu_study_2020,EST
220829_Estonia_UniversityOfTartu_Stage28_PopAdj,220829_Estonia_UniversityOfTartu_Stage28,The study on the prevalence of the coronavirus in Estonia,2023-01-30,Institutional Report,National,Repeated cross-sectional study,Estonia,,,Men and women 18 and over will be included in the study. People from 17 regions of Estonia will be included in the sample of the study: from every county and separately from Tallinn and Tartu.,The study will not include people who cannot or do not wish to participate in it.,2022-08-17,2022-08-29,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2431,0.8840000000000001,0.8540000000000001,0.913,True,,True,,True,Stratified probability,Quantitative IgG antibody test for coronavirus,Synlab,CLIA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,University of Tartu,University of Tartu,Not Unity-Aligned,https://ut.ee/et/sisu/koroonaviiruse-levimuse-seireuuringu-antikehade-analuusi-tulemused,2022-09-08,2022-09-08,Unverified,university_of_tartu_study_2020,EST
220829_Estonia_UniversityOfTartu_Stage28_UnAdj,220829_Estonia_UniversityOfTartu_Stage28,The study on the prevalence of the coronavirus in Estonia,2023-01-30,Institutional Report,National,Repeated cross-sectional study,Estonia,,,Men and women 18 and over will be included in the study. People from 17 regions of Estonia will be included in the sample of the study: from every county and separately from Tallinn and Tartu.,The study will not include people who cannot or do not wish to participate in it.,2022-08-17,2022-08-29,Household and community samples,All,Multiple groups,18.0,,Analysis,,2431,0.9543,,,,,,,,Stratified probability,Quantitative IgG antibody test for coronavirus,Synlab,CLIA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,University of Tartu,University of Tartu,Not Unity-Aligned,https://ut.ee/et/sisu/koroonaviiruse-levimuse-seireuuringu-antikehade-analuusi-tulemused,2022-09-08,2022-09-08,Unverified,university_of_tartu_study_2020,EST
220926_Estonia_UniversityOfTartu_Stage29_PopAdj,220926_Estonia_UniversityOfTartu_Stage29,The study on the prevalence of the coronavirus in Estonia,2023-01-30,Institutional Report,National,Repeated cross-sectional study,Estonia,,,Men and women 18 and over will be included in the study. People from 17 regions of Estonia will be included in the sample of the study: from every county and separately from Tallinn and Tartu.,The study will not include people who cannot or do not wish to participate in it.,2022-09-15,2022-09-26,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2184,0.9159999999999999,0.904,0.9279999999999999,True,,True,,True,Stratified probability,Quantitative IgG antibody test for coronavirus,Synlab,CLIA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,University of Tartu,University of Tartu,Not Unity-Aligned,https://ut.ee/et/sisu/koroonaviiruse-levimuse-seireuuringu-antikehade-analuusi-tulemused,2022-10-04,2022-10-04,Unverified,university_of_tartu_study_2020,EST
220926_Estonia_UniversityOfTartu_Stage29_UnAdj,220926_Estonia_UniversityOfTartu_Stage29,The study on the prevalence of the coronavirus in Estonia,2023-01-30,Institutional Report,National,Repeated cross-sectional study,Estonia,,,Men and women 18 and over will be included in the study. People from 17 regions of Estonia will be included in the sample of the study: from every county and separately from Tallinn and Tartu.,The study will not include people who cannot or do not wish to participate in it.,2022-09-15,2022-09-26,Household and community samples,All,Multiple groups,18.0,,Analysis,,2184,0.9573999999999999,,,,,,,,Stratified probability,Quantitative IgG antibody test for coronavirus,Synlab,CLIA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,University of Tartu,University of Tartu,Not Unity-Aligned,https://ut.ee/et/sisu/koroonaviiruse-levimuse-seireuuringu-antikehade-analuusi-tulemused,2022-10-04,2022-10-04,Unverified,university_of_tartu_study_2020,EST
221024_Estonia_UniversityOfTartu_Stage30_PopAdj,221024_Estonia_UniversityOfTartu_Stage30,The study on the prevalence of the coronavirus in Estonia,2023-01-30,Institutional Report,National,Repeated cross-sectional study,Estonia,,,Men and women 18 and over will be included in the study. People from 17 regions of Estonia will be included in the sample of the study: from every county and separately from Tallinn and Tartu.,The study will not include people who cannot or do not wish to participate in it.,2022-10-12,2022-10-24,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2056,0.914,0.9009999999999999,0.9259999999999999,True,,True,,True,Stratified probability,Quantitative IgG antibody test for coronavirus,Synlab,CLIA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,University of Tartu,University of Tartu,Not Unity-Aligned,https://ut.ee/et/sisu/koroonaviiruse-levimuse-seireuuringu-antikehade-analuusi-tulemused,2022-11-01,2022-11-01,Unverified,university_of_tartu_study_2020,EST
221024_Estonia_UniversityOfTartu_Stage30_UnAdj,221024_Estonia_UniversityOfTartu_Stage30,The study on the prevalence of the coronavirus in Estonia,2023-01-30,Institutional Report,National,Repeated cross-sectional study,Estonia,,,Men and women 18 and over will be included in the study. People from 17 regions of Estonia will be included in the sample of the study: from every county and separately from Tallinn and Tartu.,The study will not include people who cannot or do not wish to participate in it.,2022-10-12,2022-10-24,Household and community samples,All,Multiple groups,18.0,,Analysis,,2056,0.9616,,,,,,,,Stratified probability,Quantitative IgG antibody test for coronavirus,Synlab,CLIA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,University of Tartu,University of Tartu,Not Unity-Aligned,https://ut.ee/et/sisu/koroonaviiruse-levimuse-seireuuringu-antikehade-analuusi-tulemused,2022-11-01,2022-11-01,Unverified,university_of_tartu_study_2020,EST
221121_Estonia_UniversityOfTartu_Stage31_PopAdj,221121_Estonia_UniversityOfTartu_Stage31,The study on the prevalence of the coronavirus in Estonia,2023-01-30,Institutional Report,National,Repeated cross-sectional study,Estonia,,,Men and women 18 and over will be included in the study. People from 17 regions of Estonia will be included in the sample of the study: from every county and separately from Tallinn and Tartu.,The study will not include people who cannot or do not wish to participate in it.,2022-11-09,2022-11-21,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,1995,0.899,0.885,0.912,True,,True,,True,Stratified probability,Quantitative IgG antibody test for coronavirus,Synlab,CLIA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,University of Tartu,University of Tartu,Not Unity-Aligned,https://ut.ee/et/sisu/koroonaviiruse-levimuse-seireuuringu-antikehade-analuusi-tulemused,2022-11-29,2023-03-19,Unverified,university_of_tartu_study_2020,EST
221121_Estonia_UniversityOfTartu_Stage31_UnAdj,221121_Estonia_UniversityOfTartu_Stage31,The study on the prevalence of the coronavirus in Estonia,2023-01-30,Institutional Report,National,Repeated cross-sectional study,Estonia,,,Men and women 18 and over will be included in the study. People from 17 regions of Estonia will be included in the sample of the study: from every county and separately from Tallinn and Tartu.,The study will not include people who cannot or do not wish to participate in it.,2022-11-09,2022-11-21,Household and community samples,All,Multiple groups,18.0,,Analysis,,1995,0.9569,,,,,,,,Stratified probability,Quantitative IgG antibody test for coronavirus,Synlab,CLIA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,University of Tartu,University of Tartu,Not Unity-Aligned,https://ut.ee/et/sisu/koroonaviiruse-levimuse-seireuuringu-antikehade-analuusi-tulemused,2022-11-29,2023-03-19,Unverified,university_of_tartu_study_2020,EST
221219_Estonia_UniversityOfTartu_Stage32_PopAdj,221219_Estonia_UniversityOfTartu_Stage32,The study on the prevalence of the coronavirus in Estonia,2023-01-30,Institutional Report,National,Repeated cross-sectional study,Estonia,,,Men and women 18 and over will be included in the study. People from 17 regions of Estonia will be included in the sample of the study: from every county and separately from Tallinn and Tartu.,The study will not include people who cannot or do not wish to participate in it.,2022-12-07,2022-12-19,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,1876,0.9059999999999999,0.892,0.919,True,,True,,True,Stratified probability,Quantitative IgG antibody test for coronavirus,Synlab,"CLIA, CMIA",Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,University of Tartu,University of Tartu,Not Unity-Aligned,https://ut.ee/et/sisu/koroonaviiruse-levimuse-seireuuringu-antikehade-analuusi-tulemused,2023-01-10,2023-03-19,Unverified,university_of_tartu_study_2020,EST
221219_Estonia_UniversityOfTartu_Stage32_UnAdj,221219_Estonia_UniversityOfTartu_Stage32,The study on the prevalence of the coronavirus in Estonia,2023-01-30,Institutional Report,National,Repeated cross-sectional study,Estonia,,,Men and women 18 and over will be included in the study. People from 17 regions of Estonia will be included in the sample of the study: from every county and separately from Tallinn and Tartu.,The study will not include people who cannot or do not wish to participate in it.,2022-12-07,2022-12-19,Household and community samples,All,Multiple groups,18.0,,Analysis,,1876,0.9568000000000001,,,,,,,,Stratified probability,Quantitative IgG antibody test for coronavirus,Synlab,"CLIA, CMIA",Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,University of Tartu,University of Tartu,Not Unity-Aligned,https://ut.ee/et/sisu/koroonaviiruse-levimuse-seireuuringu-antikehade-analuusi-tulemused,2023-01-10,2023-03-19,Unverified,university_of_tartu_study_2020,EST
230130_Estonia_UniversityOfTartu_Stage33_PopAdj,230130_Estonia_UniversityOfTartu_Stage33,The study on the prevalence of the coronavirus in Estonia,2023-01-30,Institutional Report,National,Repeated cross-sectional study,Estonia,,,Men and women 18 and over will be included in the study. People from 17 regions of Estonia will be included in the sample of the study: from every county and separately from Tallinn and Tartu.,The study will not include people who cannot or do not wish to participate in it.,2023-01-18,2023-01-30,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2152,0.932,0.921,0.943,True,,True,,True,Stratified probability,Quantitative IgG antibody test for coronavirus,Synlab,"CLIA, CMIA",Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,University of Tartu,University of Tartu,Not Unity-Aligned,https://ut.ee/et/sisu/koroonaviiruse-levimuse-seireuuringu-antikehade-analuusi-tulemused,2023-02-17,2024-03-09,Unverified,university_of_tartu_study_2020,EST
200922_AddisAbaba_KuwaitUniversity_GenPop,200922_AddisAbaba_KuwaitUniversity,"SARS-CoV-2 Serosurvey in Addis Ababa, Ethiopia",2020-09-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,Oromia,Addis Ababa,"Age 14 years or older, resident in Addis Ababa for all of November 2019–February 2020, and no travel outside Ethiopia since November 1, 2019","Sore throat, runny nose, cough or difficulty breathing, and/or hospitalized or quarantined in the last 28 days; measured temperature > 99.6 Fahrenheit, resting heart rate > 100/minute, and/or resting respiratory rate > 25/minute; incarceration for a crime; unwilling to participate; or unable to consent",2020-05-18,2020-05-21,Residual sera,All,Multiple groups,,,Primary Estimate,,99,0.03,0.006,0.086,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,0.9990000000000001,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,John Kempen,Kuwait University,Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.20-0816,2020-12-06,2024-03-01,Verified,kempen_sars-cov-2_2020,ETH
201013_AddisAbaba_MinistryOfHealthEthiopia_TestAdj_PopUnAdj,201013_AddisAbaba_MinistryOfHealthEthiopia,"Sero-prevalence of anti-SARS-CoV-2 Antibodies in Addis Ababa, Ethiopia",2020-10-13,Preprint,Local,Cross-sectional survey ,Ethiopia,,Addis Ababa,"The study population were adult (≥ 18 years), residents of Addis Ababa, with no history of known contact with confirmed COVID-19 cases and no recent history of travel out of Ethiopia in the past four months prior to the period of data collection"," Individuals who were unable to consent, those with unstable mental state and suspected to have acute SARS-CoV-2 infection were excluded",2020-04-23,2020-04-28,Household and community samples,All,Adults (18-64 years),18.0,,Primary Estimate,Test Adj,301,0.08800000000000001,0.055,0.11599999999999999,True,True,,,,Simplified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Plasma,"['IgG', 'IgM']",,Validated by manufacturers,0.8790000000000001,1.0,['Moderate'],Yes,Yes,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Berhanu Alemu,"Ministry of Health, Ethiopia",Not Unity-Aligned,https://www.biorxiv.org/content/10.1101/2020.10.13.337287v1,2020-12-11,2023-07-04,Verified,alemu_sero-prevalence_2020,ETH
201013_AddisAbaba_MinistryOfHealthEthiopia_<50,201013_AddisAbaba_MinistryOfHealthEthiopia,"Sero-prevalence of anti-SARS-CoV-2 Antibodies in Addis Ababa, Ethiopia",2020-10-13,Preprint,Local,Cross-sectional survey ,Ethiopia,,Addis Ababa,"The study population were adult (≥ 18 years), residents of Addis Ababa, with no history of known contact with confirmed COVID-19 cases and no recent history of travel out of Ethiopia in the past four months prior to the period of data collection"," Individuals who were unable to consent, those with unstable mental state and suspected to have acute SARS-CoV-2 infection were excluded",2020-04-23,2020-04-28,Household and community samples,All,Adults (18-64 years),18.0,50.0,Age,<50 years of age,267,0.08199999999999999,,,,,,,,Simplified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Plasma,"['IgG', 'IgM']",,Validated by manufacturers,0.8790000000000001,1.0,['Moderate'],Yes,Yes,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Berhanu Alemu,"Ministry of Health, Ethiopia",Not Unity-Aligned,https://www.biorxiv.org/content/10.1101/2020.10.13.337287v1,2020-12-11,2024-03-01,Verified,alemu_sero-prevalence_2020,ETH
201013_AddisAbaba_MinistryOfHealthEthiopia_Male,201013_AddisAbaba_MinistryOfHealthEthiopia,"Sero-prevalence of anti-SARS-CoV-2 Antibodies in Addis Ababa, Ethiopia",2020-10-13,Preprint,Local,Cross-sectional survey ,Ethiopia,,Addis Ababa,"The study population were adult (≥ 18 years), residents of Addis Ababa, with no history of known contact with confirmed COVID-19 cases and no recent history of travel out of Ethiopia in the past four months prior to the period of data collection"," Individuals who were unable to consent, those with unstable mental state and suspected to have acute SARS-CoV-2 infection were excluded",2020-04-23,2020-04-28,Household and community samples,Male,Adults (18-64 years),18.0,,Sex/Gender,Males,188,0.09,,,,,,,,Simplified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Plasma,"['IgG', 'IgM']",,Validated by manufacturers,0.8790000000000001,1.0,['Moderate'],Yes,Yes,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Berhanu Alemu,"Ministry of Health, Ethiopia",Not Unity-Aligned,https://www.biorxiv.org/content/10.1101/2020.10.13.337287v1,2020-12-11,2024-03-01,Verified,alemu_sero-prevalence_2020,ETH
201013_AddisAbaba_MinistryOfHealthEthiopia_TestUnadj_PopUnadj,201013_AddisAbaba_MinistryOfHealthEthiopia,"Sero-prevalence of anti-SARS-CoV-2 Antibodies in Addis Ababa, Ethiopia",2020-10-13,Preprint,Local,Cross-sectional survey ,Ethiopia,,Addis Ababa,"The study population were adult (≥ 18 years), residents of Addis Ababa, with no history of known contact with confirmed COVID-19 cases and no recent history of travel out of Ethiopia in the past four months prior to the period of data collection"," Individuals who were unable to consent, those with unstable mental state and suspected to have acute SARS-CoV-2 infection were excluded",2020-04-23,2020-04-28,Household and community samples,All,Adults (18-64 years),18.0,,Analysis,"Pop unadj, test unadj",301,0.076,,,,,,,True,Simplified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Plasma,"['IgG', 'IgM']",,Validated by manufacturers,0.8790000000000001,1.0,['Moderate'],Yes,Yes,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Berhanu Alemu,"Ministry of Health, Ethiopia",Not Unity-Aligned,https://www.biorxiv.org/content/10.1101/2020.10.13.337287v1,2020-12-11,2024-03-01,Verified,alemu_sero-prevalence_2020,ETH
201013_AddisAbaba_MinistryOfHealthEthiopia_=>50,201013_AddisAbaba_MinistryOfHealthEthiopia,"Sero-prevalence of anti-SARS-CoV-2 Antibodies in Addis Ababa, Ethiopia",2020-10-13,Preprint,Local,Cross-sectional survey ,Ethiopia,,Addis Ababa,"The study population were adult (≥ 18 years), residents of Addis Ababa, with no history of known contact with confirmed COVID-19 cases and no recent history of travel out of Ethiopia in the past four months prior to the period of data collection"," Individuals who were unable to consent, those with unstable mental state and suspected to have acute SARS-CoV-2 infection were excluded",2020-04-23,2020-04-28,Household and community samples,All,Adults (18-64 years),50.0,,Age,=>50,34,0.028999999999999998,,,,,,,,Simplified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Plasma,"['IgG', 'IgM']",,Validated by manufacturers,0.8790000000000001,1.0,['Moderate'],Yes,Yes,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Berhanu Alemu,"Ministry of Health, Ethiopia",Not Unity-Aligned,https://www.biorxiv.org/content/10.1101/2020.10.13.337287v1,2020-12-11,2024-03-01,Verified,alemu_sero-prevalence_2020,ETH
201013_AddisAbaba_MinistryOfHealthEthiopia_Female,201013_AddisAbaba_MinistryOfHealthEthiopia,"Sero-prevalence of anti-SARS-CoV-2 Antibodies in Addis Ababa, Ethiopia",2020-10-13,Preprint,Local,Cross-sectional survey ,Ethiopia,,Addis Ababa,"The study population were adult (≥ 18 years), residents of Addis Ababa, with no history of known contact with confirmed COVID-19 cases and no recent history of travel out of Ethiopia in the past four months prior to the period of data collection"," Individuals who were unable to consent, those with unstable mental state and suspected to have acute SARS-CoV-2 infection were excluded",2020-04-23,2020-04-28,Household and community samples,Female,Adults (18-64 years),18.0,,Sex/Gender,Females,113,0.054000000000000006,,,,,,,,Simplified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Plasma,"['IgG', 'IgM']",,Validated by manufacturers,0.8790000000000001,1.0,['Moderate'],Yes,Yes,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Berhanu Alemu,"Ministry of Health, Ethiopia",Not Unity-Aligned,https://www.biorxiv.org/content/10.1101/2020.10.13.337287v1,2020-12-11,2024-03-01,Verified,alemu_sero-prevalence_2020,ETH
210507_Ethiopia_EthiopianPublicHealthInstitute_AddisAbaba,210507_Ethiopia_EthiopianPublicHealthInstitute_AddisAbaba,Prevalence of SARS-CoV-2 in urban and rural Ethiopia: Randomized household serosurveys reveal level of spread during the first wave of the pandemic,2021-05-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,Oromia Region,Addis Ababa,"one participant per household in Addis Ababa, aged 18 or above, was chosen at random for antibody testing",,2020-07-22,2020-09-02,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,956,0.035,0.017,0.054000000000000006,True,True,True,,,Stratified probability,Coretests COVID-19 IgM/IgG Ab Test,Core Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.6900000000000001,0.97,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Saro Abdella,Ethiopian Public Health Institute,Unity-Aligned,http://dx.doi.org/10.1016/j.eclinm.2021.100880,2021-05-28,2023-08-15,Verified,abdella_prevalence_2021,ETH
210507_Ethiopia_EthiopianPublicHealthInstitute_AddisAbaba_Female,210507_Ethiopia_EthiopianPublicHealthInstitute_AddisAbaba,Prevalence of SARS-CoV-2 in urban and rural Ethiopia: Randomized household serosurveys reveal level of spread during the first wave of the pandemic,2021-05-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,Oromia Region,Addis Ababa,"one participant per household in Addis Ababa, aged 18 or above, was chosen at random for antibody testing",,2020-07-22,2020-09-02,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,583,0.032,0.015,0.051,,True,True,,,Stratified probability,Coretests COVID-19 IgM/IgG Ab Test,Core Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.6900000000000001,0.97,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Saro Abdella,Ethiopian Public Health Institute,Unity-Aligned,http://dx.doi.org/10.1016/j.eclinm.2021.100880,2021-08-13,2023-08-15,Verified,abdella_prevalence_2021,ETH
210507_Ethiopia_EthiopianPublicHealthInstitute_AddisAbaba_Male,210507_Ethiopia_EthiopianPublicHealthInstitute_AddisAbaba,Prevalence of SARS-CoV-2 in urban and rural Ethiopia: Randomized household serosurveys reveal level of spread during the first wave of the pandemic,2021-05-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,Oromia Region,Addis Ababa,"one participant per household in Addis Ababa, aged 18 or above, was chosen at random for antibody testing",,2020-07-22,2020-09-02,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,373,0.04,0.016,0.066,,True,True,,,Stratified probability,Coretests COVID-19 IgM/IgG Ab Test,Core Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.6900000000000001,0.97,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Saro Abdella,Ethiopian Public Health Institute,Unity-Aligned,http://dx.doi.org/10.1016/j.eclinm.2021.100880,2021-08-13,2023-08-15,Verified,abdella_prevalence_2021,ETH
210507_Ethiopia_EthiopianPublicHealthInstitute_AddisAbaba_unadj,210507_Ethiopia_EthiopianPublicHealthInstitute_AddisAbaba,Prevalence of SARS-CoV-2 in urban and rural Ethiopia: Randomized household serosurveys reveal level of spread during the first wave of the pandemic,2021-05-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,Oromia Region,Addis Ababa,"one participant per household in Addis Ababa, aged 18 or above, was chosen at random for antibody testing",,2020-07-22,2020-09-02,Household and community samples,All,Multiple groups,18.0,,Analysis,,956,0.0471,,,,,,,True,Stratified probability,Coretests COVID-19 IgM/IgG Ab Test,Core Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.6900000000000001,0.97,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Saro Abdella,Ethiopian Public Health Institute,Unity-Aligned,http://dx.doi.org/10.1016/j.eclinm.2021.100880,2021-08-13,2024-03-01,Verified,abdella_prevalence_2021,ETH
210507_Ethiopia_EthiopianPublicHealthInstitute_AddisAbaba_Age35-49,210507_Ethiopia_EthiopianPublicHealthInstitute_AddisAbaba,Prevalence of SARS-CoV-2 in urban and rural Ethiopia: Randomized household serosurveys reveal level of spread during the first wave of the pandemic,2021-05-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,Oromia Region,Addis Ababa,"one participant per household in Addis Ababa, aged 18 or above, was chosen at random for antibody testing",,2020-07-22,2020-09-02,Household and community samples,All,Adults (18-64 years),35.0,49.0,Age,,268,0.045,0.018000000000000002,0.076,,True,True,,,Stratified probability,Coretests COVID-19 IgM/IgG Ab Test,Core Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.6900000000000001,0.97,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Saro Abdella,Ethiopian Public Health Institute,Unity-Aligned,http://dx.doi.org/10.1016/j.eclinm.2021.100880,2021-08-13,2023-08-15,Verified,abdella_prevalence_2021,ETH
210507_Ethiopia_EthiopianPublicHealthInstitute_AddisAbaba_Age50-64,210507_Ethiopia_EthiopianPublicHealthInstitute_AddisAbaba,Prevalence of SARS-CoV-2 in urban and rural Ethiopia: Randomized household serosurveys reveal level of spread during the first wave of the pandemic,2021-05-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,Oromia Region,Addis Ababa,"one participant per household in Addis Ababa, aged 18 or above, was chosen at random for antibody testing",,2020-07-22,2020-09-02,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,,162,0.046,0.017,0.087,,True,True,,,Stratified probability,Coretests COVID-19 IgM/IgG Ab Test,Core Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.6900000000000001,0.97,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Saro Abdella,Ethiopian Public Health Institute,Unity-Aligned,http://dx.doi.org/10.1016/j.eclinm.2021.100880,2021-08-13,2023-08-15,Verified,abdella_prevalence_2021,ETH
210507_Ethiopia_EthiopianPublicHealthInstitute_AddisAbaba_Age18-34,210507_Ethiopia_EthiopianPublicHealthInstitute_AddisAbaba,Prevalence of SARS-CoV-2 in urban and rural Ethiopia: Randomized household serosurveys reveal level of spread during the first wave of the pandemic,2021-05-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,Oromia Region,Addis Ababa,"one participant per household in Addis Ababa, aged 18 or above, was chosen at random for antibody testing",,2020-07-22,2020-09-02,Household and community samples,All,Adults (18-64 years),18.0,34.0,Age,,461,0.027999999999999997,0.01,0.05,,True,True,,,Stratified probability,Coretests COVID-19 IgM/IgG Ab Test,Core Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.6900000000000001,0.97,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Saro Abdella,Ethiopian Public Health Institute,Unity-Aligned,http://dx.doi.org/10.1016/j.eclinm.2021.100880,2021-08-13,2023-08-15,Verified,abdella_prevalence_2021,ETH
210507_Ethiopia_EthiopianPublicHealthInstitute_AddisAbaba_Age65-90,210507_Ethiopia_EthiopianPublicHealthInstitute_AddisAbaba,Prevalence of SARS-CoV-2 in urban and rural Ethiopia: Randomized household serosurveys reveal level of spread during the first wave of the pandemic,2021-05-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,Oromia Region,Addis Ababa,"one participant per household in Addis Ababa, aged 18 or above, was chosen at random for antibody testing",,2020-07-22,2020-09-02,Household and community samples,All,Seniors (65+ years),65.0,90.0,Age,,65,0.051,0.017,0.105,,True,True,,,Stratified probability,Coretests COVID-19 IgM/IgG Ab Test,Core Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.6900000000000001,0.97,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Saro Abdella,Ethiopian Public Health Institute,Unity-Aligned,http://dx.doi.org/10.1016/j.eclinm.2021.100880,2021-08-13,2023-08-15,Verified,abdella_prevalence_2021,ETH
210507_Ethiopia_EthiopianPublicHealthInstitute_JimmaRegion,210507_Ethiopia_EthiopianPublicHealthInstitute_JimmaRegion,Prevalence of SARS-CoV-2 in urban and rural Ethiopia: Randomized household serosurveys reveal level of spread during the first wave of the pandemic,2021-05-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,Oromia Region,Jimma,"one participant per household in Jimma Region, aged 18 or above, was chosen at random for antibody testing",,2020-07-22,2020-09-02,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,900,0.006,0.001,0.018000000000000002,True,True,True,,,Stratified probability,Coretests COVID-19 IgM/IgG Ab Test,Core Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.6900000000000001,0.97,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Saro Abdella,Ethiopian Public Health Institute,Unity-Aligned,http://dx.doi.org/10.1016/j.eclinm.2021.100880,2021-05-28,2023-08-15,Verified,abdella_prevalence_2021,ETH
210507_Ethiopia_EthiopianPublicHealthInstitute_JimmaRegion_Female,210507_Ethiopia_EthiopianPublicHealthInstitute_JimmaRegion,Prevalence of SARS-CoV-2 in urban and rural Ethiopia: Randomized household serosurveys reveal level of spread during the first wave of the pandemic,2021-05-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,Oromia Region,Jimma,"one participant per household in Jimma Region, aged 18 or above, was chosen at random for antibody testing",,2020-07-22,2020-09-02,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,474,0.008,0.001,0.02,,True,True,,,Stratified probability,Coretests COVID-19 IgM/IgG Ab Test,Core Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.6900000000000001,0.97,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Saro Abdella,Ethiopian Public Health Institute,Unity-Aligned,http://dx.doi.org/10.1016/j.eclinm.2021.100880,2021-08-13,2023-08-15,Verified,abdella_prevalence_2021,ETH
210507_Ethiopia_EthiopianPublicHealthInstitute_JimmaRegion_Age35-49,210507_Ethiopia_EthiopianPublicHealthInstitute_JimmaRegion,Prevalence of SARS-CoV-2 in urban and rural Ethiopia: Randomized household serosurveys reveal level of spread during the first wave of the pandemic,2021-05-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,Oromia Region,Jimma,"one participant per household in Jimma Region, aged 18 or above, was chosen at random for antibody testing",,2020-07-22,2020-09-02,Household and community samples,All,Adults (18-64 years),35.0,49.0,Age,,258,0.008,0.001,0.02,,True,True,,,Stratified probability,Coretests COVID-19 IgM/IgG Ab Test,Core Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.6900000000000001,0.97,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Saro Abdella,Ethiopian Public Health Institute,Unity-Aligned,http://dx.doi.org/10.1016/j.eclinm.2021.100880,2021-08-13,2023-08-15,Verified,abdella_prevalence_2021,ETH
210507_Ethiopia_EthiopianPublicHealthInstitute_JimmaRegion_Age18-34,210507_Ethiopia_EthiopianPublicHealthInstitute_JimmaRegion,Prevalence of SARS-CoV-2 in urban and rural Ethiopia: Randomized household serosurveys reveal level of spread during the first wave of the pandemic,2021-05-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,Oromia Region,Jimma,"one participant per household in Jimma Region, aged 18 or above, was chosen at random for antibody testing",,2020-07-22,2020-09-02,Household and community samples,All,Adults (18-64 years),18.0,34.0,Age,,477,0.008,0.001,0.019,,True,True,,,Stratified probability,Coretests COVID-19 IgM/IgG Ab Test,Core Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.6900000000000001,0.97,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Saro Abdella,Ethiopian Public Health Institute,Unity-Aligned,http://dx.doi.org/10.1016/j.eclinm.2021.100880,2021-08-13,2023-08-15,Verified,abdella_prevalence_2021,ETH
210507_Ethiopia_EthiopianPublicHealthInstitute_JimmaRegion_Male,210507_Ethiopia_EthiopianPublicHealthInstitute_JimmaRegion,Prevalence of SARS-CoV-2 in urban and rural Ethiopia: Randomized household serosurveys reveal level of spread during the first wave of the pandemic,2021-05-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,Oromia Region,Jimma,"one participant per household in Jimma Region, aged 18 or above, was chosen at random for antibody testing",,2020-07-22,2020-09-02,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,426,0.006999999999999999,0.001,0.018000000000000002,,True,True,,,Stratified probability,Coretests COVID-19 IgM/IgG Ab Test,Core Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.6900000000000001,0.97,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Saro Abdella,Ethiopian Public Health Institute,Unity-Aligned,http://dx.doi.org/10.1016/j.eclinm.2021.100880,2021-08-13,2023-08-15,Verified,abdella_prevalence_2021,ETH
210507_Ethiopia_EthiopianPublicHealthInstitute_JimmaRegion_Age50-64,210507_Ethiopia_EthiopianPublicHealthInstitute_JimmaRegion,Prevalence of SARS-CoV-2 in urban and rural Ethiopia: Randomized household serosurveys reveal level of spread during the first wave of the pandemic,2021-05-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,Oromia Region,Jimma,"one participant per household in Jimma Region, aged 18 or above, was chosen at random for antibody testing",,2020-07-22,2020-09-02,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,,117,0.008,0.001,0.02,,True,True,,,Stratified probability,Coretests COVID-19 IgM/IgG Ab Test,Core Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.6900000000000001,0.97,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Saro Abdella,Ethiopian Public Health Institute,Unity-Aligned,http://dx.doi.org/10.1016/j.eclinm.2021.100880,2021-08-13,2023-08-15,Verified,abdella_prevalence_2021,ETH
210507_Ethiopia_EthiopianPublicHealthInstitute_JimmaRegion_Age65-90,210507_Ethiopia_EthiopianPublicHealthInstitute_JimmaRegion,Prevalence of SARS-CoV-2 in urban and rural Ethiopia: Randomized household serosurveys reveal level of spread during the first wave of the pandemic,2021-05-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,Oromia Region,Jimma,"one participant per household in Jimma Region, aged 18 or above, was chosen at random for antibody testing",,2020-07-22,2020-09-02,Household and community samples,All,Seniors (65+ years),65.0,90.0,Age,,48,0.008,0.001,0.021,,True,True,,,Stratified probability,Coretests COVID-19 IgM/IgG Ab Test,Core Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.6900000000000001,0.97,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Saro Abdella,Ethiopian Public Health Institute,Unity-Aligned,http://dx.doi.org/10.1016/j.eclinm.2021.100880,2021-08-13,2023-08-15,Verified,abdella_prevalence_2021,ETH
210507_Ethiopia_EthiopianPublicHealthInstitute_JimmaRegion_unadj,210507_Ethiopia_EthiopianPublicHealthInstitute_JimmaRegion,Prevalence of SARS-CoV-2 in urban and rural Ethiopia: Randomized household serosurveys reveal level of spread during the first wave of the pandemic,2021-05-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,Oromia Region,Jimma,"one participant per household in Jimma Region, aged 18 or above, was chosen at random for antibody testing",,2020-07-22,2020-09-02,Household and community samples,All,Multiple groups,18.0,,Analysis,,900,0.0122,,,,,,,True,Stratified probability,Coretests COVID-19 IgM/IgG Ab Test,Core Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.6900000000000001,0.97,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Saro Abdella,Ethiopian Public Health Institute,Unity-Aligned,http://dx.doi.org/10.1016/j.eclinm.2021.100880,2021-08-13,2024-03-01,Verified,abdella_prevalence_2021,ETH
210710_EthiopiaDireDawa_JimmaUniversityInstituteofHealth_Primary,210710_EthiopiaDireDawa_JimmaUniversityInstituteofHealth,"Seroprevalence of SARS-CoV-2 antibody among individuals aged above 15 years and residing in congregate settings in Dire Dawa city administration, Ethiopia.",2021-07-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,,Dire Dawa city,SARS-CoV-2 serosurvey was conducted among individuals aged above 15 years and residing in randomly selected households from purposively selected 11 enumeration areas in overcrowded neighborhoods. ,"Sixty-six (66) samples were not included into this analysis due to grossly hemolyzed specimens 21 (3.8%), information mismatch on request form 14 (2.1%), insufficient specimen volume 18 (2.7%), and missing labels on container 13 (2.0%).",2020-06-15,2020-07-30,Household and community samples,All,Multiple groups,15.0,,Primary Estimate,,684,0.032,0.02,0.048,True,,,,True,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Tamrat Shaweno,Jimma University Institute of Health,Unity-Aligned,https://dx.doi.org/10.1186/s41182-021-00347-7,2021-07-19,2024-03-01,Verified,shaweno_seroprevalence_2021,ETH
210710_EthiopiaDireDawa_JimmaUniversityInstituteofHealth_Female,210710_EthiopiaDireDawa_JimmaUniversityInstituteofHealth,"Seroprevalence of SARS-CoV-2 antibody among individuals aged above 15 years and residing in congregate settings in Dire Dawa city administration, Ethiopia.",2021-07-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,,Dire Dawa city,SARS-CoV-2 serosurvey was conducted among individuals aged above 15 years and residing in randomly selected households from purposively selected 11 enumeration areas in overcrowded neighborhoods. ,"Sixty-six (66) samples were not included into this analysis due to grossly hemolyzed specimens 21 (3.8%), information mismatch on request form 14 (2.1%), insufficient specimen volume 18 (2.7%), and missing labels on container 13 (2.0%).",2020-06-15,2020-07-30,Household and community samples,Female,Multiple groups,15.0,,Sex/Gender,,377,0.033,0.01,0.05,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Tamrat Shaweno,Jimma University Institute of Health,Unity-Aligned,https://dx.doi.org/10.1186/s41182-021-00347-7,2021-07-19,2024-03-01,Verified,shaweno_seroprevalence_2021,ETH
210710_EthiopiaDireDawa_JimmaUniversityInstituteofHealth_25-34yrs,210710_EthiopiaDireDawa_JimmaUniversityInstituteofHealth,"Seroprevalence of SARS-CoV-2 antibody among individuals aged above 15 years and residing in congregate settings in Dire Dawa city administration, Ethiopia.",2021-07-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,,Dire Dawa city,SARS-CoV-2 serosurvey was conducted among individuals aged above 15 years and residing in randomly selected households from purposively selected 11 enumeration areas in overcrowded neighborhoods. ,"Sixty-six (66) samples were not included into this analysis due to grossly hemolyzed specimens 21 (3.8%), information mismatch on request form 14 (2.1%), insufficient specimen volume 18 (2.7%), and missing labels on container 13 (2.0%).",2020-06-15,2020-07-30,Household and community samples,All,Adults (18-64 years),25.0,,Age,25-34 ,182,0.022000000000000002,0.001,0.04,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Tamrat Shaweno,Jimma University Institute of Health,Unity-Aligned,https://dx.doi.org/10.1186/s41182-021-00347-7,2021-07-19,2024-03-01,Verified,shaweno_seroprevalence_2021,ETH
210710_EthiopiaDireDawa_JimmaUniversityInstituteofHealth_45-90yrs,210710_EthiopiaDireDawa_JimmaUniversityInstituteofHealth,"Seroprevalence of SARS-CoV-2 antibody among individuals aged above 15 years and residing in congregate settings in Dire Dawa city administration, Ethiopia.",2021-07-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,,Dire Dawa city,SARS-CoV-2 serosurvey was conducted among individuals aged above 15 years and residing in randomly selected households from purposively selected 11 enumeration areas in overcrowded neighborhoods. ,"Sixty-six (66) samples were not included into this analysis due to grossly hemolyzed specimens 21 (3.8%), information mismatch on request form 14 (2.1%), insufficient specimen volume 18 (2.7%), and missing labels on container 13 (2.0%).",2020-06-15,2020-07-30,Household and community samples,All,Multiple groups,45.0,,Age,45-90,191,0.022000000000000002,0.001,0.04,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Tamrat Shaweno,Jimma University Institute of Health,Unity-Aligned,https://dx.doi.org/10.1186/s41182-021-00347-7,2021-07-19,2024-03-01,Verified,shaweno_seroprevalence_2021,ETH
210710_EthiopiaDireDawa_JimmaUniversityInstituteofHealth_Male,210710_EthiopiaDireDawa_JimmaUniversityInstituteofHealth,"Seroprevalence of SARS-CoV-2 antibody among individuals aged above 15 years and residing in congregate settings in Dire Dawa city administration, Ethiopia.",2021-07-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,,Dire Dawa city,SARS-CoV-2 serosurvey was conducted among individuals aged above 15 years and residing in randomly selected households from purposively selected 11 enumeration areas in overcrowded neighborhoods. ,"Sixty-six (66) samples were not included into this analysis due to grossly hemolyzed specimens 21 (3.8%), information mismatch on request form 14 (2.1%), insufficient specimen volume 18 (2.7%), and missing labels on container 13 (2.0%).",2020-06-15,2020-07-30,Household and community samples,Male,Multiple groups,15.0,,Sex/Gender,,307,0.034,0.01,0.05,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Tamrat Shaweno,Jimma University Institute of Health,Unity-Aligned,https://dx.doi.org/10.1186/s41182-021-00347-7,2021-07-19,2024-03-01,Verified,shaweno_seroprevalence_2021,ETH
210710_EthiopiaDireDawa_JimmaUniversityInstituteofHealth_15-24yrs,210710_EthiopiaDireDawa_JimmaUniversityInstituteofHealth,"Seroprevalence of SARS-CoV-2 antibody among individuals aged above 15 years and residing in congregate settings in Dire Dawa city administration, Ethiopia.",2021-07-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,,Dire Dawa city,SARS-CoV-2 serosurvey was conducted among individuals aged above 15 years and residing in randomly selected households from purposively selected 11 enumeration areas in overcrowded neighborhoods. ,"Sixty-six (66) samples were not included into this analysis due to grossly hemolyzed specimens 21 (3.8%), information mismatch on request form 14 (2.1%), insufficient specimen volume 18 (2.7%), and missing labels on container 13 (2.0%).",2020-06-15,2020-07-30,Household and community samples,All,Multiple groups,15.0,,Age,15-24,180,0.052000000000000005,0.02,0.08,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Tamrat Shaweno,Jimma University Institute of Health,Unity-Aligned,https://dx.doi.org/10.1186/s41182-021-00347-7,2021-07-19,2024-03-01,Verified,shaweno_seroprevalence_2021,ETH
210710_EthiopiaDireDawa_JimmaUniversityInstituteofHealth_35-44yrs,210710_EthiopiaDireDawa_JimmaUniversityInstituteofHealth,"Seroprevalence of SARS-CoV-2 antibody among individuals aged above 15 years and residing in congregate settings in Dire Dawa city administration, Ethiopia.",2021-07-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,,Dire Dawa city,SARS-CoV-2 serosurvey was conducted among individuals aged above 15 years and residing in randomly selected households from purposively selected 11 enumeration areas in overcrowded neighborhoods. ,"Sixty-six (66) samples were not included into this analysis due to grossly hemolyzed specimens 21 (3.8%), information mismatch on request form 14 (2.1%), insufficient specimen volume 18 (2.7%), and missing labels on container 13 (2.0%).",2020-06-15,2020-07-30,Household and community samples,All,Adults (18-64 years),35.0,,Age,35-44,131,0.04,0.006,0.07,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Tamrat Shaweno,Jimma University Institute of Health,Unity-Aligned,https://dx.doi.org/10.1186/s41182-021-00347-7,2021-07-19,2024-03-01,Verified,shaweno_seroprevalence_2021,ETH
210815_Ethiopia_FederalMinistryofHealth_Overall_Adjusted,210815_Ethiopia_FederalMinistryofHealth,Seroprevalence and risk factors for SARS-CoV-2 Infection in selected urban areas in Ethiopia: a cross-sectional evaluation during July 2020,2021-08-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ethiopia,,,"In Ethiopia, each town is divided into enumeration areas (EAs) with clear geographic demarcation. Each EA has on average 200 households. 219 EAs (76 EAs in Addis Ababa and 143 EAs in other towns) were selected randomly. All households within the chosen EAs were listed and then 40 households were randomly selected. All individuals ≥15 years of age in the randomly selected households were eligible to participate.",,2020-06-24,2020-07-08,Household and community samples,All,Multiple groups,15.0,,Primary Estimate,,16932,0.035,0.032,0.038,True,True,True,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by developers,0.545,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Enyew Birru Tadesse,Federal Ministry of Health,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.08.028,2021-09-21,2023-08-15,Verified,tadesse_seroprevalence_2021,ETH
210815_Ethiopia_FederalMinistryofHealth_Male,210815_Ethiopia_FederalMinistryofHealth,Seroprevalence and risk factors for SARS-CoV-2 Infection in selected urban areas in Ethiopia: a cross-sectional evaluation during July 2020,2021-08-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ethiopia,,,"In Ethiopia, each town is divided into enumeration areas (EAs) with clear geographic demarcation. Each EA has on average 200 households. 219 EAs (76 EAs in Addis Ababa and 143 EAs in other towns) were selected randomly. All households within the chosen EAs were listed and then 40 households were randomly selected. All individuals ≥15 years of age in the randomly selected households were eligible to participate.",,2020-06-24,2020-07-08,Household and community samples,Male,Multiple groups,15.0,,Sex/Gender,,8235,0.02,0.016,0.023,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by developers,0.545,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Enyew Birru Tadesse,Federal Ministry of Health,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.08.028,2021-09-21,2024-03-01,Verified,tadesse_seroprevalence_2021,ETH
210815_Ethiopia_FederalMinistryofHealth_Age_21-40,210815_Ethiopia_FederalMinistryofHealth,Seroprevalence and risk factors for SARS-CoV-2 Infection in selected urban areas in Ethiopia: a cross-sectional evaluation during July 2020,2021-08-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ethiopia,,,"In Ethiopia, each town is divided into enumeration areas (EAs) with clear geographic demarcation. Each EA has on average 200 households. 219 EAs (76 EAs in Addis Ababa and 143 EAs in other towns) were selected randomly. All households within the chosen EAs were listed and then 40 households were randomly selected. All individuals ≥15 years of age in the randomly selected households were eligible to participate.",,2020-06-24,2020-07-08,Household and community samples,All,Adults (18-64 years),21.0,40.0,Age,21-40,9501,0.019,0.016,0.021,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by developers,0.545,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Enyew Birru Tadesse,Federal Ministry of Health,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.08.028,2021-09-21,2024-03-01,Verified,tadesse_seroprevalence_2021,ETH
210815_Ethiopia_FederalMinistryofHealth_Age_>65,210815_Ethiopia_FederalMinistryofHealth,Seroprevalence and risk factors for SARS-CoV-2 Infection in selected urban areas in Ethiopia: a cross-sectional evaluation during July 2020,2021-08-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ethiopia,,,"In Ethiopia, each town is divided into enumeration areas (EAs) with clear geographic demarcation. Each EA has on average 200 households. 219 EAs (76 EAs in Addis Ababa and 143 EAs in other towns) were selected randomly. All households within the chosen EAs were listed and then 40 households were randomly selected. All individuals ≥15 years of age in the randomly selected households were eligible to participate.",,2020-06-24,2020-07-08,Household and community samples,All,Seniors (65+ years),66.0,,Age,>65,745,0.012,0.006,0.023,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by developers,0.545,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Enyew Birru Tadesse,Federal Ministry of Health,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.08.028,2021-09-21,2024-03-01,Verified,tadesse_seroprevalence_2021,ETH
210815_Ethiopia_FederalMinistryofHealth_Age_15-20,210815_Ethiopia_FederalMinistryofHealth,Seroprevalence and risk factors for SARS-CoV-2 Infection in selected urban areas in Ethiopia: a cross-sectional evaluation during July 2020,2021-08-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ethiopia,,,"In Ethiopia, each town is divided into enumeration areas (EAs) with clear geographic demarcation. Each EA has on average 200 households. 219 EAs (76 EAs in Addis Ababa and 143 EAs in other towns) were selected randomly. All households within the chosen EAs were listed and then 40 households were randomly selected. All individuals ≥15 years of age in the randomly selected households were eligible to participate.",,2020-06-24,2020-07-08,Household and community samples,All,Multiple groups,15.0,20.0,Age,15-20,3286,0.018000000000000002,0.013999999999999999,0.024,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by developers,0.545,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Enyew Birru Tadesse,Federal Ministry of Health,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.08.028,2021-09-21,2024-03-01,Verified,tadesse_seroprevalence_2021,ETH
210815_Ethiopia_FederalMinistryofHealth_Female,210815_Ethiopia_FederalMinistryofHealth,Seroprevalence and risk factors for SARS-CoV-2 Infection in selected urban areas in Ethiopia: a cross-sectional evaluation during July 2020,2021-08-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ethiopia,,,"In Ethiopia, each town is divided into enumeration areas (EAs) with clear geographic demarcation. Each EA has on average 200 households. 219 EAs (76 EAs in Addis Ababa and 143 EAs in other towns) were selected randomly. All households within the chosen EAs were listed and then 40 households were randomly selected. All individuals ≥15 years of age in the randomly selected households were eligible to participate.",,2020-06-24,2020-07-08,Household and community samples,Female,Multiple groups,15.0,,Sex/Gender,,8696,0.018000000000000002,0.016,0.021,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by developers,0.545,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Enyew Birru Tadesse,Federal Ministry of Health,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.08.028,2021-09-21,2024-03-01,Verified,tadesse_seroprevalence_2021,ETH
210815_Ethiopia_FederalMinistryofHealth_Age_41-65,210815_Ethiopia_FederalMinistryofHealth,Seroprevalence and risk factors for SARS-CoV-2 Infection in selected urban areas in Ethiopia: a cross-sectional evaluation during July 2020,2021-08-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ethiopia,,,"In Ethiopia, each town is divided into enumeration areas (EAs) with clear geographic demarcation. Each EA has on average 200 households. 219 EAs (76 EAs in Addis Ababa and 143 EAs in other towns) were selected randomly. All households within the chosen EAs were listed and then 40 households were randomly selected. All individuals ≥15 years of age in the randomly selected households were eligible to participate.",,2020-06-24,2020-07-08,Household and community samples,All,Adults (18-64 years),41.0,65.0,Age,41-65,3341,0.02,0.015,0.025,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by developers,0.545,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Enyew Birru Tadesse,Federal Ministry of Health,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.08.028,2021-09-21,2024-03-01,Verified,tadesse_seroprevalence_2021,ETH
210815_Ethiopia_FederalMinistryofHealth_Overall_Unadjusted,210815_Ethiopia_FederalMinistryofHealth,Seroprevalence and risk factors for SARS-CoV-2 Infection in selected urban areas in Ethiopia: a cross-sectional evaluation during July 2020,2021-08-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ethiopia,,,"In Ethiopia, each town is divided into enumeration areas (EAs) with clear geographic demarcation. Each EA has on average 200 households. 219 EAs (76 EAs in Addis Ababa and 143 EAs in other towns) were selected randomly. All households within the chosen EAs were listed and then 40 households were randomly selected. All individuals ≥15 years of age in the randomly selected households were eligible to participate.",,2020-06-24,2020-07-08,Household and community samples,All,Multiple groups,15.0,,Analysis,,16932,0.019,0.017,0.021,,,,,True,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by developers,0.545,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Enyew Birru Tadesse,Federal Ministry of Health,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.08.028,2021-09-21,2024-03-01,Verified,tadesse_seroprevalence_2021,ETH
211101_Ethiopia_UniversityofMunich_AddisAbaba_AddisKetema_Round1,211101_Ethiopia_UniversityofMunich_AddisAbaba_AddisKetema_Round1,Seroepidemiology and model-based prediction of SARS-CoV-2 in Ethiopia: longitudinal cohort study among front-line hospital workers and communities.,2021-11-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,,Addis Ababa,"Only one person from each household was recruited. Inclusion criteria were age 18 years or older, written informed consent, and willingness to provide blood samples by venepuncture.",,2021-01-02,2021-01-22,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,218,0.542,0.47500000000000003,0.6070000000000001,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],Yes,No,No,No,Yes,Yes,Yes,Yes,Unclear,Esayas Gudina,University of Munich,Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(21)00386-7,2022-01-23,2024-03-01,Verified,gudina_seroepidemiology_2021,ETH
211101_Ethiopia_UniversityofMunich_AddisAbaba_AddisKetema_Round2,211101_Ethiopia_UniversityofMunich_AddisAbaba_AddisKetema_Round2,Seroepidemiology and model-based prediction of SARS-CoV-2 in Ethiopia: longitudinal cohort study among front-line hospital workers and communities.,2021-11-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,,Addis Ababa,"Only one person from each household was recruited. Inclusion criteria were age 18 years or older, written informed consent, and willingness to provide blood samples by venepuncture.",,2021-02-11,2021-02-26,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,151,0.5820000000000001,0.503,0.66,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],Yes,No,No,No,Yes,Yes,Yes,Yes,Unclear,Esayas Gudina,University of Munich,Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(21)00386-7,2022-01-24,2024-03-01,Verified,gudina_seroepidemiology_2021,ETH
211101_Ethiopia_UniversityofMunich_AddisAbaba_AddisKetema_Round3,211101_Ethiopia_UniversityofMunich_AddisAbaba_AddisKetema_Round3,Seroepidemiology and model-based prediction of SARS-CoV-2 in Ethiopia: longitudinal cohort study among front-line hospital workers and communities.,2021-11-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,,Addis Ababa,"Only one person from each household was recruited. Inclusion criteria were age 18 years or older, written informed consent, and willingness to provide blood samples by venepuncture.",,2021-04-08,2021-04-10,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,176,0.7270000000000001,0.659,0.7909999999999999,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],Yes,No,No,No,Yes,Yes,Yes,Yes,Unclear,Esayas Gudina,University of Munich,Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(21)00386-7,2021-11-04,2024-03-01,Verified,gudina_seroepidemiology_2021,ETH
211101_Ethiopia_UniversityofMunich_AddisAbaba_Yeka_Round1,211101_Ethiopia_UniversityofMunich_AddisAbaba_Yeka_Round1,Seroepidemiology and model-based prediction of SARS-CoV-2 in Ethiopia: longitudinal cohort study among front-line hospital workers and communities.,2021-11-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,,Addis Ababa,"Only one person from each household was recruited. Inclusion criteria were age 18 years or older, written informed consent, and willingness to provide blood samples by venepuncture.",,2020-12-05,2021-02-04,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,224,0.397,0.334,0.46299999999999997,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],Yes,No,No,No,Yes,Yes,Yes,Yes,Unclear,Esayas Gudina,University of Munich,Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(21)00386-7,2022-01-23,2024-03-01,Verified,gudina_seroepidemiology_2021,ETH
211101_Ethiopia_UniversityofMunich_AddisAbaba_Yeka_Round2,211101_Ethiopia_UniversityofMunich_AddisAbaba_Yeka_Round2,Seroepidemiology and model-based prediction of SARS-CoV-2 in Ethiopia: longitudinal cohort study among front-line hospital workers and communities.,2021-11-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,,Addis Ababa,"Only one person from each household was recruited. Inclusion criteria were age 18 years or older, written informed consent, and willingness to provide blood samples by venepuncture.",,2021-02-01,2021-03-07,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,149,0.457,0.379,0.537,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],Yes,No,No,No,Yes,Yes,Yes,Yes,Unclear,Esayas Gudina,University of Munich,Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(21)00386-7,2022-01-23,2024-03-01,Verified,gudina_seroepidemiology_2021,ETH
211101_Ethiopia_UniversityofMunich_AddisAbaba_Yeka_Round3,211101_Ethiopia_UniversityofMunich_AddisAbaba_Yeka_Round3,Seroepidemiology and model-based prediction of SARS-CoV-2 in Ethiopia: longitudinal cohort study among front-line hospital workers and communities.,2021-11-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,,Addis Ababa,"Only one person from each household was recruited. Inclusion criteria were age 18 years or older, written informed consent, and willingness to provide blood samples by venepuncture.",,2021-04-01,2021-04-03,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,188,0.5479999999999999,0.47700000000000004,0.619,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],Yes,No,No,No,Yes,Yes,Yes,Yes,Unclear,Esayas Gudina,University of Munich,Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(21)00386-7,2021-11-04,2024-03-01,Verified,gudina_seroepidemiology_2021,ETH
211101_Ethiopia_UniversityofMunich_HCW_AddisAbaba_Round1,211101_Ethiopia_UniversityofMunich_HCW_AddisAbaba_Round1,Seroepidemiology and model-based prediction of SARS-CoV-2 in Ethiopia: longitudinal cohort study among front-line hospital workers and communities.,2021-11-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,,Addis Ababa,"Front-line hospital workers from outpatient and inpatient units—including clinical staff, medical interns, cleaners, guards, food handlers, and administrative personnel— were recruited at both hospitals.",,2020-08-05,2020-09-03,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,487,0.109,0.083,0.138,True,,,,True,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],No,Unclear,No,No,Yes,Yes,Yes,Yes,Unclear,Esayas Gudina,University of Munich,Not Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(21)00386-7,2022-01-23,2024-03-01,Verified,gudina_seroepidemiology_2021,ETH
211101_Ethiopia_UniversityofMunich_HCW_AddisAbaba_Round2,211101_Ethiopia_UniversityofMunich_HCW_AddisAbaba_Round2,Seroepidemiology and model-based prediction of SARS-CoV-2 in Ethiopia: longitudinal cohort study among front-line hospital workers and communities.,2021-11-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,,Addis Ababa,"Front-line hospital workers from outpatient and inpatient units—including clinical staff, medical interns, cleaners, guards, food handlers, and administrative personnel— were recruited at both hospitals.",,2020-12-02,2021-02-08,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,317,0.436,0.381,0.49,True,,,,True,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],No,Unclear,No,No,Yes,Yes,Yes,Yes,Unclear,Esayas Gudina,University of Munich,Not Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(21)00386-7,2022-01-23,2024-03-01,Verified,gudina_seroepidemiology_2021,ETH
211101_Ethiopia_UniversityofMunich_HCW_AddisAbaba_Round3,211101_Ethiopia_UniversityofMunich_HCW_AddisAbaba_Round3,Seroepidemiology and model-based prediction of SARS-CoV-2 in Ethiopia: longitudinal cohort study among front-line hospital workers and communities.,2021-11-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,,Addis Ababa,"Front-line hospital workers from outpatient and inpatient units—including clinical staff, medical interns, cleaners, guards, food handlers, and administrative personnel— were recruited at both hospitals.",,2021-01-19,2021-03-12,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,121,0.537,0.44799999999999995,0.625,True,,,,True,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],No,Unclear,No,No,Yes,Yes,Yes,Yes,Unclear,Esayas Gudina,University of Munich,Not Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(21)00386-7,2021-11-04,2024-03-01,Verified,gudina_seroepidemiology_2021,ETH
211101_Ethiopia_UniversityofMunich_HCW_Jimma_Round1,211101_Ethiopia_UniversityofMunich_HCW_Jimma_Round1,Seroepidemiology and model-based prediction of SARS-CoV-2 in Ethiopia: longitudinal cohort study among front-line hospital workers and communities.,2021-11-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,,Jimma,"Front-line hospital workers from outpatient and inpatient units—including clinical staff, medical interns, cleaners, guards, food handlers, and administrative personnel— were recruited at both hospitals.",,2020-11-09,2020-11-29,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,510,0.308,0.269,0.348,True,,,,True,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],Yes,Unclear,No,No,Yes,Yes,Yes,Yes,Unclear,Esayas Gudina,University of Munich,Not Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(21)00386-7,2022-01-23,2024-03-01,Verified,gudina_seroepidemiology_2021,ETH
211101_Ethiopia_UniversityofMunich_HCW_Jimma_Round2,211101_Ethiopia_UniversityofMunich_HCW_Jimma_Round2,Seroepidemiology and model-based prediction of SARS-CoV-2 in Ethiopia: longitudinal cohort study among front-line hospital workers and communities.,2021-11-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,,Jimma,"Front-line hospital workers from outpatient and inpatient units—including clinical staff, medical interns, cleaners, guards, food handlers, and administrative personnel— were recruited at both hospitals.",,2020-12-13,2021-01-11,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,434,0.456,0.41000000000000003,0.503,True,,,,True,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],Yes,Unclear,No,No,Yes,Yes,Yes,Yes,Unclear,Esayas Gudina,University of Munich,Not Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(21)00386-7,2022-01-23,2024-03-01,Verified,gudina_seroepidemiology_2021,ETH
211101_Ethiopia_UniversityofMunich_HCW_Jimma_Round3,211101_Ethiopia_UniversityofMunich_HCW_Jimma_Round3,Seroepidemiology and model-based prediction of SARS-CoV-2 in Ethiopia: longitudinal cohort study among front-line hospital workers and communities.,2021-11-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,,Jimma,"Front-line hospital workers from outpatient and inpatient units—including clinical staff, medical interns, cleaners, guards, food handlers, and administrative personnel— were recruited at both hospitals.",,2021-01-05,2021-02-15,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,372,0.561,0.511,0.611,True,,,,True,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],Yes,Unclear,No,No,Yes,Yes,Yes,Yes,Unclear,Esayas Gudina,University of Munich,Not Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(21)00386-7,2021-11-04,2024-03-01,Verified,gudina_seroepidemiology_2021,ETH
211101_Ethiopia_UniversityofMunich_JimmaRural_Round1,211101_Ethiopia_UniversityofMunich_JimmaRural_Round1,Seroepidemiology and model-based prediction of SARS-CoV-2 in Ethiopia: longitudinal cohort study among front-line hospital workers and communities.,2021-11-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,,Jimma,"Only one person from each household was recruited. Inclusion criteria were age 18 years or older, written informed consent, and willingness to provide blood samples by venepuncture.",,2020-12-03,2021-01-27,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,238,0.18,0.135,0.23199999999999998,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],Yes,No,No,No,Yes,Yes,Yes,Yes,Unclear,Esayas Gudina,University of Munich,Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(21)00386-7,2022-01-23,2024-03-01,Verified,gudina_seroepidemiology_2021,ETH
211101_Ethiopia_UniversityofMunich_JimmaRural_Round2,211101_Ethiopia_UniversityofMunich_JimmaRural_Round2,Seroepidemiology and model-based prediction of SARS-CoV-2 in Ethiopia: longitudinal cohort study among front-line hospital workers and communities.,2021-11-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,,Jimma,"Only one person from each household was recruited. Inclusion criteria were age 18 years or older, written informed consent, and willingness to provide blood samples by venepuncture.",,2021-01-21,2021-02-25,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,133,0.263,0.19100000000000003,0.34299999999999997,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],Yes,No,No,No,Yes,Yes,Yes,Yes,Unclear,Esayas Gudina,University of Munich,Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(21)00386-7,2022-01-23,2024-03-01,Verified,gudina_seroepidemiology_2021,ETH
211101_Ethiopia_UniversityofMunich_JimmaRural_Round3,211101_Ethiopia_UniversityofMunich_JimmaRural_Round3,Seroepidemiology and model-based prediction of SARS-CoV-2 in Ethiopia: longitudinal cohort study among front-line hospital workers and communities.,2021-11-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,,Jimma,"Only one person from each household was recruited. Inclusion criteria were age 18 years or older, written informed consent, and willingness to provide blood samples by venepuncture.",,2021-02-04,2021-03-16,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,100,0.31,0.223,0.40299999999999997,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],Yes,No,No,No,Yes,Yes,Yes,Yes,Unclear,Esayas Gudina,University of Munich,Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(21)00386-7,2021-11-04,2024-03-01,Verified,gudina_seroepidemiology_2021,ETH
211101_Ethiopia_UniversityofMunich_JimmaUrban_Round1,211101_Ethiopia_UniversityofMunich_JimmaUrban_Round1,Seroepidemiology and model-based prediction of SARS-CoV-2 in Ethiopia: longitudinal cohort study among front-line hospital workers and communities.,2021-11-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,,Jimma,"Only one person from each household was recruited. Inclusion criteria were age 18 years or older, written informed consent, and willingness to provide blood samples by venepuncture.",,2020-12-01,2021-02-01,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,297,0.32299999999999995,0.27,0.379,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],Yes,No,No,No,Yes,Yes,Yes,Yes,Unclear,Esayas Gudina,University of Munich,Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(21)00386-7,2022-01-23,2024-03-01,Verified,gudina_seroepidemiology_2021,ETH
211101_Ethiopia_UniversityofMunich_JimmaUrban_Round2,211101_Ethiopia_UniversityofMunich_JimmaUrban_Round2,Seroepidemiology and model-based prediction of SARS-CoV-2 in Ethiopia: longitudinal cohort study among front-line hospital workers and communities.,2021-11-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,,Jimma,"Only one person from each household was recruited. Inclusion criteria were age 18 years or older, written informed consent, and willingness to provide blood samples by venepuncture.",,2021-01-02,2021-02-04,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,191,0.408,0.33899999999999997,0.479,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],Yes,No,No,No,Yes,Yes,Yes,Yes,Unclear,Esayas Gudina,University of Munich,Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(21)00386-7,2022-01-23,2024-03-01,Verified,gudina_seroepidemiology_2021,ETH
211101_Ethiopia_UniversityofMunich_JimmaUrban_Round3,211101_Ethiopia_UniversityofMunich_JimmaUrban_Round3,Seroepidemiology and model-based prediction of SARS-CoV-2 in Ethiopia: longitudinal cohort study among front-line hospital workers and communities.,2021-11-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,,Jimma,"Only one person from each household was recruited. Inclusion criteria were age 18 years or older, written informed consent, and willingness to provide blood samples by venepuncture.",,2021-02-02,2021-03-15,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,166,0.452,0.37700000000000006,0.527,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],Yes,No,No,No,Yes,Yes,Yes,Yes,Unclear,Esayas Gudina,University of Munich,Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(21)00386-7,2021-11-04,2024-03-01,Verified,gudina_seroepidemiology_2021,ETH
211124_EastHararghe_UniversityofLondon_Overall,211124_EastHararghe_UniversityofLondon,Seroprevalence of anti-SARS-CoV-2 antibodies in women attending antenatal care in eastern Ethiopia: a facility-based surveillance.,2021-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ethiopia,"Oromia, Harari","Haramaya, Harar","""Hiwot Fana Hospital, Aweday Health Centre and Haramaya Hospital. The study population comprised 3306 pregnant women attending their first antenatal care in these three facilities during the surveillance period.""","""A total 78 women were excluded because they were not willing to provide blood sample.""",2020-04-01,2021-03-31,Pregnant or parturient women,Female,Adults (18-64 years),14.0,45.0,Primary Estimate,,1447,0.057,0.046,0.07,True,,,,True,Simplified probability,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,LFIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,0.988,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Nega Assefa,The London School of Hygiene & Tropical Medicine,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-055834,2021-12-02,2024-03-01,Verified,assefa_seroprevalence_2021-1,ETH
211124_EastHararghe_UniversityofLondon_RegionHiwotFanaHospital,211124_EastHararghe_UniversityofLondon,Seroprevalence of anti-SARS-CoV-2 antibodies in women attending antenatal care in eastern Ethiopia: a facility-based surveillance.,2021-11-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,Harari,Harar,"""Hiwot Fana Hospital, Aweday Health Centre and Haramaya Hospital. The study population comprised 3306 pregnant women attending their first antenatal care in these three facilities during the surveillance period.""","""A total 78 women were excluded because they were not willing to provide blood sample.""",2020-04-01,2021-03-31,Pregnant or parturient women,Female,Adults (18-64 years),14.0,45.0,Geographical area,Hiwot Fana Hospital,695,0.0504,,,,,,,,Simplified probability,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,LFIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,0.988,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Nega Assefa,The London School of Hygiene & Tropical Medicine,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-055834,2021-12-02,2024-03-01,Verified,assefa_seroprevalence_2021-1,ETH
211124_EastHararghe_UniversityofLondon_Age20-24,211124_EastHararghe_UniversityofLondon,Seroprevalence of anti-SARS-CoV-2 antibodies in women attending antenatal care in eastern Ethiopia: a facility-based surveillance.,2021-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ethiopia,"Oromia, Harari","Haramaya, Harar","""Hiwot Fana Hospital, Aweday Health Centre and Haramaya Hospital. The study population comprised 3306 pregnant women attending their first antenatal care in these three facilities during the surveillance period.""","""A total 78 women were excluded because they were not willing to provide blood sample.""",2020-04-01,2021-03-31,Pregnant or parturient women,Female,Adults (18-64 years),20.0,24.0,Age,20-24,588,0.0714,,,,,,,,Simplified probability,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,LFIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,0.988,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Nega Assefa,The London School of Hygiene & Tropical Medicine,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-055834,2021-12-02,2024-03-01,Verified,assefa_seroprevalence_2021-1,ETH
211124_EastHararghe_UniversityofLondon_RegionHaramayaHospital,211124_EastHararghe_UniversityofLondon,Seroprevalence of anti-SARS-CoV-2 antibodies in women attending antenatal care in eastern Ethiopia: a facility-based surveillance.,2021-11-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,Oromia,Haramaya,"""Hiwot Fana Hospital, Aweday Health Centre and Haramaya Hospital. The study population comprised 3306 pregnant women attending their first antenatal care in these three facilities during the surveillance period.""","""A total 78 women were excluded because they were not willing to provide blood sample.""",2020-04-01,2021-03-31,Pregnant or parturient women,Female,Adults (18-64 years),14.0,45.0,Geographical area,Haramaya Hospital,19,0.0,,,,,,,,Simplified probability,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,LFIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,0.988,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Nega Assefa,The London School of Hygiene & Tropical Medicine,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-055834,2021-12-02,2024-03-01,Verified,assefa_seroprevalence_2021-1,ETH
211124_EastHararghe_UniversityofLondon_Age35+,211124_EastHararghe_UniversityofLondon,Seroprevalence of anti-SARS-CoV-2 antibodies in women attending antenatal care in eastern Ethiopia: a facility-based surveillance.,2021-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ethiopia,"Oromia, Harari","Haramaya, Harar","""Hiwot Fana Hospital, Aweday Health Centre and Haramaya Hospital. The study population comprised 3306 pregnant women attending their first antenatal care in these three facilities during the surveillance period.""","""A total 78 women were excluded because they were not willing to provide blood sample.""",2020-04-01,2021-03-31,Pregnant or parturient women,Female,Adults (18-64 years),35.0,45.0,Age,>=35,56,0.0179,,,,,,,,Simplified probability,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,LFIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,0.988,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Nega Assefa,The London School of Hygiene & Tropical Medicine,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-055834,2021-12-02,2024-03-01,Verified,assefa_seroprevalence_2021-1,ETH
211124_EastHararghe_UniversityofLondon_Age14-19,211124_EastHararghe_UniversityofLondon,Seroprevalence of anti-SARS-CoV-2 antibodies in women attending antenatal care in eastern Ethiopia: a facility-based surveillance.,2021-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ethiopia,"Oromia, Harari","Haramaya, Harar","""Hiwot Fana Hospital, Aweday Health Centre and Haramaya Hospital. The study population comprised 3306 pregnant women attending their first antenatal care in these three facilities during the surveillance period.""","""A total 78 women were excluded because they were not willing to provide blood sample.""",2020-04-01,2021-03-31,Pregnant or parturient women,Female,Children and Youth (0-17 years),14.0,19.0,Age,14-19,192,0.0365,,,,,,,,Simplified probability,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,LFIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,0.988,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Nega Assefa,The London School of Hygiene & Tropical Medicine,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-055834,2021-12-02,2024-03-01,Verified,assefa_seroprevalence_2021-1,ETH
211124_EastHararghe_UniversityofLondon_Age25-29,211124_EastHararghe_UniversityofLondon,Seroprevalence of anti-SARS-CoV-2 antibodies in women attending antenatal care in eastern Ethiopia: a facility-based surveillance.,2021-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ethiopia,"Oromia, Harari","Haramaya, Harar","""Hiwot Fana Hospital, Aweday Health Centre and Haramaya Hospital. The study population comprised 3306 pregnant women attending their first antenatal care in these three facilities during the surveillance period.""","""A total 78 women were excluded because they were not willing to provide blood sample.""",2020-04-01,2021-03-31,Pregnant or parturient women,Female,Adults (18-64 years),25.0,29.0,Age,25-29,400,0.06,,,,,,,,Simplified probability,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,LFIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,0.988,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Nega Assefa,The London School of Hygiene & Tropical Medicine,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-055834,2021-12-02,2024-03-01,Verified,assefa_seroprevalence_2021-1,ETH
211124_EastHararghe_UniversityofLondon_February,211124_EastHararghe_UniversityofLondon,Seroprevalence of anti-SARS-CoV-2 antibodies in women attending antenatal care in eastern Ethiopia: a facility-based surveillance.,2021-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ethiopia,"Oromia, Harari","Haramaya, Harar","""Hiwot Fana Hospital, Aweday Health Centre and Haramaya Hospital. The study population comprised 3306 pregnant women attending their first antenatal care in these three facilities during the surveillance period.""","""A total 78 women were excluded because they were not willing to provide blood sample.""",2020-04-01,2021-03-31,Pregnant or parturient women,Female,Adults (18-64 years),14.0,45.0,Time frame,February,160,0.11800000000000001,,,,,,,,Simplified probability,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,LFIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,0.988,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Nega Assefa,The London School of Hygiene & Tropical Medicine,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-055834,2021-12-03,2024-03-01,Verified,assefa_seroprevalence_2021-1,ETH
211124_EastHararghe_UniversityofLondon_RegionAwodayHealthCentre,211124_EastHararghe_UniversityofLondon,Seroprevalence of anti-SARS-CoV-2 antibodies in women attending antenatal care in eastern Ethiopia: a facility-based surveillance.,2021-11-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ethiopia,Oromia,Haramaya,"""Hiwot Fana Hospital, Aweday Health Centre and Haramaya Hospital. The study population comprised 3306 pregnant women attending their first antenatal care in these three facilities during the surveillance period.""","""A total 78 women were excluded because they were not willing to provide blood sample.""",2020-04-01,2021-03-31,Pregnant or parturient women,Female,Adults (18-64 years),14.0,45.0,Geographical area,Awoday Health Centre,733,0.0655,,,,,,,,Simplified probability,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,LFIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,0.988,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Nega Assefa,The London School of Hygiene & Tropical Medicine,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-055834,2021-12-02,2024-03-01,Verified,assefa_seroprevalence_2021-1,ETH
211124_EastHararghe_UniversityofLondon_Age30-34,211124_EastHararghe_UniversityofLondon,Seroprevalence of anti-SARS-CoV-2 antibodies in women attending antenatal care in eastern Ethiopia: a facility-based surveillance.,2021-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ethiopia,"Oromia, Harari","Haramaya, Harar","""Hiwot Fana Hospital, Aweday Health Centre and Haramaya Hospital. The study population comprised 3306 pregnant women attending their first antenatal care in these three facilities during the surveillance period.""","""A total 78 women were excluded because they were not willing to provide blood sample.""",2020-04-01,2021-03-31,Pregnant or parturient women,Female,Adults (18-64 years),30.0,34.0,Age,30-34,210,0.0429,,,,,,,,Simplified probability,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,LFIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,0.988,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Nega Assefa,The London School of Hygiene & Tropical Medicine,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-055834,2021-12-02,2024-03-01,Verified,assefa_seroprevalence_2021-1,ETH
20220207_Ethiopia_WoldiaUniversity,20220207_Ethiopia_WoldiaUniversity,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG-antibody seroprevalence among quarantined population, during the first wave of COVID-19 pandemic, In North West Ethiopia (from 30 April to 30 May 2020)",2022-02-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ethiopia,North West Ethiopia,Asosa and Pawe COVID-19 treatment centres. ,Quarantined individuals during the first wave of COVID-19 pandemic.,Individuals who had a history of diagnosed as suspected cases of COVID-19 infection were excluded during the interview whatever serologic tests were done.,2020-04-30,2020-05-30,Multiple populations,All,Multiple groups,15.0,,Primary Estimate,,446,0.046900000000000004,0.031000000000000003,0.07200000000000001,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Fassikaw Kebede,Woldia University,Not Unity-Aligned,https://dx.doi.org/10.1177/20503121221076931,2022-02-25,2024-03-01,Unverified,kebede_severe_2022,ETH
220316_Ethiopia_ArmauerHansenResearchInstitute,220316_Ethiopia_ArmauerHansenResearchInstitute,High seroprevalence of anti-SARS-CoV-2 antibodies among Ethiopian healthcare workers,2022-03-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ethiopia,,,HCW from 5 hospitals in Ethiopia,,2020-12-15,2021-02-15,Health care workers and caregivers,All,Adults (18-64 years),20.0,60.0,Primary Estimate,,1997,0.39799999999999996,0.374,0.41700000000000004,True,,,,True,Entire sample,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.6729999999999999,0.9770000000000001,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Tesfaye Gelanew,Armauer Hansen Research Institute,Not Unity-Aligned,https://doi.org/10.1186/s12879-022-07247-z,2022-03-23,2022-07-16,Unverified,gelanew_high_2022,ETH
230203_Oromia_JimmaUniversity,230203_Oromia_JimmaUniversity,Escalating spread of SARS-CoV-2 infection after school reopening among students in hotspot districts of Oromia Region in Ethiopia: Longitudinal study.,2023-02-03,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Ethiopia,Oromia,,A prospective cohort study involving students aged 10 years and older were used,,2020-12-01,2020-12-31,Students and Daycares,All,Multiple groups,10.0,,Primary Estimate,,1884,0.257,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Dabesa Gobena,Jimma University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0280801,2023-03-10,2024-03-01,Unverified,gobena_escalating_2023,ETH
230615_Hawassa_HawassaUniversity_Baseline,230615_Hawassa_HawassaUniversity,"SARS-CoV-2 Infection-and mRNA Vaccine-induced Humoral Immunity among Schoolchildren in Hawassa, Ethiopia",2023-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Ethiopia,,Hawassa,School children (elementary and secondary),,2021-12-01,2021-12-08,Students and Daycares,All,Children and Youth (0-17 years),7.0,19.0,Primary Estimate,,419,0.518,0.47,0.565,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Yared Merid,Hawassa University,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2023.1163688,2023-07-29,2023-08-15,Unverified,merid_sars-cov-2_2023,ETH
200727_ FaroeIslands_TheFaroeseHospitalSystem_GenPop_TestAdj,200727_ FaroeIslands_TheFaroeseHospitalSystem,"Seroprevalence of SARS-CoV-2-Specific Antibodies, Faroe Islands",2020-07-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Faroe Islands,Faroe Islands,,"From the Faroese Population Registry, we randomly sampled 1,500 persons and invited them by letter to a clinical visit at 1 of 6 study sites around the islands mainly during week 18 (April 27–May 1, 2020) independently of previous positive PCR test result. ",,2020-04-27,2020-05-01,Household and community samples,All,Adults (18-64 years),0.0,,Primary Estimate,,1075,0.006999999999999999,,,True,True,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,University of the Faroe Islands,Unity-Aligned,http://dx.doi.org/10.3201/eid2611.202736,2020-09-27,2023-07-04,Verified,petersen_seroprevalence_2020,FRO
200727_FaroeIslands_TheFaroeseHospitalSystem_DetailedAge70-79Yr_UnAdj,200727_ FaroeIslands_TheFaroeseHospitalSystem,"Seroprevalence of SARS-CoV-2-Specific Antibodies, Faroe Islands",2020-07-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Faroe Islands,Faroe Islands,,"From the Faroese Population Registry, we randomly sampled 1,500 persons and invited them by letter to a clinical visit at 1 of 6 study sites around the islands mainly during week 18 (April 27–May 1, 2020) independently of previous positive PCR test result. ",,2020-04-27,2020-05-01,Household and community samples,All,Seniors (65+ years),70.0,79.0,Age,70-79,98,0.0204,0.002,0.07200000000000001,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,University of the Faroe Islands,Unity-Aligned,http://dx.doi.org/10.3201/eid2611.202736,2020-09-28,2024-03-01,Verified,petersen_seroprevalence_2020,FRO
200727_FaroeIslandsVágar_TheFaroeseHospitalSystem_Overall_UnAdj,200727_ FaroeIslands_TheFaroeseHospitalSystem,"Seroprevalence of SARS-CoV-2-Specific Antibodies, Faroe Islands",2020-07-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Faroe Islands,Faroe Islands,,"From the Faroese Population Registry, we randomly sampled 1,500 persons and invited them by letter to a clinical visit at 1 of 6 study sites around the islands mainly during week 18 (April 27–May 1, 2020) independently of previous positive PCR test result. ",,2020-04-27,2020-05-01,Household and community samples,All,Adults (18-64 years),0.0,,Geographical area,Vagar,74,0.013500000000000002,0.0,0.073,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,University of the Faroe Islands,Unity-Aligned,http://dx.doi.org/10.3201/eid2611.202736,2020-09-28,2024-03-01,Verified,petersen_seroprevalence_2020,FRO
200727_FaroeIslands_TheFaroeseHospitalSystem_DetailedAge60-69Yr_UnAdj,200727_ FaroeIslands_TheFaroeseHospitalSystem,"Seroprevalence of SARS-CoV-2-Specific Antibodies, Faroe Islands",2020-07-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Faroe Islands,Faroe Islands,,"From the Faroese Population Registry, we randomly sampled 1,500 persons and invited them by letter to a clinical visit at 1 of 6 study sites around the islands mainly during week 18 (April 27–May 1, 2020) independently of previous positive PCR test result. ",,2020-04-27,2020-05-01,Household and community samples,All,Adults (18-64 years),60.0,69.0,Age,60-69,151,0.006620000000000001,0.0,0.036000000000000004,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,University of the Faroe Islands,Unity-Aligned,http://dx.doi.org/10.3201/eid2611.202736,2020-09-28,2024-03-01,Verified,petersen_seroprevalence_2020,FRO
200727_FaroeIslands_TheFaroeseHospitalSystem_DetailedAge40-49Yr_UnAdj,200727_ FaroeIslands_TheFaroeseHospitalSystem,"Seroprevalence of SARS-CoV-2-Specific Antibodies, Faroe Islands",2020-07-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Faroe Islands,Faroe Islands,,"From the Faroese Population Registry, we randomly sampled 1,500 persons and invited them by letter to a clinical visit at 1 of 6 study sites around the islands mainly during week 18 (April 27–May 1, 2020) independently of previous positive PCR test result. ",,2020-04-27,2020-05-01,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,148,0.0,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,University of the Faroe Islands,Unity-Aligned,http://dx.doi.org/10.3201/eid2611.202736,2020-09-28,2024-03-01,Verified,petersen_seroprevalence_2020,FRO
200727_FaroeIslands_TheFaroeseHospitalSystem_DetailedAge50-59Yr_UnAdj,200727_ FaroeIslands_TheFaroeseHospitalSystem,"Seroprevalence of SARS-CoV-2-Specific Antibodies, Faroe Islands",2020-07-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Faroe Islands,Faroe Islands,,"From the Faroese Population Registry, we randomly sampled 1,500 persons and invited them by letter to a clinical visit at 1 of 6 study sites around the islands mainly during week 18 (April 27–May 1, 2020) independently of previous positive PCR test result. ",,2020-04-27,2020-05-01,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,154,0.006500000000000001,0.0,0.036000000000000004,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,University of the Faroe Islands,Unity-Aligned,http://dx.doi.org/10.3201/eid2611.202736,2020-09-28,2024-03-01,Verified,petersen_seroprevalence_2020,FRO
200727_FaroeIslands_TheFaroeseHospitalSystem_DetailedAge20-29Yr_UnAdj,200727_ FaroeIslands_TheFaroeseHospitalSystem,"Seroprevalence of SARS-CoV-2-Specific Antibodies, Faroe Islands",2020-07-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Faroe Islands,Faroe Islands,,"From the Faroese Population Registry, we randomly sampled 1,500 persons and invited them by letter to a clinical visit at 1 of 6 study sites around the islands mainly during week 18 (April 27–May 1, 2020) independently of previous positive PCR test result. ",,2020-04-27,2020-05-01,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,116,0.008620000000000001,0.0,0.047,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,University of the Faroe Islands,Unity-Aligned,http://dx.doi.org/10.3201/eid2611.202736,2020-09-28,2024-03-01,Verified,petersen_seroprevalence_2020,FRO
200727_FaroeIslands_TheFaroeseHospitalSystem_DetailedAge90+Yr_UnAdj,200727_ FaroeIslands_TheFaroeseHospitalSystem,"Seroprevalence of SARS-CoV-2-Specific Antibodies, Faroe Islands",2020-07-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Faroe Islands,Faroe Islands,,"From the Faroese Population Registry, we randomly sampled 1,500 persons and invited them by letter to a clinical visit at 1 of 6 study sites around the islands mainly during week 18 (April 27–May 1, 2020) independently of previous positive PCR test result. ",,2020-04-27,2020-05-01,Household and community samples,All,Seniors (65+ years),90.0,,Age,>=90,10,0.0,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,University of the Faroe Islands,Unity-Aligned,http://dx.doi.org/10.3201/eid2611.202736,2020-09-28,2024-03-01,Verified,petersen_seroprevalence_2020,FRO
200727_FaroeIslands_TheFaroeseHospitalSystem_DetailedAge80-89Yr_UnAdj,200727_ FaroeIslands_TheFaroeseHospitalSystem,"Seroprevalence of SARS-CoV-2-Specific Antibodies, Faroe Islands",2020-07-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Faroe Islands,Faroe Islands,,"From the Faroese Population Registry, we randomly sampled 1,500 persons and invited them by letter to a clinical visit at 1 of 6 study sites around the islands mainly during week 18 (April 27–May 1, 2020) independently of previous positive PCR test result. ",,2020-04-27,2020-05-01,Household and community samples,All,Seniors (65+ years),80.0,89.0,Age,80-89,30,0.0,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,University of the Faroe Islands,Unity-Aligned,http://dx.doi.org/10.3201/eid2611.202736,2020-09-28,2024-03-01,Verified,petersen_seroprevalence_2020,FRO
200727_FaroeIslands_TheFaroeseHospitalSystem_DetailedFemales_UnAdj,200727_ FaroeIslands_TheFaroeseHospitalSystem,"Seroprevalence of SARS-CoV-2-Specific Antibodies, Faroe Islands",2020-07-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Faroe Islands,Faroe Islands,,"From the Faroese Population Registry, we randomly sampled 1,500 persons and invited them by letter to a clinical visit at 1 of 6 study sites around the islands mainly during week 18 (April 27–May 1, 2020) independently of previous positive PCR test result. ",,2020-04-27,2020-05-01,Household and community samples,Female,Adults (18-64 years),0.0,,Sex/Gender,Female,537,0.005600000000000001,0.001,0.016,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,University of the Faroe Islands,Unity-Aligned,http://dx.doi.org/10.3201/eid2611.202736,2020-09-28,2024-03-01,Verified,petersen_seroprevalence_2020,FRO
200727_FaroeIslands_TheFaroeseHospitalSystem_DetailedAge30-39Yr_UnAdj,200727_ FaroeIslands_TheFaroeseHospitalSystem,"Seroprevalence of SARS-CoV-2-Specific Antibodies, Faroe Islands",2020-07-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Faroe Islands,Faroe Islands,,"From the Faroese Population Registry, we randomly sampled 1,500 persons and invited them by letter to a clinical visit at 1 of 6 study sites around the islands mainly during week 18 (April 27–May 1, 2020) independently of previous positive PCR test result. ",,2020-04-27,2020-05-01,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,126,0.0,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,University of the Faroe Islands,Unity-Aligned,http://dx.doi.org/10.3201/eid2611.202736,2020-09-28,2024-03-01,Verified,petersen_seroprevalence_2020,FRO
200727_FaroeIslandsNorðoyggjar_TheFaroeseHospitalSystem_Overall_UnAdj,200727_ FaroeIslands_TheFaroeseHospitalSystem,"Seroprevalence of SARS-CoV-2-Specific Antibodies, Faroe Islands",2020-07-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Faroe Islands,Faroe Islands,,"From the Faroese Population Registry, we randomly sampled 1,500 persons and invited them by letter to a clinical visit at 1 of 6 study sites around the islands mainly during week 18 (April 27–May 1, 2020) independently of previous positive PCR test result. ",,2020-04-27,2020-05-01,Household and community samples,All,Adults (18-64 years),0.0,,Geographical area,Norooyggjar,114,0.0,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,University of the Faroe Islands,Unity-Aligned,http://dx.doi.org/10.3201/eid2611.202736,2020-09-28,2024-03-01,Verified,petersen_seroprevalence_2020,FRO
200727_FaroeIslandsStreymoy_TheFaroeseHospitalSystem_Overall_UnAdj,200727_ FaroeIslands_TheFaroeseHospitalSystem,"Seroprevalence of SARS-CoV-2-Specific Antibodies, Faroe Islands",2020-07-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Faroe Islands,Faroe Islands,,"From the Faroese Population Registry, we randomly sampled 1,500 persons and invited them by letter to a clinical visit at 1 of 6 study sites around the islands mainly during week 18 (April 27–May 1, 2020) independently of previous positive PCR test result. ",,2020-04-27,2020-05-01,Household and community samples,All,Adults (18-64 years),0.0,,Geographical area,Streymoy,530,0.005659999999999999,0.001,0.016,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,University of the Faroe Islands,Unity-Aligned,http://dx.doi.org/10.3201/eid2611.202736,2020-09-28,2024-03-01,Verified,petersen_seroprevalence_2020,FRO
200727_FaroeIslands_TheFaroeseHospitalSystem_Overall_UnAdj,200727_ FaroeIslands_TheFaroeseHospitalSystem,"Seroprevalence of SARS-CoV-2-Specific Antibodies, Faroe Islands",2020-07-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Faroe Islands,Faroe Islands,,"From the Faroese Population Registry, we randomly sampled 1,500 persons and invited them by letter to a clinical visit at 1 of 6 study sites around the islands mainly during week 18 (April 27–May 1, 2020) independently of previous positive PCR test result. ",,2020-04-27,2020-05-01,Household and community samples,All,Adults (18-64 years),0.0,,Analysis,,1075,0.006,0.001,0.012,,,,,True,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,University of the Faroe Islands,Unity-Aligned,http://dx.doi.org/10.3201/eid2611.202736,2020-09-28,2024-03-01,Verified,petersen_seroprevalence_2020,FRO
200727_FaroeIslands_TheFaroeseHospitalSystem_DetailedAge10-19Yr_UnAdj,200727_ FaroeIslands_TheFaroeseHospitalSystem,"Seroprevalence of SARS-CoV-2-Specific Antibodies, Faroe Islands",2020-07-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Faroe Islands,Faroe Islands,,"From the Faroese Population Registry, we randomly sampled 1,500 persons and invited them by letter to a clinical visit at 1 of 6 study sites around the islands mainly during week 18 (April 27–May 1, 2020) independently of previous positive PCR test result. ",,2020-04-27,2020-05-01,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,150,0.00666,0.0,0.037000000000000005,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,University of the Faroe Islands,Unity-Aligned,http://dx.doi.org/10.3201/eid2611.202736,2020-09-28,2024-03-01,Verified,petersen_seroprevalence_2020,FRO
200727_FaroeIslandsSandoyogSuðuroy_TheFaroeseHospitalSystem_Overall_UnAdj,200727_ FaroeIslands_TheFaroeseHospitalSystem,"Seroprevalence of SARS-CoV-2-Specific Antibodies, Faroe Islands",2020-07-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Faroe Islands,Faroe Islands,,"From the Faroese Population Registry, we randomly sampled 1,500 persons and invited them by letter to a clinical visit at 1 of 6 study sites around the islands mainly during week 18 (April 27–May 1, 2020) independently of previous positive PCR test result. ",,2020-04-27,2020-05-01,Household and community samples,All,Adults (18-64 years),0.0,,Geographical area,Sandoyog,106,0.00943,0.0,0.051,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,University of the Faroe Islands,Unity-Aligned,http://dx.doi.org/10.3201/eid2611.202736,2020-09-28,2024-03-01,Verified,petersen_seroprevalence_2020,FRO
200727_FaroeIslands_TheFaroeseHospitalSystem_DetailedAge0-9Yr_UnAdj,200727_ FaroeIslands_TheFaroeseHospitalSystem,"Seroprevalence of SARS-CoV-2-Specific Antibodies, Faroe Islands",2020-07-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Faroe Islands,Faroe Islands,,"From the Faroese Population Registry, we randomly sampled 1,500 persons and invited them by letter to a clinical visit at 1 of 6 study sites around the islands mainly during week 18 (April 27–May 1, 2020) independently of previous positive PCR test result. ",,2020-04-27,2020-05-01,Household and community samples,All,Children and Youth (0-17 years),0.0,9.0,Age,0-9,92,0.0,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,University of the Faroe Islands,Unity-Aligned,http://dx.doi.org/10.3201/eid2611.202736,2020-09-28,2024-03-01,Verified,petersen_seroprevalence_2020,FRO
200727_FaroeIslandsEysturoy_TheFaroeseHospitalSystem_Overall_UnAdj,200727_ FaroeIslands_TheFaroeseHospitalSystem,"Seroprevalence of SARS-CoV-2-Specific Antibodies, Faroe Islands",2020-07-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Faroe Islands,Faroe Islands,,"From the Faroese Population Registry, we randomly sampled 1,500 persons and invited them by letter to a clinical visit at 1 of 6 study sites around the islands mainly during week 18 (April 27–May 1, 2020) independently of previous positive PCR test result. ",,2020-04-27,2020-05-01,Household and community samples,All,Adults (18-64 years),0.0,,Geographical area,Eysturoy,251,0.00398,0.0,0.022000000000000002,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,University of the Faroe Islands,Unity-Aligned,http://dx.doi.org/10.3201/eid2611.202736,2020-09-28,2024-03-01,Verified,petersen_seroprevalence_2020,FRO
200727_FaroeIslands_TheFaroeseHospitalSystem_DetailedMales_UnAdj,200727_ FaroeIslands_TheFaroeseHospitalSystem,"Seroprevalence of SARS-CoV-2-Specific Antibodies, Faroe Islands",2020-07-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Faroe Islands,Faroe Islands,,"From the Faroese Population Registry, we randomly sampled 1,500 persons and invited them by letter to a clinical visit at 1 of 6 study sites around the islands mainly during week 18 (April 27–May 1, 2020) independently of previous positive PCR test result. ",,2020-04-27,2020-05-01,Household and community samples,Male,Adults (18-64 years),0.0,,Sex/Gender,Male,538,0.00557,0.001,0.016,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,University of the Faroe Islands,Unity-Aligned,http://dx.doi.org/10.3201/eid2611.202736,2020-09-28,2024-03-01,Verified,petersen_seroprevalence_2020,FRO
210826_FaroeIslands_UniversityoftheFaroeIslands_TestAdjusted,210826_FaroeIslands_UniversityoftheFaroeIslands,"Seroprevalence of SARS-CoV-2-Specific Antibodies among Quarantined Close Contacts of COVID-19 Patients, Faroe Islands, 2020",2021-08-26,Journal Article (Peer-Reviewed),National,Retrospective cohort,Faroe Islands,,,"""we invited all close contacts of the 187 patients with confirmed COVID-19 in the Faroe Islands""

""all 854 close contacts of COVID-19 patients identified during March 3–April 22, 2020.""

""close contacts that had not tested positive by RT-PCR were eligible for participation in this study""",Positive RT-PCR test for COVID-19,2020-05-01,2020-09-15,Contacts of COVID patients,All,Multiple groups,,,Primary Estimate,Test adjusted estimate,584,0.053,0.035,0.075,True,True,,,,Entire sample,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Maria Petersen,University of the Faroe Islands,Not Unity-Aligned,https://wwwnc.cdc.gov/eid/article/27/11/20-4948_article,2021-09-28,2023-08-15,Unverified,petersen_early_2021,FRO
211110_FaroeIslands_TheFaroeseHospitalSystem_TestAdj,211110_FaroeIslands_TheFaroeseHospitalSystem,"Low Seroprevalence among Undetected COVID-19 Cases, Faroe Islands, November 2020.",2021-11-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Faroe Islands,,,,Previous positive reverse transcription PCR (RT-PCR) result. Also excluded 2 newborns,2020-11-21,2020-11-30,Household and community samples,All,Multiple groups,1.0,98.0,Primary Estimate,,960,0.004,0.001,0.01,True,True,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,The Faroese Hospital System,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2801.210917,2021-11-18,2023-08-15,Verified,petersen_low_2021,FRO
211110_FaroeIslands_TheFaroeseHospitalSystem_0-9,211110_FaroeIslands_TheFaroeseHospitalSystem,"Low Seroprevalence among Undetected COVID-19 Cases, Faroe Islands, November 2020.",2021-11-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Faroe Islands,,,,Previous positive reverse transcription PCR (RT-PCR) result. Also excluded 2 newborns,2020-11-21,2020-11-30,Household and community samples,All,Children and Youth (0-17 years),1.0,9.0,Age,0-9 years old ,33,0.03,0.0008,0.158,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,The Faroese Hospital System,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2801.210917,2021-11-18,2024-03-01,Verified,petersen_low_2021,FRO
211110_FaroeIslands_TheFaroeseHospitalSystem_Nordoyggjar,211110_FaroeIslands_TheFaroeseHospitalSystem,"Low Seroprevalence among Undetected COVID-19 Cases, Faroe Islands, November 2020.",2021-11-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Faroe Islands,Nordoyggjar,,,Previous positive reverse transcription PCR (RT-PCR) result. Also excluded 2 newborns,2020-11-21,2020-11-30,Household and community samples,All,Multiple groups,1.0,98.0,Geographical area,,114,0.0,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,The Faroese Hospital System,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2801.210917,2021-11-18,2024-03-01,Verified,petersen_low_2021,FRO
211110_FaroeIslands_TheFaroeseHospitalSystem_Female,211110_FaroeIslands_TheFaroeseHospitalSystem,"Low Seroprevalence among Undetected COVID-19 Cases, Faroe Islands, November 2020.",2021-11-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Faroe Islands,,,,Previous positive reverse transcription PCR (RT-PCR) result. Also excluded 2 newborns,2020-11-21,2020-11-30,Household and community samples,Female,Multiple groups,1.0,98.0,Sex/Gender,,501,0.004,0.0005,0.013999999999999999,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,The Faroese Hospital System,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2801.210917,2021-11-18,2024-03-01,Verified,petersen_low_2021,FRO
211110_FaroeIslands_TheFaroeseHospitalSystem_Male,211110_FaroeIslands_TheFaroeseHospitalSystem,"Low Seroprevalence among Undetected COVID-19 Cases, Faroe Islands, November 2020.",2021-11-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Faroe Islands,,,,Previous positive reverse transcription PCR (RT-PCR) result. Also excluded 2 newborns,2020-11-21,2020-11-30,Household and community samples,Male,Multiple groups,1.0,98.0,Sex/Gender,,459,0.002,0.0001,0.012,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,The Faroese Hospital System,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2801.210917,2021-11-18,2024-03-01,Verified,petersen_low_2021,FRO
211110_FaroeIslands_TheFaroeseHospitalSystem_40-49,211110_FaroeIslands_TheFaroeseHospitalSystem,"Low Seroprevalence among Undetected COVID-19 Cases, Faroe Islands, November 2020.",2021-11-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Faroe Islands,,,,Previous positive reverse transcription PCR (RT-PCR) result. Also excluded 2 newborns,2020-11-21,2020-11-30,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49 years-old,135,0.0,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,The Faroese Hospital System,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2801.210917,2021-11-18,2024-03-01,Verified,petersen_low_2021,FRO
211110_FaroeIslands_TheFaroeseHospitalSystem_Eysturoy,211110_FaroeIslands_TheFaroeseHospitalSystem,"Low Seroprevalence among Undetected COVID-19 Cases, Faroe Islands, November 2020.",2021-11-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Faroe Islands,Eysturoy,,,Previous positive reverse transcription PCR (RT-PCR) result. Also excluded 2 newborns,2020-11-21,2020-11-30,Household and community samples,All,Multiple groups,1.0,98.0,Geographical area,,216,0.0,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,The Faroese Hospital System,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2801.210917,2021-11-18,2024-03-01,Verified,petersen_low_2021,FRO
211110_FaroeIslands_TheFaroeseHospitalSystem_Crude,211110_FaroeIslands_TheFaroeseHospitalSystem,"Low Seroprevalence among Undetected COVID-19 Cases, Faroe Islands, November 2020.",2021-11-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Faroe Islands,,,,Previous positive reverse transcription PCR (RT-PCR) result. Also excluded 2 newborns,2020-11-21,2020-11-30,Household and community samples,All,Multiple groups,1.0,98.0,Analysis,,960,0.003,0.0006,0.009000000000000001,,,,,True,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,The Faroese Hospital System,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2801.210917,2021-11-18,2024-03-01,Verified,petersen_low_2021,FRO
211110_FaroeIslands_TheFaroeseHospitalSystem_>=90,211110_FaroeIslands_TheFaroeseHospitalSystem,"Low Seroprevalence among Undetected COVID-19 Cases, Faroe Islands, November 2020.",2021-11-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Faroe Islands,,,,Previous positive reverse transcription PCR (RT-PCR) result. Also excluded 2 newborns,2020-11-21,2020-11-30,Household and community samples,All,Seniors (65+ years),90.0,98.0,Age,>=90 years-old,7,0.0,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,The Faroese Hospital System,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2801.210917,2021-11-18,2024-03-01,Verified,petersen_low_2021,FRO
211110_FaroeIslands_TheFaroeseHospitalSystem_20-29,211110_FaroeIslands_TheFaroeseHospitalSystem,"Low Seroprevalence among Undetected COVID-19 Cases, Faroe Islands, November 2020.",2021-11-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Faroe Islands,,,,Previous positive reverse transcription PCR (RT-PCR) result. Also excluded 2 newborns,2020-11-21,2020-11-30,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29 years-old,88,0.0,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,The Faroese Hospital System,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2801.210917,2021-11-18,2024-03-01,Verified,petersen_low_2021,FRO
211110_FaroeIslands_TheFaroeseHospitalSystem_30-39,211110_FaroeIslands_TheFaroeseHospitalSystem,"Low Seroprevalence among Undetected COVID-19 Cases, Faroe Islands, November 2020.",2021-11-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Faroe Islands,,,,Previous positive reverse transcription PCR (RT-PCR) result. Also excluded 2 newborns,2020-11-21,2020-11-30,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39 years-old,134,0.0,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,The Faroese Hospital System,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2801.210917,2021-11-18,2024-03-01,Verified,petersen_low_2021,FRO
211110_FaroeIslands_TheFaroeseHospitalSystem_SandoyogSuduroy,211110_FaroeIslands_TheFaroeseHospitalSystem,"Low Seroprevalence among Undetected COVID-19 Cases, Faroe Islands, November 2020.",2021-11-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Faroe Islands,Sandoy og Suduroy	,,,Previous positive reverse transcription PCR (RT-PCR) result. Also excluded 2 newborns,2020-11-21,2020-11-30,Household and community samples,All,Multiple groups,1.0,98.0,Geographical area,,108,0.009000000000000001,0.0002,0.051,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,The Faroese Hospital System,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2801.210917,2021-11-18,2024-03-01,Verified,petersen_low_2021,FRO
211110_FaroeIslands_TheFaroeseHospitalSystem_50-59,211110_FaroeIslands_TheFaroeseHospitalSystem,"Low Seroprevalence among Undetected COVID-19 Cases, Faroe Islands, November 2020.",2021-11-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Faroe Islands,,,,Previous positive reverse transcription PCR (RT-PCR) result. Also excluded 2 newborns,2020-11-21,2020-11-30,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59 years-old,191,0.0,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,The Faroese Hospital System,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2801.210917,2021-11-18,2024-03-01,Verified,petersen_low_2021,FRO
211110_FaroeIslands_TheFaroeseHospitalSystem_Vagar,211110_FaroeIslands_TheFaroeseHospitalSystem,"Low Seroprevalence among Undetected COVID-19 Cases, Faroe Islands, November 2020.",2021-11-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Faroe Islands,Vagar,,,Previous positive reverse transcription PCR (RT-PCR) result. Also excluded 2 newborns,2020-11-21,2020-11-30,Household and community samples,All,Multiple groups,1.0,98.0,Geographical area,,49,0.0,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,The Faroese Hospital System,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2801.210917,2021-11-18,2024-03-01,Verified,petersen_low_2021,FRO
211110_FaroeIslands_TheFaroeseHospitalSystem_80-89,211110_FaroeIslands_TheFaroeseHospitalSystem,"Low Seroprevalence among Undetected COVID-19 Cases, Faroe Islands, November 2020.",2021-11-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Faroe Islands,,,,Previous positive reverse transcription PCR (RT-PCR) result. Also excluded 2 newborns,2020-11-21,2020-11-30,Household and community samples,All,Seniors (65+ years),80.0,89.0,Age,80-89 years-old,36,0.0,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,The Faroese Hospital System,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2801.210917,2021-11-18,2024-03-01,Verified,petersen_low_2021,FRO
211110_FaroeIslands_TheFaroeseHospitalSystem_10-19,211110_FaroeIslands_TheFaroeseHospitalSystem,"Low Seroprevalence among Undetected COVID-19 Cases, Faroe Islands, November 2020.",2021-11-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Faroe Islands,,,,Previous positive reverse transcription PCR (RT-PCR) result. Also excluded 2 newborns,2020-11-21,2020-11-30,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19 years-old,76,0.0,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,The Faroese Hospital System,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2801.210917,2021-11-18,2024-03-01,Verified,petersen_low_2021,FRO
211110_FaroeIslands_TheFaroeseHospitalSystem_60-69,211110_FaroeIslands_TheFaroeseHospitalSystem,"Low Seroprevalence among Undetected COVID-19 Cases, Faroe Islands, November 2020.",2021-11-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Faroe Islands,,,,Previous positive reverse transcription PCR (RT-PCR) result. Also excluded 2 newborns,2020-11-21,2020-11-30,Household and community samples,All,Adults (18-64 years),60.0,69.0,Age,60-69 years-old,157,0.013000000000000001,0.002,0.045,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,The Faroese Hospital System,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2801.210917,2021-11-18,2024-03-01,Verified,petersen_low_2021,FRO
211110_FaroeIslands_TheFaroeseHospitalSystem_Streymoy,211110_FaroeIslands_TheFaroeseHospitalSystem,"Low Seroprevalence among Undetected COVID-19 Cases, Faroe Islands, November 2020.",2021-11-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Faroe Islands,Streymoy,,,Previous positive reverse transcription PCR (RT-PCR) result. Also excluded 2 newborns,2020-11-21,2020-11-30,Household and community samples,All,Multiple groups,1.0,98.0,Geographical area,,473,0.004,0.0005,0.015,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,The Faroese Hospital System,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2801.210917,2021-11-18,2024-03-01,Verified,petersen_low_2021,FRO
211110_FaroeIslands_TheFaroeseHospitalSystem_70-79,211110_FaroeIslands_TheFaroeseHospitalSystem,"Low Seroprevalence among Undetected COVID-19 Cases, Faroe Islands, November 2020.",2021-11-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Faroe Islands,,,,Previous positive reverse transcription PCR (RT-PCR) result. Also excluded 2 newborns,2020-11-21,2020-11-30,Household and community samples,All,Seniors (65+ years),70.0,79.0,Age,70-79 years-old,103,0.0,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Skaalum Petersen,The Faroese Hospital System,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2801.210917,2021-11-18,2024-03-01,Verified,petersen_low_2021,FRO
221219_Fiji_NationalCriticalCareAndTraumaResponseCentre,221219_Fiji_NationalCriticalCareAndTraumaResponseCentre,"Rapid SARS-CoV-2 Seroprevalence Survey in Central and Western Divisions of Fiji, 2021.",2022-12-19,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Fiji,Central and Western Divisions,,"The study population comprised persons deemed at higher risk for SARS-CoV-2 infection who were 8–70 years of age and located in Central and Western Divisions of Fiji. Persons at higher risk of infection included those who worked in healthcare, tourism, hospitality, retail, transportation, and education industries and primary or secondary school students.",,2021-11-24,2021-12-01,Multiple populations,All,Multiple groups,8.0,70.0,Primary Estimate,,539,0.9550000000000001,0.934,0.971,True,,,,True,Stratified non-probability,Wantai SARS-CoV-2 IgG ELISA,Beijing Wantai Biological,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9670000000000001,0.975,['High'],,No,No,Yes,,No,Yes,Yes,,Stephanie Curtis,National Critical Care and Trauma Response Centre,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2901.221514,2023-01-12,2024-03-01,Unverified,curtis_rapid_2023,FJI
201213_Helsinki_UniversityofHelsinki_HCW_unadj,201213_Helsinki_UniversityofHelsinki,"SARS-CoV-2 infections among healthcare workers at Helsinki University Hospital, Finland, spring 2020: serosurvey, symptoms and risk factors.",2020-12-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Finland,Uusimaa,Helsinki,"HCWs on selected wards (part of them with known SARS-CoV-2 exposure, others with none identified)",,2020-04-22,2020-05-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Overall primary reported by author,1095,0.03,,,True,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Abbott Architect SARS-CoV-2 IgG,Author designed (Neutralization Assay)","EUROIMMUN,Abbott Laboratories,NA",Multiple Types,Serum,IgG,,,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Anu Kantele,University of Helsinki,Not Unity-Aligned,https://dx.doi.org/10.1016/j.tmaid.2020.101949,2021-02-01,2024-03-01,Verified,kantele_sars-cov-2_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W16,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W16,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-04-12,2020-04-18,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,362,0.0028000000000000004,0.0005,0.015500000000000002,True,,,,True,Simplified probability,"Author designed (Neutralization Assay),Author designed (IFA) - MULTIPLEXED",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],Yes,Yes,No,No,No,Yes,Yes,No,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W17,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W17,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-04-19,2020-04-25,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,674,0.003,0.0008,0.0108,True,,,,True,Simplified probability,"Author designed (Neutralization Assay),Author designed (IFA) - MULTIPLEXED",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,No,,Yes,Yes,No,,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W18,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W18,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-04-26,2020-05-02,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,426,0.0047,0.0013000000000000002,0.017,True,,,,True,Simplified probability,"Author designed (Neutralization Assay),Author designed (IFA) - MULTIPLEXED",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],Yes,Yes,No,No,No,Yes,Yes,No,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W19,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W19,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-05-03,2020-05-09,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,514,0.0,0.0,0.0074,True,,,,True,Simplified probability,"Author designed (Neutralization Assay),Author designed (IFA) - MULTIPLEXED",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],Yes,Yes,No,No,No,Yes,Yes,No,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W20,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W20,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-05-10,2020-05-16,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,401,0.0025,0.0004,0.013999999999999999,True,,,,True,Simplified probability,"Author designed (Neutralization Assay),Author designed (IFA) - MULTIPLEXED",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],Yes,Yes,No,No,No,Yes,Yes,No,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W21,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W21,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-05-17,2020-05-23,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,210,0.0048,0.0008,0.0265,True,,,,True,Simplified probability,"Author designed (Neutralization Assay),Author designed (IFA) - MULTIPLEXED",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],Yes,Yes,No,No,No,Yes,Yes,No,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W22,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W22,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-05-24,2020-05-30,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,178,0.0,0.0,0.0211,True,,,,True,Simplified probability,"Author designed (Neutralization Assay),Author designed (IFA) - MULTIPLEXED",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],Yes,Yes,No,No,No,Yes,Yes,No,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W23,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W23,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-05-31,2020-06-06,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,214,0.0047,0.0008,0.026000000000000002,True,,,,True,Simplified probability,"Author designed (Neutralization Assay),Author designed (Multiplex)",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],Yes,Yes,No,No,No,Yes,Yes,No,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W24,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W24,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-06-07,2020-06-13,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,174,0.0,0.0,0.0216,True,,,,True,Simplified probability,"Author designed (Neutralization Assay),Author designed (Multiplex)",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],Yes,Yes,No,No,No,Yes,Yes,No,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W25,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W25,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-06-14,2020-06-20,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,78,0.0,0.0,0.046900000000000004,True,,,,True,Simplified probability,"Author designed (Neutralization Assay),Author designed (Multiplex)",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],Yes,Yes,No,No,No,Yes,Yes,No,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W26,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W26,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-06-21,2020-06-27,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,32,0.0,0.0,0.1072,True,,,,True,Simplified probability,"Author designed (Neutralization Assay),Author designed (Multiplex)",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],Yes,Yes,No,No,No,Yes,Yes,No,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W27,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W27,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-06-28,2020-07-04,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,85,0.0,0.0,0.0432,True,,,,True,Simplified probability,"Author designed (Neutralization Assay),Author designed (Multiplex)",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],Yes,Yes,No,No,No,Yes,Yes,No,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W28,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W28,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-07-05,2020-07-11,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,51,0.0,0.0,0.07,True,,,,True,Simplified probability,"Author designed (Neutralization Assay),Author designed (Multiplex)",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],Yes,Yes,No,No,No,Yes,Yes,No,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W29,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W29,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-07-12,2020-07-18,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,7,0.0,0.0,0.3543,True,,,,True,Simplified probability,"Author designed (Neutralization Assay),Author designed (Multiplex)",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],Yes,Yes,No,No,No,Yes,Yes,No,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W30,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W30,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-07-19,2020-07-25,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,9,0.11109999999999999,0.0199,0.435,True,,,,True,Simplified probability,"Author designed (Neutralization Assay),Author designed (Multiplex)",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],Yes,Yes,No,No,No,Yes,Yes,No,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W31,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W31,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-07-26,2020-08-01,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,75,0.013300000000000001,0.0024,0.0717,True,,,,True,Simplified probability,"Author designed (Neutralization Assay),Author designed (Multiplex)",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],Yes,Yes,No,No,No,Yes,Yes,No,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W32,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W32,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-08-02,2020-08-08,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,49,0.0204,0.0036,0.1069,True,,,,True,Simplified probability,"Author designed (Neutralization Assay),Author designed (Multiplex)",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],Yes,Yes,No,No,No,Yes,Yes,No,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W33,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W33,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-08-09,2020-08-15,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,64,0.0,0.0,0.056600000000000004,True,,,,True,Simplified probability,"Author designed (Neutralization Assay),Author designed (Multiplex)",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],Yes,Yes,No,No,No,Yes,Yes,No,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W34,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W34,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-08-16,2020-08-22,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,63,0.0,0.0,0.0575,True,,,,True,Simplified probability,"Author designed (Neutralization Assay),Author designed (Multiplex)",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],Yes,Yes,No,No,No,Yes,Yes,No,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W35,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W35,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-08-23,2020-08-29,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,48,0.020800000000000003,0.0037,0.109,True,,,,True,Simplified probability,"Author designed (Neutralization Assay),Author designed (Multiplex)",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],Yes,Yes,No,No,No,Yes,Yes,No,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W36,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W36,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-08-30,2020-09-05,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,63,0.0,0.0,0.0575,True,,,,True,Simplified probability,"Author designed (Neutralization Assay),Author designed (Multiplex)",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],Yes,Yes,No,No,No,Yes,Yes,No,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W37,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W37,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-09-06,2020-09-12,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,54,0.0,0.0,0.0664,True,,,,True,Simplified probability,"Author designed (Neutralization Assay),Author designed (Multiplex)",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],Yes,Yes,No,No,No,Yes,Yes,No,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W38,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W38,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-09-13,2020-09-19,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,48,0.020800000000000003,0.0037,0.109,True,,,,True,Simplified probability,"Author designed (Neutralization Assay),Author designed (Multiplex)",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],Yes,Yes,No,No,No,Yes,Yes,No,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W39,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W39,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-09-20,2020-09-26,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,56,0.0179,0.0032,0.0945,True,,,,True,Simplified probability,"Author designed (Neutralization Assay),Author designed (Multiplex)",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],Yes,Yes,No,No,No,Yes,Yes,No,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W40,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W40,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-09-27,2020-10-03,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,60,0.0167,0.0029,0.0886,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W41,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W41,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-10-04,2020-10-10,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,51,0.0,0.0,0.07,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W42,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W42,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-10-11,2020-10-17,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,59,0.0169,0.003,0.09,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W43,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W43,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-10-18,2020-10-24,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,55,0.0,0.0,0.0653,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W44,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W44,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-10-25,2020-10-31,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,56,0.0179,0.0032,0.0945,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W45,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W45,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-11-01,2020-11-07,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,55,0.0545,0.0187,0.1485,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W46,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W46,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-11-08,2020-11-14,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,52,0.0192,0.0034000000000000002,0.1012,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W47,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W47,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-11-15,2020-11-21,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,64,0.031200000000000002,0.0086,0.107,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W48,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W48,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-11-22,2020-11-28,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,85,0.0353,0.0121,0.0987,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W49,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W49,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-11-29,2020-12-05,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,80,0.025,0.0069,0.0866,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W50,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W50,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-12-06,2020-12-12,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,106,0.0094,0.0017000000000000001,0.051500000000000004,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W51,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W51,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-12-13,2020-12-19,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,115,0.0087,0.0015,0.047599999999999996,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W52,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W52,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-12-20,2020-12-26,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,65,0.0,0.0,0.0558,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2020-W53,211007_Finland_FinnishInstituteforHealthandWelfare_2020-W53,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2020-12-27,2021-01-02,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,26,0.0,0.0,0.12869999999999998,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W01,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W01,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-01-03,2021-01-09,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,12,0.0,0.0,0.2425,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W02,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W02,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-01-10,2021-01-16,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,6,0.0,0.0,0.39030000000000004,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W03,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W03,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-01-17,2021-01-23,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,5,0.0,0.0,0.43450000000000005,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W04,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W04,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-01-24,2021-01-30,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,30,0.0,0.0,0.1135,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W05,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W05,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-01-31,2021-02-06,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,110,0.0273,0.009300000000000001,0.0771,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W06,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W06,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-02-07,2021-02-13,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,111,0.0541,0.025,0.1129,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W07,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W07,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-02-14,2021-02-20,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,69,0.0725,0.0313,0.1587,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W08,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W08,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-02-21,2021-02-27,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,123,0.065,0.0333,0.1231,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W09,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W09,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-02-28,2021-03-06,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,132,0.0227,0.0078000000000000005,0.0647,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W10,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W10,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-03-07,2021-03-13,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,64,0.031200000000000002,0.0086,0.107,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W11,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W11,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-03-14,2021-03-20,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,104,0.06730000000000001,0.033,0.1325,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W12,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W12,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-03-21,2021-03-27,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,73,0.10560000000000001,0.0666,0.2016,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W13,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W13,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-03-28,2021-04-03,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,60,0.0833,0.0361,0.1807,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W14,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W14,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-04-04,2021-04-10,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,59,0.0678,0.0267,0.1618,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W15,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W15,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-04-11,2021-04-17,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,29,0.1379,0.055,0.3056,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W16,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W16,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-04-18,2021-04-24,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,102,0.1863,0.1226,0.2727,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W17,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W17,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-04-25,2021-05-01,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,109,0.22940000000000002,0.1605,0.31670000000000004,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W18,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W18,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-05-02,2021-05-08,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,74,0.2838,0.1937,0.39520000000000005,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W19,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W19,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-05-09,2021-05-15,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,52,0.26920000000000005,0.1677,0.4035,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W20,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W20,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-05-16,2021-05-22,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,86,0.44189999999999996,0.34159999999999996,0.5471,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W21,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W21,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-05-23,2021-05-29,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,93,0.49460000000000004,0.39530000000000004,0.5944,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W22,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W22,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-05-30,2021-06-05,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,39,0.4872,0.3387,0.638,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W23,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W23,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-06-06,2021-06-12,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,68,0.6029,0.4842,0.7107,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W24,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W24,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-06-13,2021-06-19,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,47,0.5745,0.4328,0.7049,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W25,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W25,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-06-20,2021-06-26,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,44,0.7273000000000001,0.5815,0.8067000000000001,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W26,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W26,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-06-27,2021-07-03,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,48,0.6875,0.5467000000000001,0.8005,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W27,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W27,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-07-04,2021-07-10,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,12,0.5833,0.3195,0.8067000000000001,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W28,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W28,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-07-11,2021-07-17,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,2,1.0,0.34240000000000004,1.0,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-09-20,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W29,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W29,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-07-18,2021-07-24,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,2,1.0,0.34240000000000004,1.0,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-10-14,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W30,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W30,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-07-25,2021-07-31,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,11,0.8181999999999999,0.523,0.9486,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-10-14,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W31,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W31,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-08-01,2021-08-07,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,42,0.9286,0.8099,0.9754,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-10-14,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W32,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W32,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-08-08,2021-08-14,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,25,0.84,0.6535,0.9359999999999999,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-10-14,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W33,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W33,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-08-15,2021-08-21,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,7,0.8571,0.4869,0.9743,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-10-14,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W34,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W34,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-08-22,2021-08-28,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,8,0.75,0.4093,0.9285,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-10-14,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W35,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W35,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-08-29,2021-09-04,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,1,0.0,0.0,0.7935,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2021-10-14,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W36,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W36,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""

""The samples have been taken from subjects 18 to 69 years of age. Subjects are invited every two weeks, but the actual participation occurs during subsequent several weeks.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-09-05,2021-09-11,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,1,1.0,0.2065,1.0,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2022-03-01,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W37,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W37,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""

""The samples have been taken from subjects 18 to 69 years of age. Subjects are invited every two weeks, but the actual participation occurs during subsequent several weeks.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-09-12,2021-09-18,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,1,1.0,0.2065,1.0,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2022-03-01,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W39,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W39,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""

""The samples have been taken from subjects 18 to 69 years of age. Subjects are invited every two weeks, but the actual participation occurs during subsequent several weeks.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-09-26,2021-10-02,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,2,0.5,0.0945,0.9055,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2022-03-01,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W42,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W42,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""

""The samples have been taken from subjects 18 to 69 years of age. Subjects are invited every two weeks, but the actual participation occurs during subsequent several weeks.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-10-17,2021-10-23,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,1,0.0,0.0,0.7935,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2022-03-01,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W43,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W43,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""

""The samples have been taken from subjects 18 to 69 years of age. Subjects are invited every two weeks, but the actual participation occurs during subsequent several weeks.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-10-24,2021-10-30,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,11,0.9091,0.6226,0.9838,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2022-03-01,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W44,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W44,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""

""The samples have been taken from subjects 18 to 69 years of age. Subjects are invited every two weeks, but the actual participation occurs during subsequent several weeks.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-10-31,2021-11-06,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,79,0.9114,0.8281999999999999,0.9564,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2022-03-01,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W45,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W45,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""

""The samples have been taken from subjects 18 to 69 years of age. Subjects are invited every two weeks, but the actual participation occurs during subsequent several weeks.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-11-07,2021-11-13,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,30,0.9333,0.7868,0.9815,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2022-03-01,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W46,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W46,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""

""The samples have been taken from subjects 18 to 69 years of age. Subjects are invited every two weeks, but the actual participation occurs during subsequent several weeks.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-11-14,2021-11-20,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,13,0.9231,0.6668999999999999,0.9863,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2022-03-01,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W47,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W47,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""

""The samples have been taken from subjects 18 to 69 years of age. Subjects are invited every two weeks, but the actual participation occurs during subsequent several weeks.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-11-21,2021-11-27,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,8,0.875,0.5291,0.9776,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2022-03-01,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W48,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W48,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""

""The samples have been taken from subjects 18 to 69 years of age. Subjects are invited every two weeks, but the actual participation occurs during subsequent several weeks.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-11-28,2021-12-04,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,4,0.75,0.3006,0.9544,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2022-03-01,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W49,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W49,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""

""The samples have been taken from subjects 18 to 69 years of age. Subjects are invited every two weeks, but the actual participation occurs during subsequent several weeks.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-12-05,2021-12-11,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,4,1.0,0.5101,1.0,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2022-03-01,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W50,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W50,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""

""The samples have been taken from subjects 18 to 69 years of age. Subjects are invited every two weeks, but the actual participation occurs during subsequent several weeks.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-12-12,2021-12-18,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,1,1.0,0.2065,1.0,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2022-03-01,2022-07-16,Verified,merit_melin_report_2021,FIN
211007_Finland_FinnishInstituteforHealthandWelfare_2021-W51,211007_Finland_FinnishInstituteforHealthandWelfare_2021-W51,THL serological population study of the coronavirus epidemic,2021-10-07,Institutional Report,National,Repeated cross-sectional study,Finland,,,"NR, seems to be simple random sampling of entire Finnish population

""We invite people to participate in the study based on random sampling of the population.""

""The samples have been taken from subjects 18 to 69 years of age. Subjects are invited every two weeks, but the actual participation occurs during subsequent several weeks.""","""you do not reside in an institution or an enhanced service housing unit under 24-hour care.""",2021-12-19,2021-12-25,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,,2,0.5,0.0945,0.9055,True,,,,True,Simplified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,No,Unclear,Yes,Yes,Unclear,Finnish institute for health and welfare,Finnish Institute for Health and Welfare,Unity-Aligned,https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly_en.html,2022-03-01,2022-07-16,Verified,merit_melin_report_2021,FIN
210912_Turku_UniversityofTurku_Overall,210912_Turku_UniversityofTurku,Low pre-vaccination SARS-CoV-2 seroprevalence in Finnish health care workers: a prospective cohort study.,2022-01-19,Journal Article (Peer-Reviewed),Local,Prospective cohort,Finland,Southwest Finland,Turku,"In May 2020, HCWs (doctors, nurses) of Turku University Hospital units caring for COVID-19 patients or handling clinical SARS-CoV-2 samples were invited to participate in the study.

In addition to clinical staff, laboratory staff working in the units operating with testing, handling, or analysing the clinical SARS-CoV-2 samples was invited to participate in the study.",Exclusion criterion was intravenous immunoglobulin treatment within previous 6 months.,2020-05-13,2020-12-17,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,222,0.08109999999999999,,,True,,,,True,Convenience,Author designed (ELISA) - MULTIPLEXED,,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.963,0.99,['High'],,No,No,Yes,,Unclear,Yes,Yes,,Paula Tahtinen,University of Turku,Not Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2027008,2022-01-26,2022-07-16,Unverified,tahtinen_low_2022,FIN
220428_Finland_UniversityofHelsinkiTime1,220428_Finland_UniversityofHelsinkiTime1,"Rapid increase in SARS-CoV-2 seroprevalence during the emergence of Omicron variant, Finland",2022-04-28,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Finland,,Helsinki,serum specimens sent to Helsinki University Hospital Laboratory (HUSLAB) for HIV serology,,2021-11-15,2021-12-19,Residual sera,All,Multiple groups,,,Primary Estimate,,500,0.052000000000000005,,,True,,,,True,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,Yes,No,No,No,Yes,Yes,Yes,Unclear,Maarit Ahava,University of Helsinki,Unity-Aligned,https://link.springer.com/article/10.1007/s10096-022-04448-x,2022-06-01,2024-03-01,Unverified,ahava_rapid_2022-1,FIN
220428_Finland_UniversityofHelsinkiTime2,220428_Finland_UniversityofHelsinkiTime2,"Rapid increase in SARS-CoV-2 seroprevalence during the emergence of Omicron variant, Finland",2022-04-28,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Finland,,Helsinki,serum specimens sent to Helsinki University Hospital Laboratory (HUSLAB) for HIV serology,,2021-01-31,2021-03-06,Residual sera,All,Multiple groups,,,Primary Estimate,,500,0.282,,,True,,,,True,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,Yes,No,No,No,Yes,Yes,Yes,Unclear,Maarit Ahava,University of Helsinki,Unity-Aligned,https://link.springer.com/article/10.1007/s10096-022-04448-x,2022-06-01,2024-03-01,Unverified,ahava_rapid_2022-1,FIN
230404_Finland_FinnishInstituteforHealthandWelfare_antiN_2020Q2,230404_Finland_FinnishInstituteforHealthandWelfare,"Changes in SARS-CoV-2 seroprevalence and population immunity in Finland, 2020-2022",2023-04-04,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Finland,"Helsinki and Uusimaa, Pirkanmaa, Northern Ostrobothnia, Northern Savonia , Southwest, Finland ",,participate in the study in forty sequential random population surveys between April 2020 and December 2022. ,Individuals living within institutional care and those previously invited to this study or the follow-up study of the serological population survey of the coronavirus epidemic [Citation15] were excluded.,2020-04-01,2020-06-30,Household and community samples,All,Multiple groups,18.0,70.0,Primary Estimate,anti-N,3450,0.02,0.01,0.04,True,,True,,True,Simplified probability,Author designed (Multiplex),,,Serum,IgG,Nucleocapsid(N-protein),Validated by developers,0.928,1.0,['Low'],No,Yes,Yes,No,No,Unclear,Yes,Yes,No,Anna Solastie,Finnish Institute for Health and Welfare,Unity-Aligned,https://dx.doi.org/10.1080/22221751.2023.2222849,2023-06-29,2023-07-04,Unverified,solastie_changes_2023,FIN
230404_Finland_FinnishInstituteforHealthandWelfare_antiS_2022Q1,230404_Finland_FinnishInstituteforHealthandWelfare,"Changes in SARS-CoV-2 seroprevalence and population immunity in Finland, 2020-2022",2023-04-04,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Finland,"Helsinki and Uusimaa, Pirkanmaa, Northern Ostrobothnia, Northern Savonia , Southwest, Finland ",,participate in the study in forty sequential random population surveys between April 2020 and December 2022. ,Individuals living within institutional care and those previously invited to this study or the follow-up study of the serological population survey of the coronavirus epidemic [Citation15] were excluded.,2022-01-01,2022-03-31,Household and community samples,All,Multiple groups,18.0,85.0,Time frame,anti-S,169,1.0,1.0,1.0,,,True,,,Simplified probability,Author designed (Multiplex),,,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,No,No,Unclear,Yes,Yes,No,Anna Solastie,Finnish Institute for Health and Welfare,Unity-Aligned,https://dx.doi.org/10.1080/22221751.2023.2222849,2023-06-29,2023-07-03,Unverified,solastie_changes_2023,FIN
230404_Finland_FinnishInstituteforHealthandWelfare_antiS_2022Q3,230404_Finland_FinnishInstituteforHealthandWelfare,"Changes in SARS-CoV-2 seroprevalence and population immunity in Finland, 2020-2022",2023-04-04,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Finland,"Helsinki and Uusimaa, Pirkanmaa, Northern Ostrobothnia, Northern Savonia , Southwest, Finland ",,participate in the study in forty sequential random population surveys between April 2020 and December 2022. ,Individuals living within institutional care and those previously invited to this study or the follow-up study of the serological population survey of the coronavirus epidemic [Citation15] were excluded.,2022-07-01,2022-09-30,Household and community samples,All,Multiple groups,18.0,85.0,Time frame,anti-S,60,0.98,0.76,1.0,,,True,,,Simplified probability,Author designed (Multiplex),,,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,No,No,Unclear,Yes,Yes,No,Anna Solastie,Finnish Institute for Health and Welfare,Unity-Aligned,https://dx.doi.org/10.1080/22221751.2023.2222849,2023-06-29,2023-07-03,Unverified,solastie_changes_2023,FIN
230404_Finland_FinnishInstituteforHealthandWelfare_antiS_2021Q4,230404_Finland_FinnishInstituteforHealthandWelfare,"Changes in SARS-CoV-2 seroprevalence and population immunity in Finland, 2020-2022",2023-04-04,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Finland,"Helsinki and Uusimaa, Pirkanmaa, Northern Ostrobothnia, Northern Savonia , Southwest, Finland ",,participate in the study in forty sequential random population surveys between April 2020 and December 2022. ,Individuals living within institutional care and those previously invited to this study or the follow-up study of the serological population survey of the coronavirus epidemic [Citation15] were excluded.,2021-10-01,2021-12-31,Household and community samples,All,Multiple groups,18.0,70.0,Time frame,anti-S,155,0.91,0.75,0.97,,,True,,,Simplified probability,Author designed (Multiplex),,,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,No,No,Unclear,Yes,Yes,No,Anna Solastie,Finnish Institute for Health and Welfare,Unity-Aligned,https://dx.doi.org/10.1080/22221751.2023.2222849,2023-06-29,2023-07-04,Unverified,solastie_changes_2023,FIN
230404_Finland_FinnishInstituteforHealthandWelfare_antiS_2020Q3,230404_Finland_FinnishInstituteforHealthandWelfare,"Changes in SARS-CoV-2 seroprevalence and population immunity in Finland, 2020-2022",2023-04-04,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Finland,"Helsinki and Uusimaa, Pirkanmaa, Northern Ostrobothnia, Northern Savonia , Southwest, Finland ",,participate in the study in forty sequential random population surveys between April 2020 and December 2022. ,Individuals living within institutional care and those previously invited to this study or the follow-up study of the serological population survey of the coronavirus epidemic [Citation15] were excluded.,2020-07-01,2020-09-30,Household and community samples,All,Multiple groups,18.0,70.0,Time frame,anti-S,687,0.02,0.0,0.09,,,True,,,Simplified probability,Author designed (Multiplex),,,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,No,No,Unclear,Yes,Yes,No,Anna Solastie,Finnish Institute for Health and Welfare,Unity-Aligned,https://dx.doi.org/10.1080/22221751.2023.2222849,2023-06-29,2023-07-04,Unverified,solastie_changes_2023,FIN
230404_Finland_FinnishInstituteforHealthandWelfare_antiS_2020Q4,230404_Finland_FinnishInstituteforHealthandWelfare,"Changes in SARS-CoV-2 seroprevalence and population immunity in Finland, 2020-2022",2023-04-04,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Finland,"Helsinki and Uusimaa, Pirkanmaa, Northern Ostrobothnia, Northern Savonia , Southwest, Finland ",,participate in the study in forty sequential random population surveys between April 2020 and December 2022. ,Individuals living within institutional care and those previously invited to this study or the follow-up study of the serological population survey of the coronavirus epidemic [Citation15] were excluded.,2020-10-01,2020-12-31,Household and community samples,All,Multiple groups,18.0,70.0,Time frame,anti-S,888,0.01,0.0,0.05,,,True,,,Simplified probability,Author designed (Multiplex),,,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,No,No,Unclear,Yes,Yes,No,Anna Solastie,Finnish Institute for Health and Welfare,Unity-Aligned,https://dx.doi.org/10.1080/22221751.2023.2222849,2023-06-29,2023-07-04,Unverified,solastie_changes_2023,FIN
230404_Finland_FinnishInstituteforHealthandWelfare_antiS_2021Q3,230404_Finland_FinnishInstituteforHealthandWelfare,"Changes in SARS-CoV-2 seroprevalence and population immunity in Finland, 2020-2022",2023-04-04,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Finland,"Helsinki and Uusimaa, Pirkanmaa, Northern Ostrobothnia, Northern Savonia , Southwest, Finland ",,participate in the study in forty sequential random population surveys between April 2020 and December 2022. ,Individuals living within institutional care and those previously invited to this study or the follow-up study of the serological population survey of the coronavirus epidemic [Citation15] were excluded.,2021-07-01,2021-09-30,Household and community samples,All,Multiple groups,18.0,70.0,Time frame,anti-S,129,0.85,0.65,0.94,,,True,,,Simplified probability,Author designed (Multiplex),,,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,No,No,Unclear,Yes,Yes,No,Anna Solastie,Finnish Institute for Health and Welfare,Unity-Aligned,https://dx.doi.org/10.1080/22221751.2023.2222849,2023-06-29,2023-07-04,Unverified,solastie_changes_2023,FIN
230404_Finland_FinnishInstituteforHealthandWelfare_antiS_2021Q1,230404_Finland_FinnishInstituteforHealthandWelfare,"Changes in SARS-CoV-2 seroprevalence and population immunity in Finland, 2020-2022",2023-04-04,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Finland,"Helsinki and Uusimaa, Pirkanmaa, Northern Ostrobothnia, Northern Savonia , Southwest, Finland ",,participate in the study in forty sequential random population surveys between April 2020 and December 2022. ,Individuals living within institutional care and those previously invited to this study or the follow-up study of the serological population survey of the coronavirus epidemic [Citation15] were excluded.,2021-01-01,2021-03-31,Household and community samples,All,Multiple groups,18.0,70.0,Time frame,anti-S,884,0.06,0.04,0.07,,,True,,,Simplified probability,Author designed (Multiplex),,,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,No,No,Unclear,Yes,Yes,No,Anna Solastie,Finnish Institute for Health and Welfare,Unity-Aligned,https://dx.doi.org/10.1080/22221751.2023.2222849,2023-06-29,2023-07-04,Unverified,solastie_changes_2023,FIN
230404_Finland_FinnishInstituteforHealthandWelfare_antiS_2022Q4,230404_Finland_FinnishInstituteforHealthandWelfare,"Changes in SARS-CoV-2 seroprevalence and population immunity in Finland, 2020-2022",2023-04-04,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Finland,"Helsinki and Uusimaa, Pirkanmaa, Northern Ostrobothnia, Northern Savonia , Southwest, Finland ",,participate in the study in forty sequential random population surveys between April 2020 and December 2022. ,Individuals living within institutional care and those previously invited to this study or the follow-up study of the serological population survey of the coronavirus epidemic [Citation15] were excluded.,2022-10-01,2022-12-31,Household and community samples,All,Multiple groups,18.0,85.0,Time frame,anti-S,1190,0.99,0.97,0.99,,,True,,,Simplified probability,Author designed (Multiplex),,,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,No,No,Unclear,Yes,Yes,No,Anna Solastie,Finnish Institute for Health and Welfare,Unity-Aligned,https://dx.doi.org/10.1080/22221751.2023.2222849,2023-06-29,2023-07-04,Unverified,solastie_changes_2023,FIN
230404_Finland_FinnishInstituteforHealthandWelfare_antiS_2022Q2,230404_Finland_FinnishInstituteforHealthandWelfare,"Changes in SARS-CoV-2 seroprevalence and population immunity in Finland, 2020-2022",2023-04-04,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Finland,"Helsinki and Uusimaa, Pirkanmaa, Northern Ostrobothnia, Northern Savonia , Southwest, Finland ",,participate in the study in forty sequential random population surveys between April 2020 and December 2022. ,Individuals living within institutional care and those previously invited to this study or the follow-up study of the serological population survey of the coronavirus epidemic [Citation15] were excluded.,2022-04-01,2022-06-30,Household and community samples,All,Multiple groups,18.0,85.0,Time frame,anti-S,1335,0.97,0.93,0.99,,,True,,,Simplified probability,Author designed (Multiplex),,,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,No,No,Unclear,Yes,Yes,No,Anna Solastie,Finnish Institute for Health and Welfare,Unity-Aligned,https://dx.doi.org/10.1080/22221751.2023.2222849,2023-06-29,2023-07-04,Unverified,solastie_changes_2023,FIN
230404_Finland_FinnishInstituteforHealthandWelfare_antiS_2021Q2,230404_Finland_FinnishInstituteforHealthandWelfare,"Changes in SARS-CoV-2 seroprevalence and population immunity in Finland, 2020-2022",2023-04-04,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Finland,"Helsinki and Uusimaa, Pirkanmaa, Northern Ostrobothnia, Northern Savonia , Southwest, Finland ",,participate in the study in forty sequential random population surveys between April 2020 and December 2022. ,Individuals living within institutional care and those previously invited to this study or the follow-up study of the serological population survey of the coronavirus epidemic [Citation15] were excluded.,2021-04-01,2021-06-30,Household and community samples,All,Multiple groups,18.0,70.0,Time frame,anti-S,847,0.45,0.17,0.76,,,True,,,Simplified probability,Author designed (Multiplex),,,Serum,IgG,Spike,Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,No,No,Unclear,Yes,Yes,No,Anna Solastie,Finnish Institute for Health and Welfare,Unity-Aligned,https://dx.doi.org/10.1080/22221751.2023.2222849,2023-06-29,2023-07-04,Unverified,solastie_changes_2023,FIN
230612_Finland_UniversityOfHelsinki_AntiS_Primary,230612_Finland_UniversityOfHelsinki,"SARS-CoV-2 infections among pregnant women, 2020, Finland – cross-testing of neutralization assays",2023-06-12,Preprint,Regional,Cross-sectional survey ,Finland,Southern Finland,,we screened antibodies against SARS-CoV-2 in 12000 pregnant women sampled in routine maternity screening between January and December 2020 to follow the development of the pandemic in Finland.,,2020-01-15,2020-12-15,Pregnant or parturient women,Female,Adults (18-64 years),14.0,61.0,Primary Estimate,Anti-S (EIM-S),12000,0.0362,,,True,,,,True,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,J Virtanen,University of Helsinki,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2023.06.07.23290927v1,2023-06-29,2024-04-24,Verified,virtanen_sars-cov-2_2023,FIN
230612_Finland_UniversityOfHelsinki_Abbott-N,230612_Finland_UniversityOfHelsinki,"SARS-CoV-2 infections among pregnant women, 2020, Finland – cross-testing of neutralization assays",2023-06-12,Preprint,Regional,Cross-sectional survey ,Finland,Southern Finland,,we screened antibodies against SARS-CoV-2 in 12000 pregnant women sampled in routine maternity screening between January and December 2020 to follow the development of the pandemic in Finland.,,2020-01-15,2020-12-15,Pregnant or parturient women,Female,Adults (18-64 years),14.0,61.0,Test used,Abbott-N,12000,0.006,,,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,J Virtanen,University of Helsinki,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2023.06.07.23290927v1,2024-04-29,2024-04-29,Verified,virtanen_sars-cov-2_2023,FIN
200501_France_ CentreLeonBerard_HCW,200501_France_CentreLeonBerard_1_Cancerpatients,Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19,2020-05-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Auvergne-Rhône-Alpes,Lyon,Cancer patients within inclusion dates with suspected COVID-19,,2020-03-01,2020-04-16,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,85,0.0588,,,True,,,,True,Convenience,TODA Coronadiag +,TODA Pharma,LFIA,Whole Blood,"['IgG', 'IgM']",,,1.0,1.0,['High'],Yes,No,No,No,No,Unclear,Yes,Yes,Unclear,M Solodky,Centre Leon Berard,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252166/,2020-07-19,2024-03-01,Verified,solodky_lower_2020,FRA
200501_France_ CentreLeonBerard_CancerPatient,200501_France_CentreLeonBerard_2_HCW,Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19,2020-05-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Auvergne-Rhône-Alpes,Lyon,Any healthcare worker who volunteered for testing ,,2020-03-01,2020-04-16,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,244,0.0533,,,True,,,,True,Sequential,TODA Coronadiag +,TODA Pharma,LFIA,Whole Blood,"['IgG', 'IgM']",,,1.0,1.0,['High'],Yes,No,No,No,Unclear,Unclear,Yes,Yes,Unclear,M Solodky,Centre Leon Berard,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252166/,2020-07-19,2024-03-01,Verified,solodky_lower_2020,FRA
200715_France_UnitedesVirusEmergents_BloodDonors,200715_France_UnitedesVirusEmergents,Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors,2020-07-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,"Provence-Alpes-Côte d'Azur, Grand-Est, Hauts-de-France, Île-de-France",,998 samples collected from blood donors during the last week of March or the first week of April 2020,"As a rule that preexisted the COVID-19 outbreak, French volunteers can give blood only if they have no history of fever or
symptom of respiratory infection in the previous 2 weeks. In addition, those with confirmed or suspected COVID-19 were deferred 28 days after the end of symptoms. Accordingly, if it remains possible that some of the seropositive donors identified had been infected at the very beginning of virus spread in France, it is likely that a majority had undergone asymptomatic or pauci-symptomatic infection in March 2020.",2020-03-25,2020-04-07,Blood donors,All,Adults (18-64 years),,,Primary Estimate,,998,0.0271,,,True,,,,True,Sequential,Author designed (Neutralization Assay),,Neutralization,Serum,,,Validated by developers,,1.0,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,,Pierre Gallian,Unite des Virus Emergents,Not Unity-Aligned,https://reader.elsevier.com/reader/sd/pii/S0166354220302941?token=72010A825B9F560E0F15AF8D56563D596F45421D41A05764732590DB465F0C2C839E77D689CCDEDEFB85BA331FE13C72,2020-08-01,2022-07-16,Verified,gallian_lower_2020,FRA
200715_France_UnitedesVirusEmergents_BloodDonors_HautRhin,200715_France_UnitedesVirusEmergents,Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors,2020-07-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Grand-Est ,,998 samples collected from blood donors during the last week of March or the first week of April 2020,"As a rule that preexisted the COVID-19 outbreak, French volunteers can give blood only if they have no history of fever or
symptom of respiratory infection in the previous 2 weeks. In addition, those with confirmed or suspected COVID-19 were deferred 28 days after the end of symptoms. Accordingly, if it remains possible that some of the seropositive donors identified had been infected at the very beginning of virus spread in France, it is likely that a majority had undergone asymptomatic or pauci-symptomatic infection in March 2020.",2020-03-25,2020-04-07,Blood donors,All,Adults (18-64 years),,,Geographical area,Haut Rhin,269,0.0409,,,,,,,,Sequential,Author designed (Neutralization Assay),,Neutralization,Serum,,,Validated by developers,,1.0,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,,Pierre Gallian,Unite des Virus Emergents,Not Unity-Aligned,https://reader.elsevier.com/reader/sd/pii/S0166354220302941?token=72010A825B9F560E0F15AF8D56563D596F45421D41A05764732590DB465F0C2C839E77D689CCDEDEFB85BA331FE13C72,2020-08-01,2022-07-16,Verified,gallian_lower_2020,FRA
200715_France_UnitedesVirusEmergents_BloodDonors_Female,200715_France_UnitedesVirusEmergents,Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors,2020-07-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,998 samples collected from blood donors during the last week of March or the first week of April 2020,"As a rule that preexisted the COVID-19 outbreak, French volunteers can give blood only if they have no history of fever or
symptom of respiratory infection in the previous 2 weeks. In addition, those with confirmed or suspected COVID-19 were deferred 28 days after the end of symptoms. Accordingly, if it remains possible that some of the seropositive donors identified had been infected at the very beginning of virus spread in France, it is likely that a majority had undergone asymptomatic or pauci-symptomatic infection in March 2020.",2020-03-25,2020-04-07,Blood donors,Female,Adults (18-64 years),,,Sex/Gender,Female,489,0.0269,,,,,,,,Sequential,Author designed (Neutralization Assay),,Neutralization,Serum,,,Validated by developers,,1.0,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,,Pierre Gallian,Unite des Virus Emergents,Not Unity-Aligned,https://reader.elsevier.com/reader/sd/pii/S0166354220302941?token=72010A825B9F560E0F15AF8D56563D596F45421D41A05764732590DB465F0C2C839E77D689CCDEDEFB85BA331FE13C72,2020-08-01,2022-07-16,Verified,gallian_lower_2020,FRA
200715_France_UnitedesVirusEmergents_BloodDonors_Male,200715_France_UnitedesVirusEmergents,Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors,2020-07-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,998 samples collected from blood donors during the last week of March or the first week of April 2020,"As a rule that preexisted the COVID-19 outbreak, French volunteers can give blood only if they have no history of fever or
symptom of respiratory infection in the previous 2 weeks. In addition, those with confirmed or suspected COVID-19 were deferred 28 days after the end of symptoms. Accordingly, if it remains possible that some of the seropositive donors identified had been infected at the very beginning of virus spread in France, it is likely that a majority had undergone asymptomatic or pauci-symptomatic infection in March 2020.",2020-03-25,2020-04-07,Blood donors,Male,Adults (18-64 years),,,Sex/Gender,Male ,509,0.0282,,,,,,,,Sequential,Author designed (Neutralization Assay),,Neutralization,Serum,,,Validated by developers,,1.0,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,,Pierre Gallian,Unite des Virus Emergents,Not Unity-Aligned,https://reader.elsevier.com/reader/sd/pii/S0166354220302941?token=72010A825B9F560E0F15AF8D56563D596F45421D41A05764732590DB465F0C2C839E77D689CCDEDEFB85BA331FE13C72,2020-08-01,2022-07-16,Verified,gallian_lower_2020,FRA
200715_France_UnitedesVirusEmergents_BloodDonors_SeineSaintDenis,200715_France_UnitedesVirusEmergents,Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors,2020-07-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France, Île-de-France,,998 samples collected from blood donors during the last week of March or the first week of April 2020,"As a rule that preexisted the COVID-19 outbreak, French volunteers can give blood only if they have no history of fever or
symptom of respiratory infection in the previous 2 weeks. In addition, those with confirmed or suspected COVID-19 were deferred 28 days after the end of symptoms. Accordingly, if it remains possible that some of the seropositive donors identified had been infected at the very beginning of virus spread in France, it is likely that a majority had undergone asymptomatic or pauci-symptomatic infection in March 2020.",2020-03-25,2020-04-07,Blood donors,All,Adults (18-64 years),,,Geographical area,Seine Saint Denis,358,0.025099999999999997,,,,,,,,Sequential,Author designed (Neutralization Assay),,Neutralization,Serum,,,Validated by developers,,1.0,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,,Pierre Gallian,Unite des Virus Emergents,Not Unity-Aligned,https://reader.elsevier.com/reader/sd/pii/S0166354220302941?token=72010A825B9F560E0F15AF8D56563D596F45421D41A05764732590DB465F0C2C839E77D689CCDEDEFB85BA331FE13C72,2020-08-01,2022-07-16,Verified,gallian_lower_2020,FRA
200715_France_UnitedesVirusEmergents_BloodDonors_Oise,200715_France_UnitedesVirusEmergents,Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors,2020-07-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Hauts-de-France,,998 samples collected from blood donors during the last week of March or the first week of April 2020,"As a rule that preexisted the COVID-19 outbreak, French volunteers can give blood only if they have no history of fever or
symptom of respiratory infection in the previous 2 weeks. In addition, those with confirmed or suspected COVID-19 were deferred 28 days after the end of symptoms. Accordingly, if it remains possible that some of the seropositive donors identified had been infected at the very beginning of virus spread in France, it is likely that a majority had undergone asymptomatic or pauci-symptomatic infection in March 2020.",2020-03-25,2020-04-07,Blood donors,All,Adults (18-64 years),,,Geographical area,Oise,74,0.0405,,,,,,,,Sequential,Author designed (Neutralization Assay),,Neutralization,Serum,,,Validated by developers,,1.0,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,,Pierre Gallian,Unite des Virus Emergents,Not Unity-Aligned,https://reader.elsevier.com/reader/sd/pii/S0166354220302941?token=72010A825B9F560E0F15AF8D56563D596F45421D41A05764732590DB465F0C2C839E77D689CCDEDEFB85BA331FE13C72,2020-08-01,2022-07-16,Verified,gallian_lower_2020,FRA
200715_France_UnitedesVirusEmergents_BloodDonors_BouchesDuRhone,200715_France_UnitedesVirusEmergents,Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors,2020-07-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Provence-Alpes-Côte d'Azur ,,998 samples collected from blood donors during the last week of March or the first week of April 2020,"As a rule that preexisted the COVID-19 outbreak, French volunteers can give blood only if they have no history of fever or
symptom of respiratory infection in the previous 2 weeks. In addition, those with confirmed or suspected COVID-19 were deferred 28 days after the end of symptoms. Accordingly, if it remains possible that some of the seropositive donors identified had been infected at the very beginning of virus spread in France, it is likely that a majority had undergone asymptomatic or pauci-symptomatic infection in March 2020.",2020-03-25,2020-04-07,Blood donors,All,Adults (18-64 years),,,Geographical area,Bouches Du Rhone ,297,0.013500000000000002,,,,,,,,Sequential,Author designed (Neutralization Assay),,Neutralization,Serum,,,Validated by developers,,1.0,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,,Pierre Gallian,Unite des Virus Emergents,Not Unity-Aligned,https://reader.elsevier.com/reader/sd/pii/S0166354220302941?token=72010A825B9F560E0F15AF8D56563D596F45421D41A05764732590DB465F0C2C839E77D689CCDEDEFB85BA331FE13C72,2020-08-01,2022-07-16,Verified,gallian_lower_2020,FRA
200722_France_PicardieUniversity_IBDPatients_Overall,200722_France_PicardieUniversity,Seroconversion of immunoglobulins to SARS-CoV2 in patients with inflammatory bowel disease patients treated by biologics,2020-07-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Somme,Amiens,"Patients who received infliximab or vedolizumab for IBD at Amiens
University Center between March 25th and May 11",,2020-03-25,2020-05-11,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,17.0,81.0,Primary Estimate,,146,0.048,,,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,,,0.9740000000000001,0.985,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Yes,Mathurin Fumery,Picardie University,Not Unity-Aligned,https://dx.doi.org/10.1093/ecco-jcc/jjaa154,2020-08-02,2024-03-01,Verified,fumery_seroconversion_2020,FRA
200827_Paris_RothschildFoundationHospital_HealthcareProfessionals,200827_Paris_RothschildFoundationHospital,Seroprevalence of SARS-Cov-2 in 646 professionals at the Rothschild Foundation Hospital (ProSeCoV study),2020-08-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Paris,Paris,Health care professional at Rothschild Foundation Hospital,not Health care professional at Rothschild Foundation Hospital,2020-06-08,2020-06-22,Health care workers and caregivers,All,Adults (18-64 years),28.0,50.0,Primary Estimate,,646,0.12,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,ELISA,Plasma,IgG,,,0.995,0.998,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Malcie Mesnil,Rothschild Foundation Hospital,Not Unity-Aligned,http://dx.doi.org/10.1016/j.accpm.2020.08.003,2020-10-21,2024-03-01,Verified,mesnil_seroprevalence_2020,FRA
200902_Lille_InstitutPasteur_BloodDonors_ELISA-N,200902_Lille_InstitutPasteur,A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations,2020-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Hauts-de-France,"Clermont, Noyon, Lille","Included samples from blood donors from the Etablissement Français du Sang (EFS) in Lille (France). The blood samples were donated in two cities, Clermont (10,000 inhabitants) on March 20 and Noyon (13,000 inhabitants) on March 24.  Note: this is the inclusion criteria for blood donors since only blood donor samples are reported here. Other groups were studied in addition to blood donors but are excluded from our analysis. ",Recent signs of infection or antibiotic treatment. Note: this is the exclusion criteria for blood donors since only blood donor samples are reported here. Other groups were studied in addition to blood donors but are excluded from our analysis. ,2020-03-20,2020-03-24,Blood donors,All,Multiple groups,,,Primary Estimate,,200,0.0,,,True,,,,True,Sequential,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,"['IgA', 'IgD', 'IgE', 'IgG', 'IgM', 'TotalAntibody']",Nucleocapsid(N-protein),Validated by developers,,0.9500000000000001,['High'],No,No,No,No,Unclear,Unclear,Yes,No,Unclear,Ludivine Grzelak,Institut Pasteur,Not Unity-Aligned,https://stm.sciencemag.org/content/12/559/eabc3103,2020-04-28,2022-07-16,Verified,grzelak_comparison_2020,FRA
200902_Lille_InstitutPasteur_BloodDonors_LIPS,200902_Lille_InstitutPasteur,A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations,2020-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Lille,"Clermont, Noyon","Included samples from blood donors from the Etablissement Français du Sang (EFS) in Lille (France). The blood samples were donated in two cities, Clermont (10,000 inhabitants) on March 20 and Noyon (13,000 inhabitants) on March 24.  Note: this is the inclusion criteria for blood donors since only blood donor samples are reported here. Other groups were studied in addition to blood donors but are excluded from our analysis. ",Recent signs of infection or antibiotic treatment. Note: this is the exclusion criteria for blood donors since only blood donor samples are reported here. Other groups were studied in addition to blood donors but are excluded from our analysis. ,2020-03-20,2020-03-24,Blood donors,All,Multiple groups,,,Test used,LIPS,200,0.0,,,,,,,,Sequential,Author designed (CLIA),,Other,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,0.99,['High'],No,No,No,No,Unclear,Unclear,Yes,No,Unclear,Ludivine Grzelak,Institut Pasteur,Not Unity-Aligned,https://stm.sciencemag.org/content/12/559/eabc3103,2020-07-11,2022-07-16,Verified,grzelak_comparison_2020,FRA
200902_Lille_InstitutPasteur_BloodDonors_S-Flow,200902_Lille_InstitutPasteur,A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations,2020-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Lille,"Clermont, Noyon","Included samples from blood donors from the Etablissement Français du Sang (EFS) in Lille (France). The blood samples were donated in two cities, Clermont (10,000 inhabitants) on March 20 and Noyon (13,000 inhabitants) on March 24.  Note: this is the inclusion criteria for blood donors since only blood donor samples are reported here. Other groups were studied in addition to blood donors but are excluded from our analysis. ",Recent signs of infection or antibiotic treatment. Note: this is the exclusion criteria for blood donors since only blood donor samples are reported here. Other groups were studied in addition to blood donors but are excluded from our analysis. ,2020-03-20,2020-03-24,Blood donors,All,Multiple groups,,,Test used,S-Flow,200,0.03,,,,,,,,Sequential,Author designed (ELISA) - Nucleocapsid,,Other,Serum,IgG,Nucleocapsid(N-protein),Validated by developers,,0.99,['High'],No,No,No,No,Unclear,Unclear,Yes,No,Unclear,Ludivine Grzelak,Institut Pasteur,Not Unity-Aligned,https://stm.sciencemag.org/content/12/559/eabc3103,2020-07-11,2022-07-16,Verified,grzelak_comparison_2020,FRA
200902_Lille_InstitutPasteur_BloodDonors_ELISA-tri-S,200902_Lille_InstitutPasteur,A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations,2020-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Lille,"Clermont, Noyon","Included samples from blood donors from the Etablissement Français du Sang (EFS) in Lille (France). The blood samples were donated in two cities, Clermont (10,000 inhabitants) on March 20 and Noyon (13,000 inhabitants) on March 24.  Note: this is the inclusion criteria for blood donors since only blood donor samples are reported here. Other groups were studied in addition to blood donors but are excluded from our analysis. ",Recent signs of infection or antibiotic treatment. Note: this is the exclusion criteria for blood donors since only blood donor samples are reported here. Other groups were studied in addition to blood donors but are excluded from our analysis. ,2020-03-20,2020-03-24,Blood donors,All,Multiple groups,,,Test used,ELISA tri-S,16,0.125,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,,0.9500000000000001,['High'],No,No,No,No,Unclear,Unclear,Yes,No,Unclear,Ludivine Grzelak,Institut Pasteur,Not Unity-Aligned,https://stm.sciencemag.org/content/12/559/eabc3103,2020-07-23,2022-07-16,Verified,grzelak_comparison_2020,FRA
200903_Paris_HopitalEuropeenGeorgesPompidou_Overall,200903_Paris_HopitalEuropeenGeorgesPompidou,"Sequential SARS-CoV-2 IgG assays as confirmatory strategy to confirm equivocal results: Hospital-wide antibody screening in 3,569 staff health care workers in Paris.",2020-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France, Île-de-France,Paris,Staff within the department of occupational medicine ,,2020-05-02,2020-06-26,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,3569,0.11900000000000001,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Helene Pere,Hopital Europeen Georges Pompidou,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcv.2020.104617,2020-11-10,2024-03-01,Verified,pere_sequential_2020,FRA
201015_Paris_ParisSaclayUniversity_unadj,201015_Paris_ParisSaclayUniversity,"Post lockdown COVID-19 seroprevalence and circulation at the time of delivery, France",2020-10-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,France,Paris,Paris,maternity ward patients admitted to the delivery room of Antoine Beclère Hospital during study period,,2020-05-04,2020-05-31,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,249,0.08,,,True,,,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,No,No,No,No,Yes,Yes,Yes,Unclear,Jeremie Mattern,Paris Saclay University,Unity-Aligned,http://dx.doi.org/10.1371/journal.pone.0240782,2021-01-16,2024-03-01,Verified,mattern_post_2020,FRA
210101_Montpellier_UniversityHospitalMontpellier_HCW,210101_Montpellier_UniversityHospitalMontpellier,Increased risks of SARS-CoV-2 nosocomial acquisition in highrisk COVID-19 units justify personal protective equipment: a cross-sectional study,2020-10-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,,Montpellier,"healthcare workers and hospital personnel volunteers from highly, mildly and unexposed COVID-19 units who had physically been present during the lockdown. Highly exposed volunteers had worked in the medical, intensive care and screening COVID-19 units, mildly exposed in the non-COVID-19 medical units, and unexposed personnel from the administration or laboratories",,2020-04-21,2020-06-03,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,647,0.0201,0.009300000000000001,0.0309,True,,,,True,Unclear,Not reported/ Unable to specify,,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,Unclear,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Marie Bistoquet,University Hospital Montpellier,Not Unity-Aligned,https://www.journalofhospitalinfection.com/article/S0195-6701(20)30505-3/fulltext,2021-05-20,2022-07-16,Verified,bistoquetIncreasedRisksSARSCoV22021,FRA
201104_Paris_CochinAPHP_HCW,201104_Paris_CochinAPHP,"Clinical characteristics and persistence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) IgG antibodies in 4,607 French healthcare workers: Comparison with European countries.",2020-11-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Île-de-France,Paris,All HCWs in the hospital Cochin APHP,,2020-05-14,2020-06-17,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,4607,0.115,0.106,0.12400000000000001,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,,IgG,,,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Chantal Delmas,Cochin APHP,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2020.1309,2021-01-23,2024-03-01,Verified,delmas_clinical_2020,FRA
201105_Corsica_UniversitédeCorse_Totaladj,201105_Corsica_UniversitédeCorse,"Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020",2020-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,"Ajaccio
Corte",patients with a blood analysis conducted in one of the two participating laboratories,"The conditions of exclusion were the following: one or more samples from the same person (only one sample was included in
the study) and/or sample with missing information on age and/or sex and/or invalid serology result (insufficient serum volume or invalid result).",2020-04-16,2020-06-15,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Primary,1973,0.0546,0.0451,0.06570000000000001,True,,True,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8640000000000001,0.9620000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Lisandru Capai,Université de Corse,Unity-Aligned,https://www.mdpi.com/2077-0383/9/11/3569,2021-01-18,2024-03-01,Verified,capai_seroprevalence_2020,FRA
201105_Corsica_UniversitédeCorse_0-9_Unadj,201105_Corsica_UniversitédeCorse,"Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020",2020-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,"Ajaccio
Corte",patients with a blood analysis conducted in one of the two participating laboratories,"The conditions of exclusion were the following: one or more samples from the same person (only one sample was included in
the study) and/or sample with missing information on age and/or sex and/or invalid serology result (insufficient serum volume or invalid result).",2020-04-16,2020-06-15,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,0-9 years - unadjusted,40,0.025,0.00063,0.1316,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8640000000000001,0.9620000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Lisandru Capai,Université de Corse,Unity-Aligned,https://www.mdpi.com/2077-0383/9/11/3569,2021-01-18,2024-03-01,Verified,capai_seroprevalence_2020,FRA
201105_Corsica_UniversitédeCorse_10-19_Adj,201105_Corsica_UniversitédeCorse,"Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020",2020-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,"Ajaccio
Corte",patients with a blood analysis conducted in one of the two participating laboratories,"The conditions of exclusion were the following: one or more samples from the same person (only one sample was included in
the study) and/or sample with missing information on age and/or sex and/or invalid serology result (insufficient serum volume or invalid result).",2020-04-16,2020-06-15,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19 years - adjusted,153,0.10439999999999999,0.062000000000000006,0.1468,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8640000000000001,0.9620000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Lisandru Capai,Université de Corse,Unity-Aligned,https://www.mdpi.com/2077-0383/9/11/3569,2021-01-18,2024-03-01,Verified,capai_seroprevalence_2020,FRA
201105_Corsica_UniversitédeCorse_90andolder_Adj,201105_Corsica_UniversitédeCorse,"Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020",2020-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,"Ajaccio
Corte",patients with a blood analysis conducted in one of the two participating laboratories,"The conditions of exclusion were the following: one or more samples from the same person (only one sample was included in
the study) and/or sample with missing information on age and/or sex and/or invalid serology result (insufficient serum volume or invalid result).",2020-04-16,2020-06-15,Residual sera,All,Seniors (65+ years),90.0,,Age,90 years and older - adjusted,89,0.0562,0.0,0.1421,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8640000000000001,0.9620000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Lisandru Capai,Université de Corse,Unity-Aligned,https://www.mdpi.com/2077-0383/9/11/3569,2021-01-18,2024-03-01,Verified,capai_seroprevalence_2020,FRA
201105_Corsica_UniversitédeCorse_Totalunadj,201105_Corsica_UniversitédeCorse,"Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020",2020-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,"Ajaccio
Corte",patients with a blood analysis conducted in one of the two participating laboratories,"The conditions of exclusion were the following: one or more samples from the same person (only one sample was included in
the study) and/or sample with missing information on age and/or sex and/or invalid serology result (insufficient serum volume or invalid result).",2020-04-16,2020-06-15,Residual sera,All,Multiple groups,0.0,,Analysis,Total participants - unadjusted,1973,0.0527,0.0433,0.0635,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8640000000000001,0.9620000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Lisandru Capai,Université de Corse,Unity-Aligned,https://www.mdpi.com/2077-0383/9/11/3569,2021-01-18,2024-03-01,Verified,capai_seroprevalence_2020,FRA
201105_Corsica_UniversitédeCorse_20-29_Adj,201105_Corsica_UniversitédeCorse,"Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020",2020-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,"Ajaccio
Corte",patients with a blood analysis conducted in one of the two participating laboratories,"The conditions of exclusion were the following: one or more samples from the same person (only one sample was included in
the study) and/or sample with missing information on age and/or sex and/or invalid serology result (insufficient serum volume or invalid result).",2020-04-16,2020-06-15,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29 years - adjusted,197,0.0351,0.009000000000000001,0.061,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8640000000000001,0.9620000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Lisandru Capai,Université de Corse,Unity-Aligned,https://www.mdpi.com/2077-0383/9/11/3569,2021-01-18,2024-03-01,Verified,capai_seroprevalence_2020,FRA
201105_Corsica_UniversitédeCorse_Female_Adj,201105_Corsica_UniversitédeCorse,"Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020",2020-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,"Ajaccio
Corte",patients with a blood analysis conducted in one of the two participating laboratories,"The conditions of exclusion were the following: one or more samples from the same person (only one sample was included in
the study) and/or sample with missing information on age and/or sex and/or invalid serology result (insufficient serum volume or invalid result).",2020-04-16,2020-06-15,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,Females - adjusted,1187,0.05740000000000001,0.0431,0.0717,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8640000000000001,0.9620000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Lisandru Capai,Université de Corse,Unity-Aligned,https://www.mdpi.com/2077-0383/9/11/3569,2021-01-18,2024-03-01,Verified,capai_seroprevalence_2020,FRA
201105_Corsica_UniversitédeCorse_40-49_Adj ,201105_Corsica_UniversitédeCorse,"Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020",2020-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,"Ajaccio
Corte",patients with a blood analysis conducted in one of the two participating laboratories,"The conditions of exclusion were the following: one or more samples from the same person (only one sample was included in
the study) and/or sample with missing information on age and/or sex and/or invalid serology result (insufficient serum volume or invalid result).",2020-04-16,2020-06-15,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49 years - adjusted,269,0.1048,0.0674,0.1421,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8640000000000001,0.9620000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Lisandru Capai,Université de Corse,Unity-Aligned,https://www.mdpi.com/2077-0383/9/11/3569,2021-01-18,2024-03-01,Verified,capai_seroprevalence_2020,FRA
201105_Corsica_UniversitédeCorse_Male_Unadj,201105_Corsica_UniversitédeCorse,"Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020",2020-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,"Ajaccio
Corte",patients with a blood analysis conducted in one of the two participating laboratories,"The conditions of exclusion were the following: one or more samples from the same person (only one sample was included in
the study) and/or sample with missing information on age and/or sex and/or invalid serology result (insufficient serum volume or invalid result).",2020-04-16,2020-06-15,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,Males - adjusted,786,0.0483,0.0344,0.0658,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8640000000000001,0.9620000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Lisandru Capai,Université de Corse,Unity-Aligned,https://www.mdpi.com/2077-0383/9/11/3569,2021-01-18,2024-03-01,Verified,capai_seroprevalence_2020,FRA
201105_Corsica_UniversitédeCorse_40-49_Unadj ,201105_Corsica_UniversitédeCorse,"Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020",2020-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,"Ajaccio
Corte",patients with a blood analysis conducted in one of the two participating laboratories,"The conditions of exclusion were the following: one or more samples from the same person (only one sample was included in
the study) and/or sample with missing information on age and/or sex and/or invalid serology result (insufficient serum volume or invalid result).",2020-04-16,2020-06-15,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49 years - unadjusted,269,0.1041,0.0703,0.1469,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8640000000000001,0.9620000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Lisandru Capai,Université de Corse,Unity-Aligned,https://www.mdpi.com/2077-0383/9/11/3569,2021-01-18,2024-03-01,Verified,capai_seroprevalence_2020,FRA
201105_Corsica_UniversitédeCorse_70-79_Adj ,201105_Corsica_UniversitédeCorse,"Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020",2020-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,"Ajaccio
Corte",patients with a blood analysis conducted in one of the two participating laboratories,"The conditions of exclusion were the following: one or more samples from the same person (only one sample was included in
the study) and/or sample with missing information on age and/or sex and/or invalid serology result (insufficient serum volume or invalid result).",2020-04-16,2020-06-15,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79 years - adjusted,237,0.0378,0.012,0.0636,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8640000000000001,0.9620000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Lisandru Capai,Université de Corse,Unity-Aligned,https://www.mdpi.com/2077-0383/9/11/3569,2021-01-18,2024-03-01,Verified,capai_seroprevalence_2020,FRA
201105_Corsica_UniversitédeCorse_80-89_Adj ,201105_Corsica_UniversitédeCorse,"Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020",2020-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,"Ajaccio
Corte",patients with a blood analysis conducted in one of the two participating laboratories,"The conditions of exclusion were the following: one or more samples from the same person (only one sample was included in
the study) and/or sample with missing information on age and/or sex and/or invalid serology result (insufficient serum volume or invalid result).",2020-04-16,2020-06-15,Residual sera,All,Seniors (65+ years),80.0,89.0,Age,80-89 years - adjusted,184,0.0252,0.0,0.0542,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8640000000000001,0.9620000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Lisandru Capai,Université de Corse,Unity-Aligned,https://www.mdpi.com/2077-0383/9/11/3569,2021-01-18,2024-03-01,Verified,capai_seroprevalence_2020,FRA
201105_Corsica_UniversitédeCorse_Female_Unadj,201105_Corsica_UniversitédeCorse,"Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020",2020-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,"Ajaccio
Corte",patients with a blood analysis conducted in one of the two participating laboratories,"The conditions of exclusion were the following: one or more samples from the same person (only one sample was included in
the study) and/or sample with missing information on age and/or sex and/or invalid serology result (insufficient serum volume or invalid result).",2020-04-16,2020-06-15,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,Females - unadjusted,1187,0.0556,0.0433,0.0702,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8640000000000001,0.9620000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Lisandru Capai,Université de Corse,Unity-Aligned,https://www.mdpi.com/2077-0383/9/11/3569,2021-01-18,2024-03-01,Verified,capai_seroprevalence_2020,FRA
201105_Corsica_UniversitédeCorse_30-39_Unadj,201105_Corsica_UniversitédeCorse,"Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020",2020-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,"Ajaccio
Corte",patients with a blood analysis conducted in one of the two participating laboratories,"The conditions of exclusion were the following: one or more samples from the same person (only one sample was included in
the study) and/or sample with missing information on age and/or sex and/or invalid serology result (insufficient serum volume or invalid result).",2020-04-16,2020-06-15,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39 years - unadjusted,235,0.0851,0.0527,0.12840000000000001,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8640000000000001,0.9620000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Lisandru Capai,Université de Corse,Unity-Aligned,https://www.mdpi.com/2077-0383/9/11/3569,2021-01-18,2024-03-01,Verified,capai_seroprevalence_2020,FRA
201105_Corsica_UniversitédeCorse_80-89_Unadj,201105_Corsica_UniversitédeCorse,"Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020",2020-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,"Ajaccio
Corte",patients with a blood analysis conducted in one of the two participating laboratories,"The conditions of exclusion were the following: one or more samples from the same person (only one sample was included in
the study) and/or sample with missing information on age and/or sex and/or invalid serology result (insufficient serum volume or invalid result).",2020-04-16,2020-06-15,Residual sera,All,Seniors (65+ years),80.0,89.0,Age,80-89 years - unadjusted,184,0.027200000000000002,0.0089,0.06230000000000001,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8640000000000001,0.9620000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Lisandru Capai,Université de Corse,Unity-Aligned,https://www.mdpi.com/2077-0383/9/11/3569,2021-01-18,2024-03-01,Verified,capai_seroprevalence_2020,FRA
201105_Corsica_UniversitédeCorse_30-39_Adj ,201105_Corsica_UniversitédeCorse,"Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020",2020-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,"Ajaccio
Corte",patients with a blood analysis conducted in one of the two participating laboratories,"The conditions of exclusion were the following: one or more samples from the same person (only one sample was included in
the study) and/or sample with missing information on age and/or sex and/or invalid serology result (insufficient serum volume or invalid result).",2020-04-16,2020-06-15,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39 years - adjusted,235,0.0888,0.0535,0.12400000000000001,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8640000000000001,0.9620000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Lisandru Capai,Université de Corse,Unity-Aligned,https://www.mdpi.com/2077-0383/9/11/3569,2021-01-18,2024-03-01,Verified,capai_seroprevalence_2020,FRA
201105_Corsica_UniversitédeCorse_90andolder_Unadj ,201105_Corsica_UniversitédeCorse,"Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020",2020-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,"Ajaccio
Corte",patients with a blood analysis conducted in one of the two participating laboratories,"The conditions of exclusion were the following: one or more samples from the same person (only one sample was included in
the study) and/or sample with missing information on age and/or sex and/or invalid serology result (insufficient serum volume or invalid result).",2020-04-16,2020-06-15,Residual sera,All,Seniors (65+ years),90.0,,Age,90 years and older - unadjusted,89,0.0562,0.018500000000000003,0.1262,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8640000000000001,0.9620000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Lisandru Capai,Université de Corse,Unity-Aligned,https://www.mdpi.com/2077-0383/9/11/3569,2021-01-18,2024-03-01,Verified,capai_seroprevalence_2020,FRA
201105_Corsica_UniversitédeCorse_Male_Adj ,201105_Corsica_UniversitédeCorse,"Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020",2020-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,"Ajaccio
Corte",patients with a blood analysis conducted in one of the two participating laboratories,"The conditions of exclusion were the following: one or more samples from the same person (only one sample was included in
the study) and/or sample with missing information on age and/or sex and/or invalid serology result (insufficient serum volume or invalid result).",2020-04-16,2020-06-15,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,Males - adjusted,786,0.051500000000000004,0.0375,0.06559999999999999,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8640000000000001,0.9620000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Lisandru Capai,Université de Corse,Unity-Aligned,https://www.mdpi.com/2077-0383/9/11/3569,2021-01-18,2024-03-01,Verified,capai_seroprevalence_2020,FRA
201105_Corsica_UniversitédeCorse_60-69_Adj ,201105_Corsica_UniversitédeCorse,"Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020",2020-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,"Ajaccio
Corte",patients with a blood analysis conducted in one of the two participating laboratories,"The conditions of exclusion were the following: one or more samples from the same person (only one sample was included in
the study) and/or sample with missing information on age and/or sex and/or invalid serology result (insufficient serum volume or invalid result).",2020-04-16,2020-06-15,Residual sera,All,Adults (18-64 years),60.0,69.0,Age,60-69 years - adjusted,273,0.0147,0.0,0.0294,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8640000000000001,0.9620000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Lisandru Capai,Université de Corse,Unity-Aligned,https://www.mdpi.com/2077-0383/9/11/3569,2021-01-18,2024-03-01,Verified,capai_seroprevalence_2020,FRA
201105_Corsica_UniversitédeCorse_10-19_Unadj,201105_Corsica_UniversitédeCorse,"Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020",2020-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,"Ajaccio
Corte",patients with a blood analysis conducted in one of the two participating laboratories,"The conditions of exclusion were the following: one or more samples from the same person (only one sample was included in
the study) and/or sample with missing information on age and/or sex and/or invalid serology result (insufficient serum volume or invalid result).",2020-04-16,2020-06-15,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19 years - unadjusted,153,0.098,0.0559,0.1565,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8640000000000001,0.9620000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Lisandru Capai,Université de Corse,Unity-Aligned,https://www.mdpi.com/2077-0383/9/11/3569,2021-01-18,2024-03-01,Verified,capai_seroprevalence_2020,FRA
201105_Corsica_UniversitédeCorse_0-9_Adj,201105_Corsica_UniversitédeCorse,"Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020",2020-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,"Ajaccio
Corte",patients with a blood analysis conducted in one of the two participating laboratories,"The conditions of exclusion were the following: one or more samples from the same person (only one sample was included in
the study) and/or sample with missing information on age and/or sex and/or invalid serology result (insufficient serum volume or invalid result).",2020-04-16,2020-06-15,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,0-9 years - adjusted,40,0.0322,0.0073,0.0571,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8640000000000001,0.9620000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Lisandru Capai,Université de Corse,Unity-Aligned,https://www.mdpi.com/2077-0383/9/11/3569,2021-01-18,2024-03-01,Verified,capai_seroprevalence_2020,FRA
201105_Corsica_UniversitédeCorse_50-59_Unadj,201105_Corsica_UniversitédeCorse,"Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020",2020-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,"Ajaccio
Corte",patients with a blood analysis conducted in one of the two participating laboratories,"The conditions of exclusion were the following: one or more samples from the same person (only one sample was included in
the study) and/or sample with missing information on age and/or sex and/or invalid serology result (insufficient serum volume or invalid result).",2020-04-16,2020-06-15,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59 years - unadjusted,296,0.0338,0.0163,0.061200000000000004,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8640000000000001,0.9620000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Lisandru Capai,Université de Corse,Unity-Aligned,https://www.mdpi.com/2077-0383/9/11/3569,2021-01-18,2024-03-01,Verified,capai_seroprevalence_2020,FRA
201105_Corsica_UniversitédeCorse_20-29_Unadj,201105_Corsica_UniversitédeCorse,"Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020",2020-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,"Ajaccio
Corte",patients with a blood analysis conducted in one of the two participating laboratories,"The conditions of exclusion were the following: one or more samples from the same person (only one sample was included in
the study) and/or sample with missing information on age and/or sex and/or invalid serology result (insufficient serum volume or invalid result).",2020-04-16,2020-06-15,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29 years - unadjusted,197,0.0355,0.0144,0.0718,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8640000000000001,0.9620000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Lisandru Capai,Université de Corse,Unity-Aligned,https://www.mdpi.com/2077-0383/9/11/3569,2021-01-18,2024-03-01,Verified,capai_seroprevalence_2020,FRA
201105_Corsica_UniversitédeCorse_70-79_Unadj,201105_Corsica_UniversitédeCorse,"Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020",2020-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,"Ajaccio
Corte",patients with a blood analysis conducted in one of the two participating laboratories,"The conditions of exclusion were the following: one or more samples from the same person (only one sample was included in
the study) and/or sample with missing information on age and/or sex and/or invalid serology result (insufficient serum volume or invalid result).",2020-04-16,2020-06-15,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79 years - unadjusted,237,0.038,0.0175,0.0709,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8640000000000001,0.9620000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Lisandru Capai,Université de Corse,Unity-Aligned,https://www.mdpi.com/2077-0383/9/11/3569,2021-01-18,2024-03-01,Verified,capai_seroprevalence_2020,FRA
201105_Corsica_UniversitédeCorse_60-69_Unadj,201105_Corsica_UniversitédeCorse,"Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020",2020-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,"Ajaccio
Corte",patients with a blood analysis conducted in one of the two participating laboratories,"The conditions of exclusion were the following: one or more samples from the same person (only one sample was included in
the study) and/or sample with missing information on age and/or sex and/or invalid serology result (insufficient serum volume or invalid result).",2020-04-16,2020-06-15,Residual sera,All,Adults (18-64 years),60.0,69.0,Age,60-69 years - unadjusted,273,0.0147,0.004,0.0371,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8640000000000001,0.9620000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Lisandru Capai,Université de Corse,Unity-Aligned,https://www.mdpi.com/2077-0383/9/11/3569,2021-01-18,2024-03-01,Verified,capai_seroprevalence_2020,FRA
201105_Corsica_UniversitédeCorse_50-59_Adj,201105_Corsica_UniversitédeCorse,"Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020",2020-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,"Ajaccio
Corte",patients with a blood analysis conducted in one of the two participating laboratories,"The conditions of exclusion were the following: one or more samples from the same person (only one sample was included in
the study) and/or sample with missing information on age and/or sex and/or invalid serology result (insufficient serum volume or invalid result).",2020-04-16,2020-06-15,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59 years - adjusted,296,0.0313,0.010700000000000001,0.0519,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8640000000000001,0.9620000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Lisandru Capai,Université de Corse,Unity-Aligned,https://www.mdpi.com/2077-0383/9/11/3569,2021-01-18,2024-03-01,Verified,capai_seroprevalence_2020,FRA
201106_Lyon_UniversitéClaudeBernardLyon_Overall,201106_Lyon_UniversitéClaudeBernardLyon,Clinical and microbiological assessments of COVID-19 in healthcare workers: a prospective longitudinal study,2020-11-06,Preprint,Local,Cross-sectional survey ,France,Auvergne-Rhône-Alpes,Lyon,"A prospective longitudinal cohort study was conducted at the university hospital of Lyon, France (Hospices Civils de Lyon, HCL) [28] in HCWs with symptoms suggesting a SARS-CoV-2 infection.","HCWs with a previous positive SARS-CoV-2 RT-PCR test were excluded. (But note this study was conducted in HCWs with symptoms suggesting a SARS-CoV-2 infection, and serology testing was conducted in those with a negative RT-PCR test at inclusion).",2020-04-10,2020-05-28,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Primary Estimate,190,0.0368,,,True,,,,True,Unclear,"VIDAS Multiparametric immunoassay system for medium throughput,Wantai SARS-CoV-2 Total Ab ELISA","Biomerieux,Beijing Wantai Biological",Multiple Types,Serum,"['IgG', 'TotalAntibody']",,,,,['High'],No,Unclear,No,No,Unclear,Yes,Yes,No,Unclear,Antonin Bal,Université Claude Bernard Lyon,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.11.04.20225862v1,2021-01-17,2024-03-01,Verified,bal_clinical_2020,FRA
201119_Paris_CentreHospitalierIntercommunalDeCréteil_Children,201119_Paris_CentreHospitalierIntercommunalDeCréteil,Assessment of SARS-CoV-2 infection by Reverse transcription-PCR and serology in the Paris area: A cross-sectional study,2020-11-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Île-de-France,Paris,"enrol children from birth to 15 years old who were consulting an ambulatory paediatrician and distributed in two groups: asymptomatic and pauci-symptomatic. Asymptomatic children were defined as children without any symptoms or signs suggesting infectious disease during the previous 7 days. They usually came for vaccination visits. In this group, we defined two subgroups of children: those previously symptomatic (fever, respiratory or digestive symptoms) between 7 days and 2 months before enrolment, and those without any previous symptoms. Pauci-symptomatic children were defined as those with fever isolated or associated with respi- ratory signs, such as cough, dysphagia, rhinorrhoea, diarrhoea, vomiting, cutaneous signs, taste loss and/ or anosmia during the previous 7 days",Children were excluded if the clinical condition at enrolment required transfer to a paediatric emergency unit or hospitalisation.,2020-04-14,2020-05-12,Residual sera,All,Children and Youth (0-17 years),0.0,15.0,Primary Estimate,Children seeking paediatric care,605,0.107,0.084,0.135,True,,,,True,Sequential,Biosynex COVID-19 BSS assay,Biosynex,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.918,0.9920000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Robert Cohen,Centre Hospitalier Intercommunal de Créteil,Unity-Aligned,http://dx.doi.org/10.1136/bmjpo-2020-000887,2021-02-28,2024-03-01,Verified,cohen_assessment_2020,FRA
201130_Strasbourg_StrasbourgUniversityHospital_Abbott,201130_Strasbourg_StrasbourgUniversityHospital,"Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France",2020-11-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Grand-Est ,Strasbourg,Individuals in acouple relationship with a COVID-19 index case. ,,2020-05-07,2020-06-26,Contacts of COVID patients,All,Adults (18-64 years),38.0,65.0,Primary Estimate,Abbott test,11,0.0,,,True,,,,True,Unclear,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,1.0,['High'],No,Unclear,No,Yes,Yes,Yes,Yes,Yes,Unclear,Floriane Gallais,Strasbourg University Hospital,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2701.203611,2021-01-23,2024-03-01,Verified,gallais_intrafamilial_2020-1,FRA
201210_ Paris_UniversitéParis-Saclay,201210_Paris_UniversitéParis-Saclay,SARS-COV-2 IgG antibody response in pregnant women at delivery,2020-12-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Île-de-France,Paris ,"One perinatal center of Paris area, Cochin Hospital (Port-Royal
Maternity, Paris, France) was considered for this preliminary
analysis. Pregnant women were prospectively included in the
study at the time of delivery between April 29, 2020 and June 26,
2020. All patients admitted to the delivery ward after 15 weeks of
gestation (WG) were offered the possibility to participate to the
study independently of the gestational age and pregnancy
complications. Patients were not referred to our center specifically
for COVID-19.","Exclusion criteria were age<18 years, refusal to participate to
the study, patient unable to read or understand the study
documents.",2020-04-29,2020-06-26,Pregnant or parturient women,Female,Adults (18-64 years),18.0,,Primary Estimate,,529,0.047,0.03,0.067,True,,,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Multiple Types,IgG,,Validated by independent authors/third party/non-developers,0.927,0.99,['High'],Yes,No,No,No,Yes,Yes,Yes,Yes,Unclear,Vassilis Tsatsarisa,Université Paris-Saclay,Unity-Aligned,https://dx.doi.org/10.1016/j.jogoh.2020.102041,2021-01-23,2024-03-01,Verified,tsatsaris_sars-cov-2_2020,FRA
201210_ Paris_UniversitéParis-Saclay_AgeOver35,201210_Paris_UniversitéParis-Saclay,SARS-COV-2 IgG antibody response in pregnant women at delivery,2020-12-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Île-de-France,Paris ,"One perinatal center of Paris area, Cochin Hospital (Port-Royal
Maternity, Paris, France) was considered for this preliminary
analysis. Pregnant women were prospectively included in the
study at the time of delivery between April 29, 2020 and June 26,
2020. All patients admitted to the delivery ward after 15 weeks of
gestation (WG) were offered the possibility to participate to the
study independently of the gestational age and pregnancy
complications. Patients were not referred to our center specifically
for COVID-19.","Exclusion criteria were age<18 years, refusal to participate to
the study, patient unable to read or understand the study
documents.",2020-04-29,2020-06-26,Pregnant or parturient women,Female,Adults (18-64 years),18.0,,Age,>=35,205,0.049,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Multiple Types,IgG,,Validated by independent authors/third party/non-developers,0.927,0.99,['High'],Yes,No,No,No,Yes,Yes,Yes,Yes,Unclear,Vassilis Tsatsarisa,Université Paris-Saclay,Unity-Aligned,https://dx.doi.org/10.1016/j.jogoh.2020.102041,2021-08-12,2024-03-01,Verified,tsatsaris_sars-cov-2_2020,FRA
201210_ Paris_UniversitéParis-Saclay_AgeBelow35,201210_Paris_UniversitéParis-Saclay,SARS-COV-2 IgG antibody response in pregnant women at delivery,2020-12-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Île-de-France,Paris ,"One perinatal center of Paris area, Cochin Hospital (Port-Royal
Maternity, Paris, France) was considered for this preliminary
analysis. Pregnant women were prospectively included in the
study at the time of delivery between April 29, 2020 and June 26,
2020. All patients admitted to the delivery ward after 15 weeks of
gestation (WG) were offered the possibility to participate to the
study independently of the gestational age and pregnancy
complications. Patients were not referred to our center specifically
for COVID-19.","Exclusion criteria were age<18 years, refusal to participate to
the study, patient unable to read or understand the study
documents.",2020-04-29,2020-06-26,Pregnant or parturient women,Female,Adults (18-64 years),18.0,,Age,<35,324,0.046,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Multiple Types,IgG,,Validated by independent authors/third party/non-developers,0.927,0.99,['High'],Yes,No,No,No,Yes,Yes,Yes,Yes,Unclear,Vassilis Tsatsarisa,Université Paris-Saclay,Unity-Aligned,https://dx.doi.org/10.1016/j.jogoh.2020.102041,2021-08-12,2024-03-01,Verified,tsatsaris_sars-cov-2_2020,FRA
201223_Paris_InstitutCurie_overall,201223_Paris_InstitutCurie,High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris,2020-12-23,Journal Article (Peer-Reviewed),Local,Prospective cohort,France, Île-de-France,Paris,"18 years of age or older volunteer participant outside of any SARS-CoV-2 acute infectious episode in the last 7 days, working at one of the three Institut Curie locations (Paris, Orsay, or Saint-Cloud) ",,2020-04-28,2020-07-31,Health care workers and caregivers,All,Multiple groups,19.0,75.0,Primary Estimate,,1847,0.11599999999999999,0.102,0.132,True,,,,True,Convenience,"Author designed (Neutralization Assay),Author designed (ELISA) - MULTIPLEXED",,Multiple Types,Serum,"['IgG', 'Neutralizing', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,0.99,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Francois Anna, Institut Curie,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/epdf/10.1002/eji.202049058,2021-03-19,2022-07-16,Verified,anna_high_2020-1,FRA
210118_France_SorbonneUniversité_primary,210118_France_SorbonneUniversité,Do not neglect SARS-CoV-2 hospitalization and fatality risks in the middle-aged adult population,2021-01-18,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,Île-de-France and Grand Est ,,Data from a seroprevalence study performed in May-June 2020 in 20-to 90-year old subjects were used. This study included sub- jects from three pre-existing general adult population cohorts from Île-de-France (N = 6348) and Grand Est (N = 3434),,2020-05-15,2020-06-15,Household and community samples,All,Multiple groups,20.0,90.0,Primary Estimate,,9782,0.0346,,,True,,,,True,Simplified probability,"Anti-SARS-CoV-2 NCP ELISA (IgG),Anti-SARS-CoV-2 ELISA IgG,Author designed (Neutralization Assay)","EUROIMMUN,NA",Multiple Types,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,No,Unclear,Nathanael Lapidus,Sorbonne Université,Not Unity-Aligned,https://dx.doi.org/10.1016/j.idnow.2020.12.007,2021-02-26,2024-03-01,Verified,lapidus_not_2021,FRA
210127_Nice_UniversitéCôted'Azur,210127_Nice_UniversitéCôted'Azur,"Humoral and Cellular Response of Frontline Health Care Workers Infected by SARS-CoV-2 in Nice, France: A Prospective Single-Center Cohort Study",2021-01-27,Journal Article (Peer-Reviewed),Local,Prospective cohort,France,Provence-Alpes-Côte d'Azur,Nice,"For this, we included volunteer frontline health care workers (HCWs) defined as those working in units providing care for patients with confirmed COVID-19, in Nice University Hospital from April 15 to May 26, 2020.",Exclusion criteria were: (1) pregnancy or breastfeeding; (2) HCWs having received previous immunosuppressive therapy for COVID-19 treatment,2020-04-15,2020-05-26,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,196,0.15,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA",EUROIMMUN,ELISA,Serum,"['IgA', 'IgG']",Spike,Validated by independent authors/third party/non-developers,1.0,,['High'],No,No,No,No,No,Yes,Yes,No,Unclear,Marion Cremoni,Université Côte d'Azur,Not Unity-Aligned,https://dx.doi.org/10.3389/fmed.2020.608804,2021-03-27,2024-03-01,Verified,cremoni_humoral_2021,FRA
210205_IledeFrance_Epicentre_Shelters,210205_IledeFrance_Epicentre,"Seroprevalence and risk factors of exposure to COVID-19 in homeless people in Paris, France: a cross-sectional study",2021-02-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Ile de France,Paris,"Individuals at food distribution sites, emergency shelters and workers residences supported by MSF in Paris and Seine-Saint-Denis",People younger than age 18 years or unwilling or unable to consent to the study were excluded from participation.,2020-06-23,2020-07-02,Persons experiencing homelessness,All,Multiple groups,18.0,,Primary Estimate,Seropositive by any of three tests,818,0.52,,,True,,,,True,Convenience,"Author designed (Neutralization Assay),Author designed (ELISA) - MULTIPLEXED",,Multiple Types,,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Thomas Roederer,Médecins sans Frontières (Epicentre) ,Not Unity-Aligned,https://www.thelancet.com/action/showPdf?pii=S2468-2667%2821%2900001-3,2021-01-23,2022-07-16,Verified,roederer_seroprevalence_2021,FRA
210205_IledeFrance_Epicentre_Shelters_45-54,210205_IledeFrance_Epicentre,"Seroprevalence and risk factors of exposure to COVID-19 in homeless people in Paris, France: a cross-sectional study",2021-02-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Ile de France,Paris,"Individuals at food distribution sites, emergency shelters and workers residences supported by MSF in Paris and Seine-Saint-Denis",People younger than age 18 years or unwilling or unable to consent to the study were excluded from participation.,2020-06-23,2020-07-02,Persons experiencing homelessness,All,Adults (18-64 years),45.0,54.0,Age,,116,0.474,0.381,0.569,,,,,,Convenience,"Author designed (Neutralization Assay),Author designed (ELISA) - MULTIPLEXED",,Multiple Types,,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Thomas Roederer,Médecins sans Frontières (Epicentre) ,Not Unity-Aligned,https://www.thelancet.com/action/showPdf?pii=S2468-2667%2821%2900001-3,2021-03-27,2022-07-16,Verified,roederer_seroprevalence_2021,FRA
210205_IledeFrance_Epicentre_Shelters_18-24,210205_IledeFrance_Epicentre,"Seroprevalence and risk factors of exposure to COVID-19 in homeless people in Paris, France: a cross-sectional study",2021-02-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Ile de France,Paris,"Individuals at food distribution sites, emergency shelters and workers residences supported by MSF in Paris and Seine-Saint-Denis",People younger than age 18 years or unwilling or unable to consent to the study were excluded from participation.,2020-06-23,2020-07-02,Persons experiencing homelessness,All,Adults (18-64 years),18.0,24.0,Age,,103,0.544,0.443,0.642,,,,,,Convenience,"Author designed (Neutralization Assay),Author designed (ELISA) - MULTIPLEXED",,Multiple Types,,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Thomas Roederer,Médecins sans Frontières (Epicentre) ,Not Unity-Aligned,https://www.thelancet.com/action/showPdf?pii=S2468-2667%2821%2900001-3,2021-03-27,2022-07-16,Verified,roederer_seroprevalence_2021,FRA
210205_IledeFrance_Epicentre_Shelters_55-64,210205_IledeFrance_Epicentre,"Seroprevalence and risk factors of exposure to COVID-19 in homeless people in Paris, France: a cross-sectional study",2021-02-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Ile de France,Paris,"Individuals at food distribution sites, emergency shelters and workers residences supported by MSF in Paris and Seine-Saint-Denis",People younger than age 18 years or unwilling or unable to consent to the study were excluded from participation.,2020-06-23,2020-07-02,Persons experiencing homelessness,All,Adults (18-64 years),55.0,64.0,Age,,100,0.51,0.408,0.611,,,,,,Convenience,"Author designed (Neutralization Assay),Author designed (ELISA) - MULTIPLEXED",,Multiple Types,,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Thomas Roederer,Médecins sans Frontières (Epicentre) ,Not Unity-Aligned,https://www.thelancet.com/action/showPdf?pii=S2468-2667%2821%2900001-3,2021-03-27,2022-07-16,Verified,roederer_seroprevalence_2021,FRA
210205_IledeFrance_Epicentre_Shelters_25-34,210205_IledeFrance_Epicentre,"Seroprevalence and risk factors of exposure to COVID-19 in homeless people in Paris, France: a cross-sectional study",2021-02-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Ile de France,Paris,"Individuals at food distribution sites, emergency shelters and workers residences supported by MSF in Paris and Seine-Saint-Denis",People younger than age 18 years or unwilling or unable to consent to the study were excluded from participation.,2020-06-23,2020-07-02,Persons experiencing homelessness,All,Adults (18-64 years),25.0,34.0,Age,,298,0.5770000000000001,0.519,0.634,,,,,,Convenience,"Author designed (Neutralization Assay),Author designed (ELISA) - MULTIPLEXED",,Multiple Types,,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Thomas Roederer,Médecins sans Frontières (Epicentre) ,Not Unity-Aligned,https://www.thelancet.com/action/showPdf?pii=S2468-2667%2821%2900001-3,2021-03-27,2022-07-16,Verified,roederer_seroprevalence_2021,FRA
210205_IledeFrance_Epicentre_Shelters_35-44,210205_IledeFrance_Epicentre,"Seroprevalence and risk factors of exposure to COVID-19 in homeless people in Paris, France: a cross-sectional study",2021-02-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Ile de France,Paris,"Individuals at food distribution sites, emergency shelters and workers residences supported by MSF in Paris and Seine-Saint-Denis",People younger than age 18 years or unwilling or unable to consent to the study were excluded from participation.,2020-06-23,2020-07-02,Persons experiencing homelessness,All,Adults (18-64 years),35.0,44.0,Age,,140,0.46399999999999997,0.38,0.55,,,,,,Convenience,"Author designed (Neutralization Assay),Author designed (ELISA) - MULTIPLEXED",,Multiple Types,,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Thomas Roederer,Médecins sans Frontières (Epicentre) ,Not Unity-Aligned,https://www.thelancet.com/action/showPdf?pii=S2468-2667%2821%2900001-3,2021-03-27,2022-07-16,Verified,roederer_seroprevalence_2021,FRA
210205_IledeFrance_Epicentre_Shelters>=65,210205_IledeFrance_Epicentre,"Seroprevalence and risk factors of exposure to COVID-19 in homeless people in Paris, France: a cross-sectional study",2021-02-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Ile de France,Paris,"Individuals at food distribution sites, emergency shelters and workers residences supported by MSF in Paris and Seine-Saint-Denis",People younger than age 18 years or unwilling or unable to consent to the study were excluded from participation.,2020-06-23,2020-07-02,Persons experiencing homelessness,All,Seniors (65+ years),65.0,,Age,,61,0.443,0.315,0.5760000000000001,,,,,,Convenience,"Author designed (Neutralization Assay),Author designed (ELISA) - MULTIPLEXED",,Multiple Types,,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Thomas Roederer,Médecins sans Frontières (Epicentre) ,Not Unity-Aligned,https://www.thelancet.com/action/showPdf?pii=S2468-2667%2821%2900001-3,2021-03-27,2022-07-16,Verified,roederer_seroprevalence_2021,FRA
210208_Paris_JeanVerdierHospital_DaycareChildren1_Overall_TestAdj,210208_Paris_JeanVerdierHospital_DaycareChildren1,"SARS-CoV-2 transmission among children and staff in daycare centres during a nationwide lockdown in France: a cross-sectional, multicentre, seroprevalence study",2021-02-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,"Île-de-France, Auvergne-Rhône-Alpes, Normandy","Paris, Annecy, Rouen","Children attending one of the 22 daycare centres during all or part of the nationwide lockdown (from March 15 to May 9, 2020) were eligible for inclusion, as were the staff who worked in these daycare centres during the same period. In each centre, we invited all staff and all parents of enrolled children to participate in the study. Recruitment was stopped after the planned number of participants had been included.",,2020-06-04,2020-07-03,Students and Daycares,All,Children and Youth (0-17 years),0.0,4.0,Primary Estimate,,327,0.037000000000000005,0.013000000000000001,0.068,True,True,,,,Convenience,Biosynex COVID-19 BSS assay,Biosynex,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.918,0.9920000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Eric Lachassinne,Jean Verdier Hospital,Not Unity-Aligned,https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(21)00024-9/fulltext,2021-02-19,2023-08-15,Verified,lachassinne_sars-cov-2_2021-1,FRA
210208_Paris_JeanVerdierHospital_DaycareStaff2_Overall_TestAdj,210208_Paris_JeanVerdierHospital_DaycareStaff2,"SARS-CoV-2 transmission among children and staff in daycare centres during a nationwide lockdown in France: a cross-sectional, multicentre, seroprevalence study",2021-02-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,"Île-de-France, Auvergne-Rhône-Alpes, Normandy","Paris, Annecy, Rouen","Children attending one of the 22 daycare centres during all or part of the nationwide lockdown (from March 15 to May 9, 2020) were eligible for inclusion, as were the staff who worked in these daycare centres during the same period. In each centre, we invited all staff and all parents of enrolled children to participate in the study. Recruitment was stopped after the planned number of participants had been included.",,2020-06-04,2020-07-03,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,197,0.068,0.032,0.115,True,True,,,,Convenience,Biosynex COVID-19 BSS assay,Biosynex,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.918,0.9920000000000001,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Eric Lachassinne,Jean Verdier Hospital,Not Unity-Aligned,https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(21)00024-9/fulltext,2021-05-10,2023-08-15,Verified,lachassinne_sars-cov-2_2021-1,FRA
210208_Paris_JeanVerdierHospital_HCW3_Overall_TestAdj,210208_Paris_JeanVerdierHospital_HCW3,"SARS-CoV-2 transmission among children and staff in daycare centres during a nationwide lockdown in France: a cross-sectional, multicentre, seroprevalence study",2021-02-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,"Île-de-France, Auvergne-Rhône-Alpes, Normandy","Paris, Annecy, Rouen","we recruited a sample of laboratory and administrative staff from six hospitals in the Paris region (n=150), Rouen (n=6), and Annecy (n=8).",,2020-06-04,2020-07-03,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,164,0.05,0.016,0.098,True,True,,,,Unclear,Biosynex COVID-19 BSS assay,Biosynex,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.918,0.9920000000000001,['High'],No,Unclear,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Eric Lachassinne,Jean Verdier Hospital,Not Unity-Aligned,https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(21)00024-9/fulltext,2021-05-10,2023-08-15,Verified,lachassinne_sars-cov-2_2021-1,FRA
210223_France_MontpellierUniversity_NursingHomeResidents,210223_France_MontpellierUniversity,"Atypical symptoms, SARS-CoV-2 test results, and immunization rates in 456 residents from eight nursing homes facing a COVID-19 outbreak",2021-02-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Occitanie,,residents of nursing homes having faced a SARS-CoV-2 outbreak in the Occitanie region between 3 March and 10 June 2020. Nursing homes reporting 10 or more residents with a positive rRT-PCR result in the Occitanie region were included.,,2020-04-21,2020-07-29,Assisted living and long-term care facilities,All,Seniors (65+ years),,,Primary Estimate,,456,0.307,,,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,No,No,Yes,Unclear,Unclear,Yes,No,,Hubert Blain, Montpellier University,Not Unity-Aligned,https://dx.doi.org/10.1093/ageing/afab050,2021-04-09,2022-07-16,Verified,blain_atypical_2021,FRA
210227_GeorgesFrancoisLeclercCancerCentre_CentreGeorgesFrancoisLeclerc_Patients_Overall,210227_GeorgesFrancoisLeclercCancerCentre_CentreGeorgesFrancoisLeclerc_Patients,Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov study,2021-02-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,,Dijon,"include all patients attending our institution from 25 May to 30 June 2020, irrespective of cancer location, stage or treatment. Patients of the Medical Oncology department (patients seen in consultation, in the outpatient unit and in- patients)",,2020-05-25,2020-06-30,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,36.0,81.0,Primary Estimate,,1011,0.017,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM', 'TotalAntibody']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.998,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Sylvain Ladoire,Centre Georges Francois Leclerc,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ejca.2021.02.027,2021-04-18,2024-03-01,Verified,ladoire_seroprevalence_2021,FRA
210227_GeorgesFrancoisLeclercCancerCentre_CentreGeorgesFrancoisLeclerc_Staff_Overall,210227_GeorgesFrancoisLeclercCancerCentre_CentreGeorgesFrancoisLeclerc_Staff,Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov study,2021-02-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,,Dijon,employees (all medical and non medical staff members) at Georges-Francois Leclerc Cancer Centre,,2020-05-11,2020-05-25,Health care workers and caregivers,All,Adults (18-64 years),21.0,55.0,Primary Estimate,,663,0.018000000000000002,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM', 'TotalAntibody']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.998,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Sylvain Ladoire,Centre Georges Francois Leclerc,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ejca.2021.02.027,2021-04-18,2024-03-01,Verified,ladoire_seroprevalence_2021,FRA
210312_Paris_SorbonneUniversite_M0,210312_Paris_SorbonneUniversite_M0,"Cumulative incidence of SARS-CoV-2 infection and associated risk factors among frontline health care workers in Paris, France: the SEROCOV prospective cohort study",2021-03-12,Preprint,Local,Prospective cohort,France,,Paris,"All medical or paramedical staff who worked in COVID-19 frontline departments (emergency, infectious diseases, intensive care units and virology laboratory) of the selected hospitals were informed about the study and asked to participate",Staff who were not active during the inclusion period were not eligible. ,2020-03-16,2020-04-24,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1060,0.059000000000000004,0.047,0.075,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Yes,Pierre Hausfater,Sorbonne Universite ,Not Unity-Aligned,10.1101/2021.03.09.21253200,2021-04-01,2024-03-01,Verified,hausfater_cumulative_2021,FRA
210312_Paris_SorbonneUniversite_M1,210312_Paris_SorbonneUniversite_M1,"Cumulative incidence of SARS-CoV-2 infection and associated risk factors among frontline health care workers in Paris, France: the SEROCOV prospective cohort study",2021-03-12,Preprint,Local,Prospective cohort,France,,Paris,"All medical or paramedical staff who worked in COVID-19 frontline departments (emergency, infectious diseases, intensive care units and virology laboratory) of the selected hospitals were informed about the study and asked to participate",Staff who were not active during the inclusion period were not eligible. ,2020-04-16,2020-05-24,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1004,0.129,0.109,0.151,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Yes,Pierre Hausfater,Sorbonne Universite ,Not Unity-Aligned,10.1101/2021.03.09.21253200,2021-04-01,2024-03-01,Verified,hausfater_cumulative_2021,FRA
210312_Paris_SorbonneUniversite_M3,210312_Paris_SorbonneUniversite_M3,"Cumulative incidence of SARS-CoV-2 infection and associated risk factors among frontline health care workers in Paris, France: the SEROCOV prospective cohort study",2021-03-12,Preprint,Local,Prospective cohort,France,,Paris,"All medical or paramedical staff who worked in COVID-19 frontline departments (emergency, infectious diseases, intensive care units and virology laboratory) of the selected hospitals were informed about the study and asked to participate",Staff who were not active during the inclusion period were not eligible. ,2020-06-16,2020-07-24,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,938,0.13,0.111,0.152,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Yes,Pierre Hausfater,Sorbonne Universite ,Not Unity-Aligned,10.1101/2021.03.09.21253200,2021-04-01,2024-03-01,Verified,hausfater_cumulative_2021,FRA
210312_Strasbourg_UniversityHospitalStrasbourg_overall,210312_Strasbourg_UniversityHospitalStrasbourg,Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients,2021-03-12,Preprint,Local,Prospective cohort,France,,Strasbourg,"KTR who received the first injection of the Moderna mRNA-1273 vaccine (100 μg) at the Strasbourg University Hospital (France) between January 21 and 28,
2021",Patients who develop symptomatic COVID-19 during the study period,2021-02-18,2021-02-25,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,241,0.10800000000000001,,,True,,,,True,Unclear,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,,,,['High'],No,Unclear,No,Yes,Yes,Yes,Yes,Yes,Yes,Ilies Benotmane,"University Hospital, Strasbourg",Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.08.21252741v1.full-text,2021-03-31,2024-03-01,Verified,benotmane_weak_2021,FRA
210322_GrandEst_StrasbourgUniversityHospital_KidneyTransplantPatients,210322_GrandEst_StrasbourgUniversityHospital,"SARS-Cov-2 Seroprevalence in a French Kidney Transplant Center Located Within a ""High Risk"" Zone",2021-03-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Grand Est,,"kidney transplant recipients transplanted at the Department of Nephrology, Strasbourg University Hospital (Grand Est, France) before March 6, 2020. Only patients with functioning graft were deemed eligible",,,2020-09-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,780,0.062000000000000006,,,True,,,,True,Convenience,"Not reported/ Unable to specify,Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG,Biosynex COVID-19 BSS assay,MAGLUMI 2019-nCoV IgM/IgG","NA,Abbott Laboratories,EUROIMMUN,Biosynex,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd)",Multiple Types,Multiple Types,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,No,Sophie Caillard,Strasbourg University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1097/TP.0000000000003766,2021-04-18,2024-03-01,Verified,caillard_sars-cov-2_2021,FRA
210415_France_InstitutPasteur_HighSchool1_overall,210415_France_InstitutPasteur_HighSchool1,"SARS-CoV-2 infection in schools in a northern French city: a retrospective serological cohort study in an area of high transmission, France, January to April 2020",2021-04-15,Journal Article (Peer-Reviewed),Local,Retrospective cohort,France,Hauts-de-France,,"High school pupils, teachers, non-teaching staff.",,2020-03-30,2020-04-04,Students and Daycares,All,Multiple groups,,,Primary Estimate,,664,0.251,,,True,,,,True,Convenience,Author designed (ELISA) - MULTIPLEXED,,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.9940000000000001,0.99,['High'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,No,Arnaud Fontanet,Institut Pasteur,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.15.2001695,2021-05-06,2022-07-16,Unverified,fontanet_sars-cov-2_2021,FRA
210415_France_InstitutPasteur_HighSchool1_12-17,210415_France_InstitutPasteur_HighSchool1,"SARS-CoV-2 infection in schools in a northern French city: a retrospective serological cohort study in an area of high transmission, France, January to April 2020",2021-04-15,Journal Article (Peer-Reviewed),Local,Retrospective cohort,France,Hauts-de-France,,"High school pupils, teachers, non-teaching staff.",,2020-03-30,2020-04-04,Students and Daycares,All,Children and Youth (0-17 years),12.0,17.0,Age,12-17,235,0.349,,,True,,,,True,Convenience,Author designed (ELISA) - MULTIPLEXED,,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.9940000000000001,0.99,['High'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,No,Arnaud Fontanet,Institut Pasteur,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.15.2001695,2022-02-07,2022-07-16,Unverified,fontanet_sars-cov-2_2021,FRA
210415_France_InstitutPasteur_HighSchool1_Under12,210415_France_InstitutPasteur_HighSchool1,"SARS-CoV-2 infection in schools in a northern French city: a retrospective serological cohort study in an area of high transmission, France, January to April 2020",2021-04-15,Journal Article (Peer-Reviewed),Local,Retrospective cohort,France,Hauts-de-France,,"High school pupils, teachers, non-teaching staff.",,2020-03-30,2020-04-04,Students and Daycares,All,Children and Youth (0-17 years),,11.0,Age,<12,8,0.0,,,True,,,,True,Convenience,Author designed (ELISA) - MULTIPLEXED,,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.9940000000000001,0.99,['High'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,No,Arnaud Fontanet,Institut Pasteur,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.15.2001695,2022-02-07,2022-07-16,Unverified,fontanet_sars-cov-2_2021,FRA
210415_France_InstitutPasteur_PrimarySchool2_12-17,210415_France_InstitutPasteur_PrimarySchool2,"SARS-CoV-2 infection in schools in a northern French city: a retrospective serological cohort study in an area of high transmission, France, January to April 2020",2021-04-15,Journal Article (Peer-Reviewed),Local,Retrospective cohort,France,Hauts-de-France,,"Primary school pupils, teachers, parents of pupils, relatives of pupils sharing the same household, and non-teaching staff.",,2020-04-28,2020-04-30,Students and Daycares,All,Children and Youth (0-17 years),12.0,17.0,Age,12-17,78,0.154,,,True,,,,True,Convenience,Author designed (ELISA) - MULTIPLEXED,,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.9940000000000001,0.99,['High'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Arnaud Fontanet,Institut Pasteur,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.15.2001695,2022-02-07,2022-07-16,Unverified,fontanet_sars-cov-2_2021,FRA
210415_France_InstitutPasteur_PrimarySchool2_overall,210415_France_InstitutPasteur_PrimarySchool2,"SARS-CoV-2 infection in schools in a northern French city: a retrospective serological cohort study in an area of high transmission, France, January to April 2020",2021-04-15,Journal Article (Peer-Reviewed),Local,Retrospective cohort,France,Hauts-de-France,,"Primary school pupils, teachers, parents of pupils, relatives of pupils sharing the same household, and non-teaching staff.",,2020-04-28,2020-04-30,Students and Daycares,All,Multiple groups,,,Primary Estimate,,1340,0.10400000000000001,,,True,,,,True,Convenience,Author designed (ELISA) - MULTIPLEXED,,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.9940000000000001,0.99,['High'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Arnaud Fontanet,Institut Pasteur,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.15.2001695,2021-05-06,2022-07-16,Unverified,fontanet_sars-cov-2_2021,FRA
210415_France_InstitutPasteur_PrimarySchool2_Under12,210415_France_InstitutPasteur_PrimarySchool2,"SARS-CoV-2 infection in schools in a northern French city: a retrospective serological cohort study in an area of high transmission, France, January to April 2020",2021-04-15,Journal Article (Peer-Reviewed),Local,Retrospective cohort,France,Hauts-de-France,,"Primary school pupils, teachers, parents of pupils, relatives of pupils sharing the same household, and non-teaching staff.",,2020-04-28,2020-04-30,Students and Daycares,All,Children and Youth (0-17 years),,11.0,Age,<12,538,0.086,,,True,,,,True,Convenience,Author designed (ELISA) - MULTIPLEXED,,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.9940000000000001,0.99,['High'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Arnaud Fontanet,Institut Pasteur,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.15.2001695,2022-02-07,2022-07-16,Unverified,fontanet_sars-cov-2_2021,FRA
210428_Europe_SorbonneUniversité_2Île-de-France,210428_Europe_SorbonneUniversité_2Île-de-France,SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study.,2021-04-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Île-de-France,,"Eligible individuals had to be older than 18 years and have a definite clinical diagnosis of rheumatoid arthritis, axial spondyloarthritis, systemic lupus erythematosus, Sjögren's syndrome, or giant cell arteritis diagnosed by experienced rheumatologists and fulfilling the respective international classification criteria.","Patients who refused to participate, did not speak or read the local language, or were unwilling to undergo routine blood collection during the study period were excluded. ",2020-06-07,2020-12-08,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,,Primary Estimate,,593,0.071,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Liaison SARS-CoV-2 S1/S2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Siemens,DiaSorin,Beckman Coulter,Roche Diagnostics",,,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,Yes,Unclear,Unclear,No,No,Unclear,David Saadoun,Sorbonne Université,Not Unity-Aligned,https://dx.doi.org/10.1016/S2665-9913(21)00112-0,2021-05-28,2024-03-01,Verified,davidsaadounetal.SARSCoV2OutbreakImmunemediated2021,FRA
210510_Paris_GroupeHospitalierNordEssonneLongjumeau,210510_Paris_GroupeHospitalierNordEssonneLongjumeau,Contribution of Serological Rapid Diagnostic Tests to the Strategy of Contact Tracing in Households Following SARS-CoV-2 Infection Diagnosis in Children.,2021-05-10,Journal Article (Peer-Reviewed),Local,Prospective cohort,France,Île-de-France,Paris,"A contact tracing strategy called COVISAN was set up in the Paris region to break the viral transmission chains, with home visits by nurses to screen close contacts of the patients with SARS-CoV-2 infection. An initial form was filled for every new SARS-CoV-2 infection case to determine the date of symptom onset and collect data on his/her living place and household contacts (identity, age, occupation or attended school, high risk factors, and suggestive symptoms of COVID-19). ",,2020-05-08,2020-07-27,Contacts of COVID patients,All,Multiple groups,,,Primary Estimate,,120,0.39,,,True,,,,True,Convenience,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,,1.0,1.0,['High'],,No,No,No,,Unclear,Yes,Yes,,Lorelei Charbonnier,Groupe Hospitalier Nord Essonne Longjumeau,Not Unity-Aligned,https://dx.doi.org/10.3389/fped.2021.638502,2021-06-05,2022-07-16,Unverified,loreleicharbonnierContributionSerologicalRapid2021,FRA
210513_Lyon_CentreHospitalierSaintJosephSaintLuc,210513_Lyon_CentreHospitalierSaintJosephSaintLuc,Specific exposure of ICU staff to SARS-CoV-2 seropositivity: a wide seroprevalence study in a French city-center hospital.,2021-05-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Auvergne-Rhône-Alpes,Lyon,"All persons who had worked at the Saint Joseph Saint Luc hospital in Lyon, Auvergne-Rhône-Alpes, France, from March 1 to April 30 2020. This included all clinical and nonclinical employees, the staff of the subcontracted cleaning company, medical interns and nursing students.",Consent not given,2020-06-08,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,971,0.09,0.08800000000000001,0.092,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.99,0.99,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Emmanuel Vivier,Centre Hospitalier Saint Joseph Saint Luc,Not Unity-Aligned,https://dx.doi.org/10.1186/s13613-021-00868-8,2021-05-29,2024-03-01,Verified,vivier_specific_2021,FRA
210518_Paris_HopitalBichat-ClaudeBernard,210518_Paris_HopitalBichat-ClaudeBernard,"Contribution of rapid lateral flow assays from capillary blood specimens to the diagnosis of COVID-19 in symptomatic healthcare workers: a pilot study in a university hospital, Paris, France.",2021-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,,Paris,"The inclusion criteria were as follows: HCW who experienced symptoms suggestive of COVID-19, for whom infection was: (i) either not documented (PCR test not performed) or (ii) cleared (PCR test negative), with an onset of symptoms between February 1 and March 30 and the end date older than 15 days: dry cough and fever with or without chest pain, anosmia, ageusia, fatigue, severe headache.","Non-inclusion criteria were non-HCW, pregnant women and protected adults.",2020-05-12,2020-06-02,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,72,0.153,0.069,0.237,True,,,,True,Convenience,"COVID-PRESTO®,NG-Test® finger-prick test,Panbio COVID-19 IgG/IgM rapid test device","AAZ LMB,NG Biotech Laboratoires,Abbott Laboratories",Multiple Types,Multiple Types,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Charlotte Charpentier,Hopital Bichat-Claude Bernard,Not Unity-Aligned,https://dx.doi.org/10.1016/j.diagmicrobio.2021.115430,2021-07-14,2024-03-01,Unverified,charpentier_contribution_2021-1,FRA
210521_France_SantePubliqueFrance_April2_Overall_PopAdj_TestAdj,210521_France_SantePubliqueFrance_April2,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-04-06,2020-04-12,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,3595,0.0414,0.033100000000000004,0.0499,True,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-06-07,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_April2_>80,210521_France_SantePubliqueFrance_April2,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-04-06,2020-04-12,Residual sera,All,Seniors (65+ years),80.0,,Age,>=80,428,0.040999999999999995,0.028999999999999998,0.055,,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_April2_40-49,210521_France_SantePubliqueFrance_April2,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-04-06,2020-04-12,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,455,0.049,0.034,0.067,,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_April2_30-39,210521_France_SantePubliqueFrance_April2,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-04-06,2020-04-12,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,461,0.037000000000000005,0.024,0.051,,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_April2_Male,210521_France_SantePubliqueFrance_April2,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-04-06,2020-04-12,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,1557,0.045,0.035,0.055999999999999994,,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_April2_20-29,210521_France_SantePubliqueFrance_April2,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-04-06,2020-04-12,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29,355,0.043,0.03,0.06,,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_April2_0-9,210521_France_SantePubliqueFrance_April2,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-04-06,2020-04-12,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,0-9,167,0.023,0.009000000000000001,0.040999999999999995,,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_April2_70-79,210521_France_SantePubliqueFrance_April2,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-04-06,2020-04-12,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,455,0.038,0.026000000000000002,0.052000000000000005,,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_April2_LuLISAS,210521_France_SantePubliqueFrance_April2,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-04-06,2020-04-12,Residual sera,All,Multiple groups,0.0,,Test used,LuLISA IgG S,3595,0.0348,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.96,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_April2_10-19,210521_France_SantePubliqueFrance_April2,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-04-06,2020-04-12,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,298,0.037000000000000005,0.023,0.053,,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_April2_60-69,210521_France_SantePubliqueFrance_April2,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-04-06,2020-04-12,Residual sera,All,Multiple groups,60.0,69.0,Age,60-69,487,0.051,0.036000000000000004,0.068,,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_April2_LuLISAN,210521_France_SantePubliqueFrance_April2,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-04-06,2020-04-12,Residual sera,All,Multiple groups,0.0,,Test used,LuLISA IgG N,3595,0.028399999999999998,,,,,,,,Stratified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by developers,0.86,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_April2_Overall_Unadj,210521_France_SantePubliqueFrance_April2,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-04-06,2020-04-12,Residual sera,All,Multiple groups,0.0,,Analysis,,3595,0.0434,,,,,,,True,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-06-07,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_April2_Female,210521_France_SantePubliqueFrance_April2,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-04-06,2020-04-12,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,2038,0.038,0.028999999999999998,0.047,,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_April2_PNT,210521_France_SantePubliqueFrance_April2,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-04-06,2020-04-12,Residual sera,All,Multiple groups,0.0,,Test used,Pseudo-neutralization assay (PNT),3595,0.0245,,,,,,,,Stratified probability,Author designed (Neutralization Assay),,Neutralization,Serum,Neutralizing,Spike,Validated by developers,0.85,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_April2_50-59,210521_France_SantePubliqueFrance_April2,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-04-06,2020-04-12,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,489,0.051,0.037000000000000005,0.068,,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_March1_Overall_PopAdj_TestAdj,210521_France_SantePubliqueFrance_March1,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-03-09,2020-03-15,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,3834,0.0040999999999999995,0.0005,0.0088,True,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-06-07,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_March1_>80,210521_France_SantePubliqueFrance_March1,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-03-09,2020-03-15,Residual sera,All,Seniors (65+ years),80.0,,Age,>=80,347,0.004,0.0,0.009000000000000001,,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_March1_40-49,210521_France_SantePubliqueFrance_March1,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-03-09,2020-03-15,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,487,0.005,0.001,0.011000000000000001,,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_March1_10-19,210521_France_SantePubliqueFrance_March1,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-03-09,2020-03-15,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,420,0.004,0.0,0.008,,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_March1_Male,210521_France_SantePubliqueFrance_March1,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-03-09,2020-03-15,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,1689,0.005,0.001,0.01,,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_March1_Overall_Unadj,210521_France_SantePubliqueFrance_March1,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-03-09,2020-03-15,Residual sera,All,Multiple groups,0.0,,Analysis,,3834,0.006999999999999999,,,,,,,True,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-06-07,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_March1_30-39,210521_France_SantePubliqueFrance_March1,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-03-09,2020-03-15,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,500,0.004,0.0,0.008,,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_March1_LuLISAS,210521_France_SantePubliqueFrance_March1,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-03-09,2020-03-15,Residual sera,All,Multiple groups,0.0,,Test used,LuLISA IgG S,3834,0.0055000000000000005,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.96,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_March1_0-9,210521_France_SantePubliqueFrance_March1,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-03-09,2020-03-15,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,0-9,359,0.002,0.0,0.006,,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_March1_60-69,210521_France_SantePubliqueFrance_March1,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-03-09,2020-03-15,Residual sera,All,Multiple groups,60.0,69.0,Age,60-69,455,0.005,0.001,0.011000000000000001,,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_March1_70-79,210521_France_SantePubliqueFrance_March1,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-03-09,2020-03-15,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,382,0.004,0.0,0.009000000000000001,,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_March1_Female,210521_France_SantePubliqueFrance_March1,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-03-09,2020-03-15,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,2145,0.004,0.0,0.008,,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_March1_20-29,210521_France_SantePubliqueFrance_March1,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-03-09,2020-03-15,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29,423,0.004,0.001,0.01,,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_March1_PNT,210521_France_SantePubliqueFrance_March1,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-03-09,2020-03-15,Residual sera,All,Multiple groups,0.0,,Test used,Pseudo-neutralization assay (PNT),3834,0.0003,,,,,,,,Stratified probability,Author designed (Neutralization Assay),,Neutralization,Serum,Neutralizing,Spike,Validated by developers,0.85,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_March1_LuLISAN,210521_France_SantePubliqueFrance_March1,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-03-09,2020-03-15,Residual sera,All,Multiple groups,0.0,,Test used,LuLISA IgG N,3834,0.0018,,,,,,,,Stratified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by developers,0.86,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_March1_50-59,210521_France_SantePubliqueFrance_March1,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-03-09,2020-03-15,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,461,0.005,0.001,0.011000000000000001,,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_May3_Overall_PopAdj_TestAdj,210521_France_SantePubliqueFrance_May3,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-05-11,2020-05-17,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,3592,0.0493,0.0402,0.0589,True,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-06-07,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_May3_70-79,210521_France_SantePubliqueFrance_May3,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-05-11,2020-05-17,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,480,0.045,0.031000000000000003,0.061,,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_May3_0-9,210521_France_SantePubliqueFrance_May3,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-05-11,2020-05-17,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,0-9,255,0.027200000000000002,0.011000000000000001,0.0487,,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_May3_Overall_Unadj,210521_France_SantePubliqueFrance_May3,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-05-11,2020-05-17,Residual sera,All,Multiple groups,0.0,,Analysis,,3592,0.0496,,,,,,,True,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-06-07,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_May3_>80,210521_France_SantePubliqueFrance_May3,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-05-11,2020-05-17,Residual sera,All,Seniors (65+ years),80.0,,Age,>=80,439,0.048,0.034,0.065,,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_May3_PNT,210521_France_SantePubliqueFrance_May3,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-05-11,2020-05-17,Residual sera,All,Multiple groups,0.0,,Test used,Pseudo-neutralization assay (PNT),3592,0.0292,,,,,,,,Stratified probability,Author designed (Neutralization Assay),,Neutralization,Serum,Neutralizing,Spike,Validated by developers,0.85,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_May3_20-29,210521_France_SantePubliqueFrance_May3,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-05-11,2020-05-17,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29,318,0.052000000000000005,0.036000000000000004,0.071,,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_May3_30-39,210521_France_SantePubliqueFrance_May3,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-05-11,2020-05-17,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,0-9,409,0.044000000000000004,0.028999999999999998,0.06,,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_May3_LuLISAS,210521_France_SantePubliqueFrance_May3,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-05-11,2020-05-17,Residual sera,All,Multiple groups,0.0,,Test used,LuLISA IgG S,3592,0.0384,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.96,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_May3_10-19,210521_France_SantePubliqueFrance_May3,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-05-11,2020-05-17,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,336,0.044000000000000004,0.028999999999999998,0.062000000000000006,,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_May3_Female,210521_France_SantePubliqueFrance_May3,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-05-11,2020-05-17,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,2049,0.0451,0.0357,0.055400000000000005,,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_May3_Male,210521_France_SantePubliqueFrance_May3,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-05-11,2020-05-17,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,1543,0.053700000000000005,0.042699999999999995,0.0655,,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_May3_LuLISAN,210521_France_SantePubliqueFrance_May3,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-05-11,2020-05-17,Residual sera,All,Multiple groups,0.0,,Test used,LuLISA IgG N,3592,0.0365,,,,,,,,Stratified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by developers,0.86,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_May3_40-49,210521_France_SantePubliqueFrance_May3,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-05-11,2020-05-17,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,0-9,390,0.059000000000000004,0.042,0.079,,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_May3_50-59,210521_France_SantePubliqueFrance_May3,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-05-11,2020-05-17,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,0-9,469,0.060599999999999994,0.0443,0.0804,,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210521_France_SantePubliqueFrance_May3_60-69,210521_France_SantePubliqueFrance_May3,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.,2021-05-21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"Guadeloupe, Martinique, French Guiana, La Reunion, Île-de-France, Centre-Val-de-Loire,  Bourgogne-Franche Comté, Normandie, Hauts-de-France, Grand-Est, Pays de la Loire, Bretagne, Nouvelle-Aquitaine, Occitanie, Auvergne-Rhône-Alpes, Corse, Provence-Alpes-Côte d'Azur",,"Residual sera included specimens from individuals of all ages undergoing routine diagnosis and monitoring in all medical specialties (biochemistry, immunology, allergy...)",Residual sera from individuals undergoing monitoring and diagnosis in infectious diseases and obstetrics.,2020-05-11,2020-05-17,Residual sera,All,Multiple groups,60.0,69.0,Age,0-9,496,0.0604,0.044000000000000004,0.0806,,True,True,,,Stratified probability,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Stephane Le Vu,Santé publique France,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23233-6,2021-08-12,2022-07-16,Verified,le_vu_prevalence_2021,FRA
210525_Paris_SamusocialDeParis_Residents_Overall,210525_Paris_SamusocialDeParis_Residents,Impact of the COVID-19 pandemic on the homeless: results from a retrospective closed cohort in France (March-May 2020),2021-05-25,Journal Article (Peer-Reviewed),Local,Retrospective cohort,France,Ile de France,Paris,All adults (≥ 18-years) present in the shelters or who died of a proven SARS-CoV-2 infection 86 between  1  March  and  31  May  2020  (cluster  dates)  were  eligible  for  inclusion  following 87 informed  consent.  Participants  who  had  left  the  centres  at  inclusion  were  contacted  and 88 offered  participation,"Exclusion of residents and staff members who refused participation, who could not give consent to the study1 and residents that died of a cause unrelated to SARS-CoV-2 infection ",2020-03-01,2020-05-31,Persons experiencing homelessness,All,Multiple groups,18.0,,Primary Estimate,,96,0.698,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.96,0.993,['High'],,No,No,Yes,,Yes,Yes,Yes,,Maya Husain,Samusocial de Paris,Not Unity-Aligned,http://dx.doi.org/10.1016/j.cmi.2021.05.039,2021-06-29,2024-03-01,Unverified,schoenhals_sars-cov-2_2021,FRA
210525_Paris_SamusocialDeParis_Staff_Overall,210525_Paris_SamusocialDeParis_Staff,Impact of the COVID-19 pandemic on the homeless: results from a retrospective closed cohort in France (March-May 2020),2021-05-25,Journal Article (Peer-Reviewed),Local,Retrospective cohort,France,Ile de France,Paris,All adults (≥ 18-years) present in the shelters or who died of a proven SARS-CoV-2 infection 86 between  1  March  and  31  May  2020  (cluster  dates)  were  eligible  for  inclusion  following 87 informed  consent.  Participants  who  had  left  the  centres  at  inclusion  were  contacted  and 88 offered  participation,"Exclusion of residents and staff members who refused participation, who could not give consent to the study1 and residents that died of a cause unrelated to SARS-CoV-2 infection ",2020-03-01,2020-05-31,Essential non-healthcare workers,All,Multiple groups,18.0,,Primary Estimate,,81,0.185,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.96,0.993,['High'],,No,No,Yes,,Yes,Yes,Yes,,Maya Husain,Samusocial de Paris,Not Unity-Aligned,http://dx.doi.org/10.1016/j.cmi.2021.05.039,2021-06-29,2024-03-01,Unverified,schoenhals_sars-cov-2_2021,FRA
210528_Lille_OscarLambretComprehensiveCancerCenter,210528_Lille_OscarLambretComprehensiveCancerCenter,Very low seroprevalence of sars-cov-2 among health care personnel (HCP) in a French northern comprehensive cancer center at the end of first national containment,2021-05-28,Presentation or Conference,Local,Cross-sectional survey ,France,Hauts-de-France,Lille,employees of the Oscar Lambret Cancer Center,,2020-05-04,2020-06-26,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,392,0.018000000000000002,0.006999999999999999,0.036000000000000004,True,,,,True,Convenience,"Not reported/ Unable to specify,Author designed (type unknown)",,LFIA,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Philippe Doutrelant,Oscar Lambret Comprehensive Cancer Center,Not Unity-Aligned,https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.e13604,2021-11-30,2023-01-02,Unverified,doutrelant_very_2021,FRA
210531_Marseille_HôpitauxdeMarseille,210531_Marseille_HôpitauxdeMarseille,"Seroprevalence of SARS-CoV-2 Antibodies Among Homeless People Living Rough, in Shelters and Squats: A Large Population-Based Study in France",2021-05-31,Preprint,Local,Cross-sectional survey ,France,Provence-Alpes-Côte d'Azur,Marseille,"A consortium of outreach teams in 48 different locations including streets, slums, squats, emergency or transitional shelters and drop-in centres participated in the inclusion process. All participants consented to receive a validated rapid assay for immunoglobulins M (IgM) and G (IgG) antibodies and to answer a questionnaire on medical health conditions, comorbidities, historic of symptoms compatible with COVID-19, with a retrospective calendar of types of accommodation since COVID-19 crisis.
Eligible individuals were aged over 18 and lived in the following typology of homelessness (according to the ETHOS - European
typology for homelessness and housing exclusion, which is aframework definition for policy and practice purposes stated at the European level) [12]: i) living rough (ETHOS1), ii) living in emergency accommodations (emergency shelters and hotels) (ETHOS2); iii) living in transitional accommodations for the homeless (ETHOS3); and iv) living in insecure accommodations (i.e., illegal occupation of lands, squat/slum or temporarily with family/friends) (ETHOS8).
","These data did not include diffuse accommodation facilities (10 settings), family shelters (3 settings) or any children from squats since 
children were excluded from the study (i.e. an Ethics Board's decision).",2020-06-01,2020-08-05,Persons experiencing homelessness,All,Adults (18-64 years),,,Primary Estimate,Homeless Population,1156,0.0562,0.028999999999999998,0.0721,True,,,,True,Convenience,Biosynex COVID-19 BSS assay,Biosynex,,,"['IgG', 'IgM']",,Validated by manufacturers,1.0,0.995,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Sandrine Loubiere,Hôpitaux de Marseille,Not Unity-Aligned,https://europepmc.org/article/PPR/PPR350578,2021-06-07,2024-03-01,Unverified,sandrineloubiereSeroprevalenceSARSCoV2Antibodies2021,FRA
210604_Nancy_UniversiteDeLorraine_Overall_PopAdj,210604_Nancy_UniversiteDeLorraine,"Seroprevalence of sars-cov-2, symptom profiles and sero-neutralization in a suburban area, france",2021-06-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Grand Est,Nancy,Adults randomly sampled from the electoral lists were invited to participate with all household members.,<5 years old,2020-06-26,2020-07-24,Household and community samples,All,Multiple groups,,,Primary Estimate,,2006,0.025,0.018000000000000002,0.033,True,,True,,,Convenience,"Platelia SARS-CoV-2 Total Ab assay,Biosynex COVID-19 BSS assay,Anti-SARS-CoV-2 ELISA IgA","Bio-rad,Biosynex,EUROIMMUN",ELISA,Serum,"['IgA', 'IgG', 'IgM', 'TotalAntibody']",,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,No,Anne Petit,Université de Lorraine,Unity-Aligned,http://dx.doi.org/10.3390/v13061076,2021-06-30,2024-03-01,Verified,v13061076,FRA
210604_Nancy_UniversiteDeLorraine_Age35-49,210604_Nancy_UniversiteDeLorraine,"Seroprevalence of sars-cov-2, symptom profiles and sero-neutralization in a suburban area, france",2021-06-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Grand Est,Nancy,Adults randomly sampled from the electoral lists were invited to participate with all household members.,<5 years old,2020-06-26,2020-07-24,Household and community samples,All,Adults (18-64 years),,,Age,35-49,350,0.0143,,,,,,,,Convenience,"Platelia SARS-CoV-2 Total Ab assay,Biosynex COVID-19 BSS assay,Anti-SARS-CoV-2 ELISA IgA","Bio-rad,Biosynex,EUROIMMUN",ELISA,Serum,"['IgA', 'IgG', 'IgM', 'TotalAntibody']",,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,No,Anne Petit,Université de Lorraine,Unity-Aligned,http://dx.doi.org/10.3390/v13061076,2022-01-26,2024-03-01,Verified,v13061076,FRA
210604_Nancy_UniversiteDeLorraine_Overall_Crude,210604_Nancy_UniversiteDeLorraine,"Seroprevalence of sars-cov-2, symptom profiles and sero-neutralization in a suburban area, france",2021-06-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Grand Est,Nancy,Adults randomly sampled from the electoral lists were invited to participate with all household members.,<5 years old,2020-06-26,2020-07-24,Household and community samples,All,Multiple groups,,,Analysis,,2006,0.021400000000000002,0.015,0.027999999999999997,,,,,True,Convenience,"Platelia SARS-CoV-2 Total Ab assay,Biosynex COVID-19 BSS assay,Anti-SARS-CoV-2 ELISA IgA","Bio-rad,Biosynex,EUROIMMUN",ELISA,Serum,"['IgA', 'IgG', 'IgM', 'TotalAntibody']",,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,No,Anne Petit,Université de Lorraine,Unity-Aligned,http://dx.doi.org/10.3390/v13061076,2022-01-26,2024-03-01,Verified,v13061076,FRA
210604_Nancy_UniversiteDeLorraine_Age50-64,210604_Nancy_UniversiteDeLorraine,"Seroprevalence of sars-cov-2, symptom profiles and sero-neutralization in a suburban area, france",2021-06-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Grand Est,Nancy,Adults randomly sampled from the electoral lists were invited to participate with all household members.,<5 years old,2020-06-26,2020-07-24,Household and community samples,All,Adults (18-64 years),,,Age,50-64,553,0.028900000000000002,,,,,,,,Convenience,"Platelia SARS-CoV-2 Total Ab assay,Biosynex COVID-19 BSS assay,Anti-SARS-CoV-2 ELISA IgA","Bio-rad,Biosynex,EUROIMMUN",ELISA,Serum,"['IgA', 'IgG', 'IgM', 'TotalAntibody']",,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,No,Anne Petit,Université de Lorraine,Unity-Aligned,http://dx.doi.org/10.3390/v13061076,2022-01-26,2024-03-01,Verified,v13061076,FRA
210604_Nancy_UniversiteDeLorraine_Age80+,210604_Nancy_UniversiteDeLorraine,"Seroprevalence of sars-cov-2, symptom profiles and sero-neutralization in a suburban area, france",2021-06-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Grand Est,Nancy,Adults randomly sampled from the electoral lists were invited to participate with all household members.,<5 years old,2020-06-26,2020-07-24,Household and community samples,All,Seniors (65+ years),,,Age,80+,112,0.0089,,,,,,,,Convenience,"Platelia SARS-CoV-2 Total Ab assay,Biosynex COVID-19 BSS assay,Anti-SARS-CoV-2 ELISA IgA","Bio-rad,Biosynex,EUROIMMUN",ELISA,Serum,"['IgA', 'IgG', 'IgM', 'TotalAntibody']",,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,No,Anne Petit,Université de Lorraine,Unity-Aligned,http://dx.doi.org/10.3390/v13061076,2022-01-26,2024-03-01,Verified,v13061076,FRA
210604_Nancy_UniversiteDeLorraine_Age5-19,210604_Nancy_UniversiteDeLorraine,"Seroprevalence of sars-cov-2, symptom profiles and sero-neutralization in a suburban area, france",2021-06-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Grand Est,Nancy,Adults randomly sampled from the electoral lists were invited to participate with all household members.,<5 years old,2020-06-26,2020-07-24,Household and community samples,All,Children and Youth (0-17 years),,,Age,5-19,203,0.0099,,,,,,,,Convenience,"Platelia SARS-CoV-2 Total Ab assay,Biosynex COVID-19 BSS assay,Anti-SARS-CoV-2 ELISA IgA","Bio-rad,Biosynex,EUROIMMUN",ELISA,Serum,"['IgA', 'IgG', 'IgM', 'TotalAntibody']",,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,No,Anne Petit,Université de Lorraine,Unity-Aligned,http://dx.doi.org/10.3390/v13061076,2022-01-26,2024-03-01,Verified,v13061076,FRA
210604_Nancy_UniversiteDeLorraine_SexMale,210604_Nancy_UniversiteDeLorraine,"Seroprevalence of sars-cov-2, symptom profiles and sero-neutralization in a suburban area, france",2021-06-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Grand Est,Nancy,Adults randomly sampled from the electoral lists were invited to participate with all household members.,<5 years old,2020-06-26,2020-07-24,Household and community samples,Male,Multiple groups,,,Sex/Gender,,902,0.0211,,,,,,,,Convenience,"Platelia SARS-CoV-2 Total Ab assay,Biosynex COVID-19 BSS assay,Anti-SARS-CoV-2 ELISA IgA","Bio-rad,Biosynex,EUROIMMUN",ELISA,Serum,"['IgA', 'IgG', 'IgM', 'TotalAntibody']",,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,No,Anne Petit,Université de Lorraine,Unity-Aligned,http://dx.doi.org/10.3390/v13061076,2022-01-26,2024-03-01,Verified,v13061076,FRA
210604_Nancy_UniversiteDeLorraine_Age20-34,210604_Nancy_UniversiteDeLorraine,"Seroprevalence of sars-cov-2, symptom profiles and sero-neutralization in a suburban area, france",2021-06-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Grand Est,Nancy,Adults randomly sampled from the electoral lists were invited to participate with all household members.,<5 years old,2020-06-26,2020-07-24,Household and community samples,All,Adults (18-64 years),,,Age,20-34,215,0.04650000000000001,,,,,,,,Convenience,"Platelia SARS-CoV-2 Total Ab assay,Biosynex COVID-19 BSS assay,Anti-SARS-CoV-2 ELISA IgA","Bio-rad,Biosynex,EUROIMMUN",ELISA,Serum,"['IgA', 'IgG', 'IgM', 'TotalAntibody']",,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,No,Anne Petit,Université de Lorraine,Unity-Aligned,http://dx.doi.org/10.3390/v13061076,2022-01-26,2024-03-01,Verified,v13061076,FRA
210604_Nancy_UniversiteDeLorraine_Age65-79,210604_Nancy_UniversiteDeLorraine,"Seroprevalence of sars-cov-2, symptom profiles and sero-neutralization in a suburban area, france",2021-06-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Grand Est,Nancy,Adults randomly sampled from the electoral lists were invited to participate with all household members.,<5 years old,2020-06-26,2020-07-24,Household and community samples,All,Seniors (65+ years),,,Age,65-79,573,0.015700000000000002,,,,,,,,Convenience,"Platelia SARS-CoV-2 Total Ab assay,Biosynex COVID-19 BSS assay,Anti-SARS-CoV-2 ELISA IgA","Bio-rad,Biosynex,EUROIMMUN",ELISA,Serum,"['IgA', 'IgG', 'IgM', 'TotalAntibody']",,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,No,Anne Petit,Université de Lorraine,Unity-Aligned,http://dx.doi.org/10.3390/v13061076,2022-01-26,2024-03-01,Verified,v13061076,FRA
210604_Nancy_UniversiteDeLorraine_SexFemale,210604_Nancy_UniversiteDeLorraine,"Seroprevalence of sars-cov-2, symptom profiles and sero-neutralization in a suburban area, france",2021-06-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Grand Est,Nancy,Adults randomly sampled from the electoral lists were invited to participate with all household members.,<5 years old,2020-06-26,2020-07-24,Household and community samples,Female,Multiple groups,,,Sex/Gender,,1104,0.0217,,,,,,,,Convenience,"Platelia SARS-CoV-2 Total Ab assay,Biosynex COVID-19 BSS assay,Anti-SARS-CoV-2 ELISA IgA","Bio-rad,Biosynex,EUROIMMUN",ELISA,Serum,"['IgA', 'IgG', 'IgM', 'TotalAntibody']",,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,No,Anne Petit,Université de Lorraine,Unity-Aligned,http://dx.doi.org/10.3390/v13061076,2022-01-26,2024-03-01,Verified,v13061076,FRA
210623_Marseille_Aix-MarseilleUniversity,210623_Marseille_Aix-MarseilleUniversity,SARS-CoV-2 rapid serological tests for field-based healthcare workers in homeless communities: a mixed-methods exploratory analysis.,2021-06-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Provence,Marseille,"Individuals were eligible to participate in the study if they were aged ≥18 years and were employed as an HCW. In this study, HCWs were defined as individuals who worked in one of the 18 NGOs and other institutions providing care to homeless people in Marseille, including, but not limited to, attending physicians, nurses, coordinators, social workers and administrators. ",No exclusion. ,2020-06-01,2020-07-31,Health care workers and caregivers,All,Multiple groups,20.0,65.0,Primary Estimate,,99,0.061,,,True,,,,True,Convenience,Biosynex COVID-19 BSS assay,Biosynex,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,Yes,Emilie Mosnier,Aix-Marseille University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.puhip.2021.100154,2021-07-06,2024-03-01,Verified,mosnier_sars-cov-2_2021,FRA
210706_France_InstitutdeCancérologiedel’Ouest_HCW_primary,210706_France_InstitutdeCancérologiedel’Ouest_HCW,Anosmia but not ageusia as a covid-19-related symptom among cancer patients-first results from the papesco-19 cohort study,2021-07-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,"Western France, Eastern France, Central France",,Participants were eligible irrespective of whether they had presented with symptoms since start of the COVID-19 outbreak.,,2020-07-17,2020-11-30,Health care workers and caregivers,All,Adults (18-64 years),19.0,66.0,Primary Estimate,,940,0.078,,,True,,,,True,Self-referral,NG-Test® finger-prick test,NG Biotech Laboratoires,LFIA,Plasma,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.953,['High'],,No,Yes,Yes,,No,Yes,No,,Ke Zhou ,Institut de Cancérologie de l’Ouest,Not Unity-Aligned,http://dx.doi.org/10.3390/cancers13143389,2021-07-13,2024-03-01,Unverified,zhou_anosmia_2021,FRA
210706_France_InstitutdeCancérologiedel’Ouest_patients_primary,210706_France_InstitutdeCancérologiedel’Ouest_patients,Anosmia but not ageusia as a covid-19-related symptom among cancer patients-first results from the papesco-19 cohort study,2021-07-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,"Western France, Eastern France, Central France",,"We included patients aged ≥18 years attending cancer centers as part of an ongoing active treatment (radiotherapy, surgery, immunotherapy or chemotherapy) or monitoring of treatment completed more than a year earlier. Participants were eligible irrespective of whether they had presented with symptoms since start of the COVID-19 outbreak.",,2020-07-17,2020-11-30,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,91.0,Primary Estimate,,878,0.067,,,True,,,,True,Convenience,NG-Test® finger-prick test,NG Biotech Laboratoires,LFIA,Plasma,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.953,['High'],,No,Yes,Yes,,No,Yes,No,,Ke Zhou ,Institut de Cancérologie de l’Ouest,Not Unity-Aligned,http://dx.doi.org/10.3390/cancers13143389,2021-07-13,2024-03-01,Unverified,zhou_anosmia_2021,FRA
210713_Strasbourg_HôpitauxUniversitairesdeStrasbourg_primary,210713_Strasbourg_HôpitauxUniversitairesdeStrasbourg,Incidence and predictors of COVID-19 and flares in patients with rare autoimmune diseases: a systematic survey and serological study at a national reference center in France.,2021-07-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,,Strasbourg,inclusion of patients with a confirmed diagnosis of autoimmune disease ,"Patients with suspected diseases were excluded. Inflammatory rheumatic diseases (e.g., rheumatoid arthritis and spondyloarthritis) were not included in our study.",2020-05-18,2020-07-02,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,469,0.066,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Renaud Felten,Hôpitaux Universitaires de Strasbourg studied patienst with rare autoimmune diseases (n=469) and found a seroprevalence of 6.6%,Not Unity-Aligned,https://dx.doi.org/10.1186/s13075-021-02565-0,2021-07-20,2022-07-16,Unverified,felten_incidence_2021,FRA
210721_Nancy_CHRUNancy_Primary,210721_Nancy_CHRUNancy,SARS-CoV-2 seroprevalence among Laboratory staff: Safe handling of COVID-19 samples.,2021-07-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,,Nancy,the whole laboratory staff of the Nancy University Hospital,,2020-04-01,2020-04-30,Health care workers and caregivers,All,Multiple groups,20.0,68.0,Primary Estimate,,396,0.023,,,True,,,,True,Entire sample,Biosynex COVID-19 BSS assay,Biosynex,LFIA,,"['IgG', 'IgM']",,,,,['High'],,Yes,No,Yes,,Yes,Yes,Yes,,C Hartard,Nancy University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2021.334,2021-07-27,2024-03-01,Unverified,hartard-sars-cov-2_2021,FRA
210722_Lyon_UniversitéClaudeBernardLyon1_overall,210722_Lyon_UniversitéClaudeBernardLyon1,Clinical and laboratory characteristics of symptomatic healthcare workers with suspected COVID-19: a prospective cohort study.,2021-07-22,Journal Article (Peer-Reviewed),Local,Prospective cohort,France,,Lyon,"HCWs with symptoms suggesting a SARS-CoV-2 infection (at least one of the following symptoms: fever, respiratory symptoms, headaches, anosmia, ageusia). The HCWs with negative SARS-CoV-2 PCR at inclusion came back one month later (V5) for SARS-CoV-2 serology testing ",HCWs with a previous positive SARS-CoV-2 RT-PCR test were excluded.,2020-05-10,2020-06-28,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,190,0.0368,,,True,,,,True,Convenience,"Wantai SARS-CoV-2 Total Ab ELISA,VIDAS® SARS-COV-2 IgG","Beijing Wantai Biological,BioMérieux",Multiple Types,Serum,"['IgG', 'TotalAntibody']",Spike,,,,['High'],No,No,No,No,No,Yes,Yes,No,Unclear,Antonin Bal,Université Claude Bernard Lyon 1,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-93828-y,2021-08-03,2024-03-01,Verified,bal_clinical_2021,FRA
210723_France_InstitutPasteur_overall_Luminex+Neut,210723_France_InstitutPasteur,Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern France.,2021-07-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,children attending hospitals in north-eastern France and adults in two hospitals. Analysed samples were either anonymous residual serum samples from medical care or samples collected in other clinical studies (INCOVPED NCT04336761) after informed consent,,2020-02-15,2020-08-15,Residual sera,All,Multiple groups,0.0,100.0,Primary Estimate,"Overall, Luminex + pseudoneutralization assay",2399,0.0529,,,True,,,,True,Convenience,"Author designed (Neutralization Assay),Author designed (Luminex)",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Envelopeprotein', 'Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,Unclear,Tom Woudenberg,Institut Pasteur,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103495,2021-08-02,2022-07-16,Verified,woudenberg_humoral_2021,FRA
210723_France_InstitutPasteur_overall_Neutralization,210723_France_InstitutPasteur,Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern France.,2021-07-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,children attending hospitals in north-eastern France and adults in two hospitals. Analysed samples were either anonymous residual serum samples from medical care or samples collected in other clinical studies (INCOVPED NCT04336761) after informed consent,,2020-02-15,2020-08-15,Residual sera,All,Multiple groups,0.0,100.0,Test used,"Overall, pseudoneutralization assay",2433,0.081,,,,,,,,Convenience,Author designed (Neutralization Assay),,Neutralization,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,Unclear,Tom Woudenberg,Institut Pasteur,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103495,2021-08-02,2022-07-16,Verified,woudenberg_humoral_2021,FRA
210723_France_InstitutPasteur_overall_LuLISA,210723_France_InstitutPasteur,Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern France.,2021-07-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,children attending hospitals in north-eastern France and adults in two hospitals. Analysed samples were either anonymous residual serum samples from medical care or samples collected in other clinical studies (INCOVPED NCT04336761) after informed consent,,2020-02-15,2020-08-15,Residual sera,All,Multiple groups,0.0,100.0,Test used,"Overall, LuLISA ",2449,0.06820000000000001,,,,,,,,Convenience,Author designed (CLIA),,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,Unclear,Tom Woudenberg,Institut Pasteur,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103495,2021-08-02,2022-07-16,Verified,woudenberg_humoral_2021,FRA
210723_France_InstitutPasteur_overall_Luminex+LuLISA,210723_France_InstitutPasteur,Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern France.,2021-07-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,children attending hospitals in north-eastern France and adults in two hospitals. Analysed samples were either anonymous residual serum samples from medical care or samples collected in other clinical studies (INCOVPED NCT04336761) after informed consent,,2020-02-15,2020-08-15,Residual sera,All,Multiple groups,0.0,100.0,Test used,"Overall, Luminex +LuLISA ",2415,0.047599999999999996,,,,,,,,Convenience,"Author designed (Luminex),Author designed (CLIA)",,Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,Unclear,Tom Woudenberg,Institut Pasteur,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103495,2021-08-02,2022-07-16,Verified,woudenberg_humoral_2021,FRA
210723_France_InstitutPasteur_overall_Feb-April,210723_France_InstitutPasteur,Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern France.,2021-07-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,children attending hospitals in north-eastern France and adults in two hospitals. Analysed samples were either anonymous residual serum samples from medical care or samples collected in other clinical studies (INCOVPED NCT04336761) after informed consent,,2020-02-15,2020-04-30,Residual sera,All,Multiple groups,0.0,100.0,Time frame,Sampling Feb to April 2020,1109,0.057,,,,,,,,Convenience,Author designed (Luminex),,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.98,0.99,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,Unclear,Tom Woudenberg,Institut Pasteur,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103495,2021-08-02,2022-07-16,Verified,woudenberg_humoral_2021,FRA
210723_France_InstitutPasteur_overall_Luminex,210723_France_InstitutPasteur,Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern France.,2021-07-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,children attending hospitals in north-eastern France and adults in two hospitals. Analysed samples were either anonymous residual serum samples from medical care or samples collected in other clinical studies (INCOVPED NCT04336761) after informed consent,,2020-02-15,2020-08-15,Residual sera,All,Multiple groups,0.0,100.0,Test used,"Overall, Luminex assay",2415,0.07200000000000001,,,,,,,,Convenience,Author designed (Luminex),,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.98,0.99,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,Unclear,Tom Woudenberg,Institut Pasteur,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103495,2021-08-02,2022-07-16,Verified,woudenberg_humoral_2021,FRA
210723_France_InstitutPasteur_overall_May-Aug,210723_France_InstitutPasteur,Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern France.,2021-07-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,children attending hospitals in north-eastern France and adults in two hospitals. Analysed samples were either anonymous residual serum samples from medical care or samples collected in other clinical studies (INCOVPED NCT04336761) after informed consent,,2020-05-01,2020-08-15,Residual sera,All,Multiple groups,0.0,100.0,Time frame,Sampling May to August 2020,1306,0.085,,,,,,,,Convenience,Author designed (Luminex),,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.98,0.99,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,Unclear,Tom Woudenberg,Institut Pasteur,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103495,2021-08-02,2022-07-16,Verified,woudenberg_humoral_2021,FRA
210723_France_InstitutPasteur_overall_LuLISA+Neut,210723_France_InstitutPasteur,Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern France.,2021-07-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,children attending hospitals in north-eastern France and adults in two hospitals. Analysed samples were either anonymous residual serum samples from medical care or samples collected in other clinical studies (INCOVPED NCT04336761) after informed consent,,2020-02-15,2020-08-15,Residual sera,All,Multiple groups,0.0,100.0,Test used,"Overall, LuLISA + pseudoneutralization assay",2433,0.046900000000000004,,,,,,,,Convenience,"Author designed (Neutralization Assay),Author designed (CLIA)",,Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,Unclear,Tom Woudenberg,Institut Pasteur,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103495,2021-08-02,2022-07-16,Verified,woudenberg_humoral_2021,FRA
210726_Corsica_UniversitédeCorse_Overall_PopTestAdj,210726_Corsica_UniversitédeCorse,Impact of the Second Epidemic Wave of SARS-CoV-2: Increased Exposure of Young People.,2021-07-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,,"""RS consisted of samples from individuals of all ages collected for routine screening or clinical management by 13 clinical laboratories located in five areas between 6 November, 2020 and 12 February, 2021""",,2020-11-06,2021-02-12,Residual sera,All,Multiple groups,0.0,101.0,Primary Estimate,,4505,0.087,,,True,True,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.903,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Lisandru Capai,Université de Corse,Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2021.715192,2021-08-17,2023-08-15,Verified,capai_impact_2021,FRA
210726_Corsica_UniversitédeCorse_20-29,210726_Corsica_UniversitédeCorse,Impact of the Second Epidemic Wave of SARS-CoV-2: Increased Exposure of Young People.,2021-07-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,,"""RS consisted of samples from individuals of all ages collected for routine screening or clinical management by 13 clinical laboratories located in five areas between 6 November, 2020 and 12 February, 2021""",,2020-11-06,2021-02-12,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29,404,0.13640000000000002,0.1042,0.16870000000000002,,,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.903,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Lisandru Capai,Université de Corse,Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2021.715192,2021-08-17,2024-03-01,Verified,capai_impact_2021,FRA
210726_Corsica_UniversitédeCorse_Female,210726_Corsica_UniversitédeCorse,Impact of the Second Epidemic Wave of SARS-CoV-2: Increased Exposure of Young People.,2021-07-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,,"""RS consisted of samples from individuals of all ages collected for routine screening or clinical management by 13 clinical laboratories located in five areas between 6 November, 2020 and 12 February, 2021""",,2020-11-06,2021-02-12,Residual sera,Female,Multiple groups,0.0,101.0,Sex/Gender,,2723,0.0706,0.0601,0.08109999999999999,,,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.903,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Lisandru Capai,Université de Corse,Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2021.715192,2021-08-17,2024-03-01,Verified,capai_impact_2021,FRA
210726_Corsica_UniversitédeCorse_80-89,210726_Corsica_UniversitédeCorse,Impact of the Second Epidemic Wave of SARS-CoV-2: Increased Exposure of Young People.,2021-07-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,,"""RS consisted of samples from individuals of all ages collected for routine screening or clinical management by 13 clinical laboratories located in five areas between 6 November, 2020 and 12 February, 2021""",,2020-11-06,2021-02-12,Residual sera,All,Seniors (65+ years),80.0,89.0,Age,80-89,519,0.0559,0.0275,0.0842,,,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.903,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Lisandru Capai,Université de Corse,Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2021.715192,2021-08-17,2024-03-01,Verified,capai_impact_2021,FRA
210726_Corsica_UniversitédeCorse_>=90,210726_Corsica_UniversitédeCorse,Impact of the Second Epidemic Wave of SARS-CoV-2: Increased Exposure of Young People.,2021-07-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,,"""RS consisted of samples from individuals of all ages collected for routine screening or clinical management by 13 clinical laboratories located in five areas between 6 November, 2020 and 12 February, 2021""",,2020-11-06,2021-02-12,Residual sera,All,Multiple groups,90.0,101.0,Age,>=90,222,0.0709,0.006600000000000001,0.1351,,,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.903,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Lisandru Capai,Université de Corse,Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2021.715192,2021-08-17,2024-03-01,Verified,capai_impact_2021,FRA
210726_Corsica_UniversitédeCorse_Overall_PopAdjTestUnadj,210726_Corsica_UniversitédeCorse,Impact of the Second Epidemic Wave of SARS-CoV-2: Increased Exposure of Young People.,2021-07-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,,"""RS consisted of samples from individuals of all ages collected for routine screening or clinical management by 13 clinical laboratories located in five areas between 6 November, 2020 and 12 February, 2021""",,2020-11-06,2021-02-12,Residual sera,All,Multiple groups,0.0,101.0,Analysis,,4505,0.0804,0.0724,0.0884,,,True,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.903,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Lisandru Capai,Université de Corse,Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2021.715192,2021-08-17,2024-03-01,Verified,capai_impact_2021,FRA
210726_Corsica_UniversitédeCorse_Overall_February2021,210726_Corsica_UniversitédeCorse,Impact of the Second Epidemic Wave of SARS-CoV-2: Increased Exposure of Young People.,2021-07-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,,"""RS consisted of samples from individuals of all ages collected for routine screening or clinical management by 13 clinical laboratories located in five areas between 6 November, 2020 and 12 February, 2021""",,2021-02-01,2021-02-12,Residual sera,All,Multiple groups,0.0,101.0,Time frame,February 2021,1254,0.08460000000000001,0.0692,0.1,,,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.903,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Lisandru Capai,Université de Corse,Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2021.715192,2021-08-19,2024-03-01,Verified,capai_impact_2021,FRA
210726_Corsica_UniversitédeCorse_December2020,210726_Corsica_UniversitédeCorse,Impact of the Second Epidemic Wave of SARS-CoV-2: Increased Exposure of Young People.,2021-07-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,,"""RS consisted of samples from individuals of all ages collected for routine screening or clinical management by 13 clinical laboratories located in five areas between 6 November, 2020 and 12 February, 2021""",,2020-12-01,2020-12-31,Residual sera,All,Multiple groups,0.0,101.0,Time frame,December 2020,1007,0.0868,0.0694,0.1041,,,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.903,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Lisandru Capai,Université de Corse,Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2021.715192,2021-08-19,2024-03-01,Verified,capai_impact_2021,FRA
210726_Corsica_UniversitédeCorse_10-19,210726_Corsica_UniversitédeCorse,Impact of the Second Epidemic Wave of SARS-CoV-2: Increased Exposure of Young People.,2021-07-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,,"""RS consisted of samples from individuals of all ages collected for routine screening or clinical management by 13 clinical laboratories located in five areas between 6 November, 2020 and 12 February, 2021""",,2020-11-06,2021-02-12,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,251,0.1092,0.0806,0.1379,,,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.903,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Lisandru Capai,Université de Corse,Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2021.715192,2021-08-17,2024-03-01,Verified,capai_impact_2021,FRA
210726_Corsica_UniversitédeCorse_30-39,210726_Corsica_UniversitédeCorse,Impact of the Second Epidemic Wave of SARS-CoV-2: Increased Exposure of Young People.,2021-07-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,,"""RS consisted of samples from individuals of all ages collected for routine screening or clinical management by 13 clinical laboratories located in five areas between 6 November, 2020 and 12 February, 2021""",,2020-11-06,2021-02-12,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,540,0.07980000000000001,0.0572,0.1024,,,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.903,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Lisandru Capai,Université de Corse,Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2021.715192,2021-08-17,2024-03-01,Verified,capai_impact_2021,FRA
210726_Corsica_UniversitédeCorse_January2021,210726_Corsica_UniversitédeCorse,Impact of the Second Epidemic Wave of SARS-CoV-2: Increased Exposure of Young People.,2021-07-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,,"""RS consisted of samples from individuals of all ages collected for routine screening or clinical management by 13 clinical laboratories located in five areas between 6 November, 2020 and 12 February, 2021""",,2021-01-01,2021-01-31,Residual sera,All,Multiple groups,0.0,101.0,Time frame,January 2021,1200,0.0809,0.0655,0.09640000000000001,,,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.903,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Lisandru Capai,Université de Corse,Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2021.715192,2021-08-19,2024-03-01,Verified,capai_impact_2021,FRA
210726_Corsica_UniversitédeCorse_0-9,210726_Corsica_UniversitédeCorse,Impact of the Second Epidemic Wave of SARS-CoV-2: Increased Exposure of Young People.,2021-07-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,,"""RS consisted of samples from individuals of all ages collected for routine screening or clinical management by 13 clinical laboratories located in five areas between 6 November, 2020 and 12 February, 2021""",,2020-11-06,2021-02-12,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,0-9,58,0.11140000000000001,0.08199999999999999,0.14070000000000002,,,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.903,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Lisandru Capai,Université de Corse,Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2021.715192,2021-08-17,2024-03-01,Verified,capai_impact_2021,FRA
210726_Corsica_UniversitédeCorse_November2020,210726_Corsica_UniversitédeCorse,Impact of the Second Epidemic Wave of SARS-CoV-2: Increased Exposure of Young People.,2021-07-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,,"""RS consisted of samples from individuals of all ages collected for routine screening or clinical management by 13 clinical laboratories located in five areas between 6 November, 2020 and 12 February, 2021""",,2020-11-06,2020-11-30,Residual sera,All,Multiple groups,0.0,101.0,Time frame,November 2020,947,0.0675,0.051500000000000004,0.0834,,,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.903,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Lisandru Capai,Université de Corse,Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2021.715192,2021-08-19,2024-03-01,Verified,capai_impact_2021,FRA
210726_Corsica_UniversitédeCorse_50-59,210726_Corsica_UniversitédeCorse,Impact of the Second Epidemic Wave of SARS-CoV-2: Increased Exposure of Young People.,2021-07-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,,"""RS consisted of samples from individuals of all ages collected for routine screening or clinical management by 13 clinical laboratories located in five areas between 6 November, 2020 and 12 February, 2021""",,2020-11-06,2021-02-12,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,695,0.07540000000000001,0.0547,0.09609999999999999,,,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.903,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Lisandru Capai,Université de Corse,Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2021.715192,2021-08-17,2024-03-01,Verified,capai_impact_2021,FRA
210726_Corsica_UniversitédeCorse_70-79,210726_Corsica_UniversitédeCorse,Impact of the Second Epidemic Wave of SARS-CoV-2: Increased Exposure of Young People.,2021-07-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,,"""RS consisted of samples from individuals of all ages collected for routine screening or clinical management by 13 clinical laboratories located in five areas between 6 November, 2020 and 12 February, 2021""",,2020-11-06,2021-02-12,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,638,0.048,0.028700000000000003,0.0672,,,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.903,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Lisandru Capai,Université de Corse,Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2021.715192,2021-08-17,2024-03-01,Verified,capai_impact_2021,FRA
210726_Corsica_UniversitédeCorse_40-49,210726_Corsica_UniversitédeCorse,Impact of the Second Epidemic Wave of SARS-CoV-2: Increased Exposure of Young People.,2021-07-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,,"""RS consisted of samples from individuals of all ages collected for routine screening or clinical management by 13 clinical laboratories located in five areas between 6 November, 2020 and 12 February, 2021""",,2020-11-06,2021-02-12,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,596,0.0687,0.04820000000000001,0.0892,,,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.903,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Lisandru Capai,Université de Corse,Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2021.715192,2021-08-17,2024-03-01,Verified,capai_impact_2021,FRA
210726_Corsica_UniversitédeCorse_Overall_Male,210726_Corsica_UniversitédeCorse,Impact of the Second Epidemic Wave of SARS-CoV-2: Increased Exposure of Young People.,2021-07-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,,"""RS consisted of samples from individuals of all ages collected for routine screening or clinical management by 13 clinical laboratories located in five areas between 6 November, 2020 and 12 February, 2021""",,2020-11-06,2021-02-12,Residual sera,Male,Multiple groups,0.0,101.0,Sex/Gender,,1782,0.0888,0.0768,0.1008,,,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.903,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Lisandru Capai,Université de Corse,Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2021.715192,2021-08-17,2024-03-01,Verified,capai_impact_2021,FRA
210726_Corsica_UniversitédeCorse_60-69,210726_Corsica_UniversitédeCorse,Impact of the Second Epidemic Wave of SARS-CoV-2: Increased Exposure of Young People.,2021-07-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Corsica,,"""RS consisted of samples from individuals of all ages collected for routine screening or clinical management by 13 clinical laboratories located in five areas between 6 November, 2020 and 12 February, 2021""",,2020-11-06,2021-02-12,Residual sera,All,Multiple groups,60.0,69.0,Age,60-69,582,0.04070000000000001,0.0246,0.0567,,,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.903,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Lisandru Capai,Université de Corse,Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2021.715192,2021-08-17,2024-03-01,Verified,capai_impact_2021,FRA
210727_FrenchAlps_AnnecyGenevoisHospital,210727_FrenchAlps_AnnecyGenevoisHospital,Effect of professional and extra-professional exposure on seroprevalence of SARS-CoV-2 infection among healthcare workers of the French alps: A multicentric cross-sectional study,2021-07-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,French Alps Region,,any volunteer healthcare institution employees could reach the occupational medicine unit to be screened for SARS-CoV-2 infection by serology testing. Medical and nursing students were also invited to be screened,,2020-06-27,2020-09-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,overall hcws in all 5 institutions,3454,0.05,0.043,0.057999999999999996,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']",,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,No,No,,Virginie Vitrat,Annecy Genevois Hospital,Not Unity-Aligned,http://dx.doi.org/10.3390/vaccines9080824,2021-08-17,2024-03-01,Verified,vitrat_effect_2021,FRA
210801_Europe_UniversityHospitalsPitiéSalpêtrière_Primary,210801_Europe_UniversityHospitalsPitiéSalpêtrière,SARS-CoV-2 outbreak in autoimmune diseases: The euro-covimid study,2021-08-01,Presentation or Conference,National,Cross-sectional survey ,France,,,"patients with five IMID (i.e. systemic lupus erythematous, Sjögren’s syndrome, rheumatoid arthritis, axial spondylarthritis or giant cell arteritis) from six tertiary-referral centers from France, Germany, Italy, Portugal, Spain and United Kingdom",,2020-06-07,2020-12-08,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,3028,0.055,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['Moderate'],,Unclear,Yes,Yes,,Unclear,Yes,No,,D Saadoun,University Hospitals Pitié Salpêtrière,Not Unity-Aligned,http://dx.doi.org/10.1136/annrheumdis-2021-eular.3368,2021-08-24,2022-07-16,Unverified,saadoun_outbreak_2021,FRA
210812_Amiens_UniversitéPicardieJules-Verne_LTC,210812_Amiens_UniversitéPicardieJules-Verne_LTC,[Covid-19 serology in nursing home and long-term care: prevalence of seroconversion in the Amiens-Picardie University Hospital].,2021-08-12,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,France,Hauts-de-France  ,Amiens,Residents of the long term care home at CHU Amiens-Picardie were asked to participate in the study. Patients who consented a few days prior to sample collection dates and present during collection dates were included.,,2020-06-15,2020-06-16,Assisted living and long-term care facilities,All,Seniors (65+ years),,,Primary Estimate,,114,0.456,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,ELISA,Serum,IgG,,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Julien Moyet,Université Picardie Jules-Verne,Not Unity-Aligned,https://www.jle.com/10.1684/pnv.2021.0952,2021-08-31,2024-03-01,Unverified,moyet_serologie_2016,FRA
210812_Amiens_UniversitéPicardieJules-Verne_NH,210812_Amiens_UniversitéPicardieJules-Verne_NH,[Covid-19 serology in nursing home and long-term care: prevalence of seroconversion in the Amiens-Picardie University Hospital].,2021-08-12,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,France,Hauts-de-France  ,Amiens,Residents of the nursing home at CHU Amiens-Picardie were asked to participate in the study. Patients who consented a few days prior to sample collection dates and present during collection dates were included.,,2020-06-15,2020-06-16,Assisted living and long-term care facilities,All,Seniors (65+ years),,,Primary Estimate,,107,0.887,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,ELISA,Serum,IgG,,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Julien Moyet,Université Picardie Jules-Verne,Not Unity-Aligned,https://www.jle.com/10.1684/pnv.2021.0952,2021-08-31,2024-03-01,Unverified,moyet_serologie_2016,FRA
210906_Strasbourg_CHUdeStrasbourg_Overall,210906_Strasbourg_CHUdeStrasbourg,High SARS-CoV-2 seroconversion rate among geriatric staff from Strasbourg University Hospitals.,2021-09-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Grand Est,Strasbourg,"From June 22th, 2020 to November 1st, 2020, SARS-CoV-2 serology was offered to all hospital staff at SUH. Both symptomatic and asymptomatic staff were included (Supplementary Table 2). ",,2020-06-22,2020-11-01,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,5694,0.08465050930000001,,,True,,,,True,Convenience,Biosynex COVID-19 BSS assay,Biosynex,LFIA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.93,0.99,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Baptiste Panaget,Centres Hospitaliers et Universitaires de Strasbourg ,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2021.402,2021-09-14,2024-03-01,Unverified,panaget_high_2021,FRA
210920_France_ToulouseUniversityHospital,210920_France_ToulouseUniversityHospital,Antibody titers and protection against a SARS-CoV-2 infection.,2021-09-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,"Healthcare workers, both vaccinated and unvaccinated",,2020-06-10,2020-07-10,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,8758,0.032,,,True,,,,True,Unclear,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,,TotalAntibody,Spike,,,,['Moderate'],Unclear,Unclear,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Chloe Dimeglio,Tolouse University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.09.013,2021-10-06,2024-03-01,Verified,dimeglio_antibody_2021,FRA
211014_Marseille_AixMarseilleUniversity,211014_Marseille_AixMarseilleUniversity,"COVID-19 outbreak among French firefighters, Marseille, France, 2020.",2021-10-14,Journal Article (Peer-Reviewed),Local,Retrospective cohort,France,,Marseille,Firefighters at a Marseilles fire station experiencing a COVID-19 outbreak. ,,2020-04-02,2020-04-06,Essential non-healthcare workers,Male,Adults (18-64 years),20.0,51.0,Primary Estimate,,85,0.258823529,,,True,,,,True,Entire sample,Author designed (type unknown),,,Serum,Neutralizing,,,,,['High'],,Yes,No,No,,Unclear,Yes,No,,Guillaume Durand,Aix Marseille University,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.41.2001676,2021-10-24,2022-07-16,Unverified,durand_covid-19_2021,FRA
211019_Paris_HopitalEuropeenGeorgesPompidou_Primary,211019_Paris_HopitalEuropeenGeorgesPompidou,No SARS-CoV-2 reinfection among staff health-care workers: Prospective hospital-wide screening during the first and second waves in Paris.,2021-10-19,Journal Article (Peer-Reviewed),Local,Prospective cohort,France,,Paris,"Volunteer HCWs from the Hopital Europeen Georges Pompidou, Assistance Publique-Hopitaux de Paris","HCW participants included during the first wave but not tested during the second wave, and those included during the second wave but not tested during the first wave were categorized as participants with not available results (NA)",2020-03-05,2020-12-04,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,3186,0.121,0.11,0.133,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Maxime Wack,Hopital Europeen Georges Pompidou,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcv.2021.104999,2021-11-03,2024-03-01,Unverified,wack_no_2021,FRA
211021_France_UNIVIsanté,211021_France_UNIVIsanté,"[Seroprevalence, risk factors and clinical presentation after the first wave of COVID-19 in nursing homes of the UNIVI group: The SEROCOVID study].",2021-10-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,"Residents of 27 EHPADs (French nursing homes)
""The only inclusion criteria were to have received a sero-rapid ELISA test, and that the resident's non-objection legal representative or his trusted person may have been collected.""",,2020-08-31,2020-10-16,Assisted living and long-term care facilities,All,Seniors (65+ years),,,Primary Estimate,,1141,0.14400000000000002,0.12400000000000001,0.16399999999999998,True,,,,True,Unclear,Author designed (ELISA) - Unknown,,ELISA,Whole Blood,IgG,,,,,['High'],,Unclear,Yes,Yes,,Unclear,Yes,No,,Marc Harboun,UNIVI santé,Not Unity-Aligned,https://dx.doi.org/10.1016/j.revmed.2021.10.330,2021-11-10,2022-07-16,Unverified,harboun_seroprevalence_2021,FRA
211026_France_UniversitéParisSaclay_May(Round1)_Primary,211026_France_UniversitéParisSaclay_May_Round1,Trends in social exposure to SARS-Cov-2 in France. Evidence from the national socio-epidemiological cohort – EPICOV,2021-10-26,Preprint,National,Repeated cross-sectional study,France,,,A population-based cohort of individuals aged 15 years or over was randomly selected from the national tax register.,Residents in nursing homes for elderly persons were excluded.,2020-05-01,2020-05-31,Household and community samples,All,Multiple groups,15.0,,Primary Estimate,,12114,0.045,0.04,0.051,True,,True,,True,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by manufacturers,0.9440000000000001,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Josiane Warszawski,Université Paris-Saclay,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.10.25.21265456v1.full-text,2021-11-03,2024-03-01,Verified,warszawski_trends_2021,FRA
211026_France_UniversitéParisSaclay_May(Round1)_Age_65-74,211026_France_UniversitéParisSaclay_May_Round1,Trends in social exposure to SARS-Cov-2 in France. Evidence from the national socio-epidemiological cohort – EPICOV,2021-10-26,Preprint,National,Repeated cross-sectional study,France,,,A population-based cohort of individuals aged 15 years or over was randomly selected from the national tax register.,Residents in nursing homes for elderly persons were excluded.,2020-05-01,2020-05-31,Household and community samples,All,Seniors (65+ years),65.0,74.0,Age,65-74,1727,0.018000000000000002,0.012,0.027000000000000003,,,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by manufacturers,0.9440000000000001,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Josiane Warszawski,Université Paris-Saclay,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.10.25.21265456v1.full-text,2021-11-03,2024-03-01,Verified,warszawski_trends_2021,FRA
211026_France_UniversitéParisSaclay_May(Round1)_Sex_Male,211026_France_UniversitéParisSaclay_May_Round1,Trends in social exposure to SARS-Cov-2 in France. Evidence from the national socio-epidemiological cohort – EPICOV,2021-10-26,Preprint,National,Repeated cross-sectional study,France,,,A population-based cohort of individuals aged 15 years or over was randomly selected from the national tax register.,Residents in nursing homes for elderly persons were excluded.,2020-05-01,2020-05-31,Household and community samples,Male,Multiple groups,,,Sex/Gender,,5469,0.039,0.031000000000000003,0.048,,,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by manufacturers,0.9440000000000001,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Josiane Warszawski,Université Paris-Saclay,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.10.25.21265456v1.full-text,2021-11-03,2024-03-01,Verified,warszawski_trends_2021,FRA
211026_France_UniversitéParisSaclay_May(Round1)_Age_15-17,211026_France_UniversitéParisSaclay_May_Round1,Trends in social exposure to SARS-Cov-2 in France. Evidence from the national socio-epidemiological cohort – EPICOV,2021-10-26,Preprint,National,Repeated cross-sectional study,France,,,A population-based cohort of individuals aged 15 years or over was randomly selected from the national tax register.,Residents in nursing homes for elderly persons were excluded.,2020-05-01,2020-05-31,Household and community samples,All,Children and Youth (0-17 years),15.0,17.0,Age,15-17,418,0.045,0.022000000000000002,0.08900000000000001,,,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by manufacturers,0.9440000000000001,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Josiane Warszawski,Université Paris-Saclay,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.10.25.21265456v1.full-text,2021-11-03,2024-03-01,Verified,warszawski_trends_2021,FRA
211026_France_UniversitéParisSaclay_May(Round1)_Age_45-54,211026_France_UniversitéParisSaclay_May_Round1,Trends in social exposure to SARS-Cov-2 in France. Evidence from the national socio-epidemiological cohort – EPICOV,2021-10-26,Preprint,National,Repeated cross-sectional study,France,,,A population-based cohort of individuals aged 15 years or over was randomly selected from the national tax register.,Residents in nursing homes for elderly persons were excluded.,2020-05-01,2020-05-31,Household and community samples,All,Adults (18-64 years),45.0,54.0,Age,45-54,2340,0.049,0.039,0.062000000000000006,,,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by manufacturers,0.9440000000000001,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Josiane Warszawski,Université Paris-Saclay,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.10.25.21265456v1.full-text,2021-11-03,2024-03-01,Verified,warszawski_trends_2021,FRA
211026_France_UniversitéParisSaclay_May(Round1)_Age_18-24,211026_France_UniversitéParisSaclay_May_Round1,Trends in social exposure to SARS-Cov-2 in France. Evidence from the national socio-epidemiological cohort – EPICOV,2021-10-26,Preprint,National,Repeated cross-sectional study,France,,,A population-based cohort of individuals aged 15 years or over was randomly selected from the national tax register.,Residents in nursing homes for elderly persons were excluded.,2020-05-01,2020-05-31,Household and community samples,All,Adults (18-64 years),18.0,24.0,Age,18-24,1042,0.048,0.03,0.076,,,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by manufacturers,0.9440000000000001,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Josiane Warszawski,Université Paris-Saclay,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.10.25.21265456v1.full-text,2021-11-03,2024-03-01,Verified,warszawski_trends_2021,FRA
211026_France_UniversitéParisSaclay_May(Round1)_Age_55-64,211026_France_UniversitéParisSaclay_May_Round1,Trends in social exposure to SARS-Cov-2 in France. Evidence from the national socio-epidemiological cohort – EPICOV,2021-10-26,Preprint,National,Repeated cross-sectional study,France,,,A population-based cohort of individuals aged 15 years or over was randomly selected from the national tax register.,Residents in nursing homes for elderly persons were excluded.,2020-05-01,2020-05-31,Household and community samples,All,Adults (18-64 years),55.0,64.0,Age,55-64,2234,0.048,0.033,0.071,,,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by manufacturers,0.9440000000000001,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Josiane Warszawski,Université Paris-Saclay,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.10.25.21265456v1.full-text,2021-11-03,2024-03-01,Verified,warszawski_trends_2021,FRA
211026_France_UniversitéParisSaclay_May(Round1)_Age_35-44 ,211026_France_UniversitéParisSaclay_May_Round1,Trends in social exposure to SARS-Cov-2 in France. Evidence from the national socio-epidemiological cohort – EPICOV,2021-10-26,Preprint,National,Repeated cross-sectional study,France,,,A population-based cohort of individuals aged 15 years or over was randomly selected from the national tax register.,Residents in nursing homes for elderly persons were excluded.,2020-05-01,2020-05-31,Household and community samples,All,Adults (18-64 years),35.0,44.0,Age,35-44,2050,0.083,0.067,0.10400000000000001,,,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by manufacturers,0.9440000000000001,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Josiane Warszawski,Université Paris-Saclay,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.10.25.21265456v1.full-text,2021-11-03,2024-03-01,Verified,warszawski_trends_2021,FRA
211026_France_UniversitéParisSaclay_May(Round1)_Age_25-34,211026_France_UniversitéParisSaclay_May_Round1,Trends in social exposure to SARS-Cov-2 in France. Evidence from the national socio-epidemiological cohort – EPICOV,2021-10-26,Preprint,National,Repeated cross-sectional study,France,,,A population-based cohort of individuals aged 15 years or over was randomly selected from the national tax register.,Residents in nursing homes for elderly persons were excluded.,2020-05-01,2020-05-31,Household and community samples,All,Adults (18-64 years),25.0,34.0,Age,25-34,1544,0.05,0.037000000000000005,0.067,,,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by manufacturers,0.9440000000000001,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Josiane Warszawski,Université Paris-Saclay,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.10.25.21265456v1.full-text,2021-11-03,2024-03-01,Verified,warszawski_trends_2021,FRA
211026_France_UniversitéParisSaclay_May(Round1)_Sex_Female,211026_France_UniversitéParisSaclay_May_Round1,Trends in social exposure to SARS-Cov-2 in France. Evidence from the national socio-epidemiological cohort – EPICOV,2021-10-26,Preprint,National,Repeated cross-sectional study,France,,,A population-based cohort of individuals aged 15 years or over was randomly selected from the national tax register.,Residents in nursing homes for elderly persons were excluded.,2020-05-01,2020-05-31,Household and community samples,Female,Multiple groups,,,Sex/Gender,,6645,0.05,0.043,0.059000000000000004,,,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by manufacturers,0.9440000000000001,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Josiane Warszawski,Université Paris-Saclay,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.10.25.21265456v1.full-text,2021-11-03,2024-03-01,Verified,warszawski_trends_2021,FRA
211026_France_UniversitéParisSaclay_May(Round1)_Age_75+,211026_France_UniversitéParisSaclay_May_Round1,Trends in social exposure to SARS-Cov-2 in France. Evidence from the national socio-epidemiological cohort – EPICOV,2021-10-26,Preprint,National,Repeated cross-sectional study,France,,,A population-based cohort of individuals aged 15 years or over was randomly selected from the national tax register.,Residents in nursing homes for elderly persons were excluded.,2020-05-01,2020-05-31,Household and community samples,All,Seniors (65+ years),75.0,,Age,75+,759,0.006999999999999999,0.004,0.013999999999999999,,,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by manufacturers,0.9440000000000001,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Josiane Warszawski,Université Paris-Saclay,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.10.25.21265456v1.full-text,2021-11-03,2024-03-01,Verified,warszawski_trends_2021,FRA
211026_France_UniversitéParisSaclay_November(Round2)_Primary,211026_France_UniversitéParisSaclay_November_Round2,Trends in social exposure to SARS-Cov-2 in France. Evidence from the national socio-epidemiological cohort – EPICOV,2021-10-26,Preprint,National,Repeated cross-sectional study,France,,,A population-based cohort of individuals aged 15 years or over was randomly selected from the national tax register.,Residents in nursing homes for elderly persons were excluded.,2020-11-01,2020-11-30,Household and community samples,All,Multiple groups,15.0,,Primary Estimate,,63524,0.062000000000000006,0.059000000000000004,0.066,True,,True,,True,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by manufacturers,0.9440000000000001,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Josiane Warszawski,Université Paris-Saclay,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.10.25.21265456v1.full-text,2021-11-03,2024-03-01,Verified,warszawski_trends_2021,FRA
211026_France_UniversitéParisSaclay_November(Round2)_Age_75+,211026_France_UniversitéParisSaclay_November_Round2,Trends in social exposure to SARS-Cov-2 in France. Evidence from the national socio-epidemiological cohort – EPICOV,2021-10-26,Preprint,National,Repeated cross-sectional study,France,,,A population-based cohort of individuals aged 15 years or over was randomly selected from the national tax register.,Residents in nursing homes for elderly persons were excluded.,2020-11-01,2020-11-30,Household and community samples,All,Seniors (65+ years),75.0,,Age,75+,3920,0.037000000000000005,0.028999999999999998,0.047,,,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by manufacturers,0.9440000000000001,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Josiane Warszawski,Université Paris-Saclay,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.10.25.21265456v1.full-text,2021-11-03,2024-03-01,Verified,warszawski_trends_2021,FRA
211026_France_UniversitéParisSaclay_November(Round2)_Sex_Male,211026_France_UniversitéParisSaclay_November_Round2,Trends in social exposure to SARS-Cov-2 in France. Evidence from the national socio-epidemiological cohort – EPICOV,2021-10-26,Preprint,National,Repeated cross-sectional study,France,,,A population-based cohort of individuals aged 15 years or over was randomly selected from the national tax register.,Residents in nursing homes for elderly persons were excluded.,2020-11-01,2020-11-30,Household and community samples,Male,Multiple groups,,,Sex/Gender,,27564,0.061,0.057,0.066,,,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by manufacturers,0.9440000000000001,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Josiane Warszawski,Université Paris-Saclay,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.10.25.21265456v1.full-text,2021-11-03,2024-03-01,Verified,warszawski_trends_2021,FRA
211026_France_UniversitéParisSaclay_November(Round2)_Sex_Female,211026_France_UniversitéParisSaclay_November_Round2,Trends in social exposure to SARS-Cov-2 in France. Evidence from the national socio-epidemiological cohort – EPICOV,2021-10-26,Preprint,National,Repeated cross-sectional study,France,,,A population-based cohort of individuals aged 15 years or over was randomly selected from the national tax register.,Residents in nursing homes for elderly persons were excluded.,2020-11-01,2020-11-30,Household and community samples,Female,Multiple groups,,,Sex/Gender,,35960,0.064,0.06,0.068,,,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by manufacturers,0.9440000000000001,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Josiane Warszawski,Université Paris-Saclay,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.10.25.21265456v1.full-text,2021-11-03,2024-03-01,Verified,warszawski_trends_2021,FRA
211026_France_UniversitéParisSaclay_November(Round2)_Age_55-64,211026_France_UniversitéParisSaclay_November_Round2,Trends in social exposure to SARS-Cov-2 in France. Evidence from the national socio-epidemiological cohort – EPICOV,2021-10-26,Preprint,National,Repeated cross-sectional study,France,,,A population-based cohort of individuals aged 15 years or over was randomly selected from the national tax register.,Residents in nursing homes for elderly persons were excluded.,2020-11-01,2020-11-30,Household and community samples,All,Adults (18-64 years),55.0,64.0,Age,55-64,12879,0.053,0.048,0.057999999999999996,,,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by manufacturers,0.9440000000000001,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Josiane Warszawski,Université Paris-Saclay,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.10.25.21265456v1.full-text,2021-11-03,2024-03-01,Verified,warszawski_trends_2021,FRA
211026_France_UniversitéParisSaclay_November(Round2)_Age_25-34,211026_France_UniversitéParisSaclay_November_Round2,Trends in social exposure to SARS-Cov-2 in France. Evidence from the national socio-epidemiological cohort – EPICOV,2021-10-26,Preprint,National,Repeated cross-sectional study,France,,,A population-based cohort of individuals aged 15 years or over was randomly selected from the national tax register.,Residents in nursing homes for elderly persons were excluded.,2020-11-01,2020-11-30,Household and community samples,All,Adults (18-64 years),25.0,34.0,Age,25-34,6816,0.07200000000000001,0.063,0.083,,,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by manufacturers,0.9440000000000001,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Josiane Warszawski,Université Paris-Saclay,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.10.25.21265456v1.full-text,2021-11-03,2024-03-01,Verified,warszawski_trends_2021,FRA
211026_France_UniversitéParisSaclay_November(Round2)_Age_45-54,211026_France_UniversitéParisSaclay_November_Round2,Trends in social exposure to SARS-Cov-2 in France. Evidence from the national socio-epidemiological cohort – EPICOV,2021-10-26,Preprint,National,Repeated cross-sectional study,France,,,A population-based cohort of individuals aged 15 years or over was randomly selected from the national tax register.,Residents in nursing homes for elderly persons were excluded.,2020-11-01,2020-11-30,Household and community samples,All,Adults (18-64 years),45.0,54.0,Age,45-54,12596,0.065,0.059000000000000004,0.07200000000000001,,,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by manufacturers,0.9440000000000001,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Josiane Warszawski,Université Paris-Saclay,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.10.25.21265456v1.full-text,2021-11-03,2024-03-01,Verified,warszawski_trends_2021,FRA
211026_France_UniversitéParisSaclay_November(Round2)_Age_15-17,211026_France_UniversitéParisSaclay_November_Round2,Trends in social exposure to SARS-Cov-2 in France. Evidence from the national socio-epidemiological cohort – EPICOV,2021-10-26,Preprint,National,Repeated cross-sectional study,France,,,A population-based cohort of individuals aged 15 years or over was randomly selected from the national tax register.,Residents in nursing homes for elderly persons were excluded.,2020-11-01,2020-11-30,Household and community samples,All,Children and Youth (0-17 years),15.0,17.0,Age,15-17,1438,0.098,0.078,0.122,,,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by manufacturers,0.9440000000000001,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Josiane Warszawski,Université Paris-Saclay,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.10.25.21265456v1.full-text,2021-11-03,2024-03-01,Verified,warszawski_trends_2021,FRA
211026_France_UniversitéParisSaclay_November(Round2)_Age_18-24,211026_France_UniversitéParisSaclay_November_Round2,Trends in social exposure to SARS-Cov-2 in France. Evidence from the national socio-epidemiological cohort – EPICOV,2021-10-26,Preprint,National,Repeated cross-sectional study,France,,,A population-based cohort of individuals aged 15 years or over was randomly selected from the national tax register.,Residents in nursing homes for elderly persons were excluded.,2020-11-01,2020-11-30,Household and community samples,All,Adults (18-64 years),18.0,24.0,Age,18-24,4919,0.1,0.086,0.115,,,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by manufacturers,0.9440000000000001,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Josiane Warszawski,Université Paris-Saclay,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.10.25.21265456v1.full-text,2021-11-03,2024-03-01,Verified,warszawski_trends_2021,FRA
211026_France_UniversitéParisSaclay_November(Round2)_Age_35-44,211026_France_UniversitéParisSaclay_November_Round2,Trends in social exposure to SARS-Cov-2 in France. Evidence from the national socio-epidemiological cohort – EPICOV,2021-10-26,Preprint,National,Repeated cross-sectional study,France,,,A population-based cohort of individuals aged 15 years or over was randomly selected from the national tax register.,Residents in nursing homes for elderly persons were excluded.,2020-11-01,2020-11-30,Household and community samples,All,Adults (18-64 years),35.0,44.0,Age,35-44,10345,0.065,0.057999999999999996,0.07400000000000001,,,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by manufacturers,0.9440000000000001,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Josiane Warszawski,Université Paris-Saclay,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.10.25.21265456v1.full-text,2021-11-03,2024-03-01,Verified,warszawski_trends_2021,FRA
211026_France_UniversitéParisSaclay_November(Round2)_Age_65-74,211026_France_UniversitéParisSaclay_November_Round2,Trends in social exposure to SARS-Cov-2 in France. Evidence from the national socio-epidemiological cohort – EPICOV,2021-10-26,Preprint,National,Repeated cross-sectional study,France,,,A population-based cohort of individuals aged 15 years or over was randomly selected from the national tax register.,Residents in nursing homes for elderly persons were excluded.,2020-11-01,2020-11-30,Household and community samples,All,Seniors (65+ years),65.0,74.0,Age,65-74,10611,0.043,0.038,0.049,,,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by manufacturers,0.9440000000000001,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Josiane Warszawski,Université Paris-Saclay,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.10.25.21265456v1.full-text,2021-11-03,2024-03-01,Verified,warszawski_trends_2021,FRA
211109_Strasbourg_StrasbourgUniversityHospitals_V0,211109_Strasbourg_StrasbourgUniversityHospitals,"COVID-19 exposure in SARS-CoV-2-seropositive hospital staff members during the first pandemic wave at Strasbourg University Hospital, France.",2021-11-09,Preprint,Local,Cross-sectional survey ,France,,Strasbourg,Participants were whom randomly selected among the entire SUH staff members by the occupational health department and invited by phone call to participate in this study.,,2020-04-06,2020-05-07,Health care workers and caregivers,All,Multiple groups,19.0,73.0,Primary Estimate,,1497,0.344,,,True,,,,True,Stratified probability,"Biosynex COVID-19 BSS assay,EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit","Biosynex,Epitope Diagnostics, Inc.",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,A Velay,Strasbourg University Hospitals,Not Unity-Aligned,https://dx.doi.org/10.1016/j.idnow.2021.11.002,2021-11-22,2024-03-01,Unverified,velay_covid-19_2021,FRA
211111_Rennes_RennesUniversityHospital_Primary,211111_Rennes_RennesUniversityHospital,Risk factors for SARS-CoV-2 infection among health care workers,2021-11-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,,Rennes,HCWs at Rennes University Hospital,,2020-05-29,2020-07-10,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,3234,0.038,,,True,,,,True,Convenience,"NG-Test® finger-prick test,Wantai SARS-CoV-2 IgG ELISA","NG Biotech Laboratoires,Beijing Wantai Biological",Multiple Types,Serum,IgG,,Validated by independent authors/third party/non-developers,,,['Moderate'],,No,Yes,Yes,,No,Yes,No,,Christophe Paris,Rennes University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ajic.2021.11.001,2021-11-24,2024-03-01,Unverified,paris_risk_2021-2,FRA
211123_Perpignan_PerpignanHospitalCenter_Overall,211123_Perpignan_PerpignanHospitalCenter,Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study.,2021-11-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Occitanie,Perpignan,"the population living in three neighbourhoods (Saint-Jacques (neighbourhood A), Haut-Vernet (neighbourhood B) and Nouveau Logis (neighbourhood C)) in the city of Perpignan

Individuals were eligible if they were 6 years old or over, had resided in the study area between 1 January 2020 and the survey date, were physically able to move to one of the study’s five purpose-built survey centres and were able to answer the survey questionnaire.",,2020-06-29,2020-07-17,Household and community samples,All,Multiple groups,6.0,,Primary Estimate,,700,0.354,0.302,0.41000000000000003,True,,True,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Spike,Validated by developers,0.995,0.998,['Moderate'],No,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Adeline Beaumont,Perpignan Hospital Center,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-053201,2021-12-01,2024-03-01,Unverified,beaumont_seroprevalence_2021,FRA
211123_Perpignan_PerpignanHospitalCenter_SexFemale,211123_Perpignan_PerpignanHospitalCenter,Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study.,2021-11-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Occitanie,Perpignan,"the population living in three neighbourhoods (Saint-Jacques (neighbourhood A), Haut-Vernet (neighbourhood B) and Nouveau Logis (neighbourhood C)) in the city of Perpignan

Individuals were eligible if they were 6 years old or over, had resided in the study area between 1 January 2020 and the survey date, were physically able to move to one of the study’s five purpose-built survey centres and were able to answer the survey questionnaire.",,2020-06-29,2020-07-17,Household and community samples,Female,Multiple groups,6.0,,Sex/Gender,,413,0.392,0.331,0.456,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Spike,Validated by developers,0.995,0.998,['Moderate'],No,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Adeline Beaumont,Perpignan Hospital Center,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-053201,2021-12-01,2024-03-01,Unverified,beaumont_seroprevalence_2021,FRA
211123_Perpignan_PerpignanHospitalCenter_Age20-64,211123_Perpignan_PerpignanHospitalCenter,Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study.,2021-11-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Occitanie,Perpignan,"the population living in three neighbourhoods (Saint-Jacques (neighbourhood A), Haut-Vernet (neighbourhood B) and Nouveau Logis (neighbourhood C)) in the city of Perpignan

Individuals were eligible if they were 6 years old or over, had resided in the study area between 1 January 2020 and the survey date, were physically able to move to one of the study’s five purpose-built survey centres and were able to answer the survey questionnaire.",,2020-06-29,2020-07-17,Household and community samples,All,Adults (18-64 years),20.0,64.0,Age,,468,0.36100000000000004,0.309,0.418,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Spike,Validated by developers,0.995,0.998,['Moderate'],No,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Adeline Beaumont,Perpignan Hospital Center,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-053201,2021-12-01,2024-03-01,Unverified,beaumont_seroprevalence_2021,FRA
211123_Perpignan_PerpignanHospitalCenter_Age15-19,211123_Perpignan_PerpignanHospitalCenter,Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study.,2021-11-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Occitanie,Perpignan,"the population living in three neighbourhoods (Saint-Jacques (neighbourhood A), Haut-Vernet (neighbourhood B) and Nouveau Logis (neighbourhood C)) in the city of Perpignan

Individuals were eligible if they were 6 years old or over, had resided in the study area between 1 January 2020 and the survey date, were physically able to move to one of the study’s five purpose-built survey centres and were able to answer the survey questionnaire.",,2020-06-29,2020-07-17,Household and community samples,All,Children and Youth (0-17 years),15.0,19.0,Age,15-19,57,0.504,0.355,0.652,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Spike,Validated by developers,0.995,0.998,['Moderate'],No,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Adeline Beaumont,Perpignan Hospital Center,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-053201,2021-12-01,2024-03-01,Unverified,beaumont_seroprevalence_2021,FRA
211123_Perpignan_PerpignanHospitalCenter_SexMale,211123_Perpignan_PerpignanHospitalCenter,Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study.,2021-11-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Occitanie,Perpignan,"the population living in three neighbourhoods (Saint-Jacques (neighbourhood A), Haut-Vernet (neighbourhood B) and Nouveau Logis (neighbourhood C)) in the city of Perpignan

Individuals were eligible if they were 6 years old or over, had resided in the study area between 1 January 2020 and the survey date, were physically able to move to one of the study’s five purpose-built survey centres and were able to answer the survey questionnaire.",,2020-06-29,2020-07-17,Household and community samples,Male,Multiple groups,6.0,,Sex/Gender,,287,0.315,0.242,0.4,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Spike,Validated by developers,0.995,0.998,['Moderate'],No,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Adeline Beaumont,Perpignan Hospital Center,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-053201,2021-12-01,2024-03-01,Unverified,beaumont_seroprevalence_2021,FRA
211123_Perpignan_PerpignanHospitalCenter_Age6-14,211123_Perpignan_PerpignanHospitalCenter,Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study.,2021-11-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Occitanie,Perpignan,"the population living in three neighbourhoods (Saint-Jacques (neighbourhood A), Haut-Vernet (neighbourhood B) and Nouveau Logis (neighbourhood C)) in the city of Perpignan

Individuals were eligible if they were 6 years old or over, had resided in the study area between 1 January 2020 and the survey date, were physically able to move to one of the study’s five purpose-built survey centres and were able to answer the survey questionnaire.",,2020-06-29,2020-07-17,Household and community samples,All,Children and Youth (0-17 years),6.0,14.0,Age,6-14,60,0.33899999999999997,0.2,0.513,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Spike,Validated by developers,0.995,0.998,['Moderate'],No,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Adeline Beaumont,Perpignan Hospital Center,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-053201,2021-12-01,2024-03-01,Unverified,beaumont_seroprevalence_2021,FRA
211123_Perpignan_PerpignanHospitalCenter_Age65+,211123_Perpignan_PerpignanHospitalCenter,Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study.,2021-11-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Occitanie,Perpignan,"the population living in three neighbourhoods (Saint-Jacques (neighbourhood A), Haut-Vernet (neighbourhood B) and Nouveau Logis (neighbourhood C)) in the city of Perpignan

Individuals were eligible if they were 6 years old or over, had resided in the study area between 1 January 2020 and the survey date, were physically able to move to one of the study’s five purpose-built survey centres and were able to answer the survey questionnaire.",,2020-06-29,2020-07-17,Household and community samples,All,Seniors (65+ years),65.0,,Age,,115,0.147,0.08900000000000001,0.23199999999999998,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Spike,Validated by developers,0.995,0.998,['Moderate'],No,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Adeline Beaumont,Perpignan Hospital Center,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-053201,2021-12-01,2024-03-01,Unverified,beaumont_seroprevalence_2021,FRA
211125_France_UnitédesVirusÉmergents_Overall_PopAdjusted,211125_France_UnitédesVirusÉmergents,"Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France.",2021-11-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,"Haut de France, Normandi, Ile de France, Bretagne, Grand Est, Bourgogne France Comte, Centre val de Loire, Auvergne Rhome Alpes, Pays de Loire, Occitanie, Nouvelle Aquitaine, Provence-Alpes-Côte d'Azur",,"Participants living in mainland France who completed the questionnaires (SAPRIS) and who agreed to the serology received a DBS kit to be returned to the centralized biobank after capillary blood collection (CEPH Biobank, Paris, France).",,2020-05-04,2020-09-30,Household and community samples,All,Multiple groups,20.0,,Primary Estimate,Pop Adjusted,82126,0.051,0.049,0.054000000000000006,True,,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.87,0.975,['High'],Yes,No,Yes,Yes,No,Yes,Yes,No,Yes,Fabrice Carrat,Unité des Virus Émergents,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01731-5,2021-12-03,2024-03-01,Verified,carrat_age_2021,FRA
211125_France_UnitédesVirusÉmergents_Age60-69,211125_France_UnitédesVirusÉmergents,"Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France.",2021-11-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,"Haut de France, Normandi, Ile de France, Bretagne, Grand Est, Bourgogne France Comte, Centre val de Loire, Auvergne Rhome Alpes, Pays de Loire, Occitanie, Nouvelle Aquitaine, Provence-Alpes-Côte d'Azur",,"Participants living in mainland France who completed the questionnaires (SAPRIS) and who agreed to the serology received a DBS kit to be returned to the centralized biobank after capillary blood collection (CEPH Biobank, Paris, France).",,2020-05-04,2020-09-30,Household and community samples,All,Seniors (65+ years),60.0,69.0,Age,,16650,0.025,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.87,0.975,['High'],Yes,No,Yes,Yes,No,Yes,Yes,No,Yes,Fabrice Carrat,Unité des Virus Émergents,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01731-5,2021-12-03,2024-03-01,Verified,carrat_age_2021,FRA
211125_France_UnitédesVirusÉmergents_RegionCentrevaldeLoire,211125_France_UnitédesVirusÉmergents,"Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France.",2021-11-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Centre val de Loire,,"Participants living in mainland France who completed the questionnaires (SAPRIS) and who agreed to the serology received a DBS kit to be returned to the centralized biobank after capillary blood collection (CEPH Biobank, Paris, France).",,2020-05-04,2020-09-30,Household and community samples,All,Multiple groups,20.0,,Geographical area,Centre val de Loire,5051,0.0396,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.87,0.975,['High'],Yes,No,Yes,Yes,No,Yes,Yes,No,Yes,Fabrice Carrat,Unité des Virus Émergents,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01731-5,2021-12-03,2024-03-01,Verified,carrat_age_2021,FRA
211125_France_UnitédesVirusÉmergents_Time1May,211125_France_UnitédesVirusÉmergents,"Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France.",2021-11-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,"Haut de France, Normandi, Ile de France, Bretagne, Grand Est, Bourgogne France Comte, Centre val de Loire, Auvergne Rhome Alpes, Pays de Loire, Occitanie, Nouvelle Aquitaine, Provence-Alpes-Côte d'Azur",,"Participants living in mainland France who completed the questionnaires (SAPRIS) and who agreed to the serology received a DBS kit to be returned to the centralized biobank after capillary blood collection (CEPH Biobank, Paris, France).",,2020-05-04,2020-05-31,Household and community samples,All,Multiple groups,20.0,,Time frame,May,14157,0.0689,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.87,0.975,['High'],Yes,No,Yes,Yes,No,Yes,Yes,No,Yes,Fabrice Carrat,Unité des Virus Émergents,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01731-5,2021-12-03,2024-03-01,Verified,carrat_age_2021,FRA
211125_France_UnitédesVirusÉmergents_Time2June,211125_France_UnitédesVirusÉmergents,"Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France.",2021-11-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,"Haut de France, Normandi, Ile de France, Bretagne, Grand Est, Bourgogne France Comte, Centre val de Loire, Auvergne Rhome Alpes, Pays de Loire, Occitanie, Nouvelle Aquitaine, Provence-Alpes-Côte d'Azur",,"Participants living in mainland France who completed the questionnaires (SAPRIS) and who agreed to the serology received a DBS kit to be returned to the centralized biobank after capillary blood collection (CEPH Biobank, Paris, France).",,2020-06-01,2020-06-30,Household and community samples,All,Multiple groups,20.0,,Time frame,June,1066,0.0525,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.87,0.975,['High'],Yes,No,Yes,Yes,No,Yes,Yes,No,Yes,Fabrice Carrat,Unité des Virus Émergents,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01731-5,2021-12-03,2024-03-01,Verified,carrat_age_2021,FRA
211125_France_UnitédesVirusÉmergents_Time4August,211125_France_UnitédesVirusÉmergents,"Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France.",2021-11-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,"Haut de France, Normandi, Ile de France, Bretagne, Grand Est, Bourgogne France Comte, Centre val de Loire, Auvergne Rhome Alpes, Pays de Loire, Occitanie, Nouvelle Aquitaine, Provence-Alpes-Côte d'Azur",,"Participants living in mainland France who completed the questionnaires (SAPRIS) and who agreed to the serology received a DBS kit to be returned to the centralized biobank after capillary blood collection (CEPH Biobank, Paris, France).",,2020-08-01,2020-08-31,Household and community samples,All,Multiple groups,20.0,,Time frame,August,16235,0.0394,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.87,0.975,['High'],Yes,No,Yes,Yes,No,Yes,Yes,No,Yes,Fabrice Carrat,Unité des Virus Émergents,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01731-5,2021-12-03,2024-03-01,Verified,carrat_age_2021,FRA
211125_France_UnitédesVirusÉmergents_Time3July,211125_France_UnitédesVirusÉmergents,"Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France.",2021-11-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,"Haut de France, Normandi, Ile de France, Bretagne, Grand Est, Bourgogne France Comte, Centre val de Loire, Auvergne Rhome Alpes, Pays de Loire, Occitanie, Nouvelle Aquitaine, Provence-Alpes-Côte d'Azur",,"Participants living in mainland France who completed the questionnaires (SAPRIS) and who agreed to the serology received a DBS kit to be returned to the centralized biobank after capillary blood collection (CEPH Biobank, Paris, France).",,2020-07-01,2020-07-31,Household and community samples,All,Multiple groups,20.0,,Time frame,July,44898,0.039700000000000006,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.87,0.975,['High'],Yes,No,Yes,Yes,No,Yes,Yes,No,Yes,Fabrice Carrat,Unité des Virus Émergents,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01731-5,2021-12-03,2024-03-01,Verified,carrat_age_2021,FRA
211125_France_UnitédesVirusÉmergents_Overall_Unadjusted_S+N,211125_France_UnitédesVirusÉmergents,"Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France.",2021-11-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,"Haut de France, Normandi, Ile de France, Bretagne, Grand Est, Bourgogne France Comte, Centre val de Loire, Auvergne Rhome Alpes, Pays de Loire, Occitanie, Nouvelle Aquitaine, Provence-Alpes-Côte d'Azur",,"Participants living in mainland France who completed the questionnaires (SAPRIS) and who agreed to the serology received a DBS kit to be returned to the centralized biobank after capillary blood collection (CEPH Biobank, Paris, France).",,2020-05-04,2020-09-30,Household and community samples,All,Multiple groups,20.0,,Test used,S +N,82126,0.023,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)",EUROIMMUN,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],Yes,No,Yes,Yes,No,Yes,Yes,No,Yes,Fabrice Carrat,Unité des Virus Émergents,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01731-5,2021-12-03,2024-03-01,Verified,carrat_age_2021,FRA
211125_France_UnitédesVirusÉmergents_RegionAuvergneRhomeAlpes,211125_France_UnitédesVirusÉmergents,"Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France.",2021-11-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Auvergne Rhome Alpes,,"Participants living in mainland France who completed the questionnaires (SAPRIS) and who agreed to the serology received a DBS kit to be returned to the centralized biobank after capillary blood collection (CEPH Biobank, Paris, France).",,2020-05-04,2020-09-30,Household and community samples,All,Multiple groups,20.0,,Geographical area,Auvergne Rhome Alpes,9647,0.0412,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.87,0.975,['High'],Yes,No,Yes,Yes,No,Yes,Yes,No,Yes,Fabrice Carrat,Unité des Virus Émergents,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01731-5,2021-12-03,2024-03-01,Verified,carrat_age_2021,FRA
211125_France_UnitédesVirusÉmergents_Age20-29,211125_France_UnitédesVirusÉmergents,"Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France.",2021-11-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,"Haut de France, Normandi, Ile de France, Bretagne, Grand Est, Bourgogne France Comte, Centre val de Loire, Auvergne Rhome Alpes, Pays de Loire, Occitanie, Nouvelle Aquitaine, Provence-Alpes-Côte d'Azur",,"Participants living in mainland France who completed the questionnaires (SAPRIS) and who agreed to the serology received a DBS kit to be returned to the centralized biobank after capillary blood collection (CEPH Biobank, Paris, France).",,2020-05-04,2020-09-30,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,1583,0.0562,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.87,0.975,['High'],Yes,No,Yes,Yes,No,Yes,Yes,No,Yes,Fabrice Carrat,Unité des Virus Émergents,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01731-5,2021-12-03,2024-03-01,Verified,carrat_age_2021,FRA
211125_France_UnitédesVirusÉmergents_SexMale,211125_France_UnitédesVirusÉmergents,"Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France.",2021-11-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,"Haut de France, Normandi, Ile de France, Bretagne, Grand Est, Bourgogne France Comte, Centre val de Loire, Auvergne Rhome Alpes, Pays de Loire, Occitanie, Nouvelle Aquitaine, Provence-Alpes-Côte d'Azur",,"Participants living in mainland France who completed the questionnaires (SAPRIS) and who agreed to the serology received a DBS kit to be returned to the centralized biobank after capillary blood collection (CEPH Biobank, Paris, France).",,2020-05-04,2020-09-30,Household and community samples,Male,Multiple groups,20.0,,Sex/Gender,,28753,0.0395,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.87,0.975,['High'],Yes,No,Yes,Yes,No,Yes,Yes,No,Yes,Fabrice Carrat,Unité des Virus Émergents,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01731-5,2021-12-03,2024-03-01,Verified,carrat_age_2021,FRA
211125_France_UnitédesVirusÉmergents_RegionPaysdeLoise,211125_France_UnitédesVirusÉmergents,"Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France.",2021-11-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Pays de Loire,,"Participants living in mainland France who completed the questionnaires (SAPRIS) and who agreed to the serology received a DBS kit to be returned to the centralized biobank after capillary blood collection (CEPH Biobank, Paris, France).",,2020-05-04,2020-09-30,Household and community samples,All,Multiple groups,20.0,,Geographical area,Pays de Loire,4629,0.0354,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.87,0.975,['High'],Yes,No,Yes,Yes,No,Yes,Yes,No,Yes,Fabrice Carrat,Unité des Virus Émergents,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01731-5,2021-12-03,2024-03-01,Verified,carrat_age_2021,FRA
211125_France_UnitédesVirusÉmergents_SexFemale,211125_France_UnitédesVirusÉmergents,"Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France.",2021-11-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,"Haut de France, Normandi, Ile de France, Bretagne, Grand Est, Bourgogne France Comte, Centre val de Loire, Auvergne Rhome Alpes, Pays de Loire, Occitanie, Nouvelle Aquitaine, Provence-Alpes-Côte d'Azur",,"Participants living in mainland France who completed the questionnaires (SAPRIS) and who agreed to the serology received a DBS kit to be returned to the centralized biobank after capillary blood collection (CEPH Biobank, Paris, France).",,2020-05-04,2020-09-30,Household and community samples,Female,Multiple groups,20.0,,Sex/Gender,,53373,0.0477,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.87,0.975,['High'],Yes,No,Yes,Yes,No,Yes,Yes,No,Yes,Fabrice Carrat,Unité des Virus Émergents,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01731-5,2021-12-03,2024-03-01,Verified,carrat_age_2021,FRA
211125_France_UnitédesVirusÉmergents_Age40-49,211125_France_UnitédesVirusÉmergents,"Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France.",2021-11-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,"Haut de France, Normandi, Ile de France, Bretagne, Grand Est, Bourgogne France Comte, Centre val de Loire, Auvergne Rhome Alpes, Pays de Loire, Occitanie, Nouvelle Aquitaine, Provence-Alpes-Côte d'Azur",,"Participants living in mainland France who completed the questionnaires (SAPRIS) and who agreed to the serology received a DBS kit to be returned to the centralized biobank after capillary blood collection (CEPH Biobank, Paris, France).",,2020-05-04,2020-09-30,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,,14822,0.0834,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.87,0.975,['High'],Yes,No,Yes,Yes,No,Yes,Yes,No,Yes,Fabrice Carrat,Unité des Virus Émergents,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01731-5,2021-12-03,2024-03-01,Verified,carrat_age_2021,FRA
211125_France_UnitédesVirusÉmergents_RegionNormandi,211125_France_UnitédesVirusÉmergents,"Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France.",2021-11-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Normandi,,"Participants living in mainland France who completed the questionnaires (SAPRIS) and who agreed to the serology received a DBS kit to be returned to the centralized biobank after capillary blood collection (CEPH Biobank, Paris, France).",,2020-05-04,2020-09-30,Household and community samples,All,Multiple groups,20.0,,Geographical area,Normandi,2800,0.0336,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.87,0.975,['High'],Yes,No,Yes,Yes,No,Yes,Yes,No,Yes,Fabrice Carrat,Unité des Virus Émergents,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01731-5,2021-12-03,2024-03-01,Verified,carrat_age_2021,FRA
211125_France_UnitédesVirusÉmergents_Age80+,211125_France_UnitédesVirusÉmergents,"Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France.",2021-11-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,"Haut de France, Normandi, Ile de France, Bretagne, Grand Est, Bourgogne France Comte, Centre val de Loire, Auvergne Rhome Alpes, Pays de Loire, Occitanie, Nouvelle Aquitaine, Provence-Alpes-Côte d'Azur",,"Participants living in mainland France who completed the questionnaires (SAPRIS) and who agreed to the serology received a DBS kit to be returned to the centralized biobank after capillary blood collection (CEPH Biobank, Paris, France).",,2020-05-04,2020-09-30,Household and community samples,All,Multiple groups,80.0,,Age,80+,3108,0.0167,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.87,0.975,['High'],Yes,No,Yes,Yes,No,Yes,Yes,No,Yes,Fabrice Carrat,Unité des Virus Émergents,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01731-5,2021-12-03,2024-03-01,Verified,carrat_age_2021,FRA
211125_France_UnitédesVirusÉmergents_Time5September,211125_France_UnitédesVirusÉmergents,"Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France.",2021-11-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,"Haut de France, Normandi, Ile de France, Bretagne, Grand Est, Bourgogne France Comte, Centre val de Loire, Auvergne Rhome Alpes, Pays de Loire, Occitanie, Nouvelle Aquitaine, Provence-Alpes-Côte d'Azur",,"Participants living in mainland France who completed the questionnaires (SAPRIS) and who agreed to the serology received a DBS kit to be returned to the centralized biobank after capillary blood collection (CEPH Biobank, Paris, France).",,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,20.0,,Time frame,September,5770,0.0392,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.87,0.975,['High'],Yes,No,Yes,Yes,No,Yes,Yes,No,Yes,Fabrice Carrat,Unité des Virus Émergents,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01731-5,2021-12-03,2024-03-01,Verified,carrat_age_2021,FRA
211125_France_UnitédesVirusÉmergents_Age50-59,211125_France_UnitédesVirusÉmergents,"Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France.",2021-11-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,"Haut de France, Normandi, Ile de France, Bretagne, Grand Est, Bourgogne France Comte, Centre val de Loire, Auvergne Rhome Alpes, Pays de Loire, Occitanie, Nouvelle Aquitaine, Provence-Alpes-Côte d'Azur",,"Participants living in mainland France who completed the questionnaires (SAPRIS) and who agreed to the serology received a DBS kit to be returned to the centralized biobank after capillary blood collection (CEPH Biobank, Paris, France).",,2020-05-04,2020-09-30,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,,14914,0.0418,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.87,0.975,['High'],Yes,No,Yes,Yes,No,Yes,Yes,No,Yes,Fabrice Carrat,Unité des Virus Émergents,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01731-5,2021-12-03,2024-03-01,Verified,carrat_age_2021,FRA
211125_France_UnitédesVirusÉmergents_Age30-39,211125_France_UnitédesVirusÉmergents,"Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France.",2021-11-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,"Haut de France, Normandi, Ile de France, Bretagne, Grand Est, Bourgogne France Comte, Centre val de Loire, Auvergne Rhome Alpes, Pays de Loire, Occitanie, Nouvelle Aquitaine, Provence-Alpes-Côte d'Azur",,"Participants living in mainland France who completed the questionnaires (SAPRIS) and who agreed to the serology received a DBS kit to be returned to the centralized biobank after capillary blood collection (CEPH Biobank, Paris, France).",,2020-05-04,2020-09-30,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,,8874,0.08800000000000001,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.87,0.975,['High'],Yes,No,Yes,Yes,No,Yes,Yes,No,Yes,Fabrice Carrat,Unité des Virus Émergents,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01731-5,2021-12-03,2024-03-01,Verified,carrat_age_2021,FRA
211125_France_UnitédesVirusÉmergents_RegionBretagne,211125_France_UnitédesVirusÉmergents,"Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France.",2021-11-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Bretagne,,"Participants living in mainland France who completed the questionnaires (SAPRIS) and who agreed to the serology received a DBS kit to be returned to the centralized biobank after capillary blood collection (CEPH Biobank, Paris, France).",,2020-05-04,2020-09-30,Household and community samples,All,Multiple groups,20.0,,Geographical area,Bretagne,5889,0.0282,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.87,0.975,['High'],Yes,No,Yes,Yes,No,Yes,Yes,No,Yes,Fabrice Carrat,Unité des Virus Émergents,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01731-5,2021-12-03,2024-03-01,Verified,carrat_age_2021,FRA
211125_France_UnitédesVirusÉmergents_Overall_Unadjusted,211125_France_UnitédesVirusÉmergents,"Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France.",2021-11-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,"Haut de France, Normandi, Ile de France, Bretagne, Grand Est, Bourgogne France Comte, Centre val de Loire, Auvergne Rhome Alpes, Pays de Loire, Occitanie, Nouvelle Aquitaine, Provence-Alpes-Côte d'Azur",,"Participants living in mainland France who completed the questionnaires (SAPRIS) and who agreed to the serology received a DBS kit to be returned to the centralized biobank after capillary blood collection (CEPH Biobank, Paris, France).",,2020-05-04,2020-09-30,Household and community samples,All,Multiple groups,20.0,,Analysis,,82126,0.044800000000000006,,,,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.87,0.975,['High'],Yes,No,Yes,Yes,No,Yes,Yes,No,Yes,Fabrice Carrat,Unité des Virus Émergents,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01731-5,2021-12-03,2024-03-01,Verified,carrat_age_2021,FRA
211125_France_UnitédesVirusÉmergents_Overall_Unadjusted_S+Neutralization,211125_France_UnitédesVirusÉmergents,"Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France.",2021-11-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,"Haut de France, Normandi, Ile de France, Bretagne, Grand Est, Bourgogne France Comte, Centre val de Loire, Auvergne Rhome Alpes, Pays de Loire, Occitanie, Nouvelle Aquitaine, Provence-Alpes-Côte d'Azur",,"Participants living in mainland France who completed the questionnaires (SAPRIS) and who agreed to the serology received a DBS kit to be returned to the centralized biobank after capillary blood collection (CEPH Biobank, Paris, France).",,2020-05-04,2020-09-30,Household and community samples,All,Multiple groups,20.0,,Test used,S + Neutralization,82126,0.015,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Author designed (Neutralization Assay)","EUROIMMUN,NA",Multiple Types,Dried Blood,"['IgG', 'Neutralizing']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],Yes,No,Yes,Yes,No,Yes,Yes,No,Yes,Fabrice Carrat,Unité des Virus Émergents,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01731-5,2021-12-03,2024-03-01,Verified,carrat_age_2021,FRA
211125_France_UnitédesVirusÉmergents_Age70-79,211125_France_UnitédesVirusÉmergents,"Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France.",2021-11-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,"Haut de France, Normandi, Ile de France, Bretagne, Grand Est, Bourgogne France Comte, Centre val de Loire, Auvergne Rhome Alpes, Pays de Loire, Occitanie, Nouvelle Aquitaine, Provence-Alpes-Côte d'Azur",,"Participants living in mainland France who completed the questionnaires (SAPRIS) and who agreed to the serology received a DBS kit to be returned to the centralized biobank after capillary blood collection (CEPH Biobank, Paris, France).",,2020-05-04,2020-09-30,Household and community samples,All,Seniors (65+ years),70.0,79.0,Age,70-79,22175,0.021800000000000003,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.87,0.975,['High'],Yes,No,Yes,Yes,No,Yes,Yes,No,Yes,Fabrice Carrat,Unité des Virus Émergents,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01731-5,2021-12-03,2024-03-01,Verified,carrat_age_2021,FRA
211125_France_UnitédesVirusÉmergents_RegionPACA,211125_France_UnitédesVirusÉmergents,"Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France.",2021-11-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Provence-Alpes-Côte d'Azur,,"Participants living in mainland France who completed the questionnaires (SAPRIS) and who agreed to the serology received a DBS kit to be returned to the centralized biobank after capillary blood collection (CEPH Biobank, Paris, France).",,2020-05-04,2020-09-30,Household and community samples,All,Multiple groups,20.0,,Geographical area,Provence-Alpes-Côte d'Azur,5063,0.031000000000000003,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.87,0.975,['High'],Yes,No,Yes,Yes,No,Yes,Yes,No,Yes,Fabrice Carrat,Unité des Virus Émergents,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01731-5,2021-12-03,2024-03-01,Verified,carrat_age_2021,FRA
211125_France_UnitédesVirusÉmergents_RegionOccitanie,211125_France_UnitédesVirusÉmergents,"Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France.",2021-11-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Occitanie,,"Participants living in mainland France who completed the questionnaires (SAPRIS) and who agreed to the serology received a DBS kit to be returned to the centralized biobank after capillary blood collection (CEPH Biobank, Paris, France).",,2020-05-04,2020-09-30,Household and community samples,All,Multiple groups,20.0,,Geographical area,Occitanie,8226,0.026600000000000002,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.87,0.975,['High'],Yes,No,Yes,Yes,No,Yes,Yes,No,Yes,Fabrice Carrat,Unité des Virus Émergents,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01731-5,2021-12-03,2024-03-01,Verified,carrat_age_2021,FRA
211125_France_UnitédesVirusÉmergents_RegionNouvelleAquitaine,211125_France_UnitédesVirusÉmergents,"Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France.",2021-11-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Nouvelle Aquitaine,,"Participants living in mainland France who completed the questionnaires (SAPRIS) and who agreed to the serology received a DBS kit to be returned to the centralized biobank after capillary blood collection (CEPH Biobank, Paris, France).",,2020-05-04,2020-09-30,Household and community samples,All,Multiple groups,20.0,,Geographical area,Nouvelle Aquitaine,10664,0.0317,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.87,0.975,['High'],Yes,No,Yes,Yes,No,Yes,Yes,No,Yes,Fabrice Carrat,Unité des Virus Émergents,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01731-5,2021-12-03,2024-03-01,Verified,carrat_age_2021,FRA
211125_France_UnitédesVirusÉmergents_RegionBourgogneFranceComte,211125_France_UnitédesVirusÉmergents,"Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France.",2021-11-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Bourgogne France Comte,,"Participants living in mainland France who completed the questionnaires (SAPRIS) and who agreed to the serology received a DBS kit to be returned to the centralized biobank after capillary blood collection (CEPH Biobank, Paris, France).",,2020-05-04,2020-09-30,Household and community samples,All,Multiple groups,20.0,,Geographical area,Bourgogne France Comte,2821,0.0429,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.87,0.975,['High'],Yes,No,Yes,Yes,No,Yes,Yes,No,Yes,Fabrice Carrat,Unité des Virus Émergents,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01731-5,2021-12-03,2024-03-01,Verified,carrat_age_2021,FRA
211125_France_UnitédesVirusÉmergents_RegionGrandEst,211125_France_UnitédesVirusÉmergents,"Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France.",2021-11-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Grand Est,,"Participants living in mainland France who completed the questionnaires (SAPRIS) and who agreed to the serology received a DBS kit to be returned to the centralized biobank after capillary blood collection (CEPH Biobank, Paris, France).",,2020-05-04,2020-09-30,Household and community samples,All,Multiple groups,20.0,,Geographical area,Grand Est,7244,0.073,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.87,0.975,['High'],Yes,No,Yes,Yes,No,Yes,Yes,No,Yes,Fabrice Carrat,Unité des Virus Émergents,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01731-5,2021-12-03,2024-03-01,Verified,carrat_age_2021,FRA
211125_France_UnitédesVirusÉmergents_RegionIledeFrance,211125_France_UnitédesVirusÉmergents,"Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France.",2021-11-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Ile de France,,"Participants living in mainland France who completed the questionnaires (SAPRIS) and who agreed to the serology received a DBS kit to be returned to the centralized biobank after capillary blood collection (CEPH Biobank, Paris, France).",,2020-05-04,2020-09-30,Household and community samples,All,Multiple groups,20.0,,Geographical area,Ile de France,15185,0.0722,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.87,0.975,['High'],Yes,No,Yes,Yes,No,Yes,Yes,No,Yes,Fabrice Carrat,Unité des Virus Émergents,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01731-5,2021-12-03,2024-03-01,Verified,carrat_age_2021,FRA
211125_France_UnitédesVirusÉmergents_RegionHautdeFrance,211125_France_UnitédesVirusÉmergents,"Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France.",2021-11-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Haut de France,,"Participants living in mainland France who completed the questionnaires (SAPRIS) and who agreed to the serology received a DBS kit to be returned to the centralized biobank after capillary blood collection (CEPH Biobank, Paris, France).",,2020-05-04,2020-09-30,Household and community samples,All,Multiple groups,20.0,,Geographical area,Haut de France,4907,0.0406,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.87,0.975,['High'],Yes,No,Yes,Yes,No,Yes,Yes,No,Yes,Fabrice Carrat,Unité des Virus Émergents,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01731-5,2021-12-03,2024-03-01,Verified,carrat_age_2021,FRA
211130_France_SorbonneParisNordUniversity_Primary,211130_France_SorbonneParisNordUniversity,Nutritional risk factors for SARS-CoV-2 infection: a prospective study within the NutriNet-Sante cohort.,2021-11-30,Journal Article (Peer-Reviewed),National,Prospective cohort,France,,,"To estimate the seroprevalence of SARS-CoV-2 infection
at the population level, participants who completed the
SAPRIS questionnaires were invited to take part in the
SAPRIS-SERO project","""Participants with ELISA-S results in the indeterminate range were excluded from the analyses."" ",2020-05-15,2020-10-15,Blood donors,All,Multiple groups,,,Primary Estimate,,7766,0.04,,,True,,,,True,Self-referral,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Melanie Deschasaux-Tanguy,Sorbonne Paris Nord University,Not Unity-Aligned,https://dx.doi.org/10.1186/s12916-021-02168-1,2021-12-06,2024-03-01,Unverified,deschasaux-tanguy_nutritional_2021,FRA
211130_France_SorbonneParisNordUniversity_Male,211130_France_SorbonneParisNordUniversity,Nutritional risk factors for SARS-CoV-2 infection: a prospective study within the NutriNet-Sante cohort.,2021-11-30,Journal Article (Peer-Reviewed),National,Prospective cohort,France,,,"To estimate the seroprevalence of SARS-CoV-2 infection
at the population level, participants who completed the
SAPRIS questionnaires were invited to take part in the
SAPRIS-SERO project","""Participants with ELISA-S results in the indeterminate range were excluded from the analyses."" ",2020-05-15,2020-10-15,Blood donors,Male,Multiple groups,,,Sex/Gender,,2224,0.0369,,,,,,,,Self-referral,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Melanie Deschasaux-Tanguy,Sorbonne Paris Nord University,Not Unity-Aligned,https://dx.doi.org/10.1186/s12916-021-02168-1,2021-12-06,2024-03-01,Unverified,deschasaux-tanguy_nutritional_2021,FRA
211130_France_SorbonneParisNordUniversity_Female,211130_France_SorbonneParisNordUniversity,Nutritional risk factors for SARS-CoV-2 infection: a prospective study within the NutriNet-Sante cohort.,2021-11-30,Journal Article (Peer-Reviewed),National,Prospective cohort,France,,,"To estimate the seroprevalence of SARS-CoV-2 infection
at the population level, participants who completed the
SAPRIS questionnaires were invited to take part in the
SAPRIS-SERO project","""Participants with ELISA-S results in the indeterminate range were excluded from the analyses."" ",2020-05-15,2020-10-15,Blood donors,Female,Multiple groups,,,Sex/Gender,,5231,0.0438,,,,,,,,Self-referral,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Melanie Deschasaux-Tanguy,Sorbonne Paris Nord University,Not Unity-Aligned,https://dx.doi.org/10.1186/s12916-021-02168-1,2021-12-06,2024-03-01,Unverified,deschasaux-tanguy_nutritional_2021,FRA
211201_NorthernFrance_CentreHospitalierdeTourcoing,211201_NorthernFrance_CentreHospitalierdeTourcoing,History of COVID-19 Symptoms and Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Northern France after the First Wave of the Pandemic.,2021-12-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Northern France,Tourcoing,All HIV-infected patients who benefited from a follow-up visit during the study period were asked to answer the questionnaire and perform a COVID-19 serological test.,"""First, patients who died from COVID-19 were not analyzed. Second, by including outpatients, most critically ill patients, especially those requiring a long hospital stay for COVID-19 may also have been excluded. However, the prolonged period of inclusion limited this selection bias.""",2020-04-01,2020-08-01,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,600,0.027000000000000003,,,True,,,,True,Convenience,Not reported/ Unable to specify,,CLIA,Plasma,"['IgG', 'IgM']",,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Agnes Meybeck,Centre Hospitalier de Tourcoing,Not Unity-Aligned,https://dx.doi.org/10.3390/microorganisms9122491,2022-01-10,2022-07-16,Unverified,meybeck_history_2021,FRA
211201_Ermont_CliniqueClaudeBernard_Overall,211201_Ermont_CliniqueClaudeBernard,SARS-CoV-2 Antibodies in Hemodialysis Patients Six Months after Infection Compared to Healthcare Workers.,2021-12-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Île-de-France,Ermont,Eligible patients were on maintenance hemodialysis during the first wave of the epidemic in France in March and April 2020 and were still alive 6 months later.,"Patients in the two dialysis centers who were diagnosed as infected with SARS-CoV-2 after the first wave of the epidemic in March and April 2020, and those who arrived from another dialysis facility with an already positive diagnosis of SARS-CoV-2 infection before, during or after the first wave of the epidemic in March and April 2020, were excluded. The hemodialysis patients who came from another dialysis center or who began hemodialysis in the two dialysis centers after the wave of the epidemic in March and April 2020 were also excluded.",2020-09-15,2020-10-15,Residual sera,All,Multiple groups,,,Primary Estimate,,299,0.197,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['High'],,No,No,No,,Yes,Yes,Yes,,Henri Boulanger,Clinique Claude Bernard,Not Unity-Aligned,https://dx.doi.org/10.1155/2021/4747221,2021-12-16,2024-03-01,Unverified,boulanger_sars-cov-2_2021,FRA
211206_CochinHospital_ParisDescartesUniversity_Overall_Nonly,211206_CochinHospital_ParisDescartesUniversity,Systematic assessment of the humoral response against SARS-CoV-2 in a French cohort of 283 patients with rheumatic diseases,2021-12-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Île-de-France,Paris,"We screened for SARS-CoV-2 infection among spondyloarthritis (SpA, n = 143) or rheumatoid arthritis (RA, n = 140) patients in our outpatient clinic at Cochin Hospital in Paris between June and August 2020. ",,2020-06-01,2020-08-31,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,N positive,283,0.028300000000000002,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,No,,Yes,Yes,Yes,,Clothilde Gros,Paris Descartes Université,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jbspin.2021.105312,2022-01-12,2024-03-01,Unverified,gros_systematic_2022,FRA
220109_France_UniversityofParisSaclay_Overall_PopAdj,220109_France_UniversityofParisSaclay,Prevalence of SARS-Cov-2 antibodies and living conditions: the French national random population-based EPICOV cohort.,2022-01-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,"""Individuals  aged  15  years  or  older  living  in  mainland  France or three of the five French overseas territories were randomly  selected  from  the  FIDELI  administrative  sampling  frame.""",,2020-05-02,2020-06-02,Household and community samples,All,Multiple groups,15.0,,Analysis,,12114,0.045,0.039,0.05,True,,True,,,Stratified non-probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Whole Blood,IgG,Spike,,0.9440000000000001,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Josiane Warszawski,University of Paris-Saclay,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06973-0,2022-01-18,2024-03-01,Verified,warszawski_prevalence_2022,FRA
220109_France_UniversityofParisSaclay_Age21-29,220109_France_UniversityofParisSaclay,Prevalence of SARS-Cov-2 antibodies and living conditions: the French national random population-based EPICOV cohort.,2022-01-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,"""Individuals  aged  15  years  or  older  living  in  mainland  France or three of the five French overseas territories were randomly  selected  from  the  FIDELI  administrative  sampling  frame.""",,2020-05-02,2020-06-02,Household and community samples,All,Adults (18-64 years),21.0,29.0,Age,21-29,1253,0.0646,,,,,,,,Stratified non-probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Whole Blood,IgG,Spike,,0.9440000000000001,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Josiane Warszawski,University of Paris-Saclay,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06973-0,2022-05-11,2024-03-01,Verified,warszawski_prevalence_2022,FRA
220109_France_UniversityofParisSaclay_SexFemale,220109_France_UniversityofParisSaclay,Prevalence of SARS-Cov-2 antibodies and living conditions: the French national random population-based EPICOV cohort.,2022-01-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,"""Individuals  aged  15  years  or  older  living  in  mainland  France or three of the five French overseas territories were randomly  selected  from  the  FIDELI  administrative  sampling  frame.""",,2020-05-02,2020-06-02,Household and community samples,Female,Multiple groups,15.0,,Sex/Gender,,6645,0.0698,,,,,,,,Stratified non-probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Whole Blood,IgG,Spike,,0.9440000000000001,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Josiane Warszawski,University of Paris-Saclay,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06973-0,2022-05-11,2024-03-01,Verified,warszawski_prevalence_2022,FRA
220109_France_UniversityofParisSaclay_Age15-20,220109_France_UniversityofParisSaclay,Prevalence of SARS-Cov-2 antibodies and living conditions: the French national random population-based EPICOV cohort.,2022-01-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,"""Individuals  aged  15  years  or  older  living  in  mainland  France or three of the five French overseas territories were randomly  selected  from  the  FIDELI  administrative  sampling  frame.""",,2020-05-02,2020-06-02,Household and community samples,All,Children and Youth (0-17 years),15.0,20.0,Age,15-20,928,0.055,,,,,,,,Stratified non-probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Whole Blood,IgG,Spike,,0.9440000000000001,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Josiane Warszawski,University of Paris-Saclay,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06973-0,2022-05-11,2024-03-01,Verified,warszawski_prevalence_2022,FRA
220109_France_UniversityofParisSaclay_Age65+,220109_France_UniversityofParisSaclay,Prevalence of SARS-Cov-2 antibodies and living conditions: the French national random population-based EPICOV cohort.,2022-01-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,"""Individuals  aged  15  years  or  older  living  in  mainland  France or three of the five French overseas territories were randomly  selected  from  the  FIDELI  administrative  sampling  frame.""",,2020-05-02,2020-06-02,Household and community samples,All,Multiple groups,65.0,,Age,65+,2486,0.0334,,,,,,,,Stratified non-probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Whole Blood,IgG,Spike,,0.9440000000000001,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Josiane Warszawski,University of Paris-Saclay,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06973-0,2022-05-11,2024-03-01,Verified,warszawski_prevalence_2022,FRA
220109_France_UniversityofParisSaclay_Age30-49,220109_France_UniversityofParisSaclay,Prevalence of SARS-Cov-2 antibodies and living conditions: the French national random population-based EPICOV cohort.,2022-01-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,"""Individuals  aged  15  years  or  older  living  in  mainland  France or three of the five French overseas territories were randomly  selected  from  the  FIDELI  administrative  sampling  frame.""",,2020-05-02,2020-06-02,Household and community samples,All,Adults (18-64 years),30.0,49.0,Age,30-49,4072,0.08990000000000001,,,,,,,,Stratified non-probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Whole Blood,IgG,Spike,,0.9440000000000001,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Josiane Warszawski,University of Paris-Saclay,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06973-0,2022-05-11,2024-03-01,Verified,warszawski_prevalence_2022,FRA
220109_France_UniversityofParisSaclay_SexMale,220109_France_UniversityofParisSaclay,Prevalence of SARS-Cov-2 antibodies and living conditions: the French national random population-based EPICOV cohort.,2022-01-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,"""Individuals  aged  15  years  or  older  living  in  mainland  France or three of the five French overseas territories were randomly  selected  from  the  FIDELI  administrative  sampling  frame.""",,2020-05-02,2020-06-02,Household and community samples,Male,Multiple groups,15.0,,Sex/Gender,,5469,0.0587,,,,,,,,Stratified non-probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Whole Blood,IgG,Spike,,0.9440000000000001,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Josiane Warszawski,University of Paris-Saclay,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06973-0,2022-05-11,2024-03-01,Verified,warszawski_prevalence_2022,FRA
220109_France_UniversityofParisSaclay_Overall_Crude,220109_France_UniversityofParisSaclay,Prevalence of SARS-Cov-2 antibodies and living conditions: the French national random population-based EPICOV cohort.,2022-01-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,"""Individuals  aged  15  years  or  older  living  in  mainland  France or three of the five French overseas territories were randomly  selected  from  the  FIDELI  administrative  sampling  frame.""",,2020-05-02,2020-06-02,Household and community samples,All,Multiple groups,15.0,,Primary Estimate,,12114,0.06480000000000001,,,,,,,True,Stratified non-probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Whole Blood,IgG,Spike,,0.9440000000000001,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Josiane Warszawski,University of Paris-Saclay,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06973-0,2022-05-12,2024-03-01,Verified,warszawski_prevalence_2022,FRA
220109_France_UniversityofParisSaclay_Age50-64,220109_France_UniversityofParisSaclay,Prevalence of SARS-Cov-2 antibodies and living conditions: the French national random population-based EPICOV cohort.,2022-01-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,"""Individuals  aged  15  years  or  older  living  in  mainland  France or three of the five French overseas territories were randomly  selected  from  the  FIDELI  administrative  sampling  frame.""",,2020-05-02,2020-06-02,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50-64,3375,0.0604,,,,,,,,Stratified non-probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Whole Blood,IgG,Spike,,0.9440000000000001,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Josiane Warszawski,University of Paris-Saclay,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06973-0,2022-05-11,2024-03-01,Verified,warszawski_prevalence_2022,FRA
220131_Dijon_CentreGeorgesFrancoisLeclerc_HCWs_Primary,"""220131_Dijon,_CentreGeorgesFrancoisLeclerc_HCWs""",Parallel evolution and differences in seroprevalence of SARS-CoV-2 antibody between patients with cancer and health care workers in a tertiary cancer centre during the first and second wave of COVID-19 pandemic: canSEROcov-II cross-sectional study,2022-01-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,,,"For this second cross-sectional study, for the recruitment of staff, all employees of the cancer centre received an email on their nominative work email address",,2021-01-12,2021-01-22,Health care workers and caregivers,All,Multiple groups,19.0,81.0,Primary Estimate,,502,0.151,,,True,,,,True,Self-referral,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Sylvain Ladoire,Centre Georges Franc ois Leclerc,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ejca.2022.01.005,2022-03-08,2024-03-01,Unverified,ladoire_parallel_2022,FRA
220131_Dijon_CentreGeorgesFrancoisLeclerc_Patients_Primary,"""220131_Dijon,_CentreGeorgesFrancoisLeclerc_Patients""",Parallel evolution and differences in seroprevalence of SARS-CoV-2 antibody between patients with cancer and health care workers in a tertiary cancer centre during the first and second wave of COVID-19 pandemic: canSEROcov-II cross-sectional study,2022-01-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,,,"For the patients, participation was proposed to all patients of the Medical Oncology department (patients seen in consultation, in the outpatient unit, and inpatients)",,2021-01-25,2021-02-26,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,26.0,98.0,Primary Estimate,,507,0.040999999999999995,,,True,,,,True,Self-referral,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Sylvain Ladoire,Centre Georges Franc ois Leclerc,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ejca.2022.01.005,2022-03-08,2024-03-01,Unverified,ladoire_parallel_2022,FRA
220210_Corte_UniversitéDeCorsePascalPaoli_TestAdjusted,220210_Corte_UniversitéDeCorsePascalPaoli,A Cross-Sectional Study of Exposure Factors Associated with Seropositivity for SARS-CoV-2 Antibodies during the Second Epidemic Wave among a Sample of the University of Corsica (France),2022-02-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,Corsica,Corte,All staff (n = 860) and students (n = 4442) of the University of Corsica were offered the possibility to participate in this study. ,Participants who did not have a blood sample or did not complete the questionnaire were excluded from this study.,2020-11-23,2021-01-31,Students and Daycares,All,Adults (18-64 years),,,Primary Estimate,,418,0.128,0.098,0.166,True,True,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.998,0.903,['High'],,No,No,Yes,,Yes,Yes,Yes,,Dorine Decarreaux,Université De Corse Pascal Paoli,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph19041953,2022-02-25,2023-08-15,Unverified,decarreauxCrosssectionalStudyExposure2022,FRA
220219_Italy_UniversityofVerona_Primary,220219_Italy_UniversityofVerona,SARS-CoV-2 vaccination elicits unconventional IgM specific responses in naive and previously COVID-19-infected individuals,2022-02-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,,,HCW samples were collected before vaccine administration (T0),HCWs without complete information,2021-01-01,2021-01-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1957,0.19100000000000003,,,True,,,,True,Unclear,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ,Architect Anti-SARS-CoV-2 IgM",Abbott Laboratories,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,Unclear,Yes,No,,Unclear,Yes,No,,Alessandra Ruggiero,University of Verona,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2022.103888,2022-03-08,2024-03-01,Unverified,ruggiero_sars-cov-2_2022,FRA
220307_Marseille_HopitauxdeMarseille_Campaign1,220307_Marseille_HopitauxdeMarseille_Campaign1,Residential Mobility of a Cohort of Homeless People in Times of Crisis: COVID-19 Pandemic in a European Metropolis,2022-03-07,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,France,Provence-Alpes-Côte d'Azur,Marseille,"at least 18 years of age
cohort study of homeless people that
were living on the streets, in shelters, or squats and slums: the COVID-Homeless survey
(registered on ClinicalTrials, NCT04408131, 29 May 2020). This study aimed to exhaustively
include participants from all shelters and outreach teams of the city (Marseille).",,2020-06-05,2020-08-05,Persons experiencing homelessness,All,Multiple groups,18.0,,Primary Estimate,,1231,0.0601,,,True,,,,True,Convenience,Biosynex COVID-19 BSS assay,Biosynex,,,"['IgG', 'IgM']",,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Agathe Allibert,Hôpitaux de Marseille,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph19053129,2022-03-22,2024-03-01,Unverified,allibert_residential_2022,FRA
220307_Marseille_HopitauxdeMarseille_Campaign2,220307_Marseille_HopitauxdeMarseille_Campaign2,Residential Mobility of a Cohort of Homeless People in Times of Crisis: COVID-19 Pandemic in a European Metropolis,2022-03-07,Journal Article (Peer-Reviewed),Local,Prospective cohort,France,Provence-Alpes-Côte d'Azur,Marseille,"at least 18 years of age
cohort study of homeless people that
were living on the streets, in shelters, or squats and slums: the COVID-Homeless survey
(registered on ClinicalTrials, NCT04408131, 29 May 2020). This study aimed to exhaustively
include participants from all shelters and outreach teams of the city (Marseille).",,2020-09-11,2020-12-18,Persons experiencing homelessness,All,Multiple groups,18.0,,Primary Estimate,,721,0.1886,,,True,,,,True,Convenience,Biosynex COVID-19 BSS assay,Biosynex,,,"['IgG', 'IgM']",,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Agathe Allibert,Hôpitaux de Marseille,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph19053129,2022-03-22,2024-03-01,Unverified,allibert_residential_2022,FRA
220308_RobertDebréHospital_ParisUniversity_Emergency,220308_RobertDebréHospital_ParisUniversity_Emergency,Is SARS-CoV-2 seroconversion a risk factor for severe and acute psychiatric symptoms in children?.,2022-03-08,Journal Article (Peer-Reviewed),Local,Prospective cohort,France,Île-de-France,Paris,"Controls were sex- and age-matched subjects admitted to the emergency department for nonpsychiatric and no history of apparent infection, living in the same low-income geographic area and sampled during the same time period (n = 52).",,2020-12-15,2021-04-15,Residual sera,All,Children and Youth (0-17 years),,,Primary Estimate,,52,0.3461,0.2233,0.4916,True,,,,True,Convenience,AdviseDX SARS-CoV-2 anti-IgG II assay,Abbott Laboratories,CLIA,Serum,IgG,Spike,,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Anael Ayrolles,Paris University,Unity-Aligned,https://dx.doi.org/10.1002/npr2.12236,2022-03-14,2024-03-01,Verified,ayrolles_is_2022,FRA
220308_RobertDebréHospital_ParisUniversity_Psychiatric,220308_RobertDebréHospital_ParisUniversity_Psychiatric,Is SARS-CoV-2 seroconversion a risk factor for severe and acute psychiatric symptoms in children?.,2022-03-08,Journal Article (Peer-Reviewed),Local,Prospective cohort,France,Île-de-France,Paris,"we included all children hospitalized from December 2020 to April 2021 (second lockdown period in France) in the child psychiatric department at the Robert Debré Hospital (Paris, France) for acute psychiatric symptoms (n = 52).",,2020-12-15,2021-04-15,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),,,Primary Estimate,,52,0.09609999999999999,0.0359,0.218,True,,,,True,Convenience,AdviseDX SARS-CoV-2 anti-IgG II assay,Abbott Laboratories,CLIA,Serum,IgG,Spike,,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Anael Ayrolles,Paris University,Not Unity-Aligned,https://dx.doi.org/10.1002/npr2.12236,2022-03-14,2024-03-01,Verified,ayrolles_is_2022,FRA
220412_Paris_AssistancePublique–HopitauxdeParis_PREVENIR_Overall,220412_Paris_AssistancePublique–HopitauxdeParis_PREVENIR,Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among HIV-Negative Participants Using Tenofovir/Emtricitabine-Based Preexposure Prophylaxis in 2020: A Substudy of the French National Agency for Research on AIDS and Viral Hepatitis PREVENIR,2022-04-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,,Paris,"Male participants using
either daily or on-demand PrEP with TDF/FTC enrolled in
the PREVENIR study conducted in the Paris area, France,
and who had a stored serum sample available were included
in this study",,2020-05-01,2020-10-31,Patients seeking care for non-COVID-19 reasons,Male,Adults (18-64 years),,,Primary Estimate,,844,0.10800000000000001,,,True,,,,True,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.98,0.99,['High'],,No,Yes,No,,Yes,Yes,Yes,,Constance Delaugerre,Universit de Paris,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac188,2022-07-13,2024-03-01,Unverified,delaugerre_severe_2022,FRA
220412_Paris_AssistancePublique–HopitauxdeParis_SAPRIS-Sero_Overall,220412_Paris_AssistancePublique–HopitauxdeParis_SAPRIS-Sero,Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among HIV-Negative Participants Using Tenofovir/Emtricitabine-Based Preexposure Prophylaxis in 2020: A Substudy of the French National Agency for Research on AIDS and Viral Hepatitis PREVENIR,2022-04-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,,Paris,"Participants unexposed to TDF/FTC were
male participants living in the Paris area included in the
SAPRIS-Sero national survey that estimates SARS-CoV-2 antibody prevalence in the French general population. Based on the factors associated with the risk of SARS-CoV-2
infection in the initial analysis of the SAPRIS cohort [11] and
on available data in both studies, the matching criteria were
age (+5 years), socio-occupational category, and date of sampling (+1 month). ",,2020-05-01,2020-10-31,Household and community samples,Male,Adults (18-64 years),,,Primary Estimate,,844,0.092,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.98,0.99,['High'],,No,Yes,No,,Yes,Yes,Yes,,Constance Delaugerre,Universit de Paris,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac188,2022-07-13,2024-03-01,Unverified,delaugerre_severe_2022,FRA
220420_France_HopitalLaPorteVerte_HCWs_Primary,220420_France_HopitalLaPorteVerte_HCWs,COVID-19 Prevalence in UNIVI Group Nursing Homes and Multilevel Geriatric Hospitals: Epidemiological Study of Immunological Status with Rapid Serological Tests for Diagnostic Guidance and Follow Up,2022-04-20,Journal Article (Peer-Reviewed),National,Prospective cohort,France,,,"Participants in this study were recruited in the 27 nursing homes (1926 residents and 1165 employees), and the three multilevel geriatric hospitals (1092 employees) that constitute the UNIVI Group’s geriatric institutions.

All employees of the 30 healthcare institutions (27 nursing homes and 3 multilevel geriatric hospitals) were invited to participate in the study, irrespective of occupation.","no exclusion criteria were defined.
",2020-07-24,2020-10-16,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,initial serology test on HCWs,1334,0.128,0.11,0.147,True,,,,True,Unclear,Not reported/ Unable to specify,,ELISA,,,,,,,['High'],,Unclear,Yes,Yes,,Unclear,Yes,No,,A. de Malherbe,UNIVI Group,Not Unity-Aligned,https://dx.doi.org/10.1007/s12603-022-1780-1,2022-05-03,2022-07-16,Unverified,de-malherbe_ovid-19_2022,FRA
220420_France_HopitalLaPorteVerte_Residents_Primary,220420_France_HopitalLaPorteVerte_Residents,COVID-19 Prevalence in UNIVI Group Nursing Homes and Multilevel Geriatric Hospitals: Epidemiological Study of Immunological Status with Rapid Serological Tests for Diagnostic Guidance and Follow Up,2022-04-20,Journal Article (Peer-Reviewed),National,Prospective cohort,France,,,"Participants in this study were recruited in the 27 nursing homes (1926 residents and 1165 employees), and the three multilevel geriatric hospitals (1092 employees) that constitute the UNIVI Group’s geriatric institutions.

All residents of the 27 nursing homes, including those under legal guardianship, were invited to participate in the study.","no exclusion criteria were defined.
",2020-07-24,2020-10-16,Assisted living and long-term care facilities,All,Seniors (65+ years),,,Primary Estimate,initial serology test on Residents,1145,0.14400000000000002,0.12400000000000001,0.166,True,,,,True,Unclear,Not reported/ Unable to specify,,ELISA,,,,,,,['Missing'],,Unclear,Yes,Yes,,Unclear,Yes,No,,A. de Malherbe,UNIVI Group,Not Unity-Aligned,https://dx.doi.org/10.1007/s12603-022-1780-1,2022-05-03,2022-07-16,Unverified,de-malherbe_ovid-19_2022,FRA
220502_Bordeaux_UnitéDeRechercheEtD’épidémiologieCliniques_Overall,220502_Bordeaux_UnitéDeRechercheEtD’épidémiologieCliniques,Suivi de la reponse serologique au virus SARS-CoV-2 chez des professionnels de sante d'un centre de lutte contre le cancer dans un contexte de pandemie de COVID19 (PRO-SERO-COV),2022-05-02,Presentation or Conference,Local,Prospective cohort,France,,Bordeaux,"The objective of the study was to assess the serological immune status to infection by SARS-CoV-2 among professionals in a cancer care establishment [Bergonié Institute].

The main eligibility criteria were: person active in March 2020 and without active infection or symptoms of COVID-19 in the 10 days before signing the consent.",,2020-06-15,2021-09-15,Health care workers and caregivers,All,Multiple groups,20.0,72.0,Primary Estimate,Jun 2020 - Sep 2021,517,0.1064,,,True,,,,True,Convenience,"Author designed (CLIA),Author designed (ELISA) -Spike",,"CLIA,ELISA",Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Unclear,Yes,No,,C. Cantarel,Unité de recherche et d’épidémiologie cliniques,Not Unity-Aligned,https://dx.doi.org/10.1016/j.respe.2022.03.083,2023-05-05,2023-05-06,Unverified,cantarel_suivi_2022,FRA
220503_France_UniversitédeCorsePascalPaoli_Neutralizing_Overall,220503_France_UniversitédeCorsePascalPaoli,Seroprevalence of SARS-CoV-2 IgG Antibodies and Factors Associated with SARS-CoV-2 IgG Neutralizing Activity among Primary Health Care Workers 6 Months after Vaccination Rollout in France,2022-05-03,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,," the PHCWs were recruited from the following four primary care research and monitoring networks: the French Sentinelles Network (GPs), the French Association of Ambulatory Pediatrics (pediatricians), the ReCOL network (dentists and assistants), and IQVIA (pharmacists and assistants).","All PHCWs were eligible to participate, except for those who had participated in a chemoprophylaxis clinical trial of SARS-CoV-2 infection.",2021-05-10,2021-08-31,Health care workers and caregivers,All,Multiple groups,21.0,79.0,Primary Estimate,,1612,0.813,0.794,0.8320000000000001,True,,,,True,Convenience,Author designed (Neutralization Assay),,Neutralization,Dried Blood,Neutralizing,,Validated by developers,,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Dorine Decarreaux,Université de Corse Pascal Paoli,Not Unity-Aligned,https://dx.doi.org/10.3390/v14050957,2022-06-04,2022-07-16,Unverified,decarreaux_seroprevalence_2022,FRA
220504_Paris_SorbonneUniversité,220504_Paris_SorbonneUniversité,Cumulative incidence of SARS-CoV-2 infection and associated risk factors among frontline health care workers in Paris: the SEROCOV cohort study.,2022-05-04,Journal Article (Peer-Reviewed),Local,Prospective cohort,France,Île-de-France,Paris,"All HCW staf (doctors—either senior physicians or residents—nurses, care assistants, laboratory technicians 
and other personals in contact with patients) who worked in COVID-19 frontline departments (emergency, 
infectious diseases, intensive care units and virology laboratory) of the selected hospitals were informed about 
the study and asked to participate.", Staf who were not active during the inclusion period were not eligible,2020-03-16,2020-04-24,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1060,0.059000000000000004,0.047,0.075,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.99,1.0,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Pierre Hausfater,Sorbonne Université,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-10945-y,2022-05-10,2024-03-01,Unverified,hausfater_cumulative_2022,FRA
220511_Amiens_CHUAmiensPicardie_Overall,220511_Amiens_CHUAmiensPicardie,Hospital-wide SARS-CoV-2 antibody screening of 4840 staff members in a University Medical Center in France: a cross-sectional study,2022-05-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,,Amiens,"All hospital employees aged over the age of 18 years and
with a serological test result and a completed questionnaire were included in the present study. All employees
could be included in the study, whether they have been
infected or not.",,2020-05-18,2020-07-26,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,4840,0.09699999999999999,0.07,0.12400000000000001,True,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'TotalAntibody']",Spike,Validated by independent authors/third party/non-developers,0.9450000000000001,1.0,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Marion Pierson-Marchandise,CHU Amiens-Picardie,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2020-047010,2022-05-24,2024-03-01,Unverified,pierson-marchandise_hospital-wide_2022,FRA
220516_Nancy_CHRU-Nancy_Overall,220516_Nancy_CHRU-Nancy,SARS-CoV-2 seroprevalence in healthcare workers and risk factors.,2022-05-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,,Nancy,All HCWs at Nancy University Hospital,,2020-05-25,2020-06-29,Health care workers and caregivers,All,Multiple groups,18.0,71.0,Primary Estimate,,4696,0.051,,,True,,,,True,Convenience,"Author designed (LFIA),MAGLUMI 2019-nCoV IgM/IgG,Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA","NA,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),EUROIMMUN",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Stephanie Weber ,CHRU-Nancy,Not Unity-Aligned,https://dx.doi.org/10.1016/j.idh.2022.05.002,2022-06-09,2024-03-01,Unverified,weber_sars-cov-2_2022,FRA
220601_Ile-de-France_HopitalPitie-Salpetriere_Overall,220601_Ile-de-France_HopitalPitie-Salpetriere,High SARS-CoV-2 seroprevalence in HIV patients originating from sub-Saharan Africa in the Ile-de-France area: Seroprevalence of SARS-CoV-2 in HIV patients,2022-06-01,Journal Article (Peer-Reviewed),Regional,Prospective cohort,France,Ile-de-France,,"All HIV-1 patients followed
in the Pitie-Salpetriere hospital were invited to participate ",,2020-04-15,2021-09-15,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),,,Primary Estimate,,1901,0.134,0.11900000000000001,0.15,True,,,,True,Convenience,Alinity i SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Basma Abdi,Hopital Pitie Salpetriere,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.05.036,2022-06-14,2024-03-01,Unverified,abdi_high_2022,FRA
220601_Paris_HopitaldeFresnes,220601_Paris_HopitaldeFresnes,SARS-CoV-2 seroprevalence in the adult detainees of the Paris area in 2021: a multicenter cross-sectional study,2022-06-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,France,,Paris,"Men and women detained in the 12 penitentiary establishments (16 wards) in the Paris area on January 6, 2021",Release or transfer to another ward,2021-01-14,2021-07-08,Persons who are incarcerated,All,Multiple groups,18.0,80.0,Primary Estimate,,1014,0.182,0.16899999999999998,0.19399999999999998,True,,True,,True,Unclear,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,Unclear,Yes,No,,Yes,Yes,No,,Guillaume Mellon,Hopital Paul Brousse,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.05.032,2022-06-24,2024-03-01,Unverified,mellon_sars-cov-2_2022,FRA
220713_AixMarseilleProvence_CentredeNéphrologieetTransplantationRénale_Caregiver_Baseline,220713_AixMarseilleProvence_CentredeNéphrologieetTransplantationRénale_Caregiver_Baseline,Presence of specific SARS-COV2 antibodies in hemodialysis patients and their caregivers after the first wave of COVID-19.,2022-07-13,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,France,,Aix-en-Provence,"""In June 2020, ... 238 caregivers from 4 dialysis facilities of the Aix-Marseille area were included in the SeroCOVIDial study""",Was on vacation at the time of the M0 visit ,2020-06-01,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,238,0.067,0.039,0.107,True,,,,True,Convenience,Biosynex COVID-19 BSS assay,Biosynex,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.8290000000000001,0.9770000000000001,['High'],,No,No,Yes,,Yes,Yes,No,,Thomas Robert,Centre de Néphrologie et Transplantation Rénale,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-15913-0,2022-07-20,2024-03-01,Unverified,robertPresenceSpecificSARSCOV22022,FRA
220713_AixMarseilleProvence_CentredeNéphrologieetTransplantationRénale_Caregiver_FU1,220713_AixMarseilleProvence_CentredeNéphrologieetTransplantationRénale_Caregiver_FU1,Presence of specific SARS-COV2 antibodies in hemodialysis patients and their caregivers after the first wave of COVID-19.,2022-07-13,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,France,,Aix-en-Provence,"""In June 2020, ... 238 caregivers from 4 dialysis facilities of the Aix-Marseille area were included in the SeroCOVIDial study""",Was on vacation at the time of the M0 visit,2020-09-01,2020-09-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,197,0.055999999999999994,0.027999999999999997,0.098,True,,,,True,Convenience,Biosynex COVID-19 BSS assay,Biosynex,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.8290000000000001,0.9770000000000001,['High'],,No,No,No,,Yes,Yes,No,,Thomas Robert,Centre de Néphrologie et Transplantation Rénale,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-15913-0,2022-07-20,2024-03-01,Unverified,robertPresenceSpecificSARSCOV22022,FRA
220713_AixMarseilleProvence_CentredeNéphrologieetTransplantationRénale_Caregiver_FU2,220713_AixMarseilleProvence_CentredeNéphrologieetTransplantationRénale_Caregiver_FU2,Presence of specific SARS-COV2 antibodies in hemodialysis patients and their caregivers after the first wave of COVID-19.,2022-07-13,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,France,,Aix-en-Provence,"""In June 2020, ... 238 caregivers from 4 dialysis facilities of the Aix-Marseille area were included in the SeroCOVIDial study""",Was on vacation at the time of the M0 visit,2020-12-01,2020-12-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,191,0.126,0.08199999999999999,0.18100000000000002,True,,,,True,Convenience,Biosynex COVID-19 BSS assay,Biosynex,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.8290000000000001,0.9770000000000001,['High'],,No,No,No,,Yes,Yes,No,,Thomas Robert,Centre de Néphrologie et Transplantation Rénale,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-15913-0,2022-07-20,2024-03-01,Unverified,robertPresenceSpecificSARSCOV22022,FRA
220713_AixMarseilleProvence_CentredeNéphrologieetTransplantationRénale_Patients_Baseline,220713_AixMarseilleProvence_CentredeNéphrologieetTransplantationRénale_Patients_Baseline,Presence of specific SARS-COV2 antibodies in hemodialysis patients and their caregivers after the first wave of COVID-19.,2022-07-13,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,France,,Aix-en-Provence,"""In June 2020, 451 HD patients ... from 4 dialysis facilities of the Aix-Marseille area were included in the SeroCOVIDial study""","Declined to participate 
Were not able to give an informed consent",2020-06-01,2020-06-30,Patients seeking care for non-COVID-19 reasons,All,Seniors (65+ years),,,Primary Estimate,,451,0.084,0.06,0.114,True,,,,True,Convenience,Biosynex COVID-19 BSS assay,Biosynex,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.8290000000000001,0.9770000000000001,['High'],,No,No,Yes,,Yes,Yes,No,,Thomas Robert,Centre de Néphrologie et Transplantation Rénale,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-15913-0,2022-07-20,2024-03-01,Unverified,robertPresenceSpecificSARSCOV22022,FRA
220713_AixMarseilleProvence_CentredeNéphrologieetTransplantationRénale_Patients_FU1,220713_AixMarseilleProvence_CentredeNéphrologieetTransplantationRénale_Patients_FU1,Presence of specific SARS-COV2 antibodies in hemodialysis patients and their caregivers after the first wave of COVID-19.,2022-07-13,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,France,,Aix-en-Provence,"""In June 2020, 451 HD patients ... from 4 dialysis facilities of the Aix-Marseille area were included in the SeroCOVIDial study""","Declined to participate 
Were not able to give an informed consent",2020-09-01,2020-09-30,Patients seeking care for non-COVID-19 reasons,All,Seniors (65+ years),,,Primary Estimate,,414,0.068,0.046,0.09699999999999999,True,,,,True,Convenience,Biosynex COVID-19 BSS assay,Biosynex,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.8290000000000001,0.9770000000000001,['High'],,No,No,No,,Yes,Yes,No,,Thomas Robert,Centre de Néphrologie et Transplantation Rénale,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-15913-0,2022-07-20,2024-03-01,Unverified,robertPresenceSpecificSARSCOV22022,FRA
220713_AixMarseilleProvence_CentredeNéphrologieetTransplantationRénale_Patients_FU2,220713_AixMarseilleProvence_CentredeNéphrologieetTransplantationRénale_Patients_FU2,Presence of specific SARS-COV2 antibodies in hemodialysis patients and their caregivers after the first wave of COVID-19.,2022-07-13,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,France,,Aix-en-Provence,"""In June 2020, 451 HD patients ... from 4 dialysis facilities of the Aix-Marseille area were included in the SeroCOVIDial study""","Declined to participate 
Were not able to give an informed consent",2020-12-01,2020-12-31,Patients seeking care for non-COVID-19 reasons,All,Seniors (65+ years),,,Primary Estimate,,382,0.138,0.105,0.177,True,,,,True,Convenience,Biosynex COVID-19 BSS assay,Biosynex,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.8290000000000001,0.9770000000000001,['High'],,No,No,No,,Yes,Yes,No,,Thomas Robert,Centre de Néphrologie et Transplantation Rénale,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-15913-0,2022-07-20,2024-03-01,Unverified,robertPresenceSpecificSARSCOV22022,FRA
220805_Ile-de-France_EtablissementFrancaisduSang_Jan2021_Euroimmun,220805_Ile-de-France_EtablissementFrancaisduSang_Jan2021,Impact of vaccination on SARS-CoV-2 seroprevalence rate in French blood donors: an assessment as of july 2021.,2022-08-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Ile-de-France ,,Voluntary blood donors,,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,,,Primary Estimate,,875,0.0857,,,True,,,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,,,IgG,Spike,,,,['High'],No,No,Yes,No,No,Yes,Yes,Yes,Unclear,Pierre Gallian,Unité des Virus Émergents,Unity-Aligned,https://dx.doi.org/10.1016/j.tracli.2022.08.002,2022-08-19,2024-04-02,Verified,gallian_impact_2022,FRA
220805_Ile-de-France_EtablissementFrancaisduSang_Jan2021_Beckman,220805_Ile-de-France_EtablissementFrancaisduSang_Jan2021,Impact of vaccination on SARS-CoV-2 seroprevalence rate in French blood donors: an assessment as of july 2021.,2022-08-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Ile-de-France ,,Voluntary blood donors,,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,,,Test used,,875,0.07540000000000001,,,,,,,,Sequential,Access SARS-CoV-2 IgG Reagent Antibody Test,Beckman Coulter,,,IgG,Spike,,,,['High'],No,No,Yes,No,No,Yes,Yes,Yes,Unclear,Pierre Gallian,Unité des Virus Émergents,Unity-Aligned,https://dx.doi.org/10.1016/j.tracli.2022.08.002,2022-08-19,2024-04-02,Verified,gallian_impact_2022,FRA
220805_Ile-de-France_EtablissementFrancaisduSang_July2021_Euroimmun,220805_Ile-de-France_EtablissementFrancaisduSang_July2021,Impact of vaccination on SARS-CoV-2 seroprevalence rate in French blood donors: an assessment as of july 2021.,2022-08-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Ile-de-France ,,Voluntary blood donors,,2021-07-01,2021-07-17,Blood donors,All,Multiple groups,,,Primary Estimate,,1001,0.8300000000000001,,,True,,,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,,,IgG,Spike,,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Pierre Gallian,Unité des Virus Émergents,Unity-Aligned,https://dx.doi.org/10.1016/j.tracli.2022.08.002,2022-08-19,2024-04-02,Verified,gallian_impact_2022,FRA
220805_Ile-de-France_EtablissementFrancaisduSang_July2021_Beckman,220805_Ile-de-France_EtablissementFrancaisduSang_July2021,Impact of vaccination on SARS-CoV-2 seroprevalence rate in French blood donors: an assessment as of july 2021.,2022-08-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Ile-de-France ,,Voluntary blood donors,,2021-07-01,2021-07-17,Blood donors,All,Multiple groups,,,Test used,,1001,0.761,,,,,,,,Sequential,Access SARS-CoV-2 IgG Reagent Antibody Test,Beckman Coulter,,,IgG,Spike,,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Pierre Gallian,Unité des Virus Émergents,Unity-Aligned,https://dx.doi.org/10.1016/j.tracli.2022.08.002,2022-08-19,2024-04-02,Verified,gallian_impact_2022,FRA
220913_HauteBretagne_CHUdeRennes,220913_HauteBretagne_CHUdeRennes,SARS-CoV-2 seroprevalence and antibodies persistence among health care workers after the first COVID-19 wave in nine hospitals in Western France,2022-09-13,Preprint,Regional,Cross-sectional survey ,France,Brittany,,All HCWs older than 18 years,"Individuals with legal protection (guardianship, curatorship)",2020-05-29,2020-07-10,Health care workers and caregivers,All,Multiple groups,18.0,,Primary Estimate,"This is described as the ""adjusted rate"" but it's not clear exactly how it was adjusted",9453,0.0106,0.0086,0.012700000000000001,True,,,,True,Unclear,NG-Test® finger-prick test,NG Biotech Laboratoires,LFIA,Whole Blood,IgG,,,,,['Moderate'],,Unclear,Yes,Yes,,No,Yes,No,,Ronan Garlantezec,CHU de Rennes,Not Unity-Aligned,https://dx.doi.org/10.1016/j.idnow.2022.09.004,2022-10-02,2024-03-01,Unverified,garlantezec_sars-cov-2_2022,FRA
221109_France_SorbonneUniversity,221109_France_SorbonneUniversity,Long-lasting Symptoms After an Acute COVID-19 Infection and Factors Associated With Their Resolution.,2022-11-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,"""This cross-sectional study is part of the SAPRIS-SERO (Santé, Pratiques, Relations et Inégalités Sociales en Population Générale Pendant la Crise COVID-19–Sérologie) survey"".

""In brief, data from 3 general, adult population–based French cohorts (E3N/E4N, CONSTANCES [Consultants des Centres d’Examens de Santé], and Nutrinet-Santé) were included in this study.""

""Only participants with internet access were invited to participate in the present study.""

""Only individuals who participated in the first 2 waves of SAPRIS-SERO questionnaires, the serologic survey, and the follow-up questionnaire were included in the analysis.""",,2020-05-01,2020-11-30,Household and community samples,All,Multiple groups,,,Primary Estimate,ELISA-S + Neutralization,53047,0.0168,,,True,,,,True,Unclear,"Anti-SARS-CoV-2 ELISA IgG,Author designed (Neutralization Assay)","EUROIMMUN,NA",Multiple Types,Dried Blood,"['IgG', 'Neutralizing']",Spike,,,,['High'],,Unclear,Yes,No,,Unclear,Yes,No,,Olivier Robineau,Sorbonne University,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.40985,2022-11-16,2024-03-01,Unverified,robineau_long-lasting_2022,FRA
221118_France_UniversitedeCorsePascalPaoli_Phase1_AntiS,221118_France_UniversitedeCorsePascalPaoli_Phase1,Eight Months of Serological Follow-Up of Anti-SARS-CoV-2 Antibodies in France: A Study among an Adult Population,2022-11-18,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,France,,Corte,"""This study included the voluntary participation of the staff and students of the University of Corsica, Corte, France. A total of 295 participants were included in the study after signing a consent form, and took part in all 3 phases of the study by providing a blood sample and completing a questionnaire at each phase.""","""People lost contact or who did not complete the questionnaire/ not collect blood sample"" in any phase",2020-11-23,2021-01-31,Multiple populations,All,Adults (18-64 years),17.0,64.0,Primary Estimate,anti-S ELISA,295,0.115,0.08199999999999999,0.159,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.903,0.998,['High'],,No,No,Yes,,Yes,Yes,Yes,,Dorine Decarreaux,Universite de Corse Pascal Paoli,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph192215257,2022-12-05,2024-03-01,Unverified,decarreaux_eight_2022,FRA
221118_France_UniversitedeCorsePascalPaoli_Phase2_AntiS,221118_France_UniversitedeCorsePascalPaoli_Phase2,Eight Months of Serological Follow-Up of Anti-SARS-CoV-2 Antibodies in France: A Study among an Adult Population,2022-11-18,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,France,,Corte,"""This study included the voluntary participation of the staff and students of the University of Corsica, Corte, France. A total of 295 participants were included in the study after signing a consent form, and took part in all 3 phases of the study by providing a blood sample and completing a questionnaire at each phase.""","""People lost contact or who did not complete the questionnaire/ not collect blood sample"" in any phase",2021-03-01,2021-05-09,Multiple populations,All,Adults (18-64 years),17.0,64.0,Primary Estimate,anti-S ELISA,295,0.105,0.07400000000000001,0.147,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.903,0.998,['High'],,No,No,Yes,,Yes,Yes,Yes,,Dorine Decarreaux,Universite de Corse Pascal Paoli,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph192215257,2022-12-05,2024-03-01,Unverified,decarreaux_eight_2022,FRA
221118_France_UniversitedeCorsePascalPaoli_Phase3_AntiS,221118_France_UniversitedeCorsePascalPaoli_Phase3,Eight Months of Serological Follow-Up of Anti-SARS-CoV-2 Antibodies in France: A Study among an Adult Population,2022-11-18,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,France,,Corte,"""This study included the voluntary participation of the staff and students of the University of Corsica, Corte, France. A total of 295 participants were included in the study after signing a consent form, and took part in all 3 phases of the study by providing a blood sample and completing a questionnaire at each phase.""","""People lost contact or who did not complete the questionnaire/ not collect blood sample"" in any phase",2021-06-14,2021-07-31,Multiple populations,All,Adults (18-64 years),17.0,64.0,Primary Estimate,anti-S ELISA,295,0.685,0.628,0.737,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.903,0.998,['High'],,No,No,Yes,,Yes,Yes,Yes,,Dorine Decarreaux,Universite de Corse Pascal Paoli,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph192215257,2022-12-05,2024-03-01,Unverified,decarreaux_eight_2022,FRA
230215_France_EtablissementFrancaisduSang_T1_Overall,230215_France_EtablissementFrancaisduSang_T1,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2020-03-27,2020-04-04,Blood donors,All,Multiple groups,18.0,70.0,Primary Estimate,,2232,0.0753,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2023-03-07,2024-04-29,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T1_41to50,230215_France_EtablissementFrancaisduSang_T1,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2020-03-27,2020-04-04,Blood donors,All,Adults (18-64 years),41.0,50.0,Age,,527,0.074,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2024-04-29,2024-04-30,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T1_18to30,230215_France_EtablissementFrancaisduSang_T1,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2020-03-27,2020-04-04,Blood donors,All,Adults (18-64 years),18.0,30.0,Age,18-30,663,0.0498,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2024-04-29,2024-04-30,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T1_31to40,230215_France_EtablissementFrancaisduSang_T1,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2020-03-27,2020-04-04,Blood donors,All,Adults (18-64 years),31.0,40.0,Age,,436,0.1399,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2024-04-29,2024-04-30,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T1_51to60,230215_France_EtablissementFrancaisduSang_T1,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2020-03-27,2020-04-04,Blood donors,All,Adults (18-64 years),51.0,60.0,Age,,408,0.049,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2024-04-29,2024-04-30,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T1_61to70,230215_France_EtablissementFrancaisduSang_T1,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2020-03-27,2020-04-04,Blood donors,All,Multiple groups,61.0,70.0,Age,,198,0.0758,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2024-04-29,2024-04-30,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T2_31to40,230215_France_EtablissementFrancaisduSang_T2,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2020-05-11,2020-05-29,Blood donors,All,Adults (18-64 years),31.0,40.0,Age,31-40,581,0.1067,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2024-04-29,2024-04-30,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T2_18to30,230215_France_EtablissementFrancaisduSang_T2,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2020-05-11,2020-05-29,Blood donors,All,Adults (18-64 years),18.0,30.0,Age,18-30,949,0.058,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2024-04-29,2024-04-30,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T2_Overall,230215_France_EtablissementFrancaisduSang_T2,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2020-05-11,2020-05-29,Blood donors,All,Multiple groups,18.0,70.0,Primary Estimate,,3241,0.0722,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2023-03-08,2024-03-01,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T2_41to50,230215_France_EtablissementFrancaisduSang_T2,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2020-05-11,2020-05-29,Blood donors,All,Adults (18-64 years),41.0,50.0,Age,41-50,692,0.0867,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2024-04-29,2024-04-30,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T2_51to60,230215_France_EtablissementFrancaisduSang_T2,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2020-05-11,2020-05-29,Blood donors,All,Adults (18-64 years),51.0,60.0,Age,51-60,618,0.0615,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2024-04-29,2024-04-30,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T2_61to70,230215_France_EtablissementFrancaisduSang_T2,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2020-05-11,2020-05-29,Blood donors,All,Multiple groups,61.0,70.0,Age,61-70,401,0.0474,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2024-04-29,2024-04-30,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T3_61to70,230215_France_EtablissementFrancaisduSang_T3,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2020-07-01,2020-07-23,Blood donors,All,Multiple groups,61.0,70.0,Age,61-70,386,0.044,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2024-04-29,2024-05-01,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T3_31to40,230215_France_EtablissementFrancaisduSang_T3,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2020-07-01,2020-07-23,Blood donors,All,Adults (18-64 years),31.0,40.0,Age,31-40,535,0.1047,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2024-04-29,2024-05-01,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T3_18to30,230215_France_EtablissementFrancaisduSang_T3,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2020-07-01,2020-07-23,Blood donors,All,Adults (18-64 years),18.0,30.0,Age,18-30,827,0.0496,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2024-04-29,2024-05-01,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T3_Overall,230215_France_EtablissementFrancaisduSang_T3,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2020-07-01,2020-07-23,Blood donors,All,Multiple groups,18.0,70.0,Primary Estimate,,2951,0.0613,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2023-03-08,2024-03-01,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T3_41to50,230215_France_EtablissementFrancaisduSang_T3,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2020-07-01,2020-07-23,Blood donors,All,Adults (18-64 years),41.0,50.0,Age,41-50,610,0.0557,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2024-04-29,2024-05-01,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T3_51to60,230215_France_EtablissementFrancaisduSang_T3,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2020-07-01,2020-07-23,Blood donors,All,Adults (18-64 years),51.0,60.0,Age,51-60,593,0.0556,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2024-04-29,2024-05-01,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T4_Overall,230215_France_EtablissementFrancaisduSang_T4,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2020-09-28,2020-10-29,Blood donors,All,Multiple groups,18.0,70.0,Primary Estimate,,6009,0.0534,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2023-03-08,2024-03-01,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T4_31to40,230215_France_EtablissementFrancaisduSang_T4,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2020-09-28,2020-10-29,Blood donors,All,Adults (18-64 years),31.0,40.0,Age,31-40,1045,0.0813,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2024-04-29,2024-05-01,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T4_18to30,230215_France_EtablissementFrancaisduSang_T4,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2020-09-28,2020-10-29,Blood donors,All,Adults (18-64 years),18.0,30.0,Age,18-30,2049,0.0483,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2024-04-29,2024-05-01,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T4_41to50,230215_France_EtablissementFrancaisduSang_T4,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2020-09-28,2020-10-29,Blood donors,All,Adults (18-64 years),41.0,50.0,Age,41-50,1178,0.0654,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2024-04-29,2024-05-01,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T4_61to70,230215_France_EtablissementFrancaisduSang_T4,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2020-09-28,2020-10-29,Blood donors,All,Multiple groups,61.0,70.0,Age,61-70,640,0.0266,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2024-04-29,2024-05-01,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T4_51to60,230215_France_EtablissementFrancaisduSang_T4,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2020-09-28,2020-10-29,Blood donors,All,Adults (18-64 years),51.0,60.0,Age,51-60,1097,0.0392,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2024-04-29,2024-05-01,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T5_51to60,230215_France_EtablissementFrancaisduSang_T5,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2020-11-03,2020-11-18,Blood donors,All,Adults (18-64 years),51.0,60.0,Age,51-60,1095,0.0557,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2024-04-29,2024-05-01,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T5_Overall,230215_France_EtablissementFrancaisduSang_T5,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2020-11-03,2020-11-18,Blood donors,All,Multiple groups,18.0,70.0,Primary Estimate,,6156,0.0781,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2023-03-08,2024-03-01,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T5_31to40,230215_France_EtablissementFrancaisduSang_T5,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2020-11-03,2020-11-18,Blood donors,All,Adults (18-64 years),31.0,40.0,Age,31-40,1308,0.0833,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2024-04-29,2024-05-01,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T5_41to50,230215_France_EtablissementFrancaisduSang_T5,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2020-11-03,2020-11-18,Blood donors,All,Adults (18-64 years),41.0,50.0,Age,41-50,1305,0.0736,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2024-04-29,2024-05-01,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T5_18to30,230215_France_EtablissementFrancaisduSang_T5,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2020-11-03,2020-11-18,Blood donors,All,Adults (18-64 years),18.0,30.0,Age,18-30,1821,0.1082,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2024-04-29,2024-05-01,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T5_61to70,230215_France_EtablissementFrancaisduSang_T5,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2020-11-03,2020-11-18,Blood donors,All,Multiple groups,61.0,70.0,Age,61-70,627,0.0287,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2024-04-29,2024-05-01,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T6_31to40,230215_France_EtablissementFrancaisduSang_T6,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2021-01-14,2021-02-09,Blood donors,All,Adults (18-64 years),31.0,40.0,Age,31-40,2191,0.0666,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2024-04-29,2024-05-01,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T6_Overall,230215_France_EtablissementFrancaisduSang_T6,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2021-01-14,2021-02-09,Blood donors,All,Multiple groups,18.0,70.0,Primary Estimate,,12016,0.0821,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2023-03-08,2024-03-01,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T6_51to60,230215_France_EtablissementFrancaisduSang_T6,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2021-01-14,2021-02-09,Blood donors,All,Adults (18-64 years),51.0,60.0,Age,51-60,2177,0.079,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2024-04-29,2024-05-01,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T6_61to70,230215_France_EtablissementFrancaisduSang_T6,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2021-01-14,2021-02-09,Blood donors,All,Multiple groups,61.0,70.0,Age,61-70,1411,0.0546,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2024-04-29,2024-05-01,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T6_18to30,230215_France_EtablissementFrancaisduSang_T6,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2021-01-14,2021-02-09,Blood donors,All,Adults (18-64 years),18.0,30.0,Age,18-30,3762,0.109,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2024-04-29,2024-05-01,Unverified,gallian_sars-cov-2_2023,FRA
230215_France_EtablissementFrancaisduSang_T6_41to50,230215_France_EtablissementFrancaisduSang_T6,"SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021",2023-02-15,Journal Article (Peer-Reviewed),,Repeated cross-sectional study,France,"mainland France, Guadeloupe, Martinique, La Réunion",,"French ""voluntary unpaid blood donors (18-70 years old) were recruited according to French regulatory requirements.""",,2021-01-14,2021-02-09,Blood donors,All,Adults (18-64 years),41.0,50.0,Age,41-50,2475,0.0731,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Pierre Gallian,Établissement Français du Sang,Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106222,2024-04-29,2024-05-01,Unverified,gallian_sars-cov-2_2023,FRA
230223_Marseille_HopitauxdeMarseille_FirstCampaign,230223_Marseille_HopitauxdeMarseille,Cumulative incidence of SARS-CoV-2 infection within the homeless population: insights from a city-wide longitudinal study,2023-02-23,Journal Article (Peer-Reviewed),Local,Prospective cohort,France,,Marseille,"""In order to focus on the homeless people the furthest
from housing, we decided to select those characterised by
the greatest residential instability: people sleeping rough,
in squats or slums, in stabilisation shelters, in emergency
shelters or hostels, respectively, corresponding to the
following categories of the European Typology on Homelessness and Housing Exclusion (ETHOS): ETHOS 1, 2,
3 and 8"" ",,2020-06-05,2020-08-05,Persons experiencing homelessness,All,Adults (18-64 years),18.0,,Primary Estimate,,1241,0.06,,,True,,,,True,Convenience,Biosynex COVID-19 BSS assay,Biosynex,LFIA,Whole Blood,"IgG, IgM",Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Emilie Mosnier,Hopitaux de Marseille,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2022-065734,2023-04-03,2024-03-01,Unverified,mosnier_cumulative_2023,FRA
230323_France_SorbonneParisNordUniversity_Primary_AntiS-AntiN-nAb,230323_France_SorbonneParisNordUniversity,ABO blood types and SARS-CoV-2 infection assessed using seroprevalence data in a large population-based sample: the SAPRIS-SERO multi-cohort study.,2023-03-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,"""In May 2020, participants from the Constances, E3N-E4N and NutriNet-Santé cohort studies answering SAPRIS questionnaires were also invited to take part in the SAPRIS-SERO project which aimed to estimate the seroprevalence of antibodies against SARS-CoV-2 at the population level, as previously described12,13.""

From https://doi.org/10.1186%2Fs12879-021-05864-8:
""SAPRIS is based on a consortia of prospective cohort studies involving ... three general population-based adult cohorts:

- 1) CONSTANCES, a “general population” cohort including 204,973 adults aged 18 to 69 at inclusion and randomly selected from 2012 to be a representative sample of the French adult population affiliated to the General Health Insurance Fund (the source population, that is, approximately 85% of the total French population) [8]. Among CONSTANCES participants, 66,881 are followed by internet, the rest through mailed questionnaires.

- 2) E3N / E4N, a multigenerational adult cohort based on a community of families with 113,000 participants (including women recruited in 1990 and still actively followed-up, their offspring and the fathers of these offspring) among whom 89,606 followed by internet, the rest through mailed questionnaires [9].

- 3) NutriNet-Santé, a nutritional general population-based internet cohort started in 2009, with 170,000 included participants among whom 151,122 were still followed-up in 2020 [10].""",,2020-05-15,2020-11-15,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,"Positive for all of ELISA-S, ELISA-NP, and SN",67340,0.0101,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG),Author designed (Neutralization Assay)","EUROIMMUN,NA","ELISA,ELISA,Neutralization Assay",Dried Blood,"['IgG', 'Neutralizing']","['Nucleocapsid (N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Melanie Deschasaux-Tanguy,Sorbonne Paris Nord University,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-023-30714-9,2023-04-26,2024-03-01,Unverified,deschasaux-tanguy_abo_2023,FRA
230323_France_SorbonneParisNordUniversity_TimeFrame_Nov,230323_France_SorbonneParisNordUniversity,ABO blood types and SARS-CoV-2 infection assessed using seroprevalence data in a large population-based sample: the SAPRIS-SERO multi-cohort study.,2023-03-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,"""In May 2020, participants from the Constances, E3N-E4N and NutriNet-Santé cohort studies answering SAPRIS questionnaires were also invited to take part in the SAPRIS-SERO project which aimed to estimate the seroprevalence of antibodies against SARS-CoV-2 at the population level, as previously described12,13.""

From https://doi.org/10.1186%2Fs12879-021-05864-8:
""SAPRIS is based on a consortia of prospective cohort studies involving ... three general population-based adult cohorts:

- 1) CONSTANCES, a “general population” cohort including 204,973 adults aged 18 to 69 at inclusion and randomly selected from 2012 to be a representative sample of the French adult population affiliated to the General Health Insurance Fund (the source population, that is, approximately 85% of the total French population) [8]. Among CONSTANCES participants, 66,881 are followed by internet, the rest through mailed questionnaires.

- 2) E3N / E4N, a multigenerational adult cohort based on a community of families with 113,000 participants (including women recruited in 1990 and still actively followed-up, their offspring and the fathers of these offspring) among whom 89,606 followed by internet, the rest through mailed questionnaires [9].

- 3) NutriNet-Santé, a nutritional general population-based internet cohort started in 2009, with 170,000 included participants among whom 151,122 were still followed-up in 2020 [10].""",,2020-11-01,2020-11-30,Household and community samples,All,Multiple groups,18.0,,Time frame,Time frame: Nov 2020,4,0.25,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.85,0.95,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Melanie Deschasaux-Tanguy,Sorbonne Paris Nord University,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-023-30714-9,2023-04-26,2024-03-01,Unverified,deschasaux-tanguy_abo_2023,FRA
230323_France_SorbonneParisNordUniversity_TimeFrame_May,230323_France_SorbonneParisNordUniversity,ABO blood types and SARS-CoV-2 infection assessed using seroprevalence data in a large population-based sample: the SAPRIS-SERO multi-cohort study.,2023-03-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,"""In May 2020, participants from the Constances, E3N-E4N and NutriNet-Santé cohort studies answering SAPRIS questionnaires were also invited to take part in the SAPRIS-SERO project which aimed to estimate the seroprevalence of antibodies against SARS-CoV-2 at the population level, as previously described12,13.""

From https://doi.org/10.1186%2Fs12879-021-05864-8:
""SAPRIS is based on a consortia of prospective cohort studies involving ... three general population-based adult cohorts:

- 1) CONSTANCES, a “general population” cohort including 204,973 adults aged 18 to 69 at inclusion and randomly selected from 2012 to be a representative sample of the French adult population affiliated to the General Health Insurance Fund (the source population, that is, approximately 85% of the total French population) [8]. Among CONSTANCES participants, 66,881 are followed by internet, the rest through mailed questionnaires.

- 2) E3N / E4N, a multigenerational adult cohort based on a community of families with 113,000 participants (including women recruited in 1990 and still actively followed-up, their offspring and the fathers of these offspring) among whom 89,606 followed by internet, the rest through mailed questionnaires [9].

- 3) NutriNet-Santé, a nutritional general population-based internet cohort started in 2009, with 170,000 included participants among whom 151,122 were still followed-up in 2020 [10].""",,2020-05-01,2020-05-31,Household and community samples,All,Multiple groups,18.0,,Time frame,Time frame: May 2020,8667,0.0765,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.85,0.95,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Melanie Deschasaux-Tanguy,Sorbonne Paris Nord University,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-023-30714-9,2023-04-26,2024-03-01,Unverified,deschasaux-tanguy_abo_2023,FRA
230323_France_SorbonneParisNordUniversity_AntiS-AntiN,230323_France_SorbonneParisNordUniversity,ABO blood types and SARS-CoV-2 infection assessed using seroprevalence data in a large population-based sample: the SAPRIS-SERO multi-cohort study.,2023-03-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,"""In May 2020, participants from the Constances, E3N-E4N and NutriNet-Santé cohort studies answering SAPRIS questionnaires were also invited to take part in the SAPRIS-SERO project which aimed to estimate the seroprevalence of antibodies against SARS-CoV-2 at the population level, as previously described12,13.""

From https://doi.org/10.1186%2Fs12879-021-05864-8:
""SAPRIS is based on a consortia of prospective cohort studies involving ... three general population-based adult cohorts:

- 1) CONSTANCES, a “general population” cohort including 204,973 adults aged 18 to 69 at inclusion and randomly selected from 2012 to be a representative sample of the French adult population affiliated to the General Health Insurance Fund (the source population, that is, approximately 85% of the total French population) [8]. Among CONSTANCES participants, 66,881 are followed by internet, the rest through mailed questionnaires.

- 2) E3N / E4N, a multigenerational adult cohort based on a community of families with 113,000 participants (including women recruited in 1990 and still actively followed-up, their offspring and the fathers of these offspring) among whom 89,606 followed by internet, the rest through mailed questionnaires [9].

- 3) NutriNet-Santé, a nutritional general population-based internet cohort started in 2009, with 170,000 included participants among whom 151,122 were still followed-up in 2020 [10].""",,2020-05-15,2020-11-15,Household and community samples,All,Multiple groups,18.0,,Test used,Positive for ELISA-S and ELISA-NP,67340,0.0176,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)",EUROIMMUN,"ELISA,ELISA",Dried Blood,IgG,"['Nucleocapsid (N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Melanie Deschasaux-Tanguy,Sorbonne Paris Nord University,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-023-30714-9,2023-04-26,2024-03-01,Unverified,deschasaux-tanguy_abo_2023,FRA
230323_France_SorbonneParisNordUniversity_TimeFrame_Aug,230323_France_SorbonneParisNordUniversity,ABO blood types and SARS-CoV-2 infection assessed using seroprevalence data in a large population-based sample: the SAPRIS-SERO multi-cohort study.,2023-03-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,"""In May 2020, participants from the Constances, E3N-E4N and NutriNet-Santé cohort studies answering SAPRIS questionnaires were also invited to take part in the SAPRIS-SERO project which aimed to estimate the seroprevalence of antibodies against SARS-CoV-2 at the population level, as previously described12,13.""

From https://doi.org/10.1186%2Fs12879-021-05864-8:
""SAPRIS is based on a consortia of prospective cohort studies involving ... three general population-based adult cohorts:

- 1) CONSTANCES, a “general population” cohort including 204,973 adults aged 18 to 69 at inclusion and randomly selected from 2012 to be a representative sample of the French adult population affiliated to the General Health Insurance Fund (the source population, that is, approximately 85% of the total French population) [8]. Among CONSTANCES participants, 66,881 are followed by internet, the rest through mailed questionnaires.

- 2) E3N / E4N, a multigenerational adult cohort based on a community of families with 113,000 participants (including women recruited in 1990 and still actively followed-up, their offspring and the fathers of these offspring) among whom 89,606 followed by internet, the rest through mailed questionnaires [9].

- 3) NutriNet-Santé, a nutritional general population-based internet cohort started in 2009, with 170,000 included participants among whom 151,122 were still followed-up in 2020 [10].""",,2020-08-01,2020-08-31,Household and community samples,All,Multiple groups,18.0,,Time frame,Time frame: Aug 2020,13660,0.0395,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.85,0.95,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Melanie Deschasaux-Tanguy,Sorbonne Paris Nord University,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-023-30714-9,2023-04-26,2024-03-01,Unverified,deschasaux-tanguy_abo_2023,FRA
230323_France_SorbonneParisNordUniversity_TimeFrame_July,230323_France_SorbonneParisNordUniversity,ABO blood types and SARS-CoV-2 infection assessed using seroprevalence data in a large population-based sample: the SAPRIS-SERO multi-cohort study.,2023-03-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,"""In May 2020, participants from the Constances, E3N-E4N and NutriNet-Santé cohort studies answering SAPRIS questionnaires were also invited to take part in the SAPRIS-SERO project which aimed to estimate the seroprevalence of antibodies against SARS-CoV-2 at the population level, as previously described12,13.""

From https://doi.org/10.1186%2Fs12879-021-05864-8:
""SAPRIS is based on a consortia of prospective cohort studies involving ... three general population-based adult cohorts:

- 1) CONSTANCES, a “general population” cohort including 204,973 adults aged 18 to 69 at inclusion and randomly selected from 2012 to be a representative sample of the French adult population affiliated to the General Health Insurance Fund (the source population, that is, approximately 85% of the total French population) [8]. Among CONSTANCES participants, 66,881 are followed by internet, the rest through mailed questionnaires.

- 2) E3N / E4N, a multigenerational adult cohort based on a community of families with 113,000 participants (including women recruited in 1990 and still actively followed-up, their offspring and the fathers of these offspring) among whom 89,606 followed by internet, the rest through mailed questionnaires [9].

- 3) NutriNet-Santé, a nutritional general population-based internet cohort started in 2009, with 170,000 included participants among whom 151,122 were still followed-up in 2020 [10].""",,2020-07-01,2020-07-31,Household and community samples,All,Multiple groups,18.0,,Time frame,Time frame: Jul 2020,39699,0.0392,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.85,0.95,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Melanie Deschasaux-Tanguy,Sorbonne Paris Nord University,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-023-30714-9,2023-04-26,2024-03-01,Unverified,deschasaux-tanguy_abo_2023,FRA
230323_France_SorbonneParisNordUniversity_TimeFrame_Jun,230323_France_SorbonneParisNordUniversity,ABO blood types and SARS-CoV-2 infection assessed using seroprevalence data in a large population-based sample: the SAPRIS-SERO multi-cohort study.,2023-03-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,"""In May 2020, participants from the Constances, E3N-E4N and NutriNet-Santé cohort studies answering SAPRIS questionnaires were also invited to take part in the SAPRIS-SERO project which aimed to estimate the seroprevalence of antibodies against SARS-CoV-2 at the population level, as previously described12,13.""

From https://doi.org/10.1186%2Fs12879-021-05864-8:
""SAPRIS is based on a consortia of prospective cohort studies involving ... three general population-based adult cohorts:

- 1) CONSTANCES, a “general population” cohort including 204,973 adults aged 18 to 69 at inclusion and randomly selected from 2012 to be a representative sample of the French adult population affiliated to the General Health Insurance Fund (the source population, that is, approximately 85% of the total French population) [8]. Among CONSTANCES participants, 66,881 are followed by internet, the rest through mailed questionnaires.

- 2) E3N / E4N, a multigenerational adult cohort based on a community of families with 113,000 participants (including women recruited in 1990 and still actively followed-up, their offspring and the fathers of these offspring) among whom 89,606 followed by internet, the rest through mailed questionnaires [9].

- 3) NutriNet-Santé, a nutritional general population-based internet cohort started in 2009, with 170,000 included participants among whom 151,122 were still followed-up in 2020 [10].""",,2020-06-01,2020-06-30,Household and community samples,All,Multiple groups,18.0,,Time frame,Time frame: Jun 2020,452,0.0553,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.85,0.95,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Melanie Deschasaux-Tanguy,Sorbonne Paris Nord University,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-023-30714-9,2023-04-26,2024-03-01,Unverified,deschasaux-tanguy_abo_2023,FRA
230323_France_SorbonneParisNordUniversity_TimeFrame_Sep,230323_France_SorbonneParisNordUniversity,ABO blood types and SARS-CoV-2 infection assessed using seroprevalence data in a large population-based sample: the SAPRIS-SERO multi-cohort study.,2023-03-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,"""In May 2020, participants from the Constances, E3N-E4N and NutriNet-Santé cohort studies answering SAPRIS questionnaires were also invited to take part in the SAPRIS-SERO project which aimed to estimate the seroprevalence of antibodies against SARS-CoV-2 at the population level, as previously described12,13.""

From https://doi.org/10.1186%2Fs12879-021-05864-8:
""SAPRIS is based on a consortia of prospective cohort studies involving ... three general population-based adult cohorts:

- 1) CONSTANCES, a “general population” cohort including 204,973 adults aged 18 to 69 at inclusion and randomly selected from 2012 to be a representative sample of the French adult population affiliated to the General Health Insurance Fund (the source population, that is, approximately 85% of the total French population) [8]. Among CONSTANCES participants, 66,881 are followed by internet, the rest through mailed questionnaires.

- 2) E3N / E4N, a multigenerational adult cohort based on a community of families with 113,000 participants (including women recruited in 1990 and still actively followed-up, their offspring and the fathers of these offspring) among whom 89,606 followed by internet, the rest through mailed questionnaires [9].

- 3) NutriNet-Santé, a nutritional general population-based internet cohort started in 2009, with 170,000 included participants among whom 151,122 were still followed-up in 2020 [10].""",,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,18.0,,Time frame,Time frame: Sep 2020,4785,0.0372,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.85,0.95,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Melanie Deschasaux-Tanguy,Sorbonne Paris Nord University,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-023-30714-9,2023-04-26,2024-03-01,Unverified,deschasaux-tanguy_abo_2023,FRA
230323_France_SorbonneParisNordUniversity_TimeFrame_Oct,230323_France_SorbonneParisNordUniversity,ABO blood types and SARS-CoV-2 infection assessed using seroprevalence data in a large population-based sample: the SAPRIS-SERO multi-cohort study.,2023-03-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,"""In May 2020, participants from the Constances, E3N-E4N and NutriNet-Santé cohort studies answering SAPRIS questionnaires were also invited to take part in the SAPRIS-SERO project which aimed to estimate the seroprevalence of antibodies against SARS-CoV-2 at the population level, as previously described12,13.""

From https://doi.org/10.1186%2Fs12879-021-05864-8:
""SAPRIS is based on a consortia of prospective cohort studies involving ... three general population-based adult cohorts:

- 1) CONSTANCES, a “general population” cohort including 204,973 adults aged 18 to 69 at inclusion and randomly selected from 2012 to be a representative sample of the French adult population affiliated to the General Health Insurance Fund (the source population, that is, approximately 85% of the total French population) [8]. Among CONSTANCES participants, 66,881 are followed by internet, the rest through mailed questionnaires.

- 2) E3N / E4N, a multigenerational adult cohort based on a community of families with 113,000 participants (including women recruited in 1990 and still actively followed-up, their offspring and the fathers of these offspring) among whom 89,606 followed by internet, the rest through mailed questionnaires [9].

- 3) NutriNet-Santé, a nutritional general population-based internet cohort started in 2009, with 170,000 included participants among whom 151,122 were still followed-up in 2020 [10].""",,2020-10-01,2020-10-31,Household and community samples,All,Multiple groups,18.0,,Time frame,Time frame: Oct 2020,73,0.0137,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.85,0.95,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Melanie Deschasaux-Tanguy,Sorbonne Paris Nord University,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-023-30714-9,2023-04-26,2024-03-01,Unverified,deschasaux-tanguy_abo_2023,FRA
230323_France_SorbonneParisNordUniversity_AntiS,230323_France_SorbonneParisNordUniversity,ABO blood types and SARS-CoV-2 infection assessed using seroprevalence data in a large population-based sample: the SAPRIS-SERO multi-cohort study.,2023-03-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,"""In May 2020, participants from the Constances, E3N-E4N and NutriNet-Santé cohort studies answering SAPRIS questionnaires were also invited to take part in the SAPRIS-SERO project which aimed to estimate the seroprevalence of antibodies against SARS-CoV-2 at the population level, as previously described12,13.""

From https://doi.org/10.1186%2Fs12879-021-05864-8:
""SAPRIS is based on a consortia of prospective cohort studies involving ... three general population-based adult cohorts:

- 1) CONSTANCES, a “general population” cohort including 204,973 adults aged 18 to 69 at inclusion and randomly selected from 2012 to be a representative sample of the French adult population affiliated to the General Health Insurance Fund (the source population, that is, approximately 85% of the total French population) [8]. Among CONSTANCES participants, 66,881 are followed by internet, the rest through mailed questionnaires.

- 2) E3N / E4N, a multigenerational adult cohort based on a community of families with 113,000 participants (including women recruited in 1990 and still actively followed-up, their offspring and the fathers of these offspring) among whom 89,606 followed by internet, the rest through mailed questionnaires [9].

- 3) NutriNet-Santé, a nutritional general population-based internet cohort started in 2009, with 170,000 included participants among whom 151,122 were still followed-up in 2020 [10].""",,2020-05-15,2020-11-15,Household and community samples,All,Multiple groups,18.0,,Test used,Positive for ELISA-S,67340,0.044,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.85,0.95,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Melanie Deschasaux-Tanguy,Sorbonne Paris Nord University,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-023-30714-9,2023-04-26,2024-03-01,Unverified,deschasaux-tanguy_abo_2023,FRA
230405_France_HopitalHotelDieu,230405_France_HopitalHotelDieu,Trust in sources of information on COVID-19 at the beginning of the pandemic's first wave and incident persistent symptoms in the population-based CONSTANCES cohort: A prospective study.,2023-04-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,"The present study is a longitudinal analysis of data from the SAPRIS and SAPRIS-SERO surveys nested in the French CONSTANCES cohort.

The French CONSTANCES population-based cohort study received ethical approval and included approximately 200,000 volunteers aged 18–69 years at inclusion between 2012 and 2019.

Volunteers were selected among individuals covered by the general insurance scheme or partner health mutual societies (in all, 85% of the French population).","Based on Supplementary Fig. 1:

- 1589 did not respond;
- 2360 did not validate their questionnaire;
- 1032 with missing data on serology test results or self-reported COVID-19;
- 2780 excluded from the analysis because they answered “I don’t know” to the self-reported COVID-19 question;
- 1312 excluded from the analysis because of they indicated having had COVID-19 after the date of their serologic testing;
- 893 excluded from the analysis because they responded “I don’t know”, “I don’t want to answer”, or “other” to the questions about income or education;
- 2182 excluded from the analysis because they answered “I don’t know” on questions about trust in information sources on COVID-19;
- 2719 excluded from because of missing data on sex, education, income, self-rated health, or trust in information sources.

To reduce the risk of false-negative results, samples with indeterminate results (ie, optical density ratio ≥ 0.8 and < 1.1) were discarded.",2020-05-15,2020-11-15,Household and community samples,All,Multiple groups,19.0,77.0,Primary Estimate,,20985,0.0419,,,True,,,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by manufacturers,0.87,0.975,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Joane Matta,Hôtel Dieu Hospital,Unity-Aligned,https://dx.doi.org/10.1016/j.jpsychores.2023.111326,2023-05-08,2024-04-22,Verified,matta_trust_2023,FRA
230501_Orleans_UnitederecherchecliniquePARADICT-O,230501_Orleans_UnitederecherchecliniquePARADICT-O,"COVID-19 seroprevalence among local authority workers from Orleans Metropole, the Community of Communes of the Terres du Val de Loire, the local public service management centre of the Loiret department and the Region Centre Val de Loire: a prospective ep",2023-05-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,France,Centre Val de Loire,,"""The studied population was composed of local authori- ties’ employees aged from 18 to 65 and working for one of the following organisations: Orléans Métropole, the CCTVL and the Région Centre Val de Loire.""",,2020-08-15,2020-12-15,Household and community samples,All,Adults (18-64 years),18.0,65.0,Primary Estimate,,3328,0.0303,,,True,,,,True,Convenience,COVID-PRESTO®,AAZ LMB,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,,1.0,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Guerrout Hanane,Unite de recherche clinique PARADICT-O,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2022-066504,2023-06-28,2024-03-01,Unverified,hananeCOVID19SeroprevalenceLocal2023,FRA
230511_France_SorbonneUniversiteprim,230511_France_SorbonneUniversite,Comparison of Depression and Anxiety Following Self-reported COVID-19-Like Symptoms vs SARS-CoV-2 Seropositivity in France,2023-05-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,"On May 2, 2020, a letter was sent to a random sample of 371 000 people 15 years or older drawn from the national administrative and tax database (covering 96.4% of the population in France), with an intentional overrepresentation of individuals living in a household below the poverty level.","Individuals living in a residential care home for the elderly or in prison were excluded.

Of 85 074 individuals 15 years or older who completed the questionnaires at the 3 collection times, 28 568 were excluded because they did not return a blood sample for serologic testing, 1994 because of missing data on outcomes or exposures, and 9252 to respect the temporal sequence (exposure must precede the outcome).",2020-10-26,2020-12-14,Household and community samples,All,Multiple groups,15.0,,Primary Estimate,,45260,0.094,0.091,0.098,True,,True,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.864,0.962,['Low'],,Yes,Yes,Yes,,Yes,Yes,No,,Alexandra Rouquette,Sorbonne University,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2023.12892,2023-05-31,2024-03-01,Unverified,rouquette_comparison_2023,FRA
230525_Bordeaux_ComprehensiveCancerCenter_12m_Overall,230525_Bordeaux_ComprehensiveCancerCenter_12m,One-Year Follow-Up of Seroprevalence of SARS-CoV-2 Infection and Anxiety among Health Workers of a French Cancer Center: The PRO-SERO-COV Study.,2023-05-25,Journal Article (Peer-Reviewed),Local,Prospective cohort,France,Nouvelle-Aquitaine,Bordeaux,"From June to September 2020, all HWs (medical and non-medical), 18 years or older, working in the center from at least March 2020 were invited to participate in the study, by a poster and mail campaign.",HWs declaring symptoms suggestive of COVID-19 or documented infection by SARS-CoV-2 within 10 days and women declaring to be pregnant or breastfeeding were not included.,2021-06-10,2021-10-04,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,Anti-N or Anti-S,462,0.9329,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Anti-SARS-CoV-2 ELISA IgG","Roche Diagnostics,EUROIMMUN","CLIA, CMIA,ELISA",Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],,No,No,No,,Yes,Yes,No,,Brice Richez,Comprehensive Cancer Center,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph20115949,2023-06-28,2024-03-01,Unverified,richez_one-year_2023,FRA
230525_Bordeaux_ComprehensiveCancerCenter_3m,230525_Bordeaux_ComprehensiveCancerCenter_3m,One-Year Follow-Up of Seroprevalence of SARS-CoV-2 Infection and Anxiety among Health Workers of a French Cancer Center: The PRO-SERO-COV Study.,2023-05-25,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,France,Nouvelle-Aquitaine,Bordeaux,"From June to September 2020, all HWs (medical and non-medical), 18 years or older, working in the center from at least March 2020 were invited to participate in the study, by a poster and mail campaign.",HWs declaring symptoms suggestive of COVID-19 or documented infection by SARS-CoV-2 within 10 days and women declaring to be pregnant or breastfeeding were not included.,2020-09-10,2021-01-26,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,500,0.062,0.041,0.083,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Anti-SARS-CoV-2 ELISA IgG","Roche Diagnostics,EUROIMMUN","CLIA, CMIA,ELISA",Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],,No,No,No,,Yes,Yes,No,,Brice Richez,Comprehensive Cancer Center,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph20115949,2023-06-28,2024-03-01,Unverified,richez_one-year_2023,FRA
230525_Bordeaux_ComprehensiveCancerCenter_Baseline,230525_Bordeaux_ComprehensiveCancerCenter_Baseline,One-Year Follow-Up of Seroprevalence of SARS-CoV-2 Infection and Anxiety among Health Workers of a French Cancer Center: The PRO-SERO-COV Study.,2023-05-25,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,France,Nouvelle-Aquitaine,Bordeaux,"From June to September 2020, all HWs (medical and non-medical), 18 years or older, working in the center from at least March 2020 were invited to participate in the study, by a poster and mail campaign.",HWs declaring symptoms suggestive of COVID-19 or documented infection by SARS-CoV-2 within 10 days and women declaring to be pregnant or breastfeeding were not included.,2020-06-18,2020-09-28,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,517,0.035,0.019,0.051,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Anti-SARS-CoV-2 ELISA IgG","Roche Diagnostics,EUROIMMUN","CLIA, CMIA,ELISA",Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],,No,No,Yes,,Yes,Yes,No,,Brice Richez,Comprehensive Cancer Center,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph20115949,2023-06-27,2024-03-01,Unverified,richez_one-year_2023,FRA
230828_France_NantesUniversite,230828_France_NantesUniversite,The risk of COVID-19 in IBD patients is increased by urban living and is not influenced by disease activity or intravenous biologics,2023-08-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,France,,,"""All patients with an established diagnosis of IBD (CD, UC or
IBD-unclassified), aged over 18, treated with either intravenous (IV)
infliximab or vedolizumab, could be included.""","""Non-inclusion criteria included
patients under legal protection (guardianship, curatorship) or under
safeguard of justice, insufficient command of French language, and
contra-indications to infliximab or vedolizumab at baseline."" ",2020-03-15,2020-06-15,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),18.0,,Primary Estimate,,1026,0.037,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,"CLIA, CMIA",Serum,"IgG, IgM, IgA",Spike,,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Margaux Lelong,Nantes Universite,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2023.1243898,2023-10-05,2024-03-01,Unverified,lelong_risk_2023,FRA
211112_FrenchGuiana_InstitutPasteurinFrenchGuiana_Overall_PopAdjusted,211112_FrenchGuiana_InstitutPasteurinFrenchGuiana,"Seroprevalence of anti-SARS-CoV-2 IgG at the first epidemic peak in French Guiana, July 2020.",2021-11-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,French Guiana,"Cayenne, Saint-Laurent-du-Maroni","Cayenne, Matoury, Mana, Apatou, Saint-Laurent-du-Maroni, Awala-Yalimapo, Iracoubo, Sinnamary, Kourou, Macouria, Cayenne, Rémire-Montjoly, Saint-Georges, Maripasoula, Papaïchton, Grand-Santi",All individuals who visited medical laboratories (n=4) located in the coastal urban area of French Guiana or health centers (n=5) located in isolated areas along the Surinamese and Brazilian borders for routine screening or clinical management were invited to participate in the study. ,Participants were not asked to participate in the study if they came for SARS-CoV-2 viral screening in the context of symptomatic infections potentially suggestive of covid-19,2020-07-15,2020-07-23,Residual sera,All,Multiple groups,0.0,87.0,Primary Estimate,,480,0.154,0.09300000000000001,0.244,True,,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.938,0.996,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,Claude Flamand,Institut Pasteur in French Guiana,Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0009945,2021-11-23,2024-03-01,Verified,flamand_seroprevalence_2021,GUF
211112_FrenchGuiana_InstitutPasteurinFrenchGuiana_Female,211112_FrenchGuiana_InstitutPasteurinFrenchGuiana,"Seroprevalence of anti-SARS-CoV-2 IgG at the first epidemic peak in French Guiana, July 2020.",2021-11-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,French Guiana,"Cayenne, Saint-Laurent-du-Maroni","Cayenne, Matoury, Mana, Apatou, Saint-Laurent-du-Maroni, Awala-Yalimapo, Iracoubo, Sinnamary, Kourou, Macouria, Cayenne, Rémire-Montjoly, Saint-Georges, Maripasoula, Papaïchton, Grand-Santi",All individuals who visited medical laboratories (n=4) located in the coastal urban area of French Guiana or health centers (n=5) located in isolated areas along the Surinamese and Brazilian borders for routine screening or clinical management were invited to participate in the study. ,Participants were not asked to participate in the study if they came for SARS-CoV-2 viral screening in the context of symptomatic infections potentially suggestive of covid-19,2020-07-15,2020-07-23,Residual sera,Female,Multiple groups,,,Sex/Gender,,327,0.10400000000000001,0.067,0.159,,,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.938,0.996,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,Claude Flamand,Institut Pasteur in French Guiana,Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0009945,2021-11-23,2024-03-01,Verified,flamand_seroprevalence_2021,GUF
211112_FrenchGuiana_InstitutPasteurinFrenchGuiana_0-9,211112_FrenchGuiana_InstitutPasteurinFrenchGuiana,"Seroprevalence of anti-SARS-CoV-2 IgG at the first epidemic peak in French Guiana, July 2020.",2021-11-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,French Guiana,"Cayenne, Saint-Laurent-du-Maroni","Cayenne, Matoury, Mana, Apatou, Saint-Laurent-du-Maroni, Awala-Yalimapo, Iracoubo, Sinnamary, Kourou, Macouria, Cayenne, Rémire-Montjoly, Saint-Georges, Maripasoula, Papaïchton, Grand-Santi",All individuals who visited medical laboratories (n=4) located in the coastal urban area of French Guiana or health centers (n=5) located in isolated areas along the Surinamese and Brazilian borders for routine screening or clinical management were invited to participate in the study. ,Participants were not asked to participate in the study if they came for SARS-CoV-2 viral screening in the context of symptomatic infections potentially suggestive of covid-19,2020-07-15,2020-07-23,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,0-9,16,0.24,0.047,0.669,,,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.938,0.996,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,Claude Flamand,Institut Pasteur in French Guiana,Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0009945,2021-11-23,2024-03-01,Verified,flamand_seroprevalence_2021,GUF
211112_FrenchGuiana_InstitutPasteurinFrenchGuiana_Overall_Unadjusted,211112_FrenchGuiana_InstitutPasteurinFrenchGuiana,"Seroprevalence of anti-SARS-CoV-2 IgG at the first epidemic peak in French Guiana, July 2020.",2021-11-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,French Guiana,"Cayenne, Saint-Laurent-du-Maroni","Cayenne, Matoury, Mana, Apatou, Saint-Laurent-du-Maroni, Awala-Yalimapo, Iracoubo, Sinnamary, Kourou, Macouria, Cayenne, Rémire-Montjoly, Saint-Georges, Maripasoula, Papaïchton, Grand-Santi",All individuals who visited medical laboratories (n=4) located in the coastal urban area of French Guiana or health centers (n=5) located in isolated areas along the Surinamese and Brazilian borders for routine screening or clinical management were invited to participate in the study. ,Participants were not asked to participate in the study if they came for SARS-CoV-2 viral screening in the context of symptomatic infections potentially suggestive of covid-19,2020-07-15,2020-07-23,Residual sera,All,Multiple groups,0.0,87.0,Analysis,,480,0.131,,,,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.938,0.996,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,Claude Flamand,Institut Pasteur in French Guiana,Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0009945,2021-11-23,2024-03-01,Verified,flamand_seroprevalence_2021,GUF
211112_FrenchGuiana_InstitutPasteurinFrenchGuiana_40-49,211112_FrenchGuiana_InstitutPasteurinFrenchGuiana,"Seroprevalence of anti-SARS-CoV-2 IgG at the first epidemic peak in French Guiana, July 2020.",2021-11-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,French Guiana,"Cayenne, Saint-Laurent-du-Maroni","Cayenne, Matoury, Mana, Apatou, Saint-Laurent-du-Maroni, Awala-Yalimapo, Iracoubo, Sinnamary, Kourou, Macouria, Cayenne, Rémire-Montjoly, Saint-Georges, Maripasoula, Papaïchton, Grand-Santi",All individuals who visited medical laboratories (n=4) located in the coastal urban area of French Guiana or health centers (n=5) located in isolated areas along the Surinamese and Brazilian borders for routine screening or clinical management were invited to participate in the study. ,Participants were not asked to participate in the study if they came for SARS-CoV-2 viral screening in the context of symptomatic infections potentially suggestive of covid-19,2020-07-15,2020-07-23,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,78,0.184,0.091,0.335,,,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.938,0.996,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,Claude Flamand,Institut Pasteur in French Guiana,Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0009945,2021-11-23,2024-03-01,Verified,flamand_seroprevalence_2021,GUF
211112_FrenchGuiana_InstitutPasteurinFrenchGuiana_60-69,211112_FrenchGuiana_InstitutPasteurinFrenchGuiana,"Seroprevalence of anti-SARS-CoV-2 IgG at the first epidemic peak in French Guiana, July 2020.",2021-11-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,French Guiana,"Cayenne, Saint-Laurent-du-Maroni","Cayenne, Matoury, Mana, Apatou, Saint-Laurent-du-Maroni, Awala-Yalimapo, Iracoubo, Sinnamary, Kourou, Macouria, Cayenne, Rémire-Montjoly, Saint-Georges, Maripasoula, Papaïchton, Grand-Santi",All individuals who visited medical laboratories (n=4) located in the coastal urban area of French Guiana or health centers (n=5) located in isolated areas along the Surinamese and Brazilian borders for routine screening or clinical management were invited to participate in the study. ,Participants were not asked to participate in the study if they came for SARS-CoV-2 viral screening in the context of symptomatic infections potentially suggestive of covid-19,2020-07-15,2020-07-23,Residual sera,All,Multiple groups,60.0,69.0,Age,60-69,34,0.11199999999999999,0.025,0.384,,,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.938,0.996,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,Claude Flamand,Institut Pasteur in French Guiana,Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0009945,2021-11-23,2024-03-01,Verified,flamand_seroprevalence_2021,GUF
211112_FrenchGuiana_InstitutPasteurinFrenchGuiana_≥70,211112_FrenchGuiana_InstitutPasteurinFrenchGuiana,"Seroprevalence of anti-SARS-CoV-2 IgG at the first epidemic peak in French Guiana, July 2020.",2021-11-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,French Guiana,"Cayenne, Saint-Laurent-du-Maroni","Cayenne, Matoury, Mana, Apatou, Saint-Laurent-du-Maroni, Awala-Yalimapo, Iracoubo, Sinnamary, Kourou, Macouria, Cayenne, Rémire-Montjoly, Saint-Georges, Maripasoula, Papaïchton, Grand-Santi",All individuals who visited medical laboratories (n=4) located in the coastal urban area of French Guiana or health centers (n=5) located in isolated areas along the Surinamese and Brazilian borders for routine screening or clinical management were invited to participate in the study. ,Participants were not asked to participate in the study if they came for SARS-CoV-2 viral screening in the context of symptomatic infections potentially suggestive of covid-19,2020-07-15,2020-07-23,Residual sera,All,Seniors (65+ years),70.0,87.0,Age,≥70,11,0.152,0.04,0.436,,,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.938,0.996,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,Claude Flamand,Institut Pasteur in French Guiana,Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0009945,2021-11-23,2024-03-01,Verified,flamand_seroprevalence_2021,GUF
211112_FrenchGuiana_InstitutPasteurinFrenchGuiana_30-39,211112_FrenchGuiana_InstitutPasteurinFrenchGuiana,"Seroprevalence of anti-SARS-CoV-2 IgG at the first epidemic peak in French Guiana, July 2020.",2021-11-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,French Guiana,"Cayenne, Saint-Laurent-du-Maroni","Cayenne, Matoury, Mana, Apatou, Saint-Laurent-du-Maroni, Awala-Yalimapo, Iracoubo, Sinnamary, Kourou, Macouria, Cayenne, Rémire-Montjoly, Saint-Georges, Maripasoula, Papaïchton, Grand-Santi",All individuals who visited medical laboratories (n=4) located in the coastal urban area of French Guiana or health centers (n=5) located in isolated areas along the Surinamese and Brazilian borders for routine screening or clinical management were invited to participate in the study. ,Participants were not asked to participate in the study if they came for SARS-CoV-2 viral screening in the context of symptomatic infections potentially suggestive of covid-19,2020-07-15,2020-07-23,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,125,0.166,0.076,0.325,,,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.938,0.996,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,Claude Flamand,Institut Pasteur in French Guiana,Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0009945,2021-11-23,2024-03-01,Verified,flamand_seroprevalence_2021,GUF
211112_FrenchGuiana_InstitutPasteurinFrenchGuiana_20-29,211112_FrenchGuiana_InstitutPasteurinFrenchGuiana,"Seroprevalence of anti-SARS-CoV-2 IgG at the first epidemic peak in French Guiana, July 2020.",2021-11-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,French Guiana,"Cayenne, Saint-Laurent-du-Maroni","Cayenne, Matoury, Mana, Apatou, Saint-Laurent-du-Maroni, Awala-Yalimapo, Iracoubo, Sinnamary, Kourou, Macouria, Cayenne, Rémire-Montjoly, Saint-Georges, Maripasoula, Papaïchton, Grand-Santi",All individuals who visited medical laboratories (n=4) located in the coastal urban area of French Guiana or health centers (n=5) located in isolated areas along the Surinamese and Brazilian borders for routine screening or clinical management were invited to participate in the study. ,Participants were not asked to participate in the study if they came for SARS-CoV-2 viral screening in the context of symptomatic infections potentially suggestive of covid-19,2020-07-15,2020-07-23,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29,105,0.096,0.037000000000000005,0.226,,,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.938,0.996,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,Claude Flamand,Institut Pasteur in French Guiana,Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0009945,2021-11-23,2024-03-01,Verified,flamand_seroprevalence_2021,GUF
211112_FrenchGuiana_InstitutPasteurinFrenchGuiana_Male,211112_FrenchGuiana_InstitutPasteurinFrenchGuiana,"Seroprevalence of anti-SARS-CoV-2 IgG at the first epidemic peak in French Guiana, July 2020.",2021-11-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,French Guiana,"Cayenne, Saint-Laurent-du-Maroni","Cayenne, Matoury, Mana, Apatou, Saint-Laurent-du-Maroni, Awala-Yalimapo, Iracoubo, Sinnamary, Kourou, Macouria, Cayenne, Rémire-Montjoly, Saint-Georges, Maripasoula, Papaïchton, Grand-Santi",All individuals who visited medical laboratories (n=4) located in the coastal urban area of French Guiana or health centers (n=5) located in isolated areas along the Surinamese and Brazilian borders for routine screening or clinical management were invited to participate in the study. ,Participants were not asked to participate in the study if they came for SARS-CoV-2 viral screening in the context of symptomatic infections potentially suggestive of covid-19,2020-07-15,2020-07-23,Residual sera,Male,Multiple groups,,,Sex/Gender,,153,0.196,0.09699999999999999,0.35600000000000004,,,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.938,0.996,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,Claude Flamand,Institut Pasteur in French Guiana,Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0009945,2021-11-23,2024-03-01,Verified,flamand_seroprevalence_2021,GUF
211112_FrenchGuiana_InstitutPasteurinFrenchGuiana_10-19,211112_FrenchGuiana_InstitutPasteurinFrenchGuiana,"Seroprevalence of anti-SARS-CoV-2 IgG at the first epidemic peak in French Guiana, July 2020.",2021-11-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,French Guiana,"Cayenne, Saint-Laurent-du-Maroni","Cayenne, Matoury, Mana, Apatou, Saint-Laurent-du-Maroni, Awala-Yalimapo, Iracoubo, Sinnamary, Kourou, Macouria, Cayenne, Rémire-Montjoly, Saint-Georges, Maripasoula, Papaïchton, Grand-Santi",All individuals who visited medical laboratories (n=4) located in the coastal urban area of French Guiana or health centers (n=5) located in isolated areas along the Surinamese and Brazilian borders for routine screening or clinical management were invited to participate in the study. ,Participants were not asked to participate in the study if they came for SARS-CoV-2 viral screening in the context of symptomatic infections potentially suggestive of covid-19,2020-07-15,2020-07-23,Residual sera,All,Multiple groups,10.0,19.0,Age,10-19,34,0.187,0.042,0.544,,,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.938,0.996,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,Claude Flamand,Institut Pasteur in French Guiana,Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0009945,2021-11-23,2024-03-01,Verified,flamand_seroprevalence_2021,GUF
211112_FrenchGuiana_InstitutPasteurinFrenchGuiana_50-59,211112_FrenchGuiana_InstitutPasteurinFrenchGuiana,"Seroprevalence of anti-SARS-CoV-2 IgG at the first epidemic peak in French Guiana, July 2020.",2021-11-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,French Guiana,"Cayenne, Saint-Laurent-du-Maroni","Cayenne, Matoury, Mana, Apatou, Saint-Laurent-du-Maroni, Awala-Yalimapo, Iracoubo, Sinnamary, Kourou, Macouria, Cayenne, Rémire-Montjoly, Saint-Georges, Maripasoula, Papaïchton, Grand-Santi",All individuals who visited medical laboratories (n=4) located in the coastal urban area of French Guiana or health centers (n=5) located in isolated areas along the Surinamese and Brazilian borders for routine screening or clinical management were invited to participate in the study. ,Participants were not asked to participate in the study if they came for SARS-CoV-2 viral screening in the context of symptomatic infections potentially suggestive of covid-19,2020-07-15,2020-07-23,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,77,0.094,0.044000000000000004,0.193,,,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.938,0.996,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,Claude Flamand,Institut Pasteur in French Guiana,Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0009945,2021-11-23,2024-03-01,Verified,flamand_seroprevalence_2021,GUF
221221_Tahiti_InstitutLouisMalarde_Primary_PopAdj,221221_Tahiti_InstitutLouisMalarde,Seroprevalence of SARS-CoV-2 Antibodies in French Polynesia and Perspective for Vaccine Strategies,2022-12-21,Preprint,Regional,Cross-sectional survey ,French Polynesia,Tahiti,,"In the present study, selection of participants was performed within the adult population of Tahiti, the most inhabited and affected island by the second COVID-19 epidemic wave in French Polynesia. Only people who had resided in Tahiti since March 2020 (date of first introduction of SARS-CoV-2 in French Polynesia) were included in the study.","Individuals who did not answer after two calls, did not meet all inclusion criteria, or refused the appointment with the nurse, were removed from the study and replaced by other individuals until the quota of participants by age group and gender was reached.

Individuals who refused to sign the consent form, answer the questionnaire, or have their blood drawn were removed from the study and replaced by other individuals until the quota of participants by age group and gender was reached.",2021-11-22,2021-12-11,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,Anti-S and/or anti-N. Age-adjusted.,673,0.9590000000000001,0.9400000000000001,0.9770000000000001,True,,True,,True,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,"CLIA, CMIA,CLIA, CMIA",Serum,"IgG, IgM, IgA","['Nucleocapsid (N-protein)', 'Spike']",,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Maite Aubry,Institut Louis Malardé,Unity-Aligned,http://doi.org/10.20944/preprints202212.0386.v1,2023-01-12,2024-03-01,Unverified,aubry_seroprevalence_2022,PYF
221221_Tahiti_InstitutLouisMalarde_Age60-69,221221_Tahiti_InstitutLouisMalarde,Seroprevalence of SARS-CoV-2 Antibodies in French Polynesia and Perspective for Vaccine Strategies,2022-12-21,Preprint,Regional,Cross-sectional survey ,French Polynesia,Tahiti,,"In the present study, selection of participants was performed within the adult population of Tahiti, the most inhabited and affected island by the second COVID-19 epidemic wave in French Polynesia. Only people who had resided in Tahiti since March 2020 (date of first introduction of SARS-CoV-2 in French Polynesia) were included in the study.","Individuals who did not answer after two calls, did not meet all inclusion criteria, or refused the appointment with the nurse, were removed from the study and replaced by other individuals until the quota of participants by age group and gender was reached.

Individuals who refused to sign the consent form, answer the questionnaire, or have their blood drawn were removed from the study and replaced by other individuals until the quota of participants by age group and gender was reached.",2021-11-22,2021-12-11,Household and community samples,All,Seniors (65+ years),60.0,69.0,Age,Age: 60-69,113,0.965,0.912,0.99,,,,,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,"CLIA, CMIA,CLIA, CMIA",Serum,"IgG, IgM, IgA","['Nucleocapsid (N-protein)', 'Spike']",,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Maite Aubry,Institut Louis Malardé,Unity-Aligned,http://doi.org/10.20944/preprints202212.0386.v1,2023-01-13,2024-03-01,Unverified,aubry_seroprevalence_2022,PYF
221221_Tahiti_InstitutLouisMalarde_AntiN,221221_Tahiti_InstitutLouisMalarde,Seroprevalence of SARS-CoV-2 Antibodies in French Polynesia and Perspective for Vaccine Strategies,2022-12-21,Preprint,Regional,Cross-sectional survey ,French Polynesia,Tahiti,,"In the present study, selection of participants was performed within the adult population of Tahiti, the most inhabited and affected island by the second COVID-19 epidemic wave in French Polynesia. Only people who had resided in Tahiti since March 2020 (date of first introduction of SARS-CoV-2 in French Polynesia) were included in the study.","Individuals who did not answer after two calls, did not meet all inclusion criteria, or refused the appointment with the nurse, were removed from the study and replaced by other individuals until the quota of participants by age group and gender was reached.

Individuals who refused to sign the consent form, answer the questionnaire, or have their blood drawn were removed from the study and replaced by other individuals until the quota of participants by age group and gender was reached.",2021-11-22,2021-12-11,Household and community samples,All,Multiple groups,18.0,,Test used,Only anti-N. Unadjusted.,673,0.5770000000000001,0.538,0.614,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,"CLIA, CMIA",Serum,"IgG, IgM, IgA",Nucleocapsid (N-protein),,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Maite Aubry,Institut Louis Malardé,Unity-Aligned,http://doi.org/10.20944/preprints202212.0386.v1,2023-01-13,2024-03-01,Unverified,aubry_seroprevalence_2022,PYF
221221_Tahiti_InstitutLouisMalarde_Primary_UnAdj,221221_Tahiti_InstitutLouisMalarde,Seroprevalence of SARS-CoV-2 Antibodies in French Polynesia and Perspective for Vaccine Strategies,2022-12-21,Preprint,Regional,Cross-sectional survey ,French Polynesia,Tahiti,,"In the present study, selection of participants was performed within the adult population of Tahiti, the most inhabited and affected island by the second COVID-19 epidemic wave in French Polynesia. Only people who had resided in Tahiti since March 2020 (date of first introduction of SARS-CoV-2 in French Polynesia) were included in the study.","Individuals who did not answer after two calls, did not meet all inclusion criteria, or refused the appointment with the nurse, were removed from the study and replaced by other individuals until the quota of participants by age group and gender was reached.

Individuals who refused to sign the consent form, answer the questionnaire, or have their blood drawn were removed from the study and replaced by other individuals until the quota of participants by age group and gender was reached.",2021-11-22,2021-12-11,Household and community samples,All,Multiple groups,18.0,,Analysis,Anti-S and/or anti-N. Unadjusted.,673,0.9570000000000001,0.9390000000000001,0.971,,,,,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,"CLIA, CMIA,CLIA, CMIA",Serum,"IgG, IgM, IgA","['Nucleocapsid (N-protein)', 'Spike']",,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Maite Aubry,Institut Louis Malardé,Unity-Aligned,http://doi.org/10.20944/preprints202212.0386.v1,2023-01-13,2024-03-01,Unverified,aubry_seroprevalence_2022,PYF
221221_Tahiti_InstitutLouisMalarde_SexFemale,221221_Tahiti_InstitutLouisMalarde,Seroprevalence of SARS-CoV-2 Antibodies in French Polynesia and Perspective for Vaccine Strategies,2022-12-21,Preprint,Regional,Cross-sectional survey ,French Polynesia,Tahiti,,"In the present study, selection of participants was performed within the adult population of Tahiti, the most inhabited and affected island by the second COVID-19 epidemic wave in French Polynesia. Only people who had resided in Tahiti since March 2020 (date of first introduction of SARS-CoV-2 in French Polynesia) were included in the study.","Individuals who did not answer after two calls, did not meet all inclusion criteria, or refused the appointment with the nurse, were removed from the study and replaced by other individuals until the quota of participants by age group and gender was reached.

Individuals who refused to sign the consent form, answer the questionnaire, or have their blood drawn were removed from the study and replaced by other individuals until the quota of participants by age group and gender was reached.",2021-11-22,2021-12-11,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,Female,344,0.9540000000000001,0.9259999999999999,0.973,,,,,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,"CLIA, CMIA,CLIA, CMIA",Serum,"IgG, IgM, IgA","['Nucleocapsid (N-protein)', 'Spike']",,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Maite Aubry,Institut Louis Malardé,Unity-Aligned,http://doi.org/10.20944/preprints202212.0386.v1,2023-01-13,2024-03-01,Unverified,aubry_seroprevalence_2022,PYF
221221_Tahiti_InstitutLouisMalarde_Age18-29,221221_Tahiti_InstitutLouisMalarde,Seroprevalence of SARS-CoV-2 Antibodies in French Polynesia and Perspective for Vaccine Strategies,2022-12-21,Preprint,Regional,Cross-sectional survey ,French Polynesia,Tahiti,,"In the present study, selection of participants was performed within the adult population of Tahiti, the most inhabited and affected island by the second COVID-19 epidemic wave in French Polynesia. Only people who had resided in Tahiti since March 2020 (date of first introduction of SARS-CoV-2 in French Polynesia) were included in the study.","Individuals who did not answer after two calls, did not meet all inclusion criteria, or refused the appointment with the nurse, were removed from the study and replaced by other individuals until the quota of participants by age group and gender was reached.

Individuals who refused to sign the consent form, answer the questionnaire, or have their blood drawn were removed from the study and replaced by other individuals until the quota of participants by age group and gender was reached.",2021-11-22,2021-12-11,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,Age: 18-29,169,0.953,0.909,0.9790000000000001,,,,,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,"CLIA, CMIA,CLIA, CMIA",Serum,"IgG, IgM, IgA","['Nucleocapsid (N-protein)', 'Spike']",,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Maite Aubry,Institut Louis Malardé,Unity-Aligned,http://doi.org/10.20944/preprints202212.0386.v1,2023-01-13,2024-03-01,Unverified,aubry_seroprevalence_2022,PYF
221221_Tahiti_InstitutLouisMalarde_Age40-59,221221_Tahiti_InstitutLouisMalarde,Seroprevalence of SARS-CoV-2 Antibodies in French Polynesia and Perspective for Vaccine Strategies,2022-12-21,Preprint,Regional,Cross-sectional survey ,French Polynesia,Tahiti,,"In the present study, selection of participants was performed within the adult population of Tahiti, the most inhabited and affected island by the second COVID-19 epidemic wave in French Polynesia. Only people who had resided in Tahiti since March 2020 (date of first introduction of SARS-CoV-2 in French Polynesia) were included in the study.","Individuals who did not answer after two calls, did not meet all inclusion criteria, or refused the appointment with the nurse, were removed from the study and replaced by other individuals until the quota of participants by age group and gender was reached.

Individuals who refused to sign the consent form, answer the questionnaire, or have their blood drawn were removed from the study and replaced by other individuals until the quota of participants by age group and gender was reached.",2021-11-22,2021-12-11,Household and community samples,All,Adults (18-64 years),40.0,59.0,Age,Age: 40-59,171,0.965,0.925,0.9870000000000001,,,,,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,"CLIA, CMIA,CLIA, CMIA",Serum,"IgG, IgM, IgA","['Nucleocapsid (N-protein)', 'Spike']",,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Maite Aubry,Institut Louis Malardé,Unity-Aligned,http://doi.org/10.20944/preprints202212.0386.v1,2023-01-13,2024-03-01,Unverified,aubry_seroprevalence_2022,PYF
221221_Tahiti_InstitutLouisMalarde_Age30-39,221221_Tahiti_InstitutLouisMalarde,Seroprevalence of SARS-CoV-2 Antibodies in French Polynesia and Perspective for Vaccine Strategies,2022-12-21,Preprint,Regional,Cross-sectional survey ,French Polynesia,Tahiti,,"In the present study, selection of participants was performed within the adult population of Tahiti, the most inhabited and affected island by the second COVID-19 epidemic wave in French Polynesia. Only people who had resided in Tahiti since March 2020 (date of first introduction of SARS-CoV-2 in French Polynesia) were included in the study.","Individuals who did not answer after two calls, did not meet all inclusion criteria, or refused the appointment with the nurse, were removed from the study and replaced by other individuals until the quota of participants by age group and gender was reached.

Individuals who refused to sign the consent form, answer the questionnaire, or have their blood drawn were removed from the study and replaced by other individuals until the quota of participants by age group and gender was reached.",2021-11-22,2021-12-11,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,Age: 30-39,163,0.9570000000000001,0.913,0.983,,,,,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,"CLIA, CMIA,CLIA, CMIA",Serum,"IgG, IgM, IgA","['Nucleocapsid (N-protein)', 'Spike']",,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Maite Aubry,Institut Louis Malardé,Unity-Aligned,http://doi.org/10.20944/preprints202212.0386.v1,2023-01-13,2024-03-01,Unverified,aubry_seroprevalence_2022,PYF
221221_Tahiti_InstitutLouisMalarde_Age70+,221221_Tahiti_InstitutLouisMalarde,Seroprevalence of SARS-CoV-2 Antibodies in French Polynesia and Perspective for Vaccine Strategies,2022-12-21,Preprint,Regional,Cross-sectional survey ,French Polynesia,Tahiti,,"In the present study, selection of participants was performed within the adult population of Tahiti, the most inhabited and affected island by the second COVID-19 epidemic wave in French Polynesia. Only people who had resided in Tahiti since March 2020 (date of first introduction of SARS-CoV-2 in French Polynesia) were included in the study.","Individuals who did not answer after two calls, did not meet all inclusion criteria, or refused the appointment with the nurse, were removed from the study and replaced by other individuals until the quota of participants by age group and gender was reached.

Individuals who refused to sign the consent form, answer the questionnaire, or have their blood drawn were removed from the study and replaced by other individuals until the quota of participants by age group and gender was reached.",2021-11-22,2021-12-11,Household and community samples,All,Seniors (65+ years),70.0,,Age,Age: ≥70,57,0.93,0.8300000000000001,0.981,,,,,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,"CLIA, CMIA,CLIA, CMIA",Serum,"IgG, IgM, IgA","['Nucleocapsid (N-protein)', 'Spike']",,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Maite Aubry,Institut Louis Malardé,Unity-Aligned,http://doi.org/10.20944/preprints202212.0386.v1,2023-01-13,2024-03-01,Unverified,aubry_seroprevalence_2022,PYF
221221_Tahiti_InstitutLouisMalarde_SexMale,221221_Tahiti_InstitutLouisMalarde,Seroprevalence of SARS-CoV-2 Antibodies in French Polynesia and Perspective for Vaccine Strategies,2022-12-21,Preprint,Regional,Cross-sectional survey ,French Polynesia,Tahiti,,"In the present study, selection of participants was performed within the adult population of Tahiti, the most inhabited and affected island by the second COVID-19 epidemic wave in French Polynesia. Only people who had resided in Tahiti since March 2020 (date of first introduction of SARS-CoV-2 in French Polynesia) were included in the study.","Individuals who did not answer after two calls, did not meet all inclusion criteria, or refused the appointment with the nurse, were removed from the study and replaced by other individuals until the quota of participants by age group and gender was reached.

Individuals who refused to sign the consent form, answer the questionnaire, or have their blood drawn were removed from the study and replaced by other individuals until the quota of participants by age group and gender was reached.",2021-11-22,2021-12-11,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,Male,329,0.961,0.9329999999999999,0.9790000000000001,,,,,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,"CLIA, CMIA,CLIA, CMIA",Serum,"IgG, IgM, IgA","['Nucleocapsid (N-protein)', 'Spike']",,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Maite Aubry,Institut Louis Malardé,Unity-Aligned,http://doi.org/10.20944/preprints202212.0386.v1,2023-01-13,2024-03-01,Unverified,aubry_seroprevalence_2022,PYF
210420_Libreville_CentreHospitalierUniversitaire(CHU)‐Mère‐Enfant_overall_unadj,210420_Libreville_CentreHospitalierUniversitaire(CHU)‐Mère‐Enfant,"Circulating anti-SARS-CoV-2 nucleocapsid (N)-protein antibodies and anti-SARS-CoV-2 spike (S)-protein antibodies in an African setting: herd immunity, not there yet!.",2021-04-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Gabon,,Libreville,,,2020-07-15,2020-10-15,Residual sera,All,Multiple groups,0.0,78.0,Primary Estimate,,1495,0.36200000000000004,,,True,,,,True,Convenience,"VIDAS Multiparametric immunoassay system for medium throughput,Elecsys® Anti‐SARS‐CoV‐2 (N)","Biomerieux,Roche Diagnostics",Multiple Types,,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,Unclear,Amandine Mveang Nzoghe,Centre Hospitalier Universitaire (CHU) ‐ Mère‐ Enfant,Unity-Aligned,https://dx.doi.org/10.1186/s13104-021-05570-3,2021-05-19,2024-03-01,Verified,mveang_nzoghe_circulating_2021,GAB
210420_Libreville_CentreHospitalierUniversitaire(CHU)‐Mère‐Enfant_Infants_unadj,210420_Libreville_CentreHospitalierUniversitaire(CHU)‐Mère‐Enfant,"Circulating anti-SARS-CoV-2 nucleocapsid (N)-protein antibodies and anti-SARS-CoV-2 spike (S)-protein antibodies in an African setting: herd immunity, not there yet!.",2021-04-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Gabon,,Libreville,,,2020-07-15,2020-10-15,Residual sera,All,Children and Youth (0-17 years),0.0,0.0,Age,,110,0.36,,,,,,,,Convenience,"VIDAS Multiparametric immunoassay system for medium throughput,Elecsys® Anti‐SARS‐CoV‐2 (N)","Biomerieux,Roche Diagnostics",Multiple Types,,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,Unclear,Amandine Mveang Nzoghe,Centre Hospitalier Universitaire (CHU) ‐ Mère‐ Enfant,Unity-Aligned,https://dx.doi.org/10.1186/s13104-021-05570-3,2021-08-12,2024-03-01,Verified,mveang_nzoghe_circulating_2021,GAB
210420_Libreville_CentreHospitalierUniversitaire(CHU)‐Mère‐Enfant_Female_unadj,210420_Libreville_CentreHospitalierUniversitaire(CHU)‐Mère‐Enfant,"Circulating anti-SARS-CoV-2 nucleocapsid (N)-protein antibodies and anti-SARS-CoV-2 spike (S)-protein antibodies in an African setting: herd immunity, not there yet!.",2021-04-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Gabon,,Libreville,,,2020-07-15,2020-10-15,Residual sera,Female,Multiple groups,18.0,85.0,Sex/Gender,,993,0.37,,,,,,,,Convenience,"VIDAS Multiparametric immunoassay system for medium throughput,Elecsys® Anti‐SARS‐CoV‐2 (N)","Biomerieux,Roche Diagnostics",Multiple Types,,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,Unclear,Amandine Mveang Nzoghe,Centre Hospitalier Universitaire (CHU) ‐ Mère‐ Enfant,Unity-Aligned,https://dx.doi.org/10.1186/s13104-021-05570-3,2021-08-12,2024-03-01,Verified,mveang_nzoghe_circulating_2021,GAB
210420_Libreville_CentreHospitalierUniversitaire(CHU)‐Mère‐Enfant_Children_unadj,210420_Libreville_CentreHospitalierUniversitaire(CHU)‐Mère‐Enfant,"Circulating anti-SARS-CoV-2 nucleocapsid (N)-protein antibodies and anti-SARS-CoV-2 spike (S)-protein antibodies in an African setting: herd immunity, not there yet!.",2021-04-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Gabon,,Libreville,,,2020-07-15,2020-10-15,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Age,,284,0.33,,,,,,,,Convenience,"VIDAS Multiparametric immunoassay system for medium throughput,Elecsys® Anti‐SARS‐CoV‐2 (N)","Biomerieux,Roche Diagnostics",Multiple Types,,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,Unclear,Amandine Mveang Nzoghe,Centre Hospitalier Universitaire (CHU) ‐ Mère‐ Enfant,Unity-Aligned,https://dx.doi.org/10.1186/s13104-021-05570-3,2021-08-12,2024-03-01,Verified,mveang_nzoghe_circulating_2021,GAB
210420_Libreville_CentreHospitalierUniversitaire(CHU)‐Mère‐Enfant_Male_unadj,210420_Libreville_CentreHospitalierUniversitaire(CHU)‐Mère‐Enfant,"Circulating anti-SARS-CoV-2 nucleocapsid (N)-protein antibodies and anti-SARS-CoV-2 spike (S)-protein antibodies in an African setting: herd immunity, not there yet!.",2021-04-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Gabon,,Libreville,,,2020-07-15,2020-10-15,Residual sera,Male,Multiple groups,45.0,78.0,Sex/Gender,,105,0.37,,,,,,,,Convenience,"VIDAS Multiparametric immunoassay system for medium throughput,Elecsys® Anti‐SARS‐CoV‐2 (N)","Biomerieux,Roche Diagnostics",Multiple Types,,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,Unclear,Amandine Mveang Nzoghe,Centre Hospitalier Universitaire (CHU) ‐ Mère‐ Enfant,Unity-Aligned,https://dx.doi.org/10.1186/s13104-021-05570-3,2021-08-12,2024-03-01,Verified,mveang_nzoghe_circulating_2021,GAB
210506_Gabon_CHUMèreEnfantFondationJeanneEbori,210506_Gabon_CHUMèreEnfantFondationJeanneEbori,Dynamic and features of SARS-CoV-2 infection in Gabon.,2021-05-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Gabon,,,Contact cases of PCR-confirmed Covid-19 patients,,2020-03-15,2020-08-15,Contacts of COVID patients,All,Multiple groups,,,Primary Estimate,,319,0.55,,,True,,,,True,Convenience,Not reported/ Unable to specify,,LFIA,Whole Blood,,,,,,['High'],Unclear,No,No,No,Unclear,Unclear,Yes,No,Unclear,Amandine Mveang Nzoghe,CHU Mère Enfant Fondation Jeanne Ebori,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-87043-y,2021-05-28,2022-07-16,Verified,mveang_nzoghe_dynamic_2021,GAB
220909_Gabon_UniversiteDeMontpellier_IgGIgM,220909_Gabon_UniversiteDeMontpellier,Trend of expansion of SARS-CoV-2 infection and COVID-19 burden in Gabon (Central Africa) in mid-2021 based on serological survey.,2022-09-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Gabon,,Urban: Libreville and Port-Gentil; Rural: Oyem,"The study participants were recruited from the general population (n = 1609), with the inclusion criteria being aged ≥ 15 years and able to provide a written informed consent.","Being vaccinated for COVID-19 was an exclu- sion criterion. Less than 5% of the national population had been vacci- nated at the time of study initiation (WHO, 2022), and thus excluding this part of the population was not expected to represent a major bias.",2021-05-15,2021-07-15,Household and community samples,All,Multiple groups,15.0,,Primary Estimate,anti- IgG or IgM,1600,0.131,0.114,0.14800000000000002,True,,,,True,Unclear,Biosynex COVID-19 BSS assay,Biosynex,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9500000000000001,0.98,['Moderate'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Berthe A.Iroungou,Universite de Montpellier ,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijregi.2022.08.006,2022-09-12,2024-03-01,Unverified,iroungou_trend_2022,GAB
220909_Gabon_UniversiteDeMontpellier_IgGIgM_15to24,220909_Gabon_UniversiteDeMontpellier,Trend of expansion of SARS-CoV-2 infection and COVID-19 burden in Gabon (Central Africa) in mid-2021 based on serological survey.,2022-09-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Gabon,,Urban: Libreville and Port-Gentil; Rural: Oyem,"The study participants were recruited from the general population (n = 1609), with the inclusion criteria being aged ≥ 15 years and able to provide a written informed consent.","Being vaccinated for COVID-19 was an exclu- sion criterion. Less than 5% of the national population had been vacci- nated at the time of study initiation (WHO, 2022), and thus excluding this part of the population was not expected to represent a major bias.",2021-05-15,2021-07-15,Household and community samples,All,Multiple groups,15.0,24.0,Age,"anti- IgG or IgM, age: 15-24",147,0.129,0.08,0.19399999999999998,,,,,,Unclear,Biosynex COVID-19 BSS assay,Biosynex,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9500000000000001,0.98,['Moderate'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Berthe A.Iroungou,Universite de Montpellier ,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijregi.2022.08.006,2022-09-12,2024-03-01,Unverified,iroungou_trend_2022,GAB
220909_Gabon_UniversiteDeMontpellier_IgGIgM_25to54,220909_Gabon_UniversiteDeMontpellier,Trend of expansion of SARS-CoV-2 infection and COVID-19 burden in Gabon (Central Africa) in mid-2021 based on serological survey.,2022-09-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Gabon,,Urban: Libreville and Port-Gentil; Rural: Oyem,"The study participants were recruited from the general population (n = 1609), with the inclusion criteria being aged ≥ 15 years and able to provide a written informed consent.","Being vaccinated for COVID-19 was an exclu- sion criterion. Less than 5% of the national population had been vacci- nated at the time of study initiation (WHO, 2022), and thus excluding this part of the population was not expected to represent a major bias.",2021-05-15,2021-07-15,Household and community samples,All,Adults (18-64 years),25.0,54.0,Age,"anti- IgG or IgM, age: 25-54",1222,0.122,0.105,0.14300000000000002,,,,,,Unclear,Biosynex COVID-19 BSS assay,Biosynex,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9500000000000001,0.98,['Moderate'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Berthe A.Iroungou,Universite de Montpellier ,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijregi.2022.08.006,2022-09-12,2024-03-01,Unverified,iroungou_trend_2022,GAB
220909_Gabon_UniversiteDeMontpellier_IgGIgM_55to64,220909_Gabon_UniversiteDeMontpellier,Trend of expansion of SARS-CoV-2 infection and COVID-19 burden in Gabon (Central Africa) in mid-2021 based on serological survey.,2022-09-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Gabon,,Urban: Libreville and Port-Gentil; Rural: Oyem,"The study participants were recruited from the general population (n = 1609), with the inclusion criteria being aged ≥ 15 years and able to provide a written informed consent.","Being vaccinated for COVID-19 was an exclu- sion criterion. Less than 5% of the national population had been vacci- nated at the time of study initiation (WHO, 2022), and thus excluding this part of the population was not expected to represent a major bias.",2021-05-15,2021-07-15,Household and community samples,All,Adults (18-64 years),55.0,64.0,Age,"anti- IgG or IgM, age: 55-64",138,0.161,0.10300000000000001,0.233,,,,,,Unclear,Biosynex COVID-19 BSS assay,Biosynex,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9500000000000001,0.98,['Moderate'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Berthe A.Iroungou,Universite de Montpellier ,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijregi.2022.08.006,2022-09-12,2024-03-01,Unverified,iroungou_trend_2022,GAB
220909_Gabon_UniversiteDeMontpellier_IgGIgM_Over65,220909_Gabon_UniversiteDeMontpellier,Trend of expansion of SARS-CoV-2 infection and COVID-19 burden in Gabon (Central Africa) in mid-2021 based on serological survey.,2022-09-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Gabon,,Urban: Libreville and Port-Gentil; Rural: Oyem,"The study participants were recruited from the general population (n = 1609), with the inclusion criteria being aged ≥ 15 years and able to provide a written informed consent.","Being vaccinated for COVID-19 was an exclu- sion criterion. Less than 5% of the national population had been vacci- nated at the time of study initiation (WHO, 2022), and thus excluding this part of the population was not expected to represent a major bias.",2021-05-15,2021-07-15,Household and community samples,All,Seniors (65+ years),65.0,,Age,"anti- IgG or IgM, age >= 65",73,0.23199999999999998,0.142,0.34600000000000003,,,,,,Unclear,Biosynex COVID-19 BSS assay,Biosynex,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9500000000000001,0.98,['Moderate'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Berthe A.Iroungou,Universite de Montpellier ,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijregi.2022.08.006,2022-09-12,2024-03-01,Unverified,iroungou_trend_2022,GAB
220909_Gabon_UniversiteDeMontpellier_IgGIgM_Urban,220909_Gabon_UniversiteDeMontpellier,Trend of expansion of SARS-CoV-2 infection and COVID-19 burden in Gabon (Central Africa) in mid-2021 based on serological survey.,2022-09-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Gabon,,Libreville and Port-Gentil,"The study participants were recruited from the general population (n = 1609), with the inclusion criteria being aged ≥ 15 years and able to provide a written informed consent.","Being vaccinated for COVID-19 was an exclu- sion criterion. Less than 5% of the national population had been vacci- nated at the time of study initiation (WHO, 2022), and thus excluding this part of the population was not expected to represent a major bias.",2021-05-15,2021-07-15,Household and community samples,All,Multiple groups,15.0,,Geographical area,"anti- IgG or IgM, urban",1352,0.12300000000000001,0.106,0.141,,,,,,Unclear,Biosynex COVID-19 BSS assay,Biosynex,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9500000000000001,0.98,['Moderate'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Berthe A.Iroungou,Universite de Montpellier ,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijregi.2022.08.006,2022-09-12,2024-03-01,Unverified,iroungou_trend_2022,GAB
220909_Gabon_UniversiteDeMontpellier_IgGIgM_Rural,220909_Gabon_UniversiteDeMontpellier,Trend of expansion of SARS-CoV-2 infection and COVID-19 burden in Gabon (Central Africa) in mid-2021 based on serological survey.,2022-09-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Gabon,,Oyem,"The study participants were recruited from the general population (n = 1609), with the inclusion criteria being aged ≥ 15 years and able to provide a written informed consent.","Being vaccinated for COVID-19 was an exclu- sion criterion. Less than 5% of the national population had been vacci- nated at the time of study initiation (WHO, 2022), and thus excluding this part of the population was not expected to represent a major bias.",2021-05-15,2021-07-15,Household and community samples,All,Multiple groups,15.0,,Geographical area,"anti- IgG or IgM, rural",248,0.17300000000000001,0.128,0.226,,,,,,Unclear,Biosynex COVID-19 BSS assay,Biosynex,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9500000000000001,0.98,['Moderate'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Berthe A.Iroungou,Universite de Montpellier ,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijregi.2022.08.006,2022-09-12,2024-03-01,Unverified,iroungou_trend_2022,GAB
230612_TheGambia_TheGambiaattheLondonSchoolofHygieneandTropicalMedicine_Postwave2,230612_TheGambia_TheGambiaattheLondonSchoolofHygieneandTropicalMedicine ,SARS-CoV-2 seroprevalence in pregnant women during the first three COVID-19 waves in The Gambia,2023-06-12,Preprint,Local,Repeated cross-sectional study,Gambia,,"Farafenni, Illiasa, Ngayen Sanjal ",Pregnant women aged 16-49,,2021-05-15,2021-06-15,Pregnant or parturient women,Female,Adults (18-64 years),,,Time frame,May - June 2021,208,0.625,0.558,0.688,True,,,,True,Convenience,"Wantai SARS-CoV-2 Total Ab ELISA,Anti-SARS-CoV-2 NCP ELISA (IgG),Anti-SARS-CoV-2 ELISA IgG","Beijing Wantai Biological,EUROIMMUN","ELISA,ELISA,ELISA",Serum,IgG,"['Nucleocapsid (N-protein)', 'Spike']",,,,['High'],,No,No,No,,Unclear,Yes,No,,Ramatoulie Janha,The Gambia at the London School of Hygiene and Tropical Medicine ,Not Unity-Aligned,10.1101/2023.06.09.23291201,2023-06-28,2024-03-01,Unverified,janha_sars-cov-2_2023,GMB
230612_TheGambia_TheGambiaattheLondonSchoolofHygieneandTropicalMedicine_Postwave3,230612_TheGambia_TheGambiaattheLondonSchoolofHygieneandTropicalMedicine ,SARS-CoV-2 seroprevalence in pregnant women during the first three COVID-19 waves in The Gambia,2023-06-12,Preprint,Local,Repeated cross-sectional study,Gambia,,"Farafenni, Illiasa, Ngayen Sanjal ",Pregnant women aged 16-49,,2021-10-15,2021-12-15,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,October - December 2021,201,0.9,0.851,0.935,True,,,,True,Convenience,"Wantai SARS-CoV-2 Total Ab ELISA,Anti-SARS-CoV-2 NCP ELISA (IgG),Anti-SARS-CoV-2 ELISA IgG","Beijing Wantai Biological,EUROIMMUN","ELISA,ELISA,ELISA",Serum,IgG,"['Nucleocapsid (N-protein)', 'Spike']",,,,['High'],,No,No,No,,Unclear,Yes,No,,Ramatoulie Janha,The Gambia at the London School of Hygiene and Tropical Medicine ,Not Unity-Aligned,10.1101/2023.06.09.23291201,2023-06-28,2024-03-01,Unverified,janha_sars-cov-2_2023,GMB
230612_TheGambia_TheGambiaattheLondonSchoolofHygieneandTropicalMedicine_Postwave1,230612_TheGambia_TheGambiaattheLondonSchoolofHygieneandTropicalMedicine ,SARS-CoV-2 seroprevalence in pregnant women during the first three COVID-19 waves in The Gambia,2023-06-12,Preprint,Local,Repeated cross-sectional study,Gambia,,"Farafenni, Illiasa, Ngayen Sanjal ",Pregnant women aged 16-49,,2020-10-15,2020-12-15,Pregnant or parturient women,Female,Adults (18-64 years),,,Time frame,October - December 2020,209,0.311,0.252,0.377,True,,,,True,Convenience,"Wantai SARS-CoV-2 Total Ab ELISA,Anti-SARS-CoV-2 NCP ELISA (IgG),Anti-SARS-CoV-2 ELISA IgG","Beijing Wantai Biological,EUROIMMUN","ELISA,ELISA,ELISA",Serum,IgG,"['Nucleocapsid (N-protein)', 'Spike']",,,,['High'],,No,No,No,,Unclear,Yes,No,,Ramatoulie Janha,The Gambia at the London School of Hygiene and Tropical Medicine ,Not Unity-Aligned,10.1101/2023.06.09.23291201,2023-06-28,2024-03-01,Unverified,janha_sars-cov-2_2023,GMB
230612_TheGambia_TheGambiaattheLondonSchoolofHygieneandTropicalMedicine_Prepandemic1,230612_TheGambia_TheGambiaattheLondonSchoolofHygieneandTropicalMedicine ,SARS-CoV-2 seroprevalence in pregnant women during the first three COVID-19 waves in The Gambia,2023-06-12,Preprint,Local,Repeated cross-sectional study,Gambia,,"Farafenni, Illiasa, Ngayen Sanjal ",Pregnant women aged 16-49,,2019-10-15,2019-12-15,Pregnant or parturient women,Female,Adults (18-64 years),,,Time frame,October - December 2019,112,0.009,0.002,0.049,True,,,,True,Convenience,"Wantai SARS-CoV-2 Total Ab ELISA,Anti-SARS-CoV-2 NCP ELISA (IgG),Anti-SARS-CoV-2 ELISA IgG","Beijing Wantai Biological,EUROIMMUN","ELISA,ELISA,ELISA",Serum,IgG,"['Nucleocapsid (N-protein)', 'Spike']",,,,['High'],,No,No,No,,Unclear,Yes,No,,Ramatoulie Janha,The Gambia at the London School of Hygiene and Tropical Medicine ,Not Unity-Aligned,10.1101/2023.06.09.23291201,2023-06-28,2024-03-01,Unverified,janha_sars-cov-2_2023,GMB
230612_TheGambia_TheGambiaattheLondonSchoolofHygieneandTropicalMedicine_Prepandemic2,230612_TheGambia_TheGambiaattheLondonSchoolofHygieneandTropicalMedicine ,SARS-CoV-2 seroprevalence in pregnant women during the first three COVID-19 waves in The Gambia,2023-06-12,Preprint,Local,Repeated cross-sectional study,Gambia,,"Farafenni, Illiasa, Ngayen Sanjal ",Pregnant women aged 16-49,,2019-02-15,2019-06-15,Pregnant or parturient women,Female,Adults (18-64 years),,,Time frame,February - June 2020,73,0.041,0.014,0.114,True,,,,True,Convenience,"Wantai SARS-CoV-2 Total Ab ELISA,Anti-SARS-CoV-2 NCP ELISA (IgG),Anti-SARS-CoV-2 ELISA IgG","Beijing Wantai Biological,EUROIMMUN","ELISA,ELISA,ELISA",Serum,IgG,"['Nucleocapsid (N-protein)', 'Spike']",,,,['High'],,No,No,No,,Unclear,Yes,No,,Ramatoulie Janha,The Gambia at the London School of Hygiene and Tropical Medicine ,Not Unity-Aligned,10.1101/2023.06.09.23291201,2023-06-28,2024-03-01,Unverified,janha_sars-cov-2_2023,GMB
200918_Tbilisi_InfectiousDiseaseResearchCenter_Total_PopTestAdj,200918_Tbilisi_InfectiousDiseaseResearchCenter,"SARS-CoV-2 antibody seroprevalence in Tbilisi, the capital city of country of Georgia",2020-09-18,Preprint,Local,Cross-sectional survey ,Georgia,Tbilisi,Tbilisi,"Eligibility criteria included age 18 years old, no confirmed SARS-CoV-2 infection and no current symptoms consistent with COVID-19.",,2020-05-18,2020-05-27,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,overall sample; weighted and adjusted for test accuracy,1086,0.0102,0.0038,0.021800000000000003,True,True,True,,,Convenience,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,0.9309999999999999,0.9920000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Tengiz Tsertsvadze,"Infectious Diseases, AIDS and Clinical Immunology Research Center",Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.18.20195024v1,2020-11-22,2023-07-04,Verified,tsertsvadze_sars-cov-2_2020,GEO
200918_Tbilisi_InfectiousDiseaseResearchCenter_Women_PopTestAdj,200918_Tbilisi_InfectiousDiseaseResearchCenter,"SARS-CoV-2 antibody seroprevalence in Tbilisi, the capital city of country of Georgia",2020-09-18,Preprint,Local,Cross-sectional survey ,Georgia,Tbilisi,Tbilisi,"Eligibility criteria included age 18 years old, no confirmed SARS-CoV-2 infection and no current symptoms consistent with COVID-19.",,2020-05-18,2020-05-27,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,Female,682,0.0121,0.0046,0.0296,,True,True,,,Convenience,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,0.9309999999999999,0.9920000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Tengiz Tsertsvadze,"Infectious Diseases, AIDS and Clinical Immunology Research Center",Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.18.20195024v1,2020-11-22,2023-07-04,Verified,tsertsvadze_sars-cov-2_2020,GEO
200918_Tbilisi_InfectiousDiseaseResearchCenter_Women,200918_Tbilisi_InfectiousDiseaseResearchCenter,"SARS-CoV-2 antibody seroprevalence in Tbilisi, the capital city of country of Georgia",2020-09-18,Preprint,Local,Cross-sectional survey ,Georgia,Tbilisi,Tbilisi,"Eligibility criteria included age 18 years old, no confirmed SARS-CoV-2 infection and no current symptoms consistent with COVID-19.",,2020-05-18,2020-05-27,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,Female,682,0.0088,0.0032,0.019,,,,,,Convenience,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,0.9309999999999999,0.9920000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Tengiz Tsertsvadze,"Infectious Diseases, AIDS and Clinical Immunology Research Center",Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.18.20195024v1,2020-11-22,2024-03-01,Verified,tsertsvadze_sars-cov-2_2020,GEO
200918_Tbilisi_InfectiousDiseaseResearchCenter_Men_PopAdj,200918_Tbilisi_InfectiousDiseaseResearchCenter,"SARS-CoV-2 antibody seroprevalence in Tbilisi, the capital city of country of Georgia",2020-09-18,Preprint,Local,Cross-sectional survey ,Georgia,Tbilisi,Tbilisi,"Eligibility criteria included age 18 years old, no confirmed SARS-CoV-2 infection and no current symptoms consistent with COVID-19.",,2020-05-18,2020-05-27,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,Men,386,0.0070999999999999995,0.001,0.0245,,,True,,,Convenience,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,0.9309999999999999,0.9920000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Tengiz Tsertsvadze,"Infectious Diseases, AIDS and Clinical Immunology Research Center",Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.18.20195024v1,2020-11-22,2024-03-01,Verified,tsertsvadze_sars-cov-2_2020,GEO
200918_Tbilisi_InfectiousDiseaseResearchCenter_Total_PopAdj,200918_Tbilisi_InfectiousDiseaseResearchCenter,"SARS-CoV-2 antibody seroprevalence in Tbilisi, the capital city of country of Georgia",2020-09-18,Preprint,Local,Cross-sectional survey ,Georgia,Tbilisi,Tbilisi,"Eligibility criteria included age 18 years old, no confirmed SARS-CoV-2 infection and no current symptoms consistent with COVID-19.",,2020-05-18,2020-05-27,Household and community samples,All,Multiple groups,18.0,,Analysis,Overall sample; weighted for population characteristics ,1086,0.0094,0.0037,0.0195,,,True,,True,Convenience,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,0.9309999999999999,0.9920000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Tengiz Tsertsvadze,"Infectious Diseases, AIDS and Clinical Immunology Research Center",Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.18.20195024v1,2020-11-22,2024-03-01,Verified,tsertsvadze_sars-cov-2_2020,GEO
200918_Tbilisi_InfectiousDiseaseResearchCenter_Age_18-64_PopTestAdj,200918_Tbilisi_InfectiousDiseaseResearchCenter,"SARS-CoV-2 antibody seroprevalence in Tbilisi, the capital city of country of Georgia",2020-09-18,Preprint,Local,Cross-sectional survey ,Georgia,Tbilisi,Tbilisi,"Eligibility criteria included age 18 years old, no confirmed SARS-CoV-2 infection and no current symptoms consistent with COVID-19.",,2020-05-18,2020-05-27,Household and community samples,All,Adults (18-64 years),18.0,64.0,Age,Age 18-64,964,0.0077,0.0024,0.0184,,True,True,,,Convenience,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,0.9309999999999999,0.9920000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Tengiz Tsertsvadze,"Infectious Diseases, AIDS and Clinical Immunology Research Center",Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.18.20195024v1,2020-11-22,2023-07-04,Verified,tsertsvadze_sars-cov-2_2020,GEO
200918_Tbilisi_InfectiousDiseaseResearchCenter_Age_18-64,200918_Tbilisi_InfectiousDiseaseResearchCenter,"SARS-CoV-2 antibody seroprevalence in Tbilisi, the capital city of country of Georgia",2020-09-18,Preprint,Local,Cross-sectional survey ,Georgia,Tbilisi,Tbilisi,"Eligibility criteria included age 18 years old, no confirmed SARS-CoV-2 infection and no current symptoms consistent with COVID-19.",,2020-05-18,2020-05-27,Household and community samples,All,Adults (18-64 years),18.0,64.0,Age,Age 18-64,964,0.0073,0.0029,0.0149,,,,,,Convenience,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,0.9309999999999999,0.9920000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Tengiz Tsertsvadze,"Infectious Diseases, AIDS and Clinical Immunology Research Center",Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.18.20195024v1,2020-11-22,2024-03-01,Verified,tsertsvadze_sars-cov-2_2020,GEO
200918_Tbilisi_InfectiousDiseaseResearchCenter_Age_65+_PopTestAdj,200918_Tbilisi_InfectiousDiseaseResearchCenter,"SARS-CoV-2 antibody seroprevalence in Tbilisi, the capital city of country of Georgia",2020-09-18,Preprint,Local,Cross-sectional survey ,Georgia,Tbilisi,Tbilisi,"Eligibility criteria included age 18 years old, no confirmed SARS-CoV-2 infection and no current symptoms consistent with COVID-19.",,2020-05-18,2020-05-27,Household and community samples,All,Seniors (65+ years),65.0,,Age,Age 65+,104,0.0239,0.0025,0.0884,,True,True,,,Convenience,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,0.9309999999999999,0.9920000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Tengiz Tsertsvadze,"Infectious Diseases, AIDS and Clinical Immunology Research Center",Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.18.20195024v1,2020-11-22,2023-07-04,Verified,tsertsvadze_sars-cov-2_2020,GEO
200918_Tbilisi_InfectiousDiseaseResearchCenter_Men_PopTestAdj,200918_Tbilisi_InfectiousDiseaseResearchCenter,"SARS-CoV-2 antibody seroprevalence in Tbilisi, the capital city of country of Georgia",2020-09-18,Preprint,Local,Cross-sectional survey ,Georgia,Tbilisi,Tbilisi,"Eligibility criteria included age 18 years old, no confirmed SARS-CoV-2 infection and no current symptoms consistent with COVID-19.",,2020-05-18,2020-05-27,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,Men,386,0.0077,0.001,0.0268,,True,True,,,Convenience,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,0.9309999999999999,0.9920000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Tengiz Tsertsvadze,"Infectious Diseases, AIDS and Clinical Immunology Research Center",Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.18.20195024v1,2020-11-22,2023-07-04,Verified,tsertsvadze_sars-cov-2_2020,GEO
200918_Tbilisi_InfectiousDiseaseResearchCenter_Age_65+,200918_Tbilisi_InfectiousDiseaseResearchCenter,"SARS-CoV-2 antibody seroprevalence in Tbilisi, the capital city of country of Georgia",2020-09-18,Preprint,Local,Cross-sectional survey ,Georgia,Tbilisi,Tbilisi,"Eligibility criteria included age 18 years old, no confirmed SARS-CoV-2 infection and no current symptoms consistent with COVID-19.",,2020-05-18,2020-05-27,Household and community samples,All,Seniors (65+ years),65.0,,Age,Age 65+,104,0.0192,0.0023,0.0677,,,,,,Convenience,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,0.9309999999999999,0.9920000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Tengiz Tsertsvadze,"Infectious Diseases, AIDS and Clinical Immunology Research Center",Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.18.20195024v1,2020-11-22,2024-03-01,Verified,tsertsvadze_sars-cov-2_2020,GEO
200918_Tbilisi_InfectiousDiseaseResearchCenter_Total,200918_Tbilisi_InfectiousDiseaseResearchCenter,"SARS-CoV-2 antibody seroprevalence in Tbilisi, the capital city of country of Georgia",2020-09-18,Preprint,Local,Cross-sectional survey ,Georgia,Tbilisi,Tbilisi,"Eligibility criteria included age 18 years old, no confirmed SARS-CoV-2 infection and no current symptoms consistent with COVID-19.",,2020-05-18,2020-05-27,Household and community samples,All,Multiple groups,18.0,,Analysis,Overall sample; crude,1086,0.0084,0.0033000000000000004,0.0159,,,,,,Convenience,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,0.9309999999999999,0.9920000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Tengiz Tsertsvadze,"Infectious Diseases, AIDS and Clinical Immunology Research Center",Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.18.20195024v1,2020-11-22,2024-03-01,Verified,tsertsvadze_sars-cov-2_2020,GEO
200918_Tbilisi_InfectiousDiseaseResearchCenter_Age_18-64_PopAdj,200918_Tbilisi_InfectiousDiseaseResearchCenter,"SARS-CoV-2 antibody seroprevalence in Tbilisi, the capital city of country of Georgia",2020-09-18,Preprint,Local,Cross-sectional survey ,Georgia,Tbilisi,Tbilisi,"Eligibility criteria included age 18 years old, no confirmed SARS-CoV-2 infection and no current symptoms consistent with COVID-19.",,2020-05-18,2020-05-27,Household and community samples,All,Adults (18-64 years),18.0,64.0,Age,Age 18-64,964,0.0070999999999999995,0.0022,0.0172,,,True,,,Convenience,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,0.9309999999999999,0.9920000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Tengiz Tsertsvadze,"Infectious Diseases, AIDS and Clinical Immunology Research Center",Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.18.20195024v1,2020-11-22,2024-03-01,Verified,tsertsvadze_sars-cov-2_2020,GEO
200918_Tbilisi_InfectiousDiseaseResearchCenter_Age_65+_PopAdj,200918_Tbilisi_InfectiousDiseaseResearchCenter,"SARS-CoV-2 antibody seroprevalence in Tbilisi, the capital city of country of Georgia",2020-09-18,Preprint,Local,Cross-sectional survey ,Georgia,Tbilisi,Tbilisi,"Eligibility criteria included age 18 years old, no confirmed SARS-CoV-2 infection and no current symptoms consistent with COVID-19.",,2020-05-18,2020-05-27,Household and community samples,All,Seniors (65+ years),65.0,,Age,Age 65+,104,0.0221,0.0018,0.08789999999999999,,,True,,,Convenience,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,0.9309999999999999,0.9920000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Tengiz Tsertsvadze,"Infectious Diseases, AIDS and Clinical Immunology Research Center",Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.18.20195024v1,2020-11-22,2024-03-01,Verified,tsertsvadze_sars-cov-2_2020,GEO
200918_Tbilisi_InfectiousDiseaseResearchCenter_Men,200918_Tbilisi_InfectiousDiseaseResearchCenter,"SARS-CoV-2 antibody seroprevalence in Tbilisi, the capital city of country of Georgia",2020-09-18,Preprint,Local,Cross-sectional survey ,Georgia,Tbilisi,Tbilisi,"Eligibility criteria included age 18 years old, no confirmed SARS-CoV-2 infection and no current symptoms consistent with COVID-19.",,2020-05-18,2020-05-27,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,Men,386,0.0078000000000000005,0.0016,0.0225,,,,,,Convenience,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,0.9309999999999999,0.9920000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Tengiz Tsertsvadze,"Infectious Diseases, AIDS and Clinical Immunology Research Center",Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.18.20195024v1,2020-11-22,2024-03-01,Verified,tsertsvadze_sars-cov-2_2020,GEO
200918_Tbilisi_InfectiousDiseaseResearchCenter_Women_PopAdj,200918_Tbilisi_InfectiousDiseaseResearchCenter,"SARS-CoV-2 antibody seroprevalence in Tbilisi, the capital city of country of Georgia",2020-09-18,Preprint,Local,Cross-sectional survey ,Georgia,Tbilisi,Tbilisi,"Eligibility criteria included age 18 years old, no confirmed SARS-CoV-2 infection and no current symptoms consistent with COVID-19.",,2020-05-18,2020-05-27,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,Female,682,0.011200000000000002,0.0031,0.028399999999999998,,,True,,,Convenience,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,0.9309999999999999,0.9920000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Tengiz Tsertsvadze,"Infectious Diseases, AIDS and Clinical Immunology Research Center",Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.18.20195024v1,2020-11-22,2024-03-01,Verified,tsertsvadze_sars-cov-2_2020,GEO
200514_Saalfeld_Thuringia_IgG,200514_Saalfeld_ThuringiaClinic,Prevalence of antibodies against COVID-19 in the staff of a COVID-19 regular ward,2020-05-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Thuringia,Saalfeld,employees of covid-19 regular ward,,2020-04-16,2020-04-21,Health care workers and caregivers,All,Adults (18-64 years),21.0,60.0,Primary Estimate,IgG,18,0.0,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Multiple Types,IgG,,Validated by independent authors/third party/non-developers,,0.985,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,No,Igor Harsch,Thuringia Clinic,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273321/pdf/HIC-15-09.pdf,2020-06-19,2024-03-01,Verified,harsch_prevalence_2020,DEU
200515_Regensburg_UniversityOfRegensburg,200515_Regensburg_UniversityOfRegensburg,Symptoms and immunoglobulin development in hospital staff exposed to a SARS-CoV-2 outbreak. ,2020-05-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Bavaria,Regensburg,All adult staff members who underwent standard RT-PCR testing and gave informed consent,,2020-03-01,2020-03-31,Health care workers and caregivers,All,Adults (18-64 years),18.0,65.0,Primary Estimate,,201,0.204,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA",EUROIMMUN,ELISA,Serum,"['IgA', 'IgG']",Spike,,,,['High'],,No,No,Yes,,Yes,Yes,No,,Susanne Brandstetter,University of Regensburg,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/abs/10.1111/pai.13278?af=R,2021-05-20,2024-03-01,Unverified,brandstetter_symptoms_2020,DEU
200525_Frankfurt_Goethe-UniversityFrankfurt_Employees,200525_Frankfurt_Goethe-UniversityFrankfurt,Epidemiological study to detect active SARS-CoV-2 infections and seropositive persons in a selected cohort of employees in the Frankfurt am Main metropolitan area,2020-05-25,Preprint,Local,Cross-sectional survey ,Germany,Hesse,Frankfurt,"Employees of Infraserv Höchst, a large industrial site operator in Frankfurt am Main. All employees allowed to participate until cohort of 1000 was reached. ",previous SARS-CoV-2 diagnosis,2020-04-06,2020-04-14,Essential non-healthcare workers,All,Adults (18-64 years),18.0,65.0,Primary Estimate,,998,0.004,0.0016300000000000002,0.01022,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,,0.9920000000000001,['High'],No,No,Yes,Yes,No,Unclear,Yes,No,Unclear,Verena Kraehling, Goethe-University Frankfurt,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.05.20.20107730v1,2020-05-26,2022-07-16,Verified,kraehling_epidemiological_2020,DEU
200615_Germany_UniversityofHannover_hcw,200615_Germany_UniversityofHannover,Prevalence of serum IgG antibodies against SARS-CoV-2 among clinic staff,2020-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Lower Saxony,Hannover,Informed consent. Employees of the BDH-Clinic Hessisch Oldendorf.,Provided an incomplete questionnaire.,2020-04-20,2020-04-30,Health care workers and caregivers,All,Multiple groups,18.0,,Primary Estimate,,385,0.0286,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,,Validated by manufacturers,0.946,0.998,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,Yes,Simone Schmidt,University of Hannover,Not Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0235417,2020-06-26,2024-03-01,Verified,schmidt_prevalence_2020,DEU
200615_Germany_UniversityofHannover_65,200615_Germany_UniversityofHannover,Prevalence of serum IgG antibodies against SARS-CoV-2 among clinic staff,2020-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Lower Saxony,Hannover,Informed consent. Employees of the BDH-Clinic Hessisch Oldendorf.,Provided an incomplete questionnaire.,2020-04-20,2020-04-30,Health care workers and caregivers,All,Seniors (65+ years),65.0,,Age,>65,6,0.0,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,,Validated by manufacturers,0.946,0.998,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,Yes,Simone Schmidt,University of Hannover,Not Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0235417,2020-07-17,2024-03-01,Verified,schmidt_prevalence_2020,DEU
200615_Germany_UniversityofHannover_50-64,200615_Germany_UniversityofHannover,Prevalence of serum IgG antibodies against SARS-CoV-2 among clinic staff,2020-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Lower Saxony,Hannover,Informed consent. Employees of the BDH-Clinic Hessisch Oldendorf.,Provided an incomplete questionnaire.,2020-04-20,2020-04-30,Health care workers and caregivers,All,Adults (18-64 years),50.0,64.0,Age,50-64,170,0.0176,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,,Validated by manufacturers,0.946,0.998,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,Yes,Simone Schmidt,University of Hannover,Not Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0235417,2020-07-17,2024-03-01,Verified,schmidt_prevalence_2020,DEU
200615_Germany_UniversityofHannover_30-49,200615_Germany_UniversityofHannover,Prevalence of serum IgG antibodies against SARS-CoV-2 among clinic staff,2020-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Lower Saxony,Hannover,Informed consent. Employees of the BDH-Clinic Hessisch Oldendorf.,Provided an incomplete questionnaire.,2020-04-20,2020-04-30,Health care workers and caregivers,All,Adults (18-64 years),30.0,49.0,Age,30-49,254,0.0276,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,,Validated by manufacturers,0.946,0.998,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,Yes,Simone Schmidt,University of Hannover,Not Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0235417,2020-07-17,2024-03-01,Verified,schmidt_prevalence_2020,DEU
200615_Germany_UniversityofHannover_18-29,200615_Germany_UniversityofHannover,Prevalence of serum IgG antibodies against SARS-CoV-2 among clinic staff,2020-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Lower Saxony,Hannover,Informed consent. Employees of the BDH-Clinic Hessisch Oldendorf.,Provided an incomplete questionnaire.,2020-04-20,2020-04-30,Health care workers and caregivers,All,Adults (18-64 years),18.0,29.0,Age,18-29,55,0.0181,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,,Validated by manufacturers,0.946,0.998,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,Yes,Simone Schmidt,University of Hannover,Not Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0235417,2020-07-17,2024-03-01,Verified,schmidt_prevalence_2020,DEU
200622_Rostock_UniversitätsmedizinRostock_Mothers_IgGorIgA,200622_Rostock_UniversitätsmedizinRostock,"Screening of Mothers in a COVID-19
  Low-Prevalence Region: Determination of SARS-CoV-2 Antibodies in 401 Mothers
  from Rostock by ELISA and Confirmation by Immunofluorescence",2020-06-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Mecklenburg-Westpomerania,Rostock,Mothers with children between the ages of 0-17,,2020-04-20,2020-04-22,Household and community samples,Female,Adults (18-64 years),,,Primary Estimate,,401,0.0,,,True,,,,True,Self-referral,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA,Author designed (type unknown)","EUROIMMUN,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,No,Unclear,Emil Reisinger ,Universitätsmedizin Rostock,Not Unity-Aligned,https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-1197-4293,2020-08-05,2024-03-01,Verified,reisinger_screening_2020,DEU
200622_Rostock_UniversitätsmedizinRostock_Mothers_IgA,200622_Rostock_UniversitätsmedizinRostock,"Screening of Mothers in a COVID-19
  Low-Prevalence Region: Determination of SARS-CoV-2 Antibodies in 401 Mothers
  from Rostock by ELISA and Confirmation by Immunofluorescence",2020-06-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Mecklenburg-Westpomerania,Rostock,Mothers with children between the ages of 0-17,,2020-04-20,2020-04-22,Household and community samples,Female,Adults (18-64 years),,,Test used,IgA,401,0.027400000000000004,,,,,,,,Self-referral,Anti-SARS-CoV-2 ELISA IgA,EUROIMMUN,ELISA,Serum,IgA,Spike,,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,No,Unclear,Emil Reisinger ,Universitätsmedizin Rostock,Not Unity-Aligned,https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-1197-4293,2020-07-20,2024-03-01,Verified,reisinger_screening_2020,DEU
200622_Rostock_UniversitätsmedizinRostock_Mothers_IgG,200622_Rostock_UniversitätsmedizinRostock,"Screening of Mothers in a COVID-19
  Low-Prevalence Region: Determination of SARS-CoV-2 Antibodies in 401 Mothers
  from Rostock by ELISA and Confirmation by Immunofluorescence",2020-06-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Mecklenburg-Westpomerania,Rostock,Mothers with children between the ages of 0-17,,2020-04-20,2020-04-22,Household and community samples,Female,Adults (18-64 years),,,Test used,IgG,401,0.0025,,,,,,,,Self-referral,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,No,Unclear,Emil Reisinger ,Universitätsmedizin Rostock,Not Unity-Aligned,https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-1197-4293,2020-07-20,2024-03-01,Verified,reisinger_screening_2020,DEU
200629_Fulda_UniversitätsmedizinMarburg_Entirecohort_IgG,200629_Fulda_UniversitätsmedizinMarburg,Studie zur immunitat gegen sars-cov-2,2020-06-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,,Fulda,Hospital employees with direct patient contact or employees of local supermarkets with direct customer contact,,2020-04-09,2020-04-16,Multiple populations,All,Multiple groups,10.0,69.0,Primary Estimate,Healthcare worker or retail worker,1780,0.00955,0.00557,0.01525,True,,,,True,Unclear,Anti-SARS-CoV-2 ELISA IgA,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.938,0.99,['Moderate'],Yes,Unclear,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Peter Kern,Universitätsmedizin Marburg,Not Unity-Aligned,http://dx.doi.org/10.1055/a-1198-1243,2020-10-11,2024-03-01,Verified,kern_studie_2020,DEU
200717_Germany_NorthRhineWestphaliaLowerSaxonyHesse_BloodDonors_PrimaryEstimate,200717_Germany_NorthRhineWestphaliaLowerSaxonyHesse_BloodDonors,"SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020.",2020-07-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,"North Rhine-Westphalia, Lower Saxony, Hesse",,"Blood donors located in three German federal states North Rhine-Westphalia (n=1,700), Lower Saxony (n=576) and Hesse (n=910). ",,2020-03-09,2020-06-03,Residual sera,All,Multiple groups,,,Primary Estimate,,3186,0.0091,0.0058,0.0124,True,,,,True,Sequential,"Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,EUROIMMUN,DiaSorin",ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,No,Yes,Yes,No,,Bastian Fischer,Heart and Diabetes Center NRW,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2020.25.28.2001285,2020-10-01,2024-03-01,Verified,fischer_sars-cov-2_2020,DEU
200717_Germany_NorthRhineWestphaliaLowerSaxonyHesse_BloodDonors_Female,200717_Germany_NorthRhineWestphaliaLowerSaxonyHesse_BloodDonors,"SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020.",2020-07-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,"North Rhine-Westphalia, Lower Saxony, Hesse",,"Blood donors located in three German federal states North Rhine-Westphalia (n=1,700), Lower Saxony (n=576) and Hesse (n=910). ",,2020-03-09,2020-06-03,Residual sera,Female,Multiple groups,,,Sex/Gender,Female ,929,0.0054,,,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,EUROIMMUN,DiaSorin",ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,No,Yes,Yes,No,,Bastian Fischer,Heart and Diabetes Center NRW,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2020.25.28.2001285,2020-10-01,2024-03-01,Verified,fischer_sars-cov-2_2020,DEU
200717_Germany_NorthRhineWestphaliaLowerSaxonyHesse_BloodDonors_LowerSaxony,200717_Germany_NorthRhineWestphaliaLowerSaxonyHesse_BloodDonors,"SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020.",2020-07-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Lower Saxony,,"Blood donors located in three German federal states North Rhine-Westphalia (n=1,700), Lower Saxony (n=576) and Hesse (n=910). ",,2020-03-09,2020-06-03,Residual sera,All,Multiple groups,,,Geographical area,Lower Saxony ,576,0.0122,0.0033000000000000004,0.021,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,EUROIMMUN,DiaSorin",ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,No,Yes,Yes,No,,Bastian Fischer,Heart and Diabetes Center NRW,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2020.25.28.2001285,2020-10-01,2024-03-01,Verified,fischer_sars-cov-2_2020,DEU
200717_Germany_NorthRhineWestphaliaLowerSaxonyHesse_BloodDonors_Hesse,200717_Germany_NorthRhineWestphaliaLowerSaxonyHesse_BloodDonors,"SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020.",2020-07-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Hesse,,"Blood donors located in three German federal states North Rhine-Westphalia (n=1,700), Lower Saxony (n=576) and Hesse (n=910). ",,2020-03-09,2020-06-03,Residual sera,All,Multiple groups,,,Geographical area,Hesse,910,0.006600000000000001,0.0013000000000000002,0.011899999999999999,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,EUROIMMUN,DiaSorin",ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,No,Yes,Yes,No,,Bastian Fischer,Heart and Diabetes Center NRW,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2020.25.28.2001285,2020-10-01,2024-03-01,Verified,fischer_sars-cov-2_2020,DEU
200717_Germany_NorthRhineWestphaliaLowerSaxonyHesse_BloodDonors_NorthRhineWestphalia,200717_Germany_NorthRhineWestphaliaLowerSaxonyHesse_BloodDonors,"SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020.",2020-07-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,North Rhine-Westphalia,,"Blood donors located in three German federal states North Rhine-Westphalia (n=1,700), Lower Saxony (n=576) and Hesse (n=910). ",,2020-03-09,2020-06-03,Residual sera,All,Multiple groups,,,Geographical area,North Rhine-Westphalia,1700,0.0094,0.0049,0.0139,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,EUROIMMUN,DiaSorin",ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,No,Yes,Yes,No,,Bastian Fischer,Heart and Diabetes Center NRW,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2020.25.28.2001285,2020-10-01,2024-03-01,Verified,fischer_sars-cov-2_2020,DEU
200717_Germany_NorthRhineWestphaliaLowerSaxonyHesse_BloodDonors_Male,200717_Germany_NorthRhineWestphaliaLowerSaxonyHesse_BloodDonors,"SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020.",2020-07-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,"North Rhine-Westphalia, Lower Saxony, Hesse",,"Blood donors located in three German federal states North Rhine-Westphalia (n=1,700), Lower Saxony (n=576) and Hesse (n=910). ",,2020-03-09,2020-06-03,Residual sera,Male,Multiple groups,,,Sex/Gender,Male ,2257,0.0106,,,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,EUROIMMUN,DiaSorin",ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,No,Yes,Yes,No,,Bastian Fischer,Heart and Diabetes Center NRW,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2020.25.28.2001285,2020-10-01,2024-03-01,Verified,fischer_sars-cov-2_2020,DEU
200717_Ilm-Kreis_JenaUniversityHospital_Overall,200717_Ilm-Kreis_JenaUniversityHospital,Seroprevalence of SARS-CoV-2 antibodies in an entirely PCR-sampled and quarantined community after a COVID-19 outbreak - the CoNAN study,2020-07-17,Preprint,Local,Cross-sectional survey ,Germany,Thuringia,,"All inhabitants of the community of Neustadt-am-Rennsteig regardless of age, gender or infections status were eligible for participation.",Individuals that do not reside in Neustadt-am-Rennsteig or that live in the adjacent community of Kahlert were not eligible for inclusion. ,2020-05-12,2020-05-22,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,620,0.0839,,,True,,,True,True,Convenience,"EDI™ Novel Coronavirus COVID-19 IgM ELISA Kit,MAGLUMI 2019-nCoV IgM/IgG,Liaison SARS-CoV-2 S1/S2 IgG,Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Epitope Diagnostics, Inc.,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),DiaSorin,Abbott Laboratories,EUROIMMUN,Roche Diagnostics",Multiple Types,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Sebastian Weis ,Jena University Hospital,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.15.20154112v1,2020-07-18,2024-03-01,Verified,weis_seroprevalence_2020,DEU
200717_Ilm-Kreis_JenaUniversityHospital_Females,200717_Ilm-Kreis_JenaUniversityHospital,Seroprevalence of SARS-CoV-2 antibodies in an entirely PCR-sampled and quarantined community after a COVID-19 outbreak - the CoNAN study,2020-07-17,Preprint,Local,Cross-sectional survey ,Germany,Thuringia,,"All inhabitants of the community of Neustadt-am-Rennsteig regardless of age, gender or infections status were eligible for participation.",Individuals that do not reside in Neustadt-am-Rennsteig or that live in the adjacent community of Kahlert were not eligible for inclusion. ,2020-05-12,2020-05-22,Household and community samples,Female,Multiple groups,0.0,,Sex/Gender,Female,296,0.07780000000000001,,,,,,True,,Convenience,"EDI™ Novel Coronavirus COVID-19 IgM ELISA Kit,MAGLUMI 2019-nCoV IgM/IgG,Liaison SARS-CoV-2 S1/S2 IgG,Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Epitope Diagnostics, Inc.,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),DiaSorin,Abbott Laboratories,EUROIMMUN,Roche Diagnostics",Multiple Types,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Sebastian Weis ,Jena University Hospital,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.15.20154112v1,2020-07-18,2024-03-01,Verified,weis_seroprevalence_2020,DEU
200717_Ilm-Kreis_JenaUniversityHospital_Males,200717_Ilm-Kreis_JenaUniversityHospital,Seroprevalence of SARS-CoV-2 antibodies in an entirely PCR-sampled and quarantined community after a COVID-19 outbreak - the CoNAN study,2020-07-17,Preprint,Local,Cross-sectional survey ,Germany,Thuringia,,"All inhabitants of the community of Neustadt-am-Rennsteig regardless of age, gender or infections status were eligible for participation.",Individuals that do not reside in Neustadt-am-Rennsteig or that live in the adjacent community of Kahlert were not eligible for inclusion. ,2020-05-12,2020-05-22,Household and community samples,Male,Multiple groups,0.0,,Sex/Gender,Male ,266,0.10529999999999999,,,,,,True,,Convenience,"EDI™ Novel Coronavirus COVID-19 IgM ELISA Kit,MAGLUMI 2019-nCoV IgM/IgG,Liaison SARS-CoV-2 S1/S2 IgG,Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Epitope Diagnostics, Inc.,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),DiaSorin,Abbott Laboratories,EUROIMMUN,Roche Diagnostics",Multiple Types,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Sebastian Weis ,Jena University Hospital,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.15.20154112v1,2020-07-18,2024-03-01,Verified,weis_seroprevalence_2020,DEU
200717_Ilm-Kreis_JenaUniversityHospital_ChildrenAdolescents,200717_Ilm-Kreis_JenaUniversityHospital,Seroprevalence of SARS-CoV-2 antibodies in an entirely PCR-sampled and quarantined community after a COVID-19 outbreak - the CoNAN study,2020-07-17,Preprint,Local,Cross-sectional survey ,Germany,Thuringia,,"All inhabitants of the community of Neustadt-am-Rennsteig regardless of age, gender or infections status were eligible for participation.",Individuals that do not reside in Neustadt-am-Rennsteig or that live in the adjacent community of Kahlert were not eligible for inclusion. ,2020-05-12,2020-05-22,Household and community samples,All,Children and Youth (0-17 years),0.0,18.0,Age,<18,58,0.0172,,,,,,True,,Convenience,"EDI™ Novel Coronavirus COVID-19 IgM ELISA Kit,MAGLUMI 2019-nCoV IgM/IgG,Liaison SARS-CoV-2 S1/S2 IgG,Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Epitope Diagnostics, Inc.,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),DiaSorin,Abbott Laboratories,EUROIMMUN,Roche Diagnostics",Multiple Types,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Sebastian Weis ,Jena University Hospital,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.15.20154112v1,2020-07-18,2024-03-01,Verified,weis_seroprevalence_2020,DEU
200723_Germany_ThuringiaClinicSaalfeld_CleaningStaffIgG,200723_Germany_ThuringiaClinicSaalfeld_1_cleaners,Seroprevalence of COVID-19 antibodies in the cleaning and oncological staff of a municipal clinic.,2020-07-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Thuringia,Saalfeld,Cleaning staff and personnel working throughgout the clinic.,,2020-06-15,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Cleaning Staff IgG,45,0.0,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Multiple Types,IgG,,Validated by independent authors/third party/non-developers,,0.985,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,Jorg Epstude,Thuringia Clinic,Not Unity-Aligned,https://dx.doi.org/10.3205/dgkh000353,2020-10-01,2024-03-01,Verified,epstude_seroprevalence_2020,DEU
200723_Germany_ThuringiaClinicSaalfeld_OncologyStaffIgG,200723_Germany_ThuringiaClinicSaalfeld_2_oncologists,Seroprevalence of COVID-19 antibodies in the cleaning and oncological staff of a municipal clinic.,2020-07-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Thuringia,Saalfeld,Medical/nursing staff on the oncology ward of Thuringia Clinic Saalfeld.,,2020-06-15,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Oncology staff IgG,20,0.05,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Multiple Types,IgG,,Validated by independent authors/third party/non-developers,,0.985,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,Jorg Epstude,Thuringia Clinic,Not Unity-Aligned,https://dx.doi.org/10.3205/dgkh000353,2020-10-01,2024-03-01,Verified,epstude_seroprevalence_2020,DEU
200731_Bremen_UniversityOfBremen_IgG/IgA,200731_Bremen_UniversityOfBremen,Low anti-SARS-CoV-2 seroprevalence among public sector employees in Bremen,2020-07-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,,Bremen,"Public service employees who had to work despite the lockdown, and may have had contact with COVID-19 infected people were included.",,2020-03-31,2020-05-16,Multiple populations,All,Adults (18-64 years),,,Primary Estimate,IgG AND IgA positive,281,0.021349999999999997,,,True,,,,True,Unclear,"Anti-SARS-CoV-2 ELISA IgA,Anti-SARS-CoV-2 ELISA IgG",EUROIMMUN,ELISA,Serum,"['IgA', 'IgG']",,Validated by manufacturers,,,['High'],Yes,Unclear,No,No,Unclear,Yes,Yes,No,Unclear,Jan Neumann,University of Bremen,Not Unity-Aligned,https://www.asu-arbeitsmedizin.com/node/153868/print,2021-03-11,2024-03-01,Verified,jan_neumann_low_2020,DEU
200806_Regensburg_UniversityofRegensburg_Baseline,200806_Regensburg_UniversityofRegensburg_Baseline,Immune response to SARS-CoV-2 in health care workers following a COVID-19 outbreak: A prospective longitudinal study,2020-08-06,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,Bavaria,Regensburg,Health care workers affected by COVID-19 outbreak or in direct contact,,2020-03-15,2020-03-29,Health care workers and caregivers,All,Adults (18-64 years),18.0,65.0,Primary Estimate,Healthcare workers with COVID-19 patient contact at baseline after outbreak (longitudinal study),171,0.006,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,Roche Diagnostics",ELISA,Serum,"['IgA', 'IgG']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,No,No,Unclear,Unclear,Yes,No,Unclear,Sara Malfertheiner,University of Regensburg,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406471/pdf/main.pdf,2020-12-02,2024-03-01,Verified,fill_malfertheiner_immune_2020,DEU
200806_Regensburg_UniversityofRegensburg_12Wks,200806_Regensburg_UniversityofRegensburg_Follow-up,Immune response to SARS-CoV-2 in health care workers following a COVID-19 outbreak: A prospective longitudinal study,2020-08-06,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,Bavaria,Regensburg,Health care workers affected by COVID-19 outbreak or in direct contact,,2020-03-15,2020-06-07,Health care workers and caregivers,All,Adults (18-64 years),18.0,65.0,Primary Estimate,Healthcare workers with COVID-19 patient contact 12 weeks after outbreak,139,0.0,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,Roche Diagnostics",ELISA,Serum,"['IgA', 'IgG']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,No,No,Unclear,Unclear,Yes,No,Unclear,Sara Malfertheiner,University of Regensburg,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406471/pdf/main.pdf,2020-12-02,2024-03-01,Verified,fill_malfertheiner_immune_2020,DEU
200807_Bavaria_UniversityHospitalMunich,200807_Bavaria_UniversityHospitalMunich,Infection with SARS-CoV-2 in primary care health care workers assessed by antibody testing,2020-08-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Bavaria,Dachau,,,2020-04-02,2020-04-06,Health care workers and caregivers,All,Adults (18-64 years),26.0,47.0,Primary Estimate,Primary estimate,151,0.026000000000000002,0.008,0.071,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Multiple Types,IgG,Spike,,,,['High'],No,No,No,Yes,No,Yes,Yes,Yes,Unclear,Korbinian Lackermair,University Hospital Munich,Not Unity-Aligned,http://dx.doi.org/10.1093/fampra/cmaa078,2020-09-25,2024-03-01,Verified,lackermair_infection_2020,DEU
200813_Northrhine-Westfalia_SpecialistPracticeAndLaboratory_IgGandOverall,200813_Northrhine-Westfalia_SpecialistPracticeAndLaboratory,The prevalence rate of anti-SARS-CoV-2-IgG is 1.2% - Screening in asymptomatic outpatients in Germany (Northrhine-Westfalia),2020-08-13,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Germany,North Rhine-Westphalia,,"Outpatients at clinic with no COVID-19 and no symptoms of an acute infection such as cough, fever or dyspnoea ",Symptoms (see above),2020-03-26,2020-06-04,Residual sera,All,Multiple groups,10.0,78.0,Primary Estimate,Overall estimate total antibodies IgG,415,0.012,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9440000000000001,0.996,['High'],Unclear,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Burkhard Herrmann,Internal medicine and laboratory medicine specialist practice and laboratory,Not Unity-Aligned,http://dx.doi.org/10.1007/s15006-020-0750-y,2021-01-05,2024-03-01,Verified,herrmann_pravalenz_2020,DEU
200824_Jena_UniversitätsklinikumJena_Pregnantwomen_Overall,200824_Jena_UniversitätsklinikumJena,"Period Prevalence of SARS-CoV-2 in an Unselected Sample of Pregnant Women in Jena, Thuringia",2020-08-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Thuringia,Jena,Pregnant women who were inpatients in the Clinic for Obstetrics at the Jena University Hospital,,2020-04-06,2020-05-13,Pregnant or parturient women,Female,Multiple groups,,,Primary Estimate,N/A - primary estimate ,180,0.006,0.0,0.017,True,,,,True,Sequential,EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit,"Epitope Diagnostics, Inc.",ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Janine Zollkau,Universitätsklinikum Jena,Unity-Aligned,https://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-1206-1033,2020-09-28,2024-03-01,Verified,zollkau_periodenpravalenz_2020,DEU
200904_Hannover_HannoverMedicalSchool_HCWs_S1IgG,200904_Hannover_HannoverMedicalSchool,Strategic Anti-SARS-CoV-2 Serology Testing in a Low Prevalence Setting: The COVID-19 Contact (CoCo) Study in Healthcare Professionals,2020-09-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Lower Saxony,Hannover,"Health care providers working at Hannover Medical School, Lower Saxony ",,2020-03-23,2020-04-17,Health care workers and caregivers,All,Adults (18-64 years),18.0,63.0,Primary Estimate,S1 IgG assay,217,0.0138,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.872,0.993,['High'],No,No,No,Yes,Unclear,Yes,Yes,No,Unclear,Georg Behrens, Hannover Medical School,Not Unity-Aligned,https://link.springer.com/article/10.1007/s40121-020-00334-1,2020-09-28,2024-03-01,Verified,behrens_strategic_2020-2,DEU
200929_Oberspreewald-Lausitz_BrandenburgUniversityofTechnologyCottbus-Senftenberg_HCW,200929_Oberspreewald-Lausitz_BrandenburgUniversityofTechnologyCottbus-Senftenberg,Testing the backbone of the healthcare system: a prospective serological-epidemiological cohort study of healthcare workers in rural Germany,2020-09-29,Preprint,Local,Prospective cohort,Germany,Brandenburg,Oberspreewald-Lausitz,"Representative sample consist of staff of medical, nursing, therapeutical, laboratory, as well as radiology and service/ administration sector.",,2020-07-01,2020-07-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,156,0.013000000000000001,,,True,,,,True,Convenience,Author designed (ELISA) - Nucleocapsid,,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by developers,0.995,0.998,['High'],Yes,No,No,Yes,Unclear,Unclear,Yes,Yes,Unclear,Stephanie Hoffmann,Brandenburg University of Technology Cottbus-Senftenberg,Not Unity-Aligned,https://doi.org/10.21203/rs.3.rs-84703/v1,2020-11-28,2022-07-16,Verified,hoffmann_testing_2020,DEU
201001_SouthwesternGermany_UniversityMedicalCenterofTheJohannesGutenbergUniversityMainz_BloodDonors_Overall,201001_SouthwesternGermany_UniversityMedicalCenterofTheJohannesGutenbergUniversityMainz,Prevalence of Severe Acute Respiratory Syndrome Coronavirus-2-specific Antibodies in German Blood Donors during the COVID-19 Pandemic,2020-10-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Southwest,,"3,880 blood donors residing in southwestern Germany. All of these donations occurred after the advent of the COVID-19 pandemic.",,2020-03-15,2020-06-15,Blood donors,All,Multiple groups,18.0,71.0,Primary Estimate,,3880,0.009000000000000001,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,,0.996,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Stefan Runkel,University Medical Center of The Johannes Gutenberg-University Mainz,Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/33073955/,2021-03-14,2024-03-01,Verified,runkel_prevalence_2020,DEU
201001_SouthwesternGermany_UniversityMedicalCenterofTheJohannesGutenbergUniversityMainz_60-71,201001_SouthwesternGermany_UniversityMedicalCenterofTheJohannesGutenbergUniversityMainz,Prevalence of Severe Acute Respiratory Syndrome Coronavirus-2-specific Antibodies in German Blood Donors during the COVID-19 Pandemic,2020-10-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Southwest,,"3,880 blood donors residing in southwestern Germany. All of these donations occurred after the advent of the COVID-19 pandemic.",,2020-03-15,2020-06-15,Blood donors,All,Seniors (65+ years),60.0,71.0,Age,60-71,282,0.0212,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,,0.996,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Stefan Runkel,University Medical Center of The Johannes Gutenberg-University Mainz,Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/33073955/,2021-03-14,2024-03-01,Verified,runkel_prevalence_2020,DEU
201001_SouthwesternGermany_UniversityMedicalCenterofTheJohannesGutenbergUniversityMainz_50-59,201001_SouthwesternGermany_UniversityMedicalCenterofTheJohannesGutenbergUniversityMainz,Prevalence of Severe Acute Respiratory Syndrome Coronavirus-2-specific Antibodies in German Blood Donors during the COVID-19 Pandemic,2020-10-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Southwest,,"3,880 blood donors residing in southwestern Germany. All of these donations occurred after the advent of the COVID-19 pandemic.",,2020-03-15,2020-06-15,Blood donors,All,Adults (18-64 years),50.0,59.0,Age,50-59,797,0.0075,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,,0.996,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Stefan Runkel,University Medical Center of The Johannes Gutenberg-University Mainz,Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/33073955/,2021-03-14,2024-03-01,Verified,runkel_prevalence_2020,DEU
201001_SouthwesternGermany_UniversityMedicalCenterofTheJohannesGutenbergUniversityMainz_30-39,201001_SouthwesternGermany_UniversityMedicalCenterofTheJohannesGutenbergUniversityMainz,Prevalence of Severe Acute Respiratory Syndrome Coronavirus-2-specific Antibodies in German Blood Donors during the COVID-19 Pandemic,2020-10-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Southwest,,"3,880 blood donors residing in southwestern Germany. All of these donations occurred after the advent of the COVID-19 pandemic.",,2020-03-15,2020-06-15,Blood donors,All,Adults (18-64 years),30.0,39.0,Age,30-39 ,772,0.0038,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,,0.996,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Stefan Runkel,University Medical Center of The Johannes Gutenberg-University Mainz,Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/33073955/,2021-03-14,2024-03-01,Verified,runkel_prevalence_2020,DEU
201001_SouthwesternGermany_UniversityMedicalCenterofTheJohannesGutenbergUniversityMainz_Female,201001_SouthwesternGermany_UniversityMedicalCenterofTheJohannesGutenbergUniversityMainz,Prevalence of Severe Acute Respiratory Syndrome Coronavirus-2-specific Antibodies in German Blood Donors during the COVID-19 Pandemic,2020-10-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Southwest,,"3,880 blood donors residing in southwestern Germany. All of these donations occurred after the advent of the COVID-19 pandemic.",,2020-03-15,2020-06-15,Blood donors,Female,Multiple groups,18.0,71.0,Sex/Gender,Female,1756,0.0108,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,,0.996,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Stefan Runkel,University Medical Center of The Johannes Gutenberg-University Mainz,Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/33073955/,2021-03-14,2024-03-01,Verified,runkel_prevalence_2020,DEU
201001_SouthwesternGermany_UniversityMedicalCenterofTheJohannesGutenbergUniversityMainz_18-29,201001_SouthwesternGermany_UniversityMedicalCenterofTheJohannesGutenbergUniversityMainz,Prevalence of Severe Acute Respiratory Syndrome Coronavirus-2-specific Antibodies in German Blood Donors during the COVID-19 Pandemic,2020-10-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Southwest,,"3,880 blood donors residing in southwestern Germany. All of these donations occurred after the advent of the COVID-19 pandemic.",,2020-03-15,2020-06-15,Blood donors,All,Adults (18-64 years),18.0,29.0,Age,18-29,1292,0.0116,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,,0.996,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Stefan Runkel,University Medical Center of The Johannes Gutenberg-University Mainz,Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/33073955/,2021-03-14,2024-03-01,Verified,runkel_prevalence_2020,DEU
201001_SouthwesternGermany_UniversityMedicalCenterofTheJohannesGutenbergUniversityMainz_Male,201001_SouthwesternGermany_UniversityMedicalCenterofTheJohannesGutenbergUniversityMainz,Prevalence of Severe Acute Respiratory Syndrome Coronavirus-2-specific Antibodies in German Blood Donors during the COVID-19 Pandemic,2020-10-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Southwest,,"3,880 blood donors residing in southwestern Germany. All of these donations occurred after the advent of the COVID-19 pandemic.",,2020-03-15,2020-06-15,Blood donors,Male,Multiple groups,18.0,71.0,Sex/Gender,Male ,2124,0.0075,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,,0.996,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Stefan Runkel,University Medical Center of The Johannes Gutenberg-University Mainz,Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/33073955/,2021-03-14,2024-03-01,Verified,runkel_prevalence_2020,DEU
201001_SouthwesternGermany_UniversityMedicalCenterofTheJohannesGutenbergUniversityMainz_40-49,201001_SouthwesternGermany_UniversityMedicalCenterofTheJohannesGutenbergUniversityMainz,Prevalence of Severe Acute Respiratory Syndrome Coronavirus-2-specific Antibodies in German Blood Donors during the COVID-19 Pandemic,2020-10-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Southwest,,"3,880 blood donors residing in southwestern Germany. All of these donations occurred after the advent of the COVID-19 pandemic.",,2020-03-15,2020-06-15,Blood donors,All,Adults (18-64 years),40.0,49.0,Age,40-49,537,0.009300000000000001,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,,0.996,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Stefan Runkel,University Medical Center of The Johannes Gutenberg-University Mainz,Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/33073955/,2021-03-14,2024-03-01,Verified,runkel_prevalence_2020,DEU
200101_Hamburg_UniversityHospitalsoftheRuhr-UniversityofBochum_Overall,200101_Hamburg_UniversityHospitalsoftheRuhr‑UniversityofBochum,Prospective Sero-epidemiological Evaluation of SARS-CoV-2 among Health Care Workers in a German Secondary Care Hospital,2020-10-16,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,Schleswig-Holstein,Hamburg,"All hospital employees and nuns aged between 18 and 90 years
at the study center were given the opportunity to participate in this
longitudinal monocentric trial.","individuals feeling too unwell to
participate at the outset of the study or lacking the capacity to
understand informed consent.",2020-04-14,2020-06-16,Health care workers and caregivers,All,Multiple groups,18.0,90.0,Primary Estimate,Overall,871,0.026400000000000003,,,True,,,,,Convenience,"recomWell SARS-CoV-2 IgG ELISA,Anti-SARS-CoV-2 ELISA IgG","Mikrogen GmbH,EUROIMMUN",ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,Unclear,Unclear,No,No,Yes,Jonas Herzberg,University Hospitals of the Ruhr‑University of Bochum,Not Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2020.10.026,2021-01-30,2024-03-01,Verified,herzberg_prospective_2021,DEU
201023_Berlin_CharitéUniversity_primary,201023_Berlin_CharitéUniversity,LOW SEROPREVALENCE OF SARS-COV-2 ANTIBODIES DURING SYSTEMATIC SCREENING FOR COVID-19 INFECTION IN A GERMAN COHORT OF KIDNEY TRANSPLANT RECIPIENTS,2020-10-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Berlin,Berlin,"From 19 March until 19 May 2020, serum samples from 223 renal and combined-renal transplant patients, clinically stable without COVID-19 symptoms. ",,2020-03-19,2020-05-19,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,,Primary Estimate,,223,0.071,,,True,,,,True,Unclear,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG),Anti-SARS-CoV-2 ELISA IgA",EUROIMMUN,Multiple Types,Serum,"['IgA', 'IgG']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,Unclear,No,Yes,Unclear,Unclear,Yes,No,Unclear,Mira Choi,Charité University,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690804/,2021-01-13,2024-03-01,Verified,choiLowSeroprevalenceSARSCoV22020,DEU
201103_Germany_UniversityofWitten,201103_Germany_UniversityofWitten,[Corona in Children: the Co-Ki Study],2020-11-03,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Germany,,,"Children presenting at sampled pediatrician offices

The request to participate also took place explicitly
for the situation that no cases of COVID-19 or SARS-CoV-2 positivity available in your own practice. ",The invitation to participate was also explicitly made for the situation that there are no cases of COVID-19 or SARS-CoV-2 positivity in one's own practice,2020-06-15,2020-09-01,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Primary Estimate,Primary estimate,731,0.11199999999999999,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 NCP ELISA (IGM),Elecsys® Anti‐SARS‐CoV‐2 (N),Anti-SARS-CoV-2 ELISA IgA","EUROIMMUN,Roche Diagnostics",Multiple Types,Multiple Types,"['IgA', 'IgG', 'IgM']",,,,,['High'],Yes,No,Yes,No,Unclear,Unclear,No,No,Unclear,Silke Schwarz,University of Witten,Not Unity-Aligned,https://dx.doi.org/10.1007/s00112-020-01050-3,2021-01-07,2024-03-01,Verified,schwarz_corona_2020,DEU
201117_Gangelt_UniversityofBonn_ v3_overall_TestAdj_IgG,201117_Gangelt_UniversityofBonn_v3,Infection fatality rate of SARS-CoV2 in a super-spreading event in Germany,2020-11-17,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Germany,Heinsberg,Gangelt,"For this cross-sectional epidemiological study, all inhabitants of Gangelt were eligible.

Sample of 600 persons aged older than 18 was drawn from a civil register, and family members of each individual was invited to participate",,2020-03-31,2020-04-06,Household and community samples,All,Multiple groups,1.0,90.0,Primary Estimate,Adjusted for cluster and test - IgG,919,0.1411,0.1115,0.1727,True,True,,True,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Plasma,IgG,,Validated by manufacturers,0.909,0.991,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Hendrik Streeck,University of Bonn,Unity-Aligned,https://www.nature.com/articles/s41467-020-19509-y,2021-04-26,2024-02-01,Verified,streeck_infection_2020-2,DEU
201117_Gangelt_UniversityofBonn_ v3_overall_Unadj_IgG ,201117_Gangelt_UniversityofBonn_v3,Infection fatality rate of SARS-CoV2 in a super-spreading event in Germany,2020-11-17,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Germany,Heinsberg,Gangelt,"For this cross-sectional epidemiological study, all inhabitants of Gangelt were eligible.

Sample of 600 persons aged older than 18 was drawn from a civil register, and family members of each individual was invited to participate",,2020-03-31,2020-04-06,Household and community samples,All,Multiple groups,1.0,90.0,Analysis,"Cluster adjusted but test unadjusted, IgG",919,0.136,,,,,,True,True,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Plasma,IgG,,Validated by manufacturers,0.909,0.991,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Hendrik Streeck,University of Bonn,Unity-Aligned,https://www.nature.com/articles/s41467-020-19509-y,2021-04-26,2024-03-01,Verified,streeck_infection_2020-2,DEU
201111_NeustadtAmRennsteig_FriedrichSchillerUniversity_Overall,201111_NeustadtAmRennsteig_FriedrichSchillerUniversity,Antibody response using six different serological assays in a completely PCR-tested community after a COVID-19 outbreak - The CoNAN study.,2020-11-19,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,Thuringia,,"Participants were enrolled from 13 May to 16 May
2020 at a central study site, set-up in the village town hall. Participants who could not come to the study site were enrolled by the local primary care physician at their respective homes until the 22 May. The sample size of the CoNAN-cohort is fixed by the number of inhabitants of the community. We aimed to include the population as completely as possible.",Individuals that did not reside in Neustadt am Rennsteig or that lived in the adjacent community of Kahlert were not eligible forinclusion,2020-05-13,2020-05-16,Household and community samples,All,Multiple groups,1.0,97.0,Primary Estimate,,620,0.084,,,True,,,,True,Self-referral,"EDI™ Novel Coronavirus COVID-19 IgM ELISA Kit,MAGLUMI 2019-nCoV IgM/IgG,Liaison SARS-CoV-2 S1/S2 IgG,Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Epitope Diagnostics, Inc.,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),DiaSorin,Abbott Laboratories,EUROIMMUN,Roche Diagnostics",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike', 'Whole-virusantigen']",,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Sebastian Weis,Friedrich Schiller University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.11.009,2021-01-27,2024-03-01,Verified,weis_antibody_2020,DEU
201111_NeustadtAmRennsteig_FriedrichSchillerUniversity_Overall_Adults,201111_NeustadtAmRennsteig_FriedrichSchillerUniversity,Antibody response using six different serological assays in a completely PCR-tested community after a COVID-19 outbreak - The CoNAN study.,2020-11-19,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,Thuringia,,"Participants were enrolled from 13 May to 16 May
2020 at a central study site, set-up in the village town hall. Participants who could not come to the study site were enrolled by the local primary care physician at their respective homes until the 22 May. The sample size of the CoNAN-cohort is fixed by the number of inhabitants of the community. We aimed to include the population as completely as possible.",Individuals that did not reside in Neustadt am Rennsteig or that lived in the adjacent community of Kahlert were not eligible forinclusion,2020-05-13,2020-05-16,Household and community samples,All,Adults (18-64 years),16.0,97.0,Age,Adults,562,0.0907,,,,,,,,Self-referral,"EDI™ Novel Coronavirus COVID-19 IgM ELISA Kit,MAGLUMI 2019-nCoV IgM/IgG,Liaison SARS-CoV-2 S1/S2 IgG,Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Epitope Diagnostics, Inc.,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),DiaSorin,Abbott Laboratories,EUROIMMUN,Roche Diagnostics",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike', 'Whole-virusantigen']",,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Sebastian Weis,Friedrich Schiller University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.11.009,2021-03-10,2024-03-01,Verified,weis_antibody_2020,DEU
201111_NeustadtAmRennsteig_FriedrichSchillerUniversity_Overall_Female,201111_NeustadtAmRennsteig_FriedrichSchillerUniversity,Antibody response using six different serological assays in a completely PCR-tested community after a COVID-19 outbreak - The CoNAN study.,2020-11-19,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,Thuringia,,"Participants were enrolled from 13 May to 16 May
2020 at a central study site, set-up in the village town hall. Participants who could not come to the study site were enrolled by the local primary care physician at their respective homes until the 22 May. The sample size of the CoNAN-cohort is fixed by the number of inhabitants of the community. We aimed to include the population as completely as possible.",Individuals that did not reside in Neustadt am Rennsteig or that lived in the adjacent community of Kahlert were not eligible forinclusion,2020-05-13,2020-05-16,Household and community samples,Female,Multiple groups,1.0,97.0,Sex/Gender,Female,318,0.0723,,,,,,,,Self-referral,"EDI™ Novel Coronavirus COVID-19 IgM ELISA Kit,MAGLUMI 2019-nCoV IgM/IgG,Liaison SARS-CoV-2 S1/S2 IgG,Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Epitope Diagnostics, Inc.,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),DiaSorin,Abbott Laboratories,EUROIMMUN,Roche Diagnostics",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike', 'Whole-virusantigen']",,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Sebastian Weis,Friedrich Schiller University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.11.009,2021-03-10,2024-03-01,Verified,weis_antibody_2020,DEU
201111_NeustadtAmRennsteig_FriedrichSchillerUniversity_Overall_Male,201111_NeustadtAmRennsteig_FriedrichSchillerUniversity,Antibody response using six different serological assays in a completely PCR-tested community after a COVID-19 outbreak - The CoNAN study.,2020-11-19,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,Thuringia,,"Participants were enrolled from 13 May to 16 May
2020 at a central study site, set-up in the village town hall. Participants who could not come to the study site were enrolled by the local primary care physician at their respective homes until the 22 May. The sample size of the CoNAN-cohort is fixed by the number of inhabitants of the community. We aimed to include the population as completely as possible.",Individuals that did not reside in Neustadt am Rennsteig or that lived in the adjacent community of Kahlert were not eligible forinclusion,2020-05-13,2020-05-16,Household and community samples,Male,Multiple groups,1.0,97.0,Sex/Gender,Male ,301,0.09300000000000001,,,,,,,,Self-referral,"EDI™ Novel Coronavirus COVID-19 IgM ELISA Kit,MAGLUMI 2019-nCoV IgM/IgG,Liaison SARS-CoV-2 S1/S2 IgG,Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Epitope Diagnostics, Inc.,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),DiaSorin,Abbott Laboratories,EUROIMMUN,Roche Diagnostics",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike', 'Whole-virusantigen']",,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Sebastian Weis,Friedrich Schiller University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.11.009,2021-03-10,2024-03-01,Verified,weis_antibody_2020,DEU
201111_NeustadtAmRennsteig_FriedrichSchillerUniversity_Overall_Kids,201111_NeustadtAmRennsteig_FriedrichSchillerUniversity,Antibody response using six different serological assays in a completely PCR-tested community after a COVID-19 outbreak - The CoNAN study.,2020-11-19,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,Thuringia,,"Participants were enrolled from 13 May to 16 May
2020 at a central study site, set-up in the village town hall. Participants who could not come to the study site were enrolled by the local primary care physician at their respective homes until the 22 May. The sample size of the CoNAN-cohort is fixed by the number of inhabitants of the community. We aimed to include the population as completely as possible.",Individuals that did not reside in Neustadt am Rennsteig or that lived in the adjacent community of Kahlert were not eligible forinclusion,2020-05-13,2020-05-16,Household and community samples,All,Children and Youth (0-17 years),1.0,16.0,Age,Children and adolescents ,58,0.017,,,,,,,,Self-referral,"EDI™ Novel Coronavirus COVID-19 IgM ELISA Kit,MAGLUMI 2019-nCoV IgM/IgG,Liaison SARS-CoV-2 S1/S2 IgG,Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Epitope Diagnostics, Inc.,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),DiaSorin,Abbott Laboratories,EUROIMMUN,Roche Diagnostics",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike', 'Whole-virusantigen']",,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Sebastian Weis,Friedrich Schiller University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.11.009,2021-03-10,2024-03-01,Verified,weis_antibody_2020,DEU
201126_Germany_RobertKochInstitute_BloodDonors_TestAdj,201126_Germany_RobertKochInstitute,Serological tests of blood donations for antibodies against SARS-CoV-2 (SeBluCo study),2020-11-26,Institutional Report,National,Cross-sectional survey ,Germany,,,Blood donors from 13 blood donation services and two virological institutes across Germany,,2020-04-15,2020-11-05,Blood donors,All,Multiple groups,18.0,72.0,Analysis,Test adjustment,48976,0.013500000000000002,,,True,True,,,,Simplified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],No,Yes,Yes,No,Yes,Unclear,Yes,No,,Robert Koch Institute,Robert Koch Institute,Not Unity-Aligned,https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Projekte_RKI/SeBluCo_Zwischenbericht.html;jsessionid=0C30892A66A0F7CDD897F3809AA3F10F.internet102,2021-01-14,2022-07-16,Verified,robert_koch_institute_serological_2020,DEU
201126_Germany_RobertKochInstitute_BloodDonors_TestUnAdj,201126_Germany_RobertKochInstitute,Serological tests of blood donations for antibodies against SARS-CoV-2 (SeBluCo study),2020-11-26,Institutional Report,National,Cross-sectional survey ,Germany,,,Blood donors from 13 blood donation services and two virological institutes across Germany,,2020-04-15,2020-11-05,Blood donors,All,Multiple groups,18.0,72.0,Primary Estimate,,48976,0.0178,,,,,,,True,Simplified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],No,Yes,Yes,No,Yes,Unclear,Yes,No,,Robert Koch Institute,Robert Koch Institute,Not Unity-Aligned,https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Projekte_RKI/SeBluCo_Zwischenbericht.html;jsessionid=0C30892A66A0F7CDD897F3809AA3F10F.internet102,2021-01-14,2022-07-16,Verified,robert_koch_institute_serological_2020,DEU
201126_Kupferzell_RobertKochInstitute_OverallAdj,201126_Kupferzell_RobertKochInstitute,"Serology- and PCR-based cumulative incidence of SARS-CoV-2 infection in adults in a successfully contained early hotspot (CoMoLo study), Germany, May to June 2020",2020-11-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Baden-Württemberg,Kupferzell,"A random sample of 3,534 Kupferzell residents aged 18
years and older from the mandatory population registry
(68.9% of the 5,128 adult residents) was invited to take
part in the study,",,2020-05-20,2020-06-09,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,Test adjusted ,2203,0.12,0.10400000000000001,0.14,True,True,,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Claudia Santos Hovener,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2020.25.47.2001752,2021-02-04,2023-07-04,Verified,santos-hovener_serology-_2020,DEU
201126_Kupferzell_RobertKochInstitute_50-64,201126_Kupferzell_RobertKochInstitute,"Serology- and PCR-based cumulative incidence of SARS-CoV-2 infection in adults in a successfully contained early hotspot (CoMoLo study), Germany, May to June 2020",2020-11-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Baden-Württemberg,Kupferzell,"A random sample of 3,534 Kupferzell residents aged 18
years and older from the mandatory population registry
(68.9% of the 5,128 adult residents) was invited to take
part in the study,",,2020-05-20,2020-06-09,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50-64 years,572,0.1329,,,,,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Claudia Santos Hovener,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2020.25.47.2001752,2021-02-18,2024-03-01,Verified,santos-hovener_serology-_2020,DEU
201126_Kupferzell_RobertKochInstitute_>65,201126_Kupferzell_RobertKochInstitute,"Serology- and PCR-based cumulative incidence of SARS-CoV-2 infection in adults in a successfully contained early hotspot (CoMoLo study), Germany, May to June 2020",2020-11-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Baden-Württemberg,Kupferzell,"A random sample of 3,534 Kupferzell residents aged 18
years and older from the mandatory population registry
(68.9% of the 5,128 adult residents) was invited to take
part in the study,",,2020-05-20,2020-06-09,Household and community samples,All,Seniors (65+ years),65.0,,Age,Older than 65 years,385,0.1351,,,,,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Claudia Santos Hovener,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2020.25.47.2001752,2021-02-18,2024-03-01,Verified,santos-hovener_serology-_2020,DEU
201126_Kupferzell_RobertKochInstitute_OverallPopAdj,201126_Kupferzell_RobertKochInstitute,"Serology- and PCR-based cumulative incidence of SARS-CoV-2 infection in adults in a successfully contained early hotspot (CoMoLo study), Germany, May to June 2020",2020-11-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Baden-Württemberg,Kupferzell,"A random sample of 3,534 Kupferzell residents aged 18
years and older from the mandatory population registry
(68.9% of the 5,128 adult residents) was invited to take
part in the study,",,2020-05-20,2020-06-09,Household and community samples,All,Multiple groups,18.0,,Analysis,"Results were weighted to the population of Kupferzell with regard to age group, sex and school education. Clustering with households was taken into account.",2203,0.113,,,,,True,,True,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Claudia Santos Hovener,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2020.25.47.2001752,2021-02-04,2024-03-01,Verified,santos-hovener_serology-_2020,DEU
201126_Kupferzell_RobertKochInstitute_FemaleAdj,201126_Kupferzell_RobertKochInstitute,"Serology- and PCR-based cumulative incidence of SARS-CoV-2 infection in adults in a successfully contained early hotspot (CoMoLo study), Germany, May to June 2020",2020-11-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Baden-Württemberg,Kupferzell,"A random sample of 3,534 Kupferzell residents aged 18
years and older from the mandatory population registry
(68.9% of the 5,128 adult residents) was invited to take
part in the study,",,2020-05-20,2020-06-09,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,Females; pop adjusted,1143,0.122,,,,,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Claudia Santos Hovener,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2020.25.47.2001752,2021-02-04,2024-03-01,Verified,santos-hovener_serology-_2020,DEU
201126_Kupferzell_RobertKochInstitute_35-49,201126_Kupferzell_RobertKochInstitute,"Serology- and PCR-based cumulative incidence of SARS-CoV-2 infection in adults in a successfully contained early hotspot (CoMoLo study), Germany, May to June 2020",2020-11-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Baden-Württemberg,Kupferzell,"A random sample of 3,534 Kupferzell residents aged 18
years and older from the mandatory population registry
(68.9% of the 5,128 adult residents) was invited to take
part in the study,",,2020-05-20,2020-06-09,Household and community samples,All,Adults (18-64 years),35.0,49.0,Age,35-49 years,533,0.09380000000000001,,,,,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Claudia Santos Hovener,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2020.25.47.2001752,2021-02-18,2024-03-01,Verified,santos-hovener_serology-_2020,DEU
201126_Kupferzell_RobertKochInstitute_MaleAdj,201126_Kupferzell_RobertKochInstitute,"Serology- and PCR-based cumulative incidence of SARS-CoV-2 infection in adults in a successfully contained early hotspot (CoMoLo study), Germany, May to June 2020",2020-11-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Baden-Württemberg,Kupferzell,"A random sample of 3,534 Kupferzell residents aged 18
years and older from the mandatory population registry
(68.9% of the 5,128 adult residents) was invited to take
part in the study,",,2020-05-20,2020-06-09,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,Male; pop adjusted,1060,0.105,,,,,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Claudia Santos Hovener,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2020.25.47.2001752,2021-02-04,2024-03-01,Verified,santos-hovener_serology-_2020,DEU
201126_Kupferzell_RobertKochInstitute_18-34,201126_Kupferzell_RobertKochInstitute,"Serology- and PCR-based cumulative incidence of SARS-CoV-2 infection in adults in a successfully contained early hotspot (CoMoLo study), Germany, May to June 2020",2020-11-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Baden-Württemberg,Kupferzell,"A random sample of 3,534 Kupferzell residents aged 18
years and older from the mandatory population registry
(68.9% of the 5,128 adult residents) was invited to take
part in the study,",,2020-05-20,2020-06-09,Household and community samples,All,Adults (18-64 years),18.0,34.0,Age,18-34 years ,713,0.09960000000000001,,,,,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Claudia Santos Hovener,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2020.25.47.2001752,2021-02-18,2024-03-01,Verified,santos-hovener_serology-_2020,DEU
201127_Germany_IfoInstitue_overall_PopAdj,201127_Germany_IfoInstitue,Die Deutschen und Corona Schlussbericht der BMG-„Corona-BUND-Studie“,2020-11-27,Institutional Report,National,Prospective cohort,Germany,,,,,2020-10-26,2020-11-18,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,9929,0.011000000000000001,0.0092,0.013300000000000001,True,,True,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,,0.998,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Clemens Fuest,ifo Institute,Unity-Aligned,https://www.ifo.de/en/publikationen/2020/monograph-authorship/die-deutschen-und-corona,2021-03-21,2024-03-01,Verified,fuest_deutschen_2020,DEU
201130_Hamburg_UniversityMedicalCenterHamburg-Eppendorf_S3,201130_Hamburg_UniversityMedicalCenterHamburg-Eppendorf,Seroprevalence of SARS-CoV-2 antibodies among hospital workers in a German tertiary care center: A sequential follow-up study,2020-11-30,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Germany,Hamburg,Hamburg,Hospital workers and NCWs at the University Medical Center Hamburg-Eppendorf,,2020-06-22,2020-07-17,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Last study period/overall study seroprevalence,1253,0.018000000000000002,0.01,0.025,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9440000000000001,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Thomas Brehm,University Medical Center Hamburg-Eppendorf,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijheh.2020.113671,2021-01-21,2024-03-01,Verified,brehm_seroprevalence_2021,DEU
201203_Tirschenreuth_MunichClinic_HCW_Overall,201203_Tirschenreuth_MunichClinic_HCW,[SARS-CoV-2 antibodies in ICU and clinic staff : From Germany's region with the highest infection rate],2020-12-03,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,Bavaria,"Tirschenreuth, Wieden",Workers at KNO-AG,,2020-06-29,2020-07-29,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,Overall HCW,1838,0.151,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,T Finkenzeller,Munich Clinic,Not Unity-Aligned,https://dx.doi.org/10.1007/s00063-020-00761-5,2021-01-27,2024-03-01,Verified,finkenzeller_sars-cov-2-antikorper_2020,DEU
201203_Tirschenreuth_MunichClinic_NMU_Overall,201203_Tirschenreuth_MunichClinic_NMU,[SARS-CoV-2 antibodies in ICU and clinic staff : From Germany's region with the highest infection rate],2020-12-03,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,Bavaria,"Tirschenreuth, Wieden","Workers at a large, non-medical company",,2020-06-29,2020-07-29,Essential non-healthcare workers,All,Adults (18-64 years),18.0,,Primary Estimate,,986,0.037000000000000005,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],Unclear,No,Yes,Yes,Unclear,Yes,Yes,Yes,No,T Finkenzeller,Munich Clinic,Not Unity-Aligned,https://dx.doi.org/10.1007/s00063-020-00761-5,2021-01-27,2024-03-01,Verified,finkenzeller_sars-cov-2-antikorper_2020,DEU
201204_Germany_SaarlandUniversity_overall,201204_Germany_SaarlandUniversity,Prevalence of SARS-CoV-2 IgG antibodies in a large prospective cohort study of elite football players in Germany (May-June 2020): implications for a testing protocol in asymptomatic individuals and estimation of the rate of undetected cases,2020-12-04,Journal Article (Peer-Reviewed),National,Prospective cohort,Germany,,,"players and staff in direct contact with players (e.g. coaches, physiotherapists) on all 36 professional soccer teams in Germany",lack of written informed consent. Primary outcome was IgG positivity,2020-06-16,2020-06-30,Non-essential workers and unemployed persons,All,Multiple groups,17.0,78.0,Primary Estimate,Football players and staff with direct contact on final follow-up dates,1007,0.0209,0.013700000000000002,0.0317,True,,,,True,Self-referral,"Anti-SARS-CoV-2 ELISA IgG,Author designed (Neutralization Assay),Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,NA,Roche Diagnostics",Multiple Types,Serum,"['IgG', 'Notreported']",,,,,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Dietrich Mack,Saarland University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.11.033,2021-01-31,2024-03-01,Verified,mack_prevalence_2020,DEU
201211_BadFeilnbach_RobertKochInstitute_primary,201211_BadFeilnbach_RobertKochInstitute,Corona monitoring locally - First key data for Bad Feilnbach,2020-12-11,News and Media,Local,Cross-sectional survey ,Germany,,Bad Feilnbach,,,2020-06-23,2020-07-04,Household and community samples,All,Multiple groups,,,Primary Estimate,,2152,0.091,,,True,True,,,True,Simplified probability,Not reported/ Unable to specify,,,,IgG,,,0.883,0.9940000000000001,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,Yes,Yes,Robert Koch Institute,Robert Koch Institute,Not Unity-Aligned,https://www.rki.de/DE/Content/Gesundheitsmonitoring/Studien/cml-studie/Factsheet_Bad_Feilnbach.html,2021-04-30,2022-07-16,Verified,noauthor_rki_nodate-1,DEU
201212_Europe_UniversityOfGlasgow_Germany2,201212_Europe_UniversityOfGlasgow_Germany2,SARS-Cov-2 viral and serological screening of staff in 31 European fertility units.,2020-12-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Germany,,"Berlin, Düsseldorf and Wiesbaden","all staff members recommencing work at the Fertility Partnership, including clinical and head office staf",,2020-04-15,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,137,0.0292,0.011399999999999999,0.0727,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,,Scott M Nelson,University of Glasgow,Not Unity-Aligned,https://dx.doi.org/10.1093/hropen/hoaa056,2021-06-07,2024-03-01,Verified,nelson_sars-cov-2_2020,DEU
201215_Straubing_RobertKochInstitut_ELISA_poptestadj,201215_Straubing_RobertKochInstitut,"Corona monitoring locally -
  Key data for Straubing",2020-12-15,News and Media,Local,Cross-sectional survey ,Germany,Bavaria,Straubing,"if they are 18 years or older, are registered residents of one of the four study municipalities, can provide written consent to participate in the study, or, where necessary, written consent is provided by a legal representative, are able to take part in the interviews (where necessary with the help of relatives) and the examinations at the
study centres or during home visits.",People who lack the necessary German language skills or where it is unclear whether they understand the study information leaflets or the consent forms are excluded from participating.,2020-09-08,2020-09-26,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2361,0.017,,,True,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,,,0.883,0.9940000000000001,['Low'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,No,Robert Koch Institute,Robert Koch Institute,Unity-Aligned,https://www.rki.de/DE/Content/Gesundheitsmonitoring/Studien/cml-studie/Factsheet_Straubing.html,2021-05-16,2023-08-15,Verified,robert_koch_institut_rki_2020,DEU
201215_Straubing_RobertKochInstitut_ELISA/Neut_popadj,201215_Straubing_RobertKochInstitut,"Corona monitoring locally -
  Key data for Straubing",2020-12-15,News and Media,Local,Cross-sectional survey ,Germany,Bavaria,Straubing,"if they are 18 years or older, are registered residents of one of the four study municipalities, can provide written consent to participate in the study, or, where necessary, written consent is provided by a legal representative, are able to take part in the interviews (where necessary with the help of relatives) and the examinations at the
study centres or during home visits.",People who lack the necessary German language skills or where it is unclear whether they understand the study information leaflets or the consent forms are excluded from participating.,2020-09-08,2020-09-26,Household and community samples,All,Multiple groups,18.0,,Test used,,2361,0.018000000000000002,,,,,True,,True,Simplified probability,"Anti-SARS-CoV-2 ELISA IgG,Author designed (Neutralization Assay)","EUROIMMUN,NA",Multiple Types,Serum,"['IgG', 'Neutralizing']",,Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,No,Robert Koch Institute,Robert Koch Institute,Unity-Aligned,https://www.rki.de/DE/Content/Gesundheitsmonitoring/Studien/cml-studie/Factsheet_Straubing.html,2021-05-16,2024-03-01,Verified,robert_koch_institut_rki_2020,DEU
201216_Germany_Ruhr-UniversityBochum_overall,201216_Germany_Ruhr-UniversityBochum,"Coronavirus Disease 2019 Associated Risk Score, Behavior, and Symptom Prevalence in German Transplant Recipients.",2020-12-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,,Bochum,One hundred twelve transplant patients consecutively visiting the outpatient department of 2 German transplant centers for scheduled visits in April and May 2020 were included. Only 99 had serology done,,2020-04-01,2020-05-31,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,99,0.030299999999999997,,,True,,,,True,Sequential,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA",EUROIMMUN,ELISA,Serum,"['IgA', 'IgG']",,,,,['High'],Yes,No,No,Yes,Yes,No,Yes,No,Yes,Constantin J Thieme,Ruhr-University Bochum,Not Unity-Aligned,https://dx.doi.org/10.1016/j.transproceed.2020.12.001,2021-02-06,2024-03-01,Verified,thieme_coronavirus_2020,DEU
201216_Heidelberg_UniversityHospitalHeidelberg_Overall,201216_Heidelberg_UniversityHospitalHeidelberg,SARS-CoV-2 Seroprevalence and Clinical Features of COVID-19 in a German Liver Transplant Recipient Cohort: A Prospective Serosurvey Study,2020-12-16,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,Baden-Württemberg,Heidelberg,"Over 18 yrs of age, and had undergone liver transplantation in the past. ",,2020-05-05,2020-08-06,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,78.0,Primary Estimate,,219,0.032,,,True,,,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,,Validated by manufacturers,0.946,0.998,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Conrad Rauber,University Hospital Heidelberg,Not Unity-Aligned,https://www.sciencedirect.com/science/article/abs/pii/S0041134520329043?via%3Dihub,2021-04-08,2024-03-01,Verified,rauber_sars-cov-2_2020,DEU
201216_Heidelberg_UniversityHospitalHeidelberg_>65,201216_Heidelberg_UniversityHospitalHeidelberg,SARS-CoV-2 Seroprevalence and Clinical Features of COVID-19 in a German Liver Transplant Recipient Cohort: A Prospective Serosurvey Study,2020-12-16,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,Baden-Württemberg,Heidelberg,"Over 18 yrs of age, and had undergone liver transplantation in the past. ",,2020-05-05,2020-08-06,Patients seeking care for non-COVID-19 reasons,All,Seniors (65+ years),65.0,78.0,Age,>65 ,44,0.0455,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,,Validated by manufacturers,0.946,0.998,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Conrad Rauber,University Hospital Heidelberg,Not Unity-Aligned,https://www.sciencedirect.com/science/article/abs/pii/S0041134520329043?via%3Dihub,2021-04-22,2024-03-01,Verified,rauber_sars-cov-2_2020,DEU
201216_Heidelberg_UniversityHospitalHeidelberg_<=65,201216_Heidelberg_UniversityHospitalHeidelberg,SARS-CoV-2 Seroprevalence and Clinical Features of COVID-19 in a German Liver Transplant Recipient Cohort: A Prospective Serosurvey Study,2020-12-16,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,Baden-Württemberg,Heidelberg,"Over 18 yrs of age, and had undergone liver transplantation in the past. ",,2020-05-05,2020-08-06,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),18.0,65.0,Age,<=65,175,0.034300000000000004,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,,Validated by manufacturers,0.946,0.998,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Conrad Rauber,University Hospital Heidelberg,Not Unity-Aligned,https://www.sciencedirect.com/science/article/abs/pii/S0041134520329043?via%3Dihub,2021-04-22,2024-03-01,Verified,rauber_sars-cov-2_2020,DEU
210102_Munich_MUCResearch,210102_Munich_MUCResearch,HIV and SARS-CoV-2 co-infection: cross-sectional findings from a German 'hotspot',2021-01-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,,Munich,"Participating in the observational Munich ArcHIV cohort, attending the center for routine laboratory controls for chronic HIV-1 infection (with or without treatment) between May 29th and July 15th, 2020",unwillingness or inability to give written informed consent,2020-05-29,2020-07-15,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),,,Primary Estimate,People living with HIV,500,0.015,0.006999999999999999,0.0313,True,True,,,True,Sequential,"recomWell SARS-CoV-2 IgG ELISA,recomLine SARS-CoV-2 IgG",Mikrogen GmbH,ELISA,,IgG,,Validated by manufacturers,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,S Noe,MUC Research,Not Unity-Aligned,https://dx.doi.org/10.1007/s15010-020-01564-8,2021-02-05,2023-07-04,Unverified,noe_hiv_2021,DEU
210103_Munich_LudwigMaximillianUniversityofMunich_Overall,210103_Munich_LudwigMaximillianUniversityofMunich,"Prospective Longitudinal Serosurvey of Health Care Workers in the First Wave of the SARS-CoV-2 Pandemic in a Quaternary Care Hospital in Munich, Germany",2021-01-03,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,,Munich,"Enrolment was performed on prespecified organizational units: 1st) Non-frontline HCWs (NF-HCWs), 2nd) Emergency Department (ED-HCWs), 3rd) Intensive Care and General Wards specifically dedicated to
care for non-COVID-19 (non-COVID-HCWs) and 4th) for COVID-19 patients (COVID-HCWs) (Figure 1). Participation in the study was voluntarily","HCWs who already seroconverted at the first visit, or those who terminated work contracts.",2020-03-24,2020-07-07,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Primary estimate,300,0.0467,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA,Liaison SARS-CoV-2 S1/S2 IgG,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,DiaSorin,Abbott Laboratories,Roche Diagnostics",Multiple Types,Serum,"['IgG', 'TotalAntibody']",,,,,['High'],No,No,No,Yes,Yes,Unclear,Yes,No,Yes,Tobias Weinberger,Ludwig Maximillian University of Munich,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1935,2021-01-23,2024-03-01,Verified,weinberger_prospective_2021,DEU
210122_Germany_HeidelbergUniversity_Children_Overall_unadj,210122_Germany_HeidelbergUniversity_Children,Prevalence of SARS-CoV-2 Infection in Children and Their Parents in Southwest Germany.,2021-01-22,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Baden-Württemberg,"Freiburg, Heidelberg, Tübingen, Ulm","Participants were eligible for enrollment if they met the fol- lowing inclusion criteria: (1) 1 child (male or female) aged 1 to 10 years, (2) 1 corresponding parent (male or female) without an age limit (the parents decided among themselves who would participate), (3) residency of the child and parent in the same household, (4) residency in the state of Baden-Württemberg, and (5) written consent to the study.","Key exclusion criteria were (1) severe congenital disease (eg, infantile cerebral palsy, severe congenital malformation), (2) congenital or acquired immunodeficiency, and (3) laboratory-confirmed SARS-CoV-2 infection in the child or participating parent before study enrollment.",2020-04-22,2020-05-15,Students and Daycares,All,Children and Youth (0-17 years),1.0,10.0,Primary Estimate,,2482,0.009000000000000001,,,True,,,,True,Self-referral,"Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N),Author designed (Luminex),Author designed (IFA) - Unknown","EUROIMMUN,Roche Diagnostics,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,0.996,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Burkhard Tonshoff,Heidelberg University,Not Unity-Aligned,https://dx.doi.org/10.1001/jamapediatrics.2021.0001,2021-02-19,2024-03-01,Verified,tonshoff_prevalence_2021,DEU
210122_Germany_HeidelbergUniversity_Children_Age1-5_unadj,210122_Germany_HeidelbergUniversity_Children,Prevalence of SARS-CoV-2 Infection in Children and Their Parents in Southwest Germany.,2021-01-22,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Baden-Württemberg,"Freiburg, Heidelberg, Tübingen, Ulm","Participants were eligible for enrollment if they met the fol- lowing inclusion criteria: (1) 1 child (male or female) aged 1 to 10 years, (2) 1 corresponding parent (male or female) without an age limit (the parents decided among themselves who would participate), (3) residency of the child and parent in the same household, (4) residency in the state of Baden-Württemberg, and (5) written consent to the study.","Key exclusion criteria were (1) severe congenital disease (eg, infantile cerebral palsy, severe congenital malformation), (2) congenital or acquired immunodeficiency, and (3) laboratory-confirmed SARS-CoV-2 infection in the child or participating parent before study enrollment.",2020-04-22,2020-05-15,Students and Daycares,All,Children and Youth (0-17 years),1.0,5.0,Age,1-5 years,1129,0.008,,,,,,,,Self-referral,"Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N),Author designed (Luminex),Author designed (IFA) - Unknown","EUROIMMUN,Roche Diagnostics,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,0.996,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Burkhard Tonshoff,Heidelberg University,Not Unity-Aligned,https://dx.doi.org/10.1001/jamapediatrics.2021.0001,2021-02-19,2024-03-01,Verified,tonshoff_prevalence_2021,DEU
210122_Germany_HeidelbergUniversity_Children_Age6-10_unadj,210122_Germany_HeidelbergUniversity_Children,Prevalence of SARS-CoV-2 Infection in Children and Their Parents in Southwest Germany.,2021-01-22,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Baden-Württemberg,"Freiburg, Heidelberg, Tübingen, Ulm","Participants were eligible for enrollment if they met the fol- lowing inclusion criteria: (1) 1 child (male or female) aged 1 to 10 years, (2) 1 corresponding parent (male or female) without an age limit (the parents decided among themselves who would participate), (3) residency of the child and parent in the same household, (4) residency in the state of Baden-Württemberg, and (5) written consent to the study.","Key exclusion criteria were (1) severe congenital disease (eg, infantile cerebral palsy, severe congenital malformation), (2) congenital or acquired immunodeficiency, and (3) laboratory-confirmed SARS-CoV-2 infection in the child or participating parent before study enrollment.",2020-04-22,2020-05-15,Students and Daycares,All,Children and Youth (0-17 years),6.0,10.0,Age,6-10 years,1353,0.01,,,,,,,,Self-referral,"Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N),Author designed (Luminex),Author designed (IFA) - Unknown","EUROIMMUN,Roche Diagnostics,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,0.996,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Burkhard Tonshoff,Heidelberg University,Not Unity-Aligned,https://dx.doi.org/10.1001/jamapediatrics.2021.0001,2021-02-19,2024-03-01,Verified,tonshoff_prevalence_2021,DEU
210122_Germany_HeidelbergUniversity_Parents_Overall_unadj,210122_Germany_HeidelbergUniversity_parents,Prevalence of SARS-CoV-2 Infection in Children and Their Parents in Southwest Germany.,2021-01-22,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Baden-Württemberg,"Freiburg, Heidelberg, Tübingen, Ulm","Participants were eligible for enrollment if they met the fol- lowing inclusion criteria: (1) 1 child (male or female) aged 1 to 10 years, (2) 1 corresponding parent (male or female) without an age limit (the parents decided among themselves who would participate), (3) residency of the child and parent in the same household, (4) residency in the state of Baden-Württemberg, and (5) written consent to the study.","Key exclusion criteria were (1) severe congenital disease (eg, infantile cerebral palsy, severe congenital malformation), (2) congenital or acquired immunodeficiency, and (3) laboratory-confirmed SARS-CoV-2 infection in the child or participating parent before study enrollment.",2020-04-22,2020-05-15,Household and community samples,All,Adults (18-64 years),23.0,66.0,Primary Estimate,,2482,0.019,,,True,,,,True,Self-referral,"Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N),Author designed (Luminex),Author designed (IFA) - Unknown","EUROIMMUN,Roche Diagnostics,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,0.996,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Burkhard Tonshoff,Heidelberg University,Not Unity-Aligned,https://dx.doi.org/10.1001/jamapediatrics.2021.0001,2021-02-19,2024-03-01,Verified,tonshoff_prevalence_2021,DEU
210129_Berlin_UniversitätsmedizinBerlin_HouseholdMembers_Overall,210129_Berlin_UniversitätsmedizinBerlin_HouseholdMembers,"SARS-CoV-2 infection and transmission in school settings during the second wave in Berlin, Germany: a cross-sectional study",2021-01-29,Preprint,Local,Repeated cross-sectional study,Germany,,Berlin,"Household membrs related to participating students or staff from each one class in 24 schools in Berlin, and related household members",,2020-11-02,2020-11-16,Household and community samples,All,Multiple groups,2.0,86.0,Primary Estimate,,576,0.013999999999999999,0.006,0.027000000000000003,True,,,,True,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['High'],Yes,Yes,No,Yes,Yes,Unclear,Yes,No,Unclear,Stefanie Theuring,Universitätsmedizin Berlin,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.01.27.21250517v1,2021-02-22,2022-07-16,Verified,theuring_sars-cov-2_2021,DEU
210129_Berlin_UniversitätsmedizinBerlin_Staff_Overall ,210129_Berlin_UniversitätsmedizinBerlin_Staff,"SARS-CoV-2 infection and transmission in school settings during the second wave in Berlin, Germany: a cross-sectional study",2021-01-29,Preprint,Local,Repeated cross-sectional study,Germany,,Berlin,"staff from each one class in 24 schools in Berlin, and related household members",,2020-11-02,2020-11-16,Essential non-healthcare workers,All,Adults (18-64 years),28.0,65.0,Primary Estimate,,141,0.013999999999999999,0.002,0.05,True,,,,True,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['High'],Yes,Yes,No,Yes,Yes,Unclear,Yes,No,Unclear,Stefanie Theuring,Universitätsmedizin Berlin,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.01.27.21250517v1,2021-02-22,2022-07-16,Verified,theuring_sars-cov-2_2021,DEU
210129_Berlin_UniversitätsmedizinBerlin_Students_Overall,210129_Berlin_UniversitätsmedizinBerlin_Students,"SARS-CoV-2 infection and transmission in school settings during the second wave in Berlin, Germany: a cross-sectional study",2021-01-29,Preprint,Local,Repeated cross-sectional study,Germany,,Berlin,"students from each one class in 24 schools in Berlin, and related household members",,2020-11-02,2020-11-16,Students and Daycares,All,Children and Youth (0-17 years),9.0,18.0,Primary Estimate,,347,0.02,0.008,0.040999999999999995,True,,,,True,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['High'],Yes,Yes,No,No,Yes,Unclear,Yes,No,Unclear,Stefanie Theuring,Universitätsmedizin Berlin,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.01.27.21250517v1,2021-02-22,2022-07-16,Verified,theuring_sars-cov-2_2021,DEU
210129_Eschweiler_St.AntoniusHospitalEschweiler_IgG,210129_Eschweiler_St.AntoniusHospitalEschweiler,"[Prevalence of SARS-CoV-2 in employees of a general hospital in Northrhine-Westphalia, Germany]",2021-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,North Rhine-Westphalia,Eschweiler,all employees of the St. Antonius Hospital Eschweiler from all areas were invited to participate in the context of preventive occupational health care.,There were no exclusion criteria,2020-04-27,2020-05-20,Health care workers and caregivers,All,Multiple groups,17.0,74.0,Primary Estimate,IgG,1212,0.033,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9440000000000001,0.996,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Martin Platten,St. Antonius Hospital Eschweiler,Not Unity-Aligned,https://dx.doi.org/10.1055/a-1322-5355,2021-02-14,2024-03-01,Verified,platten_pravalenz_2021,DEU
210203_HeinsbergDistrict_UniversityHospitalDusseldorf_NeutralizationAssay,210203_HeinsbergDistrict_UniversityHospitalDusseldorf,Sensitivity of anti-SARS-CoV-2 serological assays in a high-prevalence setting,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,,,Contacts of the superspreader,,2020-04-09,2020-04-09,Contacts of COVID patients,All,Multiple groups,18.0,70.0,Primary Estimate,Test used: in-house neutralization assay,42,0.619,,,True,,,,True,Convenience,Author designed (Neutralization Assay),,Neutralization,Serum,"['IgA', 'IgG']",Spike,,,,['High'],No,No,No,Yes,No,Unclear,Yes,No,,Lisa Muller,University Hospital Dusseldorf,Not Unity-Aligned,https://dx.doi.org/10.1007/s10096-021-04169-7,2021-04-09,2022-07-16,Verified,muller_sensitivity_2021,DEU
210203_Dusseldorf_InstituteOfMedicalSociology_overall_TestAdj,210203_Dusseldorf_InstituteOfMedicalSociology_SERODUSI,Seroprevalence COVID-19 Düsseldorf: SERODUS I & II,2021-02-03,Institutional Report,Local,Cross-sectional survey ,Germany,,Düsseldorf,"Main residence in Düsseldorf
- 18-30 years old
- Person is able to take part in the questioning and to
to participate in the investigation
- Knowledge of German, English, Turkish
or the Arabic language","Acute COVID-19 illness or equivalent
Symptoms (e.g. fever, cough)
- Unprotected contact with a COVID-19
Patients in the last 14 days and none of their own
negative COVID-19 test (i.e. PCR detection of
Virus DNA negative in revenge / nasal swab)
- Presence of coagulation diseases
- Person is unable to provide a written,
to give informed consent.
- Other reasons (e.g. not able to travel) related to this
lead that participation in survey and
Investigation is not possible",2020-11-02,2020-11-23,Household and community samples,All,Adults (18-64 years),18.0,30.0,Primary Estimate,,2186,0.031000000000000003,0.024,0.04,True,True,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.998,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Insa Backhaus,Institute Of Medical Sociology,Not Unity-Aligned,https://www.uniklinik-duesseldorf.de/patienten-besucher/klinikeninstitutezentren/institut-fuer-medizinische-soziologie/das-institut/forschung/serodus,2021-03-09,2023-07-04,Verified,backhaus_seropravalenz_2021,DEU
210203_Dusseldorf_InstituteOfMedicalSociology_Male,210203_Dusseldorf_InstituteOfMedicalSociology_SERODUSI,Seroprevalence COVID-19 Düsseldorf: SERODUS I & II,2021-02-03,Institutional Report,Local,Cross-sectional survey ,Germany,,Düsseldorf,"Main residence in Düsseldorf
- 18-30 years old
- Person is able to take part in the questioning and to
to participate in the investigation
- Knowledge of German, English, Turkish
or the Arabic language","Acute COVID-19 illness or equivalent
Symptoms (e.g. fever, cough)
- Unprotected contact with a COVID-19
Patients in the last 14 days and none of their own
negative COVID-19 test (i.e. PCR detection of
Virus DNA negative in revenge / nasal swab)
- Presence of coagulation diseases
- Person is unable to provide a written,
to give informed consent.
- Other reasons (e.g. not able to travel) related to this
lead that participation in survey and
Investigation is not possible",2020-11-02,2020-11-23,Household and community samples,Male,Adults (18-64 years),18.0,30.0,Sex/Gender,,857,0.038,0.027000000000000003,0.053,,True,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.998,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Insa Backhaus,Institute Of Medical Sociology,Not Unity-Aligned,https://www.uniklinik-duesseldorf.de/patienten-besucher/klinikeninstitutezentren/institut-fuer-medizinische-soziologie/das-institut/forschung/serodus,2021-03-09,2023-07-04,Verified,backhaus_seropravalenz_2021,DEU
210203_Dusseldorf_InstituteOfMedicalSociology_Female,210203_Dusseldorf_InstituteOfMedicalSociology_SERODUSI,Seroprevalence COVID-19 Düsseldorf: SERODUS I & II,2021-02-03,Institutional Report,Local,Cross-sectional survey ,Germany,,Düsseldorf,"Main residence in Düsseldorf
- 18-30 years old
- Person is able to take part in the questioning and to
to participate in the investigation
- Knowledge of German, English, Turkish
or the Arabic language","Acute COVID-19 illness or equivalent
Symptoms (e.g. fever, cough)
- Unprotected contact with a COVID-19
Patients in the last 14 days and none of their own
negative COVID-19 test (i.e. PCR detection of
Virus DNA negative in revenge / nasal swab)
- Presence of coagulation diseases
- Person is unable to provide a written,
to give informed consent.
- Other reasons (e.g. not able to travel) related to this
lead that participation in survey and
Investigation is not possible",2020-11-02,2020-11-23,Household and community samples,Female,Adults (18-64 years),18.0,30.0,Sex/Gender,,1327,0.027000000000000003,0.019,0.037000000000000005,,True,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.998,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Insa Backhaus,Institute Of Medical Sociology,Not Unity-Aligned,https://www.uniklinik-duesseldorf.de/patienten-besucher/klinikeninstitutezentren/institut-fuer-medizinische-soziologie/das-institut/forschung/serodus,2021-03-09,2023-07-04,Verified,backhaus_seropravalenz_2021,DEU
210203_Dusseldorf_InstituteOfMedicalSociology_overall_Unadj,210203_Dusseldorf_InstituteOfMedicalSociology_SERODUSI,Seroprevalence COVID-19 Düsseldorf: SERODUS I & II,2021-02-03,Institutional Report,Local,Cross-sectional survey ,Germany,,Düsseldorf,"Main residence in Düsseldorf
- 18-30 years old
- Person is able to take part in the questioning and to
to participate in the investigation
- Knowledge of German, English, Turkish
or the Arabic language","Acute COVID-19 illness or equivalent
Symptoms (e.g. fever, cough)
- Unprotected contact with a COVID-19
Patients in the last 14 days and none of their own
negative COVID-19 test (i.e. PCR detection of
Virus DNA negative in revenge / nasal swab)
- Presence of coagulation diseases
- Person is unable to provide a written,
to give informed consent.
- Other reasons (e.g. not able to travel) related to this
lead that participation in survey and
Investigation is not possible",2020-11-02,2020-11-23,Household and community samples,All,Adults (18-64 years),18.0,30.0,Analysis,,2186,0.033,0.026000000000000002,0.040999999999999995,,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.998,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Insa Backhaus,Institute Of Medical Sociology,Not Unity-Aligned,https://www.uniklinik-duesseldorf.de/patienten-besucher/klinikeninstitutezentren/institut-fuer-medizinische-soziologie/das-institut/forschung/serodus,2021-03-09,2024-03-01,Verified,backhaus_seropravalenz_2021,DEU
210203_Dusseldorf_InstituteOfMedicalSociology_age20-29,210203_Dusseldorf_InstituteOfMedicalSociology_SERODUSI,Seroprevalence COVID-19 Düsseldorf: SERODUS I & II,2021-02-03,Institutional Report,Local,Cross-sectional survey ,Germany,,Düsseldorf,"Main residence in Düsseldorf
- 18-30 years old
- Person is able to take part in the questioning and to
to participate in the investigation
- Knowledge of German, English, Turkish
or the Arabic language","Acute COVID-19 illness or equivalent
Symptoms (e.g. fever, cough)
- Unprotected contact with a COVID-19
Patients in the last 14 days and none of their own
negative COVID-19 test (i.e. PCR detection of
Virus DNA negative in revenge / nasal swab)
- Presence of coagulation diseases
- Person is unable to provide a written,
to give informed consent.
- Other reasons (e.g. not able to travel) related to this
lead that participation in survey and
Investigation is not possible",2020-11-02,2020-11-23,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,age 20-29,1737,0.034,0.023,0.049,,True,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.998,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Insa Backhaus,Institute Of Medical Sociology,Not Unity-Aligned,https://www.uniklinik-duesseldorf.de/patienten-besucher/klinikeninstitutezentren/institut-fuer-medizinische-soziologie/das-institut/forschung/serodus,2021-03-09,2023-07-04,Verified,backhaus_seropravalenz_2021,DEU
210203_Dusseldorf_InstituteOfMedicalSociology_age<20,210203_Dusseldorf_InstituteOfMedicalSociology_SERODUSI,Seroprevalence COVID-19 Düsseldorf: SERODUS I & II,2021-02-03,Institutional Report,Local,Cross-sectional survey ,Germany,,Düsseldorf,"Main residence in Düsseldorf
- 18-30 years old
- Person is able to take part in the questioning and to
to participate in the investigation
- Knowledge of German, English, Turkish
or the Arabic language","Acute COVID-19 illness or equivalent
Symptoms (e.g. fever, cough)
- Unprotected contact with a COVID-19
Patients in the last 14 days and none of their own
negative COVID-19 test (i.e. PCR detection of
Virus DNA negative in revenge / nasal swab)
- Presence of coagulation diseases
- Person is unable to provide a written,
to give informed consent.
- Other reasons (e.g. not able to travel) related to this
lead that participation in survey and
Investigation is not possible",2020-11-02,2020-11-23,Household and community samples,All,Adults (18-64 years),18.0,19.0,Age,age <20,139,0.027000000000000003,0.009000000000000001,0.07,,True,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.998,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Insa Backhaus,Institute Of Medical Sociology,Not Unity-Aligned,https://www.uniklinik-duesseldorf.de/patienten-besucher/klinikeninstitutezentren/institut-fuer-medizinische-soziologie/das-institut/forschung/serodus,2021-03-09,2023-07-04,Verified,backhaus_seropravalenz_2021,DEU
210203_Dusseldorf_InstituteOfMedicalSociology_age30-39,210203_Dusseldorf_InstituteOfMedicalSociology_SERODUSI,Seroprevalence COVID-19 Düsseldorf: SERODUS I & II,2021-02-03,Institutional Report,Local,Cross-sectional survey ,Germany,,Düsseldorf,"Main residence in Düsseldorf
- 18-30 years old
- Person is able to take part in the questioning and to
to participate in the investigation
- Knowledge of German, English, Turkish
or the Arabic language","Acute COVID-19 illness or equivalent
Symptoms (e.g. fever, cough)
- Unprotected contact with a COVID-19
Patients in the last 14 days and none of their own
negative COVID-19 test (i.e. PCR detection of
Virus DNA negative in revenge / nasal swab)
- Presence of coagulation diseases
- Person is unable to provide a written,
to give informed consent.
- Other reasons (e.g. not able to travel) related to this
lead that participation in survey and
Investigation is not possible",2020-11-02,2020-11-23,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,age 26-30,294,0.028999999999999998,0.02,0.04,,True,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.998,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Insa Backhaus,Institute Of Medical Sociology,Not Unity-Aligned,https://www.uniklinik-duesseldorf.de/patienten-besucher/klinikeninstitutezentren/institut-fuer-medizinische-soziologie/das-institut/forschung/serodus,2021-03-09,2023-07-04,Verified,backhaus_seropravalenz_2021,DEU
210203_Dusseldorf_InstituteOfMedicalSociology_SERODUSII_overall_TestAdj,210203_Dusseldorf_InstituteOfMedicalSociology_SERODUSII,Seroprevalence COVID-19 Düsseldorf: SERODUS I & II,2021-02-03,Institutional Report,Local,Cross-sectional survey ,Germany,,Düsseldorf,"≥ 18 years
- Members of the Düsseldorf fire brigade
- Person is able to participate in the interview and
to participate in the investigation
- Knowledge of German, English,
Turkish, or the Arabic language","Acute COVID-19 illness or equivalent
Symptoms (e.g. fever, cough)
- Unprotected contact with a COVID-19
Patients in the last 14 days and none of their own
negative COVID-19 test (i.e. PCR detection of
Virus DNA negative in revenge / nasal swab)
- Presence of coagulation diseases
- Person is incapable of writing
to give informed consent
- Other reasons (e.g. not able to travel) related to this
lead that participation in survey and
Investigation is not possible",2020-11-23,2020-11-27,Essential non-healthcare workers,All,Adults (18-64 years),18.0,65.0,Primary Estimate,,745,0.044000000000000004,0.031000000000000003,0.062000000000000006,True,True,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Insa Backhaus,Institute Of Medical Sociology,Not Unity-Aligned,https://www.uniklinik-duesseldorf.de/patienten-besucher/klinikeninstitutezentren/institut-fuer-medizinische-soziologie/das-institut/forschung/serodus,2021-03-09,2023-07-04,Verified,backhaus_seropravalenz_2021,DEU
210203_Dusseldorf_InstituteOfMedicalSociology_SERODUSII_age<20,210203_Dusseldorf_InstituteOfMedicalSociology_SERODUSII,Seroprevalence COVID-19 Düsseldorf: SERODUS I & II,2021-02-03,Institutional Report,Local,Cross-sectional survey ,Germany,,Düsseldorf,"≥ 18 years
- Members of the Düsseldorf fire brigade
- Person is able to participate in the interview and
to participate in the investigation
- Knowledge of German, English,
Turkish, or the Arabic language","Acute COVID-19 illness or equivalent
Symptoms (e.g. fever, cough)
- Unprotected contact with a COVID-19
Patients in the last 14 days and none of their own
negative COVID-19 test (i.e. PCR detection of
Virus DNA negative in revenge / nasal swab)
- Presence of coagulation diseases
- Person is incapable of writing
to give informed consent
- Other reasons (e.g. not able to travel) related to this
lead that participation in survey and
Investigation is not possible",2020-11-23,2020-11-27,Essential non-healthcare workers,All,Adults (18-64 years),18.0,19.0,Age,,18,0.054000000000000006,0.004,0.257,,True,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Insa Backhaus,Institute Of Medical Sociology,Not Unity-Aligned,https://www.uniklinik-duesseldorf.de/patienten-besucher/klinikeninstitutezentren/institut-fuer-medizinische-soziologie/das-institut/forschung/serodus,2021-03-09,2023-07-04,Verified,backhaus_seropravalenz_2021,DEU
210203_Dusseldorf_InstituteOfMedicalSociology_SERODUSII_50-65,210203_Dusseldorf_InstituteOfMedicalSociology_SERODUSII,Seroprevalence COVID-19 Düsseldorf: SERODUS I & II,2021-02-03,Institutional Report,Local,Cross-sectional survey ,Germany,,Düsseldorf,"≥ 18 years
- Members of the Düsseldorf fire brigade
- Person is able to participate in the interview and
to participate in the investigation
- Knowledge of German, English,
Turkish, or the Arabic language","Acute COVID-19 illness or equivalent
Symptoms (e.g. fever, cough)
- Unprotected contact with a COVID-19
Patients in the last 14 days and none of their own
negative COVID-19 test (i.e. PCR detection of
Virus DNA negative in revenge / nasal swab)
- Presence of coagulation diseases
- Person is incapable of writing
to give informed consent
- Other reasons (e.g. not able to travel) related to this
lead that participation in survey and
Investigation is not possible",2020-11-23,2020-11-27,Essential non-healthcare workers,All,Adults (18-64 years),50.0,65.0,Age,,187,0.03,0.013000000000000001,0.067,,True,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Insa Backhaus,Institute Of Medical Sociology,Not Unity-Aligned,https://www.uniklinik-duesseldorf.de/patienten-besucher/klinikeninstitutezentren/institut-fuer-medizinische-soziologie/das-institut/forschung/serodus,2021-03-09,2023-07-04,Verified,backhaus_seropravalenz_2021,DEU
210203_Dusseldorf_InstituteOfMedicalSociology_SERODUSII_40-49,210203_Dusseldorf_InstituteOfMedicalSociology_SERODUSII,Seroprevalence COVID-19 Düsseldorf: SERODUS I & II,2021-02-03,Institutional Report,Local,Cross-sectional survey ,Germany,,Düsseldorf,"≥ 18 years
- Members of the Düsseldorf fire brigade
- Person is able to participate in the interview and
to participate in the investigation
- Knowledge of German, English,
Turkish, or the Arabic language","Acute COVID-19 illness or equivalent
Symptoms (e.g. fever, cough)
- Unprotected contact with a COVID-19
Patients in the last 14 days and none of their own
negative COVID-19 test (i.e. PCR detection of
Virus DNA negative in revenge / nasal swab)
- Presence of coagulation diseases
- Person is incapable of writing
to give informed consent
- Other reasons (e.g. not able to travel) related to this
lead that participation in survey and
Investigation is not possible",2020-11-23,2020-11-27,Essential non-healthcare workers,All,Adults (18-64 years),40.0,49.0,Age,,168,0.034,0.015,0.07400000000000001,,True,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Insa Backhaus,Institute Of Medical Sociology,Not Unity-Aligned,https://www.uniklinik-duesseldorf.de/patienten-besucher/klinikeninstitutezentren/institut-fuer-medizinische-soziologie/das-institut/forschung/serodus,2021-03-09,2023-07-04,Verified,backhaus_seropravalenz_2021,DEU
210203_Dusseldorf_InstituteOfMedicalSociology_SERODUSII_20-29,210203_Dusseldorf_InstituteOfMedicalSociology_SERODUSII,Seroprevalence COVID-19 Düsseldorf: SERODUS I & II,2021-02-03,Institutional Report,Local,Cross-sectional survey ,Germany,,Düsseldorf,"≥ 18 years
- Members of the Düsseldorf fire brigade
- Person is able to participate in the interview and
to participate in the investigation
- Knowledge of German, English,
Turkish, or the Arabic language","Acute COVID-19 illness or equivalent
Symptoms (e.g. fever, cough)
- Unprotected contact with a COVID-19
Patients in the last 14 days and none of their own
negative COVID-19 test (i.e. PCR detection of
Virus DNA negative in revenge / nasal swab)
- Presence of coagulation diseases
- Person is incapable of writing
to give informed consent
- Other reasons (e.g. not able to travel) related to this
lead that participation in survey and
Investigation is not possible",2020-11-23,2020-11-27,Essential non-healthcare workers,All,Adults (18-64 years),20.0,29.0,Age,,146,0.07400000000000001,0.040999999999999995,0.129,,True,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Insa Backhaus,Institute Of Medical Sociology,Not Unity-Aligned,https://www.uniklinik-duesseldorf.de/patienten-besucher/klinikeninstitutezentren/institut-fuer-medizinische-soziologie/das-institut/forschung/serodus,2021-03-09,2023-07-04,Verified,backhaus_seropravalenz_2021,DEU
210203_Dusseldorf_InstituteOfMedicalSociology_SERODUSII_30-39,210203_Dusseldorf_InstituteOfMedicalSociology_SERODUSII,Seroprevalence COVID-19 Düsseldorf: SERODUS I & II,2021-02-03,Institutional Report,Local,Cross-sectional survey ,Germany,,Düsseldorf,"≥ 18 years
- Members of the Düsseldorf fire brigade
- Person is able to participate in the interview and
to participate in the investigation
- Knowledge of German, English,
Turkish, or the Arabic language","Acute COVID-19 illness or equivalent
Symptoms (e.g. fever, cough)
- Unprotected contact with a COVID-19
Patients in the last 14 days and none of their own
negative COVID-19 test (i.e. PCR detection of
Virus DNA negative in revenge / nasal swab)
- Presence of coagulation diseases
- Person is incapable of writing
to give informed consent
- Other reasons (e.g. not able to travel) related to this
lead that participation in survey and
Investigation is not possible",2020-11-23,2020-11-27,Essential non-healthcare workers,All,Adults (18-64 years),30.0,39.0,Age,,211,0.040999999999999995,0.021,0.078,,True,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Insa Backhaus,Institute Of Medical Sociology,Not Unity-Aligned,https://www.uniklinik-duesseldorf.de/patienten-besucher/klinikeninstitutezentren/institut-fuer-medizinische-soziologie/das-institut/forschung/serodus,2021-03-09,2023-07-04,Verified,backhaus_seropravalenz_2021,DEU
210212_Bavaria_ GermanResearchCenterForEnvironmentalHealth_Children_overall,210212_Bavaria_ GermanResearchCenterForEnvironmentalHealth_Children,A Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than Reported Cases in Children,2021-02-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Bavaria,,"Biobanked blood samples obtained between Jan 2020 and July 2020 from children participating in Fr1da, a public health research study in Bavaria, Germany that offers screening for type 1 diabetes-associated autoantibodies to children without a previous diagnosis of diabetes in the context of Well-Child Care visits",,2020-01-01,2020-07-31,Residual sera,All,Children and Youth (0-17 years),0.0,18.0,Primary Estimate,,11884,0.0069,,,True,,,,True,Convenience,Author designed (CLIA),,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.973,1.0,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Markus Hippich, German Research Center for Environmental Health,Unity-Aligned,https://www.cell.com/med/fulltext/S2666-6340(20)30020-9?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2666634020300209%3Fshowall%3Dtrue,2021-03-18,2022-07-16,Verified,hippich_public_2021,DEU
210212_Bavaria_ GermanResearchCenterForEnvironmentalHealth_Children_March,210212_Bavaria_ GermanResearchCenterForEnvironmentalHealth_Children,A Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than Reported Cases in Children,2021-02-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Bavaria,,"Biobanked blood samples obtained between Jan 2020 and July 2020 from children participating in Fr1da, a public health research study in Bavaria, Germany that offers screening for type 1 diabetes-associated autoantibodies to children without a previous diagnosis of diabetes in the context of Well-Child Care visits",,2020-03-01,2020-03-31,Residual sera,All,Children and Youth (0-17 years),0.0,18.0,Time frame,March 2020,1099,0.0009,,,,,,,,Convenience,Author designed (CLIA),,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.973,1.0,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Markus Hippich, German Research Center for Environmental Health,Unity-Aligned,https://www.cell.com/med/fulltext/S2666-6340(20)30020-9?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2666634020300209%3Fshowall%3Dtrue,2021-07-01,2022-07-16,Verified,hippich_public_2021,DEU
210212_Bavaria_ GermanResearchCenterForEnvironmentalHealth_Children_July,210212_Bavaria_ GermanResearchCenterForEnvironmentalHealth_Children,A Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than Reported Cases in Children,2021-02-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Bavaria,,"Biobanked blood samples obtained between Jan 2020 and July 2020 from children participating in Fr1da, a public health research study in Bavaria, Germany that offers screening for type 1 diabetes-associated autoantibodies to children without a previous diagnosis of diabetes in the context of Well-Child Care visits",,2020-07-01,2020-07-31,Residual sera,All,Children and Youth (0-17 years),0.0,18.0,Time frame,July 2020,2746,0.0091,,,,,,,,Convenience,Author designed (CLIA),,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.973,1.0,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Markus Hippich, German Research Center for Environmental Health,Unity-Aligned,https://www.cell.com/med/fulltext/S2666-6340(20)30020-9?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2666634020300209%3Fshowall%3Dtrue,2021-07-01,2022-07-16,Verified,hippich_public_2021,DEU
210212_Bavaria_ GermanResearchCenterForEnvironmentalHealth_Children_overall_RBDOnly,210212_Bavaria_ GermanResearchCenterForEnvironmentalHealth_Children,A Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than Reported Cases in Children,2021-02-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Bavaria,,"Biobanked blood samples obtained between Jan 2020 and July 2020 from children participating in Fr1da, a public health research study in Bavaria, Germany that offers screening for type 1 diabetes-associated autoantibodies to children without a previous diagnosis of diabetes in the context of Well-Child Care visits",,2020-01-01,2020-07-31,Residual sera,All,Children and Youth (0-17 years),0.0,18.0,Test used,Results for the anti-RBD screening only,11884,0.0146,,,,,,,,Convenience,Author designed (CLIA),,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9867,0.9932,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Markus Hippich, German Research Center for Environmental Health,Unity-Aligned,https://www.cell.com/med/fulltext/S2666-6340(20)30020-9?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2666634020300209%3Fshowall%3Dtrue,2021-03-18,2022-07-16,Verified,hippich_public_2021,DEU
210212_Bavaria_ GermanResearchCenterForEnvironmentalHealth_Children_February,210212_Bavaria_ GermanResearchCenterForEnvironmentalHealth_Children,A Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than Reported Cases in Children,2021-02-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Bavaria,,"Biobanked blood samples obtained between Jan 2020 and July 2020 from children participating in Fr1da, a public health research study in Bavaria, Germany that offers screening for type 1 diabetes-associated autoantibodies to children without a previous diagnosis of diabetes in the context of Well-Child Care visits",,2020-02-01,2020-02-29,Residual sera,All,Children and Youth (0-17 years),0.0,18.0,Time frame,February 2020,1026,0.0,,,,,,,,Convenience,Author designed (CLIA),,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.973,1.0,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Markus Hippich, German Research Center for Environmental Health,Unity-Aligned,https://www.cell.com/med/fulltext/S2666-6340(20)30020-9?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2666634020300209%3Fshowall%3Dtrue,2021-07-01,2022-07-16,Verified,hippich_public_2021,DEU
210212_Bavaria_ GermanResearchCenterForEnvironmentalHealth_Children_May,210212_Bavaria_ GermanResearchCenterForEnvironmentalHealth_Children,A Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than Reported Cases in Children,2021-02-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Bavaria,,"Biobanked blood samples obtained between Jan 2020 and July 2020 from children participating in Fr1da, a public health research study in Bavaria, Germany that offers screening for type 1 diabetes-associated autoantibodies to children without a previous diagnosis of diabetes in the context of Well-Child Care visits",,2020-05-01,2020-05-31,Residual sera,All,Children and Youth (0-17 years),0.0,18.0,Time frame,May 2020,2822,0.0074,,,,,,,,Convenience,Author designed (CLIA),,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.973,1.0,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Markus Hippich, German Research Center for Environmental Health,Unity-Aligned,https://www.cell.com/med/fulltext/S2666-6340(20)30020-9?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2666634020300209%3Fshowall%3Dtrue,2021-07-01,2022-07-16,Verified,hippich_public_2021,DEU
210212_Bavaria_ GermanResearchCenterForEnvironmentalHealth_Children_April,210212_Bavaria_ GermanResearchCenterForEnvironmentalHealth_Children,A Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than Reported Cases in Children,2021-02-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Bavaria,,"Biobanked blood samples obtained between Jan 2020 and July 2020 from children participating in Fr1da, a public health research study in Bavaria, Germany that offers screening for type 1 diabetes-associated autoantibodies to children without a previous diagnosis of diabetes in the context of Well-Child Care visits",,2020-04-01,2020-04-30,Residual sera,All,Children and Youth (0-17 years),0.0,18.0,Time frame,April 2020,1472,0.0061,,,,,,,,Convenience,Author designed (CLIA),,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.973,1.0,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Markus Hippich, German Research Center for Environmental Health,Unity-Aligned,https://www.cell.com/med/fulltext/S2666-6340(20)30020-9?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2666634020300209%3Fshowall%3Dtrue,2021-07-01,2022-07-16,Verified,hippich_public_2021,DEU
210212_Bavaria_ GermanResearchCenterForEnvironmentalHealth_Children_June,210212_Bavaria_ GermanResearchCenterForEnvironmentalHealth_Children,A Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than Reported Cases in Children,2021-02-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Bavaria,,"Biobanked blood samples obtained between Jan 2020 and July 2020 from children participating in Fr1da, a public health research study in Bavaria, Germany that offers screening for type 1 diabetes-associated autoantibodies to children without a previous diagnosis of diabetes in the context of Well-Child Care visits",,2020-06-01,2020-06-30,Residual sera,All,Children and Youth (0-17 years),0.0,18.0,Time frame,June 2020,2206,0.0113,,,,,,,,Convenience,Author designed (CLIA),,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.973,1.0,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Markus Hippich, German Research Center for Environmental Health,Unity-Aligned,https://www.cell.com/med/fulltext/S2666-6340(20)30020-9?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2666634020300209%3Fshowall%3Dtrue,2021-07-01,2022-07-16,Verified,hippich_public_2021,DEU
210212_Bavaria_ GermanResearchCenterForEnvironmentalHealth_Children_January,210212_Bavaria_ GermanResearchCenterForEnvironmentalHealth_Children,A Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than Reported Cases in Children,2021-02-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Bavaria,,"Biobanked blood samples obtained between Jan 2020 and July 2020 from children participating in Fr1da, a public health research study in Bavaria, Germany that offers screening for type 1 diabetes-associated autoantibodies to children without a previous diagnosis of diabetes in the context of Well-Child Care visits",,2020-01-01,2020-01-31,Residual sera,All,Children and Youth (0-17 years),0.0,18.0,Time frame,January 2020,513,0.0019,,,,,,,,Convenience,Author designed (CLIA),,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.973,1.0,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Markus Hippich, German Research Center for Environmental Health,Unity-Aligned,https://www.cell.com/med/fulltext/S2666-6340(20)30020-9?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2666634020300209%3Fshowall%3Dtrue,2021-07-01,2022-07-16,Verified,hippich_public_2021,DEU
210212_Bavaria_ GermanResearchCenterForEnvironmentalHealth_Newborns_overall,210212_Bavaria_ GermanResearchCenterForEnvironmentalHealth_Newborns,A Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than Reported Cases in Children,2021-02-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Bavaria,,"Biobanked dried blood spot samples from April to June 2020 from newborns enrolled in the Freder1k study, which offers screening for increased genetic risk of type 1 diabetes as a path for enrollment into primary prevention trials among children in Bavaria, Germany",,2020-04-01,2020-06-30,Pregnant or parturient women,All,Adults (18-64 years),,,Primary Estimate,,1916,0.0047,,,True,,,,True,Convenience,Author designed (ELISA) - MULTIPLEXED,,Other,Dried Blood,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.973,1.0,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,,Markus Hippich, German Research Center for Environmental Health,Not Unity-Aligned,https://www.cell.com/med/fulltext/S2666-6340(20)30020-9?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2666634020300209%3Fshowall%3Dtrue,2021-03-18,2022-07-16,Verified,hippich_public_2021,DEU
210212_Bavaria_ GermanResearchCenterForEnvironmentalHealth_Newborns_overall_RBDOnly,210212_Bavaria_ GermanResearchCenterForEnvironmentalHealth_Newborns,A Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than Reported Cases in Children,2021-02-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Bavaria,,"Biobanked dried blood spot samples from April to June 2020 from newborns enrolled in the Freder1k study, which offers screening for increased genetic risk of type 1 diabetes as a path for enrollment into primary prevention trials among children in Bavaria, Germany",,2020-04-01,2020-06-30,Pregnant or parturient women,All,Adults (18-64 years),,,Test used,Results for the anti-RBD screening only,1916,0.0151,,,,,,,,Convenience,Author designed (ELISA) - MULTIPLEXED,,Other,Dried Blood,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9867,0.9932,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,,Markus Hippich, German Research Center for Environmental Health,Not Unity-Aligned,https://www.cell.com/med/fulltext/S2666-6340(20)30020-9?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2666634020300209%3Fshowall%3Dtrue,2021-03-18,2022-07-16,Verified,hippich_public_2021,DEU
210217_Berlin-Mitte_RobertKochInstit_ELISA_testadj_popadj,210217_Berlin-Mitte_RobertKochInstitut,"Corona monitoring locally -
  Key data for Berlin-Mitte",2021-02-17,News and Media,Local,Cross-sectional survey ,Germany,Berlin,Berlin-Mitte,"if they are 18 years or older, are registered residents of one of the four study municipalities, can provide written consent to participate in the study, or, where necessary, written consent is provided by a legal representative, are able to take part in the interviews (where necessary with the help of relatives) and the examinations at the",People who lack the necessary German language skills or where it is unclear whether they understand the study information leaflets or the consent forms are excluded from participating,2020-11-17,2020-12-05,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2287,0.044000000000000004,,,True,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,,,,,['Low'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Yes,Robert Koch Institut,Robert Koch Institut,Unity-Aligned,https://www.rki.de/DE/Content/Gesundheitsmonitoring/Studien/cml-studie/Factsheet_Berlin-Mitte.html,2021-05-18,2023-08-15,Verified,robert_koch_institut_rki_2021,DEU
210217_Berlin-Mitte_RobertKochInstit_ELISA/Neut_popadj,210217_Berlin-Mitte_RobertKochInstitut,"Corona monitoring locally -
  Key data for Berlin-Mitte",2021-02-17,News and Media,Local,Cross-sectional survey ,Germany,Berlin,Berlin-Mitte,"if they are 18 years or older, are registered residents of one of the four study municipalities, can provide written consent to participate in the study, or, where necessary, written consent is provided by a legal representative, are able to take part in the interviews (where necessary with the help of relatives) and the examinations at the",People who lack the necessary German language skills or where it is unclear whether they understand the study information leaflets or the consent forms are excluded from participating,2020-11-17,2020-12-05,Household and community samples,All,Multiple groups,18.0,,Test used,,2287,0.024,,,,True,True,,True,Simplified probability,"Anti-SARS-CoV-2 NCP ELISA (IgG),Author designed (Neutralization Assay)","EUROIMMUN,NA",Multiple Types,Serum,"['IgG', 'Neutralizing']",,,,,['Low'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Yes,Robert Koch Institut,Robert Koch Institut,Unity-Aligned,https://www.rki.de/DE/Content/Gesundheitsmonitoring/Studien/cml-studie/Factsheet_Berlin-Mitte.html,2021-05-18,2023-08-15,Verified,robert_koch_institut_rki_2021,DEU
210219_Jena_JenaUniversityHospital_Overall,210219_Jena_JenaUniversityHospital,"Prospective surveillance study in a 1,400-bed university hospital: COVID-19 exposure at home was the main risk factor for SARS-CoV-2 point seroprevalence among hospital staff",2021-02-19,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,Thuringia,Jena,"Being a contracted staff member of JUH, working in a predefined hospital area and willing to sign a written informed consent were the only inclusion criteria.","Individuals working outside these pre‐categorized risk areas (namely laboratory personal where at least a proportion deals with COVID‐19 related clinical specimens but has no patient contact), participating outside the planned study period or who did not provide a blood sample were excluded",2020-05-19,2020-06-19,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,660,0.027000000000000003,0.016,0.043,True,,,,True,Convenience,"EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit,Elecsys® Anti‐SARS‐CoV‐2 (N)","Epitope Diagnostics, Inc.,Roche Diagnostics",Multiple Types,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Christina Bahrs,Jena University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1111/tbed.14041,2021-03-13,2024-03-01,Verified,bahrs_prospective_2021,DEU
210223_Regensberg_HospitalStHedwigOfTheOrderOfStJohn_IgG+,210223_Regensberg_HospitalStHedwigOfTheOrderOfStJohn,Peripartal anti-SARS-CoV-2-IgA/IgG in asymptomatic pregnant women during regional SARS-CoV-2-outbreak,2021-02-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Bavaria,Regensberg,"all asymptomatic pregnant women who
presented themselves for childbirth or scheduled caesarean delivery
between 09.04.2020 and 30.04.2020 were screened for SARS-CoV-2 by determining IgA and IgG and included in the present analysis without any exclusion.",No exclusion,2020-04-09,2020-04-30,Pregnant or parturient women,Female,Adults (18-64 years),17.0,46.0,Primary Estimate,,151,0.02,,,True,,,,True,Sequential,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA",EUROIMMUN,ELISA,Multiple Types,IgG,Spike,,,,['High'],No,No,No,No,Yes,Yes,Yes,No,,Sebastian Hausler,Hospital St Hedwig of the Order of St John,Unity-Aligned,https://dx.doi.org/10.1515/jpm-2021-0001,2021-04-18,2024-03-01,Verified,hausler_peripartal_2021,DEU
210302_Dresden_TechnischeUniversitätDresden,210302_Dresden_TechnischeUniversitätDresden,Lower Household Transmission Rates of SARS-CoV-2 from Children Compared to Adults - Results from the FamilyCoviDD19-Study,2021-03-02,Preprint,Local,Cross-sectional survey ,Germany,Saxony,Dresden,"From June 2020 on, SARS-CoV-2-PCR-positive persons and their household members in Dresden, a city in
Saxony/Germany with approximately 557000 inhabitants, were invited via the local health department to
participate in the FamilyCoviDD19-study.",,2020-06-15,2021-01-15,Contacts of COVID patients,All,Multiple groups,,,Primary Estimate,Primary,248,0.34270000000000006,,,True,,,,True,Sequential,"Liaison SARS-CoV-2 S1/S2 IgG,Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG","DiaSorin,Abbott Laboratories,EUROIMMUN",Multiple Types,,IgG,Spike,,,,['High'],Yes,No,No,No,Unclear,Unclear,Yes,No,Unclear,Lukas Galow,Technische Universität Dresden,Not Unity-Aligned,10.2139/ssrn.3790443,2021-05-02,2024-03-01,Unverified,galow_lower_2021,DEU
210308_Berlin_UniversitatmedizinBerlin,210308_Berlin_UniversitatmedizinBerlin,"Sars-cov-2 infection, risk perception, behaviour and preventive measures at schools in berlin, germany, during the early post-lockdown phase: A cross-sectional study",2021-03-08,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Germany,,Berlin,,,2020-06-11,2020-06-19,Multiple populations,All,Multiple groups,8.0,65.0,Primary Estimate,School staff and students,527,0.013000000000000001,,,True,,,,True,Stratified non-probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,,,,,['High'],,No,No,No,,Yes,Yes,Yes,,Franziska Hommes,Universitatmedizin Berlin,Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph18052739,2021-05-11,2024-03-01,Unverified,hommes_sars-cov-2_2021,DEU
210310_Bavaria_BrandenburgMedicalSchoolTheodorFontane,210310_Bavaria_BrandenburgMedicalSchoolTheodorFontane,"Risk to Radiology Staff for Occupational COVID-19 Infection in a High-Risk and a Low-Risk Region in Germany: Lessons from the ""First Wave""",2021-03-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Bavaria,Wieden,Hospital personnel at two locations in Germany,,2020-07-17,2020-07-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1838,0.151,0.134,0.167,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,,,,['High'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Thomas Finkenzeller,Brandenburg Medical School Theodor Fontane,Not Unity-Aligned,https://dx.doi.org/10.1055/a-1393-6668,2021-04-16,2024-03-01,Verified,finkenzeller_risk_2021,DEU
210310_Brandenburg_BrandenburgMedicalSchoolTheodorFontane,210310_Brandenburg_BrandenburgMedicalSchoolTheodorFontane,"Risk to Radiology Staff for Occupational COVID-19 Infection in a High-Risk and a Low-Risk Region in Germany: Lessons from the ""First Wave""",2021-03-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Brandenburg,,Hospital personnel at two locations in Germany,,2020-07-17,2020-07-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,585,0.021,0.012,0.038,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA",EUROIMMUN,ELISA,Serum,"['IgA', 'IgG']",,,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,No,Unclear,Thomas Finkenzeller,Brandenburg Medical School Theodor Fontane,Not Unity-Aligned,https://dx.doi.org/10.1055/a-1393-6668,2021-04-16,2024-03-01,Verified,finkenzeller_risk_2021,DEU
210315_Thuringia_ThuringiaClinic_COVIDStaff_overall,210315_Thuringia_ThuringiaClinic_COVIDStaff,"Antibody titers and rapid antigen testing in elderly patients with SARS-CoV-2 pneumonia vs. staff of ICU and ""Covid-19"" wards.",2021-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Thuringia,Saalfeld/Saale,"COVID-19 doctors, nurses and cleaning personnel at Thuringia Clinic",,2020-10-01,2020-10-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Overall COVID staff,18,0.055999999999999994,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,,Validated by manufacturers,,0.985,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Jorg Epstude,Thuringia Clinic,Not Unity-Aligned,https://dx.doi.org/10.3205/dgkh000382,2021-05-14,2024-03-01,Verified,epstude_antibody_2021,DEU
210315_Thuringia_ThuringiaClinic_ICU_Overall,210315_Thuringia_ThuringiaClinic_ICU,"Antibody titers and rapid antigen testing in elderly patients with SARS-CoV-2 pneumonia vs. staff of ICU and ""Covid-19"" wards.",2021-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Thuringia,Saalfeld/Saale,"ICU doctors, nurses and cleaning personnel at Thuringia Clinic",,2020-10-01,2020-10-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Overall ICU staff,50,0.0,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA",EUROIMMUN,ELISA,Serum,"['IgA', 'IgG']",,Validated by manufacturers,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,No,Unclear,Jorg Epstude,Thuringia Clinic,Not Unity-Aligned,https://dx.doi.org/10.3205/dgkh000382,2021-05-14,2024-03-01,Verified,epstude_antibody_2021,DEU
210317_Bavaria_LudwigMaximiliansUniversityMunich_Overall,210317_Bavaria_LudwigMaximiliansUniversityMunich,[Pandemic management in a psychiatric care hospital : SARS-CoV-2 antibody tests as a tool for risk estimation].,2021-03-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Bavaria,Wasserburg,The immunoassay test procedure was offered to all asymptomatic employees in a one-step approach,,2020-05-15,2020-06-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,HCWs overall,1342,0.08800000000000001,,,True,,,,True,Convenience,Not reported/ Unable to specify,,CLIA,Serum,TotalAntibody,,Validated by manufacturers,1.0,0.998,['High'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,Yes,M Rentrop,Ludwig Maximilians University Munich,Not Unity-Aligned,https://dx.doi.org/10.1007/s00115-021-01101-4,2021-05-17,2022-07-16,Verified,rentrop_pandemiemanagement_2021,DEU
210220_Dresden_DresdenUniversityOfTechnology_December,210220_Dresden_DresdenUniversityOfTechnology_December,SARS-CoV-2 transmissions in students and teachers: Seroprevalence follow-up study in a German secondary school in November and December 2020,2021-03-24,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,Saxony,Dresden,,,2020-12-10,2020-12-11,Students and Daycares,All,Multiple groups,14.0,57.0,Primary Estimate,,237,0.068,0.038,0.10099999999999999,True,,,,True,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG","DiaSorin,Abbott Laboratories,EUROIMMUN",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Jakob Armann,Dresden University of Technology ,Not Unity-Aligned,http://dx.doi.org/10.1136/bmjpo-2021-001036,2021-05-17,2024-03-01,Unverified,armann_sars-cov-2_2021,DEU
210220_Dresden_DresdenUniversityOfTechnology_November,210220_Dresden_DresdenUniversityOfTechnology_November,SARS-CoV-2 transmissions in students and teachers: Seroprevalence follow-up study in a German secondary school in November and December 2020,2021-03-24,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,Saxony,Dresden,,,2020-11-03,2020-11-06,Students and Daycares,All,Multiple groups,14.0,56.0,Primary Estimate,,302,0.017,0.003,0.033,True,,,,True,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG","DiaSorin,Abbott Laboratories,EUROIMMUN",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Jakob Armann,Dresden University of Technology ,Not Unity-Aligned,http://dx.doi.org/10.1136/bmjpo-2021-001036,2021-05-17,2024-03-01,Unverified,armann_sars-cov-2_2021,DEU
210330_Munich_UniversityHospitalLMUMunich_TestAdj,210330_Munich_UniversityHospitalLMUMunich,Prevalence and Risk Factors of Infection in the Representative COVID-19 Cohort Munich,2021-03-30,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Germany,Bavaria,Munich,14 years or older. ,,2020-04-05,2020-06-12,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,Most adjusted estimate,5313,0.0182,0.0128,0.023700000000000002,True,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.886,0.9972,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Michael Pritsch,University Hospital LMU Munich,Unity-Aligned,https://dx.doi.org/10.3390/ijerph18073572,2021-05-23,2023-08-15,Verified,pritsch_prevalence_2021,DEU
210330_Munich_UniversityHospitalLMUMunich_PopAdj,210330_Munich_UniversityHospitalLMUMunich,Prevalence and Risk Factors of Infection in the Representative COVID-19 Cohort Munich,2021-03-30,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Germany,Bavaria,Munich,14 years or older. ,,2020-04-05,2020-06-12,Household and community samples,All,Multiple groups,0.0,,Analysis,,5313,0.0189,0.0141,0.023700000000000002,,,True,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.886,0.9972,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Michael Pritsch,University Hospital LMU Munich,Unity-Aligned,https://dx.doi.org/10.3390/ijerph18073572,2021-05-23,2024-03-01,Verified,pritsch_prevalence_2021,DEU
210331_SchleswigHolstein_RuhrUniversityBochum_HCW,210331_SchleswigHolstein_RuhrUniversityBochum_HCW,Half Year Longitudinal Seroprevalence of SARS-CoV-2-antibodies and Rule Compliance in German Hospital Employees,2021-03-31,Preprint,Local,Prospective cohort,Germany,Schleswig-Holstein,,"Within the first study period starting in April 2020 all hospital employees and nuns between
18 and 90 years were given the opportunity to participate in this trial.",,2020-04-14,2020-10-20,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,268,0.0075,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Liaison SARS-CoV-2 S1/S2 IgG,Abbott Architect SARS-CoV-2 IgG","EUROIMMUN,DiaSorin,Abbott Laboratories",ELISA,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Jonas Herzberg,Ruhr University Bochum,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.29.21254538v1,2021-05-02,2024-03-01,Unverified,herzberg_half_2021,DEU
210331_SchleswigHolstein_RuhrUniversityBochum_NonHCW,210331_SchleswigHolstein_RuhrUniversityBochum_NonHCW,Half Year Longitudinal Seroprevalence of SARS-CoV-2-antibodies and Rule Compliance in German Hospital Employees,2021-03-31,Preprint,Local,Prospective cohort,Germany,Schleswig-Holstein,,"Within the first study period starting in April 2020 all hospital employees and nuns between
18 and 90 years were given the opportunity to participate in this trial.",,2020-04-14,2020-10-20,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,138,0.0072,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Liaison SARS-CoV-2 S1/S2 IgG,Abbott Architect SARS-CoV-2 IgG","EUROIMMUN,DiaSorin,Abbott Laboratories",ELISA,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Jonas Herzberg,Ruhr University Bochum,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.29.21254538v1,2021-05-24,2024-03-01,Unverified,herzberg_half_2021,DEU
210402_Bavaria_GermanResearchCenterforEnvironmentalHealth_firstwave_primary,210402_Bavaria_GermanResearchCenterforEnvironmentalHealth_firstwave,A Public Health Antibody Screening Indicates a Marked Increase of SARS-CoV-2 Exposure Rate in Children during the Second Wave.,2021-04-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Bavaria,,,,2020-01-15,2020-08-15,Household and community samples,All,Children and Youth (0-17 years),1.0,10.0,Primary Estimate,,15523,0.0068000000000000005,0.005600000000000001,0.008199999999999999,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,No,Unclear,Yes,No,Unclear,Markus Hippich,German Research Center for Environmental Health,Not Unity-Aligned,https://dx.doi.org/10.1016/j.medj.2021.03.019,2021-05-19,2022-07-16,Verified,hippich_public_2021-1,DEU
210402_Bavaria_GermanResearchCenterforEnvironmentalHealth_secondwave_primary,210402_Bavaria_GermanResearchCenterforEnvironmentalHealth_secondwave,A Public Health Antibody Screening Indicates a Marked Increase of SARS-CoV-2 Exposure Rate in Children during the Second Wave.,2021-04-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Bavaria,,,,2020-09-15,2021-02-15,Household and community samples,All,Children and Youth (0-17 years),1.0,10.0,Primary Estimate,,11380,0.0392,0.0357,0.0429,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,No,Unclear,Yes,No,Unclear,Markus Hippich,German Research Center for Environmental Health,Not Unity-Aligned,https://dx.doi.org/10.1016/j.medj.2021.03.019,2021-05-19,2022-07-16,Verified,hippich_public_2021-1,DEU
210403_Mainz_JohannesGutenbergUniversity_overall_unadj,210403_Mainz_JohannesGutenbergUniversity,Covid-19-importance for patients on the waiting list and after kidney transplantation-a single center evaluation in 2020-2021,2021-04-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Rhineland-Palatinate,Mainz,,,2020-01-01,2021-02-28,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,248,0.0524,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],No,No,No,No,Unclear,Yes,Yes,Yes,Unclear, Simone C Boedecker,Johannes Gutenberg University,Not Unity-Aligned,http://dx.doi.org/10.3390/pathogens10040429,2021-05-19,2024-03-01,Verified,boedecker_covid-19importance_2021,DEU
210404_Tirschenreuth_ FriedrichAlexanderUniversity_primary,210404_Tirschenreuth_ FriedrichAlexanderUniversity,Estimates and determinants of SARS-CoV-2 seroprevalence and infection fatality ratio using latent class analysis: the population-based Tirschenreuth study in the hardest-hit German county in spring 2020,2021-04-04,Preprint,Local,Cross-sectional survey ,Germany,Bavaria,,"Inclusion criteria were legal age and univalent consent of custodial
parents for those aged < 18 years, German language skills sufficiently good to understand the participant
information and to respond to the questionnaire","Children below 14 years and individuals with legal guardian
were excluded from participation. ",2020-06-28,2020-07-10,Household and community samples,All,Multiple groups,14.0,,Primary Estimate,,4201,0.0864,,,True,,,,True,Simplified probability,"iFlash-SARS-CoV-2 IgM/IgG,Elecsys® Anti‐SARS‐CoV‐2 (N),Author designed (ELISA) -Spike","Shenzhen Yhlo Biotech Co. Ltd,Roche Diagnostics,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Yes,Ralf Wagner,Friedrich-Alexander University,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.29.21254343v1,2021-05-19,2024-03-01,Verified,wagner_estimates_2021,DEU
210408_Germany_HeinrichHeineUniversityDuesseldorf_Physicians,210408_Germany_HeinrichHeineUniversityDuesseldorf,Prevalence of SARS-COV-2 positivity in 516 German intensive care and emergency physicians studied by seroprevalence of antibodies National Covid Survey Germany (NAT-COV-SURV),2021-04-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Germany,,,"From June 16th to July 2nd 2020 we recruited physicians from all over Germany who attended certified registered training courses for intensive care or emergency medicine in the
city of Arnsberg in Northrhine-Westfalia.",,2020-06-16,2020-07-02,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,516,0.031000000000000003,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Detlef Kindgen Milles,Heinrich-Heine University Duesseldorf,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0248813,2021-04-24,2024-03-01,Unverified,kindgen-milles_prevalence_2021,DEU
210408_Germany_BundeswehrInstituteofMicrobiology_overall,210408_Germany_BundeswehrInstituteofMicrobiology,Sars-cov-2 seroprevalence among health care workers-a voluntary screening study in a regional medical center in southern germany,2021-04-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,,Offenburg,"exclusively to HCWs at the major hospital facility of the regional medical center... As this study was performed at an early stage of the pandemic, no further specific inclusion or exclusion criteria were applied other than the strict requirement for direct and regular patient contact, thus excluding administrative staff among others",,2020-04-02,2020-04-08,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Healthcare workers,198,0.035,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA",EUROIMMUN,ELISA,,"['IgA', 'IgG']",,,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,No,Unclear,Katharina Muller,Bundeswehr Institute of Microbiology,Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph18083910,2021-05-07,2024-03-01,Verified,muller_sars-cov-2_2021,DEU
210409_Bonn_UniversityOfBonn_RhinelandStudy1_overall_Unadj_ELISA,210409_Bonn_UniversityOfBonn_RhinelandStudy1,"Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany",2021-04-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,North Rhine-Westphalia,Bonn,"Participants who were already enrolled in the Rhineland study, aged 30 and above of two geographically defined areas until March 18, 2020 ",Insufficient command of the german language to provide informed consent. ,2020-04-24,2020-06-30,Household and community samples,All,Multiple groups,30.0,,Primary Estimate,,4755,0.0097,0.0072,0.013000000000000001,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,,Validated by manufacturers,0.9440000000000001,0.996,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,N Ahmad Aziz,University of Bonn,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-22351-5,2021-05-22,2024-03-01,Verified,aziz_seroprevalence_2021,DEU
210409_Bonn_UniversityOfBonn_Voluntary2_overall_Unadj_ELISA,210409_Bonn_UniversityOfBonn_Voluntary2,"Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany",2021-04-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,North Rhine-Westphalia,Bonn,Individuals aged 30 and over of two geographically defined areas (eligible for Rhineland study) but had not yet participated in the Rhineland Study and who actively approached us to indicate their willingness to participate in the serosurvey and become prospective participants,Insufficient command of the german language to provide informed consent. ,2020-04-24,2020-06-30,Household and community samples,All,Multiple groups,30.0,,Primary Estimate,,360,0.0194,0.0084,0.0442,True,,,,True,Self-referral,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,,Validated by manufacturers,0.9440000000000001,0.996,['High'],No,No,No,No,Unclear,Yes,Yes,Yes,Unclear,N Ahmad Aziz,University of Bonn,Not Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-22351-5,2021-05-22,2024-03-01,Verified,aziz_seroprevalence_2021,DEU
210413_Tubingen_EberhardKarlsUniversitatTubingen,210413_Tubingen_EberhardKarlsUniversitatTubingen,Testing for SARS-CoV-2 seroprevalence: experiences of a tertiary eye centre,2021-04-13,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,Baden-Württemberg,Tubingen,"The design contained no exclusion criteria, but included a combination of a pseudonymised survey and the performance of multiple assays.",,2020-05-01,2020-05-01,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,318,0.027999999999999997,0.015,0.053,True,,,,True,Convenience,"ADVIA Centaur Immunoassay System,Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Siemens,EUROIMMUN,Roche Diagnostics",Multiple Types,,,Nucleocapsid(N-protein),,,,['High'],,No,No,No,,Unclear,Yes,No,,Focke Ziemssen,Eberhard Karls Universitat Tubingen,Not Unity-Aligned,https://bmjophth.bmj.com/content/bmjophth/6/1/e000688.full.pdf,2021-06-01,2024-03-01,Unverified,fockeziemssenetal.TestingSARSCoV2Seroprevalence2021,DEU
210422_Brandenburg_MedicalSchoolTheodorFontane_baseline_primary,210422_Brandenburg_MedicalSchoolTheodorFontane_baseline,Prevalence and Course of IgA and IgG Antibodies against SARS-CoV-2 in Healthcare Workers during the First Wave of the COVID-19 Outbreak in Germany: Interim Results from an Ongoing Observational Cohort Study.,2021-04-22,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Germany,Brandenburg,"Brandenburg/Havel, Neuruppin",HCW working in two centers of a medical school in the federal state of Brandenburg in Germany.,,2020-03-30,2020-04-07,Health care workers and caregivers,All,Adults (18-64 years),19.0,65.0,Primary Estimate,,1013,0.021,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9500000000000001,0.9620000000000001,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,Unclear,Mark Reinwald ,Brandenburg Medical School Theodor Fontane,Not Unity-Aligned,https://dx.doi.org/10.3390/healthcare9050498,2021-05-20,2024-03-01,Verified,reinwald_prevalence_2021,DEU
210422_Brandenburg_MedicalSchoolTheodorFontane_followup_primary,210422_Brandenburg_MedicalSchoolTheodorFontane_followup,Prevalence and Course of IgA and IgG Antibodies against SARS-CoV-2 in Healthcare Workers during the First Wave of the COVID-19 Outbreak in Germany: Interim Results from an Ongoing Observational Cohort Study.,2021-04-22,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Germany,Brandenburg,"Brandenburg/Havel, Neuruppin",HCW working in two centers of a medical school in the federal state of Brandenburg in Germany.,,2020-05-31,2020-06-06,Health care workers and caregivers,All,Adults (18-64 years),19.0,65.0,Primary Estimate,,811,0.022000000000000002,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9500000000000001,0.9620000000000001,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,Unclear,Mark Reinwald ,Brandenburg Medical School Theodor Fontane,Not Unity-Aligned,https://dx.doi.org/10.3390/healthcare9050498,2021-05-20,2024-03-01,Verified,reinwald_prevalence_2021,DEU
210425_Essen_UniversityHospitalEssen,210425_Essen_UniversityHospitalEssen,SARS-CoV-2 Seroprevalence in Healthcare Workers in Germany: A Follow-Up Study.,2021-04-25,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,North Rhine-Westphalia,Essen,HCW of the University Hospital Essen were asked to take part in the study.,,2020-10-01,2020-12-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Third Observational Period: October–December 2020,315,0.051,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9440000000000001,0.996,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Johannes Korth,University Hospital Essen,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph18094540,2021-05-20,2024-03-01,Verified,korth_sars-cov-2_2021,DEU
210427_Germany_HelmholtzCentreForInfectionResearch,210427_Germany_HelmholtzCentreForInfectionResearch ,SARS-CoV-2 Seroprevalence in Germany - A Population Based Sequential Study in Five Regions,2021-04-27,Preprint,National,Cross-sectional survey ,Germany,,,"Individuals who received a written invitation, provided written informed consent and did not have contraindications for giving a blood sample were eligible for the study. All study materials were provided in German. Individuals with suspected or confirmed SARS-CoV-2 infections were not excluded. >=18 yrs

Individuals with suspected or confirmed SARS-CoV-2 infections were not excluded. ",,2020-07-15,2020-12-15,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,13405,0.02,,,True,,,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Daniela Gornyk,Helmholtz Centre for Infection Research,Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3834300,2021-05-10,2024-03-01,Verified,gornyk_sars-cov-2_2021,DEU
210428_Europe_SorbonneUniversité_1Nordrhein-Westfalen,210428_Europe_SorbonneUniversité_1Nordrhein-Westfalen,SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study.,2021-04-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Nordrhein-Westfalen,,"Eligible individuals had to be older than 18 years and have a definite clinical diagnosis of rheumatoid arthritis, axial spondyloarthritis, systemic lupus erythematosus, Sjögren's syndrome, or giant cell arteritis diagnosed by experienced rheumatologists and fulfilling the respective international classification criteria.","Patients who refused to participate, did not speak or read the local language, or were unwilling to undergo routine blood collection during the study period were excluded. ",2020-06-07,2020-12-08,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,,Primary Estimate,,624,0.008,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Liaison SARS-CoV-2 S1/S2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Siemens,DiaSorin,Beckman Coulter,Roche Diagnostics",,,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,Unclear,Unclear,No,No,Unclear,David Saadoun,Sorbonne Université,Not Unity-Aligned,https://dx.doi.org/10.1016/S2665-9913(21)00112-0,2021-05-30,2024-03-01,Verified,davidsaadounetal.SARSCoV2OutbreakImmunemediated2021,DEU
210429_Munich_GermanResearchCenterForEnvironmentalHealth_overall_popadj_testadj,210429_Munich_GermanResearchCenterForEnvironmentalHealth,From first to second wave: follow-up of the prospective Covid-19 cohort (KoCo19) in Munich (Germany),2021-04-29,Preprint,Local,Prospective cohort,Germany,,Munich,All household members older than 13 years,Indeterminate DBS results,2020-11-02,2021-01-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,4433,0.036000000000000004,0.028999999999999998,0.043,True,True,True,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Dried Blood,,,Validated by independent authors/third party/non-developers,0.9920000000000001,0.9870000000000001,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Katja Radon,German Research Center for Environmental Health,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.04.27.21256133v1,2021-05-14,2023-08-15,Verified,radon_first_2021,DEU
210429_Munich_GermanResearchCenterForEnvironmentalHealth_overall_unadj,210429_Munich_GermanResearchCenterForEnvironmentalHealth,From first to second wave: follow-up of the prospective Covid-19 cohort (KoCo19) in Munich (Germany),2021-04-29,Preprint,Local,Prospective cohort,Germany,,Munich,All household members older than 13 years,Indeterminate DBS results,2020-11-02,2021-01-31,Household and community samples,All,Multiple groups,,,Analysis,,4433,0.031000000000000003,0.025,0.038,,,,True,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Dried Blood,,,Validated by independent authors/third party/non-developers,0.9920000000000001,0.9870000000000001,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Katja Radon,German Research Center for Environmental Health,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.04.27.21256133v1,2021-05-14,2024-03-01,Verified,radon_first_2021,DEU
210429_Germany_BoehringerIngelheim_primary,210429_Germany_BoehringerIngelheim,Pilot study of an occupational healthcare program to assess the SARS-CoV-2 infection and immune status of employees in a large pharmaceutical company,2021-04-29,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Germany,,,"employees aged between 20 and 63 years, from four BI sites in Germany who did not have previous COVID-19 diagnosis",,2020-04-15,2020-06-15,Essential non-healthcare workers,All,Adults (18-64 years),20.0,63.0,Primary Estimate,,121,0.0165,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.55,1.0,['High'],Yes,No,No,Yes,Yes,Yes,Yes,No,Unclear,Petra C Moroni Zentgraf,Boehringer Ingelheim,Not Unity-Aligned,https://dx.doi.org/10.1080/03007995.2021.1914943,2021-05-22,2024-03-01,Verified,moroni-zentgraf_pilot_2021,DEU
210506_Berlin_FreieUniversitätBerlin,210506_Berlin_FreieUniversitätBerlin,"SARS-CoV-2 infections in kindergartens and associated households at the start of the second wave in Berlin, Germany - a cross sectional study.",2021-05-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Berlin,Berlin,"Twelve Berlin kindergartens were visited in this cross-sectional study between September 28 and October 2, 2020

At each kindergarten, we aimed at recruiting 20 children and 5 staff, whenever possible, belonging to one care-group. Household members of children and staff were invited to also
participate in the survey.",,2020-09-28,2020-10-02,Students and Daycares,All,Multiple groups,,,Primary Estimate,,720,0.0014000000000000002,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Marlene Thielecke,Freie Universität Berlin,Not Unity-Aligned,https://dx.doi.org/10.1093/eurpub/ckab079,2021-05-28,2024-03-01,Unverified,marlenethieleckeetal.SARSCoV2InfectionsKindergartens2021,DEU
210512_Lübeck_UniversityofLübeck_TotalStudy,210512_Lübeck_UniversityofLübeck,Cohort-based surveillance of SARS-CoV2 transmission mirrors infection rates at the population level a one-year longitudinal study,2021-05-12,Preprint,Local,Prospective cohort,Germany,,Lubeck,Adults in the Lubeck area,,2020-05-06,2021-02-01,Household and community samples,All,Multiple groups,18.0,79.0,Primary Estimate,,3051,0.0344,,,True,,,,True,Self-referral,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Christine Klein,University of Lübeck,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.05.10.21256966v1.full-text,2021-06-02,2024-03-01,Verified,klein_cohort-based_2021,DEU
210512_Lübeck_UniversityofLübeck_Baseline,210512_Lübeck_UniversityofLübeck,Cohort-based surveillance of SARS-CoV2 transmission mirrors infection rates at the population level a one-year longitudinal study,2021-05-12,Preprint,Local,Prospective cohort,Germany,,Lubeck,Adults in the Lubeck area,,2020-05-06,2020-05-31,Household and community samples,All,Multiple groups,18.0,79.0,Time frame,,3051,0.0079,,,,,,,,Self-referral,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Christine Klein,University of Lübeck,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.05.10.21256966v1.full-text,2021-06-02,2024-03-01,Verified,klein_cohort-based_2021,DEU
210512_Lübeck_UniversityofLübeck_Female,210512_Lübeck_UniversityofLübeck,Cohort-based surveillance of SARS-CoV2 transmission mirrors infection rates at the population level a one-year longitudinal study,2021-05-12,Preprint,Local,Prospective cohort,Germany,,Lubeck,Adults in the Lubeck area,,2020-05-06,2021-02-01,Household and community samples,Female,Multiple groups,18.0,79.0,Sex/Gender,,1710,0.024,,,,,,,,Self-referral,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Christine Klein,University of Lübeck,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.05.10.21256966v1.full-text,2021-06-02,2024-03-01,Verified,klein_cohort-based_2021,DEU
210512_Lübeck_UniversityofLübeck_Male,210512_Lübeck_UniversityofLübeck,Cohort-based surveillance of SARS-CoV2 transmission mirrors infection rates at the population level a one-year longitudinal study,2021-05-12,Preprint,Local,Prospective cohort,Germany,,Lubeck,Adults in the Lubeck area,,2020-05-06,2021-02-01,Household and community samples,Male,Multiple groups,18.0,79.0,Sex/Gender,,1341,0.046,,,,,,,,Self-referral,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Christine Klein,University of Lübeck,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.05.10.21256966v1.full-text,2021-06-02,2024-03-01,Verified,klein_cohort-based_2021,DEU
210513_Ulm_UlmUniversity_Overall,210513_Ulm_UlmUniversity,Longitudinal SARS-CoV-2 infection study at Ulm University: Test and hygiene concepts for classroom teaching during the pandemic in medical school,2021-05-13,Preprint,Local,Prospective cohort,Germany,Baden-Württemberg,Ulm,"All students of the first three years of medical school (semesters 1, 3, 5, and 6), as well as dental students of the first and second semester were invited to participate after informed written consent and institute staff",,2020-11-15,2021-03-07,Multiple populations,All,Adults (18-64 years),,,Primary Estimate,Overall students and staff ,818,0.145,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by manufacturers,0.988,0.9998,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Michael Schon,Ulm University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.05.04.21256382v2.full-text,2021-05-28,2024-03-01,Unverified,schon_longitudinal_2021,DEU
210520_NorthRhine-Westphalia_RuhrUniversityBochum,210520_NorthRhine-Westphalia_RuhrUniversityBochum,COVID-19: Hotspot hospital?- seroprevalence of SARS-CoV-2 antibodies in hospital employees in a secondary care hospital network in Germany: Intermediate results of a prospective surveillance study,2021-05-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,North Rhine-Westphalia,,Employees were included if they put their laboratory number on a 3 paged document so that we could assign the sample to the person. This written informed consent included a questionnaire and agreement on providing a blood sample (not exceeding 9 ml of venous blood).,,2020-07-01,2020-09-30,Health care workers and caregivers,All,Adults (18-64 years),16.0,,Primary Estimate,,907,0.0143,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.99,0.99,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Anke Hildebrandt ,Ruhr University Bochum,Not Unity-Aligned,10.1016/j.ijheh.2021.113771,2021-07-29,2024-03-01,Unverified,hildebrandt_covid-19_2021,DEU
210610_Saxony_TechnischeUniversitätDresden_Students_MayJune_1_overall,210610_Saxony_TechnischeUniversitätDresden_Students_MayJune_1,SARS-CoV-2 seroprevalence in students and teachers: a longitudinal study from May to October 2020 in German secondary schools.,2021-06-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Germany,Saxony,,Students grade 8-11 in 13 secondary schools,,2020-05-25,2020-06-30,Students and Daycares,All,Children and Youth (0-17 years),,,Primary Estimate,,1538,0.0072,,,True,,,,True,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG","DiaSorin,Abbott Laboratories,EUROIMMUN",Multiple Types,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Carolin Kirsten,Technische Universität Dresden,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-049876,2021-06-21,2024-03-01,Unverified,kirsten_sars-cov-2_2021,DEU
210610_Saxony_TechnischeUniversitätDresden_Teachers_MayJune_3_overall,210610_Saxony_TechnischeUniversitätDresden_Teachers_MayJune_3,SARS-CoV-2 seroprevalence in students and teachers: a longitudinal study from May to October 2020 in German secondary schools.,2021-06-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Germany,Saxony,,Teachers in 13 secondary schools,,2020-05-25,2020-06-30,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,507,0.002,,,True,,,,True,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG","DiaSorin,Abbott Laboratories,EUROIMMUN",Multiple Types,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Carolin Kirsten,Technische Universität Dresden,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-049876,2021-06-22,2024-03-01,Unverified,kirsten_sars-cov-2_2021,DEU
210618_Bonn_BonnUniversityHospital_primary,210618_Bonn_BonnUniversityHospital,SARS-CoV-2 seroconversions and chains of infection in healthcare professionals in a German maximum care provider (The CoSHeP study).,2021-06-18,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,,Bonn,"employees from emergency room, internal medicine intensive care unit, infectious diseases ward, and infectious diseases outpatient clinic ",No exclusion criteria,2020-12-15,2021-01-15,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,118,0.14,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,ELISA,Serum,IgG,,Validated by manufacturers,0.995,0.995,['High'],,No,No,Yes,,Yes,Yes,Yes,,Kathrin van Bremen,Bonn University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01641-6,2021-07-06,2024-03-01,Unverified,van_bremen_sars-cov-2_2021,DEU
210625_Germany_RobertKochInstitute_overall,210625_Germany_RobertKochInstitute,Socioeconomic position and SARS-CoV-2 infections: seroepidemiological findings from a German nationwide dynamic cohort,2021-06-25,Preprint,National,Cross-sectional survey ,Germany,,,Germany’s resident population in private households,,2020-10-15,2021-02-15,Household and community samples,All,Multiple groups,18.0,99.0,Primary Estimate,,15122,0.013000000000000001,,,True,,True,True,True,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,,,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Jens Hoebel,German Institute for Economic Research,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.06.21.21259001v1.full-text,2021-07-07,2024-03-01,Verified,hoebel_socioeconomic_2021,DEU
210701_Heilbronn_SLKClinicsHeilbronn_Primary,210701_Heilbronn_SLKClinicsHeilbronn ,Assessment of sars-cov-2 infection among healthcare workers of a german covid-19 treatment center,2021-07-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Baden-Württemberg,Heilbronn,All employees aged ≥ 14 years were invited to participate in this study on a voluntary basis.,,2020-07-01,2020-07-21,Health care workers and caregivers,All,Multiple groups,14.0,,Primary Estimate,,3066,0.031000000000000003,,,True,,,,True,Convenience,"ADVIA Centaur Immunoassay System,Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)","Siemens,Abbott Laboratories,DiaSorin,EUROIMMUN",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,1.0,,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Lionel Larribere,SLK Clinics Heilbronn ,Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph18137057,2021-07-14,2024-03-01,Verified,larribere_assessment_2021,DEU
210714_Baden-Württemberg_UlmUniversityHospital_Employees2_overall,210714_Baden-Württemberg_UlmUniversityHospital_Employees2,[COVID-19 pandemic-related burden and SARS-CoV-2 prevalence in care facilities].,2021-07-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Baden-Württemberg,Alb-Danube district and Ulm ,Care facility employees in 7 facilities in the Alb-Danube District (ADK) and in the city of Ulm ,"According to the requirements of the ethics committee, AK testing was only offered to subjects capable of giving consent",2020-07-27,2020-08-25,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,394,0.0025,,,True,,,,True,Convenience,Not reported/ Unable to specify,,CLIA,Serum,,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Lukas Perkhofer,Ulm University Hospital ,Not Unity-Aligned,https://dx.doi.org/10.1007/s00391-021-01931-6,2021-07-18,2022-07-16,Unverified,perkhofer_covid-19-pandemie-bedingte_2021,DEU
210714_Baden-Württemberg_UlmUniversityHospital_Residents1_overall,210714_Baden-Württemberg_UlmUniversityHospital_Residents1,[COVID-19 pandemic-related burden and SARS-CoV-2 prevalence in care facilities].,2021-07-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Baden-Württemberg,Alb-Danube district and Ulm ,Care facility residents in 7 facilities in the Alb-Danube District (ADK) and in the city of Ulm ,"According to the requirements of the ethics committee, AK testing was only offered to subjects capable of giving consent",2020-07-27,2020-08-25,Assisted living and long-term care facilities,All,Multiple groups,,,Primary Estimate,,100,0.01,,,True,,,,True,Convenience,Not reported/ Unable to specify,,CLIA,Serum,,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Lukas Perkhofer,Ulm University Hospital ,Not Unity-Aligned,https://dx.doi.org/10.1007/s00391-021-01931-6,2021-07-18,2022-07-16,Unverified,perkhofer_covid-19-pandemie-bedingte_2021,DEU
210726_Dresden_TechnischeUniversitatDresden_200715-201115_Adults,210726_Dresden_TechnischeUniversitatDresden_200715-201115,Prevalence and Transmission of Severe Acute Respiratory Syndrome Coronavirus Type 2 in Childcare Facilities: A Longitudinal Study,2021-07-26,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,Saxony,Dresden,"Children aged 1-6 years, their parents, and childcare workers
in 14 childcare facilities in Dresden were invited to participate
in the KiTaCoviDD19-study.",,2020-07-15,2020-11-15,Multiple populations,All,Multiple groups,17.0,72.0,Primary Estimate,,350,0.006,,,True,,,,True,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG","DiaSorin,Abbott Laboratories,EUROIMMUN",Multiple Types,Serum,IgG,Spike,,,,['High'],,No,No,No,,Unclear,Yes,No,,Luise Haag,Technische Universitat Dresden,Not Unity-Aligned,http://dx.doi.org/10.1016/j.jpeds.2021.07.054,2021-09-14,2024-03-01,Unverified,haag_prevalence_2021-2,DEU
210726_Dresden_TechnischeUniversitatDresden_200715-201115_Children,210726_Dresden_TechnischeUniversitatDresden_200715-201115,Prevalence and Transmission of Severe Acute Respiratory Syndrome Coronavirus Type 2 in Childcare Facilities: A Longitudinal Study,2021-07-26,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,Saxony,Dresden,"Children aged 1-6 years, their parents, and childcare workers
in 14 childcare facilities in Dresden were invited to participate
in the KiTaCoviDD19-study.",,2020-07-15,2020-11-15,Students and Daycares,All,Children and Youth (0-17 years),0.0,6.0,Age,age: 1-6,232,0.008,,,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Anti-SARS-CoV-2 ELISA IgG","Abbott Laboratories,DiaSorin,EUROIMMUN",Multiple Types,,IgG,Spike,,,,['High'],,No,No,No,,Unclear,Yes,No,,Luise Haag,Technische Universitat Dresden,Not Unity-Aligned,http://dx.doi.org/10.1016/j.jpeds.2021.07.054,2021-09-14,2024-03-01,Unverified,haag_prevalence_2021-2,DEU
210726_Dresden_TechnischeUniversitatDresden_201116-210131_Adults,210726_Dresden_TechnischeUniversitatDresden_201116-210131,Prevalence and Transmission of Severe Acute Respiratory Syndrome Coronavirus Type 2 in Childcare Facilities: A Longitudinal Study,2021-07-26,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,Saxony,Dresden,"Children aged 1-6 years, their parents, and childcare workers
in 14 childcare facilities in Dresden were invited to participate
in the KiTaCoviDD19-study.",,2020-07-16,2021-01-31,Multiple populations,All,Multiple groups,17.0,72.0,Primary Estimate,,424,0.113,,,True,,,,True,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,Anti-SARS-CoV-2 ELISA IgG,Abbott Architect SARS-CoV-2 IgG","DiaSorin,EUROIMMUN,Abbott Laboratories",Multiple Types,Serum,IgG,Spike,,,,['High'],,No,No,No,,Unclear,Yes,No,,Luise Haag,Technische Universitat Dresden\,Not Unity-Aligned,http://dx.doi.org/10.1016/j.jpeds.2021.07.054,2021-09-14,2024-03-01,Unverified,haag_prevalence_2021-2,DEU
210726_Dresden_TechnischeUniversitatDresden_201116-210131_Children,210726_Dresden_TechnischeUniversitatDresden_201116-210131,Prevalence and Transmission of Severe Acute Respiratory Syndrome Coronavirus Type 2 in Childcare Facilities: A Longitudinal Study,2021-07-26,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,Saxony,Dresden,"Children aged 1-6 years, their parents, and childcare workers
in 14 childcare facilities in Dresden were invited to participate
in the KiTaCoviDD19-study.",,2020-07-16,2021-01-31,Students and Daycares,All,Children and Youth (0-17 years),0.0,6.0,Age,age: 0-6,222,0.068,,,,,,,,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,Anti-SARS-CoV-2 ELISA IgG,Abbott Architect SARS-CoV-2 IgG","DiaSorin,EUROIMMUN,Abbott Laboratories",Multiple Types,,IgG,Spike,,,,['High'],,No,No,No,,Unclear,Yes,No,,Luise Haag,Technische Universitat Dresden\,Not Unity-Aligned,http://dx.doi.org/10.1016/j.jpeds.2021.07.054,2021-09-14,2024-03-01,Unverified,haag_prevalence_2021-2,DEU
210803_Mainz_UniversityMedicalCentreOfMainz_Adj,210803_Mainz_UniversityMedicalCentreOfMainz,An Epidemiological Cohort Study of SARS-CoV-2 and COVID-19 in German Healthcare Workers – Interim Analysis after Six Months of Follow-up,2021-08-03,Preprint,Local,Prospective cohort,Germany,Rhineland-Palatinate,Mainz,All HCWs at UM Mainz were eligible for enrolment,,2020-08-15,2020-10-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,3664,0.0189,0.0139,0.024700000000000003,True,True,,,,Convenience,Not reported/ Unable to specify,,,Serum,"['IgG', 'IgM']",,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Stephan Gehring,University Medical Centre of Mainz,Not Unity-Aligned,https://www.researchsquare.com/article/rs-688656/v1,2021-08-11,2022-07-16,Unverified,stephangehringEpidemiologicalCohortStudy2021,DEU
210811_Munich_LudwigMaximiliansUniversitatMunich_overall,210811_Munich_LudwigMaximiliansUniversitatMunich,In-depth profiling of COVID-19 risk factors and preventive measures in healthcare workers.,2021-08-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,,Munich,"Between May 27th and August 12th, 2020, we invited all 11,580 employees of the LMU Klinikum, a quaternary care university hospital complex with two centers in Munich, Germany, to enroll in this cross-sectional study.",,2020-05-27,2020-08-12,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,7554,0.022000000000000002,0.0189,0.0255,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N),recomLine SARS-CoV-2 IgG,Author designed (ELISA) - Unknown","Abbott Laboratories,EUROIMMUN,Roche Diagnostics,Mikrogen GmbH,NA",Multiple Types,Serum,"['IgG', 'TotalAntibody']",,Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Paul Wratil,Ludwig Maximilians UNiversitat Munich (LMU Munich),Not Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01672-z,2021-08-16,2024-03-01,Unverified,wratil_-depth_2021-1,DEU
210820_Hamburg_UniversitätHamburg_primary,210820_Hamburg_UniversitätHamburg,Low SARS-CoV-2 seroprevalence but high perception of risk among healthcare workers at children's hospital before second pandemic wave in Germany.,2021-08-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,,Hamburg,"Staff members across all sectors were invited to participate, including trainees and non-clinical staff. Non-clinical HCWs, while presumably at a lower exposure risk, were included to diversify our sample. ","We excluded individuals with congenital or acquired immunodeficiencies, those who had been absent from work since before COVID-19 emerged in Germany, and minors under the age of 18 years.",2020-08-19,2020-09-18,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,619,0.0032500000000000003,0.00039,0.0117,True,,,,True,Stratified non-probability,Anti-SARS-CoV-2 NCP ELISA (IgG),EUROIMMUN,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.946,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Marietta Neumann,Universität Hamburg,Not Unity-Aligned,https://dx.doi.org/10.1007/s12519-021-00447-8,2021-08-31,2024-03-01,Verified,neumann_low_2021,DEU
210826_Berlin_UniversitätsmedizinBerlin_HouseholdMembers_Primary,210826_Berlin_UniversitätsmedizinBerlin_HouseholdMembers,"SARS-CoV-2 infection and transmission in school settings during the second COVID-19 wave: a cross-sectional study, Berlin, Germany, November 2020.",2021-08-26,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Germany,,Berlin,"In the first round in June, the proportion of students participating per class was 65% (range: 13–96). Hereafter, students and staff were considered index participants. In this second round in November, household members of index participants were also invited to participate.","Three schools unable to participate were replaced by randomly
resampled substitutes.",2020-11-02,2020-11-16,Household and community samples,All,Multiple groups,2.0,86.0,Primary Estimate,,576,0.013999999999999999,0.006,0.027000000000000003,True,,,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,,,,,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Stefanie Theuring,Universitätsmedizin Berlin,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.34.2100184,2021-09-07,2024-03-01,Verified,theuring_sars-cov-2_2021_1,DEU
210826_Berlin_UniversitätsmedizinBerlin_PrimaryStudent_Primary,210826_Berlin_UniversitätsmedizinBerlin_PrimaryStudent,"SARS-CoV-2 infection and transmission in school settings during the second COVID-19 wave: a cross-sectional study, Berlin, Germany, November 2020.",2021-08-26,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Germany,,Berlin,"Primary classes were selected among grades 3–5 (8–12 year-olds)

We aimed to examine 20 students per class. In the first round in June, the proportion of students participating per class was 65% (range: 13–96). Hereafter, students and staff were considered index participants. In this second round in November, household members of index participants were also invited to participate.","Three schools unable to participate were replaced by randomly
resampled substitutes.",2020-11-02,2020-11-16,Students and Daycares,All,Children and Youth (0-17 years),9.0,13.0,Primary Estimate,,174,0.011000000000000001,,,True,,,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,,,,,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Stefanie Theuring,Universitätsmedizin Berlin,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.34.2100184,2021-09-07,2024-03-01,Verified,theuring_sars-cov-2_2021_1,DEU
210826_Berlin_UniversitätsmedizinBerlin_SecondaryStudent_Primary,210826_Berlin_UniversitätsmedizinBerlin_SecondaryStudent,"SARS-CoV-2 infection and transmission in school settings during the second COVID-19 wave: a cross-sectional study, Berlin, Germany, November 2020.",2021-08-26,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Germany,,Berlin,"Secondary classes were selected among grades 9–11 (13–17 year-olds)

We aimed to examine 20 students per class. In the first round in June, the proportion of students participating per class was 65% (range: 13–96). Hereafter, students and staff were considered index participants. In this second round in November, household members of index participants were also invited to participate.","Three schools unable to participate were replaced by randomly
resampled substitutes.",2020-11-02,2020-11-16,Students and Daycares,All,Children and Youth (0-17 years),14.0,18.0,Primary Estimate,,173,0.028999999999999998,,,True,,,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,,,,,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Stefanie Theuring,Universitätsmedizin Berlin,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.34.2100184,2021-09-07,2024-03-01,Verified,theuring_sars-cov-2_2021_1,DEU
210826_Berlin_UniversitätsmedizinBerlin_Staff_Primary,210826_Berlin_UniversitätsmedizinBerlin_Staff,"SARS-CoV-2 infection and transmission in school settings during the second COVID-19 wave: a cross-sectional study, Berlin, Germany, November 2020.",2021-08-26,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Germany,,Berlin,"We aimed to examine up to 10 members of staff per class. 

In the first round in June, the proportion of students participating per class was 65% (range: 13–96). Hereafter, students and staff were considered index participants. In this second round in November, household members of index participants were also invited to participate.","Three schools unable to participate were replaced by randomly
resampled substitutes.",2020-11-02,2020-11-16,Essential non-healthcare workers,All,Adults (18-64 years),28.0,65.0,Primary Estimate,,141,0.013999999999999999,0.002,0.05,True,,,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,,,,,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Stefanie Theuring,Universitätsmedizin Berlin,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.34.2100184,2021-09-07,2024-03-01,Verified,theuring_sars-cov-2_2021_1,DEU
210901_Saxony-Anhalt_OttoVonGuerickeUniversityMagdeburg,210901_Saxony-Anhalt_OttoVonGuerickeUniversityMagdeburg,A longitudinal regional cohort study to assess the seroprevalence of antibodies against SARS-CoV-2 in repeat blood donors,2021-09-01,Presentation or Conference,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Germany,Saxony-Anhalt,Magdeburg,Blood donors from Magdeburg and surrounding areas,,2021-01-21,2021-04-21,Blood donors,All,Adults (18-64 years),,,Primary Estimate,,2236,0.129,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Stephan Werner Kramer,Otto Von Guericke University Magdeburg,Not Unity-Aligned,https://dx.doi.org/10.1159/000518751,2022-02-22,2022-07-16,Unverified,54JahrestagungDeutschen2021,DEU
210901_Dusseldorf_HeinrichHeineUniversityDusseldorf,210901_Dusseldorf_HeinrichHeineUniversityDusseldorf,High rate of clinically unrecognized SARS-CoV-2 infections in pediatric palliative care patients.,2021-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,North Rhine-Westphalia,Dusseldorf,"""pediatric and young adult palliative patients aged 0.5 to 28 years""","""Due to the rapidly progressive nature of end-stage malignancies, no patients with oncological diseases were included in the study.""",2020-12-17,2021-02-19,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,1.0,28.0,Primary Estimate,,39,0.256,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,,,,,['High'],No,No,No,Yes,No,Yes,Yes,Yes,Yes,Benedikt Botticher,Heinrich Heine University ,Not Unity-Aligned,https://dx.doi.org/10.1007/s00431-021-04242-5,2021-09-07,2024-03-01,Verified,botticher_high_2021,DEU
210916_Augsburg_UniversityHospitalofAugsburg_HCW,210916_Augsburg_UniversityHospitalofAugsburg,Evaluation of the ESGE recommendations for COVID-19 pre-endoscopy risk-stratification in a high-volume center in Germany.,2021-09-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Bavaria,Augsburg,employees and staff of the endoscopic outpatient department.,,2020-12-24,2020-12-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,43,0.023,,,True,,,,True,Convenience,NADAL® COVID-19 IgG/IgM Test,nal von minden GmbH,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],,No,No,No,,Yes,Yes,Yes,,Stephan Zellmer,University Hospital of Augsburg,Not Unity-Aligned,https://dx.doi.org/10.1055/a-1526-1169,2021-09-28,2024-03-01,Unverified,zellmer_evaluation_2021,DEU
210925_Hamburg_UniversityMedicalCenterHamburg-Eppendorf,210925_Hamburg_UniversityMedicalCenterHamburg-Eppendorf,Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic.,2021-09-25,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Germany,,Hamburg,Hospital workers from the University Medical Center Hamburg-Eppendorf ,,2021-05-11,2021-05-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,872,0.927,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,,Spike,Validated by manufacturers,0.998,1.0,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Thomas Theo Brehm,the University Medical Center Hamburg-Eppendorf,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijheh.2021.113851,2021-10-12,2024-03-01,Unverified,brehm_low_2021-1,DEU
211004_Bavaria_UniversityofRegensburg_ELISA-ELECSYS-Neutralization,211004_Bavaria_UniversityofRegensburg,"Symptoms, SARS-CoV-2 Antibodies, and Neutralization Capacity in a Cross Sectional-Population of German Children",2021-10-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Bavaria,"Tirschenreuth, Regensburg city and county, and Oberbayern/ alpine region","Invitation to participate for children aged 1–14 years was
based on two approaches: 
(a) All children of that age group who were scheduled for a prevention program visit in 2020 with the respective pediatrician 
(b) all children of families who actively wanted
to participate were also tested (own intention to participate). Siblings older than 14 years were allowed to
participate in the study, as for ethical reasons, children older than 14 could not be excluded from antibody testing if families presented them together with younger siblings for testing. ",Age greater than 17 years. ,2020-05-22,2020-07-22,Multiple general populations,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,1) Positive on either ELISA or ELECSYS and 2) Positive on neutralization,2832,0.0477,,,True,,,,True,Simplified probability,"Author designed (ELISA) -Spike,Elecsys® Anti‐SARS‐CoV‐2 (N),Author designed (Neutralization Assay)","NA,Roche Diagnostics",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Otto Laub,University of Regensburg,Unity-Aligned,http://dx.doi.org/10.3389/fped.2021.678937,2021-11-02,2024-03-01,Verified,laub_symptoms_2021,DEU
211004_Bavaria_UniversityofRegensburg_ELISA-ELECSYS_11-17,211004_Bavaria_UniversityofRegensburg,"Symptoms, SARS-CoV-2 Antibodies, and Neutralization Capacity in a Cross Sectional-Population of German Children",2021-10-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Bavaria,"Tirschenreuth, Regensburg city and county, and Oberbayern/ alpine region","Invitation to participate for children aged 1–14 years was
based on two approaches: 
(a) All children of that age group who were scheduled for a prevention program visit in 2020 with the respective pediatrician 
(b) all children of families who actively wanted
to participate were also tested (own intention to participate). Siblings older than 14 years were allowed to
participate in the study, as for ethical reasons, children older than 14 could not be excluded from antibody testing if families presented them together with younger siblings for testing. ",Age greater than 17 years. ,2020-05-22,2020-07-22,Multiple general populations,All,Children and Youth (0-17 years),11.0,17.0,Age,11-17,684,0.073,,,,,,,,Simplified probability,"Author designed (ELISA) -Spike,Elecsys® Anti‐SARS‐CoV‐2 (N)","NA,Roche Diagnostics",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Otto Laub,University of Regensburg,Unity-Aligned,http://dx.doi.org/10.3389/fped.2021.678937,2021-11-05,2024-03-01,Verified,laub_symptoms_2021,DEU
211004_Bavaria_UniversityofRegensburg_ELISA-ELECSYS_Female,211004_Bavaria_UniversityofRegensburg,"Symptoms, SARS-CoV-2 Antibodies, and Neutralization Capacity in a Cross Sectional-Population of German Children",2021-10-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Bavaria,"Tirschenreuth, Regensburg city and county, and Oberbayern/ alpine region","Invitation to participate for children aged 1–14 years was
based on two approaches: 
(a) All children of that age group who were scheduled for a prevention program visit in 2020 with the respective pediatrician 
(b) all children of families who actively wanted
to participate were also tested (own intention to participate). Siblings older than 14 years were allowed to
participate in the study, as for ethical reasons, children older than 14 could not be excluded from antibody testing if families presented them together with younger siblings for testing. ",Age greater than 17 years. ,2020-05-22,2020-07-22,Multiple general populations,Female,Children and Youth (0-17 years),,,Sex/Gender,,1288,0.0621,,,,,,,,Simplified probability,"Author designed (ELISA) -Spike,Elecsys® Anti‐SARS‐CoV‐2 (N)","NA,Roche Diagnostics",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Otto Laub,University of Regensburg,Unity-Aligned,http://dx.doi.org/10.3389/fped.2021.678937,2021-11-05,2024-03-01,Verified,laub_symptoms_2021,DEU
211004_Bavaria_UniversityofRegensburg_ELISA-ELECSYS_Male,211004_Bavaria_UniversityofRegensburg,"Symptoms, SARS-CoV-2 Antibodies, and Neutralization Capacity in a Cross Sectional-Population of German Children",2021-10-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Bavaria,"Tirschenreuth, Regensburg city and county, and Oberbayern/ alpine region","Invitation to participate for children aged 1–14 years was
based on two approaches: 
(a) All children of that age group who were scheduled for a prevention program visit in 2020 with the respective pediatrician 
(b) all children of families who actively wanted
to participate were also tested (own intention to participate). Siblings older than 14 years were allowed to
participate in the study, as for ethical reasons, children older than 14 could not be excluded from antibody testing if families presented them together with younger siblings for testing. ",Age greater than 17 years. ,2020-05-22,2020-07-22,Multiple general populations,Male,Children and Youth (0-17 years),,,Sex/Gender,,1462,0.056100000000000004,,,,,,,,Simplified probability,"Author designed (ELISA) -Spike,Elecsys® Anti‐SARS‐CoV‐2 (N)","NA,Roche Diagnostics",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Otto Laub,University of Regensburg,Unity-Aligned,http://dx.doi.org/10.3389/fped.2021.678937,2021-11-05,2024-03-01,Verified,laub_symptoms_2021,DEU
211004_Bavaria_UniversityofRegensburg_ELISA-ELECSYS_7-10,211004_Bavaria_UniversityofRegensburg,"Symptoms, SARS-CoV-2 Antibodies, and Neutralization Capacity in a Cross Sectional-Population of German Children",2021-10-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Bavaria,"Tirschenreuth, Regensburg city and county, and Oberbayern/ alpine region","Invitation to participate for children aged 1–14 years was
based on two approaches: 
(a) All children of that age group who were scheduled for a prevention program visit in 2020 with the respective pediatrician 
(b) all children of families who actively wanted
to participate were also tested (own intention to participate). Siblings older than 14 years were allowed to
participate in the study, as for ethical reasons, children older than 14 could not be excluded from antibody testing if families presented them together with younger siblings for testing. ",Age greater than 17 years. ,2020-05-22,2020-07-22,Multiple general populations,All,Children and Youth (0-17 years),7.0,10.0,Age,7-10,849,0.057,,,,,,,,Simplified probability,"Author designed (ELISA) -Spike,Elecsys® Anti‐SARS‐CoV‐2 (N)","NA,Roche Diagnostics",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Otto Laub,University of Regensburg,Unity-Aligned,http://dx.doi.org/10.3389/fped.2021.678937,2021-11-05,2024-03-01,Verified,laub_symptoms_2021,DEU
211004_Bavaria_UniversityofRegensburg_ELISA-ELECSYS,211004_Bavaria_UniversityofRegensburg,"Symptoms, SARS-CoV-2 Antibodies, and Neutralization Capacity in a Cross Sectional-Population of German Children",2021-10-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Bavaria,"Tirschenreuth, Regensburg city and county, and Oberbayern/ alpine region","Invitation to participate for children aged 1–14 years was
based on two approaches: 
(a) All children of that age group who were scheduled for a prevention program visit in 2020 with the respective pediatrician 
(b) all children of families who actively wanted
to participate were also tested (own intention to participate). Siblings older than 14 years were allowed to
participate in the study, as for ethical reasons, children older than 14 could not be excluded from antibody testing if families presented them together with younger siblings for testing. ",Age greater than 17 years. ,2020-05-22,2020-07-22,Multiple general populations,All,Children and Youth (0-17 years),0.0,17.0,Test used,Positive on either ELISA or ECLECSYS,2832,0.0572,,,,,,,,Simplified probability,"Author designed (ELISA) -Spike,Elecsys® Anti‐SARS‐CoV‐2 (N)","NA,Roche Diagnostics",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Otto Laub,University of Regensburg,Unity-Aligned,http://dx.doi.org/10.3389/fped.2021.678937,2021-11-05,2024-03-01,Verified,laub_symptoms_2021,DEU
211004_Bavaria_UniversityofRegensburg_ELISA-ELECSYS_0-6,211004_Bavaria_UniversityofRegensburg,"Symptoms, SARS-CoV-2 Antibodies, and Neutralization Capacity in a Cross Sectional-Population of German Children",2021-10-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Bavaria,"Tirschenreuth, Regensburg city and county, and Oberbayern/ alpine region","Invitation to participate for children aged 1–14 years was
based on two approaches: 
(a) All children of that age group who were scheduled for a prevention program visit in 2020 with the respective pediatrician 
(b) all children of families who actively wanted
to participate were also tested (own intention to participate). Siblings older than 14 years were allowed to
participate in the study, as for ethical reasons, children older than 14 could not be excluded from antibody testing if families presented them together with younger siblings for testing. ",Age greater than 17 years. ,2020-05-22,2020-07-22,Multiple general populations,All,Children and Youth (0-17 years),0.0,6.0,Age,0-6,1299,0.049,,,,,,,,Simplified probability,"Author designed (ELISA) -Spike,Elecsys® Anti‐SARS‐CoV‐2 (N)","NA,Roche Diagnostics",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Otto Laub,University of Regensburg,Unity-Aligned,http://dx.doi.org/10.3389/fped.2021.678937,2021-11-05,2024-03-01,Verified,laub_symptoms_2021,DEU
211005_Munich_LMUMunich_TestAdjusted,211005_Munich_LMUMunich,SARS-CoV-2 antibody seroprevalence in a large neuroimmunological patient cohort,2021-10-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Bavaria,Munich,"all patients who were admitted to the neuroimmunology outpatient clinic of LMU Hospital in Munich, Germany",,2020-05-14,2020-09-30,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,Test adjusted,509,0.012700000000000001,0.0046,0.0244,True,True,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Anti-SARS-CoV-2 ELISA IgG","Roche Diagnostics,EUROIMMUN",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Katharina Eisenhut,LMU Munich,Not Unity-Aligned,https://dx.doi.org/10.1007/s00415-021-10818-w,2021-10-14,2023-08-15,Unverified,eisenhut_sars-cov-2_2021,DEU
211011_NorthRhineWestphalia_UniversityofDuisburgEssen_Overall,211011_NorthRhineWestphalia_UniversityofDuisburgEssen,Discrepancy between frequent occurrence of COVID-19-like symptoms and low seroconversion rates among healthcare workers.,2021-10-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,North Rhine-Westphalia,,"Doctors and medical staff from 100 registered GP practices in North Rhine-Westphalia, Germany.",,2020-06-01,2020-07-31,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,861,0.008100000000000001,,,True,,,,True,Unclear,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Anti-SARS-CoV-2 ELISA IgG,Author designed (Neutralization Assay)","Abbott Laboratories,DiaSorin,EUROIMMUN,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,Unclear,Yes,No,,Yes,Yes,No,,Dorothea Dehnen,University of Duisburg-Essen,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27385,2021-10-19,2024-03-01,Unverified,dehnen_discrepancy_2021,DEU
211012_Essen_EssenUniversityHospital_overall,211012_Essen_EssenUniversityHospital,[SARS-CoV-2 IgG seroprevalence in personnel of the extraclinical fight against the COVID-19 pandemic].,2021-10-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,,Essen,employees (61.9%) of the professional fire brigade and aid organizations in the urban area,,2020-05-28,2020-05-29,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,729,0.008199999999999999,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,,0.958,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Bastian Brune,Essen University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1007/s10049-021-00948-z,2021-10-27,2024-03-01,Unverified,brune_sars-cov-2-igg-antikorperseropravalenz_2021,DEU
211012_Germany_UniversitätWürzburg_Overall,211012_Germany_UniversitätWürzburg,[Seroprevalence of COVID-19 and Psychosocial Effects in the General Population: Results of the STAAB-COVID-One Program].,2021-10-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Bavaria,Würzburg,,,2020-06-01,2020-10-31,Household and community samples,All,Multiple groups,30.0,79.0,Primary Estimate,,3034,0.011000000000000001,0.006999999999999999,0.015,True,,,,True,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Felizitas Eichner,Universität Würzburg,Unity-Aligned,https://dx.doi.org/10.1055/a-1630-7601,2021-10-20,2024-03-01,Verified,eichner_seropravalenz_2021,DEU
211012_Germany_UniversitätWürzburg_50-59,211012_Germany_UniversitätWürzburg,[Seroprevalence of COVID-19 and Psychosocial Effects in the General Population: Results of the STAAB-COVID-One Program].,2021-10-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Bavaria,Würzburg,,,2020-06-01,2020-10-31,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,,859,0.012,,,,,,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Felizitas Eichner,Universität Würzburg,Unity-Aligned,https://dx.doi.org/10.1055/a-1630-7601,2021-11-05,2024-03-01,Verified,eichner_seropravalenz_2021,DEU
211012_Germany_UniversitätWürzburg_SexFemale,211012_Germany_UniversitätWürzburg,[Seroprevalence of COVID-19 and Psychosocial Effects in the General Population: Results of the STAAB-COVID-One Program].,2021-10-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Bavaria,Würzburg,,,2020-06-01,2020-10-31,Household and community samples,Female,Multiple groups,30.0,79.0,Sex/Gender,,1577,0.008,,,,,,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Felizitas Eichner,Universität Würzburg,Unity-Aligned,https://dx.doi.org/10.1055/a-1630-7601,2021-11-04,2024-03-01,Verified,eichner_seropravalenz_2021,DEU
211012_Germany_UniversitätWürzburg_60-69,211012_Germany_UniversitätWürzburg,[Seroprevalence of COVID-19 and Psychosocial Effects in the General Population: Results of the STAAB-COVID-One Program].,2021-10-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Bavaria,Würzburg,,,2020-06-01,2020-10-31,Household and community samples,All,Seniors (65+ years),60.0,69.0,Age,,860,0.005,,,,,,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Felizitas Eichner,Universität Würzburg,Unity-Aligned,https://dx.doi.org/10.1055/a-1630-7601,2021-11-05,2024-03-01,Verified,eichner_seropravalenz_2021,DEU
211012_Germany_UniversitätWürzburg_SexMale,211012_Germany_UniversitätWürzburg,[Seroprevalence of COVID-19 and Psychosocial Effects in the General Population: Results of the STAAB-COVID-One Program].,2021-10-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Bavaria,Würzburg,,,2020-06-01,2020-10-31,Household and community samples,Male,Multiple groups,30.0,79.0,Sex/Gender,,1424,0.013999999999999999,,,,,,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Felizitas Eichner,Universität Würzburg,Unity-Aligned,https://dx.doi.org/10.1055/a-1630-7601,2021-11-04,2024-03-01,Verified,eichner_seropravalenz_2021,DEU
211012_Germany_UniversitätWürzburg_40-49,211012_Germany_UniversitätWürzburg,[Seroprevalence of COVID-19 and Psychosocial Effects in the General Population: Results of the STAAB-COVID-One Program].,2021-10-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Bavaria,Würzburg,,,2020-06-01,2020-10-31,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,,733,0.015,,,,,,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Felizitas Eichner,Universität Würzburg,Unity-Aligned,https://dx.doi.org/10.1055/a-1630-7601,2021-11-05,2024-03-01,Verified,eichner_seropravalenz_2021,DEU
211012_Germany_UniversitätWürzburg_30-39,211012_Germany_UniversitätWürzburg,[Seroprevalence of COVID-19 and Psychosocial Effects in the General Population: Results of the STAAB-COVID-One Program].,2021-10-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Bavaria,Würzburg,,,2020-06-01,2020-10-31,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,,256,0.02,,,,,,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Felizitas Eichner,Universität Würzburg,Unity-Aligned,https://dx.doi.org/10.1055/a-1630-7601,2021-11-05,2024-03-01,Verified,eichner_seropravalenz_2021,DEU
211012_Germany_UniversitätWürzburg_70-79,211012_Germany_UniversitätWürzburg,[Seroprevalence of COVID-19 and Psychosocial Effects in the General Population: Results of the STAAB-COVID-One Program].,2021-10-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Bavaria,Würzburg,,,2020-06-01,2020-10-31,Household and community samples,All,Seniors (65+ years),70.0,79.0,Age,70-79,293,0.01,,,,,,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Felizitas Eichner,Universität Würzburg,Unity-Aligned,https://dx.doi.org/10.1055/a-1630-7601,2021-11-05,2024-03-01,Verified,eichner_seropravalenz_2021,DEU
211025_Baden-Württemberg_HeidelbergUniversityHospital_overall,211025_Baden-Württemberg_HeidelbergUniversityHospital,"Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 in Households with Children, Southwest Germany, May-August 2020.",2021-10-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Baden-Württemberg,"Alb-Donau, Breisgau-Hochschwarzwald, Heidelberg/Rhein-Neckar, Karlsruhe, Mannheim, Neckar-Odenwald, Reutlingen, and Tübingen",members of households with 1 index case-patient with a previous SARS-CoV-2 infection confirmed by RT-PCR from a nasopharyngeal or oropharyngeal swab specimen.,,2020-05-11,2020-08-01,Contacts of COVID patients,All,Multiple groups,0.0,81.0,Primary Estimate,Overall ,1220,0.3279,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),recomWell SARS-CoV-2 IgG ELISA,Atellica® IM SARS-CoV-2 Total (COV2T)","Roche Diagnostics,Mikrogen GmbH,Siemens",Multiple Types,Serum,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,No,No,Unclear,Maximilian Stich,Heidelberg University Hospital,Not Unity-Aligned,https://wwwnc.cdc.gov/eid/article/27/12/21-0978_article,2021-11-02,2024-03-01,Unverified,stich_transmission_2021,DEU
211025_Baden-Württemberg_HeidelbergUniversityHospital_6-11,211025_Baden-Württemberg_HeidelbergUniversityHospital,"Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 in Households with Children, Southwest Germany, May-August 2020.",2021-10-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Baden-Württemberg,"Alb-Donau, Breisgau-Hochschwarzwald, Heidelberg/Rhein-Neckar, Karlsruhe, Mannheim, Neckar-Odenwald, Reutlingen, and Tübingen",members of households with 1 index case-patient with a previous SARS-CoV-2 infection confirmed by RT-PCR from a nasopharyngeal or oropharyngeal swab specimen.,,2020-05-11,2020-08-01,Contacts of COVID patients,All,Children and Youth (0-17 years),6.0,11.0,Age,6-11,257,0.307,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),recomWell SARS-CoV-2 IgG ELISA,Atellica® IM SARS-CoV-2 Total (COV2T)","Roche Diagnostics,Mikrogen GmbH,Siemens",Multiple Types,Serum,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,No,No,Unclear,Maximilian Stich,Heidelberg University Hospital,Not Unity-Aligned,https://wwwnc.cdc.gov/eid/article/27/12/21-0978_article,2022-02-11,2024-03-01,Unverified,stich_transmission_2021,DEU
211025_Baden-Württemberg_HeidelbergUniversityHospital_0-5,211025_Baden-Württemberg_HeidelbergUniversityHospital,"Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 in Households with Children, Southwest Germany, May-August 2020.",2021-10-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Baden-Württemberg,"Alb-Donau, Breisgau-Hochschwarzwald, Heidelberg/Rhein-Neckar, Karlsruhe, Mannheim, Neckar-Odenwald, Reutlingen, and Tübingen",members of households with 1 index case-patient with a previous SARS-CoV-2 infection confirmed by RT-PCR from a nasopharyngeal or oropharyngeal swab specimen.,,2020-05-11,2020-08-01,Contacts of COVID patients,All,Children and Youth (0-17 years),0.0,5.0,Age,0-5,177,0.266,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),recomWell SARS-CoV-2 IgG ELISA,Atellica® IM SARS-CoV-2 Total (COV2T)","Roche Diagnostics,Mikrogen GmbH,Siemens",Multiple Types,Serum,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,No,No,Unclear,Maximilian Stich,Heidelberg University Hospital,Not Unity-Aligned,https://wwwnc.cdc.gov/eid/article/27/12/21-0978_article,2022-02-11,2024-03-01,Unverified,stich_transmission_2021,DEU
211025_Baden-Württemberg_HeidelbergUniversityHospital_12-17,211025_Baden-Württemberg_HeidelbergUniversityHospital,"Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 in Households with Children, Southwest Germany, May-August 2020.",2021-10-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Baden-Württemberg,"Alb-Donau, Breisgau-Hochschwarzwald, Heidelberg/Rhein-Neckar, Karlsruhe, Mannheim, Neckar-Odenwald, Reutlingen, and Tübingen",members of households with 1 index case-patient with a previous SARS-CoV-2 infection confirmed by RT-PCR from a nasopharyngeal or oropharyngeal swab specimen.,,2020-05-11,2020-08-01,Contacts of COVID patients,All,Children and Youth (0-17 years),12.0,17.0,Age,12-17,244,0.27899999999999997,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),recomWell SARS-CoV-2 IgG ELISA,Atellica® IM SARS-CoV-2 Total (COV2T)","Roche Diagnostics,Mikrogen GmbH,Siemens",Multiple Types,Serum,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,No,No,Unclear,Maximilian Stich,Heidelberg University Hospital,Not Unity-Aligned,https://wwwnc.cdc.gov/eid/article/27/12/21-0978_article,2022-02-11,2024-03-01,Unverified,stich_transmission_2021,DEU
211101_Germany_RuhrUniversityBochum,211101_Germany_RuhrUniversityBochum,Low Serological Prevalence of SARS-CoV-2 Antibodies in Cancer Patients at a German University Oncology Center.,2021-11-01,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,,Bochum,"To be eligible for enrollment, patients had to have suspected or proven infection with SARS-CoV-2 and/or belonged to one or more specified risk groups, including cancer patients.",,2020-08-15,2021-02-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,88.0,Primary Estimate,,110,0.0909,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.995,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Oliver Overheu,Ruhr-University Bochum,Not Unity-Aligned,https://dx.doi.org/10.1159/000520572,2021-11-11,2024-03-01,Unverified,overheu_low_2021,DEU
211112_Ruhr_RuhrUniversityBochum_Primary,211112_Ruhr_RuhrUniversityBochum,Longitudinal Rise in Seroprevalence of SARS-CoV-2 Infections in Children in Western Germany-A Blind Spot in Epidemiology?.,2021-11-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Ruhr,"Bochum, Gütersloh, Herne","Asymptomatic children and adolescents who attended outpatient pediatric practices from June 2020 to February 2021 in the Ruhr region, located in Western Germany, for scheduled mandatory routine examinations (U—untersuchungen) from 6 months to 18 years of age were invited to participate in the study",,2020-06-15,2021-02-15,Residual sera,All,Children and Youth (0-17 years),0.0,18.0,Primary Estimate,,2145,0.0256,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),,,,['High'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Folke Brinkmann,Ruhr University Bochum,Unity-Aligned,https://dx.doi.org/10.3390/idr13040088,2021-12-07,2024-03-01,Verified,brinkmann_2021_longitudinal,DEU
211112_Ruhr_RuhrUniversityBochum_6-9,211112_Ruhr_RuhrUniversityBochum,Longitudinal Rise in Seroprevalence of SARS-CoV-2 Infections in Children in Western Germany-A Blind Spot in Epidemiology?.,2021-11-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Ruhr,"Bochum, Gütersloh, Herne","Asymptomatic children and adolescents who attended outpatient pediatric practices from June 2020 to February 2021 in the Ruhr region, located in Western Germany, for scheduled mandatory routine examinations (U—untersuchungen) from 6 months to 18 years of age were invited to participate in the study",,2020-06-15,2021-02-15,Residual sera,All,Children and Youth (0-17 years),6.0,6.0,Age,6-9,310,0.0226,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),,,,['High'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Folke Brinkmann,Ruhr University Bochum,Unity-Aligned,https://dx.doi.org/10.3390/idr13040088,2021-12-07,2024-03-01,Verified,brinkmann_2021_longitudinal,DEU
211112_Ruhr_RuhrUniversityBochum_Female,211112_Ruhr_RuhrUniversityBochum,Longitudinal Rise in Seroprevalence of SARS-CoV-2 Infections in Children in Western Germany-A Blind Spot in Epidemiology?.,2021-11-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Ruhr,"Bochum, Gütersloh, Herne","Asymptomatic children and adolescents who attended outpatient pediatric practices from June 2020 to February 2021 in the Ruhr region, located in Western Germany, for scheduled mandatory routine examinations (U—untersuchungen) from 6 months to 18 years of age were invited to participate in the study",,2020-06-15,2021-02-15,Residual sera,Female,Children and Youth (0-17 years),0.0,18.0,Sex/Gender,,1032,0.0252,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),,,,['High'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Folke Brinkmann,Ruhr University Bochum,Unity-Aligned,https://dx.doi.org/10.3390/idr13040088,2021-12-07,2024-03-01,Verified,brinkmann_2021_longitudinal,DEU
211112_Ruhr_RuhrUniversityBochum_0-5,211112_Ruhr_RuhrUniversityBochum,Longitudinal Rise in Seroprevalence of SARS-CoV-2 Infections in Children in Western Germany-A Blind Spot in Epidemiology?.,2021-11-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Ruhr,"Bochum, Gütersloh, Herne","Asymptomatic children and adolescents who attended outpatient pediatric practices from June 2020 to February 2021 in the Ruhr region, located in Western Germany, for scheduled mandatory routine examinations (U—untersuchungen) from 6 months to 18 years of age were invited to participate in the study",,2020-06-15,2021-02-15,Residual sera,All,Children and Youth (0-17 years),0.0,5.0,Age,0-5,1227,0.027700000000000002,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),,,,['High'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Folke Brinkmann,Ruhr University Bochum,Unity-Aligned,https://dx.doi.org/10.3390/idr13040088,2021-12-07,2024-03-01,Verified,brinkmann_2021_longitudinal,DEU
211112_Ruhr_RuhrUniversityBochum_Male,211112_Ruhr_RuhrUniversityBochum,Longitudinal Rise in Seroprevalence of SARS-CoV-2 Infections in Children in Western Germany-A Blind Spot in Epidemiology?.,2021-11-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Ruhr,"Bochum, Gütersloh, Herne","Asymptomatic children and adolescents who attended outpatient pediatric practices from June 2020 to February 2021 in the Ruhr region, located in Western Germany, for scheduled mandatory routine examinations (U—untersuchungen) from 6 months to 18 years of age were invited to participate in the study",,2020-06-15,2021-02-15,Residual sera,Male,Children and Youth (0-17 years),0.0,18.0,Sex/Gender,,1112,0.026099999999999998,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),,,,['High'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Folke Brinkmann,Ruhr University Bochum,Unity-Aligned,https://dx.doi.org/10.3390/idr13040088,2021-12-07,2024-03-01,Verified,brinkmann_2021_longitudinal,DEU
211112_Ruhr_RuhrUniversityBochum_10-18,211112_Ruhr_RuhrUniversityBochum,Longitudinal Rise in Seroprevalence of SARS-CoV-2 Infections in Children in Western Germany-A Blind Spot in Epidemiology?.,2021-11-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Ruhr,"Bochum, Gütersloh, Herne","Asymptomatic children and adolescents who attended outpatient pediatric practices from June 2020 to February 2021 in the Ruhr region, located in Western Germany, for scheduled mandatory routine examinations (U—untersuchungen) from 6 months to 18 years of age were invited to participate in the study",,2020-06-15,2021-02-15,Residual sera,All,Children and Youth (0-17 years),10.0,9.0,Age,10-18,597,0.0235,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),,,,['High'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Folke Brinkmann,Ruhr University Bochum,Unity-Aligned,https://dx.doi.org/10.3390/idr13040088,2021-12-07,2024-03-01,Verified,brinkmann_2021_longitudinal,DEU
211122_Germany_SaarlandUniversity_PEP/PrEP_Primary,211122_Germany_SaarlandUniversity_PEP/PrEP,IgG seroprevalence of COVID-19 among people living with HIV or at high risk of HIV in south-west Germany: A seroprevalence study.,2021-11-22,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,South-west Germany,,Individuals who received post- or pre-exposure (PEP/PrEP) HIV prophylaxis and who are at risk of acquiring HIV,,2020-04-01,2020-06-30,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,50,0.06,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,Roche Diagnostics",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Yes,Yes,No,,Dominic Kaddu-Mulindwa,Saarland University,Not Unity-Aligned,https://dx.doi.org/10.1111/hiv.13207,2021-12-01,2024-03-01,Unverified,kaddumulindwa_igg_2021,DEU
211122_Germany_SaarlandUniversity_PLWH_Primary,211122_Germany_SaarlandUniversity_PLWH,IgG seroprevalence of COVID-19 among people living with HIV or at high risk of HIV in south-west Germany: A seroprevalence study.,2021-11-22,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,South-west Germany,,PLWH in the south-west of Germany in two HIV centres.,,2020-04-01,2020-06-30,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,81.0,Primary Estimate,,594,0.018500000000000003,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,Roche Diagnostics",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Yes,Yes,No,,Dominic Kaddu-Mulindwa,Saarland University,Not Unity-Aligned,https://dx.doi.org/10.1111/hiv.13207,2021-12-01,2024-03-01,Unverified,kaddumulindwa_igg_2021,DEU
211113_Hannover_HannoverMedicalSchool_Overall_Roche+Neut,211113_Hannover_HannoverMedicalSchool,Children and Adolescents' Behavioral Patterns in Response to Escalating COVID-19 Restriction Reveal Sex and Age Differences.,2021-11-23,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,Lower Saxony,Hannover,"open to all students (grades 5–13) attending a secondary school in Hannover, Germany",,2020-06-15,2021-06-15,Students and Daycares,All,Children and Youth (0-17 years),11.0,19.0,Primary Estimate,,667,0.0165,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Author designed (Neutralization Assay)","Roche Diagnostics,NA",Multiple Types,Serum,"['Neutralizing', 'TotalAntibody']","['Notreported', 'Spike']",,,,['Moderate'],,No,Yes,No,,Yes,Yes,No,,Mira Paulsen,Hannover Medical School,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jadohealth.2021.11.021,2022-01-13,2022-07-16,Unverified,paulsen_children_2021,DEU
211124_Germany_RobertKochInstitute_Primary,211124_Germany_RobertKochInstitute,Germany's low SARS-CoV-2 seroprevalence confirms effective containment in 2020: Results of the nationwide RKI-SOEP study,2021-11-24,Preprint,National,Prospective cohort,Germany,,,German residents who are a part of the nationwide RKI-SOEP study.,,2020-10-15,2020-11-15,Household and community samples,All,Multiple groups,18.0,99.0,Primary Estimate,,14781,0.013000000000000001,0.009000000000000001,0.017,True,True,True,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8109999999999999,0.997,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Hannelore Neuhauser,Robert Koch Institute,Not Unity-Aligned,10.1101/2021.11.22.21266711,2021-11-30,2023-08-15,Unverified,neuhauser_germanys_2021,DEU
211124_Germany_RobertKochInstitute_Age_80-99,211124_Germany_RobertKochInstitute,Germany's low SARS-CoV-2 seroprevalence confirms effective containment in 2020: Results of the nationwide RKI-SOEP study,2021-11-24,Preprint,National,Prospective cohort,Germany,,,German residents who are a part of the nationwide RKI-SOEP study.,,2020-10-15,2020-11-15,Household and community samples,All,Seniors (65+ years),80.0,99.0,Age,80-99,655,0.002,0.002,0.017,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8109999999999999,0.997,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Hannelore Neuhauser,Robert Koch Institute,Not Unity-Aligned,10.1101/2021.11.22.21266711,2021-11-30,2023-08-15,Unverified,neuhauser_germanys_2021,DEU
211124_Germany_RobertKochInstitute_Age_50-64,211124_Germany_RobertKochInstitute,Germany's low SARS-CoV-2 seroprevalence confirms effective containment in 2020: Results of the nationwide RKI-SOEP study,2021-11-24,Preprint,National,Prospective cohort,Germany,,,German residents who are a part of the nationwide RKI-SOEP study.,,2020-10-15,2020-11-15,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50-64,4846,0.013000000000000001,0.006999999999999999,0.021,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8109999999999999,0.997,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Hannelore Neuhauser,Robert Koch Institute,Not Unity-Aligned,10.1101/2021.11.22.21266711,2021-11-30,2023-08-15,Unverified,neuhauser_germanys_2021,DEU
211124_Germany_RobertKochInstitute_Age_18-34,211124_Germany_RobertKochInstitute,Germany's low SARS-CoV-2 seroprevalence confirms effective containment in 2020: Results of the nationwide RKI-SOEP study,2021-11-24,Preprint,National,Prospective cohort,Germany,,,German residents who are a part of the nationwide RKI-SOEP study.,,2020-10-15,2020-11-15,Household and community samples,All,Adults (18-64 years),18.0,34.0,Age,18-34,2741,0.02,0.011000000000000001,0.035,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8109999999999999,0.997,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Hannelore Neuhauser,Robert Koch Institute,Not Unity-Aligned,10.1101/2021.11.22.21266711,2021-11-30,2023-08-15,Unverified,neuhauser_germanys_2021,DEU
211124_Germany_RobertKochInstitute_Age_35-49,211124_Germany_RobertKochInstitute,Germany's low SARS-CoV-2 seroprevalence confirms effective containment in 2020: Results of the nationwide RKI-SOEP study,2021-11-24,Preprint,National,Prospective cohort,Germany,,,German residents who are a part of the nationwide RKI-SOEP study.,,2020-10-15,2020-11-15,Household and community samples,All,Adults (18-64 years),35.0,49.0,Age,35-49,3484,0.012,0.005,0.024,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8109999999999999,0.997,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Hannelore Neuhauser,Robert Koch Institute,Not Unity-Aligned,10.1101/2021.11.22.21266711,2021-11-30,2023-08-15,Unverified,neuhauser_germanys_2021,DEU
211124_Germany_RobertKochInstitute_Sex_Female,211124_Germany_RobertKochInstitute,Germany's low SARS-CoV-2 seroprevalence confirms effective containment in 2020: Results of the nationwide RKI-SOEP study,2021-11-24,Preprint,National,Prospective cohort,Germany,,,German residents who are a part of the nationwide RKI-SOEP study.,,2020-10-15,2020-11-15,Household and community samples,Female,Multiple groups,18.0,99.0,Sex/Gender,,7938,0.011000000000000001,0.006,0.017,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8109999999999999,0.997,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Hannelore Neuhauser,Robert Koch Institute,Not Unity-Aligned,10.1101/2021.11.22.21266711,2021-11-30,2023-08-15,Unverified,neuhauser_germanys_2021,DEU
211124_Germany_RobertKochInstitute_Age_65-79,211124_Germany_RobertKochInstitute,Germany's low SARS-CoV-2 seroprevalence confirms effective containment in 2020: Results of the nationwide RKI-SOEP study,2021-11-24,Preprint,National,Prospective cohort,Germany,,,German residents who are a part of the nationwide RKI-SOEP study.,,2020-10-15,2020-11-15,Household and community samples,All,Seniors (65+ years),65.0,79.0,Age,65-79,3055,0.006,0.002,0.013000000000000001,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8109999999999999,0.997,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Hannelore Neuhauser,Robert Koch Institute,Not Unity-Aligned,10.1101/2021.11.22.21266711,2021-11-30,2023-08-15,Unverified,neuhauser_germanys_2021,DEU
211124_Germany_RobertKochInstitute_Sex_Male,211124_Germany_RobertKochInstitute,Germany's low SARS-CoV-2 seroprevalence confirms effective containment in 2020: Results of the nationwide RKI-SOEP study,2021-11-24,Preprint,National,Prospective cohort,Germany,,,German residents who are a part of the nationwide RKI-SOEP study.,,2020-10-15,2020-11-15,Household and community samples,Male,Multiple groups,18.0,99.0,Sex/Gender,,6843,0.015,0.01,0.021,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8109999999999999,0.997,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Hannelore Neuhauser,Robert Koch Institute,Not Unity-Aligned,10.1101/2021.11.22.21266711,2021-11-30,2023-08-15,Unverified,neuhauser_germanys_2021,DEU
211125_NorthRhine-Westphalia_UniversitiyClinicsHamburgEppendorf_Apr2020_Overall,211125_NorthRhine-Westphalia_UniversitiyClinicsHamburgEppendorf_Apr2020,Cumulative incidence of SARS-CoV-2 infections in health workers in Germany,2021-11-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,North Rhine-Westphalia,,HW of a general hospital in North-Rhine-Westphalia,,2020-04-01,2020-04-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1212,0.022000000000000002,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,IgG,,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Albert Nienhaus,St. Antonius Hospital,Not Unity-Aligned,10.1183/13993003.congress-2021.PA3187,2022-03-03,2022-07-16,Unverified,nienhaus_cumulative_2021,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Aachen1_Overall_PopTestAdj,211203_Germany_HelmholtzCenterforInfectionResearch_Aachen1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,North Rhine-Westphalia,Aachen,Residents of Aachen >18 years of age.,Vaccinated subjects,2020-09-09,2020-10-09,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2023,0.02,0.01,0.028999999999999998,True,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Aachen1_>79,211203_Germany_HelmholtzCenterforInfectionResearch_Aachen1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,North Rhine-Westphalia,Aachen,Residents of Aachen >18 years of age.,Vaccinated subjects,2020-09-09,2020-10-09,Household and community samples,All,Multiple groups,18.0,,Age,>79,93,0.054000000000000006,0.022000000000000002,0.126,,,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2024-03-01,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Aachen1_66-79,211203_Germany_HelmholtzCenterforInfectionResearch_Aachen1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,North Rhine-Westphalia,Aachen,Residents of Aachen >18 years of age.,Vaccinated subjects,2020-09-09,2020-10-09,Household and community samples,All,Multiple groups,18.0,,Age,66-79,346,0.016,0.001,0.033,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Aachen1_46-65,211203_Germany_HelmholtzCenterforInfectionResearch_Aachen1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,North Rhine-Westphalia,Aachen,Residents of Aachen >18 years of age.,Vaccinated subjects,2020-09-09,2020-10-09,Household and community samples,All,Multiple groups,18.0,,Age,46-65,800,0.02,0.006,0.034,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Aachen1_Overall_PopAdj,211203_Germany_HelmholtzCenterforInfectionResearch_Aachen1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,North Rhine-Westphalia,Aachen,Residents of Aachen >18 years of age.,Vaccinated subjects,2020-09-09,2020-10-09,Household and community samples,All,Multiple groups,18.0,,Analysis,,2023,0.023,0.017,0.031000000000000003,,,True,,True,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2024-03-01,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Aachen1_18-25,211203_Germany_HelmholtzCenterforInfectionResearch_Aachen1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,North Rhine-Westphalia,Aachen,Residents of Aachen >18 years of age.,Vaccinated subjects,2020-09-09,2020-10-09,Household and community samples,All,Multiple groups,18.0,,Age,18-25,205,0.027000000000000003,0.002,0.054000000000000006,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Aachen1_26-45,211203_Germany_HelmholtzCenterforInfectionResearch_Aachen1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,North Rhine-Westphalia,Aachen,Residents of Aachen >18 years of age.,Vaccinated subjects,2020-09-09,2020-10-09,Household and community samples,All,Multiple groups,18.0,,Age,26-45,579,0.008,0.0,0.017,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Aachen2_Overall_PopTestAdj,211203_Germany_HelmholtzCenterforInfectionResearch_Aachen2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,North Rhine-Westphalia,Aachen,Residents of Aachen >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2021-01-27,2021-02-23,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,1888,0.052000000000000005,0.036000000000000004,0.069,True,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Aachen2_Overall_PopAdj,211203_Germany_HelmholtzCenterforInfectionResearch_Aachen2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,North Rhine-Westphalia,Aachen,Residents of Aachen >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2021-01-27,2021-02-23,Household and community samples,All,Multiple groups,18.0,,Analysis,,1888,0.054000000000000006,0.044000000000000004,0.065,,,True,,True,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2024-03-01,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Aachen2_66-79,211203_Germany_HelmholtzCenterforInfectionResearch_Aachen2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,North Rhine-Westphalia,Aachen,Residents of Aachen >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2021-01-27,2021-02-23,Household and community samples,All,Multiple groups,18.0,,Age,66-79,331,0.044000000000000004,0.016,0.073,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Aachen2_46-65,211203_Germany_HelmholtzCenterforInfectionResearch_Aachen2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,North Rhine-Westphalia,Aachen,Residents of Aachen >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2021-01-27,2021-02-23,Household and community samples,All,Multiple groups,18.0,,Age,46-65,759,0.061,0.038,0.083,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Aachen2_26-45,211203_Germany_HelmholtzCenterforInfectionResearch_Aachen2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,North Rhine-Westphalia,Aachen,Residents of Aachen >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2021-01-27,2021-02-23,Household and community samples,All,Multiple groups,18.0,,Age,26-45,537,0.033,0.013000000000000001,0.055,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Aachen2_>79,211203_Germany_HelmholtzCenterforInfectionResearch_Aachen2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,North Rhine-Westphalia,Aachen,Residents of Aachen >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2021-01-27,2021-02-23,Household and community samples,All,Multiple groups,18.0,,Age,>79,72,0.078,0.034,0.16899999999999998,,,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2024-03-01,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Aachen2_18-25,211203_Germany_HelmholtzCenterforInfectionResearch_Aachen2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,North Rhine-Westphalia,Aachen,Residents of Aachen >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2021-01-27,2021-02-23,Household and community samples,All,Multiple groups,18.0,,Age,18-25,189,0.063,0.023,0.106,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Chemnitz1_Overall_PopTestAdj,211203_Germany_HelmholtzCenterforInfectionResearch_Chemnitz1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Saxony,Chemnitz,Residents of Chemnitz >18 years of age.,Vaccinated subjects,2021-03-03,2021-04-01,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2702,0.14300000000000002,0.12,0.165,True,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Chemnitz1_Overall_PopAdj,211203_Germany_HelmholtzCenterforInfectionResearch_Chemnitz1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Saxony,Chemnitz,Residents of Chemnitz >18 years of age.,Vaccinated subjects,2021-03-03,2021-04-01,Household and community samples,All,Multiple groups,18.0,,Analysis,,2702,0.131,0.115,0.149,,,True,,True,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2024-03-01,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Chemnitz1_26-45,211203_Germany_HelmholtzCenterforInfectionResearch_Chemnitz1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Saxony,Chemnitz,Residents of Chemnitz >18 years of age.,Vaccinated subjects,2021-03-03,2021-04-01,Household and community samples,All,Multiple groups,18.0,,Age,26-45,725,0.133,0.10300000000000001,0.163,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Chemnitz1_>79,211203_Germany_HelmholtzCenterforInfectionResearch_Chemnitz1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Saxony,Chemnitz,Residents of Chemnitz >18 years of age.,Vaccinated subjects,2021-03-03,2021-04-01,Household and community samples,All,Multiple groups,18.0,,Age,>79,50,0.218,0.122,0.359,,,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2024-03-01,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Chemnitz1_46-65,211203_Germany_HelmholtzCenterforInfectionResearch_Chemnitz1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Saxony,Chemnitz,Residents of Chemnitz >18 years of age.,Vaccinated subjects,2021-03-03,2021-04-01,Household and community samples,All,Multiple groups,18.0,,Age,46-65,1137,0.139,0.115,0.165,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Chemnitz1_66-79,211203_Germany_HelmholtzCenterforInfectionResearch_Chemnitz1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Saxony,Chemnitz,Residents of Chemnitz >18 years of age.,Vaccinated subjects,2021-03-03,2021-04-01,Household and community samples,All,Multiple groups,18.0,,Age,66-79,651,0.11199999999999999,0.083,0.142,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Chemnitz1_18-25,211203_Germany_HelmholtzCenterforInfectionResearch_Chemnitz1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Saxony,Chemnitz,Residents of Chemnitz >18 years of age.,Vaccinated subjects,2021-03-03,2021-04-01,Household and community samples,All,Multiple groups,18.0,,Age,18-25,139,0.129,0.069,0.19399999999999998,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Chemnitz2_Overall_PopTestAdj,211203_Germany_HelmholtzCenterforInfectionResearch_Chemnitz2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Saxony,Chemnitz,Residents of Chemnitz >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2021-07-21,2021-08-17,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,358,0.374,0.315,0.434,True,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Chemnitz2_Overall_PopAdj,211203_Germany_HelmholtzCenterforInfectionResearch_Chemnitz2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Saxony,Chemnitz,Residents of Chemnitz >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2021-07-21,2021-08-17,Household and community samples,All,Multiple groups,18.0,,Analysis,,358,0.324,0.27399999999999997,0.378,,,True,,True,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2024-03-01,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Chemnitz2_66-79&>79,211203_Germany_HelmholtzCenterforInfectionResearch_Chemnitz2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Saxony,Chemnitz,Residents of Chemnitz >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2021-07-21,2021-08-17,Household and community samples,All,Multiple groups,18.0,,Age,66-79,72,0.626,0.489,0.757,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Chemnitz2_18-25&26-45,211203_Germany_HelmholtzCenterforInfectionResearch_Chemnitz2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Saxony,Chemnitz,Residents of Chemnitz >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2021-07-21,2021-08-17,Household and community samples,All,Multiple groups,18.0,,Age,18-25,127,0.19100000000000003,0.11699999999999999,0.271,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Chemnitz2_46-65,211203_Germany_HelmholtzCenterforInfectionResearch_Chemnitz2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Saxony,Chemnitz,Residents of Chemnitz >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2021-07-21,2021-08-17,Household and community samples,All,Multiple groups,18.0,,Age,46-65,159,0.344,0.26,0.428,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Freiburg1_Overall_PopTestAdj,211203_Germany_HelmholtzCenterforInfectionResearch_Freiburg1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Baden-Württemberg,Freiburg,Residents of Freiburg >18 years of age.,Vaccinated subjects,2020-08-05,2020-09-01,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2867,0.012,0.005,0.019,True,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Freiburg1_>79,211203_Germany_HelmholtzCenterforInfectionResearch_Freiburg1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Baden-Württemberg,Freiburg,Residents of Freiburg >18 years of age.,Vaccinated subjects,2020-08-05,2020-09-01,Household and community samples,All,Multiple groups,18.0,,Age,>79,126,0.0,0.0,0.0,,,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2024-03-01,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Freiburg1_18-25,211203_Germany_HelmholtzCenterforInfectionResearch_Freiburg1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Baden-Württemberg,Freiburg,Residents of Freiburg >18 years of age.,Vaccinated subjects,2020-08-05,2020-09-01,Household and community samples,All,Multiple groups,18.0,,Age,18-25,271,0.011000000000000001,0.0,0.025,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Freiburg1_26-45,211203_Germany_HelmholtzCenterforInfectionResearch_Freiburg1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Baden-Württemberg,Freiburg,Residents of Freiburg >18 years of age.,Vaccinated subjects,2020-08-05,2020-09-01,Household and community samples,All,Multiple groups,18.0,,Age,26-45,1029,0.013000000000000001,0.002,0.023,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Freiburg1_46-65,211203_Germany_HelmholtzCenterforInfectionResearch_Freiburg1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Baden-Württemberg,Freiburg,Residents of Freiburg >18 years of age.,Vaccinated subjects,2020-08-05,2020-09-01,Household and community samples,All,Multiple groups,18.0,,Age,46-65,1007,0.011000000000000001,0.01,0.21,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Freiburg1_66-79,211203_Germany_HelmholtzCenterforInfectionResearch_Freiburg1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Baden-Württemberg,Freiburg,Residents of Freiburg >18 years of age.,Vaccinated subjects,2020-08-05,2020-09-01,Household and community samples,All,Multiple groups,18.0,,Age,66-79,434,0.015,0.002,0.03,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Freiburg1_Overall_PopAdj,211203_Germany_HelmholtzCenterforInfectionResearch_Freiburg1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Baden-Württemberg,Freiburg,Residents of Freiburg >18 years of age.,Vaccinated subjects,2020-08-05,2020-09-01,Household and community samples,All,Multiple groups,18.0,,Analysis,,2867,0.015,0.011000000000000001,0.02,,,True,,True,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2024-03-01,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Freiburg2_Overall_PopTestAdj,211203_Germany_HelmholtzCenterforInfectionResearch_Freiburg2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Baden-Württemberg,Freiburg,Residents of Freiburg >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2020-11-18,2020-12-15,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2867,0.02,0.01,0.031000000000000003,True,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Freiburg2_18-25,211203_Germany_HelmholtzCenterforInfectionResearch_Freiburg2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Baden-Württemberg,Freiburg,Residents of Freiburg >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2020-11-18,2020-12-15,Household and community samples,All,Multiple groups,18.0,,Age,18-25,170,0.022000000000000002,0.001,0.048,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Freiburg2_26-45,211203_Germany_HelmholtzCenterforInfectionResearch_Freiburg2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Baden-Württemberg,Freiburg,Residents of Freiburg >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2020-11-18,2020-12-15,Household and community samples,All,Multiple groups,18.0,,Age,26-45,661,0.021,0.006,0.037000000000000005,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Freiburg2_>79,211203_Germany_HelmholtzCenterforInfectionResearch_Freiburg2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Baden-Württemberg,Freiburg,Residents of Freiburg >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2020-11-18,2020-12-15,Household and community samples,All,Multiple groups,18.0,,Age,>79,55,0.044000000000000004,0.01,0.16399999999999998,,,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2024-03-01,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Freiburg2_46-65,211203_Germany_HelmholtzCenterforInfectionResearch_Freiburg2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Baden-Württemberg,Freiburg,Residents of Freiburg >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2020-11-18,2020-12-15,Household and community samples,All,Multiple groups,18.0,,Age,46-65,627,0.013999999999999999,0.001,0.027000000000000003,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Freiburg2_66-79,211203_Germany_HelmholtzCenterforInfectionResearch_Freiburg2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Baden-Württemberg,Freiburg,Residents of Freiburg >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2020-11-18,2020-12-15,Household and community samples,All,Multiple groups,18.0,,Age,66-79,275,0.015,0.0,0.033,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Freiburg2_Overall_PopAdj,211203_Germany_HelmholtzCenterforInfectionResearch_Freiburg2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Baden-Württemberg,Freiburg,Residents of Freiburg >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2020-11-18,2020-12-15,Household and community samples,All,Multiple groups,18.0,,Analysis,,2867,0.024,0.021,0.037000000000000005,,,True,,True,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2024-03-01,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Greifswald_Overall_PopTestAdj,211203_Germany_HelmholtzCenterforInfectionResearch_Greifswald,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Mecklenburg-Vorpommern,Greifswald,Residents of Greifswald >18 years of age.,Vaccinated subjects,2021-06-08,2021-06-08,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,954,0.136,0.102,0.171,True,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Greifswald_Overall_PopAdj,211203_Germany_HelmholtzCenterforInfectionResearch_Greifswald,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Mecklenburg-Vorpommern,Greifswald,Residents of Greifswald >18 years of age.,Vaccinated subjects,2021-06-08,2021-06-08,Household and community samples,All,Multiple groups,18.0,,Analysis,,954,0.11599999999999999,0.094,0.14300000000000002,,,True,,True,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2024-03-01,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Greifswald_18-25,211203_Germany_HelmholtzCenterforInfectionResearch_Greifswald,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Mecklenburg-Vorpommern,Greifswald,Residents of Greifswald >18 years of age.,Vaccinated subjects,2021-06-08,2021-06-08,Household and community samples,All,Multiple groups,18.0,,Age,18-25,109,0.095,0.06,0.131,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Greifswald_26-45,211203_Germany_HelmholtzCenterforInfectionResearch_Greifswald,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Mecklenburg-Vorpommern,Greifswald,Residents of Greifswald >18 years of age.,Vaccinated subjects,2021-06-08,2021-06-08,Household and community samples,All,Multiple groups,18.0,,Age,26-45,387,0.105,0.07,0.14300000000000002,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Greifswald_66-79&>79,211203_Germany_HelmholtzCenterforInfectionResearch_Greifswald,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Mecklenburg-Vorpommern,Greifswald,Residents of Greifswald >18 years of age.,Vaccinated subjects,2021-06-08,2021-06-08,Household and community samples,All,Multiple groups,18.0,,Age,66-79,75,0.158,0.073,0.252,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Greifswald_46-65,211203_Germany_HelmholtzCenterforInfectionResearch_Greifswald,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Mecklenburg-Vorpommern,Greifswald,Residents of Greifswald >18 years of age.,Vaccinated subjects,2021-06-08,2021-06-08,Household and community samples,All,Multiple groups,18.0,,Age,46-65,383,0.138,0.099,0.179,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Magdeburg1_Overall_PopTestAdj,211203_Germany_HelmholtzCenterforInfectionResearch_Magdeburg1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Saxony-Anhalt,Magdeburg,Residents of Magdeburg >18 years of age.,Vaccinated subjects,2020-11-18,2020-12-15,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2713,0.02,0.011000000000000001,0.028999999999999998,True,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Magdeburg1_26-45,211203_Germany_HelmholtzCenterforInfectionResearch_Magdeburg1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Saxony-Anhalt,Magdeburg,Residents of Magdeburg >18 years of age.,Vaccinated subjects,2020-11-18,2020-12-15,Household and community samples,All,Multiple groups,18.0,,Age,26-45,806,0.026000000000000002,0.011000000000000001,0.042,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Magdeburg1_66-79,211203_Germany_HelmholtzCenterforInfectionResearch_Magdeburg1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Saxony-Anhalt,Magdeburg,Residents of Magdeburg >18 years of age.,Vaccinated subjects,2020-11-18,2020-12-15,Household and community samples,All,Multiple groups,18.0,,Age,66-79,571,0.009000000000000001,0.0,0.02,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Magdeburg1_Overall_PopAdj,211203_Germany_HelmholtzCenterforInfectionResearch_Magdeburg1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Saxony-Anhalt,Magdeburg,Residents of Magdeburg >18 years of age.,Vaccinated subjects,2020-11-18,2020-12-15,Household and community samples,All,Multiple groups,18.0,,Analysis,,2713,0.024,0.019,0.031000000000000003,,,True,,True,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2024-03-01,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Magdeburg1_>79,211203_Germany_HelmholtzCenterforInfectionResearch_Magdeburg1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Saxony-Anhalt,Magdeburg,Residents of Magdeburg >18 years of age.,Vaccinated subjects,2020-11-18,2020-12-15,Household and community samples,All,Multiple groups,18.0,,Age,>79,212,0.05,0.027000000000000003,0.09300000000000001,,,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2024-03-01,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Magdeburg1_18-25,211203_Germany_HelmholtzCenterforInfectionResearch_Magdeburg1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Saxony-Anhalt,Magdeburg,Residents of Magdeburg >18 years of age.,Vaccinated subjects,2020-11-18,2020-12-15,Household and community samples,All,Multiple groups,18.0,,Age,18-25,144,0.021,0.0,0.047,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Magdeburg1_46-65,211203_Germany_HelmholtzCenterforInfectionResearch_Magdeburg1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Saxony-Anhalt,Magdeburg,Residents of Magdeburg >18 years of age.,Vaccinated subjects,2020-11-18,2020-12-15,Household and community samples,All,Multiple groups,18.0,,Age,46-65,980,0.011000000000000001,0.01,0.022000000000000002,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Magdeburg2_Overall_PopTestAdj,211203_Germany_HelmholtzCenterforInfectionResearch_Magdeburg2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Saxony-Anhalt,Magdeburg,Residents of Magdeburg >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2021-04-07,2021-05-05,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,1118,0.092,0.069,0.11599999999999999,True,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Magdeburg2_26-45,211203_Germany_HelmholtzCenterforInfectionResearch_Magdeburg2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Saxony-Anhalt,Magdeburg,Residents of Magdeburg >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2021-04-07,2021-05-05,Household and community samples,All,Multiple groups,18.0,,Age,26-45,385,0.066,0.037000000000000005,0.098,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Magdeburg2_18-25,211203_Germany_HelmholtzCenterforInfectionResearch_Magdeburg2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Saxony-Anhalt,Magdeburg,Residents of Magdeburg >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2021-04-07,2021-05-05,Household and community samples,All,Multiple groups,18.0,,Age,18-25,85,0.087,0.024,0.157,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Magdeburg2_Overall_PopAdj,211203_Germany_HelmholtzCenterforInfectionResearch_Magdeburg2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Saxony-Anhalt,Magdeburg,Residents of Magdeburg >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2021-04-07,2021-05-05,Household and community samples,All,Multiple groups,18.0,,Analysis,,1118,0.06,0.037000000000000005,0.09699999999999999,,,True,,True,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2024-03-01,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Magdeburg2_46-65,211203_Germany_HelmholtzCenterforInfectionResearch_Magdeburg2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Saxony-Anhalt,Magdeburg,Residents of Magdeburg >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2021-04-07,2021-05-05,Household and community samples,All,Multiple groups,18.0,,Age,46-65,450,0.08800000000000001,0.057999999999999996,0.121,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Magdeburg2_66-79&>79,211203_Germany_HelmholtzCenterforInfectionResearch_Magdeburg2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Saxony-Anhalt,Magdeburg,Residents of Magdeburg >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2021-04-07,2021-05-05,Household and community samples,All,Multiple groups,18.0,,Age,66-79 & >79,198,0.128,0.076,0.18100000000000002,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Osnabruck1_Overall_PopTestAdj,211203_Germany_HelmholtzCenterforInfectionResearch_Osnabruck1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Lower Saxony,Osnabruck,Residents of Osnabruck >18 years of age.,Vaccinated subjects,2020-10-15,2020-11-15,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2923,0.011000000000000001,0.004,0.017,True,,,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2024-03-01,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Osnabruck1_46-65,211203_Germany_HelmholtzCenterforInfectionResearch_Osnabruck1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Lower Saxony,Osnabruck,Residents of Osnabruck >18 years of age.,Vaccinated subjects,2020-10-15,2020-11-15,Household and community samples,All,Multiple groups,18.0,,Age,46-65,1345,0.008,0.0,0.015,,,,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2024-03-01,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Osnabruck1_26-45,211203_Germany_HelmholtzCenterforInfectionResearch_Osnabruck1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Lower Saxony,Osnabruck,Residents of Osnabruck >18 years of age.,Vaccinated subjects,2020-10-15,2020-11-15,Household and community samples,All,Multiple groups,18.0,,Age,26-45,780,0.011000000000000001,0.001,0.021,,,,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2024-03-01,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Osnabruck1_Overall_PopAdj,211203_Germany_HelmholtzCenterforInfectionResearch_Osnabruck1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Lower Saxony,Osnabruck,Residents of Osnabruck >18 years of age.,Vaccinated subjects,2020-10-15,2020-11-15,Household and community samples,All,Multiple groups,18.0,,Analysis,,2923,0.013000000000000001,0.01,0.018000000000000002,,,,,True,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2024-03-01,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Osnabruck1_18-25,211203_Germany_HelmholtzCenterforInfectionResearch_Osnabruck1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Lower Saxony,Osnabruck,Residents of Osnabruck >18 years of age.,Vaccinated subjects,2020-10-15,2020-11-15,Household and community samples,All,Multiple groups,18.0,,Age,18-25,229,0.013000000000000001,0.0,0.03,,,,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2024-03-01,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Osnabruck1_66-79,211203_Germany_HelmholtzCenterforInfectionResearch_Osnabruck1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Lower Saxony,Osnabruck,Residents of Osnabruck >18 years of age.,Vaccinated subjects,2020-10-15,2020-11-15,Household and community samples,All,Multiple groups,18.0,,Age,66-79,462,0.013999999999999999,0.001,0.027999999999999997,,,,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2024-03-01,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Osnabruck1_>79,211203_Germany_HelmholtzCenterforInfectionResearch_Osnabruck1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Lower Saxony,Osnabruck,Residents of Osnabruck >18 years of age.,Vaccinated subjects,2020-10-15,2020-11-15,Household and community samples,All,Multiple groups,18.0,,Age,>79,107,0.0,0.0,0.0,,,,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2024-03-01,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Osnabruck2_Overall_PopTestAdj,211203_Germany_HelmholtzCenterforInfectionResearch_Osnabruck2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Lower Saxony,Osnabruck,Residents of Osnabruck >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2021-03-01,2021-03-31,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,1611,0.037000000000000005,0.021,0.052000000000000005,True,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Osnabruck2_Overall_PopAdj,211203_Germany_HelmholtzCenterforInfectionResearch_Osnabruck2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Lower Saxony,Osnabruck,Residents of Osnabruck >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2021-03-01,2021-03-31,Household and community samples,All,Multiple groups,18.0,,Analysis,,1611,0.040999999999999995,0.032,0.052000000000000005,,,True,,True,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2024-03-01,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Osnabruck2_46-65,211203_Germany_HelmholtzCenterforInfectionResearch_Osnabruck2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Lower Saxony,Osnabruck,Residents of Osnabruck >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2021-03-01,2021-03-31,Household and community samples,All,Multiple groups,18.0,,Age,46-65,713,0.043,0.022000000000000002,0.064,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Osnabruck2_66-79&>79,211203_Germany_HelmholtzCenterforInfectionResearch_Osnabruck2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Lower Saxony,Osnabruck,Residents of Osnabruck >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2021-03-01,2021-03-31,Household and community samples,All,Multiple groups,18.0,,Age,66-79 & >79,285,0.033,0.006,0.061,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Osnabruck2_26-45,211203_Germany_HelmholtzCenterforInfectionResearch_Osnabruck2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Lower Saxony,Osnabruck,Residents of Osnabruck >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2021-03-01,2021-03-31,Household and community samples,All,Multiple groups,18.0,,Age,26-45,459,0.027000000000000003,0.006,0.049,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Osnabruck2_18-25,211203_Germany_HelmholtzCenterforInfectionResearch_Osnabruck2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Lower Saxony,Osnabruck,Residents of Osnabruck >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2021-03-01,2021-03-31,Household and community samples,All,Multiple groups,18.0,,Age,18-25,154,0.05,0.012,0.09300000000000001,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Reutlingen1_Overall_PopTestAdj,211203_Germany_HelmholtzCenterforInfectionResearch_Reutlingen1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Baden-Württemberg,Reutlingen,Residents of Reutlingen >18 years of age.,Vaccinated subjects,2020-07-01,2020-07-28,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2407,0.02,0.01,0.03,True,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Reutlingen1_26-45,211203_Germany_HelmholtzCenterforInfectionResearch_Reutlingen1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Baden-Württemberg,Reutlingen,Residents of Reutlingen >18 years of age.,Vaccinated subjects,2020-07-01,2020-07-28,Household and community samples,All,Multiple groups,18.0,,Age,26-45,637,0.016,0.002,0.03,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Reutlingen1_>79,211203_Germany_HelmholtzCenterforInfectionResearch_Reutlingen1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Baden-Württemberg,Reutlingen,Residents of Reutlingen >18 years of age.,Vaccinated subjects,2020-07-01,2020-07-28,Household and community samples,All,Multiple groups,18.0,,Age,>79,120,0.011000000000000001,0.001,0.07400000000000001,,,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2024-03-01,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Reutlingen1_46-65,211203_Germany_HelmholtzCenterforInfectionResearch_Reutlingen1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Baden-Württemberg,Reutlingen,Residents of Reutlingen >18 years of age.,Vaccinated subjects,2020-07-01,2020-07-28,Household and community samples,All,Multiple groups,18.0,,Age,46-65,1032,0.019,0.005,0.033,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Reutlingen1_18-25,211203_Germany_HelmholtzCenterforInfectionResearch_Reutlingen1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Baden-Württemberg,Reutlingen,Residents of Reutlingen >18 years of age.,Vaccinated subjects,2020-07-01,2020-07-28,Household and community samples,All,Multiple groups,18.0,,Age,18-25,255,0.042,0.013000000000000001,0.07400000000000001,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Reutlingen1_Overall_PopAdj,211203_Germany_HelmholtzCenterforInfectionResearch_Reutlingen1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Baden-Württemberg,Reutlingen,Residents of Reutlingen >18 years of age.,Vaccinated subjects,2020-07-01,2020-07-28,Household and community samples,All,Multiple groups,18.0,,Analysis,,2407,0.026000000000000002,0.02,0.033,,,True,,True,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2024-03-01,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Reutlingen1_66-79,211203_Germany_HelmholtzCenterforInfectionResearch_Reutlingen1,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Baden-Württemberg,Reutlingen,Residents of Reutlingen >18 years of age.,Vaccinated subjects,2020-07-01,2020-07-28,Household and community samples,All,Multiple groups,18.0,,Age,66-79,363,0.02,0.002,0.039,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Reutlingen2_Overall_PopTestAdj,211203_Germany_HelmholtzCenterforInfectionResearch_Reutlingen2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Baden-Württemberg,Reutlingen,Residents of Reutlingen >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2020-10-14,2020-11-10,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2360,0.021,0.012,0.032,True,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Reutlingen2_Overall_PopAdj,211203_Germany_HelmholtzCenterforInfectionResearch_Reutlingen2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Baden-Württemberg,Reutlingen,Residents of Reutlingen >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2020-10-14,2020-11-10,Household and community samples,All,Multiple groups,18.0,,Analysis,,2360,0.027999999999999997,0.021,0.037000000000000005,,,True,,True,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2024-03-01,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Reutlingen2_26-45,211203_Germany_HelmholtzCenterforInfectionResearch_Reutlingen2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Baden-Württemberg,Reutlingen,Residents of Reutlingen >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2020-10-14,2020-11-10,Household and community samples,All,Multiple groups,18.0,,Age,26-45,637,0.013000000000000001,0.001,0.026000000000000002,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Reutlingen2_18-25,211203_Germany_HelmholtzCenterforInfectionResearch_Reutlingen2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Baden-Württemberg,Reutlingen,Residents of Reutlingen >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2020-10-14,2020-11-10,Household and community samples,All,Multiple groups,18.0,,Age,18-25,202,0.018000000000000002,0.0,0.039,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Reutlingen2__66-79,211203_Germany_HelmholtzCenterforInfectionResearch_Reutlingen2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Baden-Württemberg,Reutlingen,Residents of Reutlingen >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2020-10-14,2020-11-10,Household and community samples,All,Multiple groups,18.0,,Age,66-79,408,0.015,0.0,0.03,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Reutlingen2_46-65,211203_Germany_HelmholtzCenterforInfectionResearch_Reutlingen2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Baden-Württemberg,Reutlingen,Residents of Reutlingen >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2020-10-14,2020-11-10,Household and community samples,All,Multiple groups,18.0,,Age,46-65,1019,0.027999999999999997,0.013000000000000001,0.043,,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2023-08-15,Unverified,gornyk_sars-cov-2_2021-1,DEU
211203_Germany_HelmholtzCenterforInfectionResearch_Reutlingen2_>79,211203_Germany_HelmholtzCenterforInfectionResearch_Reutlingen2,SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions,2021-12-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,Baden-Württemberg,Reutlingen,Residents of Reutlingen >18 years of age.,Vaccinated subjects and follow-up participants (from round 1),2020-10-14,2020-11-10,Household and community samples,All,Multiple groups,18.0,,Age,>79,94,0.054000000000000006,0.017,0.155,,,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.883,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Daniela Gornyk,Helmholtz Center for Infection Research,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2021.0364,2022-03-09,2024-03-01,Unverified,gornyk_sars-cov-2_2021-1,DEU
211209_Dusseldorf_HeinrichHeineUniversityDusseldorf_TestAdj,211209_Dusseldorf_HeinrichHeineUniversityDusseldorf,Underascertainment of COVID-19 cases among first responders: a seroepidemiological study,2021-12-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,,Düsseldorf,The entire personnel from the fire department of Düsseldorf was invited to participate.,,2020-11-27,2020-12-04,Essential non-healthcare workers,All,Adults (18-64 years),18.0,,Primary Estimate,,745,0.04,0.031000000000000003,0.062000000000000006,True,True,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Insa Backhaus,Heinrich Heine University Düsseldorf,Not Unity-Aligned,https://dx.doi.org/10.1093/occmed/kqab164,2022-01-17,2023-08-15,Unverified,backhaus_underascertainment_2021,DEU
211215_Marburg_PhilippsUniversityMarburg_Overall,211215_Marburg_PhilippsUniversityMarburg,"Prevalence of SARS-CoV-2 antibodies in hospital employees, Central Germany",2021-12-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Hesse,Marburg,,"""Samples arriving with incomplete documentation were excluded and discarded.""",2020-05-28,2020-06-19,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Overall,3623,0.0036,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N),Wantai SARS-CoV-2 Total Ab ELISA,Author designed (Neutralization Assay)","EUROIMMUN,Roche Diagnostics,Beijing Wantai Biological,NA",Other,Serum,"['IgG', 'Neutralizing', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Yes,Yes,No,,Christian Keller,Philipps University Marburg,Not Unity-Aligned,https://doi.org/10.1515/labmed-2021-0107,2022-02-10,2024-03-01,Unverified,keller_prevalence_2021,DEU
211124_Cologne_UniversityHospitalOfCologne,211124_Cologne_UniversityHospitalOfCologne,Immune Responses to SARS-CoV-2 Infection and Vaccination in Dialysis Patients and Kidney Transplant Recipients.,2021-12-21,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,North Rhine-Westphalia,Cologne,dialysis patients performed at the University Hospital Cologne,,2020-04-15,2021-04-15,Residual sera,All,Multiple groups,,,Primary Estimate,,203,0.0296,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['High'],,No,No,No,,Yes,Yes,Yes,,Patrick Affeldt,University Hospital of Cologne,Not Unity-Aligned,https://dx.doi.org/10.3390/microorganisms10010004,2022-02-10,2024-03-01,Unverified,affeldt_immune_2021,DEU
211223_Friedrich-AlexanderUniversityErlangen-Nuremberg_Erlangen_GenPop3_Overall,211223_Friedrich-AlexanderUniversityErlangen-Nuremberg_Erlangen_GenPop3,"Impact of cytokine inhibitor therapy on the prevalence, seroconversion rate and longevity of the humoral immune response against SARS-CoV-2 in an unvaccinated cohort.",2021-12-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Bavaria,Erlangen,population-dwelling nonhealthcare controls (NHC),Subjects who already had received a SARSCoV-2 vaccination were excluded from the study. These participants were not allowed to have a diagnosis of any IMID.,2020-12-15,2021-03-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,1184,0.0709,0.057,0.08710000000000001,True,,,,True,Unclear,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['Moderate'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,David Simon,Friedrich-Alexander University (FAU) Erlangen-Nuremberg,Not Unity-Aligned,https://dx.doi.org/10.1002/art.42035,2022-01-12,2024-03-01,Unverified,simon_impact_2021,DEU
211223_Friedrich-AlexanderUniversityErlangen-Nuremberg_Erlangen_HCW2_Overall,211223_Friedrich-AlexanderUniversityErlangen-Nuremberg_Erlangen_HCW2,"Impact of cytokine inhibitor therapy on the prevalence, seroconversion rate and longevity of the humoral immune response against SARS-CoV-2 in an unvaccinated cohort.",2021-12-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Bavaria,Erlangen,"healthcare professionals (HC) (physicians, nurses and
technicians).  ",Subjects who already had received a SARSCoV-2 vaccination were excluded from the study. These participants were not allowed to have a diagnosis of any IMID.,2020-12-15,2021-03-15,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,455,0.1121,0.08460000000000001,0.14470000000000002,True,,,,True,Unclear,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],,Unclear,No,Yes,,Yes,Yes,Yes,,David Simon,Friedrich-Alexander University (FAU) Erlangen-Nuremberg,Not Unity-Aligned,https://dx.doi.org/10.1002/art.42035,2022-01-12,2024-03-01,Unverified,simon_impact_2021,DEU
211223_Friedrich-AlexanderUniversityErlangen-Nuremberg_Erlangen_Patients1_Overall,211223_Friedrich-AlexanderUniversityErlangen-Nuremberg_Erlangen_Patients1,"Impact of cytokine inhibitor therapy on the prevalence, seroconversion rate and longevity of the humoral immune response against SARS-CoV-2 in an unvaccinated cohort.",2021-12-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Bavaria,Erlangen," Briefly, the study recruited IMID patients with either no treatment with or receiving treatment with
conventional synthetic (cs), biologic (b) or targeted synthetic (ts) disease modifying anti-rheumatic
drugs (DMARDs). For the cross-sectional analysis, we included all
subjects who provided samples during the second wave of sample collection",Subjects who already had received a SARSCoV-2 vaccination were excluded from the study. ,2020-12-15,2021-03-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,2869,0.042,,,True,,,,True,Unclear,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['Moderate'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,David Simon,Friedrich-Alexander University (FAU) Erlangen-Nuremberg,Not Unity-Aligned,https://dx.doi.org/10.1002/art.42035,2022-01-12,2024-03-01,Unverified,simon_impact_2021,DEU
220103_Regensburg_UniversityHospitalRegensburg,220103_Regensburg_UniversityHospitalRegensburg,[Low incidence of SARS-CoV-2 infections in healthcare workers at a tertiary care hospital: Results of a prospective serological cohort study of the first and second COVID-19 pandemic wave],2022-01-03,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,Bavaria,Regensburg,Medical staff working in the care involved in the treatment of COVID-19 patients,,2020-03-15,2021-02-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,205,0.051,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Anti-SARS-CoV-2 ELISA IgG","Roche Diagnostics,EUROIMMUN",ELISA,,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,No,Yes,No,,Julian Hupf,University Hospital Regensburg,Not Unity-Aligned,https://dx.doi.org/10.1007/s00063-021-00890-5,2022-01-12,2024-03-01,Unverified,hupfNiedrigeInzidenzSARSCoV2022,DEU
220104_Wuerzburg_UniversityHospitalWuerzburg_ChildcareWorkers_AfterStudy,220104_Wuerzburg_UniversityHospitalWuerzburg_ChildcareWorkers_AfterStudy,Feasibility of SARS-CoV-2 Surveillance Testing Among Children and Childcare Workers at German Day Care Centers: A Nonrandomized Controlled Trial,2022-01-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Bavaria,Wuerzburg,"childcare workers from 9 daycare centres within the study region of Wuerzburg, Germany participated.",,2021-03-01,2021-03-15,Essential non-healthcare workers,All,Multiple groups,,,Primary Estimate,,109,0.045899999999999996,,,True,,,,True,Convenience,"Panbio COVID-19 IgG/IgM rapid test device,SERION ELISA agile SARS-CoV-2,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Institut Virion/Serion,Roche Diagnostics",Multiple Types,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Unclear,Yes,No,,Johannes Forster,University Hospital Wuerzburg,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.42057,2022-01-10,2024-03-01,Unverified,forster_feasibility_2022,DEU
220104_Wuerzburg_UniversityHospitalWuerzburg_ChildcareWorkers_BeforeStudy,220104_Wuerzburg_UniversityHospitalWuerzburg_ChildcareWorkers_BeforeStudy,Feasibility of SARS-CoV-2 Surveillance Testing Among Children and Childcare Workers at German Day Care Centers: A Nonrandomized Controlled Trial,2022-01-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Bavaria,Wuerzburg,"childcare workers from 9 daycare centres within the study region of Wuerzburg, Germany participated.",,2020-10-01,2020-10-15,Essential non-healthcare workers,All,Multiple groups,,,Primary Estimate,,139,0.006999999999999999,,,True,,,,True,Convenience,"Panbio COVID-19 IgG/IgM rapid test device,SERION ELISA agile SARS-CoV-2,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Institut Virion/Serion,Roche Diagnostics",Multiple Types,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Unclear,Yes,No,,Johannes Forster,University Hospital Wuerzburg,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.42057,2022-01-10,2024-03-01,Unverified,forster_feasibility_2022,DEU
220104_Wuerzburg_UniversityHospitalWuerzburg_Children_AfterStudy,220104_Wuerzburg_UniversityHospitalWuerzburg_Children_AfterStudy,Feasibility of SARS-CoV-2 Surveillance Testing Among Children and Childcare Workers at German Day Care Centers: A Nonrandomized Controlled Trial,2022-01-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Bavaria,Wuerzburg,"children from 9 daycare centres within the study region of Wuerzburg, Germany participated.",,2021-03-01,2021-03-15,Students and Daycares,All,Children and Youth (0-17 years),1.0,5.0,Primary Estimate,,338,0.023700000000000002,,,True,,,,True,Convenience,"Panbio COVID-19 IgG/IgM rapid test device,SERION ELISA agile SARS-CoV-2,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Institut Virion/Serion,Roche Diagnostics",Multiple Types,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Unclear,Yes,No,,Johannes Forster,University Hospital Wuerzburg,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.42057,2022-01-10,2024-03-01,Unverified,forster_feasibility_2022,DEU
220104_Wuerzburg_UniversityHospitalWuerzburg_Children_BeforeStudy,220104_Wuerzburg_UniversityHospitalWuerzburg_Children_BeforeStudy,Feasibility of SARS-CoV-2 Surveillance Testing Among Children and Childcare Workers at German Day Care Centers: A Nonrandomized Controlled Trial,2022-01-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Bavaria,Wuerzburg,"children from 9 daycare centres within the study region of Wuerzburg, Germany participated.",,2020-10-01,2020-10-15,Students and Daycares,All,Children and Youth (0-17 years),1.0,5.0,Primary Estimate,,381,0.003,,,True,,,,True,Convenience,"Panbio COVID-19 IgG/IgM rapid test device,SERION ELISA agile SARS-CoV-2,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Institut Virion/Serion,Roche Diagnostics",Multiple Types,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Unclear,Yes,No,,Johannes Forster,University Hospital Wuerzburg,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.42057,2022-01-10,2024-03-01,Unverified,forster_feasibility_2022,DEU
220111_Germany_UniversityMedicineGreifswald_Overall,220111_Germany_UniversityMedicineGreifswald,Prevalence of SARS-CoV-2 IgG antibodies among dental teams in Germany.,2022-01-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Germany,"Berlin, Hamburg, Saxony, Baden-Württemberg, North Rhine-Westphalia","Berlin, Hamburg, Dresden, Stuttgart, Cologne","individuals (dentists, dental nurses, and dental prophylaxis nurses) who work at licensed private dental practices in 5 regions of Germany ((1) Berlin, (2) Hamburg, (3) Dresden, (4) Stuttgart, and (5) Cologne/Düsseldorf).","Participants who did not complete the questionnaire (n = 297) or failed to provide a dry blood sample as instructed (n = 10) were excluded. A total of 200 participants had to be excluded due to vaccination. Furthermore, we excluded 14 participants who reported being previously tested positive for SARS-CoV-2 but no antibodies in their dry blood sample could be detected, thus leaving us with data from 2784 participants.",2021-01-15,2021-04-21,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,2784,0.052000000000000005,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by manufacturers,0.9440000000000001,0.996,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Maria Mksoud,University Medicine Greifswald,Not Unity-Aligned,https://dx.doi.org/10.1007/s00784-021-04363-z,2022-01-18,2024-03-01,Unverified,mksoud_prevalence_2022,DEU
220121_Bavaria_LudwigMaximiliansUniversitat_Children_Overall,220121_Bavaria_LudwigMaximiliansUniversitat_Children,SARS-CoV-2 surveillance (09/2020 - 03/2021) in elementary schools and daycare facilities in Bavaria,2022-01-21,Preprint,Regional,Cross-sectional survey ,Germany,Bavaria,,"child aged 1 to 10 years attending the participating facilities at the day of assessment and written informed consent provided by participants or their legal representatives. In addition, individuals had to be in a state of health permitting to visit the facilities as outlined by the latest corona guidelines from the department of health at the time of assessment",,2021-06-15,2021-07-15,Students and Daycares,All,Children and Youth (0-17 years),,,Primary Estimate,,509,0.077,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Dried Blood,TotalAntibody,Nucleocapsid(N-protein),,,,['High'],,No,No,No,,Yes,Yes,Yes,,Anna Kern,Ludwig-Maximilians-Universitat,Not Unity-Aligned,10.1101/2022.01.18.22269445,2022-02-01,2024-03-01,Unverified,kern_sars-cov-2_2022,DEU
220121_Bavaria_LudwigMaximiliansUniversitat_Teachers_Overall,220121_Bavaria_LudwigMaximiliansUniversitat_Teachers,SARS-CoV-2 surveillance (09/2020 - 03/2021) in elementary schools and daycare facilities in Bavaria,2022-01-21,Preprint,Regional,Cross-sectional survey ,Germany,Bavaria,,"teachers / daycare staff attending the participating facilities at the day of assessment and written informed consent provided by participants or their legal representatives. In addition, individuals had to be in a state of health permitting to visit the facilities as outlined by the latest corona guidelines from the department of health at the time of assessment",,2021-06-15,2021-07-15,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,202,0.045,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Dried Blood,TotalAntibody,Nucleocapsid(N-protein),,,,['High'],,No,No,No,,Yes,Yes,Yes,,Anna Kern,Ludwig-Maximilians-Universitat,Not Unity-Aligned,10.1101/2022.01.18.22269445,2022-02-01,2024-03-01,Unverified,kern_sars-cov-2_2022,DEU
220124_Berlin_RobertKochInstitute_Dec2020_TestAdj,220124_Berlin_RobertKochInstitute_Dec2020,Longitudinal SARS-CoV-2 seroepidemiological investigation among healthcare workers at a tertiary care hospital in Germany.,2022-01-24,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,,"Berlin
","HCWs from the tertiary care hospital ‘Unfallkrankenhaus Berlin (ukb)’ in Berlin, Germany. We asked all 2500 HCWs to participate. HCWs included clinical personnel as well as personnel without direct patient contact. ",,2020-12-08,2020-12-20,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Test adjusted,1223,0.046,0.0334,0.0611,True,True,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Wantai SARS-CoV-2 Total Ab ELISA,Author designed (Neutralization Assay)","EUROIMMUN,Beijing Wantai Biological,NA",Multiple Types,Serum,"['IgG', 'Neutralizing', 'TotalAntibody']",Spike,Validated by manufacturers,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Sara Tomczyk,BG Klinikum Unfallkrankenhaus Berlin gGmbH,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07057-3,2022-02-01,2023-08-15,Unverified,tomczyk_longitudinal_2022,DEU
220124_Berlin_RobertKochInstitute_MayJune2020_Overall,220124_Berlin_RobertKochInstitute_MayJune2020,Longitudinal SARS-CoV-2 seroepidemiological investigation among healthcare workers at a tertiary care hospital in Germany.,2022-01-24,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,,Berlin,"HCWs from the tertiary care hospital ‘Unfallkrankenhaus Berlin (ukb)’ in Berlin, Germany. We asked all 2500 HCWs to participate. HCWs included clinical personnel as well as personnel without direct patient contact. ","NR
",2020-05-18,2020-06-10,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1477,0.012,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Wantai SARS-CoV-2 Total Ab ELISA,Author designed (Neutralization Assay)","EUROIMMUN,Beijing Wantai Biological,NA",Multiple Types,Serum,"['IgG', 'Neutralizing', 'TotalAntibody']",Spike,Validated by manufacturers,,,['High'],,No,Yes,Yes,,Yes,Yes,No,,Sara Tomczyk,BG Klinikum Unfallkrankenhaus Berlin gGmbH,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07057-3,2022-02-01,2024-03-01,Unverified,tomczyk_longitudinal_2022,DEU
220131_Munich_TechnicalUniversityofMunich_Overall,220131_Munich_TechnicalUniversityofMunich,"Infection Control Measures and Prevalence of SARS-CoV-2 IgG among 4,554 University Hospital Employees, Munich, Germany.",2022-01-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Bavaria,Munich,"All clinical and nonclinical Munich rechts der Isar staff >18 years of age (n = 6,305) and medical students at the Technical University of Munich (n = 1,699) were invited to participate.","Appendix Figure 1:
interval blood test/questionnaire > 4 weeks;
withdrew consent;
no consent for publication.",2020-04-14,2020-05-29,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,4554,0.024,0.019,0.028999999999999998,True,,,,True,Convenience,"iFlash-SARS-CoV-2 IgM/IgG,Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED,Elecsys® Anti‐SARS‐CoV‐2 (N)","Shenzhen Yhlo Biotech Co. Ltd,EUROIMMUN,NA,Roche Diagnostics",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Johanna Erber,Technical University Munich,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2803.204436,2022-03-03,2024-03-01,Unverified,erber_infection_2022,DEU
220131_Munich_TechnicalUniversityofMunich_Age_31–40,220131_Munich_TechnicalUniversityofMunich,"Infection Control Measures and Prevalence of SARS-CoV-2 IgG among 4,554 University Hospital Employees, Munich, Germany.",2022-01-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Bavaria,Munich,"All clinical and nonclinical Munich rechts der Isar staff >18 years of age (n = 6,305) and medical students at the Technical University of Munich (n = 1,699) were invited to participate.","Appendix Figure 1:
interval blood test/questionnaire > 4 weeks;
withdrew consent;
no consent for publication.",2020-04-14,2020-05-29,Health care workers and caregivers,All,Adults (18-64 years),31.0,40.0,Age,Age: 31–40,1134,0.0168,,,,,,,,Convenience,"iFlash-SARS-CoV-2 IgM/IgG,Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED,Elecsys® Anti‐SARS‐CoV‐2 (N)","Shenzhen Yhlo Biotech Co. Ltd,EUROIMMUN,NA,Roche Diagnostics",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Johanna Erber,Technical University Munich,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2803.204436,2022-03-06,2024-03-01,Unverified,erber_infection_2022,DEU
220131_Munich_TechnicalUniversityofMunich_Age_51–60,220131_Munich_TechnicalUniversityofMunich,"Infection Control Measures and Prevalence of SARS-CoV-2 IgG among 4,554 University Hospital Employees, Munich, Germany.",2022-01-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Bavaria,Munich,"All clinical and nonclinical Munich rechts der Isar staff >18 years of age (n = 6,305) and medical students at the Technical University of Munich (n = 1,699) were invited to participate.","Appendix Figure 1:
interval blood test/questionnaire > 4 weeks;
withdrew consent;
no consent for publication.",2020-04-14,2020-05-29,Health care workers and caregivers,All,Adults (18-64 years),51.0,60.0,Age,Age: 51–60,766,0.0392,,,,,,,,Convenience,"iFlash-SARS-CoV-2 IgM/IgG,Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED,Elecsys® Anti‐SARS‐CoV‐2 (N)","Shenzhen Yhlo Biotech Co. Ltd,EUROIMMUN,NA,Roche Diagnostics",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Johanna Erber,Technical University Munich,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2803.204436,2022-03-06,2024-03-01,Unverified,erber_infection_2022,DEU
220131_Munich_TechnicalUniversityofMunich_Age_>60,220131_Munich_TechnicalUniversityofMunich,"Infection Control Measures and Prevalence of SARS-CoV-2 IgG among 4,554 University Hospital Employees, Munich, Germany.",2022-01-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Bavaria,Munich,"All clinical and nonclinical Munich rechts der Isar staff >18 years of age (n = 6,305) and medical students at the Technical University of Munich (n = 1,699) were invited to participate.","Appendix Figure 1:
interval blood test/questionnaire > 4 weeks;
withdrew consent;
no consent for publication.",2020-04-14,2020-05-29,Health care workers and caregivers,All,Adults (18-64 years),60.0,,Age,Age: >60,274,0.0146,,,,,,,,Convenience,"iFlash-SARS-CoV-2 IgM/IgG,Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED,Elecsys® Anti‐SARS‐CoV‐2 (N)","Shenzhen Yhlo Biotech Co. Ltd,EUROIMMUN,NA,Roche Diagnostics",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Johanna Erber,Technical University Munich,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2803.204436,2022-03-06,2024-03-01,Unverified,erber_infection_2022,DEU
220131_Munich_TechnicalUniversityofMunich_Age_18–30,220131_Munich_TechnicalUniversityofMunich,"Infection Control Measures and Prevalence of SARS-CoV-2 IgG among 4,554 University Hospital Employees, Munich, Germany.",2022-01-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Bavaria,Munich,"All clinical and nonclinical Munich rechts der Isar staff >18 years of age (n = 6,305) and medical students at the Technical University of Munich (n = 1,699) were invited to participate.","Appendix Figure 1:
interval blood test/questionnaire > 4 weeks;
withdrew consent;
no consent for publication.",2020-04-14,2020-05-29,Health care workers and caregivers,All,Adults (18-64 years),18.0,30.0,Age,Age: 18-30,1622,0.022799999999999997,,,,,,,,Convenience,"iFlash-SARS-CoV-2 IgM/IgG,Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED,Elecsys® Anti‐SARS‐CoV‐2 (N)","Shenzhen Yhlo Biotech Co. Ltd,EUROIMMUN,NA,Roche Diagnostics",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Johanna Erber,Technical University Munich,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2803.204436,2022-03-06,2024-03-01,Unverified,erber_infection_2022,DEU
220131_Munich_TechnicalUniversityofMunich_Age_41–50,220131_Munich_TechnicalUniversityofMunich,"Infection Control Measures and Prevalence of SARS-CoV-2 IgG among 4,554 University Hospital Employees, Munich, Germany.",2022-01-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Bavaria,Munich,"All clinical and nonclinical Munich rechts der Isar staff >18 years of age (n = 6,305) and medical students at the Technical University of Munich (n = 1,699) were invited to participate.","Appendix Figure 1:
interval blood test/questionnaire > 4 weeks;
withdrew consent;
no consent for publication.",2020-04-14,2020-05-29,Health care workers and caregivers,All,Adults (18-64 years),41.0,50.0,Age,Age: 41–50,758,0.023700000000000002,,,,,,,,Convenience,"iFlash-SARS-CoV-2 IgM/IgG,Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED,Elecsys® Anti‐SARS‐CoV‐2 (N)","Shenzhen Yhlo Biotech Co. Ltd,EUROIMMUN,NA,Roche Diagnostics",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Johanna Erber,Technical University Munich,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2803.204436,2022-03-06,2024-03-01,Unverified,erber_infection_2022,DEU
220211_Hamburg_UniversityMedicalCenterHamburg-Eppendorf_Primary,220211_Hamburg_UniversityMedicalCenterHamburg-Eppendorf,Long-term antibody response to SARS-CoV-2 in children,2022-02-11,Preprint,Local,Prospective cohort,Germany,,Hamburg,The inclusion criteria were i) children or teenagers aged 0-18 years ii) patient in one of the participating centers or volunteer in the central C19.CHILD Study Clinic iii) informed consent from parents or guardians iv) informed consent from children >7 years (unless not capable).,The exclusion criteria were i) prematurity <37 weeks of gestation ii) informed consent of parents or guardians not possible in spoken word or otherwise iii) informed consent not given.,2020-05-11,2020-06-30,Household and community samples,All,Children and Youth (0-17 years),,17.0,Primary Estimate,,4657,0.0144,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Liaison SARS-CoV-2 S1/S2 IgG","Roche Diagnostics,DiaSorin",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,No,Yes,Yes,No,Yes,Gabor Dunay,University Medical Center Hamburg-Eppendorf,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.11.22270611v1.full-text,2022-02-22,2024-03-01,Unverified,dunay_long-term_2022,DEU
220211_Hamburg_UniversityMedicalCenterHamburg-Eppendorf_Female,220211_Hamburg_UniversityMedicalCenterHamburg-Eppendorf,Long-term antibody response to SARS-CoV-2 in children,2022-02-11,Preprint,Local,Prospective cohort,Germany,,Hamburg,The inclusion criteria were i) children or teenagers aged 0-18 years ii) patient in one of the participating centers or volunteer in the central C19.CHILD Study Clinic iii) informed consent from parents or guardians iv) informed consent from children >7 years (unless not capable).,The exclusion criteria were i) prematurity <37 weeks of gestation ii) informed consent of parents or guardians not possible in spoken word or otherwise iii) informed consent not given.,2020-05-11,2020-06-30,Household and community samples,Female,Children and Youth (0-17 years),,,Sex/Gender,,2205,0.015,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Liaison SARS-CoV-2 S1/S2 IgG","Roche Diagnostics,DiaSorin",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,No,Yes,Yes,No,Yes,Gabor Dunay,University Medical Center Hamburg-Eppendorf,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.11.22270611v1.full-text,2022-02-22,2024-03-01,Unverified,dunay_long-term_2022,DEU
220211_Hamburg_UniversityMedicalCenterHamburg-Eppendorf_Male,220211_Hamburg_UniversityMedicalCenterHamburg-Eppendorf,Long-term antibody response to SARS-CoV-2 in children,2022-02-11,Preprint,Local,Prospective cohort,Germany,,Hamburg,The inclusion criteria were i) children or teenagers aged 0-18 years ii) patient in one of the participating centers or volunteer in the central C19.CHILD Study Clinic iii) informed consent from parents or guardians iv) informed consent from children >7 years (unless not capable).,The exclusion criteria were i) prematurity <37 weeks of gestation ii) informed consent of parents or guardians not possible in spoken word or otherwise iii) informed consent not given.,2020-05-11,2020-06-30,Household and community samples,Male,Children and Youth (0-17 years),,,Sex/Gender,,2452,0.0139,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Liaison SARS-CoV-2 S1/S2 IgG","Roche Diagnostics,DiaSorin",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,No,Yes,Yes,No,Yes,Gabor Dunay,University Medical Center Hamburg-Eppendorf,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.11.22270611v1.full-text,2022-02-22,2024-03-01,Unverified,dunay_long-term_2022,DEU
220216_LowerSaxony_LeibnizUniversityHannover_Overall,220216_LowerSaxony_LeibnizUniversityHannover,"Combined Prospective Seroconversion and PCR Data of Selected Cohorts Indicate a High Rate of Subclinical SARS-CoV-2 Infections-an Open Observational Study in Lower Saxony, Germany.",2022-02-16,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,Lower Saxony,"Hannover, Goettingen","""Study subjects belonged to three different groups located in the southern part of Lower Saxony, Germany: The first group, defined as “education/ culture,” included employees from universities, theater, schools, administration in and close to Hannover, Germany. The second group, defined as “company,” consisted of employees of a biotechnological company in Goettingen, Germany. The third group included both employees and residents of retirement and nursing homes in and close to Hannover (designated as “nursing homes”).""

""The following RKI [Robert Koch Institute] guidelines were used to invite and select subjects: being over 50 years of age, having comorbidities such as diabetes, obesity, cardiac, pulmonary, circulatory or immunocompromising diseases, or taking immunosuppressants.""

Although the authors stated ""being over 50 years of age"" as a guideline for subject selection, Fig 2 shows study participants ranged from 15 to 104 years of age.",,2020-09-15,2021-06-15,Multiple populations,All,Multiple groups,15.0,104.0,Primary Estimate,,1883,0.0616,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),SARS-CoV-2 ViraChip IgG","Roche Diagnostics,Viramed Biotech AG",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Yes,Yes,No,,Rebecca Jonczyk,Leibniz University Hannover,Not Unity-Aligned,https://dx.doi.org/10.1128/spectrum.01512-21,2022-02-24,2024-03-01,Unverified,jonczyk_combined_2022,DEU
220219_Eschweiler_StAntoniusHospitalEschweiler_Round1,220219_Eschweiler_StAntoniusHospitalEschweiler_Round1,Cumulative Incidence of SARS-CoV-2 in Healthcare Workers at a General Hospital in Germany during the Pandemic-A Longitudinal Analysis,2022-02-19,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,North Rhine-Westphalia,Eschweiler,St. Antonius Hospital staff (healthcare workers),None,2020-04-15,2020-05-15,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,April/May 2020,1211,0.033,,,True,,,,True,Convenience,Anti-SARS-CoV-2 NCP ELISA (IgG),EUROIMMUN,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Martin Platten,St. Antonius Hospital Eschweiler ,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph19042429,2022-03-08,2024-03-01,Unverified,platten_cumulative_2022,DEU
220219_Eschweiler_StAntoniusHospitalEschweiler_Round2,220219_Eschweiler_StAntoniusHospitalEschweiler_Round2,Cumulative Incidence of SARS-CoV-2 in Healthcare Workers at a General Hospital in Germany during the Pandemic-A Longitudinal Analysis,2022-02-19,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,North Rhine-Westphalia,Eschweiler,St. Antonius Hospital staff (healthcare workers),None,2020-09-01,2020-09-30,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,September 2020,1023,0.03,,,True,,,,True,Convenience,Anti-SARS-CoV-2 NCP ELISA (IgG),EUROIMMUN,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Martin Platten,St. Antonius Hospital Eschweiler ,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph19042429,2022-03-09,2024-03-01,Unverified,platten_cumulative_2022,DEU
220219_Eschweiler_StAntoniusHospitalEschweiler_Round3,220219_Eschweiler_StAntoniusHospitalEschweiler_Round3,Cumulative Incidence of SARS-CoV-2 in Healthcare Workers at a General Hospital in Germany during the Pandemic-A Longitudinal Analysis,2022-02-19,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,North Rhine-Westphalia,Eschweiler,St. Antonius Hospital staff (healthcare workers),None,2020-11-15,2020-12-15,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,November/December 2020,1074,0.052000000000000005,,,True,,,,True,Convenience,Anti-SARS-CoV-2 NCP ELISA (IgG),EUROIMMUN,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Martin Platten,St. Antonius Hospital Eschweiler ,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph19042429,2022-03-09,2024-03-01,Unverified,platten_cumulative_2022,DEU
220219_Eschweiler_StAntoniusHospitalEschweiler_Round4,220219_Eschweiler_StAntoniusHospitalEschweiler_Round4,Cumulative Incidence of SARS-CoV-2 in Healthcare Workers at a General Hospital in Germany during the Pandemic-A Longitudinal Analysis,2022-02-19,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,North Rhine-Westphalia,Eschweiler,St. Antonius Hospital staff (healthcare workers),None,2021-04-01,2021-04-30,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,April 2021,1040,0.099,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)",EUROIMMUN,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,No,,Unclear,No,No,,Martin Platten,St. Antonius Hospital Eschweiler ,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph19042429,2022-03-09,2024-03-01,Unverified,platten_cumulative_2022,DEU
220219_Germany_StVincenzHospital,220219_Germany_StVincenzHospital,Seroprevalence of SARS-CoV-2 Antibodies in Employees of Three Hospitals of a Secondary Care Hospital Network in Germany and an Associated Fire Brigade: Results of a Repeated Cross-Sectional Surveillance Study over 1 Year,2022-02-19,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Germany,,,"The study was a single center study conducted at the St. Vincenz Hospital Datteln (VHD) with 316 beds and the main departments: internal medicine, surgery, gynaecology, obstetrics, and urology.

All employees were invited to take part.",,2020-06-15,2021-06-15,Health care workers and caregivers,All,Multiple groups,16.0,,Primary Estimate,,1842,0.132,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.99,0.99,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Anke Hildebradnt,St. Vincenz Hospital,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph19042402,2022-03-09,2024-03-01,Unverified,hildebrandt_serooprevalence_2022,DEU
220220_Hamburg_UniversityHeartAndVascularCenter_overall,220220_Hamburg_UniversityHeartAndVascularCenter,SARS-CoV-2 seropositivity in children with chronic preconditions: Is it safe to send sick children to daycare and school? Data from the C19-child study,2022-02-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,,Hamburg,children of less than 18 years in pediatric hospitals and among healthy volunteers ,,2020-05-09,2020-06-30,Household and community samples,All,Children and Youth (0-17 years),,18.0,Primary Estimate,,4657,0.013000000000000001,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],,Unclear,Yes,No,,Unclear,Yes,No,,J Olfe,University Heart and Vascular Center,Not Unity-Aligned,https://dx.doi.org/10.1055/s-0042-1742988,2022-03-24,2022-07-16,Unverified,olfe_sars-cov-2_2022,DEU
220225_Erlangen_FriedrichAlexanderUniversity_Period1_Overall,220225_Erlangen_FriedrichAlexanderUniversity_Period1,Continuous monitoring of SARS-CoV-2 seroprevalence in children using residual blood samples from routine clinical chemistry,2022-02-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,"Bavaria
","Erlangen
","""Residual blood samples (lithium heparin plasma) of all inpatients and outpatients aged 0–17 years with a
visit during the time periods and a routine diagnostic blood test in the laboratory of the Hospital were stored for possible inclusion for the SARS-CoV-2 antibody analyses""","""Samples with not enough residual blood were excluded""",2020-10-15,2020-11-15,Residual sera,All,Children and Youth (0-17 years),,17.0,Primary Estimate,Anti S,872,0.013999999999999999,,,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Felix Wachter,Friedrich Alexander University,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0037,2022-03-07,2024-03-01,Unverified,wachter_continuous_2022,DEU
220225_Erlangen_FriedrichAlexanderUniversity_Period1_Age3-5,220225_Erlangen_FriedrichAlexanderUniversity_Period1,Continuous monitoring of SARS-CoV-2 seroprevalence in children using residual blood samples from routine clinical chemistry,2022-02-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,"Bavaria
","Erlangen
","""Residual blood samples (lithium heparin plasma) of all inpatients and outpatients aged 0–17 years with a
visit during the time periods and a routine diagnostic blood test in the laboratory of the Hospital were stored for possible inclusion for the SARS-CoV-2 antibody analyses""","""Samples with not enough residual blood were excluded""",2020-10-15,2020-11-15,Residual sera,All,Children and Youth (0-17 years),,17.0,Age,3-5,128,0.015600000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Felix Wachter,Friedrich Alexander University,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0037,2022-05-26,2024-03-01,Unverified,wachter_continuous_2022,DEU
220225_Erlangen_FriedrichAlexanderUniversity_Period1_SexFemale,220225_Erlangen_FriedrichAlexanderUniversity_Period1,Continuous monitoring of SARS-CoV-2 seroprevalence in children using residual blood samples from routine clinical chemistry,2022-02-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,"Bavaria
","Erlangen
","""Residual blood samples (lithium heparin plasma) of all inpatients and outpatients aged 0–17 years with a
visit during the time periods and a routine diagnostic blood test in the laboratory of the Hospital were stored for possible inclusion for the SARS-CoV-2 antibody analyses""","""Samples with not enough residual blood were excluded""",2020-10-15,2020-11-15,Residual sera,Female,Children and Youth (0-17 years),,17.0,Sex/Gender,,413,0.0073,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Felix Wachter,Friedrich Alexander University,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0037,2022-05-26,2024-03-01,Unverified,wachter_continuous_2022,DEU
220225_Erlangen_FriedrichAlexanderUniversity_Period1_Age10-14,220225_Erlangen_FriedrichAlexanderUniversity_Period1,Continuous monitoring of SARS-CoV-2 seroprevalence in children using residual blood samples from routine clinical chemistry,2022-02-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,"Bavaria
","Erlangen
","""Residual blood samples (lithium heparin plasma) of all inpatients and outpatients aged 0–17 years with a
visit during the time periods and a routine diagnostic blood test in the laboratory of the Hospital were stored for possible inclusion for the SARS-CoV-2 antibody analyses""","""Samples with not enough residual blood were excluded""",2020-10-15,2020-11-15,Residual sera,All,Children and Youth (0-17 years),,17.0,Age,10-14,234,0.021400000000000002,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Felix Wachter,Friedrich Alexander University,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0037,2022-05-26,2024-03-01,Unverified,wachter_continuous_2022,DEU
220225_Erlangen_FriedrichAlexanderUniversity_Period1_Age6-9,220225_Erlangen_FriedrichAlexanderUniversity_Period1,Continuous monitoring of SARS-CoV-2 seroprevalence in children using residual blood samples from routine clinical chemistry,2022-02-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,"Bavaria
","Erlangen
","""Residual blood samples (lithium heparin plasma) of all inpatients and outpatients aged 0–17 years with a
visit during the time periods and a routine diagnostic blood test in the laboratory of the Hospital were stored for possible inclusion for the SARS-CoV-2 antibody analyses""","""Samples with not enough residual blood were excluded""",2020-10-15,2020-11-15,Residual sera,All,Children and Youth (0-17 years),,17.0,Age,6-9,162,0.0062,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Felix Wachter,Friedrich Alexander University,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0037,2022-05-26,2024-03-01,Unverified,wachter_continuous_2022,DEU
220225_Erlangen_FriedrichAlexanderUniversity_Period1_SexMale,220225_Erlangen_FriedrichAlexanderUniversity_Period1,Continuous monitoring of SARS-CoV-2 seroprevalence in children using residual blood samples from routine clinical chemistry,2022-02-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,"Bavaria
","Erlangen
","""Residual blood samples (lithium heparin plasma) of all inpatients and outpatients aged 0–17 years with a
visit during the time periods and a routine diagnostic blood test in the laboratory of the Hospital were stored for possible inclusion for the SARS-CoV-2 antibody analyses""","""Samples with not enough residual blood were excluded""",2020-10-15,2020-11-15,Residual sera,Male,Children and Youth (0-17 years),,17.0,Sex/Gender,,459,0.0196,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Felix Wachter,Friedrich Alexander University,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0037,2022-05-26,2024-03-01,Unverified,wachter_continuous_2022,DEU
220225_Erlangen_FriedrichAlexanderUniversity_Period1_Age0-2,220225_Erlangen_FriedrichAlexanderUniversity_Period1,Continuous monitoring of SARS-CoV-2 seroprevalence in children using residual blood samples from routine clinical chemistry,2022-02-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,"Bavaria
","Erlangen
","""Residual blood samples (lithium heparin plasma) of all inpatients and outpatients aged 0–17 years with a
visit during the time periods and a routine diagnostic blood test in the laboratory of the Hospital were stored for possible inclusion for the SARS-CoV-2 antibody analyses""","""Samples with not enough residual blood were excluded""",2020-10-15,2020-11-15,Residual sera,All,Children and Youth (0-17 years),,17.0,Age,0-2,197,0.0152,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Felix Wachter,Friedrich Alexander University,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0037,2022-05-26,2024-03-01,Unverified,wachter_continuous_2022,DEU
220225_Erlangen_FriedrichAlexanderUniversity_Period1_TestAntiN,220225_Erlangen_FriedrichAlexanderUniversity_Period1,Continuous monitoring of SARS-CoV-2 seroprevalence in children using residual blood samples from routine clinical chemistry,2022-02-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,"Bavaria
","Erlangen
","""Residual blood samples (lithium heparin plasma) of all inpatients and outpatients aged 0–17 years with a
visit during the time periods and a routine diagnostic blood test in the laboratory of the Hospital were stored for possible inclusion for the SARS-CoV-2 antibody analyses""","""Samples with not enough residual blood were excluded""",2020-10-15,2020-11-15,Residual sera,All,Children and Youth (0-17 years),,17.0,Test used,Anti N,872,0.0126,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Felix Wachter,Friedrich Alexander University,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0037,2022-05-26,2024-03-01,Unverified,wachter_continuous_2022,DEU
220225_Erlangen_FriedrichAlexanderUniversity_Period1_Age15-17,220225_Erlangen_FriedrichAlexanderUniversity_Period1,Continuous monitoring of SARS-CoV-2 seroprevalence in children using residual blood samples from routine clinical chemistry,2022-02-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,"Bavaria
","Erlangen
","""Residual blood samples (lithium heparin plasma) of all inpatients and outpatients aged 0–17 years with a
visit during the time periods and a routine diagnostic blood test in the laboratory of the Hospital were stored for possible inclusion for the SARS-CoV-2 antibody analyses""","""Samples with not enough residual blood were excluded""",2020-10-15,2020-11-15,Residual sera,All,Children and Youth (0-17 years),,17.0,Age,15-17,151,0.006600000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Felix Wachter,Friedrich Alexander University,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0037,2022-05-26,2024-03-01,Unverified,wachter_continuous_2022,DEU
220225_Erlangen_FriedrichAlexanderUniversity_Period2_Overall,220225_Erlangen_FriedrichAlexanderUniversity_Period2,Continuous monitoring of SARS-CoV-2 seroprevalence in children using residual blood samples from routine clinical chemistry,2022-02-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,"Bavaria
","Erlangen
","""Residual blood samples (lithium heparin plasma) of all inpatients and outpatients aged 0–17 years with a
visit during the time periods and a routine diagnostic blood test in the laboratory of the Hospital were stored for possible inclusion for the SARS-CoV-2 antibody analyses""","""Samples with not enough residual blood were excluded""",2021-04-01,2021-04-30,Residual sera,All,Children and Youth (0-17 years),,17.0,Primary Estimate,Anti S,808,0.092,,,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Felix Wachter,Friedrich Alexander University,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0037,2022-03-07,2024-03-01,Unverified,wachter_continuous_2022,DEU
220225_Erlangen_FriedrichAlexanderUniversity_Period2_SexMale,220225_Erlangen_FriedrichAlexanderUniversity_Period2,Continuous monitoring of SARS-CoV-2 seroprevalence in children using residual blood samples from routine clinical chemistry,2022-02-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,"Bavaria
","Erlangen
","""Residual blood samples (lithium heparin plasma) of all inpatients and outpatients aged 0–17 years with a
visit during the time periods and a routine diagnostic blood test in the laboratory of the Hospital were stored for possible inclusion for the SARS-CoV-2 antibody analyses""","""Samples with not enough residual blood were excluded""",2021-04-01,2021-04-30,Residual sera,Male,Children and Youth (0-17 years),,17.0,Sex/Gender,,808,0.092,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Felix Wachter,Friedrich Alexander University,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0037,2022-05-26,2024-03-01,Unverified,wachter_continuous_2022,DEU
220225_Erlangen_FriedrichAlexanderUniversity_Period2_Age10-14,220225_Erlangen_FriedrichAlexanderUniversity_Period2,Continuous monitoring of SARS-CoV-2 seroprevalence in children using residual blood samples from routine clinical chemistry,2022-02-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,"Bavaria
","Erlangen
","""Residual blood samples (lithium heparin plasma) of all inpatients and outpatients aged 0–17 years with a
visit during the time periods and a routine diagnostic blood test in the laboratory of the Hospital were stored for possible inclusion for the SARS-CoV-2 antibody analyses""","""Samples with not enough residual blood were excluded""",2021-04-01,2021-04-30,Residual sera,All,Children and Youth (0-17 years),,17.0,Age,10-14,196,0.09179999999999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Felix Wachter,Friedrich Alexander University,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0037,2022-05-26,2024-03-01,Unverified,wachter_continuous_2022,DEU
220225_Erlangen_FriedrichAlexanderUniversity_Period2_Age15-17,220225_Erlangen_FriedrichAlexanderUniversity_Period2,Continuous monitoring of SARS-CoV-2 seroprevalence in children using residual blood samples from routine clinical chemistry,2022-02-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,"Bavaria
","Erlangen
","""Residual blood samples (lithium heparin plasma) of all inpatients and outpatients aged 0–17 years with a
visit during the time periods and a routine diagnostic blood test in the laboratory of the Hospital were stored for possible inclusion for the SARS-CoV-2 antibody analyses""","""Samples with not enough residual blood were excluded""",2021-04-01,2021-04-30,Residual sera,All,Children and Youth (0-17 years),,17.0,Age,15-17,154,0.0909,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Felix Wachter,Friedrich Alexander University,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0037,2022-05-26,2024-03-01,Unverified,wachter_continuous_2022,DEU
220225_Erlangen_FriedrichAlexanderUniversity_Period2_Age0-2,220225_Erlangen_FriedrichAlexanderUniversity_Period2,Continuous monitoring of SARS-CoV-2 seroprevalence in children using residual blood samples from routine clinical chemistry,2022-02-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,"Bavaria
","Erlangen
","""Residual blood samples (lithium heparin plasma) of all inpatients and outpatients aged 0–17 years with a
visit during the time periods and a routine diagnostic blood test in the laboratory of the Hospital were stored for possible inclusion for the SARS-CoV-2 antibody analyses""","""Samples with not enough residual blood were excluded""",2021-04-01,2021-04-30,Residual sera,All,Children and Youth (0-17 years),,17.0,Age,0-2,198,0.12119999999999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Felix Wachter,Friedrich Alexander University,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0037,2022-05-26,2024-03-01,Unverified,wachter_continuous_2022,DEU
220225_Erlangen_FriedrichAlexanderUniversity_Period2_Age3-5,220225_Erlangen_FriedrichAlexanderUniversity_Period2,Continuous monitoring of SARS-CoV-2 seroprevalence in children using residual blood samples from routine clinical chemistry,2022-02-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,"Bavaria
","Erlangen
","""Residual blood samples (lithium heparin plasma) of all inpatients and outpatients aged 0–17 years with a
visit during the time periods and a routine diagnostic blood test in the laboratory of the Hospital were stored for possible inclusion for the SARS-CoV-2 antibody analyses""","""Samples with not enough residual blood were excluded""",2021-04-01,2021-04-30,Residual sera,All,Children and Youth (0-17 years),,17.0,Age,3-5,117,0.0684,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Felix Wachter,Friedrich Alexander University,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0037,2022-05-26,2024-03-01,Unverified,wachter_continuous_2022,DEU
220225_Erlangen_FriedrichAlexanderUniversity_Period2_Age6-9,220225_Erlangen_FriedrichAlexanderUniversity_Period2,Continuous monitoring of SARS-CoV-2 seroprevalence in children using residual blood samples from routine clinical chemistry,2022-02-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,"Bavaria
","Erlangen
","""Residual blood samples (lithium heparin plasma) of all inpatients and outpatients aged 0–17 years with a
visit during the time periods and a routine diagnostic blood test in the laboratory of the Hospital were stored for possible inclusion for the SARS-CoV-2 antibody analyses""","""Samples with not enough residual blood were excluded""",2021-04-01,2021-04-30,Residual sera,All,Children and Youth (0-17 years),,17.0,Age,6-9,143,0.0699,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Felix Wachter,Friedrich Alexander University,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0037,2022-05-26,2024-03-01,Unverified,wachter_continuous_2022,DEU
220225_Erlangen_FriedrichAlexanderUniversity_Period2_TestAntiN,220225_Erlangen_FriedrichAlexanderUniversity_Period2,Continuous monitoring of SARS-CoV-2 seroprevalence in children using residual blood samples from routine clinical chemistry,2022-02-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,"Bavaria
","Erlangen
","""Residual blood samples (lithium heparin plasma) of all inpatients and outpatients aged 0–17 years with a
visit during the time periods and a routine diagnostic blood test in the laboratory of the Hospital were stored for possible inclusion for the SARS-CoV-2 antibody analyses""","""Samples with not enough residual blood were excluded""",2021-04-01,2021-04-30,Residual sera,All,Children and Youth (0-17 years),,17.0,Test used,Anti N,808,0.061900000000000004,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Felix Wachter,Friedrich Alexander University,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0037,2022-05-26,2024-03-01,Unverified,wachter_continuous_2022,DEU
220225_Erlangen_FriedrichAlexanderUniversity_Period2_SexFemale,220225_Erlangen_FriedrichAlexanderUniversity_Period2,Continuous monitoring of SARS-CoV-2 seroprevalence in children using residual blood samples from routine clinical chemistry,2022-02-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,"Bavaria
","Erlangen
","""Residual blood samples (lithium heparin plasma) of all inpatients and outpatients aged 0–17 years with a
visit during the time periods and a routine diagnostic blood test in the laboratory of the Hospital were stored for possible inclusion for the SARS-CoV-2 antibody analyses""","""Samples with not enough residual blood were excluded""",2021-04-01,2021-04-30,Residual sera,Female,Children and Youth (0-17 years),,17.0,Sex/Gender,,808,0.092,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Felix Wachter,Friedrich Alexander University,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0037,2022-05-26,2024-03-01,Unverified,wachter_continuous_2022,DEU
220225_Erlangen_FriedrichAlexanderUniversity_Period3_Overall,220225_Erlangen_FriedrichAlexanderUniversity_Period3,Continuous monitoring of SARS-CoV-2 seroprevalence in children using residual blood samples from routine clinical chemistry,2022-02-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,"Bavaria
","Erlangen
","""Residual blood samples (lithium heparin plasma) of all inpatients and outpatients aged 0–17 years with a
visit during the time periods and a routine diagnostic blood test in the laboratory of the Hospital were stored for possible inclusion for the SARS-CoV-2 antibody analyses""","""Samples with not enough residual blood were excluded""",2021-06-15,2021-07-15,Residual sera,All,Children and Youth (0-17 years),,17.0,Primary Estimate,Anti S,946,0.146,,,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Felix Wachter,Friedrich Alexander University,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0037,2022-03-07,2024-03-01,Unverified,wachter_continuous_2022,DEU
220225_Erlangen_FriedrichAlexanderUniversity_Period3_SexMale,220225_Erlangen_FriedrichAlexanderUniversity_Period3,Continuous monitoring of SARS-CoV-2 seroprevalence in children using residual blood samples from routine clinical chemistry,2022-02-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,"Bavaria
","Erlangen
","""Residual blood samples (lithium heparin plasma) of all inpatients and outpatients aged 0–17 years with a
visit during the time periods and a routine diagnostic blood test in the laboratory of the Hospital were stored for possible inclusion for the SARS-CoV-2 antibody analyses""","""Samples with not enough residual blood were excluded""",2021-06-15,2021-07-15,Residual sera,Male,Children and Youth (0-17 years),,17.0,Sex/Gender,,946,0.146,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Felix Wachter,Friedrich Alexander University,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0037,2022-05-26,2024-03-01,Unverified,wachter_continuous_2022,DEU
220225_Erlangen_FriedrichAlexanderUniversity_Period3_Age10-14,220225_Erlangen_FriedrichAlexanderUniversity_Period3,Continuous monitoring of SARS-CoV-2 seroprevalence in children using residual blood samples from routine clinical chemistry,2022-02-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,"Bavaria
","Erlangen
","""Residual blood samples (lithium heparin plasma) of all inpatients and outpatients aged 0–17 years with a
visit during the time periods and a routine diagnostic blood test in the laboratory of the Hospital were stored for possible inclusion for the SARS-CoV-2 antibody analyses""","""Samples with not enough residual blood were excluded""",2021-06-15,2021-07-15,Residual sera,All,Children and Youth (0-17 years),,17.0,Age,10-14,255,0.10980000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Felix Wachter,Friedrich Alexander University,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0037,2022-05-26,2024-03-01,Unverified,wachter_continuous_2022,DEU
220225_Erlangen_FriedrichAlexanderUniversity_Period3_Age15-17,220225_Erlangen_FriedrichAlexanderUniversity_Period3,Continuous monitoring of SARS-CoV-2 seroprevalence in children using residual blood samples from routine clinical chemistry,2022-02-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,"Bavaria
","Erlangen
","""Residual blood samples (lithium heparin plasma) of all inpatients and outpatients aged 0–17 years with a
visit during the time periods and a routine diagnostic blood test in the laboratory of the Hospital were stored for possible inclusion for the SARS-CoV-2 antibody analyses""","""Samples with not enough residual blood were excluded""",2021-06-15,2021-07-15,Residual sera,All,Children and Youth (0-17 years),,17.0,Age,15-17,165,0.2061,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Felix Wachter,Friedrich Alexander University,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0037,2022-05-26,2024-03-01,Unverified,wachter_continuous_2022,DEU
220225_Erlangen_FriedrichAlexanderUniversity_Period3_SexFemale,220225_Erlangen_FriedrichAlexanderUniversity_Period3,Continuous monitoring of SARS-CoV-2 seroprevalence in children using residual blood samples from routine clinical chemistry,2022-02-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,"Bavaria
","Erlangen
","""Residual blood samples (lithium heparin plasma) of all inpatients and outpatients aged 0–17 years with a
visit during the time periods and a routine diagnostic blood test in the laboratory of the Hospital were stored for possible inclusion for the SARS-CoV-2 antibody analyses""","""Samples with not enough residual blood were excluded""",2021-06-15,2021-07-15,Residual sera,Female,Children and Youth (0-17 years),,17.0,Sex/Gender,,946,0.146,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Felix Wachter,Friedrich Alexander University,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0037,2022-05-26,2024-03-01,Unverified,wachter_continuous_2022,DEU
220225_Erlangen_FriedrichAlexanderUniversity_Period3_Age6-9,220225_Erlangen_FriedrichAlexanderUniversity_Period3,Continuous monitoring of SARS-CoV-2 seroprevalence in children using residual blood samples from routine clinical chemistry,2022-02-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,"Bavaria
","Erlangen
","""Residual blood samples (lithium heparin plasma) of all inpatients and outpatients aged 0–17 years with a
visit during the time periods and a routine diagnostic blood test in the laboratory of the Hospital were stored for possible inclusion for the SARS-CoV-2 antibody analyses""","""Samples with not enough residual blood were excluded""",2021-06-15,2021-07-15,Residual sera,All,Children and Youth (0-17 years),,17.0,Age,6-9,175,0.1371,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Felix Wachter,Friedrich Alexander University,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0037,2022-05-26,2024-03-01,Unverified,wachter_continuous_2022,DEU
220225_Erlangen_FriedrichAlexanderUniversity_Period3_Age0-2,220225_Erlangen_FriedrichAlexanderUniversity_Period3,Continuous monitoring of SARS-CoV-2 seroprevalence in children using residual blood samples from routine clinical chemistry,2022-02-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,"Bavaria
","Erlangen
","""Residual blood samples (lithium heparin plasma) of all inpatients and outpatients aged 0–17 years with a
visit during the time periods and a routine diagnostic blood test in the laboratory of the Hospital were stored for possible inclusion for the SARS-CoV-2 antibody analyses""","""Samples with not enough residual blood were excluded""",2021-06-15,2021-07-15,Residual sera,All,Children and Youth (0-17 years),,17.0,Age,0-2,196,0.17350000000000002,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Felix Wachter,Friedrich Alexander University,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0037,2022-05-26,2024-03-01,Unverified,wachter_continuous_2022,DEU
220225_Erlangen_FriedrichAlexanderUniversity_Period3_TestAntiN,220225_Erlangen_FriedrichAlexanderUniversity_Period3,Continuous monitoring of SARS-CoV-2 seroprevalence in children using residual blood samples from routine clinical chemistry,2022-02-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,"Bavaria
","Erlangen
","""Residual blood samples (lithium heparin plasma) of all inpatients and outpatients aged 0–17 years with a
visit during the time periods and a routine diagnostic blood test in the laboratory of the Hospital were stored for possible inclusion for the SARS-CoV-2 antibody analyses""","""Samples with not enough residual blood were excluded""",2021-06-15,2021-07-15,Residual sera,All,Children and Youth (0-17 years),,17.0,Test used,Anti N,946,0.08560000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Felix Wachter,Friedrich Alexander University,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0037,2022-05-26,2024-03-01,Unverified,wachter_continuous_2022,DEU
220225_Erlangen_FriedrichAlexanderUniversity_Period3_Age3-5,220225_Erlangen_FriedrichAlexanderUniversity_Period3,Continuous monitoring of SARS-CoV-2 seroprevalence in children using residual blood samples from routine clinical chemistry,2022-02-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,"Bavaria
","Erlangen
","""Residual blood samples (lithium heparin plasma) of all inpatients and outpatients aged 0–17 years with a
visit during the time periods and a routine diagnostic blood test in the laboratory of the Hospital were stored for possible inclusion for the SARS-CoV-2 antibody analyses""","""Samples with not enough residual blood were excluded""",2021-06-15,2021-07-15,Residual sera,All,Children and Youth (0-17 years),,17.0,Age,3-5,155,0.1161,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Felix Wachter,Friedrich Alexander University,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0037,2022-05-26,2024-03-01,Unverified,wachter_continuous_2022,DEU
220301_Wurselen_UniversityHospitalHamburgEppendorf_Overall,220301_Wurselen_UniversityHospitalHamburgEppendorf,COVID-19 infections in staff of an emergency care hospital after the first wave of the pandemic in Germany.,2022-03-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,North Rhine-Westphalia,Würselen,"All [hospital] staff [at Rhine-Maas hospital (RMK)] were given the opportunity to take part in the study irrespective of whether they worked closely with patients.

All staff who tested positive for SARS-CoV-2 by PCR testing after February 2020 were also included in the study.","There were no exclusion criteria.

In the analysis stage, ""eight participants were excluded due to failure to complete the questionnaires, and 14 participants were excluded due to missing information.""",2020-06-19,2020-07-17,Health care workers and caregivers,All,Multiple groups,17.0,83.0,Primary Estimate,,903,0.0543,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Philipp Stuven,University Hospital Hamburg Eppendorf,Not Unity-Aligned,https://dx.doi.org/10.3205/dgkh000407,2022-03-24,2024-03-01,Unverified,stuven_covid-19_2022,DEU
220308_UniversityMedicalCenterHamburgEppendorf_UniversityofHamburg,220308_UniversityMedicalCenterHamburgEppendorf_UniversityofHamburg,Three separate spike antigen exposures by COVID-19 vaccination or SARS-CoV-2 infection elicit strong humoral immune responses in healthcare workers,2022-03-08,Preprint,Local,Prospective cohort,Germany,Hamburg,Hamburg,"""Hospital workers of the University Medical Center Hamburg-Eppendorf participating in our ongoing longitudinal study were invited to provide a serum sample between January 17 and 31, 2022.""",,2022-01-17,2022-01-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,697,0.0976,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Thomas Brehm,University of Hamburg,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.06.22271718v1.full-text,2022-03-17,2024-03-01,Unverified,brehm_three_2022,DEU
220323_Dusseldorf_HeinrichHeineUniversity_TestAdjusted,220323_Dusseldorf_HeinrichHeineUniversity,SARS-CoV-2 seroprevalence and determinants of infection in young adults: a population-based seroepidemiological study.,2022-03-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,North Rhine-Westphalia,Dusseldorf,All individuals aged 18-30 years who were registered in Düsseldorf in October 2020,,2020-11-02,2020-11-27,Household and community samples,All,Adults (18-64 years),18.0,30.0,Primary Estimate,,2186,0.031000000000000003,0.024,0.04,True,True,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Insa Backhaus,Heinrich Heine University,Unity-Aligned,https://dx.doi.org/10.1016/j.puhe.2022.03.009,2022-05-27,2023-08-15,Verified,backhaus_sars-cov-2_2022,DEU
220323_Dusseldorf_HeinrichHeineUniversity_Age_26-30,220323_Dusseldorf_HeinrichHeineUniversity,SARS-CoV-2 seroprevalence and determinants of infection in young adults: a population-based seroepidemiological study.,2022-03-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,North Rhine-Westphalia,Dusseldorf,All individuals aged 18-30 years who were registered in Düsseldorf in October 2020,,2020-11-02,2020-11-27,Household and community samples,All,Adults (18-64 years),26.0,30.0,Age,26-30,1218,0.0304,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Insa Backhaus,Heinrich Heine University,Unity-Aligned,https://dx.doi.org/10.1016/j.puhe.2022.03.009,2022-05-12,2024-03-01,Verified,backhaus_sars-cov-2_2022,DEU
220323_Dusseldorf_HeinrichHeineUniversity_Sex_Female,220323_Dusseldorf_HeinrichHeineUniversity,SARS-CoV-2 seroprevalence and determinants of infection in young adults: a population-based seroepidemiological study.,2022-03-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,North Rhine-Westphalia,Dusseldorf,All individuals aged 18-30 years who were registered in Düsseldorf in October 2020,,2020-11-02,2020-11-27,Household and community samples,Female,Adults (18-64 years),18.0,30.0,Sex/Gender,,1327,0.0286,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Insa Backhaus,Heinrich Heine University,Unity-Aligned,https://dx.doi.org/10.1016/j.puhe.2022.03.009,2022-05-12,2024-03-01,Verified,backhaus_sars-cov-2_2022,DEU
220323_Dusseldorf_HeinrichHeineUniversity_Age_20-25,220323_Dusseldorf_HeinrichHeineUniversity,SARS-CoV-2 seroprevalence and determinants of infection in young adults: a population-based seroepidemiological study.,2022-03-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,North Rhine-Westphalia,Dusseldorf,All individuals aged 18-30 years who were registered in Düsseldorf in October 2020,,2020-11-02,2020-11-27,Household and community samples,All,Adults (18-64 years),20.0,25.0,Age,20-25,813,0.0357,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Insa Backhaus,Heinrich Heine University,Unity-Aligned,https://dx.doi.org/10.1016/j.puhe.2022.03.009,2022-05-12,2024-03-01,Verified,backhaus_sars-cov-2_2022,DEU
220323_Dusseldorf_HeinrichHeineUniversity_Age_<20,220323_Dusseldorf_HeinrichHeineUniversity,SARS-CoV-2 seroprevalence and determinants of infection in young adults: a population-based seroepidemiological study.,2022-03-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,North Rhine-Westphalia,Dusseldorf,All individuals aged 18-30 years who were registered in Düsseldorf in October 2020,,2020-11-02,2020-11-27,Household and community samples,All,Adults (18-64 years),18.0,20.0,Age,<20,139,0.0288,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Insa Backhaus,Heinrich Heine University,Unity-Aligned,https://dx.doi.org/10.1016/j.puhe.2022.03.009,2022-05-12,2024-03-01,Verified,backhaus_sars-cov-2_2022,DEU
220323_Dusseldorf_HeinrichHeineUniversity_Age_Missing,220323_Dusseldorf_HeinrichHeineUniversity,SARS-CoV-2 seroprevalence and determinants of infection in young adults: a population-based seroepidemiological study.,2022-03-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,North Rhine-Westphalia,Dusseldorf,All individuals aged 18-30 years who were registered in Düsseldorf in October 2020,,2020-11-02,2020-11-27,Household and community samples,All,Adults (18-64 years),18.0,30.0,Age,Missing,16,0.125,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Insa Backhaus,Heinrich Heine University,Unity-Aligned,https://dx.doi.org/10.1016/j.puhe.2022.03.009,2022-05-12,2024-03-01,Verified,backhaus_sars-cov-2_2022,DEU
220323_Dusseldorf_HeinrichHeineUniversity_Primary,220323_Dusseldorf_HeinrichHeineUniversity,SARS-CoV-2 seroprevalence and determinants of infection in young adults: a population-based seroepidemiological study.,2022-03-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,North Rhine-Westphalia,Dusseldorf,All individuals aged 18-30 years who were registered in Düsseldorf in October 2020,,2020-11-02,2020-11-27,Household and community samples,All,Adults (18-64 years),18.0,30.0,Analysis,,2186,0.033,0.026000000000000002,0.040999999999999995,,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Insa Backhaus,Heinrich Heine University,Unity-Aligned,https://dx.doi.org/10.1016/j.puhe.2022.03.009,2022-05-12,2024-03-01,Verified,backhaus_sars-cov-2_2022,DEU
220323_Dusseldorf_HeinrichHeineUniversity_Sex_Male,220323_Dusseldorf_HeinrichHeineUniversity,SARS-CoV-2 seroprevalence and determinants of infection in young adults: a population-based seroepidemiological study.,2022-03-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,North Rhine-Westphalia,Dusseldorf,All individuals aged 18-30 years who were registered in Düsseldorf in October 2020,,2020-11-02,2020-11-27,Household and community samples,Male,Adults (18-64 years),18.0,30.0,Sex/Gender,,857,0.039700000000000006,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Insa Backhaus,Heinrich Heine University,Unity-Aligned,https://dx.doi.org/10.1016/j.puhe.2022.03.009,2022-05-12,2024-03-01,Verified,backhaus_sars-cov-2_2022,DEU
20220324_German_FriedrichSchillerUniversity_Primary,20220324_German_FriedrichSchillerUniversity,One year monitoring of SARS-CoV-2 prevalence in a German cohort of patients with cystic fibrosis,2022-03-24,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,,Jena,"Of the 175 CF patients attended at the CF Center of the Jena University Hospital, 156 patients participated in the monitoring",,2020-02-15,2021-03-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,156,0.042,0.017,0.098,True,True,,,,Self-referral,"Liaison SARS-CoV-2 S1/S2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","DiaSorin,Roche Diagnostics",Multiple Types,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],,No,No,Yes,,Unclear,Yes,Yes,,Anke Jaudszus,Friedrich Schiller University,Not Unity-Aligned,https://dx.doi.org/10.1186/s12890-022-01900-8,2022-04-05,2023-08-15,Unverified,jaudszus_one_2022,DEU
220415_GreaterLubeckArea_UniversityofLubeck_Overall,220415_GreaterLubeckArea_UniversityofLubeck,One-year surveillance of SARS-CoV-2 transmission of the ELISA cohort: A model for population-based monitoring of infection risk,2022-04-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,Schleswig-Holstein,Lubeck,"""3000 people who represent ~1% of the population living in our catchment area, a major tourist region on the Baltic Sea in Northern Germany for the entire first year of the pandemic""",,2020-05-06,2021-02-01,Household and community samples,All,Multiple groups,18.0,79.0,Primary Estimate,one year observation,3051,0.027999999999999997,,,True,,,,True,Self-referral,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Whole Blood,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Christine Klein,University of Lubeck ,Not Unity-Aligned,https://dx.doi.org/10.1126/sciadv.abm5016,2022-05-17,2024-03-01,Verified,klein_one-year_nodate,DEU
220415_GreaterLubeckArea_UniversityofLubeck_Nov16,220415_GreaterLubeckArea_UniversityofLubeck,One-year surveillance of SARS-CoV-2 transmission of the ELISA cohort: A model for population-based monitoring of infection risk,2022-04-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,Schleswig-Holstein,Lubeck,"""3000 people who represent ~1% of the population living in our catchment area, a major tourist region on the Baltic Sea in Northern Germany for the entire first year of the pandemic""",,2020-11-16,2020-11-16,Household and community samples,All,Multiple groups,18.0,79.0,Time frame,examination 6: starting from November 16 2020,2547,0.018500000000000003,,,,,,,,Self-referral,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Whole Blood,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Christine Klein,University of Lubeck ,Not Unity-Aligned,https://dx.doi.org/10.1126/sciadv.abm5016,2022-05-17,2024-03-01,Verified,klein_one-year_nodate,DEU
220415_GreaterLubeckArea_UniversityofLubeck_May6,220415_GreaterLubeckArea_UniversityofLubeck,One-year surveillance of SARS-CoV-2 transmission of the ELISA cohort: A model for population-based monitoring of infection risk,2022-04-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,Schleswig-Holstein,Lubeck,"""3000 people who represent ~1% of the population living in our catchment area, a major tourist region on the Baltic Sea in Northern Germany for the entire first year of the pandemic""",,2020-05-06,2020-05-06,Household and community samples,All,Multiple groups,18.0,79.0,Time frame,examination 1: starting from May 6 2020,3051,0.0079,,,,,,,,Self-referral,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Whole Blood,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Christine Klein,University of Lubeck ,Not Unity-Aligned,https://dx.doi.org/10.1126/sciadv.abm5016,2022-04-29,2024-03-01,Verified,klein_one-year_nodate,DEU
220415_GreaterLubeckArea_UniversityofLubeck_Jun12,220415_GreaterLubeckArea_UniversityofLubeck,One-year surveillance of SARS-CoV-2 transmission of the ELISA cohort: A model for population-based monitoring of infection risk,2022-04-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,Schleswig-Holstein,Lubeck,"""3000 people who represent ~1% of the population living in our catchment area, a major tourist region on the Baltic Sea in Northern Germany for the entire first year of the pandemic""",,2020-06-12,2020-06-12,Household and community samples,All,Multiple groups,18.0,79.0,Time frame,examination 3: starting from June 12 2020,2890,0.01,,,,,,,,Self-referral,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Whole Blood,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Christine Klein,University of Lubeck ,Not Unity-Aligned,https://dx.doi.org/10.1126/sciadv.abm5016,2022-05-17,2024-03-01,Verified,klein_one-year_nodate,DEU
220415_GreaterLubeckArea_UniversityofLubeck_Aug24,220415_GreaterLubeckArea_UniversityofLubeck,One-year surveillance of SARS-CoV-2 transmission of the ELISA cohort: A model for population-based monitoring of infection risk,2022-04-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,Schleswig-Holstein,Lubeck,"""3000 people who represent ~1% of the population living in our catchment area, a major tourist region on the Baltic Sea in Northern Germany for the entire first year of the pandemic""",,2020-08-24,2020-08-24,Household and community samples,All,Multiple groups,18.0,79.0,Time frame,examination 5: starting from Aug 24 2020,2295,0.015300000000000001,,,,,,,,Self-referral,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Whole Blood,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Christine Klein,University of Lubeck ,Not Unity-Aligned,https://dx.doi.org/10.1126/sciadv.abm5016,2022-05-17,2024-03-01,Verified,klein_one-year_nodate,DEU
220415_GreaterLubeckArea_UniversityofLubeck_Feb1,220415_GreaterLubeckArea_UniversityofLubeck,One-year surveillance of SARS-CoV-2 transmission of the ELISA cohort: A model for population-based monitoring of infection risk,2022-04-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,Schleswig-Holstein,Lubeck,"""3000 people who represent ~1% of the population living in our catchment area, a major tourist region on the Baltic Sea in Northern Germany for the entire first year of the pandemic""",,2021-02-01,2021-02-01,Household and community samples,All,Multiple groups,18.0,79.0,Time frame,examination 7: starting from February 1 2020,2371,0.0358,,,,,,,,Self-referral,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Whole Blood,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Christine Klein,University of Lubeck ,Not Unity-Aligned,https://dx.doi.org/10.1126/sciadv.abm5016,2022-05-17,2024-03-01,Verified,klein_one-year_nodate,DEU
220415_GreaterLubeckArea_UniversityofLubeck_Jul1,220415_GreaterLubeckArea_UniversityofLubeck,One-year surveillance of SARS-CoV-2 transmission of the ELISA cohort: A model for population-based monitoring of infection risk,2022-04-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,Schleswig-Holstein,Lubeck,"""3000 people who represent ~1% of the population living in our catchment area, a major tourist region on the Baltic Sea in Northern Germany for the entire first year of the pandemic""",,2020-07-01,2020-07-01,Household and community samples,All,Multiple groups,18.0,79.0,Time frame,examination 4: starting from July 1 2020,2731,0.0106,,,,,,,,Self-referral,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Whole Blood,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Christine Klein,University of Lubeck ,Not Unity-Aligned,https://dx.doi.org/10.1126/sciadv.abm5016,2022-05-17,2024-03-01,Verified,klein_one-year_nodate,DEU
220415_GreaterLubeckArea_UniversityofLubeck_May25,220415_GreaterLubeckArea_UniversityofLubeck,One-year surveillance of SARS-CoV-2 transmission of the ELISA cohort: A model for population-based monitoring of infection risk,2022-04-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,Schleswig-Holstein,Lubeck,"""3000 people who represent ~1% of the population living in our catchment area, a major tourist region on the Baltic Sea in Northern Germany for the entire first year of the pandemic""",,2020-05-25,2020-05-25,Household and community samples,All,Multiple groups,18.0,79.0,Time frame,examination 2: starting from May 25 2020,2974,0.008100000000000001,,,,,,,,Self-referral,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Whole Blood,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Christine Klein,University of Lubeck ,Not Unity-Aligned,https://dx.doi.org/10.1126/sciadv.abm5016,2022-05-17,2024-03-01,Verified,klein_one-year_nodate,DEU
220402_Germany_CharitéResearchOrganisationGmbH_Feb2021-Mar2021,220402_Germany_CharitéResearchOrganisationGmbH_Feb2021-Mar2021,Longitudinal study of SARS-CoV-2 infections in different employee groups of long distance train services from June 2020 until February 2021 in Germany,2022-04-20,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Germany,,,"Train drivers, train attendants, and maintenance workers employed by Deutsche Bahn Fernverkehr AG. ","Exclude employees who lost their eligibility (e.g. due to retirement or a change in eligibility). Participants with missing or borderline test results were excluded
from the analysis. 
",2021-02-24,2021-03-02,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,1014,0.065,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Whole Blood,IgG,Spike,Validated by manufacturers,0.9440000000000001,0.996,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,HyoungJin Kim,Deutsche Bahn AG,Not Unity-Aligned,https://dx.doi.org/10.1017/S095026882200070X,2022-05-24,2024-03-01,Unverified,kim_longitudinal_2022,DEU
220402_Germany_CharitéResearchOrganisationGmbH_June2020-July2020,220402_Germany_CharitéResearchOrganisationGmbH_June2020-July2020,Longitudinal study of SARS-CoV-2 infections in different employee groups of long distance train services from June 2020 until February 2021 in Germany,2022-04-20,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Germany,,,"Train drivers, train attendants, and maintenance workers employed by Deutsche Bahn Fernverkehr AG. ","Exclude employees who lost their eligibility (e.g. due to retirement or a change in eligibility). Participants with missing or borderline test results were excluded
from the analysis. 
",2020-06-29,2020-07-03,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,1064,0.019,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Whole Blood,IgG,Spike,Validated by manufacturers,0.9440000000000001,0.996,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,HyoungJin Kim,Deutsche Bahn AG,Not Unity-Aligned,https://dx.doi.org/10.1017/S095026882200070X,2022-05-24,2024-03-01,Unverified,kim_longitudinal_2022,DEU
220402_Germany_CharitéResearchOrganisationGmbH_Oct2020-Oct2020,220402_Germany_CharitéResearchOrganisationGmbH_Oct2020-Oct2020,Longitudinal study of SARS-CoV-2 infections in different employee groups of long distance train services from June 2020 until February 2021 in Germany,2022-04-20,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Germany,,,"Train drivers, train attendants, and maintenance workers employed by Deutsche Bahn Fernverkehr AG. ","Exclude employees who lost their eligibility (e.g. due to retirement or a change in eligibility). Participants with missing or borderline test results were excluded
from the analysis. 
",2020-10-26,2020-10-30,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,1076,0.024,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Whole Blood,IgG,Spike,Validated by manufacturers,0.9440000000000001,0.996,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,HyoungJin Kim,Deutsche Bahn AG,Not Unity-Aligned,https://dx.doi.org/10.1017/S095026882200070X,2022-05-24,2024-03-01,Unverified,kim_longitudinal_2022,DEU
220423_EasternSaxony_TechnischeUniversitatDresden_Students_JuneJuly21,220423_EasternSaxony_TechnischeUniversitatDresden_Students_JuneJuly21,Seroprevalence of SARS-CoV-2 in German secondary schools from October 2020 to July 2021: a longitudinal study,2022-04-23,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Germany,Eastern Saxony,,"Students of grades 8–12 in 14 secondary
schools in Eastern Saxony were invited to participate in the
SchoolCoviDD19 study. Schools were chosen by the state
office for schools and education (Landesamt für Schule und
Bildung—LASUB) without the involvement of the study
team. At each school, all eligible students were
invited to participate.",Vaccinated against SARS-CoV-2,2021-06-15,2021-07-15,Students and Daycares,All,Children and Youth (0-17 years),,,Primary Estimate,,841,0.215,0.188,0.244,True,,,,True,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG","DiaSorin,Abbott Laboratories,EUROIMMUN",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Carolin Kirsten,Technische Universität Dresden,Not Unity-Aligned,https://dx.doi.org/10.1007/s15010-022-01824-9,2022-05-04,2024-03-01,Unverified,kirsten_seroprevalence_2022,DEU
220423_EasternSaxony_TechnischeUniversitatDresden_Students_MarchApril21,220423_EasternSaxony_TechnischeUniversitatDresden_Students_MarchApril21,Seroprevalence of SARS-CoV-2 in German secondary schools from October 2020 to July 2021: a longitudinal study,2022-04-23,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Germany,Eastern Saxony,,"Students of grades 8–12 in 14 secondary
schools in Eastern Saxony were invited to participate in the
SchoolCoviDD19 study. Schools were chosen by the state
office for schools and education (Landesamt für Schule und
Bildung—LASUB) without the involvement of the study
team. At each school, all eligible students were
invited to participate.",Vaccinated against SARS-CoV-2,2021-03-15,2021-04-15,Students and Daycares,All,Children and Youth (0-17 years),,,Primary Estimate,,1580,0.128,0.113,0.146,True,,,,True,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG","DiaSorin,Abbott Laboratories,EUROIMMUN",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Carolin Kirsten,Technische Universität Dresden,Not Unity-Aligned,https://dx.doi.org/10.1007/s15010-022-01824-9,2022-05-04,2024-03-01,Unverified,kirsten_seroprevalence_2022,DEU
220423_EasternSaxony_TechnischeUniversitatDresden_Teachers_JuneJuly21,220423_EasternSaxony_TechnischeUniversitatDresden_Teachers_JuneJuly21,Seroprevalence of SARS-CoV-2 in German secondary schools from October 2020 to July 2021: a longitudinal study,2022-04-23,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Germany,Eastern Saxony,,"Teachers of grades 8–12 in 14 secondary
schools in Eastern Saxony were invited to participate in the
SchoolCoviDD19 study. Schools were chosen by the state
office for schools and education (Landesamt für Schule und
Bildung—LASUB) without the involvement of the study
team. At each school, all eligible teachers were
invited to participate.",Vaccinated against SARS-CoV-2,2021-06-15,2021-07-15,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,46,0.304,0.174,0.435,True,,,,True,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG","DiaSorin,Abbott Laboratories,EUROIMMUN",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,No,,Unclear,Yes,No,,Carolin Kirsten,Technische Universität Dresden,Not Unity-Aligned,https://dx.doi.org/10.1007/s15010-022-01824-9,2022-05-04,2024-03-01,Unverified,kirsten_seroprevalence_2022,DEU
220423_EasternSaxony_TechnischeUniversitatDresden_Teachers_MarchApril21,220423_EasternSaxony_TechnischeUniversitatDresden_Teachers_MarchApril21,Seroprevalence of SARS-CoV-2 in German secondary schools from October 2020 to July 2021: a longitudinal study,2022-04-23,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Germany,Eastern Saxony,,"Teachers of grades 8–12 in 14 secondary
schools in Eastern Saxony were invited to participate in the
SchoolCoviDD19 study. Schools were chosen by the state
office for schools and education (Landesamt für Schule und
Bildung—LASUB) without the involvement of the study
team. At each school, all eligible teachers were
invited to participate.",Vaccinated against SARS-CoV-2,2021-03-15,2021-04-15,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,364,0.096,0.066,0.126,True,,,,True,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG","DiaSorin,Abbott Laboratories,EUROIMMUN",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Carolin Kirsten,Technische Universität Dresden,Not Unity-Aligned,https://dx.doi.org/10.1007/s15010-022-01824-9,2022-05-04,2024-03-01,Unverified,kirsten_seroprevalence_2022,DEU
220518_Saarland_SaarlandUniversityMedicalCenter_PopTestAdj,220518_Saarland_SaarlandUniversityMedicalCenter,German federal-state-wide seroprevalence study of 1st SARS-CoV-2 pandemic wave shows importance of long-term antibody test performance.,2022-05-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Saarland,,"10,000 inhabitants aged 18 years or older representative for the Saarland population with respect to age, sex and location were sampled ",,2020-07-22,2020-10-15,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2940,0.0032,,,True,True,True,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.993,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Stefan Lohse,Saarland University Medical Center,Unity-Aligned,https://dx.doi.org/10.1038/s43856-022-00100-z,2022-06-01,2024-03-22,Verified,lohse_german_2022,DEU
220518_Saarland_SaarlandUniversityMedicalCenter_18-69,220518_Saarland_SaarlandUniversityMedicalCenter,German federal-state-wide seroprevalence study of 1st SARS-CoV-2 pandemic wave shows importance of long-term antibody test performance.,2022-05-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Saarland,,"10,000 inhabitants aged 18 years or older representative for the Saarland population with respect to age, sex and location were sampled ",,2020-07-22,2020-10-15,Household and community samples,All,Adults (18-64 years),18.0,,Age,18-69,2500,0.009000000000000001,0.0062,0.0147,,,,,,Simplified probability,Anti-SARS-CoV-2 NCP ELISA (IgG),EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.993,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Stefan Lohse,Saarland University Medical Center,Unity-Aligned,https://dx.doi.org/10.1038/s43856-022-00100-z,2022-06-01,2024-03-22,Verified,lohse_german_2022,DEU
220518_Saarland_SaarlandUniversityMedicalCenter_Abbott,220518_Saarland_SaarlandUniversityMedicalCenter,German federal-state-wide seroprevalence study of 1st SARS-CoV-2 pandemic wave shows importance of long-term antibody test performance.,2022-05-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Saarland,,"10,000 inhabitants aged 18 years or older representative for the Saarland population with respect to age, sex and location were sampled ",,2020-07-22,2020-10-15,Household and community samples,All,Multiple groups,18.0,,Test used,Abbott-IgG,2940,0.0117,0.0087,0.0178,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.8890000000000001,0.9940000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Stefan Lohse,Saarland University Medical Center,Unity-Aligned,https://dx.doi.org/10.1038/s43856-022-00100-z,2022-06-01,2024-03-22,Verified,lohse_german_2022,DEU
220518_Saarland_SaarlandUniversityMedicalCenter_PopAdj,220518_Saarland_SaarlandUniversityMedicalCenter,German federal-state-wide seroprevalence study of 1st SARS-CoV-2 pandemic wave shows importance of long-term antibody test performance.,2022-05-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Saarland,,"10,000 inhabitants aged 18 years or older representative for the Saarland population with respect to age, sex and location were sampled ",,2020-07-22,2020-10-15,Household and community samples,All,Multiple groups,18.0,,Analysis,,2940,0.0097,0.0070999999999999995,0.015500000000000002,,,True,,True,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.993,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Stefan Lohse,Saarland University Medical Center,Unity-Aligned,https://dx.doi.org/10.1038/s43856-022-00100-z,2022-06-01,2024-03-22,Verified,lohse_german_2022,DEU
220518_Saarland_SaarlandUniversityMedicalCenter_Roche,220518_Saarland_SaarlandUniversityMedicalCenter,German federal-state-wide seroprevalence study of 1st SARS-CoV-2 pandemic wave shows importance of long-term antibody test performance.,2022-05-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Saarland,,"10,000 inhabitants aged 18 years or older representative for the Saarland population with respect to age, sex and location were sampled ",,2020-07-22,2020-10-15,Household and community samples,All,Multiple groups,18.0,,Test used,Roche-Ig,2940,0.0092,0.0067,0.0148,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.903,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Stefan Lohse,Saarland University Medical Center,Unity-Aligned,https://dx.doi.org/10.1038/s43856-022-00100-z,2022-06-01,2024-03-22,Verified,lohse_german_2022,DEU
220518_Saarland_SaarlandUniversityMedicalCenter_Female,220518_Saarland_SaarlandUniversityMedicalCenter,German federal-state-wide seroprevalence study of 1st SARS-CoV-2 pandemic wave shows importance of long-term antibody test performance.,2022-05-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Saarland,,"10,000 inhabitants aged 18 years or older representative for the Saarland population with respect to age, sex and location were sampled ",,2020-07-22,2020-10-15,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,1662,0.0105,0.0067,0.018500000000000003,,,,,,Simplified probability,Anti-SARS-CoV-2 NCP ELISA (IgG),EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.993,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Stefan Lohse,Saarland University Medical Center,Unity-Aligned,https://dx.doi.org/10.1038/s43856-022-00100-z,2022-06-01,2024-03-22,Verified,lohse_german_2022,DEU
220518_Saarland_SaarlandUniversityMedicalCenter_Male,220518_Saarland_SaarlandUniversityMedicalCenter,German federal-state-wide seroprevalence study of 1st SARS-CoV-2 pandemic wave shows importance of long-term antibody test performance.,2022-05-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Saarland,,"10,000 inhabitants aged 18 years or older representative for the Saarland population with respect to age, sex and location were sampled ",,2020-07-22,2020-10-15,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,1278,0.0089,0.0053,0.0174,,,,,,Simplified probability,Anti-SARS-CoV-2 NCP ELISA (IgG),EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8490000000000001,0.993,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Stefan Lohse,Saarland University Medical Center,Unity-Aligned,https://dx.doi.org/10.1038/s43856-022-00100-z,2022-06-01,2024-03-22,Verified,lohse_german_2022,DEU
220526_Germany_UniversitätsmedizinBerlin,220526_Germany_UniversitätsmedizinBerlin,SARS-CoV-2 Antibody Prevalence in Adult Patients with Short Bowel Syndrome - A German Multicenter Cross-Sectional Study.,2022-05-26,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Germany,,,Patients with  SBS managed  atthree  tertiary  care  centers  across  Germany  were included  in  the  studybetween  1stof  January  2021  and  31stof January 2022.,,2021-01-01,2022-01-31,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,119,0.0756,,,True,,,,True,Sequential,Not reported/ Unable to specify,,Neutralization,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Elisabeth Bluthner,Universitätsmedizin Berlin,Not Unity-Aligned,https://dx.doi.org/10.1002/jpen.2410,2022-05-31,2022-07-16,Unverified,bluthner_sars-cov-2_nodate,DEU
220527_Tirschenreuth_UniversityofRegensburg_Baseline,220527_Tirschenreuth_UniversityofRegensburg_Baseline,"Time Trend in SARS-CoV-2 Seropositivity, Surveillance Detection- and Infection Fatality Ratio until Spring 2021 in the Tirschenreuth County-Results from a Population-Based Longitudinal Study in Germany",2022-05-27,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Germany,Tirschenreuth District,,"""4203 randomly selected inhabitants of Tirschenreuth aged 14 years or older participated in the baseline survey of the TiKoCo study (response rate: 64.3%)""",,2020-06-01,2020-06-30,Household and community samples,All,Multiple groups,14.0,,Primary Estimate,,4181,0.0895,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sebastian Einhauser,University of Regensburg,Not Unity-Aligned,https://dx.doi.org/10.3390/v14061168,2022-06-24,2024-03-01,Unverified,einhauser_time_2022,DEU
220527_Tirschenreuth_UniversityofRegensburg_Baseline_Male,220527_Tirschenreuth_UniversityofRegensburg_Baseline,"Time Trend in SARS-CoV-2 Seropositivity, Surveillance Detection- and Infection Fatality Ratio until Spring 2021 in the Tirschenreuth County-Results from a Population-Based Longitudinal Study in Germany",2022-05-27,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Germany,Tirschenreuth District,,"""4203 randomly selected inhabitants of Tirschenreuth aged 14 years or older participated in the baseline survey of the TiKoCo study (response rate: 64.3%)""",,2020-06-01,2020-06-30,Household and community samples,Male,Multiple groups,14.0,,Sex/Gender,,2023,0.08800000000000001,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sebastian Einhauser,University of Regensburg,Not Unity-Aligned,https://dx.doi.org/10.3390/v14061168,2022-06-24,2024-03-01,Unverified,einhauser_time_2022,DEU
220527_Tirschenreuth_UniversityofRegensburg_Baseline_Female,220527_Tirschenreuth_UniversityofRegensburg_Baseline,"Time Trend in SARS-CoV-2 Seropositivity, Surveillance Detection- and Infection Fatality Ratio until Spring 2021 in the Tirschenreuth County-Results from a Population-Based Longitudinal Study in Germany",2022-05-27,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Germany,Tirschenreuth District,,"""4203 randomly selected inhabitants of Tirschenreuth aged 14 years or older participated in the baseline survey of the TiKoCo study (response rate: 64.3%)""",,2020-06-01,2020-06-30,Household and community samples,Female,Multiple groups,14.0,,Sex/Gender,,2158,0.0908,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sebastian Einhauser,University of Regensburg,Not Unity-Aligned,https://dx.doi.org/10.3390/v14061168,2022-06-24,2024-03-01,Unverified,einhauser_time_2022,DEU
220527_Tirschenreuth_UniversityofRegensburg_FollowUp1,220527_Tirschenreuth_UniversityofRegensburg_FollowUp1,"Time Trend in SARS-CoV-2 Seropositivity, Surveillance Detection- and Infection Fatality Ratio until Spring 2021 in the Tirschenreuth County-Results from a Population-Based Longitudinal Study in Germany",2022-05-27,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Germany,Tirschenreuth District,,"""4203 randomly selected inhabitants of Tirschenreuth aged 14 years or older participated in the baseline survey of the TiKoCo study (response rate: 64.3%)""",,2020-11-01,2020-11-30,Household and community samples,All,Multiple groups,14.0,,Primary Estimate,,3513,0.10220000000000001,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sebastian Einhauser,University of Regensburg,Not Unity-Aligned,https://dx.doi.org/10.3390/v14061168,2022-06-24,2024-03-01,Unverified,einhauser_time_2022,DEU
220527_Tirschenreuth_UniversityofRegensburg_FollowUp1_Female,220527_Tirschenreuth_UniversityofRegensburg_FollowUp1,"Time Trend in SARS-CoV-2 Seropositivity, Surveillance Detection- and Infection Fatality Ratio until Spring 2021 in the Tirschenreuth County-Results from a Population-Based Longitudinal Study in Germany",2022-05-27,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Germany,Tirschenreuth District,,"""4203 randomly selected inhabitants of Tirschenreuth aged 14 years or older participated in the baseline survey of the TiKoCo study (response rate: 64.3%)""",,2020-11-01,2020-11-30,Household and community samples,Female,Multiple groups,14.0,,Sex/Gender,,1861,0.1026,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sebastian Einhauser,University of Regensburg,Not Unity-Aligned,https://dx.doi.org/10.3390/v14061168,2022-06-24,2024-03-01,Unverified,einhauser_time_2022,DEU
220527_Tirschenreuth_UniversityofRegensburg_FollowUp1_Male,220527_Tirschenreuth_UniversityofRegensburg_FollowUp1,"Time Trend in SARS-CoV-2 Seropositivity, Surveillance Detection- and Infection Fatality Ratio until Spring 2021 in the Tirschenreuth County-Results from a Population-Based Longitudinal Study in Germany",2022-05-27,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Germany,Tirschenreuth District,,"""4203 randomly selected inhabitants of Tirschenreuth aged 14 years or older participated in the baseline survey of the TiKoCo study (response rate: 64.3%)""",,2020-11-01,2020-11-30,Household and community samples,Male,Multiple groups,14.0,,Sex/Gender,,1652,0.1017,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sebastian Einhauser,University of Regensburg,Not Unity-Aligned,https://dx.doi.org/10.3390/v14061168,2022-06-24,2024-03-01,Unverified,einhauser_time_2022,DEU
220527_Tirschenreuth_UniversityofRegensburg_FollowUp2,220527_Tirschenreuth_UniversityofRegensburg_FollowUp2,"Time Trend in SARS-CoV-2 Seropositivity, Surveillance Detection- and Infection Fatality Ratio until Spring 2021 in the Tirschenreuth County-Results from a Population-Based Longitudinal Study in Germany",2022-05-27,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Germany,Tirschenreuth District,,"""4203 randomly selected inhabitants of Tirschenreuth aged 14 years or older participated in the baseline survey of the TiKoCo study (response rate: 64.3%)""",,2021-04-01,2021-04-30,Household and community samples,All,Multiple groups,14.0,,Primary Estimate,,3177,0.1568,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sebastian Einhauser,University of Regensburg,Not Unity-Aligned,https://dx.doi.org/10.3390/v14061168,2022-06-24,2024-03-01,Unverified,einhauser_time_2022,DEU
220527_Tirschenreuth_UniversityofRegensburg_FollowUp2_Female,220527_Tirschenreuth_UniversityofRegensburg_FollowUp2,"Time Trend in SARS-CoV-2 Seropositivity, Surveillance Detection- and Infection Fatality Ratio until Spring 2021 in the Tirschenreuth County-Results from a Population-Based Longitudinal Study in Germany",2022-05-27,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Germany,Tirschenreuth District,,"""4203 randomly selected inhabitants of Tirschenreuth aged 14 years or older participated in the baseline survey of the TiKoCo study (response rate: 64.3%)""",,2021-04-01,2021-04-30,Household and community samples,Female,Multiple groups,14.0,,Sex/Gender,,1710,0.15560000000000002,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sebastian Einhauser,University of Regensburg,Not Unity-Aligned,https://dx.doi.org/10.3390/v14061168,2022-06-24,2024-03-01,Unverified,einhauser_time_2022,DEU
220527_Tirschenreuth_UniversityofRegensburg_FollowUp2_Male,220527_Tirschenreuth_UniversityofRegensburg_FollowUp2,"Time Trend in SARS-CoV-2 Seropositivity, Surveillance Detection- and Infection Fatality Ratio until Spring 2021 in the Tirschenreuth County-Results from a Population-Based Longitudinal Study in Germany",2022-05-27,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Germany,Tirschenreuth District,,"""4203 randomly selected inhabitants of Tirschenreuth aged 14 years or older participated in the baseline survey of the TiKoCo study (response rate: 64.3%)""",,2021-04-01,2021-04-30,Household and community samples,Male,Multiple groups,14.0,,Sex/Gender,,1467,0.15810000000000002,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sebastian Einhauser,University of Regensburg,Not Unity-Aligned,https://dx.doi.org/10.3390/v14061168,2022-06-24,2024-03-01,Unverified,einhauser_time_2022,DEU
220601_Stuttgart_UniversityofCologne_Primary(S-IgG),220601_Stuttgart_UniversityofCologne,The humoral immune response more than one year after SARS-CoV-2 infection: low detection rate of anti-nucleocapsid antibodies via Euroimmun ELISA.,2022-06-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Baden-Württemberg,Stuttgart,"Residents of Stuttgart, Germany, greater than 5 years old",,2021-06-15,2021-07-14,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,Anti-S-IgG,454,0.716,,,True,,,,True,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.98,1.0,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Unclear,Gregor Paul,University of Cologne,Unity-Aligned,https://dx.doi.org/10.1007/s15010-022-01830-x,2022-06-11,2024-03-23,Verified,paul_humoral_2022,DEU
220606_Germany_Ludwig-MaximiliansUniversityofMunich_Overall,220606_Germany_Ludwig-MaximiliansUniversityofMunich,"Cross-sectional seroprevalence surveys of SARS-CoV-2 antibodies in children in Germany, June 2020 to May 2021",2022-06-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Germany,,"Hamburg, Hannover, Berlin, Krefeld, Dusseldorf, Aachen, Gießen, Dresden, Wurzburg, Mannheim, Homburg (town), Freiburg, Munich","Children (aged ≤ 17 years). In 14 paediatric hospitals across Germany, participants were recruited during their inpatient or outpatient stay, irrespectively of the medical purpose of the stay.","Children with corrected gestational age less
than 37 completed weeks, severe congenital or acquired immune deficiencies, immunosuppression due to chemotherapy or stem cell transplantation, treatment
due to life-threatening emergencies, and children already vaccinated against SARS-CoV-2 were excluded from participation.",2020-06-01,2021-05-31,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,,10358,0.045,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Anna-Lisa Sorg,Heidelberg University,Not Unity-Aligned,https://doi.org/10.1038/s41467-022-30482-6,2022-06-14,2024-03-01,Unverified,sorg_cross-sectional_2022,DEU
220606_Germany_Ludwig-MaximiliansUniversityofMunich_Time3,220606_Germany_Ludwig-MaximiliansUniversityofMunich,"Cross-sectional seroprevalence surveys of SARS-CoV-2 antibodies in children in Germany, June 2020 to May 2021",2022-06-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Germany,,"Hamburg, Hannover, Berlin, Krefeld, Dusseldorf, Aachen, Gießen, Dresden, Wurzburg, Mannheim, Homburg (town), Freiburg, Munich","Children (aged ≤ 17 years). In 14 paediatric hospitals across Germany, participants were recruited during their inpatient or outpatient stay, irrespectively of the medical purpose of the stay.","Children with corrected gestational age less
than 37 completed weeks, severe congenital or acquired immune deficiencies, immunosuppression due to chemotherapy or stem cell transplantation, treatment
due to life-threatening emergencies, and children already vaccinated against SARS-CoV-2 were excluded from participation.",2021-03-01,2021-05-31,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Time frame,March - May 2021,1838,0.091,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Anna-Lisa Sorg,Heidelberg University,Not Unity-Aligned,https://doi.org/10.1038/s41467-022-30482-6,2022-06-14,2024-03-01,Unverified,sorg_cross-sectional_2022,DEU
220606_Germany_Ludwig-MaximiliansUniversityofMunich_12-17,220606_Germany_Ludwig-MaximiliansUniversityofMunich,"Cross-sectional seroprevalence surveys of SARS-CoV-2 antibodies in children in Germany, June 2020 to May 2021",2022-06-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Germany,,"Hamburg, Hannover, Berlin, Krefeld, Dusseldorf, Aachen, Gießen, Dresden, Wurzburg, Mannheim, Homburg (town), Freiburg, Munich","Children (aged ≤ 17 years). In 14 paediatric hospitals across Germany, participants were recruited during their inpatient or outpatient stay, irrespectively of the medical purpose of the stay.","Children with corrected gestational age less
than 37 completed weeks, severe congenital or acquired immune deficiencies, immunosuppression due to chemotherapy or stem cell transplantation, treatment
due to life-threatening emergencies, and children already vaccinated against SARS-CoV-2 were excluded from participation.",2020-06-01,2021-05-31,Residual sera,All,Children and Youth (0-17 years),12.0,17.0,Age,12-17,4152,0.044000000000000004,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Anna-Lisa Sorg,Heidelberg University,Not Unity-Aligned,https://doi.org/10.1038/s41467-022-30482-6,2022-06-14,2024-03-01,Unverified,sorg_cross-sectional_2022,DEU
220606_Germany_Ludwig-MaximiliansUniversityofMunich_Time2,220606_Germany_Ludwig-MaximiliansUniversityofMunich,"Cross-sectional seroprevalence surveys of SARS-CoV-2 antibodies in children in Germany, June 2020 to May 2021",2022-06-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Germany,,"Hamburg, Hannover, Berlin, Krefeld, Dusseldorf, Aachen, Gießen, Dresden, Wurzburg, Mannheim, Homburg (town), Freiburg, Munich","Children (aged ≤ 17 years). In 14 paediatric hospitals across Germany, participants were recruited during their inpatient or outpatient stay, irrespectively of the medical purpose of the stay.","Children with corrected gestational age less
than 37 completed weeks, severe congenital or acquired immune deficiencies, immunosuppression due to chemotherapy or stem cell transplantation, treatment
due to life-threatening emergencies, and children already vaccinated against SARS-CoV-2 were excluded from participation.",2020-10-01,2021-02-28,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Time frame,October 2020 - February 2021,4276,0.049,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Anna-Lisa Sorg,Heidelberg University,Not Unity-Aligned,https://doi.org/10.1038/s41467-022-30482-6,2022-06-14,2024-03-01,Unverified,sorg_cross-sectional_2022,DEU
220606_Germany_Ludwig-MaximiliansUniversityofMunich_Female,220606_Germany_Ludwig-MaximiliansUniversityofMunich,"Cross-sectional seroprevalence surveys of SARS-CoV-2 antibodies in children in Germany, June 2020 to May 2021",2022-06-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Germany,,"Hamburg, Hannover, Berlin, Krefeld, Dusseldorf, Aachen, Gießen, Dresden, Wurzburg, Mannheim, Homburg (town), Freiburg, Munich","Children (aged ≤ 17 years). In 14 paediatric hospitals across Germany, participants were recruited during their inpatient or outpatient stay, irrespectively of the medical purpose of the stay.","Children with corrected gestational age less
than 37 completed weeks, severe congenital or acquired immune deficiencies, immunosuppression due to chemotherapy or stem cell transplantation, treatment
due to life-threatening emergencies, and children already vaccinated against SARS-CoV-2 were excluded from participation.",2020-06-01,2021-05-31,Residual sera,Female,Children and Youth (0-17 years),0.0,17.0,Sex/Gender,,5228,0.046,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Anna-Lisa Sorg,Heidelberg University,Not Unity-Aligned,https://doi.org/10.1038/s41467-022-30482-6,2022-06-14,2024-03-01,Unverified,sorg_cross-sectional_2022,DEU
220606_Germany_Ludwig-MaximiliansUniversityofMunich_Time1,220606_Germany_Ludwig-MaximiliansUniversityofMunich,"Cross-sectional seroprevalence surveys of SARS-CoV-2 antibodies in children in Germany, June 2020 to May 2021",2022-06-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Germany,,"Hamburg, Hannover, Berlin, Krefeld, Dusseldorf, Aachen, Gießen, Dresden, Wurzburg, Mannheim, Homburg (town), Freiburg, Munich","Children (aged ≤ 17 years). In 14 paediatric hospitals across Germany, participants were recruited during their inpatient or outpatient stay, irrespectively of the medical purpose of the stay.","Children with corrected gestational age less
than 37 completed weeks, severe congenital or acquired immune deficiencies, immunosuppression due to chemotherapy or stem cell transplantation, treatment
due to life-threatening emergencies, and children already vaccinated against SARS-CoV-2 were excluded from participation.",2020-06-01,2020-09-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Time frame,June - September 2020,4244,0.02,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Anna-Lisa Sorg,Heidelberg University,Not Unity-Aligned,https://doi.org/10.1038/s41467-022-30482-6,2022-06-14,2024-03-01,Unverified,sorg_cross-sectional_2022,DEU
220606_Germany_Ludwig-MaximiliansUniversityofMunich_<3,220606_Germany_Ludwig-MaximiliansUniversityofMunich,"Cross-sectional seroprevalence surveys of SARS-CoV-2 antibodies in children in Germany, June 2020 to May 2021",2022-06-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Germany,,"Hamburg, Hannover, Berlin, Krefeld, Dusseldorf, Aachen, Gießen, Dresden, Wurzburg, Mannheim, Homburg (town), Freiburg, Munich","Children (aged ≤ 17 years). In 14 paediatric hospitals across Germany, participants were recruited during their inpatient or outpatient stay, irrespectively of the medical purpose of the stay.","Children with corrected gestational age less
than 37 completed weeks, severe congenital or acquired immune deficiencies, immunosuppression due to chemotherapy or stem cell transplantation, treatment
due to life-threatening emergencies, and children already vaccinated against SARS-CoV-2 were excluded from participation.",2020-06-01,2021-05-31,Residual sera,All,Children and Youth (0-17 years),0.0,2.0,Age,<3,1479,0.066,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Anna-Lisa Sorg,Heidelberg University,Not Unity-Aligned,https://doi.org/10.1038/s41467-022-30482-6,2022-06-14,2024-03-01,Unverified,sorg_cross-sectional_2022,DEU
220606_Germany_Ludwig-MaximiliansUniversityofMunich_Male,220606_Germany_Ludwig-MaximiliansUniversityofMunich,"Cross-sectional seroprevalence surveys of SARS-CoV-2 antibodies in children in Germany, June 2020 to May 2021",2022-06-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Germany,,"Hamburg, Hannover, Berlin, Krefeld, Dusseldorf, Aachen, Gießen, Dresden, Wurzburg, Mannheim, Homburg (town), Freiburg, Munich","Children (aged ≤ 17 years). In 14 paediatric hospitals across Germany, participants were recruited during their inpatient or outpatient stay, irrespectively of the medical purpose of the stay.","Children with corrected gestational age less
than 37 completed weeks, severe congenital or acquired immune deficiencies, immunosuppression due to chemotherapy or stem cell transplantation, treatment
due to life-threatening emergencies, and children already vaccinated against SARS-CoV-2 were excluded from participation.",2020-06-01,2021-05-31,Residual sera,Male,Children and Youth (0-17 years),0.0,17.0,Sex/Gender,,5110,0.043,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Anna-Lisa Sorg,Heidelberg University,Not Unity-Aligned,https://doi.org/10.1038/s41467-022-30482-6,2022-06-14,2024-03-01,Unverified,sorg_cross-sectional_2022,DEU
220606_Germany_Ludwig-MaximiliansUniversityofMunich_3-11,220606_Germany_Ludwig-MaximiliansUniversityofMunich,"Cross-sectional seroprevalence surveys of SARS-CoV-2 antibodies in children in Germany, June 2020 to May 2021",2022-06-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Germany,,"Hamburg, Hannover, Berlin, Krefeld, Dusseldorf, Aachen, Gießen, Dresden, Wurzburg, Mannheim, Homburg (town), Freiburg, Munich","Children (aged ≤ 17 years). In 14 paediatric hospitals across Germany, participants were recruited during their inpatient or outpatient stay, irrespectively of the medical purpose of the stay.","Children with corrected gestational age less
than 37 completed weeks, severe congenital or acquired immune deficiencies, immunosuppression due to chemotherapy or stem cell transplantation, treatment
due to life-threatening emergencies, and children already vaccinated against SARS-CoV-2 were excluded from participation.",2020-06-01,2021-05-31,Residual sera,All,Children and Youth (0-17 years),3.0,11.0,Age,3-11,4727,0.039,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Anna-Lisa Sorg,Heidelberg University,Not Unity-Aligned,https://doi.org/10.1038/s41467-022-30482-6,2022-06-14,2024-03-01,Unverified,sorg_cross-sectional_2022,DEU
220706_Bavaria_Ludwig-Maximilians-Universität_Children1,220706_Bavaria_Ludwig-Maximilians-Universität_Children1,"Surveillance of Acute SARS-CoV-2 Infections in Elementary Schools and Daycare Facilities in Bavaria, Germany (09/2020-03/2021)",2022-07-06,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Germany,Bavaria,,"Participants were eligible for enrollment if they met the
following inclusion criteria: child aged 1 to 10 years or
teachers/daycare staff attending the participating facilities at the
day of assessment and written informed consent provided by
participants or their legal representatives. In addition, individuals
had to be in a state of health permitting to visit the facilities as
outlined by the latest corona guidelines from the department of
health at the time of assessment

The COVID Kids Bavaria study is a large, multi-center, open cohort study investigating the distribution of SARS-CoV-2 among children and staff in daycare facilities and elementary schools in Bavaria, Germany. Six study centers were involved representing all Bavarian university children’s hospitals (LudwigMaximilians-Universität München, Technische Universität München, Augsburg, Erlangen, Regensburg, Würzburg).",,2021-06-01,2021-07-31,Students and Daycares,All,Children and Youth (0-17 years),,,Primary Estimate,,315,0.0857,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,Serum,IgG,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Anna Kern,Ludwig-Maximilians-Universität,Not Unity-Aligned,https://dx.doi.org/10.3389/fped.2022.888498,2022-08-17,2022-08-26,Unverified,kern_surveillance_2022,DEU
220706_Bavaria_Ludwig-Maximilians-Universität_Staff2,220706_Bavaria_Ludwig-Maximilians-Universität_Staff2,"Surveillance of Acute SARS-CoV-2 Infections in Elementary Schools and Daycare Facilities in Bavaria, Germany (09/2020-03/2021)",2022-07-06,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Germany,Bavaria,,"Participants were eligible for enrollment if they met the
following inclusion criteria: child aged 1 to 10 years or
teachers/daycare staff attending the participating facilities at the
day of assessment and written informed consent provided by
participants or their legal representatives. In addition, individuals
had to be in a state of health permitting to visit the facilities as
outlined by the latest corona guidelines from the department of
health at the time of assessment

The COVID Kids Bavaria study is a large, multi-center, open cohort study investigating the distribution of SARS-CoV-2 among children and staff in daycare facilities and elementary schools in Bavaria, Germany. Six study centers were involved representing all Bavarian university children’s hospitals (LudwigMaximilians-Universität München, Technische Universität München, Augsburg, Erlangen, Regensburg, Würzburg).",,2021-06-01,2021-07-31,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,123,0.048780000000000004,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,Serum,IgG,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Anna Kern,Ludwig-Maximilians-Universität,Not Unity-Aligned,https://dx.doi.org/10.3389/fped.2022.888498,2022-08-17,2022-08-26,Unverified,kern_surveillance_2022,DEU
220811_Augsburg_UniversityofAugsburg_Children,220811_Augsburg_UniversityofAugsburg_Children,Longitudinal change in SARS-CoV-2 seroprevalence in 3-to 16-year-old children: The Augsburg Plus study.,2022-08-11,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,,Ausburg,"""Children from the collaborating institutions aged 3–16 years and one of their parents were included in the study""",COVID-19 symptoms ,2020-12-15,2021-08-15,Students and Daycares,All,Children and Youth (0-17 years),3.0,16.0,Primary Estimate,,363,0.044000000000000004,0.026000000000000002,0.07200000000000001,True,,,,True,Convenience,"NADAL® COVID-19 IgG/IgM Test,Anti-SARS-CoV-2 QuantiVac ELISA ,Elecsys® Anti‐SARS‐CoV‐2 (S),recomLine SARS-CoV-2 IgG","nal von minden GmbH,EUROIMMUN,Roche Diagnostics,Mikrogen GmbH",LFIA,Whole Blood,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Vincenza Leona,University of Augsburg,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0272874,2022-08-24,2024-03-01,Unverified,leone_longitudinal_2022,DEU
220811_Augsburg_UniversityofAugsburg_Educators,220811_Augsburg_UniversityofAugsburg_Educators,Longitudinal change in SARS-CoV-2 seroprevalence in 3-to 16-year-old children: The Augsburg Plus study.,2022-08-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,,Ausburg,"""Children from the collaborating institutions aged 3–16 years and one of their parents were included in the study""",COVID-19 symptoms ,2020-12-15,2021-08-15,Students and Daycares,All,Adults (18-64 years),,,Primary Estimate,,297,0.057,0.035,0.092,True,,,,True,Convenience,"NADAL® COVID-19 IgG/IgM Test,Anti-SARS-CoV-2 QuantiVac ELISA ,Elecsys® Anti‐SARS‐CoV‐2 (S),recomLine SARS-CoV-2 IgG","nal von minden GmbH,EUROIMMUN,Roche Diagnostics,Mikrogen GmbH",LFIA,Whole Blood,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Vincenza Leona,University of Augsburg,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0272874,2022-08-24,2024-03-01,Unverified,leone_longitudinal_2022,DEU
220811_Augsburg_UniversityofAugsburg_Parents,220811_Augsburg_UniversityofAugsburg_Parents,Longitudinal change in SARS-CoV-2 seroprevalence in 3-to 16-year-old children: The Augsburg Plus study.,2022-08-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,,Ausburg,"""Children from the collaborating institutions aged 3–16 years and one of their parents were included in the study""",COVID-19 symptoms ,2020-12-15,2021-08-15,Students and Daycares,All,Adults (18-64 years),,,Primary Estimate,,81,0.049,0.026000000000000002,0.128,True,,,,True,Convenience,"NADAL® COVID-19 IgG/IgM Test,Anti-SARS-CoV-2 QuantiVac ELISA ,Elecsys® Anti‐SARS‐CoV‐2 (S),recomLine SARS-CoV-2 IgG","nal von minden GmbH,EUROIMMUN,Roche Diagnostics,Mikrogen GmbH",LFIA,Whole Blood,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Vincenza Leona,University of Augsburg,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0272874,2022-08-24,2024-03-01,Unverified,leone_longitudinal_2022,DEU
220901_Germany_BielefeldUniversity_overall,220901_Germany_BielefeldUniversity,COVID-19 after the first wave of the pandemic among employees from a German university hospital: prevalence and questionnaire data.,2022-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,,Bielefeld,"""Beginning in June 2020, all hospital employees were offered free SARS-CoV-2 antibody testing by the hospital's own occu- pational health service (inclusion criterion). """,,2020-06-01,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),19.0,66.0,Primary Estimate,,382,0.015700000000000002,,,True,True,True,,True,Convenience,SARS-CoV-2 Rapid Antibody Test,Roche Diagnostics,CLIA,,IgG,,Validated by manufacturers,1.0,0.998,['High'],,No,No,Yes,,Yes,Yes,Yes,,Anna Catharina Sellmeier,Bielefeld University,Not Unity-Aligned,https://dx.doi.org/10.25122/jml-2022-0126,2022-11-29,2023-03-19,Unverified,zotero-4902,DEU
220917_Germany_LudwigMaximiliansUniversityMunich_Overall,220917_Germany_LudwigMaximiliansUniversityMunich,Association of SARS-CoV-2 Seropositivity With Myalgic Encephalomyelitis and/or Chronic Fatigue Syndrome Among Children and Adolescents in Germany,2022-09-27,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Germany,"Baden-Württember, Bavaria, Lower Saxony, Saxony, North Rhine-Westphalia","Mannheim, Freiburg, Munich, Würzburg, Hannover, Dresden, Krefeld, Aachen","""We performed a substudy of the SARS-CoV-2 KIDS study, which conducted hospital-based, multicenter cross-sectional surveys on the seroprevalence of anti–SARS-CoV-2 IgG antibodies in children [aged 5-17 years] in Germany from May 1 to October 31, 2021. Participants were recruited during their inpatient or outpatient stay in a pediatric hospital, regardless of the medical purpose of the stay.""","""Children with a corrected gestational age of less than 37 completed weeks, severe congenital or acquired immune deficiencies, immunosuppression due to chemotherapy or stem cell transplant, treatment due to life-threatening emergencies, and vaccination against SARS-CoV-2 were excluded from participation. Repeated participation was not possible.""

""Patients who did not answer more than 2 questions about ME/CFS symptoms were excluded from the analysis.""

From eFigure 1:
""Missing values for sex, date of enrolment or date of birth"",
"">2 missing values in the long-COVID part"".",2021-05-01,2021-10-31,Residual sera,All,Children and Youth (0-17 years),5.0,17.0,Primary Estimate,,634,0.1577,,,True,,,,True,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9440000000000001,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Anna-Lisa Sorg,Ludwig-Maximilians-University Munich,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.33454,2022-10-06,2024-03-01,Unverified,sorg_association_2022,DEU
221019_BerlinBrandenburgArea_IMDBerlinPotsdam_nAb,221019_BerlinBrandenburgArea_IMDBerlinPotsdam,Outliers Matter-Correlation between S1 IgG SARS-CoV-2 Antibodies and Neutralizing SARS-CoV-2 Antibodies,2022-10-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Province of Brandenburg,Berlin-Brandenburg area,"""We thus examined 2994 consecutive blood samples of outpatients from the Berlin-Brandenburg area in Germany in which IgG antibodies against the S1 protein of the SARS-CoV-2 virus as well as neutralizing SARS-CoV-2 virus antibodies were determined from the same sample.""",,2021-04-01,2021-08-30,Residual sera,All,Multiple groups,,,Primary Estimate,Neutralizing antibodies,2994,0.7889,,,True,,,,True,Sequential,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,GenScript,ELISA,Serum,Neutralizing,Spike,Validated by developers,0.973,0.9940000000000001,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Berthold Hocher,Institute of Clinical Chemistry (IMD) Berlin-Potsdam,Unity-Aligned,https://dx.doi.org/10.3390/microorganisms10102067,2022-11-03,2024-04-17,Verified,hocher_outliers_2022,DEU
221019_BerlinBrandenburgArea_IMDBerlinPotsdam_ELISA,221019_BerlinBrandenburgArea_IMDBerlinPotsdam,Outliers Matter-Correlation between S1 IgG SARS-CoV-2 Antibodies and Neutralizing SARS-CoV-2 Antibodies,2022-10-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Province of Brandenburg,Berlin-Brandenburg area,"""We thus examined 2994 consecutive blood samples of outpatients from the Berlin-Brandenburg area in Germany in which IgG antibodies against the S1 protein of the SARS-CoV-2 virus as well as neutralizing SARS-CoV-2 virus antibodies were determined from the same sample.""",,2021-04-01,2021-08-30,Residual sera,All,Multiple groups,,,Test used,S1 IgG antibodies,2994,0.8093000000000001,,,,,,,,Sequential,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Berthold Hocher,Institute of Clinical Chemistry (IMD) Berlin-Potsdam,Unity-Aligned,https://dx.doi.org/10.3390/microorganisms10102067,2022-11-03,2024-04-17,Verified,hocher_outliers_2022,DEU
221101_Bavaria_ GermanResearchCenterforEnvironmentalHealth_wave1,221101_Bavaria_ GermanResearchCenterforEnvironmentalHealth_wave1,SARS-CoV-2 Seroprevalence in Preschool and School-Age Children,2022-11-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Bavaria,,"""The members of our cohort are participants in the Fr1da study in Bavaria (n ~ 167 000), a public health screening program for presymptomatic type 1 diabetes launched in 2015 (10, 11). All children in Bavaria aged 2–10 years (more precisely 1.75–10.99 years) with no previous diagnosis of diabetes are eligible to take part. The participants’ first-degree relatives aged 1–17 years (more precisely 1.0–17.99 years) can also be screened.""",,2020-03-15,2020-04-15,Household and community samples,All,Children and Youth (0-17 years),1.0,10.0,Primary Estimate,,2550,0.00352941176,,,True,,,,True,Convenience,Luciferase immunoprecipitation system (LIPS),,Other,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Raffael Ott, German Research Center for Environmental Health,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2022.0355,2023-03-08,2023-03-19,Unverified,ottSARSCoV2SeroprevalencePreschool2022,DEU
221101_Bavaria_ GermanResearchCenterforEnvironmentalHealth_wave2,221101_Bavaria_ GermanResearchCenterforEnvironmentalHealth_wave2,SARS-CoV-2 Seroprevalence in Preschool and School-Age Children,2022-11-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Bavaria,,"""The members of our cohort are participants in the Fr1da study in Bavaria (n ~ 167 000), a public health screening program for presymptomatic type 1 diabetes launched in 2015 (10, 11). All children in Bavaria aged 2–10 years (more precisely 1.75–10.99 years) with no previous diagnosis of diabetes are eligible to take part. The participants’ first-degree relatives aged 1–17 years (more precisely 1.0–17.99 years) can also be screened.""",,2020-09-15,2021-01-15,Household and community samples,All,Children and Youth (0-17 years),1.0,10.0,Primary Estimate,,10896,0.02716593245,,,True,,,,True,Convenience,Luciferase immunoprecipitation system (LIPS),,Other,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Raffael Ott, German Research Center for Environmental Health,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2022.0355,2023-03-08,2023-03-19,Unverified,ottSARSCoV2SeroprevalencePreschool2022,DEU
221101_Bavaria_ GermanResearchCenterforEnvironmentalHealth_wave3,221101_Bavaria_ GermanResearchCenterforEnvironmentalHealth_wave3,SARS-CoV-2 Seroprevalence in Preschool and School-Age Children,2022-11-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Bavaria,,"""The members of our cohort are participants in the Fr1da study in Bavaria (n ~ 167 000), a public health screening program for presymptomatic type 1 diabetes launched in 2015 (10, 11). All children in Bavaria aged 2–10 years (more precisely 1.75–10.99 years) with no previous diagnosis of diabetes are eligible to take part. The participants’ first-degree relatives aged 1–17 years (more precisely 1.0–17.99 years) can also be screened.""",,2021-02-15,2021-05-15,Household and community samples,All,Children and Youth (0-17 years),1.0,10.0,Primary Estimate,,10478,0.0852261882,,,True,,,,True,Convenience,Luciferase immunoprecipitation system (LIPS),,Other,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Raffael Ott, German Research Center for Environmental Health,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2022.0355,2023-03-08,2023-03-19,Unverified,ottSARSCoV2SeroprevalencePreschool2022,DEU
221101_Bavaria_ GermanResearchCenterforEnvironmentalHealth_wave4,221101_Bavaria_ GermanResearchCenterforEnvironmentalHealth_wave4,SARS-CoV-2 Seroprevalence in Preschool and School-Age Children,2022-11-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Bavaria,,"""The members of our cohort are participants in the Fr1da study in Bavaria (n ~ 167 000), a public health screening program for presymptomatic type 1 diabetes launched in 2015 (10, 11). All children in Bavaria aged 2–10 years (more precisely 1.75–10.99 years) with no previous diagnosis of diabetes are eligible to take part. The participants’ first-degree relatives aged 1–17 years (more precisely 1.0–17.99 years) can also be screened.""",,2021-08-15,2021-12-15,Household and community samples,All,Children and Youth (0-17 years),1.0,10.0,Primary Estimate,,9100,0.1301098901,,,True,,,,True,Convenience,Luciferase immunoprecipitation system (LIPS),,Other,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Raffael Ott, German Research Center for Environmental Health,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2022.0355,2023-03-08,2023-03-19,Unverified,ottSARSCoV2SeroprevalencePreschool2022,DEU
221101_Bavaria_ GermanResearchCenterforEnvironmentalHealth_wave5,221101_Bavaria_ GermanResearchCenterforEnvironmentalHealth_wave5,SARS-CoV-2 Seroprevalence in Preschool and School-Age Children,2022-11-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Germany,Bavaria,,"""The members of our cohort are participants in the Fr1da study in Bavaria (n ~ 167 000), a public health screening program for presymptomatic type 1 diabetes launched in 2015 (10, 11). All children in Bavaria aged 2–10 years (more precisely 1.75–10.99 years) with no previous diagnosis of diabetes are eligible to take part. The participants’ first-degree relatives aged 1–17 years (more precisely 1.0–17.99 years) can also be screened.""",,2022-01-15,2022-05-01,Household and community samples,All,Children and Youth (0-17 years),1.0,10.0,Primary Estimate,,9489,0.5047950258,,,True,,,,True,Convenience,Luciferase immunoprecipitation system (LIPS),,Other,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Raffael Ott, German Research Center for Environmental Health,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2022.0355,2023-03-08,2023-03-22,Unverified,ottSARSCoV2SeroprevalencePreschool2022,DEU
221111_Wurzburg_Unknown_AntiS,221111_Wurzburg_Unknown,High Seroprevalence of SARS-CoV-2 in Preschool Children in July 2022,2022-11-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Bavaria,Wurzburg,preschool children (age 2–6 years) at nine day-care centers in Würzburg,,2022-07-01,2022-07-31,Students and Daycares,All,Children and Youth (0-17 years),2.0,6.0,Primary Estimate,Roche anti-S,277,0.696,0.643,0.751,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Dried Blood,TotalAntibody,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,G Engels,Unknown,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2022.0345,2023-02-06,2024-03-01,Unverified,engels_high_2022,DEU
221111_Bavaria_GermanResearchCentreforEnvironmentalHealth_Wave1_Age5-10,221111_Bavaria_GermanResearchCentreforEnvironmentalHealth_Wave1_Children,SARS-CoV-2 Seroprevalence in Preschool and School-Age Children-Population Screening Findings From January 2020 to June 2022.,2022-11-11,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Germany,Bavaria,,"""All children in Bavaria who are 2-10 years old (1.75-10.99 years to be precise) and who have not previously been diagnosed with diabetes can take part.""",,2020-03-01,2020-04-30,Residual sera,All,Children and Youth (0-17 years),5.0,10.0,Primary Estimate,5-10,612,0.004,0.0,0.008,,,,,,Unclear,Luciferase immunoprecipitation system (LIPS),,Other,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['Moderate'],,Unclear,Yes,No,,Unclear,Yes,No,,Raffael Ott,German Research Centre for Environmental Health,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2022.0355,2022-11-17,2022-11-18,Unverified,ott_sars-cov-2_2022,DEU
221111_Bavaria_GermanResearchCentreforEnvironmentalHealth_Wave1_Age1-4,221111_Bavaria_GermanResearchCentreforEnvironmentalHealth_Wave1_Infants,SARS-CoV-2 Seroprevalence in Preschool and School-Age Children-Population Screening Findings From January 2020 to June 2022.,2022-11-11,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Germany,Bavaria,,"""All children in Bavaria who are 2-10 years old (1.75-10.99 years to be precise) and who have not previously been diagnosed with diabetes can take part.""",,2020-03-01,2020-04-30,Residual sera,All,Children and Youth (0-17 years),1.0,4.0,Primary Estimate,1-4,1938,0.003,0.001,0.005,,,,,,Unclear,Luciferase immunoprecipitation system (LIPS),,Other,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['Moderate'],,Unclear,Yes,No,,Unclear,Yes,No,,Raffael Ott,German Research Centre for Environmental Health,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2022.0355,2022-11-17,2022-11-18,Unverified,ott_sars-cov-2_2022,DEU
221111_Bavaria_GermanResearchCentreforEnvironmentalHealth_Wave2_Age5-10,221111_Bavaria_GermanResearchCentreforEnvironmentalHealth_Wave2_Children,SARS-CoV-2 Seroprevalence in Preschool and School-Age Children-Population Screening Findings From January 2020 to June 2022.,2022-11-11,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Germany,Bavaria,,"""All children in Bavaria who are 2-10 years old (1.75-10.99 years to be precise) and who have not previously been diagnosed with diabetes can take part.""",,2020-09-01,2021-01-31,Residual sera,All,Children and Youth (0-17 years),5.0,10.0,Primary Estimate,5-10,3694,0.035,0.006999999999999999,0.081,,,,,,Unclear,Luciferase immunoprecipitation system (LIPS),,Other,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['Moderate'],,Unclear,Yes,No,,Unclear,Yes,No,,Raffael Ott,German Research Centre for Environmental Health,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2022.0355,2022-11-17,2022-11-18,Unverified,ott_sars-cov-2_2022,DEU
221111_Bavaria_GermanResearchCentreforEnvironmentalHealth_Wave2_Age1-4,221111_Bavaria_GermanResearchCentreforEnvironmentalHealth_Wave2_Infants,SARS-CoV-2 Seroprevalence in Preschool and School-Age Children-Population Screening Findings From January 2020 to June 2022.,2022-11-11,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Germany,Bavaria,,"""All children in Bavaria who are 2-10 years old (1.75-10.99 years to be precise) and who have not previously been diagnosed with diabetes can take part.""",,2020-09-01,2021-01-31,Residual sera,All,Children and Youth (0-17 years),1.0,4.0,Primary Estimate,1-4,7202,0.021,0.006,0.054000000000000006,,,,,,Unclear,Luciferase immunoprecipitation system (LIPS),,Other,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['Moderate'],,Unclear,Yes,No,,Unclear,Yes,No,,Raffael Ott,German Research Centre for Environmental Health,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2022.0355,2022-11-17,2022-11-18,Unverified,ott_sars-cov-2_2022,DEU
221111_Bavaria_GermanResearchCentreforEnvironmentalHealth_Wave3_Age5-10,221111_Bavaria_GermanResearchCentreforEnvironmentalHealth_Wave3_Children,SARS-CoV-2 Seroprevalence in Preschool and School-Age Children-Population Screening Findings From January 2020 to June 2022.,2022-11-11,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Germany,Bavaria,,"""All children in Bavaria who are 2-10 years old (1.75-10.99 years to be precise) and who have not previously been diagnosed with diabetes can take part.""",,2021-02-01,2021-05-31,Residual sera,All,Children and Youth (0-17 years),5.0,10.0,Primary Estimate,5-10,4236,0.102,0.084,0.131,,,,,,Unclear,Luciferase immunoprecipitation system (LIPS),,Other,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['Moderate'],,Unclear,Yes,No,,Unclear,Yes,No,,Raffael Ott,German Research Centre for Environmental Health,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2022.0355,2022-11-17,2022-11-18,Unverified,ott_sars-cov-2_2022,DEU
221111_Bavaria_GermanResearchCentreforEnvironmentalHealth_Wave3_Age1-4,221111_Bavaria_GermanResearchCentreforEnvironmentalHealth_Wave3_Infants,SARS-CoV-2 Seroprevalence in Preschool and School-Age Children-Population Screening Findings From January 2020 to June 2022.,2022-11-11,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Germany,Bavaria,,"""All children in Bavaria who are 2-10 years old (1.75-10.99 years to be precise) and who have not previously been diagnosed with diabetes can take part.""",,2021-02-01,2021-05-31,Residual sera,All,Children and Youth (0-17 years),1.0,4.0,Primary Estimate,1-4,6242,0.076,0.054000000000000006,0.087,,,,,,Unclear,Luciferase immunoprecipitation system (LIPS),,Other,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['Moderate'],,Unclear,Yes,No,,Unclear,Yes,No,,Raffael Ott,German Research Centre for Environmental Health,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2022.0355,2022-11-17,2022-11-18,Unverified,ott_sars-cov-2_2022,DEU
221111_Bavaria_GermanResearchCentreforEnvironmentalHealth_Wave4_Age5-10,221111_Bavaria_GermanResearchCentreforEnvironmentalHealth_Wave4_Children,SARS-CoV-2 Seroprevalence in Preschool and School-Age Children-Population Screening Findings From January 2020 to June 2022.,2022-11-11,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Germany,Bavaria,,"""All children in Bavaria who are 2-10 years old (1.75-10.99 years to be precise) and who have not previously been diagnosed with diabetes can take part.""",,2021-08-01,2021-12-31,Residual sera,All,Children and Youth (0-17 years),5.0,10.0,Primary Estimate,5-10,3474,0.135,0.073,0.24100000000000002,,,,,,Unclear,Luciferase immunoprecipitation system (LIPS),,Other,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['Moderate'],,Unclear,Yes,No,,Unclear,Yes,No,,Raffael Ott,German Research Centre for Environmental Health,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2022.0355,2022-11-17,2022-11-18,Unverified,ott_sars-cov-2_2022,DEU
221111_Bavaria_GermanResearchCentreforEnvironmentalHealth_Wave4_Age1-4,221111_Bavaria_GermanResearchCentreforEnvironmentalHealth_Wave4_Infants,SARS-CoV-2 Seroprevalence in Preschool and School-Age Children-Population Screening Findings From January 2020 to June 2022.,2022-11-11,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Germany,Bavaria,,"""All children in Bavaria who are 2-10 years old (1.75-10.99 years to be precise) and who have not previously been diagnosed with diabetes can take part.""",,2021-08-01,2021-12-31,Residual sera,All,Children and Youth (0-17 years),1.0,4.0,Primary Estimate,1-4,5626,0.121,0.086,0.162,,,,,,Unclear,Luciferase immunoprecipitation system (LIPS),,Other,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['Moderate'],,Unclear,Yes,No,,Unclear,Yes,No,,Raffael Ott,German Research Centre for Environmental Health,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2022.0355,2022-11-17,2022-11-18,Unverified,ott_sars-cov-2_2022,DEU
221111_Bavaria_GermanResearchCentreforEnvironmentalHealth_Wave5_age5-10,221111_Bavaria_GermanResearchCentreforEnvironmentalHealth_Wave5_Children,SARS-CoV-2 Seroprevalence in Preschool and School-Age Children-Population Screening Findings From January 2020 to June 2022.,2022-11-11,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Germany,Bavaria,,"""All children in Bavaria who are 2-10 years old (1.75-10.99 years to be precise) and who have not previously been diagnosed with diabetes can take part.""",,2022-01-01,2022-05-31,Residual sera,All,Children and Youth (0-17 years),5.0,10.0,Primary Estimate,5-10,3418,0.63,0.349,0.809,,,,,,Unclear,Luciferase immunoprecipitation system (LIPS),,Other,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['Moderate'],,Unclear,Yes,No,,Unclear,Yes,No,,Raffael Ott,German Research Centre for Environmental Health,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2022.0355,2022-11-17,2022-11-18,Unverified,ott_sars-cov-2_2022,DEU
221111_Bavaria_GermanResearchCentreforEnvironmentalHealth_Wave5_Age 1-4,221111_Bavaria_GermanResearchCentreforEnvironmentalHealth_Wave5_Infants,SARS-CoV-2 Seroprevalence in Preschool and School-Age Children-Population Screening Findings From January 2020 to June 2022.,2022-11-11,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Germany,Bavaria,,"""All children in Bavaria who are 2-10 years old (1.75-10.99 years to be precise) and who have not previously been diagnosed with diabetes can take part.""",,2022-01-01,2022-05-31,Residual sera,All,Children and Youth (0-17 years),1.0,4.0,Primary Estimate,1-4,6071,0.43700000000000006,0.19100000000000003,0.63,,,,,,Unclear,Luciferase immunoprecipitation system (LIPS),,Other,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['Moderate'],,Unclear,Yes,No,,Unclear,Yes,No,,Raffael Ott,German Research Centre for Environmental Health,Not Unity-Aligned,https://dx.doi.org/10.3238/arztebl.m2022.0355,2022-11-17,2022-11-18,Unverified,ott_sars-cov-2_2022,DEU
221114_Gemany_RobertKochInstitute_TestAdj,221114_Gemany_RobertKochInstitute,Nationally representative results on SARS-CoV-2 seroprevalence and testing in Germany at the end of 2020.,2022-11-14,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Germany,,,"The study was designed as an extraordinary wave of a dynamic population-based cohort study, the Socio-Economic Panel (SOEP). The SOEP is a nationwide longitudinal multidisciplinary household survey.",,2020-10-06,2021-02-28,Household and community samples,All,Multiple groups,18.0,99.0,Primary Estimate,overall test adjusted,14781,0.013000000000000001,0.009000000000000001,0.017,True,True,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8109999999999999,0.997,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Hannelore Neuhauser,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-23821-6,2022-12-14,2024-04-18,Verified,neuhauser_nationally_2022,DEU
221114_Gemany_RobertKochInstitute_Male,221114_Gemany_RobertKochInstitute,Nationally representative results on SARS-CoV-2 seroprevalence and testing in Germany at the end of 2020.,2022-11-14,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Germany,,,"The study was designed as an extraordinary wave of a dynamic population-based cohort study, the Socio-Economic Panel (SOEP). The SOEP is a nationwide longitudinal multidisciplinary household survey.",,2020-10-06,2021-02-28,Household and community samples,Male,Multiple groups,18.0,99.0,Sex/Gender,male test adjusted,6843,0.016,,,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8109999999999999,0.997,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Hannelore Neuhauser,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-23821-6,2022-12-14,2024-04-18,Verified,neuhauser_nationally_2022,DEU
221114_Gemany_RobertKochInstitute_Age80to99,221114_Gemany_RobertKochInstitute,Nationally representative results on SARS-CoV-2 seroprevalence and testing in Germany at the end of 2020.,2022-11-14,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Germany,,,"The study was designed as an extraordinary wave of a dynamic population-based cohort study, the Socio-Economic Panel (SOEP). The SOEP is a nationwide longitudinal multidisciplinary household survey.",,2020-10-06,2021-02-28,Household and community samples,All,Seniors (65+ years),80.0,99.0,Age,age: 80-99 test adjusted,655,0.006,,,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8109999999999999,0.997,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Hannelore Neuhauser,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-23821-6,2022-12-14,2024-04-18,Verified,neuhauser_nationally_2022,DEU
221114_Gemany_RobertKochInstitute_Female,221114_Gemany_RobertKochInstitute,Nationally representative results on SARS-CoV-2 seroprevalence and testing in Germany at the end of 2020.,2022-11-14,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Germany,,,"The study was designed as an extraordinary wave of a dynamic population-based cohort study, the Socio-Economic Panel (SOEP). The SOEP is a nationwide longitudinal multidisciplinary household survey.",,2020-10-06,2021-02-28,Household and community samples,Female,Multiple groups,18.0,99.0,Sex/Gender,female test adjusted,7938,0.01,,,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8109999999999999,0.997,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Hannelore Neuhauser,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-23821-6,2022-12-14,2024-04-18,Verified,neuhauser_nationally_2022,DEU
221114_Gemany_RobertKochInstitute_Age65to79,221114_Gemany_RobertKochInstitute,Nationally representative results on SARS-CoV-2 seroprevalence and testing in Germany at the end of 2020.,2022-11-14,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Germany,,,"The study was designed as an extraordinary wave of a dynamic population-based cohort study, the Socio-Economic Panel (SOEP). The SOEP is a nationwide longitudinal multidisciplinary household survey.",,2020-10-06,2021-02-28,Household and community samples,All,Seniors (65+ years),65.0,79.0,Age,age: 65-79 test adjusted,3055,0.013,,,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8109999999999999,0.997,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Hannelore Neuhauser,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-23821-6,2022-12-14,2024-04-18,Verified,neuhauser_nationally_2022,DEU
221114_Gemany_RobertKochInstitute_Age18to34,221114_Gemany_RobertKochInstitute,Nationally representative results on SARS-CoV-2 seroprevalence and testing in Germany at the end of 2020.,2022-11-14,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Germany,,,"The study was designed as an extraordinary wave of a dynamic population-based cohort study, the Socio-Economic Panel (SOEP). The SOEP is a nationwide longitudinal multidisciplinary household survey.",,2020-10-06,2021-02-28,Household and community samples,All,Children and Youth (0-17 years),18.0,34.0,Age,age: 18-34 test adjusted,2741,0.017,,,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8109999999999999,0.997,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Hannelore Neuhauser,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-23821-6,2022-12-14,2024-04-18,Verified,neuhauser_nationally_2022,DEU
221114_Gemany_RobertKochInstitute_Crude,221114_Gemany_RobertKochInstitute,Nationally representative results on SARS-CoV-2 seroprevalence and testing in Germany at the end of 2020.,2022-11-14,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Germany,,,"The study was designed as an extraordinary wave of a dynamic population-based cohort study, the Socio-Economic Panel (SOEP). The SOEP is a nationwide longitudinal multidisciplinary household survey.",,2020-10-06,2021-02-28,Household and community samples,All,Multiple groups,18.0,99.0,Analysis,overall crude,14781,0.013000000000000001,,,,,,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8109999999999999,0.997,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Hannelore Neuhauser,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-23821-6,2022-12-14,2024-04-18,Verified,neuhauser_nationally_2022,DEU
221114_Gemany_RobertKochInstitute_Age50o64,221114_Gemany_RobertKochInstitute,Nationally representative results on SARS-CoV-2 seroprevalence and testing in Germany at the end of 2020.,2022-11-14,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Germany,,,"The study was designed as an extraordinary wave of a dynamic population-based cohort study, the Socio-Economic Panel (SOEP). The SOEP is a nationwide longitudinal multidisciplinary household survey.",,2020-10-06,2021-02-28,Household and community samples,All,Children and Youth (0-17 years),50.0,64.0,Age,age: 50-64 test adjusted,4846,0.014,,,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8109999999999999,0.997,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Hannelore Neuhauser,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-23821-6,2022-12-14,2024-04-18,Verified,neuhauser_nationally_2022,DEU
221114_Gemany_RobertKochInstitute_Age35to49,221114_Gemany_RobertKochInstitute,Nationally representative results on SARS-CoV-2 seroprevalence and testing in Germany at the end of 2020.,2022-11-14,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Germany,,,"The study was designed as an extraordinary wave of a dynamic population-based cohort study, the Socio-Economic Panel (SOEP). The SOEP is a nationwide longitudinal multidisciplinary household survey.",,2020-10-06,2021-02-28,Household and community samples,All,Children and Youth (0-17 years),35.0,49.0,Age,age: 35-49 test adjusted,3484,0.01,,,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8109999999999999,0.997,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Hannelore Neuhauser,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-23821-6,2022-12-14,2024-04-18,Verified,neuhauser_nationally_2022,DEU
221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin_Overall_1test,221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin,Analysis of a German blood donor cohort reveals a high number of undetected SARS-CoV-2 infections and sex-specific differences in humoral immune response,2022-12-16,Journal Article (Peer-Reviewed),National,Prospective cohort,Germany,"North Rhine-Westphalia, Lower Saxony, Hesse",,"regular blood donors located in the three German federal states North Rhine-Westphalia, Lower Saxony and Hesse between July 2020 and June 2021",donors reported that they did not have current or recent diseases and had no physically detectable symptoms of infection such as fever or an increased leukocyte count.,2020-07-01,2021-06-30,Blood donors,All,Adults (18-64 years),,,Primary Estimate,Euroimmun S,3759,0.261,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,No,No,Yes,Yes,Yes,,Bastian Fischer,Institut fur Laboratoriums- und Transfusionsmedizin,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0279195#sec008,2022-02-24,2024-03-01,Verified,fischerAnalysisGermanBlood2022,DEU
221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin_202011,221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin,Analysis of a German blood donor cohort reveals a high number of undetected SARS-CoV-2 infections and sex-specific differences in humoral immune response,2022-12-16,Journal Article (Peer-Reviewed),National,Prospective cohort,Germany,"North Rhine-Westphalia, Lower Saxony, Hesse",,"regular blood donors located in the three German federal states North Rhine-Westphalia, Lower Saxony and Hesse between July 2020 and June 2021",donors reported that they did not have current or recent diseases and had no physically detectable symptoms of infection such as fever or an increased leukocyte count.,2020-11-01,2020-11-30,Blood donors,All,Adults (18-64 years),,,Time frame,"November, 2020",1597,0.0031,0.001,0.0073,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)",EUROIMMUN,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,No,No,Yes,Yes,Yes,,Bastian Fischer,Institut fur Laboratoriums- und Transfusionsmedizin,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0279195#sec008,2022-02-24,2024-03-01,Verified,fischerAnalysisGermanBlood2022,DEU
221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin_202010,221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin,Analysis of a German blood donor cohort reveals a high number of undetected SARS-CoV-2 infections and sex-specific differences in humoral immune response,2022-12-16,Journal Article (Peer-Reviewed),National,Prospective cohort,Germany,"North Rhine-Westphalia, Lower Saxony, Hesse",,"regular blood donors located in the three German federal states North Rhine-Westphalia, Lower Saxony and Hesse between July 2020 and June 2021",donors reported that they did not have current or recent diseases and had no physically detectable symptoms of infection such as fever or an increased leukocyte count.,2020-10-01,2020-10-31,Blood donors,All,Adults (18-64 years),,,Time frame,"October, 2020",1378,0.0029,0.0008,0.0074,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)",EUROIMMUN,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,No,No,Yes,Yes,Yes,,Bastian Fischer,Institut fur Laboratoriums- und Transfusionsmedizin,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0279195#sec008,2022-02-24,2024-03-01,Verified,fischerAnalysisGermanBlood2022,DEU
221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin_202009,221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin,Analysis of a German blood donor cohort reveals a high number of undetected SARS-CoV-2 infections and sex-specific differences in humoral immune response,2022-12-16,Journal Article (Peer-Reviewed),National,Prospective cohort,Germany,"North Rhine-Westphalia, Lower Saxony, Hesse",,"regular blood donors located in the three German federal states North Rhine-Westphalia, Lower Saxony and Hesse between July 2020 and June 2021",donors reported that they did not have current or recent diseases and had no physically detectable symptoms of infection such as fever or an increased leukocyte count.,2020-09-01,2020-09-30,Blood donors,All,Adults (18-64 years),,,Time frame,"September, 2020",1501,0.002,0.0004,0.0058,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)",EUROIMMUN,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,No,No,Yes,Yes,Yes,,Bastian Fischer,Institut fur Laboratoriums- und Transfusionsmedizin,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0279195#sec008,2022-02-24,2024-03-01,Verified,fischerAnalysisGermanBlood2022,DEU
221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin_AreaLowerSaxony,221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin,Analysis of a German blood donor cohort reveals a high number of undetected SARS-CoV-2 infections and sex-specific differences in humoral immune response,2022-12-16,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Germany,Lower Saxony,,"regular blood donors located in the three German federal states North Rhine-Westphalia, Lower Saxony and Hesse between July 2020 and June 2021",donors reported that they did not have current or recent diseases and had no physically detectable symptoms of infection such as fever or an increased leukocyte count.,2020-07-01,2021-06-30,Blood donors,All,Adults (18-64 years),,,Geographical area,Lower Saxony,816,0.051500000000000004,0.0373,0.0689,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,SARS-CoV-2 IgG II Quant ","EUROIMMUN,Abbott Laboratories",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,No,No,Yes,Yes,Yes,,Bastian Fischer,Institut fur Laboratoriums- und Transfusionsmedizin,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0279195#sec008,2022-02-24,2024-04-20,Verified,fischerAnalysisGermanBlood2022,DEU
221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin_202007,221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin,Analysis of a German blood donor cohort reveals a high number of undetected SARS-CoV-2 infections and sex-specific differences in humoral immune response,2022-12-16,Journal Article (Peer-Reviewed),National,Prospective cohort,Germany,"North Rhine-Westphalia, Lower Saxony, Hesse",,"regular blood donors located in the three German federal states North Rhine-Westphalia, Lower Saxony and Hesse between July 2020 and June 2021",donors reported that they did not have current or recent diseases and had no physically detectable symptoms of infection such as fever or an increased leukocyte count.,2020-07-01,2020-07-31,Blood donors,All,Adults (18-64 years),,,Time frame,"July, 2020",1460,0.0075,0.0038,0.0134,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)",EUROIMMUN,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,No,No,Yes,Yes,Yes,,Bastian Fischer,Institut fur Laboratoriums- und Transfusionsmedizin,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0279195#sec008,2022-02-24,2024-03-01,Verified,fischerAnalysisGermanBlood2022,DEU
221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin_202012,221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin,Analysis of a German blood donor cohort reveals a high number of undetected SARS-CoV-2 infections and sex-specific differences in humoral immune response,2022-12-16,Journal Article (Peer-Reviewed),National,Prospective cohort,Germany,"North Rhine-Westphalia, Lower Saxony, Hesse",,"regular blood donors located in the three German federal states North Rhine-Westphalia, Lower Saxony and Hesse between July 2020 and June 2021",donors reported that they did not have current or recent diseases and had no physically detectable symptoms of infection such as fever or an increased leukocyte count.,2020-12-01,2020-12-31,Blood donors,All,Adults (18-64 years),,,Time frame,"December, 2020",1251,0.0144,0.0085,0.0226,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)",EUROIMMUN,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,No,No,Yes,Yes,Yes,,Bastian Fischer,Institut fur Laboratoriums- und Transfusionsmedizin,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0279195#sec008,2022-02-24,2024-03-01,Verified,fischerAnalysisGermanBlood2022,DEU
221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin_202106,221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin,Analysis of a German blood donor cohort reveals a high number of undetected SARS-CoV-2 infections and sex-specific differences in humoral immune response,2022-12-16,Journal Article (Peer-Reviewed),National,Prospective cohort,Germany,"North Rhine-Westphalia, Lower Saxony, Hesse",,"regular blood donors located in the three German federal states North Rhine-Westphalia, Lower Saxony and Hesse between July 2020 and June 2021",donors reported that they did not have current or recent diseases and had no physically detectable symptoms of infection such as fever or an increased leukocyte count.,2021-06-01,2021-06-30,Blood donors,All,Adults (18-64 years),,,Time frame,"June, 2021",996,0.023100000000000002,0.0147,0.0344,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)",EUROIMMUN,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,No,No,Yes,Yes,Yes,,Bastian Fischer,Institut fur Laboratoriums- und Transfusionsmedizin,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0279195#sec008,2022-02-24,2024-03-01,Verified,fischerAnalysisGermanBlood2022,DEU
221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin_AreaNorthRhine-Westphalia,221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin,Analysis of a German blood donor cohort reveals a high number of undetected SARS-CoV-2 infections and sex-specific differences in humoral immune response,2022-12-16,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Germany,North Rhine-Westphalia,,"regular blood donors located in the three German federal states North Rhine-Westphalia, Lower Saxony and Hesse between July 2020 and June 2021",donors reported that they did not have current or recent diseases and had no physically detectable symptoms of infection such as fever or an increased leukocyte count.,2020-07-01,2021-06-30,Blood donors,All,Adults (18-64 years),,,Geographical area,North Rhine-Westphalia,1672,0.0562,0.045700000000000005,0.0684,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,SARS-CoV-2 IgG II Quant ","EUROIMMUN,Abbott Laboratories",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,No,No,Yes,Yes,Yes,,Bastian Fischer,Institut fur Laboratoriums- und Transfusionsmedizin,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0279195#sec008,2022-02-24,2024-04-20,Verified,fischerAnalysisGermanBlood2022,DEU
221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin_AreaHesse,221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin,Analysis of a German blood donor cohort reveals a high number of undetected SARS-CoV-2 infections and sex-specific differences in humoral immune response,2022-12-16,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Germany,Hesse,,"regular blood donors located in the three German federal states North Rhine-Westphalia, Lower Saxony and Hesse between July 2020 and June 2021",donors reported that they did not have current or recent diseases and had no physically detectable symptoms of infection such as fever or an increased leukocyte count.,2020-07-01,2021-06-30,Blood donors,All,Adults (18-64 years),,,Geographical area,Hesse,1271,0.055099999999999996,0.0432,0.06910000000000001,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,SARS-CoV-2 IgG II Quant ","EUROIMMUN,Abbott Laboratories",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,No,No,Yes,Yes,Yes,,Bastian Fischer,Institut fur Laboratoriums- und Transfusionsmedizin,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0279195#sec008,2022-02-24,2024-04-20,Verified,fischerAnalysisGermanBlood2022,DEU
221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin_Overall_3tests,221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin,Analysis of a German blood donor cohort reveals a high number of undetected SARS-CoV-2 infections and sex-specific differences in humoral immune response,2022-12-16,Journal Article (Peer-Reviewed),National,Prospective cohort,Germany,"North Rhine-Westphalia, Lower Saxony, Hesse",,"regular blood donors located in the three German federal states North Rhine-Westphalia, Lower Saxony and Hesse between July 2020 and June 2021",donors reported that they did not have current or recent diseases and had no physically detectable symptoms of infection such as fever or an increased leukocyte count.,2020-07-01,2021-06-30,Blood donors,All,Adults (18-64 years),,,Test used,"Euroimmun S, Abbott S, Euroimmun N",3759,0.05480000000000001,0.0477,0.0625,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG),SARS-CoV-2 IgG II Quant ","EUROIMMUN,Abbott Laboratories",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,No,No,Yes,Yes,Yes,,Bastian Fischer,Institut fur Laboratoriums- und Transfusionsmedizin,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0279195#sec008,2022-02-24,2024-04-20,Verified,fischerAnalysisGermanBlood2022,DEU
221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin_202102,221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin,Analysis of a German blood donor cohort reveals a high number of undetected SARS-CoV-2 infections and sex-specific differences in humoral immune response,2022-12-16,Journal Article (Peer-Reviewed),National,Prospective cohort,Germany,"North Rhine-Westphalia, Lower Saxony, Hesse",,"regular blood donors located in the three German federal states North Rhine-Westphalia, Lower Saxony and Hesse between July 2020 and June 2021",donors reported that they did not have current or recent diseases and had no physically detectable symptoms of infection such as fever or an increased leukocyte count.,2021-02-01,2021-02-28,Blood donors,All,Adults (18-64 years),,,Time frame,"February, 2021",1058,0.0388,0.027999999999999997,0.052199999999999996,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)",EUROIMMUN,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,No,No,Yes,Yes,Yes,,Bastian Fischer,Institut fur Laboratoriums- und Transfusionsmedizin,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0279195#sec008,2022-02-24,2024-03-01,Verified,fischerAnalysisGermanBlood2022,DEU
221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin_Overall_2tests,221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin,Analysis of a German blood donor cohort reveals a high number of undetected SARS-CoV-2 infections and sex-specific differences in humoral immune response,2022-12-16,Journal Article (Peer-Reviewed),National,Prospective cohort,Germany,"North Rhine-Westphalia, Lower Saxony, Hesse",,"regular blood donors located in the three German federal states North Rhine-Westphalia, Lower Saxony and Hesse between July 2020 and June 2021",donors reported that they did not have current or recent diseases and had no physically detectable symptoms of infection such as fever or an increased leukocyte count.,2020-07-01,2021-06-30,Blood donors,All,Adults (18-64 years),,,Test used,"Euroimmun S, Abbott S",3759,0.24,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,SARS-CoV-2 IgG II Quant ","EUROIMMUN,Abbott Laboratories",Multiple Types,Serum,IgG,Spike,,,,['High'],No,No,Yes,No,No,Yes,Yes,Yes,,Bastian Fischer,Institut fur Laboratoriums- und Transfusionsmedizin,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0279195#sec008,2022-02-24,2024-04-20,Verified,fischerAnalysisGermanBlood2022,DEU
221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin_202104,221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin,Analysis of a German blood donor cohort reveals a high number of undetected SARS-CoV-2 infections and sex-specific differences in humoral immune response,2022-12-16,Journal Article (Peer-Reviewed),National,Prospective cohort,Germany,"North Rhine-Westphalia, Lower Saxony, Hesse",,"regular blood donors located in the three German federal states North Rhine-Westphalia, Lower Saxony and Hesse between July 2020 and June 2021",donors reported that they did not have current or recent diseases and had no physically detectable symptoms of infection such as fever or an increased leukocyte count.,2021-04-01,2021-04-30,Blood donors,All,Adults (18-64 years),,,Time frame,"April, 2021",996,0.0181,0.010700000000000001,0.028399999999999998,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)",EUROIMMUN,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,No,No,Yes,Yes,Yes,,Bastian Fischer,Institut fur Laboratoriums- und Transfusionsmedizin,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0279195#sec008,2022-02-24,2024-03-01,Verified,fischerAnalysisGermanBlood2022,DEU
221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin_202101,221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin,Analysis of a German blood donor cohort reveals a high number of undetected SARS-CoV-2 infections and sex-specific differences in humoral immune response,2022-12-16,Journal Article (Peer-Reviewed),National,Prospective cohort,Germany,"North Rhine-Westphalia, Lower Saxony, Hesse",,"regular blood donors located in the three German federal states North Rhine-Westphalia, Lower Saxony and Hesse between July 2020 and June 2021",donors reported that they did not have current or recent diseases and had no physically detectable symptoms of infection such as fever or an increased leukocyte count.,2021-01-01,2021-01-31,Blood donors,All,Adults (18-64 years),,,Time frame,"January, 2021",1122,0.020499999999999997,0.013000000000000001,0.030600000000000002,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)",EUROIMMUN,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,No,No,Yes,Yes,Yes,,Bastian Fischer,Institut fur Laboratoriums- und Transfusionsmedizin,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0279195#sec008,2022-02-24,2024-03-01,Verified,fischerAnalysisGermanBlood2022,DEU
221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin_202105,221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin,Analysis of a German blood donor cohort reveals a high number of undetected SARS-CoV-2 infections and sex-specific differences in humoral immune response,2022-12-16,Journal Article (Peer-Reviewed),National,Prospective cohort,Germany,"North Rhine-Westphalia, Lower Saxony, Hesse",,"regular blood donors located in the three German federal states North Rhine-Westphalia, Lower Saxony and Hesse between July 2020 and June 2021",donors reported that they did not have current or recent diseases and had no physically detectable symptoms of infection such as fever or an increased leukocyte count.,2021-05-01,2021-05-31,Blood donors,All,Adults (18-64 years),,,Time frame,"May, 2021",1296,0.0131,0.0077,0.0209,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)",EUROIMMUN,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,No,No,Yes,Yes,Yes,,Bastian Fischer,Institut fur Laboratoriums- und Transfusionsmedizin,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0279195#sec008,2022-02-24,2024-03-01,Verified,fischerAnalysisGermanBlood2022,DEU
221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin_202103,221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin,Analysis of a German blood donor cohort reveals a high number of undetected SARS-CoV-2 infections and sex-specific differences in humoral immune response,2022-12-16,Journal Article (Peer-Reviewed),National,Prospective cohort,Germany,"North Rhine-Westphalia, Lower Saxony, Hesse",,"regular blood donors located in the three German federal states North Rhine-Westphalia, Lower Saxony and Hesse between July 2020 and June 2021",donors reported that they did not have current or recent diseases and had no physically detectable symptoms of infection such as fever or an increased leukocyte count.,2021-03-01,2021-03-31,Blood donors,All,Adults (18-64 years),,,Time frame,"March, 2021",1623,0.0179,0.012,0.0256,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)",EUROIMMUN,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,No,No,Yes,Yes,Yes,,Bastian Fischer,Institut fur Laboratoriums- und Transfusionsmedizin,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0279195#sec008,2022-02-24,2024-03-01,Verified,fischerAnalysisGermanBlood2022,DEU
221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin_202008,221216_Germany_InstitutfurLaboratoriumsundTransfusionsmedizin,Analysis of a German blood donor cohort reveals a high number of undetected SARS-CoV-2 infections and sex-specific differences in humoral immune response,2022-12-16,Journal Article (Peer-Reviewed),National,Prospective cohort,Germany,"North Rhine-Westphalia, Lower Saxony, Hesse",,"regular blood donors located in the three German federal states North Rhine-Westphalia, Lower Saxony and Hesse between July 2020 and June 2021",donors reported that they did not have current or recent diseases and had no physically detectable symptoms of infection such as fever or an increased leukocyte count.,2020-08-01,2020-08-31,Blood donors,All,Adults (18-64 years),,,Time frame,"August, 2020",1939,0.0072,0.004,0.0121,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)",EUROIMMUN,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,No,No,Yes,Yes,Yes,,Bastian Fischer,Institut fur Laboratoriums- und Transfusionsmedizin,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0279195#sec008,2022-02-24,2024-03-01,Verified,fischerAnalysisGermanBlood2022,DEU
221217_Germany_UniversityofRegensburg_Baseline,221217_Germany_UniversityofRegensburg,Higher Infection Risk among Health Care Workers and Lower Risk among Smokers Persistent across SARS-CoV-2 Waves-Longitudinal Results from the Population-Based TiKoCo Seroprevalence Study.,2022-12-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Germany,Bavaria,,"""at least 14 years living in the Tirschenreuth county, Germany, """,,2020-06-28,2020-07-13,Household and community samples,All,Multiple groups,14.0,,Primary Estimate,,4181,0.08900000000000001,,,True,,,,True,Simplified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,"CLIA, CMIA,CLIA, CMIA",Serum,"IgG, IgM, IgA","['Nucleocapsid (N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Felix Gunther,University of Regensburg,Unity-Aligned,https://dx.doi.org/10.3390/ijerph192416996,2023-01-10,2024-04-20,Verified,gunther_higher_2022,DEU
221217_Germany_UniversityofRegensburg_Baseline_Age_20-49,221217_Germany_UniversityofRegensburg,Higher Infection Risk among Health Care Workers and Lower Risk among Smokers Persistent across SARS-CoV-2 Waves-Longitudinal Results from the Population-Based TiKoCo Seroprevalence Study.,2022-12-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Germany,Bavaria,,"""at least 14 years living in the Tirschenreuth county, Germany, """,,2020-06-28,2020-07-13,Household and community samples,All,Adults (18-64 years),20.0,49.0,Age,20-49,1707,0.086,,,,,,,,Simplified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,"CLIA, CMIA,CLIA, CMIA",Serum,"IgG, IgM, IgA","['Nucleocapsid (N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Felix Gunther,University of Regensburg,Unity-Aligned,https://dx.doi.org/10.3390/ijerph192416996,2023-01-10,2024-04-20,Verified,gunther_higher_2022,DEU
221217_Germany_UniversityofRegensburg_Baseline_Age_70+,221217_Germany_UniversityofRegensburg,Higher Infection Risk among Health Care Workers and Lower Risk among Smokers Persistent across SARS-CoV-2 Waves-Longitudinal Results from the Population-Based TiKoCo Seroprevalence Study.,2022-12-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Germany,Bavaria,,"""at least 14 years living in the Tirschenreuth county, Germany, """,,2020-06-28,2020-07-13,Household and community samples,All,Seniors (65+ years),70.0,,Age,70+,625,0.085,,,,,,,,Simplified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,"CLIA, CMIA,CLIA, CMIA",Serum,"IgG, IgM, IgA","['Nucleocapsid (N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Felix Gunther,University of Regensburg,Unity-Aligned,https://dx.doi.org/10.3390/ijerph192416996,2023-01-10,2024-04-20,Verified,gunther_higher_2022,DEU
221217_Germany_UniversityofRegensburg_Baseline_Age_14-19,221217_Germany_UniversityofRegensburg,Higher Infection Risk among Health Care Workers and Lower Risk among Smokers Persistent across SARS-CoV-2 Waves-Longitudinal Results from the Population-Based TiKoCo Seroprevalence Study.,2022-12-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Germany,Bavaria,,"""at least 14 years living in the Tirschenreuth county, Germany, """,,2020-06-28,2020-07-13,Household and community samples,All,Children and Youth (0-17 years),14.0,19.0,Age,14-19,225,0.107,,,,,,,,Simplified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,"CLIA, CMIA,CLIA, CMIA",Serum,"IgG, IgM, IgA","['Nucleocapsid (N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Felix Gunther,University of Regensburg,Unity-Aligned,https://dx.doi.org/10.3390/ijerph192416996,2023-01-10,2024-04-20,Verified,gunther_higher_2022,DEU
221217_Germany_UniversityofRegensburg_Baseline_Age_50-69,221217_Germany_UniversityofRegensburg,Higher Infection Risk among Health Care Workers and Lower Risk among Smokers Persistent across SARS-CoV-2 Waves-Longitudinal Results from the Population-Based TiKoCo Seroprevalence Study.,2022-12-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Germany,Bavaria,,"""at least 14 years living in the Tirschenreuth county, Germany, """,,2020-06-28,2020-07-13,Household and community samples,All,Adults (18-64 years),50.0,69.0,Age,50-69,1624,0.09300000000000001,,,,,,,,Simplified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,"CLIA, CMIA,CLIA, CMIA",Serum,"IgG, IgM, IgA","['Nucleocapsid (N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Felix Gunther,University of Regensburg,Unity-Aligned,https://dx.doi.org/10.3390/ijerph192416996,2023-01-10,2024-04-20,Verified,gunther_higher_2022,DEU
221217_Germany_UniversityofRegensburg_Followup1,221217_Germany_UniversityofRegensburg,Higher Infection Risk among Health Care Workers and Lower Risk among Smokers Persistent across SARS-CoV-2 Waves-Longitudinal Results from the Population-Based TiKoCo Seroprevalence Study.,2022-12-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Germany,Bavaria,,"""at least 14 years living in the Tirschenreuth county, Germany, """,,2020-11-16,2020-11-27,Household and community samples,All,Multiple groups,14.0,,Time frame,"Nov. 16, 2020 - Nov. 27, 2020",3513,0.1,,,,,,,,Simplified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,"CLIA, CMIA,CLIA, CMIA",Serum,"IgG, IgM, IgA","['Nucleocapsid (N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Felix Gunther,University of Regensburg,Unity-Aligned,https://dx.doi.org/10.3390/ijerph192416996,2023-01-10,2024-04-20,Verified,gunther_higher_2022,DEU
221217_Germany_UniversityofRegensburg_Followup2,221217_Germany_UniversityofRegensburg,Higher Infection Risk among Health Care Workers and Lower Risk among Smokers Persistent across SARS-CoV-2 Waves-Longitudinal Results from the Population-Based TiKoCo Seroprevalence Study.,2022-12-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Germany,Bavaria,,"""at least 14 years living in the Tirschenreuth county, Germany, """,,2020-04-19,2021-04-30,Household and community samples,All,Multiple groups,14.0,,Time frame,"Apr. 19, 2021 to Apr. 30, 2021",3374,0.10300000000000001,,,,,,,,Simplified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,"CLIA, CMIA,CLIA, CMIA",Serum,"IgG, IgM, IgA","['Nucleocapsid (N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Felix Gunther,University of Regensburg,Unity-Aligned,https://dx.doi.org/10.3390/ijerph192416996,2023-01-10,2024-04-20,Verified,gunther_higher_2022,DEU
230109_Munich_UniversitatdeBarcelona_Month0,230109_Munich_UniversitatdeBarcelona,RBD-Based ELISA and Luminex Predict Anti-SARS-CoV-2 Surrogate-Neutralizing Activity in Two Longitudinal Cohorts of German and Spanish Health Care Workers.,2023-01-09,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,,Munich,"From April to October 2020, 4,554 HCW of the University Hospital München rechts der Isar of TUM (Germany) and affiliated teaching hospitals were recruited within the EPI-SARS (“Establishment and validation of epitope-specific SARS-CoV-2 blood-based testingmethods”) and SeCoMRI studies.",,2020-04-01,2020-04-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,month 0 test result using Luminex,218,0.61,,,True,,,,True,Unclear,Author designed (Luminex),,Luminex,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.9578,1.0,['High'],,Unclear,No,Yes,,Unclear,Yes,Yes,,Ruth Aguilar,"Universitat de Barcelona, Technical University of Munich",Not Unity-Aligned,https://dx.doi.org/10.1128/spectrum.03165-22,2023-01-24,2023-03-22,Unverified,aguilar_rbd-based_2023,DEU
230215_Jena_JenaUniversityHospital_Primary,230215_Jena_JenaUniversityHospital,Non-patient-related SARS-CoV-2 exposure from colleagues and household members poses the highest infection risk for hospital employees in a German university hospital: follow-up of the prospective Co-HCW seroprevalence study.,2023-02-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,Thuringia,Jena,"Participants including hospital staff and administration staff were recruited between 19th May 2020 and 19th June 2020. For the present analysis, only participants were considered who completed the last study visit in 2021 and did not change the COVID-19 risk area according to their risk of a contact with COVID 19 patients at work (low, intermediate and high risk) during the study.



","Individuals working outside these pre-categorized risk areas (namely laboratory personal where at least a proportion deals with COVID-19 related clinical specimens but has no patient contact), participating outside the planned study period or who did not provide a blood sample were excluded.",2021-04-26,2021-06-22,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,round-3 overall estimate,406,0.783,,,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.97,0.97,['High'],,No,No,Yes,,Yes,Yes,Yes,,Christina Bahrs,Jena University Hospital ,Not Unity-Aligned,https://dx.doi.org/10.1007/s15010-023-01995-z,2022-10-17,2024-03-01,Unverified,bahrs_non-patient-related_2023,DEU
230319_Germany_RobertKochInstitute_2020Dec,230319_Germany_RobertKochInstitute_2020Dec,Seroprevalence of SARS-CoV-2 in the German HIV-1 Seroconverter Cohort,2023-03-19,Presentation or Conference,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Germany,,,"Plasma samples from the HIV-1 Seroconverter Cohort, a prospective longitudinal multicentre study that includes people living with HIV whose date of seroconversion is fairly well defined, were obtained.",,2020-12-01,2020-12-31,Residual sera,All,Multiple groups,,,Primary Estimate,,73,0.041,,,True,,,,True,Sequential,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)",EUROIMMUN,"ELISA,ELISA",Plasma,,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,No,Yes,No,,Oliver Hohn,Robert Koch Institute,Not Unity-Aligned,https://dx.doi.org/10.1111/hiv.13464,2023-05-06,2024-03-01,Unverified,hohn_seroprevalence_2023,DEU
230319_Germany_RobertKochInstitute_2021Dec,230319_Germany_RobertKochInstitute_2021Dec,Seroprevalence of SARS-CoV-2 in the German HIV-1 Seroconverter Cohort,2023-03-19,Presentation or Conference,National,Prospective cohort,Germany,,,"Plasma samples from the HIV-1 Seroconverter Cohort, a prospective longitudinal multicentre study that includes people living with HIV whose date of seroconversion is fairly well defined, were obtained.",,2021-12-01,2021-12-31,Residual sera,All,Multiple groups,,,Primary Estimate,,52,0.9231,,,True,,,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Plasma,,Spike,,,,['High'],,No,No,No,,Yes,Yes,Yes,,Oliver Hohn,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.1111/hiv.13464,2023-05-06,2024-03-01,Unverified,hohn_seroprevalence_2023,DEU
230319_Germany_RobertKochInstitute_2021Jan,230319_Germany_RobertKochInstitute_2021Jan,Seroprevalence of SARS-CoV-2 in the German HIV-1 Seroconverter Cohort,2023-03-19,Presentation or Conference,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Germany,,,"Plasma samples from the HIV-1 Seroconverter Cohort, a prospective longitudinal multicentre study that includes people living with HIV whose date of seroconversion is fairly well defined, were obtained.",,2021-01-01,2021-01-31,Residual sera,All,Multiple groups,,,Primary Estimate,,103,0.039,,,True,,,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Plasma,,Spike,,,,['High'],,No,No,No,,Yes,Yes,Yes,,Oliver Hohn,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.1111/hiv.13464,2023-05-06,2024-03-01,Unverified,hohn_seroprevalence_2023,DEU
230319_Germany_RobertKochInstitute_2021Jul,230319_Germany_RobertKochInstitute_2021Jul,Seroprevalence of SARS-CoV-2 in the German HIV-1 Seroconverter Cohort,2023-03-19,Presentation or Conference,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Germany,,,"Plasma samples from the HIV-1 Seroconverter Cohort, a prospective longitudinal multicentre study that includes people living with HIV whose date of seroconversion is fairly well defined, were obtained.",,2021-07-01,2021-07-31,Residual sera,All,Multiple groups,,,Primary Estimate,,171,0.9064,,,True,,,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Plasma,,Spike,,,,['High'],,No,No,No,,Yes,Yes,Yes,,Oliver Hohn,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.1111/hiv.13464,2023-05-06,2024-03-01,Unverified,hohn_seroprevalence_2023,DEU
230319_Germany_RobertKochInstitute_2021May_AntiS_Primary,230319_Germany_RobertKochInstitute_2021May,Seroprevalence of SARS-CoV-2 in the German HIV-1 Seroconverter Cohort,2023-03-19,Presentation or Conference,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Germany,,,"Plasma samples from the HIV-1 Seroconverter Cohort, a prospective longitudinal multicentre study that includes people living with HIV whose date of seroconversion is fairly well defined, were obtained.",,2021-05-01,2021-05-31,Residual sera,All,Multiple groups,,,Primary Estimate,,94,0.33,,,True,,,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Plasma,,Spike,,,,['High'],,No,No,No,,Yes,Yes,Yes,,Oliver Hohn,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.1111/hiv.13464,2023-05-06,2024-03-01,Unverified,hohn_seroprevalence_2023,DEU
230319_Germany_RobertKochInstitute_2021May_AntiN,230319_Germany_RobertKochInstitute_2021May,Seroprevalence of SARS-CoV-2 in the German HIV-1 Seroconverter Cohort,2023-03-19,Presentation or Conference,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Germany,,,"Plasma samples from the HIV-1 Seroconverter Cohort, a prospective longitudinal multicentre study that includes people living with HIV whose date of seroconversion is fairly well defined, were obtained.",,2021-05-01,2021-05-31,Residual sera,All,Multiple groups,,,Test used,,94,0.032,,,,,,,,Sequential,Anti-SARS-CoV-2 NCP ELISA (IgG),EUROIMMUN,ELISA,Plasma,,Nucleocapsid(N-protein),,,,['High'],,No,No,No,,Yes,Yes,Yes,,Oliver Hohn,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.1111/hiv.13464,2023-05-06,2024-03-01,Unverified,hohn_seroprevalence_2023,DEU
230401_Germany_UniversitätsmedizinBerlin,230401_Germany_UniversitätsmedizinBerlin,Results From Multicenter Sars-Cov-2 Antibody Prevalence Study In Patients With Short Bowel Syndrome In Germany,2023-04-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Germany,,,"""short bowel syndrome patients with intestinal insufficiency and intestinal failure were included at three different German tertiary care canters from January 2021 until January 2022""",,2021-01-15,2022-01-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,119,0.076,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,Nucleocapsid(N-protein),,,,['High'],,No,No,No,,Unclear,Yes,No,,E. Bluthner,Universitätsmedizin Berlin,Not Unity-Aligned,https://dx.doi.org/10.1016/j.clnesp.2022.09.547,2023-08-01,2023-08-15,Unverified,blüthnerResultsMulticenterSarsCov22023,DEU
230402_Germany_RobertKochInstitute_Overall,230402_Germany_RobertKochInstitute,"Monitoring the SARS-CoV-2 Pandemic: Prevalence of Antibodies in a Large, Repetitive Cross-Sectional Study of Blood Donors in Germany-Results from the SeBluCo Study 2020-2022.",2023-04-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,,Hamburg,"""In this study, we included residual specimens of blood donations from the participating blood establishments (BE) in Germany from April 2020 to April 2021, September 2021, and April/May 2022."" 

""Specimens were collected using convenience sampling techniques. All donors were symptom-free at donation. Donor selection guidelines mandated that after a resolved coronavirus disease (COVID)-19 infection, donors had to be deferred for four weeks. SARS-CoV-2 vaccination did not result in deferral""","""Donors who were explicitly invited to
donate SARS-CoV-2 convalescent plasma were excluded.""",2020-05-03,2022-05-21,Blood donors,All,Adults (18-64 years),,,Primary Estimate,,134510,0.173,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,Roche Diagnostics",Multiple Types,,"['IgG', 'IgG, IgM, IgA']","['Nucleocapsid (N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Ruth Offergeld,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.3390/pathogens12040551,2024-03-29,2024-03-29,Verified,offergeld_monitoring_2023,DEU
230402_Germany_RobertKochInstitute_2020Weeks35-38,230402_Germany_RobertKochInstitute,"Monitoring the SARS-CoV-2 Pandemic: Prevalence of Antibodies in a Large, Repetitive Cross-Sectional Study of Blood Donors in Germany-Results from the SeBluCo Study 2020-2022.",2023-04-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,,Hamburg,"""In this study, we included residual specimens of blood donations from the participating blood establishments (BE) in Germany from April 2020 to April 2021, September 2021, and April/May 2022."" 

""Specimens were collected using convenience sampling techniques. All donors were symptom-free at donation. Donor selection guidelines mandated that after a resolved coronavirus disease (COVID)-19 infection, donors had to be deferred for four weeks. SARS-CoV-2 vaccination did not result in deferral""","""Donors who were explicitly invited to
donate SARS-CoV-2 convalescent plasma were excluded.""",2020-08-23,2020-09-19,Blood donors,All,Adults (18-64 years),,,Time frame,2020 Weeks 35-38,9987,0.011,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,Roche Diagnostics",Multiple Types,,"['IgG', 'IgG, IgM, IgA']","['Nucleocapsid (N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Ruth Offergeld,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.3390/pathogens12040551,2023-06-01,2024-03-29,Verified,offergeld_monitoring_2023,DEU
230402_Germany_RobertKochInstitute_2020Weeks31-34,230402_Germany_RobertKochInstitute,"Monitoring the SARS-CoV-2 Pandemic: Prevalence of Antibodies in a Large, Repetitive Cross-Sectional Study of Blood Donors in Germany-Results from the SeBluCo Study 2020-2022.",2023-04-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,,Hamburg,"""In this study, we included residual specimens of blood donations from the participating blood establishments (BE) in Germany from April 2020 to April 2021, September 2021, and April/May 2022."" 

""Specimens were collected using convenience sampling techniques. All donors were symptom-free at donation. Donor selection guidelines mandated that after a resolved coronavirus disease (COVID)-19 infection, donors had to be deferred for four weeks. SARS-CoV-2 vaccination did not result in deferral""","""Donors who were explicitly invited to
donate SARS-CoV-2 convalescent plasma were excluded.""",2020-07-26,2020-08-22,Blood donors,All,Adults (18-64 years),,,Time frame,2020 Weeks 31-34,10205,0.008,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,Roche Diagnostics",Multiple Types,,"['IgG', 'IgG, IgM, IgA']","['Nucleocapsid (N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Ruth Offergeld,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.3390/pathogens12040551,2023-06-01,2024-03-29,Verified,offergeld_monitoring_2023,DEU
230402_Germany_RobertKochInstitute_2021Weeks6-9,230402_Germany_RobertKochInstitute,"Monitoring the SARS-CoV-2 Pandemic: Prevalence of Antibodies in a Large, Repetitive Cross-Sectional Study of Blood Donors in Germany-Results from the SeBluCo Study 2020-2022.",2023-04-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,,Hamburg,"""In this study, we included residual specimens of blood donations from the participating blood establishments (BE) in Germany from April 2020 to April 2021, September 2021, and April/May 2022."" 

""Specimens were collected using convenience sampling techniques. All donors were symptom-free at donation. Donor selection guidelines mandated that after a resolved coronavirus disease (COVID)-19 infection, donors had to be deferred for four weeks. SARS-CoV-2 vaccination did not result in deferral""","""Donors who were explicitly invited to
donate SARS-CoV-2 convalescent plasma were excluded.""",2021-02-07,2021-03-06,Blood donors,All,Adults (18-64 years),,,Time frame,2021 Weeks 6-9,9749,0.09,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,Roche Diagnostics",Multiple Types,,"['IgG', 'IgG, IgM, IgA']","['Nucleocapsid (N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Ruth Offergeld,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.3390/pathogens12040551,2023-06-01,2024-03-29,Verified,offergeld_monitoring_2023,DEU
230402_Germany_RobertKochInstitute_2021Weeks36-37,230402_Germany_RobertKochInstitute,"Monitoring the SARS-CoV-2 Pandemic: Prevalence of Antibodies in a Large, Repetitive Cross-Sectional Study of Blood Donors in Germany-Results from the SeBluCo Study 2020-2022.",2023-04-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,,Hamburg,"""In this study, we included residual specimens of blood donations from the participating blood establishments (BE) in Germany from April 2020 to April 2021, September 2021, and April/May 2022."" 

""Specimens were collected using convenience sampling techniques. All donors were symptom-free at donation. Donor selection guidelines mandated that after a resolved coronavirus disease (COVID)-19 infection, donors had to be deferred for four weeks. SARS-CoV-2 vaccination did not result in deferral""","""Donors who were explicitly invited to
donate SARS-CoV-2 convalescent plasma were excluded.""",2021-09-05,2021-09-18,Blood donors,All,Adults (18-64 years),,,Time frame,2021 Weeks 36-37,5094,0.872,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,Roche Diagnostics",Multiple Types,,"['IgG', 'IgG, IgM, IgA']","['Nucleocapsid (N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Ruth Offergeld,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.3390/pathogens12040551,2023-06-01,2024-03-29,Verified,offergeld_monitoring_2023,DEU
230402_Germany_RobertKochInstitute_2020Weeks27-30,230402_Germany_RobertKochInstitute,"Monitoring the SARS-CoV-2 Pandemic: Prevalence of Antibodies in a Large, Repetitive Cross-Sectional Study of Blood Donors in Germany-Results from the SeBluCo Study 2020-2022.",2023-04-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,,Hamburg,"""In this study, we included residual specimens of blood donations from the participating blood establishments (BE) in Germany from April 2020 to April 2021, September 2021, and April/May 2022."" 

""Specimens were collected using convenience sampling techniques. All donors were symptom-free at donation. Donor selection guidelines mandated that after a resolved coronavirus disease (COVID)-19 infection, donors had to be deferred for four weeks. SARS-CoV-2 vaccination did not result in deferral""","""Donors who were explicitly invited to
donate SARS-CoV-2 convalescent plasma were excluded.""",2020-06-28,2020-07-25,Blood donors,All,Adults (18-64 years),,,Time frame,2020 Weeks 27-30,10053,0.009,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,Roche Diagnostics",Multiple Types,,"['IgG', 'IgG, IgM, IgA']","['Nucleocapsid (N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Ruth Offergeld,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.3390/pathogens12040551,2023-06-01,2024-03-29,Verified,offergeld_monitoring_2023,DEU
230402_Germany_RobertKochInstitute_2020Weeks47-50,230402_Germany_RobertKochInstitute,"Monitoring the SARS-CoV-2 Pandemic: Prevalence of Antibodies in a Large, Repetitive Cross-Sectional Study of Blood Donors in Germany-Results from the SeBluCo Study 2020-2022.",2023-04-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,,Hamburg,"""In this study, we included residual specimens of blood donations from the participating blood establishments (BE) in Germany from April 2020 to April 2021, September 2021, and April/May 2022."" 

""Specimens were collected using convenience sampling techniques. All donors were symptom-free at donation. Donor selection guidelines mandated that after a resolved coronavirus disease (COVID)-19 infection, donors had to be deferred for four weeks. SARS-CoV-2 vaccination did not result in deferral""","""Donors who were explicitly invited to
donate SARS-CoV-2 convalescent plasma were excluded.""",2020-11-15,2020-12-12,Blood donors,All,Adults (18-64 years),,,Time frame,2020 Weeks 47-50,7048,0.02,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,Roche Diagnostics",Multiple Types,,"['IgG', 'IgG, IgM, IgA']","['Nucleocapsid (N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Ruth Offergeld,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.3390/pathogens12040551,2023-06-01,2024-03-29,Verified,offergeld_monitoring_2023,DEU
230402_Germany_RobertKochInstitute_2022Weeks17-20,230402_Germany_RobertKochInstitute,"Monitoring the SARS-CoV-2 Pandemic: Prevalence of Antibodies in a Large, Repetitive Cross-Sectional Study of Blood Donors in Germany-Results from the SeBluCo Study 2020-2022.",2023-04-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,,Hamburg,"""In this study, we included residual specimens of blood donations from the participating blood establishments (BE) in Germany from April 2020 to April 2021, September 2021, and April/May 2022."" 

""Specimens were collected using convenience sampling techniques. All donors were symptom-free at donation. Donor selection guidelines mandated that after a resolved coronavirus disease (COVID)-19 infection, donors had to be deferred for four weeks. SARS-CoV-2 vaccination did not result in deferral""","""Donors who were explicitly invited to
donate SARS-CoV-2 convalescent plasma were excluded.""",2022-04-24,2022-05-21,Blood donors,All,Adults (18-64 years),,,Time frame,2022 Weeks 17-20,14034,0.989,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,Roche Diagnostics",Multiple Types,,"['IgG', 'IgG, IgM, IgA']","['Nucleocapsid (N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Ruth Offergeld,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.3390/pathogens12040551,2023-06-01,2024-03-29,Verified,offergeld_monitoring_2023,DEU
230402_Germany_RobertKochInstitute_2021Weeks2-5,230402_Germany_RobertKochInstitute,"Monitoring the SARS-CoV-2 Pandemic: Prevalence of Antibodies in a Large, Repetitive Cross-Sectional Study of Blood Donors in Germany-Results from the SeBluCo Study 2020-2022.",2023-04-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,,Hamburg,"""In this study, we included residual specimens of blood donations from the participating blood establishments (BE) in Germany from April 2020 to April 2021, September 2021, and April/May 2022."" 

""Specimens were collected using convenience sampling techniques. All donors were symptom-free at donation. Donor selection guidelines mandated that after a resolved coronavirus disease (COVID)-19 infection, donors had to be deferred for four weeks. SARS-CoV-2 vaccination did not result in deferral""","""Donors who were explicitly invited to
donate SARS-CoV-2 convalescent plasma were excluded.""",2021-01-10,2021-02-06,Blood donors,All,Adults (18-64 years),,,Time frame,2021 Weeks 2-5,9559,0.041,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,Roche Diagnostics",Multiple Types,,"['IgG', 'IgG, IgM, IgA']","['Nucleocapsid (N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Ruth Offergeld,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.3390/pathogens12040551,2023-06-01,2024-03-29,Verified,offergeld_monitoring_2023,DEU
230402_Germany_RobertKochInstitute_2020Weeks23-26,230402_Germany_RobertKochInstitute,"Monitoring the SARS-CoV-2 Pandemic: Prevalence of Antibodies in a Large, Repetitive Cross-Sectional Study of Blood Donors in Germany-Results from the SeBluCo Study 2020-2022.",2023-04-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,,Hamburg,"""In this study, we included residual specimens of blood donations from the participating blood establishments (BE) in Germany from April 2020 to April 2021, September 2021, and April/May 2022."" 

""Specimens were collected using convenience sampling techniques. All donors were symptom-free at donation. Donor selection guidelines mandated that after a resolved coronavirus disease (COVID)-19 infection, donors had to be deferred for four weeks. SARS-CoV-2 vaccination did not result in deferral""","""Donors who were explicitly invited to
donate SARS-CoV-2 convalescent plasma were excluded.""",2020-05-31,2020-06-27,Blood donors,All,Adults (18-64 years),,,Time frame,2020 Weeks 23-26,9699,0.011,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,Roche Diagnostics",Multiple Types,,"['IgG', 'IgG, IgM, IgA']","['Nucleocapsid (N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Ruth Offergeld,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.3390/pathogens12040551,2023-06-01,2024-03-29,Verified,offergeld_monitoring_2023,DEU
230402_Germany_RobertKochInstitute_2021Weeks10-13,230402_Germany_RobertKochInstitute,"Monitoring the SARS-CoV-2 Pandemic: Prevalence of Antibodies in a Large, Repetitive Cross-Sectional Study of Blood Donors in Germany-Results from the SeBluCo Study 2020-2022.",2023-04-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,,Hamburg,"""In this study, we included residual specimens of blood donations from the participating blood establishments (BE) in Germany from April 2020 to April 2021, September 2021, and April/May 2022."" 

""Specimens were collected using convenience sampling techniques. All donors were symptom-free at donation. Donor selection guidelines mandated that after a resolved coronavirus disease (COVID)-19 infection, donors had to be deferred for four weeks. SARS-CoV-2 vaccination did not result in deferral""","""Donors who were explicitly invited to
donate SARS-CoV-2 convalescent plasma were excluded.""",2021-03-07,2021-04-03,Blood donors,All,Adults (18-64 years),,,Time frame,2021 Weeks 10-13,9388,0.113,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,Roche Diagnostics",Multiple Types,,"['IgG', 'IgG, IgM, IgA']","['Nucleocapsid (N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Ruth Offergeld,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.3390/pathogens12040551,2023-06-01,2024-03-29,Verified,offergeld_monitoring_2023,DEU
230402_Germany_RobertKochInstitute_2020Weeks19-22,230402_Germany_RobertKochInstitute,"Monitoring the SARS-CoV-2 Pandemic: Prevalence of Antibodies in a Large, Repetitive Cross-Sectional Study of Blood Donors in Germany-Results from the SeBluCo Study 2020-2022.",2023-04-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,,Hamburg,"""In this study, we included residual specimens of blood donations from the participating blood establishments (BE) in Germany from April 2020 to April 2021, September 2021, and April/May 2022."" 

""Specimens were collected using convenience sampling techniques. All donors were symptom-free at donation. Donor selection guidelines mandated that after a resolved coronavirus disease (COVID)-19 infection, donors had to be deferred for four weeks. SARS-CoV-2 vaccination did not result in deferral""","""Donors who were explicitly invited to
donate SARS-CoV-2 convalescent plasma were excluded.""",2020-05-03,2020-05-30,Blood donors,All,Adults (18-64 years),,,Time frame,2020 Weeks 19-22,5795,0.01,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,Roche Diagnostics",Multiple Types,,"['IgG', 'IgG, IgM, IgA']","['Nucleocapsid (N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Ruth Offergeld,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.3390/pathogens12040551,2023-06-01,2024-03-29,Verified,offergeld_monitoring_2023,DEU
230402_Germany_RobertKochInstitute_2020Weeks39-42,230402_Germany_RobertKochInstitute,"Monitoring the SARS-CoV-2 Pandemic: Prevalence of Antibodies in a Large, Repetitive Cross-Sectional Study of Blood Donors in Germany-Results from the SeBluCo Study 2020-2022.",2023-04-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,,Hamburg,"""In this study, we included residual specimens of blood donations from the participating blood establishments (BE) in Germany from April 2020 to April 2021, September 2021, and April/May 2022."" 

""Specimens were collected using convenience sampling techniques. All donors were symptom-free at donation. Donor selection guidelines mandated that after a resolved coronavirus disease (COVID)-19 infection, donors had to be deferred for four weeks. SARS-CoV-2 vaccination did not result in deferral""","""Donors who were explicitly invited to
donate SARS-CoV-2 convalescent plasma were excluded.""",2020-09-20,2020-10-17,Blood donors,All,Adults (18-64 years),,,Time frame,2020 Weeks 39-42,9989,0.013,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,Roche Diagnostics",Multiple Types,,"['IgG', 'IgG, IgM, IgA']","['Nucleocapsid (N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Ruth Offergeld,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.3390/pathogens12040551,2023-06-01,2024-03-29,Verified,offergeld_monitoring_2023,DEU
230402_Germany_RobertKochInstitute_2021Weeks14-17,230402_Germany_RobertKochInstitute,"Monitoring the SARS-CoV-2 Pandemic: Prevalence of Antibodies in a Large, Repetitive Cross-Sectional Study of Blood Donors in Germany-Results from the SeBluCo Study 2020-2022.",2023-04-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,,Hamburg,"""In this study, we included residual specimens of blood donations from the participating blood establishments (BE) in Germany from April 2020 to April 2021, September 2021, and April/May 2022."" 

""Specimens were collected using convenience sampling techniques. All donors were symptom-free at donation. Donor selection guidelines mandated that after a resolved coronavirus disease (COVID)-19 infection, donors had to be deferred for four weeks. SARS-CoV-2 vaccination did not result in deferral""","""Donors who were explicitly invited to
donate SARS-CoV-2 convalescent plasma were excluded.""",2021-04-04,2021-05-01,Blood donors,All,Adults (18-64 years),,,Time frame,2021 Weeks 14-17,9511,0.168,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,Roche Diagnostics",Multiple Types,,"['IgG', 'IgG, IgM, IgA']","['Nucleocapsid (N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Ruth Offergeld,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.3390/pathogens12040551,2023-06-01,2024-03-29,Verified,offergeld_monitoring_2023,DEU
230402_Germany_RobertKochInstitute_2020Weeks51-01,230402_Germany_RobertKochInstitute,"Monitoring the SARS-CoV-2 Pandemic: Prevalence of Antibodies in a Large, Repetitive Cross-Sectional Study of Blood Donors in Germany-Results from the SeBluCo Study 2020-2022.",2023-04-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,,Hamburg,"""In this study, we included residual specimens of blood donations from the participating blood establishments (BE) in Germany from April 2020 to April 2021, September 2021, and April/May 2022."" 

""Specimens were collected using convenience sampling techniques. All donors were symptom-free at donation. Donor selection guidelines mandated that after a resolved coronavirus disease (COVID)-19 infection, donors had to be deferred for four weeks. SARS-CoV-2 vaccination did not result in deferral""","""Donors who were explicitly invited to
donate SARS-CoV-2 convalescent plasma were excluded.""",2020-12-13,2021-01-09,Blood donors,All,Adults (18-64 years),,,Time frame,2020 Week 51 - 2021 Week 01,6743,0.03,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,Roche Diagnostics",Multiple Types,,"['IgG', 'IgG, IgM, IgA']","['Nucleocapsid (N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Ruth Offergeld,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.3390/pathogens12040551,2023-06-01,2024-03-29,Verified,offergeld_monitoring_2023,DEU
230402_Germany_RobertKochInstitute_2020Weeks43-46,230402_Germany_RobertKochInstitute,"Monitoring the SARS-CoV-2 Pandemic: Prevalence of Antibodies in a Large, Repetitive Cross-Sectional Study of Blood Donors in Germany-Results from the SeBluCo Study 2020-2022.",2023-04-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,,Hamburg,"""In this study, we included residual specimens of blood donations from the participating blood establishments (BE) in Germany from April 2020 to April 2021, September 2021, and April/May 2022."" 

""Specimens were collected using convenience sampling techniques. All donors were symptom-free at donation. Donor selection guidelines mandated that after a resolved coronavirus disease (COVID)-19 infection, donors had to be deferred for four weeks. SARS-CoV-2 vaccination did not result in deferral""","""Donors who were explicitly invited to
donate SARS-CoV-2 convalescent plasma were excluded.""",2020-10-18,2020-11-14,Blood donors,All,Adults (18-64 years),,,Time frame,2020 Weeks 43-46,6719,0.016,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,Roche Diagnostics",Multiple Types,,"['IgG', 'IgG, IgM, IgA']","['Nucleocapsid (N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Ruth Offergeld,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.3390/pathogens12040551,2023-06-01,2024-03-29,Verified,offergeld_monitoring_2023,DEU
230403_Gangelt_GermanCenterforInfectionResearch_Visit1,230403_Gangelt_GermanCenterforInfectionResearch_Visit1,Analysis of fatality impact and seroprevalence surveys in a community sustaining a SARS-CoV-2 superspreading event.,2023-04-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Germany,North Rhine-Westphalia,Gangelt,Participants in Gangelt who participated in a previous study (https://doi.org/10.1038/s41467-020-19509-y) by the same authors ,,2020-10-01,2020-10-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,583,0.18100000000000002,0.13699999999999998,0.23,True,True,,,True,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Plasma,IgG,Spike,Validated by manufacturers,0.909,0.991,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Yes,Enrico Richter,German Center for Infection Research,Unity-Aligned,https://dx.doi.org/10.1038/s41598-023-32441-7,2022-02-09,2024-04-28,Verified,richter_analysis_2023,DEU
230403_Gangelt_GermanCenterforInfectionResearch_Visit2,230403_Gangelt_GermanCenterforInfectionResearch_Visit2,Analysis of fatality impact and seroprevalence surveys in a community sustaining a SARS-CoV-2 superspreading event.,2023-04-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Germany,North Rhine-Westphalia,Gangelt,Participants in Gangelt who participated in a previous study (https://doi.org/10.1038/s41467-020-19509-y) by the same authors ,,2021-01-01,2021-01-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,488,0.21,0.162,0.261,True,True,,,True,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Plasma,IgG,Spike,Validated by manufacturers,0.909,0.991,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,No,Enrico Richter,German Center for Infection Research,Unity-Aligned,https://dx.doi.org/10.1038/s41598-023-32441-7,2022-02-09,2023-08-15,Verified,richter_analysis_2023,DEU
230403_Gangelt_GermanCenterforInfectionResearch_Visit3,230403_Gangelt_GermanCenterforInfectionResearch_Visit3,Analysis of fatality impact and seroprevalence surveys in a community sustaining a SARS-CoV-2 superspreading event.,2023-04-03,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,North Rhine-Westphalia,Gangelt,Participants in Gangelt who participated in a previous study (https://doi.org/10.1038/s41467-020-19509-y) by the same authors ,,2021-04-01,2021-04-30,Household and community samples,All,Multiple groups,,,Primary Estimate,,406,0.359,0.3,0.42,True,True,,,True,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Plasma,IgG,Spike,Validated by manufacturers,0.909,0.991,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,No,Enrico Richter,German Center for Infection Research,Unity-Aligned,https://dx.doi.org/10.1038/s41598-023-32441-7,2022-02-09,2024-04-28,Verified,richter_analysis_2023,DEU
230428_Germany_UniversityHospitalMagdeburg,230428_Germany_UniversityHospitalMagdeburg,Cohort profile: a longitudinal regional cohort study to assess COVID-19 seroprevalence in blood donors - baseline characteristics of the SeMaCo study participants,2023-04-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,Saxony-Anhalt,Magdeburg,Blood donors from the city of Magdeburg; completion of contact and vaccination questionnaires; ,"""Participants who did not indicate on the informed consent form that their blood samples should be analysed for SARS-CoV-2 antibodies were excluded. Similarly, invalid blood samples were not considered for analyses within the study. """,2021-01-20,2021-04-30,Blood donors,All,Multiple groups,18.0,84.0,Primary Estimate,,2195,0.13,,,True,,,,True,Convenience,LIAISON® SARS-CoV-2 TrimericS IgG,DiaSorin,CLIA,Serum,IgG,Spike,,0.987,0.995,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,Unclear,Robert Pohl,University Hospital Magdeburg,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2022-068472,2023-05-31,2024-04-22,Verified,pohl_cohort_2023,DEU
230420_Hamburg_UniversityMedicalCentreHamburg-Eppendorf_Baseline,230420_Hamburg_UniversityMedicalCentreHamburg-Eppendorf,Longitudinal SARS-CoV-2 Seroprevalence among Employees in Outpatient Care Services in Hamburg.,2023-04-20,Journal Article (Peer-Reviewed),Local,Prospective cohort,Germany,,Hamburg,"""Employees in outpatient care services in Hamburg were included in this observational study""",,2020-07-15,2020-09-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,678,0.012,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Anti-SARS-CoV-2 NCP ELISA (IgG)","EUROIMMUN,Roche Diagnostics",Multiple Types,Serum,"['IgG', 'IgG, IgM, IgA']","['Nucleocapsid (N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Anja Schablon,University Medical Centre Hamburg-Eppendorf ,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph20085599,2023-05-31,2024-03-01,Unverified,schablon_longitudinal_2023,DEU
230606_Germany_UniversityHospitalWürzburg,230606_Germany_UniversityHospitalWürzburg,"SARS-CoV-2 sero-immunity and quality of life in children and adolescents in relation to infections and vaccinations: the IMMUNEBRIDGE KIDS cross-sectional study, 2022",2023-06-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Germany,,"Würzburg, Bochum, Dresden",blood sampling in children aged 2–17 years,,2022-07-01,2022-10-15,Students and Daycares,All,Children and Youth (0-17 years),2.0,17.0,Primary Estimate,,497,0.865,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Yes,Yes,Yes,,Geraldine Engels,University Hospital Würzburg,Not Unity-Aligned,https://dx.doi.org/10.1007/s15010-023-02052-5,2023-06-30,2024-03-01,Unverified,engelsSARSCoV2SeroimmunityQuality2023,DEU
230611_Berlin_Humboldt-UniversitätzuBerlin,230611_Berlin_Humboldt-UniversitätzuBerlin,"Seropositivity and flight-associated risk factors for SARS-CoV-2 infection among asylum seekers arriving in Berlin, Germany - a cross-sectional study.",2023-06-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,,Berlin,"""We conducted an observational, cross-sectional study on asylum seekers arriving in Berlin, Germany. ... In this manuscript, the term ‘asylum seeker’ defines a legal status of a person who awaits a decision on their residence status in the country of refuge while the term ‘refugee’ commonly refers to a person outside the individual home country due to feared persecution for various reasons ... All individuals (aged ≥18 years) arriving in Berlin and with the aim of applying for asylum were invited to participate in the study""","""Two participants had been vaccinated against SARS-CoV-2 before recruitment and were excluded from statistical analysis""",2021-03-24,2021-06-15,Residual sera,All,Multiple groups,18.0,,Primary Estimate,,954,0.251,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Ariadne Brandt,Humboldt-Universität zu Berlin,Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2023.1134546,2023-08-01,2024-04-30,Verified,brandtSeropositivityFlightassociatedRisk2023,DEU
230624_Hamburg_UniversityMedicalCenterHamburg-Eppendorf_Dec20,230624_Hamburg_UniversityMedicalCenterHamburg-Eppendorf_Dec20,Pilot study in Hamburg on the prevalence of SARS-CoV-2 infections and pandemic survey in the German funeral industry,2023-06-24,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,,Hamburg,"""At ILM Hamburg, a self-designed questionnaire was dis- tributed to employees of funeral homes and crematoria in Hamburg who were professionally directly involved with persons in Hamburg who had died from SARS-CoV-2.""","NR
",2020-12-01,2020-12-15,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,44,0.023,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",Spike,Validated by manufacturers,0.988,1.0,['High'],,No,No,Yes,,Yes,Yes,Yes,,Julia Schadler,University Medical Center Hamburg-Eppendorf,Not Unity-Aligned,https://dx.doi.org/10.1007/s12024-023-00661-y,2023-08-01,2024-03-01,Unverified,schädlerPilotStudyHamburg2023,DEU
230624_Hamburg_UniversityMedicalCenterHamburg-Eppendorf_June2021,230624_Hamburg_UniversityMedicalCenterHamburg-Eppendorf_June2021,Pilot study in Hamburg on the prevalence of SARS-CoV-2 infections and pandemic survey in the German funeral industry,2023-06-24,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,,Hamburg,"""At ILM Hamburg, a self-designed questionnaire was dis- tributed to employees of funeral homes and crematoria in Hamburg who were professionally directly involved with persons in Hamburg who had died from SARS-CoV-2.""",,2021-06-01,2021-06-30,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,33,0.485,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",Spike,Validated by manufacturers,0.988,1.0,['High'],,No,No,No,,Yes,Yes,Yes,,Julia Schadler,University Medical Center Hamburg-Eppendorf,Not Unity-Aligned,https://dx.doi.org/10.1007/s12024-023-00661-y,2023-08-01,2024-03-01,Unverified,schädlerPilotStudyHamburg2023,DEU
230713_Munich_GermanResearchCentreforEnvironmentalHealth_baseline,230713_Munich_GermanResearchCentreforEnvironmentalHealth_baseline,The representative COVID-19 cohort Munich (KoCo19): from the beginning of the pandemic to the Delta virus variant,2023-07-13,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Germany,,Munich,"""We randomly sampled the Munich cohort of private households between April 5th and June 12th, 2020. Only household members 14 years and older who gave written informed consent were included in the cohort. For participants younger than 18 years, informed consent was obtained from the parents as well as the par- ticipants themselves.""","""exclusion of children and residents not living in private households. """,2020-04-05,2020-06-12,Household and community samples,All,Multiple groups,14.0,,Primary Estimate,April 5 - June 12 2020,5313,0.016,0.011,0.021,True,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Dried Blood,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.992,0.987,['Moderate'],Yes,Yes,Yes,No,No,Yes,Yes,Yes,Unclear,Ronan Le Gleut,German Research Centre for Environmental Health,Unity-Aligned,https://dx.doi.org/10.1186/s12879-023-08435-1,2023-08-24,2024-03-01,Unverified,legleutRepresentativeCOVID19Cohort2023,DEU
230717_Munich_TechnicalUniversityofMunich,230717_Munich_TechnicalUniversityofMunich,Seroconversion rate of SARS-CoV-2 IgG antibodies and dating behaviour in HIV-PrEP users in a German metropolis during the COVID-19 pandemic,2023-07-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,,Munich,"""All MSM using HIV PrEP and aged above 18 years at a tertiary university hospital in Munich, Germany, were evaluated for eligibility and considered for inclusion be- tween May 2020 and October 2021.""","""Only subjects with at least two visits were evaluated, therefore 11 MSM without serologic follow-up were excluded""",2020-05-15,2021-09-15,Residual sera,Male,Adults (18-64 years),18.0,,Primary Estimate,,124,0.073,,,True,,,,True,Convenience,iFlash-SARS-CoV-2 S1 IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.938,0.993,['High'],No,No,No,No,No,Yes,Yes,Yes,Unclear,Simon Weidlich,Technical University of Munich,Unity-Aligned,https://dx.doi.org/10.1177/09564624231190419,2023-08-24,2024-03-01,Unverified,weidlichSeroconversionRateSARSCoV22023,DEU
230728_Rostock_RostockUniversityMedicalCenter,230728_Rostock_RostockUniversityMedicalCenter,"Prevalence of SARS-CoV-2 RNA and antibody-detection, and vaccination status in patients with ocular vascular occlusion.",2023-07-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,,Rostock,"""All patients, which presented with ocular vascular occlusion from January 2017 until December 2021 at the Department of Ophthalmology were included in this study.""",,2021-01-15,2021-12-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,35.0,95.0,Primary Estimate,,94,0.029,,,True,,,,True,Sequential,Not reported/ Unable to specify,,CLIA,Serum,,Nucleocapsid(N-protein),,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Adrianna Dera,Rostock University Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1097/IAE.0000000000003907,2023-08-23,2023-08-25,Unverified,deraPrevalenceSARSCoV2RNA2022,DEU
230802_Germany_UniversityOfMunster_PopAdj_AntiS,230802_Germany_UniversityOfMunster,Estimates of protection levels against SARS-CoV-2 infection and severe COVID-19 in Germany before the 2022/2023 winter season: the IMMUNEBRIDGE project.,2023-08-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Germany,,,"A total of 33,637 participants from 9 studies surveyed between June and November 2022 were included. Online Resource 1, Table S1 describes the different participating studies.

... antibodies against SARS-Cov-2 were measured in four existing population-based cohort studies: the ELISA-Study [7, 13], MuSPAD [4], the German National Cohort (NAKO) [8], and STAAB [5]. Four new cross-sectional studies were set up, one to provide regional depth (GUIDE Study; DRKS00029693 [6]) and three to provide relevant data on children (studies of the University Hospitals in Dresden (adolescents; DRKS00022549), Bochum (school children) [2], and Würzburg (pre-school children; Wü-Kita-CoV) [3, 14]). Studies were included if they were able to quickly survey and sample in the general population regionally or supra-regionally, and provide the MDS.","Different sub-studies had different age restrictions which are listed in Supplement 1 Table S1. Nevertheless, all are >1 years of age.

Table 3 title:
Participants from IMMUNEBRIDGE_ED were excluded from this analysis as were participants with missing age information (n=132).",2022-06-15,2022-11-30,Household and community samples,All,Multiple groups,1.0,,Primary Estimate,Age standardized anti-S,31566,0.948,0.942,0.954,True,,True,,True,Unclear,"Elecsys® Anti‐SARS‐CoV‐2 (S),Anti-SARS-CoV-2 QuantiVac ELISA ","Roche Diagnostics,EUROIMMUN",Multiple Types,Multiple Types,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],,Unclear,Yes,Yes,,Unclear,No,No,,Berit Lange,University of Münster,Not Unity-Aligned,https://dx.doi.org/10.1007/s15010-023-02071-2,2023-08-21,2024-03-01,Unverified,lange_estimates_2023-1,DEU
230802_Germany_UniversityOfMunster_PopAdj_AntiN,230802_Germany_UniversityOfMunster,Estimates of protection levels against SARS-CoV-2 infection and severe COVID-19 in Germany before the 2022/2023 winter season: the IMMUNEBRIDGE project.,2023-08-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Germany,,,"A total of 33,637 participants from 9 studies surveyed between June and November 2022 were included. Online Resource 1, Table S1 describes the different participating studies.

... antibodies against SARS-Cov-2 were measured in four existing population-based cohort studies: the ELISA-Study [7, 13], MuSPAD [4], the German National Cohort (NAKO) [8], and STAAB [5]. Four new cross-sectional studies were set up, one to provide regional depth (GUIDE Study; DRKS00029693 [6]) and three to provide relevant data on children (studies of the University Hospitals in Dresden (adolescents; DRKS00022549), Bochum (school children) [2], and Würzburg (pre-school children; Wü-Kita-CoV) [3, 14]). Studies were included if they were able to quickly survey and sample in the general population regionally or supra-regionally, and provide the MDS.","Different sub-studies had different age restrictions which are listed in Supplement 1 Table S1. Nevertheless, all are >1 years of age.

Table 3 title:
Participants from IMMUNEBRIDGE_ED were excluded from this analysis as were participants with missing age information (n=132).",2022-06-15,2022-11-30,Household and community samples,All,Multiple groups,1.0,,Test used,Age standardized anti-N,31580,0.518,0.51,0.527,,,True,,,Unclear,"Elecsys® Anti‐SARS‐CoV‐2 (N),Anti-SARS-CoV-2 NCP ELISA (IgG)","Roche Diagnostics,EUROIMMUN",Multiple Types,Multiple Types,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,,,['High'],,Unclear,Yes,Yes,,Unclear,No,No,,Berit Lange,University of Münster,Not Unity-Aligned,https://dx.doi.org/10.1007/s15010-023-02071-2,2023-08-22,2024-03-01,Unverified,lange_estimates_2023-1,DEU
230821_Germany_RobertKochInstitute,230821_Germany_RobertKochInstitute,Long-term health consequences among individuals with SARS-CoV-2 infection compared to individuals without infection: results of the population-based cohort study CoMoLo Follow-up,2023-08-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Germany,,"Kupferzell, Bad Feilnbach, Straubing, Berlin-Mitte","The CoMoLo baseline study was a population-based study to investigate the seroprevalence of SARS-CoV-2 antibodies in four selected municipalities in Germany that were particularly affected by the COVID-19 pandemic in the year 2020 (i.e. with a reported cumulative SARS-CoV-2 incidence of more than 500 cases per 100,000 inhabitants before the start of the study). At baseline, random samples of adults (aged ≥ 18 years, n = 8999) from the local population registration offices were asked to visit a temporary study center to collect a blood sample and an oropharyngeal swab and to complete a short written questionnaire.","Fig 1:
- No valid consent for follow-up invitation (n=609)
- Deceased (n=18)
- No follow-up participation (n=2900)
- Missing IgG or PCR test at baseline study center (n=22)
- Missing self-report on laboratory-based physician diagnosis of COVID-19 at short baseline questionnaire (n=115)
- Missing self-report on laboratory test (n=16) or on physician diagnosis of COVID-19 at detailed baseline questionnaire (n=203)
- Missing self-report on PCR test at detailed follow-up questionnaire (n=35)
- First-time SARS-CoV-2 infection during follow-up based on self-report of positive PCR test at detailed follow-up questionnaire (n=264)",2020-05-15,2020-12-15,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,4817,0.06,,,True,,,,True,Simplified probability,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Christin Heidemann,Robert Koch Institute,Unity-Aligned,https://dx.doi.org/10.1186/s12889-023-16524-8,2023-09-22,2024-03-01,Unverified,heidemann_long-term_2023,DEU
210706_Ghana_UniversityOfGhana_Phase1_Overall,210706_Ghana_UniversityOfGhana_Phase1,Trends of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody prevalence in selected regions across Ghana,2021-07-06,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Ghana,"Greater Acra Region, Central Region, Eastern Region, Upper East Region","Accra, Kasoa, Cape Coast, Akropong, Navrongo, Bolgatanga","""This study included individuals aged 4 years and above across all study sites.""

""Phase I participants were invited to volunteer for the study at two shopping malls, three major markets/lorry stations (ML1-3), two research institutes involved in COVID-19 work (R1) and COVID-19 testing (RC), and three major hospitals, one of which was a COVID-19 treatment centre (H1, H2, and HC). Phase II screened participants at one market (ML4), one research centre (R1) and two hospitals (H1, H4) while Phase III screened participants at ML1 and across two towns in the Upper East Region (C1). During Phase IV, the exposure levels of upper-income earners were evaluated by screening at 2 malls (M1
and M3) and a repeat screening at H2. In addition, the exposure level in a small town (C3) in the Eastern Region, near Accra, was estimated.""","""Participants with recorded temperature above 37.5°C were excluded.""
""Screening at hospitals and research facilities included only staff members and their close contacts; patients at the hospitals were excluded from this study.""",2020-07-27,2020-09-14,Multiple general populations,All,Multiple groups,4.0,,Primary Estimate,,1305,0.19,,,True,,,,True,Convenience,UNSCIENCE COVID-19 IgG/IgM antibody Rapid Test Kit,Wuhan UNscience Biotechnology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.66,0.9400000000000001,['High'],,No,Yes,Yes,,Yes,Yes,No,,Peter Kojo Quashie,University of Ghana,Not Unity-Aligned,https://wellcomeopenresearch.org/articles/6-173,2021-07-13,2024-03-01,Unverified,quashie_trends_2021-1,GHA
210706_Ghana_UniversityOfGhana_Phase2_Overall,210706_Ghana_UniversityOfGhana_Phase2,Trends of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody prevalence in selected regions across Ghana,2021-07-06,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Ghana,"Greater Acra Region, Central Region, Eastern Region","Accra, Kasoa, Cape Coast, Akropong, Navrongo, Bolgatanga","""This study included individuals aged 4 years and above across all study sites.""

""Phase I participants were invited to volunteer for the study at two shopping malls, three major markets/lorry stations (ML1-3), two research institutes involved in COVID-19 work (R1) and COVID-19 testing (RC), and three major hospitals, one of which was a COVID-19 treatment centre (H1, H2, and HC). Phase II screened participants at one market (ML4), one research centre (R1) and two hospitals (H1, H4) while Phase III screened participants at ML1 and across two towns in the Upper East Region (C1). During Phase IV, the exposure levels of upper-income earners were evaluated by screening at 2 malls (M1
and M3) and a repeat screening at H2. In addition, the exposure level in a small town (C3) in the Eastern Region, near Accra, was estimated.""","""Participants with recorded temperature above 37.5°C were excluded.""
""Screening at hospitals and research facilities included only staff members and their close contacts; patients at the hospitals were excluded from this study.""",2020-10-01,2020-10-31,Multiple general populations,All,Multiple groups,4.0,,Primary Estimate,Phase 2 - October 2020,395,0.152,,,True,,,,True,Convenience,UNSCIENCE COVID-19 IgG/IgM antibody Rapid Test Kit,Wuhan UNscience Biotechnology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.66,0.9400000000000001,['High'],,No,No,Yes,,Yes,Yes,No,,Peter Kojo Quashie,University of Ghana,Not Unity-Aligned,https://wellcomeopenresearch.org/articles/6-173,2021-07-13,2024-03-01,Unverified,quashie_trends_2021-1,GHA
210706_Ghana_UniversityOfGhana_Phase3_Overall,210706_Ghana_UniversityOfGhana_Phase3,Trends of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody prevalence in selected regions across Ghana,2021-07-06,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Ghana,"Greater Acra Region, Central Region, Eastern Region","Accra, Kasoa, Cape Coast, Akropong, Navrongo, Bolgatanga","""This study included individuals aged 4 years and above across all study sites.""

""Phase I participants were invited to volunteer for the study at two shopping malls, three major markets/lorry stations (ML1-3), two research institutes involved in COVID-19 work (R1) and COVID-19 testing (RC), and three major hospitals, one of which was a COVID-19 treatment centre (H1, H2, and HC). Phase II screened participants at one market (ML4), one research centre (R1) and two hospitals (H1, H4) while Phase III screened participants at ML1 and across two towns in the Upper East Region (C1). During Phase IV, the exposure levels of upper-income earners were evaluated by screening at 2 malls (M1
and M3) and a repeat screening at H2. In addition, the exposure level in a small town (C3) in the Eastern Region, near Accra, was estimated.""","""Participants with recorded temperature above 37.5°C were excluded.""
""Screening at hospitals and research facilities included only staff members and their close contacts; patients at the hospitals were excluded from this study.""",2020-12-01,2020-12-31,Multiple general populations,All,Multiple groups,4.0,,Primary Estimate,Phase 3 - December 2020,393,0.09699999999999999,,,True,,,,True,Convenience,UNSCIENCE COVID-19 IgG/IgM antibody Rapid Test Kit,Wuhan UNscience Biotechnology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.66,0.9400000000000001,['High'],,No,No,Yes,,Yes,Yes,No,,Peter Kojo Quashie,University of Ghana,Not Unity-Aligned,https://wellcomeopenresearch.org/articles/6-173,2021-07-13,2024-03-01,Unverified,quashie_trends_2021-1,GHA
210706_Ghana_UniversityOfGhana_Phase4_Overall,210706_Ghana_UniversityOfGhana_Phase4,Trends of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody prevalence in selected regions across Ghana,2021-07-06,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Ghana,"Greater Acra Region, Central Region, Eastern Region","Accra, Kasoa, Cape Coast, Akropong, Navrongo, Bolgatanga","""This study included individuals aged 4 years and above across all study sites.""

""Phase I participants were invited to volunteer for the study at two shopping malls, three major markets/lorry stations (ML1-3), two research institutes involved in COVID-19 work (R1) and COVID-19 testing (RC), and three major hospitals, one of which was a COVID-19 treatment centre (H1, H2, and HC). Phase II screened participants at one market (ML4), one research centre (R1) and two hospitals (H1, H4) while Phase III screened participants at ML1 and across two towns in the Upper East Region (C1). During Phase IV, the exposure levels of upper-income earners were evaluated by screening at 2 malls (M1
and M3) and a repeat screening at H2. In addition, the exposure level in a small town (C3) in the Eastern Region, near Accra, was estimated.""","""Participants with recorded temperature above 37.5°C were excluded.""
""Screening at hospitals and research facilities included only staff members and their close contacts; patients at the hospitals were excluded from this study.""",2021-02-01,2021-02-28,Multiple general populations,All,Multiple groups,4.0,,Primary Estimate,Phase 4 - February 2021,636,0.228,,,True,,,,True,Convenience,UNSCIENCE COVID-19 IgG/IgM antibody Rapid Test Kit,Wuhan UNscience Biotechnology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.66,0.9400000000000001,['High'],,No,Yes,Yes,,Yes,Yes,No,,Peter Kojo Quashie,University of Ghana,Not Unity-Aligned,https://wellcomeopenresearch.org/articles/6-173,2021-07-13,2024-03-01,Unverified,quashie_trends_2021-1,GHA
220905_Germany_BernhardNochtInsituteForTropicalMedicine_Ghana_Adj,220905_Germany_BernhardNochtInsituteForTropicalMedicine_Ghana,"High seroprevalence of SARS-CoV-2 in Burkina-Faso, Ghana and Madagascar in 2021: a population-based study.",2022-09-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ghana,Ashanti,Kumasi,A minimum age of 10 years and a requirement of no existing health problems contraindicating blood sample collection were applied.,Households were excluded from analysis in the case of ID mismatches,2021-02-17,2021-05-10,Household and community samples,All,Multiple groups,10.0,,Primary Estimate,test and pop adjusted,340,0.41200000000000003,0.34500000000000003,0.49,True,True,True,,,Stratified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Nicole S. Struck,Bernhard Nocht Insitute for Tropical Medicine,Not Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13918-y,2022-09-12,2022-09-12,Unverified,struck_high_2022,GHA
220905_Germany_BernhardNochtInsituteForTropicalMedicine_Ghana_Crude,220905_Germany_BernhardNochtInsituteForTropicalMedicine_Ghana,"High seroprevalence of SARS-CoV-2 in Burkina-Faso, Ghana and Madagascar in 2021: a population-based study.",2022-09-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ghana,Ashanti,Kumasi,A minimum age of 10 years and a requirement of no existing health problems contraindicating blood sample collection were applied.,Households were excluded from analysis in the case of ID mismatches,2021-02-17,2021-05-10,Household and community samples,All,Multiple groups,10.0,,Analysis,,340,0.38799999999999996,,,,,,,True,Stratified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Nicole S. Struck,Bernhard Nocht Insitute for Tropical Medicine,Not Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13918-y,2022-09-12,2022-09-12,Unverified,struck_high_2022,GHA
220919_Accra_NoguchiMemorialInstituteforMedicalResearch,220919_Accra_NoguchiMemorialInstituteforMedicalResearch,"Determination of SARS-CoV-2 Variants and Seroprevalence in Accra, Ghana during the Delta-Omicron Waves",2022-09-26,Preprint,Local,Cross-sectional survey ,Ghana,,Accra,Households in National Sampling Frame from the Ghana Statistical Service,,2021-12-01,2021-12-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,1027,0.868,,,True,,,,True,Stratified non-probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,,,,['Moderate'],Yes,No,Yes,No,No,Yes,Yes,Yes,Unclear,Irene Owusu Donkor,Noguchi Memorial Institute for Medical Research,Unity-Aligned,10.20944/preprints202209.0390.v1,2022-10-09,2024-04-15,Verified,donkor_determination_2022,GHA
221017_Kumasi_CITIID_Primary,221017_Kumasi_CITIID,SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa,2022-10-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ghana,,Kumasi,"""Healthcare workers, university staff, and university students were randomly selected from peripheral vaccination sites in Kumasi, Ghana"".

""The study design also comprised of a prospective longitudinal cohort study of adult patients who were eligible to receive their first-dose vaccination between 3 March 2021 and 11 March 2021 and prospectively recruited into the study. Participants were enroled based on their willingness to be vaccinated with two doses of AZD1222 8–12 weeks apart following signed informed consent.""",,2021-03-03,2021-03-11,Multiple populations,All,Adults (18-64 years),,,Primary Estimate,Anti-N or Anti-RBD,527,0.3871,,,True,,,,True,Simplified probability,Author designed (Luminex),,Luminex,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,Yes,No,Yes,,Unclear,Yes,No,,Adam Abdullahi,Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID),Not Unity-Aligned,https://doi.org/10.1038/s41467-022-33792-x,2022-10-25,2022-11-18,Unverified,abdullahi_sars-cov-2_2022-1,GHA
221214_Accra_UniversityOfGhana_July3,221214_Accra_UniversityOfGhana_July3,Population-based sero-epidemiological investigation of the dynamics of SARS-CoV-2 infections in the Greater Accra Region of Ghana.,2022-12-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ghana,,Accra,individual household members across 4 districts in Accra Ghana,,2021-07-01,2021-07-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,1346,0.396,0.348,0.446,True,,True,,True,Simplified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,1.0,0.997,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Benedicta Ayiedu Mensah,University of Ghana,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-25598-0,2023-01-12,2024-03-26,Verified,mensah_population-based_2022,GHA
221214_Accra_UniversityOfGhana_March2,221214_Accra_UniversityOfGhana_March2,Population-based sero-epidemiological investigation of the dynamics of SARS-CoV-2 infections in the Greater Accra Region of Ghana.,2022-12-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ghana,,Accra,individual household members across 4 districts in Accra Ghana,,2021-03-01,2021-03-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,1013,0.257,0.22399999999999998,0.29300000000000004,True,,True,,True,Simplified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,1.0,0.997,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Benedicta Ayiedu Mensah,University of Ghana,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-25598-0,2023-01-12,2024-03-26,Verified,mensah_population-based_2022,GHA
221214_Accra_UniversityOfGhana_November1,221214_Accra_UniversityOfGhana_November1,Population-based sero-epidemiological investigation of the dynamics of SARS-CoV-2 infections in the Greater Accra Region of Ghana.,2022-12-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ghana,,Accra,individual household members across 4 districts in Accra Ghana,,2020-11-01,2020-11-30,Household and community samples,All,Multiple groups,,,Primary Estimate,,1238,0.138,0.11900000000000001,0.161,True,,True,,True,Simplified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,1.0,0.997,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Benedicta Ayiedu Mensah,University of Ghana,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-25598-0,2023-01-12,2024-03-26,Verified,mensah_population-based_2022,GHA
230505_Ghana_UniversityofGhana_Overall_PopAdj,230505_Ghana_UniversityofGhana,Modeling SARS-CoV-2 antibody seroprevalence and its determinants in Ghana: A nationally representative cross-sectional survey.,2023-05-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ghana,,,"Individuals within the household aged 5 years and older in the age groups 5–9; 10–19, 20–39, 40–59 and 60+ were listed and the kish grid technique of selection was used to choose individuals for interview. One person was sampled in each household.","Individuals were excluded if they refused or were unable to give informed consent; did not accept venipuncture; and were in prisons, camps, boarding houses, hostels, and hotels.",2021-02-15,2021-12-15,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,,5348,0.671,0.6564,0.6854,True,,True,,True,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.944,1.0,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Irene Donkor,University of Ghana,Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0001851,2023-06-02,2024-04-30,Verified,owusu_donkor_modeling_2023,GHA
230505_Ghana_UniversityofGhana_Age60+,230505_Ghana_UniversityofGhana,Modeling SARS-CoV-2 antibody seroprevalence and its determinants in Ghana: A nationally representative cross-sectional survey.,2023-05-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ghana,,,"Individuals within the household aged 5 years and older in the age groups 5–9; 10–19, 20–39, 40–59 and 60+ were listed and the kish grid technique of selection was used to choose individuals for interview. One person was sampled in each household.","Individuals were excluded if they refused or were unable to give informed consent; did not accept venipuncture; and were in prisons, camps, boarding houses, hostels, and hotels.",2021-02-15,2021-12-15,Household and community samples,All,Seniors (65+ years),60.0,,Age,60+,467,0.6081,0.5631,0.6514,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.944,1.0,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Irene Donkor,University of Ghana,Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0001851,2024-04-30,2024-04-30,Verified,owusu_donkor_modeling_2023,GHA
230505_Ghana_UniversityofGhana_Age20-39,230505_Ghana_UniversityofGhana,Modeling SARS-CoV-2 antibody seroprevalence and its determinants in Ghana: A nationally representative cross-sectional survey.,2023-05-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ghana,,,"Individuals within the household aged 5 years and older in the age groups 5–9; 10–19, 20–39, 40–59 and 60+ were listed and the kish grid technique of selection was used to choose individuals for interview. One person was sampled in each household.","Individuals were excluded if they refused or were unable to give informed consent; did not accept venipuncture; and were in prisons, camps, boarding houses, hostels, and hotels.",2021-02-15,2021-12-15,Household and community samples,All,Adults (18-64 years),20.0,39.0,Age,20-39,1852,0.6901,0.6686,0.7107,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.944,1.0,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Irene Donkor,University of Ghana,Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0001851,2024-04-30,2024-04-30,Verified,owusu_donkor_modeling_2023,GHA
230505_Ghana_UniversityofGhana_Age40-59,230505_Ghana_UniversityofGhana,Modeling SARS-CoV-2 antibody seroprevalence and its determinants in Ghana: A nationally representative cross-sectional survey.,2023-05-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ghana,,,"Individuals within the household aged 5 years and older in the age groups 5–9; 10–19, 20–39, 40–59 and 60+ were listed and the kish grid technique of selection was used to choose individuals for interview. One person was sampled in each household.","Individuals were excluded if they refused or were unable to give informed consent; did not accept venipuncture; and were in prisons, camps, boarding houses, hostels, and hotels.",2021-02-15,2021-12-15,Household and community samples,All,Adults (18-64 years),40.0,59.0,Age,40-59,830,0.6446,0.6114,0.6764,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.944,1.0,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Irene Donkor,University of Ghana,Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0001851,2024-04-30,2024-04-30,Verified,owusu_donkor_modeling_2023,GHA
230505_Ghana_UniversityofGhana_Age<20,230505_Ghana_UniversityofGhana,Modeling SARS-CoV-2 antibody seroprevalence and its determinants in Ghana: A nationally representative cross-sectional survey.,2023-05-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ghana,,,"Individuals within the household aged 5 years and older in the age groups 5–9; 10–19, 20–39, 40–59 and 60+ were listed and the kish grid technique of selection was used to choose individuals for interview. One person was sampled in each household.","Individuals were excluded if they refused or were unable to give informed consent; did not accept venipuncture; and were in prisons, camps, boarding houses, hostels, and hotels.",2021-02-15,2021-12-15,Household and community samples,All,Children and Youth (0-17 years),5.0,19.0,Age,<20,2199,0.6271,0.6067,0.6471,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.944,1.0,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Irene Donkor,University of Ghana,Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0001851,2024-04-30,2024-04-30,Verified,owusu_donkor_modeling_2023,GHA
200806_Greece_UniversityofThessaly_Overall,200806_Greece_UniversityofThessaly,"Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020",2020-08-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Greece,"Central Macedonia, Attica, Peloponnese, Thessaly, Western Macedonia, Central Greece, Western Greece, Epirus",,"Blood samples were collected by using the leftover
sampling methodology (residual sera from the general
population). We applied a geographically stratified
sampling plan based on regional units (NUTS level 3)
to produce a representative sample, taking into consideration
age group (0–29, 30–49, 50–69, ≥ 70 years)
and sex.

The samples were collected from individuals who visited the laboratories for a check-up, chronic disease follow-up or
other reasons unrelated to COVID-19.",,2020-03-01,2020-04-30,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,6586,0.0036,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.84,0.997,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Zacharoula Bogogiannidou,University of Thessaly,Unity-Aligned,https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.31.2001369,2020-10-03,2024-03-01,Verified,bogogiannidou_repeated_2020,GRC
200806_Greece_UniversityofThessaly_April_PopAdj,200806_Greece_UniversityofThessaly,"Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020",2020-08-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Greece,"Central Macedonia, Attica, Peloponnese, Thessaly, Western Macedonia, Central Greece, Western Greece, Epirus",,"Blood samples were collected by using the leftover
sampling methodology (residual sera from the general
population). We applied a geographically stratified
sampling plan based on regional units (NUTS level 3)
to produce a representative sample, taking into consideration
age group (0–29, 30–49, 50–69, ≥ 70 years)
and sex.

The samples were collected from individuals who visited the laboratories for a check-up, chronic disease follow-up or
other reasons unrelated to COVID-19.",,2020-04-01,2020-04-30,Residual sera,All,Multiple groups,0.0,,Analysis,Adjusted for population,4511,0.0049,0.0029,0.006999999999999999,,,True,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.84,0.997,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Zacharoula Bogogiannidou,University of Thessaly,Unity-Aligned,https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.31.2001369,2020-10-03,2024-03-01,Verified,bogogiannidou_repeated_2020,GRC
200806_Greece_UniversityofThessaly_Females,200806_Greece_UniversityofThessaly,"Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020",2020-08-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Greece,"Central Macedonia, Attica, Peloponnese, Thessaly, Western Macedonia, Central Greece, Western Greece, Epirus",,"Blood samples were collected by using the leftover
sampling methodology (residual sera from the general
population). We applied a geographically stratified
sampling plan based on regional units (NUTS level 3)
to produce a representative sample, taking into consideration
age group (0–29, 30–49, 50–69, ≥ 70 years)
and sex.

The samples were collected from individuals who visited the laboratories for a check-up, chronic disease follow-up or
other reasons unrelated to COVID-19.",,2020-03-01,2020-04-30,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,Female ,3621,0.0047,,,,True,True,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.84,0.997,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Zacharoula Bogogiannidou,University of Thessaly,Unity-Aligned,https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.31.2001369,2020-10-03,2023-07-04,Verified,bogogiannidou_repeated_2020,GRC
200806_Greece_UniversityofThessaly_30-49,200806_Greece_UniversityofThessaly,"Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020",2020-08-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Greece,"Central Macedonia, Attica, Peloponnese, Thessaly, Western Macedonia, Central Greece, Western Greece, Epirus",,"Blood samples were collected by using the leftover
sampling methodology (residual sera from the general
population). We applied a geographically stratified
sampling plan based on regional units (NUTS level 3)
to produce a representative sample, taking into consideration
age group (0–29, 30–49, 50–69, ≥ 70 years)
and sex.

The samples were collected from individuals who visited the laboratories for a check-up, chronic disease follow-up or
other reasons unrelated to COVID-19.",,2020-03-01,2020-04-30,Residual sera,All,Adults (18-64 years),30.0,49.0,Age,30-49,2066,0.001,,,,True,True,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.84,0.997,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Zacharoula Bogogiannidou,University of Thessaly,Unity-Aligned,https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.31.2001369,2020-10-03,2023-07-04,Verified,bogogiannidou_repeated_2020,GRC
200806_Greece_UniversityofThessaly_March_Unadj,200806_Greece_UniversityofThessaly,"Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020",2020-08-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Greece,"Central Macedonia, Attica, Peloponnese, Thessaly, Western Macedonia, Central Greece, Western Greece, Epirus",,"Blood samples were collected by using the leftover
sampling methodology (residual sera from the general
population). We applied a geographically stratified
sampling plan based on regional units (NUTS level 3)
to produce a representative sample, taking into consideration
age group (0–29, 30–49, 50–69, ≥ 70 years)
and sex.

The samples were collected from individuals who visited the laboratories for a check-up, chronic disease follow-up or
other reasons unrelated to COVID-19.",,2020-03-01,2020-03-31,Residual sera,All,Multiple groups,0.0,,Time frame,March,2075,0.0024,0.0003,0.0045000000000000005,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.84,0.997,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Zacharoula Bogogiannidou,University of Thessaly,Unity-Aligned,https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.31.2001369,2020-10-03,2024-03-01,Verified,bogogiannidou_repeated_2020,GRC
200806_Greece_UniversityofThessaly_Males,200806_Greece_UniversityofThessaly,"Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020",2020-08-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Greece,"Central Macedonia, Attica, Peloponnese, Thessaly, Western Macedonia, Central Greece, Western Greece, Epirus",,"Blood samples were collected by using the leftover
sampling methodology (residual sera from the general
population). We applied a geographically stratified
sampling plan based on regional units (NUTS level 3)
to produce a representative sample, taking into consideration
age group (0–29, 30–49, 50–69, ≥ 70 years)
and sex.

The samples were collected from individuals who visited the laboratories for a check-up, chronic disease follow-up or
other reasons unrelated to COVID-19.",,2020-03-01,2020-04-30,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,Male,3001,0.0023,,,,True,True,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.84,0.997,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Zacharoula Bogogiannidou,University of Thessaly,Unity-Aligned,https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.31.2001369,2020-10-03,2023-07-04,Verified,bogogiannidou_repeated_2020,GRC
200806_Greece_UniversityofThessaly_April_PopTestAdj,200806_Greece_UniversityofThessaly,"Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020",2020-08-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Greece,"Central Macedonia, Attica, Peloponnese, Thessaly, Western Macedonia, Central Greece, Western Greece, Epirus",,"Blood samples were collected by using the leftover
sampling methodology (residual sera from the general
population). We applied a geographically stratified
sampling plan based on regional units (NUTS level 3)
to produce a representative sample, taking into consideration
age group (0–29, 30–49, 50–69, ≥ 70 years)
and sex.

The samples were collected from individuals who visited the laboratories for a check-up, chronic disease follow-up or
other reasons unrelated to COVID-19.",,2020-04-01,2020-04-30,Residual sera,All,Multiple groups,0.0,,Analysis,Adjusted for test and population,4511,0.0025,0.0002,0.005,,True,True,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.84,0.997,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Zacharoula Bogogiannidou,University of Thessaly,Unity-Aligned,https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.31.2001369,2020-10-26,2023-07-04,Verified,bogogiannidou_repeated_2020,GRC
200806_Greece_UniversityofThessaly_March_PopAdj,200806_Greece_UniversityofThessaly,"Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020",2020-08-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Greece,"Central Macedonia, Attica, Peloponnese, Thessaly, Western Macedonia, Central Greece, Western Greece, Epirus",,"Blood samples were collected by using the leftover
sampling methodology (residual sera from the general
population). We applied a geographically stratified
sampling plan based on regional units (NUTS level 3)
to produce a representative sample, taking into consideration
age group (0–29, 30–49, 50–69, ≥ 70 years)
and sex.

The samples were collected from individuals who visited the laboratories for a check-up, chronic disease follow-up or
other reasons unrelated to COVID-19.",,2020-03-01,2020-03-31,Residual sera,All,Multiple groups,0.0,,Analysis,"Adjusted for age, sex",2075,0.0027,0.0005,0.0049,,,True,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.84,0.997,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Zacharoula Bogogiannidou,University of Thessaly,Unity-Aligned,https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.31.2001369,2020-10-03,2024-03-01,Verified,bogogiannidou_repeated_2020,GRC
200806_Greece_UniversityofThessaly_0-29,200806_Greece_UniversityofThessaly,"Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020",2020-08-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Greece,"Central Macedonia, Attica, Peloponnese, Thessaly, Western Macedonia, Central Greece, Western Greece, Epirus",,"Blood samples were collected by using the leftover
sampling methodology (residual sera from the general
population). We applied a geographically stratified
sampling plan based on regional units (NUTS level 3)
to produce a representative sample, taking into consideration
age group (0–29, 30–49, 50–69, ≥ 70 years)
and sex.

The samples were collected from individuals who visited the laboratories for a check-up, chronic disease follow-up or
other reasons unrelated to COVID-19.",,2020-03-01,2020-04-30,Residual sera,All,Multiple groups,0.0,29.0,Age,0-29 ,1464,0.0027,,,,True,True,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.84,0.997,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Zacharoula Bogogiannidou,University of Thessaly,Unity-Aligned,https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.31.2001369,2020-10-03,2023-07-04,Verified,bogogiannidou_repeated_2020,GRC
200806_Greece_UniversityofThessaly_Urban,200806_Greece_UniversityofThessaly,"Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020",2020-08-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Greece,"Attica, Thessaly",,"Blood samples were collected by using the leftover
sampling methodology (residual sera from the general
population). We applied a geographically stratified
sampling plan based on regional units (NUTS level 3)
to produce a representative sample, taking into consideration
age group (0–29, 30–49, 50–69, ≥ 70 years)
and sex.

The samples were collected from individuals who visited the laboratories for a check-up, chronic disease follow-up or
other reasons unrelated to COVID-19.",,2020-03-01,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Urban areas (Attica and Thessaloniki) ,2069,0.0063,,,,True,True,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.84,0.997,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Zacharoula Bogogiannidou,University of Thessaly,Unity-Aligned,https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.31.2001369,2020-10-03,2023-07-04,Verified,bogogiannidou_repeated_2020,GRC
200806_Greece_UniversityofThessaly_April_TestAdj,200806_Greece_UniversityofThessaly,"Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020",2020-08-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Greece,"Central Macedonia, Attica, Peloponnese, Thessaly, Western Macedonia, Central Greece, Western Greece, Epirus",,"Blood samples were collected by using the leftover
sampling methodology (residual sera from the general
population). We applied a geographically stratified
sampling plan based on regional units (NUTS level 3)
to produce a representative sample, taking into consideration
age group (0–29, 30–49, 50–69, ≥ 70 years)
and sex.

The samples were collected from individuals who visited the laboratories for a check-up, chronic disease follow-up or
other reasons unrelated to COVID-19.",,2020-04-01,2020-04-30,Residual sera,All,Multiple groups,0.0,,Analysis,Adjusted for test,4511,0.0023,0.0,0.0048,,True,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.84,0.997,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Zacharoula Bogogiannidou,University of Thessaly,Unity-Aligned,https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.31.2001369,2020-10-03,2023-07-04,Verified,bogogiannidou_repeated_2020,GRC
200806_Greece_UniversityofThessaly_Non-urban,200806_Greece_UniversityofThessaly,"Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020",2020-08-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Greece,"Central Macedonia, Peloponnese, Western Macedonia, Central Greece, Western Greece, Epirus",,"Blood samples were collected by using the leftover
sampling methodology (residual sera from the general
population). We applied a geographically stratified
sampling plan based on regional units (NUTS level 3)
to produce a representative sample, taking into consideration
age group (0–29, 30–49, 50–69, ≥ 70 years)
and sex.

The samples were collected from individuals who visited the laboratories for a check-up, chronic disease follow-up or
other reasons unrelated to COVID-19.",,2020-03-01,2020-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Non-urban areas,4517,0.0024,,,,True,True,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.84,0.997,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Zacharoula Bogogiannidou,University of Thessaly,Unity-Aligned,https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.31.2001369,2020-10-03,2023-07-04,Verified,bogogiannidou_repeated_2020,GRC
200806_Greece_UniversityofThessaly_March_TestAdj,200806_Greece_UniversityofThessaly,"Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020",2020-08-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Greece,"Central Macedonia, Attica, Peloponnese, Thessaly, Western Macedonia, Central Greece, Western Greece, Epirus",,"Blood samples were collected by using the leftover
sampling methodology (residual sera from the general
population). We applied a geographically stratified
sampling plan based on regional units (NUTS level 3)
to produce a representative sample, taking into consideration
age group (0–29, 30–49, 50–69, ≥ 70 years)
and sex.

The samples were collected from individuals who visited the laboratories for a check-up, chronic disease follow-up or
other reasons unrelated to COVID-19.",,2020-03-01,2020-03-31,Residual sera,All,Multiple groups,0.0,,Analysis,Adjusted for test,2075,0.0,0.0,0.0023,,True,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.84,0.997,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Zacharoula Bogogiannidou,University of Thessaly,Unity-Aligned,https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.31.2001369,2020-10-03,2023-07-04,Verified,bogogiannidou_repeated_2020,GRC
200806_Greece_UniversityofThessaly_March_PopTestAdj,200806_Greece_UniversityofThessaly,"Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020",2020-08-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Greece,"Central Macedonia, Attica, Peloponnese, Thessaly, Western Macedonia, Central Greece, Western Greece, Epirus",,"Blood samples were collected by using the leftover
sampling methodology (residual sera from the general
population). We applied a geographically stratified
sampling plan based on regional units (NUTS level 3)
to produce a representative sample, taking into consideration
age group (0–29, 30–49, 50–69, ≥ 70 years)
and sex.

The samples were collected from individuals who visited the laboratories for a check-up, chronic disease follow-up or
other reasons unrelated to COVID-19.",,2020-03-01,2020-03-31,Residual sera,All,Multiple groups,0.0,,Analysis,Adjusted for test and population,2075,0.0002,0.0,0.0025,,True,True,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.84,0.997,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Zacharoula Bogogiannidou,University of Thessaly,Unity-Aligned,https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.31.2001369,2020-10-26,2023-07-04,Verified,bogogiannidou_repeated_2020,GRC
200806_Greece_UniversityofThessaly_April_Unadj,200806_Greece_UniversityofThessaly,"Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020",2020-08-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Greece,"Central Macedonia, Attica, Peloponnese, Thessaly, Western Macedonia, Central Greece, Western Greece, Epirus",,"Blood samples were collected by using the leftover
sampling methodology (residual sera from the general
population). We applied a geographically stratified
sampling plan based on regional units (NUTS level 3)
to produce a representative sample, taking into consideration
age group (0–29, 30–49, 50–69, ≥ 70 years)
and sex.

The samples were collected from individuals who visited the laboratories for a check-up, chronic disease follow-up or
other reasons unrelated to COVID-19.",,2020-04-01,2020-04-30,Residual sera,All,Multiple groups,0.0,,Time frame,April,4511,0.0042,0.0023,0.0061,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.84,0.997,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Zacharoula Bogogiannidou,University of Thessaly,Unity-Aligned,https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.31.2001369,2020-10-03,2024-03-01,Verified,bogogiannidou_repeated_2020,GRC
200806_Greece_UniversityofThessaly_50-69,200806_Greece_UniversityofThessaly,"Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020",2020-08-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Greece,"Central Macedonia, Attica, Peloponnese, Thessaly, Western Macedonia, Central Greece, Western Greece, Epirus",,"Blood samples were collected by using the leftover
sampling methodology (residual sera from the general
population). We applied a geographically stratified
sampling plan based on regional units (NUTS level 3)
to produce a representative sample, taking into consideration
age group (0–29, 30–49, 50–69, ≥ 70 years)
and sex.

The samples were collected from individuals who visited the laboratories for a check-up, chronic disease follow-up or
other reasons unrelated to COVID-19.",,2020-03-01,2020-04-30,Residual sera,All,Adults (18-64 years),50.0,69.0,Age,50-69,1762,0.0045000000000000005,,,,True,True,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.84,0.997,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Zacharoula Bogogiannidou,University of Thessaly,Unity-Aligned,https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.31.2001369,2020-10-03,2023-07-04,Verified,bogogiannidou_repeated_2020,GRC
200806_Greece_UniversityofThessaly_>70,200806_Greece_UniversityofThessaly,"Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020",2020-08-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Greece,"Central Macedonia, Attica, Peloponnese, Thessaly, Western Macedonia, Central Greece, Western Greece, Epirus",,"Blood samples were collected by using the leftover
sampling methodology (residual sera from the general
population). We applied a geographically stratified
sampling plan based on regional units (NUTS level 3)
to produce a representative sample, taking into consideration
age group (0–29, 30–49, 50–69, ≥ 70 years)
and sex.

The samples were collected from individuals who visited the laboratories for a check-up, chronic disease follow-up or
other reasons unrelated to COVID-19.",,2020-03-01,2020-04-30,Residual sera,All,Seniors (65+ years),70.0,,Age,70 and over,1294,0.0077,,,,True,True,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.84,0.997,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Zacharoula Bogogiannidou,University of Thessaly,Unity-Aligned,https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.31.2001369,2020-10-03,2023-07-04,Verified,bogogiannidou_repeated_2020,GRC
200921_Athens_NationalandKapodistrianUniversityofAthens_OverallAdj,200921_Athens_NationalandKapodistrianUniversityofAthens,"Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report",2020-09-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Greece,,Athens,"National and Kapodistrian University of Athens (NKUA) members, comprising faculty members/laboratory assistants, scientific affiliates, administrative officers, undergraduate and postgraduate students",,2020-06-15,2020-07-15,Non-essential workers and unemployed persons,All,Multiple groups,18.0,74.0,Primary Estimate,,2500,0.009300000000000001,0.0027,0.0209,True,True,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9981000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Ourania Tsitsilonis ,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.3390/life10090214,2020-11-09,2023-08-15,Verified,tsitsilonis_seroprevalence_2020,GRC
200921_Athens_NationalandKapodistrianUniversityofAthens_18-34Unadj,200921_Athens_NationalandKapodistrianUniversityofAthens,"Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report",2020-09-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Greece,,Athens,"National and Kapodistrian University of Athens (NKUA) members, comprising faculty members/laboratory assistants, scientific affiliates, administrative officers, undergraduate and postgraduate students",,2020-06-15,2020-07-15,Non-essential workers and unemployed persons,All,Adults (18-64 years),18.0,34.0,Age,"18-34, unadjusted",1268,0.0087,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9981000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Ourania Tsitsilonis ,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.3390/life10090214,2020-11-09,2024-03-01,Verified,tsitsilonis_seroprevalence_2020,GRC
200921_Athens_NationalandKapodistrianUniversityofAthens_55-74Adj,200921_Athens_NationalandKapodistrianUniversityofAthens,"Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report",2020-09-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Greece,,Athens,"National and Kapodistrian University of Athens (NKUA) members, comprising faculty members/laboratory assistants, scientific affiliates, administrative officers, undergraduate and postgraduate students",,2020-06-15,2020-07-15,Non-essential workers and unemployed persons,All,Multiple groups,55.0,74.0,Age,"55-74, adjusted",309,0.014199999999999999,0.0033000000000000004,0.0354,,True,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9980999999999998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Ourania Tsitsilonis ,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.3390/life10090214,2020-11-09,2023-08-15,Verified,tsitsilonis_seroprevalence_2020,GRC
200921_Athens_NationalandKapodistrianUniversityofAthens_AgeUnkown,200921_Athens_NationalandKapodistrianUniversityofAthens,"Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report",2020-09-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Greece,,Athens,"National and Kapodistrian University of Athens (NKUA) members, comprising faculty members/laboratory assistants, scientific affiliates, administrative officers, undergraduate and postgraduate students",,2020-06-15,2020-07-15,Non-essential workers and unemployed persons,All,Multiple groups,18.0,74.0,Age,Age unknown,7,0.0,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9980999999999997,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Ourania Tsitsilonis ,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.3390/life10090214,2020-11-09,2024-03-01,Verified,tsitsilonis_seroprevalence_2020,GRC
200921_Athens_NationalandKapodistrianUniversityofAthens_35-54Adj,200921_Athens_NationalandKapodistrianUniversityofAthens,"Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report",2020-09-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Greece,,Athens,"National and Kapodistrian University of Athens (NKUA) members, comprising faculty members/laboratory assistants, scientific affiliates, administrative officers, undergraduate and postgraduate students",,2020-06-15,2020-07-15,Non-essential workers and unemployed persons,All,Adults (18-64 years),35.0,54.0,Age,"35-54, adjusted",916,0.0078000000000000005,0.0025,0.0166,,True,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9981000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Ourania Tsitsilonis ,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.3390/life10090214,2020-11-09,2023-08-15,Verified,tsitsilonis_seroprevalence_2020,GRC
200921_Athens_NationalandKapodistrianUniversityofAthens_18-34Adj,200921_Athens_NationalandKapodistrianUniversityofAthens,"Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report",2020-09-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Greece,,Athens,"National and Kapodistrian University of Athens (NKUA) members, comprising faculty members/laboratory assistants, scientific affiliates, administrative officers, undergraduate and postgraduate students",,2020-06-15,2020-07-15,Non-essential workers and unemployed persons,All,Adults (18-64 years),18.0,34.0,Age,"18-34, adjusted",1268,0.0067,0.0023,0.013500000000000002,,True,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9981000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Ourania Tsitsilonis ,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.3390/life10090214,2020-11-09,2023-08-15,Verified,tsitsilonis_seroprevalence_2020,GRC
200921_Athens_NationalandKapodistrianUniversityofAthens_55-74Unadj,200921_Athens_NationalandKapodistrianUniversityofAthens,"Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report",2020-09-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Greece,,Athens,"National and Kapodistrian University of Athens (NKUA) members, comprising faculty members/laboratory assistants, scientific affiliates, administrative officers, undergraduate and postgraduate students",,2020-06-15,2020-07-15,Non-essential workers and unemployed persons,All,Multiple groups,55.0,74.0,Age,"55-74, unadjusted",309,0.016200000000000003,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9980999999999998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Ourania Tsitsilonis ,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.3390/life10090214,2020-11-09,2024-03-01,Verified,tsitsilonis_seroprevalence_2020,GRC
200921_Athens_NationalandKapodistrianUniversityofAthens_35-54Unadj,200921_Athens_NationalandKapodistrianUniversityofAthens,"Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report",2020-09-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Greece,,Athens,"National and Kapodistrian University of Athens (NKUA) members, comprising faculty members/laboratory assistants, scientific affiliates, administrative officers, undergraduate and postgraduate students",,2020-06-15,2020-07-15,Non-essential workers and unemployed persons,All,Adults (18-64 years),35.0,54.0,Age,"35-54, unadjusted",916,0.0098,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9980999999999999,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Ourania Tsitsilonis ,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.3390/life10090214,2020-11-09,2024-03-01,Verified,tsitsilonis_seroprevalence_2020,GRC
201027_Athens_NationalandKapodistrianUniversityofAthens_Overall,201027_Athens_NationalandKapodistrianUniversityofAthens,"Anti-SARS-CoV-2 antibody detection in healthcare workers of two tertiary hospitals in Athens, Greece",2020-10-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Greece,Attica,Athens,"321 health workers, from two tertiary hospitals in Athens, Greece were recruited following ethical approval from the Boards of both hospitals. All participants, including doctors, nurses and assistive personnel, signed informed consents and filled health-related questioners.",Participants which had been tested positive for SARS-CoV-2 by PCR were excluded.,2020-04-25,2020-05-10,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,321,0.021800000000000003,,,True,,,,True,Unclear,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.93,1.0,['High'],Yes,Unclear,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Panayiotis Vlachoyiannopoulosa,National and Kapodistrian University of Athens/Laiko University Hospital,Not Unity-Aligned,http://dx.doi.org/10.1016/j.clim.2020.108619,2021-01-12,2024-03-01,Verified,vlachoyiannopoulos_anti-sars-cov-2_2020,GRC
201203_Athens_UniversityOfAthens_Overall_BothAdj,201203_Athens_UniversityOfAthens,Antibodies against SARS-CoV-2 among health care workers in a country with low burden of COVID-19,2020-12-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Greece,Attica,Athens,"Two groups were investigated 1)first-line healthcare workers(FL-HCWs),defined as personnel whose activities involve contact with patients, and 2) second-line healthcare workers (SL-HCWs), such as office employees, technical personnel, cleaning personnel, etc",,2020-04-13,2020-05-15,Health care workers and caregivers,All,Multiple groups,18.0,70.0,Primary Estimate,Adjusted for age and test performance,1495,0.0126,0.0043,0.0326,True,True,True,,,Convenience,GenBody COVID-19 IgM/IgG,GenBody Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.741,1.0,['Moderate'],No,No,Yes,Yes,Yes,No,Yes,Yes,Yes,Mina Psichogiou,University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0243025,2021-02-07,2023-08-15,Verified,psichogiou_antibodies_2020-1,GRC
210107_Greece_UniversityCollegeLondon_PaediatricHCW,210107_Greece_UniversityCollegeLondon,Cross Sectional Prevalence of SARS-CoV-2 antibodies in Health Care Workers in Paediatric Facilities in Eight Countries,2021-01-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Greece,,,"This was part of a larger study undertaken in HCWs in paediatric facilities in seven European sites and one South African site. Staff of all categories in each healthcare setting were invited to join the study, irrespective of symptoms or whether they suspected they had previously had COVID-19. ",,2020-06-19,2020-07-16,Health care workers and caregivers,All,Adults (18-64 years),18.0,67.0,Primary Estimate,,77,0.013000000000000001,0.0023,0.07,True,,,,True,Convenience,"EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit,Meso Scale Discovery multiplex assay","Epitope Diagnostics, Inc.,Meso Scale Discovery",ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,No,No,Unclear,Yes,Yes,No,Unclear,D Goldblatt,University College London,Not Unity-Aligned,http://dx.doi.org/10.1016/j.jhin.2020.12.019,2021-03-13,2024-03-01,Verified,goldblatt_cross-sectional_2021,GRC
210302_Athens_NationalandKapodistrianUniversityofAthens_PopTestAdj,210302_Athens_NationalandKapodistrianUniversityofAthens,Sars-cov-2 infection is asymptomatic in nearly half of adults with robust anti-spike protein receptor-binding domain antibody response,2021-03-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Greece,Attica,Athens,"faculty members/laboratory assistants, scientific affiliates, administrative officers, undergraduate, and postgraduate students of NKUA",,2020-06-15,2020-11-15,Multiple populations,All,Multiple groups,18.0,82.0,Primary Estimate,Population and test adjusted,4996,0.016,0.0092,0.025400000000000002,True,True,True,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981000000000001,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Ourania Tsitsilonis,National and Kapodistrian University of Athens,Not Unity-Aligned,http://dx.doi.org/10.3390/vaccines9030207,2021-05-14,2023-08-15,Verified,tsitsilonis_sars-cov-2_2021,GRC
210513_Greece_UniversityThessaly_TestPopAdj,210513_Greece_UniversityThessaly,"Repeated Leftover Serosurvey of SARS-CoV-2 IgG Antibodies in Greece, May to August 2020.",2021-05-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Greece,,,"The leftover serum samples were collected from a nationwide laboratory network, including both private microbiological laboratories as well as microbiological and biochemical laboratories of public hospitals. A total of 36 laboratories participated. The samples were derived from individuals who visited the laboratories for routine screening and reasons unrelated to COVID-19.","Our positive results reflect mainly mild or asymptomatic cases, since confirmed COVID-19 cases that occurred during the same month were excluded from the sampling framework.",2020-05-01,2020-08-31,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,20110,0.0019,0.0008,0.003,True,True,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,0.997,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Zacharoula Bogogiannidou,University of Thessaly,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines9050504,2021-06-07,2023-08-15,Unverified,Bogogiannidou_repeated_2021,GRC
210513_Greece_UniversityThessaly_PopAdj,210513_Greece_UniversityThessaly,"Repeated Leftover Serosurvey of SARS-CoV-2 IgG Antibodies in Greece, May to August 2020.",2021-05-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Greece,,,"The leftover serum samples were collected from a nationwide laboratory network, including both private microbiological laboratories as well as microbiological and biochemical laboratories of public hospitals. A total of 36 laboratories participated. The samples were derived from individuals who visited the laboratories for routine screening and reasons unrelated to COVID-19.","Our positive results reflect mainly mild or asymptomatic cases, since confirmed COVID-19 cases that occurred during the same month were excluded from the sampling framework.",2020-05-01,2020-08-31,Household and community samples,All,Multiple groups,0.0,,Analysis,,20110,0.0046,0.0037,0.0055000000000000005,,,True,,True,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,0.997,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Zacharoula Bogogiannidou,University of Thessaly,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines9050504,2021-06-07,2024-03-01,Unverified,Bogogiannidou_repeated_2021,GRC
210623_Deskati_UniversityOfThessaly_Primary,210623_Deskati_UniversityOfThessaly,Understanding covid-19 epidemiology and implications for control: The experience from a greek semi-closed community,2021-06-23,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Greece,West Macedonia,Deskati,All the residents of Deskati were invited to participate in the study,There were no exclusion criteria,2021-01-29,2021-01-29,Household and community samples,All,Multiple groups,9.0,92.0,Primary Estimate,,388,0.17800000000000002,,,True,,,,True,Convenience,"Rapid Test 2019-nCoV Total Ig,Abbott Architect SARS-CoV-2 IgG","Prognosis Biotech,Abbott Laboratories",Multiple Types,Multiple Types,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,No,No,Ourania S. Kotsiou,University of Thessaly,Unity-Aligned,http://dx.doi.org/10.3390/jcm10132765,2021-07-07,2024-03-01,Verified,kotsiou_understanding_2021,GRC
210623_Deskati_UniversityOfThessaly_CLIA,210623_Deskati_UniversityOfThessaly,Understanding covid-19 epidemiology and implications for control: The experience from a greek semi-closed community,2021-06-23,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Greece,West Macedonia,Deskati,All the residents of Deskati were invited to participate in the study,There were no exclusion criteria,2021-01-29,2021-01-29,Household and community samples,All,Multiple groups,9.0,92.0,Test used,ELISA,388,0.13,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9990000000000001,1.0,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,No,No,Ourania S. Kotsiou,University of Thessaly,Unity-Aligned,http://dx.doi.org/10.3390/jcm10132765,2021-07-07,2024-03-01,Verified,kotsiou_understanding_2021,GRC
210623_Deskati_UniversityOfThessaly_LFIA,210623_Deskati_UniversityOfThessaly,Understanding covid-19 epidemiology and implications for control: The experience from a greek semi-closed community,2021-06-23,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Greece,West Macedonia,Deskati,All the residents of Deskati were invited to participate in the study,There were no exclusion criteria,2021-01-29,2021-01-29,Household and community samples,All,Multiple groups,9.0,92.0,Test used,LFIA,69,0.45,,,,,,,,Convenience,Rapid Test 2019-nCoV Total Ig,Prognosis Biotech,LFIA,Whole Blood,"['IgA', 'IgG', 'IgM']",Spike,Validated by manufacturers,0.9875,1.0,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,No,No,Ourania S. Kotsiou,University of Thessaly,Unity-Aligned,http://dx.doi.org/10.3390/jcm10132765,2021-07-07,2024-03-01,Verified,kotsiou_understanding_2021,GRC
210430_AghiaSophiaChildrensHospital_Athens_HCW,210430_AghiaSophiaChildrensHospital_Athens,SARS-CoV-2 seroepidemiological study in healthcare workers and discordant results using seven different diagnostic methods.,2021-07-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Greece,Atica,Athens,"The HCWs included medical professionals (medical doctors, nurses, biologists, technicians) and nonmedical personnel of the hospital (administrative staff, cleaners, etc.), who voluntarily were checked for their SARS-CoV-2 antibody status",,2020-06-01,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1216,0.006600000000000001,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Elizabeth‑Barbara Tatsi,"The ""Aghia Sophia"" Children's Hospital ",Not Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01653-2,2021-07-13,2024-03-01,Verified,tatsi_sars-cov-2_2021,GRC
210731_Greece_NationalandKapodistrianUniversityofAthens_Primary,210731_Greece_NationalandKapodistrianUniversityofAthens,Low seropositivity for SARS-CoV-2 antibodies among healthcare workers after the first COVID-19 pandemic wave in Greece.,2021-07-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Greece,,,"HCWs in the Greek National Health System were offered a free SARS-CoV-2 IgG antibody test, regardless of symptoms. The test was performed on a voluntary and anonymous basis and was offered irrespective of past history of COVID-19.",,2020-06-01,2020-07-09,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,57418,0.006600717545,,,True,True,True,,True,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,Other,Multiple Types,IgG,Nucleocapsid(N-protein),,1.0,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Petros Galanis,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1016/j.puhe.2021.07.029,2021-09-12,2023-08-15,Unverified,galanis_low_2021,GRC
210731_Greece_NationalandKapodistrianUniversityofAthens_Age_Over60,210731_Greece_NationalandKapodistrianUniversityofAthens,Low seropositivity for SARS-CoV-2 antibodies among healthcare workers after the first COVID-19 pandemic wave in Greece.,2021-07-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Greece,,,"HCWs in the Greek National Health System were offered a free SARS-CoV-2 IgG antibody test, regardless of symptoms. The test was performed on a voluntary and anonymous basis and was offered irrespective of past history of COVID-19.",,2020-06-01,2020-07-09,Health care workers and caregivers,All,Adults (18-64 years),,,Age,>=60,4534,0.005072783414000001,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,Other,Multiple Types,IgG,Nucleocapsid(N-protein),,1.0,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Petros Galanis,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1016/j.puhe.2021.07.029,2021-09-12,2024-03-01,Unverified,galanis_low_2021,GRC
210731_Greece_NationalandKapodistrianUniversityofAthens_Age_18to39,210731_Greece_NationalandKapodistrianUniversityofAthens,Low seropositivity for SARS-CoV-2 antibodies among healthcare workers after the first COVID-19 pandemic wave in Greece.,2021-07-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Greece,,,"HCWs in the Greek National Health System were offered a free SARS-CoV-2 IgG antibody test, regardless of symptoms. The test was performed on a voluntary and anonymous basis and was offered irrespective of past history of COVID-19.",,2020-06-01,2020-07-09,Health care workers and caregivers,All,Adults (18-64 years),,,Age,18-39,12957,0.006019912017,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,Other,Multiple Types,IgG,Nucleocapsid(N-protein),,1.0,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Petros Galanis,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1016/j.puhe.2021.07.029,2021-09-12,2024-03-01,Unverified,galanis_low_2021,GRC
210731_Greece_NationalandKapodistrianUniversityofAthens_Age_50to59,210731_Greece_NationalandKapodistrianUniversityofAthens,Low seropositivity for SARS-CoV-2 antibodies among healthcare workers after the first COVID-19 pandemic wave in Greece.,2021-07-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Greece,,,"HCWs in the Greek National Health System were offered a free SARS-CoV-2 IgG antibody test, regardless of symptoms. The test was performed on a voluntary and anonymous basis and was offered irrespective of past history of COVID-19.",,2020-06-01,2020-07-09,Health care workers and caregivers,All,Adults (18-64 years),,,Age,50-59,18511,0.007346982875,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,Other,Multiple Types,IgG,Nucleocapsid(N-protein),,1.0,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Petros Galanis,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1016/j.puhe.2021.07.029,2021-09-12,2024-03-01,Unverified,galanis_low_2021,GRC
210731_Greece_NationalandKapodistrianUniversityofAthens_Age_40to49,210731_Greece_NationalandKapodistrianUniversityofAthens,Low seropositivity for SARS-CoV-2 antibodies among healthcare workers after the first COVID-19 pandemic wave in Greece.,2021-07-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Greece,,,"HCWs in the Greek National Health System were offered a free SARS-CoV-2 IgG antibody test, regardless of symptoms. The test was performed on a voluntary and anonymous basis and was offered irrespective of past history of COVID-19.",,2020-06-01,2020-07-09,Health care workers and caregivers,All,Adults (18-64 years),,,Age,40-49,17838,0.005830250028,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,Other,Multiple Types,IgG,Nucleocapsid(N-protein),,1.0,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Petros Galanis,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1016/j.puhe.2021.07.029,2021-09-12,2024-03-01,Unverified,galanis_low_2021,GRC
211101_Thrace_UniversityGeneralHospitalOfAlexandroupolis_Primary,211101_Thrace_UniversityGeneralHospitalOfAlexandroupolis,"Prevalence of anti-SARS-CoV-2 IgG antibodies in a group of patients, a control group, and healthcare workers of thrace area in Greece, by the use of two distinct methods",2021-11-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Greece,Thrace,,"Furthermore, HWs of the University General Hospital of Alexandroupolis (Hospital 1), as well as workers from General Hospital of Didymoteicho (Hospital 2), Healthcare Centers of Alexandroupolis (HC 1), Orestiada (HC 2) Sufli, (HC 3), Dikaia (HC 4) and Samothraki (HC 5) (Figure 1), as high-risk group were also recruited in this study.",HWs who were ill or quarantined during the study period were excluded.,2020-06-15,2020-07-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1036,0.0058,,,True,,,,True,Self-referral,"EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit,Abbott Architect SARS-CoV-2 IgG","Epitope Diagnostics, Inc.,Abbott Laboratories",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Theocharis Konstantinidis,University General Hospital of Alexandroupolis,Not Unity-Aligned,http://dx.doi.org/10.18683/germs.2021.1274,2021-11-01,2024-03-01,Unverified,konstantinidis_prevalence_2021,GRC
211123_Athens_UniversityofAthens_June_Overall,211123_Athens_UniversityofAthens_June,"A study of the evolution of the third COVID-19 pandemic wave in the Athens metropolitan area, Greece, through two cross-sectional seroepidemiological surveys: March, June 2021.",2021-11-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Greece,Attica,Athens,"Participants were selected randomly among asymptomatic 
persons referred for blood sampling, irrespective of demographic or other 
characteristics, history of SARS-CoV-2 infection or COVID-19 vaccination, or reason 
for blood testing.","Symptomatic persons, persons whose permanent residence was out 
of Athens metropolitan area and healthcare personnel were excluded from the study. ",2021-06-01,2021-06-22,Residual sera,All,Multiple groups,,,Primary Estimate,,901,0.557,,,True,,,,True,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Helena Maltezou,University of Athens,Unity-Aligned,https://dx.doi.org/10.1002/jmv.27465,2021-12-01,2024-03-01,Verified,maltezou_study_2021,GRC
211123_Athens_UniversityofAthens_June_SexFemale,211123_Athens_UniversityofAthens_June,"A study of the evolution of the third COVID-19 pandemic wave in the Athens metropolitan area, Greece, through two cross-sectional seroepidemiological surveys: March, June 2021.",2021-11-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Greece,Attica,Athens,"Participants were selected randomly among asymptomatic 
persons referred for blood sampling, irrespective of demographic or other 
characteristics, history of SARS-CoV-2 infection or COVID-19 vaccination, or reason 
for blood testing.","Symptomatic persons, persons whose permanent residence was out 
of Athens metropolitan area and healthcare personnel were excluded from the study. ",2021-06-01,2021-06-22,Residual sera,Female,Multiple groups,,,Sex/Gender,,523,0.555,,,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Helena Maltezou,University of Athens,Unity-Aligned,https://dx.doi.org/10.1002/jmv.27465,2021-12-01,2024-03-01,Verified,maltezou_study_2021,GRC
211123_Athens_UniversityofAthens_June_SexMale,211123_Athens_UniversityofAthens_June,"A study of the evolution of the third COVID-19 pandemic wave in the Athens metropolitan area, Greece, through two cross-sectional seroepidemiological surveys: March, June 2021.",2021-11-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Greece,Attica,Athens,"Participants were selected randomly among asymptomatic 
persons referred for blood sampling, irrespective of demographic or other 
characteristics, history of SARS-CoV-2 infection or COVID-19 vaccination, or reason 
for blood testing.","Symptomatic persons, persons whose permanent residence was out 
of Athens metropolitan area and healthcare personnel were excluded from the study. ",2021-06-01,2021-06-22,Residual sera,Male,Multiple groups,,,Sex/Gender,,378,0.569,,,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Helena Maltezou,University of Athens,Unity-Aligned,https://dx.doi.org/10.1002/jmv.27465,2021-12-01,2024-03-01,Verified,maltezou_study_2021,GRC
211123_Athens_UniversityofAthens_March_Overall,211123_Athens_UniversityofAthens_March,"A study of the evolution of the third COVID-19 pandemic wave in the Athens metropolitan area, Greece, through two cross-sectional seroepidemiological surveys: March, June 2021.",2021-11-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Greece,Attica,Athens,"Participants were selected randomly among asymptomatic 
persons referred for blood sampling, irrespective of demographic or other 
characteristics, history of SARS-CoV-2 infection or COVID-19 vaccination, or reason 
for blood testing.","Symptomatic persons, persons whose permanent residence was out 
of Athens metropolitan area and healthcare personnel were excluded from the study. ",2021-03-01,2021-03-22,Residual sera,All,Multiple groups,,,Primary Estimate,,764,0.11599999999999999,,,True,,,,True,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Helena Maltezou,University of Athens,Unity-Aligned,https://dx.doi.org/10.1002/jmv.27465,2021-12-01,2024-03-01,Verified,maltezou_study_2021,GRC
211123_Athens_UniversityofAthens_March_SexMale,211123_Athens_UniversityofAthens_March,"A study of the evolution of the third COVID-19 pandemic wave in the Athens metropolitan area, Greece, through two cross-sectional seroepidemiological surveys: March, June 2021.",2021-11-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Greece,Attica,Athens,"Participants were selected randomly among asymptomatic 
persons referred for blood sampling, irrespective of demographic or other 
characteristics, history of SARS-CoV-2 infection or COVID-19 vaccination, or reason 
for blood testing.","Symptomatic persons, persons whose permanent residence was out 
of Athens metropolitan area and healthcare personnel were excluded from the study. ",2021-03-01,2021-03-22,Residual sera,Male,Multiple groups,,,Sex/Gender,,340,0.142,,,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Helena Maltezou,University of Athens,Unity-Aligned,https://dx.doi.org/10.1002/jmv.27465,2021-12-01,2024-03-01,Verified,maltezou_study_2021,GRC
211123_Athens_UniversityofAthens_March_SexFemale,211123_Athens_UniversityofAthens_March,"A study of the evolution of the third COVID-19 pandemic wave in the Athens metropolitan area, Greece, through two cross-sectional seroepidemiological surveys: March, June 2021.",2021-11-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Greece,Attica,Athens,"Participants were selected randomly among asymptomatic 
persons referred for blood sampling, irrespective of demographic or other 
characteristics, history of SARS-CoV-2 infection or COVID-19 vaccination, or reason 
for blood testing.","Symptomatic persons, persons whose permanent residence was out 
of Athens metropolitan area and healthcare personnel were excluded from the study. ",2021-03-01,2021-03-22,Residual sera,Female,Multiple groups,,,Sex/Gender,,424,0.095,,,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Helena Maltezou,University of Athens,Unity-Aligned,https://dx.doi.org/10.1002/jmv.27465,2021-12-01,2024-03-01,Verified,maltezou_study_2021,GRC
211231_Deskati_UniversityofThessaly_Overall,211231_Deskati_UniversityofThessaly,Defining antibody seroprevalence and duration of humoral responses to sars-cov-2 infection and/or vaccination in a greek community,2021-12-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Greece,West Macedonia,Deskati ,All the residents of Deskati who had been recruited to the first serosurveillance program (conducted in January 2021 [9]) were invited to participate in the follow-up program by the local authority and had been notified of the time and place thereof. Participants were recruited by announcing the research in the media while local officials organized a one-month recruitment campaign.,There were no exclusion criteria.,2021-06-06,2021-06-06,Household and community samples,All,Multiple groups,,,Primary Estimate,,69,0.7970999999999999,,,True,,,,True,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9990000000000001,1.0,['High'],Yes,No,No,Yes,Yes,Yes,Yes,Yes,No,Ourania Kotsiou,University of Thessaly,Unity-Aligned,https://dx.doi.org/10.3390/ijerph19010407,2022-01-08,2024-03-01,Verified,kotsiou_defining_2022,GRC
211231_Deskati_UniversityofThessaly_Male,211231_Deskati_UniversityofThessaly,Defining antibody seroprevalence and duration of humoral responses to sars-cov-2 infection and/or vaccination in a greek community,2021-12-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Greece,West Macedonia,Deskati ,All the residents of Deskati who had been recruited to the first serosurveillance program (conducted in January 2021 [9]) were invited to participate in the follow-up program by the local authority and had been notified of the time and place thereof. Participants were recruited by announcing the research in the media while local officials organized a one-month recruitment campaign.,There were no exclusion criteria.,2021-06-06,2021-06-06,Household and community samples,Male,Multiple groups,,,Sex/Gender,,31,0.871,,,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9990000000000001,1.0,['High'],Yes,No,No,Yes,Yes,Yes,Yes,Yes,No,Ourania Kotsiou,University of Thessaly,Unity-Aligned,https://dx.doi.org/10.3390/ijerph19010407,2022-01-08,2024-03-01,Verified,kotsiou_defining_2022,GRC
211231_Deskati_UniversityofThessaly_Female,211231_Deskati_UniversityofThessaly,Defining antibody seroprevalence and duration of humoral responses to sars-cov-2 infection and/or vaccination in a greek community,2021-12-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Greece,West Macedonia,Deskati ,All the residents of Deskati who had been recruited to the first serosurveillance program (conducted in January 2021 [9]) were invited to participate in the follow-up program by the local authority and had been notified of the time and place thereof. Participants were recruited by announcing the research in the media while local officials organized a one-month recruitment campaign.,There were no exclusion criteria.,2021-06-06,2021-06-06,Household and community samples,Female,Multiple groups,,,Sex/Gender,,38,0.7368000000000001,,,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9990000000000001,1.0,['High'],Yes,No,No,Yes,Yes,Yes,Yes,Yes,No,Ourania Kotsiou,University of Thessaly,Unity-Aligned,https://dx.doi.org/10.3390/ijerph19010407,2022-01-08,2024-03-01,Verified,kotsiou_defining_2022,GRC
211231_Deskati_UniversityofThessaly_VaccinatedYES,211231_Deskati_UniversityofThessaly,Defining antibody seroprevalence and duration of humoral responses to sars-cov-2 infection and/or vaccination in a greek community,2021-12-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Greece,West Macedonia,Deskati ,All the residents of Deskati who had been recruited to the first serosurveillance program (conducted in January 2021 [9]) were invited to participate in the follow-up program by the local authority and had been notified of the time and place thereof. Participants were recruited by announcing the research in the media while local officials organized a one-month recruitment campaign.,There were no exclusion criteria.,2021-06-06,2021-06-06,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,Vaccination YES,43,1.0,,,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9990000000000001,1.0,['High'],Yes,No,No,Yes,Yes,Yes,Yes,Yes,No,Ourania Kotsiou,University of Thessaly,Unity-Aligned,https://dx.doi.org/10.3390/ijerph19010407,2022-01-08,2024-03-01,Verified,kotsiou_defining_2022,GRC
211231_Deskati_UniversityofThessaly_VaccinatedNO,211231_Deskati_UniversityofThessaly,Defining antibody seroprevalence and duration of humoral responses to sars-cov-2 infection and/or vaccination in a greek community,2021-12-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Greece,West Macedonia,Deskati ,All the residents of Deskati who had been recruited to the first serosurveillance program (conducted in January 2021 [9]) were invited to participate in the follow-up program by the local authority and had been notified of the time and place thereof. Participants were recruited by announcing the research in the media while local officials organized a one-month recruitment campaign.,There were no exclusion criteria.,2021-06-06,2021-06-06,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,Vaccination NO,26,0.4615,,,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9990000000000001,1.0,['High'],Yes,No,No,Yes,Yes,Yes,Yes,Yes,No,Ourania Kotsiou,University of Thessaly,Unity-Aligned,https://dx.doi.org/10.3390/ijerph19010407,2022-01-08,2024-03-01,Verified,kotsiou_defining_2022,GRC
220121_Athens_NationalandKapodistrianUniversityofAthens_Overall,220121_Athens_NationalandKapodistrianUniversityofAthens,Seroepidemiology of SARS-CoV-2 in pediatric population during a 16-month period prior to vaccination.,2022-01-21,Journal Article (Peer-Reviewed),Local,Prospective cohort,Greece,,Athens,"""children who presented in the emergency department or were admitted for any reason to the‘'Aghia Sophia’’Children's Hospital""","""Children with proven COVID‐19 infection either withSARS‐CoV‐2 PCR or with the rapid test were excluded from the study. """,2020-05-01,2021-08-31,Residual sera,All,Children and Youth (0-17 years),,16.0,Primary Estimate,,3099,0.111,,,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,0.995,0.998,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Filippos Filippatos,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27608,2022-02-03,2022-07-16,Unverified,filippatos_seroepidemiology_2022,GRC
220121_Athens_NationalandKapodistrianUniversityofAthens_1st_Overall,220121_Athens_NationalandKapodistrianUniversityofAthens_1st,Seroepidemiology of SARS-CoV-2 in pediatric population during a 16-month period prior to vaccination.,2022-01-21,Journal Article (Peer-Reviewed),Local,Prospective cohort,Greece,,Athens,"""children who presented in the emergency department or were admitted for any reason to the‘'Aghia Sophia’’Children's Hospital""","""Children with proven COVID‐19 infection either withSARS‐CoV‐2 PCR or with the rapid test were excluded from the study. """,2020-05-01,2020-08-31,Residual sera,All,Children and Youth (0-17 years),0.0,16.0,Primary Estimate,,793,0.0139,,,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,0.995,0.998,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Filippos Filippatos,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27608,2022-02-18,2022-07-16,Unverified,filippatos_seroepidemiology_2022,GRC
220121_Athens_NationalandKapodistrianUniversityofAthens_1st_12-16,220121_Athens_NationalandKapodistrianUniversityofAthens_1st,Seroepidemiology of SARS-CoV-2 in pediatric population during a 16-month period prior to vaccination.,2022-01-21,Journal Article (Peer-Reviewed),Local,Prospective cohort,Greece,,Athens,"""children who presented in the emergency department or were admitted for any reason to the‘'Aghia Sophia’’Children's Hospital""","""Children with proven COVID‐19 infection either withSARS‐CoV‐2 PCR or with the rapid test were excluded from the study. """,2020-05-01,2020-08-31,Residual sera,All,Children and Youth (0-17 years),12.0,16.0,Age,12-16,129,0.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,0.995,0.998,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Filippos Filippatos,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27608,2022-02-18,2022-07-16,Unverified,filippatos_seroepidemiology_2022,GRC
220121_Athens_NationalandKapodistrianUniversityofAthens_1st_4-6,220121_Athens_NationalandKapodistrianUniversityofAthens_1st,Seroepidemiology of SARS-CoV-2 in pediatric population during a 16-month period prior to vaccination.,2022-01-21,Journal Article (Peer-Reviewed),Local,Prospective cohort,Greece,,Athens,"""children who presented in the emergency department or were admitted for any reason to the‘'Aghia Sophia’’Children's Hospital""","""Children with proven COVID‐19 infection either withSARS‐CoV‐2 PCR or with the rapid test were excluded from the study. """,2020-05-01,2020-08-31,Residual sera,All,Children and Youth (0-17 years),4.0,6.0,Age,4-6,66,0.0758,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,0.995,0.998,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Filippos Filippatos,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27608,2022-02-18,2022-07-16,Unverified,filippatos_seroepidemiology_2022,GRC
220121_Athens_NationalandKapodistrianUniversityofAthens_1st_0-1,220121_Athens_NationalandKapodistrianUniversityofAthens_1st,Seroepidemiology of SARS-CoV-2 in pediatric population during a 16-month period prior to vaccination.,2022-01-21,Journal Article (Peer-Reviewed),Local,Prospective cohort,Greece,,Athens,"""children who presented in the emergency department or were admitted for any reason to the‘'Aghia Sophia’’Children's Hospital""","""Children with proven COVID‐19 infection either withSARS‐CoV‐2 PCR or with the rapid test were excluded from the study. """,2020-05-01,2020-08-31,Residual sera,All,Children and Youth (0-17 years),0.0,1.0,Age,0-1,213,0.0235,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,0.995,0.998,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Filippos Filippatos,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27608,2022-02-18,2022-07-16,Unverified,filippatos_seroepidemiology_2022,GRC
220121_Athens_NationalandKapodistrianUniversityofAthens_1st_1-4,220121_Athens_NationalandKapodistrianUniversityofAthens_1st,Seroepidemiology of SARS-CoV-2 in pediatric population during a 16-month period prior to vaccination.,2022-01-21,Journal Article (Peer-Reviewed),Local,Prospective cohort,Greece,,Athens,"""children who presented in the emergency department or were admitted for any reason to the‘'Aghia Sophia’’Children's Hospital""","""Children with proven COVID‐19 infection either withSARS‐CoV‐2 PCR or with the rapid test were excluded from the study. """,2020-05-01,2020-08-31,Residual sera,All,Children and Youth (0-17 years),1.0,4.0,Age,1-4,145,0.0069,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,0.995,0.998,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Filippos Filippatos,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27608,2022-02-18,2022-07-16,Unverified,filippatos_seroepidemiology_2022,GRC
220121_Athens_NationalandKapodistrianUniversityofAthens_1st_6-12,220121_Athens_NationalandKapodistrianUniversityofAthens_1st,Seroepidemiology of SARS-CoV-2 in pediatric population during a 16-month period prior to vaccination.,2022-01-21,Journal Article (Peer-Reviewed),Local,Prospective cohort,Greece,,Athens,"""children who presented in the emergency department or were admitted for any reason to the‘'Aghia Sophia’’Children's Hospital""","""Children with proven COVID‐19 infection either withSARS‐CoV‐2 PCR or with the rapid test were excluded from the study. """,2020-05-01,2020-08-31,Residual sera,All,Children and Youth (0-17 years),6.0,12.0,Age,6-12,240,0.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,0.995,0.998,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Filippos Filippatos,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27608,2022-02-18,2022-07-16,Unverified,filippatos_seroepidemiology_2022,GRC
220121_Athens_NationalandKapodistrianUniversityofAthens_2nd_0-1,220121_Athens_NationalandKapodistrianUniversityofAthens_2nd,Seroepidemiology of SARS-CoV-2 in pediatric population during a 16-month period prior to vaccination.,2022-01-21,Journal Article (Peer-Reviewed),Local,Prospective cohort,Greece,,Athens,"""children who presented in the emergency department or were admitted for any reason to the‘'Aghia Sophia’’Children's Hospital""","""Children with proven COVID‐19 infection either withSARS‐CoV‐2 PCR or with the rapid test were excluded from the study. """,2020-09-01,2020-12-31,Residual sera,All,Children and Youth (0-17 years),0.0,1.0,Age,0-1,211,0.109,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,0.995,0.998,['High'],,Unclear,No,Yes,,Unclear,Yes,No,,Filippos Filippatos,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27608,2022-02-18,2022-07-16,Unverified,filippatos_seroepidemiology_2022,GRC
220121_Athens_NationalandKapodistrianUniversityofAthens_2nd_1-4,220121_Athens_NationalandKapodistrianUniversityofAthens_2nd,Seroepidemiology of SARS-CoV-2 in pediatric population during a 16-month period prior to vaccination.,2022-01-21,Journal Article (Peer-Reviewed),Local,Prospective cohort,Greece,,Athens,"""children who presented in the emergency department or were admitted for any reason to the‘'Aghia Sophia’’Children's Hospital""","""Children with proven COVID‐19 infection either withSARS‐CoV‐2 PCR or with the rapid test were excluded from the study. """,2020-09-01,2020-12-31,Residual sera,All,Children and Youth (0-17 years),1.0,4.0,Age,1-4,151,0.0728,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,0.995,0.998,['High'],,Unclear,No,Yes,,Unclear,Yes,No,,Filippos Filippatos,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27608,2022-02-18,2022-07-16,Unverified,filippatos_seroepidemiology_2022,GRC
220121_Athens_NationalandKapodistrianUniversityofAthens_2nd_4-6,220121_Athens_NationalandKapodistrianUniversityofAthens_2nd,Seroepidemiology of SARS-CoV-2 in pediatric population during a 16-month period prior to vaccination.,2022-01-21,Journal Article (Peer-Reviewed),Local,Prospective cohort,Greece,,Athens,"""children who presented in the emergency department or were admitted for any reason to the‘'Aghia Sophia’’Children's Hospital""","""Children with proven COVID‐19 infection either withSARS‐CoV‐2 PCR or with the rapid test were excluded from the study. """,2020-09-01,2020-12-31,Residual sera,All,Children and Youth (0-17 years),4.0,6.0,Age,4-6,51,0.1373,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,0.995,0.998,['High'],,Unclear,No,Yes,,Unclear,Yes,No,,Filippos Filippatos,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27608,2022-02-18,2022-07-16,Unverified,filippatos_seroepidemiology_2022,GRC
220121_Athens_NationalandKapodistrianUniversityofAthens_2nd_12-16,220121_Athens_NationalandKapodistrianUniversityofAthens_2nd,Seroepidemiology of SARS-CoV-2 in pediatric population during a 16-month period prior to vaccination.,2022-01-21,Journal Article (Peer-Reviewed),Local,Prospective cohort,Greece,,Athens,"""children who presented in the emergency department or were admitted for any reason to the‘'Aghia Sophia’’Children's Hospital""","""Children with proven COVID‐19 infection either withSARS‐CoV‐2 PCR or with the rapid test were excluded from the study. """,2020-09-01,2020-12-31,Residual sera,All,Children and Youth (0-17 years),12.0,16.0,Age,12-16,128,0.10160000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,0.995,0.998,['High'],,Unclear,No,Yes,,Unclear,Yes,No,,Filippos Filippatos,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27608,2022-02-18,2022-07-16,Unverified,filippatos_seroepidemiology_2022,GRC
220121_Athens_NationalandKapodistrianUniversityofAthens_2nd_6-12,220121_Athens_NationalandKapodistrianUniversityofAthens_2nd,Seroepidemiology of SARS-CoV-2 in pediatric population during a 16-month period prior to vaccination.,2022-01-21,Journal Article (Peer-Reviewed),Local,Prospective cohort,Greece,,Athens,"""children who presented in the emergency department or were admitted for any reason to the‘'Aghia Sophia’’Children's Hospital""","""Children with proven COVID‐19 infection either withSARS‐CoV‐2 PCR or with the rapid test were excluded from the study. """,2020-09-01,2020-12-31,Residual sera,All,Children and Youth (0-17 years),6.0,12.0,Age,6-12,234,0.0556,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,0.995,0.998,['High'],,Unclear,No,Yes,,Unclear,Yes,No,,Filippos Filippatos,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27608,2022-02-18,2022-07-16,Unverified,filippatos_seroepidemiology_2022,GRC
220121_Athens_NationalandKapodistrianUniversityofAthens_3rd_4-6,220121_Athens_NationalandKapodistrianUniversityofAthens_3rd,Seroepidemiology of SARS-CoV-2 in pediatric population during a 16-month period prior to vaccination.,2022-01-21,Journal Article (Peer-Reviewed),Local,Prospective cohort,Greece,,Athens,"""children who presented in the emergency department or were admitted for any reason to the‘'Aghia Sophia’’Children's Hospital""","""Children with proven COVID‐19 infection either withSARS‐CoV‐2 PCR or with the rapid test were excluded from the study. """,2021-01-01,2021-04-30,Residual sera,All,Children and Youth (0-17 years),4.0,6.0,Age,4-6,67,0.209,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,0.995,0.998,['High'],,Unclear,No,Yes,,Unclear,Yes,No,,Filippos Filippatos,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27608,2022-02-19,2022-07-16,Unverified,filippatos_seroepidemiology_2022,GRC
220121_Athens_NationalandKapodistrianUniversityofAthens_3rd_12-16,220121_Athens_NationalandKapodistrianUniversityofAthens_3rd,Seroepidemiology of SARS-CoV-2 in pediatric population during a 16-month period prior to vaccination.,2022-01-21,Journal Article (Peer-Reviewed),Local,Prospective cohort,Greece,,Athens,"""children who presented in the emergency department or were admitted for any reason to the‘'Aghia Sophia’’Children's Hospital""","""Children with proven COVID‐19 infection either withSARS‐CoV‐2 PCR or with the rapid test were excluded from the study. """,2021-01-01,2021-04-30,Residual sera,All,Children and Youth (0-17 years),12.0,16.0,Age,12-16,120,0.15,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,0.995,0.998,['High'],,Unclear,No,Yes,,Unclear,Yes,No,,Filippos Filippatos,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27608,2022-02-19,2022-07-16,Unverified,filippatos_seroepidemiology_2022,GRC
220121_Athens_NationalandKapodistrianUniversityofAthens_3rd_1-4,220121_Athens_NationalandKapodistrianUniversityofAthens_3rd,Seroepidemiology of SARS-CoV-2 in pediatric population during a 16-month period prior to vaccination.,2022-01-21,Journal Article (Peer-Reviewed),Local,Prospective cohort,Greece,,Athens,"""children who presented in the emergency department or were admitted for any reason to the‘'Aghia Sophia’’Children's Hospital""","""Children with proven COVID‐19 infection either withSARS‐CoV‐2 PCR or with the rapid test were excluded from the study. """,2021-01-01,2021-04-30,Residual sera,All,Children and Youth (0-17 years),1.0,4.0,Age,1-4,156,0.16030000000000003,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,0.995,0.998,['High'],,Unclear,No,Yes,,Unclear,Yes,No,,Filippos Filippatos,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27608,2022-02-19,2022-07-16,Unverified,filippatos_seroepidemiology_2022,GRC
220121_Athens_NationalandKapodistrianUniversityofAthens_3rd_6-12,220121_Athens_NationalandKapodistrianUniversityofAthens_3rd,Seroepidemiology of SARS-CoV-2 in pediatric population during a 16-month period prior to vaccination.,2022-01-21,Journal Article (Peer-Reviewed),Local,Prospective cohort,Greece,,Athens,"""children who presented in the emergency department or were admitted for any reason to the‘'Aghia Sophia’’Children's Hospital""","""Children with proven COVID‐19 infection either withSARS‐CoV‐2 PCR or with the rapid test were excluded from the study. """,2021-01-01,2021-04-30,Residual sera,All,Children and Youth (0-17 years),6.0,12.0,Age,6-12,179,0.1341,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,0.995,0.998,['High'],,Unclear,No,Yes,,Unclear,Yes,No,,Filippos Filippatos,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27608,2022-02-19,2022-07-16,Unverified,filippatos_seroepidemiology_2022,GRC
220121_Athens_NationalandKapodistrianUniversityofAthens_3rd_0-1,220121_Athens_NationalandKapodistrianUniversityofAthens_3rd,Seroepidemiology of SARS-CoV-2 in pediatric population during a 16-month period prior to vaccination.,2022-01-21,Journal Article (Peer-Reviewed),Local,Prospective cohort,Greece,,Athens,"""children who presented in the emergency department or were admitted for any reason to the‘'Aghia Sophia’’Children's Hospital""","""Children with proven COVID‐19 infection either withSARS‐CoV‐2 PCR or with the rapid test were excluded from the study. """,2021-01-01,2021-04-30,Residual sera,All,Children and Youth (0-17 years),0.0,1.0,Age,0-1,253,0.20550000000000002,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,0.995,0.998,['High'],,Unclear,No,Yes,,Unclear,Yes,No,,Filippos Filippatos,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27608,2022-02-18,2022-07-16,Unverified,filippatos_seroepidemiology_2022,GRC
220121_Athens_NationalandKapodistrianUniversityofAthens_4th_6-12,220121_Athens_NationalandKapodistrianUniversityofAthens_4th,Seroepidemiology of SARS-CoV-2 in pediatric population during a 16-month period prior to vaccination.,2022-01-21,Journal Article (Peer-Reviewed),Local,Prospective cohort,Greece,,Athens,"""children who presented in the emergency department or were admitted for any reason to the‘'Aghia Sophia’’Children's Hospital""","""Children with proven COVID‐19 infection either withSARS‐CoV‐2 PCR or with the rapid test were excluded from the study. """,2021-05-01,2021-08-31,Residual sera,All,Children and Youth (0-17 years),6.0,12.0,Age,6-12,229,0.1441,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,0.995,0.998,['High'],,Unclear,No,Yes,,Unclear,Yes,No,,Filippos Filippatos,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27608,2022-02-19,2022-07-16,Unverified,filippatos_seroepidemiology_2022,GRC
220121_Athens_NationalandKapodistrianUniversityofAthens_4th_0-1,220121_Athens_NationalandKapodistrianUniversityofAthens_4th,Seroepidemiology of SARS-CoV-2 in pediatric population during a 16-month period prior to vaccination.,2022-01-21,Journal Article (Peer-Reviewed),Local,Prospective cohort,Greece,,Athens,"""children who presented in the emergency department or were admitted for any reason to the‘'Aghia Sophia’’Children's Hospital""","""Children with proven COVID‐19 infection either withSARS‐CoV‐2 PCR or with the rapid test were excluded from the study. """,2021-05-01,2021-08-31,Residual sera,All,Children and Youth (0-17 years),0.0,1.0,Age,0-1,160,0.2,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,0.995,0.998,['High'],,Unclear,No,Yes,,Unclear,Yes,No,,Filippos Filippatos,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27608,2022-02-19,2022-07-16,Unverified,filippatos_seroepidemiology_2022,GRC
220121_Athens_NationalandKapodistrianUniversityofAthens_4th_1-4,220121_Athens_NationalandKapodistrianUniversityofAthens_4th,Seroepidemiology of SARS-CoV-2 in pediatric population during a 16-month period prior to vaccination.,2022-01-21,Journal Article (Peer-Reviewed),Local,Prospective cohort,Greece,,Athens,"""children who presented in the emergency department or were admitted for any reason to the‘'Aghia Sophia’’Children's Hospital""","""Children with proven COVID‐19 infection either withSARS‐CoV‐2 PCR or with the rapid test were excluded from the study. """,2021-05-01,2021-08-31,Residual sera,All,Children and Youth (0-17 years),1.0,4.0,Age,1-4,190,0.1895,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,0.995,0.998,['High'],,Unclear,No,Yes,,Unclear,Yes,No,,Filippos Filippatos,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27608,2022-02-19,2022-07-16,Unverified,filippatos_seroepidemiology_2022,GRC
220121_Athens_NationalandKapodistrianUniversityofAthens_4th_12-16,220121_Athens_NationalandKapodistrianUniversityofAthens_4th,Seroepidemiology of SARS-CoV-2 in pediatric population during a 16-month period prior to vaccination.,2022-01-21,Journal Article (Peer-Reviewed),Local,Prospective cohort,Greece,,Athens,"""children who presented in the emergency department or were admitted for any reason to the‘'Aghia Sophia’’Children's Hospital""","""Children with proven COVID‐19 infection either withSARS‐CoV‐2 PCR or with the rapid test were excluded from the study. """,2021-05-01,2021-08-31,Residual sera,All,Children and Youth (0-17 years),12.0,16.0,Age,12-16,124,0.16940000000000002,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,0.995,0.998,['High'],,Unclear,No,Yes,,Unclear,Yes,No,,Filippos Filippatos,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27608,2022-02-19,2022-07-16,Unverified,filippatos_seroepidemiology_2022,GRC
220121_Athens_NationalandKapodistrianUniversityofAthens_4th_4-6,220121_Athens_NationalandKapodistrianUniversityofAthens_4th,Seroepidemiology of SARS-CoV-2 in pediatric population during a 16-month period prior to vaccination.,2022-01-21,Journal Article (Peer-Reviewed),Local,Prospective cohort,Greece,,Athens,"""children who presented in the emergency department or were admitted for any reason to the‘'Aghia Sophia’’Children's Hospital""","""Children with proven COVID‐19 infection either withSARS‐CoV‐2 PCR or with the rapid test were excluded from the study. """,2021-05-01,2021-08-31,Residual sera,All,Children and Youth (0-17 years),4.0,6.0,Age,4-6,53,0.20750000000000002,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,0.995,0.998,['High'],,Unclear,No,Yes,,Unclear,Yes,No,,Filippos Filippatos,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27608,2022-02-19,2022-07-16,Unverified,filippatos_seroepidemiology_2022,GRC
220125_Greece_UniversityofThessaly_Overall,220125_Greece_UniversityofThessaly_Overall,SARS-CoV-2 Sero-Surveillance in Greece: Evolution over Time and Epidemiological Attributes during the Pre-Vaccination Pandemic Era,2022-01-25,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Greece,,,Individuals who visited the laboratories for routine screening and reasons unrelated to COVID-19.,,2020-03-01,2020-12-31,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,55947,0.0126,,,True,,,,True,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,0.997,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Michalis Koureas,University of Thessaly,Unity-Aligned,https://www.mdpi.com/2075-4418/12/2/295,2022-05-28,2024-03-01,Verified,koureas_sars-cov-2_2022,GRC
220125_Greece_UniversityofThessaly_October2020_PopAdj,220125_Greece_UniversityofThessaly_Overall,SARS-CoV-2 Sero-Surveillance in Greece: Evolution over Time and Epidemiological Attributes during the Pre-Vaccination Pandemic Era,2022-01-25,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Greece,,,Individuals who visited the laboratories for routine screening and reasons unrelated to COVID-19.,,2020-10-01,2020-10-31,Residual sera,All,Multiple groups,0.0,,Time frame,,8160,0.0181,0.013700000000000002,0.0225,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,0.997,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Michalis Koureas,University of Thessaly,Unity-Aligned,https://www.mdpi.com/2075-4418/12/2/295,2022-02-25,2024-03-01,Verified,koureas_sars-cov-2_2022,GRC
220125_Greece_UniversityofThessaly_September2020_PopAdj,220125_Greece_UniversityofThessaly_Overall,SARS-CoV-2 Sero-Surveillance in Greece: Evolution over Time and Epidemiological Attributes during the Pre-Vaccination Pandemic Era,2022-01-25,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Greece,,,Individuals who visited the laboratories for routine screening and reasons unrelated to COVID-19.,,2020-09-01,2020-09-30,Residual sera,All,Multiple groups,0.0,,Time frame,,7789,0.0111,0.0075,0.0148,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,0.997,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Michalis Koureas,University of Thessaly,Unity-Aligned,https://www.mdpi.com/2075-4418/12/2/295,2022-02-25,2024-03-01,Verified,koureas_sars-cov-2_2022,GRC
220125_Greece_UniversityofThessaly_December2020_PopAdj,220125_Greece_UniversityofThessaly_Overall,SARS-CoV-2 Sero-Surveillance in Greece: Evolution over Time and Epidemiological Attributes during the Pre-Vaccination Pandemic Era,2022-01-25,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Greece,,,Individuals who visited the laboratories for routine screening and reasons unrelated to COVID-19.,,2020-12-01,2020-12-31,Residual sera,All,Multiple groups,0.0,,Time frame,,6231,0.0791,0.067,0.0913,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,0.997,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Michalis Koureas,University of Thessaly,Unity-Aligned,https://www.mdpi.com/2075-4418/12/2/295,2022-02-25,2024-03-01,Verified,koureas_sars-cov-2_2022,GRC
220125_Greece_UniversityofThessaly_November2020_PopAdj,220125_Greece_UniversityofThessaly_Overall,SARS-CoV-2 Sero-Surveillance in Greece: Evolution over Time and Epidemiological Attributes during the Pre-Vaccination Pandemic Era,2022-01-25,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Greece,,,Individuals who visited the laboratories for routine screening and reasons unrelated to COVID-19.,,2020-11-01,2020-11-30,Residual sera,All,Multiple groups,0.0,,Time frame,,7069,0.030600000000000002,0.024,0.037200000000000004,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,0.997,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,No,,Michalis Koureas,University of Thessaly,Unity-Aligned,https://www.mdpi.com/2075-4418/12/2/295,2022-02-25,2024-03-01,Verified,koureas_sars-cov-2_2022,GRC
220517_Greece_UniversityofThessaly_Domokos_Overall,220517_Greece_UniversityofThessaly_Domokos,Lessons We Have Learned Regarding Seroprevalence in High and Low SARS-CoV-2 Contexts in Greece before the Omicron Pandemic Wave,2022-05-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Greece,Phthiotis,Dokomos,All the residents of Malesina and Domokos were invited to participate in the pro- gram by the local authority and had been notified of the time and place thereof.,"NR ""xclusion criteria were not considered as we aimed for a population-centered, epidemiological approach, i.e., an attempt to capture an accurate reflection of the population under study, rather than a specific subset.""",2021-07-09,2021-07-09,Household and community samples,All,Multiple groups,,,Primary Estimate,,151,0.775,,,True,,,,True,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,1.0,['High'],,No,No,Yes,,Yes,Yes,Yes,,Ourania Kotsiou,University of Thessaly,Unity-Aligned,https://dx.doi.org/10.3390/ijerph19106110,2022-06-02,2024-03-01,Unverified,kotsiou_lessions_2022,GRC
220517_Greece_UniversityofThessaly_Domokos_Male,220517_Greece_UniversityofThessaly_Domokos,Lessons We Have Learned Regarding Seroprevalence in High and Low SARS-CoV-2 Contexts in Greece before the Omicron Pandemic Wave,2022-05-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Greece,Phthiotis,Dokomos,All the residents of Malesina and Domokos were invited to participate in the pro- gram by the local authority and had been notified of the time and place thereof.,"NR ""xclusion criteria were not considered as we aimed for a population-centered, epidemiological approach, i.e., an attempt to capture an accurate reflection of the population under study, rather than a specific subset.""",2021-07-09,2021-07-09,Household and community samples,Male,Multiple groups,,,Sex/Gender,,84,0.798,,,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,1.0,['High'],,No,No,Yes,,Yes,Yes,Yes,,Ourania Kotsiou,University of Thessaly,Unity-Aligned,https://dx.doi.org/10.3390/ijerph19106110,2022-06-02,2024-03-01,Unverified,kotsiou_lessions_2022,GRC
220517_Greece_UniversityofThessaly_Domokos_NotVaccinated,220517_Greece_UniversityofThessaly_Domokos,Lessons We Have Learned Regarding Seroprevalence in High and Low SARS-CoV-2 Contexts in Greece before the Omicron Pandemic Wave,2022-05-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Greece,Phthiotis,Dokomos,All the residents of Malesina and Domokos were invited to participate in the pro- gram by the local authority and had been notified of the time and place thereof.,"NR ""xclusion criteria were not considered as we aimed for a population-centered, epidemiological approach, i.e., an attempt to capture an accurate reflection of the population under study, rather than a specific subset.""",2021-07-09,2021-07-09,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,not vaccinated,51,0.373,,,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,1.0,['High'],,No,No,Yes,,Yes,Yes,Yes,,Ourania Kotsiou,University of Thessaly,Unity-Aligned,https://dx.doi.org/10.3390/ijerph19106110,2022-06-02,2024-03-01,Unverified,kotsiou_lessions_2022,GRC
220517_Greece_UniversityofThessaly_Domokos_Female,220517_Greece_UniversityofThessaly_Domokos,Lessons We Have Learned Regarding Seroprevalence in High and Low SARS-CoV-2 Contexts in Greece before the Omicron Pandemic Wave,2022-05-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Greece,Phthiotis,Dokomos,All the residents of Malesina and Domokos were invited to participate in the pro- gram by the local authority and had been notified of the time and place thereof.,"NR ""xclusion criteria were not considered as we aimed for a population-centered, epidemiological approach, i.e., an attempt to capture an accurate reflection of the population under study, rather than a specific subset.""",2021-07-09,2021-07-09,Household and community samples,Female,Multiple groups,,,Sex/Gender,,67,0.746,,,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,1.0,['High'],,No,No,Yes,,Yes,Yes,Yes,,Ourania Kotsiou,University of Thessaly,Unity-Aligned,https://dx.doi.org/10.3390/ijerph19106110,2022-06-02,2024-03-01,Unverified,kotsiou_lessions_2022,GRC
220517_Greece_UniversityofThessaly_Domokos_Vaccinated,220517_Greece_UniversityofThessaly_Domokos,Lessons We Have Learned Regarding Seroprevalence in High and Low SARS-CoV-2 Contexts in Greece before the Omicron Pandemic Wave,2022-05-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Greece,Phthiotis,Dokomos,All the residents of Malesina and Domokos were invited to participate in the pro- gram by the local authority and had been notified of the time and place thereof.,"NR ""xclusion criteria were not considered as we aimed for a population-centered, epidemiological approach, i.e., an attempt to capture an accurate reflection of the population under study, rather than a specific subset.""",2021-07-09,2021-07-09,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,fully/partially vaccinated,100,0.98,,,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,1.0,['High'],,No,No,Yes,,Yes,Yes,Yes,,Ourania Kotsiou,University of Thessaly,Unity-Aligned,https://dx.doi.org/10.3390/ijerph19106110,2022-06-02,2024-03-01,Unverified,kotsiou_lessions_2022,GRC
220517_Greece_UniversityofThessaly_Malesina_Overall,220517_Greece_UniversityofThessaly_Malesina,Lessons We Have Learned Regarding Seroprevalence in High and Low SARS-CoV-2 Contexts in Greece before the Omicron Pandemic Wave,2022-05-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Greece,Phthiotis,Malesina,All the residents of Malesina and Domokos were invited to participate in the pro- gram by the local authority and had been notified of the time and place thereof.,"NR ""xclusion criteria were not considered as we aimed for a population-centered, epidemiological approach, i.e., an attempt to capture an accurate reflection of the population under study, rather than a specific subset.""",2021-06-14,2021-06-16,Household and community samples,All,Multiple groups,,,Primary Estimate,,525,0.775,,,True,,,,True,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,1.0,['High'],,No,No,Yes,,Yes,Yes,Yes,,Ourania Kotsiou,University of Thessaly,Unity-Aligned,https://dx.doi.org/10.3390/ijerph19106110,2022-06-02,2024-03-01,Unverified,kotsiou_lessions_2022,GRC
220517_Greece_UniversityofThessaly_Malesina_Male,220517_Greece_UniversityofThessaly_Malesina,Lessons We Have Learned Regarding Seroprevalence in High and Low SARS-CoV-2 Contexts in Greece before the Omicron Pandemic Wave,2022-05-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Greece,Phthiotis,Malesina,All the residents of Malesina and Domokos were invited to participate in the pro- gram by the local authority and had been notified of the time and place thereof.,"NR ""xclusion criteria were not considered as we aimed for a population-centered, epidemiological approach, i.e., an attempt to capture an accurate reflection of the population under study, rather than a specific subset.""",2021-06-14,2021-06-16,Household and community samples,Male,Multiple groups,,,Sex/Gender,,150,0.873,,,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,1.0,['High'],,No,No,Yes,,Yes,Yes,Yes,,Ourania Kotsiou,University of Thessaly,Unity-Aligned,https://dx.doi.org/10.3390/ijerph19106110,2022-06-02,2024-03-01,Unverified,kotsiou_lessions_2022,GRC
220517_Greece_UniversityofThessaly_Malesina_Vaccinated,220517_Greece_UniversityofThessaly_Malesina,Lessons We Have Learned Regarding Seroprevalence in High and Low SARS-CoV-2 Contexts in Greece before the Omicron Pandemic Wave,2022-05-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Greece,Phthiotis,Malesina,All the residents of Malesina and Domokos were invited to participate in the pro- gram by the local authority and had been notified of the time and place thereof.,"NR ""xclusion criteria were not considered as we aimed for a population-centered, epidemiological approach, i.e., an attempt to capture an accurate reflection of the population under study, rather than a specific subset.""",2021-06-14,2021-06-16,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,fully/partially vaccinated,218,0.908,,,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,1.0,['High'],,No,No,Yes,,Yes,Yes,Yes,,Ourania Kotsiou,University of Thessaly,Unity-Aligned,https://dx.doi.org/10.3390/ijerph19106110,2022-06-02,2024-03-01,Unverified,kotsiou_lessions_2022,GRC
220517_Greece_UniversityofThessaly_Malesina_NotVaccinated,220517_Greece_UniversityofThessaly_Malesina,Lessons We Have Learned Regarding Seroprevalence in High and Low SARS-CoV-2 Contexts in Greece before the Omicron Pandemic Wave,2022-05-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Greece,Phthiotis,Malesina,All the residents of Malesina and Domokos were invited to participate in the pro- gram by the local authority and had been notified of the time and place thereof.,"NR ""xclusion criteria were not considered as we aimed for a population-centered, epidemiological approach, i.e., an attempt to capture an accurate reflection of the population under study, rather than a specific subset.""",2021-06-14,2021-06-16,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,not vaccinated,307,0.6809999999999999,,,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,1.0,['High'],,No,No,Yes,,Yes,Yes,Yes,,Ourania Kotsiou,University of Thessaly,Unity-Aligned,https://dx.doi.org/10.3390/ijerph19106110,2022-06-02,2024-03-01,Unverified,kotsiou_lessions_2022,GRC
220517_Greece_UniversityofThessaly_Malesina_Female,220517_Greece_UniversityofThessaly_Malesina,Lessons We Have Learned Regarding Seroprevalence in High and Low SARS-CoV-2 Contexts in Greece before the Omicron Pandemic Wave,2022-05-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Greece,Phthiotis,Malesina,All the residents of Malesina and Domokos were invited to participate in the pro- gram by the local authority and had been notified of the time and place thereof.,"NR ""xclusion criteria were not considered as we aimed for a population-centered, epidemiological approach, i.e., an attempt to capture an accurate reflection of the population under study, rather than a specific subset.""",2021-06-14,2021-06-16,Household and community samples,Female,Multiple groups,,,Sex/Gender,,375,0.736,,,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,1.0,['High'],,No,No,Yes,,Yes,Yes,Yes,,Ourania Kotsiou,University of Thessaly,Unity-Aligned,https://dx.doi.org/10.3390/ijerph19106110,2022-06-02,2024-03-01,Unverified,kotsiou_lessions_2022,GRC
221019_Athens_NationalandKapodistrianUniversityofAthens_Overall,221019_Athens_NationalandKapodistrianUniversityofAthens,SARS-CoV-2 seroepidemiology in pediatric population during Delta and Omicron predominance,2022-10-19,Journal Article (Peer-Reviewed),Local,Prospective cohort,Greece,,Athens,Children hospitalized in ‘Aghia Sophia’ Children’s Hospital for any reason. Children's serum samples prospectively collected from 01/09/2021 to 30/04/2022.,"Children with proven SARS-CoV-2 infection either with SARS-CoV-2 molecular testing or with the rapid test were excluded from the study. If a child was admitted to the hospital more than once within the study period and the results of his antibody test results were positive, only those of the first positive result were included in the analysis. Serum samples from children admitted to the Departments of Oncology, Bleeding Disorders or B-Thalassemia were excluded from the study due to transfusions or immunocompromised conditions that may affect antibody detection.",2021-09-01,2022-04-30,Blood donors,All,Children and Youth (0-17 years),0.0,16.0,Primary Estimate,8 month estimate,1312,0.386,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Filippos Filippatos,Nationaland Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268822001601,2022-11-17,2024-03-01,Unverified,filippatos_sars-cov-2_2022,GRC
221019_Athens_NationalandKapodistrianUniversityofAthens_Omicron,221019_Athens_NationalandKapodistrianUniversityofAthens,SARS-CoV-2 seroepidemiology in pediatric population during Delta and Omicron predominance,2022-10-19,Journal Article (Peer-Reviewed),Local,Prospective cohort,Greece,,Athens,Children hospitalized in ‘Aghia Sophia’ Children’s Hospital for any reason. Children's serum samples prospectively collected from 01/09/2021 to 30/04/2022.,"Children with proven SARS-CoV-2 infection either with SARS-CoV-2 molecular testing or with the rapid test were excluded from the study. If a child was admitted to the hospital more than once within the study period and the results of his antibody test results were positive, only those of the first positive result were included in the analysis. Serum samples from children admitted to the Departments of Oncology, Bleeding Disorders or B-Thalassemia were excluded from the study due to transfusions or immunocompromised conditions that may affect antibody detection.",2022-01-01,2022-04-30,Blood donors,All,Children and Youth (0-17 years),0.0,16.0,Time frame,4 month estimate in Omicron period,619,0.485,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Filippos Filippatos,Nationaland Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268822001601,2022-11-17,2024-03-01,Unverified,filippatos_sars-cov-2_2022,GRC
221019_Athens_NationalandKapodistrianUniversityofAthens_Delta,221019_Athens_NationalandKapodistrianUniversityofAthens,SARS-CoV-2 seroepidemiology in pediatric population during Delta and Omicron predominance,2022-10-19,Journal Article (Peer-Reviewed),Local,Prospective cohort,Greece,,Athens,Children hospitalized in ‘Aghia Sophia’ Children’s Hospital for any reason. Children's serum samples prospectively collected from 01/09/2021 to 30/04/2022.,"Children with proven SARS-CoV-2 infection either with SARS-CoV-2 molecular testing or with the rapid test were excluded from the study. If a child was admitted to the hospital more than once within the study period and the results of his antibody test results were positive, only those of the first positive result were included in the analysis. Serum samples from children admitted to the Departments of Oncology, Bleeding Disorders or B-Thalassemia were excluded from the study due to transfusions or immunocompromised conditions that may affect antibody detection.",2021-09-01,2021-12-31,Blood donors,All,Children and Youth (0-17 years),0.0,16.0,Time frame,4 month estimate in Delta period,693,0.297,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Filippos Filippatos,Nationaland Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268822001601,2022-11-17,2024-03-01,Unverified,filippatos_sars-cov-2_2022,GRC
221116_Greece_NationalandKapodistrianUniversityofAthens_Children,221116_Greece_NationalandKapodistrianUniversityofAthens_Children,Seroprevalence of anti-SARS-CoV-2 antibodies among children and their parents in Greece.,2022-11-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Greece,,,"""Children and adolescents 0–16 years of age and their parents presenting in the emergency department or in the outpatient clinics or admitted to the hospital for any reason were candidates for enrollment in the study.""","""Children or parents, who had symptoms consistent with acute COVID-19, according to the Centers for Disease Control and Prevention (CDC) definition [19] and/or a
positive SARS-CoV-2 PCR test at the time of enrollment were
excluded, in order to avoid the overestimation of the SARSCoV-2 infection prevalence. In addition, parents who had
received COVID-19 vaccination before enrollment and participants with congenital or acquired immunodeficiency were also excluded from the study.""",2021-03-01,2021-06-30,Residual sera,All,Children and Youth (0-17 years),,,Primary Estimate,,427,0.138,,,True,,,,True,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Dimitra Dimopoulou,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1007/s00431-022-04681-8,2022-11-30,2024-03-01,Unverified,dimopoulou_seroprevalence_2022,GRC
221116_Greece_NationalandKapodistrianUniversityofAthens_Children_Sex_Male,221116_Greece_NationalandKapodistrianUniversityofAthens_Children,Seroprevalence of anti-SARS-CoV-2 antibodies among children and their parents in Greece.,2022-11-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Greece,,,"""Children and adolescents 0–16 years of age and their parents presenting in the emergency department or in the outpatient clinics or admitted to the hospital for any reason were candidates for enrollment in the study.""","""Children or parents, who had symptoms consistent with acute COVID-19, according to the Centers for Disease Control and Prevention (CDC) definition [19] and/or a
positive SARS-CoV-2 PCR test at the time of enrollment were
excluded, in order to avoid the overestimation of the SARSCoV-2 infection prevalence. In addition, parents who had
received COVID-19 vaccination before enrollment and participants with congenital or acquired immunodeficiency were also excluded from the study.""",2021-03-01,2021-06-30,Residual sera,Male,Children and Youth (0-17 years),,,Sex/Gender,,219,0.132,,,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Dimitra Dimopoulou,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1007/s00431-022-04681-8,2022-11-30,2024-03-01,Unverified,dimopoulou_seroprevalence_2022,GRC
221116_Greece_NationalandKapodistrianUniversityofAthens_Children_Sex_Female,221116_Greece_NationalandKapodistrianUniversityofAthens_Children,Seroprevalence of anti-SARS-CoV-2 antibodies among children and their parents in Greece.,2022-11-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Greece,,,"""Children and adolescents 0–16 years of age and their parents presenting in the emergency department or in the outpatient clinics or admitted to the hospital for any reason were candidates for enrollment in the study.""","""Children or parents, who had symptoms consistent with acute COVID-19, according to the Centers for Disease Control and Prevention (CDC) definition [19] and/or a
positive SARS-CoV-2 PCR test at the time of enrollment were
excluded, in order to avoid the overestimation of the SARSCoV-2 infection prevalence. In addition, parents who had
received COVID-19 vaccination before enrollment and participants with congenital or acquired immunodeficiency were also excluded from the study.""",2021-03-01,2021-06-30,Residual sera,Female,Children and Youth (0-17 years),,,Sex/Gender,,195,0.154,,,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Dimitra Dimopoulou,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1007/s00431-022-04681-8,2022-11-30,2024-03-01,Unverified,dimopoulou_seroprevalence_2022,GRC
221116_Greece_NationalandKapodistrianUniversityofAthens_Parents,221116_Greece_NationalandKapodistrianUniversityofAthens_Parents,Seroprevalence of anti-SARS-CoV-2 antibodies among children and their parents in Greece.,2022-11-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Greece,,,"""Children and adolescents 0–16 years of age and their parents presenting in the emergency department or in the outpatient clinics or admitted to the hospital for any reason were candidates for enrollment in the study.""","""Children or parents, who had symptoms consistent with acute COVID-19, according to the Centers for Disease Control and Prevention (CDC) definition [19] and/or a
positive SARS-CoV-2 PCR test at the time of enrollment were
excluded, in order to avoid the overestimation of the SARSCoV-2 infection prevalence. In addition, parents who had
received COVID-19 vaccination before enrollment and participants with congenital or acquired immunodeficiency were also excluded from the study.""",2021-03-01,2021-06-30,Residual sera,All,Adults (18-64 years),,,Primary Estimate,,396,0.16399999999999998,,,True,,,,True,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Dimitra Dimopoulou,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1007/s00431-022-04681-8,2022-11-30,2024-03-01,Unverified,dimopoulou_seroprevalence_2022,GRC
221116_Greece_NationalandKapodistrianUniversityofAthens_Parents_Sex_Male,221116_Greece_NationalandKapodistrianUniversityofAthens_Parents,Seroprevalence of anti-SARS-CoV-2 antibodies among children and their parents in Greece.,2022-11-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Greece,,,"""Children and adolescents 0–16 years of age and their parents presenting in the emergency department or in the outpatient clinics or admitted to the hospital for any reason were candidates for enrollment in the study.""","""Children or parents, who had symptoms consistent with acute COVID-19, according to the Centers for Disease Control and Prevention (CDC) definition [19] and/or a
positive SARS-CoV-2 PCR test at the time of enrollment were
excluded, in order to avoid the overestimation of the SARSCoV-2 infection prevalence. In addition, parents who had
received COVID-19 vaccination before enrollment and participants with congenital or acquired immunodeficiency were also excluded from the study.""",2021-03-01,2021-06-30,Residual sera,Male,Adults (18-64 years),,,Sex/Gender,,96,0.125,,,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Dimitra Dimopoulou,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1007/s00431-022-04681-8,2022-11-30,2024-03-01,Unverified,dimopoulou_seroprevalence_2022,GRC
221116_Greece_NationalandKapodistrianUniversityofAthens_Parents_Sex_Female,221116_Greece_NationalandKapodistrianUniversityofAthens_Parents,Seroprevalence of anti-SARS-CoV-2 antibodies among children and their parents in Greece.,2022-11-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Greece,,,"""Children and adolescents 0–16 years of age and their parents presenting in the emergency department or in the outpatient clinics or admitted to the hospital for any reason were candidates for enrollment in the study.""","""Children or parents, who had symptoms consistent with acute COVID-19, according to the Centers for Disease Control and Prevention (CDC) definition [19] and/or a
positive SARS-CoV-2 PCR test at the time of enrollment were
excluded, in order to avoid the overestimation of the SARSCoV-2 infection prevalence. In addition, parents who had
received COVID-19 vaccination before enrollment and participants with congenital or acquired immunodeficiency were also excluded from the study.""",2021-03-01,2021-06-30,Residual sera,Female,Adults (18-64 years),,,Sex/Gender,,296,0.179,,,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Dimitra Dimopoulou,National and Kapodistrian University of Athens,Not Unity-Aligned,https://dx.doi.org/10.1007/s00431-022-04681-8,2022-11-30,2024-03-01,Unverified,dimopoulou_seroprevalence_2022,GRC
210929_PointAPitre_UniversityHospitalofGuadeloupe,210929_PointAPitreAbimes_UniversityHospitalofGuadeloupe,Seroprevalence of SARS-CoV-2 IgG antibodies among workers in the University Hospital of Guadeloupe.,2021-09-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Guadeloupe,Pointe-à-Pitre,Pointe-à-Pitre,"All employees at this hospital were eligible for screening, on a voluntary basis.",,2020-07-01,2020-10-28,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,892,0.05,0.036000000000000004,0.065,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Vincenzo Palmeri, University Hospital of Guadeloupe,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/34625780/,2021-10-20,2024-03-01,Unverified,palmeri_seroprevalence_2021,GLP
211102_Guatemala_UnidadNacionaldeOftalmología_HCW,211102_Guatemala_UnidadNacionaldeOftalmología,SARS-CoV-2 seroprevalence in healthcare workers in a high-volume ophthalmology centre in Guatemala.,2021-11-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Guatemala,,Guatemala City,all staff working at UNO,,2020-11-25,2020-11-25,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,94,0.18,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,1.0,0.9981000000000001,['High'],,No,No,Yes,,Yes,Yes,Yes,,Pamela Davila Siliezar,Unidad Nacional de Oftalmología,Not Unity-Aligned,https://dx.doi.org/10.1080/07853890.2021.1993325,2021-11-10,2024-03-01,Unverified,davila-siliezar_sars-cov-2_2021,GTM
220224_Guatemala_ColoradoSchoolofPublicHealth_Overall,220224_Guatemala_ColoradoSchoolofPublicHealth,"SARS-CoV-2 seroprevalence, vaccination, and hesitancy in agricultural workers in Guatemala",2022-02-24,Preprint,National,Cross-sectional survey ,Guatemala,,,"Agricultural workers over 18 years of age who applied to work at
a sugar cane agro-industrial company were recruited. ",,2021-08-15,2021-11-15,Essential non-healthcare workers,All,Adults (18-64 years),19.0,,Primary Estimate,,4343,0.294,,,True,,,,True,Convenience,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],,No,Yes,Yes,,No,Yes,No,,Diva Calvimontes,Colorado School of Public Health,Not Unity-Aligned,10.1101/2022.02.22.22270907,2022-03-02,2024-03-01,Unverified,calvimontes_sars-cov-2_2022,GTM
220721_Guatemala_CentersforDiseaseControlandPrevention_Overall,220721_Guatemala_CentersforDiseaseControlandPrevention,"High SARS-CoV-2 Seroprevalence and Rapid Neutralizing Antibody Decline among Agricultural Workers in Rural Guatemala, June 2020-March 2021.",2022-07-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Guatemala,"The southwestern
coastal lowlands",,"eligible workers at a large agribusiness—comprising nine worksites in the southwestern
coastal lowlands of Guatemala—were offered enrolment in the study. Eligibility criteria
included age >18 years, plans to continue employment with the agribusiness >1 year, access
to a telephone, and agreement to allow use of company-based absenteeism and job performance records.",,2020-06-15,2020-12-15,Essential non-healthcare workers,All,Adults (18-64 years),19.0,,Primary Estimate,,1334,0.462,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9500000000000001,0.998,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Chelsea Iwamoto,Colorado School of Public Health,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10071160,2022-08-03,2024-03-01,Unverified,iwamoto_high_2022,GTM
221212_USA_RTIInternational_Guatemala,221212_USA_RTIInternational_Guatemala,"COVID-19 Antibody Positivity Over Time and Pregnancy Outcomes in Seven Low-and-Middle-Income Countries: A Prospective, Observational Study of the Global Network for Women's and Children's Health Research.",2022-12-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Guatemala,,,"""The COVID-19 antibody study, embedded within the MNHR, included a sub-set of women who were approached at delivery and enrolled. We collected a serum sample at or near delivery for each mother who was approached and consented.""", Women who did not consent to give blood for testing. Indeterminate results are excluded. ,2020-11-01,2020-11-30,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,2011,0.172,,,True,,,,True,Convenience,ELISA SARS-CoV-2 IgG Test System,Zeus,ELISA,Serum,IgG,"Nucleocapsid (N-protein), Spike",,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Robert L. Goldenberg,RTI International,Unity-Aligned,https://dx.doi.org/10.1111/1471-0528.17366,2022-12-24,2024-03-01,Unverified,goldenberg_covid-19_2022,GTM
230720_Guatemala_JawaharlalNehruMedicalCollege_Overall,230720_Guatemala_JawaharlalNehruMedicalCollege,COVID-19 symptoms and antibody positivity among unvaccinated pregnant women: An observational study in seven countries from the Global Network,2023-07-20,Journal Article (Peer-Reviewed),National,Prospective cohort,Guatemala,,,staff (registry administrators [RAs]) identified pregnant women in their respective clusters,vaccinated pregnant women,2020-10-01,2022-06-30,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,2358,0.23,,,True,,,,True,Stratified non-probability,Not reported/ Unable to specify,,,Serum,,,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Avinash Kavi,Jawaharlal Nehru Medical College,Not Unity-Aligned,https://dx.doi.org/10.1111/1471-0528.17604,2023-08-22,2023-08-23,Unverified,kavi_covid-19_2023,GTM
220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey1_Overall,220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey1,"High and Rapid Increase in Seroprevalence for SARS-CoV-2 in Conakry, Guinea: Results From 3 Successive Cross-Sectional Surveys (ANRS COV16-ARIACOV).",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Guinea,,Conakry,Gen pop of Conakry,,2020-12-02,2020-12-26,Household and community samples,All,Multiple groups,,,Primary Estimate,,535,0.17300000000000001,0.12400000000000001,0.23800000000000002,True,,True,,True,Stratified non-probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,0.997,['Moderate'],Yes,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,Abou Soumah,Université Gamal Abdel Nasser de Conakry ,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac152,2022-05-12,2024-03-01,Verified,soumah_high_2022,GIN
220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey1_Age_20-39,220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey1,"High and Rapid Increase in Seroprevalence for SARS-CoV-2 in Conakry, Guinea: Results From 3 Successive Cross-Sectional Surveys (ANRS COV16-ARIACOV).",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Guinea,,Conakry,Gen pop of Conakry,,2020-12-02,2020-12-26,Household and community samples,All,Adults (18-64 years),20.0,39.0,Age,20-39,133,0.113,0.066,0.187,,,True,,,Stratified non-probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,0.997,['Moderate'],Yes,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,Abou Soumah,Université Gamal Abdel Nasser de Conakry ,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac152,2022-05-12,2024-03-01,Verified,soumah_high_2022,GIN
220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey1_Sex_Male,220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey1,"High and Rapid Increase in Seroprevalence for SARS-CoV-2 in Conakry, Guinea: Results From 3 Successive Cross-Sectional Surveys (ANRS COV16-ARIACOV).",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Guinea,,Conakry,Gen pop of Conakry,,2020-12-02,2020-12-26,Household and community samples,Male,Multiple groups,,,Sex/Gender,,212,0.136,0.09,0.2,,,True,,,Stratified non-probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,0.997,['Moderate'],Yes,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,Abou Soumah,Université Gamal Abdel Nasser de Conakry ,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac152,2022-05-12,2024-03-01,Verified,soumah_high_2022,GIN
220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey1_Age_0-19,220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey1,"High and Rapid Increase in Seroprevalence for SARS-CoV-2 in Conakry, Guinea: Results From 3 Successive Cross-Sectional Surveys (ANRS COV16-ARIACOV).",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Guinea,,Conakry,Gen pop of Conakry,,2020-12-02,2020-12-26,Household and community samples,All,Children and Youth (0-17 years),0.0,19.0,Age,0-19,190,0.189,0.121,0.284,,,True,,,Stratified non-probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,0.997,['Moderate'],Yes,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,Abou Soumah,Université Gamal Abdel Nasser de Conakry ,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac152,2022-05-12,2024-03-01,Verified,soumah_high_2022,GIN
220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey1_Age_>=40,220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey1,"High and Rapid Increase in Seroprevalence for SARS-CoV-2 in Conakry, Guinea: Results From 3 Successive Cross-Sectional Surveys (ANRS COV16-ARIACOV).",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Guinea,,Conakry,Gen pop of Conakry,,2020-12-02,2020-12-26,Household and community samples,All,Adults (18-64 years),40.0,,Age,>=40,212,0.226,0.163,0.306,,,True,,,Stratified non-probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,0.997,['Moderate'],Yes,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,Abou Soumah,Université Gamal Abdel Nasser de Conakry ,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac152,2022-05-12,2024-03-01,Verified,soumah_high_2022,GIN
220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey1_Sex_Female,220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey1,"High and Rapid Increase in Seroprevalence for SARS-CoV-2 in Conakry, Guinea: Results From 3 Successive Cross-Sectional Surveys (ANRS COV16-ARIACOV).",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Guinea,,Conakry,Gen pop of Conakry,,2020-12-02,2020-12-26,Household and community samples,Female,Multiple groups,,,Sex/Gender,,304,0.201,0.135,0.289,,,True,,,Stratified non-probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,0.997,['Moderate'],Yes,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,Abou Soumah,Université Gamal Abdel Nasser de Conakry ,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac152,2022-05-12,2024-03-01,Verified,soumah_high_2022,GIN
220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey2_Overall,220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey2,"High and Rapid Increase in Seroprevalence for SARS-CoV-2 in Conakry, Guinea: Results From 3 Successive Cross-Sectional Surveys (ANRS COV16-ARIACOV).",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Guinea,,Conakry,Gen pop of Conakry,,2020-12-02,2020-12-26,Household and community samples,All,Multiple groups,,,Primary Estimate,,1195,0.289,0.256,0.324,True,,True,,True,Stratified non-probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,0.997,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Abou Soumah,Université Gamal Abdel Nasser de Conakry ,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac152,2022-05-12,2024-03-01,Verified,soumah_high_2022,GIN
220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey2_Sex_Male,220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey2,"High and Rapid Increase in Seroprevalence for SARS-CoV-2 in Conakry, Guinea: Results From 3 Successive Cross-Sectional Surveys (ANRS COV16-ARIACOV).",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Guinea,,Conakry,Gen pop of Conakry,,2020-12-02,2020-12-26,Household and community samples,Male,Multiple groups,,,Sex/Gender,,538,0.287,0.249,0.329,,,True,,,Stratified non-probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,0.997,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Abou Soumah,Université Gamal Abdel Nasser de Conakry ,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac152,2022-05-12,2024-03-01,Verified,soumah_high_2022,GIN
220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey2_Age_>=40,220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey2,"High and Rapid Increase in Seroprevalence for SARS-CoV-2 in Conakry, Guinea: Results From 3 Successive Cross-Sectional Surveys (ANRS COV16-ARIACOV).",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Guinea,,Conakry,Gen pop of Conakry,,2020-12-02,2020-12-26,Household and community samples,All,Adults (18-64 years),40.0,,Age,>=40,289,0.436,0.365,0.51,,,True,,,Stratified non-probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,0.997,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Abou Soumah,Université Gamal Abdel Nasser de Conakry ,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac152,2022-05-12,2024-03-01,Verified,soumah_high_2022,GIN
220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey2_Age_20-39,220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey2,"High and Rapid Increase in Seroprevalence for SARS-CoV-2 in Conakry, Guinea: Results From 3 Successive Cross-Sectional Surveys (ANRS COV16-ARIACOV).",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Guinea,,Conakry,Gen pop of Conakry,,2020-12-02,2020-12-26,Household and community samples,All,Adults (18-64 years),20.0,39.0,Age,20-39,309,0.317,0.258,0.383,,,True,,,Stratified non-probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,0.997,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Abou Soumah,Université Gamal Abdel Nasser de Conakry ,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac152,2022-05-12,2024-03-01,Verified,soumah_high_2022,GIN
220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey2_Sex_Female,220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey2,"High and Rapid Increase in Seroprevalence for SARS-CoV-2 in Conakry, Guinea: Results From 3 Successive Cross-Sectional Surveys (ANRS COV16-ARIACOV).",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Guinea,,Conakry,Gen pop of Conakry,,2020-12-02,2020-12-26,Household and community samples,Female,Multiple groups,,,Sex/Gender,,657,0.292,0.251,0.336,,,True,,,Stratified non-probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,0.997,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Abou Soumah,Université Gamal Abdel Nasser de Conakry ,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac152,2022-05-12,2024-03-01,Verified,soumah_high_2022,GIN
220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey2_Age_0-19,220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey2,"High and Rapid Increase in Seroprevalence for SARS-CoV-2 in Conakry, Guinea: Results From 3 Successive Cross-Sectional Surveys (ANRS COV16-ARIACOV).",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Guinea,,Conakry,Gen pop of Conakry,,2020-12-02,2020-12-26,Household and community samples,All,Children and Youth (0-17 years),0.0,19.0,Age,0-19,597,0.231,0.193,0.275,,,True,,,Stratified non-probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,0.997,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Abou Soumah,Université Gamal Abdel Nasser de Conakry ,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac152,2022-05-12,2024-03-01,Verified,soumah_high_2022,GIN
220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey3_Overall,220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey3,"High and Rapid Increase in Seroprevalence for SARS-CoV-2 in Conakry, Guinea: Results From 3 Successive Cross-Sectional Surveys (ANRS COV16-ARIACOV).",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Guinea,,Conakry,Gen pop of Conakry,,2020-12-02,2020-12-26,Household and community samples,All,Multiple groups,,,Primary Estimate,,1073,0.424,0.395,0.45299999999999996,True,,True,,True,Stratified non-probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,0.997,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Abou Soumah,Université Gamal Abdel Nasser de Conakry ,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac152,2022-05-12,2024-03-01,Verified,soumah_high_2022,GIN
220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey3_Age_20-39,220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey3,"High and Rapid Increase in Seroprevalence for SARS-CoV-2 in Conakry, Guinea: Results From 3 Successive Cross-Sectional Surveys (ANRS COV16-ARIACOV).",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Guinea,,Conakry,Gen pop of Conakry,,2020-12-02,2020-12-26,Household and community samples,All,Adults (18-64 years),20.0,39.0,Age,20-39,298,0.46299999999999997,0.408,0.519,,,True,,,Stratified non-probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,0.997,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Abou Soumah,Université Gamal Abdel Nasser de Conakry ,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac152,2022-05-12,2024-03-01,Verified,soumah_high_2022,GIN
220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey3_Sex_Female,220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey3,"High and Rapid Increase in Seroprevalence for SARS-CoV-2 in Conakry, Guinea: Results From 3 Successive Cross-Sectional Surveys (ANRS COV16-ARIACOV).",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Guinea,,Conakry,Gen pop of Conakry,,2020-12-02,2020-12-26,Household and community samples,Female,Multiple groups,,,Sex/Gender,,634,0.418,0.379,0.459,,,True,,,Stratified non-probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,0.997,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Abou Soumah,Université Gamal Abdel Nasser de Conakry ,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac152,2022-05-12,2024-03-01,Verified,soumah_high_2022,GIN
220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey3_Age_0-19,220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey3,"High and Rapid Increase in Seroprevalence for SARS-CoV-2 in Conakry, Guinea: Results From 3 Successive Cross-Sectional Surveys (ANRS COV16-ARIACOV).",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Guinea,,Conakry,Gen pop of Conakry,,2020-12-02,2020-12-26,Household and community samples,All,Children and Youth (0-17 years),0.0,19.0,Age,0-19,516,0.355,0.313,0.39799999999999996,,,True,,,Stratified non-probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,0.997,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Abou Soumah,Université Gamal Abdel Nasser de Conakry ,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac152,2022-05-12,2024-03-01,Verified,soumah_high_2022,GIN
220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey3_Age_>=40,220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey3,"High and Rapid Increase in Seroprevalence for SARS-CoV-2 in Conakry, Guinea: Results From 3 Successive Cross-Sectional Surveys (ANRS COV16-ARIACOV).",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Guinea,,Conakry,Gen pop of Conakry,,2020-12-02,2020-12-26,Household and community samples,All,Adults (18-64 years),40.0,,Age,>=40,258,0.589,0.526,0.649,,,True,,,Stratified non-probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,0.997,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Abou Soumah,Université Gamal Abdel Nasser de Conakry ,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac152,2022-05-12,2024-03-01,Verified,soumah_high_2022,GIN
220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey3_Sex_Male,220322_Conakry_UniversiteGamalAbdelNasserdeConakry_Survey3,"High and Rapid Increase in Seroprevalence for SARS-CoV-2 in Conakry, Guinea: Results From 3 Successive Cross-Sectional Surveys (ANRS COV16-ARIACOV).",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Guinea,,Conakry,Gen pop of Conakry,,2020-12-02,2020-12-26,Household and community samples,Male,Multiple groups,,,Sex/Gender,,438,0.433,0.385,0.48200000000000004,,,True,,,Stratified non-probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,0.997,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Abou Soumah,Université Gamal Abdel Nasser de Conakry ,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac152,2022-05-12,2024-03-01,Verified,soumah_high_2022,GIN
230420_Conakry_CentralHospitalofYaounde_PopAdj,230420_Conakry_CentralHospitalofYaounde,"Large Diffusion of Severe Acute Respiratory Syndrome Coronavirus 2 After the Successive Epidemiological Waves, Including Omicron, in Guinea and Cameroon: Implications for Vaccine Strategies.",2023-04-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Guinea,,Conakry,All persons belonging to the selected household were eligible. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9155890/),,2022-05-15,2022-06-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,1386,0.7157,0.6748,0.7533,True,,True,,True,Simplified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Mamadou Diallo,Central Hospital of Yaounde,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofad216,2023-06-02,2024-04-27,Verified,diallo_large_2023,GIN
230420_Conakry_CentralHospitalofYaounde_Age20-39,230420_Conakry_CentralHospitalofYaounde,"Large Diffusion of Severe Acute Respiratory Syndrome Coronavirus 2 After the Successive Epidemiological Waves, Including Omicron, in Guinea and Cameroon: Implications for Vaccine Strategies.",2023-04-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Guinea,,Conakry,All persons belonging to the selected household were eligible. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9155890/),,2022-05-15,2022-06-15,Household and community samples,All,Adults (18-64 years),20.0,39.0,Age,20-39,370,0.7838,,,,,,,,Simplified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Mamadou Diallo,Central Hospital of Yaounde,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofad216,2024-04-27,2024-04-27,Verified,diallo_large_2023,GIN
230420_Conakry_CentralHospitalofYaounde_Age40+,230420_Conakry_CentralHospitalofYaounde,"Large Diffusion of Severe Acute Respiratory Syndrome Coronavirus 2 After the Successive Epidemiological Waves, Including Omicron, in Guinea and Cameroon: Implications for Vaccine Strategies.",2023-04-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Guinea,,Conakry,All persons belonging to the selected household were eligible. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9155890/),,2022-05-15,2022-06-15,Household and community samples,All,Multiple groups,40.0,,Age,40+,276,0.8406,,,,,,,,Simplified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Mamadou Diallo,Central Hospital of Yaounde,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofad216,2024-04-27,2024-04-27,Verified,diallo_large_2023,GIN
230420_Conakry_CentralHospitalofYaounde_Age0-19,230420_Conakry_CentralHospitalofYaounde,"Large Diffusion of Severe Acute Respiratory Syndrome Coronavirus 2 After the Successive Epidemiological Waves, Including Omicron, in Guinea and Cameroon: Implications for Vaccine Strategies.",2023-04-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Guinea,,Conakry,All persons belonging to the selected household were eligible. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9155890/),,2022-05-15,2022-06-15,Household and community samples,All,Children and Youth (0-17 years),0.0,19.0,Age,0-19,740,0.6432,,,,,,,,Simplified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Mamadou Diallo,Central Hospital of Yaounde,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofad216,2024-04-27,2024-04-27,Verified,diallo_large_2023,GIN
211203_Bissau_UniversityofSouthernDenmark,211203_Bissau_UniversityofSouthernDenmark,"SARS-CoV-2 serosurvey among adults involved in healthcare and health research in Guinea-Bissau, West Africa",2021-12-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Guinea-Bissau,,Bissau,"Office staff members, and staff placed at three health centers in the
study area and the nearby national hospital (cohort of staff at the Bandim
Health Project).",,2020-11-09,2020-11-24,Health care workers and caregivers,All,Multiple groups,19.0,70.0,Primary Estimate,,140,0.18,,,True,,,,True,Convenience,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,IgG,,Validated by manufacturers,0.9,1.0,['High'],,No,No,No,,Yes,Yes,Yes,,Christine Benn,University of Southern Denmark,Not Unity-Aligned,https://dx.doi.org/10.1016/j.puhe.2021.11.013,2022-01-18,2024-03-01,Unverified,benn_sars-cov-2_2022,GNB
220601_Bissau_IndepthNetwork_Overall,220601_Bissau_IndepthNetwork,SARS-CoV-2 seroprevalence among people living with HIV in Guinea-Bissau,2022-06-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Guinea-Bissau,,Bissau,"""Participants of the study were PLWH attending follow-up at the HIV clinic at Hospital National Simao Mendes (HNSM) who agreed to participate on the day of follow-up.""

""All participants were aged 18 years or older.""",,2021-06-01,2021-10-01,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,,Primary Estimate,,293,0.43,,,True,,,,True,Stratified non-probability,2019-nCoV IgG/IgM Rapid Test Cassette,Hanghzhou AllTest Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),,,,['High'],,No,No,No,,No,Yes,No,,A. Dutschke,Indepth Network,Not Unity-Aligned,https://dx.doi.org/10.1016/j.puhe.2022.05.017,2022-07-12,2024-03-01,Unverified,dutschke_sars-cov-2_2022,GNB
220320_Haiti_UniversityOfFlorida_Overall,220320_Haiti_UniversityOfFlorida,SARS-CoV-2 infections in infants in Haiti 2020-2021; evidence from a serological cohort,2022-03-20,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Haiti,,Port Au Prince," infants born to enrolled mothers, with visits scheduled at 0, 4, 12, and 18-30 months of age",,2019-06-15,2021-03-15,Residual sera,All,Children and Youth (0-17 years),0.0,3.0,Primary Estimate,,257,0.167,0.127,0.218,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Rigan Louis,University of Florida,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.17.22272561v1.full-text,2022-03-31,2022-07-16,Unverified,louis_sars-cov-2_2022,HTI
220804_Haiti_LomaLindaUniversity_male_testadj,220804_Haiti_LomaLindaUniversity,SARS-CoV-2 Seroprevalence at an Urban Hospital in Haiti.,2022-08-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Haiti,,Port-au-Prince,"""patients aged one to 89 years old who were seen at the Haiti Adventist Hospital (HAH) laboratory between December 17, 2020, and July 3, 2021, with an order requiring a blood draw""","""We excluded patients outside of the age range and those who did not verbally consent to the study.""
""We excluded nine participants who were aged greater than 89 (n=3), aged less than one (n=2), or had results that were not properly recorded (n=4).""",2020-12-17,2021-07-03,Residual sera,Male,Multiple groups,1.0,89.0,Sex/Gender,Male,218,0.289,0.231,0.35600000000000004,True,True,,,,Convenience,The BioSys Plus COVID-19 IgM/IgG Rapid Test,BioSys Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,0.935,1.0,['High'],No,No,No,Yes,No,Yes,Yes,Yes,No,Robert Price ,Loma Linda University School of Medicine,Unity-Aligned,https://dx.doi.org/10.7759/cureus.27690,2022-09-16,2024-04-02,Verified,priceSARSCoV2SeroprevalenceUrban2022,HTI
220804_Haiti_LomaLindaUniversity_65+_unadj,220804_Haiti_LomaLindaUniversity,SARS-CoV-2 Seroprevalence at an Urban Hospital in Haiti.,2022-08-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Haiti,,Port-au-Prince,"""patients aged one to 89 years old who were seen at the Haiti Adventist Hospital (HAH) laboratory between December 17, 2020, and July 3, 2021, with an order requiring a blood draw""","""We excluded patients outside of the age range and those who did not verbally consent to the study.""
""We excluded nine participants who were aged greater than 89 (n=3), aged less than one (n=2), or had results that were not properly recorded (n=4).""",2020-12-17,2021-07-03,Residual sera,All,Seniors (65+ years),65.0,89.0,Age,65+,65,0.42700000000000005,,,,,,,,Convenience,The BioSys Plus COVID-19 IgM/IgG Rapid Test,BioSys Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,0.935,1.0,['High'],No,No,No,Yes,No,Yes,Yes,Yes,No,Robert Price ,Loma Linda University School of Medicine,Unity-Aligned,https://dx.doi.org/10.7759/cureus.27690,2022-09-16,2024-04-02,Verified,priceSARSCoV2SeroprevalenceUrban2022,HTI
220804_Haiti_LomaLindaUniversity_overall_testadj,220804_Haiti_LomaLindaUniversity,SARS-CoV-2 Seroprevalence at an Urban Hospital in Haiti.,2022-08-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Haiti,,Port-au-Prince,"""patients aged one to 89 years old who were seen at the Haiti Adventist Hospital (HAH) laboratory between December 17, 2020, and July 3, 2021, with an order requiring a blood draw""","""We excluded patients outside of the age range and those who did not verbally consent to the study.""
""We excluded nine participants who were aged greater than 89 (n=3), aged less than one (n=2), or had results that were not properly recorded (n=4).""",2020-12-17,2021-07-03,Residual sera,All,Multiple groups,1.0,89.0,Primary Estimate,,533,0.287,0.249,0.329,,True,,,,Convenience,The BioSys Plus COVID-19 IgM/IgG Rapid Test,BioSys Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,0.935,1.0,['High'],No,No,No,Yes,No,Yes,Yes,Yes,No,Robert Price ,Loma Linda University School of Medicine,Unity-Aligned,https://dx.doi.org/10.7759/cureus.27690,2022-09-16,2024-04-02,Verified,priceSARSCoV2SeroprevalenceUrban2022,HTI
220804_Haiti_LomaLindaUniversity_1to17_unadj,220804_Haiti_LomaLindaUniversity,SARS-CoV-2 Seroprevalence at an Urban Hospital in Haiti.,2022-08-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Haiti,,Port-au-Prince,"""patients aged one to 89 years old who were seen at the Haiti Adventist Hospital (HAH) laboratory between December 17, 2020, and July 3, 2021, with an order requiring a blood draw""","""We excluded patients outside of the age range and those who did not verbally consent to the study.""
""We excluded nine participants who were aged greater than 89 (n=3), aged less than one (n=2), or had results that were not properly recorded (n=4).""",2020-12-17,2021-07-03,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Age,1-17,36,0.055999999999999994,,,,,,,,Convenience,The BioSys Plus COVID-19 IgM/IgG Rapid Test,BioSys Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,0.935,1.0,['High'],No,No,No,Yes,No,Yes,Yes,Yes,No,Robert Price ,Loma Linda University School of Medicine,Unity-Aligned,https://dx.doi.org/10.7759/cureus.27690,2022-09-16,2024-04-02,Verified,priceSARSCoV2SeroprevalenceUrban2022,HTI
220804_Haiti_LomaLindaUniversity_male_unadj,220804_Haiti_LomaLindaUniversity,SARS-CoV-2 Seroprevalence at an Urban Hospital in Haiti.,2022-08-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Haiti,,Port-au-Prince,"""patients aged one to 89 years old who were seen at the Haiti Adventist Hospital (HAH) laboratory between December 17, 2020, and July 3, 2021, with an order requiring a blood draw""","""We excluded patients outside of the age range and those who did not verbally consent to the study.""
""We excluded nine participants who were aged greater than 89 (n=3), aged less than one (n=2), or had results that were not properly recorded (n=4).""",2020-12-17,2021-07-03,Residual sera,Male,Multiple groups,1.0,89.0,Sex/Gender,Male,218,0.271,,,,,,,,Convenience,The BioSys Plus COVID-19 IgM/IgG Rapid Test,BioSys Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,0.935,1.0,['High'],No,No,No,Yes,No,Yes,Yes,Yes,No,Robert Price ,Loma Linda University School of Medicine,Unity-Aligned,https://dx.doi.org/10.7759/cureus.27690,2022-09-16,2024-04-02,Verified,priceSARSCoV2SeroprevalenceUrban2022,HTI
220804_Haiti_LomaLindaUniversity_female_unadj,220804_Haiti_LomaLindaUniversity,SARS-CoV-2 Seroprevalence at an Urban Hospital in Haiti.,2022-08-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Haiti,,Port-au-Prince,"""patients aged one to 89 years old who were seen at the Haiti Adventist Hospital (HAH) laboratory between December 17, 2020, and July 3, 2021, with an order requiring a blood draw""","""We excluded patients outside of the age range and those who did not verbally consent to the study.""
""We excluded nine participants who were aged greater than 89 (n=3), aged less than one (n=2), or had results that were not properly recorded (n=4).""",2020-12-17,2021-07-03,Residual sera,Female,Multiple groups,1.0,89.0,Sex/Gender,Female,315,0.267,,,,,,,,Convenience,The BioSys Plus COVID-19 IgM/IgG Rapid Test,BioSys Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,0.935,1.0,['High'],No,No,No,Yes,No,Yes,Yes,Yes,No,Robert Price ,Loma Linda University School of Medicine,Unity-Aligned,https://dx.doi.org/10.7759/cureus.27690,2022-09-16,2024-04-02,Verified,priceSARSCoV2SeroprevalenceUrban2022,HTI
220804_Haiti_LomaLindaUniversity_65+_testadj,220804_Haiti_LomaLindaUniversity,SARS-CoV-2 Seroprevalence at an Urban Hospital in Haiti.,2022-08-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Haiti,,Port-au-Prince,"""patients aged one to 89 years old who were seen at the Haiti Adventist Hospital (HAH) laboratory between December 17, 2020, and July 3, 2021, with an order requiring a blood draw""","""We excluded patients outside of the age range and those who did not verbally consent to the study.""
""We excluded nine participants who were aged greater than 89 (n=3), aged less than one (n=2), or had results that were not properly recorded (n=4).""",2020-12-17,2021-07-03,Residual sera,All,Seniors (65+ years),65.0,89.0,Age,65+,65,0.461,0.33899999999999997,0.59,,True,,,,Convenience,The BioSys Plus COVID-19 IgM/IgG Rapid Test,BioSys Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,0.935,1.0,['High'],No,No,No,Yes,No,Yes,Yes,Yes,No,Robert Price ,Loma Linda University School of Medicine,Unity-Aligned,https://dx.doi.org/10.7759/cureus.27690,2022-09-16,2024-04-02,Verified,priceSARSCoV2SeroprevalenceUrban2022,HTI
220804_Haiti_LomaLindaUniversity_female_testadj,220804_Haiti_LomaLindaUniversity,SARS-CoV-2 Seroprevalence at an Urban Hospital in Haiti.,2022-08-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Haiti,,Port-au-Prince,"""patients aged one to 89 years old who were seen at the Haiti Adventist Hospital (HAH) laboratory between December 17, 2020, and July 3, 2021, with an order requiring a blood draw""","""We excluded patients outside of the age range and those who did not verbally consent to the study.""
""We excluded nine participants who were aged greater than 89 (n=3), aged less than one (n=2), or had results that were not properly recorded (n=4).""",2020-12-17,2021-07-03,Residual sera,Female,Multiple groups,1.0,89.0,Sex/Gender,Female,315,0.28500000000000003,0.23600000000000002,0.34,,True,,,,Convenience,The BioSys Plus COVID-19 IgM/IgG Rapid Test,BioSys Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,0.935,1.0,['High'],No,No,No,Yes,No,Yes,Yes,Yes,No,Robert Price ,Loma Linda University School of Medicine,Unity-Aligned,https://dx.doi.org/10.7759/cureus.27690,2022-09-16,2024-04-02,Verified,priceSARSCoV2SeroprevalenceUrban2022,HTI
220804_Haiti_LomaLindaUniversity_overall_unadj,220804_Haiti_LomaLindaUniversity,SARS-CoV-2 Seroprevalence at an Urban Hospital in Haiti.,2022-08-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Haiti,,Port-au-Prince,"""patients aged one to 89 years old who were seen at the Haiti Adventist Hospital (HAH) laboratory between December 17, 2020, and July 3, 2021, with an order requiring a blood draw""","""We excluded patients outside of the age range and those who did not verbally consent to the study.""
""We excluded nine participants who were aged greater than 89 (n=3), aged less than one (n=2), or had results that were not properly recorded (n=4).""",2020-12-17,2021-07-03,Residual sera,All,Multiple groups,1.0,89.0,Analysis,,533,0.2664,,,,,,,True,Convenience,The BioSys Plus COVID-19 IgM/IgG Rapid Test,BioSys Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,0.935,1.0,['High'],No,No,No,Yes,No,Yes,Yes,Yes,No,Robert Price ,Loma Linda University School of Medicine,Unity-Aligned,https://dx.doi.org/10.7759/cureus.27690,2022-09-16,2024-04-02,Verified,priceSARSCoV2SeroprevalenceUrban2022,HTI
220804_Haiti_LomaLindaUniversity_50to64_testadj,220804_Haiti_LomaLindaUniversity,SARS-CoV-2 Seroprevalence at an Urban Hospital in Haiti.,2022-08-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Haiti,,Port-au-Prince,"""patients aged one to 89 years old who were seen at the Haiti Adventist Hospital (HAH) laboratory between December 17, 2020, and July 3, 2021, with an order requiring a blood draw""","""We excluded patients outside of the age range and those who did not verbally consent to the study.""
""We excluded nine participants who were aged greater than 89 (n=3), aged less than one (n=2), or had results that were not properly recorded (n=4).""",2020-12-17,2021-07-03,Residual sera,All,Adults (18-64 years),50.0,64.0,Age,50-64,87,0.406,0.304,0.518,,True,,,,Convenience,The BioSys Plus COVID-19 IgM/IgG Rapid Test,BioSys Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,0.935,1.0,['High'],No,No,No,Yes,No,Yes,Yes,Yes,No,Robert Price ,Loma Linda University School of Medicine,Unity-Aligned,https://dx.doi.org/10.7759/cureus.27690,2022-09-16,2024-04-02,Verified,priceSARSCoV2SeroprevalenceUrban2022,HTI
220804_Haiti_LomaLindaUniversity_50to64_unadj,220804_Haiti_LomaLindaUniversity,SARS-CoV-2 Seroprevalence at an Urban Hospital in Haiti.,2022-08-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Haiti,,Port-au-Prince,"""patients aged one to 89 years old who were seen at the Haiti Adventist Hospital (HAH) laboratory between December 17, 2020, and July 3, 2021, with an order requiring a blood draw""","""We excluded patients outside of the age range and those who did not verbally consent to the study.""
""We excluded nine participants who were aged greater than 89 (n=3), aged less than one (n=2), or had results that were not properly recorded (n=4).""",2020-12-17,2021-07-03,Residual sera,All,Adults (18-64 years),50.0,64.0,Age,50-64,87,0.379,,,,,,,,Convenience,The BioSys Plus COVID-19 IgM/IgG Rapid Test,BioSys Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,0.935,1.0,['High'],No,No,No,Yes,No,Yes,Yes,Yes,No,Robert Price ,Loma Linda University School of Medicine,Unity-Aligned,https://dx.doi.org/10.7759/cureus.27690,2022-09-16,2024-04-02,Verified,priceSARSCoV2SeroprevalenceUrban2022,HTI
220804_Haiti_LomaLindaUniversity_18to49_testadj,220804_Haiti_LomaLindaUniversity,SARS-CoV-2 Seroprevalence at an Urban Hospital in Haiti.,2022-08-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Haiti,,Port-au-Prince,"""patients aged one to 89 years old who were seen at the Haiti Adventist Hospital (HAH) laboratory between December 17, 2020, and July 3, 2021, with an order requiring a blood draw""","""We excluded patients outside of the age range and those who did not verbally consent to the study.""
""We excluded nine participants who were aged greater than 89 (n=3), aged less than one (n=2), or had results that were not properly recorded (n=4).""",2020-12-17,2021-07-03,Residual sera,All,Adults (18-64 years),18.0,49.0,Age,18-49,335,0.24300000000000002,0.198,0.29300000000000004,,True,,,,Convenience,The BioSys Plus COVID-19 IgM/IgG Rapid Test,BioSys Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,0.935,1.0,['High'],No,No,No,Yes,No,Yes,Yes,Yes,No,Robert Price ,Loma Linda University School of Medicine,Unity-Aligned,https://dx.doi.org/10.7759/cureus.27690,2022-09-16,2024-04-02,Verified,priceSARSCoV2SeroprevalenceUrban2022,HTI
220804_Haiti_LomaLindaUniversity_1to17_testadj,220804_Haiti_LomaLindaUniversity,SARS-CoV-2 Seroprevalence at an Urban Hospital in Haiti.,2022-08-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Haiti,,Port-au-Prince,"""patients aged one to 89 years old who were seen at the Haiti Adventist Hospital (HAH) laboratory between December 17, 2020, and July 3, 2021, with an order requiring a blood draw""","""We excluded patients outside of the age range and those who did not verbally consent to the study.""
""We excluded nine participants who were aged greater than 89 (n=3), aged less than one (n=2), or had results that were not properly recorded (n=4).""",2020-12-17,2021-07-03,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Age,1-17,36,0.059000000000000004,0.016,0.19399999999999998,,True,,,,Convenience,The BioSys Plus COVID-19 IgM/IgG Rapid Test,BioSys Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,0.935,1.0,['High'],No,No,No,Yes,No,Yes,Yes,Yes,No,Robert Price ,Loma Linda University School of Medicine,Unity-Aligned,https://dx.doi.org/10.7759/cureus.27690,2022-09-16,2024-04-02,Verified,priceSARSCoV2SeroprevalenceUrban2022,HTI
220804_Haiti_LomaLindaUniversity_18to49_unadj,220804_Haiti_LomaLindaUniversity,SARS-CoV-2 Seroprevalence at an Urban Hospital in Haiti.,2022-08-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Haiti,,Port-au-Prince,"""patients aged one to 89 years old who were seen at the Haiti Adventist Hospital (HAH) laboratory between December 17, 2020, and July 3, 2021, with an order requiring a blood draw""","""We excluded patients outside of the age range and those who did not verbally consent to the study.""
""We excluded nine participants who were aged greater than 89 (n=3), aged less than one (n=2), or had results that were not properly recorded (n=4).""",2020-12-17,2021-07-03,Residual sera,All,Adults (18-64 years),18.0,49.0,Age,18-49,335,0.227,,,,,,,,Convenience,The BioSys Plus COVID-19 IgM/IgG Rapid Test,BioSys Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,0.935,1.0,['High'],No,No,No,Yes,No,Yes,Yes,Yes,No,Robert Price ,Loma Linda University School of Medicine,Unity-Aligned,https://dx.doi.org/10.7759/cureus.27690,2022-09-16,2024-04-02,Verified,priceSARSCoV2SeroprevalenceUrban2022,HTI
220825_Haiti_UniversityOfFlorida_Overall,220825_Haiti_UniversityOfFlorida,SARS-CoV-2 infections in infants in Haiti 2020-2021; evidence from a seroepidemiological cohort,2022-08-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Haiti,Port-au-Prince Arrondissement,,"""infants born to mothers enrolled in the study"".

""Mothers in the study were recruited from an antenatal clinic in Gressier, Haiti, between April 2018 and August 2019. Inclusion criteria included age of 18 years or older, pregnancy, the ability to provide informed consent, and no known medical or psychological problems.""",,2019-02-15,2021-03-15,Residual sera,All,Children and Youth (0-17 years),0.0,3.0,Primary Estimate,,257,0.167,0.127,0.218,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Rigan Louis,University of Florida,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273482,2022-08-30,2022-09-01,Unverified,louis_sars-cov-2_2022-1,HTI
210203_VaticanCity_UniversitàCattolicadelSacroCuore_Overall,210203_VaticanCity_UniversitàCattolicadelSacroCuore,SARS-CoV-2 seroprevalence in the Vatican City State,2021-02-03,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Holy See,Vatican City State,Vatican City,"residents and employees of the Vatican City State,
regardless of symptoms or contacts with positive cases",repeated tests over time on the same subject were not included,2020-06-08,2021-01-04,Household and community samples,All,Multiple groups,,,Primary Estimate,Overall,1539,0.0435,,,True,,,,True,Convenience,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Whole Blood,TotalAntibody,Spike,Validated by manufacturers,0.9748000000000001,0.998,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Massimo Ralli,Università Cattolica del Sacro Cuore,Unity-Aligned,https://dx.doi.org/10.1016/j.ejim.2021.01.029,2021-03-24,2024-03-01,Verified,ralli_sars-cov-2_2021,VAT
210203_VaticanCity_UniversitàCattolicadelSacroCuore_timeframe_jan,210203_VaticanCity_UniversitàCattolicadelSacroCuore,SARS-CoV-2 seroprevalence in the Vatican City State,2021-02-03,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Holy See,Vatican City State,Vatican City,"residents and employees of the Vatican City State,
regardless of symptoms or contacts with positive cases",repeated tests over time on the same subject were not included,2021-01-01,2021-01-04,Household and community samples,All,Multiple groups,,,Time frame,Januay,17,0.0589,,,,,,,,Convenience,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Whole Blood,TotalAntibody,Spike,Validated by manufacturers,0.9748000000000001,0.998,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Massimo Ralli,Università Cattolica del Sacro Cuore,Unity-Aligned,https://dx.doi.org/10.1016/j.ejim.2021.01.029,2021-07-07,2024-03-01,Unverified,ralli_sars-cov-2_2021,VAT
210203_VaticanCity_UniversitàCattolicadelSacroCuore_timeframe_sep,210203_VaticanCity_UniversitàCattolicadelSacroCuore,SARS-CoV-2 seroprevalence in the Vatican City State,2021-02-03,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Holy See,Vatican City State,Vatican City,"residents and employees of the Vatican City State,
regardless of symptoms or contacts with positive cases",repeated tests over time on the same subject were not included,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Time frame,September,514,0.0311,,,,,,,,Convenience,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Whole Blood,TotalAntibody,Spike,Validated by manufacturers,0.9748000000000001,0.998,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Massimo Ralli,Università Cattolica del Sacro Cuore,Unity-Aligned,https://dx.doi.org/10.1016/j.ejim.2021.01.029,2021-07-07,2024-03-01,Unverified,ralli_sars-cov-2_2021,VAT
210203_VaticanCity_UniversitàCattolicadelSacroCuore_timeframe_august,210203_VaticanCity_UniversitàCattolicadelSacroCuore,SARS-CoV-2 seroprevalence in the Vatican City State,2021-02-03,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Holy See,Vatican City State,Vatican City,"residents and employees of the Vatican City State,
regardless of symptoms or contacts with positive cases",repeated tests over time on the same subject were not included,2020-08-01,2020-08-31,Household and community samples,All,Multiple groups,,,Time frame,August,105,0.0381,,,,,,,,Convenience,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Whole Blood,TotalAntibody,Spike,Validated by manufacturers,0.9748000000000001,0.998,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Massimo Ralli,Università Cattolica del Sacro Cuore,Unity-Aligned,https://dx.doi.org/10.1016/j.ejim.2021.01.029,2021-07-07,2024-03-01,Unverified,ralli_sars-cov-2_2021,VAT
210203_VaticanCity_UniversitàCattolicadelSacroCuore_timeframe_dec,210203_VaticanCity_UniversitàCattolicadelSacroCuore,SARS-CoV-2 seroprevalence in the Vatican City State,2021-02-03,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Holy See,Vatican City State,Vatican City,"residents and employees of the Vatican City State,
regardless of symptoms or contacts with positive cases",repeated tests over time on the same subject were not included,2020-12-01,2020-12-31,Household and community samples,All,Multiple groups,,,Time frame,December,188,0.09570000000000001,,,,,,,,Convenience,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Whole Blood,TotalAntibody,Spike,Validated by manufacturers,0.9748000000000001,0.998,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Massimo Ralli,Università Cattolica del Sacro Cuore,Unity-Aligned,https://dx.doi.org/10.1016/j.ejim.2021.01.029,2021-07-07,2024-03-01,Unverified,ralli_sars-cov-2_2021,VAT
210203_VaticanCity_UniversitàCattolicadelSacroCuore_timeframe_nov,210203_VaticanCity_UniversitàCattolicadelSacroCuore,SARS-CoV-2 seroprevalence in the Vatican City State,2021-02-03,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Holy See,Vatican City State,Vatican City,"residents and employees of the Vatican City State,
regardless of symptoms or contacts with positive cases",repeated tests over time on the same subject were not included,2020-11-01,2020-11-30,Household and community samples,All,Multiple groups,,,Time frame,November,209,0.0766,,,,,,,,Convenience,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Whole Blood,TotalAntibody,Spike,Validated by manufacturers,0.9748000000000001,0.998,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Massimo Ralli,Università Cattolica del Sacro Cuore,Unity-Aligned,https://dx.doi.org/10.1016/j.ejim.2021.01.029,2021-07-07,2024-03-01,Unverified,ralli_sars-cov-2_2021,VAT
210203_VaticanCity_UniversitàCattolicadelSacroCuore_timeframe_oct,210203_VaticanCity_UniversitàCattolicadelSacroCuore,SARS-CoV-2 seroprevalence in the Vatican City State,2021-02-03,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Holy See,Vatican City State,Vatican City,"residents and employees of the Vatican City State,
regardless of symptoms or contacts with positive cases",repeated tests over time on the same subject were not included,2020-10-01,2020-10-31,Household and community samples,All,Multiple groups,,,Time frame,October,339,0.0206,,,,,,,,Convenience,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Whole Blood,TotalAntibody,Spike,Validated by manufacturers,0.9748000000000001,0.998,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Massimo Ralli,Università Cattolica del Sacro Cuore,Unity-Aligned,https://dx.doi.org/10.1016/j.ejim.2021.01.029,2021-07-07,2024-03-01,Unverified,ralli_sars-cov-2_2021,VAT
210203_VaticanCity_UniversitàCattolicadelSacroCuore_timeframe_july,210203_VaticanCity_UniversitàCattolicadelSacroCuore,SARS-CoV-2 seroprevalence in the Vatican City State,2021-02-03,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Holy See,Vatican City State,Vatican City,"residents and employees of the Vatican City State,
regardless of symptoms or contacts with positive cases",repeated tests over time on the same subject were not included,2020-07-01,2020-07-31,Household and community samples,All,Multiple groups,,,Time frame,July,100,0.01,,,,,,,,Convenience,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Whole Blood,TotalAntibody,Spike,Validated by manufacturers,0.9748000000000001,0.998,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Massimo Ralli,Università Cattolica del Sacro Cuore,Unity-Aligned,https://dx.doi.org/10.1016/j.ejim.2021.01.029,2021-07-07,2024-03-01,Unverified,ralli_sars-cov-2_2021,VAT
210203_VaticanCity_UniversitàCattolicadelSacroCuore_timeframe_june,210203_VaticanCity_UniversitàCattolicadelSacroCuore,SARS-CoV-2 seroprevalence in the Vatican City State,2021-02-03,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Holy See,Vatican City State,Vatican City,"residents and employees of the Vatican City State,
regardless of symptoms or contacts with positive cases",repeated tests over time on the same subject were not included,2020-06-08,2020-06-30,Household and community samples,All,Multiple groups,,,Time frame,June,67,0.059699999999999996,,,,,,,,Convenience,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Whole Blood,TotalAntibody,Spike,Validated by manufacturers,0.9748000000000001,0.998,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Massimo Ralli,Università Cattolica del Sacro Cuore,Unity-Aligned,https://dx.doi.org/10.1016/j.ejim.2021.01.029,2021-07-07,2024-03-01,Unverified,ralli_sars-cov-2_2021,VAT
201217_Honduras_ColegioMédico_OverallGenpop,201217_Honduras_ColegioMédico,"Seroepidemiological surveillance of SARS-CoV-2 circulation in 41 municipalities in Honduras wth no reports of active cases, COVID-19, June 16-23, 2020",2020-12-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Honduras,,,"Inclusion:
1. Person over 5 years old
2. Person whose birthday was closest to the day of the test and who agreed to participate in the study.
3. In the event that the first did not accept, the next person whose birthday was closest to the day of the test was chosen (replacement technique).

","Exclusion :
1. Person who refused to give assent or informed consent
2. Person with contraindication for capillary puncture (edema, insufficient perfusion, coagulation disorders)
3. Children under 5 years of age due to the difficulty in taking a blood sample and receiving consen",2020-06-16,2020-06-23,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,,792,0.062000000000000006,,,True,,,,True,Stratified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.934,0.9770000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Mario Rene Mejia Nunez ,Colegio Médico,Unity-Aligned,https://revistas.ucr.ac.cr/index.php/psm/article/view/43261/46175,2021-04-16,2022-07-16,Verified,rene_mejia_nunez_vista_2020,HND
201217_Honduras_ColegioMédico_Colon,201217_Honduras_ColegioMédico,"Seroepidemiological surveillance of SARS-CoV-2 circulation in 41 municipalities in Honduras wth no reports of active cases, COVID-19, June 16-23, 2020",2020-12-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Honduras,Colon,,"Inclusion:
1. Person over 5 years old
2. Person whose birthday was closest to the day of the test and who agreed to participate in the study.
3. In the event that the first did not accept, the next person whose birthday was closest to the day of the test was chosen (replacement technique).

","Exclusion :
1. Person who refused to give assent or informed consent
2. Person with contraindication for capillary puncture (edema, insufficient perfusion, coagulation disorders)
3. Children under 5 years of age due to the difficulty in taking a blood sample and receiving consen",2020-06-16,2020-06-23,Household and community samples,All,Multiple groups,5.0,,Geographical area,Colon,57,0.053,,,,,,,,Stratified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.934,0.9770000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Mario Rene Mejia Nunez ,Colegio Médico,Unity-Aligned,https://revistas.ucr.ac.cr/index.php/psm/article/view/43261/46175,2021-04-16,2022-07-16,Verified,rene_mejia_nunez_vista_2020,HND
201217_Honduras_ColegioMédico_Olancho,201217_Honduras_ColegioMédico,"Seroepidemiological surveillance of SARS-CoV-2 circulation in 41 municipalities in Honduras wth no reports of active cases, COVID-19, June 16-23, 2020",2020-12-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Honduras,Olancho,,"Inclusion:
1. Person over 5 years old
2. Person whose birthday was closest to the day of the test and who agreed to participate in the study.
3. In the event that the first did not accept, the next person whose birthday was closest to the day of the test was chosen (replacement technique).

","Exclusion :
1. Person who refused to give assent or informed consent
2. Person with contraindication for capillary puncture (edema, insufficient perfusion, coagulation disorders)
3. Children under 5 years of age due to the difficulty in taking a blood sample and receiving consen",2020-06-16,2020-06-23,Household and community samples,All,Multiple groups,5.0,,Geographical area,Olancho,57,0.0,,,,,,,,Stratified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.934,0.9770000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Mario Rene Mejia Nunez ,Colegio Médico,Unity-Aligned,https://revistas.ucr.ac.cr/index.php/psm/article/view/43261/46175,2021-04-16,2022-07-16,Verified,rene_mejia_nunez_vista_2020,HND
201217_Honduras_ColegioMédico_Atlantida,201217_Honduras_ColegioMédico,"Seroepidemiological surveillance of SARS-CoV-2 circulation in 41 municipalities in Honduras wth no reports of active cases, COVID-19, June 16-23, 2020",2020-12-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Honduras,Atlantida,,"Inclusion:
1. Person over 5 years old
2. Person whose birthday was closest to the day of the test and who agreed to participate in the study.
3. In the event that the first did not accept, the next person whose birthday was closest to the day of the test was chosen (replacement technique).

","Exclusion :
1. Person who refused to give assent or informed consent
2. Person with contraindication for capillary puncture (edema, insufficient perfusion, coagulation disorders)
3. Children under 5 years of age due to the difficulty in taking a blood sample and receiving consen",2020-06-16,2020-06-23,Household and community samples,All,Multiple groups,5.0,,Geographical area,Atlantida,57,0.018000000000000002,,,,,,,,Stratified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.934,0.9770000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Mario Rene Mejia Nunez ,Colegio Médico,Unity-Aligned,https://revistas.ucr.ac.cr/index.php/psm/article/view/43261/46175,2021-04-16,2022-07-16,Verified,rene_mejia_nunez_vista_2020,HND
201217_Honduras_ColegioMédico_GraciasADios,201217_Honduras_ColegioMédico,"Seroepidemiological surveillance of SARS-CoV-2 circulation in 41 municipalities in Honduras wth no reports of active cases, COVID-19, June 16-23, 2020",2020-12-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Honduras,Gracias a Dios,,"Inclusion:
1. Person over 5 years old
2. Person whose birthday was closest to the day of the test and who agreed to participate in the study.
3. In the event that the first did not accept, the next person whose birthday was closest to the day of the test was chosen (replacement technique).

","Exclusion :
1. Person who refused to give assent or informed consent
2. Person with contraindication for capillary puncture (edema, insufficient perfusion, coagulation disorders)
3. Children under 5 years of age due to the difficulty in taking a blood sample and receiving consen",2020-06-16,2020-06-23,Household and community samples,All,Multiple groups,5.0,,Geographical area,Gracias a Dios,59,0.051,,,,,,,,Stratified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.934,0.9770000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Mario Rene Mejia Nunez ,Colegio Médico,Unity-Aligned,https://revistas.ucr.ac.cr/index.php/psm/article/view/43261/46175,2021-04-16,2022-07-16,Verified,rene_mejia_nunez_vista_2020,HND
201217_Honduras_ColegioMédico_Choluteca,201217_Honduras_ColegioMédico,"Seroepidemiological surveillance of SARS-CoV-2 circulation in 41 municipalities in Honduras wth no reports of active cases, COVID-19, June 16-23, 2020",2020-12-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Honduras,Choluteca,,"Inclusion:
1. Person over 5 years old
2. Person whose birthday was closest to the day of the test and who agreed to participate in the study.
3. In the event that the first did not accept, the next person whose birthday was closest to the day of the test was chosen (replacement technique).

","Exclusion :
1. Person who refused to give assent or informed consent
2. Person with contraindication for capillary puncture (edema, insufficient perfusion, coagulation disorders)
3. Children under 5 years of age due to the difficulty in taking a blood sample and receiving consen",2020-06-16,2020-06-23,Household and community samples,All,Multiple groups,5.0,,Geographical area,Choluteca,54,0.24100000000000002,,,,,,,,Stratified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.934,0.9770000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Mario Rene Mejia Nunez ,Colegio Médico,Unity-Aligned,https://revistas.ucr.ac.cr/index.php/psm/article/view/43261/46175,2021-04-16,2022-07-16,Verified,rene_mejia_nunez_vista_2020,HND
201217_Honduras_ColegioMédico_40-49,201217_Honduras_ColegioMédico,"Seroepidemiological surveillance of SARS-CoV-2 circulation in 41 municipalities in Honduras wth no reports of active cases, COVID-19, June 16-23, 2020",2020-12-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Honduras,,,"Inclusion:
1. Person over 5 years old
2. Person whose birthday was closest to the day of the test and who agreed to participate in the study.
3. In the event that the first did not accept, the next person whose birthday was closest to the day of the test was chosen (replacement technique).

","Exclusion :
1. Person who refused to give assent or informed consent
2. Person with contraindication for capillary puncture (edema, insufficient perfusion, coagulation disorders)
3. Children under 5 years of age due to the difficulty in taking a blood sample and receiving consen",2020-06-16,2020-06-23,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,147,0.0748,,,,,,,,Stratified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.934,0.9770000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Mario Rene Mejia Nunez ,Colegio Médico,Unity-Aligned,https://revistas.ucr.ac.cr/index.php/psm/article/view/43261/46175,2021-04-16,2022-07-16,Verified,rene_mejia_nunez_vista_2020,HND
201217_Honduras_ColegioMédico_FranciscoMorazán,201217_Honduras_ColegioMédico,"Seroepidemiological surveillance of SARS-CoV-2 circulation in 41 municipalities in Honduras wth no reports of active cases, COVID-19, June 16-23, 2020",2020-12-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Honduras,Francisco Morazán,,"Inclusion:
1. Person over 5 years old
2. Person whose birthday was closest to the day of the test and who agreed to participate in the study.
3. In the event that the first did not accept, the next person whose birthday was closest to the day of the test was chosen (replacement technique).

","Exclusion :
1. Person who refused to give assent or informed consent
2. Person with contraindication for capillary puncture (edema, insufficient perfusion, coagulation disorders)
3. Children under 5 years of age due to the difficulty in taking a blood sample and receiving consen",2020-06-16,2020-06-23,Household and community samples,All,Multiple groups,5.0,,Geographical area,Francisco Morazán,38,0.026000000000000002,,,,,,,,Stratified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.934,0.9770000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Mario Rene Mejia Nunez ,Colegio Médico,Unity-Aligned,https://revistas.ucr.ac.cr/index.php/psm/article/view/43261/46175,2021-04-16,2022-07-16,Verified,rene_mejia_nunez_vista_2020,HND
201217_Honduras_ColegioMédico_Copan,201217_Honduras_ColegioMédico,"Seroepidemiological surveillance of SARS-CoV-2 circulation in 41 municipalities in Honduras wth no reports of active cases, COVID-19, June 16-23, 2020",2020-12-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Honduras,Copan,,"Inclusion:
1. Person over 5 years old
2. Person whose birthday was closest to the day of the test and who agreed to participate in the study.
3. In the event that the first did not accept, the next person whose birthday was closest to the day of the test was chosen (replacement technique).

","Exclusion :
1. Person who refused to give assent or informed consent
2. Person with contraindication for capillary puncture (edema, insufficient perfusion, coagulation disorders)
3. Children under 5 years of age due to the difficulty in taking a blood sample and receiving consen",2020-06-16,2020-06-23,Household and community samples,All,Multiple groups,5.0,,Geographical area,Copan,38,0.184,,,,,,,,Stratified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.934,0.9770000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Mario Rene Mejia Nunez ,Colegio Médico,Unity-Aligned,https://revistas.ucr.ac.cr/index.php/psm/article/view/43261/46175,2021-04-16,2022-07-16,Verified,rene_mejia_nunez_vista_2020,HND
201217_Honduras_ColegioMédico_30-39,201217_Honduras_ColegioMédico,"Seroepidemiological surveillance of SARS-CoV-2 circulation in 41 municipalities in Honduras wth no reports of active cases, COVID-19, June 16-23, 2020",2020-12-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Honduras,,,"Inclusion:
1. Person over 5 years old
2. Person whose birthday was closest to the day of the test and who agreed to participate in the study.
3. In the event that the first did not accept, the next person whose birthday was closest to the day of the test was chosen (replacement technique).

","Exclusion :
1. Person who refused to give assent or informed consent
2. Person with contraindication for capillary puncture (edema, insufficient perfusion, coagulation disorders)
3. Children under 5 years of age due to the difficulty in taking a blood sample and receiving consen",2020-06-16,2020-06-23,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,194,0.0258,,,,,,,,Stratified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.934,0.9770000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Mario Rene Mejia Nunez ,Colegio Médico,Unity-Aligned,https://revistas.ucr.ac.cr/index.php/psm/article/view/43261/46175,2021-04-16,2022-07-16,Verified,rene_mejia_nunez_vista_2020,HND
201217_Honduras_ColegioMédico_SantaBárbara,201217_Honduras_ColegioMédico,"Seroepidemiological surveillance of SARS-CoV-2 circulation in 41 municipalities in Honduras wth no reports of active cases, COVID-19, June 16-23, 2020",2020-12-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Honduras,Santa Bárbara,,"Inclusion:
1. Person over 5 years old
2. Person whose birthday was closest to the day of the test and who agreed to participate in the study.
3. In the event that the first did not accept, the next person whose birthday was closest to the day of the test was chosen (replacement technique).

","Exclusion :
1. Person who refused to give assent or informed consent
2. Person with contraindication for capillary puncture (edema, insufficient perfusion, coagulation disorders)
3. Children under 5 years of age due to the difficulty in taking a blood sample and receiving consen",2020-06-16,2020-06-23,Household and community samples,All,Multiple groups,5.0,,Geographical area,Santa Bárbara,59,0.017,,,,,,,,Stratified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.934,0.9770000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Mario Rene Mejia Nunez ,Colegio Médico,Unity-Aligned,https://revistas.ucr.ac.cr/index.php/psm/article/view/43261/46175,2021-04-16,2022-07-16,Verified,rene_mejia_nunez_vista_2020,HND
201217_Honduras_ColegioMédico_ElParaíso,201217_Honduras_ColegioMédico,"Seroepidemiological surveillance of SARS-CoV-2 circulation in 41 municipalities in Honduras wth no reports of active cases, COVID-19, June 16-23, 2020",2020-12-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Honduras,El Paraíso,,"Inclusion:
1. Person over 5 years old
2. Person whose birthday was closest to the day of the test and who agreed to participate in the study.
3. In the event that the first did not accept, the next person whose birthday was closest to the day of the test was chosen (replacement technique).

","Exclusion :
1. Person who refused to give assent or informed consent
2. Person with contraindication for capillary puncture (edema, insufficient perfusion, coagulation disorders)
3. Children under 5 years of age due to the difficulty in taking a blood sample and receiving consen",2020-06-16,2020-06-23,Household and community samples,All,Multiple groups,5.0,,Geographical area,El Paraíso,55,0.127,,,,,,,,Stratified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.934,0.9770000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Mario Rene Mejia Nunez ,Colegio Médico,Unity-Aligned,https://revistas.ucr.ac.cr/index.php/psm/article/view/43261/46175,2021-04-16,2022-07-16,Verified,rene_mejia_nunez_vista_2020,HND
201217_Honduras_ColegioMédico_50-59,201217_Honduras_ColegioMédico,"Seroepidemiological surveillance of SARS-CoV-2 circulation in 41 municipalities in Honduras wth no reports of active cases, COVID-19, June 16-23, 2020",2020-12-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Honduras,,,"Inclusion:
1. Person over 5 years old
2. Person whose birthday was closest to the day of the test and who agreed to participate in the study.
3. In the event that the first did not accept, the next person whose birthday was closest to the day of the test was chosen (replacement technique).

","Exclusion :
1. Person who refused to give assent or informed consent
2. Person with contraindication for capillary puncture (edema, insufficient perfusion, coagulation disorders)
3. Children under 5 years of age due to the difficulty in taking a blood sample and receiving consen",2020-06-16,2020-06-23,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,118,0.08470000000000001,,,,,,,,Stratified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.934,0.9770000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Mario Rene Mejia Nunez ,Colegio Médico,Unity-Aligned,https://revistas.ucr.ac.cr/index.php/psm/article/view/43261/46175,2021-04-16,2022-07-16,Verified,rene_mejia_nunez_vista_2020,HND
201217_Honduras_ColegioMédico_Octepeque,201217_Honduras_ColegioMédico,"Seroepidemiological surveillance of SARS-CoV-2 circulation in 41 municipalities in Honduras wth no reports of active cases, COVID-19, June 16-23, 2020",2020-12-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Honduras,Octepeque,,"Inclusion:
1. Person over 5 years old
2. Person whose birthday was closest to the day of the test and who agreed to participate in the study.
3. In the event that the first did not accept, the next person whose birthday was closest to the day of the test was chosen (replacement technique).

","Exclusion :
1. Person who refused to give assent or informed consent
2. Person with contraindication for capillary puncture (edema, insufficient perfusion, coagulation disorders)
3. Children under 5 years of age due to the difficulty in taking a blood sample and receiving consen",2020-06-16,2020-06-23,Household and community samples,All,Multiple groups,5.0,,Geographical area,Octepeque,37,0.0,,,,,,,,Stratified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.934,0.9770000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Mario Rene Mejia Nunez ,Colegio Médico,Unity-Aligned,https://revistas.ucr.ac.cr/index.php/psm/article/view/43261/46175,2021-04-16,2022-07-16,Verified,rene_mejia_nunez_vista_2020,HND
201217_Honduras_ColegioMédico_10-19,201217_Honduras_ColegioMédico,"Seroepidemiological surveillance of SARS-CoV-2 circulation in 41 municipalities in Honduras wth no reports of active cases, COVID-19, June 16-23, 2020",2020-12-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Honduras,,,"Inclusion:
1. Person over 5 years old
2. Person whose birthday was closest to the day of the test and who agreed to participate in the study.
3. In the event that the first did not accept, the next person whose birthday was closest to the day of the test was chosen (replacement technique).

","Exclusion :
1. Person who refused to give assent or informed consent
2. Person with contraindication for capillary puncture (edema, insufficient perfusion, coagulation disorders)
3. Children under 5 years of age due to the difficulty in taking a blood sample and receiving consen",2020-06-16,2020-06-23,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,37,0.081,,,,,,,,Stratified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.934,0.9770000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Mario Rene Mejia Nunez ,Colegio Médico,Unity-Aligned,https://revistas.ucr.ac.cr/index.php/psm/article/view/43261/46175,2021-04-16,2022-07-16,Verified,rene_mejia_nunez_vista_2020,HND
201217_Honduras_ColegioMédico_60+,201217_Honduras_ColegioMédico,"Seroepidemiological surveillance of SARS-CoV-2 circulation in 41 municipalities in Honduras wth no reports of active cases, COVID-19, June 16-23, 2020",2020-12-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Honduras,,,"Inclusion:
1. Person over 5 years old
2. Person whose birthday was closest to the day of the test and who agreed to participate in the study.
3. In the event that the first did not accept, the next person whose birthday was closest to the day of the test was chosen (replacement technique).

","Exclusion :
1. Person who refused to give assent or informed consent
2. Person with contraindication for capillary puncture (edema, insufficient perfusion, coagulation disorders)
3. Children under 5 years of age due to the difficulty in taking a blood sample and receiving consen",2020-06-16,2020-06-23,Household and community samples,All,Seniors (65+ years),60.0,,Age,60+,96,0.0625,,,,,,,,Stratified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.934,0.9770000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Mario Rene Mejia Nunez ,Colegio Médico,Unity-Aligned,https://revistas.ucr.ac.cr/index.php/psm/article/view/43261/46175,2021-04-16,2022-07-16,Verified,rene_mejia_nunez_vista_2020,HND
201217_Honduras_ColegioMédico_Lempira,201217_Honduras_ColegioMédico,"Seroepidemiological surveillance of SARS-CoV-2 circulation in 41 municipalities in Honduras wth no reports of active cases, COVID-19, June 16-23, 2020",2020-12-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Honduras,Lempira,,"Inclusion:
1. Person over 5 years old
2. Person whose birthday was closest to the day of the test and who agreed to participate in the study.
3. In the event that the first did not accept, the next person whose birthday was closest to the day of the test was chosen (replacement technique).

","Exclusion :
1. Person who refused to give assent or informed consent
2. Person with contraindication for capillary puncture (edema, insufficient perfusion, coagulation disorders)
3. Children under 5 years of age due to the difficulty in taking a blood sample and receiving consen",2020-06-16,2020-06-23,Household and community samples,All,Multiple groups,5.0,,Geographical area,Lempira,37,0.054000000000000006,,,,,,,,Stratified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.934,0.9770000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Mario Rene Mejia Nunez ,Colegio Médico,Unity-Aligned,https://revistas.ucr.ac.cr/index.php/psm/article/view/43261/46175,2021-04-16,2022-07-16,Verified,rene_mejia_nunez_vista_2020,HND
201217_Honduras_ColegioMédico_Male,201217_Honduras_ColegioMédico,"Seroepidemiological surveillance of SARS-CoV-2 circulation in 41 municipalities in Honduras wth no reports of active cases, COVID-19, June 16-23, 2020",2020-12-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Honduras,,,"Inclusion:
1. Person over 5 years old
2. Person whose birthday was closest to the day of the test and who agreed to participate in the study.
3. In the event that the first did not accept, the next person whose birthday was closest to the day of the test was chosen (replacement technique).

","Exclusion :
1. Person who refused to give assent or informed consent
2. Person with contraindication for capillary puncture (edema, insufficient perfusion, coagulation disorders)
3. Children under 5 years of age due to the difficulty in taking a blood sample and receiving consen",2020-06-16,2020-06-23,Household and community samples,Male,Multiple groups,5.0,,Sex/Gender,Male,359,0.0752,,,,,,,,Stratified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.934,0.9770000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Mario Rene Mejia Nunez ,Colegio Médico,Unity-Aligned,https://revistas.ucr.ac.cr/index.php/psm/article/view/43261/46175,2021-04-16,2022-07-16,Verified,rene_mejia_nunez_vista_2020,HND
201217_Honduras_ColegioMédico_LaPaz,201217_Honduras_ColegioMédico,"Seroepidemiological surveillance of SARS-CoV-2 circulation in 41 municipalities in Honduras wth no reports of active cases, COVID-19, June 16-23, 2020",2020-12-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Honduras,La Paz,,"Inclusion:
1. Person over 5 years old
2. Person whose birthday was closest to the day of the test and who agreed to participate in the study.
3. In the event that the first did not accept, the next person whose birthday was closest to the day of the test was chosen (replacement technique).

","Exclusion :
1. Person who refused to give assent or informed consent
2. Person with contraindication for capillary puncture (edema, insufficient perfusion, coagulation disorders)
3. Children under 5 years of age due to the difficulty in taking a blood sample and receiving consen",2020-06-16,2020-06-23,Household and community samples,All,Multiple groups,5.0,,Geographical area,La Paz,24,0.0,,,,,,,,Stratified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.934,0.9770000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Mario Rene Mejia Nunez ,Colegio Médico,Unity-Aligned,https://revistas.ucr.ac.cr/index.php/psm/article/view/43261/46175,2021-04-16,2022-07-16,Verified,rene_mejia_nunez_vista_2020,HND
201217_Honduras_ColegioMédico_Yoro,201217_Honduras_ColegioMédico,"Seroepidemiological surveillance of SARS-CoV-2 circulation in 41 municipalities in Honduras wth no reports of active cases, COVID-19, June 16-23, 2020",2020-12-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Honduras,Yoro,,"Inclusion:
1. Person over 5 years old
2. Person whose birthday was closest to the day of the test and who agreed to participate in the study.
3. In the event that the first did not accept, the next person whose birthday was closest to the day of the test was chosen (replacement technique).

","Exclusion :
1. Person who refused to give assent or informed consent
2. Person with contraindication for capillary puncture (edema, insufficient perfusion, coagulation disorders)
3. Children under 5 years of age due to the difficulty in taking a blood sample and receiving consen",2020-06-16,2020-06-23,Household and community samples,All,Multiple groups,5.0,,Geographical area,Yoro,25,0.08,,,,,,,,Stratified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.934,0.9770000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Mario Rene Mejia Nunez ,Colegio Médico,Unity-Aligned,https://revistas.ucr.ac.cr/index.php/psm/article/view/43261/46175,2021-04-16,2022-07-16,Verified,rene_mejia_nunez_vista_2020,HND
201217_Honduras_ColegioMédico_20-29,201217_Honduras_ColegioMédico,"Seroepidemiological surveillance of SARS-CoV-2 circulation in 41 municipalities in Honduras wth no reports of active cases, COVID-19, June 16-23, 2020",2020-12-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Honduras,,,"Inclusion:
1. Person over 5 years old
2. Person whose birthday was closest to the day of the test and who agreed to participate in the study.
3. In the event that the first did not accept, the next person whose birthday was closest to the day of the test was chosen (replacement technique).

","Exclusion :
1. Person who refused to give assent or informed consent
2. Person with contraindication for capillary puncture (edema, insufficient perfusion, coagulation disorders)
3. Children under 5 years of age due to the difficulty in taking a blood sample and receiving consen",2020-06-16,2020-06-23,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,200,0.07,,,,,,,,Stratified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.934,0.9770000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Mario Rene Mejia Nunez ,Colegio Médico,Unity-Aligned,https://revistas.ucr.ac.cr/index.php/psm/article/view/43261/46175,2021-04-16,2022-07-16,Verified,rene_mejia_nunez_vista_2020,HND
201217_Honduras_ColegioMédico_Valle,201217_Honduras_ColegioMédico,"Seroepidemiological surveillance of SARS-CoV-2 circulation in 41 municipalities in Honduras wth no reports of active cases, COVID-19, June 16-23, 2020",2020-12-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Honduras,Valle,,"Inclusion:
1. Person over 5 years old
2. Person whose birthday was closest to the day of the test and who agreed to participate in the study.
3. In the event that the first did not accept, the next person whose birthday was closest to the day of the test was chosen (replacement technique).

","Exclusion :
1. Person who refused to give assent or informed consent
2. Person with contraindication for capillary puncture (edema, insufficient perfusion, coagulation disorders)
3. Children under 5 years of age due to the difficulty in taking a blood sample and receiving consen",2020-06-16,2020-06-23,Household and community samples,All,Multiple groups,5.0,,Geographical area,Valle,37,0.135,,,,,,,,Stratified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.934,0.9770000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Mario Rene Mejia Nunez ,Colegio Médico,Unity-Aligned,https://revistas.ucr.ac.cr/index.php/psm/article/view/43261/46175,2021-04-16,2022-07-16,Verified,rene_mejia_nunez_vista_2020,HND
201217_Honduras_ColegioMédico_Female,201217_Honduras_ColegioMédico,"Seroepidemiological surveillance of SARS-CoV-2 circulation in 41 municipalities in Honduras wth no reports of active cases, COVID-19, June 16-23, 2020",2020-12-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Honduras,,,"Inclusion:
1. Person over 5 years old
2. Person whose birthday was closest to the day of the test and who agreed to participate in the study.
3. In the event that the first did not accept, the next person whose birthday was closest to the day of the test was chosen (replacement technique).

","Exclusion :
1. Person who refused to give assent or informed consent
2. Person with contraindication for capillary puncture (edema, insufficient perfusion, coagulation disorders)
3. Children under 5 years of age due to the difficulty in taking a blood sample and receiving consen",2020-06-16,2020-06-23,Household and community samples,Female,Multiple groups,5.0,,Sex/Gender,Female,433,0.051,,,,,,,,Stratified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.934,0.9770000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Mario Rene Mejia Nunez ,Colegio Médico,Unity-Aligned,https://revistas.ucr.ac.cr/index.php/psm/article/view/43261/46175,2021-04-16,2022-07-16,Verified,rene_mejia_nunez_vista_2020,HND
201217_Honduras_ColegioMédico_Comayagua,201217_Honduras_ColegioMédico,"Seroepidemiological surveillance of SARS-CoV-2 circulation in 41 municipalities in Honduras wth no reports of active cases, COVID-19, June 16-23, 2020",2020-12-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Honduras,Comayagua,,"Inclusion:
1. Person over 5 years old
2. Person whose birthday was closest to the day of the test and who agreed to participate in the study.
3. In the event that the first did not accept, the next person whose birthday was closest to the day of the test was chosen (replacement technique).

","Exclusion :
1. Person who refused to give assent or informed consent
2. Person with contraindication for capillary puncture (edema, insufficient perfusion, coagulation disorders)
3. Children under 5 years of age due to the difficulty in taking a blood sample and receiving consen",2020-06-16,2020-06-23,Household and community samples,All,Multiple groups,5.0,,Geographical area,Comayagua,76,0.039,,,,,,,,Stratified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.934,0.9770000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Mario Rene Mejia Nunez ,Colegio Médico,Unity-Aligned,https://revistas.ucr.ac.cr/index.php/psm/article/view/43261/46175,2021-04-16,2022-07-16,Verified,rene_mejia_nunez_vista_2020,HND
 201217_Honduras_ColegioMédico_Intibucá,201217_Honduras_ColegioMédico,"Seroepidemiological surveillance of SARS-CoV-2 circulation in 41 municipalities in Honduras wth no reports of active cases, COVID-19, June 16-23, 2020",2020-12-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Honduras,Intibuca,,"Inclusion:
1. Person over 5 years old
2. Person whose birthday was closest to the day of the test and who agreed to participate in the study.
3. In the event that the first did not accept, the next person whose birthday was closest to the day of the test was chosen (replacement technique).

","Exclusion :
1. Person who refused to give assent or informed consent
2. Person with contraindication for capillary puncture (edema, insufficient perfusion, coagulation disorders)
3. Children under 5 years of age due to the difficulty in taking a blood sample and receiving consen",2020-06-16,2020-06-23,Household and community samples,All,Multiple groups,5.0,,Geographical area,Intibuca,57,0.0,,,,,,,,Stratified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.934,0.9770000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Mario Rene Mejia Nunez ,Colegio Médico,Unity-Aligned,https://revistas.ucr.ac.cr/index.php/psm/article/view/43261/46175,2021-04-16,2022-07-16,Verified,rene_mejia_nunez_vista_2020,HND
200717_Hungary_SemmelweisUniversity__GenPop_PopAdj,200717_Hungary_SemmelweisUniversity,"Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary",2020-07-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Hungary,,,"The target population included individuals aged
14 years or older, living in private households in Hungary. Note* ""For serological testing, blood samples were obtained from all participants at the age of 18 or older; under 18 years of age, blood testing was optional""",,2020-05-01,2020-05-16,Household and community samples,All,Multiple groups,14.0,,Primary Estimate,,10474,0.0068000000000000005,0.005,0.0086,True,,True,,True,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Bela Merkely,Semmelweis University,Unity-Aligned,https://dx.doi.org/10.1007/s11357-020-00226-9,2020-08-01,2024-03-01,Verified,merkely_novel_2020-1,HUN
200717_Hungary_SemmelweisUniversity_Age14to39_PopAdj,200717_Hungary_SemmelweisUniversity,"Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary",2020-07-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Hungary,,,"The target population included individuals aged
14 years or older, living in private households in Hungary. Note* ""For serological testing, blood samples were obtained from all participants at the age of 18 or older; under 18 years of age, blood testing was optional""",,2020-05-01,2020-05-16,Household and community samples,All,Adults (18-64 years),14.0,39.0,Age,14-39,3353,0.005600000000000001,0.0027,0.0086,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Bela Merkely,Semmelweis University,Unity-Aligned,https://dx.doi.org/10.1007/s11357-020-00226-9,2020-08-01,2024-03-01,Verified,merkely_novel_2020-1,HUN
200717_Hungary_SemmelweisUniversity__GenPop_NothernHungary_PopAdj,200717_Hungary_SemmelweisUniversity,"Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary",2020-07-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Hungary,,,"The target population included individuals aged
14 years or older, living in private households in Hungary. Note* ""For serological testing, blood samples were obtained from all participants at the age of 18 or older; under 18 years of age, blood testing was optional""",,2020-05-01,2020-05-16,Household and community samples,All,Multiple groups,14.0,,Geographical area,Northern  Hungary,1458,0.0045000000000000005,0.00046,0.0085,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Bela Merkely,Semmelweis University,Unity-Aligned,https://dx.doi.org/10.1007/s11357-020-00226-9,2020-08-01,2024-03-01,Verified,merkely_novel_2020-1,HUN
200717_Hungary_SemmelweisUniversity__GenPop_SoutherGreatPlain_PopAdj,200717_Hungary_SemmelweisUniversity,"Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary",2020-07-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Hungary,,,"The target population included individuals aged
14 years or older, living in private households in Hungary. Note* ""For serological testing, blood samples were obtained from all participants at the age of 18 or older; under 18 years of age, blood testing was optional""",,2020-05-01,2020-05-16,Household and community samples,All,Multiple groups,14.0,,Geographical area,Southern Great Plain,1434,0.0062,0.0022,0.0103,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Bela Merkely,Semmelweis University,Unity-Aligned,https://dx.doi.org/10.1007/s11357-020-00226-9,2020-08-01,2024-03-01,Verified,merkely_novel_2020-1,HUN
200717_Hungary_SemmelweisUniversity__Age40to64_PopAdj,200717_Hungary_SemmelweisUniversity,"Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary",2020-07-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Hungary,,,"The target population included individuals aged
14 years or older, living in private households in Hungary. Note* ""For serological testing, blood samples were obtained from all participants at the age of 18 or older; under 18 years of age, blood testing was optional""",,2020-05-01,2020-05-16,Household and community samples,All,Adults (18-64 years),40.0,64.0,Age,40-64,4735,0.006999999999999999,0.0044,0.0096,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Bela Merkely,Semmelweis University,Unity-Aligned,https://dx.doi.org/10.1007/s11357-020-00226-9,2020-08-01,2024-03-01,Verified,merkely_novel_2020-1,HUN
200717_Hungary_SemmelweisUniversity__GenPop_Budapest_PopAdj,200717_Hungary_SemmelweisUniversity,"Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary",2020-07-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Hungary,,,"The target population included individuals aged
14 years or older, living in private households in Hungary. Note* ""For serological testing, blood samples were obtained from all participants at the age of 18 or older; under 18 years of age, blood testing was optional""",,2020-05-01,2020-05-16,Household and community samples,All,Multiple groups,14.0,,Geographical area,Budapest ,987,0.009000000000000001,0.0029,0.0152,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Bela Merkely,Semmelweis University,Unity-Aligned,https://dx.doi.org/10.1007/s11357-020-00226-9,2020-08-01,2024-03-01,Verified,merkely_novel_2020-1,HUN
200717_Hungary_SemmelweisUniversity__Female_PopAdj,200717_Hungary_SemmelweisUniversity,"Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary",2020-07-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Hungary,,,"The target population included individuals aged
14 years or older, living in private households in Hungary. Note* ""For serological testing, blood samples were obtained from all participants at the age of 18 or older; under 18 years of age, blood testing was optional""",,2020-05-01,2020-05-16,Household and community samples,Female,Multiple groups,14.0,,Sex/Gender,Female,5610,0.0067,0.0042,0.0092,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Bela Merkely,Semmelweis University,Unity-Aligned,https://dx.doi.org/10.1007/s11357-020-00226-9,2020-08-01,2024-03-01,Verified,merkely_novel_2020-1,HUN
200717_Hungary_SemmelweisUniversity__Age14to39,200717_Hungary_SemmelweisUniversity,"Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary",2020-07-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Hungary,,,"The target population included individuals aged
14 years or older, living in private households in Hungary. Note* ""For serological testing, blood samples were obtained from all participants at the age of 18 or older; under 18 years of age, blood testing was optional""",,2020-05-01,2020-05-16,Household and community samples,All,Adults (18-64 years),14.0,39.0,Age,14-39,3353,0.00536832687,,,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Bela Merkely,Semmelweis University,Unity-Aligned,https://dx.doi.org/10.1007/s11357-020-00226-9,2020-08-01,2024-03-01,Verified,merkely_novel_2020-1,HUN
200717_Hungary_SemmelweisUniversity_GenPop,200717_Hungary_SemmelweisUniversity,"Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary",2020-07-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Hungary,,,"The target population included individuals aged
14 years or older, living in private households in Hungary. Note* ""For serological testing, blood samples were obtained from all participants at the age of 18 or older; under 18 years of age, blood testing was optional""",,2020-05-01,2020-05-16,Household and community samples,All,Multiple groups,14.0,,Analysis,Unadjusted,10474,0.006,,,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Bela Merkely,Semmelweis University,Unity-Aligned,https://dx.doi.org/10.1007/s11357-020-00226-9,2020-08-01,2024-03-01,Verified,merkely_novel_2020-1,HUN
200717_Hungary_SemmelweisUniversity__Age65+_PopAdj,200717_Hungary_SemmelweisUniversity,"Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary",2020-07-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Hungary,,,"The target population included individuals aged
14 years or older, living in private households in Hungary. Note* ""For serological testing, blood samples were obtained from all participants at the age of 18 or older; under 18 years of age, blood testing was optional""",,2020-05-01,2020-05-16,Household and community samples,All,Seniors (65+ years),65.0,,Age,>=65,2386,0.0083,0.0039000000000000003,0.0126,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Bela Merkely,Semmelweis University,Unity-Aligned,https://dx.doi.org/10.1007/s11357-020-00226-9,2020-08-01,2024-03-01,Verified,merkely_novel_2020-1,HUN
200717_Hungary_SemmelweisUniversity__Age40to64,200717_Hungary_SemmelweisUniversity,"Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary",2020-07-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Hungary,,,"The target population included individuals aged
14 years or older, living in private households in Hungary. Note* ""For serological testing, blood samples were obtained from all participants at the age of 18 or older; under 18 years of age, blood testing was optional""",,2020-05-01,2020-05-16,Household and community samples,All,Adults (18-64 years),40.0,64.0,Age,40-64,4735,0.006969376980000001,,,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Bela Merkely,Semmelweis University,Unity-Aligned,https://dx.doi.org/10.1007/s11357-020-00226-9,2020-08-01,2024-03-01,Verified,merkely_novel_2020-1,HUN
200717_Hungary_SemmelweisUniversity__GenPop_WesternTransdanubia_PopAdj,200717_Hungary_SemmelweisUniversity,"Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary",2020-07-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Hungary,,,"The target population included individuals aged
14 years or older, living in private households in Hungary. Note* ""For serological testing, blood samples were obtained from all participants at the age of 18 or older; under 18 years of age, blood testing was optional""",,2020-05-01,2020-05-16,Household and community samples,All,Multiple groups,14.0,,Geographical area,Western Transdanubia,1480,0.0085,0.004,0.0129,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Bela Merkely,Semmelweis University,Unity-Aligned,https://dx.doi.org/10.1007/s11357-020-00226-9,2020-08-01,2024-03-01,Verified,merkely_novel_2020-1,HUN
200717_Hungary_SemmelweisUniversity__Male,200717_Hungary_SemmelweisUniversity,"Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary",2020-07-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Hungary,,,"The target population included individuals aged
14 years or older, living in private households in Hungary. Note* ""For serological testing, blood samples were obtained from all participants at the age of 18 or older; under 18 years of age, blood testing was optional""",,2020-05-01,2020-05-16,Household and community samples,Male,Multiple groups,14.0,,Sex/Gender,Male ,4864,0.00719,,,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Bela Merkely,Semmelweis University,Unity-Aligned,https://dx.doi.org/10.1007/s11357-020-00226-9,2020-08-01,2024-03-01,Verified,merkely_novel_2020-1,HUN
200717_Hungary_SemmelweisUniversity__GenPop_CentralTransdanubia_PopAdj,200717_Hungary_SemmelweisUniversity,"Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary",2020-07-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Hungary,,,"The target population included individuals aged
14 years or older, living in private households in Hungary. Note* ""For serological testing, blood samples were obtained from all participants at the age of 18 or older; under 18 years of age, blood testing was optional""",,2020-05-01,2020-05-16,Household and community samples,All,Multiple groups,14.0,,Geographical area,Central Transdanubia,1606,0.0068000000000000005,0.0029,0.010700000000000001,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Bela Merkely,Semmelweis University,Unity-Aligned,https://dx.doi.org/10.1007/s11357-020-00226-9,2020-08-01,2024-03-01,Verified,merkely_novel_2020-1,HUN
200717_Hungary_SemmelweisUniversity__GenPop_PestCounty_PopAdj,200717_Hungary_SemmelweisUniversity,"Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary",2020-07-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Hungary,,,"The target population included individuals aged
14 years or older, living in private households in Hungary. Note* ""For serological testing, blood samples were obtained from all participants at the age of 18 or older; under 18 years of age, blood testing was optional""",,2020-05-01,2020-05-16,Household and community samples,All,Multiple groups,14.0,,Geographical area,Pest County,768,0.0064,0.00094,0.0118,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Bela Merkely,Semmelweis University,Unity-Aligned,https://dx.doi.org/10.1007/s11357-020-00226-9,2020-08-01,2024-03-01,Verified,merkely_novel_2020-1,HUN
200717_Hungary_SemmelweisUniversity__GenPop_SouthernTransdanubia_PopAdj,200717_Hungary_SemmelweisUniversity,"Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary",2020-07-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Hungary,,,"The target population included individuals aged
14 years or older, living in private households in Hungary. Note* ""For serological testing, blood samples were obtained from all participants at the age of 18 or older; under 18 years of age, blood testing was optional""",,2020-05-01,2020-05-16,Household and community samples,All,Multiple groups,14.0,,Geographical area,Souther Transdanubia,1335,0.0046,0.0014000000000000002,0.0079,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Bela Merkely,Semmelweis University,Unity-Aligned,https://dx.doi.org/10.1007/s11357-020-00226-9,2020-08-01,2024-03-01,Verified,merkely_novel_2020-1,HUN
200717_Hungary_SemmelweisUniversity__Female,200717_Hungary_SemmelweisUniversity,"Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary",2020-07-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Hungary,,,"The target population included individuals aged
14 years or older, living in private households in Hungary. Note* ""For serological testing, blood samples were obtained from all participants at the age of 18 or older; under 18 years of age, blood testing was optional""",,2020-05-01,2020-05-16,Household and community samples,Female,Multiple groups,14.0,,Sex/Gender,Female,5610,0.0062,,,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Bela Merkely,Semmelweis University,Unity-Aligned,https://dx.doi.org/10.1007/s11357-020-00226-9,2020-08-01,2024-03-01,Verified,merkely_novel_2020-1,HUN
200717_Hungary_SemmelweisUniversity__GenPop_NorthernGreatPlain_PopAdj,200717_Hungary_SemmelweisUniversity,"Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary",2020-07-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Hungary,,,"The target population included individuals aged
14 years or older, living in private households in Hungary. Note* ""For serological testing, blood samples were obtained from all participants at the age of 18 or older; under 18 years of age, blood testing was optional""",,2020-05-01,2020-05-16,Household and community samples,All,Multiple groups,14.0,,Geographical area,Northern Great Plain,1406,0.006999999999999999,0.0022,0.0118,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Bela Merkely,Semmelweis University,Unity-Aligned,https://dx.doi.org/10.1007/s11357-020-00226-9,2020-08-01,2024-03-01,Verified,merkely_novel_2020-1,HUN
200717_Hungary_SemmelweisUniversity__Age65+,200717_Hungary_SemmelweisUniversity,"Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary",2020-07-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Hungary,,,"The target population included individuals aged
14 years or older, living in private households in Hungary. Note* ""For serological testing, blood samples were obtained from all participants at the age of 18 or older; under 18 years of age, blood testing was optional""",,2020-05-01,2020-05-16,Household and community samples,All,Seniors (65+ years),65.0,,Age,>=65,2386,0.00796311819,,,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Bela Merkely,Semmelweis University,Unity-Aligned,https://dx.doi.org/10.1007/s11357-020-00226-9,2020-08-01,2024-03-01,Verified,merkely_novel_2020-1,HUN
200717_Hungary_SemmelweisUniversity__Male_PopAdj,200717_Hungary_SemmelweisUniversity,"Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary",2020-07-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Hungary,,,"The target population included individuals aged
14 years or older, living in private households in Hungary. Note* ""For serological testing, blood samples were obtained from all participants at the age of 18 or older; under 18 years of age, blood testing was optional""",,2020-05-01,2020-05-16,Household and community samples,Male,Multiple groups,14.0,,Sex/Gender,Male ,4864,0.006999999999999999,0.0044,0.0095,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Bela Merkely,Semmelweis University,Unity-Aligned,https://dx.doi.org/10.1007/s11357-020-00226-9,2020-08-01,2024-03-01,Verified,merkely_novel_2020-1,HUN
211215_Budapest_SemmelweisUniversity_HungarianIntProgram,211215_Budapest_SemmelweisUniversity_HungarianIntProgram,"Acute SARS-CoV-2 infection and seropositivity among healthcare workers and medical students in summer 2020, Hungary.",2021-12-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Hungary,Central Hungary,Budapest,"Medical students + HCWs: Employees of those organizational and related service units (mainte- nance, security, reception, administration) involved in direct patient care were included Among these students, those who were involved actively in voluntary healthcare or as part of their practical train- ing were included."," Since the first restric- tive measures, employees of theoretical institutions of the university had been working in home office and used online systems; thus, they were excluded from the study.",2020-07-01,2020-08-01,Students and Daycares,All,Adults (18-64 years),,,Primary Estimate,Hungarian international program med students,682,0.016,0.006999999999999999,0.026000000000000002,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Annamaria Kosztin,Semmelweis University,Not Unity-Aligned,https://dx.doi.org/10.13075/ijomeh.1896.01804,2022-01-11,2024-03-01,Unverified,kosztin_acute_2021,HUN
211215_Budapest_SemmelweisUniversity_HungarianProgram,211215_Budapest_SemmelweisUniversity_HungarianProgram,"Acute SARS-CoV-2 infection and seropositivity among healthcare workers and medical students in summer 2020, Hungary.",2021-12-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Hungary,Central Hungary,Budapest,"Medical students + HCWs: Employees of those organizational and related service units (mainte- nance, security, reception, administration) involved in direct patient care were included Among these students, those who were involved actively in voluntary healthcare or as part of their practical train- ing were included."," Since the first restric- tive measures, employees of theoretical institutions of the university had been working in home office and used online systems; thus, they were excluded from the study.",2020-07-01,2020-08-01,Students and Daycares,All,Adults (18-64 years),,,Primary Estimate,Hungarian program med students,956,0.006,0.0,0.011000000000000001,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Annamaria Kosztin,Semmelweis University,Not Unity-Aligned,https://dx.doi.org/10.13075/ijomeh.1896.01804,2022-01-11,2024-03-01,Unverified,kosztin_acute_2021,HUN
211215_Budapest_SemmelweisUniversity_IntStudents,211215_Budapest_SemmelweisUniversity_IntStudents,"Acute SARS-CoV-2 infection and seropositivity among healthcare workers and medical students in summer 2020, Hungary.",2021-12-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Hungary,Central Hungary,Budapest,"Medical students + HCWs: Employees of those organizational and related service units (mainte- nance, security, reception, administration) involved in direct patient care were included Among these students, those who were involved actively in voluntary healthcare or as part of their practical train- ing were included."," Since the first restric- tive measures, employees of theoretical institutions of the university had been working in home office and used online systems; thus, they were excluded from the study.",2020-07-01,2020-08-01,Students and Daycares,All,Adults (18-64 years),,,Primary Estimate,International med students,1832,0.021,0.013999999999999999,0.027000000000000003,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Annamaria Kosztin,Semmelweis University,Not Unity-Aligned,https://dx.doi.org/10.13075/ijomeh.1896.01804,2022-01-11,2024-03-01,Unverified,kosztin_acute_2021,HUN
211215_Budapest_SemmelweisUniversity_OtherHCW,211215_Budapest_SemmelweisUniversity_OtherHCW,"Acute SARS-CoV-2 infection and seropositivity among healthcare workers and medical students in summer 2020, Hungary.",2021-12-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Hungary,Central Hungary,Budapest,"Medical students + HCWs: Employees of those organizational and related service units (mainte- nance, security, reception, administration) involved in direct patient care were included Among these students, those who were involved actively in voluntary healthcare or as part of their practical train- ing were included."," Since the first restric- tive measures, employees of theoretical institutions of the university had been working in home office and used online systems; thus, they were excluded from the study.",2020-07-01,2020-08-01,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Other HCW,2926,0.018000000000000002,0.013999999999999999,0.023,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Annamaria Kosztin,Semmelweis University,Not Unity-Aligned,https://dx.doi.org/10.13075/ijomeh.1896.01804,2022-01-11,2024-03-01,Unverified,kosztin_acute_2021,HUN
211215_Budapest_SemmelweisUniversity_Physicians,211215_Budapest_SemmelweisUniversity_Physicians,"Acute SARS-CoV-2 infection and seropositivity among healthcare workers and medical students in summer 2020, Hungary.",2021-12-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Hungary,Central Hungary,Budapest,"Medical students + HCWs: Employees of those organizational and related service units (mainte- nance, security, reception, administration) involved in direct patient care were included Among these students, those who were involved actively in voluntary healthcare or as part of their practical train- ing were included."," Since the first restric- tive measures, employees of theoretical institutions of the university had been working in home office and used online systems; thus, they were excluded from the study.",2020-07-01,2020-08-01,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Physicians,1552,0.015,0.009000000000000001,0.022000000000000002,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Annamaria Kosztin,Semmelweis University,Not Unity-Aligned,https://dx.doi.org/10.13075/ijomeh.1896.01804,2022-01-11,2024-03-01,Unverified,kosztin_acute_2021,HUN
230329_Budapest_UniversityOfVeterinaryMedicineBudapest_1MultiplePop,230329_Budapest_UniversityOfVeterinaryMedicineBudapest_1MultiplePop,Asymptomatic and Mild SARS-CoV-2 Infections in a Hungarian Outpatient Cohort in the First Year of the COVID-19 Pandemic.,2023-03-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Hungary,,Budapest,"The study population consisted of outpatient adults with mild or no COVID-19 symptoms and was divided into subpopulations with different levels of exposure.

The participants of the study included (1) patients who visited the CMC clinic between April 2020 and March 2021 with mild symptoms that were potentially attributable to COVID-19; (2) patients who visited the clinic because of medical problems unrelated to COVID-19 but who were nonetheless interested in testing for possible SARS-CoV-2 infection; (3) employees of the clinic; or (4) people who needed to know their SARS-CoV-2-related status for business or travel purposes.",,2020-04-15,2021-03-15,Multiple populations,All,Multiple groups,20.0,96.0,Primary Estimate,Overall period from Apr 2020 to Mar 2021,3771,0.129,0.1189,0.1405,True,,,,True,Convenience,"Diapro,Author designed (ELISA) -Unknown","Palex,NA",ELISA,Serum,IgG,"['Spike', 'Whole-virusantigen']",Validated by manufacturers,,,['High'],,No,Yes,Yes,,Unclear,No,No,,Istvan Jankovics,University of Veterinary Medicine Budapest,Not Unity-Aligned,https://dx.doi.org/10.3390/tropicalmed8040204,2023-05-30,2024-03-01,Unverified,jankovics_asymptomatic_2023,HUN
230329_Budapest_UniversityOfVeterinaryMedicineBudapest_2CovidContacts,230329_Budapest_UniversityOfVeterinaryMedicineBudapest_2CovidContacts,Asymptomatic and Mild SARS-CoV-2 Infections in a Hungarian Outpatient Cohort in the First Year of the COVID-19 Pandemic.,2023-03-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Hungary,,Budapest,"The study population consisted of outpatient adults with mild or no COVID-19 symptoms and was divided into subpopulations with different levels of exposure.

The participants of the study included (1) patients who visited the CMC clinic between April 2020 and March 2021 with mild symptoms that were potentially attributable to COVID-19; (2) patients who visited the clinic because of medical problems unrelated to COVID-19 but who were nonetheless interested in testing for possible SARS-CoV-2 infection; (3) employees of the clinic; or (4) people who needed to know their SARS-CoV-2-related status for business or travel purposes.",,2020-04-15,2021-03-15,Contacts of COVID patients,All,Multiple groups,20.0,96.0,Primary Estimate,Overall period from Apr 2020 to Mar 2021,571,0.106,0.0827,0.1351,True,,,,True,Convenience,"Diapro,Author designed (ELISA) -Unknown","Palex,NA",ELISA,Serum,IgG,"['Spike', 'Whole-virusantigen']",Validated by manufacturers,,,['High'],,No,No,No,,Unclear,No,No,,Istvan Jankovics,University of Veterinary Medicine Budapest,Not Unity-Aligned,https://dx.doi.org/10.3390/tropicalmed8040204,2023-05-30,2024-03-01,Unverified,jankovics_asymptomatic_2023,HUN
200901_Iceland_deCODEGenetics_OverallPopAdj,200901_Iceland_deCODEGenetics,Humoral Immune Response to SARS-CoV-2 in Iceland,2020-09-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iceland,,,"Sampled several groups - for seroprevalence, groups who had not been tested for PCR or tested negative PCR for coronavirus","Ran one analysis excluding COVID-19 confirmed, but inclusionary result also available",2020-04-27,2020-06-12,Household and community samples,All,Multiple groups,,,Primary Estimate,Overall gen pop national estimate ,23452,0.003,,,True,,True,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Wantai SARS-CoV-2 Total Ab ELISA","Roche Diagnostics,Beijing Wantai Biological",CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by manufacturers,0.9109999999999999,,['High'],No,No,Yes,No,Yes,Yes,Yes,No,Unclear,Daniel Gudbjartsson,deCODE Genetics,Unity-Aligned,http://dx.doi.org/10.1056/NEJMoa2026116,2020-10-13,2024-03-01,Verified,gudbjartsson_humoral_2020,ISL
200901_Iceland_deCODEGenetics_HealthCareWest,200901_Iceland_deCODEGenetics,Humoral Immune Response to SARS-CoV-2 in Iceland,2020-09-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iceland,West Iceland,,"Sampled several groups - for seroprevalence, groups who had not been tested for PCR or tested negative PCR for coronavirus","Ran one analysis excluding COVID-19 confirmed, but inclusionary result also available",2020-05-05,2020-06-12,Household and community samples,All,Multiple groups,,,Geographical area,Subgroup of the health care cohort in West Iceland,1135,0.003,0.001,0.006999999999999999,,,True,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Wantai SARS-CoV-2 Total Ab ELISA","Roche Diagnostics,Beijing Wantai Biological",CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by manufacturers,0.9109999999999999,,['High'],No,No,Yes,No,Yes,Yes,Yes,No,Unclear,Daniel Gudbjartsson,deCODE Genetics,Unity-Aligned,http://dx.doi.org/10.1056/NEJMoa2026116,2020-10-14,2024-03-01,Verified,gudbjartsson_humoral_2020,ISL
200901_Iceland_deCODEGenetics_HealthCareReykjavik,200901_Iceland_deCODEGenetics,Humoral Immune Response to SARS-CoV-2 in Iceland,2020-09-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iceland,Greater Reykjavík,Reykjavik,"Sampled several groups - for seroprevalence, groups who had not been tested for PCR or tested negative PCR for coronavirus","Ran one analysis excluding COVID-19 confirmed, but inclusionary result also available",2020-05-05,2020-06-12,Household and community samples,All,Multiple groups,,,Geographical area,Subgroup of the health care cohort in Reykjavik,11522,0.003,0.002,0.004,,,True,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Wantai SARS-CoV-2 Total Ab ELISA","Roche Diagnostics,Beijing Wantai Biological",CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by manufacturers,0.9109999999999999,,['High'],No,No,Yes,No,Yes,Yes,Yes,No,Unclear,Daniel Gudbjartsson,deCODE Genetics,Unity-Aligned,http://dx.doi.org/10.1056/NEJMoa2026116,2020-10-14,2024-03-01,Verified,gudbjartsson_humoral_2020,ISL
200901_Iceland_deCODEGenetics_HealthCareNortheast,200901_Iceland_deCODEGenetics,Humoral Immune Response to SARS-CoV-2 in Iceland,2020-09-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iceland,Northeast Iceland,,"Sampled several groups - for seroprevalence, groups who had not been tested for PCR or tested negative PCR for coronavirus","Ran one analysis excluding COVID-19 confirmed, but inclusionary result also available",2020-05-05,2020-06-12,Household and community samples,All,Multiple groups,,,Geographical area,Subgroup of the health care cohort in Northeast Iceland,1750,0.001,0.0,0.004,,,True,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Wantai SARS-CoV-2 Total Ab ELISA","Roche Diagnostics,Beijing Wantai Biological",CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by manufacturers,0.9109999999999999,,['High'],No,No,Yes,No,Yes,Yes,Yes,No,Unclear,Daniel Gudbjartsson,deCODE Genetics,Unity-Aligned,http://dx.doi.org/10.1056/NEJMoa2026116,2020-10-14,2024-03-01,Verified,gudbjartsson_humoral_2020,ISL
200901_Iceland_deCODEGenetics_HealthCareSPeninsula,200901_Iceland_deCODEGenetics,Humoral Immune Response to SARS-CoV-2 in Iceland,2020-09-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iceland,Iceland Southern Peninsula,,"Sampled several groups - for seroprevalence, groups who had not been tested for PCR or tested negative PCR for coronavirus","Ran one analysis excluding COVID-19 confirmed, but inclusionary result also available",2020-05-05,2020-06-12,Household and community samples,All,Multiple groups,,,Geographical area,Subgroup of the health care cohort in Southern Peninsula,1231,0.004,0.001,0.008,,,True,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Wantai SARS-CoV-2 Total Ab ELISA","Roche Diagnostics,Beijing Wantai Biological",CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by manufacturers,0.9109999999999999,,['High'],No,No,Yes,No,Yes,Yes,Yes,No,Unclear,Daniel Gudbjartsson,deCODE Genetics,Unity-Aligned,http://dx.doi.org/10.1056/NEJMoa2026116,2020-10-14,2024-03-01,Verified,gudbjartsson_humoral_2020,ISL
200901_Iceland_deCODEGenetics_Early2020,200901_Iceland_deCODEGenetics,Humoral Immune Response to SARS-CoV-2 in Iceland,2020-09-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iceland,,,"Sampled several groups - for seroprevalence, groups who had not been tested for PCR or tested negative PCR for coronavirus","Ran one analysis excluding COVID-19 confirmed, but inclusionary result also available",2020-02-18,2020-03-09,Household and community samples,All,Multiple groups,,,Time frame,deCODE health study in Feb/March 2020,470,0.009000000000000001,0.003,0.02,,,True,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Wantai SARS-CoV-2 Total Ab ELISA","Roche Diagnostics,Beijing Wantai Biological",CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by manufacturers,0.9109999999999999,,['High'],No,No,Yes,No,Yes,Yes,Yes,No,Unclear,Daniel Gudbjartsson,deCODE Genetics,Unity-Aligned,http://dx.doi.org/10.1056/NEJMoa2026116,2020-10-13,2024-03-01,Verified,gudbjartsson_humoral_2020,ISL
200901_Iceland_deCODEGenetics_HealthCareNorthwest,200901_Iceland_deCODEGenetics,Humoral Immune Response to SARS-CoV-2 in Iceland,2020-09-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iceland,Northwest Iceland,,"Sampled several groups - for seroprevalence, groups who had not been tested for PCR or tested negative PCR for coronavirus","Ran one analysis excluding COVID-19 confirmed, but inclusionary result also available",2020-05-05,2020-06-12,Household and community samples,All,Multiple groups,,,Geographical area,Subgroup of the health care cohort in Northwest Iceland,397,0.001,0.0,0.008,,,True,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Wantai SARS-CoV-2 Total Ab ELISA","Roche Diagnostics,Beijing Wantai Biological",CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by manufacturers,0.9109999999999999,,['High'],No,No,Yes,No,Yes,Yes,Yes,No,Unclear,Daniel Gudbjartsson,deCODE Genetics,Unity-Aligned,http://dx.doi.org/10.1056/NEJMoa2026116,2020-10-14,2024-03-01,Verified,gudbjartsson_humoral_2020,ISL
200901_Iceland_deCODEGenetics_HealthCareEast,200901_Iceland_deCODEGenetics,Humoral Immune Response to SARS-CoV-2 in Iceland,2020-09-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iceland,East Iceland,,"Sampled several groups - for seroprevalence, groups who had not been tested for PCR or tested negative PCR for coronavirus","Ran one analysis excluding COVID-19 confirmed, but inclusionary result also available",2020-05-05,2020-06-12,Household and community samples,All,Multiple groups,,,Geographical area,Subgroup of the health care cohort in East Iceland,517,0.0,0.0,0.004,,,True,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Wantai SARS-CoV-2 Total Ab ELISA","Roche Diagnostics,Beijing Wantai Biological",CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by manufacturers,0.9109999999999999,,['High'],No,No,Yes,No,Yes,Yes,Yes,No,Unclear,Daniel Gudbjartsson,deCODE Genetics,Unity-Aligned,http://dx.doi.org/10.1056/NEJMoa2026116,2020-10-14,2024-03-01,Verified,gudbjartsson_humoral_2020,ISL
200901_Iceland_deCODEGenetics_HealthCareSouth,200901_Iceland_deCODEGenetics,Humoral Immune Response to SARS-CoV-2 in Iceland,2020-09-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iceland,South Iceland,,"Sampled several groups - for seroprevalence, groups who had not been tested for PCR or tested negative PCR for coronavirus","Ran one analysis excluding COVID-19 confirmed, but inclusionary result also available",2020-05-05,2020-06-12,Household and community samples,All,Multiple groups,,,Geographical area,Subgroup of the health care cohort in South Iceland,1731,0.002,0.001,0.004,,,True,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Wantai SARS-CoV-2 Total Ab ELISA","Roche Diagnostics,Beijing Wantai Biological",CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by manufacturers,0.9109999999999999,,['High'],No,No,Yes,No,Yes,Yes,Yes,No,Unclear,Daniel Gudbjartsson,deCODE Genetics,Unity-Aligned,http://dx.doi.org/10.1056/NEJMoa2026116,2020-10-14,2024-03-01,Verified,gudbjartsson_humoral_2020,ISL
200901_Iceland_deCODEGenetics_HealthCareVestfirdir,200901_Iceland_deCODEGenetics,Humoral Immune Response to SARS-CoV-2 in Iceland,2020-09-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iceland,Vestfirdir,,"Sampled several groups - for seroprevalence, groups who had not been tested for PCR or tested negative PCR for coronavirus","Ran one analysis excluding COVID-19 confirmed, but inclusionary result also available",2020-05-05,2020-06-12,Household and community samples,All,Multiple groups,,,Geographical area,Subgroup of the health care cohort in Vestfirdir,326,0.0,0.0,0.006,,,True,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Wantai SARS-CoV-2 Total Ab ELISA","Roche Diagnostics,Beijing Wantai Biological",CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by manufacturers,0.9109999999999999,,['High'],No,No,Yes,No,Yes,Yes,Yes,No,Unclear,Daniel Gudbjartsson,deCODE Genetics,Unity-Aligned,http://dx.doi.org/10.1056/NEJMoa2026116,2020-10-14,2024-03-01,Verified,gudbjartsson_humoral_2020,ISL
200606_Bengaluru_SJICSR_Staff,200606_Bengaluru_SJICSR,Covid-19: Jayadeva says its survey hints at herd immunity,2020-06-06,News and Media,Local,Cross-sectional survey ,India,Karnataka,Bengaluru,One thousand Sri Jayadeva Institute of Cardiovascular Sciences and Research Staff Members aged 30 to 40 years old. ,,2020-05-23,2020-06-06,Health care workers and caregivers,All,Adults (18-64 years),30.0,40.0,Primary Estimate,,1000,0.01,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,IgG,,,,,['High'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Sunitha Rao,Sri Jayadeva Institute of Cardiovascular Sciences and Research,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://timesofindia.indiatimes.com/city/bengaluru/covid-19-jayadeva-says-its-survey-hints-at-herd-immunity/articleshow/76228490.cms&ct=ga&cd=CAAYADIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNHrh7Scfh82driNisE_8HVxMcpd8Q,2020-06-27,2022-07-16,Verified,rao_covid-19_2020,IND
200614_Thiruvananthapuram_HealthDepartment_GenPop,200614_Thiruvanathapuram_HealthDepartment,Initial trend: Positivity rate low in antibody testing,2020-06-14,News and Media,Local,Cross-sectional survey ,India,Kerala,Thiruvananthapuram,"Samples are being collected from five categories, which will cover healthcare workers who directly handle Covid patients and those in non-Covid hospitals, police personnel, field level health workers, workers in ration shops, food and grocery delivery boys, those in contact with interstate truck drivers, guest workers, persons under home quarantine, those under vulnerable category (above 60 years of age), personnel from general population and expatriates after 14 days of arrivals in the state after May 7.",,2020-06-09,2020-06-12,Household and community samples,All,Multiple groups,,,Primary Estimate,,450,0.0267,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,Multiple Types,"['IgG', 'IgM']",,,,,['High'],Yes,Unclear,No,No,Unclear,Unclear,Yes,No,Unclear,Aswin Kumar,Thiruvanathapuram Health Department,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://timesofindia.indiatimes.com/city/thiruvananthapuram/initial-trend-positivity-rate-low-in-antibody-testing/articleshow/76363847.cms&ct=ga&cd=CAAYADIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNHcN3WpGsIDw6iptLnm7KkY9Nl-tg,2020-07-06,2022-07-16,Verified,aswin_kumar_initial_2020,IND
200719_Lucknow_India_KingGeorgeMedicalUniversity_BloodDonors,200719_Lucknow_India_KingGeorgeMedicalUniversity,4% 'healthy' blood donors in Lucknow found with Covid antibodies,2020-07-19,News and Media,Local,Cross-sectional survey ,India,Uttar Pradesh,Lucknow,'Healthy' persons who donated blood in the department in the last two weeks.,,2020-07-05,2020-07-19,Blood donors,All,Multiple groups,,,Primary Estimate,,1235,0.037000000000000005,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,IgG,,,,,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Yusra Husain,King George's Medical University,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://timesofindia.indiatimes.com/city/lucknow/4-healthy-blood-donors-in-city-found-with-covid-antibodies/articleshow/77044828.cms&ct=ga&cd=CAAYBjIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNHrdF6GLOiOPUVeEg19jMKbusa8DA,2020-08-01,2022-07-16,Verified,yusra_husain_4_2020,IND
200721_Haryana_IntegratedDiseaseSurveillanceProgramme_GenPop,200721_Haryana_IntegratedDiseaseSurveillanceProgramme,"Pvt lab says 16-20% sero-prevalence in Gurugram, health dept distances itself from data",2020-07-21,News and Media,Regional,Cross-sectional survey ,India,Haryana,"Gurugram, Faridabad, Ambala, Panchkula, Sonipat","Under the survey, people who have a higher exposure to contract the coronavirus are covered. It includes population groups, such as shopkeepers, drivers, police personnel, health workers, pregnant women among others, as directed by the ICMR guidelines.",,2020-06-21,2020-07-15,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,,1544,0.12,,,True,,,,True,Stratified probability,Not reported/ Unable to specify,,ELISA,Whole Blood,IgG,,,,,['Moderate'],No,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,Prayag Arora Desai,Haryana Health Department,Not Unity-Aligned,https://www.hindustantimes.com/gurugram/pvt-lab-says-16-20-sero-prevalence-in-gurugram-health-dept-distances-itself-from-data/story-265qYKX4XhRPeMVc5HrKEO.html,2020-07-31,2022-07-16,Verified,arora-desai_pvt_2020,IND
200721_Haryana_IntegratedDiseaseSurveillanceProgramme_Gurugram,200721_Haryana_IntegratedDiseaseSurveillanceProgramme,"Pvt lab says 16-20% sero-prevalence in Gurugram, health dept distances itself from data",2020-07-21,News and Media,Local,Cross-sectional survey ,India,Haryana,Gurugram,"Under the survey, people who have a higher exposure to contract the coronavirus are covered. It includes population groups, such as shopkeepers, drivers, police personnel, health workers, pregnant women among others, as directed by the ICMR guidelines.",,2020-06-21,2020-07-15,Household and community samples,All,Adults (18-64 years),,,Geographical area,Gurugram,454,0.1233,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Whole Blood,IgG,,,,,['Moderate'],No,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,Prayag Arora Desai,Haryana Health Department,Not Unity-Aligned,https://www.hindustantimes.com/gurugram/pvt-lab-says-16-20-sero-prevalence-in-gurugram-health-dept-distances-itself-from-data/story-265qYKX4XhRPeMVc5HrKEO.html,2020-07-31,2022-07-16,Verified,arora-desai_pvt_2020,IND
200721_Haryana_IntegratedDiseaseSurveillanceProgramme_Ambala,200721_Haryana_IntegratedDiseaseSurveillanceProgramme,"Pvt lab says 16-20% sero-prevalence in Gurugram, health dept distances itself from data",2020-07-21,News and Media,Local,Cross-sectional survey ,India,Haryana,Ambala,"Under the survey, people who have a higher exposure to contract the coronavirus are covered. It includes population groups, such as shopkeepers, drivers, police personnel, health workers, pregnant women among others, as directed by the ICMR guidelines.",,2020-06-21,2020-07-15,Household and community samples,All,Adults (18-64 years),,,Geographical area,Ambala,176,0.1534,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Whole Blood,IgG,,,,,['Moderate'],No,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,Prayag Arora Desai,Haryana Health Department,Not Unity-Aligned,https://www.hindustantimes.com/gurugram/pvt-lab-says-16-20-sero-prevalence-in-gurugram-health-dept-distances-itself-from-data/story-265qYKX4XhRPeMVc5HrKEO.html,2020-07-31,2022-07-16,Verified,arora-desai_pvt_2020,IND
200721_Haryana_IntegratedDiseaseSurveillanceProgramme_Panchkula,200721_Haryana_IntegratedDiseaseSurveillanceProgramme,"Pvt lab says 16-20% sero-prevalence in Gurugram, health dept distances itself from data",2020-07-21,News and Media,Local,Cross-sectional survey ,India,Haryana,Panchkula,"Under the survey, people who have a higher exposure to contract the coronavirus are covered. It includes population groups, such as shopkeepers, drivers, police personnel, health workers, pregnant women among others, as directed by the ICMR guidelines.",,2020-06-21,2020-07-15,Household and community samples,All,Adults (18-64 years),,,Geographical area,Panchkula,355,0.02535,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Whole Blood,IgG,,,,,['Moderate'],No,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,Prayag Arora Desai,Haryana Health Department,Not Unity-Aligned,https://www.hindustantimes.com/gurugram/pvt-lab-says-16-20-sero-prevalence-in-gurugram-health-dept-distances-itself-from-data/story-265qYKX4XhRPeMVc5HrKEO.html,2020-07-31,2022-07-16,Verified,arora-desai_pvt_2020,IND
200721_Haryana_IntegratedDiseaseSurveillanceProgramme_Faridabad,200721_Haryana_IntegratedDiseaseSurveillanceProgramme,"Pvt lab says 16-20% sero-prevalence in Gurugram, health dept distances itself from data",2020-07-21,News and Media,Local,Cross-sectional survey ,India,Haryana,Faridabad,"Under the survey, people who have a higher exposure to contract the coronavirus are covered. It includes population groups, such as shopkeepers, drivers, police personnel, health workers, pregnant women among others, as directed by the ICMR guidelines.",,2020-06-21,2020-07-15,Household and community samples,All,Adults (18-64 years),,,Geographical area,Faridabad,209,0.134,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Whole Blood,IgG,,,,,['Moderate'],No,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,Prayag Arora Desai,Haryana Health Department,Not Unity-Aligned,https://www.hindustantimes.com/gurugram/pvt-lab-says-16-20-sero-prevalence-in-gurugram-health-dept-distances-itself-from-data/story-265qYKX4XhRPeMVc5HrKEO.html,2020-07-31,2022-07-16,Verified,arora-desai_pvt_2020,IND
200721_Haryana_IntegratedDiseaseSurveillanceProgramme_Sonepat,200721_Haryana_IntegratedDiseaseSurveillanceProgramme,"Pvt lab says 16-20% sero-prevalence in Gurugram, health dept distances itself from data",2020-07-21,News and Media,Local,Cross-sectional survey ,India,Haryana,Sonepat,"Under the survey, people who have a higher exposure to contract the coronavirus are covered. It includes population groups, such as shopkeepers, drivers, police personnel, health workers, pregnant women among others, as directed by the ICMR guidelines.",,2020-06-21,2020-07-15,Household and community samples,All,Adults (18-64 years),,,Geographical area,Sonepat,350,0.1714,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Whole Blood,IgG,,,,,['Moderate'],No,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,Prayag Arora Desai,Haryana Health Department,Not Unity-Aligned,https://www.hindustantimes.com/gurugram/pvt-lab-says-16-20-sero-prevalence-in-gurugram-health-dept-distances-itself-from-data/story-265qYKX4XhRPeMVc5HrKEO.html,2020-07-31,2022-07-16,Verified,arora-desai_pvt_2020,IND
200723_Delhi_IndianCentreforDiseaseControl_GenPop,200723_Delhi_IndianCentreforDiseaseControl,"Sero-prevalence study conducted by National Center for Disease Control NCDC, MoHFW, in Delhi, June 2020",2020-07-21,Institutional Report,Regional,Cross-sectional survey ,India,NCT Delhi,,"Recent survey collected samples from across 11 districts of the capital, which were then divided into two groups — of less than 18 years and older. No other information provided. ",,2020-06-27,2020-07-10,Household and community samples,All,Multiple groups,,,Primary Estimate,,21387,0.2348,,,True,,,,True,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,,IgG,,Validated by independent authors/third party/non-developers,0.9870000000000001,1.0,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Ministry of Health and Family Welfare,Indian Center for Disease Control,Unity-Aligned,https://pib.gov.in/PressReleaseIframePage.aspx?PRID=1640137,2020-08-02,2024-03-01,Verified,pib_delhi_sero-prevalence_2020,IND
200723_India_Thyrocare_GenPop,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,National,Cross-sectional survey ,India,,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Primary Estimate,,53000,0.15,,,True,,,,True,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Thane,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Maharashtra,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Thane ,2742,0.33799999999999997,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Warangal,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Telangana,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Warangal,287,0.129,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Aurangabad,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Maharashtra,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Aurangabad,158,0.203,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Erode,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Tamil Nadu,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Erode,312,0.231,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Pune,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Maharashtra,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Pune,2089,0.126,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_North24Parganas,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,West Bengal,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,North 24 Parganas,1288,0.156,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Gurgaon,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Haryana,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Gurgaon,1264,0.17300000000000001,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Bhojpur,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Bihar,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Bhojpur,207,0.21300000000000002,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Hyderabad,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Telangana,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Hyderabad,5957,0.212,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Bangalore,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Karnataka,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Bangalore ,4455,0.155,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Mahesana,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Gujarat,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Mahseana,159,0.132,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_South24Parganas,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,West Bengal,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,South 24 Parganas ,352,0.182,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_GautamBuddhaNagar,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Uttar Pradesh,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Gautam Buddha Nagar,1370,0.23600000000000002,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Coimbatore,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Tamil Nadu,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Coimbatore,279,0.039,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_WestGodavari,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Andhra Pradesh,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,West Godavari,143,0.14,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Kolhapur,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Maharashtra,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Kolhapur,144,0.063,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Thanjavur,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Tamil Nadu,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Thanjavur,118,0.059000000000000004,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_NaviMumbai,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Maharashtra,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Navi Mumbai,284,0.165,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Faridabad,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Haryana,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Faridabad,590,0.215,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Nalgonda,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Telangana,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Nalgonda,299,0.22100000000000003,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Ranchi,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Jharkhand,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Ranshi,302,0.129,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Bellary,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Karnataka,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Bellary,1163,0.039,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Ananthapur,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Andhra Pradesh,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Ananthapur,266,0.19899999999999998,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_NewDehli,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,NCT Delhi,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,New Dehli ,4290,0.342,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Vadodara,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Gujarat,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Vadodara,244,0.156,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Kolkata,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,West Bengal,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Kolkata,1724,0.20800000000000002,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Alibaug,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Maharashtra,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Alibaug,7752,0.057999999999999996,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Jaipur,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Rajasthan,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Jaipur,232,0.134,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_SouthGoa,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Goa,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,South Goa,335,0.113,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Visakhapatnam,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Andhra Pradesh,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Visakhapantam,438,0.096,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Lucknow,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Uttar Pradesh,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Lucknow,279,0.09,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Surat,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Gujarat,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Surat,1227,0.21300000000000002,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Kannchipuram,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Tamil Nadu,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Kanchipuram,257,0.14,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Hooghly,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,West Bengal,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Hooghly ,194,0.242,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Bhagalpur,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Bihar,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Bhagalpur,161,0.18600000000000003,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Chittoor,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Andhra Pradesh,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Chittoor,408,0.091,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Muzaffarpur,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Bihar,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Muzaffarpur,481,0.168,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Khorda,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Odisha,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Khorda,163,0.147,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Samastipur,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Bihar,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Samastipur,108,0.278,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Vaishali,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Bihar,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Vaishali,228,0.197,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_MahabubNagar,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Telangana,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Mahabub Nagar,248,0.18100000000000002,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Mumbai,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Maharashtra,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Mumbai,5682,0.276,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Guntur,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Andhra Pradesh,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Guntur,249,0.092,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Dharwad,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Karnataka,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Dharwad,123,0.106,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Tiruvallur,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Tamil Nadu,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Tiruvallur,216,0.273,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Ghaziabad,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Uttar Pradesh,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Ghaziabad,402,0.231,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Medak,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Telangana,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Medak,194,0.12400000000000001,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Howrah,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,West Bengal,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Howrah,177,0.215,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Khammam,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Telangana,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Khammam,127,0.17300000000000001,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Pondicherry,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Tamil Nadu,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Pondicherry,110,0.064,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Bardhaman,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,West Bengal,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Bardhaman,173,0.11599999999999999,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_EastSinghbhum,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Jharkhand,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,East Singhbhum,3369,0.075,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Mahendragarh,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Haryana,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Mahendragarh,261,0.019,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_KarimNagar,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Telangana,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Karim Nagar,142,0.155,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_EastGodavari,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Andhra Pradesh,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,East Godavari,179,0.14,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Ganjam,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Odisha,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Ganjam,115,0.165,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Bulandshahr,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Uttar Pradesh,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Bulandshahr,206,0.146,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Patna,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Bihar,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Patna,4153,0.188,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Katihar,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Bihar,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Katihar,513,0.096,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Madurai,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Tamil Nadu,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Madurai,199,0.327,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Nashik,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Maharashtra,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Nashi,777,0.154,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Chennai,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Tamil Nadu,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Chennai,970,0.3,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Bhopal,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Madhya Pradesh,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Bhopal,148,0.08800000000000001,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Ahmedabad,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Gujarat,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Ahmedebad,3299,0.18100000000000002,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_Valsad,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Gujarat,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,Valsad,321,0.252,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
200723_India_Thyrocare_GenPop_Region_KVRangareddy,200723_India_Thyrocare,"COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report",2020-07-23,News and Media,Local,Cross-sectional survey ,India,Telangana,,random tests conducted between June 28 and July 19 in only those areas where we have conducted at least 50 tests,,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,,,Geographical area,K.V.Rangareddy,2546,0.20600000000000002,,,,,,,,Simplified probability,Not reported/ Unable to specify,,Multiple Types,,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Unclear,India com News Desk,Thyrocare,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/&ct=ga&cd=CAAYBTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGDZBY0JyrN9eer5kq9FJfLncpL8Q,2020-08-04,2022-07-16,Verified,indiacom_news_desk_covid-19_2020-1,IND
201708_Pune_AshokaUniversity_primary,201708_Pune_AshokaUniversity,First sero survey shows extensive spread of Covid-19: From 36.1% to 65.4% in selected areas sampled in Pune,2020-08-17,News and Media,Local,Cross-sectional survey ,India,Maharashtra,Pune,,,2020-07-20,2020-08-05,Household and community samples,All,Multiple groups,,,Primary Estimate,,1664,0.515,,,True,,,,True,Stratified probability,Author designed (ELISA) - Unknown,,,Serum,IgG,,Validated by developers,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,Anuradha Mascarenhas,Ashoka University,Not Unity-Aligned,https://indianexpress.com/article/cities/pune/first-sero-survey-shows-extensive-spread-of-covid-19-from-36-1-to-65-4-in-selected-areas-sampled-in-pune-6558853/,2021-06-17,2022-07-16,Unverified,mascarenhas_first_2020,IND
200820_Punjab_PunjabSeroSurvey_genpop,200820_Punjab_PunjabSeroSurvey,Punjab Sero-survey Report: 27.7% people in containment zones have antibodies against Covid,2020-08-20,News and Media,Regional,Cross-sectional survey ,India,Punjab,,"For the Punjab survey, the selected containment zones, which had reported the highest number of Covid cases, were located one each in Patiala, SAS Nagar, Ludhiana, Jalandhar, and Amritsar districts. The sample included 250 people from each zone. From each of the selected households, one adult above the age of 18 was randomly chosen for the survey.",,2020-08-01,2020-08-17,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,1250,0.277,,,True,,,,True,Simplified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Unclear,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,Express News Service,,Not Unity-Aligned,https://indianexpress.com/article/india/punjab-sero-survey-report-27-7-people-in-containment-zones-have-antibodies-against-covid-6563226/,2021-04-26,2022-07-16,Verified,noauthor_punjab_2020,IND
200826_Andhra_CollegeOfVeterinary Sciences_Anantapur2,200826_Andhra_CollegeOfVeterinary Sciences_Anantapur2,"Andhra’s second sero survey begins today, 45,000 samples to be collected from 9 districts",2020-08-26,News and Media,Regional,Cross-sectional survey ,India,Andhra,,,,2020-08-07,2020-08-12,Household and community samples,All,Multiple groups,,,Primary Estimate,,3750,0.167,,,True,,,,True,Unclear,Not reported/ Unable to specify,,CLIA,,IgG,,,,,['High'],,Unclear,Yes,No,,Unclear,Yes,No,,Dr K Rambabu,College of Veterinary Sciences,Not Unity-Aligned,https://theprint.in/health/andhras-second-sero-survey-begins-today-45000-samples-to-be-collected-from-9-districts/489208/,2021-06-23,2022-07-16,Unverified,drkrambabuAndhraSecondSero2020,IND
200826_Andhra_CollegeOfVeterinary Sciences_EastGodavari3,200826_Andhra_CollegeOfVeterinary Sciences_EastGodavari3,"Andhra’s second sero survey begins today, 45,000 samples to be collected from 9 districts",2020-08-26,News and Media,Regional,Cross-sectional survey ,India,Andhra,,,,2020-08-07,2020-08-12,Household and community samples,All,Multiple groups,,,Primary Estimate,,3750,0.14400000000000002,,,True,,,,True,Unclear,Not reported/ Unable to specify,,CLIA,,IgG,,,,,['High'],,Unclear,Yes,No,,Unclear,Yes,No,,Dr K Rambabu,College of Veterinary Sciences,Not Unity-Aligned,https://theprint.in/health/andhras-second-sero-survey-begins-today-45000-samples-to-be-collected-from-9-districts/489208/,2021-06-23,2022-07-16,Unverified,drkrambabuAndhraSecondSero2020,IND
200826_Andhra_CollegeOfVeterinarySciences_Krishna1,200826_Andhra_CollegeOfVeterinary Sciences_Krishna1,"Andhra’s second sero survey begins today, 45,000 samples to be collected from 9 districts",2020-08-26,News and Media,Regional,Cross-sectional survey ,India,Andhra,,,,2020-08-07,2020-08-12,Household and community samples,All,Multiple groups,,,Primary Estimate,,3750,0.217,,,True,,,,True,Unclear,Not reported/ Unable to specify,,CLIA,,IgG,,,,,['High'],,Unclear,Yes,No,,Unclear,Yes,No,,Dr K Rambabu,College of Veterinary Sciences,Not Unity-Aligned,https://theprint.in/health/andhras-second-sero-survey-begins-today-45000-samples-to-be-collected-from-9-districts/489208/,2021-06-23,2022-07-16,Unverified,drkrambabuAndhraSecondSero2020,IND
200826_Andhra_CollegeOfVeterinary Sciences_Nellore4,200826_Andhra_CollegeOfVeterinary Sciences_Nellore4,"Andhra’s second sero survey begins today, 45,000 samples to be collected from 9 districts",2020-08-26,News and Media,Regional,Cross-sectional survey ,India,Andhra,,,,2020-08-07,2020-08-12,Household and community samples,All,Multiple groups,,,Primary Estimate,,3750,0.08199999999999999,,,True,,,,True,Unclear,Not reported/ Unable to specify,,CLIA,,IgG,,,,,['High'],,Unclear,Yes,No,,Unclear,Yes,No,,Dr K Rambabu,College of Veterinary Sciences,Not Unity-Aligned,https://theprint.in/health/andhras-second-sero-survey-begins-today-45000-samples-to-be-collected-from-9-districts/489208/,2021-06-23,2022-07-16,Unverified,drkrambabuAndhraSecondSero2020,IND
200831_Mumbai_NITI-Aayog_HCW,200831_Mumbai_NITI-Aayog_HCW,SARS-CoV2 Serological Survey in Mumbai by NITI-BMC-TIFR: Preliminary Report of Round-2,2020-08-31,Institutional Report,Local,Cross-sectional survey ,India,,Mumbai,,,2020-08-16,2020-08-29,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,728,0.273,0.24100000000000002,0.306,True,,,,True,Unclear,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.93,1.0,['High'],Unclear,Unclear,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Ullas Kolthur Seetharam,NITI-Aayog,Not Unity-Aligned,https://www.tifr.res.in/TSN/article/Mumbai-Serosurvey%20Technical%20report-NITI_BMC-Round-2%20for%20TIFR%20website.pdf,2021-05-06,2024-03-01,Verified,kolthur-seetharam_sars-cov2_2020,IND
200831_Mumbai_NITI-Aayog_Non-Slum_overall,200831_Mumbai_NITI-Aayog_Non-Slum,SARS-CoV2 Serological Survey in Mumbai by NITI-BMC-TIFR: Preliminary Report of Round-2,2020-08-31,Institutional Report,Local,Cross-sectional survey ,India,,Mumbai,"Sampling included people who may have been
symptomatic and recovered or asymptomatic, without distinction",Sampling excluded those who were in institutionalized quarantine facilities (i.e. during the study period). No sampling was done in active containment zones (i.e. during the study period).,2020-08-16,2020-08-29,Household and community samples,All,Multiple groups,12.0,,Primary Estimate,,2176,0.17500000000000002,0.159,0.19100000000000003,True,,True,,True,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.93,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ullas Kolthur Seetharam,NITI-Aayog,Unity-Aligned,https://www.tifr.res.in/TSN/article/Mumbai-Serosurvey%20Technical%20report-NITI_BMC-Round-2%20for%20TIFR%20website.pdf,2021-05-06,2024-03-01,Verified,kolthur-seetharam_sars-cov2_2020,IND
200831_Mumbai_NITI-Aayog_Non-SlumMale,200831_Mumbai_NITI-Aayog_Non-Slum,SARS-CoV2 Serological Survey in Mumbai by NITI-BMC-TIFR: Preliminary Report of Round-2,2020-08-31,Institutional Report,Local,Cross-sectional survey ,India,,Mumbai,"Sampling included people who may have been
symptomatic and recovered or asymptomatic, without distinction",Sampling excluded those who were in institutionalized quarantine facilities (i.e. during the study period). No sampling was done in active containment zones (i.e. during the study period).,2020-08-16,2020-08-29,Household and community samples,Male,Multiple groups,12.0,,Sex/Gender,Male,1452,0.167,0.14800000000000002,0.187,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.93,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ullas Kolthur Seetharam,NITI-Aayog,Unity-Aligned,https://www.tifr.res.in/TSN/article/Mumbai-Serosurvey%20Technical%20report-NITI_BMC-Round-2%20for%20TIFR%20website.pdf,2021-05-06,2024-03-01,Verified,kolthur-seetharam_sars-cov2_2020,IND
200831_Mumbai_NITI-Aayog_Non-SlumFemale,200831_Mumbai_NITI-Aayog_Non-Slum,SARS-CoV2 Serological Survey in Mumbai by NITI-BMC-TIFR: Preliminary Report of Round-2,2020-08-31,Institutional Report,Local,Cross-sectional survey ,India,,Mumbai,"Sampling included people who may have been
symptomatic and recovered or asymptomatic, without distinction",Sampling excluded those who were in institutionalized quarantine facilities (i.e. during the study period). No sampling was done in active containment zones (i.e. during the study period).,2020-08-16,2020-08-29,Household and community samples,Female,Multiple groups,12.0,,Sex/Gender,Female,721,0.17600000000000002,0.14800000000000002,0.204,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.93,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ullas Kolthur Seetharam,NITI-Aayog,Unity-Aligned,https://www.tifr.res.in/TSN/article/Mumbai-Serosurvey%20Technical%20report-NITI_BMC-Round-2%20for%20TIFR%20website.pdf,2021-05-06,2024-03-01,Verified,kolthur-seetharam_sars-cov2_2020,IND
200831_Mumbai_NITI-Aayog_Non-SlumAge_12-24,200831_Mumbai_NITI-Aayog_Non-Slum,SARS-CoV2 Serological Survey in Mumbai by NITI-BMC-TIFR: Preliminary Report of Round-2,2020-08-31,Institutional Report,Local,Cross-sectional survey ,India,,Mumbai,"Sampling included people who may have been
symptomatic and recovered or asymptomatic, without distinction",Sampling excluded those who were in institutionalized quarantine facilities (i.e. during the study period). No sampling was done in active containment zones (i.e. during the study period).,2020-08-16,2020-08-29,Household and community samples,All,Children and Youth (0-17 years),12.0,24.0,Age,12-24,233,0.185,0.135,0.23399999999999999,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.93,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ullas Kolthur Seetharam,NITI-Aayog,Unity-Aligned,https://www.tifr.res.in/TSN/article/Mumbai-Serosurvey%20Technical%20report-NITI_BMC-Round-2%20for%20TIFR%20website.pdf,2021-05-06,2024-03-01,Verified,kolthur-seetharam_sars-cov2_2020,IND
200831_Mumbai_NITI-Aayog_Non-SlumAge_61+,200831_Mumbai_NITI-Aayog_Non-Slum,SARS-CoV2 Serological Survey in Mumbai by NITI-BMC-TIFR: Preliminary Report of Round-2,2020-08-31,Institutional Report,Local,Cross-sectional survey ,India,,Mumbai,"Sampling included people who may have been
symptomatic and recovered or asymptomatic, without distinction",Sampling excluded those who were in institutionalized quarantine facilities (i.e. during the study period). No sampling was done in active containment zones (i.e. during the study period).,2020-08-16,2020-08-29,Household and community samples,All,Seniors (65+ years),61.0,,Age,61+,349,0.132,0.096,0.167,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.93,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ullas Kolthur Seetharam,NITI-Aayog,Unity-Aligned,https://www.tifr.res.in/TSN/article/Mumbai-Serosurvey%20Technical%20report-NITI_BMC-Round-2%20for%20TIFR%20website.pdf,2021-05-06,2024-03-01,Verified,kolthur-seetharam_sars-cov2_2020,IND
200831_Mumbai_NITI-Aayog_Non-SlumAge_25-40,200831_Mumbai_NITI-Aayog_Non-Slum,SARS-CoV2 Serological Survey in Mumbai by NITI-BMC-TIFR: Preliminary Report of Round-2,2020-08-31,Institutional Report,Local,Cross-sectional survey ,India,,Mumbai,"Sampling included people who may have been
symptomatic and recovered or asymptomatic, without distinction",Sampling excluded those who were in institutionalized quarantine facilities (i.e. during the study period). No sampling was done in active containment zones (i.e. during the study period).,2020-08-16,2020-08-29,Household and community samples,All,Adults (18-64 years),25.0,40.0,Age,25-40,628,0.166,0.13699999999999998,0.195,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.93,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ullas Kolthur Seetharam,NITI-Aayog,Unity-Aligned,https://www.tifr.res.in/TSN/article/Mumbai-Serosurvey%20Technical%20report-NITI_BMC-Round-2%20for%20TIFR%20website.pdf,2021-05-06,2024-03-01,Verified,kolthur-seetharam_sars-cov2_2020,IND
200831_Mumbai_NITI-Aayog_Non-SlumAge_41-60,200831_Mumbai_NITI-Aayog_Non-Slum,SARS-CoV2 Serological Survey in Mumbai by NITI-BMC-TIFR: Preliminary Report of Round-2,2020-08-31,Institutional Report,Local,Cross-sectional survey ,India,,Mumbai,"Sampling included people who may have been
symptomatic and recovered or asymptomatic, without distinction",Sampling excluded those who were in institutionalized quarantine facilities (i.e. during the study period). No sampling was done in active containment zones (i.e. during the study period).,2020-08-16,2020-08-29,Household and community samples,All,Adults (18-64 years),41.0,60.0,Age,41-60,964,0.18600000000000003,0.161,0.21,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.93,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ullas Kolthur Seetharam,NITI-Aayog,Unity-Aligned,https://www.tifr.res.in/TSN/article/Mumbai-Serosurvey%20Technical%20report-NITI_BMC-Round-2%20for%20TIFR%20website.pdf,2021-05-06,2024-03-01,Verified,kolthur-seetharam_sars-cov2_2020,IND
200831_Mumbai_NITI-Aayog_Slums_overall,200831_Mumbai_NITI-Aayog_Slums,SARS-CoV2 Serological Survey in Mumbai by NITI-BMC-TIFR: Preliminary Report of Round-2,2020-08-31,Institutional Report,Local,Cross-sectional survey ,India,,Mumbai,"Sampling included people who may have been
symptomatic and recovered or asymptomatic, without distinction",Sampling excluded those who were in institutionalized quarantine facilities (i.e. during the study period). No sampling was done in active containment zones (i.e. during the study period).,2020-08-16,2020-08-29,Persons living in slums,All,Multiple groups,12.0,,Primary Estimate,,3024,0.449,0.43200000000000005,0.467,True,,True,,True,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.93,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ullas Kolthur Seetharam,NITI-Aayog,Unity-Aligned,https://www.tifr.res.in/TSN/article/Mumbai-Serosurvey%20Technical%20report-NITI_BMC-Round-2%20for%20TIFR%20website.pdf,2021-05-06,2024-03-01,Verified,kolthur-seetharam_sars-cov2_2020,IND
200831_Mumbai_NITI-Aayog_SlumsMale,200831_Mumbai_NITI-Aayog_Slums,SARS-CoV2 Serological Survey in Mumbai by NITI-BMC-TIFR: Preliminary Report of Round-2,2020-08-31,Institutional Report,Local,Cross-sectional survey ,India,,Mumbai,"Sampling included people who may have been
symptomatic and recovered or asymptomatic, without distinction",Sampling excluded those who were in institutionalized quarantine facilities (i.e. during the study period). No sampling was done in active containment zones (i.e. during the study period).,2020-08-16,2020-08-29,Persons living in slums,Male,Multiple groups,12.0,,Sex/Gender,Male,1619,0.444,0.42,0.46799999999999997,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.93,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ullas Kolthur Seetharam,NITI-Aayog,Unity-Aligned,https://www.tifr.res.in/TSN/article/Mumbai-Serosurvey%20Technical%20report-NITI_BMC-Round-2%20for%20TIFR%20website.pdf,2021-05-06,2024-03-01,Verified,kolthur-seetharam_sars-cov2_2020,IND
200831_Mumbai_NITI-Aayog_SlumsFemale,200831_Mumbai_NITI-Aayog_Slums,SARS-CoV2 Serological Survey in Mumbai by NITI-BMC-TIFR: Preliminary Report of Round-2,2020-08-31,Institutional Report,Local,Cross-sectional survey ,India,,Mumbai,"Sampling included people who may have been
symptomatic and recovered or asymptomatic, without distinction",Sampling excluded those who were in institutionalized quarantine facilities (i.e. during the study period). No sampling was done in active containment zones (i.e. during the study period).,2020-08-16,2020-08-29,Persons living in slums,Female,Multiple groups,12.0,,Sex/Gender,Female,1405,0.462,0.436,0.488,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.93,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ullas Kolthur Seetharam,NITI-Aayog,Unity-Aligned,https://www.tifr.res.in/TSN/article/Mumbai-Serosurvey%20Technical%20report-NITI_BMC-Round-2%20for%20TIFR%20website.pdf,2021-05-06,2024-03-01,Verified,kolthur-seetharam_sars-cov2_2020,IND
200831_Mumbai_NITI-Aayog_SlumsAge_61+,200831_Mumbai_NITI-Aayog_Slums,SARS-CoV2 Serological Survey in Mumbai by NITI-BMC-TIFR: Preliminary Report of Round-2,2020-08-31,Institutional Report,Local,Cross-sectional survey ,India,,Mumbai,"Sampling included people who may have been
symptomatic and recovered or asymptomatic, without distinction",Sampling excluded those who were in institutionalized quarantine facilities (i.e. during the study period). No sampling was done in active containment zones (i.e. during the study period).,2020-08-16,2020-08-29,Persons living in slums,All,Seniors (65+ years),61.0,,Age,61,226,0.48200000000000004,0.41700000000000004,0.547,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.93,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ullas Kolthur Seetharam,NITI-Aayog,Unity-Aligned,https://www.tifr.res.in/TSN/article/Mumbai-Serosurvey%20Technical%20report-NITI_BMC-Round-2%20for%20TIFR%20website.pdf,2021-05-06,2024-03-01,Verified,kolthur-seetharam_sars-cov2_2020,IND
200831_Mumbai_NITI-Aayog_SlumsAge_25-40,200831_Mumbai_NITI-Aayog_Slums,SARS-CoV2 Serological Survey in Mumbai by NITI-BMC-TIFR: Preliminary Report of Round-2,2020-08-31,Institutional Report,Local,Cross-sectional survey ,India,,Mumbai,"Sampling included people who may have been
symptomatic and recovered or asymptomatic, without distinction",Sampling excluded those who were in institutionalized quarantine facilities (i.e. during the study period). No sampling was done in active containment zones (i.e. during the study period).,2020-08-16,2020-08-29,Persons living in slums,All,Adults (18-64 years),25.0,40.0,Age,25-40,1099,0.424,0.395,0.45299999999999996,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.93,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ullas Kolthur Seetharam,NITI-Aayog,Unity-Aligned,https://www.tifr.res.in/TSN/article/Mumbai-Serosurvey%20Technical%20report-NITI_BMC-Round-2%20for%20TIFR%20website.pdf,2021-05-06,2024-03-01,Verified,kolthur-seetharam_sars-cov2_2020,IND
200831_Mumbai_NITI-Aayog_SlumsAge_12-24,200831_Mumbai_NITI-Aayog_Slums,SARS-CoV2 Serological Survey in Mumbai by NITI-BMC-TIFR: Preliminary Report of Round-2,2020-08-31,Institutional Report,Local,Cross-sectional survey ,India,,Mumbai,"Sampling included people who may have been
symptomatic and recovered or asymptomatic, without distinction",Sampling excluded those who were in institutionalized quarantine facilities (i.e. during the study period). No sampling was done in active containment zones (i.e. during the study period).,2020-08-16,2020-08-29,Persons living in slums,All,Children and Youth (0-17 years),12.0,24.0,Age,12-24,637,0.408,0.37,0.446,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.93,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ullas Kolthur Seetharam,NITI-Aayog,Unity-Aligned,https://www.tifr.res.in/TSN/article/Mumbai-Serosurvey%20Technical%20report-NITI_BMC-Round-2%20for%20TIFR%20website.pdf,2021-05-06,2024-03-01,Verified,kolthur-seetharam_sars-cov2_2020,IND
200831_Mumbai_NITI-Aayog_SlumsAge_41-60,200831_Mumbai_NITI-Aayog_Slums,SARS-CoV2 Serological Survey in Mumbai by NITI-BMC-TIFR: Preliminary Report of Round-2,2020-08-31,Institutional Report,Local,Cross-sectional survey ,India,,Mumbai,"Sampling included people who may have been
symptomatic and recovered or asymptomatic, without distinction",Sampling excluded those who were in institutionalized quarantine facilities (i.e. during the study period). No sampling was done in active containment zones (i.e. during the study period).,2020-08-16,2020-08-29,Persons living in slums,All,Adults (18-64 years),41.0,60.0,Age,41-60,1060,0.503,0.473,0.533,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.93,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ullas Kolthur Seetharam,NITI-Aayog,Unity-Aligned,https://www.tifr.res.in/TSN/article/Mumbai-Serosurvey%20Technical%20report-NITI_BMC-Round-2%20for%20TIFR%20website.pdf,2021-05-06,2024-03-01,Verified,kolthur-seetharam_sars-cov2_2020,IND
200901_Aurangabad_GovernmentMedicalSchool_overall,200901_Aurangabad_GovernmentMedicalSchool,SEROPREVALENCE OF COVID-19 IN AURANGABAD DISTRICT ,2020-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,,"individuals above 18 years of age, who had been residents of Aurangabad district for more than 6 months",non-consenting and migrant population,2020-08-10,2020-08-19,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,6571,0.057999999999999996,,,True,,,,True,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,No,Yes,Unclear,Yes,No,Yes,J V Dixit,"Government Medical School, Aurangabad",Not Unity-Aligned,https://ijcrt.org/papers/IJCRT2009467.pdf,2021-04-26,2022-07-16,Verified,dixit_seroprevalence_2020,IND
200901_Aurangabad_GovernmentMedicalSchool_age31-40,200901_Aurangabad_GovernmentMedicalSchool,SEROPREVALENCE OF COVID-19 IN AURANGABAD DISTRICT ,2020-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,,"individuals above 18 years of age, who had been residents of Aurangabad district for more than 6 months",non-consenting and migrant population,2020-08-10,2020-08-19,Household and community samples,All,Adults (18-64 years),31.0,40.0,Age,31-40,1844,0.09164859002,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,No,Yes,Unclear,Yes,No,Yes,J V Dixit,"Government Medical School, Aurangabad",Not Unity-Aligned,https://ijcrt.org/papers/IJCRT2009467.pdf,2021-04-26,2022-07-16,Verified,dixit_seroprevalence_2020,IND
200901_Aurangabad_GovernmentMedicalSchool_age51-60,200901_Aurangabad_GovernmentMedicalSchool,SEROPREVALENCE OF COVID-19 IN AURANGABAD DISTRICT ,2020-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,,"individuals above 18 years of age, who had been residents of Aurangabad district for more than 6 months",non-consenting and migrant population,2020-08-10,2020-08-19,Household and community samples,All,Adults (18-64 years),51.0,60.0,Age,51-60,761,0.09592641261000001,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,No,Yes,Unclear,Yes,No,Yes,J V Dixit,"Government Medical School, Aurangabad",Not Unity-Aligned,https://ijcrt.org/papers/IJCRT2009467.pdf,2021-04-26,2022-07-16,Verified,dixit_seroprevalence_2020,IND
200901_Aurangabad_GovernmentMedicalSchool_age71-80,200901_Aurangabad_GovernmentMedicalSchool,SEROPREVALENCE OF COVID-19 IN AURANGABAD DISTRICT ,2020-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,,"individuals above 18 years of age, who had been residents of Aurangabad district for more than 6 months",non-consenting and migrant population,2020-08-10,2020-08-19,Household and community samples,All,Seniors (65+ years),71.0,80.0,Age,71-80,99,0.0404040404,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,No,Yes,Unclear,Yes,No,Yes,J V Dixit,"Government Medical School, Aurangabad",Not Unity-Aligned,https://ijcrt.org/papers/IJCRT2009467.pdf,2021-04-26,2022-07-16,Verified,dixit_seroprevalence_2020,IND
200901_Aurangabad_GovernmentMedicalSchool_age41-50,200901_Aurangabad_GovernmentMedicalSchool,SEROPREVALENCE OF COVID-19 IN AURANGABAD DISTRICT ,2020-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,,"individuals above 18 years of age, who had been residents of Aurangabad district for more than 6 months",non-consenting and migrant population,2020-08-10,2020-08-19,Household and community samples,All,Adults (18-64 years),41.0,50.0,Age,41-50,1356,0.1039823009,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,No,Yes,Unclear,Yes,No,Yes,J V Dixit,"Government Medical School, Aurangabad",Not Unity-Aligned,https://ijcrt.org/papers/IJCRT2009467.pdf,2021-04-26,2022-07-16,Verified,dixit_seroprevalence_2020,IND
200901_Aurangabad_GovernmentMedicalSchool_female,200901_Aurangabad_GovernmentMedicalSchool,SEROPREVALENCE OF COVID-19 IN AURANGABAD DISTRICT ,2020-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,,"individuals above 18 years of age, who had been residents of Aurangabad district for more than 6 months",non-consenting and migrant population,2020-08-10,2020-08-19,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,female,2859,0.0864,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,No,Yes,Unclear,Yes,No,Yes,J V Dixit,"Government Medical School, Aurangabad",Not Unity-Aligned,https://ijcrt.org/papers/IJCRT2009467.pdf,2021-04-26,2022-07-16,Verified,dixit_seroprevalence_2020,IND
200901_Aurangabad_GovernmentMedicalSchool_age>80,200901_Aurangabad_GovernmentMedicalSchool,SEROPREVALENCE OF COVID-19 IN AURANGABAD DISTRICT ,2020-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,,"individuals above 18 years of age, who had been residents of Aurangabad district for more than 6 months",non-consenting and migrant population,2020-08-10,2020-08-19,Household and community samples,All,Seniors (65+ years),81.0,,Age,>80,23,0.04347826087,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,No,Yes,Unclear,Yes,No,Yes,J V Dixit,"Government Medical School, Aurangabad",Not Unity-Aligned,https://ijcrt.org/papers/IJCRT2009467.pdf,2021-04-26,2022-07-16,Verified,dixit_seroprevalence_2020,IND
200901_Aurangabad_GovernmentMedicalSchool_age61-70,200901_Aurangabad_GovernmentMedicalSchool,SEROPREVALENCE OF COVID-19 IN AURANGABAD DISTRICT ,2020-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,,"individuals above 18 years of age, who had been residents of Aurangabad district for more than 6 months",non-consenting and migrant population,2020-08-10,2020-08-19,Household and community samples,All,Seniors (65+ years),61.0,70.0,Age,61-70,427,0.07962529274,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,No,Yes,Unclear,Yes,No,Yes,J V Dixit,"Government Medical School, Aurangabad",Not Unity-Aligned,https://ijcrt.org/papers/IJCRT2009467.pdf,2021-04-26,2022-07-16,Verified,dixit_seroprevalence_2020,IND
200901_Aurangabad_GovernmentMedicalSchool_male,200901_Aurangabad_GovernmentMedicalSchool,SEROPREVALENCE OF COVID-19 IN AURANGABAD DISTRICT ,2020-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,,"individuals above 18 years of age, who had been residents of Aurangabad district for more than 6 months",non-consenting and migrant population,2020-08-10,2020-08-19,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,male,3750,0.1008,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,No,Yes,Unclear,Yes,No,Yes,J V Dixit,"Government Medical School, Aurangabad",Not Unity-Aligned,https://ijcrt.org/papers/IJCRT2009467.pdf,2021-04-26,2022-07-16,Verified,dixit_seroprevalence_2020,IND
200901_Aurangabad_GovernmentMedicalSchool_age18-20,200901_Aurangabad_GovernmentMedicalSchool,SEROPREVALENCE OF COVID-19 IN AURANGABAD DISTRICT ,2020-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,,"individuals above 18 years of age, who had been residents of Aurangabad district for more than 6 months",non-consenting and migrant population,2020-08-10,2020-08-19,Household and community samples,All,Adults (18-64 years),18.0,20.0,Age,18-20,367,0.09536784741,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,No,Yes,Unclear,Yes,No,Yes,J V Dixit,"Government Medical School, Aurangabad",Not Unity-Aligned,https://ijcrt.org/papers/IJCRT2009467.pdf,2021-04-26,2022-07-16,Verified,dixit_seroprevalence_2020,IND
200901_Aurangabad_GovernmentMedicalSchool_age21-30,200901_Aurangabad_GovernmentMedicalSchool,SEROPREVALENCE OF COVID-19 IN AURANGABAD DISTRICT ,2020-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,,"individuals above 18 years of age, who had been residents of Aurangabad district for more than 6 months",non-consenting and migrant population,2020-08-10,2020-08-19,Household and community samples,All,Adults (18-64 years),21.0,30.0,Age,21-30,1732,0.09699769053000001,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,No,Yes,Unclear,Yes,No,Yes,J V Dixit,"Government Medical School, Aurangabad",Not Unity-Aligned,https://ijcrt.org/papers/IJCRT2009467.pdf,2021-04-26,2022-07-16,Verified,dixit_seroprevalence_2020,IND
200903_NewDelhi_MaxSuperSpecialtyHospital_Overall,200903_NewDelhi_MaxSuperSpecialtyHospital,SARS-CoV-2 antibody seroprevalence and stability in a tertiary care hospital-setting,2020-09-03,Preprint,Local,Prospective cohort,India,NCT Delhi,New Delhi,Employees of Max Hospital and individuals visiting the hospital for COVID-19 testing,,2020-04-15,2020-08-15,Multiple populations,All,Multiple groups,,,Primary Estimate,,780,0.195,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9450000000000001,0.9940000000000001,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Samreen Siddiqui,Max Super Specialty Hospital,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.02.20186486v1,2020-11-06,2024-03-01,Verified,siddiqui_sars-cov-2_2020,IND
200903_NewDelhi_MaxSuperSpecialtyHospital_>60,200903_NewDelhi_MaxSuperSpecialtyHospital,SARS-CoV-2 antibody seroprevalence and stability in a tertiary care hospital-setting,2020-09-03,Preprint,Local,Prospective cohort,India,NCT Delhi,New Delhi,Employees of Max Hospital and individuals visiting the hospital for COVID-19 testing,,2020-04-15,2020-08-15,Multiple populations,All,Seniors (65+ years),61.0,,Age,>60 years old,33,0.242,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9450000000000001,0.9940000000000001,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Samreen Siddiqui,Max Super Specialty Hospital,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.02.20186486v1,2020-11-06,2024-03-01,Verified,siddiqui_sars-cov-2_2020,IND
200903_NewDelhi_MaxSuperSpecialtyHospital_51-60,200903_NewDelhi_MaxSuperSpecialtyHospital,SARS-CoV-2 antibody seroprevalence and stability in a tertiary care hospital-setting,2020-09-03,Preprint,Local,Prospective cohort,India,NCT Delhi,New Delhi,Employees of Max Hospital and individuals visiting the hospital for COVID-19 testing,,2020-04-15,2020-08-15,Multiple populations,All,Adults (18-64 years),51.0,60.0,Age,51-60 years old,74,0.257,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9450000000000001,0.9940000000000001,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Samreen Siddiqui,Max Super Specialty Hospital,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.02.20186486v1,2020-11-06,2024-03-01,Verified,siddiqui_sars-cov-2_2020,IND
200903_NewDelhi_MaxSuperSpecialtyHospital_41-50,200903_NewDelhi_MaxSuperSpecialtyHospital,SARS-CoV-2 antibody seroprevalence and stability in a tertiary care hospital-setting,2020-09-03,Preprint,Local,Prospective cohort,India,NCT Delhi,New Delhi,Employees of Max Hospital and individuals visiting the hospital for COVID-19 testing,,2020-04-15,2020-08-15,Multiple populations,All,Adults (18-64 years),41.0,50.0,Age,41-50  years old,139,0.245,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9450000000000001,0.9940000000000001,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Samreen Siddiqui,Max Super Specialty Hospital,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.02.20186486v1,2020-11-06,2024-03-01,Verified,siddiqui_sars-cov-2_2020,IND
200903_NewDelhi_MaxSuperSpecialtyHospital_18-20,200903_NewDelhi_MaxSuperSpecialtyHospital,SARS-CoV-2 antibody seroprevalence and stability in a tertiary care hospital-setting,2020-09-03,Preprint,Local,Prospective cohort,India,NCT Delhi,New Delhi,Employees of Max Hospital and individuals visiting the hospital for COVID-19 testing,,2020-04-15,2020-08-15,Multiple populations,All,Adults (18-64 years),18.0,20.0,Age,18-20 year olds,19,0.158,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9450000000000001,0.9940000000000001,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Samreen Siddiqui,Max Super Specialty Hospital,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.02.20186486v1,2020-11-06,2024-03-01,Verified,siddiqui_sars-cov-2_2020,IND
200903_NewDelhi_MaxSuperSpecialtyHospital_31-40,200903_NewDelhi_MaxSuperSpecialtyHospital,SARS-CoV-2 antibody seroprevalence and stability in a tertiary care hospital-setting,2020-09-03,Preprint,Local,Prospective cohort,India,NCT Delhi,New Delhi,Employees of Max Hospital and individuals visiting the hospital for COVID-19 testing,,2020-04-15,2020-08-15,Multiple populations,All,Adults (18-64 years),31.0,40.0,Age,31-40  years old,204,0.20600000000000002,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9450000000000001,0.9940000000000001,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Samreen Siddiqui,Max Super Specialty Hospital,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.02.20186486v1,2020-11-06,2024-03-01,Verified,siddiqui_sars-cov-2_2020,IND
200903_NewDelhi_MaxSuperSpecialtyHospital_21-30,200903_NewDelhi_MaxSuperSpecialtyHospital,SARS-CoV-2 antibody seroprevalence and stability in a tertiary care hospital-setting,2020-09-03,Preprint,Local,Prospective cohort,India,NCT Delhi,New Delhi,Employees of Max Hospital and individuals visiting the hospital for COVID-19 testing,,2020-04-15,2020-08-15,Multiple populations,All,Adults (18-64 years),21.0,30.0,Age,21-30 years old,311,0.14800000000000002,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9450000000000001,0.9940000000000001,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Samreen Siddiqui,Max Super Specialty Hospital,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.02.20186486v1,2020-11-06,2024-03-01,Verified,siddiqui_sars-cov-2_2020,IND
200903_Ahmedabad_AhmedabadMunicipalCorporation,200903_Ahmedabad_AhmedabadMunicipalCorporation,"Second survey in Ahmedabad: Sero-positivity up by 5.6 per cent since June, no herd immunity yet",2020-09-03,News and Media,Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,,,2020-08-15,2020-08-29,Household and community samples,All,Multiple groups,,,Primary Estimate,,10310,0.2324,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],,Unclear,Yes,No,,Unclear,Yes,No,,Express News Service ,Ahmedabad Municipal Corporation,Not Unity-Aligned,https://indianexpress.com/article/cities/ahmedabad/second-survey-in-ahmedabad-sero-positivity-up-by-5-6-per-cent-since-june-no-herd-immunity-yet-6580951/,2021-06-23,2022-07-16,Unverified,expressnewsserviceSecondSurveyAhmedabad2020,IND
200908_India_DepartmentCommunityMedicine_Primary,200908_India_DepartmentCommunityMedicine,Sero-survey In Haryana: 8 Per Cent Of People Surveyed In The State Have COVID-19 Antibodies,2020-09-08,News and Media,Regional,Repeated cross-sectional study,India,Haryana,,As many as 850 samples each were collected from 22 districts and the collection was done both in urban and rural areas of the state of Haryana,,2020-08-01,2020-08-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,18905,0.08,,,,,,,True,Stratified non-probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Banega Swasth India,Indian Department of Community Medicine,Not Unity-Aligned,https://swachhindia.ndtv.com/sero-survey-in-haryana-8-per-cent-of-people-surveyed-in-the-state-have-covid-19-antibodies-49375/,2021-06-20,2022-07-16,Unverified,banega_sero_2020,IND
200914_PaschimMedinipur_MedicalCollegeKolkata_Overall,200914_PaschimMedinipur_MedicalCollegeKolkata,"Sero-surveillance (IgG) of SARS-CoV-2 among Asymptomatic General population of Paschim Medinipur District, West Bengal, India(Conducted during last week of July and 1st week of August 2020) - A Joint Venture of VRDL Lab (ICMR), Midnapore Medical College &",2020-09-14,Preprint,Regional,Cross-sectional survey ,India,West Bengal,,Asymptomatic general population of Paschim Medinipur District,,2020-07-26,2020-08-08,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,Overall estimate,458,0.0415,0.0252,0.064,True,,,,True,Stratified probability,ErbaLisa COVID-19 IgG ELISA Kit,Calbiotech Inc.,ELISA,Serum,IgG,,Validated by manufacturers,0.983,0.981,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Unclear,Parthasarathi Satpati,Medical College Kolkata,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.12.20193219v1,2020-11-05,2024-03-01,Verified,satpati_sero-surveillance_2020,IND
200914_PaschimMedinipur_MedicalCollegeKolkata_Chandrakona,200914_PaschimMedinipur_MedicalCollegeKolkata,"Sero-surveillance (IgG) of SARS-CoV-2 among Asymptomatic General population of Paschim Medinipur District, West Bengal, India(Conducted during last week of July and 1st week of August 2020) - A Joint Venture of VRDL Lab (ICMR), Midnapore Medical College &",2020-09-14,Preprint,Regional,Cross-sectional survey ,India,West Bengal,Chandrakona,Asymptomatic general population of Paschim Medinipur District,,2020-07-26,2020-08-08,Household and community samples,All,Multiple groups,,,Geographical area,Chandrakona Municipality,15,0.0,,,,,,,,Stratified probability,ErbaLisa COVID-19 IgG ELISA Kit,Calbiotech Inc.,ELISA,Serum,IgG,,Validated by manufacturers,0.983,0.981,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Unclear,Parthasarathi Satpati,Medical College Kolkata,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.12.20193219v1,2020-11-05,2024-03-01,Verified,satpati_sero-surveillance_2020,IND
200914_PaschimMedinipur_MedicalCollegeKolkata_Chandrakona1,200914_PaschimMedinipur_MedicalCollegeKolkata,"Sero-surveillance (IgG) of SARS-CoV-2 among Asymptomatic General population of Paschim Medinipur District, West Bengal, India(Conducted during last week of July and 1st week of August 2020) - A Joint Venture of VRDL Lab (ICMR), Midnapore Medical College &",2020-09-14,Preprint,Regional,Cross-sectional survey ,India,West Bengal,Chanrakona,Asymptomatic general population of Paschim Medinipur District,,2020-07-26,2020-08-08,Household and community samples,All,Multiple groups,,,Geographical area,Chandrakona I,15,0.0,,,,,,,,Stratified probability,ErbaLisa COVID-19 IgG ELISA Kit,Calbiotech Inc.,ELISA,Serum,IgG,,Validated by manufacturers,0.983,0.981,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Unclear,Parthasarathi Satpati,Medical College Kolkata,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.12.20193219v1,2020-11-05,2024-03-01,Verified,satpati_sero-surveillance_2020,IND
200914_PaschimMedinipur_MedicalCollegeKolkata_Ghatal,200914_PaschimMedinipur_MedicalCollegeKolkata,"Sero-surveillance (IgG) of SARS-CoV-2 among Asymptomatic General population of Paschim Medinipur District, West Bengal, India(Conducted during last week of July and 1st week of August 2020) - A Joint Venture of VRDL Lab (ICMR), Midnapore Medical College &",2020-09-14,Preprint,Regional,Cross-sectional survey ,India,West Bengal,Ghatal,Asymptomatic general population of Paschim Medinipur District,,2020-07-26,2020-08-08,Household and community samples,All,Multiple groups,,,Geographical area,Ghatal Municipality,16,0.125,0.015500000000000002,0.3835,,,,,,Stratified probability,ErbaLisa COVID-19 IgG ELISA Kit,Calbiotech Inc.,ELISA,Serum,IgG,,Validated by manufacturers,0.983,0.981,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Unclear,Parthasarathi Satpati,Medical College Kolkata,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.12.20193219v1,2020-11-05,2024-03-01,Verified,satpati_sero-surveillance_2020,IND
200914_PaschimMedinipur_MedicalCollegeKolkata_Pingla,200914_PaschimMedinipur_MedicalCollegeKolkata,"Sero-surveillance (IgG) of SARS-CoV-2 among Asymptomatic General population of Paschim Medinipur District, West Bengal, India(Conducted during last week of July and 1st week of August 2020) - A Joint Venture of VRDL Lab (ICMR), Midnapore Medical College &",2020-09-14,Preprint,Regional,Cross-sectional survey ,India,West Bengal,Pingla,Asymptomatic general population of Paschim Medinipur District,,2020-07-26,2020-08-08,Household and community samples,All,Multiple groups,,,Geographical area,Pingla,16,0.0,,,,,,,,Stratified probability,ErbaLisa COVID-19 IgG ELISA Kit,Calbiotech Inc.,ELISA,Serum,IgG,,Validated by manufacturers,0.983,0.981,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Unclear,Parthasarathi Satpati,Medical College Kolkata,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.12.20193219v1,2020-11-05,2024-03-01,Verified,satpati_sero-surveillance_2020,IND
200914_PaschimMedinipur_MedicalCollegeKolkata_46-59yrs,200914_PaschimMedinipur_MedicalCollegeKolkata,"Sero-surveillance (IgG) of SARS-CoV-2 among Asymptomatic General population of Paschim Medinipur District, West Bengal, India(Conducted during last week of July and 1st week of August 2020) - A Joint Venture of VRDL Lab (ICMR), Midnapore Medical College &",2020-09-14,Preprint,Regional,Cross-sectional survey ,India,West Bengal,,Asymptomatic general population of Paschim Medinipur District,,2020-07-26,2020-08-08,Household and community samples,All,Adults (18-64 years),46.0,59.0,Age,Age 46-59,101,0.0396,,,,,,,,Stratified probability,ErbaLisa COVID-19 IgG ELISA Kit,Calbiotech Inc.,ELISA,Serum,IgG,,Validated by manufacturers,0.983,0.981,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Unclear,Parthasarathi Satpati,Medical College Kolkata,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.12.20193219v1,2020-11-05,2024-03-01,Verified,satpati_sero-surveillance_2020,IND
200914_PaschimMedinipur_MedicalCollegeKolkata_Keshpur,200914_PaschimMedinipur_MedicalCollegeKolkata,"Sero-surveillance (IgG) of SARS-CoV-2 among Asymptomatic General population of Paschim Medinipur District, West Bengal, India(Conducted during last week of July and 1st week of August 2020) - A Joint Venture of VRDL Lab (ICMR), Midnapore Medical College &",2020-09-14,Preprint,Regional,Cross-sectional survey ,India,West Bengal,Keshpur,Asymptomatic general population of Paschim Medinipur District,,2020-07-26,2020-08-08,Household and community samples,All,Multiple groups,,,Geographical area,Keshpur,31,0.0,,,,,,,,Stratified probability,ErbaLisa COVID-19 IgG ELISA Kit,Calbiotech Inc.,ELISA,Serum,IgG,,Validated by manufacturers,0.983,0.981,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Unclear,Parthasarathi Satpati,Medical College Kolkata,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.12.20193219v1,2020-11-05,2024-03-01,Verified,satpati_sero-surveillance_2020,IND
200914_PaschimMedinipur_MedicalCollegeKolkata_DantanII,200914_PaschimMedinipur_MedicalCollegeKolkata,"Sero-surveillance (IgG) of SARS-CoV-2 among Asymptomatic General population of Paschim Medinipur District, West Bengal, India(Conducted during last week of July and 1st week of August 2020) - A Joint Venture of VRDL Lab (ICMR), Midnapore Medical College &",2020-09-14,Preprint,Regional,Cross-sectional survey ,India,West Bengal,Dantan,Asymptomatic general population of Paschim Medinipur District,,2020-07-26,2020-08-08,Household and community samples,All,Multiple groups,,,Geographical area,Dantan II,15,0.0,,,,,,,,Stratified probability,ErbaLisa COVID-19 IgG ELISA Kit,Calbiotech Inc.,ELISA,Serum,IgG,,Validated by manufacturers,0.983,0.981,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Unclear,Parthasarathi Satpati,Medical College Kolkata,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.12.20193219v1,2020-11-05,2024-03-01,Verified,satpati_sero-surveillance_2020,IND
200914_PaschimMedinipur_MedicalCollegeKolkata_11-19yrs,200914_PaschimMedinipur_MedicalCollegeKolkata,"Sero-surveillance (IgG) of SARS-CoV-2 among Asymptomatic General population of Paschim Medinipur District, West Bengal, India(Conducted during last week of July and 1st week of August 2020) - A Joint Venture of VRDL Lab (ICMR), Midnapore Medical College &",2020-09-14,Preprint,Regional,Cross-sectional survey ,India,West Bengal,,Asymptomatic general population of Paschim Medinipur District,,2020-07-26,2020-08-08,Household and community samples,All,Children and Youth (0-17 years),11.0,19.0,Age,Age 11-19,28,0.10710000000000001,,,,,,,,Stratified probability,ErbaLisa COVID-19 IgG ELISA Kit,Calbiotech Inc.,ELISA,Serum,IgG,,Validated by manufacturers,0.983,0.981,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Unclear,Parthasarathi Satpati,Medical College Kolkata,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.12.20193219v1,2020-11-05,2024-03-01,Verified,satpati_sero-surveillance_2020,IND
200914_PaschimMedinipur_MedicalCollegeKolkata_DaspurII,200914_PaschimMedinipur_MedicalCollegeKolkata,"Sero-surveillance (IgG) of SARS-CoV-2 among Asymptomatic General population of Paschim Medinipur District, West Bengal, India(Conducted during last week of July and 1st week of August 2020) - A Joint Venture of VRDL Lab (ICMR), Midnapore Medical College &",2020-09-14,Preprint,Regional,Cross-sectional survey ,India,West Bengal,Daspur,Asymptomatic general population of Paschim Medinipur District,,2020-07-26,2020-08-08,Household and community samples,All,Multiple groups,,,Geographical area,Daspur II,92,0.0978,0.045700000000000005,0.1776,,,,,,Stratified probability,ErbaLisa COVID-19 IgG ELISA Kit,Calbiotech Inc.,ELISA,Serum,IgG,,Validated by manufacturers,0.983,0.981,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Unclear,Parthasarathi Satpati,Medical College Kolkata,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.12.20193219v1,2020-11-05,2024-03-01,Verified,satpati_sero-surveillance_2020,IND
200914_PaschimMedinipur_MedicalCollegeKolkata_DaspurI,200914_PaschimMedinipur_MedicalCollegeKolkata,"Sero-surveillance (IgG) of SARS-CoV-2 among Asymptomatic General population of Paschim Medinipur District, West Bengal, India(Conducted during last week of July and 1st week of August 2020) - A Joint Venture of VRDL Lab (ICMR), Midnapore Medical College &",2020-09-14,Preprint,Regional,Cross-sectional survey ,India,West Bengal,Daspur,Asymptomatic general population of Paschim Medinipur District,,2020-07-26,2020-08-08,Household and community samples,All,Multiple groups,,,Geographical area,Daspur I,75,0.04,0.0083,0.1125,,,,,,Stratified probability,ErbaLisa COVID-19 IgG ELISA Kit,Calbiotech Inc.,ELISA,Serum,IgG,,Validated by manufacturers,0.983,0.981,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Unclear,Parthasarathi Satpati,Medical College Kolkata,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.12.20193219v1,2020-11-05,2024-03-01,Verified,satpati_sero-surveillance_2020,IND
200914_PaschimMedinipur_MedicalCollegeKolkata_Garhbeta,200914_PaschimMedinipur_MedicalCollegeKolkata,"Sero-surveillance (IgG) of SARS-CoV-2 among Asymptomatic General population of Paschim Medinipur District, West Bengal, India(Conducted during last week of July and 1st week of August 2020) - A Joint Venture of VRDL Lab (ICMR), Midnapore Medical College &",2020-09-14,Preprint,Regional,Cross-sectional survey ,India,West Bengal,Garhbeta,Asymptomatic general population of Paschim Medinipur District,,2020-07-26,2020-08-08,Household and community samples,All,Multiple groups,,,Geographical area,Garhbeta I Block,15,0.0,,,,,,,,Stratified probability,ErbaLisa COVID-19 IgG ELISA Kit,Calbiotech Inc.,ELISA,Serum,IgG,,Validated by manufacturers,0.983,0.981,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Unclear,Parthasarathi Satpati,Medical College Kolkata,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.12.20193219v1,2020-11-05,2024-03-01,Verified,satpati_sero-surveillance_2020,IND
200914_PaschimMedinipur_MedicalCollegeKolkata_60+yrs,200914_PaschimMedinipur_MedicalCollegeKolkata,"Sero-surveillance (IgG) of SARS-CoV-2 among Asymptomatic General population of Paschim Medinipur District, West Bengal, India(Conducted during last week of July and 1st week of August 2020) - A Joint Venture of VRDL Lab (ICMR), Midnapore Medical College &",2020-09-14,Preprint,Regional,Cross-sectional survey ,India,West Bengal,,Asymptomatic general population of Paschim Medinipur District,,2020-07-26,2020-08-08,Household and community samples,All,Seniors (65+ years),60.0,,Age,Age 60+,38,0.0263,,,,,,,,Stratified probability,ErbaLisa COVID-19 IgG ELISA Kit,Calbiotech Inc.,ELISA,Serum,IgG,,Validated by manufacturers,0.983,0.981,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Unclear,Parthasarathi Satpati,Medical College Kolkata,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.12.20193219v1,2020-11-05,2024-03-01,Verified,satpati_sero-surveillance_2020,IND
200914_PaschimMedinipur_MedicalCollegeKolkata_0-5yrs,200914_PaschimMedinipur_MedicalCollegeKolkata,"Sero-surveillance (IgG) of SARS-CoV-2 among Asymptomatic General population of Paschim Medinipur District, West Bengal, India(Conducted during last week of July and 1st week of August 2020) - A Joint Venture of VRDL Lab (ICMR), Midnapore Medical College &",2020-09-14,Preprint,Regional,Cross-sectional survey ,India,West Bengal,,Asymptomatic general population of Paschim Medinipur District,,2020-07-26,2020-08-08,Household and community samples,All,Children and Youth (0-17 years),0.0,5.0,Age,Age 0-5,1,0.0,,,,,,,,Stratified probability,ErbaLisa COVID-19 IgG ELISA Kit,Calbiotech Inc.,ELISA,Serum,IgG,,Validated by manufacturers,0.983,0.981,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Unclear,Parthasarathi Satpati,Medical College Kolkata,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.12.20193219v1,2020-11-05,2024-03-01,Verified,satpati_sero-surveillance_2020,IND
200914_PaschimMedinipur_MedicalCollegeKolkata_20-45yrs,200914_PaschimMedinipur_MedicalCollegeKolkata,"Sero-surveillance (IgG) of SARS-CoV-2 among Asymptomatic General population of Paschim Medinipur District, West Bengal, India(Conducted during last week of July and 1st week of August 2020) - A Joint Venture of VRDL Lab (ICMR), Midnapore Medical College &",2020-09-14,Preprint,Regional,Cross-sectional survey ,India,West Bengal,,Asymptomatic general population of Paschim Medinipur District,,2020-07-26,2020-08-08,Household and community samples,All,Adults (18-64 years),20.0,45.0,Age,Age 20-45,290,0.0379,,,,,,,,Stratified probability,ErbaLisa COVID-19 IgG ELISA Kit,Calbiotech Inc.,ELISA,Serum,IgG,,Validated by manufacturers,0.983,0.981,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Unclear,Parthasarathi Satpati,Medical College Kolkata,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.12.20193219v1,2020-11-05,2024-03-01,Verified,satpati_sero-surveillance_2020,IND
200914_PaschimMedinipur_MedicalCollegeKolkata_GhatalBlock,200914_PaschimMedinipur_MedicalCollegeKolkata,"Sero-surveillance (IgG) of SARS-CoV-2 among Asymptomatic General population of Paschim Medinipur District, West Bengal, India(Conducted during last week of July and 1st week of August 2020) - A Joint Venture of VRDL Lab (ICMR), Midnapore Medical College &",2020-09-14,Preprint,Regional,Cross-sectional survey ,India,West Bengal,Ghatal,Asymptomatic general population of Paschim Medinipur District,,2020-07-26,2020-08-08,Household and community samples,All,Multiple groups,,,Geographical area,Ghatal Block,30,0.0,,,,,,,,Stratified probability,ErbaLisa COVID-19 IgG ELISA Kit,Calbiotech Inc.,ELISA,Serum,IgG,,Validated by manufacturers,0.983,0.981,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Unclear,Parthasarathi Satpati,Medical College Kolkata,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.12.20193219v1,2020-11-05,2024-03-01,Verified,satpati_sero-surveillance_2020,IND
200914_PaschimMedinipur_MedicalCollegeKolkata_Male,200914_PaschimMedinipur_MedicalCollegeKolkata,"Sero-surveillance (IgG) of SARS-CoV-2 among Asymptomatic General population of Paschim Medinipur District, West Bengal, India(Conducted during last week of July and 1st week of August 2020) - A Joint Venture of VRDL Lab (ICMR), Midnapore Medical College &",2020-09-14,Preprint,Regional,Cross-sectional survey ,India,West Bengal,,Asymptomatic general population of Paschim Medinipur District,,2020-07-26,2020-08-08,Household and community samples,Male,Multiple groups,,,Sex/Gender,Males,287,0.052300000000000006,,,,,,,,Stratified probability,ErbaLisa COVID-19 IgG ELISA Kit,Calbiotech Inc.,ELISA,Serum,IgG,,Validated by manufacturers,0.983,0.981,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Unclear,Parthasarathi Satpati,Medical College Kolkata,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.12.20193219v1,2020-11-05,2024-03-01,Verified,satpati_sero-surveillance_2020,IND
200914_PaschimMedinipur_MedicalCollegeKolkata_Midnapore,200914_PaschimMedinipur_MedicalCollegeKolkata,"Sero-surveillance (IgG) of SARS-CoV-2 among Asymptomatic General population of Paschim Medinipur District, West Bengal, India(Conducted during last week of July and 1st week of August 2020) - A Joint Venture of VRDL Lab (ICMR), Midnapore Medical College &",2020-09-14,Preprint,Regional,Cross-sectional survey ,India,West Bengal,Midnapore,Asymptomatic general population of Paschim Medinipur District,,2020-07-26,2020-08-08,Household and community samples,All,Multiple groups,,,Geographical area,Midnapore Municipality,16,0.0625,0.0016,0.3023,,,,,,Stratified probability,ErbaLisa COVID-19 IgG ELISA Kit,Calbiotech Inc.,ELISA,Serum,IgG,,Validated by manufacturers,0.983,0.981,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Unclear,Parthasarathi Satpati,Medical College Kolkata,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.12.20193219v1,2020-11-05,2024-03-01,Verified,satpati_sero-surveillance_2020,IND
200914_PaschimMedinipur_MedicalCollegeKolkata_Female,200914_PaschimMedinipur_MedicalCollegeKolkata,"Sero-surveillance (IgG) of SARS-CoV-2 among Asymptomatic General population of Paschim Medinipur District, West Bengal, India(Conducted during last week of July and 1st week of August 2020) - A Joint Venture of VRDL Lab (ICMR), Midnapore Medical College &",2020-09-14,Preprint,Regional,Cross-sectional survey ,India,West Bengal,,Asymptomatic general population of Paschim Medinipur District,,2020-07-26,2020-08-08,Household and community samples,Female,Multiple groups,,,Sex/Gender,Females,171,0.0234,,,,,,,,Stratified probability,ErbaLisa COVID-19 IgG ELISA Kit,Calbiotech Inc.,ELISA,Serum,IgG,,Validated by manufacturers,0.983,0.981,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Unclear,Parthasarathi Satpati,Medical College Kolkata,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.12.20193219v1,2020-11-05,2024-03-01,Verified,satpati_sero-surveillance_2020,IND
200914_PaschimMedinipur_MedicalCollegeKolkata_DantanI,200914_PaschimMedinipur_MedicalCollegeKolkata,"Sero-surveillance (IgG) of SARS-CoV-2 among Asymptomatic General population of Paschim Medinipur District, West Bengal, India(Conducted during last week of July and 1st week of August 2020) - A Joint Venture of VRDL Lab (ICMR), Midnapore Medical College &",2020-09-14,Preprint,Regional,Cross-sectional survey ,India,West Bengal,Dantan,Asymptomatic general population of Paschim Medinipur District,,2020-07-26,2020-08-08,Household and community samples,All,Multiple groups,,,Geographical area,Dantan I,14,0.0,,,,,,,,Stratified probability,ErbaLisa COVID-19 IgG ELISA Kit,Calbiotech Inc.,ELISA,Serum,IgG,,Validated by manufacturers,0.983,0.981,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Unclear,Parthasarathi Satpati,Medical College Kolkata,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.12.20193219v1,2020-11-05,2024-03-01,Verified,satpati_sero-surveillance_2020,IND
200914_PaschimMedinipur_MedicalCollegeKolkata_KGP,200914_PaschimMedinipur_MedicalCollegeKolkata,"Sero-surveillance (IgG) of SARS-CoV-2 among Asymptomatic General population of Paschim Medinipur District, West Bengal, India(Conducted during last week of July and 1st week of August 2020) - A Joint Venture of VRDL Lab (ICMR), Midnapore Medical College &",2020-09-14,Preprint,Regional,Cross-sectional survey ,India,West Bengal,KGP Municipality,Asymptomatic general population of Paschim Medinipur District,,2020-07-26,2020-08-08,Household and community samples,All,Multiple groups,,,Geographical area,KGP Municipality,108,0.037000000000000005,0.0102,0.09210000000000002,,,,,,Stratified probability,ErbaLisa COVID-19 IgG ELISA Kit,Calbiotech Inc.,ELISA,Serum,IgG,,Validated by manufacturers,0.983,0.981,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Unclear,Parthasarathi Satpati,Medical College Kolkata,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.12.20193219v1,2020-11-05,2024-03-01,Verified,satpati_sero-surveillance_2020,IND
200916_Kerala_AmritaInstituteofMedicalSciencesandResearchCentre,200916_Kerala_AmritaInstituteofMedicalSciences&ResearchCentre,"SARS-CoV-2 antibodies in healthcare workers in a large university hospital, Kerala, India",2020-09-16,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,India,Kerala,,healthcare workers in a 1200- bed university teaching hospital were recruited,,2020-07-11,2020-07-24,Health care workers and caregivers,All,Multiple groups,19.0,70.0,Primary Estimate,Overall estimate,635,0.0,,,True,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']",,,,,['High'],Yes,No,Yes,No,Yes,Unclear,Yes,No,Unclear,Anil Kumar,Amrita Institute of Medical Sciences & Research Centre,Not Unity-Aligned,http://dx.doi.org/10.1016/j.cmi.2020.09.013,2021-02-06,2024-03-01,Verified,kumar_sars-cov-2_2021,IND
201017_Ujjain_TheTimesOfIndia_primary,201017_Ujjain_TheTimesOfIndia,"11.9%  seroprevalence in Ujjain, finds survey",2020-09-17,News and Media,Regional,Cross-sectional survey ,India,Madhya Pradesh,,,,2020-08-27,2020-08-30,Household and community samples,All,Multiple groups,,,Primary Estimate,,3000,0.11900000000000001,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,Amarjeet Singh,The Times of India,Not Unity-Aligned,https://timesofindia.indiatimes.com/city/bhopal/11-9-seroprevalence-in-ujjain-finds-survey/articleshow/78159395.cms,2021-04-22,2022-07-16,Verified,sep_17_119_nodate,IND
200917_India_MinistryofHealth&FamilyWelfare_OverallPopTestAdj,200917_India_MinistryofHealth&FamilyWelfare,"Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020",2020-09-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,General population - individuals aged 18 yr or more in selected representative 736 districts in India,,2020-05-11,2020-06-04,Household and community samples,All,Multiple groups,18.0,,Analysis,"Overall, test adjusted",28000,0.0073,0.0034000000000000002,0.0113,True,True,True,,,Stratified probability,"Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Anti-SARS-CoV-2 ELISA IgG","Zydus Diagnostics,EUROIMMUN",ELISA,Serum,IgG,"['Spike', 'Whole-virusantigen']",,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Yes,Manoj Murhekar,Indian Council of Medical Research,Not Unity-Aligned,http://dx.doi.org/10.4103/ijmr.IJMR_3290_20,2020-11-26,2023-08-15,Verified,murhekar_prevalence_2020,IND
200917_India_MinistryofHealth&FamilyWelfare_OtherSex,200917_India_MinistryofHealth&FamilyWelfare,"Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020",2020-09-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,General population - individuals aged 18 yr or more in selected representative 736 districts in India,,2020-05-11,2020-06-04,Household and community samples,Other,Multiple groups,18.0,,Sex/Gender,Other sex/gender,27,0.0,,,,,,,,Stratified probability,"Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Anti-SARS-CoV-2 ELISA IgG","Zydus Diagnostics,EUROIMMUN",ELISA,Serum,IgG,"['Spike', 'Whole-virusantigen']",,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Yes,Manoj Murhekar,Indian Council of Medical Research,Not Unity-Aligned,http://dx.doi.org/10.4103/ijmr.IJMR_3290_20,2020-11-26,2024-03-01,Verified,murhekar_prevalence_2020,IND
200917_India_MinistryofHealth&FamilyWelfare_OverallPopAdj,200917_India_MinistryofHealth&FamilyWelfare,"Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020",2020-09-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,General population - individuals aged 18 yr or more in selected representative 736 districts in India,,2020-05-11,2020-06-04,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,"Overall, population adjusted",28000,0.0064,0.003,0.0099,,,True,True,True,Stratified probability,"Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Anti-SARS-CoV-2 ELISA IgG","Zydus Diagnostics,EUROIMMUN",ELISA,Serum,IgG,"['Spike', 'Whole-virusantigen']",,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Yes,Manoj Murhekar,Indian Council of Medical Research,Not Unity-Aligned,http://dx.doi.org/10.4103/ijmr.IJMR_3290_20,2020-11-26,2024-03-01,Verified,murhekar_prevalence_2020,IND
200917_India_MinistryofHealth&FamilyWelfare_Female,200917_India_MinistryofHealth&FamilyWelfare,"Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020",2020-09-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,General population - individuals aged 18 yr or more in selected representative 736 districts in India,,2020-05-11,2020-06-04,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,Females,14390,0.0046,,,,,,,,Stratified probability,"Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Anti-SARS-CoV-2 ELISA IgG","Zydus Diagnostics,EUROIMMUN",ELISA,Serum,IgG,"['Spike', 'Whole-virusantigen']",,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Yes,Manoj Murhekar,Indian Council of Medical Research,Not Unity-Aligned,http://dx.doi.org/10.4103/ijmr.IJMR_3290_20,2020-11-26,2024-03-01,Verified,murhekar_prevalence_2020,IND
200917_India_MinistryofHealth&FamilyWelfare_60+,200917_India_MinistryofHealth&FamilyWelfare,"Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020",2020-09-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,General population - individuals aged 18 yr or more in selected representative 736 districts in India,,2020-05-11,2020-06-04,Household and community samples,All,Seniors (65+ years),60.0,,Age,Age 60+,4848,0.005600000000000001,,,,,,,,Stratified probability,"Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Anti-SARS-CoV-2 ELISA IgG","Zydus Diagnostics,EUROIMMUN",ELISA,Serum,IgG,"['Spike', 'Whole-virusantigen']",,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Yes,Manoj Murhekar,Indian Council of Medical Research,Not Unity-Aligned,http://dx.doi.org/10.4103/ijmr.IJMR_3290_20,2020-11-26,2024-03-01,Verified,murhekar_prevalence_2020,IND
200917_India_MinistryofHealth&FamilyWelfare_Overall,200917_India_MinistryofHealth&FamilyWelfare,"Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020",2020-09-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,General population - individuals aged 18 yr or more in selected representative 736 districts in India,,2020-05-11,2020-06-04,Household and community samples,All,Multiple groups,18.0,,Analysis,"Overall, crude",28000,0.005600000000000001,0.0048,0.006600000000000001,,,,,,Stratified probability,"Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Anti-SARS-CoV-2 ELISA IgG","Zydus Diagnostics,EUROIMMUN",ELISA,Serum,IgG,"['Spike', 'Whole-virusantigen']",,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Yes,Manoj Murhekar,Indian Council of Medical Research,Not Unity-Aligned,http://dx.doi.org/10.4103/ijmr.IJMR_3290_20,2020-11-26,2024-03-01,Verified,murhekar_prevalence_2020,IND
200917_India_MinistryofHealth&FamilyWelfare_Male,200917_India_MinistryofHealth&FamilyWelfare,"Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020",2020-09-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,General population - individuals aged 18 yr or more in selected representative 736 districts in India,,2020-05-11,2020-06-04,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,Males,13514,0.0067,,,,,,,,Stratified probability,"Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Anti-SARS-CoV-2 ELISA IgG","Zydus Diagnostics,EUROIMMUN",ELISA,Serum,IgG,"['Spike', 'Whole-virusantigen']",,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Yes,Manoj Murhekar,Indian Council of Medical Research,Not Unity-Aligned,http://dx.doi.org/10.4103/ijmr.IJMR_3290_20,2020-11-26,2024-03-01,Verified,murhekar_prevalence_2020,IND
200917_India_MinistryofHealth&FamilyWelfare_18-45,200917_India_MinistryofHealth&FamilyWelfare,"Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020",2020-09-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,General population - individuals aged 18 yr or more in selected representative 736 districts in India,,2020-05-11,2020-06-04,Household and community samples,All,Adults (18-64 years),18.0,45.0,Age,Age 18-45,13552,0.005,,,,,,,,Stratified probability,"Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Anti-SARS-CoV-2 ELISA IgG","Zydus Diagnostics,EUROIMMUN",ELISA,Serum,IgG,"['Spike', 'Whole-virusantigen']",,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Yes,Manoj Murhekar,Indian Council of Medical Research,Not Unity-Aligned,http://dx.doi.org/10.4103/ijmr.IJMR_3290_20,2020-11-26,2024-03-01,Verified,murhekar_prevalence_2020,IND
200917_India_MinistryofHealth&FamilyWelfare_46-60,200917_India_MinistryofHealth&FamilyWelfare,"Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020",2020-09-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,General population - individuals aged 18 yr or more in selected representative 736 districts in India,,2020-05-11,2020-06-04,Household and community samples,All,Adults (18-64 years),45.0,60.0,Age,Age 46-60,9525,0.006500000000000001,,,,,,,,Stratified probability,"Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Anti-SARS-CoV-2 ELISA IgG","Zydus Diagnostics,EUROIMMUN",ELISA,Serum,IgG,"['Spike', 'Whole-virusantigen']",,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Yes,Manoj Murhekar,Indian Council of Medical Research,Not Unity-Aligned,http://dx.doi.org/10.4103/ijmr.IJMR_3290_20,2020-11-26,2024-03-01,Verified,murhekar_prevalence_2020,IND
200922_Delhi_NationalCenterforDiseaseControlIndia_Survey1_PopAdj,200922_Delhi_NationalCentreforDiseaseControlIndia_Survey1,Serial SARS-CoV-2 Seropravelence Studies in Delhi July-August 2020: Indications of Pre-existing Cross-reactive Antibodies and Implications for Disease Progression,2020-09-22,Preprint,Local,Cross-sectional survey ,India,NCT Delhi,New Delhi,"General population of Delhi, India",,2020-06-26,2020-07-10,Household and community samples,All,Multiple groups,,,Primary Estimate,,21387,0.2348,0.22960000000000003,0.2401,True,,True,,True,Unclear,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Multiple Types,IgG,Spike,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['High'],Unclear,Unclear,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Smarajit Dey,National Centre for Disease Control,Not Unity-Aligned,https://www.researchsquare.com/article/rs-80259/v1,2020-11-18,2024-03-01,Verified,noauthor_serial_2020,IND
200922_Delhi_NationalCenterforDiseaseControlIndia_Survey1_TestAdj,200922_Delhi_NationalCentreforDiseaseControlIndia_Survey1,Serial SARS-CoV-2 Seropravelence Studies in Delhi July-August 2020: Indications of Pre-existing Cross-reactive Antibodies and Implications for Disease Progression,2020-09-22,Preprint,Local,Cross-sectional survey ,India,NCT Delhi,New Delhi,"General population of Delhi, India",,2020-06-26,2020-07-10,Household and community samples,All,Multiple groups,,,Analysis,Test Adjusted,21387,0.22829999999999998,,,,True,,,,Unclear,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Multiple Types,IgG,Spike,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['High'],Unclear,Unclear,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Smarajit Dey,National Centre for Disease Control,Not Unity-Aligned,https://www.researchsquare.com/article/rs-80259/v1,2020-11-18,2023-08-15,Verified,noauthor_serial_2020,IND
200922_Delhi_NationalCenterforDiseaseControlIndia_Survey2_PopAdj,200922_Delhi_NationalCentreforDiseaseControlIndia_Survey2,Serial SARS-CoV-2 Seropravelence Studies in Delhi July-August 2020: Indications of Pre-existing Cross-reactive Antibodies and Implications for Disease Progression,2020-09-22,Preprint,Local,Cross-sectional survey ,India,NCT Delhi,New Delhi,"General population of Delhi, India",,2020-08-01,2020-08-07,Household and community samples,All,Multiple groups,,,Primary Estimate,,15311,0.29100000000000004,0.2851,0.2995,True,,True,,True,Unclear,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Multiple Types,IgG,Spike,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['High'],Unclear,Unclear,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Smarajit Dey,National Centre for Disease Control,Not Unity-Aligned,https://www.researchsquare.com/article/rs-80259/v1,2020-11-18,2024-03-01,Verified,noauthor_serial_2020,IND
200922_Delhi_NationalCenterforDiseaseControlIndia_Survey2_TestAdj,200922_Delhi_NationalCentreforDiseaseControlIndia_Survey2,Serial SARS-CoV-2 Seropravelence Studies in Delhi July-August 2020: Indications of Pre-existing Cross-reactive Antibodies and Implications for Disease Progression,2020-09-22,Preprint,Local,Cross-sectional survey ,India,NCT Delhi,New Delhi,"General population of Delhi, India",,2020-08-01,2020-08-07,Household and community samples,All,Multiple groups,,,Analysis,Test Adjusted,15311,0.2784,,,,True,,,,Unclear,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Multiple Types,IgG,Spike,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['High'],Unclear,Unclear,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Smarajit Dey,National Centre for Disease Control,Not Unity-Aligned,https://www.researchsquare.com/article/rs-80259/v1,2020-11-18,2023-08-15,Verified,noauthor_serial_2020,IND
200930_Kerala_GovernmentOfKerala_August,200930_Kerala_GovernmentOfKerala_August,ICMR Sero Surveillance 2nd Round-Kerala,2020-09-30,Institutional Report,Regional,Repeated cross-sectional study,India,Kerala,"Ernakulam, Palakkad, Thrissur","The survey was conducted in the general population among individuals aged 18 years or
more in selected representative 736 districts in India. Samples are collected
from three districts of Kerala (Ernakulam, Palakkad and Thrissur).",,2020-08-24,2020-08-26,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,1281,0.008,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,Government of Kerala,Indian Medical Research Council,Not Unity-Aligned,https://arogyakeralam.gov.in/wp-content/uploads/2020/03/Technical-Paper-COVID-19-ICMR-Sero-Surveillance-Study.docx.pdf,2021-05-20,2022-07-16,Verified, government_of_kerala_covid-19_2020,IND
200930_Kerala_GovernmentOfKerala_May,200930_Kerala_GovernmentOfKerala_May,ICMR Sero Surveillance 2nd Round-Kerala,2020-09-30,Institutional Report,Regional,Repeated cross-sectional study,India,Kerala,"Ernakulam, Palakkad, Thrissur","The survey was conducted in the general population among individuals aged 18 years or
more in selected representative 736 districts in India. Samples are collected
from three districts of Kerala (Ernakulam, Palakkad and Thrissur).",,2020-05-18,2020-05-23,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,1193,0.0033000000000000004,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,Government of Kerala,Indian Medical Research Council,Not Unity-Aligned,https://arogyakeralam.gov.in/wp-content/uploads/2020/03/Technical-Paper-COVID-19-ICMR-Sero-Surveillance-Study.docx.pdf,2021-05-20,2022-07-16,Verified, government_of_kerala_covid-19_2020,IND
201011_Assam_Srijanasom_overall,201011_Assam_Srijanasom,"Assam’s sero-survey found 23.7
  per cent Seroprevalence in the state",2020-10-11,News and Media,Regional,Cross-sectional survey ,India,Assam,,,,2020-08-23,2020-09-26,Household and community samples,All,Multiple groups,5.0,65.0,Primary Estimate,,2390,0.237,,,True,,,,True,Unclear,Not reported/ Unable to specify,,CLIA,Serum,IgG,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,Bikash Singh,Srijanasom,Not Unity-Aligned,https://economictimes.indiatimes.com/news/politics-and-nation/assams-sero-survey-found-23-7-per-cent-seroprevalence-in-the-state/articleshow/78606153.cms,2021-05-14,2022-07-16,Verified,noauthor_assams_nodate,IND
201027_DistrictSrinagar_GovernmentMedicalCollege_Overall,201027_DistrictSrinagar_GovernmentMedicalCollege,"SARS-CoV-2 seroprevalence in healthcare workers of dedicated-COVID hospitals and non–COVID hospitals of District Srinagar, Kashmir",2020-10-27,Preprint,Local,Cross-sectional survey ,India,Kashmir,,"All frontline healthcare workers,including doctors, administrative and laboratory personnel, technicians, field workers who were involved in surveillance activity, and other supporting staff, were part of the study.",,2020-06-15,2020-06-29,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Overall HCW,2905,0.025,0.02,0.031000000000000003,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,1.0,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,No,Muhammad Salim Khan,Government Medical College,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.23.20218164v1.full-text,2021-03-16,2024-03-01,Verified,khan_sars-cov-2_2020,IND
201027_DistrictSrinagar_GovernmentMedicalCollege_Age_50+,201027_DistrictSrinagar_GovernmentMedicalCollege,"SARS-CoV-2 seroprevalence in healthcare workers of dedicated-COVID hospitals and non–COVID hospitals of District Srinagar, Kashmir",2020-10-27,Preprint,Local,Cross-sectional survey ,India,Kashmir,,"All frontline healthcare workers,including doctors, administrative and laboratory personnel, technicians, field workers who were involved in surveillance activity, and other supporting staff, were part of the study.",,2020-06-15,2020-06-29,Health care workers and caregivers,All,Adults (18-64 years),50.0,,Age,50+,588,0.02,0.012,0.036000000000000004,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,1.0,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,No,Muhammad Salim Khan,Government Medical College,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.23.20218164v1.full-text,2021-03-18,2024-03-01,Verified,khan_sars-cov-2_2020,IND
201027_DistrictSrinagar_GovernmentMedicalCollege_Age_<30,201027_DistrictSrinagar_GovernmentMedicalCollege,"SARS-CoV-2 seroprevalence in healthcare workers of dedicated-COVID hospitals and non–COVID hospitals of District Srinagar, Kashmir",2020-10-27,Preprint,Local,Cross-sectional survey ,India,Kashmir,,"All frontline healthcare workers,including doctors, administrative and laboratory personnel, technicians, field workers who were involved in surveillance activity, and other supporting staff, were part of the study.",,2020-06-15,2020-06-29,Health care workers and caregivers,All,Adults (18-64 years),,30.0,Age,<30,705,0.034,0.023,0.05,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,1.0,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,No,Muhammad Salim Khan,Government Medical College,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.23.20218164v1.full-text,2021-03-18,2024-03-01,Verified,khan_sars-cov-2_2020,IND
201027_DistrictSrinagar_GovernmentMedicalCollege_Age_30-49,201027_DistrictSrinagar_GovernmentMedicalCollege,"SARS-CoV-2 seroprevalence in healthcare workers of dedicated-COVID hospitals and non–COVID hospitals of District Srinagar, Kashmir",2020-10-27,Preprint,Local,Cross-sectional survey ,India,Kashmir,,"All frontline healthcare workers,including doctors, administrative and laboratory personnel, technicians, field workers who were involved in surveillance activity, and other supporting staff, were part of the study.",,2020-06-15,2020-06-29,Health care workers and caregivers,All,Adults (18-64 years),30.0,49.0,Age,30-49,1612,0.022000000000000002,0.016,0.031000000000000003,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,1.0,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,No,Muhammad Salim Khan,Government Medical College,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.23.20218164v1.full-text,2021-03-18,2024-03-01,Verified,khan_sars-cov-2_2020,IND
201031_Bhubaneswar_RegionalMedicalResearchCentre_overall,201031_Bhubaneswar_RegionalMedicalResearchCentre,Survey: 50% of Bhubaneswar residents have antibodies,2020-10-31,News and Media,Local,Cross-sectional survey ,India,,Bhubaneswar,"Residents of Bhubaneswar: 1,403 persons, who were picked up randomly from 25 of the city's 67 wards. ",,2020-10-16,2020-10-18,Household and community samples,All,Multiple groups,,,Primary Estimate,,1403,0.5,,,True,,,,True,Simplified probability,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,Riyan Ramanath,The Regional Medical Research Centre in Bhubaneswar,Not Unity-Aligned,https://timesofindia.indiatimes.com/city/bhubaneswar/survey-50-of-bhubaneswar-residents-have-antibodies/articleshow/78966615.cms,2021-03-07,2022-07-16,Verified,ramanath_survey_nodate,IND
201102_India_DepartmentCommunityMedicine_Primary,201102_India_DepartmentCommunityMedicine,"Second sero survey in Haryana shows 14.8% of population infected with Covid, up from 8%",2020-11-02,News and Media,Regional,Repeated cross-sectional study,India,Haryana,,All 22 districts of the Haryana state with a sample size of more than 700 people in each district.,,2020-10-01,2020-10-14,Household and community samples,All,Multiple groups,,,Primary Estimate,,16512,0.14800000000000002,,,,,,,True,Stratified non-probability,Not reported/ Unable to specify,,,,,,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Chitleen K Sethi,Indian Department of Community Medicine,Not Unity-Aligned,https://theprint.in/india/second-sero-survey-in-haryana-shows-14-8-of-population-infected-with-covid-up-from-8/535798/,2021-06-20,2022-07-16,Unverified,sethi_second_2020,IND
201103_Haryan_TheHindu_primary,201103_Haryan_TheHindu,6% rise in seropositivity among Delhi’s neighbours,2020-11-03,News and Media,Regional,Cross-sectional survey ,India,Haryan,,,,2020-10-18,2020-10-24,Household and community samples,All,Multiple groups,,,Primary Estimate,,16477,0.1476,,,True,,,,True,Stratified probability,Not reported/ Unable to specify,,,,,,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,Ashok Kumar,Unclear,Not Unity-Aligned,https://www.thehindu.com/news/cities/Delhi/6-rise-in-seropositivity-among-delhis-neighbours/article33006634.ece,2021-04-22,2022-07-16,Verified,noauthor_6_2020,IND
201104_India_HindujaHospital_GenPop,201104_India_HindujaHospital,Duration of anti-SARS-CoV-2 antibodies much shorter in India,2020-11-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,Healthcare workers (HCW) working in three Government run hospitals in Mumbai. ,,2020-06-01,2020-06-30,Health care workers and caregivers,All,Multiple groups,20.0,,Primary Estimate,,801,0.111,0.091,0.135,True,,,,True,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,Nucleocapsid(N-protein),,0.998,1.0,['High'],No,Unclear,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Nishant Kumar,Postgraduate Institute of Medical Education and Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.vaccine.2020.10.094,2021-01-18,2024-03-01,Verified,kumar_duration_2021-1,IND
201104_India_HindujaHospital_40-60,201104_India_HindujaHospital,Duration of anti-SARS-CoV-2 antibodies much shorter in India,2020-11-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,Healthcare workers (HCW) working in three Government run hospitals in Mumbai. ,,2020-06-01,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),40.0,60.0,Age,40-60 years,380,0.12400000000000001,0.094,0.161,,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,Nucleocapsid(N-protein),,0.998,1.0,['High'],No,Unclear,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Nishant Kumar,Postgraduate Institute of Medical Education and Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.vaccine.2020.10.094,2021-01-18,2024-03-01,Verified,kumar_duration_2021-1,IND
201104_India_HindujaHospital_20-40,201104_India_HindujaHospital,Duration of anti-SARS-CoV-2 antibodies much shorter in India,2020-11-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,Healthcare workers (HCW) working in three Government run hospitals in Mumbai. ,,2020-06-01,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),20.0,40.0,Age,20-40 years,413,0.099,0.07400000000000001,0.132,,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,Nucleocapsid(N-protein),,0.998,1.0,['High'],No,Unclear,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Nishant Kumar,Postgraduate Institute of Medical Education and Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.vaccine.2020.10.094,2021-01-18,2024-03-01,Verified,kumar_duration_2021-1,IND
201104_India_HindujaHospital_60+,201104_India_HindujaHospital,Duration of anti-SARS-CoV-2 antibodies much shorter in India,2020-11-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,Healthcare workers (HCW) working in three Government run hospitals in Mumbai. ,,2020-06-01,2020-06-30,Health care workers and caregivers,All,Seniors (65+ years),61.0,,Age,60+ years,8,0.125,0.022000000000000002,0.47100000000000003,,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,Nucleocapsid(N-protein),,0.998,1.0,['High'],No,Unclear,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Nishant Kumar,Postgraduate Institute of Medical Education and Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.vaccine.2020.10.094,2021-01-18,2024-03-01,Verified,kumar_duration_2021-1,IND
201109_Kolkata_ApolloGleneaglesHospitalsGastroDept_Overall,201109_Kolkata_ApolloGleneaglesHospitalsGastroDept,COVID-19 prevalence among health-care workers of Gastroenterology department: An audit from a tertiary-care hospital in India,2020-11-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,West Bengal,Kolkata,"The department of Gastroenterology at the Apollo Gleneagles Hospitals, Kolkata, India, has 117 HCWs. These include consultants, residents, technicians, nurses, executives, housekeeping staff, and dieticians. All the 117 HCWs were requested to participate in the study and provided informed consent. ",,2020-08-01,2020-08-31,Health care workers and caregivers,All,Adults (18-64 years),20.0,61.0,Primary Estimate,,117,0.3248,,,True,,,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Yes,Mahesh Goenka,Apollo Gleneagles Hospitals,Not Unity-Aligned,http://dx.doi.org/10.1002/jgh3.12447,2021-01-30,2024-03-01,Verified,goenka_covid-19_2021,IND
201109_Kokalta_ApolloGleneaglesHospitals_HCW_Overall,201109_Kokalta_ApolloGleneaglesHospitals,Seroprevalence of COVID-19 Amongst Health Care Workers in a Tertiary Care Hospital of a Metropolitan City from India.,2020-11-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,West Bengal,Kolkata,Hospital employees at Apollo Gleneagles Hospitals,COVID RT-PCR positive during study period,2020-07-12,2020-08-23,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,HCW overall,1122,0.11939999999999999,,,True,,,,True,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Mahesh Goenka,Apollo Gleneagles Hospitals,Not Unity-Aligned,https://www.japi.org/x264a444/seroprevalence-of-covid-19-amongst-health-care-workers-in-a-tertiary-care-hospital-of-a-metropolitan-city-from-india,2021-01-18,2024-03-01,Verified,goenka_seroprevalence_2020,IND
201109_Kokalta_ApolloGleneaglesHospitals_HCW_Age_<30,201109_Kokalta_ApolloGleneaglesHospitals,Seroprevalence of COVID-19 Amongst Health Care Workers in a Tertiary Care Hospital of a Metropolitan City from India.,2020-11-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,West Bengal,Kolkata,Hospital employees at Apollo Gleneagles Hospitals,COVID RT-PCR positive during study period,2020-07-12,2020-08-23,Health care workers and caregivers,All,Adults (18-64 years),,29.0,Age,<30 years,364,0.11813000000000001,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Mahesh Goenka,Apollo Gleneagles Hospitals,Not Unity-Aligned,https://www.japi.org/x264a444/seroprevalence-of-covid-19-amongst-health-care-workers-in-a-tertiary-care-hospital-of-a-metropolitan-city-from-india,2021-01-18,2024-03-01,Verified,goenka_seroprevalence_2020,IND
201109_Kokalta_ApolloGleneaglesHospitals_HCW_Age_>50,201109_Kokalta_ApolloGleneaglesHospitals,Seroprevalence of COVID-19 Amongst Health Care Workers in a Tertiary Care Hospital of a Metropolitan City from India.,2020-11-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,West Bengal,Kolkata,Hospital employees at Apollo Gleneagles Hospitals,COVID RT-PCR positive during study period,2020-07-12,2020-08-23,Health care workers and caregivers,All,Adults (18-64 years),51.0,,Age,>50 years,93,0.03226,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Mahesh Goenka,Apollo Gleneagles Hospitals,Not Unity-Aligned,https://www.japi.org/x264a444/seroprevalence-of-covid-19-amongst-health-care-workers-in-a-tertiary-care-hospital-of-a-metropolitan-city-from-india,2021-01-18,2024-03-01,Verified,goenka_seroprevalence_2020,IND
201109_Kokalta_ApolloGleneaglesHospitals_HCW_Age_30-50,201109_Kokalta_ApolloGleneaglesHospitals,Seroprevalence of COVID-19 Amongst Health Care Workers in a Tertiary Care Hospital of a Metropolitan City from India.,2020-11-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,West Bengal,Kolkata,Hospital employees at Apollo Gleneagles Hospitals,COVID RT-PCR positive during study period,2020-07-12,2020-08-23,Health care workers and caregivers,All,Adults (18-64 years),30.0,50.0,Age,30-50 years,665,0.13233,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Mahesh Goenka,Apollo Gleneagles Hospitals,Not Unity-Aligned,https://www.japi.org/x264a444/seroprevalence-of-covid-19-amongst-health-care-workers-in-a-tertiary-care-hospital-of-a-metropolitan-city-from-india,2021-01-18,2024-03-01,Verified,goenka_seroprevalence_2020,IND
201111_Srinagar_GovernmentMedicalCollegeSrinagar,201111_Srinagar_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2 specific IgG antibodies in District Srinagar, northern India – A cross-sectional study",2020-11-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Srinagar,District Srinagar,We invited all adult patients (>18 years) coming to the selected hospitals during the study period for participation in the study. We purposively selected 20 hospitals across the District so that the chosen hospitals spread across all areas of the District. ,"Hospitals with very meager patient visits (specifically, we excluded hospitals with less than 100 patient visits per month)
were not selected.",2020-07-01,2020-07-15,Residual sera,All,Multiple groups,18.0,,Primary Estimate,"Overall participants, population adjusted",2906,0.036000000000000004,0.028999999999999998,0.043,True,,True,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,S Muhammad Salim Khan,Government Medical College Srinagar,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0239303,2021-04-09,2024-03-01,Verified,khan_seroprevalence_2020,IND
201111_Srinagar_GovernmentMedicalCollegeSrinagar_Under30,201111_Srinagar_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2 specific IgG antibodies in District Srinagar, northern India – A cross-sectional study",2020-11-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Srinagar,District Srinagar,We invited all adult patients (>18 years) coming to the selected hospitals during the study period for participation in the study. We purposively selected 20 hospitals across the District so that the chosen hospitals spread across all areas of the District. ,"Hospitals with very meager patient visits (specifically, we excluded hospitals with less than 100 patient visits per month)
were not selected.",2020-07-01,2020-07-15,Residual sera,All,Adults (18-64 years),18.0,29.0,Age,Ages 18-30,836,0.02,0.013000000000000001,0.032,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,S Muhammad Salim Khan,Government Medical College Srinagar,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0239303,2021-04-09,2024-03-01,Verified,khan_seroprevalence_2020,IND
201111_Srinagar_GovernmentMedicalCollegeSrinagar_PopUnadj,201111_Srinagar_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2 specific IgG antibodies in District Srinagar, northern India – A cross-sectional study",2020-11-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Srinagar,District Srinagar,We invited all adult patients (>18 years) coming to the selected hospitals during the study period for participation in the study. We purposively selected 20 hospitals across the District so that the chosen hospitals spread across all areas of the District. ,"Hospitals with very meager patient visits (specifically, we excluded hospitals with less than 100 patient visits per month)
were not selected.",2020-07-01,2020-07-15,Residual sera,All,Multiple groups,18.0,,Analysis,"Overall participants, unadjusted estimate",2906,0.038,0.032,0.046,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,S Muhammad Salim Khan,Government Medical College Srinagar,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0239303,2021-04-09,2024-03-01,Verified,khan_seroprevalence_2020,IND
201111_Srinagar_GovernmentMedicalCollegeSrinagar_Female,201111_Srinagar_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2 specific IgG antibodies in District Srinagar, northern India – A cross-sectional study",2020-11-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Srinagar,District Srinagar,We invited all adult patients (>18 years) coming to the selected hospitals during the study period for participation in the study. We purposively selected 20 hospitals across the District so that the chosen hospitals spread across all areas of the District. ,"Hospitals with very meager patient visits (specifically, we excluded hospitals with less than 100 patient visits per month)
were not selected.",2020-07-01,2020-07-15,Residual sera,Female,Multiple groups,18.0,,Sex/Gender,Female,1443,0.033,0.025,0.044000000000000004,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,S Muhammad Salim Khan,Government Medical College Srinagar,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0239303,2021-04-09,2024-03-01,Verified,khan_seroprevalence_2020,IND
201111_Srinagar_GovernmentMedicalCollegeSrinagar_Over70,201111_Srinagar_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2 specific IgG antibodies in District Srinagar, northern India – A cross-sectional study",2020-11-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Srinagar,District Srinagar,We invited all adult patients (>18 years) coming to the selected hospitals during the study period for participation in the study. We purposively selected 20 hospitals across the District so that the chosen hospitals spread across all areas of the District. ,"Hospitals with very meager patient visits (specifically, we excluded hospitals with less than 100 patient visits per month)
were not selected.",2020-07-01,2020-07-15,Residual sera,All,Seniors (65+ years),70.0,,Age,Ages 70 or over,90,0.033,0.011000000000000001,0.098,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,S Muhammad Salim Khan,Government Medical College Srinagar,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0239303,2021-04-09,2024-03-01,Verified,khan_seroprevalence_2020,IND
201111_Srinagar_GovernmentMedicalCollegeSrinagar_30to49,201111_Srinagar_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2 specific IgG antibodies in District Srinagar, northern India – A cross-sectional study",2020-11-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Srinagar,District Srinagar,We invited all adult patients (>18 years) coming to the selected hospitals during the study period for participation in the study. We purposively selected 20 hospitals across the District so that the chosen hospitals spread across all areas of the District. ,"Hospitals with very meager patient visits (specifically, we excluded hospitals with less than 100 patient visits per month)
were not selected.",2020-07-01,2020-07-15,Residual sera,All,Adults (18-64 years),30.0,49.0,Age,Ages 30-49,1424,0.040999999999999995,0.032,0.053,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,S Muhammad Salim Khan,Government Medical College Srinagar,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0239303,2021-04-09,2024-03-01,Verified,khan_seroprevalence_2020,IND
201111_Srinagar_GovernmentMedicalCollegeSrinagar_50to69,201111_Srinagar_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2 specific IgG antibodies in District Srinagar, northern India – A cross-sectional study",2020-11-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Srinagar,District Srinagar,We invited all adult patients (>18 years) coming to the selected hospitals during the study period for participation in the study. We purposively selected 20 hospitals across the District so that the chosen hospitals spread across all areas of the District. ,"Hospitals with very meager patient visits (specifically, we excluded hospitals with less than 100 patient visits per month)
were not selected.",2020-07-01,2020-07-15,Residual sera,All,Adults (18-64 years),50.0,69.0,Age,Ages 50-69,556,0.057999999999999996,0.040999999999999995,0.08,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,S Muhammad Salim Khan,Government Medical College Srinagar,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0239303,2021-04-09,2024-03-01,Verified,khan_seroprevalence_2020,IND
201111_Srinagar_GovernmentMedicalCollegeSrinagar_Male,201111_Srinagar_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2 specific IgG antibodies in District Srinagar, northern India – A cross-sectional study",2020-11-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Srinagar,District Srinagar,We invited all adult patients (>18 years) coming to the selected hospitals during the study period for participation in the study. We purposively selected 20 hospitals across the District so that the chosen hospitals spread across all areas of the District. ,"Hospitals with very meager patient visits (specifically, we excluded hospitals with less than 100 patient visits per month)
were not selected.",2020-07-01,2020-07-15,Residual sera,Male,Multiple groups,18.0,,Sex/Gender,Male,1463,0.043,0.034,0.055,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,S Muhammad Salim Khan,Government Medical College Srinagar,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0239303,2021-04-09,2024-03-01,Verified,khan_seroprevalence_2020,IND
201113_Mumbai_TataInstituteforFundamentalResearch_nonslums_adj,201113_Mumbai_TataInstituteforFundamentalResearch_NonSlums,"Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India",2020-11-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,Individuals aged 12 years or older were eligible;,those who did not consent or had contraindications to venipuncture were excluded.,2020-06-29,2020-07-19,Household and community samples,All,Multiple groups,12.0,,Primary Estimate,Non slums pop test adj,2702,0.171,0.158,0.184,True,True,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Anup Malani,Tata Institute for Fundamental Research,Unity-Aligned,http://dx.doi.org/10.1016/S2214-109X%2820%2930467-8,2021-02-22,2023-07-04,Verified,malani_seroprevalence_2021,IND
201113_Mumbai_TataInstituteforFundamentalResearch_nonslums_25-39,201113_Mumbai_TataInstituteforFundamentalResearch_NonSlums,"Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India",2020-11-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,Individuals aged 12 years or older were eligible;,those who did not consent or had contraindications to venipuncture were excluded.,2020-06-29,2020-07-19,Household and community samples,All,Adults (18-64 years),25.0,39.0,Age,age 25-39,733,0.158,0.154,0.162,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Anup Malani,Tata Institute for Fundamental Research,Unity-Aligned,http://dx.doi.org/10.1016/S2214-109X%2820%2930467-8,2021-07-23,2024-03-01,Unverified,malani_seroprevalence_2021,IND
201113_Mumbai_TataInstituteforFundamentalResearch_nonslums_61+,201113_Mumbai_TataInstituteforFundamentalResearch_NonSlums,"Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India",2020-11-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,Individuals aged 12 years or older were eligible;,those who did not consent or had contraindications to venipuncture were excluded.,2020-06-29,2020-07-19,Household and community samples,All,Seniors (65+ years),61.0,,Age,ages 61+,444,0.122,0.115,0.129,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Anup Malani,Tata Institute for Fundamental Research,Unity-Aligned,http://dx.doi.org/10.1016/S2214-109X%2820%2930467-8,2021-07-23,2024-03-01,Verified,malani_seroprevalence_2021,IND
201113_Mumbai_TataInstituteforFundamentalResearch_nonslums_popadj,201113_Mumbai_TataInstituteforFundamentalResearch_NonSlums,"Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India",2020-11-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,Individuals aged 12 years or older were eligible;,those who did not consent or had contraindications to venipuncture were excluded.,2020-06-29,2020-07-19,Household and community samples,All,Multiple groups,12.0,,Analysis,non slums overall pop adj only,2702,0.16,0.14800000000000002,0.172,,,True,,True,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Anup Malani,Tata Institute for Fundamental Research,Unity-Aligned,http://dx.doi.org/10.1016/S2214-109X%2820%2930467-8,2021-03-08,2024-03-01,Verified,malani_seroprevalence_2021,IND
201113_Mumbai_TataInstituteforFundamentalResearch_nonslums_12-24,201113_Mumbai_TataInstituteforFundamentalResearch_NonSlums,"Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India",2020-11-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,Individuals aged 12 years or older were eligible;,those who did not consent or had contraindications to venipuncture were excluded.,2020-06-29,2020-07-19,Household and community samples,All,Children and Youth (0-17 years),12.0,24.0,Age,age 12-24,176,0.18300000000000002,0.131,0.23500000000000001,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Anup Malani,Tata Institute for Fundamental Research,Unity-Aligned,http://dx.doi.org/10.1016/S2214-109X%2820%2930467-8,2021-07-23,2024-03-01,Verified,malani_seroprevalence_2021,IND
201113_Mumbai_TataInstituteforFundamentalResearch_Dahisar-nonslum_adj,201113_Mumbai_TataInstituteforFundamentalResearch_NonSlums,"Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India",2020-11-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,Individuals aged 12 years or older were eligible;,those who did not consent or had contraindications to venipuncture were excluded.,2020-06-29,2020-07-19,Household and community samples,All,Multiple groups,12.0,,Geographical area,Dahisar,578,0.584,0.568,0.599,,True,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Anup Malani,Tata Institute for Fundamental Research,Unity-Aligned,http://dx.doi.org/10.1016/S2214-109X%2820%2930467-8,2021-02-22,2023-07-04,Verified,malani_seroprevalence_2021,IND
201113_Mumbai_TataInstituteforFundamentalResearch_Matunga-nonslum_adj,201113_Mumbai_TataInstituteforFundamentalResearch_NonSlums,"Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India",2020-11-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,Individuals aged 12 years or older were eligible;,those who did not consent or had contraindications to venipuncture were excluded.,2020-06-29,2020-07-19,Household and community samples,All,Multiple groups,12.0,,Geographical area,Matunga,1183,0.177,0.154,0.201,,True,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Anup Malani,Tata Institute for Fundamental Research,Unity-Aligned,http://dx.doi.org/10.1016/S2214-109X%2820%2930467-8,2021-02-22,2023-07-04,Verified,malani_seroprevalence_2021,IND
201113_Mumbai_TataInstituteforFundamentalResearch_ChemburWest-nonslum_adj,201113_Mumbai_TataInstituteforFundamentalResearch_NonSlums,"Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India",2020-11-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,Individuals aged 12 years or older were eligible;,those who did not consent or had contraindications to venipuncture were excluded.,2020-06-29,2020-07-19,Household and community samples,All,Multiple groups,12.0,,Geographical area,Chembur West,941,0.128,0.10099999999999999,0.154,,True,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Anup Malani,Tata Institute for Fundamental Research,Unity-Aligned,http://dx.doi.org/10.1016/S2214-109X%2820%2930467-8,2021-02-22,2023-07-04,Verified,malani_seroprevalence_2021,IND
201113_Mumbai_TataInstituteforFundamentalResearch_nonslums_Female,201113_Mumbai_TataInstituteforFundamentalResearch_NonSlums,"Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India",2020-11-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,Individuals aged 12 years or older were eligible;,those who did not consent or had contraindications to venipuncture were excluded.,2020-06-29,2020-07-19,Household and community samples,Female,Multiple groups,12.0,,Sex/Gender,female,802,0.0182,0.0045000000000000005,0.0317,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Anup Malani,Tata Institute for Fundamental Research,Unity-Aligned,http://dx.doi.org/10.1016/S2214-109X%2820%2930467-8,2021-07-23,2024-03-01,Verified,malani_seroprevalence_2021,IND
201113_Mumbai_TataInstituteforFundamentalResearch_nonslums_40-60,201113_Mumbai_TataInstituteforFundamentalResearch_NonSlums,"Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India",2020-11-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,Individuals aged 12 years or older were eligible;,those who did not consent or had contraindications to venipuncture were excluded.,2020-06-29,2020-07-19,Household and community samples,All,Adults (18-64 years),40.0,60.0,Age,age 40-60,1349,0.15,0.142,0.157,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Anup Malani,Tata Institute for Fundamental Research,Unity-Aligned,http://dx.doi.org/10.1016/S2214-109X%2820%2930467-8,2021-07-23,2024-03-01,Unverified,malani_seroprevalence_2021,IND
201113_Mumbai_TataInstituteforFundamentalResearch_slums_testpopadj,201113_Mumbai_TataInstituteforFundamentalResearch_Slums,"Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India",2020-11-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,Individuals aged 12 years or older were eligible;,those who did not consent or had contraindications to venipuncture were excluded.,2020-06-29,2020-07-19,Persons living in slums,All,Multiple groups,12.0,,Primary Estimate,Slums overall pop test adj,4202,0.583,0.568,0.599,True,True,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Anup Malani,Tata Institute for Fundamental Research,Unity-Aligned,http://dx.doi.org/10.1016/S2214-109X%2820%2930467-8,2021-02-22,2023-07-04,Verified,malani_seroprevalence_2021,IND
201113_Mumbai_TataInstituteforFundamentalResearch_ChemburWest-slum_adj,201113_Mumbai_TataInstituteforFundamentalResearch_Slums,"Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India",2020-11-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,Individuals aged 12 years or older were eligible;,those who did not consent or had contraindications to venipuncture were excluded.,2020-06-29,2020-07-19,Persons living in slums,All,Multiple groups,12.0,,Geographical area,Chembur West,1511,0.594,0.569,0.618,,True,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Anup Malani,Tata Institute for Fundamental Research,Unity-Aligned,http://dx.doi.org/10.1016/S2214-109X%2820%2930467-8,2021-02-22,2023-07-04,Verified,malani_seroprevalence_2021,IND
201113_Mumbai_TataInstituteforFundamentalResearch_slums_60+,201113_Mumbai_TataInstituteforFundamentalResearch_Slums,"Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India",2020-11-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,Individuals aged 12 years or older were eligible;,those who did not consent or had contraindications to venipuncture were excluded.,2020-06-29,2020-07-19,Persons living in slums,All,Seniors (65+ years),60.0,,Age,60+,325,0.599,0.569,0.628,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Anup Malani,Tata Institute for Fundamental Research,Unity-Aligned,http://dx.doi.org/10.1016/S2214-109X%2820%2930467-8,2021-07-23,2024-03-01,Unverified,malani_seroprevalence_2021,IND
201113_Mumbai_TataInstituteforFundamentalResearch_slums_12-24,201113_Mumbai_TataInstituteforFundamentalResearch_Slums,"Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India",2020-11-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,Individuals aged 12 years or older were eligible;,those who did not consent or had contraindications to venipuncture were excluded.,2020-06-29,2020-07-19,Persons living in slums,All,Children and Youth (0-17 years),12.0,24.0,Age,12-24,702,0.53,0.46299999999999997,0.5970000000000001,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Anup Malani,Tata Institute for Fundamental Research,Unity-Aligned,http://dx.doi.org/10.1016/S2214-109X%2820%2930467-8,2021-07-23,2024-03-01,Unverified,malani_seroprevalence_2021,IND
201113_Mumbai_TataInstituteforFundamentalResearch_slums_Female,201113_Mumbai_TataInstituteforFundamentalResearch_Slums,"Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India",2020-11-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,Individuals aged 12 years or older were eligible;,those who did not consent or had contraindications to venipuncture were excluded.,2020-06-29,2020-07-19,Persons living in slums,Female,Multiple groups,12.0,,Sex/Gender,female,2280,0.0604,0.0227,0.098,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Anup Malani,Tata Institute for Fundamental Research,Unity-Aligned,http://dx.doi.org/10.1016/S2214-109X%2820%2930467-8,2021-07-23,2024-03-01,Unverified,malani_seroprevalence_2021,IND
201113_Mumbai_TataInstituteforFundamentalResearch_Matunga-slum_adj,201113_Mumbai_TataInstituteforFundamentalResearch_Slums,"Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India",2020-11-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,Individuals aged 12 years or older were eligible;,those who did not consent or had contraindications to venipuncture were excluded.,2020-06-29,2020-07-19,Persons living in slums,All,Multiple groups,12.0,,Geographical area,Matunga,2121,0.614,0.593,0.635,,True,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Anup Malani,Tata Institute for Fundamental Research,Unity-Aligned,http://dx.doi.org/10.1016/S2214-109X%2820%2930467-8,2021-02-22,2023-07-04,Verified,malani_seroprevalence_2021,IND
201113_Mumbai_TataInstituteforFundamentalResearch_slums_40-60,201113_Mumbai_TataInstituteforFundamentalResearch_Slums,"Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India",2020-11-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,Individuals aged 12 years or older were eligible;,those who did not consent or had contraindications to venipuncture were excluded.,2020-06-29,2020-07-19,Persons living in slums,All,Adults (18-64 years),40.0,59.0,Age,40-60,1695,0.563,0.519,0.608,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Anup Malani,Tata Institute for Fundamental Research,Unity-Aligned,http://dx.doi.org/10.1016/S2214-109X%2820%2930467-8,2021-07-23,2024-03-01,Unverified,malani_seroprevalence_2021,IND
201113_Mumbai_TataInstituteforFundamentalResearch_slums_popadj,201113_Mumbai_TataInstituteforFundamentalResearch_Slums,"Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India",2020-11-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,Individuals aged 12 years or older were eligible;,those who did not consent or had contraindications to venipuncture were excluded.,2020-06-29,2020-07-19,Persons living in slums,All,Multiple groups,12.0,,Analysis,Slums overall pop adj only,4202,0.541,0.527,0.555,,,True,,True,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Anup Malani,Tata Institute for Fundamental Research,Unity-Aligned,http://dx.doi.org/10.1016/S2214-109X%2820%2930467-8,2021-03-08,2024-03-01,Verified,malani_seroprevalence_2021,IND
201113_Mumbai_TataInstituteforFundamentalResearch_slums_25-39,201113_Mumbai_TataInstituteforFundamentalResearch_Slums,"Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India",2020-11-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,Individuals aged 12 years or older were eligible;,those who did not consent or had contraindications to venipuncture were excluded.,2020-06-29,2020-07-19,Persons living in slums,All,Adults (18-64 years),25.0,39.0,Age,25-39,1480,0.48,0.459,0.502,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Anup Malani,Tata Institute for Fundamental Research,Unity-Aligned,http://dx.doi.org/10.1016/S2214-109X%2820%2930467-8,2021-07-23,2024-03-01,Unverified,malani_seroprevalence_2021,IND
201113_Mumbai_TataInstituteforFundamentalResearch_Dahisar-slum_adj,201113_Mumbai_TataInstituteforFundamentalResearch_Slums,"Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India",2020-11-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,Individuals aged 12 years or older were eligible;,those who did not consent or had contraindications to venipuncture were excluded.,2020-06-29,2020-07-19,Persons living in slums,All,Multiple groups,12.0,,Geographical area,Dahisar,570,0.551,0.509,0.593,,True,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Anup Malani,Tata Institute for Fundamental Research,Unity-Aligned,http://dx.doi.org/10.1016/S2214-109X%2820%2930467-8,2021-02-22,2023-07-04,Verified,malani_seroprevalence_2021,IND
201130_PuneCity_IndianInstituteOfScienceEducationAndResearch_OverallAdj,201130_PuneCity_IndianInstituteOfScienceEducationAndResearch,Community prevalence of antibodies to SARS-CoV-2 and correlates of protective immunity in five localities in an Indian metropolitan city,2020-11-30,Preprint,Local,Cross-sectional survey ,India,Maharashtra,Pune,"gen public of  Pune. One consenting adult per household, above 18 years of age was selected following a pre-decided age and sex distribution criteria14."," Currently ill, febrile individuals were excluded, though, those who had an illness episode, including COVID-19, in the past but were well at recruitment remained eligible for recruitment. Active containment zones were excluded because of operational challenges",2020-07-20,2020-08-05,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,1659,0.513,0.399,0.624,True,,True,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Aurnab Ghose,Indian Institute of Science Education and Research,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.11.17.20228155v2.full-text,2021-02-12,2022-07-16,Verified,ghose_community_2020,IND
201130_PuneCity_IndianInstituteOfScienceEducationAndResearch_31-50,201130_PuneCity_IndianInstituteOfScienceEducationAndResearch,Community prevalence of antibodies to SARS-CoV-2 and correlates of protective immunity in five localities in an Indian metropolitan city,2020-11-30,Preprint,Local,Cross-sectional survey ,India,Maharashtra,Pune,"gen public of  Pune. One consenting adult per household, above 18 years of age was selected following a pre-decided age and sex distribution criteria14."," Currently ill, febrile individuals were excluded, though, those who had an illness episode, including COVID-19, in the past but were well at recruitment remained eligible for recruitment. Active containment zones were excluded because of operational challenges",2020-07-20,2020-08-05,Household and community samples,All,Adults (18-64 years),31.0,50.0,Age,Aged 31-50,677,0.523,0.41000000000000003,0.634,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Aurnab Ghose,Indian Institute of Science Education and Research,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.11.17.20228155v2.full-text,2021-02-12,2022-07-16,Verified,ghose_community_2020,IND
201130_PuneCity_IndianInstituteOfScienceEducationAndResearch_Male,201130_PuneCity_IndianInstituteOfScienceEducationAndResearch,Community prevalence of antibodies to SARS-CoV-2 and correlates of protective immunity in five localities in an Indian metropolitan city,2020-11-30,Preprint,Local,Cross-sectional survey ,India,Maharashtra,Pune,"gen public of  Pune. One consenting adult per household, above 18 years of age was selected following a pre-decided age and sex distribution criteria14."," Currently ill, febrile individuals were excluded, though, those who had an illness episode, including COVID-19, in the past but were well at recruitment remained eligible for recruitment. Active containment zones were excluded because of operational challenges",2020-07-20,2020-08-05,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,Males,801,0.527,0.41700000000000004,0.635,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Aurnab Ghose,Indian Institute of Science Education and Research,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.11.17.20228155v2.full-text,2021-02-12,2022-07-16,Verified,ghose_community_2020,IND
201130_PuneCity_IndianInstituteOfScienceEducationAndResearch_Female,201130_PuneCity_IndianInstituteOfScienceEducationAndResearch,Community prevalence of antibodies to SARS-CoV-2 and correlates of protective immunity in five localities in an Indian metropolitan city,2020-11-30,Preprint,Local,Cross-sectional survey ,India,Maharashtra,Pune,"gen public of  Pune. One consenting adult per household, above 18 years of age was selected following a pre-decided age and sex distribution criteria14."," Currently ill, febrile individuals were excluded, though, those who had an illness episode, including COVID-19, in the past but were well at recruitment remained eligible for recruitment. Active containment zones were excluded because of operational challenges",2020-07-20,2020-08-05,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,females,858,0.49700000000000005,0.375,0.62,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Aurnab Ghose,Indian Institute of Science Education and Research,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.11.17.20228155v2.full-text,2021-02-12,2022-07-16,Verified,ghose_community_2020,IND
201130_PuneCity_IndianInstituteOfScienceEducationAndResearch_OverallUnAdj,201130_PuneCity_IndianInstituteOfScienceEducationAndResearch,Community prevalence of antibodies to SARS-CoV-2 and correlates of protective immunity in five localities in an Indian metropolitan city,2020-11-30,Preprint,Local,Cross-sectional survey ,India,Maharashtra,Pune,"gen public of  Pune. One consenting adult per household, above 18 years of age was selected following a pre-decided age and sex distribution criteria14."," Currently ill, febrile individuals were excluded, though, those who had an illness episode, including COVID-19, in the past but were well at recruitment remained eligible for recruitment. Active containment zones were excluded because of operational challenges",2020-07-20,2020-08-05,Household and community samples,All,Multiple groups,18.0,,Analysis,Unadjusted,1659,0.517,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Aurnab Ghose,Indian Institute of Science Education and Research,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.11.17.20228155v2.full-text,2021-02-12,2022-07-16,Verified,ghose_community_2020,IND
201130_PuneCity_IndianInstituteOfScienceEducationAndResearch_>65,201130_PuneCity_IndianInstituteOfScienceEducationAndResearch,Community prevalence of antibodies to SARS-CoV-2 and correlates of protective immunity in five localities in an Indian metropolitan city,2020-11-30,Preprint,Local,Cross-sectional survey ,India,Maharashtra,Pune,"gen public of  Pune. One consenting adult per household, above 18 years of age was selected following a pre-decided age and sex distribution criteria14."," Currently ill, febrile individuals were excluded, though, those who had an illness episode, including COVID-19, in the past but were well at recruitment remained eligible for recruitment. Active containment zones were excluded because of operational challenges",2020-07-20,2020-08-05,Household and community samples,All,Seniors (65+ years),66.0,,Age,Over the age of 65,171,0.384,0.276,0.506,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Aurnab Ghose,Indian Institute of Science Education and Research,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.11.17.20228155v2.full-text,2021-02-12,2022-07-16,Verified,ghose_community_2020,IND
201130_PuneCity_IndianInstituteOfScienceEducationAndResearch_18-30,201130_PuneCity_IndianInstituteOfScienceEducationAndResearch,Community prevalence of antibodies to SARS-CoV-2 and correlates of protective immunity in five localities in an Indian metropolitan city,2020-11-30,Preprint,Local,Cross-sectional survey ,India,Maharashtra,Pune,"gen public of  Pune. One consenting adult per household, above 18 years of age was selected following a pre-decided age and sex distribution criteria14."," Currently ill, febrile individuals were excluded, though, those who had an illness episode, including COVID-19, in the past but were well at recruitment remained eligible for recruitment. Active containment zones were excluded because of operational challenges",2020-07-20,2020-08-05,Household and community samples,All,Adults (18-64 years),18.0,30.0,Age,Aged 18-30,394,0.515,0.392,0.636,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Aurnab Ghose,Indian Institute of Science Education and Research,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.11.17.20228155v2.full-text,2021-02-12,2022-07-16,Verified,ghose_community_2020,IND
201130_PuneCity_IndianInstituteOfScienceEducationAndResearch_51-65,201130_PuneCity_IndianInstituteOfScienceEducationAndResearch,Community prevalence of antibodies to SARS-CoV-2 and correlates of protective immunity in five localities in an Indian metropolitan city,2020-11-30,Preprint,Local,Cross-sectional survey ,India,Maharashtra,Pune,"gen public of  Pune. One consenting adult per household, above 18 years of age was selected following a pre-decided age and sex distribution criteria14."," Currently ill, febrile individuals were excluded, though, those who had an illness episode, including COVID-19, in the past but were well at recruitment remained eligible for recruitment. Active containment zones were excluded because of operational challenges",2020-07-20,2020-08-05,Household and community samples,All,Adults (18-64 years),51.0,65.0,Age,Aged 51-65,417,0.546,0.39799999999999996,0.687,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Aurnab Ghose,Indian Institute of Science Education and Research,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.11.17.20228155v2.full-text,2021-02-12,2022-07-16,Verified,ghose_community_2020,IND
201207_Mumbai_KokilabenDhirubhaiAmbaniHospital_hcw_primaryest,201207_Mumbai_KokilabenDhirubhaiAmbaniHospital,"Prevalence of COVID-19 antibodies in healthcare workers at the peak of the pandemic in Mumbai, India: A preliminary study.",2020-12-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,"HCWs (1) who either had mild symptoms compatible with COVID‑19
in the past and who were not tested for COVID‑19 and (2)
asymptomatic HCWs (consultants, junior medical doctors,
nurses, laboratory technicians, security staff, porters, healthcare
assistants, housekeeping and physiotherapists) working in the
COVID and non‑COVID areas of the hospital. ",,2020-06-01,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,208,0.125,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",CLIA,Serum,,,,,,['High'],No,No,No,No,No,Yes,Yes,No,No,Tanu Singhal,Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute,Not Unity-Aligned,https://dx.doi.org/10.4103/ijmm.IJMM_20_308,2021-01-12,2024-03-01,Verified,singhal_prevalence_2020,IND
201214_Ahmedabad_ MunicipalMedicalCollege_genpop_primary,201214_Ahmedabad_ MunicipalMedicalCollege,Assessing seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city of India: a cross-sectional study,2020-12-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,"all irrespective of age, sex, acute/past
COVID-19 infection","included refusal to give informed verbal consent or any contraindication
to venipuncture.",2020-06-16,2020-07-07,Residual sera,All,Multiple groups,0.0,99.0,Primary Estimate,genpop,29891,0.1761,0.1718,0.1804,True,,,,True,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9237000000000001,0.9790000000000001,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Om Prakash, Municipal Medical College ,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2020-044101,2021-02-02,2024-03-01,Verified,prakash_assessing_2021,IND
201214_Ahmedabad_ MunicipalMedicalCollege_age_80to89,201214_Ahmedabad_ MunicipalMedicalCollege,Assessing seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city of India: a cross-sectional study,2020-12-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,"all irrespective of age, sex, acute/past
COVID-19 infection","included refusal to give informed verbal consent or any contraindication
to venipuncture.",2020-06-16,2020-07-07,Residual sera,All,Seniors (65+ years),80.0,89.0,Age,80 to 89,142,0.1549,0.09970000000000001,0.22510000000000002,,,,,,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9237000000000001,0.9790000000000001,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Om Prakash, Municipal Medical College ,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2020-044101,2021-02-02,2024-03-01,Verified,prakash_assessing_2021,IND
201214_Ahmedabad_ MunicipalMedicalCollege_age_0to9,201214_Ahmedabad_ MunicipalMedicalCollege,Assessing seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city of India: a cross-sectional study,2020-12-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,"all irrespective of age, sex, acute/past
COVID-19 infection","included refusal to give informed verbal consent or any contraindication
to venipuncture.",2020-06-16,2020-07-07,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,0 to 9 years,92,0.18480000000000002,0.1115,0.2793,,,,,,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9237000000000001,0.9790000000000001,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Om Prakash, Municipal Medical College ,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2020-044101,2021-02-02,2024-03-01,Verified,prakash_assessing_2021,IND
201214_Ahmedabad_ MunicipalMedicalCollege_sex_female,201214_Ahmedabad_ MunicipalMedicalCollege,Assessing seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city of India: a cross-sectional study,2020-12-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,"all irrespective of age, sex, acute/past
COVID-19 infection","included refusal to give informed verbal consent or any contraindication
to venipuncture.",2020-06-16,2020-07-07,Residual sera,Female,Multiple groups,0.0,99.0,Sex/Gender,Female,13847,0.17980000000000002,,,,,,,,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9237000000000001,0.9790000000000001,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Om Prakash, Municipal Medical College ,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2020-044101,2021-02-02,2024-03-01,Verified,prakash_assessing_2021,IND
201214_Ahmedabad_ MunicipalMedicalCollege_age_30to39,201214_Ahmedabad_ MunicipalMedicalCollege,Assessing seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city of India: a cross-sectional study,2020-12-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,"all irrespective of age, sex, acute/past
COVID-19 infection","included refusal to give informed verbal consent or any contraindication
to venipuncture.",2020-06-16,2020-07-07,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30 to 39,7334,0.1643,0.156,0.17300000000000001,,,,,,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9237000000000001,0.9790000000000001,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Om Prakash, Municipal Medical College ,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2020-044101,2021-02-02,2024-03-01,Verified,prakash_assessing_2021,IND
201214_Ahmedabad_ MunicipalMedicalCollege_age_40to49,201214_Ahmedabad_ MunicipalMedicalCollege,Assessing seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city of India: a cross-sectional study,2020-12-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,"all irrespective of age, sex, acute/past
COVID-19 infection","included refusal to give informed verbal consent or any contraindication
to venipuncture.",2020-06-16,2020-07-07,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40 to 49,5999,0.19940000000000002,0.1895,0.2097,,,,,,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9237000000000001,0.9790000000000001,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Om Prakash, Municipal Medical College ,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2020-044101,2021-02-02,2024-03-01,Verified,prakash_assessing_2021,IND
201214_Ahmedabad_ MunicipalMedicalCollege_sex_male,201214_Ahmedabad_ MunicipalMedicalCollege,Assessing seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city of India: a cross-sectional study,2020-12-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,"all irrespective of age, sex, acute/past
COVID-19 infection","included refusal to give informed verbal consent or any contraindication
to venipuncture.",2020-06-16,2020-07-07,Residual sera,Male,Multiple groups,0.0,99.0,Sex/Gender,,16044,0.1729,,,,,,,,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9237000000000001,0.9790000000000001,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Om Prakash, Municipal Medical College ,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2020-044101,2021-02-02,2024-03-01,Verified,prakash_assessing_2021,IND
201214_Ahmedabad_ MunicipalMedicalCollege_age_70to79,201214_Ahmedabad_ MunicipalMedicalCollege,Assessing seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city of India: a cross-sectional study,2020-12-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,"all irrespective of age, sex, acute/past
COVID-19 infection","included refusal to give informed verbal consent or any contraindication
to venipuncture.",2020-06-16,2020-07-07,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70 to 79,796,0.19469999999999998,0.16870000000000002,0.2237,,,,,,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9237000000000001,0.9790000000000001,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Om Prakash, Municipal Medical College ,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2020-044101,2021-02-02,2024-03-01,Verified,prakash_assessing_2021,IND
201214_Ahmedabad_ MunicipalMedicalCollege_age_50to59,201214_Ahmedabad_ MunicipalMedicalCollege,Assessing seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city of India: a cross-sectional study,2020-12-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,"all irrespective of age, sex, acute/past
COVID-19 infection","included refusal to give informed verbal consent or any contraindication
to venipuncture.",2020-06-16,2020-07-07,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50 to 59,4357,0.1962,0.1847,0.20829999999999999,,,,,,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9237000000000001,0.9790000000000001,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Om Prakash, Municipal Medical College ,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2020-044101,2021-02-02,2024-03-01,Verified,prakash_assessing_2021,IND
201214_Ahmedabad_ MunicipalMedicalCollege_age_20to29,201214_Ahmedabad_ MunicipalMedicalCollege,Assessing seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city of India: a cross-sectional study,2020-12-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,"all irrespective of age, sex, acute/past
COVID-19 infection","included refusal to give informed verbal consent or any contraindication
to venipuncture.",2020-06-16,2020-07-07,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20 to 29,7678,0.15660000000000002,0.1486,0.1649,,,,,,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9237000000000001,0.9790000000000001,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Om Prakash, Municipal Medical College ,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2020-044101,2021-02-02,2024-03-01,Verified,prakash_assessing_2021,IND
201214_Ahmedabad_ MunicipalMedicalCollege_age_90to99,201214_Ahmedabad_ MunicipalMedicalCollege,Assessing seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city of India: a cross-sectional study,2020-12-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,"all irrespective of age, sex, acute/past
COVID-19 infection","included refusal to give informed verbal consent or any contraindication
to venipuncture.",2020-06-16,2020-07-07,Residual sera,All,Seniors (65+ years),90.0,99.0,Age,90 to 99,9,0.22219999999999998,0.0281,0.6001,,,,,,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9237000000000001,0.9790000000000001,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Om Prakash, Municipal Medical College ,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2020-044101,2021-02-02,2024-03-01,Verified,prakash_assessing_2021,IND
201214_Ahmedabad_ MunicipalMedicalCollege_age_10to19,201214_Ahmedabad_ MunicipalMedicalCollege,Assessing seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city of India: a cross-sectional study,2020-12-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,"all irrespective of age, sex, acute/past
COVID-19 infection","included refusal to give informed verbal consent or any contraindication
to venipuncture.",2020-06-16,2020-07-07,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,10 to 19,1239,0.1598,0.1405,0.1813,,,,,,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9237000000000001,0.9790000000000001,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Om Prakash, Municipal Medical College ,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2020-044101,2021-02-02,2024-03-01,Verified,prakash_assessing_2021,IND
201214_Ahmedabad_ MunicipalMedicalCollege_age_60to69,201214_Ahmedabad_ MunicipalMedicalCollege,Assessing seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city of India: a cross-sectional study,2020-12-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,"all irrespective of age, sex, acute/past
COVID-19 infection","included refusal to give informed verbal consent or any contraindication
to venipuncture.",2020-06-16,2020-07-07,Residual sera,All,Adults (18-64 years),60.0,69.0,Age,60 to 69,2245,0.18309999999999998,0.16760000000000003,0.1996,,,,,,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9237000000000001,0.9790000000000001,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Om Prakash, Municipal Medical College ,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2020-044101,2021-02-02,2024-03-01,Verified,prakash_assessing_2021,IND
201203_Mumbai_MGMInstituteOfHealthSciences,201203_Mumbai_MGMInstituteOfHealthSciences,Seroprevalence of anti-SARS-CoV-2 antibodies in Mumbai: a population-based study,2020-12-30,Journal Article (Peer-Reviewed),Local,Retrospective cohort,India,Maharashtra,Mumbai,"We enrolled in 2077 
employees of IndusInd bank after obtaining 
written informed consent",,2020-07-17,2020-07-31,Essential non-healthcare workers,All,Multiple groups,20.0,65.0,Primary Estimate,,2077,0.25370000000000004,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Samant Parineeta,Mahatma Gandhi Mission Institute of Health Sciences,Not Unity-Aligned,https://dx.doi.org/10.36848/PMR/2020/12100.50430,2022-05-17,2022-07-16,Unverified,parineeta_m_seroprevalence_2020,IND
210101_Kerala_GovernmentofKerala,210101_Kerala_GovernmentofKerala,ICMR - Serological Surveillance Report - Round 3,2021-01-01,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,The survey was conducted in the general population among individuals aged 18 years or more in selected representative 736 districts in India. ,,2020-12-20,2020-12-30,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,1246,0.11599999999999999,0.09910000000000001,0.135,True,,,,True,Unclear,Not reported/ Unable to specify,,,,IgG,,,,,['High'],,Unclear,Yes,No,,Unclear,Yes,No,,Government of Kerala,Government of Kerala Department of Health & Family Welfare,Not Unity-Aligned,https://health.kerala.gov.in/pdf/Technical-paper-COVID-19-Sero-Surveillance-Round-3-ICMR.pdf,2021-11-18,2022-07-16,Unverified,government_of_kerala_technical_2021-1,IND
210104_Chennai_KanchiKamakotiCHILDSTrustHospital_overall,210104_Chennai_KanchiKamakotiCHILDSTrustHospital,Seroprevalence to SARS-CoV-2 Among Healthcare Workers in an Exclusive Pediatric Hospital,2021-01-04,Preprint,Local,Cross-sectional survey ,India,Tamil Nadu,Chennai,HCWs at the Kanchi Kamakoti CHILDS Trust Hospital who consented to the study were recruited.,,2020-07-30,2020-08-07,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,95,0.168,,,True,,,,True,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Manoj Madhusudan,"Kanchi Kamakoti CHILDS Trust Hospital,",Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/33408287/,2021-02-04,2023-07-04,Unverified,madhusudan_seroprevalence_2021,IND
210114_Puducherry_JawaharlalInstitute_August_primary,210114_Puducherry_JawaharlalInstitute_August,"Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August-October 2020",2021-01-14,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,Puducherry,,General pop 18+,,2020-08-11,2020-08-16,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,869,0.049,0.035,0.064,True,,,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Sitanshu Sekhar Kar,Jawaharlal Institute,Unity-Aligned,https://dx.doi.org/10.3201/2702.204480,2021-02-16,2024-03-01,Verified,kar_prevalence_2021,IND
210114_Puducherry_JawaharlalInstitute_August_Male,210114_Puducherry_JawaharlalInstitute_August,"Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August-October 2020",2021-01-14,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,Puducherry,,General pop 18+,,2020-08-11,2020-08-16,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,439,0.036000000000000004,0.019,0.054000000000000006,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Sitanshu Sekhar Kar,Jawaharlal Institute,Unity-Aligned,https://dx.doi.org/10.3201/2702.204480,2021-08-13,2024-03-01,Verified,kar_prevalence_2021,IND
210114_Puducherry_JawaharlalInstitute_August_Female,210114_Puducherry_JawaharlalInstitute_August,"Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August-October 2020",2021-01-14,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,Puducherry,,General pop 18+,,2020-08-11,2020-08-16,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,428,0.063,0.04,0.086,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Sitanshu Sekhar Kar,Jawaharlal Institute,Unity-Aligned,https://dx.doi.org/10.3201/2702.204480,2021-08-13,2024-03-01,Verified,kar_prevalence_2021,IND
210114_Puducherry_JawaharlalInstitute_August_Age45-59,210114_Puducherry_JawaharlalInstitute_August,"Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August-October 2020",2021-01-14,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,Puducherry,,General pop 18+,,2020-08-11,2020-08-16,Household and community samples,All,Adults (18-64 years),45.0,59.0,Age,45-59,242,0.054000000000000006,0.025,0.08199999999999999,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Sitanshu Sekhar Kar,Jawaharlal Institute,Unity-Aligned,https://dx.doi.org/10.3201/2702.204480,2021-08-13,2024-03-01,Verified,kar_prevalence_2021,IND
210114_Puducherry_JawaharlalInstitute_August_Age18-29,210114_Puducherry_JawaharlalInstitute_August,"Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August-October 2020",2021-01-14,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,Puducherry,,General pop 18+,,2020-08-11,2020-08-16,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,18-29,170,0.047,0.015,0.078,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Sitanshu Sekhar Kar,Jawaharlal Institute,Unity-Aligned,https://dx.doi.org/10.3201/2702.204480,2021-08-13,2024-03-01,Verified,kar_prevalence_2021,IND
210114_Puducherry_JawaharlalInstitute_August_Age30-44,210114_Puducherry_JawaharlalInstitute_August,"Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August-October 2020",2021-01-14,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,Puducherry,,General pop 18+,,2020-08-11,2020-08-16,Household and community samples,All,Adults (18-64 years),30.0,44.0,Age,30-44,295,0.044000000000000004,0.021,0.067,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Sitanshu Sekhar Kar,Jawaharlal Institute,Unity-Aligned,https://dx.doi.org/10.3201/2702.204480,2021-08-13,2024-03-01,Verified,kar_prevalence_2021,IND
210114_Puducherry_JawaharlalInstitute_August_Age60+,210114_Puducherry_JawaharlalInstitute_August,"Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August-October 2020",2021-01-14,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,Puducherry,,General pop 18+,,2020-08-11,2020-08-16,Household and community samples,All,Seniors (65+ years),60.0,,Age,>=60,162,0.055999999999999994,0.02,0.091,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Sitanshu Sekhar Kar,Jawaharlal Institute,Unity-Aligned,https://dx.doi.org/10.3201/2702.204480,2021-08-13,2024-03-01,Verified,kar_prevalence_2021,IND
210114_Puducherry_JawaharlalInstitute_Oct_primary,210114_Puducherry_JawaharlalInstitute_October,"Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August-October 2020",2021-01-14,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,Puducherry,,General pop 18+,,2020-10-12,2020-10-16,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,October,900,0.34500000000000003,0.315,0.37700000000000006,True,,,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Sitanshu Sekhar Kar,Jawaharlal Institute,Unity-Aligned,https://dx.doi.org/10.3201/2702.204480,2021-02-16,2024-03-01,Verified,kar_prevalence_2021,IND
210114_Puducherry_JawaharlalInstitute_Oct_Age30-44,210114_Puducherry_JawaharlalInstitute_October,"Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August-October 2020",2021-01-14,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,Puducherry,,General pop 18+,,2020-10-12,2020-10-16,Household and community samples,All,Adults (18-64 years),30.0,44.0,Age,30-44,252,0.365,0.308,0.42600000000000005,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Sitanshu Sekhar Kar,Jawaharlal Institute,Unity-Aligned,https://dx.doi.org/10.3201/2702.204480,2021-08-13,2024-03-01,Verified,kar_prevalence_2021,IND
210114_Puducherry_JawaharlalInstitute_Oct_Male,210114_Puducherry_JawaharlalInstitute_October,"Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August-October 2020",2021-01-14,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,Puducherry,,General pop 18+,,2020-10-12,2020-10-16,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,406,0.31,0.267,0.35600000000000004,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Sitanshu Sekhar Kar,Jawaharlal Institute,Unity-Aligned,https://dx.doi.org/10.3201/2702.204480,2021-08-13,2024-03-01,Verified,kar_prevalence_2021,IND
210114_Puducherry_JawaharlalInstitute_Oct_Age18-29,210114_Puducherry_JawaharlalInstitute_October,"Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August-October 2020",2021-01-14,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,Puducherry,,General pop 18+,,2020-10-12,2020-10-16,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,18-29,180,0.322,0.258,0.39299999999999996,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Sitanshu Sekhar Kar,Jawaharlal Institute,Unity-Aligned,https://dx.doi.org/10.3201/2702.204480,2021-08-13,2024-03-01,Verified,kar_prevalence_2021,IND
210114_Puducherry_JawaharlalInstitute_Oct_Female,210114_Puducherry_JawaharlalInstitute_October,"Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August-October 2020",2021-01-14,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,Puducherry,,General pop 18+,,2020-10-12,2020-10-16,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,491,0.37200000000000005,0.331,0.41600000000000004,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Sitanshu Sekhar Kar,Jawaharlal Institute,Unity-Aligned,https://dx.doi.org/10.3201/2702.204480,2021-08-13,2024-03-01,Verified,kar_prevalence_2021,IND
210114_Puducherry_JawaharlalInstitute_Oct_Age60+,210114_Puducherry_JawaharlalInstitute_October,"Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August-October 2020",2021-01-14,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,Puducherry,,General pop 18+,,2020-10-12,2020-10-16,Household and community samples,All,Seniors (65+ years),60.0,,Age,>=60,209,0.287,0.23,0.35100000000000003,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Sitanshu Sekhar Kar,Jawaharlal Institute,Unity-Aligned,https://dx.doi.org/10.3201/2702.204480,2021-08-13,2024-03-01,Verified,kar_prevalence_2021,IND
210114_Puducherry_JawaharlalInstitute_Oct_Age45-59,210114_Puducherry_JawaharlalInstitute_October,"Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August-October 2020",2021-01-14,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,Puducherry,,General pop 18+,,2020-10-12,2020-10-16,Household and community samples,All,Adults (18-64 years),45.0,59.0,Age,45-59,259,0.39,0.332,0.45,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Sitanshu Sekhar Kar,Jawaharlal Institute,Unity-Aligned,https://dx.doi.org/10.3201/2702.204480,2021-08-13,2024-03-01,Verified,kar_prevalence_2021,IND
210114_Puducherry_JawaharlalInstitute_Sep_primary,210114_Puducherry_JawaharlalInstitute_September,"Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August-October 2020",2021-01-14,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,Puducherry,,General pop 18+,,2020-09-10,2020-09-16,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,September,898,0.207,0.18,0.233,True,,,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Sitanshu Sekhar Kar,Jawaharlal Institute,Unity-Aligned,https://dx.doi.org/10.3201/2702.204480,2021-02-16,2024-03-01,Verified,kar_prevalence_2021,IND
210114_Puducherry_JawaharlalInstitute_Sep_Female,210114_Puducherry_JawaharlalInstitute_September,"Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August-October 2020",2021-01-14,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,Puducherry,,General pop 18+,,2020-09-10,2020-09-16,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,455,0.2,0.163,0.23600000000000002,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Sitanshu Sekhar Kar,Jawaharlal Institute,Unity-Aligned,https://dx.doi.org/10.3201/2702.204480,2021-08-13,2024-03-01,Verified,kar_prevalence_2021,IND
210114_Puducherry_JawaharlalInstitute_Sep_Age45-59,210114_Puducherry_JawaharlalInstitute_September,"Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August-October 2020",2021-01-14,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,Puducherry,,General pop 18+,,2020-09-10,2020-09-16,Household and community samples,All,Adults (18-64 years),45.0,59.0,Age,45-59,271,0.23600000000000002,0.185,0.287,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Sitanshu Sekhar Kar,Jawaharlal Institute,Unity-Aligned,https://dx.doi.org/10.3201/2702.204480,2021-08-13,2024-03-01,Verified,kar_prevalence_2021,IND
210114_Puducherry_JawaharlalInstitute_Sep_Age30-44,210114_Puducherry_JawaharlalInstitute_September,"Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August-October 2020",2021-01-14,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,Puducherry,,General pop 18+,,2020-09-10,2020-09-16,Household and community samples,All,Adults (18-64 years),30.0,44.0,Age,30-44,277,0.209,0.162,0.257,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Sitanshu Sekhar Kar,Jawaharlal Institute,Unity-Aligned,https://dx.doi.org/10.3201/2702.204480,2021-08-13,2024-03-01,Verified,kar_prevalence_2021,IND
210114_Puducherry_JawaharlalInstitute_Sep_Age18-29,210114_Puducherry_JawaharlalInstitute_September,"Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August-October 2020",2021-01-14,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,Puducherry,,General pop 18+,,2020-09-10,2020-09-16,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,18-29,165,0.2,0.139,0.261,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Sitanshu Sekhar Kar,Jawaharlal Institute,Unity-Aligned,https://dx.doi.org/10.3201/2702.204480,2021-08-13,2024-03-01,Verified,kar_prevalence_2021,IND
210114_Puducherry_JawaharlalInstitute_Sep_Age60+,210114_Puducherry_JawaharlalInstitute_September,"Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August-October 2020",2021-01-14,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,Puducherry,,General pop 18+,,2020-09-10,2020-09-16,Household and community samples,All,Seniors (65+ years),60.0,,Age,>=60,185,0.167,0.114,0.22100000000000003,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Sitanshu Sekhar Kar,Jawaharlal Institute,Unity-Aligned,https://dx.doi.org/10.3201/2702.204480,2021-08-13,2024-03-01,Verified,kar_prevalence_2021,IND
210114_Puducherry_JawaharlalInstitute_Sep_Male,210114_Puducherry_JawaharlalInstitute_September,"Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August-October 2020",2021-01-14,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,Puducherry,,General pop 18+,,2020-09-10,2020-09-16,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,443,0.214,0.17600000000000002,0.252,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Sitanshu Sekhar Kar,Jawaharlal Institute,Unity-Aligned,https://dx.doi.org/10.3201/2702.204480,2021-08-13,2024-03-01,Verified,kar_prevalence_2021,IND
210120_Chennai_NationalInstituteOfEpidemiology_primary_adj,210120_Chennai_NationalInstituteOfEpidemiology,"Population-Based Serosurvey for Severe Acute Respiratory Syndrome Coronavirus 2 Transmission, Chennai, India",2021-01-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Chennai,We conducted a household-based cross-sectional sur- vey among usual residents >10 years of age in Greater Chennai Corporation. We included all eligible persons in the household who consented,,2020-07-01,2020-07-31,Household and community samples,All,Multiple groups,10.0,,Primary Estimate,,12405,0.184,0.14800000000000002,0.226,True,True,True,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Sriram Selvaraju,National Institute of Epidemiology,Unity-Aligned,https://dx.doi.org/10.3201/eid2702.203938,2021-02-21,2023-07-04,Verified,selvaraju_population-based_2021,IND
210120_Chennai_NationalInstituteOfEpidemiology_primary_transgender,210120_Chennai_NationalInstituteOfEpidemiology,"Population-Based Serosurvey for Severe Acute Respiratory Syndrome Coronavirus 2 Transmission, Chennai, India",2021-01-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Chennai,We conducted a household-based cross-sectional sur- vey among usual residents >10 years of age in Greater Chennai Corporation. We included all eligible persons in the household who consented,,2020-07-01,2020-07-31,Household and community samples,Other,Multiple groups,10.0,,Sex/Gender,,41,0.027999999999999997,0.0,0.273,,True,True,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Sriram Selvaraju,National Institute of Epidemiology,Unity-Aligned,https://dx.doi.org/10.3201/eid2702.203938,2021-02-21,2023-07-04,Verified,selvaraju_population-based_2021,IND
210120_Chennai_NationalInstituteOfEpidemiology_primary_age50-59,210120_Chennai_NationalInstituteOfEpidemiology,"Population-Based Serosurvey for Severe Acute Respiratory Syndrome Coronavirus 2 Transmission, Chennai, India",2021-01-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Chennai,We conducted a household-based cross-sectional sur- vey among usual residents >10 years of age in Greater Chennai Corporation. We included all eligible persons in the household who consented,,2020-07-01,2020-07-31,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,,1927,0.201,0.158,0.252,,True,True,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Sriram Selvaraju,National Institute of Epidemiology,Unity-Aligned,https://dx.doi.org/10.3201/eid2702.203938,2021-02-21,2023-07-04,Verified,selvaraju_population-based_2021,IND
210120_Chennai_NationalInstituteOfEpidemiology_primary_age20-29,210120_Chennai_NationalInstituteOfEpidemiology,"Population-Based Serosurvey for Severe Acute Respiratory Syndrome Coronavirus 2 Transmission, Chennai, India",2021-01-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Chennai,We conducted a household-based cross-sectional sur- vey among usual residents >10 years of age in Greater Chennai Corporation. We included all eligible persons in the household who consented,,2020-07-01,2020-07-31,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,,2105,0.20800000000000002,0.165,0.259,,True,True,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Sriram Selvaraju,National Institute of Epidemiology,Unity-Aligned,https://dx.doi.org/10.3201/eid2702.203938,2021-02-21,2023-07-04,Verified,selvaraju_population-based_2021,IND
210120_Chennai_NationalInstituteOfEpidemiology_primary_age10-19,210120_Chennai_NationalInstituteOfEpidemiology,"Population-Based Serosurvey for Severe Acute Respiratory Syndrome Coronavirus 2 Transmission, Chennai, India",2021-01-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Chennai,We conducted a household-based cross-sectional sur- vey among usual residents >10 years of age in Greater Chennai Corporation. We included all eligible persons in the household who consented,,2020-07-01,2020-07-31,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,1473,0.189,0.14400000000000002,0.237,,True,True,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Sriram Selvaraju,National Institute of Epidemiology,Unity-Aligned,https://dx.doi.org/10.3201/eid2702.203938,2021-02-21,2023-07-04,Verified,selvaraju_population-based_2021,IND
210120_Chennai_NationalInstituteOfEpidemiology_primary_age40-49,210120_Chennai_NationalInstituteOfEpidemiology,"Population-Based Serosurvey for Severe Acute Respiratory Syndrome Coronavirus 2 Transmission, Chennai, India",2021-01-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Chennai,We conducted a household-based cross-sectional sur- vey among usual residents >10 years of age in Greater Chennai Corporation. We included all eligible persons in the household who consented,,2020-07-01,2020-07-31,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,,2353,0.193,0.152,0.242,,True,True,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Sriram Selvaraju,National Institute of Epidemiology,Unity-Aligned,https://dx.doi.org/10.3201/eid2702.203938,2021-02-21,2023-07-04,Verified,selvaraju_population-based_2021,IND
210120_Chennai_NationalInstituteOfEpidemiology_primary_male,210120_Chennai_NationalInstituteOfEpidemiology,"Population-Based Serosurvey for Severe Acute Respiratory Syndrome Coronavirus 2 Transmission, Chennai, India",2021-01-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Chennai,We conducted a household-based cross-sectional sur- vey among usual residents >10 years of age in Greater Chennai Corporation. We included all eligible persons in the household who consented,,2020-07-01,2020-07-31,Household and community samples,Male,Multiple groups,10.0,,Sex/Gender,,5785,0.163,0.129,0.203,,True,True,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Sriram Selvaraju,National Institute of Epidemiology,Unity-Aligned,https://dx.doi.org/10.3201/eid2702.203938,2021-02-21,2023-07-04,Verified,selvaraju_population-based_2021,IND
210120_Chennai_NationalInstituteOfEpidemiology_primary_age30-39,210120_Chennai_NationalInstituteOfEpidemiology,"Population-Based Serosurvey for Severe Acute Respiratory Syndrome Coronavirus 2 Transmission, Chennai, India",2021-01-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Chennai,We conducted a household-based cross-sectional sur- vey among usual residents >10 years of age in Greater Chennai Corporation. We included all eligible persons in the household who consented,,2020-07-01,2020-07-31,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,,2353,0.182,0.14300000000000002,0.228,,True,True,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Sriram Selvaraju,National Institute of Epidemiology,Unity-Aligned,https://dx.doi.org/10.3201/eid2702.203938,2021-02-21,2023-07-04,Verified,selvaraju_population-based_2021,IND
210120_Chennai_NationalInstituteOfEpidemiology_primary_female,210120_Chennai_NationalInstituteOfEpidemiology,"Population-Based Serosurvey for Severe Acute Respiratory Syndrome Coronavirus 2 Transmission, Chennai, India",2021-01-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Chennai,We conducted a household-based cross-sectional sur- vey among usual residents >10 years of age in Greater Chennai Corporation. We included all eligible persons in the household who consented,,2020-07-01,2020-07-31,Household and community samples,Female,Multiple groups,10.0,,Sex/Gender,,6493,0.203,0.16399999999999998,0.25,,True,True,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Sriram Selvaraju,National Institute of Epidemiology,Unity-Aligned,https://dx.doi.org/10.3201/eid2702.203938,2021-02-21,2023-07-04,Verified,selvaraju_population-based_2021,IND
210120_Chennai_NationalInstituteOfEpidemiology_analysis_popadj,210120_Chennai_NationalInstituteOfEpidemiology,"Population-Based Serosurvey for Severe Acute Respiratory Syndrome Coronavirus 2 Transmission, Chennai, India",2021-01-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Chennai,We conducted a household-based cross-sectional sur- vey among usual residents >10 years of age in Greater Chennai Corporation. We included all eligible persons in the household who consented,,2020-07-01,2020-07-31,Household and community samples,All,Multiple groups,10.0,,Analysis,,12405,0.187,0.151,0.22899999999999998,,,True,True,True,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Sriram Selvaraju,National Institute of Epidemiology,Unity-Aligned,https://dx.doi.org/10.3201/eid2702.203938,2021-02-21,2024-03-01,Verified,selvaraju_population-based_2021,IND
210120_Chennai_NationalInstituteOfEpidemiology_primary_age60+,210120_Chennai_NationalInstituteOfEpidemiology,"Population-Based Serosurvey for Severe Acute Respiratory Syndrome Coronavirus 2 Transmission, Chennai, India",2021-01-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Chennai,We conducted a household-based cross-sectional sur- vey among usual residents >10 years of age in Greater Chennai Corporation. We included all eligible persons in the household who consented,,2020-07-01,2020-07-31,Household and community samples,All,Seniors (65+ years),60.0,,Age,,2108,0.131,0.099,0.171,,True,True,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Sriram Selvaraju,National Institute of Epidemiology,Unity-Aligned,https://dx.doi.org/10.3201/eid2702.203938,2021-02-21,2023-07-04,Verified,selvaraju_population-based_2021,IND
210127_India_ICRM_overall_adj,210127_India_ICRM,"SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey",2021-01-27,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,We did a second household serosurvey among individuals aged 10 years or older in the same 700 villages or wards within 70 districts in India that were included in the first serosurvey.,Individuals aged younger than 10 years and households that did not respond at the time of survey were excluded.,2020-08-18,2020-09-20,Household and community samples,All,Multiple groups,10.0,,Primary Estimate,Pop adj and test adj,29082,0.066,0.057999999999999996,0.07400000000000001,True,True,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Manoj V Murhekar,The Indian Council of Medical Research (ICMR),Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(20)30544-1,2021-03-17,2023-07-04,Verified,murhekar_sars-cov-2_2021,IND
210127_India_ICRM_age10-17,210127_India_ICRM,"SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey",2021-01-27,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,We did a second household serosurvey among individuals aged 10 years or older in the same 700 villages or wards within 70 districts in India that were included in the first serosurvey.,Individuals aged younger than 10 years and households that did not respond at the time of survey were excluded.,2020-08-18,2020-09-20,Household and community samples,All,Children and Youth (0-17 years),10.0,17.0,Age,age 10-17,3021,0.054000000000000006,0.045,0.064,,True,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Manoj V Murhekar,The Indian Council of Medical Research (ICMR),Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(20)30544-1,2021-03-17,2023-07-04,Verified,murhekar_sars-cov-2_2021,IND
210127_India_ICRM_age>60,210127_India_ICRM,"SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey",2021-01-27,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,We did a second household serosurvey among individuals aged 10 years or older in the same 700 villages or wards within 70 districts in India that were included in the first serosurvey.,Individuals aged younger than 10 years and households that did not respond at the time of survey were excluded.,2020-08-18,2020-09-20,Household and community samples,All,Seniors (65+ years),61.0,,Age,age > 60,2768,0.062000000000000006,0.052000000000000005,0.073,,True,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Manoj V Murhekar,The Indian Council of Medical Research (ICMR),Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(20)30544-1,2021-03-17,2023-07-04,Verified,murhekar_sars-cov-2_2021,IND
210127_India_ICRM_age45-60,210127_India_ICRM,"SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey",2021-01-27,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,We did a second household serosurvey among individuals aged 10 years or older in the same 700 villages or wards within 70 districts in India that were included in the first serosurvey.,Individuals aged younger than 10 years and households that did not respond at the time of survey were excluded.,2020-08-18,2020-09-20,Household and community samples,All,Adults (18-64 years),45.0,60.0,Age,age 45-60,6630,0.065,0.057,0.075,,True,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Manoj V Murhekar,The Indian Council of Medical Research (ICMR),Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(20)30544-1,2021-03-17,2023-07-04,Verified,murhekar_sars-cov-2_2021,IND
210127_India_ICRM_female,210127_India_ICRM,"SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey",2021-01-27,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,We did a second household serosurvey among individuals aged 10 years or older in the same 700 villages or wards within 70 districts in India that were included in the first serosurvey.,Individuals aged younger than 10 years and households that did not respond at the time of survey were excluded.,2020-08-18,2020-09-20,Household and community samples,Female,Multiple groups,10.0,,Sex/Gender,female,14191,0.065,0.057,0.073,,True,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Manoj V Murhekar,The Indian Council of Medical Research (ICMR),Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(20)30544-1,2021-03-17,2023-07-04,Verified,murhekar_sars-cov-2_2021,IND
210127_India_ICRM_male,210127_India_ICRM,"SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey",2021-01-27,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,We did a second household serosurvey among individuals aged 10 years or older in the same 700 villages or wards within 70 districts in India that were included in the first serosurvey.,Individuals aged younger than 10 years and households that did not respond at the time of survey were excluded.,2020-08-18,2020-09-20,Household and community samples,Male,Multiple groups,10.0,,Sex/Gender,male,14870,0.067,0.059000000000000004,0.075,,True,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Manoj V Murhekar,The Indian Council of Medical Research (ICMR),Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(20)30544-1,2021-03-17,2023-07-04,Verified,murhekar_sars-cov-2_2021,IND
210127_India_ICRM_age18-44,210127_India_ICRM,"SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey",2021-01-27,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,We did a second household serosurvey among individuals aged 10 years or older in the same 700 villages or wards within 70 districts in India that were included in the first serosurvey.,Individuals aged younger than 10 years and households that did not respond at the time of survey were excluded.,2020-08-18,2020-09-20,Household and community samples,All,Adults (18-64 years),18.0,44.0,Age,age 18-44,16663,0.069,0.061,0.077,,True,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Manoj V Murhekar,The Indian Council of Medical Research (ICMR),Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(20)30544-1,2021-03-17,2023-07-04,Verified,murhekar_sars-cov-2_2021,IND
210127_India_ICRM_overall_PopAdjTestUnadj,210127_India_ICRM,"SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey",2021-01-27,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,We did a second household serosurvey among individuals aged 10 years or older in the same 700 villages or wards within 70 districts in India that were included in the first serosurvey.,Individuals aged younger than 10 years and households that did not respond at the time of survey were excluded.,2020-08-18,2020-09-20,Household and community samples,All,Multiple groups,10.0,,Analysis,Pop adj and test unadj,29082,0.07,0.062000000000000006,0.078,,,True,,True,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Manoj V Murhekar,The Indian Council of Medical Research (ICMR),Unity-Aligned,https://dx.doi.org/10.1016/S2214-109X(20)30544-1,2021-03-17,2024-03-01,Verified,murhekar_sars-cov-2_2021,IND
210201_Chennai_KanchiKamakotiCHILDSTrustHospital_overall_IgG,210201_Chennai_KanchiKamakotiCHILDSTrustHospital,Correlation of SARS-CoV-2 serology and clinical phenotype amongst hospitalised children in a tertiary children's hospital in India,2021-02-01,Preprint,Local,Cross-sectional survey ,India,Tamil Nadu,Chennai,"We conducted a prospective cross-sectional study of children older than 1 month admitted to Kanchi Kamakoti CHILDS Trust Hospital (KKCTH), a tertiary children’s hospital in Chennai, India from 1 June 2020 to 30 September 2020 and report the symptomatology and clinical findings of infection. The study team approached caregivers of all children admitted to hospital for participation in the study. ",Neonates and those with insufficient blood supply.,2020-06-01,2020-09-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,,463,0.196,0.154,0.225,True,,,,True,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],No,No,No,Yes,Yes,Unclear,Yes,No,No,Aishwarya Venkataraman,Bristol Royal Hospital for Children,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.01.29.21250660v1,2021-03-03,2023-07-04,Verified,venkataraman_correlation_2021,IND
210202_Delhi_DelhiGovernment,210202_Delhi_DelhiGovernment,"After Delhi's 5th serosurvey, health minister Jain says don’t let guard down",2021-02-02,News and Media,Local,Cross-sectional survey ,India,,Delhi,,,2021-01-15,2021-01-23,Household and community samples,All,Multiple groups,,,Primary Estimate,,28000,0.5613,,,True,,,,True,Unclear,Not reported/ Unable to specify,,CLIA,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,Mallika Soni,Delhi Government,Not Unity-Aligned,https://www.hindustantimes.com/india-news/after-5th-serosurvey-health-minister-jain-says-don-t-let-your-guard-down-101612264692531.html,2021-04-15,2022-07-16,Verified,soni_after_2021,IND
211104_Karnataka_Mapmygenome_primary_adj,211104_Karnataka_Mapmygenome,"Prevalence of SARS-CoV-2 in Karnataka, India",2021-02-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Karnataka,,"Our study sample was drawn from an existing, representative sample of a panel survey, the
Center for Monitoring Indian Economy’s Consumer Pyramids Household Survey (CPHS). The
CPHS, collected by the Center for Monitoring Indian Economy (CMIE), is the world’s largest
longitudinal household panel data set.",,2020-06-15,2020-08-29,Household and community samples,All,Multiple groups,12.0,,Primary Estimate,,1197,0.467,0.433,0.5,True,True,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,Validated by developers,0.8470000000000001,1.0,['Low'],Yes,Yes,Yes,No,Yes,Unclear,Yes,Yes,No,Manoj Mohanan,Mapmygenome,Not Unity-Aligned,https://dx.doi.org/10.1001/jama.2021.0332,2021-02-08,2022-07-16,Verified,mohanan_prevalence_2021,IND
211104_Karnataka_Mapmygenome_analysis_popadj,211104_Karnataka_Mapmygenome,"Prevalence of SARS-CoV-2 in Karnataka, India",2021-02-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Karnataka,,"Our study sample was drawn from an existing, representative sample of a panel survey, the
Center for Monitoring Indian Economy’s Consumer Pyramids Household Survey (CPHS). The
CPHS, collected by the Center for Monitoring Indian Economy (CMIE), is the world’s largest
longitudinal household panel data set.",,2020-06-15,2020-08-29,Household and community samples,All,Multiple groups,12.0,,Analysis,,1197,0.396,0.35700000000000004,0.434,,,True,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,Validated by developers,0.8470000000000001,1.0,['Low'],Yes,Yes,Yes,No,Yes,Unclear,Yes,Yes,No,Manoj Mohanan,Mapmygenome,Not Unity-Aligned,https://dx.doi.org/10.1001/jama.2021.0332,2021-02-20,2022-07-16,Verified,mohanan_prevalence_2021,IND
210205_India_ICRM_overall,210205_India_ICRM,ICMR sero survey: One in five Indians exposed to Covid-19,2021-02-05,News and Media,National,Cross-sectional survey ,India,,,General population of India ,,2020-12-17,2021-01-08,Household and community samples,All,Multiple groups,10.0,,Primary Estimate,,28589,0.215,,,True,,,,True,Stratified probability,Not reported/ Unable to specify,,,,,,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,BBC News,The Indian Council of Medical Research (ICMR),Not Unity-Aligned,https://www.bbc.com/news/world-asia-india-55945382,2021-03-17,2022-07-16,Verified,noauthor_icmr_2021,IND
210215_Patna_AllIndiaInstituteOfMedicalSciences_Overall,210215_Patna_AllIndiaInstituteOfMedicalSciences,Seroprevalence of igg against sars-cov-2 and its determinants among healthcare workers of a covid-19 dedicated hospital of India,2021-02-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Bihar,Patna,any HCW who was working in AIIMS-Patna during the study period were included ,HCW who were not work- ing in the institute and unwilling to participate were excluded,2020-09-01,2020-09-30,Health care workers and caregivers,All,Adults (18-64 years),20.0,56.0,Primary Estimate,,919,0.133,0.11199999999999999,0.156,True,,,,True,Convenience,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.998,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,No,Mala Mahto,All India Institute of Medical Sciences,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010601/,2021-04-15,2024-03-01,Verified,mahto_seroprevalence_2021,IND
210301_Ahmedabad_SmtNHLMunicipalMedicalCollege_Overall,210301_Ahmedabad_SmtNHLMunicipalMedicalCollege,"Prevalence of seropositivity to sars-cov-2 among health care workers in tertiary covid-19 hospital, ahmedabad, gujarat",2021-03-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,"The study was conducted on HCWs that included doctors, nurses, laboratory technicians and assistants, house-keeping, Securities, Guest Relationship Executives (GRE), Pharmacy, biomedical engineer, billing, Information Technology (IT), administrative and food supplying staff etc., who are working in SVPIMSR.",Those HCWs who joined within last 15 days were excluded from study. ,2020-07-01,2020-07-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1333,0.2776,,,True,,,,True,Unclear,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['High'],Yes,Unclear,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Jemil Makadia,Smt NHL Municipal Medical College,Not Unity-Aligned,http://dx.doi.org/10.7860/JCDR/2021/46817.14599,2021-04-17,2024-03-01,Verified,makadia_prevalence_2021,IND
210301_NewDelhi_AllIndiaInstituteofMedicalSciences_Overall,210301_NewDelhi_AllIndiaInstituteofMedicalSciences,Seroprevalence of antibodies to SARS-CoV-2 in healthcare workers & implications of infection control practice in India,2021-03-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,NCT Delhi,New Delhi,Hospital staff of tertiary care health facility,,2020-06-22,2020-07-24,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,Overall HCWs,3739,0.1302,,,True,,,,True,Convenience,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,"['IgG', 'IgM']",Spike,,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Ritu Gupta,All India Institute of Medical Sciences,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/33642348/,2021-03-24,2024-03-01,Verified,gupta_seroprevalence_2021,IND
210311_NewDelhi_AllIndiaInstituteOfMedicalSciences_Overall,210311_NewDelhi_AllIndiaInstituteOfMedicalSciences,Seroprevalence of SARS-Coronavirus 2 among asymptomatic healthy blood donors from healthcare and non-healthcare settings: Implications for safety of blood donors and blood collection staff during blood donation,2021-03-11,Journal Article (Peer-Reviewed),Local,Retrospective cohort,India,,,,,2020-04-15,2020-07-15,Blood donors,All,Adults (18-64 years),18.0,62.0,Primary Estimate,,1191,0.095,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Whole Blood,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Hem Chandra Pandey,All India Institute of Medical Sciences ,Unity-Aligned,https://dx.doi.org/10.1016/j.transci.2021.103118,2021-04-18,2024-03-01,Verified,pandey_seroprevalence_2021,IND
210311_NewDelhi_AllIndiaInstituteOfMedicalSciences_Female,210311_NewDelhi_AllIndiaInstituteOfMedicalSciences,Seroprevalence of SARS-Coronavirus 2 among asymptomatic healthy blood donors from healthcare and non-healthcare settings: Implications for safety of blood donors and blood collection staff during blood donation,2021-03-11,Journal Article (Peer-Reviewed),Local,Retrospective cohort,India,,,,,2020-04-15,2020-07-15,Blood donors,Female,Adults (18-64 years),18.0,62.0,Sex/Gender,,52,0.038,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Whole Blood,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Hem Chandra Pandey,All India Institute of Medical Sciences ,Unity-Aligned,https://dx.doi.org/10.1016/j.transci.2021.103118,2021-04-18,2024-03-01,Verified,pandey_seroprevalence_2021,IND
210311_NewDelhi_AllIndiaInstituteOfMedicalSciences_Male,210311_NewDelhi_AllIndiaInstituteOfMedicalSciences,Seroprevalence of SARS-Coronavirus 2 among asymptomatic healthy blood donors from healthcare and non-healthcare settings: Implications for safety of blood donors and blood collection staff during blood donation,2021-03-11,Journal Article (Peer-Reviewed),Local,Retrospective cohort,India,,,,,2020-04-15,2020-07-15,Blood donors,Male,Adults (18-64 years),18.0,62.0,Sex/Gender,,1139,0.09699999999999999,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Whole Blood,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Hem Chandra Pandey,All India Institute of Medical Sciences ,Unity-Aligned,https://dx.doi.org/10.1016/j.transci.2021.103118,2021-04-18,2024-03-01,Verified,pandey_seroprevalence_2021,IND
210311_Vellore_UniversityOfEdinburgh_CommunitySurvey1_overall,210311_Vellore_UniversityOfEdinburgh_CommunitySurvey1,The Burden of COVID-19 Infection in a Rural Tamil Nadu Community,2021-03-11,Preprint,Local,Repeated cross-sectional study,India,Tamil Nadu,,"Residents of the rural communities of Vellore District, Tamil Nadu that are coffered within the Rural Unit of Health and Social Affairs (RUHSA)",,2020-07-06,2020-08-20,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,,501,0.022000000000000002,0.008,0.034,True,,,,True,Simplified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Siemens,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,No,,Rita Isaac,University of Edinburgh,Unity-Aligned,https://www.researchsquare.com/article/rs-289385/v1,2021-03-30,2024-03-01,Verified,isaac_burden_2021,IND
210311_Vellore_UniversityOfEdinburgh_CommunitySurvey1_COV2G,210311_Vellore_UniversityOfEdinburgh_CommunitySurvey1,The Burden of COVID-19 Infection in a Rural Tamil Nadu Community,2021-03-11,Preprint,Local,Repeated cross-sectional study,India,Tamil Nadu,,"Residents of the rural communities of Vellore District, Tamil Nadu that are coffered within the Rural Unit of Health and Social Affairs (RUHSA)",,2020-07-06,2020-08-20,Household and community samples,All,Multiple groups,5.0,,Test used,COV2G,501,0.01,,,,,,,,Simplified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,No,,Rita Isaac,University of Edinburgh,Unity-Aligned,https://www.researchsquare.com/article/rs-289385/v1,2021-03-30,2024-03-01,Verified,isaac_burden_2021,IND
210311_Vellore_UniversityOfEdinburgh_CommunitySurvey1_female,210311_Vellore_UniversityOfEdinburgh_CommunitySurvey1,The Burden of COVID-19 Infection in a Rural Tamil Nadu Community,2021-03-11,Preprint,Local,Repeated cross-sectional study,India,Tamil Nadu,,"Residents of the rural communities of Vellore District, Tamil Nadu that are coffered within the Rural Unit of Health and Social Affairs (RUHSA)",,2020-07-06,2020-08-20,Household and community samples,Female,Multiple groups,5.0,,Sex/Gender,female,255,0.0235,,,,,,,,Simplified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Siemens,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,No,,Rita Isaac,University of Edinburgh,Unity-Aligned,https://www.researchsquare.com/article/rs-289385/v1,2021-03-30,2024-03-01,Verified,isaac_burden_2021,IND
210311_Vellore_UniversityOfEdinburgh_CommunitySurvey1_Elecsys,210311_Vellore_UniversityOfEdinburgh_CommunitySurvey1,The Burden of COVID-19 Infection in a Rural Tamil Nadu Community,2021-03-11,Preprint,Local,Repeated cross-sectional study,India,Tamil Nadu,,"Residents of the rural communities of Vellore District, Tamil Nadu that are coffered within the Rural Unit of Health and Social Affairs (RUHSA)",,2020-07-06,2020-08-20,Household and community samples,All,Multiple groups,5.0,,Test used,Elecsys,501,0.02,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,No,,Rita Isaac,University of Edinburgh,Unity-Aligned,https://www.researchsquare.com/article/rs-289385/v1,2021-03-30,2024-03-01,Verified,isaac_burden_2021,IND
210311_Vellore_UniversityOfEdinburgh_CommunitySurvey1_male,210311_Vellore_UniversityOfEdinburgh_CommunitySurvey1,The Burden of COVID-19 Infection in a Rural Tamil Nadu Community,2021-03-11,Preprint,Local,Repeated cross-sectional study,India,Tamil Nadu,,"Residents of the rural communities of Vellore District, Tamil Nadu that are coffered within the Rural Unit of Health and Social Affairs (RUHSA)",,2020-07-06,2020-08-20,Household and community samples,Male,Multiple groups,5.0,,Sex/Gender,male,246,0.0203,,,,,,,,Simplified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Siemens,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,No,,Rita Isaac,University of Edinburgh,Unity-Aligned,https://www.researchsquare.com/article/rs-289385/v1,2021-03-30,2024-03-01,Verified,isaac_burden_2021,IND
210311_Vellore_UniversityOfEdinburgh_CommunitySurvey2_overall ,210311_Vellore_UniversityOfEdinburgh_CommunitySurvey2,The Burden of COVID-19 Infection in a Rural Tamil Nadu Community,2021-03-11,Preprint,Local,Repeated cross-sectional study,India,Tamil Nadu,,"Residents of the rural communities of Vellore District, Tamil Nadu that are coffered within the Rural Unit of Health and Social Affairs (RUHSA)",,2020-11-06,2020-11-20,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,200,0.22,0.163,0.277,True,,,,True,Simplified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Siemens,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,No,,Rita Isaac,University of Edinburgh,Unity-Aligned,https://www.researchsquare.com/article/rs-289385/v1,2021-03-30,2024-03-01,Verified,isaac_burden_2021,IND
210311_Vellore_UniversityOfEdinburgh_CommunitySurvey2_Elecsys ,210311_Vellore_UniversityOfEdinburgh_CommunitySurvey2,The Burden of COVID-19 Infection in a Rural Tamil Nadu Community,2021-03-11,Preprint,Local,Repeated cross-sectional study,India,Tamil Nadu,,"Residents of the rural communities of Vellore District, Tamil Nadu that are coffered within the Rural Unit of Health and Social Affairs (RUHSA)",,2020-11-06,2020-11-20,Household and community samples,All,Multiple groups,18.0,,Test used,Elecsys,200,0.19,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,No,,Rita Isaac,University of Edinburgh,Unity-Aligned,https://www.researchsquare.com/article/rs-289385/v1,2021-03-30,2024-03-01,Verified,isaac_burden_2021,IND
210311_Vellore_UniversityOfEdinburgh_CommunitySurvey2_male,210311_Vellore_UniversityOfEdinburgh_CommunitySurvey2,The Burden of COVID-19 Infection in a Rural Tamil Nadu Community,2021-03-11,Preprint,Local,Repeated cross-sectional study,India,Tamil Nadu,,"Residents of the rural communities of Vellore District, Tamil Nadu that are coffered within the Rural Unit of Health and Social Affairs (RUHSA)",,2020-11-06,2020-11-20,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,male,73,0.192,,,,,,,,Simplified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Siemens,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,No,,Rita Isaac,University of Edinburgh,Unity-Aligned,https://www.researchsquare.com/article/rs-289385/v1,2021-03-30,2024-03-01,Verified,isaac_burden_2021,IND
210311_Vellore_UniversityOfEdinburgh_CommunitySurvey2_COV2G,210311_Vellore_UniversityOfEdinburgh_CommunitySurvey2,The Burden of COVID-19 Infection in a Rural Tamil Nadu Community,2021-03-11,Preprint,Local,Repeated cross-sectional study,India,Tamil Nadu,,"Residents of the rural communities of Vellore District, Tamil Nadu that are coffered within the Rural Unit of Health and Social Affairs (RUHSA)",,2020-11-06,2020-11-20,Household and community samples,All,Multiple groups,18.0,,Test used,COV2G,200,0.18,,,,,,,,Simplified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,No,,Rita Isaac,University of Edinburgh,Unity-Aligned,https://www.researchsquare.com/article/rs-289385/v1,2021-03-30,2024-03-01,Verified,isaac_burden_2021,IND
210311_Vellore_UniversityOfEdinburgh_CommunitySurvey2_female,210311_Vellore_UniversityOfEdinburgh_CommunitySurvey2,The Burden of COVID-19 Infection in a Rural Tamil Nadu Community,2021-03-11,Preprint,Local,Repeated cross-sectional study,India,Tamil Nadu,,"Residents of the rural communities of Vellore District, Tamil Nadu that are coffered within the Rural Unit of Health and Social Affairs (RUHSA)",,2020-11-06,2020-11-20,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,female,127,0.23600000000000002,,,,,,,,Simplified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Elecsys® Anti‐SARS‐CoV‐2 (N)","Siemens,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,No,,Rita Isaac,University of Edinburgh,Unity-Aligned,https://www.researchsquare.com/article/rs-289385/v1,2021-03-30,2024-03-01,Verified,isaac_burden_2021,IND
210320_Ahmedabad_AMCMETMedicalCollege_Overall,210320_Ahmedabad_AMCMETMedicalCollege,Severe acute respiratory syndrome coronavirus 2 immunoglobulin G antibody: Seroprevalence among contacts of COVID-19 cases.,2021-03-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,contacts of COVID-19 cases,,2020-08-17,2020-08-31,Contacts of COVID patients,All,Multiple groups,,,Primary Estimate,Contacts overall,3973,0.31920000000000004,0.3048,0.33380000000000004,True,,,,True,Stratified non-probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9237000000000001,0.9790000000000001,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Om Prakash,AMC MET Medical College,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/33753682/,2021-05-19,2024-03-01,Verified,prakash_severe_2021,IND
210321_Jamshedpur_TataMainHospital_OverallHCW,210321_Jamshedpur_TataMainHospital,"Serosurveillance of Health Care Workers in a COVID Hospital: Immune Response, and Its Longevity",2021-03-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Jharkhand,Jamshedpur,"All HCWs working in the hospital, either in direct or indirect contact with the patients infected with coronavirus, were included in the study. The participants were included irrespective of age, gender, presence of co-morbidities, and having a history of being tested positive for coronavirus infection.",HCWs who were not present in the hospital due to any reason during the study period were excluded from the study. Some HCWs who withdrew their consent to participate in the study were not included in the final determination and analysis of results.,2020-10-07,2020-11-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Overall HCW,2110,0.438,,,True,,,,True,Convenience,Access SARS-CoV-2 IgG Reagent Antibody Test,Beckman Coulter,CLIA,Serum,IgG,Spike,Validated by manufacturers,1.0,0.986,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Minakshi Mishra,Tata Main Hospital,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/33898113/,2021-05-21,2024-03-01,Verified,mishra_serosurveillance_2021,IND
210324_India_UniversityofToronto_genpop_overall_unadj,210324_India_UniversityofToronto,SARS-CoV-2 Seroprevalence in 12 Cities of India from July-December 2020,2021-03-24,Preprint,National,Repeated cross-sectional study,India,"Maharashtra, West Bengal, Tamil Nadu, Karnataka, Gujarat, Rajasthan, Bihar, Andhra Pradesh","Mumbia, Delhi, Kolkata, Chennai, Bangalore, Ahmedabad, Pune, Surat, Jaipur, Nagpur, Coimbatore, Visakhapatnam","We included 448,518 people of all ages who underwent testing for SARS-CoV-2 antibodies between June 12,
2020 and December 31, 2020 by Thyrocare Laboratories.12 Thyrocare conducts central laboratory testing in
Navi Mumbai from over 2200 franchised collection centers in all major cities in India. Thyrocare charges 600-
750 Rupees (US$8-10) for an antibody test.",,2020-06-12,2020-12-31,Household and community samples,All,Multiple groups,,,Primary Estimate,Overall unadjusted,448518,0.31,,,True,,,,True,Self-referral,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Arokiaswamy Velumani,University of Toronto ,Not Unity-Aligned,10.1101/2021.03.19.21253429,2021-05-22,2024-03-01,Verified,velumani_sars-cov-2_2021,IND
210324_India_UniversityofToronto_genpop_Nov,210324_India_UniversityofToronto,SARS-CoV-2 Seroprevalence in 12 Cities of India from July-December 2020,2021-03-24,Preprint,National,Repeated cross-sectional study,India,"Maharashtra, West Bengal, Tamil Nadu, Karnataka, Gujarat, Rajasthan, Bihar, Andhra Pradesh","Mumbia, Delhi, Kolkata, Chennai, Bangalore, Ahmedabad, Pune, Surat, Jaipur, Nagpur, Coimbatore, Visakhapatnam","We included 448,518 people of all ages who underwent testing for SARS-CoV-2 antibodies between June 12,
2020 and December 31, 2020 by Thyrocare Laboratories.12 Thyrocare conducts central laboratory testing in
Navi Mumbai from over 2200 franchised collection centers in all major cities in India. Thyrocare charges 600-
750 Rupees (US$8-10) for an antibody test.",,2020-11-01,2020-11-30,Household and community samples,All,Multiple groups,,,Time frame,Nov pop adj,40482,0.444,,,,,True,,,Self-referral,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Arokiaswamy Velumani,University of Toronto ,Not Unity-Aligned,10.1101/2021.03.19.21253429,2021-05-22,2024-03-01,Verified,velumani_sars-cov-2_2021,IND
210324_India_UniversityofToronto_genpop_female_unadj,210324_India_UniversityofToronto,SARS-CoV-2 Seroprevalence in 12 Cities of India from July-December 2020,2021-03-24,Preprint,National,Repeated cross-sectional study,India,"Maharashtra, West Bengal, Tamil Nadu, Karnataka, Gujarat, Rajasthan, Bihar, Andhra Pradesh","Mumbia, Delhi, Kolkata, Chennai, Bangalore, Ahmedabad, Pune, Surat, Jaipur, Nagpur, Coimbatore, Visakhapatnam","We included 448,518 people of all ages who underwent testing for SARS-CoV-2 antibodies between June 12,
2020 and December 31, 2020 by Thyrocare Laboratories.12 Thyrocare conducts central laboratory testing in
Navi Mumbai from over 2200 franchised collection centers in all major cities in India. Thyrocare charges 600-
750 Rupees (US$8-10) for an antibody test.",,2020-06-12,2020-12-31,Household and community samples,Female,Multiple groups,,,Sex/Gender,female unadjusted,139560,0.34600000000000003,,,,,,,,Self-referral,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Arokiaswamy Velumani,University of Toronto ,Not Unity-Aligned,10.1101/2021.03.19.21253429,2021-07-23,2024-03-01,Verified,velumani_sars-cov-2_2021,IND
210324_India_UniversityofToronto_genpop_age20-44_unadj,210324_India_UniversityofToronto,SARS-CoV-2 Seroprevalence in 12 Cities of India from July-December 2020,2021-03-24,Preprint,National,Repeated cross-sectional study,India,"Maharashtra, West Bengal, Tamil Nadu, Karnataka, Gujarat, Rajasthan, Bihar, Andhra Pradesh","Mumbia, Delhi, Kolkata, Chennai, Bangalore, Ahmedabad, Pune, Surat, Jaipur, Nagpur, Coimbatore, Visakhapatnam","We included 448,518 people of all ages who underwent testing for SARS-CoV-2 antibodies between June 12,
2020 and December 31, 2020 by Thyrocare Laboratories.12 Thyrocare conducts central laboratory testing in
Navi Mumbai from over 2200 franchised collection centers in all major cities in India. Thyrocare charges 600-
750 Rupees (US$8-10) for an antibody test.",,2020-06-12,2020-12-31,Household and community samples,All,Adults (18-64 years),20.0,44.0,Age,age 20-44 unadjusted,274288,0.278,,,,,,,,Self-referral,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Arokiaswamy Velumani,University of Toronto ,Not Unity-Aligned,10.1101/2021.03.19.21253429,2021-07-23,2024-03-01,Verified,velumani_sars-cov-2_2021,IND
210324_India_UniversityofToronto_genpop_AbbottRocheConcordant_unadj,210324_India_UniversityofToronto,SARS-CoV-2 Seroprevalence in 12 Cities of India from July-December 2020,2021-03-24,Preprint,National,Repeated cross-sectional study,India,"Maharashtra, West Bengal, Tamil Nadu, Karnataka, Gujarat, Rajasthan, Bihar, Andhra Pradesh","Mumbia, Delhi, Kolkata, Chennai, Bangalore, Ahmedabad, Pune, Surat, Jaipur, Nagpur, Coimbatore, Visakhapatnam","We included 448,518 people of all ages who underwent testing for SARS-CoV-2 antibodies between June 12,
2020 and December 31, 2020 by Thyrocare Laboratories.12 Thyrocare conducts central laboratory testing in
Navi Mumbai from over 2200 franchised collection centers in all major cities in India. Thyrocare charges 600-
750 Rupees (US$8-10) for an antibody test.",,2020-06-12,2020-12-31,Household and community samples,All,Multiple groups,,,Test used,Roche assay unadj,118499,0.271,,,,,,,,Self-referral,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Arokiaswamy Velumani,University of Toronto ,Not Unity-Aligned,10.1101/2021.03.19.21253429,2021-07-23,2024-03-01,Verified,velumani_sars-cov-2_2021,IND
210324_India_UniversityofToronto_genpop_Discordant_Abbott_unadj,210324_India_UniversityofToronto,SARS-CoV-2 Seroprevalence in 12 Cities of India from July-December 2020,2021-03-24,Preprint,National,Repeated cross-sectional study,India,"Maharashtra, West Bengal, Tamil Nadu, Karnataka, Gujarat, Rajasthan, Bihar, Andhra Pradesh","Mumbia, Delhi, Kolkata, Chennai, Bangalore, Ahmedabad, Pune, Surat, Jaipur, Nagpur, Coimbatore, Visakhapatnam","We included 448,518 people of all ages who underwent testing for SARS-CoV-2 antibodies between June 12,
2020 and December 31, 2020 by Thyrocare Laboratories.12 Thyrocare conducts central laboratory testing in
Navi Mumbai from over 2200 franchised collection centers in all major cities in India. Thyrocare charges 600-
750 Rupees (US$8-10) for an antibody test.",,2020-06-12,2020-12-31,Household and community samples,All,Multiple groups,,,Test used,Roche assay unadj,8687,0.315,,,,,,,,Self-referral,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Arokiaswamy Velumani,University of Toronto ,Not Unity-Aligned,10.1101/2021.03.19.21253429,2021-07-23,2024-03-01,Verified,velumani_sars-cov-2_2021,IND
210324_India_UniversityofToronto_genpop_Abbott_unadj,210324_India_UniversityofToronto,SARS-CoV-2 Seroprevalence in 12 Cities of India from July-December 2020,2021-03-24,Preprint,National,Repeated cross-sectional study,India,"Maharashtra, West Bengal, Tamil Nadu, Karnataka, Gujarat, Rajasthan, Bihar, Andhra Pradesh","Mumbia, Delhi, Kolkata, Chennai, Bangalore, Ahmedabad, Pune, Surat, Jaipur, Nagpur, Coimbatore, Visakhapatnam","We included 448,518 people of all ages who underwent testing for SARS-CoV-2 antibodies between June 12,
2020 and December 31, 2020 by Thyrocare Laboratories.12 Thyrocare conducts central laboratory testing in
Navi Mumbai from over 2200 franchised collection centers in all major cities in India. Thyrocare charges 600-
750 Rupees (US$8-10) for an antibody test.",,2020-06-12,2020-12-31,Household and community samples,All,Multiple groups,,,Test used,Abbott assay unadj,218111,0.305,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Arokiaswamy Velumani,University of Toronto ,Not Unity-Aligned,10.1101/2021.03.19.21253429,2021-07-23,2024-03-01,Verified,velumani_sars-cov-2_2021,IND
210324_India_UniversityofToronto_genpop_age<20_unadj,210324_India_UniversityofToronto,SARS-CoV-2 Seroprevalence in 12 Cities of India from July-December 2020,2021-03-24,Preprint,National,Repeated cross-sectional study,India,"Maharashtra, West Bengal, Tamil Nadu, Karnataka, Gujarat, Rajasthan, Bihar, Andhra Pradesh","Mumbia, Delhi, Kolkata, Chennai, Bangalore, Ahmedabad, Pune, Surat, Jaipur, Nagpur, Coimbatore, Visakhapatnam","We included 448,518 people of all ages who underwent testing for SARS-CoV-2 antibodies between June 12,
2020 and December 31, 2020 by Thyrocare Laboratories.12 Thyrocare conducts central laboratory testing in
Navi Mumbai from over 2200 franchised collection centers in all major cities in India. Thyrocare charges 600-
750 Rupees (US$8-10) for an antibody test.",,2020-06-12,2020-12-31,Household and community samples,All,Children and Youth (0-17 years),,20.0,Age,age <20 unadjusted,23339,0.32,,,,,,,,Self-referral,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Arokiaswamy Velumani,University of Toronto ,Not Unity-Aligned,10.1101/2021.03.19.21253429,2021-07-23,2024-03-01,Verified,velumani_sars-cov-2_2021,IND
210324_India_UniversityofToronto_genpop_male_unadj,210324_India_UniversityofToronto,SARS-CoV-2 Seroprevalence in 12 Cities of India from July-December 2020,2021-03-24,Preprint,National,Repeated cross-sectional study,India,"Maharashtra, West Bengal, Tamil Nadu, Karnataka, Gujarat, Rajasthan, Bihar, Andhra Pradesh","Mumbia, Delhi, Kolkata, Chennai, Bangalore, Ahmedabad, Pune, Surat, Jaipur, Nagpur, Coimbatore, Visakhapatnam","We included 448,518 people of all ages who underwent testing for SARS-CoV-2 antibodies between June 12,
2020 and December 31, 2020 by Thyrocare Laboratories.12 Thyrocare conducts central laboratory testing in
Navi Mumbai from over 2200 franchised collection centers in all major cities in India. Thyrocare charges 600-
750 Rupees (US$8-10) for an antibody test.",,2020-06-12,2020-12-31,Household and community samples,Male,Multiple groups,,,Sex/Gender,male unadjusted,308958,0.299,,,,,,,,Self-referral,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Arokiaswamy Velumani,University of Toronto ,Not Unity-Aligned,10.1101/2021.03.19.21253429,2021-07-23,2024-03-01,Verified,velumani_sars-cov-2_2021,IND
210324_India_UniversityofToronto_genpop_Oct,210324_India_UniversityofToronto,SARS-CoV-2 Seroprevalence in 12 Cities of India from July-December 2020,2021-03-24,Preprint,National,Repeated cross-sectional study,India,"Maharashtra, West Bengal, Tamil Nadu, Karnataka, Gujarat, Rajasthan, Bihar, Andhra Pradesh","Mumbia, Delhi, Kolkata, Chennai, Bangalore, Ahmedabad, Pune, Surat, Jaipur, Nagpur, Coimbatore, Visakhapatnam","We included 448,518 people of all ages who underwent testing for SARS-CoV-2 antibodies between June 12,
2020 and December 31, 2020 by Thyrocare Laboratories.12 Thyrocare conducts central laboratory testing in
Navi Mumbai from over 2200 franchised collection centers in all major cities in India. Thyrocare charges 600-
750 Rupees (US$8-10) for an antibody test.",,2020-10-01,2020-10-31,Household and community samples,All,Multiple groups,,,Time frame,Oct pop adj,73831,0.399,,,,,True,,,Self-referral,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Arokiaswamy Velumani,University of Toronto ,Not Unity-Aligned,10.1101/2021.03.19.21253429,2021-05-22,2024-03-01,Verified,velumani_sars-cov-2_2021,IND
210324_India_UniversityofToronto_genpop_Jul,210324_India_UniversityofToronto,SARS-CoV-2 Seroprevalence in 12 Cities of India from July-December 2020,2021-03-24,Preprint,National,Repeated cross-sectional study,India,"Maharashtra, West Bengal, Tamil Nadu, Karnataka, Gujarat, Rajasthan, Bihar, Andhra Pradesh","Mumbia, Delhi, Kolkata, Chennai, Bangalore, Ahmedabad, Pune, Surat, Jaipur, Nagpur, Coimbatore, Visakhapatnam","We included 448,518 people of all ages who underwent testing for SARS-CoV-2 antibodies between June 12,
2020 and December 31, 2020 by Thyrocare Laboratories.12 Thyrocare conducts central laboratory testing in
Navi Mumbai from over 2200 franchised collection centers in all major cities in India. Thyrocare charges 600-
750 Rupees (US$8-10) for an antibody test.",,2020-07-01,2020-07-31,Household and community samples,All,Multiple groups,,,Time frame,July pop adj,68474,0.18100000000000002,,,,,True,,,Self-referral,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Arokiaswamy Velumani,University of Toronto ,Not Unity-Aligned,10.1101/2021.03.19.21253429,2021-05-22,2024-03-01,Verified,velumani_sars-cov-2_2021,IND
210324_India_UniversityofToronto_genpop_Dec,210324_India_UniversityofToronto,SARS-CoV-2 Seroprevalence in 12 Cities of India from July-December 2020,2021-03-24,Preprint,National,Repeated cross-sectional study,India,"Maharashtra, West Bengal, Tamil Nadu, Karnataka, Gujarat, Rajasthan, Bihar, Andhra Pradesh","Mumbia, Delhi, Kolkata, Chennai, Bangalore, Ahmedabad, Pune, Surat, Jaipur, Nagpur, Coimbatore, Visakhapatnam","We included 448,518 people of all ages who underwent testing for SARS-CoV-2 antibodies between June 12,
2020 and December 31, 2020 by Thyrocare Laboratories.12 Thyrocare conducts central laboratory testing in
Navi Mumbai from over 2200 franchised collection centers in all major cities in India. Thyrocare charges 600-
750 Rupees (US$8-10) for an antibody test.",,2020-12-01,2020-12-31,Household and community samples,All,Multiple groups,,,Time frame,Dec pop adj,26600,0.465,,,,,True,,,Self-referral,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Arokiaswamy Velumani,University of Toronto ,Not Unity-Aligned,10.1101/2021.03.19.21253429,2021-05-22,2024-03-01,Verified,velumani_sars-cov-2_2021,IND
210324_India_UniversityofToronto_genpop_age45-69_unadj,210324_India_UniversityofToronto,SARS-CoV-2 Seroprevalence in 12 Cities of India from July-December 2020,2021-03-24,Preprint,National,Repeated cross-sectional study,India,"Maharashtra, West Bengal, Tamil Nadu, Karnataka, Gujarat, Rajasthan, Bihar, Andhra Pradesh","Mumbia, Delhi, Kolkata, Chennai, Bangalore, Ahmedabad, Pune, Surat, Jaipur, Nagpur, Coimbatore, Visakhapatnam","We included 448,518 people of all ages who underwent testing for SARS-CoV-2 antibodies between June 12,
2020 and December 31, 2020 by Thyrocare Laboratories.12 Thyrocare conducts central laboratory testing in
Navi Mumbai from over 2200 franchised collection centers in all major cities in India. Thyrocare charges 600-
750 Rupees (US$8-10) for an antibody test.",,2020-06-12,2020-12-31,Household and community samples,All,Adults (18-64 years),45.0,69.0,Age,age 45-69 unadjusted,135627,0.375,,,,,,,,Self-referral,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Arokiaswamy Velumani,University of Toronto ,Not Unity-Aligned,10.1101/2021.03.19.21253429,2021-07-23,2024-03-01,Verified,velumani_sars-cov-2_2021,IND
210324_India_UniversityofToronto_genpop_Discordant_Roche_unadj ,210324_India_UniversityofToronto,SARS-CoV-2 Seroprevalence in 12 Cities of India from July-December 2020,2021-03-24,Preprint,National,Repeated cross-sectional study,India,"Maharashtra, West Bengal, Tamil Nadu, Karnataka, Gujarat, Rajasthan, Bihar, Andhra Pradesh","Mumbia, Delhi, Kolkata, Chennai, Bangalore, Ahmedabad, Pune, Surat, Jaipur, Nagpur, Coimbatore, Visakhapatnam","We included 448,518 people of all ages who underwent testing for SARS-CoV-2 antibodies between June 12,
2020 and December 31, 2020 by Thyrocare Laboratories.12 Thyrocare conducts central laboratory testing in
Navi Mumbai from over 2200 franchised collection centers in all major cities in India. Thyrocare charges 600-
750 Rupees (US$8-10) for an antibody test.",,2020-06-12,2020-12-31,Household and community samples,All,Multiple groups,,,Test used,Roche assay unadj,8687,0.685,,,,,,,,Self-referral,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Arokiaswamy Velumani,University of Toronto ,Not Unity-Aligned,10.1101/2021.03.19.21253429,2021-07-23,2024-03-01,Verified,velumani_sars-cov-2_2021,IND
210324_India_UniversityofToronto_genpop_Sep,210324_India_UniversityofToronto,SARS-CoV-2 Seroprevalence in 12 Cities of India from July-December 2020,2021-03-24,Preprint,National,Repeated cross-sectional study,India,"Maharashtra, West Bengal, Tamil Nadu, Karnataka, Gujarat, Rajasthan, Bihar, Andhra Pradesh","Mumbia, Delhi, Kolkata, Chennai, Bangalore, Ahmedabad, Pune, Surat, Jaipur, Nagpur, Coimbatore, Visakhapatnam","We included 448,518 people of all ages who underwent testing for SARS-CoV-2 antibodies between June 12,
2020 and December 31, 2020 by Thyrocare Laboratories.12 Thyrocare conducts central laboratory testing in
Navi Mumbai from over 2200 franchised collection centers in all major cities in India. Thyrocare charges 600-
750 Rupees (US$8-10) for an antibody test.",,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Time frame,Sep pop adj,116395,0.316,,,,,True,,,Self-referral,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Arokiaswamy Velumani,University of Toronto ,Not Unity-Aligned,10.1101/2021.03.19.21253429,2021-05-22,2024-03-01,Verified,velumani_sars-cov-2_2021,IND
210324_India_UniversityofToronto_genpop_Aug,210324_India_UniversityofToronto,SARS-CoV-2 Seroprevalence in 12 Cities of India from July-December 2020,2021-03-24,Preprint,National,Repeated cross-sectional study,India,"Maharashtra, West Bengal, Tamil Nadu, Karnataka, Gujarat, Rajasthan, Bihar, Andhra Pradesh","Mumbia, Delhi, Kolkata, Chennai, Bangalore, Ahmedabad, Pune, Surat, Jaipur, Nagpur, Coimbatore, Visakhapatnam","We included 448,518 people of all ages who underwent testing for SARS-CoV-2 antibodies between June 12,
2020 and December 31, 2020 by Thyrocare Laboratories.12 Thyrocare conducts central laboratory testing in
Navi Mumbai from over 2200 franchised collection centers in all major cities in India. Thyrocare charges 600-
750 Rupees (US$8-10) for an antibody test.",,2020-08-01,2020-08-31,Household and community samples,All,Multiple groups,,,Time frame,Aug pop adj,117438,0.264,,,,,True,,,Self-referral,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Arokiaswamy Velumani,University of Toronto ,Not Unity-Aligned,10.1101/2021.03.19.21253429,2021-05-22,2024-03-01,Verified,velumani_sars-cov-2_2021,IND
210324_India_UniversityofToronto_genpop_age70+_unadj,210324_India_UniversityofToronto,SARS-CoV-2 Seroprevalence in 12 Cities of India from July-December 2020,2021-03-24,Preprint,National,Repeated cross-sectional study,India,"Maharashtra, West Bengal, Tamil Nadu, Karnataka, Gujarat, Rajasthan, Bihar, Andhra Pradesh","Mumbia, Delhi, Kolkata, Chennai, Bangalore, Ahmedabad, Pune, Surat, Jaipur, Nagpur, Coimbatore, Visakhapatnam","We included 448,518 people of all ages who underwent testing for SARS-CoV-2 antibodies between June 12,
2020 and December 31, 2020 by Thyrocare Laboratories.12 Thyrocare conducts central laboratory testing in
Navi Mumbai from over 2200 franchised collection centers in all major cities in India. Thyrocare charges 600-
750 Rupees (US$8-10) for an antibody test.",,2020-06-12,2020-12-31,Household and community samples,All,Seniors (65+ years),70.0,,Age,age 70+ unadjusted,15264,0.391,,,,,,,,Self-referral,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Arokiaswamy Velumani,University of Toronto ,Not Unity-Aligned,10.1101/2021.03.19.21253429,2021-07-23,2024-03-01,Verified,velumani_sars-cov-2_2021,IND
210324_India_UniversityofToronto_genpop_Roche_unadj,210324_India_UniversityofToronto,SARS-CoV-2 Seroprevalence in 12 Cities of India from July-December 2020,2021-03-24,Preprint,National,Repeated cross-sectional study,India,"Maharashtra, West Bengal, Tamil Nadu, Karnataka, Gujarat, Rajasthan, Bihar, Andhra Pradesh","Mumbia, Delhi, Kolkata, Chennai, Bangalore, Ahmedabad, Pune, Surat, Jaipur, Nagpur, Coimbatore, Visakhapatnam","We included 448,518 people of all ages who underwent testing for SARS-CoV-2 antibodies between June 12,
2020 and December 31, 2020 by Thyrocare Laboratories.12 Thyrocare conducts central laboratory testing in
Navi Mumbai from over 2200 franchised collection centers in all major cities in India. Thyrocare charges 600-
750 Rupees (US$8-10) for an antibody test.",,2020-06-12,2020-12-31,Household and community samples,All,Multiple groups,,,Test used,Roche assay unadj,103221,0.245,,,,,,,,Self-referral,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Arokiaswamy Velumani,University of Toronto ,Not Unity-Aligned,10.1101/2021.03.19.21253429,2021-07-23,2024-03-01,Verified,velumani_sars-cov-2_2021,IND
210326_Bhubaneswar_ICMRRegionalMedicalResearchCentre_December_AnaesthesiaHCW,210326_Bhubaneswar_ICMRRegionalMedicalResearchCentre_December,Seroprevalence of IgG antibody against SARS-CoV-2 among health care workers of anaesthesia departments from various hospital settings in India,2021-03-26,Preprint,Local,Repeated cross-sectional study,India,,Bhubaneswar,"A total of 128 HCWs participated in the first serological survey in September 2020 and 164 HCWs in the second survey conducted in December 2020 from 12 hospitals in Bhubaneswar, India. All the participants were working in the anaesthesia department and responsible to deliver care and services to critical patients, either directly as physicians or nurses, or indirectly as technicians, administrative staffs or other support staffs. Only the willing participants were included in this study",,2020-12-01,2020-12-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,164,0.384,0.309,0.46299999999999997,True,,,,True,Unclear,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Debaprasad Parai,ICMR-Regional Medical Research Centre (Government of India),Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.20.21253819v2,2021-04-09,2024-03-01,Verified,parai_seroprevalence_2021,IND
210326_Bhubaneswar_ICMRRegionalMedicalResearchCentre_September_AnaesthesiaHCW,210326_Bhubaneswar_ICMRRegionalMedicalResearchCentre_September,Seroprevalence of IgG antibody against SARS-CoV-2 among health care workers of anaesthesia departments from various hospital settings in India,2021-03-26,Preprint,Local,Repeated cross-sectional study,India,,Bhubaneswar,"A total of 128 HCWs participated in the first serological survey in September 2020 and 164 HCWs in the second survey conducted in December 2020 from 12 hospitals in Bhubaneswar, India. All the participants were working in the anaesthesia department and responsible to deliver care and services to critical patients, either directly as physicians or nurses, or indirectly as technicians, administrative staffs or other support staffs. Only the willing participants were included in this study",,2020-09-01,2020-09-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,128,0.125,0.073,0.195,True,,,,True,Unclear,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['High'],No,Unclear,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Debaprasad Parai,ICMR-Regional Medical Research Centre (Government of India),Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.20.21253819v2,2021-04-09,2024-03-01,Verified,parai_seroprevalence_2021,IND
210303_Jabalpur_NationalCentreForDiseaseControl_TestPopAdj,210303_Jabalpur_NationalCentreForDiseaseControl,"Cross-sectional Study on Sero-Prevalence of SARS-CoV-2 Infection in Jabalpur, Madhya Pradesh, India",2021-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Madya Pradesh,Jabalpur,"Only those who have been residing in Jabalpur since March 1, 2020 were included. All individuals aged 1 to less than
18 years for whom parents or guardian are willing to give
assent and any individual who is 18 years and above and
is ready to give consent for participation were included in
the study.",Individuals who did not give consent or who did not respond were excluded from the study. Individuals not in compos mentis or those who were intoxicated too were excluded.,2020-12-11,2020-12-21,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,Test and pop adjusted,9279,0.2942,0.2841,0.3042,True,True,True,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Sudarshan Ramaswamy,National Centre for Disease Control,Unity-Aligned,https://web.archive.org/web/20210410213821/http://medical.advancedresearchpublications.com/index.php/Journal-CommunicableDiseases/article/view/536,2021-04-27,2023-08-15,Verified,noauthor_cross-sectional_2021,IND
210303_Jabalpur_NationalCentreForDiseaseControl_Male,210303_Jabalpur_NationalCentreForDiseaseControl,"Cross-sectional Study on Sero-Prevalence of SARS-CoV-2 Infection in Jabalpur, Madhya Pradesh, India",2021-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Madya Pradesh,Jabalpur,"Only those who have been residing in Jabalpur since March 1, 2020 were included. All individuals aged 1 to less than
18 years for whom parents or guardian are willing to give
assent and any individual who is 18 years and above and
is ready to give consent for participation were included in
the study.",Individuals who did not give consent or who did not respond were excluded from the study. Individuals not in compos mentis or those who were intoxicated too were excluded.,2020-12-11,2020-12-21,Household and community samples,Male,Multiple groups,0.0,,Sex/Gender,,3629,0.3177,0.3011,0.3343,,True,True,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Sudarshan Ramaswamy,National Centre for Disease Control,Unity-Aligned,https://web.archive.org/web/20210410213821/http://medical.advancedresearchpublications.com/index.php/Journal-CommunicableDiseases/article/view/536,2021-04-27,2023-08-15,Verified,noauthor_cross-sectional_2021,IND
210303_Jabalpur_NationalCentreForDiseaseControl_0-18yrs,210303_Jabalpur_NationalCentreForDiseaseControl,"Cross-sectional Study on Sero-Prevalence of SARS-CoV-2 Infection in Jabalpur, Madhya Pradesh, India",2021-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Madya Pradesh,Jabalpur,"Only those who have been residing in Jabalpur since March 1, 2020 were included. All individuals aged 1 to less than
18 years for whom parents or guardian are willing to give
assent and any individual who is 18 years and above and
is ready to give consent for participation were included in
the study.",Individuals who did not give consent or who did not respond were excluded from the study. Individuals not in compos mentis or those who were intoxicated too were excluded.,2020-12-11,2020-12-21,Household and community samples,All,Children and Youth (0-17 years),0.0,18.0,Age,0-18 yrs old,1023,0.2807,0.2503,0.311,,True,True,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Sudarshan Ramaswamy,National Centre for Disease Control,Unity-Aligned,https://web.archive.org/web/20210410213821/http://medical.advancedresearchpublications.com/index.php/Journal-CommunicableDiseases/article/view/536,2021-04-27,2023-08-15,Verified,noauthor_cross-sectional_2021,IND
210303_Jabalpur_NationalCentreForDiseaseControl_19-45yrs,210303_Jabalpur_NationalCentreForDiseaseControl,"Cross-sectional Study on Sero-Prevalence of SARS-CoV-2 Infection in Jabalpur, Madhya Pradesh, India",2021-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Madya Pradesh,Jabalpur,"Only those who have been residing in Jabalpur since March 1, 2020 were included. All individuals aged 1 to less than
18 years for whom parents or guardian are willing to give
assent and any individual who is 18 years and above and
is ready to give consent for participation were included in
the study.",Individuals who did not give consent or who did not respond were excluded from the study. Individuals not in compos mentis or those who were intoxicated too were excluded.,2020-12-11,2020-12-21,Household and community samples,All,Adults (18-64 years),19.0,45.0,Age,19-45 yrs old,5413,0.2843,0.2712,0.2974,,True,True,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Sudarshan Ramaswamy,National Centre for Disease Control,Unity-Aligned,https://web.archive.org/web/20210410213821/http://medical.advancedresearchpublications.com/index.php/Journal-CommunicableDiseases/article/view/536,2021-04-27,2023-08-15,Verified,noauthor_cross-sectional_2021,IND
210303_Jabalpur_NationalCentreForDiseaseControl_46-60yrs,210303_Jabalpur_NationalCentreForDiseaseControl,"Cross-sectional Study on Sero-Prevalence of SARS-CoV-2 Infection in Jabalpur, Madhya Pradesh, India",2021-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Madya Pradesh,Jabalpur,"Only those who have been residing in Jabalpur since March 1, 2020 were included. All individuals aged 1 to less than
18 years for whom parents or guardian are willing to give
assent and any individual who is 18 years and above and
is ready to give consent for participation were included in
the study.",Individuals who did not give consent or who did not respond were excluded from the study. Individuals not in compos mentis or those who were intoxicated too were excluded.,2020-12-11,2020-12-21,Household and community samples,All,Adults (18-64 years),46.0,60.0,Age,46-60 yrs old,1875,0.33130000000000004,0.3079,0.3547,,True,True,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Sudarshan Ramaswamy,National Centre for Disease Control,Unity-Aligned,https://web.archive.org/web/20210410213821/http://medical.advancedresearchpublications.com/index.php/Journal-CommunicableDiseases/article/view/536,2021-04-27,2023-08-15,Verified,noauthor_cross-sectional_2021,IND
210303_Jabalpur_NationalCentreForDiseaseControl_>60,210303_Jabalpur_NationalCentreForDiseaseControl,"Cross-sectional Study on Sero-Prevalence of SARS-CoV-2 Infection in Jabalpur, Madhya Pradesh, India",2021-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Madya Pradesh,Jabalpur,"Only those who have been residing in Jabalpur since March 1, 2020 were included. All individuals aged 1 to less than
18 years for whom parents or guardian are willing to give
assent and any individual who is 18 years and above and
is ready to give consent for participation were included in
the study.",Individuals who did not give consent or who did not respond were excluded from the study. Individuals not in compos mentis or those who were intoxicated too were excluded.,2020-12-11,2020-12-21,Household and community samples,All,Seniors (65+ years),61.0,,Age,Over 60 yrs of age,968,0.2919,0.2602,0.3234,,True,True,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Sudarshan Ramaswamy,National Centre for Disease Control,Unity-Aligned,https://web.archive.org/web/20210410213821/http://medical.advancedresearchpublications.com/index.php/Journal-CommunicableDiseases/article/view/536,2021-04-27,2023-08-15,Verified,noauthor_cross-sectional_2021,IND
210303_Jabalpur_NationalCentreForDiseaseControl_Female,210303_Jabalpur_NationalCentreForDiseaseControl,"Cross-sectional Study on Sero-Prevalence of SARS-CoV-2 Infection in Jabalpur, Madhya Pradesh, India",2021-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Madya Pradesh,Jabalpur,"Only those who have been residing in Jabalpur since March 1, 2020 were included. All individuals aged 1 to less than
18 years for whom parents or guardian are willing to give
assent and any individual who is 18 years and above and
is ready to give consent for participation were included in
the study.",Individuals who did not give consent or who did not respond were excluded from the study. Individuals not in compos mentis or those who were intoxicated too were excluded.,2020-12-11,2020-12-21,Household and community samples,Female,Multiple groups,0.0,,Sex/Gender,,5650,0.2791,0.2663,0.2919,,True,True,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Sudarshan Ramaswamy,National Centre for Disease Control,Unity-Aligned,https://web.archive.org/web/20210410213821/http://medical.advancedresearchpublications.com/index.php/Journal-CommunicableDiseases/article/view/536,2021-04-27,2023-08-15,Verified,noauthor_cross-sectional_2021,IND
210303_Jabalpur_NationalCentreForDiseaseControl_PopAdj,210303_Jabalpur_NationalCentreForDiseaseControl,"Cross-sectional Study on Sero-Prevalence of SARS-CoV-2 Infection in Jabalpur, Madhya Pradesh, India",2021-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Madya Pradesh,Jabalpur,"Only those who have been residing in Jabalpur since March 1, 2020 were included. All individuals aged 1 to less than
18 years for whom parents or guardian are willing to give
assent and any individual who is 18 years and above and
is ready to give consent for participation were included in
the study.",Individuals who did not give consent or who did not respond were excluded from the study. Individuals not in compos mentis or those who were intoxicated too were excluded.,2020-12-11,2020-12-21,Household and community samples,All,Multiple groups,0.0,,Analysis,pop adjusted,9279,0.287,0.2781,0.2963,,,True,,True,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Sudarshan Ramaswamy,National Centre for Disease Control,Unity-Aligned,https://web.archive.org/web/20210410213821/http://medical.advancedresearchpublications.com/index.php/Journal-CommunicableDiseases/article/view/536,2021-04-27,2024-03-01,Verified,noauthor_cross-sectional_2021,IND
210401_Srinagar_GovernmentMedicalCollegeSrinagar_Primary,210401_Srinagar_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS CoV 2 specific Ig G antibodies in District Srinagar, Kashmir: a population based study",2021-04-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Kashmir,Srinagar,adults (>18 years) of Srinagar district was conducted from 17 October to 20 October 2020.,,2020-10-17,2020-10-20,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,Overall gen pop,2418,0.406,0.387,0.42600000000000005,True,,,,True,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.996,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Taha Ayub,Government Medical College Srinagar,Unity-Aligned,https://www.ijcmph.com/index.php/ijcmph/article/view/7827,2021-05-19,2024-03-01,Verified,ayub_seroprevalence_2021,IND
210401_Srinagar_GovernmentMedicalCollegeSrinagar_51-70,210401_Srinagar_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS CoV 2 specific Ig G antibodies in District Srinagar, Kashmir: a population based study",2021-04-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Kashmir,Srinagar,adults (>18 years) of Srinagar district was conducted from 17 October to 20 October 2020.,,2020-10-17,2020-10-20,Household and community samples,All,Adults (18-64 years),51.0,70.0,Age,51-70,573,0.428,0.387,0.46799999999999997,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.996,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Taha Ayub,Government Medical College Srinagar,Unity-Aligned,https://www.ijcmph.com/index.php/ijcmph/article/view/7827,2021-08-05,2024-03-01,Verified,ayub_seroprevalence_2021,IND
210401_Srinagar_GovernmentMedicalCollegeSrinagar_31-50,210401_Srinagar_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS CoV 2 specific Ig G antibodies in District Srinagar, Kashmir: a population based study",2021-04-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Kashmir,Srinagar,adults (>18 years) of Srinagar district was conducted from 17 October to 20 October 2020.,,2020-10-17,2020-10-20,Household and community samples,All,Adults (18-64 years),31.0,50.0,Age,31-50,1047,0.394,0.365,0.424,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.996,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Taha Ayub,Government Medical College Srinagar,Unity-Aligned,https://www.ijcmph.com/index.php/ijcmph/article/view/7827,2021-08-05,2024-03-01,Verified,ayub_seroprevalence_2021,IND
210401_Srinagar_GovernmentMedicalCollegeSrinagar_71+,210401_Srinagar_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS CoV 2 specific Ig G antibodies in District Srinagar, Kashmir: a population based study",2021-04-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Kashmir,Srinagar,adults (>18 years) of Srinagar district was conducted from 17 October to 20 October 2020.,,2020-10-17,2020-10-20,Household and community samples,All,Seniors (65+ years),71.0,,Age,71+,67,0.522,0.402,0.639,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.996,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Taha Ayub,Government Medical College Srinagar,Unity-Aligned,https://www.ijcmph.com/index.php/ijcmph/article/view/7827,2021-08-05,2024-03-01,Verified,ayub_seroprevalence_2021,IND
210401_Srinagar_GovernmentMedicalCollegeSrinagar_Female,210401_Srinagar_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS CoV 2 specific Ig G antibodies in District Srinagar, Kashmir: a population based study",2021-04-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Kashmir,Srinagar,adults (>18 years) of Srinagar district was conducted from 17 October to 20 October 2020.,,2020-10-17,2020-10-20,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,Female,1052,0.445,0.41500000000000004,0.47600000000000003,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.996,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Taha Ayub,Government Medical College Srinagar,Unity-Aligned,https://www.ijcmph.com/index.php/ijcmph/article/view/7827,2021-08-05,2024-03-01,Verified,ayub_seroprevalence_2021,IND
210401_Srinagar_GovernmentMedicalCollegeSrinagar_<30,210401_Srinagar_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS CoV 2 specific Ig G antibodies in District Srinagar, Kashmir: a population based study",2021-04-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Kashmir,Srinagar,adults (>18 years) of Srinagar district was conducted from 17 October to 20 October 2020.,,2020-10-17,2020-10-20,Household and community samples,All,Adults (18-64 years),18.0,30.0,Age,<30,731,0.39799999999999996,0.363,0.434,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.996,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Taha Ayub,Government Medical College Srinagar,Unity-Aligned,https://www.ijcmph.com/index.php/ijcmph/article/view/7827,2021-08-05,2024-03-01,Verified,ayub_seroprevalence_2021,IND
210401_Srinagar_GovernmentMedicalCollegeSrinagar_Male,210401_Srinagar_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS CoV 2 specific Ig G antibodies in District Srinagar, Kashmir: a population based study",2021-04-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Kashmir,Srinagar,adults (>18 years) of Srinagar district was conducted from 17 October to 20 October 2020.,,2020-10-17,2020-10-20,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,Male,1366,0.37700000000000006,0.35100000000000003,0.40299999999999997,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.996,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Taha Ayub,Government Medical College Srinagar,Unity-Aligned,https://www.ijcmph.com/index.php/ijcmph/article/view/7827,2021-08-05,2024-03-01,Verified,ayub_seroprevalence_2021,IND
20210406_Kashmir_GovernmentMedicalCollegeSringar_PopTestAdj,20210406_Kashmir_GovernmentMedicalCollegeSringar,"Results of a Population-Based Survey to Estimate the Seroprevalence of SARS-CoV-2 Specific IgG Antibodies in Kashmir, India, Seven Months after the Appearance of the First COVID-19 Case",2021-04-06,Preprint,Regional,Cross-sectional survey ,India,Kashmir,,All adults ≥18 years of age were eligible to participate in the study.,,2020-10-17,2020-11-04,Household and community samples,All,Adults (18-64 years),18.0,,Primary Estimate,,6230,0.36700000000000005,0.34299999999999997,0.392,True,True,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Muhammad Khan,Government Medical College Sringar,Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3820632,2021-04-26,2024-02-02,Verified,khan_results_2021,IND
20210406_Kashmir_GovernmentMedicalCollegeSringar_30-49yrr_PopAdj,20210406_Kashmir_GovernmentMedicalCollegeSringar,"Results of a Population-Based Survey to Estimate the Seroprevalence of SARS-CoV-2 Specific IgG Antibodies in Kashmir, India, Seven Months after the Appearance of the First COVID-19 Case",2021-04-06,Preprint,Regional,Cross-sectional survey ,India,Kashmir,,All adults ≥18 years of age were eligible to participate in the study.,,2020-10-17,2020-11-04,Household and community samples,All,Adults (18-64 years),30.0,49.0,Age,30-49 yrs old,2672,0.363,0.335,0.39299999999999996,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Muhammad Khan,Government Medical College Sringar,Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3820632,2021-04-26,2024-03-01,Verified,khan_results_2021,IND
20210406_Kashmir_GovernmentMedicalCollegeSringar_18-29yrr_PopAdj,20210406_Kashmir_GovernmentMedicalCollegeSringar,"Results of a Population-Based Survey to Estimate the Seroprevalence of SARS-CoV-2 Specific IgG Antibodies in Kashmir, India, Seven Months after the Appearance of the First COVID-19 Case",2021-04-06,Preprint,Regional,Cross-sectional survey ,India,Kashmir,,All adults ≥18 years of age were eligible to participate in the study.,,2020-10-17,2020-11-04,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,18-29 yrs old,1513,0.337,0.30100000000000005,0.376,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Muhammad Khan,Government Medical College Sringar,Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3820632,2021-04-26,2024-03-01,Verified,khan_results_2021,IND
20210406_Kashmir_GovernmentMedicalCollegeSringar_PopAdj,20210406_Kashmir_GovernmentMedicalCollegeSringar,"Results of a Population-Based Survey to Estimate the Seroprevalence of SARS-CoV-2 Specific IgG Antibodies in Kashmir, India, Seven Months after the Appearance of the First COVID-19 Case",2021-04-06,Preprint,Regional,Cross-sectional survey ,India,Kashmir,,All adults ≥18 years of age were eligible to participate in the study.,,2020-10-17,2020-11-04,Household and community samples,All,Adults (18-64 years),18.0,,Analysis,Population adjusted only,6230,0.369,0.34500000000000003,0.394,,,True,,True,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Muhammad Khan,Government Medical College Sringar,Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3820632,2021-04-26,2024-03-01,Verified,khan_results_2021,IND
20210406_Kashmir_GovernmentMedicalCollegeSringar_Maler_PopAdj,20210406_Kashmir_GovernmentMedicalCollegeSringar,"Results of a Population-Based Survey to Estimate the Seroprevalence of SARS-CoV-2 Specific IgG Antibodies in Kashmir, India, Seven Months after the Appearance of the First COVID-19 Case",2021-04-06,Preprint,Regional,Cross-sectional survey ,India,Kashmir,,All adults ≥18 years of age were eligible to participate in the study.,,2020-10-17,2020-11-04,Household and community samples,Male,Adults (18-64 years),18.0,,Sex/Gender,Males,3126,0.36100000000000004,0.335,0.389,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Muhammad Khan,Government Medical College Sringar,Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3820632,2021-04-26,2024-03-01,Verified,khan_results_2021,IND
20210406_Kashmir_GovernmentMedicalCollegeSringar_>=70r_PopAdj,20210406_Kashmir_GovernmentMedicalCollegeSringar,"Results of a Population-Based Survey to Estimate the Seroprevalence of SARS-CoV-2 Specific IgG Antibodies in Kashmir, India, Seven Months after the Appearance of the First COVID-19 Case",2021-04-06,Preprint,Regional,Cross-sectional survey ,India,Kashmir,,All adults ≥18 years of age were eligible to participate in the study.,,2020-10-17,2020-11-04,Household and community samples,All,Seniors (65+ years),70.0,,Age,>= 70 yr old,402,0.45299999999999996,0.378,0.53,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Muhammad Khan,Government Medical College Sringar,Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3820632,2021-04-26,2024-03-01,Verified,khan_results_2021,IND
20210406_Kashmir_GovernmentMedicalCollegeSringar_Femaler_PopAdj,20210406_Kashmir_GovernmentMedicalCollegeSringar,"Results of a Population-Based Survey to Estimate the Seroprevalence of SARS-CoV-2 Specific IgG Antibodies in Kashmir, India, Seven Months after the Appearance of the First COVID-19 Case",2021-04-06,Preprint,Regional,Cross-sectional survey ,India,Kashmir,,All adults ≥18 years of age were eligible to participate in the study.,,2020-10-17,2020-11-04,Household and community samples,Female,Adults (18-64 years),18.0,,Sex/Gender,Female,3104,0.378,0.34500000000000003,0.413,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Muhammad Khan,Government Medical College Sringar,Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3820632,2021-04-26,2024-03-01,Verified,khan_results_2021,IND
20210406_Kashmir_GovernmentMedicalCollegeSringar_50-69yrr_PopAdj,20210406_Kashmir_GovernmentMedicalCollegeSringar,"Results of a Population-Based Survey to Estimate the Seroprevalence of SARS-CoV-2 Specific IgG Antibodies in Kashmir, India, Seven Months after the Appearance of the First COVID-19 Case",2021-04-06,Preprint,Regional,Cross-sectional survey ,India,Kashmir,,All adults ≥18 years of age were eligible to participate in the study.,,2020-10-17,2020-11-04,Household and community samples,All,Multiple groups,50.0,69.0,Age,50-69 yrs old,1643,0.425,0.38799999999999996,0.462,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Muhammad Khan,Government Medical College Sringar,Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3820632,2021-04-26,2024-03-01,Verified,khan_results_2021,IND
210408_Indore_NationalCentreforDiseaseControl_Primary,210408_Indore_NationalCentreforDiseaseControl,"Seroprevalence of anti-SARS-CoV-2 antibodies in Indore, Madhya Pradesh: A community-based cross-sectional study, August 2020.",2021-04-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Madhya Pradesh,Indore,A cross‑sectional study was conducted in all the 85 wards of Indore Municipal Corporation (IMC) between 11 and 23 August 2020. The list of households available with the revenue department of IMC was used to select the households randomly through computer‑generated random numbers. Individuals had to be ≥1 year old. ,,2020-08-11,2020-08-23,Household and community samples,All,Multiple groups,1.0,,Primary Estimate,,7103,0.0775,0.0714,0.0836,True,True,True,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,Whole-virusantigen,Validated by manufacturers,0.9209999999999999,0.9770000000000001,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Salil Sakalle,National Centre for Disease Control,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2015_20,2021-06-07,2023-08-15,Unverified,salilsakalleSeroprevalenceAntiSARSCoV2Antibodies2021,IND
210408_Indore_NationalCentreforDiseaseControl_Age_18-45,210408_Indore_NationalCentreforDiseaseControl,"Seroprevalence of anti-SARS-CoV-2 antibodies in Indore, Madhya Pradesh: A community-based cross-sectional study, August 2020.",2021-04-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Madhya Pradesh,Indore,A cross‑sectional study was conducted in all the 85 wards of Indore Municipal Corporation (IMC) between 11 and 23 August 2020. The list of households available with the revenue department of IMC was used to select the households randomly through computer‑generated random numbers. Individuals had to be ≥1 year old. ,,2020-08-11,2020-08-23,Household and community samples,All,Adults (18-64 years),18.0,45.0,Age,18-45,3098,0.0713,,,,,,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,Whole-virusantigen,Validated by manufacturers,0.9209999999999999,0.9770000000000001,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Salil Sakalle,National Centre for Disease Control,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2015_20,2021-08-25,2024-03-01,Unverified,salilsakalleSeroprevalenceAntiSARSCoV2Antibodies2021,IND
210408_Indore_NationalCentreforDiseaseControl_Female,210408_Indore_NationalCentreforDiseaseControl,"Seroprevalence of anti-SARS-CoV-2 antibodies in Indore, Madhya Pradesh: A community-based cross-sectional study, August 2020.",2021-04-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Madhya Pradesh,Indore,A cross‑sectional study was conducted in all the 85 wards of Indore Municipal Corporation (IMC) between 11 and 23 August 2020. The list of households available with the revenue department of IMC was used to select the households randomly through computer‑generated random numbers. Individuals had to be ≥1 year old. ,,2020-08-11,2020-08-23,Household and community samples,Female,Multiple groups,1.0,,Sex/Gender,,3423,0.075,,,,,,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,Whole-virusantigen,Validated by manufacturers,0.9209999999999999,0.9770000000000001,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Salil Sakalle,National Centre for Disease Control,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2015_20,2021-08-25,2024-03-01,Unverified,salilsakalleSeroprevalenceAntiSARSCoV2Antibodies2021,IND
210408_Indore_NationalCentreforDiseaseControl_Male,210408_Indore_NationalCentreforDiseaseControl,"Seroprevalence of anti-SARS-CoV-2 antibodies in Indore, Madhya Pradesh: A community-based cross-sectional study, August 2020.",2021-04-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Madhya Pradesh,Indore,A cross‑sectional study was conducted in all the 85 wards of Indore Municipal Corporation (IMC) between 11 and 23 August 2020. The list of households available with the revenue department of IMC was used to select the households randomly through computer‑generated random numbers. Individuals had to be ≥1 year old. ,,2020-08-11,2020-08-23,Household and community samples,Male,Multiple groups,1.0,,Sex/Gender,,3680,0.079,,,,,,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,Whole-virusantigen,Validated by manufacturers,0.9209999999999999,0.9770000000000001,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Salil Sakalle,National Centre for Disease Control,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2015_20,2021-08-25,2024-03-01,Unverified,salilsakalleSeroprevalenceAntiSARSCoV2Antibodies2021,IND
210408_Indore_NationalCentreforDiseaseControl_Age_>60,210408_Indore_NationalCentreforDiseaseControl,"Seroprevalence of anti-SARS-CoV-2 antibodies in Indore, Madhya Pradesh: A community-based cross-sectional study, August 2020.",2021-04-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Madhya Pradesh,Indore,A cross‑sectional study was conducted in all the 85 wards of Indore Municipal Corporation (IMC) between 11 and 23 August 2020. The list of households available with the revenue department of IMC was used to select the households randomly through computer‑generated random numbers. Individuals had to be ≥1 year old. ,,2020-08-11,2020-08-23,Household and community samples,All,Multiple groups,60.0,,Age,>60,464,0.08410000000000001,,,,,,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,Whole-virusantigen,Validated by manufacturers,0.9209999999999999,0.9770000000000001,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Salil Sakalle,National Centre for Disease Control,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2015_20,2021-08-25,2024-03-01,Unverified,salilsakalleSeroprevalenceAntiSARSCoV2Antibodies2021,IND
210408_Indore_NationalCentreforDiseaseControl_Age_<18,210408_Indore_NationalCentreforDiseaseControl,"Seroprevalence of anti-SARS-CoV-2 antibodies in Indore, Madhya Pradesh: A community-based cross-sectional study, August 2020.",2021-04-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Madhya Pradesh,Indore,A cross‑sectional study was conducted in all the 85 wards of Indore Municipal Corporation (IMC) between 11 and 23 August 2020. The list of households available with the revenue department of IMC was used to select the households randomly through computer‑generated random numbers. Individuals had to be ≥1 year old. ,,2020-08-11,2020-08-23,Household and community samples,All,Children and Youth (0-17 years),1.0,18.0,Age,<18,2435,0.0727,,,,,,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,Whole-virusantigen,Validated by manufacturers,0.9209999999999999,0.9770000000000001,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Salil Sakalle,National Centre for Disease Control,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2015_20,2021-08-25,2024-03-01,Unverified,salilsakalleSeroprevalenceAntiSARSCoV2Antibodies2021,IND
210408_Indore_NationalCentreforDiseaseControl_Age_45-60,210408_Indore_NationalCentreforDiseaseControl,"Seroprevalence of anti-SARS-CoV-2 antibodies in Indore, Madhya Pradesh: A community-based cross-sectional study, August 2020.",2021-04-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Madhya Pradesh,Indore,A cross‑sectional study was conducted in all the 85 wards of Indore Municipal Corporation (IMC) between 11 and 23 August 2020. The list of households available with the revenue department of IMC was used to select the households randomly through computer‑generated random numbers. Individuals had to be ≥1 year old. ,,2020-08-11,2020-08-23,Household and community samples,All,Adults (18-64 years),45.0,60.0,Age,45-60,1106,0.1003,,,,,,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,Whole-virusantigen,Validated by manufacturers,0.9209999999999999,0.9770000000000001,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Salil Sakalle,National Centre for Disease Control,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2015_20,2021-08-25,2024-03-01,Unverified,salilsakalleSeroprevalenceAntiSARSCoV2Antibodies2021,IND
210408_Indore_NationalCentreforDiseaseControl_Age_18andabove,210408_Indore_NationalCentreforDiseaseControl,"Seroprevalence of anti-SARS-CoV-2 antibodies in Indore, Madhya Pradesh: A community-based cross-sectional study, August 2020.",2021-04-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Madhya Pradesh,Indore,A cross‑sectional study was conducted in all the 85 wards of Indore Municipal Corporation (IMC) between 11 and 23 August 2020. The list of households available with the revenue department of IMC was used to select the households randomly through computer‑generated random numbers. Individuals had to be ≥1 year old. ,,2020-08-11,2020-08-23,Household and community samples,All,Multiple groups,18.0,,Age,≥18,4668,0.0795,,,,,,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,Whole-virusantigen,Validated by manufacturers,0.9209999999999999,0.9770000000000001,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Salil Sakalle,National Centre for Disease Control,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2015_20,2021-08-25,2024-03-01,Unverified,salilsakalleSeroprevalenceAntiSARSCoV2Antibodies2021,IND
210408_Indore_NationalCentreforDiseaseControl_Analysis,210408_Indore_NationalCentreforDiseaseControl,"Seroprevalence of anti-SARS-CoV-2 antibodies in Indore, Madhya Pradesh: A community-based cross-sectional study, August 2020.",2021-04-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Madhya Pradesh,Indore,A cross‑sectional study was conducted in all the 85 wards of Indore Municipal Corporation (IMC) between 11 and 23 August 2020. The list of households available with the revenue department of IMC was used to select the households randomly through computer‑generated random numbers. Individuals had to be ≥1 year old. ,,2020-08-11,2020-08-23,Household and community samples,All,Multiple groups,1.0,,Analysis,,7103,0.0772,,,,,,,True,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,Whole-virusantigen,Validated by manufacturers,0.9209999999999999,0.9770000000000001,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Salil Sakalle,National Centre for Disease Control,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2015_20,2021-08-25,2024-03-01,Unverified,salilsakalleSeroprevalenceAntiSARSCoV2Antibodies2021,IND
210408_Malegaon_MunicipalCorporationofMalegaon_genpop_overall,210408_Malegaon_MunicipalCorporationofMalegaon,"Seroprevalence of anti-SARS-CoV-2 of IgG antibody by ELISA: Community-based, cross-sectional study from urban area of Malegaon, Maharashtra.",2021-04-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Malegaon,"The community-based cross sectional study was conducted in total 98 closed containment zones demarcated by Municipal Corporation, Malegaon. ",,2020-07-25,2020-08-20,Household and community samples,All,Multiple groups,15.0,70.0,Primary Estimate,,336,0.4,0.35000000000000003,0.45,True,,,,True,Stratified non-probability,Not reported/ Unable to specify,,ELISA,,IgG,,Validated by independent authors/third party/non-developers,0.93,1.0,['High'],Yes,No,No,Yes,Yes,Unclear,Yes,Yes,Unclear,Pallavi Saple,The Municipality of Malegaon ,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140273/,2021-06-06,2022-07-16,Verified,saple_seroprevalence_2021,IND
210408_Malegaon_MunicipalCorporationofMalegaon_genpop_36-45,210408_Malegaon_MunicipalCorporationofMalegaon,"Seroprevalence of anti-SARS-CoV-2 of IgG antibody by ELISA: Community-based, cross-sectional study from urban area of Malegaon, Maharashtra.",2021-04-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Malegaon,"The community-based cross sectional study was conducted in total 98 closed containment zones demarcated by Municipal Corporation, Malegaon. ",,2020-07-25,2020-08-20,Household and community samples,All,Adults (18-64 years),36.0,45.0,Age,age 36-45,84,0.44,,,,,,,,Stratified non-probability,Not reported/ Unable to specify,,ELISA,,IgG,,Validated by independent authors/third party/non-developers,0.93,1.0,['High'],Yes,No,No,Yes,Yes,Unclear,Yes,Yes,Unclear,Pallavi Saple,The Municipality of Malegaon ,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140273/,2021-06-06,2022-07-16,Verified,saple_seroprevalence_2021,IND
210408_Malegaon_MunicipalCorporationofMalegaon_genpop_26-35,210408_Malegaon_MunicipalCorporationofMalegaon,"Seroprevalence of anti-SARS-CoV-2 of IgG antibody by ELISA: Community-based, cross-sectional study from urban area of Malegaon, Maharashtra.",2021-04-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Malegaon,"The community-based cross sectional study was conducted in total 98 closed containment zones demarcated by Municipal Corporation, Malegaon. ",,2020-07-25,2020-08-20,Household and community samples,All,Adults (18-64 years),26.0,35.0,Age,age 26-35,107,0.33,,,,,,,,Stratified non-probability,Not reported/ Unable to specify,,ELISA,,IgG,,Validated by independent authors/third party/non-developers,0.93,1.0,['High'],Yes,No,No,Yes,Yes,Unclear,Yes,Yes,Unclear,Pallavi Saple,The Municipality of Malegaon ,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140273/,2021-06-06,2022-07-16,Verified,saple_seroprevalence_2021,IND
210408_Malegaon_MunicipalCorporationofMalegaon_genpop_male,210408_Malegaon_MunicipalCorporationofMalegaon,"Seroprevalence of anti-SARS-CoV-2 of IgG antibody by ELISA: Community-based, cross-sectional study from urban area of Malegaon, Maharashtra.",2021-04-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Malegaon,"The community-based cross sectional study was conducted in total 98 closed containment zones demarcated by Municipal Corporation, Malegaon. ",,2020-07-25,2020-08-20,Household and community samples,Male,Multiple groups,15.0,70.0,Sex/Gender,,175,0.35000000000000003,,,,,,,,Stratified non-probability,Not reported/ Unable to specify,,ELISA,,IgG,,Validated by independent authors/third party/non-developers,0.93,1.0,['High'],Yes,No,No,Yes,Yes,Unclear,Yes,Yes,Unclear,Pallavi Saple,The Municipality of Malegaon ,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140273/,2021-06-06,2022-07-16,Verified,saple_seroprevalence_2021,IND
210408_Malegaon_MunicipalCorporationofMalegaon_genpop_46-60,210408_Malegaon_MunicipalCorporationofMalegaon,"Seroprevalence of anti-SARS-CoV-2 of IgG antibody by ELISA: Community-based, cross-sectional study from urban area of Malegaon, Maharashtra.",2021-04-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Malegaon,"The community-based cross sectional study was conducted in total 98 closed containment zones demarcated by Municipal Corporation, Malegaon. ",,2020-07-25,2020-08-20,Household and community samples,All,Adults (18-64 years),46.0,60.0,Age,age 46-60,69,0.45,,,,,,,,Stratified non-probability,Not reported/ Unable to specify,,ELISA,,IgG,,Validated by independent authors/third party/non-developers,0.93,1.0,['High'],Yes,No,No,Yes,Yes,Unclear,Yes,Yes,Unclear,Pallavi Saple,The Municipality of Malegaon ,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140273/,2021-06-06,2022-07-16,Verified,saple_seroprevalence_2021,IND
210408_Malegaon_MunicipalCorporationofMalegaon_genpop_female,210408_Malegaon_MunicipalCorporationofMalegaon,"Seroprevalence of anti-SARS-CoV-2 of IgG antibody by ELISA: Community-based, cross-sectional study from urban area of Malegaon, Maharashtra.",2021-04-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Malegaon,"The community-based cross sectional study was conducted in total 98 closed containment zones demarcated by Municipal Corporation, Malegaon. ",,2020-07-25,2020-08-20,Household and community samples,Female,Multiple groups,15.0,70.0,Sex/Gender,,161,0.45,,,,,,,,Stratified non-probability,Not reported/ Unable to specify,,ELISA,,IgG,,Validated by independent authors/third party/non-developers,0.93,1.0,['High'],Yes,No,No,Yes,Yes,Unclear,Yes,Yes,Unclear,Pallavi Saple,The Municipality of Malegaon ,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140273/,2021-06-06,2022-07-16,Verified,saple_seroprevalence_2021,IND
210408_Malegaon_MunicipalCorporationofMalegaon_genpop_15-25,210408_Malegaon_MunicipalCorporationofMalegaon,"Seroprevalence of anti-SARS-CoV-2 of IgG antibody by ELISA: Community-based, cross-sectional study from urban area of Malegaon, Maharashtra.",2021-04-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Malegaon,"The community-based cross sectional study was conducted in total 98 closed containment zones demarcated by Municipal Corporation, Malegaon. ",,2020-07-25,2020-08-20,Household and community samples,All,Multiple groups,15.0,25.0,Age,,64,0.42,,,,,,,,Stratified non-probability,Not reported/ Unable to specify,,ELISA,,IgG,,Validated by independent authors/third party/non-developers,0.93,1.0,['High'],Yes,No,No,Yes,Yes,Unclear,Yes,Yes,Unclear,Pallavi Saple,The Municipality of Malegaon ,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140273/,2021-06-06,2022-07-16,Verified,saple_seroprevalence_2021,IND
210408_Malegaon_MunicipalCorporationofMalegaon_genpop_61-70,210408_Malegaon_MunicipalCorporationofMalegaon,"Seroprevalence of anti-SARS-CoV-2 of IgG antibody by ELISA: Community-based, cross-sectional study from urban area of Malegaon, Maharashtra.",2021-04-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Malegaon,"The community-based cross sectional study was conducted in total 98 closed containment zones demarcated by Municipal Corporation, Malegaon. ",,2020-07-25,2020-08-20,Household and community samples,All,Multiple groups,61.0,70.0,Age,age 61-70,12,0.42,,,,,,,,Stratified non-probability,Not reported/ Unable to specify,,ELISA,,IgG,,Validated by independent authors/third party/non-developers,0.93,1.0,['High'],Yes,No,No,Yes,Yes,Unclear,Yes,Yes,Unclear,Pallavi Saple,The Municipality of Malegaon ,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140273/,2021-06-06,2022-07-16,Verified,saple_seroprevalence_2021,IND
210409_NewDelhi_MaulanaAzadMedicalCollege,210409_NewDelhi_MaulanaAzadMedicalCollege,"Seroprevalence of antibodies to SARS-CoV-2 and predictors of seropositivity among employees of a teaching hospital in New Delhi, India.",2021-04-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,National Capital Territory of Delhi,New Delhi,"We included doctors, nurses, housekeeping staff, biomedical waste collectors, and administrative staff in the study",,2020-08-15,2020-09-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Overall HCW,1401,0.121,0.10400000000000001,0.138,True,,,,True,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.924,0.9790000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Pragya Sharma,Maulana Azad Medical College,Not Unity-Aligned,https://dx.doi.org/10.24171/j.phrp.2021.12.2.06,2021-05-31,2024-03-01,Verified,sharma_seroprevalence_2021,IND
210411_India_BanarasHinduUniversity_Overall,210411_India_BanarasHinduUniversity,Estimation of real-infection and immunity against SARS-CoV-2 in Indian populations,2021-04-11,Preprint,National,Cross-sectional survey ,India,,,"healthy working individuals who have neither
been diagnosed with COVID-19, nor had been sick with any associated symptom in the
recent past. Our focus was to
screen people from urban vendor group who are relatively more exposed in society, e.g.
roadside workers, roadside fruit-vegetable sellers, rikshaw pullers, autorickshaw
drivers, milkmen, hawkers etc. With these stringent criteria, we screened unrelated
people who have not lived together. ","we excluded those individuals in our survey whose family
members have ever been diagnosed with the COVID-19 in the past",2020-09-15,2020-12-15,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,,2301,0.3055,0.287,0.325,True,,,,True,Simplified probability,Coviscreen kit total antibody (IgM+IgA+IgG),"Biosense Technologies, India",,Multiple Types,"['IgA', 'IgG', 'IgM', 'TotalAntibody']",,Validated by manufacturers,1.0,0.99,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Prajjval Singh,Banaras Hindu University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.05.21251118v2,2021-04-14,2024-03-01,Unverified,singh_estimation_2021,IND
210411_India_BanarasHinduUniversity_Mirzapur,210411_India_BanarasHinduUniversity,Estimation of real-infection and immunity against SARS-CoV-2 in Indian populations,2021-04-11,Preprint,Local,Cross-sectional survey ,India,Uttar Pradesh,,"healthy working individuals who have neither
been diagnosed with COVID-19, nor had been sick with any associated symptom in the
recent past. Our focus was to
screen people from urban vendor group who are relatively more exposed in society, e.g.
roadside workers, roadside fruit-vegetable sellers, rikshaw pullers, autorickshaw
drivers, milkmen, hawkers etc. With these stringent criteria, we screened unrelated
people who have not lived together. ","we excluded those individuals in our survey whose family
members have ever been diagnosed with the COVID-19 in the past",2020-10-01,2020-10-31,Household and community samples,All,Adults (18-64 years),,,Geographical area,Mirzapur,100,0.3,0.219,0.396,,,,,,Simplified probability,Coviscreen kit total antibody (IgM+IgA+IgG),"Biosense Technologies, India",,Multiple Types,"['IgA', 'IgG', 'IgM', 'TotalAntibody']",,Validated by manufacturers,1.0,0.99,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Prajjval Singh,Banaras Hindu University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.05.21251118v2,2021-04-14,2024-03-01,Unverified,singh_estimation_2021,IND
210411_India_BanarasHinduUniversity_Varanasi,210411_India_BanarasHinduUniversity,Estimation of real-infection and immunity against SARS-CoV-2 in Indian populations,2021-04-11,Preprint,Local,Cross-sectional survey ,India,Uttar Pradesh,,"healthy working individuals who have neither
been diagnosed with COVID-19, nor had been sick with any associated symptom in the
recent past. Our focus was to
screen people from urban vendor group who are relatively more exposed in society, e.g.
roadside workers, roadside fruit-vegetable sellers, rikshaw pullers, autorickshaw
drivers, milkmen, hawkers etc. With these stringent criteria, we screened unrelated
people who have not lived together. ","we excluded those individuals in our survey whose family
members have ever been diagnosed with the COVID-19 in the past",2020-09-15,2020-12-15,Household and community samples,All,Adults (18-64 years),,,Geographical area,Varanasi,406,0.409,0.36200000000000004,0.457,,,,,,Simplified probability,Coviscreen kit total antibody (IgM+IgA+IgG),"Biosense Technologies, India",,Multiple Types,"['IgA', 'IgG', 'IgM', 'TotalAntibody']",,Validated by manufacturers,1.0,0.99,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Prajjval Singh,Banaras Hindu University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.05.21251118v2,2021-04-14,2024-03-01,Unverified,singh_estimation_2021,IND
210411_India_BanarasHinduUniversity_Gorakhpur,210411_India_BanarasHinduUniversity,Estimation of real-infection and immunity against SARS-CoV-2 in Indian populations,2021-04-11,Preprint,Local,Cross-sectional survey ,India,Uttar Pradesh,,"healthy working individuals who have neither
been diagnosed with COVID-19, nor had been sick with any associated symptom in the
recent past. Our focus was to
screen people from urban vendor group who are relatively more exposed in society, e.g.
roadside workers, roadside fruit-vegetable sellers, rikshaw pullers, autorickshaw
drivers, milkmen, hawkers etc. With these stringent criteria, we screened unrelated
people who have not lived together. ","we excluded those individuals in our survey whose family
members have ever been diagnosed with the COVID-19 in the past",2020-10-01,2020-10-31,Household and community samples,All,Adults (18-64 years),,,Geographical area,Gorakhpur,98,0.38799999999999996,0.297,0.48700000000000004,,,,,,Simplified probability,Coviscreen kit total antibody (IgM+IgA+IgG),"Biosense Technologies, India",,Multiple Types,"['IgA', 'IgG', 'IgM', 'TotalAntibody']",,Validated by manufacturers,1.0,0.99,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Prajjval Singh,Banaras Hindu University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.05.21251118v2,2021-04-14,2024-03-01,Unverified,singh_estimation_2021,IND
210411_India_BanarasHinduUniversity_Raipur,210411_India_BanarasHinduUniversity,Estimation of real-infection and immunity against SARS-CoV-2 in Indian populations,2021-04-11,Preprint,Local,Cross-sectional survey ,India,Chhattishgarh,,"healthy working individuals who have neither
been diagnosed with COVID-19, nor had been sick with any associated symptom in the
recent past. Our focus was to
screen people from urban vendor group who are relatively more exposed in society, e.g.
roadside workers, roadside fruit-vegetable sellers, rikshaw pullers, autorickshaw
drivers, milkmen, hawkers etc. With these stringent criteria, we screened unrelated
people who have not lived together. ","we excluded those individuals in our survey whose family
members have ever been diagnosed with the COVID-19 in the past",2020-09-01,2020-09-30,Household and community samples,All,Adults (18-64 years),,,Geographical area,Raipur,100,0.01,0.002,0.054000000000000006,,,,,,Simplified probability,Coviscreen kit total antibody (IgM+IgA+IgG),"Biosense Technologies, India",,Multiple Types,"['IgA', 'IgG', 'IgM', 'TotalAntibody']",,Validated by manufacturers,1.0,0.99,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Prajjval Singh,Banaras Hindu University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.05.21251118v2,2021-04-14,2024-03-01,Unverified,singh_estimation_2021,IND
210411_India_BanarasHinduUniversity_Singrauli,210411_India_BanarasHinduUniversity,Estimation of real-infection and immunity against SARS-CoV-2 in Indian populations,2021-04-11,Preprint,Local,Cross-sectional survey ,India,Madhya Pradesh,,"healthy working individuals who have neither
been diagnosed with COVID-19, nor had been sick with any associated symptom in the
recent past. Our focus was to
screen people from urban vendor group who are relatively more exposed in society, e.g.
roadside workers, roadside fruit-vegetable sellers, rikshaw pullers, autorickshaw
drivers, milkmen, hawkers etc. With these stringent criteria, we screened unrelated
people who have not lived together. ","we excluded those individuals in our survey whose family
members have ever been diagnosed with the COVID-19 in the past",2020-09-15,2020-12-15,Household and community samples,All,Adults (18-64 years),,,Geographical area,Singrauli,384,0.154,0.121,0.193,,,,,,Simplified probability,Coviscreen kit total antibody (IgM+IgA+IgG),"Biosense Technologies, India",,Multiple Types,"['IgA', 'IgG', 'IgM', 'TotalAntibody']",,Validated by manufacturers,1.0,0.99,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Prajjval Singh,Banaras Hindu University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.05.21251118v2,2021-04-14,2024-03-01,Unverified,singh_estimation_2021,IND
210411_India_BanarasHinduUniversity_Kolkata,210411_India_BanarasHinduUniversity,Estimation of real-infection and immunity against SARS-CoV-2 in Indian populations,2021-04-11,Preprint,Local,Cross-sectional survey ,India,West Bengal,,"healthy working individuals who have neither
been diagnosed with COVID-19, nor had been sick with any associated symptom in the
recent past. Our focus was to
screen people from urban vendor group who are relatively more exposed in society, e.g.
roadside workers, roadside fruit-vegetable sellers, rikshaw pullers, autorickshaw
drivers, milkmen, hawkers etc. With these stringent criteria, we screened unrelated
people who have not lived together. ","we excluded those individuals in our survey whose family
members have ever been diagnosed with the COVID-19 in the past",2020-12-01,2020-12-31,Household and community samples,All,Adults (18-64 years),,,Geographical area,Kolkata,100,0.08,0.042,0.15,,,,,,Simplified probability,Coviscreen kit total antibody (IgM+IgA+IgG),"Biosense Technologies, India",,Multiple Types,"['IgA', 'IgG', 'IgM', 'TotalAntibody']",,Validated by manufacturers,1.0,0.99,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Prajjval Singh,Banaras Hindu University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.05.21251118v2,2021-04-14,2024-03-01,Unverified,singh_estimation_2021,IND
210411_India_BanarasHinduUniversity_Ghazipur,210411_India_BanarasHinduUniversity,Estimation of real-infection and immunity against SARS-CoV-2 in Indian populations,2021-04-11,Preprint,Local,Cross-sectional survey ,India,Uttar Pradesh,,"healthy working individuals who have neither
been diagnosed with COVID-19, nor had been sick with any associated symptom in the
recent past. Our focus was to
screen people from urban vendor group who are relatively more exposed in society, e.g.
roadside workers, roadside fruit-vegetable sellers, rikshaw pullers, autorickshaw
drivers, milkmen, hawkers etc. With these stringent criteria, we screened unrelated
people who have not lived together. ","we excluded those individuals in our survey whose family
members have ever been diagnosed with the COVID-19 in the past",2020-09-15,2020-12-15,Household and community samples,All,Adults (18-64 years),,,Geographical area,Ghazipur,128,0.47700000000000004,0.392,0.563,,,,,,Simplified probability,Coviscreen kit total antibody (IgM+IgA+IgG),"Biosense Technologies, India",,Multiple Types,"['IgA', 'IgG', 'IgM', 'TotalAntibody']",,Validated by manufacturers,1.0,0.99,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Prajjval Singh,Banaras Hindu University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.05.21251118v2,2021-04-14,2024-03-01,Unverified,singh_estimation_2021,IND
210411_India_BanarasHinduUniversity_Sagar,210411_India_BanarasHinduUniversity,Estimation of real-infection and immunity against SARS-CoV-2 in Indian populations,2021-04-11,Preprint,Local,Cross-sectional survey ,India,Madhya Pradesh,,"healthy working individuals who have neither
been diagnosed with COVID-19, nor had been sick with any associated symptom in the
recent past. Our focus was to
screen people from urban vendor group who are relatively more exposed in society, e.g.
roadside workers, roadside fruit-vegetable sellers, rikshaw pullers, autorickshaw
drivers, milkmen, hawkers etc. With these stringent criteria, we screened unrelated
people who have not lived together. ","we excluded those individuals in our survey whose family
members have ever been diagnosed with the COVID-19 in the past",2020-09-15,2020-12-15,Household and community samples,All,Adults (18-64 years),,,Geographical area,Sagar,250,0.392,0.334,0.454,,,,,,Simplified probability,Coviscreen kit total antibody (IgM+IgA+IgG),"Biosense Technologies, India",,Multiple Types,"['IgA', 'IgG', 'IgM', 'TotalAntibody']",,Validated by manufacturers,1.0,0.99,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Prajjval Singh,Banaras Hindu University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.05.21251118v2,2021-04-14,2024-03-01,Unverified,singh_estimation_2021,IND
210411_India_BanarasHinduUniversity_Lucknow,210411_India_BanarasHinduUniversity,Estimation of real-infection and immunity against SARS-CoV-2 in Indian populations,2021-04-11,Preprint,Local,Cross-sectional survey ,India,Uttar Pradesh,,"healthy working individuals who have neither
been diagnosed with COVID-19, nor had been sick with any associated symptom in the
recent past. Our focus was to
screen people from urban vendor group who are relatively more exposed in society, e.g.
roadside workers, roadside fruit-vegetable sellers, rikshaw pullers, autorickshaw
drivers, milkmen, hawkers etc. With these stringent criteria, we screened unrelated
people who have not lived together. ","we excluded those individuals in our survey whose family
members have ever been diagnosed with the COVID-19 in the past",2020-10-01,2020-10-31,Household and community samples,All,Adults (18-64 years),,,Geographical area,Lucknow,72,0.375,0.272,0.49100000000000005,,,,,,Simplified probability,Coviscreen kit total antibody (IgM+IgA+IgG),"Biosense Technologies, India",,Multiple Types,"['IgA', 'IgG', 'IgM', 'TotalAntibody']",,Validated by manufacturers,1.0,0.99,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Prajjval Singh,Banaras Hindu University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.05.21251118v2,2021-04-14,2024-03-01,Unverified,singh_estimation_2021,IND
210411_India_BanarasHinduUniversity_Baroda,210411_India_BanarasHinduUniversity,Estimation of real-infection and immunity against SARS-CoV-2 in Indian populations,2021-04-11,Preprint,Local,Cross-sectional survey ,India,Gujarat,,"healthy working individuals who have neither
been diagnosed with COVID-19, nor had been sick with any associated symptom in the
recent past. Our focus was to
screen people from urban vendor group who are relatively more exposed in society, e.g.
roadside workers, roadside fruit-vegetable sellers, rikshaw pullers, autorickshaw
drivers, milkmen, hawkers etc. With these stringent criteria, we screened unrelated
people who have not lived together. ","we excluded those individuals in our survey whose family
members have ever been diagnosed with the COVID-19 in the past",2020-12-01,2020-12-31,Household and community samples,All,Adults (18-64 years),,,Geographical area,Baroda,50,0.28,0.17500000000000002,0.41700000000000004,,,,,,Simplified probability,Coviscreen kit total antibody (IgM+IgA+IgG),"Biosense Technologies, India",,Multiple Types,"['IgA', 'IgG', 'IgM', 'TotalAntibody']",,Validated by manufacturers,1.0,0.99,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Prajjval Singh,Banaras Hindu University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.05.21251118v2,2021-04-14,2024-03-01,Unverified,singh_estimation_2021,IND
210411_India_BanarasHinduUniversity_Ahmedabad,210411_India_BanarasHinduUniversity,Estimation of real-infection and immunity against SARS-CoV-2 in Indian populations,2021-04-11,Preprint,Local,Cross-sectional survey ,India,Gujarat,,"healthy working individuals who have neither
been diagnosed with COVID-19, nor had been sick with any associated symptom in the
recent past. Our focus was to
screen people from urban vendor group who are relatively more exposed in society, e.g.
roadside workers, roadside fruit-vegetable sellers, rikshaw pullers, autorickshaw
drivers, milkmen, hawkers etc. With these stringent criteria, we screened unrelated
people who have not lived together. ","we excluded those individuals in our survey whose family
members have ever been diagnosed with the COVID-19 in the past",2020-12-01,2020-12-31,Household and community samples,All,Adults (18-64 years),,,Geographical area,Ahmedabad,50,0.46,0.329,0.5970000000000001,,,,,,Simplified probability,Coviscreen kit total antibody (IgM+IgA+IgG),"Biosense Technologies, India",,Multiple Types,"['IgA', 'IgG', 'IgM', 'TotalAntibody']",,Validated by manufacturers,1.0,0.99,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Prajjval Singh,Banaras Hindu University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.05.21251118v2,2021-04-14,2024-03-01,Unverified,singh_estimation_2021,IND
210411_India_BanarasHinduUniversity_Mangalore,210411_India_BanarasHinduUniversity,Estimation of real-infection and immunity against SARS-CoV-2 in Indian populations,2021-04-11,Preprint,Local,Cross-sectional survey ,India,Karnataka,,"healthy working individuals who have neither
been diagnosed with COVID-19, nor had been sick with any associated symptom in the
recent past. Our focus was to
screen people from urban vendor group who are relatively more exposed in society, e.g.
roadside workers, roadside fruit-vegetable sellers, rikshaw pullers, autorickshaw
drivers, milkmen, hawkers etc. With these stringent criteria, we screened unrelated
people who have not lived together. ","we excluded those individuals in our survey whose family
members have ever been diagnosed with the COVID-19 in the past",2020-12-01,2020-12-31,Household and community samples,All,Adults (18-64 years),,,Geographical area,Mangalore,200,0.275,0.218,0.341,,,,,,Simplified probability,Coviscreen kit total antibody (IgM+IgA+IgG),"Biosense Technologies, India",,Multiple Types,"['IgA', 'IgG', 'IgM', 'TotalAntibody']",,Validated by manufacturers,1.0,0.9899999999999995,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Prajjval Singh,Banaras Hindu University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.05.21251118v2,2021-04-14,2024-03-01,Unverified,singh_estimation_2021,IND
210411_India_BanarasHinduUniversity_Jhansi,210411_India_BanarasHinduUniversity,Estimation of real-infection and immunity against SARS-CoV-2 in Indian populations,2021-04-11,Preprint,Local,Cross-sectional survey ,India,Uttar Pradesh,,"healthy working individuals who have neither
been diagnosed with COVID-19, nor had been sick with any associated symptom in the
recent past. Our focus was to
screen people from urban vendor group who are relatively more exposed in society, e.g.
roadside workers, roadside fruit-vegetable sellers, rikshaw pullers, autorickshaw
drivers, milkmen, hawkers etc. With these stringent criteria, we screened unrelated
people who have not lived together. ","we excluded those individuals in our survey whose family
members have ever been diagnosed with the COVID-19 in the past",2020-11-01,2020-11-30,Household and community samples,All,Adults (18-64 years),,,Geographical area,Jhansi,100,0.07,0.035,0.138,,,,,,Simplified probability,Coviscreen kit total antibody (IgM+IgA+IgG),"Biosense Technologies, India",,Multiple Types,"['IgA', 'IgG', 'IgM', 'TotalAntibody']",,Validated by manufacturers,1.0,0.99,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Prajjval Singh,Banaras Hindu University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.05.21251118v2,2021-04-14,2024-03-01,Unverified,singh_estimation_2021,IND
210411_India_BanarasHinduUniversity_Jaunpur,210411_India_BanarasHinduUniversity,Estimation of real-infection and immunity against SARS-CoV-2 in Indian populations,2021-04-11,Preprint,Local,Cross-sectional survey ,India,Uttar Pradesh,,"healthy working individuals who have neither
been diagnosed with COVID-19, nor had been sick with any associated symptom in the
recent past. Our focus was to
screen people from urban vendor group who are relatively more exposed in society, e.g.
roadside workers, roadside fruit-vegetable sellers, rikshaw pullers, autorickshaw
drivers, milkmen, hawkers etc. With these stringent criteria, we screened unrelated
people who have not lived together. ","we excluded those individuals in our survey whose family
members have ever been diagnosed with the COVID-19 in the past",2020-09-15,2020-12-15,Household and community samples,All,Adults (18-64 years),,,Geographical area,Jaunpur,263,0.441,0.38200000000000006,0.563,,,,,,Simplified probability,Coviscreen kit total antibody (IgM+IgA+IgG),"Biosense Technologies, India",,Multiple Types,"['IgA', 'IgG', 'IgM', 'TotalAntibody']",,Validated by manufacturers,1.0,0.99,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Prajjval Singh,Banaras Hindu University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.05.21251118v2,2021-04-14,2024-03-01,Unverified,singh_estimation_2021,IND
210418_Delhi_CouncilofScientificandIndustrialResearchInstituteofGenomicsandIntegrativeBiology_HCW,210418_Delhi_CouncilofScientificandIndustrialResearchInstituteofGenomicsandIntegrativeBiology,Effect Monitoring and Insights from Vaccination program of Healthcare Workforce from a tertiary level hospital in India against SARS-CoV-2,2021-04-18,Preprint,Regional,Prospective cohort,India,Delhi,,health care workers (HCW) at the Max Hospital Group who were to receive the Covishield vaccine,,2021-01-01,2021-01-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,307,0.42,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,,,Spike,,,,['High'],,No,No,No,,Yes,Yes,Yes,,Rajat Ujjainia,Council of Scientific and Industrial Research Institute of Genomics and Integrative Biology,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.28.21252621v3,2021-05-23,2024-03-01,Unverified,ujjainia_effect_2021,IND
210420_Kashmir_GovernmentMedicalCollege,210420_Kashmir_GovernmentMedicalCollege,"SARS-CoV-2 Seroprevalence Among Healthcare Workers by Workplace Exposure Risk in Kashmir, India.",2021-04-20,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Kashmir,,"All frontline HCWs, including physicians, administrative and laboratory personnel, technicians, field workers involved in surveillance activity, and other supporting staff were eligible for the study.

The test result was considered positive for SARS-CoV-2 IgG if the index value was ≥1.4, consistent with guidance provided by the manufacturer.15",,2020-06-15,2020-06-29,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,Healthcare workers,2905,0.025,0.02,0.031000000000000003,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.99,['Moderate'],,No,Yes,No,,Unclear,Yes,Yes,,Muhammad Salim Khan,Government Medical College,Not Unity-Aligned,https://dx.doi.org/10.12788/jhm.3609,2021-05-26,2022-07-16,Unverified,muhammadsalimkhanSARSCoV2SeroprevalenceHealthcare2021,IND
210427_Bhubaneswar_IndianCouncilOfMedicalResearch_overall,210427_Bhubaneswar_IndianCouncilOfMedicalResearch,"Seroprevalence of SARS-CoV-2 in Bhubaneswar, India: findings from 3 rounds of community surveys",2021-04-27,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,India,Odisha,Bhubaneswar,Adults residing in the city since at least the past 3 months and who agreed to provide written informed consent for data and sample collection were included in the study.,"We excluded pregnant women, bed-ridden patients, and those with recognizable cognitive impairment.",2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,1403,0.4904,0.46390000000000003,0.5168,True,,True,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Jaya Singh Kshatri,Indian Council of Medical Research,Unity-Aligned,https://www.cambridge.org/core/journals/epidemiology-and-infection/article/seroprevalence-of-sarscov2-in-bhubaneswar-india-findings-from-3-rounds-of-community-surveys/29A7905F297A1EFA68749AC3C6383300,2021-05-13,2024-03-01,Verified,kshatri_seroprevalence_nodate,IND
210501_Ahmedabad_MunicipalMedicalCollege_ContactCases,210501_Ahmedabad_MunicipalMedicalCollege_ContactCases,Reassessing the population based Seroprevalence for IgG antibodies against SARS COV2 in Ahmedabad,2021-05-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Ahmedabad,"After an informed written consent, individuals from general
population were enrolled without any exception.",,2020-10-15,2020-10-31,Contacts of COVID patients,All,Multiple groups,,,Primary Estimate,,2038,0.2605,,,True,,,,True,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['High'],Unclear,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Om Prakash,Municipal Medical College,Not Unity-Aligned,https://www.nepjol.info/index.php/AJMS/article/view/35099,2021-08-13,2024-03-01,Verified,prakash_reassessing_2021,IND
210501_Ahmedabad_MunicipalMedicalCollege_Genpop_primary,210501_Ahmedabad_MunicipalMedicalCollege_Genpop,Reassessing the population based Seroprevalence for IgG antibodies against SARS COV2 in Ahmedabad,2021-05-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Ahmedabad,"After an informed written consent, individuals from general
population were enrolled without any exception.",,2020-10-15,2020-10-31,Household and community samples,All,Multiple groups,1.0,94.0,Primary Estimate,,17009,0.242,0.23570000000000002,0.24850000000000003,True,,,,True,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Om Prakash,Municipal Medical College,Unity-Aligned,https://www.nepjol.info/index.php/AJMS/article/view/35099,2021-05-22,2024-03-01,Verified,prakash_reassessing_2021,IND
210501_Ahmedabad_MunicipalMedicalCollege_Genpop_Age30-39,210501_Ahmedabad_MunicipalMedicalCollege_Genpop,Reassessing the population based Seroprevalence for IgG antibodies against SARS COV2 in Ahmedabad,2021-05-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Ahmedabad,"After an informed written consent, individuals from general
population were enrolled without any exception.",,2020-10-15,2020-10-31,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,3940,0.2175,0.2049,0.23070000000000002,,,,,,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Om Prakash,Municipal Medical College,Unity-Aligned,https://www.nepjol.info/index.php/AJMS/article/view/35099,2021-08-13,2024-03-01,Verified,prakash_reassessing_2021,IND
210501_Ahmedabad_MunicipalMedicalCollege_Genpop_Age80-89,210501_Ahmedabad_MunicipalMedicalCollege_Genpop,Reassessing the population based Seroprevalence for IgG antibodies against SARS COV2 in Ahmedabad,2021-05-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Ahmedabad,"After an informed written consent, individuals from general
population were enrolled without any exception.",,2020-10-15,2020-10-31,Household and community samples,All,Seniors (65+ years),80.0,89.0,Age,80-89,81,0.2716,0.17870000000000003,0.38189999999999996,,,,,,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Om Prakash,Municipal Medical College,Unity-Aligned,https://www.nepjol.info/index.php/AJMS/article/view/35099,2021-08-13,2024-03-01,Verified,prakash_reassessing_2021,IND
210501_Ahmedabad_MunicipalMedicalCollege_Genpop_Age70-79,210501_Ahmedabad_MunicipalMedicalCollege_Genpop,Reassessing the population based Seroprevalence for IgG antibodies against SARS COV2 in Ahmedabad,2021-05-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Ahmedabad,"After an informed written consent, individuals from general
population were enrolled without any exception.",,2020-10-15,2020-10-31,Household and community samples,All,Seniors (65+ years),70.0,79.0,Age,70-79,442,0.31,0.2686,0.3546,,,,,,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Om Prakash,Municipal Medical College,Unity-Aligned,https://www.nepjol.info/index.php/AJMS/article/view/35099,2021-08-13,2024-03-01,Verified,prakash_reassessing_2021,IND
210501_Ahmedabad_MunicipalMedicalCollege_Genpop_Male,210501_Ahmedabad_MunicipalMedicalCollege_Genpop,Reassessing the population based Seroprevalence for IgG antibodies against SARS COV2 in Ahmedabad,2021-05-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Ahmedabad,"After an informed written consent, individuals from general
population were enrolled without any exception.",,2020-10-15,2020-10-31,Household and community samples,Male,Multiple groups,,,Sex/Gender,,9612,0.2372,,,,,,,,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Om Prakash,Municipal Medical College,Unity-Aligned,https://www.nepjol.info/index.php/AJMS/article/view/35099,2021-08-13,2024-03-01,Verified,prakash_reassessing_2021,IND
210501_Ahmedabad_MunicipalMedicalCollege_Genpop_Age40-49,210501_Ahmedabad_MunicipalMedicalCollege_Genpop,Reassessing the population based Seroprevalence for IgG antibodies against SARS COV2 in Ahmedabad,2021-05-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Ahmedabad,"After an informed written consent, individuals from general
population were enrolled without any exception.",,2020-10-15,2020-10-31,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,2773,0.2636,0.2475,0.2803,,,,,,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Om Prakash,Municipal Medical College,Unity-Aligned,https://www.nepjol.info/index.php/AJMS/article/view/35099,2021-08-13,2024-03-01,Verified,prakash_reassessing_2021,IND
210501_Ahmedabad_MunicipalMedicalCollege_Genpop_Age20-20,210501_Ahmedabad_MunicipalMedicalCollege_Genpop,Reassessing the population based Seroprevalence for IgG antibodies against SARS COV2 in Ahmedabad,2021-05-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Ahmedabad,"After an informed written consent, individuals from general
population were enrolled without any exception.",,2020-10-15,2020-10-31,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,4803,0.209,0.1978,0.2208,,,,,,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Om Prakash,Municipal Medical College,Unity-Aligned,https://www.nepjol.info/index.php/AJMS/article/view/35099,2021-08-13,2024-03-01,Verified,prakash_reassessing_2021,IND
210501_Ahmedabad_MunicipalMedicalCollege_Genpop_Age60-69,210501_Ahmedabad_MunicipalMedicalCollege_Genpop,Reassessing the population based Seroprevalence for IgG antibodies against SARS COV2 in Ahmedabad,2021-05-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Ahmedabad,"After an informed written consent, individuals from general
population were enrolled without any exception.",,2020-10-15,2020-10-31,Household and community samples,All,Seniors (65+ years),60.0,69.0,Age,60-69,1352,0.2929,0.2693,0.3177,,,,,,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Om Prakash,Municipal Medical College,Unity-Aligned,https://www.nepjol.info/index.php/AJMS/article/view/35099,2021-08-13,2024-03-01,Verified,prakash_reassessing_2021,IND
210501_Ahmedabad_MunicipalMedicalCollege_Genpop_Age50-59,210501_Ahmedabad_MunicipalMedicalCollege_Genpop,Reassessing the population based Seroprevalence for IgG antibodies against SARS COV2 in Ahmedabad,2021-05-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Ahmedabad,"After an informed written consent, individuals from general
population were enrolled without any exception.",,2020-10-15,2020-10-31,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,2146,0.2964,0.2774,0.316,,,,,,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Om Prakash,Municipal Medical College,Unity-Aligned,https://www.nepjol.info/index.php/AJMS/article/view/35099,2021-08-13,2024-03-01,Verified,prakash_reassessing_2021,IND
210501_Ahmedabad_MunicipalMedicalCollege_Genpop_Age10-19,210501_Ahmedabad_MunicipalMedicalCollege_Genpop,Reassessing the population based Seroprevalence for IgG antibodies against SARS COV2 in Ahmedabad,2021-05-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Ahmedabad,"After an informed written consent, individuals from general
population were enrolled without any exception.",,2020-10-15,2020-10-31,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19 ,1354,0.21789999999999998,0.1967,0.24059999999999998,,,,,,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Om Prakash,Municipal Medical College,Unity-Aligned,https://www.nepjol.info/index.php/AJMS/article/view/35099,2021-08-13,2024-03-01,Verified,prakash_reassessing_2021,IND
210501_Ahmedabad_MunicipalMedicalCollege_Genpop_Age0-9,210501_Ahmedabad_MunicipalMedicalCollege_Genpop,Reassessing the population based Seroprevalence for IgG antibodies against SARS COV2 in Ahmedabad,2021-05-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Ahmedabad,"After an informed written consent, individuals from general
population were enrolled without any exception.",,2020-10-15,2020-10-31,Household and community samples,All,Children and Youth (0-17 years),0.0,99.0,Age,0-9,114,0.3246,0.2399,0.4186,,,,,,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Om Prakash,Municipal Medical College,Unity-Aligned,https://www.nepjol.info/index.php/AJMS/article/view/35099,2021-08-13,2024-03-01,Verified,prakash_reassessing_2021,IND
210501_Ahmedabad_MunicipalMedicalCollege_Genpop_Age90-99,210501_Ahmedabad_MunicipalMedicalCollege_Genpop,Reassessing the population based Seroprevalence for IgG antibodies against SARS COV2 in Ahmedabad,2021-05-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Ahmedabad,"After an informed written consent, individuals from general
population were enrolled without any exception.",,2020-10-15,2020-10-31,Household and community samples,All,Seniors (65+ years),90.0,99.0,Age,90-99,4,0.5,0.0676,0.9324,,,,,,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Om Prakash,Municipal Medical College,Unity-Aligned,https://www.nepjol.info/index.php/AJMS/article/view/35099,2021-08-13,2024-03-01,Verified,prakash_reassessing_2021,IND
210501_Ahmedabad_MunicipalMedicalCollege_Genpop_Female,210501_Ahmedabad_MunicipalMedicalCollege_Genpop,Reassessing the population based Seroprevalence for IgG antibodies against SARS COV2 in Ahmedabad,2021-05-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Ahmedabad,"After an informed written consent, individuals from general
population were enrolled without any exception.",,2020-10-15,2020-10-31,Household and community samples,Female,Multiple groups,,,Sex/Gender,,7397,0.2483,,,,,,,,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Om Prakash,Municipal Medical College,Unity-Aligned,https://www.nepjol.info/index.php/AJMS/article/view/35099,2021-08-13,2024-03-01,Verified,prakash_reassessing_2021,IND
210501_Ahmedabad_MunicipalMedicalCollege_HCW,210501_Ahmedabad_MunicipalMedicalCollege_HCW,Reassessing the population based Seroprevalence for IgG antibodies against SARS COV2 in Ahmedabad,2021-05-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Ahmedabad,"After an informed written consent, individuals from general
population were enrolled without any exception.",,2020-10-15,2020-10-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1737,0.2084,,,True,,,,True,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['High'],Unclear,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Om Prakash,Municipal Medical College,Not Unity-Aligned,https://www.nepjol.info/index.php/AJMS/article/view/35099,2021-08-13,2024-03-01,Verified,prakash_reassessing_2021,IND
210508_Ahmedabad_GujaratUniversity,210508_Ahmedabad_GujaratUniversity,SARS-CoV2 IgG antibody: Seroprevalence among health care workers.,2021-05-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,"the sample included a mix of doctors, nurses, paramedical, field level health care workers etc – all directly or indirectly associated with the health care field. ",,2020-08-15,2020-08-31,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,Healthcare Workers,1710,0.2365,0.217,0.25730000000000003,True,,,,True,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9237000000000001,0.9790000000000001,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Om Prakash,"Smt. Nathiba Hargovandas Lakhmichand (NHL) Municipal Medical College, Gujarat University",Not Unity-Aligned,https://dx.doi.org/10.1016/j.cegh.2021.100766,2021-06-03,2024-03-01,Unverified,omprakashetal.SARSCoV2IgGAntibody2021,IND
210518_Odisha_ICMR-RegionalMedicalResearchCentre_BAM_GenderAdj,210518_Odisha_ICMR-RegionalMedicalResearchCentre_BAM,"Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India.",2021-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Odisha,Berhampur,Adults residing in the city for at least the past 3 months and who agreed to provide written informed consent for data and sample collection were included in the study. ,"We excluded pregnant women, bedridden patients, and those with recognizable cognitive impairment. ",2020-08-01,2020-08-31,Household and community samples,All,Multiple groups,,,Primary Estimate,Gender-weighted population adjustment,1375,0.3114,0.28690000000000004,0.33659999999999995,True,,True,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Jaya Singh Kshatri,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89877-y,2021-09-04,2024-03-01,Verified,jayasinghkshatrietal.SerologicalSurveysInform2021,IND
210518_Odisha_ICMR-RegionalMedicalResearchCentre_BAM_Female,210518_Odisha_ICMR-RegionalMedicalResearchCentre_BAM,"Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India.",2021-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Odisha,Berhampur,Adults residing in the city for at least the past 3 months and who agreed to provide written informed consent for data and sample collection were included in the study. ,"We excluded pregnant women, bedridden patients, and those with recognizable cognitive impairment. ",2020-08-01,2020-08-31,Household and community samples,Female,Multiple groups,,,Sex/Gender,,528,0.31620000000000004,0.244,0.31760000000000005,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Jaya Singh Kshatri,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89877-y,2021-09-04,2024-03-01,Verified,jayasinghkshatrietal.SerologicalSurveysInform2021,IND
210518_Odisha_ICMR-RegionalMedicalResearchCentre_BAM_20-29,210518_Odisha_ICMR-RegionalMedicalResearchCentre_BAM,"Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India.",2021-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Odisha,Berhampur,Adults residing in the city for at least the past 3 months and who agreed to provide written informed consent for data and sample collection were included in the study. ,"We excluded pregnant women, bedridden patients, and those with recognizable cognitive impairment. ",2020-08-01,2020-08-31,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,146,0.3356,0.2596,0.4183,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Jaya Singh Kshatri,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89877-y,2021-09-04,2024-03-01,Verified,jayasinghkshatrietal.SerologicalSurveysInform2021,IND
210518_Odisha_ICMR-RegionalMedicalResearchCentre_BAM_UnAdj,210518_Odisha_ICMR-RegionalMedicalResearchCentre_BAM,"Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India.",2021-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Odisha,Berhampur,Adults residing in the city for at least the past 3 months and who agreed to provide written informed consent for data and sample collection were included in the study. ,"We excluded pregnant women, bedridden patients, and those with recognizable cognitive impairment. ",2020-08-01,2020-08-31,Household and community samples,All,Multiple groups,,,Analysis,,1375,0.3105,0.2861,0.3357,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Jaya Singh Kshatri,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89877-y,2021-09-04,2024-03-01,Verified,jayasinghkshatrietal.SerologicalSurveysInform2021,IND
210518_Odisha_ICMR-RegionalMedicalResearchCentre_BAM_60andover,210518_Odisha_ICMR-RegionalMedicalResearchCentre_BAM,"Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India.",2021-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Odisha,Berhampur,Adults residing in the city for at least the past 3 months and who agreed to provide written informed consent for data and sample collection were included in the study. ,"We excluded pregnant women, bedridden patients, and those with recognizable cognitive impairment. ",2020-08-01,2020-08-31,Household and community samples,All,Seniors (65+ years),60.0,,Age,>=60,312,0.2852,0.23579999999999998,0.33880000000000005,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Jaya Singh Kshatri,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89877-y,2021-09-04,2024-03-01,Verified,jayasinghkshatrietal.SerologicalSurveysInform2021,IND
210518_Odisha_ICMR-RegionalMedicalResearchCentre_BAM_under20,210518_Odisha_ICMR-RegionalMedicalResearchCentre_BAM,"Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India.",2021-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Odisha,Berhampur,Adults residing in the city for at least the past 3 months and who agreed to provide written informed consent for data and sample collection were included in the study. ,"We excluded pregnant women, bedridden patients, and those with recognizable cognitive impairment. ",2020-08-01,2020-08-31,Household and community samples,All,Children and Youth (0-17 years),,19.0,Age,<20,31,0.258,0.1185,0.4461,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Jaya Singh Kshatri,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89877-y,2021-09-04,2024-03-01,Verified,jayasinghkshatrietal.SerologicalSurveysInform2021,IND
210518_Odisha_ICMR-RegionalMedicalResearchCentre_BAM_30-39,210518_Odisha_ICMR-RegionalMedicalResearchCentre_BAM,"Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India.",2021-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Odisha,Berhampur,Adults residing in the city for at least the past 3 months and who agreed to provide written informed consent for data and sample collection were included in the study. ,"We excluded pregnant women, bedridden patients, and those with recognizable cognitive impairment. ",2020-08-01,2020-08-31,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,251,0.35850000000000004,0.2992,0.42119999999999996,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Jaya Singh Kshatri,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89877-y,2021-09-04,2024-03-01,Verified,jayasinghkshatrietal.SerologicalSurveysInform2021,IND
210518_Odisha_ICMR-RegionalMedicalResearchCentre_BAM_Male,210518_Odisha_ICMR-RegionalMedicalResearchCentre_BAM,"Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India.",2021-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Odisha,Berhampur,Adults residing in the city for at least the past 3 months and who agreed to provide written informed consent for data and sample collection were included in the study. ,"We excluded pregnant women, bedridden patients, and those with recognizable cognitive impairment. ",2020-08-01,2020-08-31,Household and community samples,Male,Multiple groups,,,Sex/Gender,,847,0.3069,0.276,0.3392,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Jaya Singh Kshatri,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89877-y,2021-09-04,2024-03-01,Verified,jayasinghkshatrietal.SerologicalSurveysInform2021,IND
210518_Odisha_ICMR-RegionalMedicalResearchCentre_BAM_50-59,210518_Odisha_ICMR-RegionalMedicalResearchCentre_BAM,"Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India.",2021-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Odisha,Berhampur,Adults residing in the city for at least the past 3 months and who agreed to provide written informed consent for data and sample collection were included in the study. ,"We excluded pregnant women, bedridden patients, and those with recognizable cognitive impairment. ",2020-08-01,2020-08-31,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,271,0.2841,0.23120000000000002,0.3418,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Jaya Singh Kshatri,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89877-y,2021-09-04,2024-03-01,Verified,jayasinghkshatrietal.SerologicalSurveysInform2021,IND
210518_Odisha_ICMR-RegionalMedicalResearchCentre_BAM_40-49,210518_Odisha_ICMR-RegionalMedicalResearchCentre_BAM,"Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India.",2021-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Odisha,Berhampur,Adults residing in the city for at least the past 3 months and who agreed to provide written informed consent for data and sample collection were included in the study. ,"We excluded pregnant women, bedridden patients, and those with recognizable cognitive impairment. ",2020-08-01,2020-08-31,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,364,0.3131,0.2658,0.36350000000000005,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Jaya Singh Kshatri,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89877-y,2021-09-04,2024-03-01,Verified,jayasinghkshatrietal.SerologicalSurveysInform2021,IND
210518_Odisha_ICMR-RegionalMedicalResearchCentre_BBS_GenderAdj,210518_Odisha_ICMR-RegionalMedicalResearchCentre_BBS,"Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India.",2021-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Odisha,Bhubaneswar,Adults residing in the city for at least the past 3 months and who agreed to provide written informed consent for data and sample collection were included in the study. ,"We excluded pregnant women, bedridden patients, and those with recognizable cognitive impairment. ",2020-08-01,2020-08-31,Household and community samples,All,Multiple groups,,,Primary Estimate,Gender-weighted population adjustment,1319,0.0524,0.040999999999999995,0.0658,True,,True,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Jaya Singh Kshatri,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89877-y,2021-09-04,2024-03-01,Verified,jayasinghkshatrietal.SerologicalSurveysInform2021,IND
210518_Odisha_ICMR-RegionalMedicalResearchCentre_BBS_UnAdj,210518_Odisha_ICMR-RegionalMedicalResearchCentre_BBS,"Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India.",2021-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Odisha,Bhubaneswar,Adults residing in the city for at least the past 3 months and who agreed to provide written informed consent for data and sample collection were included in the study. ,"We excluded pregnant women, bedridden patients, and those with recognizable cognitive impairment. ",2020-08-01,2020-08-31,Household and community samples,All,Multiple groups,,,Analysis,,1319,0.052300000000000006,0.04309,0.0647,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Jaya Singh Kshatri,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89877-y,2021-09-04,2024-03-01,Verified,jayasinghkshatrietal.SerologicalSurveysInform2021,IND
210518_Odisha_ICMR-RegionalMedicalResearchCentre_BBS_40-49,210518_Odisha_ICMR-RegionalMedicalResearchCentre_BBS,"Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India.",2021-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Odisha,Bhubaneswar,Adults residing in the city for at least the past 3 months and who agreed to provide written informed consent for data and sample collection were included in the study. ,"We excluded pregnant women, bedridden patients, and those with recognizable cognitive impairment. ",2020-08-01,2020-08-31,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,311,0.0257,0.0111,0.05,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Jaya Singh Kshatri,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89877-y,2021-09-04,2024-03-01,Verified,jayasinghkshatrietal.SerologicalSurveysInform2021,IND
210518_Odisha_ICMR-RegionalMedicalResearchCentre_BBS_30-39,210518_Odisha_ICMR-RegionalMedicalResearchCentre_BBS,"Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India.",2021-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Odisha,Bhubaneswar,Adults residing in the city for at least the past 3 months and who agreed to provide written informed consent for data and sample collection were included in the study. ,"We excluded pregnant women, bedridden patients, and those with recognizable cognitive impairment. ",2020-08-01,2020-08-31,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,298,0.0771,0.0495,0.1135,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Jaya Singh Kshatri,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89877-y,2021-09-04,2024-03-01,Verified,jayasinghkshatrietal.SerologicalSurveysInform2021,IND
210518_Odisha_ICMR-RegionalMedicalResearchCentre_BBS_Male,210518_Odisha_ICMR-RegionalMedicalResearchCentre_BBS,"Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India.",2021-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Odisha,Bhubaneswar,Adults residing in the city for at least the past 3 months and who agreed to provide written informed consent for data and sample collection were included in the study. ,"We excluded pregnant women, bedridden patients, and those with recognizable cognitive impairment. ",2020-08-01,2020-08-31,Household and community samples,Male,Multiple groups,,,Sex/Gender,,891,0.0516,0.038,0.06820000000000001,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Jaya Singh Kshatri,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89877-y,2021-09-04,2024-03-01,Verified,jayasinghkshatrietal.SerologicalSurveysInform2021,IND
210518_Odisha_ICMR-RegionalMedicalResearchCentre_BBS_50-59,210518_Odisha_ICMR-RegionalMedicalResearchCentre_BBS,"Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India.",2021-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Odisha,Bhubaneswar,Adults residing in the city for at least the past 3 months and who agreed to provide written informed consent for data and sample collection were included in the study. ,"We excluded pregnant women, bedridden patients, and those with recognizable cognitive impairment. ",2020-08-01,2020-08-31,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,258,0.0348,0.016,0.0651,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Jaya Singh Kshatri,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89877-y,2021-09-04,2024-03-01,Verified,jayasinghkshatrietal.SerologicalSurveysInform2021,IND
210518_Odisha_ICMR-RegionalMedicalResearchCentre_BBS_60andover,210518_Odisha_ICMR-RegionalMedicalResearchCentre_BBS,"Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India.",2021-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Odisha,Bhubaneswar,Adults residing in the city for at least the past 3 months and who agreed to provide written informed consent for data and sample collection were included in the study. ,"We excluded pregnant women, bedridden patients, and those with recognizable cognitive impairment. ",2020-08-01,2020-08-31,Household and community samples,All,Seniors (65+ years),60.0,,Age,>=60,176,0.0738,0.039900000000000005,0.1229,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Jaya Singh Kshatri,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89877-y,2021-09-04,2024-03-01,Verified,jayasinghkshatrietal.SerologicalSurveysInform2021,IND
210518_Odisha_ICMR-RegionalMedicalResearchCentre_BBS_20-29,210518_Odisha_ICMR-RegionalMedicalResearchCentre_BBS,"Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India.",2021-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Odisha,Bhubaneswar,Adults residing in the city for at least the past 3 months and who agreed to provide written informed consent for data and sample collection were included in the study. ,"We excluded pregnant women, bedridden patients, and those with recognizable cognitive impairment. ",2020-08-01,2020-08-31,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,229,0.0524,0.0273,0.0897,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Jaya Singh Kshatri,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89877-y,2021-09-04,2024-03-01,Verified,jayasinghkshatrietal.SerologicalSurveysInform2021,IND
210518_Odisha_ICMR-RegionalMedicalResearchCentre_BBS_Female,210518_Odisha_ICMR-RegionalMedicalResearchCentre_BBS,"Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India.",2021-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Odisha,Bhubaneswar,Adults residing in the city for at least the past 3 months and who agreed to provide written informed consent for data and sample collection were included in the study. ,"We excluded pregnant women, bedridden patients, and those with recognizable cognitive impairment. ",2020-08-01,2020-08-31,Household and community samples,Female,Multiple groups,,,Sex/Gender,,428,0.053700000000000005,0.034300000000000004,0.0795,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Jaya Singh Kshatri,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89877-y,2021-09-04,2024-03-01,Verified,jayasinghkshatrietal.SerologicalSurveysInform2021,IND
210518_Odisha_ICMR-RegionalMedicalResearchCentre_BBS_<20,210518_Odisha_ICMR-RegionalMedicalResearchCentre_BBS,"Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India.",2021-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Odisha,Bhubaneswar,Adults residing in the city for at least the past 3 months and who agreed to provide written informed consent for data and sample collection were included in the study. ,"We excluded pregnant women, bedridden patients, and those with recognizable cognitive impairment. ",2020-08-01,2020-08-31,Household and community samples,All,Children and Youth (0-17 years),,19.0,Age,<20,47,0.0851,0.0236,0.20370000000000002,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Jaya Singh Kshatri,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89877-y,2021-09-04,2024-03-01,Verified,jayasinghkshatrietal.SerologicalSurveysInform2021,IND
210518_Odisha_ICMR-RegionalMedicalResearchCentre_RKL_GenderADj,210518_Odisha_ICMR-RegionalMedicalResearchCentre_RKL,"Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India.",2021-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Odisha,Rourkela,Adults residing in the city for at least the past 3 months and who agreed to provide written informed consent for data and sample collection were included in the study. ,"We excluded pregnant women, bedridden patients, and those with recognizable cognitive impairment. ",2020-08-01,2020-08-31,Household and community samples,All,Multiple groups,,,Primary Estimate,Gender-weighted population adjustment,1452,0.2459,0.22390000000000002,0.2688,True,,True,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Jaya Singh Kshatri,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89877-y,2021-09-04,2024-03-01,Verified,jayasinghkshatrietal.SerologicalSurveysInform2021,IND
210518_Odisha_ICMR-RegionalMedicalResearchCentre_RKL_Male,210518_Odisha_ICMR-RegionalMedicalResearchCentre_RKL,"Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India.",2021-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Odisha,Rourkela,Adults residing in the city for at least the past 3 months and who agreed to provide written informed consent for data and sample collection were included in the study. ,"We excluded pregnant women, bedridden patients, and those with recognizable cognitive impairment. ",2020-08-01,2020-08-31,Household and community samples,Male,Multiple groups,,,Sex/Gender,,855,0.21280000000000002,0.1858,0.24180000000000001,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Jaya Singh Kshatri,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89877-y,2021-09-04,2024-03-01,Verified,jayasinghkshatrietal.SerologicalSurveysInform2021,IND
210518_Odisha_ICMR-RegionalMedicalResearchCentre_RKL_50-59,210518_Odisha_ICMR-RegionalMedicalResearchCentre_RKL,"Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India.",2021-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Odisha,Rourkela,Adults residing in the city for at least the past 3 months and who agreed to provide written informed consent for data and sample collection were included in the study. ,"We excluded pregnant women, bedridden patients, and those with recognizable cognitive impairment. ",2020-08-01,2020-08-31,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,287,0.22640000000000002,0.1793,0.2793,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Jaya Singh Kshatri,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89877-y,2021-09-04,2024-03-01,Verified,jayasinghkshatrietal.SerologicalSurveysInform2021,IND
210518_Odisha_ICMR-RegionalMedicalResearchCentre_RKL_30-39,210518_Odisha_ICMR-RegionalMedicalResearchCentre_RKL,"Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India.",2021-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Odisha,Rourkela,Adults residing in the city for at least the past 3 months and who agreed to provide written informed consent for data and sample collection were included in the study. ,"We excluded pregnant women, bedridden patients, and those with recognizable cognitive impairment. ",2020-08-01,2020-08-31,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,344,0.23829999999999998,0.1943,0.28690000000000004,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Jaya Singh Kshatri,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89877-y,2021-09-04,2024-03-01,Verified,jayasinghkshatrietal.SerologicalSurveysInform2021,IND
210518_Odisha_ICMR-RegionalMedicalResearchCentre_RKL_60andover,210518_Odisha_ICMR-RegionalMedicalResearchCentre_RKL,"Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India.",2021-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Odisha,Rourkela,Adults residing in the city for at least the past 3 months and who agreed to provide written informed consent for data and sample collection were included in the study. ,"We excluded pregnant women, bedridden patients, and those with recognizable cognitive impairment. ",2020-08-01,2020-08-31,Household and community samples,All,Seniors (65+ years),60.0,,Age,>=60,214,0.28500000000000003,0.22219999999999998,0.3505,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Jaya Singh Kshatri,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89877-y,2021-09-04,2024-03-01,Verified,jayasinghkshatrietal.SerologicalSurveysInform2021,IND
210518_Odisha_ICMR-RegionalMedicalResearchCentre_RKL_Female,210518_Odisha_ICMR-RegionalMedicalResearchCentre_RKL,"Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India.",2021-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Odisha,Rourkela,Adults residing in the city for at least the past 3 months and who agreed to provide written informed consent for data and sample collection were included in the study. ,"We excluded pregnant women, bedridden patients, and those with recognizable cognitive impairment. ",2020-08-01,2020-08-31,Household and community samples,Female,Multiple groups,,,Sex/Gender,,597,0.2747,0.23920000000000002,0.3124,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Jaya Singh Kshatri,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89877-y,2021-09-04,2024-03-01,Verified,jayasinghkshatrietal.SerologicalSurveysInform2021,IND
210518_Odisha_ICMR-RegionalMedicalResearchCentre_RKL_under20,210518_Odisha_ICMR-RegionalMedicalResearchCentre_RKL,"Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India.",2021-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Odisha,Rourkela,Adults residing in the city for at least the past 3 months and who agreed to provide written informed consent for data and sample collection were included in the study. ,"We excluded pregnant women, bedridden patients, and those with recognizable cognitive impairment. ",2020-08-01,2020-08-31,Household and community samples,All,Children and Youth (0-17 years),,19.0,Age,<20,39,0.20510000000000003,0.0929,0.36460000000000004,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Jaya Singh Kshatri,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89877-y,2021-09-04,2024-03-01,Verified,jayasinghkshatrietal.SerologicalSurveysInform2021,IND
210518_Odisha_ICMR-RegionalMedicalResearchCentre_RKL_40-49,210518_Odisha_ICMR-RegionalMedicalResearchCentre_RKL,"Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India.",2021-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Odisha,Rourkela,Adults residing in the city for at least the past 3 months and who agreed to provide written informed consent for data and sample collection were included in the study. ,"We excluded pregnant women, bedridden patients, and those with recognizable cognitive impairment. ",2020-08-01,2020-08-31,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,351,0.2279,0.185,0.2754,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Jaya Singh Kshatri,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89877-y,2021-09-04,2024-03-01,Verified,jayasinghkshatrietal.SerologicalSurveysInform2021,IND
210518_Odisha_ICMR-RegionalMedicalResearchCentre_RKL_UnAdj,210518_Odisha_ICMR-RegionalMedicalResearchCentre_RKL,"Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India.",2021-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Odisha,Rourkela,Adults residing in the city for at least the past 3 months and who agreed to provide written informed consent for data and sample collection were included in the study. ,"We excluded pregnant women, bedridden patients, and those with recognizable cognitive impairment. ",2020-08-01,2020-08-31,Household and community samples,All,Multiple groups,,,Analysis,,1452,0.2382,0.2162,0.261,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Jaya Singh Kshatri,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89877-y,2021-09-04,2024-03-01,Verified,jayasinghkshatrietal.SerologicalSurveysInform2021,IND
210518_Odisha_ICMR-RegionalMedicalResearchCentre_RKL_20-29,210518_Odisha_ICMR-RegionalMedicalResearchCentre_RKL,"Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India.",2021-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Odisha,Rourkela,Adults residing in the city for at least the past 3 months and who agreed to provide written informed consent for data and sample collection were included in the study. ,"We excluded pregnant women, bedridden patients, and those with recognizable cognitive impairment. ",2020-08-01,2020-08-31,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,217,0.2304,0.1761,0.2922,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Jaya Singh Kshatri,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89877-y,2021-09-04,2024-03-01,Verified,jayasinghkshatrietal.SerologicalSurveysInform2021,IND
210521_Bengaluru_BangaloreMedicalCollege,210521_Bengaluru_BangaloreMedicalCollege,One in five has antibodies against Covid in slums in Bengalu: Study,2021-05-21,News and Media,Local,Cross-sectional survey ,India,Karnataka,Bangalore,A house-to-house survey was conducted by 12 medical teams which tested 728 persons (above 18 years) in 24 slum pockets.,,2021-04-15,2021-04-22,Persons living in slums,All,Multiple groups,18.0,,Primary Estimate,,728,0.203,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Ranganath TS,Bangalore Medical College and Research Institute,Not Unity-Aligned,https://timesofindia.indiatimes.com/city/bengaluru/one-in-five-has-antibodies-against-covid-in-slums-in-bengaluru-study/articleshow/82825325.cms,2021-05-27,2022-07-16,Unverified,ranganathtsOneFiveHas2021,IND
210521_Karnataka_IndianInstituteOfPublicHealth_Primary,210521_Karnataka_IndianInstituteOfPublicHealth,"The burden of active infection and anti-SARS-CoV-2 IgG antibodies in the general population: Results from a statewide sentinel-based population survey in Karnataka, India",2021-05-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Karnataka,,The participants included only adults aged ≥18 years,The survey excluded those already diagnosed with SARS-CoV-2 infection or those who did not agree to provide informed consent to participate in the survey,2020-09-03,2020-09-16,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,15624,0.168,0.155,0.18100000000000002,True,True,True,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,Whole-virusantigen,,0.9209999999999999,0.9770000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Giridhara Babu,Indian Institute of Public Health,Not Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.05.043,2021-06-08,2024-02-01,Verified,babu_burden_2021,IND
210521_Karnataka_IndianInstituteOfPublicHealth_Unadj,210521_Karnataka_IndianInstituteOfPublicHealth,"The burden of active infection and anti-SARS-CoV-2 IgG antibodies in the general population: Results from a statewide sentinel-based population survey in Karnataka, India",2021-05-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Karnataka,,The participants included only adults aged ≥18 years,The survey excluded those already diagnosed with SARS-CoV-2 infection or those who did not agree to provide informed consent to participate in the survey,2020-09-03,2020-09-16,Household and community samples,All,Multiple groups,18.0,,Analysis,,15624,0.157,,,,,,,True,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,Whole-virusantigen,,0.9209999999999999,0.9770000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Giridhara Babu,Indian Institute of Public Health,Not Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.05.043,2021-06-08,2024-03-01,Verified,babu_burden_2021,IND
210601_Chennai_GovernmentKilpaukMedicalCollege,210601_Chennai_GovernmentKilpaukMedicalCollege,"Evaluation of IgG antibody response to severe acute respiratory syndrome Coronavirus-2 in healthcare workers in a tertiary care centre, Chennai, India",2021-06-01,Journal Article (Peer-Reviewed),Local,Prospective cohort,India,Tamil Nadu,Chennai,HCWs who were RT-PCR negative.,"Subjects with allergic rhinitis and asthmatic bronchitis were excluded from the study population

For this extraction, I excluded RT-PCR positive individuals as separate subgroups were reported.",2020-04-15,2020-12-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,45,0.2666,,,True,,,,True,Convenience,COVID KAVACH (KAWACH) IgG Microlisa (Microwell ELISA),J. Mitra & Co. Pvt. Ltd,ELISA,Serum,IgG,,,,,['High'],,No,No,No,,Yes,Yes,Yes,,Therese Dhason,Government Kilpauk Medical College,Not Unity-Aligned,http://dx.doi.org/10.7860/JCDR/2021/48889.14995,2021-06-29,2024-03-01,Unverified,dhason_evaluation_2021,IND
210601_Kerala_GovernmentofKerala,210601_Kerala_GovernmentofKerala,ICMR - Serological Surveillance Report - Round 4,2021-06-01,Institutional Report,National,Cross-sectional survey ,India,,,Resident of India over 6 years of age,,2021-05-01,2021-05-31,Household and community samples,All,Multiple groups,6.0,,Primary Estimate,,28975,0.6759999999999999,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,IgG,Spike,,,,['High'],,Unclear,Yes,No,,Unclear,Yes,No,,Government of Kerala,Government of Kerala Department of Health & Family Welfare,Not Unity-Aligned,https://health.kerala.gov.in/pdf/Technical_paper_COVID_19_Sero_Surveillance_Round_4_ICMR.pdf,2021-11-18,2022-07-16,Unverified,government_of_kerala_technical_2021,IND
210616_India_AllIndiaInstituteOfMedicalSciences_DelhiUrban1,210616_India_AllIndiaInstituteOfMedicalSciences_1DelhiUrban,Serological prevalence of SARS-CoV-2 antibody among children and young age (between age 2-17 years) group in India: An interim result from a large multi-centric population-based seroepidemiological study,2021-06-16,Preprint,Local,Prospective cohort,India,National Capital Territory of Delhi,New Delhi,In each site both urban and rural area population have been planned to be included. ,,2021-03-15,2021-03-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,1001,0.747,,,True,,,,True,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,https://europepmc.org/article/PPR/PPR357490,2021-06-22,2024-03-01,Verified,misra_serological_2021,IND
210616_India_AllIndiaInstituteOfMedicalSciences_DelhiUrban1_<18years,210616_India_AllIndiaInstituteOfMedicalSciences_1DelhiUrban,Serological prevalence of SARS-CoV-2 antibody among children and young age (between age 2-17 years) group in India: An interim result from a large multi-centric population-based seroepidemiological study,2021-06-16,Preprint,Local,Prospective cohort,India,National Capital Territory of Delhi,New Delhi,In each site both urban and rural area population have been planned to be included. ,,2021-03-15,2021-03-31,Household and community samples,All,Children and Youth (0-17 years),1.0,17.0,Age,<18,92,0.7390000000000001,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,https://europepmc.org/article/PPR/PPR357490,2021-09-08,2024-03-01,Verified,misra_serological_2021,IND
210616_India_AllIndiaInstituteOfMedicalSciences_DelhiUrban1_>=18years,210616_India_AllIndiaInstituteOfMedicalSciences_1DelhiUrban,Serological prevalence of SARS-CoV-2 antibody among children and young age (between age 2-17 years) group in India: An interim result from a large multi-centric population-based seroepidemiological study,2021-06-16,Preprint,Local,Prospective cohort,India,National Capital Territory of Delhi,New Delhi,In each site both urban and rural area population have been planned to be included. ,,2021-03-15,2021-03-31,Household and community samples,All,Multiple groups,18.0,,Age,>=18,909,0.748,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,https://europepmc.org/article/PPR/PPR357490,2021-09-08,2024-03-01,Verified,misra_serological_2021,IND
210616_India_AllIndiaInstituteOfMedicalSciences_DelhiRural2,210616_India_AllIndiaInstituteOfMedicalSciences_2DelhiRural,Serological prevalence of SARS-CoV-2 antibody among children and young age (between age 2-17 years) group in India: An interim result from a large multi-centric population-based seroepidemiological study,2021-06-16,Preprint,Local,Prospective cohort,India,"Haryana
","Faridabad
",In each site both urban and rural area population have been planned to be included. ,,2021-04-12,2021-05-22,Household and community samples,All,Multiple groups,,,Primary Estimate,,1059,0.593,,,True,,,,True,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,https://europepmc.org/article/PPR/PPR357490,2021-06-22,2024-03-01,Verified,misra_serological_2021,IND
210616_India_AllIndiaInstituteOfMedicalSciences_DelhiRural2_>=18years,210616_India_AllIndiaInstituteOfMedicalSciences_2DelhiRural,Serological prevalence of SARS-CoV-2 antibody among children and young age (between age 2-17 years) group in India: An interim result from a large multi-centric population-based seroepidemiological study,2021-06-16,Preprint,Local,Prospective cohort,India,"Haryana
","Faridabad
",In each site both urban and rural area population have been planned to be included. ,,2021-04-12,2021-05-22,Household and community samples,All,Multiple groups,18.0,,Age,>=18,870,0.588,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,https://europepmc.org/article/PPR/PPR357490,2021-09-08,2024-03-01,Verified,misra_serological_2021,IND
210616_India_AllIndiaInstituteOfMedicalSciences_DelhiRural2_<18years,210616_India_AllIndiaInstituteOfMedicalSciences_2DelhiRural,Serological prevalence of SARS-CoV-2 antibody among children and young age (between age 2-17 years) group in India: An interim result from a large multi-centric population-based seroepidemiological study,2021-06-16,Preprint,Local,Prospective cohort,India,"Haryana
","Faridabad
",In each site both urban and rural area population have been planned to be included. ,,2021-04-12,2021-05-22,Household and community samples,All,Children and Youth (0-17 years),1.0,17.0,Age,<18,189,0.614,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,https://europepmc.org/article/PPR/PPR357490,2021-09-08,2024-03-01,Verified,misra_serological_2021,IND
210616_India_AllIndiaInstituteOfMedicalSciences_Bhubaneswar3,210616_India_AllIndiaInstituteOfMedicalSciences_3Bhubaneswar,Serological prevalence of SARS-CoV-2 antibody among children and young age (between age 2-17 years) group in India: An interim result from a large multi-centric population-based seroepidemiological study,2021-06-16,Preprint,Local,Prospective cohort,India,Odisha,Bhubaneswar,In each site both urban and rural area population have been planned to be included. ,,2021-03-22,2021-05-07,Household and community samples,All,Multiple groups,,,Primary Estimate,,1000,0.526,,,True,,,,True,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,https://europepmc.org/article/PPR/PPR357490,2021-06-22,2024-03-01,Verified,misra_serological_2021,IND
210616_India_AllIndiaInstituteOfMedicalSciences_Bhubaneswar3_>=18years,210616_India_AllIndiaInstituteOfMedicalSciences_3Bhubaneswar,Serological prevalence of SARS-CoV-2 antibody among children and young age (between age 2-17 years) group in India: An interim result from a large multi-centric population-based seroepidemiological study,2021-06-16,Preprint,Local,Prospective cohort,India,Odisha,Bhubaneswar,In each site both urban and rural area population have been planned to be included. ,,2021-03-22,2021-05-07,Household and community samples,All,Multiple groups,18.0,,Age,>=18,835,0.54,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,https://europepmc.org/article/PPR/PPR357490,2021-09-08,2024-03-01,Verified,misra_serological_2021,IND
210616_India_AllIndiaInstituteOfMedicalSciences_Bhubaneswar3_<18years,210616_India_AllIndiaInstituteOfMedicalSciences_3Bhubaneswar,Serological prevalence of SARS-CoV-2 antibody among children and young age (between age 2-17 years) group in India: An interim result from a large multi-centric population-based seroepidemiological study,2021-06-16,Preprint,Local,Prospective cohort,India,Odisha,Bhubaneswar,In each site both urban and rural area population have been planned to be included. ,,2021-03-22,2021-05-07,Household and community samples,All,Children and Youth (0-17 years),1.0,17.0,Age,<18,165,0.454,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,https://europepmc.org/article/PPR/PPR357490,2021-09-08,2024-03-01,Verified,misra_serological_2021,IND
210616_India_AllIndiaInstituteOfMedicalSciences_Gorakhpur4,210616_India_AllIndiaInstituteOfMedicalSciences_4Gorakhpur,Serological prevalence of SARS-CoV-2 antibody among children and young age (between age 2-17 years) group in India: An interim result from a large multi-centric population-based seroepidemiological study,2021-06-16,Preprint,Local,Prospective cohort,India,Uttar Pradesh,Gorakhpur,In each site both urban and rural area population have been planned to be included. ,,2021-04-22,2021-06-10,Household and community samples,All,Multiple groups,,,Primary Estimate,,448,0.8790000000000001,,,True,,,,True,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,https://europepmc.org/article/PPR/PPR357490,2021-06-22,2024-03-01,Verified,misra_serological_2021,IND
210616_India_AllIndiaInstituteOfMedicalSciences_Gorakhpur4_>=18years,210616_India_AllIndiaInstituteOfMedicalSciences_4Gorakhpur,Serological prevalence of SARS-CoV-2 antibody among children and young age (between age 2-17 years) group in India: An interim result from a large multi-centric population-based seroepidemiological study,2021-06-16,Preprint,Local,Prospective cohort,India,Uttar Pradesh,Gorakhpur,In each site both urban and rural area population have been planned to be included. ,,2021-04-22,2021-06-10,Household and community samples,All,Multiple groups,18.0,,Age,>=18,340,0.903,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,https://europepmc.org/article/PPR/PPR357490,2021-09-08,2024-03-01,Verified,misra_serological_2021,IND
210616_India_AllIndiaInstituteOfMedicalSciences_Gorakhpur4_<18years,210616_India_AllIndiaInstituteOfMedicalSciences_4Gorakhpur,Serological prevalence of SARS-CoV-2 antibody among children and young age (between age 2-17 years) group in India: An interim result from a large multi-centric population-based seroepidemiological study,2021-06-16,Preprint,Local,Prospective cohort,India,Uttar Pradesh,Gorakhpur,In each site both urban and rural area population have been planned to be included. ,,2021-04-22,2021-06-10,Household and community samples,All,Children and Youth (0-17 years),1.0,17.0,Age,<18,108,0.8059999999999999,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,https://europepmc.org/article/PPR/PPR357490,2021-09-08,2024-03-01,Verified,misra_serological_2021,IND
210616_India_AllIndiaInstituteOfMedicalSciences_Agartala5,210616_India_AllIndiaInstituteOfMedicalSciences_5Agartala,Serological prevalence of SARS-CoV-2 antibody among children and young age (between age 2-17 years) group in India: An interim result from a large multi-centric population-based seroepidemiological study,2021-06-16,Preprint,Local,Prospective cohort,India,Tripura,Agartala,In each site both urban and rural area population have been planned to be included. ,,2021-03-26,2021-06-01,Household and community samples,All,Multiple groups,,,Primary Estimate,,1001,0.519,,,True,,,,True,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,https://europepmc.org/article/PPR/PPR357490,2021-06-22,2024-03-01,Verified,misra_serological_2021,IND
210616_India_AllIndiaInstituteOfMedicalSciences_Agartala5_>=18years,210616_India_AllIndiaInstituteOfMedicalSciences_5Agartala,Serological prevalence of SARS-CoV-2 antibody among children and young age (between age 2-17 years) group in India: An interim result from a large multi-centric population-based seroepidemiological study,2021-06-16,Preprint,Local,Prospective cohort,India,Tripura,Agartala,In each site both urban and rural area population have been planned to be included. ,,2021-03-26,2021-06-01,Household and community samples,All,Multiple groups,18.0,,Age,>=18,855,0.556,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,https://europepmc.org/article/PPR/PPR357490,2021-09-08,2024-03-01,Verified,misra_serological_2021,IND
210616_India_AllIndiaInstituteOfMedicalSciences_Agartala5_<18years,210616_India_AllIndiaInstituteOfMedicalSciences_5Agartala,Serological prevalence of SARS-CoV-2 antibody among children and young age (between age 2-17 years) group in India: An interim result from a large multi-centric population-based seroepidemiological study,2021-06-16,Preprint,Local,Prospective cohort,India,Tripura,Agartala,In each site both urban and rural area population have been planned to be included. ,,2021-03-26,2021-06-01,Household and community samples,All,Children and Youth (0-17 years),1.0,17.0,Age,<18,146,0.308,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,https://europepmc.org/article/PPR/PPR357490,2021-09-08,2024-03-01,Verified,misra_serological_2021,IND
210620_Delhi_AllIndiaInstituteOfMedicalScience,210620_Delhi_AllIndiaInstituteOfMedicalScience,Seroprevalence of COVID-19 in HIV Population,2021-06-20,Preprint,Local,Cross-sectional survey ,India,,New Delhi,"PLHA visiting the centre, aged between 18 years and above at the time of recruitment, were eligible to participate",Patients presenting with features suggestive of COVID-19 disease; were excluded,2020-09-01,2020-11-30,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,,Primary Estimate,,164,0.14,0.091,0.203,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9400000000000001,1.0,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Shivdas Rajaram Naik,All India Institute Of Medical Science,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.06.17.21259066v1.full-text,2021-06-30,2024-03-01,Verified,naik_seroprevalence_2021,IND
210701_India_IndianCouncilOfMedicalResearch_HCWs_TestPopAdj,210701_Dummy_India_IndianCouncilOfMedicalResearch_HCWs,"SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020-January 2021",2021-07-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,"Two to three subdistrict-level public health facilities (e.g.,
‘taluk’ or subdivisional hospital, community or primary health
centre) closest to the selected cluster/s for the household survey
were selected from each of the 70 districts identified for the
general population survey. All consenting individuals working in
these facilities were included to ensure participation of

100 HCWs from each district.",,2020-12-18,2021-01-06,Health care workers and caregivers,All,Multiple groups,10.0,,Primary Estimate,,7385,0.256,0.23500000000000001,0.278,True,True,True,,,Stratified probability,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Serum,IgG,Spike,Validated by manufacturers,1.0,0.9990000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Manoj V Murhekar,Indian Council of Medical Research,Not Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.05.040,2021-09-13,2023-08-15,Verified,murhekar_sars-cov-2_2021,IND
210701_India_IndianCouncilOfMedicalResearch_HCWs_Age18-44,210701_Dummy_India_IndianCouncilOfMedicalResearch_HCWs,"SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020-January 2021",2021-07-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,"Two to three subdistrict-level public health facilities (e.g.,
‘taluk’ or subdivisional hospital, community or primary health
centre) closest to the selected cluster/s for the household survey
were selected from each of the 70 districts identified for the
general population survey. All consenting individuals working in
these facilities were included to ensure participation of

100 HCWs from each district.",,2020-12-18,2021-01-06,Health care workers and caregivers,All,Adults (18-64 years),18.0,44.0,Age,18-44,5351,0.24,0.219,0.263,,True,True,,,Stratified probability,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Serum,IgG,Spike,Validated by manufacturers,1.0,0.9990000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Manoj V Murhekar,Indian Council of Medical Research,Not Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.05.040,2021-09-13,2023-08-15,Verified,murhekar_sars-cov-2_2021,IND
210701_India_IndianCouncilOfMedicalResearch_HCWs_Age45-60,210701_Dummy_India_IndianCouncilOfMedicalResearch_HCWs,"SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020-January 2021",2021-07-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,"Two to three subdistrict-level public health facilities (e.g.,
‘taluk’ or subdivisional hospital, community or primary health
centre) closest to the selected cluster/s for the household survey
were selected from each of the 70 districts identified for the
general population survey. All consenting individuals working in
these facilities were included to ensure participation of

100 HCWs from each district.",,2020-12-18,2021-01-06,Health care workers and caregivers,All,Adults (18-64 years),45.0,60.0,Age,45-60,1956,0.299,0.271,0.329,,True,True,,,Stratified probability,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Serum,IgG,Spike,Validated by manufacturers,1.0,0.9990000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Manoj V Murhekar,Indian Council of Medical Research,Not Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.05.040,2021-09-13,2023-08-15,Verified,murhekar_sars-cov-2_2021,IND
210701_India_IndianCouncilOfMedicalResearch_HCWs_Age60+,210701_Dummy_India_IndianCouncilOfMedicalResearch_HCWs,"SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020-January 2021",2021-07-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,"Two to three subdistrict-level public health facilities (e.g.,
‘taluk’ or subdivisional hospital, community or primary health
centre) closest to the selected cluster/s for the household survey
were selected from each of the 70 districts identified for the
general population survey. All consenting individuals working in
these facilities were included to ensure participation of

100 HCWs from each district.",,2020-12-18,2021-01-06,Health care workers and caregivers,All,Multiple groups,60.0,,Age,>60,78,0.21600000000000003,0.138,0.322,,True,True,,,Stratified probability,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Serum,IgG,Spike,Validated by manufacturers,1.0,0.9990000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Manoj V Murhekar,Indian Council of Medical Research,Not Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.05.040,2021-09-13,2023-08-15,Verified,murhekar_sars-cov-2_2021,IND
210701_India_IndianCouncilOfMedicalResearch_GenPop_TestPopAdj,210701_India_IndianCouncilOfMedicalResearch_GenPop,"SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020-January 2021",2021-07-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,"All household members aged 10 years and above who were
permanent resident of the area were enumerated and consenting individuals present at the time of visit of survey team were included in the survey.",No additional visits were made to include households which were locked or household members who were not present at the time of the first visit.,2020-12-18,2021-01-06,Household and community samples,All,Multiple groups,10.0,,Primary Estimate,,28598,0.24100000000000002,0.23,0.253,True,True,True,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Manoj V Murhekar,Indian Council of Medical Research,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.05.040,2021-09-13,2023-08-15,Verified,murhekar_sars-cov-2_2021,IND
210701_India_IndianCouncilOfMedicalResearch_GenPop_Age18-44,210701_India_IndianCouncilOfMedicalResearch_GenPop,"SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020-January 2021",2021-07-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,"All household members aged 10 years and above who were
permanent resident of the area were enumerated and consenting individuals present at the time of visit of survey team were included in the survey.",No additional visits were made to include households which were locked or household members who were not present at the time of the first visit.,2020-12-18,2021-01-06,Household and community samples,All,Adults (18-64 years),18.0,44.0,Age,18-44,16333,0.222,0.21100000000000002,0.23399999999999999,,True,True,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Manoj V Murhekar,Indian Council of Medical Research,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.05.040,2021-09-13,2023-08-15,Verified,murhekar_sars-cov-2_2021,IND
210701_India_IndianCouncilOfMedicalResearch_GenPop_Age10-17,210701_India_IndianCouncilOfMedicalResearch_GenPop,"SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020-January 2021",2021-07-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,"All household members aged 10 years and above who were
permanent resident of the area were enumerated and consenting individuals present at the time of visit of survey team were included in the survey.",No additional visits were made to include households which were locked or household members who were not present at the time of the first visit.,2020-12-18,2021-01-06,Household and community samples,All,Children and Youth (0-17 years),10.0,17.0,Age,10-17,2290,0.272,0.249,0.294,,True,True,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Manoj V Murhekar,Indian Council of Medical Research,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.05.040,2021-09-13,2023-08-15,Verified,murhekar_sars-cov-2_2021,IND
210701_India_IndianCouncilOfMedicalResearch_GenPop_PopAdj,210701_India_IndianCouncilOfMedicalResearch_GenPop,"SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020-January 2021",2021-07-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,"All household members aged 10 years and above who were
permanent resident of the area were enumerated and consenting individuals present at the time of visit of survey team were included in the survey.",No additional visits were made to include households which were locked or household members who were not present at the time of the first visit.,2020-12-18,2021-01-06,Household and community samples,All,Multiple groups,10.0,,Analysis,,28598,0.24600000000000002,0.23500000000000001,0.257,,,True,,True,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Manoj V Murhekar,Indian Council of Medical Research,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.05.040,2021-09-13,2024-03-01,Verified,murhekar_sars-cov-2_2021,IND
210701_India_IndianCouncilOfMedicalResearch_GenPop_Male,210701_India_IndianCouncilOfMedicalResearch_GenPop,"SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020-January 2021",2021-07-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,"All household members aged 10 years and above who were
permanent resident of the area were enumerated and consenting individuals present at the time of visit of survey team were included in the survey.",No additional visits were made to include households which were locked or household members who were not present at the time of the first visit.,2020-12-18,2021-01-06,Household and community samples,Male,Multiple groups,10.0,,Sex/Gender,,13817,0.23199999999999998,0.22100000000000003,0.245,,True,True,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Manoj V Murhekar,Indian Council of Medical Research,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.05.040,2021-09-13,2023-08-15,Verified,murhekar_sars-cov-2_2021,IND
210701_India_IndianCouncilOfMedicalResearch_GenPop_Age45-60,210701_India_IndianCouncilOfMedicalResearch_GenPop,"SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020-January 2021",2021-07-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,"All household members aged 10 years and above who were
permanent resident of the area were enumerated and consenting individuals present at the time of visit of survey team were included in the survey.",No additional visits were made to include households which were locked or household members who were not present at the time of the first visit.,2020-12-18,2021-01-06,Household and community samples,All,Adults (18-64 years),45.0,60.0,Age,45-60,6938,0.267,0.252,0.282,,True,True,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Manoj V Murhekar,Indian Council of Medical Research,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.05.040,2021-09-13,2023-08-15,Verified,murhekar_sars-cov-2_2021,IND
210701_India_IndianCouncilOfMedicalResearch_GenPop_Female,210701_India_IndianCouncilOfMedicalResearch_GenPop,"SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020-January 2021",2021-07-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,"All household members aged 10 years and above who were
permanent resident of the area were enumerated and consenting individuals present at the time of visit of survey team were included in the survey.",No additional visits were made to include households which were locked or household members who were not present at the time of the first visit.,2020-12-18,2021-01-06,Household and community samples,Female,Multiple groups,10.0,,Sex/Gender,,14763,0.249,0.237,0.263,,True,True,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Manoj V Murhekar,Indian Council of Medical Research,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.05.040,2021-09-13,2023-08-15,Verified,murhekar_sars-cov-2_2021,IND
210701_India_IndianCouncilOfMedicalResearch_GenPop_Age60+,210701_India_IndianCouncilOfMedicalResearch_GenPop,"SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020-January 2021",2021-07-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,"All household members aged 10 years and above who were
permanent resident of the area were enumerated and consenting individuals present at the time of visit of survey team were included in the survey.",No additional visits were made to include households which were locked or household members who were not present at the time of the first visit.,2020-12-18,2021-01-06,Household and community samples,All,Multiple groups,60.0,,Age,>60,3037,0.263,0.24300000000000002,0.28300000000000003,,True,True,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Manoj V Murhekar,Indian Council of Medical Research,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.05.040,2021-09-13,2023-08-15,Verified,murhekar_sars-cov-2_2021,IND
210701_Kerala_ JubileeMissionMedicalCollegeandResearchInstitute_primary,210701_Kerala_ JubileeMissionMedicalCollegeandResearchInstitute,"Serosurveillance of SARS-CoV-2 among the healthcare workers of a tertiary care teaching institution during the post lockdown phase in Central Kerala, India",2021-07-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Kerala,"All categories of staff
working in the hospital and medical college ",,2020-12-20,2020-12-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,423,0.08750000000000001,0.06230000000000001,0.1186,True,,,,True,Stratified non-probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,1.0,['High'],,No,No,Yes,,Yes,Yes,Yes,,Aboobacker Mohamed Rafi, Jubilee Mission Medical College and Research Institute,Not Unity-Aligned,https://www.jcdr.net/articles/PDF/15154/48703_CE[Ra1]_F(SL)_PF1(AG_OM)_PFA(KM_AnK)%20PB(AG_AnK)_PN(KM).pdf,2021-08-12,2024-03-01,Unverified,aboobacker_mohamed_rafi_serosurveillance_nodate,IND
210702_Jaipur_AllIndiaInstituteOfMedicalSciences_2,210702_Jaipur_AllIndiaInstituteOfMedicalSciences_2,"COVID-19 seropositivity among non-medical frontline office staff from two cities in Rajasthan, India.",2021-07-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Rajasthan,Jaipur,"Asymptomatic individuals who were willing to provide 3–5 ml 
venous blood after informed written consent were included in 
the study",,2020-08-04,2020-08-04,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,41,0.13640000000000002,,,True,,,,True,Unclear,COVID KAVACH (KAWACH) IgG Microlisa (Microwell ELISA),J. Mitra & Co. Pvt. Ltd,ELISA,Serum,IgG,,,,,['High'],,Unclear,No,No,,Yes,Yes,Yes,,Vidhi Jain,All India Institute Of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2381_20,2021-08-04,2024-03-01,Unverified,jainvidhiCOVID19SeropositivityNonmedical2021,IND
210702_Jodhpur_AllIndiaInstituteOfMedicalSciences_1,210702_Jodhpur_AllIndiaInstituteOfMedicalSciences_1,"COVID-19 seropositivity among non-medical frontline office staff from two cities in Rajasthan, India.",2021-07-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Rajasthan,Jodhpur,"Asymptomatic individuals who were willing to provide 3–5 ml 
venous blood after informed written consent were included in 
the study",,2020-07-28,2020-07-28,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,22,0.0244,,,True,,,,True,Unclear,COVID KAVACH (KAWACH) IgG Microlisa (Microwell ELISA),J. Mitra & Co. Pvt. Ltd,ELISA,Serum,IgG,,,,,['High'],,Unclear,No,No,,Yes,Yes,Yes,,Vidhi Jain,All India Institute Of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2381_20,2021-08-04,2024-03-01,Unverified,jainvidhiCOVID19SeropositivityNonmedical2021,IND
210702_Ahmedabad_AMC-MET-MedicalCollege_Primary,210702_Ahmedabad_AMC-MET-MedicalCollege,Population-based seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city.,2021-07-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,Population was selected from the field area of each Urban Primary Health Centres (UPHC) - 75 UPHCs within 48 wards across 7 zones in Ahmedabad city. Participants had to give informed written consent.,The only exclusion criteria included any contraindication to venipuncture. ,2020-08-15,2020-08-31,Household and community samples,All,Multiple groups,2.0,99.0,Primary Estimate,,10310,0.2324,0.2243,0.24059999999999998,True,,,,True,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Om Prakash,AMC MET Medical College,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2062_20,2021-08-04,2024-03-01,Verified,prakashomPopulationbasedSeropositivityIgG2021,IND
210702_Ahmedabad_AMC-MET-MedicalCollege_40-49,210702_Ahmedabad_AMC-MET-MedicalCollege,Population-based seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city.,2021-07-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,Population was selected from the field area of each Urban Primary Health Centres (UPHC) - 75 UPHCs within 48 wards across 7 zones in Ahmedabad city. Participants had to give informed written consent.,The only exclusion criteria included any contraindication to venipuncture. ,2020-08-15,2020-08-31,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,1758,0.2281,0.2091,0.2483,,,,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Om Prakash,AMC MET Medical College,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2062_20,2021-08-04,2024-03-01,Verified,prakashomPopulationbasedSeropositivityIgG2021,IND
210702_Ahmedabad_AMC-MET-MedicalCollege_80-89,210702_Ahmedabad_AMC-MET-MedicalCollege,Population-based seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city.,2021-07-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,Population was selected from the field area of each Urban Primary Health Centres (UPHC) - 75 UPHCs within 48 wards across 7 zones in Ahmedabad city. Participants had to give informed written consent.,The only exclusion criteria included any contraindication to venipuncture. ,2020-08-15,2020-08-31,Household and community samples,All,Seniors (65+ years),80.0,89.0,Age,80-89,43,0.25579999999999997,0.1352,0.4117,,,,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Om Prakash,AMC MET Medical College,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2062_20,2021-08-04,2024-03-01,Verified,prakashomPopulationbasedSeropositivityIgG2021,IND
210702_Ahmedabad_AMC-MET-MedicalCollege_30-39,210702_Ahmedabad_AMC-MET-MedicalCollege,Population-based seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city.,2021-07-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,Population was selected from the field area of each Urban Primary Health Centres (UPHC) - 75 UPHCs within 48 wards across 7 zones in Ahmedabad city. Participants had to give informed written consent.,The only exclusion criteria included any contraindication to venipuncture. ,2020-08-15,2020-08-31,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,2437,0.2052,0.18960000000000002,0.2217,,,,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Om Prakash,AMC MET Medical College,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2062_20,2021-08-04,2024-03-01,Verified,prakashomPopulationbasedSeropositivityIgG2021,IND
210702_Ahmedabad_AMC-MET-MedicalCollege_10-19,210702_Ahmedabad_AMC-MET-MedicalCollege,Population-based seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city.,2021-07-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,Population was selected from the field area of each Urban Primary Health Centres (UPHC) - 75 UPHCs within 48 wards across 7 zones in Ahmedabad city. Participants had to give informed written consent.,The only exclusion criteria included any contraindication to venipuncture. ,2020-08-15,2020-08-31,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,738,0.2588,0.2285,0.2916,,,,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Om Prakash,AMC MET Medical College,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2062_20,2021-08-04,2024-03-01,Verified,prakashomPopulationbasedSeropositivityIgG2021,IND
210702_Ahmedabad_AMC-MET-MedicalCollege_Male,210702_Ahmedabad_AMC-MET-MedicalCollege,Population-based seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city.,2021-07-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,Population was selected from the field area of each Urban Primary Health Centres (UPHC) - 75 UPHCs within 48 wards across 7 zones in Ahmedabad city. Participants had to give informed written consent.,The only exclusion criteria included any contraindication to venipuncture. ,2020-08-15,2020-08-31,Household and community samples,Male,Multiple groups,2.0,99.0,Sex/Gender,,6168,0.2181,,,,,,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Om Prakash,AMC MET Medical College,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2062_20,2021-08-04,2024-03-01,Verified,prakashomPopulationbasedSeropositivityIgG2021,IND
210702_Ahmedabad_AMC-MET-MedicalCollege_0-9,210702_Ahmedabad_AMC-MET-MedicalCollege,Population-based seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city.,2021-07-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,Population was selected from the field area of each Urban Primary Health Centres (UPHC) - 75 UPHCs within 48 wards across 7 zones in Ahmedabad city. Participants had to give informed written consent.,The only exclusion criteria included any contraindication to venipuncture. ,2020-08-15,2020-08-31,Household and community samples,All,Children and Youth (0-17 years),0.0,9.0,Age,0-9,67,0.19399999999999998,0.1076,0.3089,,,,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Om Prakash,AMC MET Medical College,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2062_20,2021-08-04,2024-03-01,Verified,prakashomPopulationbasedSeropositivityIgG2021,IND
210702_Ahmedabad_AMC-MET-MedicalCollege_20-29,210702_Ahmedabad_AMC-MET-MedicalCollege,Population-based seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city.,2021-07-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,Population was selected from the field area of each Urban Primary Health Centres (UPHC) - 75 UPHCs within 48 wards across 7 zones in Ahmedabad city. Participants had to give informed written consent.,The only exclusion criteria included any contraindication to venipuncture. ,2020-08-15,2020-08-31,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,3024,0.2004,0.1865,0.215,,,,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Om Prakash,AMC MET Medical College,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2062_20,2021-08-04,2024-03-01,Verified,prakashomPopulationbasedSeropositivityIgG2021,IND
210702_Ahmedabad_AMC-MET-MedicalCollege_90-99,210702_Ahmedabad_AMC-MET-MedicalCollege,Population-based seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city.,2021-07-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,Population was selected from the field area of each Urban Primary Health Centres (UPHC) - 75 UPHCs within 48 wards across 7 zones in Ahmedabad city. Participants had to give informed written consent.,The only exclusion criteria included any contraindication to venipuncture. ,2020-08-15,2020-08-31,Household and community samples,All,Seniors (65+ years),90.0,99.0,Age,90-99,4,0.25,0.0063,0.8059000000000001,,,,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Om Prakash,AMC MET Medical College,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2062_20,2021-08-04,2024-03-01,Verified,prakashomPopulationbasedSeropositivityIgG2021,IND
210702_Ahmedabad_AMC-MET-lMedicalCollege_70-79,210702_Ahmedabad_AMC-MET-MedicalCollege,Population-based seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city.,2021-07-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,Population was selected from the field area of each Urban Primary Health Centres (UPHC) - 75 UPHCs within 48 wards across 7 zones in Ahmedabad city. Participants had to give informed written consent.,The only exclusion criteria included any contraindication to venipuncture. ,2020-08-15,2020-08-31,Household and community samples,All,Seniors (65+ years),70.0,79.0,Age,70-79,249,0.34140000000000004,0.2827,0.40390000000000004,,,,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Om Prakash,AMC MET Medical College,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2062_20,2021-08-04,2024-03-01,Verified,prakashomPopulationbasedSeropositivityIgG2021,IND
210702_Ahmedabad_AMC-MET-MedicalCollege_Female,210702_Ahmedabad_AMC-MET-MedicalCollege,Population-based seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city.,2021-07-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,Population was selected from the field area of each Urban Primary Health Centres (UPHC) - 75 UPHCs within 48 wards across 7 zones in Ahmedabad city. Participants had to give informed written consent.,The only exclusion criteria included any contraindication to venipuncture. ,2020-08-15,2020-08-31,Household and community samples,Female,Multiple groups,2.0,99.0,Sex/Gender,,4142,0.25370000000000004,,,,,,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Om Prakash,AMC MET Medical College,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2062_20,2021-08-04,2024-03-01,Verified,prakashomPopulationbasedSeropositivityIgG2021,IND
210702_Ahmedabad_AMC-MET-MedicalCollege_60-69,210702_Ahmedabad_AMC-MET-MedicalCollege,Population-based seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city.,2021-07-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,Population was selected from the field area of each Urban Primary Health Centres (UPHC) - 75 UPHCs within 48 wards across 7 zones in Ahmedabad city. Participants had to give informed written consent.,The only exclusion criteria included any contraindication to venipuncture. ,2020-08-15,2020-08-31,Household and community samples,All,Multiple groups,60.0,69.0,Age,60-69,727,0.32189999999999996,0.2889,0.3567,,,,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Om Prakash,AMC MET Medical College,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2062_20,2021-08-04,2024-03-01,Verified,prakashomPopulationbasedSeropositivityIgG2021,IND
210702_Ahmedabad_AMC-MET-MedicalCollege_50-59,210702_Ahmedabad_AMC-MET-MedicalCollege,Population-based seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city.,2021-07-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,Population was selected from the field area of each Urban Primary Health Centres (UPHC) - 75 UPHCs within 48 wards across 7 zones in Ahmedabad city. Participants had to give informed written consent.,The only exclusion criteria included any contraindication to venipuncture. ,2020-08-15,2020-08-31,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,1263,0.2803,0.25620000000000004,0.3057,,,,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Om Prakash,AMC MET Medical College,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2062_20,2021-08-04,2024-03-01,Verified,prakashomPopulationbasedSeropositivityIgG2021,IND
210710_SouthIndia_AravindEyeHospital_Primary,210710_SouthIndia_AravindEyeHospital,Seroprevalence of SARS-CoV-2 specific IgG antibodies among eye care workers in South India.,2021-07-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,South India,,"The participants included all employees above 40 years including the leadership team, Medical consultant, mid-level ophthalmic assistants (MLOPs), administrative and support staff who were actively participating in the day-today management of the hospital.",,2020-08-19,2020-08-28,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,1313,0.158,,,True,,,,True,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by developers,0.9209999999999999,0.997,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Rajapandian Karthikeyan,Aravind Eye Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2021.06.014,2021-07-19,2024-03-01,Unverified,karthikeyan_seroprevalence_2021,IND
210710_SouthIndia_AravindEyeHospital_20minus,210710_SouthIndia_AravindEyeHospital,Seroprevalence of SARS-CoV-2 specific IgG antibodies among eye care workers in South India.,2021-07-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,South India,,"The participants included all employees above 40 years including the leadership team, Medical consultant, mid-level ophthalmic assistants (MLOPs), administrative and support staff who were actively participating in the day-today management of the hospital.",,2020-08-19,2020-08-28,Health care workers and caregivers,All,Multiple groups,,,Age,<20 ,1313,0.158,,,,,,,,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by developers,0.9209999999999999,0.997,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Rajapandian Karthikeyan,Aravind Eye Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2021.06.014,2021-07-19,2024-03-01,Unverified,karthikeyan_seroprevalence_2021,IND
210710_SouthIndia_AravindEyeHospital_5160,210710_SouthIndia_AravindEyeHospital,Seroprevalence of SARS-CoV-2 specific IgG antibodies among eye care workers in South India.,2021-07-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,South India,,"The participants included all employees above 40 years including the leadership team, Medical consultant, mid-level ophthalmic assistants (MLOPs), administrative and support staff who were actively participating in the day-today management of the hospital.",,2020-08-19,2020-08-28,Health care workers and caregivers,All,Multiple groups,,,Age,51-60,1313,0.158,,,,,,,,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by developers,0.9209999999999999,0.997,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Rajapandian Karthikeyan,Aravind Eye Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2021.06.014,2021-07-19,2024-03-01,Unverified,karthikeyan_seroprevalence_2021,IND
210710_SouthIndia_AravindEyeHospital_3140,210710_SouthIndia_AravindEyeHospital,Seroprevalence of SARS-CoV-2 specific IgG antibodies among eye care workers in South India.,2021-07-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,South India,,"The participants included all employees above 40 years including the leadership team, Medical consultant, mid-level ophthalmic assistants (MLOPs), administrative and support staff who were actively participating in the day-today management of the hospital.",,2020-08-19,2020-08-28,Health care workers and caregivers,All,Multiple groups,,,Age,31-40,1313,0.158,,,,,,,,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by developers,0.9209999999999999,0.997,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Rajapandian Karthikeyan,Aravind Eye Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2021.06.014,2021-07-19,2024-03-01,Unverified,karthikeyan_seroprevalence_2021,IND
210710_SouthIndia_AravindEyeHospital_2130,210710_SouthIndia_AravindEyeHospital,Seroprevalence of SARS-CoV-2 specific IgG antibodies among eye care workers in South India.,2021-07-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,South India,,"The participants included all employees above 40 years including the leadership team, Medical consultant, mid-level ophthalmic assistants (MLOPs), administrative and support staff who were actively participating in the day-today management of the hospital.",,2020-08-19,2020-08-28,Health care workers and caregivers,All,Multiple groups,,,Age,21-30,1313,0.158,,,,,,,,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by developers,0.9209999999999999,0.997,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Rajapandian Karthikeyan,Aravind Eye Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2021.06.014,2021-07-19,2024-03-01,Unverified,karthikeyan_seroprevalence_2021,IND
210710_SouthIndia_AravindEyeHospital_4150,210710_SouthIndia_AravindEyeHospital,Seroprevalence of SARS-CoV-2 specific IgG antibodies among eye care workers in South India.,2021-07-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,South India,,"The participants included all employees above 40 years including the leadership team, Medical consultant, mid-level ophthalmic assistants (MLOPs), administrative and support staff who were actively participating in the day-today management of the hospital.",,2020-08-19,2020-08-28,Health care workers and caregivers,All,Multiple groups,,,Age,41-50,1313,0.158,,,,,,,,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by developers,0.9209999999999999,0.997,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Rajapandian Karthikeyan,Aravind Eye Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2021.06.014,2021-07-19,2024-03-01,Unverified,karthikeyan_seroprevalence_2021,IND
210710_SouthIndia_AravindEyeHospital_60plus,210710_SouthIndia_AravindEyeHospital,Seroprevalence of SARS-CoV-2 specific IgG antibodies among eye care workers in South India.,2021-07-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,South India,,"The participants included all employees above 40 years including the leadership team, Medical consultant, mid-level ophthalmic assistants (MLOPs), administrative and support staff who were actively participating in the day-today management of the hospital.",,2020-08-19,2020-08-28,Health care workers and caregivers,All,Multiple groups,,,Age,>60,1313,0.158,,,,,,,,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by developers,0.9209999999999999,0.997,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Rajapandian Karthikeyan,Aravind Eye Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2021.06.014,2021-07-19,2024-03-01,Unverified,karthikeyan_seroprevalence_2021,IND
210721_India_IndianCouncilOfMedicalResearch_genpop_overall,210721_India_IndianCouncilOfMedicalResearch,Antibodies in 68% Indians,2021-07-21,News and Media,National,Cross-sectional survey ,India,,,General population over the age of 6,"NR
",2021-06-20,2021-07-10,Household and community samples,All,Multiple groups,6.0,,Primary Estimate,,28975,0.6759999999999999,,,True,,,,True,Simplified probability,Not reported/ Unable to specify,,,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,Rhythma Kaul,Indian Council of Medical Research,Not Unity-Aligned,https://www.hindustantimes.com/india-news/antibodies-in-68-indians-101626804217418.html,2021-07-26,2022-07-16,Verified,kaul_antibodies_2021,IND
210721_India_IndianCouncilOfMedicalResearch_genpop_onedose,210721_India_IndianCouncilOfMedicalResearch,Antibodies in 68% Indians,2021-07-21,News and Media,National,Cross-sectional survey ,India,,,General population over the age of 6,"NR
",2021-06-20,2021-07-10,Household and community samples,All,Multiple groups,6.0,,COVID-19 vaccination status,One dose,5038,0.81,,,,,,,,Simplified probability,Not reported/ Unable to specify,,,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,Rhythma Kaul,Indian Council of Medical Research,Not Unity-Aligned,https://www.hindustantimes.com/india-news/antibodies-in-68-indians-101626804217418.html,2021-07-26,2022-07-16,Verified,kaul_antibodies_2021,IND
210721_India_IndianCouncilOfMedicalResearch_genpop_twodoses,210721_India_IndianCouncilOfMedicalResearch,Antibodies in 68% Indians,2021-07-21,News and Media,National,Cross-sectional survey ,India,,,General population over the age of 6,"NR
",2021-06-20,2021-07-10,Household and community samples,All,Multiple groups,6.0,,COVID-19 vaccination status,Two doses,2631,0.9,,,,,,,,Simplified probability,Not reported/ Unable to specify,,,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,Rhythma Kaul,Indian Council of Medical Research,Not Unity-Aligned,https://www.hindustantimes.com/india-news/antibodies-in-68-indians-101626804217418.html,2021-07-26,2022-07-16,Verified,kaul_antibodies_2021,IND
210721_India_IndianCouncilOfMedicalResearch_genpop_unvaccinated,210721_India_IndianCouncilOfMedicalResearch,Antibodies in 68% Indians,2021-07-21,News and Media,National,Cross-sectional survey ,India,,,General population over the age of 6,"NR
",2021-06-20,2021-07-10,Household and community samples,All,Multiple groups,6.0,,COVID-19 vaccination status,Vaccinated no,12607,0.623,,,,,,,,Simplified probability,Not reported/ Unable to specify,,,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,Rhythma Kaul,Indian Council of Medical Research,Not Unity-Aligned,https://www.hindustantimes.com/india-news/antibodies-in-68-indians-101626804217418.html,2021-07-26,2022-07-16,Verified,kaul_antibodies_2021,IND
210722_Kerala_GovernmentMedicalCollegeThiruvananthapuram_TestAdj,210722_Kerala_GovernmentMedicalCollegeThiruvananthapuram,Prevalence of SARS CoV-2 infection among Health Care Workers of a hybrid tertiary COVID 19 hospital in Kerala,2021-07-22,Preprint,Local,Cross-sectional survey ,India,Kerala,Thiruvananthapuram,"From 3550 HCWs at GMCT, 979 HCW were selected by stratified random sampling. Risk categorization into high-risk and low risk was done based on job setting. High risk group HCWs was defined as those involved in direct care of patients with COVID 19 and low risk group included HCWs working in non-COVID pool. ","HCWs who were not willing to participate were excluded from
the study.",2021-01-08,2021-01-19,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,940,0.212,,,True,True,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,,Validated by manufacturers,0.9,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,S J Jessy,Government Medical College Thiruvananthapuram,Not Unity-Aligned,10.1101/2021.07.19.21260792,2021-07-29,2023-08-15,Unverified,jessy_prevalence_2021,IND
210722_Kolkata_IndianStatisticalInstitute_Primary,210722_Kolkata_IndianStatisticalInstitute,Seroprevalence and Dynamics of anti-SARS-CoV-2 antibody among healthcare workers following ChAdOx1 nCoV-19 vaccination,2021-07-22,Preprint,Local,Cross-sectional survey ,India,West Bengal,Kolkata,Health care workers at a tertiary care hospital in Kolkata (Nilratan Sircar Medical College & Hospital),Participants with symptoms suggestive of recent infection or positive RT-PCR test result within last 14 days were excluded from the study.,2020-11-15,2021-01-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Total Ab,313,0.4,,,True,,,,True,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,,,,['Moderate'],No,Yes,No,Yes,Yes,Yes,Yes,Yes,No,Soma Sarkar,Indian Statistical Institute,Not Unity-Aligned,10.1101/2021.07.20.21260278,2021-07-28,2024-03-01,Verified,sarkar_seroprevalence_2021,IND
210726_India_ArmedForcesMedicalCollege,210726_India_ArmedForcesMedicalCollege,"Seropositivity of severe acute respiratory syndrome coronavirus 2 infection among healthcare workers of the Armed Forces medical services, India: A multicentric study.",2021-07-26,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,"Jaipur, Pune, Ahmedabad, Kolkata, Delhi, Jammu, Mumbai, Bangalore","All HCWs in the selected hospital
were included in the study.",,2020-08-21,2020-11-20,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,3253,0.197,0.185,0.217,True,,,,True,Simplified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Multiple Types,IgG,,,0.924,0.9790000000000001,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Subhadeep Ghosh,Armed Forces Medical College,Not Unity-Aligned,https://dx.doi.org/10.1016/j.mjafi.2021.03.020,2021-08-12,2024-03-01,Unverified,ghoshSeropositivitySevereAcute2021,IND
210721_Pune_ArmedForcesMedicalCollege,210721_Pune_ArmedForcesMedicalCollege,Estimating the proportion and IgG antibody response to SARS-CoV-2 in individuals joining a central educational institute from different parts of India by Enzyme-linked immunosorbent assay (ELISA) based serology.,2021-07-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Pune,"The study population included all personnel reporting to the institute for training courses, permanent posting or joining back from leave during the study period of 2 months (16 June to 16 August 2020).",Exclusion criteria-Any personnel reported for a short visit of lesser than 14 days.,2020-06-16,2020-08-16,Non-essential workers and unemployed persons,All,Adults (18-64 years),21.0,53.0,Primary Estimate,overall,413,0.075,0.053,0.10400000000000001,True,,,,True,Convenience,ErbaLisa COVID-19 IgG ELISA Kit,Calbiotech Inc.,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.98,0.99,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Sourav Sen,Armed Forces Medical College,Not Unity-Aligned,https://dx.doi.org/10.1016/j.mjafi.2021.02.008,2021-08-11,2024-03-01,Unverified,sen_estimating_2021,IND
210801_India_SevenHillsDedicatedCovidHospital,210801_India_SevenHillsDedicatedCovidHospital,Seroprevalence of SARS-CoV-2 Antibodies and Associated Factors in Health Care Workers.,2021-08-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,"Doctors, nurses, security staff, and other staff working
in this DCH were considered as HCWs and were included in the study. HCWs working for more than 14 days in this DCH and who gave voluntary informed consent were included.",HCWs who were pregnant or lactating at the time of study were excluded.,2020-12-15,2021-02-15,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,1005,0.12300000000000001,,,True,,,,True,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,Multiple Types,Serum,IgG,,Validated by manufacturers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Chavhan Santosh,Seven Hills Dedicated Covid Hospital,Not Unity-Aligned,https://europepmc.org/article/med/34472805,2021-09-15,2022-07-16,Unverified,santosh_seroprevalence_2021,IND
210802_Delhi_ DirectorateGeneralHealthServices_Aug1_PopTestAdj,210802_Delhi_ DirectorateGeneralHealthServices_Aug1,"The seroprevalence of severe acute respiratory syndrome coronavirus 2 in Delhi, India: a repeated population-based seroepidemiological study.",2021-08-02,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,NCT Delhi,,The inclusion criteria were age ≥5 years and residents of Delhi for at least the past six months,"participant in the previous round of the serosurvey and those medically contraindicated for venepuncture
were excluded.",2020-08-01,2020-08-07,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,,14779,0.2839,0.27649999999999997,0.2914,True,True,True,,,Stratified probability,COVID KAVACH (KAWACH) IgG Microlisa (Microwell ELISA),J. Mitra & Co. Pvt. Ltd,ELISA,Whole Blood,IgG,,Validated by developers,0.9209999999999999,0.9770000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Nandini Sharma,Government of National Capital Territory of Delhi,Unity-Aligned,https://dx.doi.org/10.1093/trstmh/trab109,2021-09-14,2023-08-15,Verified,sharma_seroprevalence_2021-1,IND
210802_Delhi_ DirectorateGeneralHealthServices_Aug1_PopAdj,210802_Delhi_ DirectorateGeneralHealthServices_Aug1,"The seroprevalence of severe acute respiratory syndrome coronavirus 2 in Delhi, India: a repeated population-based seroepidemiological study.",2021-08-02,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,NCT Delhi,,The inclusion criteria were age ≥5 years and residents of Delhi for at least the past six months,"participant in the previous round of the serosurvey and those medically contraindicated for venepuncture
were excluded.",2020-08-01,2020-08-07,Household and community samples,All,Multiple groups,5.0,,Analysis,,14779,0.2884,0.2811,0.2957,,,True,,True,Stratified probability,COVID KAVACH (KAWACH) IgG Microlisa (Microwell ELISA),J. Mitra & Co. Pvt. Ltd,ELISA,Whole Blood,IgG,,Validated by developers,0.9209999999999999,0.9770000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Nandini Sharma,Government of National Capital Territory of Delhi,Unity-Aligned,https://dx.doi.org/10.1093/trstmh/trab109,2021-09-14,2024-03-01,Verified,sharma_seroprevalence_2021-1,IND
210802_Delhi_ DirectorateGeneralHealthServices_Oct3_PopTestAdj,210802_Delhi_ DirectorateGeneralHealthServices_Oct3,"The seroprevalence of severe acute respiratory syndrome coronavirus 2 in Delhi, India: a repeated population-based seroepidemiological study.",2021-08-02,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,NCT Delhi,,The inclusion criteria were age ≥5 years and residents of Delhi for at least the past six months,"participant in the previous round of the serosurvey and those medically contraindicated for venepuncture
were excluded.",2020-10-15,2020-10-21,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,,14905,0.24710000000000001,0.2401,0.25420000000000004,True,True,True,,,Stratified probability,ErbaLisa COVID-19 IgG ELISA Kit,Calbiotech Inc.,ELISA,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9912000000000001,0.9933,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Nandini Sharma,Government of National Capital Territory of Delhi,Unity-Aligned,https://dx.doi.org/10.1093/trstmh/trab109,2021-09-14,2023-08-15,Verified,sharma_seroprevalence_2021-1,IND
210802_Delhi_ DirectorateGeneralHealthServices_Oct3_PopAdj,210802_Delhi_ DirectorateGeneralHealthServices_Oct3,"The seroprevalence of severe acute respiratory syndrome coronavirus 2 in Delhi, India: a repeated population-based seroepidemiological study.",2021-08-02,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,NCT Delhi,,The inclusion criteria were age ≥5 years and residents of Delhi for at least the past six months,"participant in the previous round of the serosurvey and those medically contraindicated for venepuncture
were excluded.",2020-10-15,2020-10-21,Household and community samples,All,Multiple groups,5.0,,Analysis,,14905,0.2521,0.2452,0.2591,,,True,,True,Stratified probability,ErbaLisa COVID-19 IgG ELISA Kit,Calbiotech Inc.,ELISA,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9912000000000001,0.9933,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Nandini Sharma,Government of National Capital Territory of Delhi,Unity-Aligned,https://dx.doi.org/10.1093/trstmh/trab109,2021-09-14,2024-03-01,Verified,sharma_seroprevalence_2021-1,IND
210802_Delhi_ DirectorateGeneralHealthServices_Sept2_PopTestAdj,210802_Delhi_ DirectorateGeneralHealthServices_Sep2,"The seroprevalence of severe acute respiratory syndrome coronavirus 2 in Delhi, India: a repeated population-based seroepidemiological study.",2021-08-02,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,NCT Delhi,,The inclusion criteria were age ≥5 years and residents of Delhi for at least the past six months,"participant in the previous round of the serosurvey and those medically contraindicated for venepuncture
were excluded.",2020-09-01,2020-09-07,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,,16953,0.2408,0.2343,0.24739999999999998,True,True,True,,,Stratified probability,ErbaLisa COVID-19 IgG ELISA Kit,Calbiotech Inc.,ELISA,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9912000000000001,0.9933,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Nandini Sharma,Government of National Capital Territory of Delhi,Unity-Aligned,https://dx.doi.org/10.1093/trstmh/trab109,2021-09-14,2023-08-15,Verified,sharma_seroprevalence_2021-1,IND
210802_Delhi_ DirectorateGeneralHealthServices_Sept2_PopAdj,210802_Delhi_ DirectorateGeneralHealthServices_Sep2,"The seroprevalence of severe acute respiratory syndrome coronavirus 2 in Delhi, India: a repeated population-based seroepidemiological study.",2021-08-02,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,NCT Delhi,,The inclusion criteria were age ≥5 years and residents of Delhi for at least the past six months,"participant in the previous round of the serosurvey and those medically contraindicated for venepuncture
were excluded.",2020-09-01,2020-09-07,Household and community samples,All,Multiple groups,5.0,,Analysis,,16953,0.2459,0.2395,0.2523,,,True,,True,Stratified probability,ErbaLisa COVID-19 IgG ELISA Kit,Calbiotech Inc.,ELISA,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9912000000000001,0.9933,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Nandini Sharma,Government of National Capital Territory of Delhi,Unity-Aligned,https://dx.doi.org/10.1093/trstmh/trab109,2021-09-14,2024-03-01,Verified,sharma_seroprevalence_2021-1,IND
210810_Odisha_IndianCouncilofMedicalResearch_primary,210810_Odisha_IndianCouncilofMedicalResearch,"Antibodies Against SARS-CoV-2 among High-Risk Groups: Findings from Serosurveys in 6 Urban Areas of Odisha, India",2021-08-10,Preprint,Regional,Cross-sectional survey ,India,Odisha,,"The study population included different high-risk groups such as health care workers, municipality and sanitary staffs, media personnel, police and security personnel, vendors, residents of slums, residents of containment zones and prisoners.",,2020-07-15,2020-11-15,Multiple populations,All,Multiple groups,,,Primary Estimate,,5434,0.349,0.336,0.36200000000000004,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Srikanta Kanungo,Indian Council of Medical Research,Not Unity-Aligned,https://www.researchsquare.com/article/rs-664559/v1,2021-08-16,2024-03-01,Verified,kanungo_antibodies_2021,IND
210811_Karnataka_IndianInstituteofPublicHealth_Overall_PopTestAdj,210811_Karnataka_IndianInstituteofPublicHealth,"Second round statewide survey for estimation of the burden of active infection and anti-SARS-CoV-2 IgG antibodies in the general population of Karnataka, India",2021-08-11,Preprint,Regional,Repeated cross-sectional study,India,Karnataka,, We included all adults ≥18 years," We excluded those already diagnosed with SARS-CoV-2 infection, those unwilling to provide a sample for the test or consent, those who had received vaccination for COVID-19, and those who already participated in Round 1.
",2021-01-25,2021-02-18,Multiple populations,All,Multiple groups,18.0,,Primary Estimate,,41228,0.156,0.149,0.163,True,True,True,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by developers,0.9237000000000001,0.9790000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Rajagopal Padma,Indian Institute of Public Health,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.10.21261842v1,2021-08-18,2023-08-15,Unverified,padma_second_2021,IND
210811_Karnataka_IndianInstituteofPublicHealth_Age_60+_PopTestAdj,210811_Karnataka_IndianInstituteofPublicHealth,"Second round statewide survey for estimation of the burden of active infection and anti-SARS-CoV-2 IgG antibodies in the general population of Karnataka, India",2021-08-11,Preprint,Regional,Repeated cross-sectional study,India,Karnataka,, We included all adults ≥18 years," We excluded those already diagnosed with SARS-CoV-2 infection, those unwilling to provide a sample for the test or consent, those who had received vaccination for COVID-19, and those who already participated in Round 1.
",2021-01-25,2021-02-18,Multiple populations,All,Seniors (65+ years),60.0,,Age,60+,7818,0.17300000000000001,0.156,0.189,,True,True,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by developers,0.9237000000000001,0.9790000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Rajagopal Padma,Indian Institute of Public Health,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.10.21261842v1,2021-08-18,2023-08-15,Unverified,padma_second_2021,IND
210811_Karnataka_IndianInstituteofPublicHealth_Age_30-39_PopTestAdj,210811_Karnataka_IndianInstituteofPublicHealth,"Second round statewide survey for estimation of the burden of active infection and anti-SARS-CoV-2 IgG antibodies in the general population of Karnataka, India",2021-08-11,Preprint,Regional,Repeated cross-sectional study,India,Karnataka,, We included all adults ≥18 years," We excluded those already diagnosed with SARS-CoV-2 infection, those unwilling to provide a sample for the test or consent, those who had received vaccination for COVID-19, and those who already participated in Round 1.
",2021-01-25,2021-02-18,Multiple populations,All,Adults (18-64 years),30.0,39.0,Age,30-39,7856,0.141,0.125,0.156,,True,True,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by developers,0.9237000000000001,0.9790000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Rajagopal Padma,Indian Institute of Public Health,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.10.21261842v1,2021-08-18,2023-08-15,Unverified,padma_second_2021,IND
210811_Karnataka_IndianInstituteofPublicHealth_Age_50-59_PopTestAdj,210811_Karnataka_IndianInstituteofPublicHealth,"Second round statewide survey for estimation of the burden of active infection and anti-SARS-CoV-2 IgG antibodies in the general population of Karnataka, India",2021-08-11,Preprint,Regional,Repeated cross-sectional study,India,Karnataka,, We included all adults ≥18 years," We excluded those already diagnosed with SARS-CoV-2 infection, those unwilling to provide a sample for the test or consent, those who had received vaccination for COVID-19, and those who already participated in Round 1.
",2021-01-25,2021-02-18,Multiple populations,All,Adults (18-64 years),50.0,59.0,Age,50-59,3967,0.168,0.145,0.192,,True,True,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by developers,0.9237000000000001,0.9790000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Rajagopal Padma,Indian Institute of Public Health,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.10.21261842v1,2021-08-18,2023-08-15,Unverified,padma_second_2021,IND
210811_Karnataka_IndianInstituteofPublicHealth_Age_18-29_PopTestAdj,210811_Karnataka_IndianInstituteofPublicHealth,"Second round statewide survey for estimation of the burden of active infection and anti-SARS-CoV-2 IgG antibodies in the general population of Karnataka, India",2021-08-11,Preprint,Regional,Repeated cross-sectional study,India,Karnataka,, We included all adults ≥18 years," We excluded those already diagnosed with SARS-CoV-2 infection, those unwilling to provide a sample for the test or consent, those who had received vaccination for COVID-19, and those who already participated in Round 1.
",2021-01-25,2021-02-18,Multiple populations,All,Adults (18-64 years),18.0,29.0,Age,18-29,15841,0.10800000000000001,0.098,0.11699999999999999,,True,True,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by developers,0.9237000000000001,0.9790000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Rajagopal Padma,Indian Institute of Public Health,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.10.21261842v1,2021-08-18,2023-08-15,Unverified,padma_second_2021,IND
210811_Karnataka_IndianInstituteofPublicHealth_Age_40-49_PopTestAdj,210811_Karnataka_IndianInstituteofPublicHealth,"Second round statewide survey for estimation of the burden of active infection and anti-SARS-CoV-2 IgG antibodies in the general population of Karnataka, India",2021-08-11,Preprint,Regional,Repeated cross-sectional study,India,Karnataka,, We included all adults ≥18 years," We excluded those already diagnosed with SARS-CoV-2 infection, those unwilling to provide a sample for the test or consent, those who had received vaccination for COVID-19, and those who already participated in Round 1.
",2021-01-25,2021-02-18,Multiple populations,All,Adults (18-64 years),40.0,49.0,Age,40-49,5745,0.174,0.155,0.19399999999999998,,True,True,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by developers,0.9237000000000001,0.9790000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Rajagopal Padma,Indian Institute of Public Health,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.10.21261842v1,2021-08-18,2023-08-15,Unverified,padma_second_2021,IND
210813_Madurai_UniversityOfCaliforniaBerkeley_Primary,210813_Madurai_UniversityOfCaliforniaBerkeley,"SARS-CoV-2 infection and mortality during the first epidemic wave in Madurai, south India: a prospective, active surveillance study",2021-08-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Tami Nadu,Madurai,"38 random GPS points, generated by a computer as
random latitude and longitude coordinates, were selected
within distinct health-unit divisions (administrative
subunits) of Madurai district, with the aim of allocating
roughly ten points per million inhabitants. Surveyors
approached households adjacent to each selected point
aiming to enrol one participant aged at least 18 years per
household, until 30 individuals were enrolled within a
cluster. Within households opting to participate, a single
member was selected to enrol at random.",,2020-10-19,2020-11-05,Household and community samples,All,Multiple groups,18.0,84.0,Primary Estimate,,1140,0.402,0.359,0.44700000000000006,True,,True,True,,Stratified probability,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,0.929,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,,Ramanan Laxminarayan,University of California Berkeley,Not Unity-Aligned,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00393-5/fulltext,2021-08-31,2022-07-16,Verified,laxminarayan_sars-cov-2_2021,IND
210813_Madurai_UniversityOfCaliforniaBerkeley_Female,210813_Madurai_UniversityOfCaliforniaBerkeley,"SARS-CoV-2 infection and mortality during the first epidemic wave in Madurai, south India: a prospective, active surveillance study",2021-08-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Tami Nadu,Madurai,"38 random GPS points, generated by a computer as
random latitude and longitude coordinates, were selected
within distinct health-unit divisions (administrative
subunits) of Madurai district, with the aim of allocating
roughly ten points per million inhabitants. Surveyors
approached households adjacent to each selected point
aiming to enrol one participant aged at least 18 years per
household, until 30 individuals were enrolled within a
cluster. Within households opting to participate, a single
member was selected to enrol at random.",,2020-10-19,2020-11-05,Household and community samples,Female,Multiple groups,18.0,84.0,Sex/Gender,,790,0.397,,,,,,,,Stratified probability,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,0.929,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,,Ramanan Laxminarayan,University of California Berkeley,Not Unity-Aligned,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00393-5/fulltext,2021-08-31,2022-07-16,Verified,laxminarayan_sars-cov-2_2021,IND
210813_Madurai_UniversityOfCaliforniaBerkeley_UnAdj,210813_Madurai_UniversityOfCaliforniaBerkeley,"SARS-CoV-2 infection and mortality during the first epidemic wave in Madurai, south India: a prospective, active surveillance study",2021-08-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Tami Nadu,Madurai,"38 random GPS points, generated by a computer as
random latitude and longitude coordinates, were selected
within distinct health-unit divisions (administrative
subunits) of Madurai district, with the aim of allocating
roughly ten points per million inhabitants. Surveyors
approached households adjacent to each selected point
aiming to enrol one participant aged at least 18 years per
household, until 30 individuals were enrolled within a
cluster. Within households opting to participate, a single
member was selected to enrol at random.",,2020-10-19,2020-11-05,Household and community samples,All,Multiple groups,18.0,84.0,Analysis,,1140,0.396,,,,,,,True,Stratified probability,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,0.929,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,,Ramanan Laxminarayan,University of California Berkeley,Not Unity-Aligned,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00393-5/fulltext,2021-08-31,2022-07-16,Verified,laxminarayan_sars-cov-2_2021,IND
210813_Madurai_UniversityOfCaliforniaBerkeley_Male,210813_Madurai_UniversityOfCaliforniaBerkeley,"SARS-CoV-2 infection and mortality during the first epidemic wave in Madurai, south India: a prospective, active surveillance study",2021-08-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Tami Nadu,Madurai,"38 random GPS points, generated by a computer as
random latitude and longitude coordinates, were selected
within distinct health-unit divisions (administrative
subunits) of Madurai district, with the aim of allocating
roughly ten points per million inhabitants. Surveyors
approached households adjacent to each selected point
aiming to enrol one participant aged at least 18 years per
household, until 30 individuals were enrolled within a
cluster. Within households opting to participate, a single
member was selected to enrol at random.",,2020-10-19,2020-11-05,Household and community samples,Male,Multiple groups,18.0,84.0,Sex/Gender,,350,0.391,,,,,,,,Stratified probability,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,0.929,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,,Ramanan Laxminarayan,University of California Berkeley,Not Unity-Aligned,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00393-5/fulltext,2021-08-31,2022-07-16,Verified,laxminarayan_sars-cov-2_2021,IND
210827_Bhubaneswar_AllIndiaInstituteOfMedicalSciences_Primary,210827_Bhubaneswar_AllIndiaInstituteOfMedicalSciences,Seroprevalence of SARS-CoV-2 antibodies among healthcare workers in a teaching hospital in Eastern India.,2021-08-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Odisha,Bhubaneswar,"HCWs working at AIIMS, with an employment gap < 2 weeks.",,2020-08-01,2020-08-08,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,821,0.039,0.026000000000000002,0.051,True,,,,True,Simplified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.991,0.9509000000000001,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Mishra Baijayantimala,All India Institute of Medical Sciences (AIIMS),Not Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2486_20,2021-10-25,2024-03-01,Unverified,mishra_seroprevalence_2021,IND
210829_Delhi_CouncilOfScientificAndIndustrialResearch_overall,210829_Delhi_CouncilOfScientificAndIndustrialResearch,"27% reinfected during 4th wave in Delhi, says study",2021-08-29,News and Media,Local,Cross-sectional survey ,India,,Delhi,,,2021-05-15,2021-06-15,Multiple populations,All,Multiple groups,,,Primary Estimate,,846,0.87,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Anonna Dutt,Council Of Scientific And Industrial Research (CSIR),Not Unity-Aligned,https://www.hindustantimes.com/india-news/covid-crisis-one-in-four-patients-in-delhi-were-reinfected-during-the-second-wave-says-preprint-study-101630175376759-amp.html,2021-09-06,2022-07-16,Unverified,dutt_27_2021,IND
210901_Potheri_SRMInstituteofScienceandTechnology_Group1_Overall,210901_Potheri_SRMInstituteofScienceandTechnology_Group1,"COVID-19 seroprevalence study in asymptomatic healthcare workers, at a tertiary healthcare centre, India",2021-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Tamil Nadu,Potheri,"Asymptomatic HCW between 18 to 60 years of age in SRM MCH & RC, a tertiary care hospital in Potheri, Chengalpattu district, Tamil Nadu, India, were included in the study.","Healthcare professionals of more than 60 years of age, those who had history of travel abroad in recent days, typical symptoms of COVID-19, immunised against COVID-19 and not giving consent were excluded from the study.",2021-01-15,2021-02-15,Health care workers and caregivers,All,Adults (18-64 years),21.0,60.0,Primary Estimate,,82,0.0976,,,True,,,,True,Convenience,Not reported/ Unable to specify,,CLIA,Serum,IgG,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Bhuvanamha Ramamurthy,SRM Institute of Science and Technology,Not Unity-Aligned,https://www.jcdr.net/article_fulltext.asp?issn=0973-709x&year=2021&volume=15&issue=9&page=EC29&issn=0973-709x&id=15422,2021-10-13,2022-07-16,Unverified,ramamurthy_covid-19_2021,IND
210901_Potheri_SRMInstituteofScienceandTechnology_Group1_31-40,210901_Potheri_SRMInstituteofScienceandTechnology_Group1,"COVID-19 seroprevalence study in asymptomatic healthcare workers, at a tertiary healthcare centre, India",2021-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Tamil Nadu,Potheri,"Asymptomatic HCW between 18 to 60 years of age in SRM MCH & RC, a tertiary care hospital in Potheri, Chengalpattu district, Tamil Nadu, India, were included in the study.","Healthcare professionals of more than 60 years of age, those who had history of travel abroad in recent days, typical symptoms of COVID-19, immunised against COVID-19 and not giving consent were excluded from the study.",2021-01-15,2021-02-15,Health care workers and caregivers,All,Adults (18-64 years),31.0,40.0,Age,31-40,20,0.2,,,,,,,,Convenience,Not reported/ Unable to specify,,CLIA,Serum,IgG,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Bhuvanamha Ramamurthy,SRM Institute of Science and Technology,Not Unity-Aligned,https://www.jcdr.net/article_fulltext.asp?issn=0973-709x&year=2021&volume=15&issue=9&page=EC29&issn=0973-709x&id=15422,2021-10-13,2022-07-16,Unverified,ramamurthy_covid-19_2021,IND
210901_Potheri_SRMInstituteofScienceandTechnology_Group1_21-30,210901_Potheri_SRMInstituteofScienceandTechnology_Group1,"COVID-19 seroprevalence study in asymptomatic healthcare workers, at a tertiary healthcare centre, India",2021-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Tamil Nadu,Potheri,"Asymptomatic HCW between 18 to 60 years of age in SRM MCH & RC, a tertiary care hospital in Potheri, Chengalpattu district, Tamil Nadu, India, were included in the study.","Healthcare professionals of more than 60 years of age, those who had history of travel abroad in recent days, typical symptoms of COVID-19, immunised against COVID-19 and not giving consent were excluded from the study.",2021-01-15,2021-02-15,Health care workers and caregivers,All,Adults (18-64 years),21.0,30.0,Age,21-30,62,0.0645,,,,,,,,Convenience,Not reported/ Unable to specify,,CLIA,Serum,IgG,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Bhuvanamha Ramamurthy,SRM Institute of Science and Technology,Not Unity-Aligned,https://www.jcdr.net/article_fulltext.asp?issn=0973-709x&year=2021&volume=15&issue=9&page=EC29&issn=0973-709x&id=15422,2021-10-13,2022-07-16,Unverified,ramamurthy_covid-19_2021,IND
210901_Potheri_SRMInstituteofScienceandTechnology_Group2_Overall,210901_Potheri_SRMInstituteofScienceandTechnology_Group2,"COVID-19 seroprevalence study in asymptomatic healthcare workers, at a tertiary healthcare centre, India",2021-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Tamil Nadu,Potheri,"Asymptomatic HCW between 18 to 60 years of age in SRM MCH & RC, a tertiary care hospital in Potheri, Chengalpattu district, Tamil Nadu, India, were included in the study.","Healthcare professionals of more than 60 years of age, those who had history of travel abroad in recent days, typical symptoms of COVID-19, immunised against COVID-19 and not giving consent were excluded from the study.",2021-01-15,2021-02-15,Health care workers and caregivers,All,Adults (18-64 years),21.0,60.0,Primary Estimate,,46,0.1304,,,True,,,,True,Convenience,Not reported/ Unable to specify,,CLIA,Serum,IgG,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Bhuvanamha Ramamurthy,SRM Institute of Science and Technology,Not Unity-Aligned,https://www.jcdr.net/article_fulltext.asp?issn=0973-709x&year=2021&volume=15&issue=9&page=EC29&issn=0973-709x&id=15422,2021-10-13,2022-07-16,Unverified,ramamurthy_covid-19_2021,IND
210901_Potheri_SRMInstituteofScienceandTechnology_Group2_21-30,210901_Potheri_SRMInstituteofScienceandTechnology_Group2,"COVID-19 seroprevalence study in asymptomatic healthcare workers, at a tertiary healthcare centre, India",2021-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Tamil Nadu,Potheri,"Asymptomatic HCW between 18 to 60 years of age in SRM MCH & RC, a tertiary care hospital in Potheri, Chengalpattu district, Tamil Nadu, India, were included in the study.","Healthcare professionals of more than 60 years of age, those who had history of travel abroad in recent days, typical symptoms of COVID-19, immunised against COVID-19 and not giving consent were excluded from the study.",2021-01-15,2021-02-15,Health care workers and caregivers,All,Adults (18-64 years),21.0,30.0,Age,21-30,26,0.0,,,,,,,,Convenience,Not reported/ Unable to specify,,CLIA,Serum,IgG,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Bhuvanamha Ramamurthy,SRM Institute of Science and Technology,Not Unity-Aligned,https://www.jcdr.net/article_fulltext.asp?issn=0973-709x&year=2021&volume=15&issue=9&page=EC29&issn=0973-709x&id=15422,2021-10-13,2022-07-16,Unverified,ramamurthy_covid-19_2021,IND
210901_Potheri_SRMInstituteofScienceandTechnology_Group2_51-60,210901_Potheri_SRMInstituteofScienceandTechnology_Group2,"COVID-19 seroprevalence study in asymptomatic healthcare workers, at a tertiary healthcare centre, India",2021-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Tamil Nadu,Potheri,"Asymptomatic HCW between 18 to 60 years of age in SRM MCH & RC, a tertiary care hospital in Potheri, Chengalpattu district, Tamil Nadu, India, were included in the study.","Healthcare professionals of more than 60 years of age, those who had history of travel abroad in recent days, typical symptoms of COVID-19, immunised against COVID-19 and not giving consent were excluded from the study.",2021-01-15,2021-02-15,Health care workers and caregivers,All,Adults (18-64 years),51.0,60.0,Age,51-60,4,0.5,,,,,,,,Convenience,Not reported/ Unable to specify,,CLIA,Serum,IgG,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Bhuvanamha Ramamurthy,SRM Institute of Science and Technology,Not Unity-Aligned,https://www.jcdr.net/article_fulltext.asp?issn=0973-709x&year=2021&volume=15&issue=9&page=EC29&issn=0973-709x&id=15422,2021-10-13,2022-07-16,Unverified,ramamurthy_covid-19_2021,IND
210901_Potheri_SRMInstituteofScienceandTechnology_Group2_31-40,210901_Potheri_SRMInstituteofScienceandTechnology_Group2,"COVID-19 seroprevalence study in asymptomatic healthcare workers, at a tertiary healthcare centre, India",2021-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Tamil Nadu,Potheri,"Asymptomatic HCW between 18 to 60 years of age in SRM MCH & RC, a tertiary care hospital in Potheri, Chengalpattu district, Tamil Nadu, India, were included in the study.","Healthcare professionals of more than 60 years of age, those who had history of travel abroad in recent days, typical symptoms of COVID-19, immunised against COVID-19 and not giving consent were excluded from the study.",2021-01-15,2021-02-15,Health care workers and caregivers,All,Adults (18-64 years),31.0,40.0,Age,31-40,12,0.16670000000000001,,,,,,,,Convenience,Not reported/ Unable to specify,,CLIA,Serum,IgG,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Bhuvanamha Ramamurthy,SRM Institute of Science and Technology,Not Unity-Aligned,https://www.jcdr.net/article_fulltext.asp?issn=0973-709x&year=2021&volume=15&issue=9&page=EC29&issn=0973-709x&id=15422,2021-10-13,2022-07-16,Unverified,ramamurthy_covid-19_2021,IND
210901_Potheri_SRMInstituteofScienceandTechnology_Group2_41-50,210901_Potheri_SRMInstituteofScienceandTechnology_Group2,"COVID-19 seroprevalence study in asymptomatic healthcare workers, at a tertiary healthcare centre, India",2021-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Tamil Nadu,Potheri,"Asymptomatic HCW between 18 to 60 years of age in SRM MCH & RC, a tertiary care hospital in Potheri, Chengalpattu district, Tamil Nadu, India, were included in the study.","Healthcare professionals of more than 60 years of age, those who had history of travel abroad in recent days, typical symptoms of COVID-19, immunised against COVID-19 and not giving consent were excluded from the study.",2021-01-15,2021-02-15,Health care workers and caregivers,All,Adults (18-64 years),41.0,50.0,Age,41-50,4,0.5,,,,,,,,Convenience,Not reported/ Unable to specify,,CLIA,Serum,IgG,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Bhuvanamha Ramamurthy,SRM Institute of Science and Technology,Not Unity-Aligned,https://www.jcdr.net/article_fulltext.asp?issn=0973-709x&year=2021&volume=15&issue=9&page=EC29&issn=0973-709x&id=15422,2021-10-13,2022-07-16,Unverified,ramamurthy_covid-19_2021,IND
210903_Maharashtra_ICMR-NationalInstituteOfImmunohematology,210903_Maharashtra_ICMR-NationalInstituteOfImmunohematology,Serosurvey for Health-Care Workers Provides Supportive Evidence for the Effectiveness of Hydroxychloroquine Prophylaxis against SARS-CoV-2 Infection.,2021-09-03,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Maharashtra,Dombivli,Only those who completed the survey questionnaire were included in the study. ,,2020-07-21,2020-08-03,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,500,0.11,,,True,,,,True,Convenience,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,,,,['High'],,No,No,No,,Yes,Yes,Yes,,Reetika Malik Yadav,ICMR-National Institute of Immunohematology,Not Unity-Aligned,https://dx.doi.org/10.2991/jegh.k.210518.001,2021-09-24,2024-03-01,Unverified,reetikamalikyadavSerosurveyHealthCareWorkers2021,IND
210906_NashikCity_GovernmentMedicalCollege_NonSlums_Overall,210906_NashikCity_GovernmentMedicalCollege_NonSlums,Seroprevalence of COVID-19 in a City in India: A Community-based Cross-Sectional Study,2021-09-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra ,Nashik,"individuals above 18 years of age, who had been residents of Nashik city for more than 6 months",excluding non-consenting and migrant population,2021-01-09,2021-01-11,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,1629,0.3812,0.3576,0.4053,True,,,,True,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Bapusaheb Nagargoje,Government Medical College,Not Unity-Aligned,https://www.jrmds.in/articles/seroprevalence-of-covid19-in-a-city-in-india-a-communitybased-crosssectional-study-83821.html,2021-11-02,2022-07-16,Verified,nagargoje_seroprevalence_2021,IND
210906_NashikCity_GovernmentMedicalCollege_NonSlums_Age51-60,210906_NashikCity_GovernmentMedicalCollege_NonSlums,Seroprevalence of COVID-19 in a City in India: A Community-based Cross-Sectional Study,2021-09-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra ,Nashik,"individuals above 18 years of age, who had been residents of Nashik city for more than 6 months",excluding non-consenting and migrant population,2021-01-09,2021-01-11,Household and community samples,All,Adults (18-64 years),51.0,60.0,Age,51-60,233,0.3348,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Bapusaheb Nagargoje,Government Medical College,Not Unity-Aligned,https://www.jrmds.in/articles/seroprevalence-of-covid19-in-a-city-in-india-a-communitybased-crosssectional-study-83821.html,2021-11-02,2022-07-16,Verified,nagargoje_seroprevalence_2021,IND
210906_NashikCity_GovernmentMedicalCollege_NonSlums_SexMale,210906_NashikCity_GovernmentMedicalCollege_NonSlums,Seroprevalence of COVID-19 in a City in India: A Community-based Cross-Sectional Study,2021-09-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra ,Nashik,"individuals above 18 years of age, who had been residents of Nashik city for more than 6 months",excluding non-consenting and migrant population,2021-01-09,2021-01-11,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,821,0.391,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Bapusaheb Nagargoje,Government Medical College,Not Unity-Aligned,https://www.jrmds.in/articles/seroprevalence-of-covid19-in-a-city-in-india-a-communitybased-crosssectional-study-83821.html,2021-11-02,2022-07-16,Verified,nagargoje_seroprevalence_2021,IND
210906_NashikCity_GovernmentMedicalCollege_NonSlums_SexFemale,210906_NashikCity_GovernmentMedicalCollege_NonSlums,Seroprevalence of COVID-19 in a City in India: A Community-based Cross-Sectional Study,2021-09-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra ,Nashik,"individuals above 18 years of age, who had been residents of Nashik city for more than 6 months",excluding non-consenting and migrant population,2021-01-09,2021-01-11,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,808,0.3713,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Bapusaheb Nagargoje,Government Medical College,Not Unity-Aligned,https://www.jrmds.in/articles/seroprevalence-of-covid19-in-a-city-in-india-a-communitybased-crosssectional-study-83821.html,2021-11-02,2022-07-16,Verified,nagargoje_seroprevalence_2021,IND
210906_NashikCity_GovernmentMedicalCollege_NonSlums_Age18-20,210906_NashikCity_GovernmentMedicalCollege_NonSlums,Seroprevalence of COVID-19 in a City in India: A Community-based Cross-Sectional Study,2021-09-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra ,Nashik,"individuals above 18 years of age, who had been residents of Nashik city for more than 6 months",excluding non-consenting and migrant population,2021-01-09,2021-01-11,Household and community samples,All,Adults (18-64 years),18.0,20.0,Age,18-20,66,0.4697,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Bapusaheb Nagargoje,Government Medical College,Not Unity-Aligned,https://www.jrmds.in/articles/seroprevalence-of-covid19-in-a-city-in-india-a-communitybased-crosssectional-study-83821.html,2021-11-02,2022-07-16,Verified,nagargoje_seroprevalence_2021,IND
210906_NashikCity_GovernmentMedicalCollege_NonSlums_Age41-50,210906_NashikCity_GovernmentMedicalCollege_NonSlums,Seroprevalence of COVID-19 in a City in India: A Community-based Cross-Sectional Study,2021-09-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra ,Nashik,"individuals above 18 years of age, who had been residents of Nashik city for more than 6 months",excluding non-consenting and migrant population,2021-01-09,2021-01-11,Household and community samples,All,Adults (18-64 years),41.0,50.0,Age,41-50,293,0.3515,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Bapusaheb Nagargoje,Government Medical College,Not Unity-Aligned,https://www.jrmds.in/articles/seroprevalence-of-covid19-in-a-city-in-india-a-communitybased-crosssectional-study-83821.html,2021-11-02,2022-07-16,Verified,nagargoje_seroprevalence_2021,IND
210906_NashikCity_GovernmentMedicalCollege_NonSlums_Age71-80,210906_NashikCity_GovernmentMedicalCollege_NonSlums,Seroprevalence of COVID-19 in a City in India: A Community-based Cross-Sectional Study,2021-09-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra ,Nashik,"individuals above 18 years of age, who had been residents of Nashik city for more than 6 months",excluding non-consenting and migrant population,2021-01-09,2021-01-11,Household and community samples,All,Seniors (65+ years),71.0,80.0,Age,71-80,73,0.3699,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Bapusaheb Nagargoje,Government Medical College,Not Unity-Aligned,https://www.jrmds.in/articles/seroprevalence-of-covid19-in-a-city-in-india-a-communitybased-crosssectional-study-83821.html,2021-11-02,2022-07-16,Verified,nagargoje_seroprevalence_2021,IND
210906_NashikCity_GovernmentMedicalCollege_NonSlums_Age61-70,210906_NashikCity_GovernmentMedicalCollege_NonSlums,Seroprevalence of COVID-19 in a City in India: A Community-based Cross-Sectional Study,2021-09-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra ,Nashik,"individuals above 18 years of age, who had been residents of Nashik city for more than 6 months",excluding non-consenting and migrant population,2021-01-09,2021-01-11,Household and community samples,All,Seniors (65+ years),61.0,70.0,Age,61-70,184,0.4457,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Bapusaheb Nagargoje,Government Medical College,Not Unity-Aligned,https://www.jrmds.in/articles/seroprevalence-of-covid19-in-a-city-in-india-a-communitybased-crosssectional-study-83821.html,2021-11-02,2022-07-16,Verified,nagargoje_seroprevalence_2021,IND
210906_NashikCity_GovernmentMedicalCollege_NonSlums_Age31-40,210906_NashikCity_GovernmentMedicalCollege_NonSlums,Seroprevalence of COVID-19 in a City in India: A Community-based Cross-Sectional Study,2021-09-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra ,Nashik,"individuals above 18 years of age, who had been residents of Nashik city for more than 6 months",excluding non-consenting and migrant population,2021-01-09,2021-01-11,Household and community samples,All,Adults (18-64 years),31.0,40.0,Age,31-40,403,0.35240000000000005,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Bapusaheb Nagargoje,Government Medical College,Not Unity-Aligned,https://www.jrmds.in/articles/seroprevalence-of-covid19-in-a-city-in-india-a-communitybased-crosssectional-study-83821.html,2021-11-02,2022-07-16,Verified,nagargoje_seroprevalence_2021,IND
210906_NashikCity_GovernmentMedicalCollege_NonSlums_Age21-30,210906_NashikCity_GovernmentMedicalCollege_NonSlums,Seroprevalence of COVID-19 in a City in India: A Community-based Cross-Sectional Study,2021-09-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra ,Nashik,"individuals above 18 years of age, who had been residents of Nashik city for more than 6 months",excluding non-consenting and migrant population,2021-01-09,2021-01-11,Household and community samples,All,Adults (18-64 years),21.0,30.0,Age,21-30,364,0.42310000000000003,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Bapusaheb Nagargoje,Government Medical College,Not Unity-Aligned,https://www.jrmds.in/articles/seroprevalence-of-covid19-in-a-city-in-india-a-communitybased-crosssectional-study-83821.html,2021-11-02,2022-07-16,Verified,nagargoje_seroprevalence_2021,IND
210906_NashikCity_GovernmentMedicalCollege_NonSlums_Age>80,210906_NashikCity_GovernmentMedicalCollege_NonSlums,Seroprevalence of COVID-19 in a City in India: A Community-based Cross-Sectional Study,2021-09-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra ,Nashik,"individuals above 18 years of age, who had been residents of Nashik city for more than 6 months",excluding non-consenting and migrant population,2021-01-09,2021-01-11,Household and community samples,All,Seniors (65+ years),81.0,,Age,>80,13,0.30770000000000003,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Bapusaheb Nagargoje,Government Medical College,Not Unity-Aligned,https://www.jrmds.in/articles/seroprevalence-of-covid19-in-a-city-in-india-a-communitybased-crosssectional-study-83821.html,2021-11-02,2022-07-16,Verified,nagargoje_seroprevalence_2021,IND
210906_NashikCity_GovernmentMedicalCollege_Slums_Overall,210906_NashikCity_GovernmentMedicalCollege_Slums,Seroprevalence of COVID-19 in a City in India: A Community-based Cross-Sectional Study,2021-09-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra ,Nashik,"individuals above 18 years of age, who had been residents of Nashik city for more than 6 months",excluding non-consenting and migrant population,2021-01-09,2021-01-11,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,726,0.42700000000000005,0.3907,0.46390000000000003,True,,,,True,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Bapusaheb Nagargoje,Government Medical College,Not Unity-Aligned,https://www.jrmds.in/articles/seroprevalence-of-covid19-in-a-city-in-india-a-communitybased-crosssectional-study-83821.html,2021-11-02,2022-07-16,Verified,nagargoje_seroprevalence_2021,IND
210906_NashikCity_GovernmentMedicalCollege_Slums_Age21-30,210906_NashikCity_GovernmentMedicalCollege_Slums,Seroprevalence of COVID-19 in a City in India: A Community-based Cross-Sectional Study,2021-09-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra ,Nashik,"individuals above 18 years of age, who had been residents of Nashik city for more than 6 months",excluding non-consenting and migrant population,2021-01-09,2021-01-11,Household and community samples,All,Adults (18-64 years),21.0,30.0,Age,21-30,211,0.3981,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Bapusaheb Nagargoje,Government Medical College,Not Unity-Aligned,https://www.jrmds.in/articles/seroprevalence-of-covid19-in-a-city-in-india-a-communitybased-crosssectional-study-83821.html,2021-11-02,2022-07-16,Verified,nagargoje_seroprevalence_2021,IND
210906_NashikCity_GovernmentMedicalCollege_Slums_Age61-70,210906_NashikCity_GovernmentMedicalCollege_Slums,Seroprevalence of COVID-19 in a City in India: A Community-based Cross-Sectional Study,2021-09-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra ,Nashik,"individuals above 18 years of age, who had been residents of Nashik city for more than 6 months",excluding non-consenting and migrant population,2021-01-09,2021-01-11,Household and community samples,All,Seniors (65+ years),61.0,70.0,Age,61-70,69,0.44930000000000003,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Bapusaheb Nagargoje,Government Medical College,Not Unity-Aligned,https://www.jrmds.in/articles/seroprevalence-of-covid19-in-a-city-in-india-a-communitybased-crosssectional-study-83821.html,2021-11-02,2022-07-16,Verified,nagargoje_seroprevalence_2021,IND
210906_NashikCity_GovernmentMedicalCollege_Slums_Age51-60,210906_NashikCity_GovernmentMedicalCollege_Slums,Seroprevalence of COVID-19 in a City in India: A Community-based Cross-Sectional Study,2021-09-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra ,Nashik,"individuals above 18 years of age, who had been residents of Nashik city for more than 6 months",excluding non-consenting and migrant population,2021-01-09,2021-01-11,Household and community samples,All,Adults (18-64 years),51.0,60.0,Age,51-60,103,0.4078,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Bapusaheb Nagargoje,Government Medical College,Not Unity-Aligned,https://www.jrmds.in/articles/seroprevalence-of-covid19-in-a-city-in-india-a-communitybased-crosssectional-study-83821.html,2021-11-02,2022-07-16,Verified,nagargoje_seroprevalence_2021,IND
210906_NashikCity_GovernmentMedicalCollege_Slums_Age31-40,210906_NashikCity_GovernmentMedicalCollege_Slums,Seroprevalence of COVID-19 in a City in India: A Community-based Cross-Sectional Study,2021-09-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra ,Nashik,"individuals above 18 years of age, who had been residents of Nashik city for more than 6 months",excluding non-consenting and migrant population,2021-01-09,2021-01-11,Household and community samples,All,Adults (18-64 years),31.0,40.0,Age,31-40,131,0.45799999999999996,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Bapusaheb Nagargoje,Government Medical College,Not Unity-Aligned,https://www.jrmds.in/articles/seroprevalence-of-covid19-in-a-city-in-india-a-communitybased-crosssectional-study-83821.html,2021-11-02,2022-07-16,Verified,nagargoje_seroprevalence_2021,IND
210906_NashikCity_GovernmentMedicalCollege_Slums_SexMale,210906_NashikCity_GovernmentMedicalCollege_Slums,Seroprevalence of COVID-19 in a City in India: A Community-based Cross-Sectional Study,2021-09-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra ,Nashik,"individuals above 18 years of age, who had been residents of Nashik city for more than 6 months",excluding non-consenting and migrant population,2021-01-09,2021-01-11,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,333,0.4204,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Bapusaheb Nagargoje,Government Medical College,Not Unity-Aligned,https://www.jrmds.in/articles/seroprevalence-of-covid19-in-a-city-in-india-a-communitybased-crosssectional-study-83821.html,2021-11-02,2022-07-16,Verified,nagargoje_seroprevalence_2021,IND
210906_NashikCity_GovernmentMedicalCollege_Slums_Age41-50,210906_NashikCity_GovernmentMedicalCollege_Slums,Seroprevalence of COVID-19 in a City in India: A Community-based Cross-Sectional Study,2021-09-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra ,Nashik,"individuals above 18 years of age, who had been residents of Nashik city for more than 6 months",excluding non-consenting and migrant population,2021-01-09,2021-01-11,Household and community samples,All,Adults (18-64 years),41.0,50.0,Age,41-50,135,0.43700000000000006,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Bapusaheb Nagargoje,Government Medical College,Not Unity-Aligned,https://www.jrmds.in/articles/seroprevalence-of-covid19-in-a-city-in-india-a-communitybased-crosssectional-study-83821.html,2021-11-02,2022-07-16,Verified,nagargoje_seroprevalence_2021,IND
210906_NashikCity_GovernmentMedicalCollege_Slums_Age>80,210906_NashikCity_GovernmentMedicalCollege_Slums,Seroprevalence of COVID-19 in a City in India: A Community-based Cross-Sectional Study,2021-09-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra ,Nashik,"individuals above 18 years of age, who had been residents of Nashik city for more than 6 months",excluding non-consenting and migrant population,2021-01-09,2021-01-11,Household and community samples,All,Seniors (65+ years),81.0,,Age,>80,4,0.75,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Bapusaheb Nagargoje,Government Medical College,Not Unity-Aligned,https://www.jrmds.in/articles/seroprevalence-of-covid19-in-a-city-in-india-a-communitybased-crosssectional-study-83821.html,2021-11-02,2022-07-16,Verified,nagargoje_seroprevalence_2021,IND
210906_NashikCity_GovernmentMedicalCollege_Slums_Age71-80,210906_NashikCity_GovernmentMedicalCollege_Slums,Seroprevalence of COVID-19 in a City in India: A Community-based Cross-Sectional Study,2021-09-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra ,Nashik,"individuals above 18 years of age, who had been residents of Nashik city for more than 6 months",excluding non-consenting and migrant population,2021-01-09,2021-01-11,Household and community samples,All,Seniors (65+ years),71.0,80.0,Age,71-80,26,0.30770000000000003,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Bapusaheb Nagargoje,Government Medical College,Not Unity-Aligned,https://www.jrmds.in/articles/seroprevalence-of-covid19-in-a-city-in-india-a-communitybased-crosssectional-study-83821.html,2021-11-02,2022-07-16,Verified,nagargoje_seroprevalence_2021,IND
210906_NashikCity_GovernmentMedicalCollege_Slums_Age18-20,210906_NashikCity_GovernmentMedicalCollege_Slums,Seroprevalence of COVID-19 in a City in India: A Community-based Cross-Sectional Study,2021-09-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra ,Nashik,"individuals above 18 years of age, who had been residents of Nashik city for more than 6 months",excluding non-consenting and migrant population,2021-01-09,2021-01-11,Household and community samples,All,Adults (18-64 years),18.0,20.0,Age,18-20,47,0.4894,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Bapusaheb Nagargoje,Government Medical College,Not Unity-Aligned,https://www.jrmds.in/articles/seroprevalence-of-covid19-in-a-city-in-india-a-communitybased-crosssectional-study-83821.html,2021-11-02,2022-07-16,Verified,nagargoje_seroprevalence_2021,IND
210906_NashikCity_GovernmentMedicalCollege_Slums_SexFemale,210906_NashikCity_GovernmentMedicalCollege_Slums,Seroprevalence of COVID-19 in a City in India: A Community-based Cross-Sectional Study,2021-09-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra ,Nashik,"individuals above 18 years of age, who had been residents of Nashik city for more than 6 months",excluding non-consenting and migrant population,2021-01-09,2021-01-11,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,393,0.4326,,,,,,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Bapusaheb Nagargoje,Government Medical College,Not Unity-Aligned,https://www.jrmds.in/articles/seroprevalence-of-covid19-in-a-city-in-india-a-communitybased-crosssectional-study-83821.html,2021-11-02,2022-07-16,Verified,nagargoje_seroprevalence_2021,IND
210913_Delhi_MaulanaAzadMedicalCollege_PopTestAdj,210913_Delhi_MaulanaAzadMedicalCollege,"Second wave of the Covid-19 pandemic in Delhi, India: high seroprevalence not a deterrent?",2021-09-13,Preprint,Regional,Cross-sectional survey ,India,Delhi,," This was a cross-sectional seroepidemiological study
among individuals of age ≥5 years recruited from 274 wards of the state of Delhi (population ~ 19.6 million) during January 11 to January 22’ 2021",,2021-01-11,2021-01-22,Household and community samples,All,Multiple groups,,,Primary Estimate,,27436,0.5613,0.5549000000000001,0.5677000000000001,True,True,True,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Whole Blood,IgG,,,0.9,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Nandini Sharma,Maulana Azad Medical College,Unity-Aligned,10.1101/2021.09.09.21263331,2021-09-21,2023-08-15,Verified,sharma_second_2021,IND
210913_Delhi_MaulanaAzadMedicalCollege_Females,210913_Delhi_MaulanaAzadMedicalCollege,"Second wave of the Covid-19 pandemic in Delhi, India: high seroprevalence not a deterrent?",2021-09-13,Preprint,Regional,Cross-sectional survey ,India,Delhi,," This was a cross-sectional seroepidemiological study
among individuals of age ≥5 years recruited from 274 wards of the state of Delhi (population ~ 19.6 million) during January 11 to January 22’ 2021",,2021-01-11,2021-01-22,Household and community samples,Female,Multiple groups,,,Sex/Gender,females,16291,0.5242,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Whole Blood,IgG,,,0.9,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Nandini Sharma,Maulana Azad Medical College,Unity-Aligned,10.1101/2021.09.09.21263331,2021-09-21,2024-03-01,Verified,sharma_second_2021,IND
210913_Delhi_MaulanaAzadMedicalCollege_<18,210913_Delhi_MaulanaAzadMedicalCollege,"Second wave of the Covid-19 pandemic in Delhi, India: high seroprevalence not a deterrent?",2021-09-13,Preprint,Regional,Cross-sectional survey ,India,Delhi,," This was a cross-sectional seroepidemiological study
among individuals of age ≥5 years recruited from 274 wards of the state of Delhi (population ~ 19.6 million) during January 11 to January 22’ 2021",,2021-01-11,2021-01-22,Household and community samples,All,Children and Youth (0-17 years),,17.0,Age,<18 ,4337,0.5243,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Whole Blood,IgG,,,0.9,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Nandini Sharma,Maulana Azad Medical College,Unity-Aligned,10.1101/2021.09.09.21263331,2021-09-21,2024-03-01,Verified,sharma_second_2021,IND
210913_Delhi_MaulanaAzadMedicalCollege_PopAdj,210913_Delhi_MaulanaAzadMedicalCollege,"Second wave of the Covid-19 pandemic in Delhi, India: high seroprevalence not a deterrent?",2021-09-13,Preprint,Regional,Cross-sectional survey ,India,Delhi,," This was a cross-sectional seroepidemiological study
among individuals of age ≥5 years recruited from 274 wards of the state of Delhi (population ~ 19.6 million) during January 11 to January 22’ 2021",,2021-01-11,2021-01-22,Household and community samples,All,Multiple groups,,,Analysis,,27436,0.5052000000000001,0.4994,0.511,,,True,,True,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Whole Blood,IgG,,,0.9,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Nandini Sharma,Maulana Azad Medical College,Unity-Aligned,10.1101/2021.09.09.21263331,2021-09-21,2024-03-01,Verified,sharma_second_2021,IND
210913_Delhi_MaulanaAzadMedicalCollege_18-49,210913_Delhi_MaulanaAzadMedicalCollege,"Second wave of the Covid-19 pandemic in Delhi, India: high seroprevalence not a deterrent?",2021-09-13,Preprint,Regional,Cross-sectional survey ,India,Delhi,," This was a cross-sectional seroepidemiological study
among individuals of age ≥5 years recruited from 274 wards of the state of Delhi (population ~ 19.6 million) during January 11 to January 22’ 2021",,2021-01-11,2021-01-22,Household and community samples,All,Adults (18-64 years),18.0,49.0,Age,18-49,18259,0.4927,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Whole Blood,IgG,,,0.9,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Nandini Sharma,Maulana Azad Medical College,Unity-Aligned,10.1101/2021.09.09.21263331,2021-09-21,2024-03-01,Verified,sharma_second_2021,IND
210913_Delhi_MaulanaAzadMedicalCollege_Males,210913_Delhi_MaulanaAzadMedicalCollege,"Second wave of the Covid-19 pandemic in Delhi, India: high seroprevalence not a deterrent?",2021-09-13,Preprint,Regional,Cross-sectional survey ,India,Delhi,," This was a cross-sectional seroepidemiological study
among individuals of age ≥5 years recruited from 274 wards of the state of Delhi (population ~ 19.6 million) during January 11 to January 22’ 2021",,2021-01-11,2021-01-22,Household and community samples,Male,Multiple groups,,,Sex/Gender,males,11861,0.48210000000000003,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Whole Blood,IgG,,,0.9,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Nandini Sharma,Maulana Azad Medical College,Unity-Aligned,10.1101/2021.09.09.21263331,2021-09-21,2024-03-01,Verified,sharma_second_2021,IND
210913_Delhi_MaulanaAzadMedicalCollege_>=50,210913_Delhi_MaulanaAzadMedicalCollege,"Second wave of the Covid-19 pandemic in Delhi, India: high seroprevalence not a deterrent?",2021-09-13,Preprint,Regional,Cross-sectional survey ,India,Delhi,," This was a cross-sectional seroepidemiological study
among individuals of age ≥5 years recruited from 274 wards of the state of Delhi (population ~ 19.6 million) during January 11 to January 22’ 2021",,2021-01-11,2021-01-22,Household and community samples,All,Multiple groups,50.0,,Age,>=50,5548,0.5377000000000001,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Whole Blood,IgG,,,0.9,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Nandini Sharma,Maulana Azad Medical College,Unity-Aligned,10.1101/2021.09.09.21263331,2021-09-21,2024-03-01,Verified,sharma_second_2021,IND
210914_Chennai_NationalInstituteofEpidemiology_Overall_PopandTestAdjusted,210914_Chennai_NationalInstituteofEpidemiology,"Monitoring the trend of SARS-CoV-2 seroprevalence in Chennai, India, July and October 2020",2021-09-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Tamil Nadu,Chennai,"Citizens of Chennai, India ≥10 years old.",,2020-10-08,2020-10-15,Household and community samples,All,Multiple groups,10.0,,Primary Estimate,Population and Test Adjustment,6366,0.30100000000000005,0.247,0.36100000000000004,True,True,True,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Muthusamy Kumar,National Institute of Epidemiology,Unity-Aligned,https://academic.oup.com/trstmh/article/115/11/1350/6370308?login=true,2021-11-30,2023-08-15,Verified,kumar_monitoring_2021,IND
210914_Chennai_NationalInstituteofEpidemiology_10-19,210914_Chennai_NationalInstituteofEpidemiology,"Monitoring the trend of SARS-CoV-2 seroprevalence in Chennai, India, July and October 2020",2021-09-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Tamil Nadu,Chennai,"Citizens of Chennai, India ≥10 years old.",,2020-10-08,2020-10-15,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,670,0.257,0.2,0.322,,,True,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Muthusamy Kumar,National Institute of Epidemiology,Unity-Aligned,https://academic.oup.com/trstmh/article/115/11/1350/6370308?login=true,2021-11-30,2024-03-01,Verified,kumar_monitoring_2021,IND
210914_Chennai_NationalInstituteofEpidemiology_Overall_PopAdjusted,210914_Chennai_NationalInstituteofEpidemiology,"Monitoring the trend of SARS-CoV-2 seroprevalence in Chennai, India, July and October 2020",2021-09-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Tamil Nadu,Chennai,"Citizens of Chennai, India ≥10 years old.",,2020-10-08,2020-10-15,Household and community samples,All,Multiple groups,10.0,,Analysis,Population Adjustment,6366,0.304,0.25,0.364,,,True,True,True,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Muthusamy Kumar,National Institute of Epidemiology,Unity-Aligned,https://academic.oup.com/trstmh/article/115/11/1350/6370308?login=true,2021-11-30,2024-03-01,Verified,kumar_monitoring_2021,IND
210914_Chennai_NationalInstituteofEpidemiology_Female,210914_Chennai_NationalInstituteofEpidemiology,"Monitoring the trend of SARS-CoV-2 seroprevalence in Chennai, India, July and October 2020",2021-09-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Tamil Nadu,Chennai,"Citizens of Chennai, India ≥10 years old.",,2020-10-08,2020-10-15,Household and community samples,Female,Multiple groups,,,Sex/Gender,,3021,0.309,0.253,0.371,,,True,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Muthusamy Kumar,National Institute of Epidemiology,Unity-Aligned,https://academic.oup.com/trstmh/article/115/11/1350/6370308?login=true,2021-11-30,2024-03-01,Verified,kumar_monitoring_2021,IND
210914_Chennai_NationalInstituteofEpidemiology_20-29,210914_Chennai_NationalInstituteofEpidemiology,"Monitoring the trend of SARS-CoV-2 seroprevalence in Chennai, India, July and October 2020",2021-09-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Tamil Nadu,Chennai,"Citizens of Chennai, India ≥10 years old.",,2020-10-08,2020-10-15,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,1341,0.292,0.23500000000000001,0.35700000000000004,,,True,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Muthusamy Kumar,National Institute of Epidemiology,Unity-Aligned,https://academic.oup.com/trstmh/article/115/11/1350/6370308?login=true,2021-11-30,2024-03-01,Verified,kumar_monitoring_2021,IND
210914_Chennai_NationalInstituteofEpidemiology_40-49,210914_Chennai_NationalInstituteofEpidemiology,"Monitoring the trend of SARS-CoV-2 seroprevalence in Chennai, India, July and October 2020",2021-09-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Tamil Nadu,Chennai,"Citizens of Chennai, India ≥10 years old.",,2020-10-08,2020-10-15,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,1171,0.33799999999999997,0.275,0.40700000000000003,,,True,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Muthusamy Kumar,National Institute of Epidemiology,Unity-Aligned,https://academic.oup.com/trstmh/article/115/11/1350/6370308?login=true,2021-11-30,2024-03-01,Verified,kumar_monitoring_2021,IND
210914_Chennai_NationalInstituteofEpidemiology_60andover,210914_Chennai_NationalInstituteofEpidemiology,"Monitoring the trend of SARS-CoV-2 seroprevalence in Chennai, India, July and October 2020",2021-09-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Tamil Nadu,Chennai,"Citizens of Chennai, India ≥10 years old.",,2020-10-08,2020-10-15,Household and community samples,All,Seniors (65+ years),60.0,,Age,≥60,917,0.275,0.21600000000000003,0.342,,,True,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Muthusamy Kumar,National Institute of Epidemiology,Unity-Aligned,https://academic.oup.com/trstmh/article/115/11/1350/6370308?login=true,2021-11-30,2024-03-01,Verified,kumar_monitoring_2021,IND
210914_Chennai_NationalInstituteofEpidemiology_50-59,210914_Chennai_NationalInstituteofEpidemiology,"Monitoring the trend of SARS-CoV-2 seroprevalence in Chennai, India, July and October 2020",2021-09-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Tamil Nadu,Chennai,"Citizens of Chennai, India ≥10 years old.",,2020-10-08,2020-10-15,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,933,0.311,0.24800000000000003,0.38200000000000006,,,True,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Muthusamy Kumar,National Institute of Epidemiology,Unity-Aligned,https://academic.oup.com/trstmh/article/115/11/1350/6370308?login=true,2021-11-30,2024-03-01,Verified,kumar_monitoring_2021,IND
210914_Chennai_NationalInstituteofEpidemiology_Male,210914_Chennai_NationalInstituteofEpidemiology,"Monitoring the trend of SARS-CoV-2 seroprevalence in Chennai, India, July and October 2020",2021-09-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Tamil Nadu,Chennai,"Citizens of Chennai, India ≥10 years old.",,2020-10-08,2020-10-15,Household and community samples,Male,Multiple groups,,,Sex/Gender,,3338,0.299,0.245,0.36,,,True,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Muthusamy Kumar,National Institute of Epidemiology,Unity-Aligned,https://academic.oup.com/trstmh/article/115/11/1350/6370308?login=true,2021-11-30,2024-03-01,Verified,kumar_monitoring_2021,IND
210914_Chennai_NationalInstituteofEpidemiology_30-39,210914_Chennai_NationalInstituteofEpidemiology,"Monitoring the trend of SARS-CoV-2 seroprevalence in Chennai, India, July and October 2020",2021-09-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Tamil Nadu,Chennai,"Citizens of Chennai, India ≥10 years old.",,2020-10-08,2020-10-15,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,1334,0.32299999999999995,0.262,0.391,,,True,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Muthusamy Kumar,National Institute of Epidemiology,Unity-Aligned,https://academic.oup.com/trstmh/article/115/11/1350/6370308?login=true,2021-11-30,2024-03-01,Verified,kumar_monitoring_2021,IND
210914_Chennai_NationalInstituteofEpidemiology_Overall_Crude,210914_Chennai_NationalInstituteofEpidemiology,"Monitoring the trend of SARS-CoV-2 seroprevalence in Chennai, India, July and October 2020",2021-09-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Tamil Nadu,Chennai,"Citizens of Chennai, India ≥10 years old.",,2020-10-08,2020-10-15,Household and community samples,All,Multiple groups,10.0,,Analysis,Crude,6366,0.3223,,,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Muthusamy Kumar,National Institute of Epidemiology,Unity-Aligned,https://academic.oup.com/trstmh/article/115/11/1350/6370308?login=true,2022-01-27,2024-03-01,Verified,kumar_monitoring_2021,IND
210918_Chandigarh_GovernmentMedicalCollegeandHospital_overall,210918_Chandigarh_GovernmentMedicalCollegeandHospital,Sero survey: 80% of Chandigarh’s adults have Covid antibodies,2021-09-18,News and Media,Local,Cross-sectional survey ,India,Punjab,Chandigarh,"people in Chandigarh, aged above 18
...

in July, the department of biochemistry collected 1,200 samples from 30 randomly selected clusters in Chandigarh:
Among these 16 were in urban areas, 11 in rehabilitation colonies and three in rural areas. Both vaccinated and unvaccinated people were sampled",,2021-07-01,2021-07-31,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,,1200,0.802,,,True,,,,True,Simplified probability,Not reported/ Unable to specify,,,,,,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,Hindustan Times Correspondent,Government Medical College and Hospital,Not Unity-Aligned,https://www.hindustantimes.com/cities/chandigarh-news/sero-survey-80-of-chandigarh-s-adults-have-covid-antibodies-101631914347989.html,2021-09-24,2022-07-16,Verified,hindustan_times_correspondent_sero_2021,IND
210919_India_TataMainHospital_Jul2021_Primary,210919_India_TataMainHospital_Jul2021,Results of Serosurveillance and Forecasting the Third Wave of COVID-19 in an Industrial District in India.,2021-09-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Jharkhand,,monthly random sample 1000-4575 individuals in the given community.,,2021-07-01,2021-07-31,Multiple populations,All,Multiple groups,,,Primary Estimate,,4575,0.75,,,True,,,,True,Unclear,Access SARS-CoV-2 IgG Reagent Antibody Test,Beckman Coulter,CLIA,Serum,IgG,Spike,Validated by manufacturers,1.0,1.0,['High'],Unclear,Unclear,Yes,Yes,No,Yes,Yes,Yes,,Deb Sanjay Nag,Tata Main Hospital,Not Unity-Aligned,https://dx.doi.org/10.7759/cureus.18097,2021-10-05,2024-03-01,Verified,nag_results_2021,IND
210919_India_TataMainHospital_Jul2021_Age45-59,210919_India_TataMainHospital_Jul2021,Results of Serosurveillance and Forecasting the Third Wave of COVID-19 in an Industrial District in India.,2021-09-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Jharkhand,,monthly random sample 1000-4575 individuals in the given community.,,2021-07-01,2021-07-31,Multiple populations,All,Adults (18-64 years),45.0,59.0,Age,age: 45-59,1488,0.75,,,,,,,,Unclear,Access SARS-CoV-2 IgG Reagent Antibody Test,Beckman Coulter,CLIA,Serum,IgG,Spike,Validated by manufacturers,1.0,1.0,['High'],Unclear,Unclear,Yes,Yes,No,Yes,Yes,Yes,,Deb Sanjay Nag,Tata Main Hospital,Not Unity-Aligned,https://dx.doi.org/10.7759/cureus.18097,2021-10-05,2024-03-01,Verified,nag_results_2021,IND
210919_India_TataMainHospital_Jul2021_AgeOver60,210919_India_TataMainHospital_Jul2021,Results of Serosurveillance and Forecasting the Third Wave of COVID-19 in an Industrial District in India.,2021-09-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Jharkhand,,monthly random sample 1000-4575 individuals in the given community.,,2021-07-01,2021-07-31,Multiple populations,All,Seniors (65+ years),60.0,,Age,age: >= 60,834,0.7000000000000001,,,,,,,,Unclear,Access SARS-CoV-2 IgG Reagent Antibody Test,Beckman Coulter,CLIA,Serum,IgG,Spike,Validated by manufacturers,1.0,1.0,['High'],Unclear,Unclear,Yes,Yes,No,Yes,Yes,Yes,,Deb Sanjay Nag,Tata Main Hospital,Not Unity-Aligned,https://dx.doi.org/10.7759/cureus.18097,2021-10-05,2024-03-01,Verified,nag_results_2021,IND
210919_India_TataMainHospital_Jul2021_Age0-9,210919_India_TataMainHospital_Jul2021,Results of Serosurveillance and Forecasting the Third Wave of COVID-19 in an Industrial District in India.,2021-09-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Jharkhand,,monthly random sample 1000-4575 individuals in the given community.,,2021-07-01,2021-07-31,Multiple populations,All,Children and Youth (0-17 years),0.0,9.0,Age,age: 0-9,21,0.38,,,,,,,,Unclear,Access SARS-CoV-2 IgG Reagent Antibody Test,Beckman Coulter,CLIA,Serum,IgG,Spike,Validated by manufacturers,1.0,1.0,['High'],Unclear,Unclear,Yes,Yes,No,Yes,Yes,Yes,,Deb Sanjay Nag,Tata Main Hospital,Not Unity-Aligned,https://dx.doi.org/10.7759/cureus.18097,2021-10-05,2024-03-01,Verified,nag_results_2021,IND
210919_India_TataMainHospital_Jul2021_Age18-44,210919_India_TataMainHospital_Jul2021,Results of Serosurveillance and Forecasting the Third Wave of COVID-19 in an Industrial District in India.,2021-09-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Jharkhand,,monthly random sample 1000-4575 individuals in the given community.,,2021-07-01,2021-07-31,Multiple populations,All,Adults (18-64 years),18.0,44.0,Age,age: 18-44,2189,0.49,,,,,,,,Unclear,Access SARS-CoV-2 IgG Reagent Antibody Test,Beckman Coulter,CLIA,Serum,IgG,Spike,Validated by manufacturers,1.0,1.0,['High'],Unclear,Unclear,Yes,Yes,No,Yes,Yes,Yes,,Deb Sanjay Nag,Tata Main Hospital,Not Unity-Aligned,https://dx.doi.org/10.7759/cureus.18097,2021-10-05,2024-03-01,Verified,nag_results_2021,IND
210919_India_TataMainHospital_Jul2021_Age10-17,210919_India_TataMainHospital_Jul2021,Results of Serosurveillance and Forecasting the Third Wave of COVID-19 in an Industrial District in India.,2021-09-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Jharkhand,,monthly random sample 1000-4575 individuals in the given community.,,2021-07-01,2021-07-31,Multiple populations,All,Children and Youth (0-17 years),10.0,17.0,Age,age: 10-17,43,0.42,,,,,,,,Unclear,Access SARS-CoV-2 IgG Reagent Antibody Test,Beckman Coulter,CLIA,Serum,IgG,Spike,Validated by manufacturers,1.0,1.0,['High'],Unclear,Unclear,Yes,Yes,No,Yes,Yes,Yes,,Deb Sanjay Nag,Tata Main Hospital,Not Unity-Aligned,https://dx.doi.org/10.7759/cureus.18097,2021-10-05,2024-03-01,Verified,nag_results_2021,IND
210921_Mumbai_UniversityofPittsburghMedicalCenter_Patients_Overall,210921_Mumbai_UniversityofPittsburghMedicalCenter_Patients,From infection to immunity - Impact of COVID-19 across nine hemodialysis centres in Mumbai,2021-09-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,All hemodialysis patients at 9 hemodialysis centres in Mumbai were included in this study.,There were no exclusion criteria.,2020-03-24,2020-05-17,Residual sera,All,Multiple groups,,,Primary Estimate,,110,0.37270000000000003,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Viswanath Billa,University of Pittsburgh Medical Center,Unity-Aligned,https://dx.doi.org/10.4103/ijn.IJN_361_20,2022-01-09,2024-03-01,Unverified,billa_infection_2021,IND
210921_Mumbai_UniversityofPittsburghMedicalCenter_Staff_Overall,210921_Mumbai_UniversityofPittsburghMedicalCenter_Staff,From infection to immunity - Impact of COVID-19 across nine hemodialysis centres in Mumbai,2021-09-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,Staff caring for patients at 9 hemodialysis centres in Mumbai were included in this study.,There were no exclusion criteria.,2020-03-24,2020-05-17,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,85,0.4353,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Viswanath Billa,University of Pittsburgh Medical Center,Not Unity-Aligned,https://dx.doi.org/10.4103/ijn.IJN_361_20,2022-01-09,2024-03-01,Unverified,billa_infection_2021,IND
210922_PimpriChinchwad_DrDYPatilVidyapeeth_Overall,210922_PimpriChinchwad_DrDYPatilVidyapeeth,"Severe acute respiratory syndrome-coronavirus-2 seroprevalence study in Pimpri-Chinchwad, Maharashtra, India coinciding with falling trend - Do the results suggest imminent herd immunity?.",2021-09-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Pimpri-Chinchwad,Inhabitants of Pimpri-Chinchwad aged 12 years and above.,,2020-10-07,2020-10-17,Household and community samples,All,Multiple groups,12.0,,Primary Estimate,,5000,0.3404,0.313,0.368,True,True,,True,True,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Yes,Amitav Banerjee,"Dr. D. Y. Patil Medical College, Hospital and Research Centre",Unity-Aligned,https://www.ijph.in/article.asp?issn=0019-557X;year=2021;volume=65;issue=3;spage=256;epage=260;aulast=Banerjee,2021-10-05,2023-08-15,Verified,banerjee_severe_2021,IND
210923_Kashmir_GovernmentMedicalCollegeSrinagar_PopAndTestAdjusted,210923_Kashmir_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2-specific IgG antibodies in Kashmir, India, 7 months after the first reported local COVID-19 case: results of a population-based seroprevalence survey from October to November 2020.",2021-09-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Kashmir,,"All adults ≥18 years of age were eligible to participate in the study from all the 10 districts of Kashmir, a valley
in northern India",We excluded people <18 years of age,2020-10-17,2020-11-04,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,Fully adjusted,6230,0.36700000000000005,0.34299999999999997,0.392,True,True,True,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Muhammad Khan,Government Medical College Srinagar,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-053791,2021-10-05,2023-08-15,Verified,khan_seroprevalence_2021,IND
210923_Kashmir_GovernmentMedicalCollegeSrinagar_Female,210923_Kashmir_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2-specific IgG antibodies in Kashmir, India, 7 months after the first reported local COVID-19 case: results of a population-based seroprevalence survey from October to November 2020.",2021-09-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Kashmir,,"All adults ≥18 years of age were eligible to participate in the study from all the 10 districts of Kashmir, a valley
in northern India",We excluded people <18 years of age,2020-10-17,2020-11-04,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,3104,0.378,0.34500000000000003,0.413,,,True,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Muhammad Khan,Government Medical College Srinagar,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-053791,2021-10-05,2024-03-01,Verified,khan_seroprevalence_2021,IND
210923_Kashmir_GovernmentMedicalCollegeSrinagar_Srinagar_Overall,210923_Kashmir_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2-specific IgG antibodies in Kashmir, India, 7 months after the first reported local COVID-19 case: results of a population-based seroprevalence survey from October to November 2020.",2021-09-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Kashmir,,"All adults ≥18 years of age were eligible to participate in the study from all the 10 districts of Kashmir, a valley
in northern India",We excluded people <18 years of age,2020-10-17,2020-11-04,Household and community samples,All,Multiple groups,18.0,,Geographical area,Srinagar,2418,0.40700000000000003,0.38799999999999996,0.42700000000000005,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Muhammad Khan,Government Medical College Srinagar,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-053791,2021-10-05,2024-03-01,Verified,khan_seroprevalence_2021,IND
210923_Kashmir_GovernmentMedicalCollegeSrinagar_Kupwara_Overall,210923_Kashmir_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2-specific IgG antibodies in Kashmir, India, 7 months after the first reported local COVID-19 case: results of a population-based seroprevalence survey from October to November 2020.",2021-09-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Kashmir,,"All adults ≥18 years of age were eligible to participate in the study from all the 10 districts of Kashmir, a valley
in northern India",We excluded people <18 years of age,2020-10-17,2020-11-04,Household and community samples,All,Multiple groups,18.0,,Geographical area,Kupwara,400,0.423,0.375,0.47200000000000003,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Muhammad Khan,Government Medical College Srinagar,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-053791,2021-10-05,2024-03-01,Verified,khan_seroprevalence_2021,IND
210923_Kashmir_GovernmentMedicalCollegeSrinagar_Budgam_Overall,210923_Kashmir_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2-specific IgG antibodies in Kashmir, India, 7 months after the first reported local COVID-19 case: results of a population-based seroprevalence survey from October to November 2020.",2021-09-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Kashmir,,"All adults ≥18 years of age were eligible to participate in the study from all the 10 districts of Kashmir, a valley
in northern India",We excluded people <18 years of age,2020-10-17,2020-11-04,Household and community samples,All,Multiple groups,18.0,,Geographical area,Baramulla,442,0.43,0.384,0.47700000000000004,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Muhammad Khan,Government Medical College Srinagar,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-053791,2021-10-05,2024-03-01,Verified,khan_seroprevalence_2021,IND
210923_Kashmir_GovernmentMedicalCollegeSrinagar_18-29,210923_Kashmir_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2-specific IgG antibodies in Kashmir, India, 7 months after the first reported local COVID-19 case: results of a population-based seroprevalence survey from October to November 2020.",2021-09-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Kashmir,,"All adults ≥18 years of age were eligible to participate in the study from all the 10 districts of Kashmir, a valley
in northern India",We excluded people <18 years of age,2020-10-17,2020-11-04,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,18-29,1513,0.337,0.30100000000000005,0.376,,,True,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Muhammad Khan,Government Medical College Srinagar,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-053791,2021-10-05,2024-03-01,Verified,khan_seroprevalence_2021,IND
210923_Kashmir_GovernmentMedicalCollegeSrinagar_Bandipora_Overall,210923_Kashmir_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2-specific IgG antibodies in Kashmir, India, 7 months after the first reported local COVID-19 case: results of a population-based seroprevalence survey from October to November 2020.",2021-09-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Kashmir,,"All adults ≥18 years of age were eligible to participate in the study from all the 10 districts of Kashmir, a valley
in northern India",We excluded people <18 years of age,2020-10-17,2020-11-04,Household and community samples,All,Multiple groups,18.0,,Geographical area,Budgam,424,0.396,0.35100000000000003,0.444,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Muhammad Khan,Government Medical College Srinagar,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-053791,2021-10-05,2024-03-01,Verified,khan_seroprevalence_2021,IND
210923_Kashmir_GovernmentMedicalCollegeSrinagar_Shopiyan_Overall,210923_Kashmir_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2-specific IgG antibodies in Kashmir, India, 7 months after the first reported local COVID-19 case: results of a population-based seroprevalence survey from October to November 2020.",2021-09-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Kashmir,,"All adults ≥18 years of age were eligible to participate in the study from all the 10 districts of Kashmir, a valley
in northern India",We excluded people <18 years of age,2020-10-17,2020-11-04,Household and community samples,All,Multiple groups,18.0,,Geographical area,Shopiyan,407,0.319,0.276,0.36600000000000005,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Muhammad Khan,Government Medical College Srinagar,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-053791,2021-10-05,2024-03-01,Verified,khan_seroprevalence_2021,IND
210923_Kashmir_GovernmentMedicalCollegeSrinagar_Baramulla_Overall,210923_Kashmir_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2-specific IgG antibodies in Kashmir, India, 7 months after the first reported local COVID-19 case: results of a population-based seroprevalence survey from October to November 2020.",2021-09-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Kashmir,,"All adults ≥18 years of age were eligible to participate in the study from all the 10 districts of Kashmir, a valley
in northern India",We excluded people <18 years of age,2020-10-17,2020-11-04,Household and community samples,All,Multiple groups,18.0,,Geographical area,Bandipora,405,0.34600000000000003,0.30100000000000005,0.39299999999999996,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Muhammad Khan,Government Medical College Srinagar,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-053791,2021-10-05,2024-03-01,Verified,khan_seroprevalence_2021,IND
210923_Kashmir_GovernmentMedicalCollegeSrinagar_50-69,210923_Kashmir_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2-specific IgG antibodies in Kashmir, India, 7 months after the first reported local COVID-19 case: results of a population-based seroprevalence survey from October to November 2020.",2021-09-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Kashmir,,"All adults ≥18 years of age were eligible to participate in the study from all the 10 districts of Kashmir, a valley
in northern India",We excluded people <18 years of age,2020-10-17,2020-11-04,Household and community samples,All,Multiple groups,50.0,69.0,Age,50-69,1643,0.425,0.38799999999999996,0.462,,,True,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Muhammad Khan,Government Medical College Srinagar,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-053791,2021-10-05,2024-03-01,Verified,khan_seroprevalence_2021,IND
210923_Kashmir_GovernmentMedicalCollegeSrinagar_over70,210923_Kashmir_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2-specific IgG antibodies in Kashmir, India, 7 months after the first reported local COVID-19 case: results of a population-based seroprevalence survey from October to November 2020.",2021-09-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Kashmir,,"All adults ≥18 years of age were eligible to participate in the study from all the 10 districts of Kashmir, a valley
in northern India",We excluded people <18 years of age,2020-10-17,2020-11-04,Household and community samples,All,Seniors (65+ years),70.0,,Age,,402,0.45299999999999996,0.378,0.53,,,True,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Muhammad Khan,Government Medical College Srinagar,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-053791,2021-10-05,2024-03-01,Verified,khan_seroprevalence_2021,IND
210923_Kashmir_GovernmentMedicalCollegeSrinagar_Kulgam_Overall,210923_Kashmir_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2-specific IgG antibodies in Kashmir, India, 7 months after the first reported local COVID-19 case: results of a population-based seroprevalence survey from October to November 2020.",2021-09-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Kashmir,,"All adults ≥18 years of age were eligible to participate in the study from all the 10 districts of Kashmir, a valley
in northern India",We excluded people <18 years of age,2020-10-17,2020-11-04,Household and community samples,All,Multiple groups,18.0,,Geographical area,Kulgam,428,0.28500000000000003,0.244,0.33,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Muhammad Khan,Government Medical College Srinagar,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-053791,2021-10-05,2024-03-01,Verified,khan_seroprevalence_2021,IND
210923_Kashmir_GovernmentMedicalCollegeSrinagar_Anantnag_Overall,210923_Kashmir_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2-specific IgG antibodies in Kashmir, India, 7 months after the first reported local COVID-19 case: results of a population-based seroprevalence survey from October to November 2020.",2021-09-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Kashmir,,"All adults ≥18 years of age were eligible to participate in the study from all the 10 districts of Kashmir, a valley
in northern India",We excluded people <18 years of age,2020-10-17,2020-11-04,Household and community samples,All,Multiple groups,18.0,,Geographical area,Anantnag,421,0.35200000000000004,0.307,0.39799999999999996,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Muhammad Khan,Government Medical College Srinagar,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-053791,2021-10-05,2024-03-01,Verified,khan_seroprevalence_2021,IND
210923_Kashmir_GovernmentMedicalCollegeSrinagar_Male,210923_Kashmir_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2-specific IgG antibodies in Kashmir, India, 7 months after the first reported local COVID-19 case: results of a population-based seroprevalence survey from October to November 2020.",2021-09-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Kashmir,,"All adults ≥18 years of age were eligible to participate in the study from all the 10 districts of Kashmir, a valley
in northern India",We excluded people <18 years of age,2020-10-17,2020-11-04,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,3126,0.36100000000000004,0.335,0.389,,,True,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Muhammad Khan,Government Medical College Srinagar,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-053791,2021-10-05,2024-03-01,Verified,khan_seroprevalence_2021,IND
210923_Kashmir_GovernmentMedicalCollegeSrinagar_Pulwama_Overall,210923_Kashmir_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2-specific IgG antibodies in Kashmir, India, 7 months after the first reported local COVID-19 case: results of a population-based seroprevalence survey from October to November 2020.",2021-09-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Kashmir,,"All adults ≥18 years of age were eligible to participate in the study from all the 10 districts of Kashmir, a valley
in northern India",We excluded people <18 years of age,2020-10-17,2020-11-04,Household and community samples,All,Multiple groups,18.0,,Geographical area,Pulwama,443,0.43100000000000005,0.386,0.478,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Muhammad Khan,Government Medical College Srinagar,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-053791,2021-10-05,2024-03-01,Verified,khan_seroprevalence_2021,IND
210923_Kashmir_GovernmentMedicalCollegeSrinagar_30-49,210923_Kashmir_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2-specific IgG antibodies in Kashmir, India, 7 months after the first reported local COVID-19 case: results of a population-based seroprevalence survey from October to November 2020.",2021-09-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Kashmir,,"All adults ≥18 years of age were eligible to participate in the study from all the 10 districts of Kashmir, a valley
in northern India",We excluded people <18 years of age,2020-10-17,2020-11-04,Household and community samples,All,Adults (18-64 years),30.0,49.0,Age,30-49,2672,0.363,0.335,0.39299999999999996,,,True,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Muhammad Khan,Government Medical College Srinagar,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-053791,2021-10-05,2024-03-01,Verified,khan_seroprevalence_2021,IND
210923_Kashmir_GovernmentMedicalCollegeSrinagar_PopAdjusted,210923_Kashmir_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2-specific IgG antibodies in Kashmir, India, 7 months after the first reported local COVID-19 case: results of a population-based seroprevalence survey from October to November 2020.",2021-09-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Kashmir,,"All adults ≥18 years of age were eligible to participate in the study from all the 10 districts of Kashmir, a valley
in northern India",We excluded people <18 years of age,2020-10-17,2020-11-04,Household and community samples,All,Multiple groups,18.0,,Analysis,Population Adjusted,6230,0.369,0.34500000000000003,0.394,,,True,True,True,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Muhammad Khan,Government Medical College Srinagar,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-053791,2021-10-05,2024-03-01,Verified,khan_seroprevalence_2021,IND
210923_Kashmir_GovernmentMedicalCollegeSrinagar_Ganderbal_Overall,210923_Kashmir_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2-specific IgG antibodies in Kashmir, India, 7 months after the first reported local COVID-19 case: results of a population-based seroprevalence survey from October to November 2020.",2021-09-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Kashmir,,"All adults ≥18 years of age were eligible to participate in the study from all the 10 districts of Kashmir, a valley
in northern India",We excluded people <18 years of age,2020-10-17,2020-11-04,Household and community samples,All,Multiple groups,18.0,,Geographical area,Ganderbal,442,0.391,0.34700000000000003,0.438,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Muhammad Khan,Government Medical College Srinagar,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-053791,2021-10-05,2024-03-01,Verified,khan_seroprevalence_2021,IND
210930_Kerala_GovernmentOfKerala_Antenatal_Primary,210930_Kerala_GovernmentOfKerala_Antenatal2,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,"The study included pregnant women in any trimester age 18-49 years attending
antenatal care clinics in Kerala","Those individuals not willing to consent for the study , severe comorbidity, active labour, presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-08-15,2021-09-15,Pregnant or parturient women,Female,Adults (18-64 years),18.0,49.0,Primary Estimate,,2274,0.654,0.634,0.674,True,,,,True,Convenience,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Antenatal_Age18-29,210930_Kerala_GovernmentOfKerala_Antenatal2,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,"The study included pregnant women in any trimester age 18-49 years attending
antenatal care clinics in Kerala","Those individuals not willing to consent for the study , severe comorbidity, active labour, presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-08-15,2021-09-15,Pregnant or parturient women,Female,Adults (18-64 years),18.0,29.0,Age,18-29,1660,0.659,,,,,,,,Convenience,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Antenatal_AbbottAntiN,210930_Kerala_GovernmentOfKerala_Antenatal2,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,"The study included pregnant women in any trimester age 18-49 years attending
antenatal care clinics in Kerala","Those individuals not willing to consent for the study , severe comorbidity, active labour, presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-08-15,2021-09-15,Pregnant or parturient women,Female,Adults (18-64 years),18.0,49.0,Test used,Abbott test,2411,0.163,0.14800000000000002,0.17800000000000002,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Antenatal_Age30-44,210930_Kerala_GovernmentOfKerala_Antenatal2,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,"The study included pregnant women in any trimester age 18-49 years attending
antenatal care clinics in Kerala","Those individuals not willing to consent for the study , severe comorbidity, active labour, presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-08-15,2021-09-15,Pregnant or parturient women,Female,Adults (18-64 years),30.0,44.0,Age,30-44,611,0.64,,,,,,,,Convenience,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Antenatal_Age45-59,210930_Kerala_GovernmentOfKerala_Antenatal2,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,"The study included pregnant women in any trimester age 18-49 years attending
antenatal care clinics in Kerala","Those individuals not willing to consent for the study , severe comorbidity, active labour, presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-08-15,2021-09-15,Pregnant or parturient women,Female,Adults (18-64 years),45.0,49.0,Age,45-49,3,0.667,,,,,,,,Convenience,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Antenatal_Vaccinated,210930_Kerala_GovernmentOfKerala_Antenatal2,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,"The study included pregnant women in any trimester age 18-49 years attending
antenatal care clinics in Kerala","Those individuals not willing to consent for the study , severe comorbidity, active labour, presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-08-15,2021-09-15,Pregnant or parturient women,Female,Adults (18-64 years),18.0,49.0,COVID-19 vaccination status,Vaccinated Yes,937,0.876,,,,,,,,Convenience,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Antenatal_Siemens_AntiS,210930_Kerala_GovernmentOfKerala_Antenatal2,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,"The study included pregnant women in any trimester age 18-49 years attending
antenatal care clinics in Kerala","Those individuals not willing to consent for the study , severe comorbidity, active labour, presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-08-15,2021-09-15,Pregnant or parturient women,Female,Adults (18-64 years),18.0,49.0,Test used,Siemens test,2355,0.642,0.623,0.662,,,,,,Convenience,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Serum,IgG,Spike,,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Antenatal_Unvaccinated,210930_Kerala_GovernmentOfKerala_Antenatal2,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,"The study included pregnant women in any trimester age 18-49 years attending
antenatal care clinics in Kerala","Those individuals not willing to consent for the study , severe comorbidity, active labour, presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-08-15,2021-09-15,Pregnant or parturient women,Female,Adults (18-64 years),18.0,49.0,COVID-19 vaccination status,Vaccinated No,1337,0.498,,,,,,,,Convenience,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Children_Primary,210930_Kerala_GovernmentOfKerala_Children3,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,Children aged 5 to 17 years from selected households in Kerala ,"Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Children and Youth (0-17 years),5.0,17.0,Primary Estimate,,1459,0.402,,,True,,,,True,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Children_Female,210930_Kerala_GovernmentOfKerala_Children3,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,Children aged 5 to 17 years from selected households in Kerala ,"Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,Female,Children and Youth (0-17 years),5.0,17.0,Sex/Gender,,756,0.435,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Children_Abbott_AntiN,210930_Kerala_GovernmentOfKerala_Children3,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,Children aged 5 to 17 years from selected households in Kerala ,"Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Children and Youth (0-17 years),5.0,17.0,Test used,Abbott test,1491,0.18,,,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Children_Age5-8,210930_Kerala_GovernmentOfKerala_Children3,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,Children aged 5 to 17 years from selected households in Kerala ,"Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Children and Youth (0-17 years),5.0,8.0,Age,5-8 ,320,0.42100000000000004,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Children_Age9-11,210930_Kerala_GovernmentOfKerala_Children3,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,Children aged 5 to 17 years from selected households in Kerala ,"Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Children and Youth (0-17 years),9.0,11.0,Age,9-11,349,0.395,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Children_Age12-14,210930_Kerala_GovernmentOfKerala_Children3,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,Children aged 5 to 17 years from selected households in Kerala ,"Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Children and Youth (0-17 years),12.0,14.0,Age,12-14,383,0.42,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Children_Age15-17,210930_Kerala_GovernmentOfKerala_Children3,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,Children aged 5 to 17 years from selected households in Kerala ,"Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Children and Youth (0-17 years),15.0,17.0,Age,15-17,407,0.373,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Children_Male,210930_Kerala_GovernmentOfKerala_Children3,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,Children aged 5 to 17 years from selected households in Kerala ,"Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,Male,Children and Youth (0-17 years),5.0,17.0,Sex/Gender,,703,0.36600000000000005,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Children_Siemens_AntiS,210930_Kerala_GovernmentOfKerala_Children3,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,Children aged 5 to 17 years from selected households in Kerala ,"Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Children and Youth (0-17 years),5.0,17.0,Test used,Siemens test,1471,0.396,,,,,,,,Stratified probability,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Coastal_Primary,210930_Kerala_GovernmentOfKerala_Coastal5,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,Over 18 years of age living in coastal regions of Kerala,"Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,1476,0.877,0.86,0.893,True,,,,True,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Coastal_Male,210930_Kerala_GovernmentOfKerala_Coastal5,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,Over 18 years of age living in coastal regions of Kerala,"Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,674,0.872,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Coastal_Age18-29,210930_Kerala_GovernmentOfKerala_Coastal5,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,Over 18 years of age living in coastal regions of Kerala,"Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,18-29,231,0.892,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Coastal_Age45-59,210930_Kerala_GovernmentOfKerala_Coastal5,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,Over 18 years of age living in coastal regions of Kerala,"Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Adults (18-64 years),45.0,59.0,Age,45-59 ,494,0.883,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Coastal_Age30-44,210930_Kerala_GovernmentOfKerala_Coastal5,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,Over 18 years of age living in coastal regions of Kerala,"Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Adults (18-64 years),30.0,44.0,Age,30-44 ,452,0.855,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Coastal_Female,210930_Kerala_GovernmentOfKerala_Coastal5,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,Over 18 years of age living in coastal regions of Kerala,"Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,802,0.88,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Coastal_Siemens_AntiS,210930_Kerala_GovernmentOfKerala_Coastal5,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,Over 18 years of age living in coastal regions of Kerala,"Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Multiple groups,18.0,,Test used,Siemens test,1514,0.866,0.8490000000000001,0.883,,,,,,Stratified probability,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Coastal_Age75,210930_Kerala_GovernmentOfKerala_Coastal5,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,Over 18 years of age living in coastal regions of Kerala,"Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Seniors (65+ years),75.0,,Age,75+,32,0.7190000000000001,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Coastal_Unvaccinated,210930_Kerala_GovernmentOfKerala_Coastal5,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,Over 18 years of age living in coastal regions of Kerala,"Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Multiple groups,18.0,,COVID-19 vaccination status,Vaccinated No,341,0.76,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Coastal_Age60-74,210930_Kerala_GovernmentOfKerala_Coastal5,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,Over 18 years of age living in coastal regions of Kerala,"Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Seniors (65+ years),60.0,74.0,Age,60-74,267,0.903,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Coastal_Abbott_AntiN,210930_Kerala_GovernmentOfKerala_Coastal5,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,Over 18 years of age living in coastal regions of Kerala,"Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Multiple groups,18.0,,Test used,Abbott test,1499,0.336,0.312,0.359,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Coastal_Vaccinated,210930_Kerala_GovernmentOfKerala_Coastal5,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,Over 18 years of age living in coastal regions of Kerala,"Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Multiple groups,18.0,,COVID-19 vaccination status,Vaccinated Yes,1135,0.9119,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_GenPop_Primary,210930_Kerala_GovernmentOfKerala_GeneralPopulation1,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,Over 18 years of age,"Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,4429,0.8261000000000001,0.8150000000000001,0.8373,True,,,,True,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_GenPop_Female,210930_Kerala_GovernmentOfKerala_GeneralPopulation1,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,Over 18 years of age,"Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,2276,0.8247,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_GenPop_Vaccinated,210930_Kerala_GovernmentOfKerala_GeneralPopulation1,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,Over 18 years of age,"Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Multiple groups,18.0,,COVID-19 vaccination status,Vaccinated Yes,3582,0.8559000000000001,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_GenPop_Age18-29,210930_Kerala_GovernmentOfKerala_GeneralPopulation1,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,Over 18 years of age,"Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,18-29,698,0.7937000000000001,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_GenPop_Age75+,210930_Kerala_GovernmentOfKerala_GeneralPopulation1,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,Over 18 years of age,"Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Seniors (65+ years),75.0,,Age,75+,123,0.7724,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_GenPop_Age45-59,210930_Kerala_GovernmentOfKerala_GeneralPopulation1,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,Over 18 years of age,"Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Adults (18-64 years),45.0,59.0,Age,45-59 ,1435,0.8578,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_GenPop_Abbott_AntiN,210930_Kerala_GovernmentOfKerala_GeneralPopulation1,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,Over 18 years of age,"Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Multiple groups,18.0,,Test used,Abbott test,4511,0.19260000000000002,0.1804,0.2034,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_GenPop_Age60-74,210930_Kerala_GovernmentOfKerala_GeneralPopulation1,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,Over 18 years of age,"Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Seniors (65+ years),60.0,74.0,Age,60-74,825,0.8570000000000001,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_GenPop_Unvaccinated,210930_Kerala_GovernmentOfKerala_GeneralPopulation1,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,Over 18 years of age,"Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Multiple groups,18.0,,COVID-19 vaccination status,Vaccinated No,847,0.7001000000000001,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_GenPop_Siemens_AntiS,210930_Kerala_GovernmentOfKerala_GeneralPopulation1,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,Over 18 years of age,"Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Multiple groups,18.0,,Test used,Siemens test,4537,0.8214,0.8092,0.8315000000000001,,,,,,Stratified probability,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_GenPop_Male,210930_Kerala_GovernmentOfKerala_GeneralPopulation1,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,Over 18 years of age,"Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,2153,0.8277,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_GenPop_Age30-44,210930_Kerala_GovernmentOfKerala_GeneralPopulation1,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,Over 18 years of age,"Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Adults (18-64 years),30.0,44.0,Age,30-44 ,1348,0.7953,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Slum_Primary,210930_Kerala_GovernmentOfKerala_Slum6,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,"Over 18 years of age, living in an urban slum in Kerala","Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Persons living in slums,All,Multiple groups,18.0,,Primary Estimate,,1706,0.853,0.8362999999999999,0.8697,True,,,,True,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Slum_Age75+,210930_Kerala_GovernmentOfKerala_Slum6,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,"Over 18 years of age, living in an urban slum in Kerala","Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Persons living in slums,All,Seniors (65+ years),75.0,,Age,75+,37,0.865,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-20,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Slum_Age30-44,210930_Kerala_GovernmentOfKerala_Slum6,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,"Over 18 years of age, living in an urban slum in Kerala","Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Persons living in slums,All,Adults (18-64 years),30.0,44.0,Age,30-44 ,547,0.835,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-20,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Slum_Age60-74,210930_Kerala_GovernmentOfKerala_Slum6,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,"Over 18 years of age, living in an urban slum in Kerala","Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Persons living in slums,All,Seniors (65+ years),60.0,74.0,Age,60-74,294,0.881,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-20,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Slum_Male,210930_Kerala_GovernmentOfKerala_Slum6,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,"Over 18 years of age, living in an urban slum in Kerala","Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Persons living in slums,Male,Multiple groups,18.0,,Sex/Gender,,713,0.843,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-20,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Slum_Vaccinated,210930_Kerala_GovernmentOfKerala_Slum6,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,"Over 18 years of age, living in an urban slum in Kerala","Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Persons living in slums,All,Multiple groups,18.0,,COVID-19 vaccination status,Vaccinated Yes,1354,0.8863,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-20,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Slum_Age45-59,210930_Kerala_GovernmentOfKerala_Slum6,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,"Over 18 years of age, living in an urban slum in Kerala","Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Persons living in slums,All,Adults (18-64 years),45.0,59.0,Age,45-59 ,577,0.8790000000000001,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-20,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Slum_Siemens_AntiS,210930_Kerala_GovernmentOfKerala_Slum6,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,"Over 18 years of age, living in an urban slum in Kerala","Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Persons living in slums,All,Multiple groups,18.0,,Test used,Siemens test,1770,0.848,0.8312999999999999,0.8647,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Slum_Unvaccinated,210930_Kerala_GovernmentOfKerala_Slum6,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,"Over 18 years of age, living in an urban slum in Kerala","Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Persons living in slums,All,Multiple groups,18.0,,COVID-19 vaccination status,Vaccinated No,352,0.7240000000000001,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-20,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Slum_AbbottAntiN,210930_Kerala_GovernmentOfKerala_Slum6,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,"Over 18 years of age, living in an urban slum in Kerala","Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Persons living in slums,All,Multiple groups,18.0,,Test used,Abbott test,1768,0.303,0.2817,0.3243,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Slum_Female,210930_Kerala_GovernmentOfKerala_Slum6,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,"Over 18 years of age, living in an urban slum in Kerala","Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Persons living in slums,Female,Multiple groups,18.0,,Sex/Gender,,993,0.86,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-20,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Slum_Age18-29,210930_Kerala_GovernmentOfKerala_Slum6,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,"Over 18 years of age, living in an urban slum in Kerala","Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Persons living in slums,All,Adults (18-64 years),18.0,29.0,Age,18-29,251,0.797,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-20,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Tribal_Primary,210930_Kerala_GovernmentOfKerala_Tribal4,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,"Over 18 years of age, resident of tribal communities/hamlets in rural Kerala","Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,1521,0.782,,,True,,,,True,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Tribal_Female,210930_Kerala_GovernmentOfKerala_Tribal4,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,"Over 18 years of age, resident of tribal communities/hamlets in rural Kerala","Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,860,0.805,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Tribal_Vaccinated,210930_Kerala_GovernmentOfKerala_Tribal4,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,"Over 18 years of age, resident of tribal communities/hamlets in rural Kerala","Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Multiple groups,18.0,,COVID-19 vaccination status,Vaccinated yes,1187,0.813,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Tribal_Age18-29,210930_Kerala_GovernmentOfKerala_Tribal4,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,"Over 18 years of age, resident of tribal communities/hamlets in rural Kerala","Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,18-29,328,0.762,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Tribal_Age75+,210930_Kerala_GovernmentOfKerala_Tribal4,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,"Over 18 years of age, resident of tribal communities/hamlets in rural Kerala","Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Seniors (65+ years),75.0,,Age,75+,33,0.6970000000000001,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Tribal_Male,210930_Kerala_GovernmentOfKerala_Tribal4,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,"Over 18 years of age, resident of tribal communities/hamlets in rural Kerala","Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,661,0.752,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Tribal_Age45-59,210930_Kerala_GovernmentOfKerala_Tribal4,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,"Over 18 years of age, resident of tribal communities/hamlets in rural Kerala","Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Adults (18-64 years),45.0,59.0,Age,45-59 ,427,0.8150000000000001,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Tribal_Age30-44,210930_Kerala_GovernmentOfKerala_Tribal4,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,"Over 18 years of age, resident of tribal communities/hamlets in rural Kerala","Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Adults (18-64 years),30.0,44.0,Age,30-44 ,506,0.745,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Tribal_Age60-74,210930_Kerala_GovernmentOfKerala_Tribal4,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,"Over 18 years of age, resident of tribal communities/hamlets in rural Kerala","Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Seniors (65+ years),60.0,74.0,Age,60-74,227,0.841,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_Kerala_GovernmentOfKerala_Tribal_Unvaccinated,210930_Kerala_GovernmentOfKerala_Tribal4,Kerala COVID-19 (SARS CoV2 IgG) Seroprevalence Study September 2021,2021-09-30,Institutional Report,Regional,Cross-sectional survey ,India,Kerala,,"Over 18 years of age, resident of tribal communities/hamlets in rural Kerala","Those individuals not willing to consent for the study , presently active COVID cases in home
treatment, persons on quarantine, travellers who have arrived in Kerala within the last 4 weeks,
and those with contraindication to venepuncture were excluded from the survey",2021-09-01,2021-09-30,Household and community samples,All,Multiple groups,18.0,,COVID-19 vaccination status,Vaccinated No,334,0.6709999999999999,,,,,,,,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Government of Kerala,Government of Kerala Department of Health,Unity-Aligned,https://health.kerala.gov.in/pdf/Sero_Surveillance_Report_aug_sep.pdf,2021-11-19,2024-03-01,Verified,department_of_health__family_welfare_government_of_kerala_covid_nodate,IND
210930_India_48FieldHealthOrganization_Primary,210930_India_48FieldHealthOrganization,Seroprevalence of SARS-COV2 Antibodies among the Serving Personnel of South Western Command: A Multi-Centric Study,2021-09-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,"Punjab, UP, Haryana, and Rajasthan",,"The inclusion criteria were all available serving personnel more than 18 years of age in the designated eight stations.

In addition, a purposive sample of those exposed to a large
number of persons or civilians (owing to their job profile
like persons in key/central appointments, salespersons in
shopping areas, drivers, guards, sentries, etc.,) were added to
the calculated sample size and analyzed separately.","individuals on leave during the study period or individuals
with any contraindication to phlebotomy.",2020-10-15,2020-11-15,Non-essential workers and unemployed persons,All,Multiple groups,18.0,,Primary Estimate,4 stations: ELISA + 4 stations: RAPID,3680,0.16570000000000001,,,True,,,,True,Stratified non-probability,"Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ","Zydus Diagnostics,SD Biosensor",Multiple Types,Serum,"['IgG', 'IgM']",,,,,['High'],,No,Yes,Yes,,Unclear,No,No,,Vikram Grewal,48 Field Health Organization,Not Unity-Aligned,https://www.marinemedicalsociety.in/article.asp?issn=0975-3605;year=2021;volume=23;issue=2;spage=171;epage=177;aulast=Grewal,2022-03-08,2024-03-01,Unverified,grewal_seroprevalence_2021,IND
211005_NewDelhi_AllIndiaInstituteofMedicalSciences_Overall,211005_NewDelhi_AllIndiaInstituteofMedicalSciences,Impact of SARS-CoV-2 on Progression of Glycemic and Cardiometabolic Variables and Changes in Insulin Indices: A Longitudinal Study.,2021-10-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Delhi,New Delhi,"Women with and without history of hyperglycemia in pregnancy and their spouses who are part of an existing cohort (aged 20–50 years) were included in this study. To be eligible, a participant should have been evaluated twice: (a) before the onset of COVID-19 outbreak (pre-COVID period; 2016–19), and (b) during the time of COVID-19 outbreak (peri-COVID period; 2020–21).","Since the study aimed to evaluate the progression of glycemic parameters, subjects with diabetes at the initial visit were excluded.",2020-01-01,2021-02-26,Household and community samples,All,Adults (18-64 years),20.0,50.0,Primary Estimate,,352,0.452,,,True,,,,True,Unclear,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,,IgG,Spike,Validated by manufacturers,0.9740000000000001,0.985,['High'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Alpesh Goyal,All India Institute of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s13300-021-01158-z,2021-10-12,2024-03-01,Unverified,goyal_impact_2021,IND
211007_NorthIndia_ArmyCollegeOfMedicalSciencesAndBaseHospitalDelhiCantt_ArmedForces_Overall,211007_NorthIndia_ArmyCollegeOfMedicalSciencesAndBaseHospitalDelhiCantt_ArmedForces,Prevaccination Seroprevalence of COVID-19 Immunoglobulin G Antibodies in Health-care Personnel and General Population after First Pandemic Wave in a Himalayan Region in North India,2021-10-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,A Himalayan Region in North India,,All individuals more than 18 years of age were included.,Individuals having contraindications to venipuncture were excluded.,2021-02-01,2021-02-28,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,400,0.34500000000000003,0.3,0.392,True,,,,True,Stratified probability,KAVACH Karwa SARS-COV 2 IgG ELISA,Karwa Enterprises,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.93,1.0,['High'],,Yes,No,Yes,,Yes,Yes,Yes,,Inam Khan,Army College of Medical Sciences and Base Hospital Delhi Cantt,Not Unity-Aligned,10.4103/jmms.jmms_73_21,2022-03-02,2024-03-01,Unverified,khan_prevaccination_2021,IND
211007_NorthIndia_ArmyCollegeOfMedicalSciencesAndBaseHospitalDelhiCantt_HCWs_Overall,211007_NorthIndia_ArmyCollegeOfMedicalSciencesAndBaseHospitalDelhiCantt_HCWs,Prevaccination Seroprevalence of COVID-19 Immunoglobulin G Antibodies in Health-care Personnel and General Population after First Pandemic Wave in a Himalayan Region in North India,2021-10-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,A Himalayan Region in North India,,All individuals more than 18 years of age were included.,Individuals having contraindications to venipuncture were excluded.,2021-02-01,2021-02-28,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,570,0.39299999999999996,0.354,0.433,True,,,,True,Stratified probability,KAVACH Karwa SARS-COV 2 IgG ELISA,Karwa Enterprises,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.93,1.0,['High'],,Yes,No,Yes,,Yes,Yes,Yes,,Inam Khan,Army College of Medical Sciences and Base Hospital Delhi Cantt,Not Unity-Aligned,10.4103/jmms.jmms_73_21,2022-03-02,2024-03-01,Unverified,khan_prevaccination_2021,IND
211011_Kerala_KeralaGovernment_Primary,211011_Kerala_KeralaGovernment,"82% adults in state have Covid-19 antibodies, says latest serosurvey in Kerala",2021-10-11,News and Media,Regional,Cross-sectional survey ,India,Kerala,,,,2021-07-04,2021-08-07,Household and community samples,All,Multiple groups,19.0,,Primary Estimate,,13000,0.826,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,Hindustan Times,Kerala Government,Not Unity-Aligned,https://www.hindustantimes.com/india-news/82-adults-in-state-have-covid-19-antibodies-says-latest-serosurvey-in-kerala-101633964468707.html,2021-10-19,2022-07-16,Verified,ht_correspondent_82_2021,IND
211013_Cuttack_SriramChandraBhanjaMedicalCollegeandHospital_Primary,211013_Cuttack_SriramChandraBhanjaMedicalCollegeandHospital,SARS COV-2- IgG antibodies in blood donors in pandemic - a game changer for policy makers.,2021-10-13,Journal Article (Peer-Reviewed),Local,Prospective cohort,India,"Odisha
",Cuttack,"1. Age group between 18-65 years
2. Those who have neither any history of fever (body temperature ≤37.3°C) nor any
respiratory symptoms for at least 28 days
4. Body temperature being normal before donation (≤37.3°C)
5. Donors were informed regarding the antibody testing against COVID 19 infections.
Only those who gave consent to be tested for SARS- COV-2 IgG antibodies were
included in the study.
6. Those with Haemoglobin >12.5g/dl, platelet count>1,50,000 per microliter of blood
and Total Leukocyte Count within normal limits were accepted.
7. All participants who were confirmed to be free from all viral infections including
Hepatitis B and C, Human immunodeficiency virus (HIV) 1 and 2 after being tested
with Enzyme linked Immosorbent Assay (ELISA) and Nucleic Acid Amplification
(NAT) testing","Following individuals with any of the following criteria/symptoms were excluded from
the study as per the Drugs and Cosmetics Act of 1940 (as amended up to the 31st December,
2016) of Govt. of India:
1. who were below 50 kg
2. under 18 years or above 65 years
3. having Haemoglobin of less than 12.5gm%
4. recently recovered after surgery
5. recently received blood transfusion
6. suffering from chronic respiratory diseases (asthmatic attack, asthmatics on
steroid)
7. cardiovascular diseases (myocardial infarction, hypertensive heart disease,
coronary artery disease, angina pectoris, rheumatic heart disease)
8. endocrine diseases (diabetes on insulin, hyper/hypothyroid, thyrotoxicosis due to
Graves’ disease)
9. chronic infection of kidney/renal failure
10. any carcinoma
11. suffering from HIV, Hepatitis B/C, Syphilis, Gonorrhoea, Leishmaniasis, leprosy

Those who presented physically identifiable symptoms of any infection, including cough,
sore throat, or fever.

Those who did not give consent to be tested for SARS- COV-2 IgG antibodies.",2020-11-01,2021-01-31,Blood donors,All,Adults (18-64 years),18.0,60.0,Primary Estimate,,1032,0.35850000000000004,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Smita Mahapatra,Sriram Chandra Bhanja Medical College and Hospital,Unity-Aligned,https://dx.doi.org/10.1016/j.tracli.2021.10.004,2021-10-26,2024-03-01,Verified,mahapatra_sars_2021,IND
211013_Cuttack_SriramChandraBhanjaMedicalCollegeandHospital_21-40,211013_Cuttack_SriramChandraBhanjaMedicalCollegeandHospital,SARS COV-2- IgG antibodies in blood donors in pandemic - a game changer for policy makers.,2021-10-13,Journal Article (Peer-Reviewed),Local,Prospective cohort,India,Odisha,Cuttack,"1. Age group between 18-65 years
2. Those who have neither any history of fever (body temperature ≤37.3°C) nor any
respiratory symptoms for at least 28 days
4. Body temperature being normal before donation (≤37.3°C)
5. Donors were informed regarding the antibody testing against COVID 19 infections.
Only those who gave consent to be tested for SARS- COV-2 IgG antibodies were
included in the study.
6. Those with Haemoglobin >12.5g/dl, platelet count>1,50,000 per microliter of blood
and Total Leukocyte Count within normal limits were accepted.
7. All participants who were confirmed to be free from all viral infections including
Hepatitis B and C, Human immunodeficiency virus (HIV) 1 and 2 after being tested
with Enzyme linked Immosorbent Assay (ELISA) and Nucleic Acid Amplification
(NAT) testing","Following individuals with any of the following criteria/symptoms were excluded from
the study as per the Drugs and Cosmetics Act of 1940 (as amended up to the 31st December,
2016) of Govt. of India:
1. who were below 50 kg
2. under 18 years or above 65 years
3. having Haemoglobin of less than 12.5gm%
4. recently recovered after surgery
5. recently received blood transfusion
6. suffering from chronic respiratory diseases (asthmatic attack, asthmatics on
steroid)
7. cardiovascular diseases (myocardial infarction, hypertensive heart disease,
coronary artery disease, angina pectoris, rheumatic heart disease)
8. endocrine diseases (diabetes on insulin, hyper/hypothyroid, thyrotoxicosis due to
Graves’ disease)
9. chronic infection of kidney/renal failure
10. any carcinoma
11. suffering from HIV, Hepatitis B/C, Syphilis, Gonorrhoea, Leishmaniasis, leprosy

Those who presented physically identifiable symptoms of any infection, including cough,
sore throat, or fever.

Those who did not give consent to be tested for SARS- COV-2 IgG antibodies.",2020-11-01,2021-01-31,Blood donors,All,Adults (18-64 years),21.0,40.0,Age,21-40 years-old,869,0.37170000000000003,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Smita Mahapatra,Sriram Chandra Bhanja Medical College and Hospital,Unity-Aligned,https://dx.doi.org/10.1016/j.tracli.2021.10.004,2021-10-26,2024-03-01,Verified,mahapatra_sars_2021,IND
211013_Cuttack_SriramChandraBhanjaMedicalCollegeandHospital_Male,211013_Cuttack_SriramChandraBhanjaMedicalCollegeandHospital,SARS COV-2- IgG antibodies in blood donors in pandemic - a game changer for policy makers.,2021-10-13,Journal Article (Peer-Reviewed),Local,Prospective cohort,India,Odisha,Cuttack,"1. Age group between 18-65 years
2. Those who have neither any history of fever (body temperature ≤37.3°C) nor any
respiratory symptoms for at least 28 days
4. Body temperature being normal before donation (≤37.3°C)
5. Donors were informed regarding the antibody testing against COVID 19 infections.
Only those who gave consent to be tested for SARS- COV-2 IgG antibodies were
included in the study.
6. Those with Haemoglobin >12.5g/dl, platelet count>1,50,000 per microliter of blood
and Total Leukocyte Count within normal limits were accepted.
7. All participants who were confirmed to be free from all viral infections including
Hepatitis B and C, Human immunodeficiency virus (HIV) 1 and 2 after being tested
with Enzyme linked Immosorbent Assay (ELISA) and Nucleic Acid Amplification
(NAT) testing","Following individuals with any of the following criteria/symptoms were excluded from
the study as per the Drugs and Cosmetics Act of 1940 (as amended up to the 31st December,
2016) of Govt. of India:
1. who were below 50 kg
2. under 18 years or above 65 years
3. having Haemoglobin of less than 12.5gm%
4. recently recovered after surgery
5. recently received blood transfusion
6. suffering from chronic respiratory diseases (asthmatic attack, asthmatics on
steroid)
7. cardiovascular diseases (myocardial infarction, hypertensive heart disease,
coronary artery disease, angina pectoris, rheumatic heart disease)
8. endocrine diseases (diabetes on insulin, hyper/hypothyroid, thyrotoxicosis due to
Graves’ disease)
9. chronic infection of kidney/renal failure
10. any carcinoma
11. suffering from HIV, Hepatitis B/C, Syphilis, Gonorrhoea, Leishmaniasis, leprosy

Those who presented physically identifiable symptoms of any infection, including cough,
sore throat, or fever.

Those who did not give consent to be tested for SARS- COV-2 IgG antibodies.",2020-11-01,2021-01-31,Blood donors,Male,Adults (18-64 years),18.0,60.0,Sex/Gender,,1025,0.358,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Smita Mahapatra,Sriram Chandra Bhanja Medical College and Hospital,Unity-Aligned,https://dx.doi.org/10.1016/j.tracli.2021.10.004,2021-10-26,2024-03-01,Verified,mahapatra_sars_2021,IND
211013_Cuttack_SriramChandraBhanjaMedicalCollegeandHospital_Female,211013_Cuttack_SriramChandraBhanjaMedicalCollegeandHospital,SARS COV-2- IgG antibodies in blood donors in pandemic - a game changer for policy makers.,2021-10-13,Journal Article (Peer-Reviewed),Local,Prospective cohort,India,Odisha,Cuttack,"1. Age group between 18-65 years
2. Those who have neither any history of fever (body temperature ≤37.3°C) nor any
respiratory symptoms for at least 28 days
4. Body temperature being normal before donation (≤37.3°C)
5. Donors were informed regarding the antibody testing against COVID 19 infections.
Only those who gave consent to be tested for SARS- COV-2 IgG antibodies were
included in the study.
6. Those with Haemoglobin >12.5g/dl, platelet count>1,50,000 per microliter of blood
and Total Leukocyte Count within normal limits were accepted.
7. All participants who were confirmed to be free from all viral infections including
Hepatitis B and C, Human immunodeficiency virus (HIV) 1 and 2 after being tested
with Enzyme linked Immosorbent Assay (ELISA) and Nucleic Acid Amplification
(NAT) testing","Following individuals with any of the following criteria/symptoms were excluded from
the study as per the Drugs and Cosmetics Act of 1940 (as amended up to the 31st December,
2016) of Govt. of India:
1. who were below 50 kg
2. under 18 years or above 65 years
3. having Haemoglobin of less than 12.5gm%
4. recently recovered after surgery
5. recently received blood transfusion
6. suffering from chronic respiratory diseases (asthmatic attack, asthmatics on
steroid)
7. cardiovascular diseases (myocardial infarction, hypertensive heart disease,
coronary artery disease, angina pectoris, rheumatic heart disease)
8. endocrine diseases (diabetes on insulin, hyper/hypothyroid, thyrotoxicosis due to
Graves’ disease)
9. chronic infection of kidney/renal failure
10. any carcinoma
11. suffering from HIV, Hepatitis B/C, Syphilis, Gonorrhoea, Leishmaniasis, leprosy

Those who presented physically identifiable symptoms of any infection, including cough,
sore throat, or fever.

Those who did not give consent to be tested for SARS- COV-2 IgG antibodies.",2020-11-01,2021-01-31,Blood donors,Female,Adults (18-64 years),18.0,60.0,Sex/Gender,,7,0.4286,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Smita Mahapatra,Sriram Chandra Bhanja Medical College and Hospital,Unity-Aligned,https://dx.doi.org/10.1016/j.tracli.2021.10.004,2021-10-26,2024-03-01,Verified,mahapatra_sars_2021,IND
211013_Odisha_GovernmentofIndia_Primary,211013_Odisha_GovernmentofIndia,Single-dose of BBV-152 and AZD1222 increases antibodies against spike glycoprotein among healthcare workers recovered from SARS-CoV-2 infection.,2021-10-13,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Odisha,,Have to have been taking either the BBV-152 or AZD1222 vaccine during the study period,,2021-01-01,2021-01-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,134,0.41000000000000003,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Debaprasad Parai,Government of India,Not Unity-Aligned,https://dx.doi.org/10.1016/j.tmaid.2021.102170,2021-10-25,2024-03-01,Unverified,parai_single-dose_2021,IND
211014_Delhi_InstituteofLiverandBiliarySciences_Primary,211014_Delhi_InstituteofLiverandBiliarySciences,SARS-Coronavirus-2 seroprevalence in asymptomatic healthy blood donors: Indicator of community spread.,2021-10-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,"Delhi
","Serum samples from
healthy eligible blood donors were collected after appropriate consent. The donor eligibility criteria were as per the Drug and Cosmetics Rules
1945 amended March 2020; any healthy adult 18–65 years of age,
weighing more than 45 kg, with hemoglobin more than 12.5gm, with
temperature, pulse, and blood pressure within normal limits as well as
having no disease/risk factor which affected donor or recipient safety
were eligible for the study.","The blood donors who did not meet the
eligibility criteria were deferred and thus excluded; additionally, those
with documented prior SARS-CoV-2 infection and those who refused to
give consent were excluded from the study.",2020-09-24,2020-10-31,Blood donors,All,Adults (18-64 years),18.0,59.0,Primary Estimate,,1066,0.2757,,,True,,,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Pratibha Kale,Institute of Liver and Biliary Sciences,Not Unity-Aligned,https://dx.doi.org/10.1016/j.transci.2021.103293,2021-11-05,2024-03-01,Verified,kale_sars-coronavirus-2_2021,IND
211014_Delhi_InstituteofLiverandBiliarySciences_Male,211014_Delhi_InstituteofLiverandBiliarySciences,SARS-Coronavirus-2 seroprevalence in asymptomatic healthy blood donors: Indicator of community spread.,2021-10-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,"Delhi
","Serum samples from
healthy eligible blood donors were collected after appropriate consent. The donor eligibility criteria were as per the Drug and Cosmetics Rules
1945 amended March 2020; any healthy adult 18–65 years of age,
weighing more than 45 kg, with hemoglobin more than 12.5gm, with
temperature, pulse, and blood pressure within normal limits as well as
having no disease/risk factor which affected donor or recipient safety
were eligible for the study.","The blood donors who did not meet the
eligibility criteria were deferred and thus excluded; additionally, those
with documented prior SARS-CoV-2 infection and those who refused to
give consent were excluded from the study.",2020-09-24,2020-10-31,Blood donors,Male,Adults (18-64 years),18.0,59.0,Sex/Gender,,1048,0.277,,,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Pratibha Kale,Institute of Liver and Biliary Sciences,Not Unity-Aligned,https://dx.doi.org/10.1016/j.transci.2021.103293,2021-11-05,2024-03-01,Verified,kale_sars-coronavirus-2_2021,IND
211014_Delhi_InstituteofLiverandBiliarySciences_Female,211014_Delhi_InstituteofLiverandBiliarySciences,SARS-Coronavirus-2 seroprevalence in asymptomatic healthy blood donors: Indicator of community spread.,2021-10-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,"Delhi
","Serum samples from
healthy eligible blood donors were collected after appropriate consent. The donor eligibility criteria were as per the Drug and Cosmetics Rules
1945 amended March 2020; any healthy adult 18–65 years of age,
weighing more than 45 kg, with hemoglobin more than 12.5gm, with
temperature, pulse, and blood pressure within normal limits as well as
having no disease/risk factor which affected donor or recipient safety
were eligible for the study.","The blood donors who did not meet the
eligibility criteria were deferred and thus excluded; additionally, those
with documented prior SARS-CoV-2 infection and those who refused to
give consent were excluded from the study.",2020-09-24,2020-10-31,Blood donors,Female,Adults (18-64 years),18.0,59.0,Sex/Gender,,18,0.166,,,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Pratibha Kale,Institute of Liver and Biliary Sciences,Not Unity-Aligned,https://dx.doi.org/10.1016/j.transci.2021.103293,2021-11-05,2024-03-01,Verified,kale_sars-coronavirus-2_2021,IND
211014_Delhi_InstituteofLiverandBiliarySciences_>45,211014_Delhi_InstituteofLiverandBiliarySciences,SARS-Coronavirus-2 seroprevalence in asymptomatic healthy blood donors: Indicator of community spread.,2021-10-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,"Delhi
","Serum samples from
healthy eligible blood donors were collected after appropriate consent. The donor eligibility criteria were as per the Drug and Cosmetics Rules
1945 amended March 2020; any healthy adult 18–65 years of age,
weighing more than 45 kg, with hemoglobin more than 12.5gm, with
temperature, pulse, and blood pressure within normal limits as well as
having no disease/risk factor which affected donor or recipient safety
were eligible for the study.","The blood donors who did not meet the
eligibility criteria were deferred and thus excluded; additionally, those
with documented prior SARS-CoV-2 infection and those who refused to
give consent were excluded from the study.",2020-09-24,2020-10-31,Blood donors,All,Adults (18-64 years),45.0,59.0,Age,>45 years-old,70,0.057999999999999996,,,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Pratibha Kale,Institute of Liver and Biliary Sciences,Not Unity-Aligned,https://dx.doi.org/10.1016/j.transci.2021.103293,2021-11-05,2024-03-01,Verified,kale_sars-coronavirus-2_2021,IND
211014_Delhi_InstituteofLiverandBiliarySciences_18-25,211014_Delhi_InstituteofLiverandBiliarySciences,SARS-Coronavirus-2 seroprevalence in asymptomatic healthy blood donors: Indicator of community spread.,2021-10-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,"Delhi
","Serum samples from
healthy eligible blood donors were collected after appropriate consent. The donor eligibility criteria were as per the Drug and Cosmetics Rules
1945 amended March 2020; any healthy adult 18–65 years of age,
weighing more than 45 kg, with hemoglobin more than 12.5gm, with
temperature, pulse, and blood pressure within normal limits as well as
having no disease/risk factor which affected donor or recipient safety
were eligible for the study.","The blood donors who did not meet the
eligibility criteria were deferred and thus excluded; additionally, those
with documented prior SARS-CoV-2 infection and those who refused to
give consent were excluded from the study.",2020-09-24,2020-10-31,Blood donors,All,Adults (18-64 years),18.0,25.0,Age,18-25 years-old,260,0.282,,,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Pratibha Kale,Institute of Liver and Biliary Sciences,Not Unity-Aligned,https://dx.doi.org/10.1016/j.transci.2021.103293,2021-11-05,2024-03-01,Verified,kale_sars-coronavirus-2_2021,IND
211014_Delhi_InstituteofLiverandBiliarySciences_26-35,211014_Delhi_InstituteofLiverandBiliarySciences,SARS-Coronavirus-2 seroprevalence in asymptomatic healthy blood donors: Indicator of community spread.,2021-10-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,"Delhi
","Serum samples from
healthy eligible blood donors were collected after appropriate consent. The donor eligibility criteria were as per the Drug and Cosmetics Rules
1945 amended March 2020; any healthy adult 18–65 years of age,
weighing more than 45 kg, with hemoglobin more than 12.5gm, with
temperature, pulse, and blood pressure within normal limits as well as
having no disease/risk factor which affected donor or recipient safety
were eligible for the study.","The blood donors who did not meet the
eligibility criteria were deferred and thus excluded; additionally, those
with documented prior SARS-CoV-2 infection and those who refused to
give consent were excluded from the study.",2020-09-24,2020-10-31,Blood donors,All,Adults (18-64 years),26.0,35.0,Age,26-35 years-old,492,0.466,,,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Pratibha Kale,Institute of Liver and Biliary Sciences,Not Unity-Aligned,https://dx.doi.org/10.1016/j.transci.2021.103293,2021-11-05,2024-03-01,Verified,kale_sars-coronavirus-2_2021,IND
211014_Delhi_InstituteofLiverandBiliarySciences_36-45,211014_Delhi_InstituteofLiverandBiliarySciences,SARS-Coronavirus-2 seroprevalence in asymptomatic healthy blood donors: Indicator of community spread.,2021-10-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,"Delhi
","Serum samples from
healthy eligible blood donors were collected after appropriate consent. The donor eligibility criteria were as per the Drug and Cosmetics Rules
1945 amended March 2020; any healthy adult 18–65 years of age,
weighing more than 45 kg, with hemoglobin more than 12.5gm, with
temperature, pulse, and blood pressure within normal limits as well as
having no disease/risk factor which affected donor or recipient safety
were eligible for the study.","The blood donors who did not meet the
eligibility criteria were deferred and thus excluded; additionally, those
with documented prior SARS-CoV-2 infection and those who refused to
give consent were excluded from the study.",2020-09-24,2020-10-31,Blood donors,All,Adults (18-64 years),36.0,45.0,Age,36-45 years-old,244,0.19399999999999998,,,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Pratibha Kale,Institute of Liver and Biliary Sciences,Not Unity-Aligned,https://dx.doi.org/10.1016/j.transci.2021.103293,2021-11-05,2024-03-01,Verified,kale_sars-coronavirus-2_2021,IND
211020_NewDelhi_ SirGangaRamHospital_Overall,211020_NewDelhi_ SirGangaRamHospital,A cross-sectional study of SARS-CoV-2 seroprevalence among asymptomatic healthcare workers in a tertiary healthcare centre: Assessing the impact of PPE guidelines.,2021-10-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,New Delhi,asymptomatic HCW at a 675 bedded tertiary care hospital in New Delhi India,Symptomatic HCW and previously Covid RTPCR positive HCW were excluded from the study.,2020-09-18,2020-09-24,Health care workers and caregivers,All,Multiple groups,20.0,89.0,Primary Estimate,,1033,0.2585,,,True,,,,True,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,,,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Chand Wattal, Sir Ganga Ram Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2021.09.011,2021-11-04,2024-03-01,Unverified,wattal_cross-sectional_2021,IND
211026_UttarPrasesh_GovernmentofUttarPradesh_primary,211026_UttarPrasesh_GovernmentofUttarPradesh,"Understanding the Prevalence and Geographic Heterogeneity of SARS-CoV-2 Infection: Findings of the First Serosurvey in Uttar Pradesh, India.",2021-10-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Uttar Pradesh,,"The first household within each segment was selected randomly and the remaining 7 households were sequentially selected thereafter. Of these 8 households, the initial 6 households were chosen for the selection of adult individuals (3 men and 3 women), while children aged 5–17 were selected from the remaining 2 households. Only one individual was randomly selected per household.",,2020-09-04,2020-09-10,Household and community samples,All,Multiple groups,,,Primary Estimate,,16012,0.222,0.215,0.22899999999999998,True,True,True,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,LFIA,Whole Blood,IgG,,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Vasanthakumar Namasivayam,Government of Uttar Pradesh,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546397/,2021-11-11,2023-08-15,Verified,namasivayam_understanding_2021,IND
211026_UttarPrasesh_GovernmentofUttarPradesh_popadjusted,211026_UttarPrasesh_GovernmentofUttarPradesh,"Understanding the Prevalence and Geographic Heterogeneity of SARS-CoV-2 Infection: Findings of the First Serosurvey in Uttar Pradesh, India.",2021-10-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Uttar Pradesh,,"The first household within each segment was selected randomly and the remaining 7 households were sequentially selected thereafter. Of these 8 households, the initial 6 households were chosen for the selection of adult individuals (3 men and 3 women), while children aged 5–17 were selected from the remaining 2 households. Only one individual was randomly selected per household.",,2020-09-04,2020-09-10,Household and community samples,All,Multiple groups,,,Analysis,,16012,0.22100000000000003,0.215,0.228,,,True,,True,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,LFIA,Whole Blood,IgG,,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Vasanthakumar Namasivayam,Government of Uttar Pradesh,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546397/,2021-11-11,2024-03-01,Verified,namasivayam_understanding_2021,IND
211026_UttarPrasesh_GovernmentofUttarPradesh_sex_male,211026_UttarPrasesh_GovernmentofUttarPradesh,"Understanding the Prevalence and Geographic Heterogeneity of SARS-CoV-2 Infection: Findings of the First Serosurvey in Uttar Pradesh, India.",2021-10-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Uttar Pradesh,,"The first household within each segment was selected randomly and the remaining 7 households were sequentially selected thereafter. Of these 8 households, the initial 6 households were chosen for the selection of adult individuals (3 men and 3 women), while children aged 5–17 were selected from the remaining 2 households. Only one individual was randomly selected per household.",,2020-09-04,2020-09-10,Household and community samples,Male,Multiple groups,,,Sex/Gender,,8253,0.22100000000000003,0.212,0.23,,,True,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,LFIA,Whole Blood,IgG,,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Vasanthakumar Namasivayam,Government of Uttar Pradesh,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546397/,2021-11-11,2024-03-01,Verified,namasivayam_understanding_2021,IND
211026_UttarPrasesh_GovernmentofUttarPradesh_age_18-39,211026_UttarPrasesh_GovernmentofUttarPradesh,"Understanding the Prevalence and Geographic Heterogeneity of SARS-CoV-2 Infection: Findings of the First Serosurvey in Uttar Pradesh, India.",2021-10-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Uttar Pradesh,,"The first household within each segment was selected randomly and the remaining 7 households were sequentially selected thereafter. Of these 8 households, the initial 6 households were chosen for the selection of adult individuals (3 men and 3 women), while children aged 5–17 were selected from the remaining 2 households. Only one individual was randomly selected per household.",,2020-09-04,2020-09-10,Household and community samples,All,Adults (18-64 years),18.0,39.0,Age,,7601,0.22399999999999998,0.215,0.233,,,True,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,LFIA,Whole Blood,IgG,,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Vasanthakumar Namasivayam,Government of Uttar Pradesh,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546397/,2021-11-11,2024-03-01,Verified,namasivayam_understanding_2021,IND
211026_UttarPrasesh_GovernmentofUttarPradesh_age_40-59,211026_UttarPrasesh_GovernmentofUttarPradesh,"Understanding the Prevalence and Geographic Heterogeneity of SARS-CoV-2 Infection: Findings of the First Serosurvey in Uttar Pradesh, India.",2021-10-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Uttar Pradesh,,"The first household within each segment was selected randomly and the remaining 7 households were sequentially selected thereafter. Of these 8 households, the initial 6 households were chosen for the selection of adult individuals (3 men and 3 women), while children aged 5–17 were selected from the remaining 2 households. Only one individual was randomly selected per household.",,2020-09-04,2020-09-10,Household and community samples,All,Adults (18-64 years),40.0,59.0,Age,,4378,0.24100000000000002,0.228,0.253,,,True,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,LFIA,Whole Blood,IgG,,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Vasanthakumar Namasivayam,Government of Uttar Pradesh,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546397/,2021-11-11,2024-03-01,Verified,namasivayam_understanding_2021,IND
211026_UttarPrasesh_GovernmentofUttarPradesh_age_5-17,211026_UttarPrasesh_GovernmentofUttarPradesh,"Understanding the Prevalence and Geographic Heterogeneity of SARS-CoV-2 Infection: Findings of the First Serosurvey in Uttar Pradesh, India.",2021-10-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Uttar Pradesh,,"The first household within each segment was selected randomly and the remaining 7 households were sequentially selected thereafter. Of these 8 households, the initial 6 households were chosen for the selection of adult individuals (3 men and 3 women), while children aged 5–17 were selected from the remaining 2 households. Only one individual was randomly selected per household.",,2020-09-04,2020-09-10,Household and community samples,All,Children and Youth (0-17 years),5.0,17.0,Age,,3493,0.187,0.174,0.201,,,True,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,LFIA,Whole Blood,IgG,,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Vasanthakumar Namasivayam,Government of Uttar Pradesh,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546397/,2021-11-11,2024-03-01,Verified,namasivayam_understanding_2021,IND
211026_UttarPrasesh_GovernmentofUttarPradesh_age_18+,211026_UttarPrasesh_GovernmentofUttarPradesh,"Understanding the Prevalence and Geographic Heterogeneity of SARS-CoV-2 Infection: Findings of the First Serosurvey in Uttar Pradesh, India.",2021-10-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Uttar Pradesh,,"The first household within each segment was selected randomly and the remaining 7 households were sequentially selected thereafter. Of these 8 households, the initial 6 households were chosen for the selection of adult individuals (3 men and 3 women), while children aged 5–17 were selected from the remaining 2 households. Only one individual was randomly selected per household.",,2020-09-04,2020-09-10,Household and community samples,All,Multiple groups,18.0,,Age,,12519,0.231,0.223,0.23800000000000002,,,True,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,LFIA,Whole Blood,IgG,,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Vasanthakumar Namasivayam,Government of Uttar Pradesh,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546397/,2021-11-11,2024-03-01,Verified,namasivayam_understanding_2021,IND
211026_UttarPrasesh_GovernmentofUttarPradesh_sex_female,211026_UttarPrasesh_GovernmentofUttarPradesh,"Understanding the Prevalence and Geographic Heterogeneity of SARS-CoV-2 Infection: Findings of the First Serosurvey in Uttar Pradesh, India.",2021-10-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Uttar Pradesh,,"The first household within each segment was selected randomly and the remaining 7 households were sequentially selected thereafter. Of these 8 households, the initial 6 households were chosen for the selection of adult individuals (3 men and 3 women), while children aged 5–17 were selected from the remaining 2 households. Only one individual was randomly selected per household.",,2020-09-04,2020-09-10,Household and community samples,Female,Multiple groups,,,Sex/Gender,,7759,0.222,0.212,0.231,,,True,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,LFIA,Whole Blood,IgG,,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Vasanthakumar Namasivayam,Government of Uttar Pradesh,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546397/,2021-11-11,2024-03-01,Verified,namasivayam_understanding_2021,IND
211026_UttarPrasesh_GovernmentofUttarPradesh_age_60+,211026_UttarPrasesh_GovernmentofUttarPradesh,"Understanding the Prevalence and Geographic Heterogeneity of SARS-CoV-2 Infection: Findings of the First Serosurvey in Uttar Pradesh, India.",2021-10-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Uttar Pradesh,,"The first household within each segment was selected randomly and the remaining 7 households were sequentially selected thereafter. Of these 8 households, the initial 6 households were chosen for the selection of adult individuals (3 men and 3 women), while children aged 5–17 were selected from the remaining 2 households. Only one individual was randomly selected per household.",,2020-09-04,2020-09-10,Household and community samples,All,Seniors (65+ years),60.0,,Age,,540,0.25,0.21300000000000002,0.292,,,True,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,LFIA,Whole Blood,IgG,,Validated by manufacturers,0.9237000000000001,0.9790000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Vasanthakumar Namasivayam,Government of Uttar Pradesh,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546397/,2021-11-11,2024-03-01,Verified,namasivayam_understanding_2021,IND
211029_Delhi_MaulanaAzadMedicalCollege,211029_Delhi_MaulanaAzadMedicalCollege,Covid antibodies found in 97% of Delhi residents,2021-10-29,News and Media,Local,Cross-sectional survey ,India,,Delhi,"Residents of Delhi's 280 wards, including the Delhi Cantonment and NDMC areas",,2020-09-24,2021-10-09,Household and community samples,All,Multiple groups,,,Primary Estimate,,28000,0.97,,,True,True,,,True,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,,,,,['Moderate'],,Yes,Yes,No,,Unclear,Yes,Yes,,The Times of India,Maulana Azad Medical College,Not Unity-Aligned,https://timesofindia.indiatimes.com/city/delhi/covid-antibodies-found-in-97-of-delhi-residents/articleshow/87350053.cms,2021-11-09,2022-07-16,Unverified,alok_k_n_mishra_covid_2021,IND
211029_Maharashtra_ArmedForcesMedicalCollege_Primary,211029_Maharashtra_ArmedForcesMedicalCollege,Impact of Safety Measures in Endoscopic Procedures in Health Care Professionals during Corona Virus Pandemic,2021-10-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Maharashtra,,HCWs who worked in the Gastroenterology department,,2020-08-01,2020-08-31,Health care workers and caregivers,All,Adults (18-64 years),20.0,61.0,Primary Estimate,,117,0.3248,,,True,,,,True,Convenience,Author designed (CLIA),,CLIA,Serum,IgG,Spike,,,,['High'],,No,No,No,,Unclear,Yes,No,,Harish Kumur,Armed Forces Medical College,Not Unity-Aligned,https://www.journaljpri.com/index.php/JPRI/article/view/33074,2021-12-07,2022-07-16,Unverified,kumur_impact_2021,IND
211029_Jatni_ICMRRegionalMedicalResearchCentre,211029_Jatni_ICMRRegionalMedicalResearchCentre,Investigating immunological interaction between lymphatic filariasis and COVID-19 infection: a preliminary evidence.,2021-10-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Odisha,Jatni,"We randomly selected two villages: Bhimpur and Padanpur, from Jatni block, and randomly included one adult (18 years and above), willing to give informed consent from every alternate household.",,2021-01-15,2021-02-15,Household and community samples,All,Multiple groups,18.0,92.0,Primary Estimate,,174,0.4253,,,True,,,,True,Simplified probability,IgG and IgM anti-SARS-CoV-2 ELISA,Diagnostic Bioprobes,ELISA,Serum,IgG,,Validated by manufacturers,0.98,0.98,['Moderate'],,Yes,No,Yes,,Unclear,Yes,Yes,,Abhinav Sinha,ICMR-Regional Medical Research Centre,Not Unity-Aligned,https://dx.doi.org/10.1080/21645515.2021.1989925,2021-11-10,2022-07-16,Unverified,sinha_investigating_2021,IND
211030_Karnataka_IndianInstituteofPublicHealth_PopTestAdj_Overall,211030_Karnataka_IndianInstituteofPublicHealth,"Second round statewide sentinel-based population survey for estimation of the burden of active infection and anti-SARS-CoV-2 IgG antibodies in the general population of Karnataka, India, during January-February 2021.",2021-10-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,Karnataka,Including eight administrative zones of the Bengaluru metropolitan area,"""We included all adults ≥ 18 years.""","""We excluded those already diagnosed with SARS-CoV-2 infection, those unwilling to provide a sample for the test or consent, those who had received vaccination for COVID-19, and those who already participated in Round 1.""",2021-01-25,2021-02-18,Multiple populations,All,Multiple groups,18.0,,Primary Estimate,Population- and test-adjusted,40030,0.156,0.149,0.163,True,True,True,,,Stratified probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,Whole-virusantigen,Validated by independent authors/third party/non-developers,0.922,0.9770000000000001,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Rajagopal Padma,Indian Institute of Public Health,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620812/,2022-06-29,2023-08-15,Unverified,padma_second_2021-1,IND
211107_India_ESICMedicalCollegeAndHospital_OverallCrude,211107_India_ESICMedicalCollegeAndHospital,Screening of Asymptomatic Healthcare Workers for SARS-COV-2 for Occult Infections: A Cross-Sectional Study.,2021-11-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Telangana,Hyderabad,"Healthcare workers with no prior COVID-19 RT-PCR positive diagnosis were included, after explaining the nature of study and informed consent was obtained.",Healthcare workers with a previous history of COVID-19 RT-PCR positive diagnosis were not included in the study.,2020-10-15,2021-01-15,Health care workers and caregivers,All,Multiple groups,19.0,,Primary Estimate,,190,0.25260000000000005,,,True,,,,True,Unclear,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,,Serum,IgG,Spike,,,,['High'],,Unclear,No,Yes,,Yes,Yes,Yes,,Lakshmi Tadi,ESIC Medical College & Hospital,Not Unity-Aligned,https://dx.doi.org/10.7759/cureus.19341,2022-01-04,2024-03-01,Unverified,tadi_screening_2021,IND
211107_India_ESICMedicalCollegeAndHospital_Age41-60,211107_India_ESICMedicalCollegeAndHospital,Screening of Asymptomatic Healthcare Workers for SARS-COV-2 for Occult Infections: A Cross-Sectional Study.,2021-11-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Telangana,Hyderabad,"Healthcare workers with no prior COVID-19 RT-PCR positive diagnosis were included, after explaining the nature of study and informed consent was obtained.",Healthcare workers with a previous history of COVID-19 RT-PCR positive diagnosis were not included in the study.,2020-10-15,2021-01-15,Health care workers and caregivers,All,Adults (18-64 years),41.0,60.0,Age,41-60,38,0.31579999999999997,,,,,,,,Unclear,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,,Serum,IgG,Spike,,,,['High'],,Unclear,No,Yes,,Yes,Yes,Yes,,Lakshmi Tadi,ESIC Medical College & Hospital,Not Unity-Aligned,https://dx.doi.org/10.7759/cureus.19341,2022-01-04,2024-03-01,Unverified,tadi_screening_2021,IND
211107_India_ESICMedicalCollegeAndHospital_Age>60,211107_India_ESICMedicalCollegeAndHospital,Screening of Asymptomatic Healthcare Workers for SARS-COV-2 for Occult Infections: A Cross-Sectional Study.,2021-11-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Telangana,Hyderabad,"Healthcare workers with no prior COVID-19 RT-PCR positive diagnosis were included, after explaining the nature of study and informed consent was obtained.",Healthcare workers with a previous history of COVID-19 RT-PCR positive diagnosis were not included in the study.,2020-10-15,2021-01-15,Health care workers and caregivers,All,Seniors (65+ years),61.0,,Age,,6,0.16670000000000001,,,,,,,,Unclear,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,,Serum,IgG,Spike,,,,['High'],,Unclear,No,Yes,,Yes,Yes,Yes,,Lakshmi Tadi,ESIC Medical College & Hospital,Not Unity-Aligned,https://dx.doi.org/10.7759/cureus.19341,2022-01-04,2024-03-01,Unverified,tadi_screening_2021,IND
211107_India_ESICMedicalCollegeAndHospital_Age19-25,211107_India_ESICMedicalCollegeAndHospital,Screening of Asymptomatic Healthcare Workers for SARS-COV-2 for Occult Infections: A Cross-Sectional Study.,2021-11-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Telangana,Hyderabad,"Healthcare workers with no prior COVID-19 RT-PCR positive diagnosis were included, after explaining the nature of study and informed consent was obtained.",Healthcare workers with a previous history of COVID-19 RT-PCR positive diagnosis were not included in the study.,2020-10-15,2021-01-15,Health care workers and caregivers,All,Adults (18-64 years),19.0,25.0,Age,19-25,26,0.26920000000000005,,,,,,,,Unclear,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,,Serum,IgG,Spike,,,,['High'],,Unclear,No,Yes,,Yes,Yes,Yes,,Lakshmi Tadi,ESIC Medical College & Hospital,Not Unity-Aligned,https://dx.doi.org/10.7759/cureus.19341,2022-01-04,2024-03-01,Unverified,tadi_screening_2021,IND
211107_India_ESICMedicalCollegeAndHospital_Age26-40,211107_India_ESICMedicalCollegeAndHospital,Screening of Asymptomatic Healthcare Workers for SARS-COV-2 for Occult Infections: A Cross-Sectional Study.,2021-11-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Telangana,Hyderabad,"Healthcare workers with no prior COVID-19 RT-PCR positive diagnosis were included, after explaining the nature of study and informed consent was obtained.",Healthcare workers with a previous history of COVID-19 RT-PCR positive diagnosis were not included in the study.,2020-10-15,2021-01-15,Health care workers and caregivers,All,Adults (18-64 years),26.0,40.0,Age,26-40,120,0.23329999999999998,,,,,,,,Unclear,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,,Serum,IgG,Spike,,,,['High'],,Unclear,No,Yes,,Yes,Yes,Yes,,Lakshmi Tadi,ESIC Medical College & Hospital,Not Unity-Aligned,https://dx.doi.org/10.7759/cureus.19341,2022-01-04,2024-03-01,Unverified,tadi_screening_2021,IND
211110_Bangalore_BangaloreBaptistHospital_Phase1_HCW_overall,211110_Bangalore_BangaloreBaptistHospital_Phase1_HCW,Are hospitals epicentres of COVID19 transmission? Findings of serial serosurveys among healthcare workers from a tertiary hospital in South India.,2021-11-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Karnataka,Bangalore,"Apparently, healthy HCW and tested negative for SARS CoV2 in the past were recruited between May–June 2020 (phase 1) and from September to November 2020 (phase 2) after informed consent. ",We excluded HCW with a history of SARS CoV2 positivity in the past.,2020-05-15,2020-06-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,211,0.0,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9720000000000001,0.998,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Sindhulina Chandrasingh,Bangalore Baptist Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2021.10.006,2021-11-24,2024-03-01,Verified,chandrasingh_are_2021,IND
211110_Bangalore_BangaloreBaptistHospital_Phase2_HCW_overall,211110_Bangalore_BangaloreBaptistHospital_Phase2_HCW,Are hospitals epicentres of COVID19 transmission? Findings of serial serosurveys among healthcare workers from a tertiary hospital in South India.,2021-11-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Karnataka,Bangalore,"Apparently, healthy HCW and tested negative for SARS CoV2 in the past were recruited between May–June 2020 (phase 1) and from September to November 2020 (phase 2) after informed consent. ",We excluded HCW with a history of SARS CoV2 positivity in the past.,2020-09-15,2020-11-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,206,0.092,0.086,0.094,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9720000000000001,0.998,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Sindhulina Chandrasingh,Bangalore Baptist Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2021.10.006,2021-11-24,2024-03-01,Verified,chandrasingh_are_2021,IND
211110_Bangalore_BangaloreBaptistHospital_Phase2_HCW_Age_<=40,211110_Bangalore_BangaloreBaptistHospital_Phase2_HCW,Are hospitals epicentres of COVID19 transmission? Findings of serial serosurveys among healthcare workers from a tertiary hospital in South India.,2021-11-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Karnataka,Bangalore,"Apparently, healthy HCW and tested negative for SARS CoV2 in the past were recruited between May–June 2020 (phase 1) and from September to November 2020 (phase 2) after informed consent. ",We excluded HCW with a history of SARS CoV2 positivity in the past.,2020-09-15,2020-11-15,Health care workers and caregivers,All,Adults (18-64 years),,40.0,Age,<=40,143,0.105,0.06,0.167,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9720000000000001,0.998,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Sindhulina Chandrasingh,Bangalore Baptist Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2021.10.006,2022-01-24,2024-03-01,Verified,chandrasingh_are_2021,IND
211110_Bangalore_BangaloreBaptistHospital_Phase2_HCW_Age_>40,211110_Bangalore_BangaloreBaptistHospital_Phase2_HCW,Are hospitals epicentres of COVID19 transmission? Findings of serial serosurveys among healthcare workers from a tertiary hospital in South India.,2021-11-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Karnataka,Bangalore,"Apparently, healthy HCW and tested negative for SARS CoV2 in the past were recruited between May–June 2020 (phase 1) and from September to November 2020 (phase 2) after informed consent. ",We excluded HCW with a history of SARS CoV2 positivity in the past.,2020-09-15,2020-11-15,Health care workers and caregivers,All,Adults (18-64 years),41.0,,Age,>40,63,0.09369999999999999,0.08449999999999999,0.09820000000000001,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9720000000000001,0.998,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Sindhulina Chandrasingh,Bangalore Baptist Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2021.10.006,2022-01-24,2024-03-01,Verified,chandrasingh_are_2021,IND
211110_Karnataka_BangaloreBaptistHospital_Phase1_BloodDonors_overall,211110_Karnataka_BangaloreBaptistHospital_Phase1_BloodDonors,Are hospitals epicentres of COVID19 transmission? Findings of serial serosurveys among healthcare workers from a tertiary hospital in South India.,2021-11-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Karnataka,,,,2020-05-15,2020-06-15,Blood donors,All,Multiple groups,,,Primary Estimate,,210,0.0,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9720000000000001,0.998,['High'],No,No,No,No,Unclear,Yes,Yes,Yes,,Sindhulina Chandrasingh,Bangalore Baptist Hospital,Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2021.10.006,2021-11-24,2024-03-01,Verified,chandrasingh_are_2021,IND
211115_TamilNadu_GovernmentofTamilNadu_Round1_Primary,211115_TamilNadu_GovernmentofTamilNadu_Round1,Seroprevalence in Tamil Nadu through India's two COVID waves: Evidence on antibody decline following infection and vaccination,2021-11-15,Preprint,Regional,Repeated cross-sectional study,India,Tamil Nadu,,"Individuals residing in Tamil Nadu and ages 18 years and older were
eligible for this study.","The exclusion criteria were refusal to consent and contraindication to
venipuncture. ",2020-10-19,2020-11-30,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,26135,0.316,0.303,0.327,True,,,True,True,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,iFlash-SARS-CoV-2 IgM/IgG","Ortho Clinical Diagnostics Inc.,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,T S Selvavinayagam,Government of Tamil Nadu,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.14.21265758v1.full-text,2021-11-23,2024-03-01,Unverified,selvavinayagam_seroprevalence_2021,IND
211115_TamilNadu_GovernmentofTamilNadu_Round1_Female,211115_TamilNadu_GovernmentofTamilNadu_Round1,Seroprevalence in Tamil Nadu through India's two COVID waves: Evidence on antibody decline following infection and vaccination,2021-11-15,Preprint,Regional,Repeated cross-sectional study,India,Tamil Nadu,,"Individuals residing in Tamil Nadu and ages 18 years and older were
eligible for this study.","The exclusion criteria were refusal to consent and contraindication to
venipuncture. ",2020-10-19,2020-11-30,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,15942,0.308,0.295,0.32,,,,True,,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,iFlash-SARS-CoV-2 IgM/IgG","Ortho Clinical Diagnostics Inc.,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,T S Selvavinayagam,Government of Tamil Nadu,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.14.21265758v1.full-text,2021-11-23,2024-03-01,Unverified,selvavinayagam_seroprevalence_2021,IND
211115_TamilNadu_GovernmentofTamilNadu_Round1_40-49,211115_TamilNadu_GovernmentofTamilNadu_Round1,Seroprevalence in Tamil Nadu through India's two COVID waves: Evidence on antibody decline following infection and vaccination,2021-11-15,Preprint,Regional,Repeated cross-sectional study,India,Tamil Nadu,,"Individuals residing in Tamil Nadu and ages 18 years and older were
eligible for this study.","The exclusion criteria were refusal to consent and contraindication to
venipuncture. ",2020-10-19,2020-11-30,Household and community samples,All,Adults (18-64 years),18.0,,Age,40-49 years-old,5227,0.317,0.3,0.335,,,,True,,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,iFlash-SARS-CoV-2 IgM/IgG","Ortho Clinical Diagnostics Inc.,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,T S Selvavinayagam,Government of Tamil Nadu,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.14.21265758v1.full-text,2021-11-23,2024-03-01,Unverified,selvavinayagam_seroprevalence_2021,IND
211115_TamilNadu_GovernmentofTamilNadu_Round1_30-39,211115_TamilNadu_GovernmentofTamilNadu_Round1,Seroprevalence in Tamil Nadu through India's two COVID waves: Evidence on antibody decline following infection and vaccination,2021-11-15,Preprint,Regional,Repeated cross-sectional study,India,Tamil Nadu,,"Individuals residing in Tamil Nadu and ages 18 years and older were
eligible for this study.","The exclusion criteria were refusal to consent and contraindication to
venipuncture. ",2020-10-19,2020-11-30,Household and community samples,All,Adults (18-64 years),18.0,,Age,30-39 years-old,6011,0.307,0.29,0.325,,,,True,,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,iFlash-SARS-CoV-2 IgM/IgG","Ortho Clinical Diagnostics Inc.,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,T S Selvavinayagam,Government of Tamil Nadu,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.14.21265758v1.full-text,2021-11-23,2024-03-01,Unverified,selvavinayagam_seroprevalence_2021,IND
211115_TamilNadu_GovernmentofTamilNadu_Round1_60-69,211115_TamilNadu_GovernmentofTamilNadu_Round1,Seroprevalence in Tamil Nadu through India's two COVID waves: Evidence on antibody decline following infection and vaccination,2021-11-15,Preprint,Regional,Repeated cross-sectional study,India,Tamil Nadu,,"Individuals residing in Tamil Nadu and ages 18 years and older were
eligible for this study.","The exclusion criteria were refusal to consent and contraindication to
venipuncture. ",2020-10-19,2020-11-30,Household and community samples,All,Adults (18-64 years),18.0,,Age,60-69 years-old,2875,0.284,0.262,0.305,,,,True,,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,iFlash-SARS-CoV-2 IgM/IgG","Ortho Clinical Diagnostics Inc.,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,T S Selvavinayagam,Government of Tamil Nadu,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.14.21265758v1.full-text,2021-11-23,2024-03-01,Unverified,selvavinayagam_seroprevalence_2021,IND
211115_TamilNadu_GovernmentofTamilNadu_Round1_Male,211115_TamilNadu_GovernmentofTamilNadu_Round1,Seroprevalence in Tamil Nadu through India's two COVID waves: Evidence on antibody decline following infection and vaccination,2021-11-15,Preprint,Regional,Repeated cross-sectional study,India,Tamil Nadu,,"Individuals residing in Tamil Nadu and ages 18 years and older were
eligible for this study.","The exclusion criteria were refusal to consent and contraindication to
venipuncture. ",2020-10-19,2020-11-30,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,10193,0.302,0.28800000000000003,0.317,,,,True,,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,iFlash-SARS-CoV-2 IgM/IgG","Ortho Clinical Diagnostics Inc.,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,T S Selvavinayagam,Government of Tamil Nadu,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.14.21265758v1.full-text,2021-11-23,2024-03-01,Unverified,selvavinayagam_seroprevalence_2021,IND
211115_TamilNadu_GovernmentofTamilNadu_Round1_50-59,211115_TamilNadu_GovernmentofTamilNadu_Round1,Seroprevalence in Tamil Nadu through India's two COVID waves: Evidence on antibody decline following infection and vaccination,2021-11-15,Preprint,Regional,Repeated cross-sectional study,India,Tamil Nadu,,"Individuals residing in Tamil Nadu and ages 18 years and older were
eligible for this study.","The exclusion criteria were refusal to consent and contraindication to
venipuncture. ",2020-10-19,2020-11-30,Household and community samples,All,Adults (18-64 years),18.0,,Age,50-59 years-old,4182,0.322,0.303,0.341,,,,True,,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,iFlash-SARS-CoV-2 IgM/IgG","Ortho Clinical Diagnostics Inc.,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,T S Selvavinayagam,Government of Tamil Nadu,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.14.21265758v1.full-text,2021-11-23,2024-03-01,Unverified,selvavinayagam_seroprevalence_2021,IND
211115_TamilNadu_GovernmentofTamilNadu_Round1_>=70,211115_TamilNadu_GovernmentofTamilNadu_Round1,Seroprevalence in Tamil Nadu through India's two COVID waves: Evidence on antibody decline following infection and vaccination,2021-11-15,Preprint,Regional,Repeated cross-sectional study,India,Tamil Nadu,,"Individuals residing in Tamil Nadu and ages 18 years and older were
eligible for this study.","The exclusion criteria were refusal to consent and contraindication to
venipuncture. ",2020-10-19,2020-11-30,Household and community samples,All,Seniors (65+ years),18.0,,Age,>=70 years-old,1568,0.265,0.237,0.292,,,,True,,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,iFlash-SARS-CoV-2 IgM/IgG","Ortho Clinical Diagnostics Inc.,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,T S Selvavinayagam,Government of Tamil Nadu,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.14.21265758v1.full-text,2021-11-23,2024-03-01,Unverified,selvavinayagam_seroprevalence_2021,IND
211115_TamilNadu_GovernmentofTamilNadu_Round1_18-29,211115_TamilNadu_GovernmentofTamilNadu_Round1,Seroprevalence in Tamil Nadu through India's two COVID waves: Evidence on antibody decline following infection and vaccination,2021-11-15,Preprint,Regional,Repeated cross-sectional study,India,Tamil Nadu,,"Individuals residing in Tamil Nadu and ages 18 years and older were
eligible for this study.","The exclusion criteria were refusal to consent and contraindication to
venipuncture. ",2020-10-19,2020-11-30,Household and community samples,All,Adults (18-64 years),18.0,,Age,18-29 years-old,6011,0.304,0.287,0.322,,,,True,,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,iFlash-SARS-CoV-2 IgM/IgG","Ortho Clinical Diagnostics Inc.,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,T S Selvavinayagam,Government of Tamil Nadu,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.14.21265758v1.full-text,2021-11-23,2024-03-01,Unverified,selvavinayagam_seroprevalence_2021,IND
211115_TamilNadu_GovernmentofTamilNadu_Round2_Primary,211115_TamilNadu_GovernmentofTamilNadu_Round2,Seroprevalence in Tamil Nadu through India's two COVID waves: Evidence on antibody decline following infection and vaccination,2021-11-15,Preprint,Regional,Repeated cross-sectional study,India,Tamil Nadu,,"Individuals residing in Tamil Nadu and ages 18 years and older were
eligible for this study.","The exclusion criteria were refusal to consent and contraindication to
venipuncture. In round 2, Chennai district was not surveyed.",2021-04-07,2021-04-30,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,21992,0.22899999999999998,0.218,0.239,True,,,True,True,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,iFlash-SARS-CoV-2 IgM/IgG","Ortho Clinical Diagnostics Inc.,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,T S Selvavinayagam,Government of Tamil Nadu,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.14.21265758v1.full-text,2021-11-23,2024-03-01,Unverified,selvavinayagam_seroprevalence_2021,IND
211115_TamilNadu_GovernmentofTamilNadu_Round2_Male,211115_TamilNadu_GovernmentofTamilNadu_Round2,Seroprevalence in Tamil Nadu through India's two COVID waves: Evidence on antibody decline following infection and vaccination,2021-11-15,Preprint,Regional,Repeated cross-sectional study,India,Tamil Nadu,,"Individuals residing in Tamil Nadu and ages 18 years and older were
eligible for this study.","The exclusion criteria were refusal to consent and contraindication to
venipuncture. In round 2, Chennai district was not surveyed.",2021-04-07,2021-04-30,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,9237,0.21300000000000002,0.2,0.226,,,,True,,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,iFlash-SARS-CoV-2 IgM/IgG","Ortho Clinical Diagnostics Inc.,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,T S Selvavinayagam,Government of Tamil Nadu,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.14.21265758v1.full-text,2021-11-23,2024-03-01,Unverified,selvavinayagam_seroprevalence_2021,IND
211115_TamilNadu_GovernmentofTamilNadu_Round2_Unvacc,211115_TamilNadu_GovernmentofTamilNadu_Round2,Seroprevalence in Tamil Nadu through India's two COVID waves: Evidence on antibody decline following infection and vaccination,2021-11-15,Preprint,Regional,Repeated cross-sectional study,India,Tamil Nadu,,"Individuals residing in Tamil Nadu and ages 18 years and older were
eligible for this study.","The exclusion criteria were refusal to consent and contraindication to
venipuncture. In round 2, Chennai district was not surveyed.",2021-04-07,2021-04-30,Household and community samples,All,Multiple groups,18.0,,COVID-19 vaccination status,Vaccinates No,18077,0.209,0.19899999999999998,0.22,,,,True,,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,iFlash-SARS-CoV-2 IgM/IgG","Ortho Clinical Diagnostics Inc.,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,T S Selvavinayagam,Government of Tamil Nadu,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.14.21265758v1.full-text,2021-11-23,2024-03-01,Unverified,selvavinayagam_seroprevalence_2021,IND
211115_TamilNadu_GovernmentofTamilNadu_Round2_Female,211115_TamilNadu_GovernmentofTamilNadu_Round2,Seroprevalence in Tamil Nadu through India's two COVID waves: Evidence on antibody decline following infection and vaccination,2021-11-15,Preprint,Regional,Repeated cross-sectional study,India,Tamil Nadu,,"Individuals residing in Tamil Nadu and ages 18 years and older were
eligible for this study.","The exclusion criteria were refusal to consent and contraindication to
venipuncture. In round 2, Chennai district was not surveyed.",2021-04-07,2021-04-30,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,12755,0.22,0.20800000000000002,0.231,,,,True,,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,iFlash-SARS-CoV-2 IgM/IgG","Ortho Clinical Diagnostics Inc.,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,T S Selvavinayagam,Government of Tamil Nadu,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.14.21265758v1.full-text,2021-11-23,2024-03-01,Unverified,selvavinayagam_seroprevalence_2021,IND
211115_TamilNadu_GovernmentofTamilNadu_Round2_30-39,211115_TamilNadu_GovernmentofTamilNadu_Round2,Seroprevalence in Tamil Nadu through India's two COVID waves: Evidence on antibody decline following infection and vaccination,2021-11-15,Preprint,Regional,Repeated cross-sectional study,India,Tamil Nadu,,"Individuals residing in Tamil Nadu and ages 18 years and older were
eligible for this study.","The exclusion criteria were refusal to consent and contraindication to
venipuncture. In round 2, Chennai district was not surveyed.",2021-04-07,2021-04-30,Household and community samples,All,Adults (18-64 years),18.0,,Age,30-39 years-old,4618,0.212,0.196,0.228,,,,True,,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,iFlash-SARS-CoV-2 IgM/IgG","Ortho Clinical Diagnostics Inc.,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,T S Selvavinayagam,Government of Tamil Nadu,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.14.21265758v1.full-text,2021-11-23,2024-03-01,Unverified,selvavinayagam_seroprevalence_2021,IND
211115_TamilNadu_GovernmentofTamilNadu_Round2_60-69,211115_TamilNadu_GovernmentofTamilNadu_Round2,Seroprevalence in Tamil Nadu through India's two COVID waves: Evidence on antibody decline following infection and vaccination,2021-11-15,Preprint,Regional,Repeated cross-sectional study,India,Tamil Nadu,,"Individuals residing in Tamil Nadu and ages 18 years and older were
eligible for this study.","The exclusion criteria were refusal to consent and contraindication to
venipuncture. In round 2, Chennai district was not surveyed.",2021-04-07,2021-04-30,Household and community samples,All,Adults (18-64 years),18.0,,Age,60-69 years-old,3079,0.228,0.21,0.24600000000000002,,,,True,,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,iFlash-SARS-CoV-2 IgM/IgG","Ortho Clinical Diagnostics Inc.,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,T S Selvavinayagam,Government of Tamil Nadu,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.14.21265758v1.full-text,2021-11-23,2024-03-01,Unverified,selvavinayagam_seroprevalence_2021,IND
211115_TamilNadu_GovernmentofTamilNadu_Round2_18-29,211115_TamilNadu_GovernmentofTamilNadu_Round2,Seroprevalence in Tamil Nadu through India's two COVID waves: Evidence on antibody decline following infection and vaccination,2021-11-15,Preprint,Regional,Repeated cross-sectional study,India,Tamil Nadu,,"Individuals residing in Tamil Nadu and ages 18 years and older were
eligible for this study.","The exclusion criteria were refusal to consent and contraindication to
venipuncture. In round 2, Chennai district was not surveyed.",2021-04-07,2021-04-30,Household and community samples,All,Adults (18-64 years),18.0,,Age,18-29 years-old,3739,0.195,0.17800000000000002,0.21100000000000002,,,,True,,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,iFlash-SARS-CoV-2 IgM/IgG","Ortho Clinical Diagnostics Inc.,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,T S Selvavinayagam,Government of Tamil Nadu,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.14.21265758v1.full-text,2021-11-23,2024-03-01,Unverified,selvavinayagam_seroprevalence_2021,IND
211115_TamilNadu_GovernmentofTamilNadu_Round2_40-49,211115_TamilNadu_GovernmentofTamilNadu_Round2,Seroprevalence in Tamil Nadu through India's two COVID waves: Evidence on antibody decline following infection and vaccination,2021-11-15,Preprint,Regional,Repeated cross-sectional study,India,Tamil Nadu,,"Individuals residing in Tamil Nadu and ages 18 years and older were
eligible for this study.","The exclusion criteria were refusal to consent and contraindication to
venipuncture. In round 2, Chennai district was not surveyed.",2021-04-07,2021-04-30,Household and community samples,All,Adults (18-64 years),18.0,,Age,40-49 years-old,4618,0.22100000000000003,0.204,0.239,,,,True,,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,iFlash-SARS-CoV-2 IgM/IgG","Ortho Clinical Diagnostics Inc.,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,T S Selvavinayagam,Government of Tamil Nadu,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.14.21265758v1.full-text,2021-11-23,2024-03-01,Unverified,selvavinayagam_seroprevalence_2021,IND
211115_TamilNadu_GovernmentofTamilNadu_Round2_>=70,211115_TamilNadu_GovernmentofTamilNadu_Round2,Seroprevalence in Tamil Nadu through India's two COVID waves: Evidence on antibody decline following infection and vaccination,2021-11-15,Preprint,Regional,Repeated cross-sectional study,India,Tamil Nadu,,"Individuals residing in Tamil Nadu and ages 18 years and older were
eligible for this study.","The exclusion criteria were refusal to consent and contraindication to
venipuncture. In round 2, Chennai district was not surveyed.",2021-04-07,2021-04-30,Household and community samples,All,Seniors (65+ years),18.0,,Age,>=70 years-ol,1759,0.215,0.19,0.239,,,,True,,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,iFlash-SARS-CoV-2 IgM/IgG","Ortho Clinical Diagnostics Inc.,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,T S Selvavinayagam,Government of Tamil Nadu,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.14.21265758v1.full-text,2021-11-23,2024-03-01,Unverified,selvavinayagam_seroprevalence_2021,IND
211115_TamilNadu_GovernmentofTamilNadu_Round2_50-59,211115_TamilNadu_GovernmentofTamilNadu_Round2,Seroprevalence in Tamil Nadu through India's two COVID waves: Evidence on antibody decline following infection and vaccination,2021-11-15,Preprint,Regional,Repeated cross-sectional study,India,Tamil Nadu,,"Individuals residing in Tamil Nadu and ages 18 years and older were
eligible for this study.","The exclusion criteria were refusal to consent and contraindication to
venipuncture. In round 2, Chennai district was not surveyed.",2021-04-07,2021-04-30,Household and community samples,All,Adults (18-64 years),18.0,,Age,50-59 years-old,3959,0.256,0.23800000000000002,0.27399999999999997,,,,True,,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,iFlash-SARS-CoV-2 IgM/IgG","Ortho Clinical Diagnostics Inc.,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,T S Selvavinayagam,Government of Tamil Nadu,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.14.21265758v1.full-text,2021-11-23,2024-03-01,Unverified,selvavinayagam_seroprevalence_2021,IND
211115_TamilNadu_GovernmentofTamilNadu_Round2_Vacc,211115_TamilNadu_GovernmentofTamilNadu_Round2,Seroprevalence in Tamil Nadu through India's two COVID waves: Evidence on antibody decline following infection and vaccination,2021-11-15,Preprint,Regional,Repeated cross-sectional study,India,Tamil Nadu,,"Individuals residing in Tamil Nadu and ages 18 years and older were
eligible for this study.","The exclusion criteria were refusal to consent and contraindication to
venipuncture. In round 2, Chennai district was not surveyed.",2021-04-07,2021-04-30,Household and community samples,All,Multiple groups,18.0,,COVID-19 vaccination status,Vaccinated Yes,3915,0.257,0.233,0.281,,,,True,,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,iFlash-SARS-CoV-2 IgM/IgG","Ortho Clinical Diagnostics Inc.,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,T S Selvavinayagam,Government of Tamil Nadu,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.14.21265758v1.full-text,2021-11-23,2024-03-01,Unverified,selvavinayagam_seroprevalence_2021,IND
211115_TamilNadu_GovernmentofTamilNadu_Round3_Primary,211115_TamilNadu_GovernmentofTamilNadu_Round3,Seroprevalence in Tamil Nadu through India's two COVID waves: Evidence on antibody decline following infection and vaccination,2021-11-15,Preprint,Regional,Repeated cross-sectional study,India,Tamil Nadu,,"Individuals residing in Tamil Nadu and ages 18 years and older were
eligible for this study.","The exclusion criteria were refusal to consent and contraindication to
venipuncture.",2021-06-28,2021-07-07,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,26592,0.6709999999999999,0.659,0.6829999999999999,True,,,True,True,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,iFlash-SARS-CoV-2 IgM/IgG","Ortho Clinical Diagnostics Inc.,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,T S Selvavinayagam,Government of Tamil Nadu,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.14.21265758v1.full-text,2021-11-23,2024-03-01,Unverified,selvavinayagam_seroprevalence_2021,IND
211115_TamilNadu_GovernmentofTamilNadu_Round3_40-49,211115_TamilNadu_GovernmentofTamilNadu_Round3,Seroprevalence in Tamil Nadu through India's two COVID waves: Evidence on antibody decline following infection and vaccination,2021-11-15,Preprint,Regional,Repeated cross-sectional study,India,Tamil Nadu,,"Individuals residing in Tamil Nadu and ages 18 years and older were
eligible for this study.","The exclusion criteria were refusal to consent and contraindication to
venipuncture.",2021-06-28,2021-07-07,Household and community samples,All,Adults (18-64 years),18.0,,Age,40-49 years-old,5850,0.667,0.65,0.684,,,,True,,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,iFlash-SARS-CoV-2 IgM/IgG","Ortho Clinical Diagnostics Inc.,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,T S Selvavinayagam,Government of Tamil Nadu,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.14.21265758v1.full-text,2021-11-23,2024-03-01,Unverified,selvavinayagam_seroprevalence_2021,IND
211115_TamilNadu_GovernmentofTamilNadu_Round3_Male,211115_TamilNadu_GovernmentofTamilNadu_Round3,Seroprevalence in Tamil Nadu through India's two COVID waves: Evidence on antibody decline following infection and vaccination,2021-11-15,Preprint,Regional,Repeated cross-sectional study,India,Tamil Nadu,,"Individuals residing in Tamil Nadu and ages 18 years and older were
eligible for this study.","The exclusion criteria were refusal to consent and contraindication to
venipuncture.",2021-06-28,2021-07-07,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,11169,0.655,0.642,0.667,,,,True,,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,iFlash-SARS-CoV-2 IgM/IgG","Ortho Clinical Diagnostics Inc.,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,T S Selvavinayagam,Government of Tamil Nadu,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.14.21265758v1.full-text,2021-11-23,2024-03-01,Unverified,selvavinayagam_seroprevalence_2021,IND
211115_TamilNadu_GovernmentofTamilNadu_Round3_18-29,211115_TamilNadu_GovernmentofTamilNadu_Round3,Seroprevalence in Tamil Nadu through India's two COVID waves: Evidence on antibody decline following infection and vaccination,2021-11-15,Preprint,Regional,Repeated cross-sectional study,India,Tamil Nadu,,"Individuals residing in Tamil Nadu and ages 18 years and older were
eligible for this study.","The exclusion criteria were refusal to consent and contraindication to
venipuncture.",2021-06-28,2021-07-07,Household and community samples,All,Adults (18-64 years),18.0,,Age,18-29 years-old,5052,0.677,0.6609999999999999,0.693,,,,True,,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,iFlash-SARS-CoV-2 IgM/IgG","Ortho Clinical Diagnostics Inc.,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,T S Selvavinayagam,Government of Tamil Nadu,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.14.21265758v1.full-text,2021-11-23,2024-03-01,Unverified,selvavinayagam_seroprevalence_2021,IND
211115_TamilNadu_GovernmentofTamilNadu_Round3_30-39,211115_TamilNadu_GovernmentofTamilNadu_Round3,Seroprevalence in Tamil Nadu through India's two COVID waves: Evidence on antibody decline following infection and vaccination,2021-11-15,Preprint,Regional,Repeated cross-sectional study,India,Tamil Nadu,,"Individuals residing in Tamil Nadu and ages 18 years and older were
eligible for this study.","The exclusion criteria were refusal to consent and contraindication to
venipuncture.",2021-06-28,2021-07-07,Household and community samples,All,Adults (18-64 years),18.0,,Age,30-39 years-old,6116,0.67,0.654,0.6859999999999999,,,,True,,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,iFlash-SARS-CoV-2 IgM/IgG","Ortho Clinical Diagnostics Inc.,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,T S Selvavinayagam,Government of Tamil Nadu,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.14.21265758v1.full-text,2021-11-23,2024-03-01,Unverified,selvavinayagam_seroprevalence_2021,IND
211115_TamilNadu_GovernmentofTamilNadu_Round3_60-69,211115_TamilNadu_GovernmentofTamilNadu_Round3,Seroprevalence in Tamil Nadu through India's two COVID waves: Evidence on antibody decline following infection and vaccination,2021-11-15,Preprint,Regional,Repeated cross-sectional study,India,Tamil Nadu,,"Individuals residing in Tamil Nadu and ages 18 years and older were
eligible for this study.","The exclusion criteria were refusal to consent and contraindication to
venipuncture.",2021-06-28,2021-07-07,Household and community samples,All,Adults (18-64 years),18.0,,Age,60-69 years-old,3191,0.65,0.628,0.672,,,,True,,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,iFlash-SARS-CoV-2 IgM/IgG","Ortho Clinical Diagnostics Inc.,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,T S Selvavinayagam,Government of Tamil Nadu,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.14.21265758v1.full-text,2021-11-23,2024-03-01,Unverified,selvavinayagam_seroprevalence_2021,IND
211115_TamilNadu_GovernmentofTamilNadu_Round3_Female,211115_TamilNadu_GovernmentofTamilNadu_Round3,Seroprevalence in Tamil Nadu through India's two COVID waves: Evidence on antibody decline following infection and vaccination,2021-11-15,Preprint,Regional,Repeated cross-sectional study,India,Tamil Nadu,,"Individuals residing in Tamil Nadu and ages 18 years and older were
eligible for this study.","The exclusion criteria were refusal to consent and contraindication to
venipuncture.",2021-06-28,2021-07-07,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,15423,0.675,0.662,0.687,,,,True,,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,iFlash-SARS-CoV-2 IgM/IgG","Ortho Clinical Diagnostics Inc.,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,T S Selvavinayagam,Government of Tamil Nadu,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.14.21265758v1.full-text,2021-11-23,2024-03-01,Unverified,selvavinayagam_seroprevalence_2021,IND
211115_TamilNadu_GovernmentofTamilNadu_Round3_50-59,211115_TamilNadu_GovernmentofTamilNadu_Round3,Seroprevalence in Tamil Nadu through India's two COVID waves: Evidence on antibody decline following infection and vaccination,2021-11-15,Preprint,Regional,Repeated cross-sectional study,India,Tamil Nadu,,"Individuals residing in Tamil Nadu and ages 18 years and older were
eligible for this study.","The exclusion criteria were refusal to consent and contraindication to
venipuncture.",2021-06-28,2021-07-07,Household and community samples,All,Adults (18-64 years),18.0,,Age,50-59 years-old,4787,0.6659999999999999,0.648,0.685,,,,True,,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,iFlash-SARS-CoV-2 IgM/IgG","Ortho Clinical Diagnostics Inc.,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,T S Selvavinayagam,Government of Tamil Nadu,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.14.21265758v1.full-text,2021-11-23,2024-03-01,Unverified,selvavinayagam_seroprevalence_2021,IND
211115_TamilNadu_GovernmentofTamilNadu_Round3_>=70,211115_TamilNadu_GovernmentofTamilNadu_Round3,Seroprevalence in Tamil Nadu through India's two COVID waves: Evidence on antibody decline following infection and vaccination,2021-11-15,Preprint,Regional,Repeated cross-sectional study,India,Tamil Nadu,,"Individuals residing in Tamil Nadu and ages 18 years and older were
eligible for this study.","The exclusion criteria were refusal to consent and contraindication to
venipuncture.",2021-06-28,2021-07-07,Household and community samples,All,Seniors (65+ years),18.0,,Age,>=70 years-old,1596,0.596,0.568,0.623,,,,True,,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,iFlash-SARS-CoV-2 IgM/IgG","Ortho Clinical Diagnostics Inc.,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,Yes,Yes,Yes,,Unclear,No,No,,T S Selvavinayagam,Government of Tamil Nadu,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.14.21265758v1.full-text,2021-11-23,2024-03-01,Unverified,selvavinayagam_seroprevalence_2021,IND
211116_NewDelhi_MaulanaAzadMedicalCollege_Overall,211116_NewDelhi_MaulanaAzadMedicalCollege,Serological response in healthcare workers at an exclusive COVID-19 facility in Delhi,2021-11-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Delhi,New Delhi,"employees at a teaching hospital in New Delhi, India (including administrative staff and healthcare workers)",,2020-08-15,2020-09-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1401,0.121,,,True,,,,True,Unclear,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,,,,['High'],,Unclear,Yes,No,,Yes,Yes,Yes,,Pradeep Kumar Bharti,Maulana Azad Medical College,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2021.08.233,2022-03-17,2024-03-01,Unverified,bharti_serological_2021,IND
211116_Mumbai_BreachCandyHospital_Overall,211116_Mumbai_BreachCandyHospital,"Seroprevelance Survey of Healthcare Workers in a Covid Care Hospital in Mumbai, India",2021-11-16,Presentation or Conference,Local,Cross-sectional survey ,India,Maharashtra,Mumbai,Being a healthcare worker in a 212-bed hospital in Mumbai,,2020-07-18,2020-07-25,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,474,0.3122,,,True,,,,True,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG",Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgG', 'TotalAntibody']",Spike,,,,['High'],,No,No,No,,Yes,Yes,No,,Seema Rohra,Breach Candy Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2021.08.251,2022-03-15,2024-03-01,Unverified,rohra_seroprevelance_2021,IND
211118_Delhi_RajivGandhiSuperSpecialityHospital,211118_Delhi_RajivGandhiSuperSpecialityHospital,Evaluation of SARS-CoV-2 antibody responses in healthcare workers at a tertiary care COVID 19 dedicated hospital in Delhi.,2021-11-18,Journal Article (Peer-Reviewed),Local,Prospective cohort,India,,Delhi,HCW,Any participant reporting flu-like illness at the time of screening was excluded from the study group.,2020-10-01,2020-10-31,Health care workers and caregivers,All,Adults (18-64 years),19.0,59.0,Primary Estimate,,305,0.21960000000000002,,,True,,,,True,Unclear,ErbaLisa COVID-19 IgG ELISA Kit,Calbiotech Inc.,ELISA,Serum,IgG,,,,,['High'],,Unclear,No,Yes,,Yes,Yes,Yes,,B.L. Sherwal,Rajiv Gandhi Super Speciality Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2021.11.006,2021-11-30,2024-03-01,Unverified,sherwal_evaluation_2021,IND
211119_Hyderabad_CSIR-CentreForCellularAndMolecularBiology_Primary,211119_Hyderabad_CSIR-CentreForCellularAndMolecularBiology,"SARS-CoV-2 seroprevalence in the city of Hyderabad, India in early 2021",2021-11-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Telangana,Hyderabad," individuals aged 10 years and above, residing in Hyderabad","Non-consenting subjects, debilitated, bed-ridden or severely sick subjects were excluded from the study.",2021-01-08,2021-01-24,Household and community samples,All,Multiple groups,10.0,,Primary Estimate,Primary,9363,0.542,0.532,0.552,True,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Avula Laxmaiah,CSIR-CentreForCellularAndMolecularBiology,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603330/,2022-06-29,2024-03-01,Unverified,laxmaiah_sars-cov-2_2021,IND
211119_Hyderabad_CSIR-CentreForCellularAndMolecularBiology_30-39,211119_Hyderabad_CSIR-CentreForCellularAndMolecularBiology,"SARS-CoV-2 seroprevalence in the city of Hyderabad, India in early 2021",2021-11-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Telangana,Hyderabad," individuals aged 10 years and above, residing in Hyderabad","Non-consenting subjects, debilitated, bed-ridden or severely sick subjects were excluded from the study.",2021-01-08,2021-01-24,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,2012,0.5670000000000001,0.545,0.589,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Avula Laxmaiah,CSIR-CentreForCellularAndMolecularBiology,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603330/,2022-06-29,2024-03-01,Unverified,laxmaiah_sars-cov-2_2021,IND
211119_Hyderabad_CSIR-CentreForCellularAndMolecularBiology_Adj_Female,211119_Hyderabad_CSIR-CentreForCellularAndMolecularBiology,"SARS-CoV-2 seroprevalence in the city of Hyderabad, India in early 2021",2021-11-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Telangana,Hyderabad," individuals aged 10 years and above, residing in Hyderabad","Non-consenting subjects, debilitated, bed-ridden or severely sick subjects were excluded from the study.",2021-01-08,2021-01-24,Household and community samples,Female,Multiple groups,10.0,,Sex/Gender,Female,5142,0.552,0.538,0.5660000000000001,,,True,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Avula Laxmaiah,CSIR-CentreForCellularAndMolecularBiology,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603330/,2022-06-29,2024-03-01,Unverified,laxmaiah_sars-cov-2_2021,IND
211119_Hyderabad_CSIR-CentreForCellularAndMolecularBiology_40-49,211119_Hyderabad_CSIR-CentreForCellularAndMolecularBiology,"SARS-CoV-2 seroprevalence in the city of Hyderabad, India in early 2021",2021-11-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Telangana,Hyderabad," individuals aged 10 years and above, residing in Hyderabad","Non-consenting subjects, debilitated, bed-ridden or severely sick subjects were excluded from the study.",2021-01-08,2021-01-24,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,1575,0.537,0.512,0.562,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Avula Laxmaiah,CSIR-CentreForCellularAndMolecularBiology,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603330/,2022-06-29,2024-03-01,Unverified,laxmaiah_sars-cov-2_2021,IND
211119_Hyderabad_CSIR-CentreForCellularAndMolecularBiology_Adj_Male,211119_Hyderabad_CSIR-CentreForCellularAndMolecularBiology,"SARS-CoV-2 seroprevalence in the city of Hyderabad, India in early 2021",2021-11-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Telangana,Hyderabad," individuals aged 10 years and above, residing in Hyderabad","Non-consenting subjects, debilitated, bed-ridden or severely sick subjects were excluded from the study.",2021-01-08,2021-01-24,Household and community samples,Male,Multiple groups,10.0,,Sex/Gender,Male,4208,0.53,0.515,0.545,,,True,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Avula Laxmaiah,CSIR-CentreForCellularAndMolecularBiology,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603330/,2022-06-29,2024-03-01,Unverified,laxmaiah_sars-cov-2_2021,IND
211119_Hyderabad_CSIR-CentreForCellularAndMolecularBiology_20-29,211119_Hyderabad_CSIR-CentreForCellularAndMolecularBiology,"SARS-CoV-2 seroprevalence in the city of Hyderabad, India in early 2021",2021-11-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Telangana,Hyderabad," individuals aged 10 years and above, residing in Hyderabad","Non-consenting subjects, debilitated, bed-ridden or severely sick subjects were excluded from the study.",2021-01-08,2021-01-24,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,2017,0.527,0.505,0.549,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Avula Laxmaiah,CSIR-CentreForCellularAndMolecularBiology,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603330/,2022-06-29,2024-03-01,Unverified,laxmaiah_sars-cov-2_2021,IND
211119_Hyderabad_CSIR-CentreForCellularAndMolecularBiology_10-19,211119_Hyderabad_CSIR-CentreForCellularAndMolecularBiology,"SARS-CoV-2 seroprevalence in the city of Hyderabad, India in early 2021",2021-11-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Telangana,Hyderabad," individuals aged 10 years and above, residing in Hyderabad","Non-consenting subjects, debilitated, bed-ridden or severely sick subjects were excluded from the study.",2021-01-08,2021-01-24,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,1542,0.546,0.521,0.5710000000000001,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Avula Laxmaiah,CSIR-CentreForCellularAndMolecularBiology,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603330/,2022-06-29,2024-03-01,Unverified,laxmaiah_sars-cov-2_2021,IND
211119_Hyderabad_CSIR-CentreForCellularAndMolecularBiology_60-69,211119_Hyderabad_CSIR-CentreForCellularAndMolecularBiology,"SARS-CoV-2 seroprevalence in the city of Hyderabad, India in early 2021",2021-11-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Telangana,Hyderabad," individuals aged 10 years and above, residing in Hyderabad","Non-consenting subjects, debilitated, bed-ridden or severely sick subjects were excluded from the study.",2021-01-08,2021-01-24,Household and community samples,All,Multiple groups,60.0,69.0,Age,60-69,736,0.51,0.474,0.546,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Avula Laxmaiah,CSIR-CentreForCellularAndMolecularBiology,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603330/,2022-06-29,2024-03-01,Unverified,laxmaiah_sars-cov-2_2021,IND
211119_Hyderabad_CSIR-CentreForCellularAndMolecularBiology_70+,211119_Hyderabad_CSIR-CentreForCellularAndMolecularBiology,"SARS-CoV-2 seroprevalence in the city of Hyderabad, India in early 2021",2021-11-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Telangana,Hyderabad," individuals aged 10 years and above, residing in Hyderabad","Non-consenting subjects, debilitated, bed-ridden or severely sick subjects were excluded from the study.",2021-01-08,2021-01-24,Household and community samples,All,Seniors (65+ years),70.0,,Age,>70,349,0.47600000000000003,0.424,0.528,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Avula Laxmaiah,CSIR-CentreForCellularAndMolecularBiology,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603330/,2022-06-29,2024-03-01,Unverified,laxmaiah_sars-cov-2_2021,IND
211119_Hyderabad_CSIR-CentreForCellularAndMolecularBiology_OtherGender,211119_Hyderabad_CSIR-CentreForCellularAndMolecularBiology,"SARS-CoV-2 seroprevalence in the city of Hyderabad, India in early 2021",2021-11-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Telangana,Hyderabad," individuals aged 10 years and above, residing in Hyderabad","Non-consenting subjects, debilitated, bed-ridden or severely sick subjects were excluded from the study.",2021-01-08,2021-01-24,Household and community samples,Other,Multiple groups,10.0,,Sex/Gender,Other,13,0.538,0.267,0.809,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Avula Laxmaiah,CSIR-CentreForCellularAndMolecularBiology,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603330/,2022-06-29,2024-03-01,Unverified,laxmaiah_sars-cov-2_2021,IND
211119_Hyderabad_CSIR-CentreForCellularAndMolecularBiology_50-59,211119_Hyderabad_CSIR-CentreForCellularAndMolecularBiology,"SARS-CoV-2 seroprevalence in the city of Hyderabad, India in early 2021",2021-11-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Telangana,Hyderabad," individuals aged 10 years and above, residing in Hyderabad","Non-consenting subjects, debilitated, bed-ridden or severely sick subjects were excluded from the study.",2021-01-08,2021-01-24,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,1132,0.5670000000000001,0.538,0.596,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Avula Laxmaiah,CSIR-CentreForCellularAndMolecularBiology,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603330/,2022-06-29,2024-03-01,Unverified,laxmaiah_sars-cov-2_2021,IND
211119_Kashmir_GovernmentMedicalCollegeSrinagarJammuKashmir_Primary,211119_Kashmir_GovernmentMedicalCollegeSrinagarJammuKashmir,"The burden of SARS-CoV-2 among healthcare workers across 16 hospitals of Kashmir, India-A seroepidemiological study.",2021-11-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Kashmir,,HCWs across sixteen hospitals (Level II and Level III) of the Kashmir Division,,2021-01-14,2021-01-17,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,2003,0.268,0.24800000000000003,0.28800000000000003,True,True,,,True,Convenience,Not reported/ Unable to specify,,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.99,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Inaamul Haq,"Government Medical College Srinagar, Jammu and Kashmir",Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0259893,2021-12-01,2022-07-16,Unverified,haq_burden_2021,IND
211201_Chennai_YRCCARE,211201_Chennai_YRCCARE,SARS CoV-2 seroprevalence and COVID-19 experience among people with HIV in India,2021-12-01,Presentation or Conference,Local,Cross-sectional survey ,India,Tamil Nadu,Chennai,"""randomly selected PWH (people with HIV) who access routine care at a community health clinic in Chennai. Enrolled participants are aged 5 years and older; ""","""individuals actively symp-tomatic for influenza-like illness (ILI) and those with ahistory of ILI in the past 2 weeks were excluded""",2020-12-15,2021-05-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,5.0,,Primary Estimate,,393,0.10400000000000001,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,RT Khan,YRGCARE,Not Unity-Aligned,https://journals.sagepub.com/doi/abs/10.1177/13596535211063242?journalCode=avta,2022-02-02,2024-03-01,Unverified,noauthor_23rd_2021,IND
211205_Jaipur_MahatmaGandhiMedicalCollege&Hospital_Overall,211205_Jaipur_MahatmaGandhiMedicalCollege&Hospital,Seroprevalence of SARS-CoV-2 IgG antibody among healthy blood donors: a single centre study.,2021-12-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Rajasthan,Jaipur,"All participants were healthy blood donors who visited to Blood Center, Mahatma Gandhi Medical College and Hospital, Jaipur and donated whole blood between mid-December 2020 to January 2021. Prospective donors could not have had flu like symptoms within the 28 days before donation or had close contact with suspected or confirmed COVID-19 cases. Candidates presenting fever (forehead temperature > 37.8 ° C) on the donation date are also deferred, i.e., Eligible participants for this study were those with no current COVID-19 symptoms and no confirmed previous SARS-CoV-2 infection or in close contact of COVID-19 confirmed cases.","Blood donors were excluded if they were diagnosed with COVID-19 disease or presented with physically identifiable symptoms of any previous infection mimicking flu like infection. We excluded those who refused to sign the informed consent form for blood donation and testing.
586 healthy voluntary blood donors were enrolled and were screened for SARS- CoV-2 IgG antibody. Out of these 586 donors, 52 donors had indeterminate values of SARS CoV-2IgG antibody, thus were excluded from the study.",2020-12-15,2021-01-15,Blood donors,All,Adults (18-64 years),,,Primary Estimate,,534,0.4288,,,True,,,,True,Sequential,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,,IgG,Spike,Validated by independent authors/third party/non-developers,0.9,1.0,['High'],,No,Yes,No,,Yes,Yes,Yes,,Ram Jaiswal,Mahatma Gandhi Medical College & Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.transci.2021.103338,2022-01-08,2024-03-01,Unverified,jaiswal_seroprevalence_2021,IND
211210_India_ICMR_GenPop_OverallTestAdjust,211210_India_ICMR_GenPop,"Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June-July 2021: A population-based cross-sectional study.",2021-12-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,"Andhra Pradesh,Assam,Bihar,Chhattisgarh,Gujarat,Haryana,Himachal Pradesh,Jammu & Kashmir,Jharkhand,Karnataka,Kerala,Madhya Pradesh,Maharashtra,Odisha,Punjab,Rajasthan,Tamil Nadu,Telangana,Uttar Pradesh,Uttarakhand,West Bengal",,"Usual resident, age ≥6 years, available at the time of the household visit and willing to participate ",Age < 6 years; locked household; guest/visitor; not willing to participate,2021-06-14,2021-07-06,Household and community samples,All,Multiple groups,6.0,,Primary Estimate,Test Adjusted,28975,0.668,0.655,0.68,True,True,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8,0.99,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Manoj Murhekar,Indian Council of Medical Research,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pmed.1003877,2021-12-29,2023-08-15,Unverified,murhekar_seroprevalence_2021,IND
211210_India_ICMR_GenPop_SexMale,211210_India_ICMR_GenPop,"Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June-July 2021: A population-based cross-sectional study.",2021-12-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,"Andhra Pradesh,Assam,Bihar,Chhattisgarh,Gujarat,Haryana,Himachal Pradesh,Jammu & Kashmir,Jharkhand,Karnataka,Kerala,Madhya Pradesh,Maharashtra,Odisha,Punjab,Rajasthan,Tamil Nadu,Telangana,Uttar Pradesh,Uttarakhand,West Bengal",,"Usual resident, age ≥6 years, available at the time of the household visit and willing to participate ",Age < 6 years; locked household; guest/visitor; not willing to participate,2021-06-14,2021-07-06,Household and community samples,Male,Multiple groups,6.0,,Sex/Gender,,13783,0.6543000000000001,,,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8,0.99,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Manoj Murhekar,Indian Council of Medical Research,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pmed.1003877,2021-12-29,2024-03-01,Unverified,murhekar_seroprevalence_2021,IND
211210_India_ICMR_GenPop_Age6-9,211210_India_ICMR_GenPop,"Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June-July 2021: A population-based cross-sectional study.",2021-12-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,"Andhra Pradesh,Assam,Bihar,Chhattisgarh,Gujarat,Haryana,Himachal Pradesh,Jammu & Kashmir,Jharkhand,Karnataka,Kerala,Madhya Pradesh,Maharashtra,Odisha,Punjab,Rajasthan,Tamil Nadu,Telangana,Uttar Pradesh,Uttarakhand,West Bengal",,"Usual resident, age ≥6 years, available at the time of the household visit and willing to participate ",Age < 6 years; locked household; guest/visitor; not willing to participate,2021-06-14,2021-07-06,Household and community samples,All,Children and Youth (0-17 years),6.0,9.0,Age,6-9,2892,0.5654,,,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8,0.99,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Manoj Murhekar,Indian Council of Medical Research,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pmed.1003877,2021-12-29,2024-03-01,Unverified,murhekar_seroprevalence_2021,IND
211210_India_ICMR_GenPop_OverallCrude_Npositive,211210_India_ICMR_GenPop,"Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June-July 2021: A population-based cross-sectional study.",2021-12-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,"Andhra Pradesh,Assam,Bihar,Chhattisgarh,Gujarat,Haryana,Himachal Pradesh,Jammu & Kashmir,Jharkhand,Karnataka,Kerala,Madhya Pradesh,Maharashtra,Odisha,Punjab,Rajasthan,Tamil Nadu,Telangana,Uttar Pradesh,Uttarakhand,West Bengal",,"Usual resident, age ≥6 years, available at the time of the household visit and willing to participate ",Age < 6 years; locked household; guest/visitor; not willing to participate,2021-06-14,2021-07-06,Household and community samples,All,Multiple groups,6.0,,Test used,N positive,28975,0.3896,,,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.614,1.0,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Manoj Murhekar,Indian Council of Medical Research,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pmed.1003877,2021-12-29,2023-08-15,Unverified,murhekar_seroprevalence_2021,IND
211210_India_ICMR_GenPop_Age45-60,211210_India_ICMR_GenPop,"Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June-July 2021: A population-based cross-sectional study.",2021-12-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,"Andhra Pradesh,Assam,Bihar,Chhattisgarh,Gujarat,Haryana,Himachal Pradesh,Jammu & Kashmir,Jharkhand,Karnataka,Kerala,Madhya Pradesh,Maharashtra,Odisha,Punjab,Rajasthan,Tamil Nadu,Telangana,Uttar Pradesh,Uttarakhand,West Bengal",,"Usual resident, age ≥6 years, available at the time of the household visit and willing to participate ",Age < 6 years; locked household; guest/visitor; not willing to participate,2021-06-14,2021-07-06,Household and community samples,All,Adults (18-64 years),45.0,60.0,Age,45-60,5545,0.7605,,,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8,0.99,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Manoj Murhekar,Indian Council of Medical Research,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pmed.1003877,2021-12-29,2024-03-01,Unverified,murhekar_seroprevalence_2021,IND
211210_India_ICMR_GenPop_SexFemale,211210_India_ICMR_GenPop,"Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June-July 2021: A population-based cross-sectional study.",2021-12-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,"Andhra Pradesh,Assam,Bihar,Chhattisgarh,Gujarat,Haryana,Himachal Pradesh,Jammu & Kashmir,Jharkhand,Karnataka,Kerala,Madhya Pradesh,Maharashtra,Odisha,Punjab,Rajasthan,Tamil Nadu,Telangana,Uttar Pradesh,Uttarakhand,West Bengal",,"Usual resident, age ≥6 years, available at the time of the household visit and willing to participate ",Age < 6 years; locked household; guest/visitor; not willing to participate,2021-06-14,2021-07-06,Household and community samples,Female,Multiple groups,6.0,,Sex/Gender,,15160,0.6790999999999999,,,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8,0.99,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Manoj Murhekar,Indian Council of Medical Research,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pmed.1003877,2021-12-29,2024-03-01,Unverified,murhekar_seroprevalence_2021,IND
211210_India_ICMR_GenPop_Vaccine2DOSE,211210_India_ICMR_GenPop,"Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June-July 2021: A population-based cross-sectional study.",2021-12-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,"Andhra Pradesh,Assam,Bihar,Chhattisgarh,Gujarat,Haryana,Himachal Pradesh,Jammu & Kashmir,Jharkhand,Karnataka,Kerala,Madhya Pradesh,Maharashtra,Odisha,Punjab,Rajasthan,Tamil Nadu,Telangana,Uttar Pradesh,Uttarakhand,West Bengal",,"Usual resident, age ≥6 years, available at the time of the household visit and willing to participate ",Age < 6 years; locked household; guest/visitor; not willing to participate,2021-06-14,2021-07-06,Household and community samples,All,Multiple groups,6.0,,COVID-19 vaccination status,Vaccination 2 Dose,2631,0.886,,,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8,0.99,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Manoj Murhekar,Indian Council of Medical Research,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pmed.1003877,2021-12-29,2024-03-01,Unverified,murhekar_seroprevalence_2021,IND
211210_India_ICMR_GenPop_VaccineNO,211210_India_ICMR_GenPop,"Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June-July 2021: A population-based cross-sectional study.",2021-12-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,"Andhra Pradesh,Assam,Bihar,Chhattisgarh,Gujarat,Haryana,Himachal Pradesh,Jammu & Kashmir,Jharkhand,Karnataka,Kerala,Madhya Pradesh,Maharashtra,Odisha,Punjab,Rajasthan,Tamil Nadu,Telangana,Uttar Pradesh,Uttarakhand,West Bengal",,"Usual resident, age ≥6 years, available at the time of the household visit and willing to participate ",Age < 6 years; locked household; guest/visitor; not willing to participate,2021-06-14,2021-07-06,Household and community samples,All,Multiple groups,6.0,,COVID-19 vaccination status,,12599,0.6158,,,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8,0.99,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Manoj Murhekar,Indian Council of Medical Research,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pmed.1003877,2021-12-29,2024-03-01,Unverified,murhekar_seroprevalence_2021,IND
211210_India_ICMR_GenPop_Age18-44,211210_India_ICMR_GenPop,"Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June-July 2021: A population-based cross-sectional study.",2021-12-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,"Andhra Pradesh,Assam,Bihar,Chhattisgarh,Gujarat,Haryana,Himachal Pradesh,Jammu & Kashmir,Jharkhand,Karnataka,Kerala,Madhya Pradesh,Maharashtra,Odisha,Punjab,Rajasthan,Tamil Nadu,Telangana,Uttar Pradesh,Uttarakhand,West Bengal",,"Usual resident, age ≥6 years, available at the time of the household visit and willing to participate ",Age < 6 years; locked household; guest/visitor; not willing to participate,2021-06-14,2021-07-06,Household and community samples,All,Adults (18-64 years),18.0,44.0,Age,18-44,12522,0.6584000000000001,,,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8,0.99,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Manoj Murhekar,Indian Council of Medical Research,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pmed.1003877,2021-12-29,2024-03-01,Unverified,murhekar_seroprevalence_2021,IND
211210_India_ICMR_GenPop_OverallCrude_S+Npositive,211210_India_ICMR_GenPop,"Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June-July 2021: A population-based cross-sectional study.",2021-12-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,"Andhra Pradesh,Assam,Bihar,Chhattisgarh,Gujarat,Haryana,Himachal Pradesh,Jammu & Kashmir,Jharkhand,Karnataka,Kerala,Madhya Pradesh,Maharashtra,Odisha,Punjab,Rajasthan,Tamil Nadu,Telangana,Uttar Pradesh,Uttarakhand,West Bengal",,"Usual resident, age ≥6 years, available at the time of the household visit and willing to participate ",Age < 6 years; locked household; guest/visitor; not willing to participate,2021-06-14,2021-07-06,Household and community samples,All,Multiple groups,6.0,,Test used,S and/or N positive,28975,0.6673,,,,,,,,Stratified probability,"ADVIA Centaur Immunoassay System,Abbott Architect SARS-CoV-2 IgG","Siemens,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Manoj Murhekar,Indian Council of Medical Research,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pmed.1003877,2021-12-29,2024-03-01,Unverified,murhekar_seroprevalence_2021,IND
211210_India_ICMR_GenPop_Age10-17,211210_India_ICMR_GenPop,"Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June-July 2021: A population-based cross-sectional study.",2021-12-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,"Andhra Pradesh,Assam,Bihar,Chhattisgarh,Gujarat,Haryana,Himachal Pradesh,Jammu & Kashmir,Jharkhand,Karnataka,Kerala,Madhya Pradesh,Maharashtra,Odisha,Punjab,Rajasthan,Tamil Nadu,Telangana,Uttar Pradesh,Uttarakhand,West Bengal",,"Usual resident, age ≥6 years, available at the time of the household visit and willing to participate ",Age < 6 years; locked household; guest/visitor; not willing to participate,2021-06-14,2021-07-06,Household and community samples,All,Children and Youth (0-17 years),10.0,17.0,Age,10-17,5798,0.6181,,,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8,0.99,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Manoj Murhekar,Indian Council of Medical Research,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pmed.1003877,2021-12-29,2024-03-01,Unverified,murhekar_seroprevalence_2021,IND
211210_India_ICMR_GenPop_VaccineCovaxin,211210_India_ICMR_GenPop,"Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June-July 2021: A population-based cross-sectional study.",2021-12-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,"Andhra Pradesh,Assam,Bihar,Chhattisgarh,Gujarat,Haryana,Himachal Pradesh,Jammu & Kashmir,Jharkhand,Karnataka,Kerala,Madhya Pradesh,Maharashtra,Odisha,Punjab,Rajasthan,Tamil Nadu,Telangana,Uttar Pradesh,Uttarakhand,West Bengal",,"Usual resident, age ≥6 years, available at the time of the household visit and willing to participate ",Age < 6 years; locked household; guest/visitor; not willing to participate,2021-06-14,2021-07-06,Household and community samples,All,Multiple groups,6.0,,COVID-19 vaccination status,Covaxin,587,0.8058,,,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8,0.99,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Manoj Murhekar,Indian Council of Medical Research,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pmed.1003877,2021-12-29,2024-03-01,Unverified,murhekar_seroprevalence_2021,IND
211210_India_ICMR_GenPop_VaccineCovishield,211210_India_ICMR_GenPop,"Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June-July 2021: A population-based cross-sectional study.",2021-12-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,"Andhra Pradesh,Assam,Bihar,Chhattisgarh,Gujarat,Haryana,Himachal Pradesh,Jammu & Kashmir,Jharkhand,Karnataka,Kerala,Madhya Pradesh,Maharashtra,Odisha,Punjab,Rajasthan,Tamil Nadu,Telangana,Uttar Pradesh,Uttarakhand,West Bengal",,"Usual resident, age ≥6 years, available at the time of the household visit and willing to participate ",Age < 6 years; locked household; guest/visitor; not willing to participate,2021-06-14,2021-07-06,Household and community samples,All,Multiple groups,6.0,,COVID-19 vaccination status,Covishield,6945,0.8281000000000001,,,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8,0.99,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Manoj Murhekar,Indian Council of Medical Research,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pmed.1003877,2021-12-29,2024-03-01,Unverified,murhekar_seroprevalence_2021,IND
211210_India_ICMR_GenPop_Age>60,211210_India_ICMR_GenPop,"Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June-July 2021: A population-based cross-sectional study.",2021-12-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,"Andhra Pradesh,Assam,Bihar,Chhattisgarh,Gujarat,Haryana,Himachal Pradesh,Jammu & Kashmir,Jharkhand,Karnataka,Kerala,Madhya Pradesh,Maharashtra,Odisha,Punjab,Rajasthan,Tamil Nadu,Telangana,Uttar Pradesh,Uttarakhand,West Bengal",,"Usual resident, age ≥6 years, available at the time of the household visit and willing to participate ",Age < 6 years; locked household; guest/visitor; not willing to participate,2021-06-14,2021-07-06,Household and community samples,All,Seniors (65+ years),61.0,,Age,,2218,0.7462000000000001,,,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8,0.99,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Manoj Murhekar,Indian Council of Medical Research,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pmed.1003877,2021-12-29,2024-03-01,Unverified,murhekar_seroprevalence_2021,IND
211210_India_ICMR_GenPop_OverallCrude_Spositive,211210_India_ICMR_GenPop,"Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June-July 2021: A population-based cross-sectional study.",2021-12-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,"Andhra Pradesh,Assam,Bihar,Chhattisgarh,Gujarat,Haryana,Himachal Pradesh,Jammu & Kashmir,Jharkhand,Karnataka,Kerala,Madhya Pradesh,Maharashtra,Odisha,Punjab,Rajasthan,Tamil Nadu,Telangana,Uttar Pradesh,Uttarakhand,West Bengal",,"Usual resident, age ≥6 years, available at the time of the household visit and willing to participate ",Age < 6 years; locked household; guest/visitor; not willing to participate,2021-06-14,2021-07-06,Household and community samples,All,Multiple groups,6.0,,Analysis,S Positive,28975,0.6346,,,,,,,True,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8,0.99,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Manoj Murhekar,Indian Council of Medical Research,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pmed.1003877,2021-12-29,2024-03-01,Unverified,murhekar_seroprevalence_2021,IND
211210_India_ICMR_GenPop_Vaccine1DOSE,211210_India_ICMR_GenPop,"Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June-July 2021: A population-based cross-sectional study.",2021-12-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,"Andhra Pradesh,Assam,Bihar,Chhattisgarh,Gujarat,Haryana,Himachal Pradesh,Jammu & Kashmir,Jharkhand,Karnataka,Kerala,Madhya Pradesh,Maharashtra,Odisha,Punjab,Rajasthan,Tamil Nadu,Telangana,Uttar Pradesh,Uttarakhand,West Bengal",,"Usual resident, age ≥6 years, available at the time of the household visit and willing to participate ",Age < 6 years; locked household; guest/visitor; not willing to participate,2021-06-14,2021-07-06,Household and community samples,All,Multiple groups,6.0,,COVID-19 vaccination status,Vaccination 1 Dose,5038,0.7970999999999999,,,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8,0.99,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Manoj Murhekar,Indian Council of Medical Research,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pmed.1003877,2021-12-29,2024-03-01,Unverified,murhekar_seroprevalence_2021,IND
211210_India_ICMR_HCW_OverallTestAdjust,211210_India_ICMR_HCW,"Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June-July 2021: A population-based cross-sectional study.",2021-12-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,"Andhra Pradesh,Assam,Bihar,Chhattisgarh,Gujarat,Haryana,Himachal Pradesh,Jammu & Kashmir,Jharkhand,Karnataka,Kerala,Madhya Pradesh,Maharashtra,Odisha,Punjab,Rajasthan,Tamil Nadu,Telangana,Uttar Pradesh,Uttarakhand,West Bengal",," Doctors, nurses, paramedical/laboratory staff, employed at the district 
hospital and sub-district (taluk/CHC) levels, available at the time of hospital visit and 
willing to participate ",Administrative and field staff of hospital; not willing to participate ,2021-06-14,2021-07-06,Health care workers and caregivers,All,Multiple groups,18.0,,Primary Estimate,Test Adjusted,7252,0.8740000000000001,0.856,0.891,True,True,,,,Convenience,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8,0.99,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Manoj Murhekar,Indian Council of Medical Research,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pmed.1003877,2021-12-29,2023-08-15,Unverified,murhekar_seroprevalence_2021,IND
211210_India_ICMR_HCW_Age>60,211210_India_ICMR_HCW,"Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June-July 2021: A population-based cross-sectional study.",2021-12-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,"Andhra Pradesh,Assam,Bihar,Chhattisgarh,Gujarat,Haryana,Himachal Pradesh,Jammu & Kashmir,Jharkhand,Karnataka,Kerala,Madhya Pradesh,Maharashtra,Odisha,Punjab,Rajasthan,Tamil Nadu,Telangana,Uttar Pradesh,Uttarakhand,West Bengal",," Doctors, nurses, paramedical/laboratory staff, employed at the district 
hospital and sub-district (taluk/CHC) levels, available at the time of hospital visit and 
willing to participate ",Administrative and field staff of hospital; not willing to participate ,2021-06-14,2021-07-06,Health care workers and caregivers,All,Seniors (65+ years),61.0,,Age,,122,0.8115000000000001,,,,,,,,Convenience,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8,0.99,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Manoj Murhekar,Indian Council of Medical Research,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pmed.1003877,2021-12-29,2024-03-01,Unverified,murhekar_seroprevalence_2021,IND
211210_India_ICMR_HCW_Age45-60,211210_India_ICMR_HCW,"Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June-July 2021: A population-based cross-sectional study.",2021-12-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,"Andhra Pradesh,Assam,Bihar,Chhattisgarh,Gujarat,Haryana,Himachal Pradesh,Jammu & Kashmir,Jharkhand,Karnataka,Kerala,Madhya Pradesh,Maharashtra,Odisha,Punjab,Rajasthan,Tamil Nadu,Telangana,Uttar Pradesh,Uttarakhand,West Bengal",," Doctors, nurses, paramedical/laboratory staff, employed at the district 
hospital and sub-district (taluk/CHC) levels, available at the time of hospital visit and 
willing to participate ",Administrative and field staff of hospital; not willing to participate ,2021-06-14,2021-07-06,Health care workers and caregivers,All,Adults (18-64 years),45.0,60.0,Age,45-60,1997,0.8443,,,,,,,,Convenience,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8,0.99,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Manoj Murhekar,Indian Council of Medical Research,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pmed.1003877,2021-12-29,2024-03-01,Unverified,murhekar_seroprevalence_2021,IND
211210_India_ICMR_HCW_Age18-44,211210_India_ICMR_HCW,"Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June-July 2021: A population-based cross-sectional study.",2021-12-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,"Andhra Pradesh,Assam,Bihar,Chhattisgarh,Gujarat,Haryana,Himachal Pradesh,Jammu & Kashmir,Jharkhand,Karnataka,Kerala,Madhya Pradesh,Maharashtra,Odisha,Punjab,Rajasthan,Tamil Nadu,Telangana,Uttar Pradesh,Uttarakhand,West Bengal",," Doctors, nurses, paramedical/laboratory staff, employed at the district 
hospital and sub-district (taluk/CHC) levels, available at the time of hospital visit and 
willing to participate ",Administrative and field staff of hospital; not willing to participate ,2021-06-14,2021-07-06,Health care workers and caregivers,All,Adults (18-64 years),18.0,44.0,Age,18-44,5133,0.8573999999999999,,,,,,,,Convenience,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8,0.99,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Manoj Murhekar,Indian Council of Medical Research,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pmed.1003877,2021-12-29,2024-03-01,Unverified,murhekar_seroprevalence_2021,IND
211214_NewDelhi_AllIndiaInstituteofMedicalSciences_overall,211214_NewDelhi_AllIndiaInstituteofMedicalSciences,SARS-CoV-2 Seroprevalence in Individuals With Type 1 and Type 2 Diabetes Compared With Controls.,2021-12-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,National Capital Territory of Delhi,New Delhi,"This study included 3 groups: group 1 (T1DM), group 2 (T2DM), and group 3 (controls—individuals without diabetes). All study participants submitted blood samples between October 1, 2020, and February 27, 2021, as a part of ongoing research projects. Participants in groups 1 and 2 were recruited from general and/or specialty endocrine clinics run by the department. T1DM was defined according to the following clinical definition: (1) age at onset of diabetes of <25 years, (2) persistent insulin requirement within 6 months from the diagnosis of diabetes, and (3) absence of pancreatic calcification and features of insulin resistance such as acanthosis nigricans. The presence of ketosis and pancreatic β-cell autoantibodies was used as an additional supportive feature. T2DM was defined according to the following clinical definition: (1) variable age at onset; (2) presence of obesity, a positive family history, and features of insulin resistance such as acanthosis nigricans; and (3) the lack of insulin dependence for glycemic control, at least early in the disease course. ",,2020-10-01,2021-02-27,Multiple populations,All,Multiple groups,,,Primary Estimate,,643,0.504,,,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Alpesh Goyal,All India Institute of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1016/j.eprac.2021.12.009,2022-01-12,2024-03-01,Unverified,goyal_sars-cov-2_2021,IND
211227_Vellore_ChristianMedicalCollege_Jan2021_PopAdj,211227_Vellore_ChristianMedicalCollege_Jan2021,"Community seroprevalence and risk factors for SARS CoV-2 infection in different subpopulations in Vellore, India and its implications for future prevention.",2021-12-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Vellore,"Permanent residents of Vellore district, Tamil Nadu in South India",,2021-01-01,2021-01-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,1228,0.28500000000000003,0.223,0.337,True,,True,,True,Stratified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,0.976,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Divya Dayanand,Christian Medical College,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.12.356,2022-01-08,2024-03-01,Verified,dayanand_community_2021,IND
211227_Vellore_ChristianMedicalCollege_Jan2021_21-40,211227_Vellore_ChristianMedicalCollege_Jan2021,"Community seroprevalence and risk factors for SARS CoV-2 infection in different subpopulations in Vellore, India and its implications for future prevention.",2021-12-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Vellore,"Permanent residents of Vellore district, Tamil Nadu in South India",,2021-01-01,2021-01-31,Household and community samples,All,Adults (18-64 years),,,Age,21-40,540,0.307,,,,,,,,Stratified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,0.976,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Divya Dayanand,Christian Medical College,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.12.356,2022-01-08,2024-03-01,Verified,dayanand_community_2021,IND
211227_Vellore_ChristianMedicalCollege_Jan2021_>60,211227_Vellore_ChristianMedicalCollege_Jan2021,"Community seroprevalence and risk factors for SARS CoV-2 infection in different subpopulations in Vellore, India and its implications for future prevention.",2021-12-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Vellore,"Permanent residents of Vellore district, Tamil Nadu in South India",,2021-01-01,2021-01-31,Household and community samples,All,Seniors (65+ years),,,Age,>60,134,0.336,,,,,,,,Stratified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,0.976,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Divya Dayanand,Christian Medical College,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.12.356,2022-01-08,2024-03-01,Verified,dayanand_community_2021,IND
211227_Vellore_ChristianMedicalCollege_Jan2021_Female,211227_Vellore_ChristianMedicalCollege_Jan2021,"Community seroprevalence and risk factors for SARS CoV-2 infection in different subpopulations in Vellore, India and its implications for future prevention.",2021-12-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Vellore,"Permanent residents of Vellore district, Tamil Nadu in South India",,2021-01-01,2021-01-31,Household and community samples,Female,Multiple groups,,,Sex/Gender,,670,0.33299999999999996,,,,,,,,Stratified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,0.976,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Divya Dayanand,Christian Medical College,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.12.356,2022-01-08,2024-03-01,Verified,dayanand_community_2021,IND
211227_Vellore_ChristianMedicalCollege_Jan2021_<20,211227_Vellore_ChristianMedicalCollege_Jan2021,"Community seroprevalence and risk factors for SARS CoV-2 infection in different subpopulations in Vellore, India and its implications for future prevention.",2021-12-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Vellore,"Permanent residents of Vellore district, Tamil Nadu in South India",,2021-01-01,2021-01-31,Household and community samples,All,Adults (18-64 years),,,Age,<20,237,0.316,,,,,,,,Stratified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,0.976,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Divya Dayanand,Christian Medical College,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.12.356,2022-01-08,2024-03-01,Verified,dayanand_community_2021,IND
211227_Vellore_ChristianMedicalCollege_Jan2021_41-60,211227_Vellore_ChristianMedicalCollege_Jan2021,"Community seroprevalence and risk factors for SARS CoV-2 infection in different subpopulations in Vellore, India and its implications for future prevention.",2021-12-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Vellore,"Permanent residents of Vellore district, Tamil Nadu in South India",,2021-01-01,2021-01-31,Household and community samples,All,Adults (18-64 years),,,Age,41-60,317,0.331,,,,,,,,Stratified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,0.976,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Divya Dayanand,Christian Medical College,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.12.356,2022-01-08,2024-03-01,Verified,dayanand_community_2021,IND
211227_Vellore_ChristianMedicalCollege_Jan2021_Male,211227_Vellore_ChristianMedicalCollege_Jan2021,"Community seroprevalence and risk factors for SARS CoV-2 infection in different subpopulations in Vellore, India and its implications for future prevention.",2021-12-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Vellore,"Permanent residents of Vellore district, Tamil Nadu in South India",,2021-01-01,2021-01-31,Household and community samples,Male,Multiple groups,,,Sex/Gender,,558,0.30100000000000005,,,,,,,,Stratified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,0.976,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Divya Dayanand,Christian Medical College,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.12.356,2022-01-08,2024-03-01,Verified,dayanand_community_2021,IND
211227_Vellore_ChristianMedicalCollege_July2021_PopAdj,211227_Vellore_ChristianMedicalCollege_July2021,"Community seroprevalence and risk factors for SARS CoV-2 infection in different subpopulations in Vellore, India and its implications for future prevention.",2021-12-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Vellore,"Permanent residents of Vellore district, Tamil Nadu in South India",,2021-07-01,2021-07-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,1205,0.716,0.628,0.805,True,,True,,True,Stratified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,0.976,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Divya Dayanand,Christian Medical College,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.12.356,2022-01-08,2024-03-01,Verified,dayanand_community_2021,IND
211227_Vellore_ChristianMedicalCollege_July2021_<20,211227_Vellore_ChristianMedicalCollege_July2021,"Community seroprevalence and risk factors for SARS CoV-2 infection in different subpopulations in Vellore, India and its implications for future prevention.",2021-12-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Vellore,"Permanent residents of Vellore district, Tamil Nadu in South India",,2021-07-01,2021-07-31,Household and community samples,All,Adults (18-64 years),,,Age,<20,217,0.747,,,,,,,,Stratified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,0.976,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Divya Dayanand,Christian Medical College,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.12.356,2022-01-08,2024-03-01,Verified,dayanand_community_2021,IND
211227_Vellore_ChristianMedicalCollege_July2021_21-40,211227_Vellore_ChristianMedicalCollege_July2021,"Community seroprevalence and risk factors for SARS CoV-2 infection in different subpopulations in Vellore, India and its implications for future prevention.",2021-12-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Vellore,"Permanent residents of Vellore district, Tamil Nadu in South India",,2021-07-01,2021-07-31,Household and community samples,All,Adults (18-64 years),,,Age,21-40,477,0.807,,,,,,,,Stratified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,0.976,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Divya Dayanand,Christian Medical College,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.12.356,2022-01-08,2024-03-01,Verified,dayanand_community_2021,IND
211227_Vellore_ChristianMedicalCollege_July2021_41-60,211227_Vellore_ChristianMedicalCollege_July2021,"Community seroprevalence and risk factors for SARS CoV-2 infection in different subpopulations in Vellore, India and its implications for future prevention.",2021-12-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Vellore,"Permanent residents of Vellore district, Tamil Nadu in South India",,2021-07-01,2021-07-31,Household and community samples,All,Adults (18-64 years),,,Age,41-60,381,0.772,,,,,,,,Stratified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,0.976,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Divya Dayanand,Christian Medical College,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.12.356,2022-01-08,2024-03-01,Verified,dayanand_community_2021,IND
211227_Vellore_ChristianMedicalCollege_July2021_Male,211227_Vellore_ChristianMedicalCollege_July2021,"Community seroprevalence and risk factors for SARS CoV-2 infection in different subpopulations in Vellore, India and its implications for future prevention.",2021-12-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Vellore,"Permanent residents of Vellore district, Tamil Nadu in South India",,2021-07-01,2021-07-31,Household and community samples,Male,Multiple groups,,,Sex/Gender,,497,0.763,,,,,,,,Stratified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,0.976,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Divya Dayanand,Christian Medical College,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.12.356,2022-01-08,2024-03-01,Verified,dayanand_community_2021,IND
211227_Vellore_ChristianMedicalCollege_July2021_Female,211227_Vellore_ChristianMedicalCollege_July2021,"Community seroprevalence and risk factors for SARS CoV-2 infection in different subpopulations in Vellore, India and its implications for future prevention.",2021-12-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Vellore,"Permanent residents of Vellore district, Tamil Nadu in South India",,2021-07-01,2021-07-31,Household and community samples,Female,Multiple groups,,,Sex/Gender,,708,0.7809999999999999,,,,,,,,Stratified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,0.976,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Divya Dayanand,Christian Medical College,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.12.356,2022-01-08,2024-03-01,Verified,dayanand_community_2021,IND
211227_Vellore_ChristianMedicalCollege_July2021_>60,211227_Vellore_ChristianMedicalCollege_July2021,"Community seroprevalence and risk factors for SARS CoV-2 infection in different subpopulations in Vellore, India and its implications for future prevention.",2021-12-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Vellore,"Permanent residents of Vellore district, Tamil Nadu in South India",,2021-07-01,2021-07-31,Household and community samples,All,Seniors (65+ years),,,Age,>60,130,0.7000000000000001,,,,,,,,Stratified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,0.976,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Divya Dayanand,Christian Medical College,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.12.356,2022-01-08,2024-03-01,Verified,dayanand_community_2021,IND
211229_Lucknow_KingGeorgeMedicalUniversity_HCWs,211229_Lucknow_KingGeorgeMedicalUniversity_HCWs,SARS-CoV-2 IgG Surveillance in Asymptomatic Blood Donors and Health Workers.,2021-12-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Uttar Pradesh,Lucknow,"HCWs included doctors, technicians, staff nurses,
attendants, sweepers, and clerks and were randomly selected. ",,2020-06-01,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,HCWs,560,0.023,0.010700000000000001,0.0357,True,,,,True,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,,,,,['High'],,Yes,No,No,,Yes,Yes,Yes,,Tulika Chandra,King George Medical University,Not Unity-Aligned,https://dx.doi.org/10.1155/2021/2404170,2022-01-11,2024-03-01,Unverified,chandra_sars-cov-2_2021,IND
211229_UttarPradesh_KingGeorgeMedicalUniversity_blooddonors_Overall,211229_UttarPradesh_KingGeorgeMedicalUniversity_blooddonors,SARS-CoV-2 IgG Surveillance in Asymptomatic Blood Donors and Health Workers.,2021-12-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Uttar Pradesh,Lucknow,"Sample collection: blood donors were allowed to donate
blood only after fulfilling all the criteria laid down by the
FDA of India with additional history of excluding
COVID-19 suspects. &is included contact history with
any COVID-19-positive patient, recent travel history, and
symptoms of COVID-19. Consent was taken regarding the
screening of COVID-19 antibodies. &ey donated blood
only after completing their fitness. In the blood units,
apart from regular screening of HIV, hepatitis B, hepatitis
C, malaria, and syphilis, testing for IgG antibodies for
COVID-19 was also performed","additional history of excluding
COVID-19 suspects. &is included contact history with
any COVID-19-positive patient, recent travel history, and
symptoms of COVID-19",2020-06-01,2020-06-30,Blood donors,All,Adults (18-64 years),18.0,,Primary Estimate,,2163,0.019,0.013600000000000001,0.0252,True,,,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Tulika Chandra,King George Medical University,Not Unity-Aligned,https://dx.doi.org/10.1155/2021/2404170,2022-01-11,2024-03-01,Unverified,chandra_sars-cov-2_2021,IND
211229_UttarPradesh_KingGeorgeMedicalUniversity_blooddonors_40-49,211229_UttarPradesh_KingGeorgeMedicalUniversity_blooddonors,SARS-CoV-2 IgG Surveillance in Asymptomatic Blood Donors and Health Workers.,2021-12-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Uttar Pradesh,Lucknow,"Sample collection: blood donors were allowed to donate
blood only after fulfilling all the criteria laid down by the
FDA of India with additional history of excluding
COVID-19 suspects. &is included contact history with
any COVID-19-positive patient, recent travel history, and
symptoms of COVID-19. Consent was taken regarding the
screening of COVID-19 antibodies. &ey donated blood
only after completing their fitness. In the blood units,
apart from regular screening of HIV, hepatitis B, hepatitis
C, malaria, and syphilis, testing for IgG antibodies for
COVID-19 was also performed","additional history of excluding
COVID-19 suspects. &is included contact history with
any COVID-19-positive patient, recent travel history, and
symptoms of COVID-19",2020-06-01,2020-06-30,Blood donors,All,Adults (18-64 years),40.0,49.0,Age,40-49,228,0.031000000000000003,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Tulika Chandra,King George Medical University,Not Unity-Aligned,https://dx.doi.org/10.1155/2021/2404170,2022-01-11,2024-03-01,Unverified,chandra_sars-cov-2_2021,IND
211229_UttarPradesh_KingGeorgeMedicalUniversity_blooddonors_50+,211229_UttarPradesh_KingGeorgeMedicalUniversity_blooddonors,SARS-CoV-2 IgG Surveillance in Asymptomatic Blood Donors and Health Workers.,2021-12-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Uttar Pradesh,Lucknow,"Sample collection: blood donors were allowed to donate
blood only after fulfilling all the criteria laid down by the
FDA of India with additional history of excluding
COVID-19 suspects. &is included contact history with
any COVID-19-positive patient, recent travel history, and
symptoms of COVID-19. Consent was taken regarding the
screening of COVID-19 antibodies. &ey donated blood
only after completing their fitness. In the blood units,
apart from regular screening of HIV, hepatitis B, hepatitis
C, malaria, and syphilis, testing for IgG antibodies for
COVID-19 was also performed","additional history of excluding
COVID-19 suspects. &is included contact history with
any COVID-19-positive patient, recent travel history, and
symptoms of COVID-19",2020-06-01,2020-06-30,Blood donors,All,Multiple groups,50.0,,Age,50+,39,0.0,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Tulika Chandra,King George Medical University,Not Unity-Aligned,https://dx.doi.org/10.1155/2021/2404170,2022-01-11,2024-03-01,Unverified,chandra_sars-cov-2_2021,IND
211229_UttarPradesh_KingGeorgeMedicalUniversity_blooddonors_Female,211229_UttarPradesh_KingGeorgeMedicalUniversity_blooddonors,SARS-CoV-2 IgG Surveillance in Asymptomatic Blood Donors and Health Workers.,2021-12-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Uttar Pradesh,Lucknow,"Sample collection: blood donors were allowed to donate
blood only after fulfilling all the criteria laid down by the
FDA of India with additional history of excluding
COVID-19 suspects. &is included contact history with
any COVID-19-positive patient, recent travel history, and
symptoms of COVID-19. Consent was taken regarding the
screening of COVID-19 antibodies. &ey donated blood
only after completing their fitness. In the blood units,
apart from regular screening of HIV, hepatitis B, hepatitis
C, malaria, and syphilis, testing for IgG antibodies for
COVID-19 was also performed","additional history of excluding
COVID-19 suspects. &is included contact history with
any COVID-19-positive patient, recent travel history, and
symptoms of COVID-19",2020-06-01,2020-06-30,Blood donors,Female,Adults (18-64 years),18.0,,Sex/Gender,,36,0.0,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Tulika Chandra,King George Medical University,Not Unity-Aligned,https://dx.doi.org/10.1155/2021/2404170,2022-01-11,2024-03-01,Unverified,chandra_sars-cov-2_2021,IND
211229_UttarPradesh_KingGeorgeMedicalUniversity_blooddonors_30-39,211229_UttarPradesh_KingGeorgeMedicalUniversity_blooddonors,SARS-CoV-2 IgG Surveillance in Asymptomatic Blood Donors and Health Workers.,2021-12-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Uttar Pradesh,Lucknow,"Sample collection: blood donors were allowed to donate
blood only after fulfilling all the criteria laid down by the
FDA of India with additional history of excluding
COVID-19 suspects. &is included contact history with
any COVID-19-positive patient, recent travel history, and
symptoms of COVID-19. Consent was taken regarding the
screening of COVID-19 antibodies. &ey donated blood
only after completing their fitness. In the blood units,
apart from regular screening of HIV, hepatitis B, hepatitis
C, malaria, and syphilis, testing for IgG antibodies for
COVID-19 was also performed","additional history of excluding
COVID-19 suspects. &is included contact history with
any COVID-19-positive patient, recent travel history, and
symptoms of COVID-19",2020-06-01,2020-06-30,Blood donors,All,Adults (18-64 years),30.0,39.0,Age,30-39,711,0.015,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Tulika Chandra,King George Medical University,Not Unity-Aligned,https://dx.doi.org/10.1155/2021/2404170,2022-01-11,2024-03-01,Unverified,chandra_sars-cov-2_2021,IND
211229_UttarPradesh_KingGeorgeMedicalUniversity_blooddonors_18-29,211229_UttarPradesh_KingGeorgeMedicalUniversity_blooddonors,SARS-CoV-2 IgG Surveillance in Asymptomatic Blood Donors and Health Workers.,2021-12-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Uttar Pradesh,Lucknow,"Sample collection: blood donors were allowed to donate
blood only after fulfilling all the criteria laid down by the
FDA of India with additional history of excluding
COVID-19 suspects. &is included contact history with
any COVID-19-positive patient, recent travel history, and
symptoms of COVID-19. Consent was taken regarding the
screening of COVID-19 antibodies. &ey donated blood
only after completing their fitness. In the blood units,
apart from regular screening of HIV, hepatitis B, hepatitis
C, malaria, and syphilis, testing for IgG antibodies for
COVID-19 was also performed","additional history of excluding
COVID-19 suspects. &is included contact history with
any COVID-19-positive patient, recent travel history, and
symptoms of COVID-19",2020-06-01,2020-06-30,Blood donors,All,Adults (18-64 years),18.0,29.0,Age,18-29,1185,0.02,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Tulika Chandra,King George Medical University,Not Unity-Aligned,https://dx.doi.org/10.1155/2021/2404170,2022-01-11,2024-03-01,Unverified,chandra_sars-cov-2_2021,IND
211229_UttarPradesh_KingGeorgeMedicalUniversity_blooddonors_male,211229_UttarPradesh_KingGeorgeMedicalUniversity_blooddonors,SARS-CoV-2 IgG Surveillance in Asymptomatic Blood Donors and Health Workers.,2021-12-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Uttar Pradesh,Lucknow,"Sample collection: blood donors were allowed to donate
blood only after fulfilling all the criteria laid down by the
FDA of India with additional history of excluding
COVID-19 suspects. &is included contact history with
any COVID-19-positive patient, recent travel history, and
symptoms of COVID-19. Consent was taken regarding the
screening of COVID-19 antibodies. &ey donated blood
only after completing their fitness. In the blood units,
apart from regular screening of HIV, hepatitis B, hepatitis
C, malaria, and syphilis, testing for IgG antibodies for
COVID-19 was also performed","additional history of excluding
COVID-19 suspects. &is included contact history with
any COVID-19-positive patient, recent travel history, and
symptoms of COVID-19",2020-06-01,2020-06-30,Blood donors,Male,Adults (18-64 years),18.0,,Sex/Gender,,2085,0.02,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Tulika Chandra,King George Medical University,Not Unity-Aligned,https://dx.doi.org/10.1155/2021/2404170,2022-01-11,2024-03-01,Unverified,chandra_sars-cov-2_2021,IND
211229_Delhi_MaulanaAzadMedicalCollege_Overall_PopTestAdj,211229_Delhi_MaulanaAzadMedicalCollege,"SARS-CoV-2 seroprevalence in Delhi, India: September October 2021: a population based seroepidemiological study",2021-12-29,Preprint,Regional,Repeated cross-sectional study,India,Delhi,Delhi,"This was a cross-sectional, seroepidemiological study among individuals aged five and above who were recruited from 274 wards in the state of Delhi from September 24 to October 14 2021.

A total of 100 participants each were enrolled from all wards except the Delhi Cantonment and the New Delhi wards.",Individuals under 5 years of age,2021-09-24,2021-10-14,Household and community samples,All,Multiple groups,,,Primary Estimate,,27811,0.975,0.97,0.98,True,True,True,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,,Validated by manufacturers,0.9,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Pragya Sharma,Maulana Azad Medical College,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.12.28.21268451v1,2022-01-12,2023-08-15,Verified,sharma_sars-cov-2_2021,IND
211229_Delhi_MaulanaAzadMedicalCollege_Sex_Female_UnAdj,211229_Delhi_MaulanaAzadMedicalCollege,"SARS-CoV-2 seroprevalence in Delhi, India: September October 2021: a population based seroepidemiological study",2021-12-29,Preprint,Regional,Repeated cross-sectional study,India,Delhi,Delhi,"This was a cross-sectional, seroepidemiological study among individuals aged five and above who were recruited from 274 wards in the state of Delhi from September 24 to October 14 2021.

A total of 100 participants each were enrolled from all wards except the Delhi Cantonment and the New Delhi wards.",Individuals under 5 years of age,2021-09-24,2021-10-14,Household and community samples,Female,Multiple groups,,,Sex/Gender,,16020,0.904744,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,,Validated by manufacturers,0.9,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Pragya Sharma,Maulana Azad Medical College,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.12.28.21268451v1,2022-01-12,2024-03-01,Verified,sharma_sars-cov-2_2021,IND
211229_Delhi_MaulanaAzadMedicalCollege_Age_18-49_UnAdj,211229_Delhi_MaulanaAzadMedicalCollege,"SARS-CoV-2 seroprevalence in Delhi, India: September October 2021: a population based seroepidemiological study",2021-12-29,Preprint,Regional,Repeated cross-sectional study,India,Delhi,Delhi,"This was a cross-sectional, seroepidemiological study among individuals aged five and above who were recruited from 274 wards in the state of Delhi from September 24 to October 14 2021.

A total of 100 participants each were enrolled from all wards except the Delhi Cantonment and the New Delhi wards.",Individuals under 5 years of age,2021-09-24,2021-10-14,Household and community samples,All,Adults (18-64 years),18.0,49.0,Age,,17195,0.9034603082,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,,Validated by manufacturers,0.9,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Pragya Sharma,Maulana Azad Medical College,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.12.28.21268451v1,2022-01-12,2024-03-01,Verified,sharma_sars-cov-2_2021,IND
211229_Delhi_MaulanaAzadMedicalCollege_COVIDVaccination_Vaccinated_UnAdj_OneDose,211229_Delhi_MaulanaAzadMedicalCollege,"SARS-CoV-2 seroprevalence in Delhi, India: September October 2021: a population based seroepidemiological study",2021-12-29,Preprint,Regional,Repeated cross-sectional study,India,Delhi,Delhi,"This was a cross-sectional, seroepidemiological study among individuals aged five and above who were recruited from 274 wards in the state of Delhi from September 24 to October 14 2021.

A total of 100 participants each were enrolled from all wards except the Delhi Cantonment and the New Delhi wards.",Individuals under 5 years of age,2021-09-24,2021-10-14,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,ONE Dose,6033,0.9509000000000001,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,,Validated by manufacturers,0.9,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Pragya Sharma,Maulana Azad Medical College,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.12.28.21268451v1,2022-05-11,2024-03-01,Verified,sharma_sars-cov-2_2021,IND
211229_Delhi_MaulanaAzadMedicalCollege_COVIDVaccination_Vaccinated_UnAdj,211229_Delhi_MaulanaAzadMedicalCollege,"SARS-CoV-2 seroprevalence in Delhi, India: September October 2021: a population based seroepidemiological study",2021-12-29,Preprint,Regional,Repeated cross-sectional study,India,Delhi,Delhi,"This was a cross-sectional, seroepidemiological study among individuals aged five and above who were recruited from 274 wards in the state of Delhi from September 24 to October 14 2021.

A total of 100 participants each were enrolled from all wards except the Delhi Cantonment and the New Delhi wards.",Individuals under 5 years of age,2021-09-24,2021-10-14,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,Vaccinated,13760,0.9494912791000001,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,,Validated by manufacturers,0.9,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Pragya Sharma,Maulana Azad Medical College,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.12.28.21268451v1,2022-01-12,2024-03-01,Verified,sharma_sars-cov-2_2021,IND
211229_Delhi_MaulanaAzadMedicalCollege_COVIDVaccination_Vaccinated_UnAdj_TwoDoses,211229_Delhi_MaulanaAzadMedicalCollege,"SARS-CoV-2 seroprevalence in Delhi, India: September October 2021: a population based seroepidemiological study",2021-12-29,Preprint,Regional,Repeated cross-sectional study,India,Delhi,Delhi,"This was a cross-sectional, seroepidemiological study among individuals aged five and above who were recruited from 274 wards in the state of Delhi from September 24 to October 14 2021.

A total of 100 participants each were enrolled from all wards except the Delhi Cantonment and the New Delhi wards.",Individuals under 5 years of age,2021-09-24,2021-10-14,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,TWO Doses,7727,0.9484,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,,Validated by manufacturers,0.9,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Pragya Sharma,Maulana Azad Medical College,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.12.28.21268451v1,2022-05-11,2024-03-01,Verified,sharma_sars-cov-2_2021,IND
211229_Delhi_MaulanaAzadMedicalCollege_Age_<18_UnAdj,211229_Delhi_MaulanaAzadMedicalCollege,"SARS-CoV-2 seroprevalence in Delhi, India: September October 2021: a population based seroepidemiological study",2021-12-29,Preprint,Regional,Repeated cross-sectional study,India,Delhi,Delhi,"This was a cross-sectional, seroepidemiological study among individuals aged five and above who were recruited from 274 wards in the state of Delhi from September 24 to October 14 2021.

A total of 100 participants each were enrolled from all wards except the Delhi Cantonment and the New Delhi wards.",Individuals under 5 years of age,2021-09-24,2021-10-14,Household and community samples,All,Children and Youth (0-17 years),,18.0,Age,,4211,0.8180954643,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,,Validated by manufacturers,0.9,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Pragya Sharma,Maulana Azad Medical College,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.12.28.21268451v1,2022-01-12,2024-03-01,Verified,sharma_sars-cov-2_2021,IND
211229_Delhi_MaulanaAzadMedicalCollege_Sex_Male_UnAdj,211229_Delhi_MaulanaAzadMedicalCollege,"SARS-CoV-2 seroprevalence in Delhi, India: September October 2021: a population based seroepidemiological study",2021-12-29,Preprint,Regional,Repeated cross-sectional study,India,Delhi,Delhi,"This was a cross-sectional, seroepidemiological study among individuals aged five and above who were recruited from 274 wards in the state of Delhi from September 24 to October 14 2021.

A total of 100 participants each were enrolled from all wards except the Delhi Cantonment and the New Delhi wards.",Individuals under 5 years of age,2021-09-24,2021-10-14,Household and community samples,Male,Multiple groups,,,Sex/Gender,,11791,0.88211,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,,Validated by manufacturers,0.9,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Pragya Sharma,Maulana Azad Medical College,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.12.28.21268451v1,2022-01-12,2024-03-01,Verified,sharma_sars-cov-2_2021,IND
211229_Delhi_MaulanaAzadMedicalCollege_Overall_PopAdj,211229_Delhi_MaulanaAzadMedicalCollege,"SARS-CoV-2 seroprevalence in Delhi, India: September October 2021: a population based seroepidemiological study",2021-12-29,Preprint,Regional,Repeated cross-sectional study,India,Delhi,Delhi,"This was a cross-sectional, seroepidemiological study among individuals aged five and above who were recruited from 274 wards in the state of Delhi from September 24 to October 14 2021.

A total of 100 participants each were enrolled from all wards except the Delhi Cantonment and the New Delhi wards.",Individuals under 5 years of age,2021-09-24,2021-10-14,Household and community samples,All,Multiple groups,,,Analysis,,27811,0.88,0.876,0.8840000000000001,,,True,,True,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,,Validated by manufacturers,0.9,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Pragya Sharma,Maulana Azad Medical College,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.12.28.21268451v1,2022-01-12,2024-03-01,Verified,sharma_sars-cov-2_2021,IND
211229_Delhi_MaulanaAzadMedicalCollege_Age_50+_UnAdj,211229_Delhi_MaulanaAzadMedicalCollege,"SARS-CoV-2 seroprevalence in Delhi, India: September October 2021: a population based seroepidemiological study",2021-12-29,Preprint,Regional,Repeated cross-sectional study,India,Delhi,Delhi,"This was a cross-sectional, seroepidemiological study among individuals aged five and above who were recruited from 274 wards in the state of Delhi from September 24 to October 14 2021.

A total of 100 participants each were enrolled from all wards except the Delhi Cantonment and the New Delhi wards.",Individuals under 5 years of age,2021-09-24,2021-10-14,Household and community samples,All,Multiple groups,50.0,,Age,,6405,0.9234972678,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,,Validated by manufacturers,0.9,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Pragya Sharma,Maulana Azad Medical College,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.12.28.21268451v1,2022-01-12,2024-03-01,Verified,sharma_sars-cov-2_2021,IND
211229_Delhi_MaulanaAzadMedicalCollege_COVIDVaccination_Unvaccinated_UnAdj,211229_Delhi_MaulanaAzadMedicalCollege,"SARS-CoV-2 seroprevalence in Delhi, India: September October 2021: a population based seroepidemiological study",2021-12-29,Preprint,Regional,Repeated cross-sectional study,India,Delhi,Delhi,"This was a cross-sectional, seroepidemiological study among individuals aged five and above who were recruited from 274 wards in the state of Delhi from September 24 to October 14 2021.

A total of 100 participants each were enrolled from all wards except the Delhi Cantonment and the New Delhi wards.",Individuals under 5 years of age,2021-09-24,2021-10-14,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,Unvaccinated,10473,0.8189630478,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,,Validated by manufacturers,0.9,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Pragya Sharma,Maulana Azad Medical College,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.12.28.21268451v1,2022-01-12,2024-03-01,Verified,sharma_sars-cov-2_2021,IND
211229_Delhi_MaulanaAzadMedicalCollege_HCW,211229_Delhi_MaulanaAzadMedicalCollege_HCW,"Seroprevalence of SARS-CoV-2 and Risk Assessment Among Healthcare Workers at a Dedicated Tertiary Care COVID-19 Hospital in Delhi, India: A Cohort Study",2021-12-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Delhi,"doctors and nurses working at a dedicated Covid-19 tertiary care government hospital in Delhi, India",the HCWs who reported any laboratory-confirmed COVID-19 case among their close contacts at the time of recruitment were excluded.,2020-12-02,2021-05-25,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,625,0.5136000000000001,,,True,,,,True,Convenience,Wantai SARS-CoV-2 IgG ELISA,Beijing Wantai Biological,ELISA,Serum,IgG,Whole-virusantigen,Validated by manufacturers,0.9470000000000001,1.0,['Moderate'],,No,Yes,Yes,,No,Yes,Yes,,Pragya Sharma,Maulana Azad Medical College,Not Unity-Aligned,https://www.cureus.com/articles/80002-seroprevalence-of-sars-cov-2-and-risk-assessment-among-healthcare-workers-at-a-dedicated-tertiary-care-covid-19-hospital-in-delhi-india-a-cohort-study,2022-01-21,2024-03-01,Unverified,pragyasharmaSeroprevalenceSARSCoV2Risk2021,IND
211231_Delhi_HamdardInstituteoMedicalSciencesandResearch,211231_Delhi_HamdardInstituteoMedicalSciencesandResearch,Asymptomatic SARS-COV-2 carriage and sero-positivity in high risk contacts of COVID-19 cases',2021-12-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Delhi,"""Any person who lives in the same household with a
laboratory-confirmed COVID19 case, anyone within 1 meter of the
confirmed case without precautions, Touched or cleaned the linens,
clothes, or dishes of the patient, had direct physical contact with a positive patient without PPE, traveled in close proximity with a positive case or touched body fluids of the case without appropriate PPE were considered as High-risk contact""","""Individuals with symptoms consistent with COVID-19 in the last 2 weeks preceding sample collection or had tested positive for SARS-COV-2 earlier, those vaccinated for SARS-COV-2, those below 18 years and above 65 years of age, or had any co-morbidities were excluded from the study.""",2020-09-15,2021-02-15,Contacts of COVID patients,All,Adults (18-64 years),18.0,65.0,Primary Estimate,,407,0.289,0.24600000000000002,0.336,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Ayan Kumar Das,Hamdard Institute of Medical Sciences & Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2021.12.012,2022-01-19,2022-07-16,Unverified,das_asymptomatic_2021,IND
220115_Jodhpur_AllIndiaInstituteofMedicalSciences_Primary,220115_Jodhpur_AllIndiaInstituteofMedicalSciences,"Anti-SARS-CoV-2 IgG status among frontline health workers involved in COVID-19 survey at Jodhpur, Rajasthan, India.",2022-01-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Rajasthan,Jodhpur,"study was carried out by the Department of Microbiology of a tertiary care hospital of Jodhpur, in collaboration with the State Health Services of Rajasthan. The Primary Health Centre at Pratap Nagar was
selected as the site of sample collection as it is the reporting
site of all household survey teams. The study participants
included all school teachers and nurses who were involved in
the door‑to‑door survey on that day and were willing to know
their anti‑SARS‑CoV‑2 antibody status.",,2020-09-02,2020-09-02,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,39,0.10300000000000001,,,True,,,,True,Entire sample,KAVACH Karwa SARS-COV 2 IgG ELISA,Karwa Enterprises,ELISA,Serum,IgG,,,,,['High'],,Yes,No,No,,Yes,Yes,Yes,,Vidhi Jain,All India Institute of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_534_21,2022-04-05,2024-03-01,Unverified,jain_anti-sars-cov-2_2022,IND
220121_NewDelhi_AllIndiaInstituteOfMedicalSciences_IBD_Overall,220121_NewDelhi_AllIndiaInstituteOfMedicalSciences_IBD,Similar risk of infection with SARS-CoV-2 in immunocompromised and immunocompetent patients with inflammatory bowel disease and healthy controls,2022-01-21,Presentation or Conference,Local,Cross-sectional survey ,India,,New Delhi,"Patients with IBD under follow-up at the IBD clinic, All India Institute of Medical Sciences, New Delhi, were included.",,2020-07-15,2021-04-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,235,0.315,,,True,,,,True,Convenience,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,B Kante,All India Institute of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/ecco-jcc/jjab232.841,2022-03-08,2024-03-01,Unverified,kante_p720_2022,IND
220121_NewDelhi_AllIndiaInstituteOfMedicalSciences_NoIBD_Overall,220121_NewDelhi_AllIndiaInstituteOfMedicalSciences_NoIBD,Similar risk of infection with SARS-CoV-2 in immunocompromised and immunocompetent patients with inflammatory bowel disease and healthy controls,2022-01-21,Presentation or Conference,Local,Cross-sectional survey ,India,,New Delhi,Healthy controls.,,2020-07-15,2021-04-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,73,0.27399999999999997,,,True,,,,True,Unclear,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Serum,IgG,Spike,,,,['High'],,Unclear,No,Yes,,Yes,Yes,Yes,,B Kante,All India Institute of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/ecco-jcc/jjab232.841,2022-03-08,2024-03-01,Unverified,kante_p720_2022,IND
220121_NewDelhi_AllIndiaInstituteOfMedicalSciences_NoIBD_Sex_Female,220121_NewDelhi_AllIndiaInstituteOfMedicalSciences_NoIBD,Similar risk of infection with SARS-CoV-2 in immunocompromised and immunocompetent patients with inflammatory bowel disease and healthy controls,2022-01-21,Presentation or Conference,Local,Cross-sectional survey ,India,,New Delhi,Healthy controls.,,2020-07-15,2021-04-15,Household and community samples,Female,Multiple groups,,,Sex/Gender,,15,0.26670000000000005,,,,,,,,Unclear,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Serum,IgG,Spike,,,,['High'],,Unclear,No,Yes,,Yes,Yes,Yes,,B Kante,All India Institute of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/ecco-jcc/jjab232.841,2022-03-08,2024-03-01,Unverified,kante_p720_2022,IND
220121_NewDelhi_AllIndiaInstituteOfMedicalSciences_NoIBD_Sex_Male,220121_NewDelhi_AllIndiaInstituteOfMedicalSciences_NoIBD,Similar risk of infection with SARS-CoV-2 in immunocompromised and immunocompetent patients with inflammatory bowel disease and healthy controls,2022-01-21,Presentation or Conference,Local,Cross-sectional survey ,India,,New Delhi,Healthy controls.,,2020-07-15,2021-04-15,Household and community samples,Male,Multiple groups,,,Sex/Gender,,58,0.2759,,,,,,,,Unclear,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Serum,IgG,Spike,,,,['High'],,Unclear,No,Yes,,Yes,Yes,Yes,,B Kante,All India Institute of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/ecco-jcc/jjab232.841,2022-03-08,2024-03-01,Unverified,kante_p720_2022,IND
220121_NewDelhi_UniversityOfOxford,220121_NewDelhi_UniversityOfOxford,"Trans-continental analysis of over, 2000 inflammatory bowel disease patients implicates geography, disease type, and exposure to immunosuppression as drivers of SARS-CoV-2 seroprevalence: Data from the ICARUS-IBD consortium",2022-01-21,Presentation or Conference,Local,Cross-sectional survey ,India,,New Delhi,IBD patients prior to vaccination,,2020-05-26,2021-09-24,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,171,0.579,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Atellica® IM SARS-CoV-2 Total (COV2T)","Roche Diagnostics,Siemens",,Serum,TotalAntibody,Spike,,,,['High'],,No,No,No,,Unclear,No,No,,S Y Wong,University of Oxford,Not Unity-Aligned,https://dx.doi.org/10.1093/ecco-jcc/jjab232.469,2022-03-08,2024-03-01,Unverified,wong_p342_2022,IND
220128_Delhi_MaulanaAzadMedicalCollege_PopAdj,220128_Delhi_MaulanaAzadMedicalCollege,"SARS-CoV-2 Seroprevalence in Delhi, India, During September-October 2021: A Population-Based Seroepidemiological Study.",2022-01-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Delhi,"individuals aged five and above who were selected from 274 wards in the state of Delhi from September 24, 2021 to October 14, 2021",Children below five years were excluded from the study due to the inherent phlebotomy challenges in the under-5 group,2021-09-24,2021-10-14,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,,27811,0.88,0.876,0.8840000000000001,True,,True,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Whole Blood,IgG,Spike,Validated by manufacturers,0.9,1.0,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Pragya Sharma,Maulana Azad Medical College,Unity-Aligned,https://dx.doi.org/10.7759/cureus.27428,2022-09-19,2024-03-01,Unverified,sharma_sars-cov-2_2022-1,IND
220128_Delhi_MaulanaAzadMedicalCollege_Under18,220128_Delhi_MaulanaAzadMedicalCollege,"SARS-CoV-2 Seroprevalence in Delhi, India, During September-October 2021: A Population-Based Seroepidemiological Study.",2022-01-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,"Delhi
",,"individuals aged five and above who were selected from 274 wards in the state of Delhi from September 24, 2021 to October 14, 2021",Children below five years were excluded from the study due to the inherent phlebotomy challenges in the under-5 group,2021-09-24,2021-10-14,Household and community samples,All,Multiple groups,,,Age,>18,3868,0.817,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Whole Blood,IgG,Spike,Validated by manufacturers,0.9,1.0,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Pragya Sharma,Maulana Azad Medical College,Unity-Aligned,https://dx.doi.org/10.7759/cureus.27428,2024-04-21,2024-04-21,Unverified,sharma_sars-cov-2_2022-1,IND
220128_Delhi_MaulanaAzadMedicalCollege_50plus,220128_Delhi_MaulanaAzadMedicalCollege,"SARS-CoV-2 Seroprevalence in Delhi, India, During September-October 2021: A Population-Based Seroepidemiological Study.",2022-01-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,"Delhi
",,"individuals aged five and above who were selected from 274 wards in the state of Delhi from September 24, 2021 to October 14, 2021",Children below five years were excluded from the study due to the inherent phlebotomy challenges in the under-5 group,2021-09-24,2021-10-14,Household and community samples,All,Multiple groups,,,Age,>=50,5596,0.922,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Whole Blood,IgG,Spike,Validated by manufacturers,0.9,1.0,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Pragya Sharma,Maulana Azad Medical College,Unity-Aligned,https://dx.doi.org/10.7759/cureus.27428,2024-04-21,2024-04-21,Unverified,sharma_sars-cov-2_2022-1,IND
220128_Delhi_MaulanaAzadMedicalCollege_UnAdj,220128_Delhi_MaulanaAzadMedicalCollege,"SARS-CoV-2 Seroprevalence in Delhi, India, During September-October 2021: A Population-Based Seroepidemiological Study.",2022-01-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Delhi,"individuals aged five and above who were selected from 274 wards in the state of Delhi from September 24, 2021 to October 14, 2021",Children below five years were excluded from the study due to the inherent phlebotomy challenges in the under-5 group,2021-09-24,2021-10-14,Household and community samples,All,Multiple groups,5.0,,Analysis,,27811,0.895,0.891,0.898,,,,,True,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Whole Blood,IgG,Spike,Validated by manufacturers,0.9,1.0,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Pragya Sharma,Maulana Azad Medical College,Unity-Aligned,https://dx.doi.org/10.7759/cureus.27428,2022-09-19,2024-03-01,Unverified,sharma_sars-cov-2_2022-1,IND
220128_Delhi_MaulanaAzadMedicalCollege_1849,220128_Delhi_MaulanaAzadMedicalCollege,"SARS-CoV-2 Seroprevalence in Delhi, India, During September-October 2021: A Population-Based Seroepidemiological Study.",2022-01-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,"Delhi
",,"individuals aged five and above who were selected from 274 wards in the state of Delhi from September 24, 2021 to October 14, 2021",Children below five years were excluded from the study due to the inherent phlebotomy challenges in the under-5 group,2021-09-24,2021-10-14,Household and community samples,All,Adults (18-64 years),,,Age,18-49,14716,0.902,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Whole Blood,IgG,Spike,Validated by manufacturers,0.9,1.0,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Pragya Sharma,Maulana Azad Medical College,Unity-Aligned,https://dx.doi.org/10.7759/cureus.27428,2024-04-21,2024-04-21,Unverified,sharma_sars-cov-2_2022-1,IND
20220130_India_ESICMedicalCollegeHospital_Primary,20220130_India_ESICMedicalCollegeHospital,SARS-CoV-2 Seroprevalence Among Whole Blood Donors During First Wave of Covid-19 Pandemic in India,2022-01-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,South India,,"The Blood donors who were found fit for routine whole
blood donation in accordance with regulations laid by the
Government of India were accepted. All the donors enrolled were healthy and had not given any history of illness/symptoms suggestive of Covid-19 (History of cold/cough/sore throat/fever/fatigue/loss of smell or taste) in self or in the family 2 weeks prior to the donation and no history of vaccination.",,2020-09-15,2021-03-15,Blood donors,All,Adults (18-64 years),18.0,58.0,Primary Estimate,,1034,0.549,0.515,0.583,True,True,,,,Self-referral,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Whole Blood,IgG,Spike,,0.963,0.9990000000000001,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Srinivasa Rao Chunchu,ESIC Medical College Hospital ,Not Unity-Aligned,https://dx.doi.org/10.1007/s12288-021-01512-y,2022-02-20,2023-08-15,Unverified,chunchu_sars-cov-2_2022,IND
20220130_India_ESICMedicalCollegeHospital_Age30to45,20220130_India_ESICMedicalCollegeHospital,SARS-CoV-2 Seroprevalence Among Whole Blood Donors During First Wave of Covid-19 Pandemic in India,2022-01-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,South India,,"The Blood donors who were found fit for routine whole
blood donation in accordance with regulations laid by the
Government of India were accepted. All the donors enrolled were healthy and had not given any history of illness/symptoms suggestive of Covid-19 (History of cold/cough/sore throat/fever/fatigue/loss of smell or taste) in self or in the family 2 weeks prior to the donation and no history of vaccination.",,2020-09-15,2021-03-15,Blood donors,All,Adults (18-64 years),30.0,45.0,Age,age: 30 - 45,377,0.469,,,,,,,,Self-referral,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Whole Blood,IgG,Spike,,0.963,0.9990000000000001,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Srinivasa Rao Chunchu,ESIC Medical College Hospital ,Not Unity-Aligned,https://dx.doi.org/10.1007/s12288-021-01512-y,2022-02-20,2024-03-01,Unverified,chunchu_sars-cov-2_2022,IND
20220130_India_ESICMedicalCollegeHospital_Female,20220130_India_ESICMedicalCollegeHospital,SARS-CoV-2 Seroprevalence Among Whole Blood Donors During First Wave of Covid-19 Pandemic in India,2022-01-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,South India,,"The Blood donors who were found fit for routine whole
blood donation in accordance with regulations laid by the
Government of India were accepted. All the donors enrolled were healthy and had not given any history of illness/symptoms suggestive of Covid-19 (History of cold/cough/sore throat/fever/fatigue/loss of smell or taste) in self or in the family 2 weeks prior to the donation and no history of vaccination.",,2020-09-15,2021-03-15,Blood donors,Female,Adults (18-64 years),18.0,58.0,Sex/Gender,,7,0.7140000000000001,,,,,,,,Self-referral,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Whole Blood,IgG,Spike,,0.963,0.9990000000000001,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Srinivasa Rao Chunchu,ESIC Medical College Hospital ,Not Unity-Aligned,https://dx.doi.org/10.1007/s12288-021-01512-y,2022-02-20,2024-03-01,Unverified,chunchu_sars-cov-2_2022,IND
20220130_India_ESICMedicalCollegeHospital_Age46to65,20220130_India_ESICMedicalCollegeHospital,SARS-CoV-2 Seroprevalence Among Whole Blood Donors During First Wave of Covid-19 Pandemic in India,2022-01-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,South India,,"The Blood donors who were found fit for routine whole
blood donation in accordance with regulations laid by the
Government of India were accepted. All the donors enrolled were healthy and had not given any history of illness/symptoms suggestive of Covid-19 (History of cold/cough/sore throat/fever/fatigue/loss of smell or taste) in self or in the family 2 weeks prior to the donation and no history of vaccination.",,2020-09-15,2021-03-15,Blood donors,All,Adults (18-64 years),46.0,58.0,Age,age: 46- 65,29,0.517,,,,,,,,Self-referral,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Whole Blood,IgG,Spike,,0.963,0.9990000000000001,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Srinivasa Rao Chunchu,ESIC Medical College Hospital ,Not Unity-Aligned,https://dx.doi.org/10.1007/s12288-021-01512-y,2022-02-20,2024-03-01,Unverified,chunchu_sars-cov-2_2022,IND
20220130_India_ESICMedicalCollegeHospital_Male,20220130_India_ESICMedicalCollegeHospital,SARS-CoV-2 Seroprevalence Among Whole Blood Donors During First Wave of Covid-19 Pandemic in India,2022-01-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,South India,,"The Blood donors who were found fit for routine whole
blood donation in accordance with regulations laid by the
Government of India were accepted. All the donors enrolled were healthy and had not given any history of illness/symptoms suggestive of Covid-19 (History of cold/cough/sore throat/fever/fatigue/loss of smell or taste) in self or in the family 2 weeks prior to the donation and no history of vaccination.",,2020-09-15,2021-03-15,Blood donors,Male,Adults (18-64 years),18.0,58.0,Sex/Gender,,1027,0.49200000000000005,,,,,,,,Self-referral,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Whole Blood,IgG,Spike,,0.963,0.9990000000000001,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Srinivasa Rao Chunchu,ESIC Medical College Hospital ,Not Unity-Aligned,https://dx.doi.org/10.1007/s12288-021-01512-y,2022-02-20,2024-03-01,Unverified,chunchu_sars-cov-2_2022,IND
20220130_India_ESICMedicalCollegeHospital_Analysis,20220130_India_ESICMedicalCollegeHospital,SARS-CoV-2 Seroprevalence Among Whole Blood Donors During First Wave of Covid-19 Pandemic in India,2022-01-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,South India,,"The Blood donors who were found fit for routine whole
blood donation in accordance with regulations laid by the
Government of India were accepted. All the donors enrolled were healthy and had not given any history of illness/symptoms suggestive of Covid-19 (History of cold/cough/sore throat/fever/fatigue/loss of smell or taste) in self or in the family 2 weeks prior to the donation and no history of vaccination.",,2020-09-15,2021-03-15,Blood donors,All,Adults (18-64 years),18.0,58.0,Analysis,,1034,0.494,0.46299999999999997,0.525,,,,,True,Self-referral,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Whole Blood,IgG,Spike,,0.963,0.9990000000000001,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Srinivasa Rao Chunchu,ESIC Medical College Hospital ,Not Unity-Aligned,https://dx.doi.org/10.1007/s12288-021-01512-y,2022-02-20,2024-03-01,Unverified,chunchu_sars-cov-2_2022,IND
20220130_India_ESICMedicalCollegeHospital_Age18to29,20220130_India_ESICMedicalCollegeHospital,SARS-CoV-2 Seroprevalence Among Whole Blood Donors During First Wave of Covid-19 Pandemic in India,2022-01-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,South India,,"The Blood donors who were found fit for routine whole
blood donation in accordance with regulations laid by the
Government of India were accepted. All the donors enrolled were healthy and had not given any history of illness/symptoms suggestive of Covid-19 (History of cold/cough/sore throat/fever/fatigue/loss of smell or taste) in self or in the family 2 weeks prior to the donation and no history of vaccination.",,2020-09-15,2021-03-15,Blood donors,All,Adults (18-64 years),18.0,30.0,Age,age: 18 - 29,628,0.507,,,,,,,,Self-referral,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Whole Blood,IgG,Spike,,0.963,0.9990000000000001,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Srinivasa Rao Chunchu,ESIC Medical College Hospital ,Not Unity-Aligned,https://dx.doi.org/10.1007/s12288-021-01512-y,2022-02-20,2024-03-01,Unverified,chunchu_sars-cov-2_2022,IND
220131_Ahmedabad_AMCMETMedicalCollege,220131_Ahmedabad_AMCMETMedicalCollege,Immunoglobulin-G antibodies against severe acute respiratory syndrome - coronavirus-2 among health-care workers: A serosurveillance study from India,2022-01-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,"HCW's from Ahmedabad, India",,2020-10-15,2020-10-31,Health care workers and caregivers,All,Multiple groups,18.0,75.0,Primary Estimate,,1737,0.2084,0.19,0.2281,True,,,,True,Stratified non-probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,,0.9237000000000001,0.9790000000000001,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Om Prakash,AMC MET Medical College,Not Unity-Aligned,10.4103/ijabmr.ijabmr_516_21,2022-03-01,2024-03-01,Unverified,prakash_immunoglobulin-g_2022,IND
220201_Gurugram_MedantaTheMedicity,220201_Gurugram_MedantaTheMedicity,Dynamics of SARS-CoV-2 Antibody Response in a Longitudinal Cohort of Healthcare Workers from India,2022-02-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Haryana,Gurugram,"healthcare workers at  Medanta- The Medicity, Gurugram, a 1250-bedded tertiary care centre in north India",,2020-06-15,2020-12-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,230,0.257,,,True,,,,True,Self-referral,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,Spike,,,,['High'],,No,No,No,,Yes,Yes,Yes,,Sonam Singla,Mendanta - The Medicity ,Not Unity-Aligned,https://dx.doi.org/10.7860/JCDR/2022/51855.16011,2022-03-09,2024-03-01,Unverified,singla_dynamics_2022,IND
220201_NewDelhi_InstituteOfMedicalSciences_Overall,220201_NewDelhi_InstituteOfMedicalSciences,Severe acute respiratory syndrome coronavirus-2 IgG antibodies among health-care workers in a tertiary care hospital in Delhi India,2022-02-01,Journal Article (Peer-Reviewed),Local,Retrospective cohort,India,,New Delhi,Health care workers of a tertiary hospital in New Delhi.,,2020-06-15,2020-08-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,800,0.1675,,,True,,,,True,Convenience,ErbaLisa® COVID-19 IgG semi quantitative kit,Erba Manneim,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Mala Chhabra,Institute of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.4103/jpsic.jpsic_15_21,2022-03-02,2024-03-01,Unverified,chhabra_severe_2021,IND
220207_Pune_ICMRNARI,220207_Pune_ICMRNARI,Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies among HIV Infected Individuals Attending ART Centre at Pune: A Cross-Sectional Study.,2022-02-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Pune,"""HIV infected adults from March 2021 through June 2021were included in the study.""",,2021-03-15,2021-06-15,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),,,Primary Estimate,,405,0.546,,,True,,,,True,Convenience,ErbaLisa® COVID-19 IgG semi quantitative kit,Erba Manneim,ELISA,Plasma,IgG,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Manisha Ghate,Indian Council of Medical Research-NationalAIDS Research Institute (ICMR-NARI),Not Unity-Aligned,https://dx.doi.org/10.1177/23259582221077943,2022-02-17,2024-03-01,Unverified,ghate_seroprevalence_2022,IND
220220_SouthAndaman_AndamanandNicobarIslandsInstituteofMedicalSciences_Overall,220220_SouthAndaman_AndamanandNicobarIslandsInstituteofMedicalSciences,"A Comparative Analysis of COVID-19 IgG Antibody Level and Socio-Demographic Status in Symptomatic and Asymptomatic Population of South Andaman, India.",2022-02-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Andaman and Nicobar Islands,South Andaman district,The consenting adults of 18 years and above were included in the study. ,The individuals suffering from any immune-deficient condition like HIV/or under chemotherapy were excluded from the study.,2020-12-15,2021-02-14,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,4089,0.39740000000000003,,,True,,,,True,Stratified probability,ErbaLisa® COVID-19 IgG semi quantitative kit,Erba Manneim,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Deepak Kumar,Andaman and Nicobar Islands Institute of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.7759/cureus.22398,2022-04-13,2024-03-01,Verified,kumar_comparative_2022,IND
220220_SouthAndaman_AndamanandNicobarIslandsInstituteofMedicalSciences_>=46,220220_SouthAndaman_AndamanandNicobarIslandsInstituteofMedicalSciences,"A Comparative Analysis of COVID-19 IgG Antibody Level and Socio-Demographic Status in Symptomatic and Asymptomatic Population of South Andaman, India.",2022-02-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Andaman and Nicobar Islands,South Andaman district,The consenting adults of 18 years and above were included in the study. ,The individuals suffering from any immune-deficient condition like HIV/or under chemotherapy were excluded from the study.,2020-12-15,2021-02-14,Household and community samples,All,Multiple groups,46.0,,Age,>=46,1532,0.42229999999999995,,,,,,,,Stratified probability,ErbaLisa® COVID-19 IgG semi quantitative kit,Erba Manneim,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Deepak Kumar,Andaman and Nicobar Islands Institute of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.7759/cureus.22398,2022-04-13,2024-03-01,Verified,kumar_comparative_2022,IND
220220_SouthAndaman_AndamanandNicobarIslandsInstituteofMedicalSciences_Female,220220_SouthAndaman_AndamanandNicobarIslandsInstituteofMedicalSciences,"A Comparative Analysis of COVID-19 IgG Antibody Level and Socio-Demographic Status in Symptomatic and Asymptomatic Population of South Andaman, India.",2022-02-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Andaman and Nicobar Islands,South Andaman district,The consenting adults of 18 years and above were included in the study. ,The individuals suffering from any immune-deficient condition like HIV/or under chemotherapy were excluded from the study.,2020-12-15,2021-02-14,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,2329,0.4118,,,,,,,,Stratified probability,ErbaLisa® COVID-19 IgG semi quantitative kit,Erba Manneim,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Deepak Kumar,Andaman and Nicobar Islands Institute of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.7759/cureus.22398,2022-04-13,2024-03-01,Verified,kumar_comparative_2022,IND
220220_SouthAndaman_AndamanandNicobarIslandsInstituteofMedicalSciences_31-45,220220_SouthAndaman_AndamanandNicobarIslandsInstituteofMedicalSciences,"A Comparative Analysis of COVID-19 IgG Antibody Level and Socio-Demographic Status in Symptomatic and Asymptomatic Population of South Andaman, India.",2022-02-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Andaman and Nicobar Islands,South Andaman district,The consenting adults of 18 years and above were included in the study. ,The individuals suffering from any immune-deficient condition like HIV/or under chemotherapy were excluded from the study.,2020-12-15,2021-02-14,Household and community samples,All,Adults (18-64 years),31.0,45.0,Age,31-45,1767,0.4029,,,,,,,,Stratified probability,ErbaLisa® COVID-19 IgG semi quantitative kit,Erba Manneim,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Deepak Kumar,Andaman and Nicobar Islands Institute of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.7759/cureus.22398,2022-04-13,2024-03-01,Verified,kumar_comparative_2022,IND
220220_SouthAndaman_AndamanandNicobarIslandsInstituteofMedicalSciences_Male,220220_SouthAndaman_AndamanandNicobarIslandsInstituteofMedicalSciences,"A Comparative Analysis of COVID-19 IgG Antibody Level and Socio-Demographic Status in Symptomatic and Asymptomatic Population of South Andaman, India.",2022-02-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Andaman and Nicobar Islands,South Andaman district,The consenting adults of 18 years and above were included in the study. ,The individuals suffering from any immune-deficient condition like HIV/or under chemotherapy were excluded from the study.,2020-12-15,2021-02-14,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,1760,0.37840000000000007,,,,,,,,Stratified probability,ErbaLisa® COVID-19 IgG semi quantitative kit,Erba Manneim,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Deepak Kumar,Andaman and Nicobar Islands Institute of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.7759/cureus.22398,2022-04-13,2024-03-01,Verified,kumar_comparative_2022,IND
220220_SouthAndaman_AndamanandNicobarIslandsInstituteofMedicalSciences_18-30,220220_SouthAndaman_AndamanandNicobarIslandsInstituteofMedicalSciences,"A Comparative Analysis of COVID-19 IgG Antibody Level and Socio-Demographic Status in Symptomatic and Asymptomatic Population of South Andaman, India.",2022-02-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Andaman and Nicobar Islands,South Andaman district,The consenting adults of 18 years and above were included in the study. ,The individuals suffering from any immune-deficient condition like HIV/or under chemotherapy were excluded from the study.,2020-12-15,2021-02-14,Household and community samples,All,Adults (18-64 years),18.0,30.0,Age,18-30,790,0.3367,,,,,,,,Stratified probability,ErbaLisa® COVID-19 IgG semi quantitative kit,Erba Manneim,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Deepak Kumar,Andaman and Nicobar Islands Institute of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.7759/cureus.22398,2022-04-13,2024-03-01,Verified,kumar_comparative_2022,IND
220223_Pondicherry_PondicherryInstituteOfMedicalSciences_1stPhase_Overall,220223_Pondicherry_PondicherryInstituteOfMedicalSciences_1stPhase,Immunoglobulin G Antibodies to SARS-CoV-2 Among Healthcare Workers at a Tertiary Care Center in South India,2022-02-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Pondicherry,"The study included hospital staff comprising of senior and junior doctors, nursing staff, technical staff dealing with samples from COVID-19 patients, and housekeeping staff involved in biomedical waste disposal in the hospital.",Individuals who had active symptoms of COVID-19 were excluded.,2020-07-15,2020-09-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,382,0.034,0.02,0.057,True,,,,True,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Aneesh Basheer,Pondicherry Institute of Medical Sciences,Not Unity-Aligned,https://doi.org/10.7759/cureus.22520,2022-03-15,2024-03-01,Unverified,basheer_immunoglobulin_2022,IND
220223_Pondicherry_PondicherryInstituteOfMedicalSciences_2ndPhase_Overall,220223_Pondicherry_PondicherryInstituteOfMedicalSciences_2ndPhase,Immunoglobulin G Antibodies to SARS-CoV-2 Among Healthcare Workers at a Tertiary Care Center in South India,2022-02-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Pondicherry,"The study included hospital staff comprising of senior and junior doctors, nursing staff, technical staff dealing with samples from COVID-19 patients, and housekeeping staff involved in biomedical waste disposal in the hospital.",Individuals who had active symptoms of COVID-19 were excluded.,2021-02-15,2021-04-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,168,0.4226,,,True,,,,True,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Aneesh Basheer,Pondicherry Institute of Medical Sciences,Not Unity-Aligned,https://doi.org/10.7759/cureus.22520,2022-03-15,2024-03-01,Unverified,basheer_immunoglobulin_2022,IND
220301_Ahmedabad_AhmedabadMunicipalCorporationMedicalEducationTrustMedicalCollege_Overall,220301_Ahmedabad_AhmedabadMunicipalCorporationMedicalEducationTrustMedicalCollege,COVID-Kavach-Based Seropositivity in the General Population of Ahmedabad: Just Before the Start of the Vaccination for the Elderly in India,2022-03-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,"Any individual from the randomly selected house from the selected polio booth field area was eligible to be included in the study, without any restrictions for age or sex. Children less than 18 years were also enrolled
with the informed written consent and assent of their parents/caretaker. The exclusion criteria did not
include HCWs or FLWs and so even vaccinated individuals (a few HCWs or FLWs) were also enrolled as part of
the study.",,2021-02-22,2021-03-01,Household and community samples,All,Multiple groups,2.0,90.0,Primary Estimate,,10136,0.2792,0.2706,0.28800000000000003,True,,,,True,Stratified non-probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9237000000000001,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Om Prakash,"Nathiba
Hargovandas Lakhmichand (NHL) Municipal Medical College",Unity-Aligned,10.7759/cureus.22759,2022-03-14,2024-03-01,Verified,prakash_covid-kavach-based_2022,IND
220301_Ahmedabad_AhmedabadMunicipalCorporationMedicalEducationTrustMedicalCollege_40-49,220301_Ahmedabad_AhmedabadMunicipalCorporationMedicalEducationTrustMedicalCollege,COVID-Kavach-Based Seropositivity in the General Population of Ahmedabad: Just Before the Start of the Vaccination for the Elderly in India,2022-03-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,"Any individual from the randomly selected house from the selected polio booth field area was eligible to be included in the study, without any restrictions for age or sex. Children less than 18 years were also enrolled
with the informed written consent and assent of their parents/caretaker. The exclusion criteria did not
include HCWs or FLWs and so even vaccinated individuals (a few HCWs or FLWs) were also enrolled as part of
the study.",,2021-02-22,2021-03-01,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,1760,0.3239,0.3024,0.3461,,,,,,Stratified non-probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9237000000000001,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Om Prakash,"Nathiba
Hargovandas Lakhmichand (NHL) Municipal Medical College",Unity-Aligned,10.7759/cureus.22759,2022-03-14,2024-03-01,Verified,prakash_covid-kavach-based_2022,IND
220301_Ahmedabad_AhmedabadMunicipalCorporationMedicalEducationTrustMedicalCollege_Vaccinated,220301_Ahmedabad_AhmedabadMunicipalCorporationMedicalEducationTrustMedicalCollege,COVID-Kavach-Based Seropositivity in the General Population of Ahmedabad: Just Before the Start of the Vaccination for the Elderly in India,2022-03-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,"Any individual from the randomly selected house from the selected polio booth field area was eligible to be included in the study, without any restrictions for age or sex. Children less than 18 years were also enrolled
with the informed written consent and assent of their parents/caretaker. The exclusion criteria did not
include HCWs or FLWs and so even vaccinated individuals (a few HCWs or FLWs) were also enrolled as part of
the study.",,2021-02-22,2021-03-01,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,,327,0.37,0.3195,0.4236,,,,,,Stratified non-probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9237000000000001,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Om Prakash,"Nathiba
Hargovandas Lakhmichand (NHL) Municipal Medical College",Unity-Aligned,10.7759/cureus.22759,2022-03-14,2024-03-01,Verified,prakash_covid-kavach-based_2022,IND
220301_Ahmedabad_AhmedabadMunicipalCorporationMedicalEducationTrustMedicalCollege_Unvaccinated,220301_Ahmedabad_AhmedabadMunicipalCorporationMedicalEducationTrustMedicalCollege,COVID-Kavach-Based Seropositivity in the General Population of Ahmedabad: Just Before the Start of the Vaccination for the Elderly in India,2022-03-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,"Any individual from the randomly selected house from the selected polio booth field area was eligible to be included in the study, without any restrictions for age or sex. Children less than 18 years were also enrolled
with the informed written consent and assent of their parents/caretaker. The exclusion criteria did not
include HCWs or FLWs and so even vaccinated individuals (a few HCWs or FLWs) were also enrolled as part of
the study.",,2021-02-22,2021-03-01,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,,9809,0.2762,,,,,,,,Stratified non-probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9237000000000001,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Om Prakash,"Nathiba
Hargovandas Lakhmichand (NHL) Municipal Medical College",Unity-Aligned,10.7759/cureus.22759,2022-03-14,2024-03-01,Verified,prakash_covid-kavach-based_2022,IND
220301_Ahmedabad_AhmedabadMunicipalCorporationMedicalEducationTrustMedicalCollege_60-69,220301_Ahmedabad_AhmedabadMunicipalCorporationMedicalEducationTrustMedicalCollege,COVID-Kavach-Based Seropositivity in the General Population of Ahmedabad: Just Before the Start of the Vaccination for the Elderly in India,2022-03-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,"Any individual from the randomly selected house from the selected polio booth field area was eligible to be included in the study, without any restrictions for age or sex. Children less than 18 years were also enrolled
with the informed written consent and assent of their parents/caretaker. The exclusion criteria did not
include HCWs or FLWs and so even vaccinated individuals (a few HCWs or FLWs) were also enrolled as part of
the study.",,2021-02-22,2021-03-01,Household and community samples,All,Adults (18-64 years),60.0,69.0,Age,60-69,979,0.3504,0.3211,0.38079999999999997,,,,,,Stratified non-probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9237000000000001,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Om Prakash,"Nathiba
Hargovandas Lakhmichand (NHL) Municipal Medical College",Unity-Aligned,10.7759/cureus.22759,2022-03-14,2024-03-01,Verified,prakash_covid-kavach-based_2022,IND
220301_Ahmedabad_AhmedabadMunicipalCorporationMedicalEducationTrustMedicalCollege_90-99,220301_Ahmedabad_AhmedabadMunicipalCorporationMedicalEducationTrustMedicalCollege,COVID-Kavach-Based Seropositivity in the General Population of Ahmedabad: Just Before the Start of the Vaccination for the Elderly in India,2022-03-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,"Any individual from the randomly selected house from the selected polio booth field area was eligible to be included in the study, without any restrictions for age or sex. Children less than 18 years were also enrolled
with the informed written consent and assent of their parents/caretaker. The exclusion criteria did not
include HCWs or FLWs and so even vaccinated individuals (a few HCWs or FLWs) were also enrolled as part of
the study.",,2021-02-22,2021-03-01,Household and community samples,All,Seniors (65+ years),90.0,90.0,Age,90-99,2,0.5,0.0126,0.9873999999999999,,,,,,Stratified non-probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9237000000000001,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Om Prakash,"Nathiba
Hargovandas Lakhmichand (NHL) Municipal Medical College",Unity-Aligned,10.7759/cureus.22759,2022-03-14,2024-03-01,Verified,prakash_covid-kavach-based_2022,IND
220301_Ahmedabad_AhmedabadMunicipalCorporationMedicalEducationTrustMedicalCollege_20-29,220301_Ahmedabad_AhmedabadMunicipalCorporationMedicalEducationTrustMedicalCollege,COVID-Kavach-Based Seropositivity in the General Population of Ahmedabad: Just Before the Start of the Vaccination for the Elderly in India,2022-03-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,"Any individual from the randomly selected house from the selected polio booth field area was eligible to be included in the study, without any restrictions for age or sex. Children less than 18 years were also enrolled
with the informed written consent and assent of their parents/caretaker. The exclusion criteria did not
include HCWs or FLWs and so even vaccinated individuals (a few HCWs or FLWs) were also enrolled as part of
the study.",,2021-02-22,2021-03-01,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,2882,0.20920000000000002,0.1948,0.2245,,,,,,Stratified non-probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9237000000000001,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Om Prakash,"Nathiba
Hargovandas Lakhmichand (NHL) Municipal Medical College",Unity-Aligned,10.7759/cureus.22759,2022-03-14,2024-03-01,Verified,prakash_covid-kavach-based_2022,IND
220301_Ahmedabad_AhmedabadMunicipalCorporationMedicalEducationTrustMedicalCollege_50-59,220301_Ahmedabad_AhmedabadMunicipalCorporationMedicalEducationTrustMedicalCollege,COVID-Kavach-Based Seropositivity in the General Population of Ahmedabad: Just Before the Start of the Vaccination for the Elderly in India,2022-03-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,"Any individual from the randomly selected house from the selected polio booth field area was eligible to be included in the study, without any restrictions for age or sex. Children less than 18 years were also enrolled
with the informed written consent and assent of their parents/caretaker. The exclusion criteria did not
include HCWs or FLWs and so even vaccinated individuals (a few HCWs or FLWs) were also enrolled as part of
the study.",,2021-02-22,2021-03-01,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,1316,0.35490000000000005,0.3295,0.3811,,,,,,Stratified non-probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9237000000000001,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Om Prakash,"Nathiba
Hargovandas Lakhmichand (NHL) Municipal Medical College",Unity-Aligned,10.7759/cureus.22759,2022-03-14,2024-03-01,Verified,prakash_covid-kavach-based_2022,IND
220301_Ahmedabad_AhmedabadMunicipalCorporationMedicalEducationTrustMedicalCollege_Female,220301_Ahmedabad_AhmedabadMunicipalCorporationMedicalEducationTrustMedicalCollege,COVID-Kavach-Based Seropositivity in the General Population of Ahmedabad: Just Before the Start of the Vaccination for the Elderly in India,2022-03-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,"Any individual from the randomly selected house from the selected polio booth field area was eligible to be included in the study, without any restrictions for age or sex. Children less than 18 years were also enrolled
with the informed written consent and assent of their parents/caretaker. The exclusion criteria did not
include HCWs or FLWs and so even vaccinated individuals (a few HCWs or FLWs) were also enrolled as part of
the study.",,2021-02-22,2021-03-01,Household and community samples,Female,Multiple groups,,,Sex/Gender,,5665,0.2701,0.25870000000000004,0.2818,,,,,,Stratified non-probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9237000000000001,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Om Prakash,"Nathiba
Hargovandas Lakhmichand (NHL) Municipal Medical College",Unity-Aligned,10.7759/cureus.22759,2022-03-14,2024-03-01,Verified,prakash_covid-kavach-based_2022,IND
220301_Ahmedabad_AhmedabadMunicipalCorporationMedicalEducationTrustMedicalCollege_30-39,220301_Ahmedabad_AhmedabadMunicipalCorporationMedicalEducationTrustMedicalCollege,COVID-Kavach-Based Seropositivity in the General Population of Ahmedabad: Just Before the Start of the Vaccination for the Elderly in India,2022-03-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,"Any individual from the randomly selected house from the selected polio booth field area was eligible to be included in the study, without any restrictions for age or sex. Children less than 18 years were also enrolled
with the informed written consent and assent of their parents/caretaker. The exclusion criteria did not
include HCWs or FLWs and so even vaccinated individuals (a few HCWs or FLWs) were also enrolled as part of
the study.",,2021-02-22,2021-03-01,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,2274,0.26780000000000004,0.25,0.2864,,,,,,Stratified non-probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9237000000000001,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Om Prakash,"Nathiba
Hargovandas Lakhmichand (NHL) Municipal Medical College",Unity-Aligned,10.7759/cureus.22759,2022-03-14,2024-03-01,Verified,prakash_covid-kavach-based_2022,IND
220301_Ahmedabad_AhmedabadMunicipalCorporationMedicalEducationTrustMedicalCollege_80-89,220301_Ahmedabad_AhmedabadMunicipalCorporationMedicalEducationTrustMedicalCollege,COVID-Kavach-Based Seropositivity in the General Population of Ahmedabad: Just Before the Start of the Vaccination for the Elderly in India,2022-03-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,"Any individual from the randomly selected house from the selected polio booth field area was eligible to be included in the study, without any restrictions for age or sex. Children less than 18 years were also enrolled
with the informed written consent and assent of their parents/caretaker. The exclusion criteria did not
include HCWs or FLWs and so even vaccinated individuals (a few HCWs or FLWs) were also enrolled as part of
the study.",,2021-02-22,2021-03-01,Household and community samples,All,Seniors (65+ years),80.0,89.0,Age,80-89,50,0.44,0.2999,0.5875,,,,,,Stratified non-probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9237000000000001,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Om Prakash,"Nathiba
Hargovandas Lakhmichand (NHL) Municipal Medical College",Unity-Aligned,10.7759/cureus.22759,2022-03-14,2024-03-01,Verified,prakash_covid-kavach-based_2022,IND
220301_Ahmedabad_AhmedabadMunicipalCorporationMedicalEducationTrustMedicalCollege_70-79,220301_Ahmedabad_AhmedabadMunicipalCorporationMedicalEducationTrustMedicalCollege,COVID-Kavach-Based Seropositivity in the General Population of Ahmedabad: Just Before the Start of the Vaccination for the Elderly in India,2022-03-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,"Any individual from the randomly selected house from the selected polio booth field area was eligible to be included in the study, without any restrictions for age or sex. Children less than 18 years were also enrolled
with the informed written consent and assent of their parents/caretaker. The exclusion criteria did not
include HCWs or FLWs and so even vaccinated individuals (a few HCWs or FLWs) were also enrolled as part of
the study.",,2021-02-22,2021-03-01,Household and community samples,All,Seniors (65+ years),70.0,79.0,Age,70-79,362,0.2928,0.2483,0.3417,,,,,,Stratified non-probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9237000000000001,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Om Prakash,"Nathiba
Hargovandas Lakhmichand (NHL) Municipal Medical College",Unity-Aligned,10.7759/cureus.22759,2022-03-14,2024-03-01,Verified,prakash_covid-kavach-based_2022,IND
220301_Ahmedabad_AhmedabadMunicipalCorporationMedicalEducationTrustMedicalCollege_0-9,220301_Ahmedabad_AhmedabadMunicipalCorporationMedicalEducationTrustMedicalCollege,COVID-Kavach-Based Seropositivity in the General Population of Ahmedabad: Just Before the Start of the Vaccination for the Elderly in India,2022-03-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,"Any individual from the randomly selected house from the selected polio booth field area was eligible to be included in the study, without any restrictions for age or sex. Children less than 18 years were also enrolled
with the informed written consent and assent of their parents/caretaker. The exclusion criteria did not
include HCWs or FLWs and so even vaccinated individuals (a few HCWs or FLWs) were also enrolled as part of
the study.",,2021-02-22,2021-03-01,Household and community samples,All,Children and Youth (0-17 years),2.0,9.0,Age,0-9,22,0.0909,0.011200000000000002,0.2916,,,,,,Stratified non-probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9237000000000001,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Om Prakash,"Nathiba
Hargovandas Lakhmichand (NHL) Municipal Medical College",Unity-Aligned,10.7759/cureus.22759,2022-03-14,2024-03-01,Verified,prakash_covid-kavach-based_2022,IND
220301_Ahmedabad_AhmedabadMunicipalCorporationMedicalEducationTrustMedicalCollege_Male,220301_Ahmedabad_AhmedabadMunicipalCorporationMedicalEducationTrustMedicalCollege,COVID-Kavach-Based Seropositivity in the General Population of Ahmedabad: Just Before the Start of the Vaccination for the Elderly in India,2022-03-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,"Any individual from the randomly selected house from the selected polio booth field area was eligible to be included in the study, without any restrictions for age or sex. Children less than 18 years were also enrolled
with the informed written consent and assent of their parents/caretaker. The exclusion criteria did not
include HCWs or FLWs and so even vaccinated individuals (a few HCWs or FLWs) were also enrolled as part of
the study.",,2021-02-22,2021-03-01,Household and community samples,Male,Multiple groups,,,Sex/Gender,,4471,0.2908,0.2776,0.3042,,,,,,Stratified non-probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9237000000000001,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Om Prakash,"Nathiba
Hargovandas Lakhmichand (NHL) Municipal Medical College",Unity-Aligned,10.7759/cureus.22759,2022-03-14,2024-03-01,Verified,prakash_covid-kavach-based_2022,IND
220301_Ahmedabad_AhmedabadMunicipalCorporationMedicalEducationTrustMedicalCollege_10-19,220301_Ahmedabad_AhmedabadMunicipalCorporationMedicalEducationTrustMedicalCollege,COVID-Kavach-Based Seropositivity in the General Population of Ahmedabad: Just Before the Start of the Vaccination for the Elderly in India,2022-03-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Gujarat,Ahmedabad,"Any individual from the randomly selected house from the selected polio booth field area was eligible to be included in the study, without any restrictions for age or sex. Children less than 18 years were also enrolled
with the informed written consent and assent of their parents/caretaker. The exclusion criteria did not
include HCWs or FLWs and so even vaccinated individuals (a few HCWs or FLWs) were also enrolled as part of
the study.",,2021-02-22,2021-03-01,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,489,0.2188,0.1844,0.2576,,,,,,Stratified non-probability,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9237000000000001,0.9790000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Om Prakash,"Nathiba
Hargovandas Lakhmichand (NHL) Municipal Medical College",Unity-Aligned,10.7759/cureus.22759,2022-03-14,2024-03-01,Verified,prakash_covid-kavach-based_2022,IND
220301_Dibrugarh_AssamMedicalCollegeandHospital,220301_Dibrugarh_AssamMedicalCollegeandHospital,Seroprevalence of SARS-CoV-2 among the Healthcare Workers of a Tertiary Care Hospital of Northeast India during First Wave of COVID-19 Pandemic: A Hospital-based Cross-sectional Study,2022-03-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Assam,Dibrugarh,">18 years of age and both genders, asymptomatic, negative for COVID-19 either by RAT or RT-PCR, working in the hospital for at least last four months. healthcare workers who deliver care and services to patients, either directly
as physicians and nurse or indirectly as assistants, technicians, and
other support staff (administrative staff, cleaning, kitchen, laundry,
maintenance, etc.,) employed under the institution were part of this
study.","Previously, COVID-19 positive or IgG positive HCWs were excluded from the study",2020-10-15,2020-12-14,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,215,0.25120000000000003,,,True,,,,True,Convenience,VIDAS® SARS-COV-2 IgG,BioMérieux,Other,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Mithu Medhi,Assam Medical College and Hospital,Not Unity-Aligned,https://dx.doi.org/10.7860/JCDR/2022/51664.16066,2022-03-21,2024-03-01,Unverified,medhi_seroprevalence_2022,IND
220303_Odisha_ICMR_Athagarh1_Overall_PopAdj,220303_Odisha_ICMR_Athagarh1,"Infection, cases due to SARS-CoV-2 in rural areas during early COVID-19 vaccination: Findings from sero-survey study in a rural cohort of eastern India.",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,India,Odisha,Athagar," Participants who were above 18 years of age, staying in that village at least for the last 3 months, and provided written informed consent to participate, were included
Badamba, and Narasinghpur) during March-April, 2021.","pregnant women, cognitive impairment, and bed-ridden patients were excluded.",2021-03-15,2021-04-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,887,0.6029,0.5698,0.6353,True,,True,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981000000000001,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Pujarini Dash,Indian Council of Medical Research–Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000346,2022-03-11,2024-03-01,Verified,dash_infection_2022,IND
220303_Odisha_ICMR_Athagarh1_Overall_Crude,220303_Odisha_ICMR_Athagarh1,"Infection, cases due to SARS-CoV-2 in rural areas during early COVID-19 vaccination: Findings from sero-survey study in a rural cohort of eastern India.",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,India,Odisha,Athagar," Participants who were above 18 years of age, staying in that village at least for the last 3 months, and provided written informed consent to participate, were included
Badamba, and Narasinghpur) during March-April, 2021.","pregnant women, cognitive impairment, and bed-ridden patients were excluded.",2021-03-15,2021-04-15,Household and community samples,All,Multiple groups,,,Analysis,,887,0.6020000000000001,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981000000000001,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Pujarini Dash,Indian Council of Medical Research–Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000346,2022-05-28,2024-03-01,Verified,dash_infection_2022,IND
220303_Odisha_ICMR_Athagarh1_Overall_TestAdj,220303_Odisha_ICMR_Athagarh1,"Infection, cases due to SARS-CoV-2 in rural areas during early COVID-19 vaccination: Findings from sero-survey study in a rural cohort of eastern India.",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,India,Odisha,Athagar," Participants who were above 18 years of age, staying in that village at least for the last 3 months, and provided written informed consent to participate, were included
Badamba, and Narasinghpur) during March-April, 2021.","pregnant women, cognitive impairment, and bed-ridden patients were excluded.",2021-03-15,2021-04-15,Household and community samples,All,Multiple groups,,,Analysis,,887,0.6021,0.569,0.6353,,True,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981000000000001,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Pujarini Dash,Indian Council of Medical Research–Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000346,2022-03-11,2023-08-15,Verified,dash_infection_2022,IND
220303_Odisha_ICMR_Badamba2_Overall_PopAdj,220303_Odisha_ICMR_Badamba2,"Infection, cases due to SARS-CoV-2 in rural areas during early COVID-19 vaccination: Findings from sero-survey study in a rural cohort of eastern India.",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,India,Odisha,Badamba," Participants who were above 18 years of age, staying in that village at least for the last 3 months, and provided written informed consent to participate, were included
Badamba, and Narasinghpur) during March-April, 2021.","pregnant women, cognitive impairment, and bed-ridden patients were excluded.",2021-03-15,2021-04-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,862,0.5547,0.5208,0.5883,True,,True,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981000000000001,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Pujarini Dash,Indian Council of Medical Research–Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000346,2022-03-11,2024-03-01,Verified,dash_infection_2022,IND
220303_Odisha_ICMR_Badamba2_Overall_TestAdj,220303_Odisha_ICMR_Badamba2,"Infection, cases due to SARS-CoV-2 in rural areas during early COVID-19 vaccination: Findings from sero-survey study in a rural cohort of eastern India.",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,India,Odisha,Badamba," Participants who were above 18 years of age, staying in that village at least for the last 3 months, and provided written informed consent to participate, were included
Badamba, and Narasinghpur) during March-April, 2021.","pregnant women, cognitive impairment, and bed-ridden patients were excluded.",2021-03-15,2021-04-15,Household and community samples,All,Multiple groups,,,Analysis,,862,0.5538000000000001,0.5199,0.5872999999999999,,True,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981000000000001,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Pujarini Dash,Indian Council of Medical Research–Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000346,2022-03-11,2023-08-15,Verified,dash_infection_2022,IND
220303_Odisha_ICMR_Badamba2_Overall_Crude,220303_Odisha_ICMR_Badamba2,"Infection, cases due to SARS-CoV-2 in rural areas during early COVID-19 vaccination: Findings from sero-survey study in a rural cohort of eastern India.",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,India,Odisha,Badamba," Participants who were above 18 years of age, staying in that village at least for the last 3 months, and provided written informed consent to participate, were included
Badamba, and Narasinghpur) during March-April, 2021.","pregnant women, cognitive impairment, and bed-ridden patients were excluded.",2021-03-15,2021-04-15,Household and community samples,All,Multiple groups,,,Analysis,,862,0.5557,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981000000000001,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Pujarini Dash,Indian Council of Medical Research–Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000346,2022-05-28,2024-03-01,Verified,dash_infection_2022,IND
220303_Odisha_ICMR_Narsinghpur3_Overall_PopAdj,220303_Odisha_ICMR_Narsinghpur3,"Infection, cases due to SARS-CoV-2 in rural areas during early COVID-19 vaccination: Findings from sero-survey study in a rural cohort of eastern India.",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,India,Odisha,Narsinghpur," Participants who were above 18 years of age, staying in that village at least for the last 3 months, and provided written informed consent to participate, were included
Badamba, and Narasinghpur) during March-April, 2021.","pregnant women, cognitive impairment, and bed-ridden patients were excluded.",2021-03-15,2021-04-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,988,0.3979,0.36710000000000004,0.4293,True,,True,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981000000000001,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Pujarini Dash,Indian Council of Medical Research–Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000346,2022-03-11,2024-03-01,Verified,dash_infection_2022,IND
220303_Odisha_ICMR_Narsinghpur3_Overall_Crude,220303_Odisha_ICMR_Narsinghpur3,"Infection, cases due to SARS-CoV-2 in rural areas during early COVID-19 vaccination: Findings from sero-survey study in a rural cohort of eastern India.",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,India,Odisha,Narsinghpur," Participants who were above 18 years of age, staying in that village at least for the last 3 months, and provided written informed consent to participate, were included
Badamba, and Narasinghpur) during March-April, 2021.","pregnant women, cognitive impairment, and bed-ridden patients were excluded.",2021-03-15,2021-04-15,Household and community samples,All,Multiple groups,,,Analysis,,988,0.3998,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981000000000001,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Pujarini Dash,Indian Council of Medical Research–Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000346,2022-05-28,2024-03-01,Verified,dash_infection_2022,IND
220303_Odisha_ICMR_Narsinghpur3_Overall_TestAdj,220303_Odisha_ICMR_Narsinghpur3,"Infection, cases due to SARS-CoV-2 in rural areas during early COVID-19 vaccination: Findings from sero-survey study in a rural cohort of eastern India.",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,India,Odisha,Narsinghpur," Participants who were above 18 years of age, staying in that village at least for the last 3 months, and provided written informed consent to participate, were included
Badamba, and Narasinghpur) during March-April, 2021.","pregnant women, cognitive impairment, and bed-ridden patients were excluded.",2021-03-15,2021-04-15,Household and community samples,All,Multiple groups,,,Analysis,,988,0.39670000000000005,0.36600000000000005,0.428,,True,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981000000000001,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Pujarini Dash,Indian Council of Medical Research–Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000346,2022-03-11,2023-08-15,Verified,dash_infection_2022,IND
220303_Odisha_ICMR_Tigiria4_Overall_PopAdj,220303_Odisha_ICMR_Tigiria4,"Infection, cases due to SARS-CoV-2 in rural areas during early COVID-19 vaccination: Findings from sero-survey study in a rural cohort of eastern India.",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,India,Odisha,Tigiria," Participants who were above 18 years of age, staying in that village at least for the last 3 months, and provided written informed consent to participate, were included
Badamba, and Narasinghpur) during March-April, 2021.","pregnant women, cognitive impairment, and bed-ridden patients were excluded.",2021-03-15,2021-04-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,885,0.6325999999999999,0.5998,0.6645000000000001,True,,True,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981000000000001,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Pujarini Dash,Indian Council of Medical Research–Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000346,2022-03-11,2024-03-01,Verified,dash_infection_2022,IND
220303_Odisha_ICMR_Tigiria4_Overall_TestAdj,220303_Odisha_ICMR_Tigiria4,"Infection, cases due to SARS-CoV-2 in rural areas during early COVID-19 vaccination: Findings from sero-survey study in a rural cohort of eastern India.",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,India,Odisha,Tigiria," Participants who were above 18 years of age, staying in that village at least for the last 3 months, and provided written informed consent to participate, were included
Badamba, and Narasinghpur) during March-April, 2021.","pregnant women, cognitive impairment, and bed-ridden patients were excluded.",2021-03-15,2021-04-15,Household and community samples,All,Multiple groups,,,Analysis,,885,0.6319,0.5992000000000001,0.6637000000000001,,True,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981000000000001,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Pujarini Dash,Indian Council of Medical Research–Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000346,2022-03-11,2023-08-15,Verified,dash_infection_2022,IND
220303_Odisha_ICMR_Tigiria4_Overall_Crude,220303_Odisha_ICMR_Tigiria4,"Infection, cases due to SARS-CoV-2 in rural areas during early COVID-19 vaccination: Findings from sero-survey study in a rural cohort of eastern India.",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,India,Odisha,Tigiria," Participants who were above 18 years of age, staying in that village at least for the last 3 months, and provided written informed consent to participate, were included
Badamba, and Narasinghpur) during March-April, 2021.","pregnant women, cognitive impairment, and bed-ridden patients were excluded.",2021-03-15,2021-04-15,Household and community samples,All,Multiple groups,,,Analysis,,885,0.6328,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9981000000000001,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Pujarini Dash,Indian Council of Medical Research–Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000346,2022-05-28,2024-03-01,Verified,dash_infection_2022,IND
220303_Chandigarh_PostGraduateInstituteofMedicalEducationandResearch_Overall,220303_Chandigarh_PostGraduateInstituteofMedicalEducationandResearch,Short Research Communication Anti-Spike Antibody Response to COVISHIELDTM (SII-ChAdOx1 nCoV-19) Vaccine in Patients with B-Cell and Plasma Cell Malignancies and Hematopoietic Cell Transplantation Recipients,2022-03-03,Journal Article (Peer-Reviewed),Local,Prospective cohort,India,Chandigarh,Chandigarh,patients with hematological malignancies and hematopoietic cell transplantation recipients at a single centre,,2021-04-15,2021-08-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,46,0.39,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,,Spike,Validated by independent authors/third party/non-developers,0.988,0.9990000000000001,['High'],,No,No,Yes,,Yes,Yes,Yes,,Madhu Chopra,Post Graduate Institute of Medical Education and Research,Not Unity-Aligned,https://dx.doi.org/10.1007/s12288-022-01528-y,2022-03-18,2024-03-01,Unverified,chopra_short_2022,IND
220308_KingGeorgesMedicalUniversity_KingGeorgesMedicalUniversity_Overall,220308_KingGeorgesMedicalUniversity_KingGeorgesMedicalUniversity,Seropositivity of Anti-SARS CoV2 IgG antibodies in health care workers of an Indian tertiary care hospital during COVID-19,2022-03-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Uttar Pradesh,Lucknow,"workers including consultants, residents, nursing staff, laboratory workers, ward boys, guards and some of office workers, working at King George's Medical University, Lucknow, India were enrolled",,2020-10-01,2020-10-31,Health care workers and caregivers,All,Adults (18-64 years),21.0,65.0,Primary Estimate,,500,0.256,,,True,,,,True,Unclear,COVID KAVACH Anti-SARS CoV-2 Human IgG ELISA,Trivitron Healthcare,ELISA,Serum,IgG,,,,,['High'],,Unclear,No,Yes,,Yes,Yes,Yes,,Anuragani Verma,King George's Medical University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2022.02.004,2022-03-25,2024-03-01,Unverified,verma_seropositivity_2022,IND
220308_KingGeorgesMedicalUniversity_KingGeorgesMedicalUniversity_<=35,220308_KingGeorgesMedicalUniversity_KingGeorgesMedicalUniversity,Seropositivity of Anti-SARS CoV2 IgG antibodies in health care workers of an Indian tertiary care hospital during COVID-19,2022-03-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Uttar Pradesh,Lucknow,"workers including consultants, residents, nursing staff, laboratory workers, ward boys, guards and some of office workers, working at King George's Medical University, Lucknow, India were enrolled",,2020-10-01,2020-10-31,Health care workers and caregivers,All,Adults (18-64 years),21.0,35.0,Age,<=35,354,0.25420000000000004,,,,,,,,Unclear,COVID KAVACH Anti-SARS CoV-2 Human IgG ELISA,Trivitron Healthcare,ELISA,Serum,IgG,,,,,['High'],,Unclear,No,Yes,,Yes,Yes,Yes,,Anuragani Verma,King George's Medical University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2022.02.004,2022-03-25,2024-03-01,Unverified,verma_seropositivity_2022,IND
220308_KingGeorgesMedicalUniversity_KingGeorgesMedicalUniversity_36-65,220308_KingGeorgesMedicalUniversity_KingGeorgesMedicalUniversity,Seropositivity of Anti-SARS CoV2 IgG antibodies in health care workers of an Indian tertiary care hospital during COVID-19,2022-03-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Uttar Pradesh,Lucknow,"workers including consultants, residents, nursing staff, laboratory workers, ward boys, guards and some of office workers, working at King George's Medical University, Lucknow, India were enrolled",,2020-10-01,2020-10-31,Health care workers and caregivers,All,Adults (18-64 years),36.0,65.0,Age,36-65,146,0.26030000000000003,,,,,,,,Unclear,COVID KAVACH Anti-SARS CoV-2 Human IgG ELISA,Trivitron Healthcare,ELISA,Serum,IgG,,,,,['High'],,Unclear,No,Yes,,Yes,Yes,Yes,,Anuragani Verma,King George's Medical University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2022.02.004,2022-03-25,2024-03-01,Unverified,verma_seropositivity_2022,IND
220310_Bangalore_BangaloreBaptistHospital_Primary,220310_Bangalore_BangaloreBaptistHospital,Seroprevalence of COVID-19 infection among vaccine naive population after the second surge (June 2020) in a rural district of South India: A community-based cross-sectional study,2022-03-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Karnataka,,Vaccine naive adults (18+),,2021-07-01,2021-07-31,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,831,0.449,0.425,0.474,True,,True,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Low'],,Yes,Yes,Yes,,Yes,Yes,No,,Carolin George,Bangalore Baptist Hospital,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0265236,2022-03-21,2024-03-01,Unverified,george_seroprevalence_2022,IND
220310_Bangalore_BangaloreBaptistHospital_Sex_Male,220310_Bangalore_BangaloreBaptistHospital,Seroprevalence of COVID-19 infection among vaccine naive population after the second surge (June 2020) in a rural district of South India: A community-based cross-sectional study,2022-03-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Karnataka,,Vaccine naive adults (18+),,2021-07-01,2021-07-31,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,344,0.663,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Low'],,Yes,Yes,Yes,,Yes,Yes,No,,Carolin George,Bangalore Baptist Hospital,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0265236,2022-03-21,2024-03-01,Unverified,george_seroprevalence_2022,IND
220310_Bangalore_BangaloreBaptistHospital_Age_51-60,220310_Bangalore_BangaloreBaptistHospital,Seroprevalence of COVID-19 infection among vaccine naive population after the second surge (June 2020) in a rural district of South India: A community-based cross-sectional study,2022-03-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Karnataka,,Vaccine naive adults (18+),,2021-07-01,2021-07-31,Household and community samples,All,Adults (18-64 years),51.0,60.0,Age,51-60,54,0.611,0.469,0.741,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Low'],,Yes,Yes,Yes,,Yes,Yes,No,,Carolin George,Bangalore Baptist Hospital,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0265236,2022-03-21,2024-03-01,Unverified,george_seroprevalence_2022,IND
220310_Bangalore_BangaloreBaptistHospital_Age_18-20,220310_Bangalore_BangaloreBaptistHospital,Seroprevalence of COVID-19 infection among vaccine naive population after the second surge (June 2020) in a rural district of South India: A community-based cross-sectional study,2022-03-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Karnataka,,Vaccine naive adults (18+),,2021-07-01,2021-07-31,Household and community samples,All,Adults (18-64 years),18.0,20.0,Age,18-20,70,0.643,0.519,0.7540000000000001,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Low'],,Yes,Yes,Yes,,Yes,Yes,No,,Carolin George,Bangalore Baptist Hospital,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0265236,2022-03-21,2024-03-01,Unverified,george_seroprevalence_2022,IND
220310_Bangalore_BangaloreBaptistHospital_Age_21-30,220310_Bangalore_BangaloreBaptistHospital,Seroprevalence of COVID-19 infection among vaccine naive population after the second surge (June 2020) in a rural district of South India: A community-based cross-sectional study,2022-03-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Karnataka,,Vaccine naive adults (18+),,2021-07-01,2021-07-31,Household and community samples,All,Adults (18-64 years),21.0,30.0,Age,21-30,236,0.648,0.584,0.7090000000000001,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Low'],,Yes,Yes,Yes,,Yes,Yes,No,,Carolin George,Bangalore Baptist Hospital,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0265236,2022-03-21,2024-03-01,Unverified,george_seroprevalence_2022,IND
220310_Bangalore_BangaloreBaptistHospital_Age_>60,220310_Bangalore_BangaloreBaptistHospital,Seroprevalence of COVID-19 infection among vaccine naive population after the second surge (June 2020) in a rural district of South India: A community-based cross-sectional study,2022-03-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Karnataka,,Vaccine naive adults (18+),,2021-07-01,2021-07-31,Household and community samples,All,Multiple groups,60.0,,Age,>60,42,0.7140000000000001,0.554,0.843,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Low'],,Yes,Yes,Yes,,Yes,Yes,No,,Carolin George,Bangalore Baptist Hospital,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0265236,2022-03-21,2024-03-01,Unverified,george_seroprevalence_2022,IND
220310_Bangalore_BangaloreBaptistHospital_Age_41-50,220310_Bangalore_BangaloreBaptistHospital,Seroprevalence of COVID-19 infection among vaccine naive population after the second surge (June 2020) in a rural district of South India: A community-based cross-sectional study,2022-03-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Karnataka,,Vaccine naive adults (18+),,2021-07-01,2021-07-31,Household and community samples,All,Adults (18-64 years),41.0,50.0,Age,41-50,150,0.5870000000000001,0.503,0.6659999999999999,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Low'],,Yes,Yes,Yes,,Yes,Yes,No,,Carolin George,Bangalore Baptist Hospital,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0265236,2022-03-21,2024-03-01,Unverified,george_seroprevalence_2022,IND
220310_Bangalore_BangaloreBaptistHospital_Sex_Female,220310_Bangalore_BangaloreBaptistHospital,Seroprevalence of COVID-19 infection among vaccine naive population after the second surge (June 2020) in a rural district of South India: A community-based cross-sectional study,2022-03-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Karnataka,,Vaccine naive adults (18+),,2021-07-01,2021-07-31,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,487,0.6020000000000001,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Low'],,Yes,Yes,Yes,,Yes,Yes,No,,Carolin George,Bangalore Baptist Hospital,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0265236,2022-03-21,2024-03-01,Unverified,george_seroprevalence_2022,IND
220310_Bangalore_BangaloreBaptistHospital_Age_31-40,220310_Bangalore_BangaloreBaptistHospital,Seroprevalence of COVID-19 infection among vaccine naive population after the second surge (June 2020) in a rural district of South India: A community-based cross-sectional study,2022-03-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Karnataka,,Vaccine naive adults (18+),,2021-07-01,2021-07-31,Household and community samples,All,Adults (18-64 years),31.0,40.0,Age,31-40,279,0.616,0.557,0.674,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Low'],,Yes,Yes,Yes,,Yes,Yes,No,,Carolin George,Bangalore Baptist Hospital,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0265236,2022-03-21,2024-03-01,Unverified,george_seroprevalence_2022,IND
220310_HimachalPradesh_DrRPGovernmentMedicalCollege_Overall,220310_HimachalPradesh_DrRPGovernmentMedicalCollege,Seroprevalence of CoVID-19 among health care professionals (HCPs) of tertiary care hospital of northern state of India.,2022-03-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Himachal Pradesh,,"""A hospital‑based survey was carried out to assess the seroprevalence of COVID‑19 infection in HCPs [health care professionals] from September 2020 to January 2021. The professionals were faculty members, resident doctors, medical officers/interns, nurses, laboratory personnel, administrative staff, and hospital support staff like ward attendants, hospitality, etc.""",,2020-09-15,2021-01-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1279,0.1267,,,True,,,,True,Convenience,COVID KAVACH Anti-SARS CoV-2 Human IgG ELISA,Trivitron Healthcare,ELISA,Serum,IgG,Whole-virusantigen,Validated by developers,0.98,1.0,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Dinesh Kumar,Dr. Rajendra Prasad Government Medical College,Not Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_288_21,2022-05-09,2024-03-01,Unverified,kumar_seroprevalence_2022,IND
220316_Mumbai_SethGSMedicalCollege_Age_31-40,220316_Mumbai_SethGSMedicalCollege,"COVID-19 Serological Survey-3 Prior to Second Wave in Mumbai, India.",2022-03-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,"""Samples were collected from patients reporting to municipal dispensaries and private laboratories receiving samples from private sector health service delivery points for investigations as per their non-COVID-19 requirements.""","""patients residing outside MCGM limits and who were vaccinated for COVID-19 were excluded.""",2021-03-01,2021-03-31,Residual sera,All,Multiple groups,31.0,40.0,Age,31-40,1905,0.3444,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Abbott Laboratories,Siemens",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,No,,Yes,Yes,No,,Gajanan Velhal,Seth GS Medical College,Not Unity-Aligned,https://dx.doi.org/10.4103/ijcm.ijcm_984_21,2022-04-17,2024-03-01,Unverified,velhal_covid-19_2022,IND
220316_Mumbai_SethGSMedicalCollege_Age_18-30,220316_Mumbai_SethGSMedicalCollege,"COVID-19 Serological Survey-3 Prior to Second Wave in Mumbai, India.",2022-03-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,"""Samples were collected from patients reporting to municipal dispensaries and private laboratories receiving samples from private sector health service delivery points for investigations as per their non-COVID-19 requirements.""","""patients residing outside MCGM limits and who were vaccinated for COVID-19 were excluded.""",2021-03-01,2021-03-31,Residual sera,All,Multiple groups,18.0,30.0,Age,18-30,2691,0.3296,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Abbott Laboratories,Siemens",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,No,,Yes,Yes,No,,Gajanan Velhal,Seth GS Medical College,Not Unity-Aligned,https://dx.doi.org/10.4103/ijcm.ijcm_984_21,2022-04-17,2024-03-01,Unverified,velhal_covid-19_2022,IND
"220316_Mumbai_SethGSMedicalCollege_Age_41-50
",220316_Mumbai_SethGSMedicalCollege,"COVID-19 Serological Survey-3 Prior to Second Wave in Mumbai, India.",2022-03-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,"""Samples were collected from patients reporting to municipal dispensaries and private laboratories receiving samples from private sector health service delivery points for investigations as per their non-COVID-19 requirements.""","""patients residing outside MCGM limits and who were vaccinated for COVID-19 were excluded.""",2021-03-01,2021-03-31,Residual sera,All,Multiple groups,41.0,50.0,Age,41-50,1758,0.3788,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Abbott Laboratories,Siemens",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,No,,Yes,Yes,No,,Gajanan Velhal,Seth GS Medical College,Not Unity-Aligned,https://dx.doi.org/10.4103/ijcm.ijcm_984_21,2022-04-17,2024-03-01,Unverified,velhal_covid-19_2022,IND
220316_Mumbai_SethGSMedicalCollege_Age_<18,220316_Mumbai_SethGSMedicalCollege,"COVID-19 Serological Survey-3 Prior to Second Wave in Mumbai, India.",2022-03-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,"""Samples were collected from patients reporting to municipal dispensaries and private laboratories receiving samples from private sector health service delivery points for investigations as per their non-COVID-19 requirements.""","""patients residing outside MCGM limits and who were vaccinated for COVID-19 were excluded.""",2021-03-01,2021-03-31,Residual sera,All,Multiple groups,,17.0,Age,<18,467,0.394,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Abbott Laboratories,Siemens",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,No,,Yes,Yes,No,,Gajanan Velhal,Seth GS Medical College,Not Unity-Aligned,https://dx.doi.org/10.4103/ijcm.ijcm_984_21,2022-04-17,2024-03-01,Unverified,velhal_covid-19_2022,IND
220316_Mumbai_SethGSMedicalCollege_Age_>61,220316_Mumbai_SethGSMedicalCollege,"COVID-19 Serological Survey-3 Prior to Second Wave in Mumbai, India.",2022-03-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,"""Samples were collected from patients reporting to municipal dispensaries and private laboratories receiving samples from private sector health service delivery points for investigations as per their non-COVID-19 requirements.""","""patients residing outside MCGM limits and who were vaccinated for COVID-19 were excluded.""",2021-03-01,2021-03-31,Residual sera,All,Multiple groups,61.0,,Age,>61,1691,0.3785,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Abbott Laboratories,Siemens",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,No,,Yes,Yes,No,,Gajanan Velhal,Seth GS Medical College,Not Unity-Aligned,https://dx.doi.org/10.4103/ijcm.ijcm_984_21,2022-04-17,2024-03-01,Unverified,velhal_covid-19_2022,IND
220316_Mumbai_SethGSMedicalCollege_Age_51-60,220316_Mumbai_SethGSMedicalCollege,"COVID-19 Serological Survey-3 Prior to Second Wave in Mumbai, India.",2022-03-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,"""Samples were collected from patients reporting to municipal dispensaries and private laboratories receiving samples from private sector health service delivery points for investigations as per their non-COVID-19 requirements.""","""patients residing outside MCGM limits and who were vaccinated for COVID-19 were excluded.""",2021-03-01,2021-03-31,Residual sera,All,Multiple groups,51.0,60.0,Age,51-60,1673,0.45530000000000004,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Abbott Laboratories,Siemens",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,No,,Yes,Yes,No,,Gajanan Velhal,Seth GS Medical College,Not Unity-Aligned,https://dx.doi.org/10.4103/ijcm.ijcm_984_21,2022-04-17,2024-03-01,Unverified,velhal_covid-19_2022,IND
220316_Mumbai_SethGSMedicalCollege,220316_Mumbai_SethGSMedicalCollege,"COVID-19 Serological Survey-3 Prior to Second Wave in Mumbai, India.",2022-03-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,"""Samples were collected from patients reporting to municipal dispensaries and private laboratories receiving samples from private sector health service delivery points for investigations as per their non-COVID-19 requirements.""","""patients residing outside MCGM limits and who were vaccinated for COVID-19 were excluded.""",2021-03-01,2021-03-31,Residual sera,All,Multiple groups,17.0,94.0,Primary Estimate,,10197,0.363,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","Abbott Laboratories,Siemens",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,No,,Yes,Yes,No,,Gajanan Velhal,Seth GS Medical College,Not Unity-Aligned,https://dx.doi.org/10.4103/ijcm.ijcm_984_21,2022-04-17,2024-03-01,Unverified,velhal_covid-19_2022,IND
220324_Ballabhgarh_AllIndiaInstituteMedicalSciences_TotalAb,220324_Ballabhgarh_AllIndiaInstituteMedicalSciences,Sero-prevalence of SARS-CoV-2 Antibodies among First Trimester Pregnant Women during the Second Wave of Pandemic in India,2022-03-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Haryana,Ballabhgarh,"women who became pregnant just before or during the COVID-19 pandemic during the second peak, from April, 2021 to August, 2021.","Only asymptomatic women who have not been diagnosed with COVID-19 in the past three months, were recruited.",2021-04-15,2021-08-15,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,IgG + IgM,220,0.773,,,True,,,,True,Convenience,"VIDAS® SARS-COV-2 IgG,VIDAS® SARS-COV-2 IgM",BioMérieux,ELISA,Serum,"['IgG', 'IgM']",Spike,,,,['High'],,No,No,No,,Unclear,Yes,No,,Aparna Sharma,All India Institute of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1002/ijgo.14189,2022-03-29,2024-03-01,Unverified,sharma_sars-cov-2_2022,IND
220324_NewDelhi_AllIndiaInstituteofMedicalSciences_IgG,220324_NewDelhi_AllIndiaInstituteofMedicalSciences,Seroprevalence of SARS-CoV-2 antibodies among first-trimester pregnant women during the second wave of the pandemic in India,2022-03-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,National Capital Territory of Delhi,New Delhi,"women in the first trimester of pregnancy (11–13 weeks of pregnancy), were included in the study.

Only asymptomatic women, who have not been diagnosed with COVID-19 in the past 3 months, were recruited.","COVID-19 symptoms, diagnosed with COVID-19 in the past 3 months",2021-04-15,2021-08-15,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,IgG,220,0.7273000000000001,0.668,0.7859999999999999,True,,,,True,Unclear,VIDAS® SARS-COV-2 IgG,BioMérieux,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],,Unclear,No,No,,Yes,Yes,Yes,,Kandala Sharma,All India Institute of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1002/ijgo.14189,2022-04-26,2024-03-01,Unverified,sharma_seroprevalence_2022,IND
220331_Chennai_BloombergSchoolofPublicHealth,220331_Chennai_BloombergSchoolofPublicHealth,Local-scale spatial variability in SARS-CoV-2 seroprevalence in an Indian megacity,2022-03-31,Presentation or Conference,Local,Cross-sectional survey ,India,Tamil Nadu,Chennai,"Households in Chennai, India",,2021-01-15,2021-05-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,4712,0.619,0.605,0.653,True,,,,True,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Whole Blood,IgG,Spike,,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Eshan U. Patel,Bloomberg School of Public Health ,Unity-Aligned,https://www.iasusa.org/tam/march-2022/,2022-06-15,2024-03-19,Verified,patel_local-scale_2022,IND
220405_NewDelhi_AllIndiaInstituteofMedicalSciences,220405_NewDelhi_AllIndiaInstituteofMedicalSciences,Mild and Asymptomatic SARS-CoV-2 Infection is Not Associated with Progression of Thyroid Dysfunction or Thyroid Autoimmunity.,2022-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,New Delhi,"""comprised of women with history of hyperglycaemia or normoglycaemia in pregnancy who were followed up in the post‐partum period along with their spouses.""",,2020-08-15,2021-02-15,Multiple general populations,All,Adults (18-64 years),,,Primary Estimate,,240,0.454,,,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['High'],No,No,No,Yes,No,Yes,Yes,Yes,Unclear,Alpesh Goyal,All India Institue of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1111/cen.14731,2022-04-13,2024-03-01,Verified,goyal_mild_2022,IND
220410_Mumbai_BEST_Primary,220410_Mumbai_BEST,"100% BEST drivers, conductors developed antibodies",2022-04-10,News and Media,Local,Cross-sectional survey ,India,Maharashtra,Mumbai,"The sample size mainly included drivers, conductors and officials from the BEST traffic wing who were on the ground ever since the pandemic broke out. All the 776 on-duty employees, who had given their samples, are fully-vaccinated and have been reporting for work as usual",,2022-03-28,2022-03-30,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,776,1.0,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Pratip Acharya,Brihanmumbai Electric Supply and Transport,Not Unity-Aligned,https://www.hindustantimes.com/cities/mumbai-news/100-best-drivers-conductors-developed-antibodies-101649607686530.html,2022-04-20,2022-07-16,Unverified,acharya_best_2022,IND
220509_Uttarakhand_AllIndiaInstituteofMedicalSciences_Overall,220509_Uttarakhand_AllIndiaInstituteofMedicalSciences,Seroprevalence of Antibodies Against SARS-CoV-2 Among Health Care Workers at a Tertiary Care Hospital in Uttarakhand: A Retrospective Study.,2022-05-09,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Uttarakhand,,"participants from e-hospital records and data available with the medical record department
713 health care workers admitted to the COVID-19 unit and who attended the COVID-19 OPD during this one month",incomplete records or missing data were excluded,2020-07-15,2020-08-14,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,704,0.0199,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,IgG,,,,,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Amit Saini,All India Institute of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.7759/cureus.24840,2022-06-30,2022-07-16,Verified,saini_seroprevalence_2022,IND
20220524_ Thrissur_JubileeMissionMedicalCollegeandResearchInstitute_IgG,20220524_ Thrissur_JubileeMissionMedicalCollegeandResearchInstitute_IgG,Seroprevalence of SARS-CoV-2 antibody among blood donors during the second wave of COVID-19 in a tertiary care centre in South India,2022-05-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Thrissur,,"conducted between March 16 and July 10, 2021; 
300 blood donors without any prior COVID-19 history or symptoms who came to a tertiary care, multispecialty hospital in south India","""Any donor who had travelled abroad or came back from abroad after January, 2020 and donors who had received COVID-19 vaccine are excluded from the study.""",2021-03-16,2021-07-10,Blood donors,Male,Adults (18-64 years),,,Primary Estimate,,300,0.153,,,True,,,,True,Sequential,Access SARS-CoV-2 IgG Reagent Antibody Test,Beckman Coulter,CLIA,Whole Blood,IgG,Spike,,,,['High'],,No,No,No,,Yes,Yes,Yes,,S. John, Jubilee Mission Medical College and Research Institute,Not Unity-Aligned,https://dx.doi.org/10.1111/vox.13285,2022-07-06,2024-03-01,Unverified,ISBT2022Abstract2022b,IND
220526_EasternIndia_ApolloGleneaglesHospitals_Adj,220526_EasternIndia_ApolloGleneaglesHospitals,Seroprevalence of anti-severe acute respiratory syndrome coronavirus 2 antibody among healthy blood donors in a hospital-based blood center in Eastern India during the COVID-19 pandemic.,2022-05-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,West Bengal,Kolkata,"Blood donors are healthy, asymptomatic individuals who donate blood selflessly and altruistically. ","At‐risk donor who had travel history, contact history, and COVID‐19 symptoms. Donors who were seroreactive for any of the infectious markers like anti‐HIV 1 and 2, HBsAg, anti‐HCV, syphilis, and malaria were excluded from the study.",2020-06-01,2020-07-31,Blood donors,All,Adults (18-64 years),18.0,65.0,Primary Estimate,test-adjusted overall,611,0.040999999999999995,0.034,0.047,True,True,,,,Self-referral,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,0.99,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Sudipta Sekhar Das,Apollo Gleneagles Hospitals,Not Unity-Aligned,https://dx.doi.org/10.4103/ajts.ajts_123_20,2022-10-11,2023-08-15,Unverified,das_seroprevalence_2022,IND
220526_EasternIndia_ApolloGleneaglesHospitals_UnAdj_Female,220526_EasternIndia_ApolloGleneaglesHospitals,Seroprevalence of anti-severe acute respiratory syndrome coronavirus 2 antibody among healthy blood donors in a hospital-based blood center in Eastern India during the COVID-19 pandemic.,2022-05-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,West Bengal,Kolkata,"Blood donors are healthy, asymptomatic individuals who donate blood selflessly and altruistically. ","At‐risk donor who had travel history, contact history, and COVID‐19 symptoms. Donors who were seroreactive for any of the infectious markers like anti‐HIV 1 and 2, HBsAg, anti‐HCV, syphilis, and malaria were excluded from the study.",2020-06-01,2020-07-31,Blood donors,Female,Adults (18-64 years),18.0,65.0,Sex/Gender,,96,0.042,,,,,,,,Self-referral,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,0.99,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Sudipta Sekhar Das,Apollo Gleneagles Hospitals,Not Unity-Aligned,https://dx.doi.org/10.4103/ajts.ajts_123_20,2022-10-11,2024-03-01,Unverified,das_seroprevalence_2022,IND
220526_EasternIndia_ApolloGleneaglesHospitals_UnAdj_Age50to65,220526_EasternIndia_ApolloGleneaglesHospitals,Seroprevalence of anti-severe acute respiratory syndrome coronavirus 2 antibody among healthy blood donors in a hospital-based blood center in Eastern India during the COVID-19 pandemic.,2022-05-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,West Bengal,Kolkata,"Blood donors are healthy, asymptomatic individuals who donate blood selflessly and altruistically. ","At‐risk donor who had travel history, contact history, and COVID‐19 symptoms. Donors who were seroreactive for any of the infectious markers like anti‐HIV 1 and 2, HBsAg, anti‐HCV, syphilis, and malaria were excluded from the study.",2020-06-01,2020-07-31,Blood donors,All,Adults (18-64 years),50.0,65.0,Age,crude age: 50-65,73,0.040999999999999995,,,,,,,,Self-referral,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,0.99,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Sudipta Sekhar Das,Apollo Gleneagles Hospitals,Not Unity-Aligned,https://dx.doi.org/10.4103/ajts.ajts_123_20,2022-10-11,2024-03-01,Unverified,das_seroprevalence_2022,IND
220526_EasternIndia_ApolloGleneaglesHospitals_UnAdj_Age35to50,220526_EasternIndia_ApolloGleneaglesHospitals,Seroprevalence of anti-severe acute respiratory syndrome coronavirus 2 antibody among healthy blood donors in a hospital-based blood center in Eastern India during the COVID-19 pandemic.,2022-05-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,West Bengal,Kolkata,"Blood donors are healthy, asymptomatic individuals who donate blood selflessly and altruistically. ","At‐risk donor who had travel history, contact history, and COVID‐19 symptoms. Donors who were seroreactive for any of the infectious markers like anti‐HIV 1 and 2, HBsAg, anti‐HCV, syphilis, and malaria were excluded from the study.",2020-06-01,2020-07-31,Blood donors,All,Adults (18-64 years),35.0,50.0,Age,crude age: 35-50,220,0.045,,,,,,,,Self-referral,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,0.99,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Sudipta Sekhar Das,Apollo Gleneagles Hospitals,Not Unity-Aligned,https://dx.doi.org/10.4103/ajts.ajts_123_20,2022-10-11,2024-03-01,Unverified,das_seroprevalence_2022,IND
220526_EasternIndia_ApolloGleneaglesHospitals_UnAdj_Age18to35,220526_EasternIndia_ApolloGleneaglesHospitals,Seroprevalence of anti-severe acute respiratory syndrome coronavirus 2 antibody among healthy blood donors in a hospital-based blood center in Eastern India during the COVID-19 pandemic.,2022-05-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,West Bengal,Kolkata,"Blood donors are healthy, asymptomatic individuals who donate blood selflessly and altruistically. ","At‐risk donor who had travel history, contact history, and COVID‐19 symptoms. Donors who were seroreactive for any of the infectious markers like anti‐HIV 1 and 2, HBsAg, anti‐HCV, syphilis, and malaria were excluded from the study.",2020-06-01,2020-07-31,Blood donors,All,Adults (18-64 years),18.0,35.0,Age,crude age: 18-35,318,0.047,,,,,,,,Self-referral,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,0.99,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Sudipta Sekhar Das,Apollo Gleneagles Hospitals,Not Unity-Aligned,https://dx.doi.org/10.4103/ajts.ajts_123_20,2022-10-11,2024-03-01,Unverified,das_seroprevalence_2022,IND
220526_EasternIndia_ApolloGleneaglesHospitals_Adj_June,220526_EasternIndia_ApolloGleneaglesHospitals,Seroprevalence of anti-severe acute respiratory syndrome coronavirus 2 antibody among healthy blood donors in a hospital-based blood center in Eastern India during the COVID-19 pandemic.,2022-05-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,West Bengal,Kolkata,"Blood donors are healthy, asymptomatic individuals who donate blood selflessly and altruistically. ","At‐risk donor who had travel history, contact history, and COVID‐19 symptoms. Donors who were seroreactive for any of the infectious markers like anti‐HIV 1 and 2, HBsAg, anti‐HCV, syphilis, and malaria were excluded from the study.",2020-06-01,2020-06-30,Blood donors,All,Adults (18-64 years),18.0,65.0,Time frame,"test-adjusted June, 2020",293,0.039,0.033,0.043,,True,,,,Self-referral,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,0.99,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Sudipta Sekhar Das,Apollo Gleneagles Hospitals,Not Unity-Aligned,https://dx.doi.org/10.4103/ajts.ajts_123_20,2022-10-11,2023-08-15,Unverified,das_seroprevalence_2022,IND
220526_EasternIndia_ApolloGleneaglesHospitals_UnAdj_Male,220526_EasternIndia_ApolloGleneaglesHospitals,Seroprevalence of anti-severe acute respiratory syndrome coronavirus 2 antibody among healthy blood donors in a hospital-based blood center in Eastern India during the COVID-19 pandemic.,2022-05-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,West Bengal,Kolkata,"Blood donors are healthy, asymptomatic individuals who donate blood selflessly and altruistically. ","At‐risk donor who had travel history, contact history, and COVID‐19 symptoms. Donors who were seroreactive for any of the infectious markers like anti‐HIV 1 and 2, HBsAg, anti‐HCV, syphilis, and malaria were excluded from the study.",2020-06-01,2020-07-31,Blood donors,Male,Adults (18-64 years),18.0,65.0,Sex/Gender,,515,0.045,,,,,,,,Self-referral,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,0.99,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Sudipta Sekhar Das,Apollo Gleneagles Hospitals,Not Unity-Aligned,https://dx.doi.org/10.4103/ajts.ajts_123_20,2022-10-11,2024-03-01,Unverified,das_seroprevalence_2022,IND
220526_EasternIndia_ApolloGleneaglesHospitals_Adj_July,220526_EasternIndia_ApolloGleneaglesHospitals,Seroprevalence of anti-severe acute respiratory syndrome coronavirus 2 antibody among healthy blood donors in a hospital-based blood center in Eastern India during the COVID-19 pandemic.,2022-05-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,West Bengal,Kolkata,"Blood donors are healthy, asymptomatic individuals who donate blood selflessly and altruistically. ","At‐risk donor who had travel history, contact history, and COVID‐19 symptoms. Donors who were seroreactive for any of the infectious markers like anti‐HIV 1 and 2, HBsAg, anti‐HCV, syphilis, and malaria were excluded from the study.",2020-07-01,2020-07-31,Blood donors,All,Adults (18-64 years),18.0,65.0,Time frame,"test-adjusted July, 2020",318,0.044000000000000004,0.038,0.049,,True,,,,Self-referral,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,0.99,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Sudipta Sekhar Das,Apollo Gleneagles Hospitals,Not Unity-Aligned,https://dx.doi.org/10.4103/ajts.ajts_123_20,2022-10-11,2023-08-15,Unverified,das_seroprevalence_2022,IND
220526_EasternIndia_ApolloGleneaglesHospitals_UnAdj,220526_EasternIndia_ApolloGleneaglesHospitals,Seroprevalence of anti-severe acute respiratory syndrome coronavirus 2 antibody among healthy blood donors in a hospital-based blood center in Eastern India during the COVID-19 pandemic.,2022-05-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,West Bengal,Kolkata,"Blood donors are healthy, asymptomatic individuals who donate blood selflessly and altruistically. ","At‐risk donor who had travel history, contact history, and COVID‐19 symptoms. Donors who were seroreactive for any of the infectious markers like anti‐HIV 1 and 2, HBsAg, anti‐HCV, syphilis, and malaria were excluded from the study.",2020-06-01,2020-07-31,Blood donors,All,Adults (18-64 years),18.0,65.0,Analysis,crude overall,611,0.044000000000000004,0.038,0.049,,,,,True,Self-referral,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,0.99,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Sudipta Sekhar Das,Apollo Gleneagles Hospitals,Not Unity-Aligned,https://dx.doi.org/10.4103/ajts.ajts_123_20,2022-10-11,2024-03-01,Unverified,das_seroprevalence_2022,IND
220531_Gurugram_SGTUniversity,220531_Gurugram_SGTUniversity,Impact of ChAdOx1 nCoV-19 (Covishield TM) Vaccination: How Long Will It Persist?.,2022-05-31,Journal Article (Peer-Reviewed),Local,Prospective cohort,India,Haryana,Gurugram,"Healthcare workers who had received
ChAdOx1 nCoV-19 (Covishield™) manufactured by the
Serum Institute of India within the first three weeks after the
introduction of COVID-19 vaccination programme in our
country were enrolled in the study","those HCWs
vaccinated with Covaxin were also excluded from the study",2021-01-15,2021-07-15,Health care workers and caregivers,All,Multiple groups,21.0,73.0,Primary Estimate,,150,0.28,,,True,,,,True,Convenience,ELISafe 19™ COVID-19 IgG ELISA Detection Kit,HiMedia Laboratories,ELISA,Serum,IgG,Spike,Validated by manufacturers,1.0,1.0,['High'],,No,No,Yes,,Yes,Yes,Yes,,Leimapokpam Devi,SGT University,Not Unity-Aligned,https://dx.doi.org/10.1155/2022/4729844,2022-06-23,2024-03-01,Unverified,devi_impact_2022,IND
220607_Mumbai_FortisMemorialResearchInstitute_Overall,220607_Mumbai_FortisMemorialResearchInstitute,"Seroprevalence of SARS-CoV-2 infection among frontline police personnel in Mumbai, India",2022-06-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Mumbai,The inclusion criteria for the study were voluntary participation and limited to the police personnel > 18 years.,,2021-01-22,2021-02-02,Essential non-healthcare workers,All,Adults (18-64 years),18.0,59.0,Primary Estimate,,3077,0.741,0.725,0.756,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,TotalAntibody,,Validated by manufacturers,1.0,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Shibal Bhartiya,Hindaju Hospital,Not Unity-Aligned,https://dx.doi.org/10.1007/s13337-022-00766-y,2022-06-29,2022-07-16,Verified,bhartiya_seroprevalence_2022,IND
220610_Delhi_MaulanaAzadMedicalCollege_Time1_Overall,220610_Delhi_MaulanaAzadMedicalCollege_Time1,"Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in children and adolescents in Delhi, India, from January to October 2021: a repeated cross-sectional analysis.",2022-06-10,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,India,,Delhi,"This was a repeated cross-sectional analysis of 5- to 17-year old participants from 2 SARS-CoV-2 seroprevalence surveys
conducted in Delhi, India",,2021-01-01,2021-01-31,Household and community samples,All,Children and Youth (0-17 years),5.0,17.0,Primary Estimate,Cruse overall,4338,0.528,0.513,0.543,True,,,,True,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Pragya Sharma,Maulana Azad Medical College,Unity-Aligned,https://dx.doi.org/10.24171/j.phrp.2022.0014,2022-07-19,2024-03-25,Verified,sharma_seroprevalence_2022-1,IND
220610_Delhi_MaulanaAzadMedicalCollege_Time1_15-17,220610_Delhi_MaulanaAzadMedicalCollege_Time1,"Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in children and adolescents in Delhi, India, from January to October 2021: a repeated cross-sectional analysis.",2022-06-10,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,India,,Delhi,"This was a repeated cross-sectional analysis of 5- to 17-year old participants from 2 SARS-CoV-2 seroprevalence surveys
conducted in Delhi, India",,2021-01-01,2021-01-31,Household and community samples,All,Children and Youth (0-17 years),15.0,17.0,Age,15-17,1879,0.52,0.49700000000000005,0.543,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Pragya Sharma,Maulana Azad Medical College,Unity-Aligned,https://dx.doi.org/10.24171/j.phrp.2022.0014,2022-07-19,2024-03-25,Verified,sharma_seroprevalence_2022-1,IND
220610_Delhi_MaulanaAzadMedicalCollege_Time1_10-14,220610_Delhi_MaulanaAzadMedicalCollege_Time1,"Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in children and adolescents in Delhi, India, from January to October 2021: a repeated cross-sectional analysis.",2022-06-10,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,India,,Delhi,"This was a repeated cross-sectional analysis of 5- to 17-year old participants from 2 SARS-CoV-2 seroprevalence surveys
conducted in Delhi, India",,2021-01-01,2021-01-31,Household and community samples,All,Children and Youth (0-17 years),10.0,14.0,Age,10-14,1757,0.545,0.522,0.569,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Pragya Sharma,Maulana Azad Medical College,Unity-Aligned,https://dx.doi.org/10.24171/j.phrp.2022.0014,2022-07-19,2024-03-25,Verified,sharma_seroprevalence_2022-1,IND
220610_Delhi_MaulanaAzadMedicalCollege_Time1_Male,220610_Delhi_MaulanaAzadMedicalCollege_Time1,"Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in children and adolescents in Delhi, India, from January to October 2021: a repeated cross-sectional analysis.",2022-06-10,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,India,,Delhi,"This was a repeated cross-sectional analysis of 5- to 17-year old participants from 2 SARS-CoV-2 seroprevalence surveys
conducted in Delhi, India",,2021-01-01,2021-01-31,Household and community samples,Male,Children and Youth (0-17 years),5.0,17.0,Sex/Gender,Sex: male,2091,0.509,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Pragya Sharma,Maulana Azad Medical College,Unity-Aligned,https://dx.doi.org/10.24171/j.phrp.2022.0014,2022-07-19,2024-03-25,Verified,sharma_seroprevalence_2022-1,IND
220610_Delhi_MaulanaAzadMedicalCollege_Time1_5-9,220610_Delhi_MaulanaAzadMedicalCollege_Time1,"Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in children and adolescents in Delhi, India, from January to October 2021: a repeated cross-sectional analysis.",2022-06-10,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,India,,Delhi,"This was a repeated cross-sectional analysis of 5- to 17-year old participants from 2 SARS-CoV-2 seroprevalence surveys
conducted in Delhi, India",,2021-01-01,2021-01-31,Household and community samples,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,701,0.484,0.446,0.521,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Pragya Sharma,Maulana Azad Medical College,Unity-Aligned,https://dx.doi.org/10.24171/j.phrp.2022.0014,2022-07-19,2024-03-25,Verified,sharma_seroprevalence_2022-1,IND
220610_Delhi_MaulanaAzadMedicalCollege_Time1_Female,220610_Delhi_MaulanaAzadMedicalCollege_Time1,"Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in children and adolescents in Delhi, India, from January to October 2021: a repeated cross-sectional analysis.",2022-06-10,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,India,,Delhi,"This was a repeated cross-sectional analysis of 5- to 17-year old participants from 2 SARS-CoV-2 seroprevalence surveys
conducted in Delhi, India",,2021-01-01,2021-01-31,Household and community samples,Female,Children and Youth (0-17 years),5.0,17.0,Sex/Gender,Sex: female,2247,0.539,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Pragya Sharma,Maulana Azad Medical College,Unity-Aligned,https://dx.doi.org/10.24171/j.phrp.2022.0014,2022-07-19,2024-03-25,Verified,sharma_seroprevalence_2022-1,IND
220610_Delhi_MaulanaAzadMedicalCollege_Time2_TestAdj,220610_Delhi_MaulanaAzadMedicalCollege_Time2,"Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in children and adolescents in Delhi, India, from January to October 2021: a repeated cross-sectional analysis.",2022-06-10,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,India,,Delhi,"This was a repeated cross-sectional analysis of 5- to 17-year old participants from 2 SARS-CoV-2 seroprevalence surveys
conducted in Delhi, India",,2021-09-15,2021-10-15,Household and community samples,All,Children and Youth (0-17 years),5.0,17.0,Primary Estimate,Test adjusted overall,4211,0.908,0.898,0.917,True,True,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Pragya Sharma,Maulana Azad Medical College,Unity-Aligned,https://dx.doi.org/10.24171/j.phrp.2022.0014,2022-07-19,2024-03-25,Verified,sharma_seroprevalence_2022-1,IND
220610_Delhi_MaulanaAzadMedicalCollege_Time2_10-14,220610_Delhi_MaulanaAzadMedicalCollege_Time2,"Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in children and adolescents in Delhi, India, from January to October 2021: a repeated cross-sectional analysis.",2022-06-10,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,India,,Delhi,"This was a repeated cross-sectional analysis of 5- to 17-year old participants from 2 SARS-CoV-2 seroprevalence surveys
conducted in Delhi, India",,2021-09-15,2021-10-15,Household and community samples,All,Children and Youth (0-17 years),10.0,14.0,Age,10-14,1836,0.828,0.81,0.8440000000000001,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Pragya Sharma,Maulana Azad Medical College,Unity-Aligned,https://dx.doi.org/10.24171/j.phrp.2022.0014,2022-07-19,2024-03-25,Verified,sharma_seroprevalence_2022-1,IND
220610_Delhi_MaulanaAzadMedicalCollege_Time2_Female,220610_Delhi_MaulanaAzadMedicalCollege_Time2,"Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in children and adolescents in Delhi, India, from January to October 2021: a repeated cross-sectional analysis.",2022-06-10,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,India,,Delhi,"This was a repeated cross-sectional analysis of 5- to 17-year old participants from 2 SARS-CoV-2 seroprevalence surveys
conducted in Delhi, India",,2021-09-15,2021-10-15,Household and community samples,Female,Children and Youth (0-17 years),5.0,17.0,Sex/Gender,Sex: female,2046,0.821,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Pragya Sharma,Maulana Azad Medical College,Unity-Aligned,https://dx.doi.org/10.24171/j.phrp.2022.0014,2022-07-19,2024-03-25,Verified,sharma_seroprevalence_2022-1,IND
220610_Delhi_MaulanaAzadMedicalCollege_Time2_Male,220610_Delhi_MaulanaAzadMedicalCollege_Time2,"Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in children and adolescents in Delhi, India, from January to October 2021: a repeated cross-sectional analysis.",2022-06-10,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,India,,Delhi,"This was a repeated cross-sectional analysis of 5- to 17-year old participants from 2 SARS-CoV-2 seroprevalence surveys
conducted in Delhi, India",,2021-09-15,2021-10-15,Household and community samples,Male,Children and Youth (0-17 years),5.0,17.0,Sex/Gender,Sex: male,2165,0.8150000000000001,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Pragya Sharma,Maulana Azad Medical College,Unity-Aligned,https://dx.doi.org/10.24171/j.phrp.2022.0014,2022-07-19,2024-03-25,Verified,sharma_seroprevalence_2022-1,IND
220610_Delhi_MaulanaAzadMedicalCollege_Time2_15-17,220610_Delhi_MaulanaAzadMedicalCollege_Time2,"Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in children and adolescents in Delhi, India, from January to October 2021: a repeated cross-sectional analysis.",2022-06-10,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,India,,Delhi,"This was a repeated cross-sectional analysis of 5- to 17-year old participants from 2 SARS-CoV-2 seroprevalence surveys
conducted in Delhi, India",,2021-09-15,2021-10-15,Household and community samples,All,Children and Youth (0-17 years),15.0,17.0,Age,15-17,1552,0.838,0.818,0.855,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Pragya Sharma,Maulana Azad Medical College,Unity-Aligned,https://dx.doi.org/10.24171/j.phrp.2022.0014,2022-07-19,2024-03-25,Verified,sharma_seroprevalence_2022-1,IND
220610_Delhi_MaulanaAzadMedicalCollege_Time2_Crude,220610_Delhi_MaulanaAzadMedicalCollege_Time2,"Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in children and adolescents in Delhi, India, from January to October 2021: a repeated cross-sectional analysis.",2022-06-10,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,India,,Delhi,"This was a repeated cross-sectional analysis of 5- to 17-year old participants from 2 SARS-CoV-2 seroprevalence surveys
conducted in Delhi, India",,2021-09-15,2021-10-15,Household and community samples,All,Children and Youth (0-17 years),5.0,17.0,Analysis,Cruse overall,4211,0.818,0.809,0.826,,,,,True,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Pragya Sharma,Maulana Azad Medical College,Unity-Aligned,https://dx.doi.org/10.24171/j.phrp.2022.0014,2022-07-19,2024-03-25,Verified,sharma_seroprevalence_2022-1,IND
220610_Delhi_MaulanaAzadMedicalCollege_Time2_5-9,220610_Delhi_MaulanaAzadMedicalCollege_Time2,"Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in children and adolescents in Delhi, India, from January to October 2021: a repeated cross-sectional analysis.",2022-06-10,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,India,,Delhi,"This was a repeated cross-sectional analysis of 5- to 17-year old participants from 2 SARS-CoV-2 seroprevalence surveys
conducted in Delhi, India",,2021-09-15,2021-10-15,Household and community samples,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,823,0.7590000000000001,0.7290000000000001,0.787,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Pragya Sharma,Maulana Azad Medical College,Unity-Aligned,https://dx.doi.org/10.24171/j.phrp.2022.0014,2022-07-19,2024-03-25,Verified,sharma_seroprevalence_2022-1,IND
220615_Hyderabad_ESICMedicalCollegeAndHospitalSanathNagar_Overall,220615_Hyderabad_ESICMedicalCollegeAndHospitalSanathNagar,"IgG Antibody Prevalence of COVID-19 among Healthcare Workers at a Tertiary Care Facility in Hyderabad, India",2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Hyderabad,"""Health care workers (HCWs) working in ESIC Hospital and Medical College (including various staff working in clinical, non-clinical, administrative, laboratory departments, housekeeping, security guards, etc. ) were invited for serological screening. The screening invitation was posted on all hospital websites and various bulletin boards and was personally communicated to all departmental chiefs.""","""HCWs with active symptoms suggestive of illness, such as fever or cold, and HCWs who could not give consent were excluded from the study.""",2020-08-10,2020-08-25,Health care workers and caregivers,All,Adults (18-64 years),21.0,,Primary Estimate,,875,0.24910000000000002,,,True,,,,True,Convenience,COVID KAVACH (KAWACH) IgG Microlisa (Microwell ELISA),J. Mitra & Co. Pvt. Ltd,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9209999999999999,0.9770000000000001,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Pravin Pissude,ESIC Medical College & Hospital Sanath Nagar,Not Unity-Aligned,https://seronjihou.files.wordpress.com/2022/06/293208.pdf,2022-07-04,2024-03-01,Unverified,pissude_igg_2022,IND
220615_Hyderabad_ESICMedicalCollegeAndHospitalSanathNagar_Age_50+,220615_Hyderabad_ESICMedicalCollegeAndHospitalSanathNagar,"IgG Antibody Prevalence of COVID-19 among Healthcare Workers at a Tertiary Care Facility in Hyderabad, India",2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Hyderabad,"""Health care workers (HCWs) working in ESIC Hospital and Medical College (including various staff working in clinical, non-clinical, administrative, laboratory departments, housekeeping, security guards, etc. ) were invited for serological screening. The screening invitation was posted on all hospital websites and various bulletin boards and was personally communicated to all departmental chiefs.""","""HCWs with active symptoms suggestive of illness, such as fever or cold, and HCWs who could not give consent were excluded from the study.""",2020-08-10,2020-08-25,Health care workers and caregivers,All,Adults (18-64 years),51.0,,Age,Age group: > 50,79,0.3038,,,,,,,,Convenience,COVID KAVACH (KAWACH) IgG Microlisa (Microwell ELISA),J. Mitra & Co. Pvt. Ltd,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9209999999999999,0.9770000000000001,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Pravin Pissude,ESIC Medical College & Hospital Sanath Nagar,Not Unity-Aligned,https://seronjihou.files.wordpress.com/2022/06/293208.pdf,2022-07-06,2024-03-01,Unverified,pissude_igg_2022,IND
220615_Hyderabad_ESICMedicalCollegeAndHospitalSanathNagar_Age_41-50,220615_Hyderabad_ESICMedicalCollegeAndHospitalSanathNagar,"IgG Antibody Prevalence of COVID-19 among Healthcare Workers at a Tertiary Care Facility in Hyderabad, India",2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Hyderabad,"""Health care workers (HCWs) working in ESIC Hospital and Medical College (including various staff working in clinical, non-clinical, administrative, laboratory departments, housekeeping, security guards, etc. ) were invited for serological screening. The screening invitation was posted on all hospital websites and various bulletin boards and was personally communicated to all departmental chiefs.""","""HCWs with active symptoms suggestive of illness, such as fever or cold, and HCWs who could not give consent were excluded from the study.""",2020-08-10,2020-08-25,Health care workers and caregivers,All,Adults (18-64 years),41.0,50.0,Age,Age group: 41-50,158,0.2785,,,,,,,,Convenience,COVID KAVACH (KAWACH) IgG Microlisa (Microwell ELISA),J. Mitra & Co. Pvt. Ltd,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9209999999999999,0.9770000000000001,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Pravin Pissude,ESIC Medical College & Hospital Sanath Nagar,Not Unity-Aligned,https://seronjihou.files.wordpress.com/2022/06/293208.pdf,2022-07-06,2024-03-01,Unverified,pissude_igg_2022,IND
220615_Hyderabad_ESICMedicalCollegeAndHospitalSanathNagar_Age_21-30,220615_Hyderabad_ESICMedicalCollegeAndHospitalSanathNagar,"IgG Antibody Prevalence of COVID-19 among Healthcare Workers at a Tertiary Care Facility in Hyderabad, India",2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Hyderabad,"""Health care workers (HCWs) working in ESIC Hospital and Medical College (including various staff working in clinical, non-clinical, administrative, laboratory departments, housekeeping, security guards, etc. ) were invited for serological screening. The screening invitation was posted on all hospital websites and various bulletin boards and was personally communicated to all departmental chiefs.""","""HCWs with active symptoms suggestive of illness, such as fever or cold, and HCWs who could not give consent were excluded from the study.""",2020-08-10,2020-08-25,Health care workers and caregivers,All,Adults (18-64 years),21.0,30.0,Age,Age group: 21-30,204,0.2353,,,,,,,,Convenience,COVID KAVACH (KAWACH) IgG Microlisa (Microwell ELISA),J. Mitra & Co. Pvt. Ltd,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9209999999999999,0.9770000000000001,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Pravin Pissude,ESIC Medical College & Hospital Sanath Nagar,Not Unity-Aligned,https://seronjihou.files.wordpress.com/2022/06/293208.pdf,2022-07-06,2024-03-01,Unverified,pissude_igg_2022,IND
220615_Hyderabad_ESICMedicalCollegeAndHospitalSanathNagar_Age_31-40,220615_Hyderabad_ESICMedicalCollegeAndHospitalSanathNagar,"IgG Antibody Prevalence of COVID-19 among Healthcare Workers at a Tertiary Care Facility in Hyderabad, India",2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Hyderabad,"""Health care workers (HCWs) working in ESIC Hospital and Medical College (including various staff working in clinical, non-clinical, administrative, laboratory departments, housekeeping, security guards, etc. ) were invited for serological screening. The screening invitation was posted on all hospital websites and various bulletin boards and was personally communicated to all departmental chiefs.""","""HCWs with active symptoms suggestive of illness, such as fever or cold, and HCWs who could not give consent were excluded from the study.""",2020-08-10,2020-08-25,Health care workers and caregivers,All,Adults (18-64 years),31.0,40.0,Age,Age group: 31-40,434,0.23500000000000001,,,,,,,,Convenience,COVID KAVACH (KAWACH) IgG Microlisa (Microwell ELISA),J. Mitra & Co. Pvt. Ltd,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9209999999999999,0.9770000000000001,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Pravin Pissude,ESIC Medical College & Hospital Sanath Nagar,Not Unity-Aligned,https://seronjihou.files.wordpress.com/2022/06/293208.pdf,2022-07-06,2024-03-01,Unverified,pissude_igg_2022,IND
220615_SouthEastAsia_MaulanaAzadMedicalCollege,220615_SouthEastAsia_MaulanaAzadMedicalCollege,SARS-CoV-2 Immunoglobulin g (IgG) kinetics in healthcare workers and their close contacts reduced risk of re-infection,2022-06-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,India,,New Delhi,The second cohort included a total of 166 undiagnosed individuals with history of contact with COVID-19 positive patients,People with a previous diagnosis of COVID-19,2020-06-22,2020-12-22,Contacts of COVID patients,All,Multiple groups,,,Primary Estimate,,166,0.373,,,True,,,,True,Convenience,ErbaLisa® COVID-19 IgG semi quantitative kit,Erba Manneim,ELISA,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Govind Mawar,Maulana Azad Medical College,Not Unity-Aligned,,2021-06-07,2024-03-01,Unverified,govind_sars_cov_2_2022,IND
220615_India_AIIMS_Overall,220615_India_AIIMS,Sero-epidemiological survey of SARS-Cov2 in urban slums of a capital city: A cross- sectional study.,2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Bihar,"Patna
",Individuals aged 18–60 years who were willing to participate and give written consent living at selected 10 slum sites in Patna,Any contraindication to venepuncture,2021-01-20,2021-02-20,Persons living in slums,All,Adults (18-64 years),18.0,60.0,Primary Estimate,,645,0.315,0.27899999999999997,0.35100000000000003,True,,True,True,True,Simplified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Santosh K. Nirala,All India Institute of Medical Science,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2127_21,2022-09-26,2024-03-31,Unverified,nirala_sero-epidemiological_2022,IND
220615_India_AIIMS_Age31to44,220615_India_AIIMS,Sero-epidemiological survey of SARS-Cov2 in urban slums of a capital city: A cross- sectional study.,2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Bihar,"Patna
",Individuals aged 18–60 years who were willing to participate and give written consent living at selected 10 slum sites in Patna,Any contraindication to venepuncture,2021-01-20,2021-02-20,Persons living in slums,All,Adults (18-64 years),18.0,60.0,Age,,236,0.355,0.29100000000000004,0.423,,,True,True,,Simplified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Santosh K. Nirala,All India Institute of Medical Science,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2127_21,2022-09-26,2024-03-31,Unverified,nirala_sero-epidemiological_2022,IND
220615_India_AIIMS_Age45to60,220615_India_AIIMS,Sero-epidemiological survey of SARS-Cov2 in urban slums of a capital city: A cross- sectional study.,2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Bihar,"Patna
",Individuals aged 18–60 years who were willing to participate and give written consent living at selected 10 slum sites in Patna,Any contraindication to venepuncture,2021-01-20,2021-02-20,Persons living in slums,All,Adults (18-64 years),18.0,60.0,Age,,246,0.231,0.17800000000000002,0.294,,,True,True,,Simplified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Santosh K. Nirala,All India Institute of Medical Science,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2127_21,2022-09-26,2024-03-31,Unverified,nirala_sero-epidemiological_2022,IND
220615_India_AIIMS_Age18to30,220615_India_AIIMS,Sero-epidemiological survey of SARS-Cov2 in urban slums of a capital city: A cross- sectional study.,2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Bihar,"Patna
",Individuals aged 18–60 years who were willing to participate and give written consent living at selected 10 slum sites in Patna,Any contraindication to venepuncture,2021-01-20,2021-02-20,Persons living in slums,All,Adults (18-64 years),18.0,60.0,Age,,163,0.414,0.34700000000000003,0.483,,,True,True,,Simplified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Santosh K. Nirala,All India Institute of Medical Science,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2127_21,2022-09-26,2024-03-31,Unverified,nirala_sero-epidemiological_2022,IND
220615_India_AIIMS_Female,220615_India_AIIMS,Sero-epidemiological survey of SARS-Cov2 in urban slums of a capital city: A cross- sectional study.,2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Bihar,"Patna
",Individuals aged 18–60 years who were willing to participate and give written consent living at selected 10 slum sites in Patna,Any contraindication to venepuncture,2021-01-20,2021-02-20,Persons living in slums,Female,Adults (18-64 years),18.0,60.0,Sex/Gender,,286,0.321,0.259,0.387,,,True,True,,Simplified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Santosh K. Nirala,All India Institute of Medical Science,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2127_21,2022-09-26,2024-03-31,Unverified,nirala_sero-epidemiological_2022,IND
220615_India_AIIMS_Male,220615_India_AIIMS,Sero-epidemiological survey of SARS-Cov2 in urban slums of a capital city: A cross- sectional study.,2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Bihar,"Patna
",Individuals aged 18–60 years who were willing to participate and give written consent living at selected 10 slum sites in Patna,Any contraindication to venepuncture,2021-01-20,2021-02-20,Persons living in slums,Male,Adults (18-64 years),18.0,60.0,Sex/Gender,,359,0.679,0.612,0.741,,,True,True,,Simplified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Santosh K. Nirala,All India Institute of Medical Science,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2127_21,2022-09-26,2024-03-31,Unverified,nirala_sero-epidemiological_2022,IND
220615_India_AllIndiaInstituteOfMedicalSciences_Adj,220615_India_AllIndiaInstituteOfMedicalSciences,Serological prevalence of SARS-CoV-2 antibody among children and young age group (between 2 and 17 years) in India: An interim result from a large multicentric population-based seroepidemiological study.,2022-06-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,"In each site, both urban and rural area populations have been planned to be included. From the first family, the recruitment process started and all family members of ≥2 years of age were included.",,2021-03-15,2021-06-10,Household and community samples,All,Multiple groups,2.0,,Primary Estimate,test-adjusted estimate,4509,0.659,0.6459999999999999,0.674,True,True,,,,Stratified non-probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,No,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2274_21,2022-09-26,2023-08-15,Unverified,misra_serological_2022,IND
220615_India_AllIndiaInstituteOfMedicalSciences_AgeOver18,220615_India_AllIndiaInstituteOfMedicalSciences,Serological prevalence of SARS-CoV-2 antibody among children and young age group (between 2 and 17 years) in India: An interim result from a large multicentric population-based seroepidemiological study.,2022-06-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,"In each site, both urban and rural area populations have been planned to be included. From the first family, the recruitment process started and all family members of ≥2 years of age were included.",,2021-03-15,2021-06-10,Household and community samples,All,Multiple groups,18.0,,Age,age: >= 18,3809,0.6729999999999999,0.658,0.688,,True,,,,Stratified non-probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,No,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2274_21,2022-09-26,2023-08-15,Unverified,misra_serological_2022,IND
220615_India_AllIndiaInstituteOfMedicalSciences_GorakhpurRural,220615_India_AllIndiaInstituteOfMedicalSciences,Serological prevalence of SARS-CoV-2 antibody among children and young age group (between 2 and 17 years) in India: An interim result from a large multicentric population-based seroepidemiological study.,2022-06-15,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Uttar Pradesh,Gorakhpur,"In each site, both urban and rural area populations have been planned to be included. From the first family, the recruitment process started and all family members of ≥2 years of age were included.",,2021-03-26,2021-06-01,Household and community samples,All,Multiple groups,2.0,,Geographical area,Gorakhpur Rural,448,0.8790000000000001,0.846,0.908,,,,,,Stratified non-probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,No,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2274_21,2022-09-26,2024-03-01,Unverified,misra_serological_2022,IND
220615_India_AllIndiaInstituteOfMedicalSciences_AgeBelow18_Female,220615_India_AllIndiaInstituteOfMedicalSciences,Serological prevalence of SARS-CoV-2 antibody among children and young age group (between 2 and 17 years) in India: An interim result from a large multicentric population-based seroepidemiological study.,2022-06-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,"In each site, both urban and rural area populations have been planned to be included. From the first family, the recruitment process started and all family members of ≥2 years of age were included.",,2021-03-15,2021-06-10,Household and community samples,Female,Multiple groups,2.0,,Sex/Gender,"age: 2-17, female",338,0.561,0.508,0.613,,True,,,,Stratified non-probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,No,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2274_21,2022-09-26,2023-08-15,Unverified,misra_serological_2022,IND
220615_India_AllIndiaInstituteOfMedicalSciences_BhubaneswarRural,220615_India_AllIndiaInstituteOfMedicalSciences,Serological prevalence of SARS-CoV-2 antibody among children and young age group (between 2 and 17 years) in India: An interim result from a large multicentric population-based seroepidemiological study.,2022-06-15,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Odisha,Bhubaneswar,"In each site, both urban and rural area populations have been planned to be included. From the first family, the recruitment process started and all family members of ≥2 years of age were included.",,2021-03-22,2021-05-27,Household and community samples,All,Multiple groups,2.0,,Geographical area,Bhubaneswar Rural,1000,0.526,0.494,0.557,,,,,,Stratified non-probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,No,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2274_21,2022-09-26,2024-03-01,Unverified,misra_serological_2022,IND
220615_India_AllIndiaInstituteOfMedicalSciences_AgartalaRural,220615_India_AllIndiaInstituteOfMedicalSciences,Serological prevalence of SARS-CoV-2 antibody among children and young age group (between 2 and 17 years) in India: An interim result from a large multicentric population-based seroepidemiological study.,2022-06-15,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Tripura,Agartala,"In each site, both urban and rural area populations have been planned to be included. From the first family, the recruitment process started and all family members of ≥2 years of age were included.",,2021-04-22,2021-06-10,Household and community samples,All,Multiple groups,2.0,,Geographical area,Agartala Rural,1001,0.519,0.488,0.551,,,,,,Stratified non-probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,No,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2274_21,2022-09-26,2024-03-01,Unverified,misra_serological_2022,IND
220615_India_AllIndiaInstituteOfMedicalSciences_DelhiRural,220615_India_AllIndiaInstituteOfMedicalSciences,Serological prevalence of SARS-CoV-2 antibody among children and young age group (between 2 and 17 years) in India: An interim result from a large multicentric population-based seroepidemiological study.,2022-06-15,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Delhi,Delhi,"In each site, both urban and rural area populations have been planned to be included. From the first family, the recruitment process started and all family members of ≥2 years of age were included.",,2021-04-12,2021-05-22,Household and community samples,All,Multiple groups,2.0,,Geographical area,Delhi Rural,1059,0.593,0.56,0.623,,,,,,Stratified non-probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,No,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2274_21,2022-09-26,2024-03-01,Unverified,misra_serological_2022,IND
220615_India_AllIndiaInstituteOfMedicalSciences_AgeBelow18_Male,220615_India_AllIndiaInstituteOfMedicalSciences,Serological prevalence of SARS-CoV-2 antibody among children and young age group (between 2 and 17 years) in India: An interim result from a large multicentric population-based seroepidemiological study.,2022-06-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,"In each site, both urban and rural area populations have been planned to be included. From the first family, the recruitment process started and all family members of ≥2 years of age were included.",,2021-03-15,2021-06-10,Household and community samples,Male,Multiple groups,2.0,,Sex/Gender,"age: 2-17, male",362,0.621,0.5670000000000001,0.6729999999999999,,True,,,,Stratified non-probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,No,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2274_21,2022-09-26,2023-08-15,Unverified,misra_serological_2022,IND
220615_India_AllIndiaInstituteOfMedicalSciences_UnAdj,220615_India_AllIndiaInstituteOfMedicalSciences,Serological prevalence of SARS-CoV-2 antibody among children and young age group (between 2 and 17 years) in India: An interim result from a large multicentric population-based seroepidemiological study.,2022-06-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,"In each site, both urban and rural area populations have been planned to be included. From the first family, the recruitment process started and all family members of ≥2 years of age were included.",,2021-03-15,2021-06-10,Household and community samples,All,Multiple groups,2.0,,Analysis,crude estimate,4509,0.623,0.609,0.638,,,,,True,Stratified non-probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,No,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2274_21,2022-09-26,2024-03-01,Unverified,misra_serological_2022,IND
220615_India_AllIndiaInstituteOfMedicalSciences_DelhiUrban,220615_India_AllIndiaInstituteOfMedicalSciences,Serological prevalence of SARS-CoV-2 antibody among children and young age group (between 2 and 17 years) in India: An interim result from a large multicentric population-based seroepidemiological study.,2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Delhi,Delhi,"In each site, both urban and rural area populations have been planned to be included. From the first family, the recruitment process started and all family members of ≥2 years of age were included.",,2021-03-15,2021-03-31,Household and community samples,All,Multiple groups,2.0,,Geographical area,Delhi Urban,1101,0.747,0.7190000000000001,0.774,,,,,,Stratified non-probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,No,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2274_21,2022-09-26,2024-03-01,Unverified,misra_serological_2022,IND
220615_India_AllIndiaInstituteOfMedicalSciences_AgeBelow18,220615_India_AllIndiaInstituteOfMedicalSciences,Serological prevalence of SARS-CoV-2 antibody among children and young age group (between 2 and 17 years) in India: An interim result from a large multicentric population-based seroepidemiological study.,2022-06-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,India,,,"In each site, both urban and rural area populations have been planned to be included. From the first family, the recruitment process started and all family members of ≥2 years of age were included.",,2021-03-15,2021-06-10,Household and community samples,All,Children and Youth (0-17 years),2.0,17.0,Age,age: 2-17,700,0.59,0.554,0.626,,True,,,,Stratified non-probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,No,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2274_21,2022-09-26,2023-08-15,Unverified,misra_serological_2022,IND
220630_Kerala_BelieversChurchMedicalCollege,220630_Kerala_BelieversChurchMedicalCollege,A cross-sectional study on the seroprevalence of the SARS-CoV-2 IgG antibody in patients with cancer from central Kerala,2022-06-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Kerala,Kottayam,"""We included patients over 18 years old who had been diagnosed with cancer and had attended the Oncology Outpatient Department.""","""We excluded patients who had been vaccinated against COVID‐19, those with hematological malignancies, and those with co‐existing auto‐immune diseases.""",2020-12-15,2021-06-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,,Primary Estimate,,100,0.11,0.048,0.171,True,,,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,1.0,1.0,['High'],,No,No,Yes,,Yes,Yes,Yes,,George Geomcy,Believers Church Medical College,Not Unity-Aligned,https://journals.lww.com/crst/Fulltext/2022/05020/A_cross_sectional_study_on_the_seroprevalence_of.4.aspx,2023-06-26,2024-03-01,Unverified,georgeCrosssectionalStudySeroprevalence2022,IND
220630_Maharashtra_YashwantraoChavanMemorialHospital,220630_Maharashtra_YashwantraoChavanMemorialHospital,"Population-based repeat cross-sectional seroprevalence survey of SARS-CoV-2 IgG antibodies in Pimpri Chinchwad Municipal Corporation Area, Maharashtra, India.",2022-06-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Pimpri Chinchwad Municipal Corporation Area,""" The study participants were from the general population aged 6 years and above of PCMC area. It was carried out between 16 June 2021 and 26 June 2021.""

""All individuals identified for recruitment into the investigation and those aged above 6 years were included in the study""","""Also, those who refused to participate and had contraindication
for venepuncture were excluded from the study. """,2021-06-16,2021-06-26,Household and community samples,All,Multiple groups,6.0,,Primary Estimate,,10082,0.8140000000000001,,,True,,,,True,Stratified non-probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,,0.927,0.9990000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Mukesh Bawa,Yashwantrao Chavan Memorial Hospital,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_1869_21,2022-09-30,2024-03-31,Verified,bawa_population-based_2022,IND
220630_Maharashtra_YashwantraoChavanMemorialHospital_Age_45-60,220630_Maharashtra_YashwantraoChavanMemorialHospital,"Population-based repeat cross-sectional seroprevalence survey of SARS-CoV-2 IgG antibodies in Pimpri Chinchwad Municipal Corporation Area, Maharashtra, India.",2022-06-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Pimpri Chinchwad Municipal Corporation Area,""" The study participants were from the general population aged 6 years and above of PCMC area. It was carried out between 16 June 2021 and 26 June 2021.""

""All individuals identified for recruitment into the investigation and those aged above 6 years were included in the study""","""Also, those who refused to participate and had contraindication
for venepuncture were excluded from the study. """,2021-06-16,2021-06-26,Household and community samples,All,Adults (18-64 years),45.0,60.0,Age,45-60,1987,0.9109999999999999,,,,,,,,Stratified non-probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,,0.927,0.9990000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Mukesh Bawa,Yashwantrao Chavan Memorial Hospital,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_1869_21,2022-09-30,2024-03-31,Verified,bawa_population-based_2022,IND
220630_Maharashtra_YashwantraoChavanMemorialHospital_Age_>60,220630_Maharashtra_YashwantraoChavanMemorialHospital,"Population-based repeat cross-sectional seroprevalence survey of SARS-CoV-2 IgG antibodies in Pimpri Chinchwad Municipal Corporation Area, Maharashtra, India.",2022-06-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Pimpri Chinchwad Municipal Corporation Area,""" The study participants were from the general population aged 6 years and above of PCMC area. It was carried out between 16 June 2021 and 26 June 2021.""

""All individuals identified for recruitment into the investigation and those aged above 6 years were included in the study""","""Also, those who refused to participate and had contraindication
for venepuncture were excluded from the study. """,2021-06-16,2021-06-26,Household and community samples,All,Multiple groups,61.0,,Age,>60,1239,0.905,,,,,,,,Stratified non-probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,,0.927,0.9990000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Mukesh Bawa,Yashwantrao Chavan Memorial Hospital,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_1869_21,2022-09-30,2024-03-31,Verified,bawa_population-based_2022,IND
220630_Maharashtra_YashwantraoChavanMemorialHospital_Age_19-44,220630_Maharashtra_YashwantraoChavanMemorialHospital,"Population-based repeat cross-sectional seroprevalence survey of SARS-CoV-2 IgG antibodies in Pimpri Chinchwad Municipal Corporation Area, Maharashtra, India.",2022-06-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Pimpri Chinchwad Municipal Corporation Area,""" The study participants were from the general population aged 6 years and above of PCMC area. It was carried out between 16 June 2021 and 26 June 2021.""

""All individuals identified for recruitment into the investigation and those aged above 6 years were included in the study""","""Also, those who refused to participate and had contraindication
for venepuncture were excluded from the study. """,2021-06-16,2021-06-26,Household and community samples,All,Adults (18-64 years),19.0,44.0,Age,19-44,5226,0.789,,,,,,,,Stratified non-probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,,0.927,0.9990000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Mukesh Bawa,Yashwantrao Chavan Memorial Hospital,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_1869_21,2022-09-30,2024-03-31,Verified,bawa_population-based_2022,IND
220630_Maharashtra_YashwantraoChavanMemorialHospital_Age_6-18,220630_Maharashtra_YashwantraoChavanMemorialHospital,"Population-based repeat cross-sectional seroprevalence survey of SARS-CoV-2 IgG antibodies in Pimpri Chinchwad Municipal Corporation Area, Maharashtra, India.",2022-06-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Pimpri Chinchwad Municipal Corporation Area,""" The study participants were from the general population aged 6 years and above of PCMC area. It was carried out between 16 June 2021 and 26 June 2021.""

""All individuals identified for recruitment into the investigation and those aged above 6 years were included in the study""","""Also, those who refused to participate and had contraindication
for venepuncture were excluded from the study. """,2021-06-16,2021-06-26,Household and community samples,All,Children and Youth (0-17 years),6.0,18.0,Age,6-18,1630,0.706,,,,,,,,Stratified non-probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,,0.927,0.9990000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Mukesh Bawa,Yashwantrao Chavan Memorial Hospital,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_1869_21,2022-09-30,2024-03-31,Verified,bawa_population-based_2022,IND
2022_Srinagar_GovernmentMedicalCollegeSrinagar_PopAdj_Overall,2022_Srinagar_GovernmentMedicalCollegeSrinagar,"SARS-CoV-2 specific IgG antibodies among participants presenting to a voluntary testing facility in Srinagar, Kashmir.",2022-06-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,India,Jammu and Kashmir,,"""Study participants were adults >18 years of age who had visited department of community medicine, GMC, Srinagar.""",,2020-09-03,2021-01-21,Multiple populations,All,Multiple groups,18.0,,Primary Estimate,Age-adjusted,2107,0.52,,,True,,True,,True,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.996,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Rafiya Kousar,Government Medical College Srinagar,Not Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2012_21,2022-09-27,2024-03-01,Unverified,kousar_sars-cov-2_2022,IND
2022_Srinagar_GovernmentMedicalCollegeSrinagar_UnAdj_AgeAbove60,2022_Srinagar_GovernmentMedicalCollegeSrinagar,"SARS-CoV-2 specific IgG antibodies among participants presenting to a voluntary testing facility in Srinagar, Kashmir.",2022-06-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,India,Jammu and Kashmir,,"""Study participants were adults >18 years of age who had visited department of community medicine, GMC, Srinagar.""",,2020-09-03,2021-01-21,Multiple populations,All,Seniors (65+ years),60.0,,Age,Age group: ≥60,163,0.6933,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.996,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Rafiya Kousar,Government Medical College Srinagar,Not Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2012_21,2022-09-27,2024-03-01,Unverified,kousar_sars-cov-2_2022,IND
2022_Srinagar_GovernmentMedicalCollegeSrinagar_UnAdj_Age20‑39,2022_Srinagar_GovernmentMedicalCollegeSrinagar,"SARS-CoV-2 specific IgG antibodies among participants presenting to a voluntary testing facility in Srinagar, Kashmir.",2022-06-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,India,Jammu and Kashmir,,"""Study participants were adults >18 years of age who had visited department of community medicine, GMC, Srinagar.""",,2020-09-03,2021-01-21,Multiple populations,All,Adults (18-64 years),20.0,39.0,Age,Age group: 20‑39,1115,0.4278,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.996,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Rafiya Kousar,Government Medical College Srinagar,Not Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2012_21,2022-09-27,2024-03-01,Unverified,kousar_sars-cov-2_2022,IND
2022_Srinagar_GovernmentMedicalCollegeSrinagar_UnAdj_AgeBelow20,2022_Srinagar_GovernmentMedicalCollegeSrinagar,"SARS-CoV-2 specific IgG antibodies among participants presenting to a voluntary testing facility in Srinagar, Kashmir.",2022-06-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,India,Jammu and Kashmir,,"""Study participants were adults >18 years of age who had visited department of community medicine, GMC, Srinagar.""",,2020-09-03,2021-01-21,Multiple populations,All,Adults (18-64 years),18.0,19.0,Age,Age group: <20,87,0.6207,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.996,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Rafiya Kousar,Government Medical College Srinagar,Not Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2012_21,2022-09-27,2024-03-01,Unverified,kousar_sars-cov-2_2022,IND
2022_Srinagar_GovernmentMedicalCollegeSrinagar_UnAdj_Age40‑59,2022_Srinagar_GovernmentMedicalCollegeSrinagar,"SARS-CoV-2 specific IgG antibodies among participants presenting to a voluntary testing facility in Srinagar, Kashmir.",2022-06-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,India,Jammu and Kashmir,,"""Study participants were adults >18 years of age who had visited department of community medicine, GMC, Srinagar.""",,2020-09-03,2021-01-21,Multiple populations,All,Adults (18-64 years),40.0,59.0,Age,Age group: 40‑59,742,0.5216,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.996,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Rafiya Kousar,Government Medical College Srinagar,Not Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2012_21,2022-09-27,2024-03-01,Unverified,kousar_sars-cov-2_2022,IND
220705_Jammu_GovernmentMedicalCollege_TestAdj_Overall,220705_Jammu_GovernmentMedicalCollege,"Seroprevalence of anti SARS-CoV-2 IgG antibodies among adults in Jammu district, India: A community-based study",2022-07-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Jammu and Kashmir,,"""There are 10 health blocks in district Jammu"". ""These health blocks include both rural and urban population"".  ""The present cross-sectional serosurvey was conducted among adults >18 yr of age, on September 30 and October 1, 2020 in all the health blocks"".",,2020-09-30,2020-10-01,Household and community samples,All,Multiple groups,18.0,98.0,Primary Estimate,Overall test adjusted,2000,0.08800000000000001,0.08779999999999999,0.0882,True,True,,,,Stratified probability,ICMR-NIV Anti-SARS CoV-2 Human IgG ELISA COVID KAVACH – MERILISA,Meril Diagnostics (Meril Life),ELISA,Serum,IgG,,Validated by manufacturers,0.9329999999999999,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Dinesh Kumar,Government Medical College,Unity-Aligned,https://dx.doi.org/10.4103/ijmr.IJMR_4489_20,2022-07-12,2024-02-12,Verified,kumar_seroprevalence_2022-1,IND
220705_Jammu_GovernmentMedicalCollege_UnAdj_Block_Sohanjana,220705_Jammu_GovernmentMedicalCollege,"Seroprevalence of anti SARS-CoV-2 IgG antibodies among adults in Jammu district, India: A community-based study",2022-07-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Jammu and Kashmir,Sohanjana,"""There are 10 health blocks in district Jammu"". ""These health blocks include both rural and urban population"".  ""The present cross-sectional serosurvey was conducted among adults >18 yr of age, on September 30 and October 1, 2020 in all the health blocks"".",,2020-09-30,2020-10-01,Household and community samples,All,Multiple groups,18.0,98.0,Geographical area,Health block: Sohanjana,199,0.0402,,,,,,,,Stratified probability,ICMR-NIV Anti-SARS CoV-2 Human IgG ELISA COVID KAVACH – MERILISA,Meril Diagnostics (Meril Life),ELISA,Serum,IgG,,Validated by manufacturers,0.9329999999999999,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Dinesh Kumar,Government Medical College,Unity-Aligned,https://dx.doi.org/10.4103/ijmr.IJMR_4489_20,2022-07-12,2024-03-01,Verified,kumar_seroprevalence_2022-1,IND
220705_Jammu_GovernmentMedicalCollege_UnAdj_Sex_Male,220705_Jammu_GovernmentMedicalCollege,"Seroprevalence of anti SARS-CoV-2 IgG antibodies among adults in Jammu district, India: A community-based study",2022-07-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Jammu and Kashmir,,"""There are 10 health blocks in district Jammu"". ""These health blocks include both rural and urban population"".  ""The present cross-sectional serosurvey was conducted among adults >18 yr of age, on September 30 and October 1, 2020 in all the health blocks"".",,2020-09-30,2020-10-01,Household and community samples,Male,Multiple groups,18.0,98.0,Sex/Gender,,1271,0.0897,,,,,,,,Stratified probability,ICMR-NIV Anti-SARS CoV-2 Human IgG ELISA COVID KAVACH – MERILISA,Meril Diagnostics (Meril Life),ELISA,Serum,IgG,,Validated by manufacturers,0.9329999999999999,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Dinesh Kumar,Government Medical College,Unity-Aligned,https://dx.doi.org/10.4103/ijmr.IJMR_4489_20,2022-07-12,2024-03-01,Verified,kumar_seroprevalence_2022-1,IND
220705_Jammu_GovernmentMedicalCollege_UnAdj_Age_51-60,220705_Jammu_GovernmentMedicalCollege,"Seroprevalence of anti SARS-CoV-2 IgG antibodies among adults in Jammu district, India: A community-based study",2022-07-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Jammu and Kashmir,,"""There are 10 health blocks in district Jammu"". ""These health blocks include both rural and urban population"".  ""The present cross-sectional serosurvey was conducted among adults >18 yr of age, on September 30 and October 1, 2020 in all the health blocks"".",,2020-09-30,2020-10-01,Household and community samples,All,Adults (18-64 years),51.0,60.0,Age,age group: 51-60,306,0.0817,,,,,,,,Stratified probability,ICMR-NIV Anti-SARS CoV-2 Human IgG ELISA COVID KAVACH – MERILISA,Meril Diagnostics (Meril Life),ELISA,Serum,IgG,,Validated by manufacturers,0.9329999999999999,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Dinesh Kumar,Government Medical College,Unity-Aligned,https://dx.doi.org/10.4103/ijmr.IJMR_4489_20,2022-07-12,2024-03-01,Verified,kumar_seroprevalence_2022-1,IND
220705_Jammu_GovernmentMedicalCollege_UnAdj_Age_70+,220705_Jammu_GovernmentMedicalCollege,"Seroprevalence of anti SARS-CoV-2 IgG antibodies among adults in Jammu district, India: A community-based study",2022-07-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Jammu and Kashmir,,"""There are 10 health blocks in district Jammu"". ""These health blocks include both rural and urban population"".  ""The present cross-sectional serosurvey was conducted among adults >18 yr of age, on September 30 and October 1, 2020 in all the health blocks"".",,2020-09-30,2020-10-01,Household and community samples,All,Seniors (65+ years),71.0,98.0,Age,age group: > 70,32,0.0625,,,,,,,,Stratified probability,ICMR-NIV Anti-SARS CoV-2 Human IgG ELISA COVID KAVACH – MERILISA,Meril Diagnostics (Meril Life),ELISA,Serum,IgG,,Validated by manufacturers,0.9329999999999999,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Dinesh Kumar,Government Medical College,Unity-Aligned,https://dx.doi.org/10.4103/ijmr.IJMR_4489_20,2022-07-12,2024-03-01,Verified,kumar_seroprevalence_2022-1,IND
220705_Jammu_GovernmentMedicalCollege_UnAdj_Block_Akhnoor,220705_Jammu_GovernmentMedicalCollege,"Seroprevalence of anti SARS-CoV-2 IgG antibodies among adults in Jammu district, India: A community-based study",2022-07-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Jammu and Kashmir,Akhnoor,"""There are 10 health blocks in district Jammu"". ""These health blocks include both rural and urban population"".  ""The present cross-sectional serosurvey was conducted among adults >18 yr of age, on September 30 and October 1, 2020 in all the health blocks"".",,2020-09-30,2020-10-01,Household and community samples,All,Multiple groups,18.0,98.0,Geographical area,Health block: Akhnoor,206,0.0922,,,,,,,,Stratified probability,ICMR-NIV Anti-SARS CoV-2 Human IgG ELISA COVID KAVACH – MERILISA,Meril Diagnostics (Meril Life),ELISA,Serum,IgG,,Validated by manufacturers,0.9329999999999999,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Dinesh Kumar,Government Medical College,Unity-Aligned,https://dx.doi.org/10.4103/ijmr.IJMR_4489_20,2022-07-12,2024-03-01,Verified,kumar_seroprevalence_2022-1,IND
220705_Jammu_GovernmentMedicalCollege_UnAdj_Block_Bishnah,220705_Jammu_GovernmentMedicalCollege,"Seroprevalence of anti SARS-CoV-2 IgG antibodies among adults in Jammu district, India: A community-based study",2022-07-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Jammu and Kashmir,Bishnah,"""There are 10 health blocks in district Jammu"". ""These health blocks include both rural and urban population"".  ""The present cross-sectional serosurvey was conducted among adults >18 yr of age, on September 30 and October 1, 2020 in all the health blocks"".",,2020-09-30,2020-10-01,Household and community samples,All,Multiple groups,18.0,98.0,Geographical area,Health block: Bishnah,197,0.12689999999999999,,,,,,,,Stratified probability,ICMR-NIV Anti-SARS CoV-2 Human IgG ELISA COVID KAVACH – MERILISA,Meril Diagnostics (Meril Life),ELISA,Serum,IgG,,Validated by manufacturers,0.9329999999999999,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Dinesh Kumar,Government Medical College,Unity-Aligned,https://dx.doi.org/10.4103/ijmr.IJMR_4489_20,2022-07-12,2024-03-01,Verified,kumar_seroprevalence_2022-1,IND
220705_Jammu_GovernmentMedicalCollege_UnAdj_Block_Marh,220705_Jammu_GovernmentMedicalCollege,"Seroprevalence of anti SARS-CoV-2 IgG antibodies among adults in Jammu district, India: A community-based study",2022-07-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Jammu and Kashmir,Marh,"""There are 10 health blocks in district Jammu"". ""These health blocks include both rural and urban population"".  ""The present cross-sectional serosurvey was conducted among adults >18 yr of age, on September 30 and October 1, 2020 in all the health blocks"".",,2020-09-30,2020-10-01,Household and community samples,All,Multiple groups,18.0,98.0,Geographical area,Health block: Marh,200,0.12,,,,,,,,Stratified probability,ICMR-NIV Anti-SARS CoV-2 Human IgG ELISA COVID KAVACH – MERILISA,Meril Diagnostics (Meril Life),ELISA,Serum,IgG,,Validated by manufacturers,0.9329999999999999,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Dinesh Kumar,Government Medical College,Unity-Aligned,https://dx.doi.org/10.4103/ijmr.IJMR_4489_20,2022-07-12,2024-03-01,Verified,kumar_seroprevalence_2022-1,IND
220705_Jammu_GovernmentMedicalCollege_UnAdj_Age_18-30,220705_Jammu_GovernmentMedicalCollege,"Seroprevalence of anti SARS-CoV-2 IgG antibodies among adults in Jammu district, India: A community-based study",2022-07-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Jammu and Kashmir,,"""There are 10 health blocks in district Jammu"". ""These health blocks include both rural and urban population"".  ""The present cross-sectional serosurvey was conducted among adults >18 yr of age, on September 30 and October 1, 2020 in all the health blocks"".",,2020-09-30,2020-10-01,Household and community samples,All,Adults (18-64 years),18.0,30.0,Age,age group: 18-30,572,0.0752,,,,,,,,Stratified probability,ICMR-NIV Anti-SARS CoV-2 Human IgG ELISA COVID KAVACH – MERILISA,Meril Diagnostics (Meril Life),ELISA,Serum,IgG,,Validated by manufacturers,0.9329999999999999,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Dinesh Kumar,Government Medical College,Unity-Aligned,https://dx.doi.org/10.4103/ijmr.IJMR_4489_20,2022-07-12,2024-03-01,Verified,kumar_seroprevalence_2022-1,IND
220705_Jammu_GovernmentMedicalCollege_UnAdj_Block_ChaukiChaura,220705_Jammu_GovernmentMedicalCollege,"Seroprevalence of anti SARS-CoV-2 IgG antibodies among adults in Jammu district, India: A community-based study",2022-07-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Jammu and Kashmir,Chauki Chaura,"""There are 10 health blocks in district Jammu"". ""These health blocks include both rural and urban population"".  ""The present cross-sectional serosurvey was conducted among adults >18 yr of age, on September 30 and October 1, 2020 in all the health blocks"".",,2020-09-30,2020-10-01,Household and community samples,All,Multiple groups,18.0,98.0,Geographical area,Health block: Chauki Chaura,200,0.035,,,,,,,,Stratified probability,ICMR-NIV Anti-SARS CoV-2 Human IgG ELISA COVID KAVACH – MERILISA,Meril Diagnostics (Meril Life),ELISA,Serum,IgG,,Validated by manufacturers,0.9329999999999999,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Dinesh Kumar,Government Medical College,Unity-Aligned,https://dx.doi.org/10.4103/ijmr.IJMR_4489_20,2022-07-12,2024-03-01,Verified,kumar_seroprevalence_2022-1,IND
220705_Jammu_GovernmentMedicalCollege_UnAdj_Age_61-70,220705_Jammu_GovernmentMedicalCollege,"Seroprevalence of anti SARS-CoV-2 IgG antibodies among adults in Jammu district, India: A community-based study",2022-07-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Jammu and Kashmir,,"""There are 10 health blocks in district Jammu"". ""These health blocks include both rural and urban population"".  ""The present cross-sectional serosurvey was conducted among adults >18 yr of age, on September 30 and October 1, 2020 in all the health blocks"".",,2020-09-30,2020-10-01,Household and community samples,All,Seniors (65+ years),61.0,70.0,Age,age group: 61-70,93,0.1075,,,,,,,,Stratified probability,ICMR-NIV Anti-SARS CoV-2 Human IgG ELISA COVID KAVACH – MERILISA,Meril Diagnostics (Meril Life),ELISA,Serum,IgG,,Validated by manufacturers,0.9329999999999999,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Dinesh Kumar,Government Medical College,Unity-Aligned,https://dx.doi.org/10.4103/ijmr.IJMR_4489_20,2022-07-12,2024-03-01,Verified,kumar_seroprevalence_2022-1,IND
220705_Jammu_GovernmentMedicalCollege_UnAdj_Age_41-50,220705_Jammu_GovernmentMedicalCollege,"Seroprevalence of anti SARS-CoV-2 IgG antibodies among adults in Jammu district, India: A community-based study",2022-07-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Jammu and Kashmir,,"""There are 10 health blocks in district Jammu"". ""These health blocks include both rural and urban population"".  ""The present cross-sectional serosurvey was conducted among adults >18 yr of age, on September 30 and October 1, 2020 in all the health blocks"".",,2020-09-30,2020-10-01,Household and community samples,All,Adults (18-64 years),41.0,50.0,Age,age group: 41-50,449,0.1002,,,,,,,,Stratified probability,ICMR-NIV Anti-SARS CoV-2 Human IgG ELISA COVID KAVACH – MERILISA,Meril Diagnostics (Meril Life),ELISA,Serum,IgG,,Validated by manufacturers,0.9329999999999999,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Dinesh Kumar,Government Medical College,Unity-Aligned,https://dx.doi.org/10.4103/ijmr.IJMR_4489_20,2022-07-12,2024-03-01,Verified,kumar_seroprevalence_2022-1,IND
220705_Jammu_GovernmentMedicalCollege_UnAdj_Block_RSPura,220705_Jammu_GovernmentMedicalCollege,"Seroprevalence of anti SARS-CoV-2 IgG antibodies among adults in Jammu district, India: A community-based study",2022-07-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Jammu and Kashmir,RS Pura,"""There are 10 health blocks in district Jammu"". ""These health blocks include both rural and urban population"".  ""The present cross-sectional serosurvey was conducted among adults >18 yr of age, on September 30 and October 1, 2020 in all the health blocks"".",,2020-09-30,2020-10-01,Household and community samples,All,Multiple groups,18.0,98.0,Geographical area,Health block: RS Pura,206,0.07769999999999999,,,,,,,,Stratified probability,ICMR-NIV Anti-SARS CoV-2 Human IgG ELISA COVID KAVACH – MERILISA,Meril Diagnostics (Meril Life),ELISA,Serum,IgG,,Validated by manufacturers,0.9329999999999999,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Dinesh Kumar,Government Medical College,Unity-Aligned,https://dx.doi.org/10.4103/ijmr.IJMR_4489_20,2022-07-12,2024-03-01,Verified,kumar_seroprevalence_2022-1,IND
220705_Jammu_GovernmentMedicalCollege_UnAdj_Overall,220705_Jammu_GovernmentMedicalCollege,"Seroprevalence of anti SARS-CoV-2 IgG antibodies among adults in Jammu district, India: A community-based study",2022-07-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Jammu and Kashmir,,"""There are 10 health blocks in district Jammu"". ""These health blocks include both rural and urban population"".  ""The present cross-sectional serosurvey was conducted among adults >18 yr of age, on September 30 and October 1, 2020 in all the health blocks"".",,2020-09-30,2020-10-01,Household and community samples,All,Multiple groups,18.0,98.0,Analysis,Overall unadjusted,2000,0.08199999999999999,0.0707,0.09480000000000001,,,,,True,Stratified probability,ICMR-NIV Anti-SARS CoV-2 Human IgG ELISA COVID KAVACH – MERILISA,Meril Diagnostics (Meril Life),ELISA,Serum,IgG,,Validated by manufacturers,0.9329999999999999,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Dinesh Kumar,Government Medical College,Unity-Aligned,https://dx.doi.org/10.4103/ijmr.IJMR_4489_20,2022-07-12,2024-03-01,Verified,kumar_seroprevalence_2022-1,IND
220705_Jammu_GovernmentMedicalCollege_UnAdj_Block_Jammu,220705_Jammu_GovernmentMedicalCollege,"Seroprevalence of anti SARS-CoV-2 IgG antibodies among adults in Jammu district, India: A community-based study",2022-07-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Jammu and Kashmir,Jammu,"""There are 10 health blocks in district Jammu"". ""These health blocks include both rural and urban population"".  ""The present cross-sectional serosurvey was conducted among adults >18 yr of age, on September 30 and October 1, 2020 in all the health blocks"".",,2020-09-30,2020-10-01,Household and community samples,All,Multiple groups,18.0,98.0,Geographical area,Health block: Jammu,199,0.07540000000000001,,,,,,,,Stratified probability,ICMR-NIV Anti-SARS CoV-2 Human IgG ELISA COVID KAVACH – MERILISA,Meril Diagnostics (Meril Life),ELISA,Serum,IgG,,Validated by manufacturers,0.9329999999999999,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Dinesh Kumar,Government Medical College,Unity-Aligned,https://dx.doi.org/10.4103/ijmr.IJMR_4489_20,2022-07-12,2024-03-01,Verified,kumar_seroprevalence_2022-1,IND
220705_Jammu_GovernmentMedicalCollege_UnAdj_Block_Kotbalwal,220705_Jammu_GovernmentMedicalCollege,"Seroprevalence of anti SARS-CoV-2 IgG antibodies among adults in Jammu district, India: A community-based study",2022-07-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Jammu and Kashmir,Kotbalwal,"""There are 10 health blocks in district Jammu"". ""These health blocks include both rural and urban population"".  ""The present cross-sectional serosurvey was conducted among adults >18 yr of age, on September 30 and October 1, 2020 in all the health blocks"".",,2020-09-30,2020-10-01,Household and community samples,All,Multiple groups,18.0,98.0,Geographical area,Health block: Kotbalwal,200,0.05,,,,,,,,Stratified probability,ICMR-NIV Anti-SARS CoV-2 Human IgG ELISA COVID KAVACH – MERILISA,Meril Diagnostics (Meril Life),ELISA,Serum,IgG,,Validated by manufacturers,0.9329999999999999,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Dinesh Kumar,Government Medical College,Unity-Aligned,https://dx.doi.org/10.4103/ijmr.IJMR_4489_20,2022-07-12,2024-03-01,Verified,kumar_seroprevalence_2022-1,IND
220705_Jammu_GovernmentMedicalCollege_UnAdj_Block_Pallanwalla,220705_Jammu_GovernmentMedicalCollege,"Seroprevalence of anti SARS-CoV-2 IgG antibodies among adults in Jammu district, India: A community-based study",2022-07-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Jammu and Kashmir,Pallanwalla,"""There are 10 health blocks in district Jammu"". ""These health blocks include both rural and urban population"".  ""The present cross-sectional serosurvey was conducted among adults >18 yr of age, on September 30 and October 1, 2020 in all the health blocks"".",,2020-09-30,2020-10-01,Household and community samples,All,Multiple groups,18.0,98.0,Geographical area,Health block: Pallanwalla,199,0.1558,,,,,,,,Stratified probability,ICMR-NIV Anti-SARS CoV-2 Human IgG ELISA COVID KAVACH – MERILISA,Meril Diagnostics (Meril Life),ELISA,Serum,IgG,,Validated by manufacturers,0.9329999999999999,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Dinesh Kumar,Government Medical College,Unity-Aligned,https://dx.doi.org/10.4103/ijmr.IJMR_4489_20,2022-07-12,2024-03-01,Verified,kumar_seroprevalence_2022-1,IND
220705_Jammu_GovernmentMedicalCollege_UnAdj_Block_Dansal,220705_Jammu_GovernmentMedicalCollege,"Seroprevalence of anti SARS-CoV-2 IgG antibodies among adults in Jammu district, India: A community-based study",2022-07-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Jammu and Kashmir,Dansal,"""There are 10 health blocks in district Jammu"". ""These health blocks include both rural and urban population"".  ""The present cross-sectional serosurvey was conducted among adults >18 yr of age, on September 30 and October 1, 2020 in all the health blocks"".",,2020-09-30,2020-10-01,Household and community samples,All,Multiple groups,18.0,98.0,Geographical area,Health block: Dansal,194,0.0464,,,,,,,,Stratified probability,ICMR-NIV Anti-SARS CoV-2 Human IgG ELISA COVID KAVACH – MERILISA,Meril Diagnostics (Meril Life),ELISA,Serum,IgG,,Validated by manufacturers,0.9329999999999999,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Dinesh Kumar,Government Medical College,Unity-Aligned,https://dx.doi.org/10.4103/ijmr.IJMR_4489_20,2022-07-12,2024-03-01,Verified,kumar_seroprevalence_2022-1,IND
220705_Jammu_GovernmentMedicalCollege_UnAdj_Age_31-40,220705_Jammu_GovernmentMedicalCollege,"Seroprevalence of anti SARS-CoV-2 IgG antibodies among adults in Jammu district, India: A community-based study",2022-07-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Jammu and Kashmir,,"""There are 10 health blocks in district Jammu"". ""These health blocks include both rural and urban population"".  ""The present cross-sectional serosurvey was conducted among adults >18 yr of age, on September 30 and October 1, 2020 in all the health blocks"".",,2020-09-30,2020-10-01,Household and community samples,All,Adults (18-64 years),31.0,40.0,Age,age group: 31-40,545,0.0697,,,,,,,,Stratified probability,ICMR-NIV Anti-SARS CoV-2 Human IgG ELISA COVID KAVACH – MERILISA,Meril Diagnostics (Meril Life),ELISA,Serum,IgG,,Validated by manufacturers,0.9329999999999999,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Dinesh Kumar,Government Medical College,Unity-Aligned,https://dx.doi.org/10.4103/ijmr.IJMR_4489_20,2022-07-12,2024-03-01,Verified,kumar_seroprevalence_2022-1,IND
220705_Jammu_GovernmentMedicalCollege_UnAdj_Sex_Female,220705_Jammu_GovernmentMedicalCollege,"Seroprevalence of anti SARS-CoV-2 IgG antibodies among adults in Jammu district, India: A community-based study",2022-07-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Jammu and Kashmir,,"""There are 10 health blocks in district Jammu"". ""These health blocks include both rural and urban population"".  ""The present cross-sectional serosurvey was conducted among adults >18 yr of age, on September 30 and October 1, 2020 in all the health blocks"".",,2020-09-30,2020-10-01,Household and community samples,Female,Multiple groups,18.0,98.0,Sex/Gender,,729,0.06860000000000001,,,,,,,,Stratified probability,ICMR-NIV Anti-SARS CoV-2 Human IgG ELISA COVID KAVACH – MERILISA,Meril Diagnostics (Meril Life),ELISA,Serum,IgG,,Validated by manufacturers,0.9329999999999999,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Dinesh Kumar,Government Medical College,Unity-Aligned,https://dx.doi.org/10.4103/ijmr.IJMR_4489_20,2022-07-12,2024-03-01,Verified,kumar_seroprevalence_2022-1,IND
220711_India_ArmedForcesMedicalCollege,220711_India_ArmedForcesMedicalCollege,Hydroxychloroquine/Chloroquine Prophylaxis among Health-care Workers: Was it Really Preventive? - Evidence from a Multicentric Cross-sectional Study.,2022-07-11,Journal Article (Peer-Reviewed),National,Prospective cohort,India,,,All HCWs working in the 8 chosen government-designated COVID-19 hospitals were eligible,""" Persons who are on long leave/course or likely to be posted out shortly would be excluded from the study"" (drawn from protocol referenced in the paper and found here: https://www.researchgate.net/publication/348991549_Sero-surveillance_of_SARS-CoV2_infection_among_health-care_workers_A_protocol)",2020-08-21,2020-11-20,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,2224,0.182,,,True,,,,True,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Arun Kumar Yadav,Armed Forces Medical College,Not Unity-Aligned,https://dx.doi.org/10.4103/ijcm.ijcm_684_21,2022-09-10,2022-09-11,Unverified,yadav_hydroxychloroquinechloroquine_2022,IND
220725_TamilNadu_GovernmentofTamilNadu_Round1,220725_TamilNadu_GovernmentofTamilNadu_Round1,"Contribution of infection and vaccination to seroprevalence through two COVID waves in Tamil Nadu, India",2022-07-25,Preprint,Regional,Repeated cross-sectional study,India,Tamil Nadu,,"Individuals residing in Tamil Nadu and ages 18 years and older were
eligible for this study.","The exclusion criteria were refusal to consent and contraindication to
venipuncture.",2020-10-19,2020-11-30,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,,26135,0.324,0.313,0.336,True,,,,True,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,iFlash-SARS-CoV-2 IgM/IgG","Ortho Clinical Diagnostics Inc.,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,No,,Unclear,No,No,,T.S. Selvavinayagam,Government of Tamil Nadu,Not Unity-Aligned,https://dx.doi.org/10.1101/2021.11.14.21265758,2022-09-23,2024-03-01,Unverified,selvavinayagam_contribution_2022,IND
220725_TamilNadu_GovernmentofTamilNadu_Round2,220725_TamilNadu_GovernmentofTamilNadu_Round2,"Contribution of infection and vaccination to seroprevalence through two COVID waves in Tamil Nadu, India",2022-07-25,Preprint,Regional,Repeated cross-sectional study,India,Tamil Nadu,,"Individuals residing in Tamil Nadu and ages 18 years and older were
eligible for this study.","The exclusion criteria were refusal to consent and contraindication to
venipuncture.",2021-04-07,2021-04-30,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,,21992,0.21600000000000003,0.20600000000000002,0.226,True,,,,True,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,iFlash-SARS-CoV-2 IgM/IgG","Ortho Clinical Diagnostics Inc.,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,No,,Unclear,No,No,,T.S. Selvavinayagam,Government of Tamil Nadu,Not Unity-Aligned,https://dx.doi.org/10.1101/2021.11.14.21265758,2022-09-23,2024-03-01,Unverified,selvavinayagam_contribution_2022,IND
220725_TamilNadu_GovernmentofTamilNadu_Round3,220725_TamilNadu_GovernmentofTamilNadu_Round3,"Contribution of infection and vaccination to seroprevalence through two COVID waves in Tamil Nadu, India",2022-07-25,Preprint,Regional,Repeated cross-sectional study,India,Tamil Nadu,,"Individuals residing in Tamil Nadu and ages 18 years and older were
eligible for this study.","The exclusion criteria were refusal to consent and contraindication to
venipuncture.",2021-06-28,2021-07-07,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,,26392,0.6920000000000001,0.682,0.7020000000000001,True,,,,True,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,iFlash-SARS-CoV-2 IgM/IgG","Ortho Clinical Diagnostics Inc.,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,No,,Unclear,No,No,,T.S. Selvavinayagam,Government of Tamil Nadu,Not Unity-Aligned,https://dx.doi.org/10.1101/2021.11.14.21265758,2022-09-23,2024-03-01,Unverified,selvavinayagam_contribution_2022,IND
220725_TamilNadu_GovernmentofTamilNadu_Round4,220725_TamilNadu_GovernmentofTamilNadu_Round4,"Contribution of infection and vaccination to seroprevalence through two COVID waves in Tamil Nadu, India",2022-07-25,Preprint,Regional,Repeated cross-sectional study,India,Tamil Nadu,,"Individuals residing in Tamil Nadu and ages 18 years and older were
eligible for this study.","The exclusion criteria were refusal to consent and contraindication to
venipuncture.",2021-12-27,2022-01-06,Household and community samples,All,Adults (18-64 years),10.0,,Primary Estimate,,32244,0.9059999999999999,0.9009999999999999,0.9109999999999999,True,,,True,True,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,iFlash-SARS-CoV-2 IgM/IgG","Ortho Clinical Diagnostics Inc.,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,No,,Unclear,No,No,,T.S. Selvavinayagam,Government of Tamil Nadu,Not Unity-Aligned,https://dx.doi.org/10.1101/2021.11.14.21265758,2022-09-20,2024-03-01,Unverified,selvavinayagam_contribution_2022,IND
220816_Delhi_AllIndiaInstituteofAyurveda_ControlGroup,220816_Delhi_AllIndiaInstituteofAyurveda_ControlGroup,"AYURAKSHA, a prophylactic Ayurvedic immunity boosting kit reducing positivity percentage of IgG COVID-19 among frontline Indian Delhi police personnel: A non-randomized controlled intervention trial.",2022-08-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,National Capital Territory of Delhi,,"""1. Either sex aged 19–60 years,
2. On duty in different units and districts of Delhi state,
3. Agreed to give consent for participation, and
4. Agreed not to take any other prophylactic medicines during
the trial period.""","""Participants should not be
1. Suffering with severe respiratory allergies and other comorbid conditions that may create bias in the outcome of
the results,
2. Infected with COVID-19 recently (within 1 month),
3. Positive for IgG COVID-19, and
4. On other prophylactic medications.""",2020-05-16,2020-07-16,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,66,0.394,,,True,,,,True,Convenience,ELISafe 19™ COVID-19 IgG ELISA Detection Kit,HiMedia Laboratories,ELISA,Serum,IgG,,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Tanuja Nesari,All India Institute of Ayurveda,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.920126,2022-09-13,2024-03-01,Unverified,nesari_ayuraksha_2022,IND
220816_Delhi_AllIndiaInstituteofAyurveda_TrialGroup,220816_Delhi_AllIndiaInstituteofAyurveda_TrialGroup,"AYURAKSHA, a prophylactic Ayurvedic immunity boosting kit reducing positivity percentage of IgG COVID-19 among frontline Indian Delhi police personnel: A non-randomized controlled intervention trial.",2022-08-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,National Capital Territory of Delhi,,"""1. Either sex aged 19–60 years,
2. On duty in different units and districts of Delhi state,
3. Agreed to give consent for participation, and
4. Agreed not to take any other prophylactic medicines during
the trial period.""","""Participants should not be
1. Suffering with severe respiratory allergies and other comorbid conditions that may create bias in the outcome of
the results,
2. Infected with COVID-19 recently (within 1 month),
3. Positive for IgG COVID-19, and
4. On other prophylactic medications.""",2020-05-16,2020-07-16,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,80,0.17500000000000002,,,True,,,,True,Convenience,ELISafe 19™ COVID-19 IgG ELISA Detection Kit,HiMedia Laboratories,ELISA,Serum,IgG,,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Tanuja Nesari,All India Institute of Ayurveda,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.920126,2022-09-13,2024-03-01,Unverified,nesari_ayuraksha_2022,IND
220822_India_AllIndiaInstituteofMedicalSciences_Overall,220822_India_AllIndiaInstituteofMedicalSciences,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in admitted patients at a tertiary referral centre in North India,2022-08-22,Preprint,National,Cross-sectional survey ,India,"Delhi, Uttar Pradesh, Haryana, Bihar, Rajasthan",,Consecutive patients (age>14 years) admitted to medicine ward/ICU at All India Institute of Medical Sciences hospital,Test for COVID-19 (RT-PCR or CB-NAAT) was positive at admission,2020-06-09,2021-04-27,Residual sera,All,Multiple groups,15.0,,Primary Estimate,,916,0.28800000000000003,,,True,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Animesh Ray,All India Institute of Medical Sciences,Not Unity-Aligned,10.1101/2022.08.19.22278876,2022-09-06,2022-09-06,Unverified,ray_seroprevalence_2022,IND
220822_India_AllIndiaInstituteofMedicalSciences_OutsideDelhi,220822_India_AllIndiaInstituteofMedicalSciences,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in admitted patients at a tertiary referral centre in North India,2022-08-22,Preprint,Regional,Cross-sectional survey ,India,"Uttar Pradesh, Haryana, Bihar, Rajasthan",,Consecutive patients (age>14 years) admitted to medicine ward/ICU at All India Institute of Medical Sciences hospital,Test for COVID-19 (RT-PCR or CB-NAAT) was positive at admission,2020-06-09,2021-04-27,Residual sera,All,Multiple groups,,,Geographical area,Outside Delhi,403,0.19899999999999998,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Animesh Ray,All India Institute of Medical Sciences,Not Unity-Aligned,10.1101/2022.08.19.22278876,2022-09-06,2022-09-06,Unverified,ray_seroprevalence_2022,IND
220822_India_AllIndiaInstituteofMedicalSciences_AugSept2020,220822_India_AllIndiaInstituteofMedicalSciences,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in admitted patients at a tertiary referral centre in North India,2022-08-22,Preprint,National,Cross-sectional survey ,India,"Delhi, Uttar Pradesh, Haryana, Bihar, Rajasthan",,Consecutive patients (age>14 years) admitted to medicine ward/ICU at All India Institute of Medical Sciences hospital,Test for COVID-19 (RT-PCR or CB-NAAT) was positive at admission,2020-08-01,2020-09-30,Residual sera,All,Multiple groups,,,Time frame,August-September 2020,231,0.23399999999999999,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Animesh Ray,All India Institute of Medical Sciences,Not Unity-Aligned,10.1101/2022.08.19.22278876,2022-09-06,2022-09-06,Unverified,ray_seroprevalence_2022,IND
220822_India_AllIndiaInstituteofMedicalSciences_Delhi,220822_India_AllIndiaInstituteofMedicalSciences,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in admitted patients at a tertiary referral centre in North India,2022-08-22,Preprint,Regional,Cross-sectional survey ,India,Delhi,,Consecutive patients (age>14 years) admitted to medicine ward/ICU at All India Institute of Medical Sciences hospital,Test for COVID-19 (RT-PCR or CB-NAAT) was positive at admission,2020-06-09,2021-04-27,Residual sera,All,Multiple groups,,,Geographical area,Delhi,513,0.324,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Animesh Ray,All India Institute of Medical Sciences,Not Unity-Aligned,10.1101/2022.08.19.22278876,2022-09-06,2022-09-06,Unverified,ray_seroprevalence_2022,IND
220822_India_AllIndiaInstituteofMedicalSciences_40-49,220822_India_AllIndiaInstituteofMedicalSciences,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in admitted patients at a tertiary referral centre in North India,2022-08-22,Preprint,National,Cross-sectional survey ,India,"Delhi, Uttar Pradesh, Haryana, Bihar, Rajasthan",,Consecutive patients (age>14 years) admitted to medicine ward/ICU at All India Institute of Medical Sciences hospital,Test for COVID-19 (RT-PCR or CB-NAAT) was positive at admission,2020-06-09,2021-04-27,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,175,0.27399999999999997,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Animesh Ray,All India Institute of Medical Sciences,Not Unity-Aligned,10.1101/2022.08.19.22278876,2022-09-06,2022-09-06,Unverified,ray_seroprevalence_2022,IND
220822_India_AllIndiaInstituteofMedicalSciences_<20,220822_India_AllIndiaInstituteofMedicalSciences,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in admitted patients at a tertiary referral centre in North India,2022-08-22,Preprint,National,Cross-sectional survey ,India,"Delhi, Uttar Pradesh, Haryana, Bihar, Rajasthan",,Consecutive patients (age>14 years) admitted to medicine ward/ICU at All India Institute of Medical Sciences hospital,Test for COVID-19 (RT-PCR or CB-NAAT) was positive at admission,2020-06-09,2021-04-27,Residual sera,All,Children and Youth (0-17 years),15.0,19.0,Age,<20,76,0.25,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Animesh Ray,All India Institute of Medical Sciences,Not Unity-Aligned,10.1101/2022.08.19.22278876,2022-09-06,2022-09-06,Unverified,ray_seroprevalence_2022,IND
220822_India_AllIndiaInstituteofMedicalSciences_FebApril2021,220822_India_AllIndiaInstituteofMedicalSciences,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in admitted patients at a tertiary referral centre in North India,2022-08-22,Preprint,National,Cross-sectional survey ,India,"Delhi, Uttar Pradesh, Haryana, Bihar, Rajasthan",,Consecutive patients (age>14 years) admitted to medicine ward/ICU at All India Institute of Medical Sciences hospital,Test for COVID-19 (RT-PCR or CB-NAAT) was positive at admission,2021-02-01,2021-04-27,Residual sera,All,Multiple groups,,,Time frame,February-April 2021,166,0.428,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Animesh Ray,All India Institute of Medical Sciences,Not Unity-Aligned,10.1101/2022.08.19.22278876,2022-09-06,2022-09-06,Unverified,ray_seroprevalence_2022,IND
220822_India_AllIndiaInstituteofMedicalSciences_50-59,220822_India_AllIndiaInstituteofMedicalSciences,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in admitted patients at a tertiary referral centre in North India,2022-08-22,Preprint,National,Cross-sectional survey ,India,"Delhi, Uttar Pradesh, Haryana, Bihar, Rajasthan",,Consecutive patients (age>14 years) admitted to medicine ward/ICU at All India Institute of Medical Sciences hospital,Test for COVID-19 (RT-PCR or CB-NAAT) was positive at admission,2020-06-09,2021-04-27,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,202,0.307,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Animesh Ray,All India Institute of Medical Sciences,Not Unity-Aligned,10.1101/2022.08.19.22278876,2022-09-06,2022-09-06,Unverified,ray_seroprevalence_2022,IND
220822_India_AllIndiaInstituteofMedicalSciences_JuneJuly2020,220822_India_AllIndiaInstituteofMedicalSciences,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in admitted patients at a tertiary referral centre in North India,2022-08-22,Preprint,National,Cross-sectional survey ,India,"Delhi, Uttar Pradesh, Haryana, Bihar, Rajasthan",,Consecutive patients (age>14 years) admitted to medicine ward/ICU at All India Institute of Medical Sciences hospital,Test for COVID-19 (RT-PCR or CB-NAAT) was positive at admission,2020-06-09,2020-07-31,Residual sera,All,Multiple groups,,,Time frame,June-July 2020,191,0.188,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Animesh Ray,All India Institute of Medical Sciences,Not Unity-Aligned,10.1101/2022.08.19.22278876,2022-09-06,2022-09-06,Unverified,ray_seroprevalence_2022,IND
220822_India_AllIndiaInstituteofMedicalSciences_DecJan2021,220822_India_AllIndiaInstituteofMedicalSciences,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in admitted patients at a tertiary referral centre in North India,2022-08-22,Preprint,National,Cross-sectional survey ,India,"Delhi, Uttar Pradesh, Haryana, Bihar, Rajasthan",,Consecutive patients (age>14 years) admitted to medicine ward/ICU at All India Institute of Medical Sciences hospital,Test for COVID-19 (RT-PCR or CB-NAAT) was positive at admission,2020-12-01,2021-01-31,Residual sera,All,Multiple groups,,,Time frame,December 2020-January 2021,172,0.32,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Animesh Ray,All India Institute of Medical Sciences,Not Unity-Aligned,10.1101/2022.08.19.22278876,2022-09-06,2022-09-06,Unverified,ray_seroprevalence_2022,IND
220822_India_AllIndiaInstituteofMedicalSciences_20-29,220822_India_AllIndiaInstituteofMedicalSciences,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in admitted patients at a tertiary referral centre in North India,2022-08-22,Preprint,National,Cross-sectional survey ,India,"Delhi, Uttar Pradesh, Haryana, Bihar, Rajasthan",,Consecutive patients (age>14 years) admitted to medicine ward/ICU at All India Institute of Medical Sciences hospital,Test for COVID-19 (RT-PCR or CB-NAAT) was positive at admission,2020-06-09,2021-04-27,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29,205,0.268,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Animesh Ray,All India Institute of Medical Sciences,Not Unity-Aligned,10.1101/2022.08.19.22278876,2022-09-06,2022-09-06,Unverified,ray_seroprevalence_2022,IND
220822_India_AllIndiaInstituteofMedicalSciences_Male,220822_India_AllIndiaInstituteofMedicalSciences,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in admitted patients at a tertiary referral centre in North India,2022-08-22,Preprint,National,Cross-sectional survey ,India,"Delhi, Uttar Pradesh, Haryana, Bihar, Rajasthan",,Consecutive patients (age>14 years) admitted to medicine ward/ICU at All India Institute of Medical Sciences hospital,Test for COVID-19 (RT-PCR or CB-NAAT) was positive at admission,2020-06-09,2021-04-27,Residual sera,Male,Multiple groups,,,Sex/Gender,,506,0.289,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Animesh Ray,All India Institute of Medical Sciences,Not Unity-Aligned,10.1101/2022.08.19.22278876,2022-09-06,2022-09-06,Unverified,ray_seroprevalence_2022,IND
220822_India_AllIndiaInstituteofMedicalSciences_>=60,220822_India_AllIndiaInstituteofMedicalSciences,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in admitted patients at a tertiary referral centre in North India,2022-08-22,Preprint,National,Cross-sectional survey ,India,"Delhi, Uttar Pradesh, Haryana, Bihar, Rajasthan",,Consecutive patients (age>14 years) admitted to medicine ward/ICU at All India Institute of Medical Sciences hospital,Test for COVID-19 (RT-PCR or CB-NAAT) was positive at admission,2020-06-09,2021-04-27,Residual sera,All,Seniors (65+ years),60.0,,Age,>=60,94,0.309,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Animesh Ray,All India Institute of Medical Sciences,Not Unity-Aligned,10.1101/2022.08.19.22278876,2022-09-06,2022-09-06,Unverified,ray_seroprevalence_2022,IND
220822_India_AllIndiaInstituteofMedicalSciences_Female,220822_India_AllIndiaInstituteofMedicalSciences,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in admitted patients at a tertiary referral centre in North India,2022-08-22,Preprint,National,Cross-sectional survey ,India,"Delhi, Uttar Pradesh, Haryana, Bihar, Rajasthan",,Consecutive patients (age>14 years) admitted to medicine ward/ICU at All India Institute of Medical Sciences hospital,Test for COVID-19 (RT-PCR or CB-NAAT) was positive at admission,2020-06-09,2021-04-27,Residual sera,Female,Multiple groups,,,Sex/Gender,,410,0.28800000000000003,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Animesh Ray,All India Institute of Medical Sciences,Not Unity-Aligned,10.1101/2022.08.19.22278876,2022-09-06,2022-09-06,Unverified,ray_seroprevalence_2022,IND
220822_India_AllIndiaInstituteofMedicalSciences_OctNov2020,220822_India_AllIndiaInstituteofMedicalSciences,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in admitted patients at a tertiary referral centre in North India,2022-08-22,Preprint,National,Cross-sectional survey ,India,"Delhi, Uttar Pradesh, Haryana, Bihar, Rajasthan",,Consecutive patients (age>14 years) admitted to medicine ward/ICU at All India Institute of Medical Sciences hospital,Test for COVID-19 (RT-PCR or CB-NAAT) was positive at admission,2020-10-01,2020-11-30,Residual sera,All,Multiple groups,,,Time frame,October-November 2020,156,0.308,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Animesh Ray,All India Institute of Medical Sciences,Not Unity-Aligned,10.1101/2022.08.19.22278876,2022-09-06,2022-09-06,Unverified,ray_seroprevalence_2022,IND
220822_India_AllIndiaInstituteofMedicalSciences_30-39,220822_India_AllIndiaInstituteofMedicalSciences,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in admitted patients at a tertiary referral centre in North India,2022-08-22,Preprint,National,Cross-sectional survey ,India,"Delhi, Uttar Pradesh, Haryana, Bihar, Rajasthan",,Consecutive patients (age>14 years) admitted to medicine ward/ICU at All India Institute of Medical Sciences hospital,Test for COVID-19 (RT-PCR or CB-NAAT) was positive at admission,2020-06-09,2021-04-27,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,162,0.302,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Animesh Ray,All India Institute of Medical Sciences,Not Unity-Aligned,10.1101/2022.08.19.22278876,2022-09-06,2022-09-06,Unverified,ray_seroprevalence_2022,IND
220901_Srinagar_ChestDiseaseGovernmentHospitalSrinagar_HCW,220901_Srinagar_ChestDiseaseGovernmentHospitalSrinagar_HCW,SARS-CoV-2 Antibody Response in Patients with Co-morbidities in Kashmir's Ethnic Population: An Observational Cohort Study,2022-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Kashmir,Srinagar,"Unvaccinated co-morbid patients (COVID-19 RT-PCR positive).
• The patients or their attendants who gave consent was included in the study.
• Ethnic Kashmiri patients.","• Vaccinated candidates.
• Non-ethnic Kashmiri patients.
• Patients on chemotherapy or radiotherapy",2020-09-15,2021-09-15,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,201,0.6417900000000001,,,,,,,,Convenience,Not reported/ Unable to specify,,CLIA,Plasma,,,Validated by manufacturers,0.8848,1.0,['High'],,No,No,No,,Unclear,Yes,No,,Aaliya Azad,"Chest Disease Government Hospital, Srinagar",Not Unity-Aligned,https://dx.doi.org/10.7860/JCDR/2022/56230.16910,2022-11-17,2022-11-17,Unverified,azad_sars-cov-2_2022,IND
220901_Srinagar_ChestDiseaseGovernmentHospitalSrinagar_Patients,220901_Srinagar_ChestDiseaseGovernmentHospitalSrinagar_Patients,SARS-CoV-2 Antibody Response in Patients with Co-morbidities in Kashmir's Ethnic Population: An Observational Cohort Study,2022-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Kashmir,Srinagar,"Unvaccinated co-morbid patients (COVID-19 RT-PCR positive).
• The patients or their attendants who gave consent was included in the study.
• Ethnic Kashmiri patients.","• Vaccinated candidates.
• Non-ethnic Kashmiri patients.
• Patients on chemotherapy or radiotherapy",2020-09-15,2021-09-15,Residual sera,All,Multiple groups,,,Primary Estimate,,1645,0.52097,,,True,,,,True,Convenience,Not reported/ Unable to specify,,CLIA,Plasma,,,Validated by manufacturers,0.8848,1.0,['High'],,No,Yes,No,,Unclear,Yes,No,,Aaliya Azad,"Chest Disease Government Hospital, Srinagar",Not Unity-Aligned,https://dx.doi.org/10.7860/JCDR/2022/56230.16910,2022-11-17,2022-11-18,Unverified,azad_sars-cov-2_2022,IND
221006_Kashmir_GovernmentMedicalCollegeSrinagar_ImpOverall,221006_Kashmir_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.",2022-10-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Kashmir,,"We designed a population-based cross-sectional study. We covered all 10 districts of Kashmir valley (Figure 1). In all 10 districts, the study was primarily focused on the general population. We extended the study to include a quota of frontline workers and antenatal women from each district to compare the results of these exposed groups. Pregnant females being the least exposed to vaccination among adults, we added a
quota of 50 pregnant females within each district to assess the seroprevalence within this vulnerable group.

All individuals 7 years of age were eligible to participate in the study.",,2021-07-05,2021-07-15,Household and community samples,All,Multiple groups,7.0,,Primary Estimate,"Any antibody, imputation, pop-adj estimate",4169,0.0904,,,True,,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,Not reported/ Unable to specify","Abbott Laboratories,NA",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Kouser Sideeq Lone,Government Medical College Srinagar,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.967447,2022-11-01,2024-03-01,Unverified,lone_seroprevalence_2022,IND
221006_Kashmir_GovernmentMedicalCollegeSrinagar_ImpAntiSIgG_WeightedMale,221006_Kashmir_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.",2022-10-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Kashmir,,"We designed a population-based cross-sectional study. We covered all 10 districts of Kashmir valley (Figure 1). In all 10 districts, the study was primarily focused on the general population. We extended the study to include a quota of frontline workers and antenatal women from each district to compare the results of these exposed groups. Pregnant females being the least exposed to vaccination among adults, we added a
quota of 50 pregnant females within each district to assess the seroprevalence within this vulnerable group.

All individuals 7 years of age were eligible to participate in the study.",,2021-07-05,2021-07-15,Household and community samples,Male,Multiple groups,7.0,,Sex/Gender,"Anti-S IgG, imputation, pop+test-adj estimate, male",2117,0.2797,0.2736,0.2859,,True,True,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9937,0.9954999999999999,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Kouser Sideeq Lone,Government Medical College Srinagar,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.967447,2022-11-01,2023-01-03,Unverified,lone_seroprevalence_2022,IND
221006_Kashmir_GovernmentMedicalCollegeSrinagar_ImpAntiNIgG_Weighted,221006_Kashmir_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.",2022-10-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Kashmir,,"We designed a population-based cross-sectional study. We covered all 10 districts of Kashmir valley (Figure 1). In all 10 districts, the study was primarily focused on the general population. We extended the study to include a quota of frontline workers and antenatal women from each district to compare the results of these exposed groups. Pregnant females being the least exposed to vaccination among adults, we added a
quota of 50 pregnant females within each district to assess the seroprevalence within this vulnerable group.

All individuals 7 years of age were eligible to participate in the study.",,2021-07-05,2021-07-15,Household and community samples,All,Multiple groups,7.0,,Test used,"Anti-N IgG, imputation, pop+test-adj estimate",4168,0.27399999999999997,,,,True,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Kouser Sideeq Lone,Government Medical College Srinagar,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.967447,2022-11-01,2023-08-15,Unverified,lone_seroprevalence_2022,IND
221006_Kashmir_GovernmentMedicalCollegeSrinagar_ImpAntiSIgG_WeightedNoVac,221006_Kashmir_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.",2022-10-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Kashmir,,"We designed a population-based cross-sectional study. We covered all 10 districts of Kashmir valley (Figure 1). In all 10 districts, the study was primarily focused on the general population. We extended the study to include a quota of frontline workers and antenatal women from each district to compare the results of these exposed groups. Pregnant females being the least exposed to vaccination among adults, we added a
quota of 50 pregnant females within each district to assess the seroprevalence within this vulnerable group.

All individuals 7 years of age were eligible to participate in the study.",,2021-07-05,2021-07-15,Household and community samples,All,Multiple groups,7.0,,COVID-19 vaccination status,"Anti-S IgG, imputation, pop+test-adj estimate, never vaccinated",1764,0.3013,0.29410000000000003,0.30870000000000003,,True,True,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9937,0.9954999999999999,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Kouser Sideeq Lone,Government Medical College Srinagar,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.967447,2022-11-01,2023-01-03,Unverified,lone_seroprevalence_2022,IND
221006_Kashmir_GovernmentMedicalCollegeSrinagar_ImpAntiSIgG_WeightedFemale,221006_Kashmir_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.",2022-10-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Kashmir,,"We designed a population-based cross-sectional study. We covered all 10 districts of Kashmir valley (Figure 1). In all 10 districts, the study was primarily focused on the general population. We extended the study to include a quota of frontline workers and antenatal women from each district to compare the results of these exposed groups. Pregnant females being the least exposed to vaccination among adults, we added a
quota of 50 pregnant females within each district to assess the seroprevalence within this vulnerable group.

All individuals 7 years of age were eligible to participate in the study.",,2021-07-05,2021-07-15,Household and community samples,Female,Multiple groups,7.0,,Sex/Gender,"Anti-S IgG, imputation, pop+test-adj estimate, female",1983,0.2828,0.2776,0.28800000000000003,,True,True,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9937,0.9954999999999999,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Kouser Sideeq Lone,Government Medical College Srinagar,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.967447,2022-11-01,2023-01-03,Unverified,lone_seroprevalence_2022,IND
221006_Kashmir_GovernmentMedicalCollegeSrinagar_ImpAntiSIgG_Weighted,221006_Kashmir_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.",2022-10-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Kashmir,,"We designed a population-based cross-sectional study. We covered all 10 districts of Kashmir valley (Figure 1). In all 10 districts, the study was primarily focused on the general population. We extended the study to include a quota of frontline workers and antenatal women from each district to compare the results of these exposed groups. Pregnant females being the least exposed to vaccination among adults, we added a
quota of 50 pregnant females within each district to assess the seroprevalence within this vulnerable group.

All individuals 7 years of age were eligible to participate in the study.",,2021-07-05,2021-07-15,Household and community samples,All,Multiple groups,7.0,,Test used,"Anti-S IgG, imputation, pop+test-adj estimate",4166,0.8447,,,,True,True,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9937,0.9954999999999999,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Kouser Sideeq Lone,Government Medical College Srinagar,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.967447,2022-11-01,2023-01-03,Unverified,lone_seroprevalence_2022,IND
221006_Kashmir_GovernmentMedicalCollegeSrinagar_ImpAntiSIgG_WeightedAge18to44,221006_Kashmir_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.",2022-10-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Kashmir,,"We designed a population-based cross-sectional study. We covered all 10 districts of Kashmir valley (Figure 1). In all 10 districts, the study was primarily focused on the general population. We extended the study to include a quota of frontline workers and antenatal women from each district to compare the results of these exposed groups. Pregnant females being the least exposed to vaccination among adults, we added a
quota of 50 pregnant females within each district to assess the seroprevalence within this vulnerable group.

All individuals 7 years of age were eligible to participate in the study.",,2021-07-05,2021-07-15,Household and community samples,All,Adults (18-64 years),18.0,44.0,Age,"Anti-S IgG, imputation, pop+test-adj estimate, age: 18-44",1638,0.2733,0.266,0.2797,,True,True,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9937,0.9954999999999999,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Kouser Sideeq Lone,Government Medical College Srinagar,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.967447,2022-11-01,2023-01-03,Unverified,lone_seroprevalence_2022,IND
221006_Kashmir_GovernmentMedicalCollegeSrinagar_NoImpOverall,221006_Kashmir_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.",2022-10-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Kashmir,,"We designed a population-based cross-sectional study. We covered all 10 districts of Kashmir valley (Figure 1). In all 10 districts, the study was primarily focused on the general population. We extended the study to include a quota of frontline workers and antenatal women from each district to compare the results of these exposed groups. Pregnant females being the least exposed to vaccination among adults, we added a
quota of 50 pregnant females within each district to assess the seroprevalence within this vulnerable group.

All individuals 7 years of age were eligible to participate in the study.",,2021-07-05,2021-07-15,Household and community samples,All,Multiple groups,7.0,,Analysis,"Any antibody, no imputation, crude estimate",3648,0.0861,,,,,,,True,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,Not reported/ Unable to specify","Abbott Laboratories,NA",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Kouser Sideeq Lone,Government Medical College Srinagar,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.967447,2022-11-01,2024-03-01,Unverified,lone_seroprevalence_2022,IND
221006_Kashmir_GovernmentMedicalCollegeSrinagar_ImpAntiSIgG_WeightedAge7to17,221006_Kashmir_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.",2022-10-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Kashmir,,"We designed a population-based cross-sectional study. We covered all 10 districts of Kashmir valley (Figure 1). In all 10 districts, the study was primarily focused on the general population. We extended the study to include a quota of frontline workers and antenatal women from each district to compare the results of these exposed groups. Pregnant females being the least exposed to vaccination among adults, we added a
quota of 50 pregnant females within each district to assess the seroprevalence within this vulnerable group.

All individuals 7 years of age were eligible to participate in the study.",,2021-07-05,2021-07-15,Household and community samples,All,Children and Youth (0-17 years),7.0,17.0,Age,"Anti-S IgG, imputation, pop+test-adj estimate, age: 7-17",1087,0.3119,0.3041,0.31980000000000003,,True,True,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9937,0.9954999999999999,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Kouser Sideeq Lone,Government Medical College Srinagar,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.967447,2022-11-01,2023-01-03,Unverified,lone_seroprevalence_2022,IND
221006_Kashmir_GovernmentMedicalCollegeSrinagar_ImpAntiSIgG_WeightedVac,221006_Kashmir_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.",2022-10-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Kashmir,,"We designed a population-based cross-sectional study. We covered all 10 districts of Kashmir valley (Figure 1). In all 10 districts, the study was primarily focused on the general population. We extended the study to include a quota of frontline workers and antenatal women from each district to compare the results of these exposed groups. Pregnant females being the least exposed to vaccination among adults, we added a
quota of 50 pregnant females within each district to assess the seroprevalence within this vulnerable group.

All individuals 7 years of age were eligible to participate in the study.",,2021-07-05,2021-07-15,Household and community samples,All,Multiple groups,7.0,,COVID-19 vaccination status,"Anti-S IgG, imputation, pop+test-adj estimate, ever vaccinated",2225,0.2604,0.2561,0.2647,,True,True,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9937,0.9954999999999999,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Kouser Sideeq Lone,Government Medical College Srinagar,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.967447,2022-11-01,2023-01-03,Unverified,lone_seroprevalence_2022,IND
221006_Kashmir_GovernmentMedicalCollegeSrinagar_ImpAntiSIgG_WeightedAgeOver60,221006_Kashmir_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.",2022-10-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Kashmir,,"We designed a population-based cross-sectional study. We covered all 10 districts of Kashmir valley (Figure 1). In all 10 districts, the study was primarily focused on the general population. We extended the study to include a quota of frontline workers and antenatal women from each district to compare the results of these exposed groups. Pregnant females being the least exposed to vaccination among adults, we added a
quota of 50 pregnant females within each district to assess the seroprevalence within this vulnerable group.

All individuals 7 years of age were eligible to participate in the study.",,2021-07-05,2021-07-15,Household and community samples,All,Seniors (65+ years),60.0,,Age,"Anti-S IgG, imputation, pop+test-adj estimate, age: >= 60",544,0.2928,0.2848,0.30100000000000005,,True,True,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9937,0.9954999999999999,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Kouser Sideeq Lone,Government Medical College Srinagar,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.967447,2022-11-01,2023-01-03,Unverified,lone_seroprevalence_2022,IND
221006_Kashmir_GovernmentMedicalCollegeSrinagar_ImpAntiSIgG_WeightedAge45to59,221006_Kashmir_GovernmentMedicalCollegeSrinagar,"Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.",2022-10-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Kashmir,,"We designed a population-based cross-sectional study. We covered all 10 districts of Kashmir valley (Figure 1). In all 10 districts, the study was primarily focused on the general population. We extended the study to include a quota of frontline workers and antenatal women from each district to compare the results of these exposed groups. Pregnant females being the least exposed to vaccination among adults, we added a
quota of 50 pregnant females within each district to assess the seroprevalence within this vulnerable group.

All individuals 7 years of age were eligible to participate in the study.",,2021-07-05,2021-07-15,Household and community samples,All,Adults (18-64 years),45.0,59.0,Age,"Anti-S IgG, imputation, pop+test-adj estimate, age: 45-59",831,0.23199999999999998,0.2257,0.2384,,True,True,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9937,0.9954999999999999,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Kouser Sideeq Lone,Government Medical College Srinagar,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.967447,2022-11-01,2023-01-03,Unverified,lone_seroprevalence_2022,IND
221014_Kerala_GovernmentMedicalCollege,221014_Kerala_GovernmentMedicalCollege,"Seroprevalence of SARS-CoV 2 antibodies & its determinants in children of 5-to-18-year age group in an urban setting, Kerala.",2022-10-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Kerala,Thiruvananthapuram,"""children in the age group of 5 to 18 years
were included.""","""The children who
were positive for COVID 19 and undergoing quarantine at
the time of the survey were excluded.""",2021-08-15,2021-10-15,Household and community samples,All,Children and Youth (0-17 years),5.0,18.0,Primary Estimate,,204,0.41700000000000004,0.349,0.4843,True,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,"IgG, IgM, IgA",Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Mini S.,Government Medical College,Not Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2465_21,2022-12-22,2024-03-01,Unverified,mini_seroprevalence_2022,IND
221014_Kerala_GovernmentMedicalCollege_Sex_Female,221014_Kerala_GovernmentMedicalCollege,"Seroprevalence of SARS-CoV 2 antibodies & its determinants in children of 5-to-18-year age group in an urban setting, Kerala.",2022-10-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Kerala,Thiruvananthapuram,"""children in the age group of 5 to 18 years
were included.""","""The children who
were positive for COVID 19 and undergoing quarantine at
the time of the survey were excluded.""",2021-08-15,2021-10-15,Household and community samples,Female,Children and Youth (0-17 years),5.0,18.0,Sex/Gender,Female,121,0.413,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,"IgG, IgM, IgA",Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Mini S.,Government Medical College,Not Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2465_21,2022-12-27,2024-03-01,Unverified,mini_seroprevalence_2022,IND
221014_Kerala_GovernmentMedicalCollege_Sex_Male,221014_Kerala_GovernmentMedicalCollege,"Seroprevalence of SARS-CoV 2 antibodies & its determinants in children of 5-to-18-year age group in an urban setting, Kerala.",2022-10-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Kerala,Thiruvananthapuram,"""children in the age group of 5 to 18 years
were included.""","""The children who
were positive for COVID 19 and undergoing quarantine at
the time of the survey were excluded.""",2021-08-15,2021-10-15,Household and community samples,Male,Children and Youth (0-17 years),5.0,18.0,Sex/Gender,Male,83,0.42200000000000004,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,"IgG, IgM, IgA",Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Mini S.,Government Medical College,Not Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_2465_21,2022-12-27,2024-03-01,Unverified,mini_seroprevalence_2022,IND
221031_Ranchi_RajendraInstituteofMedicalSciences,221031_Ranchi_RajendraInstituteofMedicalSciences,Estimation of anti-SARS-CoV-2 IgG titre among blood donors in Ranchi,2022-10-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Jharkhand,Ranchi,"""All blood donors aged 18–60 years were allowed to donate and who
met the criteria for blood donation""",,2021-02-06,2021-04-20,Blood donors,All,Adults (18-64 years),18.0,60.0,Primary Estimate,,5140,0.675,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),,0.998,0.995,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Sushma Kumari,Rajendra Institute of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_727_22,2023-01-19,2024-03-24,Verified,kumari_estimation_2022,IND
221031_Ranchi_RajendraInstituteofMedicalSciences_32-45,221031_Ranchi_RajendraInstituteofMedicalSciences,Estimation of anti-SARS-CoV-2 IgG titre among blood donors in Ranchi,2022-10-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Jharkhand,Ranchi,"""All blood donors aged 18–60 years were allowed to donate and who
met the criteria for blood donation""",,2021-02-06,2021-04-20,Blood donors,All,Adults (18-64 years),32.0,45.0,Age,32-45,1570,0.6688,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),,0.998,0.995,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Sushma Kumari,Rajendra Institute of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_727_22,2024-03-24,2024-03-24,Verified,kumari_estimation_2022,IND
221031_Ranchi_RajendraInstituteofMedicalSciences_46-60,221031_Ranchi_RajendraInstituteofMedicalSciences,Estimation of anti-SARS-CoV-2 IgG titre among blood donors in Ranchi,2022-10-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Jharkhand,Ranchi,"""All blood donors aged 18–60 years were allowed to donate and who
met the criteria for blood donation""",,2021-02-06,2021-04-20,Blood donors,All,Adults (18-64 years),46.0,60.0,Age,46-60,333,0.6276,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),,0.998,0.995,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Sushma Kumari,Rajendra Institute of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_727_22,2024-03-24,2024-03-24,Verified,kumari_estimation_2022,IND
221031_Ranchi_RajendraInstituteofMedicalSciences_18-31,221031_Ranchi_RajendraInstituteofMedicalSciences,Estimation of anti-SARS-CoV-2 IgG titre among blood donors in Ranchi,2022-10-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Jharkhand,Ranchi,"""All blood donors aged 18–60 years were allowed to donate and who
met the criteria for blood donation""",,2021-02-06,2021-04-20,Blood donors,All,Adults (18-64 years),18.0,31.0,Age,18-31,3237,0.683,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),,0.998,0.995,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Sushma Kumari,Rajendra Institute of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.4103/jfmpc.jfmpc_727_22,2024-03-24,2024-03-24,Verified,kumari_estimation_2022,IND
221107_Bangalore_BangaloreBaptistHospital,221107_Bangalore_BangaloreBaptistHospital,Seroprevalence of SARS CoV-2 among children after the second surge (June 2021) in a rural district of South India: Findings and lessons from a population-based survey,2022-11-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Karnataka,,Children aged 0-18 years,"""Children who were seriously ill with any other chronic conditions or had any established comorbidities were excluded.""",2021-06-14,2021-07-13,Household and community samples,All,Multiple groups,0.0,18.0,Primary Estimate,Primary estimate,412,0.459,0.41,0.508,True,,,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,,,TotalAntibody,,Validated by manufacturers,,,['High'],,Yes,Yes,Yes,,Unclear,Yes,No,,Carolin Elizabeth George,Bangalore Baptist Hospital,Not Unity-Aligned,https://dx.doi.org/10.3389/fped.2022.997684,2023-03-09,2023-03-22,Unverified,george_seroprevalence_2022-1,IND
221109_India_CouncilOfScientificAndIndustrialResearch_202008_TestAdjusted,221109_India_CouncilOfScientificAndIndustrialResearch_202008,Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India,2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India," Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim",,"The study was conducted among the population
of Jorhat district, Assam.",,2020-08-01,2020-08-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,724,0.1061,0.0837,0.1285,True,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.998,1.0,['High'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Romi Wahengbam,Council of Scientific and Industrial Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2022.10.011,2022-11-22,2024-03-01,Unverified,wahengbam_seroepidemiological_2022-1,IND
221109_India_CouncilOfScientificAndIndustrialResearch_202008_Age>60,221109_India_CouncilOfScientificAndIndustrialResearch_202008,Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India,2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India," Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim",,"The study was conducted among the population
of Jorhat district, Assam.",,2020-08-01,2020-08-31,Household and community samples,All,Multiple groups,61.0,,Age,>60,92,0.0652,,,,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.998,1.0,['High'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Romi Wahengbam,Council of Scientific and Industrial Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2022.10.011,2022-11-22,2024-03-01,Unverified,wahengbam_seroepidemiological_2022-1,IND
221109_India_CouncilOfScientificAndIndustrialResearch_202008_Overall,221109_India_CouncilOfScientificAndIndustrialResearch_202008,Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India,2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India," Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim",,"The study was conducted among the population
of Jorhat district, Assam.",,2020-08-01,2020-08-31,Household and community samples,All,Multiple groups,,,Analysis,,724,0.10640000000000001,,,,,,,True,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.998,1.0,['High'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Romi Wahengbam,Council of Scientific and Industrial Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2022.10.011,2022-11-22,2024-03-01,Unverified,wahengbam_seroepidemiological_2022-1,IND
221109_India_CouncilOfScientificAndIndustrialResearch_202008_Age<30,221109_India_CouncilOfScientificAndIndustrialResearch_202008,Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India,2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India," Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim",,"The study was conducted among the population
of Jorhat district, Assam.",,2020-08-01,2020-08-31,Household and community samples,All,Multiple groups,,29.0,Age,<30,179,0.1061,,,,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.998,1.0,['High'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Romi Wahengbam,Council of Scientific and Industrial Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2022.10.011,2022-11-22,2024-03-01,Unverified,wahengbam_seroepidemiological_2022-1,IND
221109_India_CouncilOfScientificAndIndustrialResearch_202008_TestVoxPressIgG,221109_India_CouncilOfScientificAndIndustrialResearch_202008,Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India,2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India," Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim",,"The study was conducted among the population
of Jorhat district, Assam.",,2020-08-01,2020-08-31,Household and community samples,All,Multiple groups,,,Test used,VoxPress IgG,724,0.0884,,,,,,,,Unclear,New Corona Virus (COVID-19) IgG / IgM Rapid Test,Voxtur Bio Ltd.,,Whole Blood,IgG,Spike,,,,['High'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Romi Wahengbam,Council of Scientific and Industrial Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2022.10.011,2022-11-22,2022-11-22,Unverified,wahengbam_seroepidemiological_2022-1,IND
221109_India_CouncilOfScientificAndIndustrialResearch_202008_Neutralizing,221109_India_CouncilOfScientificAndIndustrialResearch_202008,Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India,2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India," Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim",,"The study was conducted among the population
of Jorhat district, Assam.",,2020-08-01,2020-08-31,Household and community samples,All,Multiple groups,,,Test used,VoxPress IgM,724,0.09670000000000001,,,,,,,,Unclear,"Elecsys® Anti‐SARS‐CoV‐2 (N),New Corona Virus (COVID-19) IgG / IgM Rapid Test,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit","Roche Diagnostics,Voxtur Bio Ltd.,GenScript",Multiple Types,Multiple Types,"['IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Romi Wahengbam,Council of Scientific and Industrial Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2022.10.011,2022-11-22,2024-03-01,Unverified,wahengbam_seroepidemiological_2022-1,IND
221109_India_CouncilOfScientificAndIndustrialResearch_202008_SexMale,221109_India_CouncilOfScientificAndIndustrialResearch_202008,Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India,2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India," Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim",,"The study was conducted among the population
of Jorhat district, Assam.",,2020-08-01,2020-08-31,Household and community samples,Male,Multiple groups,,,Sex/Gender,,521,0.1152,,,,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.998,1.0,['High'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Romi Wahengbam,Council of Scientific and Industrial Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2022.10.011,2022-11-22,2024-03-01,Unverified,wahengbam_seroepidemiological_2022-1,IND
221109_India_CouncilOfScientificAndIndustrialResearch_202008_TestVoxPressIgM,221109_India_CouncilOfScientificAndIndustrialResearch_202008,Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India,2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India," Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim",,"The study was conducted among the population
of Jorhat district, Assam.",,2020-08-01,2020-08-31,Household and community samples,All,Multiple groups,,,Test used,VoxPress IgM,724,0.0097,,,,,,,,Unclear,New Corona Virus (COVID-19) IgG / IgM Rapid Test,Voxtur Bio Ltd.,,Whole Blood,IgM,Spike,,,,['High'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Romi Wahengbam,Council of Scientific and Industrial Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2022.10.011,2022-11-22,2022-11-22,Unverified,wahengbam_seroepidemiological_2022-1,IND
221109_India_CouncilOfScientificAndIndustrialResearch_202008_Age30-60,221109_India_CouncilOfScientificAndIndustrialResearch_202008,Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India,2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India," Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim",,"The study was conducted among the population
of Jorhat district, Assam.",,2020-08-01,2020-08-31,Household and community samples,All,Adults (18-64 years),30.0,60.0,Age,30-60,453,0.11480000000000001,,,,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.998,1.0,['High'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Romi Wahengbam,Council of Scientific and Industrial Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2022.10.011,2022-11-22,2024-03-01,Unverified,wahengbam_seroepidemiological_2022-1,IND
221109_India_CouncilOfScientificAndIndustrialResearch_202008_SexFemale,221109_India_CouncilOfScientificAndIndustrialResearch_202008,Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India,2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India," Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim",,"The study was conducted among the population
of Jorhat district, Assam.",,2020-08-01,2020-08-31,Household and community samples,Female,Multiple groups,,,Sex/Gender,,203,0.0837,,,,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.998,1.0,['High'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Romi Wahengbam,Council of Scientific and Industrial Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2022.10.011,2022-11-22,2024-03-01,Unverified,wahengbam_seroepidemiological_2022-1,IND
221109_India_CouncilOfScientificAndIndustrialResearch_202102_TestAdjusted,221109_India_CouncilOfScientificAndIndustrialResearch_202102,Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India,2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India," Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim",,"The study was conducted among the population
of Jorhat district, Assam.",,2021-02-01,2021-02-28,Household and community samples,All,Multiple groups,,,Primary Estimate,,866,0.4021,0.36950000000000005,0.43479999999999996,True,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.998,1.0,['High'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Romi Wahengbam,Council of Scientific and Industrial Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2022.10.011,2022-11-22,2024-03-01,Unverified,wahengbam_seroepidemiological_2022-1,IND
221109_India_CouncilOfScientificAndIndustrialResearch_202102_Age30-60,221109_India_CouncilOfScientificAndIndustrialResearch_202102,Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India,2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India," Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim",,"The study was conducted among the population
of Jorhat district, Assam.",,2021-02-01,2021-02-28,Household and community samples,All,Adults (18-64 years),30.0,60.0,Age,30-60,493,0.3935,,,,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.998,1.0,['High'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Romi Wahengbam,Council of Scientific and Industrial Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2022.10.011,2022-11-22,2024-03-01,Unverified,wahengbam_seroepidemiological_2022-1,IND
221109_India_CouncilOfScientificAndIndustrialResearch_202102_Neutralizing,221109_India_CouncilOfScientificAndIndustrialResearch_202102,Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India,2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India," Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim",,"The study was conducted among the population
of Jorhat district, Assam.",,2021-02-01,2021-02-28,Household and community samples,All,Multiple groups,,,Test used,VoxPress IgM,866,0.2102,,,,,,,,Unclear,"Elecsys® Anti‐SARS‐CoV‐2 (N),New Corona Virus (COVID-19) IgG / IgM Rapid Test,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit","Roche Diagnostics,Voxtur Bio Ltd.,GenScript",Multiple Types,Multiple Types,"['IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Romi Wahengbam,Council of Scientific and Industrial Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2022.10.011,2022-11-22,2024-03-01,Unverified,wahengbam_seroepidemiological_2022-1,IND
221109_India_CouncilOfScientificAndIndustrialResearch_202102_Overall,221109_India_CouncilOfScientificAndIndustrialResearch_202102,Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India,2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India," Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim",,"The study was conducted among the population
of Jorhat district, Assam.",,2021-02-01,2021-02-28,Household and community samples,All,Multiple groups,,,Analysis,,866,0.40299999999999997,,,,,,,True,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.998,1.0,['High'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Romi Wahengbam,Council of Scientific and Industrial Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2022.10.011,2022-11-22,2024-03-01,Unverified,wahengbam_seroepidemiological_2022-1,IND
221109_India_CouncilOfScientificAndIndustrialResearch_202102_TestVoxPressIgG,221109_India_CouncilOfScientificAndIndustrialResearch_202102,Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India,2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India," Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim",,"The study was conducted among the population
of Jorhat district, Assam.",,2021-02-01,2021-02-28,Household and community samples,All,Multiple groups,,,Test used,VoxPress IgG,866,0.1686,,,,,,,,Unclear,New Corona Virus (COVID-19) IgG / IgM Rapid Test,Voxtur Bio Ltd.,,Whole Blood,IgG,Spike,,,,['High'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Romi Wahengbam,Council of Scientific and Industrial Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2022.10.011,2022-11-22,2022-11-22,Unverified,wahengbam_seroepidemiological_2022-1,IND
221109_India_CouncilOfScientificAndIndustrialResearch_202102_Age<30,221109_India_CouncilOfScientificAndIndustrialResearch_202102,Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India,2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India," Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim",,"The study was conducted among the population
of Jorhat district, Assam.",,2021-02-01,2021-02-28,Household and community samples,All,Multiple groups,,29.0,Age,<30,306,0.41500000000000004,,,,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.998,1.0,['High'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Romi Wahengbam,Council of Scientific and Industrial Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2022.10.011,2022-11-22,2024-03-01,Unverified,wahengbam_seroepidemiological_2022-1,IND
221109_India_CouncilOfScientificAndIndustrialResearch_202102_TestVoxPressIgM,221109_India_CouncilOfScientificAndIndustrialResearch_202102,Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India,2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India," Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim",,"The study was conducted among the population
of Jorhat district, Assam.",,2021-02-01,2021-02-28,Household and community samples,All,Multiple groups,,,Test used,VoxPress IgM,866,0.0358,,,,,,,,Unclear,New Corona Virus (COVID-19) IgG / IgM Rapid Test,Voxtur Bio Ltd.,,Whole Blood,IgM,Spike,,,,['High'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Romi Wahengbam,Council of Scientific and Industrial Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2022.10.011,2022-11-22,2022-11-22,Unverified,wahengbam_seroepidemiological_2022-1,IND
221109_India_CouncilOfScientificAndIndustrialResearch_202102_Age>60,221109_India_CouncilOfScientificAndIndustrialResearch_202102,Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India,2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India," Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim",,"The study was conducted among the population
of Jorhat district, Assam.",,2021-02-01,2021-02-28,Household and community samples,All,Multiple groups,61.0,,Age,>60,67,0.4179,,,,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.998,1.0,['High'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Romi Wahengbam,Council of Scientific and Industrial Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2022.10.011,2022-11-22,2024-03-01,Unverified,wahengbam_seroepidemiological_2022-1,IND
221109_India_CouncilOfScientificAndIndustrialResearch_202102_SexFemale,221109_India_CouncilOfScientificAndIndustrialResearch_202102,Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India,2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India," Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim",,"The study was conducted among the population
of Jorhat district, Assam.",,2021-02-01,2021-02-28,Household and community samples,Female,Multiple groups,,,Sex/Gender,,253,0.3597,,,,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.998,1.0,['High'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Romi Wahengbam,Council of Scientific and Industrial Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2022.10.011,2022-11-22,2024-03-01,Unverified,wahengbam_seroepidemiological_2022-1,IND
221109_India_CouncilOfScientificAndIndustrialResearch_202102_SexMale,221109_India_CouncilOfScientificAndIndustrialResearch_202102,Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India,2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India," Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim",,"The study was conducted among the population
of Jorhat district, Assam.",,2021-02-01,2021-02-28,Household and community samples,Male,Multiple groups,,,Sex/Gender,,613,0.42090000000000005,,,,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.998,1.0,['High'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Romi Wahengbam,Council of Scientific and Industrial Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2022.10.011,2022-11-22,2024-03-01,Unverified,wahengbam_seroepidemiological_2022-1,IND
221109_India_CouncilOfScientificAndIndustrialResearch_202106_TestAdjusted,221109_India_CouncilOfScientificAndIndustrialResearch_202106,Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India,2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India," Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim",,"The study was conducted among the population
of Jorhat district, Assam.",,2021-06-01,2021-06-30,Household and community samples,All,Multiple groups,,,Primary Estimate,,436,0.4623,0.4155,0.5091,True,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.998,1.0,['High'],,Unclear,No,Yes,,Yes,Yes,Yes,,Romi Wahengbam,Council of Scientific and Industrial Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2022.10.011,2022-11-22,2024-03-01,Unverified,wahengbam_seroepidemiological_2022-1,IND
221109_India_CouncilOfScientificAndIndustrialResearch_202106_TestVoxPressIgM,221109_India_CouncilOfScientificAndIndustrialResearch_202106,Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India,2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India," Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim",,"The study was conducted among the population
of Jorhat district, Assam.",,2021-06-01,2021-06-30,Household and community samples,All,Multiple groups,,,Test used,VoxPress IgM,436,0.0367,,,,,,,,Unclear,New Corona Virus (COVID-19) IgG / IgM Rapid Test,Voxtur Bio Ltd.,,Whole Blood,IgM,Spike,,,,['High'],,Unclear,No,Yes,,Yes,Yes,Yes,,Romi Wahengbam,Council of Scientific and Industrial Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2022.10.011,2022-11-22,2022-11-22,Unverified,wahengbam_seroepidemiological_2022-1,IND
221109_India_CouncilOfScientificAndIndustrialResearch_202106_TestVoxPressIgG,221109_India_CouncilOfScientificAndIndustrialResearch_202106,Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India,2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India," Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim",,"The study was conducted among the population
of Jorhat district, Assam.",,2021-06-01,2021-06-30,Household and community samples,All,Multiple groups,,,Test used,VoxPress IgG,436,0.1583,,,,,,,,Unclear,New Corona Virus (COVID-19) IgG / IgM Rapid Test,Voxtur Bio Ltd.,,Whole Blood,IgG,Spike,,,,['High'],,Unclear,No,Yes,,Yes,Yes,Yes,,Romi Wahengbam,Council of Scientific and Industrial Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2022.10.011,2022-11-22,2022-11-22,Unverified,wahengbam_seroepidemiological_2022-1,IND
221109_India_CouncilOfScientificAndIndustrialResearch_202106_Age<30,221109_India_CouncilOfScientificAndIndustrialResearch_202106,Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India,2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India," Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim",,"The study was conducted among the population
of Jorhat district, Assam.",,2021-06-01,2021-06-30,Household and community samples,All,Multiple groups,,29.0,Age,<30,121,0.2397,,,,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.998,1.0,['High'],,Unclear,No,Yes,,Yes,Yes,Yes,,Romi Wahengbam,Council of Scientific and Industrial Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2022.10.011,2022-11-22,2024-03-01,Unverified,wahengbam_seroepidemiological_2022-1,IND
221109_India_CouncilOfScientificAndIndustrialResearch_202106_SexFemale,221109_India_CouncilOfScientificAndIndustrialResearch_202106,Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India,2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India," Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim",,"The study was conducted among the population
of Jorhat district, Assam.",,2021-06-01,2021-06-30,Household and community samples,Female,Multiple groups,,,Sex/Gender,,122,0.18030000000000002,,,,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.998,1.0,['High'],,Unclear,No,Yes,,Yes,Yes,Yes,,Romi Wahengbam,Council of Scientific and Industrial Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2022.10.011,2022-11-22,2024-03-01,Unverified,wahengbam_seroepidemiological_2022-1,IND
221109_India_CouncilOfScientificAndIndustrialResearch_202106_SexMale,221109_India_CouncilOfScientificAndIndustrialResearch_202106,Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India,2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India," Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim",,"The study was conducted among the population
of Jorhat district, Assam.",,2021-06-01,2021-06-30,Household and community samples,Male,Multiple groups,,,Sex/Gender,,314,0.5732,,,,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.998,1.0,['High'],,Unclear,No,Yes,,Yes,Yes,Yes,,Romi Wahengbam,Council of Scientific and Industrial Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2022.10.011,2022-11-22,2024-03-01,Unverified,wahengbam_seroepidemiological_2022-1,IND
221109_India_CouncilOfScientificAndIndustrialResearch_202106_Neutralizing,221109_India_CouncilOfScientificAndIndustrialResearch_202106,Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India,2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India," Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim",,"The study was conducted among the population
of Jorhat district, Assam.",,2021-06-01,2021-06-30,Household and community samples,All,Multiple groups,,,Test used,VoxPress IgM,436,0.3211,,,,,,,,Unclear,"Elecsys® Anti‐SARS‐CoV‐2 (N),New Corona Virus (COVID-19) IgG / IgM Rapid Test,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit","Roche Diagnostics,Voxtur Bio Ltd.,GenScript",Multiple Types,Multiple Types,"['IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,Unclear,No,Yes,,Yes,Yes,Yes,,Romi Wahengbam,Council of Scientific and Industrial Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2022.10.011,2022-11-22,2024-03-01,Unverified,wahengbam_seroepidemiological_2022-1,IND
221109_India_CouncilOfScientificAndIndustrialResearch_202106_Age30-60,221109_India_CouncilOfScientificAndIndustrialResearch_202106,Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India,2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India," Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim",,"The study was conducted among the population
of Jorhat district, Assam.",,2021-06-01,2021-06-30,Household and community samples,All,Adults (18-64 years),30.0,60.0,Age,30-60,287,0.5401,,,,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.998,1.0,['High'],,Unclear,No,Yes,,Yes,Yes,Yes,,Romi Wahengbam,Council of Scientific and Industrial Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2022.10.011,2022-11-22,2024-03-01,Unverified,wahengbam_seroepidemiological_2022-1,IND
221109_India_CouncilOfScientificAndIndustrialResearch_202106_Overall,221109_India_CouncilOfScientificAndIndustrialResearch_202106,Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India,2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India," Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim",,"The study was conducted among the population
of Jorhat district, Assam.",,2021-06-01,2021-06-30,Household and community samples,All,Multiple groups,,,Analysis,,436,0.4633,,,,,,,True,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.998,1.0,['High'],,Unclear,No,Yes,,Yes,Yes,Yes,,Romi Wahengbam,Council of Scientific and Industrial Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2022.10.011,2022-11-22,2024-03-01,Unverified,wahengbam_seroepidemiological_2022-1,IND
221109_India_CouncilOfScientificAndIndustrialResearch_202106_Age>60,221109_India_CouncilOfScientificAndIndustrialResearch_202106,Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India,2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India," Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim",,"The study was conducted among the population
of Jorhat district, Assam.",,2021-06-01,2021-06-30,Household and community samples,All,Multiple groups,61.0,,Age,>60,28,0.6429,,,,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.998,1.0,['High'],,Unclear,No,Yes,,Yes,Yes,Yes,,Romi Wahengbam,Council of Scientific and Industrial Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijmmb.2022.10.011,2022-11-22,2024-03-01,Unverified,wahengbam_seroepidemiological_2022-1,IND
221109_Odisha_ICMRRegionalMedicalResearchCentre_Primary,221109_Odisha_ICMRRegionalMedicalResearchCentre,Serological survey for SARS-CoV-2 antibodies among tribal communities of Odisha post-second wave.,2022-11-09,Presentation or Conference,Regional,Cross-sectional survey ,India,Odisha,,residents of seven tribal districts of Odisha,,2021-08-30,2021-09-16,Household and community samples,All,Multiple groups,,,Primary Estimate,anti-N overall estimate,2855,0.728,0.701,0.753,True,,True,,True,Stratified probability,Not reported/ Unable to specify,,,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,No,,Unclear,Yes,No,,Jaya Singh Kshatri,ICMR Regional Medical Research Centre,Not Unity-Aligned,https://dx.doi.org/10.4103/ijmr.ijmr_3428_21,2022-11-17,2022-11-17,Unverified,kshatri_serological_2022,IND
221109_Jharkhand_ICMRRegionalMedicalResearchCentre_round1_overall,221109_Jharkhand_ICMRRegionalMedicalResearchCentre_round1,"Trend in seroprevalence of SARS-CoV-2 (IgG antibody) among tribal-dominated population: Findings from Jharkhand, India.",2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,Jharkhand,,"""The same 10 districts of the State were selected during both rounds of serosurveys. Individuals aged more than 18 yr were included in the survey after obtaining informed consent for data and blood sample collection.""","""Bedridden patients, pregnant women, and individuals with recognizable cognitive impairment were excluded.""",2020-06-01,2020-06-30,Household and community samples,All,Multiple groups,19.0,,Primary Estimate,,4761,0.0054,0.0036,0.008,True,,,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),,1.0,0.995,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Amarendra Mahapatra,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.4103/ijmr.ijmr_3040_21,2022-11-17,2024-03-01,Unverified,mahapatra_trend_2022,IND
221109_Jharkhand_ICMRRegionalMedicalResearchCentre_round1_female,221109_Jharkhand_ICMRRegionalMedicalResearchCentre_round1,"Trend in seroprevalence of SARS-CoV-2 (IgG antibody) among tribal-dominated population: Findings from Jharkhand, India.",2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,Jharkhand,,"""The same 10 districts of the State were selected during both rounds of serosurveys. Individuals aged more than 18 yr were included in the survey after obtaining informed consent for data and blood sample collection.""","""Bedridden patients, pregnant women, and individuals with recognizable cognitive impairment were excluded.""",2020-06-01,2020-06-30,Household and community samples,Female,Multiple groups,19.0,,Sex/Gender,,1752,0.0045000000000000005,0.0019,0.0089,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),,1.0,0.995,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Amarendra Mahapatra,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.4103/ijmr.ijmr_3040_21,2022-11-17,2024-03-01,Unverified,mahapatra_trend_2022,IND
221109_Jharkhand_ICMRRegionalMedicalResearchCentre_round1_male,221109_Jharkhand_ICMRRegionalMedicalResearchCentre_round1,"Trend in seroprevalence of SARS-CoV-2 (IgG antibody) among tribal-dominated population: Findings from Jharkhand, India.",2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,Jharkhand,,"""The same 10 districts of the State were selected during both rounds of serosurveys. Individuals aged more than 18 yr were included in the survey after obtaining informed consent for data and blood sample collection.""","""Bedridden patients, pregnant women, and individuals with recognizable cognitive impairment were excluded.""",2020-06-01,2020-06-30,Household and community samples,Male,Multiple groups,19.0,,Sex/Gender,,3009,0.0073,0.0045000000000000005,0.011000000000000001,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),,1.0,0.995,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Amarendra Mahapatra,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.4103/ijmr.ijmr_3040_21,2022-11-17,2024-03-01,Unverified,mahapatra_trend_2022,IND
221109_Jharkhand_ICMRRegionalMedicalResearchCentre_round1_45to59,221109_Jharkhand_ICMRRegionalMedicalResearchCentre_round1,"Trend in seroprevalence of SARS-CoV-2 (IgG antibody) among tribal-dominated population: Findings from Jharkhand, India.",2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,Jharkhand,,"""The same 10 districts of the State were selected during both rounds of serosurveys. Individuals aged more than 18 yr were included in the survey after obtaining informed consent for data and blood sample collection.""","""Bedridden patients, pregnant women, and individuals with recognizable cognitive impairment were excluded.""",2020-06-01,2020-06-30,Household and community samples,All,Adults (18-64 years),45.0,59.0,Age,45-49,1181,0.0084,0.004,0.015500000000000002,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),,1.0,0.995,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Amarendra Mahapatra,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.4103/ijmr.ijmr_3040_21,2022-11-17,2024-03-01,Unverified,mahapatra_trend_2022,IND
221109_Jharkhand_ICMRRegionalMedicalResearchCentre_round1_19to44,221109_Jharkhand_ICMRRegionalMedicalResearchCentre_round1,"Trend in seroprevalence of SARS-CoV-2 (IgG antibody) among tribal-dominated population: Findings from Jharkhand, India.",2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,Jharkhand,,"""The same 10 districts of the State were selected during both rounds of serosurveys. Individuals aged more than 18 yr were included in the survey after obtaining informed consent for data and blood sample collection.""","""Bedridden patients, pregnant women, and individuals with recognizable cognitive impairment were excluded.""",2020-06-01,2020-06-30,Household and community samples,All,Adults (18-64 years),19.0,44.0,Age,19-44,3112,0.005699999999999999,0.0034000000000000002,0.0091,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),,1.0,0.995,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Amarendra Mahapatra,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.4103/ijmr.ijmr_3040_21,2022-11-17,2024-03-01,Unverified,mahapatra_trend_2022,IND
221109_Jharkhand_ICMRRegionalMedicalResearchCentre_round1_60plus,221109_Jharkhand_ICMRRegionalMedicalResearchCentre_round1,"Trend in seroprevalence of SARS-CoV-2 (IgG antibody) among tribal-dominated population: Findings from Jharkhand, India.",2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,Jharkhand,,"""The same 10 districts of the State were selected during both rounds of serosurveys. Individuals aged more than 18 yr were included in the survey after obtaining informed consent for data and blood sample collection.""","""Bedridden patients, pregnant women, and individuals with recognizable cognitive impairment were excluded.""",2020-06-01,2020-06-30,Household and community samples,All,Multiple groups,60.0,,Age,60+,468,0.0042,0.0005,0.015300000000000001,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),,1.0,0.995,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Amarendra Mahapatra,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.4103/ijmr.ijmr_3040_21,2022-11-17,2024-03-01,Unverified,mahapatra_trend_2022,IND
221109_Jharkhand_ICMRRegionalMedicalResearchCentre_round2_overall,221109_Jharkhand_ICMRRegionalMedicalResearchCentre_round2,"Trend in seroprevalence of SARS-CoV-2 (IgG antibody) among tribal-dominated population: Findings from Jharkhand, India.",2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,Jharkhand,,"""The same 10 districts of the State were selected during both rounds of serosurveys. Individuals aged more than 18 yr were included in the survey after obtaining informed consent for data and blood sample collection.""","""Bedridden patients, pregnant women, and individuals with recognizable cognitive impairment were excluded.""",2021-02-01,2021-02-28,Household and community samples,All,Multiple groups,19.0,,Primary Estimate,,3855,0.41960000000000003,0.40159999999999996,0.4322,True,,,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),,1.0,0.995,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Amarendra Mahapatra,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.4103/ijmr.ijmr_3040_21,2022-11-17,2024-03-01,Unverified,mahapatra_trend_2022,IND
221109_Jharkhand_ICMRRegionalMedicalResearchCentre_round2_45to59,221109_Jharkhand_ICMRRegionalMedicalResearchCentre_round2,"Trend in seroprevalence of SARS-CoV-2 (IgG antibody) among tribal-dominated population: Findings from Jharkhand, India.",2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,Jharkhand,,"""The same 10 districts of the State were selected during both rounds of serosurveys. Individuals aged more than 18 yr were included in the survey after obtaining informed consent for data and blood sample collection.""","""Bedridden patients, pregnant women, and individuals with recognizable cognitive impairment were excluded.""",2021-02-01,2021-02-28,Household and community samples,All,Adults (18-64 years),45.0,59.0,Age,45-49,878,0.4635,0.4301,0.49710000000000004,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),,1.0,0.995,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Amarendra Mahapatra,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.4103/ijmr.ijmr_3040_21,2022-11-17,2024-03-01,Unverified,mahapatra_trend_2022,IND
221109_Jharkhand_ICMRRegionalMedicalResearchCentre_round2_male,221109_Jharkhand_ICMRRegionalMedicalResearchCentre_round2,"Trend in seroprevalence of SARS-CoV-2 (IgG antibody) among tribal-dominated population: Findings from Jharkhand, India.",2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,Jharkhand,,"""The same 10 districts of the State were selected during both rounds of serosurveys. Individuals aged more than 18 yr were included in the survey after obtaining informed consent for data and blood sample collection.""","""Bedridden patients, pregnant women, and individuals with recognizable cognitive impairment were excluded.""",2021-02-01,2021-02-28,Household and community samples,Male,Multiple groups,19.0,,Sex/Gender,,2288,0.5135000000000001,0.4929,0.5342,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),,1.0,0.995,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Amarendra Mahapatra,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.4103/ijmr.ijmr_3040_21,2022-11-17,2024-03-01,Unverified,mahapatra_trend_2022,IND
221109_Jharkhand_ICMRRegionalMedicalResearchCentre_round2_female,221109_Jharkhand_ICMRRegionalMedicalResearchCentre_round2,"Trend in seroprevalence of SARS-CoV-2 (IgG antibody) among tribal-dominated population: Findings from Jharkhand, India.",2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,Jharkhand,,"""The same 10 districts of the State were selected during both rounds of serosurveys. Individuals aged more than 18 yr were included in the survey after obtaining informed consent for data and blood sample collection.""","""Bedridden patients, pregnant women, and individuals with recognizable cognitive impairment were excluded.""",2021-02-01,2021-02-28,Household and community samples,Female,Multiple groups,19.0,,Sex/Gender,,1567,0.337,0.3146,0.36100000000000004,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),,1.0,0.995,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Amarendra Mahapatra,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.4103/ijmr.ijmr_3040_21,2022-11-17,2024-03-01,Unverified,mahapatra_trend_2022,IND
221109_Jharkhand_ICMRRegionalMedicalResearchCentre_round2_60plus,221109_Jharkhand_ICMRRegionalMedicalResearchCentre_round2,"Trend in seroprevalence of SARS-CoV-2 (IgG antibody) among tribal-dominated population: Findings from Jharkhand, India.",2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,Jharkhand,,"""The same 10 districts of the State were selected during both rounds of serosurveys. Individuals aged more than 18 yr were included in the survey after obtaining informed consent for data and blood sample collection.""","""Bedridden patients, pregnant women, and individuals with recognizable cognitive impairment were excluded.""",2021-02-01,2021-02-28,Household and community samples,All,Multiple groups,60.0,,Age,60+,411,0.36,0.31370000000000003,0.4086,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),,1.0,0.995,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Amarendra Mahapatra,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.4103/ijmr.ijmr_3040_21,2022-11-17,2024-03-01,Unverified,mahapatra_trend_2022,IND
221109_Jharkhand_ICMRRegionalMedicalResearchCentre_round2_19to44,221109_Jharkhand_ICMRRegionalMedicalResearchCentre_round2,"Trend in seroprevalence of SARS-CoV-2 (IgG antibody) among tribal-dominated population: Findings from Jharkhand, India.",2022-11-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,India,Jharkhand,,"""The same 10 districts of the State were selected during both rounds of serosurveys. Individuals aged more than 18 yr were included in the survey after obtaining informed consent for data and blood sample collection.""","""Bedridden patients, pregnant women, and individuals with recognizable cognitive impairment were excluded.""",2021-02-01,2021-02-28,Household and community samples,All,Adults (18-64 years),19.0,44.0,Age,19-44,2566,0.4473,0.428,0.4669,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),,1.0,0.995,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Amarendra Mahapatra,ICMR-Regional Medical Research Centre,Unity-Aligned,https://dx.doi.org/10.4103/ijmr.ijmr_3040_21,2022-11-17,2024-03-01,Unverified,mahapatra_trend_2022,IND
221111_Ernakulam_AmritaInstituteOfMedicalSciences_Overall,221111_Ernakulam_AmritaInstituteOfMedicalSciences,"Seroprevalence of COVID-19 antibody among children aged 5-17 years in an urban and rural area of Ernakulam District, Kerala.",2022-11-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Kerala,Ernakulam,The study participants included children aged 5–17 years of age,children infected with SARS‑CoV‑2 at the time of the study were excluded from the study,2021-09-15,2021-11-15,Household and community samples,All,Children and Youth (0-17 years),5.0,17.0,Primary Estimate,,349,0.478,,,True,,,,True,Unclear,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by manufacturers,1.0,0.988,['Moderate'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Saanu Sidharthan,Amrita Institute of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.4103/ijph.ijph_1082_22,2022-12-07,2024-03-01,Unverified,sidharthan_seroprevalence_2022,IND
221111_Ernakulam_AmritaInstituteOfMedicalSciences_Age5to11,221111_Ernakulam_AmritaInstituteOfMedicalSciences,"Seroprevalence of COVID-19 antibody among children aged 5-17 years in an urban and rural area of Ernakulam District, Kerala.",2022-11-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Kerala,Ernakulam,The study participants included children aged 5–17 years of age,children infected with SARS‑CoV‑2 at the time of the study were excluded from the study,2021-09-15,2021-11-15,Household and community samples,All,Children and Youth (0-17 years),5.0,11.0,Age,age: 5-11,99,0.578,,,,,,,,Unclear,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by manufacturers,1.0,0.988,['Moderate'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Saanu Sidharthan,Amrita Institute of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.4103/ijph.ijph_1082_22,2022-12-07,2024-03-01,Unverified,sidharthan_seroprevalence_2022,IND
221111_Ernakulam_AmritaInstituteOfMedicalSciences_Age12to17,221111_Ernakulam_AmritaInstituteOfMedicalSciences,"Seroprevalence of COVID-19 antibody among children aged 5-17 years in an urban and rural area of Ernakulam District, Kerala.",2022-11-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Kerala,Ernakulam,The study participants included children aged 5–17 years of age,children infected with SARS‑CoV‑2 at the time of the study were excluded from the study,2021-09-15,2021-11-15,Household and community samples,All,Children and Youth (0-17 years),12.0,17.0,Age,age: 12-17,250,0.44,,,,,,,,Unclear,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by manufacturers,1.0,0.988,['Moderate'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Saanu Sidharthan,Amrita Institute of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.4103/ijph.ijph_1082_22,2022-12-07,2024-03-01,Unverified,sidharthan_seroprevalence_2022,IND
221119_TamilNadu_PanimalarMedicalCollegeHospital,221119_TamilNadu_PanimalarMedicalCollegeHospital&ResearchInstitute,"Impact of COVID-19 Vaccination on Seroprevalence of SARS-CoV-2 among the Health Care Workers in a Tertiary Care Centre, South India",2022-11-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Tamil Nadu,,HCWs at tertiary care centre in Tamil Nadu,,2021-01-15,2021-04-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,157,0.382,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Divyaa Elangovan,Panimalar Medical College Hospital & Research Institute,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10111967,2023-04-03,2024-03-01,Unverified,elangovan_impact_2022,IND
221226_Delhi_AllIndiaInstituteofMedicalSciences_Wantai,221226_Delhi_AllIndiaInstituteofMedicalSciences,Test concordance and diagnostic accuracy of three serological assays for detection of anti-SARS-CoV-2 antibody: result from a population-based sero-epidemiological study in Delhi,2022-12-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Delhi,,"""Any participants with age more than equal to 1 year were included""","""The participants not willing to give blood sample were
excluded.""",2021-03-15,2021-09-15,Household and community samples,All,Multiple groups,1.0,,Primary Estimate,,3491,0.7809999999999999,,,True,,,,True,Stratified non-probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,0.9450000000000001,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07805-5,2022-12-27,2024-04-19,Verified,misra_test_2022,IND
221226_Delhi_AllIndiaInstituteofMedicalSciences_AbbottCLIA,221226_Delhi_AllIndiaInstituteofMedicalSciences,Test concordance and diagnostic accuracy of three serological assays for detection of anti-SARS-CoV-2 antibody: result from a population-based sero-epidemiological study in Delhi,2022-12-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Delhi,,"""Any participants with age more than equal to 1 year were included""","""The participants not willing to give blood sample were
excluded.""",2021-03-15,2021-09-15,Household and community samples,All,Multiple groups,1.0,,Test used,Abbott CLIA,3491,0.318,,,,,,,,Stratified non-probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07805-5,2022-12-27,2024-04-19,Verified,misra_test_2022,IND
221226_Delhi_AllIndiaInstituteofMedicalSciences_QBRD,221226_Delhi_AllIndiaInstituteofMedicalSciences,Test concordance and diagnostic accuracy of three serological assays for detection of anti-SARS-CoV-2 antibody: result from a population-based sero-epidemiological study in Delhi,2022-12-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Delhi,,"""Any participants with age more than equal to 1 year were included""","""The participants not willing to give blood sample were
excluded.""",2021-03-15,2021-09-15,Household and community samples,All,Multiple groups,1.0,,Test used,In-house QRBD,3357,0.752,,,,,,,,Stratified non-probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,1.0,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07805-5,2022-12-27,2024-04-19,Verified,misra_test_2022,IND
221212_USA_RTIInternational_Belagavi,221212_USA_RTIInternational_Belagavi,"COVID-19 Antibody Positivity Over Time and Pregnancy Outcomes in Seven Low-and-Middle-Income Countries: A Prospective, Observational Study of the Global Network for Women's and Children's Health Research.",2022-12-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Belagavi,"""The COVID-19 antibody study, embedded within the MNHR, included a sub-set of women who were approached at delivery and enrolled. We collected a serum sample at or near delivery for each mother who was approached and consented.""", Women who did not consent to give blood for testing. Indeterminate results are excluded. ,2020-12-01,2020-12-31,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,1639,0.391,,,True,,,,True,Convenience,ELISA SARS-CoV-2 IgG Test System,Zeus,ELISA,Serum,IgG,"Nucleocapsid (N-protein), Spike",,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Robert L. Goldenberg,RTI International,Unity-Aligned,https://dx.doi.org/10.1111/1471-0528.17366,2022-12-24,2024-03-01,Unverified,goldenberg_covid-19_2022,IND
221212_USA_RTIInternational_Nagpur,221212_USA_RTIInternational_Nagpur,"COVID-19 Antibody Positivity Over Time and Pregnancy Outcomes in Seven Low-and-Middle-Income Countries: A Prospective, Observational Study of the Global Network for Women's and Children's Health Research.",2022-12-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,Nagpur,"""The COVID-19 antibody study, embedded within the MNHR, included a sub-set of women who were approached at delivery and enrolled. We collected a serum sample at or near delivery for each mother who was approached and consented.""", Women who did not consent to give blood for testing. Indeterminate results are excluded. ,2020-11-01,2020-11-30,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,882,0.44799999999999995,,,True,,,,True,Convenience,ELISA SARS-CoV-2 IgG Test System,Zeus,ELISA,Serum,IgG,"Nucleocapsid (N-protein), Spike",,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Robert L. Goldenberg,RTI International,Unity-Aligned,https://dx.doi.org/10.1111/1471-0528.17366,2022-12-24,2024-03-01,Unverified,goldenberg_covid-19_2022,IND
230101_HimachalPradesh_IGCM_Primary,230101_HimachalPradesh_IGMC,"Seroprevalence of SARS-CoV-2 among Children Visiting a Tertiary Hospital in Himachal Pradesh, India",2023-01-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Himachal Pradesh,Shimla,"""Every alternate child/adolescent attending the outdoor department or admitted in the paediatric indoor facility during the study period, whose caretakers consented for the study were recruited in the study""","""All those children and guardians, denying consent were not enrolled in the study.""",2021-10-15,2022-03-15,Residual sera,All,Children and Youth (0-17 years),0.0,18.0,Primary Estimate,"IgG, IgM, IgM and IgG (IgG OR other antibodies)",500,0.186,,,True,,,,True,Convenience,IgG and IgM anti-SARS-CoV-2 ELISA,Diagnostic Bioprobes,,Serum,"['IgG', 'IgM']",Spike,,0.98,0.98,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,Unclear,Pancham Kumar,Dr. Rajendra Prasad Government Medical College,Unity-Aligned,https://dx.doi.org/10.7860/JCDR/2023/59945.17429,2023-03-09,2024-03-26,Verified,kumar_seroprevalence_2023,IND
230103_Gurugram_MedantaTheMedicity_Overall,230103_Gurugram_MedantaTheMedicity,Seroprevalence of Covid-19 infection among healthcare workers: A study from a tertiary care hospital in the National Capital Region of India.,2023-01-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Haryana,Gurugram,"""All healthcare personnel of Medanta Hospital who consented to participate were eligible for inclusion.""","""Those who had participated in Covid-19 drug trials, or had received immunoglobulins and/or convalescent plasma within the past 3 months were excluded.""",2021-01-12,2021-02-13,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,3258,0.462,0.444,0.479,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Sushila Kataria,Medanta–The Medicity,Not Unity-Aligned,https://dx.doi.org/10.25259/NMJI_345_21,2023-02-17,2024-03-01,Unverified,kataria_seroprevalence_2023,IND
230120_NewDelhi_HamdardInstituteOfMedicalSciencesAndResearch_Baseline_Overall,230120_NewDelhi_HamdardInstituteOfMedicalSciencesAndResearch_Baseline,"Assessment of potential risk factors for COVID-19 among health care workers in a health care setting in Delhi, India -a cohort study",2023-01-20,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,India,,New Delhi,"Inclusion criteria. All HCWs exposed to COVID-19 patients receiving care in this healthcare facility within 72 hours of confirmation of the diagnosis with
• Close contact (within 1 meter) with a laboratory-confirmed case, or
• Exposure to patient’s blood or body fluids, or
• Exposure to patient’s used materials, devices, or equipment, or
• Exposure to environmental surfaces around the confirmed case, including their bed, table, wheelchair, ward corridor, etc.

Those who gave written informed consent were included.","Exclusion criteria.
• HCWs who also worked in another healthcare facility
• HCWs who had already contracted or were positive or had a confirmed COVID-19 case among their household/close contacts.
• HCWs who were clinically serious and could not participate in the study.",2020-12-15,2021-05-18,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,192,0.62,0.549,0.6859999999999999,True,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"IgG, IgM, IgA",Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Mridu Dudeja,Hamdard Institute of Medical Sciences and Research,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0265290,2023-02-10,2024-03-01,Unverified,dudeja_assessment_2023,IND
230120_NewDelhi_HamdardInstituteOfMedicalSciencesAndResearch_Followup_Overall,230120_NewDelhi_HamdardInstituteOfMedicalSciencesAndResearch_Followup,"Assessment of potential risk factors for COVID-19 among health care workers in a health care setting in Delhi, India -a cohort study",2023-01-20,Journal Article (Peer-Reviewed),Local,Prospective cohort,India,,New Delhi,"Inclusion criteria. All HCWs exposed to COVID-19 patients receiving care in this healthcare facility within 72 hours of confirmation of the diagnosis with
• Close contact (within 1 meter) with a laboratory-confirmed case, or
• Exposure to patient’s blood or body fluids, or
• Exposure to patient’s used materials, devices, or equipment, or
• Exposure to environmental surfaces around the confirmed case, including their bed, table, wheelchair, ward corridor, etc.

Those who gave written informed consent were included.","Exclusion criteria.
• HCWs who also worked in another healthcare facility
• HCWs who had already contracted or were positive or had a confirmed COVID-19 case among their household/close contacts.
• HCWs who were clinically serious and could not participate in the study.",2021-01-12,2021-06-15,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,139,0.777,,,True,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"IgG, IgM, IgA",Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Mridu Dudeja,Hamdard Institute of Medical Sciences and Research,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0265290,2023-02-10,2024-03-01,Unverified,dudeja_assessment_2023,IND
230204_India_AllIndiaInstituteofMedicalSciences,230204_India_AllIndiaInstituteofMedicalSciences,High seroprevalence against SARS-CoV-2 in non-vaccinated patients with inflammatory bowel disease from Northern India. ,2023-02-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,,,"""enrolled outpatients with IBD (both
ulcerative colitis [UC] and Crohn’s disease [CD]), attending
the IBD clinic between July 2020 and April 2021. Healthy
contacts of patients were included as healthy controls (HCs).
Adult patients with IBD, age>18 years and willing to give
consent were included""","""Patients on biologics were excluded
from the study.""",2020-07-15,2021-04-15,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),18.0,,Primary Estimate,,235,0.32,,,True,,,,True,Convenience,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Bhaskar Kante,All India Institute of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12664-022-01310-y,2023-03-10,2024-03-01,Unverified,kante_high_2023,IND
230321_Hyderabad_NationalInstituteOfNutrition,230321_Hyderabad_NationalInstituteOfNutrition,"Impact of COVID-19 during pregnancy on placental pathology, maternal and neonatal outcome - A cross-sectional study on anemic term pregnant women from a tertiary care hospital in southern India",2023-03-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Telangana,Hyderabad,"Consecutive pregnant women (N=212) in labor, admitted for delivery in the hospital, and who were willing to participate were enrolled after taking written informed consent.

All women aged between 18–49 years, at 37-40 weeks of gestation, who were either primi or multiparous, and who did not receive any treatment for viral infections in their last trimester of pregnancy, were allowed to take part in the study.","Those suffering from kidney disease, rheumatoid disease, diabetes mellitus, hypertension, acquired immune deficiency syndrome (AIDS), on immunosuppressant drugs, and who had complicated conditions such as ectopic pregnancy and hydatidiform mole were not included in the study.",2021-08-15,2021-11-15,Pregnant or parturient women,Female,Adults (18-64 years),18.0,49.0,Primary Estimate,,212,0.5755,,,True,,,,True,Sequential,Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA,Zydus Diagnostics,ELISA,Serum,IgG,"Spike, Whole-virus antigen",,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,M. V. Surekha,National Institute of Nutrition,Not Unity-Aligned,https://dx.doi.org/10.3389/fendo.2023.1092104,2023-05-05,2024-03-01,Unverified,surekha_impact_2023,IND
230323_ Itanagar_TomoRibaInstituteofHealthandMedicalSciences,230323_ Itanagar_TomoRibaInstituteofHealthandMedicalSciences,"Seroprevalence of IgG and IgM Antibodies against SARS-CoV-2 Infection in Inhabitants of Itanagar Capital Region, Arunachal Pradesh, India.",2023-03-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Arunachal Pradesh,Itanagar,"""Participants above five years of age who had re- sided in ICR region for more than a year, subjects regardless of whether or not they had been in- fected by or vaccinated against SARS-CoV-2 even if partially.""","""Residents aged under five years and those not willing to participate in the study were excluded.""",2021-09-15,2021-11-15,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,,1031,0.9224,,,True,,,,True,Stratified probability,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Multiple Types,"['IgG', 'IgM']",,Validated by manufacturers,0.94,0.987,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Hage Nobin,Tomo Riba Institute of Health and Medical Sciences,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231152/,2023-06-29,2024-04-22,Verified,nobinSeroprevalenceIgGIgM2023,IND
230323_ Itanagar_TomoRibaInstituteofHealthandMedicalSciences_Age18-44_IgG,230323_ Itanagar_TomoRibaInstituteofHealthandMedicalSciences,"Seroprevalence of IgG and IgM Antibodies against SARS-CoV-2 Infection in Inhabitants of Itanagar Capital Region, Arunachal Pradesh, India.",2023-03-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Arunachal Pradesh,Itanagar,"""Participants above five years of age who had re- sided in ICR region for more than a year, subjects regardless of whether or not they had been in- fected by or vaccinated against SARS-CoV-2 even if partially.""","""Residents aged under five years and those not willing to participate in the study were excluded.""",2021-09-15,2021-11-15,Household and community samples,All,Adults (18-64 years),18.0,44.0,Age,18-44,714,0.9468,,,,,,,,Stratified probability,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Multiple Types,"['IgG', 'IgM']",,Validated by manufacturers,0.94,0.987,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Hage Nobin,Tomo Riba Institute of Health and Medical Sciences,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231152/,2024-04-22,2024-04-22,Verified,nobinSeroprevalenceIgGIgM2023,IND
230323_ Itanagar_TomoRibaInstituteofHealthandMedicalSciences_Age5-17_IgG,230323_ Itanagar_TomoRibaInstituteofHealthandMedicalSciences,"Seroprevalence of IgG and IgM Antibodies against SARS-CoV-2 Infection in Inhabitants of Itanagar Capital Region, Arunachal Pradesh, India.",2023-03-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Arunachal Pradesh,Itanagar,"""Participants above five years of age who had re- sided in ICR region for more than a year, subjects regardless of whether or not they had been in- fected by or vaccinated against SARS-CoV-2 even if partially.""","""Residents aged under five years and those not willing to participate in the study were excluded.""",2021-09-15,2021-11-15,Household and community samples,All,Children and Youth (0-17 years),5.0,17.0,Age,5-17,111,0.7117,,,,,,,,Stratified probability,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Multiple Types,"['IgG', 'IgM']",,Validated by manufacturers,0.94,0.987,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Hage Nobin,Tomo Riba Institute of Health and Medical Sciences,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231152/,2024-04-22,2024-04-22,Verified,nobinSeroprevalenceIgGIgM2023,IND
230323_ Itanagar_TomoRibaInstituteofHealthandMedicalSciences_Age45-65_IgG,230323_ Itanagar_TomoRibaInstituteofHealthandMedicalSciences,"Seroprevalence of IgG and IgM Antibodies against SARS-CoV-2 Infection in Inhabitants of Itanagar Capital Region, Arunachal Pradesh, India.",2023-03-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Arunachal Pradesh,Itanagar,"""Participants above five years of age who had re- sided in ICR region for more than a year, subjects regardless of whether or not they had been in- fected by or vaccinated against SARS-CoV-2 even if partially.""","""Residents aged under five years and those not willing to participate in the study were excluded.""",2021-09-15,2021-11-15,Household and community samples,All,Adults (18-64 years),45.0,65.0,Age,45-65,202,0.9554,,,,,,,,Stratified probability,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Multiple Types,"['IgG', 'IgM']",,Validated by manufacturers,0.94,0.987,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Hage Nobin,Tomo Riba Institute of Health and Medical Sciences,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231152/,2024-04-22,2024-04-22,Verified,nobinSeroprevalenceIgGIgM2023,IND
230323_ Itanagar_TomoRibaInstituteofHealthandMedicalSciences_Age>65_IgG,230323_ Itanagar_TomoRibaInstituteofHealthandMedicalSciences,"Seroprevalence of IgG and IgM Antibodies against SARS-CoV-2 Infection in Inhabitants of Itanagar Capital Region, Arunachal Pradesh, India.",2023-03-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Arunachal Pradesh,Itanagar,"""Participants above five years of age who had re- sided in ICR region for more than a year, subjects regardless of whether or not they had been in- fected by or vaccinated against SARS-CoV-2 even if partially.""","""Residents aged under five years and those not willing to participate in the study were excluded.""",2021-09-15,2021-11-15,Household and community samples,All,Seniors (65+ years),66.0,,Age,>65,4,0.75,,,,,,,,Stratified probability,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Multiple Types,"['IgG', 'IgM']",,Validated by manufacturers,0.94,0.987,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Hage Nobin,Tomo Riba Institute of Health and Medical Sciences,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231152/,2024-04-22,2024-04-22,Verified,nobinSeroprevalenceIgGIgM2023,IND
230421_Chennai_JohnsHopkinsBloombergSchoolofPublicHealth_AntiS_TestAdj_Overall,230421_Chennai_JohnsHopkinsBloombergSchoolofPublicHealth,"A Mixture Model for Estimating SARS-CoV-2 Seroprevalence in Chennai, India",2023-04-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Tamil Nadu,Chennai,"We conducted a cross-sectional, household-based serosurvey to measure the seroprevalence of SARS-CoV-2 antibodies in Chennai, India.

The goal was to enroll as many individuals 5 years of age and older as possible from each household.",,2021-01-09,2021-05-13,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,Anti-S; test adjusted,4629,0.657,0.622,0.706,True,True,,,,Stratified probability,AdviseDX SARS-CoV-2 anti-IgG II assay,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.956,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Matt Hitchings,Johns Hopkins Bloomberg School of Public Health,Unity-Aligned,https://dx.doi.org/10.1093/aje/kwad103,2023-05-24,2024-04-22,Verified,hitchings_mixture_2023,IND
230421_Chennai_JohnsHopkinsBloombergSchoolofPublicHealth_AntiS_UnAdj,230421_Chennai_JohnsHopkinsBloombergSchoolofPublicHealth,"A Mixture Model for Estimating SARS-CoV-2 Seroprevalence in Chennai, India",2023-04-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Tamil Nadu,Chennai,"We conducted a cross-sectional, household-based serosurvey to measure the seroprevalence of SARS-CoV-2 antibodies in Chennai, India.

The goal was to enroll as many individuals 5 years of age and older as possible from each household.",,2021-01-09,2021-05-13,Household and community samples,All,Multiple groups,5.0,,Analysis,Anti-S; unadjusted,4629,0.62,0.606,0.634,,,,,True,Stratified probability,AdviseDX SARS-CoV-2 anti-IgG II assay,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.956,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Matt Hitchings,Johns Hopkins Bloomberg School of Public Health,Unity-Aligned,https://dx.doi.org/10.1093/aje/kwad103,2023-05-25,2024-04-22,Verified,hitchings_mixture_2023,IND
230421_Chennai_JohnsHopkinsBloombergSchoolofPublicHealth_AntiN_UnAdj,230421_Chennai_JohnsHopkinsBloombergSchoolofPublicHealth,"A Mixture Model for Estimating SARS-CoV-2 Seroprevalence in Chennai, India",2023-04-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Tamil Nadu,Chennai,"We conducted a cross-sectional, household-based serosurvey to measure the seroprevalence of SARS-CoV-2 antibodies in Chennai, India.

The goal was to enroll as many individuals 5 years of age and older as possible from each household.",,2021-01-09,2021-05-13,Household and community samples,All,Multiple groups,5.0,,Test used,Anti-N; unadjusted,4677,0.135,0.126,0.145,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.857,0.999,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Matt Hitchings,Johns Hopkins Bloomberg School of Public Health,Unity-Aligned,https://dx.doi.org/10.1093/aje/kwad103,2023-05-25,2024-04-22,Verified,hitchings_mixture_2023,IND
230423_WesternMaharashtra_KEMHospitalResearchCentre,230423_WesternMaharashtra_KEMHospitalResearchCentre,"Seroprevalence of SARS-CoV-2 specific Immunoglobin G antibodies in rural population of Western Maharashtra, India.",2023-04-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,India,Western Maharashtra,,"Maharashtra, India gen pop",,2021-01-15,2021-06-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,14274,0.45,,,True,,,,True,Stratified probability,Not reported/ Unable to specify,,,,,,,,,['Moderate'],,Yes,Yes,No,,Unclear,Yes,No,,Dhiraj Agarwal,KEM Hospital Research Centre,Not Unity-Aligned,https://dx.doi.org/10.7189/jogh.13.06011,2023-06-02,2023-06-03,Unverified,agarwal_seroprevalence_2023,IND
230515_India_LakshmiHospital_Overall,230515_India_LakshmiHospital,Severe acute respiratory syndrome Coronavirus 2 antibodies in ST-segment elevation myocardial infarction patients and its impact on thrombus in the coronaries,2023-05-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,India,Kerala,Palakkad,Consecutive STEMI patients admitted to the coronary care unit at this tertiary care center and undergoing PAMI,,2020-11-15,2021-07-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,Consecutive STEMI patients with Ab test available,177,0.203,,,True,,,,True,Sequential,Author designed (CLIA),,CLIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,1.0,0.9981,['High'],,No,No,No,,Unclear,Yes,Yes,,Jayagopal Pallakshmi,Lakshmi Hospital,Not Unity-Aligned,https://dx.doi.org/10.4103/jicc.jicc_40_22,2023-08-22,2023-08-25,Unverified,jayagopal_severe_2023,IND
230524_Kerala_JubileeMissionMedicalCollegeandResearchInstitute,230524_Kerala_JubileeMissionMedicalCollegeandResearchInstitute,Seroprevalence of SARS-CoV-2(Covid-19) antibody among blood donors in a tertiary care centre in South India,2023-05-24,Preprint,Local,Cross-sectional survey ,India,Kerala,,"""Age > 18 years and <60 years, who fulfil the Donor criteria of D&C Act 
Donors with no symptoms of COVID-19 in the past 28 days""","Donors who had a history of COVID-19 
Any donor who had a close contact with other COVID-19 patients in the last 28 days
Any donor who had travelled abroad or came back from abroad after January,2020
Donors who have received COVID-19 vaccine
Donors not willing to participate in the study 
All exclusions as per the donor deferral criteria of D&C Act and NACO guidelines for COVID-19 pandemic.
",2021-03-15,2021-07-15,Blood donors,All,Adults (18-64 years),18.0,60.0,Primary Estimate,,300,0.153,,,True,,,,True,Sequential,"Access SARS-CoV-2 IgG Reagent Antibody Test,Access SARS CoV-2 IgM Antibody Test","Beckman Coulter,Beckman coulter",CLIA,Whole Blood,"['IgG', 'IgM']",Spike,,,,['High'],,No,No,Yes,,Yes,Yes,No,,Sherin John,Jubilee Mission Medical College and Research Institute,Not Unity-Aligned,https://doi.org/10.22541/au.168493759.96200562/v1,2023-06-28,2024-03-01,Unverified,john_seroprevalence_2023,IND
230619_India_AllIndiaInstituteofMedicalSciences_Round1_Overall,230619_India_AllIndiaInstituteofMedicalSciences_Round1,"Anti-SARS-CoV-2 Antibody Kinetics up to 6 months of follow-up: Result from a Nation-wide Population-based, Age Stratified Sero-Epidemiological Prospective Cohort Study in India",2023-06-19,Preprint,National,Repeated cross-sectional study,India,"state of Delhi, Odisha, Uttar Pradesh, Pondicherry, and Tripura",,"10,000 participants from rural and urban areas in five states and measured SARS-CoV-2 antibodies in serum in three follow-up rounds.

The study was conducted at five selected study sites in India. The study sites were Delhi, Bhubaneswar, Gorakhpur, Pondicherry, and Agartala situated in the state of Delhi, Odisha, Uttar Pradesh, Pondicherry, and Tripura respectively","NR
",2021-03-03,2021-08-18,Household and community samples,All,Multiple groups,1.0,,Primary Estimate,,10110,0.739,0.731,0.748,True,,,,True,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.944,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,10.1101/2023.06.15.23291475,2023-07-28,2024-05-01,Verified,misra_anti-sars-cov-2_2023,IND
230619_India_AllIndiaInstituteofMedicalSciences_Round1_NotVaccinated,230619_India_AllIndiaInstituteofMedicalSciences_Round1,"Anti-SARS-CoV-2 Antibody Kinetics up to 6 months of follow-up: Result from a Nation-wide Population-based, Age Stratified Sero-Epidemiological Prospective Cohort Study in India",2023-06-19,Preprint,National,Repeated cross-sectional study,India,"state of Delhi, Odisha, Uttar Pradesh, Pondicherry, and Tripura",,"10,000 participants from rural and urban areas in five states and measured SARS-CoV-2 antibodies in serum in three follow-up rounds.

The study was conducted at five selected study sites in India. The study sites were Delhi, Bhubaneswar, Gorakhpur, Pondicherry, and Agartala situated in the state of Delhi, Odisha, Uttar Pradesh, Pondicherry, and Tripura respectively","NR
",2021-03-03,2021-08-18,Household and community samples,All,Multiple groups,1.0,,COVID-19 vaccination status,non-vaccinated of people from all five sites in round 1,6915,0.681,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.944,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,10.1101/2023.06.15.23291475,2023-07-28,2024-05-01,Verified,misra_anti-sars-cov-2_2023,IND
230619_India_AllIndiaInstituteofMedicalSciences_Round1_Age<18,230619_India_AllIndiaInstituteofMedicalSciences_Round1,"Anti-SARS-CoV-2 Antibody Kinetics up to 6 months of follow-up: Result from a Nation-wide Population-based, Age Stratified Sero-Epidemiological Prospective Cohort Study in India",2023-06-19,Preprint,National,Repeated cross-sectional study,India,"state of Delhi, Odisha, Uttar Pradesh, Pondicherry, and Tripura",,"10,000 participants from rural and urban areas in five states and measured SARS-CoV-2 antibodies in serum in three follow-up rounds.

The study was conducted at five selected study sites in India. The study sites were Delhi, Bhubaneswar, Gorakhpur, Pondicherry, and Agartala situated in the state of Delhi, Odisha, Uttar Pradesh, Pondicherry, and Tripura respectively","NR
",2021-03-03,2021-08-18,Household and community samples,All,Children and Youth (0-17 years),1.0,17.0,Age,<18,1542,0.671,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.944,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,10.1101/2023.06.15.23291475,2024-04-30,2024-05-01,Verified,misra_anti-sars-cov-2_2023,IND
230619_India_AllIndiaInstituteofMedicalSciences_Round1_Vaccinated,230619_India_AllIndiaInstituteofMedicalSciences_Round1,"Anti-SARS-CoV-2 Antibody Kinetics up to 6 months of follow-up: Result from a Nation-wide Population-based, Age Stratified Sero-Epidemiological Prospective Cohort Study in India",2023-06-19,Preprint,National,Repeated cross-sectional study,India,"state of Delhi, Odisha, Uttar Pradesh, Pondicherry, and Tripura",,"10,000 participants from rural and urban areas in five states and measured SARS-CoV-2 antibodies in serum in three follow-up rounds.

The study was conducted at five selected study sites in India. The study sites were Delhi, Bhubaneswar, Gorakhpur, Pondicherry, and Agartala situated in the state of Delhi, Odisha, Uttar Pradesh, Pondicherry, and Tripura respectively","NR
",2021-03-03,2021-08-18,Household and community samples,All,Multiple groups,1.0,,COVID-19 vaccination status,vaccinated of people from all five sites in round 1,3186,0.865,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.944,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,10.1101/2023.06.15.23291475,2023-07-28,2024-05-01,Verified,misra_anti-sars-cov-2_2023,IND
230619_India_AllIndiaInstituteofMedicalSciences_Round1_Age18+,230619_India_AllIndiaInstituteofMedicalSciences_Round1,"Anti-SARS-CoV-2 Antibody Kinetics up to 6 months of follow-up: Result from a Nation-wide Population-based, Age Stratified Sero-Epidemiological Prospective Cohort Study in India",2023-06-19,Preprint,National,Repeated cross-sectional study,India,"state of Delhi, Odisha, Uttar Pradesh, Pondicherry, and Tripura",,"10,000 participants from rural and urban areas in five states and measured SARS-CoV-2 antibodies in serum in three follow-up rounds.

The study was conducted at five selected study sites in India. The study sites were Delhi, Bhubaneswar, Gorakhpur, Pondicherry, and Agartala situated in the state of Delhi, Odisha, Uttar Pradesh, Pondicherry, and Tripura respectively","NR
",2021-03-03,2021-08-18,Household and community samples,All,Adults (18-64 years),18.0,,Age,18+,8568,0.752,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.944,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,10.1101/2023.06.15.23291475,2024-04-30,2024-05-01,Verified,misra_anti-sars-cov-2_2023,IND
230619_India_AllIndiaInstituteofMedicalSciences_Round2_Overall,230619_India_AllIndiaInstituteofMedicalSciences_Round2,"Anti-SARS-CoV-2 Antibody Kinetics up to 6 months of follow-up: Result from a Nation-wide Population-based, Age Stratified Sero-Epidemiological Prospective Cohort Study in India",2023-06-19,Preprint,National,Repeated cross-sectional study,India,"state of Delhi, Odisha, Uttar Pradesh, Pondicherry, and Tripura",,"10,000 participants from rural and urban areas in five states and measured SARS-CoV-2 antibodies in serum in three follow-up rounds.

The study was conducted at five selected study sites in India. The study sites were Delhi, Bhubaneswar, Gorakhpur, Pondicherry, and Agartala situated in the state of Delhi, Odisha, Uttar Pradesh, Pondicherry, and Tripura respectively","NR
",2021-05-27,2021-12-10,Household and community samples,All,Multiple groups,1.0,,Primary Estimate,,6503,0.907,0.899,0.914,True,,,,True,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.944,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,10.1101/2023.06.15.23291475,2023-07-28,2024-05-01,Verified,misra_anti-sars-cov-2_2023,IND
230619_India_AllIndiaInstituteofMedicalSciences_Round2_Age<18,230619_India_AllIndiaInstituteofMedicalSciences_Round2,"Anti-SARS-CoV-2 Antibody Kinetics up to 6 months of follow-up: Result from a Nation-wide Population-based, Age Stratified Sero-Epidemiological Prospective Cohort Study in India",2023-06-19,Preprint,National,Repeated cross-sectional study,India,"state of Delhi, Odisha, Uttar Pradesh, Pondicherry, and Tripura",,"10,000 participants from rural and urban areas in five states and measured SARS-CoV-2 antibodies in serum in three follow-up rounds.

The study was conducted at five selected study sites in India. The study sites were Delhi, Bhubaneswar, Gorakhpur, Pondicherry, and Agartala situated in the state of Delhi, Odisha, Uttar Pradesh, Pondicherry, and Tripura respectively","NR
",2021-05-27,2021-12-10,Household and community samples,All,Children and Youth (0-17 years),1.0,17.0,Age,<18,992,0.823,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.944,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,10.1101/2023.06.15.23291475,2024-04-30,2024-05-01,Verified,misra_anti-sars-cov-2_2023,IND
230619_India_AllIndiaInstituteofMedicalSciences_Round2_Vaccinated,230619_India_AllIndiaInstituteofMedicalSciences_Round2,"Anti-SARS-CoV-2 Antibody Kinetics up to 6 months of follow-up: Result from a Nation-wide Population-based, Age Stratified Sero-Epidemiological Prospective Cohort Study in India",2023-06-19,Preprint,National,Repeated cross-sectional study,India,"state of Delhi, Odisha, Uttar Pradesh, Pondicherry, and Tripura",,"10,000 participants from rural and urban areas in five states and measured SARS-CoV-2 antibodies in serum in three follow-up rounds.

The study was conducted at five selected study sites in India. The study sites were Delhi, Bhubaneswar, Gorakhpur, Pondicherry, and Agartala situated in the state of Delhi, Odisha, Uttar Pradesh, Pondicherry, and Tripura respectively","NR
",2021-05-27,2021-12-10,Household and community samples,All,Multiple groups,1.0,,COVID-19 vaccination status,vaccinated of people from all five sites in round 2,3822,0.941,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.944,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,10.1101/2023.06.15.23291475,2023-07-28,2024-05-01,Verified,misra_anti-sars-cov-2_2023,IND
230619_India_AllIndiaInstituteofMedicalSciences_Round2_NotVaccinated,230619_India_AllIndiaInstituteofMedicalSciences_Round2,"Anti-SARS-CoV-2 Antibody Kinetics up to 6 months of follow-up: Result from a Nation-wide Population-based, Age Stratified Sero-Epidemiological Prospective Cohort Study in India",2023-06-19,Preprint,National,Repeated cross-sectional study,India,"state of Delhi, Odisha, Uttar Pradesh, Pondicherry, and Tripura",,"10,000 participants from rural and urban areas in five states and measured SARS-CoV-2 antibodies in serum in three follow-up rounds.

The study was conducted at five selected study sites in India. The study sites were Delhi, Bhubaneswar, Gorakhpur, Pondicherry, and Agartala situated in the state of Delhi, Odisha, Uttar Pradesh, Pondicherry, and Tripura respectively","NR
",2021-05-27,2021-12-10,Household and community samples,All,Multiple groups,1.0,,COVID-19 vaccination status,non-vaccinated of people from all five sites in round 2,2672,0.858,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.944,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,10.1101/2023.06.15.23291475,2023-07-28,2024-05-01,Verified,misra_anti-sars-cov-2_2023,IND
230619_India_AllIndiaInstituteofMedicalSciences_Round2_Age18+,230619_India_AllIndiaInstituteofMedicalSciences_Round2,"Anti-SARS-CoV-2 Antibody Kinetics up to 6 months of follow-up: Result from a Nation-wide Population-based, Age Stratified Sero-Epidemiological Prospective Cohort Study in India",2023-06-19,Preprint,National,Repeated cross-sectional study,India,"state of Delhi, Odisha, Uttar Pradesh, Pondicherry, and Tripura",,"10,000 participants from rural and urban areas in five states and measured SARS-CoV-2 antibodies in serum in three follow-up rounds.

The study was conducted at five selected study sites in India. The study sites were Delhi, Bhubaneswar, Gorakhpur, Pondicherry, and Agartala situated in the state of Delhi, Odisha, Uttar Pradesh, Pondicherry, and Tripura respectively","NR
",2021-05-27,2021-12-10,Household and community samples,All,Adults (18-64 years),18.0,,Age,18+,5511,0.922,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.944,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,10.1101/2023.06.15.23291475,2024-04-30,2024-05-01,Verified,misra_anti-sars-cov-2_2023,IND
230619_India_AllIndiaInstituteofMedicalSciences_Round3_Overall,230619_India_AllIndiaInstituteofMedicalSciences_Round3,"Anti-SARS-CoV-2 Antibody Kinetics up to 6 months of follow-up: Result from a Nation-wide Population-based, Age Stratified Sero-Epidemiological Prospective Cohort Study in India",2023-06-19,Preprint,National,Repeated cross-sectional study,India,"state of Delhi, Odisha, Uttar Pradesh, Pondicherry, and Tripura",,"10,000 participants from rural and urban areas in five states and measured SARS-CoV-2 antibodies in serum in three follow-up rounds.

The study was conducted at five selected study sites in India. The study sites were Delhi, Bhubaneswar, Gorakhpur, Pondicherry, and Agartala situated in the state of Delhi, Odisha, Uttar Pradesh, Pondicherry, and Tripura respectively","NR
",2021-08-26,2021-01-14,Household and community samples,All,Multiple groups,1.0,,Primary Estimate,,5564,0.929,0.922,0.936,True,,,,True,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.944,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,10.1101/2023.06.15.23291475,2023-07-28,2024-05-01,Verified,misra_anti-sars-cov-2_2023,IND
230619_India_AllIndiaInstituteofMedicalSciences_Round3_Age18+,230619_India_AllIndiaInstituteofMedicalSciences_Round3,"Anti-SARS-CoV-2 Antibody Kinetics up to 6 months of follow-up: Result from a Nation-wide Population-based, Age Stratified Sero-Epidemiological Prospective Cohort Study in India",2023-06-19,Preprint,National,Repeated cross-sectional study,India,"state of Delhi, Odisha, Uttar Pradesh, Pondicherry, and Tripura",,"10,000 participants from rural and urban areas in five states and measured SARS-CoV-2 antibodies in serum in three follow-up rounds.

The study was conducted at five selected study sites in India. The study sites were Delhi, Bhubaneswar, Gorakhpur, Pondicherry, and Agartala situated in the state of Delhi, Odisha, Uttar Pradesh, Pondicherry, and Tripura respectively","NR
",2021-08-26,2021-01-14,Household and community samples,All,Adults (18-64 years),18.0,,Age,18+,4769,0.942,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.944,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,10.1101/2023.06.15.23291475,2024-04-30,2024-05-01,Verified,misra_anti-sars-cov-2_2023,IND
230619_India_AllIndiaInstituteofMedicalSciences_Round3_NotVaccinated,230619_India_AllIndiaInstituteofMedicalSciences_Round3,"Anti-SARS-CoV-2 Antibody Kinetics up to 6 months of follow-up: Result from a Nation-wide Population-based, Age Stratified Sero-Epidemiological Prospective Cohort Study in India",2023-06-19,Preprint,National,Repeated cross-sectional study,India,"state of Delhi, Odisha, Uttar Pradesh, Pondicherry, and Tripura",,"10,000 participants from rural and urban areas in five states and measured SARS-CoV-2 antibodies in serum in three follow-up rounds.

The study was conducted at five selected study sites in India. The study sites were Delhi, Bhubaneswar, Gorakhpur, Pondicherry, and Agartala situated in the state of Delhi, Odisha, Uttar Pradesh, Pondicherry, and Tripura respectively","NR
",2021-08-26,2021-01-14,Household and community samples,All,Multiple groups,1.0,,COVID-19 vaccination status,non-vaccinated of people from all five sites in round 3,1555,0.875,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.944,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,10.1101/2023.06.15.23291475,2023-07-28,2024-05-01,Verified,misra_anti-sars-cov-2_2023,IND
230619_India_AllIndiaInstituteofMedicalSciences_Round3_Vaccinated,230619_India_AllIndiaInstituteofMedicalSciences_Round3,"Anti-SARS-CoV-2 Antibody Kinetics up to 6 months of follow-up: Result from a Nation-wide Population-based, Age Stratified Sero-Epidemiological Prospective Cohort Study in India",2023-06-19,Preprint,National,Repeated cross-sectional study,India,"state of Delhi, Odisha, Uttar Pradesh, Pondicherry, and Tripura",,"10,000 participants from rural and urban areas in five states and measured SARS-CoV-2 antibodies in serum in three follow-up rounds.

The study was conducted at five selected study sites in India. The study sites were Delhi, Bhubaneswar, Gorakhpur, Pondicherry, and Agartala situated in the state of Delhi, Odisha, Uttar Pradesh, Pondicherry, and Tripura respectively","NR
",2021-08-26,2021-01-14,Household and community samples,All,Multiple groups,1.0,,COVID-19 vaccination status,vaccinated of people from all five sites in round 3,4000,0.95,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.944,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,10.1101/2023.06.15.23291475,2023-07-28,2024-05-01,Verified,misra_anti-sars-cov-2_2023,IND
230619_India_AllIndiaInstituteofMedicalSciences_Round3_Age<18,230619_India_AllIndiaInstituteofMedicalSciences_Round3,"Anti-SARS-CoV-2 Antibody Kinetics up to 6 months of follow-up: Result from a Nation-wide Population-based, Age Stratified Sero-Epidemiological Prospective Cohort Study in India",2023-06-19,Preprint,National,Repeated cross-sectional study,India,"state of Delhi, Odisha, Uttar Pradesh, Pondicherry, and Tripura",,"10,000 participants from rural and urban areas in five states and measured SARS-CoV-2 antibodies in serum in three follow-up rounds.

The study was conducted at five selected study sites in India. The study sites were Delhi, Bhubaneswar, Gorakhpur, Pondicherry, and Agartala situated in the state of Delhi, Odisha, Uttar Pradesh, Pondicherry, and Tripura respectively","NR
",2021-08-26,2021-01-14,Household and community samples,All,Children and Youth (0-17 years),1.0,17.0,Age,<18,795,0.851,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.944,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Puneet Misra,All India Institute of Medical Sciences,Unity-Aligned,10.1101/2023.06.15.23291475,2024-04-30,2024-05-01,Verified,misra_anti-sars-cov-2_2023,IND
230624_India_MountSinai,230624_India_MountSinai,Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium,2023-06-24,Journal Article (Peer-Reviewed),National,Prospective cohort,India,,,"Our initial core objective was to include all adult patients with IBD who entered the infusion center for vedolizumab or infliximab (originator or biosimilars), as well as intravenous ustekinumab induction, regardless of history of known COVID-19 infection, and without any exclusion criteria.",None,2020-05-15,2021-12-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,219,0.6301,,,True,,,,True,Convenience,SARS-CoV-2 Rapid Antibody Test,Roche Diagnostics,LFIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Yes,Yes,Yes,,Serre-Yu Wong,Mount Sinai,Not Unity-Aligned,https://dx.doi.org/10.1093/ibd/izad097,2023-08-02,2024-03-01,Unverified,wong_geography_2023,IND
230720_India_JawaharlalNehruMedicalCollege_Overall,230720_India_JawaharlalNehruMedicalCollege,COVID-19 symptoms and antibody positivity among unvaccinated pregnant women: An observational study in seven countries from the Global Network,2023-07-20,Journal Article (Peer-Reviewed),National,Prospective cohort,India,,,staff (registry administrators [RAs]) identified pregnant women in their respective clusters,vaccinated pregnant women,2020-10-01,2022-06-30,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,3007,0.487,,,True,,,,True,Stratified non-probability,Not reported/ Unable to specify,,,Serum,,,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Avinash Kavi,Jawaharlal Nehru Medical College,Not Unity-Aligned,https://dx.doi.org/10.1111/1471-0528.17604,2023-08-22,2023-08-23,Unverified,kavi_covid-19_2023,IND
230911_Malegaon_ MaharashtraUniversityofHealthSciences,230911_Malegaon_ MaharashtraUniversityofHealthSciences,COVID-19 Pandemic in Malegaon: SUTRA over the Three Waves,2023-09-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,India,Maharashtra,Malegaon,subjects above 18-year-old who gave consent for interview and blood collection,,2022-01-12,2022-01-18,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2454,0.9393,,,True,,,,True,Stratified probability,COVID KAVACH (KAWACH) IgG Microlisa (Microwell ELISA),J. Mitra & Co. Pvt. Ltd,ELISA,Serum,"['IgG', 'Neutralizing']",Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Prashant Shivgunde,Maharashtra University of Health Sciences,Unity-Aligned,https://dx.doi.org/10.1007/s12088-023-01096-3,2023-10-05,2024-04-22,Verified,shivgunde_covid-19_2023,IND
210506_EastJava_KobeUniversity,210506_EastJava_KobeUniversity,"Seroepidemiological
  study of SARS-CoV-2 infection in East Java, Indonesia",2021-05-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Indonesia,East Java,"Surabaya, Jombang","""The inclusion criteria were workers (medical personnel, laboratory technician and other staff) and non-COVID-19 patients in medical facilities as well as general population in the community.""",The exclusion criterion was persons less than 16 years old,2020-06-15,2020-12-15,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,,1819,0.114,,,True,,,,True,Convenience,2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,Nanjing Vazyme Medical Technology Co. Ltd,LFIA,Serum,IgG,,Validated by manufacturers,0.9154000000000001,0.9702,['Moderate'],Yes,No,Yes,Yes,Yes,No,Yes,Yes,Yes,Ni Luh Ayu Megasari,Kobe University,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0251234,2021-05-18,2024-03-01,Verified,megasari_seroepidemiological_2021,IDN
210506_EastJava_KobeUniversity_30-39,210506_EastJava_KobeUniversity,"Seroepidemiological
  study of SARS-CoV-2 infection in East Java, Indonesia",2021-05-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Indonesia,East Java,"Surabaya, Jombang","""The inclusion criteria were workers (medical personnel, laboratory technician and other staff) and non-COVID-19 patients in medical facilities as well as general population in the community.""",The exclusion criterion was persons less than 16 years old,2020-06-15,2020-12-15,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,366,0.139,,,,,,,,Convenience,2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,Nanjing Vazyme Medical Technology Co. Ltd,LFIA,Serum,IgG,,Validated by manufacturers,0.9154000000000001,0.9702,['Moderate'],Yes,No,Yes,Yes,Yes,No,Yes,Yes,Yes,Ni Luh Ayu Megasari,Kobe University,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0251234,2021-09-04,2024-03-01,Verified,megasari_seroepidemiological_2021,IDN
210506_EastJava_KobeUniversity_40-49,210506_EastJava_KobeUniversity,"Seroepidemiological
  study of SARS-CoV-2 infection in East Java, Indonesia",2021-05-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Indonesia,East Java,"Surabaya, Jombang","""The inclusion criteria were workers (medical personnel, laboratory technician and other staff) and non-COVID-19 patients in medical facilities as well as general population in the community.""",The exclusion criterion was persons less than 16 years old,2020-06-15,2020-12-15,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,271,0.14800000000000002,,,,,,,,Convenience,2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,Nanjing Vazyme Medical Technology Co. Ltd,LFIA,Serum,IgG,,Validated by manufacturers,0.9154000000000001,0.9702,['Moderate'],Yes,No,Yes,Yes,Yes,No,Yes,Yes,Yes,Ni Luh Ayu Megasari,Kobe University,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0251234,2021-09-04,2024-03-01,Verified,megasari_seroepidemiological_2021,IDN
210506_EastJava_KobeUniversity_50-59,210506_EastJava_KobeUniversity,"Seroepidemiological
  study of SARS-CoV-2 infection in East Java, Indonesia",2021-05-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Indonesia,East Java,"Surabaya, Jombang","""The inclusion criteria were workers (medical personnel, laboratory technician and other staff) and non-COVID-19 patients in medical facilities as well as general population in the community.""",The exclusion criterion was persons less than 16 years old,2020-06-15,2020-12-15,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,345,0.122,,,,,,,,Convenience,2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,Nanjing Vazyme Medical Technology Co. Ltd,LFIA,Serum,IgG,,Validated by manufacturers,0.9154000000000001,0.9702,['Moderate'],Yes,No,Yes,Yes,Yes,No,Yes,Yes,Yes,Ni Luh Ayu Megasari,Kobe University,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0251234,2021-09-04,2024-03-01,Verified,megasari_seroepidemiological_2021,IDN
210506_EastJava_KobeUniversity_Male,210506_EastJava_KobeUniversity,"Seroepidemiological
  study of SARS-CoV-2 infection in East Java, Indonesia",2021-05-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Indonesia,East Java,"Surabaya, Jombang","""The inclusion criteria were workers (medical personnel, laboratory technician and other staff) and non-COVID-19 patients in medical facilities as well as general population in the community.""",The exclusion criterion was persons less than 16 years old,2020-06-15,2020-12-15,Household and community samples,Male,Multiple groups,16.0,,Sex/Gender,,859,0.107,,,,,,,,Convenience,2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,Nanjing Vazyme Medical Technology Co. Ltd,LFIA,Serum,IgG,,Validated by manufacturers,0.9154000000000001,0.9702,['Moderate'],Yes,No,Yes,Yes,Yes,No,Yes,Yes,Yes,Ni Luh Ayu Megasari,Kobe University,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0251234,2021-09-04,2024-03-01,Verified,megasari_seroepidemiological_2021,IDN
210506_EastJava_KobeUniversity_60over,210506_EastJava_KobeUniversity,"Seroepidemiological
  study of SARS-CoV-2 infection in East Java, Indonesia",2021-05-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Indonesia,East Java,"Surabaya, Jombang","""The inclusion criteria were workers (medical personnel, laboratory technician and other staff) and non-COVID-19 patients in medical facilities as well as general population in the community.""",The exclusion criterion was persons less than 16 years old,2020-06-15,2020-12-15,Household and community samples,All,Seniors (65+ years),60.0,,Age,>=60,170,0.129,,,,,,,,Convenience,2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,Nanjing Vazyme Medical Technology Co. Ltd,LFIA,Serum,IgG,,Validated by manufacturers,0.9154000000000001,0.9702,['Moderate'],Yes,No,Yes,Yes,Yes,No,Yes,Yes,Yes,Ni Luh Ayu Megasari,Kobe University,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0251234,2021-09-04,2024-03-01,Verified,megasari_seroepidemiological_2021,IDN
210506_EastJava_KobeUniversity_16-19,210506_EastJava_KobeUniversity,"Seroepidemiological
  study of SARS-CoV-2 infection in East Java, Indonesia",2021-05-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Indonesia,East Java,"Surabaya, Jombang","""The inclusion criteria were workers (medical personnel, laboratory technician and other staff) and non-COVID-19 patients in medical facilities as well as general population in the community.""",The exclusion criterion was persons less than 16 years old,2020-06-15,2020-12-15,Household and community samples,All,Children and Youth (0-17 years),16.0,19.0,Age,16-19,69,0.11599999999999999,,,,,,,,Convenience,2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,Nanjing Vazyme Medical Technology Co. Ltd,LFIA,Serum,IgG,,Validated by manufacturers,0.9154000000000001,0.9702,['Moderate'],Yes,No,Yes,Yes,Yes,No,Yes,Yes,Yes,Ni Luh Ayu Megasari,Kobe University,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0251234,2021-09-04,2024-03-01,Verified,megasari_seroepidemiological_2021,IDN
210506_EastJava_KobeUniversity_20-29,210506_EastJava_KobeUniversity,"Seroepidemiological
  study of SARS-CoV-2 infection in East Java, Indonesia",2021-05-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Indonesia,East Java,"Surabaya, Jombang","""The inclusion criteria were workers (medical personnel, laboratory technician and other staff) and non-COVID-19 patients in medical facilities as well as general population in the community.""",The exclusion criterion was persons less than 16 years old,2020-06-15,2020-12-15,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,598,0.07400000000000001,,,,,,,,Convenience,2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,Nanjing Vazyme Medical Technology Co. Ltd,LFIA,Serum,IgG,,Validated by manufacturers,0.9154000000000001,0.9702,['Moderate'],Yes,No,Yes,Yes,Yes,No,Yes,Yes,Yes,Ni Luh Ayu Megasari,Kobe University,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0251234,2021-09-04,2024-03-01,Verified,megasari_seroepidemiological_2021,IDN
210506_EastJava_KobeUniversity_Female,210506_EastJava_KobeUniversity,"Seroepidemiological
  study of SARS-CoV-2 infection in East Java, Indonesia",2021-05-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Indonesia,East Java,"Surabaya, Jombang","""The inclusion criteria were workers (medical personnel, laboratory technician and other staff) and non-COVID-19 patients in medical facilities as well as general population in the community.""",The exclusion criterion was persons less than 16 years old,2020-06-15,2020-12-15,Household and community samples,Female,Multiple groups,16.0,,Sex/Gender,,960,0.12,,,,,,,,Convenience,2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,Nanjing Vazyme Medical Technology Co. Ltd,LFIA,Serum,IgG,,Validated by manufacturers,0.9154000000000001,0.9702,['Moderate'],Yes,No,Yes,Yes,Yes,No,Yes,Yes,Yes,Ni Luh Ayu Megasari,Kobe University,Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0251234,2021-09-04,2024-03-01,Verified,megasari_seroepidemiological_2021,IDN
211223_TanjungPriok_CenterforIndonesia’sStrategicDevelopmentInitiatives_Primary,211223_TanjungPriok_CenterforIndonesia’sStrategicDevelopmentInitiatives,"Seroprevalence of antibodies against SARS-Cov-2 in the high impacted sub-district in Jakarta, Indonesia.",2021-12-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Indonesia,,Jakarta,"i) residing in Tanjung Priok sub-district for at least six months, ii) aged
15–65 years, iii) not in a COVID-19 isolation/quarantine period, iv) being able to come to the
location of blood sample collection.",,2020-11-23,2021-02-19,Household and community samples,All,Adults (18-64 years),15.0,65.0,Primary Estimate,,3196,0.2852,0.2544,0.3181,True,,True,,True,Simplified probability,Not reported/ Unable to specify,,CLIA,Serum,,,Validated by manufacturers,,0.9981000000000001,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Olivia Herlinda,"World Health Organization, Geneva, Switzerland",Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0261931,2022-01-09,2022-07-16,Unverified,herlinda_seroprevalence_2021,IDN
211223_TanjungPriok_CenterforIndonesia’sStrategicDevelopmentInitiatives_35-44,211223_TanjungPriok_CenterforIndonesia’sStrategicDevelopmentInitiatives,"Seroprevalence of antibodies against SARS-Cov-2 in the high impacted sub-district in Jakarta, Indonesia.",2021-12-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Indonesia,,Jakarta,"i) residing in Tanjung Priok sub-district for at least six months, ii) aged
15–65 years, iii) not in a COVID-19 isolation/quarantine period, iv) being able to come to the
location of blood sample collection.",,2020-11-23,2021-02-19,Household and community samples,All,Adults (18-64 years),35.0,44.0,Age,35-44,816,0.27190000000000003,,,,,True,,,Simplified probability,Not reported/ Unable to specify,,CLIA,Serum,,,Validated by manufacturers,,0.9981000000000001,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Olivia Herlinda,"World Health Organization, Geneva, Switzerland",Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0261931,2022-01-09,2022-07-16,Unverified,herlinda_seroprevalence_2021,IDN
211223_TanjungPriok_CenterforIndonesia’sStrategicDevelopmentInitiatives_Male,211223_TanjungPriok_CenterforIndonesia’sStrategicDevelopmentInitiatives,"Seroprevalence of antibodies against SARS-Cov-2 in the high impacted sub-district in Jakarta, Indonesia.",2021-12-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Indonesia,,Jakarta,"i) residing in Tanjung Priok sub-district for at least six months, ii) aged
15–65 years, iii) not in a COVID-19 isolation/quarantine period, iv) being able to come to the
location of blood sample collection.",,2020-11-23,2021-02-19,Household and community samples,Male,Adults (18-64 years),,,Sex/Gender,,1604,0.2664,,,,,True,,,Simplified probability,Not reported/ Unable to specify,,CLIA,Serum,,,Validated by manufacturers,,0.9981000000000001,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Olivia Herlinda,"World Health Organization, Geneva, Switzerland",Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0261931,2022-01-09,2022-07-16,Unverified,herlinda_seroprevalence_2021,IDN
211223_TanjungPriok_CenterforIndonesia’sStrategicDevelopmentInitiatives_15-19,211223_TanjungPriok_CenterforIndonesia’sStrategicDevelopmentInitiatives,"Seroprevalence of antibodies against SARS-Cov-2 in the high impacted sub-district in Jakarta, Indonesia.",2021-12-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Indonesia,,Jakarta,"i) residing in Tanjung Priok sub-district for at least six months, ii) aged
15–65 years, iii) not in a COVID-19 isolation/quarantine period, iv) being able to come to the
location of blood sample collection.",,2020-11-23,2021-02-19,Household and community samples,All,Children and Youth (0-17 years),15.0,19.0,Age,15-19,333,0.2519,,,,,True,,,Simplified probability,Not reported/ Unable to specify,,CLIA,Serum,,,Validated by manufacturers,,0.9981000000000001,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Olivia Herlinda,"World Health Organization, Geneva, Switzerland",Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0261931,2022-01-09,2022-07-16,Unverified,herlinda_seroprevalence_2021,IDN
211223_TanjungPriok_CenterforIndonesia’sStrategicDevelopmentInitiatives_25-34,211223_TanjungPriok_CenterforIndonesia’sStrategicDevelopmentInitiatives,"Seroprevalence of antibodies against SARS-Cov-2 in the high impacted sub-district in Jakarta, Indonesia.",2021-12-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Indonesia,,Jakarta,"i) residing in Tanjung Priok sub-district for at least six months, ii) aged
15–65 years, iii) not in a COVID-19 isolation/quarantine period, iv) being able to come to the
location of blood sample collection.",,2020-11-23,2021-02-19,Household and community samples,All,Adults (18-64 years),25.0,34.0,Age,25-34,709,0.2565,,,,,True,,,Simplified probability,Not reported/ Unable to specify,,CLIA,Serum,,,Validated by manufacturers,,0.9981000000000001,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Olivia Herlinda,"World Health Organization, Geneva, Switzerland",Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0261931,2022-01-09,2022-07-16,Unverified,herlinda_seroprevalence_2021,IDN
211223_TanjungPriok_CenterforIndonesia’sStrategicDevelopmentInitiatives_Female,211223_TanjungPriok_CenterforIndonesia’sStrategicDevelopmentInitiatives,"Seroprevalence of antibodies against SARS-Cov-2 in the high impacted sub-district in Jakarta, Indonesia.",2021-12-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Indonesia,,Jakarta,"i) residing in Tanjung Priok sub-district for at least six months, ii) aged
15–65 years, iii) not in a COVID-19 isolation/quarantine period, iv) being able to come to the
location of blood sample collection.",,2020-11-23,2021-02-19,Household and community samples,Female,Adults (18-64 years),,,Sex/Gender,,1591,0.3042,,,,,True,,,Simplified probability,Not reported/ Unable to specify,,CLIA,Serum,,,Validated by manufacturers,,0.9981000000000001,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Olivia Herlinda,"World Health Organization, Geneva, Switzerland",Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0261931,2022-01-09,2022-07-16,Unverified,herlinda_seroprevalence_2021,IDN
211223_TanjungPriok_CenterforIndonesia’sStrategicDevelopmentInitiatives_45-65,211223_TanjungPriok_CenterforIndonesia’sStrategicDevelopmentInitiatives,"Seroprevalence of antibodies against SARS-Cov-2 in the high impacted sub-district in Jakarta, Indonesia.",2021-12-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Indonesia,,Jakarta,"i) residing in Tanjung Priok sub-district for at least six months, ii) aged
15–65 years, iii) not in a COVID-19 isolation/quarantine period, iv) being able to come to the
location of blood sample collection.",,2020-11-23,2021-02-19,Household and community samples,All,Adults (18-64 years),45.0,65.0,Age,45-65,1001,0.3236,,,,,True,,,Simplified probability,Not reported/ Unable to specify,,CLIA,Serum,,,Validated by manufacturers,,0.9981000000000001,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Olivia Herlinda,"World Health Organization, Geneva, Switzerland",Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0261931,2022-01-09,2022-07-16,Unverified,herlinda_seroprevalence_2021,IDN
211223_TanjungPriok_CenterforIndonesia’sStrategicDevelopmentInitiatives_20-24,211223_TanjungPriok_CenterforIndonesia’sStrategicDevelopmentInitiatives,"Seroprevalence of antibodies against SARS-Cov-2 in the high impacted sub-district in Jakarta, Indonesia.",2021-12-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Indonesia,,Jakarta,"i) residing in Tanjung Priok sub-district for at least six months, ii) aged
15–65 years, iii) not in a COVID-19 isolation/quarantine period, iv) being able to come to the
location of blood sample collection.",,2020-11-23,2021-02-19,Household and community samples,All,Adults (18-64 years),20.0,24.0,Age,20-24,336,0.2968,,,,,True,,,Simplified probability,Not reported/ Unable to specify,,CLIA,Serum,,,Validated by manufacturers,,0.9981000000000001,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Olivia Herlinda,"World Health Organization, Geneva, Switzerland",Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0261931,2022-01-09,2022-07-16,Unverified,herlinda_seroprevalence_2021,IDN
220101_Bali_SanjiwaniHospital,220101_Bali_SanjiwaniHospital,Detection of sars-cov-2 antibodies among the pre-vaccine population in bali,2022-01-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Indonesia,,,"""The study was performed in March 2021 at two vaccination centers in Bali. """,,2021-03-01,2021-03-31,Household and community samples,All,Multiple groups,16.0,77.0,Primary Estimate,,510,0.373,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.988,1.0,['High'],No,No,No,Yes,No,Yes,Yes,Yes,Unclear,A.G. Budhitresna,Sanjiwani Hospital,Unity-Aligned,http://www.researchtrends.net/tia/abstract.asp?in=0&vn=23&tid=36&aid=7026&pub=2022&type=3,2023-08-01,2024-03-01,Unverified,budhitresnaDetectionSARSCoV2Antibodies2022,IDN
220110_Surabaya_AirlanggaUniversity,220110_Surabaya_AirlanggaUniversity,Viral shedding and the durability of IgG antibodies to SARS-CoV-2.,2022-01-10,Journal Article (Peer-Reviewed),Local,Prospective cohort,Indonesia,East Java,Surabaya,"Staff members working at a medical research institution in Surabaya, Indonesia",,2020-05-15,2021-02-15,Health care workers and caregivers,All,Adults (18-64 years),21.0,52.0,Primary Estimate,,45,0.289,,,True,,,,True,Unclear,2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,Nanjing Vazyme Medical Technology Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",Spike,,0.9154000000000001,0.9702,['High'],,Unclear,No,No,,No,Yes,Yes,,Maria Lusida,Airlangga University,Not Unity-Aligned,https://dx.doi.org/10.1111/1348-0421.12962,2022-01-19,2024-03-01,Unverified,lusida_viral_2022,IDN
220609_Indonesia_UniversitasGadjahMada_Primary,220609_Indonesia_UniversitasGadjahMada,"Seroprevalence of SARS-CoV-2 and risk factors in Bantul Regency, Yogyakarta, Indonesia",2022-06-09,Preprint,Local,Cross-sectional survey ,Indonesia,Yogyakarta,,"Participants must meet inclusion criteria as follows: residing in the study location at least six months before the survey commences, age of 5 years old or older, able to communicate verbally.",people who cannot be sampled due to untoward illness (including immunocompromised individuals who have a history of blood disorders and people with mental disorders).,2021-03-15,2021-04-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,425,0.311,,,True,,,,True,Stratified probability,Human Anti-2019 n-CoV(N) IgG ELISA Kit V1.5,FineTest,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.7000000000000001,0.8300000000000001,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Riris Andono Ahmad,Universitas Gadjah Mada,Not Unity-Aligned,10.1101/2022.06.07.22276128,2022-06-15,2022-07-16,Unverified,ahmad_seroprevalence_2022,IDN
220609_Indonesia_UniversitasGadjahMada_Female,220609_Indonesia_UniversitasGadjahMada,"Seroprevalence of SARS-CoV-2 and risk factors in Bantul Regency, Yogyakarta, Indonesia",2022-06-09,Preprint,Local,Cross-sectional survey ,Indonesia,Yogyakarta,,"Participants must meet inclusion criteria as follows: residing in the study location at least six months before the survey commences, age of 5 years old or older, able to communicate verbally.",people who cannot be sampled due to untoward illness (including immunocompromised individuals who have a history of blood disorders and people with mental disorders).,2021-03-15,2021-04-15,Household and community samples,Female,Multiple groups,,,Sex/Gender,,251,0.319,,,,,,,,Stratified probability,Human Anti-2019 n-CoV(N) IgG ELISA Kit V1.5,FineTest,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.7000000000000001,0.8300000000000001,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Riris Andono Ahmad,Universitas Gadjah Mada,Not Unity-Aligned,10.1101/2022.06.07.22276128,2022-06-15,2022-07-16,Unverified,ahmad_seroprevalence_2022,IDN
220609_Indonesia_UniversitasGadjahMada_Age45to54,220609_Indonesia_UniversitasGadjahMada,"Seroprevalence of SARS-CoV-2 and risk factors in Bantul Regency, Yogyakarta, Indonesia",2022-06-09,Preprint,Local,Cross-sectional survey ,Indonesia,Yogyakarta,,"Participants must meet inclusion criteria as follows: residing in the study location at least six months before the survey commences, age of 5 years old or older, able to communicate verbally.",people who cannot be sampled due to untoward illness (including immunocompromised individuals who have a history of blood disorders and people with mental disorders).,2021-03-15,2021-04-15,Household and community samples,All,Adults (18-64 years),45.0,54.0,Age,age: 45-54,92,0.348,,,,,,,,Stratified probability,Human Anti-2019 n-CoV(N) IgG ELISA Kit V1.5,FineTest,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.7000000000000001,0.8300000000000001,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Riris Andono Ahmad,Universitas Gadjah Mada,Not Unity-Aligned,10.1101/2022.06.07.22276128,2022-06-15,2022-07-16,Unverified,ahmad_seroprevalence_2022,IDN
220609_Indonesia_UniversitasGadjahMada_AgeBelow14,220609_Indonesia_UniversitasGadjahMada,"Seroprevalence of SARS-CoV-2 and risk factors in Bantul Regency, Yogyakarta, Indonesia",2022-06-09,Preprint,Local,Cross-sectional survey ,Indonesia,Yogyakarta,,"Participants must meet inclusion criteria as follows: residing in the study location at least six months before the survey commences, age of 5 years old or older, able to communicate verbally.",people who cannot be sampled due to untoward illness (including immunocompromised individuals who have a history of blood disorders and people with mental disorders).,2021-03-15,2021-04-15,Household and community samples,All,Children and Youth (0-17 years),,14.0,Age,age: <= 14,16,0.0,,,,,,,,Stratified probability,Human Anti-2019 n-CoV(N) IgG ELISA Kit V1.5,FineTest,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.7000000000000001,0.8300000000000001,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Riris Andono Ahmad,Universitas Gadjah Mada,Not Unity-Aligned,10.1101/2022.06.07.22276128,2022-06-15,2022-07-16,Unverified,ahmad_seroprevalence_2022,IDN
220609_Indonesia_UniversitasGadjahMada_Vaccinated,220609_Indonesia_UniversitasGadjahMada,"Seroprevalence of SARS-CoV-2 and risk factors in Bantul Regency, Yogyakarta, Indonesia",2022-06-09,Preprint,Local,Cross-sectional survey ,Indonesia,Yogyakarta,,"Participants must meet inclusion criteria as follows: residing in the study location at least six months before the survey commences, age of 5 years old or older, able to communicate verbally.",people who cannot be sampled due to untoward illness (including immunocompromised individuals who have a history of blood disorders and people with mental disorders).,2021-03-15,2021-04-15,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,at least one dose,13,0.6920000000000001,,,,,,,,Stratified probability,Human Anti-2019 n-CoV(N) IgG ELISA Kit V1.5,FineTest,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.7000000000000001,0.8300000000000001,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Riris Andono Ahmad,Universitas Gadjah Mada,Not Unity-Aligned,10.1101/2022.06.07.22276128,2022-06-15,2022-07-16,Unverified,ahmad_seroprevalence_2022,IDN
220609_Indonesia_UniversitasGadjahMada_Age55to64,220609_Indonesia_UniversitasGadjahMada,"Seroprevalence of SARS-CoV-2 and risk factors in Bantul Regency, Yogyakarta, Indonesia",2022-06-09,Preprint,Local,Cross-sectional survey ,Indonesia,Yogyakarta,,"Participants must meet inclusion criteria as follows: residing in the study location at least six months before the survey commences, age of 5 years old or older, able to communicate verbally.",people who cannot be sampled due to untoward illness (including immunocompromised individuals who have a history of blood disorders and people with mental disorders).,2021-03-15,2021-04-15,Household and community samples,All,Adults (18-64 years),55.0,64.0,Age,age: 55-64,71,0.43700000000000006,,,,,,,,Stratified probability,Human Anti-2019 n-CoV(N) IgG ELISA Kit V1.5,FineTest,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.7000000000000001,0.8300000000000001,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Riris Andono Ahmad,Universitas Gadjah Mada,Not Unity-Aligned,10.1101/2022.06.07.22276128,2022-06-15,2022-07-16,Unverified,ahmad_seroprevalence_2022,IDN
220609_Indonesia_UniversitasGadjahMada_Age15to24,220609_Indonesia_UniversitasGadjahMada,"Seroprevalence of SARS-CoV-2 and risk factors in Bantul Regency, Yogyakarta, Indonesia",2022-06-09,Preprint,Local,Cross-sectional survey ,Indonesia,Yogyakarta,,"Participants must meet inclusion criteria as follows: residing in the study location at least six months before the survey commences, age of 5 years old or older, able to communicate verbally.",people who cannot be sampled due to untoward illness (including immunocompromised individuals who have a history of blood disorders and people with mental disorders).,2021-03-15,2021-04-15,Household and community samples,All,Multiple groups,15.0,24.0,Age,age: 15-24,52,0.154,,,,,,,,Stratified probability,Human Anti-2019 n-CoV(N) IgG ELISA Kit V1.5,FineTest,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.7000000000000001,0.8300000000000001,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Riris Andono Ahmad,Universitas Gadjah Mada,Not Unity-Aligned,10.1101/2022.06.07.22276128,2022-06-15,2022-07-16,Unverified,ahmad_seroprevalence_2022,IDN
220609_Indonesia_UniversitasGadjahMada_AgeOver64,220609_Indonesia_UniversitasGadjahMada,"Seroprevalence of SARS-CoV-2 and risk factors in Bantul Regency, Yogyakarta, Indonesia",2022-06-09,Preprint,Local,Cross-sectional survey ,Indonesia,Yogyakarta,,"Participants must meet inclusion criteria as follows: residing in the study location at least six months before the survey commences, age of 5 years old or older, able to communicate verbally.",people who cannot be sampled due to untoward illness (including immunocompromised individuals who have a history of blood disorders and people with mental disorders).,2021-03-15,2021-04-15,Household and community samples,All,Seniors (65+ years),65.0,,Age,age: >= 65,53,0.37700000000000006,,,,,,,,Stratified probability,Human Anti-2019 n-CoV(N) IgG ELISA Kit V1.5,FineTest,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.7000000000000001,0.8300000000000001,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Riris Andono Ahmad,Universitas Gadjah Mada,Not Unity-Aligned,10.1101/2022.06.07.22276128,2022-06-15,2022-07-16,Unverified,ahmad_seroprevalence_2022,IDN
220609_Indonesia_UniversitasGadjahMada_Age35to44,220609_Indonesia_UniversitasGadjahMada,"Seroprevalence of SARS-CoV-2 and risk factors in Bantul Regency, Yogyakarta, Indonesia",2022-06-09,Preprint,Local,Cross-sectional survey ,Indonesia,Yogyakarta,,"Participants must meet inclusion criteria as follows: residing in the study location at least six months before the survey commences, age of 5 years old or older, able to communicate verbally.",people who cannot be sampled due to untoward illness (including immunocompromised individuals who have a history of blood disorders and people with mental disorders).,2021-03-15,2021-04-15,Household and community samples,All,Adults (18-64 years),35.0,44.0,Age,age: 35-44,90,0.36700000000000005,,,,,,,,Stratified probability,Human Anti-2019 n-CoV(N) IgG ELISA Kit V1.5,FineTest,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.7000000000000001,0.8300000000000001,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Riris Andono Ahmad,Universitas Gadjah Mada,Not Unity-Aligned,10.1101/2022.06.07.22276128,2022-06-15,2022-07-16,Unverified,ahmad_seroprevalence_2022,IDN
220609_Indonesia_UniversitasGadjahMada_NotVaccinated,220609_Indonesia_UniversitasGadjahMada,"Seroprevalence of SARS-CoV-2 and risk factors in Bantul Regency, Yogyakarta, Indonesia",2022-06-09,Preprint,Local,Cross-sectional survey ,Indonesia,Yogyakarta,,"Participants must meet inclusion criteria as follows: residing in the study location at least six months before the survey commences, age of 5 years old or older, able to communicate verbally.",people who cannot be sampled due to untoward illness (including immunocompromised individuals who have a history of blood disorders and people with mental disorders).,2021-03-15,2021-04-15,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,not yet,412,0.299,,,,,,,,Stratified probability,Human Anti-2019 n-CoV(N) IgG ELISA Kit V1.5,FineTest,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.7000000000000001,0.8300000000000001,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Riris Andono Ahmad,Universitas Gadjah Mada,Not Unity-Aligned,10.1101/2022.06.07.22276128,2022-06-15,2022-07-16,Unverified,ahmad_seroprevalence_2022,IDN
220609_Indonesia_UniversitasGadjahMada_Male,220609_Indonesia_UniversitasGadjahMada,"Seroprevalence of SARS-CoV-2 and risk factors in Bantul Regency, Yogyakarta, Indonesia",2022-06-09,Preprint,Local,Cross-sectional survey ,Indonesia,Yogyakarta,,"Participants must meet inclusion criteria as follows: residing in the study location at least six months before the survey commences, age of 5 years old or older, able to communicate verbally.",people who cannot be sampled due to untoward illness (including immunocompromised individuals who have a history of blood disorders and people with mental disorders).,2021-03-15,2021-04-15,Household and community samples,Male,Multiple groups,,,Sex/Gender,,174,0.299,,,,,,,,Stratified probability,Human Anti-2019 n-CoV(N) IgG ELISA Kit V1.5,FineTest,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.7000000000000001,0.8300000000000001,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Riris Andono Ahmad,Universitas Gadjah Mada,Not Unity-Aligned,10.1101/2022.06.07.22276128,2022-06-15,2022-07-16,Unverified,ahmad_seroprevalence_2022,IDN
220609_Indonesia_UniversitasGadjahMada_Age25to34,220609_Indonesia_UniversitasGadjahMada,"Seroprevalence of SARS-CoV-2 and risk factors in Bantul Regency, Yogyakarta, Indonesia",2022-06-09,Preprint,Local,Cross-sectional survey ,Indonesia,Yogyakarta,,"Participants must meet inclusion criteria as follows: residing in the study location at least six months before the survey commences, age of 5 years old or older, able to communicate verbally.",people who cannot be sampled due to untoward illness (including immunocompromised individuals who have a history of blood disorders and people with mental disorders).,2021-03-15,2021-04-15,Household and community samples,All,Adults (18-64 years),25.0,34.0,Age,age: 25-34,51,0.157,,,,,,,,Stratified probability,Human Anti-2019 n-CoV(N) IgG ELISA Kit V1.5,FineTest,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.7000000000000001,0.8300000000000001,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Riris Andono Ahmad,Universitas Gadjah Mada,Not Unity-Aligned,10.1101/2022.06.07.22276128,2022-06-15,2022-07-16,Unverified,ahmad_seroprevalence_2022,IDN
220831_Bali_UniversitasUdayana_Round1_Weighted,220831_Bali_UniversitasUdayana_Round1,Seroprevalence of SARS-CoV-2 antibodies in Bali Province: Indonesia shows underdetection of COVID-19 cases by routine surveillance.,2022-08-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Indonesia,Bali,,"Cross-sectional sero-surveys were conducted in two rounds between 14 October– 24
December 2020. Specimen collection for round 1 occurred from 14 October– 14 November
and for round 2 from 15 November– 24 December. Urban (Denpasar) compared to rural (outside
Denpasar) stratification was done.

A household was defined as a group of persons who reside in the same place and prepare meals together. All members of selected households who were >= 1 year of age were eligible if informed consent was obtained by either the participant of the parent or guardian.",Samples that did not pass quality check were excluded from the analysis.,2020-10-14,2020-11-14,Household and community samples,All,Multiple groups,1.0,,Primary Estimate,,1154,0.1804,0.0998,0.261,True,,True,,True,Stratified probability,Author designed (Luminex),,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anak A. S. Sawitri,Universitas Udayana,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0000727,2023-04-25,2023-04-26,Unverified,sawitri_seroprevalence_2022,IDN
220831_Bali_UniversitasUdayana_Round1_Unweighted,220831_Bali_UniversitasUdayana_Round1,Seroprevalence of SARS-CoV-2 antibodies in Bali Province: Indonesia shows underdetection of COVID-19 cases by routine surveillance.,2022-08-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Indonesia,Bali,,"Cross-sectional sero-surveys were conducted in two rounds between 14 October– 24
December 2020. Specimen collection for round 1 occurred from 14 October– 14 November
and for round 2 from 15 November– 24 December. Urban (Denpasar) compared to rural (outside
Denpasar) stratification was done.

A household was defined as a group of persons who reside in the same place and prepare meals together. All members of selected households who were >= 1 year of age were eligible if informed consent was obtained by either the participant of the parent or guardian.",Samples that did not pass quality check were excluded from the analysis.,2020-10-14,2020-11-14,Household and community samples,All,Multiple groups,1.0,,Analysis,,1154,0.1672,0.1457,0.1888,,,,,True,Stratified probability,Author designed (Luminex),,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anak A. S. Sawitri,Universitas Udayana,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0000727,2023-04-25,2023-04-26,Unverified,sawitri_seroprevalence_2022,IDN
220831_Bali_UniversitasUdayana_Round2_Weighted,220831_Bali_UniversitasUdayana_Round2,Seroprevalence of SARS-CoV-2 antibodies in Bali Province: Indonesia shows underdetection of COVID-19 cases by routine surveillance.,2022-08-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Indonesia,Bali,,"Cross-sectional sero-surveys were conducted in two rounds between 14 October– 24
December 2020. Specimen collection for round 1 occurred from 14 October– 14 November
and for round 2 from 15 November– 24 December. Urban (Denpasar) compared to rural (outside
Denpasar) stratification was done.

A household was defined as a group of persons who reside in the same place and prepare meals together. All members of selected households who were >= 1 year of age were eligible if informed consent was obtained by either the participant of the parent or guardian.",Samples that did not pass quality check were excluded from the analysis.,2020-11-15,2020-12-24,Household and community samples,All,Multiple groups,1.0,,Primary Estimate,,1391,0.1571,0.1115,0.2028,True,,True,,True,Stratified probability,Author designed (Luminex),,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anak A. S. Sawitri,Universitas Udayana,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0000727,2023-04-25,2023-04-26,Unverified,sawitri_seroprevalence_2022,IDN
220831_Bali_UniversitasUdayana_Round2_Unweighted,220831_Bali_UniversitasUdayana_Round2,Seroprevalence of SARS-CoV-2 antibodies in Bali Province: Indonesia shows underdetection of COVID-19 cases by routine surveillance.,2022-08-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Indonesia,Bali,,"Cross-sectional sero-surveys were conducted in two rounds between 14 October– 24
December 2020. Specimen collection for round 1 occurred from 14 October– 14 November
and for round 2 from 15 November– 24 December. Urban (Denpasar) compared to rural (outside
Denpasar) stratification was done.

A household was defined as a group of persons who reside in the same place and prepare meals together. All members of selected households who were >= 1 year of age were eligible if informed consent was obtained by either the participant of the parent or guardian.",Samples that did not pass quality check were excluded from the analysis.,2020-11-15,2020-12-24,Household and community samples,All,Multiple groups,1.0,,Analysis,,1391,0.1812,0.1609,0.2014,,,,,True,Stratified probability,Author designed (Luminex),,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anak A. S. Sawitri,Universitas Udayana,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0000727,2023-04-25,2023-04-26,Unverified,sawitri_seroprevalence_2022,IDN
230626_Yogyakarta_NursingUniversitasGadjahMada,230626_Yogyakarta_NursingUniversitasGadjahMada,"Seroprevalence of SARS-CoV-2 and risk factors in Bantul Regency in March-April 2021, Yogyakarta, Indonesia.",2023-06-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Indonesia,,Yogyakarta,"Participants must meet the following inclusion criteria: residing in the study location at least six months before the survey commences, age of 5 years old or older, able to communicate verbally, give written consent to participate in the research or consent from parents/ guardians for respondents under 18 years old. Participants aged 13–17 were interviewed by their parents/guardians. However, for participants under 13 years old, interviews were conducted with the parents.","Meanwhile, the exclusion criteria include people with existing chronic illnesses (including immunocompromised individuals with a history of blood disorders and people with mental disorders).",2021-03-15,2021-04-15,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,,425,0.311,,,True,,,,True,Stratified probability,Human Anti-2019 n-CoV(N) IgG ELISA Kit V1.5,FineTest,ELISA,Plasma,IgG,Spike,,,,['High'],,Yes,No,No,,Unclear,Yes,No,,Riris Andono Ahmad,Nursing Universitas Gadjah Mada,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0000698,2023-08-02,2023-08-15,Unverified,wusthoff_seroprevalence_2023,IDN
201110_Tehran_TehranUniversityofMedicalSciences_unadj,201110_Tehran_TehranUniversityofMedicalSciences,Antibody Rapid Test Results in Emergency Medical Services Personnel during COVID-19 Pandemic; a Cross Sectional study.,2020-11-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),Tehran,Tehran,"Groups of EMS personnel working for Tehran EMS Center were invited for participation in this study. EMS personnel with any of the below criteria were included: 1) Confirmed COVID-19 cases based on the results of RT-PCR test and/or non-enhanced chest CT-scan. 2) Those who had COVID-19 symptoms since the onset of the epidemic, and did not undergo any diagnostic test or whose test results were negative. 3) Asymptomatic ones who had exposure to suspected or con- firmed COVID-19 teammates, and did not undergo diagnos- tic tests or whose test results were negative.","All EMS personnel who were unwilling to participate, refused to perform further required paraclinical investigation, and filled out the checklist incompletely, were excluded.",2020-03-20,2020-05-20,Essential non-healthcare workers,All,Adults (18-64 years),21.0,59.0,Primary Estimate,Overall IgG and/or IgM,243,0.4156,,,True,,,,True,Convenience,COVID-19 IgM/IgG rapid test,Karma Azma Andish Co.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.711,0.5870000000000001,['High'],Yes,No,No,Yes,Unclear,Unclear,Yes,No,Unclear,Peyman Saberian,Tehran University of Medical Sciences,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720855/,2021-01-23,2022-07-16,Verified,saberian_antibody_2020,IRN
201206_Tehran_HighInstituteforResearchandEducationinTransfusionMedicine,201206_Tehran_HighInstituteforResearchandEducationinTransfusionMedicine,"Prevalence of SARS-CoV-2 Specific Antibodies in the Staff of a Children's Hospital, in Tehran, Iran",2020-12-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),Tehran,Tehran,The inclusion criteria included all Mofid children's hospital staff who were presented in the period of this study,,2020-04-20,2020-05-05,Health care workers and caregivers,All,Adults (18-64 years),18.0,62.0,Primary Estimate,,475,0.294,,,True,,,,True,Convenience,2019-nCoV IgG/IgM Rapid Test Cassette,Hanghzhou AllTest Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9990000000000001,0.98,['High'],Yes,No,No,Yes,Unclear,No,Yes,Yes,Unclear,Shahnaz Armin,High Institute for Research and Education in Transfusion Medicine,Not Unity-Aligned,https://sites.kowsarpub.com/jjm/articles/108592.html,2021-01-27,2024-03-01,Verified,armin_prevalence_2020,IRN
201206_Tehran_HighInstituteforResearchandEducationinTransfusionMedicine_<40,201206_Tehran_HighInstituteforResearchandEducationinTransfusionMedicine,"Prevalence of SARS-CoV-2 Specific Antibodies in the Staff of a Children's Hospital, in Tehran, Iran",2020-12-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),Tehran,Tehran,The inclusion criteria included all Mofid children's hospital staff who were presented in the period of this study,,2020-04-20,2020-05-05,Health care workers and caregivers,All,Adults (18-64 years),,39.0,Age,<40 years,318,0.2516,,,,,,,,Convenience,2019-nCoV IgG/IgM Rapid Test Cassette,Hanghzhou AllTest Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9990000000000001,0.98,['High'],Yes,No,No,Yes,Unclear,No,Yes,Yes,Unclear,Shahnaz Armin,High Institute for Research and Education in Transfusion Medicine,Not Unity-Aligned,https://sites.kowsarpub.com/jjm/articles/108592.html,2021-03-04,2024-03-01,Verified,armin_prevalence_2020,IRN
201206_Tehran_HighInstituteforResearchandEducationinTransfusionMedicine_40-62,201206_Tehran_HighInstituteforResearchandEducationinTransfusionMedicine,"Prevalence of SARS-CoV-2 Specific Antibodies in the Staff of a Children's Hospital, in Tehran, Iran",2020-12-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),Tehran,Tehran,The inclusion criteria included all Mofid children's hospital staff who were presented in the period of this study,,2020-04-20,2020-05-05,Health care workers and caregivers,All,Adults (18-64 years),40.0,62.0,Age,40-62 years,157,0.3822,,,,,,,,Convenience,2019-nCoV IgG/IgM Rapid Test Cassette,Hanghzhou AllTest Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9990000000000001,0.98,['High'],Yes,No,No,Yes,Unclear,No,Yes,Yes,Unclear,Shahnaz Armin,High Institute for Research and Education in Transfusion Medicine,Not Unity-Aligned,https://sites.kowsarpub.com/jjm/articles/108592.html,2021-03-04,2024-03-01,Verified,armin_prevalence_2020,IRN
201215_Iran_TehranUniversityofMedicalSciences_GenPop1_overall_PopTestAdj,201215_Iran_TehranUniversityofMedicalSciences_GenPop1,SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study,2020-12-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,"Ahvaz, Ardabil, Babol , Esfahan , Gorgan, Hamedan, Kerman, Kermanshah, Mashhad, Qom, Rasht, Sanandaj, Sari, Shiraz, Tabriz, Tehran, Urmia, Zahedan","We randomly selected and invited study participants from the general population from the cities included in the study, without specific inclusion or exclusion criteria",without specific inclusion or exclusion criteria,2020-04-17,2020-06-02,Household and community samples,All,Multiple groups,,,Primary Estimate,,3530,0.171,0.146,0.195,True,True,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hossein Poustchi,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/S1473-3099%2820%2930858-6,2021-02-06,2023-08-15,Verified,poustchi_sars-cov-2_2020,IRN
201215_Iran_TehranUniversityofMedicalSciences_GenPop1_age<=19_PopAdj,201215_Iran_TehranUniversityofMedicalSciences_GenPop1,SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study,2020-12-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,"Ahvaz, Ardabil, Babol , Esfahan , Gorgan, Hamedan, Kerman, Kermanshah, Mashhad, Qom, Rasht, Sanandaj, Sari, Shiraz, Tabriz, Tehran, Urmia, Zahedan","We randomly selected and invited study participants from the general population from the cities included in the study, without specific inclusion or exclusion criteria",without specific inclusion or exclusion criteria,2020-04-17,2020-06-02,Household and community samples,All,Children and Youth (0-17 years),,19.0,Age,≤19,140,0.154,0.051,0.269,,,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hossein Poustchi,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/S1473-3099%2820%2930858-6,2021-02-06,2024-03-01,Verified,poustchi_sars-cov-2_2020,IRN
201215_Iran_TehranUniversityofMedicalSciences_GenPop1_Babol _PopTestAdj,201215_Iran_TehranUniversityofMedicalSciences_GenPop1,SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study,2020-12-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),,Babol ,"We randomly selected and invited study participants from the general population from the cities included in the study, without specific inclusion or exclusion criteria",without specific inclusion or exclusion criteria,2020-04-17,2020-06-02,Household and community samples,All,Multiple groups,,,Geographical area,Babol ,91,0.22399999999999998,0.11900000000000001,0.35100000000000003,,True,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hossein Poustchi,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/S1473-3099%2820%2930858-6,2021-03-06,2023-08-15,Verified,poustchi_sars-cov-2_2020,IRN
201215_Iran_TehranUniversityofMedicalSciences_GenPop1_Mashhad_PopTestAdj,201215_Iran_TehranUniversityofMedicalSciences_GenPop1,SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study,2020-12-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),,Mashhad,"We randomly selected and invited study participants from the general population from the cities included in the study, without specific inclusion or exclusion criteria",without specific inclusion or exclusion criteria,2020-04-17,2020-06-02,Household and community samples,All,Multiple groups,,,Geographical area,Mashhad,176,0.14800000000000002,0.08199999999999999,0.231,,True,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hossein Poustchi,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/S1473-3099%2820%2930858-6,2021-03-06,2023-08-15,Verified,poustchi_sars-cov-2_2020,IRN
201215_Iran_TehranUniversityofMedicalSciences_GenPop1_male_PopAdj,201215_Iran_TehranUniversityofMedicalSciences_GenPop1,SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study,2020-12-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,"Ahvaz, Ardabil, Babol , Esfahan , Gorgan, Hamedan, Kerman, Kermanshah, Mashhad, Qom, Rasht, Sanandaj, Sari, Shiraz, Tabriz, Tehran, Urmia, Zahedan","We randomly selected and invited study participants from the general population from the cities included in the study, without specific inclusion or exclusion criteria",without specific inclusion or exclusion criteria,2020-04-17,2020-06-02,Household and community samples,Male,Multiple groups,,,Sex/Gender,,1795,0.165,0.134,0.19899999999999998,,,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hossein Poustchi,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/S1473-3099%2820%2930858-6,2021-02-06,2024-03-01,Verified,poustchi_sars-cov-2_2020,IRN
201215_Iran_TehranUniversityofMedicalSciences_GenPop1_Kermanshah_PopTestAdj,201215_Iran_TehranUniversityofMedicalSciences_GenPop1,SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study,2020-12-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),,Kermanshah,"We randomly selected and invited study participants from the general population from the cities included in the study, without specific inclusion or exclusion criteria",without specific inclusion or exclusion criteria,2020-04-17,2020-06-02,Household and community samples,All,Multiple groups,,,Geographical area,Kermanshah,133,0.17300000000000001,0.053,0.309,,True,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hossein Poustchi,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/S1473-3099%2820%2930858-6,2021-03-06,2023-08-15,Verified,poustchi_sars-cov-2_2020,IRN
201215_Iran_TehranUniversityofMedicalSciences_GenPop1_age30-39_PopAdj,201215_Iran_TehranUniversityofMedicalSciences_GenPop1,SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study,2020-12-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,"Ahvaz, Ardabil, Babol , Esfahan , Gorgan, Hamedan, Kerman, Kermanshah, Mashhad, Qom, Rasht, Sanandaj, Sari, Shiraz, Tabriz, Tehran, Urmia, Zahedan","We randomly selected and invited study participants from the general population from the cities included in the study, without specific inclusion or exclusion criteria",without specific inclusion or exclusion criteria,2020-04-17,2020-06-02,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30–39,992,0.158,0.11699999999999999,0.204,,,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hossein Poustchi,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/S1473-3099%2820%2930858-6,2021-02-06,2024-03-01,Verified,poustchi_sars-cov-2_2020,IRN
201215_Iran_TehranUniversityofMedicalSciences_GenPop1_Kerman_PopTestAdj,201215_Iran_TehranUniversityofMedicalSciences_GenPop1,SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study,2020-12-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),,Kerman,"We randomly selected and invited study participants from the general population from the cities included in the study, without specific inclusion or exclusion criteria",without specific inclusion or exclusion criteria,2020-04-17,2020-06-02,Household and community samples,All,Multiple groups,,,Geographical area,Kerman,108,0.08199999999999999,0.022000000000000002,0.166,,True,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hossein Poustchi,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/S1473-3099%2820%2930858-6,2021-03-06,2023-08-15,Verified,poustchi_sars-cov-2_2020,IRN
201215_Iran_TehranUniversityofMedicalSciences_GenPop1_Sanandaj_PopTestAdj,201215_Iran_TehranUniversityofMedicalSciences_GenPop1,SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study,2020-12-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),,Sanandaj,"We randomly selected and invited study participants from the general population from the cities included in the study, without specific inclusion or exclusion criteria",without specific inclusion or exclusion criteria,2020-04-17,2020-06-02,Household and community samples,All,Multiple groups,,,Geographical area,Sanandaj,96,0.017,0.0,0.06,,True,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hossein Poustchi,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/S1473-3099%2820%2930858-6,2021-03-06,2023-08-15,Verified,poustchi_sars-cov-2_2020,IRN
201215_Iran_TehranUniversityofMedicalSciences_GenPop1_Gorgan_PopTestAdj,201215_Iran_TehranUniversityofMedicalSciences_GenPop1,SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study,2020-12-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),,Gorgan,"We randomly selected and invited study participants from the general population from the cities included in the study, without specific inclusion or exclusion criteria",without specific inclusion or exclusion criteria,2020-04-17,2020-06-02,Household and community samples,All,Multiple groups,,,Geographical area,Gorgan,125,0.439,0.314,0.583,,True,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hossein Poustchi,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/S1473-3099%2820%2930858-6,2021-03-06,2023-08-15,Verified,poustchi_sars-cov-2_2020,IRN
201215_Iran_TehranUniversityofMedicalSciences_GenPop1_age20-29_PopAdj,201215_Iran_TehranUniversityofMedicalSciences_GenPop1,SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study,2020-12-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,"Ahvaz, Ardabil, Babol , Esfahan , Gorgan, Hamedan, Kerman, Kermanshah, Mashhad, Qom, Rasht, Sanandaj, Sari, Shiraz, Tabriz, Tehran, Urmia, Zahedan","We randomly selected and invited study participants from the general population from the cities included in the study, without specific inclusion or exclusion criteria",without specific inclusion or exclusion criteria,2020-04-17,2020-06-02,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20–29,470,0.087,0.047,0.132,,,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hossein Poustchi,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/S1473-3099%2820%2930858-6,2021-02-06,2024-03-01,Verified,poustchi_sars-cov-2_2020,IRN
201215_Iran_TehranUniversityofMedicalSciences_GenPop1_Sari_PopTestAdj,201215_Iran_TehranUniversityofMedicalSciences_GenPop1,SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study,2020-12-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),,Sari,"We randomly selected and invited study participants from the general population from the cities included in the study, without specific inclusion or exclusion criteria",without specific inclusion or exclusion criteria,2020-04-17,2020-06-02,Household and community samples,All,Multiple groups,,,Geographical area,Sari,175,0.147,0.078,0.22399999999999998,,True,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hossein Poustchi,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/S1473-3099%2820%2930858-6,2021-03-06,2023-08-15,Verified,poustchi_sars-cov-2_2020,IRN
201215_Iran_TehranUniversityofMedicalSciences_GenPop1_Qom_PopTestAdj,201215_Iran_TehranUniversityofMedicalSciences_GenPop1,SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study,2020-12-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),,Qom,"We randomly selected and invited study participants from the general population from the cities included in the study, without specific inclusion or exclusion criteria",without specific inclusion or exclusion criteria,2020-04-17,2020-06-02,Household and community samples,All,Multiple groups,,,Geographical area,Qom,108,0.585,0.37200000000000005,0.8390000000000001,,True,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hossein Poustchi,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/S1473-3099%2820%2930858-6,2021-03-06,2023-08-15,Verified,poustchi_sars-cov-2_2020,IRN
201215_Iran_TehranUniversityofMedicalSciences_GenPop1_age50-59_PopAdj,201215_Iran_TehranUniversityofMedicalSciences_GenPop1,SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study,2020-12-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,"Ahvaz, Ardabil, Babol , Esfahan , Gorgan, Hamedan, Kerman, Kermanshah, Mashhad, Qom, Rasht, Sanandaj, Sari, Shiraz, Tabriz, Tehran, Urmia, Zahedan","We randomly selected and invited study participants from the general population from the cities included in the study, without specific inclusion or exclusion criteria",without specific inclusion or exclusion criteria,2020-04-17,2020-06-02,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50–59,590,0.214,0.16,0.272,,,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hossein Poustchi,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/S1473-3099%2820%2930858-6,2021-02-06,2024-03-01,Verified,poustchi_sars-cov-2_2020,IRN
201215_Iran_TehranUniversityofMedicalSciences_GenPop1_age40-49_PopAdj,201215_Iran_TehranUniversityofMedicalSciences_GenPop1,SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study,2020-12-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,"Ahvaz, Ardabil, Babol , Esfahan , Gorgan, Hamedan, Kerman, Kermanshah, Mashhad, Qom, Rasht, Sanandaj, Sari, Shiraz, Tabriz, Tehran, Urmia, Zahedan","We randomly selected and invited study participants from the general population from the cities included in the study, without specific inclusion or exclusion criteria",without specific inclusion or exclusion criteria,2020-04-17,2020-06-02,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40–49,937,0.189,0.146,0.23199999999999998,,,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hossein Poustchi,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/S1473-3099%2820%2930858-6,2021-02-06,2024-03-01,Verified,poustchi_sars-cov-2_2020,IRN
201215_Iran_TehranUniversityofMedicalSciences_GenPop1_Shiraz_PopTestAdj,201215_Iran_TehranUniversityofMedicalSciences_GenPop1,SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study,2020-12-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),,Shiraz,"We randomly selected and invited study participants from the general population from the cities included in the study, without specific inclusion or exclusion criteria",without specific inclusion or exclusion criteria,2020-04-17,2020-06-02,Household and community samples,All,Multiple groups,,,Geographical area,Shiraz,124,0.073,0.012,0.145,,True,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hossein Poustchi,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/S1473-3099%2820%2930858-6,2021-03-06,2023-08-15,Verified,poustchi_sars-cov-2_2020,IRN
201215_Iran_TehranUniversityofMedicalSciences_GenPop1_overall_PopAdj,201215_Iran_TehranUniversityofMedicalSciences_GenPop1,SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study,2020-12-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,"Ahvaz, Ardabil, Babol , Esfahan , Gorgan, Hamedan, Kerman, Kermanshah, Mashhad, Qom, Rasht, Sanandaj, Sari, Shiraz, Tabriz, Tehran, Urmia, Zahedan","We randomly selected and invited study participants from the general population from the cities included in the study, without specific inclusion or exclusion criteria",without specific inclusion or exclusion criteria,2020-04-17,2020-06-02,Household and community samples,All,Multiple groups,,,Analysis,,3530,0.129,0.113,0.145,,,True,,True,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hossein Poustchi,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/S1473-3099%2820%2930858-6,2021-02-06,2024-03-01,Verified,poustchi_sars-cov-2_2020,IRN
201215_Iran_TehranUniversityofMedicalSciences_GenPop1_Tehran_PopTestAdj,201215_Iran_TehranUniversityofMedicalSciences_GenPop1,SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study,2020-12-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),,Tehran,"We randomly selected and invited study participants from the general population from the cities included in the study, without specific inclusion or exclusion criteria",without specific inclusion or exclusion criteria,2020-04-17,2020-06-02,Household and community samples,All,Multiple groups,,,Geographical area,Tehran,1572,0.163,0.135,0.195,,True,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hossein Poustchi,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/S1473-3099%2820%2930858-6,2021-03-06,2023-08-15,Verified,poustchi_sars-cov-2_2020,IRN
201215_Iran_TehranUniversityofMedicalSciences_GenPop1_Rasht_PopTestAdj,201215_Iran_TehranUniversityofMedicalSciences_GenPop1,SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study,2020-12-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),,Rasht,"We randomly selected and invited study participants from the general population from the cities included in the study, without specific inclusion or exclusion criteria",without specific inclusion or exclusion criteria,2020-04-17,2020-06-02,Household and community samples,All,Multiple groups,,,Geographical area,Rasht,99,0.726,0.539,0.9279999999999999,,True,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hossein Poustchi,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/S1473-3099%2820%2930858-6,2021-03-06,2023-08-15,Verified,poustchi_sars-cov-2_2020,IRN
201215_Iran_TehranUniversityofMedicalSciences_GenPop1_Hamedan_PopTestAdj,201215_Iran_TehranUniversityofMedicalSciences_GenPop1,SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study,2020-12-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),,Hamedan,"We randomly selected and invited study participants from the general population from the cities included in the study, without specific inclusion or exclusion criteria",without specific inclusion or exclusion criteria,2020-04-17,2020-06-02,Household and community samples,All,Multiple groups,,,Geographical area,Hamedan,108,0.083,0.016,0.17,,True,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hossein Poustchi,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/S1473-3099%2820%2930858-6,2021-03-06,2023-08-15,Verified,poustchi_sars-cov-2_2020,IRN
201215_Iran_TehranUniversityofMedicalSciences_GenPop1_age60+_PopAdj,201215_Iran_TehranUniversityofMedicalSciences_GenPop1,SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study,2020-12-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,"Ahvaz, Ardabil, Babol , Esfahan , Gorgan, Hamedan, Kerman, Kermanshah, Mashhad, Qom, Rasht, Sanandaj, Sari, Shiraz, Tabriz, Tehran, Urmia, Zahedan","We randomly selected and invited study participants from the general population from the cities included in the study, without specific inclusion or exclusion criteria",without specific inclusion or exclusion criteria,2020-04-17,2020-06-02,Household and community samples,All,Seniors (65+ years),60.0,,Age,≥60,401,0.292,0.214,0.375,,,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hossein Poustchi,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/S1473-3099%2820%2930858-6,2021-02-06,2024-03-01,Verified,poustchi_sars-cov-2_2020,IRN
201215_Iran_TehranUniversityofMedicalSciences_GenPop1_Ahvaz_PopTestAdj,201215_Iran_TehranUniversityofMedicalSciences_GenPop1,SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study,2020-12-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),,Ahvaz,"We randomly selected and invited study participants from the general population from the cities included in the study, without specific inclusion or exclusion criteria",without specific inclusion or exclusion criteria,2020-04-17,2020-06-02,Household and community samples,All,Multiple groups,,,Geographical area,Ahvaz,100,0.094,0.006999999999999999,0.21600000000000003,,True,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hossein Poustchi,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/S1473-3099%2820%2930858-6,2021-03-06,2023-08-15,Verified,poustchi_sars-cov-2_2020,IRN
201215_Iran_TehranUniversityofMedicalSciences_GenPop1_female_PopAdj,201215_Iran_TehranUniversityofMedicalSciences_GenPop1,SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study,2020-12-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,"Ahvaz, Ardabil, Babol , Esfahan , Gorgan, Hamedan, Kerman, Kermanshah, Mashhad, Qom, Rasht, Sanandaj, Sari, Shiraz, Tabriz, Tehran, Urmia, Zahedan","We randomly selected and invited study participants from the general population from the cities included in the study, without specific inclusion or exclusion criteria",without specific inclusion or exclusion criteria,2020-04-17,2020-06-02,Household and community samples,Female,Multiple groups,,,Sex/Gender,Female,1735,0.17500000000000002,0.14300000000000002,0.20800000000000002,,,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hossein Poustchi,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/S1473-3099%2820%2930858-6,2021-02-06,2024-03-01,Verified,poustchi_sars-cov-2_2020,IRN
201215_Iran_TehranUniversityofMedicalSciences_GenPop1_Tabriz_PopTestAdj,201215_Iran_TehranUniversityofMedicalSciences_GenPop1,SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study,2020-12-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),,Tabriz,"We randomly selected and invited study participants from the general population from the cities included in the study, without specific inclusion or exclusion criteria",without specific inclusion or exclusion criteria,2020-04-17,2020-06-02,Household and community samples,All,Multiple groups,,,Geographical area,Tabriz,103,0.055999999999999994,0.0,0.13,,True,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hossein Poustchi,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/S1473-3099%2820%2930858-6,2021-03-06,2023-08-15,Verified,poustchi_sars-cov-2_2020,IRN
201215_Iran_TehranUniversityofMedicalSciences_GenPop1_Zahedan_PopTestAdj,201215_Iran_TehranUniversityofMedicalSciences_GenPop1,SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study,2020-12-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),,Zahedan,"We randomly selected and invited study participants from the general population from the cities included in the study, without specific inclusion or exclusion criteria",without specific inclusion or exclusion criteria,2020-04-17,2020-06-02,Household and community samples,All,Multiple groups,,,Geographical area,Zahedan,105,0.121,0.023,0.233,,True,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hossein Poustchi,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/S1473-3099%2820%2930858-6,2021-03-06,2023-08-15,Verified,poustchi_sars-cov-2_2020,IRN
201215_Iran_TehranUniversityofMedicalSciences_GenPop1_Esfahan _PopTestAdj,201215_Iran_TehranUniversityofMedicalSciences_GenPop1,SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study,2020-12-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),,Esfahan ,"We randomly selected and invited study participants from the general population from the cities included in the study, without specific inclusion or exclusion criteria",without specific inclusion or exclusion criteria,2020-04-17,2020-06-02,Household and community samples,All,Multiple groups,,,Geographical area,Esfahan ,119,0.027000000000000003,0.0,0.098,,True,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hossein Poustchi,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/S1473-3099%2820%2930858-6,2021-03-06,2023-08-15,Verified,poustchi_sars-cov-2_2020,IRN
201215_Iran_TehranUniversityofMedicalSciences_GenPop1_Urmia_PopTestAdj,201215_Iran_TehranUniversityofMedicalSciences_GenPop1,SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study,2020-12-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),,Urmia,"We randomly selected and invited study participants from the general population from the cities included in the study, without specific inclusion or exclusion criteria",without specific inclusion or exclusion criteria,2020-04-17,2020-06-02,Household and community samples,All,Multiple groups,,,Geographical area,Urmia,101,0.1,0.002,0.24300000000000002,,True,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hossein Poustchi,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/S1473-3099%2820%2930858-6,2021-03-06,2023-08-15,Verified,poustchi_sars-cov-2_2020,IRN
201215_Iran_TehranUniversityofMedicalSciences_GenPop1_Ardabil_PopTestAdj,201215_Iran_TehranUniversityofMedicalSciences_GenPop1,SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study,2020-12-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),,Ardabil,"We randomly selected and invited study participants from the general population from the cities included in the study, without specific inclusion or exclusion criteria",without specific inclusion or exclusion criteria,2020-04-17,2020-06-02,Household and community samples,All,Multiple groups,,,Geographical area,Ardabil,87,0.2,0.032,0.46799999999999997,,True,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hossein Poustchi,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/S1473-3099%2820%2930858-6,2021-03-06,2023-08-15,Verified,poustchi_sars-cov-2_2020,IRN
201215_Iran_TehranUniversityofMedicalSciences_HighRisk2_overall_PopTestAdj ,201215_Iran_TehranUniversityofMedicalSciences_HighRisk2,SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study,2020-12-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,"Ahvaz, Ardabil, Babol , Esfahan , Gorgan, Hamedan, Kerman, Kermanshah, Mashhad, Qom, Rasht, Sanandaj, Sari, Shiraz, Tabriz, Tehran, Urmia, Zahedan","We randomly selected and invited study participants from occupations with a  high risk of SARS-CoV-2 exposure (eg, front-line health and pharmacy workers, taxi drivers, and cashiers or other customer-facing staff) from the cities included in the study, without specific inclusion or exclusion criteria ",,2020-04-17,2020-06-02,Multiple populations,All,Multiple groups,,,Primary Estimate,,5372,0.2,0.185,0.217,True,True,,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Yes,Hossein Poustchi,Tehran University of Medical Sciences,Not Unity-Aligned,http://dx.doi.org/10.1016/S1473-3099%2820%2930858-6,2021-02-06,2023-08-15,Verified,poustchi_sars-cov-2_2020,IRN
201221_Guilan_TehranUniversityofMedicalSciences_overall,201221_Guilan_TehranUniversityofMedicalSciences,"Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020",2020-12-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iran (Islamic Republic of),Guilan,,"All persons living in a household, regardless of age, were invited through multistage cluster random sampling",,2020-04-11,2020-04-19,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,Design (pop) and test adjustment,528,0.222,0.16399999999999998,0.28500000000000003,True,True,True,,,Stratified probability,VivaDiag COVID-19 IgM/IgG Rapid Test,VivaChek Biotech (Hangzhou) Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.833,0.99,['Moderate'],Yes,Yes,No,Yes,Unclear,Yes,Yes,Yes,No,Maryam Shakiba,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.3201/eid2702.201960,2021-01-23,2023-07-04,Verified,shakiba_seroprevalence_2021,IRN
201221_Guilan_TehranUniversityofMedicalSciences_male,201221_Guilan_TehranUniversityofMedicalSciences,"Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020",2020-12-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iran (Islamic Republic of),Guilan,,"All persons living in a household, regardless of age, were invited through multistage cluster random sampling",,2020-04-11,2020-04-19,Household and community samples,Male,Multiple groups,0.0,,Sex/Gender,,257,0.19,0.127,0.254,,True,True,,,Stratified probability,VivaDiag COVID-19 IgM/IgG Rapid Test,VivaChek Biotech (Hangzhou) Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.833,0.99,['Moderate'],Yes,Yes,No,Yes,Unclear,Yes,Yes,Yes,No,Maryam Shakiba,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.3201/eid2702.201960,2021-01-23,2023-07-04,Verified,shakiba_seroprevalence_2021,IRN
201221_Guilan_TehranUniversityofMedicalSciences_female,201221_Guilan_TehranUniversityofMedicalSciences,"Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020",2020-12-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iran (Islamic Republic of),Guilan,,"All persons living in a household, regardless of age, were invited through multistage cluster random sampling",,2020-04-11,2020-04-19,Household and community samples,Female,Multiple groups,0.0,,Sex/Gender,Female,271,0.256,0.154,0.368,,True,True,,,Stratified probability,VivaDiag COVID-19 IgM/IgG Rapid Test,VivaChek Biotech (Hangzhou) Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.833,0.99,['Moderate'],Yes,Yes,No,Yes,Unclear,Yes,Yes,Yes,No,Maryam Shakiba,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.3201/eid2702.201960,2021-01-23,2023-07-04,Verified,shakiba_seroprevalence_2021,IRN
201221_Guilan_TehranUniversityofMedicalSciences_age60+,201221_Guilan_TehranUniversityofMedicalSciences,"Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020",2020-12-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iran (Islamic Republic of),Guilan,,"All persons living in a household, regardless of age, were invited through multistage cluster random sampling",,2020-04-11,2020-04-19,Household and community samples,All,Seniors (65+ years),60.0,,Age,60+,72,0.257,0.166,0.36100000000000004,,True,True,,,Stratified probability,VivaDiag COVID-19 IgM/IgG Rapid Test,VivaChek Biotech (Hangzhou) Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.833,0.99,['Moderate'],Yes,Yes,No,Yes,Unclear,Yes,Yes,Yes,No,Maryam Shakiba,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.3201/eid2702.201960,2021-01-23,2023-07-04,Verified,shakiba_seroprevalence_2021,IRN
201221_Guilan_TehranUniversityofMedicalSciences_overall_popadj,201221_Guilan_TehranUniversityofMedicalSciences,"Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020",2020-12-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iran (Islamic Republic of),Guilan,,"All persons living in a household, regardless of age, were invited through multistage cluster random sampling",,2020-04-11,2020-04-19,Household and community samples,All,Multiple groups,0.0,,Analysis,Design (pop) adjustment,528,0.22100000000000003,0.19,0.26,,,True,,True,Stratified probability,VivaDiag COVID-19 IgM/IgG Rapid Test,VivaChek Biotech (Hangzhou) Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.833,0.99,['Moderate'],Yes,Yes,No,Yes,Unclear,Yes,Yes,Yes,No,Maryam Shakiba,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.3201/eid2702.201960,2021-01-23,2024-03-01,Verified,shakiba_seroprevalence_2021,IRN
201221_Guilan_TehranUniversityofMedicalSciences_age<5,201221_Guilan_TehranUniversityofMedicalSciences,"Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020",2020-12-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iran (Islamic Republic of),Guilan,,"All persons living in a household, regardless of age, were invited through multistage cluster random sampling",,2020-04-11,2020-04-19,Household and community samples,All,Children and Youth (0-17 years),,4.0,Age,<5,26,0.098,0.009000000000000001,0.226,,True,True,,,Stratified probability,VivaDiag COVID-19 IgM/IgG Rapid Test,VivaChek Biotech (Hangzhou) Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.833,0.99,['Moderate'],Yes,Yes,No,Yes,Unclear,Yes,Yes,Yes,No,Maryam Shakiba,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.3201/eid2702.201960,2021-01-23,2023-07-04,Verified,shakiba_seroprevalence_2021,IRN
201221_Guilan_TehranUniversityofMedicalSciences_age5-17,201221_Guilan_TehranUniversityofMedicalSciences,"Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020",2020-12-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iran (Islamic Republic of),Guilan,,"All persons living in a household, regardless of age, were invited through multistage cluster random sampling",,2020-04-11,2020-04-19,Household and community samples,All,Children and Youth (0-17 years),5.0,17.0,Age,5-17,101,0.19100000000000003,0.11199999999999999,0.275,,True,True,,,Stratified probability,VivaDiag COVID-19 IgM/IgG Rapid Test,VivaChek Biotech (Hangzhou) Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.833,0.99,['Moderate'],Yes,Yes,No,Yes,Unclear,Yes,Yes,Yes,No,Maryam Shakiba,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.3201/eid2702.201960,2021-01-23,2023-07-04,Verified,shakiba_seroprevalence_2021,IRN
201221_Guilan_TehranUniversityofMedicalSciences_age18-59,201221_Guilan_TehranUniversityofMedicalSciences,"Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020",2020-12-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iran (Islamic Republic of),Guilan,,"All persons living in a household, regardless of age, were invited through multistage cluster random sampling",,2020-04-11,2020-04-19,Household and community samples,All,Adults (18-64 years),18.0,59.0,Age,18-59,329,0.24100000000000002,0.17500000000000002,0.316,,True,True,,,Stratified probability,VivaDiag COVID-19 IgM/IgG Rapid Test,VivaChek Biotech (Hangzhou) Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.833,0.99,['Moderate'],Yes,Yes,No,Yes,Unclear,Yes,Yes,Yes,No,Maryam Shakiba,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.3201/eid2702.201960,2021-01-23,2023-07-04,Verified,shakiba_seroprevalence_2021,IRN
201223_RafsanjanCounty_UniversityofPecs,201223_RafsanjanCounty_UniversityofPecs,A contact tracing prospective cohort retrieving epidemiological facts on SARS-CoV-2 transmission aspects; a serological analysis,2020-12-23,Preprint,Local,Prospective cohort,Iran (Islamic Republic of),Kerman,,Household contacts of patients with RT-PCR confirmed Covid-19,Refusal to participate,2020-03-01,2020-04-30,Contacts of COVID patients,All,Multiple groups,1.0,91.0,Primary Estimate,Overall estimate,238,0.1555,,,True,,,,True,Sequential,Not reported/ Unable to specify,,,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,Yes,Unclear,Unclear,Yes,No,No,Reza Vazirinejad,University of Pecs,Not Unity-Aligned,https://europepmc.org/article/ppr/ppr257302#fulltext--permissions-,2021-02-02,2022-07-16,Verified,vazirinejad_contact_2020-1,IRN
2101_Zahedan_TehranUniversityofMedicalSciences,2101_Zahedan_TehranUniversityofMedicalSciences_IVDU,The seroprevalence of COVID-19 in intravenous drug users in comparison to non-drug users,2021-01-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),Sistan and Balouchestan,Zahedan,"Male IVDU (intravenous drug users) randomly recruited through a drop- in center in Zahedan, the largest city and capital of Sistan & Balouchestan province, as well as a mobile van that distributes food and clean syringes to homeless drug abusers throughout the city. ",,2020-07-01,2020-07-31,Persons experiencing homelessness,Male,Adults (18-64 years),,,Primary Estimate,,167,0.09699999999999999,,,True,,,,True,Convenience,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",,,,,['High'],No,No,No,No,No,Yes,Yes,Yes,Unclear,Zahra Mohammadi,Tehran University of Medical Sciences,Not Unity-Aligned,http://dx.doi.org/10.34172/mejdd.2021.206a,2021-03-14,2024-03-01,Verified,mohammadi_seroprevalence_2021,IRN
2101_Zahedan_TehranUniversityofMedicalSciences_NonDrugUsers,2101_Zahedan_TehranUniversityofMedicalSciences_NonDrugUsers,The seroprevalence of COVID-19 in intravenous drug users in comparison to non-drug users,2021-01-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),Sistan and Balouchestan,Zahedan,"male non drug users in Sistan and Balouchestan province: The population census at Zahedan Health Centers was used to randomly select and recruit N-DU for comparison. Given that all IVDU were male, only male N-DU were selected to be included in this study",women,2020-07-01,2020-07-31,Household and community samples,Male,Adults (18-64 years),,,Primary Estimate,,134,0.048,,,True,,,,True,Simplified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",,,,,['High'],No,Yes,No,No,No,Yes,Yes,Yes,Unclear,Zahra Mohammadi,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.34172/mejdd.2021.206a,2021-03-14,2024-03-01,Verified,mohammadi_seroprevalence_2021,IRN
210105_Mazandaran_MazandaranUniversityofMedicalSciences_OverallPopAdj,210105_Mazandaran_MazandaranUniversityofMedicalSciences,"Seroprevalence of SARS-CoV-2 in Mazandaran province, Iran",2021-01-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iran (Islamic Republic of),Mazandaran,,all the household members older than seven years old were the population of our study,"The exclusion criteria were: (1) living in retirement homes, prisons, or boarding schools, (2) being intolerant for disinfectants, (3) being in the treatment process of COVID-19, and (4) not cooperating until the end of the study.",2020-03-15,2020-05-15,Household and community samples,All,Multiple groups,7.0,,Primary Estimate,overall pop adj,1588,0.1729,0.1484,0.1779,True,,True,,True,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.59,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Seyed Abbas Mousavi,Mazandaran University of Medical Sciences,Unity-Aligned,https://www.apjtm.org/article.asp?issn=1995-7645;year=2021;volume=14;issue=1;spage=10;epage=16;aulast=Mousavi,2021-03-17,2024-03-01,Verified,mousavi_seroprevalence_2021,IRN
210105_Mazandaran_MazandaranUniversityofMedicalSciences_40-49,210105_Mazandaran_MazandaranUniversityofMedicalSciences,"Seroprevalence of SARS-CoV-2 in Mazandaran province, Iran",2021-01-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iran (Islamic Republic of),Mazandaran,,all the household members older than seven years old were the population of our study,"The exclusion criteria were: (1) living in retirement homes, prisons, or boarding schools, (2) being intolerant for disinfectants, (3) being in the treatment process of COVID-19, and (4) not cooperating until the end of the study.",2020-03-15,2020-05-15,Household and community samples,Female,Adults (18-64 years),40.0,49.0,Age,40-49,381,0.21789999999999998,0.16519999999999999,0.2812,,,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.59,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Seyed Abbas Mousavi,Mazandaran University of Medical Sciences,Unity-Aligned,https://www.apjtm.org/article.asp?issn=1995-7645;year=2021;volume=14;issue=1;spage=10;epage=16;aulast=Mousavi,2021-03-17,2024-03-01,Verified,mousavi_seroprevalence_2021,IRN
210105_Mazandaran_MazandaranUniversityofMedicalSciences_30-39,210105_Mazandaran_MazandaranUniversityofMedicalSciences,"Seroprevalence of SARS-CoV-2 in Mazandaran province, Iran",2021-01-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iran (Islamic Republic of),Mazandaran,,all the household members older than seven years old were the population of our study,"The exclusion criteria were: (1) living in retirement homes, prisons, or boarding schools, (2) being intolerant for disinfectants, (3) being in the treatment process of COVID-19, and (4) not cooperating until the end of the study.",2020-03-15,2020-05-15,Household and community samples,Female,Adults (18-64 years),30.0,39.0,Age,30-39,340,0.1645,0.115,0.2252,,,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.59,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Seyed Abbas Mousavi,Mazandaran University of Medical Sciences,Unity-Aligned,https://www.apjtm.org/article.asp?issn=1995-7645;year=2021;volume=14;issue=1;spage=10;epage=16;aulast=Mousavi,2021-03-17,2024-03-01,Verified,mousavi_seroprevalence_2021,IRN
210105_Mazandaran_MazandaranUniversityofMedicalSciences_50-59,210105_Mazandaran_MazandaranUniversityofMedicalSciences,"Seroprevalence of SARS-CoV-2 in Mazandaran province, Iran",2021-01-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iran (Islamic Republic of),Mazandaran,,all the household members older than seven years old were the population of our study,"The exclusion criteria were: (1) living in retirement homes, prisons, or boarding schools, (2) being intolerant for disinfectants, (3) being in the treatment process of COVID-19, and (4) not cooperating until the end of the study.",2020-03-15,2020-05-15,Household and community samples,Female,Seniors (65+ years),50.0,59.0,Age,50-59,325,0.2711,0.20670000000000002,0.3455,,,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.59,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Seyed Abbas Mousavi,Mazandaran University of Medical Sciences,Unity-Aligned,https://www.apjtm.org/article.asp?issn=1995-7645;year=2021;volume=14;issue=1;spage=10;epage=16;aulast=Mousavi,2021-03-17,2024-03-01,Verified,mousavi_seroprevalence_2021,IRN
210105_Mazandaran_MazandaranUniversityofMedicalSciences_10-19,210105_Mazandaran_MazandaranUniversityofMedicalSciences,"Seroprevalence of SARS-CoV-2 in Mazandaran province, Iran",2021-01-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iran (Islamic Republic of),Mazandaran,,all the household members older than seven years old were the population of our study,"The exclusion criteria were: (1) living in retirement homes, prisons, or boarding schools, (2) being intolerant for disinfectants, (3) being in the treatment process of COVID-19, and (4) not cooperating until the end of the study.",2020-03-15,2020-05-15,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,111,0.1526,0.0782,0.27,,,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.59,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Seyed Abbas Mousavi,Mazandaran University of Medical Sciences,Unity-Aligned,https://www.apjtm.org/article.asp?issn=1995-7645;year=2021;volume=14;issue=1;spage=10;epage=16;aulast=Mousavi,2021-03-17,2024-03-01,Verified,mousavi_seroprevalence_2021,IRN
210105_Mazandaran_MazandaranUniversityofMedicalSciences_Male,210105_Mazandaran_MazandaranUniversityofMedicalSciences,"Seroprevalence of SARS-CoV-2 in Mazandaran province, Iran",2021-01-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iran (Islamic Republic of),Mazandaran,,all the household members older than seven years old were the population of our study,"The exclusion criteria were: (1) living in retirement homes, prisons, or boarding schools, (2) being intolerant for disinfectants, (3) being in the treatment process of COVID-19, and (4) not cooperating until the end of the study.",2020-03-15,2020-05-15,Household and community samples,Male,Multiple groups,7.0,,Sex/Gender,,725,0.2057,0.1674,0.2494,,,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.59,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Seyed Abbas Mousavi,Mazandaran University of Medical Sciences,Unity-Aligned,https://www.apjtm.org/article.asp?issn=1995-7645;year=2021;volume=14;issue=1;spage=10;epage=16;aulast=Mousavi,2021-03-17,2024-03-01,Verified,mousavi_seroprevalence_2021,IRN
210105_Mazandaran_MazandaranUniversityofMedicalSciences_>=70,210105_Mazandaran_MazandaranUniversityofMedicalSciences,"Seroprevalence of SARS-CoV-2 in Mazandaran province, Iran",2021-01-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iran (Islamic Republic of),Mazandaran,,all the household members older than seven years old were the population of our study,"The exclusion criteria were: (1) living in retirement homes, prisons, or boarding schools, (2) being intolerant for disinfectants, (3) being in the treatment process of COVID-19, and (4) not cooperating until the end of the study.",2020-03-15,2020-05-15,Household and community samples,Female,Seniors (65+ years),70.0,,Age,70+,83,0.22460000000000002,0.1213,0.37310000000000004,,,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.59,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Seyed Abbas Mousavi,Mazandaran University of Medical Sciences,Unity-Aligned,https://www.apjtm.org/article.asp?issn=1995-7645;year=2021;volume=14;issue=1;spage=10;epage=16;aulast=Mousavi,2021-03-17,2024-03-01,Verified,mousavi_seroprevalence_2021,IRN
210105_Mazandaran_MazandaranUniversityofMedicalSciences_Female,210105_Mazandaran_MazandaranUniversityofMedicalSciences,"Seroprevalence of SARS-CoV-2 in Mazandaran province, Iran",2021-01-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iran (Islamic Republic of),Mazandaran,,all the household members older than seven years old were the population of our study,"The exclusion criteria were: (1) living in retirement homes, prisons, or boarding schools, (2) being intolerant for disinfectants, (3) being in the treatment process of COVID-19, and (4) not cooperating until the end of the study.",2020-03-15,2020-05-15,Household and community samples,Female,Multiple groups,7.0,,Sex/Gender,,863,0.21989999999999998,0.1838,0.2605,,,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.59,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Seyed Abbas Mousavi,Mazandaran University of Medical Sciences,Unity-Aligned,https://www.apjtm.org/article.asp?issn=1995-7645;year=2021;volume=14;issue=1;spage=10;epage=16;aulast=Mousavi,2021-03-17,2024-03-01,Verified,mousavi_seroprevalence_2021,IRN
210105_Mazandaran_MazandaranUniversityofMedicalSciences_7-9,210105_Mazandaran_MazandaranUniversityofMedicalSciences,"Seroprevalence of SARS-CoV-2 in Mazandaran province, Iran",2021-01-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iran (Islamic Republic of),Mazandaran,,all the household members older than seven years old were the population of our study,"The exclusion criteria were: (1) living in retirement homes, prisons, or boarding schools, (2) being intolerant for disinfectants, (3) being in the treatment process of COVID-19, and (4) not cooperating until the end of the study.",2020-03-15,2020-05-15,Household and community samples,All,Children and Youth (0-17 years),7.0,9.0,Age,7-9,11,0.154,0.0077,0.6797,,,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.59,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Seyed Abbas Mousavi,Mazandaran University of Medical Sciences,Unity-Aligned,https://www.apjtm.org/article.asp?issn=1995-7645;year=2021;volume=14;issue=1;spage=10;epage=16;aulast=Mousavi,2021-03-17,2024-03-01,Verified,mousavi_seroprevalence_2021,IRN
210105_Mazandaran_MazandaranUniversityofMedicalSciences_20-29,210105_Mazandaran_MazandaranUniversityofMedicalSciences,"Seroprevalence of SARS-CoV-2 in Mazandaran province, Iran",2021-01-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iran (Islamic Republic of),Mazandaran,,all the household members older than seven years old were the population of our study,"The exclusion criteria were: (1) living in retirement homes, prisons, or boarding schools, (2) being intolerant for disinfectants, (3) being in the treatment process of COVID-19, and (4) not cooperating until the end of the study.",2020-03-15,2020-05-15,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,131,0.21989999999999998,0.1349,0.33299999999999996,,,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.59,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Seyed Abbas Mousavi,Mazandaran University of Medical Sciences,Unity-Aligned,https://www.apjtm.org/article.asp?issn=1995-7645;year=2021;volume=14;issue=1;spage=10;epage=16;aulast=Mousavi,2021-03-17,2024-03-01,Verified,mousavi_seroprevalence_2021,IRN
210105_Mazandaran_MazandaranUniversityofMedicalSciences_60-69,210105_Mazandaran_MazandaranUniversityofMedicalSciences,"Seroprevalence of SARS-CoV-2 in Mazandaran province, Iran",2021-01-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iran (Islamic Republic of),Mazandaran,,all the household members older than seven years old were the population of our study,"The exclusion criteria were: (1) living in retirement homes, prisons, or boarding schools, (2) being intolerant for disinfectants, (3) being in the treatment process of COVID-19, and (4) not cooperating until the end of the study.",2020-03-15,2020-05-15,Household and community samples,Female,Multiple groups,60.0,69.0,Age,60-69,206,0.22210000000000002,0.15230000000000002,0.3104,,,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.59,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Seyed Abbas Mousavi,Mazandaran University of Medical Sciences,Unity-Aligned,https://www.apjtm.org/article.asp?issn=1995-7645;year=2021;volume=14;issue=1;spage=10;epage=16;aulast=Mousavi,2021-03-22,2024-03-01,Verified,mousavi_seroprevalence_2021,IRN
210217_Shiraz_ShirazUniversityOfMedicalSciences_Overall,210217_Shiraz_ShirazUniversityOfMedicalSciences,Prevalence of anti-sars-cov-2 antibody in hospital staff in double-center setting: A preliminary report of a cohort study from Iran,2021-02-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),Fars,Shiraz City,"HS including medical, paramedical, and administrative staff from two main hospitals of Shiraz City,",,2020-07-13,2020-08-05,Health care workers and caregivers,All,Multiple groups,21.0,76.0,Primary Estimate,,494,0.059000000000000004,,,True,,,,True,Convenience,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,,Kamran Bagheri Lankarani,Shiraz University of Medical Sciences,Not Unity-Aligned,http://dx.doi.org/10.5812/semj.112681 ,2021-04-16,2024-03-01,Verified,bagheri_lankarani_prevalence_2021,IRN
210301_Tehran_ShahidBeheshtiUniversityOfMedicalSciences_HCWs_Overall,210301_Tehran_ShahidBeheshtiUniversityOfMedicalSciences_HCWs,"Prevalence of Anti-SARS-CoV-2 Specific Antibodies in Health-Care Workers Compared to General Population during an Early Phase of the Pandemic, Tehran-Iran",2021-03-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),Tehran Province,Tehran,"""In this cross-sectional study, 72 whole blood were collected from HCWs (doctors, nurses, allied health professionals, administrators and others; 37.5% male) who have been working in Masih Daneshvari hospital as one of the main COVID-19 admission centers in Tehran, during April 4 to 6, 2020.""",,2020-04-04,2020-04-06,Health care workers and caregivers,All,Adults (18-64 years),23.0,66.0,Primary Estimate,,72,0.3194,,,True,,,,True,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,,,['High'],,Unclear,No,Yes,,Yes,Yes,Yes,,Sahar Mortezagholi,Shahid Beheshti University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.22034/iji.2021.88168.1851,2022-10-05,2024-03-01,Unverified,mortezagholi_prevalence_2021,IRN
210301_Tehran_ShahidBeheshtiUniversityOfMedicalSciences_NonHCWs_Overall,210301_Tehran_ShahidBeheshtiUniversityOfMedicalSciences_NonHCWs,"Prevalence of Anti-SARS-CoV-2 Specific Antibodies in Health-Care Workers Compared to General Population during an Early Phase of the Pandemic, Tehran-Iran",2021-03-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),Tehran Province,Tehran,"""Besides, 2021 whole blood samples were obtained from low risk general population (74.5% male) who has been working in private sectors and governmental organizations outside of the health system.""",,2020-04-04,2020-04-06,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,2021,0.1776,,,True,,,,True,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,,,['High'],,Unclear,Yes,No,,Yes,Yes,Yes,,Sahar Mortezagholi,Shahid Beheshti University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.22034/iji.2021.88168.1851,2021-04-27,2024-03-01,Unverified,mortezagholi_prevalence_2021,IRN
210323_Tabriz_TabrizUniversityofMedicalSciences,210323_Tabriz_TabrizUniversityofMedicalSciences,Prevalence of SARS-CoV-2 Specific Antibodies in Asymptomatic Hemodialysis Patients.,2021-03-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),East Azerbaijan Province,Tabriz,Patients with end-stage maintenance hemodialysis,,2020-06-01,2020-06-30,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,Overall HD patients - asymptomatic,288,0.10099999999999999,,,True,,,,True,Sequential,Author designed (ELISA) - MULTIPLEXED,,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.93,0.98,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,Unclear,Jalal Etemadi,Tabriz University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1080/08820139.2021.1899202,2021-05-21,2022-07-16,Verified,etemadi_prevalence_2021,IRN
210413_Tabriz_TabrizUniversityOfMedicalSciences_overall_unadj_IgG_anti-S,210413_Tabriz_TabrizUniversityOfMedicalSciences,Application of newly developed SARS-CoV2 serology test along with real-time PCR for early detection in health care workers and on-time plasma donation.,2021-04-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),,Tabriz,Employees working at different hospitals affiliated with Tabriz University of medical sciences in Tabriz city between the ages of 24–60,,2020-04-15,2020-06-15,Health care workers and caregivers,All,Adults (18-64 years),24.0,60.0,Primary Estimate,,609,0.060700000000000004,,,True,,,,True,Unclear,Author designed (ELISA) - MULTIPLEXED,,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.9375,0.98,['Moderate'],Yes,Unclear,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Mohammad Sadegh Soltani Zangbar,Tabriz University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1016/j.genrep.2021.101140,2021-05-19,2022-07-16,Verified,soltani-zangbar_application_2021,IRN
210420_Iran_TehranUniversityOfMedicalSciences,210420_Iran_TehranUniversityOfMedicalSciences,SARS-CoV-2 serological assay and viral testing: a report of professional football setting.,2021-04-20,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,,"We enrolled all football premier league (Persian Gulf
league) and second division (Azadegan League)
teams.",,2020-09-15,2020-10-15,Non-essential workers and unemployed persons,Male,Adults (18-64 years),,,Primary Estimate,,1243,0.179,0.158,0.201,True,,,,True,Entire sample,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.794,0.973,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,No,Yes,Bahar Hassanmirzaei,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1136/postgradmedj-2021-140176,2021-05-27,2024-03-01,Verified,hassanmirzaei_sars-cov-2_2021,IRN
210605_Tehran_ShahidBeheshtiUniversityOfMedicalSciences_Overall,210605_Tehran_ShahidBeheshtiUniversityOfMedicalSciences,Evaluation of Serologic Changes of IgG and IgM Antibodies Associated with SARS-COV-2 in Cancer Patients: A Cohort Seroprevalence Study.,2021-06-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),Tehran,Tehran,"Patients in all age groups and with any type of cancer
who have been diagnosed during the last five years
were evaluated for inclusion in this study. Also, to be
eligible for this study, patients had to be in remission
or have stable disease in which they have received their
latest anticancer therapy over 2 months ago","Patients
in active phase of the treatment were excluded from
the study",2020-06-15,2020-07-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,168,0.17260000000000003,,,True,,,,True,Convenience,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,1.0,,['High'],,No,No,No,,Yes,Yes,Yes,,Maliheh Arab,Shahid Beheshti University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.31557/APJCP.2021.22.6.1667,2021-07-06,2024-03-01,Unverified,arab_evaluation_2021,IRN
210607_Iran_TehranUniversityofMedicalSciences_Primary,210607_Iran_TehranUniversityofMedicalSciences,Prevalence of COVID-19 in Iran: results of the first survey of the Iranian COVID-19 Serological Surveillance programme,2021-06-07,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,,"People with a unique Iranian national identification number registered in the primary health-care electronic health record systems (PHC-EHRS) (SIB, SINA and NAB), who were 6 years of age or older and had sufficient physical ability to attend blood sampling centers were included.",Individuals who had contraindications for venous blood sampling were excluded.,2020-08-03,2020-10-31,Household and community samples,All,Multiple groups,6.0,109.0,Primary Estimate,,11256,0.142,0.133,0.152,True,True,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.74,0.98,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Kazem Khalagi ,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/j.cmi.2021.06.002,2021-07-07,2023-08-15,Verified,khalagi_prevalence_2021-1,IRN
210607_Iran_TehranUniversityofMedicalSciences_PopAdj,210607_Iran_TehranUniversityofMedicalSciences,Prevalence of COVID-19 in Iran: results of the first survey of the Iranian COVID-19 Serological Surveillance programme,2021-06-07,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,,"People with a unique Iranian national identification number registered in the primary health-care electronic health record systems (PHC-EHRS) (SIB, SINA and NAB), who were 6 years of age or older and had sufficient physical ability to attend blood sampling centers were included.",Individuals who had contraindications for venous blood sampling were excluded.,2020-08-03,2020-10-31,Household and community samples,All,Multiple groups,6.0,109.0,Analysis,,11256,0.11800000000000001,0.109,0.127,,,True,,True,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.74,0.98,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Kazem Khalagi ,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/j.cmi.2021.06.002,2021-07-07,2024-03-01,Verified,khalagi_prevalence_2021-1,IRN
210607_Iran_TehranUniversityofMedicalSciences_Male,210607_Iran_TehranUniversityofMedicalSciences,Prevalence of COVID-19 in Iran: results of the first survey of the Iranian COVID-19 Serological Surveillance programme,2021-06-07,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,,"People with a unique Iranian national identification number registered in the primary health-care electronic health record systems (PHC-EHRS) (SIB, SINA and NAB), who were 6 years of age or older and had sufficient physical ability to attend blood sampling centers were included.",Individuals who had contraindications for venous blood sampling were excluded.,2020-08-03,2020-10-31,Household and community samples,Male,Multiple groups,,,Sex/Gender,,5406,0.146,0.134,0.159,,True,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.74,0.98,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Kazem Khalagi ,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/j.cmi.2021.06.002,2021-07-30,2023-08-15,Verified,khalagi_prevalence_2021-1,IRN
210607_Iran_TehranUniversityofMedicalSciences_Age6-17,210607_Iran_TehranUniversityofMedicalSciences,Prevalence of COVID-19 in Iran: results of the first survey of the Iranian COVID-19 Serological Surveillance programme,2021-06-07,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,,"People with a unique Iranian national identification number registered in the primary health-care electronic health record systems (PHC-EHRS) (SIB, SINA and NAB), who were 6 years of age or older and had sufficient physical ability to attend blood sampling centers were included.",Individuals who had contraindications for venous blood sampling were excluded.,2020-08-03,2020-10-31,Household and community samples,All,Children and Youth (0-17 years),6.0,17.0,Age,6-17,2302,0.115,0.099,0.134,,True,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.74,0.98,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Kazem Khalagi ,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/j.cmi.2021.06.002,2021-07-30,2023-08-15,Verified,khalagi_prevalence_2021-1,IRN
210607_Iran_TehranUniversityofMedicalSciences_Age18-39,210607_Iran_TehranUniversityofMedicalSciences,Prevalence of COVID-19 in Iran: results of the first survey of the Iranian COVID-19 Serological Surveillance programme,2021-06-07,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,,"People with a unique Iranian national identification number registered in the primary health-care electronic health record systems (PHC-EHRS) (SIB, SINA and NAB), who were 6 years of age or older and had sufficient physical ability to attend blood sampling centers were included.",Individuals who had contraindications for venous blood sampling were excluded.,2020-08-03,2020-10-31,Household and community samples,All,Adults (18-64 years),18.0,39.0,Age,18-39,4496,0.11599999999999999,0.105,0.128,,True,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.74,0.98,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Kazem Khalagi ,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/j.cmi.2021.06.002,2021-07-30,2023-08-15,Verified,khalagi_prevalence_2021-1,IRN
210607_Iran_TehranUniversityofMedicalSciences_Female,210607_Iran_TehranUniversityofMedicalSciences,Prevalence of COVID-19 in Iran: results of the first survey of the Iranian COVID-19 Serological Surveillance programme,2021-06-07,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,,"People with a unique Iranian national identification number registered in the primary health-care electronic health record systems (PHC-EHRS) (SIB, SINA and NAB), who were 6 years of age or older and had sufficient physical ability to attend blood sampling centers were included.",Individuals who had contraindications for venous blood sampling were excluded.,2020-08-03,2020-10-31,Household and community samples,Female,Multiple groups,,,Sex/Gender,,5850,0.138,0.125,0.152,,True,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.74,0.98,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Kazem Khalagi ,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/j.cmi.2021.06.002,2021-07-30,2023-08-15,Verified,khalagi_prevalence_2021-1,IRN
210607_Iran_TehranUniversityofMedicalSciences_Unadj,210607_Iran_TehranUniversityofMedicalSciences,Prevalence of COVID-19 in Iran: results of the first survey of the Iranian COVID-19 Serological Surveillance programme,2021-06-07,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,,"People with a unique Iranian national identification number registered in the primary health-care electronic health record systems (PHC-EHRS) (SIB, SINA and NAB), who were 6 years of age or older and had sufficient physical ability to attend blood sampling centers were included.",Individuals who had contraindications for venous blood sampling were excluded.,2020-08-03,2020-10-31,Household and community samples,All,Multiple groups,6.0,109.0,Analysis,,11256,0.11599999999999999,0.11,0.12,,,,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.74,0.98,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Kazem Khalagi ,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/j.cmi.2021.06.002,2021-07-30,2024-03-01,Verified,khalagi_prevalence_2021-1,IRN
210607_Iran_TehranUniversityofMedicalSciences_Age60+,210607_Iran_TehranUniversityofMedicalSciences,Prevalence of COVID-19 in Iran: results of the first survey of the Iranian COVID-19 Serological Surveillance programme,2021-06-07,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,,"People with a unique Iranian national identification number registered in the primary health-care electronic health record systems (PHC-EHRS) (SIB, SINA and NAB), who were 6 years of age or older and had sufficient physical ability to attend blood sampling centers were included.",Individuals who had contraindications for venous blood sampling were excluded.,2020-08-03,2020-10-31,Household and community samples,All,Seniors (65+ years),60.0,109.0,Age,,1358,0.19399999999999998,0.17,0.22100000000000003,,True,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.74,0.98,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Kazem Khalagi ,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/j.cmi.2021.06.002,2021-07-30,2023-08-15,Verified,khalagi_prevalence_2021-1,IRN
210607_Iran_TehranUniversityofMedicalSciences_Age40-59,210607_Iran_TehranUniversityofMedicalSciences,Prevalence of COVID-19 in Iran: results of the first survey of the Iranian COVID-19 Serological Surveillance programme,2021-06-07,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,,"People with a unique Iranian national identification number registered in the primary health-care electronic health record systems (PHC-EHRS) (SIB, SINA and NAB), who were 6 years of age or older and had sufficient physical ability to attend blood sampling centers were included.",Individuals who had contraindications for venous blood sampling were excluded.,2020-08-03,2020-10-31,Household and community samples,All,Adults (18-64 years),40.0,59.0,Age,40-59,3100,0.14300000000000002,0.128,0.16,,True,True,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.74,0.98,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Kazem Khalagi ,Tehran University of Medical Sciences,Unity-Aligned,http://dx.doi.org/10.1016/j.cmi.2021.06.002,2021-07-30,2023-08-15,Verified,khalagi_prevalence_2021-1,IRN
210714_Iran_TarbiatModaresUniversity_primary,210714_Iran_TarbiatModaresUniversity,SARS-CoV-2 seroprevalence in asymptomatic or mild symptomatic people and symptomatic patients with negative PCR results: The hidden perspective in epidemiological reports,2021-07-14,Preprint,National,Cross-sectional survey ,Iran (Islamic Republic of),,"Tehran, Mashhad","Only extracting group 1:
""peripheral venous blood samples were collected from two groups of people from Tehran and Mashhad cities: (1) asymptomatic, mildly symptomatic, or symptomatic volunteer participants who have not referred to medical centers due to COVID-19 symptoms and (2) severe symptomatic hospitalized patients with negative PCR results.""","""Symptomatic volunteers at sampling time were excluded from volunteer group.""",2020-05-30,2020-06-17,Multiple populations,All,Multiple groups,5.0,92.0,Primary Estimate,,716,0.17300000000000001,0.08800000000000001,0.258,True,True,,True,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.941,0.983,['High'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Nazila Hajiahmadi,Tarbiat Modares University,Not Unity-Aligned,10.1101/2021.07.11.21260336,2021-07-20,2023-08-15,Unverified,hajiahmadi_sars-cov-2_2021,IRN
210816_Iran_HighInstituteForResearchEducationInTransfusionMedicine_Primary,210816_Iran_HighInstituteForResearchEducationInTransfusionMedicine,Positive anti-SARS-CoV-2 rapid serological test results among asymptomatic blood donors.,2021-08-21,Preprint,National,Cross-sectional survey ,Iran (Islamic Republic of),,,"Since our target population was the blood donors of the country. Quota sampling from 31 provinces over the country was used.

Participants have read and approved the study consent form. Screening and pre-donation prosses of the participant donors who approved to sign the consent form were 10 to 15 minutes more than other donors.","Donors who were accepted for blood donation were asked to participate in our study, if they were not diagnosed COVID-19 with PCR, CT Scan or any clinical feature detected by a physician.",2020-05-18,2020-05-27,Blood donors,All,Multiple groups,,,Primary Estimate,,1339,0.12090000000000001,0.1034,0.1384,True,True,True,,,Stratified non-probability,2019-nCoV IgG/IgM Rapid Test Cassette,Hanghzhou AllTest Biotech Co. Ltd,LFIA,Plasma,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.85,1.0,['Moderate'],Yes,No,Yes,Yes,No,No,Yes,Yes,,Ali Arabkhazaeli,High Institute for Research and Education in Transfusion Medicine ,Not Unity-Aligned,https://dx.doi.org/10.1016/j.tracli.2021.08.008,2021-08-30,2023-08-15,Verified,arabkhazaeli_positive_2021,IRN
210816_Iran_HighInstituteForResearchEducationInTransfusionMedicine_Unadj,210816_Iran_HighInstituteForResearchEducationInTransfusionMedicine,Positive anti-SARS-CoV-2 rapid serological test results among asymptomatic blood donors.,2021-08-21,Preprint,National,Cross-sectional survey ,Iran (Islamic Republic of),,,"Since our target population was the blood donors of the country. Quota sampling from 31 provinces over the country was used.

Participants have read and approved the study consent form. Screening and pre-donation prosses of the participant donors who approved to sign the consent form were 10 to 15 minutes more than other donors.","Donors who were accepted for blood donation were asked to participate in our study, if they were not diagnosed COVID-19 with PCR, CT Scan or any clinical feature detected by a physician.",2020-05-18,2020-05-27,Blood donors,All,Multiple groups,,,Analysis,,1339,0.1202,,,,,,,True,Stratified non-probability,2019-nCoV IgG/IgM Rapid Test Cassette,Hanghzhou AllTest Biotech Co. Ltd,LFIA,Plasma,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.85,1.0,['Moderate'],Yes,No,Yes,Yes,No,No,Yes,Yes,,Ali Arabkhazaeli,High Institute for Research and Education in Transfusion Medicine ,Not Unity-Aligned,https://dx.doi.org/10.1016/j.tracli.2021.08.008,2021-08-30,2024-03-01,Verified,arabkhazaeli_positive_2021,IRN
210827_Birjand_BirjandUniversityOfMedicalSciences,210827_Birjand_BirjandUniversityOfMedicalSciences,The high level of adherence of personal protective equipment in health care workers efficiently protects them from COVID-19 infection.,2021-08-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),South Khorasan Province,Birjand,Healthcare workers of two COVID-19 referral hospitals of Birjand University of Medical Sciences,,2020-07-15,2020-08-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,137,0.051,,,True,,,,True,Convenience,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.941,0.983,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,Yes,Malihe Zangoue,Birjand University Of MedicalSciences,Not Unity-Aligned,https://dx.doi.org/10.3233/WOR-210634,2021-08-31,2024-03-01,Verified,zangoueHighLevelAdherence2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-05_to_2020-06_Overall,210930_Tehran_TehranUniversityofMedicalSciences_2020-05_to_2020-06,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-05-01,2020-06-30,Household and community samples,All,Multiple groups,,,Primary Estimate,,573,0.0977,,,True,,,,True,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-05_to_2020-06_Female,210930_Tehran_TehranUniversityofMedicalSciences_2020-05_to_2020-06,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-05-01,2020-06-30,Household and community samples,Female,Multiple groups,,,Sex/Gender,,224,0.1027,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-05_to_2020-06_35-49,210930_Tehran_TehranUniversityofMedicalSciences_2020-05_to_2020-06,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-05-01,2020-06-30,Household and community samples,All,Adults (18-64 years),35.0,49.0,Age,35-49,208,0.06730000000000001,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-05_to_2020-06_Male,210930_Tehran_TehranUniversityofMedicalSciences_2020-05_to_2020-06,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-05-01,2020-06-30,Household and community samples,Male,Multiple groups,,,Sex/Gender,,349,0.09460000000000002,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-05_to_2020-06_50-64,210930_Tehran_TehranUniversityofMedicalSciences_2020-05_to_2020-06,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-05-01,2020-06-30,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50-64,82,0.2195,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-05_to_2020-06_ >= 65,210930_Tehran_TehranUniversityofMedicalSciences_2020-05_to_2020-06,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-05-01,2020-06-30,Household and community samples,All,Seniors (65+ years),65.0,,Age,,26,0.11539999999999999,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-05_to_2020-06_Under18,210930_Tehran_TehranUniversityofMedicalSciences_2020-05_to_2020-06,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-05-01,2020-06-30,Household and community samples,All,Children and Youth (0-17 years),,18.0,Age,<18,83,0.09640000000000001,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-05_to_2020-06_19-34,210930_Tehran_TehranUniversityofMedicalSciences_2020-05_to_2020-06,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-05-01,2020-06-30,Household and community samples,All,Adults (18-64 years),19.0,34.0,Age,,174,0.0747,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-05_to_2020-06_IgM,210930_Tehran_TehranUniversityofMedicalSciences_2020-05_to_2020-06,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-05-01,2020-06-30,Household and community samples,All,Multiple groups,,,Test used,,573,0.0454,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgM,,,0.794,0.973,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-20,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-07_to_2020-08_Overall,210930_Tehran_TehranUniversityofMedicalSciences_2020-07_to_2020-08,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-07-01,2020-08-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,1221,0.2039,,,True,,,,True,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],Yes,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-07_to_2020-08_IgM,210930_Tehran_TehranUniversityofMedicalSciences_2020-07_to_2020-08,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-07-01,2020-08-31,Household and community samples,All,Multiple groups,,,Test used,,1221,0.127,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgM,,,0.794,0.973,['High'],Yes,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-20,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-07_to_2020-08_19-34,210930_Tehran_TehranUniversityofMedicalSciences_2020-07_to_2020-08,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-07-01,2020-08-31,Household and community samples,All,Adults (18-64 years),19.0,34.0,Age,,363,0.10740000000000001,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],Yes,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-07_to_2020-08_50-64,210930_Tehran_TehranUniversityofMedicalSciences_2020-07_to_2020-08,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-07-01,2020-08-31,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50-64,207,0.3188,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],Yes,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-07_to_2020-08_Male,210930_Tehran_TehranUniversityofMedicalSciences_2020-07_to_2020-08,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-07-01,2020-08-31,Household and community samples,Male,Multiple groups,,,Sex/Gender,,597,0.21780000000000002,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],Yes,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-07_to_2020-08_Under18,210930_Tehran_TehranUniversityofMedicalSciences_2020-07_to_2020-08,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-07-01,2020-08-31,Household and community samples,All,Children and Youth (0-17 years),,18.0,Age,<18,135,0.19260000000000002,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],Yes,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-07_to_2020-08_ >= 65,210930_Tehran_TehranUniversityofMedicalSciences_2020-07_to_2020-08,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-07-01,2020-08-31,Household and community samples,All,Seniors (65+ years),65.0,,Age,,90,0.3444,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],Yes,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-07_to_2020-08_35-49,210930_Tehran_TehranUniversityofMedicalSciences_2020-07_to_2020-08,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-07-01,2020-08-31,Household and community samples,All,Adults (18-64 years),35.0,49.0,Age,35-49,426,0.20420000000000002,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],Yes,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-07_to_2020-08_Female,210930_Tehran_TehranUniversityofMedicalSciences_2020-07_to_2020-08,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-07-01,2020-08-31,Household and community samples,Female,Multiple groups,,,Sex/Gender,,627,0.1898,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],Yes,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-09_to_2020-10_Overall,210930_Tehran_TehranUniversityofMedicalSciences_2020-09_to_2020-10,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-09-01,2020-10-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,1387,0.3367,,,True,,,,True,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-09_to_2020-10_35-49,210930_Tehran_TehranUniversityofMedicalSciences_2020-09_to_2020-10,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-09-01,2020-10-31,Household and community samples,All,Adults (18-64 years),35.0,49.0,Age,35-49,444,0.3311,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-09_to_2020-10_Female,210930_Tehran_TehranUniversityofMedicalSciences_2020-09_to_2020-10,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-09-01,2020-10-31,Household and community samples,Female,Multiple groups,,,Sex/Gender,,707,0.34509999999999996,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-09_to_2020-10_50-64,210930_Tehran_TehranUniversityofMedicalSciences_2020-09_to_2020-10,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-09-01,2020-10-31,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50-64,265,0.40750000000000003,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-09_to_2020-10_Under18,210930_Tehran_TehranUniversityofMedicalSciences_2020-09_to_2020-10,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-09-01,2020-10-31,Household and community samples,All,Children and Youth (0-17 years),,18.0,Age,<18,124,0.24190000000000003,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-09_to_2020-10_IgM,210930_Tehran_TehranUniversityofMedicalSciences_2020-09_to_2020-10,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-09-01,2020-10-31,Household and community samples,All,Multiple groups,,,Test used,,1387,0.217,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgM,,,0.794,0.973,['High'],No,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-20,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-09_to_2020-10_Male,210930_Tehran_TehranUniversityofMedicalSciences_2020-09_to_2020-10,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-09-01,2020-10-31,Household and community samples,Male,Multiple groups,,,Sex/Gender,,681,0.3275,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-09_to_2020-10_19-34,210930_Tehran_TehranUniversityofMedicalSciences_2020-09_to_2020-10,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-09-01,2020-10-31,Household and community samples,All,Adults (18-64 years),19.0,34.0,Age,,390,0.2821,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-09_to_2020-10_ >= 65,210930_Tehran_TehranUniversityofMedicalSciences_2020-09_to_2020-10,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-09-01,2020-10-31,Household and community samples,All,Seniors (65+ years),65.0,,Age,,164,0.439,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-11_to_2020-12_Overall,210930_Tehran_TehranUniversityofMedicalSciences_2020-11_to_2020-12,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-11-01,2020-12-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,1074,0.4581,,,True,,,,True,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-11_to_2020-12_ >= 65,210930_Tehran_TehranUniversityofMedicalSciences_2020-11_to_2020-12,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-11-01,2020-12-31,Household and community samples,All,Seniors (65+ years),65.0,,Age,,112,0.6875,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-11_to_2020-12_35-49,210930_Tehran_TehranUniversityofMedicalSciences_2020-11_to_2020-12,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-11-01,2020-12-31,Household and community samples,All,Adults (18-64 years),35.0,49.0,Age,35-49,351,0.41880000000000006,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-11_to_2020-12_IgM,210930_Tehran_TehranUniversityofMedicalSciences_2020-11_to_2020-12,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-11-01,2020-12-31,Household and community samples,All,Multiple groups,,,Test used,,1074,0.2421,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgM,,,0.794,0.973,['High'],No,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-20,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-11_to_2020-12_Female,210930_Tehran_TehranUniversityofMedicalSciences_2020-11_to_2020-12,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-11-01,2020-12-31,Household and community samples,Female,Multiple groups,,,Sex/Gender,,578,0.4585,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-11_to_2020-12_50-64,210930_Tehran_TehranUniversityofMedicalSciences_2020-11_to_2020-12,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-11-01,2020-12-31,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50-64,260,0.55,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-11_to_2020-12_Male,210930_Tehran_TehranUniversityofMedicalSciences_2020-11_to_2020-12,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-11-01,2020-12-31,Household and community samples,Male,Multiple groups,,,Sex/Gender,,496,0.45770000000000005,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-11_to_2020-12_Under18,210930_Tehran_TehranUniversityofMedicalSciences_2020-11_to_2020-12,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-11-01,2020-12-31,Household and community samples,All,Children and Youth (0-17 years),,18.0,Age,<18,60,0.3,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2020-11_to_2020-12_19-34,210930_Tehran_TehranUniversityofMedicalSciences_2020-11_to_2020-12,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2020-11-01,2020-12-31,Household and community samples,All,Adults (18-64 years),19.0,34.0,Age,,291,0.3677,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2021-01_to_2021-02_Overall,210930_Tehran_TehranUniversityofMedicalSciences_2021-01_to_2021-02,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2021-01-01,2021-02-28,Household and community samples,All,Multiple groups,,,Primary Estimate,,294,0.3605,,,True,,,,True,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2021-01_to_2021-02_50-64,210930_Tehran_TehranUniversityofMedicalSciences_2021-01_to_2021-02,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2021-01-01,2021-02-28,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50-64,63,0.381,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2021-01_to_2021-02_Female,210930_Tehran_TehranUniversityofMedicalSciences_2021-01_to_2021-02,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2021-01-01,2021-02-28,Household and community samples,Female,Multiple groups,,,Sex/Gender,,166,0.3494,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2021-01_to_2021-02_Under18,210930_Tehran_TehranUniversityofMedicalSciences_2021-01_to_2021-02,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2021-01-01,2021-02-28,Household and community samples,All,Children and Youth (0-17 years),,18.0,Age,<18,20,0.25,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2021-01_to_2021-02_ >= 65,210930_Tehran_TehranUniversityofMedicalSciences_2021-01_to_2021-02,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2021-01-01,2021-02-28,Household and community samples,All,Seniors (65+ years),65.0,,Age,,32,0.5,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2021-01_to_2021-02_IgM,210930_Tehran_TehranUniversityofMedicalSciences_2021-01_to_2021-02,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2021-01-01,2021-02-28,Household and community samples,All,Multiple groups,,,Test used,,294,0.09179999999999999,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgM,,,0.794,0.973,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-20,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2021-01_to_2021-02_35-49,210930_Tehran_TehranUniversityofMedicalSciences_2021-01_to_2021-02,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2021-01-01,2021-02-28,Household and community samples,All,Adults (18-64 years),35.0,49.0,Age,35-49,103,0.3204,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2021-01_to_2021-02_19-34,210930_Tehran_TehranUniversityofMedicalSciences_2021-01_to_2021-02,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2021-01-01,2021-02-28,Household and community samples,All,Adults (18-64 years),19.0,34.0,Age,,76,0.36840000000000006,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2021-01_to_2021-02_Male,210930_Tehran_TehranUniversityofMedicalSciences_2021-01_to_2021-02,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2021-01-01,2021-02-28,Household and community samples,Male,Multiple groups,,,Sex/Gender,,128,0.375,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2021-03_to_2021-04_Overall,210930_Tehran_TehranUniversityofMedicalSciences_2021-03_to_2021-04,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2021-03-01,2021-04-30,Household and community samples,All,Multiple groups,,,Primary Estimate,,367,0.25070000000000003,,,True,,,,True,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2021-03_to_2021-04_Under18,210930_Tehran_TehranUniversityofMedicalSciences_2021-03_to_2021-04,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2021-03-01,2021-04-30,Household and community samples,All,Children and Youth (0-17 years),,18.0,Age,<18,18,0.2778,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2021-03_to_2021-04_IgM,210930_Tehran_TehranUniversityofMedicalSciences_2021-03_to_2021-04,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2021-03-01,2021-04-30,Household and community samples,All,Multiple groups,,,Test used,,367,0.1216,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgM,,,0.794,0.973,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-20,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2021-03_to_2021-04_Female,210930_Tehran_TehranUniversityofMedicalSciences_2021-03_to_2021-04,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2021-03-01,2021-04-30,Household and community samples,Female,Multiple groups,,,Sex/Gender,,190,0.21050000000000002,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2021-03_to_2021-04_ >= 65,210930_Tehran_TehranUniversityofMedicalSciences_2021-03_to_2021-04,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2021-03-01,2021-04-30,Household and community samples,All,Seniors (65+ years),65.0,,Age,,30,0.6,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2021-03_to_2021-04_35-49,210930_Tehran_TehranUniversityofMedicalSciences_2021-03_to_2021-04,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2021-03-01,2021-04-30,Household and community samples,All,Adults (18-64 years),35.0,49.0,Age,35-49,139,0.2446,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2021-03_to_2021-04_Male,210930_Tehran_TehranUniversityofMedicalSciences_2021-03_to_2021-04,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2021-03-01,2021-04-30,Household and community samples,Male,Multiple groups,,,Sex/Gender,,177,0.2938,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2021-03_to_2021-04_19-34,210930_Tehran_TehranUniversityofMedicalSciences_2021-03_to_2021-04,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2021-03-01,2021-04-30,Household and community samples,All,Adults (18-64 years),19.0,34.0,Age,,129,0.1318,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
210930_Tehran_TehranUniversityofMedicalSciences_2021-03_to_2021-04_50-64,210930_Tehran_TehranUniversityofMedicalSciences_2021-03_to_2021-04,"SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021.",2021-09-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Iran (Islamic Republic of),Tehran,Tehran,"""individuals referred to private laboratories in north, south, east, and west parts of Tehran""",,2021-03-01,2021-04-30,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50-64,51,0.3529,,,,,,,,Unclear,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,,IgG,,,0.941,0.983,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Zahra Heydarifard,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1007/s12250-021-00446-z,2021-10-05,2024-03-01,Verified,heydarifard_sars-cov-2_2021,IRN
211007_WestOfIran_KurdistanUniversityOfMedicalSciences_Overall,211007_WestOfIran_KurdistanUniversityOfMedicalSciences,"Seroepidemiology of COVID-19 in high-risk occupational groups in west of Iran, November 2020",2021-10-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iran (Islamic Republic of),"Three provinces of Kurdistan, Kermanshah, and Hamedan.","Three cities of Sanandaj, Kermanshah, and Hamedan.",Being at least 18 years old and willing to participate in the study.,"Individuals with contraindications to intravenous blood sampling, such as those with coagulation problems due to medication or hemophilia, and those with fear of needles and blood donation were excluded from the study.",2020-11-05,2020-11-15,Essential non-healthcare workers,All,Multiple groups,18.0,,Primary Estimate,,1106,0.287,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Ghobad Moradi,Kurdistan University of Medical Sciences,Not Unity-Aligned,http://jmums.mazums.ac.ir/article-1-16926-en.html,2022-01-13,2024-03-01,Unverified,moradi_seroepidemiology_2021,IRN
211022_Guilan_GuilanUniversityofMedical Sciences,211022_Guilan_GuilanUniversityofMedical Sciences,"High Seroprevalence of SARS-CoV-2 (COVID-19)-Specific Antibodies among Healthcare Workers: A Cross-Sectional Study in Guilan, Iran.",2021-10-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),Guilan,Rasht,Workers in a healthcare setting,,2020-04-15,2020-05-15,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,503,0.39,0.348,0.433,True,,,,True,Simplified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Whole Blood,"['IgG', 'IgM']",,,0.941,,['High'],,Yes,No,Yes,,No,Yes,No,,Heydar Balou,Guilan University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1155/2021/9081491,2021-11-02,2024-03-01,Unverified,balou_high_2021,IRN
211026_Iran_NeyshaburUniversityofMedicalSciences_Overall,211026_Iran_NeyshaburUniversityofMedicalSciences,Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after one year of the COVID-19 Pandemic.,2021-10-26,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),"Razavi Khorasan Province, Mazandaran Province","Neyshabur, Sabzevar, Babol","Included cancer patients referred for vaccination program in a network of cancer care centers in cities of Neyshabur, Sabzevar, and Babol, Iran. All patients with a definitive diagnosis of
cancer either on active treatment or follow up who gave their consent were eligible to participate. A total of 270 volunteers aged more than 18 years with hematological and/or solid malignancies
with or without treatment were included in the study and gave informed written consent.","Patients with positive RT-PCR for COVID-19 in less than
four weeks were excluded.",2021-04-01,2021-06-30,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,85.0,Primary Estimate,,270,0.29300000000000004,,,True,,,,True,Sequential,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.941,0.983,['High'],,No,No,Yes,,Yes,Yes,Yes,,Seyed Alireza Javadinia,Neyshabur University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1080/07357907.2021.1995742,2021-11-02,2024-03-01,Unverified,javadinia_multicenter_2021,IRN
211026_Iran_NeyshaburUniversityofMedicalSciences_40-60,211026_Iran_NeyshaburUniversityofMedicalSciences,Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after one year of the COVID-19 Pandemic.,2021-10-26,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),"Razavi Khorasan Province, Mazandaran Province","Neyshabur, Sabzevar, Babol","Included cancer patients referred for vaccination program in a network of cancer care centers in cities of Neyshabur, Sabzevar, and Babol, Iran. All patients with a definitive diagnosis of
cancer either on active treatment or follow up who gave their consent were eligible to participate. A total of 270 volunteers aged more than 18 years with hematological and/or solid malignancies
with or without treatment were included in the study and gave informed written consent.","Patients with positive RT-PCR for COVID-19 in less than
four weeks were excluded.",2021-04-01,2021-06-30,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),40.0,60.0,Age,40-60,147,0.32,,,,,,,,Sequential,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.941,0.983,['High'],,No,No,Yes,,Yes,Yes,Yes,,Seyed Alireza Javadinia,Neyshabur University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1080/07357907.2021.1995742,2021-11-02,2024-03-01,Unverified,javadinia_multicenter_2021,IRN
211026_Iran_NeyshaburUniversityofMedicalSciences_<=40,211026_Iran_NeyshaburUniversityofMedicalSciences,Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after one year of the COVID-19 Pandemic.,2021-10-26,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),"Razavi Khorasan Province, Mazandaran Province","Neyshabur, Sabzevar, Babol","Included cancer patients referred for vaccination program in a network of cancer care centers in cities of Neyshabur, Sabzevar, and Babol, Iran. All patients with a definitive diagnosis of
cancer either on active treatment or follow up who gave their consent were eligible to participate. A total of 270 volunteers aged more than 18 years with hematological and/or solid malignancies
with or without treatment were included in the study and gave informed written consent.","Patients with positive RT-PCR for COVID-19 in less than
four weeks were excluded.",2021-04-01,2021-06-30,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),18.0,40.0,Age,≤40,48,0.188,,,,,,,,Sequential,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.941,0.983,['High'],,No,No,Yes,,Yes,Yes,Yes,,Seyed Alireza Javadinia,Neyshabur University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1080/07357907.2021.1995742,2021-11-02,2024-03-01,Unverified,javadinia_multicenter_2021,IRN
211026_Iran_NeyshaburUniversityofMedicalSciences_>=60,211026_Iran_NeyshaburUniversityofMedicalSciences,Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after one year of the COVID-19 Pandemic.,2021-10-26,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),"Razavi Khorasan Province, Mazandaran Province","Neyshabur, Sabzevar, Babol","Included cancer patients referred for vaccination program in a network of cancer care centers in cities of Neyshabur, Sabzevar, and Babol, Iran. All patients with a definitive diagnosis of
cancer either on active treatment or follow up who gave their consent were eligible to participate. A total of 270 volunteers aged more than 18 years with hematological and/or solid malignancies
with or without treatment were included in the study and gave informed written consent.","Patients with positive RT-PCR for COVID-19 in less than
four weeks were excluded.",2021-04-01,2021-06-30,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,60.0,85.0,Age,≥60,75,0.307,,,,,,,,Sequential,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.941,0.983,['High'],,No,No,Yes,,Yes,Yes,Yes,,Seyed Alireza Javadinia,Neyshabur University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1080/07357907.2021.1995742,2021-11-02,2024-03-01,Unverified,javadinia_multicenter_2021,IRN
211202_Tehran_ImamHosseinHospital,211202_Tehran_ImamHosseinHospital,Routine COVID-19 testing may not be necessary for most cancer patients.,2021-12-02,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Iran (Islamic Republic of),Tehran,Tehran,Cancer patients from all over Iran who were referred to be treated for cancer in the clinical oncology department of Imam Hossein Hospital,,2020-08-01,2020-10-30,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,20.0,,Primary Estimate,,107,0.1401869,,,True,,,,True,Convenience,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Ali Motlagh,Imam Hossein Hospital,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-02692-3,2021-12-14,2024-03-01,Unverified,motlagh_routine_2021,IRN
220123_Shiraz_ShirazUniversityOfMedicalSciences,220123_Shiraz_ShirazUniversityOfMedicalSciences,Seroprevalence of Anti-SARS-CoV-2 Antibodies in High-Risk Occupational and Low-Risk Groups in Southwestern Iran,2022-01-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),Fars Province,Shiraz,"including 162 low-risk subjects who were normal populations and 204 of COVID-19 exposure staff employed in Namazi hospitals in Shiraz, Iran","However, 338 participants did not give their basic demographic data (such as age) and symptoms and were excluded from the study",2020-07-15,2020-09-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,366,0.33340000000000003,,,True,,,,True,Unclear,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by developers,,,['High'],,Unclear,No,No,,Unclear,Yes,No,,Nasrin Aliabadi,Shiraz University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.5812/jjm-126975,2022-10-05,2022-10-05,Unverified,aliabadi_seroprevalence_2022,IRN
220208_Ardabil_ArdabilUniversityOfMedicalSciences_IgGIgM,220208_Ardabil_ArdabilUniversityOfMedicalSciences,Seroprevalence of SARS-CoV-2 Antibodies and its Risk Factors in the North-West of Iran: A Population-Based Cross-Sectional Study,2022-02-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),Ardabil,Ardabil,"""living in urban and rural areas of Ardabil"".",,2020-05-20,2020-06-07,Household and community samples,All,Multiple groups,,,Primary Estimate,IgG + IgM,1013,0.1211,,,True,,,,True,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.941,0.983,['Moderate'],Yes,Yes,Yes,No,No,Yes,Yes,Yes,Unclear,Hamed Zandian,Ardabil University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.2174/18749445-v15-e2201140,2022-04-21,2024-03-01,Verified,zandian_seroprevalence_2022,IRN
220225_Qom_TehranUniversityOfMedicalSciences,220225_Qom_TehranUniversityOfMedicalSciences,"A one year follow of patients with multiple sclerosis during COVID-19 pandemic: A cross-sectional study in Qom province, Iran",2022-02-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iran (Islamic Republic of),Qom Province,,"202 patients with a diagnosis of MS and negative self-reported history of COVID-19 at the beginning of the pandemic, were enrolled.","Patients with a self-reported history of COVID-19 prior to enrollment, patients who attempted to conceive, and those who were pregnant or in the postpartum period were excluded.",2020-06-01,2020-08-01,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,,Primary Estimate,,202,0.12869999999999998,,,True,,,,True,Convenience,Author designed (ELISA) -Unknown,,,,IgG,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Sepideh Paybast,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1016/j.msard.2022.103712,2022-03-17,2022-07-16,Unverified,paybast_one_2022,IRN
220306_Tehran_IranUniversity,220306_Tehran_IranUniversity,SARS-CoV-2 Infection in Iranian People Living with Human Immunodeficiency Virus-1 Infection,2022-03-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),Tehran Province,Tehran,"From June 2020 to October 2020, 155 consecutive Iranian HIV-1-infected patients were examined in this cross-sectional study. These patients were treated in clinics or hospitals affiliated with the Iran University of Medical Sciences (IUMS), Tehran, Iran.",,2020-06-15,2020-10-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,155,0.065,,,True,,,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9,1.0,['High'],,No,No,Yes,,Yes,Yes,Yes,,"Saba Garshasbi
",Iran University,Not Unity-Aligned,https://dx.doi.org/10.5812/JJM.121929,2022-05-02,2024-03-01,Unverified,garshasbi_sars-cov-2_2022,IRN
220324_Tehran_TehranUniversityofMedicalSciences_Overall_TestAdjusted,220324_Tehran_TehranUniversityofMedicalSciences,"SARS-CoV-2 Seroprevalence Among Health Care Workers in Major Private and Public Hospitals With COVID-19 Patient's Referral in Tehran, Iran.",2022-03-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),,Tehran,"HCWs from three public and two private hospitals, selected randomly as a pilot, were included.",,2020-04-15,2020-06-15,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,2065,0.226,0.20199999999999999,0.251,True,True,,,,Convenience,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Moderate'],,No,Yes,Yes,,No,Yes,Yes,,Maryam Darvishian,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.832003,2022-04-22,2023-08-15,Unverified,darvishian_sars-cov-2_2022,IRN
220324_Tehran_TehranUniversityofMedicalSciences_Age<30,220324_Tehran_TehranUniversityofMedicalSciences,"SARS-CoV-2 Seroprevalence Among Health Care Workers in Major Private and Public Hospitals With COVID-19 Patient's Referral in Tehran, Iran.",2022-03-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),,Tehran,"HCWs from three public and two private hospitals, selected randomly as a pilot, were included.",,2020-04-15,2020-06-15,Health care workers and caregivers,All,Multiple groups,,29.0,Age,<30,439,0.139,,,,,,,,Convenience,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Moderate'],,No,Yes,Yes,,No,Yes,Yes,,Maryam Darvishian,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.832003,2022-04-22,2024-03-01,Unverified,darvishian_sars-cov-2_2022,IRN
220324_Tehran_TehranUniversityofMedicalSciences_Age50-59,220324_Tehran_TehranUniversityofMedicalSciences,"SARS-CoV-2 Seroprevalence Among Health Care Workers in Major Private and Public Hospitals With COVID-19 Patient's Referral in Tehran, Iran.",2022-03-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),,Tehran,"HCWs from three public and two private hospitals, selected randomly as a pilot, were included.",,2020-04-15,2020-06-15,Health care workers and caregivers,All,Adults (18-64 years),50.0,59.0,Age,,222,0.17120000000000002,,,,,,,,Convenience,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Moderate'],,No,Yes,Yes,,No,Yes,Yes,,Maryam Darvishian,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.832003,2022-04-22,2024-03-01,Unverified,darvishian_sars-cov-2_2022,IRN
220324_Tehran_TehranUniversityofMedicalSciences_Age30-39,220324_Tehran_TehranUniversityofMedicalSciences,"SARS-CoV-2 Seroprevalence Among Health Care Workers in Major Private and Public Hospitals With COVID-19 Patient's Referral in Tehran, Iran.",2022-03-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),,Tehran,"HCWs from three public and two private hospitals, selected randomly as a pilot, were included.",,2020-04-15,2020-06-15,Health care workers and caregivers,All,Adults (18-64 years),30.0,39.0,Age,,839,0.16090000000000002,,,,,,,,Convenience,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Moderate'],,No,Yes,Yes,,No,Yes,Yes,,Maryam Darvishian,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.832003,2022-04-22,2024-03-01,Unverified,darvishian_sars-cov-2_2022,IRN
220324_Tehran_TehranUniversityofMedicalSciences_Age>=60,220324_Tehran_TehranUniversityofMedicalSciences,"SARS-CoV-2 Seroprevalence Among Health Care Workers in Major Private and Public Hospitals With COVID-19 Patient's Referral in Tehran, Iran.",2022-03-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),,Tehran,"HCWs from three public and two private hospitals, selected randomly as a pilot, were included.",,2020-04-15,2020-06-15,Health care workers and caregivers,All,Seniors (65+ years),60.0,,Age,>=60,27,0.2593,,,,,,,,Convenience,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Moderate'],,No,Yes,Yes,,No,Yes,Yes,,Maryam Darvishian,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.832003,2022-04-22,2024-03-01,Unverified,darvishian_sars-cov-2_2022,IRN
220324_Tehran_TehranUniversityofMedicalSciences_Age40-49,220324_Tehran_TehranUniversityofMedicalSciences,"SARS-CoV-2 Seroprevalence Among Health Care Workers in Major Private and Public Hospitals With COVID-19 Patient's Referral in Tehran, Iran.",2022-03-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),,Tehran,"HCWs from three public and two private hospitals, selected randomly as a pilot, were included.",,2020-04-15,2020-06-15,Health care workers and caregivers,All,Adults (18-64 years),40.0,49.0,Age,,496,0.1855,,,,,,,,Convenience,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Moderate'],,No,Yes,Yes,,No,Yes,Yes,,Maryam Darvishian,Tehran University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.832003,2022-04-22,2024-03-01,Unverified,darvishian_sars-cov-2_2022,IRN
220523_Iran_TehranUniversityofMedicalSciences_OverallPopTestAdjust,220523_Iran_TehranUniversityofMedicalSciences,Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study.,2022-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,"Ahvaz,Ardabil,Babol,Gorgan,Hamedan,Kerman,Kermanshah,Mashhad,Qom,Sanandaj,Sari,Shiraz,Tabriz,Tehran,Urmia,Zahedan",individuals who were aged ≥10 years old,"excluded those who were inaccessible or unwilling to participate in the study.

we did not enroll high-risk individuals in the present study, that is, we did not include high-risk occupational groups (such as healthcare workers, etc.).",2021-01-15,2021-03-15,Household and community samples,All,Multiple groups,10.0,90.0,Primary Estimate,Test Adjust,7411,0.342,0.31,0.373,True,True,True,,,Simplified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Mohammad Zamani,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13464-7,2022-06-03,2023-08-15,Unverified,zamani_seroprevalence_2022,IRN
220523_Iran_TehranUniversityofMedicalSciences_AreaArdabil,220523_Iran_TehranUniversityofMedicalSciences,Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study.,2022-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,Ardabil,individuals who were aged ≥10 years old,"excluded those who were inaccessible or unwilling to participate in the study.

we did not enroll high-risk individuals in the present study, that is, we did not include high-risk occupational groups (such as healthcare workers, etc.).",2021-01-15,2021-03-15,Household and community samples,All,Multiple groups,10.0,90.0,Geographical area,Ardabil,384,0.28800000000000003,0.228,0.348,,,True,,,Simplified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Mohammad Zamani,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13464-7,2022-06-03,2024-03-01,Unverified,zamani_seroprevalence_2022,IRN
220523_Iran_TehranUniversityofMedicalSciences_Age60-90,220523_Iran_TehranUniversityofMedicalSciences,Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study.,2022-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,"Ahvaz,Ardabil,Babol,Gorgan,Hamedan,Kerman,Kermanshah,Mashhad,Qom,Sanandaj,Sari,Shiraz,Tabriz,Tehran,Urmia,Zahedan",individuals who were aged ≥10 years old,"excluded those who were inaccessible or unwilling to participate in the study.

we did not enroll high-risk individuals in the present study, that is, we did not include high-risk occupational groups (such as healthcare workers, etc.).",2021-01-15,2021-03-15,Household and community samples,All,Seniors (65+ years),60.0,90.0,Age,60-90,645,0.344,0.281,0.406,,,True,,,Simplified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Mohammad Zamani,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13464-7,2022-06-03,2024-03-01,Unverified,zamani_seroprevalence_2022,IRN
220523_Iran_TehranUniversityofMedicalSciences_AreaBabol,220523_Iran_TehranUniversityofMedicalSciences,Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study.,2022-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,Babol,individuals who were aged ≥10 years old,"excluded those who were inaccessible or unwilling to participate in the study.

we did not enroll high-risk individuals in the present study, that is, we did not include high-risk occupational groups (such as healthcare workers, etc.).",2021-01-15,2021-03-15,Household and community samples,All,Multiple groups,10.0,90.0,Geographical area,Babol,383,0.231,0.14300000000000002,0.318,,,True,,,Simplified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Mohammad Zamani,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13464-7,2022-06-03,2024-03-01,Unverified,zamani_seroprevalence_2022,IRN
220523_Iran_TehranUniversityofMedicalSciences_AreaQom,220523_Iran_TehranUniversityofMedicalSciences,Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study.,2022-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,Qom,individuals who were aged ≥10 years old,"excluded those who were inaccessible or unwilling to participate in the study.

we did not enroll high-risk individuals in the present study, that is, we did not include high-risk occupational groups (such as healthcare workers, etc.).",2021-01-15,2021-03-15,Household and community samples,All,Multiple groups,10.0,90.0,Geographical area,Qom,385,0.272,0.18100000000000002,0.36200000000000004,,,True,,,Simplified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Mohammad Zamani,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13464-7,2022-06-03,2024-03-01,Unverified,zamani_seroprevalence_2022,IRN
220523_Iran_TehranUniversityofMedicalSciences_OverallCrude,220523_Iran_TehranUniversityofMedicalSciences,Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study.,2022-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,"Ahvaz,Ardabil,Babol,Gorgan,Hamedan,Kerman,Kermanshah,Mashhad,Qom,Sanandaj,Sari,Shiraz,Tabriz,Tehran,Urmia,Zahedan",individuals who were aged ≥10 years old,"excluded those who were inaccessible or unwilling to participate in the study.

we did not enroll high-risk individuals in the present study, that is, we did not include high-risk occupational groups (such as healthcare workers, etc.).",2021-01-15,2021-03-15,Household and community samples,All,Multiple groups,10.0,90.0,Analysis,Crude,7411,0.23800000000000002,0.228,0.24800000000000003,,,True,,,Simplified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Mohammad Zamani,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13464-7,2022-06-03,2024-03-01,Unverified,zamani_seroprevalence_2022,IRN
220523_Iran_TehranUniversityofMedicalSciences_Age20-29,220523_Iran_TehranUniversityofMedicalSciences,Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study.,2022-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,"Ahvaz,Ardabil,Babol,Gorgan,Hamedan,Kerman,Kermanshah,Mashhad,Qom,Sanandaj,Sari,Shiraz,Tabriz,Tehran,Urmia,Zahedan",individuals who were aged ≥10 years old,"excluded those who were inaccessible or unwilling to participate in the study.

we did not enroll high-risk individuals in the present study, that is, we did not include high-risk occupational groups (such as healthcare workers, etc.).",2021-01-15,2021-03-15,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,879,0.209,0.172,0.247,,,True,,,Simplified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Mohammad Zamani,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13464-7,2022-06-03,2024-03-01,Unverified,zamani_seroprevalence_2022,IRN
220523_Iran_TehranUniversityofMedicalSciences_AreaGorgan,220523_Iran_TehranUniversityofMedicalSciences,Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study.,2022-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,Gorgan,individuals who were aged ≥10 years old,"excluded those who were inaccessible or unwilling to participate in the study.

we did not enroll high-risk individuals in the present study, that is, we did not include high-risk occupational groups (such as healthcare workers, etc.).",2021-01-15,2021-03-15,Household and community samples,All,Multiple groups,10.0,90.0,Geographical area,Gorgan,330,0.22399999999999998,0.107,0.341,,,True,,,Simplified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Mohammad Zamani,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13464-7,2022-06-03,2024-03-01,Unverified,zamani_seroprevalence_2022,IRN
220523_Iran_TehranUniversityofMedicalSciences_Age50-59,220523_Iran_TehranUniversityofMedicalSciences,Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study.,2022-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,"Ahvaz,Ardabil,Babol,Gorgan,Hamedan,Kerman,Kermanshah,Mashhad,Qom,Sanandaj,Sari,Shiraz,Tabriz,Tehran,Urmia,Zahedan",individuals who were aged ≥10 years old,"excluded those who were inaccessible or unwilling to participate in the study.

we did not enroll high-risk individuals in the present study, that is, we did not include high-risk occupational groups (such as healthcare workers, etc.).",2021-01-15,2021-03-15,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,,1272,0.25,0.21100000000000002,0.29,,,True,,,Simplified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Mohammad Zamani,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13464-7,2022-06-03,2024-03-01,Unverified,zamani_seroprevalence_2022,IRN
220523_Iran_TehranUniversityofMedicalSciences_AreaUrmia,220523_Iran_TehranUniversityofMedicalSciences,Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study.,2022-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,Urmia,individuals who were aged ≥10 years old,"excluded those who were inaccessible or unwilling to participate in the study.

we did not enroll high-risk individuals in the present study, that is, we did not include high-risk occupational groups (such as healthcare workers, etc.).",2021-01-15,2021-03-15,Household and community samples,All,Multiple groups,10.0,90.0,Geographical area,Urmia,389,0.184,0.12400000000000001,0.24300000000000002,,,True,,,Simplified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Mohammad Zamani,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13464-7,2022-06-03,2024-03-01,Unverified,zamani_seroprevalence_2022,IRN
220523_Iran_TehranUniversityofMedicalSciences_AreaKermanshah,220523_Iran_TehranUniversityofMedicalSciences,Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study.,2022-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,Kermanshah,individuals who were aged ≥10 years old,"excluded those who were inaccessible or unwilling to participate in the study.

we did not enroll high-risk individuals in the present study, that is, we did not include high-risk occupational groups (such as healthcare workers, etc.).",2021-01-15,2021-03-15,Household and community samples,All,Multiple groups,10.0,90.0,Geographical area,Kermanshah,389,0.24100000000000002,0.174,0.307,,,True,,,Simplified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Mohammad Zamani,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13464-7,2022-06-03,2024-03-01,Unverified,zamani_seroprevalence_2022,IRN
220523_Iran_TehranUniversityofMedicalSciences_AreaTabriz,220523_Iran_TehranUniversityofMedicalSciences,Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study.,2022-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,Tabriz,individuals who were aged ≥10 years old,"excluded those who were inaccessible or unwilling to participate in the study.

we did not enroll high-risk individuals in the present study, that is, we did not include high-risk occupational groups (such as healthcare workers, etc.).",2021-01-15,2021-03-15,Household and community samples,All,Multiple groups,10.0,90.0,Geographical area,Tabriz,485,0.32799999999999996,0.247,0.408,,,True,,,Simplified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Mohammad Zamani,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13464-7,2022-06-03,2024-03-01,Unverified,zamani_seroprevalence_2022,IRN
220523_Iran_TehranUniversityofMedicalSciences_Age10-19,220523_Iran_TehranUniversityofMedicalSciences,Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study.,2022-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,"Ahvaz,Ardabil,Babol,Gorgan,Hamedan,Kerman,Kermanshah,Mashhad,Qom,Sanandaj,Sari,Shiraz,Tabriz,Tehran,Urmia,Zahedan",individuals who were aged ≥10 years old,"excluded those who were inaccessible or unwilling to participate in the study.

we did not enroll high-risk individuals in the present study, that is, we did not include high-risk occupational groups (such as healthcare workers, etc.).",2021-01-15,2021-03-15,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,362,0.209,0.147,0.272,,,True,,,Simplified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Mohammad Zamani,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13464-7,2022-06-03,2024-03-01,Unverified,zamani_seroprevalence_2022,IRN
220523_Iran_TehranUniversityofMedicalSciences_AreaShiraz,220523_Iran_TehranUniversityofMedicalSciences,Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study.,2022-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,Shiraz,individuals who were aged ≥10 years old,"excluded those who were inaccessible or unwilling to participate in the study.

we did not enroll high-risk individuals in the present study, that is, we did not include high-risk occupational groups (such as healthcare workers, etc.).",2021-01-15,2021-03-15,Household and community samples,All,Multiple groups,10.0,90.0,Geographical area,Shiraz,485,0.18100000000000002,0.131,0.23199999999999998,,,True,,,Simplified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Mohammad Zamani,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13464-7,2022-06-03,2024-03-01,Unverified,zamani_seroprevalence_2022,IRN
220523_Iran_TehranUniversityofMedicalSciences_Age40-49,220523_Iran_TehranUniversityofMedicalSciences,Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study.,2022-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,"Ahvaz,Ardabil,Babol,Gorgan,Hamedan,Kerman,Kermanshah,Mashhad,Qom,Sanandaj,Sari,Shiraz,Tabriz,Tehran,Urmia,Zahedan",individuals who were aged ≥10 years old,"excluded those who were inaccessible or unwilling to participate in the study.

we did not enroll high-risk individuals in the present study, that is, we did not include high-risk occupational groups (such as healthcare workers, etc.).",2021-01-15,2021-03-15,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,,2051,0.23399999999999999,0.19899999999999998,0.268,,,True,,,Simplified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Mohammad Zamani,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13464-7,2022-06-03,2024-03-01,Unverified,zamani_seroprevalence_2022,IRN
220523_Iran_TehranUniversityofMedicalSciences_AreaAhvaz,220523_Iran_TehranUniversityofMedicalSciences,Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study.,2022-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,Ahvaz,individuals who were aged ≥10 years old,"excluded those who were inaccessible or unwilling to participate in the study.

we did not enroll high-risk individuals in the present study, that is, we did not include high-risk occupational groups (such as healthcare workers, etc.).",2021-01-15,2021-03-15,Household and community samples,All,Multiple groups,10.0,90.0,Geographical area,Ahvaz,393,0.177,0.051,0.303,,,True,,,Simplified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Mohammad Zamani,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13464-7,2022-06-03,2024-03-01,Unverified,zamani_seroprevalence_2022,IRN
220523_Iran_TehranUniversityofMedicalSciences_OverallPopAdjust,220523_Iran_TehranUniversityofMedicalSciences,Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study.,2022-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,"Ahvaz,Ardabil,Babol,Gorgan,Hamedan,Kerman,Kermanshah,Mashhad,Qom,Sanandaj,Sari,Shiraz,Tabriz,Tehran,Urmia,Zahedan",individuals who were aged ≥10 years old,"excluded those who were inaccessible or unwilling to participate in the study.

we did not enroll high-risk individuals in the present study, that is, we did not include high-risk occupational groups (such as healthcare workers, etc.).",2021-01-15,2021-03-15,Household and community samples,All,Multiple groups,10.0,90.0,Analysis,Pop Adjust,7411,0.24,0.218,0.262,,,True,,True,Simplified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Mohammad Zamani,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13464-7,2022-06-03,2024-03-01,Unverified,zamani_seroprevalence_2022,IRN
220523_Iran_TehranUniversityofMedicalSciences_AreaZahedan,220523_Iran_TehranUniversityofMedicalSciences,Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study.,2022-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,Zahedan,individuals who were aged ≥10 years old,"excluded those who were inaccessible or unwilling to participate in the study.

we did not enroll high-risk individuals in the present study, that is, we did not include high-risk occupational groups (such as healthcare workers, etc.).",2021-01-15,2021-03-15,Household and community samples,All,Multiple groups,10.0,90.0,Geographical area,Zahedan,382,0.162,0.098,0.226,,,True,,,Simplified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Mohammad Zamani,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13464-7,2022-06-03,2024-03-01,Unverified,zamani_seroprevalence_2022,IRN
220523_Iran_TehranUniversityofMedicalSciences_SexFemale,220523_Iran_TehranUniversityofMedicalSciences,Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study.,2022-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,"Ahvaz,Ardabil,Babol,Gorgan,Hamedan,Kerman,Kermanshah,Mashhad,Qom,Sanandaj,Sari,Shiraz,Tabriz,Tehran,Urmia,Zahedan",individuals who were aged ≥10 years old,"excluded those who were inaccessible or unwilling to participate in the study.

we did not enroll high-risk individuals in the present study, that is, we did not include high-risk occupational groups (such as healthcare workers, etc.).",2021-01-15,2021-03-15,Household and community samples,Female,Multiple groups,10.0,90.0,Sex/Gender,,3690,0.24300000000000002,0.215,0.271,,,True,,,Simplified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Mohammad Zamani,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13464-7,2022-06-03,2024-03-01,Unverified,zamani_seroprevalence_2022,IRN
220523_Iran_TehranUniversityofMedicalSciences_Age30-39,220523_Iran_TehranUniversityofMedicalSciences,Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study.,2022-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,"Ahvaz,Ardabil,Babol,Gorgan,Hamedan,Kerman,Kermanshah,Mashhad,Qom,Sanandaj,Sari,Shiraz,Tabriz,Tehran,Urmia,Zahedan",individuals who were aged ≥10 years old,"excluded those who were inaccessible or unwilling to participate in the study.

we did not enroll high-risk individuals in the present study, that is, we did not include high-risk occupational groups (such as healthcare workers, etc.).",2021-01-15,2021-03-15,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,,2202,0.231,0.192,0.269,,,True,,,Simplified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Mohammad Zamani,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13464-7,2022-06-03,2024-03-01,Unverified,zamani_seroprevalence_2022,IRN
220523_Iran_TehranUniversityofMedicalSciences_AreaKerman,220523_Iran_TehranUniversityofMedicalSciences,Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study.,2022-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,Kerman,individuals who were aged ≥10 years old,"excluded those who were inaccessible or unwilling to participate in the study.

we did not enroll high-risk individuals in the present study, that is, we did not include high-risk occupational groups (such as healthcare workers, etc.).",2021-01-15,2021-03-15,Household and community samples,All,Multiple groups,10.0,90.0,Geographical area,Kerman,355,0.145,0.09300000000000001,0.197,,,True,,,Simplified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Mohammad Zamani,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13464-7,2022-06-03,2024-03-01,Unverified,zamani_seroprevalence_2022,IRN
220523_Iran_TehranUniversityofMedicalSciences_AreaHamedan,220523_Iran_TehranUniversityofMedicalSciences,Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study.,2022-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,Hamedan,individuals who were aged ≥10 years old,"excluded those who were inaccessible or unwilling to participate in the study.

we did not enroll high-risk individuals in the present study, that is, we did not include high-risk occupational groups (such as healthcare workers, etc.).",2021-01-15,2021-03-15,Household and community samples,All,Multiple groups,10.0,90.0,Geographical area,Hamedan,391,0.275,0.217,0.33299999999999996,,,True,,,Simplified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Mohammad Zamani,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13464-7,2022-06-03,2024-03-01,Unverified,zamani_seroprevalence_2022,IRN
220523_Iran_TehranUniversityofMedicalSciences_AreaSanandaj,220523_Iran_TehranUniversityofMedicalSciences,Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study.,2022-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,Sanandaj,individuals who were aged ≥10 years old,"excluded those who were inaccessible or unwilling to participate in the study.

we did not enroll high-risk individuals in the present study, that is, we did not include high-risk occupational groups (such as healthcare workers, etc.).",2021-01-15,2021-03-15,Household and community samples,All,Multiple groups,10.0,90.0,Geographical area,Sanandaj,388,0.27899999999999997,0.222,0.336,,,True,,,Simplified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Mohammad Zamani,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13464-7,2022-06-03,2024-03-01,Unverified,zamani_seroprevalence_2022,IRN
220523_Iran_TehranUniversityofMedicalSciences_AreaSari,220523_Iran_TehranUniversityofMedicalSciences,Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study.,2022-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,Sari,individuals who were aged ≥10 years old,"excluded those who were inaccessible or unwilling to participate in the study.

we did not enroll high-risk individuals in the present study, that is, we did not include high-risk occupational groups (such as healthcare workers, etc.).",2021-01-15,2021-03-15,Household and community samples,All,Multiple groups,10.0,90.0,Geographical area,Sari,400,0.159,0.09,0.227,,,True,,,Simplified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Mohammad Zamani,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13464-7,2022-06-03,2024-03-01,Unverified,zamani_seroprevalence_2022,IRN
220523_Iran_TehranUniversityofMedicalSciences_AreaMashhad,220523_Iran_TehranUniversityofMedicalSciences,Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study.,2022-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,Mashhad,individuals who were aged ≥10 years old,"excluded those who were inaccessible or unwilling to participate in the study.

we did not enroll high-risk individuals in the present study, that is, we did not include high-risk occupational groups (such as healthcare workers, etc.).",2021-01-15,2021-03-15,Household and community samples,All,Multiple groups,10.0,90.0,Geographical area,Mashhad,691,0.247,0.177,0.317,,,True,,,Simplified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Mohammad Zamani,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13464-7,2022-06-03,2024-03-01,Unverified,zamani_seroprevalence_2022,IRN
220523_Iran_TehranUniversityofMedicalSciences_AreaTehran,220523_Iran_TehranUniversityofMedicalSciences,Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study.,2022-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,Tehran,individuals who were aged ≥10 years old,"excluded those who were inaccessible or unwilling to participate in the study.

we did not enroll high-risk individuals in the present study, that is, we did not include high-risk occupational groups (such as healthcare workers, etc.).",2021-01-15,2021-03-15,Household and community samples,All,Multiple groups,10.0,90.0,Geographical area,Tehran,1181,0.249,0.2,0.298,,,True,,,Simplified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Mohammad Zamani,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13464-7,2022-06-03,2024-03-01,Unverified,zamani_seroprevalence_2022,IRN
220523_Iran_TehranUniversityofMedicalSciences_SexMale,220523_Iran_TehranUniversityofMedicalSciences,Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study.,2022-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,"Ahvaz,Ardabil,Babol,Gorgan,Hamedan,Kerman,Kermanshah,Mashhad,Qom,Sanandaj,Sari,Shiraz,Tabriz,Tehran,Urmia,Zahedan",individuals who were aged ≥10 years old,"excluded those who were inaccessible or unwilling to participate in the study.

we did not enroll high-risk individuals in the present study, that is, we did not include high-risk occupational groups (such as healthcare workers, etc.).",2021-01-15,2021-03-15,Household and community samples,Male,Multiple groups,10.0,90.0,Sex/Gender,,3721,0.237,0.204,0.269,,,True,,,Simplified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.669,0.9820000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Mohammad Zamani,Tehran University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13464-7,2022-06-03,2024-03-01,Unverified,zamani_seroprevalence_2022,IRN
220526_Iran_ShahidBeheshtiUniversityOfMedicalSciences_CD2,220526_Iran_ShahidBeheshtiUniversityOfMedicalSciences_CD2,High prevalence of SARS-Coronavirus-2 in patients with inflammatory bowel disease and the role of soluble angiotensin converting Enzyme2,2022-05-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),,"Tehran, Mashhad, Qazvin, Karaj, Isfahan, and Bandar Abbas","Patients with IBD referred to Research Institute for Gastroenterology and Liver DIseases (RIGLD) affiliated to Shahid Beheshti University of Medical Sciences in Tehran

The inclusion criteria for selecting the subjects in the present research were undergoing diagnostic colonoscopy and IBD approved by a pathologist.",,2020-06-15,2020-11-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,153,0.2353,,,True,,,,True,Convenience,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.941,0.983,['High'],,No,No,Yes,,Yes,Yes,Yes,,Shabnam Shahrokh,Shahid Beheshti University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1080/13813455.2022.2080228,2022-06-08,2024-03-01,Unverified,shahrokh_high_2022,IRN
220526_Iran_ShahidBeheshtiUniversityOfMedicalSciences_NonIBD3,220526_Iran_ShahidBeheshtiUniversityOfMedicalSciences_NonIBD3,High prevalence of SARS-Coronavirus-2 in patients with inflammatory bowel disease and the role of soluble angiotensin converting Enzyme2,2022-05-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),,"Tehran, Mashhad, Qazvin, Karaj, Isfahan, and Bandar Abbas","Patients with IBD referred to Research Institute for Gastroenterology and Liver DIseases (RIGLD) affiliated to Shahid Beheshti University of Medical Sciences in Tehran

The inclusion criteria for selecting the subjects in the present research were undergoing diagnostic colonoscopy and IBD approved by a pathologist.",,2020-06-15,2020-11-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,46,0.7391,,,True,,,,True,Convenience,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.941,0.983,['High'],,No,No,Yes,,Yes,Yes,Yes,,Shabnam Shahrokh,Shahid Beheshti University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1080/13813455.2022.2080228,2022-06-08,2024-03-01,Unverified,shahrokh_high_2022,IRN
220526_Iran_ShahidBeheshtiUniversityOfMedicalSciences_UC1,220526_Iran_ShahidBeheshtiUniversityOfMedicalSciences_UC1,High prevalence of SARS-Coronavirus-2 in patients with inflammatory bowel disease and the role of soluble angiotensin converting Enzyme2,2022-05-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),,"Tehran, Mashhad, Qazvin, Karaj, Isfahan, and Bandar Abbas","Patients with IBD referred to Research Institute for Gastroenterology and Liver DIseases (RIGLD) affiliated to Shahid Beheshti University of Medical Sciences in Tehran

The inclusion criteria for selecting the subjects in the present research were undergoing diagnostic colonoscopy and IBD approved by a pathologist.",,2020-06-15,2020-11-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,381,0.1916,,,True,,,,True,Convenience,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.941,0.983,['High'],,No,No,Yes,,Yes,Yes,Yes,,Shabnam Shahrokh,Shahid Beheshti University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1080/13813455.2022.2080228,2022-06-08,2024-03-01,Unverified,shahrokh_high_2022,IRN
220901_Ravansar_KermanshahUniversityofMedicalSciences,220901_Ravansar_KermanshahUniversityofMedicalSciences,Seroprevalence and Cumulative Incidence of COVID-19 in Ravansar Cohort Study Participants 2020: A Cross-Sectional Study,2022-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),,Ravansar,18 or older,,2020-10-22,2020-11-18,Household and community samples,All,Adults (18-64 years),18.0,,Primary Estimate,,716,0.3516,0.3164,0.3879,True,,,,True,Unclear,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Maryam Aghajarinezhad,Kermanshah University of Medical Sciences,Unity-Aligned,https://irje.tums.ac.ir/browse.php?a_id=6920&sid=1&slc_lang=en,2023-05-03,2024-04-09,Verified,aghajarinezhad_seroprevalence_2022,IRN
220906_Iran_HIRETM_Overall,220906_Iran_HIRETM,Estimate of anti-SARS-CoV-2 spike IgG antibodies prevalence among Iranian population based on blood donations: A serial cross-sectional study during the third wave of the pandemic,2022-09-06,Preprint,National,Repeated cross-sectional study,Iran (Islamic Republic of),,,"all participants adhered to the particular criteria because of the COVID-19 outbreak, including a 28-day deferral after complete resolution of symptoms for blood donors diagnosed with COVID-19 or suspected respiratory infections and a 28-day deferral for donors who have had close contact with COVID-19 patients (10), have been added for blood donor eligibility.","37 subjects were excluded; 47 subjects did not have sufficient samples, and 290 had borderline serologic results",2020-09-01,2020-11-30,Blood donors,All,Adults (18-64 years),18.0,65.0,Analysis,unadjusted,10352,0.2489,,,True,,,,True,Stratified non-probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.9897,0.9942000000000001,['Missing'],,Unclear,Yes,Yes,,Unclear,Yes,No,,Fahimeh Ranjbar Kermani,High Institute for Research and Education in Transfusion Medicine,Not Unity-Aligned,https://dx.doi.org/10.1016/j.tracli.2022.09.003,2022-09-19,2024-03-01,Unverified,ranjbar-kermani_estimate_2022,IRN
220906_Iran_HIRETM_AgeOver45,220906_Iran_HIRETM,Estimate of anti-SARS-CoV-2 spike IgG antibodies prevalence among Iranian population based on blood donations: A serial cross-sectional study during the third wave of the pandemic,2022-09-06,Preprint,National,Repeated cross-sectional study,Iran (Islamic Republic of),,,"all participants adhered to the particular criteria because of the COVID-19 outbreak, including a 28-day deferral after complete resolution of symptoms for blood donors diagnosed with COVID-19 or suspected respiratory infections and a 28-day deferral for donors who have had close contact with COVID-19 patients (10), have been added for blood donor eligibility.","37 subjects were excluded; 47 subjects did not have sufficient samples, and 290 had borderline serologic results",2020-09-01,2020-11-30,Blood donors,All,Adults (18-64 years),45.0,65.0,Age,age: > 45,2670,0.2515,0.227,0.2761,,True,True,,,Stratified non-probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.9897,0.9942000000000001,['Missing'],,Unclear,Yes,Yes,,Unclear,Yes,No,,Fahimeh Ranjbar Kermani,High Institute for Research and Education in Transfusion Medicine,Not Unity-Aligned,https://dx.doi.org/10.1016/j.tracli.2022.09.003,2022-09-19,2023-08-15,Unverified,ranjbar-kermani_estimate_2022,IRN
220906_Iran_HIRETM_AgeBelow30,220906_Iran_HIRETM,Estimate of anti-SARS-CoV-2 spike IgG antibodies prevalence among Iranian population based on blood donations: A serial cross-sectional study during the third wave of the pandemic,2022-09-06,Preprint,National,Repeated cross-sectional study,Iran (Islamic Republic of),,,"all participants adhered to the particular criteria because of the COVID-19 outbreak, including a 28-day deferral after complete resolution of symptoms for blood donors diagnosed with COVID-19 or suspected respiratory infections and a 28-day deferral for donors who have had close contact with COVID-19 patients (10), have been added for blood donor eligibility.","37 subjects were excluded; 47 subjects did not have sufficient samples, and 290 had borderline serologic results",2020-09-01,2020-11-30,Blood donors,All,Adults (18-64 years),18.0,29.0,Age,age: < 30,2925,0.2463,0.2211,0.2716,,True,True,,,Stratified non-probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.9897,0.9942000000000001,['Missing'],,Unclear,Yes,Yes,,Unclear,Yes,No,,Fahimeh Ranjbar Kermani,High Institute for Research and Education in Transfusion Medicine,Not Unity-Aligned,https://dx.doi.org/10.1016/j.tracli.2022.09.003,2022-09-19,2023-08-15,Unverified,ranjbar-kermani_estimate_2022,IRN
220906_Iran_HIRETM_Female,220906_Iran_HIRETM,Estimate of anti-SARS-CoV-2 spike IgG antibodies prevalence among Iranian population based on blood donations: A serial cross-sectional study during the third wave of the pandemic,2022-09-06,Preprint,National,Repeated cross-sectional study,Iran (Islamic Republic of),,,"all participants adhered to the particular criteria because of the COVID-19 outbreak, including a 28-day deferral after complete resolution of symptoms for blood donors diagnosed with COVID-19 or suspected respiratory infections and a 28-day deferral for donors who have had close contact with COVID-19 patients (10), have been added for blood donor eligibility.","37 subjects were excluded; 47 subjects did not have sufficient samples, and 290 had borderline serologic results",2020-09-01,2020-11-30,Blood donors,Female,Adults (18-64 years),18.0,65.0,Sex/Gender,,1930,0.251,0.2252,0.27690000000000003,,True,True,,,Stratified non-probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.9897,0.9942000000000001,['Missing'],,Unclear,Yes,Yes,,Unclear,Yes,No,,Fahimeh Ranjbar Kermani,High Institute for Research and Education in Transfusion Medicine,Not Unity-Aligned,https://dx.doi.org/10.1016/j.tracli.2022.09.003,2022-09-19,2023-08-15,Unverified,ranjbar-kermani_estimate_2022,IRN
220906_Iran_HIRETM_Oct,220906_Iran_HIRETM,Estimate of anti-SARS-CoV-2 spike IgG antibodies prevalence among Iranian population based on blood donations: A serial cross-sectional study during the third wave of the pandemic,2022-09-06,Preprint,National,Repeated cross-sectional study,Iran (Islamic Republic of),,,"all participants adhered to the particular criteria because of the COVID-19 outbreak, including a 28-day deferral after complete resolution of symptoms for blood donors diagnosed with COVID-19 or suspected respiratory infections and a 28-day deferral for donors who have had close contact with COVID-19 patients (10), have been added for blood donor eligibility.","37 subjects were excluded; 47 subjects did not have sufficient samples, and 290 had borderline serologic results",2020-10-01,2020-10-31,Blood donors,All,Adults (18-64 years),18.0,65.0,Time frame,"Oct 2020, pop and test adjusted",3697,0.2267,0.207,0.2465,,True,True,,,Stratified non-probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.9897,0.9942000000000001,['Missing'],,Unclear,Yes,Yes,,Unclear,Yes,No,,Fahimeh Ranjbar Kermani,High Institute for Research and Education in Transfusion Medicine,Not Unity-Aligned,https://dx.doi.org/10.1016/j.tracli.2022.09.003,2022-09-19,2023-08-15,Unverified,ranjbar-kermani_estimate_2022,IRN
220906_Iran_HIRETM_Age30to45,220906_Iran_HIRETM,Estimate of anti-SARS-CoV-2 spike IgG antibodies prevalence among Iranian population based on blood donations: A serial cross-sectional study during the third wave of the pandemic,2022-09-06,Preprint,National,Repeated cross-sectional study,Iran (Islamic Republic of),,,"all participants adhered to the particular criteria because of the COVID-19 outbreak, including a 28-day deferral after complete resolution of symptoms for blood donors diagnosed with COVID-19 or suspected respiratory infections and a 28-day deferral for donors who have had close contact with COVID-19 patients (10), have been added for blood donor eligibility.","37 subjects were excluded; 47 subjects did not have sufficient samples, and 290 had borderline serologic results",2020-09-01,2020-11-30,Blood donors,All,Adults (18-64 years),30.0,45.0,Age,age: 30-45,4757,0.2551,0.2325,0.2777,,True,True,,,Stratified non-probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.9897,0.9942000000000001,['Missing'],,Unclear,Yes,Yes,,Unclear,Yes,No,,Fahimeh Ranjbar Kermani,High Institute for Research and Education in Transfusion Medicine,Not Unity-Aligned,https://dx.doi.org/10.1016/j.tracli.2022.09.003,2022-09-19,2023-08-15,Unverified,ranjbar-kermani_estimate_2022,IRN
220906_Iran_HIRETM_Sept,220906_Iran_HIRETM,Estimate of anti-SARS-CoV-2 spike IgG antibodies prevalence among Iranian population based on blood donations: A serial cross-sectional study during the third wave of the pandemic,2022-09-06,Preprint,National,Repeated cross-sectional study,Iran (Islamic Republic of),,,"all participants adhered to the particular criteria because of the COVID-19 outbreak, including a 28-day deferral after complete resolution of symptoms for blood donors diagnosed with COVID-19 or suspected respiratory infections and a 28-day deferral for donors who have had close contact with COVID-19 patients (10), have been added for blood donor eligibility.","37 subjects were excluded; 47 subjects did not have sufficient samples, and 290 had borderline serologic results",2020-09-01,2020-09-30,Blood donors,All,Adults (18-64 years),18.0,65.0,Time frame,"Sept 2020, pop and test adjusted",3840,0.1959,0.1718,0.22,,True,True,,,Stratified non-probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.9897,0.9942000000000001,['Missing'],,Unclear,Yes,Yes,,Unclear,Yes,No,,Fahimeh Ranjbar Kermani,High Institute for Research and Education in Transfusion Medicine,Not Unity-Aligned,https://dx.doi.org/10.1016/j.tracli.2022.09.003,2022-09-19,2023-08-15,Unverified,ranjbar-kermani_estimate_2022,IRN
220906_Iran_HIRETM_Male,220906_Iran_HIRETM,Estimate of anti-SARS-CoV-2 spike IgG antibodies prevalence among Iranian population based on blood donations: A serial cross-sectional study during the third wave of the pandemic,2022-09-06,Preprint,National,Repeated cross-sectional study,Iran (Islamic Republic of),,,"all participants adhered to the particular criteria because of the COVID-19 outbreak, including a 28-day deferral after complete resolution of symptoms for blood donors diagnosed with COVID-19 or suspected respiratory infections and a 28-day deferral for donors who have had close contact with COVID-19 patients (10), have been added for blood donor eligibility.","37 subjects were excluded; 47 subjects did not have sufficient samples, and 290 had borderline serologic results",2020-09-01,2020-11-30,Blood donors,Male,Adults (18-64 years),18.0,65.0,Sex/Gender,,8422,0.2516,0.24050000000000002,0.26280000000000003,,True,True,,,Stratified non-probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.9897,0.9942000000000001,['Missing'],,Unclear,Yes,Yes,,Unclear,Yes,No,,Fahimeh Ranjbar Kermani,High Institute for Research and Education in Transfusion Medicine,Not Unity-Aligned,https://dx.doi.org/10.1016/j.tracli.2022.09.003,2022-09-19,2023-08-15,Unverified,ranjbar-kermani_estimate_2022,IRN
220906_Iran_HIRETM_Nov,220906_Iran_HIRETM,Estimate of anti-SARS-CoV-2 spike IgG antibodies prevalence among Iranian population based on blood donations: A serial cross-sectional study during the third wave of the pandemic,2022-09-06,Preprint,National,Repeated cross-sectional study,Iran (Islamic Republic of),,,"all participants adhered to the particular criteria because of the COVID-19 outbreak, including a 28-day deferral after complete resolution of symptoms for blood donors diagnosed with COVID-19 or suspected respiratory infections and a 28-day deferral for donors who have had close contact with COVID-19 patients (10), have been added for blood donor eligibility.","37 subjects were excluded; 47 subjects did not have sufficient samples, and 290 had borderline serologic results",2020-11-01,2020-11-30,Blood donors,All,Adults (18-64 years),18.0,65.0,Time frame,Nov 2020 pop and test adjusted,3152,0.32630000000000003,0.2993,0.3533,,True,True,,,Stratified non-probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.9897,0.9942000000000001,['Missing'],,Unclear,Yes,Yes,,Unclear,Yes,No,,Fahimeh Ranjbar Kermani,High Institute for Research and Education in Transfusion Medicine,Not Unity-Aligned,https://dx.doi.org/10.1016/j.tracli.2022.09.003,2022-09-19,2023-08-15,Unverified,ranjbar-kermani_estimate_2022,IRN
221219_Iran_UniversityTehran_Overall,221219_Iran_UniversityTehran,"Association of Anti-N and -S Seroprevalence in Asymptom atic, Mildly Symptomatic, and Symptomatic SARS-COV-2 Natural Infection",2022-12-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),"Razavi Khorasan, Tehran","Mashhad, Tehran","Asymptomatic, middle symptomatic, or symptomatic volunteer participants who did not refer to medical centers due to COVID-19 symptoms",,2020-05-30,2020-06-17,Household and community samples,All,Multiple groups,5.0,92.0,Primary Estimate,,716,0.177,,,True,,,,True,Self-referral,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Nazila Hajiahmadi,"University, Tehran",Not Unity-Aligned,https://dx.doi.org/10.52547/iem.8.4.357,2023-06-30,2024-03-01,Unverified,hajiahmadi_association_2022,IRN
221223_ Isfahan_IsfahanUniversityofMedicalSciences_overall,221223_ Isfahan_IsfahanUniversityofMedicalSciences,The Seroprevalence and Seropositivity of SARS-CoV-2 among Healthcare Workers during the Third Pandemic Wave.,2022-12-23,Journal Article (Peer-Reviewed),Local,Prospective cohort,Iran (Islamic Republic of),,Isfahan,""" An invitation describing the study’s objectives was sent to the hospital’s virtual groups and all hospital personnel with direct or indirect contact with COVID-19 patients were invited to participate.""","""Administrative personnel were excluded from the study. """,2020-10-19,2021-02-17,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,300,0.37,,,True,,,,True,Convenience,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Atefeh Vaezi ,Isfahan University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.3390/antib12010002,2023-02-09,2024-03-01,Unverified,vaeziSeroprevalenceSeropositivitySARSCoV22023,IRN
230225_Isfahan_IsfahanUniversityofMedical Sciences_overall,230225_Isfahan_IsfahanUniversityofMedical Sciences,"SARS-CoV-2 Seroprevalence among Health-Care Workers in Isfahan, Iran.",2023-02-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),,Isfahan,"""Inclusion criteria were being employees or learners in the [Khorshid and Amin hospitals of Isfahan University of Medical Sciences]"".","""People who had temporarily worked in these hospitals were not included in the study""",2020-10-23,2020-12-21,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,200,0.385,,,True,,,,True,Stratified non-probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.941,0.983,['Missing'],,No,No,Yes,,Yes,Yes,Yes,,Soodabeh Rostami,Isfahan University of Medical Sciences,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086646/ ,2023-05-03,2024-03-01,Unverified,rostami_sars-cov-2_2023,IRN
230320_Tabriz_TabrizUniversityOfMedicalSciences_Primary,230320_Tabriz_TabrizUniversityOfMedicalSciences,Potent SARS-CoV2-specific T-cell response in asymptomatic hemodialysis patients with hidden COVID-19 infection history,2023-03-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),,Tabriz,"""A total of 104 [end-stage renal disease (ESRD)] patients receiving in-center hemodialysis (ICHD) in Imam Reza Hospital (Tabriz, Iran) were recruited between July 10 and 20, 2021.""","""The exclusion criteria were as follows: (1) All patients with a history of confirmed COVID-19 infection; (2) all patients with a history of vaccination against COVID-19; (3) all patients who had one or more COVID-19 like symptoms at the time of sampling, including cough, fever, loss or change of taste or smell, digestive symptoms, breath shortness.""",2021-07-10,2021-07-20,Residual sera,All,Multiple groups,,,Primary Estimate,,104,0.4327,,,True,,,,True,Convenience,Author designed (ELISA) - Unknown,,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.9375,0.98,['High'],,No,No,Yes,,Unclear,Yes,Yes,,Jalal Etemadi,Tabriz University of Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1002/jcla.24863,2023-04-10,2023-04-11,Unverified,etemadi_potent_2023,IRN
230329_Kermanshah_KermanshahUniversityofMedicalSciences_IgG/IgM,230329_Kermanshah_KermanshahUniversityofMedicalSciences,"Seroprevalence of SARS-Cov-2 Virus Infection In Kermanshah, Iran: A Population-based Cross-Sectional Study",2023-03-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iran (Islamic Republic of),Kermanshah,,All individuals from the prespecified location were brought into the study regardless of previous COVID-19 infection history.,"The exclusion criterion consisted of the unwillingness to participate in the study, inability to answer the questions, and residence in that area for
less than a year.",2020-11-15,2020-12-20,Household and community samples,All,Multiple groups,,,Primary Estimate,IgG or IgM,1967,0.202,,,True,,,,True,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.941,0.983,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Fatemeh Khosravi Shadmani,Kermanshah University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.2174/18749445-v16-230303-2022-92,2023-05-29,2024-04-22,Verified,shadmani_seroprevalence_2023,IRN
230329_Kermanshah_KermanshahUniversityofMedicalSciences_IgG/IgM_Age15-45,230329_Kermanshah_KermanshahUniversityofMedicalSciences,"Seroprevalence of SARS-Cov-2 Virus Infection In Kermanshah, Iran: A Population-based Cross-Sectional Study",2023-03-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iran (Islamic Republic of),Kermanshah,,All individuals from the prespecified location were brought into the study regardless of previous COVID-19 infection history.,"The exclusion criterion consisted of the unwillingness to participate in the study, inability to answer the questions, and residence in that area for
less than a year.",2020-11-15,2020-12-20,Household and community samples,All,Multiple groups,15.0,45.0,Age,15-45,1135,0.1947,,,,,,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.941,0.983,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Fatemeh Khosravi Shadmani,Kermanshah University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.2174/18749445-v16-230303-2022-92,2024-04-22,2024-04-22,Verified,shadmani_seroprevalence_2023,IRN
230329_Kermanshah_KermanshahUniversityofMedicalSciences_IgG/IgM_Age45-60,230329_Kermanshah_KermanshahUniversityofMedicalSciences,"Seroprevalence of SARS-Cov-2 Virus Infection In Kermanshah, Iran: A Population-based Cross-Sectional Study",2023-03-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iran (Islamic Republic of),Kermanshah,,All individuals from the prespecified location were brought into the study regardless of previous COVID-19 infection history.,"The exclusion criterion consisted of the unwillingness to participate in the study, inability to answer the questions, and residence in that area for
less than a year.",2020-11-15,2020-12-20,Household and community samples,All,Adults (18-64 years),45.0,60.0,Age,45-60,397,0.2065,,,,,,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.941,0.983,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Fatemeh Khosravi Shadmani,Kermanshah University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.2174/18749445-v16-230303-2022-92,2024-04-22,2024-04-22,Verified,shadmani_seroprevalence_2023,IRN
230329_Kermanshah_KermanshahUniversityofMedicalSciences_IgG,230329_Kermanshah_KermanshahUniversityofMedicalSciences,"Seroprevalence of SARS-Cov-2 Virus Infection In Kermanshah, Iran: A Population-based Cross-Sectional Study",2023-03-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iran (Islamic Republic of),Kermanshah,,All individuals from the prespecified location were brought into the study regardless of previous COVID-19 infection history.,"The exclusion criterion consisted of the unwillingness to participate in the study, inability to answer the questions, and residence in that area for
less than a year.",2020-11-15,2020-12-20,Household and community samples,All,Multiple groups,,,Test used,IgG,1967,0.186,,,,,,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Fatemeh Khosravi Shadmani,Kermanshah University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.2174/18749445-v16-230303-2022-92,2023-05-29,2024-04-22,Verified,shadmani_seroprevalence_2023,IRN
230329_Kermanshah_KermanshahUniversityofMedicalSciences_IgM,230329_Kermanshah_KermanshahUniversityofMedicalSciences,"Seroprevalence of SARS-Cov-2 Virus Infection In Kermanshah, Iran: A Population-based Cross-Sectional Study",2023-03-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iran (Islamic Republic of),Kermanshah,,All individuals from the prespecified location were brought into the study regardless of previous COVID-19 infection history.,"The exclusion criterion consisted of the unwillingness to participate in the study, inability to answer the questions, and residence in that area for
less than a year.",2020-11-15,2020-12-20,Household and community samples,All,Multiple groups,,,Test used,IgM,1967,0.074,,,,,,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,IgM,,Validated by manufacturers,0.941,0.983,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Fatemeh Khosravi Shadmani,Kermanshah University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.2174/18749445-v16-230303-2022-92,2023-05-29,2024-04-22,Verified,shadmani_seroprevalence_2023,IRN
230329_Kermanshah_KermanshahUniversityofMedicalSciences_IgG/IgM_Age>60,230329_Kermanshah_KermanshahUniversityofMedicalSciences,"Seroprevalence of SARS-Cov-2 Virus Infection In Kermanshah, Iran: A Population-based Cross-Sectional Study",2023-03-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iran (Islamic Republic of),Kermanshah,,All individuals from the prespecified location were brought into the study regardless of previous COVID-19 infection history.,"The exclusion criterion consisted of the unwillingness to participate in the study, inability to answer the questions, and residence in that area for
less than a year.",2020-11-15,2020-12-20,Household and community samples,All,Seniors (65+ years),61.0,,Age,>60,193,0.2228,,,,,,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.941,0.983,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Fatemeh Khosravi Shadmani,Kermanshah University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.2174/18749445-v16-230303-2022-92,2024-04-22,2024-04-22,Verified,shadmani_seroprevalence_2023,IRN
230329_Kermanshah_KermanshahUniversityofMedicalSciences_IgG/IgM_Age<15,230329_Kermanshah_KermanshahUniversityofMedicalSciences,"Seroprevalence of SARS-Cov-2 Virus Infection In Kermanshah, Iran: A Population-based Cross-Sectional Study",2023-03-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iran (Islamic Republic of),Kermanshah,,All individuals from the prespecified location were brought into the study regardless of previous COVID-19 infection history.,"The exclusion criterion consisted of the unwillingness to participate in the study, inability to answer the questions, and residence in that area for
less than a year.",2020-11-15,2020-12-20,Household and community samples,All,Children and Youth (0-17 years),,15.0,Age,<15,242,0.2149,,,,,,,,Stratified probability,ELISA kit Pishtaz Teb Diagnostics,Pishtaz Diagnostics Iran,ELISA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.941,0.983,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Fatemeh Khosravi Shadmani,Kermanshah University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.2174/18749445-v16-230303-2022-92,2024-04-22,2024-04-22,Verified,shadmani_seroprevalence_2023,IRN
230530_Iran_HighInstituteForResearchAndEducationInTransfusionMedicine_PopTestAdj,230530_Iran_HighInstituteForResearchAndEducationInTransfusionMedicine,Serological Profile of SARS-CoV-2 in Unvaccinated Blood Donors: A Nationwide Study During the Fifth Wave of the Pandemic in Iran,2023-05-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,,"This population-based cross-sectional study was conducted on blood donors from all 31 provincial capitals and some satellite blood donation sites between 25 August2021 and 15 September 2021.

This study was performed on unvaccinated blood donors.","candidate blood donors had to pass donation eligibility criteria regarding the COVID-19 outbreak along with the previous criteria, including ""a 28-day deferral after complete resolution of symptoms for blood donors diagnosed with COVID-19 or suspected respiratory infections"" and ""a 28-day deferral for blood donors who have had close contact with COVID-19 patients"" (13).

Participants who had neither negative nor positive results in the test (borderline results) were excluded from further investigations.",2021-08-25,2021-09-15,Blood donors,All,Adults (18-64 years),18.0,69.0,Primary Estimate,Pop (age and sex) and test adjusted,3339,0.5267,0.5014,0.5521,True,True,True,,,Stratified non-probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9897,0.9942,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Fahimeh Ranjbar Kermani,High Institute for Research and Education in Transfusion Medicine,Not Unity-Aligned,https://dx.doi.org/10.5812/jjm-135768,2023-06-28,2023-07-04,Unverified,ranjbar_kermani_serological_2023,IRN
230530_Iran_HighInstituteForResearchAndEducationInTransfusionMedicine_PopAdj,230530_Iran_HighInstituteForResearchAndEducationInTransfusionMedicine,Serological Profile of SARS-CoV-2 in Unvaccinated Blood Donors: A Nationwide Study During the Fifth Wave of the Pandemic in Iran,2023-05-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Iran (Islamic Republic of),,,"This population-based cross-sectional study was conducted on blood donors from all 31 provincial capitals and some satellite blood donation sites between 25 August2021 and 15 September 2021.

This study was performed on unvaccinated blood donors.","candidate blood donors had to pass donation eligibility criteria regarding the COVID-19 outbreak along with the previous criteria, including ""a 28-day deferral after complete resolution of symptoms for blood donors diagnosed with COVID-19 or suspected respiratory infections"" and ""a 28-day deferral for blood donors who have had close contact with COVID-19 patients"" (13).

Participants who had neither negative nor positive results in the test (borderline results) were excluded from further investigations.",2021-08-25,2021-09-15,Blood donors,All,Adults (18-64 years),18.0,69.0,Analysis,Age and sex adjusted,3339,0.524,0.4991,0.549,,,True,,True,Stratified non-probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9897,0.9942,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Fahimeh Ranjbar Kermani,High Institute for Research and Education in Transfusion Medicine,Not Unity-Aligned,https://dx.doi.org/10.5812/jjm-135768,2023-06-28,2024-03-01,Unverified,ranjbar_kermani_serological_2023,IRN
230627_Tehran_ShahidBeheshtiUniversityofMedicalSciences,230627_Tehran_ShahidBeheshtiUniversityofMedicalSciences,"Seroepidemiological and Molecular Survey for the Detection of SARS-CoV-2 Infection among Children in Iran, September 2020 to June 2021: 1-Year Cross-Sectional Study.",2023-06-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iran (Islamic Republic of),,Tehran,"""Children residing in Tehran and aged 0 to 14 years at the time of recruitment were considered eligible to participate.""","""Families who refused to provide informed consent, or declared a contraindication to venipuncture, were excluded from the study. """,2020-09-19,2021-06-21,Household and community samples,All,Children and Youth (0-17 years),0.0,14.0,Primary Estimate,,1517,0.332,,,True,,True,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Roxana Mansour Ghanaie,Shahid Beheshti University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.3390/microorganisms11071672,2023-08-23,2024-04-21,Verified,mansour_ghanaie_seroepidemiological_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_overall,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,National,Cross-sectional survey ,Iran (Islamic Republic of),,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Multiple groups,25.0,,Primary Estimate,overall,16610,0.217,,,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2023-09-22,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Markazi ,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,Regional,Cross-sectional survey ,Iran (Islamic Republic of),Markazi ,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Multiple groups,25.0,,Geographical area,Markazi ,485,0.256,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2023-09-22,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Zanjan,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,Regional,Cross-sectional survey ,Iran (Islamic Republic of),Zanjan,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Multiple groups,25.0,,Geographical area,Zanjan,780,0.25,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2023-09-22,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Yazd,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,Regional,Cross-sectional survey ,Iran (Islamic Republic of),Yazd,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Multiple groups,25.0,,Geographical area,Yazd,387,0.235,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2023-09-22,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Holestan,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,Regional,Cross-sectional survey ,Iran (Islamic Republic of),Holestan,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Multiple groups,25.0,,Geographical area,Holestan,524,0.225,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2023-09-22,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Age_50-59,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,National,Cross-sectional survey ,Iran (Islamic Republic of),,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59 years,3405,0.2367,0.2173,0.2562,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2024-04-29,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Qom ,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,Regional,Cross-sectional survey ,Iran (Islamic Republic of),Qom ,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Multiple groups,25.0,,Geographical area,Qom ,413,0.232,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2023-09-22,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Age_30-39,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,National,Cross-sectional survey ,Iran (Islamic Republic of),,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39 years,3978,0.1629,0.1474,0.1784,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2024-04-29,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Khuzestan ,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,Regional,Cross-sectional survey ,Iran (Islamic Republic of),Khuzestan ,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Multiple groups,25.0,,Geographical area,Khuzestan ,597,0.141,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2023-09-22,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Khorasan-Razavi ,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,Regional,Cross-sectional survey ,Iran (Islamic Republic of),Khorasan-Razavi ,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Multiple groups,25.0,,Geographical area,Khorasan-Razavi ,1001,0.246,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2023-09-22,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Hamedan,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,Regional,Cross-sectional survey ,Iran (Islamic Republic of),Hamedan,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Multiple groups,25.0,,Geographical area,Hamedan,570,0.242,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2023-09-22,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Kurdistan ,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,Regional,Cross-sectional survey ,Iran (Islamic Republic of),Kurdistan ,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Multiple groups,25.0,,Geographical area,Kurdistan ,579,0.313,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2023-09-22,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Sistan and Baluchistan,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,Regional,Cross-sectional survey ,Iran (Islamic Republic of),Sistan and Baluchistan,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Multiple groups,25.0,,Geographical area,Sistan and Baluchistan,609,0.163,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2023-09-22,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Mazandaran ,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,Regional,Cross-sectional survey ,Iran (Islamic Republic of),Mazandaran ,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Multiple groups,25.0,,Geographical area,Mazandaran ,514,0.177,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2023-09-22,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Isfahan,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,Regional,Cross-sectional survey ,Iran (Islamic Republic of),Isfahan,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Multiple groups,25.0,,Geographical area,Isfahan,581,0.215,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2023-09-22,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Lorestan ,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,Regional,Cross-sectional survey ,Iran (Islamic Republic of),Lorestan ,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Multiple groups,25.0,,Geographical area,Lorestan ,604,0.225,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2023-09-22,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Age_40-49,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,National,Cross-sectional survey ,Iran (Islamic Republic of),,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49 years,3968,0.2005,0.1831,0.218,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2024-04-29,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Semnan ,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,Regional,Cross-sectional survey ,Iran (Islamic Republic of),Semnan ,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Multiple groups,25.0,,Geographical area,Semnan ,451,0.22,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2023-09-22,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Bushehr ,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,Regional,Cross-sectional survey ,Iran (Islamic Republic of),Bushehr ,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Multiple groups,25.0,,Geographical area,Bushehr ,515,0.124,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2023-09-22,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Hormozgan,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,Regional,Cross-sectional survey ,Iran (Islamic Republic of),Hormozgan,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Multiple groups,25.0,,Geographical area,Hormozgan,365,0.104,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2023-09-22,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Gilan,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,Regional,Cross-sectional survey ,Iran (Islamic Republic of),Gilan,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Multiple groups,25.0,,Geographical area,Gilan,372,0.159,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2023-09-22,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Ardebil ,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,Regional,Cross-sectional survey ,Iran (Islamic Republic of),Ardebil ,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Multiple groups,25.0,,Geographical area,Ardebil ,423,0.265,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2023-09-22,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Age_25-29,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,National,Cross-sectional survey ,Iran (Islamic Republic of),,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Adults (18-64 years),25.0,29.0,Age,25-29 years,1390,0.1507,0.1272,0.1742,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2024-04-29,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Kohgiluyeh and Boyer-Ahmad,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,Regional,Cross-sectional survey ,Iran (Islamic Republic of),Kohgiluyeh and Boyer-Ahmad,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Multiple groups,25.0,,Geographical area,Kohgiluyeh and Boyer-Ahmad,492,0.167,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2023-09-22,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Tehran,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,Regional,Cross-sectional survey ,Iran (Islamic Republic of),Tehran,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Multiple groups,25.0,,Geographical area,Tehran,1099,0.216,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2023-09-22,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Khorasan-North ,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,Regional,Cross-sectional survey ,Iran (Islamic Republic of),Khorasan-North ,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Multiple groups,25.0,,Geographical area,Khorasan-North ,578,0.182,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2023-09-22,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Kerman,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,Regional,Cross-sectional survey ,Iran (Islamic Republic of),Kerman,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Multiple groups,25.0,,Geographical area,Kerman,376,0.16,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2023-09-22,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
"230825_Iran_TehranUniversityofMedicalSciences_Chahar Mahaal
and Bakhtiari",230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,Regional,Cross-sectional survey ,Iran (Islamic Republic of),"Chahar Mahaal
and Bakhtiari",,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Multiple groups,25.0,,Geographical area,"Chahar Mahaal
and Bakhtiari",478,0.226,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2023-09-22,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Azarbayejan-West ,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,Regional,Cross-sectional survey ,Iran (Islamic Republic of),Azarbayejan-West ,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Multiple groups,25.0,,Geographical area,Azarbayejan-West ,538,0.314,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2023-09-22,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Azarbayejan-East ,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,Regional,Cross-sectional survey ,Iran (Islamic Republic of),Azarbayejan-East ,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Multiple groups,25.0,,Geographical area,Azarbayejan-East ,483,0.224,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2023-09-22,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Qazvin ,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,Regional,Cross-sectional survey ,Iran (Islamic Republic of),Qazvin ,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Multiple groups,25.0,,Geographical area,Qazvin ,415,0.207,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2023-09-22,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Age_60+,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,National,Cross-sectional survey ,Iran (Islamic Republic of),,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Seniors (65+ years),60.0,,Age,60+ years,3869,0.2571,0.2374,0.2768,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2024-04-29,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Khorasan-South ,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,Regional,Cross-sectional survey ,Iran (Islamic Republic of),Khorasan-South ,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Multiple groups,25.0,,Geographical area,Khorasan-South ,510,0.237,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2023-09-22,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Kermanshah,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,Regional,Cross-sectional survey ,Iran (Islamic Republic of),Kermanshah,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Multiple groups,25.0,,Geographical area,Kermanshah,404,0.225,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2023-09-22,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Fars,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,Regional,Cross-sectional survey ,Iran (Islamic Republic of),Fars,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Multiple groups,25.0,,Geographical area,Fars,870,0.225,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2023-09-22,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Ilam,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,Regional,Cross-sectional survey ,Iran (Islamic Republic of),Ilam,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Multiple groups,25.0,,Geographical area,Ilam,369,0.279,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2023-09-22,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
230825_Iran_TehranUniversityofMedicalSciences_Alborz ,230825_Iran_TehranUniversityofMedicalSciences,Seroprevalence of Immunoglobulin G against SARS-CoV-2 in Iran at National and Sub- National Levels: Population-based Sero-Epidemiological Data from STEPS Survey 2021,2023-08-25,Preprint,Regional,Cross-sectional survey ,Iran (Islamic Republic of),Alborz ,,"""the data were extracted from the STEP-wise approach to non- communicable disease risk factor surveillance (STEPS) 2021 survey, which was conducted with the participation of 27,874 adults aged more than 18 from 31 provinces of Iran""",,2021-02-15,2021-04-15,Household and community samples,All,Multiple groups,25.0,,Geographical area,Alborz ,237,0.152,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,Validated by manufacturers,0.941,0.983,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Mohammadreza Azangou-Khyavy,Tehran University of Medical Sciences,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-3143444/v1,2023-09-22,2024-04-29,Verified,azangou-khyavy_seroprevalence_2023,IRN
220411_Babylon_UniversityofBabylon_IgG,220411_Babylon_UniversityofBabylon,"Role of Antibodies against SARS-COV-2 in the Detection of Corona Virus, its Transmissibility and Immunological Status Determination among Different Population in Babylon Province",2022-04-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iraq,Babylon Province,,patients who visited various clinical specialties in the outpatient departments and patient’s residents in the Al-Sadiq Hospital in Babylon Province.,"Pregnant women, patients without clear confirmation about their previous infection of COVID-19 were excluded.",2021-01-15,2021-03-22,Residual sera,All,Multiple groups,2.0,80.0,Primary Estimate,IgG,553,0.3779,,,True,,,,True,Unclear,Biozek Medical COVID-19 Rapid Test,Biozek,LFIA,Serum,IgG,,,,,['High'],,Unclear,No,Yes,,Unclear,Yes,No,,Dalia Al-Saray,Department of Clinical Laboratory Sciences,Not Unity-Aligned,https://dx.doi.org/10.3889/oamjms.2022.9372,2022-06-14,2024-03-01,Unverified,al-saray_role_2022,IRQ
220728_Zakho_GeneralDirectorateofDuhokEducation_Overall,220728_Zakho_GeneralDirectorateofDuhokEducation,"Prevalence of SARS -CoV-2 IgG/IgM antibodies among patients in Zakho City, Kurdistan, Iraq",2022-07-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iraq,Duhok,Zakho,"Individuals who visited the laboratory of the Newroz private hospital and
medical center in Zakho district (Duhok province)",,2020-07-15,2020-09-15,Residual sera,All,Multiple groups,5.0,70.0,Primary Estimate,,489,0.2658,,,True,,,,True,Convenience,VIDAS® SARS-COV-2 IgG,BioMérieux,IFA,Serum,IgG,,Validated by manufacturers,0.966,0.999,['High'],No,No,No,Yes,No,Yes,Yes,Yes,Unclear,Ali Saeed,General Directorate of Duhok Education,Unity-Aligned,https://dx.doi.org/10.3855/jidc.15825,2022-08-08,2024-04-02,Verified,saeed_prevalence_2022,IRQ
220728_Zakho_GeneralDirectorateofDuhokEducation_21-30,220728_Zakho_GeneralDirectorateofDuhokEducation,"Prevalence of SARS -CoV-2 IgG/IgM antibodies among patients in Zakho City, Kurdistan, Iraq",2022-07-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iraq,Duhok,Zakho,"Individuals who visited the laboratory of the Newroz private hospital and
medical center in Zakho district (Duhok province)",,2020-07-15,2020-09-15,Residual sera,All,Adults (18-64 years),21.0,30.0,Age,21-30,139,0.2086,,,,,,,,Convenience,VIDAS® SARS-COV-2 IgG,BioMérieux,IFA,Serum,IgG,,Validated by manufacturers,0.966,0.999,['High'],No,No,No,Yes,No,Yes,Yes,Yes,Unclear,Ali Saeed,General Directorate of Duhok Education,Unity-Aligned,https://dx.doi.org/10.3855/jidc.15825,2022-08-08,2024-04-02,Verified,saeed_prevalence_2022,IRQ
220728_Zakho_GeneralDirectorateofDuhokEducation_<21,220728_Zakho_GeneralDirectorateofDuhokEducation,"Prevalence of SARS -CoV-2 IgG/IgM antibodies among patients in Zakho City, Kurdistan, Iraq",2022-07-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iraq,Duhok,Zakho,"Individuals who visited the laboratory of the Newroz private hospital and
medical center in Zakho district (Duhok province)",,2020-07-15,2020-09-15,Residual sera,All,Children and Youth (0-17 years),5.0,20.0,Age,<21,26,0.07690000000000001,,,,,,,,Convenience,VIDAS® SARS-COV-2 IgG,BioMérieux,IFA,Serum,IgG,,Validated by manufacturers,0.966,0.999,['High'],No,No,No,Yes,No,Yes,Yes,Yes,Unclear,Ali Saeed,General Directorate of Duhok Education,Unity-Aligned,https://dx.doi.org/10.3855/jidc.15825,2022-08-08,2024-04-02,Verified,saeed_prevalence_2022,IRQ
220728_Zakho_GeneralDirectorateofDuhokEducation_31-40,220728_Zakho_GeneralDirectorateofDuhokEducation,"Prevalence of SARS -CoV-2 IgG/IgM antibodies among patients in Zakho City, Kurdistan, Iraq",2022-07-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iraq,Duhok,Zakho,"Individuals who visited the laboratory of the Newroz private hospital and
medical center in Zakho district (Duhok province)",,2020-07-15,2020-09-15,Residual sera,All,Adults (18-64 years),31.0,40.0,Age,31-40,150,0.2866,,,,,,,,Convenience,VIDAS® SARS-COV-2 IgG,BioMérieux,IFA,Serum,IgG,,Validated by manufacturers,0.966,0.999,['High'],No,No,No,Yes,No,Yes,Yes,Yes,Unclear,Ali Saeed,General Directorate of Duhok Education,Unity-Aligned,https://dx.doi.org/10.3855/jidc.15825,2022-08-08,2024-04-02,Verified,saeed_prevalence_2022,IRQ
220728_Zakho_GeneralDirectorateofDuhokEducation_Female,220728_Zakho_GeneralDirectorateofDuhokEducation,"Prevalence of SARS -CoV-2 IgG/IgM antibodies among patients in Zakho City, Kurdistan, Iraq",2022-07-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iraq,Duhok,Zakho,"Individuals who visited the laboratory of the Newroz private hospital and
medical center in Zakho district (Duhok province)",,2020-07-15,2020-09-15,Residual sera,Female,Multiple groups,,,Sex/Gender,Female,163,0.2515,,,,,,,,Convenience,VIDAS® SARS-COV-2 IgG,BioMérieux,IFA,Serum,IgG,,Validated by manufacturers,0.966,0.999,['High'],No,No,No,Yes,No,Yes,Yes,Yes,Unclear,Ali Saeed,General Directorate of Duhok Education,Unity-Aligned,https://dx.doi.org/10.3855/jidc.15825,2022-08-08,2024-04-02,Verified,saeed_prevalence_2022,IRQ
220728_Zakho_GeneralDirectorateofDuhokEducation_>60,220728_Zakho_GeneralDirectorateofDuhokEducation,"Prevalence of SARS -CoV-2 IgG/IgM antibodies among patients in Zakho City, Kurdistan, Iraq",2022-07-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iraq,Duhok,Zakho,"Individuals who visited the laboratory of the Newroz private hospital and
medical center in Zakho district (Duhok province)",,2020-07-15,2020-09-15,Residual sera,All,Seniors (65+ years),61.0,70.0,Age,>60,34,0.3823,,,,,,,,Convenience,VIDAS® SARS-COV-2 IgG,BioMérieux,IFA,Serum,IgG,,Validated by manufacturers,0.966,0.999,['High'],No,No,No,Yes,No,Yes,Yes,Yes,Unclear,Ali Saeed,General Directorate of Duhok Education,Unity-Aligned,https://dx.doi.org/10.3855/jidc.15825,2022-08-08,2024-04-02,Verified,saeed_prevalence_2022,IRQ
220728_Zakho_GeneralDirectorateofDuhokEducation_51-60,220728_Zakho_GeneralDirectorateofDuhokEducation,"Prevalence of SARS -CoV-2 IgG/IgM antibodies among patients in Zakho City, Kurdistan, Iraq",2022-07-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iraq,Duhok,Zakho,"Individuals who visited the laboratory of the Newroz private hospital and
medical center in Zakho district (Duhok province)",,2020-07-15,2020-09-15,Residual sera,All,Adults (18-64 years),51.0,60.0,Age,51-60,52,0.40380000000000005,,,,,,,,Convenience,VIDAS® SARS-COV-2 IgG,BioMérieux,IFA,Serum,IgG,,Validated by manufacturers,0.966,0.999,['High'],No,No,No,Yes,No,Yes,Yes,Yes,Unclear,Ali Saeed,General Directorate of Duhok Education,Unity-Aligned,https://dx.doi.org/10.3855/jidc.15825,2022-08-08,2024-04-02,Verified,saeed_prevalence_2022,IRQ
220728_Zakho_GeneralDirectorateofDuhokEducation_Male,220728_Zakho_GeneralDirectorateofDuhokEducation,"Prevalence of SARS -CoV-2 IgG/IgM antibodies among patients in Zakho City, Kurdistan, Iraq",2022-07-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iraq,Duhok,Zakho,"Individuals who visited the laboratory of the Newroz private hospital and
medical center in Zakho district (Duhok province)",,2020-07-15,2020-09-15,Residual sera,Male,Multiple groups,,,Sex/Gender,Male,326,0.273,,,,,,,,Convenience,VIDAS® SARS-COV-2 IgG,BioMérieux,IFA,Serum,IgG,,Validated by manufacturers,0.966,0.999,['High'],No,No,No,Yes,No,Yes,Yes,Yes,Unclear,Ali Saeed,General Directorate of Duhok Education,Unity-Aligned,https://dx.doi.org/10.3855/jidc.15825,2022-08-08,2024-04-02,Verified,saeed_prevalence_2022,IRQ
220728_Zakho_GeneralDirectorateofDuhokEducation_41-50,220728_Zakho_GeneralDirectorateofDuhokEducation,"Prevalence of SARS -CoV-2 IgG/IgM antibodies among patients in Zakho City, Kurdistan, Iraq",2022-07-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Iraq,Duhok,Zakho,"Individuals who visited the laboratory of the Newroz private hospital and
medical center in Zakho district (Duhok province)",,2020-07-15,2020-09-15,Residual sera,All,Adults (18-64 years),41.0,50.0,Age,41-50,88,0.25,,,,,,,,Convenience,VIDAS® SARS-COV-2 IgG,BioMérieux,IFA,Serum,IgG,,Validated by manufacturers,0.966,0.999,['High'],No,No,No,Yes,No,Yes,Yes,Yes,Unclear,Ali Saeed,General Directorate of Duhok Education,Unity-Aligned,https://dx.doi.org/10.3855/jidc.15825,2022-08-08,2024-04-02,Verified,saeed_prevalence_2022,IRQ
230727_DuhokGovernorate_UniversityOfDuhok_Overall,230727_DuhokGovernorate_UniversityOfDuhok,"A study of anti-SARS-CoV-2 antibody positivity in Duhok City, Iraq",2023-07-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Iraq,Duhok Governorate,,"This study was carried out in the Duhok Governorate of the Kurdistan Region of Iraq.

The study population included participants from six different districts within Duhok that include Amedye, Akre, Bardarash, Zakho, Semel, and Duhok City.

We asked the people who visited healthcare centers in different districts to participate in the project voluntarily.",Patients with immunodeficiency and those who received immunosuppressive and corticosteroid therapy were excluded from the study. People who were vaccinated or did not give their consent were excluded from the study.,2021-01-10,2021-12-30,Residual sera,All,Multiple groups,,,Primary Estimate,,743,0.6258,,,True,,,,True,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,,,,['High'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Nawfal Hussein,University of Duhok,Not Unity-Aligned,https://dx.doi.org/10.3855/jidc.17518,2023-08-22,2024-03-01,Unverified,hussein_study_2023,IRQ
200817_Ireland_HPSC_genpop_popadj,200817_Ireland_HPSC,"Preliminary report of the results of the  Study to Investigate COVID-19 Infection in People Living in Ireland (SCOPI): A national seroprevalence study, June-July  2020",2020-08-17,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Ireland,"Connaught, Leinster","Dublin, Sligo", People from 12 to 69 years of age were eligible to take part in the study. Participation was limited to this age group because of the practical difficulties of obtaining blood samples from children under 12 years of age and because people aged 70 years and above were advised to stay at home and not to undertake non-essential journeys at the time the study was being carried out. ,,2020-06-22,2020-07-16,Household and community samples,All,Adults (18-64 years),12.0,69.0,Primary Estimate,,1733,0.017,0.011000000000000001,0.024,True,,True,,True,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,Coronavirus Antibody Rapid Test","Abbott Laboratories,Fortress Diagnostics",CLIA,Multiple Types,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,No,Derval Igoe ,HSE Health Protection Surveillance Centre (HPSC) ,Not Unity-Aligned,https://www.hpsc.ie/a-z/respiratory/coronavirus/novelcoronavirus/scopi/SCOPI%20report%20preliminary%20results%20final%20version.pdf,2020-10-18,2024-03-01,Verified,derval_igoe_preliminary_2020,IRL
200817_Ireland_HPSC_genpop_Sligo,200817_Ireland_HPSC,"Preliminary report of the results of the  Study to Investigate COVID-19 Infection in People Living in Ireland (SCOPI): A national seroprevalence study, June-July  2020",2020-08-17,Institutional Report,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Ireland,Connaught,Sligo, People from 12 to 69 years of age were eligible to take part in the study. Participation was limited to this age group because of the practical difficulties of obtaining blood samples from children under 12 years of age and because people aged 70 years and above were advised to stay at home and not to undertake non-essential journeys at the time the study was being carried out. ,,2020-06-22,2020-07-16,Household and community samples,All,Adults (18-64 years),12.0,69.0,Geographical area,Sligo,820,0.0061,0.002,0.013999999999999999,,,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,Coronavirus Antibody Rapid Test","Abbott Laboratories,Fortress Diagnostics",CLIA,Multiple Types,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,No,Derval Igoe ,HSE Health Protection Surveillance Centre (HPSC) ,Not Unity-Aligned,https://www.hpsc.ie/a-z/respiratory/coronavirus/novelcoronavirus/scopi/SCOPI%20report%20preliminary%20results%20final%20version.pdf,2020-10-18,2024-03-01,Verified,derval_igoe_preliminary_2020,IRL
200817_Ireland_HPSC_genpop_Dublin,200817_Ireland_HPSC,"Preliminary report of the results of the  Study to Investigate COVID-19 Infection in People Living in Ireland (SCOPI): A national seroprevalence study, June-July  2020",2020-08-17,Institutional Report,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Ireland,Leinster,Dublin, People from 12 to 69 years of age were eligible to take part in the study. Participation was limited to this age group because of the practical difficulties of obtaining blood samples from children under 12 years of age and because people aged 70 years and above were advised to stay at home and not to undertake non-essential journeys at the time the study was being carried out. ,,2020-06-22,2020-07-16,Household and community samples,All,Adults (18-64 years),12.0,69.0,Geographical area,Dublin,913,0.031000000000000003,0.021,0.045,,,True,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,Coronavirus Antibody Rapid Test","Abbott Laboratories,Fortress Diagnostics",CLIA,Multiple Types,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,No,Derval Igoe ,HSE Health Protection Surveillance Centre (HPSC) ,Not Unity-Aligned,https://www.hpsc.ie/a-z/respiratory/coronavirus/novelcoronavirus/scopi/SCOPI%20report%20preliminary%20results%20final%20version.pdf,2020-10-18,2024-03-01,Verified,derval_igoe_preliminary_2020,IRL
200817_Ireland_HPSC_Genpop_unadj,200817_Ireland_HPSC,"Preliminary report of the results of the  Study to Investigate COVID-19 Infection in People Living in Ireland (SCOPI): A national seroprevalence study, June-July  2020",2020-08-17,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Ireland,"Connaught, Leinster","Dublin, Sligo", People from 12 to 69 years of age were eligible to take part in the study. Participation was limited to this age group because of the practical difficulties of obtaining blood samples from children under 12 years of age and because people aged 70 years and above were advised to stay at home and not to undertake non-essential journeys at the time the study was being carried out. ,,2020-06-22,2020-07-16,Household and community samples,All,Adults (18-64 years),12.0,69.0,Analysis,,1733,0.019,,,,,,,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,Coronavirus Antibody Rapid Test","Abbott Laboratories,Fortress Diagnostics",CLIA,Multiple Types,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,No,Derval Igoe ,HSE Health Protection Surveillance Centre (HPSC) ,Not Unity-Aligned,https://www.hpsc.ie/a-z/respiratory/coronavirus/novelcoronavirus/scopi/SCOPI%20report%20preliminary%20results%20final%20version.pdf,2020-10-27,2024-03-01,Verified,derval_igoe_preliminary_2020,IRL
210212_Dublin_RotundaHospital,210212_Dublin_RotundaHospital,Persistence of SARS-CoV-2 antibodies and symptoms in an Irish Healthcare Worker (HCW) setting: Results of the CAST Study,2021-02-12,Preprint,Local,Prospective cohort,Ireland,Leinster,Dublin,"symptomatic and asymptomatic healthcare workers employed at the Rotunda Maternity Hospital to participate in the CAST study. Additional eligibility criteria for enrolment in the CAST study included staff being currently employed at the hospital, those fluent in English, and those aged ≥18 years.",,2020-05-12,2020-07-31,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,Asymptomatic HCWs,51,0.04,,,True,,,,True,Convenience,Captia™ Anti-SARS-CoV-2 (IgG) ELISA,Trinity Biotech,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9592,1.0,['High'],No,No,No,No,Unclear,Yes,Yes,Yes,No,Joanna Griffin,Rotunda Hospital,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.10.20248323v1.full-text,2021-03-26,2024-03-01,Verified,griffin_persistence_2021,IRL
210518_Mid-WestIreland_UniversityofLimerick_Patients2,210518_Mid-WestIreland_UniversityofLimerick_Patients2,Seroprevalence study of SARS-CoV-2 infection in General Practice in Ireland. ,2021-05-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,Munster,,Participants needed to be 18 years of age or over and able to provide consent and be either staff or a patient at one of the general practice sites. ,Exclusion criteria were cognitive impairment; severe psychiatric illness; use of immunologic agents; or pregnancy.,2020-06-15,2020-07-10,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,799,0.126,0.08,0.17,True,True,,,True,Convenience,SARS CoV-2 IgM/IgG Antibody Assay Colloidal Gold Complex test,Maccura Biotechnology Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by manufacturers,,,['Moderate'],,No,Yes,No,,Unclear,Yes,Yes,,Michael Edmund O'Callaghan,University of Limerick,Not Unity-Aligned,https://dx.doi.org/10.3399/BJGPO.2021.0038,2021-06-02,2022-07-16,Unverified,michaeledmundocallaghanSeroprevalenceStudySARSCoV22021,IRL
210518_Mid-WestIreland_UniversityofLimerick_Staff1,210518_Mid-WestIreland_UniversityofLimerick_Staff1,Seroprevalence study of SARS-CoV-2 infection in General Practice in Ireland. ,2021-05-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,Munster,,Participants needed to be 18 years of age or over and able to provide consent and be either staff or a patient at one of the general practice sites. ,Exclusion criteria were cognitive impairment; severe psychiatric illness; use of immunologic agents; or pregnancy.,2020-06-15,2020-07-10,Health care workers and caregivers,All,Multiple groups,18.0,,Primary Estimate,,172,0.111,0.04,0.19,True,True,,,True,Convenience,SARS CoV-2 IgM/IgG Antibody Assay Colloidal Gold Complex test,Maccura Biotechnology Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by manufacturers,,,['High'],,No,No,No,,Unclear,Yes,Yes,,Michael Edmund O'Callaghan,University of Limerick,Not Unity-Aligned,https://dx.doi.org/10.3399/BJGPO.2021.0038,2021-06-01,2022-07-16,Unverified,michaeledmundocallaghanSeroprevalenceStudySARSCoV22021,IRL
210526_Ireland_TrinityCollege,210526_Ireland_TrinityCollege,SARS-CoV-2 Antibody Testing in Healthcare Workers: a comparison of the clinical performance of three commercially available antibody assays,2021-05-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,,,"All staff members of both hospitals were invited to participate in 
an online self-administered consent process and online questionnaire, followed by blood sampling for SARS-CoV-2 antibody testing. ",,2020-10-01,2020-10-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,5787,0.095,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Niamh Allen,"Trinity College, University of Dublin",Not Unity-Aligned,https://europepmc.org/article/PPR/PPR347943,2021-06-07,2024-03-01,Unverified,Allen_SARS-CoV-2_2021,IRL
210602_Dublin_UniversityCollegeDublin_overall_Unadj,210602_Dublin_UniversityCollegeDublin,EXPRESS: Performance characteristics of five SARS-CoV-2 serological assays: clinical utility in healthcare workers.,2021-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ireland,Leinster,Dublin,,,2020-06-15,2020-09-15,Multiple populations,All,Adults (18-64 years),,,Primary Estimate,,109,0.0092,,,True,,,,True,Unclear,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG),Coronavirus Antibody Rapid Test,Elecsys® Anti‐SARS‐CoV‐2 (N),Liaison SARS-CoV-2 S1/S2 IgG","EUROIMMUN,Fortress Diagnostics,Roche Diagnostics,DiaSorin",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,Unclear,No,No,Unclear,Unclear,Yes,No,Unclear,Emma Heffernan,University College Dublin,Not Unity-Aligned,https://dx.doi.org/10.1177/00045632211012728,2021-05-22,2024-03-01,Verified,heffernan_express_2021,IRL
210608_SouthWestOfIreland_CorkUniversityHospital,210608_SouthWestOfIreland_CorkUniversityHospital,Seroprevalence study of SARS-CoV-2 antibodies in healthcare workers following the first wave of the COVID-19 pandemic in a tertiary-level hospital in the south of Ireland,2021-06-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,Munster,Cork,"HCWs aged 18 years or over, fluent in English working 
in CUH or affiliated centres in the region were eligible 
to participate. HCWs were defined as those who deliver 
care and services to patients, either directly as physicians 
or nurses, healthcare attendants, or other support staff 
(porters, administrative officers, cleaning, maintenance, 
etc).","HCWs who tested positive by RT-PCR for SARS-CoV-2 
within 30 days of recruitment to the study or reporting 
symptoms of COVID-19 at time of recruitment were 
deemed ineligible to participate. However, there were no 
diagnosed infections among staff in our institution in the 
30 days prior to enrolment",2020-05-27,2020-07-07,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,404,0.0149,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['High'],,No,No,No,,Yes,Yes,Yes,,Eamonn Faller,Cork University Hospital,Not Unity-Aligned,http://dx.doi.org/10.1136/bmjopen-2021-051415,2021-06-30,2024-03-01,Unverified,fallerSeroprevalenceStudySARSCoV22021,IRL
210630_Dublin_TrinityCollegeDublin_Overall,210630_Dublin_TrinityCollegeDublin,High anti-SARS-CoV-2 antibody seroprevalence in healthcare workers in an Irish university teaching hospital.,2021-06-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ireland,,Dublin,Healthcare workers at Tallaght University Hospital ,,2020-07-15,2020-10-15,Health care workers and caregivers,All,Adults (18-64 years),20.0,69.0,Primary Estimate,Overall,1176,0.179,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.861,1.0,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,No,Ann Leonard,Trinity College Dublin,Not Unity-Aligned,https://dx.doi.org/10.1007/s11845-021-02690-4,2021-07-05,2024-03-01,Verified,leonard_high_2021,IRL
210630_Dublin_TrinityCollegeDublin_60-69,210630_Dublin_TrinityCollegeDublin,High anti-SARS-CoV-2 antibody seroprevalence in healthcare workers in an Irish university teaching hospital.,2021-06-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ireland,,Dublin,Healthcare workers at Tallaght University Hospital ,,2020-07-15,2020-10-15,Health care workers and caregivers,All,Seniors (65+ years),60.0,69.0,Age,60-69,98,0.135,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.861,1.0,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,No,Ann Leonard,Trinity College Dublin,Not Unity-Aligned,https://dx.doi.org/10.1007/s11845-021-02690-4,2021-07-09,2024-03-01,Verified,leonard_high_2021,IRL
210630_Dublin_TrinityCollegeDublin_50-59,210630_Dublin_TrinityCollegeDublin,High anti-SARS-CoV-2 antibody seroprevalence in healthcare workers in an Irish university teaching hospital.,2021-06-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ireland,,Dublin,Healthcare workers at Tallaght University Hospital ,,2020-07-15,2020-10-15,Health care workers and caregivers,All,Adults (18-64 years),50.0,59.0,Age,50-59,216,0.167,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.861,1.0,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,No,Ann Leonard,Trinity College Dublin,Not Unity-Aligned,https://dx.doi.org/10.1007/s11845-021-02690-4,2021-07-09,2024-03-01,Verified,leonard_high_2021,IRL
210630_Dublin_TrinityCollegeDublin_40-49,210630_Dublin_TrinityCollegeDublin,High anti-SARS-CoV-2 antibody seroprevalence in healthcare workers in an Irish university teaching hospital.,2021-06-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ireland,,Dublin,Healthcare workers at Tallaght University Hospital ,,2020-07-15,2020-10-15,Health care workers and caregivers,All,Adults (18-64 years),40.0,49.0,Age,40-49,323,0.152,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.861,1.0,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,No,Ann Leonard,Trinity College Dublin,Not Unity-Aligned,https://dx.doi.org/10.1007/s11845-021-02690-4,2021-07-09,2024-03-01,Verified,leonard_high_2021,IRL
210630_Dublin_TrinityCollegeDublin_20-29,210630_Dublin_TrinityCollegeDublin,High anti-SARS-CoV-2 antibody seroprevalence in healthcare workers in an Irish university teaching hospital.,2021-06-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ireland,,Dublin,Healthcare workers at Tallaght University Hospital ,,2020-07-15,2020-10-15,Health care workers and caregivers,All,Adults (18-64 years),20.0,29.0,Age,20-29,200,0.3,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.861,1.0,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,No,Ann Leonard,Trinity College Dublin,Not Unity-Aligned,https://dx.doi.org/10.1007/s11845-021-02690-4,2021-07-09,2024-03-01,Verified,leonard_high_2021,IRL
210630_Dublin_TrinityCollegeDublin_30-39,210630_Dublin_TrinityCollegeDublin,High anti-SARS-CoV-2 antibody seroprevalence in healthcare workers in an Irish university teaching hospital.,2021-06-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ireland,,Dublin,Healthcare workers at Tallaght University Hospital ,,2020-07-15,2020-10-15,Health care workers and caregivers,All,Adults (18-64 years),30.0,39.0,Age,30-39,338,0.157,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.861,1.0,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,No,Ann Leonard,Trinity College Dublin,Not Unity-Aligned,https://dx.doi.org/10.1007/s11845-021-02690-4,2021-07-09,2024-03-01,Verified,leonard_high_2021,IRL
210707_Dublin_StJames'sHospital,210707_Dublin_StJames'sHospital,SARS-CoV-2 anti-nucleocapsid assay performance in healthcare workers at baseline and 6 months.,2021-07-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ireland,Leinster,Dublin,A total of 49 healthcare workers (32 female and 17 male) participated in the study.,,2020-04-01,2020-04-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,49,0.29,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,,,['High'],,No,No,No,,Yes,Yes,Yes,,Colm Kerr,St. James’s Hospital,Not Unity-Aligned,https://dx.doi.org/10.1007/s11845-021-02700-5,2021-07-14,2024-03-01,Unverified,kerrSARSCoV2AntinucleocapsidAssay2021,IRL
210709_Dublin_HSENationalDrugTreatmentCentre_overall,210709_Dublin_HSENationalDrugTreatmentCentre,A cross-section observational study on the seroprevalence of antibodies to COVID-19 in patients receiving opiate agonist treatment.,2021-07-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ireland,,Dublin,Patients on OAT attending an inner city Dublin drug treatment centre were invited to participate in the study,"Exclusion criteria were lack of willingness to participate, or the lack of ability to provide informed consent.",2020-07-15,2020-10-15,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),25.0,64.0,Primary Estimate,,103,0.019,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG, SARS-CoV-2 ELISA","Abbott Laboratories,DiaSorin,Fortress Diagnostics",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Fiona Fenton,HSE National Drug Treatment Centre,Not Unity-Aligned,https://dx.doi.org/10.1007/s11845-021-02660-w,2021-07-18,2024-03-01,Unverified,fenton_cross-section_2021,IRL
210824_Ireland_UniversityofLimerick_HCW_TestAdjusted,210824_Ireland_UniversityofLimerick_HCW,SARS-CoV-2 infection in general practice in Ireland: a seroprevalence study,2021-08-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,Midwest Region,,"Participants needed to be aged ≥18 years and able to provide consent, and be either staff or a patient at one of the general practice sites.",Exclusion criteria were: cognitive impairment; severe psychiatric illness; use of immunologic agents; or pregnancy.,2020-06-15,2020-07-10,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Test Adjusted,171,0.111,0.042,0.18600000000000003,True,True,,,,Stratified non-probability,SARS CoV-2 IgM/IgG Antibody Assay Colloidal Gold Complex test,Maccura Biotechnology Ltd,LFIA,Whole Blood,IgG,Spike,Validated by developers,0.71,0.98,['High'],Yes,No,No,No,Unclear,Unclear,Yes,Yes,Unclear,Michael O'Callaghan,University of Limerick,Not Unity-Aligned,http://dx.doi.org/10.3399/BJGPO.2021.0038,2021-10-20,2022-07-16,Verified,ocallaghan_sars-cov-2_2021,IRL
210824_Ireland_UniversityofLimerick_Patients_TestAdjusted,210824_Ireland_UniversityofLimerick_Patients,SARS-CoV-2 infection in general practice in Ireland: a seroprevalence study,2021-08-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,Midwest Region,,"Participants needed to be aged ≥18 years and able to provide consent, and be either staff or a patient at one of the general practice sites.",Exclusion criteria were: cognitive impairment; severe psychiatric illness; use of immunologic agents; or pregnancy.,2020-06-15,2020-07-10,Residual sera,All,Multiple groups,18.0,,Primary Estimate,Test Adjusted,796,0.126,0.075,0.166,True,True,,,,Stratified non-probability,SARS CoV-2 IgM/IgG Antibody Assay Colloidal Gold Complex test,Maccura Biotechnology Ltd,LFIA,Whole Blood,IgG,Spike,Validated by developers,0.71,0.98,['High'],Yes,No,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Michael O'Callaghan,University of Limerick,Not Unity-Aligned,http://dx.doi.org/10.3399/BJGPO.2021.0038,2021-10-20,2022-07-16,Verified,ocallaghan_sars-cov-2_2021,IRL
210824_Ireland_UniversityofLimerick_Patients_Crude,210824_Ireland_UniversityofLimerick_Patients,SARS-CoV-2 infection in general practice in Ireland: a seroprevalence study,2021-08-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,Midwest Region,,"Participants needed to be aged ≥18 years and able to provide consent, and be either staff or a patient at one of the general practice sites.",Exclusion criteria were: cognitive impairment; severe psychiatric illness; use of immunologic agents; or pregnancy.,2020-06-15,2020-07-10,Residual sera,All,Multiple groups,18.0,,Analysis,Crude,796,0.1043,,,,,,,True,Stratified non-probability,SARS CoV-2 IgM/IgG Antibody Assay Colloidal Gold Complex test,Maccura Biotechnology Ltd,LFIA,Whole Blood,IgG,Spike,Validated by developers,0.71,0.98,['High'],Yes,No,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Michael O'Callaghan,University of Limerick,Not Unity-Aligned,http://dx.doi.org/10.3399/BJGPO.2021.0038,2021-10-20,2022-07-16,Verified,ocallaghan_sars-cov-2_2021,IRL
210826_Dublin_MaterMisericordiaeUniversityHospital,210826_Dublin_MaterMisericordiaeUniversityHospital,"Rapid and Laboratory SARS-CoV-2 Antibody Testing in High-Risk Hospital Associated Cohorts of Unknown COVID-19 Exposure, a Validation and Epidemiological Study After the First Wave of the Pandemic.",2021-08-26,Journal Article (Peer-Reviewed),Local,Prospective cohort,Ireland,,Dublin,"Candidates were required to be patients or staff of the H/O directorate, be dialysis patients attending MMUH, be over 18 years of age and have capacity to consent to be included in the study. Individuals were excluded from the study if they had ever had a diagnosis of COVID-19 with confirmatory nasopharyngeal (N-P) polymerase chain reaction (PCR) testing, if they had typical symptoms of COVID-19 at the time of recruitment, or if they were currently receiving intravenous immunoglobulin (IVIG) as reports of reactive antibodies to SARS-CoV-2 in commercially available IVIG have been reported (20).","Although participants were asymptomatic for typical symptoms of COVID-19 at the time of the study, this cohort represents individuals whose prior exposure to COVID-19 since the onset of the first wave in March 2020 is unknown and unconfirmed, as routine antigen testing was not available at that time.",2020-06-24,2020-07-06,Multiple populations,All,Multiple groups,19.0,90.0,Primary Estimate,,157,0.064,,,True,,,,True,Unclear,"COVID-19 Rapid Test Kit IgG + IgM,Abbott Architect SARS-CoV-2 IgG,Architect Anti-SARS-CoV-2 IgM,Elecsys® Anti‐SARS‐CoV‐2 (N)","Superbio Biomedical Company ,Abbott Laboratories,Roche Diagnostics",Neutralization,Multiple Types,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['High'],,Unclear,No,Yes,,Unclear,Yes,No,,Brendan O'Kelly,Mater Misericordiae University Hospital,Not Unity-Aligned,https://dx.doi.org/10.3389/fmed.2021.642318,2021-09-24,2024-03-01,Unverified,"Rapid and Laboratory SARS-CoV-2 Antibody Testing in High-Risk Hospital Associated Cohorts of Unknown COVID-19 Exposure, a Validation and Epidemiological Study After the First Wave of the Pandemic",IRL
211115_Ireland_RoyalCollegeofSurgeonsinIreland,211115_Ireland_RoyalCollegeofSurgeonsinIreland,Babies born in the 1st 2020 lockdown: Early data from the CORAL study,2021-11-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"Infants born in March, April and May 2020, during Ireland’s 1 st  COVID- 19 pandemic Lockdown. Invitations were sent to families of 3065 term, singleton babies.","Exclusion  criteria  were  ante-  natal  PCR-   proven SARSCoV- 2 in a parent or co- dwelling person, IV antibiotics in neonatal period, multiple births and major congenital anomalies.",2020-03-15,2020-05-15,Perinatal,All,Children and Youth (0-17 years),,,Primary Estimate,,200,0.015,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],,Unclear,No,No,,Unclear,Yes,No,,Marguerite Lawler,Royal College of Surgeons in Ireland,Not Unity-Aligned,http://dx.doi.org/10.1111/all.15095,2021-12-13,2022-07-16,Unverified,lawler_babies_2021,IRL
211125_Ireland_IrishBloodTransfusionService_Primary,211125_Ireland_IrishBloodTransfusionService,Confirmed circulation of SARS-CoV-2 in Irish blood donors prior to first national notification of infection.,2021-11-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"Population
age distributions included ages of eligible donors only (18 – 70).","The donor sample population comprised of eligible blood donors,
aged between 18 and 70 years, all of whom would have been excluded
from donation if they had symptoms compatible with, and/or known
exposure to COVID-19 in the previous 28 days.",2020-02-15,2020-09-15,Blood donors,All,Multiple groups,18.0,70.0,Primary Estimate,,8509,0.024100000000000003,0.0209,0.0276,True,,True,,True,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ,Not reported/ Unable to specify, SARS-CoV-2 ELISA","Abbott Laboratories,NA,Fortress Diagnostics",Multiple Types,Plasma,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Dearbhla Butler,Irish Blood Transfusion Service,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcv.2021.105045,2021-12-13,2024-03-01,Unverified,butler_confirmed_2022,IRL
211125_Ireland_IrishBloodTransfusionService_June,211125_Ireland_IrishBloodTransfusionService,Confirmed circulation of SARS-CoV-2 in Irish blood donors prior to first national notification of infection.,2021-11-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"Population
age distributions included ages of eligible donors only (18 – 70).","The donor sample population comprised of eligible blood donors,
aged between 18 and 70 years, all of whom would have been excluded
from donation if they had symptoms compatible with, and/or known
exposure to COVID-19 in the previous 28 days.",2020-06-01,2020-06-30,Blood donors,All,Multiple groups,,,Time frame,,1365,0.0271,0.0191,0.0374,,,,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ,Not reported/ Unable to specify, SARS-CoV-2 ELISA","Abbott Laboratories,NA,Fortress Diagnostics",Multiple Types,Plasma,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Dearbhla Butler,Irish Blood Transfusion Service,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcv.2021.105045,2021-12-13,2024-03-01,Unverified,butler_confirmed_2022,IRL
211125_Ireland_IrishBloodTransfusionService_40-49,211125_Ireland_IrishBloodTransfusionService,Confirmed circulation of SARS-CoV-2 in Irish blood donors prior to first national notification of infection.,2021-11-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"Population
age distributions included ages of eligible donors only (18 – 70).","The donor sample population comprised of eligible blood donors,
aged between 18 and 70 years, all of whom would have been excluded
from donation if they had symptoms compatible with, and/or known
exposure to COVID-19 in the previous 28 days.",2020-02-15,2020-09-15,Blood donors,All,Adults (18-64 years),40.0,49.0,Age,40-49,2271,0.015,0.010400000000000001,0.0209,,,True,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ,Not reported/ Unable to specify, SARS-CoV-2 ELISA","Abbott Laboratories,NA,Fortress Diagnostics",Multiple Types,Plasma,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Dearbhla Butler,Irish Blood Transfusion Service,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcv.2021.105045,2021-12-13,2024-03-01,Unverified,butler_confirmed_2022,IRL
211125_Ireland_IrishBloodTransfusionService_Feb,211125_Ireland_IrishBloodTransfusionService,Confirmed circulation of SARS-CoV-2 in Irish blood donors prior to first national notification of infection.,2021-11-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"Population
age distributions included ages of eligible donors only (18 – 70).","The donor sample population comprised of eligible blood donors,
aged between 18 and 70 years, all of whom would have been excluded
from donation if they had symptoms compatible with, and/or known
exposure to COVID-19 in the previous 28 days.",2020-02-01,2020-02-29,Blood donors,All,Multiple groups,,,Time frame,,1047,0.0019,0.0002,0.0069,,,,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ,Not reported/ Unable to specify","Abbott Laboratories,NA",Multiple Types,Plasma,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Dearbhla Butler,Irish Blood Transfusion Service,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcv.2021.105045,2021-12-13,2024-03-01,Unverified,butler_confirmed_2022,IRL
211125_Ireland_IrishBloodTransfusionService_Sept,211125_Ireland_IrishBloodTransfusionService,Confirmed circulation of SARS-CoV-2 in Irish blood donors prior to first national notification of infection.,2021-11-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"Population
age distributions included ages of eligible donors only (18 – 70).","The donor sample population comprised of eligible blood donors,
aged between 18 and 70 years, all of whom would have been excluded
from donation if they had symptoms compatible with, and/or known
exposure to COVID-19 in the previous 28 days.",2020-09-01,2020-09-30,Blood donors,All,Multiple groups,,,Time frame,,666,0.0255,0.0149,0.0409,,,,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ,Not reported/ Unable to specify, SARS-CoV-2 ELISA","Abbott Laboratories,NA,Fortress Diagnostics",Multiple Types,Plasma,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Dearbhla Butler,Irish Blood Transfusion Service,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcv.2021.105045,2021-12-13,2024-03-01,Unverified,butler_confirmed_2022,IRL
211125_Ireland_IrishBloodTransfusionService_Male,211125_Ireland_IrishBloodTransfusionService,Confirmed circulation of SARS-CoV-2 in Irish blood donors prior to first national notification of infection.,2021-11-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"Population
age distributions included ages of eligible donors only (18 – 70).","The donor sample population comprised of eligible blood donors,
aged between 18 and 70 years, all of whom would have been excluded
from donation if they had symptoms compatible with, and/or known
exposure to COVID-19 in the previous 28 days.",2020-02-15,2020-09-15,Blood donors,Male,Multiple groups,,,Sex/Gender,,4842,0.018600000000000002,0.015,0.0229,,,True,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ,Not reported/ Unable to specify, SARS-CoV-2 ELISA","Abbott Laboratories,NA,Fortress Diagnostics",Multiple Types,Plasma,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Dearbhla Butler,Irish Blood Transfusion Service,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcv.2021.105045,2021-12-13,2024-03-01,Unverified,butler_confirmed_2022,IRL
211125_Ireland_IrishBloodTransfusionService_Female,211125_Ireland_IrishBloodTransfusionService,Confirmed circulation of SARS-CoV-2 in Irish blood donors prior to first national notification of infection.,2021-11-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"Population
age distributions included ages of eligible donors only (18 – 70).","The donor sample population comprised of eligible blood donors,
aged between 18 and 70 years, all of whom would have been excluded
from donation if they had symptoms compatible with, and/or known
exposure to COVID-19 in the previous 28 days.",2020-02-15,2020-09-15,Blood donors,Female,Multiple groups,,,Sex/Gender,,3667,0.024300000000000002,0.0197,0.0296,,,True,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ,Not reported/ Unable to specify, SARS-CoV-2 ELISA","Abbott Laboratories,NA,Fortress Diagnostics",Multiple Types,Plasma,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Dearbhla Butler,Irish Blood Transfusion Service,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcv.2021.105045,2021-12-13,2024-03-01,Unverified,butler_confirmed_2022,IRL
211125_Ireland_IrishBloodTransfusionService_>=60,211125_Ireland_IrishBloodTransfusionService,Confirmed circulation of SARS-CoV-2 in Irish blood donors prior to first national notification of infection.,2021-11-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"Population
age distributions included ages of eligible donors only (18 – 70).","The donor sample population comprised of eligible blood donors,
aged between 18 and 70 years, all of whom would have been excluded
from donation if they had symptoms compatible with, and/or known
exposure to COVID-19 in the previous 28 days.",2020-02-15,2020-09-15,Blood donors,All,Seniors (65+ years),60.0,70.0,Age,>=60,1200,0.0167,0.0102,0.0257,,,True,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ,Not reported/ Unable to specify, SARS-CoV-2 ELISA","Abbott Laboratories,NA,Fortress Diagnostics",Multiple Types,Plasma,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Dearbhla Butler,Irish Blood Transfusion Service,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcv.2021.105045,2021-12-13,2024-03-01,Unverified,butler_confirmed_2022,IRL
211125_Ireland_IrishBloodTransfusionService_Mar,211125_Ireland_IrishBloodTransfusionService,Confirmed circulation of SARS-CoV-2 in Irish blood donors prior to first national notification of infection.,2021-11-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"Population
age distributions included ages of eligible donors only (18 – 70).","The donor sample population comprised of eligible blood donors,
aged between 18 and 70 years, all of whom would have been excluded
from donation if they had symptoms compatible with, and/or known
exposure to COVID-19 in the previous 28 days.",2020-03-01,2020-03-31,Blood donors,All,Multiple groups,,,Time frame,,1033,0.0029,0.0006,0.0085,,,,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ,Not reported/ Unable to specify","Abbott Laboratories,NA",Multiple Types,Plasma,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Dearbhla Butler,Irish Blood Transfusion Service,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcv.2021.105045,2021-12-13,2024-03-01,Unverified,butler_confirmed_2022,IRL
211125_Ireland_IrishBloodTransfusionService_May,211125_Ireland_IrishBloodTransfusionService,Confirmed circulation of SARS-CoV-2 in Irish blood donors prior to first national notification of infection.,2021-11-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"Population
age distributions included ages of eligible donors only (18 – 70).","The donor sample population comprised of eligible blood donors,
aged between 18 and 70 years, all of whom would have been excluded
from donation if they had symptoms compatible with, and/or known
exposure to COVID-19 in the previous 28 days.",2020-05-01,2020-05-31,Blood donors,All,Multiple groups,,,Time frame,,1277,0.028999999999999998,0.0204,0.039900000000000005,,,,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ,Not reported/ Unable to specify, SARS-CoV-2 ELISA","Abbott Laboratories,NA,Fortress Diagnostics",Multiple Types,Plasma,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Dearbhla Butler,Irish Blood Transfusion Service,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcv.2021.105045,2021-12-13,2024-03-01,Unverified,butler_confirmed_2022,IRL
211125_Ireland_IrishBloodTransfusionService_Connacht,211125_Ireland_IrishBloodTransfusionService,Confirmed circulation of SARS-CoV-2 in Irish blood donors prior to first national notification of infection.,2021-11-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,Connacht,,"Population
age distributions included ages of eligible donors only (18 – 70).","The donor sample population comprised of eligible blood donors,
aged between 18 and 70 years, all of whom would have been excluded
from donation if they had symptoms compatible with, and/or known
exposure to COVID-19 in the previous 28 days.",2020-02-15,2020-09-15,Blood donors,All,Multiple groups,,,Geographical area,,649,0.0123,0.0053,0.024300000000000002,,,True,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ,Not reported/ Unable to specify, SARS-CoV-2 ELISA","Abbott Laboratories,NA,Fortress Diagnostics",Multiple Types,Plasma,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Dearbhla Butler,Irish Blood Transfusion Service,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcv.2021.105045,2021-12-13,2024-03-01,Unverified,butler_confirmed_2022,IRL
211125_Ireland_IrishBloodTransfusionService_July,211125_Ireland_IrishBloodTransfusionService,Confirmed circulation of SARS-CoV-2 in Irish blood donors prior to first national notification of infection.,2021-11-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"Population
age distributions included ages of eligible donors only (18 – 70).","The donor sample population comprised of eligible blood donors,
aged between 18 and 70 years, all of whom would have been excluded
from donation if they had symptoms compatible with, and/or known
exposure to COVID-19 in the previous 28 days.",2020-07-01,2020-07-31,Blood donors,All,Multiple groups,,,Time frame,,1116,0.026000000000000002,0.0174,0.0373,,,,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ,Not reported/ Unable to specify, SARS-CoV-2 ELISA","Abbott Laboratories,NA,Fortress Diagnostics",Multiple Types,Plasma,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Dearbhla Butler,Irish Blood Transfusion Service,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcv.2021.105045,2021-12-13,2024-03-01,Unverified,butler_confirmed_2022,IRL
211125_Ireland_IrishBloodTransfusionService_18-29,211125_Ireland_IrishBloodTransfusionService,Confirmed circulation of SARS-CoV-2 in Irish blood donors prior to first national notification of infection.,2021-11-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"Population
age distributions included ages of eligible donors only (18 – 70).","The donor sample population comprised of eligible blood donors,
aged between 18 and 70 years, all of whom would have been excluded
from donation if they had symptoms compatible with, and/or known
exposure to COVID-19 in the previous 28 days.",2020-02-15,2020-09-15,Blood donors,All,Adults (18-64 years),18.0,29.0,Age,18-29,1133,0.053,0.0404,0.06820000000000001,,,True,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ,Not reported/ Unable to specify, SARS-CoV-2 ELISA","Abbott Laboratories,NA,Fortress Diagnostics",Multiple Types,Plasma,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Dearbhla Butler,Irish Blood Transfusion Service,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcv.2021.105045,2021-12-13,2024-03-01,Unverified,butler_confirmed_2022,IRL
211125_Ireland_IrishBloodTransfusionService_Ulster,211125_Ireland_IrishBloodTransfusionService,Confirmed circulation of SARS-CoV-2 in Irish blood donors prior to first national notification of infection.,2021-11-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,Ulster,,"Population
age distributions included ages of eligible donors only (18 – 70).","The donor sample population comprised of eligible blood donors,
aged between 18 and 70 years, all of whom would have been excluded
from donation if they had symptoms compatible with, and/or known
exposure to COVID-19 in the previous 28 days.",2020-02-15,2020-09-15,Blood donors,All,Multiple groups,,,Geographical area,,648,0.0139,0.0063,0.0263,,,True,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ,Not reported/ Unable to specify, SARS-CoV-2 ELISA","Abbott Laboratories,NA,Fortress Diagnostics",Multiple Types,Plasma,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Dearbhla Butler,Irish Blood Transfusion Service,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcv.2021.105045,2021-12-13,2024-03-01,Unverified,butler_confirmed_2022,IRL
211125_Ireland_IrishBloodTransfusionService_Apr,211125_Ireland_IrishBloodTransfusionService,Confirmed circulation of SARS-CoV-2 in Irish blood donors prior to first national notification of infection.,2021-11-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"Population
age distributions included ages of eligible donors only (18 – 70).","The donor sample population comprised of eligible blood donors,
aged between 18 and 70 years, all of whom would have been excluded
from donation if they had symptoms compatible with, and/or known
exposure to COVID-19 in the previous 28 days.",2020-04-01,2020-04-30,Blood donors,All,Multiple groups,,,Time frame,,1342,0.0291,0.0207,0.039700000000000006,,,,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ,Not reported/ Unable to specify, SARS-CoV-2 ELISA","Abbott Laboratories,NA,Fortress Diagnostics",Multiple Types,Plasma,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Dearbhla Butler,Irish Blood Transfusion Service,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcv.2021.105045,2021-12-13,2024-03-01,Unverified,butler_confirmed_2022,IRL
211125_Ireland_IrishBloodTransfusionService_50-59,211125_Ireland_IrishBloodTransfusionService,Confirmed circulation of SARS-CoV-2 in Irish blood donors prior to first national notification of infection.,2021-11-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"Population
age distributions included ages of eligible donors only (18 – 70).","The donor sample population comprised of eligible blood donors,
aged between 18 and 70 years, all of whom would have been excluded
from donation if they had symptoms compatible with, and/or known
exposure to COVID-19 in the previous 28 days.",2020-02-15,2020-09-15,Blood donors,All,Adults (18-64 years),50.0,59.0,Age,50-59,2241,0.0121,0.0079,0.0175,,,True,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ,Not reported/ Unable to specify, SARS-CoV-2 ELISA","Abbott Laboratories,NA,Fortress Diagnostics",Multiple Types,Plasma,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Dearbhla Butler,Irish Blood Transfusion Service,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcv.2021.105045,2021-12-13,2024-03-01,Unverified,butler_confirmed_2022,IRL
211125_Ireland_IrishBloodTransfusionService_Aug,211125_Ireland_IrishBloodTransfusionService,Confirmed circulation of SARS-CoV-2 in Irish blood donors prior to first national notification of infection.,2021-11-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"Population
age distributions included ages of eligible donors only (18 – 70).","The donor sample population comprised of eligible blood donors,
aged between 18 and 70 years, all of whom would have been excluded
from donation if they had symptoms compatible with, and/or known
exposure to COVID-19 in the previous 28 days.",2020-08-01,2020-08-31,Blood donors,All,Multiple groups,,,Time frame,,663,0.0347,0.022000000000000002,0.0521,,,,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ,Not reported/ Unable to specify, SARS-CoV-2 ELISA","Abbott Laboratories,NA,Fortress Diagnostics",Multiple Types,Plasma,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Dearbhla Butler,Irish Blood Transfusion Service,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcv.2021.105045,2021-12-13,2024-03-01,Unverified,butler_confirmed_2022,IRL
211125_Ireland_IrishBloodTransfusionService_Munster,211125_Ireland_IrishBloodTransfusionService,Confirmed circulation of SARS-CoV-2 in Irish blood donors prior to first national notification of infection.,2021-11-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,Munster,,"Population
age distributions included ages of eligible donors only (18 – 70).","The donor sample population comprised of eligible blood donors,
aged between 18 and 70 years, all of whom would have been excluded
from donation if they had symptoms compatible with, and/or known
exposure to COVID-19 in the previous 28 days.",2020-02-15,2020-09-15,Blood donors,All,Multiple groups,,,Geographical area,,2257,0.018600000000000002,0.0134,0.0252,,,True,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ,Not reported/ Unable to specify, SARS-CoV-2 ELISA","Abbott Laboratories,NA,Fortress Diagnostics",Multiple Types,Plasma,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Dearbhla Butler,Irish Blood Transfusion Service,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcv.2021.105045,2021-12-13,2024-03-01,Unverified,butler_confirmed_2022,IRL
211125_Ireland_IrishBloodTransfusionService_30-39,211125_Ireland_IrishBloodTransfusionService,Confirmed circulation of SARS-CoV-2 in Irish blood donors prior to first national notification of infection.,2021-11-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"Population
age distributions included ages of eligible donors only (18 – 70).","The donor sample population comprised of eligible blood donors,
aged between 18 and 70 years, all of whom would have been excluded
from donation if they had symptoms compatible with, and/or known
exposure to COVID-19 in the previous 28 days.",2020-02-15,2020-09-15,Blood donors,All,Adults (18-64 years),30.0,39.0,Age,30-39,1664,0.0355,0.027000000000000003,0.045700000000000005,,,True,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ,Not reported/ Unable to specify, SARS-CoV-2 ELISA","Abbott Laboratories,NA,Fortress Diagnostics",Multiple Types,Plasma,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Dearbhla Butler,Irish Blood Transfusion Service,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcv.2021.105045,2021-12-13,2024-03-01,Unverified,butler_confirmed_2022,IRL
211125_Ireland_IrishBloodTransfusionService_Leinster,211125_Ireland_IrishBloodTransfusionService,Confirmed circulation of SARS-CoV-2 in Irish blood donors prior to first national notification of infection.,2021-11-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,"Leinster
",,"Population
age distributions included ages of eligible donors only (18 – 70).","The donor sample population comprised of eligible blood donors,
aged between 18 and 70 years, all of whom would have been excluded
from donation if they had symptoms compatible with, and/or known
exposure to COVID-19 in the previous 28 days.",2020-02-15,2020-09-15,Blood donors,All,Multiple groups,,,Geographical area,,4955,0.029500000000000002,0.0248,0.0347,,,True,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ,Not reported/ Unable to specify, SARS-CoV-2 ELISA","Abbott Laboratories,NA,Fortress Diagnostics",Multiple Types,Plasma,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Dearbhla Butler,Irish Blood Transfusion Service,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcv.2021.105045,2021-12-13,2024-03-01,Unverified,butler_confirmed_2022,IRL
211202_Ireland_HealthProtectionSurveillanceCentre_Dublin_OverallWeighted,211202_Ireland_HealthProtectionSurveillanceCentre_Dublin,"The Study to Investigate COVID-19 Infection in People Living in Ireland (SCOPI): A seroprevalence study, June to July 2020.",2021-12-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ireland,,,"we selected random samples of people in each of two defined geographic areas, counties Dublin (population aged 12–69 years: n=1,021,801) and Sligo (population aged 12–69 years: n=47,718), which have high and low incidence of notified COVID-19 cases, respectively, which together represent 30% of the national population in this age group. Within age–sex strata, we selected participants using simple random sampling.","We excluded those 
under 12 years as phlebotomy is difficult in young children, and people aged 70 and older as they had been advised to stay at home during this study period.",2020-06-22,2020-07-16,Household and community samples,All,Multiple groups,12.0,69.0,Primary Estimate,Population adjusted,913,0.031200000000000002,0.020499999999999997,0.0453,True,,True,,True,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,Wantai SARS-CoV-2 Total Ab ELISA","Abbott Laboratories,Beijing Wantai Biological",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,No,Laura Heavey,Health Protection Surveillance Centre,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.48.2001741,2021-12-15,2024-03-01,Verified,heavey_study_2021,IRL
211202_Ireland_HealthProtectionSurveillanceCentre_Dublin_OverallCrude,211202_Ireland_HealthProtectionSurveillanceCentre_Dublin,"The Study to Investigate COVID-19 Infection in People Living in Ireland (SCOPI): A seroprevalence study, June to July 2020.",2021-12-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ireland,,,"we selected random samples of people in each of two defined geographic areas, counties Dublin (population aged 12–69 years: n=1,021,801) and Sligo (population aged 12–69 years: n=47,718), which have high and low incidence of notified COVID-19 cases, respectively, which together represent 30% of the national population in this age group. Within age–sex strata, we selected participants using simple random sampling.","We excluded those 
under 12 years as phlebotomy is difficult in young children, and people aged 70 and older as they had been advised to stay at home during this study period.",2020-06-22,2020-07-16,Household and community samples,All,Multiple groups,12.0,69.0,Analysis,Crude,913,0.030699999999999998,,,,,,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,Wantai SARS-CoV-2 Total Ab ELISA","Abbott Laboratories,Beijing Wantai Biological",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,No,Laura Heavey,Health Protection Surveillance Centre,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.48.2001741,2021-12-15,2024-03-01,Verified,heavey_study_2021,IRL
211202_Ireland_HealthProtectionSurveillanceCentre_Dublin_Age50–59,211202_Ireland_HealthProtectionSurveillanceCentre_Dublin,"The Study to Investigate COVID-19 Infection in People Living in Ireland (SCOPI): A seroprevalence study, June to July 2020.",2021-12-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ireland,,,"we selected random samples of people in each of two defined geographic areas, counties Dublin (population aged 12–69 years: n=1,021,801) and Sligo (population aged 12–69 years: n=47,718), which have high and low incidence of notified COVID-19 cases, respectively, which together represent 30% of the national population in this age group. Within age–sex strata, we selected participants using simple random sampling.","We excluded those 
under 12 years as phlebotomy is difficult in young children, and people aged 70 and older as they had been advised to stay at home during this study period.",2020-06-22,2020-07-16,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50–59,153,0.0193,0.0039000000000000003,0.0558,,,,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,Wantai SARS-CoV-2 Total Ab ELISA","Abbott Laboratories,Beijing Wantai Biological",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,No,Laura Heavey,Health Protection Surveillance Centre,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.48.2001741,2021-12-15,2024-03-01,Verified,heavey_study_2021,IRL
211202_Ireland_HealthProtectionSurveillanceCentre_Dublin_Age40–49,211202_Ireland_HealthProtectionSurveillanceCentre_Dublin,"The Study to Investigate COVID-19 Infection in People Living in Ireland (SCOPI): A seroprevalence study, June to July 2020.",2021-12-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ireland,,,"we selected random samples of people in each of two defined geographic areas, counties Dublin (population aged 12–69 years: n=1,021,801) and Sligo (population aged 12–69 years: n=47,718), which have high and low incidence of notified COVID-19 cases, respectively, which together represent 30% of the national population in this age group. Within age–sex strata, we selected participants using simple random sampling.","We excluded those 
under 12 years as phlebotomy is difficult in young children, and people aged 70 and older as they had been advised to stay at home during this study period.",2020-06-22,2020-07-16,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40–49,189,0.0309,0.011200000000000002,0.0667,,,,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,Wantai SARS-CoV-2 Total Ab ELISA","Abbott Laboratories,Beijing Wantai Biological",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,No,Laura Heavey,Health Protection Surveillance Centre,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.48.2001741,2021-12-15,2024-03-01,Verified,heavey_study_2021,IRL
211202_Ireland_HealthProtectionSurveillanceCentre_Dublin_Age30–39,211202_Ireland_HealthProtectionSurveillanceCentre_Dublin,"The Study to Investigate COVID-19 Infection in People Living in Ireland (SCOPI): A seroprevalence study, June to July 2020.",2021-12-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ireland,,,"we selected random samples of people in each of two defined geographic areas, counties Dublin (population aged 12–69 years: n=1,021,801) and Sligo (population aged 12–69 years: n=47,718), which have high and low incidence of notified COVID-19 cases, respectively, which together represent 30% of the national population in this age group. Within age–sex strata, we selected participants using simple random sampling.","We excluded those 
under 12 years as phlebotomy is difficult in young children, and people aged 70 and older as they had been advised to stay at home during this study period.",2020-06-22,2020-07-16,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30–39,171,0.0298,0.0097,0.0684,,,,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,Wantai SARS-CoV-2 Total Ab ELISA","Abbott Laboratories,Beijing Wantai Biological",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,No,Laura Heavey,Health Protection Surveillance Centre,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.48.2001741,2021-12-15,2024-03-01,Verified,heavey_study_2021,IRL
211202_Ireland_HealthProtectionSurveillanceCentre_Dublin_Age20–29,211202_Ireland_HealthProtectionSurveillanceCentre_Dublin,"The Study to Investigate COVID-19 Infection in People Living in Ireland (SCOPI): A seroprevalence study, June to July 2020.",2021-12-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ireland,,,"we selected random samples of people in each of two defined geographic areas, counties Dublin (population aged 12–69 years: n=1,021,801) and Sligo (population aged 12–69 years: n=47,718), which have high and low incidence of notified COVID-19 cases, respectively, which together represent 30% of the national population in this age group. Within age–sex strata, we selected participants using simple random sampling.","We excluded those 
under 12 years as phlebotomy is difficult in young children, and people aged 70 and older as they had been advised to stay at home during this study period.",2020-06-22,2020-07-16,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20–29,147,0.04650000000000001,0.018600000000000002,0.0942,,,,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,Wantai SARS-CoV-2 Total Ab ELISA","Abbott Laboratories,Beijing Wantai Biological",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,No,Laura Heavey,Health Protection Surveillance Centre,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.48.2001741,2021-12-15,2024-03-01,Verified,heavey_study_2021,IRL
211202_Ireland_HealthProtectionSurveillanceCentre_Dublin_Age12–19,211202_Ireland_HealthProtectionSurveillanceCentre_Dublin,"The Study to Investigate COVID-19 Infection in People Living in Ireland (SCOPI): A seroprevalence study, June to July 2020.",2021-12-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ireland,,,"we selected random samples of people in each of two defined geographic areas, counties Dublin (population aged 12–69 years: n=1,021,801) and Sligo (population aged 12–69 years: n=47,718), which have high and low incidence of notified COVID-19 cases, respectively, which together represent 30% of the national population in this age group. Within age–sex strata, we selected participants using simple random sampling.","We excluded those 
under 12 years as phlebotomy is difficult in young children, and people aged 70 and older as they had been advised to stay at home during this study period.",2020-06-22,2020-07-16,Household and community samples,All,Children and Youth (0-17 years),12.0,19.0,Age,12–19,90,0.0223,0.0026000000000000003,0.0792,,,,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,Wantai SARS-CoV-2 Total Ab ELISA","Abbott Laboratories,Beijing Wantai Biological",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,No,Laura Heavey,Health Protection Surveillance Centre,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.48.2001741,2021-12-15,2024-03-01,Verified,heavey_study_2021,IRL
211202_Ireland_HealthProtectionSurveillanceCentre_Dublin_Age60–69,211202_Ireland_HealthProtectionSurveillanceCentre_Dublin,"The Study to Investigate COVID-19 Infection in People Living in Ireland (SCOPI): A seroprevalence study, June to July 2020.",2021-12-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ireland,,,"we selected random samples of people in each of two defined geographic areas, counties Dublin (population aged 12–69 years: n=1,021,801) and Sligo (population aged 12–69 years: n=47,718), which have high and low incidence of notified COVID-19 cases, respectively, which together represent 30% of the national population in this age group. Within age–sex strata, we selected participants using simple random sampling.","We excluded those 
under 12 years as phlebotomy is difficult in young children, and people aged 70 and older as they had been advised to stay at home during this study period.",2020-06-22,2020-07-16,Household and community samples,All,Seniors (65+ years),60.0,69.0,Age,60–69,163,0.0322,0.0105,0.0734,,,,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,Wantai SARS-CoV-2 Total Ab ELISA","Abbott Laboratories,Beijing Wantai Biological",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,No,Laura Heavey,Health Protection Surveillance Centre,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.48.2001741,2021-12-15,2024-03-01,Verified,heavey_study_2021,IRL
211202_Ireland_HealthProtectionSurveillanceCentre_Dublin_SexFemale,211202_Ireland_HealthProtectionSurveillanceCentre_Dublin,"The Study to Investigate COVID-19 Infection in People Living in Ireland (SCOPI): A seroprevalence study, June to July 2020.",2021-12-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ireland,,,"we selected random samples of people in each of two defined geographic areas, counties Dublin (population aged 12–69 years: n=1,021,801) and Sligo (population aged 12–69 years: n=47,718), which have high and low incidence of notified COVID-19 cases, respectively, which together represent 30% of the national population in this age group. Within age–sex strata, we selected participants using simple random sampling.","We excluded those 
under 12 years as phlebotomy is difficult in young children, and people aged 70 and older as they had been advised to stay at home during this study period.",2020-06-22,2020-07-16,Household and community samples,Female,Multiple groups,12.0,69.0,Sex/Gender,,492,0.0361,0.0212,0.0571,,,,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,Wantai SARS-CoV-2 Total Ab ELISA","Abbott Laboratories,Beijing Wantai Biological",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,No,Laura Heavey,Health Protection Surveillance Centre,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.48.2001741,2021-12-15,2024-03-01,Verified,heavey_study_2021,IRL
211202_Ireland_HealthProtectionSurveillanceCentre_Dublin_SexMale,211202_Ireland_HealthProtectionSurveillanceCentre_Dublin,"The Study to Investigate COVID-19 Infection in People Living in Ireland (SCOPI): A seroprevalence study, June to July 2020.",2021-12-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ireland,,,"we selected random samples of people in each of two defined geographic areas, counties Dublin (population aged 12–69 years: n=1,021,801) and Sligo (population aged 12–69 years: n=47,718), which have high and low incidence of notified COVID-19 cases, respectively, which together represent 30% of the national population in this age group. Within age–sex strata, we selected participants using simple random sampling.","We excluded those 
under 12 years as phlebotomy is difficult in young children, and people aged 70 and older as they had been advised to stay at home during this study period.",2020-06-22,2020-07-16,Household and community samples,Male,Multiple groups,12.0,69.0,Sex/Gender,,421,0.026099999999999998,0.0123,0.04820000000000001,,,,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,Wantai SARS-CoV-2 Total Ab ELISA","Abbott Laboratories,Beijing Wantai Biological",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,No,Laura Heavey,Health Protection Surveillance Centre,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.48.2001741,2021-12-15,2024-03-01,Verified,heavey_study_2021,IRL
211202_Ireland_HealthProtectionSurveillanceCentre_Sligo_OverallWeighted,211202_Ireland_HealthProtectionSurveillanceCentre_Sligo,"The Study to Investigate COVID-19 Infection in People Living in Ireland (SCOPI): A seroprevalence study, June to July 2020.",2021-12-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ireland,,,"we selected random samples of people in each of two defined geographic areas, counties Dublin (population aged 12–69 years: n=1,021,801) and Sligo (population aged 12–69 years: n=47,718), which have high and low incidence of notified COVID-19 cases, respectively, which together represent 30% of the national population in this age group. Within age–sex strata, we selected participants using simple random sampling.","We excluded those 
under 12 years as phlebotomy is difficult in young children, and people aged 70 and older as they had been advised to stay at home during this study period.",2020-06-22,2020-07-16,Household and community samples,All,Multiple groups,12.0,69.0,Primary Estimate,Population adjusted,820,0.0058,0.0018,0.0138,True,,True,,True,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,Wantai SARS-CoV-2 Total Ab ELISA","Abbott Laboratories,Beijing Wantai Biological",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,No,Laura Heavey,Health Protection Surveillance Centre,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.48.2001741,2021-12-15,2024-03-01,Verified,heavey_study_2021,IRL
211202_Ireland_HealthProtectionSurveillanceCentre_Sligo_OverallCrude,211202_Ireland_HealthProtectionSurveillanceCentre_Sligo,"The Study to Investigate COVID-19 Infection in People Living in Ireland (SCOPI): A seroprevalence study, June to July 2020.",2021-12-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ireland,,,"we selected random samples of people in each of two defined geographic areas, counties Dublin (population aged 12–69 years: n=1,021,801) and Sligo (population aged 12–69 years: n=47,718), which have high and low incidence of notified COVID-19 cases, respectively, which together represent 30% of the national population in this age group. Within age–sex strata, we selected participants using simple random sampling.","We excluded those 
under 12 years as phlebotomy is difficult in young children, and people aged 70 and older as they had been advised to stay at home during this study period.",2020-06-22,2020-07-16,Household and community samples,All,Multiple groups,12.0,69.0,Analysis,Crude,820,0.0061,,,,,,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,Wantai SARS-CoV-2 Total Ab ELISA","Abbott Laboratories,Beijing Wantai Biological",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,No,Laura Heavey,Health Protection Surveillance Centre,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.48.2001741,2021-12-15,2024-03-01,Verified,heavey_study_2021,IRL
211202_Ireland_HealthProtectionSurveillanceCentre_Sligo_Age40–69,211202_Ireland_HealthProtectionSurveillanceCentre_Sligo,"The Study to Investigate COVID-19 Infection in People Living in Ireland (SCOPI): A seroprevalence study, June to July 2020.",2021-12-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ireland,,,"we selected random samples of people in each of two defined geographic areas, counties Dublin (population aged 12–69 years: n=1,021,801) and Sligo (population aged 12–69 years: n=47,718), which have high and low incidence of notified COVID-19 cases, respectively, which together represent 30% of the national population in this age group. Within age–sex strata, we selected participants using simple random sampling.","We excluded those 
under 12 years as phlebotomy is difficult in young children, and people aged 70 and older as they had been advised to stay at home during this study period.",2020-06-22,2020-07-16,Household and community samples,All,Adults (18-64 years),40.0,69.0,Age,40-69,480,0.0088,0.0024,0.0225,,,,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,Wantai SARS-CoV-2 Total Ab ELISA","Abbott Laboratories,Beijing Wantai Biological",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,No,Laura Heavey,Health Protection Surveillance Centre,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.48.2001741,2021-12-15,2024-03-01,Verified,heavey_study_2021,IRL
211202_Ireland_HealthProtectionSurveillanceCentre_Sligo_Age12–39,211202_Ireland_HealthProtectionSurveillanceCentre_Sligo,"The Study to Investigate COVID-19 Infection in People Living in Ireland (SCOPI): A seroprevalence study, June to July 2020.",2021-12-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ireland,,,"we selected random samples of people in each of two defined geographic areas, counties Dublin (population aged 12–69 years: n=1,021,801) and Sligo (population aged 12–69 years: n=47,718), which have high and low incidence of notified COVID-19 cases, respectively, which together represent 30% of the national population in this age group. Within age–sex strata, we selected participants using simple random sampling.","We excluded those 
under 12 years as phlebotomy is difficult in young children, and people aged 70 and older as they had been advised to stay at home during this study period.",2020-06-22,2020-07-16,Household and community samples,All,Multiple groups,12.0,39.0,Age,12-39,340,0.0026000000000000003,0.0,0.015600000000000001,,,,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,Wantai SARS-CoV-2 Total Ab ELISA","Abbott Laboratories,Beijing Wantai Biological",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,No,Laura Heavey,Health Protection Surveillance Centre,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.48.2001741,2021-12-15,2024-03-01,Verified,heavey_study_2021,IRL
211202_Ireland_HealthProtectionSurveillanceCentre_Sligo_SexMale,211202_Ireland_HealthProtectionSurveillanceCentre_Sligo,"The Study to Investigate COVID-19 Infection in People Living in Ireland (SCOPI): A seroprevalence study, June to July 2020.",2021-12-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ireland,,,"we selected random samples of people in each of two defined geographic areas, counties Dublin (population aged 12–69 years: n=1,021,801) and Sligo (population aged 12–69 years: n=47,718), which have high and low incidence of notified COVID-19 cases, respectively, which together represent 30% of the national population in this age group. Within age–sex strata, we selected participants using simple random sampling.","We excluded those 
under 12 years as phlebotomy is difficult in young children, and people aged 70 and older as they had been advised to stay at home during this study period.",2020-06-22,2020-07-16,Household and community samples,Male,Multiple groups,12.0,69.0,Sex/Gender,,355,0.0072,0.0012,0.0227,,,,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,Wantai SARS-CoV-2 Total Ab ELISA","Abbott Laboratories,Beijing Wantai Biological",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,No,Laura Heavey,Health Protection Surveillance Centre,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.48.2001741,2021-12-15,2024-03-01,Verified,heavey_study_2021,IRL
211202_Ireland_HealthProtectionSurveillanceCentre_Sligo_SexFemale,211202_Ireland_HealthProtectionSurveillanceCentre_Sligo,"The Study to Investigate COVID-19 Infection in People Living in Ireland (SCOPI): A seroprevalence study, June to July 2020.",2021-12-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ireland,,,"we selected random samples of people in each of two defined geographic areas, counties Dublin (population aged 12–69 years: n=1,021,801) and Sligo (population aged 12–69 years: n=47,718), which have high and low incidence of notified COVID-19 cases, respectively, which together represent 30% of the national population in this age group. Within age–sex strata, we selected participants using simple random sampling.","We excluded those 
under 12 years as phlebotomy is difficult in young children, and people aged 70 and older as they had been advised to stay at home during this study period.",2020-06-22,2020-07-16,Household and community samples,Female,Multiple groups,12.0,69.0,Sex/Gender,,465,0.0044,0.0005,0.0159,,,,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,Wantai SARS-CoV-2 Total Ab ELISA","Abbott Laboratories,Beijing Wantai Biological",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,No,Laura Heavey,Health Protection Surveillance Centre,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.48.2001741,2021-12-15,2024-03-01,Verified,heavey_study_2021,IRL
220414_Ireland_HealthProtectionSurveillanceCentre_AntiS_Adj,220414_Ireland_HealthProtectionSurveillanceCentre,"Seroprevalence of antibodies to SARS-CoV-2, Ireland: findings from blood donor residual sera surveillance 18 October 2021 – 14 January 2022",2022-04-14,Institutional Report,Local,Cross-sectional survey ,Ireland,,"Dublin, Cork","All three fixed site blood donation clinics in Ireland, two of which are in Dublin and one in Cork, participated in the cross-sectional weekly collection of residual sera over a 12-week period from the week beginning 17 October 2021 to 14 January, 2022.

Sequential sampling of blood donors aged 20 years and older took place until a target of 500 specimens was reached per week, or no other eligible specimens were available.","specimens that were not of sufficient volume, and specimens that were not apheresis donations, haemolysed, icteric, or lipaemic.",2021-10-17,2022-01-14,Blood donors,All,Multiple groups,20.0,79.0,Primary Estimate,anti-S adjusted,5226,0.9840000000000001,0.98,0.99,True,True,,,,Sequential,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,,Multiple Types,IgG,Spike,Validated by manufacturers,0.9870000000000001,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/SEU%20IBTS%2012%20week%20surveillance%20report.pdf,2022-07-25,2024-05-02,Verified,health_seroprevalence_2022,IRL
220414_Ireland_HealthProtectionSurveillanceCentre_AntiN_UnAdj,220414_Ireland_HealthProtectionSurveillanceCentre,"Seroprevalence of antibodies to SARS-CoV-2, Ireland: findings from blood donor residual sera surveillance 18 October 2021 – 14 January 2022",2022-04-14,Institutional Report,Local,Cross-sectional survey ,Ireland,,"Dublin, Cork","All three fixed site blood donation clinics in Ireland, two of which are in Dublin and one in Cork, participated in the cross-sectional weekly collection of residual sera over a 12-week period from the week beginning 17 October 2021 to 14 January, 2022.

Sequential sampling of blood donors aged 20 years and older took place until a target of 500 specimens was reached per week, or no other eligible specimens were available.","specimens that were not of sufficient volume, and specimens that were not apheresis donations, haemolysed, icteric, or lipaemic.",2021-10-17,2022-01-14,Blood donors,All,Multiple groups,20.0,79.0,Test used,anti-N unadjusted,5226,0.1389,,,,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/SEU%20IBTS%2012%20week%20surveillance%20report.pdf,2022-07-25,2024-05-02,Verified,health_seroprevalence_2022,IRL
220414_Ireland_HealthProtectionSurveillanceCentre_AntiN_Adj_Wk2,220414_Ireland_HealthProtectionSurveillanceCentre,"Seroprevalence of antibodies to SARS-CoV-2, Ireland: findings from blood donor residual sera surveillance 18 October 2021 – 14 January 2022",2022-04-14,Institutional Report,Local,Cross-sectional survey ,Ireland,,"Dublin, Cork","All three fixed site blood donation clinics in Ireland, two of which are in Dublin and one in Cork, participated in the cross-sectional weekly collection of residual sera over a 12-week period from the week beginning 17 October 2021 to 14 January, 2022.

Sequential sampling of blood donors aged 20 years and older took place until a target of 500 specimens was reached per week, or no other eligible specimens were available.","specimens that were not of sufficient volume, and specimens that were not apheresis donations, haemolysed, icteric, or lipaemic.",2021-10-24,2021-10-30,Blood donors,All,Multiple groups,20.0,79.0,Time frame,anti-N sampling week 2,499,0.11900000000000001,0.092,0.151,,True,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/SEU%20IBTS%2012%20week%20surveillance%20report.pdf,2022-07-25,2024-05-02,Verified,health_seroprevalence_2022,IRL
220414_Ireland_HealthProtectionSurveillanceCentre_AntiN_Adj_Wk10,220414_Ireland_HealthProtectionSurveillanceCentre,"Seroprevalence of antibodies to SARS-CoV-2, Ireland: findings from blood donor residual sera surveillance 18 October 2021 – 14 January 2022",2022-04-14,Institutional Report,Local,Cross-sectional survey ,Ireland,,"Dublin, Cork","All three fixed site blood donation clinics in Ireland, two of which are in Dublin and one in Cork, participated in the cross-sectional weekly collection of residual sera over a 12-week period from the week beginning 17 October 2021 to 14 January, 2022.

Sequential sampling of blood donors aged 20 years and older took place until a target of 500 specimens was reached per week, or no other eligible specimens were available.","specimens that were not of sufficient volume, and specimens that were not apheresis donations, haemolysed, icteric, or lipaemic.",2021-12-19,2021-12-25,Blood donors,All,Multiple groups,20.0,79.0,Time frame,anti-N sampling week 10,500,0.18600000000000003,0.153,0.223,,True,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/SEU%20IBTS%2012%20week%20surveillance%20report.pdf,2022-07-25,2024-05-02,Verified,health_seroprevalence_2022,IRL
220414_Ireland_HealthProtectionSurveillanceCentre_AntiS_Adj_Age20to29,220414_Ireland_HealthProtectionSurveillanceCentre,"Seroprevalence of antibodies to SARS-CoV-2, Ireland: findings from blood donor residual sera surveillance 18 October 2021 – 14 January 2022",2022-04-14,Institutional Report,Local,Cross-sectional survey ,Ireland,,"Dublin, Cork","All three fixed site blood donation clinics in Ireland, two of which are in Dublin and one in Cork, participated in the cross-sectional weekly collection of residual sera over a 12-week period from the week beginning 17 October 2021 to 14 January, 2022.

Sequential sampling of blood donors aged 20 years and older took place until a target of 500 specimens was reached per week, or no other eligible specimens were available.","specimens that were not of sufficient volume, and specimens that were not apheresis donations, haemolysed, icteric, or lipaemic.",2021-10-17,2022-01-14,Blood donors,All,Adults (18-64 years),20.0,29.0,Age,"anti-S adjusted, age: 20-29",816,0.997,0.986,1.0,,True,,,,Sequential,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,,Multiple Types,IgG,Spike,Validated by manufacturers,0.9870000000000001,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/SEU%20IBTS%2012%20week%20surveillance%20report.pdf,2022-07-25,2024-05-02,Verified,health_seroprevalence_2022,IRL
220414_Ireland_HealthProtectionSurveillanceCentre_AntiS_Adj_Male,220414_Ireland_HealthProtectionSurveillanceCentre,"Seroprevalence of antibodies to SARS-CoV-2, Ireland: findings from blood donor residual sera surveillance 18 October 2021 – 14 January 2022",2022-04-14,Institutional Report,Local,Cross-sectional survey ,Ireland,,"Dublin, Cork","All three fixed site blood donation clinics in Ireland, two of which are in Dublin and one in Cork, participated in the cross-sectional weekly collection of residual sera over a 12-week period from the week beginning 17 October 2021 to 14 January, 2022.

Sequential sampling of blood donors aged 20 years and older took place until a target of 500 specimens was reached per week, or no other eligible specimens were available.","specimens that were not of sufficient volume, and specimens that were not apheresis donations, haemolysed, icteric, or lipaemic.",2021-10-17,2022-01-14,Blood donors,Male,Multiple groups,20.0,79.0,Sex/Gender,anti-S adjusted,3416,0.981,0.9740000000000001,0.986,,True,,,,Sequential,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,,Multiple Types,IgG,Spike,Validated by manufacturers,0.9870000000000001,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/SEU%20IBTS%2012%20week%20surveillance%20report.pdf,2022-07-25,2024-05-02,Verified,health_seroprevalence_2022,IRL
220414_Ireland_HealthProtectionSurveillanceCentre_AntiN_Adj_Wk11,220414_Ireland_HealthProtectionSurveillanceCentre,"Seroprevalence of antibodies to SARS-CoV-2, Ireland: findings from blood donor residual sera surveillance 18 October 2021 – 14 January 2022",2022-04-14,Institutional Report,Local,Cross-sectional survey ,Ireland,,"Dublin, Cork","All three fixed site blood donation clinics in Ireland, two of which are in Dublin and one in Cork, participated in the cross-sectional weekly collection of residual sera over a 12-week period from the week beginning 17 October 2021 to 14 January, 2022.

Sequential sampling of blood donors aged 20 years and older took place until a target of 500 specimens was reached per week, or no other eligible specimens were available.","specimens that were not of sufficient volume, and specimens that were not apheresis donations, haemolysed, icteric, or lipaemic.",2022-01-02,2022-01-08,Blood donors,All,Multiple groups,20.0,79.0,Time frame,anti-N sampling week 11,303,0.21600000000000003,0.17300000000000001,0.267,,True,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/SEU%20IBTS%2012%20week%20surveillance%20report.pdf,2022-07-25,2024-05-02,Verified,health_seroprevalence_2022,IRL
220414_Ireland_HealthProtectionSurveillanceCentre_AntiS_Adj_Female,220414_Ireland_HealthProtectionSurveillanceCentre,"Seroprevalence of antibodies to SARS-CoV-2, Ireland: findings from blood donor residual sera surveillance 18 October 2021 – 14 January 2022",2022-04-14,Institutional Report,Local,Cross-sectional survey ,Ireland,,"Dublin, Cork","All three fixed site blood donation clinics in Ireland, two of which are in Dublin and one in Cork, participated in the cross-sectional weekly collection of residual sera over a 12-week period from the week beginning 17 October 2021 to 14 January, 2022.

Sequential sampling of blood donors aged 20 years and older took place until a target of 500 specimens was reached per week, or no other eligible specimens were available.","specimens that were not of sufficient volume, and specimens that were not apheresis donations, haemolysed, icteric, or lipaemic.",2021-10-17,2022-01-14,Blood donors,Female,Multiple groups,20.0,79.0,Sex/Gender,anti-S adjusted,1810,0.9920000000000001,0.9840000000000001,0.997,,True,,,,Sequential,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,,Multiple Types,IgG,Spike,Validated by manufacturers,0.9870000000000001,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/SEU%20IBTS%2012%20week%20surveillance%20report.pdf,2022-07-25,2024-05-02,Verified,health_seroprevalence_2022,IRL
220414_Ireland_HealthProtectionSurveillanceCentre_AntiN_Adj_Wk6,220414_Ireland_HealthProtectionSurveillanceCentre,"Seroprevalence of antibodies to SARS-CoV-2, Ireland: findings from blood donor residual sera surveillance 18 October 2021 – 14 January 2022",2022-04-14,Institutional Report,Local,Cross-sectional survey ,Ireland,,"Dublin, Cork","All three fixed site blood donation clinics in Ireland, two of which are in Dublin and one in Cork, participated in the cross-sectional weekly collection of residual sera over a 12-week period from the week beginning 17 October 2021 to 14 January, 2022.

Sequential sampling of blood donors aged 20 years and older took place until a target of 500 specimens was reached per week, or no other eligible specimens were available.","specimens that were not of sufficient volume, and specimens that were not apheresis donations, haemolysed, icteric, or lipaemic.",2021-11-21,2021-11-27,Blood donors,All,Multiple groups,20.0,79.0,Time frame,anti-N sampling week 6,410,0.121,0.092,0.157,,True,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/SEU%20IBTS%2012%20week%20surveillance%20report.pdf,2022-07-25,2024-05-02,Verified,health_seroprevalence_2022,IRL
220414_Ireland_HealthProtectionSurveillanceCentre_AntiN_Adj_Wk7,220414_Ireland_HealthProtectionSurveillanceCentre,"Seroprevalence of antibodies to SARS-CoV-2, Ireland: findings from blood donor residual sera surveillance 18 October 2021 – 14 January 2022",2022-04-14,Institutional Report,Local,Cross-sectional survey ,Ireland,,"Dublin, Cork","All three fixed site blood donation clinics in Ireland, two of which are in Dublin and one in Cork, participated in the cross-sectional weekly collection of residual sera over a 12-week period from the week beginning 17 October 2021 to 14 January, 2022.

Sequential sampling of blood donors aged 20 years and older took place until a target of 500 specimens was reached per week, or no other eligible specimens were available.","specimens that were not of sufficient volume, and specimens that were not apheresis donations, haemolysed, icteric, or lipaemic.",2021-11-28,2021-12-04,Blood donors,All,Multiple groups,20.0,79.0,Time frame,anti-N sampling week 7,376,0.12400000000000001,0.09300000000000001,0.163,,True,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/SEU%20IBTS%2012%20week%20surveillance%20report.pdf,2022-07-25,2024-05-02,Verified,health_seroprevalence_2022,IRL
220414_Ireland_HealthProtectionSurveillanceCentre_AntiN_Adj_Wk3,220414_Ireland_HealthProtectionSurveillanceCentre,"Seroprevalence of antibodies to SARS-CoV-2, Ireland: findings from blood donor residual sera surveillance 18 October 2021 – 14 January 2022",2022-04-14,Institutional Report,Local,Cross-sectional survey ,Ireland,,"Dublin, Cork","All three fixed site blood donation clinics in Ireland, two of which are in Dublin and one in Cork, participated in the cross-sectional weekly collection of residual sera over a 12-week period from the week beginning 17 October 2021 to 14 January, 2022.

Sequential sampling of blood donors aged 20 years and older took place until a target of 500 specimens was reached per week, or no other eligible specimens were available.","specimens that were not of sufficient volume, and specimens that were not apheresis donations, haemolysed, icteric, or lipaemic.",2021-10-31,2021-11-06,Blood donors,All,Multiple groups,20.0,79.0,Time frame,anti-N sampling week 3,585,0.09699999999999999,0.07400000000000001,0.12400000000000001,,True,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/SEU%20IBTS%2012%20week%20surveillance%20report.pdf,2022-07-25,2024-05-02,Verified,health_seroprevalence_2022,IRL
220414_Ireland_HealthProtectionSurveillanceCentre_AntiN_Adj_Wk5,220414_Ireland_HealthProtectionSurveillanceCentre,"Seroprevalence of antibodies to SARS-CoV-2, Ireland: findings from blood donor residual sera surveillance 18 October 2021 – 14 January 2022",2022-04-14,Institutional Report,Local,Cross-sectional survey ,Ireland,,"Dublin, Cork","All three fixed site blood donation clinics in Ireland, two of which are in Dublin and one in Cork, participated in the cross-sectional weekly collection of residual sera over a 12-week period from the week beginning 17 October 2021 to 14 January, 2022.

Sequential sampling of blood donors aged 20 years and older took place until a target of 500 specimens was reached per week, or no other eligible specimens were available.","specimens that were not of sufficient volume, and specimens that were not apheresis donations, haemolysed, icteric, or lipaemic.",2021-11-14,2021-11-20,Blood donors,All,Multiple groups,20.0,79.0,Time frame,anti-N sampling week 5,309,0.126,0.092,0.16899999999999998,,True,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/SEU%20IBTS%2012%20week%20surveillance%20report.pdf,2022-07-25,2024-05-02,Verified,health_seroprevalence_2022,IRL
220414_Ireland_HealthProtectionSurveillanceCentre_AntiN_Adj_Wk12,220414_Ireland_HealthProtectionSurveillanceCentre,"Seroprevalence of antibodies to SARS-CoV-2, Ireland: findings from blood donor residual sera surveillance 18 October 2021 – 14 January 2022",2022-04-14,Institutional Report,Local,Cross-sectional survey ,Ireland,,"Dublin, Cork","All three fixed site blood donation clinics in Ireland, two of which are in Dublin and one in Cork, participated in the cross-sectional weekly collection of residual sera over a 12-week period from the week beginning 17 October 2021 to 14 January, 2022.

Sequential sampling of blood donors aged 20 years and older took place until a target of 500 specimens was reached per week, or no other eligible specimens were available.","specimens that were not of sufficient volume, and specimens that were not apheresis donations, haemolysed, icteric, or lipaemic.",2022-01-09,2022-01-14,Blood donors,All,Multiple groups,20.0,79.0,Time frame,anti-N sampling week 12,501,0.204,0.17,0.242,,True,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/SEU%20IBTS%2012%20week%20surveillance%20report.pdf,2022-07-25,2024-05-02,Verified,health_seroprevalence_2022,IRL
220414_Ireland_HealthProtectionSurveillanceCentre_AntiS_UnAdj,220414_Ireland_HealthProtectionSurveillanceCentre,"Seroprevalence of antibodies to SARS-CoV-2, Ireland: findings from blood donor residual sera surveillance 18 October 2021 – 14 January 2022",2022-04-14,Institutional Report,Local,Cross-sectional survey ,Ireland,,"Dublin, Cork","All three fixed site blood donation clinics in Ireland, two of which are in Dublin and one in Cork, participated in the cross-sectional weekly collection of residual sera over a 12-week period from the week beginning 17 October 2021 to 14 January, 2022.

Sequential sampling of blood donors aged 20 years and older took place until a target of 500 specimens was reached per week, or no other eligible specimens were available.","specimens that were not of sufficient volume, and specimens that were not apheresis donations, haemolysed, icteric, or lipaemic.",2021-10-17,2022-01-14,Blood donors,All,Multiple groups,20.0,79.0,Analysis,anti-S unadjusted,5226,0.973,0.968,0.9770000000000001,,,,,True,Sequential,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,,Multiple Types,IgG,Spike,Validated by manufacturers,0.9870000000000001,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/SEU%20IBTS%2012%20week%20surveillance%20report.pdf,2022-07-25,2024-05-02,Verified,health_seroprevalence_2022,IRL
220414_Ireland_HealthProtectionSurveillanceCentre_AntiN_Adj_Wk4,220414_Ireland_HealthProtectionSurveillanceCentre,"Seroprevalence of antibodies to SARS-CoV-2, Ireland: findings from blood donor residual sera surveillance 18 October 2021 – 14 January 2022",2022-04-14,Institutional Report,Local,Cross-sectional survey ,Ireland,,"Dublin, Cork","All three fixed site blood donation clinics in Ireland, two of which are in Dublin and one in Cork, participated in the cross-sectional weekly collection of residual sera over a 12-week period from the week beginning 17 October 2021 to 14 January, 2022.

Sequential sampling of blood donors aged 20 years and older took place until a target of 500 specimens was reached per week, or no other eligible specimens were available.","specimens that were not of sufficient volume, and specimens that were not apheresis donations, haemolysed, icteric, or lipaemic.",2021-11-07,2021-11-13,Blood donors,All,Multiple groups,20.0,79.0,Time frame,anti-N sampling week 4,455,0.079,0.055999999999999994,0.109,,True,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/SEU%20IBTS%2012%20week%20surveillance%20report.pdf,2022-07-25,2024-05-02,Verified,health_seroprevalence_2022,IRL
220414_Ireland_HealthProtectionSurveillanceCentre_AntiN_Adj_Wk8,220414_Ireland_HealthProtectionSurveillanceCentre,"Seroprevalence of antibodies to SARS-CoV-2, Ireland: findings from blood donor residual sera surveillance 18 October 2021 – 14 January 2022",2022-04-14,Institutional Report,Local,Cross-sectional survey ,Ireland,,"Dublin, Cork","All three fixed site blood donation clinics in Ireland, two of which are in Dublin and one in Cork, participated in the cross-sectional weekly collection of residual sera over a 12-week period from the week beginning 17 October 2021 to 14 January, 2022.

Sequential sampling of blood donors aged 20 years and older took place until a target of 500 specimens was reached per week, or no other eligible specimens were available.","specimens that were not of sufficient volume, and specimens that were not apheresis donations, haemolysed, icteric, or lipaemic.",2021-12-05,2021-12-11,Blood donors,All,Multiple groups,20.0,79.0,Time frame,anti-N sampling week 8,372,0.145,0.11199999999999999,0.185,,True,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/SEU%20IBTS%2012%20week%20surveillance%20report.pdf,2022-07-25,2024-05-02,Verified,health_seroprevalence_2022,IRL
220414_Ireland_HealthProtectionSurveillanceCentre_AntiS_Adj_Age50to59,220414_Ireland_HealthProtectionSurveillanceCentre,"Seroprevalence of antibodies to SARS-CoV-2, Ireland: findings from blood donor residual sera surveillance 18 October 2021 – 14 January 2022",2022-04-14,Institutional Report,Local,Cross-sectional survey ,Ireland,,"Dublin, Cork","All three fixed site blood donation clinics in Ireland, two of which are in Dublin and one in Cork, participated in the cross-sectional weekly collection of residual sera over a 12-week period from the week beginning 17 October 2021 to 14 January, 2022.

Sequential sampling of blood donors aged 20 years and older took place until a target of 500 specimens was reached per week, or no other eligible specimens were available.","specimens that were not of sufficient volume, and specimens that were not apheresis donations, haemolysed, icteric, or lipaemic.",2021-10-17,2022-01-14,Blood donors,All,Adults (18-64 years),50.0,59.0,Age,"anti-S adjusted, age: 50-59",1231,0.98,0.968,0.988,,True,,,,Sequential,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,,Multiple Types,IgG,Spike,Validated by manufacturers,0.9870000000000001,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/SEU%20IBTS%2012%20week%20surveillance%20report.pdf,2022-07-25,2024-05-02,Verified,health_seroprevalence_2022,IRL
220414_Ireland_HealthProtectionSurveillanceCentre_AntiN_Adj_Wk1,220414_Ireland_HealthProtectionSurveillanceCentre,"Seroprevalence of antibodies to SARS-CoV-2, Ireland: findings from blood donor residual sera surveillance 18 October 2021 – 14 January 2022",2022-04-14,Institutional Report,Local,Cross-sectional survey ,Ireland,,"Dublin, Cork","All three fixed site blood donation clinics in Ireland, two of which are in Dublin and one in Cork, participated in the cross-sectional weekly collection of residual sera over a 12-week period from the week beginning 17 October 2021 to 14 January, 2022.

Sequential sampling of blood donors aged 20 years and older took place until a target of 500 specimens was reached per week, or no other eligible specimens were available.","specimens that were not of sufficient volume, and specimens that were not apheresis donations, haemolysed, icteric, or lipaemic.",2021-10-17,2021-10-23,Blood donors,All,Multiple groups,20.0,79.0,Time frame,anti-N sampling week 1,456,0.11,0.084,0.14300000000000002,,True,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/SEU%20IBTS%2012%20week%20surveillance%20report.pdf,2022-07-25,2024-05-02,Verified,health_seroprevalence_2022,IRL
220414_Ireland_HealthProtectionSurveillanceCentre_AntiN_Adj_Wk9,220414_Ireland_HealthProtectionSurveillanceCentre,"Seroprevalence of antibodies to SARS-CoV-2, Ireland: findings from blood donor residual sera surveillance 18 October 2021 – 14 January 2022",2022-04-14,Institutional Report,Local,Cross-sectional survey ,Ireland,,"Dublin, Cork","All three fixed site blood donation clinics in Ireland, two of which are in Dublin and one in Cork, participated in the cross-sectional weekly collection of residual sera over a 12-week period from the week beginning 17 October 2021 to 14 January, 2022.

Sequential sampling of blood donors aged 20 years and older took place until a target of 500 specimens was reached per week, or no other eligible specimens were available.","specimens that were not of sufficient volume, and specimens that were not apheresis donations, haemolysed, icteric, or lipaemic.",2021-12-12,2021-12-18,Blood donors,All,Multiple groups,20.0,79.0,Time frame,anti-N sampling week 9,460,0.125,0.09699999999999999,0.159,,True,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/SEU%20IBTS%2012%20week%20surveillance%20report.pdf,2022-07-25,2024-05-02,Verified,health_seroprevalence_2022,IRL
220414_Ireland_HealthProtectionSurveillanceCentre_AntiS_Adj_Age70to79,220414_Ireland_HealthProtectionSurveillanceCentre,"Seroprevalence of antibodies to SARS-CoV-2, Ireland: findings from blood donor residual sera surveillance 18 October 2021 – 14 January 2022",2022-04-14,Institutional Report,Local,Cross-sectional survey ,Ireland,,"Dublin, Cork","All three fixed site blood donation clinics in Ireland, two of which are in Dublin and one in Cork, participated in the cross-sectional weekly collection of residual sera over a 12-week period from the week beginning 17 October 2021 to 14 January, 2022.

Sequential sampling of blood donors aged 20 years and older took place until a target of 500 specimens was reached per week, or no other eligible specimens were available.","specimens that were not of sufficient volume, and specimens that were not apheresis donations, haemolysed, icteric, or lipaemic.",2021-10-17,2022-01-14,Blood donors,All,Seniors (65+ years),70.0,79.0,Age,"anti-S adjusted, age: 70-79",90,1.0,0.97,1.0,,True,,,,Sequential,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,,Multiple Types,IgG,Spike,Validated by manufacturers,0.9870000000000001,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/SEU%20IBTS%2012%20week%20surveillance%20report.pdf,2022-07-25,2024-05-02,Verified,health_seroprevalence_2022,IRL
220414_Ireland_HealthProtectionSurveillanceCentre_AntiS_Adj_Age60to69,220414_Ireland_HealthProtectionSurveillanceCentre,"Seroprevalence of antibodies to SARS-CoV-2, Ireland: findings from blood donor residual sera surveillance 18 October 2021 – 14 January 2022",2022-04-14,Institutional Report,Local,Cross-sectional survey ,Ireland,,"Dublin, Cork","All three fixed site blood donation clinics in Ireland, two of which are in Dublin and one in Cork, participated in the cross-sectional weekly collection of residual sera over a 12-week period from the week beginning 17 October 2021 to 14 January, 2022.

Sequential sampling of blood donors aged 20 years and older took place until a target of 500 specimens was reached per week, or no other eligible specimens were available.","specimens that were not of sufficient volume, and specimens that were not apheresis donations, haemolysed, icteric, or lipaemic.",2021-10-17,2022-01-14,Blood donors,All,Multiple groups,60.0,69.0,Age,"anti-S adjusted, age: 60-69",731,0.9870000000000001,0.973,0.996,,True,,,,Sequential,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,,Multiple Types,IgG,Spike,Validated by manufacturers,0.9870000000000001,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/SEU%20IBTS%2012%20week%20surveillance%20report.pdf,2022-07-25,2024-05-02,Verified,health_seroprevalence_2022,IRL
220414_Ireland_HealthProtectionSurveillanceCentre_AntiS_Adj_Age30to39,220414_Ireland_HealthProtectionSurveillanceCentre,"Seroprevalence of antibodies to SARS-CoV-2, Ireland: findings from blood donor residual sera surveillance 18 October 2021 – 14 January 2022",2022-04-14,Institutional Report,Local,Cross-sectional survey ,Ireland,,"Dublin, Cork","All three fixed site blood donation clinics in Ireland, two of which are in Dublin and one in Cork, participated in the cross-sectional weekly collection of residual sera over a 12-week period from the week beginning 17 October 2021 to 14 January, 2022.

Sequential sampling of blood donors aged 20 years and older took place until a target of 500 specimens was reached per week, or no other eligible specimens were available.","specimens that were not of sufficient volume, and specimens that were not apheresis donations, haemolysed, icteric, or lipaemic.",2021-10-17,2022-01-14,Blood donors,All,Adults (18-64 years),30.0,39.0,Age,"anti-S adjusted, age: 30-39",1216,0.985,0.9740000000000001,0.9920000000000001,,True,,,,Sequential,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,,Multiple Types,IgG,Spike,Validated by manufacturers,0.9870000000000001,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/SEU%20IBTS%2012%20week%20surveillance%20report.pdf,2022-07-25,2024-05-02,Verified,health_seroprevalence_2022,IRL
220414_Ireland_HealthProtectionSurveillanceCentre_AntiS_Adj_Age40to49,220414_Ireland_HealthProtectionSurveillanceCentre,"Seroprevalence of antibodies to SARS-CoV-2, Ireland: findings from blood donor residual sera surveillance 18 October 2021 – 14 January 2022",2022-04-14,Institutional Report,Local,Cross-sectional survey ,Ireland,,"Dublin, Cork","All three fixed site blood donation clinics in Ireland, two of which are in Dublin and one in Cork, participated in the cross-sectional weekly collection of residual sera over a 12-week period from the week beginning 17 October 2021 to 14 January, 2022.

Sequential sampling of blood donors aged 20 years and older took place until a target of 500 specimens was reached per week, or no other eligible specimens were available.","specimens that were not of sufficient volume, and specimens that were not apheresis donations, haemolysed, icteric, or lipaemic.",2021-10-17,2022-01-14,Blood donors,All,Adults (18-64 years),40.0,49.0,Age,"anti-S adjusted, age: 40-49",1142,0.976,0.9640000000000001,0.986,,True,,,,Sequential,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,,Multiple Types,IgG,Spike,Validated by manufacturers,0.9870000000000001,0.996,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/SEU%20IBTS%2012%20week%20surveillance%20report.pdf,2022-07-25,2024-05-02,Verified,health_seroprevalence_2022,IRL
220603_Ireland_HealthProtectionSurveillanceCentre_Adult_antiS_Adj,220603_Ireland_HealthProtectionSurveillanceCentre_Adult,Seroprevalence of antibodies to SARS-CoV-2 in children aged 1-12 years and adults aged 18+ years: results from National Serosurveillance Programme Collection Cycle 1,2022-06-03,Institutional Report,National,Cross-sectional survey ,Ireland,,,"For adult specimens sourced from the remaining seven acute-hospital clinical chemistry laboratories, residual sera from general practice with blood collection dates between 30 January and 19 February 2022 were collected.",,2022-01-30,2022-02-19,Residual sera,All,Multiple groups,18.0,95.0,Primary Estimate,,1410,0.965,0.9520000000000001,0.975,True,True,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/NSP%20combined%20adult%20paeds%20cycle%201%20report_final.pdf,2022-07-25,2024-05-03,Verified,health_seroprevalence_2022_1,IRL
220603_Ireland_HealthProtectionSurveillanceCentre_Adult_antiS-N_Adj_Age70to79,220603_Ireland_HealthProtectionSurveillanceCentre_Adult,Seroprevalence of antibodies to SARS-CoV-2 in children aged 1-12 years and adults aged 18+ years: results from National Serosurveillance Programme Collection Cycle 1,2022-06-03,Institutional Report,National,Cross-sectional survey ,Ireland,,,"For adult specimens sourced from the remaining seven acute-hospital clinical chemistry laboratories, residual sera from general practice with blood collection dates between 30 January and 19 February 2022 were collected.",,2022-01-30,2022-02-19,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,"anti-S and N, age: 70-79",122,0.138,0.08800000000000001,0.21100000000000002,,True,,,,Convenience,"SARS-CoV-2 IgG II Quant ,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/NSP%20combined%20adult%20paeds%20cycle%201%20report_final.pdf,2022-07-25,2024-05-03,Verified,health_seroprevalence_2022_1,IRL
220603_Ireland_HealthProtectionSurveillanceCentre_Adult_antiS_Adj_Male,220603_Ireland_HealthProtectionSurveillanceCentre_Adult,Seroprevalence of antibodies to SARS-CoV-2 in children aged 1-12 years and adults aged 18+ years: results from National Serosurveillance Programme Collection Cycle 1,2022-06-03,Institutional Report,National,Cross-sectional survey ,Ireland,,,"For adult specimens sourced from the remaining seven acute-hospital clinical chemistry laboratories, residual sera from general practice with blood collection dates between 30 January and 19 February 2022 were collected.",,2022-01-30,2022-02-19,Residual sera,Male,Multiple groups,18.0,95.0,Sex/Gender,,675,0.9740000000000001,0.9570000000000001,0.986,,True,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/NSP%20combined%20adult%20paeds%20cycle%201%20report_final.pdf,2022-07-25,2024-05-03,Verified,health_seroprevalence_2022_1,IRL
220603_Ireland_HealthProtectionSurveillanceCentre_Adult_antiS_Adj_Age30to39,220603_Ireland_HealthProtectionSurveillanceCentre_Adult,Seroprevalence of antibodies to SARS-CoV-2 in children aged 1-12 years and adults aged 18+ years: results from National Serosurveillance Programme Collection Cycle 1,2022-06-03,Institutional Report,National,Cross-sectional survey ,Ireland,,,"For adult specimens sourced from the remaining seven acute-hospital clinical chemistry laboratories, residual sera from general practice with blood collection dates between 30 January and 19 February 2022 were collected.",,2022-01-30,2022-02-19,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,"anti-S, age: 30-39",286,0.9550000000000001,0.922,0.9770000000000001,,True,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/NSP%20combined%20adult%20paeds%20cycle%201%20report_final.pdf,2022-07-25,2024-05-03,Verified,health_seroprevalence_2022_1,IRL
220603_Ireland_HealthProtectionSurveillanceCentre_Adult_antiS-N_Adj_Age18to29,220603_Ireland_HealthProtectionSurveillanceCentre_Adult,Seroprevalence of antibodies to SARS-CoV-2 in children aged 1-12 years and adults aged 18+ years: results from National Serosurveillance Programme Collection Cycle 1,2022-06-03,Institutional Report,National,Cross-sectional survey ,Ireland,,,"For adult specimens sourced from the remaining seven acute-hospital clinical chemistry laboratories, residual sera from general practice with blood collection dates between 30 January and 19 February 2022 were collected.",,2022-01-30,2022-02-19,Residual sera,All,Adults (18-64 years),18.0,29.0,Age,"anti-S and N, age: 18-29",242,0.51,0.44700000000000006,0.573,,True,,,,Convenience,"SARS-CoV-2 IgG II Quant ,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/NSP%20combined%20adult%20paeds%20cycle%201%20report_final.pdf,2022-07-25,2024-05-03,Verified,health_seroprevalence_2022_1,IRL
220603_Ireland_HealthProtectionSurveillanceCentre_Adult_antiS_Adj_Age50to59,220603_Ireland_HealthProtectionSurveillanceCentre_Adult,Seroprevalence of antibodies to SARS-CoV-2 in children aged 1-12 years and adults aged 18+ years: results from National Serosurveillance Programme Collection Cycle 1,2022-06-03,Institutional Report,National,Cross-sectional survey ,Ireland,,,"For adult specimens sourced from the remaining seven acute-hospital clinical chemistry laboratories, residual sera from general practice with blood collection dates between 30 January and 19 February 2022 were collected.",,2022-01-30,2022-02-19,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,"anti-S, age: 50-59",252,0.96,0.924,0.981,,True,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/NSP%20combined%20adult%20paeds%20cycle%201%20report_final.pdf,2022-07-25,2024-05-03,Verified,health_seroprevalence_2022_1,IRL
220603_Ireland_HealthProtectionSurveillanceCentre_Adult_antiS_Adj_Age18to29,220603_Ireland_HealthProtectionSurveillanceCentre_Adult,Seroprevalence of antibodies to SARS-CoV-2 in children aged 1-12 years and adults aged 18+ years: results from National Serosurveillance Programme Collection Cycle 1,2022-06-03,Institutional Report,National,Cross-sectional survey ,Ireland,,,"For adult specimens sourced from the remaining seven acute-hospital clinical chemistry laboratories, residual sera from general practice with blood collection dates between 30 January and 19 February 2022 were collected.",,2022-01-30,2022-02-19,Residual sera,All,Adults (18-64 years),18.0,29.0,Age,"anti-S, age: 18-29",242,0.9279999999999999,0.886,0.9570000000000001,,True,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/NSP%20combined%20adult%20paeds%20cycle%201%20report_final.pdf,2022-07-25,2024-05-03,Verified,health_seroprevalence_2022_1,IRL
220603_Ireland_HealthProtectionSurveillanceCentre_Adult_antiS_Adj_Age70to79,220603_Ireland_HealthProtectionSurveillanceCentre_Adult,Seroprevalence of antibodies to SARS-CoV-2 in children aged 1-12 years and adults aged 18+ years: results from National Serosurveillance Programme Collection Cycle 1,2022-06-03,Institutional Report,National,Cross-sectional survey ,Ireland,,,"For adult specimens sourced from the remaining seven acute-hospital clinical chemistry laboratories, residual sera from general practice with blood collection dates between 30 January and 19 February 2022 were collected.",,2022-01-30,2022-02-19,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,"anti-S, age: 70-79",122,1.0,0.981,1.0,,True,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/NSP%20combined%20adult%20paeds%20cycle%201%20report_final.pdf,2022-07-25,2024-05-03,Verified,health_seroprevalence_2022_1,IRL
220603_Ireland_HealthProtectionSurveillanceCentre_Adult_antiS_Adj_Age40to49,220603_Ireland_HealthProtectionSurveillanceCentre_Adult,Seroprevalence of antibodies to SARS-CoV-2 in children aged 1-12 years and adults aged 18+ years: results from National Serosurveillance Programme Collection Cycle 1,2022-06-03,Institutional Report,National,Cross-sectional survey ,Ireland,,,"For adult specimens sourced from the remaining seven acute-hospital clinical chemistry laboratories, residual sera from general practice with blood collection dates between 30 January and 19 February 2022 were collected.",,2022-01-30,2022-02-19,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,"anti-S, age: 40-49",275,0.975,0.9450000000000001,0.9920000000000001,,True,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/NSP%20combined%20adult%20paeds%20cycle%201%20report_final.pdf,2022-07-25,2024-05-03,Verified,health_seroprevalence_2022_1,IRL
220603_Ireland_HealthProtectionSurveillanceCentre_Adult_antiS_UnAdj,220603_Ireland_HealthProtectionSurveillanceCentre_Adult,Seroprevalence of antibodies to SARS-CoV-2 in children aged 1-12 years and adults aged 18+ years: results from National Serosurveillance Programme Collection Cycle 1,2022-06-03,Institutional Report,National,Cross-sectional survey ,Ireland,,,"For adult specimens sourced from the remaining seven acute-hospital clinical chemistry laboratories, residual sera from general practice with blood collection dates between 30 January and 19 February 2022 were collected.",,2022-01-30,2022-02-19,Residual sera,All,Multiple groups,18.0,95.0,Analysis,,1410,0.953,0.941,0.963,,,,,True,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/NSP%20combined%20adult%20paeds%20cycle%201%20report_final.pdf,2022-07-25,2024-05-03,Verified,health_seroprevalence_2022_1,IRL
220603_Ireland_HealthProtectionSurveillanceCentre_Adult_antiS-N_Adj_AgeOver80,220603_Ireland_HealthProtectionSurveillanceCentre_Adult,Seroprevalence of antibodies to SARS-CoV-2 in children aged 1-12 years and adults aged 18+ years: results from National Serosurveillance Programme Collection Cycle 1,2022-06-03,Institutional Report,National,Cross-sectional survey ,Ireland,,,"For adult specimens sourced from the remaining seven acute-hospital clinical chemistry laboratories, residual sera from general practice with blood collection dates between 30 January and 19 February 2022 were collected.",,2022-01-30,2022-02-19,Residual sera,All,Seniors (65+ years),80.0,95.0,Age,"anti-S and N, age: 80-95",56,0.23199999999999998,0.14,0.358,,True,,,,Convenience,"SARS-CoV-2 IgG II Quant ,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/NSP%20combined%20adult%20paeds%20cycle%201%20report_final.pdf,2022-07-25,2024-05-03,Verified,health_seroprevalence_2022_1,IRL
220603_Ireland_HealthProtectionSurveillanceCentre_Adult_antiS_Adj_AgeOver80,220603_Ireland_HealthProtectionSurveillanceCentre_Adult,Seroprevalence of antibodies to SARS-CoV-2 in children aged 1-12 years and adults aged 18+ years: results from National Serosurveillance Programme Collection Cycle 1,2022-06-03,Institutional Report,National,Cross-sectional survey ,Ireland,,,"For adult specimens sourced from the remaining seven acute-hospital clinical chemistry laboratories, residual sera from general practice with blood collection dates between 30 January and 19 February 2022 were collected.",,2022-01-30,2022-02-19,Residual sera,All,Seniors (65+ years),80.0,89.0,Age,"anti-S, age: 80-95",56,0.958,0.8640000000000001,0.993,,True,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/NSP%20combined%20adult%20paeds%20cycle%201%20report_final.pdf,2022-07-25,2024-05-03,Verified,health_seroprevalence_2022_1,IRL
220603_Ireland_HealthProtectionSurveillanceCentre_Adult_antiS-N_Adj_Age40to49,220603_Ireland_HealthProtectionSurveillanceCentre_Adult,Seroprevalence of antibodies to SARS-CoV-2 in children aged 1-12 years and adults aged 18+ years: results from National Serosurveillance Programme Collection Cycle 1,2022-06-03,Institutional Report,National,Cross-sectional survey ,Ireland,,,"For adult specimens sourced from the remaining seven acute-hospital clinical chemistry laboratories, residual sera from general practice with blood collection dates between 30 January and 19 February 2022 were collected.",,2022-01-30,2022-02-19,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,"anti-S and N, age: 40-49",275,0.32799999999999996,0.27399999999999997,0.385,,True,,,,Convenience,"SARS-CoV-2 IgG II Quant ,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/NSP%20combined%20adult%20paeds%20cycle%201%20report_final.pdf,2022-07-25,2024-05-03,Verified,health_seroprevalence_2022_1,IRL
220603_Ireland_HealthProtectionSurveillanceCentre_Adult_antiS-N_Adj_Age50to59,220603_Ireland_HealthProtectionSurveillanceCentre_Adult,Seroprevalence of antibodies to SARS-CoV-2 in children aged 1-12 years and adults aged 18+ years: results from National Serosurveillance Programme Collection Cycle 1,2022-06-03,Institutional Report,National,Cross-sectional survey ,Ireland,,,"For adult specimens sourced from the remaining seven acute-hospital clinical chemistry laboratories, residual sera from general practice with blood collection dates between 30 January and 19 February 2022 were collected.",,2022-01-30,2022-02-19,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,"anti-S and N, age: 50-59",252,0.322,0.267,0.38200000000000006,,True,,,,Convenience,"SARS-CoV-2 IgG II Quant ,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/NSP%20combined%20adult%20paeds%20cycle%201%20report_final.pdf,2022-07-25,2024-05-03,Verified,health_seroprevalence_2022_1,IRL
220603_Ireland_HealthProtectionSurveillanceCentre_Adult_antiS_Adj_Age60to69,220603_Ireland_HealthProtectionSurveillanceCentre_Adult,Seroprevalence of antibodies to SARS-CoV-2 in children aged 1-12 years and adults aged 18+ years: results from National Serosurveillance Programme Collection Cycle 1,2022-06-03,Institutional Report,National,Cross-sectional survey ,Ireland,,,"For adult specimens sourced from the remaining seven acute-hospital clinical chemistry laboratories, residual sera from general practice with blood collection dates between 30 January and 19 February 2022 were collected.",,2022-01-30,2022-02-19,Residual sera,All,Multiple groups,60.0,69.0,Age,"anti-S, age: 60-69",177,0.9890000000000001,0.9540000000000001,1.0,,True,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/NSP%20combined%20adult%20paeds%20cycle%201%20report_final.pdf,2022-07-25,2024-05-03,Verified,health_seroprevalence_2022_1,IRL
220603_Ireland_HealthProtectionSurveillanceCentre_Adult_antiS-N_Adj_Age60to69,220603_Ireland_HealthProtectionSurveillanceCentre_Adult,Seroprevalence of antibodies to SARS-CoV-2 in children aged 1-12 years and adults aged 18+ years: results from National Serosurveillance Programme Collection Cycle 1,2022-06-03,Institutional Report,National,Cross-sectional survey ,Ireland,,,"For adult specimens sourced from the remaining seven acute-hospital clinical chemistry laboratories, residual sera from general practice with blood collection dates between 30 January and 19 February 2022 were collected.",,2022-01-30,2022-02-19,Residual sera,All,Multiple groups,60.0,69.0,Age,"anti-S and N, age: 60-69",177,0.271,0.21100000000000002,0.341,,True,,,,Convenience,"SARS-CoV-2 IgG II Quant ,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/NSP%20combined%20adult%20paeds%20cycle%201%20report_final.pdf,2022-07-25,2024-05-03,Verified,health_seroprevalence_2022_1,IRL
220603_Ireland_HealthProtectionSurveillanceCentre_Adult_antiS-N_Adj_Age30to39,220603_Ireland_HealthProtectionSurveillanceCentre_Adult,Seroprevalence of antibodies to SARS-CoV-2 in children aged 1-12 years and adults aged 18+ years: results from National Serosurveillance Programme Collection Cycle 1,2022-06-03,Institutional Report,National,Cross-sectional survey ,Ireland,,,"For adult specimens sourced from the remaining seven acute-hospital clinical chemistry laboratories, residual sera from general practice with blood collection dates between 30 January and 19 February 2022 were collected.",,2022-01-30,2022-02-19,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,"anti-S and N, age: 30-39",286,0.38200000000000006,0.327,0.44,,True,,,,Convenience,"SARS-CoV-2 IgG II Quant ,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/NSP%20combined%20adult%20paeds%20cycle%201%20report_final.pdf,2022-07-25,2024-05-03,Verified,health_seroprevalence_2022_1,IRL
220603_Ireland_HealthProtectionSurveillanceCentre_Adult_antiS_Adj_Female,220603_Ireland_HealthProtectionSurveillanceCentre_Adult,Seroprevalence of antibodies to SARS-CoV-2 in children aged 1-12 years and adults aged 18+ years: results from National Serosurveillance Programme Collection Cycle 1,2022-06-03,Institutional Report,National,Cross-sectional survey ,Ireland,,,"For adult specimens sourced from the remaining seven acute-hospital clinical chemistry laboratories, residual sera from general practice with blood collection dates between 30 January and 19 February 2022 were collected.",,2022-01-30,2022-02-19,Residual sera,Female,Multiple groups,18.0,95.0,Sex/Gender,,735,0.9550000000000001,0.9359999999999999,0.9770000000000001,,True,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/NSP%20combined%20adult%20paeds%20cycle%201%20report_final.pdf,2022-07-25,2024-05-03,Verified,health_seroprevalence_2022_1,IRL
220603_Ireland_HealthProtectionSurveillanceCentre_Adult_antiS-N_Adj,220603_Ireland_HealthProtectionSurveillanceCentre_Adult,Seroprevalence of antibodies to SARS-CoV-2 in children aged 1-12 years and adults aged 18+ years: results from National Serosurveillance Programme Collection Cycle 1,2022-06-03,Institutional Report,National,Cross-sectional survey ,Ireland,,,"For adult specimens sourced from the remaining seven acute-hospital clinical chemistry laboratories, residual sera from general practice with blood collection dates between 30 January and 19 February 2022 were collected.",,2022-01-30,2022-02-19,Residual sera,All,Multiple groups,20.0,95.0,Test used,anti-S and N,1410,0.342,0.317,0.36700000000000005,,True,,,True,Convenience,"SARS-CoV-2 IgG II Quant ,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/NSP%20combined%20adult%20paeds%20cycle%201%20report_final.pdf,2022-07-25,2024-05-03,Verified,health_seroprevalence_2022_1,IRL
220603_Ireland_HealthProtectionSurveillanceCentre_Children_antiS-N_Adj_Age5to12,220603_Ireland_HealthProtectionSurveillanceCentre_Children,Seroprevalence of antibodies to SARS-CoV-2 in children aged 1-12 years and adults aged 18+ years: results from National Serosurveillance Programme Collection Cycle 1,2022-06-03,Institutional Report,Local,Cross-sectional survey ,Ireland,,Dublin,"For paediatric specimens sourced from the clinical chemistry laboratory in Children’s Health Ireland (CHI) at Temple Street, the residual sera specimens were sourced from:
• CHI at Temple Street Emergency Department, General Paediatric Medical Outpatient Clinic, and Phlebotomy Clinic
• CHI at Connolly Hospital Urgent Care Centre

Residual serum specimens were selected, aliquoted and submitted in anonymised batch format to the UCD NVRL SSU between 31 January 2022 and 18 February 2022.",,2022-01-30,2022-02-18,Residual sera,All,Children and Youth (0-17 years),5.0,12.0,Test used,"anti-S and N, age: 5-12",111,0.379,0.294,0.473,True,True,,,True,Convenience,"SARS-CoV-2 IgG II Quant ,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/NSP%20combined%20adult%20paeds%20cycle%201%20report_final.pdf,2022-07-25,2024-05-03,Unverified,health_seroprevalence_2022_1,IRL
220603_Ireland_HealthProtectionSurveillanceCentre_Children_antiS_Adj,220603_Ireland_HealthProtectionSurveillanceCentre_Children,Seroprevalence of antibodies to SARS-CoV-2 in children aged 1-12 years and adults aged 18+ years: results from National Serosurveillance Programme Collection Cycle 1,2022-06-03,Institutional Report,Local,Cross-sectional survey ,Ireland,,Dublin,"For paediatric specimens sourced from the clinical chemistry laboratory in Children’s Health Ireland (CHI) at Temple Street, the residual sera specimens were sourced from:
• CHI at Temple Street Emergency Department, General Paediatric Medical Outpatient Clinic, and Phlebotomy Clinic
• CHI at Connolly Hospital Urgent Care Centre

Residual serum specimens were selected, aliquoted and submitted in anonymised batch format to the UCD NVRL SSU between 31 January 2022 and 18 February 2022.",,2022-01-30,2022-02-18,Residual sera,All,Children and Youth (0-17 years),1.0,12.0,Primary Estimate,anti-S adjusted,170,0.384,0.313,0.46,True,True,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],,No,No,Yes,,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/NSP%20combined%20adult%20paeds%20cycle%201%20report_final.pdf,2022-07-25,2023-08-15,Unverified,health_seroprevalence_2022_1,IRL
220603_Ireland_HealthProtectionSurveillanceCentre_Children_antiS_Adj_Age1to4,220603_Ireland_HealthProtectionSurveillanceCentre_Children,Seroprevalence of antibodies to SARS-CoV-2 in children aged 1-12 years and adults aged 18+ years: results from National Serosurveillance Programme Collection Cycle 1,2022-06-03,Institutional Report,Local,Cross-sectional survey ,Ireland,,Dublin,"For paediatric specimens sourced from the clinical chemistry laboratory in Children’s Health Ireland (CHI) at Temple Street, the residual sera specimens were sourced from:
• CHI at Temple Street Emergency Department, General Paediatric Medical Outpatient Clinic, and Phlebotomy Clinic
• CHI at Connolly Hospital Urgent Care Centre

Residual serum specimens were selected, aliquoted and submitted in anonymised batch format to the UCD NVRL SSU between 31 January 2022 and 18 February 2022.",,2022-01-30,2022-02-18,Residual sera,All,Children and Youth (0-17 years),1.0,4.0,Age,"anti-S, age 1-4",59,0.28800000000000003,0.187,0.41600000000000004,True,True,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],,No,No,Yes,,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/NSP%20combined%20adult%20paeds%20cycle%201%20report_final.pdf,2022-07-25,2024-05-03,Unverified,health_seroprevalence_2022_1,IRL
220603_Ireland_HealthProtectionSurveillanceCentre_Children_antiS_Adj_Male,220603_Ireland_HealthProtectionSurveillanceCentre_Children,Seroprevalence of antibodies to SARS-CoV-2 in children aged 1-12 years and adults aged 18+ years: results from National Serosurveillance Programme Collection Cycle 1,2022-06-03,Institutional Report,Local,Cross-sectional survey ,Ireland,,Dublin,"For paediatric specimens sourced from the clinical chemistry laboratory in Children’s Health Ireland (CHI) at Temple Street, the residual sera specimens were sourced from:
• CHI at Temple Street Emergency Department, General Paediatric Medical Outpatient Clinic, and Phlebotomy Clinic
• CHI at Connolly Hospital Urgent Care Centre

Residual serum specimens were selected, aliquoted and submitted in anonymised batch format to the UCD NVRL SSU between 31 January 2022 and 18 February 2022.",,2022-01-30,2022-02-18,Residual sera,Male,Children and Youth (0-17 years),1.0,12.0,Sex/Gender,,86,0.36200000000000004,0.267,0.469,True,True,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],,No,No,Yes,,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/NSP%20combined%20adult%20paeds%20cycle%201%20report_final.pdf,2022-07-25,2024-05-03,Unverified,health_seroprevalence_2022_1,IRL
220603_Ireland_HealthProtectionSurveillanceCentre_Children_antiS_UnAdj,220603_Ireland_HealthProtectionSurveillanceCentre_Children,Seroprevalence of antibodies to SARS-CoV-2 in children aged 1-12 years and adults aged 18+ years: results from National Serosurveillance Programme Collection Cycle 1,2022-06-03,Institutional Report,Local,Cross-sectional survey ,Ireland,,Dublin,"For paediatric specimens sourced from the clinical chemistry laboratory in Children’s Health Ireland (CHI) at Temple Street, the residual sera specimens were sourced from:
• CHI at Temple Street Emergency Department, General Paediatric Medical Outpatient Clinic, and Phlebotomy Clinic
• CHI at Connolly Hospital Urgent Care Centre

Residual serum specimens were selected, aliquoted and submitted in anonymised batch format to the UCD NVRL SSU between 31 January 2022 and 18 February 2022.",,2022-01-30,2022-02-18,Residual sera,All,Children and Youth (0-17 years),1.0,12.0,Analysis,anti-S unadjusted,170,0.38200000000000006,0.313,0.457,True,,,,True,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],,No,No,Yes,,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/NSP%20combined%20adult%20paeds%20cycle%201%20report_final.pdf,2022-07-25,2024-05-03,Unverified,health_seroprevalence_2022_1,IRL
220603_Ireland_HealthProtectionSurveillanceCentre_Children_antiS_Adj_Female,220603_Ireland_HealthProtectionSurveillanceCentre_Children,Seroprevalence of antibodies to SARS-CoV-2 in children aged 1-12 years and adults aged 18+ years: results from National Serosurveillance Programme Collection Cycle 1,2022-06-03,Institutional Report,Local,Cross-sectional survey ,Ireland,,Dublin,"For paediatric specimens sourced from the clinical chemistry laboratory in Children’s Health Ireland (CHI) at Temple Street, the residual sera specimens were sourced from:
• CHI at Temple Street Emergency Department, General Paediatric Medical Outpatient Clinic, and Phlebotomy Clinic
• CHI at Connolly Hospital Urgent Care Centre

Residual serum specimens were selected, aliquoted and submitted in anonymised batch format to the UCD NVRL SSU between 31 January 2022 and 18 February 2022.",,2022-01-30,2022-02-18,Residual sera,Female,Children and Youth (0-17 years),1.0,12.0,Sex/Gender,,84,0.40700000000000003,0.307,0.516,True,True,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],,No,No,Yes,,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/NSP%20combined%20adult%20paeds%20cycle%201%20report_final.pdf,2022-07-25,2024-05-03,Unverified,health_seroprevalence_2022_1,IRL
220603_Ireland_HealthProtectionSurveillanceCentre_Children_antiS_Adj_Age5to12,220603_Ireland_HealthProtectionSurveillanceCentre_Children,Seroprevalence of antibodies to SARS-CoV-2 in children aged 1-12 years and adults aged 18+ years: results from National Serosurveillance Programme Collection Cycle 1,2022-06-03,Institutional Report,Local,Cross-sectional survey ,Ireland,,Dublin,"For paediatric specimens sourced from the clinical chemistry laboratory in Children’s Health Ireland (CHI) at Temple Street, the residual sera specimens were sourced from:
• CHI at Temple Street Emergency Department, General Paediatric Medical Outpatient Clinic, and Phlebotomy Clinic
• CHI at Connolly Hospital Urgent Care Centre

Residual serum specimens were selected, aliquoted and submitted in anonymised batch format to the UCD NVRL SSU between 31 January 2022 and 18 February 2022.",,2022-01-30,2022-02-18,Residual sera,All,Children and Youth (0-17 years),5.0,12.0,Age,"anti-S, age 5-12",111,0.435,0.34500000000000003,0.53,True,True,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],,No,No,Yes,,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/NSP%20combined%20adult%20paeds%20cycle%201%20report_final.pdf,2022-07-25,2024-05-03,Unverified,health_seroprevalence_2022_1,IRL
221004_Ireland_HealthProtectionSurveillanceCentre_2022Jan_TestAdj_Overall,221004_Ireland_HealthProtectionSurveillanceCentre_2022Jan,Seroprevalence of SARS-CoV-2 antibodies in children,2022-10-04,Institutional Report,National,Repeated cross-sectional study,Ireland,,,"""This report provides information on SARS-CoV-2 seroprevalence in children aged up to 17 years.""

""Residual sera specimens are blood samples that were originally collected for clinical testing and are now due to be discarded.""

""Paediatric specimens are mainly sourced from Children’s Health Ireland (CHI) at Temple Street, with six samples (from children aged 17) sourced from adult hospitals; Cork University Hospital, Letterkenny University Hospital, St. Vincent’s University Hospital and Tallaght University Hospital.""

""CHI at Connolly Hospital Urgent Care Centre Blood specimens are only regarded as residual 28 days following completion of the tests ordered.""","""Six sample from Tallaght University Hospital were omitted from analysis as they were collected in February and did not align with the collection dates for paediatric specimens.""",2021-12-20,2022-01-20,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,Test-adjusted,170,0.384,0.313,0.46,True,True,,,,Unclear,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],No,Unclear,No,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/LSN_paediatric_SCreport.html,2022-10-06,2024-04-16,Verified,health_protection_surveillance_centre_seroprevalence_2022,IRL
221004_Ireland_HealthProtectionSurveillanceCentre_2022Jan_UnAdj_SexFemale,221004_Ireland_HealthProtectionSurveillanceCentre_2022Jan,Seroprevalence of SARS-CoV-2 antibodies in children,2022-10-04,Institutional Report,National,Repeated cross-sectional study,Ireland,,,"""This report provides information on SARS-CoV-2 seroprevalence in children aged up to 17 years.""

""Residual sera specimens are blood samples that were originally collected for clinical testing and are now due to be discarded.""

""Paediatric specimens are mainly sourced from Children’s Health Ireland (CHI) at Temple Street, with six samples (from children aged 17) sourced from adult hospitals; Cork University Hospital, Letterkenny University Hospital, St. Vincent’s University Hospital and Tallaght University Hospital.""

""CHI at Connolly Hospital Urgent Care Centre Blood specimens are only regarded as residual 28 days following completion of the tests ordered.""","""Six sample from Tallaght University Hospital were omitted from analysis as they were collected in February and did not align with the collection dates for paediatric specimens.""",2021-12-20,2022-01-20,Residual sera,Female,Children and Youth (0-17 years),0.0,17.0,Sex/Gender,,84,0.4048,,,,,,,,Unclear,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],No,Unclear,No,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/LSN_paediatric_SCreport.html,2022-10-08,2024-04-16,Verified,health_protection_surveillance_centre_seroprevalence_2022,IRL
221004_Ireland_HealthProtectionSurveillanceCentre_2022Jan_UnAdj_Overall,221004_Ireland_HealthProtectionSurveillanceCentre_2022Jan,Seroprevalence of SARS-CoV-2 antibodies in children,2022-10-04,Institutional Report,National,Repeated cross-sectional study,Ireland,,,"""This report provides information on SARS-CoV-2 seroprevalence in children aged up to 17 years.""

""Residual sera specimens are blood samples that were originally collected for clinical testing and are now due to be discarded.""

""Paediatric specimens are mainly sourced from Children’s Health Ireland (CHI) at Temple Street, with six samples (from children aged 17) sourced from adult hospitals; Cork University Hospital, Letterkenny University Hospital, St. Vincent’s University Hospital and Tallaght University Hospital.""

""CHI at Connolly Hospital Urgent Care Centre Blood specimens are only regarded as residual 28 days following completion of the tests ordered.""","""Six sample from Tallaght University Hospital were omitted from analysis as they were collected in February and did not align with the collection dates for paediatric specimens.""",2021-12-20,2022-01-20,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Analysis,Unadjusted,170,0.3824,,,,,,,True,Unclear,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],No,Unclear,No,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/LSN_paediatric_SCreport.html,2022-10-08,2024-04-16,Verified,health_protection_surveillance_centre_seroprevalence_2022,IRL
221004_Ireland_HealthProtectionSurveillanceCentre_2022Jan_UnAdj_Age5-12,221004_Ireland_HealthProtectionSurveillanceCentre_2022Jan,Seroprevalence of SARS-CoV-2 antibodies in children,2022-10-04,Institutional Report,National,Repeated cross-sectional study,Ireland,,,"""This report provides information on SARS-CoV-2 seroprevalence in children aged up to 17 years.""

""Residual sera specimens are blood samples that were originally collected for clinical testing and are now due to be discarded.""

""Paediatric specimens are mainly sourced from Children’s Health Ireland (CHI) at Temple Street, with six samples (from children aged 17) sourced from adult hospitals; Cork University Hospital, Letterkenny University Hospital, St. Vincent’s University Hospital and Tallaght University Hospital.""

""CHI at Connolly Hospital Urgent Care Centre Blood specimens are only regarded as residual 28 days following completion of the tests ordered.""","""Six sample from Tallaght University Hospital were omitted from analysis as they were collected in February and did not align with the collection dates for paediatric specimens.""",2021-12-20,2022-01-20,Residual sera,All,Children and Youth (0-17 years),5.0,12.0,Age,,97,0.4536,,,,,,,,Unclear,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],No,Unclear,No,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/LSN_paediatric_SCreport.html,2022-10-08,2024-04-16,Verified,health_protection_surveillance_centre_seroprevalence_2022,IRL
221004_Ireland_HealthProtectionSurveillanceCentre_2022Jan_UnAdj_SexMale,221004_Ireland_HealthProtectionSurveillanceCentre_2022Jan,Seroprevalence of SARS-CoV-2 antibodies in children,2022-10-04,Institutional Report,National,Repeated cross-sectional study,Ireland,,,"""This report provides information on SARS-CoV-2 seroprevalence in children aged up to 17 years.""

""Residual sera specimens are blood samples that were originally collected for clinical testing and are now due to be discarded.""

""Paediatric specimens are mainly sourced from Children’s Health Ireland (CHI) at Temple Street, with six samples (from children aged 17) sourced from adult hospitals; Cork University Hospital, Letterkenny University Hospital, St. Vincent’s University Hospital and Tallaght University Hospital.""

""CHI at Connolly Hospital Urgent Care Centre Blood specimens are only regarded as residual 28 days following completion of the tests ordered.""","""Six sample from Tallaght University Hospital were omitted from analysis as they were collected in February and did not align with the collection dates for paediatric specimens.""",2021-12-20,2022-01-20,Residual sera,Male,Children and Youth (0-17 years),0.0,17.0,Sex/Gender,,86,0.3605,,,,,,,,Unclear,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],No,Unclear,No,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/LSN_paediatric_SCreport.html,2022-10-08,2024-04-16,Verified,health_protection_surveillance_centre_seroprevalence_2022,IRL
221004_Ireland_HealthProtectionSurveillanceCentre_2022Jan_UnAdj_Age0-4,221004_Ireland_HealthProtectionSurveillanceCentre_2022Jan,Seroprevalence of SARS-CoV-2 antibodies in children,2022-10-04,Institutional Report,National,Repeated cross-sectional study,Ireland,,,"""This report provides information on SARS-CoV-2 seroprevalence in children aged up to 17 years.""

""Residual sera specimens are blood samples that were originally collected for clinical testing and are now due to be discarded.""

""Paediatric specimens are mainly sourced from Children’s Health Ireland (CHI) at Temple Street, with six samples (from children aged 17) sourced from adult hospitals; Cork University Hospital, Letterkenny University Hospital, St. Vincent’s University Hospital and Tallaght University Hospital.""

""CHI at Connolly Hospital Urgent Care Centre Blood specimens are only regarded as residual 28 days following completion of the tests ordered.""","""Six sample from Tallaght University Hospital were omitted from analysis as they were collected in February and did not align with the collection dates for paediatric specimens.""",2021-12-20,2022-01-20,Residual sera,All,Children and Youth (0-17 years),0.0,4.0,Age,,73,0.2877,,,,,,,,Unclear,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],No,Unclear,No,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/LSN_paediatric_SCreport.html,2022-10-08,2024-04-16,Verified,health_protection_surveillance_centre_seroprevalence_2022,IRL
221004_Ireland_HealthProtectionSurveillanceCentre_2022Jul_TestAdj_Overall,221004_Ireland_HealthProtectionSurveillanceCentre_2022Jul,Seroprevalence of SARS-CoV-2 antibodies in children,2022-10-04,Institutional Report,National,Repeated cross-sectional study,Ireland,,,"""This report provides information on SARS-CoV-2 seroprevalence in children aged up to 17 years.""

""Residual sera specimens are blood samples that were originally collected for clinical testing and are now due to be discarded.""

""Paediatric specimens are mainly sourced from Children’s Health Ireland (CHI) at Temple Street, with six samples (from children aged 17) sourced from adult hospitals; Cork University Hospital, Letterkenny University Hospital, St. Vincent’s University Hospital and Tallaght University Hospital.""

""CHI at Connolly Hospital Urgent Care Centre Blood specimens are only regarded as residual 28 days following completion of the tests ordered.""","""Six sample from Tallaght University Hospital were omitted from analysis as they were collected in February and did not align with the collection dates for paediatric specimens.""",2022-07-04,2022-07-16,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,Test-adjusted,72,0.8570000000000001,0.755,0.923,True,True,,,,Unclear,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],No,Unclear,No,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/LSN_paediatric_SCreport.html,2022-10-08,2024-04-16,Verified,health_protection_surveillance_centre_seroprevalence_2022,IRL
221004_Ireland_HealthProtectionSurveillanceCentre_2022Jul_UnAdj_Overall,221004_Ireland_HealthProtectionSurveillanceCentre_2022Jul,Seroprevalence of SARS-CoV-2 antibodies in children,2022-10-04,Institutional Report,National,Repeated cross-sectional study,Ireland,,,"""This report provides information on SARS-CoV-2 seroprevalence in children aged up to 17 years.""

""Residual sera specimens are blood samples that were originally collected for clinical testing and are now due to be discarded.""

""Paediatric specimens are mainly sourced from Children’s Health Ireland (CHI) at Temple Street, with six samples (from children aged 17) sourced from adult hospitals; Cork University Hospital, Letterkenny University Hospital, St. Vincent’s University Hospital and Tallaght University Hospital.""

""CHI at Connolly Hospital Urgent Care Centre Blood specimens are only regarded as residual 28 days following completion of the tests ordered.""","""Six sample from Tallaght University Hospital were omitted from analysis as they were collected in February and did not align with the collection dates for paediatric specimens.""",2022-07-04,2022-07-16,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Analysis,Unadjusted,72,0.8472,,,,,,,True,Unclear,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],No,Unclear,No,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/LSN_paediatric_SCreport.html,2022-10-08,2024-04-16,Verified,health_protection_surveillance_centre_seroprevalence_2022,IRL
221004_Ireland_HealthProtectionSurveillanceCentre_2022Jul_UnAdj_SexFemale,221004_Ireland_HealthProtectionSurveillanceCentre_2022Jul,Seroprevalence of SARS-CoV-2 antibodies in children,2022-10-04,Institutional Report,National,Repeated cross-sectional study,Ireland,,,"""This report provides information on SARS-CoV-2 seroprevalence in children aged up to 17 years.""

""Residual sera specimens are blood samples that were originally collected for clinical testing and are now due to be discarded.""

""Paediatric specimens are mainly sourced from Children’s Health Ireland (CHI) at Temple Street, with six samples (from children aged 17) sourced from adult hospitals; Cork University Hospital, Letterkenny University Hospital, St. Vincent’s University Hospital and Tallaght University Hospital.""

""CHI at Connolly Hospital Urgent Care Centre Blood specimens are only regarded as residual 28 days following completion of the tests ordered.""","""Six sample from Tallaght University Hospital were omitted from analysis as they were collected in February and did not align with the collection dates for paediatric specimens.""",2022-07-04,2022-07-16,Residual sera,Female,Children and Youth (0-17 years),0.0,17.0,Sex/Gender,,34,0.9118,,,,,,,,Unclear,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],No,Unclear,No,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/LSN_paediatric_SCreport.html,2022-10-08,2024-04-16,Verified,health_protection_surveillance_centre_seroprevalence_2022,IRL
221004_Ireland_HealthProtectionSurveillanceCentre_2022Jul_UnAdj_SexMale,221004_Ireland_HealthProtectionSurveillanceCentre_2022Jul,Seroprevalence of SARS-CoV-2 antibodies in children,2022-10-04,Institutional Report,National,Repeated cross-sectional study,Ireland,,,"""This report provides information on SARS-CoV-2 seroprevalence in children aged up to 17 years.""

""Residual sera specimens are blood samples that were originally collected for clinical testing and are now due to be discarded.""

""Paediatric specimens are mainly sourced from Children’s Health Ireland (CHI) at Temple Street, with six samples (from children aged 17) sourced from adult hospitals; Cork University Hospital, Letterkenny University Hospital, St. Vincent’s University Hospital and Tallaght University Hospital.""

""CHI at Connolly Hospital Urgent Care Centre Blood specimens are only regarded as residual 28 days following completion of the tests ordered.""","""Six sample from Tallaght University Hospital were omitted from analysis as they were collected in February and did not align with the collection dates for paediatric specimens.""",2022-07-04,2022-07-16,Residual sera,Male,Children and Youth (0-17 years),0.0,17.0,Sex/Gender,,38,0.7895000000000001,,,,,,,,Unclear,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],No,Unclear,No,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/LSN_paediatric_SCreport.html,2022-10-08,2024-04-16,Verified,health_protection_surveillance_centre_seroprevalence_2022,IRL
221004_Ireland_HealthProtectionSurveillanceCentre_2022Jul_UnAdj_Age5-12,221004_Ireland_HealthProtectionSurveillanceCentre_2022Jul,Seroprevalence of SARS-CoV-2 antibodies in children,2022-10-04,Institutional Report,National,Repeated cross-sectional study,Ireland,,,"""This report provides information on SARS-CoV-2 seroprevalence in children aged up to 17 years.""

""Residual sera specimens are blood samples that were originally collected for clinical testing and are now due to be discarded.""

""Paediatric specimens are mainly sourced from Children’s Health Ireland (CHI) at Temple Street, with six samples (from children aged 17) sourced from adult hospitals; Cork University Hospital, Letterkenny University Hospital, St. Vincent’s University Hospital and Tallaght University Hospital.""

""CHI at Connolly Hospital Urgent Care Centre Blood specimens are only regarded as residual 28 days following completion of the tests ordered.""","""Six sample from Tallaght University Hospital were omitted from analysis as they were collected in February and did not align with the collection dates for paediatric specimens.""",2022-07-04,2022-07-16,Residual sera,All,Children and Youth (0-17 years),5.0,12.0,Age,,32,0.9063,,,,,,,,Unclear,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],No,Unclear,No,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/LSN_paediatric_SCreport.html,2022-10-08,2024-04-16,Verified,health_protection_surveillance_centre_seroprevalence_2022,IRL
221004_Ireland_HealthProtectionSurveillanceCentre_2022Jul_UnAdj_Age13-17,221004_Ireland_HealthProtectionSurveillanceCentre_2022Jul,Seroprevalence of SARS-CoV-2 antibodies in children,2022-10-04,Institutional Report,National,Repeated cross-sectional study,Ireland,,,"""This report provides information on SARS-CoV-2 seroprevalence in children aged up to 17 years.""

""Residual sera specimens are blood samples that were originally collected for clinical testing and are now due to be discarded.""

""Paediatric specimens are mainly sourced from Children’s Health Ireland (CHI) at Temple Street, with six samples (from children aged 17) sourced from adult hospitals; Cork University Hospital, Letterkenny University Hospital, St. Vincent’s University Hospital and Tallaght University Hospital.""

""CHI at Connolly Hospital Urgent Care Centre Blood specimens are only regarded as residual 28 days following completion of the tests ordered.""","""Six sample from Tallaght University Hospital were omitted from analysis as they were collected in February and did not align with the collection dates for paediatric specimens.""",2022-07-04,2022-07-16,Residual sera,All,Children and Youth (0-17 years),13.0,17.0,Age,,22,0.9545,,,,,,,,Unclear,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],No,Unclear,No,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/LSN_paediatric_SCreport.html,2022-10-08,2024-04-16,Verified,health_protection_surveillance_centre_seroprevalence_2022,IRL
221004_Ireland_HealthProtectionSurveillanceCentre_2022Jul_UnAdj_Age0-4,221004_Ireland_HealthProtectionSurveillanceCentre_2022Jul,Seroprevalence of SARS-CoV-2 antibodies in children,2022-10-04,Institutional Report,National,Repeated cross-sectional study,Ireland,,,"""This report provides information on SARS-CoV-2 seroprevalence in children aged up to 17 years.""

""Residual sera specimens are blood samples that were originally collected for clinical testing and are now due to be discarded.""

""Paediatric specimens are mainly sourced from Children’s Health Ireland (CHI) at Temple Street, with six samples (from children aged 17) sourced from adult hospitals; Cork University Hospital, Letterkenny University Hospital, St. Vincent’s University Hospital and Tallaght University Hospital.""

""CHI at Connolly Hospital Urgent Care Centre Blood specimens are only regarded as residual 28 days following completion of the tests ordered.""","""Six sample from Tallaght University Hospital were omitted from analysis as they were collected in February and did not align with the collection dates for paediatric specimens.""",2022-07-04,2022-07-16,Residual sera,All,Children and Youth (0-17 years),0.0,4.0,Age,,18,0.6111,,,,,,,,Unclear,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],No,Unclear,No,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/LSN_paediatric_SCreport.html,2022-10-08,2024-04-16,Verified,health_protection_surveillance_centre_seroprevalence_2022,IRL
221004_Ireland_HealthProtectionSurveillanceCentre_2022Jun_TestAdj_Overall,221004_Ireland_HealthProtectionSurveillanceCentre_2022Jun,Seroprevalence of SARS-CoV-2 antibodies in children,2022-10-04,Institutional Report,National,Repeated cross-sectional study,Ireland,,,"""This report provides information on SARS-CoV-2 seroprevalence in children aged up to 17 years.""

""Residual sera specimens are blood samples that were originally collected for clinical testing and are now due to be discarded.""

""Paediatric specimens are mainly sourced from Children’s Health Ireland (CHI) at Temple Street, with six samples (from children aged 17) sourced from adult hospitals; Cork University Hospital, Letterkenny University Hospital, St. Vincent’s University Hospital and Tallaght University Hospital.""

""CHI at Connolly Hospital Urgent Care Centre Blood specimens are only regarded as residual 28 days following completion of the tests ordered.""","""Six sample from Tallaght University Hospital were omitted from analysis as they were collected in February and did not align with the collection dates for paediatric specimens.""",2022-05-30,2022-06-10,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,Test-adjusted,207,0.8250000000000001,0.766,0.873,True,True,,,,Unclear,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],No,Unclear,No,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/LSN_paediatric_SCreport.html,2022-10-08,2024-04-16,Verified,health_protection_surveillance_centre_seroprevalence_2022,IRL
221004_Ireland_HealthProtectionSurveillanceCentre_2022Jun_UnAdj_SexMale,221004_Ireland_HealthProtectionSurveillanceCentre_2022Jun,Seroprevalence of SARS-CoV-2 antibodies in children,2022-10-04,Institutional Report,National,Repeated cross-sectional study,Ireland,,,"""This report provides information on SARS-CoV-2 seroprevalence in children aged up to 17 years.""

""Residual sera specimens are blood samples that were originally collected for clinical testing and are now due to be discarded.""

""Paediatric specimens are mainly sourced from Children’s Health Ireland (CHI) at Temple Street, with six samples (from children aged 17) sourced from adult hospitals; Cork University Hospital, Letterkenny University Hospital, St. Vincent’s University Hospital and Tallaght University Hospital.""

""CHI at Connolly Hospital Urgent Care Centre Blood specimens are only regarded as residual 28 days following completion of the tests ordered.""","""Six sample from Tallaght University Hospital were omitted from analysis as they were collected in February and did not align with the collection dates for paediatric specimens.""",2022-05-30,2022-06-10,Residual sera,Male,Children and Youth (0-17 years),0.0,17.0,Sex/Gender,,103,0.8155,,,,,,,,Unclear,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],No,Unclear,No,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/LSN_paediatric_SCreport.html,2022-10-08,2024-04-16,Verified,health_protection_surveillance_centre_seroprevalence_2022,IRL
221004_Ireland_HealthProtectionSurveillanceCentre_2022Jun_UnAdj_Age13-17,221004_Ireland_HealthProtectionSurveillanceCentre_2022Jun,Seroprevalence of SARS-CoV-2 antibodies in children,2022-10-04,Institutional Report,National,Repeated cross-sectional study,Ireland,,,"""This report provides information on SARS-CoV-2 seroprevalence in children aged up to 17 years.""

""Residual sera specimens are blood samples that were originally collected for clinical testing and are now due to be discarded.""

""Paediatric specimens are mainly sourced from Children’s Health Ireland (CHI) at Temple Street, with six samples (from children aged 17) sourced from adult hospitals; Cork University Hospital, Letterkenny University Hospital, St. Vincent’s University Hospital and Tallaght University Hospital.""

""CHI at Connolly Hospital Urgent Care Centre Blood specimens are only regarded as residual 28 days following completion of the tests ordered.""","""Six sample from Tallaght University Hospital were omitted from analysis as they were collected in February and did not align with the collection dates for paediatric specimens.""",2022-05-30,2022-06-10,Residual sera,All,Children and Youth (0-17 years),13.0,17.0,Age,,32,0.9063,,,,,,,,Unclear,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],No,Unclear,No,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/LSN_paediatric_SCreport.html,2022-10-08,2024-04-16,Verified,health_protection_surveillance_centre_seroprevalence_2022,IRL
221004_Ireland_HealthProtectionSurveillanceCentre_2022Jun_UnAdj_Age5-12,221004_Ireland_HealthProtectionSurveillanceCentre_2022Jun,Seroprevalence of SARS-CoV-2 antibodies in children,2022-10-04,Institutional Report,National,Repeated cross-sectional study,Ireland,,,"""This report provides information on SARS-CoV-2 seroprevalence in children aged up to 17 years.""

""Residual sera specimens are blood samples that were originally collected for clinical testing and are now due to be discarded.""

""Paediatric specimens are mainly sourced from Children’s Health Ireland (CHI) at Temple Street, with six samples (from children aged 17) sourced from adult hospitals; Cork University Hospital, Letterkenny University Hospital, St. Vincent’s University Hospital and Tallaght University Hospital.""

""CHI at Connolly Hospital Urgent Care Centre Blood specimens are only regarded as residual 28 days following completion of the tests ordered.""","""Six sample from Tallaght University Hospital were omitted from analysis as they were collected in February and did not align with the collection dates for paediatric specimens.""",2022-05-30,2022-06-10,Residual sera,All,Children and Youth (0-17 years),5.0,12.0,Age,,95,0.8632,,,,,,,,Unclear,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],No,Unclear,No,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/LSN_paediatric_SCreport.html,2022-10-08,2024-04-16,Verified,health_protection_surveillance_centre_seroprevalence_2022,IRL
221004_Ireland_HealthProtectionSurveillanceCentre_2022Jun_UnAdj_Overall,221004_Ireland_HealthProtectionSurveillanceCentre_2022Jun,Seroprevalence of SARS-CoV-2 antibodies in children,2022-10-04,Institutional Report,National,Repeated cross-sectional study,Ireland,,,"""This report provides information on SARS-CoV-2 seroprevalence in children aged up to 17 years.""

""Residual sera specimens are blood samples that were originally collected for clinical testing and are now due to be discarded.""

""Paediatric specimens are mainly sourced from Children’s Health Ireland (CHI) at Temple Street, with six samples (from children aged 17) sourced from adult hospitals; Cork University Hospital, Letterkenny University Hospital, St. Vincent’s University Hospital and Tallaght University Hospital.""

""CHI at Connolly Hospital Urgent Care Centre Blood specimens are only regarded as residual 28 days following completion of the tests ordered.""","""Six sample from Tallaght University Hospital were omitted from analysis as they were collected in February and did not align with the collection dates for paediatric specimens.""",2022-05-30,2022-06-10,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Analysis,Unadjusted,207,0.8164,,,,,,,True,Unclear,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],No,Unclear,No,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/LSN_paediatric_SCreport.html,2022-10-08,2024-04-16,Verified,health_protection_surveillance_centre_seroprevalence_2022,IRL
221004_Ireland_HealthProtectionSurveillanceCentre_2022Jun_UnAdj_SexFemale,221004_Ireland_HealthProtectionSurveillanceCentre_2022Jun,Seroprevalence of SARS-CoV-2 antibodies in children,2022-10-04,Institutional Report,National,Repeated cross-sectional study,Ireland,,,"""This report provides information on SARS-CoV-2 seroprevalence in children aged up to 17 years.""

""Residual sera specimens are blood samples that were originally collected for clinical testing and are now due to be discarded.""

""Paediatric specimens are mainly sourced from Children’s Health Ireland (CHI) at Temple Street, with six samples (from children aged 17) sourced from adult hospitals; Cork University Hospital, Letterkenny University Hospital, St. Vincent’s University Hospital and Tallaght University Hospital.""

""CHI at Connolly Hospital Urgent Care Centre Blood specimens are only regarded as residual 28 days following completion of the tests ordered.""","""Six sample from Tallaght University Hospital were omitted from analysis as they were collected in February and did not align with the collection dates for paediatric specimens.""",2022-05-30,2022-06-10,Residual sera,Female,Children and Youth (0-17 years),0.0,17.0,Sex/Gender,,104,0.8173,,,,,,,,Unclear,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],No,Unclear,No,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/LSN_paediatric_SCreport.html,2022-10-08,2024-04-16,Verified,health_protection_surveillance_centre_seroprevalence_2022,IRL
221004_Ireland_HealthProtectionSurveillanceCentre_2022Jun_UnAdj_Age0-4,221004_Ireland_HealthProtectionSurveillanceCentre_2022Jun,Seroprevalence of SARS-CoV-2 antibodies in children,2022-10-04,Institutional Report,National,Repeated cross-sectional study,Ireland,,,"""This report provides information on SARS-CoV-2 seroprevalence in children aged up to 17 years.""

""Residual sera specimens are blood samples that were originally collected for clinical testing and are now due to be discarded.""

""Paediatric specimens are mainly sourced from Children’s Health Ireland (CHI) at Temple Street, with six samples (from children aged 17) sourced from adult hospitals; Cork University Hospital, Letterkenny University Hospital, St. Vincent’s University Hospital and Tallaght University Hospital.""

""CHI at Connolly Hospital Urgent Care Centre Blood specimens are only regarded as residual 28 days following completion of the tests ordered.""","""Six sample from Tallaght University Hospital were omitted from analysis as they were collected in February and did not align with the collection dates for paediatric specimens.""",2022-05-30,2022-06-10,Residual sera,All,Children and Youth (0-17 years),0.0,4.0,Age,,80,0.725,,,,,,,,Unclear,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9875,0.9954999999999999,['High'],No,Unclear,No,Yes,Yes,Yes,Yes,Yes,,Health Protection Surveillance Centre,Health Protection Surveillance Centre,Unity-Aligned,https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/reports/LSN_paediatric_SCreport.html,2022-10-08,2024-04-16,Verified,health_protection_surveillance_centre_seroprevalence_2022,IRL
230126_Ireland_StJamesHospital_Primary,230126_Ireland_StJamesHospital,"SARS-CoV-2 epidemiology, antibody dynamics, and neutralisation capacity in Irish healthcare workers in the era of booster COVID-19 vaccinations.",2023-01-26,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Ireland,,Dublin city and Galway city,"""All HCWs who participated in the previous PRECISE study phase in April 2021 were invited to participate. Enrolment in this group was offered regardless of vaccination history or intent to receive further COVID-19 vaccine doses.""","""Seventy-one participants were excluded due to having already received a booster vaccination at time of sampling"".",2021-11-10,2021-11-23,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,2344,0.234,0.217,0.251,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,"CLIA, CMIA,CLIA, CMIA",Serum,"IgG, IgM, IgA","['Nucleocapsid (N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Yes,Yes,No,,Jonathan McGrath,St. James’s Hospital,Not Unity-Aligned,https://dx.doi.org/10.3389/fmed.2023.1078022,2023-03-03,2024-03-01,Unverified,mcgrath_sars-cov-2_2023,IRL
230424_Ireland_NationalBloodCentre_wave1_overall_adj,230424_Ireland_NationalBloodCentre_wave1,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"""A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised according to the time period at which they were collected. ... Samples collected from February to September 2020 represent Wave 1 of the pandemic (n = 8509)... """,,2020-02-15,2020-09-15,Blood donors,All,Adults (18-64 years),18.0,,Primary Estimate,,8509,0.0248,0.0216,0.0284,True,,True,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.988,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2023-06-01,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave1_overall_unadj,230424_Ireland_NationalBloodCentre_wave1,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"""A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised according to the time period at which they were collected. ... Samples collected from February to September 2020 represent Wave 1 of the pandemic (n = 8509)... """,,2020-02-15,2020-09-15,Blood donors,All,Adults (18-64 years),18.0,,Analysis,,8509,0.022,0.0189,0.0254,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.988,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2023-06-01,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave1_Connacht_unadj,230424_Ireland_NationalBloodCentre_wave1,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,Connacht,,"""A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised according to the time period at which they were collected. ... Samples collected from February to September 2020 represent Wave 1 of the pandemic (n = 8509)... """,,2020-02-15,2020-09-15,Blood donors,All,Adults (18-64 years),18.0,,Geographical area,,649,0.0077,0.0025,0.018,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.988,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2023-06-01,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave1_Ulster_adj,230424_Ireland_NationalBloodCentre_wave1,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,Ulster,,"""A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised according to the time period at which they were collected. ... Samples collected from February to September 2020 represent Wave 1 of the pandemic (n = 8509)... """,,2020-02-15,2020-09-15,Blood donors,All,Adults (18-64 years),18.0,,Geographical area,,648,0.0108,0.0043,0.0222,,,True,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.988,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2023-06-01,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave1_Ulster_unadj,230424_Ireland_NationalBloodCentre_wave1,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,Ulster,,"""A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised according to the time period at which they were collected. ... Samples collected from February to September 2020 represent Wave 1 of the pandemic (n = 8509)... """,,2020-02-15,2020-09-15,Blood donors,All,Adults (18-64 years),18.0,,Geographical area,,648,0.0139,0.0063,0.0263,,,True,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.988,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2023-06-01,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave1_Age60+,230424_Ireland_NationalBloodCentre_wave1,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"""A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised according to the time period at which they were collected. ... Samples collected from February to September 2020 represent Wave 1 of the pandemic (n = 8509)... """,,2020-02-15,2020-09-15,Blood donors,All,Seniors (65+ years),60.0,,Age,,1200,0.0158,0.0095,0.0247,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.988,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2024-04-29,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave1_Connacht_adj,230424_Ireland_NationalBloodCentre_wave1,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,Connacht,,"""A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised according to the time period at which they were collected. ... Samples collected from February to September 2020 represent Wave 1 of the pandemic (n = 8509)... """,,2020-02-15,2020-09-15,Blood donors,All,Adults (18-64 years),18.0,,Geographical area,,649,0.0123,0.0053,0.0243,,,True,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.988,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2023-06-01,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave1_Munster_adj,230424_Ireland_NationalBloodCentre_wave1,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,Munster,,"""A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised according to the time period at which they were collected. ... Samples collected from February to September 2020 represent Wave 1 of the pandemic (n = 8509)... """,,2020-02-15,2020-09-15,Blood donors,All,Adults (18-64 years),18.0,,Geographical area,,2257,0.0168,0.0119,0.0231,,,True,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.988,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2023-06-01,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave1_Munster_unadj,230424_Ireland_NationalBloodCentre_wave1,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,Munster,,"""A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised according to the time period at which they were collected. ... Samples collected from February to September 2020 represent Wave 1 of the pandemic (n = 8509)... """,,2020-02-15,2020-09-15,Blood donors,All,Adults (18-64 years),18.0,,Geographical area,,2257,0.0164,0.0115,0.0226,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.988,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2023-06-01,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave1_Age30-39,230424_Ireland_NationalBloodCentre_wave1,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"""A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised according to the time period at which they were collected. ... Samples collected from February to September 2020 represent Wave 1 of the pandemic (n = 8509)... """,,2020-02-15,2020-09-15,Blood donors,All,Adults (18-64 years),30.0,39.0,Age,,1664,0.0276,0.0202,0.0369,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.988,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2024-04-29,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave1_Age18-29,230424_Ireland_NationalBloodCentre_wave1,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"""A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised according to the time period at which they were collected. ... Samples collected from February to September 2020 represent Wave 1 of the pandemic (n = 8509)... """,,2020-02-15,2020-09-15,Blood donors,All,Adults (18-64 years),18.0,29.0,Age,,1133,0.0406,0.0297,0.0541,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.988,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2024-04-29,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave1_Age50-59,230424_Ireland_NationalBloodCentre_wave1,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"""A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised according to the time period at which they were collected. ... Samples collected from February to September 2020 represent Wave 1 of the pandemic (n = 8509)... """,,2020-02-15,2020-09-15,Blood donors,All,Adults (18-64 years),50.0,59.0,Age,,2241,0.0165,0.0116,0.0228,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.988,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2024-04-29,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave1_Leinster_adj,230424_Ireland_NationalBloodCentre_wave1,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,Leinster,,"""A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised according to the time period at which they were collected. ... Samples collected from February to September 2020 represent Wave 1 of the pandemic (n = 8509)... """,,2020-02-15,2020-09-15,Blood donors,All,Adults (18-64 years),18.0,,Geographical area,,4955,0.026,0.0217,0.0309,,,True,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.988,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2023-06-01,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave1_Age40-49,230424_Ireland_NationalBloodCentre_wave1,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"""A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised according to the time period at which they were collected. ... Samples collected from February to September 2020 represent Wave 1 of the pandemic (n = 8509)... """,,2020-02-15,2020-09-15,Blood donors,All,Adults (18-64 years),40.0,49.0,Age,,2271,0.0172,0.0122,0.0235,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.988,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2024-04-29,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave1_Leinster_unadj,230424_Ireland_NationalBloodCentre_wave1,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,Leinster,,"""A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised according to the time period at which they were collected. ... Samples collected from February to September 2020 represent Wave 1 of the pandemic (n = 8509)... """,,2020-02-15,2020-09-15,Blood donors,All,Adults (18-64 years),18.0,,Geographical area,,4955,0.0274,0.023,0.0325,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.988,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2023-06-01,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave2_overall_adj,230424_Ireland_NationalBloodCentre_wave2,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised ac- cording to the time period at which they were collected. ... samples from November to December 2020 represent Wave 2 (n = 1014) """,,2020-11-15,2020-12-15,Blood donors,All,Adults (18-64 years),18.0,,Primary Estimate,,1014,0.0669,0.0521,0.085,True,,True,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.988,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2023-06-01,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave2_Munster_adj,230424_Ireland_NationalBloodCentre_wave2,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,Munster,,"A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised ac- cording to the time period at which they were collected. ... samples from November to December 2020 represent Wave 2 (n = 1014) """,,2020-11-15,2020-12-15,Blood donors,All,Adults (18-64 years),18.0,,Geographical area,,305,0.0361,0.018,0.0645,,,True,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.988,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2023-06-01,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave2_Leinster_adj,230424_Ireland_NationalBloodCentre_wave2,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,Leinster,,"A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised ac- cording to the time period at which they were collected. ... samples from November to December 2020 represent Wave 2 (n = 1014) """,,2020-11-15,2020-12-15,Blood donors,All,Adults (18-64 years),18.0,,Geographical area,,589,0.0372,0.0234,0.0566,,,True,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.988,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2023-06-01,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave2_Age60+,230424_Ireland_NationalBloodCentre_wave2,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised ac- cording to the time period at which they were collected. ... samples from November to December 2020 represent Wave 2 (n = 1014) """,,2020-11-15,2020-12-15,Blood donors,All,Seniors (65+ years),60.0,,Age,60+,142,0.0493,0.0198,0.1016,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.988,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2024-04-30,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave2_Ulster_unadj,230424_Ireland_NationalBloodCentre_wave2,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,Ulster,,"A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised ac- cording to the time period at which they were collected. ... samples from November to December 2020 represent Wave 2 (n = 1014) """,,2020-11-15,2020-12-15,Blood donors,All,Adults (18-64 years),18.0,,Geographical area,,86,0.0,0.0,0.0,,,True,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.988,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2023-06-01,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave2_overall_unadj,230424_Ireland_NationalBloodCentre_wave2,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised ac- cording to the time period at which they were collected. ... samples from November to December 2020 represent Wave 2 (n = 1014) """,,2020-11-15,2020-12-15,Blood donors,All,Adults (18-64 years),18.0,,Analysis,,1014,0.0355,0.0249,0.0492,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.988,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2023-06-01,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave2_Age30-39,230424_Ireland_NationalBloodCentre_wave2,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised ac- cording to the time period at which they were collected. ... samples from November to December 2020 represent Wave 2 (n = 1014) """,,2020-11-15,2020-12-15,Blood donors,All,Adults (18-64 years),30.0,39.0,Age,30-39,195,0.0359,0.0144,0.074,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.988,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2024-04-30,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave2_Age50-59,230424_Ireland_NationalBloodCentre_wave2,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised ac- cording to the time period at which they were collected. ... samples from November to December 2020 represent Wave 2 (n = 1014) """,,2020-11-15,2020-12-15,Blood donors,All,Adults (18-64 years),50.0,59.0,Age,50-59,276,0.0326,0.0149,0.0619,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.988,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2024-04-30,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave2_Munster_unadj,230424_Ireland_NationalBloodCentre_wave2,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,Munster,,"A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised ac- cording to the time period at which they were collected. ... samples from November to December 2020 represent Wave 2 (n = 1014) """,,2020-11-15,2020-12-15,Blood donors,All,Adults (18-64 years),18.0,,Geographical area,,305,0.0393,0.0203,0.0687,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.988,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2023-06-01,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave2_Age40-49,230424_Ireland_NationalBloodCentre_wave2,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised ac- cording to the time period at which they were collected. ... samples from November to December 2020 represent Wave 2 (n = 1014) """,,2020-11-15,2020-12-15,Blood donors,All,Adults (18-64 years),40.0,49.0,Age,40-49,264,0.0227,0.0047,0.0407,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.988,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2024-04-30,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave2_Ulster_adj,230424_Ireland_NationalBloodCentre_wave2,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,Ulster,,"A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised ac- cording to the time period at which they were collected. ... samples from November to December 2020 represent Wave 2 (n = 1014) """,,2020-11-15,2020-12-15,Blood donors,All,Adults (18-64 years),18.0,,Geographical area,,86,0.0,0.0,0.0,,,True,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.988,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2023-06-01,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave2_Leinster_unadj,230424_Ireland_NationalBloodCentre_wave2,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,Leinster,,"A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised ac- cording to the time period at which they were collected. ... samples from November to December 2020 represent Wave 2 (n = 1014) """,,2020-11-15,2020-12-15,Blood donors,All,Adults (18-64 years),18.0,,Geographical area,,589,0.039,0.0248,0.0586,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.988,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2023-06-01,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave2_Age18-29,230424_Ireland_NationalBloodCentre_wave2,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised ac- cording to the time period at which they were collected. ... samples from November to December 2020 represent Wave 2 (n = 1014) """,,2020-11-15,2020-12-15,Blood donors,All,Adults (18-64 years),18.0,29.0,Age,18-29,137,0.0511,0.0205,0.1053,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.988,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2024-04-30,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave2_Connacht_unadj,230424_Ireland_NationalBloodCentre_wave2,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,Connacht,,"A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised ac- cording to the time period at which they were collected. ... samples from November to December 2020 represent Wave 2 (n = 1014) """,,2020-11-15,2020-12-15,Blood donors,All,Adults (18-64 years),18.0,,Geographical area,,34,0.0294,0.0007,0.1639,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.988,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2023-06-01,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave2_Connacht_adj,230424_Ireland_NationalBloodCentre_wave2,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,Connacht,,"A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised ac- cording to the time period at which they were collected. ... samples from November to December 2020 represent Wave 2 (n = 1014) """,,2020-11-15,2020-12-15,Blood donors,All,Adults (18-64 years),18.0,,Geographical area,,34,0.0882,0.0182,0.2579,,,True,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.988,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2023-06-01,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave3_overall_adj,230424_Ireland_NationalBloodCentre_wave3,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised ac- cording to the time period at which they were collected. ... samples collected from February to March 2021 represent Wave 3 (n = 1009).""",,2021-02-15,2021-03-15,Blood donors,All,Adults (18-64 years),18.0,,Primary Estimate,,1009,0.1076,0.0887,0.1303,True,,True,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],No,No,Yes,Yes,No,Yes,Yes,No,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2023-06-01,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave3_Munster_adj,230424_Ireland_NationalBloodCentre_wave3,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,Munster,,"A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised ac- cording to the time period at which they were collected. ... samples collected from February to March 2021 represent Wave 3 (n = 1009).""",,2021-02-15,2021-03-15,Blood donors,All,Adults (18-64 years),18.0,,Geographical area,,323,0.0442,0.0237,0.0727,,,True,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],No,No,Yes,Yes,No,Yes,Yes,No,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2023-06-01,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave3_Age60+,230424_Ireland_NationalBloodCentre_wave3,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised ac- cording to the time period at which they were collected. ... samples collected from February to March 2021 represent Wave 3 (n = 1009).""",,2021-02-15,2021-03-15,Blood donors,All,Seniors (65+ years),60.0,,Age,60+,157,0.0764,0.0348,0.118,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],No,No,Yes,Yes,No,Yes,Yes,No,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2024-04-30,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave3_overall_unadj,230424_Ireland_NationalBloodCentre_wave3,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised ac- cording to the time period at which they were collected. ... samples collected from February to March 2021 represent Wave 3 (n = 1009).""",,2021-02-15,2021-03-15,Blood donors,All,Adults (18-64 years),18.0,,Analysis,,1009,0.0753,0.0594,0.0943,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],No,No,Yes,Yes,No,Yes,Yes,No,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2023-06-01,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave3_Leinster_unadj,230424_Ireland_NationalBloodCentre_wave3,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,Leinster,,"A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised ac- cording to the time period at which they were collected. ... samples collected from February to March 2021 represent Wave 3 (n = 1009).""",,2021-02-15,2021-03-15,Blood donors,All,Adults (18-64 years),18.0,,Geographical area,,562,0.0925,0.0685,0.1165,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],No,No,Yes,Yes,No,Yes,Yes,No,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2023-06-01,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave3_Ulster_unadj,230424_Ireland_NationalBloodCentre_wave3,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,Ulster,,"A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised ac- cording to the time period at which they were collected. ... samples collected from February to March 2021 represent Wave 3 (n = 1009).""",,2021-02-15,2021-03-15,Blood donors,All,Adults (18-64 years),18.0,,Geographical area,,86,0.0349,0.0072,0.102,,,True,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],No,No,Yes,Yes,No,Yes,Yes,No,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2023-06-01,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave3_Age50-59,230424_Ireland_NationalBloodCentre_wave3,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised ac- cording to the time period at which they were collected. ... samples collected from February to March 2021 represent Wave 3 (n = 1009).""",,2021-02-15,2021-03-15,Blood donors,All,Adults (18-64 years),50.0,59.0,Age,50-59,228,0.0746,0.0434,0.1194,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],No,No,Yes,Yes,No,Yes,Yes,No,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2024-04-30,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave3_Ulster_adj,230424_Ireland_NationalBloodCentre_wave3,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,Ulster,,"A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised ac- cording to the time period at which they were collected. ... samples collected from February to March 2021 represent Wave 3 (n = 1009).""",,2021-02-15,2021-03-15,Blood donors,All,Adults (18-64 years),18.0,,Geographical area,,86,0.0233,0.0028,0.084,,,True,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],No,No,Yes,Yes,No,Yes,Yes,No,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2023-06-01,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave3_Age18-29,230424_Ireland_NationalBloodCentre_wave3,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised ac- cording to the time period at which they were collected. ... samples collected from February to March 2021 represent Wave 3 (n = 1009).""",,2021-02-15,2021-03-15,Blood donors,All,Adults (18-64 years),18.0,29.0,Age,18-29,149,0.1208,0.0716,0.1909,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],No,No,Yes,Yes,No,Yes,Yes,No,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2024-04-30,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave3_Munster_unadj,230424_Ireland_NationalBloodCentre_wave3,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,Munster,,"A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised ac- cording to the time period at which they were collected. ... samples collected from February to March 2021 represent Wave 3 (n = 1009).""",,2021-02-15,2021-03-15,Blood donors,All,Adults (18-64 years),18.0,,Geographical area,,323,0.0526,0.0307,0.0843,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],No,No,Yes,Yes,No,Yes,Yes,No,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2023-06-01,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave3_Age30-39,230424_Ireland_NationalBloodCentre_wave3,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised ac- cording to the time period at which they were collected. ... samples collected from February to March 2021 represent Wave 3 (n = 1009).""",,2021-02-15,2021-03-15,Blood donors,All,Adults (18-64 years),30.0,39.0,Age,30-39,197,0.0508,0.0243,0.0934,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],No,No,Yes,Yes,No,Yes,Yes,No,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2024-04-30,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave3_Age40-49,230424_Ireland_NationalBloodCentre_wave3,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Ireland,,,"A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised ac- cording to the time period at which they were collected. ... samples collected from February to March 2021 represent Wave 3 (n = 1009).""",,2021-02-15,2021-03-15,Blood donors,All,Adults (18-64 years),40.0,49.0,Age,40-49,278,0.0683,0.0412,0.1067,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],No,No,Yes,Yes,No,Yes,Yes,No,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2024-04-30,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave3_Leinster_adj,230424_Ireland_NationalBloodCentre_wave3,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,Leinster,,"A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised ac- cording to the time period at which they were collected. ... samples collected from February to March 2021 represent Wave 3 (n = 1009).""",,2021-02-15,2021-03-15,Blood donors,All,Adults (18-64 years),18.0,,Geographical area,,562,0.1233,0.0944,0.1592,,,True,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],No,No,Yes,Yes,No,Yes,Yes,No,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2023-06-01,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave3_Connacht_adj,230424_Ireland_NationalBloodCentre_wave3,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,Connacht,,"A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised ac- cording to the time period at which they were collected. ... samples collected from February to March 2021 represent Wave 3 (n = 1009).""",,2021-02-15,2021-03-15,Blood donors,All,Adults (18-64 years),18.0,,Geographical area,,38,0.325,0.1632,0.5516,,,True,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],No,No,Yes,Yes,No,Yes,Yes,No,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2023-06-01,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
230424_Ireland_NationalBloodCentre_wave3_Connacht_unadj,230424_Ireland_NationalBloodCentre_wave3,The changing profile of SARS-CoV-2 serology in Irish blood donors.,2023-04-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Ireland,Connacht,,"A selection of anonymised blood donor samples received by the Irish Blood Transfusion Service (IBTS) between February 2020 and December 2021 were analysed for antibodies to SARS-CoV-2 and categorised ac- cording to the time period at which they were collected. ... samples collected from February to March 2021 represent Wave 3 (n = 1009).""",,2021-02-15,2021-03-15,Blood donors,All,Adults (18-64 years),18.0,,Geographical area,,38,0.1053,0.0287,0.2695,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],No,No,Yes,Yes,No,Yes,Yes,No,,Dermot Coyne,"National Blood Centre
",Unity-Aligned,https://dx.doi.org/10.1016/j.gloepi.2023.100108,2023-06-01,2024-04-30,Verified,coyneChangingProfileSARSCoV22023,IRL
200601_Israel_PandemicTaskForce_GenPop,200601_Israel_PandemicTaskForce,Initial antibody tests indicate 200000  Israelis have had COVID-19 - report,2020-06-02,News and Media,National,Cross-sectional survey ,Israel,Israel,,"Those tested are a representative sample of the population in age, gender and place of residence, the Haaretz daily said in its report Tuesday.",,2020-06-01,2020-06-02,Household and community samples,All,Multiple groups,,,Primary Estimate,,1700,0.025,,,True,,,,True,Stratified probability,Not reported/ Unable to specify,,,Whole Blood,IgG,,,,,['Moderate'],Yes,Yes,Yes,No,Yes,Unclear,Yes,No,Unclear,Michael Bachner,Israeli Pandemic Task Force,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.timesofisrael.com/initial-antibody-tests-indicate-200000-israelis-have-had-covid-19-report/&ct=ga&cd=CAAYBjIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNHYeXqD2hIEiNnZoH5qLiVlZKxQjg,2020-06-03,2023-12-13,Verified,bachner_initial_2020,ISR
201008_BneiBrak_CentralBureauofStatistics_primary,201008_BneiBrak_CentralBureauofStatistics,Antibody Tests  Show a Third in Israeli ultra-Orthodox Hot Spot Had Coronavirus,2020-10-08,News and Media,Local,Cross-sectional survey ,Israel,,Bnei Brak,The municipality received a sample pool of names from the statistics bureau and its representatives called the people and persuaded them to take part in the survey.,,2020-06-15,2020-08-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,3500,0.146,,,True,,,,True,Stratified probability,Not reported/ Unable to specify,,,,,,,,,['Moderate'],Yes,Yes,Yes,No,Yes,Unclear,Yes,No,Unclear,Aaron Rabinowitz,The Central Bureau of Statistics ,Not Unity-Aligned,https://www.haaretz.com/israel-news/.premium-antibody-tests-30-percent-of-bnei-brak-residents-have-been-infected-with-covid-1.9217689,2021-04-23,2022-07-16,Verified,noauthor_antibody_nodate,ISR
210412_TelAviv_TelAvivUniversity,210412_TelAviv_TelAvivUniversity,Prevalence of COVID-19 and Seroprevalence to SARS-CoV-2 in a Rheumatologic Patients Population from a Tertiary Referral Clinic in Israel.,2021-04-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Israel,,Tel Aviv,"Inclusion criteria were as follows: age
≥ 18 years consent to complete missing data from information
in their electronic case files, and having an AIIRD
(rheumatoid arthritis (RA), spondyloarthritis (SpA,
including ankylosing spondylitis, peripheral SpA, reactive
arthritis and IBD-associated SpA), psoriatic arthritis (PsA),
systemic lupus erythematosus (SLE), Sjögren syndrome
(SS), systemic sclerosis (SSc), idiopathic inflammatory
myositis (IIM), sarcoidosis, antineutrophil cytoplasmic
antibody (ANCA)-associated vasculitis (AAV), giant cell
arthritis (GCA), polymyalgia rheumatica (PMR), Behçet
disease, antiphospholipid syndrome (APS), noninflammatory
rheumatic disease (osteoarthritis, OA),
gout, calcium pyrophosphate deposition disease and
fibromyalgia).","Exclusion criteria were age under 18 years,
inability to give consent and unwillingness to participate.
In caseswhere the patient did not know his diagnosis, the
informationwas completed from the electronic case file.",2020-05-01,2020-05-31,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,,Primary Estimate,Patients with autoimmune inflammatory rheumatologic diseases,242,0.0207,,,True,,,,True,Sequential,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA",EUROIMMUN,ELISA,,"['IgA', 'IgG']",,Validated by manufacturers,1.0,0.985,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,No,Tali Eviatar ,Tel Aviv University,Not Unity-Aligned,https://dx.doi.org/10.1111/imj.15202,2021-05-22,2024-03-01,Verified,eviatar_prevalence_2021,ISR
210416_Safed_ZivMedicalCentre_overall_unadj,210416_Safed_ZivMedicalCentre,"SARS-CoV-2 Immunogenicity in individuals infected before and after COVID-19 vaccination: Israel, January-March 2021: Implications for vaccination policy",2021-04-16,Preprint,Local,Prospective cohort,Israel,,Safed,All employees of Ziv Medical Centre,,2020-12-15,2021-03-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,725,0.0345,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,No,Kamal Abu Jabal,Ziv Medical Centre,Not Unity-Aligned,10.1101/2021.04.11.21255273,2021-05-22,2024-03-01,Verified,jabal_sars-cov-2_2021,ISR
210421_Israel_MinistryofHealth_genpop_primary,210421_Israel_MinistryofHealth,Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel,2021-04-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Israel,,,The study population included insured individuals who arrived at the HMOs to undergo a blood test for any reason. ,"Excluding participants with missing age and/or sex data, invalid test results",2020-06-28,2020-09-14,Household and community samples,All,Multiple groups,,,Primary Estimate,,54357,0.046,0.044000000000000004,0.048,True,,True,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",ELISA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Shay Reicher,Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1007/s10654-021-00749-1,2021-05-20,2024-03-01,Verified,reicher_nationwide_2021,ISR
210421_Israel_MinistryofHealth_genpop_female,210421_Israel_MinistryofHealth,Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel,2021-04-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Israel,,,The study population included insured individuals who arrived at the HMOs to undergo a blood test for any reason. ,"Excluding participants with missing age and/or sex data, invalid test results",2020-06-28,2020-09-14,Household and community samples,Female,Multiple groups,,,Sex/Gender,,22518,0.031000000000000003,0.028999999999999998,0.033,,,True,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",ELISA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Shay Reicher,Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1007/s10654-021-00749-1,2021-07-16,2024-03-01,Unverified,reicher_nationwide_2021,ISR
210421_Israel_MinistryofHealth_genpop_age20-29,210421_Israel_MinistryofHealth,Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel,2021-04-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Israel,,,The study population included insured individuals who arrived at the HMOs to undergo a blood test for any reason. ,"Excluding participants with missing age and/or sex data, invalid test results",2020-06-28,2020-09-14,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,7049,0.048,0.043,0.053,,,True,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",ELISA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Shay Reicher,Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1007/s10654-021-00749-1,2021-07-16,2024-03-01,Unverified,reicher_nationwide_2021,ISR
210421_Israel_MinistryofHealth_genpop_age70+,210421_Israel_MinistryofHealth,Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel,2021-04-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Israel,,,The study population included insured individuals who arrived at the HMOs to undergo a blood test for any reason. ,"Excluding participants with missing age and/or sex data, invalid test results",2020-06-28,2020-09-14,Household and community samples,All,Multiple groups,,,Age,>70,6937,0.017,0.013999999999999999,0.02,,,True,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",ELISA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Shay Reicher,Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1007/s10654-021-00749-1,2021-07-16,2024-03-01,Unverified,reicher_nationwide_2021,ISR
210421_Israel_MinistryofHealth_genpop_age30-39,210421_Israel_MinistryofHealth,Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel,2021-04-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Israel,,,The study population included insured individuals who arrived at the HMOs to undergo a blood test for any reason. ,"Excluding participants with missing age and/or sex data, invalid test results",2020-06-28,2020-09-14,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,8556,0.037000000000000005,0.033,0.040999999999999995,,,True,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",ELISA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Shay Reicher,Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1007/s10654-021-00749-1,2021-07-16,2024-03-01,Unverified,reicher_nationwide_2021,ISR
210421_Israel_MinistryofHealth_genpop_Haifadistrict,210421_Israel_MinistryofHealth,Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel,2021-04-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Israel,Haifa District,,The study population included insured individuals who arrived at the HMOs to undergo a blood test for any reason. ,"Excluding participants with missing age and/or sex data, invalid test results",2020-06-28,2020-09-14,Household and community samples,All,Multiple groups,,,Geographical area,Haifa district,5582,0.011000000000000001,0.008,0.013999999999999999,,,True,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",ELISA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Shay Reicher,Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1007/s10654-021-00749-1,2021-07-19,2024-03-01,Unverified,reicher_nationwide_2021,ISR
210421_Israel_MinistryofHealth_genpop_TelAvivdistrict,210421_Israel_MinistryofHealth,Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel,2021-04-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Israel,Tel Aviv district,,The study population included insured individuals who arrived at the HMOs to undergo a blood test for any reason. ,"Excluding participants with missing age and/or sex data, invalid test results",2020-06-28,2020-09-14,Household and community samples,All,Multiple groups,,,Geographical area,Tel Aviv district,10457,0.022000000000000002,0.02,0.025,,,True,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",ELISA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Shay Reicher,Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1007/s10654-021-00749-1,2021-07-19,2024-03-01,Unverified,reicher_nationwide_2021,ISR
210421_Israel_MinistryofHealth_genpop_male,210421_Israel_MinistryofHealth,Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel,2021-04-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Israel,,,The study population included insured individuals who arrived at the HMOs to undergo a blood test for any reason. ,"Excluding participants with missing age and/or sex data, invalid test results",2020-06-28,2020-09-14,Household and community samples,Male,Multiple groups,,,Sex/Gender,,31839,0.049,0.046,0.052000000000000005,,,True,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",ELISA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Shay Reicher,Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1007/s10654-021-00749-1,2021-07-16,2024-03-01,Unverified,reicher_nationwide_2021,ISR
210421_Israel_MinistryofHealth_genpop_age0-9,210421_Israel_MinistryofHealth,Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel,2021-04-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Israel,,,The study population included insured individuals who arrived at the HMOs to undergo a blood test for any reason. ,"Excluding participants with missing age and/or sex data, invalid test results",2020-06-28,2020-09-14,Household and community samples,All,Children and Youth (0-17 years),0.0,9.0,Age,0-9,1699,0.055999999999999994,0.045,0.068,,,True,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",ELISA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Shay Reicher,Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1007/s10654-021-00749-1,2021-07-16,2024-03-01,Unverified,reicher_nationwide_2021,ISR
210421_Israel_MinistryofHealth_genpop_Jerusalemdistrict,210421_Israel_MinistryofHealth,Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel,2021-04-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Israel,Jerusalem district,,The study population included insured individuals who arrived at the HMOs to undergo a blood test for any reason. ,"Excluding participants with missing age and/or sex data, invalid test results",2020-06-28,2020-09-14,Household and community samples,All,Multiple groups,,,Geographical area,Jerusalem district,8462,0.09300000000000001,0.087,0.1,,,True,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",ELISA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Shay Reicher,Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1007/s10654-021-00749-1,2021-07-19,2024-03-01,Unverified,reicher_nationwide_2021,ISR
210421_Israel_MinistryofHealth_genpop_age50-59,210421_Israel_MinistryofHealth,Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel,2021-04-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Israel,,,The study population included insured individuals who arrived at the HMOs to undergo a blood test for any reason. ,"Excluding participants with missing age and/or sex data, invalid test results",2020-06-28,2020-09-14,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,8348,0.037000000000000005,0.033,0.040999999999999995,,,True,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",ELISA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Shay Reicher,Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1007/s10654-021-00749-1,2021-07-16,2024-03-01,Unverified,reicher_nationwide_2021,ISR
210421_Israel_MinistryofHealth_genpop_age40-49,210421_Israel_MinistryofHealth,Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel,2021-04-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Israel,,,The study population included insured individuals who arrived at the HMOs to undergo a blood test for any reason. ,"Excluding participants with missing age and/or sex data, invalid test results",2020-06-28,2020-09-14,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,8856,0.040999999999999995,0.037000000000000005,0.046,,,True,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",ELISA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Shay Reicher,Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1007/s10654-021-00749-1,2021-07-16,2024-03-01,Unverified,reicher_nationwide_2021,ISR
210421_Israel_MinistryofHealth_genpop_Southerndistrict,210421_Israel_MinistryofHealth,Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel,2021-04-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Israel,South district,,The study population included insured individuals who arrived at the HMOs to undergo a blood test for any reason. ,"Excluding participants with missing age and/or sex data, invalid test results",2020-06-28,2020-09-14,Household and community samples,All,Multiple groups,,,Geographical area,South district,3710,0.039,0.033,0.045,,,True,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",ELISA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Shay Reicher,Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1007/s10654-021-00749-1,2021-07-19,2024-03-01,Unverified,reicher_nationwide_2021,ISR
210421_Israel_MinistryofHealth_genpop_age60-69,210421_Israel_MinistryofHealth,Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel,2021-04-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Israel,,,The study population included insured individuals who arrived at the HMOs to undergo a blood test for any reason. ,"Excluding participants with missing age and/or sex data, invalid test results",2020-06-28,2020-09-14,Household and community samples,All,Multiple groups,60.0,69.0,Age,60-69,8750,0.026000000000000002,0.023,0.028999999999999998,,,True,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",ELISA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Shay Reicher,Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1007/s10654-021-00749-1,2021-07-16,2024-03-01,Unverified,reicher_nationwide_2021,ISR
210421_Israel_MinistryofHealth_genpop_age10-19,210421_Israel_MinistryofHealth,Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel,2021-04-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Israel,,,The study population included insured individuals who arrived at the HMOs to undergo a blood test for any reason. ,"Excluding participants with missing age and/or sex data, invalid test results",2020-06-28,2020-09-14,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,4165,0.078,0.07,0.086,,,True,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",ELISA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Shay Reicher,Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1007/s10654-021-00749-1,2021-07-16,2024-03-01,Unverified,reicher_nationwide_2021,ISR
210421_Israel_MinistryofHealth_genpop_Centraldistrict,210421_Israel_MinistryofHealth,Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel,2021-04-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Israel,Central district,,The study population included insured individuals who arrived at the HMOs to undergo a blood test for any reason. ,"Excluding participants with missing age and/or sex data, invalid test results",2020-06-28,2020-09-14,Household and community samples,All,Multiple groups,,,Geographical area,Central district ,15169,0.036000000000000004,0.034,0.04,,,True,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",ELISA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Shay Reicher,Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1007/s10654-021-00749-1,2021-07-19,2024-03-01,Unverified,reicher_nationwide_2021,ISR
210421_Israel_MinistryofHealth_genpop_Northerndistrict,210421_Israel_MinistryofHealth,Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel,2021-04-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Israel,"Northern District
",,The study population included insured individuals who arrived at the HMOs to undergo a blood test for any reason. ,"Excluding participants with missing age and/or sex data, invalid test results",2020-06-28,2020-09-14,Household and community samples,All,Multiple groups,,,Geographical area,North district,5397,0.019,0.016,0.023,,,True,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",ELISA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Shay Reicher,Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1007/s10654-021-00749-1,2021-07-19,2024-03-01,Unverified,reicher_nationwide_2021,ISR
210624_Modiin_IsraelMinistryOfHealth_Primary,210624_Modiin_IsraelMinistryOfHealth,SARS-CoV-2 outbreak in a synagogue community: Longevity and strength of anti-SARS-CoV-2 IgG responses,2021-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Israel,,Modiin,"All members of the Hoshen synagogue community (approximately 600 individuals, adults and children) that were potentially exposed to SARS-CoV-2 outbreak in mid-March 2020",Consent not given,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,283,0.1661,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Author designed (ELISA) -Spike","Abbott Laboratories,DiaSorin,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,No,No,Yael Gozlan,Israel Ministry of Health,Unity-Aligned,http://dx.doi.org/10.1017/S0950268821001369,2021-07-14,2024-03-01,Verified,gozlan_sars-cov-2_2021,ISR
210624_Modiin_IsraelMinistryOfHealth_Age19+,210624_Modiin_IsraelMinistryOfHealth,SARS-CoV-2 outbreak in a synagogue community: Longevity and strength of anti-SARS-CoV-2 IgG responses,2021-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Israel,,Modiin,"All members of the Hoshen synagogue community (approximately 600 individuals, adults and children) that were potentially exposed to SARS-CoV-2 outbreak in mid-March 2020",Consent not given,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,0.0,,Age,,185,0.162,,,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Author designed (ELISA) -Spike","Abbott Laboratories,DiaSorin,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,No,No,Yael Gozlan,Israel Ministry of Health,Unity-Aligned,http://dx.doi.org/10.1017/S0950268821001369,2021-07-14,2024-03-01,Verified,gozlan_sars-cov-2_2021,ISR
210624_Modiin_IsraelMinistryOfHealth_RBD ELISA,210624_Modiin_IsraelMinistryOfHealth,SARS-CoV-2 outbreak in a synagogue community: Longevity and strength of anti-SARS-CoV-2 IgG responses,2021-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Israel,,Modiin,"All members of the Hoshen synagogue community (approximately 600 individuals, adults and children) that were potentially exposed to SARS-CoV-2 outbreak in mid-March 2020",Consent not given,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,0.0,,Test used,In house RBD ELISA,283,0.1696,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,No,No,Yael Gozlan,Israel Ministry of Health,Unity-Aligned,http://dx.doi.org/10.1017/S0950268821001369,2021-07-14,2022-07-16,Verified,gozlan_sars-cov-2_2021,ISR
210624_Modiin_IsraelMinistryOfHealth_Age11-19,210624_Modiin_IsraelMinistryOfHealth,SARS-CoV-2 outbreak in a synagogue community: Longevity and strength of anti-SARS-CoV-2 IgG responses,2021-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Israel,,Modiin,"All members of the Hoshen synagogue community (approximately 600 individuals, adults and children) that were potentially exposed to SARS-CoV-2 outbreak in mid-March 2020",Consent not given,2020-09-01,2020-09-30,Household and community samples,All,Children and Youth (0-17 years),0.0,,Age,,83,0.18100000000000002,,,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Author designed (ELISA) -Spike","Abbott Laboratories,DiaSorin,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,No,No,Yael Gozlan,Israel Ministry of Health,Unity-Aligned,http://dx.doi.org/10.1017/S0950268821001369,2021-07-14,2024-03-01,Verified,gozlan_sars-cov-2_2021,ISR
210624_Modiin_IsraelMinistryOfHealth_Age0-10,210624_Modiin_IsraelMinistryOfHealth,SARS-CoV-2 outbreak in a synagogue community: Longevity and strength of anti-SARS-CoV-2 IgG responses,2021-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Israel,,Modiin,"All members of the Hoshen synagogue community (approximately 600 individuals, adults and children) that were potentially exposed to SARS-CoV-2 outbreak in mid-March 2020",Consent not given,2020-09-01,2020-09-30,Household and community samples,All,Children and Youth (0-17 years),0.0,,Age,,15,0.133,,,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Author designed (ELISA) -Spike","Abbott Laboratories,DiaSorin,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,No,No,Yael Gozlan,Israel Ministry of Health,Unity-Aligned,http://dx.doi.org/10.1017/S0950268821001369,2021-07-14,2024-03-01,Verified,gozlan_sars-cov-2_2021,ISR
210624_Modiin_IsraelMinistryOfHealth_Abbott,210624_Modiin_IsraelMinistryOfHealth,SARS-CoV-2 outbreak in a synagogue community: Longevity and strength of anti-SARS-CoV-2 IgG responses,2021-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Israel,,Modiin,"All members of the Hoshen synagogue community (approximately 600 individuals, adults and children) that were potentially exposed to SARS-CoV-2 outbreak in mid-March 2020",Consent not given,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,0.0,,Test used,Abbott CLIA,283,0.0954,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,No,No,Yael Gozlan,Israel Ministry of Health,Unity-Aligned,http://dx.doi.org/10.1017/S0950268821001369,2021-07-14,2024-03-01,Verified,gozlan_sars-cov-2_2021,ISR
210624_Modiin_IsraelMinistryOfHealth_DiaSorin,210624_Modiin_IsraelMinistryOfHealth,SARS-CoV-2 outbreak in a synagogue community: Longevity and strength of anti-SARS-CoV-2 IgG responses,2021-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Israel,,Modiin,"All members of the Hoshen synagogue community (approximately 600 individuals, adults and children) that were potentially exposed to SARS-CoV-2 outbreak in mid-March 2020",Consent not given,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,0.0,,Test used,DiaSorin CLIA,283,0.1731,,,,,,,,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,No,No,Yael Gozlan,Israel Ministry of Health,Unity-Aligned,http://dx.doi.org/10.1017/S0950268821001369,2021-07-14,2024-03-01,Verified,gozlan_sars-cov-2_2021,ISR
210624_Israel_TelAvivUniversity_overall,210624_Israel_TelAvivUniversity,"Sero-Prevalence and Sero-Incidence of Antibodies to SARS-CoV-2 in Health Care Workers in Israel, Prior to Mass COVID-19 Vaccination.",2021-06-24,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Israel,,,"HCWs [physicians, nurses, and others (technicians and administrative staff)], employees of nine general medical centers in Israel: Shamir (Assaf Harofe), Beilinson, HaSharon, Meir, Wolfson, Hadassah Ein Kerem, Sha'arei Zedek, Laniado, and Hillel Yaffe medical centers.",,2020-04-15,2020-05-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,874,0.011000000000000001,0.006,0.021,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,Roche Diagnostics",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Unclear,Khitam Muhsen,Tel Aviv University,Not Unity-Aligned,https://dx.doi.org/10.3389/fmed.2021.689994,2021-07-20,2024-03-01,Verified,muhsen_sero-prevalence_2021,ISR
210715_Israel_ShaareZedekMedicalCenter_Primary,210715_Israel_ShaareZedekMedicalCenter,SARS-CoV-2 antibodies started to decline just four months after COVID-19 infection in a paediatric population,2021-07-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Israel,,Jerusalem,All patients under 18 years of age who presented to the PED during the study period were eligible to participate if they required blood tests or intravenous access for any clinical reason.,"Children under the age of three months were later excluded from the analysis, as antibodies detected in their blood may have been maternal antibodies that transferred though the placenta in-utero. Patients with blood samples that were unsuitable for laboratory testing, for technical reasons, were also excluded from the final analysis",2020-10-18,2021-01-12,Residual sera,All,Children and Youth (0-17 years),0.0,18.0,Primary Estimate,,1138,0.1,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Adin Breuer,Shaare Zedek Medical Center,Unity-Aligned,http://dx.doi.org/10.1111/apa.16031,2021-08-03,2024-03-01,Verified,sars-cov-2_breuer_2021,ISR
210715_Israel_ShaareZedekMedicalCenter_Age6to12,210715_Israel_ShaareZedekMedicalCenter,SARS-CoV-2 antibodies started to decline just four months after COVID-19 infection in a paediatric population,2021-07-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Israel,,Jerusalem,All patients under 18 years of age who presented to the PED during the study period were eligible to participate if they required blood tests or intravenous access for any clinical reason.,"Children under the age of three months were later excluded from the analysis, as antibodies detected in their blood may have been maternal antibodies that transferred though the placenta in-utero. Patients with blood samples that were unsuitable for laboratory testing, for technical reasons, were also excluded from the final analysis",2020-10-18,2021-01-12,Residual sera,All,Children and Youth (0-17 years),6.0,12.0,Age,6-12 years,222,0.135,,,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Adin Breuer,Shaare Zedek Medical Center,Unity-Aligned,http://dx.doi.org/10.1111/apa.16031,2021-08-03,2024-03-01,Verified,sars-cov-2_breuer_2021,ISR
210715_Israel_ShaareZedekMedicalCenter_Age12to18,210715_Israel_ShaareZedekMedicalCenter,SARS-CoV-2 antibodies started to decline just four months after COVID-19 infection in a paediatric population,2021-07-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Israel,,Jerusalem,All patients under 18 years of age who presented to the PED during the study period were eligible to participate if they required blood tests or intravenous access for any clinical reason.,"Children under the age of three months were later excluded from the analysis, as antibodies detected in their blood may have been maternal antibodies that transferred though the placenta in-utero. Patients with blood samples that were unsuitable for laboratory testing, for technical reasons, were also excluded from the final analysis",2020-10-18,2021-01-12,Residual sera,All,Children and Youth (0-17 years),12.0,18.0,Age,12-18 years,268,0.142,,,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Adin Breuer,Shaare Zedek Medical Center,Unity-Aligned,http://dx.doi.org/10.1111/apa.16031,2021-08-03,2024-03-01,Verified,sars-cov-2_breuer_2021,ISR
210715_Israel_ShaareZedekMedicalCenter_Age1to3,210715_Israel_ShaareZedekMedicalCenter,SARS-CoV-2 antibodies started to decline just four months after COVID-19 infection in a paediatric population,2021-07-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Israel,,Jerusalem,All patients under 18 years of age who presented to the PED during the study period were eligible to participate if they required blood tests or intravenous access for any clinical reason.,"Children under the age of three months were later excluded from the analysis, as antibodies detected in their blood may have been maternal antibodies that transferred though the placenta in-utero. Patients with blood samples that were unsuitable for laboratory testing, for technical reasons, were also excluded from the final analysis",2020-10-18,2021-01-12,Residual sera,All,Children and Youth (0-17 years),1.0,3.0,Age,1-3 years,283,0.07400000000000001,,,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Adin Breuer,Shaare Zedek Medical Center,Unity-Aligned,http://dx.doi.org/10.1111/apa.16031,2021-08-03,2024-03-01,Verified,sars-cov-2_breuer_2021,ISR
210715_Israel_ShaareZedekMedicalCenter_Age3to12Month,210715_Israel_ShaareZedekMedicalCenter,SARS-CoV-2 antibodies started to decline just four months after COVID-19 infection in a paediatric population,2021-07-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Israel,,Jerusalem,All patients under 18 years of age who presented to the PED during the study period were eligible to participate if they required blood tests or intravenous access for any clinical reason.,"Children under the age of three months were later excluded from the analysis, as antibodies detected in their blood may have been maternal antibodies that transferred though the placenta in-utero. Patients with blood samples that were unsuitable for laboratory testing, for technical reasons, were also excluded from the final analysis",2020-10-18,2021-01-12,Residual sera,All,Children and Youth (0-17 years),0.0,1.0,Age,3-12 months,219,0.059000000000000004,,,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Adin Breuer,Shaare Zedek Medical Center,Unity-Aligned,http://dx.doi.org/10.1111/apa.16031,2021-08-03,2024-03-01,Verified,sars-cov-2_breuer_2021,ISR
210715_Israel_ShaareZedekMedicalCenter_Female,210715_Israel_ShaareZedekMedicalCenter,SARS-CoV-2 antibodies started to decline just four months after COVID-19 infection in a paediatric population,2021-07-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Israel,,Jerusalem,All patients under 18 years of age who presented to the PED during the study period were eligible to participate if they required blood tests or intravenous access for any clinical reason.,"Children under the age of three months were later excluded from the analysis, as antibodies detected in their blood may have been maternal antibodies that transferred though the placenta in-utero. Patients with blood samples that were unsuitable for laboratory testing, for technical reasons, were also excluded from the final analysis",2020-10-18,2021-01-12,Residual sera,Female,Children and Youth (0-17 years),0.0,18.0,Sex/Gender,,499,0.084,,,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Adin Breuer,Shaare Zedek Medical Center,Unity-Aligned,http://dx.doi.org/10.1111/apa.16031,2021-08-03,2024-03-01,Verified,sars-cov-2_breuer_2021,ISR
210715_Israel_ShaareZedekMedicalCenter_Age3to6,210715_Israel_ShaareZedekMedicalCenter,SARS-CoV-2 antibodies started to decline just four months after COVID-19 infection in a paediatric population,2021-07-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Israel,,Jerusalem,All patients under 18 years of age who presented to the PED during the study period were eligible to participate if they required blood tests or intravenous access for any clinical reason.,"Children under the age of three months were later excluded from the analysis, as antibodies detected in their blood may have been maternal antibodies that transferred though the placenta in-utero. Patients with blood samples that were unsuitable for laboratory testing, for technical reasons, were also excluded from the final analysis",2020-10-18,2021-01-12,Residual sera,All,Children and Youth (0-17 years),3.0,6.0,Age,3-6 years,146,0.08199999999999999,,,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Adin Breuer,Shaare Zedek Medical Center,Unity-Aligned,http://dx.doi.org/10.1111/apa.16031,2021-08-03,2024-03-01,Verified,sars-cov-2_breuer_2021,ISR
210715_Israel_ShaareZedekMedicalCenter_Male,210715_Israel_ShaareZedekMedicalCenter,SARS-CoV-2 antibodies started to decline just four months after COVID-19 infection in a paediatric population,2021-07-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Israel,,Jerusalem,All patients under 18 years of age who presented to the PED during the study period were eligible to participate if they required blood tests or intravenous access for any clinical reason.,"Children under the age of three months were later excluded from the analysis, as antibodies detected in their blood may have been maternal antibodies that transferred though the placenta in-utero. Patients with blood samples that were unsuitable for laboratory testing, for technical reasons, were also excluded from the final analysis",2020-10-18,2021-01-12,Residual sera,Male,Children and Youth (0-17 years),0.0,18.0,Sex/Gender,,639,0.113,,,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Adin Breuer,Shaare Zedek Medical Center,Unity-Aligned,http://dx.doi.org/10.1111/apa.16031,2021-08-03,2024-03-01,Verified,sars-cov-2_breuer_2021,ISR
210907_TelAviv_TelAvivUniversity_Overall,210907_TelAviv_TelAvivUniversity,Seroprevalence of SARS-CoV-2 antibodies in patients with autoimmune inflammatory rheumatic diseases,2021-09-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Israel,,Tel Aviv,"""Consecutive patients,18 years of age or older, were recruited into the study after obtaining a written informed consent, according to the following inclusion criteria: rheumatoid arthritis (RA) fulfilling ACR/EULAR 2010 classification criteria (35); psoriatic arthritis (PsA) fulfilling Classification Criteria for Psoriatic Arthritis (36); axial spondyloarthritis (axSpA) fulfilling ASAS classification criteria (37), SLE fulfilling 1997 ACR (38) or 2012 SLICC criteria (39), systemic vasculitis: largevessel vasculitis (LVV), antineutrophil cytoplasmic antibody associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis and eosinophilic GPA fulfilling Chapel Hill Consensus Conference definitions (40).""","""Patients vaccinated against SARS-CoV-2 prior to the study were excluded.""",2020-09-15,2021-03-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,95.0,Primary Estimate,,572,0.0524,,,True,,,,True,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Yes,Yes,No,,Tali Eviatar,Tel Aviv University,Not Unity-Aligned,https://dx.doi.org/10.55563/clinexprheumatol/ykin5p,2022-07-24,2024-03-01,Unverified,eviatar_seroprevalence_2022,ISR
210924_BneiBrak_MayaneiHayeshuaMedicalCenter_primary,210924_BneiBrak_MayaneiHayeshuaMedicalCenter,Titers of SARS CoV-2 antibodies in cord blood of neonates whose mothers contracted SARS CoV-2 (COVID-19) during pregnancy and in those whose mothers were vaccinated with mRNA to SARS CoV-2 during pregnancy.,2021-09-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Israel,Tel Aviv District,Bnei Brak,"women who delivered singleton livebirths at the Mayanei Hayeshua Medical Center in Bnei Brak, Israel between February 28th and March 8th, 2021.
...Group 3 included 21 women who were not vaccinated and had no evidence of SARS-CoV-2 infection during pregnancy (negative serology and negative RT-PCR test).",,2021-02-28,2021-03-08,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,21,0.0,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],,No,No,No,,Yes,Yes,Yes,,Lior Kashani-Ligumsky,Mayanei Hayeshua Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1038/s41372-021-01216-1,2021-10-06,2024-03-01,Unverified,kashani-ligumsky_titers_2021,ISR
211001_Israel_MaccabiHealthcareServices_Overall_TestAdjusted,211001_Israel_MaccabiHealthcareServices,"COVID-19 seropositive rates between the Waves, Israel",2021-10-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Israel,,,Members of all HMOs (4 in Israel) who visited a service branch at one of the target sites between 28 June 2020 and 27 July 2020 for the purposes of getting a blood test for any reason were invited to participate.,,2020-06-28,2020-07-27,Residual sera,All,Multiple groups,20.0,,Primary Estimate,,15459,0.0191,,,True,True,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,LIAISON® SARS-CoV-2 TrimericS IgG","Abbott Laboratories,DiaSorin",CLIA,,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Anat Ekka Zohar,Maccabi Healthcare Services,Unity-Aligned,https://www.ima.org.il/MedicineIMAJ/viewarticle.aspx?year=2021&month=10&page=611,2021-11-30,2023-08-15,Verified,ekka_zohar_covid-19_2021,ISR
211001_Israel_MaccabiHealthcareServices_Overall_Unadjusted,211001_Israel_MaccabiHealthcareServices,"COVID-19 seropositive rates between the Waves, Israel",2021-10-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Israel,,,Members of all HMOs (4 in Israel) who visited a service branch at one of the target sites between 28 June 2020 and 27 July 2020 for the purposes of getting a blood test for any reason were invited to participate.,,2020-06-28,2020-07-27,Residual sera,All,Multiple groups,20.0,,Analysis,,15459,0.0105,,,,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,LIAISON® SARS-CoV-2 TrimericS IgG","Abbott Laboratories,DiaSorin",CLIA,,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Anat Ekka Zohar,Maccabi Healthcare Services,Unity-Aligned,https://www.ima.org.il/MedicineIMAJ/viewarticle.aspx?year=2021&month=10&page=611,2021-11-30,2024-03-01,Verified,ekka_zohar_covid-19_2021,ISR
211006_Israel_IsraelInstituteforBiologicalResearch,211006_Israel_IsraelInstituteforBiologicalResearch,A Serological Snapshot of COVID-19 Initial Stages in Israel by a 6-Plex Antigen Array.,2021-10-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Israel,,,"Healthy adult subjects from all over the country. Must have tested negative to a qRT-PCR test to be included in the ""healthy"" subject group.",Positive qRT-PCR test,2020-04-24,2020-04-24,Household and community samples,All,Multiple groups,20.0,70.0,Primary Estimate,,146,0.0,,,True,,,,True,Convenience,Author designed (type unknown),,,,IgG,"['Nucleocapsid(N-protein)', 'Spike', 'Whole-virusantigen']",Validated by developers,0.9820000000000001,1.0,['High'],Unclear,No,No,Yes,Unclear,Unclear,Yes,Yes,Unclear,Morly Fisher,Israel Institute for Biological Research,Not Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00870-21,2021-10-12,2022-07-16,Verified,fisher_serological_2021,ISR
211015_Jerusalem_ShaareZedekMedicalCenter,211015_Jerusalem_ShaareZedekMedicalCenter,"COVID-19 in children and young adults with kidney disease: risk factors, clinical features and serological response.",2021-10-15,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Israel,Jerusalem District,Jerusalem,"For the pediatric kidney disease population, the inclusion criteria: patients <20 years old followed at the SZMC pediatric nephrology clinic. 
For the young adult kidney disease population, the inclusion criteria: age 20 - 35 year old Kidney Transplant Recipients who underwent transplantation as children and continue to be followed at the SZMC clinic. ","""No serological tests were done after COVID-19 vaccination.""",2020-12-01,2021-02-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,0.0,35.0,Primary Estimate,,249,0.18072289160000002,,,True,,,,True,Entire sample,"SARS-CoV-2 IgG II Quant ,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],,Yes,No,Yes,,Yes,Yes,No,,Jenny Weinbrand-Goichberg,Shaare Zedek Medical Centre (SZMC),Not Unity-Aligned,https://dx.doi.org/10.1007/s40620-021-01171-2,2021-10-25,2024-03-01,Unverified,weinbrand-goichberg_covid-19_2021,ISR
211202_Israel_Tel-AvivUniversity,211202_Israel_Tel-AvivUniversity,"Immunoglobulin (Ig)A seropositivity against SARS-CoV-2 in healthcare workers in Israel, 4 April to 13 July 2020: an observational study.",2021-12-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Israel,Tel Aviv District,Ramat Gan,Asymptomatic HCW with no known history of COVID-19,"HCW who were diagnosed with COVID-19 before the
survey were excluded.",2020-04-04,2020-07-13,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,428,0.006999999999999999,0.0024,0.02,True,,,,True,Self-referral,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.818,0.98,['High'],,No,No,Yes,,Yes,Yes,No,,Yaniv Lustig,Tel-Aviv University,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.48.2001690,2021-12-14,2024-03-01,Unverified,lustig_immunoglobulin_2021,ISR
211202_Israel_TelAvivUniversity_Overall,211202_Israel_TelAvivUniversity,"Under-diagnosis of SARS-CoV-2 infections among children aged 0-15 years, a nationwide seroprevalence study, Israel, January 2020 to March 2021.",2021-12-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Israel,,,Serum samples collected between 1 January 2020 and 31 March 2021 from children aged 0–15 years,,2020-01-01,2021-03-31,Residual sera,All,Children and Youth (0-17 years),0.0,15.0,Primary Estimate,,2765,0.0564,0.048,0.066,True,,,,True,Convenience,"Author designed (ELISA) -Spike,Author designed (Neutralization Assay)",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Victoria Indenbaum,Tel Aviv University,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.48.2101040,2021-12-15,2022-07-16,Verified,indenbaum_under-diagnosis_2021,ISR
211202_Israel_TelAvivUniversity_DistrictTelAviv,211202_Israel_TelAvivUniversity,"Under-diagnosis of SARS-CoV-2 infections among children aged 0-15 years, a nationwide seroprevalence study, Israel, January 2020 to March 2021.",2021-12-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Israel,TelAviv,,Serum samples collected between 1 January 2020 and 31 March 2021 from children aged 0–15 years,,2020-01-01,2021-03-31,Residual sera,All,Children and Youth (0-17 years),0.0,15.0,Geographical area,TelAviv,225,0.0756,0.045,0.11800000000000001,,,,,,Convenience,"Author designed (ELISA) -Spike,Author designed (Neutralization Assay)",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Victoria Indenbaum,Tel Aviv University,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.48.2101040,2021-12-15,2022-07-16,Verified,indenbaum_under-diagnosis_2021,ISR
211202_Israel_TelAvivUniversity_Age1-4,211202_Israel_TelAvivUniversity,"Under-diagnosis of SARS-CoV-2 infections among children aged 0-15 years, a nationwide seroprevalence study, Israel, January 2020 to March 2021.",2021-12-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Israel,,,Serum samples collected between 1 January 2020 and 31 March 2021 from children aged 0–15 years,,2020-01-01,2021-03-31,Residual sera,All,Children and Youth (0-17 years),1.0,4.0,Age,1-4,729,0.0466,0.032,0.065,,,,,,Convenience,"Author designed (ELISA) -Spike,Author designed (Neutralization Assay)",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Victoria Indenbaum,Tel Aviv University,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.48.2101040,2021-12-15,2022-07-16,Verified,indenbaum_under-diagnosis_2021,ISR
211202_Israel_TelAvivUniversity_DistrictNorth,211202_Israel_TelAvivUniversity,"Under-diagnosis of SARS-CoV-2 infections among children aged 0-15 years, a nationwide seroprevalence study, Israel, January 2020 to March 2021.",2021-12-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Israel,North,,Serum samples collected between 1 January 2020 and 31 March 2021 from children aged 0–15 years,,2020-01-01,2021-03-31,Residual sera,All,Children and Youth (0-17 years),0.0,15.0,Geographical area,North,489,0.053200000000000004,0.035,0.077,,,,,,Convenience,"Author designed (ELISA) -Spike,Author designed (Neutralization Assay)",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Victoria Indenbaum,Tel Aviv University,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.48.2101040,2021-12-15,2022-07-16,Verified,indenbaum_under-diagnosis_2021,ISR
211202_Israel_TelAvivUniversity_Age0-1,211202_Israel_TelAvivUniversity,"Under-diagnosis of SARS-CoV-2 infections among children aged 0-15 years, a nationwide seroprevalence study, Israel, January 2020 to March 2021.",2021-12-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Israel,,,Serum samples collected between 1 January 2020 and 31 March 2021 from children aged 0–15 years,,2020-01-01,2021-03-31,Residual sera,All,Children and Youth (0-17 years),0.0,1.0,Age,0-1,143,0.049,,,,,,,,Convenience,"Author designed (ELISA) -Spike,Author designed (Neutralization Assay)",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Victoria Indenbaum,Tel Aviv University,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.48.2101040,2021-12-15,2022-07-16,Verified,indenbaum_under-diagnosis_2021,ISR
211202_Israel_TelAvivUniversity_Age10-11,211202_Israel_TelAvivUniversity,"Under-diagnosis of SARS-CoV-2 infections among children aged 0-15 years, a nationwide seroprevalence study, Israel, January 2020 to March 2021.",2021-12-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Israel,,,Serum samples collected between 1 January 2020 and 31 March 2021 from children aged 0–15 years,,2020-01-01,2021-03-31,Residual sera,All,Children and Youth (0-17 years),10.0,11.0,Age,10-11,314,0.0605,0.037000000000000005,0.09300000000000001,,,,,,Convenience,"Author designed (ELISA) -Spike,Author designed (Neutralization Assay)",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Victoria Indenbaum,Tel Aviv University,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.48.2101040,2021-12-15,2022-07-16,Verified,indenbaum_under-diagnosis_2021,ISR
211202_Israel_TelAvivUniversity_DistrictSouth,211202_Israel_TelAvivUniversity,"Under-diagnosis of SARS-CoV-2 infections among children aged 0-15 years, a nationwide seroprevalence study, Israel, January 2020 to March 2021.",2021-12-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Israel,South,,Serum samples collected between 1 January 2020 and 31 March 2021 from children aged 0–15 years,,2020-01-01,2021-03-31,Residual sera,All,Children and Youth (0-17 years),0.0,15.0,Geographical area,South,755,0.0371,0.025,0.053,,,,,,Convenience,"Author designed (ELISA) -Spike,Author designed (Neutralization Assay)",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Victoria Indenbaum,Tel Aviv University,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.48.2101040,2021-12-15,2022-07-16,Verified,indenbaum_under-diagnosis_2021,ISR
211202_Israel_TelAvivUniversity_Age5-9,211202_Israel_TelAvivUniversity,"Under-diagnosis of SARS-CoV-2 infections among children aged 0-15 years, a nationwide seroprevalence study, Israel, January 2020 to March 2021.",2021-12-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Israel,,,Serum samples collected between 1 January 2020 and 31 March 2021 from children aged 0–15 years,,2020-01-01,2021-03-31,Residual sera,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,685,0.0555,0.04,0.075,,,,,,Convenience,"Author designed (ELISA) -Spike,Author designed (Neutralization Assay)",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Victoria Indenbaum,Tel Aviv University,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.48.2101040,2021-12-15,2022-07-16,Verified,indenbaum_under-diagnosis_2021,ISR
211202_Israel_TelAvivUniversity_DistrictJudeaAndSamaria,211202_Israel_TelAvivUniversity,"Under-diagnosis of SARS-CoV-2 infections among children aged 0-15 years, a nationwide seroprevalence study, Israel, January 2020 to March 2021.",2021-12-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Israel,Judea and Samaria,,Serum samples collected between 1 January 2020 and 31 March 2021 from children aged 0–15 years,,2020-01-01,2021-03-31,Residual sera,All,Children and Youth (0-17 years),0.0,15.0,Geographical area,Judea and Samaria,170,0.0941,0.055,0.14800000000000002,,,,,,Convenience,"Author designed (ELISA) -Spike,Author designed (Neutralization Assay)",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Victoria Indenbaum,Tel Aviv University,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.48.2101040,2021-12-15,2022-07-16,Verified,indenbaum_under-diagnosis_2021,ISR
211202_Israel_TelAvivUniversity_Age12-15,211202_Israel_TelAvivUniversity,"Under-diagnosis of SARS-CoV-2 infections among children aged 0-15 years, a nationwide seroprevalence study, Israel, January 2020 to March 2021.",2021-12-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Israel,,,Serum samples collected between 1 January 2020 and 31 March 2021 from children aged 0–15 years,,2020-01-01,2021-03-31,Residual sera,All,Children and Youth (0-17 years),12.0,15.0,Age,12-15,894,0.0649,0.05,0.083,,,,,,Convenience,"Author designed (ELISA) -Spike,Author designed (Neutralization Assay)",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Victoria Indenbaum,Tel Aviv University,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.48.2101040,2021-12-15,2022-07-16,Verified,indenbaum_under-diagnosis_2021,ISR
211202_Israel_TelAvivUniversity_DistrictCentral,211202_Israel_TelAvivUniversity,"Under-diagnosis of SARS-CoV-2 infections among children aged 0-15 years, a nationwide seroprevalence study, Israel, January 2020 to March 2021.",2021-12-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Israel,Central,,Serum samples collected between 1 January 2020 and 31 March 2021 from children aged 0–15 years,,2020-01-01,2021-03-31,Residual sera,All,Children and Youth (0-17 years),0.0,15.0,Geographical area,Central,599,0.0534,0.037000000000000005,0.075,,,,,,Convenience,"Author designed (ELISA) -Spike,Author designed (Neutralization Assay)",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Victoria Indenbaum,Tel Aviv University,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.48.2101040,2021-12-15,2022-07-16,Verified,indenbaum_under-diagnosis_2021,ISR
211202_Israel_TelAvivUniversity_SexMale,211202_Israel_TelAvivUniversity,"Under-diagnosis of SARS-CoV-2 infections among children aged 0-15 years, a nationwide seroprevalence study, Israel, January 2020 to March 2021.",2021-12-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Israel,,,Serum samples collected between 1 January 2020 and 31 March 2021 from children aged 0–15 years,,2020-01-01,2021-03-31,Residual sera,Male,Children and Youth (0-17 years),0.0,15.0,Sex/Gender,,1436,0.0571,0.046,0.07,,,,,,Convenience,"Author designed (ELISA) -Spike,Author designed (Neutralization Assay)",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Victoria Indenbaum,Tel Aviv University,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.48.2101040,2021-12-15,2022-07-16,Verified,indenbaum_under-diagnosis_2021,ISR
211202_Israel_TelAvivUniversity_SexFemale,211202_Israel_TelAvivUniversity,"Under-diagnosis of SARS-CoV-2 infections among children aged 0-15 years, a nationwide seroprevalence study, Israel, January 2020 to March 2021.",2021-12-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Israel,,,Serum samples collected between 1 January 2020 and 31 March 2021 from children aged 0–15 years,,2020-01-01,2021-03-31,Residual sera,Female,Children and Youth (0-17 years),0.0,15.0,Sex/Gender,,1329,0.055700000000000006,0.044000000000000004,0.069,,,,,,Convenience,"Author designed (ELISA) -Spike,Author designed (Neutralization Assay)",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Victoria Indenbaum,Tel Aviv University,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.48.2101040,2021-12-15,2022-07-16,Verified,indenbaum_under-diagnosis_2021,ISR
211202_Israel_TelAvivUniversity_DistrictJerusalem,211202_Israel_TelAvivUniversity,"Under-diagnosis of SARS-CoV-2 infections among children aged 0-15 years, a nationwide seroprevalence study, Israel, January 2020 to March 2021.",2021-12-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Israel,Jerusalem,,Serum samples collected between 1 January 2020 and 31 March 2021 from children aged 0–15 years,,2020-01-01,2021-03-31,Residual sera,All,Children and Youth (0-17 years),0.0,15.0,Geographical area,Jerusalem,191,0.1099,0.069,0.163,,,,,,Convenience,"Author designed (ELISA) -Spike,Author designed (Neutralization Assay)",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Victoria Indenbaum,Tel Aviv University,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.48.2101040,2021-12-15,2022-07-16,Verified,indenbaum_under-diagnosis_2021,ISR
211202_Israel_TelAvivUniversity_DistrictHaifa,211202_Israel_TelAvivUniversity,"Under-diagnosis of SARS-CoV-2 infections among children aged 0-15 years, a nationwide seroprevalence study, Israel, January 2020 to March 2021.",2021-12-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Israel,Haifa,,Serum samples collected between 1 January 2020 and 31 March 2021 from children aged 0–15 years,,2020-01-01,2021-03-31,Residual sera,All,Children and Youth (0-17 years),0.0,15.0,Geographical area,Haifa,336,0.047599999999999996,0.027999999999999997,0.076,,,,,,Convenience,"Author designed (ELISA) -Spike,Author designed (Neutralization Assay)",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Victoria Indenbaum,Tel Aviv University,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2021.26.48.2101040,2021-12-15,2022-07-16,Verified,indenbaum_under-diagnosis_2021,ISR
220426_NorthernIsrael_RambamHealthCareCampus_Overall,220426_NorthernIsrael_RambamHealthCareCampus,COVID-19: Healthcare Workers May Be at Greater Risk Outside Their Work Environment-A Retrospective Observational Study.,2022-04-26,Journal Article (Peer-Reviewed),Regional,Retrospective cohort,Israel,Northern Israel,,"All HCW at the hospital. The hospital employs 5,478
workers from both cities and villages, residing from
the center of Israel to the far north.",,2020-11-15,2020-11-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,4519,0.046,,,True,,,,True,Convenience,"Not reported/ Unable to specify,Liaison SARS-CoV-2 S1/S2 IgG","NA,DiaSorin",CLIA,Serum,IgG,"['Notreported', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Khetam Hussein,Rambam Health Care Campus,Not Unity-Aligned,https://dx.doi.org/10.5041/RMMJ.10469,2022-05-05,2024-03-01,Unverified,the_infection_control_unit_rambam_health_care_campus_haifa_israel_covid-19_2022,ISR
220524_EmekMedicalCenter_EmekMedicalCenter_Overall,220524_EmekMedicalCenter_EmekMedicalCenter,Seroprevalence of SARS-CoV2 among Healthcare Workers: A Prospective Study.,2022-05-24,Journal Article (Peer-Reviewed),Local,Prospective cohort,Israel,Northern District,Afula,HCWs of the Emek Medical Center ,,2020-04-01,2021-04-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,101,0.099,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Carmel Kasher,Emek Medical Center,Not Unity-Aligned,https://www.ima.org.il/MedicineIMAJ/viewarticle.aspx?year=2022&month=05&page=284,2022-06-04,2024-03-01,Unverified,kasher_seroprevalence_2022,ISR
220716_Israel_ BaruchPadehMedicalCenter_Overall,220716_Israel_ BaruchPadehMedicalCenter,Should pregnant women be screened for SARS-CoV-2 infection? A prospective multicenter cohort study.,2022-07-16,Journal Article (Peer-Reviewed),Local,Prospective cohort,Israel,North District,"Tiberias, Afula","Women between the ages of 18 and 50 (either pregnant or not pregnant). "" Pregnant women were recruited if the last menstrual period (LMP) was before March 2, 2020 (2nd March 2020 was chosen as an LMP as that is 14 days prior to 16th March 2020) to make sure that they were pregnant throughou the COVID-19 pandemic. Non-pregnant women were recruited if they were not pregnant during the same period""",Women with COVID symptoms at any time during the pandemic were excluded,2020-07-14,2021-02-03,Multiple populations,Female,Adults (18-64 years),18.0,50.0,Primary Estimate,,297,0.034,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",Multiple Types,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,No,,Yes,Yes,No,,Enav Yefet,Emek Medical Centre,Not Unity-Aligned,https://dx.doi.org/10.1002/ijgo.14359,2022-07-28,2024-03-01,Unverified,yefet_should_2022,ISR
221005_Israel_ChaimShebaMedicalCenter_Primary,221005_Israel_ChaimShebaMedicalCenter,"Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020-July 2021.",2022-10-05,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Israel,,,"""Adults aged 16 years and older"", ""individuals who performed routine or diagnostic blood tests between January 2020 and July 2021 in the following laboratories: the Soroka laboratory of the Clalit Health Maintenance Organization (HMO) (non-hospitalized patients) in the south of Israel, the Haifa and Western Galilee laboratory of the Clalit HMO in northern Israel, the Jerusalem Clalit HMO in Central Israel, the Mayanei Hayeshua Medical Center in Bnei-Brak, and the National Blood Service (NBS) of the Medical Emergency Services in Israel (Magen David Adom) in central Israel""",,2020-01-15,2021-07-15,Residual sera,All,Multiple groups,16.0,103.0,Primary Estimate,,9517,0.2831774719,,,True,,,,True,Entire sample,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.88,0.98,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Ravit Bassal,Chaim Sheba Medical Centre,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10101663,2022-11-03,2023-02-03,Unverified,bassal_estimated_2022,ISR
221005_Israel_ChaimShebaMedicalCenter_Geography_TelAviv,221005_Israel_ChaimShebaMedicalCenter,"Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020-July 2021.",2022-10-05,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Israel,Tel Aviv District,,"""Adults aged 16 years and older"", ""individuals who performed routine or diagnostic blood tests between January 2020 and July 2021 in the following laboratories: the Soroka laboratory of the Clalit Health Maintenance Organization (HMO) (non-hospitalized patients) in the south of Israel, the Haifa and Western Galilee laboratory of the Clalit HMO in northern Israel, the Jerusalem Clalit HMO in Central Israel, the Mayanei Hayeshua Medical Center in Bnei-Brak, and the National Blood Service (NBS) of the Medical Emergency Services in Israel (Magen David Adom) in central Israel""",,2020-01-15,2021-07-15,Residual sera,All,Multiple groups,16.0,103.0,Geographical area,Tel Aviv,929,0.3057050592,,,,,,,,Entire sample,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.88,0.98,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Ravit Bassal,Chaim Sheba Medical Centre,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10101663,2022-11-03,2022-11-03,Unverified,bassal_estimated_2022,ISR
221005_Israel_ChaimShebaMedicalCenter_Period_Jan-Jul2021,221005_Israel_ChaimShebaMedicalCenter,"Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020-July 2021.",2022-10-05,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Israel,,,"""Adults aged 16 years and older"", ""individuals who performed routine or diagnostic blood tests between January 2020 and July 2021 in the following laboratories: the Soroka laboratory of the Clalit Health Maintenance Organization (HMO) (non-hospitalized patients) in the south of Israel, the Haifa and Western Galilee laboratory of the Clalit HMO in northern Israel, the Jerusalem Clalit HMO in Central Israel, the Mayanei Hayeshua Medical Center in Bnei-Brak, and the National Blood Service (NBS) of the Medical Emergency Services in Israel (Magen David Adom) in central Israel""",,2021-01-01,2021-07-15,Residual sera,All,Multiple groups,16.0,103.0,Time frame,January 2021-July 2021,3478,0.7032777458,,,,,,,,Entire sample,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.88,0.98,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Ravit Bassal,Chaim Sheba Medical Centre,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10101663,2022-11-03,2022-11-03,Unverified,bassal_estimated_2022,ISR
221005_Israel_ChaimShebaMedicalCenter_Age_65.00+,221005_Israel_ChaimShebaMedicalCenter,"Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020-July 2021.",2022-10-05,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Israel,,,"""Adults aged 16 years and older"", ""individuals who performed routine or diagnostic blood tests between January 2020 and July 2021 in the following laboratories: the Soroka laboratory of the Clalit Health Maintenance Organization (HMO) (non-hospitalized patients) in the south of Israel, the Haifa and Western Galilee laboratory of the Clalit HMO in northern Israel, the Jerusalem Clalit HMO in Central Israel, the Mayanei Hayeshua Medical Center in Bnei-Brak, and the National Blood Service (NBS) of the Medical Emergency Services in Israel (Magen David Adom) in central Israel""",,2020-01-15,2021-07-15,Residual sera,All,Seniors (65+ years),65.0,103.0,Age,65.00+,2167,0.26949700050000003,,,,,,,,Entire sample,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.88,0.98,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Ravit Bassal,Chaim Sheba Medical Centre,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10101663,2022-11-03,2022-11-03,Unverified,bassal_estimated_2022,ISR
221005_Israel_ChaimShebaMedicalCenter_Geography_Jerusalem,221005_Israel_ChaimShebaMedicalCenter,"Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020-July 2021.",2022-10-05,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Israel,Jerusalem District,,"""Adults aged 16 years and older"", ""individuals who performed routine or diagnostic blood tests between January 2020 and July 2021 in the following laboratories: the Soroka laboratory of the Clalit Health Maintenance Organization (HMO) (non-hospitalized patients) in the south of Israel, the Haifa and Western Galilee laboratory of the Clalit HMO in northern Israel, the Jerusalem Clalit HMO in Central Israel, the Mayanei Hayeshua Medical Center in Bnei-Brak, and the National Blood Service (NBS) of the Medical Emergency Services in Israel (Magen David Adom) in central Israel""",,2020-01-15,2021-07-15,Residual sera,All,Multiple groups,16.0,103.0,Geographical area,Jerusalem,1379,0.3096446701,,,,,,,,Entire sample,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.88,0.98,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Ravit Bassal,Chaim Sheba Medical Centre,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10101663,2022-11-03,2022-11-03,Unverified,bassal_estimated_2022,ISR
221005_Israel_ChaimShebaMedicalCenter_Geography_JudeaandSamaria,221005_Israel_ChaimShebaMedicalCenter,"Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020-July 2021.",2022-10-05,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Israel,Judea and Samaria District,,"""Adults aged 16 years and older"", ""individuals who performed routine or diagnostic blood tests between January 2020 and July 2021 in the following laboratories: the Soroka laboratory of the Clalit Health Maintenance Organization (HMO) (non-hospitalized patients) in the south of Israel, the Haifa and Western Galilee laboratory of the Clalit HMO in northern Israel, the Jerusalem Clalit HMO in Central Israel, the Mayanei Hayeshua Medical Center in Bnei-Brak, and the National Blood Service (NBS) of the Medical Emergency Services in Israel (Magen David Adom) in central Israel""",,2020-01-15,2021-07-15,Residual sera,All,Multiple groups,16.0,103.0,Geographical area,Judea and Samaria,501,0.28942115770000004,,,,,,,,Entire sample,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.88,0.98,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Ravit Bassal,Chaim Sheba Medical Centre,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10101663,2022-11-03,2022-11-03,Unverified,bassal_estimated_2022,ISR
221005_Israel_ChaimShebaMedicalCenter_Geography_South,221005_Israel_ChaimShebaMedicalCenter,"Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020-July 2021.",2022-10-05,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Israel,South District,,"""Adults aged 16 years and older"", ""individuals who performed routine or diagnostic blood tests between January 2020 and July 2021 in the following laboratories: the Soroka laboratory of the Clalit Health Maintenance Organization (HMO) (non-hospitalized patients) in the south of Israel, the Haifa and Western Galilee laboratory of the Clalit HMO in northern Israel, the Jerusalem Clalit HMO in Central Israel, the Mayanei Hayeshua Medical Center in Bnei-Brak, and the National Blood Service (NBS) of the Medical Emergency Services in Israel (Magen David Adom) in central Israel""",,2020-01-15,2021-07-15,Residual sera,All,Multiple groups,16.0,103.0,Geographical area,South,2556,0.23278560250000002,,,,,,,,Entire sample,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.88,0.98,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Ravit Bassal,Chaim Sheba Medical Centre,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10101663,2022-11-03,2022-11-03,Unverified,bassal_estimated_2022,ISR
221005_Israel_ChaimShebaMedicalCenter_Age_40.00-64.99,221005_Israel_ChaimShebaMedicalCenter,"Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020-July 2021.",2022-10-05,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Israel,,,"""Adults aged 16 years and older"", ""individuals who performed routine or diagnostic blood tests between January 2020 and July 2021 in the following laboratories: the Soroka laboratory of the Clalit Health Maintenance Organization (HMO) (non-hospitalized patients) in the south of Israel, the Haifa and Western Galilee laboratory of the Clalit HMO in northern Israel, the Jerusalem Clalit HMO in Central Israel, the Mayanei Hayeshua Medical Center in Bnei-Brak, and the National Blood Service (NBS) of the Medical Emergency Services in Israel (Magen David Adom) in central Israel""",,2020-01-15,2021-07-15,Residual sera,All,Adults (18-64 years),40.0,64.0,Age,40.00-64.99,2953,0.3054520826,,,,,,,,Entire sample,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.88,0.98,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Ravit Bassal,Chaim Sheba Medical Centre,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10101663,2022-11-03,2022-11-03,Unverified,bassal_estimated_2022,ISR
221005_Israel_ChaimShebaMedicalCenter_Geography_Haifa,221005_Israel_ChaimShebaMedicalCenter,"Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020-July 2021.",2022-10-05,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Israel,Haifa District,,"""Adults aged 16 years and older"", ""individuals who performed routine or diagnostic blood tests between January 2020 and July 2021 in the following laboratories: the Soroka laboratory of the Clalit Health Maintenance Organization (HMO) (non-hospitalized patients) in the south of Israel, the Haifa and Western Galilee laboratory of the Clalit HMO in northern Israel, the Jerusalem Clalit HMO in Central Israel, the Mayanei Hayeshua Medical Center in Bnei-Brak, and the National Blood Service (NBS) of the Medical Emergency Services in Israel (Magen David Adom) in central Israel""",,2020-01-15,2021-07-15,Residual sera,All,Multiple groups,16.0,103.0,Geographical area,Haifa,892,0.2791479821,,,,,,,,Entire sample,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.88,0.98,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Ravit Bassal,Chaim Sheba Medical Centre,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10101663,2022-11-03,2022-11-03,Unverified,bassal_estimated_2022,ISR
221005_Israel_ChaimShebaMedicalCenter_Geography_North,221005_Israel_ChaimShebaMedicalCenter,"Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020-July 2021.",2022-10-05,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Israel,North DIstrict,,"""Adults aged 16 years and older"", ""individuals who performed routine or diagnostic blood tests between January 2020 and July 2021 in the following laboratories: the Soroka laboratory of the Clalit Health Maintenance Organization (HMO) (non-hospitalized patients) in the south of Israel, the Haifa and Western Galilee laboratory of the Clalit HMO in northern Israel, the Jerusalem Clalit HMO in Central Israel, the Mayanei Hayeshua Medical Center in Bnei-Brak, and the National Blood Service (NBS) of the Medical Emergency Services in Israel (Magen David Adom) in central Israel""",,2020-01-15,2021-07-15,Residual sera,All,Multiple groups,16.0,103.0,Geographical area,North,2382,0.3173803526,,,,,,,,Entire sample,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.88,0.98,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Ravit Bassal,Chaim Sheba Medical Centre,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10101663,2022-11-03,2022-11-03,Unverified,bassal_estimated_2022,ISR
221005_Israel_ChaimShebaMedicalCenter_Sex_Female,221005_Israel_ChaimShebaMedicalCenter,"Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020-July 2021.",2022-10-05,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Israel,,,"""Adults aged 16 years and older"", ""individuals who performed routine or diagnostic blood tests between January 2020 and July 2021 in the following laboratories: the Soroka laboratory of the Clalit Health Maintenance Organization (HMO) (non-hospitalized patients) in the south of Israel, the Haifa and Western Galilee laboratory of the Clalit HMO in northern Israel, the Jerusalem Clalit HMO in Central Israel, the Mayanei Hayeshua Medical Center in Bnei-Brak, and the National Blood Service (NBS) of the Medical Emergency Services in Israel (Magen David Adom) in central Israel""",,2020-01-15,2021-07-15,Residual sera,Female,Multiple groups,16.0,103.0,Sex/Gender,,5167,0.2874008129,,,,,,,,Entire sample,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.88,0.98,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Ravit Bassal,Chaim Sheba Medical Centre,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10101663,2022-11-03,2022-11-03,Unverified,bassal_estimated_2022,ISR
221005_Israel_ChaimShebaMedicalCenter_Geography_Central,221005_Israel_ChaimShebaMedicalCenter,"Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020-July 2021.",2022-10-05,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Israel,Central District,,"""Adults aged 16 years and older"", ""individuals who performed routine or diagnostic blood tests between January 2020 and July 2021 in the following laboratories: the Soroka laboratory of the Clalit Health Maintenance Organization (HMO) (non-hospitalized patients) in the south of Israel, the Haifa and Western Galilee laboratory of the Clalit HMO in northern Israel, the Jerusalem Clalit HMO in Central Israel, the Mayanei Hayeshua Medical Center in Bnei-Brak, and the National Blood Service (NBS) of the Medical Emergency Services in Israel (Magen David Adom) in central Israel""",,2020-01-15,2021-07-15,Residual sera,All,Multiple groups,16.0,103.0,Geographical area,Central,855,0.298245614,,,,,,,,Entire sample,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.88,0.98,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Ravit Bassal,Chaim Sheba Medical Centre,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10101663,2022-11-03,2022-11-03,Unverified,bassal_estimated_2022,ISR
221005_Israel_ChaimShebaMedicalCenter_Sex_Male,221005_Israel_ChaimShebaMedicalCenter,"Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020-July 2021.",2022-10-05,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Israel,,,"""Adults aged 16 years and older"", ""individuals who performed routine or diagnostic blood tests between January 2020 and July 2021 in the following laboratories: the Soroka laboratory of the Clalit Health Maintenance Organization (HMO) (non-hospitalized patients) in the south of Israel, the Haifa and Western Galilee laboratory of the Clalit HMO in northern Israel, the Jerusalem Clalit HMO in Central Israel, the Mayanei Hayeshua Medical Center in Bnei-Brak, and the National Blood Service (NBS) of the Medical Emergency Services in Israel (Magen David Adom) in central Israel""",,2020-01-15,2021-07-15,Residual sera,Male,Multiple groups,16.0,103.0,Sex/Gender,,4353,0.2779692166,,,,,,,,Entire sample,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.88,0.98,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Ravit Bassal,Chaim Sheba Medical Centre,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10101663,2022-11-03,2022-11-03,Unverified,bassal_estimated_2022,ISR
221005_Israel_ChaimShebaMedicalCenter_Age_16.00-39.99,221005_Israel_ChaimShebaMedicalCenter,"Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020-July 2021.",2022-10-05,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Israel,,,"""Adults aged 16 years and older"", ""individuals who performed routine or diagnostic blood tests between January 2020 and July 2021 in the following laboratories: the Soroka laboratory of the Clalit Health Maintenance Organization (HMO) (non-hospitalized patients) in the south of Israel, the Haifa and Western Galilee laboratory of the Clalit HMO in northern Israel, the Jerusalem Clalit HMO in Central Israel, the Mayanei Hayeshua Medical Center in Bnei-Brak, and the National Blood Service (NBS) of the Medical Emergency Services in Israel (Magen David Adom) in central Israel""",,2020-01-15,2021-07-15,Residual sera,All,Adults (18-64 years),16.0,39.0,Age,16.00-39.99,4397,0.2749602001,,,,,,,,Entire sample,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.88,0.98,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Ravit Bassal,Chaim Sheba Medical Centre,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10101663,2022-11-03,2022-11-03,Unverified,bassal_estimated_2022,ISR
221005_Israel_ChaimShebaMedicalCenter_Period_Jan-Dec2020,221005_Israel_ChaimShebaMedicalCenter,"Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020-July 2021.",2022-10-05,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Israel,,,"""Adults aged 16 years and older"", ""individuals who performed routine or diagnostic blood tests between January 2020 and July 2021 in the following laboratories: the Soroka laboratory of the Clalit Health Maintenance Organization (HMO) (non-hospitalized patients) in the south of Israel, the Haifa and Western Galilee laboratory of the Clalit HMO in northern Israel, the Jerusalem Clalit HMO in Central Israel, the Mayanei Hayeshua Medical Center in Bnei-Brak, and the National Blood Service (NBS) of the Medical Emergency Services in Israel (Magen David Adom) in central Israel""",,2020-01-15,2020-12-31,Residual sera,All,Multiple groups,16.0,100.0,Time frame,January 2020-December 2020,6039,0.04123199205,,,,,,,,Entire sample,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.88,0.98,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Ravit Bassal,Chaim Sheba Medical Centre,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10101663,2022-11-03,2022-11-03,Unverified,bassal_estimated_2022,ISR
200430_Bergamo_ATSBergamo_GeneralPopulation_AnalyzedLab1,200430_Bergamo_ATSBergamo,"Bergamo serological tests, the results of Nembro and Alzano arrive: 61% positive",2020-04-30,News and Media,Local,Cross-sectional survey ,Italy,Lombardy,"Alzano, Nembro",,,2020-04-23,2020-04-28,Household and community samples,All,Multiple groups,,,Primary Estimate,,750,0.61,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,Armando Di Landro,ATS Bergamo,Not Unity-Aligned,https://bergamo.corriere.it/notizie/cronaca/20_aprile_30/coronavirus-bergamo-primi-risultati-test-61percento-positivi-85e8e36c-8a6b-11ea-94d3-9879860c12b6.shtml?refresh_ce-cp,2020-06-02,2022-07-16,Verified,di_landro_bergamo_2020,ITA
200430_Bergamo_ATSBergamo_GeneralPopulation_AnalyzedLab2,200430_Bergamo_ATSBergamo,"Bergamo serological tests, the results of Nembro and Alzano arrive: 61% positive",2020-04-30,News and Media,Local,Cross-sectional survey ,Italy,Lombardy,"Alzano, Nembro",,,2020-04-23,2020-04-28,Household and community samples,All,Multiple groups,,,Analysis,Analysed by a different lab,750,0.585,,,,,,,,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,Armando Di Landro,ATS Bergamo,Not Unity-Aligned,https://bergamo.corriere.it/notizie/cronaca/20_aprile_30/coronavirus-bergamo-primi-risultati-test-61percento-positivi-85e8e36c-8a6b-11ea-94d3-9879860c12b6.shtml?refresh_ce-cp,2020-06-02,2022-07-16,Verified,di_landro_bergamo_2020,ITA
200430_Bergamo_HospitalofBergamo_HCW,200430_Bergamo_HospitalofBergamo,"Bergamo serological tests, the results of Nembro and Alzano arrive: 61% positive",2020-04-30,News and Media,Local,Cross-sectional survey ,Italy,Lombardy,Bergamo,,,,2020-04-24,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,3000,0.13,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,Armando Di Landro,Hospital of Bergamo,Not Unity-Aligned,https://bergamo.corriere.it/notizie/cronaca/20_aprile_30/coronavirus-bergamo-primi-risultati-test-61percento-positivi-85e8e36c-8a6b-11ea-94d3-9879860c12b6.shtml?refresh_ce-cp,2020-06-02,2022-07-16,Verified,di_landro_bergamo_2020,ITA
200508_Bari_IstitutoTumoriGPaolo_HCW_IgG,200508_Bari_IstitutoTumoriGPaolo,COVID-19 SCREENING AND MONITORING OF ASYMPTOMATIC HEALTH WORKERS WITH A RAPID SEROLOGICAL TEST,2020-05-08,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Italy,Puglia,Bari,"Asymptomatic HCW employed at INstituto TUmori G. Paolo II, IRCCS.",,2020-03-26,2020-04-17,Health care workers and caregivers,All,Adults (18-64 years),20.0,73.0,Primary Estimate,,606,0.0033000000000000004,,,True,,,,True,Convenience,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Plasma,IgG,,,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Angelo Virgilio Paradiso,Istituto Tumori G. Paolo II,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.05.05.20086017v1,2020-05-14,2024-03-01,Verified,paradiso_covid-19_2020,ITA
200609_Bergamo_HealthAgency_GenPop,200609_Bergamo_BergamoHealthAgency,Over half of people tested in Italy's  Bergamo have COVID-19 antibodies,2020-06-09,News and Media,Regional,Cross-sectional survey ,Italy,Lombardy,,Residents in Bergamo,,2020-04-23,2020-06-03,Household and community samples,All,Multiple groups,,,Primary Estimate,,9965,0.5700000000000001,,,True,,,,True,Simplified probability,Not reported/ Unable to specify,,,,,,,,,['Moderate'],Yes,Yes,Yes,No,Yes,Unclear,Yes,No,Unclear,Angelo Amante,Bergamo Health Agency,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.thejakartapost.com/news/2020/06/09/over-half-of-people-tested-in-italys-bergamo-have-covid-19-antibodies.html&ct=ga&cd=CAAYAjIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNEF-NEDdVnSHZTUUTQEQL5px8dXmw,2020-07-06,2022-07-16,Verified,angelo_amante_over_2020,ITA
200609_Milan_UniMilan_OverallAb,200609_Milan_UniversityofMilan,"SARS-CoV-2 infection among asymptomatic homebound subjects in Milan, Italy",2020-06-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,asymptomatic patients who were in lockdown,"any participants who had symptoms at the time of, or sometime within the previous 14 days were not included (flu, dyspnea, etc)",2020-03-30,2020-03-31,Household and community samples,All,Adults (18-64 years),,,Test used,,197,0.1015,,,True,,,,,Self-referral,"Wantai SARS-CoV-2 Total Ab ELISA,Anti-SARS-CoV-2 ELISA IgG,Wantai SARS-CoV-2 IgM ELISA","Beijing Wantai Biological,EUROIMMUN",ELISA,Plasma,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],Yes,No,No,No,No,Yes,Yes,Yes,Yes,Gregorio Milani,University of Milan,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280100/pdf/main.pdf,2020-06-23,2024-03-01,Verified,milani_sars-cov-2_2020,ITA
200609_Milan_uniMilan_TotalAb,200609_Milan_UniversityofMilan,"SARS-CoV-2 infection among asymptomatic homebound subjects in Milan, Italy",2020-06-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,asymptomatic patients who were in lockdown,"any participants who had symptoms at the time of, or sometime within the previous 14 days were not included (flu, dyspnea, etc)",2020-03-30,2020-03-31,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,One test used,197,0.055999999999999994,,,,,,,True,Self-referral,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,,,['High'],Yes,No,No,No,No,Yes,Yes,Yes,Yes,Gregorio Milani,University of Milan,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280100/pdf/main.pdf,2020-06-23,2024-03-01,Verified,milani_sars-cov-2_2020,ITA
200617_Italy_D.CotugnoHospital_HCW_IgG,200617_Italy_D.CotugnoHospital,"COVID-19 among healthcare workers in a specialist infectious diseases setting in Naples, Southern Italy: results of a cross-sectional surveillance study",2020-06-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Campania,Naples,"All HCWs (medical doctors, nurses, and care workers) who worked in the ED between 26th February and 23rd March

Completed a surveillance test according to the study protocol;asymptomatic at the time of surveillance; and gave consent for the use of personal data.",,2020-03-23,2020-04-02,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,115,0.0174,,,True,,,,True,Convenience,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Whole Blood,IgG,,,,,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,Francesco Fusco,D. Cotugno’ Hospital,Not Unity-Aligned,https://www.journalofhospitalinfection.com/article/S0195-6701(20)30306-6/fulltext,2020-07-18,2024-03-01,Verified,fusco_covid-19_2020,ITA
200619_Rome_UniversityofRome_IgG,200619_Rome_UniversityofRome,Prevalence of Sars-Cov-2 Infection in Health Workers (HWs) and Diagnostic Test Performance: The Experience of a Teaching Hospital in Central Italy.,2020-06-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lazio,Rome,HCWs at a teaching hospital in Rome who had participated in the RT-PCR test,,2020-04-07,2020-04-27,Health care workers and caregivers,All,Adults (18-64 years),19.0,69.0,Primary Estimate,,1084,0.006999999999999999,,,True,,,,True,Convenience,2019-nCoV IgM/IgG CLIA,Medical Systems,CLIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,0.5,0.991,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,No,,Edith Lahner,University of Rome,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7345358/,2020-07-21,2022-07-16,Verified,lahner_prevalence_2020,ITA
200704_Milan_SantagostinoMedicalCenter_FamilyMembersMiddleAge,200704_Milan_SantagostinoMedicalCenter_Family,"Covid-19 exposure risk for family members
  of healthcare workers: an observational study.",2020-07-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,family members of health care workers in a COVID-19 hospital in Milan ,,2020-05-02,2020-05-31,Family of essential workers,All,Multiple groups,4.0,85.0,Age,Middle aged family members of health care workers (mean age 42 +/- 12),33,0.6970000000000001,,,,,,,,Convenience,PRIMA COVID-19 IgG/IgM Rapid Test,PRIMA Lab S.A.,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by manufacturers,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Dioscoridi Lorenzo,Santagostino Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2020.06.106,2020-07-30,2024-03-01,Verified,lorenzo_covid-19_2020,ITA
200704_Milan_SantagostinoMedicalCenter_FamilyMembers,200704_Milan_SantagostinoMedicalCenter_Family,"Covid-19 exposure risk for family members
  of healthcare workers: an observational study.",2020-07-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,family members of health care workers in a COVID-19 hospital in Milan ,,2020-05-02,2020-05-31,Family of essential workers,All,Multiple groups,4.0,85.0,Primary Estimate,Family members of health care workers,81,0.321,,,,,,,,Convenience,PRIMA COVID-19 IgG/IgM Rapid Test,PRIMA Lab S.A.,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by manufacturers,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Dioscoridi Lorenzo,Santagostino Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2020.06.106,2020-07-30,2024-03-01,Verified,lorenzo_covid-19_2020,ITA
200704_Milan_SantagostinoMedicalCenter_FamilyMembersOld,200704_Milan_SantagostinoMedicalCenter_Family,"Covid-19 exposure risk for family members
  of healthcare workers: an observational study.",2020-07-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,family members of health care workers in a COVID-19 hospital in Milan ,,2020-05-02,2020-05-31,Family of essential workers,All,Multiple groups,4.0,85.0,Age,Old family members of health care workers (mean age 79 +/- 6),3,1.0,,,,,,,,Convenience,PRIMA COVID-19 IgG/IgM Rapid Test,PRIMA Lab S.A.,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by manufacturers,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Dioscoridi Lorenzo,Santagostino Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2020.06.106,2020-07-30,2024-03-01,Verified,lorenzo_covid-19_2020,ITA
200704_Milan_SantagostinoMedicalCenter_FamilyMembersYoung,200704_Milan_SantagostinoMedicalCenter_Family,"Covid-19 exposure risk for family members
  of healthcare workers: an observational study.",2020-07-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,family members of health care workers in a COVID-19 hospital in Milan ,,2020-05-02,2020-05-31,Family of essential workers,All,Multiple groups,4.0,85.0,Age,Young family members of health care workers (mean age 11 +/- 7),45,0.0,,,,,,,,Convenience,PRIMA COVID-19 IgG/IgM Rapid Test,PRIMA Lab S.A.,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by manufacturers,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Dioscoridi Lorenzo,Santagostino Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2020.06.106,2020-07-30,2024-03-01,Verified,lorenzo_covid-19_2020,ITA
200704_Milan_SantagostinoMedicalCenter_HCWs,200704_Milan_SantagostinoMedicalCenter_HCW,"Covid-19 exposure risk for family members
  of healthcare workers: an observational study.",2020-07-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,Health care workers in a COVID-19 hospital in Milan ,,2020-05-02,2020-05-31,Health care workers and caregivers,All,Multiple groups,4.0,85.0,Primary Estimate,Healthcare worker,38,0.053,,,,,,,,Convenience,PRIMA COVID-19 IgG/IgM Rapid Test,PRIMA Lab S.A.,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by manufacturers,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Dioscoridi Lorenzo,Santagostino Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2020.06.106,2020-07-30,2024-03-01,Verified,lorenzo_covid-19_2020,ITA
200707_Turin_University of Turin_PregnantWomen_IgGonly,200707_Turin_UniversityofTurin,"The ""scar"" of a pandemic: cumulative incidence of COVID-19 during the first trimester of pregnancy.",2020-07-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Piedmont,Turin,"Twelve week pregnant women attending Sant’Anna Hospital, Piedmont Region, Turin, Italy for fetal nuchal translucency measurement between April 16 and June 4, 2020 were invited to participate in the study. ",,2020-04-16,2020-06-04,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,138,0.05797,,,True,,,,True,Sequential,AFIAS COVID-19 Ab assay,Boditech Med Inc.,LFIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Stefano Cosma,University of Turin,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.26267,2020-08-01,2024-03-01,Verified,cosma_scar_2020,ITA
200721_Arezzo_OspedaleSanDonato_Total,200721_Arezzo_OspedaleSanDonato,Comparison of serologic and molecular SARS-CoV 2 results in a large cohort in Southern Tuscany demonstrates a role for serologic testing to increase diagnostic sensitivity,2020-07-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Tuscany,Arezzo,"From March 17 to 21, 2020, we analyzed 516 nasopharyngeal swabs from patients in the Emergency Room (ER) and from subjects undergoing health surveillance by territorial and hospital prevention departments. All patients provided informed consent in accordance with the Declaration of Helsinki.",,2020-03-17,2020-03-21,Residual sera,All,Adults (18-64 years),,,Primary Estimate,,516,0.13,,,True,,,,True,Sequential,Acro Biotech COVID-19 IgM/IgG Rapid POC test,ACRO Biotech Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.37,0.9400000000000001,['High'],Yes,No,No,Yes,No,Yes,Yes,No,Unclear,Alessandro Pancrazzi,Ospedale San Donato,Unity-Aligned,http://dx.doi.org/10.1016/j.clinbiochem.2020.07.002,2020-09-28,2024-03-01,Verified,pancrazzi_comparison_2020,ITA
200721_Lodi_A.S.S.T.Lodi_HCW_overall,200721_Lodi_A.S.S.T.Lodi_HCW,"SARS-CoV-2 Antibody Prevalence in Health Care Workers of Lodi Hospital, the COVID-19 Italian Epicentre",2020-07-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy Region,,The study population included all health care workers (medical personnel and non medical personnel) regardless of the type of employment contract. ,,2020-04-23,2020-05-05,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,2415,0.168,,,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Alessandro  Baracco,A.S.S.T. Lodi ,Not Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3650227,2021-04-21,2024-03-01,Verified,baracco_sars-cov-2_2020,ITA
200721_Lodi_A.S.S.T.Lodi_genpop,200721_Lodi_A.S.S.T.Lodi_genpop,"SARS-CoV-2 Antibody Prevalence in Health Care Workers of Lodi Hospital, the COVID-19 Italian Epicentre",2020-07-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy region,Lodi,People belonging to the general population,,2020-04-23,2020-05-05,Household and community samples,All,Multiple groups,,,Primary Estimate,,1792,0.298,,,True,,,,True,Simplified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Alessandro  Baracco,A.S.S.T.Lodi,Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3650227,2021-04-21,2024-03-01,Verified,baracco_sars-cov-2_2020,ITA
200721_Lodi_A.S.S.T.Lodi_age<44,200721_Lodi_A.S.S.T.Lodi_genpop,"SARS-CoV-2 Antibody Prevalence in Health Care Workers of Lodi Hospital, the COVID-19 Italian Epicentre",2020-07-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy region,Lodi,People belonging to the general population,,2020-04-23,2020-05-05,Household and community samples,All,Adults (18-64 years),,44.0,Age,age < 44,819,0.2576312576,,,,,,,,Simplified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Alessandro  Baracco,A.S.S.T.Lodi,Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3650227,2021-04-21,2024-03-01,Verified,baracco_sars-cov-2_2020,ITA
200721_Lodi_A.S.S.T.Lodi_age55-65,200721_Lodi_A.S.S.T.Lodi_genpop,"SARS-CoV-2 Antibody Prevalence in Health Care Workers of Lodi Hospital, the COVID-19 Italian Epicentre",2020-07-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy region,Lodi,People belonging to the general population,,2020-04-23,2020-05-05,Household and community samples,All,Adults (18-64 years),55.0,65.0,Age,age 55-65,350,0.34857142860000007,,,,,,,,Simplified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Alessandro  Baracco,A.S.S.T.Lodi,Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3650227,2021-04-21,2024-03-01,Verified,baracco_sars-cov-2_2020,ITA
200721_Lodi_A.S.S.T.Lodi_age>66,200721_Lodi_A.S.S.T.Lodi_genpop,"SARS-CoV-2 Antibody Prevalence in Health Care Workers of Lodi Hospital, the COVID-19 Italian Epicentre",2020-07-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy region,Lodi,People belonging to the general population,,2020-04-23,2020-05-05,Household and community samples,All,Seniors (65+ years),66.0,,Age,age > 66,136,0.5294117647000001,,,,,,,,Simplified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Alessandro  Baracco,A.S.S.T.Lodi,Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3650227,2021-04-21,2024-03-01,Verified,baracco_sars-cov-2_2020,ITA
200721_Lodi_A.S.S.T.Lodi_age45-54,200721_Lodi_A.S.S.T.Lodi_genpop,"SARS-CoV-2 Antibody Prevalence in Health Care Workers of Lodi Hospital, the COVID-19 Italian Epicentre",2020-07-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy region,Lodi,People belonging to the general population,,2020-04-23,2020-05-05,Household and community samples,All,Adults (18-64 years),45.0,54.0,Age,age 45-54,487,0.2648870637,,,,,,,,Simplified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Alessandro  Baracco,A.S.S.T.Lodi,Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3650227,2021-04-21,2024-03-01,Verified,baracco_sars-cov-2_2020,ITA
200721_Lodi_A.S.S.T.Lodi_female,200721_Lodi_A.S.S.T.Lodi_genpop,"SARS-CoV-2 Antibody Prevalence in Health Care Workers of Lodi Hospital, the COVID-19 Italian Epicentre",2020-07-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy region,Lodi,People belonging to the general population,,2020-04-23,2020-05-05,Household and community samples,Female,Multiple groups,,,Sex/Gender,female,1159,0.28472821400000003,,,,,,,,Simplified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Alessandro  Baracco,A.S.S.T.Lodi,Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3650227,2021-04-21,2024-03-01,Verified,baracco_sars-cov-2_2020,ITA
200721_Lodi_A.S.S.T.Lodi_male,200721_Lodi_A.S.S.T.Lodi_genpop,"SARS-CoV-2 Antibody Prevalence in Health Care Workers of Lodi Hospital, the COVID-19 Italian Epicentre",2020-07-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy region,Lodi,People belonging to the general population,,2020-04-23,2020-05-05,Household and community samples,Male,Multiple groups,,,Sex/Gender,male,633,0.3222748815,,,,,,,,Simplified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Alessandro  Baracco,A.S.S.T.Lodi,Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3650227,2021-04-21,2024-03-01,Verified,baracco_sars-cov-2_2020,ITA
200728_Prato_SantoStefanoHospital_Overall,200728_Prato_SantoStefanoHospital,Universal screening for SARS-CoV-2 in pregnant women admitted for delivery: how to manage antibody testing?,2020-07-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Tuscany,Prato,All pregnant women admitted for delivery. All women were asymptomatic for COVID-19. ,,2020-04-04,2020-05-16,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,134,0.044800000000000006,,,True,,,,True,Sequential,Acro Biotech COVID-19 IgM/IgG Rapid POC test,ACRO Biotech Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,Yes,Anna Cavaliere,Santo Stefano Hospital,Unity-Aligned,http://dx.doi.org/10.1080/14767058.2020.1793317,2020-09-29,2024-03-01,Verified,cavaliere_universal_2020,ITA
200729_Milan_UniversitadegliStudidiMilano_Overall_IgG,200729_Milan_UniversitadegliStudidiMilano,SARS-CoV-2 specific serological pattern in healthcare workers of an Italian COVID-19 forefront hospital,2020-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,Healthy workers of San Paolo University General Hospital. Different types of workers were recruited. ,,2020-04-02,2020-04-16,Health care workers and caregivers,All,Adults (18-64 years),20.0,69.0,Primary Estimate,,202,0.07400000000000001,0.038,0.11,True,,,,True,Convenience,COVID-19 IgM-IgG Dual Antibody Rapid Test,"BioMedomics, Inc.",LFIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.887,0.9059999999999999,['High'],Yes,No,No,Yes,Yes,Yes,Yes,No,Unclear,Giovanni Sotgiu,Università degli Studi di Milano ,Not Unity-Aligned,https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-020-01237-0,2020-09-29,2024-03-01,Verified,sotgiu_sars-cov-2_2020,ITA
200729_Milan_UniversitadegliStudidiMilano_20_29_IgM,200729_Milan_UniversitadegliStudidiMilano,SARS-CoV-2 specific serological pattern in healthcare workers of an Italian COVID-19 forefront hospital,2020-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,Healthy workers of San Paolo University General Hospital. Different types of workers were recruited. ,,2020-04-02,2020-04-16,Health care workers and caregivers,All,Adults (18-64 years),20.0,29.0,Age,20-29 ,27,0.259,0.094,0.424,,,,,,Convenience,COVID-19 IgM-IgG Dual Antibody Rapid Test,"BioMedomics, Inc.",LFIA,Serum,IgM,Spike,Validated by independent authors/third party/non-developers,0.887,0.9059999999999999,['High'],Yes,No,No,Yes,Yes,Yes,Yes,No,Unclear,Giovanni Sotgiu,Università degli Studi di Milano ,Not Unity-Aligned,https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-020-01237-0,2020-09-29,2024-03-01,Verified,sotgiu_sars-cov-2_2020,ITA
200729_Milan_UniversitadegliStudidiMilano_50_59_IgM,200729_Milan_UniversitadegliStudidiMilano,SARS-CoV-2 specific serological pattern in healthcare workers of an Italian COVID-19 forefront hospital,2020-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,Healthy workers of San Paolo University General Hospital. Different types of workers were recruited. ,,2020-04-02,2020-04-16,Health care workers and caregivers,All,Adults (18-64 years),50.0,59.0,Age,50-59,51,0.157,0.057,0.257,,,,,,Convenience,COVID-19 IgM-IgG Dual Antibody Rapid Test,"BioMedomics, Inc.",LFIA,Serum,IgM,Spike,Validated by independent authors/third party/non-developers,0.887,0.9059999999999999,['High'],Yes,No,No,Yes,Yes,Yes,Yes,No,Unclear,Giovanni Sotgiu,Università degli Studi di Milano ,Not Unity-Aligned,https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-020-01237-0,2020-09-29,2024-03-01,Verified,sotgiu_sars-cov-2_2020,ITA
200729_Milan_UniversitadegliStudidiMilano_60_69_IgG,200729_Milan_UniversitadegliStudidiMilano,SARS-CoV-2 specific serological pattern in healthcare workers of an Italian COVID-19 forefront hospital,2020-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,Healthy workers of San Paolo University General Hospital. Different types of workers were recruited. ,,2020-04-02,2020-04-16,Health care workers and caregivers,All,Adults (18-64 years),60.0,69.0,Age,60-69,23,0.044000000000000004,0.04,0.128,,,,,,Convenience,COVID-19 IgM-IgG Dual Antibody Rapid Test,"BioMedomics, Inc.",LFIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.887,0.9059999999999999,['High'],Yes,No,No,Yes,Yes,Yes,Yes,No,Unclear,Giovanni Sotgiu,Università degli Studi di Milano ,Not Unity-Aligned,https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-020-01237-0,2020-09-29,2024-03-01,Verified,sotgiu_sars-cov-2_2020,ITA
200729_Milan_UniversitadegliStudidiMilano_30_39_IgG,200729_Milan_UniversitadegliStudidiMilano,SARS-CoV-2 specific serological pattern in healthcare workers of an Italian COVID-19 forefront hospital,2020-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,Healthy workers of San Paolo University General Hospital. Different types of workers were recruited. ,,2020-04-02,2020-04-16,Health care workers and caregivers,All,Adults (18-64 years),30.0,39.0,Age,30-39,44,0.023,0.021,0.067,,,,,,Convenience,COVID-19 IgM-IgG Dual Antibody Rapid Test,"BioMedomics, Inc.",LFIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.887,0.9059999999999999,['High'],Yes,No,No,Yes,Yes,Yes,Yes,No,Unclear,Giovanni Sotgiu,Università degli Studi di Milano ,Not Unity-Aligned,https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-020-01237-0,2020-09-29,2024-03-01,Verified,sotgiu_sars-cov-2_2020,ITA
200729_Milan_UniversitadegliStudidiMilano_50_59_IgG,200729_Milan_UniversitadegliStudidiMilano,SARS-CoV-2 specific serological pattern in healthcare workers of an Italian COVID-19 forefront hospital,2020-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,Healthy workers of San Paolo University General Hospital. Different types of workers were recruited. ,,2020-04-02,2020-04-16,Health care workers and caregivers,All,Adults (18-64 years),50.0,59.0,Age,50-59,51,0.098,0.016,0.18,,,,,,Convenience,COVID-19 IgM-IgG Dual Antibody Rapid Test,"BioMedomics, Inc.",LFIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.887,0.9059999999999999,['High'],Yes,No,No,Yes,Yes,Yes,Yes,No,Unclear,Giovanni Sotgiu,Università degli Studi di Milano ,Not Unity-Aligned,https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-020-01237-0,2020-09-29,2024-03-01,Verified,sotgiu_sars-cov-2_2020,ITA
200729_Milan_UniversitadegliStudidiMilano_60_69_IgM,200729_Milan_UniversitadegliStudidiMilano,SARS-CoV-2 specific serological pattern in healthcare workers of an Italian COVID-19 forefront hospital,2020-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,Healthy workers of San Paolo University General Hospital. Different types of workers were recruited. ,,2020-04-02,2020-04-16,Health care workers and caregivers,All,Adults (18-64 years),60.0,69.0,Age,60-69,23,0.304,0.11599999999999999,0.49200000000000005,,,,,,Convenience,COVID-19 IgM-IgG Dual Antibody Rapid Test,"BioMedomics, Inc.",LFIA,Serum,IgM,Spike,Validated by independent authors/third party/non-developers,0.887,0.9059999999999999,['High'],Yes,No,No,Yes,Yes,Yes,Yes,No,Unclear,Giovanni Sotgiu,Università degli Studi di Milano ,Not Unity-Aligned,https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-020-01237-0,2020-09-29,2024-03-01,Verified,sotgiu_sars-cov-2_2020,ITA
200729_Milan_UniversitadegliStudidiMilano_20_29_IgG,200729_Milan_UniversitadegliStudidiMilano,SARS-CoV-2 specific serological pattern in healthcare workers of an Italian COVID-19 forefront hospital,2020-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,Healthy workers of San Paolo University General Hospital. Different types of workers were recruited. ,,2020-04-02,2020-04-16,Health care workers and caregivers,All,Adults (18-64 years),20.0,29.0,Age,20-29 ,27,0.14800000000000002,0.013999999999999999,0.282,,,,,,Convenience,COVID-19 IgM-IgG Dual Antibody Rapid Test,"BioMedomics, Inc.",LFIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.887,0.9059999999999999,['High'],Yes,No,No,Yes,Yes,Yes,Yes,No,Unclear,Giovanni Sotgiu,Università degli Studi di Milano ,Not Unity-Aligned,https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-020-01237-0,2020-09-29,2024-03-01,Verified,sotgiu_sars-cov-2_2020,ITA
200729_Milan_UniversitadegliStudidiMilano_40_49_IgM,200729_Milan_UniversitadegliStudidiMilano,SARS-CoV-2 specific serological pattern in healthcare workers of an Italian COVID-19 forefront hospital,2020-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,Healthy workers of San Paolo University General Hospital. Different types of workers were recruited. ,,2020-04-02,2020-04-16,Health care workers and caregivers,All,Adults (18-64 years),40.0,49.0,Age,40-49,57,0.053,0.005,0.111,,,,,,Convenience,COVID-19 IgM-IgG Dual Antibody Rapid Test,"BioMedomics, Inc.",LFIA,Serum,IgM,Spike,Validated by independent authors/third party/non-developers,0.887,0.9059999999999999,['High'],Yes,No,No,Yes,Yes,Yes,Yes,No,Unclear,Giovanni Sotgiu,Università degli Studi di Milano ,Not Unity-Aligned,https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-020-01237-0,2020-09-29,2024-03-01,Verified,sotgiu_sars-cov-2_2020,ITA
200729_Milan_UniversitadegliStudidiMilano_40_49_IgG,200729_Milan_UniversitadegliStudidiMilano,SARS-CoV-2 specific serological pattern in healthcare workers of an Italian COVID-19 forefront hospital,2020-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,Healthy workers of San Paolo University General Hospital. Different types of workers were recruited. ,,2020-04-02,2020-04-16,Health care workers and caregivers,All,Adults (18-64 years),40.0,49.0,Age,40-49,57,0.07,0.004,0.136,,,,,,Convenience,COVID-19 IgM-IgG Dual Antibody Rapid Test,"BioMedomics, Inc.",LFIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.887,0.9059999999999999,['High'],Yes,No,No,Yes,Yes,Yes,Yes,No,Unclear,Giovanni Sotgiu,Università degli Studi di Milano ,Not Unity-Aligned,https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-020-01237-0,2020-09-29,2024-03-01,Verified,sotgiu_sars-cov-2_2020,ITA
200729_Milan_UniversitadegliStudidiMilano_30_39_IgM,200729_Milan_UniversitadegliStudidiMilano,SARS-CoV-2 specific serological pattern in healthcare workers of an Italian COVID-19 forefront hospital,2020-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,Healthy workers of San Paolo University General Hospital. Different types of workers were recruited. ,,2020-04-02,2020-04-16,Health care workers and caregivers,All,Adults (18-64 years),30.0,39.0,Age,30-39,44,0.091,0.006,0.17600000000000002,,,,,,Convenience,COVID-19 IgM-IgG Dual Antibody Rapid Test,"BioMedomics, Inc.",LFIA,Serum,IgM,Spike,Validated by independent authors/third party/non-developers,0.887,0.9059999999999999,['High'],Yes,No,No,Yes,Yes,Yes,Yes,No,Unclear,Giovanni Sotgiu,Università degli Studi di Milano ,Not Unity-Aligned,https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-020-01237-0,2020-09-29,2024-03-01,Verified,sotgiu_sars-cov-2_2020,ITA
200803_Italy_ItalianMinistryOfHealth_Overall,200803_Italy_ItalianMinistryOfHealth,FIRST RESULTS OF THE SEROPREVALENCE SURVEY ON SARS-CoV-2,2020-08-03,Institutional Report,National,Cross-sectional survey ,Italy,"Abruzzo, Basilicata, Calabria, Campania, Emilia Romagna, Friuli-Venezia Giulia, Lazio, Liguria, Lombardy, Marche, Molise, Piemonte, Trentino-Alto Adige, Puglia, Sardegna, Sicily, Tuscany, Umbria, Valle D'Aosta, Veneto",,"The people selected were also asked to respond to a specific questionnaire  prepared by Istat, in agreement with the Technical Scientific Committee.",,2020-05-25,2020-07-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,64660,0.025,,,True,,,,True,Stratified non-probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Instituto Nazionale di Statistica,Italian Ministry of Health,Unity-Aligned,https://www.istat.it/it/files//2020/08/ReportPrimiRisultatiIndagineSiero.pdf,2020-10-04,2024-03-01,Verified,instituto_nazionale_di_statistica_primi_2020,ITA
200804_Tuscany_ArezzoHospital_HealthcareWorkers_Overall,200804_Tuscany_ArezzoHospital,Detection of asymptomatic SARS-CoV-2 infections among healthcare workers: results from a large-scale screening program based on rapid serological testing.,2020-08-04,Preprint,Regional,Cross-sectional survey ,Italy,Tuscany,,"The Tuscany Region screening was directed to all healthcare workers in public structures, and offered voluntarily to all personnel who underwent a rapid serological test at their institution",,2020-04-01,2020-04-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,17098,0.031000000000000003,,,True,,,,True,Convenience,"Screen Test COVID-19 2019-nCOV IgG/IgM,COVID-19 IgG/IgM Rapid Test","Screen Italia S.R.L,Zhejiang Orient Gene Biotech",LFIA,Multiple Types,"['IgG', 'IgM']",,,,,['High'],Yes,No,Yes,No,Unclear,Yes,Yes,No,Unclear,Francesca Carozzi,Arezzo Hospital,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.30.20149567v1,2020-09-27,2024-03-01,Verified,carozzi_detection_2020,ITA
200806_Lombardy_BrunoKesslerFoundation,200806_Lombardy_BrunoKesslerFoundation,"Age-specific SARS-CoV-2 infection fatality ratio and associated risk factors, Italy, February to April 2020",2020-08-06,Journal Article (Peer-Reviewed),Regional,Retrospective cohort,Italy,Lombardy,,COVID-19 contacts belonging to clusters in a contact tracing database (i.e. groups of contacts identified by one positive index case) where all individuals were tested against SARS-CoV-2 infection either through nasal swabs during the contact tracing operations or through retrospective IgG serological testing,excluded the index cases as they were often identified because of their symptoms and may therefore have been at higher risk of severe disease.,2020-04-16,2020-05-25,Contacts of COVID patients,All,Multiple groups,,,Primary Estimate,Overall estimate,4120,0.531,,,True,,,,True,Stratified non-probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,,,IgG,Spike,Validated by independent authors/third party/non-developers,0.9440000000000001,0.983,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Piero Poletti,Bruno Kessler Foundation,Not Unity-Aligned,http://dx.doi.org/10.2807/1560-7917.ES.2020.25.31.2001383,2021-01-21,2024-03-01,Verified,poletti_age-specific_2020,ITA
200806_Milan_UniversityofMilan_Overall,200806_Milan_UniversityofMilan,Low seroprevalence of SARS-CoV-2 infection among healthcare workers of the largest children hospital in Milan during the pandemic wave,2020-08-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,"HCW and non-HCW at Buzzi Hospital, Milan. All had no symptoms of COVID-19 at the time of blood collection. ",,2020-04-15,2020-04-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,663,0.0513,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,,,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Antonella Amendola,University of Milan,Not Unity-Aligned,http://dx.doi.org/10.1017/ice.2020.401,2020-10-25,2024-03-01,Verified,amendola_low_2020,ITA
200808_Italy_UniversityofTurin_CLLPatients_Overall,200808_Italy_UniversityofTurin,All that glisters is not COVID: low prevalence of seroconversion against SARS-CoV-2 in a pediatric cohort of patients with Chilblain-like lesions,2020-08-08,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Italy,Piedmont,"Turin, Novara, Alessandria, Verbania","children who 43 developed CLL during the SARS-CoV-2 outbreak in Italy, between March 8th and April 30th, 2020.",,2020-03-08,2020-04-30,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),6.0,17.0,Primary Estimate,,24,0.125,,,True,,,,,Convenience,"2019-nCoV IgM/IgG CLIA,Liaison SARS-CoV-2 S1/S2 IgG,ERADIKIT™ COVID19-IgG Indirect ELISA for the detection of anti SARS-CoV2","Medical Systems,DiaSorin,In3diagnostic",Multiple Types,Multiple Types,IgG,,,,,['High'],Yes,No,No,Yes,Unclear,Unclear,Yes,No,Unclear,Marco Denina ,University of Turin,Not Unity-Aligned,http://dx.doi.org/10.1016/j.jaad.2020.08.021,2020-09-25,2024-03-01,Verified,denina_all_2020,ITA
200813_Foggia_UniversityofFoggia_OverallIgG/IgM,200813_Foggia_UniversityofFoggia,Results from a survey in healthy blood donors in South Eastern Italy indicate that we are far away from herd immunity to SARS-CoV-2,2020-08-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy, Apulia,Foggia,"Blood donors (Age 18 to 65)  referring to the Transfusional
Center at the “Ospedali Riuniti” University Hospital (Foggia, Italy)","Active infection or medical conditions, recent surgical procedures, stay in endemic areas, reported risk factors for parenterally acquired infections, chronic degenerative conditions, diagnosis of cancer or high risk of cardiovascular events.",2020-05-01,2020-05-31,Blood donors,All,Adults (18-64 years),18.0,65.0,Primary Estimate,IgG or IgM,904,0.0099,,,True,,,,True,Convenience,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Multiple Types,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Jose Ramon Fiore,University of Foggia,Unity-Aligned,https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.26425,2020-09-27,2024-03-01,Verified,fiore_results_2020,ITA
200813_Foggia_UniversityofFoggia_Age26-35,200813_Foggia_UniversityofFoggia,Results from a survey in healthy blood donors in South Eastern Italy indicate that we are far away from herd immunity to SARS-CoV-2,2020-08-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy, Apulia,Foggia,"Blood donors (Age 18 to 65)  referring to the Transfusional
Center at the “Ospedali Riuniti” University Hospital (Foggia, Italy)","Active infection or medical conditions, recent surgical procedures, stay in endemic areas, reported risk factors for parenterally acquired infections, chronic degenerative conditions, diagnosis of cancer or high risk of cardiovascular events.",2020-05-01,2020-05-31,Blood donors,All,Adults (18-64 years),26.0,35.0,Age,26-35,195,0.02,,,,,,,,Convenience,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Multiple Types,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Jose Ramon Fiore,University of Foggia,Unity-Aligned,https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.26425,2020-09-27,2024-03-01,Verified,fiore_results_2020,ITA
200813_Foggia_UniversityofFoggia_Age56-65,200813_Foggia_UniversityofFoggia,Results from a survey in healthy blood donors in South Eastern Italy indicate that we are far away from herd immunity to SARS-CoV-2,2020-08-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy, Apulia,Foggia,"Blood donors (Age 18 to 65)  referring to the Transfusional
Center at the “Ospedali Riuniti” University Hospital (Foggia, Italy)","Active infection or medical conditions, recent surgical procedures, stay in endemic areas, reported risk factors for parenterally acquired infections, chronic degenerative conditions, diagnosis of cancer or high risk of cardiovascular events.",2020-05-01,2020-05-31,Blood donors,All,Adults (18-64 years),56.0,65.0,Age,56-65,149,0.02,,,,,,,,Convenience,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Multiple Types,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Jose Ramon Fiore,University of Foggia,Unity-Aligned,https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.26425,2020-09-27,2024-03-01,Verified,fiore_results_2020,ITA
200813_Foggia_UniversityofFoggia_Males,200813_Foggia_UniversityofFoggia,Results from a survey in healthy blood donors in South Eastern Italy indicate that we are far away from herd immunity to SARS-CoV-2,2020-08-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy, Apulia,Foggia,"Blood donors (Age 18 to 65)  referring to the Transfusional
Center at the “Ospedali Riuniti” University Hospital (Foggia, Italy)","Active infection or medical conditions, recent surgical procedures, stay in endemic areas, reported risk factors for parenterally acquired infections, chronic degenerative conditions, diagnosis of cancer or high risk of cardiovascular events.",2020-05-01,2020-05-31,Blood donors,Male,Adults (18-64 years),18.0,65.0,Sex/Gender,Males,665,0.0075,,,,,,,,Convenience,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Multiple Types,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Jose Ramon Fiore,University of Foggia,Unity-Aligned,https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.26425,2020-09-27,2024-03-01,Verified,fiore_results_2020,ITA
200813_Foggia_UniversityofFoggia_Age18-25,200813_Foggia_UniversityofFoggia,Results from a survey in healthy blood donors in South Eastern Italy indicate that we are far away from herd immunity to SARS-CoV-2,2020-08-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy, Apulia,Foggia,"Blood donors (Age 18 to 65)  referring to the Transfusional
Center at the “Ospedali Riuniti” University Hospital (Foggia, Italy)","Active infection or medical conditions, recent surgical procedures, stay in endemic areas, reported risk factors for parenterally acquired infections, chronic degenerative conditions, diagnosis of cancer or high risk of cardiovascular events.",2020-05-01,2020-05-31,Blood donors,All,Adults (18-64 years),18.0,65.0,Age,18-25,112,0.0089,,,,,,,,Convenience,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Multiple Types,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Jose Ramon Fiore,University of Foggia,Unity-Aligned,https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.26425,2020-09-27,2024-03-01,Verified,fiore_results_2020,ITA
200813_Foggia_UniversityofFoggia_Age36-45,200813_Foggia_UniversityofFoggia,Results from a survey in healthy blood donors in South Eastern Italy indicate that we are far away from herd immunity to SARS-CoV-2,2020-08-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy, Apulia,Foggia,"Blood donors (Age 18 to 65)  referring to the Transfusional
Center at the “Ospedali Riuniti” University Hospital (Foggia, Italy)","Active infection or medical conditions, recent surgical procedures, stay in endemic areas, reported risk factors for parenterally acquired infections, chronic degenerative conditions, diagnosis of cancer or high risk of cardiovascular events.",2020-05-01,2020-05-31,Blood donors,All,Adults (18-64 years),36.0,45.0,Age,36-45,202,0.0049,,,,,,,,Convenience,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Multiple Types,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Jose Ramon Fiore,University of Foggia,Unity-Aligned,https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.26425,2020-09-27,2024-03-01,Verified,fiore_results_2020,ITA
200813_Foggia_UniversityofFoggia_Age46-55,200813_Foggia_UniversityofFoggia,Results from a survey in healthy blood donors in South Eastern Italy indicate that we are far away from herd immunity to SARS-CoV-2,2020-08-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy, Apulia,Foggia,"Blood donors (Age 18 to 65)  referring to the Transfusional
Center at the “Ospedali Riuniti” University Hospital (Foggia, Italy)","Active infection or medical conditions, recent surgical procedures, stay in endemic areas, reported risk factors for parenterally acquired infections, chronic degenerative conditions, diagnosis of cancer or high risk of cardiovascular events.",2020-05-01,2020-05-31,Blood donors,All,Adults (18-64 years),46.0,55.0,Age,46-55,246,0.0,,,,,,,,Convenience,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Multiple Types,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Jose Ramon Fiore,University of Foggia,Unity-Aligned,https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.26425,2020-09-27,2024-03-01,Verified,fiore_results_2020,ITA
200813_Foggia_UniversityofFoggia_Females,200813_Foggia_UniversityofFoggia,Results from a survey in healthy blood donors in South Eastern Italy indicate that we are far away from herd immunity to SARS-CoV-2,2020-08-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy, Apulia,Foggia,"Blood donors (Age 18 to 65)  referring to the Transfusional
Center at the “Ospedali Riuniti” University Hospital (Foggia, Italy)","Active infection or medical conditions, recent surgical procedures, stay in endemic areas, reported risk factors for parenterally acquired infections, chronic degenerative conditions, diagnosis of cancer or high risk of cardiovascular events.",2020-05-01,2020-05-31,Blood donors,Female,Adults (18-64 years),18.0,65.0,Sex/Gender,Females,239,0.016,,,,,,,,Convenience,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Multiple Types,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Jose Ramon Fiore,University of Foggia,Unity-Aligned,https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.26425,2020-09-27,2024-03-01,Verified,fiore_results_2020,ITA
200818_Brescia_UniversityofBrescia_Overall,200818_Brescia_UniversityofBrescia,The Spread of SARS-CoV-2 Infection Among the Medical Oncology Staff of ASST Spedali Civili of Brescia: Efficacy of Preventive Measures,2020-08-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Brescia,All HCWs were tested,,2020-04-27,2020-04-27,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,76,0.11800000000000001,,,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,,Serum,IgG,Spike,,,,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,Yes,Alberto Dalla Volta,University of Brescia,Not Unity-Aligned,http://dx.doi.org/10.3389/fonc.2020.01574,2020-10-15,2024-03-01,Verified,dalla_volta_spread_2020,ITA
200823_Bergamo_HospitalPapaGiovanniXXIII_Overall,200823_Bergamo_HospitalPapaGiovanniXXIII,Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Patients With Inflammatory Bowel Disease Under Biologic Treatment,2020-08-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Bergamo,"This study includes all IBD patients (children and adults) undergoing biologic therapy (Infliximab, Adalimumab, Golimumab, Ustekinumab and Vedolizumab) followed at our center during the Italian COVID-19 outbreak.
",,2020-03-04,2020-07-10,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,90,0.21100000000000002,,,True,,,,True,Convenience,VivaDiag COVID-19 IgM/IgG Rapid Test,VivaChek Biotech (Hangzhou) Co. Ltd,LFIA,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,Yes,Lorenzo Norsa,Papa Giovani XXII,Not Unity-Aligned,http://dx.doi.org/10.1053/j.gastro.2020.08.046,2020-10-15,2024-03-01,Verified,norsa_asymptomatic_2020,ITA
200823_Bergamo_HospitalPapaGiovanniXXIII_<28,200823_Bergamo_HospitalPapaGiovanniXXIII,Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Patients With Inflammatory Bowel Disease Under Biologic Treatment,2020-08-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Bergamo,"This study includes all IBD patients (children and adults) undergoing biologic therapy (Infliximab, Adalimumab, Golimumab, Ustekinumab and Vedolizumab) followed at our center during the Italian COVID-19 outbreak.
",,2020-03-04,2020-07-10,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,27.0,Age,<28,32,0.125,,,,,,,,Convenience,VivaDiag COVID-19 IgM/IgG Rapid Test,VivaChek Biotech (Hangzhou) Co. Ltd,LFIA,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,Yes,Lorenzo Norsa,Papa Giovani XXII,Not Unity-Aligned,http://dx.doi.org/10.1053/j.gastro.2020.08.046,2020-10-15,2024-03-01,Verified,norsa_asymptomatic_2020,ITA
200823_Bergamo_HospitalPapaGiovanniXXIII_28-47,200823_Bergamo_HospitalPapaGiovanniXXIII,Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Patients With Inflammatory Bowel Disease Under Biologic Treatment,2020-08-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Bergamo,"This study includes all IBD patients (children and adults) undergoing biologic therapy (Infliximab, Adalimumab, Golimumab, Ustekinumab and Vedolizumab) followed at our center during the Italian COVID-19 outbreak.
",,2020-03-04,2020-07-10,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),28.0,47.0,Age,28-47,27,0.111,,,,,,,,Convenience,VivaDiag COVID-19 IgM/IgG Rapid Test,VivaChek Biotech (Hangzhou) Co. Ltd,LFIA,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,Yes,Lorenzo Norsa,Papa Giovani XXII,Not Unity-Aligned,http://dx.doi.org/10.1053/j.gastro.2020.08.046,2020-10-15,2024-03-01,Verified,norsa_asymptomatic_2020,ITA
200823_Bergamo_HospitalPapaGiovanniXXIII_>47,200823_Bergamo_HospitalPapaGiovanniXXIII,Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Patients With Inflammatory Bowel Disease Under Biologic Treatment,2020-08-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Bergamo,"This study includes all IBD patients (children and adults) undergoing biologic therapy (Infliximab, Adalimumab, Golimumab, Ustekinumab and Vedolizumab) followed at our center during the Italian COVID-19 outbreak.
",,2020-03-04,2020-07-10,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,47.0,,Age,>47,41,0.29300000000000004,,,,,,,,Convenience,VivaDiag COVID-19 IgM/IgG Rapid Test,VivaChek Biotech (Hangzhou) Co. Ltd,LFIA,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,Yes,Lorenzo Norsa,Papa Giovani XXII,Not Unity-Aligned,http://dx.doi.org/10.1053/j.gastro.2020.08.046,2020-10-15,2024-03-01,Verified,norsa_asymptomatic_2020,ITA
200826_Veneto_UniversityHospitalOfPadova,200826_Veneto_UniversityHospitalOfPadova,SARS-CoV-2 serosurvey in health care workers of the Veneto Region,2020-08-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Veneto,,Healthcare workers in the main hospitals of the Veneto Region.,,2020-02-22,2020-05-29,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,8285,0.046,0.040999999999999995,0.05,True,,,,True,Unclear,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.73,0.98,['Moderate'],Yes,Unclear,Yes,Yes,Yes,Yes,Yes,No,Unclear,Mario Plebani,University Hospital Of Padova,Not Unity-Aligned,https://www.degruyter.com/document/doi/10.1515/cclm-2020-1236/html,2021-04-08,2024-03-01,Verified,plebani_sars-cov-2_2020,ITA
200827_LiguriaLombardia_UniversityofGenoa_Overall,200827_LiguriaLombardia_UniversityofGenoa,Prevalence of Antibodies to SARS-CoV-2 in Italian Adults and Associated Risk Factors,2020-08-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,"Lombardy, Liguria",,We included non-hospitalized participants (aged > 18 years) who voluntarily tested for SARS-CoV-2 antibodies in an outpatient setting. ,,2020-03-01,2020-04-30,Residual sera,All,Adults (18-64 years),18.0,,Primary Estimate,,3609,0.11,0.1,0.121,True,,,,True,Convenience,"MAGLUMI 2019-nCoV IgM/IgG,Realy-Tech 2019 nCOV/COVID-19 IgG/IgM Rapid Test,Biosynex COVID-19 BSS assay","Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),Hangzhou Realy Tech Co. Ltd,Biosynex",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,Yes,Unclear,No,No,Unclear,Antonio Vena,University of Genoa,Not Unity-Aligned,https://dx.doi.org/10.3390/jcm9092780,2020-10-15,2024-03-01,Verified,vena_prevalence_2020,ITA
200827_LiguriaLombardia_UniversityofGenoa_Male,200827_LiguriaLombardia_UniversityofGenoa,Prevalence of Antibodies to SARS-CoV-2 in Italian Adults and Associated Risk Factors,2020-08-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,"Lombardy, Liguria",,We included non-hospitalized participants (aged > 18 years) who voluntarily tested for SARS-CoV-2 antibodies in an outpatient setting. ,,2020-03-01,2020-04-30,Residual sera,Male,Adults (18-64 years),18.0,,Sex/Gender,Male,1602,0.092,,,,,,,,Convenience,"MAGLUMI 2019-nCoV IgM/IgG,Realy-Tech 2019 nCOV/COVID-19 IgG/IgM Rapid Test,Biosynex COVID-19 BSS assay","Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),Hangzhou Realy Tech Co. Ltd,Biosynex",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,Yes,Unclear,No,No,Unclear,Antonio Vena,University of Genoa,Not Unity-Aligned,https://dx.doi.org/10.3390/jcm9092780,2020-10-15,2024-03-01,Verified,vena_prevalence_2020,ITA
200827_LiguriaLombardia_UniversityofGenoa_46-55,200827_LiguriaLombardia_UniversityofGenoa,Prevalence of Antibodies to SARS-CoV-2 in Italian Adults and Associated Risk Factors,2020-08-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,"Lombardy, Liguria",,We included non-hospitalized participants (aged > 18 years) who voluntarily tested for SARS-CoV-2 antibodies in an outpatient setting. ,,2020-03-01,2020-04-30,Residual sera,All,Adults (18-64 years),46.0,55.0,Age,46-55,929,0.09699999999999999,,,,,,,,Convenience,"MAGLUMI 2019-nCoV IgM/IgG,Realy-Tech 2019 nCOV/COVID-19 IgG/IgM Rapid Test,Biosynex COVID-19 BSS assay","Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),Hangzhou Realy Tech Co. Ltd,Biosynex",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,Yes,Unclear,No,No,Unclear,Antonio Vena,University of Genoa,Not Unity-Aligned,https://dx.doi.org/10.3390/jcm9092780,2020-10-15,2024-03-01,Verified,vena_prevalence_2020,ITA
200827_LiguriaLombardia_UniversityofGenoa_36-45,200827_LiguriaLombardia_UniversityofGenoa,Prevalence of Antibodies to SARS-CoV-2 in Italian Adults and Associated Risk Factors,2020-08-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,"Lombardy, Liguria",,We included non-hospitalized participants (aged > 18 years) who voluntarily tested for SARS-CoV-2 antibodies in an outpatient setting. ,,2020-03-01,2020-04-30,Residual sera,All,Adults (18-64 years),36.0,45.0,Age,36-45,631,0.071,,,,,,,,Convenience,"MAGLUMI 2019-nCoV IgM/IgG,Realy-Tech 2019 nCOV/COVID-19 IgG/IgM Rapid Test,Biosynex COVID-19 BSS assay","Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),Hangzhou Realy Tech Co. Ltd,Biosynex",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,Yes,Unclear,No,No,Unclear,Antonio Vena,University of Genoa,Not Unity-Aligned,https://dx.doi.org/10.3390/jcm9092780,2020-10-15,2024-03-01,Verified,vena_prevalence_2020,ITA
200827_LiguriaLombardia_UniversityofGenoa_CasaDellaSaluteDiGenova,200827_LiguriaLombardia_UniversityofGenoa,Prevalence of Antibodies to SARS-CoV-2 in Italian Adults and Associated Risk Factors,2020-08-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,"Lombardy, Liguria",,We included non-hospitalized participants (aged > 18 years) who voluntarily tested for SARS-CoV-2 antibodies in an outpatient setting. ,,2020-03-01,2020-04-30,Residual sera,All,Adults (18-64 years),18.0,,Geographical area,Tests done at the Casa della salute di genova,544,0.162,0.132,0.195,,,,,,Convenience,Biosynex COVID-19 BSS assay,Biosynex,LFIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.887,0.9059999999999999,['High'],No,No,Yes,Yes,Yes,Unclear,No,No,Unclear,Antonio Vena,University of Genoa,Not Unity-Aligned,https://dx.doi.org/10.3390/jcm9092780,2020-10-15,2024-03-01,Verified,vena_prevalence_2020,ITA
200827_LiguriaLombardia_UniversityofGenoa_Female,200827_LiguriaLombardia_UniversityofGenoa,Prevalence of Antibodies to SARS-CoV-2 in Italian Adults and Associated Risk Factors,2020-08-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,"Lombardy, Liguria",,We included non-hospitalized participants (aged > 18 years) who voluntarily tested for SARS-CoV-2 antibodies in an outpatient setting. ,,2020-03-01,2020-04-30,Residual sera,Female,Adults (18-64 years),18.0,,Sex/Gender,Female,2007,0.125,,,,,,,,Convenience,"MAGLUMI 2019-nCoV IgM/IgG,Realy-Tech 2019 nCOV/COVID-19 IgG/IgM Rapid Test,Biosynex COVID-19 BSS assay","Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),Hangzhou Realy Tech Co. Ltd,Biosynex",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,Yes,Unclear,No,No,Unclear,Antonio Vena,University of Genoa,Not Unity-Aligned,https://dx.doi.org/10.3390/jcm9092780,2020-10-15,2024-03-01,Verified,vena_prevalence_2020,ITA
200827_LiguriaLombardia_UniversityofGenoa_IstitutoDiagnosticoVarelli,200827_LiguriaLombardia_UniversityofGenoa,Prevalence of Antibodies to SARS-CoV-2 in Italian Adults and Associated Risk Factors,2020-08-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,"Lombardy, Liguria",,We included non-hospitalized participants (aged > 18 years) who voluntarily tested for SARS-CoV-2 antibodies in an outpatient setting. ,,2020-03-01,2020-04-30,Residual sera,All,Adults (18-64 years),18.0,,Geographical area,Tests done at Istituto Diagnostico Varelli,1180,0.08,0.065,0.09699999999999999,,,,,,Convenience,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.956,0.96,['High'],No,No,Yes,Yes,Yes,Unclear,No,No,Unclear,Antonio Vena,University of Genoa,Not Unity-Aligned,https://dx.doi.org/10.3390/jcm9092780,2020-10-15,2024-03-01,Verified,vena_prevalence_2020,ITA
200827_LiguriaLombardia_UniversityofGenoa_18-35,200827_LiguriaLombardia_UniversityofGenoa,Prevalence of Antibodies to SARS-CoV-2 in Italian Adults and Associated Risk Factors,2020-08-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,"Lombardy, Liguria",,We included non-hospitalized participants (aged > 18 years) who voluntarily tested for SARS-CoV-2 antibodies in an outpatient setting. ,,2020-03-01,2020-04-30,Residual sera,All,Adults (18-64 years),18.0,35.0,Age,18-35,556,0.11900000000000001,,,,,,,,Convenience,"MAGLUMI 2019-nCoV IgM/IgG,Realy-Tech 2019 nCOV/COVID-19 IgG/IgM Rapid Test,Biosynex COVID-19 BSS assay","Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),Hangzhou Realy Tech Co. Ltd,Biosynex",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,Yes,Unclear,No,No,Unclear,Antonio Vena,University of Genoa,Not Unity-Aligned,https://dx.doi.org/10.3390/jcm9092780,2020-10-15,2024-03-01,Verified,vena_prevalence_2020,ITA
200827_LiguriaLombardia_UniversityofGenoa_MedicalCenter,200827_LiguriaLombardia_UniversityofGenoa,Prevalence of Antibodies to SARS-CoV-2 in Italian Adults and Associated Risk Factors,2020-08-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,"Lombardy, Liguria",,We included non-hospitalized participants (aged > 18 years) who voluntarily tested for SARS-CoV-2 antibodies in an outpatient setting. ,,2020-03-01,2020-04-30,Residual sera,All,Adults (18-64 years),18.0,,Geographical area,Tests done at the Medical center,1885,0.115,0.10099999999999999,0.13,,,,,,Convenience,Realy-Tech 2019 nCOV/COVID-19 IgG/IgM Rapid Test,Hangzhou Realy Tech Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9670000000000001,0.937,['High'],No,No,Yes,Yes,Yes,Unclear,No,No,Unclear,Antonio Vena,University of Genoa,Not Unity-Aligned,https://dx.doi.org/10.3390/jcm9092780,2020-10-15,2024-03-01,Verified,vena_prevalence_2020,ITA
200827_LiguriaLombardia_UniversityofGenoa_>55,200827_LiguriaLombardia_UniversityofGenoa,Prevalence of Antibodies to SARS-CoV-2 in Italian Adults and Associated Risk Factors,2020-08-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,"Lombardy, Liguria",,We included non-hospitalized participants (aged > 18 years) who voluntarily tested for SARS-CoV-2 antibodies in an outpatient setting. ,,2020-03-01,2020-04-30,Residual sera,All,Multiple groups,56.0,,Age,>55 years,1493,0.132,,,,,,,,Convenience,"MAGLUMI 2019-nCoV IgM/IgG,Realy-Tech 2019 nCOV/COVID-19 IgG/IgM Rapid Test,Biosynex COVID-19 BSS assay","Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),Hangzhou Realy Tech Co. Ltd,Biosynex",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,Yes,Unclear,No,No,Unclear,Antonio Vena,University of Genoa,Not Unity-Aligned,https://dx.doi.org/10.3390/jcm9092780,2020-10-15,2024-03-01,Verified,vena_prevalence_2020,ITA
200907_Bari_PoliclinicoHospital_Overall,200907_Bari_PoliclinicoHospital,The Light and Shadow of Rapid Serological Tests for SARS-CoV-2 Infection: Results from a Study in a Large Emergency Department,2020-09-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy, Apulia,Bari,"The study population comprised a convenience sample of consecutive series of patients (n = 819) who were admitted to the ED of the Policlinico Hospital of Bari, Italy, between 23 March and 21 April 2020

patients were divided into two groups: those admitted to the ED with
symptoms suggestive of COVID-19, mainly respiratory symptoms 
termed the “RS group”), and those admitted to the ED with acute clinical conditions but no respiratory symptoms (termed the “non-RS
group”).",,2020-03-23,2020-04-21,Residual sera,All,Multiple groups,,,Primary Estimate,All patients inlcluded,819,0.0855,,,True,,,,True,Sequential,VivaDiag COVID-19 IgM/IgG Rapid Test,VivaChek Biotech (Hangzhou) Co. Ltd,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.35100000000000003,0.973,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Daniela Loconsole,Policlinico Hospital,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph17186493,2020-10-14,2024-03-01,Verified,loconsole_light_2020,ITA
200915_Naples_AziendaOspedalieradiRilievoNazionaleSantobonoPausilipon_HCW,200915_Naples_AziendaOspedalieradiRilievoNazionaleSantobonoPausilipon_HCW2,Successful management plan of COVID-19 in a pediatric hemato-oncology department: A single-centre experience,2020-09-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Campania,Naples,Healthcare workers underwent rapid serological tests in the Hemato-Oncology Department of the Santobono-Pausilipon Hospital from 3 April until 29 May 2020.,,2020-04-03,2020-05-29,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,249,0.0201,,,True,,,,True,Convenience,"VivaDiag COVID-19 IgM/IgG Rapid Test,Not reported/ Unable to specify","VivaChek Biotech (Hangzhou) Co. Ltd,NA",LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],No,No,No,No,No,Unclear,Yes,No,Unclear,Pio Stellato,Azienda Ospedaliera di Rilievo Nazionale Santobono Pausilipon,Not Unity-Aligned,http://dx.doi.org/10.1136/bmjpo-2020-000818,2020-12-15,2024-03-01,Verified,stellato_successful_2020,ITA
200915_Naples_AziendaOspedalieradiRilievoNazionaleSantobonoPausilipon_Patients&Caregivers,200915_Naples_AziendaOspedalieradiRilievoNazionaleSantobonoPausilipon_Patients1,Successful management plan of COVID-19 in a pediatric hemato-oncology department: A single-centre experience,2020-09-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Campania,Naples,"All paediatric patients and their caregivers from From 3 April until 29 May 2020 underwent rapid serological tests in the Hemato-Oncology Department of the Santobono-Pausilipon Hospital. All patients and their caregivers underwent rapid serological tests every 6 days in zone 1 (surveillance and screening zone of the department) before admission.
",,2020-04-03,2020-05-29,Multiple populations,All,Multiple groups,,,Primary Estimate,,1397,0.00429,,,True,,,,True,Convenience,"VivaDiag COVID-19 IgM/IgG Rapid Test,Not reported/ Unable to specify","VivaChek Biotech (Hangzhou) Co. Ltd,NA",LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,No,No,Unclear,Yes,No,,Pio Stellato,Azienda Ospedaliera di Rilievo Nazionale Santobono Pausilipon,Not Unity-Aligned,http://dx.doi.org/10.1136/bmjpo-2020-000818,2020-12-15,2024-03-01,Verified,stellato_successful_2020,ITA
201006_Turin_UniversityofTorino_TotalHCWs,201006_Turin_UniversityofTorino,"Risk for SARS-CoV-2 Infection in Healthcare Workers, Turin, Italy",2020-10-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Piemonte,Torino (Turin),"Active healthcare workers (n = 7,457) from Azienda Sanitaria Locale Città di Torino public hos- pitals and outpatient services (Turin, Italy)",,2020-04-17,2020-05-20,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,5444,0.069,,,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9790000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Andrea Calcagno,University of Torino,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2701.203027,2020-12-10,2024-03-01,Verified,calcagno_risk_2021,ITA
201008_Udine_UniversityofUdine_SCTrecipients,201008_Udine_UniversityofUdine,"Screening Procedure for SARS-CoV-2 infection combining Triage, nasopharyngeal swab and serological test in allogeneic stem cell transplantation Recipients Undergoing Outpatient Post Transplant Follow-Up",2020-10-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Udine,Udine,Allogeneic stem cell transplant recipients undergoing post SCT outpatient monitoring ,,2020-04-01,2020-05-30,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,23.0,73.0,Primary Estimate,Allogenic stem cell transplant recipients,70,0.0143,,,True,,,,True,Sequential,COVID-19 IgG/IgM Rapid Test Cassette,Cellex Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9375,0.9640000000000001,['High'],Yes,No,No,Yes,Unclear,No,Yes,No,Unclear,Alessandra Sperotto,The University of Udine,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.26586,2021-01-18,2024-03-01,Verified,sperotto_screening_2020,ITA
201020_Milan_UniversitàdegliStudidiMilano_Patients1_Overall,201020_Milan_UniversitàdegliStudidiMilano_Patients1,"Incidence of sars-cov-2 infection in patients with active cancer: Mono-institutional series of a comprehensive cancer institution in lombardy during the covid-19 pandemic (Niguarda Cancer Center, Milano, Italy)",2020-10-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,Patients with active cancer (solid tumor requiring anti-cancer treatment or supportive care),,2020-04-15,2020-05-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,42,0.095,,,True,,,,True,Unclear,Not reported/ Unable to specify,,CLIA,Whole Blood,IgG,,,,,['High'],No,Unclear,No,No,Unclear,Unclear,Yes,No,Unclear,Andrea Sartore Bianchi,Università degli Studi di Milano,Not Unity-Aligned,http://dx.doi.org/10.1177/0300891620953388,2021-03-27,2022-07-16,Verified,bianchi_incidence_2020,ITA
201020_Milan_UniversitàdegliStudidiMilano_Physicians2_Overall,201020_Milan_UniversitàdegliStudidiMilano_Physicians2,"Incidence of sars-cov-2 infection in patients with active cancer: Mono-institutional series of a comprehensive cancer institution in lombardy during the covid-19 pandemic (Niguarda Cancer Center, Milano, Italy)",2020-10-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,,,2020-04-15,2020-05-15,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,34,0.0588,,,True,,,,True,Convenience,Not reported/ Unable to specify,,CLIA,Whole Blood,IgG,,,,,['High'],No,No,No,No,Unclear,Unclear,Yes,No,Unclear,Andrea Sartore Bianchi,Università degli Studi di Milano,Not Unity-Aligned,http://dx.doi.org/10.1177/0300891620953388,2021-04-20,2022-07-16,Verified,bianchi_incidence_2020,ITA
201020_Sondrio_AltoLario-OncologiaMedicaSondrio_Overall,201020_Sondrio_AltoLario-OncologiaMedicaSondrio,Rapid serological test in the covid-19 era: Our experience,2020-10-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Sondrio,Asymptomatic health care workers,,2020-03-01,2020-10-19,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,220,0.11359999999999999,,,True,,,,True,Convenience,NADAL® COVID-19 IgG/IgM Test,nal von minden GmbH,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.941,0.9920000000000001,['High'],Unclear,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,G Caponigro ,"ASST della Valtellina 
Alto Lario-Oncologia Medica Sondrio",Not Unity-Aligned,http://dx.doi.org/10.1177/0300891620953388,2021-04-04,2024-03-01,Verified,caponigro_rapid_2020,ITA
201020_DipartimentoOncologicoAziendaUslToscanaCentroFirenze_Florence,201020_DipartimentoOncologicoAziendaUslToscanaCentroFirenze_Florence,Sars-cov-2 screening and monitoring in cancer patients: Azienda USL toscana centro oncology department experience,2020-10-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Tuscany,Florence, patients receiving chemo- or radio- therapy,,2020-05-11,2020-05-17,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,Primary ,1145,0.023,,,True,,,,True,Sequential,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,Unclear,Francesca Martella ,Azienda Usl Toscana Centro Oncology,Not Unity-Aligned,http://dx.doi.org/10.1177/0300891620953388,2021-03-27,2022-07-16,Verified,martella_sars-cov-2_2020,ITA
201021_Italy_IRCCS_Overall_IgG_unadj,201021_Italy_IRCCS,Seroconversion in patients with cancer and oncology healthcare workers infected by SARS-CoV-2,2020-10-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Lombardy,,"patients/health professionals already confirmed to be positive for SARS-CoV-2 by RT-PCR assays on nasal/pharyngeal swab specimens; patients or health professionals who are suspected of being infected with SARS-CoV-2, defined as a history of contact with confirmed cases before the onset of illness or subjects with at least one clinical manifestation or imaging characteristics of COVID-19 in the last week before accrual in the trial; patients with cancer who are considered at high risk for infection and eligible for active therapy and/or major surgery.",Subjects diagnosed with bacterial or viral pneumonia in previous 3 months,2020-03-30,2020-05-11,Multiple populations,All,Multiple groups,,,Primary Estimate,,166,0.4157,,,True,,,,True,Convenience,PRIMA COVID-19 IgG/IgM Rapid Test,PRIMA Lab S.A.,,Whole Blood,IgG,,,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,,Antonio Marra,Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS),Not Unity-Aligned,https://dx.doi.org/10.1016/j.annonc.2020.10.473,2021-01-16,2024-03-01,Verified,marra_seroconversion_2020,ITA
201027_Perugia_UniversityofPerugia_HIVNegative2_Overall,201027_Perugia_UniversityofPerugia_HIVNegative2,Seroprevalence of anti-SARS-CoV2 Antibodies in Umbrian Persons Living with HIV,2020-10-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Umbria,Perugia,"HIV-seronegative individuals    tested    in    the    mentioned    period,",,2020-05-04,2020-05-31,Multiple populations,All,Multiple groups,,,Primary Estimate,,2843,0.054000000000000006,,,True,,,,True,Unclear,Screen Test COVID-19 2019-nCOV IgG/IgM,Screen Italia S.R.L,LFIA,Whole Blood,IgG,,Validated by manufacturers,,,['High'],Unclear,Unclear,Yes,No,Unclear,No,Yes,No,Unclear,Chiara Papalini,University of Perugia,Not Unity-Aligned,https://dx.doi.org/10.4084/MJHID.2020.080,2021-02-27,2024-03-01,Verified,papalini_seroprevalence_2020,ITA
201027_Perugia_UniversityofPerugia_HIVPositive1_PLWHIgG,201027_Perugia_UniversityofPerugia_HIVPositive1,Seroprevalence of anti-SARS-CoV2 Antibodies in Umbrian Persons Living with HIV,2020-10-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Umbria,Perugia,Asymptomatic persons  living  with  HIV,,2020-05-04,2020-05-31,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,10.0,83.0,Primary Estimate,Primary estimate,270,0.037000000000000005,,,True,,,,True,Sequential,Screen Test COVID-19 2019-nCOV IgG/IgM,Screen Italia S.R.L,LFIA,Whole Blood,IgG,,Validated by manufacturers,,,['High'],No,No,No,No,Unclear,No,Yes,No,,Chiara Papalini,University of Perugia,Not Unity-Aligned,https://dx.doi.org/10.4084/MJHID.2020.080,2021-01-10,2024-03-01,Verified,papalini_seroprevalence_2020,ITA
201031_VillaCaldari_IstitutoZooprofilatticoSperimentaleDell’AbruzzoEdelMoliseG.Caporale_Overall,201031_VillaCaldari_IstitutoZooprofilatticoSperimentaleDell’AbruzzoEdelMoliseGCaporale,A COVID-19 Hotspot Area: Activities and Epidemiological Findings.,2020-10-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Abruzzo,Villa Caldari,persons officially registered as residents in Villa Caldari,,2020-04-18,2020-04-19,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,667,0.109,0.08800000000000001,0.135,True,,,,True,Entire sample,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.93,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Francesa Cito,Istituto Zooprofilattico Sperimentale dell’Abruzzo e del Molise G. Caporale ,Unity-Aligned,https://dx.doi.org/10.3390/microorganisms8111711,2021-01-22,2024-03-01,Verified,cito_covid-19_2020,ITA
201031_VillaCaldari_IstitutoZooprofilatticoSperimentaleDell’AbruzzoEdelMoliseG.Caporale_Male,201031_VillaCaldari_IstitutoZooprofilatticoSperimentaleDell’AbruzzoEdelMoliseGCaporale,A COVID-19 Hotspot Area: Activities and Epidemiological Findings.,2020-10-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Abruzzo,Villa Caldari,persons officially registered as residents in Villa Caldari,,2020-04-18,2020-04-19,Household and community samples,Male,Multiple groups,0.0,,Sex/Gender,Male,352,0.111,0.08199999999999999,0.14800000000000002,,,,,,Entire sample,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.93,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Francesa Cito,Istituto Zooprofilattico Sperimentale dell’Abruzzo e del Molise G. Caporale ,Unity-Aligned,https://dx.doi.org/10.3390/microorganisms8111711,2021-01-22,2024-03-01,Verified,cito_covid-19_2020,ITA
201031_VillaCaldari_IstitutoZooprofilatticoSperimentaleDell’AbruzzoEdelMoliseG.Caporale_Female,201031_VillaCaldari_IstitutoZooprofilatticoSperimentaleDell’AbruzzoEdelMoliseGCaporale,A COVID-19 Hotspot Area: Activities and Epidemiological Findings.,2020-10-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Abruzzo,Villa Caldari,persons officially registered as residents in Villa Caldari,,2020-04-18,2020-04-19,Household and community samples,Female,Multiple groups,0.0,,Sex/Gender,Female,335,0.10800000000000001,0.079,0.147,,,,,,Entire sample,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.93,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Francesa Cito,Istituto Zooprofilattico Sperimentale dell’Abruzzo e del Molise G. Caporale ,Unity-Aligned,https://dx.doi.org/10.3390/microorganisms8111711,2021-01-22,2024-03-01,Verified,cito_covid-19_2020,ITA
201031_Veneto_NationalAssociationofCompanyandCompetentDoctors,201031_Veneto_NationalAssociationofCompanyandCompetentDoctors,Effectiveness of the measures aimed at containing Sars-cov-2 virus spreading in work settings: a survey in companies based in the Veneto region of Italy,2020-10-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Veneto,,Workers at Nine manufacturing companies in the province of Padua were selected,"Those on sick leave, those operated in smart worki",2020-04-11,2020-04-29,Essential non-healthcare workers,All,Adults (18-64 years),19.0,69.0,Primary Estimate,Overall,1267,0.0158,,,True,,,,True,Convenience,"Not reported/ Unable to specify,MAGLUMI 2019-nCoV IgM/IgG","NA,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd)",Multiple Types,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,No,Danilo Bontadi,National Association of Company and Competent Doctors,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809981/,2021-03-16,2024-03-01,Verified,d_effectiveness_2020,ITA
201031_Milan_SanRaffaeleScientificInstitute_HCW_IgG,201031_Milan_SanRaffaeleScientificInstitute,"SARS-CoV-2 IgG/IgM Rapid Test as a Diagnostic Tool in Hospitalized Patients and Healthcare Workers, at a large Teaching Hospital in northern Italy, during the 2020 COVID-19 Pandemic",2020-10-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,,,2020-03-15,2020-04-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,IgG,40,0.05,,,True,,,,True,Convenience,"PRIMA COVID-19 IgG/IgM Rapid Test,Liaison SARS-CoV-2 S1/S2 IgG","PRIMA Lab S.A.,DiaSorin",Multiple Types,Whole Blood,IgG,,,,,['High'],No,No,No,Yes,Unclear,No,Yes,No,Unclear,Diana Canetti,San Raffaele Scientific Institute,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/33135083/,2021-01-12,2024-03-01,Verified,canetti_sars-cov-2_2020,ITA
201101_ Borgosesia_ASLVercelli_overall,201101_ Borgosesia_ASLVercelli,"[Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].",2020-11-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Piedmont,Borgosesia,Over the age of 18,,2020-05-23,2020-05-24,Household and community samples,All,Multiple groups,18.0,97.0,Primary Estimate,,4987,0.049,0.0433,0.0555,True,,,,True,Self-referral,PRIMA COVID-19 IgG/IgM Rapid Test,PRIMA Lab S.A.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,1.0,0.98,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,No,Daniela Alessi,ASL Vercelli,Not Unity-Aligned,https://dx.doi.org/10.19191/EP20.5-6.S2.119,2021-02-08,2024-03-01,Verified,allesi_seroprevalence_2020,ITA
201101_ Borgosesia_ASLVercelli_30-39yrs,201101_ Borgosesia_ASLVercelli,"[Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].",2020-11-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Piedmont,Borgosesia,Over the age of 18,,2020-05-23,2020-05-24,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39 yrs,500,0.036000000000000004,,,,,,,,Self-referral,PRIMA COVID-19 IgG/IgM Rapid Test,PRIMA Lab S.A.,LFIA,Whole Blood,IgG,,Validated by manufacturers,1.0,0.98,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,No,Daniela Alessi,ASL Vercelli,Not Unity-Aligned,https://dx.doi.org/10.19191/EP20.5-6.S2.119,2021-03-08,2024-03-01,Verified,allesi_seroprevalence_2020,ITA
201101_ Borgosesia_ASLVercelli_50-59yrs ,201101_ Borgosesia_ASLVercelli,"[Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].",2020-11-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Piedmont,Borgosesia,Over the age of 18,,2020-05-23,2020-05-24,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59 yrs,987,0.0395,,,,,,,,Self-referral,PRIMA COVID-19 IgG/IgM Rapid Test,PRIMA Lab S.A.,LFIA,Whole Blood,IgG,,Validated by manufacturers,1.0,0.98,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,No,Daniela Alessi,ASL Vercelli,Not Unity-Aligned,https://dx.doi.org/10.19191/EP20.5-6.S2.119,2021-03-08,2024-03-01,Verified,allesi_seroprevalence_2020,ITA
201101_ Borgosesia_ASLVercelli_18-29yrs,201101_ Borgosesia_ASLVercelli,"[Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].",2020-11-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Piedmont,Borgosesia,Over the age of 18,,2020-05-23,2020-05-24,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,18-29 yrs,533,0.0281,,,,,,,,Self-referral,PRIMA COVID-19 IgG/IgM Rapid Test,PRIMA Lab S.A.,LFIA,Whole Blood,IgG,,Validated by manufacturers,1.0,0.98,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,No,Daniela Alessi,ASL Vercelli,Not Unity-Aligned,https://dx.doi.org/10.19191/EP20.5-6.S2.119,2021-03-08,2024-03-01,Verified,allesi_seroprevalence_2020,ITA
201101_ Borgosesia_ASLVercelli_60-69yrs  ,201101_ Borgosesia_ASLVercelli,"[Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].",2020-11-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Piedmont,Borgosesia,Over the age of 18,,2020-05-23,2020-05-24,Household and community samples,All,Adults (18-64 years),60.0,69.0,Age,60-69 yrs,962,0.053,,,,,,,,Self-referral,PRIMA COVID-19 IgG/IgM Rapid Test,PRIMA Lab S.A.,LFIA,Whole Blood,IgG,,Validated by manufacturers,1.0,0.98,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,No,Daniela Alessi,ASL Vercelli,Not Unity-Aligned,https://dx.doi.org/10.19191/EP20.5-6.S2.119,2021-03-08,2024-03-01,Verified,allesi_seroprevalence_2020,ITA
201101_ Borgosesia_ASLVercelli_40-49yrs ,201101_ Borgosesia_ASLVercelli,"[Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].",2020-11-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Piedmont,Borgosesia,Over the age of 18,,2020-05-23,2020-05-24,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49 yrs,733,0.031400000000000004,,,,,,,,Self-referral,PRIMA COVID-19 IgG/IgM Rapid Test,PRIMA Lab S.A.,LFIA,Whole Blood,IgG,,Validated by manufacturers,1.0,0.98,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,No,Daniela Alessi,ASL Vercelli,Not Unity-Aligned,https://dx.doi.org/10.19191/EP20.5-6.S2.119,2021-03-08,2024-03-01,Verified,allesi_seroprevalence_2020,ITA
201101_ Borgosesia_ASLVercelli_Male,201101_ Borgosesia_ASLVercelli,"[Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].",2020-11-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Piedmont,Borgosesia,Over the age of 18,,2020-05-23,2020-05-24,Household and community samples,Male,Multiple groups,18.0,97.0,Sex/Gender,Male,2262,0.0424,,,,,,,,Self-referral,PRIMA COVID-19 IgG/IgM Rapid Test,PRIMA Lab S.A.,LFIA,Whole Blood,IgG,,Validated by manufacturers,1.0,0.98,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,No,Daniela Alessi,ASL Vercelli,Not Unity-Aligned,https://dx.doi.org/10.19191/EP20.5-6.S2.119,2021-03-08,2024-03-01,Verified,allesi_seroprevalence_2020,ITA
201101_ Borgosesia_ASLVercelli_Female,201101_ Borgosesia_ASLVercelli,"[Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].",2020-11-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Piedmont,Borgosesia,Over the age of 18,,2020-05-23,2020-05-24,Household and community samples,Female,Multiple groups,18.0,97.0,Sex/Gender,Female,2703,0.041100000000000005,,,,,,,,Self-referral,PRIMA COVID-19 IgG/IgM Rapid Test,PRIMA Lab S.A.,LFIA,Whole Blood,IgG,,Validated by manufacturers,1.0,0.98,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,No,Daniela Alessi,ASL Vercelli,Not Unity-Aligned,https://dx.doi.org/10.19191/EP20.5-6.S2.119,2021-03-08,2024-03-01,Verified,allesi_seroprevalence_2020,ITA
201101_ Borgosesia_ASLVercelli_70-79yrs   ,201101_ Borgosesia_ASLVercelli,"[Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].",2020-11-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Piedmont,Borgosesia,Over the age of 18,,2020-05-23,2020-05-24,Household and community samples,All,Seniors (65+ years),70.0,79.0,Age,70-79 yrs,819,0.058600000000000006,,,,,,,,Self-referral,PRIMA COVID-19 IgG/IgM Rapid Test,PRIMA Lab S.A.,LFIA,Whole Blood,IgG,,Validated by manufacturers,1.0,0.98,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,No,Daniela Alessi,ASL Vercelli,Not Unity-Aligned,https://dx.doi.org/10.19191/EP20.5-6.S2.119,2021-03-08,2024-03-01,Verified,allesi_seroprevalence_2020,ITA
201101_ Borgosesia_ASLVercelli_>80yrs,201101_ Borgosesia_ASLVercelli,"[Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].",2020-11-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Piedmont,Borgosesia,Over the age of 18,,2020-05-23,2020-05-24,Household and community samples,All,Seniors (65+ years),80.0,,Age,>80 yrs,364,0.0302,,,,,,,,Self-referral,PRIMA COVID-19 IgG/IgM Rapid Test,PRIMA Lab S.A.,LFIA,Whole Blood,IgG,,Validated by manufacturers,1.0,0.98,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,No,Daniela Alessi,ASL Vercelli,Not Unity-Aligned,https://dx.doi.org/10.19191/EP20.5-6.S2.119,2021-03-08,2024-03-01,Verified,allesi_seroprevalence_2020,ITA
201103_Cagliari_UniversityofCagliari_SurgicalPatients_IGGorIGM,201103_Cagliari_UniversityofCagliari,Seroprevalence of SARS-Cov-2 in the setting of a non-dedicated COVID-19 hospital in a low CoV-2 incidence area: Implications for surgery.,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Sardinia,Cagliari,"patients admitted to the Department of General and Endocrine Surgery of University Hospital of Cagliari from March 31 – June 30, 2020.",,2020-03-31,2020-06-30,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),,,Primary Estimate,,86,0.057999999999999996,,,True,,,,True,Convenience,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Yes,Fabio Medas, University of Cagliari,Not Unity-Aligned,https://dx.doi.org/10.1016/j.amsu.2020.11.006,2021-01-09,2024-03-01,Verified,medas_seroprevalence_2020,ITA
201105_Italy_UniversityofVerona_overall_unadj,201105_Italy_UniversityofVerona,Serological prevalence of SARS-CoV-2 infection among chronicmyeloid leukemia patients undergoing tyrosine kinase inhibitortreatment in italy (COVID-19-hem study),2020-11-05,Journal Article (Peer-Reviewed),National,Prospective cohort,Italy,"Veneto, Lazio and Friuli-Venezia Giulia",,"All consecutive CML patients coming to the participating Centers were offered to participate to the study, which was approved by local IRBs. Patients in Treatment Free Remission (TFR) phase (i.e. not taking TKI at the time of pandemic) were included as a control group. ",,2020-05-18,2020-07-29,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,27.0,93.0,Primary Estimate,Chronic Myeloid Leukemia Patients undergoing Tyrosine Kinase Inhibitor Treatment,339,0.0147,,,True,,,,True,Sequential,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],No,No,No,Yes,Unclear,Unclear,Yes,No,,Massimiliano Bonifacio,University of Verona,Not Unity-Aligned,http://dx.doi.org/10.1182/blood-2020-140032,2021-04-12,2022-07-16,Verified,bonifacio_serological_2020,ITA
201119_Italy_UniversityofCagliari_MilanoGenPop3_GenPop,201119_Italy_UniversityofCagliari_HealthyControls2,Seroprevalence of SARS-CoV2 in IBD patients treated with biological therapy,2020-11-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,"Otherwise healthy subjects in Milan, age matched for sex and age to IBD cohort",The key exclusion criteria were: 1. Inability to give informed consent,2020-04-15,2020-06-15,Household and community samples,All,Multiple groups,18.0,80.0,Primary Estimate,General population of Milan,129,0.07,0.044000000000000004,0.096,True,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG']",Spike,,0.9764,0.9520000000000001,['High'],No,No,No,Yes,Unclear,Unclear,Yes,No,,Roberto Berte,University of Cagliari,Not Unity-Aligned,https://dx.doi.org/10.1093/ecco-jcc/jjaa237,2021-01-23,2022-07-16,Verified,berte_seroprevalence_2020,ITA
201119_Italy_UniversityofCagliari_Milano1_IBDPatients,201119_Italy_UniversityofCagliari_IBDOverall1,Seroprevalence of SARS-CoV2 in IBD patients treated with biological therapy,2020-11-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,"Milan, Cagliari, Erlangen","Patients with ulcerative colitis or Crohn’s disease for at least 6 months, aged between 18 and 80 years
13 and undergoing regular administration of biological therapy were enrolled between April and June 2020
14 in Milan at the Policlinico Hospital, at the Policlinico Hospital of Cagliari and at the Erlangen University
15 Hospital, Germany. The key inclusion criteria were: 1. Confirmed diagnosis of Crohn’s disease or
16 ulcerative colitis from at least 12 months. 2. Age between 18 and 80 years. 3. Intravenous treatment
17 with infliximab, vedolizumab and ustekinumab for at least 6 months at the time of enrollment.",The key exclusion criteria were: 1. Inability to give informed consent,2020-04-15,2020-06-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,80.0,Primary Estimate,IBD Patients,354,0.023,0.008,0.038,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG']",Spike,,0.9764,0.9520000000000001,['High'],No,No,No,Yes,Unclear,Unclear,Yes,No,Unclear,Roberto Berte,University of Cagliari,Not Unity-Aligned,https://dx.doi.org/10.1093/ecco-jcc/jjaa237,2021-01-23,2022-07-16,Verified,berte_seroprevalence_2020,ITA
201109_Milan_UniversitadegliStudidiMilano_patients_antiN_S,201109_Milan_UniversitadegliStudidiMilano,"Effectiveness of infection-containment measures on SARS-CoV-2 seroprevalence and circulation from May to July 2020, in Milan, Italy",2020-11-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy ,Milan,"All consecutive subjects presenting at the ASST Grande
Ospedale Metropolitano Niguarda (Niguarda hospital) ER, or admitted for any reason (including day-hospitals)","Patients who, during the period under analysis, entered our centre in the context of a postCOVID molecular follow-up, were excluded from the analysis. All subjects with symptomatic
COVID-19 previously diagnosed by RT-PCR, and who were already followed or hospitalized before the start of screening, were also excluded.",2020-05-11,2020-07-05,Residual sera,All,Multiple groups,,,Test used,Hospital and emergency patients - used an anti-N 'screening' and anti-S 'confirmatory' test,2753,0.0334,,,True,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Yes,Valeria Cento,Universita degli Studi di Milano,Not Unity-Aligned,http://dx.doi.org/10.1371/journal.pone.0242765,2021-01-23,2024-03-01,Verified,cento_effectiveness_2020,ITA
201109_Milan_UniversitadegliStudidiMilano_patients_antiN,201109_Milan_UniversitadegliStudidiMilano,"Effectiveness of infection-containment measures on SARS-CoV-2 seroprevalence and circulation from May to July 2020, in Milan, Italy",2020-11-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy ,Milan,"All consecutive subjects presenting at the ASST Grande
Ospedale Metropolitano Niguarda (Niguarda hospital) ER, or admitted for any reason (including day-hospitals)","Patients who, during the period under analysis, entered our centre in the context of a postCOVID molecular follow-up, were excluded from the analysis. All subjects with symptomatic
COVID-19 previously diagnosed by RT-PCR, and who were already followed or hospitalized before the start of screening, were also excluded.",2020-05-11,2020-07-05,Residual sera,All,Multiple groups,,,Primary Estimate,Hospital and emergency department patients,2753,0.051,0.043,0.059000000000000004,,,,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9209999999999999,0.998,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Yes,Valeria Cento,Universita degli Studi di Milano,Not Unity-Aligned,http://dx.doi.org/10.1371/journal.pone.0242765,2021-01-23,2024-03-01,Verified,cento_effectiveness_2020,ITA
201126_Naples_UniversityofNaples_HighRisk,201126_Naples_UniversityofNaples_HighRisk,Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg,2020-11-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Campania,Naples,(1) healthcare staff from COVID-19 wards; (2) consent to participate; (3) no history of MS or other central nervous system diseases; (4) no history of chronic diseases and treatments; (5) residence in the Campania Region of Italy.,"(3) previous COVID-19 diagnosis; (4) COVID-19 symptoms (e.g., cough, fever, anosmia, difficulty breathing), either active or in the past 14 days. In particular, as per University policy, all individuals with symptoms of COVID-19 (e.g., cough, fever, anosmia, difficulty breathing), either active or in the past 14 days, ",2020-05-11,2020-06-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Healthcare workers on Covid-19 ward,235,0.106,,,True,,,,True,Convenience,Diagnostic kit for SARS-CoV-2 IgM/IgG Antibody (Colloidal Gold),Shanghai Kehua Bio-engineering (KHB) Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,,0.66,0.966,['High'],Yes,No,No,Yes,Yes,Unclear,Yes,No,Yes,Nicola Capasso,University of Naples,Not Unity-Aligned,https://dx.doi.org/10.3390/jcm9124066,2021-01-31,2023-07-04,Verified,capasso_prevalence_2020,ITA
201126_Naples_UniversityofNaples_LowRisk,201126_Naples_UniversityofNaples_LowRisk,Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg,2020-11-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Campania, Naples,1) university staff from non-clinical departments who had been self-isolating at home during lockdown; (2) consent to participate; (3) no history of MS or other central nervous system diseases; (4) no history of chronic diseases and treatments; (5) residence in the Campania Region of Italy.,"(3) previous COVID-19 diagnosis; (4) COVID-19 symptoms (e.g., cough, fever, anosmia, difficulty breathing), either active or in the past 14 days. In particular, as per University policy, all individuals with symptoms of COVID-19 (e.g., cough, fever, anosmia, difficulty breathing), either active or in the past 14 days, ",2020-05-11,2020-06-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,University staff,862,0.013000000000000001,,,True,,,,True,Convenience,Diagnostic kit for SARS-CoV-2 IgM/IgG Antibody (Colloidal Gold),Shanghai Kehua Bio-engineering (KHB) Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,,0.66,0.966,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Nicola Capasso,University of Naples,Not Unity-Aligned,https://dx.doi.org/10.3390/jcm9124066,2021-01-31,2023-07-04,Verified,capasso_prevalence_2020,ITA
201126_Naples_UniversityofNaples_MS,201126_Naples_UniversityofNaples_MS,Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg,2020-11-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Campania,Naples,(1) diagnosis of MS [16]; (2) consent to participate; (3) scheduled consultation at the MS Centre from 11 May to 15 June 2020; (4) residence in the Campania Region of Italy.,"(1) age <18 years; (2) incomplete records; (3) previous COVID-19 diagnosis; (4) COVID-19 symptoms (e.g., cough, fever, anosmia, difficulty breathing), either active or in the past 14 days",2020-05-11,2020-06-15,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),,,Primary Estimate,,310,0.028999999999999998,,,True,,,,True,Sequential,Diagnostic kit for SARS-CoV-2 IgM/IgG Antibody (Colloidal Gold),Shanghai Kehua Bio-engineering (KHB) Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,,0.66,0.966,['High'],Yes,No,No,Yes,Yes,Unclear,Yes,No,Yes,Nicola Capasso,University of Naples,Not Unity-Aligned,https://dx.doi.org/10.3390/jcm9124066,2021-01-31,2023-07-04,Verified,capasso_prevalence_2020,ITA
201127_Trento_AziendaProvincialeperiServiziSanitari_OverallAdj,201127_Trento_AziendaProvincialeperiServiziSanitari,Prevalence of SARS-CoV-2 IgG antibodies in an area of North-eastern Italy with a high incidence of COVID-19 cases: a population-based study.,2020-11-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Trento,,"All citizens above 10 years of age resident in five municipalities of the Autonomous Province of Trento, with the highest incidence of coronavirus disease 2019 (COVID-19) cases",Individuals with severe disease or who were institutionalized in nursing homes were excluded.,2020-05-05,2020-05-15,Household and community samples,All,Multiple groups,10.0,98.0,Primary Estimate,,6075,0.257,,,True,True,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Paola Stefanelli,Azienda Provinciale per i Servizi Sanitari,Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.11.013,2021-01-23,2023-07-04,Verified,stefanelli_prevalence_2020,ITA
201127_Trento_AziendaProvincialeperiServiziSanitari_OverallCrude,201127_Trento_AziendaProvincialeperiServiziSanitari,Prevalence of SARS-CoV-2 IgG antibodies in an area of North-eastern Italy with a high incidence of COVID-19 cases: a population-based study.,2020-11-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Trento,,"All citizens above 10 years of age resident in five municipalities of the Autonomous Province of Trento, with the highest incidence of coronavirus disease 2019 (COVID-19) cases",Individuals with severe disease or who were institutionalized in nursing homes were excluded.,2020-05-05,2020-05-15,Household and community samples,All,Multiple groups,10.0,98.0,Analysis,Overall crude for academic primary. ,6075,0.231,,,,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Paola Stefanelli,Azienda Provinciale per i Servizi Sanitari,Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.11.013,2021-01-23,2024-03-01,Verified,stefanelli_prevalence_2020,ITA
201127_Trento_AziendaProvincialeperiServiziSanitari_<20Crude,201127_Trento_AziendaProvincialeperiServiziSanitari,Prevalence of SARS-CoV-2 IgG antibodies in an area of North-eastern Italy with a high incidence of COVID-19 cases: a population-based study.,2020-11-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Trento,,"All citizens above 10 years of age resident in five municipalities of the Autonomous Province of Trento, with the highest incidence of coronavirus disease 2019 (COVID-19) cases",Individuals with severe disease or who were institutionalized in nursing homes were excluded.,2020-05-05,2020-05-15,Household and community samples,All,Children and Youth (0-17 years),10.0,20.0,Age,<20 crude,667,0.251,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Paola Stefanelli,Azienda Provinciale per i Servizi Sanitari,Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.11.013,2021-03-04,2024-03-01,Verified,stefanelli_prevalence_2020,ITA
201127_Trento_AziendaProvincialeperiServiziSanitari_30-39Crude,201127_Trento_AziendaProvincialeperiServiziSanitari,Prevalence of SARS-CoV-2 IgG antibodies in an area of North-eastern Italy with a high incidence of COVID-19 cases: a population-based study.,2020-11-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Trento,,"All citizens above 10 years of age resident in five municipalities of the Autonomous Province of Trento, with the highest incidence of coronavirus disease 2019 (COVID-19) cases",Individuals with severe disease or who were institutionalized in nursing homes were excluded.,2020-05-05,2020-05-15,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39 crude,720,0.228,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Paola Stefanelli,Azienda Provinciale per i Servizi Sanitari,Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.11.013,2021-03-04,2024-03-01,Verified,stefanelli_prevalence_2020,ITA
201127_Trento_AziendaProvincialeperiServiziSanitari_70+Crude,201127_Trento_AziendaProvincialeperiServiziSanitari,Prevalence of SARS-CoV-2 IgG antibodies in an area of North-eastern Italy with a high incidence of COVID-19 cases: a population-based study.,2020-11-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Trento,,"All citizens above 10 years of age resident in five municipalities of the Autonomous Province of Trento, with the highest incidence of coronavirus disease 2019 (COVID-19) cases",Individuals with severe disease or who were institutionalized in nursing homes were excluded.,2020-05-05,2020-05-15,Household and community samples,All,Seniors (65+ years),70.0,98.0,Age,70+ crude,976,0.179,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Paola Stefanelli,Azienda Provinciale per i Servizi Sanitari,Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.11.013,2021-03-04,2024-03-01,Verified,stefanelli_prevalence_2020,ITA
201127_Trento_AziendaProvincialeperiServiziSanitari_<20Adj,201127_Trento_AziendaProvincialeperiServiziSanitari,Prevalence of SARS-CoV-2 IgG antibodies in an area of North-eastern Italy with a high incidence of COVID-19 cases: a population-based study.,2020-11-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Trento,,"All citizens above 10 years of age resident in five municipalities of the Autonomous Province of Trento, with the highest incidence of coronavirus disease 2019 (COVID-19) cases",Individuals with severe disease or who were institutionalized in nursing homes were excluded.,2020-05-05,2020-05-15,Household and community samples,All,Children and Youth (0-17 years),10.0,20.0,Age,<20 test adj,667,0.27899999999999997,,,,True,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Paola Stefanelli,Azienda Provinciale per i Servizi Sanitari,Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.11.013,2021-01-23,2023-07-04,Verified,stefanelli_prevalence_2020,ITA
201127_Trento_AziendaProvincialeperiServiziSanitari_FemaleAdj,201127_Trento_AziendaProvincialeperiServiziSanitari,Prevalence of SARS-CoV-2 IgG antibodies in an area of North-eastern Italy with a high incidence of COVID-19 cases: a population-based study.,2020-11-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Trento,,"All citizens above 10 years of age resident in five municipalities of the Autonomous Province of Trento, with the highest incidence of coronavirus disease 2019 (COVID-19) cases",Individuals with severe disease or who were institutionalized in nursing homes were excluded.,2020-05-05,2020-05-15,Household and community samples,Female,Multiple groups,10.0,98.0,Sex/Gender,Female,3116,0.24300000000000002,,,,True,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Paola Stefanelli,Azienda Provinciale per i Servizi Sanitari,Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.11.013,2021-01-23,2023-07-04,Verified,stefanelli_prevalence_2020,ITA
201127_Trento_AziendaProvincialeperiServiziSanitari_40-49Crude,201127_Trento_AziendaProvincialeperiServiziSanitari,Prevalence of SARS-CoV-2 IgG antibodies in an area of North-eastern Italy with a high incidence of COVID-19 cases: a population-based study.,2020-11-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Trento,,"All citizens above 10 years of age resident in five municipalities of the Autonomous Province of Trento, with the highest incidence of coronavirus disease 2019 (COVID-19) cases",Individuals with severe disease or who were institutionalized in nursing homes were excluded.,2020-05-05,2020-05-15,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49 crude,917,0.264,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Paola Stefanelli,Azienda Provinciale per i Servizi Sanitari,Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.11.013,2021-03-04,2024-03-01,Verified,stefanelli_prevalence_2020,ITA
201127_Trento_AziendaProvincialeperiServiziSanitari_70+Adj,201127_Trento_AziendaProvincialeperiServiziSanitari,Prevalence of SARS-CoV-2 IgG antibodies in an area of North-eastern Italy with a high incidence of COVID-19 cases: a population-based study.,2020-11-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Trento,,"All citizens above 10 years of age resident in five municipalities of the Autonomous Province of Trento, with the highest incidence of coronavirus disease 2019 (COVID-19) cases",Individuals with severe disease or who were institutionalized in nursing homes were excluded.,2020-05-05,2020-05-15,Household and community samples,All,Seniors (65+ years),70.0,98.0,Age,70+ test adj,976,0.2,,,,True,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Paola Stefanelli,Azienda Provinciale per i Servizi Sanitari,Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.11.013,2021-01-23,2023-07-04,Verified,stefanelli_prevalence_2020,ITA
201127_Trento_AziendaProvincialeperiServiziSanitari_50-59Adj,201127_Trento_AziendaProvincialeperiServiziSanitari,Prevalence of SARS-CoV-2 IgG antibodies in an area of North-eastern Italy with a high incidence of COVID-19 cases: a population-based study.,2020-11-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Trento,,"All citizens above 10 years of age resident in five municipalities of the Autonomous Province of Trento, with the highest incidence of coronavirus disease 2019 (COVID-19) cases",Individuals with severe disease or who were institutionalized in nursing homes were excluded.,2020-05-05,2020-05-15,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59 test adj,1149,0.254,,,,True,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Paola Stefanelli,Azienda Provinciale per i Servizi Sanitari,Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.11.013,2021-01-23,2023-07-04,Verified,stefanelli_prevalence_2020,ITA
201127_Trento_AziendaProvincialeperiServiziSanitari_FemaleCrude,201127_Trento_AziendaProvincialeperiServiziSanitari,Prevalence of SARS-CoV-2 IgG antibodies in an area of North-eastern Italy with a high incidence of COVID-19 cases: a population-based study.,2020-11-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Trento,,"All citizens above 10 years of age resident in five municipalities of the Autonomous Province of Trento, with the highest incidence of coronavirus disease 2019 (COVID-19) cases",Individuals with severe disease or who were institutionalized in nursing homes were excluded.,2020-05-05,2020-05-15,Household and community samples,Female,Multiple groups,10.0,98.0,Sex/Gender,Female,3116,0.218,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Paola Stefanelli,Azienda Provinciale per i Servizi Sanitari,Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.11.013,2021-03-04,2024-03-01,Verified,stefanelli_prevalence_2020,ITA
201127_Trento_AziendaProvincialeperiServiziSanitari_MaleAdj,201127_Trento_AziendaProvincialeperiServiziSanitari,Prevalence of SARS-CoV-2 IgG antibodies in an area of North-eastern Italy with a high incidence of COVID-19 cases: a population-based study.,2020-11-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Trento,,"All citizens above 10 years of age resident in five municipalities of the Autonomous Province of Trento, with the highest incidence of coronavirus disease 2019 (COVID-19) cases",Individuals with severe disease or who were institutionalized in nursing homes were excluded.,2020-05-05,2020-05-15,Household and community samples,Male,Multiple groups,10.0,98.0,Sex/Gender,Male,2959,0.271,,,,True,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Paola Stefanelli,Azienda Provinciale per i Servizi Sanitari,Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.11.013,2021-01-23,2023-07-04,Verified,stefanelli_prevalence_2020,ITA
201127_Trento_AziendaProvincialeperiServiziSanitari_40-49Adj,201127_Trento_AziendaProvincialeperiServiziSanitari,Prevalence of SARS-CoV-2 IgG antibodies in an area of North-eastern Italy with a high incidence of COVID-19 cases: a population-based study.,2020-11-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Trento,,"All citizens above 10 years of age resident in five municipalities of the Autonomous Province of Trento, with the highest incidence of coronavirus disease 2019 (COVID-19) cases",Individuals with severe disease or who were institutionalized in nursing homes were excluded.,2020-05-05,2020-05-15,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49 test adj,917,0.294,,,,True,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Paola Stefanelli,Azienda Provinciale per i Servizi Sanitari,Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.11.013,2021-01-23,2023-07-04,Verified,stefanelli_prevalence_2020,ITA
201127_Trento_AziendaProvincialeperiServiziSanitari_30-39Adj,201127_Trento_AziendaProvincialeperiServiziSanitari,Prevalence of SARS-CoV-2 IgG antibodies in an area of North-eastern Italy with a high incidence of COVID-19 cases: a population-based study.,2020-11-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Trento,,"All citizens above 10 years of age resident in five municipalities of the Autonomous Province of Trento, with the highest incidence of coronavirus disease 2019 (COVID-19) cases",Individuals with severe disease or who were institutionalized in nursing homes were excluded.,2020-05-05,2020-05-15,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39 test adj,720,0.253,,,,True,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Paola Stefanelli,Azienda Provinciale per i Servizi Sanitari,Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.11.013,2021-01-23,2023-07-04,Verified,stefanelli_prevalence_2020,ITA
201127_Trento_AziendaProvincialeperiServiziSanitari_60-69Adj,201127_Trento_AziendaProvincialeperiServiziSanitari,Prevalence of SARS-CoV-2 IgG antibodies in an area of North-eastern Italy with a high incidence of COVID-19 cases: a population-based study.,2020-11-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Trento,,"All citizens above 10 years of age resident in five municipalities of the Autonomous Province of Trento, with the highest incidence of coronavirus disease 2019 (COVID-19) cases",Individuals with severe disease or who were institutionalized in nursing homes were excluded.,2020-05-05,2020-05-15,Household and community samples,All,Adults (18-64 years),60.0,69.0,Age,60-69 test adj,965,0.249,,,,True,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Paola Stefanelli,Azienda Provinciale per i Servizi Sanitari,Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.11.013,2021-01-23,2023-07-04,Verified,stefanelli_prevalence_2020,ITA
201127_Trento_AziendaProvincialeperiServiziSanitari_MaleCrude,201127_Trento_AziendaProvincialeperiServiziSanitari,Prevalence of SARS-CoV-2 IgG antibodies in an area of North-eastern Italy with a high incidence of COVID-19 cases: a population-based study.,2020-11-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Trento,,"All citizens above 10 years of age resident in five municipalities of the Autonomous Province of Trento, with the highest incidence of coronavirus disease 2019 (COVID-19) cases",Individuals with severe disease or who were institutionalized in nursing homes were excluded.,2020-05-05,2020-05-15,Household and community samples,Male,Multiple groups,10.0,98.0,Sex/Gender,Male,2959,0.244,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Paola Stefanelli,Azienda Provinciale per i Servizi Sanitari,Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.11.013,2021-03-04,2024-03-01,Verified,stefanelli_prevalence_2020,ITA
201127_Trento_AziendaProvincialeperiServiziSanitari_20-29Adj,201127_Trento_AziendaProvincialeperiServiziSanitari,Prevalence of SARS-CoV-2 IgG antibodies in an area of North-eastern Italy with a high incidence of COVID-19 cases: a population-based study.,2020-11-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Trento,,"All citizens above 10 years of age resident in five municipalities of the Autonomous Province of Trento, with the highest incidence of coronavirus disease 2019 (COVID-19) cases",Individuals with severe disease or who were institutionalized in nursing homes were excluded.,2020-05-05,2020-05-15,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29 test adj,704,0.28300000000000003,,,,True,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Paola Stefanelli,Azienda Provinciale per i Servizi Sanitari,Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.11.013,2021-01-23,2023-07-04,Verified,stefanelli_prevalence_2020,ITA
201127_Trento_AziendaProvincialeperiServiziSanitari_50-59Crude,201127_Trento_AziendaProvincialeperiServiziSanitari,Prevalence of SARS-CoV-2 IgG antibodies in an area of North-eastern Italy with a high incidence of COVID-19 cases: a population-based study.,2020-11-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Trento,,"All citizens above 10 years of age resident in five municipalities of the Autonomous Province of Trento, with the highest incidence of coronavirus disease 2019 (COVID-19) cases",Individuals with severe disease or who were institutionalized in nursing homes were excluded.,2020-05-05,2020-05-15,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59 crude,1149,0.22899999999999998,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Paola Stefanelli,Azienda Provinciale per i Servizi Sanitari,Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.11.013,2021-03-04,2024-03-01,Verified,stefanelli_prevalence_2020,ITA
201127_Trento_AziendaProvincialeperiServiziSanitari_20-29Crude,201127_Trento_AziendaProvincialeperiServiziSanitari,Prevalence of SARS-CoV-2 IgG antibodies in an area of North-eastern Italy with a high incidence of COVID-19 cases: a population-based study.,2020-11-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Trento,,"All citizens above 10 years of age resident in five municipalities of the Autonomous Province of Trento, with the highest incidence of coronavirus disease 2019 (COVID-19) cases",Individuals with severe disease or who were institutionalized in nursing homes were excluded.,2020-05-05,2020-05-15,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29 crude,704,0.255,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Paola Stefanelli,Azienda Provinciale per i Servizi Sanitari,Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.11.013,2021-03-04,2024-03-01,Verified,stefanelli_prevalence_2020,ITA
201127_Trento_AziendaProvincialeperiServiziSanitari_60-69Crude,201127_Trento_AziendaProvincialeperiServiziSanitari,Prevalence of SARS-CoV-2 IgG antibodies in an area of North-eastern Italy with a high incidence of COVID-19 cases: a population-based study.,2020-11-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Trento,,"All citizens above 10 years of age resident in five municipalities of the Autonomous Province of Trento, with the highest incidence of coronavirus disease 2019 (COVID-19) cases",Individuals with severe disease or who were institutionalized in nursing homes were excluded.,2020-05-05,2020-05-15,Household and community samples,All,Adults (18-64 years),60.0,69.0,Age,60-69 crude,965,0.22399999999999998,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Paola Stefanelli,Azienda Provinciale per i Servizi Sanitari,Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2020.11.013,2021-03-04,2024-03-01,Verified,stefanelli_prevalence_2020,ITA
201213_Foggia_AziendaOspedalieraUniversitariaPoliclinicoRiunitiDiFoggia_HCW,201213_Foggia_AziendaOspedalieraUniversitariaPoliclinicoRiunitiDiFoggia,SARS-COV-2 Serological Profile in Healthcare Professionals of a Southern Italy Hospital,2020-12-13,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Italy,"Apulia, Province of Foggia",Foggia,"Policlinico Riuniti Hospital healthcare workers. From 17 March to 18 May 2020, we enrolled a total of 3242 employees all with no SARS-CoV-2 symptoms and no history of previous positive testing.",,2020-03-17,2020-05-18,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Overall HCW,3242,0.019,0.013999999999999999,0.023,True,,,,True,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.97,0.988,['High'],Yes,No,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Armando De Carlo,Azienda Ospedaliera-Universitaria Policlinico Riuniti di Foggia,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph17249324,2021-02-05,2022-07-16,Verified,de_carlo_sars-cov-2_2020,ITA
201217_Naples_UniversityofCampania_ELISA,201217_Naples_UniversityofCampania,Assessment and Comparison of Two Serological Approaches for the Surveillance of Health Workers Exposed to SARS-CoV-2,2020-12-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,Italy,Campania,Naples,All HCWs employed at the University of CampaniaCOVID_19 unit were included in the study,,2020-03-27,2020-08-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,ELISA test,65,0.0,,,True,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,No,Yes,No,Yes,Yes,Yes,Unclear,Antonio Russo,University of Campania,Not Unity-Aligned,https://dx.doi.org/10.2147/IDR.S282652,2021-02-01,2024-03-01,Verified,russo_passessment_2020,ITA
201219_Tuscany_UniversityOfFlorence_Overall,201219_Tuscany_UniversityOfFlorence,"SARS-CoV-2 Seroprevalence Survey in People Involved in Different Essential Activities during the General Lock-Down Phase in the Province of Prato (Tuscany, Italy)",2020-12-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Prato,,"The study sample wascomposed of people aged 18 years or older involved in different activities considered essential duringthe lock-down period. In particular, the following population groups were invited to participate in thestudy: workers of the Local Health Authority (LHA), workers and volunteers of the Civil Protection,and public employees of the Province of Prato and of the municipalities of Cantagallo, Carmignano,Montemurlo, Poggio a Caiano, Vaiano, and Vernio.  All the people belonging to these populationgroups in the Province of Prato were invited to participate",,2020-05-01,2020-05-31,Multiple populations,All,Multiple groups,18.0,,Primary Estimate,Overall,4656,0.03,0.025,0.035,True,,,,True,Convenience,LYHER Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Combo Test Kit(Colloidal Gold) ,Hangzhou Laihe Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,1.0,0.988,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Vieri Lastrucci,University of Florence,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines8040778,2021-01-23,2024-03-01,Verified,lastrucci_sars-cov-2_2020,ITA
201221_Lombardy_ATSMilan_cohabitants,201221_Lombardy_ATSMilan_cohabitants,SARS-CoV-2 pandemia in Lombardy: the impact on family Paediatricians,2020-12-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Lombardy,,paediatricians relatives,,2020-04-01,2020-04-30,Family of essential workers,All,Adults (18-64 years),,,Primary Estimate,,755,0.244,,,True,,,,True,Convenience,Acro Biotech COVID-19 IgM/IgG Rapid POC test,ACRO Biotech Inc,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,0.96,0.792,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Rinaldo Missaglia,University of Milano-Bicocca,Not Unity-Aligned,https://ijponline.biomedcentral.com/articles/10.1186/s13052-020-00950-0,2021-05-21,2024-03-01,Verified,missaglia_sars-cov-2_2020,ITA
201221_Lombardy_ATSMilan_peds,201221_Lombardy_ATSMilan_peds,SARS-CoV-2 pandemia in Lombardy: the impact on family Paediatricians,2020-12-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Lombardy,,family paediatricians,,2020-04-01,2020-04-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,377,0.149,,,True,,,,True,Convenience,Acro Biotech COVID-19 IgM/IgG Rapid POC test,ACRO Biotech Inc,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,0.96,0.792,['High'],Yes,No,No,Yes,Yes,Yes,Yes,No,Unclear,Rinaldo Missaglia,University of Milano-Bicocca,Not Unity-Aligned,https://ijponline.biomedcentral.com/articles/10.1186/s13052-020-00950-0,2021-05-21,2024-03-01,Verified,missaglia_sars-cov-2_2020,ITA
201221_Lombardy_ATSMilan_staff,201221_Lombardy_ATSMilan_staff,SARS-CoV-2 pandemia in Lombardy: the impact on family Paediatricians,2020-12-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Lombardy,,staff members of paediatric clinics,,2020-04-01,2020-04-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,108,0.157,,,True,,,,True,Convenience,Acro Biotech COVID-19 IgM/IgG Rapid POC test,ACRO Biotech Inc,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,0.96,0.792,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,No,Unclear,Rinaldo Missaglia,University of Milano-Bicocca,Not Unity-Aligned,https://ijponline.biomedcentral.com/articles/10.1186/s13052-020-00950-0,2021-05-21,2024-03-01,Verified,missaglia_sars-cov-2_2020,ITA
201222_Rome_EleemosynariaApostolica_overall,201222_Rome_EleemosynariaApostolica,"Assessment of SARS-CoV-2 infection through rapid serology testing in the homeless population in the City of Rome, Italy. Preliminary results",2020-12-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lazio,Rome,Homeless persons attending mobile healthcare facility as a patient,"symptoms suggestive of COVID-19, such as fever >37.5°C, cough, tiredness, sore throat and breathing difficulties at the time of the admission and in the 14 days before",2020-04-14,2020-07-31,Multiple populations,All,Multiple groups,10.0,80.0,Primary Estimate,,173,0.018000000000000002,,,True,,,,True,Convenience,Biozek Medical COVID-19 Rapid Test,Biozek,LFIA,Whole Blood,"['IgG', 'IgM']",,,0.96,0.96,['High'],Yes,No,No,Yes,Unclear,Unclear,Yes,No,Unclear,Massimo Ralli,Eleemosynaria Apostolica,Not Unity-Aligned,https://dx.doi.org/10.4081/jphr.2020.1986,2021-01-23,2024-03-01,Verified,ralli_assessment_2020,ITA
201223_Bergamo_OspedalePapaGiovanniXXIII_overall,201223_Bergamo_OspedalePapaGiovanniXXIII,Prevalence and Clinical Impact of SARS-CoV-2 Silent Carriers Among Actively Treated Patients with Cancer During the COVID-19 Pandemic.,2020-12-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Bergamo,"patients with cancer, who were scheduled for an anticancer treatment in the outpatient facility of our hospital and who remained asymptomatic or had been previously only mildly symptomatic for COVID‐19 and who were not receiving any anti‐COVID‐19 therapy,",experienced overt and/or severe symptomatic COVID-19 illness,2020-04-01,2020-04-30,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,19.0,89.0,Primary Estimate,,560,0.31,,,True,,,,True,Sequential,NADAL® COVID-19 IgG/IgM Test,nal von minden GmbH,LFIA,Plasma,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9209999999999999,0.9920000000000001,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Alberto Zambelli,Ospedale Papa Giovanni XXIII,Not Unity-Aligned,https://dx.doi.org/10.1002/onco.13654,2021-02-03,2024-03-01,Verified,zambelli_1676mo_2020,ITA
201231_Modena_OspedaleCivileS.AgostinoEstense_overall,201231_Modena_OspedaleCivileS.AgostinoEstense,The prevalence of antibodies to SARS-CoV-2 in healthcare workers of Modena. the screening on more than 7000 subjects,2020-12-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Emilia-Romagna Region,Modena,We evaluated the prevalence of IgG and IgM antibodies (Abs) anti SARS-CoV-2 in HCWs affiliated to AUSL of Modena. We analysed data on asymptomatic HCWs,,2020-03-30,2020-05-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,7711,0.05,,,True,,,,True,Convenience,Not reported/ Unable to specify,,CLIA,,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,Unclear,Valentina Pecoraro,Ospedale Civile S.Agostino Estense,Not Unity-Aligned,https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/covidwho-984696,2021-02-12,2022-07-16,Verified,pecoraro_prevalence_2020,ITA
210105_SanGiovaniRotondo_FondazioneCasaSollievoDellaSofferenza_overall,210105_SanGiovaniRotondo_FondazioneCasaSollievoDellaSofferenza,Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs,2021-01-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,San Giovanni Rotondo,"All patients followed up at the IBD center at the Casa Sollievo della Sofferenza Research Hospital (San Giovanni Rotondo, Italy) who received at least one injection of a biologic drug for IBD from May 2020 on, were enrolled. ",,2020-05-01,2020-06-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,245,0.0088,,,True,,,,True,Convenience,"Diagnostic kit for SARS-CoV-2 IgM/IgG Antibody (Colloidal Gold),SARS-CoV-2 ELISA IgM, IgG, and IgA","Shanghai Kehua Bio-engineering (KHB) Co. Ltd,Tecan",Multiple Types,,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],No,No,No,Yes,Yes,Unclear,Yes,No,Unclear,Fabrizio Bossa,Fondazione Casa Sollievo della Sofferenza,Not Unity-Aligned,http://dx.doi.org/10.1016/j.dld.2020.12.120,2021-02-13,2022-07-16,Verified,bossa_impact_2021,ITA
210109_GiglioIsland_UniversitàdegliStudidiMilano,210109_GiglioIsland_UniversitàdegliStudidiMilano,The Conundrum of Giglio Island: unraveling the dynamics of an apparent resistance to COVID-19. A descriptive study,2021-01-09,Preprint,Local,Cross-sectional survey ,Italy,Tuscany,Giglio Island,"We invited the adult resident population, present on the island",,2020-04-29,2020-05-03,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,,723,0.0040999999999999995,,,True,,,,True,Self-referral,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by manufacturers,0.8790000000000001,1.0,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Antonio Bognanni,Università degli Studi di Milano,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.01.08.20248948v1,2021-01-31,2024-03-01,Verified,bognanni_conundrum_2021,ITA
210112_ArianoIrpino_Zoo-ProphylacticInstituteOfSouthernItaly_overall,210112_ArianoIrpino_Zoo-ProphylacticInstituteOfSouthernItaly,"Seroprevalence of SARS-CoV-2-specific antibodies in the town of Ariano Irpino (Avellino, Campania, Italy): a population-based study",2021-01-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Province of Avellino in the Campania region,Ariano Irpino,"Screening was offered to all citizens inhabiting Ariano Irpino regardless of age but not to institutionalized citizens (e.g., those hospitalized or in prison). Only asymptomatic individuals and those who had not previously tested positive for SARS-CoV-2 on RT-PCR were included in the study",,2020-05-16,2020-05-19,Household and community samples,All,Multiple groups,,,Primary Estimate,,13218,0.055999999999999994,0.052000000000000005,0.06,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Pellegrino Cerino,The Zoo-Prophylactic Institute of Southern Italy,Unity-Aligned,https://www.future-science.com/doi/10.2144/fsoa-2020-0203,2021-03-04,2024-03-01,Verified,cerino_seroprevalence_2021,ITA
210112_ArianoIrpino_Zoo-ProphylacticInstituteOfSouthernItaly_age>65,210112_ArianoIrpino_Zoo-ProphylacticInstituteOfSouthernItaly,"Seroprevalence of SARS-CoV-2-specific antibodies in the town of Ariano Irpino (Avellino, Campania, Italy): a population-based study",2021-01-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Province of Avellino in the Campania region,Ariano Irpino,"Screening was offered to all citizens inhabiting Ariano Irpino regardless of age but not to institutionalized citizens (e.g., those hospitalized or in prison). Only asymptomatic individuals and those who had not previously tested positive for SARS-CoV-2 on RT-PCR were included in the study",,2020-05-16,2020-05-19,Household and community samples,All,Seniors (65+ years),65.0,,Age,>65,2604,0.04,0.033,0.048,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Pellegrino Cerino,The Zoo-Prophylactic Institute of Southern Italy,Unity-Aligned,https://www.future-science.com/doi/10.2144/fsoa-2020-0203,2021-03-04,2024-03-01,Verified,cerino_seroprevalence_2021,ITA
210112_ArianoIrpino_Zoo-ProphylacticInstituteOfSouthernItaly_age15-18,210112_ArianoIrpino_Zoo-ProphylacticInstituteOfSouthernItaly,"Seroprevalence of SARS-CoV-2-specific antibodies in the town of Ariano Irpino (Avellino, Campania, Italy): a population-based study",2021-01-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Province of Avellino in the Campania region,Ariano Irpino,"Screening was offered to all citizens inhabiting Ariano Irpino regardless of age but not to institutionalized citizens (e.g., those hospitalized or in prison). Only asymptomatic individuals and those who had not previously tested positive for SARS-CoV-2 on RT-PCR were included in the study",,2020-05-16,2020-05-19,Household and community samples,All,Children and Youth (0-17 years),15.0,18.0,Age,15-18,457,0.061,0.040999999999999995,0.087,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Pellegrino Cerino,The Zoo-Prophylactic Institute of Southern Italy,Unity-Aligned,https://www.future-science.com/doi/10.2144/fsoa-2020-0203,2021-03-04,2024-03-01,Verified,cerino_seroprevalence_2021,ITA
210112_ArianoIrpino_Zoo-ProphylacticInstituteOfSouthernItaly_males,210112_ArianoIrpino_Zoo-ProphylacticInstituteOfSouthernItaly,"Seroprevalence of SARS-CoV-2-specific antibodies in the town of Ariano Irpino (Avellino, Campania, Italy): a population-based study",2021-01-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Province of Avellino in the Campania region,Ariano Irpino,"Screening was offered to all citizens inhabiting Ariano Irpino regardless of age but not to institutionalized citizens (e.g., those hospitalized or in prison). Only asymptomatic individuals and those who had not previously tested positive for SARS-CoV-2 on RT-PCR were included in the study",,2020-05-16,2020-05-19,Household and community samples,Male,Multiple groups,,,Sex/Gender,,6474,0.053,0.047,0.057999999999999996,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Pellegrino Cerino,The Zoo-Prophylactic Institute of Southern Italy,Unity-Aligned,https://www.future-science.com/doi/10.2144/fsoa-2020-0203,2021-03-04,2024-03-01,Verified,cerino_seroprevalence_2021,ITA
210112_ArianoIrpino_Zoo-ProphylacticInstituteOfSouthernItaly_age0-14,210112_ArianoIrpino_Zoo-ProphylacticInstituteOfSouthernItaly,"Seroprevalence of SARS-CoV-2-specific antibodies in the town of Ariano Irpino (Avellino, Campania, Italy): a population-based study",2021-01-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Province of Avellino in the Campania region,Ariano Irpino,"Screening was offered to all citizens inhabiting Ariano Irpino regardless of age but not to institutionalized citizens (e.g., those hospitalized or in prison). Only asymptomatic individuals and those who had not previously tested positive for SARS-CoV-2 on RT-PCR were included in the study",,2020-05-16,2020-05-19,Household and community samples,All,Children and Youth (0-17 years),0.0,14.0,Age,0-14,516,0.13,0.102,0.162,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Pellegrino Cerino,The Zoo-Prophylactic Institute of Southern Italy,Unity-Aligned,https://www.future-science.com/doi/10.2144/fsoa-2020-0203,2021-03-04,2024-03-01,Verified,cerino_seroprevalence_2021,ITA
210112_ArianoIrpino_Zoo-ProphylacticInstituteOfSouthernItaly_age19-65,210112_ArianoIrpino_Zoo-ProphylacticInstituteOfSouthernItaly,"Seroprevalence of SARS-CoV-2-specific antibodies in the town of Ariano Irpino (Avellino, Campania, Italy): a population-based study",2021-01-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Province of Avellino in the Campania region,Ariano Irpino,"Screening was offered to all citizens inhabiting Ariano Irpino regardless of age but not to institutionalized citizens (e.g., those hospitalized or in prison). Only asymptomatic individuals and those who had not previously tested positive for SARS-CoV-2 on RT-PCR were included in the study",,2020-05-16,2020-05-19,Household and community samples,All,Adults (18-64 years),19.0,65.0,Age,19-65,9641,0.055999999999999994,0.051,0.061,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Pellegrino Cerino,The Zoo-Prophylactic Institute of Southern Italy,Unity-Aligned,https://www.future-science.com/doi/10.2144/fsoa-2020-0203,2021-03-04,2024-03-01,Verified,cerino_seroprevalence_2021,ITA
210112_ArianoIrpino_Zoo-ProphylacticInstituteOfSouthernItaly_females,210112_ArianoIrpino_Zoo-ProphylacticInstituteOfSouthernItaly,"Seroprevalence of SARS-CoV-2-specific antibodies in the town of Ariano Irpino (Avellino, Campania, Italy): a population-based study",2021-01-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Province of Avellino in the Campania region,Ariano Irpino,"Screening was offered to all citizens inhabiting Ariano Irpino regardless of age but not to institutionalized citizens (e.g., those hospitalized or in prison). Only asymptomatic individuals and those who had not previously tested positive for SARS-CoV-2 on RT-PCR were included in the study",,2020-05-16,2020-05-19,Household and community samples,Female,Multiple groups,,,Sex/Gender,,6744,0.059000000000000004,0.054000000000000006,0.065,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Pellegrino Cerino,The Zoo-Prophylactic Institute of Southern Italy,Unity-Aligned,https://www.future-science.com/doi/10.2144/fsoa-2020-0203,2021-03-04,2024-03-01,Verified,cerino_seroprevalence_2021,ITA
210111_Pavia_University of Pavia_overall,210111_Pavia_University of Pavia,Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients,2021-01-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Pavia,"Between 27th April 2020 and 3rd May 2020 (the last week of Italy’s national lockdown due to the first wave of COVID-19), neurologists with expertise in MS contacted, by phone, all patients followed at the Multiple Sclerosis Center of the Mondino Foundation, Pavia, Italy who: i) had a diagnosis of MS according to the
2010 revised McDonald diagnostic criteria (Polman et al., 2011); and ii) had been under treatment with NTZ or FTY for at least 3 months.",,2020-05-04,2020-06-03,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),,,Primary Estimate,patients with MS,104,0.13460000000000003,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,,,,,['High'],No,No,No,Yes,No,Yes,Yes,Yes,Yes,Giulia Mallucci,University of Pavia,Not Unity-Aligned,https://doi.org/10.1016/j.msard.2021.102754,2021-02-03,2024-03-01,Verified,mallucci_safety_2021,ITA
210125_TerreRoveresche_UniversityOfUrbinoCarloBo_Overall,210125_TerreRoveresche_UniversityOfUrbinoCarloBo,"Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection in an Italian cohort in Marche Region, Italy",2021-01-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Le Marche Region,Municipality of Terre Roveresche,"The recruitment was conducted by family and occupational doctors firstly involving workers at greater risk of contagion (i.e. HCWs, shop assistants, and police officers) selected by the Local Health Authority and the municipality, and secondly involving all volunteers who wanted to participate in the survey.",,2020-03-15,2020-06-15,Multiple populations,All,Multiple groups,20.0,82.0,Primary Estimate,,341,0.14400000000000002,,,True,,,,True,Convenience,IgG and IgM anti-SARS-CoV-2 ELISA,Diagnostic Bioprobes,ELISA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],No,No,No,Yes,Yes,Unclear,Yes,No,Unclear,Mauro De Santi,University of Urbino Carlo Bo,Not Unity-Aligned,https://dx.doi.org/10.23750/abm.v92i1.10847,2021-04-13,2022-07-16,Verified,de_santi_seroprevalence_2021,ITA
210125_TerreRoveresche_UniversityOfUrbinoCarloBo_age20-29,210125_TerreRoveresche_UniversityOfUrbinoCarloBo,"Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection in an Italian cohort in Marche Region, Italy",2021-01-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Le Marche Region,Municipality of Terre Roveresche,"The recruitment was conducted by family and occupational doctors firstly involving workers at greater risk of contagion (i.e. HCWs, shop assistants, and police officers) selected by the Local Health Authority and the municipality, and secondly involving all volunteers who wanted to participate in the survey.",,2020-03-15,2020-06-15,Multiple populations,All,Adults (18-64 years),20.0,29.0,Age,age 20-29,38,0.105,,,,,,,,Convenience,IgG and IgM anti-SARS-CoV-2 ELISA,Diagnostic Bioprobes,ELISA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],No,No,No,Yes,Yes,Unclear,Yes,No,Unclear,Mauro De Santi,University of Urbino Carlo Bo,Not Unity-Aligned,https://dx.doi.org/10.23750/abm.v92i1.10847,2021-04-13,2022-07-16,Verified,de_santi_seroprevalence_2021,ITA
210125_TerreRoveresche_UniversityOfUrbinoCarloBo_age50-59,210125_TerreRoveresche_UniversityOfUrbinoCarloBo,"Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection in an Italian cohort in Marche Region, Italy",2021-01-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Le Marche Region,Municipality of Terre Roveresche,"The recruitment was conducted by family and occupational doctors firstly involving workers at greater risk of contagion (i.e. HCWs, shop assistants, and police officers) selected by the Local Health Authority and the municipality, and secondly involving all volunteers who wanted to participate in the survey.",,2020-03-15,2020-06-15,Multiple populations,All,Adults (18-64 years),50.0,59.0,Age,age 50-59,87,0.161,,,,,,,,Convenience,IgG and IgM anti-SARS-CoV-2 ELISA,Diagnostic Bioprobes,ELISA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],No,No,No,Yes,Yes,Unclear,Yes,No,Unclear,Mauro De Santi,University of Urbino Carlo Bo,Not Unity-Aligned,https://dx.doi.org/10.23750/abm.v92i1.10847,2021-04-13,2022-07-16,Verified,de_santi_seroprevalence_2021,ITA
210125_TerreRoveresche_UniversityOfUrbinoCarloBo_age30-39,210125_TerreRoveresche_UniversityOfUrbinoCarloBo,"Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection in an Italian cohort in Marche Region, Italy",2021-01-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Le Marche Region,Municipality of Terre Roveresche,"The recruitment was conducted by family and occupational doctors firstly involving workers at greater risk of contagion (i.e. HCWs, shop assistants, and police officers) selected by the Local Health Authority and the municipality, and secondly involving all volunteers who wanted to participate in the survey.",,2020-03-15,2020-06-15,Multiple populations,All,Adults (18-64 years),30.0,39.0,Age,age 30-39,59,0.136,,,,,,,,Convenience,IgG and IgM anti-SARS-CoV-2 ELISA,Diagnostic Bioprobes,ELISA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],No,No,No,Yes,Yes,Unclear,Yes,No,Unclear,Mauro De Santi,University of Urbino Carlo Bo,Not Unity-Aligned,https://dx.doi.org/10.23750/abm.v92i1.10847,2021-04-13,2022-07-16,Verified,de_santi_seroprevalence_2021,ITA
210125_TerreRoveresche_UniversityOfUrbinoCarloBo_age60-69,210125_TerreRoveresche_UniversityOfUrbinoCarloBo,"Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection in an Italian cohort in Marche Region, Italy",2021-01-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Le Marche Region,Municipality of Terre Roveresche,"The recruitment was conducted by family and occupational doctors firstly involving workers at greater risk of contagion (i.e. HCWs, shop assistants, and police officers) selected by the Local Health Authority and the municipality, and secondly involving all volunteers who wanted to participate in the survey.",,2020-03-15,2020-06-15,Multiple populations,All,Adults (18-64 years),60.0,69.0,Age,age 60-69,43,0.209,,,,,,,,Convenience,IgG and IgM anti-SARS-CoV-2 ELISA,Diagnostic Bioprobes,ELISA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],No,No,No,Yes,Yes,Unclear,Yes,No,Unclear,Mauro De Santi,University of Urbino Carlo Bo,Not Unity-Aligned,https://dx.doi.org/10.23750/abm.v92i1.10847,2021-04-13,2022-07-16,Verified,de_santi_seroprevalence_2021,ITA
210125_TerreRoveresche_UniversityOfUrbinoCarloBo_age40-49,210125_TerreRoveresche_UniversityOfUrbinoCarloBo,"Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection in an Italian cohort in Marche Region, Italy",2021-01-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Le Marche Region,Municipality of Terre Roveresche,"The recruitment was conducted by family and occupational doctors firstly involving workers at greater risk of contagion (i.e. HCWs, shop assistants, and police officers) selected by the Local Health Authority and the municipality, and secondly involving all volunteers who wanted to participate in the survey.",,2020-03-15,2020-06-15,Multiple populations,All,Adults (18-64 years),40.0,49.0,Age,age 40-49,92,0.109,,,,,,,,Convenience,IgG and IgM anti-SARS-CoV-2 ELISA,Diagnostic Bioprobes,ELISA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],No,No,No,Yes,Yes,Unclear,Yes,No,Unclear,Mauro De Santi,University of Urbino Carlo Bo,Not Unity-Aligned,https://dx.doi.org/10.23750/abm.v92i1.10847,2021-04-13,2022-07-16,Verified,de_santi_seroprevalence_2021,ITA
210125_TerreRoveresche_UniversityOfUrbinoCarloBo_age70+,210125_TerreRoveresche_UniversityOfUrbinoCarloBo,"Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection in an Italian cohort in Marche Region, Italy",2021-01-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Le Marche Region,Municipality of Terre Roveresche,"The recruitment was conducted by family and occupational doctors firstly involving workers at greater risk of contagion (i.e. HCWs, shop assistants, and police officers) selected by the Local Health Authority and the municipality, and secondly involving all volunteers who wanted to participate in the survey.",,2020-03-15,2020-06-15,Multiple populations,All,Seniors (65+ years),70.0,82.0,Age,age 70+,10,0.3,,,,,,,,Convenience,IgG and IgM anti-SARS-CoV-2 ELISA,Diagnostic Bioprobes,ELISA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],No,No,No,Yes,Yes,Unclear,Yes,No,Unclear,Mauro De Santi,University of Urbino Carlo Bo,Not Unity-Aligned,https://dx.doi.org/10.23750/abm.v92i1.10847,2021-04-13,2022-07-16,Verified,de_santi_seroprevalence_2021,ITA
210127_Merano_FranzTappeinerHospital_HCW_primary,210127_Merano_FranzTappeinerHospital_HCW,Evaluating the longitudinal effectiveness of preventive measures against COVID-19 and seroprevalence of IgG antibodies to SARS-CoV-2 in cancer outpatients and healthcare workers,2021-01-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Merano,from 22 June to 17 July 2020 all healthcare workers at Franz Tappeiner Hospital Merano who underwent SARS-CoV-2 PCR baseline testing were tested for the presence of IgG antibodies ,,2020-06-22,2020-07-17,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,36,0.055,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['High'],,No,No,No,,Yes,Yes,Yes,,Dominic Fong,Franz Tappeiner Hospital,Not Unity-Aligned,https://dx.doi.org/10.1007/s00508-020-01807-6,2021-02-23,2024-03-01,Unverified,fong_evaluating_2021,ITA
210127_Merano_FranzTappeinerHospital_patients_primary,210127_Merano_FranzTappeinerHospital_patients,Evaluating the longitudinal effectiveness of preventive measures against COVID-19 and seroprevalence of IgG antibodies to SARS-CoV-2 in cancer outpatients and healthcare workers,2021-01-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Merano,from 22 June to 17 July 2020 a total of 250 consecutive cancer patients treated at the outpatient de- partment of the “Franz Tappeiner” Hospital Merano who underwent SARS-CoV-2 PCR baseline testing were tested for the presence of IgG antibodies ,,2020-06-22,2020-07-17,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,Cancer patients,250,0.008,,,True,,,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['High'],No,No,No,No,No,Yes,Yes,Yes,Unclear,Dominic Fong,Franz Tappeiner Hospital,Not Unity-Aligned,https://dx.doi.org/10.1007/s00508-020-01807-6,2021-02-23,2024-03-01,Verified,fong_evaluating_2021,ITA
210127_UniversityHospitalofBari_UniversityofBari_overall_IgG_unadj,210127_UniversityHospitalofBari_UniversityofBari,Large-scale IgM and IgG SARS-CoV-2 serological screening among healthcare workers with a low infection prevalence based on nasopharyngeal swab tests in an Italian university hospital: perspectives for public health,2021-01-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Puglia,Bari,"All HCWs of the University Hospital of Bari, Italy underwent a preventive protocol that required them to undergo a NST in case of close contact with COVID-19 patients or evidence of SARS-CoV-2 symptoms onset (anosmia, ageusia, fever, asthenia, sore throat, rhinorrhea, cough, diarrhea, and dyspnea). All HCWs subject to NST, after 14–21 days, underwent sera collection for SARS-CoV-2 IgM and IgG determination.",,2020-04-08,2020-06-07,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,2407,0.023700000000000002,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.5,0.9799,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,No,Luigi Vimercati,University of Bari,Not Unity-Aligned,https://dx.doi.org/10.1016/j.envres.2021.110793,2021-03-11,2024-03-01,Verified,vimercati_large-scale_2021,ITA
210203_Milan_FondazioneIRCCSCa'GrandaOspedaleMaggiore_GenPop_UnAdj,210203_Milan_FondazioneIRCCSCa'GrandeOspedaleMaggiore ,SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,"Blood donors, who were apparently healthy subjects, aged 18-70 years, donating blood between Feb 24 and Apr 8 in Milan","Exclusion criteria were any active infection or other active medical conditions, recent surgical procedures, trips in areas with endemic infective diseases, reported risk factors for parenterally acquired infections, chronic degenerative conditions except stable arterial hypertension, type 2 diabetes or dyslipidemia under control with lifestyle or pharmacological therapy, diagnosis of cancer or high risk of cardiovascular events. Also, must be free of recent symptoms possibly related to COVID-19, nor had close contact with confirmed cases. Af ter March 2nd, they had to be symptom free during the preceding 14 days, and not to have had unprotected contact with suspected cases",2020-02-24,2020-04-08,Blood donors,All,Adults (18-64 years),18.0,70.0,Primary Estimate,Unadjusted,789,0.051,,,True,,,,True,Convenience,PRIMA COVID-19 IgG/IgM Rapid Test,PRIMA Lab S.A.,LFIA,Plasma,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Luca Valenti, Fondazione IRCCS Ca' Granda Ospedale Maggiore ,Unity-Aligned,https://dx.doi.org/10.2450/2021.0324-20,2020-05-21,2024-03-01,Verified,valenti_sars-cov-2_2021,ITA
210203_Milan_FondazioneIRCCSCa'GrandaOspedaleMaggiore_GenPop_OutbreakEndTestAdj,210203_Milan_FondazioneIRCCSCa'GrandeOspedaleMaggiore ,SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,"Blood donors, who were apparently healthy subjects, aged 18-70 years, donating blood between Feb 24 and Apr 8 in Milan","Exclusion criteria were any active infection or other active medical conditions, recent surgical procedures, trips in areas with endemic infective diseases, reported risk factors for parenterally acquired infections, chronic degenerative conditions except stable arterial hypertension, type 2 diabetes or dyslipidemia under control with lifestyle or pharmacological therapy, diagnosis of cancer or high risk of cardiovascular events. Also, must be free of recent symptoms possibly related to COVID-19, nor had close contact with confirmed cases. Af ter March 2nd, they had to be symptom free during the preceding 14 days, and not to have had unprotected contact with suspected cases",2020-03-16,2020-04-08,Blood donors,All,Adults (18-64 years),18.0,70.0,Time frame,Total outbreak period,789,0.0525,0.024,0.09,,,,,,Convenience,PRIMA COVID-19 IgG/IgM Rapid Test,PRIMA Lab S.A.,LFIA,Plasma,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Luca Valenti, Fondazione IRCCS Ca' Granda Ospedale Maggiore ,Unity-Aligned,https://dx.doi.org/10.2450/2021.0324-20,2020-07-12,2024-03-01,Verified,valenti_sars-cov-2_2021,ITA
210203_Milan_FondazioneIRCCSCa'GrandaOspedaleMaggiore_GenPop_TimeFrame_0316-0329,210203_Milan_FondazioneIRCCSCa'GrandeOspedaleMaggiore ,SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,"Blood donors, who were apparently healthy subjects, aged 18-70 years, donating blood between Feb 24 and Apr 8 in Milan","Exclusion criteria were any active infection or other active medical conditions, recent surgical procedures, trips in areas with endemic infective diseases, reported risk factors for parenterally acquired infections, chronic degenerative conditions except stable arterial hypertension, type 2 diabetes or dyslipidemia under control with lifestyle or pharmacological therapy, diagnosis of cancer or high risk of cardiovascular events. Also, must be free of recent symptoms possibly related to COVID-19, nor had close contact with confirmed cases. Af ter March 2nd, they had to be symptom free during the preceding 14 days, and not to have had unprotected contact with suspected cases",2020-03-16,2020-03-29,Blood donors,All,Adults (18-64 years),18.0,70.0,Time frame,0316-0329,220,0.07272727273,,,,,,,,Convenience,PRIMA COVID-19 IgG/IgM Rapid Test,PRIMA Lab S.A.,LFIA,Plasma,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Luca Valenti, Fondazione IRCCS Ca' Granda Ospedale Maggiore ,Unity-Aligned,https://dx.doi.org/10.2450/2021.0324-20,2021-03-15,2024-03-01,Verified,valenti_sars-cov-2_2021,ITA
210203_Milan_FondazioneIRCCSCa'GrandaOspedaleMaggiore_GenPop_TimeFrame_0302-0315,210203_Milan_FondazioneIRCCSCa'GrandeOspedaleMaggiore ,SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,"Blood donors, who were apparently healthy subjects, aged 18-70 years, donating blood between Feb 24 and Apr 8 in Milan","Exclusion criteria were any active infection or other active medical conditions, recent surgical procedures, trips in areas with endemic infective diseases, reported risk factors for parenterally acquired infections, chronic degenerative conditions except stable arterial hypertension, type 2 diabetes or dyslipidemia under control with lifestyle or pharmacological therapy, diagnosis of cancer or high risk of cardiovascular events. Also, must be free of recent symptoms possibly related to COVID-19, nor had close contact with confirmed cases. Af ter March 2nd, they had to be symptom free during the preceding 14 days, and not to have had unprotected contact with suspected cases",2020-03-02,2020-03-15,Blood donors,All,Adults (18-64 years),18.0,70.0,Time frame,0302-0315,263,0.034220532320000004,,,,,,,,Convenience,PRIMA COVID-19 IgG/IgM Rapid Test,PRIMA Lab S.A.,LFIA,Plasma,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Luca Valenti, Fondazione IRCCS Ca' Granda Ospedale Maggiore ,Unity-Aligned,https://dx.doi.org/10.2450/2021.0324-20,2021-03-15,2024-03-01,Verified,valenti_sars-cov-2_2021,ITA
210203_Milan_FondazioneIRCCSCa'GrandaOspedaleMaggiore_Male(andother),210203_Milan_FondazioneIRCCSCa'GrandeOspedaleMaggiore ,SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,"Blood donors, who were apparently healthy subjects, aged 18-70 years, donating blood between Feb 24 and Apr 8 in Milan","Exclusion criteria were any active infection or other active medical conditions, recent surgical procedures, trips in areas with endemic infective diseases, reported risk factors for parenterally acquired infections, chronic degenerative conditions except stable arterial hypertension, type 2 diabetes or dyslipidemia under control with lifestyle or pharmacological therapy, diagnosis of cancer or high risk of cardiovascular events. Also, must be free of recent symptoms possibly related to COVID-19, nor had close contact with confirmed cases. Af ter March 2nd, they had to be symptom free during the preceding 14 days, and not to have had unprotected contact with suspected cases",2020-02-24,2020-04-08,Blood donors,Male,Adults (18-64 years),18.0,70.0,Sex/Gender,Male,523,0.05740000000000001,,,,,,,,Convenience,PRIMA COVID-19 IgG/IgM Rapid Test,PRIMA Lab S.A.,LFIA,Plasma,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Luca Valenti, Fondazione IRCCS Ca' Granda Ospedale Maggiore ,Unity-Aligned,https://dx.doi.org/10.2450/2021.0324-20,2020-07-12,2024-03-01,Verified,valenti_sars-cov-2_2021,ITA
210203_Milan_FondazioneIRCCSCa'GrandaOspedaleMaggiore_GenPop_TimeFrame_0224-0301,210203_Milan_FondazioneIRCCSCa'GrandeOspedaleMaggiore ,SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,"Blood donors, who were apparently healthy subjects, aged 18-70 years, donating blood between Feb 24 and Apr 8 in Milan","Exclusion criteria were any active infection or other active medical conditions, recent surgical procedures, trips in areas with endemic infective diseases, reported risk factors for parenterally acquired infections, chronic degenerative conditions except stable arterial hypertension, type 2 diabetes or dyslipidemia under control with lifestyle or pharmacological therapy, diagnosis of cancer or high risk of cardiovascular events. Also, must be free of recent symptoms possibly related to COVID-19, nor had close contact with confirmed cases. Af ter March 2nd, they had to be symptom free during the preceding 14 days, and not to have had unprotected contact with suspected cases",2020-02-24,2020-03-01,Blood donors,All,Adults (18-64 years),18.0,70.0,Time frame,0224-0301,246,0.0487804878,,,,,,,,Convenience,PRIMA COVID-19 IgG/IgM Rapid Test,PRIMA Lab S.A.,LFIA,Plasma,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Luca Valenti, Fondazione IRCCS Ca' Granda Ospedale Maggiore ,Unity-Aligned,https://dx.doi.org/10.2450/2021.0324-20,2021-03-15,2024-03-01,Verified,valenti_sars-cov-2_2021,ITA
210203_Milan_FondazioneIRCCSCa'GrandaOspedaleMaggiore_Females,210203_Milan_FondazioneIRCCSCa'GrandeOspedaleMaggiore ,SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,"Blood donors, who were apparently healthy subjects, aged 18-70 years, donating blood between Feb 24 and Apr 8 in Milan","Exclusion criteria were any active infection or other active medical conditions, recent surgical procedures, trips in areas with endemic infective diseases, reported risk factors for parenterally acquired infections, chronic degenerative conditions except stable arterial hypertension, type 2 diabetes or dyslipidemia under control with lifestyle or pharmacological therapy, diagnosis of cancer or high risk of cardiovascular events. Also, must be free of recent symptoms possibly related to COVID-19, nor had close contact with confirmed cases. Af ter March 2nd, they had to be symptom free during the preceding 14 days, and not to have had unprotected contact with suspected cases",2020-02-24,2020-04-08,Blood donors,Female,Adults (18-64 years),18.0,70.0,Sex/Gender,Female,266,0.0376,,,,,,,,Convenience,PRIMA COVID-19 IgG/IgM Rapid Test,PRIMA Lab S.A.,LFIA,Plasma,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Luca Valenti, Fondazione IRCCS Ca' Granda Ospedale Maggiore ,Unity-Aligned,https://dx.doi.org/10.2450/2021.0324-20,2020-07-12,2024-03-01,Verified,valenti_sars-cov-2_2021,ITA
210203_Milan_FondazioneIRCCSCa'GrandaOspedaleMaggiore_GenPop_TimeFrame_0330-0408,210203_Milan_FondazioneIRCCSCa'GrandeOspedaleMaggiore ,SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,"Blood donors, who were apparently healthy subjects, aged 18-70 years, donating blood between Feb 24 and Apr 8 in Milan","Exclusion criteria were any active infection or other active medical conditions, recent surgical procedures, trips in areas with endemic infective diseases, reported risk factors for parenterally acquired infections, chronic degenerative conditions except stable arterial hypertension, type 2 diabetes or dyslipidemia under control with lifestyle or pharmacological therapy, diagnosis of cancer or high risk of cardiovascular events. Also, must be free of recent symptoms possibly related to COVID-19, nor had close contact with confirmed cases. Af ter March 2nd, they had to be symptom free during the preceding 14 days, and not to have had unprotected contact with suspected cases",2020-03-30,2020-04-08,Blood donors,All,Adults (18-64 years),18.0,70.0,Time frame,0330-0408,60,0.06666666667,,,,,,,,Convenience,PRIMA COVID-19 IgG/IgM Rapid Test,PRIMA Lab S.A.,LFIA,Plasma,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Luca Valenti, Fondazione IRCCS Ca' Granda Ospedale Maggiore ,Unity-Aligned,https://dx.doi.org/10.2450/2021.0324-20,2021-03-15,2024-03-01,Verified,valenti_sars-cov-2_2021,ITA
210203_Milan_FondazioneIRCCSCa'GrandaOspedaleMaggiore_GenPop_OutbreakStartTestAdj,210203_Milan_FondazioneIRCCSCa'GrandeOspedaleMaggiore ,SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan,2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,"Blood donors, who were apparently healthy subjects, aged 18-70 years, donating blood between Feb 24 and Apr 8 in Milan","Exclusion criteria were any active infection or other active medical conditions, recent surgical procedures, trips in areas with endemic infective diseases, reported risk factors for parenterally acquired infections, chronic degenerative conditions except stable arterial hypertension, type 2 diabetes or dyslipidemia under control with lifestyle or pharmacological therapy, diagnosis of cancer or high risk of cardiovascular events. Also, must be free of recent symptoms possibly related to COVID-19, nor had close contact with confirmed cases. Af ter March 2nd, they had to be symptom free during the preceding 14 days, and not to have had unprotected contact with suspected cases",2020-02-24,2020-03-15,Blood donors,All,Adults (18-64 years),18.0,70.0,Time frame,Start of outbreak,789,0.027000000000000003,0.003,0.06,,True,,,,Convenience,PRIMA COVID-19 IgG/IgM Rapid Test,PRIMA Lab S.A.,LFIA,Plasma,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Luca Valenti, Fondazione IRCCS Ca' Granda Ospedale Maggiore ,Unity-Aligned,https://dx.doi.org/10.2450/2021.0324-20,2020-07-12,2023-07-04,Verified,valenti_sars-cov-2_2021,ITA
210204_Milan_ASSTFatebenefratelliSacco_PhaseI_overall,210204_Milan_ASSTFatebenefratelliSacco_PhaseI,"Dynamics of the seroprevalence of SARS-CoV-2 antibodies among healthcare workers at a COVID-19 referral hospital in Milan, Italy",2021-02-04,Journal Article (Peer-Reviewed),Local,Prospective cohort,Italy,,Mlilan,"This cohort study evaluated the dynamics of SARS-CoV-2 sero- prevalence among the hospital’s HCWs between 21 February and 27 May 2020. All of the hospital personnel (696 nurses, 346 doctors, 205 health service assistants including cleaners, 188 administrative staff and 115 healthcare technicians) were invited to participate in the 3-month serological survey on a voluntary basis and those who agreed gave the written informed consent to the storage of their anonymised data in a protected database.",,2020-03-04,2020-03-12,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,679,0.004,,,True,True,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.78,1.0,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Laura Milazzo,ASST Fatebenefratelli Sacco,Not Unity-Aligned,http://dx.doi.org/10.1136/oemed-2020-107060,2021-02-12,2023-07-04,Unverified,milazzo_dynamics_2021,ITA
210204_Milan_ASSTFatebenefratelliSacco_PhaseII,210204_Milan_ASSTFatebenefratelliSacco_PhaseII,"Dynamics of the seroprevalence of SARS-CoV-2 antibodies among healthcare workers at a COVID-19 referral hospital in Milan, Italy",2021-02-04,Journal Article (Peer-Reviewed),Local,Prospective cohort,Italy,,Mlilan,"This cohort study evaluated the dynamics of SARS-CoV-2 sero- prevalence among the hospital’s HCWs between 21 February and 27 May 2020. All of the hospital personnel (696 nurses, 346 doctors, 205 health service assistants including cleaners, 188 administrative staff and 115 healthcare technicians) were invited to participate in the 3-month serological survey on a voluntary basis and those who agreed gave the written informed consent to the storage of their anonymised data in a protected database.",,2020-04-14,2020-04-22,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,608,0.042,,,True,True,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.78,1.0,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Laura Milazzo,ASST Fatebenefratelli Sacco,Not Unity-Aligned,http://dx.doi.org/10.1136/oemed-2020-107060,2021-02-12,2023-07-04,Unverified,milazzo_dynamics_2021,ITA
210204_Milan_ASSTFatebenefratelliSacco_PhaseIII,210204_Milan_ASSTFatebenefratelliSacco_PhaseIII,"Dynamics of the seroprevalence of SARS-CoV-2 antibodies among healthcare workers at a COVID-19 referral hospital in Milan, Italy",2021-02-04,Journal Article (Peer-Reviewed),Local,Prospective cohort,Italy,,Mlilan,"This cohort study evaluated the dynamics of SARS-CoV-2 sero- prevalence among the hospital’s HCWs between 21 February and 27 May 2020. All of the hospital personnel (696 nurses, 346 doctors, 205 health service assistants including cleaners, 188 administrative staff and 115 healthcare technicians) were invited to participate in the 3-month serological survey on a voluntary basis and those who agreed gave the written informed consent to the storage of their anonymised data in a protected database.",,2020-05-20,2020-05-27,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,629,0.046,,,True,True,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.78,1.0,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Laura Milazzo,ASST Fatebenefratelli Sacco,Not Unity-Aligned,http://dx.doi.org/10.1136/oemed-2020-107060,2021-02-12,2023-07-04,Unverified,milazzo_dynamics_2021,ITA
210204_Milan_UniversityOfMilan_Overall,210204_Milan_UniversityOfMilan,Serological Profile of Children and Young Adults with at Least One SARS-CoV-2 Positive Cohabitant: An Observational Study,2021-02-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,"The analyzed sample included children between 4 and 16 years of age who belonged to families with at least one positive swab result for COVID-19 and living in one of the five municipalities of the Milan Metropolitan Area: the districts of Segrate (MI), Vimodrone (MI),Peschiera Borromeo (MI), Crema (CR), and Lodi (LO).","Subjects were excluded if they were younger than 4 or older than 16, if their house-hold lacked at least one cohabitant with a previous positive swab result, or if their legalrepresentatives did not provide informed consent.
",2020-06-13,2020-08-06,Contacts of COVID patients,All,Children and Youth (0-17 years),4.0,16.0,Primary Estimate,,49,0.163,,,True,,,,True,Convenience,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,No,Marco Farronato ,University of Milan,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph18041488,2021-03-19,2024-03-01,Verified,farronato_serological_2021,ITA
210209_Catania_UniversityofCatania,210209_Catania_UniversityofCatania,SARS-CoV-2 Seroprevalence Post-First Wave among Primary Care Physicians in Catania (Italy),2021-02-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Sicily,Catania,GPs working in the province of Catania,,2020-06-15,2020-07-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,133,0.03,,,True,,,,True,Convenience,NovaLisa® SARS-CoV-2 IgG/IgM,NovaTec Immundiagnostics GmbH,ELISA,Serum,IgG,,,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,Yes,Caterina Ledda ,University of Catania,Not Unity-Aligned,https://dx.doi.org/10.3390/tropicalmed6010021,2021-03-14,2024-03-01,Verified,ledda_sars-cov-2_2021,ITA
210220_Lazio_ UniversitàCattolicadelSacroCuore_Overall,210220_Lazio_ UniversitàCattolicadelSacroCuore,Low seroprevalence of SARS-CoV-2 antibodies in cirrhotic patients,2021-02-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lazio,Rome,Patients affected by liver cirrhosis attending the outpatient liver clinic of the Fondazione Policlinico Universitario Agostino Gemelli IRCCS were consecutively enrolled starting from May 25th to August 10th 2020. ,,2020-05-25,2020-08-10,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),,,Primary Estimate,,202,0.015,,,True,,,,True,Convenience,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Serum,,,,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Yes,Fabio Del Zompo,Università Cattolica del Sacro Cuore,Not Unity-Aligned,https://dx.doi.org/10.1016/j.dld.2021.02.015,2021-03-27,2024-03-01,Verified,zompo_low_2021,ITA
210204_Milan_ FoundationIRCCS Ca'GrandaOspedaleMaggiorePoliclinico_overall_adj,210204_Milan_ FoundationIRCCS Ca'GrandaOspedaleMaggiorePoliclinico,"Seroprevalence of anti-SARS-CoV-2 IgG among healthcare workers of a large university hospital in Milan, Lombardy, Italy: a cross-sectional study",2021-02-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,"healthcare workers at IRCCS Ca' Granda Ospedale Maggiore Policlinico (tertiary hospital centre in Milan, Italy).",,2020-04-27,2020-06-12,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,4055,0.064,,,True,True,,,,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9740000000000001,0.985,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Andrea Lombardi,Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2020-047216,2021-04-03,2023-08-15,Verified,lombardi_seroprevalence_2021,ITA
210224_NortheastItaly_PaduaUniversityHospital_HCW,210224_NortheastItaly_PaduaUniversityHospital,A longitudinal study of healthcare workers surveillance during the ongoing COVID-19 Epidemics in Italy: is SARS-CoV-2 still a threat for the Health-care System?,2021-02-24,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Italy,Veneto Region,Padua,"HCW working at Padua University Hospital, a tertiary-care hospital in the Veneto Region (Northeast Italy). Included HCW working in the Emergency Unit or the Infectious Disease Unit (IDU). The IDU was dedicated to the admission of confirmed COVID-19 patients. HCW included clinicians, nurses, and healthcare assistants.",,2020-04-08,2020-05-29,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,344,0.0785,,,True,,,,True,Convenience,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.9120999999999999,0.973,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,Yes,F Barbaro,Padua University Hospital ,Not Unity-Aligned,https://doi.org/10.1101/2021.02.23.21249481,2021-03-25,2024-03-01,Verified,Barbaro_longitudinal_2021,ITA
210224_Castiglioned'Adda_UniversityofMilan_Overall,210224_Castiglioned’Adda_UniversityofMilan,"Prevalence of SARS-CoV-2 in an area of unrestricted viral circulation: Mass seroepidemiological screening in Castiglione d'Adda, Italy",2021-02-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Castiglione D’Adda,Entire population of the town of Castiglione D'Adda,Did not consent to participate,2020-05-18,2020-06-07,Household and community samples,All,Multiple groups,0.0,102.0,Primary Estimate,,4143,0.222,,,True,,,,True,Entire sample,PRIMA COVID-19 IgG/IgM Rapid Test,PRIMA Lab S.A.,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,1.0,0.96,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Gabriele Pagani,University of Milan,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0246513,2021-04-17,2024-03-01,Verified,pagani_prevalence_2021,ITA
210224_Castiglioned'Adda_UniversityofMilan_CLIA,210224_Castiglioned’Adda_UniversityofMilan,"Prevalence of SARS-CoV-2 in an area of unrestricted viral circulation: Mass seroepidemiological screening in Castiglione d'Adda, Italy",2021-02-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Castiglione D’Adda,Entire population of the town of Castiglione D'Adda,Did not consent to participate,2020-05-18,2020-06-07,Household and community samples,Female,Multiple groups,0.0,102.0,Test used,CLIA - Abbott,509,0.226,0.172,0.29100000000000004,,,,,,Stratified probability,PRIMA COVID-19 IgG/IgM Rapid Test,PRIMA Lab S.A.,CLIA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Gabriele Pagani,University of Milan,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0246513,2021-06-10,2024-03-01,Verified,pagani_prevalence_2021,ITA
210224_Castiglioned'Adda_UniversityofMilan_female,210224_Castiglioned’Adda_UniversityofMilan,"Prevalence of SARS-CoV-2 in an area of unrestricted viral circulation: Mass seroepidemiological screening in Castiglione d'Adda, Italy",2021-02-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Castiglione D’Adda,Entire population of the town of Castiglione D'Adda,Did not consent to participate,2020-05-18,2020-06-07,Household and community samples,Female,Multiple groups,0.0,102.0,Sex/Gender,Female,2125,0.23500000000000001,,,,,,,,Entire sample,PRIMA COVID-19 IgG/IgM Rapid Test,PRIMA Lab S.A.,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,1.0,0.96,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Gabriele Pagani,University of Milan,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0246513,2021-04-17,2024-03-01,Verified,pagani_prevalence_2021,ITA
210224_Castiglioned'Adda_UniversityofMilan_male,210224_Castiglioned’Adda_UniversityofMilan,"Prevalence of SARS-CoV-2 in an area of unrestricted viral circulation: Mass seroepidemiological screening in Castiglione d'Adda, Italy",2021-02-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Castiglione D’Adda,Entire population of the town of Castiglione D'Adda,Did not consent to participate,2020-05-18,2020-06-07,Household and community samples,Male,Multiple groups,0.0,102.0,Sex/Gender,Male,2018,0.207,,,,,,,,Entire sample,PRIMA COVID-19 IgG/IgM Rapid Test,PRIMA Lab S.A.,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,1.0,0.96,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Gabriele Pagani,University of Milan,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0246513,2021-04-17,2024-03-01,Verified,pagani_prevalence_2021,ITA
210225_Brescia_UniversityofBrescia_HCW,210225_Brescia_UniversityofBrescia,"Serological Response to SARS-CoV-2 in Health Care Workers Employed in a Large Tertiary Hospital in Lombardy, Northern Italy",2021-02-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Brescia,"HCWs employed at Spedali Civili General Hospital during the pandemic - those who deliver care/services to the patients (physicians, nurses, assisstants, technicians, admin officers, cleaning, maintenance, pharmacists)

being registered at the Spedali Civili Human Resources De-partment, being older than 17 years, and having answered to the online survey.","We excluded subjects who did not work during the pandemic or who did not giveblood  sample  for  serology  testing  because  of  whatever  reason  (e.g.,  sick  leave,  vaca-tion, etc)",2020-04-26,2020-05-31,Health care workers and caregivers,All,Adults (18-64 years),17.0,,Primary Estimate,,1893,0.22899999999999998,,,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9570000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Agnese Comelli,University of Brescia,Not Unity-Aligned,https://dx.doi.org/10.3390/microorganisms9030488,2021-04-15,2024-03-01,Verified,comelli_serological_2021,ITA
210226_Turin_UniversityofTurin_Pharmacists,210226_Turin_UniversityofTurin,Community Pharmacy Practice in Italy during the COVID-19 (SARS-CoV-2) Pandemic: Regulatory Changes and a Cross-Sectional Analysis of Seroprevalence,2021-02-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Turin,,Criteria for participation in the study were that volunteers had to have worked in a community pharmacy or para-pharmacy open to the public in the period between 25 February 2020 and 1 May 2020 in the province of Turin,,2020-07-01,2020-07-31,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,286,0.035,,,True,,,,True,Self-referral,PRIMA COVID-19 IgG/IgM Rapid Test,PRIMA Lab S.A.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,1.0,0.98,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,No,Francesca Baratta,University of Turin,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph18052302,2021-04-09,2024-03-01,Verified,baratta_community_2021,ITA
210226_UniversityOfTurin_Turin,210226_UniversityOfTurin_Turin,Prenatal Biochemical and Ultrasound Markers in COVID-19 Pregnant Patients: A Prospective Case-Control Study,2021-02-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Piedmont,Turin,"Consecutive 12-week pregnant patients attending our institution for noninvasive pre-natal diagnosis or admitted to the care units for obstetric or COVID-19-related symptoms,between 16 April and 22 June 2020 were invited to participate in the study.

Only women with last menstruation at most one month later than the date of thefirst reported case of COVID-19 infection in Piedmont (22 February 2020) were consideredeligible for inclusion in the study, so as to exclude the possibility of COVID-19 serocon-version before pregnancy","Exclusion criteria were delivery scheduled at another hospital,inability to give informed consent, and aged less than 18 years old",2020-04-16,2020-06-22,Pregnant or parturient women,Female,Adults (18-64 years),18.0,,Primary Estimate,,164,0.09699999999999999,,,True,,,,True,Convenience,AFIAS COVID-19 Ab assay,Boditech Med Inc.,LFIA,Serum,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Yes,Stefano Cosma,University of Turin,Not Unity-Aligned,https://dx.doi.org/10.3390/diagnostics11030398,2021-04-17,2024-03-01,Verified,cosma_prenatal_2021,ITA
210302_Milan_FondazioneIRCCSIstitutoNazionaleDeiTumori_HCW_overall,210302_Milan_FondazioneIRCCSIstitutoNazionaleDeiTumori,Sars-cov-2 serology monitoring of a cancer center staff in the pandemic most infected italian region,2021-03-02,Journal Article (Peer-Reviewed),Local,Prospective cohort,Italy,,Milan,Healthcare professionals working at INT,,2020-04-09,2020-09-09,Health care workers and caregivers,All,Adults (18-64 years),23.0,69.0,Primary Estimate,,110,0.2,,,True,,,,True,Simplified probability,IgG and IgM anti-SARS-CoV-2 ELISA,Diagnostic Bioprobes,ELISA,Plasma,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,Yes,No,Yes,Unclear,Unclear,Yes,No,Unclear,Chiara Maura Ciniselli,Fondazione IRCCS Istituto Nazionale dei Tumori (INT),Not Unity-Aligned,http://dx.doi.org/10.3390/cancers13051035,2021-03-24,2022-07-16,Verified,ciniselli_sars-cov-2_2021,ITA
210303_Lodi_IRCCSPoliclinico_overall_CLIA,210303_Lodi_UniversityOfPavia,Seroprevalence of SARS-CoV-2 in blood donors from the Lodi Red Zone and adjacent Lodi metropolitan and suburban area,2021-03-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy region,Lodi,Individuals in Lombardy Region,,2020-03-18,2020-06-24,Blood donors,All,Multiple groups,,,Primary Estimate,CLIA assay,1922,0.197,,,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Irene Cassaniti,IRCCS Policlinico,Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2021.01.030,2021-03-31,2024-03-01,Verified,cassaniti_seroprevalence_2021,ITA
210303_Lodi_IRCCSPoliclinico_Neutralization,210303_Lodi_UniversityOfPavia,Seroprevalence of SARS-CoV-2 in blood donors from the Lodi Red Zone and adjacent Lodi metropolitan and suburban area,2021-03-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy region,Lodi,Individuals in Lombardy Region,,2020-03-18,2020-06-24,Blood donors,All,Multiple groups,,,Test used,Neutralization assay,1139,0.217,,,,,,,,Convenience,Author designed (Neutralization Assay),,Neutralization,,,Whole-virusantigen,,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Irene Cassaniti,IRCCS Policlinico,Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2021.01.030,2021-03-31,2022-07-16,Verified,cassaniti_seroprevalence_2021,ITA
210304_Milan_UniversityOfMilanBicocca_Overall,210304_Milan_UniversityOfMilanBicocca,Occupational Exposure in the Lombardy Region (Italy) to SARS-CoV-2 Infection: Results from the MUSTANG–OCCUPATION–COVID-19 Study,2021-03-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy region,,"Institutions were selected on the basis of their estimable risks of infection exposure before and during the Italian lockdown period (9 March–18 May) and their willingness to participate. For this purpose, they were selected: (i) an academic institution, where workers came into contact with hundreds of people on a daily basis before the introduction of lockdown measures; (ii) press agencies, whose workers continued their work during the epidemic period (both from home and in their place of work); (iii) a law enforcement agency, who performed their duty during the lockdown; (iv) a healthcare facility, where HCWs came in contact with COVID-19 patients.
All workers of the involved institutions were invited to participate in the study. In order to be included in the survey, participants must be aged 18 years or over, be employed in one of the selected institutions, and not being previously tested for SARS-CoV-2 infection.",patients in quarantine for active disease and those in COVID-19 surveillance post-hospital discharge.,2020-05-07,2020-10-31,Essential non-healthcare workers,All,Multiple groups,18.0,,Primary Estimate,Overall,2255,0.0483,,,,,,,,Convenience,"COVID-19 IgG,COVID-19 IgM",Technogenetics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,1.0,0.986,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Paola Della Valle,University of Milan Bicocca,Not Unity-Aligned,https://www.mdpi.com/1660-4601/18/5/2567,2021-05-22,2022-07-16,Verified,dellavalleOccupationalExposureLombardy2021,ITA
210306_Rome_UniversitaCattolicadelSacroCuore_VenousBloodTest_overall,210306_Rome_UniversitaCattolicadelSacroCuore,COVID-19 seroprevalence among healthcare workers of a large COVID Hospital in Rome reveals strengths and limits of two different serological tests,2021-03-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Rome,"HCW at  Fondazione Policlinico Universitario A. Gemelli (FPG) IRCSS were enrolled via a hospital e-mail system, on a voluntary basis, medical, non-medical HCWs and administrative staff",,2020-06-04,2020-07-03,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,4694,0.011899999999999999,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,,IgG,Spike,Validated by independent authors/third party/non-developers,0.7879,0.9936,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Giuseppe Vetrugno,Università Cattolica del Sacro Cuore,Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph18052650,2021-02-09,2024-03-01,Verified,vetrugno_covid-19_2021-1,ITA
210306_Rome_UniversitaCattolicadelSacroCuore_VenousBloodTest_>56yo,210306_Rome_UniversitaCattolicadelSacroCuore,COVID-19 seroprevalence among healthcare workers of a large COVID Hospital in Rome reveals strengths and limits of two different serological tests,2021-03-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Rome,"HCW at  Fondazione Policlinico Universitario A. Gemelli (FPG) IRCSS were enrolled via a hospital e-mail system, on a voluntary basis, medical, non-medical HCWs and administrative staff",,2020-06-04,2020-07-03,Health care workers and caregivers,All,Multiple groups,57.0,,Age,>56,874,0.0092,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,,IgG,Spike,Validated by independent authors/third party/non-developers,0.7879,0.9936,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Giuseppe Vetrugno,Università Cattolica del Sacro Cuore,Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph18052650,2021-02-09,2024-03-01,Verified,vetrugno_covid-19_2021-1,ITA
210306_Rome_UniversitaCattolicadelSacroCuore_VenousBloodTest_<36yo,210306_Rome_UniversitaCattolicadelSacroCuore,COVID-19 seroprevalence among healthcare workers of a large COVID Hospital in Rome reveals strengths and limits of two different serological tests,2021-03-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Rome,"HCW at  Fondazione Policlinico Universitario A. Gemelli (FPG) IRCSS were enrolled via a hospital e-mail system, on a voluntary basis, medical, non-medical HCWs and administrative staff",,2020-06-04,2020-07-03,Health care workers and caregivers,All,Adults (18-64 years),,35.0,Age,<36 ,1414,0.0115,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,,IgG,Spike,Validated by independent authors/third party/non-developers,0.7879,0.9936,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Giuseppe Vetrugno,Università Cattolica del Sacro Cuore,Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph18052650,2021-02-09,2024-03-01,Verified,vetrugno_covid-19_2021-1,ITA
210306_Rome_UniversitaCattolicadelSacroCuore_VenousBloodTest_36-45,210306_Rome_UniversitaCattolicadelSacroCuore,COVID-19 seroprevalence among healthcare workers of a large COVID Hospital in Rome reveals strengths and limits of two different serological tests,2021-03-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Rome,"HCW at  Fondazione Policlinico Universitario A. Gemelli (FPG) IRCSS were enrolled via a hospital e-mail system, on a voluntary basis, medical, non-medical HCWs and administrative staff",,2020-06-04,2020-07-03,Health care workers and caregivers,All,Adults (18-64 years),36.0,45.0,Age,36-45,1127,0.0098,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,,IgG,Spike,Validated by independent authors/third party/non-developers,0.7879,0.9936,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Giuseppe Vetrugno,Università Cattolica del Sacro Cuore,Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph18052650,2021-02-09,2024-03-01,Verified,vetrugno_covid-19_2021-1,ITA
210306_Rome_UniversitaCattolicadelSacroCuore_VenousBloodTest_46-55,210306_Rome_UniversitaCattolicadelSacroCuore,COVID-19 seroprevalence among healthcare workers of a large COVID Hospital in Rome reveals strengths and limits of two different serological tests,2021-03-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Rome,"HCW at  Fondazione Policlinico Universitario A. Gemelli (FPG) IRCSS were enrolled via a hospital e-mail system, on a voluntary basis, medical, non-medical HCWs and administrative staff",,2020-06-04,2020-07-03,Health care workers and caregivers,All,Adults (18-64 years),46.0,55.0,Age,46-55,1240,0.006500000000000001,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,,IgG,Spike,Validated by independent authors/third party/non-developers,0.7879,0.9936,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Giuseppe Vetrugno,Università Cattolica del Sacro Cuore,Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph18052650,2021-02-09,2024-03-01,Verified,vetrugno_covid-19_2021-1,ITA
210309_Benevento_UniversitàdegliStudidelSannio_Overall,210309_Benevento_UniversitàdegliStudidelSannio,Seroprevalence of Anti-SARS-CoV-2 IgG and IgM among Adults over 65 Years Old in the South of Italy,2021-03-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Campania,," 65-year-old adults living in the district of Benevento (Campania, Italy), without COVID-19 symptoms",institutionalized people excluded,2020-09-01,2020-09-30,Household and community samples,All,Seniors (65+ years),65.0,,Primary Estimate,Overall LFIA,1383,0.047,,,True,,,,True,Convenience,Leccurate SARS-CoV-2 Antibody Rapid Test Kit (Colloidal Gold Immunochromatography),Beijing Lepu Medical Technology,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.986,0.976,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Immacolata Polvere,Università degli Studi del Sannio,Unity-Aligned,https://dx.doi.org/10.3390/diagnostics11030483,2021-04-21,2024-03-01,Verified,polvere_seroprevalence_2021,ITA
210309_Benevento_UniversitàdegliStudidelSannio_80-84,210309_Benevento_UniversitàdegliStudidelSannio,Seroprevalence of Anti-SARS-CoV-2 IgG and IgM among Adults over 65 Years Old in the South of Italy,2021-03-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Campania,," 65-year-old adults living in the district of Benevento (Campania, Italy), without COVID-19 symptoms",institutionalized people excluded,2020-09-01,2020-09-30,Household and community samples,All,Seniors (65+ years),80.0,84.0,Age,80-84,168,0.0536,,,,,,,,Convenience,Leccurate SARS-CoV-2 Antibody Rapid Test Kit (Colloidal Gold Immunochromatography),Beijing Lepu Medical Technology,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.986,0.976,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Immacolata Polvere,Università degli Studi del Sannio,Unity-Aligned,https://dx.doi.org/10.3390/diagnostics11030483,2021-04-21,2024-03-01,Verified,polvere_seroprevalence_2021,ITA
210309_Benevento_UniversitàdegliStudidelSannio_Male,210309_Benevento_UniversitàdegliStudidelSannio,Seroprevalence of Anti-SARS-CoV-2 IgG and IgM among Adults over 65 Years Old in the South of Italy,2021-03-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Campania,," 65-year-old adults living in the district of Benevento (Campania, Italy), without COVID-19 symptoms",institutionalized people excluded,2020-09-01,2020-09-30,Household and community samples,Male,Seniors (65+ years),65.0,,Sex/Gender,Male,743,0.0444,,,,,,,,Convenience,Leccurate SARS-CoV-2 Antibody Rapid Test Kit (Colloidal Gold Immunochromatography),Beijing Lepu Medical Technology,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.986,0.976,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Immacolata Polvere,Università degli Studi del Sannio,Unity-Aligned,https://dx.doi.org/10.3390/diagnostics11030483,2021-04-21,2024-03-01,Verified,polvere_seroprevalence_2021,ITA
210309_Benevento_UniversitàdegliStudidelSannio_65-69,210309_Benevento_UniversitàdegliStudidelSannio,Seroprevalence of Anti-SARS-CoV-2 IgG and IgM among Adults over 65 Years Old in the South of Italy,2021-03-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Campania,," 65-year-old adults living in the district of Benevento (Campania, Italy), without COVID-19 symptoms",institutionalized people excluded,2020-09-01,2020-09-30,Household and community samples,All,Seniors (65+ years),65.0,69.0,Age,65-69,220,0.0455,,,,,,,,Convenience,Leccurate SARS-CoV-2 Antibody Rapid Test Kit (Colloidal Gold Immunochromatography),Beijing Lepu Medical Technology,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.986,0.976,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Immacolata Polvere,Università degli Studi del Sannio,Unity-Aligned,https://dx.doi.org/10.3390/diagnostics11030483,2021-04-21,2024-03-01,Verified,polvere_seroprevalence_2021,ITA
210309_Benevento_UniversitàdegliStudidelSannio_85+,210309_Benevento_UniversitàdegliStudidelSannio,Seroprevalence of Anti-SARS-CoV-2 IgG and IgM among Adults over 65 Years Old in the South of Italy,2021-03-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Campania,," 65-year-old adults living in the district of Benevento (Campania, Italy), without COVID-19 symptoms",institutionalized people excluded,2020-09-01,2020-09-30,Household and community samples,All,Seniors (65+ years),85.0,,Age,85+,59,0.0339,,,,,,,,Convenience,Leccurate SARS-CoV-2 Antibody Rapid Test Kit (Colloidal Gold Immunochromatography),Beijing Lepu Medical Technology,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.986,0.976,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Immacolata Polvere,Università degli Studi del Sannio,Unity-Aligned,https://dx.doi.org/10.3390/diagnostics11030483,2021-04-21,2024-03-01,Verified,polvere_seroprevalence_2021,ITA
210309_Benevento_UniversitàdegliStudidelSannio_75-79,210309_Benevento_UniversitàdegliStudidelSannio,Seroprevalence of Anti-SARS-CoV-2 IgG and IgM among Adults over 65 Years Old in the South of Italy,2021-03-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Campania,," 65-year-old adults living in the district of Benevento (Campania, Italy), without COVID-19 symptoms",institutionalized people excluded,2020-09-01,2020-09-30,Household and community samples,All,Seniors (65+ years),75.0,79.0,Age,75-79,343,0.055400000000000005,,,,,,,,Convenience,Leccurate SARS-CoV-2 Antibody Rapid Test Kit (Colloidal Gold Immunochromatography),Beijing Lepu Medical Technology,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.986,0.976,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Immacolata Polvere,Università degli Studi del Sannio,Unity-Aligned,https://dx.doi.org/10.3390/diagnostics11030483,2021-04-21,2024-03-01,Verified,polvere_seroprevalence_2021,ITA
210309_Benevento_UniversitàdegliStudidelSannio_Female,210309_Benevento_UniversitàdegliStudidelSannio,Seroprevalence of Anti-SARS-CoV-2 IgG and IgM among Adults over 65 Years Old in the South of Italy,2021-03-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Campania,," 65-year-old adults living in the district of Benevento (Campania, Italy), without COVID-19 symptoms",institutionalized people excluded,2020-09-01,2020-09-30,Household and community samples,Female,Seniors (65+ years),65.0,,Sex/Gender,Female,640,0.05,,,,,,,,Convenience,Leccurate SARS-CoV-2 Antibody Rapid Test Kit (Colloidal Gold Immunochromatography),Beijing Lepu Medical Technology,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.986,0.976,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Immacolata Polvere,Università degli Studi del Sannio,Unity-Aligned,https://dx.doi.org/10.3390/diagnostics11030483,2021-04-21,2024-03-01,Verified,polvere_seroprevalence_2021,ITA
210309_Benevento_UniversitàdegliStudidelSannio_70-74,210309_Benevento_UniversitàdegliStudidelSannio,Seroprevalence of Anti-SARS-CoV-2 IgG and IgM among Adults over 65 Years Old in the South of Italy,2021-03-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Campania,," 65-year-old adults living in the district of Benevento (Campania, Italy), without COVID-19 symptoms",institutionalized people excluded,2020-09-01,2020-09-30,Household and community samples,All,Seniors (65+ years),70.0,74.0,Age,70-74,593,0.0422,,,,,,,,Convenience,Leccurate SARS-CoV-2 Antibody Rapid Test Kit (Colloidal Gold Immunochromatography),Beijing Lepu Medical Technology,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.986,0.976,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Immacolata Polvere,Università degli Studi del Sannio,Unity-Aligned,https://dx.doi.org/10.3390/diagnostics11030483,2021-04-21,2024-03-01,Verified,polvere_seroprevalence_2021,ITA
210309_Benevento_UniversitàdegliStudidelSannio_ConfirmatoryAssay,210309_Benevento_UniversitàdegliStudidelSannio,Seroprevalence of Anti-SARS-CoV-2 IgG and IgM among Adults over 65 Years Old in the South of Italy,2021-03-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Campania,," 65-year-old adults living in the district of Benevento (Campania, Italy), without COVID-19 symptoms",institutionalized people excluded,2020-09-01,2020-09-30,Household and community samples,All,Seniors (65+ years),65.0,,Test used,Samples which were confirmed by ELISA + In House assay,1383,0.022000000000000002,,,,,,,,Convenience,"Leccurate SARS-CoV-2 Antibody Rapid Test Kit (Colloidal Gold Immunochromatography),SARS-CoV-2 IgG/IgM ELISA Kit IMMUNO-COVID19,Author designed (ELISA) - Unknown","Beijing Lepu Medical Technology,Tecno Bios srl,NA",Multiple Types,Multiple Types,"['IgG', 'IgM']","['Membraneprotein', 'Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Immacolata Polvere,Università degli Studi del Sannio,Unity-Aligned,https://dx.doi.org/10.3390/diagnostics11030483,2021-04-21,2024-03-01,Verified,polvere_seroprevalence_2021,ITA
210317_Bolzano_HospitalofBolzano,210317_Bolzano_HospitalofBolzano,Antibodies against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) in individuals with and without COVID-19 vaccination: A method comparison of two different commercially available serological assays from the same manufacturer.,2021-03-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Trentino-Alto Adige/Südtirol,Bolzano,all serological determinations made in the period from 29/10/2020 to 28/12/2020 in the Department of Clinical Pathology of Bolzano,vaccinated,2020-10-29,2020-12-28,Residual sera,All,Multiple groups,0.0,100.0,Primary Estimate,overall anti-spike CLIA,3033,0.34500000000000003,,,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Thomas Mueller,Hospital of Bolzano,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cca.2021.03.007,2021-05-17,2024-03-01,Verified,mueller_antibodies_2021,ITA
210320_GardenaValley_HospitalOfBolzano_PopAdj_TestAdj,210320_GardenaValley_HospitalOfBolzano,Prevalence and determinants of serum antibodies to SARS-CoV-2 in the general population of the Gardena Valley,2021-03-20,Preprint,Local,Cross-sectional survey ,Italy,,"Gardena Valley ( Ortisei, Santa Cristina, and Selva, the main municipalities)","6+ years old, ","Excluding pregnant women and <6 year old children, and excluding sampling from nursing homes. ",2020-05-26,2020-06-08,Household and community samples,All,Multiple groups,6.0,,Primary Estimate,,2106,0.269,0.252,0.28600000000000003,True,True,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9690000000000001,0.9990000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Roberto Melotti,Hospital of Bolzano,Unity-Aligned,10.1101/2021.03.19.21253883,2021-05-12,2023-08-15,Verified,melotti_prevalence_2021,ITA
210320_GardenaValley_HospitalOfBolzano_Females ,210320_GardenaValley_HospitalOfBolzano,Prevalence and determinants of serum antibodies to SARS-CoV-2 in the general population of the Gardena Valley,2021-03-20,Preprint,Local,Cross-sectional survey ,Italy,,"Gardena Valley ( Ortisei, Santa Cristina, and Selva, the main municipalities)","6+ years old, ","Excluding pregnant women and <6 year old children, and excluding sampling from nursing homes. ",2020-05-26,2020-06-08,Household and community samples,Female,Multiple groups,6.0,,Sex/Gender,,929,0.23800000000000002,0.215,0.263,,True,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9690000000000001,0.9990000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Roberto Melotti,Hospital of Bolzano,Unity-Aligned,10.1101/2021.03.19.21253883,2021-05-12,2023-08-15,Verified,melotti_prevalence_2021,ITA
210320_GardenaValley_HospitalOfBolzano_Males,210320_GardenaValley_HospitalOfBolzano,Prevalence and determinants of serum antibodies to SARS-CoV-2 in the general population of the Gardena Valley,2021-03-20,Preprint,Local,Cross-sectional survey ,Italy,,"Gardena Valley ( Ortisei, Santa Cristina, and Selva, the main municipalities)","6+ years old, ","Excluding pregnant women and <6 year old children, and excluding sampling from nursing homes. ",2020-05-26,2020-06-08,Household and community samples,Male,Multiple groups,6.0,,Sex/Gender,,884,0.28300000000000003,0.258,0.31,,True,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9690000000000001,0.9990000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Roberto Melotti,Hospital of Bolzano,Unity-Aligned,10.1101/2021.03.19.21253883,2021-05-12,2023-08-15,Verified,melotti_prevalence_2021,ITA
210320_GardenaValley_HospitalOfBolzano_Unadj,210320_GardenaValley_HospitalOfBolzano,Prevalence and determinants of serum antibodies to SARS-CoV-2 in the general population of the Gardena Valley,2021-03-20,Preprint,Local,Cross-sectional survey ,Italy,,"Gardena Valley ( Ortisei, Santa Cristina, and Selva, the main municipalities)","6+ years old, ","Excluding pregnant women and <6 year old children, and excluding sampling from nursing homes. ",2020-05-26,2020-06-08,Household and community samples,All,Multiple groups,6.0,,Analysis,,2106,0.2616,,,,,,,True,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9690000000000001,0.9990000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Roberto Melotti,Hospital of Bolzano,Unity-Aligned,10.1101/2021.03.19.21253883,2021-07-29,2024-03-01,Verified,melotti_prevalence_2021,ITA
210320_Cogne_UniversitàDiTorino_genpop_overall,210320_Cogne_UniversitàDiTorino,The effects of physical distancing and lockdown to restrain SARS-CoV-2 outbreak in the Italian Municipality of Cogne,2021-03-20,Preprint,Local,Prospective cohort,Italy,Valle D'Aosta,Cogne,people living to Cogne down town and spending there a considerable fraction of their time,Children under 14 years old were excluded from the survey.,2020-06-04,2020-06-05,Household and community samples,All,Multiple groups,,,Primary Estimate,,857,0.0338,,,True,,,,True,Entire sample,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,F Truc,Università di Torino,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.19.21253962v1.full-text,2021-05-14,2022-07-16,Verified,truc_effects_2021,ITA
210320_Cogne_UniversitàDiTorino_genpop_female,210320_Cogne_UniversitàDiTorino,The effects of physical distancing and lockdown to restrain SARS-CoV-2 outbreak in the Italian Municipality of Cogne,2021-03-20,Preprint,Local,Prospective cohort,Italy,Valle D'Aosta,Cogne,people living to Cogne down town and spending there a considerable fraction of their time,Children under 14 years old were excluded from the survey.,2020-06-04,2020-06-05,Household and community samples,Female,Multiple groups,,,Sex/Gender,,464,0.0345,,,,,,,,Entire sample,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,F Truc,Università di Torino,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.19.21253962v1.full-text,2021-07-23,2022-07-16,Verified,truc_effects_2021,ITA
210320_Cogne_UniversitàDiTorino_genpop_50-75,210320_Cogne_UniversitàDiTorino,The effects of physical distancing and lockdown to restrain SARS-CoV-2 outbreak in the Italian Municipality of Cogne,2021-03-20,Preprint,Local,Prospective cohort,Italy,Valle D'Aosta,Cogne,people living to Cogne down town and spending there a considerable fraction of their time,Children under 14 years old were excluded from the survey.,2020-06-04,2020-06-05,Household and community samples,All,Multiple groups,,,Age,50-75,357,0.0308,,,,,,,,Entire sample,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,F Truc,Università di Torino,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.19.21253962v1.full-text,2021-07-23,2022-07-16,Verified,truc_effects_2021,ITA
210320_Cogne_UniversitàDiTorino_genpop_male,210320_Cogne_UniversitàDiTorino,The effects of physical distancing and lockdown to restrain SARS-CoV-2 outbreak in the Italian Municipality of Cogne,2021-03-20,Preprint,Local,Prospective cohort,Italy,Valle D'Aosta,Cogne,people living to Cogne down town and spending there a considerable fraction of their time,Children under 14 years old were excluded from the survey.,2020-06-04,2020-06-05,Household and community samples,Male,Multiple groups,,,Sex/Gender,,393,0.033100000000000004,,,,,,,,Entire sample,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,F Truc,Università di Torino,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.19.21253962v1.full-text,2021-07-23,2022-07-16,Verified,truc_effects_2021,ITA
210320_Cogne_UniversitàDiTorino_genpop_25-49,210320_Cogne_UniversitàDiTorino,The effects of physical distancing and lockdown to restrain SARS-CoV-2 outbreak in the Italian Municipality of Cogne,2021-03-20,Preprint,Local,Prospective cohort,Italy,Valle D'Aosta,Cogne,people living to Cogne down town and spending there a considerable fraction of their time,Children under 14 years old were excluded from the survey.,2020-06-04,2020-06-05,Household and community samples,All,Adults (18-64 years),,,Age,25-49,261,0.046,,,,,,,,Entire sample,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,F Truc,Università di Torino,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.19.21253962v1.full-text,2021-07-23,2022-07-16,Verified,truc_effects_2021,ITA
210320_Cogne_UniversitàDiTorino_genpop_14-24,210320_Cogne_UniversitàDiTorino,The effects of physical distancing and lockdown to restrain SARS-CoV-2 outbreak in the Italian Municipality of Cogne,2021-03-20,Preprint,Local,Prospective cohort,Italy,Valle D'Aosta,Cogne,people living to Cogne down town and spending there a considerable fraction of their time,Children under 14 years old were excluded from the survey.,2020-06-04,2020-06-05,Household and community samples,All,Multiple groups,,,Age,14-24,130,0.0154,,,,,,,,Entire sample,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,F Truc,Università di Torino,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.19.21253962v1.full-text,2021-07-23,2022-07-16,Verified,truc_effects_2021,ITA
210320_Cogne_UniversitàDiTorino_genpop_76+,210320_Cogne_UniversitàDiTorino,The effects of physical distancing and lockdown to restrain SARS-CoV-2 outbreak in the Italian Municipality of Cogne,2021-03-20,Preprint,Local,Prospective cohort,Italy,Valle D'Aosta,Cogne,people living to Cogne down town and spending there a considerable fraction of their time,Children under 14 years old were excluded from the survey.,2020-06-04,2020-06-05,Household and community samples,All,Seniors (65+ years),,,Age,>=76,109,0.0367,,,,,,,,Entire sample,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,F Truc,Università di Torino,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.19.21253962v1.full-text,2021-07-23,2022-07-16,Verified,truc_effects_2021,ITA
210324_Milan_UniversityofMilan_UniversityEmployees,210324_Milan_UniversityofMilan,"Detection of IgM, IgG and SARS-CoV-2 RNA among the personnel of the University of Milan, March through May 2020: the UNICORN study",2021-03-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Milan,"For the UNICORN study, eligible were all the personnel
of the University of Milan, which include a total of 3973 employers.","Exclusion criteria included: subjects
with fever, any symptoms of influenza-like
infections or dyspnoea at the moment of the recruitment or in the 14 previous days, subjects with close and prolonged contact with any person positive for SARS-CoV- 2 or with signs
or symptoms suggestive for infection in the previous 14
days (eg, a household member with respiratory symptoms
or fever).",2020-05-13,2020-06-23,Non-essential workers and unemployed persons,All,Multiple groups,,,Primary Estimate,,1826,0.113,,,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,Plasma,IgG,Spike,Validated by manufacturers,0.8570000000000001,0.981,['High'],,No,Yes,No,,Unclear,Yes,No,,Gregorio Milani,University of Milan,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2020-046800,2021-04-24,2022-07-16,Unverified,milani_detection_2021,ITA
210324_UniversiteCatholiquedeLouvain_Piedmont_workers,210324_UniversiteCatholiquedeLouvain_Piedmont,Diagnostic value of igm and igg detection in covid-19 diagnosis by the mobile laboratory b-life: A massive testing strategy in the piedmont region,2021-03-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,PIedmont,,"regional civil protection (CP), police, healthcare personnel, and volunteers working in the COVID pandemic phase",,2020-06-20,2020-07-23,Multiple populations,All,Multiple groups,19.0,80.0,Primary Estimate,,6033,0.048,,,True,,,,True,Convenience,QuickZen® COVID-19 IgM/IgG kit,"ZenTech, Angleur, Belgium",LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by manufacturers,,,['Moderate'],Yes,No,Yes,No,No,Yes,Yes,Yes,Unclear,Omar Nyabi,Université Catholique de Louvain,Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph18073372,2021-05-22,2024-03-01,Verified,bartschDiscreteSARSCoV2Antibody2021,ITA
210324_NorthernItaly_UniversitàDegliStudiDelPiemonteOrientale_HCW,210324_NorthernItaly_UniversitàDegliStudiDelPiemonteOrientale,High seroprevalence of sars-cov-2 among healthcare workers in a north italy hospital,2021-03-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Piedmont,Vercelli,"all personnel in LHS Vercelli were invited to test for SARS- CoV-2 serology as the Italian Region Council decided to organize a seroprevalence screening among all the healthcare workers. The tested population included HCWs as well as technical and administrative staff; we decided to also include in our study workers without a permanent employment. LHS Vercelli encompasses 2 main hospitals (Vercelli “Sant’Andrea” Hospital and Borgosesia “Santi Pietro e Paolo” Hospital), as well as Territorial Medical and Administrative services. HCW included nurses/physiotherapists, physicians, healthcare assistants, administrative staff, technical staff, and other.",The only exclusion criterion was the absence of patient’s consent. Two subjects were excluded from our study because serological results were doubtful.,2020-05-08,2020-06-03,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,2250,0.1711,0.1555,0.18670000000000003,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,0.9790000000000001,0.985,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Chiara Airoldi,Università degli Studi del Piemonte Orientale,Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph18073343,2021-04-09,2024-03-01,Verified,airoldi_high_2021,ITA
210325_Rome_UniversityofRomeTorVergata_IBDPatients,210325_Rome_UniversityofRomeTorVergata,Low prevalence of SARS-CoV-2 infection in inflammatory bowel disease,2021-03-25,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Italy,,Rome,"IBD patients showing no major signs or symptoms of SARS- CoV-2 infection and followed-up in our referral centre (“Tor Vergata University Hospital”, Rome, Lazio, Italy)

Inclusion criteria were: (1) age ≥18 years; (2) diagnosis of Crohn's Disease (CD) or ulcerative colitis (UC); (3) regular follow-up; (4) available demographic and clinical char- acteristics; (5) ability to understand the study design; (6) written informed consent","Exclusion criteria: (1) diagnosis or history of SARS-CoV-2 infection; (2) signs, symptoms and/or risk fac- tors for SARS-CoV-2 infection ≤14 days before enrollment (≥2 among: sore-throat, weakness, fever, cough, arthralgias, weight loss, recent contacts with COVID-19 patients); (3) ongoing clinical trial; (4) pregnancy; (5) psychiatric or severe diseases",2020-05-27,2020-07-21,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),19.0,77.0,Primary Estimate,,218,0.013700000000000002,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Ludovica Scucchi,University of Rome Tor Vergata,Not Unity-Aligned,https://www.europeanreview.org/wp/wp-content/uploads/2418-2424.pdf,2021-04-09,2024-03-01,Verified,scucchi_low_2021,ITA
210312_Venice_TheVenetoEyeBankFoundation,210312_Venice_TheVenetoEyeBankFoundation,Corneal transplantation during the COVID-19 pandemic: An operational guide.,2021-03-27,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Italy,Veneto region,Venice,"Patients scheduled for keratoplasty confirming the willingness to undergo graft, and those with corneal complaints requiring urgent keratoplasty followed the procedures described below.",,2020-03-15,2020-05-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,17.0,92.0,Primary Estimate,,30,0.0333,,,True,,,,True,Sequential,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Yes,Antonella Franch,The Veneto Eye Bank Foundation,Not Unity-Aligned,https://dx.doi.org/10.1177/11206721211006565,2021-05-18,2024-03-01,Verified,franch_corneal_2021,ITA
210722_Rome_SapienzaUniversityOfRome_Overall,210722_Rome_SapienzaUniversityOfRome,Gastrointestinal endoscopy can be safely performed during pandemic SARS-CoV-2 infection in Central Italy,2021-03-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lazio,Rome,Staff involved in endoscopy procedures,Endoscopic retrograde cholangiopancreatography procedures/associated staff.,2020-03-09,2020-04-15,Health care workers and caregivers,All,Adults (18-64 years),29.0,68.0,Primary Estimate,,16,0.0,,,,,,,,Convenience,2019-nCoV IgM/IgG CLIA,Medical Systems,CLIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],No,No,No,No,Yes,Unclear,Yes,No,,Emanuele Dilaghi,Sapienza University of Rome,Not Unity-Aligned,https://dx.doi.org/10.1097/MEG.0000000000002155,2021-05-19,2022-07-16,Verified,dilaghi_gastrointestinal_2021,ITA
210331_Naples_IstitutoNazionaleTumori_CancerPatients,210331_Naples_IstitutoNazionaleTumori_CancerPatients,Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis,2021-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,"Naples
",cancer patients admitted to Istituto Nazionale Tumori – IRCCS “Fondazione G. Pascale” in Naples (Italy),,2020-03-30,2020-05-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,885,0.0542,,,True,,,True,True,Convenience,Leccurate SARS-CoV-2 Antibody Rapid Test Kit (Colloidal Gold Immunochromatography),Beijing Lepu Medical Technology,Other,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria Isgro,Istituto Nazionale Tumori,Not Unity-Aligned,https://dx.doi.org/10.1186/s12967-021-02798-2,2021-04-30,2024-03-01,Verified,isgro_immunotherapy_2021,ITA
210331_Naples_IstitutoNazionaleTumori_HCWs,210331_Naples_IstitutoNazionaleTumori_HCWs,Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis,2021-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Naples,cancer patients admitted to Istituto Nazionale Tumori – IRCCS “Fondazione G. Pascale” in Naples (Italy) and 1050 healthcare providers working in the same hospital,,2020-03-30,2020-05-15,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,1050,0.046,0.033,0.059000000000000004,True,,,True,True,Convenience,Leccurate SARS-CoV-2 Antibody Rapid Test Kit (Colloidal Gold Immunochromatography),Beijing Lepu Medical Technology,Other,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Maria Isgro,Istituto Nazionale Tumori,Not Unity-Aligned,https://dx.doi.org/10.1186/s12967-021-02798-2,2021-04-30,2024-03-01,Verified,isgro_immunotherapy_2021,ITA
201007_Turin_UniversityofTurin_primary,201007_Turin_UniversityofTurin,Coronavirus disease 2019 and first-trimester spontaneous abortion: a case-control study of 225 pregnant patients,2021-04-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Turin,"Women who had been referred to our hospital for pregnancy loss care during the first 13 weeks of pregnancy between February 22 and May 21, 2020 were contacted and enrolled (case group). All women who had access to our emergency room or to the pregnancy loss management service were contacted after being traced through our hospital’s database. Women 12 weeks pregnant who were admitted to our hospital for fetal nuchal translucency (NT) between April 16, 2020, and May 21, 2020, were the control group.","To exclude the possibilityof COVID-19 seroconversion before pregnancy, only women with last menstruation before that date  were considered eligible for inclusion. ",2020-02-22,2020-05-21,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,225,0.09300000000000001,,,True,,,,True,Convenience,"AFIAS COVID-19 Ab assay,Liaison SARS-CoV-2 S1/S2 IgG","Boditech Med Inc.,DiaSorin",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,No,Yes,No,Yes,No,Unclear,Stefano Cosma,University of Turin,Not Unity-Aligned,http://dx.doi.org/10.1016/j.ajog.2020.10.005,2021-05-18,2024-03-01,Verified,cosma_coronavirus_2021,ITA
210402_Italy_FondazioneIstitutoStomatologicoItaliano_DentalStaff,210402_Italy_FondazioneIstitutoStomatologicoItaliano,"SARS-CoV-2 Infection among the Dental Staff from Lombardy Region, Italy",2021-04-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Italy,"Como, Lecco, Monza-Brianza, Sondrio, Varese, Bergamo, Brescia  Cremona, Lodi, Mantova, Pavia, Milan",,"In order to be eligible for the study, subjects had to be 18 years or older and be part of the following working categories: dentists, dental technicians, resident dental doctors,
dental hygienists, prosthodontic students, dental hygiene students, dental office assistants, nurses, laboratory technicians, administrative, secretaries, managers working in dental public or private institute or dental clinical centers located in Lombardy.",Subjects who did not work in dental setting or refused to participate to the study were excluded from the study. Volunteers were recruited through mailing list and social networks.,2020-05-28,2020-09-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,499,0.10800000000000001,,,True,,,,True,Convenience,Diagnostic kit for SARS-CoV-2 IgM/IgG Antibody (Colloidal Gold),Shanghai Kehua Bio-engineering (KHB) Co. Ltd,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.951,0.993,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Silvano Gallus,Fondazione Istituto Stomatologico Italiano,Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph18073711,2021-05-02,2022-07-16,Unverified,gallus_sars-cov-2_2021,ITA
210404_Marche_UniversitàPolitecnicadelleMarche_ConfirmationAssay,210404_Marche_UniversitàPolitecnicadelleMarche,"Seroprevalence of sars-cov-2-specific antibodies in cancer patients undergoing active systemic treatment: A single-center experience from the marche region, italy",2021-04-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Marche,Ancona,All consecutive patients who received systemic anticancer treatment (administered intravenously or subcutaneously/intramuscularly) at the UNIVPM outpatient and inpatient clinic between 1 July and 26 October 2020 were asked to be included in the TACCO (“serological Test detecting Anti-sars-Cov-2 at Clinica Oncologica”) procedure. Patients receiving oral anticancer treatments were included only if oral therapy was given as part of a treatment regimen that also included intravenous or subcutaneous therapy. , Patients receiving systemic treatment for hematological cancers were excluded from the procedure.,2020-07-01,2020-10-26,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,94.0,Primary Estimate,LFIA confirmed with CLIA,949,0.006999999999999999,,,True,,,,True,Sequential,"COVID-19 IgG/IgM Rapid Test,iFlash-SARS-CoV-2 IgM/IgG","Zhejiang Orient Gene Biotech,Shenzhen Yhlo Biotech Co. Ltd",Multiple Types,Multiple Types,"['IgG', 'IgM']",,,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Luca Cantini,Università Politecnica delle Marche,Not Unity-Aligned,http://dx.doi.org/10.3390/jcm10071503,2021-04-21,2024-03-01,Verified,cantini_seroprevalence_2021,ITA
210415_Campania_UniversityofNapoli,210415_Campania_UniversityofNapoli,Estimating asymptomatic SARS-CoV-2 infections in a geographic area of low disease incidence.,2021-04-15,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Campania,,"None of the symptoms frequently associated
with the infection, such as fever, cough, fatigue etc.,
in the past five months. They had stayed in the Campania
Region at least since December 1, 2019.",,2020-05-11,2020-05-18,Household and community samples,All,Multiple groups,19.0,68.0,Primary Estimate,"Healthy, asymptomatic volunteers",388,0.018000000000000002,0.0069,0.0291,True,,,,True,Simplified probability,NovaLisa® SARS-CoV-2 IgG/IgM,NovaTec Immundiagnostics GmbH,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9490000000000001,0.9620000000000001,['High'],Yes,Yes,No,No,Unclear,Yes,Yes,No,Unclear,Valeria Caturano ,University of Napoli ,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06054-2,2021-05-22,2024-03-01,Verified,caturano_estimating_2021,ITA
210419_Turin_AziendaOspedalieraOrdineMauriziano_Primary,210419_Turin_AziendaOspedalieraOrdineMauriziano,Risk factors of SARS‐CoV‐2 seroprevalence among hospital employees in Italy: a single‐centre study,2021-04-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Piedmont,Turin,"All 1650 hospital employees (including administrative personnel, technicians and healthcare practitioners) were eligible and invited to participate by internal electronic mail.",,2020-05-08,2020-05-15,Health care workers and caregivers,All,Multiple groups,21.0,70.0,Primary Estimate,,1562,0.098,,,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.841,0.937,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Marco Daperno,Azienda Ospedaliera Ordine Mauriziano,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.1111/imj.15201,2021-05-20,2024-03-01,Verified,daperno_risk_2021,ITA
210420_Foggia_UniversityOfFoggia,210420_Foggia_UniversityOfFoggia,Low Prevalence of Antibodies to SARS-CoV-2 and Undetectable Viral Load in Seropositive Blood Donors from South-Eastern Italy,2021-04-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Apulia,Foggia,Blood donors who had presented for blood donation at the University Hospital in Foggia from March to June 2020,Criteria for exclusion of donors were (1) age <18 years or >65 years; (2) body weight <50 kg; (3) hemoglobin value <12.5 g/dL for females and 13.5 g/dL for males; (4) history of jaundice; (5) sickle cell disease; (6) hypertension; (7) current fever; or (8) reported previously diagnosed SARS-CoV-2 infection,2020-03-15,2020-06-15,Blood donors,All,Adults (18-64 years),18.0,65.0,Primary Estimate,,1797,0.01,,,True,,,,True,Sequential,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,MAGLUMI 2019-nCoV IgM/IgG","Ortho Clinical Diagnostics Inc.,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd)",CLIA,Serum,"['IgG', 'TotalAntibody']",Spike,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Mariantonietta Di Stefano,University of Foggia,Not Unity-Aligned,https://www.karger.com/Article/Abstract/515258,2021-05-20,2024-03-01,Verified,stefano_low_2021,ITA
210420_Foggia_UniversityOfFoggia_Male,210420_Foggia_UniversityOfFoggia,Low Prevalence of Antibodies to SARS-CoV-2 and Undetectable Viral Load in Seropositive Blood Donors from South-Eastern Italy,2021-04-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,"Apulia
","Foggia
",Blood donors who had presented for blood donation at the University Hospital in Foggia from March to June 2020,Criteria for exclusion of donors were (1) age <18 years or >65 years; (2) body weight <50 kg; (3) hemoglobin value <12.5 g/dL for females and 13.5 g/dL for males; (4) history of jaundice; (5) sickle cell disease; (6) hypertension; (7) current fever; or (8) reported previously diagnosed SARS-CoV-2 infection,2020-03-15,2020-06-15,Blood donors,Male,Adults (18-64 years),18.0,65.0,Sex/Gender,,1338,0.01,,,,,,,,Sequential,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,MAGLUMI 2019-nCoV IgM/IgG","Ortho Clinical Diagnostics Inc.,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd)",CLIA,Serum,"['IgG', 'TotalAntibody']",Spike,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Mariantonietta Di Stefano,University of Foggia,Not Unity-Aligned,https://www.karger.com/Article/Abstract/515258,2021-09-20,2024-03-01,Verified,stefano_low_2021,ITA
210420_Foggia_UniversityOfFoggia_Female,210420_Foggia_UniversityOfFoggia,Low Prevalence of Antibodies to SARS-CoV-2 and Undetectable Viral Load in Seropositive Blood Donors from South-Eastern Italy,2021-04-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Apulia,Foggia,Blood donors who had presented for blood donation at the University Hospital in Foggia from March to June 2020,Criteria for exclusion of donors were (1) age <18 years or >65 years; (2) body weight <50 kg; (3) hemoglobin value <12.5 g/dL for females and 13.5 g/dL for males; (4) history of jaundice; (5) sickle cell disease; (6) hypertension; (7) current fever; or (8) reported previously diagnosed SARS-CoV-2 infection,2020-03-15,2020-06-15,Blood donors,Female,Adults (18-64 years),18.0,65.0,Sex/Gender,,459,0.011000000000000001,,,,,,,,Sequential,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,MAGLUMI 2019-nCoV IgM/IgG","Ortho Clinical Diagnostics Inc.,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd)",CLIA,Serum,"['IgG', 'TotalAntibody']",Spike,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Mariantonietta Di Stefano,University of Foggia,Not Unity-Aligned,https://www.karger.com/Article/Abstract/515258,2021-09-20,2024-03-01,Verified,stefano_low_2021,ITA
210428_Europe_SorbonneUniversité_5EmiliaRomagna,210428_Europe_SorbonneUniversité_5EmiliaRomagna,SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study.,2021-04-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Emilia Romagna,,"Eligible individuals had to be older than 18 years and have a definite clinical diagnosis of rheumatoid arthritis, axial spondyloarthritis, systemic lupus erythematosus, Sjögren's syndrome, or giant cell arteritis diagnosed by experienced rheumatologists and fulfilling the respective international classification criteria.","Patients who refused to participate, did not speak or read the local language, or were unwilling to undergo routine blood collection during the study period were excluded. ",2020-06-07,2020-12-08,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,,Primary Estimate,,522,0.015,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Liaison SARS-CoV-2 S1/S2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Siemens,DiaSorin,Beckman Coulter,Roche Diagnostics",,,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,Yes,Unclear,Unclear,No,No,Unclear,David Saadoun,Sorbonne Université,Not Unity-Aligned,https://dx.doi.org/10.1016/S2665-9913(21)00112-0,2021-05-30,2024-03-01,Verified,davidsaadounetal.SARSCoV2OutbreakImmunemediated2021,ITA
210429_SouthernItaly_UniversityofCampania,210429_SouthernItaly_UniversityofCampania,"Seroprevalence
  of SARS-CoV-2 Antibodies in Adults and Healthcare Workers in Southern Italy",2021-04-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Southern Italy,"Caserta, Naples","The study population consisted of participants: (1) who were in contact with patients such as HCWs and medical students; (2) who were not in contact with patients, but with HCWs,
such as technicians, laboratory assistants, custodians, cleaners, and administrative staff of the Teaching Hospital; (3) non-medical students, faculty members, research fellows and
administrative staff of non-medical University Departments.",,2020-09-21,2020-12-31,Multiple populations,All,Multiple groups,18.0,,Primary Estimate,,2394,0.058499999999999996,,,True,,,,True,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,DiaSorin",CLIA,Serum,TotalAntibody,,Validated by manufacturers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Francesco Napolitano,University of Campania,Not Unity-Aligned,https://www.mdpi.com/1660-4601/18/9/4761,2021-05-22,2024-03-01,Unverified,napolitano_seroprevalence_2021,ITA
210501_Rome_SapienzaUniversity,210501_Rome_SapienzaUniversity,Asymptomatic individuals positive for anti-SARS-CoV-2 antibodies negative on molecular swab.,2021-05-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lazio,Rome,,,2020-05-15,2020-06-15,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,17377,0.0122,,,True,,,,True,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (S)","DiaSorin,Roche Diagnostics",CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],No,No,Yes,No,Unclear,Unclear,No,No,Unclear,Guido Antonelli,Sapienza University,Not Unity-Aligned,https://dx.doi.org/10.1016/S2666-5247(21)00083-5,2021-05-28,2024-03-01,Verified,antonelli_asymptomatic_2021,ITA
210504_Cagliari_UniversityofCagliari_SurgicalPatients_IGGorIGM,210504_Cagliari_UniversityofCagliari,Seroprevalence of SARS-CoV-2 in unselected surgical patients: An update from an unicentric regional study.,2021-05-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Sardinia,Cagliari,"patients admitted to the Department of General and Endocrine Surgery of University Hospital of Cagliari from September 1 –  December 10, 2020.",,2020-09-01,2020-12-10,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,121,0.107,,,True,,,,True,Convenience,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Serum,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Federico Cappellacci, University of Cagliari,Not Unity-Aligned,https://dx.doi.org/10.1016/j.amsu.2021.102375,2021-05-29,2024-03-01,Verified,Cappellacci_seroprevalence_2021,ITA
210519_Lombardy_ASSTGaetanoPini-CTOInstitute,210519_Lombardy_ASSTGaetanoPini-CTOInstitute,"Seroprevalence of anti-SARS-CoV-2 antibodies in rheumatic patients treated with biological and targeted therapy living in lombardy, Italy (mainstream project)",2021-05-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Lombardy,,"Included patients with confirmed RA (rheumatoid arthritis) or SpA (spondyloarthritis) treated with biologic (b-) or targeted synthetic (ts-) disease modifying drugs (DMARDs) from Lombardy, Italy",,2020-05-04,2020-06-16,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),,,Primary Estimate,,300,0.18600000000000003,0.146,0.23399999999999999,True,,,,True,Unclear,Author designed (ELISA) - MULTIPLEXED,,ELISA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Unclear,Unclear,No,Yes,Unclear,Unclear,Yes,No,Unclear,Ennio Giulio Favalli,"The ASST Gaetano Pini-CTO
Institute",Not Unity-Aligned,http://dx.doi.org/10.1136/annrheumdis-2021-eular.594,2021-08-24,2022-07-16,Verified,favalli_pos0048_2021,ITA
210528_Bari_IRCCSIstitutoTumoriGiovanniPaoloII_Baseline,210528_Bari_IRCCSIstitutoTumoriGiovanniPaoloII,Prospective Observational COVID-19 Screening and Monitoring of Asymptomatic Cancer Center Health-Care Workers with a Rapid Serological Test.,2021-05-28,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Italy,Puglia,Bari,"Only asymptomatic HCWs were enrolled, defined initially as absence of cough, fever, dyspnoea, acute onset of anosmia, ageusia or dysgeusia",,2020-03-26,2020-03-31,Health care workers and caregivers,All,Multiple groups,20.0,73.0,Primary Estimate,,606,0.011000000000000001,,,True,,,,True,Convenience,VivaDiag COVID-19 IgM/IgG Rapid Test,VivaChek Biotech (Hangzhou) Co. Ltd,LFIA,Multiple Types,"['IgG', 'IgM']",,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Angelo Virgilio Paradiso,IRCCS Istituto Tumori “Giovanni Paolo II” ,Not Unity-Aligned,https://dx.doi.org/10.3390/diagnostics11060975,2021-06-08,2024-03-01,Unverified, paradiso_prospective_2021,ITA
210603_Italy_UniversityHospitalCittaDellaSalute_Healthcare,210603_Italy_UniversityHospitalCittaDellaSalute_Healthcare,"Prevalence, persistence, and factors associated with sars-cov-2 igg seropositivity in a large cohort of healthcare workers in a tertiary care university hospital in northern italy",2021-06-03,Journal Article (Peer-Reviewed),Local,Prospective cohort,Italy,Piedmont,Turin,"All the workers at the University Hospital Città della Salute e della Scienza di Torino (CSS) (Turin, Piedmont region, Figure S1), including employees, students, medical residents, and fellows, for a total
of 11,115 subjects, were invited to participate starting in April 2020. All the subjects who tested positive or equivocal at the first phase were invited to be retested at the beginning of September 2020; blood samples were collected between
28 September and 20 November 2020, i.e., at the beginning of the second pandemic wave
(Figure S1).",,2020-05-04,2020-07-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,8769,0.076,0.071,0.08199999999999999,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Gitana Scozzari,University Hospital Città Della Salute e Della Scienza di Torino,Not Unity-Aligned,http://dx.doi.org/10.3390/v13061064,2021-07-05,2024-03-01,Unverified,scozzari_prevalence_2021,ITA
210603_Italy_UniversityHospitalCittaDellaSalute_University,210603_Italy_UniversityHospitalCittaDellaSalute_University,"Prevalence, persistence, and factors associated with sars-cov-2 igg seropositivity in a large cohort of healthcare workers in a tertiary care university hospital in northern italy",2021-06-03,Journal Article (Peer-Reviewed),Local,Prospective cohort,Italy,Piedmont,Turin,"We invited all the 3679 workers of the University of Turin (UNITO), an adult population with no professional risk for SARS-CoV-2 infection. All the subjects who tested positive or equivocal at the first phase were invited to be retested at the beginning of September 2020; blood samples were collected between 28 September and 20 November 2020, i.e., at the beginning of the second pandemic wave
(Figure S1).",,2020-06-29,2020-07-29,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,1185,0.033,0.024,0.045,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Gitana Scozzari,University Hospital Città Della Salute e Della Scienza di Torino,Not Unity-Aligned,http://dx.doi.org/10.3390/v13061064,2021-07-05,2024-03-01,Unverified,scozzari_prevalence_2021,ITA
210505_Trieste_ItalianNationalInstituteOfHealth,210505_Trieste_ItalianNationalInstituteOfHealth,Prevalence of SARS-CoV-2 infection in Italian pediatric population: a regional seroepidemiological study.,2021-06-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,,Trieste,"Both inpatient and outpatients referring to pediatric wards, day hospital, and emergency department were included, based on two inclusion criteria: age < 18 years and need for blood test for any reason. ","Refusal to participate to the study, risk factors for ongoing SARS-CoV-2 infection (typical symptoms, recent positive nasopharyngeal swab, contact with confirmed or suspected cases, travelling abroad), and/or immunodeficiency, either primitive or secondary, were considered as exclusion criteria.",2021-01-05,2021-01-31,Blood donors,All,Children and Youth (0-17 years),,,Primary Estimate,,169,0.095,,,True,,,,True,Sequential,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,,IgG,,,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Manola Comar,Italian National Institute of Health,Not Unity-Aligned,https://dx.doi.org/10.1186/s13052-021-01074-9,2021-06-21,2024-03-01,Unverified,manolacomarPrevalenceSARSCoV2Infection2021,ITA
210505_Trieste_ItalianNationalInstituteOfHealth_12to17,210505_Trieste_ItalianNationalInstituteOfHealth,Prevalence of SARS-CoV-2 infection in Italian pediatric population: a regional seroepidemiological study.,2021-06-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,,Trieste,"Both inpatient and outpatients referring to pediatric wards, day hospital, and emergency department were included, based on two inclusion criteria: age < 18 years and need for blood test for any reason. ","Refusal to participate to the study, risk factors for ongoing SARS-CoV-2 infection (typical symptoms, recent positive nasopharyngeal swab, contact with confirmed or suspected cases, travelling abroad), and/or immunodeficiency, either primitive or secondary, were considered as exclusion criteria.",2021-01-05,2021-01-31,Blood donors,All,Children and Youth (0-17 years),12.0,17.0,Age,"12-17
",80,0.08800000000000001,,,,,,,,Sequential,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,,IgG,,,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Manola Comar,Italian National Institute of Health,Not Unity-Aligned,https://dx.doi.org/10.1186/s13052-021-01074-9,2022-02-19,2024-03-01,Unverified,manolacomarPrevalenceSARSCoV2Infection2021,ITA
210505_Trieste_ItalianNationalInstituteOfHealth_6to11,210505_Trieste_ItalianNationalInstituteOfHealth,Prevalence of SARS-CoV-2 infection in Italian pediatric population: a regional seroepidemiological study.,2021-06-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,,Trieste,"Both inpatient and outpatients referring to pediatric wards, day hospital, and emergency department were included, based on two inclusion criteria: age < 18 years and need for blood test for any reason. ","Refusal to participate to the study, risk factors for ongoing SARS-CoV-2 infection (typical symptoms, recent positive nasopharyngeal swab, contact with confirmed or suspected cases, travelling abroad), and/or immunodeficiency, either primitive or secondary, were considered as exclusion criteria.",2021-01-05,2021-01-31,Blood donors,All,Children and Youth (0-17 years),6.0,11.0,Age,6-11,61,0.098,,,,,,,,Sequential,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,,IgG,,,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Manola Comar,Italian National Institute of Health,Not Unity-Aligned,https://dx.doi.org/10.1186/s13052-021-01074-9,2022-02-19,2024-03-01,Unverified,manolacomarPrevalenceSARSCoV2Infection2021,ITA
210505_Trieste_ItalianNationalInstituteOfHealth_Under5,210505_Trieste_ItalianNationalInstituteOfHealth,Prevalence of SARS-CoV-2 infection in Italian pediatric population: a regional seroepidemiological study.,2021-06-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,,Trieste,"Both inpatient and outpatients referring to pediatric wards, day hospital, and emergency department were included, based on two inclusion criteria: age < 18 years and need for blood test for any reason. ","Refusal to participate to the study, risk factors for ongoing SARS-CoV-2 infection (typical symptoms, recent positive nasopharyngeal swab, contact with confirmed or suspected cases, travelling abroad), and/or immunodeficiency, either primitive or secondary, were considered as exclusion criteria.",2021-01-05,2021-01-31,Blood donors,All,Children and Youth (0-17 years),,5.0,Age,<=5,28,0.107,,,,,,,,Sequential,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,,IgG,,,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Manola Comar,Italian National Institute of Health,Not Unity-Aligned,https://dx.doi.org/10.1186/s13052-021-01074-9,2022-02-19,2024-03-01,Unverified,manolacomarPrevalenceSARSCoV2Infection2021,ITA
210607_Italy_UniversityofMilan_Cohabitants3,210607_Italy_UniversityofMilan_Cohabitants3,Prevalence of SARS-CoV-2-IgG Antibodies in Children with CKD or Immunosuppression.,2021-06-07,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Italy,,,"Inclusion criteria were age <18 years and one of the following diagnoses: primary or secondary GN and idiopathic nephrotic syndrome requiring long-term immunosuppressive therapy, CKD stages 3–5, dialysis, or kidney transplant. National rates of participation were calculated estimating the number of prevalent cases.
https://cjasn.asnjournals.org/content/16/3/449",,2020-07-15,2020-09-15,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),,,Primary Estimate,Cohabitants,271,0.03,,,True,,,,True,Stratified probability,Not reported/ Unable to specify,,,,IgG,,,,,['High'],,Yes,No,No,,Unclear,Yes,No,,William Morello,University of Milan,Not Unity-Aligned,https://dx.doi.org/10.2215/CJN.00330121,2021-06-21,2022-07-16,Unverified,morelloPrevalenceSARSCoV2IgGAntibodies2021,ITA
210607_Italy_UniversityofMilan_Patients1,210607_Italy_UniversityofMilan_Patients1,Prevalence of SARS-CoV-2-IgG Antibodies in Children with CKD or Immunosuppression.,2021-06-07,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Italy,,,"Inclusion criteria were age <18 years and one of the following diagnoses: primary or secondary GN and idiopathic nephrotic syndrome requiring long-term immunosuppressive therapy, CKD stages 3–5, dialysis, or kidney transplant. National rates of participation were calculated estimating the number of prevalent cases.
https://cjasn.asnjournals.org/content/16/3/449",,2020-07-15,2020-09-15,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),,,Primary Estimate,Patients,178,0.017,,,True,,,,True,Stratified probability,Not reported/ Unable to specify,,,,IgG,,,,,['High'],,Yes,No,No,,Unclear,Yes,No,,William Morello,University of Milan,Not Unity-Aligned,https://dx.doi.org/10.2215/CJN.00330121,2021-06-21,2022-07-16,Unverified,morelloPrevalenceSARSCoV2IgGAntibodies2021,ITA
210607_Italy_UniversityofMilan_Siblings2,210607_Italy_UniversityofMilan_Siblings2,Prevalence of SARS-CoV-2-IgG Antibodies in Children with CKD or Immunosuppression.,2021-06-07,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Italy,,,"Inclusion criteria were age <18 years and one of the following diagnoses: primary or secondary GN and idiopathic nephrotic syndrome requiring long-term immunosuppressive therapy, CKD stages 3–5, dialysis, or kidney transplant. National rates of participation were calculated estimating the number of prevalent cases.
https://cjasn.asnjournals.org/content/16/3/449",,2020-07-15,2020-09-15,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),,,Primary Estimate,Siblings,90,0.07,,,True,,,,True,Stratified probability,Not reported/ Unable to specify,,,,IgG,,,,,['High'],,Yes,No,No,,Unclear,Yes,No,,William Morello,University of Milan,Not Unity-Aligned,https://dx.doi.org/10.2215/CJN.00330121,2021-06-21,2022-07-16,Unverified,morelloPrevalenceSARSCoV2IgGAntibodies2021,ITA
210610_Lombardy_HumanitasUniversity_HCW_overall,210610_Lombardy_HumanitasUniversity,"SARS-CoV-2 serology in 4000 health care and administrative staff across seven sites in Lombardy, Italy.",2021-06-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Lombardy ,"Milan, Rozzano, Varese, Castellanza and Bergamo","employees of 7 different healthcare facilities, one including a research center and a University, located across the Lombardy region",,2020-04-28,2020-05-16,Health care workers and caregivers,All,Multiple groups,21.0,86.0,Primary Estimate,"Overall, unadjusted",3985,0.13,,,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.904,0.985,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria Teresa Sandri,Humanitas University,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-91773-4,2021-06-21,2024-03-01,Verified,sandri_sars-cov-2_2021,ITA
210611_Padova_UniversityOfPadova_HCW_Overall,210611_Padova_UniversityOfPadova_HCWs,SARS-CoV-2 Infection in Spondyloarthritis Patients Treated With Biotechnological Drugs: A Study on Serology.,2021-06-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Province of Padova,Padova,"Consecutive patients with a diagnosis of axial or peripheral
spondyloarthritis by the rheumatologist, classified as axSpA or
peripheral SpA according to the ASAS classification criteria (7, 8),
attending the Spondyloarthritis Clinic of our Rheumatology Unit, in
the period 1st June-7th August 2020, were recruited during regular
outpatient clinic. Inclusion criteria were: age≥18 years old, ongoing
therapy with biotechnological agents or small molecules.","Exclusion criteria were: inability to sign informed consent, therapy with
conventional synthetic DMARDs (csDMARDs) alone",2020-06-01,2020-08-07,Health care workers and caregivers,All,Multiple groups,18.0,,Primary Estimate,,95,0.084,,,True,,,,True,Convenience,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Serum,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Augusta Ortolan,University of Padova,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2021.682850,2021-07-06,2024-03-01,Unverified,ortolan_sars-cov-2_2021,ITA
210611_Padova_UniversityOfPadova_SpAPatients_Overall,210611_Padova_UniversityOfPadova_SpAPatients,SARS-CoV-2 Infection in Spondyloarthritis Patients Treated With Biotechnological Drugs: A Study on Serology.,2021-06-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Province of Padova,Padova,"Consecutive patients with a diagnosis of axial or peripheral
spondyloarthritis by the rheumatologist, classified as axSpA or
peripheral SpA according to the ASAS classification criteria (7, 8),
attending the Spondyloarthritis Clinic of our Rheumatology Unit, in
the period 1st June-7th August 2020, were recruited during regular
outpatient clinic. Inclusion criteria were: age≥18 years old, ongoing
therapy with biotechnological agents or small molecules.","Exclusion criteria were: inability to sign informed consent, therapy with
conventional synthetic DMARDs (csDMARDs) alone",2020-06-01,2020-08-07,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,,Primary Estimate,,200,0.125,,,True,,,,True,Convenience,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Serum,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Augusta Ortolan,University of Padova,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2021.682850,2021-07-06,2024-03-01,Unverified,ortolan_sars-cov-2_2021,ITA
210614_Verona_UniversityofVerona,210614_Verona_UniversityofVerona,Sars-cov-2 infection in health workers: Analysis from verona sieroepid study during the pre-vaccination era,2021-06-14,Journal Article (Peer-Reviewed),Local,Prospective cohort,Italy,Province of Verona,Verona ,"All health workers at the University Hospital of Verona, consent, present between 7:00 am, and 11:00 am at fasting or having eaten only a light breakfast.",,2020-04-28,2020-07-20,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Healthcare workers,5299,0.06,0.053,0.066,True,,,,True,Convenience,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),LFIA,Serum,"['IgG', 'IgM']",,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Stefano Porru,University of Verona,Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph18126446,2021-06-20,2024-03-01,Unverified,porru_sars-cov-2_2021,ITA
210625_Emilia-Romagna_UniversityofMilan_primary,210625_Emilia-Romagna_UniversityofMilan,Epidemiology of SARS-CoV-2 Infection Evaluated by Immunochromatographic Rapid Testing for the Determination of IgM and IgG Against SARS-CoV-2 in a Cohort of Mask Wearing Workers in the Metal-Mechanical Sector in an Area With a High Incidence of COVID-19.,2021-06-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,"Calerno, Parma, Spilamberto",,employees of the Crown Imballaggi company were enrolled in the study. All of them were metal-mechanical workers who had never stopped working even during the pandemic period,,2020-06-01,2020-06-30,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,815,0.038,,,True,,,,True,Convenience,PRIMA COVID-19 IgG/IgM Rapid Test,PRIMA Lab S.A.,LFIA,,"['IgG', 'IgM']",,Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Susanna Esposito,University of Milan,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2021.628098,2021-07-19,2024-03-01,Unverified,esposito_epidemiology_2021,ITA
210626_Torno_SaccoUniversityHospital_Residents1,210626_Torno_SaccoUniversityHospital_Residents1,Preventing COVID-19 in assisted living facilities: An impossible task pending vaccination roll out.,2021-06-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Torno,"The Cesare e Emilio Prandoni Onlus assisted living facility consists of 62 rooms: 46 single and 16 double rooms. During the first observational period (23 February – 22 June 2020), there were 82 residents and 53 members of staff (two of the members of staff did not complete the questionnaire). None of the eight deaths recorded during the study period were due to infectious diseases (the number of deaths recorded during the same period of 2018 and 2019 was respectively 10 and 9). Accordingly, data on 74 residents and 51 staff members were considered in the final analyses.",,2020-06-01,2020-06-22,Assisted living and long-term care facilities,All,Seniors (65+ years),,,Primary Estimate,,74,0.0,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,Multiple Types,IgG,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Mario Tagliabue,Sacco University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.pmedr.2021.101471,2021-07-12,2022-07-16,Unverified,tagliabuePreventingCOVID19Assisted2021,ITA
210626_Torno_SaccoUniversityHospital_Staff2,210626_Torno_SaccoUniversityHospital_Staff2,Preventing COVID-19 in assisted living facilities: An impossible task pending vaccination roll out.,2021-06-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Torno,"The Cesare e Emilio Prandoni Onlus assisted living facility consists of 62 rooms: 46 single and 16 double rooms. During the first observational period (23 February – 22 June 2020), there were 82 residents and 53 members of staff (two of the members of staff did not complete the questionnaire). None of the eight deaths recorded during the study period were due to infectious diseases (the number of deaths recorded during the same period of 2018 and 2019 was respectively 10 and 9). Accordingly, data on 74 residents and 51 staff members were considered in the final analyses.",,2020-06-01,2020-06-22,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,51,0.0,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,Multiple Types,IgG,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Mario Tagliabue,Sacco University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.pmedr.2021.101471,2021-07-12,2022-07-16,Unverified,tagliabuePreventingCOVID19Assisted2021,ITA
210628_Lombardy_UniversityofPavia_patients_primary,210628_Lombardy_UniversityofPavia_patients,"A Pilot Study on Covid and Autism: Prevalence, Clinical Presentation and Vaccine Side Effects.",2021-06-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,,,,2020-05-15,2020-05-31,Assisted living and long-term care facilities,All,Adults (18-64 years),,,Primary Estimate,,36,0.36100000000000004,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG']",Spike,Validated by developers,0.97,0.86,['High'],,No,No,Yes,,Unclear,Yes,No,,Natascia Brondino ,University of Pavia,Not Unity-Aligned,https://dx.doi.org/10.3390/brainsci11070860,2021-07-12,2022-07-16,Unverified,brondino_pilot_2021,ITA
210628_Lombardy_UniversityofPavia_staff_primary,210628_Lombardy_UniversityofPavia_staff,"A Pilot Study on Covid and Autism: Prevalence, Clinical Presentation and Vaccine Side Effects.",2021-06-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,,,,2020-05-15,2020-05-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,35,0.34299999999999997,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG']",Spike,Validated by developers,0.97,0.86,['High'],,No,No,Yes,,Unclear,Yes,No,,Natascia Brondino ,University of Pavia,Not Unity-Aligned,https://dx.doi.org/10.3390/brainsci11070860,2021-07-12,2022-07-16,Unverified,brondino_pilot_2021,ITA
210703_Rome_FondazionePoliclinicoUniversitario_Primary,210703_Rome_FondazionePoliclinicoUniversitario,"Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak.",2021-07-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Rome,"systematically collect, and store residual plasma samples obtained from routine viral load measurements (plasma HIV-RNA) from the same outpatients. Specifically, we decided to assay all samples
available from March to April because only a small number of samples were available due to the reduced flow of patients during the lockdown period. For the remaining periods, we randomly selected a convenient sample size, i.e., 50% of the residual samples per month. We did not establish specific inclusion/exclusion criteria, and we excluded samples only when associated clinical/laboratory data were missing.","We did not establish specific inclusion/exclusion criteria, and we excluded samples only when associated clinical/laboratory data were missing.",2020-03-01,2020-11-30,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),,,Primary Estimate,,1106,0.0072,,,True,,,,True,Sequential,"Atellica® IM SARS-CoV-2 Total (COV2T),Anti-SARS-CoV-2 ELISA IgG","Siemens,EUROIMMUN",Multiple Types,Plasma,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,No,Yes,No,,Francesca Lombardi,Fondazione Policlinico Universitario,Not Unity-Aligned,https://dx.doi.org/10.3390/diagnostics11071154,2021-07-12,2024-03-01,Unverified,lombardi_seroprevalence_2021,ITA
210706_Italy_FondazioneIRCCSPoliclinicoSanMatteo_Primary,210706_Italy_FondazioneIRCCSPoliclinicoSanMatteo,Incidence of SARS-CoV-2 infection in health care workers from Northern Italy based on antibody status: immune protection from secondary infection- A retrospective observational case-controlled study,2021-07-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Italy,"Pavia, Lecco, Piacenza",,"A cohort of 9,610 healthcare workers (2,567 male and 7,043 female; median age 47 years, range 21-70 years) from three hospitals in Northern Italy (Fondazione IRCCS Policlinico San Matteo, Pavia; Alessandro Manzoni Hospital, Lecco; Guglielmo da Saliceto Hospital, Piacenza), involved in Covid-19 diagnosis and clinical care, were stratified according to SARS-CoV-2 seropositivity",,2020-04-29,2020-05-29,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,9610,0.152,,,True,,,,True,Unclear,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by manufacturers,,,['High'],No,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Francesca Rovida ,Fondazione IRCCS Policlinico San Matteo,Not Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.07.003,2021-08-10,2024-03-01,Verified,10.1016/j.ijid.2021.07.003,ITA
210706_Lombardy_BrunoKesslerFoundation_HCW,210706_Lombardy_BrunoKesslerFoundation,Seroprevalence of and Risk Factors Associated With SARS-CoV-2 Infection in Health Care Workers During the Early COVID-19 Pandemic in Italy.,2021-07-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Lombardy region,,"""The target population consisted of HCWs working in private and public accredited hospitals or research hospitals (Fondazione Istituto di Ricovero e Cura a Carattere Scientifico) or providing any health care service or support to health care services in the region.""",,2020-04-01,2020-06-26,Health care workers and caregivers,All,Multiple groups,19.0,83.0,Primary Estimate,,82961,0.122,0.12,0.12400000000000001,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9440000000000001,0.983,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Piero Poletti,Bruno Kessler Foundation,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.15699,2021-07-21,2024-03-01,Unverified,poletti_seroprevalence_2021,ITA
210719_Vo_UniversityOfPadova_Overall_Adj,210719_Vo_UniversityOfPadova,SARS-CoV-2 antibody dynamics and transmission from community-wide serological testing in the Italian municipality of Vo'.,2021-07-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Padova,Vo,Population of Vo',Excluding indeterminant assay results,2020-05-01,2020-05-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,2602,0.035,0.027999999999999997,0.043,True,True,,,,Entire sample,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N),Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,Roche Diagnostics,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Yes,Ilaria Dorigatti,University of Padova,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-24622-7,2021-09-08,2023-08-15,Verified,dorigatti_sars-cov-2_2021-1,ITA
210719_Vo_UniversityOfPadova_Overall_DiaSorin,210719_Vo_UniversityOfPadova,SARS-CoV-2 antibody dynamics and transmission from community-wide serological testing in the Italian municipality of Vo'.,2021-07-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Padova,Vo,Population of Vo',Excluding indeterminant assay results,2020-05-01,2020-05-31,Household and community samples,All,Multiple groups,,,Test used,,2594,0.052000000000000005,0.044000000000000004,0.061,,,,,,Entire sample,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8520000000000001,1.0,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Yes,Ilaria Dorigatti,University of Padova,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-24622-7,2021-07-29,2024-03-01,Verified,dorigatti_sars-cov-2_2021-1,ITA
210719_Vo_UniversityOfPadova_Overall_Roche,210719_Vo_UniversityOfPadova,SARS-CoV-2 antibody dynamics and transmission from community-wide serological testing in the Italian municipality of Vo'.,2021-07-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Padova,Vo,Population of Vo',Excluding indeterminant assay results,2020-05-01,2020-05-31,Household and community samples,All,Multiple groups,,,Test used,,2457,0.04,0.033,0.049,,,,,,Entire sample,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9390000000000001,0.976,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Yes,Ilaria Dorigatti,University of Padova,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-24622-7,2021-07-29,2024-03-01,Verified,dorigatti_sars-cov-2_2021-1,ITA
210719_Vo_UniversityOfPadova_Overall_Abbott,210719_Vo_UniversityOfPadova,SARS-CoV-2 antibody dynamics and transmission from community-wide serological testing in the Italian municipality of Vo'.,2021-07-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Padova,Vo,Population of Vo',Excluding indeterminant assay results,2020-05-01,2020-05-31,Household and community samples,All,Multiple groups,,,Test used,,2457,0.039,0.031000000000000003,0.047,,,,,,Entire sample,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9390000000000001,1.0,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Yes,Ilaria Dorigatti,University of Padova,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-24622-7,2021-07-29,2024-03-01,Verified,dorigatti_sars-cov-2_2021-1,ITA
210719_Vo_UniversityOfPadova_Overall_Unadj,210719_Vo_UniversityOfPadova,SARS-CoV-2 antibody dynamics and transmission from community-wide serological testing in the Italian municipality of Vo'.,2021-07-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Padova,Vo,Population of Vo',Excluding indeterminant assay results,2020-05-01,2020-05-31,Household and community samples,All,Multiple groups,,,Analysis,,2602,0.062000000000000006,,,,,,,True,Entire sample,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N),Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,Roche Diagnostics,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Yes,Ilaria Dorigatti,University of Padova,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-24622-7,2021-09-08,2024-03-01,Verified,dorigatti_sars-cov-2_2021-1,ITA
210720_Italy_UniversityofGenoa,210720_Italy_UniversityofGenoa,Effect of SARS-CoV-2 mRNA Vaccination in MS Patients Treated With Disease Modifying Therapies,2021-07-20,Preprint,National,Prospective cohort,Italy,,,"Adult pwMS, with or without a previous SARS-CoV-2 infection
111 who were scheduled for SARS-CoVv-2 vaccination, were included in the study","Main reason for study exclusion were the presence of known allergic reactions to components of the vaccine and/or any relevant comorbidities requiring additional treatments with B-cell–targeted  therapies, lymphocyte-trafficking blockers, alemtuzumab, anti-CD4 antibody, cladribine, cyclophosphamide, mitoxantrone, azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, total body irradiation, or bone marrow transplantation.",2021-03-04,2021-07-09,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),,,Primary Estimate,,1022,0.11199999999999999,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Maria Pia Sormani,University of Genoa,Not Unity-Aligned,10.2139/ssrn.3886420,2021-07-28,2024-03-01,Unverified,sormani_effect_2021,ITA
210724_Brescia-Lombardy_UniversityOfBrescia_Residents1,210724_Brescia-Lombardy_UniversityOfBrescia_Residents1,"Rapid Point-Of-Care Serology and Clinical History Assessment Increase Protection Provided by RT-PCR Screening: A Pilot Study Involving Three Nursing Homes in Brescia, a Hotspot of Lombardy.",2021-07-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Province of Brescia,Brescia,The cohort of this study included residents and staff of three differently sized care homes in Brescia (Italy) managed by the same medical direction during the COVID-19 outbreak,Testing was non-practicable for one resident.,2020-05-19,2020-06-30,Assisted living and long-term care facilities,All,Multiple groups,,,Primary Estimate,Residents,246,0.24,,,True,,,,True,Convenience,Coretests COVID-19 IgM/IgG Ab Test,Core Technology Co. Ltd,LFIA,,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.976,1.0,['High'],,No,No,Yes,,Yes,Yes,Yes,,Antonella Savio,University Of Brescia,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2021.649524,2021-07-20,2024-03-01,Unverified,savioRapidPointofcareSerology2021,ITA
210724_Brescia-Lombardy_UniversityOfBrescia_Staff2,210724_Brescia-Lombardy_UniversityOfBrescia_Staff2,"Rapid Point-Of-Care Serology and Clinical History Assessment Increase Protection Provided by RT-PCR Screening: A Pilot Study Involving Three Nursing Homes in Brescia, a Hotspot of Lombardy.",2021-07-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Province of Brescia,Brescia,The cohort of this study included residents and staff of three differently sized care homes in Brescia (Italy) managed by the same medical direction during the COVID-19 outbreak,A single HCW was excluded because she was quarantined at home.,2020-04-23,2020-05-14,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,Staff,286,0.1678,,,True,,,,True,Convenience,Coretests COVID-19 IgM/IgG Ab Test,Core Technology Co. Ltd,LFIA,,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.976,1.0,['High'],,No,No,Yes,,Yes,Yes,Yes,,Antonella Savio,University Of Brescia,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2021.649524,2021-07-20,2024-03-01,Unverified,savioRapidPointofcareSerology2021,ITA
210726_Florence_MeyerChildren'sUniversityHospital,210726_Florence_MeyerChildren'sUniversityHospital,Surveillance on Healthcare Workers During the First Wave of SARS-CoV-2 Pandemic in Italy: The Experience of a Tertiary Care Pediatric Hospital.,2021-07-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,"Tuscany
",Florence,workers (including administrative staff) at Meyer Children's University Hospital in Florence,,2020-04-02,2020-05-06,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,overall hcws,1502,0.027999999999999997,,,True,,,,True,Convenience,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Valentina Guarnieri,Meyer Children's University Hospital,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2021.644702,2021-08-17,2024-03-01,Unverified,guarnieri_surveillance_2021,ITA
210727_Modena_UniversityofModenaandReggioEmilia_Overall,210727_Modena_UniversityofModenaandReggioEmilia,Frequency of anti-sars-cov-2 antibodies in various occupational sectors in an industrialized area of northern italy from may to october 2020,2021-07-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Modena,,"Active non-healthcare workers in Modena: ""Considering these exclusions, the source population included all workers in the province of Modena employed in companies classified with codes A to N, plus the codes R, S and U, according to the ISIC classification.""","""HCWs, ISIC code 'Q. Human health and social work activities'
....ISIC code 'O', i.e., Public administration and defense activities
....ISIC code 'P', i.e., Education—as in the case of Public Administration personnel
....ISIC code 'T', i.e., Activities of households as employers, undifferentiated goods- and services-producing activities of households for own use.""",2020-05-18,2020-10-05,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,246608,0.0045000000000000005,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Alberto Modenese,University of Modena and Reggio Emilia,Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph18157948,2021-08-02,2022-07-16,Unverified,modenese_frequency_2021,ITA
210730_Abruzzo_GDannunzioUniversity,210730_Abruzzo_GDannunzioUniversity,Evaluation of IgG seroprevalence of the Sars-Cov-2 in different worker categories,2021-07-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Abruzzo,,"Workers in the Abruzzo region in the following sectors:
Manufacturing - textile
Manufacturing - machines, tools, robotics
Chemicals and hydroelectricity
Education
Security systems design
Hospital cleaning and maintenance",,2020-08-01,2020-10-20,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,IgG,216,0.0509,,,True,,,,True,Unclear,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Serum,IgG,,Validated by manufacturers,0.9120999999999999,0.973,['High'],,Unclear,No,Yes,,Yes,Yes,Yes,,E Toniato,G. D'Annunzio University,Not Unity-Aligned,https://www.biolifesas.org/biolife/wp-content/uploads/2021/07/S3-Toniato-15.pdf,2022-01-18,2024-03-01,Unverified,toniato_evaluation_2021,ITA
210804_Italy_UniversityofCampania_Primary,210804_Italy_UniversityofCampania,Blood donor serological screening for SARS-CoV-2 as a tool to estimate the prevalence of asymptomatic infection in a low-intermediate endemic area of southern Italy after the first wave of the pandemic.,2021-08-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Campania (Southern Italy),,Routine blood donor volunteers. ,,2020-04-21,2020-06-10,Blood donors,All,Multiple groups,18.0,69.0,Primary Estimate,,1808,0.008296460177,,,True,,,,True,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9450000000000001,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Federica Calo,University of Campania,Unity-Aligned,https://dx.doi.org/10.2450/2021.0196-21,2021-11-03,2024-03-01,Verified,calo_blood_2021,ITA
210804_Italy_UniversityofCampania_Age_40-49,210804_Italy_UniversityofCampania,Blood donor serological screening for SARS-CoV-2 as a tool to estimate the prevalence of asymptomatic infection in a low-intermediate endemic area of southern Italy after the first wave of the pandemic.,2021-08-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Campania (Southern Italy),,Routine blood donor volunteers. ,,2020-04-21,2020-06-10,Blood donors,All,Adults (18-64 years),40.0,49.0,Age,40-49,579,0.00518134715,,,,,,,,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9450000000000001,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Federica Calo,University of Campania,Unity-Aligned,https://dx.doi.org/10.2450/2021.0196-21,2021-11-03,2024-03-01,Verified,calo_blood_2021,ITA
210804_Italy_UniversityofCampania_Age_30-39,210804_Italy_UniversityofCampania,Blood donor serological screening for SARS-CoV-2 as a tool to estimate the prevalence of asymptomatic infection in a low-intermediate endemic area of southern Italy after the first wave of the pandemic.,2021-08-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Campania (Southern Italy),,Routine blood donor volunteers. ,,2020-04-21,2020-06-10,Blood donors,All,Adults (18-64 years),30.0,39.0,Age,30-39,371,0.01347708895,,,,,,,,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9450000000000001,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Federica Calo,University of Campania,Unity-Aligned,https://dx.doi.org/10.2450/2021.0196-21,2021-11-03,2024-03-01,Verified,calo_blood_2021,ITA
210804_Italy_UniversityofCampania_Timeframe_June2020,210804_Italy_UniversityofCampania,Blood donor serological screening for SARS-CoV-2 as a tool to estimate the prevalence of asymptomatic infection in a low-intermediate endemic area of southern Italy after the first wave of the pandemic.,2021-08-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Campania (Southern Italy),,Routine blood donor volunteers. ,,2020-06-01,2020-06-10,Blood donors,All,Multiple groups,18.0,69.0,Time frame,June 2020,143,0.027972027970000004,,,,,,,,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9450000000000001,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Federica Calo,University of Campania,Unity-Aligned,https://dx.doi.org/10.2450/2021.0196-21,2021-11-03,2024-03-01,Verified,calo_blood_2021,ITA
210804_Italy_UniversityofCampania_Age_18-29,210804_Italy_UniversityofCampania,Blood donor serological screening for SARS-CoV-2 as a tool to estimate the prevalence of asymptomatic infection in a low-intermediate endemic area of southern Italy after the first wave of the pandemic.,2021-08-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Campania (Southern Italy),,Routine blood donor volunteers. ,,2020-04-21,2020-06-10,Blood donors,All,Adults (18-64 years),18.0,29.0,Age,18-29,308,0.00974025974,,,,,,,,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9450000000000001,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Federica Calo,University of Campania,Unity-Aligned,https://dx.doi.org/10.2450/2021.0196-21,2021-11-03,2024-03-01,Verified,calo_blood_2021,ITA
210804_Italy_UniversityofCampania_Sex_Female,210804_Italy_UniversityofCampania,Blood donor serological screening for SARS-CoV-2 as a tool to estimate the prevalence of asymptomatic infection in a low-intermediate endemic area of southern Italy after the first wave of the pandemic.,2021-08-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Campania (Southern Italy),,Routine blood donor volunteers. ,,2020-04-21,2020-06-10,Blood donors,Female,Multiple groups,18.0,69.0,Sex/Gender,,661,0.006051437216,,,,,,,,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9450000000000001,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Federica Calo,University of Campania,Unity-Aligned,https://dx.doi.org/10.2450/2021.0196-21,2021-11-03,2024-03-01,Verified,calo_blood_2021,ITA
210804_Italy_UniversityofCampania_Timeframe_April2020,210804_Italy_UniversityofCampania,Blood donor serological screening for SARS-CoV-2 as a tool to estimate the prevalence of asymptomatic infection in a low-intermediate endemic area of southern Italy after the first wave of the pandemic.,2021-08-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Campania (Southern Italy),,Routine blood donor volunteers. ,,2020-04-21,2020-04-30,Blood donors,All,Multiple groups,18.0,69.0,Time frame,April 2020,476,0.004201680672,,,,,,,,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9450000000000001,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Federica Calo,University of Campania,Unity-Aligned,https://dx.doi.org/10.2450/2021.0196-21,2021-11-03,2024-03-01,Verified,calo_blood_2021,ITA
210804_Italy_UniversityofCampania_Timeframe_May2020,210804_Italy_UniversityofCampania,Blood donor serological screening for SARS-CoV-2 as a tool to estimate the prevalence of asymptomatic infection in a low-intermediate endemic area of southern Italy after the first wave of the pandemic.,2021-08-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Campania (Southern Italy),,Routine blood donor volunteers. ,,2020-05-01,2020-05-31,Blood donors,All,Multiple groups,18.0,69.0,Time frame,May 2020,1189,0.007569386039,,,,,,,,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9450000000000001,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Federica Calo,University of Campania,Unity-Aligned,https://dx.doi.org/10.2450/2021.0196-21,2021-11-03,2024-03-01,Verified,calo_blood_2021,ITA
210804_Italy_UniversityofCampania_Age_50-59,210804_Italy_UniversityofCampania,Blood donor serological screening for SARS-CoV-2 as a tool to estimate the prevalence of asymptomatic infection in a low-intermediate endemic area of southern Italy after the first wave of the pandemic.,2021-08-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Campania (Southern Italy),,Routine blood donor volunteers. ,,2020-04-21,2020-06-10,Blood donors,All,Adults (18-64 years),50.0,59.0,Age,50-59,438,0.0068493150680000005,,,,,,,,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9450000000000001,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Federica Calo,University of Campania,Unity-Aligned,https://dx.doi.org/10.2450/2021.0196-21,2021-11-03,2024-03-01,Verified,calo_blood_2021,ITA
210804_Italy_UniversityofCampania_Age_60-69,210804_Italy_UniversityofCampania,Blood donor serological screening for SARS-CoV-2 as a tool to estimate the prevalence of asymptomatic infection in a low-intermediate endemic area of southern Italy after the first wave of the pandemic.,2021-08-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Campania (Southern Italy),,Routine blood donor volunteers. ,,2020-04-21,2020-06-10,Blood donors,All,Multiple groups,60.0,69.0,Age,60-69,108,0.009259259259,,,,,,,,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9450000000000001,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Federica Calo,University of Campania,Unity-Aligned,https://dx.doi.org/10.2450/2021.0196-21,2021-11-03,2024-03-01,Verified,calo_blood_2021,ITA
210804_Italy_UniversityofCampania_Sex_Male,210804_Italy_UniversityofCampania,Blood donor serological screening for SARS-CoV-2 as a tool to estimate the prevalence of asymptomatic infection in a low-intermediate endemic area of southern Italy after the first wave of the pandemic.,2021-08-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Campania (Southern Italy),,Routine blood donor volunteers. ,,2020-04-21,2020-06-10,Blood donors,Male,Multiple groups,18.0,69.0,Sex/Gender,,1147,0.009590235397,,,,,,,,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9450000000000001,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Federica Calo,University of Campania,Unity-Aligned,https://dx.doi.org/10.2450/2021.0196-21,2021-11-03,2024-03-01,Verified,calo_blood_2021,ITA
210808_North-WesternItaly_UniversitàDelPiemonteOrientale,210808_North-WesternItaly_UniversitàDelPiemonteOrientale,Seroprevalence of SARS-CoV-2 Among Workers in Northern Italy.,2021-08-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,,"Torino, Biella, Cuneo, Novara","This study analyzed the data of more than 220000 workers tested for SARS-CoV-2 between 28 March and 7 August 2020, recorded by the private healthcare center ‘Centro Polispecialistico Privato Medicina del Lavoro’ (CDC) that is located in North-West Italy (Piedmont region).",,2020-04-28,2020-08-07,Essential non-healthcare workers,All,Multiple groups,,,Primary Estimate,,23568,0.0497,0.046900000000000004,0.0525,True,,,,True,Convenience,ELISA SARS-CoV-2 IgG Test System,Zeus,ELISA,Multiple Types,IgG,,,0.9329999999999999,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Chiara Airoldi,Università del Piemonte Orientale,Not Unity-Aligned,https://dx.doi.org/10.1093/annweh/wxab062,2021-08-18,2024-03-01,Unverified,airoldiSeroprevalenceSARSCoV2Workers2021,ITA
210827_Italy_AOUCittàdellaSaluteedellaScienzadiTorino,210827_Italy_AOUCittàdellaSaluteedellaScienzadiTorino,SCREENING FOR SARS-CoV-2 NEUTRALIZING ANTIBODIES IN CIRRHOTIC PATIENTS WAITING FOR LIVER TRANSPLANTATION: IMPACT ON DONOR POOL EXPANSION,2021-08-27,Presentation or Conference,Local,Cross-sectional survey ,Italy,Piedmont,Turin,each patient on the LT waiting list was tested for SARS-CoV-2 neutralizing antibodies,,2020-11-25,2021-02-12,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,98,0.22399999999999998,,,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,,,IgG,Spike,,,,['High'],,No,No,No,,Yes,Yes,Yes,,Margherita Saracco,AOU Citta della Salute e della Scienza di Torino,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.1111/tri.13944,2021-09-13,2024-03-01,Unverified,saracco_screening_2021,ITA
210827_Modena_UniversityofModenaandReggioEmilia_Overall,210827_Modena_UniversityofModenaandReggioEmilia,Seroprevalence of anti-SARS-CoV-2 antibodies in the Northern Italy population before the COVID-19 second wave.,2021-08-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Province of Modena,Modena,"Workers and individuals who went to the private Test Laboratory of Modena Workers for a serological test between June 1-September 25, 2020. Workers were referred by their companies, which strongly recommended that their employees be tested. The remaining individuals were admitted to the facility through self-referral, and were not asked to report the reasons for which they sought testing.","For subjects who took the test more than once during the study period, only their most recent test result was considered and the previous ones were excluded from the analysis.",2020-06-01,2020-09-25,Multiple populations,All,Multiple groups,,,Primary Estimate,,7561,0.047,0.042,0.052000000000000005,True,,,,True,Self-referral,"Elecsys® Anti‐SARS‐CoV‐2 (N),Diagnostic kit for SARS-CoV-2 IgM/IgG Antibody (Colloidal Gold),Anti-SARS-CoV-2 ELISA IgA,Anti-SARS-CoV-2 ELISA IgG","Roche Diagnostics,Shanghai Kehua Bio-engineering (KHB) Co. Ltd,EUROIMMUN",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']",,Validated by manufacturers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Nausicaa Berselli,University of Modena and Reggio Emilia,Not Unity-Aligned,https://dx.doi.org/10.13075/ijomeh.1896.01826,2021-09-21,2024-03-01,Unverified,berselli_seroprevalence_2021,ITA
210827_Modena_UniversityofModenaandReggioEmilia_Age_50-59,210827_Modena_UniversityofModenaandReggioEmilia,Seroprevalence of anti-SARS-CoV-2 antibodies in the Northern Italy population before the COVID-19 second wave.,2021-08-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Province of Modena,Modena,"Workers and individuals who went to the private Test Laboratory of Modena Workers for a serological test between June 1-September 25, 2020. Workers were referred by their companies, which strongly recommended that their employees be tested. The remaining individuals were admitted to the facility through self-referral, and were not asked to report the reasons for which they sought testing.","For subjects who took the test more than once during the study period, only their most recent test result was considered and the previous ones were excluded from the analysis.",2020-06-01,2020-09-25,Multiple populations,All,Adults (18-64 years),50.0,59.0,Age,50-59,1641,0.048,,,,,,,,Self-referral,"Elecsys® Anti‐SARS‐CoV‐2 (N),Diagnostic kit for SARS-CoV-2 IgM/IgG Antibody (Colloidal Gold),Anti-SARS-CoV-2 ELISA IgA,Anti-SARS-CoV-2 ELISA IgG","Roche Diagnostics,Shanghai Kehua Bio-engineering (KHB) Co. Ltd,EUROIMMUN",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']",,Validated by manufacturers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Nausicaa Berselli,University of Modena and Reggio Emilia,Not Unity-Aligned,https://dx.doi.org/10.13075/ijomeh.1896.01826,2021-09-21,2024-03-01,Unverified,berselli_seroprevalence_2021,ITA
210827_Modena_UniversityofModenaandReggioEmilia_Age_20-29,210827_Modena_UniversityofModenaandReggioEmilia,Seroprevalence of anti-SARS-CoV-2 antibodies in the Northern Italy population before the COVID-19 second wave.,2021-08-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Province of Modena,Modena,"Workers and individuals who went to the private Test Laboratory of Modena Workers for a serological test between June 1-September 25, 2020. Workers were referred by their companies, which strongly recommended that their employees be tested. The remaining individuals were admitted to the facility through self-referral, and were not asked to report the reasons for which they sought testing.","For subjects who took the test more than once during the study period, only their most recent test result was considered and the previous ones were excluded from the analysis.",2020-06-01,2020-09-25,Multiple populations,All,Adults (18-64 years),20.0,29.0,Age,20-29,1229,0.037000000000000005,,,,,,,,Self-referral,"Elecsys® Anti‐SARS‐CoV‐2 (N),Diagnostic kit for SARS-CoV-2 IgM/IgG Antibody (Colloidal Gold),Anti-SARS-CoV-2 ELISA IgA,Anti-SARS-CoV-2 ELISA IgG","Roche Diagnostics,Shanghai Kehua Bio-engineering (KHB) Co. Ltd,EUROIMMUN",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']",,Validated by manufacturers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Nausicaa Berselli,University of Modena and Reggio Emilia,Not Unity-Aligned,https://dx.doi.org/10.13075/ijomeh.1896.01826,2021-09-21,2024-03-01,Unverified,berselli_seroprevalence_2021,ITA
210827_Modena_UniversityofModenaandReggioEmilia_Age_60-69,210827_Modena_UniversityofModenaandReggioEmilia,Seroprevalence of anti-SARS-CoV-2 antibodies in the Northern Italy population before the COVID-19 second wave.,2021-08-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Province of Modena,Modena,"Workers and individuals who went to the private Test Laboratory of Modena Workers for a serological test between June 1-September 25, 2020. Workers were referred by their companies, which strongly recommended that their employees be tested. The remaining individuals were admitted to the facility through self-referral, and were not asked to report the reasons for which they sought testing.","For subjects who took the test more than once during the study period, only their most recent test result was considered and the previous ones were excluded from the analysis.",2020-06-01,2020-09-25,Multiple populations,All,Multiple groups,60.0,69.0,Age,60-69,643,0.073,0.053,0.09300000000000001,,,,,,Self-referral,"Elecsys® Anti‐SARS‐CoV‐2 (N),Diagnostic kit for SARS-CoV-2 IgM/IgG Antibody (Colloidal Gold),Anti-SARS-CoV-2 ELISA IgA,Anti-SARS-CoV-2 ELISA IgG","Roche Diagnostics,Shanghai Kehua Bio-engineering (KHB) Co. Ltd,EUROIMMUN",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']",,Validated by manufacturers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Nausicaa Berselli,University of Modena and Reggio Emilia,Not Unity-Aligned,https://dx.doi.org/10.13075/ijomeh.1896.01826,2021-09-21,2024-03-01,Unverified,berselli_seroprevalence_2021,ITA
210827_Modena_UniversityofModenaandReggioEmilia_Age_40-49,210827_Modena_UniversityofModenaandReggioEmilia,Seroprevalence of anti-SARS-CoV-2 antibodies in the Northern Italy population before the COVID-19 second wave.,2021-08-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Province of Modena,Modena,"Workers and individuals who went to the private Test Laboratory of Modena Workers for a serological test between June 1-September 25, 2020. Workers were referred by their companies, which strongly recommended that their employees be tested. The remaining individuals were admitted to the facility through self-referral, and were not asked to report the reasons for which they sought testing.","For subjects who took the test more than once during the study period, only their most recent test result was considered and the previous ones were excluded from the analysis.",2020-06-01,2020-09-25,Multiple populations,All,Adults (18-64 years),40.0,49.0,Age,40-49,1915,0.037000000000000005,,,,,,,,Self-referral,"Elecsys® Anti‐SARS‐CoV‐2 (N),Diagnostic kit for SARS-CoV-2 IgM/IgG Antibody (Colloidal Gold),Anti-SARS-CoV-2 ELISA IgA,Anti-SARS-CoV-2 ELISA IgG","Roche Diagnostics,Shanghai Kehua Bio-engineering (KHB) Co. Ltd,EUROIMMUN",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']",,Validated by manufacturers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Nausicaa Berselli,University of Modena and Reggio Emilia,Not Unity-Aligned,https://dx.doi.org/10.13075/ijomeh.1896.01826,2021-09-21,2024-03-01,Unverified,berselli_seroprevalence_2021,ITA
210827_Modena_UniversityofModenaandReggioEmilia_Age_<20,210827_Modena_UniversityofModenaandReggioEmilia,Seroprevalence of anti-SARS-CoV-2 antibodies in the Northern Italy population before the COVID-19 second wave.,2021-08-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Province of Modena,Modena,"Workers and individuals who went to the private Test Laboratory of Modena Workers for a serological test between June 1-September 25, 2020. Workers were referred by their companies, which strongly recommended that their employees be tested. The remaining individuals were admitted to the facility through self-referral, and were not asked to report the reasons for which they sought testing.","For subjects who took the test more than once during the study period, only their most recent test result was considered and the previous ones were excluded from the analysis.",2020-06-01,2020-09-25,Multiple populations,All,Children and Youth (0-17 years),,20.0,Age,<20,248,0.048,,,,,,,,Self-referral,"Elecsys® Anti‐SARS‐CoV‐2 (N),Diagnostic kit for SARS-CoV-2 IgM/IgG Antibody (Colloidal Gold),Anti-SARS-CoV-2 ELISA IgA,Anti-SARS-CoV-2 ELISA IgG","Roche Diagnostics,Shanghai Kehua Bio-engineering (KHB) Co. Ltd,EUROIMMUN",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']",,Validated by manufacturers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Nausicaa Berselli,University of Modena and Reggio Emilia,Not Unity-Aligned,https://dx.doi.org/10.13075/ijomeh.1896.01826,2021-09-21,2024-03-01,Unverified,berselli_seroprevalence_2021,ITA
210827_Modena_UniversityofModenaandReggioEmilia_Age_30-39,210827_Modena_UniversityofModenaandReggioEmilia,Seroprevalence of anti-SARS-CoV-2 antibodies in the Northern Italy population before the COVID-19 second wave.,2021-08-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Province of Modena,Modena,"Workers and individuals who went to the private Test Laboratory of Modena Workers for a serological test between June 1-September 25, 2020. Workers were referred by their companies, which strongly recommended that their employees be tested. The remaining individuals were admitted to the facility through self-referral, and were not asked to report the reasons for which they sought testing.","For subjects who took the test more than once during the study period, only their most recent test result was considered and the previous ones were excluded from the analysis.",2020-06-01,2020-09-25,Multiple populations,All,Adults (18-64 years),30.0,39.0,Age,30-39,1505,0.037000000000000005,,,,,,,,Self-referral,"Elecsys® Anti‐SARS‐CoV‐2 (N),Diagnostic kit for SARS-CoV-2 IgM/IgG Antibody (Colloidal Gold),Anti-SARS-CoV-2 ELISA IgA,Anti-SARS-CoV-2 ELISA IgG","Roche Diagnostics,Shanghai Kehua Bio-engineering (KHB) Co. Ltd,EUROIMMUN",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']",,Validated by manufacturers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Nausicaa Berselli,University of Modena and Reggio Emilia,Not Unity-Aligned,https://dx.doi.org/10.13075/ijomeh.1896.01826,2021-09-21,2024-03-01,Unverified,berselli_seroprevalence_2021,ITA
210827_Modena_UniversityofModenaandReggioEmilia_Age_70+,210827_Modena_UniversityofModenaandReggioEmilia,Seroprevalence of anti-SARS-CoV-2 antibodies in the Northern Italy population before the COVID-19 second wave.,2021-08-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Province of Modena,Modena,"Workers and individuals who went to the private Test Laboratory of Modena Workers for a serological test between June 1-September 25, 2020. Workers were referred by their companies, which strongly recommended that their employees be tested. The remaining individuals were admitted to the facility through self-referral, and were not asked to report the reasons for which they sought testing.","For subjects who took the test more than once during the study period, only their most recent test result was considered and the previous ones were excluded from the analysis.",2020-06-01,2020-09-25,Multiple populations,All,Seniors (65+ years),70.0,,Age,70+,380,0.11800000000000001,0.086,0.151,,,,,,Self-referral,"Elecsys® Anti‐SARS‐CoV‐2 (N),Diagnostic kit for SARS-CoV-2 IgM/IgG Antibody (Colloidal Gold),Anti-SARS-CoV-2 ELISA IgA,Anti-SARS-CoV-2 ELISA IgG","Roche Diagnostics,Shanghai Kehua Bio-engineering (KHB) Co. Ltd,EUROIMMUN",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']",,Validated by manufacturers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Nausicaa Berselli,University of Modena and Reggio Emilia,Not Unity-Aligned,https://dx.doi.org/10.13075/ijomeh.1896.01826,2021-09-21,2024-03-01,Unverified,berselli_seroprevalence_2021,ITA
210831_Berica_StBortoloHospital_MaglumiAnti-S,210831_Berica_StBortoloHospital,Comparison of Anti-SARS-CoV-2 S1 Receptor-Binding Domain Antibody Immunoassays in Health Care Workers Before and After the BNT162b2 mRNA Vaccine.,2021-08-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Italy,,Vicenza,"Participants were health care professionals who tested negative to previous SARS-CoV-2 infection through a real-time polymerase chain reaction (PCR) method
before and after the BNT162b2 vaccine.","Vaccinated individuals, those who tested positive to previous SARS-CoV-2 infection through a real-time polymerase chain reaction (PCR) method",2020-12-15,2021-02-15,Health care workers and caregivers,All,Adults (18-64 years),38.0,55.0,Primary Estimate,Assay: Maglumi SARS-CoV-2 S-RBD IgG (CLIA),70,0.028999999999999998,,,,,,,,Convenience,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,1.0,0.996,['High'],,No,No,Yes,,Yes,Yes,Yes,,Mariarosa Carta,St Bortolo Hospital,Not Unity-Aligned,https://dx.doi.org/10.1093/ajcp/aqab107,2021-09-08,2024-03-01,Unverified,carta_comparison_2021,ITA
210831_Italy_UniversityofVerona_Overall,210831_Italy_UniversityofVerona,The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population.,2021-08-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Italy,"Veneto, Friuli-Venezia Giulia, and Lazio",,"Patients with CML attending five outpatient hematological centers in three Italian regions  (Veneto, Friuli-Venezia Giulia, and Lazio). The inclusion criteria comprehended an established diagnosis of CML according to the World Health Organization criteria and age ≥18 years. ","No exclusion criteria have been envisaged, except for the unwillingness to sign a written informed consent. Patients enrolled in clinical trials were not excluded unless the participation to other experimental, non-pharmacological studies was formally precluded by the study protocol.",2020-05-18,2020-11-03,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,20.0,94.0,Primary Estimate,,564,0.0195,0.010900000000000002,0.0346,True,,,,True,Sequential,COVID-19 IgG/IgM Rapid Test Cassette,Menarini Diagnostics,LFIA,,"['IgG', 'IgM']",,Validated by manufacturers,,1.0,['High'],,No,No,Yes,,Yes,Yes,Yes,,Massimiliano Bonifacio,University of Verona,Not Unity-Aligned,https://dx.doi.org/10.1002/cam4.4179,2021-09-07,2024-03-01,Unverified,bonifacio_serological_2021,ITA
210902_Milan_UniversityofMilan_January2021_Overall,210902_Milan_UniversityofMilan_January2021,Does school reopening affect SARS-CoV-2 seroprevalence among school-age children in Milan?,2021-09-02,Journal Article (Peer-Reviewed),Local,Prospective cohort,Italy,Lombardy,Milan,"Prospective multicenter SARS-CoV-2 serologic testing program across 15 different Institutes, representative of different territorial areas of Milan. Recruitment was organized through awareness campaigns at school and study participation was completely voluntary.
Subjects were eligible if aged from 3 to 18 years old.","""We excluded 214 (16.1%) patients, because for 13 (0.9%) of them the results were borderline/inconclusive and not repeated at, at least, one of the two timepoint, and for 201 (15.2%) the samples were insufficient/inadequate to perform the analysis.""",2021-01-15,2021-01-29,Students and Daycares,All,Children and Youth (0-17 years),3.0,18.0,Primary Estimate,,1109,0.125,0.106,0.146,True,,,,True,Convenience,GSP1/DELFIA1 anti SARS-CoV2 kit,PerkinElmer,Other,Dried Blood,IgG,Spike,Validated by manufacturers,0.96,1.0,['Moderate'],Unclear,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Lucia Barcellini,University of Milan,Not Unity-Aligned,http://dx.doi.org/10.1371/journal.pone.0257046,2021-09-14,2024-03-01,Unverified,barcellini_does_2021,ITA
210902_Milan_UniversityofMilan_January2021_Age_14-18,210902_Milan_UniversityofMilan_January2021,Does school reopening affect SARS-CoV-2 seroprevalence among school-age children in Milan?,2021-09-02,Journal Article (Peer-Reviewed),Local,Prospective cohort,Italy,Lombardy,Milan,"Prospective multicenter SARS-CoV-2 serologic testing program across 15 different Institutes, representative of different territorial areas of Milan. Recruitment was organized through awareness campaigns at school and study participation was completely voluntary.
Subjects were eligible if aged from 3 to 18 years old.","""We excluded 214 (16.1%) patients, because for 13 (0.9%) of them the results were borderline/inconclusive and not repeated at, at least, one of the two timepoint, and for 201 (15.2%) the samples were insufficient/inadequate to perform the analysis.""",2021-01-15,2021-01-29,Students and Daycares,All,Children and Youth (0-17 years),14.0,18.0,Age,Age: 14-18 years,158,0.10130000000000002,,,,,,,,Convenience,GSP1/DELFIA1 anti SARS-CoV2 kit,PerkinElmer,Other,Dried Blood,IgG,Spike,Validated by manufacturers,0.96,1.0,['Moderate'],Unclear,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Lucia Barcellini,University of Milan,Not Unity-Aligned,http://dx.doi.org/10.1371/journal.pone.0257046,2022-02-16,2024-03-01,Unverified,barcellini_does_2021,ITA
210902_Milan_UniversityofMilan_January2021_Age_11-13,210902_Milan_UniversityofMilan_January2021,Does school reopening affect SARS-CoV-2 seroprevalence among school-age children in Milan?,2021-09-02,Journal Article (Peer-Reviewed),Local,Prospective cohort,Italy,Lombardy,Milan,"Prospective multicenter SARS-CoV-2 serologic testing program across 15 different Institutes, representative of different territorial areas of Milan. Recruitment was organized through awareness campaigns at school and study participation was completely voluntary.
Subjects were eligible if aged from 3 to 18 years old.","""We excluded 214 (16.1%) patients, because for 13 (0.9%) of them the results were borderline/inconclusive and not repeated at, at least, one of the two timepoint, and for 201 (15.2%) the samples were insufficient/inadequate to perform the analysis.""",2021-01-15,2021-01-29,Students and Daycares,All,Children and Youth (0-17 years),11.0,13.0,Age,Age: 11-13 years,320,0.1219,,,,,,,,Convenience,GSP1/DELFIA1 anti SARS-CoV2 kit,PerkinElmer,Other,Dried Blood,IgG,Spike,Validated by manufacturers,0.96,1.0,['Moderate'],Unclear,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Lucia Barcellini,University of Milan,Not Unity-Aligned,http://dx.doi.org/10.1371/journal.pone.0257046,2022-02-16,2024-03-01,Unverified,barcellini_does_2021,ITA
210902_Milan_UniversityofMilan_January2021_Age_6-10,210902_Milan_UniversityofMilan_January2021,Does school reopening affect SARS-CoV-2 seroprevalence among school-age children in Milan?,2021-09-02,Journal Article (Peer-Reviewed),Local,Prospective cohort,Italy,Lombardy,Milan,"Prospective multicenter SARS-CoV-2 serologic testing program across 15 different Institutes, representative of different territorial areas of Milan. Recruitment was organized through awareness campaigns at school and study participation was completely voluntary.
Subjects were eligible if aged from 3 to 18 years old.","""We excluded 214 (16.1%) patients, because for 13 (0.9%) of them the results were borderline/inconclusive and not repeated at, at least, one of the two timepoint, and for 201 (15.2%) the samples were insufficient/inadequate to perform the analysis.""",2021-01-15,2021-01-29,Students and Daycares,All,Children and Youth (0-17 years),6.0,10.0,Age,Age: 6-10 years,592,0.1334,,,,,,,,Convenience,GSP1/DELFIA1 anti SARS-CoV2 kit,PerkinElmer,Other,Dried Blood,IgG,Spike,Validated by manufacturers,0.96,1.0,['Moderate'],Unclear,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Lucia Barcellini,University of Milan,Not Unity-Aligned,http://dx.doi.org/10.1371/journal.pone.0257046,2022-02-16,2024-03-01,Unverified,barcellini_does_2021,ITA
210902_Milan_UniversityofMilan_January2021_Age_3-5,210902_Milan_UniversityofMilan_January2021,Does school reopening affect SARS-CoV-2 seroprevalence among school-age children in Milan?,2021-09-02,Journal Article (Peer-Reviewed),Local,Prospective cohort,Italy,Lombardy,Milan,"Prospective multicenter SARS-CoV-2 serologic testing program across 15 different Institutes, representative of different territorial areas of Milan. Recruitment was organized through awareness campaigns at school and study participation was completely voluntary.
Subjects were eligible if aged from 3 to 18 years old.","""We excluded 214 (16.1%) patients, because for 13 (0.9%) of them the results were borderline/inconclusive and not repeated at, at least, one of the two timepoint, and for 201 (15.2%) the samples were insufficient/inadequate to perform the analysis.""",2021-01-15,2021-01-29,Students and Daycares,All,Children and Youth (0-17 years),3.0,5.0,Age,Age: 3-5 years,39,0.1282,,,,,,,,Convenience,GSP1/DELFIA1 anti SARS-CoV2 kit,PerkinElmer,Other,Dried Blood,IgG,Spike,Validated by manufacturers,0.96,1.0,['Moderate'],Unclear,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Lucia Barcellini,University of Milan,Not Unity-Aligned,http://dx.doi.org/10.1371/journal.pone.0257046,2022-02-16,2024-03-01,Unverified,barcellini_does_2021,ITA
210902_Milan_UniversityofMilan_September2020_Overall,210902_Milan_UniversityofMilan_September2020,Does school reopening affect SARS-CoV-2 seroprevalence among school-age children in Milan?,2021-09-02,Journal Article (Peer-Reviewed),Local,Prospective cohort,Italy,Lombardy,Milan,"Prospective multicenter SARS-CoV-2 serologic testing program across 15 different Institutes, representative of different territorial areas of Milan. Recruitment was organized through awareness campaigns at school and study participation was completely voluntary.
Subjects were eligible if aged from 3 to 18 years old.","""We excluded 214 (16.1%) patients, because for 13 (0.9%) of them the results were borderline/inconclusive and not repeated at, at least, one of the two timepoint, and for 201 (15.2%) the samples were insufficient/inadequate to perform the analysis.""",2020-09-07,2020-09-14,Students and Daycares,All,Children and Youth (0-17 years),3.0,18.0,Primary Estimate,,1109,0.027999999999999997,0.019,0.039,True,,,,True,Convenience,GSP1/DELFIA1 anti SARS-CoV2 kit,PerkinElmer,Other,Dried Blood,IgG,Spike,Validated by manufacturers,0.96,1.0,['Moderate'],Unclear,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Lucia Barcellini,University of Milan,Not Unity-Aligned,http://dx.doi.org/10.1371/journal.pone.0257046,2021-09-14,2024-03-01,Unverified,barcellini_does_2021,ITA
210902_Milan_UniversityofMilan_September2020_Age_6-10,210902_Milan_UniversityofMilan_September2020,Does school reopening affect SARS-CoV-2 seroprevalence among school-age children in Milan?,2021-09-02,Journal Article (Peer-Reviewed),Local,Prospective cohort,Italy,Lombardy,Milan,"Prospective multicenter SARS-CoV-2 serologic testing program across 15 different Institutes, representative of different territorial areas of Milan. Recruitment was organized through awareness campaigns at school and study participation was completely voluntary.
Subjects were eligible if aged from 3 to 18 years old.","""We excluded 214 (16.1%) patients, because for 13 (0.9%) of them the results were borderline/inconclusive and not repeated at, at least, one of the two timepoint, and for 201 (15.2%) the samples were insufficient/inadequate to perform the analysis.""",2020-09-07,2020-09-14,Students and Daycares,All,Children and Youth (0-17 years),6.0,10.0,Age,Age: 6-10 years,608,0.0329,,,,,,,,Convenience,GSP1/DELFIA1 anti SARS-CoV2 kit,PerkinElmer,Other,Dried Blood,IgG,Spike,Validated by manufacturers,0.96,1.0,['Moderate'],Unclear,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Lucia Barcellini,University of Milan,Not Unity-Aligned,http://dx.doi.org/10.1371/journal.pone.0257046,2022-02-16,2024-03-01,Unverified,barcellini_does_2021,ITA
210902_Milan_UniversityofMilan_September2020_Age_14-18,210902_Milan_UniversityofMilan_September2020,Does school reopening affect SARS-CoV-2 seroprevalence among school-age children in Milan?,2021-09-02,Journal Article (Peer-Reviewed),Local,Prospective cohort,Italy,Lombardy,Milan,"Prospective multicenter SARS-CoV-2 serologic testing program across 15 different Institutes, representative of different territorial areas of Milan. Recruitment was organized through awareness campaigns at school and study participation was completely voluntary.
Subjects were eligible if aged from 3 to 18 years old.","""We excluded 214 (16.1%) patients, because for 13 (0.9%) of them the results were borderline/inconclusive and not repeated at, at least, one of the two timepoint, and for 201 (15.2%) the samples were insufficient/inadequate to perform the analysis.""",2020-09-07,2020-09-14,Students and Daycares,All,Children and Youth (0-17 years),14.0,18.0,Age,Age: 14-18 years,133,0.0301,,,,,,,,Convenience,GSP1/DELFIA1 anti SARS-CoV2 kit,PerkinElmer,Other,Dried Blood,IgG,Spike,Validated by manufacturers,0.96,1.0,['Moderate'],Unclear,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Lucia Barcellini,University of Milan,Not Unity-Aligned,http://dx.doi.org/10.1371/journal.pone.0257046,2022-02-16,2024-03-01,Unverified,barcellini_does_2021,ITA
210902_Milan_UniversityofMilan_September2020_Age_3-5,210902_Milan_UniversityofMilan_September2020,Does school reopening affect SARS-CoV-2 seroprevalence among school-age children in Milan?,2021-09-02,Journal Article (Peer-Reviewed),Local,Prospective cohort,Italy,Lombardy,Milan,"Prospective multicenter SARS-CoV-2 serologic testing program across 15 different Institutes, representative of different territorial areas of Milan. Recruitment was organized through awareness campaigns at school and study participation was completely voluntary.
Subjects were eligible if aged from 3 to 18 years old.","""We excluded 214 (16.1%) patients, because for 13 (0.9%) of them the results were borderline/inconclusive and not repeated at, at least, one of the two timepoint, and for 201 (15.2%) the samples were insufficient/inadequate to perform the analysis.""",2020-09-07,2020-09-14,Students and Daycares,All,Children and Youth (0-17 years),3.0,5.0,Age,Age: 3-5 years,70,0.0143,,,,,,,,Convenience,GSP1/DELFIA1 anti SARS-CoV2 kit,PerkinElmer,Other,Dried Blood,IgG,Spike,Validated by manufacturers,0.96,1.0,['Moderate'],Unclear,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Lucia Barcellini,University of Milan,Not Unity-Aligned,http://dx.doi.org/10.1371/journal.pone.0257046,2022-02-16,2024-03-01,Unverified,barcellini_does_2021,ITA
210902_Milan_UniversityofMilan_September2020_Age_11-13,210902_Milan_UniversityofMilan_September2020,Does school reopening affect SARS-CoV-2 seroprevalence among school-age children in Milan?,2021-09-02,Journal Article (Peer-Reviewed),Local,Prospective cohort,Italy,Lombardy,Milan,"Prospective multicenter SARS-CoV-2 serologic testing program across 15 different Institutes, representative of different territorial areas of Milan. Recruitment was organized through awareness campaigns at school and study participation was completely voluntary.
Subjects were eligible if aged from 3 to 18 years old.","""We excluded 214 (16.1%) patients, because for 13 (0.9%) of them the results were borderline/inconclusive and not repeated at, at least, one of the two timepoint, and for 201 (15.2%) the samples were insufficient/inadequate to perform the analysis.""",2020-09-07,2020-09-14,Students and Daycares,All,Children and Youth (0-17 years),11.0,13.0,Age,Age: 11-13 years,298,0.0201,,,,,,,,Convenience,GSP1/DELFIA1 anti SARS-CoV2 kit,PerkinElmer,Other,Dried Blood,IgG,Spike,Validated by manufacturers,0.96,1.0,['Moderate'],Unclear,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Lucia Barcellini,University of Milan,Not Unity-Aligned,http://dx.doi.org/10.1371/journal.pone.0257046,2022-02-16,2024-03-01,Unverified,barcellini_does_2021,ITA
210908_Italy_UniversityofFlorence_Players,210908_Italy_UniversityofFlorence_Players,"Soccer in the time of COVID-19: One year report from an Italian top league club, March 2020 - February 2021",2021-09-08,Journal Article (Peer-Reviewed),Local,Prospective cohort,Italy,,,"""All team players and staff members were screened 72–96 h before the first training session by both SARS-CoV-2 RT-PCR on NPS and immunoglobulin G (IgG)/IgM serological testing""

All players and staff of ""an Italian top league soccer team""",,2020-05-14,2020-05-15,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,27,0.67,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,IgG,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Michele Spinicci,University of Florence,Not Unity-Aligned,http://dx.doi.org/10.1017/S0950268821002065,2021-09-27,2022-07-16,Unverified,spinicci_soccer_2021,ITA
210908_Italy_UniversityofFlorence_Staff,210908_Italy_UniversityofFlorence_Staff,"Soccer in the time of COVID-19: One year report from an Italian top league club, March 2020 - February 2021",2021-09-08,Journal Article (Peer-Reviewed),Local,Prospective cohort,Italy,,,"""All team players and staff members were screened 72–96 h before the first training session by both SARS-CoV-2 RT-PCR on NPS and immunoglobulin G (IgG)/IgM serological testing""

All players and staff of ""an Italian top league soccer team""",,2020-05-14,2020-05-15,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,26,0.65,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,IgG,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Michele Spinicci,University of Florence,Not Unity-Aligned,http://dx.doi.org/10.1017/S0950268821002065,2021-09-27,2022-07-16,Unverified,spinicci_soccer_2021,ITA
210909_Milan_FondazioneIRCCSCa’GrandaOspedaleMaggiorePoliclinico,210909_Milan_FondazioneIRCCSCa’GrandaOspedaleMaggiorePoliclinico,Anti-SARS-CoV-2 immunoglobulin profile in patients with celiac disease living in a high incidence area.,2021-09-09,Journal Article (Peer-Reviewed),Local,Prospective cohort,Italy,,Milan,"Celiac disease (CD) patients scheduled for an appointment during the March to May lockdown at the “Center for the Prevention and Diagnosis of Celiac Disease”, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico in Milan","NR
",2020-04-20,2020-06-30,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,109,0.18350000000000002,,,True,,,,True,Convenience,Author designed (Multiplex),,ELISA,Serum,"['IgA', 'IgG']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Luca Elli,Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico,Not Unity-Aligned,https://dx.doi.org/10.1016/j.dld.2021.08.027,2021-10-05,2022-07-16,Unverified,elli_anti-sars-cov-2_2021,ITA
210917_Gussago_FondazionePoliambulanzaHospital,210917_Gussago_FondazionePoliambulanzaHospital,Antibody response after bnt162b2 vaccination in healthcare workers previously exposed and not exposed to sars-cov-2,2021-09-17,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Italy,Brescia,Gussago ,"""healthcare workers older than 18 years of age, working in Fondazione Richiedei (Gussago, BS, Italy), who underwent SARS-CoV-2 testing before and after BNT162b2 vaccination between 1 January 2021 and 1 April 2021""","""Exclusion criteria were: pregnancy, age < 18 years, not having received
two doses of SARS-CoV-2 vaccine.""",2021-01-01,2021-04-01,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,337,0.37979999999999997,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,Whole Blood,TotalAntibody,Spike,Validated by developers,,,['Moderate'],,Unclear,Yes,Yes,,Unclear,Yes,No,,Marcello Salvaggio,Fondazione Poliambulanza Hospital,Not Unity-Aligned,http://dx.doi.org/10.3390/jcm10184204,2021-09-29,2022-07-16,Unverified,salvaggio_antibody_2021,ITA
210920_Genoa_UniversitàdegliStudidiGenova_overall,210920_Genoa_UniversitàdegliStudidiGenova,Incidence and Immunomic Features of Apyretic COVID-19 in Patients Affected by Solid Tumors: A Prospective Cohort Study,2021-09-20,Preprint,Local,Prospective cohort,Italy,Liguria,Genoa,"Inclusion criteria were: informed written consent; diagnosis of solid tumor in any stage, undergoing active treatment; outpatient access for an active, scheduled treatment to U01H and H04 units of the Cancer Center of Ospedale Policlinico San Martino; corporeal temperature < 37 °C when accessing the Cancer Center facility.","Exclusion criteria were: diagnosis of hematologic malignancy in the five years preceding the study; previously confirmed SARS-CoV-2 infection; CT elevation > 37 °C when accessing the Cancer Center facility; COVID-19 suggestive symptoms in the period following the first confirmed case in Italy, i.e. February 21st 2020. Suggestive COVID-19 symptoms included fatigue, dry cough, anorexia, myalgias, dyspnea, sputum production, fever (> 38 °C) and low-grade fever (37-38 °C), anosmia, dysgeusia, headache, sore throat, rhinorrhea, suggestive gastrointestinal symptoms, suggestive dermatologic findings.",2020-04-14,2020-08-23,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,27.0,90.0,Primary Estimate,,446,0.031400000000000004,,,True,,,,True,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Unclear,Yes,No,,Francesco Ravera,Università degli Studi di Genova,Not Unity-Aligned,https://www.researchsquare.com/article/rs-864803/v1,2021-09-28,2022-07-16,Unverified,ravera_incidence_2021,ITA
210929_CasolaDiNapoli_UniversityOfSalerno_Overall,210929_CasolaDiNapoli_UniversityOfSalerno,Associated screening for HCV and SARS-Cov2 infection in an urban area of Southern Italy: a cohort study.,2021-09-29,Journal Article (Peer-Reviewed),Local,Prospective cohort,Italy,Naples,City of Napoli,,Aged <6 years and resident abroad at the time. ,2020-06-25,2020-07-12,Household and community samples,All,Multiple groups,6.0,,Primary Estimate,,2738,0.013999999999999999,,,True,,,,True,Self-referral,VivaDiag COVID-19 IgM/IgG Rapid Test,VivaChek Biotech (Hangzhou) Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Yes,Carmine Coppola,University of Salerno,Not Unity-Aligned,https://dx.doi.org/10.1111/jvh.13623,2021-10-06,2024-03-01,Verified,coppola_associated_2021-1,ITA
210930_Novara_UniversityofPiemonteOrientale_nonpregnant_overall,210930_Novara_UniversityofPiemonteOrientale_nonpregnant,COVID-19 seroprevalence in a group of pregnant women compared to a group of non-pregnant women,2021-09-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,"Novara
",Novara City,"including 344 pregnant
women, above 18 weeks of gestation, aged between 18 and
40, attending the obstetrical clinic of the “Maggiore della
Carit
a” Hospital–Novara. The control group consisted of 588
non-pregnant women from the same area and the same age
group",,2020-04-27,2020-07-01,Household and community samples,Female,Adults (18-64 years),18.0,40.0,Primary Estimate,,588,0.128,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],,Unclear,No,No,,Unclear,Yes,No,,Viviana Piccirllo,University of Piemonte Orientale,Not Unity-Aligned,http://dx.doi.org/10.1080/14767058.2021.1962370,2021-11-24,2022-07-16,Unverified,piccirllo_covid-19_2021,ITA
210930_Novara_UniversityofPiemonteOrientale_pregnant_overall,210930_Novara_UniversityofPiemonteOrientale_pregnant,COVID-19 seroprevalence in a group of pregnant women compared to a group of non-pregnant women,2021-09-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Novara,Novara City,"including 344 pregnant
women, above 18 weeks of gestation, aged between 18 and
40, attending the obstetrical clinic of the “Maggiore della
Carit
a” Hospital–Novara",,2020-04-27,2020-07-01,Pregnant or parturient women,Female,Adults (18-64 years),18.0,40.0,Primary Estimate,,344,0.026000000000000002,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Viviana Piccirllo,University of Piemonte Orientale,Not Unity-Aligned,http://dx.doi.org/10.1080/14767058.2021.1962370,2021-11-24,2022-07-16,Unverified,piccirllo_covid-19_2021,ITA
211001_Verona_IRCCSSacroCuoreDonCalabriaHospital_HCW_overall,211001_Verona_IRCCSSacroCuoreDonCalabriaHospital_HCW,A Seroprevalence Study of Anti-SARS-CoV-2 Antibodies in Patients with Inflammatory Bowel Disease during the Second Wave of the COVID-19 Pandemic in Italy.,2021-10-01,Journal Article (Peer-Reviewed),Local,Prospective cohort,Italy,Verona,Negrar di Valpolicella,"The non-IBD control group consisted of healthcare professionals working at the Sacro Cuore-Don Calabria Hospital, who had given a blood sample for SARS-CoV-2 antibody testing in January 2021, prior to being vaccinated against COVID-19.",,2021-01-01,2021-01-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,2209,0.13,,,True,,,,True,Convenience,"LIAISON SARS-CoV-2 S1/S2 IgM,Liaison SARS-CoV-2 S1/S2 IgG",DiaSorin,,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Yes,Yes,No,,Mirko Di Ruscio,IRCCS Sacro Cuore Don Calabria Hospital,Not Unity-Aligned,https://dx.doi.org/10.3390/medicina57101048,2021-11-02,2024-03-01,Unverified,di_ruscio_seroprevalence_2021,ITA
211001_Verona_IRCCSSacroCuoreDonCalabriaHospital_IBDpatients,211001_Verona_IRCCSSacroCuoreDonCalabriaHospital_IBDpatients,A Seroprevalence Study of Anti-SARS-CoV-2 Antibodies in Patients with Inflammatory Bowel Disease during the Second Wave of the COVID-19 Pandemic in Italy.,2021-10-01,Journal Article (Peer-Reviewed),Local,Prospective cohort,Italy,Verona,Negrar di Valpolicella,"Eligible patients were those who consecutively attended our referral center between 7 December 2020 and 31 January 2021.
Men and women with a diagnosis of IBD established at least 6 months prior, and who were undergoing biological or conventional treatment were included in the study.",Treatment with thiopurines and a lack of informed consent constituted the exclusion criteria.,2020-12-07,2021-01-31,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),,,Primary Estimate,,386,0.10400000000000001,,,True,,,,True,Convenience,"LIAISON SARS-CoV-2 S1/S2 IgM,Liaison SARS-CoV-2 S1/S2 IgG",DiaSorin,,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,No,Yes,,Yes,Yes,No,,Mirko Di Ruscio,IRCCS Sacro Cuore Don Calabria Hospital,Not Unity-Aligned,https://dx.doi.org/10.3390/medicina57101048,2021-11-02,2024-03-01,Unverified,di_ruscio_seroprevalence_2021,ITA
211001_Italy_UniversityofUrbino,211001_Italy_UniversityofUrbino,Prevalence of sars-cov-2 infection in the workplace: results of a year of investigation in the marche nord companies,2021-10-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Marche,,Workers of 35 companies associated with Confindustria Pesaro Urbino.,,2020-05-15,2021-04-15,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,10000,0.0519,,,True,,,,True,Convenience,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Chiara Orlandi,University of Urbino,Not Unity-Aligned,http://dx.doi.org/10.23750/abm.v92iS6.12238,2021-10-26,2022-07-16,Unverified,orlandi_prevalence_2021,ITA
211004_Lombardy_UniversityOfPavia,211004_Lombardy_UniversityOfPavia,SARS-CoV-2 Serology In Patients On Biological Therapy or Apremilast For Psoriasis: A Study of 93 Patients in the Italian Red Zone.,2021-10-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Lombardy,,"All patients were over the age of 18, and under systemic therapy with biological drugs or apremilast for psoriasis.",,2020-06-15,2021-05-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,,Primary Estimate,,93,0.13,,,True,,,,True,Unclear,Not reported/ Unable to specify,,ELISA,,IgG,,,,,['High'],,Unclear,No,Yes,,Unclear,Yes,No,,Syed M A Ahmed,University Of Pavia,Not Unity-Aligned,https://dx.doi.org/10.1111/jdv.17721,2021-10-12,2022-07-16,Unverified,ahmedsmaSARSCoV2SerologyPatients2021,ITA
211006_Italy_IRCCSOrthopedicInstituteGaleazzi_IOG-CSS,211006_Italy_IRCCSOrthopedicInstituteGaleazzi_IOG-CSS,Quantitative serological evaluation as a valuable tool in the COVID-19 vaccination campaign.,2021-10-06,Journal Article (Peer-Reviewed),National,Prospective cohort,Italy,"Lombardy, Apulia","Milan, San Giovanni Rotondo","Healthcare professionals working at the IRCCS Orthopedic Institute Galeazzi (IOG) in Milan, Italy, or the IRCCS Casa Sollievo della Sofferenza Hospital (CSS), in San Giovanni Rotondo, Italy who received the Comirnaty vaccine between January 4th and February 12th, 2021.","""No exclusion criteria were applied.""",2021-01-04,2021-02-12,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,950,0.18420000000000003,,,True,,,,True,Unclear,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Serum,IgG,Spike,Validated by manufacturers,1.0,0.9990000000000001,['Moderate'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Davide Ferrari,IRCCS Orthopedic Institute Galeazzi,Not Unity-Aligned,https://dx.doi.org/10.1515/cclm-2021-0364,2021-10-14,2024-03-01,Unverified,ferrari_quantitative_2021,ITA
211006_Italy_IRCCSOrthopedicInstituteGaleazzi_OSR,211006_Italy_IRCCSOrthopedicInstituteGaleazzi_OSR,Quantitative serological evaluation as a valuable tool in the COVID-19 vaccination campaign.,2021-10-06,Journal Article (Peer-Reviewed),Local,Prospective cohort,Italy,Lombardy,Milan,"Healthcare professionals working at the IRCCS San Raffaele Hospital (OSR) in Milan, Italy who received the Comirnaty vaccine between January 4th and February 12th, 2021.","""No exclusion criteria were applied.""",2021-01-04,2021-02-12,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,3340,0.0913,,,True,,,,True,Unclear,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Unclear,Yes,Yes,,Yes,Yes,No,,Davide Ferrari,IRCCS Orthopedic Institute Galeazzi,Not Unity-Aligned,https://dx.doi.org/10.1515/cclm-2021-0364,2021-10-14,2024-03-01,Unverified,ferrari_quantitative_2021,ITA
211011_SanSiro_ASSTFatebenefratelliSacco_primary,211011_SanSiro_ASSTFatebenefratelliSacco,"Differences in the prevalence of sars-cov-2 infection and access to care between italians and non-italians in a social-housing neighbourhood of milan, italy",2021-10-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lombardy,Milan,The entire population currently living in the neighbourhood was eligible to participate in the study on a voluntary basis. Information about the study was publicised in e-mails and flyers displayed in communal areas and distributed by volunteers. Only subjects aged at least 18 years or older were included in the analysis.,,2020-12-23,2021-02-19,Household and community samples,All,Multiple groups,,,Primary Estimate,,2044,0.11199999999999999,,,True,,,,True,Self-referral,COVID-19 IgG,Technogenetics,Other,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Gabriele Pagani,ASST Fatebenefratelli Sacco,Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph182010621,2021-10-20,2022-07-16,Unverified,pagani_differences_2021,ITA
211011_Italy_AziendaUSLofModena_Overall,211011_Italy_AziendaUSLofModena,The big data analysis application to evaluate the clinical utility of igm anti sars-cov-2 determination: the experience of modena,2021-10-11,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Italy,,,All samples collected between 11 March and 30 September 2020,,2020-03-11,2020-09-30,Residual sera,All,Multiple groups,,,Primary Estimate,,42911,0.055,,,True,,,,True,Convenience,"Author designed (LFIA),Author designed (CLIA)",,Multiple Types,Serum,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Valentina Pecoraro,University-Hospital of Padova,Not Unity-Aligned,https://doi.org/10.1515/cclm-2021-1071,2022-03-15,2022-07-16,Unverified,pecoraro_big_2021,ITA
211014_Milan_UniversitàdegliStudidiMilano_Primary,211014_Milan_UniversitàdegliStudidiMilano,Trends and risk factors of SARS-CoV-2 infection in asymptomatic blood donors.,2021-10-14,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Italy,,Milan,"Participants were asymptomatic repeat blood donors (age 18–70 years), enrolled within the prospective section secondphase of the Fondazione COVID-19 Donors Study (CoDS), presenting for blood donation at the Milan Blood Center","To qualify for a blood donation the candidates should have not been infected by SARS-CoV-2, have symptoms possibly related to infection, or have been in close/unprotected contact with infected individuals in the preceding 14 days. The minimum interdonation interval was 12 weeks.",2020-07-01,2021-02-23,Blood donors,All,Multiple groups,18.0,70.0,Primary Estimate,,10680,0.059000000000000004,,,True,,,,True,Sequential,"PRIMA COVID-19 IgG/IgM Rapid Test,Liaison SARS-CoV-2 S1/S2 IgG","PRIMA Lab S.A.,DiaSorin",Multiple Types,Multiple Types,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],No,No,Yes,Yes,No,No,Yes,No,No,Luca Valenti,Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milano,Not Unity-Aligned,https://dx.doi.org/10.1111/trf.16693,2021-10-20,2024-03-01,Verified,valenti_trends_2021,ITA
211025_Piacenza_1AUSLPiacenza,211025_Piacenza_1AUSLPiacenza,ELBA03 Efficacy and Safety of COVID-19 Vaccine in Cancer Patients,2021-10-25,Presentation or Conference,Local,Cross-sectional survey ,Italy,Emilia-Romagna,Piacenza,cancer patients with solid tumors who underwent a program of COVID-19 vaccinations at the Azienda Unita Sanitaria Locale di Piacenza,,2021-03-20,2021-05-29,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,28.0,86.0,Primary Estimate,,293,0.0717,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,Serum,IgG,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Biasini C,Azienda Unita Sanitaria Locale di Piacenza,Not Unity-Aligned,http://dx.doi.org/10.1177/03008916211041664,2021-12-15,2022-07-16,Unverified,biasini_elba03_2021,ITA
211027_SicilianRegion_UniversityOfCatania_Primary,211027_SicilianRegion_UniversityOfCatania,How to Prevent SARS-CoV-2 Transmission in the Agri-Food Industry during the First Pandemic Wave: Effects on Seroprevalence,2021-10-27,Journal Article (Peer-Reviewed),Local,Prospective cohort,Italy,Sicilian,,"Given the purpose of the study, only one inclusion criterion was used: performing work in the business, during the study period.","workers who performed work remotely, even partially, were excluded from the study.",2020-04-01,2020-06-30,Non-essential workers and unemployed persons,All,Multiple groups,,,Primary Estimate,,328,0.0003,,,True,,,,True,Entire sample,Not reported/ Unable to specify,,,Whole Blood,"['IgG', 'IgM']",,,,,['High'],,Yes,No,Yes,,Unclear,Yes,No,,Ermanno Vitale,University of Catania ,Not Unity-Aligned,https://www.mdpi.com/2076-3417/11/21/10051/htm,2021-11-30,2022-07-16,Unverified,vitale_how_2021,ITA
211028_Italy_FondazioneIRCCS_STest,211028_Italy_FondazioneIRCCS,"Kidney transplant rejection rate in screened patients for anti-SARS-CoV-2 antibodies, during COVID-19 pandemic in Northern Italy.",2021-10-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Pavia,kidney transplant recipients,,2020-06-15,2020-12-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,201,0.14400000000000002,,,True,,,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],,No,No,No,,Yes,Yes,Yes,,Anna Lia Asti,IRCCS San Matteo Hospital ,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/34783351/,2021-11-22,2024-03-01,Unverified,asti_kidney_2021,ITA
211028_UniversityHospitalofTrieste_University of Trieste,211028_UniversityHospitalofTrieste_University of Trieste,Low sensitivity of rapid tests detecting anti-CoV-2 IgG and IgM in health care workers' serum for COVID-19 screening.,2021-10-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Northeast Italy,Trieste,Health care workers followed by the  Unit of  Occupational  Medicine at  University Hospital of Trieste (NE-Italy) because of symptoms suggesting  COVID-19    infection or ex-posed to  COVID-19  patients without suitable personal protective equipment for more than 15 minutes or for any time during aerosol generated procedures (20).,,2020-05-15,2020-09-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,389,0.34700000000000003,,,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Francesca Filon,University of Trieste,Not Unity-Aligned,https://dx.doi.org/10.23749/mdl.v112i5.11798,2021-11-09,2024-03-01,Unverified,larese_filon_low_2021,ITA
211106_Milan_PoliclinicoSMatteoUniversity_Overall,211106_Lombardy_PoliclinicoSMatteoUniversity,The True Prevalence of SARS-CoV-2 Infection in an Italian Cohort of Patients with Inflammatory Arthritis: A Seroepidemiological Study,2021-11-06,Presentation or Conference,Regional,Cross-sectional survey ,Italy,Lombardy,,"Cohort of patients with rheumatoid arthritis or spondyloarthritis treated with biologic (b-) or targeted synthetic (ts-) DMARDs, living in a COVID-19 high-endemic area (Lombardy, Italy).

""Methods: A seroprevalence cross-sectional study was conducted in the period between 4th May and 16th June 2020, including consecutive patients with confirmed RA or SpA treated with b- or tsDMARDs.""",,2020-05-04,2020-06-16,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,IgG OR IgM OR IgA,300,0.18670000000000003,0.146,0.23399999999999999,True,,,,True,Sequential,Not reported/ Unable to specify,,ELISA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Gabriella Maioli,Policlinico S. Matteo University,Not Unity-Aligned,https://acrabstracts.org/abstract/the-true-prevalence-of-sars-cov-2-infection-in-an-italian-cohort-of-patients-with-inflammatory-arthritis-a-seroepidemiological-study/,2022-03-09,2022-07-16,Unverified,gabriella_maioli_true_2021,ITA
211106_Milan_PoliclinicoSMatteoUniversity_Age65+,211106_Lombardy_PoliclinicoSMatteoUniversity,The True Prevalence of SARS-CoV-2 Infection in an Italian Cohort of Patients with Inflammatory Arthritis: A Seroepidemiological Study,2021-11-06,Presentation or Conference,Regional,Cross-sectional survey ,Italy,Lombardy,,"Cohort of patients with rheumatoid arthritis or spondyloarthritis treated with biologic (b-) or targeted synthetic (ts-) DMARDs, living in a COVID-19 high-endemic area (Lombardy, Italy).

""Methods: A seroprevalence cross-sectional study was conducted in the period between 4th May and 16th June 2020, including consecutive patients with confirmed RA or SpA treated with b- or tsDMARDs.""",,2020-05-04,2020-06-16,Patients seeking care for non-COVID-19 reasons,All,Seniors (65+ years),65.0,,Age,65+,71,0.08449999999999999,,,,,,,,Sequential,Not reported/ Unable to specify,,ELISA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Gabriella Maioli,Policlinico S. Matteo University,Not Unity-Aligned,https://acrabstracts.org/abstract/the-true-prevalence-of-sars-cov-2-infection-in-an-italian-cohort-of-patients-with-inflammatory-arthritis-a-seroepidemiological-study/,2022-03-09,2022-07-16,Unverified,gabriella_maioli_true_2021,ITA
211106_Milan_PoliclinicoSMatteoUniversity_Age<65,211106_Lombardy_PoliclinicoSMatteoUniversity,The True Prevalence of SARS-CoV-2 Infection in an Italian Cohort of Patients with Inflammatory Arthritis: A Seroepidemiological Study,2021-11-06,Presentation or Conference,Regional,Cross-sectional survey ,Italy,Lombardy,,"Cohort of patients with rheumatoid arthritis or spondyloarthritis treated with biologic (b-) or targeted synthetic (ts-) DMARDs, living in a COVID-19 high-endemic area (Lombardy, Italy).

""Methods: A seroprevalence cross-sectional study was conducted in the period between 4th May and 16th June 2020, including consecutive patients with confirmed RA or SpA treated with b- or tsDMARDs.""",,2020-05-04,2020-06-16,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),,64.0,Age,<65,229,0.0524,,,,,,,,Sequential,Not reported/ Unable to specify,,ELISA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Gabriella Maioli,Policlinico S. Matteo University,Not Unity-Aligned,https://acrabstracts.org/abstract/the-true-prevalence-of-sars-cov-2-infection-in-an-italian-cohort-of-patients-with-inflammatory-arthritis-a-seroepidemiological-study/,2022-03-09,2022-07-16,Unverified,gabriella_maioli_true_2021,ITA
211110_Modena_UniversityofModenaandReggioEmilia,211110_Modena_UniversityofModenaandReggioEmilia,eP034 Usefulness of serological antibodies assays to better evaluate the prevalence of SARS-CoV-2 infection in youths with type 1 diabetes,2021-11-10,Presentation or Conference,Local,Cross-sectional survey ,Italy,,Modena,children and adolescents with T1D,,2021-01-15,2021-06-15,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),,,Primary Estimate,,85,0.1529,,,True,,,,True,Unclear,Author designed (CLIA),,CLIA,Serum,IgG,,,,,['High'],,Unclear,No,No,,Unclear,Yes,No,,B Predieri,University of Modena and Reggio Emilia,Not Unity-Aligned,http://dx.doi.org/10.1111/pedi.13269,2021-12-14,2022-07-16,Unverified,predieri_ep034_2021,ITA
211111_Verona_UniversityofVerona,211111_Verona_UniversityofVerona,Inflammatory peripheral neuropathies during the covid-19 pandemic: Is there a relation?,2021-11-11,Presentation or Conference,Local,Retrospective cohort,Italy,Veneto,Verona,"We retrospectively identified patients with acute inflammatory PNS conditions referred to our laboratory for anti-ganglioside, anti-MAG and/or anti-onconeural antibodies testing during the SARS-CoV-2 pandemic (January 1st to December 31st, 2020).",,2020-01-01,2020-12-31,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,49,0.184,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgA,Anti-SARS-CoV-2 ELISA IgG,Liaison SARS-CoV-2 S1/S2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test","EUROIMMUN,DiaSorin,Beckman Coulter",Multiple Types,Serum,"['IgA', 'IgG']",Spike,,,,['High'],,No,No,No,,Unclear,Yes,No,,M Trentinaglia,University of Verona,Not Unity-Aligned,http://dx.doi.org/10.1111/jns.12472,2021-12-15,2024-03-01,Unverified,trentinaglia_inflammatory_2021,ITA
211115_Foggia_UniversityHospital“Ospedali Riuniti”Foggia_general_primary,211115_Foggia_UniversityHospitalOspedali RiunitiFoggia_general,Increased SARS-CoV-2 seroprevalence in healthy blood donors after the second pandemic wave in South-Eastern Italy: evidence for asymptomatic young donors as potential virus spreaders.,2021-11-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Foggia,"blood donors visiting the Transfusion Centre at the “Riuniti” University
Hospital, Foggia, Italy, for blood donation were enrolled in the study.","Exclusion criteria were symptoms, signs of or laboratory analysis indicating any active infection or medical conditions, reported risk factors for parenterally acquired infections, chronic degenerative conditions, diagnosis of cancer, or high risk of cardiovascular events. ",2020-05-15,2021-03-15,Blood donors,All,Multiple groups,18.0,,Primary Estimate,,8183,0.063,,,True,,,,True,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total",Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgG', 'TotalAntibody']",,,,,['Moderate'],Unclear,No,Yes,Yes,Yes,Yes,Yes,No,,Francescopaolo Antonucci,University Hospital “Ospedali Riuniti” Foggia,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.2003856,2021-11-25,2024-03-01,Verified,antonucci_increased_2021,ITA
211115_Foggia_UniversityHospital“Ospedali Riuniti”Foggia_dec2020,211115_Foggia_UniversityHospitalOspedali RiunitiFoggia_general,Increased SARS-CoV-2 seroprevalence in healthy blood donors after the second pandemic wave in South-Eastern Italy: evidence for asymptomatic young donors as potential virus spreaders.,2021-11-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Foggia,"blood donors visiting the Transfusion Centre at the “Riuniti” University
Hospital, Foggia, Italy, for blood donation were enrolled in the study.","Exclusion criteria were symptoms, signs of or laboratory analysis indicating any active infection or medical conditions, reported risk factors for parenterally acquired infections, chronic degenerative conditions, diagnosis of cancer, or high risk of cardiovascular events. ",2020-12-01,2020-12-31,Blood donors,All,Multiple groups,18.0,,Time frame,,826,0.109,,,,,,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total",Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgG', 'TotalAntibody']",,,,,['Moderate'],Unclear,No,Yes,Yes,Yes,Yes,Yes,No,,Francescopaolo Antonucci,University Hospital “Ospedali Riuniti” Foggia,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.2003856,2021-11-25,2024-03-01,Verified,antonucci_increased_2021,ITA
211115_Foggia_UniversityHospital“Ospedali Riuniti”Foggia_age36to45,211115_Foggia_UniversityHospitalOspedali RiunitiFoggia_general,Increased SARS-CoV-2 seroprevalence in healthy blood donors after the second pandemic wave in South-Eastern Italy: evidence for asymptomatic young donors as potential virus spreaders.,2021-11-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Foggia,"blood donors visiting the Transfusion Centre at the “Riuniti” University
Hospital, Foggia, Italy, for blood donation were enrolled in the study.","Exclusion criteria were symptoms, signs of or laboratory analysis indicating any active infection or medical conditions, reported risk factors for parenterally acquired infections, chronic degenerative conditions, diagnosis of cancer, or high risk of cardiovascular events. ",2020-05-15,2021-03-15,Blood donors,All,Adults (18-64 years),36.0,45.0,Age,,1942,0.06333676622,,,,,,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total",Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgG', 'TotalAntibody']",,,,,['Moderate'],Unclear,No,Yes,Yes,Yes,Yes,Yes,No,,Francescopaolo Antonucci,University Hospital “Ospedali Riuniti” Foggia,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.2003856,2022-01-21,2024-03-01,Verified,antonucci_increased_2021,ITA
211115_Foggia_UniversityHospital“Ospedali Riuniti”Foggia_oct2020,211115_Foggia_UniversityHospitalOspedali RiunitiFoggia_general,Increased SARS-CoV-2 seroprevalence in healthy blood donors after the second pandemic wave in South-Eastern Italy: evidence for asymptomatic young donors as potential virus spreaders.,2021-11-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Foggia,"blood donors visiting the Transfusion Centre at the “Riuniti” University
Hospital, Foggia, Italy, for blood donation were enrolled in the study.","Exclusion criteria were symptoms, signs of or laboratory analysis indicating any active infection or medical conditions, reported risk factors for parenterally acquired infections, chronic degenerative conditions, diagnosis of cancer, or high risk of cardiovascular events. ",2020-10-01,2020-10-31,Blood donors,All,Multiple groups,18.0,,Time frame,,835,0.016,,,,,,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total",Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgG', 'TotalAntibody']",,,,,['Moderate'],Unclear,No,Yes,Yes,Yes,Yes,Yes,No,,Francescopaolo Antonucci,University Hospital “Ospedali Riuniti” Foggia,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.2003856,2021-11-25,2024-03-01,Verified,antonucci_increased_2021,ITA
211115_Foggia_UniversityHospital“Ospedali Riuniti”Foggia_May2020,211115_Foggia_UniversityHospitalOspedali RiunitiFoggia_general,Increased SARS-CoV-2 seroprevalence in healthy blood donors after the second pandemic wave in South-Eastern Italy: evidence for asymptomatic young donors as potential virus spreaders.,2021-11-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Foggia,"blood donors visiting the Transfusion Centre at the “Riuniti” University
Hospital, Foggia, Italy, for blood donation were enrolled in the study.","Exclusion criteria were symptoms, signs of or laboratory analysis indicating any active infection or medical conditions, reported risk factors for parenterally acquired infections, chronic degenerative conditions, diagnosis of cancer, or high risk of cardiovascular events. ",2020-05-15,2020-05-31,Blood donors,All,Multiple groups,18.0,,Time frame,,883,0.01,,,,,,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total",Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgG', 'TotalAntibody']",,,,,['Moderate'],Unclear,No,Yes,Yes,Yes,Yes,Yes,No,,Francescopaolo Antonucci,University Hospital “Ospedali Riuniti” Foggia,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.2003856,2021-11-25,2024-03-01,Verified,antonucci_increased_2021,ITA
211115_Foggia_UniversityHospital“Ospedali Riuniti”Foggia_sept2020,211115_Foggia_UniversityHospitalOspedali RiunitiFoggia_general,Increased SARS-CoV-2 seroprevalence in healthy blood donors after the second pandemic wave in South-Eastern Italy: evidence for asymptomatic young donors as potential virus spreaders.,2021-11-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Foggia,"blood donors visiting the Transfusion Centre at the “Riuniti” University
Hospital, Foggia, Italy, for blood donation were enrolled in the study.","Exclusion criteria were symptoms, signs of or laboratory analysis indicating any active infection or medical conditions, reported risk factors for parenterally acquired infections, chronic degenerative conditions, diagnosis of cancer, or high risk of cardiovascular events. ",2020-09-01,2020-09-30,Blood donors,All,Multiple groups,18.0,,Time frame,,901,0.013000000000000001,,,,,,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total",Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgG', 'TotalAntibody']",,,,,['Moderate'],Unclear,No,Yes,Yes,Yes,Yes,Yes,No,,Francescopaolo Antonucci,University Hospital “Ospedali Riuniti” Foggia,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.2003856,2021-11-25,2024-03-01,Verified,antonucci_increased_2021,ITA
211115_Foggia_UniversityHospital“Ospedali Riuniti”Foggia_july2020,211115_Foggia_UniversityHospitalOspedali RiunitiFoggia_general,Increased SARS-CoV-2 seroprevalence in healthy blood donors after the second pandemic wave in South-Eastern Italy: evidence for asymptomatic young donors as potential virus spreaders.,2021-11-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Foggia,"blood donors visiting the Transfusion Centre at the “Riuniti” University
Hospital, Foggia, Italy, for blood donation were enrolled in the study.","Exclusion criteria were symptoms, signs of or laboratory analysis indicating any active infection or medical conditions, reported risk factors for parenterally acquired infections, chronic degenerative conditions, diagnosis of cancer, or high risk of cardiovascular events. ",2020-07-01,2020-07-31,Blood donors,All,Multiple groups,18.0,,Time frame,,645,0.016,,,,,,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total",Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgG', 'TotalAntibody']",,,,,['Moderate'],Unclear,No,Yes,Yes,Yes,Yes,Yes,No,,Francescopaolo Antonucci,University Hospital “Ospedali Riuniti” Foggia,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.2003856,2021-11-25,2024-03-01,Verified,antonucci_increased_2021,ITA
211115_Foggia_UniversityHospital“Ospedali Riuniti”Foggia_female,211115_Foggia_UniversityHospitalOspedali RiunitiFoggia_general,Increased SARS-CoV-2 seroprevalence in healthy blood donors after the second pandemic wave in South-Eastern Italy: evidence for asymptomatic young donors as potential virus spreaders.,2021-11-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Foggia,"blood donors visiting the Transfusion Centre at the “Riuniti” University
Hospital, Foggia, Italy, for blood donation were enrolled in the study.","Exclusion criteria were symptoms, signs of or laboratory analysis indicating any active infection or medical conditions, reported risk factors for parenterally acquired infections, chronic degenerative conditions, diagnosis of cancer, or high risk of cardiovascular events. ",2020-05-15,2021-03-15,Blood donors,Female,Multiple groups,18.0,,Sex/Gender,,2047,0.06301905227,,,,,,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total",Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgG', 'TotalAntibody']",,,,,['Moderate'],Unclear,No,Yes,Yes,Yes,Yes,Yes,No,,Francescopaolo Antonucci,University Hospital “Ospedali Riuniti” Foggia,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.2003856,2022-01-21,2024-03-01,Verified,antonucci_increased_2021,ITA
211115_Foggia_UniversityHospital“Ospedali Riuniti”Foggia_age46to55,211115_Foggia_UniversityHospitalOspedali RiunitiFoggia_general,Increased SARS-CoV-2 seroprevalence in healthy blood donors after the second pandemic wave in South-Eastern Italy: evidence for asymptomatic young donors as potential virus spreaders.,2021-11-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Foggia,"blood donors visiting the Transfusion Centre at the “Riuniti” University
Hospital, Foggia, Italy, for blood donation were enrolled in the study.","Exclusion criteria were symptoms, signs of or laboratory analysis indicating any active infection or medical conditions, reported risk factors for parenterally acquired infections, chronic degenerative conditions, diagnosis of cancer, or high risk of cardiovascular events. ",2020-05-15,2021-03-15,Blood donors,All,Adults (18-64 years),46.0,55.0,Age,,2391,0.0547887913,,,,,,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total",Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgG', 'TotalAntibody']",,,,,['Moderate'],Unclear,No,Yes,Yes,Yes,Yes,Yes,No,,Francescopaolo Antonucci,University Hospital “Ospedali Riuniti” Foggia,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.2003856,2022-01-21,2024-03-01,Verified,antonucci_increased_2021,ITA
211115_Foggia_UniversityHospital“Ospedali Riuniti”Foggia_age18to25,211115_Foggia_UniversityHospitalOspedali RiunitiFoggia_general,Increased SARS-CoV-2 seroprevalence in healthy blood donors after the second pandemic wave in South-Eastern Italy: evidence for asymptomatic young donors as potential virus spreaders.,2021-11-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Foggia,"blood donors visiting the Transfusion Centre at the “Riuniti” University
Hospital, Foggia, Italy, for blood donation were enrolled in the study.","Exclusion criteria were symptoms, signs of or laboratory analysis indicating any active infection or medical conditions, reported risk factors for parenterally acquired infections, chronic degenerative conditions, diagnosis of cancer, or high risk of cardiovascular events. ",2020-05-15,2021-03-15,Blood donors,All,Adults (18-64 years),18.0,25.0,Age,,1030,0.07378640777,,,,,,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total",Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgG', 'TotalAntibody']",,,,,['Moderate'],Unclear,No,Yes,Yes,Yes,Yes,Yes,No,,Francescopaolo Antonucci,University Hospital “Ospedali Riuniti” Foggia,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.2003856,2022-01-21,2024-03-01,Verified,antonucci_increased_2021,ITA
211115_Foggia_UniversityHospital“Ospedali Riuniti”Foggia_august2020,211115_Foggia_UniversityHospitalOspedali RiunitiFoggia_general,Increased SARS-CoV-2 seroprevalence in healthy blood donors after the second pandemic wave in South-Eastern Italy: evidence for asymptomatic young donors as potential virus spreaders.,2021-11-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Foggia,"blood donors visiting the Transfusion Centre at the “Riuniti” University
Hospital, Foggia, Italy, for blood donation were enrolled in the study.","Exclusion criteria were symptoms, signs of or laboratory analysis indicating any active infection or medical conditions, reported risk factors for parenterally acquired infections, chronic degenerative conditions, diagnosis of cancer, or high risk of cardiovascular events. ",2020-08-01,2020-08-31,Blood donors,All,Multiple groups,18.0,,Time frame,,667,0.012,,,,,,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total",Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgG', 'TotalAntibody']",,,,,['Moderate'],Unclear,No,Yes,Yes,Yes,Yes,Yes,No,,Francescopaolo Antonucci,University Hospital “Ospedali Riuniti” Foggia,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.2003856,2021-11-25,2024-03-01,Verified,antonucci_increased_2021,ITA
211115_Foggia_UniversityHospital“Ospedali Riuniti”Foggia_age26to35,211115_Foggia_UniversityHospitalOspedali RiunitiFoggia_general,Increased SARS-CoV-2 seroprevalence in healthy blood donors after the second pandemic wave in South-Eastern Italy: evidence for asymptomatic young donors as potential virus spreaders.,2021-11-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Foggia,"blood donors visiting the Transfusion Centre at the “Riuniti” University
Hospital, Foggia, Italy, for blood donation were enrolled in the study.","Exclusion criteria were symptoms, signs of or laboratory analysis indicating any active infection or medical conditions, reported risk factors for parenterally acquired infections, chronic degenerative conditions, diagnosis of cancer, or high risk of cardiovascular events. ",2020-05-15,2021-03-15,Blood donors,All,Adults (18-64 years),26.0,35.0,Age,,1628,0.06756756757,,,,,,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total",Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgG', 'TotalAntibody']",,,,,['Moderate'],Unclear,No,Yes,Yes,Yes,Yes,Yes,No,,Francescopaolo Antonucci,University Hospital “Ospedali Riuniti” Foggia,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.2003856,2022-01-21,2024-03-01,Verified,antonucci_increased_2021,ITA
211115_Foggia_UniversityHospital“Ospedali Riuniti”Foggia_jan2021,211115_Foggia_UniversityHospitalOspedali RiunitiFoggia_general,Increased SARS-CoV-2 seroprevalence in healthy blood donors after the second pandemic wave in South-Eastern Italy: evidence for asymptomatic young donors as potential virus spreaders.,2021-11-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Foggia,"blood donors visiting the Transfusion Centre at the “Riuniti” University
Hospital, Foggia, Italy, for blood donation were enrolled in the study.","Exclusion criteria were symptoms, signs of or laboratory analysis indicating any active infection or medical conditions, reported risk factors for parenterally acquired infections, chronic degenerative conditions, diagnosis of cancer, or high risk of cardiovascular events. ",2021-01-01,2021-01-31,Blood donors,All,Multiple groups,18.0,,Time frame,,796,0.107,,,,,,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total",Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgG', 'TotalAntibody']",,,,,['Moderate'],Unclear,No,Yes,Yes,Yes,Yes,Yes,No,,Francescopaolo Antonucci,University Hospital “Ospedali Riuniti” Foggia,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.2003856,2021-11-25,2024-03-01,Verified,antonucci_increased_2021,ITA
211115_Foggia_UniversityHospital“Ospedali Riuniti”Foggia_march2021,211115_Foggia_UniversityHospitalOspedali RiunitiFoggia_general,Increased SARS-CoV-2 seroprevalence in healthy blood donors after the second pandemic wave in South-Eastern Italy: evidence for asymptomatic young donors as potential virus spreaders.,2021-11-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Foggia,"blood donors visiting the Transfusion Centre at the “Riuniti” University
Hospital, Foggia, Italy, for blood donation were enrolled in the study.","Exclusion criteria were symptoms, signs of or laboratory analysis indicating any active infection or medical conditions, reported risk factors for parenterally acquired infections, chronic degenerative conditions, diagnosis of cancer, or high risk of cardiovascular events. ",2021-03-01,2021-03-15,Blood donors,All,Multiple groups,18.0,,Time frame,,484,0.188,,,,,,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total",Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgG', 'TotalAntibody']",,,,,['Moderate'],Unclear,No,Yes,Yes,Yes,Yes,Yes,No,,Francescopaolo Antonucci,University Hospital “Ospedali Riuniti” Foggia,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.2003856,2021-11-25,2024-03-01,Verified,antonucci_increased_2021,ITA
211115_Foggia_UniversityHospital“Ospedali Riuniti”Foggia_male,211115_Foggia_UniversityHospitalOspedali RiunitiFoggia_general,Increased SARS-CoV-2 seroprevalence in healthy blood donors after the second pandemic wave in South-Eastern Italy: evidence for asymptomatic young donors as potential virus spreaders.,2021-11-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Foggia,"blood donors visiting the Transfusion Centre at the “Riuniti” University
Hospital, Foggia, Italy, for blood donation were enrolled in the study.","Exclusion criteria were symptoms, signs of or laboratory analysis indicating any active infection or medical conditions, reported risk factors for parenterally acquired infections, chronic degenerative conditions, diagnosis of cancer, or high risk of cardiovascular events. ",2020-05-15,2021-03-15,Blood donors,Male,Multiple groups,18.0,,Sex/Gender,,6136,0.06307040417,,,,,,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total",Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgG', 'TotalAntibody']",,,,,['Moderate'],Unclear,No,Yes,Yes,Yes,Yes,Yes,No,,Francescopaolo Antonucci,University Hospital “Ospedali Riuniti” Foggia,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.2003856,2022-01-21,2024-03-01,Verified,antonucci_increased_2021,ITA
211115_Foggia_UniversityHospital“Ospedali Riuniti”Foggia_ageover65,211115_Foggia_UniversityHospitalOspedali RiunitiFoggia_general,Increased SARS-CoV-2 seroprevalence in healthy blood donors after the second pandemic wave in South-Eastern Italy: evidence for asymptomatic young donors as potential virus spreaders.,2021-11-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Foggia,"blood donors visiting the Transfusion Centre at the “Riuniti” University
Hospital, Foggia, Italy, for blood donation were enrolled in the study.","Exclusion criteria were symptoms, signs of or laboratory analysis indicating any active infection or medical conditions, reported risk factors for parenterally acquired infections, chronic degenerative conditions, diagnosis of cancer, or high risk of cardiovascular events. ",2020-05-15,2021-03-15,Blood donors,All,Seniors (65+ years),66.0,,Age,,73,0.013698630140000001,,,,,,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total",Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgG', 'TotalAntibody']",,,,,['Moderate'],Unclear,No,Yes,Yes,Yes,Yes,Yes,No,,Francescopaolo Antonucci,University Hospital “Ospedali Riuniti” Foggia,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.2003856,2022-01-21,2024-03-01,Verified,antonucci_increased_2021,ITA
211115_Foggia_UniversityHospital“Ospedali Riuniti”Foggia_june2020,211115_Foggia_UniversityHospitalOspedali RiunitiFoggia_general,Increased SARS-CoV-2 seroprevalence in healthy blood donors after the second pandemic wave in South-Eastern Italy: evidence for asymptomatic young donors as potential virus spreaders.,2021-11-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Foggia,"blood donors visiting the Transfusion Centre at the “Riuniti” University
Hospital, Foggia, Italy, for blood donation were enrolled in the study.","Exclusion criteria were symptoms, signs of or laboratory analysis indicating any active infection or medical conditions, reported risk factors for parenterally acquired infections, chronic degenerative conditions, diagnosis of cancer, or high risk of cardiovascular events. ",2020-06-01,2020-06-30,Blood donors,All,Multiple groups,18.0,,Time frame,,789,0.013999999999999999,,,,,,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total",Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgG', 'TotalAntibody']",,,,,['Moderate'],Unclear,No,Yes,Yes,Yes,Yes,Yes,No,,Francescopaolo Antonucci,University Hospital “Ospedali Riuniti” Foggia,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.2003856,2021-11-25,2024-03-01,Verified,antonucci_increased_2021,ITA
211115_Foggia_UniversityHospital“Ospedali Riuniti”Foggia_age56to65,211115_Foggia_UniversityHospitalOspedali RiunitiFoggia_general,Increased SARS-CoV-2 seroprevalence in healthy blood donors after the second pandemic wave in South-Eastern Italy: evidence for asymptomatic young donors as potential virus spreaders.,2021-11-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Foggia,"blood donors visiting the Transfusion Centre at the “Riuniti” University
Hospital, Foggia, Italy, for blood donation were enrolled in the study.","Exclusion criteria were symptoms, signs of or laboratory analysis indicating any active infection or medical conditions, reported risk factors for parenterally acquired infections, chronic degenerative conditions, diagnosis of cancer, or high risk of cardiovascular events. ",2020-05-15,2021-03-15,Blood donors,All,Adults (18-64 years),56.0,65.0,Age,,1119,0.06702412869,,,,,,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total",Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgG', 'TotalAntibody']",,,,,['Moderate'],Unclear,No,Yes,Yes,Yes,Yes,Yes,No,,Francescopaolo Antonucci,University Hospital “Ospedali Riuniti” Foggia,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.2003856,2022-01-21,2024-03-01,Verified,antonucci_increased_2021,ITA
211115_Foggia_UniversityHospital“Ospedali Riuniti”Foggia_nov2020,211115_Foggia_UniversityHospitalOspedali RiunitiFoggia_general,Increased SARS-CoV-2 seroprevalence in healthy blood donors after the second pandemic wave in South-Eastern Italy: evidence for asymptomatic young donors as potential virus spreaders.,2021-11-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Foggia,"blood donors visiting the Transfusion Centre at the “Riuniti” University
Hospital, Foggia, Italy, for blood donation were enrolled in the study.","Exclusion criteria were symptoms, signs of or laboratory analysis indicating any active infection or medical conditions, reported risk factors for parenterally acquired infections, chronic degenerative conditions, diagnosis of cancer, or high risk of cardiovascular events. ",2020-11-01,2020-11-30,Blood donors,All,Multiple groups,18.0,,Time frame,,560,0.068,,,,,,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total",Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgG', 'TotalAntibody']",,,,,['Moderate'],Unclear,No,Yes,Yes,Yes,Yes,Yes,No,,Francescopaolo Antonucci,University Hospital “Ospedali Riuniti” Foggia,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.2003856,2021-11-25,2024-03-01,Verified,antonucci_increased_2021,ITA
211115_Foggia_UniversityHospital“Ospedali Riuniti”Foggia_feb2021,211115_Foggia_UniversityHospitalOspedali RiunitiFoggia_general,Increased SARS-CoV-2 seroprevalence in healthy blood donors after the second pandemic wave in South-Eastern Italy: evidence for asymptomatic young donors as potential virus spreaders.,2021-11-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Foggia,"blood donors visiting the Transfusion Centre at the “Riuniti” University
Hospital, Foggia, Italy, for blood donation were enrolled in the study.","Exclusion criteria were symptoms, signs of or laboratory analysis indicating any active infection or medical conditions, reported risk factors for parenterally acquired infections, chronic degenerative conditions, diagnosis of cancer, or high risk of cardiovascular events. ",2021-02-01,2021-02-28,Blood donors,All,Multiple groups,18.0,,Time frame,,798,0.187,,,,,,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total",Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgG', 'TotalAntibody']",,,,,['Moderate'],Unclear,No,Yes,Yes,Yes,Yes,Yes,No,,Francescopaolo Antonucci,University Hospital “Ospedali Riuniti” Foggia,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.2003856,2021-11-25,2024-03-01,Verified,antonucci_increased_2021,ITA
211116_Italy_BambinoGesuChildrensHospital,211116_Italy_BambinoGesuChildrensHospital,SARS-COV2 Seroprevalence in a Cohort of Perinatally HIV Infected Children and Young Adults From May to December 2020 in Italy,2021-11-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Rome,"""85 HIV infected-people aged between 5 and 34 years old attending their regular follow-up at Bambino Gesù Children’s Hospital in Rome from May to January 2021.""",,2020-05-01,2021-01-31,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,5.0,34.0,Primary Estimate,,85,0.057999999999999996,,,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,,,,,['High'],,No,No,No,,Yes,Yes,Yes,,Chiara Casamento Tumeo,Bambino Gesù Children’s Hospital,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1061389/v1,2021-11-24,2024-03-01,Unverified,tumeo_sars-cov2_2021,ITA
211120_Italy_UniversitàCattolicadelSacroCuore_Primary,211120_Italy_UniversitàCattolicadelSacroCuore,Seroprevalence of sars-cov-2 in a large cohort of italian police officers,2021-11-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Italy,,,"Subjects had to be on duty, not previously tested for
anti-SARS-CoV-2 antibodies and provide an informed consent",Reported that: No exclusion criteria was applied. ,2020-04-15,2020-07-15,Essential non-healthcare workers,All,Multiple groups,19.0,66.0,Primary Estimate,,10535,0.048,0.044000000000000004,0.053,True,,,,True,Self-referral,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by manufacturers,,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Sergio Garbarino,Università Cattolica del Sacro Cuore,Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph182212201,2021-11-29,2024-03-01,Unverified,garbarino_seroprevalence_2021,ITA
211201_Veneto_MonastierDiTrevisoHospital_Primary,211201_Veneto_MonastierDiTrevisoHospital,Epidemiological study in a small rural area of Veneto (Italian region) during Sars-Cov-2 Pandemia.,2021-12-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Veneto,,"The study involved one subject per family within a population of about 4400 people in the town of Monastier di Treviso (Veneto Region, Italy). This has approximately 1750 families, with an average of 2.49 subjects per family (source: Municipality of Monastier di Treviso). A total of 922 people was recruited (about a quarter of the area’s population). Recruitment was random and families remained free to participate; generally, the ones most
at risk and the ones who had certainly been infected participated.",,2020-05-04,2020-07-15,Household and community samples,All,Multiple groups,0.0,100.0,Primary Estimate,,922,0.021,,,True,,,,True,Stratified probability,Not reported/ Unable to specify,,Other,Whole Blood,IgG,,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Marco Bassanello,Monastier di Treviso Hospital,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-02654-9,2021-12-06,2022-07-16,Unverified,bassanello_epidemiological_2021,ITA
211201_Veneto_MonastierDiTrevisoHospital_Age40to49,211201_Veneto_MonastierDiTrevisoHospital,Epidemiological study in a small rural area of Veneto (Italian region) during Sars-Cov-2 Pandemia.,2021-12-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Veneto,,"The study involved one subject per family within a population of about 4400 people in the town of Monastier di Treviso (Veneto Region, Italy). This has approximately 1750 families, with an average of 2.49 subjects per family (source: Municipality of Monastier di Treviso). A total of 922 people was recruited (about a quarter of the area’s population). Recruitment was random and families remained free to participate; generally, the ones most
at risk and the ones who had certainly been infected participated.",,2020-05-04,2020-07-15,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,age: 40-49,156,0.0256,,,,,,,,Stratified probability,Not reported/ Unable to specify,,Other,Whole Blood,IgG,,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Marco Bassanello,Monastier di Treviso Hospital,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-02654-9,2021-12-06,2022-07-16,Unverified,bassanello_epidemiological_2021,ITA
211201_Veneto_MonastierDiTrevisoHospital_Female,211201_Veneto_MonastierDiTrevisoHospital,Epidemiological study in a small rural area of Veneto (Italian region) during Sars-Cov-2 Pandemia.,2021-12-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Veneto,,"The study involved one subject per family within a population of about 4400 people in the town of Monastier di Treviso (Veneto Region, Italy). This has approximately 1750 families, with an average of 2.49 subjects per family (source: Municipality of Monastier di Treviso). A total of 922 people was recruited (about a quarter of the area’s population). Recruitment was random and families remained free to participate; generally, the ones most
at risk and the ones who had certainly been infected participated.",,2020-05-04,2020-07-15,Household and community samples,Female,Multiple groups,0.0,100.0,Sex/Gender,,470,0.0255,,,,,,,,Stratified probability,Not reported/ Unable to specify,,Other,Whole Blood,IgG,,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Marco Bassanello,Monastier di Treviso Hospital,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-02654-9,2021-12-06,2022-07-16,Unverified,bassanello_epidemiological_2021,ITA
211201_Veneto_MonastierDiTrevisoHospital_Age30to39,211201_Veneto_MonastierDiTrevisoHospital,Epidemiological study in a small rural area of Veneto (Italian region) during Sars-Cov-2 Pandemia.,2021-12-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Veneto,,"The study involved one subject per family within a population of about 4400 people in the town of Monastier di Treviso (Veneto Region, Italy). This has approximately 1750 families, with an average of 2.49 subjects per family (source: Municipality of Monastier di Treviso). A total of 922 people was recruited (about a quarter of the area’s population). Recruitment was random and families remained free to participate; generally, the ones most
at risk and the ones who had certainly been infected participated.",,2020-05-04,2020-07-15,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,age: 30-39,136,0.0147,,,,,,,,Stratified probability,Not reported/ Unable to specify,,Other,Whole Blood,IgG,,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Marco Bassanello,Monastier di Treviso Hospital,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-02654-9,2021-12-06,2022-07-16,Unverified,bassanello_epidemiological_2021,ITA
211201_Veneto_MonastierDiTrevisoHospital_Age50to59,211201_Veneto_MonastierDiTrevisoHospital,Epidemiological study in a small rural area of Veneto (Italian region) during Sars-Cov-2 Pandemia.,2021-12-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Veneto,,"The study involved one subject per family within a population of about 4400 people in the town of Monastier di Treviso (Veneto Region, Italy). This has approximately 1750 families, with an average of 2.49 subjects per family (source: Municipality of Monastier di Treviso). A total of 922 people was recruited (about a quarter of the area’s population). Recruitment was random and families remained free to participate; generally, the ones most
at risk and the ones who had certainly been infected participated.",,2020-05-04,2020-07-15,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,age: 50-59,162,0.043,,,,,,,,Stratified probability,Not reported/ Unable to specify,,Other,Whole Blood,IgG,,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Marco Bassanello,Monastier di Treviso Hospital,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-02654-9,2021-12-06,2022-07-16,Unverified,bassanello_epidemiological_2021,ITA
211201_Veneto_MonastierDiTrevisoHospital_Age0to29,211201_Veneto_MonastierDiTrevisoHospital,Epidemiological study in a small rural area of Veneto (Italian region) during Sars-Cov-2 Pandemia.,2021-12-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Veneto,,"The study involved one subject per family within a population of about 4400 people in the town of Monastier di Treviso (Veneto Region, Italy). This has approximately 1750 families, with an average of 2.49 subjects per family (source: Municipality of Monastier di Treviso). A total of 922 people was recruited (about a quarter of the area’s population). Recruitment was random and families remained free to participate; generally, the ones most
at risk and the ones who had certainly been infected participated.",,2020-05-04,2020-07-15,Household and community samples,All,Multiple groups,0.0,29.0,Age,age: 0-29,73,0.013700000000000002,,,,,,,,Stratified probability,Not reported/ Unable to specify,,Other,Whole Blood,IgG,,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Marco Bassanello,Monastier di Treviso Hospital,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-02654-9,2021-12-06,2022-07-16,Unverified,bassanello_epidemiological_2021,ITA
211201_Veneto_MonastierDiTrevisoHospital_Male,211201_Veneto_MonastierDiTrevisoHospital,Epidemiological study in a small rural area of Veneto (Italian region) during Sars-Cov-2 Pandemia.,2021-12-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Veneto,,"The study involved one subject per family within a population of about 4400 people in the town of Monastier di Treviso (Veneto Region, Italy). This has approximately 1750 families, with an average of 2.49 subjects per family (source: Municipality of Monastier di Treviso). A total of 922 people was recruited (about a quarter of the area’s population). Recruitment was random and families remained free to participate; generally, the ones most
at risk and the ones who had certainly been infected participated.",,2020-05-04,2020-07-15,Household and community samples,Male,Multiple groups,0.0,100.0,Sex/Gender,,452,0.015,,,,,,,,Stratified probability,Not reported/ Unable to specify,,Other,Whole Blood,IgG,,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Marco Bassanello,Monastier di Treviso Hospital,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-02654-9,2021-12-06,2022-07-16,Unverified,bassanello_epidemiological_2021,ITA
211201_Veneto_MonastierDiTrevisoHospital_Age80to100,211201_Veneto_MonastierDiTrevisoHospital,Epidemiological study in a small rural area of Veneto (Italian region) during Sars-Cov-2 Pandemia.,2021-12-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Veneto,,"The study involved one subject per family within a population of about 4400 people in the town of Monastier di Treviso (Veneto Region, Italy). This has approximately 1750 families, with an average of 2.49 subjects per family (source: Municipality of Monastier di Treviso). A total of 922 people was recruited (about a quarter of the area’s population). Recruitment was random and families remained free to participate; generally, the ones most
at risk and the ones who had certainly been infected participated.",,2020-05-04,2020-07-15,Household and community samples,All,Seniors (65+ years),80.0,100.0,Age,age: 80-100,52,0.0,,,,,,,,Stratified probability,Not reported/ Unable to specify,,Other,Whole Blood,IgG,,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Marco Bassanello,Monastier di Treviso Hospital,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-02654-9,2021-12-06,2022-07-16,Unverified,bassanello_epidemiological_2021,ITA
211201_Veneto_MonastierDiTrevisoHospital_Age70to79,211201_Veneto_MonastierDiTrevisoHospital,Epidemiological study in a small rural area of Veneto (Italian region) during Sars-Cov-2 Pandemia.,2021-12-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Veneto,,"The study involved one subject per family within a population of about 4400 people in the town of Monastier di Treviso (Veneto Region, Italy). This has approximately 1750 families, with an average of 2.49 subjects per family (source: Municipality of Monastier di Treviso). A total of 922 people was recruited (about a quarter of the area’s population). Recruitment was random and families remained free to participate; generally, the ones most
at risk and the ones who had certainly been infected participated.",,2020-05-04,2020-07-15,Household and community samples,All,Seniors (65+ years),70.0,79.0,Age,age: 70-79,145,0.0,,,,,,,,Stratified probability,Not reported/ Unable to specify,,Other,Whole Blood,IgG,,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Marco Bassanello,Monastier di Treviso Hospital,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-02654-9,2021-12-06,2022-07-16,Unverified,bassanello_epidemiological_2021,ITA
211201_Veneto_MonastierDiTrevisoHospital_Age60to69,211201_Veneto_MonastierDiTrevisoHospital,Epidemiological study in a small rural area of Veneto (Italian region) during Sars-Cov-2 Pandemia.,2021-12-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Veneto,,"The study involved one subject per family within a population of about 4400 people in the town of Monastier di Treviso (Veneto Region, Italy). This has approximately 1750 families, with an average of 2.49 subjects per family (source: Municipality of Monastier di Treviso). A total of 922 people was recruited (about a quarter of the area’s population). Recruitment was random and families remained free to participate; generally, the ones most
at risk and the ones who had certainly been infected participated.",,2020-05-04,2020-07-15,Household and community samples,All,Seniors (65+ years),60.0,69.0,Age,age: 60-69,180,0.0444,,,,,,,,Stratified probability,Not reported/ Unable to specify,,Other,Whole Blood,IgG,,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Marco Bassanello,Monastier di Treviso Hospital,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-02654-9,2021-12-06,2022-07-16,Unverified,bassanello_epidemiological_2021,ITA
211210_Rome_UniversityofRomeTorVergata,211210_Rome_UniversityofRomeTorVergata,Factors associated with pre-vaccination sars-cov-2 infection risk among hospital nurses facing covid-19 outbreak,2021-12-10,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Italy,,Rome,"Nurses who underwent
occupational COVID-19 screening at the occupational medicine service of a Rome COVID
hospital (Tor Vergata hospital) from 1 March 2020 to 31 December 2020.",,2020-03-01,2020-12-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,918,0.021,,,True,,,,True,Convenience,Not reported/ Unable to specify,,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.986,0.995,['High'],,No,Yes,No,,Unclear,Yes,Yes,,Luca Coppeta,University of Rome Tor Vergata,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph182413053,2022-01-02,2022-07-16,Unverified,coppeta_factors_2021,ITA
211212_Italy_UniversitàdegliStudidiMilano_Overall,211212_Italy_UniversitàdegliStudidiMilano,SARS-CoV-2 antibodies among people with cystic fibrosis prior to the vaccination campaign: A seroprevalence study in two specialized centres in Northern Italy.,2021-12-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Northern Italy,,"All pwCF aged ≥12 years participating in the vaccination campaign against SARS-CoV-2 between March and June 2021, were asked to participate in this cross-sectional study.",,2021-03-15,2021-06-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,12.0,81.0,Primary Estimate,,434,0.1475,0.115,0.184,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.988,1.0,['High'],,No,No,Yes,,Yes,Yes,Yes,,Gianfranco Alicandro,Università degli Studi di Milano,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcf.2021.12.011,2022-01-10,2024-03-01,Unverified,alicandro_sars-cov-2_2021,ITA
211212_Italy_UniversitàdegliStudidiMilano_Age25-39,211212_Italy_UniversitàdegliStudidiMilano,SARS-CoV-2 antibodies among people with cystic fibrosis prior to the vaccination campaign: A seroprevalence study in two specialized centres in Northern Italy.,2021-12-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Northern Italy,,"All pwCF aged ≥12 years participating in the vaccination campaign against SARS-CoV-2 between March and June 2021, were asked to participate in this cross-sectional study.",,2021-03-15,2021-06-15,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),25.0,39.0,Age,25-39,142,0.1338,0.083,0.201,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.988,1.0,['High'],,No,No,Yes,,Yes,Yes,Yes,,Gianfranco Alicandro,Università degli Studi di Milano,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcf.2021.12.011,2022-01-10,2024-03-01,Unverified,alicandro_sars-cov-2_2021,ITA
211212_Italy_UniversitàdegliStudidiMilano_Age18-24,211212_Italy_UniversitàdegliStudidiMilano,SARS-CoV-2 antibodies among people with cystic fibrosis prior to the vaccination campaign: A seroprevalence study in two specialized centres in Northern Italy.,2021-12-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Northern Italy,,"All pwCF aged ≥12 years participating in the vaccination campaign against SARS-CoV-2 between March and June 2021, were asked to participate in this cross-sectional study.",,2021-03-15,2021-06-15,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),18.0,24.0,Age,18-24,110,0.2182,0.145,0.307,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.988,1.0,['High'],,No,No,Yes,,Yes,Yes,Yes,,Gianfranco Alicandro,Università degli Studi di Milano,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcf.2021.12.011,2022-01-10,2024-03-01,Unverified,alicandro_sars-cov-2_2021,ITA
211212_Italy_UniversitàdegliStudidiMilano_Age12-17,211212_Italy_UniversitàdegliStudidiMilano,SARS-CoV-2 antibodies among people with cystic fibrosis prior to the vaccination campaign: A seroprevalence study in two specialized centres in Northern Italy.,2021-12-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Northern Italy,,"All pwCF aged ≥12 years participating in the vaccination campaign against SARS-CoV-2 between March and June 2021, were asked to participate in this cross-sectional study.",,2021-03-15,2021-06-15,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),12.0,17.0,Age,12-17,64,0.1094,0.045,0.212,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.988,1.0,['High'],,No,No,Yes,,Yes,Yes,Yes,,Gianfranco Alicandro,Università degli Studi di Milano,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcf.2021.12.011,2022-01-10,2024-03-01,Unverified,alicandro_sars-cov-2_2021,ITA
211212_Italy_UniversitàdegliStudidiMilano_Age40+,211212_Italy_UniversitàdegliStudidiMilano,SARS-CoV-2 antibodies among people with cystic fibrosis prior to the vaccination campaign: A seroprevalence study in two specialized centres in Northern Italy.,2021-12-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Northern Italy,,"All pwCF aged ≥12 years participating in the vaccination campaign against SARS-CoV-2 between March and June 2021, were asked to participate in this cross-sectional study.",,2021-03-15,2021-06-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,40.0,81.0,Age,40+,118,0.1186,0.066,0.19100000000000003,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.988,1.0,['High'],,No,No,Yes,,Yes,Yes,Yes,,Gianfranco Alicandro,Università degli Studi di Milano,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcf.2021.12.011,2022-01-10,2024-03-01,Unverified,alicandro_sars-cov-2_2021,ITA
211207_Milan_SanGiuseppeHospital_Total1stWave,211207_Milan_SanGiuseppeHospital,Prevalence of SARS-CoV-2 amongst ophthalmologists throughout the first and second waves of the pandemic.,2021-12-17,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Italy,,Milan,"staff of the Ophthalmic Unit (ophthalmologists, residents, and orthoptists) who completed the questionnaire (see below) and who underwent a nasopharyngeal/oropharyngeal swab and blood test for the presence of SARS-CoV-2 antibodies during the first and second waves who were willing to participate in the study.",,2020-03-15,2020-05-15,Health care workers and caregivers,All,Adults (18-64 years),24.0,61.0,Primary Estimate,Mar - May 2020 total Ab,25,0.04,,,True,,,,True,Self-referral,"COVID-19 IgG,COVID-19 IgM",Technogenetics,LFIA,Serum,"['IgG', 'IgM']",,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Matteo Sacchi,San Giuseppe Hospital,Not Unity-Aligned,https://dx.doi.org/10.1097/MD.0000000000028192,2022-01-09,2022-07-16,Unverified,sacchi_prevalence_2021,ITA
211218_Italy_SanRaffaeleUniversity_Overall,211218_Italy_SanRaffaeleUniversity,"COVID-19 in Solid Organ Transplant Recipient: Exploring Cumulative Incidence, Seroprevalence and Risk Factors for Disease Severity.",2021-12-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Milan,Milan,"Recipients aged ≥18 years with a functioning kidney, pancreas or islet transplant, attending the outpatient follow-up clinic at the IRCCS Ospedale San Raffaele between February 2020 and April 2021 were invited to enter this study",,2020-02-15,2021-04-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,291,0.10310000000000001,,,True,,,,True,Convenience,Author designed (CLIA),,CLIA,Serum,IgG,Spike,Validated by developers,0.97,1.0,['High'],,No,No,Yes,,Unclear,Yes,Yes,,Rossana Caldara,Vita-Salute San Raffaele University,Not Unity-Aligned,https://dx.doi.org/10.3390/biology10121349,2022-01-14,2022-07-16,Unverified,caldara_covid-19_2021,ITA
220111_Rome_GemelliUniversityHospital,220111_Rome_GemelliUniversityHospital,Short- and mid-term multidisciplinary outcomes of newborns exposed to SARS-CoV-2 in utero or during the perinatal period: preliminary findings.,2022-01-11,Journal Article (Peer-Reviewed),Local,Prospective cohort,Italy,Lazio,Rome,"For this study, we included all newborns or fetuses:
– That were delivered from pregnant women with a documented
SARS-CoV-2 infection during any period of
pregnancy, including time of delivery;
– Whose parents agreed to enroll a multidisciplinary follow-up detailed below; and
– Had written informed consent to participate from a legal guardian.","- Newborns delivered from mothers with a suspected but
undocumented SARS-CoV-2 infection,
- Newborns whose mothers developed symptoms and were
diagnosed with SARS-CoV-2 infection after delivery,
and
- Newborns whose parents did not provide written
informed consent to participate from a legal guardian.",2020-03-01,2021-04-30,Perinatal,All,Children and Youth (0-17 years),0.0,1.0,Primary Estimate,,59,0.1525,,,True,,,,True,Convenience,COVID-19 ELISA IgG,Vircell S.L.,ELISA,Serum,IgG,,Validated by manufacturers,0.85,0.98,['High'],,No,No,No,,No,Yes,No,,Danilo Buonsenso,Gemelli University,Not Unity-Aligned,https://dx.doi.org/10.1007/s00431-021-04319-1,2022-01-27,2024-03-01,Unverified,buonsenso_short-_2022,ITA
220121_NorthItaly_UniversityofPiemonteOrientale,220121_NorthItaly_UniversityofPiemonteOrientale,DOP21 Potential mechanisms linking biological therapies on SARS-CoV-2 susceptibility in Inflammatory Bowel Disease patients,2022-01-21,Presentation or Conference,Regional,Cross-sectional survey ,Italy,North Italy,,IBD patients in North Italy,,2020-04-15,2021-04-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,238,0.042,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,Serum,,,,,,['High'],,Unclear,No,No,,Unclear,Yes,No,,L Pisani,University of Piemonte Orientale,Not Unity-Aligned,https://dx.doi.org/10.1093/ecco-jcc/jjab232.060,2022-03-09,2022-07-16,Unverified,pisani_dop21_2022,ITA
220202_Friuli-VeneziaGiulia_SantaMariadellaMisericordiaHospital_Overall,220202_Friuli-VeneziaGiulia_SantaMariadellaMisericordiaHospital,"Detection of SARS-CoV-2 infection prevalence in 860 cancer patients with a combined screening procedure including triage, molecular nasopharyngeal swabs and rapid serological test. A report from the first epidemic wave.",2022-02-02,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Italy,Friuli-Venezia Giulia,,"The criteria for inclusion in the study were: 1) diagnosis of malignancy under active anticancer therapy; 2) access to the onco-hematologic outpatient department, from May 01, 2020,
to June 15, 2020, with a completion of a self-reported triage questionnaire; 3) performance of
at least one molecular naso-pharyngeal swab (NPS) and one rapid serologic test for SARSCoV-2 during the study period; 4) age > 18 years; 5) signature of written informed consent.",,2020-05-01,2020-06-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,17.0,91.0,Primary Estimate,,860,0.016200000000000003,,,True,,,,True,Sequential,COVID-19 IgG/IgM Rapid Test Cassette,Cellex Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9840000000000001,0.9640000000000001,['High'],,No,Yes,Yes,,No,Yes,No,,Anna Candoni,Santa Maria della Misericordia Hospital,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0262784,2022-02-09,2024-03-01,Unverified,candoni_detection_2022,ITA
220212_Friuli-VeneziaGiulia_UniversityofTrieste_Period1_Overall,220212_Friuli-VeneziaGiulia_UniversityofTrieste_Period1,"Evolution of SARS-CoV-2 IgG Seroprevalence in Children and Factors Associated with Seroconversion: Results from a Multiple Time-Points Study in Friuli-Venezia Giulia Region, Italy.",2022-02-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Italy,"Friuli-Venezia Giulia
Region",,"Those who accessed
the Research Institute for Maternal and Child Health “Burlo Garofolo” in Trieste, a referral
regional hospital, in FVG, and who needed a blood test for any reason","Age > 18 years,
risk factors for an ongoing SARS-CoV-2 infection (i.e., typical symptoms, recent positive
nasopharyngeal swab, contact with a confirmed or a suspected case in the 14 days before
the blood sample, travelling abroad in the 14 days before the blood sample), partial or
full anti-SARS-CoV-2 vaccination (which started in Italy for children over 11 years in June
2021), and/or immunodeficiency, either primitive or secondary, were considered exclusion
criteria, together with refusal to participate to the study",2021-01-01,2021-02-28,Students and Daycares,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,,217,0.111,,,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Marzia Lazzerini,IRCCS “Burlo Garofolo”,Not Unity-Aligned,https://dx.doi.org/10.3390/children9020246,2022-03-08,2024-03-01,Unverified,lazzerini_evolution_2022,ITA
220212_Friuli-VeneziaGiulia_UniversityofTrieste_Period2_Overall,220212_Friuli-VeneziaGiulia_UniversityofTrieste_Period2,"Evolution of SARS-CoV-2 IgG Seroprevalence in Children and Factors Associated with Seroconversion: Results from a Multiple Time-Points Study in Friuli-Venezia Giulia Region, Italy.",2022-02-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Italy,"Friuli-Venezia Giulia
Region",,"Those who accessed
the Research Institute for Maternal and Child Health “Burlo Garofolo” in Trieste, a referral
regional hospital, in FVG, and who needed a blood test for any reason","Age > 18 years,
risk factors for an ongoing SARS-CoV-2 infection (i.e., typical symptoms, recent positive
nasopharyngeal swab, contact with a confirmed or a suspected case in the 14 days before
the blood sample, travelling abroad in the 14 days before the blood sample), partial or
full anti-SARS-CoV-2 vaccination (which started in Italy for children over 11 years in June
2021), and/or immunodeficiency, either primitive or secondary, were considered exclusion
criteria, together with refusal to participate to the study",2021-04-01,2021-05-31,Students and Daycares,All,Children and Youth (0-17 years),0.0,18.0,Primary Estimate,,208,0.154,,,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Marzia Lazzerini,IRCCS “Burlo Garofolo”,Not Unity-Aligned,https://dx.doi.org/10.3390/children9020246,2022-03-08,2024-03-01,Unverified,lazzerini_evolution_2022,ITA
220212_Friuli-VeneziaGiulia_UniversityofTrieste_Period3_Overall,220212_Friuli-VeneziaGiulia_UniversityofTrieste_Period3,"Evolution of SARS-CoV-2 IgG Seroprevalence in Children and Factors Associated with Seroconversion: Results from a Multiple Time-Points Study in Friuli-Venezia Giulia Region, Italy.",2022-02-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Italy,"Friuli-Venezia Giulia
Region",,"Those who accessed
the Research Institute for Maternal and Child Health “Burlo Garofolo” in Trieste, a referral
regional hospital, in FVG, and who needed a blood test for any reason","Age > 18 years,
risk factors for an ongoing SARS-CoV-2 infection (i.e., typical symptoms, recent positive
nasopharyngeal swab, contact with a confirmed or a suspected case in the 14 days before
the blood sample, travelling abroad in the 14 days before the blood sample), partial or
full anti-SARS-CoV-2 vaccination (which started in Italy for children over 11 years in June
2021), and/or immunodeficiency, either primitive or secondary, were considered exclusion
criteria, together with refusal to participate to the study",2021-06-01,2021-07-31,Students and Daycares,All,Children and Youth (0-17 years),0.0,18.0,Primary Estimate,,169,0.11800000000000001,,,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Marzia Lazzerini,IRCCS “Burlo Garofolo”,Not Unity-Aligned,https://dx.doi.org/10.3390/children9020246,2022-03-08,2024-03-01,Unverified,lazzerini_evolution_2022,ITA
220224_Piedmont_UniversityOfTurin_HCWs,220224_Piedmont_UniversityOfTurin_HCWs,"A cross-sectional study of SARS-CoV-2 seropositivity among healthcare workers and residents of long-term facilities in Italy, January 2021",2022-02-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Region of Piedmont,"Alessandria, Cuneo, Turin","HCWs (medical doctors, nurses, and ancillary staff) of LTCFs and one hospital in the region of Piedmont, in Northern Italy.

All the subjects were unvaccinated, as the samples were collected the day before vaccination was scheduled.",,2021-01-01,2021-01-31,Health care workers and caregivers,All,Multiple groups,19.0,76.0,Primary Estimate,,495,0.5313,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.932,0.998,['High'],,No,No,Yes,,Yes,Yes,Yes,,Valerio Bordino,University of Turin,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27670,2022-03-09,2024-03-01,Unverified,bordino_crosssectional_2022,ITA
220224_Piedmont_UniversityOfTurin_LTCFsResidents,220224_Piedmont_UniversityOfTurin_LTCFsResidents,"A cross-sectional study of SARS-CoV-2 seropositivity among healthcare workers and residents of long-term facilities in Italy, January 2021",2022-02-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Region of Piedmont,"Alessandria, Cuneo, Turin","Residents of LTCFs [long‐term care facilities] in the region of Piedmont, in Northern Italy.

All the subjects were unvaccinated, as the samples were collected the day before vaccination was scheduled.",,2021-01-01,2021-01-31,Assisted living and long-term care facilities,All,Multiple groups,51.0,106.0,Primary Estimate,,163,0.6503,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.932,0.998,['High'],,No,No,Yes,,Yes,Yes,Yes,,Valerio Bordino,University of Turin,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27670,2022-03-09,2024-03-01,Unverified,bordino_crosssectional_2022,ITA
220227_Verona_UniversityofVerona_Controls_Overall,220227_Verona_UniversityofVerona_Controls,Is there a correlation between MOGAD and SARS-CoV-2 infection?.,2022-02-27,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Italy,,Verona,"An equal number of MOG-Abs seronegative
age and time-matched controls were then selected from our Laboratory of Neuropathology, University Hospital of Verona",,2020-08-01,2021-05-31,Residual sera,All,Multiple groups,,,Primary Estimate,,30,0.2,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgA,Anti-SARS-CoV-2 ELISA IgG,Liaison SARS-CoV-2 S1/S2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,Elecsys® Anti‐SARS‐CoV‐2 (S)","EUROIMMUN,DiaSorin,Beckman Coulter,Roche Diagnostics",Multiple Types,,"['IgA', 'IgG', 'TotalAntibody']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,No,,Unclear,Yes,No,,Sara Mariotto,University of Verona,Not Unity-Aligned,https://dx.doi.org/10.1111/ene.15304,2022-03-08,2024-03-01,Unverified,mariotto_is_2022,ITA
220227_Verona_UniversityofVerona_Patients_Overall,220227_Verona_UniversityofVerona_Patients,Is there a correlation between MOGAD and SARS-CoV-2 infection?.,2022-02-27,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Italy,,Verona,"We retrospectively identified consecutive treatment naive patients tested MOG-IgG positive
for the first time in our Laboratory of Neuropathology, University Hospital of Verona",,2020-08-01,2021-05-31,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,30,0.4,,,True,,,,True,Sequential,"Anti-SARS-CoV-2 ELISA IgA,Anti-SARS-CoV-2 ELISA IgG,Liaison SARS-CoV-2 S1/S2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,Elecsys® Anti‐SARS‐CoV‐2 (S)","EUROIMMUN,DiaSorin,Beckman Coulter,Roche Diagnostics",Multiple Types,,"['IgA', 'IgG', 'TotalAntibody']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,No,,Unclear,Yes,No,,Sara Mariotto,University of Verona,Not Unity-Aligned,https://dx.doi.org/10.1111/ene.15304,2022-03-08,2024-03-01,Unverified,mariotto_is_2022,ITA
220228_Italy_FedericoIIUniversityOfNaples_ECLIA,220228_Italy_FedericoIIUniversityOfNaples,A comparison of a SARS-CoV-2 rapid-test and serological-test in a Public Health Hospital,2022-02-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Naples,,"The participants were enrolled on a voluntary basis undergoing both the rapid and serological test, prior triage, after signing informed consent forms. The participants belonged to a homogeneous and casual group of Federico II University employees.",,2020-05-15,2020-10-09,Blood donors,All,Multiple groups,20.0,82.0,Primary Estimate,Elecsys - ECLIA,1100,0.01,,,True,,,,True,Self-referral,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,0.99,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Giovanni Dell’Aversana Orabona,Federico II University of Naples,Not Unity-Aligned,https://dx.doi.org/10.3855/jidc.15144,2022-04-07,2024-03-01,Unverified,orabona_comparison_2022,ITA
220228_Italy_FedericoIIUniversityOfNaples_Rapid,220228_Italy_FedericoIIUniversityOfNaples,A comparison of a SARS-CoV-2 rapid-test and serological-test in a Public Health Hospital,2022-02-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Naples,,"The participants were enrolled on a voluntary basis undergoing both the rapid and serological test, prior triage, after signing informed consent forms. The participants belonged to a homogeneous and casual group of Federico II University employees.",,2020-05-15,2020-10-09,Blood donors,All,Multiple groups,20.0,82.0,Test used,VivaCheck - Rapid,1100,0.0036,,,,,,,,Self-referral,VivaDiag COVID-19 IgM/IgG Rapid Test,VivaChek Biotech (Hangzhou) Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,0.9963,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Giovanni Dell’Aversana Orabona,Federico II University of Naples,Not Unity-Aligned,https://dx.doi.org/10.3855/jidc.15144,2022-04-07,2024-03-01,Unverified,orabona_comparison_2022,ITA
220311_Lombardy_UniversitàdegliStudidiMilano_Overall,220311_Lombardy_UniversitàdegliStudidiMilano,The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study.,2022-03-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Lombardy,,"patients aged ≥18 years and living in Lombardy, diagnosed with rheumatoid arthritis (RA) or spondyloarthritis (SpA), with a follow-up visit scheduled between 4th May and 16th June 2020 at the outpatient rheumatology clinic of ASST Gaetano Pini-CTO Institute in Milan, a tertiary referral medical institution.",,2020-05-04,2020-06-16,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,,Primary Estimate,,358,0.1844,0.14,0.23199999999999998,True,,,,True,Convenience,"COVID-19 IgG – ELISA,COVID-19 IgM – ELISA,COVID-19 IgA – ELISA",Diagnostic Bioprobes,ELISA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Ennio Favalli,Università degli Studi di Milano,Not Unity-Aligned,https://dx.doi.org/10.3389/fmed.2022.850858,2022-04-11,2022-07-16,Unverified,favalli_impact_2022,ITA
220316_Cremona_ASSTCremona_Overall,220316_Cremona_ASSTCremona,"SARS-CoV-2 in inflammatory bowel disease population: Antibodies, disease and correlation with therapy.",2022-03-16,Journal Article (Peer-Reviewed),Local,Prospective cohort,Italy,,Cremona,Patients affected by IBD (Crohn’s disease or ulcerative colitis) followed-up at ASST Cremona ,,2020-04-22,2020-05-31,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,103,0.184,,,True,,,,True,Sequential,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.971,0.8890000000000001,['High'],,No,No,Yes,,Yes,Yes,No,,Clara Conti,ASST Cremona,Not Unity-Aligned,https://dx.doi.org/10.4253/wjge.v14.i3.153,2022-04-27,2024-03-01,Unverified,conti_sars-cov-2_2022,ITA
220420_Italy_SanAgostinoEstenseCivilHospital,220420_Italy_SanAgostinoEstenseCivilHospital,Big Data analysis to evaluate the clinical utility of IgM anti SARS-CoV-2 determination: The Modena experience,2022-04-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Modena,Modena,data already present in the database of the USL of Modena were analyzed; subjects with positive results were subsequently contacted by the Department of Hygiene and Public Health for the execution of an oral- or nasopharyngeal swab for the search for viral RNA for definitive diagnosis,,2020-03-11,2020-09-30,Multiple populations,All,Multiple groups,,,Primary Estimate,,533,0.159,,,True,,,,True,Convenience,"iFlash-SARS-CoV-2 IgM/IgG,Rapid Test SARS-CoV-2 IgM/IgG Gold","Shenzhen Yhlo Biotech Co. Ltd,Technogenetics",Multiple Types,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Unclear,Yes,No,,Valentina Pecoraro,San'Agostino Estense Civil Hospital,Not Unity-Aligned,https://dx.doi.org/10.19186/BC_2022.014,2022-08-23,2024-03-01,Unverified,valentinaApplicazioneAnalisiBig2022,ITA
220501_TorVergataUniversityHospital_UniversityofRome_Overall,220501_TorVergataUniversityHospital_UniversityofRome,SARS-CoV-2 Igg seroprevalence in IBD patients treated with biologics: first vs. second pandemic wave in a prospective study.,2022-05-01,Journal Article (Peer-Reviewed),Local,Prospective cohort,Italy,,Rome,"Members of the original study and 

1) age ≥ 18
years; 2) well defined diagnosis of IBD, according to current guidelines17,18; 3) regular follow-up;
4) inclusion in our previous study14; 5) biologic
treatment at the time of enrollment in the previous
study (≥ 6 months duration)14, including either intravenous or subcutaneous administration (i.e., infliximab, adalimumab, golimumab, vedolizumab,
ustekinumab); 6) written informed consent. ","Exclusion criteria from original study: (1) diagnosis or history of SARS-CoV-2 infection; (2) signs, symptoms and/or risk fac- tors for SARS-CoV-2 infection ≤14 days before enrollment (≥2 among: sore-throat, weakness, fever, cough, arthralgias, weight loss, recent contacts with COVID-19 patients); (3) ongoing clinical trial; (4) pregnancy; (5) psychiatric or severe diseases

In addition: SARS-CoV-2 vaccination",2020-11-15,2021-03-15,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),21.0,67.0,Primary Estimate,,85,0.0941,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,M Mossa,Tor Vergata University of Rome,Not Unity-Aligned,https://dx.doi.org/10.26355/eurrev_202205_28875,2022-06-08,2022-07-16,Unverified,mossa_sars-cov-2_2022,ITA
220504_Italy_IRCCS,220504_Italy_IRCCS,A SERUM METABOLOMICS ANALYSIS TO UNDERSTAND THE INTERPLAY BETWEEN BIOLOGICAL THERAPIES IN IBD PATIENTS AND SUSCEPTIBILITY TO SARS-COV-2 INFECTION,2022-05-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,NR (North Italy area),,"""238 IBD patients (N=145 Crohn disease, N=93 Ulcerative colitis) of the North Italy area were enrolled""",,2020-04-15,2021-04-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,238,0.0672,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,Serum,,,,,,['High'],,Unclear,No,No,,Unclear,Yes,No,,L.F. Pisani ,IRCCS Policlinico San Donato,Not Unity-Aligned,https://dx.doi.org/10.1016/S1590-8658%2822%2900327-9,2022-08-30,2022-09-23,Unverified,pisaniOC10SERUM2022,ITA
220512_Milan_ MaggiorePoliclinicoHospital,220512_Milan_ MaggiorePoliclinicoHospital,Prevalence and Risk Factors for Anti-SARS-CoV-2 Antibody in Chronic Kidney Disease (Dialysis Independent and Not),2022-05-12,Journal Article (Peer-Reviewed),Local,Prospective cohort,Italy,Lombardy,Milan,Patients with chronic kidney disease,,2020-08-10,2021-02-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,,Primary Estimate,,302,0.205298013,,,True,,,,True,Convenience,Not reported/ Unable to specify,,Other,Multiple Types,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.861,0.9890000000000001,['High'],,No,No,Yes,,Unclear,Yes,No,,Mariana Siddi,Maggiore Policlinico Hospital,Not Unity-Aligned,https://dx.doi.org/10.3390/pathogens11050572,2022-06-10,2022-07-16,Unverified,siddi_prevalence_2022,ITA
220512_Milan_UniversityofMilan,220512_Milan_UniversityofMilan,SARS-CoV-2 Seroprevalence Among School-Age Children in Milan: How Has It Changed With the Fourth Pandemic Wave?,2022-05-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Milan,,Children 2–11 years old atending 11 pre-schools and primary schools in the province of Milan.,insufficient blood sample collected,2022-02-16,2022-02-28,Students and Daycares,All,Children and Youth (0-17 years),2.0,11.0,Primary Estimate,,665,0.5669,,,True,,,,True,Unclear,GSP1/DELFIA1 anti SARS-CoV2 kit,PerkinElmer,,Dried Blood,IgG,Spike,,,,['Moderate'],,Unclear,Yes,No,,Yes,Yes,Yes,,Alessandra Mari,University of Milan,Not Unity-Aligned,https://dx.doi.org/10.1097/INF.0000000000003583,2022-06-07,2024-03-01,Unverified,mari_sars-cov-2_2022,ITA
220602_Milan_UniversityVita-SaluteSanRaffaele,220602_Milan_UniversityVita-SaluteSanRaffaele,Evaluation of antibody titer kinetics and SARS-CoV-2 infections in a large cohort of healthcare professionals ten months after administration of the BNT162b2 vaccine,2022-06-06,Journal Article (Peer-Reviewed),Local,Prospective cohort,Italy,Lombardy,Milan,"This study included 1172 HCPs (766 females aged 49.0 ± 16.7 years
old and 406 males aged 52.0 ± 20.0 years old) from the San Raffaele
Hospital, Milan, Italy, who received both the first and second dose (21
± 1 days interval between the two doses) during January and February
2021",,2021-01-15,2021-02-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1172,0.0812,,,True,,,,True,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,,,['Moderate'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Davide Ferrari,University Vita-Salute San Raffaele,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jim.2022.113293,2022-06-20,2024-03-01,Unverified,ferrari_evaluation_2022,ITA
220614_Rome_HospitalPhysiotherapyInstitutes,220614_Rome_HospitalPhysiotherapyInstitutes,Unequal Access to Testing and Vaccination Services for the Homeless and Undocumented Population During COVID-19 Pandemic,2022-06-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Lazio,Rome,homeless and undocumented in Rome,,2020-03-15,2021-10-15,Persons experiencing homelessness,All,Multiple groups,,,Primary Estimate,,632,0.5031,,,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Aldo Morrone,Hospital Physiotherapy Institutes,Not Unity-Aligned,https://dx.doi.org/10.3389/ijph.2022.1604851,2022-07-25,2024-03-01,Unverified,morrone_unequal_2022,ITA
220622_Lombardy_VittoreBuzziChildren'sHospital,220622_Lombardy_VittoreBuzziChildren'sHospital,"Impact of COVID-19 pandemic on children with inflammatory bowel disease: Our experience from an IBD Centre in Lombardy, Italian SARS-COV-2 epicentre",2022-06-22,Presentation or Conference,Regional,Cross-sectional survey ,Italy,Lombardy,,"""IBD children (age range: 9-17 years), under the care of our IBD clinic in Lombardy, were enrolled from January to May 2021""",,2021-01-15,2021-05-15,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),9.0,17.0,Primary Estimate,,29,0.172,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,Nucleocapsid(N-protein),,,,['High'],,No,No,Yes,,Unclear,Yes,No,,L. Gianolio,Vittore Buzzi Children's Hospital,Not Unity-Aligned,https://dx.doi.org/10.1097/MPG.0000000000003446,2022-08-03,2022-08-26,Unverified,gianolio_impact_2022,ITA
220627_EmiliaRomagnaRegion_UniversityOfModenaAndReggioEmilia_Overall,220627_EmiliaRomagnaRegion_UniversityOfModenaAndReggioEmilia,"Seroprevalence Survey of Anti-SARS-CoV-2 Antibodies in a Population of Emilia-Romagna Region, Northern Italy",2022-06-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,"Emilia-Romagna Region; including provinces of Modena, Reggio Emilia, Parma, Bologna, and other provinces.",,"""we included all the adults tested for SARS-CoV-2 serological screening that were referred to the Test laboratory during the period between 26 September 2020 and 26 March 2021: workers referred by their companies, which recommended that their employees were tested, as well as self-referred individuals voluntarily admitted to the facility to undergo SARS-CoV-2 testing.""",,2020-09-26,2021-03-26,Multiple populations,All,Multiple groups,,,Primary Estimate,,5128,0.1131,,,True,,,,True,Self-referral,"Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Diagnostic kit for SARS-CoV-2 IgM/IgG Antibody (Colloidal Gold)","Roche Diagnostics,Shanghai Kehua Bio-engineering (KHB) Co. Ltd",Multiple Types,Serum,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],,No,Yes,Yes,,Unclear,No,No,,Stefania Paduano,University of Modena and Reggio Emilia,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph19137882,2022-07-04,2022-07-29,Unverified,paduano_seroprevalence_2022,ITA
220627_EmiliaRomagnaRegion_UniversityOfModenaAndReggioEmilia_Age_20-29,220627_EmiliaRomagnaRegion_UniversityOfModenaAndReggioEmilia,"Seroprevalence Survey of Anti-SARS-CoV-2 Antibodies in a Population of Emilia-Romagna Region, Northern Italy",2022-06-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,"Emilia-Romagna Region; including provinces of Modena, Reggio Emilia, Parma, Bologna, and other provinces.",,"""we included all the adults tested for SARS-CoV-2 serological screening that were referred to the Test laboratory during the period between 26 September 2020 and 26 March 2021: workers referred by their companies, which recommended that their employees were tested, as well as self-referred individuals voluntarily admitted to the facility to undergo SARS-CoV-2 testing.""",,2020-09-26,2021-03-26,Multiple populations,All,Adults (18-64 years),20.0,29.0,Age,Age group: 20-29 years,929,0.0764,,,,,,,,Self-referral,"Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Diagnostic kit for SARS-CoV-2 IgM/IgG Antibody (Colloidal Gold)","Roche Diagnostics,Shanghai Kehua Bio-engineering (KHB) Co. Ltd",Multiple Types,Serum,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],,No,Yes,Yes,,Unclear,No,No,,Stefania Paduano,University of Modena and Reggio Emilia,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph19137882,2022-07-08,2022-07-29,Unverified,paduano_seroprevalence_2022,ITA
220627_EmiliaRomagnaRegion_UniversityOfModenaAndReggioEmilia_Age_≥70,220627_EmiliaRomagnaRegion_UniversityOfModenaAndReggioEmilia,"Seroprevalence Survey of Anti-SARS-CoV-2 Antibodies in a Population of Emilia-Romagna Region, Northern Italy",2022-06-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,"Emilia-Romagna Region; including provinces of Modena, Reggio Emilia, Parma, Bologna, and other provinces.",,"""we included all the adults tested for SARS-CoV-2 serological screening that were referred to the Test laboratory during the period between 26 September 2020 and 26 March 2021: workers referred by their companies, which recommended that their employees were tested, as well as self-referred individuals voluntarily admitted to the facility to undergo SARS-CoV-2 testing.""",,2020-09-26,2021-03-26,Multiple populations,All,Seniors (65+ years),70.0,,Age,,267,0.17980000000000002,,,,,,,,Self-referral,"Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Diagnostic kit for SARS-CoV-2 IgM/IgG Antibody (Colloidal Gold)","Roche Diagnostics,Shanghai Kehua Bio-engineering (KHB) Co. Ltd",Multiple Types,Serum,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],,No,Yes,Yes,,Unclear,No,No,,Stefania Paduano,University of Modena and Reggio Emilia,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph19137882,2022-07-08,2022-07-29,Unverified,paduano_seroprevalence_2022,ITA
220627_EmiliaRomagnaRegion_UniversityOfModenaAndReggioEmilia_Age_40-49,220627_EmiliaRomagnaRegion_UniversityOfModenaAndReggioEmilia,"Seroprevalence Survey of Anti-SARS-CoV-2 Antibodies in a Population of Emilia-Romagna Region, Northern Italy",2022-06-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,"Emilia-Romagna Region; including provinces of Modena, Reggio Emilia, Parma, Bologna, and other provinces.",,"""we included all the adults tested for SARS-CoV-2 serological screening that were referred to the Test laboratory during the period between 26 September 2020 and 26 March 2021: workers referred by their companies, which recommended that their employees were tested, as well as self-referred individuals voluntarily admitted to the facility to undergo SARS-CoV-2 testing.""",,2020-09-26,2021-03-26,Multiple populations,All,Adults (18-64 years),40.0,49.0,Age,,1276,0.11130000000000001,,,,,,,,Self-referral,"Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Diagnostic kit for SARS-CoV-2 IgM/IgG Antibody (Colloidal Gold)","Roche Diagnostics,Shanghai Kehua Bio-engineering (KHB) Co. Ltd",Multiple Types,Serum,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],,No,Yes,Yes,,Unclear,No,No,,Stefania Paduano,University of Modena and Reggio Emilia,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph19137882,2022-07-08,2022-07-29,Unverified,paduano_seroprevalence_2022,ITA
220627_EmiliaRomagnaRegion_UniversityOfModenaAndReggioEmilia_Age_30-39,220627_EmiliaRomagnaRegion_UniversityOfModenaAndReggioEmilia,"Seroprevalence Survey of Anti-SARS-CoV-2 Antibodies in a Population of Emilia-Romagna Region, Northern Italy",2022-06-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,"Emilia-Romagna Region; including provinces of Modena, Reggio Emilia, Parma, Bologna, and other provinces.",,"""we included all the adults tested for SARS-CoV-2 serological screening that were referred to the Test laboratory during the period between 26 September 2020 and 26 March 2021: workers referred by their companies, which recommended that their employees were tested, as well as self-referred individuals voluntarily admitted to the facility to undergo SARS-CoV-2 testing.""",,2020-09-26,2021-03-26,Multiple populations,All,Adults (18-64 years),30.0,39.0,Age,,1048,0.0725,,,,,,,,Self-referral,"Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Diagnostic kit for SARS-CoV-2 IgM/IgG Antibody (Colloidal Gold)","Roche Diagnostics,Shanghai Kehua Bio-engineering (KHB) Co. Ltd",Multiple Types,Serum,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],,No,Yes,Yes,,Unclear,No,No,,Stefania Paduano,University of Modena and Reggio Emilia,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph19137882,2022-07-08,2022-07-29,Unverified,paduano_seroprevalence_2022,ITA
220627_EmiliaRomagnaRegion_UniversityOfModenaAndReggioEmilia_Age_<20,220627_EmiliaRomagnaRegion_UniversityOfModenaAndReggioEmilia,"Seroprevalence Survey of Anti-SARS-CoV-2 Antibodies in a Population of Emilia-Romagna Region, Northern Italy",2022-06-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,"Emilia-Romagna Region; including provinces of Modena, Reggio Emilia, Parma, Bologna, and other provinces.",,"""we included all the adults tested for SARS-CoV-2 serological screening that were referred to the Test laboratory during the period between 26 September 2020 and 26 March 2021: workers referred by their companies, which recommended that their employees were tested, as well as self-referred individuals voluntarily admitted to the facility to undergo SARS-CoV-2 testing.""",,2020-09-26,2021-03-26,Multiple populations,All,Adults (18-64 years),,19.0,Age,Age group: <20 years,123,0.17070000000000002,,,,,,,,Self-referral,"Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Diagnostic kit for SARS-CoV-2 IgM/IgG Antibody (Colloidal Gold)","Roche Diagnostics,Shanghai Kehua Bio-engineering (KHB) Co. Ltd",Multiple Types,Serum,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],,No,Yes,Yes,,Unclear,No,No,,Stefania Paduano,University of Modena and Reggio Emilia,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph19137882,2022-07-08,2022-07-29,Unverified,paduano_seroprevalence_2022,ITA
220627_EmiliaRomagnaRegion_UniversityOfModenaAndReggioEmilia_Age_50-59,220627_EmiliaRomagnaRegion_UniversityOfModenaAndReggioEmilia,"Seroprevalence Survey of Anti-SARS-CoV-2 Antibodies in a Population of Emilia-Romagna Region, Northern Italy",2022-06-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,"Emilia-Romagna Region; including provinces of Modena, Reggio Emilia, Parma, Bologna, and other provinces.",,"""we included all the adults tested for SARS-CoV-2 serological screening that were referred to the Test laboratory during the period between 26 September 2020 and 26 March 2021: workers referred by their companies, which recommended that their employees were tested, as well as self-referred individuals voluntarily admitted to the facility to undergo SARS-CoV-2 testing.""",,2020-09-26,2021-03-26,Multiple populations,All,Adults (18-64 years),50.0,59.0,Age,,1054,0.13470000000000001,,,,,,,,Self-referral,"Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Diagnostic kit for SARS-CoV-2 IgM/IgG Antibody (Colloidal Gold)","Roche Diagnostics,Shanghai Kehua Bio-engineering (KHB) Co. Ltd",Multiple Types,Serum,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],,No,Yes,Yes,,Unclear,No,No,,Stefania Paduano,University of Modena and Reggio Emilia,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph19137882,2022-07-08,2022-07-29,Unverified,paduano_seroprevalence_2022,ITA
220627_EmiliaRomagnaRegion_UniversityOfModenaAndReggioEmilia_Age_60-69,220627_EmiliaRomagnaRegion_UniversityOfModenaAndReggioEmilia,"Seroprevalence Survey of Anti-SARS-CoV-2 Antibodies in a Population of Emilia-Romagna Region, Northern Italy",2022-06-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,"Emilia-Romagna Region; including provinces of Modena, Reggio Emilia, Parma, Bologna, and other provinces.",,"""we included all the adults tested for SARS-CoV-2 serological screening that were referred to the Test laboratory during the period between 26 September 2020 and 26 March 2021: workers referred by their companies, which recommended that their employees were tested, as well as self-referred individuals voluntarily admitted to the facility to undergo SARS-CoV-2 testing.""",,2020-09-26,2021-03-26,Multiple populations,All,Adults (18-64 years),60.0,69.0,Age,,431,0.1856,,,,,,,,Self-referral,"Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Diagnostic kit for SARS-CoV-2 IgM/IgG Antibody (Colloidal Gold)","Roche Diagnostics,Shanghai Kehua Bio-engineering (KHB) Co. Ltd",Multiple Types,Serum,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],,No,Yes,Yes,,Unclear,No,No,,Stefania Paduano,University of Modena and Reggio Emilia,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph19137882,2022-07-08,2022-07-29,Unverified,paduano_seroprevalence_2022,ITA
220630_Udine_UniversityofUdine,220630_Udine_UniversityofUdine,Low risk of nosocomial severe acute respiratory syndrome-coronavirus-2 infection in patients with liver disease admitted to a hepatology unit at an academic hospital: A single-center experience.,2022-06-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Friuli Venezia Giulia region,Udine,"""We enrolled all consecutive patients carrying a diagnosis of liver disease who were admitted to the hepatology and liver transplantation unit of the University of Udine’s academic hospital in Italy""",,2020-03-01,2020-10-31,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),,,Primary Estimate,,143,0.006999999999999999,,,True,,,,True,Sequential,"ADVIA Centaur Immunoassay System,iFlash-SARS-CoV-2 IgM/IgG","Siemens,Shenzhen Yhlo Biotech Co. Ltd",CLIA,Serum,"['IgG', 'IgM']",Spike,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Pierluigi Toniutto,University of Udine,Not Unity-Aligned,https://dx.doi.org/10.1007/s12664-022-01241-8,2022-07-07,2024-03-01,Unverified,toniutto_low_2022,ITA
220630_Tuscany_UniversityofSiena,220630_Tuscany_UniversityofSiena,"SARS-CoV-2 Circulation during the First Year of the Pandemic: A Seroprevalence Study from January to December 2020 in Tuscany, Italy",2022-06-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Italy,Tuscany,,"""Human  serum  samples  were  anonymously  collected  from  January  to  the  end  ofDecember 2020 in Siena as residual samples for unknown diagnostic purposes and stored at the laboratory of Molecular Epidemiology of the University of Siena, Italy, in compliance with Italian ethics laws. """,,2020-01-28,2020-12-31,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,2480,0.0315,,,True,,,,True,Sequential,"ENZY-WELL SARS-CoV-2 IgG,ENZY-WELL SARS-CoV-2 IgM,Author designed (ELISA) -Spike","Diesse,NA",ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Serena Marchi,University of Siena,Not Unity-Aligned,https://dx.doi.org/10.3390/v14071441,2022-07-21,2024-03-01,Unverified,marchi_sars-cov-2_2022,ITA
220728_Italy_CittàdellaSaluteedellaScienzadiTorino_Primary,220728_Italy_CittàdellaSaluteedellaScienzadiTorino,Increase in newly diagnosed type 1 diabetes and serological evidence of recent SARS-CoV-2 infection: Is there a connection?,2022-07-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Italy,,Turin,"patients who presented to the emergency department for T1D new onset between October 15, 2020, and April 15, 2021, aged between 0 and 14 years, in the Turin area (Piedmont, Italy).",,2020-10-15,2021-04-15,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),,18.0,Primary Estimate,,39,0.23,,,True,,,,True,Sequential,ERADIKIT™ COVID19-IgG Indirect ELISA for the detection of anti SARS-CoV2,In3diagnostic,ELISA,,IgG,,Validated by independent authors/third party/non-developers,0.96,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Marco Denina,Città della Salute e della Scienza di Torino,Not Unity-Aligned,https://dx.doi.org/10.3389/fmed.2022.927099,2022-08-24,2024-03-01,Unverified,denina_increase_2022,ITA
220811_Veneto_UniversityHospitalOfPadova_2020Aug_Overall,220811_Veneto_UniversityHospitalOfPadova_2020Aug,Serological Evidence and Self-reported Outcomes in Patients with Adrenal Insufficiency during the first waves of COVID-19 in the North-East Italy,2022-08-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Veneto,,"Patients with adrenal insufficiency, ""resident in Veneto and followed-up in our out clinical of Endocrine Unit.""",,2020-08-01,2020-08-15,Residual sera,All,Multiple groups,,,Primary Estimate,,84,0.0,,,True,,,,True,Sequential,Not reported/ Unable to specify,,,,IgG,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Chiara Sabbadin,University-Hospital of Padova,Not Unity-Aligned,https://dx.doi.org/10.2174/1871530322666220811103755,2022-08-22,2023-12-13,Unverified,sabbadin_serological_2022,ITA
220811_Veneto_UniversityHospitalOfPadova_2021MarApr_Overall,220811_Veneto_UniversityHospitalOfPadova_2021MarApr,Serological Evidence and Self-reported Outcomes in Patients with Adrenal Insufficiency during the first waves of COVID-19 in the North-East Italy,2022-08-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Veneto,,"Patients with adrenal insufficiency, ""resident in Veneto and followed-up in our out clinical of Endocrine Unit.""",,2021-03-15,2021-04-15,Residual sera,All,Multiple groups,,,Primary Estimate,,84,0.09519999999999999,,,True,,,,True,Sequential,Not reported/ Unable to specify,,,,IgG,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Chiara Sabbadin,University-Hospital of Padova,Not Unity-Aligned,https://dx.doi.org/10.2174/1871530322666220811103755,2022-08-22,2022-08-22,Unverified,sabbadin_serological_2022,ITA
220915_Turin_UniversityofTurin_Survey1,220915_Turin_UniversityofTurin_Survey1,Seroprevalence of infection-induced SARS-CoV-2 antibodies among health care users of Northern Italy: results from two serosurveys (October-November 2019 and September-October 2021),2022-09-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Italy,Piedmont,Turin,"""residual sera were obtained from outpatients aged 6 – 90 years undergoing routine haematochemical tests at the Città della Salute e della Scienza, a tertiary-care and teaching hospital of Turin, which is
an important referral center for the entire region of Piedmont, in North-western Italy.""","""Patients with cancer, immunodeficiency, or undergoing 
immunosuppressive therapy were excluded from the study.""",2019-10-15,2019-11-15,Residual sera,All,Multiple groups,6.0,90.0,Primary Estimate,,353,0.0141,,,True,,,,True,Sequential,"Anti-SARS-CoV-2 ELISA IgG,BioPlex 2200 SARS-CoV-2 IgG Panel","EUROIMMUN,Bio-rad",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,No,,No,Yes,No,,Constanza Vicentini,University of Turin,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2022.09.017,2022-09-29,2024-03-01,Unverified,vicentini_seroprevalence_2022,ITA
220915_Turin_UniversityofTurin_Survey1_Age_21-40,220915_Turin_UniversityofTurin_Survey1,Seroprevalence of infection-induced SARS-CoV-2 antibodies among health care users of Northern Italy: results from two serosurveys (October-November 2019 and September-October 2021),2022-09-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Italy,Piedmont,Turin,"""residual sera were obtained from outpatients aged 6 – 90 years undergoing routine haematochemical tests at the Città della Salute e della Scienza, a tertiary-care and teaching hospital of Turin, which is
an important referral center for the entire region of Piedmont, in North-western Italy.""","""Patients with cancer, immunodeficiency, or undergoing 
immunosuppressive therapy were excluded from the study.""",2019-10-15,2019-11-15,Residual sera,All,Adults (18-64 years),21.0,40.0,Age,21-40,137,0.0146,,,,,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgG,BioPlex 2200 SARS-CoV-2 IgG Panel","EUROIMMUN,Bio-rad",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,No,,No,Yes,No,,Constanza Vicentini,University of Turin,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2022.09.017,2022-09-29,2024-03-01,Unverified,vicentini_seroprevalence_2022,ITA
220915_Turin_UniversityofTurin_Survey1_Age_>75,220915_Turin_UniversityofTurin_Survey1,Seroprevalence of infection-induced SARS-CoV-2 antibodies among health care users of Northern Italy: results from two serosurveys (October-November 2019 and September-October 2021),2022-09-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Italy,Piedmont,Turin,"""residual sera were obtained from outpatients aged 6 – 90 years undergoing routine haematochemical tests at the Città della Salute e della Scienza, a tertiary-care and teaching hospital of Turin, which is
an important referral center for the entire region of Piedmont, in North-western Italy.""","""Patients with cancer, immunodeficiency, or undergoing 
immunosuppressive therapy were excluded from the study.""",2019-10-15,2019-11-15,Residual sera,All,Seniors (65+ years),75.0,,Age,>75,16,0.0,,,,,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgG,BioPlex 2200 SARS-CoV-2 IgG Panel","EUROIMMUN,Bio-rad",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,No,,No,Yes,No,,Constanza Vicentini,University of Turin,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2022.09.017,2022-09-29,2024-03-01,Unverified,vicentini_seroprevalence_2022,ITA
220915_Turin_UniversityofTurin_Survey1_Age_6-20,220915_Turin_UniversityofTurin_Survey1,Seroprevalence of infection-induced SARS-CoV-2 antibodies among health care users of Northern Italy: results from two serosurveys (October-November 2019 and September-October 2021),2022-09-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Italy,Piedmont,Turin,"""residual sera were obtained from outpatients aged 6 – 90 years undergoing routine haematochemical tests at the Città della Salute e della Scienza, a tertiary-care and teaching hospital of Turin, which is
an important referral center for the entire region of Piedmont, in North-western Italy.""","""Patients with cancer, immunodeficiency, or undergoing 
immunosuppressive therapy were excluded from the study.""",2019-10-15,2019-11-15,Residual sera,All,Multiple groups,6.0,20.0,Age,6-20,158,0.019,,,,,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgG,BioPlex 2200 SARS-CoV-2 IgG Panel","EUROIMMUN,Bio-rad",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,No,,No,Yes,No,,Constanza Vicentini,University of Turin,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2022.09.017,2022-09-29,2024-03-01,Unverified,vicentini_seroprevalence_2022,ITA
220915_Turin_UniversityofTurin_Survey1_Age_51-64,220915_Turin_UniversityofTurin_Survey1,Seroprevalence of infection-induced SARS-CoV-2 antibodies among health care users of Northern Italy: results from two serosurveys (October-November 2019 and September-October 2021),2022-09-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Italy,Piedmont,Turin,"""residual sera were obtained from outpatients aged 6 – 90 years undergoing routine haematochemical tests at the Città della Salute e della Scienza, a tertiary-care and teaching hospital of Turin, which is
an important referral center for the entire region of Piedmont, in North-western Italy.""","""Patients with cancer, immunodeficiency, or undergoing 
immunosuppressive therapy were excluded from the study.""",2019-10-15,2019-11-15,Residual sera,All,Adults (18-64 years),51.0,64.0,Age,51-64,16,0.0,,,,,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgG,BioPlex 2200 SARS-CoV-2 IgG Panel","EUROIMMUN,Bio-rad",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,No,,No,Yes,No,,Constanza Vicentini,University of Turin,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2022.09.017,2022-09-29,2024-03-01,Unverified,vicentini_seroprevalence_2022,ITA
220915_Turin_UniversityofTurin_Survey1_Age_65-74,220915_Turin_UniversityofTurin_Survey1,Seroprevalence of infection-induced SARS-CoV-2 antibodies among health care users of Northern Italy: results from two serosurveys (October-November 2019 and September-October 2021),2022-09-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Italy,Piedmont,Turin,"""residual sera were obtained from outpatients aged 6 – 90 years undergoing routine haematochemical tests at the Città della Salute e della Scienza, a tertiary-care and teaching hospital of Turin, which is
an important referral center for the entire region of Piedmont, in North-western Italy.""","""Patients with cancer, immunodeficiency, or undergoing 
immunosuppressive therapy were excluded from the study.""",2019-10-15,2019-11-15,Residual sera,All,Seniors (65+ years),65.0,74.0,Age,65-74,16,0.0,,,,,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgG,BioPlex 2200 SARS-CoV-2 IgG Panel","EUROIMMUN,Bio-rad",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,No,,No,Yes,No,,Constanza Vicentini,University of Turin,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2022.09.017,2022-09-29,2024-03-01,Unverified,vicentini_seroprevalence_2022,ITA
220915_Turin_UniversityofTurin_Survey1_Age_41-50,220915_Turin_UniversityofTurin_Survey1,Seroprevalence of infection-induced SARS-CoV-2 antibodies among health care users of Northern Italy: results from two serosurveys (October-November 2019 and September-October 2021),2022-09-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Italy,Piedmont,Turin,"""residual sera were obtained from outpatients aged 6 – 90 years undergoing routine haematochemical tests at the Città della Salute e della Scienza, a tertiary-care and teaching hospital of Turin, which is
an important referral center for the entire region of Piedmont, in North-western Italy.""","""Patients with cancer, immunodeficiency, or undergoing 
immunosuppressive therapy were excluded from the study.""",2019-10-15,2019-11-15,Residual sera,All,Adults (18-64 years),41.0,50.0,Age,41-50,10,0.0,,,,,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgG,BioPlex 2200 SARS-CoV-2 IgG Panel","EUROIMMUN,Bio-rad",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,No,,No,Yes,No,,Constanza Vicentini,University of Turin,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2022.09.017,2022-09-29,2024-03-01,Unverified,vicentini_seroprevalence_2022,ITA
220915_Turin_UniversityofTurin_Survey2,220915_Turin_UniversityofTurin_Survey2,Seroprevalence of infection-induced SARS-CoV-2 antibodies among health care users of Northern Italy: results from two serosurveys (October-November 2019 and September-October 2021),2022-09-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Italy,Piedmont,Turin,"""residual sera were obtained from outpatients aged 6 – 90 years undergoing routine haematochemical tests at the Città della Salute e della Scienza, a tertiary-care and teaching hospital of Turin, which is
an important referral center for the entire region of Piedmont, in North-western Italy.""","""Patients with cancer, immunodeficiency, or undergoing 
immunosuppressive therapy were excluded from the study.""",2021-09-15,2021-10-15,Residual sera,All,Multiple groups,6.0,90.0,Primary Estimate,,363,0.807,,,True,,,,True,Sequential,"Anti-SARS-CoV-2 ELISA IgG,BioPlex 2200 SARS-CoV-2 IgG Panel","EUROIMMUN,Bio-rad",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,No,,No,Yes,No,,Constanza Vicentini,University of Turin,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2022.09.017,2022-09-29,2024-03-01,Unverified,vicentini_seroprevalence_2022,ITA
220915_Turin_UniversityofTurin_Survey2_Age_65-74,220915_Turin_UniversityofTurin_Survey2,Seroprevalence of infection-induced SARS-CoV-2 antibodies among health care users of Northern Italy: results from two serosurveys (October-November 2019 and September-October 2021),2022-09-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Italy,Piedmont,Turin,"""residual sera were obtained from outpatients aged 6 – 90 years undergoing routine haematochemical tests at the Città della Salute e della Scienza, a tertiary-care and teaching hospital of Turin, which is
an important referral center for the entire region of Piedmont, in North-western Italy.""","""Patients with cancer, immunodeficiency, or undergoing 
immunosuppressive therapy were excluded from the study.""",2021-09-15,2021-10-15,Residual sera,All,Seniors (65+ years),65.0,74.0,Age,65-74,16,0.875,,,,,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgG,BioPlex 2200 SARS-CoV-2 IgG Panel","EUROIMMUN,Bio-rad",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,No,,No,Yes,No,,Constanza Vicentini,University of Turin,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2022.09.017,2022-09-29,2024-03-01,Unverified,vicentini_seroprevalence_2022,ITA
220915_Turin_UniversityofTurin_Survey2_Age_>75,220915_Turin_UniversityofTurin_Survey2,Seroprevalence of infection-induced SARS-CoV-2 antibodies among health care users of Northern Italy: results from two serosurveys (October-November 2019 and September-October 2021),2022-09-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Italy,Piedmont,Turin,"""residual sera were obtained from outpatients aged 6 – 90 years undergoing routine haematochemical tests at the Città della Salute e della Scienza, a tertiary-care and teaching hospital of Turin, which is
an important referral center for the entire region of Piedmont, in North-western Italy.""","""Patients with cancer, immunodeficiency, or undergoing 
immunosuppressive therapy were excluded from the study.""",2021-09-15,2021-10-15,Residual sera,All,Seniors (65+ years),75.0,,Age,>75,16,0.938,,,,,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgG,BioPlex 2200 SARS-CoV-2 IgG Panel","EUROIMMUN,Bio-rad",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,No,,No,Yes,No,,Constanza Vicentini,University of Turin,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2022.09.017,2022-09-29,2024-03-01,Unverified,vicentini_seroprevalence_2022,ITA
220915_Turin_UniversityofTurin_Survey2_Age_51-64,220915_Turin_UniversityofTurin_Survey2,Seroprevalence of infection-induced SARS-CoV-2 antibodies among health care users of Northern Italy: results from two serosurveys (October-November 2019 and September-October 2021),2022-09-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Italy,Piedmont,Turin,"""residual sera were obtained from outpatients aged 6 – 90 years undergoing routine haematochemical tests at the Città della Salute e della Scienza, a tertiary-care and teaching hospital of Turin, which is
an important referral center for the entire region of Piedmont, in North-western Italy.""","""Patients with cancer, immunodeficiency, or undergoing 
immunosuppressive therapy were excluded from the study.""",2021-09-15,2021-10-15,Residual sera,All,Adults (18-64 years),51.0,64.0,Age,51-64,16,0.688,,,,,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgG,BioPlex 2200 SARS-CoV-2 IgG Panel","EUROIMMUN,Bio-rad",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,No,,No,Yes,No,,Constanza Vicentini,University of Turin,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2022.09.017,2022-09-29,2024-03-01,Unverified,vicentini_seroprevalence_2022,ITA
220915_Turin_UniversityofTurin_Survey2_Age_41-50,220915_Turin_UniversityofTurin_Survey2,Seroprevalence of infection-induced SARS-CoV-2 antibodies among health care users of Northern Italy: results from two serosurveys (October-November 2019 and September-October 2021),2022-09-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Italy,Piedmont,Turin,"""residual sera were obtained from outpatients aged 6 – 90 years undergoing routine haematochemical tests at the Città della Salute e della Scienza, a tertiary-care and teaching hospital of Turin, which is
an important referral center for the entire region of Piedmont, in North-western Italy.""","""Patients with cancer, immunodeficiency, or undergoing 
immunosuppressive therapy were excluded from the study.""",2021-09-15,2021-10-15,Residual sera,All,Adults (18-64 years),41.0,50.0,Age,41-50,10,0.9,,,,,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgG,BioPlex 2200 SARS-CoV-2 IgG Panel","EUROIMMUN,Bio-rad",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,No,,No,Yes,No,,Constanza Vicentini,University of Turin,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2022.09.017,2022-09-29,2024-03-01,Unverified,vicentini_seroprevalence_2022,ITA
220915_Turin_UniversityofTurin_Survey2_Age_21-40,220915_Turin_UniversityofTurin_Survey2,Seroprevalence of infection-induced SARS-CoV-2 antibodies among health care users of Northern Italy: results from two serosurveys (October-November 2019 and September-October 2021),2022-09-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Italy,Piedmont,Turin,"""residual sera were obtained from outpatients aged 6 – 90 years undergoing routine haematochemical tests at the Città della Salute e della Scienza, a tertiary-care and teaching hospital of Turin, which is
an important referral center for the entire region of Piedmont, in North-western Italy.""","""Patients with cancer, immunodeficiency, or undergoing 
immunosuppressive therapy were excluded from the study.""",2021-09-15,2021-10-15,Residual sera,All,Adults (18-64 years),21.0,40.0,Age,21-40,140,0.8140000000000001,,,,,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgG,BioPlex 2200 SARS-CoV-2 IgG Panel","EUROIMMUN,Bio-rad",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,No,,No,Yes,No,,Constanza Vicentini,University of Turin,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2022.09.017,2022-09-29,2024-03-01,Unverified,vicentini_seroprevalence_2022,ITA
220915_Turin_UniversityofTurin_Survey2_Age_6-20,220915_Turin_UniversityofTurin_Survey2,Seroprevalence of infection-induced SARS-CoV-2 antibodies among health care users of Northern Italy: results from two serosurveys (October-November 2019 and September-October 2021),2022-09-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Italy,Piedmont,Turin,"""residual sera were obtained from outpatients aged 6 – 90 years undergoing routine haematochemical tests at the Città della Salute e della Scienza, a tertiary-care and teaching hospital of Turin, which is
an important referral center for the entire region of Piedmont, in North-western Italy.""","""Patients with cancer, immunodeficiency, or undergoing 
immunosuppressive therapy were excluded from the study.""",2021-09-15,2021-10-15,Residual sera,All,Multiple groups,6.0,20.0,Age,6-20,165,0.7759999999999999,,,,,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgG,BioPlex 2200 SARS-CoV-2 IgG Panel","EUROIMMUN,Bio-rad",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,No,,No,Yes,No,,Constanza Vicentini,University of Turin,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2022.09.017,2022-09-29,2024-03-01,Unverified,vicentini_seroprevalence_2022,ITA
221009_Lombardy_IRCCSPoliclinicoSanDonato,221009_Lombardy_IRCCSPoliclinicoSanDonato,Serum proteomics and metabolomics study on susceptibility to SARS-CoV-2 infection in IBD patients,2022-10-09,Presentation or Conference,Regional,Cross-sectional survey ,Italy,Lombardy,,"""Between April 2020 and April 2022, 238 IBD patients (N=145 Crohn disease, N=93 Ulcerative colitis) and 45 healthy controls (HC) of the North Italy area were enrolled and serum samples were collected.""

Seroprevalence is only reported for IBD patients (and not the healthy controls).",,2020-04-15,2022-04-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,238,0.09240000000000001,,,True,,,,True,Convenience,BioPlex 2200 SARS-CoV-2 IgG Panel,Bio-rad,,Serum,IgG,,,,,['High'],,No,No,No,,Yes,Yes,Yes,,L.F. Pisani,IRCCS Policlinico San Donato,Not Unity-Aligned,https://dx.doi.org/10.1002/ueg2.12294,2022-11-21,2024-03-01,Unverified,pisani_serum_2022,ITA
221026_TrentinoAltoAdige_UniversityofPadova_overall,221026_TrentinoAltoAdige_UniversityofPadova,Seroprevalence of SARS-CoV-2 antibodies in Italy in newborn dried blood spots.,2022-10-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Italy,Trentino,,"""From January 2020 through December 2021, DBS samples were collected 2–3 days after birth from infants born in the Trentino Alto Adige region, Italy. """,,2020-01-01,2021-12-31,Residual sera,All,Children and Youth (0-17 years),0.0,0.0,Primary Estimate,,2400,0.11460000000000001,,,True,,,,True,Sequential,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,0.9319999999999993,0.998,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Luisa Galla,University of Padova,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0948,2022-11-02,2024-04-17,Verified,gallaSeroprevalenceSARSCoV2Antibodies2022,ITA
221026_TrentinoAltoAdige_UniversityofPadova_month4,221026_TrentinoAltoAdige_UniversityofPadova,Seroprevalence of SARS-CoV-2 antibodies in Italy in newborn dried blood spots.,2022-10-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Italy,Trentino,,"""From January 2020 through December 2021, DBS samples were collected 2–3 days after birth from infants born in the Trentino Alto Adige region, Italy. """,,2020-04-01,2020-04-30,Residual sera,All,Children and Youth (0-17 years),0.0,0.0,Time frame,Apr 2020,100,0.02,,,,,,,,Sequential,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,0.932,0.998,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Luisa Galla,University of Padova,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0948,2022-11-02,2024-04-17,Verified,gallaSeroprevalenceSARSCoV2Antibodies2022,ITA
221026_TrentinoAltoAdige_UniversityofPadova_month13,221026_TrentinoAltoAdige_UniversityofPadova,Seroprevalence of SARS-CoV-2 antibodies in Italy in newborn dried blood spots.,2022-10-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Italy,Trentino,,"""From January 2020 through December 2021, DBS samples were collected 2–3 days after birth from infants born in the Trentino Alto Adige region, Italy. """,,2021-01-01,2021-01-31,Residual sera,All,Children and Youth (0-17 years),0.0,0.0,Time frame,Jan  2021,100,0.1,,,,,,,,Sequential,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,0.932,0.998,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Luisa Galla,University of Padova,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0948,2022-11-02,2024-04-17,Verified,gallaSeroprevalenceSARSCoV2Antibodies2022,ITA
221026_TrentinoAltoAdige_UniversityofPadova_month18,221026_TrentinoAltoAdige_UniversityofPadova,Seroprevalence of SARS-CoV-2 antibodies in Italy in newborn dried blood spots.,2022-10-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Italy,Trentino,,"""From January 2020 through December 2021, DBS samples were collected 2–3 days after birth from infants born in the Trentino Alto Adige region, Italy. """,,2021-06-01,2021-06-30,Residual sera,All,Children and Youth (0-17 years),0.0,0.0,Time frame,Jun 2021,100,0.11,,,,,,,,Sequential,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,0.9319999999999997,0.998,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Luisa Galla,University of Padova,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0948,2022-11-02,2024-04-17,Verified,gallaSeroprevalenceSARSCoV2Antibodies2022,ITA
221026_TrentinoAltoAdige_UniversityofPadova_month19,221026_TrentinoAltoAdige_UniversityofPadova,Seroprevalence of SARS-CoV-2 antibodies in Italy in newborn dried blood spots.,2022-10-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Italy,Trentino,,"""From January 2020 through December 2021, DBS samples were collected 2–3 days after birth from infants born in the Trentino Alto Adige region, Italy. """,,2021-07-01,2021-07-31,Residual sera,All,Children and Youth (0-17 years),0.0,0.0,Time frame,Jul 2021,100,0.13,,,,,,,,Sequential,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,0.9319999999999996,0.998,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Luisa Galla,University of Padova,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0948,2022-11-02,2024-04-17,Verified,gallaSeroprevalenceSARSCoV2Antibodies2022,ITA
221026_TrentinoAltoAdige_UniversityofPadova_month8,221026_TrentinoAltoAdige_UniversityofPadova,Seroprevalence of SARS-CoV-2 antibodies in Italy in newborn dried blood spots.,2022-10-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Italy,Trentino,,"""From January 2020 through December 2021, DBS samples were collected 2–3 days after birth from infants born in the Trentino Alto Adige region, Italy. """,,2020-08-01,2020-08-31,Residual sera,All,Children and Youth (0-17 years),0.0,0.0,Time frame,Aug 2020,100,0.0,,,,,,,,Sequential,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,0.932,0.998,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Luisa Galla,University of Padova,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0948,2022-11-02,2024-04-17,Verified,gallaSeroprevalenceSARSCoV2Antibodies2022,ITA
221026_TrentinoAltoAdige_UniversityofPadova_month15,221026_TrentinoAltoAdige_UniversityofPadova,Seroprevalence of SARS-CoV-2 antibodies in Italy in newborn dried blood spots.,2022-10-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Italy,Trentino,,"""From January 2020 through December 2021, DBS samples were collected 2–3 days after birth from infants born in the Trentino Alto Adige region, Italy. """,,2021-03-01,2021-03-31,Residual sera,All,Children and Youth (0-17 years),0.0,0.0,Time frame,Mar 2021,100,0.15,,,,,,,,Sequential,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,0.932,0.998,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Luisa Galla,University of Padova,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0948,2022-11-02,2024-04-17,Verified,gallaSeroprevalenceSARSCoV2Antibodies2022,ITA
221026_TrentinoAltoAdige_UniversityofPadova_month22,221026_TrentinoAltoAdige_UniversityofPadova,Seroprevalence of SARS-CoV-2 antibodies in Italy in newborn dried blood spots.,2022-10-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Italy,Trentino,,"""From January 2020 through December 2021, DBS samples were collected 2–3 days after birth from infants born in the Trentino Alto Adige region, Italy. """,,2021-10-01,2021-10-31,Residual sera,All,Children and Youth (0-17 years),0.0,0.0,Time frame,Oct 2021,100,0.32,,,,,,,,Sequential,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,0.9319999999999995,0.998,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Luisa Galla,University of Padova,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0948,2022-11-02,2024-04-17,Verified,gallaSeroprevalenceSARSCoV2Antibodies2022,ITA
221026_TrentinoAltoAdige_UniversityofPadova_month17,221026_TrentinoAltoAdige_UniversityofPadova,Seroprevalence of SARS-CoV-2 antibodies in Italy in newborn dried blood spots.,2022-10-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Italy,Trentino,,"""From January 2020 through December 2021, DBS samples were collected 2–3 days after birth from infants born in the Trentino Alto Adige region, Italy. """,,2021-05-01,2021-05-31,Residual sera,All,Children and Youth (0-17 years),0.0,0.0,Time frame,May 2021,100,0.14,,,,,,,,Sequential,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,0.9319999999999997,0.998,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Luisa Galla,University of Padova,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0948,2022-11-02,2024-04-17,Verified,gallaSeroprevalenceSARSCoV2Antibodies2022,ITA
221026_TrentinoAltoAdige_UniversityofPadova_month9,221026_TrentinoAltoAdige_UniversityofPadova,Seroprevalence of SARS-CoV-2 antibodies in Italy in newborn dried blood spots.,2022-10-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Italy,Trentino,,"""From January 2020 through December 2021, DBS samples were collected 2–3 days after birth from infants born in the Trentino Alto Adige region, Italy. """,,2020-09-01,2020-09-30,Residual sera,All,Children and Youth (0-17 years),0.0,0.0,Time frame,Sep 2020,100,0.02,,,,,,,,Sequential,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,0.932,0.998,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Luisa Galla,University of Padova,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0948,2022-11-02,2024-04-17,Verified,gallaSeroprevalenceSARSCoV2Antibodies2022,ITA
221026_TrentinoAltoAdige_UniversityofPadova_month2,221026_TrentinoAltoAdige_UniversityofPadova,Seroprevalence of SARS-CoV-2 antibodies in Italy in newborn dried blood spots.,2022-10-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Italy,Trentino,,"""From January 2020 through December 2021, DBS samples were collected 2–3 days after birth from infants born in the Trentino Alto Adige region, Italy. """,,2020-02-01,2020-02-28,Residual sera,All,Children and Youth (0-17 years),0.0,0.0,Time frame,Feb 2020,100,0.0,,,,,,,,Sequential,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,0.932,0.998,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Luisa Galla,University of Padova,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0948,2022-11-02,2024-04-17,Verified,gallaSeroprevalenceSARSCoV2Antibodies2022,ITA
221026_TrentinoAltoAdige_UniversityofPadova_month23,221026_TrentinoAltoAdige_UniversityofPadova,Seroprevalence of SARS-CoV-2 antibodies in Italy in newborn dried blood spots.,2022-10-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Italy,Trentino,,"""From January 2020 through December 2021, DBS samples were collected 2–3 days after birth from infants born in the Trentino Alto Adige region, Italy. """,,2021-11-01,2021-11-30,Residual sera,All,Children and Youth (0-17 years),0.0,0.0,Time frame,Nov 2021,100,0.47000000000000003,,,,,,,,Sequential,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,0.9319999999999994,0.998,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Luisa Galla,University of Padova,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0948,2022-11-02,2024-04-17,Verified,gallaSeroprevalenceSARSCoV2Antibodies2022,ITA
221026_TrentinoAltoAdige_UniversityofPadova_month5,221026_TrentinoAltoAdige_UniversityofPadova,Seroprevalence of SARS-CoV-2 antibodies in Italy in newborn dried blood spots.,2022-10-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Italy,Trentino,,"""From January 2020 through December 2021, DBS samples were collected 2–3 days after birth from infants born in the Trentino Alto Adige region, Italy. """,,2020-05-01,2020-05-31,Residual sera,All,Children and Youth (0-17 years),0.0,0.0,Time frame,May 2020,100,0.01,,,,,,,,Sequential,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,0.932,0.998,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Luisa Galla,University of Padova,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0948,2022-11-02,2024-04-17,Verified,gallaSeroprevalenceSARSCoV2Antibodies2022,ITA
221026_TrentinoAltoAdige_UniversityofPadova_month14,221026_TrentinoAltoAdige_UniversityofPadova,Seroprevalence of SARS-CoV-2 antibodies in Italy in newborn dried blood spots.,2022-10-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Italy,Trentino,,"""From January 2020 through December 2021, DBS samples were collected 2–3 days after birth from infants born in the Trentino Alto Adige region, Italy. """,,2021-02-01,2021-02-28,Residual sera,All,Children and Youth (0-17 years),0.0,0.0,Time frame,Feb 2021,100,0.18,,,,,,,,Sequential,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,0.932,0.998,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Luisa Galla,University of Padova,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0948,2022-11-02,2024-04-17,Verified,gallaSeroprevalenceSARSCoV2Antibodies2022,ITA
221026_TrentinoAltoAdige_UniversityofPadova_month12,221026_TrentinoAltoAdige_UniversityofPadova,Seroprevalence of SARS-CoV-2 antibodies in Italy in newborn dried blood spots.,2022-10-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Italy,Trentino,,"""From January 2020 through December 2021, DBS samples were collected 2–3 days after birth from infants born in the Trentino Alto Adige region, Italy. """,,2020-12-01,2020-12-31,Residual sera,All,Children and Youth (0-17 years),0.0,0.0,Time frame,Dec 2020,100,0.06,,,,,,,,Sequential,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,0.932,0.998,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Luisa Galla,University of Padova,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0948,2022-11-02,2024-04-17,Verified,gallaSeroprevalenceSARSCoV2Antibodies2022,ITA
221026_TrentinoAltoAdige_UniversityofPadova_month21,221026_TrentinoAltoAdige_UniversityofPadova,Seroprevalence of SARS-CoV-2 antibodies in Italy in newborn dried blood spots.,2022-10-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Italy,Trentino,,"""From January 2020 through December 2021, DBS samples were collected 2–3 days after birth from infants born in the Trentino Alto Adige region, Italy. """,,2021-09-01,2021-09-30,Residual sera,All,Children and Youth (0-17 years),0.0,0.0,Time frame,Sep 2021,100,0.18,,,,,,,,Sequential,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,0.9319999999999995,0.998,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Luisa Galla,University of Padova,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0948,2022-11-02,2024-04-17,Verified,gallaSeroprevalenceSARSCoV2Antibodies2022,ITA
221026_TrentinoAltoAdige_UniversityofPadova_month20,221026_TrentinoAltoAdige_UniversityofPadova,Seroprevalence of SARS-CoV-2 antibodies in Italy in newborn dried blood spots.,2022-10-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Italy,Trentino,,"""From January 2020 through December 2021, DBS samples were collected 2–3 days after birth from infants born in the Trentino Alto Adige region, Italy. """,,2021-08-01,2021-08-31,Residual sera,All,Children and Youth (0-17 years),0.0,0.0,Time frame,Aug 2021,100,0.17,,,,,,,,Sequential,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,0.9319999999999996,0.998,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Luisa Galla,University of Padova,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0948,2022-11-02,2024-04-17,Verified,gallaSeroprevalenceSARSCoV2Antibodies2022,ITA
221026_TrentinoAltoAdige_UniversityofPadova_month10,221026_TrentinoAltoAdige_UniversityofPadova,Seroprevalence of SARS-CoV-2 antibodies in Italy in newborn dried blood spots.,2022-10-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Italy,Trentino,,"""From January 2020 through December 2021, DBS samples were collected 2–3 days after birth from infants born in the Trentino Alto Adige region, Italy. """,,2020-10-01,2020-10-31,Residual sera,All,Children and Youth (0-17 years),0.0,0.0,Time frame,Oct 2020,100,0.0,,,,,,,,Sequential,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,0.932,0.998,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Luisa Galla,University of Padova,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0948,2022-11-02,2024-04-17,Verified,gallaSeroprevalenceSARSCoV2Antibodies2022,ITA
221026_TrentinoAltoAdige_UniversityofPadova_month6,221026_TrentinoAltoAdige_UniversityofPadova,Seroprevalence of SARS-CoV-2 antibodies in Italy in newborn dried blood spots.,2022-10-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Italy,Trentino,,"""From January 2020 through December 2021, DBS samples were collected 2–3 days after birth from infants born in the Trentino Alto Adige region, Italy. """,,2020-06-01,2020-06-30,Residual sera,All,Children and Youth (0-17 years),0.0,0.0,Time frame,Jun 2020,100,0.03,,,,,,,,Sequential,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,0.932,0.998,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Luisa Galla,University of Padova,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0948,2022-11-02,2024-04-17,Verified,gallaSeroprevalenceSARSCoV2Antibodies2022,ITA
221026_TrentinoAltoAdige_UniversityofPadova_month24,221026_TrentinoAltoAdige_UniversityofPadova,Seroprevalence of SARS-CoV-2 antibodies in Italy in newborn dried blood spots.,2022-10-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Italy,Trentino,,"""From January 2020 through December 2021, DBS samples were collected 2–3 days after birth from infants born in the Trentino Alto Adige region, Italy. """,,2021-12-01,2021-12-31,Residual sera,All,Children and Youth (0-17 years),0.0,0.0,Time frame,Dec 2021,100,0.45,,,,,,,,Sequential,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,0.9319999999999994,0.998,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Luisa Galla,University of Padova,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0948,2022-11-02,2024-04-17,Verified,gallaSeroprevalenceSARSCoV2Antibodies2022,ITA
221026_TrentinoAltoAdige_UniversityofPadova_month7,221026_TrentinoAltoAdige_UniversityofPadova,Seroprevalence of SARS-CoV-2 antibodies in Italy in newborn dried blood spots.,2022-10-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Italy,Trentino,,"""From January 2020 through December 2021, DBS samples were collected 2–3 days after birth from infants born in the Trentino Alto Adige region, Italy. """,,2020-07-01,2020-07-31,Residual sera,All,Children and Youth (0-17 years),0.0,0.0,Time frame,Jul 2020,100,0.04,,,,,,,,Sequential,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,0.932,0.998,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Luisa Galla,University of Padova,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0948,2022-11-02,2024-04-17,Verified,gallaSeroprevalenceSARSCoV2Antibodies2022,ITA
221026_TrentinoAltoAdige_UniversityofPadova_month1,221026_TrentinoAltoAdige_UniversityofPadova,Seroprevalence of SARS-CoV-2 antibodies in Italy in newborn dried blood spots.,2022-10-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Italy,Trentino,,"""From January 2020 through December 2021, DBS samples were collected 2–3 days after birth from infants born in the Trentino Alto Adige region, Italy. """,,2020-01-01,2020-01-31,Residual sera,All,Children and Youth (0-17 years),0.0,0.0,Time frame,Jan  2020,100,0.0,,,,,,,,Sequential,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,0.932,0.998,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Luisa Galla,University of Padova,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0948,2022-11-02,2024-04-17,Verified,gallaSeroprevalenceSARSCoV2Antibodies2022,ITA
221026_TrentinoAltoAdige_UniversityofPadova_month3,221026_TrentinoAltoAdige_UniversityofPadova,Seroprevalence of SARS-CoV-2 antibodies in Italy in newborn dried blood spots.,2022-10-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Italy,Trentino,,"""From January 2020 through December 2021, DBS samples were collected 2–3 days after birth from infants born in the Trentino Alto Adige region, Italy. """,,2020-03-01,2020-03-31,Residual sera,All,Children and Youth (0-17 years),0.0,0.0,Time frame,Mar 2020,100,0.01,,,,,,,,Sequential,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,0.932,0.998,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Luisa Galla,University of Padova,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0948,2022-11-02,2024-04-17,Verified,gallaSeroprevalenceSARSCoV2Antibodies2022,ITA
221026_TrentinoAltoAdige_UniversityofPadova_month16,221026_TrentinoAltoAdige_UniversityofPadova,Seroprevalence of SARS-CoV-2 antibodies in Italy in newborn dried blood spots.,2022-10-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Italy,Trentino,,"""From January 2020 through December 2021, DBS samples were collected 2–3 days after birth from infants born in the Trentino Alto Adige region, Italy. """,,2021-04-01,2021-04-30,Residual sera,All,Children and Youth (0-17 years),0.0,0.0,Time frame,Apr 2021,100,0.12,,,,,,,,Sequential,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,0.9319999999999998,0.998,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Luisa Galla,University of Padova,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0948,2022-11-02,2024-04-17,Verified,gallaSeroprevalenceSARSCoV2Antibodies2022,ITA
221026_TrentinoAltoAdige_UniversityofPadova_month11,221026_TrentinoAltoAdige_UniversityofPadova,Seroprevalence of SARS-CoV-2 antibodies in Italy in newborn dried blood spots.,2022-10-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Italy,Trentino,,"""From January 2020 through December 2021, DBS samples were collected 2–3 days after birth from infants born in the Trentino Alto Adige region, Italy. """,,2020-11-01,2020-11-30,Residual sera,All,Children and Youth (0-17 years),0.0,0.0,Time frame,Nov 2020,100,0.04,,,,,,,,Sequential,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,0.932,0.998,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Luisa Galla,University of Padova,Unity-Aligned,https://dx.doi.org/10.1515/cclm-2022-0948,2022-11-02,2024-04-17,Verified,gallaSeroprevalenceSARSCoV2Antibodies2022,ITA
221229_TurinAndMilan_UniversityOfTurin,221229_TurinAndMilan_UniversityOfTurin,Possible Impact of Vitamin D Status and Supplementation on SARS-CoV-2 Infection Risk and COVID-19 Symptoms in a Cohort of Patients with Inflammatory Bowel Disease,2022-12-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,"Turin, Milan","""Inclusion criteria: a confirmed diagnosis of IBD according to the guidelines of the European Crohn’s and Colitis Organization (ECCO) [30]; age over 18 years old; willingness to participate in the study and signing of informed consent.""","""Exclusion criteria: execution of the anti-SARS-CoV-2 vaccine"".",2021-01-15,2021-04-15,Residual sera,All,Multiple groups,18.0,,Primary Estimate,,106,0.28300000000000003,,,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Amedeo De Nicolo,University of Turin,Not Unity-Aligned,https://dx.doi.org/10.3390/nu15010169,2023-01-24,2024-03-01,Unverified,de_nicolo_possible_2022,ITA
230112_Rome_UniversitàdegliStudiNiccolòCusano,230112_Rome_UniversitàdegliStudiNiccolòCusano,"Analisi retrospettiva della sieroprevalenza in una coorte di studenti universitari di Roma tra settembre 2020 e luglio 2021, Retrospective analysis of seroprevalence in a cohort of university students of Rome (Italy) between September 2020 and July 2021",2023-01-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Rome,Asymptomatic University Students at Università degli Studi Niccolò Cusano,,2020-09-15,2021-07-15,Students and Daycares,All,Adults (18-64 years),,,Primary Estimate,,2423,0.026000000000000002,0.02,0.033,True,,,,True,Convenience,"Author designed (LFIA),Author designed (type unknown)",,Multiple Types,,"['IgG', 'IgM']",,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Alessandra Ulivieri,Università degli Studi Niccolò Cusano,Not Unity-Aligned,https://dx.doi.org/10.19191/EP22.5-6.A461.088,2023-02-10,2023-03-19,Unverified,ulivieri_retrospective_2023,ITA
230204_Apulia_UniversityofSiena_Primary,230204_Apulia_UniversityofSiena,"SARS-CoV-2 epidemiological trend before vaccination era: a seroprevalence study in Apulia, Southern Italy, in 2020",2023-02-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Apulia Region,Bari,None provided,None provided,2020-01-01,2020-12-31,Residual sera,All,Multiple groups,3.0,99.0,Primary Estimate,Primary estimate,1325,0.066,,,True,,,,True,Simplified probability,ENZY-WELL SARS-CoV-2 IgG,Diesse,ELISA,Serum,IgG,,,0.925,0.958,['High'],,Yes,Yes,No,,No,Yes,No,,Serena Marchi,University of Siena,Not Unity-Aligned,https://dx.doi.org/10.1007/s10389-023-01834-3,2023-03-09,2024-03-01,Unverified,marchi_sars-cov-2_2023,ITA
230204_Apulia_UniversityofSiena_Nov-Dec,230204_Apulia_UniversityofSiena,"SARS-CoV-2 epidemiological trend before vaccination era: a seroprevalence study in Apulia, Southern Italy, in 2020",2023-02-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Apulia Region,Bari,None provided,None provided,2020-11-01,2020-12-31,Residual sera,All,Multiple groups,,,Time frame,November - December,229,0.096,,,,,,,,Simplified probability,ENZY-WELL SARS-CoV-2 IgG,Diesse,ELISA,Serum,IgG,,,0.925,0.958,['High'],,Yes,Yes,No,,No,Yes,No,,Serena Marchi,University of Siena,Not Unity-Aligned,https://dx.doi.org/10.1007/s10389-023-01834-3,2023-03-09,2024-03-01,Unverified,marchi_sars-cov-2_2023,ITA
230204_Apulia_UniversityofSiena_Mar-Apr,230204_Apulia_UniversityofSiena,"SARS-CoV-2 epidemiological trend before vaccination era: a seroprevalence study in Apulia, Southern Italy, in 2020",2023-02-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Apulia Region,Bari,None provided,None provided,2020-03-01,2020-04-30,Residual sera,All,Multiple groups,,,Time frame,March - April,116,0.026,,,,,,,,Simplified probability,ENZY-WELL SARS-CoV-2 IgG,Diesse,ELISA,Serum,IgG,,,0.925,0.958,['High'],,Yes,Yes,No,,No,Yes,No,,Serena Marchi,University of Siena,Not Unity-Aligned,https://dx.doi.org/10.1007/s10389-023-01834-3,2023-03-09,2024-03-01,Unverified,marchi_sars-cov-2_2023,ITA
230204_Apulia_UniversityofSiena_Jul-Aug,230204_Apulia_UniversityofSiena,"SARS-CoV-2 epidemiological trend before vaccination era: a seroprevalence study in Apulia, Southern Italy, in 2020",2023-02-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Apulia Region,Bari,None provided,None provided,2020-07-01,2020-08-31,Residual sera,All,Multiple groups,,,Time frame,July - August,177,0.096,,,,,,,,Simplified probability,ENZY-WELL SARS-CoV-2 IgG,Diesse,ELISA,Serum,IgG,,,0.925,0.958,['High'],,Yes,Yes,No,,No,Yes,No,,Serena Marchi,University of Siena,Not Unity-Aligned,https://dx.doi.org/10.1007/s10389-023-01834-3,2023-03-09,2024-03-01,Unverified,marchi_sars-cov-2_2023,ITA
230204_Apulia_UniversityofSiena_Sep-Oct,230204_Apulia_UniversityofSiena,"SARS-CoV-2 epidemiological trend before vaccination era: a seroprevalence study in Apulia, Southern Italy, in 2020",2023-02-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Apulia Region,Bari,None provided,None provided,2020-09-01,2020-10-31,Residual sera,All,Multiple groups,,,Time frame,September - October,287,0.073,,,,,,,,Simplified probability,ENZY-WELL SARS-CoV-2 IgG,Diesse,ELISA,Serum,IgG,,,0.925,0.958,['High'],,Yes,Yes,No,,No,Yes,No,,Serena Marchi,University of Siena,Not Unity-Aligned,https://dx.doi.org/10.1007/s10389-023-01834-3,2023-03-09,2024-03-01,Unverified,marchi_sars-cov-2_2023,ITA
230204_Apulia_UniversityofSiena_May-Jun,230204_Apulia_UniversityofSiena,"SARS-CoV-2 epidemiological trend before vaccination era: a seroprevalence study in Apulia, Southern Italy, in 2020",2023-02-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Apulia Region,Bari,None provided,None provided,2020-05-01,2020-06-30,Residual sera,All,Multiple groups,,,Time frame,May - June,300,0.07,,,,,,,,Simplified probability,ENZY-WELL SARS-CoV-2 IgG,Diesse,ELISA,Serum,IgG,,,0.925,0.958,['High'],,Yes,Yes,No,,No,Yes,No,,Serena Marchi,University of Siena,Not Unity-Aligned,https://dx.doi.org/10.1007/s10389-023-01834-3,2023-03-09,2024-03-01,Unverified,marchi_sars-cov-2_2023,ITA
230204_Apulia_UniversityofSiena_Jan-Feb,230204_Apulia_UniversityofSiena,"SARS-CoV-2 epidemiological trend before vaccination era: a seroprevalence study in Apulia, Southern Italy, in 2020",2023-02-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,Apulia Region,Bari,None provided,None provided,2020-01-01,2020-02-29,Residual sera,All,Multiple groups,,,Time frame,January-February,216,0.019,,,,,,,,Simplified probability,ENZY-WELL SARS-CoV-2 IgG,Diesse,ELISA,Serum,IgG,,,0.925,0.958,['High'],,Yes,Yes,No,,No,Yes,No,,Serena Marchi,University of Siena,Not Unity-Aligned,https://dx.doi.org/10.1007/s10389-023-01834-3,2023-03-09,2024-03-01,Unverified,marchi_sars-cov-2_2023,ITA
230404_Verona_InstitutoDiRicoveroECuraACaratterre_April-May2020_Primary,230404_Verona_InstitutoDiRicoveroECuraACaratterre_April-May2020,"Two-Year Cohort Study of SARS-CoV-2, Verona, Italy, 2020-2022",2023-04-04,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Italy,Veneto,Verona,>10 years of age lived in Verona,,2020-04-25,2020-05-08,Household and community samples,All,Multiple groups,10.0,,Primary Estimate,,1515,0.027,,,True,,,,True,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Zeno Bisoffi,Instituto di Ricovero e Cura A Caratterre,Unity-Aligned,https://dx.doi.org/10.3201/eid2904.221268,2023-04-03,2024-04-30,Verified,bisoffi_two-year_2023,ITA
230404_Verona_InstitutoDiRicoveroECuraACaratterre_November2021_Nucleocapsid_Primary,230404_Verona_InstitutoDiRicoveroECuraACaratterre_November2021,"Two-Year Cohort Study of SARS-CoV-2, Verona, Italy, 2020-2022",2023-04-04,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Italy,Veneto,Verona,>10 years of age lived in Verona,,2021-11-01,2021-11-30,Household and community samples,All,Multiple groups,,,Primary Estimate,Nucleocapsid ,897,0.178,,,True,,,,True,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,Yes,Yes,No,,Yes,Yes,Yes,,Zeno Bisoffi,Instituto di Ricovero e Cura A Caratterre,Unity-Aligned,https://dx.doi.org/10.3201/eid2904.221268,2023-04-03,2024-04-30,Verified,bisoffi_two-year_2023,ITA
230404_Verona_InstitutoDiRicoveroECuraACaratterre_November2021_Spike,230404_Verona_InstitutoDiRicoveroECuraACaratterre_November2021,"Two-Year Cohort Study of SARS-CoV-2, Verona, Italy, 2020-2022",2023-04-04,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Italy,Veneto,Verona,>10 years of age lived in Verona,,2021-11-01,2021-11-30,Household and community samples,All,Multiple groups,,,Test used,Spike protein,896,0.927,,,,,,,,Simplified probability,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,,,,['High'],,Yes,Yes,No,,Yes,Yes,Yes,,Zeno Bisoffi,Instituto di Ricovero e Cura A Caratterre,Unity-Aligned,https://dx.doi.org/10.3201/eid2904.221268,2023-04-03,2024-04-30,Verified,bisoffi_two-year_2023,ITA
230422_Brescia_UniversityOfBrescia,230422_Brescia_UniversityOfBrescia,Timing and implications for immune response to vaccine in SARS-CoV-2 breakthrough infections,2023-04-22,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Italy,,Brescia,"The study population included all HCWs employed at the Spedali Civili General Hospital when the vaccination campaign started in Italy.

All subjects who received the first dose of SARS-COV-2 vaccine before May 6th 2021 were tested for anti-N total Ig at the time of the first vaccine dose (T0).","Regarding exclusion criteria, we excluded from this analysis.
i. HCWs who did not receive COVID-19 vaccination before May 6th 2021.",2020-12-27,2021-05-06,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,6862,0.3177,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Stefania Arsuffi,University of Brescia,Not Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.106716,2023-05-30,2023-05-31,Unverified,arsuffi_timing_2023,ITA
230512_Verona_UniversityOfVerona_wConfirmatoryTest_Overall,230512_Verona_UniversityOfVerona,SARS-CoV-2 antibodies in inflammatory neurological conditions: a multicentre retrospective comparative study,2023-05-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Verona,"Herein, we assess SARS-CoV-2 seropositivity in a consecutive cohort of patients referred for neurological autoantibody testing.

We retrospectively identified patients referred to the Laboratory of Neuropathology, University Hospital of Verona, Italy, for testing of autoantibodies.","Of the 391 consecutive patient samples, we excluded 39 samples of patients with a chronic disease or referred during a relapse of a known condition and 13 patients in whom only CSF was available.",2020-03-01,2020-08-31,Residual sera,All,Multiple groups,,,Primary Estimate,,339,0.0472,,,True,,,,True,Sequential,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA,LIAISON® SARS-CoV-2 TrimericS IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,Elecsys® Anti‐SARS‐CoV‐2 (S)","EUROIMMUN,DiaSorin,Beckman Coulter,Roche Diagnostics","ELISA,ELISA,CLIA,CLIA, CMIA,CLIA, CMIA",Serum,"['IgA', 'IgG', 'TotalAntibody']",Spike,,,,['High'],,No,No,No,,Unclear,Yes,No,,Cecilia Zivelonghi,University of Verona,Not Unity-Aligned,https://dx.doi.org/10.1007/s12026-023-09384-2,2023-05-31,2024-03-01,Unverified,zivelonghi_sars-cov-2_2023,ITA
230512_Verona_UniversityOfVerona_w/oConfirmatoryTest_IgGorIgA,230512_Verona_UniversityOfVerona,SARS-CoV-2 antibodies in inflammatory neurological conditions: a multicentre retrospective comparative study,2023-05-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Verona,"Herein, we assess SARS-CoV-2 seropositivity in a consecutive cohort of patients referred for neurological autoantibody testing.

We retrospectively identified patients referred to the Laboratory of Neuropathology, University Hospital of Verona, Italy, for testing of autoantibodies.","Of the 391 consecutive patient samples, we excluded 39 samples of patients with a chronic disease or referred during a relapse of a known condition and 13 patients in whom only CSF was available.",2020-03-01,2020-08-31,Residual sera,All,Multiple groups,,,Test used,,339,0.0678,,,,,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA",EUROIMMUN,"ELISA,ELISA",Serum,"['IgA', 'IgG']",Spike,,,,['High'],,No,No,No,,Unclear,Yes,No,,Cecilia Zivelonghi,University of Verona,Not Unity-Aligned,https://dx.doi.org/10.1007/s12026-023-09384-2,2023-05-31,2024-03-01,Unverified,zivelonghi_sars-cov-2_2023,ITA
230530_Modena_UniversityOfModenaAndReggioEmilia_antiS_Primary,230530_Modena_UniversityOfModenaAndReggioEmilia,"Long-Term SARS-CoV-2 Antibody Seroprevalence in Blood Donors, Italy.",2023-05-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Modena,"We evaluated SARS-CoV-2 antibody levels and types in a voluntary blood donor (VBD) population in Modena, Italy, at different timepoints from the beginning of the COVID-19 pandemic.",,2020-07-15,2020-12-15,Blood donors,All,Multiple groups,18.0,,Primary Estimate,Anti-spike,25657,0.0002,,,True,,,,True,Sequential,Architect Anti-SARS-CoV-2 IgM,Abbott Laboratories,CLIA,Serum,IgM,Spike,,,,['High'],,No,Yes,Yes,,No,Yes,No,,Martina Ferrari,University of Modena and Reggio Emilia,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2907.221745,2023-06-28,2024-03-01,Unverified,ferrari_long-term_2023,ITA
230530_Modena_UniversityOfModenaAndReggioEmilia_antiN,230530_Modena_UniversityOfModenaAndReggioEmilia,"Long-Term SARS-CoV-2 Antibody Seroprevalence in Blood Donors, Italy.",2023-05-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Modena,"We evaluated SARS-CoV-2 antibody levels and types in a voluntary blood donor (VBD) population in Modena, Italy, at different timepoints from the beginning of the COVID-19 pandemic.",,2020-07-15,2020-12-15,Blood donors,All,Multiple groups,18.0,,Test used,Anti-nucleocapsid,25657,0.035,,,,,,,,Sequential,Alinity i SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,No,Yes,No,,Martina Ferrari,University of Modena and Reggio Emilia,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2907.221745,2023-06-28,2024-03-01,Unverified,ferrari_long-term_2023,ITA
230609_Tuscany_NorthWesternTuscanyBloodBank,230609_Tuscany_NorthWesternTuscanyBloodBank,Serum anti-Spike immunoglobulin G levels in random blood donors in Italy: High-titre convalescent plasma is easier than ever to procure,2023-06-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Italy,,Tuscany,"""donors attending our area in two different seasons (300 n November 2022 and 299 in February 2023)""",,2022-11-15,2023-02-15,Blood donors,All,Adults (18-64 years),,,Primary Estimate,,599,0.978,,,True,,,,True,Sequential,Alinity i SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,1.0,0.99,['High'],No,No,No,No,No,Yes,Yes,Yes,Unclear,Daniele Focosi,North-Western Tuscany Blood Bank,Unity-Aligned,https://dx.doi.org/10.1111/vox.13498,2023-08-24,2024-03-01,Unverified,focosi_serum_2023,ITA
230713_Puglia_VitoFazziHospital,230713_Puglia_VitoFazziHospital,Association between ABO blood groups and SARS-CoV-2 infection in blood donors of Puglia region,2023-07-13,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Italy,Apulia,,"""healthy blood donors who donated blood to one of the 22 Transfusion Centers in the Puglia region between September 1, 2020, and February
28, 2021, and whose samples were processed by the three
Regional Biological Qualifcation Centres (BQC) of blood and blood hemocomponents of Bari, Lecce, and Foggia"".

""In particular, due to eligibility criteria in Italy, children aged younger than 18 years and elderly older than 65 years cannot donate blood and were not included in this study.""","Excluded symptomatic ""All patients were asymptomatic at the time of admission to blood donation"".

Data on 36,006 individuals were screened, and 297 records were excluded due to missing information (age, Rh).",2020-09-01,2021-02-28,Blood donors,All,Adults (18-64 years),18.0,65.0,Primary Estimate,,35709,0.068,,,True,,,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,0.979,0.996,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Alessia Damiani,Vito Fazzi Hospital,Not Unity-Aligned,https://dx.doi.org/10.1007/s00277-023-05331-1,2023-08-24,2024-04-22,Verified,damiani_association_2023,ITA
210211_Kingston_UniversityOfTheWestIndies_Overall,210211_Kingston_UniversityOfTheWestIndies,"SARS-CoV-2 Seroprevalence Among Antenatal Clinic Attendees in Kingston, Jamaica, September-November 2020",2021-02-11,Preprint,Local,Cross-sectional survey ,Jamaica,,Kingston,Residual sera from women attending the UHWI atenatal clinic in March 2020 and from Sept-Nov 2020,,2020-03-01,2020-11-30,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,249,0.1486,,,True,,,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.8,0.9615000000000001,['High'],No,No,No,No,Unclear,Yes,Yes,No,,TeAnne Chisolm,University of the West Indies,Unity-Aligned,10.1101/2021.02.08.21251367,2021-03-18,2024-03-01,Verified,chisolm_sars-cov-2_2021,JAM
210211_Kingston_UniversityOfTheWestIndies_timeframe_sep,210211_Kingston_UniversityOfTheWestIndies,"SARS-CoV-2 Seroprevalence Among Antenatal Clinic Attendees in Kingston, Jamaica, September-November 2020",2021-02-11,Preprint,Local,Cross-sectional survey ,Jamaica,,Kingston,Residual sera from women attending the UHWI atenatal clinic in March 2020 and from Sept-Nov 2020,,2020-09-01,2020-09-30,Pregnant or parturient women,Female,Adults (18-64 years),,,Time frame,,77,0.069,,,,True,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.8,0.9615000000000001,['High'],No,No,No,No,Unclear,Yes,Yes,No,,TeAnne Chisolm,University of the West Indies,Unity-Aligned,10.1101/2021.02.08.21251367,2021-07-07,2023-08-15,Unverified,chisolm_sars-cov-2_2021,JAM
210211_Kingston_UniversityOfTheWestIndies_timeframe_nov,210211_Kingston_UniversityOfTheWestIndies,"SARS-CoV-2 Seroprevalence Among Antenatal Clinic Attendees in Kingston, Jamaica, September-November 2020",2021-02-11,Preprint,Local,Cross-sectional survey ,Jamaica,,Kingston,Residual sera from women attending the UHWI atenatal clinic in March 2020 and from Sept-Nov 2020,,2020-11-01,2020-11-30,Pregnant or parturient women,Female,Adults (18-64 years),,,Time frame,,77,0.24,,,,True,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.8,0.9615000000000001,['High'],No,No,No,No,Unclear,Yes,Yes,No,,TeAnne Chisolm,University of the West Indies,Unity-Aligned,10.1101/2021.02.08.21251367,2021-07-07,2023-08-15,Unverified,chisolm_sars-cov-2_2021,JAM
210211_Kingston_UniversityOfTheWestIndies_timeframe_oct,210211_Kingston_UniversityOfTheWestIndies,"SARS-CoV-2 Seroprevalence Among Antenatal Clinic Attendees in Kingston, Jamaica, September-November 2020",2021-02-11,Preprint,Local,Cross-sectional survey ,Jamaica,,Kingston,Residual sera from women attending the UHWI atenatal clinic in March 2020 and from Sept-Nov 2020,,2020-10-01,2020-10-31,Pregnant or parturient women,Female,Adults (18-64 years),,,Time frame,,78,0.16899999999999998,,,,True,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.8,0.9615000000000001,['High'],No,No,No,No,Unclear,Yes,Yes,No,,TeAnne Chisolm,University of the West Indies,Unity-Aligned,10.1101/2021.02.08.21251367,2021-07-07,2023-08-15,Unverified,chisolm_sars-cov-2_2021,JAM
210211_Kingston_UniversityOfTheWestIndies_timeframe_mar,210211_Kingston_UniversityOfTheWestIndies,"SARS-CoV-2 Seroprevalence Among Antenatal Clinic Attendees in Kingston, Jamaica, September-November 2020",2021-02-11,Preprint,Local,Cross-sectional survey ,Jamaica,,Kingston,Residual sera from women attending the UHWI atenatal clinic in March 2020 and from Sept-Nov 2020,,2020-03-01,2020-03-31,Pregnant or parturient women,Female,Adults (18-64 years),,,Time frame,,17,0.0,,,,True,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.8,0.9615000000000001,['High'],No,No,No,No,Unclear,Yes,Yes,No,,TeAnne Chisolm,University of the West Indies,Unity-Aligned,10.1101/2021.02.08.21251367,2021-07-07,2023-08-15,Unverified,chisolm_sars-cov-2_2021,JAM
220921_Kingston_TheUniversityoftheWestIndies_ANC_overall,220921_Kingston_TheUniversityoftheWestIndies_ANC,"Prevalence of SARS-CoV-2 Antibodies after the Omicron Surge, Kingston, Jamaica, 2022.",2022-09-21,Preprint,Local,Cross-sectional survey ,Jamaica,,Kingston,"""serum samples submitted during March 16 – May 5, 2022, from the Comprehensive Health Centre (CHC) Antenatal (ANC), Non-communicable Diseases (NCD) and Sexually Transmitted Infections (STI) Clinics""",,2022-03-16,2022-05-05,Residual sera,Female,Adults (18-64 years),,,Primary Estimate,,335,0.8985,,,True,,,,True,Sequential,"Abbott Architect SARS-CoV-2 IgG,AdviseDX SARS-CoV-2 anti-IgG II assay",Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Yes,Yes,No,,Joshua Anzinger,The University of the West Indies,Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280173,2022-10-05,2024-03-01,Unverified,anzinger_prevalence_2022,JAM
220921_Kingston_TheUniversityoftheWestIndies_ANC_20to29,220921_Kingston_TheUniversityoftheWestIndies_ANC,"Prevalence of SARS-CoV-2 Antibodies after the Omicron Surge, Kingston, Jamaica, 2022.",2022-09-21,Preprint,Local,Cross-sectional survey ,Jamaica,,Kingston,"""serum samples submitted during March 16 – May 5, 2022, from the Comprehensive Health Centre (CHC) Antenatal (ANC), Non-communicable Diseases (NCD) and Sexually Transmitted Infections (STI) Clinics""",,2022-03-16,2022-05-05,Residual sera,Female,Adults (18-64 years),20.0,29.0,Age,20-29,193,0.9067000000000001,,,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,AdviseDX SARS-CoV-2 anti-IgG II assay",Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Yes,Yes,No,,Joshua Anzinger,The University of the West Indies,Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280173,2022-10-05,2024-03-01,Unverified,anzinger_prevalence_2022,JAM
220921_Kingston_TheUniversityoftheWestIndies_ANC_30to39,220921_Kingston_TheUniversityoftheWestIndies_ANC,"Prevalence of SARS-CoV-2 Antibodies after the Omicron Surge, Kingston, Jamaica, 2022.",2022-09-21,Preprint,Local,Cross-sectional survey ,Jamaica,,Kingston,"""serum samples submitted during March 16 – May 5, 2022, from the Comprehensive Health Centre (CHC) Antenatal (ANC), Non-communicable Diseases (NCD) and Sexually Transmitted Infections (STI) Clinics""",,2022-03-16,2022-05-05,Residual sera,Female,Adults (18-64 years),30.0,39.0,Age,30-39,98,0.898,,,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,AdviseDX SARS-CoV-2 anti-IgG II assay",Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Yes,Yes,No,,Joshua Anzinger,The University of the West Indies,Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280173,2022-10-05,2024-03-01,Unverified,anzinger_prevalence_2022,JAM
220921_Kingston_TheUniversityoftheWestIndies_ANC_lessthan20,220921_Kingston_TheUniversityoftheWestIndies_ANC,"Prevalence of SARS-CoV-2 Antibodies after the Omicron Surge, Kingston, Jamaica, 2022.",2022-09-21,Preprint,Local,Cross-sectional survey ,Jamaica,,Kingston,"""serum samples submitted during March 16 – May 5, 2022, from the Comprehensive Health Centre (CHC) Antenatal (ANC), Non-communicable Diseases (NCD) and Sexually Transmitted Infections (STI) Clinics""",,2022-03-16,2022-05-05,Residual sera,Female,Adults (18-64 years),,19.0,Age,<20,35,0.8571,,,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,AdviseDX SARS-CoV-2 anti-IgG II assay",Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Yes,Yes,No,,Joshua Anzinger,The University of the West Indies,Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280173,2022-10-05,2024-03-01,Unverified,anzinger_prevalence_2022,JAM
220921_Kingston_TheUniversityoftheWestIndies_ANC_40plus,220921_Kingston_TheUniversityoftheWestIndies_ANC,"Prevalence of SARS-CoV-2 Antibodies after the Omicron Surge, Kingston, Jamaica, 2022.",2022-09-21,Preprint,Local,Cross-sectional survey ,Jamaica,,Kingston,"""serum samples submitted during March 16 – May 5, 2022, from the Comprehensive Health Centre (CHC) Antenatal (ANC), Non-communicable Diseases (NCD) and Sexually Transmitted Infections (STI) Clinics""",,2022-03-16,2022-05-05,Residual sera,Female,Adults (18-64 years),40.0,,Age,40+,9,0.8889,,,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,AdviseDX SARS-CoV-2 anti-IgG II assay",Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Yes,Yes,No,,Joshua Anzinger,The University of the West Indies,Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280173,2022-10-05,2024-03-01,Unverified,anzinger_prevalence_2022,JAM
220921_Kingston_TheUniversityoftheWestIndies_NCD_overall,220921_Kingston_TheUniversityoftheWestIndies_NCD,"Prevalence of SARS-CoV-2 Antibodies after the Omicron Surge, Kingston, Jamaica, 2022.",2022-09-21,Preprint,Local,Cross-sectional survey ,Jamaica,,Kingston,"""serum samples submitted during March 16 – May 5, 2022, from the Comprehensive Health Centre (CHC) Antenatal (ANC), Non-communicable Diseases (NCD) and Sexually Transmitted Infections (STI) Clinics""

"" Samples for this cross-sectional study were collected and tested irrespective of age except for the NCD clinic in which only samples from persons ≥50 years of age were selected ""","NR
",2022-03-16,2022-05-05,Residual sera,All,Multiple groups,50.0,,Primary Estimate,,831,0.8664000000000001,,,True,,,,True,Sequential,"Abbott Architect SARS-CoV-2 IgG,AdviseDX SARS-CoV-2 anti-IgG II assay",Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Yes,Yes,No,,Joshua Anzinger,The University of the West Indies,Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280173,2022-10-05,2024-03-01,Unverified,anzinger_prevalence_2022,JAM
220921_Kingston_TheUniversityoftheWestIndies_NCD_male,220921_Kingston_TheUniversityoftheWestIndies_NCD,"Prevalence of SARS-CoV-2 Antibodies after the Omicron Surge, Kingston, Jamaica, 2022.",2022-09-21,Preprint,Local,Cross-sectional survey ,Jamaica,,Kingston,"""serum samples submitted during March 16 – May 5, 2022, from the Comprehensive Health Centre (CHC) Antenatal (ANC), Non-communicable Diseases (NCD) and Sexually Transmitted Infections (STI) Clinics""

"" Samples for this cross-sectional study were collected and tested irrespective of age except for the NCD clinic in which only samples from persons ≥50 years of age were selected ""","NR
",2022-03-16,2022-05-05,Residual sera,Male,Multiple groups,50.0,,Sex/Gender,,212,0.8395999999999999,,,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,AdviseDX SARS-CoV-2 anti-IgG II assay",Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Yes,Yes,No,,Joshua Anzinger,The University of the West Indies,Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280173,2022-10-05,2024-03-01,Unverified,anzinger_prevalence_2022,JAM
220921_Kingston_TheUniversityoftheWestIndies_NCD_60to69,220921_Kingston_TheUniversityoftheWestIndies_NCD,"Prevalence of SARS-CoV-2 Antibodies after the Omicron Surge, Kingston, Jamaica, 2022.",2022-09-21,Preprint,Local,Cross-sectional survey ,Jamaica,,Kingston,"""serum samples submitted during March 16 – May 5, 2022, from the Comprehensive Health Centre (CHC) Antenatal (ANC), Non-communicable Diseases (NCD) and Sexually Transmitted Infections (STI) Clinics""

"" Samples for this cross-sectional study were collected and tested irrespective of age except for the NCD clinic in which only samples from persons ≥50 years of age were selected ""","NR
",2022-03-16,2022-05-05,Residual sera,All,Adults (18-64 years),60.0,69.0,Age,60-69,293,0.8874,,,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,AdviseDX SARS-CoV-2 anti-IgG II assay",Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Yes,Yes,No,,Joshua Anzinger,The University of the West Indies,Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280173,2022-10-05,2024-03-01,Unverified,anzinger_prevalence_2022,JAM
220921_Kingston_TheUniversityoftheWestIndies_NCD_70to79,220921_Kingston_TheUniversityoftheWestIndies_NCD,"Prevalence of SARS-CoV-2 Antibodies after the Omicron Surge, Kingston, Jamaica, 2022.",2022-09-21,Preprint,Local,Cross-sectional survey ,Jamaica,,Kingston,"""serum samples submitted during March 16 – May 5, 2022, from the Comprehensive Health Centre (CHC) Antenatal (ANC), Non-communicable Diseases (NCD) and Sexually Transmitted Infections (STI) Clinics""

"" Samples for this cross-sectional study were collected and tested irrespective of age except for the NCD clinic in which only samples from persons ≥50 years of age were selected ""","NR
",2022-03-16,2022-05-05,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,180,0.8667,,,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,AdviseDX SARS-CoV-2 anti-IgG II assay",Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Yes,Yes,No,,Joshua Anzinger,The University of the West Indies,Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280173,2022-10-05,2024-03-01,Unverified,anzinger_prevalence_2022,JAM
220921_Kingston_TheUniversityoftheWestIndies_NCD_80plus,220921_Kingston_TheUniversityoftheWestIndies_NCD,"Prevalence of SARS-CoV-2 Antibodies after the Omicron Surge, Kingston, Jamaica, 2022.",2022-09-21,Preprint,Local,Cross-sectional survey ,Jamaica,,Kingston,"""serum samples submitted during March 16 – May 5, 2022, from the Comprehensive Health Centre (CHC) Antenatal (ANC), Non-communicable Diseases (NCD) and Sexually Transmitted Infections (STI) Clinics""

"" Samples for this cross-sectional study were collected and tested irrespective of age except for the NCD clinic in which only samples from persons ≥50 years of age were selected ""","NR
",2022-03-16,2022-05-05,Residual sera,All,Seniors (65+ years),80.0,,Age,80+,72,0.7639,,,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,AdviseDX SARS-CoV-2 anti-IgG II assay",Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Yes,Yes,No,,Joshua Anzinger,The University of the West Indies,Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280173,2022-10-05,2024-03-01,Unverified,anzinger_prevalence_2022,JAM
220921_Kingston_TheUniversityoftheWestIndies_NCD_50to59,220921_Kingston_TheUniversityoftheWestIndies_NCD,"Prevalence of SARS-CoV-2 Antibodies after the Omicron Surge, Kingston, Jamaica, 2022.",2022-09-21,Preprint,Local,Cross-sectional survey ,Jamaica,,Kingston,"""serum samples submitted during March 16 – May 5, 2022, from the Comprehensive Health Centre (CHC) Antenatal (ANC), Non-communicable Diseases (NCD) and Sexually Transmitted Infections (STI) Clinics""

"" Samples for this cross-sectional study were collected and tested irrespective of age except for the NCD clinic in which only samples from persons ≥50 years of age were selected ""","NR
",2022-03-16,2022-05-05,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,286,0.8706,,,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,AdviseDX SARS-CoV-2 anti-IgG II assay",Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Yes,Yes,No,,Joshua Anzinger,The University of the West Indies,Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280173,2022-10-05,2024-03-01,Unverified,anzinger_prevalence_2022,JAM
220921_Kingston_TheUniversityoftheWestIndies_NCD_female,220921_Kingston_TheUniversityoftheWestIndies_NCD,"Prevalence of SARS-CoV-2 Antibodies after the Omicron Surge, Kingston, Jamaica, 2022.",2022-09-21,Preprint,Local,Cross-sectional survey ,Jamaica,,Kingston,"""serum samples submitted during March 16 – May 5, 2022, from the Comprehensive Health Centre (CHC) Antenatal (ANC), Non-communicable Diseases (NCD) and Sexually Transmitted Infections (STI) Clinics""

"" Samples for this cross-sectional study were collected and tested irrespective of age except for the NCD clinic in which only samples from persons ≥50 years of age were selected ""","NR
",2022-03-16,2022-05-05,Residual sera,Female,Multiple groups,50.0,,Sex/Gender,,619,0.8756,,,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,AdviseDX SARS-CoV-2 anti-IgG II assay",Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Yes,Yes,No,,Joshua Anzinger,The University of the West Indies,Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280173,2022-10-05,2024-03-01,Unverified,anzinger_prevalence_2022,JAM
220921_Kingston_TheUniversityoftheWestIndies_STI_overall,220921_Kingston_TheUniversityoftheWestIndies_STI,"Prevalence of SARS-CoV-2 Antibodies after the Omicron Surge, Kingston, Jamaica, 2022.",2022-09-21,Preprint,Local,Cross-sectional survey ,Jamaica,,Kingston,"""serum samples submitted during March 16 – May 5, 2022, from the Comprehensive Health Centre (CHC) Antenatal (ANC), Non-communicable Diseases (NCD) and Sexually Transmitted Infections (STI) Clinics""",,2022-03-16,2022-05-05,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,374,0.9118,,,True,,,,True,Sequential,"Abbott Architect SARS-CoV-2 IgG,AdviseDX SARS-CoV-2 anti-IgG II assay",Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Yes,Yes,No,,Joshua Anzinger,The University of the West Indies,Not Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280173,2022-10-05,2024-03-01,Unverified,anzinger_prevalence_2022,JAM
220921_Kingston_TheUniversityoftheWestIndies_STI_60to69,220921_Kingston_TheUniversityoftheWestIndies_STI,"Prevalence of SARS-CoV-2 Antibodies after the Omicron Surge, Kingston, Jamaica, 2022.",2022-09-21,Preprint,Local,Cross-sectional survey ,Jamaica,,Kingston,"""serum samples submitted during March 16 – May 5, 2022, from the Comprehensive Health Centre (CHC) Antenatal (ANC), Non-communicable Diseases (NCD) and Sexually Transmitted Infections (STI) Clinics""",,2022-03-16,2022-05-05,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),60.0,69.0,Age,60-69,21,0.9523999999999999,,,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,AdviseDX SARS-CoV-2 anti-IgG II assay",Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Yes,Yes,No,,Joshua Anzinger,The University of the West Indies,Not Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280173,2022-10-05,2024-03-01,Unverified,anzinger_prevalence_2022,JAM
220921_Kingston_TheUniversityoftheWestIndies_STI_70to79,220921_Kingston_TheUniversityoftheWestIndies_STI,"Prevalence of SARS-CoV-2 Antibodies after the Omicron Surge, Kingston, Jamaica, 2022.",2022-09-21,Preprint,Local,Cross-sectional survey ,Jamaica,,Kingston,"""serum samples submitted during March 16 – May 5, 2022, from the Comprehensive Health Centre (CHC) Antenatal (ANC), Non-communicable Diseases (NCD) and Sexually Transmitted Infections (STI) Clinics""",,2022-03-16,2022-05-05,Patients seeking care for non-COVID-19 reasons,All,Seniors (65+ years),70.0,79.0,Age,70-79,5,1.0,,,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,AdviseDX SARS-CoV-2 anti-IgG II assay",Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Yes,Yes,No,,Joshua Anzinger,The University of the West Indies,Not Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280173,2022-10-05,2024-03-01,Unverified,anzinger_prevalence_2022,JAM
220921_Kingston_TheUniversityoftheWestIndies_STI_lessthan20,220921_Kingston_TheUniversityoftheWestIndies_STI,"Prevalence of SARS-CoV-2 Antibodies after the Omicron Surge, Kingston, Jamaica, 2022.",2022-09-21,Preprint,Local,Cross-sectional survey ,Jamaica,,Kingston,"""serum samples submitted during March 16 – May 5, 2022, from the Comprehensive Health Centre (CHC) Antenatal (ANC), Non-communicable Diseases (NCD) and Sexually Transmitted Infections (STI) Clinics""",,2022-03-16,2022-05-05,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),,19.0,Age,<20,60,0.9500000000000001,,,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,AdviseDX SARS-CoV-2 anti-IgG II assay",Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Yes,Yes,No,,Joshua Anzinger,The University of the West Indies,Not Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280173,2022-10-05,2024-03-01,Unverified,anzinger_prevalence_2022,JAM
220921_Kingston_TheUniversityoftheWestIndies_STI_20to29,220921_Kingston_TheUniversityoftheWestIndies_STI,"Prevalence of SARS-CoV-2 Antibodies after the Omicron Surge, Kingston, Jamaica, 2022.",2022-09-21,Preprint,Local,Cross-sectional survey ,Jamaica,,Kingston,"""serum samples submitted during March 16 – May 5, 2022, from the Comprehensive Health Centre (CHC) Antenatal (ANC), Non-communicable Diseases (NCD) and Sexually Transmitted Infections (STI) Clinics""",,2022-03-16,2022-05-05,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),20.0,29.0,Age,20-29,135,0.9333,,,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,AdviseDX SARS-CoV-2 anti-IgG II assay",Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Yes,Yes,No,,Joshua Anzinger,The University of the West Indies,Not Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280173,2022-10-05,2024-03-01,Unverified,anzinger_prevalence_2022,JAM
220921_Kingston_TheUniversityoftheWestIndies_STI_30to39,220921_Kingston_TheUniversityoftheWestIndies_STI,"Prevalence of SARS-CoV-2 Antibodies after the Omicron Surge, Kingston, Jamaica, 2022.",2022-09-21,Preprint,Local,Cross-sectional survey ,Jamaica,,Kingston,"""serum samples submitted during March 16 – May 5, 2022, from the Comprehensive Health Centre (CHC) Antenatal (ANC), Non-communicable Diseases (NCD) and Sexually Transmitted Infections (STI) Clinics""",,2022-03-16,2022-05-05,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),30.0,39.0,Age,30-39,69,0.9420000000000001,,,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,AdviseDX SARS-CoV-2 anti-IgG II assay",Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Yes,Yes,No,,Joshua Anzinger,The University of the West Indies,Not Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280173,2022-10-05,2024-03-01,Unverified,anzinger_prevalence_2022,JAM
220921_Kingston_TheUniversityoftheWestIndies_STI_50to59,220921_Kingston_TheUniversityoftheWestIndies_STI,"Prevalence of SARS-CoV-2 Antibodies after the Omicron Surge, Kingston, Jamaica, 2022.",2022-09-21,Preprint,Local,Cross-sectional survey ,Jamaica,,Kingston,"""serum samples submitted during March 16 – May 5, 2022, from the Comprehensive Health Centre (CHC) Antenatal (ANC), Non-communicable Diseases (NCD) and Sexually Transmitted Infections (STI) Clinics""",,2022-03-16,2022-05-05,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),50.0,59.0,Age,50-59,33,0.8788,,,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,AdviseDX SARS-CoV-2 anti-IgG II assay",Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Yes,Yes,No,,Joshua Anzinger,The University of the West Indies,Not Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280173,2022-10-05,2024-03-01,Unverified,anzinger_prevalence_2022,JAM
220921_Kingston_TheUniversityoftheWestIndies_STI_80plus,220921_Kingston_TheUniversityoftheWestIndies_STI,"Prevalence of SARS-CoV-2 Antibodies after the Omicron Surge, Kingston, Jamaica, 2022.",2022-09-21,Preprint,Local,Cross-sectional survey ,Jamaica,,Kingston,"""serum samples submitted during March 16 – May 5, 2022, from the Comprehensive Health Centre (CHC) Antenatal (ANC), Non-communicable Diseases (NCD) and Sexually Transmitted Infections (STI) Clinics""",,2022-03-16,2022-05-05,Patients seeking care for non-COVID-19 reasons,All,Seniors (65+ years),80.0,,Age,80+,2,0.5,,,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,AdviseDX SARS-CoV-2 anti-IgG II assay",Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Yes,Yes,No,,Joshua Anzinger,The University of the West Indies,Not Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280173,2022-10-05,2024-03-01,Unverified,anzinger_prevalence_2022,JAM
220921_Kingston_TheUniversityoftheWestIndies_STI_40to49,220921_Kingston_TheUniversityoftheWestIndies_STI,"Prevalence of SARS-CoV-2 Antibodies after the Omicron Surge, Kingston, Jamaica, 2022.",2022-09-21,Preprint,Local,Cross-sectional survey ,Jamaica,,Kingston,"""serum samples submitted during March 16 – May 5, 2022, from the Comprehensive Health Centre (CHC) Antenatal (ANC), Non-communicable Diseases (NCD) and Sexually Transmitted Infections (STI) Clinics""",,2022-03-16,2022-05-05,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),40.0,49.0,Age,40-49,49,0.7755,,,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,AdviseDX SARS-CoV-2 anti-IgG II assay",Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Yes,Yes,No,,Joshua Anzinger,The University of the West Indies,Not Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280173,2022-10-05,2024-03-01,Unverified,anzinger_prevalence_2022,JAM
200515_Tokyo_UniversityOfTokyo,200515_Tokyo_UniversityOfTokyo,About antibody positive rate test results in Tokyo,2020-05-15,Presentation or Conference,Regional,Cross-sectional survey ,Japan,Tokyo Prefecture,Tokyo,,,2020-05-01,2020-05-02,Residual sera,All,Multiple groups,,,Primary Estimate,,500,0.006,,,True,,,,True,Convenience,Not reported/ Unable to specify,,CLIA,Serum,"['IgG', 'IgM']",,,,,['High'],No,No,No,No,Unclear,Unclear,Yes,No,,Tatsuhiko Kodama,University of Tokyo,Not Unity-Aligned,https://www.rcast.u-tokyo.ac.jp/ja/news/release/20200515.html,2021-06-02,2022-07-16,Verified,tatsuhiko_kodama_about_2020,JPN
200621_Japan_SoftBank_EmployeesFamiliesClients,200621_Japan_SoftBank_Employees,Japanese firm's blanket testing of employees  could serve as model,2020-06-21,News and Media,Local,Cross-sectional survey ,Japan,,,"family members, clients, employees of SoftBank, or medical workers",,2020-05-12,2020-05-18,Multiple populations,All,Multiple groups,,,Primary Estimate,"SoftBank employees, clients, and their family members",38216,0.0023,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,No,Yes,No,Unclear,Unclear,Yes,No,Unclear,Simon Denyer,SoftBank,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.lmtonline.com/news/article/Japanese-firm-s-blanket-testing-of-employees-15355433.php&ct=ga&cd=CAEYHCoUMTM4NjAwODY3NjE3NzkyOTU2ODYyGjkwZGVhOTg5OTRlOTE4NTk6Y29tOmVuOlVT&usg=AFQjCNGl9_tc35Q3fUbB67SoWaNsH2ltMw,2020-06-27,2022-07-16,Verified,denyer_japanese_2020-1,JPN
200621_Japan_SoftBank_HCW,200621_Japan_SoftBank_HCW,Japanese firm's blanket testing of employees  could serve as model,2020-06-21,News and Media,Local,Cross-sectional survey ,Japan,,,,,2020-05-12,2020-05-18,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,Healthcare worker,5850,0.0179,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,No,Yes,No,Unclear,Unclear,Yes,No,Unclear,Simon Denyer,SoftBank,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.lmtonline.com/news/article/Japanese-firm-s-blanket-testing-of-employees-15355433.php&ct=ga&cd=CAEYHCoUMTM4NjAwODY3NjE3NzkyOTU2ODYyGjkwZGVhOTg5OTRlOTE4NTk6Y29tOmVuOlVT&usg=AFQjCNGl9_tc35Q3fUbB67SoWaNsH2ltMw,2020-06-27,2022-07-16,Verified,denyer_japanese_2020-1,JPN
200721_Tokyo_NavitasClinicTachikawa_Overall,200721_Tokyo_NavitasClinicTachikawa,Geographical Profiles of COVID-19 Outbreak in Tokyo: An Analysis of the Primary Care Clinic–Based Point-of-Care Antibody Testing,2020-07-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,"Kantō, Chūbu ","Tokyo, Kangawa, Saitama, Chiba, Yamanashi",subjects have been recruited by web posting of clinics. The two community clinics located in the major railway stations in Tokyo (Navitas Clinic Shinjuku and Tachikawa),Symptomatic patients,2020-04-20,2020-05-20,Household and community samples,All,Multiple groups,,,Primary Estimate,,1071,0.0383,0.0276,0.0516,True,,,,True,Self-referral,SARS-CoV-2 antibody detection kit (IgM/IgG),Kurabo Industries Ltd,LFIA,Whole Blood,IgG,,Validated by manufacturers,0.7640000000000001,1.0,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Morihito Takita,Navitas Clinic Tachikawa,Not Unity-Aligned,https://dx.doi.org/10.1177/2150132720942695,2020-07-17,2022-07-16,Verified,takita_geographical_2020,JPN
200721_Tokyo_NavitasClinicTachikawa_GeneralPopNeighboringPrefecturesTokyo,200721_Tokyo_NavitasClinicTachikawa,Geographical Profiles of COVID-19 Outbreak in Tokyo: An Analysis of the Primary Care Clinic–Based Point-of-Care Antibody Testing,2020-07-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,"Kantō, Chūbu ","Kangawa, Saitama, Chiba, Yamanashi",subjects have been recruited by web posting of clinics. The two community clinics located in the major railway stations in Tokyo (Navitas Clinic Shinjuku and Tachikawa),Symptomatic patients,2020-04-20,2020-05-20,Household and community samples,All,Multiple groups,,,Geographical area,neighbouring prefectures of tokyo,173,0.052000000000000005,0.024100000000000003,0.0965,,,,,,Self-referral,SARS-CoV-2 antibody detection kit (IgM/IgG),Kurabo Industries Ltd,LFIA,Whole Blood,IgG,,Validated by manufacturers,0.7640000000000001,1.0,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Morihito Takita,Navitas Clinic Tachikawa,Not Unity-Aligned,https://dx.doi.org/10.1177/2150132720942695,2020-06-05,2022-07-16,Verified,takita_geographical_2020,JPN
200721_Tokyo_NavitasClinicTachikawa_Period1,200721_Tokyo_NavitasClinicTachikawa,Geographical Profiles of COVID-19 Outbreak in Tokyo: An Analysis of the Primary Care Clinic–Based Point-of-Care Antibody Testing,2020-07-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,"Kantō, Chūbu ","Tokyo, Kangawa, Saitama, Chiba, Yamanashi",subjects have been recruited by web posting of clinics. The two community clinics located in the major railway stations in Tokyo (Navitas Clinic Shinjuku and Tachikawa),Symptomatic patients,2020-04-21,2020-04-30,Household and community samples,All,Multiple groups,,,Time frame,"April 21-30, 2020",308,0.0552,0.0325,0.08689999999999999,,,,,,Self-referral,SARS-CoV-2 antibody detection kit (IgM/IgG),Kurabo Industries Ltd,LFIA,Whole Blood,IgG,,Validated by manufacturers,0.7640000000000001,1.0,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Morihito Takita,Navitas Clinic Tachikawa,Not Unity-Aligned,https://dx.doi.org/10.1177/2150132720942695,2020-08-02,2022-07-16,Verified,takita_geographical_2020,JPN
200721_Tokyo_NavitasClinicTachikawa_18-34,200721_Tokyo_NavitasClinicTachikawa,Geographical Profiles of COVID-19 Outbreak in Tokyo: An Analysis of the Primary Care Clinic–Based Point-of-Care Antibody Testing,2020-07-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,Kantō,Tokyo,subjects have been recruited by web posting of clinics. The two community clinics located in the major railway stations in Tokyo (Navitas Clinic Shinjuku and Tachikawa),Symptomatic patients,2020-04-20,2020-05-20,Household and community samples,All,Adults (18-64 years),18.0,34.0,Age,18-34,134,0.0821,0.0417,0.1421,,,,,,Self-referral,SARS-CoV-2 antibody detection kit (IgM/IgG),Kurabo Industries Ltd,LFIA,Whole Blood,IgG,,Validated by manufacturers,0.7640000000000001,1.0,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Morihito Takita,Navitas Clinic Tachikawa,Not Unity-Aligned,https://dx.doi.org/10.1177/2150132720942695,2020-07-17,2022-07-16,Verified,takita_geographical_2020,JPN
200721_Tokyo_NavitasClinicTachikawa_Females,200721_Tokyo_NavitasClinicTachikawa,Geographical Profiles of COVID-19 Outbreak in Tokyo: An Analysis of the Primary Care Clinic–Based Point-of-Care Antibody Testing,2020-07-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,Kantō,Tokyo,subjects have been recruited by web posting of clinics. The two community clinics located in the major railway stations in Tokyo (Navitas Clinic Shinjuku and Tachikawa),Symptomatic patients,2020-04-20,2020-05-20,Household and community samples,Female,Multiple groups,,,Sex/Gender,Female,495,0.0384,0.0233,0.0593,,,,,,Self-referral,SARS-CoV-2 antibody detection kit (IgM/IgG),Kurabo Industries Ltd,LFIA,Whole Blood,IgG,,Validated by manufacturers,0.7640000000000001,1.0,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Morihito Takita,Navitas Clinic Tachikawa,Not Unity-Aligned,https://dx.doi.org/10.1177/2150132720942695,2020-07-17,2022-07-16,Verified,takita_geographical_2020,JPN
200721_Tokyo_NavitasClinicTachikawa_Period3,200721_Tokyo_NavitasClinicTachikawa,Geographical Profiles of COVID-19 Outbreak in Tokyo: An Analysis of the Primary Care Clinic–Based Point-of-Care Antibody Testing,2020-07-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,"Kantō, Chūbu ","Tokyo, Kangawa, Saitama, Chiba, Yamanashi",subjects have been recruited by web posting of clinics. The two community clinics located in the major railway stations in Tokyo (Navitas Clinic Shinjuku and Tachikawa),Symptomatic patients,2020-05-10,2020-05-20,Household and community samples,All,Multiple groups,,,Time frame,"May 10-20, 2020",253,0.011899999999999999,0.0025,0.034300000000000004,,,,,,Self-referral,SARS-CoV-2 antibody detection kit (IgM/IgG),Kurabo Industries Ltd,LFIA,Whole Blood,IgG,,Validated by manufacturers,0.7640000000000001,1.0,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Morihito Takita,Navitas Clinic Tachikawa,Not Unity-Aligned,https://dx.doi.org/10.1177/2150132720942695,2020-08-02,2022-07-16,Verified,takita_geographical_2020,JPN
200721_Tokyo_NavitasClinicTachikawa_GeneralPopCentralTokyo,200721_Tokyo_NavitasClinicTachikawa,Geographical Profiles of COVID-19 Outbreak in Tokyo: An Analysis of the Primary Care Clinic–Based Point-of-Care Antibody Testing,2020-07-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,Kantō,Tokyo,subjects have been recruited by web posting of clinics. The two community clinics located in the major railway stations in Tokyo (Navitas Clinic Shinjuku and Tachikawa),Symptomatic patients,2020-04-20,2020-05-20,Household and community samples,All,Multiple groups,,,Geographical area,"central tokyo, with 23 special wards",565,0.0478,0.0317,0.0688,,,,,,Self-referral,SARS-CoV-2 antibody detection kit (IgM/IgG),Kurabo Industries Ltd,LFIA,Whole Blood,IgG,,Validated by manufacturers,0.7640000000000001,1.0,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Morihito Takita,Navitas Clinic Tachikawa,Not Unity-Aligned,https://dx.doi.org/10.1177/2150132720942695,2020-06-05,2022-07-16,Verified,takita_geographical_2020,JPN
200721_Tokyo_NavitasClinicTachikawa_Male,200721_Tokyo_NavitasClinicTachikawa,Geographical Profiles of COVID-19 Outbreak in Tokyo: An Analysis of the Primary Care Clinic–Based Point-of-Care Antibody Testing,2020-07-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,Kantō,Tokyo,subjects have been recruited by web posting of clinics. The two community clinics located in the major railway stations in Tokyo (Navitas Clinic Shinjuku and Tachikawa),Symptomatic patients,2020-04-20,2020-05-20,Household and community samples,Male,Multiple groups,,,Sex/Gender,Male,576,0.0382,0.024100000000000003,0.057300000000000004,,,,,,Self-referral,SARS-CoV-2 antibody detection kit (IgM/IgG),Kurabo Industries Ltd,LFIA,Whole Blood,IgG,,Validated by manufacturers,0.7640000000000001,1.0,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Morihito Takita,Navitas Clinic Tachikawa,Not Unity-Aligned,https://dx.doi.org/10.1177/2150132720942695,2020-07-17,2022-07-16,Verified,takita_geographical_2020,JPN
200721_Tokyo_NavitasClinicTachikawa_<17,200721_Tokyo_NavitasClinicTachikawa,Geographical Profiles of COVID-19 Outbreak in Tokyo: An Analysis of the Primary Care Clinic–Based Point-of-Care Antibody Testing,2020-07-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,Kantō,Tokyo,subjects have been recruited by web posting of clinics. The two community clinics located in the major railway stations in Tokyo (Navitas Clinic Shinjuku and Tachikawa),Symptomatic patients,2020-04-20,2020-05-20,Household and community samples,All,Children and Youth (0-17 years),0.0,17.0,Age,<17,13,0.0,,,,,,,,Self-referral,SARS-CoV-2 antibody detection kit (IgM/IgG),Kurabo Industries Ltd,LFIA,Whole Blood,IgG,,Validated by manufacturers,0.7640000000000001,1.0,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Morihito Takita,Navitas Clinic Tachikawa,Not Unity-Aligned,https://dx.doi.org/10.1177/2150132720942695,2020-07-17,2022-07-16,Verified,takita_geographical_2020,JPN
200721_Tokyo_NavitasClinicTachikawa_35-54,200721_Tokyo_NavitasClinicTachikawa,Geographical Profiles of COVID-19 Outbreak in Tokyo: An Analysis of the Primary Care Clinic–Based Point-of-Care Antibody Testing,2020-07-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,Kantō,Tokyo,subjects have been recruited by web posting of clinics. The two community clinics located in the major railway stations in Tokyo (Navitas Clinic Shinjuku and Tachikawa),Symptomatic patients,2020-04-20,2020-05-20,Household and community samples,All,Adults (18-64 years),35.0,54.0,Age,35-54,653,0.0291,0.0176,0.0451,,,,,,Self-referral,SARS-CoV-2 antibody detection kit (IgM/IgG),Kurabo Industries Ltd,LFIA,Whole Blood,IgG,,Validated by manufacturers,0.7640000000000001,1.0,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Morihito Takita,Navitas Clinic Tachikawa,Not Unity-Aligned,https://dx.doi.org/10.1177/2150132720942695,2020-07-17,2022-07-16,Verified,takita_geographical_2020,JPN
200721_Tokyo_NavitasClinicTachikawa_GeneralPopSuburbanTokyo,200721_Tokyo_NavitasClinicTachikawa,Geographical Profiles of COVID-19 Outbreak in Tokyo: An Analysis of the Primary Care Clinic–Based Point-of-Care Antibody Testing,2020-07-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,Kantō,Tokyo,subjects have been recruited by web posting of clinics. The two community clinics located in the major railway stations in Tokyo (Navitas Clinic Shinjuku and Tachikawa),Symptomatic patients,2020-04-20,2020-05-20,Household and community samples,All,Multiple groups,,,Geographical area,suburban tokyo,317,0.0158,0.0051,0.0364,,,,,,Self-referral,SARS-CoV-2 antibody detection kit (IgM/IgG),Kurabo Industries Ltd,LFIA,Whole Blood,IgG,,Validated by manufacturers,0.7640000000000001,1.0,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Morihito Takita,Navitas Clinic Tachikawa,Not Unity-Aligned,https://dx.doi.org/10.1177/2150132720942695,2020-06-05,2022-07-16,Verified,takita_geographical_2020,JPN
200721_Tokyo_NavitasClinicTachikawa_Period2,200721_Tokyo_NavitasClinicTachikawa,Geographical Profiles of COVID-19 Outbreak in Tokyo: An Analysis of the Primary Care Clinic–Based Point-of-Care Antibody Testing,2020-07-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,"Kantō, Chūbu ","Tokyo, Kangawa, Saitama, Chiba, Yamanashi",subjects have been recruited by web posting of clinics. The two community clinics located in the major railway stations in Tokyo (Navitas Clinic Shinjuku and Tachikawa),Symptomatic patients,2020-05-01,2020-05-10,Household and community samples,All,Multiple groups,,,Time frame,"May 1-10, 2020",510,0.0412,0.0257,0.06230000000000001,,,,,,Self-referral,SARS-CoV-2 antibody detection kit (IgM/IgG),Kurabo Industries Ltd,LFIA,Whole Blood,IgG,,Validated by manufacturers,0.7640000000000001,1.0,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Morihito Takita,Navitas Clinic Tachikawa,Not Unity-Aligned,https://dx.doi.org/10.1177/2150132720942695,2020-08-02,2022-07-16,Verified,takita_geographical_2020,JPN
200721_Tokyo_NavitasClinicTachikawa_>55,200721_Tokyo_NavitasClinicTachikawa,Geographical Profiles of COVID-19 Outbreak in Tokyo: An Analysis of the Primary Care Clinic–Based Point-of-Care Antibody Testing,2020-07-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,Kantō,Tokyo,subjects have been recruited by web posting of clinics. The two community clinics located in the major railway stations in Tokyo (Navitas Clinic Shinjuku and Tachikawa),Symptomatic patients,2020-04-20,2020-05-20,Household and community samples,All,Multiple groups,55.0,,Age,>=55,271,0.0406,0.0204,0.07150000000000001,,,,,,Self-referral,SARS-CoV-2 antibody detection kit (IgM/IgG),Kurabo Industries Ltd,LFIA,Whole Blood,IgG,,Validated by manufacturers,0.7640000000000001,1.0,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Morihito Takita,Navitas Clinic Tachikawa,Not Unity-Aligned,https://dx.doi.org/10.1177/2150132720942695,2020-07-17,2022-07-16,Verified,takita_geographical_2020,JPN
200727_Japan_HealthandWelfareDepartment_primary,200727_Japan_HealthandWelfareDepartment,About  the results of the antibody prevalence survey against the new coronavirus at  medical institutions in the prefecture,2020-07-27,News and Media,Regional,Cross-sectional survey ,Japan,prefecture 3,,"those who collected blood at three medical institutions in the prefecture (Kikita, Kinaka, Kinan) and consented to participate in this survey (1,000 people at each hospital)
",,2020-06-15,2020-06-28,Residual sera,All,Multiple groups,,,Primary Estimate,,3000,0.0,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,IgG,,,,,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,Unclear,Okuda,Health and Welfare Department,Not Unity-Aligned,http://wave.pref.wakayama.lg.jp/news/kensei/shiryo.php?sid=31587,2021-04-22,2022-07-16,Verified,noauthor__nodate,JPN
200730_Sapporo_HokkaidoUniversityGraduateSchoolofMedicine_LiverDiseasePatientsMarch2020,200730_Sapporo_HokkaidoUniversityGraduateSchoolofMedicine_1_March,Time-dependent changes in the seroprevalence of COVID-19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID-19.,2020-07-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Hokkaido,Sapporo,"They included 300 consecutive outpatients with liver disease, who were asymptomatic for COVID-19, and who had visited the hospital and had their serum preserved March 2020",,2020-03-01,2020-03-31,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,20.0,80.0,Primary Estimate,,300,0.003,0.0,0.018000000000000002,True,,,,True,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.998,['High'],No,Unclear,No,Yes,Yes,Yes,Yes,Yes,Yes,Goki Suda,Hokkaido University Graduate School of Medicine,Not Unity-Aligned,https://dx.doi.org/10.1111/hepr.13551,2020-10-01,2024-03-01,Verified,suda_time-dependent_2020-1,JPN
200730_Sapporo_HokkaidoUniversityGraduateSchoolofMedicine_LiverDiseasePatientsMay2020,200730_Sapporo_HokkaidoUniversityGraduateSchoolofMedicine_2_May,Time-dependent changes in the seroprevalence of COVID-19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID-19.,2020-07-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Hokkaido,Sapporo,"They included 300 consecutive outpatients with liver disease, who were asymptomatic for COVID-19, and who had visited the hospital and had their serum preserved May 2020",,2020-05-01,2020-05-31,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,20.0,84.0,Primary Estimate,,300,0.0,0.0,0.0,True,,,,True,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.998,['High'],No,Unclear,No,Yes,Yes,Yes,Yes,Yes,Yes,Goki Suda,Hokkaido University Graduate School of Medicine,Not Unity-Aligned,https://dx.doi.org/10.1111/hepr.13551,2020-10-01,2024-03-01,Verified,suda_time-dependent_2020-1,JPN
200906_Kanagawa_KanagawaPhysiciansAssociation_Control,200906_Kanagawa_KanagawaPhysiciansAssociation_Control,Survey of the current status of subclinical coronavirus disease 2019 (COVID-19),2020-09-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,Kanagawa Prefecture,,"1)
Patients who regularly visit medical institutions that belong to the Kanagawa Physicians Association, or doctors or nurses who work in medical institutions that belong to the Kanagawa Physicians Association (because this is a study in Kanagawa Prefecture and in order to know the current status of subclinical infections among doctors and nurses)

2)
Any age (to collect data from a wide range of age groups)

3)
Those who live in Japan and can be followed up continuously (positive patients may be followed up continuously)

4)
Those who gave consent to participate in the study (including consent from legal guardians for minors)","In addition to the other exclusion criteria, inclusion in the control group necessitated no underlying disease.

""Of all
participants, those who were not doctors or nurses and who had no
underlying disease were categorized into the control group""

1)
Those who had confirmed COVID-19 (because this study investigates the current status of subclinical infections)

2)
Those who had common cold-like symptoms such as fever within 21 days (to prevent transmission to healthcare workers. It has been reported that IgG antibodies against SARS-CoV-2 increase 2–3 weeks after the onset of COVID-19 [19])

3)
Those who had symptoms of common cold or fever 37.5 °C or higher that continued for at least 4 days in 2020 (these individuals may have been infected with the novel coronavirus and are not suitable for the investigation of subclinical infection)

4)
Those who experienced strong lassitude or feeling of dyspnea in 2020 (the same as above)

∗When this study was started, the government was ordering that those who have symptoms described in exclusion criteria 3) and 4) should go to specialized medical institutions because infection with the novel coronavirus is suspected.",2020-05-18,2020-06-24,Residual sera,All,Multiple groups,,,Primary Estimate,,111,0.0,,,,,,,,Convenience,Author designed (ELISA) - Unknown,,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],,No,No,Yes,,Unclear,Yes,Yes,,Ikuro Matsuba,Kanagawa Physicians Association,Not Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S1341321X20303251,2022-02-01,2022-07-16,Unverified,matsuba_survey_2020,JPN
200906_Kanagawa_KanagawaPhysiciansAssociation_HCWs_PopAdjust,200906_Kanagawa_KanagawaPhysiciansAssociation_HCWs,Survey of the current status of subclinical coronavirus disease 2019 (COVID-19),2020-09-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,Kanagawa Prefecture,,"1)
Patients who regularly visit medical institutions that belong to the Kanagawa Physicians Association, or doctors or nurses who work in medical institutions that belong to the Kanagawa Physicians Association (because this is a study in Kanagawa Prefecture and in order to know the current status of subclinical infections among doctors and nurses)

2)
Any age (to collect data from a wide range of age groups)

3)
Those who live in Japan and can be followed up continuously (positive patients may be followed up continuously)

4)
Those who gave consent to participate in the study (including consent from legal guardians for minors)","1)
Those who had confirmed COVID-19 (because this study investigates the current status of subclinical infections)

2)
Those who had common cold-like symptoms such as fever within 21 days (to prevent transmission to healthcare workers. It has been reported that IgG antibodies against SARS-CoV-2 increase 2–3 weeks after the onset of COVID-19 [19])

3)
Those who had symptoms of common cold or fever 37.5 °C or higher that continued for at least 4 days in 2020 (these individuals may have been infected with the novel coronavirus and are not suitable for the investigation of subclinical infection)

4)
Those who experienced strong lassitude or feeling of dyspnea in 2020 (the same as above)

∗When this study was started, the government was ordering that those who have symptoms described in exclusion criteria 3) and 4) should go to specialized medical institutions because infection with the novel coronavirus is suspected.",2020-05-18,2020-06-24,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,504,0.021,,,True,,True,,,Convenience,Author designed (ELISA) - Unknown,,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,1.0,['Moderate'],,No,No,Yes,,Unclear,Yes,Yes,,Ikuro Matsuba,Kanagawa Physicians Association,Not Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S1341321X20303251,2022-02-01,2022-07-16,Unverified,matsuba_survey_2020,JPN
200906_Kanagawa_KanagawaPhysiciansAssociation_Patients_PopAdjust,200906_Kanagawa_KanagawaPhysiciansAssociation_Patients,Survey of the current status of subclinical coronavirus disease 2019 (COVID-19),2020-09-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,Kanagawa Prefecture,,"1)
Patients who regularly visit medical institutions that belong to the Kanagawa Physicians Association, or doctors or nurses who work in medical institutions that belong to the Kanagawa Physicians Association (because this is a study in Kanagawa Prefecture and in order to know the current status of subclinical infections among doctors and nurses)

2)
Any age (to collect data from a wide range of age groups)

3)
Those who live in Japan and can be followed up continuously (positive patients may be followed up continuously)

4)
Those who gave consent to participate in the study (including consent from legal guardians for minors)","1)
Those who had confirmed COVID-19 (because this study investigates the current status of subclinical infections)

2)
Those who had common cold-like symptoms such as fever within 21 days (to prevent transmission to healthcare workers. It has been reported that IgG antibodies against SARS-CoV-2 increase 2–3 weeks after the onset of COVID-19 [19])

3)
Those who had symptoms of common cold or fever 37.5 °C or higher that continued for at least 4 days in 2020 (these individuals may have been infected with the novel coronavirus and are not suitable for the investigation of subclinical infection)

4)
Those who experienced strong lassitude or feeling of dyspnea in 2020 (the same as above)

∗When this study was started, the government was ordering that those who have symptoms described in exclusion criteria 3) and 4) should go to specialized medical institutions because infection with the novel coronavirus is suspected.",2020-05-18,2020-06-24,Residual sera,All,Multiple groups,,,Primary Estimate,,988,0.027000000000000003,,,True,,True,,,Convenience,Author designed (ELISA) - Unknown,,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Ikuro Matsuba,Kanagawa Physicians Association,Not Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S1341321X20303251,2022-02-01,2022-07-16,Unverified,matsuba_survey_2020,JPN
200906_Kanagawa_KanagawaPhysiciansAssociation_Patients_Crude,200906_Kanagawa_KanagawaPhysiciansAssociation_Patients,Survey of the current status of subclinical coronavirus disease 2019 (COVID-19),2020-09-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,Kanagawa Prefecture,,"1)
Patients who regularly visit medical institutions that belong to the Kanagawa Physicians Association, or doctors or nurses who work in medical institutions that belong to the Kanagawa Physicians Association (because this is a study in Kanagawa Prefecture and in order to know the current status of subclinical infections among doctors and nurses)

2)
Any age (to collect data from a wide range of age groups)

3)
Those who live in Japan and can be followed up continuously (positive patients may be followed up continuously)

4)
Those who gave consent to participate in the study (including consent from legal guardians for minors)","1)
Those who had confirmed COVID-19 (because this study investigates the current status of subclinical infections)

2)
Those who had common cold-like symptoms such as fever within 21 days (to prevent transmission to healthcare workers. It has been reported that IgG antibodies against SARS-CoV-2 increase 2–3 weeks after the onset of COVID-19 [19])

3)
Those who had symptoms of common cold or fever 37.5 °C or higher that continued for at least 4 days in 2020 (these individuals may have been infected with the novel coronavirus and are not suitable for the investigation of subclinical infection)

4)
Those who experienced strong lassitude or feeling of dyspnea in 2020 (the same as above)

∗When this study was started, the government was ordering that those who have symptoms described in exclusion criteria 3) and 4) should go to specialized medical institutions because infection with the novel coronavirus is suspected.",2020-05-18,2020-06-24,Residual sera,All,Multiple groups,,,Analysis,,988,0.0294,,,,,,,True,Convenience,Author designed (ELISA) - Unknown,,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Ikuro Matsuba,Kanagawa Physicians Association,Not Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S1341321X20303251,2022-02-01,2022-07-16,Unverified,matsuba_survey_2020,JPN
200920_Tokyo_NationalCenterForGlobalHealthAndMedicine_Overall,200920_Tokyo_NationalCenterForGlobalHealthAndMedicine,Effectiveness of personal protective equipment in preventing severe acute respiratory syndrome coronavirus 2 infection among healthcare workers,2020-09-09,Journal Article (Peer-Reviewed),Local,Prospective cohort,Japan,,Tokyo,"HCWs with close contact with COVID-19 patients were recruited for the study. Close contact was defined as either talking with pa- tients at close range (within 1 m), touching patients for examina- tion and/or care, or taking samples such as nasopharyngeal swabs or blood",,2020-02-14,2020-04-03,Health care workers and caregivers,All,Adults (18-64 years),20.0,,Primary Estimate,,49,0.0,,,True,,,,True,Convenience,"Author designed (Neutralization Assay),Author designed (ELISA) -Unknown",,Multiple Types,,"['IgG', 'Neutralizing']",,,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,No,,Tetsuya Suzuki,National Center for Global Health and Medicine,Not Unity-Aligned,http://dx.doi.org/10.1016/j.jiac.2020.09.006,2021-04-11,2022-07-16,Verified,suzuki_effectiveness_2021,JPN
200911_Osaka_ToyonakaMunicipalHospital_Overall,200911_Osaka_ToyonakaMunicipalHospital,"Seroprevalence of SARS-CoV-2 Antibodies Among 925 Staff Members in an Urban Hospital Accepting COVID-19 Patients in Osaka Prefecture, Japan",2020-09-11,Preprint,Local,Cross-sectional survey ,Japan,Kansai,Osaka,All hospital staff at the Toyonaka Municipal Hospital,Those who refused to take part in this study; those who did not have enough extra blood drawn to undergo antibody testing; and those who were not identified because they mistyped their personal ten-digit identification code,2020-06-12,2020-06-19,Health care workers and caregivers,All,Adults (18-64 years),20.0,,Primary Estimate,Overall estimate of health care workers,925,0.0043,0.0017000000000000001,0.011000000000000001,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Yes,Tsutomu Nishida,Toyonaka Municipal Hospital,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.10.20191866v1,2020-10-22,2024-03-01,Verified,nishida_seroprevalence_2020,JPN
200911_Osaka_ToyonakaMunicipalHospital_30-39,200911_Osaka_ToyonakaMunicipalHospital,"Seroprevalence of SARS-CoV-2 Antibodies Among 925 Staff Members in an Urban Hospital Accepting COVID-19 Patients in Osaka Prefecture, Japan",2020-09-11,Preprint,Local,Cross-sectional survey ,Japan,Kansai,Osaka,All hospital staff at the Toyonaka Municipal Hospital,Those who refused to take part in this study; those who did not have enough extra blood drawn to undergo antibody testing; and those who were not identified because they mistyped their personal ten-digit identification code,2020-06-12,2020-06-19,Health care workers and caregivers,All,Adults (18-64 years),30.0,39.0,Age,Age group 30-39 years old,225,0.0044,0.00079,0.025,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Yes,Tsutomu Nishida,Toyonaka Municipal Hospital,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.10.20191866v1,2020-10-23,2024-03-01,Verified,nishida_seroprevalence_2020,JPN
200911_Osaka_ToyonakaMunicipalHospital_20-29,200911_Osaka_ToyonakaMunicipalHospital,"Seroprevalence of SARS-CoV-2 Antibodies Among 925 Staff Members in an Urban Hospital Accepting COVID-19 Patients in Osaka Prefecture, Japan",2020-09-11,Preprint,Local,Cross-sectional survey ,Japan,Kansai,Osaka,All hospital staff at the Toyonaka Municipal Hospital,Those who refused to take part in this study; those who did not have enough extra blood drawn to undergo antibody testing; and those who were not identified because they mistyped their personal ten-digit identification code,2020-06-12,2020-06-19,Health care workers and caregivers,All,Adults (18-64 years),20.0,29.0,Age,Age group 20-29 years old,234,0.0,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Yes,Tsutomu Nishida,Toyonaka Municipal Hospital,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.10.20191866v1,2020-10-23,2024-03-01,Verified,nishida_seroprevalence_2020,JPN
200911_Osaka_ToyonakaMunicipalHospital_50-69,200911_Osaka_ToyonakaMunicipalHospital,"Seroprevalence of SARS-CoV-2 Antibodies Among 925 Staff Members in an Urban Hospital Accepting COVID-19 Patients in Osaka Prefecture, Japan",2020-09-11,Preprint,Local,Cross-sectional survey ,Japan,Kansai,Osaka,All hospital staff at the Toyonaka Municipal Hospital,Those who refused to take part in this study; those who did not have enough extra blood drawn to undergo antibody testing; and those who were not identified because they mistyped their personal ten-digit identification code,2020-06-12,2020-06-19,Health care workers and caregivers,All,Adults (18-64 years),50.0,69.0,Age,Age group 50-69 years old,216,0.009300000000000001,0.0025,0.033,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Yes,Tsutomu Nishida,Toyonaka Municipal Hospital,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.10.20191866v1,2020-10-23,2024-03-01,Verified,nishida_seroprevalence_2020,JPN
200911_Osaka_ToyonakaMunicipalHospital_40-49,200911_Osaka_ToyonakaMunicipalHospital,"Seroprevalence of SARS-CoV-2 Antibodies Among 925 Staff Members in an Urban Hospital Accepting COVID-19 Patients in Osaka Prefecture, Japan",2020-09-11,Preprint,Local,Cross-sectional survey ,Japan,Kansai,Osaka,All hospital staff at the Toyonaka Municipal Hospital,Those who refused to take part in this study; those who did not have enough extra blood drawn to undergo antibody testing; and those who were not identified because they mistyped their personal ten-digit identification code,2020-06-12,2020-06-19,Health care workers and caregivers,All,Adults (18-64 years),40.0,49.0,Age,Age group 40-49 years old,250,0.004,0.0007099999999999999,0.022000000000000002,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Yes,Tsutomu Nishida,Toyonaka Municipal Hospital,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.10.20191866v1,2020-10-23,2024-03-01,Verified,nishida_seroprevalence_2020,JPN
201008_Fujisawa_ShonanFujisawaTokushukaiHospital_MedicalStaff,201008_Fujisawa_ShonanFujisawaTokushukaiHospital,SARS-CoV-2 IgG Seroprevalence among Medical Staff in a General Hospital that Treated COVID-19 Patients in Japan: Retrospective Evaluation of Nosocomial Infection Control,2020-10-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Kanagawa,Fujisawa,"Assessed 806 medical staff during an annual medical check-up conducted between 1st June and 30th July 2020. Apart from one staff member who had mild COVID-19 in April 2020, none of the staff had been confirmed to have COVID-19 at any time. The study included 66 doctors, 363 nurses, 40 pharmacists, 37 radiology technicians, 57 laboratory medical technologists, 58 rehabilitation therapists and 185 other occupations",,2020-06-01,2020-07-30,Health care workers and caregivers,All,Adults (18-64 years),21.0,83.0,Primary Estimate,All of medical staff (direct contact and no direct contact),806,0.0074,0.0027,0.0161,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,M Hibino,Shonan Fujisawa Tokushukai Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jhin.2020.10.001,2020-11-24,2024-03-01,Verified,hibino_sars-cov-2_2020,JPN
201120_Japan_TokyoNationalHospital_overall,201120_Japan_TokyoNationalHospital,Detection of anti-SARS-CoV-2 antibodies in patients with rheumatoid arthritis,2020-11-20,Preprint,Local,Cross-sectional survey ,Japan,,Tokyo,The RA patents fulfilled American College of Rheumatology criteria for RA [8] or Rheumatoid Arthritis Classification Criteria [9] and had not been diagnosed as COVID-19 before the collection of sera. ,,2020-06-01,2020-10-30,Patients seeking care for non-COVID-19 reasons,All,Seniors (65+ years),,,Primary Estimate,,93,0.161,,,True,,,,,Convenience,"GenBody COVID-19 IgM/IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","GenBody Inc.,Roche Diagnostics",Multiple Types,Serum,"['IgG', 'IgM']","['Notreported', 'Nucleocapsid(N-protein)']",,,,['High'],No,No,No,No,No,Unclear,Yes,No,Unclear,Shomi Oka,Tokyo National Hospital,Not Unity-Aligned,https://www.researchsquare.com/article/rs-112294/v1,2021-02-07,2024-03-01,Verified,oka_detection_2020,JPN
201207_Kyoto_NationalHospitalOrganizationKyotoMedicalCenter,201207_Kyoto_NationalHospitalOrganizationKyotoMedicalCenter,Quantitative SARS-CoV-2 antibody screening of healthcare workers in the southern part of Kyoto city during the COVID-19 peri-pandemic period,2020-12-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Kansai,Kyoto,"medical doctors, nurses, and ward clerks employed at our hospital between April 10 and April 20, 2020. All participants were asymptomatic and worked within any of the following departments: infectious disease, respiratory medicine, otolaryngology, or emergency medicine. Healthcare workers from these departments were selected as they were considered more likely to treat patients with suspected COVID- 19, of which they might not have been aware",,2020-04-10,2020-04-20,Health care workers and caregivers,All,Adults (18-64 years),20.0,,Primary Estimate,Overall estimate,92,0.054000000000000006,,,True,,,,True,Convenience,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,Kohei Fujita,National Hospital Organization Kyoto Medical Center,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2020.595348,2021-02-01,2024-03-01,Verified,fujita_quantitative_2020,JPN
201216_Utsunomiya_TokyoMedicalandDentalUniversity_PopAdj,201216_Utsunomiya_TokyoMedicalandDentalUniversity,"Seroprevalence of SARS‐CoV‐2 in Utsunomiya City, Greater Tokyo, after the first pandemic in 2020",2020-12-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,Tochigi Prefecture,Utsunomiya City,"households in Utsunomiya City, Tochigi Prefecture, Greater Tokyo, Japan.",,2020-06-14,2020-07-05,Household and community samples,All,Multiple groups,,,Primary Estimate,Population adjusted,742,0.0123,0.0017000000000000001,0.022799999999999997,True,,True,,True,Simplified probability,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,,Validated by manufacturers,0.973,0.963,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,No,Nobutoshi Nawa,Tokyo Medical and Dental University,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/full/10.1002/jgf2.408,2021-05-13,2022-07-16,Verified,nawa_seroprevalence_2021,JPN
201216_Utsunomiya_TokyoMedicalandDentalUniversity_PopAdj_age18-65,201216_Utsunomiya_TokyoMedicalandDentalUniversity,"Seroprevalence of SARS‐CoV‐2 in Utsunomiya City, Greater Tokyo, after the first pandemic in 2020",2020-12-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,Tochigi Prefecture,Utsunomiya City,"households in Utsunomiya City, Tochigi Prefecture, Greater Tokyo, Japan.",,2020-06-14,2020-07-05,Household and community samples,All,Adults (18-64 years),,,Age,Population adjusted age 18-65,463,0.0129,0.0014000000000000002,0.024300000000000002,,,True,,,Simplified probability,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,,Validated by manufacturers,0.973,0.963,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,No,Nobutoshi Nawa,Tokyo Medical and Dental University,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/full/10.1002/jgf2.408,2021-06-03,2022-07-16,Verified,nawa_seroprevalence_2021,JPN
201216_Utsunomiya_TokyoMedicalandDentalUniversity_PopAdj_age<10,201216_Utsunomiya_TokyoMedicalandDentalUniversity,"Seroprevalence of SARS‐CoV‐2 in Utsunomiya City, Greater Tokyo, after the first pandemic in 2020",2020-12-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,Tochigi Prefecture,Utsunomiya City,"households in Utsunomiya City, Tochigi Prefecture, Greater Tokyo, Japan.",,2020-06-14,2020-07-05,Household and community samples,All,Children and Youth (0-17 years),,,Age,Population adjusted age <10,56,0.0,0.0,0.0,,,True,,,Simplified probability,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,,Validated by manufacturers,0.973,0.963,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,No,Nobutoshi Nawa,Tokyo Medical and Dental University,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/full/10.1002/jgf2.408,2021-06-03,2022-07-16,Verified,nawa_seroprevalence_2021,JPN
201216_Utsunomiya_TokyoMedicalandDentalUniversity_PopAdj_age10-17,201216_Utsunomiya_TokyoMedicalandDentalUniversity,"Seroprevalence of SARS‐CoV‐2 in Utsunomiya City, Greater Tokyo, after the first pandemic in 2020",2020-12-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,Tochigi Prefecture,Utsunomiya City,"households in Utsunomiya City, Tochigi Prefecture, Greater Tokyo, Japan.",,2020-06-14,2020-07-05,Household and community samples,All,Children and Youth (0-17 years),,,Age,Population adjusted age 10-17,42,0.0,0.0,0.0,,,True,,,Simplified probability,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,,Validated by manufacturers,0.973,0.963,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,No,Nobutoshi Nawa,Tokyo Medical and Dental University,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/full/10.1002/jgf2.408,2021-06-03,2022-07-16,Verified,nawa_seroprevalence_2021,JPN
201216_Utsunomiya_TokyoMedicalandDentalUniversity_PopAdj_female,201216_Utsunomiya_TokyoMedicalandDentalUniversity,"Seroprevalence of SARS‐CoV‐2 in Utsunomiya City, Greater Tokyo, after the first pandemic in 2020",2020-12-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,Tochigi Prefecture,Utsunomiya City,"households in Utsunomiya City, Tochigi Prefecture, Greater Tokyo, Japan.",,2020-06-14,2020-07-05,Household and community samples,Female,Multiple groups,,,Sex/Gender,Population adjusted female,390,0.0,0.0,0.0,,,True,,,Simplified probability,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,,Validated by manufacturers,0.973,0.963,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,No,Nobutoshi Nawa,Tokyo Medical and Dental University,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/full/10.1002/jgf2.408,2021-06-03,2022-07-16,Verified,nawa_seroprevalence_2021,JPN
201216_Utsunomiya_TokyoMedicalandDentalUniversity_PopAdj_male,201216_Utsunomiya_TokyoMedicalandDentalUniversity,"Seroprevalence of SARS‐CoV‐2 in Utsunomiya City, Greater Tokyo, after the first pandemic in 2020",2020-12-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,Tochigi Prefecture,Utsunomiya City,"households in Utsunomiya City, Tochigi Prefecture, Greater Tokyo, Japan.",,2020-06-14,2020-07-05,Household and community samples,Male,Multiple groups,,,Sex/Gender,Population adjusted male,352,0.019,0.0005,0.0376,,,True,,,Simplified probability,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,,Validated by manufacturers,0.973,0.963,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,No,Nobutoshi Nawa,Tokyo Medical and Dental University,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/full/10.1002/jgf2.408,2021-06-03,2022-07-16,Verified,nawa_seroprevalence_2021,JPN
201216_Utsunomiya_TokyoMedicalandDentalUniversity_PopAdj_age65+,201216_Utsunomiya_TokyoMedicalandDentalUniversity,"Seroprevalence of SARS‐CoV‐2 in Utsunomiya City, Greater Tokyo, after the first pandemic in 2020",2020-12-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,Tochigi Prefecture,Utsunomiya City,"households in Utsunomiya City, Tochigi Prefecture, Greater Tokyo, Japan.",,2020-06-14,2020-07-05,Household and community samples,All,Seniors (65+ years),,,Age,Population adjusted age 65+,181,0.0,0.0,0.0,,,True,,,Simplified probability,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,,Validated by manufacturers,0.973,0.963,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,No,Nobutoshi Nawa,Tokyo Medical and Dental University,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/full/10.1002/jgf2.408,2021-06-03,2022-07-16,Verified,nawa_seroprevalence_2021,JPN
201230_Fukushima_ HirataCentralHospital_CLIA_IgG,201230_Fukushima_ HirataCentralHospital,The difference between IgM and IgG antibody prevalence in different serological assays for COVID-19; lessons from the examination of healthcare workers,2020-12-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Fukushima Prefecture,Hirata,"Hospital staff at Seireikai group, a private health care group located in the central part of Fukushima Prefecture, Japan.",,2020-05-08,2020-05-28,Health care workers and caregivers,All,Multiple groups,18.0,78.0,Primary Estimate,,637,0.0094,,,True,,,,True,Unclear,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,Unclear,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Yurie Kobashi, Hirata Central Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.intimp.2020.107360,2021-02-16,2023-07-04,Verified,noauthor_difference_2021,JPN
210113_Wakayama_WakayamaMedicalUniversity_overall,210113_Wakayama_WakayamaMedicalUniversity,Immunochromatographic SARS-CoV-2 IgG antibody assay: a cross-sectional study conducted at Wakayama Medical University in Japan,2021-01-13,Preprint,Local,Cross-sectional survey ,Japan,,Wakayama,"Volunteers––doctors, nurses, pharmacists, medical technicians, clerks, researchers, and other professionals (childminders, secretaries, medical interns, etc.)––working at Wakayama Medical Hospital or its branch (medical university) having asymptomatic COVID-19 were enrolled",,2020-07-07,2020-09-15,Health care workers and caregivers,All,Multiple groups,19.0,77.0,Primary Estimate,,1528,0.0079,0.0034000000000000002,0.0122,True,True,,,True,Convenience,SARS-CoV-2 antibody detection kit (IgM/IgG),Kurabo Industries Ltd,LFIA,Whole Blood,IgG,,Validated by manufacturers,0.7640000000000001,1.0,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Sadahiro Iwabuchi,Wakayama Medical University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.01.10.21249421v1,2021-02-07,2022-07-16,Unverified,iwabuchi_immunochromatographic_2021,JPN
210120_Japan_ResearchInstituteOfTuberculosis_GenPop,210120_Japan_ResearchInstituteOfTuberculosis,"Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020",2021-01-20,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Japan,,"Tokyo, Osaka, Miyagi","We conducted a seroprevalence survey of SARS- CoV-2 infection in 3 prefectures of Japan: Tokyo, Osaka, and Miyagi. Eligible participants were persons >20 years of age living in Japan.",The Tokyo and Miyagi prefectures excluded otherwise eligible participants with temperatures ≥37.5°C. ,2020-06-01,2020-06-07,Household and community samples,All,Multiple groups,20.0,,Primary Estimate,,7950,0.001,0.0004,0.002,True,,,,True,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG","Roche Diagnostics,Abbott Laboratories",CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),Validated by manufacturers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,No,Takashi Yoshiyama,Government of Japan,Unity-Aligned,https://dx.doi.org/10.3201/eid2702.204088,2021-02-28,2024-03-01,Verified,yoshiyama_prevalence_2021,JPN
210120_Japan_ResearchInstituteOfTuberculosis_GenPop_60-69,210120_Japan_ResearchInstituteOfTuberculosis,"Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020",2021-01-20,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Japan,,"Tokyo, Osaka, Miyagi","We conducted a seroprevalence survey of SARS- CoV-2 infection in 3 prefectures of Japan: Tokyo, Osaka, and Miyagi. Eligible participants were persons >20 years of age living in Japan.",The Tokyo and Miyagi prefectures excluded otherwise eligible participants with temperatures ≥37.5°C. ,2020-06-01,2020-06-07,Household and community samples,All,Adults (18-64 years),60.0,69.0,Age,60-69,1320,0.0008,0.0,0.0042,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),Validated by manufacturers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,No,Takashi Yoshiyama,Government of Japan,Unity-Aligned,https://dx.doi.org/10.3201/eid2702.204088,2021-02-28,2024-03-01,Verified,yoshiyama_prevalence_2021,JPN
210120_Japan_ResearchInstituteOfTuberculosis_GenPop_Tokyo,210120_Japan_ResearchInstituteOfTuberculosis,"Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020",2021-01-20,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,,Tokyo,"We conducted a seroprevalence survey of SARS- CoV-2 infection in 3 prefectures of Japan: Tokyo, Osaka, and Miyagi. Eligible participants were persons >20 years of age living in Japan.",The Tokyo and Miyagi prefectures excluded otherwise eligible participants with temperatures ≥37.5°C. ,2020-06-01,2020-06-07,Household and community samples,All,Multiple groups,20.0,,Geographical area,Tokyo,1971,0.001,0.0001,0.0037,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),Validated by manufacturers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,No,Takashi Yoshiyama,Government of Japan,Unity-Aligned,https://dx.doi.org/10.3201/eid2702.204088,2021-02-28,2024-03-01,Verified,yoshiyama_prevalence_2021,JPN
210120_Japan_ResearchInstituteOfTuberculosis_GenPop_Osaka,210120_Japan_ResearchInstituteOfTuberculosis,"Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020",2021-01-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,,Osaka,"We conducted a seroprevalence survey of SARS- CoV-2 infection in 3 prefectures of Japan: Tokyo, Osaka, and Miyagi. Eligible participants were persons >20 years of age living in Japan.",The Tokyo and Miyagi prefectures excluded otherwise eligible participants with temperatures ≥37.5°C. ,2020-06-01,2020-06-07,Household and community samples,All,Multiple groups,20.0,,Geographical area,Osaka,2970,0.0017000000000000001,0.0005,0.0039000000000000003,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),Validated by manufacturers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,No,Takashi Yoshiyama,Government of Japan,Unity-Aligned,https://dx.doi.org/10.3201/eid2702.204088,2021-02-28,2024-03-01,Verified,yoshiyama_prevalence_2021,JPN
210120_Japan_ResearchInstituteOfTuberculosis_GenPop_50-59,210120_Japan_ResearchInstituteOfTuberculosis,"Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020",2021-01-20,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Japan,,"Tokyo, Osaka, Miyagi","We conducted a seroprevalence survey of SARS- CoV-2 infection in 3 prefectures of Japan: Tokyo, Osaka, and Miyagi. Eligible participants were persons >20 years of age living in Japan.",The Tokyo and Miyagi prefectures excluded otherwise eligible participants with temperatures ≥37.5°C. ,2020-06-01,2020-06-07,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,1463,0.0,0.0,0.0025,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),Validated by manufacturers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,No,Takashi Yoshiyama,Government of Japan,Unity-Aligned,https://dx.doi.org/10.3201/eid2702.204088,2021-02-28,2024-03-01,Verified,yoshiyama_prevalence_2021,JPN
210120_Japan_ResearchInstituteOfTuberculosis_GenPop_AbbottTest,210120_Japan_ResearchInstituteOfTuberculosis,"Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020",2021-01-20,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Japan,,"Tokyo, Osaka, Miyagi","We conducted a seroprevalence survey of SARS- CoV-2 infection in 3 prefectures of Japan: Tokyo, Osaka, and Miyagi. Eligible participants were persons >20 years of age living in Japan.",The Tokyo and Miyagi prefectures excluded otherwise eligible participants with temperatures ≥37.5°C. ,2020-06-01,2020-06-07,Household and community samples,All,Multiple groups,20.0,,Test used,Abbott Test,7950,0.0019,,,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,0.996,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,No,Takashi Yoshiyama,Government of Japan,Unity-Aligned,https://dx.doi.org/10.3201/eid2702.204088,2021-02-28,2024-03-01,Verified,yoshiyama_prevalence_2021,JPN
210120_Japan_ResearchInstituteOfTuberculosis_GenPop_RocheTest,210120_Japan_ResearchInstituteOfTuberculosis,"Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020",2021-01-20,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Japan,,"Tokyo, Osaka, Miyagi","We conducted a seroprevalence survey of SARS- CoV-2 infection in 3 prefectures of Japan: Tokyo, Osaka, and Miyagi. Eligible participants were persons >20 years of age living in Japan.",The Tokyo and Miyagi prefectures excluded otherwise eligible participants with temperatures ≥37.5°C. ,2020-06-01,2020-06-07,Household and community samples,All,Multiple groups,20.0,,Test used,Roche Test,7950,0.0019,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,No,Takashi Yoshiyama,Government of Japan,Unity-Aligned,https://dx.doi.org/10.3201/eid2702.204088,2021-02-28,2024-03-01,Verified,yoshiyama_prevalence_2021,JPN
210120_Japan_ResearchInstituteOfTuberculosis_GenPop_30-39,210120_Japan_ResearchInstituteOfTuberculosis,"Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020",2021-01-20,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Japan,,"Tokyo, Osaka, Miyagi","We conducted a seroprevalence survey of SARS- CoV-2 infection in 3 prefectures of Japan: Tokyo, Osaka, and Miyagi. Eligible participants were persons >20 years of age living in Japan.",The Tokyo and Miyagi prefectures excluded otherwise eligible participants with temperatures ≥37.5°C. ,2020-06-01,2020-06-07,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39 ,1216,0.0025,0.0005,0.0072,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),Validated by manufacturers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,No,Takashi Yoshiyama,Government of Japan,Unity-Aligned,https://dx.doi.org/10.3201/eid2702.204088,2021-02-28,2024-03-01,Verified,yoshiyama_prevalence_2021,JPN
210120_Japan_ResearchInstituteOfTuberculosis_GenPop_40-49,210120_Japan_ResearchInstituteOfTuberculosis,"Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020",2021-01-20,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Japan,,"Tokyo, Osaka, Miyagi","We conducted a seroprevalence survey of SARS- CoV-2 infection in 3 prefectures of Japan: Tokyo, Osaka, and Miyagi. Eligible participants were persons >20 years of age living in Japan.",The Tokyo and Miyagi prefectures excluded otherwise eligible participants with temperatures ≥37.5°C. ,2020-06-01,2020-06-07,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,1599,0.0,0.0,0.0023,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),Validated by manufacturers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,No,Takashi Yoshiyama,Government of Japan,Unity-Aligned,https://dx.doi.org/10.3201/eid2702.204088,2021-02-28,2024-03-01,Verified,yoshiyama_prevalence_2021,JPN
210120_Japan_ResearchInstituteOfTuberculosis_GenPop_70-79,210120_Japan_ResearchInstituteOfTuberculosis,"Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020",2021-01-20,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Japan,,"Tokyo, Osaka, Miyagi","We conducted a seroprevalence survey of SARS- CoV-2 infection in 3 prefectures of Japan: Tokyo, Osaka, and Miyagi. Eligible participants were persons >20 years of age living in Japan.",The Tokyo and Miyagi prefectures excluded otherwise eligible participants with temperatures ≥37.5°C. ,2020-06-01,2020-06-07,Household and community samples,All,Seniors (65+ years),70.0,79.0,Age,70-79,1134,0.0009,0.0,0.0049,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),Validated by manufacturers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,No,Takashi Yoshiyama,Government of Japan,Unity-Aligned,https://dx.doi.org/10.3201/eid2702.204088,2021-02-28,2024-03-01,Verified,yoshiyama_prevalence_2021,JPN
210120_Japan_ResearchInstituteOfTuberculosis_GenPop_>80,210120_Japan_ResearchInstituteOfTuberculosis,"Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020",2021-01-20,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Japan,,"Tokyo, Osaka, Miyagi","We conducted a seroprevalence survey of SARS- CoV-2 infection in 3 prefectures of Japan: Tokyo, Osaka, and Miyagi. Eligible participants were persons >20 years of age living in Japan.",The Tokyo and Miyagi prefectures excluded otherwise eligible participants with temperatures ≥37.5°C. ,2020-06-01,2020-06-07,Household and community samples,All,Seniors (65+ years),80.0,,Age,>=80,340,0.0,0.0,0.0108,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),Validated by manufacturers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,No,Takashi Yoshiyama,Government of Japan,Unity-Aligned,https://dx.doi.org/10.3201/eid2702.204088,2021-02-28,2024-03-01,Verified,yoshiyama_prevalence_2021,JPN
210120_Japan_ResearchInstituteOfTuberculosis_GenPop_Miyagi,210120_Japan_ResearchInstituteOfTuberculosis,"Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020",2021-01-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,,Miyagi,"We conducted a seroprevalence survey of SARS- CoV-2 infection in 3 prefectures of Japan: Tokyo, Osaka, and Miyagi. Eligible participants were persons >20 years of age living in Japan.",The Tokyo and Miyagi prefectures excluded otherwise eligible participants with temperatures ≥37.5°C. ,2020-06-01,2020-06-07,Household and community samples,All,Multiple groups,20.0,,Geographical area,Miyagi,3009,0.0003,0.0,0.0019,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),Validated by manufacturers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,No,Takashi Yoshiyama,Government of Japan,Unity-Aligned,https://dx.doi.org/10.3201/eid2702.204088,2021-02-28,2024-03-01,Verified,yoshiyama_prevalence_2021,JPN
210120_Japan_ResearchInstituteOfTuberculosis_GenPop_Female,210120_Japan_ResearchInstituteOfTuberculosis,"Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020",2021-01-20,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Japan,,"Tokyo, Osaka, Miyagi","We conducted a seroprevalence survey of SARS- CoV-2 infection in 3 prefectures of Japan: Tokyo, Osaka, and Miyagi. Eligible participants were persons >20 years of age living in Japan.",The Tokyo and Miyagi prefectures excluded otherwise eligible participants with temperatures ≥37.5°C. ,2020-06-01,2020-06-07,Household and community samples,Female,Multiple groups,20.0,,Sex/Gender,,4292,0.0012,0.0004,0.0027,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),Validated by manufacturers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,No,Takashi Yoshiyama,Government of Japan,Unity-Aligned,https://dx.doi.org/10.3201/eid2702.204088,2021-02-28,2024-03-01,Verified,yoshiyama_prevalence_2021,JPN
210120_Japan_ResearchInstituteOfTuberculosis_GenPop_20-29,210120_Japan_ResearchInstituteOfTuberculosis,"Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020",2021-01-20,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Japan,,"Tokyo, Osaka, Miyagi","We conducted a seroprevalence survey of SARS- CoV-2 infection in 3 prefectures of Japan: Tokyo, Osaka, and Miyagi. Eligible participants were persons >20 years of age living in Japan.",The Tokyo and Miyagi prefectures excluded otherwise eligible participants with temperatures ≥37.5°C. ,2020-06-01,2020-06-07,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,878,0.0034000000000000002,0.0007000000000000001,0.01,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),Validated by manufacturers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,No,Takashi Yoshiyama,Government of Japan,Unity-Aligned,https://dx.doi.org/10.3201/eid2702.204088,2021-02-28,2024-03-01,Verified,yoshiyama_prevalence_2021,JPN
210120_Japan_ResearchInstituteOfTuberculosis_GenPop_Male,210120_Japan_ResearchInstituteOfTuberculosis,"Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020",2021-01-20,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Japan,,"Tokyo, Osaka, Miyagi","We conducted a seroprevalence survey of SARS- CoV-2 infection in 3 prefectures of Japan: Tokyo, Osaka, and Miyagi. Eligible participants were persons >20 years of age living in Japan.",The Tokyo and Miyagi prefectures excluded otherwise eligible participants with temperatures ≥37.5°C. ,2020-06-01,2020-06-07,Household and community samples,Male,Multiple groups,20.0,,Sex/Gender,,3658,0.0008,0.0002,0.0024,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),Validated by manufacturers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,No,Takashi Yoshiyama,Government of Japan,Unity-Aligned,https://dx.doi.org/10.3201/eid2702.204088,2021-02-28,2024-03-01,Verified,yoshiyama_prevalence_2021,JPN
210129_Hyogo_KobeUniversityGraduateSchoolOfMedicine_Overall,210129_Hyogo_KobeUniversityGraduateSchoolOfMedicine,"Seroepidemiological Survey of the Antibody for Severe Acute Respiratory Syndrome Coronavirus 2 with Neutralizing Activity at Hospitals: A Cross-sectional Study in Hyogo Prefecture, Japan",2021-01-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,Kansai,,"residual blood of patients who visited or were admitted to the five hospitals and a foundation in Hyogo Prefecture were selected and tested for antibodies against SARS-CoV-2. The six participating facilities
were Kobe University Hospital (Ko), anonymous X Hospital
(X), Hyogo Prefectural Nishinomiya Hospital (NI), Hyogo
Prefectural Amagasaki General Medical Center (AM), Hyogo
Prefecture Health Promotion Association (HE), and Hyogo
Prefectural Kobe Children’s Hospital (CH), which are located
from west to east in Hyogo Prefecture.",,2020-08-06,2020-10-01,Residual sera,All,Multiple groups,0.0,99.0,Primary Estimate,Positive for one or both tests,10377,0.006,,,True,,,,True,Sequential,"Nucleocapsid HISCL™-5000/HISCL-800 Automated Immunoassay Systems,Elecsys® Anti‐SARS‐CoV‐2 (N),Spike HISCL™-5000/HISCL-800 Automated Immunoassay Systems","Sysmex,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,,Koichi Furukawa,Kobe University Graduate School of Medicine,Not Unity-Aligned,https://dx.doi.org/10.31662/jmaj.2020-0094,2021-03-20,2024-03-01,Verified,noauthor_seroepidemiological_2021,JPN
210129_Hyogo_KobeUniversityGraduateSchoolOfMedicine_Female,210129_Hyogo_KobeUniversityGraduateSchoolOfMedicine,"Seroepidemiological Survey of the Antibody for Severe Acute Respiratory Syndrome Coronavirus 2 with Neutralizing Activity at Hospitals: A Cross-sectional Study in Hyogo Prefecture, Japan",2021-01-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,Kansai,,"residual blood of patients who visited or were admitted to the five hospitals and a foundation in Hyogo Prefecture were selected and tested for antibodies against SARS-CoV-2. The six participating facilities
were Kobe University Hospital (Ko), anonymous X Hospital
(X), Hyogo Prefectural Nishinomiya Hospital (NI), Hyogo
Prefectural Amagasaki General Medical Center (AM), Hyogo
Prefecture Health Promotion Association (HE), and Hyogo
Prefectural Kobe Children’s Hospital (CH), which are located
from west to east in Hyogo Prefecture.",,2020-08-06,2020-10-01,Residual sera,Female,Multiple groups,0.0,99.0,Sex/Gender,"Female, Positive for one or both tests",5193,0.0048,,,,,,,,Sequential,"Nucleocapsid HISCL™-5000/HISCL-800 Automated Immunoassay Systems,Elecsys® Anti‐SARS‐CoV‐2 (N),Spike HISCL™-5000/HISCL-800 Automated Immunoassay Systems","Sysmex,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,,Koichi Furukawa,Kobe University Graduate School of Medicine,Not Unity-Aligned,https://dx.doi.org/10.31662/jmaj.2020-0094,2021-04-19,2024-03-01,Verified,noauthor_seroepidemiological_2021,JPN
210129_Hyogo_KobeUniversityGraduateSchoolOfMedicine_ElecsysECLIA,210129_Hyogo_KobeUniversityGraduateSchoolOfMedicine,"Seroepidemiological Survey of the Antibody for Severe Acute Respiratory Syndrome Coronavirus 2 with Neutralizing Activity at Hospitals: A Cross-sectional Study in Hyogo Prefecture, Japan",2021-01-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,Kansai,,"residual blood of patients who visited or were admitted to the five hospitals and a foundation in Hyogo Prefecture were selected and tested for antibodies against SARS-CoV-2. The six participating facilities
were Kobe University Hospital (Ko), anonymous X Hospital
(X), Hyogo Prefectural Nishinomiya Hospital (NI), Hyogo
Prefectural Amagasaki General Medical Center (AM), Hyogo
Prefecture Health Promotion Association (HE), and Hyogo
Prefectural Kobe Children’s Hospital (CH), which are located
from west to east in Hyogo Prefecture.",,2020-08-06,2020-10-01,Residual sera,All,Multiple groups,0.0,99.0,Test used,"ECLIA (Roche, Elecsys test)",10377,0.0026000000000000003,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,,Koichi Furukawa,Kobe University Graduate School of Medicine,Not Unity-Aligned,https://dx.doi.org/10.31662/jmaj.2020-0094,2021-03-20,2024-03-01,Verified,noauthor_seroepidemiological_2021,JPN
210129_Hyogo_KobeUniversityGraduateSchoolOfMedicine_SysmexCLIA,210129_Hyogo_KobeUniversityGraduateSchoolOfMedicine,"Seroepidemiological Survey of the Antibody for Severe Acute Respiratory Syndrome Coronavirus 2 with Neutralizing Activity at Hospitals: A Cross-sectional Study in Hyogo Prefecture, Japan",2021-01-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,Kansai,,"residual blood of patients who visited or were admitted to the five hospitals and a foundation in Hyogo Prefecture were selected and tested for antibodies against SARS-CoV-2. The six participating facilities
were Kobe University Hospital (Ko), anonymous X Hospital
(X), Hyogo Prefectural Nishinomiya Hospital (NI), Hyogo
Prefectural Amagasaki General Medical Center (AM), Hyogo
Prefecture Health Promotion Association (HE), and Hyogo
Prefectural Kobe Children’s Hospital (CH), which are located
from west to east in Hyogo Prefecture.",,2020-08-06,2020-10-01,Residual sera,All,Multiple groups,0.0,99.0,Test used,"Sysmex, CLIA test",10377,0.0049,,,,,,,,Sequential,"Nucleocapsid HISCL™-5000/HISCL-800 Automated Immunoassay Systems,Spike HISCL™-5000/HISCL-800 Automated Immunoassay Systems",Sysmex,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,,Koichi Furukawa,Kobe University Graduate School of Medicine,Not Unity-Aligned,https://dx.doi.org/10.31662/jmaj.2020-0094,2021-03-20,2022-07-16,Verified,noauthor_seroepidemiological_2021,JPN
210129_Hyogo_KobeUniversityGraduateSchoolOfMedicine_Male,210129_Hyogo_KobeUniversityGraduateSchoolOfMedicine,"Seroepidemiological Survey of the Antibody for Severe Acute Respiratory Syndrome Coronavirus 2 with Neutralizing Activity at Hospitals: A Cross-sectional Study in Hyogo Prefecture, Japan",2021-01-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,Kansai,,"residual blood of patients who visited or were admitted to the five hospitals and a foundation in Hyogo Prefecture were selected and tested for antibodies against SARS-CoV-2. The six participating facilities
were Kobe University Hospital (Ko), anonymous X Hospital
(X), Hyogo Prefectural Nishinomiya Hospital (NI), Hyogo
Prefectural Amagasaki General Medical Center (AM), Hyogo
Prefecture Health Promotion Association (HE), and Hyogo
Prefectural Kobe Children’s Hospital (CH), which are located
from west to east in Hyogo Prefecture.",,2020-08-06,2020-10-01,Residual sera,Male,Multiple groups,0.0,99.0,Sex/Gender,"Male, Positive for one or both tests",5184,0.0075,,,,,,,,Sequential,"Nucleocapsid HISCL™-5000/HISCL-800 Automated Immunoassay Systems,Elecsys® Anti‐SARS‐CoV‐2 (N),Spike HISCL™-5000/HISCL-800 Automated Immunoassay Systems","Sysmex,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,,Koichi Furukawa,Kobe University Graduate School of Medicine,Not Unity-Aligned,https://dx.doi.org/10.31662/jmaj.2020-0094,2021-04-19,2024-03-01,Verified,noauthor_seroepidemiological_2021,JPN
210201_Yamagata_YamagataUniversity_Overall,210201_Yamagata_YamagataUniversity,"Seroepidemiology of SARS-CoV-2, Yamagata, Japan, June 2020.",2021-02-01,Institutional Report,Local,Cross-sectional survey ,Japan,Yamagata prefecture,Yamagata,Residual sera obtained from patients who visited the outpatient clinic of Yamagata University Hospital for any acute medical condition during 1–4 June 2020 ,,2020-06-01,2020-06-04,Residual sera,All,Multiple groups,,,Primary Estimate,,1009,0.005,0.00062,0.009300000000000001,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,,0.998,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,,Keita Morikane,Yamagata University,Unity-Aligned,https://dx.doi.org/10.5365/wpsar.2020.11.3.012,2021-06-23,2024-03-01,Verified,morikane_seroepidemiology_2021,JPN
210206_YokohamaCity_YokohamaCityUniversity,210206_YokohamaCity_YokohamaCityUniversity,SARS-CoV-2 prevalence in saliva and gastric and intestinal fluid in patients undergoing gastrointestinal endoscopy in COVID-19 endemic areas: prospective cross-sectional study in Japan,2021-02-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Kanagawa Prefecture,Yokohama City,"The inclusion criteria were as follows: (i) low-risk
patients; (ii) non-emergency GIE cases; (iii) outpatients;
(iv) patients who provided written informed consent for
study participation.","The exclusion criteria were as follows: (i) high-risk
patients (high-risk patients were assessed to identify the
purpose and urgency of GIE, and if the procedure was
judged as a non-emergency, it was postponed); (ii) emergency
cases (in emergency cases, it was difficult to obtain
informed consent); (iii) in patients (our hospital conducted
universal COVID-19 screening before permitting patients to
enter the hospital, and in-patient samples had already
undergone real-time reverse transcription polymerase chain
reaction [RT-PCR]); and (iv) patients not willing to participate
in the study.",2020-06-01,2020-07-31,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),,,Primary Estimate,,432,0.039,,,True,,,,True,Sequential,Author designed (ELISA) - MULTIPLEXED,,ELISA,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,No,Yes,Unclear,Unclear,Yes,No,No,Shigeta Miyake,Yokohama City University,Not Unity-Aligned,http://dx.doi.org/10.1111/den.13945,2021-04-04,2022-07-16,Verified,miyake_severe_nodate,JPN
210212_Hiroshima_HiroshimaUniversity_overall,210212_Hiroshima_HiroshimaUniversity,About the result of the 2nd new coronavirus antibody prevalence survey,2021-02-12,Institutional Report,Regional,Cross-sectional survey ,Japan,Hiroshima Prefecture,"Hiroshima, Fukuyama, Miyoshi, and Higashi-Hiroshima","Residents of 5 municipalities (Hiroshima City, Fukuyama City, Miyoshi City, Higashi Hiroshima City and Kitahiroshima Town) of Hiroshima Prefecture",,2020-10-15,2020-11-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,2396,0.0025,,,True,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,No,Prefecture of Hiroshima,Hiroshima University ,Unity-Aligned,https://www.chugoku-np.co.jp/local/news/article.php?comment_id=726622&comment_sub_id=0&category_id=256,2021-04-30,2024-03-01,Verified,prefecture_of_hiroshima_about_2021,JPN
210223_Osaka_KyotoUniversity_RLA_Overall,210223_Osaka_KyotoUniversity,"Radioligand Assay-Based Detection of Antibodies against
SARS-CoV-2 in Hospital Workers Treating Patients with Severe COVID-19 in Japan",2021-02-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Honshu,Osaka,Employees of Osaka General Medical Center providing treatment to patients with severe COVID-19,,2020-07-08,2020-07-22,Health care workers and caregivers,All,Adults (18-64 years),21.0,69.0,Primary Estimate,RLA assay,1000,0.004,,,True,,,,True,Convenience,Author designed (ELISA) - Nucleocapsid,,Other,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,Yes,Yes,No,Unclear,Yes,No,No,Hidenori Matsunaga,Kyoto University,Not Unity-Aligned,https://www.mdpi.com/1999-4915/13/2/347,2021-05-23,2022-07-16,Verified,matsunaga_radioligand_2021,JPN
210226_Iwate_IwatePrefecturalCentralHospital_HCW_Abbot&Roche,210226_Iwate_IwatePrefecturalCentralHospital,"Orthogonal antibody testing for COVID-19 among healthcare workers in a non-epidemic place and time:Japan's Iwate Prefecture, May 18-31, 2020",2021-02-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Honshu,Morioka,"HCWs (physicians, nurses, pharmacists, radiographers, laboratory technicians, and medical office workers) who work at Iwate Prefectural Central Hospital in the city of Morioka, Japan,  underwent annual health checkups in May ",,2020-05-18,2020-05-29,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1000,0.0,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N),Instant-view® IgG/IgM Antibody COVID- 19 test","Abbott Laboratories,Roche Diagnostics,Alfa Scientific Designs",CLIA,Serum,IgG,,,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,No,,Akihiro Nakamura,Iwate Prefectural Central Hospital,Not Unity-Aligned,https://dx.doi.org/10.5387/fms.2020-21,2020-07-17,2024-03-01,Verified,nakamura_orthogonal_2020,JPN
210315_FukuokaCity_KanenokumaHospital_Residents,210315_FukuokaCity_KanenokumaHospital_Residents,Genetic testing and serological screening for SARS-CoV-2 infection in a COVID-19 outbreak in a nursing facility in Japan,2021-03-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,Japan,,Fukuoka City,Residents of a long-term care facility in Japan,,2020-04-23,2020-06-15,Assisted living and long-term care facilities,All,Seniors (65+ years),,,Primary Estimate,,76,0.0789,,,True,,,,True,Convenience,"Not reported/ Unable to specify,2019-nCoV IgG/IgM Rapid Test Cassette","NA,Hanghzhou AllTest Biotech Co. Ltd",Multiple Types,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),,,,['High'],No,No,No,No,Unclear,Unclear,Yes,No,Unclear,Yong Chong,Kanenokuma Hospital,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-05972-5,2021-05-13,2024-03-01,Verified,chong_genetic_2020,JPN
210315_FukuokaCity_KanenokumaHospital_Staff,210315_FukuokaCity_KanenokumaHospital_Staff,Genetic testing and serological screening for SARS-CoV-2 infection in a COVID-19 outbreak in a nursing facility in Japan,2021-03-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,Japan,,Fukuoka City,PCR-negative residents and staff of a long-term care facility in Japan,,2020-04-23,2020-06-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,40,0.0,,,True,,,,True,Convenience,"Not reported/ Unable to specify,2019-nCoV IgG/IgM Rapid Test Cassette","NA,Hanghzhou AllTest Biotech Co. Ltd",Multiple Types,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),,,,['High'],No,No,No,No,Unclear,Unclear,Yes,No,Unclear,Yong Chong,Kanenokuma Hospital,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-05972-5,2021-05-13,2024-03-01,Verified,chong_genetic_2020,JPN
210324_Morioka_IwatePrefecturalCentralHospital_hcw,210324_Morioka_IwatePrefecturalCentralHospital,"Seroprevalence of antibodies to SARS‐CoV‐2 in healthcare workers in a nonepidemic region, Japan: A hospital‐based study on May, 2020",2021-03-24,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Japan,Tonoku,Morioka,"Blood samples were taken during the annual health checkups of 1706 healthcare workers (physicians, nurses, pharmacists, radiographers, laboratory technicians, and medical office workers) on May 18–29, 2020",,2020-05-18,2020-05-19,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Iwate Prefectural Central Hospital,1404,0.0,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",Multiple Types,Serum,IgG,,Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Akihiro Nakamura,Iwate Prefectural Central Hospital ,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.1002/jmv.26962,2021-05-16,2024-03-01,Verified,nakamura_seroprevalence_2020-1,JPN
210330_ Aichi_JapanMinistryOfHealth3_overall,210330_ Aichi_3JapanMinistryOfHealth,1.35% in Tokyo have antibodies against the coronavirus,2021-03-30,News and Media,Regional,Cross-sectional survey ,Japan,Aichi Prefecture,,,,2020-12-14,2020-12-26,Household and community samples,All,Multiple groups,,,Primary Estimate,Aichi Prefecture,2960,0.0070999999999999995,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Bharat Express News,Japan Ministry of Health,Not Unity-Aligned,https://www.thebharatexpressnews.com/1-35-in-tokyo-have-antibodies-against-the-coronavirus/,2021-04-11,2022-07-16,Unverified,the_bharat_express_news_135_2021,JPN
210330_ Fukuoka_JapanMinistryOfHealth5_overall,210330_ Fukuoka_5JapanMinistryOfHealth,1.35% in Tokyo have antibodies against the coronavirus,2021-03-30,News and Media,Regional,Cross-sectional survey ,Japan,Fukuoka Prefecture,,,,2020-12-14,2020-12-26,Household and community samples,All,Multiple groups,,,Primary Estimate,Fukuoka Prefecture,3078,0.0042,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Bharat Express News,Japan Ministry of Health,Not Unity-Aligned,https://www.thebharatexpressnews.com/1-35-in-tokyo-have-antibodies-against-the-coronavirus/,2021-04-11,2022-07-16,Unverified,the_bharat_express_news_135_2021,JPN
210330_Miyagi_JapanMinistryOfHealth4_overall,210330_ Miyagi _4JapanMinistryOfHealth,1.35% in Tokyo have antibodies against the coronavirus,2021-03-30,News and Media,Regional,Cross-sectional survey ,Japan,Miyagi Prefecture,,,,2020-12-14,2020-12-26,Household and community samples,All,Multiple groups,,,Primary Estimate,Miyagi Prefecture,2860,0.0014000000000000002,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Bharat Express News,Japan Ministry of Health,Not Unity-Aligned,https://www.thebharatexpressnews.com/1-35-in-tokyo-have-antibodies-against-the-coronavirus/,2021-04-11,2022-07-16,Unverified,the_bharat_express_news_135_2021,JPN
210330_Osaka_JapanMinistryOfHealth2_overall,210330_Osaka_2JapanMinistryOfHealth,1.35% in Tokyo have antibodies against the coronavirus,2021-03-30,News and Media,Regional,Cross-sectional survey ,Japan,Osaka Prefecture,,,,2020-12-14,2020-12-26,Household and community samples,All,Multiple groups,,,Primary Estimate,Osaka Prefecture,2746,0.0069,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Bharat Express News,Japan Ministry of Health,Not Unity-Aligned,https://www.thebharatexpressnews.com/1-35-in-tokyo-have-antibodies-against-the-coronavirus/,2021-04-11,2022-07-16,Unverified,the_bharat_express_news_135_2021,JPN
210330_Tokyo_JapanMinistryOfHealth1_overall,210330_Tokyo_1JapanMinistryOfHealth,1.35% in Tokyo have antibodies against the coronavirus,2021-03-30,News and Media,Regional,Cross-sectional survey ,Japan,Tokyo Prefecture,,,,2020-12-14,2020-12-26,Household and community samples,All,Multiple groups,,,Primary Estimate,Tokyo Prefecture,3399,0.013500000000000002,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Bharat Express News,Japan Ministry of Health,Not Unity-Aligned,https://www.thebharatexpressnews.com/1-35-in-tokyo-have-antibodies-against-the-coronavirus/,2021-04-11,2022-07-16,Unverified,the_bharat_express_news_135_2021,JPN
210405_Japan_SOUSEIKAI_Overall,210405_Japan_SOUSEIKAI,Sars-cov-2 seroprevalence among healthcare workers in general hospitals and clinics in Japan,2021-04-05,Journal Article (Peer-Reviewed),Local,Prospective cohort,Japan,"Fukuoka, Kumamoto, Tokyo",,,,2020-08-15,2020-10-15,Health care workers and caregivers,All,Multiple groups,20.0,83.0,Primary Estimate,,2160,0.017,,,True,,,,True,Convenience,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.873,1.0,['High'],Yes,No,Yes,Yes,Yes,No,Yes,No,Unclear,Tatsuya Yoshihara,SOUSEIKAI Medical Group,Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph18073786,2021-05-13,2024-03-01,Verified,yoshihara_sars-cov-2_2021,JPN
210416_Tokyo_JuntendoUniversity_HCW_Overall_testadj,210416_Tokyo_JuntendoUniversity,SARS-CoV-2 seroprevalence in healthcare workers at a frontline hospital in Tokyo,2021-04-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Kantō,Tokyo,"Mandatory health checkup of employees working at the Juntendo University Hospital
and employees and students of the Juntendo University Graduate School of Medicine, Tokyo, Japan. A total of 4147 participants underwent antibody identification from blood specimens.",,2020-07-06,2020-08-21,Health care workers and caregivers,All,Multiple groups,20.0,,Primary Estimate,,4147,0.0038,0.0022,0.0063,True,True,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hiroshi Fukuda,Juntendo Univesity,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-87688-9,2021-05-22,2023-07-04,Verified,fukuda_sars-cov-2_2020,JPN
210416_Tokyo_JuntendoUniversity_HCW_60-69,210416_Tokyo_JuntendoUniversity,SARS-CoV-2 seroprevalence in healthcare workers at a frontline hospital in Tokyo,2021-04-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Kantō,Tokyo,"Mandatory health checkup of employees working at the Juntendo University Hospital
and employees and students of the Juntendo University Graduate School of Medicine, Tokyo, Japan. A total of 4147 participants underwent antibody identification from blood specimens.",,2020-07-06,2020-08-21,Health care workers and caregivers,All,Adults (18-64 years),60.0,69.0,Age,60-69 years of age,193,0.005200000000000001,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hiroshi Fukuda,Juntendo Univesity,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-87688-9,2021-05-22,2024-03-01,Verified,fukuda_sars-cov-2_2020,JPN
210416_Tokyo_JuntendoUniversity_HCW_>70,210416_Tokyo_JuntendoUniversity,SARS-CoV-2 seroprevalence in healthcare workers at a frontline hospital in Tokyo,2021-04-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Kantō,Tokyo,"Mandatory health checkup of employees working at the Juntendo University Hospital
and employees and students of the Juntendo University Graduate School of Medicine, Tokyo, Japan. A total of 4147 participants underwent antibody identification from blood specimens.",,2020-07-06,2020-08-21,Health care workers and caregivers,All,Seniors (65+ years),70.0,,Age,>= 70 years of age,48,0.0,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hiroshi Fukuda,Juntendo Univesity,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-87688-9,2021-05-22,2024-03-01,Verified,fukuda_sars-cov-2_2020,JPN
210416_Tokyo_JuntendoUniversity_HCW_50-59,210416_Tokyo_JuntendoUniversity,SARS-CoV-2 seroprevalence in healthcare workers at a frontline hospital in Tokyo,2021-04-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Kantō,Tokyo,"Mandatory health checkup of employees working at the Juntendo University Hospital
and employees and students of the Juntendo University Graduate School of Medicine, Tokyo, Japan. A total of 4147 participants underwent antibody identification from blood specimens.",,2020-07-06,2020-08-21,Health care workers and caregivers,All,Adults (18-64 years),50.0,59.0,Age,50-59 years of age,424,0.0024,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hiroshi Fukuda,Juntendo Univesity,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-87688-9,2021-05-22,2024-03-01,Verified,fukuda_sars-cov-2_2020,JPN
210416_Tokyo_JuntendoUniversity_HCW_20-29,210416_Tokyo_JuntendoUniversity,SARS-CoV-2 seroprevalence in healthcare workers at a frontline hospital in Tokyo,2021-04-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Kantō,Tokyo,"Mandatory health checkup of employees working at the Juntendo University Hospital
and employees and students of the Juntendo University Graduate School of Medicine, Tokyo, Japan. A total of 4147 participants underwent antibody identification from blood specimens.",,2020-07-06,2020-08-21,Health care workers and caregivers,All,Adults (18-64 years),20.0,29.0,Age,20-29 years of age,1461,0.0027,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hiroshi Fukuda,Juntendo Univesity,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-87688-9,2021-05-22,2024-03-01,Verified,fukuda_sars-cov-2_2020,JPN
210416_Tokyo_JuntendoUniversity_HCW_30-39,210416_Tokyo_JuntendoUniversity,SARS-CoV-2 seroprevalence in healthcare workers at a frontline hospital in Tokyo,2021-04-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Kantō,Tokyo,"Mandatory health checkup of employees working at the Juntendo University Hospital
and employees and students of the Juntendo University Graduate School of Medicine, Tokyo, Japan. A total of 4147 participants underwent antibody identification from blood specimens.",,2020-07-06,2020-08-21,Health care workers and caregivers,All,Adults (18-64 years),30.0,39.0,Age,30-39 years of age,1245,0.004,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hiroshi Fukuda,Juntendo Univesity,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-87688-9,2021-05-22,2024-03-01,Verified,fukuda_sars-cov-2_2020,JPN
210416_Tokyo_JuntendoUniversity_HCW_40-49,210416_Tokyo_JuntendoUniversity,SARS-CoV-2 seroprevalence in healthcare workers at a frontline hospital in Tokyo,2021-04-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Kantō,Tokyo,"Mandatory health checkup of employees working at the Juntendo University Hospital
and employees and students of the Juntendo University Graduate School of Medicine, Tokyo, Japan. A total of 4147 participants underwent antibody identification from blood specimens.",,2020-07-06,2020-08-21,Health care workers and caregivers,All,Adults (18-64 years),40.0,49.0,Age,40-49 years of age,776,0.0039000000000000003,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Hiroshi Fukuda,Juntendo Univesity,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-87688-9,2021-05-22,2024-03-01,Verified,fukuda_sars-cov-2_2020,JPN
210417_Itami_ItamiCityHospital,210417_Itami_ItamiCityHospital,Challenges and responses of elective orthopaedic surgery during the second wave of COVID-19.,2021-04-17,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Japan,Kansai,Itami,592 consecutive patients were admitted to inpatients wards for elective orthopaedic surgery and were included in the study.,"If patients presented with any positive TOCC risk factors and/or exhibited symptoms, they were referred to a COVID-19 outpatient clinic. Thus, none of the included patients exhibited TOCC risk factors or COVID-19 symptoms.",2020-05-15,2020-11-20,Residual sera,All,Multiple groups,,,Primary Estimate,,592,0.022000000000000002,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],,Unclear,No,Yes,,Unclear,Yes,No,,Tsuyoshi Nakai,Itami City Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jos.2021.02.017,2021-05-25,2022-07-16,Unverified,tsuyoshinakaiChallengesResponsesElective2021,JPN
210419_Kobe_KobeMedicalCenterGeneralHospital_Outpatients_PopAdj,210419_Kobe_KobeMedicalCenterGeneralHospital,"Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-sectional study",2021-04-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Hyogo Prefecture,Kobe,"Patients who visited outpatient clinics of the Kobe City Medical Center General Hospital, and received blood testing for any reason between March 31 and Apr 7", Patients who visited the emergency department or the designated fever consultation service were excluded to avoid the overestimation of SARS-Cov-2 infection,2020-03-31,2020-04-07,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,1000,0.027000000000000003,0.018000000000000002,0.039,True,,True,,True,Simplified probability,SARS-CoV-2 antibody detection kit (IgM/IgG),Kurabo Industries Ltd,LFIA,Serum,IgG,,,0.7637999999999999,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,Unclear,Yes,No,,Asaka Doi,Kobe City Medical Center General Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cegh.2021.100747,2020-05-01,2022-07-16,Verified,doi_estimation_2021,JPN
210419_Kobe_KobeMedicalCenterGeneralHospital_OutpatientsAge40-49,210419_Kobe_KobeMedicalCenterGeneralHospital,"Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-sectional study",2021-04-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Hyogo Prefecture,Kobe,"Patients who visited outpatient clinics of the Kobe City Medical Center General Hospital, and received blood testing for any reason between March 31 and Apr 7", Patients who visited the emergency department or the designated fever consultation service were excluded to avoid the overestimation of SARS-Cov-2 infection,2020-03-31,2020-04-07,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,155,0.0323,,,,,,,,Simplified probability,SARS-CoV-2 antibody detection kit (IgM/IgG),Kurabo Industries Ltd,LFIA,Serum,IgG,,,0.7637999999999999,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,Unclear,Yes,No,,Asaka Doi,Kobe City Medical Center General Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cegh.2021.100747,2020-07-27,2022-07-16,Verified,doi_estimation_2021,JPN
210419_Kobe_KobeMedicalCenterGeneralHospital_OutpatientsAge10-19,210419_Kobe_KobeMedicalCenterGeneralHospital,"Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-sectional study",2021-04-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Hyogo Prefecture,Kobe,"Patients who visited outpatient clinics of the Kobe City Medical Center General Hospital, and received blood testing for any reason between March 31 and Apr 7", Patients who visited the emergency department or the designated fever consultation service were excluded to avoid the overestimation of SARS-Cov-2 infection,2020-03-31,2020-04-07,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,27,0.0,,,,,,,,Simplified probability,SARS-CoV-2 antibody detection kit (IgM/IgG),Kurabo Industries Ltd,LFIA,Serum,IgG,,,0.7637999999999999,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,Unclear,Yes,No,,Asaka Doi,Kobe City Medical Center General Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cegh.2021.100747,2020-07-27,2022-07-16,Verified,doi_estimation_2021,JPN
210419_Kobe_KobeMedicalCenterGeneralHospital_OutpatientsAge50-59,210419_Kobe_KobeMedicalCenterGeneralHospital,"Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-sectional study",2021-04-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Hyogo Prefecture,Kobe,"Patients who visited outpatient clinics of the Kobe City Medical Center General Hospital, and received blood testing for any reason between March 31 and Apr 7", Patients who visited the emergency department or the designated fever consultation service were excluded to avoid the overestimation of SARS-Cov-2 infection,2020-03-31,2020-04-07,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,164,0.037000000000000005,,,,,,,,Simplified probability,SARS-CoV-2 antibody detection kit (IgM/IgG),Kurabo Industries Ltd,LFIA,Serum,IgG,,,0.7637999999999999,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,Unclear,Yes,No,,Asaka Doi,Kobe City Medical Center General Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cegh.2021.100747,2020-07-27,2022-07-16,Verified,doi_estimation_2021,JPN
210419_Kobe_KobeMedicalCenterGeneralHospital_OutpatientsAge80-89,210419_Kobe_KobeMedicalCenterGeneralHospital,"Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-sectional study",2021-04-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Hyogo Prefecture,Kobe,"Patients who visited outpatient clinics of the Kobe City Medical Center General Hospital, and received blood testing for any reason between March 31 and Apr 7", Patients who visited the emergency department or the designated fever consultation service were excluded to avoid the overestimation of SARS-Cov-2 infection,2020-03-31,2020-04-07,Residual sera,All,Seniors (65+ years),80.0,89.0,Age,80-89,164,0.03,,,,,,,,Simplified probability,SARS-CoV-2 antibody detection kit (IgM/IgG),Kurabo Industries Ltd,LFIA,Serum,IgG,,,0.7637999999999999,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,Unclear,Yes,No,,Asaka Doi,Kobe City Medical Center General Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cegh.2021.100747,2020-07-27,2022-07-16,Verified,doi_estimation_2021,JPN
210419_Kobe_KobeMedicalCenterGeneralHospital_OutpatientsAge20-29,210419_Kobe_KobeMedicalCenterGeneralHospital,"Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-sectional study",2021-04-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Hyogo Prefecture,Kobe,"Patients who visited outpatient clinics of the Kobe City Medical Center General Hospital, and received blood testing for any reason between March 31 and Apr 7", Patients who visited the emergency department or the designated fever consultation service were excluded to avoid the overestimation of SARS-Cov-2 infection,2020-03-31,2020-04-07,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29,36,0.0,,,,,,,,Simplified probability,SARS-CoV-2 antibody detection kit (IgM/IgG),Kurabo Industries Ltd,LFIA,Serum,IgG,,,0.7637999999999999,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,Unclear,Yes,No,,Asaka Doi,Kobe City Medical Center General Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cegh.2021.100747,2020-07-27,2022-07-16,Verified,doi_estimation_2021,JPN
210419_Kobe_KobeMedicalCenterGeneralHospital_OutpatientsAge70-79,210419_Kobe_KobeMedicalCenterGeneralHospital,"Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-sectional study",2021-04-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Hyogo Prefecture,Kobe,"Patients who visited outpatient clinics of the Kobe City Medical Center General Hospital, and received blood testing for any reason between March 31 and Apr 7", Patients who visited the emergency department or the designated fever consultation service were excluded to avoid the overestimation of SARS-Cov-2 infection,2020-03-31,2020-04-07,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,166,0.054000000000000006,,,,,,,,Simplified probability,SARS-CoV-2 antibody detection kit (IgM/IgG),Kurabo Industries Ltd,LFIA,Serum,IgG,,,0.7637999999999999,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,Unclear,Yes,No,,Asaka Doi,Kobe City Medical Center General Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cegh.2021.100747,2020-07-27,2022-07-16,Verified,doi_estimation_2021,JPN
210419_Kobe_KobeMedicalCenterGeneralHospital_OutpatientsFemale,210419_Kobe_KobeMedicalCenterGeneralHospital,"Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-sectional study",2021-04-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Hyogo Prefecture,Kobe,"Patients who visited outpatient clinics of the Kobe City Medical Center General Hospital, and received blood testing for any reason between March 31 and Apr 7", Patients who visited the emergency department or the designated fever consultation service were excluded to avoid the overestimation of SARS-Cov-2 infection,2020-03-31,2020-04-07,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,Female ,511,0.033,,,,,,,,Simplified probability,SARS-CoV-2 antibody detection kit (IgM/IgG),Kurabo Industries Ltd,LFIA,Serum,IgG,,,0.7637999999999999,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,Unclear,Yes,No,,Asaka Doi,Kobe City Medical Center General Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cegh.2021.100747,2020-07-27,2022-07-16,Verified,doi_estimation_2021,JPN
210419_Kobe_KobeMedicalCenterGeneralHospital_OutpatientsAgeOver90,210419_Kobe_KobeMedicalCenterGeneralHospital,"Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-sectional study",2021-04-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Hyogo Prefecture,Kobe,"Patients who visited outpatient clinics of the Kobe City Medical Center General Hospital, and received blood testing for any reason between March 31 and Apr 7", Patients who visited the emergency department or the designated fever consultation service were excluded to avoid the overestimation of SARS-Cov-2 infection,2020-03-31,2020-04-07,Residual sera,All,Seniors (65+ years),90.0,,Age,>90,19,0.0,,,,,,,,Simplified probability,SARS-CoV-2 antibody detection kit (IgM/IgG),Kurabo Industries Ltd,LFIA,Serum,IgG,,,0.7637999999999999,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,Unclear,Yes,No,,Asaka Doi,Kobe City Medical Center General Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cegh.2021.100747,2020-07-27,2022-07-16,Verified,doi_estimation_2021,JPN
210419_Kobe_KobeMedicalCenterGeneralHospital_OutpatientsAge30-39,210419_Kobe_KobeMedicalCenterGeneralHospital,"Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-sectional study",2021-04-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Hyogo Prefecture,Kobe,"Patients who visited outpatient clinics of the Kobe City Medical Center General Hospital, and received blood testing for any reason between March 31 and Apr 7", Patients who visited the emergency department or the designated fever consultation service were excluded to avoid the overestimation of SARS-Cov-2 infection,2020-03-31,2020-04-07,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,90,0.033,,,,,,,,Simplified probability,SARS-CoV-2 antibody detection kit (IgM/IgG),Kurabo Industries Ltd,LFIA,Serum,IgG,,,0.7637999999999999,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,Unclear,Yes,No,,Asaka Doi,Kobe City Medical Center General Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cegh.2021.100747,2020-07-27,2022-07-16,Verified,doi_estimation_2021,JPN
210419_Kobe_KobeMedicalCenterGeneralHospital_OutpatientsAgeUnder10,210419_Kobe_KobeMedicalCenterGeneralHospital,"Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-sectional study",2021-04-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Hyogo Prefecture,Kobe,"Patients who visited outpatient clinics of the Kobe City Medical Center General Hospital, and received blood testing for any reason between March 31 and Apr 7", Patients who visited the emergency department or the designated fever consultation service were excluded to avoid the overestimation of SARS-Cov-2 infection,2020-03-31,2020-04-07,Residual sera,All,Children and Youth (0-17 years),0.0,10.0,Age,<10 ,8,0.0,,,,,,,,Simplified probability,SARS-CoV-2 antibody detection kit (IgM/IgG),Kurabo Industries Ltd,LFIA,Serum,IgG,,,0.7637999999999999,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,Unclear,Yes,No,,Asaka Doi,Kobe City Medical Center General Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cegh.2021.100747,2020-07-27,2022-07-16,Verified,doi_estimation_2021,JPN
210419_Kobe_KobeMedicalCenterGeneralHospital_OutpatientsMale,210419_Kobe_KobeMedicalCenterGeneralHospital,"Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-sectional study",2021-04-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Hyogo Prefecture,Kobe,"Patients who visited outpatient clinics of the Kobe City Medical Center General Hospital, and received blood testing for any reason between March 31 and Apr 7", Patients who visited the emergency department or the designated fever consultation service were excluded to avoid the overestimation of SARS-Cov-2 infection,2020-03-31,2020-04-07,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,Male ,489,0.033,,,,,,,,Simplified probability,SARS-CoV-2 antibody detection kit (IgM/IgG),Kurabo Industries Ltd,LFIA,Serum,IgG,,,0.7637999999999999,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,Unclear,Yes,No,,Asaka Doi,Kobe City Medical Center General Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cegh.2021.100747,2020-07-27,2022-07-16,Verified,doi_estimation_2021,JPN
210419_Kobe_KobeMedicalCenterGeneralHospital_OutpatientsAge60-69,210419_Kobe_KobeMedicalCenterGeneralHospital,"Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-sectional study",2021-04-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Hyogo Prefecture,Kobe,"Patients who visited outpatient clinics of the Kobe City Medical Center General Hospital, and received blood testing for any reason between March 31 and Apr 7", Patients who visited the emergency department or the designated fever consultation service were excluded to avoid the overestimation of SARS-Cov-2 infection,2020-03-31,2020-04-07,Residual sera,All,Adults (18-64 years),60.0,69.0,Age,60-69,171,0.028999999999999998,,,,,,,,Simplified probability,SARS-CoV-2 antibody detection kit (IgM/IgG),Kurabo Industries Ltd,LFIA,Serum,IgG,,,0.7637999999999999,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,Unclear,Yes,No,,Asaka Doi,Kobe City Medical Center General Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cegh.2021.100747,2020-07-27,2022-07-16,Verified,doi_estimation_2021,JPN
210430_Tokyo_NationalCenterForGlobalHealthAndMedicine_Primary,210430_Tokyo_NationalCenterForGlobalHealthAndMedicine,"Consistency of the results of rapid serological tests for SARS-CoV-2 among healthcare workers in a large national hospital in Tokyo, Japan.",2021-04-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Tokyo Prefecture,Tokyo,workers at the National Center for Global Health and Medicine; targeted mainly those engaged in COVID-19-related work or who worked in a department with a high risk of exposure to SARS-CoV-2 infection,,2020-07-01,2020-07-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1228,0.0008,0.0002,0.0045000000000000005,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9990000000000001,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Shohei Yamamoto,National Center for Global Health and Medicine,Not Unity-Aligned,https://dx.doi.org/10.35772/ghm.2021.01022,2021-05-30,2024-03-01,Verified,yamamoto_consistency_2021,JPN
210504_Okinawa_OkinawaInstituteOfScienceAndTechnology,210504_Okinawa_OkinawaInstituteOfScienceAndTechnology,COVID-19 serological survey using micro blood sampling.,2021-05-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Okinawa Prefecture,Okinawa,Students and employees of the Okinawa Insitute of Science and Technology,,2020-08-01,2020-08-31,Multiple populations,All,Adults (18-64 years),,,Primary Estimate,Overall estimate,675,0.0,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.925,1.0,['High'],,No,Yes,No,,Unclear,Yes,Yes,,Melissa M Matthews,Okinawa Institute of Science and Technology,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-88850-z,2021-06-07,2024-02-01,Verified,matthews_covid-19_2021,JPN
20210524_NCGM_Japan_hcw,20210524_NCGM_Japan,Seroprevalence of SARS-CoV-2 antibodies in a national hospital and affiliated facility after the second epidemic wave of Japan.,2021-05-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,,"Tokyo, Chiba",We invited all NCGM staff (Toyama and Kohnodai areas) and asked participants to complete a questionnaire and donate venous blood in October (Toyama) and December (Kohnodai) 2020. ,,2020-10-01,2020-12-31,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,2563,0.006999999999999999,0.0042,0.0111,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,EUROIMMUN,Roche Diagnostics",Multiple Types,,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Shohei Yamamoto,The National Center for Global Health and Medicine (NCGM),Not Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.05.017,2021-06-06,2024-03-01,Unverified,yamamoto_seroprevalence_2021,JPN
210528_Tokyo_NationalCancerCenterHospital_HCW_primary,210528_Tokyo_NationalCancerCenterHospital_HCW,Difference in SARS-CoV-2 Antibody Status Between Patients With Cancer and Health Care Workers During the COVID-19 Pandemic in Japan.,2021-05-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,,Tokyo,Participants without suspected symptoms of COVID-19 were eligible.,,2020-09-01,2020-10-30,Health care workers and caregivers,All,Multiple groups,20.0,70.0,Primary Estimate,,1190,0.0067,0.0029,0.013200000000000002,True,,,,True,Convenience,"Nucleocapsid HISCL™-5000/HISCL-800 Automated Immunoassay Systems,Spike HISCL™-5000/HISCL-800 Automated Immunoassay Systems",Sysmex,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Shu Yazaki,National Cancer Center Hospital,Not Unity-Aligned,https://dx.doi.org/10.1001/jamaoncol.2021.2159,2021-06-07,2022-07-16,Unverified,yazaki_difference_2021,JPN
210528_Tokyo_NationalCancerCenterHospital_patients_primary,210528_Tokyo_NationalCancerCenterHospital_patients,Difference in SARS-CoV-2 Antibody Status Between Patients With Cancer and Health Care Workers During the COVID-19 Pandemic in Japan.,2021-05-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,,Tokyo,All inpatients and outpatients with cancer aged 16 years or older were considered eligible,,2020-08-03,2020-08-31,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,21.0,88.0,Primary Estimate,,500,0.01,0.0033000000000000004,0.0232,True,,,,True,Convenience,"Nucleocapsid HISCL™-5000/HISCL-800 Automated Immunoassay Systems,Spike HISCL™-5000/HISCL-800 Automated Immunoassay Systems",Sysmex,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Shu Yazaki,National Cancer Center Hospital,Not Unity-Aligned,https://dx.doi.org/10.1001/jamaoncol.2021.2159,2021-06-07,2022-07-16,Unverified,yazaki_difference_2021,JPN
210529_Yokohama_YokohamaDai-ichiHospital,210529_Yokohama_YokohamaDai-ichiHospital,Assessment of sars-cov-2 antibodies in patients on hemodialysis,2021-05-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,,Yokohama,HD patients who were managed per Japanese Society for Dialysis Therapy guidelines in the context of COVID-19,,2020-08-01,2020-12-14,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,55,0.0364,,,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Takayasu Taira,Yokohama Dai-ichi Hospital,Not Unity-Aligned,http://dx.doi.org/10.1093/ndt/gfab098.0019,2021-09-13,2024-03-01,Unverified,tairaMO827ASSESSMENTSARSCOV2ANTIBODIES2021,JPN
210608_Tokyo_BostonChildrensHospital_May26-June9,210608_Tokyo_MedicalCorporationKoshikai_20200526-20200609,Dynamic change of COVID-19 seroprevalence among asymptomatic office workers in Tokyo from May through Dec 2020 during the second waves of COVID-19,2021-06-08,Preprint,Local,Repeated cross-sectional study,Japan,Tokyo Prefecture,Tokyo,Employee at selected large Japanese company (unidentified) from one of 11 locations accross Tokyo,"Participants having fever, cough, or shortness of breath at the time of testing were excluded",2020-05-26,2020-06-09,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,51,0.0588,,,True,,,,True,Convenience,Healgen COVID-19 Antibody Rapid Test,Aurora Biomed Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,No,Sawako Hibino,Medical Corporation Koshikai ,Not Unity-Aligned,https://www.researchsquare.com/article/rs-564670/v1,2021-06-21,2024-03-01,Verified,hibino_dynamic_2021,JPN
210608_Tokyo_BostonChildrensHospital_June10-June23,210608_Tokyo_MedicalCorporationKoshikai_20200610-20200623,Dynamic change of COVID-19 seroprevalence among asymptomatic office workers in Tokyo from May through Dec 2020 during the second waves of COVID-19,2021-06-08,Preprint,Local,Repeated cross-sectional study,Japan,Tokyo Prefecture,Tokyo,Employee at selected large Japanese company (unidentified) from one of 11 locations accross Tokyo,"Participants having fever, cough, or shortness of breath at the time of testing were excluded",2020-06-10,2020-06-23,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,119,0.05,,,True,,,,True,Convenience,Healgen COVID-19 Antibody Rapid Test,Aurora Biomed Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,No,Sawako Hibino,Medical Corporation Koshikai ,Not Unity-Aligned,https://www.researchsquare.com/article/rs-564670/v1,2021-06-21,2024-03-01,Verified,hibino_dynamic_2021,JPN
210608_Tokyo_BostonChildrensHospital_June24-July7,210608_Tokyo_MedicalCorporationKoshikai_20200624-20200707,Dynamic change of COVID-19 seroprevalence among asymptomatic office workers in Tokyo from May through Dec 2020 during the second waves of COVID-19,2021-06-08,Preprint,Local,Repeated cross-sectional study,Japan,Tokyo Prefecture,Tokyo,Employee at selected large Japanese company (unidentified) from one of 11 locations accross Tokyo,"Participants having fever, cough, or shortness of breath at the time of testing were excluded",2020-06-24,2020-07-07,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,187,0.25670000000000004,,,True,,,,True,Convenience,Healgen COVID-19 Antibody Rapid Test,Aurora Biomed Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,No,Sawako Hibino,Medical Corporation Koshikai ,Not Unity-Aligned,https://www.researchsquare.com/article/rs-564670/v1,2021-06-21,2024-03-01,Verified,hibino_dynamic_2021,JPN
210608_Tokyo_BostonChildrensHospital_July8-July21,210608_Tokyo_MedicalCorporationKoshikai_20200708-20200721,Dynamic change of COVID-19 seroprevalence among asymptomatic office workers in Tokyo from May through Dec 2020 during the second waves of COVID-19,2021-06-08,Preprint,Local,Repeated cross-sectional study,Japan,Tokyo Prefecture,Tokyo,Employee at selected large Japanese company (unidentified) from one of 11 locations accross Tokyo,"Participants having fever, cough, or shortness of breath at the time of testing were excluded",2020-07-08,2020-07-21,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,256,0.371,,,True,,,,True,Convenience,Healgen COVID-19 Antibody Rapid Test,Aurora Biomed Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,No,Sawako Hibino,Medical Corporation Koshikai ,Not Unity-Aligned,https://www.researchsquare.com/article/rs-564670/v1,2021-06-21,2024-03-01,Verified,hibino_dynamic_2021,JPN
210608_Tokyo_BostonChildrensHospital_July22-August4,210608_Tokyo_MedicalCorporationKoshikai_20200722-20200804,Dynamic change of COVID-19 seroprevalence among asymptomatic office workers in Tokyo from May through Dec 2020 during the second waves of COVID-19,2021-06-08,Preprint,Local,Repeated cross-sectional study,Japan,Tokyo Prefecture,Tokyo,Employee at selected large Japanese company (unidentified) from one of 11 locations accross Tokyo,"Participants having fever, cough, or shortness of breath at the time of testing were excluded",2020-07-22,2020-08-04,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,175,0.3886,,,True,,,,True,Convenience,Healgen COVID-19 Antibody Rapid Test,Aurora Biomed Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,No,Sawako Hibino,Medical Corporation Koshikai ,Not Unity-Aligned,https://www.researchsquare.com/article/rs-564670/v1,2021-06-21,2024-03-01,Verified,hibino_dynamic_2021,JPN
210608_Tokyo_BostonChildrensHospital_August5-August18,210608_Tokyo_MedicalCorporationKoshikai_20200805-20200818,Dynamic change of COVID-19 seroprevalence among asymptomatic office workers in Tokyo from May through Dec 2020 during the second waves of COVID-19,2021-06-08,Preprint,Local,Repeated cross-sectional study,Japan,Tokyo Prefecture,Tokyo,Employee at selected large Japanese company (unidentified) from one of 11 locations accross Tokyo,"Participants having fever, cough, or shortness of breath at the time of testing were excluded",2020-08-05,2020-08-18,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,115,0.41740000000000005,,,True,,,,True,Convenience,Healgen COVID-19 Antibody Rapid Test,Aurora Biomed Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,No,Sawako Hibino,Medical Corporation Koshikai ,Not Unity-Aligned,https://www.researchsquare.com/article/rs-564670/v1,2021-06-21,2024-03-01,Verified,hibino_dynamic_2021,JPN
210608_Tokyo_BostonChildrensHospital_August19-September2,210608_Tokyo_MedicalCorporationKoshikai_20200819-20200902,Dynamic change of COVID-19 seroprevalence among asymptomatic office workers in Tokyo from May through Dec 2020 during the second waves of COVID-19,2021-06-08,Preprint,Local,Repeated cross-sectional study,Japan,Tokyo Prefecture,Tokyo,Employee at selected large Japanese company (unidentified) from one of 11 locations accross Tokyo,"Participants having fever, cough, or shortness of breath at the time of testing were excluded",2020-08-19,2020-09-02,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,62,0.46770000000000006,,,True,,,,True,Convenience,Healgen COVID-19 Antibody Rapid Test,Aurora Biomed Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,No,Sawako Hibino,Medical Corporation Koshikai ,Not Unity-Aligned,https://www.researchsquare.com/article/rs-564670/v1,2021-06-21,2024-03-01,Verified,hibino_dynamic_2021,JPN
210612_Tokyo_TheUniversityOfTokyo_overall,210612_Tokyo_TheUniversityOfTokyo,"Epidemiological study using IgM and IgG antibody titers against SARS-CoV-2 in The University of Tokyo, Japan (UT-CATS).",2021-06-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,,Tokyo,"students, staff, and faculty members of The University of Tokyo from June 2020 to October 2020",,2020-06-11,2020-10-28,Multiple populations,All,Multiple groups,,,Primary Estimate,,6609,0.0048,,,True,,,,True,Self-referral,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Akihisa Mitani,The University of Tokyo,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jiac.2021.06.008,2021-06-30,2022-07-16,Verified,mitani_epidemiological_2021,JPN
210614_Fukushima_HirataCentralHospital_May_CLIA_IgG,210614_Fukushima_HirataCentralHospital_May,"Seroprevalence of SARS-CoV-2 antibodies among hospital staff in rural Central Fukushima, Japan: A historical cohort study.",2021-06-14,Journal Article (Peer-Reviewed),Local,Prospective cohort,Japan,Fukushima,Ishikawa District,participants who worked as Seireikai group staff and agreed to participate in this study in the analysis.,,2020-05-08,2020-05-28,Health care workers and caregivers,All,Multiple groups,18.0,78.0,Primary Estimate,CLIA IgG estimate,515,0.0097,0.0032,0.0225,True,,,,True,Entire sample,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,Spike,Validated by developers,0.973,0.963,['High'],,Yes,No,Yes,,Unclear,Yes,No,,Yurie Kobashi,Hirata Central Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.intimp.2021.107884,2021-07-19,2022-07-16,Unverified,kobashi_seroprevalence_2021,JPN
210614_Fukushima_HirataCentralHospital_May_1844_IgG,210614_Fukushima_HirataCentralHospital_May,"Seroprevalence of SARS-CoV-2 antibodies among hospital staff in rural Central Fukushima, Japan: A historical cohort study.",2021-06-14,Journal Article (Peer-Reviewed),Local,Prospective cohort,Japan,Fukushima,Ishikawa District,participants who worked as Seireikai group staff and agreed to participate in this study in the analysis.,,2020-05-08,2020-05-28,Health care workers and caregivers,All,Adults (18-64 years),18.0,44.0,Age,CLIA/RDT IgG; Age: 18-44,258,0.046,,,,,,,,Entire sample,"iFlash-SARS-CoV-2 IgM/IgG,2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit","Shenzhen Yhlo Biotech Co. Ltd,Nanjing Vazyme Medical Technology Co. Ltd",Multiple Types,Serum,IgG,Spike,Validated by developers,,,['High'],,Yes,No,Yes,,Unclear,Yes,No,,Yurie Kobashi,Hirata Central Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.intimp.2021.107884,2021-07-19,2024-03-01,Unverified,kobashi_seroprevalence_2021,JPN
210614_Fukushima_HirataCentralHospital_May_6578_IgG,210614_Fukushima_HirataCentralHospital_May,"Seroprevalence of SARS-CoV-2 antibodies among hospital staff in rural Central Fukushima, Japan: A historical cohort study.",2021-06-14,Journal Article (Peer-Reviewed),Local,Prospective cohort,Japan,Fukushima,Ishikawa District,participants who worked as Seireikai group staff and agreed to participate in this study in the analysis.,,2020-05-08,2020-05-28,Health care workers and caregivers,All,Seniors (65+ years),65.0,78.0,Age,CLIA/RDT IgG; Age: 65-78,39,0.128,,,,,,,,Entire sample,"iFlash-SARS-CoV-2 IgM/IgG,2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit","Shenzhen Yhlo Biotech Co. Ltd,Nanjing Vazyme Medical Technology Co. Ltd",Multiple Types,Serum,IgG,Spike,Validated by developers,,,['High'],,Yes,No,Yes,,Unclear,Yes,No,,Yurie Kobashi,Hirata Central Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.intimp.2021.107884,2021-07-19,2024-03-01,Unverified,kobashi_seroprevalence_2021,JPN
210614_Fukushima_HirataCentralHospital_May_4564_IgG,210614_Fukushima_HirataCentralHospital_May,"Seroprevalence of SARS-CoV-2 antibodies among hospital staff in rural Central Fukushima, Japan: A historical cohort study.",2021-06-14,Journal Article (Peer-Reviewed),Local,Prospective cohort,Japan,Fukushima,Ishikawa District,participants who worked as Seireikai group staff and agreed to participate in this study in the analysis.,,2020-05-08,2020-05-28,Health care workers and caregivers,All,Adults (18-64 years),45.0,64.0,Age,CLIA/RDT IgG; Age: 45-64,218,0.105,,,,,,,,Entire sample,"iFlash-SARS-CoV-2 IgM/IgG,2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit","Shenzhen Yhlo Biotech Co. Ltd,Nanjing Vazyme Medical Technology Co. Ltd",Multiple Types,Serum,IgG,Spike,Validated by developers,,,['High'],,Yes,No,Yes,,Unclear,Yes,No,,Yurie Kobashi,Hirata Central Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.intimp.2021.107884,2021-07-19,2024-03-01,Unverified,kobashi_seroprevalence_2021,JPN
210614_Fukushima_HirataCentralHospital_Oct_CLIA_IgG,210614_Fukushima_HirataCentralHospital_Oct,"Seroprevalence of SARS-CoV-2 antibodies among hospital staff in rural Central Fukushima, Japan: A historical cohort study.",2021-06-14,Journal Article (Peer-Reviewed),Local,Prospective cohort,Japan,Fukushima,Ishikawa District,participants who worked as Seireikai group staff and agreed to participate in this study in the analysis.,,2020-10-05,2020-10-23,Health care workers and caregivers,All,Multiple groups,18.0,78.0,Primary Estimate,CLIA IgG estimate,515,0.0039000000000000003,0.0005,0.013999999999999999,True,,,,True,Entire sample,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,Spike,Validated by developers,0.973,0.963,['High'],,Yes,No,Yes,,Unclear,Yes,No,,Yurie Kobashi,Hirata Central Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.intimp.2021.107884,2021-07-19,2022-07-16,Unverified,kobashi_seroprevalence_2021,JPN
210614_Fukushima_HirataCentralHospital_Oct_1844_IgG,210614_Fukushima_HirataCentralHospital_Oct,"Seroprevalence of SARS-CoV-2 antibodies among hospital staff in rural Central Fukushima, Japan: A historical cohort study.",2021-06-14,Journal Article (Peer-Reviewed),Local,Prospective cohort,Japan,Fukushima,Ishikawa District,participants who worked as Seireikai group staff and agreed to participate in this study in the analysis.,,2020-10-05,2020-10-23,Health care workers and caregivers,All,Adults (18-64 years),18.0,44.0,Age,CLIA/RDT IgG; Age: 18-44,258,0.0077,,,,,,,,Entire sample,"iFlash-SARS-CoV-2 IgM/IgG,2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit","Shenzhen Yhlo Biotech Co. Ltd,Nanjing Vazyme Medical Technology Co. Ltd",Multiple Types,Serum,IgG,Spike,Validated by developers,,,['High'],,Yes,No,Yes,,Unclear,Yes,No,,Yurie Kobashi,Hirata Central Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.intimp.2021.107884,2021-07-19,2024-03-01,Unverified,kobashi_seroprevalence_2021,JPN
210614_Fukushima_HirataCentralHospital_Oct_4564_IgG,210614_Fukushima_HirataCentralHospital_Oct,"Seroprevalence of SARS-CoV-2 antibodies among hospital staff in rural Central Fukushima, Japan: A historical cohort study.",2021-06-14,Journal Article (Peer-Reviewed),Local,Prospective cohort,Japan,Fukushima,Ishikawa District,participants who worked as Seireikai group staff and agreed to participate in this study in the analysis.,,2020-10-05,2020-10-23,Health care workers and caregivers,All,Adults (18-64 years),45.0,64.0,Age,CLIA/RDT IgG; Age: 45-64,218,0.036000000000000004,,,,,,,,Entire sample,"iFlash-SARS-CoV-2 IgM/IgG,2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit","Shenzhen Yhlo Biotech Co. Ltd,Nanjing Vazyme Medical Technology Co. Ltd",Multiple Types,Serum,IgG,Spike,Validated by developers,,,['High'],,Yes,No,Yes,,Unclear,Yes,No,,Yurie Kobashi,Hirata Central Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.intimp.2021.107884,2021-07-19,2024-03-01,Unverified,kobashi_seroprevalence_2021,JPN
210614_Fukushima_HirataCentralHospital_Oct_6578_IgG,210614_Fukushima_HirataCentralHospital_Oct,"Seroprevalence of SARS-CoV-2 antibodies among hospital staff in rural Central Fukushima, Japan: A historical cohort study.",2021-06-14,Journal Article (Peer-Reviewed),Local,Prospective cohort,Japan,Fukushima,Ishikawa District,participants who worked as Seireikai group staff and agreed to participate in this study in the analysis.,,2020-10-05,2020-10-23,Health care workers and caregivers,All,Seniors (65+ years),65.0,78.0,Age,CLIA/RDT IgG; Age: 65-78,39,0.026000000000000002,,,,,,,,Entire sample,"iFlash-SARS-CoV-2 IgM/IgG,2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit","Shenzhen Yhlo Biotech Co. Ltd,Nanjing Vazyme Medical Technology Co. Ltd",Multiple Types,Serum,IgG,Spike,Validated by developers,,,['High'],,Yes,No,Yes,,Unclear,Yes,No,,Yurie Kobashi,Hirata Central Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.intimp.2021.107884,2021-07-19,2024-03-01,Unverified,kobashi_seroprevalence_2021,JPN
210619_Tokyo_KeioUniversityHealthCenter,210619_Tokyo_KeioUniversityHealthCenter,"SARS-CoV-2 Infection among Medical Institution Faculty and Healthcare Workers in Tokyo, Japan.",2021-06-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,,Tokyo,Faculty of Keio University School of Medicine and healthcare workers of Keio University Hospital,,2020-08-01,2020-08-31,Health care workers and caregivers,All,Adults (18-64 years),20.0,66.0,Primary Estimate,,2320,0.008620000000000001,0.00527,0.01328,True,,,,True,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Tomoyasu Nishimura,Keio University Health Center,Not Unity-Aligned,https://dx.doi.org/10.2169/internalmedicine.7033-21,2021-07-07,2022-07-16,Verified,nishimura_sars-cov-2_2021,JPN
210625_Osaka_ ToyonakaMunicipalHospital_Overall,210625_Osaka_ ToyonakaMunicipalHospital,"Seroprevalence of SARS-CoV-2 antibodies among 925 staff members in an urban hospital accepting COVID-19 patients in Osaka prefecture, Japan: A cross-sectional study.",2021-06-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Osaka Prefecture,Osaka,We invited all our hospital staff planning to undergo a regular health check-up to participate in this study via the intranet at our hospital.,those who refused to take part in this study; those who did not have enough extra blood drawn to undergo antibody testing; and those who were not identified because they mistyped their personal ten-digit identification code,2020-06-12,2020-06-19,Health care workers and caregivers,All,Adults (18-64 years),20.0,69.0,Primary Estimate,Overall,925,0.0043,0.0017000000000000001,0.011000000000000001,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Tsutomu Nishida, Toyonaka Municipal Hospital,Not Unity-Aligned,https://dx.doi.org/10.1097/MD.0000000000026433,2021-06-30,2024-03-01,Verified,nishida_seroprevalence_2021,JPN
210625_Osaka_ ToyonakaMunicipalHospital_50-69,210625_Osaka_ ToyonakaMunicipalHospital,"Seroprevalence of SARS-CoV-2 antibodies among 925 staff members in an urban hospital accepting COVID-19 patients in Osaka prefecture, Japan: A cross-sectional study.",2021-06-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Osaka Prefecture,Osaka,We invited all our hospital staff planning to undergo a regular health check-up to participate in this study via the intranet at our hospital.,those who refused to take part in this study; those who did not have enough extra blood drawn to undergo antibody testing; and those who were not identified because they mistyped their personal ten-digit identification code,2020-06-12,2020-06-19,Health care workers and caregivers,All,Adults (18-64 years),50.0,59.0,Age,50-59,216,0.009300000000000001,0.0025,0.033,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Tsutomu Nishida, Toyonaka Municipal Hospital,Not Unity-Aligned,https://dx.doi.org/10.1097/MD.0000000000026433,2021-07-12,2024-03-01,Verified,nishida_seroprevalence_2021,JPN
210625_Osaka_ ToyonakaMunicipalHospital_30-39,210625_Osaka_ ToyonakaMunicipalHospital,"Seroprevalence of SARS-CoV-2 antibodies among 925 staff members in an urban hospital accepting COVID-19 patients in Osaka prefecture, Japan: A cross-sectional study.",2021-06-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Osaka Prefecture,Osaka,We invited all our hospital staff planning to undergo a regular health check-up to participate in this study via the intranet at our hospital.,those who refused to take part in this study; those who did not have enough extra blood drawn to undergo antibody testing; and those who were not identified because they mistyped their personal ten-digit identification code,2020-06-12,2020-06-19,Health care workers and caregivers,All,Adults (18-64 years),30.0,39.0,Age,30-39,225,0.0044,0.00079,0.025,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Tsutomu Nishida, Toyonaka Municipal Hospital,Not Unity-Aligned,https://dx.doi.org/10.1097/MD.0000000000026433,2021-07-12,2024-03-01,Verified,nishida_seroprevalence_2021,JPN
210625_Osaka_ ToyonakaMunicipalHospital_20-29,210625_Osaka_ ToyonakaMunicipalHospital,"Seroprevalence of SARS-CoV-2 antibodies among 925 staff members in an urban hospital accepting COVID-19 patients in Osaka prefecture, Japan: A cross-sectional study.",2021-06-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Osaka Prefecture,Osaka,We invited all our hospital staff planning to undergo a regular health check-up to participate in this study via the intranet at our hospital.,those who refused to take part in this study; those who did not have enough extra blood drawn to undergo antibody testing; and those who were not identified because they mistyped their personal ten-digit identification code,2020-06-12,2020-06-19,Health care workers and caregivers,All,Adults (18-64 years),20.0,29.0,Age,20-29,234,0.0,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Tsutomu Nishida, Toyonaka Municipal Hospital,Not Unity-Aligned,https://dx.doi.org/10.1097/MD.0000000000026433,2021-07-12,2024-03-01,Verified,nishida_seroprevalence_2021,JPN
210625_Osaka_ ToyonakaMunicipalHospital_40-49,210625_Osaka_ ToyonakaMunicipalHospital,"Seroprevalence of SARS-CoV-2 antibodies among 925 staff members in an urban hospital accepting COVID-19 patients in Osaka prefecture, Japan: A cross-sectional study.",2021-06-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Osaka Prefecture,Osaka,We invited all our hospital staff planning to undergo a regular health check-up to participate in this study via the intranet at our hospital.,those who refused to take part in this study; those who did not have enough extra blood drawn to undergo antibody testing; and those who were not identified because they mistyped their personal ten-digit identification code,2020-06-12,2020-06-19,Health care workers and caregivers,All,Adults (18-64 years),40.0,49.0,Age,40-49,250,0.004,0.0007099999999999999,0.022000000000000002,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Tsutomu Nishida, Toyonaka Municipal Hospital,Not Unity-Aligned,https://dx.doi.org/10.1097/MD.0000000000026433,2021-07-12,2024-03-01,Verified,nishida_seroprevalence_2021,JPN
210719_Kanagawa_OsakaCityUniversity,210719_Kanagawa_OsakaCityUniversity,Serological testing reveals the hidden COVID-19 burden among healthcare workers experiencing a SARS-CoV-2 nosocomial outbreak,2021-07-19,Preprint,Local,Cross-sectional survey ,Japan,Kanagawa,Yokohama City,Those who tested negative on NAT or did not receive NAT during mass testing period during nosocomial outbreak two months prior to this study,,2020-06-30,2020-07-02,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,377,0.0716,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit","Abbott Laboratories,GenScript",Multiple Types,Serum,"['IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Unclear,Yes,No,,Yu Nakagama,Osaka City University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.15.21260585v1.full-text,2021-07-28,2024-03-01,Unverified,nakagama_serological_2021,JPN
210727_Tokyo_MusashinoRed CrossHospital_Baseline,210727_Tokyo_MusashinoRed CrossHospital,The dynamics of quantitative SARS-CoV-2 anti-spike IgG response to BNT162b2 vaccination.,2021-07-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,,Tokyo,,Participants who failed to take a blood test at least once were not included in this study.,2021-03-15,2021-05-15,Essential non-healthcare workers,All,Multiple groups,22.0,75.0,Primary Estimate,Medical staff before vaccination,59,0.0,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,1.0,0.996,['High'],,No,No,Yes,,Yes,Yes,Yes,,Shun Kaneko,Musashino Red Cross Hospital,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27231,2021-08-04,2024-03-01,Unverified,kaneko_dynamics_2021,JPN
210820_AichiPrefecture_FujitaHealthUniversity,210820_AichiPrefecture_FujitaHealthUniversity,Antibody testing for COVID-19 in patients with acute coronary syndrome in Aichi Prefecture.,2021-08-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Aichi Prefecture,Toyoake,"35 consecutive patients who presented with ACS and required PCI during the period from August 17, 2020 through September 30, 2020",,2020-08-17,2020-09-30,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,35,0.0,,,True,,,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,,Masataka Yoshinaga,Fujita Health University,Not Unity-Aligned,https://dx.doi.org/10.20407/fmj.2020-032,2022-05-24,2024-03-01,Verified,yoshinaga_antibody_2022,JPN
211011_SaitamaCity_JichiMedicalUniversity_cohort_HCW_primary,211011_SaitamaCity_JichiMedicalUniversity_cohort,Comprehensive infection control measures prevent hospital-acquired severe acute respiratory syndrome coronavirus 2 infection: A single-center prospective cohort study and seroprevalence survey.,2021-10-11,Journal Article (Peer-Reviewed),Local,Prospective cohort,Japan,Saitama Prefecture,Saitama City,"The participants were HCWs who had been working at the medical center since April 2020. The participants in the cohort study were physicians and nurses working at the critical care center, COVID-19 ward, and the intensive care unit and who had many opportunities to directly engage in the treatment of patients with COVID-19. Participants in the cohort study were limited to doctors and nurses because this cohort focused on HCWs who had direct contact with patients with COVID-19, which is associated with a high risk of infection. From May 2020 to July 2020, doctors and nurses were the only HCWs in direct contact with COVID-19 patients, who worked full time in the COVID-19 ward, and could continue to participate in our study.
....
All participants in the cohort study also participated in the cross-sectional study",,2020-05-15,2020-07-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,116,0.0,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.9981000000000001,['High'],,No,No,Yes,,Yes,Yes,Yes,,Hiroshi Hori,Jichi Medical University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0257513,2021-10-19,2024-03-01,Unverified,hori_comprehensive_2021,JPN
211011_SaitamaCity_JichiMedicalUniversity_crosssectional_HCW,211011_SaitamaCity_JichiMedicalUniversity_crosssectional,Comprehensive infection control measures prevent hospital-acquired severe acute respiratory syndrome coronavirus 2 infection: A single-center prospective cohort study and seroprevalence survey.,2021-10-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Saitama Prefecture,Saitama City,"The cross-sectional study included physicians, nurses, nursing assistants, therapists, midwives, pharmacists, radiologic technologists, clinical technologists, and clinical engineers. This study included occupations other than doctors and nurses to assess the risk of infection according to occupation.",,2020-07-05,2020-07-19,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,607,0.0016500000000000002,8e-05,0.0106,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Author designed (type unknown)","Abbott Laboratories,NA",Multiple Types,Serum,IgG,,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Hiroshi Hori,Jichi Medical University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0257513,2021-10-19,2024-03-01,Unverified,hori_comprehensive_2021,JPN
211029_OsakaCity_OsakaCityGeneralHospital_Overall,211029_OsakaCity_OsakaCityGeneralHospital,Recent Outpatient Services in General Internal Medicine: 6.4% of Symptomatic Patients Were Post-Acute COVID-19.,2021-10-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Osaka Prefecture,Osaka City,"New patients aged 18 years or older who visited the Department of Internal Medicine at Osaka City General Hospital with any kind of undiagnosed symptoms, and who consented to study participation.","(i) Patients in whom a diagnosis was already or almost confirmed at the time of the first visit, for example, a request for continued medical care for rheumatoid arthritis, or detailed examination of a tumor, (ii) Patients who visited us for a secondary examination of laboratory abnormalities without symptoms, (iii) Patients who had already received some form of SARS-CoV-2 vaccine or had had COVID-19, and (iv) Patients who were so immunocompromised that they could not be expected to produce globulins, as in X-linked agammaglobulinemia.",2020-11-01,2021-03-31,Residual sera,All,Multiple groups,18.0,,Primary Estimate,,94,0.064,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.995,0.998,['High'],,No,No,No,,Yes,Yes,Yes,,Yusuke Hanioka,Osaka City General Hospital,Not Unity-Aligned,https://dx.doi.org/10.2147/IJGM.S330525,2021-11-17,2024-03-01,Unverified,hanioka_recent_2021,JPN
211030_Aichi_NationalCenterforGeriatricsandGerontology_Primary,211030_Aichi_NationalCenterforGeriatricsandGerontology,Prevalence of SARS-CoV-2 antibodies after one-year follow up among workers in a research institute in Japan.,2021-10-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Japan,Aichi Prefecture,,HCWs who were included in the first cross-sectional study in June 2020 following the 1st wave of the pandemic,,2021-06-01,2021-06-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,556,0.937,,,True,,,,True,Convenience,Spike HISCL™-5000/HISCL-800 Automated Immunoassay Systems,Sysmex,CLIA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Akihiko Nishikimi,National Center for Geriatrics and Gerontology,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.10.021,2021-11-10,2022-07-16,Unverified,nishikimi_prevalence_2021,JPN
211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience_Overall,211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience,"Serologic survey of IgG against SARS-CoV-2 among hospital visitors without a history of SARS-CoV-2 infection in Tokyo, 2020-2021.",2021-11-13,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,,Tokyo,Residual sera of consenting patients from 14 Tokyo hospitals who chose not to opt-out of the study were included,participants diagnosed with COVID-19 or exhibiting any COVID-19-related symptoms at the time of blood collection,2020-09-01,2021-03-31,Residual sera,All,Multiple groups,,,Primary Estimate,Crude,23234,0.0183,0.0166,0.0201,True,,,,True,Simplified probability,"iFlash-SARS-CoV-2 IgM/IgG,iFlash-SARS-CoV-2 S1 IgG",Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,1.0,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Takahiro Sanada,Tokyo Metropolitan Institute of Medical Science,Not Unity-Aligned,https://dx.doi.org/10.2188/jea.JE20210324,2021-11-22,2024-03-01,Unverified,sanada_serologic_2021,JPN
211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience_Time6Feb,211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience,"Serologic survey of IgG against SARS-CoV-2 among hospital visitors without a history of SARS-CoV-2 infection in Tokyo, 2020-2021.",2021-11-13,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,,Tokyo,Residual sera of consenting patients from 14 Tokyo hospitals who chose not to opt-out of the study were included,participants diagnosed with COVID-19 or exhibiting any COVID-19-related symptoms at the time of blood collection,2021-02-01,2021-02-28,Residual sera,All,Multiple groups,,,Time frame,2021-02,2711,0.0296,0.022799999999999997,0.07780000000000001,,,True,,,Simplified probability,"iFlash-SARS-CoV-2 IgM/IgG,iFlash-SARS-CoV-2 S1 IgG",Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,1.0,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Takahiro Sanada,Tokyo Metropolitan Institute of Medical Science,Not Unity-Aligned,https://dx.doi.org/10.2188/jea.JE20210324,2021-11-22,2024-03-01,Unverified,sanada_serologic_2021,JPN
211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience_Overall_S1Only,211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience,"Serologic survey of IgG against SARS-CoV-2 among hospital visitors without a history of SARS-CoV-2 infection in Tokyo, 2020-2021.",2021-11-13,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,,Tokyo,Residual sera of consenting patients from 14 Tokyo hospitals who chose not to opt-out of the study were included,participants diagnosed with COVID-19 or exhibiting any COVID-19-related symptoms at the time of blood collection,2020-09-01,2021-03-31,Residual sera,All,Multiple groups,,,Test used,S1,23234,0.014199999999999999,0.012700000000000001,0.0158,,,,,,Simplified probability,iFlash-SARS-CoV-2 S1 IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.983,1.0,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Takahiro Sanada,Tokyo Metropolitan Institute of Medical Science,Not Unity-Aligned,https://dx.doi.org/10.2188/jea.JE20210324,2021-11-22,2024-03-01,Unverified,sanada_serologic_2021,JPN
211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience_Age<=19,211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience,"Serologic survey of IgG against SARS-CoV-2 among hospital visitors without a history of SARS-CoV-2 infection in Tokyo, 2020-2021.",2021-11-13,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,,Tokyo,Residual sera of consenting patients from 14 Tokyo hospitals who chose not to opt-out of the study were included,participants diagnosed with COVID-19 or exhibiting any COVID-19-related symptoms at the time of blood collection,2020-09-01,2021-03-31,Residual sera,All,Children and Youth (0-17 years),,,Age,<=19,681,0.0103,0.0040999999999999995,0.0211,,,,,,Simplified probability,"iFlash-SARS-CoV-2 IgM/IgG,iFlash-SARS-CoV-2 S1 IgG",Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,1.0,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Takahiro Sanada,Tokyo Metropolitan Institute of Medical Science,Not Unity-Aligned,https://dx.doi.org/10.2188/jea.JE20210324,2021-11-22,2024-03-01,Unverified,sanada_serologic_2021,JPN
211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience_SexMale,211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience,"Serologic survey of IgG against SARS-CoV-2 among hospital visitors without a history of SARS-CoV-2 infection in Tokyo, 2020-2021.",2021-11-13,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,,Tokyo,Residual sera of consenting patients from 14 Tokyo hospitals who chose not to opt-out of the study were included,participants diagnosed with COVID-19 or exhibiting any COVID-19-related symptoms at the time of blood collection,2020-09-01,2021-03-31,Residual sera,Male,Multiple groups,,,Sex/Gender,,11553,0.0167,0.0144,0.0192,,,,,,Simplified probability,"iFlash-SARS-CoV-2 IgM/IgG,iFlash-SARS-CoV-2 S1 IgG",Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,1.0,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Takahiro Sanada,Tokyo Metropolitan Institute of Medical Science,Not Unity-Aligned,https://dx.doi.org/10.2188/jea.JE20210324,2021-11-22,2024-03-01,Unverified,sanada_serologic_2021,JPN
211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience_Overall_SpikeOnly,211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience,"Serologic survey of IgG against SARS-CoV-2 among hospital visitors without a history of SARS-CoV-2 infection in Tokyo, 2020-2021.",2021-11-13,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,,Tokyo,Residual sera of consenting patients from 14 Tokyo hospitals who chose not to opt-out of the study were included,participants diagnosed with COVID-19 or exhibiting any COVID-19-related symptoms at the time of blood collection,2020-09-01,2021-03-31,Residual sera,All,Multiple groups,,,Test used,Spike,23234,0.010400000000000001,0.0092,0.0118,,,,,,Simplified probability,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Takahiro Sanada,Tokyo Metropolitan Institute of Medical Science,Not Unity-Aligned,https://dx.doi.org/10.2188/jea.JE20210324,2021-11-22,2022-07-16,Unverified,sanada_serologic_2021,JPN
211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience_Time3Nov,211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience,"Serologic survey of IgG against SARS-CoV-2 among hospital visitors without a history of SARS-CoV-2 infection in Tokyo, 2020-2021.",2021-11-13,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,,Tokyo,Residual sera of consenting patients from 14 Tokyo hospitals who chose not to opt-out of the study were included,participants diagnosed with COVID-19 or exhibiting any COVID-19-related symptoms at the time of blood collection,2020-11-01,2020-11-30,Residual sera,All,Multiple groups,,,Time frame,2020-11,3438,0.016200000000000003,0.0121,0.0386,,,True,,,Simplified probability,"iFlash-SARS-CoV-2 IgM/IgG,iFlash-SARS-CoV-2 S1 IgG",Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,1.0,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Takahiro Sanada,Tokyo Metropolitan Institute of Medical Science,Not Unity-Aligned,https://dx.doi.org/10.2188/jea.JE20210324,2021-11-22,2024-03-01,Unverified,sanada_serologic_2021,JPN
211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience_Time2Oct,211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience,"Serologic survey of IgG against SARS-CoV-2 among hospital visitors without a history of SARS-CoV-2 infection in Tokyo, 2020-2021.",2021-11-13,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,,Tokyo,Residual sera of consenting patients from 14 Tokyo hospitals who chose not to opt-out of the study were included,participants diagnosed with COVID-19 or exhibiting any COVID-19-related symptoms at the time of blood collection,2020-10-01,2020-10-31,Residual sera,All,Multiple groups,,,Time frame,2020-10,4006,0.0091,0.0068000000000000005,0.0291,,,True,,,Simplified probability,"iFlash-SARS-CoV-2 IgM/IgG,iFlash-SARS-CoV-2 S1 IgG",Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,1.0,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Takahiro Sanada,Tokyo Metropolitan Institute of Medical Science,Not Unity-Aligned,https://dx.doi.org/10.2188/jea.JE20210324,2021-11-22,2024-03-01,Unverified,sanada_serologic_2021,JPN
211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience_Time7Mar,211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience,"Serologic survey of IgG against SARS-CoV-2 among hospital visitors without a history of SARS-CoV-2 infection in Tokyo, 2020-2021.",2021-11-13,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,,Tokyo,Residual sera of consenting patients from 14 Tokyo hospitals who chose not to opt-out of the study were included,participants diagnosed with COVID-19 or exhibiting any COVID-19-related symptoms at the time of blood collection,2021-03-01,2021-03-31,Residual sera,All,Multiple groups,,,Time frame,2021-03,3034,0.034,0.026099999999999998,0.0608,,,True,,,Simplified probability,"iFlash-SARS-CoV-2 IgM/IgG,iFlash-SARS-CoV-2 S1 IgG",Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,1.0,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Takahiro Sanada,Tokyo Metropolitan Institute of Medical Science,Not Unity-Aligned,https://dx.doi.org/10.2188/jea.JE20210324,2021-11-22,2024-03-01,Unverified,sanada_serologic_2021,JPN
211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience_Age20-39,211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience,"Serologic survey of IgG against SARS-CoV-2 among hospital visitors without a history of SARS-CoV-2 infection in Tokyo, 2020-2021.",2021-11-13,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,,Tokyo,Residual sera of consenting patients from 14 Tokyo hospitals who chose not to opt-out of the study were included,participants diagnosed with COVID-19 or exhibiting any COVID-19-related symptoms at the time of blood collection,2020-09-01,2021-03-31,Residual sera,All,Adults (18-64 years),,,Age,20-39,2145,0.0242,0.0182,0.0317,,,,,,Simplified probability,"iFlash-SARS-CoV-2 IgM/IgG,iFlash-SARS-CoV-2 S1 IgG",Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,1.0,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Takahiro Sanada,Tokyo Metropolitan Institute of Medical Science,Not Unity-Aligned,https://dx.doi.org/10.2188/jea.JE20210324,2021-11-22,2024-03-01,Unverified,sanada_serologic_2021,JPN
211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience_Age40-59,211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience,"Serologic survey of IgG against SARS-CoV-2 among hospital visitors without a history of SARS-CoV-2 infection in Tokyo, 2020-2021.",2021-11-13,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,,Tokyo,Residual sera of consenting patients from 14 Tokyo hospitals who chose not to opt-out of the study were included,participants diagnosed with COVID-19 or exhibiting any COVID-19-related symptoms at the time of blood collection,2020-09-01,2021-03-31,Residual sera,All,Adults (18-64 years),,,Age,40-59,5170,0.0211,0.0173,0.025400000000000002,,,,,,Simplified probability,"iFlash-SARS-CoV-2 IgM/IgG,iFlash-SARS-CoV-2 S1 IgG",Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,1.0,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Takahiro Sanada,Tokyo Metropolitan Institute of Medical Science,Not Unity-Aligned,https://dx.doi.org/10.2188/jea.JE20210324,2021-11-22,2024-03-01,Unverified,sanada_serologic_2021,JPN
211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience_Time1Sep,211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience,"Serologic survey of IgG against SARS-CoV-2 among hospital visitors without a history of SARS-CoV-2 infection in Tokyo, 2020-2021.",2021-11-13,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,,Tokyo,Residual sera of consenting patients from 14 Tokyo hospitals who chose not to opt-out of the study were included,participants diagnosed with COVID-19 or exhibiting any COVID-19-related symptoms at the time of blood collection,2020-09-01,2020-09-30,Residual sera,All,Multiple groups,,,Time frame,2020-09,3837,0.0115,0.008199999999999999,0.0546,,,True,,,Simplified probability,"iFlash-SARS-CoV-2 IgM/IgG,iFlash-SARS-CoV-2 S1 IgG",Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,1.0,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Takahiro Sanada,Tokyo Metropolitan Institute of Medical Science,Not Unity-Aligned,https://dx.doi.org/10.2188/jea.JE20210324,2021-11-22,2024-03-01,Unverified,sanada_serologic_2021,JPN
211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience_SexFemale,211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience,"Serologic survey of IgG against SARS-CoV-2 among hospital visitors without a history of SARS-CoV-2 infection in Tokyo, 2020-2021.",2021-11-13,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,,Tokyo,Residual sera of consenting patients from 14 Tokyo hospitals who chose not to opt-out of the study were included,participants diagnosed with COVID-19 or exhibiting any COVID-19-related symptoms at the time of blood collection,2020-09-01,2021-03-31,Residual sera,Female,Multiple groups,,,Sex/Gender,,11681,0.0199,0.0174,0.0226,,,,,,Simplified probability,"iFlash-SARS-CoV-2 IgM/IgG,iFlash-SARS-CoV-2 S1 IgG",Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,1.0,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Takahiro Sanada,Tokyo Metropolitan Institute of Medical Science,Not Unity-Aligned,https://dx.doi.org/10.2188/jea.JE20210324,2021-11-22,2024-03-01,Unverified,sanada_serologic_2021,JPN
211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience_Overall_SpikeANDS1,211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience,"Serologic survey of IgG against SARS-CoV-2 among hospital visitors without a history of SARS-CoV-2 infection in Tokyo, 2020-2021.",2021-11-13,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,,Tokyo,Residual sera of consenting patients from 14 Tokyo hospitals who chose not to opt-out of the study were included,participants diagnosed with COVID-19 or exhibiting any COVID-19-related symptoms at the time of blood collection,2020-09-01,2021-03-31,Residual sera,All,Multiple groups,,,Test used,Spike AND S1,23234,0.0063,0.0053,0.0074,,,,,,Simplified probability,"iFlash-SARS-CoV-2 IgM/IgG,iFlash-SARS-CoV-2 S1 IgG",Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,1.0,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Takahiro Sanada,Tokyo Metropolitan Institute of Medical Science,Not Unity-Aligned,https://dx.doi.org/10.2188/jea.JE20210324,2021-11-22,2024-03-01,Unverified,sanada_serologic_2021,JPN
211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience_Age>=80,211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience,"Serologic survey of IgG against SARS-CoV-2 among hospital visitors without a history of SARS-CoV-2 infection in Tokyo, 2020-2021.",2021-11-13,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,,Tokyo,Residual sera of consenting patients from 14 Tokyo hospitals who chose not to opt-out of the study were included,participants diagnosed with COVID-19 or exhibiting any COVID-19-related symptoms at the time of blood collection,2020-09-01,2021-03-31,Residual sera,All,Seniors (65+ years),,,Age,>=80,4761,0.012,0.0091,0.015500000000000002,,,,,,Simplified probability,"iFlash-SARS-CoV-2 IgM/IgG,iFlash-SARS-CoV-2 S1 IgG",Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,1.0,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Takahiro Sanada,Tokyo Metropolitan Institute of Medical Science,Not Unity-Aligned,https://dx.doi.org/10.2188/jea.JE20210324,2021-11-22,2024-03-01,Unverified,sanada_serologic_2021,JPN
211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience_Time4Dec,211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience,"Serologic survey of IgG against SARS-CoV-2 among hospital visitors without a history of SARS-CoV-2 infection in Tokyo, 2020-2021.",2021-11-13,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,,Tokyo,Residual sera of consenting patients from 14 Tokyo hospitals who chose not to opt-out of the study were included,participants diagnosed with COVID-19 or exhibiting any COVID-19-related symptoms at the time of blood collection,2020-12-01,2020-12-31,Residual sera,All,Multiple groups,,,Time frame,2020-12,3152,0.0183,0.0141,0.0438,,,True,,,Simplified probability,"iFlash-SARS-CoV-2 IgM/IgG,iFlash-SARS-CoV-2 S1 IgG",Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,1.0,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Takahiro Sanada,Tokyo Metropolitan Institute of Medical Science,Not Unity-Aligned,https://dx.doi.org/10.2188/jea.JE20210324,2021-11-22,2024-03-01,Unverified,sanada_serologic_2021,JPN
211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience_Time5Jan,211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience,"Serologic survey of IgG against SARS-CoV-2 among hospital visitors without a history of SARS-CoV-2 infection in Tokyo, 2020-2021.",2021-11-13,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,,Tokyo,Residual sera of consenting patients from 14 Tokyo hospitals who chose not to opt-out of the study were included,participants diagnosed with COVID-19 or exhibiting any COVID-19-related symptoms at the time of blood collection,2021-01-01,2021-01-31,Residual sera,All,Multiple groups,,,Time frame,2021-01,3056,0.0182,0.0138,0.0596,,,True,,,Simplified probability,"iFlash-SARS-CoV-2 IgM/IgG,iFlash-SARS-CoV-2 S1 IgG",Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,1.0,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Takahiro Sanada,Tokyo Metropolitan Institute of Medical Science,Not Unity-Aligned,https://dx.doi.org/10.2188/jea.JE20210324,2021-11-22,2024-03-01,Unverified,sanada_serologic_2021,JPN
211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience_Age60-79,211113_Tokyo_TokyoMetropolitanInstituteofMedicalScience,"Serologic survey of IgG against SARS-CoV-2 among hospital visitors without a history of SARS-CoV-2 infection in Tokyo, 2020-2021.",2021-11-13,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,,Tokyo,Residual sera of consenting patients from 14 Tokyo hospitals who chose not to opt-out of the study were included,participants diagnosed with COVID-19 or exhibiting any COVID-19-related symptoms at the time of blood collection,2020-09-01,2021-03-31,Residual sera,All,Seniors (65+ years),,,Age,60-79,10477,0.0191,0.0166,0.0219,,,,,,Simplified probability,"iFlash-SARS-CoV-2 IgM/IgG,iFlash-SARS-CoV-2 S1 IgG",Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,1.0,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Takahiro Sanada,Tokyo Metropolitan Institute of Medical Science,Not Unity-Aligned,https://dx.doi.org/10.2188/jea.JE20210324,2021-11-22,2024-03-01,Unverified,sanada_serologic_2021,JPN
211119_IwateMedicalUniversity_IwateMedicalUniversity,211119_IwateMedicalUniversity_IwateMedicalUniversity,Investigation of antibody level by the presence or absence of side effects after the new coronavirus vaccine,2021-11-19,Presentation or Conference,Local,Cross-sectional survey ,Japan,Tohoku,Morioke,healthcare workers at Iwate Medical University,,2021-03-15,2021-05-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,10,0.0,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],,Unclear,No,No,,Unclear,Yes,No,,Hiromi Nagashima,Iwate Medical University,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/full/10.1111/resp.14150_356,2022-01-12,2022-07-16,Unverified,nagashima_investigation_2021,JPN
121203_Tochigi_JichiMedicalUniversity_Apr-May2020,121203_Tochigi_JichiMedicalUniversity_Apr-May2020,Low prevalence of SARS-CoV-2 specific antibodies among endoscopists and their assistants in a university hospital in Tochigi prefecture-A single-center study.,2021-12-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Shimotsuke,Tochigi,HCW at the Jichi Medical University Hospital,Doctors with less than 2-year-experience were excluded.,2020-04-15,2020-05-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,54,0.037037037,,,True,,,,True,Entire sample,"2019-nCoV IgG Rapid Test,iFlash-SARS-CoV-2 S1 IgG,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),SARS-CoV-2 IgG II Quant ","Innovita Biological Technology Co. Ltd,Shenzhen Yhlo Biotech Co. Ltd,Roche Diagnostics,Abbott Laboratories",Multiple Types,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,Yes,No,No,,Unclear,Yes,No,,Kouichi Miura,Jichi Medical University,Not Unity-Aligned,https://dx.doi.org/10.1002/deo2.79,2022-03-28,2024-03-01,Unverified,miura_low_2022,JPN
121203_Tochigi_JichiMedicalUniversity_Dec2020-Mar2021,121203_Tochigi_JichiMedicalUniversity_Dec2020-Mar2021,Low prevalence of SARS-CoV-2 specific antibodies among endoscopists and their assistants in a university hospital in Tochigi prefecture-A single-center study.,2021-12-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Shimotsuke,Tochigi,HCW at the Jichi Medical University Hospital,Doctors with less than 2-year-experience were excluded.,2020-12-15,2021-03-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,86,0.011627907,,,True,,,,True,Entire sample,"2019-nCoV IgG Rapid Test,iFlash-SARS-CoV-2 S1 IgG,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),SARS-CoV-2 IgG II Quant ","Innovita Biological Technology Co. Ltd,Shenzhen Yhlo Biotech Co. Ltd,Roche Diagnostics,Abbott Laboratories",Multiple Types,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,Yes,No,No,,Unclear,Yes,No,,Kouichi Miura,Jichi Medical University,Not Unity-Aligned,https://dx.doi.org/10.1002/deo2.79,2022-03-28,2024-03-01,Unverified,miura_low_2022,JPN
121203_Tochigi_JichiMedicalUniversity_Jun-Nov2020,121203_Tochigi_JichiMedicalUniversity_Jun-Nov2020,Low prevalence of SARS-CoV-2 specific antibodies among endoscopists and their assistants in a university hospital in Tochigi prefecture-A single-center study.,2021-12-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Shimotsuke,Tochigi,HCW at the Jichi Medical University Hospital,Doctors with less than 2-year-experience were excluded.,2020-06-15,2020-11-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,349,0.0143266476,,,True,,,,True,Entire sample,"2019-nCoV IgG Rapid Test,iFlash-SARS-CoV-2 S1 IgG,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),SARS-CoV-2 IgG II Quant ","Innovita Biological Technology Co. Ltd,Shenzhen Yhlo Biotech Co. Ltd,Roche Diagnostics,Abbott Laboratories",Multiple Types,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,Yes,No,No,,Unclear,Yes,No,,Kouichi Miura,Jichi Medical University,Not Unity-Aligned,https://dx.doi.org/10.1002/deo2.79,2022-03-28,2024-03-01,Unverified,miura_low_2022,JPN
211205_Tokyo_UniversityofTokyo_iFlashIgG,211205_Tokyo_UniversityofTokyo,Interpretations of SARS-CoV-2 IgM and IgG antibody titers in the seroepidemiological study of asymptomatic healthy volunteers.,2021-12-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,,Tokyo,"asymptomatic subjects among students, staff, and faculty members of the University of Tokyo, Japan

All participants were 18 years or older.",,2020-06-11,2020-12-22,Multiple populations,All,Adults (18-64 years),18.0,,Primary Estimate,YHLO IgG,10039,0.0023,,,True,,,,True,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Akihisa Mitani,University of Tokyo,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jiac.2021.11.020,2022-01-04,2022-07-16,Unverified,mitani_interpretations_2021,JPN
211228_Kanagawa_ ShonanFujisawaTokushukaiHospital_AbbottIgG-S,211228_Kanagawa_ ShonanFujisawaTokushukaiHospital,Antibody Responses to the BNT162b2 mRNA Vaccine in Healthcare Workers in a General Hospital in Japan: A Comparison of Two Assays for Anti-spike Protein Immunoglobulin G.,2021-12-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Japan,,Kanagawa,"HCWs at our hospital who were 20 years old and
wished to be vaccinated were eligible for enrollment. Those
who had a history of SARS-CoV-2 infection were allowed
to participate, provided they had completed the isolation period and had clinically recovered.",". Potential participants were
excluded if they met any of the following conditions: 1) had
already received a COVID-19 vaccine, 2) were in the active
phase of COVID-19, 3) did not wish to be vaccinated of
their own choice, or 4) did not provide their informed consent",2021-04-15,2021-05-15,Health care workers and caregivers,All,Adults (18-64 years),20.0,,Primary Estimate,Abbott IgG-S Test,100,0.05,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],,No,No,Yes,,Yes,Yes,Yes,,Makoto Hibino, Shonan Fujisawa Tokushukai Hospital,Not Unity-Aligned,https://dx.doi.org/10.2169/internalmedicine.8704-21,2022-01-13,2024-03-01,Unverified,hibino_antibody_2022,JPN
220112_KantohDistrict_EPSHoldingsInc,220112_KantohDistrict_EPSHoldingsInc,Prevalence of Salivary IgA Reacting with SARS-CoV-2 among Japanese People Unexposed to the Virus,2022-01-12,Preprint,Regional,Cross-sectional survey ,Japan,,,"To have Japanese racial
background; to have had no history or experience of diagnosed COVID-19, SARS-CoV-2 PCRpositive, nor COVID-19-related symptoms; and to have had not experienced common cold-like
symptoms during the preceding two weeks.","Individuals were excluded if: they have had received
anti-SARS-CoV-2 vaccination; they were under treatment for systemic diseases or injuries; they
had oral mucosal diseases with local bleeding; or they had participated in another clinical study
within one month prior to the current study period.",2021-04-26,2021-08-01,Household and community samples,All,Multiple groups,,,Primary Estimate,,139,0.1223,0.0729,0.1886,True,,,,True,Convenience,Author designed (ELISA) - MULTIPLEXED,,ELISA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Keiichi Tsukinoki,"EPS Holdings, Inc.",Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.01.09.22268986v2.full-text,2022-01-17,2022-07-16,Unverified,tsukinoki_prevalence_2022,JPN
220121_Hyogo_UniversityOfOxford,220121_Hyogo_UniversityOfOxford,"Trans-continental analysis of over, 2000 inflammatory bowel disease patients implicates geography, disease type, and exposure to immunosuppression as drivers of SARS-CoV-2 seroprevalence: Data from the ICARUS-IBD consortium",2022-01-21,Presentation or Conference,Local,Cross-sectional survey ,Japan,,Hyogo,IBD patients prior to vaccination,,2020-05-26,2021-09-24,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,339,0.0236,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Atellica® IM SARS-CoV-2 Total (COV2T)","Roche Diagnostics,Siemens",,Serum,TotalAntibody,Spike,,,,['High'],,No,No,No,,Unclear,No,No,,S Y Wong,University of Oxford,Not Unity-Aligned,https://dx.doi.org/10.1093/ecco-jcc/jjab232.469,2022-03-08,2024-03-01,Unverified,wong_p342_2022,JPN
20220201_Japan_YokohamaMunicipalCitizenHospital_Primary,20220201_Japan_YokohamaMunicipalCitizenHospital,Rapid screening for severe acute respiratory syndrome coronavirus 2 infection with a combined point-of-care antigen test and an immunoglobulin G antibody test.,2022-02-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Kanagawa Prefecture,Yokohama,"All patients who visited the ED between February 1, 2021 and May 31, 2021 and underwent rapid antigen and IgG antibody tests and RT-PCR for diagnosis or screening for COVID-19, regardless of the reason for the visit, were included in the study.",,2021-02-01,2021-05-31,Residual sera,All,Multiple groups,,,Primary Estimate,,1070,0.033,,,,,,,True,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.24600000000000002,0.9790000000000001,['High'],No,No,Yes,No,No,Yes,Yes,No,,Kosuke Mori,Yokohama Municipal Citizen’s Hospital,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0263327,2022-02-10,2024-03-01,Unverified,mori_rapid_2022,JPN
220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_1stSurveyMain_Overall,220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_1stSurveyMain,"SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Okinawa Prefecture,,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,2020-07-01,2020-07-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,392,0.0,0.0,0.009000000000000001,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.925,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Kenji Mizumoto,Okinawa Prefecture Epidemiological Statistics and Analysis Committee,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.02.22271759v1.full-text,2022-04-07,2022-07-16,Verified,mizumoto_sars-cov-2_2022,JPN
220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_1stSurveyMain_Child,220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_1stSurveyMain,"SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Okinawa Prefecture,,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,2020-07-01,2020-07-31,Household and community samples,All,Children and Youth (0-17 years),,19.0,Age,Children: 0-19,18,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.925,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Kenji Mizumoto,Okinawa Prefecture Epidemiological Statistics and Analysis Committee,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.02.22271759v1.full-text,2022-05-18,2022-07-16,Verified,mizumoto_sars-cov-2_2022,JPN
220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_1stSurveyMain_Adult,220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_1stSurveyMain,"SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Okinawa Prefecture,,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,2020-07-01,2020-07-31,Household and community samples,All,Adults (18-64 years),20.0,59.0,Age,Adult: 20-59,167,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.925,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Kenji Mizumoto,Okinawa Prefecture Epidemiological Statistics and Analysis Committee,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.02.22271759v1.full-text,2022-05-18,2022-07-16,Verified,mizumoto_sars-cov-2_2022,JPN
220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_1stSurveyMain_Male,220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_1stSurveyMain,"SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Okinawa Prefecture,,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,2020-07-01,2020-07-31,Household and community samples,Male,Multiple groups,,,Sex/Gender,,175,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.925,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Kenji Mizumoto,Okinawa Prefecture Epidemiological Statistics and Analysis Committee,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.02.22271759v1.full-text,2022-05-18,2022-07-16,Verified,mizumoto_sars-cov-2_2022,JPN
220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_1stSurveyMain_Senior,220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_1stSurveyMain,"SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Okinawa Prefecture,,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,2020-07-01,2020-07-31,Household and community samples,All,Seniors (65+ years),60.0,,Age,Senior: >= 60,207,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.925,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Kenji Mizumoto,Okinawa Prefecture Epidemiological Statistics and Analysis Committee,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.02.22271759v1.full-text,2022-05-18,2022-07-16,Verified,mizumoto_sars-cov-2_2022,JPN
220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_1stSurveyMain_Female,220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_1stSurveyMain,"SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Okinawa Prefecture,,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,2020-07-01,2020-07-31,Household and community samples,Female,Multiple groups,,,Sex/Gender,,217,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.925,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Kenji Mizumoto,Okinawa Prefecture Epidemiological Statistics and Analysis Committee,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.02.22271759v1.full-text,2022-05-18,2022-07-16,Verified,mizumoto_sars-cov-2_2022,JPN
220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_2ndSurveyMain_Overall,220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_2ndSurveyMain,"SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Okinawa Prefecture,,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,2020-10-01,2020-12-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,1448,0.006,0.002,0.011000000000000001,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.925,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Kenji Mizumoto,Okinawa Prefecture Epidemiological Statistics and Analysis Committee,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.02.22271759v1.full-text,2022-04-07,2022-07-16,Verified,mizumoto_sars-cov-2_2022,JPN
220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_2ndSurveyMain_Female,220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_2ndSurveyMain,"SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Okinawa Prefecture,,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,2020-10-01,2020-12-31,Household and community samples,Female,Multiple groups,,,Sex/Gender,,759,0.006999999999999999,0.002,0.015,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.925,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Kenji Mizumoto,Okinawa Prefecture Epidemiological Statistics and Analysis Committee,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.02.22271759v1.full-text,2022-05-18,2022-07-16,Verified,mizumoto_sars-cov-2_2022,JPN
220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_2ndSurveyMain_Senior,220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_2ndSurveyMain,"SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Okinawa Prefecture,,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,2020-10-01,2020-12-31,Household and community samples,All,Seniors (65+ years),60.0,,Age,Senior: >= 60,804,0.005,0.001,0.013000000000000001,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.925,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Kenji Mizumoto,Okinawa Prefecture Epidemiological Statistics and Analysis Committee,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.02.22271759v1.full-text,2022-05-18,2022-07-16,Verified,mizumoto_sars-cov-2_2022,JPN
220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_2ndSurveyMain_Male,220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_2ndSurveyMain,"SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Okinawa Prefecture,,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,2020-10-01,2020-12-31,Household and community samples,Male,Multiple groups,,,Sex/Gender,,689,0.004,0.001,0.013000000000000001,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.925,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Kenji Mizumoto,Okinawa Prefecture Epidemiological Statistics and Analysis Committee,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.02.22271759v1.full-text,2022-05-18,2022-07-16,Verified,mizumoto_sars-cov-2_2022,JPN
220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_2ndSurveyMain_Adult,220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_2ndSurveyMain,"SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Okinawa Prefecture,,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,2020-10-01,2020-12-31,Household and community samples,All,Adults (18-64 years),20.0,59.0,Age,Adult: 20-59,551,0.006999999999999999,0.002,0.018000000000000002,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.925,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Kenji Mizumoto,Okinawa Prefecture Epidemiological Statistics and Analysis Committee,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.02.22271759v1.full-text,2022-05-18,2022-07-16,Verified,mizumoto_sars-cov-2_2022,JPN
220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_2ndSurveyMain_Child,220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_2ndSurveyMain,"SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Okinawa Prefecture,,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,2020-10-01,2020-12-31,Household and community samples,All,Children and Youth (0-17 years),,19.0,Age,Children: 0-19,93,0.0,0.0,0.039,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.925,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Kenji Mizumoto,Okinawa Prefecture Epidemiological Statistics and Analysis Committee,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.02.22271759v1.full-text,2022-05-18,2022-07-16,Verified,mizumoto_sars-cov-2_2022,JPN
220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_2ndSurveyRemote_Overall,220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_2ndSurveyRemote,"SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Okinawa Prefecture,,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,2020-10-01,2020-12-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,144,0.0,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.925,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Kenji Mizumoto,Okinawa Prefecture Epidemiological Statistics and Analysis Committee,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.02.22271759v1.full-text,2022-05-18,2022-07-16,Verified,mizumoto_sars-cov-2_2022,JPN
220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_2ndSurveyRemote_Senior,220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_2ndSurveyRemote,"SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Okinawa Prefecture,,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,2020-10-01,2020-12-31,Household and community samples,All,Seniors (65+ years),60.0,,Age,Senior: >= 60,107,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.925,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Kenji Mizumoto,Okinawa Prefecture Epidemiological Statistics and Analysis Committee,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.02.22271759v1.full-text,2022-05-18,2022-07-16,Verified,mizumoto_sars-cov-2_2022,JPN
220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_2ndSurveyRemote_Male,220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_2ndSurveyRemote,"SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Okinawa Prefecture,,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,2020-10-01,2020-12-31,Household and community samples,Male,Multiple groups,,,Sex/Gender,,76,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.925,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Kenji Mizumoto,Okinawa Prefecture Epidemiological Statistics and Analysis Committee,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.02.22271759v1.full-text,2022-05-18,2022-07-16,Verified,mizumoto_sars-cov-2_2022,JPN
220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_2ndSurveyRemote_Adult,220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_2ndSurveyRemote,"SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Okinawa Prefecture,,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,2020-10-01,2020-12-31,Household and community samples,All,Adults (18-64 years),20.0,59.0,Age,Adult: 20-59,32,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.925,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Kenji Mizumoto,Okinawa Prefecture Epidemiological Statistics and Analysis Committee,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.02.22271759v1.full-text,2022-05-18,2022-07-16,Verified,mizumoto_sars-cov-2_2022,JPN
220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_2ndSurveyRemote_Female,220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_2ndSurveyRemote,"SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Okinawa Prefecture,,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,2020-10-01,2020-12-31,Household and community samples,Female,Multiple groups,,,Sex/Gender,,68,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.925,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Kenji Mizumoto,Okinawa Prefecture Epidemiological Statistics and Analysis Committee,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.02.22271759v1.full-text,2022-05-18,2022-07-16,Verified,mizumoto_sars-cov-2_2022,JPN
220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_2ndSurveyRemote_Child,220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_2ndSurveyRemote,"SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Okinawa Prefecture,,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,2020-10-01,2020-12-31,Household and community samples,All,Children and Youth (0-17 years),,19.0,Age,Children: 0-19,5,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.925,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Kenji Mizumoto,Okinawa Prefecture Epidemiological Statistics and Analysis Committee,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.02.22271759v1.full-text,2022-05-18,2022-07-16,Verified,mizumoto_sars-cov-2_2022,JPN
220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_3rdSurveyMain_Overall,220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_3rdSurveyMain,"SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Okinawa Prefecture,,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,2021-02-01,2021-02-28,Household and community samples,All,Multiple groups,,,Primary Estimate,,582,0.013999999999999999,0.002,0.057999999999999996,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.925,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Kenji Mizumoto,Okinawa Prefecture Epidemiological Statistics and Analysis Committee,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.02.22271759v1.full-text,2022-04-07,2022-07-16,Verified,mizumoto_sars-cov-2_2022,JPN
220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_3rdSurveyMain_Child,220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_3rdSurveyMain,"SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Okinawa Prefecture,,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,2021-02-01,2021-02-28,Household and community samples,All,Children and Youth (0-17 years),,19.0,Age,,33,0.0,0.0,0.106,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.925,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Kenji Mizumoto,Okinawa Prefecture Epidemiological Statistics and Analysis Committee,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.02.22271759v1.full-text,2022-05-18,2022-07-16,Verified,mizumoto_sars-cov-2_2022,JPN
220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_3rdSurveyMain_Male,220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_3rdSurveyMain,"SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Okinawa Prefecture,,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,2021-02-01,2021-02-28,Household and community samples,Male,Multiple groups,,,Sex/Gender,,281,0.011000000000000001,0.002,0.031000000000000003,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.925,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Kenji Mizumoto,Okinawa Prefecture Epidemiological Statistics and Analysis Committee,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.02.22271759v1.full-text,2022-05-18,2022-07-16,Verified,mizumoto_sars-cov-2_2022,JPN
220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_3rdSurveyMain_Senior,220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_3rdSurveyMain,"SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Okinawa Prefecture,,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,2021-02-01,2021-02-28,Household and community samples,All,Seniors (65+ years),60.0,,Age,,346,0.009000000000000001,0.002,0.025,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.925,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Kenji Mizumoto,Okinawa Prefecture Epidemiological Statistics and Analysis Committee,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.02.22271759v1.full-text,2022-05-18,2022-07-16,Verified,mizumoto_sars-cov-2_2022,JPN
220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_3rdSurveyMain_Adults,220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_3rdSurveyMain,"SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Okinawa Prefecture,,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,2021-02-01,2021-02-28,Household and community samples,All,Adults (18-64 years),20.0,59.0,Age,,203,0.025,0.008,0.057,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.925,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Kenji Mizumoto,Okinawa Prefecture Epidemiological Statistics and Analysis Committee,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.02.22271759v1.full-text,2022-05-18,2022-07-16,Verified,mizumoto_sars-cov-2_2022,JPN
220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_3rdSurveyMain_Female,220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_3rdSurveyMain,"SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Okinawa Prefecture,,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,2021-02-01,2021-02-28,Household and community samples,Female,Multiple groups,,,Sex/Gender,,301,0.017,0.005,0.038,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.925,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Kenji Mizumoto,Okinawa Prefecture Epidemiological Statistics and Analysis Committee,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.02.22271759v1.full-text,2022-05-18,2022-07-16,Verified,mizumoto_sars-cov-2_2022,JPN
220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_3rdSurveyRemote_Overall,220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_3rdSurveyRemote,"SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Okinawa Prefecture,,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,2021-02-01,2021-02-28,Household and community samples,All,Multiple groups,,,Primary Estimate,,123,0.016,0.002,0.057999999999999996,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.925,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Kenji Mizumoto,Okinawa Prefecture Epidemiological Statistics and Analysis Committee,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.02.22271759v1.full-text,2022-05-18,2022-07-16,Verified,mizumoto_sars-cov-2_2022,JPN
220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_3rdSurveyRemote_Female,220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_3rdSurveyRemote,"SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Okinawa Prefecture,,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,2021-02-01,2021-02-28,Household and community samples,Female,Multiple groups,,,Sex/Gender,,51,0.02,0.0,0.10400000000000001,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.925,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Kenji Mizumoto,Okinawa Prefecture Epidemiological Statistics and Analysis Committee,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.02.22271759v1.full-text,2022-05-18,2022-07-16,Verified,mizumoto_sars-cov-2_2022,JPN
220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_3rdSurveyRemote_Male,220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_3rdSurveyRemote,"SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Okinawa Prefecture,,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,2021-02-01,2021-02-28,Household and community samples,Male,Multiple groups,,,Sex/Gender,,72,0.013999999999999999,0.0,0.075,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.925,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Kenji Mizumoto,Okinawa Prefecture Epidemiological Statistics and Analysis Committee,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.02.22271759v1.full-text,2022-05-18,2022-07-16,Verified,mizumoto_sars-cov-2_2022,JPN
220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_3rdSurveyRemote_Child,220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_3rdSurveyRemote,"SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Okinawa Prefecture,,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,2021-02-01,2021-02-28,Household and community samples,All,Children and Youth (0-17 years),,19.0,Age,,5,0.0,0.0,0.522,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.925,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Kenji Mizumoto,Okinawa Prefecture Epidemiological Statistics and Analysis Committee,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.02.22271759v1.full-text,2022-05-18,2022-07-16,Verified,mizumoto_sars-cov-2_2022,JPN
220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_3rdSurveyRemote_Senior,220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_3rdSurveyRemote,"SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Okinawa Prefecture,,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,2021-02-01,2021-02-28,Household and community samples,All,Seniors (65+ years),60.0,,Age,,78,0.013000000000000001,0.0,0.069,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.925,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Kenji Mizumoto,Okinawa Prefecture Epidemiological Statistics and Analysis Committee,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.02.22271759v1.full-text,2022-05-18,2022-07-16,Verified,mizumoto_sars-cov-2_2022,JPN
220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_3rdSurveyRemote_Adult,220303_Okinawa_OkinawaPrefectureEpidemiologicalStatisticsAndAnalysisCommittee_3rdSurveyRemote,"SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021",2022-03-03,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Okinawa Prefecture,,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded,2021-02-01,2021-02-28,Household and community samples,All,Adults (18-64 years),20.0,59.0,Age,,40,0.025,0.001,0.132,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.925,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Kenji Mizumoto,Okinawa Prefecture Epidemiological Statistics and Analysis Committee,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.02.22271759v1.full-text,2022-05-18,2022-07-16,Verified,mizumoto_sars-cov-2_2022,JPN
220327_Yokohama_YokohamaCityUniversity_Popadj,220327_Yokohama_YokohamaCityUniversity,"Analysis of humoral immunity against emerging SARS-CoV-2 variants: a population-based prevalence study in Yokohama, Japan",2022-03-27,Preprint,Local,Cross-sectional survey ,Japan,Kanagawa Prefecture,Yokohama,Randomly selected residents from Yokohoma City aged 20-74,No confirmed diagnosis of COVID-19 within 2 weeks of study entry,2022-01-30,2022-02-28,Household and community samples,All,Multiple groups,20.0,74.0,Primary Estimate,,1277,0.9420000000000001,0.93,0.9540000000000001,True,,True,,True,Simplified probability,AIA-CL SARS-CoV-2 SP-IgG,TOSOH,CLIA,Serum,IgG,Spike,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Atsushi Goto,Yokohama City University,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.26.22272766v1.full-text,2022-04-05,2024-03-01,Verified,goto_analysis_2022,JPN
220327_Yokohama_YokohamaCityUniversity_Unadj,220327_Yokohama_YokohamaCityUniversity,"Analysis of humoral immunity against emerging SARS-CoV-2 variants: a population-based prevalence study in Yokohama, Japan",2022-03-27,Preprint,Local,Cross-sectional survey ,Japan,Kanagawa Prefecture,Yokohama,Randomly selected residents from Yokohoma City aged 20-74,No confirmed diagnosis of COVID-19 within 2 weeks of study entry,2022-01-30,2022-02-28,Household and community samples,All,Multiple groups,20.0,74.0,Analysis,,1277,0.9420000000000001,0.9279999999999999,0.9540000000000001,,,,,,Simplified probability,AIA-CL SARS-CoV-2 SP-IgG,TOSOH,CLIA,Serum,IgG,Spike,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Atsushi Goto,Yokohama City University,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.26.22272766v1.full-text,2022-04-06,2024-03-01,Verified,goto_analysis_2022,JPN
220331_Maebashi_GunmaUniversityHospital_Overall,220331_Maebashi_GunmaUniversityHospital,Serological Screening of Immunoglobulin G against SARS-CoV-2 Nucleocapsid and Spike Protein before and after Two Vaccine Doses among Healthcare Workers in Japan.,2022-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,Gunma Prefecture,Maebashi,"Healthcare workers at the Gunma University Hospital, Gunma, Japan (physicians, nurses, laboratory medical technologists, X-ray technicians, therapist, pharmacologist, and officers)",,2021-03-01,2021-03-31,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,771,0.0039000000000000003,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,CLIA,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,No,,Yes,Yes,No,,Suguru Hiramoto,Gunma University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1620/tjem.2022.J017,2022-04-06,2024-03-01,Unverified,hiramoto_serological_2022,JPN
220405_Japan_KobeUniversity_Baseline_OverallAntiS,220405_Japan_KobeUniversity_Baseline,Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron's outbreak.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Japan,Hyogo Prefecture,Kobe,"The serum samples were collected from individuals who underwent a health check-up at the clinics of Hyogo Prefecture Health Promotion Association.

The history of vaccination and infection were not included as selection or exclusion criteria. ","Exclusion is only for the individuals who
declared opt-out.",2021-07-19,2021-08-06,Residual sera,All,Adults (18-64 years),19.0,83.0,Primary Estimate,Anti-S,1000,0.387,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Zhenxiao Ren,Kobe Univesity,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266270,2022-04-22,2022-07-16,Unverified,ren_large-scale_2022-1,JPN
220405_Japan_KobeUniversity_Baseline_Age60-69,220405_Japan_KobeUniversity_Baseline,Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron's outbreak.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Japan,Hyogo Prefecture,Kobe,"The serum samples were collected from individuals who underwent a health check-up at the clinics of Hyogo Prefecture Health Promotion Association.

The history of vaccination and infection were not included as selection or exclusion criteria. ","Exclusion is only for the individuals who
declared opt-out.",2021-07-19,2021-08-06,Residual sera,All,Seniors (65+ years),60.0,69.0,Age,60-69,174,0.7069,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Zhenxiao Ren,Kobe Univesity,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266270,2022-04-22,2022-07-16,Unverified,ren_large-scale_2022-1,JPN
220405_Japan_KobeUniversity_Baseline_SexMale,220405_Japan_KobeUniversity_Baseline,Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron's outbreak.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Japan,Hyogo Prefecture,Kobe,"The serum samples were collected from individuals who underwent a health check-up at the clinics of Hyogo Prefecture Health Promotion Association.

The history of vaccination and infection were not included as selection or exclusion criteria. ","Exclusion is only for the individuals who
declared opt-out.",2021-07-19,2021-08-06,Residual sera,Male,Multiple groups,20.0,83.0,Sex/Gender,,587,0.3884,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Zhenxiao Ren,Kobe Univesity,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266270,2022-04-22,2022-07-16,Unverified,ren_large-scale_2022-1,JPN
220405_Japan_KobeUniversity_Baseline_Age40-49,220405_Japan_KobeUniversity_Baseline,Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron's outbreak.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Japan,Hyogo Prefecture,Kobe,"The serum samples were collected from individuals who underwent a health check-up at the clinics of Hyogo Prefecture Health Promotion Association.

The history of vaccination and infection were not included as selection or exclusion criteria. ","Exclusion is only for the individuals who
declared opt-out.",2021-07-19,2021-08-06,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,243,0.2757,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Zhenxiao Ren,Kobe Univesity,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266270,2022-04-22,2022-07-16,Unverified,ren_large-scale_2022-1,JPN
220405_Japan_KobeUniversity_Baseline_Age30-39,220405_Japan_KobeUniversity_Baseline,Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron's outbreak.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Japan,Hyogo Prefecture,Kobe,"The serum samples were collected from individuals who underwent a health check-up at the clinics of Hyogo Prefecture Health Promotion Association.

The history of vaccination and infection were not included as selection or exclusion criteria. ","Exclusion is only for the individuals who
declared opt-out.",2021-07-19,2021-08-06,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,179,0.3128,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Zhenxiao Ren,Kobe Univesity,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266270,2022-04-22,2022-07-16,Unverified,ren_large-scale_2022-1,JPN
220405_Japan_KobeUniversity_Baseline_Age20-29,220405_Japan_KobeUniversity_Baseline,Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron's outbreak.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Japan,Hyogo Prefecture,Kobe,"The serum samples were collected from individuals who underwent a health check-up at the clinics of Hyogo Prefecture Health Promotion Association.

The history of vaccination and infection were not included as selection or exclusion criteria. ","Exclusion is only for the individuals who
declared opt-out.",2021-07-19,2021-08-06,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29,123,0.187,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Zhenxiao Ren,Kobe Univesity,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266270,2022-04-22,2022-07-16,Unverified,ren_large-scale_2022-1,JPN
220405_Japan_KobeUniversity_Baseline_OverallAntiN,220405_Japan_KobeUniversity_Baseline,Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron's outbreak.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Japan,Hyogo Prefecture,Kobe,"The serum samples were collected from individuals who underwent a health check-up at the clinics of Hyogo Prefecture Health Promotion Association.

The history of vaccination and infection were not included as selection or exclusion criteria. ","Exclusion is only for the individuals who
declared opt-out.",2021-07-19,2021-08-06,Residual sera,All,Multiple groups,19.0,83.0,Test used,Anti-N,1000,0.021,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.958,0.995,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Zhenxiao Ren,Kobe Univesity,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266270,2022-04-22,2024-03-01,Unverified,ren_large-scale_2022-1,JPN
220405_Japan_KobeUniversity_Baseline_Age70-83,220405_Japan_KobeUniversity_Baseline,Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron's outbreak.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Japan,Hyogo Prefecture,Kobe,"The serum samples were collected from individuals who underwent a health check-up at the clinics of Hyogo Prefecture Health Promotion Association.

The history of vaccination and infection were not included as selection or exclusion criteria. ","Exclusion is only for the individuals who
declared opt-out.",2021-07-19,2021-08-06,Residual sera,All,Seniors (65+ years),70.0,83.0,Age,70-83,41,0.9024,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Zhenxiao Ren,Kobe Univesity,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266270,2022-04-22,2022-07-16,Unverified,ren_large-scale_2022-1,JPN
220405_Japan_KobeUniversity_Baseline_SexFemale,220405_Japan_KobeUniversity_Baseline,Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron's outbreak.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Japan,Hyogo Prefecture,Kobe,"The serum samples were collected from individuals who underwent a health check-up at the clinics of Hyogo Prefecture Health Promotion Association.

The history of vaccination and infection were not included as selection or exclusion criteria. ","Exclusion is only for the individuals who
declared opt-out.",2021-07-19,2021-08-06,Residual sera,Female,Multiple groups,19.0,78.0,Sex/Gender,,413,0.385,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Zhenxiao Ren,Kobe Univesity,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266270,2022-04-22,2022-07-16,Unverified,ren_large-scale_2022-1,JPN
220405_Japan_KobeUniversity_Baseline_Age50-59,220405_Japan_KobeUniversity_Baseline,Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron's outbreak.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Japan,Hyogo Prefecture,Kobe,"The serum samples were collected from individuals who underwent a health check-up at the clinics of Hyogo Prefecture Health Promotion Association.

The history of vaccination and infection were not included as selection or exclusion criteria. ","Exclusion is only for the individuals who
declared opt-out.",2021-07-19,2021-08-06,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,236,0.33899999999999997,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Zhenxiao Ren,Kobe Univesity,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266270,2022-04-22,2022-07-16,Unverified,ren_large-scale_2022-1,JPN
220405_Japan_KobeUniversity_Baseline_Age18-19,220405_Japan_KobeUniversity_Baseline,Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron's outbreak.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Japan,Hyogo Prefecture,Kobe,"The serum samples were collected from individuals who underwent a health check-up at the clinics of Hyogo Prefecture Health Promotion Association.

The history of vaccination and infection were not included as selection or exclusion criteria. ","Exclusion is only for the individuals who
declared opt-out.",2021-07-19,2021-08-06,Residual sera,All,Adults (18-64 years),19.0,19.0,Age,18-19,4,0.25,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Zhenxiao Ren,Kobe Univesity,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266270,2022-04-22,2022-07-16,Unverified,ren_large-scale_2022-1,JPN
220405_Japan_KobeUniversity_FollowUp_OverallAntiS,220405_Japan_KobeUniversity_FollowUp,Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron's outbreak.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Japan,Hyogo Prefecture,Kobe,"The serum samples were collected from individuals who underwent a health check-up at the clinics of Hyogo Prefecture Health Promotion Association.

The history of vaccination and infection were not included as selection or exclusion criteria. ","Exclusion is only for the individuals who
declared opt-out.",2021-11-22,2021-12-08,Residual sera,All,Adults (18-64 years),18.0,79.0,Primary Estimate,Anti-S,1000,0.908,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Zhenxiao Ren,Kobe Univesity,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266270,2022-04-22,2022-07-16,Unverified,ren_large-scale_2022-1,JPN
220405_Japan_KobeUniversity_FollowUp_SexMale,220405_Japan_KobeUniversity_FollowUp,Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron's outbreak.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Japan,Hyogo Prefecture,Kobe,"The serum samples were collected from individuals who underwent a health check-up at the clinics of Hyogo Prefecture Health Promotion Association.

The history of vaccination and infection were not included as selection or exclusion criteria. ","Exclusion is only for the individuals who
declared opt-out.",2021-11-22,2021-12-08,Residual sera,Male,Multiple groups,19.0,79.0,Sex/Gender,,508,0.8996,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Zhenxiao Ren,Kobe Univesity,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266270,2022-04-22,2022-07-16,Unverified,ren_large-scale_2022-1,JPN
220405_Japan_KobeUniversity_FollowUp_Age70-83,220405_Japan_KobeUniversity_FollowUp,Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron's outbreak.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Japan,Hyogo Prefecture,Kobe,"The serum samples were collected from individuals who underwent a health check-up at the clinics of Hyogo Prefecture Health Promotion Association.

The history of vaccination and infection were not included as selection or exclusion criteria. ","Exclusion is only for the individuals who
declared opt-out.",2021-11-22,2021-12-08,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-83,40,0.925,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Zhenxiao Ren,Kobe Univesity,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266270,2022-04-22,2022-07-16,Unverified,ren_large-scale_2022-1,JPN
220405_Japan_KobeUniversity_FollowUp_Age18-19,220405_Japan_KobeUniversity_FollowUp,Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron's outbreak.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Japan,Hyogo Prefecture,Kobe,"The serum samples were collected from individuals who underwent a health check-up at the clinics of Hyogo Prefecture Health Promotion Association.

The history of vaccination and infection were not included as selection or exclusion criteria. ","Exclusion is only for the individuals who
declared opt-out.",2021-11-22,2021-12-08,Residual sera,All,Adults (18-64 years),18.0,19.0,Age,18-19,3,1.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Zhenxiao Ren,Kobe Univesity,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266270,2022-04-22,2022-07-16,Unverified,ren_large-scale_2022-1,JPN
220405_Japan_KobeUniversity_FollowUp_Age50-59,220405_Japan_KobeUniversity_FollowUp,Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron's outbreak.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Japan,Hyogo Prefecture,Kobe,"The serum samples were collected from individuals who underwent a health check-up at the clinics of Hyogo Prefecture Health Promotion Association.

The history of vaccination and infection were not included as selection or exclusion criteria. ","Exclusion is only for the individuals who
declared opt-out.",2021-11-22,2021-12-08,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,265,0.8981,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Zhenxiao Ren,Kobe Univesity,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266270,2022-04-22,2022-07-16,Unverified,ren_large-scale_2022-1,JPN
220405_Japan_KobeUniversity_FollowUp_SexFemale,220405_Japan_KobeUniversity_FollowUp,Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron's outbreak.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Japan,Hyogo Prefecture,Kobe,"The serum samples were collected from individuals who underwent a health check-up at the clinics of Hyogo Prefecture Health Promotion Association.

The history of vaccination and infection were not included as selection or exclusion criteria. ","Exclusion is only for the individuals who
declared opt-out.",2021-11-22,2021-12-08,Residual sera,Female,Multiple groups,18.0,75.0,Sex/Gender,,492,0.9126000000000001,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Zhenxiao Ren,Kobe Univesity,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266270,2022-04-22,2022-07-16,Unverified,ren_large-scale_2022-1,JPN
220405_Japan_KobeUniversity_FollowUp_Age30-39,220405_Japan_KobeUniversity_FollowUp,Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron's outbreak.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Japan,Hyogo Prefecture,Kobe,"The serum samples were collected from individuals who underwent a health check-up at the clinics of Hyogo Prefecture Health Promotion Association.

The history of vaccination and infection were not included as selection or exclusion criteria. ","Exclusion is only for the individuals who
declared opt-out.",2021-11-22,2021-12-08,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,149,0.8725,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Zhenxiao Ren,Kobe Univesity,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266270,2022-04-22,2022-07-16,Unverified,ren_large-scale_2022-1,JPN
220405_Japan_KobeUniversity_FollowUp_Age20-29,220405_Japan_KobeUniversity_FollowUp,Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron's outbreak.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Japan,Hyogo Prefecture,Kobe,"The serum samples were collected from individuals who underwent a health check-up at the clinics of Hyogo Prefecture Health Promotion Association.

The history of vaccination and infection were not included as selection or exclusion criteria. ","Exclusion is only for the individuals who
declared opt-out.",2021-11-22,2021-12-08,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29,104,0.8845999999999999,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Zhenxiao Ren,Kobe Univesity,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266270,2022-04-22,2022-07-16,Unverified,ren_large-scale_2022-1,JPN
220405_Japan_KobeUniversity_FollowUp_Age60-69,220405_Japan_KobeUniversity_FollowUp,Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron's outbreak.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Japan,Hyogo Prefecture,Kobe,"The serum samples were collected from individuals who underwent a health check-up at the clinics of Hyogo Prefecture Health Promotion Association.

The history of vaccination and infection were not included as selection or exclusion criteria. ","Exclusion is only for the individuals who
declared opt-out.",2021-11-22,2021-12-08,Residual sera,All,Seniors (65+ years),60.0,69.0,Age,60-69,182,0.9615000000000001,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Zhenxiao Ren,Kobe Univesity,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266270,2022-04-22,2022-07-16,Unverified,ren_large-scale_2022-1,JPN
220405_Japan_KobeUniversity_FollowUp_Age40-49,220405_Japan_KobeUniversity_FollowUp,Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron's outbreak.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Japan,Hyogo Prefecture,Kobe,"The serum samples were collected from individuals who underwent a health check-up at the clinics of Hyogo Prefecture Health Promotion Association.

The history of vaccination and infection were not included as selection or exclusion criteria. ","Exclusion is only for the individuals who
declared opt-out.",2021-11-22,2021-12-08,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,257,0.9066,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Zhenxiao Ren,Kobe Univesity,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266270,2022-04-22,2022-07-16,Unverified,ren_large-scale_2022-1,JPN
220405_Japan_KobeUniversity_FollowUp_OverallAntiN,220405_Japan_KobeUniversity_FollowUp,Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron's outbreak.,2022-04-05,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Japan,Hyogo Prefecture,Kobe,"The serum samples were collected from individuals who underwent a health check-up at the clinics of Hyogo Prefecture Health Promotion Association.

The history of vaccination and infection were not included as selection or exclusion criteria. ","Exclusion is only for the individuals who
declared opt-out.",2021-11-22,2021-12-08,Residual sera,All,Multiple groups,18.0,79.0,Test used,Anti-N,1000,0.039,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.958,0.995,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Zhenxiao Ren,Kobe Univesity,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266270,2022-04-22,2024-03-01,Unverified,ren_large-scale_2022-1,JPN
220520_Tokyo_TokyoShinagawaHospital_RBD,220520_Tokyo_TokyoShinagawaHospital,Detection of silent infection of severe acute respiratory syndrome coronavirus 2 by serological tests,2022-05-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,,Tokyo,685 HCW’s at Tokyo Shinagawa Hospital were included in this study after obtaining written informed consent.,,2021-03-15,2021-04-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,IgG (RBD),685,0.095,,,True,,,,True,Unclear,Architect Anti-SARS-CoV-2 IgM,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.96,1.0,['Moderate'],,Unclear,Yes,Yes,,No,Yes,Yes,,Masashi Nishimura,Tokyo Shinagawa Hospital,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0267566,2022-06-02,2024-03-01,Unverified,nishimura_detection_2022,JPN
220524_Tokyo_JuntendoUniversity_PostVaccination2021_AntiN,220524_Tokyo_JuntendoUniversity_PostVaccination2021,Antibody response and seroprevalence in healthcare workers after the BNT162b2 vaccination in a University Hospital at Tokyo.,2022-05-24,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,,Tokyo,"""we enrolled a large number of employees in our hospital who received the BNT162b2 mRNA vaccine.""

""The serum samples of participants who have received the BNT162b2 vaccine by May 13, 2021 at the university were collected from the residual blood samples taken at the annual health checkups (June 2021) at the university.""",,2021-06-01,2021-06-30,Health care workers and caregivers,All,Multiple groups,20.0,,Primary Estimate,,2202,0.0159,,,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Gene Igawa,Juntendo University,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-12809-x,2022-06-04,2024-03-01,Unverified,igawa_antibody_2022,JPN
220524_Tokyo_JuntendoUniversity_PreVaccination2020_AntiS,220524_Tokyo_JuntendoUniversity_PreVaccination2020,Antibody response and seroprevalence in healthcare workers after the BNT162b2 vaccination in a University Hospital at Tokyo.,2022-05-24,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,,Tokyo,"HCWs at a first line hospital in Tokyo, Japan.

""Serum collected in 2020, which were stored in − 80 ℃, were used as pre-vaccination samples.""",,2020-07-06,2020-08-21,Health care workers and caregivers,All,Multiple groups,20.0,,Primary Estimate,,2203,0.013200000000000002,,,True,,,,True,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Serum,TotalAntibody,Spike,Validated by manufacturers,,0.9998,['High'],,Unclear,Yes,No,,Yes,Yes,Yes,,Gene Igawa,Juntendo University,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-12809-x,2022-06-04,2024-03-01,Unverified,igawa_antibody_2022,JPN
220524_Japan_KanagawaDentalUniversity_Primary,220524_Japan_KanagawaDentalUniversity,Prevalence of Saliva Immunoglobulin A Antibodies Reactive with Severe Acute Respiratory Syndrome Coronavirus 2 among Japanese People Unexposed to the Virus.,2022-05-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,Kantoh region,,"""Japanese   racial   background;   to   have   had   no history   or   experience   of diagnosed    COVID-19,    SARS-CoV-2    PCR-positive,    nor    COVID-19-related symptoms;  and  to  have  had  not  experienced  common  cold-like  symptoms  during the  preceding  two  weeks""","""Individuals  were  excluded  if:  they  have  had  received anti-SARS-CoV-2 vaccination; they were under treatment  for systemic diseases or injuries;   they   had   oral   mucosal   diseases   with   local   bleeding;   or   they   had participated  in  another  clinical  study  within  one  month  prior  to  the  current  study period""",2021-04-08,2021-08-02,Multiple populations,All,Multiple groups,3.0,75.0,Primary Estimate,,180,0.5278,0.4521,0.6025,True,,,,True,Unclear,Author designed (ELISA) -Spike,,ELISA,Saliva,IgA,Spike,,,,['High'],,Unclear,No,Yes,,Unclear,Yes,No,,Keiichi Tsukinoki,Teikyo University,Not Unity-Aligned,https://dx.doi.org/10.1111/1348-0421.13011,2022-06-05,2022-07-16,Unverified,tsukinoki_prevalence_2022-1,JPN
220524_Japan_KanagawaDentalUniversity_Age_20-35,220524_Japan_KanagawaDentalUniversity,Prevalence of Saliva Immunoglobulin A Antibodies Reactive with Severe Acute Respiratory Syndrome Coronavirus 2 among Japanese People Unexposed to the Virus.,2022-05-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,Kantoh region,,"""Japanese   racial   background;   to   have   had   no history   or   experience   of diagnosed    COVID-19,    SARS-CoV-2    PCR-positive,    nor    COVID-19-related symptoms;  and  to  have  had  not  experienced  common  cold-like  symptoms  during the  preceding  two  weeks""","""Individuals  were  excluded  if:  they  have  had  received anti-SARS-CoV-2 vaccination; they were under treatment  for systemic diseases or injuries;   they   had   oral   mucosal   diseases   with   local   bleeding;   or   they   had participated  in  another  clinical  study  within  one  month  prior  to  the  current  study period""",2021-04-08,2021-05-08,Multiple populations,All,Adults (18-64 years),20.0,35.0,Age,20-35,45,0.2,0.0958,0.34600000000000003,,,,,,Unclear,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,Unclear,No,Yes,,Unclear,Yes,No,,Keiichi Tsukinoki,Teikyo University,Not Unity-Aligned,https://dx.doi.org/10.1111/1348-0421.13011,2022-06-05,2022-07-16,Unverified,tsukinoki_prevalence_2022-1,JPN
220524_Japan_KanagawaDentalUniversity_Age_>=51,220524_Japan_KanagawaDentalUniversity,Prevalence of Saliva Immunoglobulin A Antibodies Reactive with Severe Acute Respiratory Syndrome Coronavirus 2 among Japanese People Unexposed to the Virus.,2022-05-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,Kantoh region,,"""Japanese   racial   background;   to   have   had   no history   or   experience   of diagnosed    COVID-19,    SARS-CoV-2    PCR-positive,    nor    COVID-19-related symptoms;  and  to  have  had  not  experienced  common  cold-like  symptoms  during the  preceding  two  weeks""","""Individuals  were  excluded  if:  they  have  had  received anti-SARS-CoV-2 vaccination; they were under treatment  for systemic diseases or injuries;   they   had   oral   mucosal   diseases   with   local   bleeding;   or   they   had participated  in  another  clinical  study  within  one  month  prior  to  the  current  study period""",2021-04-08,2021-05-08,Multiple populations,All,Multiple groups,51.0,75.0,Age,>=51,52,0.0385,0.0047,0.13210000000000002,,,,,,Unclear,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,Unclear,No,Yes,,Unclear,Yes,No,,Keiichi Tsukinoki,Teikyo University,Not Unity-Aligned,https://dx.doi.org/10.1111/1348-0421.13011,2022-06-05,2022-07-16,Unverified,tsukinoki_prevalence_2022-1,JPN
220524_Japan_KanagawaDentalUniversity_Age_<20,220524_Japan_KanagawaDentalUniversity,Prevalence of Saliva Immunoglobulin A Antibodies Reactive with Severe Acute Respiratory Syndrome Coronavirus 2 among Japanese People Unexposed to the Virus.,2022-05-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,Kantoh region,,"""Japanese   racial   background;   to   have   had   no history   or   experience   of diagnosed    COVID-19,    SARS-CoV-2    PCR-positive,    nor    COVID-19-related symptoms;  and  to  have  had  not  experienced  common  cold-like  symptoms  during the  preceding  two  weeks""","""Individuals  were  excluded  if:  they  have  had  received anti-SARS-CoV-2 vaccination; they were under treatment  for systemic diseases or injuries;   they   had   oral   mucosal   diseases   with   local   bleeding;   or   they   had participated  in  another  clinical  study  within  one  month  prior  to  the  current  study period""",2021-04-08,2021-08-02,Residual sera,All,Children and Youth (0-17 years),3.0,19.0,Age,<20,41,0.6585,0.4941,0.7992,,,,,,Unclear,Author designed (ELISA) -Spike,,ELISA,Saliva,IgA,Spike,,,,['High'],,Unclear,No,Yes,,Unclear,Yes,No,,Keiichi Tsukinoki,Teikyo University,Not Unity-Aligned,https://dx.doi.org/10.1111/1348-0421.13011,2022-06-05,2022-07-16,Unverified,tsukinoki_prevalence_2022-1,JPN
220524_Japan_KanagawaDentalUniversity_Age_36-50,220524_Japan_KanagawaDentalUniversity,Prevalence of Saliva Immunoglobulin A Antibodies Reactive with Severe Acute Respiratory Syndrome Coronavirus 2 among Japanese People Unexposed to the Virus.,2022-05-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,Kantoh region,,"""Japanese   racial   background;   to   have   had   no history   or   experience   of diagnosed    COVID-19,    SARS-CoV-2    PCR-positive,    nor    COVID-19-related symptoms;  and  to  have  had  not  experienced  common  cold-like  symptoms  during the  preceding  two  weeks""","""Individuals  were  excluded  if:  they  have  had  received anti-SARS-CoV-2 vaccination; they were under treatment  for systemic diseases or injuries;   they   had   oral   mucosal   diseases   with   local   bleeding;   or   they   had participated  in  another  clinical  study  within  one  month  prior  to  the  current  study period""",2021-04-08,2021-05-08,Multiple populations,All,Adults (18-64 years),36.0,50.0,Age,36-50,42,0.1429,0.0543,0.2854,,,,,,Unclear,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,Unclear,No,Yes,,Unclear,Yes,No,,Keiichi Tsukinoki,Teikyo University,Not Unity-Aligned,https://dx.doi.org/10.1111/1348-0421.13011,2022-06-05,2022-07-16,Unverified,tsukinoki_prevalence_2022-1,JPN
220530_Tokyo_KitasatoUniversitySchoolofMedicine,220530_Tokyo_KitasatoUniversitySchoolofMedicine,Pre-vaccination Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in Workers at Three Japanese Hospitals.,2022-05-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,,Tokyo,"""Routine health check-ups of the staff of three hospitals of the Kitasato Institute in Japan and tested the leftover serum samples""",,2020-06-08,2020-07-04,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,3677,0.0034999999999999996,0.0019,0.006,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),,1.0,0.998,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Yoko Takayama,Kitasato University School of Medicine,Not Unity-Aligned,https://dx.doi.org/10.1272/jnms.JNMS.2022_89-511,2022-06-09,2024-03-01,Unverified,takayama_pre-vaccination_2022,JPN
220531_Toon_EhimeUniversity_HCWs_1stSurvey_TwoAssays,220531_Toon_EhimeUniversity_HCWs_1stSurvey,"Two-Year Seroprevalence Surveys of SARS-CoV-2 Antibodies among Outpatients and Healthcare Workers in Ehime, Japan",2022-05-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Ehime Prefecture,Toon,"""We conducted two-year seroprevalence surveys of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies among outpatients and healthcare workers (HCWs) at Ehime University Hospital.""","""the number of HCWs was limited because those receiving regular medical checks without blood sampling were excluded.""",2020-06-11,2020-06-17,Health care workers and caregivers,All,Adults (18-64 years),20.0,66.0,Primary Estimate,Positive for both assays (Roche and Abbott).,743,0.0,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG","Roche Diagnostics,Abbott Laboratories",CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Yes,Yes,No,,Koichiro Suemori,Ehime University,Not Unity-Aligned,https://dx.doi.org/10.7883/yoken.JJID.2022.155,2022-06-07,2024-03-01,Unverified,suemori_two-year_2022,JPN
220531_Toon_EhimeUniversity_HCWs_2ndSurvey_TwoAssays,220531_Toon_EhimeUniversity_HCWs_2ndSurvey,"Two-Year Seroprevalence Surveys of SARS-CoV-2 Antibodies among Outpatients and Healthcare Workers in Ehime, Japan",2022-05-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Ehime Prefecture,Toon,"""We conducted two-year seroprevalence surveys of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies among outpatients and healthcare workers (HCWs) at Ehime University Hospital.""","""the number of HCWs was limited because those receiving regular medical checks without blood sampling were excluded.""",2020-12-08,2020-12-11,Health care workers and caregivers,All,Adults (18-64 years),23.0,65.0,Primary Estimate,Positive for both assays (Roche and Abbott).,407,0.0,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG","Roche Diagnostics,Abbott Laboratories",CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),,,,['High'],,No,No,Yes,,Yes,Yes,No,,Koichiro Suemori,Ehime University,Not Unity-Aligned,https://dx.doi.org/10.7883/yoken.JJID.2022.155,2022-10-06,2024-03-01,Unverified,suemori_two-year_2022,JPN
220531_Toon_EhimeUniversity_HCWs_3rdSurvey_TwoAssays,220531_Toon_EhimeUniversity_HCWs_3rdSurvey,"Two-Year Seroprevalence Surveys of SARS-CoV-2 Antibodies among Outpatients and Healthcare Workers in Ehime, Japan",2022-05-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Ehime Prefecture,Toon,"""We conducted two-year seroprevalence surveys of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies among outpatients and healthcare workers (HCWs) at Ehime University Hospital.""","""the number of HCWs was limited because those receiving regular medical checks without blood sampling were excluded.""",2021-07-10,2021-07-16,Health care workers and caregivers,All,Adults (18-64 years),20.0,67.0,Primary Estimate,Positive for both assays (Roche and Abbott).,804,0.00124,0.00021999999999999998,0.006999999999999999,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG","Roche Diagnostics,Abbott Laboratories",CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Yes,Yes,No,,Koichiro Suemori,Ehime University,Not Unity-Aligned,https://dx.doi.org/10.7883/yoken.JJID.2022.155,2022-10-06,2024-03-01,Unverified,suemori_two-year_2022,JPN
220531_Toon_EhimeUniversity_HCWs_4thSurvey_TwoAssays,220531_Toon_EhimeUniversity_HCWs_4thSurvey,"Two-Year Seroprevalence Surveys of SARS-CoV-2 Antibodies among Outpatients and Healthcare Workers in Ehime, Japan",2022-05-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Ehime Prefecture,Toon,"""We conducted two-year seroprevalence surveys of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies among outpatients and healthcare workers (HCWs) at Ehime University Hospital.""","""the number of HCWs was limited because those receiving regular medical checks without blood sampling were excluded.""",2021-12-07,2021-12-10,Health care workers and caregivers,All,Adults (18-64 years),24.0,66.0,Primary Estimate,Positive for both assays (Roche and Abbott).,415,0.0,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG","Roche Diagnostics,Abbott Laboratories",CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),,,,['High'],,No,No,Yes,,Yes,Yes,No,,Koichiro Suemori,Ehime University,Not Unity-Aligned,https://dx.doi.org/10.7883/yoken.JJID.2022.155,2022-10-06,2024-03-01,Unverified,suemori_two-year_2022,JPN
220531_Toon_EhimeUniversity_Outpatients_1stSurvey_TwoAssays,220531_Toon_EhimeUniversity_Outpatients_1stSurvey,"Two-Year Seroprevalence Surveys of SARS-CoV-2 Antibodies among Outpatients and Healthcare Workers in Ehime, Japan",2022-05-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Ehime Prefecture,Toon,"""We conducted two-year seroprevalence surveys of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies among outpatients and healthcare workers (HCWs) at Ehime University Hospital.""",,2020-06-11,2020-06-17,Residual sera,All,Multiple groups,0.0,96.0,Primary Estimate,Positive for both assays (Roche and Abbott).,1000,0.001,0.00017999999999999998,0.005600000000000001,True,,,,True,Simplified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG","Roche Diagnostics,Abbott Laboratories",CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Koichiro Suemori,Ehime University,Unity-Aligned,https://dx.doi.org/10.7883/yoken.JJID.2022.155,2022-06-07,2024-03-01,Unverified,suemori_two-year_2022,JPN
220531_Toon_EhimeUniversity_Outpatients_2ndSurvey_TwoAssays,220531_Toon_EhimeUniversity_Outpatients_2ndSurvey,"Two-Year Seroprevalence Surveys of SARS-CoV-2 Antibodies among Outpatients and Healthcare Workers in Ehime, Japan",2022-05-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Ehime Prefecture,Toon,"""We conducted two-year seroprevalence surveys of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies among outpatients and healthcare workers (HCWs) at Ehime University Hospital.""",,2020-12-08,2020-12-11,Residual sera,All,Multiple groups,0.0,97.0,Primary Estimate,Positive for both assays (Roche and Abbott).,1000,0.0,,,True,,,,True,Simplified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG","Roche Diagnostics,Abbott Laboratories",CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Koichiro Suemori,Ehime University,Unity-Aligned,https://dx.doi.org/10.7883/yoken.JJID.2022.155,2022-10-06,2024-03-01,Unverified,suemori_two-year_2022,JPN
220531_Toon_EhimeUniversity_Outpatients_3rdSurvey_TwoAssays,220531_Toon_EhimeUniversity_Outpatients_3rdSurvey,"Two-Year Seroprevalence Surveys of SARS-CoV-2 Antibodies among Outpatients and Healthcare Workers in Ehime, Japan",2022-05-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Ehime Prefecture,Toon,"""We conducted two-year seroprevalence surveys of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies among outpatients and healthcare workers (HCWs) at Ehime University Hospital.""",,2021-07-10,2021-07-16,Residual sera,All,Multiple groups,0.0,94.0,Primary Estimate,Positive for both assays (Roche and Abbott).,1000,0.0,,,True,,,,True,Simplified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG","Roche Diagnostics,Abbott Laboratories",CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Koichiro Suemori,Ehime University,Unity-Aligned,https://dx.doi.org/10.7883/yoken.JJID.2022.155,2022-10-06,2024-03-01,Unverified,suemori_two-year_2022,JPN
220531_Toon_EhimeUniversity_Outpatients_4thSurvey_TwoAssays,220531_Toon_EhimeUniversity_Outpatients_4thSurvey,"Two-Year Seroprevalence Surveys of SARS-CoV-2 Antibodies among Outpatients and Healthcare Workers in Ehime, Japan",2022-05-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,Ehime Prefecture,Toon,"""We conducted two-year seroprevalence surveys of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies among outpatients and healthcare workers (HCWs) at Ehime University Hospital.""",,2021-12-07,2021-12-10,Residual sera,All,Multiple groups,0.0,94.0,Primary Estimate,Positive for both assays (Roche and Abbott).,1000,0.0,,,True,,,,True,Simplified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG","Roche Diagnostics,Abbott Laboratories",CLIA,Serum,"['IgG', 'TotalAntibody']",Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Koichiro Suemori,Ehime University,Unity-Aligned,https://dx.doi.org/10.7883/yoken.JJID.2022.155,2022-10-06,2024-03-01,Unverified,suemori_two-year_2022,JPN
220624_Shiga_ShigaUniversityofMedicalScience,220624_Shiga_ShigaUniversityofMedicalScience,"Serology suggests adequate safety measures to protect healthcare workers from COVID-19 in Shiga Prefecture, Japan",2022-06-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Japan,Shiga Prefecture,,HCW's from 9 public hospitals,,2021-02-15,2021-02-26,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1237,0.0178,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Abbott Architect SARS-CoV-2 IgG","Roche Diagnostics,Abbott Laboratories",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,No,,Yes,Yes,No,,Tokuchiro Chano,Shiga University of Medical Science,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0270334,2022-07-07,2024-03-01,Unverified,chano_serology_2022,JPN
20220707_Hiroshima_HiroshimaUniversity_Aug-Sep2020_Overall,20220707_Hiroshima_Hiroshima University_Aug-Sep2020,A longitudinal study of anti-SARS-CoV-2 antibody seroprevalence in a random sample of the general population in Hiroshima in 2020.,2022-07-07,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Japan,Chūgoku Region,"Hiroshima, Fukuyama, Higashi-Hiroshima, Miyoshi, and Kita-Hiroshima",Individuals were included based on the Basic Resident Register,Only adults over the age of 20 were included,2020-08-01,2020-09-30,Household and community samples,All,Multiple groups,20.0,,Primary Estimate,,3025,0.0003,0.0,0.001,True,,,,True,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Qualitative Elecsys Anti-SARS-CoV-2 Probe","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,GenScript,Roche Diagnostics",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,Yes,Yes,No,,Unclear,Yes,No,,Aya Sugiyama,Hiroshima University,Not Unity-Aligned,https://dx.doi.org/10.1265/ehpm.22-00016,2022-07-27,2024-03-01,Unverified,sugiyama_longitudinal_2022,JPN
20220707_Hiroshima_Hiroshima University_Jan-Feb2021_Overall,20220707_Hiroshima_Hiroshima University_Jan-Feb2021,A longitudinal study of anti-SARS-CoV-2 antibody seroprevalence in a random sample of the general population in Hiroshima in 2020.,2022-07-07,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Japan,Chūgoku Region,"Hiroshima, Fukuyama, Higashi-Hiroshima, Miyoshi, and Kita-Hiroshima",Individuals were included based on the Basic Resident Register,Only adults over the age of 20 were included,2021-01-01,2021-02-28,Household and community samples,All,Multiple groups,20.0,,Primary Estimate,,2351,0.003,0.0008,0.005200000000000001,True,,,,True,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Qualitative Elecsys Anti-SARS-CoV-2 Probe","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,GenScript,Roche Diagnostics",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,Yes,Yes,No,,Unclear,Yes,No,,Aya Sugiyama,Hiroshima University,Not Unity-Aligned,https://dx.doi.org/10.1265/ehpm.22-00016,2022-07-27,2024-03-01,Unverified,sugiyama_longitudinal_2022,JPN
20220707_Hiroshima_Hiroshima University_Oct-Nov2020_Overall,20220707_Hiroshima_Hiroshima University_Oct-Nov2020,A longitudinal study of anti-SARS-CoV-2 antibody seroprevalence in a random sample of the general population in Hiroshima in 2020.,2022-07-07,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Japan,Chūgoku Region,"Hiroshima, Fukuyama, Higashi-Hiroshima, Miyoshi, and Kita-Hiroshima",Individuals were included based on the Basic Resident Register,Only adults over the age of 20 were included,2020-10-01,2020-11-30,Household and community samples,All,Multiple groups,20.0,,Primary Estimate,,2396,0.0008,0.0,0.002,True,,,,True,Stratified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Qualitative Elecsys Anti-SARS-CoV-2 Probe","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,GenScript,Roche Diagnostics",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,Yes,Yes,No,,Unclear,Yes,No,,Aya Sugiyama,Hiroshima University,Not Unity-Aligned,https://dx.doi.org/10.1265/ehpm.22-00016,2022-07-27,2024-03-01,Unverified,sugiyama_longitudinal_2022,JPN
220712_Japan_UniversityofTokyo_0to9,220712_Japan_UniversityofTokyo_0to9,"Age-stratified seroprevalence of antibodies against SARS-CoV-2 in the pre- and post-vaccination era, February 2020-March 2022, Japan",2022-07-12,Preprint,Local,Repeated cross-sectional study,Japan,,Tokyo,"""The study subjects were patients who visited ... Japanese Red Cross Ashikaga Hospital, Keio University Hospital, National Hospital Organization Saitama Hospital, Eiju General Hospital, Yokohama City University Medical Center, Yokohama City University Hospital, Keiyu Hospital, or Zama Children􏱛s Clinic, Japan, between February 2020 and March 2022.""","""However, patients positive for SARS-CoV-2 nucleic acid test or antigen test were excluded.""",2020-01-01,2020-01-31,Hospital visitors,All,Children and Youth (0-17 years),0.0,9.0,Primary Estimate,,148,0.0,,,True,,,,True,Convenience,ELISA SARS-CoV-2 IgG Test System,Zeus,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.995,['High'],,No,No,No,,Yes,Yes,Yes,,Seiya Yamayoshi,University of Tokyo,Not Unity-Aligned,https://doi.org/10.1101/2022.07.11.22277481,2022-07-21,2024-03-01,Unverified,yamayoshi_age-stratified_2022,JPN
220712_Japan_UniversityofTokyo_10to19,220712_Japan_UniversityofTokyo_10to19,"Age-stratified seroprevalence of antibodies against SARS-CoV-2 in the pre- and post-vaccination era, February 2020-March 2022, Japan",2022-07-12,Preprint,Local,Repeated cross-sectional study,Japan,,Tokyo,"""The study subjects were patients who visited ... Japanese Red Cross Ashikaga Hospital, Keio University Hospital, National Hospital Organization Saitama Hospital, Eiju General Hospital, Yokohama City University Medical Center, Yokohama City University Hospital, Keiyu Hospital, or Zama Children􏱛s Clinic, Japan, between February 2020 and March 2022.""","""However, patients positive for SARS-CoV-2 nucleic acid test or antigen test were excluded.""",2020-01-01,2020-01-31,Hospital visitors,All,Children and Youth (0-17 years),10.0,19.0,Primary Estimate,,81,0.025,,,True,,,,True,Convenience,ELISA SARS-CoV-2 IgG Test System,Zeus,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.995,['High'],,No,No,No,,Yes,Yes,Yes,,Seiya Yamayoshi,University of Tokyo,Not Unity-Aligned,https://doi.org/10.1101/2022.07.11.22277481,2022-07-21,2024-03-01,Unverified,yamayoshi_age-stratified_2022,JPN
220712_Japan_UniversityofTokyo_20to29,220712_Japan_UniversityofTokyo_20to29,"Age-stratified seroprevalence of antibodies against SARS-CoV-2 in the pre- and post-vaccination era, February 2020-March 2022, Japan",2022-07-12,Preprint,Local,Repeated cross-sectional study,Japan,,Tokyo,"""The study subjects were patients who visited ... Japanese Red Cross Ashikaga Hospital, Keio University Hospital, National Hospital Organization Saitama Hospital, Eiju General Hospital, Yokohama City University Medical Center, Yokohama City University Hospital, Keiyu Hospital, or Zama Children􏱛s Clinic, Japan, between February 2020 and March 2022.""","""However, patients positive for SARS-CoV-2 nucleic acid test or antigen test were excluded.""",2020-01-01,2020-01-31,Hospital visitors,All,Adults (18-64 years),20.0,29.0,Primary Estimate,,134,0.08199999999999999,,,True,,,,True,Convenience,ELISA SARS-CoV-2 IgG Test System,Zeus,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.995,['High'],,No,No,No,,Yes,Yes,Yes,,Seiya Yamayoshi,University of Tokyo,Not Unity-Aligned,https://doi.org/10.1101/2022.07.11.22277481,2022-07-21,2024-03-01,Unverified,yamayoshi_age-stratified_2022,JPN
220712_Japan_UniversityofTokyo_30to39,220712_Japan_UniversityofTokyo_30to39,"Age-stratified seroprevalence of antibodies against SARS-CoV-2 in the pre- and post-vaccination era, February 2020-March 2022, Japan",2022-07-12,Preprint,Local,Repeated cross-sectional study,Japan,,Tokyo,"""The study subjects were patients who visited ... Japanese Red Cross Ashikaga Hospital, Keio University Hospital, National Hospital Organization Saitama Hospital, Eiju General Hospital, Yokohama City University Medical Center, Yokohama City University Hospital, Keiyu Hospital, or Zama Children􏱛s Clinic, Japan, between February 2020 and March 2022.""","""However, patients positive for SARS-CoV-2 nucleic acid test or antigen test were excluded.""",2020-01-01,2020-01-31,Hospital visitors,All,Adults (18-64 years),30.0,39.0,Primary Estimate,,244,0.057,,,True,,,,True,Convenience,ELISA SARS-CoV-2 IgG Test System,Zeus,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.995,['High'],,No,No,No,,Yes,Yes,Yes,,Seiya Yamayoshi,University of Tokyo,Not Unity-Aligned,https://doi.org/10.1101/2022.07.11.22277481,2022-07-21,2024-03-01,Unverified,yamayoshi_age-stratified_2022,JPN
220712_Japan_UniversityofTokyo_40to49,220712_Japan_UniversityofTokyo_40to49,"Age-stratified seroprevalence of antibodies against SARS-CoV-2 in the pre- and post-vaccination era, February 2020-March 2022, Japan",2022-07-12,Preprint,Local,Repeated cross-sectional study,Japan,,Tokyo,"""The study subjects were patients who visited ... Japanese Red Cross Ashikaga Hospital, Keio University Hospital, National Hospital Organization Saitama Hospital, Eiju General Hospital, Yokohama City University Medical Center, Yokohama City University Hospital, Keiyu Hospital, or Zama Children􏱛s Clinic, Japan, between February 2020 and March 2022.""","""However, patients positive for SARS-CoV-2 nucleic acid test or antigen test were excluded.""",2020-01-01,2020-01-31,Hospital visitors,All,Adults (18-64 years),40.0,49.0,Primary Estimate,,213,0.027999999999999997,,,True,,,,True,Convenience,ELISA SARS-CoV-2 IgG Test System,Zeus,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.995,['High'],,No,No,No,,Yes,Yes,Yes,,Seiya Yamayoshi,University of Tokyo,Not Unity-Aligned,https://doi.org/10.1101/2022.07.11.22277481,2022-07-21,2024-03-01,Unverified,yamayoshi_age-stratified_2022,JPN
220712_Japan_UniversityofTokyo_50to59,220712_Japan_UniversityofTokyo_50to59,"Age-stratified seroprevalence of antibodies against SARS-CoV-2 in the pre- and post-vaccination era, February 2020-March 2022, Japan",2022-07-12,Preprint,Local,Repeated cross-sectional study,Japan,,Tokyo,"""The study subjects were patients who visited ... Japanese Red Cross Ashikaga Hospital, Keio University Hospital, National Hospital Organization Saitama Hospital, Eiju General Hospital, Yokohama City University Medical Center, Yokohama City University Hospital, Keiyu Hospital, or Zama Children􏱛s Clinic, Japan, between February 2020 and March 2022.""","""However, patients positive for SARS-CoV-2 nucleic acid test or antigen test were excluded.""",2020-01-01,2020-01-31,Hospital visitors,All,Adults (18-64 years),50.0,59.0,Primary Estimate,,298,0.02,,,True,,,,True,Convenience,ELISA SARS-CoV-2 IgG Test System,Zeus,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.995,['High'],,No,No,No,,Yes,Yes,Yes,,Seiya Yamayoshi,University of Tokyo,Not Unity-Aligned,https://doi.org/10.1101/2022.07.11.22277481,2022-07-21,2024-03-01,Unverified,yamayoshi_age-stratified_2022,JPN
220712_Japan_UniversityofTokyo_60to69,220712_Japan_UniversityofTokyo_60to69,"Age-stratified seroprevalence of antibodies against SARS-CoV-2 in the pre- and post-vaccination era, February 2020-March 2022, Japan",2022-07-12,Preprint,Local,Repeated cross-sectional study,Japan,,Tokyo,"""The study subjects were patients who visited ... Japanese Red Cross Ashikaga Hospital, Keio University Hospital, National Hospital Organization Saitama Hospital, Eiju General Hospital, Yokohama City University Medical Center, Yokohama City University Hospital, Keiyu Hospital, or Zama Children􏱛s Clinic, Japan, between February 2020 and March 2022.""","""However, patients positive for SARS-CoV-2 nucleic acid test or antigen test were excluded.""",2020-01-01,2020-01-31,Hospital visitors,All,Multiple groups,60.0,69.0,Primary Estimate,,358,0.042,,,True,,,,True,Convenience,ELISA SARS-CoV-2 IgG Test System,Zeus,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.995,['High'],,No,No,No,,Yes,Yes,Yes,,Seiya Yamayoshi,University of Tokyo,Not Unity-Aligned,https://doi.org/10.1101/2022.07.11.22277481,2022-07-21,2024-03-01,Unverified,yamayoshi_age-stratified_2022,JPN
220712_Japan_UniversityofTokyo_70to79,220712_Japan_UniversityofTokyo_70to79,"Age-stratified seroprevalence of antibodies against SARS-CoV-2 in the pre- and post-vaccination era, February 2020-March 2022, Japan",2022-07-12,Preprint,Local,Repeated cross-sectional study,Japan,,Tokyo,"""The study subjects were patients who visited ... Japanese Red Cross Ashikaga Hospital, Keio University Hospital, National Hospital Organization Saitama Hospital, Eiju General Hospital, Yokohama City University Medical Center, Yokohama City University Hospital, Keiyu Hospital, or Zama Children􏱛s Clinic, Japan, between February 2020 and March 2022.""","""However, patients positive for SARS-CoV-2 nucleic acid test or antigen test were excluded.""",2020-01-01,2020-01-31,Hospital visitors,All,Seniors (65+ years),70.0,79.0,Primary Estimate,,554,0.04,,,True,,,,True,Convenience,ELISA SARS-CoV-2 IgG Test System,Zeus,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.995,['High'],,No,No,No,,Yes,Yes,Yes,,Seiya Yamayoshi,University of Tokyo,Not Unity-Aligned,https://doi.org/10.1101/2022.07.11.22277481,2022-07-21,2024-03-01,Unverified,yamayoshi_age-stratified_2022,JPN
220712_Japan_UniversityofTokyo_80plus,220712_Japan_UniversityofTokyo_80plus,"Age-stratified seroprevalence of antibodies against SARS-CoV-2 in the pre- and post-vaccination era, February 2020-March 2022, Japan",2022-07-12,Preprint,Local,Repeated cross-sectional study,Japan,,Tokyo,"""The study subjects were patients who visited ... Japanese Red Cross Ashikaga Hospital, Keio University Hospital, National Hospital Organization Saitama Hospital, Eiju General Hospital, Yokohama City University Medical Center, Yokohama City University Hospital, Keiyu Hospital, or Zama Children􏱛s Clinic, Japan, between February 2020 and March 2022.""","""However, patients positive for SARS-CoV-2 nucleic acid test or antigen test were excluded.""",2020-01-01,2020-01-31,Hospital visitors,All,Seniors (65+ years),80.0,,Primary Estimate,,355,0.037000000000000005,,,True,,,,True,Convenience,ELISA SARS-CoV-2 IgG Test System,Zeus,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.995,['High'],,No,No,No,,Yes,Yes,Yes,,Seiya Yamayoshi,University of Tokyo,Not Unity-Aligned,https://doi.org/10.1101/2022.07.11.22277481,2022-07-22,2024-03-01,Unverified,yamayoshi_age-stratified_2022,JPN
210126_Japan_ChubuUniversity,210126_Japan_ChubuUniversity,Prevalence of SARS-CoV-2 antibodies among university athletic club members: A cross-sectional survey.,2022-08-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,,,Members of two university sports clubs at a private university in Japan. ,Students previously known and tested to be infected by COVID19. ,2021-01-26,2021-01-26,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,,129,0.039,,,True,,,,True,Convenience,SARS-CoV-2 Rapid Antibody Test,Roche Diagnostics,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9903000000000001,0.9865,['High'],,No,No,Yes,,Yes,Yes,Yes,,Yukihiro Mori,Chubu University,Not Unity-Aligned,https://dx.doi.org/10.5582/ddt.2022.01048,2022-09-12,2024-03-01,Unverified,mori_prevalence_2022,JPN
221026_Kyoto_KyotoUniversity_Overall,221026_Kyoto_KyotoUniversity,Efficacy and safety of the SARS-CoV-2 mRNA vaccine in lung transplant recipients: a possible trigger of rejection,2022-10-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,,Kyoto,"""Lung transplant recipients managed at Kyoto University, who were ≥ 18 years age, and who underwent transplantation over one year previously were eligible for inclusion in this observational prospective cohort study.""

""Serum samples were collected shortly before and three weeks after the initial dose, and four weeks after the second dose."" [Only baseline is extracted here].",,2021-06-15,2021-10-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,,Primary Estimate,,18,0.0,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,Validated by manufacturers,1.0,0.998,['High'],,No,No,Yes,,Yes,Yes,Yes,,Yasufumi Goda,Kyoto University,Not Unity-Aligned,https://dx.doi.org/10.1007/s11748-022-01887-3,2022-11-03,2024-03-01,Unverified,goda_efficacy_2022,JPN
221121_Niigata_NiigataUniversity_Residents_AntiS,221121_Niigata_NiigataUniversity_Residents,"Assessing the Pre-Vaccination Anti-SARS-CoV-2 IgG Seroprevalence among Residents and Staff in Nursing Home in Niigata, Japan, November 2020",2022-11-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,,Niigata,"“remaining elderly residents and staff approximately, six
months after the outbreak in a nursing home in Niigata, Japan""",”excluding the two who were unable to have serum samples collected“,2021-04-01,2021-04-30,Assisted living and long-term care facilities,All,Seniors (65+ years),,,Primary Estimate,overall anti-S,39,0.41000000000000003,,,True,,,,True,Unclear,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,"CLIA, CMIA",,IgG,Spike,,,,['High'],,Unclear,No,Yes,,Yes,Yes,Yes,,Keita Wagatsuma,Niigata University,Not Unity-Aligned,https://dx.doi.org/10.3390/v14112581,2022-12-14,2024-03-01,Unverified,wagatsuma_assessing_2022,JPN
221121_Niigata_NiigataUniversity_Staff_AntiS,221121_Niigata_NiigataUniversity_Staff,"Assessing the Pre-Vaccination Anti-SARS-CoV-2 IgG Seroprevalence among Residents and Staff in Nursing Home in Niigata, Japan, November 2020",2022-11-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,,Niigata,"“remaining elderly residents and staff approximately, six
months after the outbreak in a nursing home in Niigata, Japan""",”excluding the two who were unable to have serum samples collected“,2021-04-01,2021-04-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,overall anti-S,62,0.129,,,True,,,,True,Unclear,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,"CLIA, CMIA",,IgG,Spike,,,,['High'],,Unclear,No,Yes,,Yes,Yes,Yes,,Keita Wagatsuma,Niigata University,Not Unity-Aligned,https://dx.doi.org/10.3390/v14112581,2022-12-14,2024-03-01,Unverified,wagatsuma_assessing_2022,JPN
221130_Japan_MinistryofHealthLabourandWelfare_Overall,221130_Japan_MinistryofHealthLabourandWelfare,"Fact-finding survey of the antibody possession rate of the new coronavirus using residual blood of test specimens at the time of blood donation (Preliminary results, summary)",2022-11-30,Institutional Report,National,Cross-sectional survey ,Japan,,,blood donors who visited the blood donation room of the Japanese Red Cross Society,"Those who have been diagnosed with a new coronavirus infection or have tested positive for the new coronavirus, and within 4 weeks after the disappearance of symptoms (from the date of specimen collection of the positive test if no symptoms). Those who are suspected of having a new coronavirus infection, including acute respiratory symptoms such as fever, cough, and dyspnea, or who are aware of discomfort in taste and smell, within 2 weeks from the date of symptom appearance and 3 days from the disappearance of symptoms. Those who are within 2 weeks from the date of the last contact with a person infected with the new coronavirus",2022-11-06,2022-11-13,Blood donors,All,Multiple groups,16.0,69.0,Primary Estimate,,8260,0.265,0.256,0.275,True,,,,True,Simplified probability,Not reported/ Unable to specify,,,,[],Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,No,,Unclear,Yes,No,,"Ministry of Health, Labour and Welfare of Japan",Ministry of Health Labour and Welfare,Not Unity-Aligned,https://www.mhlw.go.jp/content/10900000/001018624.pdf,2023-01-09,2023-03-19,Unverified,suzuki_fact-finding_2023,JPN
230201_Japan_NationalInstituteofInfectiousDiseases_February2022_AntiN_PopAdj,230201_Japan_NationalInstituteofInfectiousDiseases_February2022,National seroepidemiological study of COVID-19 after the initial rollout of vaccines: Before and at the peak of the Omicron-dominant period in Japan.,2023-02-01,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Japan,"Miyagi, Tokyo, Aichi, Osaka, and Fukuoka prefectures",,"Residents of Miyagi, Tokyo, Aichi, Osaka, and Fukuoka prefecture, >20 years old ",,2022-02-15,2022-03-15,Household and community samples,All,Multiple groups,20.0,,Primary Estimate,,8147,0.014,0.01,0.021,True,,True,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"IgG, IgM, IgA",Nucleocapsid(N-protein),,0.994,0.981,[{'error': '#ERROR!'}],Yes,No,{'error': '#ERROR!'},Yes,No,{'error': '#ERROR!'},Yes,{'error': '#ERROR!'},Unclear,Takeshi Arashiro, National Institute of Infectious Diseases,{'error': '#ERROR!'},https://dx.doi.org/10.1111/irv.13094,2024-04-02,2024-04-02,Verified,arashiro_national_2023,JPN
230201_Japan_NationalInstituteofInfectiousDiseases_February2022_AntiS_PopAdj,230201_Japan_NationalInstituteofInfectiousDiseases_February2022,National seroepidemiological study of COVID-19 after the initial rollout of vaccines: Before and at the peak of the Omicron-dominant period in Japan.,2023-02-01,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Japan,"Miyagi, Tokyo, Aichi, Osaka, and Fukuoka prefectures",,"Residents of Miyagi, Tokyo, Aichi, Osaka, and Fukuoka prefecture, >20 years old ",,2022-02-15,2022-03-15,Household and community samples,All,Multiple groups,20.0,,Primary Estimate,,8147,0.967,0.958,0.975,True,,True,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,"IgG, IgM, IgA",Spike,,0.977,1.0,[{'error': '#ERROR!'}],Yes,No,{'error': '#ERROR!'},Yes,No,{'error': '#ERROR!'},Yes,{'error': '#ERROR!'},Unclear,Takeshi Arashiro, National Institute of Infectious Diseases,{'error': '#ERROR!'},https://dx.doi.org/10.1111/irv.13094,2024-04-02,2024-04-02,Verified,arashiro_national_2023,JPN
230201_Japan_NationalInstituteofInfectiousDiseases_February2022_AntiS_Unadj,230201_Japan_NationalInstituteofInfectiousDiseases_February2022,National seroepidemiological study of COVID-19 after the initial rollout of vaccines: Before and at the peak of the Omicron-dominant period in Japan.,2023-02-01,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Japan,"Miyagi, Tokyo, Aichi, Osaka, and Fukuoka prefectures",,"Residents of Miyagi, Tokyo, Aichi, Osaka, and Fukuoka prefecture, >20 years old ",,2022-02-15,2022-03-15,Household and community samples,All,Multiple groups,20.0,,Analysis,,8147,0.966,0.962,0.976,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,"IgG, IgM, IgA",Spike,,0.977,1.0,[{'error': '#ERROR!'}],Yes,No,{'error': '#ERROR!'},Yes,No,{'error': '#ERROR!'},Yes,{'error': '#ERROR!'},Unclear,Takeshi Arashiro, National Institute of Infectious Diseases,{'error': '#ERROR!'},https://dx.doi.org/10.1111/irv.13094,2023-04-06,2024-04-02,Verified,arashiro_national_2023,JPN
230201_Japan_NationalInstituteofInfectiousDiseases_February2022_AntiN_Unadj,230201_Japan_NationalInstituteofInfectiousDiseases_February2022,National seroepidemiological study of COVID-19 after the initial rollout of vaccines: Before and at the peak of the Omicron-dominant period in Japan.,2023-02-01,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Japan,"Miyagi, Tokyo, Aichi, Osaka, and Fukuoka prefectures",,"Residents of Miyagi, Tokyo, Aichi, Osaka, and Fukuoka prefecture, >20 years old ",,2022-02-15,2022-03-15,Household and community samples,All,Multiple groups,20.0,,Analysis,,8147,0.015,0.01,0.022,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"IgG, IgM, IgA",Nucleocapsid(N-protein),,0.994,0.981,[{'error': '#ERROR!'}],Yes,No,{'error': '#ERROR!'},Yes,No,{'error': '#ERROR!'},Yes,{'error': '#ERROR!'},Unclear,Takeshi Arashiro, National Institute of Infectious Diseases,{'error': '#ERROR!'},https://dx.doi.org/10.1111/irv.13094,2024-04-02,2024-04-02,Verified,arashiro_national_2023,JPN
230228_Japan_NationalInstituteofInfectiousDiseases,230228_Japan_NationalInstituteofInfectiousDiseases,Specific COVID-19 risk behaviors and the preventive effect of personal protective equipment among healthcare workers in Japan.,2023-02-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Japan,,,"""Participants were recruited from hospitals where COVID-19 outbreaks occurred between March and August 2020 in Japan (15). Not only front-line healthcare workers but also affiliated workers such as cleaning staff
were included.""","""As we focused on the risk in nosocomial settings, participants with contact histories outside their facilities were excluded from the analyses.""",2020-08-03,2020-11-13,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,1899,0.085,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Reiko Shimbashi,National Institute of Infectious Diseases,Not Unity-Aligned,https://dx.doi.org/10.35772/ghm.2022.01060,2023-03-21,2024-03-01,Unverified,shimbashi_specific_2023,JPN
230308_Tokyo_NationalCenterforGlobalHealthandMedicine_4th,230308_Tokyo_NationalCenterforGlobalHealthandMedicine_December2021,Cumulative and undiagnosed SARS-CoV-2 infection among the staff of a medical research center in Tokyo after the emergence of variants,2023-03-08,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,,Tokyo,"staffs worked at of National Center for Global Health and Medicine, Toyama center (located in central Tokyo, approximately 2500 staff) or three in Kohnodai areas (located in western Chiba, approximately 700 staff).",,2021-12-01,2021-12-31,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,4th survey,943,0.051,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG","Roche Diagnostics,Abbott Laboratories",CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Tetsuya Mizoue,National Center for Global Health and Medicine,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268823000353,2023-03-31,2024-03-01,Unverified,mizoue_cumulative_2023,JPN
230308_Tokyo_NationalCenterforGlobalHealthandMedicine_7th,230308_Tokyo_NationalCenterforGlobalHealthandMedicine_December2022,Cumulative and undiagnosed SARS-CoV-2 infection among the staff of a medical research center in Tokyo after the emergence of variants,2023-03-08,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,,Tokyo,"staffs worked at of National Center for Global Health and Medicine, Toyama center (located in central Tokyo, approximately 2500 staff) or three in Kohnodai areas (located in western Chiba, approximately 700 staff).",,2022-12-01,2022-12-31,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,7th survey,1639,0.369,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG","Roche Diagnostics,Abbott Laboratories",CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Tetsuya Mizoue,National Center for Global Health and Medicine,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268823000353,2023-03-31,2024-03-01,Unverified,mizoue_cumulative_2023,JPN
230308_Tokyo_NationalCenterforGlobalHealthandMedicine_3rd,230308_Tokyo_NationalCenterforGlobalHealthandMedicine_June2021,Cumulative and undiagnosed SARS-CoV-2 infection among the staff of a medical research center in Tokyo after the emergence of variants,2023-03-08,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,,Tokyo,"staffs worked at of National Center for Global Health and Medicine, Toyama center (located in central Tokyo, approximately 2500 staff) or three in Kohnodai areas (located in western Chiba, approximately 700 staff).",,2021-06-01,2021-06-30,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,3rd survey,2770,0.019,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG","Roche Diagnostics,Abbott Laboratories",CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Tetsuya Mizoue,National Center for Global Health and Medicine,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268823000353,2023-03-31,2024-03-01,Unverified,mizoue_cumulative_2023,JPN
230308_Tokyo_NationalCenterforGlobalHealthandMedicine_6th,230308_Tokyo_NationalCenterforGlobalHealthandMedicine_June2022,Cumulative and undiagnosed SARS-CoV-2 infection among the staff of a medical research center in Tokyo after the emergence of variants,2023-03-08,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,,Tokyo,"staffs worked at of National Center for Global Health and Medicine, Toyama center (located in central Tokyo, approximately 2500 staff) or three in Kohnodai areas (located in western Chiba, approximately 700 staff).",,2022-06-01,2022-06-30,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,6th survey,2653,0.164,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG","Roche Diagnostics,Abbott Laboratories",CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Tetsuya Mizoue,National Center for Global Health and Medicine,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268823000353,2023-03-31,2024-03-01,Unverified,mizoue_cumulative_2023,JPN
230308_Tokyo_NationalCenterforGlobalHealthandMedicine_5th,230308_Tokyo_NationalCenterforGlobalHealthandMedicine_March2022,Cumulative and undiagnosed SARS-CoV-2 infection among the staff of a medical research center in Tokyo after the emergence of variants,2023-03-08,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Japan,,Tokyo,"staffs worked at of National Center for Global Health and Medicine, Toyama center (located in central Tokyo, approximately 2500 staff) or three in Kohnodai areas (located in western Chiba, approximately 700 staff).",,2022-03-01,2022-03-31,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,5th survey,1517,0.08,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG","Roche Diagnostics,Abbott Laboratories",CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Tetsuya Mizoue,National Center for Global Health and Medicine,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268823000353,2023-03-31,2024-03-01,Unverified,mizoue_cumulative_2023,JPN
230327_Tokyo_JuntendoUniversityFacultyofMedicine_Overall,230327_Tokyo_JuntendoUniversityFacultyofMedicine,Increased SARS-CoV-2 seroprevalence and spread of infection without awareness among healthcare workers through 2020-2022 in a Japanese medical center.,2023-03-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Japan,,Tokyo,"""In this cohort study, HCWs in Juntendo University Hospital (JUH) who participated in annual health checkups in 2022 at the university were recruited and gave consent for serologi- cal analysis. HCWs included medical doctors, nurses, laboratory personnel, paramedics, administrative staff, researchers, and others. ""","""Those with insufficient amounts of serum samples to measure N-specific antibody titers were excluded.""",2022-06-08,2022-06-20,Health care workers and caregivers,All,Adults (18-64 years),20.0,,Primary Estimate,,3788,0.177,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Missing'],,No,Yes,Yes,,Yes,Yes,Yes,,Rie Kanamori,Juntendo University Faculty of Medicine,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-023-32193-4,2023-05-03,2024-03-01,Unverified,kanamoriIncreasedSARSCoV2Seroprevalence2023,JPN
230624_Japan_MountSinai,230624_Japan_MountSinai,Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium,2023-06-24,Journal Article (Peer-Reviewed),National,Prospective cohort,Japan,,,"Our initial core objective was to include all adult patients with IBD who entered the infusion center for vedolizumab or infliximab (originator or biosimilars), as well as intravenous ustekinumab induction, regardless of history of known COVID-19 infection, and without any exclusion criteria.",None,2020-05-15,2021-12-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,339,0.0295,,,True,,,,True,Convenience,SARS-CoV-2 Rapid Antibody Test,Roche Diagnostics,LFIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Yes,Yes,Yes,,Serre-Yu Wong,Mount Sinai,Not Unity-Aligned,https://dx.doi.org/10.1093/ibd/izad097,2023-08-02,2024-03-01,Unverified,wong_geography_2023,JPN
230717_Japan_JapaneseRedCrossSociety_overall_adj,230717_Japan_JapaneseRedCrossSociety,"Infection-Induced SARS-CoV-2 Seroprevalence among Blood Donors, Japan, 2022.",2023-07-17,Institutional Report,National,Cross-sectional survey ,Japan,,,"""Participants were blood donors to the Japanese Red Cross Society during November 6–13, 2022 (Figure 1, panel A). To be included, participants had to be 16–69 years of age at the time of donation and have provided whole blood or blood components. ""","""Persons were not permitted to donate blood if they had been diagnosed with or tested positive for COVID-19 and were <4 weeks after symptom resolution or, for as- ymptomatic persons, sample collection; if they had acute COVID-19–related signs or symptoms (e.g., fever, cough, breathing difficulty) or experienced al- tered senses of taste or smell during the period be- tween 2 weeks after symptom onset and 3 days after resolution; or if they were close contacts of confirmed COVID-19 case-patients and <2 weeks after most re- cent contact.""",2022-11-06,2022-11-13,Blood donors,All,Multiple groups,16.0,69.0,Primary Estimate,,8260,0.286,0.276,0.296,True,,True,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,,,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Ryo Kinoshita,Japanese Red Cross Society,Not Unity-Aligned,"https://wwwnc.cdc.gov/eid/article/29/9/23-0365_article#:~:text=A%20nationwide%20survey%20of%20SARS,CI%2027.6%25%E2%80%9329.6%25 ",2023-08-23,2023-08-25,Unverified,kinoshitaInfectionInducedSARSCoV2Seroprevalence,JPN
200508_Jersey_StatisticsJersey_Round1_GenPopAdj_TestAdj,200508_Jersey_StatisticsJersey_Round1,SARS-CoV-2: Prevalence of antibodies in Jersey - Preliminary Analysis,2020-05-08,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Jersey,Jersey,,A list of 700 private addresses were randomly drawn from the Jersey Land and Property Register (JLPR) which formed the basis of the sample for this study; in respect of the adult resident population living in private households,"The sample drawn excluded communal establishments (such as care homes), commercial properties and a small number of other properties known not to be residential in nature.

The survey did not perform testing on anyone aged under 16 years and did not include residents of communal establishments (such as care homes).",2020-04-29,2020-05-05,Household and community samples,All,Multiple groups,16.0,,Analysis,Sampling error (population adjustment) and sensitivity adjustment (test adjustment),855,0.031000000000000003,0.018000000000000002,0.044000000000000004,True,True,True,,,Stratified probability,COVID-19 IgG/IgM Rapid Test Cassette,Healgen,LFIA,Whole Blood,"['IgG', 'IgM']",,,0.833,1.0,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Yes,Statistics Jersey,Government of Jersey,Unity-Aligned,https://www.gov.je/SiteCollectionDocuments/Government%20and%20administration/R%20Prevalence%20of%20antibodies%202020508%20SJ.pdf,2020-06-02,2023-07-04,Verified,statistics_jersey_sars-cov-2_2020-3,JEY
200508_Jersey_StatisticsJersey_Round1_GenPopAdj_TestUnAdj,200508_Jersey_StatisticsJersey_Round1,SARS-CoV-2: Prevalence of antibodies in Jersey - Preliminary Analysis,2020-05-08,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Jersey,Jersey,,A list of 700 private addresses were randomly drawn from the Jersey Land and Property Register (JLPR) which formed the basis of the sample for this study; in respect of the adult resident population living in private households,"The sample drawn excluded communal establishments (such as care homes), commercial properties and a small number of other properties known not to be residential in nature.

The survey did not perform testing on anyone aged under 16 years and did not include residents of communal establishments (such as care homes).",2020-04-29,2020-05-05,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,Adjusted population; no test adjustment,855,0.026000000000000002,0.013999999999999999,0.038,,,True,,True,Stratified probability,COVID-19 IgG/IgM Rapid Test Cassette,Healgen,LFIA,Whole Blood,"['IgG', 'IgM']",,,0.833,1.0,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Yes,Statistics Jersey,Government of Jersey,Unity-Aligned,https://www.gov.je/SiteCollectionDocuments/Government%20and%20administration/R%20Prevalence%20of%20antibodies%202020508%20SJ.pdf,2020-07-18,2024-03-01,Verified,statistics_jersey_sars-cov-2_2020-3,JEY
200508_Jersey_StatisticsJersey__Round1_GenPopUnAdj_TestUnAdj,200508_Jersey_StatisticsJersey_Round1,SARS-CoV-2: Prevalence of antibodies in Jersey - Preliminary Analysis,2020-05-08,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Jersey,Jersey,,A list of 700 private addresses were randomly drawn from the Jersey Land and Property Register (JLPR) which formed the basis of the sample for this study; in respect of the adult resident population living in private households,"The sample drawn excluded communal establishments (such as care homes), commercial properties and a small number of other properties known not to be residential in nature.

The survey did not perform testing on anyone aged under 16 years and did not include residents of communal establishments (such as care homes).",2020-04-29,2020-05-05,Household and community samples,All,Multiple groups,16.0,,Analysis,"Unadjusted; ""observed prevalence""",855,0.028999999999999998,,,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test Cassette,Healgen,LFIA,Whole Blood,"['IgG', 'IgM']",,,0.833,1.0,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Yes,Statistics Jersey,Government of Jersey,Unity-Aligned,https://www.gov.je/SiteCollectionDocuments/Government%20and%20administration/R%20Prevalence%20of%20antibodies%202020508%20SJ.pdf,2020-07-18,2024-03-01,Verified,statistics_jersey_sars-cov-2_2020-3,JEY
200520_Jersey_JerseyStatistics_Round2_GenPop_TestAdj,200520_Jersey_JerseyStatistics_Round2,SARS-CoV-2: Prevalence of antibodies in Jersey - Community survey – round 2,2020-06-09,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Jersey,Jersey,,"Adult residents living in private households, above the age of 16.","Under 16 years, or residents of communal establishments, such as care homes.",2020-05-15,2020-05-27,Household and community samples,All,Multiple groups,16.0,,Analysis,Adjusted: test,1062,0.042,0.028999999999999998,0.055,True,True,,,,Stratified probability,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,0.9,0.9939,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Statistics Jersey,Statistics Jersey,Unity-Aligned,https://www.gov.je/SiteCollectionDocuments/Government%20and%20administration/R%20Prevalence%20of%20antibodies%2020200609%20SJ.pdf,2020-07-25,2023-07-04,Verified,statistics_jersey_sars-cov-2_2020-2,JEY
200520_Jersey_JerseyStatistics_Round2_16-34,200520_Jersey_JerseyStatistics_Round2,SARS-CoV-2: Prevalence of antibodies in Jersey - Community survey – round 2,2020-06-09,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Jersey,Jersey,,"Adult residents living in private households, above the age of 16.","Under 16 years, or residents of communal establishments, such as care homes.",2020-05-15,2020-05-27,Household and community samples,All,Adults (18-64 years),16.0,34.0,Age,16-34,247,0.043,,,,,,,,Stratified probability,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,0.9,0.9939,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Statistics Jersey,Statistics Jersey,Unity-Aligned,https://www.gov.je/SiteCollectionDocuments/Government%20and%20administration/R%20Prevalence%20of%20antibodies%2020200609%20SJ.pdf,2020-07-25,2024-03-01,Verified,statistics_jersey_sars-cov-2_2020-2,JEY
200520_Jersey_JerseyStatistics_Round2_65+,200520_Jersey_JerseyStatistics_Round2,SARS-CoV-2: Prevalence of antibodies in Jersey - Community survey – round 2,2020-06-09,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Jersey,Jersey,,"Adult residents living in private households, above the age of 16.","Under 16 years, or residents of communal establishments, such as care homes.",2020-05-15,2020-05-27,Household and community samples,All,Seniors (65+ years),65.0,,Age,>=64,47,0.067,,,,,,,,Stratified probability,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,0.9,0.9939,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Statistics Jersey,Statistics Jersey,Unity-Aligned,https://www.gov.je/SiteCollectionDocuments/Government%20and%20administration/R%20Prevalence%20of%20antibodies%2020200609%20SJ.pdf,2020-07-25,2024-03-01,Verified,statistics_jersey_sars-cov-2_2020-2,JEY
200520_Jersey_JerseyStatistics_Round2_Females,200520_Jersey_JerseyStatistics_Round2,SARS-CoV-2: Prevalence of antibodies in Jersey - Community survey – round 2,2020-06-09,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Jersey,Jersey,,"Adult residents living in private households, above the age of 16.","Under 16 years, or residents of communal establishments, such as care homes.",2020-05-15,2020-05-27,Household and community samples,Female,Multiple groups,16.0,,Sex/Gender,Female,586,0.033,,,,,,,,Stratified probability,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,0.9,0.9939,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Statistics Jersey,Statistics Jersey,Unity-Aligned,https://www.gov.je/SiteCollectionDocuments/Government%20and%20administration/R%20Prevalence%20of%20antibodies%2020200609%20SJ.pdf,2020-07-25,2024-03-01,Verified,statistics_jersey_sars-cov-2_2020-2,JEY
200520_Jersey_JerseyStatistics_Round2_GenPop_TestUnAdjPopAdj,200520_Jersey_JerseyStatistics_Round2,SARS-CoV-2: Prevalence of antibodies in Jersey - Community survey – round 2,2020-06-09,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Jersey,Jersey,,"Adult residents living in private households, above the age of 16.","Under 16 years, or residents of communal establishments, such as care homes.",2020-05-15,2020-05-27,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,,1062,0.044000000000000004,0.031000000000000003,0.057,,,True,True,True,Stratified probability,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,0.9,0.9939,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Statistics Jersey,Statistics Jersey,Unity-Aligned,https://www.gov.je/SiteCollectionDocuments/Government%20and%20administration/R%20Prevalence%20of%20antibodies%2020200609%20SJ.pdf,2020-07-25,2024-03-01,Verified,statistics_jersey_sars-cov-2_2020-2,JEY
200520_Jersey_JerseyStatistics_Round2_55-64,200520_Jersey_JerseyStatistics_Round2,SARS-CoV-2: Prevalence of antibodies in Jersey - Community survey – round 2,2020-06-09,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Jersey,Jersey,,"Adult residents living in private households, above the age of 16.","Under 16 years, or residents of communal establishments, such as care homes.",2020-05-15,2020-05-27,Household and community samples,All,Adults (18-64 years),55.0,64.0,Age,55-64,211,0.044000000000000004,,,,,,,,Stratified probability,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,0.9,0.9939,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Statistics Jersey,Statistics Jersey,Unity-Aligned,https://www.gov.je/SiteCollectionDocuments/Government%20and%20administration/R%20Prevalence%20of%20antibodies%2020200609%20SJ.pdf,2020-07-25,2024-03-01,Verified,statistics_jersey_sars-cov-2_2020-2,JEY
200520_Jersey_JerseyStatistics_Round2_GenPop_PopUnadjTestUnadj,200520_Jersey_JerseyStatistics_Round2,SARS-CoV-2: Prevalence of antibodies in Jersey - Community survey – round 2,2020-06-09,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Jersey,Jersey,,"Adult residents living in private households, above the age of 16.","Under 16 years, or residents of communal establishments, such as care homes.",2020-05-15,2020-05-27,Household and community samples,All,Multiple groups,16.0,,Analysis,Unadjusted,1062,0.042,,,,,,,,Stratified probability,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,0.9,0.9939,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Statistics Jersey,Statistics Jersey,Unity-Aligned,https://www.gov.je/SiteCollectionDocuments/Government%20and%20administration/R%20Prevalence%20of%20antibodies%2020200609%20SJ.pdf,2020-07-29,2024-03-01,Verified,statistics_jersey_sars-cov-2_2020-2,JEY
200520_Jersey_JerseyStatistics_Round2_35-44,200520_Jersey_JerseyStatistics_Round2,SARS-CoV-2: Prevalence of antibodies in Jersey - Community survey – round 2,2020-06-09,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Jersey,Jersey,,"Adult residents living in private households, above the age of 16.","Under 16 years, or residents of communal establishments, such as care homes.",2020-05-15,2020-05-27,Household and community samples,All,Adults (18-64 years),35.0,44.0,Age,35-44,168,0.003,,,,,,,,Stratified probability,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,0.9,0.9939,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Statistics Jersey,Statistics Jersey,Unity-Aligned,https://www.gov.je/SiteCollectionDocuments/Government%20and%20administration/R%20Prevalence%20of%20antibodies%2020200609%20SJ.pdf,2020-07-25,2024-03-01,Verified,statistics_jersey_sars-cov-2_2020-2,JEY
200520_Jersey_JerseyStatistics_Round2_Males,200520_Jersey_JerseyStatistics_Round2,SARS-CoV-2: Prevalence of antibodies in Jersey - Community survey – round 2,2020-06-09,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Jersey,Jersey,,"Adult residents living in private households, above the age of 16.","Under 16 years, or residents of communal establishments, such as care homes.",2020-05-15,2020-05-27,Household and community samples,Male,Multiple groups,16.0,,Sex/Gender,Male,476,0.051,,,,,,,,Stratified probability,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,0.9,0.9939,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Statistics Jersey,Statistics Jersey,Unity-Aligned,https://www.gov.je/SiteCollectionDocuments/Government%20and%20administration/R%20Prevalence%20of%20antibodies%2020200609%20SJ.pdf,2020-07-25,2024-03-01,Verified,statistics_jersey_sars-cov-2_2020-2,JEY
200520_Jersey_JerseyStatistics_Round2_Semi-urban,200520_Jersey_JerseyStatistics_Round2,SARS-CoV-2: Prevalence of antibodies in Jersey - Community survey – round 2,2020-06-09,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Jersey,Jersey,,"Adult residents living in private households, above the age of 16.","Under 16 years, or residents of communal establishments, such as care homes.",2020-05-15,2020-05-27,Household and community samples,All,Multiple groups,16.0,,Geographical area,semi-urban (sub-urban),391,0.046,,,,,,,,Stratified probability,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,0.9,0.9939,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Statistics Jersey,Statistics Jersey,Unity-Aligned,https://www.gov.je/SiteCollectionDocuments/Government%20and%20administration/R%20Prevalence%20of%20antibodies%2020200609%20SJ.pdf,2020-07-25,2024-03-01,Verified,statistics_jersey_sars-cov-2_2020-2,JEY
200520_Jersey_JerseyStatistics_Round2_45-54,200520_Jersey_JerseyStatistics_Round2,SARS-CoV-2: Prevalence of antibodies in Jersey - Community survey – round 2,2020-06-09,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Jersey,Jersey,,"Adult residents living in private households, above the age of 16.","Under 16 years, or residents of communal establishments, such as care homes.",2020-05-15,2020-05-27,Household and community samples,All,Adults (18-64 years),45.0,54.0,Age,45-54,189,0.055,,,,,,,,Stratified probability,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,0.9,0.9939,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Statistics Jersey,Statistics Jersey,Unity-Aligned,https://www.gov.je/SiteCollectionDocuments/Government%20and%20administration/R%20Prevalence%20of%20antibodies%2020200609%20SJ.pdf,2020-07-25,2024-03-01,Verified,statistics_jersey_sars-cov-2_2020-2,JEY
200707_Jersey_StatisticsJersey_Round3_TestAdj_PopAdj,200707_Jersey_StatisticsJersey_Round3,SARS-CoV-2: Prevalence of antibodies in Jersey Community Survey - Round 3,2020-07-07,Institutional Report,National,Prospective cohort,Jersey,,, All individuals aged 16 and over who formed part of the selected household were asked to participate in the survey.,"The survey did not perform testing on any person aged under 16 years and did not include residents of communal establishments (such as care homes).

The sample drawn excluded communal establishments (such as care homes), commercial properties and a small number of other properties known not to be residential in nature.",2020-06-21,2020-06-27,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,,1386,0.04,0.027999999999999997,0.052000000000000005,True,True,True,,,Simplified probability,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9,0.9939,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Statistics Jersey,Statistics Jersey,Unity-Aligned,https://www.gov.je/SiteCollectionDocuments/Government%20and%20administration/R%20Prevalence%20of%20antibodies%2020200707%20SJ.pdf,2021-04-30,2023-08-15,Verified,statistics_jersey_sars-cov-2_2020,JEY
200707_Jersey_StatisticsJersey_Round3_age45-54,200707_Jersey_StatisticsJersey_Round3,SARS-CoV-2: Prevalence of antibodies in Jersey Community Survey - Round 3,2020-07-07,Institutional Report,National,Prospective cohort,Jersey,,, All individuals aged 16 and over who formed part of the selected household were asked to participate in the survey.,"The survey did not perform testing on any person aged under 16 years and did not include residents of communal establishments (such as care homes).

The sample drawn excluded communal establishments (such as care homes), commercial properties and a small number of other properties known not to be residential in nature.",2020-06-21,2020-06-27,Household and community samples,All,Adults (18-64 years),45.0,54.0,Age,Ages 45-54,244,0.022000000000000002,,,,,,,,Simplified probability,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9,0.9939,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Statistics Jersey,Statistics Jersey,Unity-Aligned,https://www.gov.je/SiteCollectionDocuments/Government%20and%20administration/R%20Prevalence%20of%20antibodies%2020200707%20SJ.pdf,2021-04-30,2024-03-01,Verified,statistics_jersey_sars-cov-2_2020,JEY
200707_Jersey_StatisticsJersey_Round3_TestUnAdj_PopAdj,200707_Jersey_StatisticsJersey_Round3,SARS-CoV-2: Prevalence of antibodies in Jersey Community Survey - Round 3,2020-07-07,Institutional Report,National,Prospective cohort,Jersey,,, All individuals aged 16 and over who formed part of the selected household were asked to participate in the survey.,"The survey did not perform testing on any person aged under 16 years and did not include residents of communal establishments (such as care homes).

The sample drawn excluded communal establishments (such as care homes), commercial properties and a small number of other properties known not to be residential in nature.",2020-06-21,2020-06-27,Household and community samples,All,Multiple groups,16.0,,Analysis,,1386,0.042,0.03,0.054000000000000006,,,True,,True,Simplified probability,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9,0.9939,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Statistics Jersey,Statistics Jersey,Unity-Aligned,https://www.gov.je/SiteCollectionDocuments/Government%20and%20administration/R%20Prevalence%20of%20antibodies%2020200707%20SJ.pdf,2021-04-30,2024-03-01,Verified,statistics_jersey_sars-cov-2_2020,JEY
200707_Jersey_StatisticsJersey_Round3_female,200707_Jersey_StatisticsJersey_Round3,SARS-CoV-2: Prevalence of antibodies in Jersey Community Survey - Round 3,2020-07-07,Institutional Report,National,Prospective cohort,Jersey,,, All individuals aged 16 and over who formed part of the selected household were asked to participate in the survey.,"The survey did not perform testing on any person aged under 16 years and did not include residents of communal establishments (such as care homes).

The sample drawn excluded communal establishments (such as care homes), commercial properties and a small number of other properties known not to be residential in nature.",2020-06-21,2020-06-27,Household and community samples,Female,Multiple groups,16.0,,Sex/Gender,female,764,0.039,,,,,,,,Simplified probability,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9,0.9939,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Statistics Jersey,Statistics Jersey,Unity-Aligned,https://www.gov.je/SiteCollectionDocuments/Government%20and%20administration/R%20Prevalence%20of%20antibodies%2020200707%20SJ.pdf,2021-04-30,2024-03-01,Verified,statistics_jersey_sars-cov-2_2020,JEY
200707_Jersey_StatisticsJersey_Round3_male,200707_Jersey_StatisticsJersey_Round3,SARS-CoV-2: Prevalence of antibodies in Jersey Community Survey - Round 3,2020-07-07,Institutional Report,National,Prospective cohort,Jersey,,, All individuals aged 16 and over who formed part of the selected household were asked to participate in the survey.,"The survey did not perform testing on any person aged under 16 years and did not include residents of communal establishments (such as care homes).

The sample drawn excluded communal establishments (such as care homes), commercial properties and a small number of other properties known not to be residential in nature.",2020-06-21,2020-06-27,Household and community samples,Male,Multiple groups,16.0,,Sex/Gender,male,623,0.042,,,,,,,,Simplified probability,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9,0.9939,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Statistics Jersey,Statistics Jersey,Unity-Aligned,https://www.gov.je/SiteCollectionDocuments/Government%20and%20administration/R%20Prevalence%20of%20antibodies%2020200707%20SJ.pdf,2021-04-30,2024-03-01,Verified,statistics_jersey_sars-cov-2_2020,JEY
200707_Jersey_StatisticsJersey_Round3_age55-64,200707_Jersey_StatisticsJersey_Round3,SARS-CoV-2: Prevalence of antibodies in Jersey Community Survey - Round 3,2020-07-07,Institutional Report,National,Prospective cohort,Jersey,,, All individuals aged 16 and over who formed part of the selected household were asked to participate in the survey.,"The survey did not perform testing on any person aged under 16 years and did not include residents of communal establishments (such as care homes).

The sample drawn excluded communal establishments (such as care homes), commercial properties and a small number of other properties known not to be residential in nature.",2020-06-21,2020-06-27,Household and community samples,All,Adults (18-64 years),55.0,64.0,Age,Ages 55-64,274,0.059000000000000004,,,,,,,,Simplified probability,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9,0.9939,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Statistics Jersey,Statistics Jersey,Unity-Aligned,https://www.gov.je/SiteCollectionDocuments/Government%20and%20administration/R%20Prevalence%20of%20antibodies%2020200707%20SJ.pdf,2021-04-30,2024-03-01,Verified,statistics_jersey_sars-cov-2_2020,JEY
200707_Jersey_StatisticsJersey_Round3_age35-44,200707_Jersey_StatisticsJersey_Round3,SARS-CoV-2: Prevalence of antibodies in Jersey Community Survey - Round 3,2020-07-07,Institutional Report,National,Prospective cohort,Jersey,,, All individuals aged 16 and over who formed part of the selected household were asked to participate in the survey.,"The survey did not perform testing on any person aged under 16 years and did not include residents of communal establishments (such as care homes).

The sample drawn excluded communal establishments (such as care homes), commercial properties and a small number of other properties known not to be residential in nature.",2020-06-21,2020-06-27,Household and community samples,All,Adults (18-64 years),35.0,44.0,Age,Ages 35-44,238,0.035,,,,,,,,Simplified probability,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9,0.9939,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Statistics Jersey,Statistics Jersey,Unity-Aligned,https://www.gov.je/SiteCollectionDocuments/Government%20and%20administration/R%20Prevalence%20of%20antibodies%2020200707%20SJ.pdf,2021-04-30,2024-03-01,Verified,statistics_jersey_sars-cov-2_2020,JEY
200707_Jersey_StatisticsJersey_Round3_age16-34,200707_Jersey_StatisticsJersey_Round3,SARS-CoV-2: Prevalence of antibodies in Jersey Community Survey - Round 3,2020-07-07,Institutional Report,National,Prospective cohort,Jersey,,, All individuals aged 16 and over who formed part of the selected household were asked to participate in the survey.,"The survey did not perform testing on any person aged under 16 years and did not include residents of communal establishments (such as care homes).

The sample drawn excluded communal establishments (such as care homes), commercial properties and a small number of other properties known not to be residential in nature.",2020-06-21,2020-06-27,Household and community samples,All,Adults (18-64 years),16.0,34.0,Age,Ages 16-34,321,0.036000000000000004,,,,,,,,Simplified probability,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9,0.9939,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Statistics Jersey,Statistics Jersey,Unity-Aligned,https://www.gov.je/SiteCollectionDocuments/Government%20and%20administration/R%20Prevalence%20of%20antibodies%2020200707%20SJ.pdf,2021-04-30,2024-03-01,Verified,statistics_jersey_sars-cov-2_2020,JEY
200707_Jersey_StatisticsJersey_Round3_age65+,200707_Jersey_StatisticsJersey_Round3,SARS-CoV-2: Prevalence of antibodies in Jersey Community Survey - Round 3,2020-07-07,Institutional Report,National,Prospective cohort,Jersey,,, All individuals aged 16 and over who formed part of the selected household were asked to participate in the survey.,"The survey did not perform testing on any person aged under 16 years and did not include residents of communal establishments (such as care homes).

The sample drawn excluded communal establishments (such as care homes), commercial properties and a small number of other properties known not to be residential in nature.",2020-06-21,2020-06-27,Household and community samples,All,Seniors (65+ years),65.0,,Age,Ages 65+,298,0.054000000000000006,,,,,,,,Simplified probability,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9,0.9939,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Statistics Jersey,Statistics Jersey,Unity-Aligned,https://www.gov.je/SiteCollectionDocuments/Government%20and%20administration/R%20Prevalence%20of%20antibodies%2020200707%20SJ.pdf,2021-04-30,2024-03-01,Verified,statistics_jersey_sars-cov-2_2020,JEY
210416_Jordan_KingHusseinCancerCenter_Grp1_June,210416_Jordan_KingHusseinCancerCenter_Grp1_June,Dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among healthy blood donors: The evolution of a pandemic,2021-04-19,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Jordan,"North, Center, South",,"Leftover sera and/or plasma collected routinely during the process of blood or apheresis platelet donations were used for the study. The donors were healthy, asymptomatic subjects between the ages of 18 and 63, who underwent routine screening to determine their acceptability for donation, as per standard practice.",,2020-01-15,2020-06-15,Blood donors,All,Adults (18-64 years),18.0,63.0,Primary Estimate,,736,0.0,0.0,0.0051,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],No,No,Yes,No,No,Yes,Yes,Yes,,Maher Sughayer,King Hussein Cancer Center,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.04.059,2021-06-08,2024-03-01,Verified,sughayer_dramatic_2021-1,JOR
210416_Jordan_KingHusseinCancerCenter_Grp2_September,210416_Jordan_KingHusseinCancerCenter_Grp2_September,Dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among healthy blood donors: The evolution of a pandemic,2021-04-19,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Jordan,"North, Center, South",,"Leftover sera and/or plasma collected routinely during the process of blood or apheresis platelet donations were used for the study. The donors were healthy, asymptomatic subjects between the ages of 18 and 63, who underwent routine screening to determine their acceptability for donation, as per standard practice.",,2020-09-01,2020-09-15,Blood donors,All,Adults (18-64 years),18.0,63.0,Primary Estimate,,348,0.0,0.0,0.0051,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],No,No,No,No,No,Yes,Yes,Yes,,Maher Sughayer,King Hussein Cancer Center,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.04.059,2021-06-08,2024-03-01,Verified,sughayer_dramatic_2021-1,JOR
210416_Jordan_KingHusseinCancerCenter_Grp3_January_TestAdj,210416_Jordan_KingHusseinCancerCenter_Grp3_January,Dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among healthy blood donors: The evolution of a pandemic,2021-04-19,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Jordan,"North, Center, South",,"Leftover sera and/or plasma collected routinely during the process of blood or apheresis platelet donations were used for the study. The donors were healthy, asymptomatic subjects between the ages of 18 and 63, who underwent routine screening to determine their acceptability for donation, as per standard practice.",,2021-01-28,2021-02-05,Blood donors,All,Adults (18-64 years),18.0,63.0,Primary Estimate,,292,0.273,0.225,0.329,True,True,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Maher Sughayer,King Hussein Cancer Center,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.04.059,2021-06-08,2023-08-15,Verified,sughayer_dramatic_2021-1,JOR
210416_Jordan_KingHusseinCancerCenter_Grp3_January_Male,210416_Jordan_KingHusseinCancerCenter_Grp3_January,Dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among healthy blood donors: The evolution of a pandemic,2021-04-19,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Jordan,"North, Center, South",,"Leftover sera and/or plasma collected routinely during the process of blood or apheresis platelet donations were used for the study. The donors were healthy, asymptomatic subjects between the ages of 18 and 63, who underwent routine screening to determine their acceptability for donation, as per standard practice.",,2021-01-28,2021-02-05,Blood donors,Male,Adults (18-64 years),18.0,63.0,Sex/Gender,,254,0.276,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Maher Sughayer,King Hussein Cancer Center,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.04.059,2021-06-08,2024-03-01,Verified,sughayer_dramatic_2021-1,JOR
210416_Jordan_KingHusseinCancerCenter_Grp3_January_UnAdj,210416_Jordan_KingHusseinCancerCenter_Grp3_January,Dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among healthy blood donors: The evolution of a pandemic,2021-04-19,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Jordan,"North, Center, South",,"Leftover sera and/or plasma collected routinely during the process of blood or apheresis platelet donations were used for the study. The donors were healthy, asymptomatic subjects between the ages of 18 and 63, who underwent routine screening to determine their acceptability for donation, as per standard practice.",,2021-01-28,2021-02-05,Blood donors,All,Adults (18-64 years),18.0,63.0,Analysis,,292,0.27399999999999997,,,,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Maher Sughayer,King Hussein Cancer Center,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.04.059,2021-06-08,2024-03-01,Verified,sughayer_dramatic_2021-1,JOR
210416_Jordan_KingHusseinCancerCenter_Grp3_January_51-65,210416_Jordan_KingHusseinCancerCenter_Grp3_January,Dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among healthy blood donors: The evolution of a pandemic,2021-04-19,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Jordan,"North, Center, South",,"Leftover sera and/or plasma collected routinely during the process of blood or apheresis platelet donations were used for the study. The donors were healthy, asymptomatic subjects between the ages of 18 and 63, who underwent routine screening to determine their acceptability for donation, as per standard practice.",,2021-01-28,2021-02-05,Blood donors,All,Adults (18-64 years),51.0,63.0,Age,,12,0.083,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Maher Sughayer,King Hussein Cancer Center,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.04.059,2021-06-08,2024-03-01,Verified,sughayer_dramatic_2021-1,JOR
210416_Jordan_KingHusseinCancerCenter_Grp3_January_31-40,210416_Jordan_KingHusseinCancerCenter_Grp3_January,Dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among healthy blood donors: The evolution of a pandemic,2021-04-19,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Jordan,"North, Center, South",,"Leftover sera and/or plasma collected routinely during the process of blood or apheresis platelet donations were used for the study. The donors were healthy, asymptomatic subjects between the ages of 18 and 63, who underwent routine screening to determine their acceptability for donation, as per standard practice.",,2021-01-28,2021-02-05,Blood donors,All,Adults (18-64 years),31.0,40.0,Age,,73,0.28800000000000003,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Maher Sughayer,King Hussein Cancer Center,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.04.059,2021-06-08,2024-03-01,Verified,sughayer_dramatic_2021-1,JOR
210416_Jordan_KingHusseinCancerCenter_Grp3_January_18-30,210416_Jordan_KingHusseinCancerCenter_Grp3_January,Dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among healthy blood donors: The evolution of a pandemic,2021-04-19,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Jordan,"North, Center, South",,"Leftover sera and/or plasma collected routinely during the process of blood or apheresis platelet donations were used for the study. The donors were healthy, asymptomatic subjects between the ages of 18 and 63, who underwent routine screening to determine their acceptability for donation, as per standard practice.",,2021-01-28,2021-02-05,Blood donors,All,Adults (18-64 years),18.0,30.0,Age,,163,0.28800000000000003,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Maher Sughayer,King Hussein Cancer Center,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.04.059,2021-06-08,2024-03-01,Verified,sughayer_dramatic_2021-1,JOR
210416_Jordan_KingHusseinCancerCenter_Grp3_January_41-50,210416_Jordan_KingHusseinCancerCenter_Grp3_January,Dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among healthy blood donors: The evolution of a pandemic,2021-04-19,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Jordan,"North, Center, South",,"Leftover sera and/or plasma collected routinely during the process of blood or apheresis platelet donations were used for the study. The donors were healthy, asymptomatic subjects between the ages of 18 and 63, who underwent routine screening to determine their acceptability for donation, as per standard practice.",,2021-01-28,2021-02-05,Blood donors,All,Adults (18-64 years),41.0,50.0,Age,,35,0.314,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Maher Sughayer,King Hussein Cancer Center,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.04.059,2021-06-08,2024-03-01,Verified,sughayer_dramatic_2021-1,JOR
210416_Jordan_KingHusseinCancerCenter_Grp3_January_Female,210416_Jordan_KingHusseinCancerCenter_Grp3_January,Dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among healthy blood donors: The evolution of a pandemic,2021-04-19,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Jordan,"North, Center, South",,"Leftover sera and/or plasma collected routinely during the process of blood or apheresis platelet donations were used for the study. The donors were healthy, asymptomatic subjects between the ages of 18 and 63, who underwent routine screening to determine their acceptability for donation, as per standard practice.",,2021-01-28,2021-02-05,Blood donors,Female,Adults (18-64 years),18.0,63.0,Sex/Gender,,38,0.263,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Maher Sughayer,King Hussein Cancer Center,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.04.059,2021-06-08,2024-03-01,Verified,sughayer_dramatic_2021-1,JOR
210710_Jordan_WorldHealthOrganization_August2020_,210710_Jordan_WorldHealthOrganization_firstRoundAugust2020,A three-phase population based sero-epidemiological study: Assessing the trend in prevalence of SARS-CoV-2 during COVID-19 pandemic in Jordan,2021-07-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Jordan,,,"All persons living in the household were invited to participate in the study, including children to ensure the calculation of age-specific attack rates. Multiple time periods of field visits were conducted to ensure the inclusion of working individuals.","Exclusion criteria included the selection of household with less than 2  members willing to  participate in  the  study, refusal to  provide informed consent and/or contraindication to venipuncture, residential institutions such as boarding schools, dormitories, hostels and prisons were excluded. Suspected, confirmed acute and prior COVID-19 infec-tion were not excluded from participation in the study. ",2020-08-01,2020-08-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,4704,0.003,0.002,0.004,True,,,,True,Stratified probability,Wantai SARS-CoV-2 IgM ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Yes,Saverio Bellizzi,World Health Organization,Unity-Aligned,http://dx.doi.org/10.1016/j.onehlt.2021.100292,2021-07-29,2024-03-01,Verified,bellizziThreephasePopulationBased2021,JOR
210710_Jordan_WorldHealthOrganization_October2020,210710_Jordan_WorldHealthOrganization_secondRoundOctober2020,A three-phase population based sero-epidemiological study: Assessing the trend in prevalence of SARS-CoV-2 during COVID-19 pandemic in Jordan,2021-07-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Jordan,,,"All persons living in the household were invited to participate in the study, including children to ensure the calculation of age-specific attack rates. Multiple time periods of field visits were conducted to ensure the inclusion of working individuals.","Exclusion criteria included the selection of household with less than 2  members willing to  participate in  the  study, refusal to  provide informed consent and/or contraindication to venipuncture, residential institutions such as boarding schools, dormitories, hostels and prisons were excluded. Suspected, confirmed acute and prior COVID-19 infec-tion were not excluded from participation in the study. ",2020-10-01,2020-10-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,5470,0.07,0.068,0.07200000000000001,True,,,,True,Stratified probability,Wantai SARS-CoV-2 IgM ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Yes,Saverio Bellizzi,World Health Organization,Unity-Aligned,http://dx.doi.org/10.1016/j.onehlt.2021.100292,2021-07-29,2024-03-01,Verified,bellizziThreephasePopulationBased2021,JOR
210710_Jordan_WorldHealthOrganization_January2021,210710_Jordan_WorldHealthOrganization_thirdRoundJanuary2021,A three-phase population based sero-epidemiological study: Assessing the trend in prevalence of SARS-CoV-2 during COVID-19 pandemic in Jordan,2021-07-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Jordan,,,"All persons living in the household were invited to participate in the study, including children to ensure the calculation of age-specific attack rates. Multiple time periods of field visits were conducted to ensure the inclusion of working individuals.","Exclusion criteria included the selection of household with less than 2  members willing to  participate in  the  study, refusal to  provide informed consent and/or contraindication to venipuncture, residential institutions such as boarding schools, dormitories, hostels and prisons were excluded. Suspected, confirmed acute and prior COVID-19 infec-tion were not excluded from participation in the study. ",2020-12-27,2021-01-06,Household and community samples,All,Multiple groups,,,Primary Estimate,,5044,0.342,0.33799999999999997,0.34600000000000003,True,,,,True,Stratified probability,Wantai SARS-CoV-2 IgM ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,No,Yes,No,Yes,Saverio Bellizzi,World Health Organization,Unity-Aligned,http://dx.doi.org/10.1016/j.onehlt.2021.100292,2021-07-29,2024-03-01,Verified,bellizziThreephasePopulationBased2021,JOR
210818_Jordan_KingHusseinCancerCenter_Primary,210818_Jordan_KingHusseinCancerCenter,A second dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among adult healthy blood donors in Jordan; have we achieved herd immunity?,2021-08-18,Preprint,National,Cross-sectional survey ,Jordan,,,Healthy adult blood donors,,2021-06-01,2021-06-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Overall Primary Estimate (Crude),536,0.7440000000000001,,,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,,0.988,1.0,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Maher Sughayer,King Hussein Cancer Center,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.15.21261584v1.full-text,2021-08-24,2024-03-01,Verified,sughayerSecondDramaticRise2021,JOR
210818_Jordan_KingHusseinCancerCenter_Unvaccinated,210818_Jordan_KingHusseinCancerCenter,A second dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among adult healthy blood donors in Jordan; have we achieved herd immunity?,2021-08-18,Preprint,National,Cross-sectional survey ,Jordan,,,Healthy adult blood donors,,2021-06-01,2021-06-30,Blood donors,All,Adults (18-64 years),18.0,68.0,COVID-19 vaccination status,Vaccinated no,258,0.5969,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,,0.988,1.0,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Maher Sughayer,King Hussein Cancer Center,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.15.21261584v1.full-text,2021-10-12,2024-03-01,Verified,sughayerSecondDramaticRise2021,JOR
210818_Jordan_KingHusseinCancerCenter_18-30,210818_Jordan_KingHusseinCancerCenter,A second dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among adult healthy blood donors in Jordan; have we achieved herd immunity?,2021-08-18,Preprint,National,Cross-sectional survey ,Jordan,,,Healthy adult blood donors,,2021-06-01,2021-06-30,Blood donors,All,Adults (18-64 years),18.0,30.0,Age,18-30,289,0.706,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,,0.988,1.0,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Maher Sughayer,King Hussein Cancer Center,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.15.21261584v1.full-text,2021-08-24,2024-03-01,Verified,sughayerSecondDramaticRise2021,JOR
210818_Jordan_KingHusseinCancerCenter_31-40,210818_Jordan_KingHusseinCancerCenter,A second dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among adult healthy blood donors in Jordan; have we achieved herd immunity?,2021-08-18,Preprint,National,Cross-sectional survey ,Jordan,,,Healthy adult blood donors,,2021-06-01,2021-06-30,Blood donors,All,Adults (18-64 years),31.0,40.0,Age,31-40,144,0.799,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,,0.988,1.0,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Maher Sughayer,King Hussein Cancer Center,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.15.21261584v1.full-text,2021-08-24,2024-03-01,Verified,sughayerSecondDramaticRise2021,JOR
210818_Jordan_KingHusseinCancerCenter_Male,210818_Jordan_KingHusseinCancerCenter,A second dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among adult healthy blood donors in Jordan; have we achieved herd immunity?,2021-08-18,Preprint,National,Cross-sectional survey ,Jordan,,,Healthy adult blood donors,,2021-06-01,2021-06-30,Blood donors,Male,Adults (18-64 years),18.0,68.0,Sex/Gender,Male,480,0.752,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,,0.988,1.0,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Maher Sughayer,King Hussein Cancer Center,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.15.21261584v1.full-text,2021-08-24,2024-03-01,Verified,sughayerSecondDramaticRise2021,JOR
210818_Jordan_KingHusseinCancerCenter_41-50,210818_Jordan_KingHusseinCancerCenter,A second dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among adult healthy blood donors in Jordan; have we achieved herd immunity?,2021-08-18,Preprint,National,Cross-sectional survey ,Jordan,,,Healthy adult blood donors,,2021-06-01,2021-06-30,Blood donors,All,Adults (18-64 years),41.0,50.0,Age,41-50,71,0.7320000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,,0.988,1.0,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Maher Sughayer,King Hussein Cancer Center,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.15.21261584v1.full-text,2021-08-24,2024-03-01,Verified,sughayerSecondDramaticRise2021,JOR
210818_Jordan_KingHusseinCancerCenter_Female,210818_Jordan_KingHusseinCancerCenter,A second dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among adult healthy blood donors in Jordan; have we achieved herd immunity?,2021-08-18,Preprint,National,Cross-sectional survey ,Jordan,,,Healthy adult blood donors,,2021-06-01,2021-06-30,Blood donors,Female,Adults (18-64 years),18.0,68.0,Sex/Gender,Female,56,0.679,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,,0.988,1.0,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Maher Sughayer,King Hussein Cancer Center,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.15.21261584v1.full-text,2021-08-24,2024-03-01,Verified,sughayerSecondDramaticRise2021,JOR
210818_Jordan_KingHusseinCancerCenter_51-68,210818_Jordan_KingHusseinCancerCenter,A second dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among adult healthy blood donors in Jordan; have we achieved herd immunity?,2021-08-18,Preprint,National,Cross-sectional survey ,Jordan,,,Healthy adult blood donors,,2021-06-01,2021-06-30,Blood donors,All,Adults (18-64 years),51.0,68.0,Age,51-68,32,0.875,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,,0.988,1.0,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Maher Sughayer,King Hussein Cancer Center,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.15.21261584v1.full-text,2021-08-24,2024-03-01,Verified,sughayerSecondDramaticRise2021,JOR
210818_Jordan_KingHusseinCancerCenter_Vaccinated,210818_Jordan_KingHusseinCancerCenter,A second dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among adult healthy blood donors in Jordan; have we achieved herd immunity?,2021-08-18,Preprint,National,Cross-sectional survey ,Jordan,,,Healthy adult blood donors,,2021-06-01,2021-06-30,Blood donors,All,Adults (18-64 years),18.0,68.0,COVID-19 vaccination status,Vaccinated yes,278,0.8813,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,,0.988,1.0,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Maher Sughayer,King Hussein Cancer Center,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.15.21261584v1.full-text,2021-10-12,2024-03-01,Verified,sughayerSecondDramaticRise2021,JOR
211015_JordanUniversityOfScienceAndTechnology_Primary,211015_JordanUniversityOfScienceAndTechnology,Prevalence of COVID-19 among blood donors: The Jordan University of Science and Technology experience.,2021-10-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,Jordan,,,blood donors that complied with the blood donation protocol. The study took place between at a tertiary-care university hospital that serves a population of 1.2 million in the north of Jordan.,,2020-09-15,2021-01-15,Blood donors,All,Adults (18-64 years),,,Primary Estimate,,1000,0.145,,,True,,,,True,Self-referral,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Ziad Elnasser,Jordan University of Science and Technology,Not Unity-Aligned,https://dx.doi.org/10.1097/MD.0000000000027537,2021-11-09,2024-03-01,Verified,elnasser_prevalence_2021,JOR
211015_JordanUniversityOfScienceAndTechnology_Male,211015_JordanUniversityOfScienceAndTechnology,Prevalence of COVID-19 among blood donors: The Jordan University of Science and Technology experience.,2021-10-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,Jordan,,,blood donors that complied with the blood donation protocol. The study took place between at a tertiary-care university hospital that serves a population of 1.2 million in the north of Jordan.,,2020-09-15,2021-01-15,Blood donors,Male,Adults (18-64 years),,,Sex/Gender,,967,0.146,,,,,,,,Self-referral,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Ziad Elnasser,Jordan University of Science and Technology,Not Unity-Aligned,https://dx.doi.org/10.1097/MD.0000000000027537,2021-11-09,2024-03-01,Verified,elnasser_prevalence_2021,JOR
211015_JordanUniversityOfScienceAndTechnology_Female,211015_JordanUniversityOfScienceAndTechnology,Prevalence of COVID-19 among blood donors: The Jordan University of Science and Technology experience.,2021-10-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,Jordan,,,blood donors that complied with the blood donation protocol. The study took place between at a tertiary-care university hospital that serves a population of 1.2 million in the north of Jordan.,,2020-09-15,2021-01-15,Blood donors,Female,Adults (18-64 years),,,Sex/Gender,,33,0.12119999999999999,,,,,,,,Self-referral,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Ziad Elnasser,Jordan University of Science and Technology,Not Unity-Aligned,https://dx.doi.org/10.1097/MD.0000000000027537,2021-11-29,2024-03-01,Verified,elnasser_prevalence_2021,JOR
220420_Amman_KingHusseinCancerCenter_Overall,220420_Amman_KingHusseinCancerCenter,Comparison of the Immunogenicity and Protective Efficacy of Various SARS-CoV-2 Vaccines among Healthcare Workers: Are Our White Coat Armies Protected?,2022-04-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Jordan,,Amman,"""In this study, we enrolled 510 HCWs from KHCC [King Hussein Cancer Center] who either received or did not receive COVID-19 vaccination.""","Having ""insufficient data"".",2021-07-15,2021-09-15,Health care workers and caregivers,All,Multiple groups,20.3,70.4,Primary Estimate,,485,0.9588,,,True,,,,True,Simplified probability,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9934999999999999,0.996,['High'],,Yes,No,Yes,,Yes,Yes,Yes,,Lina Souan,King Hussein Cancer Center,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10050642,2022-05-18,2024-03-01,Unverified,souan_comparison_2022,JOR
220905_Jordan_JordanMinistryofHealth_overall,220905_Jordan_JordanMinistryofHealth,"SARS-CoV-2 Seroepidemiological Investigation in Jordan: Seroprevalence, Herd Immunity, and Vaccination Coverage. A Population-Based National Study",2022-09-05,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Jordan,,,"""A household was defined as a group of 2 or more individuals living in the same residence. A convenient household sample was selected from each governorate as defined by the Jordan Department of Statistics census blocks. ""","""Individuals who refused to give informed consent or had a contraindication to venipuncture, households with less than two members, and residential institutions, such as boarding schools, dormitories, hostels, and prisons were excluded from the study""",2021-06-27,2021-08-05,Household and community samples,All,Multiple groups,,,Primary Estimate,,8821,0.741,0.731,0.7490000000000001,True,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,0.9670000000000001,0.975,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Sami Sheikh Ali,Jordan Ministry of Health,Unity-Aligned,https://doi.org/10.2147/IJGM.S371711,2022-09-22,2024-04-19,Verified,sheikh_ali_sars-cov-2_2022,JOR
220905_Jordan_JordanMinistryofHealth_5to9,220905_Jordan_JordanMinistryofHealth,"SARS-CoV-2 Seroepidemiological Investigation in Jordan: Seroprevalence, Herd Immunity, and Vaccination Coverage. A Population-Based National Study",2022-09-05,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Jordan,,,"""A household was defined as a group of 2 or more individuals living in the same residence. A convenient household sample was selected from each governorate as defined by the Jordan Department of Statistics census blocks. ""","""Individuals who refused to give informed consent or had a contraindication to venipuncture, households with less than two members, and residential institutions, such as boarding schools, dormitories, hostels, and prisons were excluded from the study""",2021-06-27,2021-08-05,Household and community samples,All,Children and Youth (0-17 years),,,Age,5-9,882,0.56,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,0.9670000000000001,0.975,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Sami Sheikh Ali,Jordan Ministry of Health,Unity-Aligned,https://doi.org/10.2147/IJGM.S371711,2022-09-22,2024-04-19,Verified,sheikh_ali_sars-cov-2_2022,JOR
220905_Jordan_JordanMinistryofHealth_10to14,220905_Jordan_JordanMinistryofHealth,"SARS-CoV-2 Seroepidemiological Investigation in Jordan: Seroprevalence, Herd Immunity, and Vaccination Coverage. A Population-Based National Study",2022-09-05,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Jordan,,,"""A household was defined as a group of 2 or more individuals living in the same residence. A convenient household sample was selected from each governorate as defined by the Jordan Department of Statistics census blocks. ""","""Individuals who refused to give informed consent or had a contraindication to venipuncture, households with less than two members, and residential institutions, such as boarding schools, dormitories, hostels, and prisons were excluded from the study""",2021-06-27,2021-08-05,Household and community samples,All,Children and Youth (0-17 years),,,Age,10-14,1147,0.633,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,0.9670000000000001,0.975,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Sami Sheikh Ali,Jordan Ministry of Health,Unity-Aligned,https://doi.org/10.2147/IJGM.S371711,2022-09-22,2024-04-19,Verified,sheikh_ali_sars-cov-2_2022,JOR
220905_Jordan_JordanMinistryofHealth_lessthan5,220905_Jordan_JordanMinistryofHealth,"SARS-CoV-2 Seroepidemiological Investigation in Jordan: Seroprevalence, Herd Immunity, and Vaccination Coverage. A Population-Based National Study",2022-09-05,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Jordan,,,"""A household was defined as a group of 2 or more individuals living in the same residence. A convenient household sample was selected from each governorate as defined by the Jordan Department of Statistics census blocks. ""","""Individuals who refused to give informed consent or had a contraindication to venipuncture, households with less than two members, and residential institutions, such as boarding schools, dormitories, hostels, and prisons were excluded from the study""",2021-06-27,2021-08-05,Household and community samples,All,Children and Youth (0-17 years),,,Age,,265,0.53,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,0.9670000000000001,0.975,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Sami Sheikh Ali,Jordan Ministry of Health,Unity-Aligned,https://doi.org/10.2147/IJGM.S371711,2022-09-22,2024-04-19,Verified,sheikh_ali_sars-cov-2_2022,JOR
220217_Kazakhstan_NazarbayevUniversitySchoolofMedicine_Overall_IgG,220217_Kazakhstan_NazarbayevUniversitySchoolofMedicine,Seropositivity of SARS-CoV-2 in the Population of Kazakhstan: A Nationwide Laboratory-Based Surveillance,2022-02-17,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Kazakhstan,,,"residual sera from “IN VITRO” laboratories, the largest private network of government-licensed laboratories in Kazakhstan (“IN VITRO” laboratories are available in all administrative units of Kazakhstan, including rural areas)",,2020-07-16,2021-07-07,Residual sera,All,Multiple groups,,,Primary Estimate,,85346,0.63,0.627,0.633,True,,,,True,Sequential,SARS- CoV-2-IgG-EIA-BEST and SARS-CoV-2- IgM-EIA-BEST ,Vector BEST,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9,1.0,['High'],No,No,Yes,No,No,Unclear,Yes,Yes,,Yuliya Semenova,Nazarbayev University School of Medicine,Unity-Aligned,https://dx.doi.org/10.3390/ijerph19042263,2022-02-28,2022-07-16,Unverified,semenova_seropositivity_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Almaty_OverallPopAdj,220315_Kazakhstan_KazakhNationalMedicalUniversity_Almaty,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Almaty,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,,4461,0.5700000000000001,0.569,0.598,True,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-05-28,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Almaty_Age5-14,220315_Kazakhstan_KazakhNationalMedicalUniversity_Almaty,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Almaty,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,All,Children and Youth (0-17 years),5.0,14.0,Age,5-14,424,0.5802,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-03-31,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Almaty_SexMale,220315_Kazakhstan_KazakhNationalMedicalUniversity_Almaty,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Almaty,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,Male,Multiple groups,5.0,,Sex/Gender,,1590,0.583,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-03-31,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Almaty_Age15-19,220315_Kazakhstan_KazakhNationalMedicalUniversity_Almaty,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Almaty,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,All,Children and Youth (0-17 years),15.0,19.0,Age,15-19,237,0.5359,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-03-31,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Almaty_Age60-69,220315_Kazakhstan_KazakhNationalMedicalUniversity_Almaty,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Almaty,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,All,Seniors (65+ years),60.0,69.0,Age,,767,0.5306000000000001,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-03-31,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Almaty_Age50-59,220315_Kazakhstan_KazakhNationalMedicalUniversity_Almaty,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Almaty,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,,664,0.6295000000000001,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-03-31,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Almaty_OverallCrude,220315_Kazakhstan_KazakhNationalMedicalUniversity_Almaty,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Almaty,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,All,Multiple groups,5.0,,Analysis,,4461,0.5700999999999999,,,,,,,True,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-05-28,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Almaty_Age20-29,220315_Kazakhstan_KazakhNationalMedicalUniversity_Almaty,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Almaty,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,565,0.6177,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-03-31,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Almaty_Age70+,220315_Kazakhstan_KazakhNationalMedicalUniversity_Almaty,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Almaty,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,All,Seniors (65+ years),70.0,,Age,,490,0.4571,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-03-31,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Almaty_Age40-49,220315_Kazakhstan_KazakhNationalMedicalUniversity_Almaty,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Almaty,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,,669,0.5815,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-03-31,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Almaty_Age30-39,220315_Kazakhstan_KazakhNationalMedicalUniversity_Almaty,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Almaty,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,,645,0.5938,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-03-31,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Almaty_SexFemale,220315_Kazakhstan_KazakhNationalMedicalUniversity_Almaty,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Almaty,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,Female,Multiple groups,5.0,,Sex/Gender,,2871,0.5629,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-03-31,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Kostanay_OverallPopAdj,220315_Kazakhstan_KazakhNationalMedicalUniversity_Kostanay,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Kostanay,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,,614,0.394,0.358,0.43700000000000006,True,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-05-28,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Kostanay_Age60-69,220315_Kazakhstan_KazakhNationalMedicalUniversity_Kostanay,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Kostanay,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,All,Seniors (65+ years),60.0,69.0,Age,,70,0.4286,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-05-28,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Kostanay_SexFemale,220315_Kazakhstan_KazakhNationalMedicalUniversity_Kostanay,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Kostanay,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,Female,Multiple groups,5.0,,Sex/Gender,,365,0.3726,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-05-28,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Kostanay_Age40-49,220315_Kazakhstan_KazakhNationalMedicalUniversity_Kostanay,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Kostanay,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,,103,0.4951,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-05-28,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Kostanay_Age50-59,220315_Kazakhstan_KazakhNationalMedicalUniversity_Kostanay,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Kostanay,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,,88,0.25,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-05-28,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Kostanay_OverallCrude,220315_Kazakhstan_KazakhNationalMedicalUniversity_Kostanay,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Kostanay,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,All,Multiple groups,5.0,,Analysis,,614,0.39409999999999995,,,,,,,True,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-05-28,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Kostanay_Age70+,220315_Kazakhstan_KazakhNationalMedicalUniversity_Kostanay,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Kostanay,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,All,Seniors (65+ years),70.0,,Age,,51,0.4118,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-05-28,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Kostanay_Age30-39,220315_Kazakhstan_KazakhNationalMedicalUniversity_Kostanay,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Kostanay,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,,125,0.408,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-05-28,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Kostanay_Age15-19,220315_Kazakhstan_KazakhNationalMedicalUniversity_Kostanay,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Kostanay,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,All,Children and Youth (0-17 years),15.0,19.0,Age,15-19,19,0.5789,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-05-28,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Kostanay_Age5-14,220315_Kazakhstan_KazakhNationalMedicalUniversity_Kostanay,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Kostanay,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,All,Children and Youth (0-17 years),5.0,14.0,Age,5-14,44,0.34090000000000004,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-05-28,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Kostanay_SexMale,220315_Kazakhstan_KazakhNationalMedicalUniversity_Kostanay,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Kostanay,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,Male,Multiple groups,5.0,,Sex/Gender,,249,0.4257,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-05-28,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Kostanay_Age20-29,220315_Kazakhstan_KazakhNationalMedicalUniversity_Kostanay,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Kostanay,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,114,0.35960000000000003,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-05-28,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Oskemen_OverallPopAdj,220315_Kazakhstan_KazakhNationalMedicalUniversity_Oskemen,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Oskemen,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,,664,0.6070000000000001,0.579,0.655,True,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-05-28,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Oskemen_Age50-59,220315_Kazakhstan_KazakhNationalMedicalUniversity_Oskemen,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Oskemen,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,,151,0.5894,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-05-28,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Oskemen_Age20-29,220315_Kazakhstan_KazakhNationalMedicalUniversity_Oskemen,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Oskemen,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,114,0.6228,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-05-28,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Oskemen_Age5-14,220315_Kazakhstan_KazakhNationalMedicalUniversity_Oskemen,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Oskemen,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,All,Children and Youth (0-17 years),5.0,14.0,Age,5-14,5,0.6,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-05-28,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Oskemen_SexMale,220315_Kazakhstan_KazakhNationalMedicalUniversity_Oskemen,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Oskemen,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,Male,Multiple groups,5.0,,Sex/Gender,,186,0.6075,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-05-28,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Oskemen_Age30-39,220315_Kazakhstan_KazakhNationalMedicalUniversity_Oskemen,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Oskemen,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,,146,0.5753,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-05-28,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Oskemen_Age40-49,220315_Kazakhstan_KazakhNationalMedicalUniversity_Oskemen,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Oskemen,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,,118,0.6102000000000001,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-05-28,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Oskemen_Age70+,220315_Kazakhstan_KazakhNationalMedicalUniversity_Oskemen,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Oskemen,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,All,Seniors (65+ years),70.0,,Age,,24,0.7083,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-05-28,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Oskemen_Age15-19,220315_Kazakhstan_KazakhNationalMedicalUniversity_Oskemen,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Oskemen,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,All,Children and Youth (0-17 years),15.0,19.0,Age,15-19,13,0.8462000000000001,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-05-28,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Oskemen_OverallCrude,220315_Kazakhstan_KazakhNationalMedicalUniversity_Oskemen,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Oskemen,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,All,Multiple groups,5.0,,Analysis,,664,0.6069,,,,,,,True,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-05-28,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Oskemen_SexFemale,220315_Kazakhstan_KazakhNationalMedicalUniversity_Oskemen,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Oskemen,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,Female,Multiple groups,5.0,,Sex/Gender,,478,0.6067,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-05-28,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220315_Kazakhstan_KazakhNationalMedicalUniversity_Oskemen_Age60-69,220315_Kazakhstan_KazakhNationalMedicalUniversity_Oskemen,Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,,Oskemen,"all individuals selected to participate in the study, aged 5 years or older, regardless of history of COVID-19 infection, as well as cases of suspected or confirmed acute or previous COVID-19 infection, to avoid underestimating the prevalence of infection in the population",the lack of informed consent; the presence of contraindications to venipuncture; children under 5 years old,2020-10-24,2021-01-11,Household and community samples,All,Seniors (65+ years),60.0,69.0,Age,,93,0.6022,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Manar Smagul,Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1002/hsr2.562,2022-05-28,2024-03-01,Verified,smagul_seroprevalence_2022,KAZ
220727_Karaganda_KaragandaMedicalUniversity_IgGorIgA_Primary,220727_Karaganda_KaragandaMedicalUniversity,"High SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccination.",2022-07-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kazakhstan,Karaganda Region,Karaganda,"""Consenting, asymptomatic adults, who had not previously received a COVID-19 vaccine, were invited to participate in the study.""","""Exclusion criteria were presence of respiratory symptoms or laboratory-confirmed COVID-19 diagnosis within two weeks prior to the study.""",2021-04-15,2021-05-15,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,IgG and/or IgA; n=99,99,0.636,0.534,0.731,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA",EUROIMMUN,ELISA,Plasma,"['IgA', 'IgG']",Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],,No,No,Yes,,Yes,Yes,No,,Irina Kadyrova,Karaganda Medical University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0272008,2022-08-25,2024-03-01,Unverified,kadyrova_high_2022,KAZ
230706_Kazakhstan_SDAsfendiyarovKazakhNationalMedicalUniversity_Overall,230706_Kazakhstan_SDAsfendiyarovKazakhNationalMedicalUniversity,"""Study of seroprevalence of SARS-CoV-2 in Kazakhstan"".",2023-07-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kazakhstan,"Akmola, Aktobe, Almaty, Atyrau, Western Kazakhstan, Zhambyl, Karaganda, Kostanai, Kyzylorda, Mangistau, Turkestan, Pavlodar, North Kazakhstan, Eastern Kazakhstan","Nur-Sultan, Almaty, Shymkent","This is a cross-sectional study of the adult population in Kazakhstan for the period from October 2021 to May 2022. We recruited 6 720 people aged 18 to 69 throughout Kazakhstan (17 regions including the cities of Almaty, Astana, and Shymkent). Participation in the study was completely voluntary.",,2021-10-15,2022-05-15,Household and community samples,All,Adults (18-64 years),18.0,69.0,Primary Estimate,IgG,6720,0.4378,,,True,,,,True,Stratified probability,Alinity i SARS-CoV-2 IgG,Abbott Laboratories,"CLIA, CMIA",Serum,IgG,Nucleocapsid (N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Mukhtar Kulimbet,S.D. Asfendiyarov Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1017/S0950268823001085,2023-08-02,2024-04-29,Verified,kulimbet_study_2023,KAZ
230706_Kazakhstan_SDAsfendiyarovKazakhNationalMedicalUniversity_Age_40-49,230706_Kazakhstan_SDAsfendiyarovKazakhNationalMedicalUniversity,"""Study of seroprevalence of SARS-CoV-2 in Kazakhstan"".",2023-07-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kazakhstan,"Akmola, Aktobe, Almaty, Atyrau, Western Kazakhstan, Zhambyl, Karaganda, Kostanai, Kyzylorda, Mangistau, Turkestan, Pavlodar, North Kazakhstan, Eastern Kazakhstan","Nur-Sultan, Almaty, Shymkent","This is a cross-sectional study of the adult population in Kazakhstan for the period from October 2021 to May 2022. We recruited 6 720 people aged 18 to 69 throughout Kazakhstan (17 regions including the cities of Almaty, Astana, and Shymkent). Participation in the study was completely voluntary.",,2021-10-15,2022-05-15,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49 years,1310,0.1949,,,,,,,,Stratified probability,Alinity i SARS-CoV-2 IgG,Abbott Laboratories,"CLIA, CMIA",Serum,IgG,Nucleocapsid (N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Mukhtar Kulimbet,S.D. Asfendiyarov Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1017/S0950268823001085,2024-04-29,2024-04-29,Verified,kulimbet_study_2023,KAZ
230706_Kazakhstan_SDAsfendiyarovKazakhNationalMedicalUniversity_Age_50-59,230706_Kazakhstan_SDAsfendiyarovKazakhNationalMedicalUniversity,"""Study of seroprevalence of SARS-CoV-2 in Kazakhstan"".",2023-07-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kazakhstan,"Akmola, Aktobe, Almaty, Atyrau, Western Kazakhstan, Zhambyl, Karaganda, Kostanai, Kyzylorda, Mangistau, Turkestan, Pavlodar, North Kazakhstan, Eastern Kazakhstan","Nur-Sultan, Almaty, Shymkent","This is a cross-sectional study of the adult population in Kazakhstan for the period from October 2021 to May 2022. We recruited 6 720 people aged 18 to 69 throughout Kazakhstan (17 regions including the cities of Almaty, Astana, and Shymkent). Participation in the study was completely voluntary.",,2021-10-15,2022-05-15,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59 years,1159,0.1725,,,,,,,,Stratified probability,Alinity i SARS-CoV-2 IgG,Abbott Laboratories,"CLIA, CMIA",Serum,IgG,Nucleocapsid (N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Mukhtar Kulimbet,S.D. Asfendiyarov Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1017/S0950268823001085,2024-04-29,2024-04-29,Verified,kulimbet_study_2023,KAZ
230706_Kazakhstan_SDAsfendiyarovKazakhNationalMedicalUniversity_Age_30-39,230706_Kazakhstan_SDAsfendiyarovKazakhNationalMedicalUniversity,"""Study of seroprevalence of SARS-CoV-2 in Kazakhstan"".",2023-07-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kazakhstan,"Akmola, Aktobe, Almaty, Atyrau, Western Kazakhstan, Zhambyl, Karaganda, Kostanai, Kyzylorda, Mangistau, Turkestan, Pavlodar, North Kazakhstan, Eastern Kazakhstan","Nur-Sultan, Almaty, Shymkent","This is a cross-sectional study of the adult population in Kazakhstan for the period from October 2021 to May 2022. We recruited 6 720 people aged 18 to 69 throughout Kazakhstan (17 regions including the cities of Almaty, Astana, and Shymkent). Participation in the study was completely voluntary.",,2021-10-15,2022-05-15,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39 years,1688,0.2512,,,,,,,,Stratified probability,Alinity i SARS-CoV-2 IgG,Abbott Laboratories,"CLIA, CMIA",Serum,IgG,Nucleocapsid (N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Mukhtar Kulimbet,S.D. Asfendiyarov Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1017/S0950268823001085,2024-04-29,2024-04-29,Verified,kulimbet_study_2023,KAZ
230706_Kazakhstan_SDAsfendiyarovKazakhNationalMedicalUniversity_Age_60-69,230706_Kazakhstan_SDAsfendiyarovKazakhNationalMedicalUniversity,"""Study of seroprevalence of SARS-CoV-2 in Kazakhstan"".",2023-07-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kazakhstan,"Akmola, Aktobe, Almaty, Atyrau, Western Kazakhstan, Zhambyl, Karaganda, Kostanai, Kyzylorda, Mangistau, Turkestan, Pavlodar, North Kazakhstan, Eastern Kazakhstan","Nur-Sultan, Almaty, Shymkent","This is a cross-sectional study of the adult population in Kazakhstan for the period from October 2021 to May 2022. We recruited 6 720 people aged 18 to 69 throughout Kazakhstan (17 regions including the cities of Almaty, Astana, and Shymkent). Participation in the study was completely voluntary.",,2021-10-15,2022-05-15,Household and community samples,All,Adults (18-64 years),60.0,69.0,Age,60-69 years,835,0.1243,,,,,,,,Stratified probability,Alinity i SARS-CoV-2 IgG,Abbott Laboratories,"CLIA, CMIA",Serum,IgG,Nucleocapsid (N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Mukhtar Kulimbet,S.D. Asfendiyarov Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1017/S0950268823001085,2024-04-29,2024-04-29,Verified,kulimbet_study_2023,KAZ
230706_Kazakhstan_SDAsfendiyarovKazakhNationalMedicalUniversity_Age_18-29,230706_Kazakhstan_SDAsfendiyarovKazakhNationalMedicalUniversity,"""Study of seroprevalence of SARS-CoV-2 in Kazakhstan"".",2023-07-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kazakhstan,"Akmola, Aktobe, Almaty, Atyrau, Western Kazakhstan, Zhambyl, Karaganda, Kostanai, Kyzylorda, Mangistau, Turkestan, Pavlodar, North Kazakhstan, Eastern Kazakhstan","Nur-Sultan, Almaty, Shymkent","This is a cross-sectional study of the adult population in Kazakhstan for the period from October 2021 to May 2022. We recruited 6 720 people aged 18 to 69 throughout Kazakhstan (17 regions including the cities of Almaty, Astana, and Shymkent). Participation in the study was completely voluntary.",,2021-10-15,2022-05-15,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,18-29 years,1728,0.2571,,,,,,,,Stratified probability,Alinity i SARS-CoV-2 IgG,Abbott Laboratories,"CLIA, CMIA",Serum,IgG,Nucleocapsid (N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Mukhtar Kulimbet,S.D. Asfendiyarov Kazakh National Medical University,Unity-Aligned,https://dx.doi.org/10.1017/S0950268823001085,2024-04-29,2024-04-29,Verified,kulimbet_study_2023,KAZ
210208_Kenya_KEMRI-WellcomeTrust_Kilifi_Overall_TestAdj,210208_Kenya_KEMRI-WellcomeTrust_KilifiNov,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in two Kenyan referral hospitals,2021-02-08,Preprint,Local,Repeated cross-sectional study,Kenya,Kilifi,Kilifi,"All mothers attending ANC for the first time, who provided a routine blood sample, were included in the study","Mothers who did not provide a sample at their first antenatal care visit, or mothers attending their second or subsequent ANC visit, were excluded.",2020-11-01,2020-11-24,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,154,0.11,0.062000000000000006,0.167,True,True,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['High'],Yes,No,No,No,Unclear,Unclear,Yes,Yes,Unclear,R Lucinde,KEMRI-Wellcome Trust,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.05.21250735v1.full-text,2021-04-15,2022-07-16,Verified,lucinde_sero-surveillance_2021,KEN
210208_Kenya_KEMRI-WellcomeTrust_Kilifi_Overall_Unadj,210208_Kenya_KEMRI-WellcomeTrust_KilifiNov,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in two Kenyan referral hospitals,2021-02-08,Preprint,Local,Repeated cross-sectional study,Kenya,,Kilifi,"All mothers attending ANC for the first time, who provided a routine blood sample, were included in the study","Mothers who did not provide a sample at their first antenatal care visit, or mothers attending their second or subsequent ANC visit, were excluded.",2020-11-01,2020-11-24,Pregnant or parturient women,Female,Adults (18-64 years),,,Analysis,,154,0.1039,,,,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['High'],Yes,No,No,No,Unclear,Unclear,Yes,Yes,Unclear,R Lucinde,KEMRI-Wellcome Trust,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.05.21250735v1.full-text,2021-04-15,2022-07-16,Verified,lucinde_sero-surveillance_2021,KEN
210208_Kenya_KEMRI-WellcomeTrust_KilifiOct_TestAdj,210208_Kenya_KEMRI-WellcomeTrust_KilifiOct,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in two Kenyan referral hospitals,2021-02-08,Preprint,Local,Repeated cross-sectional study,Kenya,,Kilifi,"All mothers attending ANC for the first time, who provided a routine blood sample, were included in the study","Mothers who did not provide a sample at their first antenatal care visit, or mothers attending their second or subsequent ANC visit, were excluded.",2020-10-01,2020-10-31,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,183,0.015,0.0007000000000000001,0.040999999999999995,True,True,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['High'],Yes,No,No,No,Unclear,Unclear,Yes,Yes,Unclear,R Lucinde,KEMRI-Wellcome Trust,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.05.21250735v1.full-text,2021-06-23,2022-07-16,Verified,lucinde_sero-surveillance_2021,KEN
210208_Kenya_KEMRI-WellcomeTrust_KilifiOct_Unadj,210208_Kenya_KEMRI-WellcomeTrust_KilifiOct,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in two Kenyan referral hospitals,2021-02-08,Preprint,Local,Repeated cross-sectional study,Kenya,,Kilifi,"All mothers attending ANC for the first time, who provided a routine blood sample, were included in the study","Mothers who did not provide a sample at their first antenatal care visit, or mothers attending their second or subsequent ANC visit, were excluded.",2020-10-01,2020-10-31,Pregnant or parturient women,Female,Adults (18-64 years),,,Analysis,,183,0.016,,,,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['High'],Yes,No,No,No,Unclear,Unclear,Yes,Yes,Unclear,R Lucinde,KEMRI-Wellcome Trust,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.05.21250735v1.full-text,2021-06-23,2022-07-16,Verified,lucinde_sero-surveillance_2021,KEN
210208_Kenya_KEMRI-WellcomeTrust_KilifiSept_TestAdj,210208_Kenya_KEMRI-WellcomeTrust_KilifiSept,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in two Kenyan referral hospitals,2021-02-08,Preprint,Local,Repeated cross-sectional study,Kenya,,Kilifi,"All mothers attending ANC for the first time, who provided a routine blood sample, were included in the study","Mothers who did not provide a sample at their first antenatal care visit, or mothers attending their second or subsequent ANC visit, were excluded.",2020-09-18,2020-09-30,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,82,0.013000000000000001,0.0004,0.047,True,True,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['High'],Yes,No,No,No,Unclear,Unclear,Yes,Yes,Unclear,R Lucinde,KEMRI-Wellcome Trust,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.05.21250735v1.full-text,2021-06-23,2022-07-16,Verified,lucinde_sero-surveillance_2021,KEN
210208_Kenya_KEMRI-WellcomeTrust_KilifiSept_Unadj,210208_Kenya_KEMRI-WellcomeTrust_KilifiSept,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in two Kenyan referral hospitals,2021-02-08,Preprint,Local,Repeated cross-sectional study,Kenya,,Kilifi,"All mothers attending ANC for the first time, who provided a routine blood sample, were included in the study","Mothers who did not provide a sample at their first antenatal care visit, or mothers attending their second or subsequent ANC visit, were excluded.",2020-09-18,2020-09-30,Pregnant or parturient women,Female,Adults (18-64 years),,,Analysis,,82,0.0,,,,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['High'],Yes,No,No,No,Unclear,Unclear,Yes,Yes,Unclear,R Lucinde,KEMRI-Wellcome Trust,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.05.21250735v1.full-text,2021-06-23,2022-07-16,Verified,lucinde_sero-surveillance_2021,KEN
210208_Kenya_KEMRI-WellcomeTrust_Nairobi_Overall_TestAdj,210208_Kenya_KEMRI-WellcomeTrust_Nairobi,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in two Kenyan referral hospitals,2021-02-08,Preprint,Local,Repeated cross-sectional study,Kenya,Nairobi,Nairobi,"All mothers attending ANC for the first time, who provided a routine blood sample, were included in the study","Mothers who did not provide a sample at their first antenatal care visit, or mothers attending their second or subsequent ANC visit, were excluded.",2020-07-30,2020-08-25,Pregnant or parturient women,Female,Adults (18-64 years),17.0,45.0,Primary Estimate,overall test adj,196,0.499,0.42700000000000005,0.58,True,True,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['High'],Yes,No,No,No,Unclear,Unclear,Yes,Yes,Unclear,R Lucinde,KEMRI-Wellcome Trust,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.05.21250735v1.full-text,2021-04-15,2022-07-16,Verified,lucinde_sero-surveillance_2021,KEN
210208_Kenya_KEMRI-WellcomeTrust_Nairobi_Overall_17-29,210208_Kenya_KEMRI-WellcomeTrust_Nairobi,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in two Kenyan referral hospitals,2021-02-08,Preprint,Local,Repeated cross-sectional study,Kenya,Nairobi,Nairobi,"All mothers attending ANC for the first time, who provided a routine blood sample, were included in the study","Mothers who did not provide a sample at their first antenatal care visit, or mothers attending their second or subsequent ANC visit, were excluded.",2020-07-30,2020-08-25,Pregnant or parturient women,Female,Adults (18-64 years),17.0,29.0,Age,17-29,91,0.418,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['High'],Yes,No,No,No,Unclear,Unclear,Yes,Yes,Unclear,R Lucinde,KEMRI-Wellcome Trust,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.05.21250735v1.full-text,2021-06-17,2022-07-16,Verified,lucinde_sero-surveillance_2021,KEN
210208_Kenya_KEMRI-WellcomeTrust_Nairobi_Overall_30-45,210208_Kenya_KEMRI-WellcomeTrust_Nairobi,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in two Kenyan referral hospitals,2021-02-08,Preprint,Local,Repeated cross-sectional study,Kenya,Nairobi,Nairobi,"All mothers attending ANC for the first time, who provided a routine blood sample, were included in the study","Mothers who did not provide a sample at their first antenatal care visit, or mothers attending their second or subsequent ANC visit, were excluded.",2020-07-30,2020-08-25,Pregnant or parturient women,Female,Adults (18-64 years),30.0,45.0,Age,30-45,90,0.489,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['High'],Yes,No,No,No,Unclear,Unclear,Yes,Yes,Unclear,R Lucinde,KEMRI-Wellcome Trust,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.05.21250735v1.full-text,2021-06-17,2022-07-16,Verified,lucinde_sero-surveillance_2021,KEN
210208_Kenya_KEMRI-WellcomeTrust_Nairobi_Overall_Unadj,210208_Kenya_KEMRI-WellcomeTrust_Nairobi,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in two Kenyan referral hospitals,2021-02-08,Preprint,Local,Repeated cross-sectional study,Kenya,Nairobi,Nairobi,"All mothers attending ANC for the first time, who provided a routine blood sample, were included in the study","Mothers who did not provide a sample at their first antenatal care visit, or mothers attending their second or subsequent ANC visit, were excluded.",2020-07-30,2020-08-25,Pregnant or parturient women,Female,Adults (18-64 years),17.0,45.0,Analysis,overall crude,196,0.4643,,,,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['High'],Yes,No,No,No,Unclear,Unclear,Yes,Yes,Unclear,R Lucinde,KEMRI-Wellcome Trust,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.05.21250735v1.full-text,2021-04-15,2022-07-16,Verified,lucinde_sero-surveillance_2021,KEN
210217_Kenya_KEMRI-WellcomeTrustResearchProgramme_TestAdj,210217_Kenya_KEMRI-WellcomeTrustResearchProgramme,Seroprevalence of anti-SARS-CoV-2 IgG antibodies among truck drivers and assistants in Kenya,2021-02-17,Preprint,National,Cross-sectional survey ,Kenya,,,Truck drivers and assistants were eligible if they were aged ≥18 years without a medical contraindication for blood sample collection.,,2020-09-30,2020-10-23,Essential non-healthcare workers,All,Adults (18-64 years),18.0,,Primary Estimate,Overall test adj,830,0.423,0.384,0.46299999999999997,True,True,,,,Convenience,Not reported/ Unable to specify,,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,E Wangeci Kagucia,KEMRI-Wellcome Trust Research Programme,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.12.21251294v1,2021-03-16,2022-07-16,Verified,kagucia_seroprevalence_2021,KEN
210421_Kenya_KEMRI-WellcomeTrustResearchProgramme_TestAdj,210421_Kenya_KEMRI-WellcomeTrustResearchProgramme,Seroprevalence of Antibodies to SARS-CoV-2 among Health Care Workers in Kenya,2021-04-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kenya,"Central, Coastal, Western",,HCWs of all cadres were eligible to participate in the study.,,2020-07-30,2020-12-04,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,Test adj,684,0.20800000000000002,0.17500000000000002,0.244,True,True,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab346,2021-05-23,2022-07-16,Verified,etyang_seroprevalence_2021,KEN
210612_Kenya_KEMRI-WellcomeTrustResearchProgramme_PrimaryTestAdj,210612_Kenya_KEMRI-WellcomeTrustResearchProgramme,Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin G Antibody Seroprevalence among Truck Drivers and Assistants in Kenya,2021-06-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Kenya,"Western Province, Coast Province ","Magarini, Busia, Malaba",Truckers and drivers’ assistants were eligible if they were aged ≥18 years without a medical  contraindication for blood sample collection.,Consent not provided,2020-09-30,2020-10-23,Essential non-healthcare workers,All,Adults (18-64 years),18.0,,Primary Estimate,Primary Test Adjusted (Overall),830,0.423,0.384,0.46299999999999997,True,True,,,,Convenience,Not reported/ Unable to specify,,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,0.99,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Eunice Kagucia,KEMRI-Wellcome Trust Research Programme,Not Unity-Aligned,http://dx.doi.org/10.1093/ofid/ofab314,2021-08-24,2022-07-16,Verified,kagucia_anti-severe_2021,KEN
210625_Kenya_KEMRI-WellcomeTrustResearchProgramme_overall_adj,210625_Kenya_KEMRI-WellcomeTrustResearchProgramme,Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya.,2021-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kenya,,,"Regional centre criteria outlines these guidelines: Individuals aged 16-65 years, weighing 50 kg, with haemoglobin of 12.5 g/dl, a normal blood pressure (systolic 120-129 mmHg and diastolic BP of 80-89 mmHg), a pulse rate of 60-100 BPM and without any history of illness in the past 6 months. ","Excluded duplicate samples, those from age-ineligible donors and those with missing data. ",2020-04-30,2020-09-30,Blood donors,All,Adults (18-64 years),15.0,64.0,Primary Estimate,,9922,0.079,0.067,0.09,True,True,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Ifedayo M. O. Adetifa,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-24062-3,2021-07-07,2022-07-16,Verified,adetifa_temporal_2021-1,KEN
210625_Kenya_KEMRI-WellcomeTrustResearchProgramme_overall_Age45-54,210625_Kenya_KEMRI-WellcomeTrustResearchProgramme,Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya.,2021-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kenya,,,"Regional centre criteria outlines these guidelines: Individuals aged 16-65 years, weighing 50 kg, with haemoglobin of 12.5 g/dl, a normal blood pressure (systolic 120-129 mmHg and diastolic BP of 80-89 mmHg), a pulse rate of 60-100 BPM and without any history of illness in the past 6 months. ","Excluded duplicate samples, those from age-ineligible donors and those with missing data. ",2020-04-30,2020-09-30,Blood donors,All,Adults (18-64 years),45.0,54.0,Age,45-54,794,0.073,0.055,0.08900000000000001,,True,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Ifedayo M. O. Adetifa,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-24062-3,2021-08-05,2022-07-16,Verified,adetifa_temporal_2021-1,KEN
210625_Kenya_KEMRI-WellcomeTrustResearchProgramme_overall_Female,210625_Kenya_KEMRI-WellcomeTrustResearchProgramme,Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya.,2021-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kenya,,,"Regional centre criteria outlines these guidelines: Individuals aged 16-65 years, weighing 50 kg, with haemoglobin of 12.5 g/dl, a normal blood pressure (systolic 120-129 mmHg and diastolic BP of 80-89 mmHg), a pulse rate of 60-100 BPM and without any history of illness in the past 6 months. ","Excluded duplicate samples, those from age-ineligible donors and those with missing data. ",2020-04-30,2020-09-30,Blood donors,Female,Adults (18-64 years),15.0,24.0,Sex/Gender,,1903,0.07400000000000001,0.059000000000000004,0.08900000000000001,,True,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Ifedayo M. O. Adetifa,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-24062-3,2021-08-05,2022-07-16,Verified,adetifa_temporal_2021-1,KEN
210625_Kenya_KEMRI-WellcomeTrustResearchProgramme_overall_Age55-64,210625_Kenya_KEMRI-WellcomeTrustResearchProgramme,Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya.,2021-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kenya,,,"Regional centre criteria outlines these guidelines: Individuals aged 16-65 years, weighing 50 kg, with haemoglobin of 12.5 g/dl, a normal blood pressure (systolic 120-129 mmHg and diastolic BP of 80-89 mmHg), a pulse rate of 60-100 BPM and without any history of illness in the past 6 months. ","Excluded duplicate samples, those from age-ineligible donors and those with missing data. ",2020-04-30,2020-09-30,Blood donors,All,Adults (18-64 years),55.0,64.0,Age,55-64,202,0.07200000000000001,0.052000000000000005,0.091,,True,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Ifedayo M. O. Adetifa,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-24062-3,2021-08-05,2022-07-16,Verified,adetifa_temporal_2021-1,KEN
210625_Kenya_KEMRI-WellcomeTrustResearchProgramme_overall_Age35-44,210625_Kenya_KEMRI-WellcomeTrustResearchProgramme,Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya.,2021-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kenya,,,"Regional centre criteria outlines these guidelines: Individuals aged 16-65 years, weighing 50 kg, with haemoglobin of 12.5 g/dl, a normal blood pressure (systolic 120-129 mmHg and diastolic BP of 80-89 mmHg), a pulse rate of 60-100 BPM and without any history of illness in the past 6 months. ","Excluded duplicate samples, those from age-ineligible donors and those with missing data. ",2020-04-30,2020-09-30,Blood donors,All,Adults (18-64 years),35.0,44.0,Age,35-44,2262,0.083,0.069,0.098,,True,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Ifedayo M. O. Adetifa,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-24062-3,2021-08-05,2022-07-16,Verified,adetifa_temporal_2021-1,KEN
210625_Kenya_KEMRI-WellcomeTrustResearchProgramme_Period3,210625_Kenya_KEMRI-WellcomeTrustResearchProgramme,Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya.,2021-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kenya,,,"Regional centre criteria outlines these guidelines: Individuals aged 16-65 years, weighing 50 kg, with haemoglobin of 12.5 g/dl, a normal blood pressure (systolic 120-129 mmHg and diastolic BP of 80-89 mmHg), a pulse rate of 60-100 BPM and without any history of illness in the past 6 months. ","Excluded duplicate samples, those from age-ineligible donors and those with missing data. ",2020-08-20,2020-09-30,Blood donors,All,Adults (18-64 years),15.0,64.0,Time frame,Aug 20 - Sep 30,3723,0.091,0.076,0.10800000000000001,,True,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Ifedayo M. O. Adetifa,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-24062-3,2021-08-05,2022-07-16,Verified,adetifa_temporal_2021-1,KEN
210625_Kenya_KEMRI-WellcomeTrustResearchProgramme_overall_Age15-24,210625_Kenya_KEMRI-WellcomeTrustResearchProgramme,Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya.,2021-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kenya,,,"Regional centre criteria outlines these guidelines: Individuals aged 16-65 years, weighing 50 kg, with haemoglobin of 12.5 g/dl, a normal blood pressure (systolic 120-129 mmHg and diastolic BP of 80-89 mmHg), a pulse rate of 60-100 BPM and without any history of illness in the past 6 months. ","Excluded duplicate samples, those from age-ineligible donors and those with missing data. ",2020-04-30,2020-09-30,Blood donors,All,Adults (18-64 years),15.0,24.0,Age,15-24,2763,0.075,0.062000000000000006,0.08800000000000001,,True,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Ifedayo M. O. Adetifa,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-24062-3,2021-08-05,2022-07-16,Verified,adetifa_temporal_2021-1,KEN
210625_Kenya_KEMRI-WellcomeTrustResearchProgramme_Period1,210625_Kenya_KEMRI-WellcomeTrustResearchProgramme,Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya.,2021-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kenya,,,"Regional centre criteria outlines these guidelines: Individuals aged 16-65 years, weighing 50 kg, with haemoglobin of 12.5 g/dl, a normal blood pressure (systolic 120-129 mmHg and diastolic BP of 80-89 mmHg), a pulse rate of 60-100 BPM and without any history of illness in the past 6 months. ","Excluded duplicate samples, those from age-ineligible donors and those with missing data. ",2020-04-30,2020-06-19,Blood donors,All,Adults (18-64 years),15.0,64.0,Time frame,Apr 30 - Jun 19,3362,0.052000000000000005,0.037000000000000005,0.067,,True,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Ifedayo M. O. Adetifa,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-24062-3,2021-08-05,2022-07-16,Verified,adetifa_temporal_2021-1,KEN
210625_Kenya_KEMRI-WellcomeTrustResearchProgramme_Period2,210625_Kenya_KEMRI-WellcomeTrustResearchProgramme,Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya.,2021-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kenya,,,"Regional centre criteria outlines these guidelines: Individuals aged 16-65 years, weighing 50 kg, with haemoglobin of 12.5 g/dl, a normal blood pressure (systolic 120-129 mmHg and diastolic BP of 80-89 mmHg), a pulse rate of 60-100 BPM and without any history of illness in the past 6 months. ","Excluded duplicate samples, those from age-ineligible donors and those with missing data. ",2020-06-20,2020-08-19,Blood donors,All,Adults (18-64 years),15.0,64.0,Time frame,June 20 - Aug 19,3837,0.091,0.07200000000000001,0.113,,True,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Ifedayo M. O. Adetifa,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-24062-3,2021-08-05,2022-07-16,Verified,adetifa_temporal_2021-1,KEN
210625_Kenya_KEMRI-WellcomeTrustResearchProgramme_overall_Unadj,210625_Kenya_KEMRI-WellcomeTrustResearchProgramme,Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya.,2021-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kenya,,,"Regional centre criteria outlines these guidelines: Individuals aged 16-65 years, weighing 50 kg, with haemoglobin of 12.5 g/dl, a normal blood pressure (systolic 120-129 mmHg and diastolic BP of 80-89 mmHg), a pulse rate of 60-100 BPM and without any history of illness in the past 6 months. ","Excluded duplicate samples, those from age-ineligible donors and those with missing data. ",2020-04-30,2020-09-30,Blood donors,All,Adults (18-64 years),15.0,64.0,Analysis,,9922,0.094,0.08800000000000001,0.099,,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Ifedayo M. O. Adetifa,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-24062-3,2021-07-07,2022-07-16,Verified,adetifa_temporal_2021-1,KEN
210625_Kenya_KEMRI-WellcomeTrustResearchProgramme_overall_Male,210625_Kenya_KEMRI-WellcomeTrustResearchProgramme,Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya.,2021-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kenya,,,"Regional centre criteria outlines these guidelines: Individuals aged 16-65 years, weighing 50 kg, with haemoglobin of 12.5 g/dl, a normal blood pressure (systolic 120-129 mmHg and diastolic BP of 80-89 mmHg), a pulse rate of 60-100 BPM and without any history of illness in the past 6 months. ","Excluded duplicate samples, those from age-ineligible donors and those with missing data. ",2020-04-30,2020-09-30,Blood donors,Male,Adults (18-64 years),15.0,64.0,Sex/Gender,,8019,0.084,0.07200000000000001,0.095,,True,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Ifedayo M. O. Adetifa,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-24062-3,2021-08-05,2022-07-16,Verified,adetifa_temporal_2021-1,KEN
210625_Kenya_KEMRI-WellcomeTrustResearchProgramme_overall_Age25-34,210625_Kenya_KEMRI-WellcomeTrustResearchProgramme,Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya.,2021-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kenya,,,"Regional centre criteria outlines these guidelines: Individuals aged 16-65 years, weighing 50 kg, with haemoglobin of 12.5 g/dl, a normal blood pressure (systolic 120-129 mmHg and diastolic BP of 80-89 mmHg), a pulse rate of 60-100 BPM and without any history of illness in the past 6 months. ","Excluded duplicate samples, those from age-ineligible donors and those with missing data. ",2020-04-30,2020-09-30,Blood donors,All,Adults (18-64 years),25.0,34.0,Age,25-34,3902,0.085,0.07200000000000001,0.098,,True,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Ifedayo M. O. Adetifa,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-24062-3,2021-08-05,2022-07-16,Verified,adetifa_temporal_2021-1,KEN
210726_Dagahaley_MédecinsSansFrontières_FamilyMembers,210726_Dagahaley_MédecinsSansFrontières_FamilyMembers,"Seroprevalence of SARS-CoV-2 Antibodies and Retrospective Mortality in a Refugee Camp, Dagahaley, Kenya",2021-07-26,Preprint,Local,Cross-sectional survey ,Kenya,,"Dagahaley camp, Daadab Refugee Complex","All CHWs and TBAs working in Dagahaley
121 camp and their household members",,2021-03-01,2021-04-14,Multiple populations,All,Multiple groups,0.0,,Primary Estimate,"overall: traditional birth attendants, community health workers, and their family members",587,0.092,,,True,,,,True,Convenience,Biosynex COVID-19 BSS assay,Biosynex,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.958,0.981,['High'],,No,No,Yes,,Yes,Yes,Yes,,Etienne Gignoux,Médicins Sans Frontières,Not Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3893538,2021-08-03,2024-03-01,Unverified,gignoux_seroprevalence_2021,KEN
210726_Dagahaley_MédecinsSansFrontières_Patients_Overall,210726_Dagahaley_MédecinsSansFrontières_Patients,"Seroprevalence of SARS-CoV-2 Antibodies and Retrospective Mortality in a Refugee Camp, Dagahaley, Kenya",2021-07-26,Preprint,Local,Cross-sectional survey ,Kenya,,"Dagahaley camp, Daadab Refugee Complex","Patients and caretakers presenting at MSF-
122 supported health centres in Dagahaley camp",,2021-03-01,2021-04-14,Multiple populations,All,Multiple groups,0.0,,Primary Estimate,,619,0.069,,,True,,,,True,Sequential,Biosynex COVID-19 BSS assay,Biosynex,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.958,0.981,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Etienne Gignoux,Médicins Sans Frontières,Not Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3893538,2021-08-03,2024-03-01,Unverified,gignoux_seroprevalence_2021,KEN
210726_Dagahaley_MédecinsSansFrontières_Patients_20-34,210726_Dagahaley_MédecinsSansFrontières_Patients,"Seroprevalence of SARS-CoV-2 Antibodies and Retrospective Mortality in a Refugee Camp, Dagahaley, Kenya",2021-07-26,Preprint,Local,Cross-sectional survey ,Kenya,,"Dagahaley camp, Daadab Refugee Complex","Patients and caretakers presenting at MSF-
122 supported health centres in Dagahaley camp",,2021-03-01,2021-04-14,Multiple populations,All,Adults (18-64 years),20.0,34.0,Age,20-34,124,0.073,,,,,,,,Sequential,Biosynex COVID-19 BSS assay,Biosynex,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.958,0.981,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Etienne Gignoux,Médicins Sans Frontières,Not Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3893538,2021-08-03,2024-03-01,Unverified,gignoux_seroprevalence_2021,KEN
210726_Dagahaley_MédecinsSansFrontières_Patients_50+,210726_Dagahaley_MédecinsSansFrontières_Patients,"Seroprevalence of SARS-CoV-2 Antibodies and Retrospective Mortality in a Refugee Camp, Dagahaley, Kenya",2021-07-26,Preprint,Local,Cross-sectional survey ,Kenya,,"Dagahaley camp, Daadab Refugee Complex","Patients and caretakers presenting at MSF-
122 supported health centres in Dagahaley camp",,2021-03-01,2021-04-14,Multiple populations,All,Adults (18-64 years),50.0,,Age,50+,164,0.122,,,,,,,,Sequential,Biosynex COVID-19 BSS assay,Biosynex,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.958,0.981,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Etienne Gignoux,Médicins Sans Frontières,Not Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3893538,2021-08-03,2024-03-01,Unverified,gignoux_seroprevalence_2021,KEN
210726_Dagahaley_MédecinsSansFrontières_Patients_0-19,210726_Dagahaley_MédecinsSansFrontières_Patients,"Seroprevalence of SARS-CoV-2 Antibodies and Retrospective Mortality in a Refugee Camp, Dagahaley, Kenya",2021-07-26,Preprint,Local,Cross-sectional survey ,Kenya,,"Dagahaley camp, Daadab Refugee Complex","Patients and caretakers presenting at MSF-
122 supported health centres in Dagahaley camp",,2021-03-01,2021-04-14,Multiple populations,All,Children and Youth (0-17 years),0.0,19.0,Age,0-19,156,0.032,,,,,,,,Sequential,Biosynex COVID-19 BSS assay,Biosynex,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.958,0.981,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Etienne Gignoux,Médicins Sans Frontières,Not Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3893538,2021-08-03,2024-03-01,Unverified,gignoux_seroprevalence_2021,KEN
210726_Dagahaley_MédecinsSansFrontières_Patients_35-49,210726_Dagahaley_MédecinsSansFrontières_Patients,"Seroprevalence of SARS-CoV-2 Antibodies and Retrospective Mortality in a Refugee Camp, Dagahaley, Kenya",2021-07-26,Preprint,Local,Cross-sectional survey ,Kenya,,"Dagahaley camp, Daadab Refugee Complex","Patients and caretakers presenting at MSF-
122 supported health centres in Dagahaley camp",,2021-03-01,2021-04-14,Multiple populations,All,Adults (18-64 years),35.0,49.0,Age,34-49,175,0.051,,,,,,,,Sequential,Biosynex COVID-19 BSS assay,Biosynex,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.958,0.981,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Etienne Gignoux,Médicins Sans Frontières,Not Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3893538,2021-08-03,2024-03-01,Unverified,gignoux_seroprevalence_2021,KEN
210826_Nairobi_KenyaMedicalResearchInstitute_Overall_PopAdjusted,210826_Nairobi_KenyaMedicalResearchInstitute,Seroprevalence and risk factors of SARS-CoV-2 infection in an urban informal settlement in Nairobi,2021-08-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kenya,Nairobi,,"All residents of the Kibera settlement in Nairobi, Kenya.  ""all household members, both adults and children, regardless of current or prior COVID-19 infection status.""",,2020-11-27,2020-12-05,Household and community samples,All,Multiple groups,,,Primary Estimate,,511,0.433,0.374,0.495,True,,True,True,True,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Patrick Munywoki,Kenya Medical Research Institute,Unity-Aligned,https://f1000research.com/articles/10-853,2021-11-04,2024-03-01,Verified,munywoki_seroprevalence_2021,KEN
210826_Nairobi_KenyaMedicalResearchInstitute_Age20-29_PopAdj,210826_Nairobi_KenyaMedicalResearchInstitute,Seroprevalence and risk factors of SARS-CoV-2 infection in an urban informal settlement in Nairobi,2021-08-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kenya,Nairobi,,"All residents of the Kibera settlement in Nairobi, Kenya.  ""all household members, both adults and children, regardless of current or prior COVID-19 infection status.""",,2020-11-27,2020-12-05,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,84,0.6070000000000001,0.478,0.723,,,True,True,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Patrick Munywoki,Kenya Medical Research Institute,Unity-Aligned,https://f1000research.com/articles/10-853,2021-11-04,2024-03-01,Verified,munywoki_seroprevalence_2021,KEN
210826_Nairobi_KenyaMedicalResearchInstitute_Age30-39_PopAdj,210826_Nairobi_KenyaMedicalResearchInstitute,Seroprevalence and risk factors of SARS-CoV-2 infection in an urban informal settlement in Nairobi,2021-08-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kenya,Nairobi,,"All residents of the Kibera settlement in Nairobi, Kenya.  ""all household members, both adults and children, regardless of current or prior COVID-19 infection status.""",,2020-11-27,2020-12-05,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,,82,0.485,0.325,0.648,,,True,True,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Patrick Munywoki,Kenya Medical Research Institute,Unity-Aligned,https://f1000research.com/articles/10-853,2021-11-04,2024-03-01,Verified,munywoki_seroprevalence_2021,KEN
210826_Nairobi_KenyaMedicalResearchInstitute_Age5-9_PopAdj,210826_Nairobi_KenyaMedicalResearchInstitute,Seroprevalence and risk factors of SARS-CoV-2 infection in an urban informal settlement in Nairobi,2021-08-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kenya,Nairobi,,"All residents of the Kibera settlement in Nairobi, Kenya.  ""all household members, both adults and children, regardless of current or prior COVID-19 infection status.""",,2020-11-27,2020-12-05,Household and community samples,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,79,0.327,0.22899999999999998,0.444,,,True,True,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Patrick Munywoki,Kenya Medical Research Institute,Unity-Aligned,https://f1000research.com/articles/10-853,2021-11-04,2024-03-01,Verified,munywoki_seroprevalence_2021,KEN
210826_Nairobi_KenyaMedicalResearchInstitute_Age10-19_PopAdj,210826_Nairobi_KenyaMedicalResearchInstitute,Seroprevalence and risk factors of SARS-CoV-2 infection in an urban informal settlement in Nairobi,2021-08-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kenya,Nairobi,,"All residents of the Kibera settlement in Nairobi, Kenya.  ""all household members, both adults and children, regardless of current or prior COVID-19 infection status.""",,2020-11-27,2020-12-05,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,150,0.418,0.33,0.511,,,True,True,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Patrick Munywoki,Kenya Medical Research Institute,Unity-Aligned,https://f1000research.com/articles/10-853,2021-11-04,2024-03-01,Verified,munywoki_seroprevalence_2021,KEN
210826_Nairobi_KenyaMedicalResearchInstitute_Age60+_PopAdj,210826_Nairobi_KenyaMedicalResearchInstitute,Seroprevalence and risk factors of SARS-CoV-2 infection in an urban informal settlement in Nairobi,2021-08-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kenya,Nairobi,,"All residents of the Kibera settlement in Nairobi, Kenya.  ""all household members, both adults and children, regardless of current or prior COVID-19 infection status.""",,2020-11-27,2020-12-05,Household and community samples,All,Seniors (65+ years),60.0,,Age,60+,7,0.526,0.132,0.89,,,True,True,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Patrick Munywoki,Kenya Medical Research Institute,Unity-Aligned,https://f1000research.com/articles/10-853,2021-11-04,2024-03-01,Verified,munywoki_seroprevalence_2021,KEN
210826_Nairobi_KenyaMedicalResearchInstitute_Overall_Unadjusted,210826_Nairobi_KenyaMedicalResearchInstitute,Seroprevalence and risk factors of SARS-CoV-2 infection in an urban informal settlement in Nairobi,2021-08-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kenya,Nairobi,,"All residents of the Kibera settlement in Nairobi, Kenya.  ""all household members, both adults and children, regardless of current or prior COVID-19 infection status.""",,2020-11-27,2020-12-05,Household and community samples,All,Multiple groups,,,Analysis,,511,0.434,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Patrick Munywoki,Kenya Medical Research Institute,Unity-Aligned,https://f1000research.com/articles/10-853,2021-11-04,2024-03-01,Verified,munywoki_seroprevalence_2021,KEN
210826_Nairobi_KenyaMedicalResearchInstitute_Age0-4_PopAdj,210826_Nairobi_KenyaMedicalResearchInstitute,Seroprevalence and risk factors of SARS-CoV-2 infection in an urban informal settlement in Nairobi,2021-08-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kenya,Nairobi,,"All residents of the Kibera settlement in Nairobi, Kenya.  ""all household members, both adults and children, regardless of current or prior COVID-19 infection status.""",,2020-11-27,2020-12-05,Household and community samples,All,Children and Youth (0-17 years),0.0,4.0,Age,0-4,41,0.076,0.024,0.21300000000000002,,,True,True,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Patrick Munywoki,Kenya Medical Research Institute,Unity-Aligned,https://f1000research.com/articles/10-853,2021-11-04,2024-03-01,Verified,munywoki_seroprevalence_2021,KEN
210826_Nairobi_KenyaMedicalResearchInstitute_SexMale_PopAdj,210826_Nairobi_KenyaMedicalResearchInstitute,Seroprevalence and risk factors of SARS-CoV-2 infection in an urban informal settlement in Nairobi,2021-08-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kenya,Nairobi,,"All residents of the Kibera settlement in Nairobi, Kenya.  ""all household members, both adults and children, regardless of current or prior COVID-19 infection status.""",,2020-11-27,2020-12-05,Household and community samples,Male,Multiple groups,,,Sex/Gender,,212,0.433,0.344,0.526,,,True,True,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Patrick Munywoki,Kenya Medical Research Institute,Unity-Aligned,https://f1000research.com/articles/10-853,2021-11-04,2024-03-01,Verified,munywoki_seroprevalence_2021,KEN
210826_Nairobi_KenyaMedicalResearchInstitute_Age40-49_PopAdj,210826_Nairobi_KenyaMedicalResearchInstitute,Seroprevalence and risk factors of SARS-CoV-2 infection in an urban informal settlement in Nairobi,2021-08-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kenya,Nairobi,,"All residents of the Kibera settlement in Nairobi, Kenya.  ""all household members, both adults and children, regardless of current or prior COVID-19 infection status.""",,2020-11-27,2020-12-05,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,,42,0.538,0.378,0.6900000000000001,,,True,True,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Patrick Munywoki,Kenya Medical Research Institute,Unity-Aligned,https://f1000research.com/articles/10-853,2021-11-04,2024-03-01,Verified,munywoki_seroprevalence_2021,KEN
210826_Nairobi_KenyaMedicalResearchInstitute_SexFemale_PopAdj,210826_Nairobi_KenyaMedicalResearchInstitute,Seroprevalence and risk factors of SARS-CoV-2 infection in an urban informal settlement in Nairobi,2021-08-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kenya,Nairobi,,"All residents of the Kibera settlement in Nairobi, Kenya.  ""all household members, both adults and children, regardless of current or prior COVID-19 infection status.""",,2020-11-27,2020-12-05,Household and community samples,Female,Multiple groups,,,Sex/Gender,,299,0.434,0.37,0.501,,,True,True,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Patrick Munywoki,Kenya Medical Research Institute,Unity-Aligned,https://f1000research.com/articles/10-853,2021-11-04,2024-03-01,Verified,munywoki_seroprevalence_2021,KEN
210826_Nairobi_KenyaMedicalResearchInstitute_Age50-59_PopAdj,210826_Nairobi_KenyaMedicalResearchInstitute,Seroprevalence and risk factors of SARS-CoV-2 infection in an urban informal settlement in Nairobi,2021-08-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kenya,Nairobi,,"All residents of the Kibera settlement in Nairobi, Kenya.  ""all household members, both adults and children, regardless of current or prior COVID-19 infection status.""",,2020-11-27,2020-12-05,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,,26,0.519,0.316,0.716,,,True,True,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9440000000000001,1.0,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Patrick Munywoki,Kenya Medical Research Institute,Unity-Aligned,https://f1000research.com/articles/10-853,2021-11-04,2024-03-01,Verified,munywoki_seroprevalence_2021,KEN
210902_Nairobi_WashingtonStateUniversity_TestAdjPopAdj,210902_Nairobi_WashingtonStateUniversity,"High seroprevalence of SARS-CoV-2 but low infection fatality ratio eight months after introduction in Nairobi, Kenya",2021-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kenya,,,Consenting residents in selected households (irrespective of age) who had lived in the city for at least six months preceding the survey were enrolled,Persons with reported or documented contraindications to venipuncture were excluded.,2020-11-02,2020-11-23,Household and community samples,All,Multiple groups,,,Primary Estimate,,1164,0.34700000000000003,0.318,0.376,True,True,True,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.9440000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Isaac Ngere,Washington State University,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.08.062,2021-10-12,2023-08-15,Verified,ngere_high_2021-1,KEN
210902_Nairobi_WashingtonStateUniversity_30-39,210902_Nairobi_WashingtonStateUniversity,"High seroprevalence of SARS-CoV-2 but low infection fatality ratio eight months after introduction in Nairobi, Kenya",2021-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kenya,,,Consenting residents in selected households (irrespective of age) who had lived in the city for at least six months preceding the survey were enrolled,Persons with reported or documented contraindications to venipuncture were excluded.,2020-11-02,2020-11-23,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,,241,0.408,0.344,0.473,,,True,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.9440000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Isaac Ngere,Washington State University,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.08.062,2021-10-12,2024-03-01,Verified,ngere_high_2021-1,KEN
210902_Nairobi_WashingtonStateUniversity_TestUnadjPopAdj,210902_Nairobi_WashingtonStateUniversity,"High seroprevalence of SARS-CoV-2 but low infection fatality ratio eight months after introduction in Nairobi, Kenya",2021-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kenya,,,Consenting residents in selected households (irrespective of age) who had lived in the city for at least six months preceding the survey were enrolled,Persons with reported or documented contraindications to venipuncture were excluded.,2020-11-02,2020-11-23,Household and community samples,All,Multiple groups,,,Analysis,,1164,0.327,0.30100000000000005,0.355,,,True,,True,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.9440000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Isaac Ngere,Washington State University,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.08.062,2021-10-12,2024-03-01,Verified,ngere_high_2021-1,KEN
210902_Nairobi_WashingtonStateUniversity_>60,210902_Nairobi_WashingtonStateUniversity,"High seroprevalence of SARS-CoV-2 but low infection fatality ratio eight months after introduction in Nairobi, Kenya",2021-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kenya,,,Consenting residents in selected households (irrespective of age) who had lived in the city for at least six months preceding the survey were enrolled,Persons with reported or documented contraindications to venipuncture were excluded.,2020-11-02,2020-11-23,Household and community samples,All,Seniors (65+ years),60.0,,Age,,40,0.226,0.07,0.381,,,True,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.9440000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Isaac Ngere,Washington State University,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.08.062,2021-10-12,2024-03-01,Verified,ngere_high_2021-1,KEN
210902_Nairobi_WashingtonStateUniversity_0-9,210902_Nairobi_WashingtonStateUniversity,"High seroprevalence of SARS-CoV-2 but low infection fatality ratio eight months after introduction in Nairobi, Kenya",2021-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kenya,,,Consenting residents in selected households (irrespective of age) who had lived in the city for at least six months preceding the survey were enrolled,Persons with reported or documented contraindications to venipuncture were excluded.,2020-11-02,2020-11-23,Household and community samples,All,Children and Youth (0-17 years),0.0,9.0,Age,0-9,179,0.185,0.13699999999999998,0.233,,,True,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.9440000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Isaac Ngere,Washington State University,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.08.062,2021-10-12,2024-03-01,Verified,ngere_high_2021-1,KEN
210902_Nairobi_WashingtonStateUniversity_Male,210902_Nairobi_WashingtonStateUniversity,"High seroprevalence of SARS-CoV-2 but low infection fatality ratio eight months after introduction in Nairobi, Kenya",2021-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kenya,,,Consenting residents in selected households (irrespective of age) who had lived in the city for at least six months preceding the survey were enrolled,Persons with reported or documented contraindications to venipuncture were excluded.,2020-11-02,2020-11-23,Household and community samples,Male,Multiple groups,,,Sex/Gender,,414,0.32,0.282,0.359,,,True,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.9440000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Isaac Ngere,Washington State University,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.08.062,2021-10-12,2024-03-01,Verified,ngere_high_2021-1,KEN
210902_Nairobi_WashingtonStateUniversity_10-19,210902_Nairobi_WashingtonStateUniversity,"High seroprevalence of SARS-CoV-2 but low infection fatality ratio eight months after introduction in Nairobi, Kenya",2021-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kenya,,,Consenting residents in selected households (irrespective of age) who had lived in the city for at least six months preceding the survey were enrolled,Persons with reported or documented contraindications to venipuncture were excluded.,2020-11-02,2020-11-23,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,244,0.316,0.25,0.38200000000000006,,,True,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.9440000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Isaac Ngere,Washington State University,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.08.062,2021-10-12,2024-03-01,Verified,ngere_high_2021-1,KEN
210902_Nairobi_WashingtonStateUniversity_Female,210902_Nairobi_WashingtonStateUniversity,"High seroprevalence of SARS-CoV-2 but low infection fatality ratio eight months after introduction in Nairobi, Kenya",2021-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kenya,,,Consenting residents in selected households (irrespective of age) who had lived in the city for at least six months preceding the survey were enrolled,Persons with reported or documented contraindications to venipuncture were excluded.,2020-11-02,2020-11-23,Household and community samples,Female,Multiple groups,,,Sex/Gender,,750,0.33299999999999996,0.295,0.371,,,True,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.9440000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Isaac Ngere,Washington State University,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.08.062,2021-10-12,2024-03-01,Verified,ngere_high_2021-1,KEN
210902_Nairobi_WashingtonStateUniversity_40-49,210902_Nairobi_WashingtonStateUniversity,"High seroprevalence of SARS-CoV-2 but low infection fatality ratio eight months after introduction in Nairobi, Kenya",2021-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kenya,,,Consenting residents in selected households (irrespective of age) who had lived in the city for at least six months preceding the survey were enrolled,Persons with reported or documented contraindications to venipuncture were excluded.,2020-11-02,2020-11-23,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,,134,0.384,0.295,0.473,,,True,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.9440000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Isaac Ngere,Washington State University,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.08.062,2021-10-12,2024-03-01,Verified,ngere_high_2021-1,KEN
210902_Nairobi_WashingtonStateUniversity_50-59,210902_Nairobi_WashingtonStateUniversity,"High seroprevalence of SARS-CoV-2 but low infection fatality ratio eight months after introduction in Nairobi, Kenya",2021-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kenya,,,Consenting residents in selected households (irrespective of age) who had lived in the city for at least six months preceding the survey were enrolled,Persons with reported or documented contraindications to venipuncture were excluded.,2020-11-02,2020-11-23,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,,61,0.36600000000000005,0.23199999999999998,0.5,,,True,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.9440000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Isaac Ngere,Washington State University,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.08.062,2021-10-12,2024-03-01,Verified,ngere_high_2021-1,KEN
210902_Nairobi_WashingtonStateUniversity_20-29,210902_Nairobi_WashingtonStateUniversity,"High seroprevalence of SARS-CoV-2 but low infection fatality ratio eight months after introduction in Nairobi, Kenya",2021-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kenya,,,Consenting residents in selected households (irrespective of age) who had lived in the city for at least six months preceding the survey were enrolled,Persons with reported or documented contraindications to venipuncture were excluded.,2020-11-02,2020-11-23,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,265,0.371,0.317,0.425,,,True,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.9440000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Isaac Ngere,Washington State University,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.08.062,2021-10-12,2024-03-01,Verified,ngere_high_2021-1,KEN
210902_Kenya_KEMRI-WellcomeTrustResearchProgramme_OverallPopAndTestAdjusted,210902_Kenya_KEMRI-WellcomeTrustResearchProgramme,"Prevalence of SARS-CoV-2 Antibodies From a National Serosurveillance of Kenyan Blood Donors, January-March 2021.",2021-09-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kenya,,,Plasma samples with complete donor demographic data and sufficient volume collected from all 6 regional transfusion centers were included and assayed for anti–spike IgG using an enzymelinked immunosorbent assay.,"Forty-four samples were excluded because of missing information, age-ineligible donors, or collection date before 2021.",2021-01-03,2021-03-15,Blood donors,All,Multiple groups,16.0,64.0,Primary Estimate,Population and Test adjusted,3018,0.485,0.452,0.521,True,True,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Moderate'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Sophie Uyoga,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://dx.doi.org/10.1001/jama.2021.15265,2021-09-09,2022-07-16,Verified,uyoga_prevalence_2021-1,KEN
210902_Kenya_KEMRI-WellcomeTrustResearchProgramme_Mombasa,210902_Kenya_KEMRI-WellcomeTrustResearchProgramme,"Prevalence of SARS-CoV-2 Antibodies From a National Serosurveillance of Kenyan Blood Donors, January-March 2021.",2021-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kenya,,Mombasa,Plasma samples with complete donor demographic data and sufficient volume collected from all 6 regional transfusion centers were included and assayed for anti–spike IgG using an enzymelinked immunosorbent assay.,"Forty-four samples were excluded because of missing information, age-ineligible donors, or collection date before 2021.",2021-01-03,2021-03-15,Blood donors,All,Multiple groups,16.0,64.0,Geographical area,Mombasa,441,0.436,0.391,0.484,,,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Moderate'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Sophie Uyoga,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://dx.doi.org/10.1001/jama.2021.15265,2021-09-09,2022-07-16,Verified,uyoga_prevalence_2021-1,KEN
210902_Kenya_KEMRI-WellcomeTrustResearchProgramme_Male,210902_Kenya_KEMRI-WellcomeTrustResearchProgramme,"Prevalence of SARS-CoV-2 Antibodies From a National Serosurveillance of Kenyan Blood Donors, January-March 2021.",2021-09-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kenya,,,Plasma samples with complete donor demographic data and sufficient volume collected from all 6 regional transfusion centers were included and assayed for anti–spike IgG using an enzymelinked immunosorbent assay.,"Forty-four samples were excluded because of missing information, age-ineligible donors, or collection date before 2021.",2021-01-03,2021-03-15,Blood donors,Male,Multiple groups,16.0,64.0,Sex/Gender,,2357,0.454,0.43,0.478,,,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Moderate'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Sophie Uyoga,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://dx.doi.org/10.1001/jama.2021.15265,2021-09-09,2022-07-16,Verified,uyoga_prevalence_2021-1,KEN
210902_Kenya_KEMRI-WellcomeTrustResearchProgramme_55-64,210902_Kenya_KEMRI-WellcomeTrustResearchProgramme,"Prevalence of SARS-CoV-2 Antibodies From a National Serosurveillance of Kenyan Blood Donors, January-March 2021.",2021-09-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kenya,,,Plasma samples with complete donor demographic data and sufficient volume collected from all 6 regional transfusion centers were included and assayed for anti–spike IgG using an enzymelinked immunosorbent assay.,"Forty-four samples were excluded because of missing information, age-ineligible donors, or collection date before 2021.",2021-01-03,2021-03-15,Blood donors,All,Adults (18-64 years),55.0,64.0,Age,55-64,41,0.439,0.37200000000000005,0.49600000000000005,,,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Moderate'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Sophie Uyoga,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://dx.doi.org/10.1001/jama.2021.15265,2021-09-09,2022-07-16,Verified,uyoga_prevalence_2021-1,KEN
210902_Kenya_KEMRI-WellcomeTrustResearchProgramme_OveralPopAdjusted,210902_Kenya_KEMRI-WellcomeTrustResearchProgramme,"Prevalence of SARS-CoV-2 Antibodies From a National Serosurveillance of Kenyan Blood Donors, January-March 2021.",2021-09-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kenya,,,Plasma samples with complete donor demographic data and sufficient volume collected from all 6 regional transfusion centers were included and assayed for anti–spike IgG using an enzymelinked immunosorbent assay.,"Forty-four samples were excluded because of missing information, age-ineligible donors, or collection date before 2021.",2021-01-03,2021-03-15,Blood donors,All,Multiple groups,16.0,64.0,Analysis,Population adjusted,3018,0.45299999999999996,0.42700000000000005,0.478,,,True,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Moderate'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Sophie Uyoga,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://dx.doi.org/10.1001/jama.2021.15265,2021-09-09,2022-07-16,Verified,uyoga_prevalence_2021-1,KEN
210902_Kenya_KEMRI-WellcomeTrustResearchProgramme_Western,210902_Kenya_KEMRI-WellcomeTrustResearchProgramme,"Prevalence of SARS-CoV-2 Antibodies From a National Serosurveillance of Kenyan Blood Donors, January-March 2021.",2021-09-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Kenya,Western,,Plasma samples with complete donor demographic data and sufficient volume collected from all 6 regional transfusion centers were included and assayed for anti–spike IgG using an enzymelinked immunosorbent assay.,"Forty-four samples were excluded because of missing information, age-ineligible donors, or collection date before 2021.",2021-01-03,2021-03-15,Blood donors,All,Multiple groups,16.0,64.0,Geographical area,Western Region,72,0.353,0.257,0.44799999999999995,,,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Moderate'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Sophie Uyoga,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://dx.doi.org/10.1001/jama.2021.15265,2021-09-09,2022-07-16,Verified,uyoga_prevalence_2021-1,KEN
210902_Kenya_KEMRI-WellcomeTrustResearchProgramme_45-54,210902_Kenya_KEMRI-WellcomeTrustResearchProgramme,"Prevalence of SARS-CoV-2 Antibodies From a National Serosurveillance of Kenyan Blood Donors, January-March 2021.",2021-09-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kenya,,,Plasma samples with complete donor demographic data and sufficient volume collected from all 6 regional transfusion centers were included and assayed for anti–spike IgG using an enzymelinked immunosorbent assay.,"Forty-four samples were excluded because of missing information, age-ineligible donors, or collection date before 2021.",2021-01-03,2021-03-15,Blood donors,All,Adults (18-64 years),45.0,54.0,Age,45-54,198,0.459,0.41600000000000004,0.51,,,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Moderate'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Sophie Uyoga,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://dx.doi.org/10.1001/jama.2021.15265,2021-09-09,2022-07-16,Verified,uyoga_prevalence_2021-1,KEN
210902_Kenya_KEMRI-WellcomeTrustResearchProgramme_RiftValley,210902_Kenya_KEMRI-WellcomeTrustResearchProgramme,"Prevalence of SARS-CoV-2 Antibodies From a National Serosurveillance of Kenyan Blood Donors, January-March 2021.",2021-09-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Kenya,Rift Valley,,Plasma samples with complete donor demographic data and sufficient volume collected from all 6 regional transfusion centers were included and assayed for anti–spike IgG using an enzymelinked immunosorbent assay.,"Forty-four samples were excluded because of missing information, age-ineligible donors, or collection date before 2021.",2021-01-03,2021-03-15,Blood donors,All,Multiple groups,16.0,64.0,Geographical area,Rift Valley Region,637,0.478,0.43700000000000006,0.52,,,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Moderate'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Sophie Uyoga,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://dx.doi.org/10.1001/jama.2021.15265,2021-09-09,2022-07-16,Verified,uyoga_prevalence_2021-1,KEN
210902_Kenya_KEMRI-WellcomeTrustResearchProgramme_EasternNorthEastern,210902_Kenya_KEMRI-WellcomeTrustResearchProgramme,"Prevalence of SARS-CoV-2 Antibodies From a National Serosurveillance of Kenyan Blood Donors, January-March 2021.",2021-09-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Kenya,"Eastern Province, North Eastern Province",,Plasma samples with complete donor demographic data and sufficient volume collected from all 6 regional transfusion centers were included and assayed for anti–spike IgG using an enzymelinked immunosorbent assay.,"Forty-four samples were excluded because of missing information, age-ineligible donors, or collection date before 2021.",2021-01-03,2021-03-15,Blood donors,All,Multiple groups,16.0,64.0,Geographical area,Eastern/North Eastern Region,595,0.455,0.41500000000000004,0.49600000000000005,,,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Moderate'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Sophie Uyoga,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://dx.doi.org/10.1001/jama.2021.15265,2021-09-09,2022-07-16,Verified,uyoga_prevalence_2021-1,KEN
210902_Kenya_KEMRI-WellcomeTrustResearchProgramme_Nyanza,210902_Kenya_KEMRI-WellcomeTrustResearchProgramme,"Prevalence of SARS-CoV-2 Antibodies From a National Serosurveillance of Kenyan Blood Donors, January-March 2021.",2021-09-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Kenya,Nyanza,,Plasma samples with complete donor demographic data and sufficient volume collected from all 6 regional transfusion centers were included and assayed for anti–spike IgG using an enzymelinked immunosorbent assay.,"Forty-four samples were excluded because of missing information, age-ineligible donors, or collection date before 2021.",2021-01-03,2021-03-15,Blood donors,All,Multiple groups,16.0,64.0,Geographical area,Nyanza Region,575,0.38,0.33799999999999997,0.423,,,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Moderate'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Sophie Uyoga,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://dx.doi.org/10.1001/jama.2021.15265,2021-09-09,2022-07-16,Verified,uyoga_prevalence_2021-1,KEN
210902_Kenya_KEMRI-WellcomeTrustResearchProgramme_Central,210902_Kenya_KEMRI-WellcomeTrustResearchProgramme,"Prevalence of SARS-CoV-2 Antibodies From a National Serosurveillance of Kenyan Blood Donors, January-March 2021.",2021-09-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Kenya,Central Province,,Plasma samples with complete donor demographic data and sufficient volume collected from all 6 regional transfusion centers were included and assayed for anti–spike IgG using an enzymelinked immunosorbent assay.,"Forty-four samples were excluded because of missing information, age-ineligible donors, or collection date before 2021.",2021-01-03,2021-03-15,Blood donors,All,Multiple groups,16.0,64.0,Geographical area,Central Region,90,0.467,0.381,0.556,,,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Moderate'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Sophie Uyoga,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://dx.doi.org/10.1001/jama.2021.15265,2021-09-09,2022-07-16,Verified,uyoga_prevalence_2021-1,KEN
210902_Kenya_KEMRI-WellcomeTrustResearchProgramme_35-44,210902_Kenya_KEMRI-WellcomeTrustResearchProgramme,"Prevalence of SARS-CoV-2 Antibodies From a National Serosurveillance of Kenyan Blood Donors, January-March 2021.",2021-09-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kenya,,,Plasma samples with complete donor demographic data and sufficient volume collected from all 6 regional transfusion centers were included and assayed for anti–spike IgG using an enzymelinked immunosorbent assay.,"Forty-four samples were excluded because of missing information, age-ineligible donors, or collection date before 2021.",2021-01-03,2021-03-15,Blood donors,All,Adults (18-64 years),35.0,44.0,Age,35-44,586,0.45299999999999996,0.41700000000000004,0.48700000000000004,,,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Moderate'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Sophie Uyoga,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://dx.doi.org/10.1001/jama.2021.15265,2021-09-09,2022-07-16,Verified,uyoga_prevalence_2021-1,KEN
210902_Kenya_KEMRI-WellcomeTrustResearchProgramme_OverallUnadjusted,210902_Kenya_KEMRI-WellcomeTrustResearchProgramme,"Prevalence of SARS-CoV-2 Antibodies From a National Serosurveillance of Kenyan Blood Donors, January-March 2021.",2021-09-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kenya,,,Plasma samples with complete donor demographic data and sufficient volume collected from all 6 regional transfusion centers were included and assayed for anti–spike IgG using an enzymelinked immunosorbent assay.,"Forty-four samples were excluded because of missing information, age-ineligible donors, or collection date before 2021.",2021-01-03,2021-03-15,Blood donors,All,Multiple groups,16.0,64.0,Analysis,Crude estimate,3018,0.44200000000000006,0.424,0.46,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Moderate'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Sophie Uyoga,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://dx.doi.org/10.1001/jama.2021.15265,2021-09-09,2022-07-16,Verified,uyoga_prevalence_2021-1,KEN
210902_Kenya_KEMRI-WellcomeTrustResearchProgramme_OtherCoast,210902_Kenya_KEMRI-WellcomeTrustResearchProgramme,"Prevalence of SARS-CoV-2 Antibodies From a National Serosurveillance of Kenyan Blood Donors, January-March 2021.",2021-09-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Kenya,The Coast Province,,Plasma samples with complete donor demographic data and sufficient volume collected from all 6 regional transfusion centers were included and assayed for anti–spike IgG using an enzymelinked immunosorbent assay.,"Forty-four samples were excluded because of missing information, age-ineligible donors, or collection date before 2021.",2021-01-03,2021-03-15,Blood donors,All,Multiple groups,16.0,64.0,Geographical area,Other Coast Region,431,0.39799999999999996,0.35100000000000003,0.44700000000000006,,,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Moderate'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Sophie Uyoga,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://dx.doi.org/10.1001/jama.2021.15265,2021-09-09,2022-07-16,Verified,uyoga_prevalence_2021-1,KEN
210902_Kenya_KEMRI-WellcomeTrustResearchProgramme_Nairobi,210902_Kenya_KEMRI-WellcomeTrustResearchProgramme,"Prevalence of SARS-CoV-2 Antibodies From a National Serosurveillance of Kenyan Blood Donors, January-March 2021.",2021-09-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Kenya,Nairobi,,Plasma samples with complete donor demographic data and sufficient volume collected from all 6 regional transfusion centers were included and assayed for anti–spike IgG using an enzymelinked immunosorbent assay.,"Forty-four samples were excluded because of missing information, age-ineligible donors, or collection date before 2021.",2021-01-03,2021-03-15,Blood donors,All,Multiple groups,16.0,64.0,Geographical area,Nairobi Region,177,0.5760000000000001,0.502,0.648,,,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Moderate'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Sophie Uyoga,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://dx.doi.org/10.1001/jama.2021.15265,2021-09-09,2022-07-16,Verified,uyoga_prevalence_2021-1,KEN
210902_Kenya_KEMRI-WellcomeTrustResearchProgramme_16-24,210902_Kenya_KEMRI-WellcomeTrustResearchProgramme,"Prevalence of SARS-CoV-2 Antibodies From a National Serosurveillance of Kenyan Blood Donors, January-March 2021.",2021-09-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kenya,,,Plasma samples with complete donor demographic data and sufficient volume collected from all 6 regional transfusion centers were included and assayed for anti–spike IgG using an enzymelinked immunosorbent assay.,"Forty-four samples were excluded because of missing information, age-ineligible donors, or collection date before 2021.",2021-01-03,2021-03-15,Blood donors,All,Multiple groups,16.0,24.0,Age,16-24,1120,0.44200000000000006,0.408,0.47200000000000003,,,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Moderate'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Sophie Uyoga,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://dx.doi.org/10.1001/jama.2021.15265,2021-09-09,2022-07-16,Verified,uyoga_prevalence_2021-1,KEN
210902_Kenya_KEMRI-WellcomeTrustResearchProgramme_Female,210902_Kenya_KEMRI-WellcomeTrustResearchProgramme,"Prevalence of SARS-CoV-2 Antibodies From a National Serosurveillance of Kenyan Blood Donors, January-March 2021.",2021-09-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kenya,,,Plasma samples with complete donor demographic data and sufficient volume collected from all 6 regional transfusion centers were included and assayed for anti–spike IgG using an enzymelinked immunosorbent assay.,"Forty-four samples were excluded because of missing information, age-ineligible donors, or collection date before 2021.",2021-01-03,2021-03-15,Blood donors,Female,Multiple groups,16.0,64.0,Sex/Gender,,661,0.451,0.41100000000000003,0.49200000000000005,,,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Moderate'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Sophie Uyoga,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://dx.doi.org/10.1001/jama.2021.15265,2021-09-09,2022-07-16,Verified,uyoga_prevalence_2021-1,KEN
210902_Kenya_KEMRI-WellcomeTrustResearchProgramme_25-34,210902_Kenya_KEMRI-WellcomeTrustResearchProgramme,"Prevalence of SARS-CoV-2 Antibodies From a National Serosurveillance of Kenyan Blood Donors, January-March 2021.",2021-09-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kenya,,,Plasma samples with complete donor demographic data and sufficient volume collected from all 6 regional transfusion centers were included and assayed for anti–spike IgG using an enzymelinked immunosorbent assay.,"Forty-four samples were excluded because of missing information, age-ineligible donors, or collection date before 2021.",2021-01-03,2021-03-15,Blood donors,All,Adults (18-64 years),25.0,34.0,Age,25-34,1073,0.46799999999999997,0.43700000000000006,0.501,,,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Moderate'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Sophie Uyoga,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://dx.doi.org/10.1001/jama.2021.15265,2021-09-09,2022-07-16,Verified,uyoga_prevalence_2021-1,KEN
211227_Kenya_KEMRI-WellcomeTrustResearchProgramme_BloodDonors_Aug2021_WANTAI,211227_Kenya_KEMRI-WellcomeTrustResearchProgramme_BloodDonors_Aug2021,Comparative performance of WANTAI ELISA for total immunoglobulin to receptor binding protein and an ELISA for IgG to spike protein in detecting SARS-CoV-2 antibodies in Kenyan populations,2021-12-27,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kenya,,,Samples from later in the pandemic (COVID-19 wave 4)/Adults investigated for blood transfusion safety,,2021-08-01,2021-08-31,Blood donors,All,Adults (18-64 years),,,Primary Estimate,Wantai test,176,0.8300000000000001,,,True,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.953,0.9790000000000001,['High'],No,No,No,No,Unclear,Yes,Yes,Yes,Unclear,James Nyagwange,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://dx.doi.org/10.1016/j.jcv.2021.105061,2022-01-09,2024-03-01,Verified,nyagwange_comparative_2022,KEN
211227_Kenya_KEMRI-WellcomeTrustResearchProgramme_BloodDonors_Aug2021_KWTRP,211227_Kenya_KEMRI-WellcomeTrustResearchProgramme_BloodDonors_Aug2021,Comparative performance of WANTAI ELISA for total immunoglobulin to receptor binding protein and an ELISA for IgG to spike protein in detecting SARS-CoV-2 antibodies in Kenyan populations,2021-12-27,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kenya,,,Samples from later in the pandemic (COVID-19 wave 4)/Adults investigated for blood transfusion safety,,2021-08-01,2021-08-31,Blood donors,All,Adults (18-64 years),,,Test used,in-house assay,176,0.773,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.9259999999999999,0.997,['High'],No,No,No,No,Unclear,Yes,Yes,Yes,Unclear,James Nyagwange,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://dx.doi.org/10.1016/j.jcv.2021.105061,2022-01-09,2022-07-16,Verified,nyagwange_comparative_2022,KEN
211227_Kenya_KEMRI-WellcomeTrustResearchProgramme_BloodDonors_May2020_Wantai,211227_Kenya_KEMRI-WellcomeTrustResearchProgramme_BloodDonors_May2020,Comparative performance of WANTAI ELISA for total immunoglobulin to receptor binding protein and an ELISA for IgG to spike protein in detecting SARS-CoV-2 antibodies in Kenyan populations,2021-12-27,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kenya,,,Samples from early in the pandemic (COVID-19 wave 1)/Adults investigated for blood transfusion safety,,2020-05-01,2020-05-31,Blood donors,All,Adults (18-64 years),,,Primary Estimate,Wantai test,176,0.0227,,,True,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Multiple Types,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.953,0.9790000000000001,['High'],No,No,No,No,Unclear,Yes,Yes,Yes,Unclear,James Nyagwange,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://dx.doi.org/10.1016/j.jcv.2021.105061,2022-01-14,2024-03-01,Verified,nyagwange_comparative_2022,KEN
211227_Kenya_KEMRI-WellcomeTrustResearchProgramme_BloodDonors_May2020_KWTRP,211227_Kenya_KEMRI-WellcomeTrustResearchProgramme_BloodDonors_May2020,Comparative performance of WANTAI ELISA for total immunoglobulin to receptor binding protein and an ELISA for IgG to spike protein in detecting SARS-CoV-2 antibodies in Kenyan populations,2021-12-27,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kenya,,,Samples from early in the pandemic (COVID-19 wave 1)/Adults investigated for blood transfusion safety,,2020-05-01,2020-05-31,Blood donors,All,Adults (18-64 years),,,Test used,in-house assay,176,0.011399999999999999,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.9259999999999999,0.997,['High'],No,No,No,No,Unclear,Yes,Yes,Yes,Unclear,James Nyagwange,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://dx.doi.org/10.1016/j.jcv.2021.105061,2022-01-14,2022-07-16,Verified,nyagwange_comparative_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_OverallAdjusted,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Kilifi,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2020-12-01,2021-04-30,Household and community samples,All,Multiple groups,,,Primary Estimate,"Test adjusted, Population adjusted",856,0.198,0.168,0.231,True,True,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_Age35-44,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Kilifi,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2020-12-01,2021-04-30,Household and community samples,All,Adults (18-64 years),35.0,44.0,Age,35-44,101,0.32670000000000005,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_Age65+,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Kilifi,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2020-12-01,2021-04-30,Household and community samples,All,Seniors (65+ years),65.0,,Age,,51,0.29410000000000003,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_Time20201201-20201231,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Kilifi,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2020-12-01,2020-12-31,Household and community samples,All,Multiple groups,,,Time frame,20201201-20201231,162,0.16670000000000001,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_Age16-24,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Kilifi,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2020-12-01,2021-04-30,Household and community samples,All,Adults (18-64 years),16.0,24.0,Age,16-24,93,0.2151,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_Time20210401-20210430,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Kilifi,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-04-01,2021-04-30,Household and community samples,All,Multiple groups,,,Time frame,20210401-20210430,145,0.2414,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_Time20210101-20210131,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Kilifi,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-01-01,2021-01-31,Household and community samples,All,Multiple groups,,,Time frame,20210101-20210131,113,0.20350000000000001,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_SexFemale,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Kilifi,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2020-12-01,2021-04-30,Household and community samples,Female,Multiple groups,,,Sex/Gender,,459,0.2004,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_Age55-64,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Kilifi,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2020-12-01,2021-04-30,Household and community samples,All,Adults (18-64 years),55.0,64.0,Age,55-64,101,0.1881,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_Time20210201-20210228,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Kilifi,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-02-01,2021-02-28,Household and community samples,All,Multiple groups,,,Time frame,20210201-20210228,239,0.17149999999999999,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_Age25-34,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Kilifi,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2020-12-01,2021-04-30,Household and community samples,All,Adults (18-64 years),25.0,34.0,Age,25-34,101,0.2079,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_Time20210301-20210331,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Kilifi,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-03-01,2021-03-31,Household and community samples,All,Multiple groups,,,Time frame,20210301-20210331,197,0.2386,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_SexMale,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Kilifi,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2020-12-01,2021-04-30,Household and community samples,Male,Multiple groups,,,Sex/Gender,,397,0.204,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_OverallCrude,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Kilifi,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2020-12-01,2021-04-30,Household and community samples,All,Multiple groups,,,Analysis,Crude,856,0.2021,,,,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_Age<16,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Kilifi,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2020-12-01,2021-04-30,Household and community samples,All,Children and Youth (0-17 years),,15.0,Age,<16,309,0.1294,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_Age45-54,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Kilifi,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2020-12-01,2021-04-30,Household and community samples,All,Adults (18-64 years),45.0,54.0,Age,45-54,100,0.25,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kisumu_OverallAdjusted,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kisumu,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Kisumu,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-02-01,2021-05-31,Household and community samples,All,Multiple groups,,,Primary Estimate,"Test adjusted, Population adjusted",853,0.381,0.341,0.424,True,True,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kisumu_Age65+,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kisumu,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Kisumu,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-02-01,2021-05-31,Household and community samples,All,Seniors (65+ years),65.0,,Age,,50,0.4,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kisumu_Time20210401-20210430,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kisumu,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Kisumu,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-04-01,2021-04-30,Household and community samples,All,Multiple groups,,,Time frame,20210401-20210430,204,0.3578,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kisumu_Age<16,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kisumu,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Kisumu,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-02-01,2021-05-31,Household and community samples,All,Children and Youth (0-17 years),,15.0,Age,<16,309,0.26539999999999997,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kisumu_Time20210501-20210531,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kisumu,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Kisumu,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-05-01,2021-05-31,Household and community samples,All,Multiple groups,,,Time frame,20210501-20210531,217,0.39170000000000005,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kisumu_Age45-54,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kisumu,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Kisumu,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-02-01,2021-05-31,Household and community samples,All,Adults (18-64 years),45.0,54.0,Age,45-54,102,0.4118,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kisumu_Time20210201-20210228,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kisumu,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Kisumu,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-02-01,2021-02-28,Household and community samples,All,Multiple groups,,,Time frame,20210201-20210228,214,0.3224,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kisumu_Age16-24,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kisumu,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Kisumu,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-02-01,2021-05-31,Household and community samples,All,Adults (18-64 years),16.0,24.0,Age,16-24,90,0.44439999999999996,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kisumu_OverallCrude,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kisumu,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Kisumu,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-02-01,2021-05-31,Household and community samples,All,Multiple groups,,,Analysis,Crude,853,0.3611,,,,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kisumu_Age25-34,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kisumu,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Kisumu,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-02-01,2021-05-31,Household and community samples,All,Adults (18-64 years),25.0,34.0,Age,25-34,103,0.3689,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kisumu_SexMale,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kisumu,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Kisumu,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-02-01,2021-05-31,Household and community samples,Male,Multiple groups,,,Sex/Gender,,393,0.33840000000000003,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kisumu_Age35-44,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kisumu,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Kisumu,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-02-01,2021-05-31,Household and community samples,All,Adults (18-64 years),35.0,44.0,Age,35-44,100,0.48,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kisumu_Time20210301-20210331,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kisumu,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Kisumu,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-03-01,2021-03-31,Household and community samples,All,Multiple groups,,,Time frame,20210301-20210331,218,0.3716,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kisumu_SexFemale,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kisumu,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Kisumu,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-02-01,2021-05-31,Household and community samples,Female,Multiple groups,,,Sex/Gender,,460,0.3804,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kisumu_Age55-64,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Kisumu,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Kisumu,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-02-01,2021-05-31,Household and community samples,All,Adults (18-64 years),55.0,64.0,Age,55-64,99,0.38380000000000003,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_OverallAdjusted,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Nairobi,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-01-01,2021-05-31,Household and community samples,All,Multiple groups,,,Primary Estimate,"Test adjusted, Population adjusted",850,0.40399999999999997,0.36,0.45,True,True,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_Age35-44,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Nairobi,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-01-01,2021-05-31,Household and community samples,All,Adults (18-64 years),35.0,44.0,Age,35-44,101,0.505,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_Time20210301-20210331,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Nairobi,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-03-01,2021-03-31,Household and community samples,All,Multiple groups,,,Time frame,20210301-20210331,186,0.414,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_SexMale,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Nairobi,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-01-01,2021-05-31,Household and community samples,Male,Multiple groups,,,Sex/Gender,,450,0.37560000000000004,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_Time20210501-20210531,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Nairobi,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-05-01,2021-05-31,Household and community samples,All,Multiple groups,,,Time frame,20210501-20210531,113,0.4779,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_Age25-34,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Nairobi,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-01-01,2021-05-31,Household and community samples,All,Adults (18-64 years),25.0,34.0,Age,25-34,92,0.35869999999999996,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_OverallCrude,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Nairobi,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-01-01,2021-05-31,Household and community samples,All,Multiple groups,,,Analysis,Crude,850,0.3788,,,,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_Time20210101-20210131,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Nairobi,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-01-01,2021-01-31,Household and community samples,All,Multiple groups,,,Time frame,20210101-20210131,124,0.3145,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_Age16-24,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Nairobi,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-01-01,2021-05-31,Household and community samples,All,Adults (18-64 years),16.0,24.0,Age,16-24,89,0.44939999999999997,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_Age65+,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Nairobi,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-01-01,2021-05-31,Household and community samples,All,Seniors (65+ years),65.0,,Age,,51,0.5686,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_Age55-64,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Nairobi,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-01-01,2021-05-31,Household and community samples,All,Adults (18-64 years),55.0,64.0,Age,55-64,101,0.4257,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_Age45-54,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Nairobi,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-01-01,2021-05-31,Household and community samples,All,Adults (18-64 years),45.0,54.0,Age,45-54,99,0.4343,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_Age<16,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Nairobi,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-01-01,2021-05-31,Household and community samples,All,Children and Youth (0-17 years),,15.0,Age,<16,317,0.2618,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_SexFemale,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Nairobi,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-01-01,2021-05-31,Household and community samples,Female,Multiple groups,,,Sex/Gender,,400,0.3825,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_Time20210201-20210228,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Nairobi,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-02-01,2021-02-28,Household and community samples,All,Multiple groups,,,Time frame,20210201-20210228,144,0.3333,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_Time20210401-20210430,220209_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi,"SARS-CoV-2 Seroprevalence in three Kenyan Health and Demographic Surveillance Sites, December 2020-May 2021",2022-02-09,Preprint,Local,Repeated cross-sectional study,Kenya,,Nairobi,"Inclusion criteria for the study were that the individual should be a resident of the
HDSS and provide consent.","Potential participants were excluded if they had a
bleeding disorder or other medical contraindication for venipuncture.",2021-04-01,2021-04-30,Household and community samples,All,Multiple groups,,,Time frame,20210401-20210430,283,0.3675,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Anthony Etyang,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.07.22270012v1.full-text,2022-02-22,2022-07-16,Verified,etyang_sars-cov-2_2022,KEN
220223_CoastalKenya_KenyaMedicalResearchInstitute_Overall,220223_CoastalKenya_KenyaMedicalResearchInstitute,Epidemiology of COVID-19 infections on routine polymerase chain reaction (PCR) and serology testing in Coastal Kenya,2022-02-23,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Kenya,,,"We conducted a retrospective analysis of surveillance data
obtained between 17th March 2020 and 30th June 2021 from the
Coastal part of Kenya, including Mombasa, Taita Taveta, Kilifi,
Kwale, Lamu and Tana River.",,2020-03-17,2020-11-15,Blood donors,All,Multiple groups,,,Primary Estimate,,2437,0.203,,,True,,,,True,Unclear,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['High'],,Unclear,Yes,Yes,,Unclear,Yes,Yes,,James Nyagwange,Kenya Medical Research Institute,Not Unity-Aligned,https://wellcomeopenresearch.org/articles/7-69,2022-03-09,2022-07-16,Unverified,nyagwange_epidemiology_2022,KEN
220223_CoastalKenya_KenyaMedicalResearchInstitute_May,220223_CoastalKenya_KenyaMedicalResearchInstitute,Epidemiology of COVID-19 infections on routine polymerase chain reaction (PCR) and serology testing in Coastal Kenya,2022-02-23,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Kenya,,,"We conducted a retrospective analysis of surveillance data
obtained between 17th March 2020 and 30th June 2021 from the
Coastal part of Kenya, including Mombasa, Taita Taveta, Kilifi,
Kwale, Lamu and Tana River.",,2020-05-01,2020-05-31,Blood donors,All,Multiple groups,,,Time frame,May 2020,91,0.231,,,,,,,,Unclear,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['High'],,Unclear,Yes,Yes,,Unclear,Yes,Yes,,James Nyagwange,Kenya Medical Research Institute,Not Unity-Aligned,https://wellcomeopenresearch.org/articles/7-69,2022-03-09,2022-07-16,Unverified,nyagwange_epidemiology_2022,KEN
220223_CoastalKenya_KenyaMedicalResearchInstitute_Oct,220223_CoastalKenya_KenyaMedicalResearchInstitute,Epidemiology of COVID-19 infections on routine polymerase chain reaction (PCR) and serology testing in Coastal Kenya,2022-02-23,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Kenya,,,"We conducted a retrospective analysis of surveillance data
obtained between 17th March 2020 and 30th June 2021 from the
Coastal part of Kenya, including Mombasa, Taita Taveta, Kilifi,
Kwale, Lamu and Tana River.",,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,,,Time frame,Oct 2020,103,0.155,,,,,,,,Unclear,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['High'],,Unclear,Yes,Yes,,Unclear,Yes,Yes,,James Nyagwange,Kenya Medical Research Institute,Not Unity-Aligned,https://wellcomeopenresearch.org/articles/7-69,2022-03-09,2022-07-16,Unverified,nyagwange_epidemiology_2022,KEN
220223_CoastalKenya_KenyaMedicalResearchInstitute_Jul,220223_CoastalKenya_KenyaMedicalResearchInstitute,Epidemiology of COVID-19 infections on routine polymerase chain reaction (PCR) and serology testing in Coastal Kenya,2022-02-23,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Kenya,,,"We conducted a retrospective analysis of surveillance data
obtained between 17th March 2020 and 30th June 2021 from the
Coastal part of Kenya, including Mombasa, Taita Taveta, Kilifi,
Kwale, Lamu and Tana River.",,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,,,Time frame,Jul 2020,325,0.2,,,,,,,,Unclear,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['High'],,Unclear,Yes,Yes,,Unclear,Yes,Yes,,James Nyagwange,Kenya Medical Research Institute,Not Unity-Aligned,https://wellcomeopenresearch.org/articles/7-69,2022-03-09,2022-07-16,Unverified,nyagwange_epidemiology_2022,KEN
220223_CoastalKenya_KenyaMedicalResearchInstitute_Aug,220223_CoastalKenya_KenyaMedicalResearchInstitute,Epidemiology of COVID-19 infections on routine polymerase chain reaction (PCR) and serology testing in Coastal Kenya,2022-02-23,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Kenya,,,"We conducted a retrospective analysis of surveillance data
obtained between 17th March 2020 and 30th June 2021 from the
Coastal part of Kenya, including Mombasa, Taita Taveta, Kilifi,
Kwale, Lamu and Tana River.",,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,,,Time frame,Aug 2020,117,0.39299999999999996,,,,,,,,Unclear,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['High'],,Unclear,Yes,Yes,,Unclear,Yes,Yes,,James Nyagwange,Kenya Medical Research Institute,Not Unity-Aligned,https://wellcomeopenresearch.org/articles/7-69,2022-03-09,2022-07-16,Unverified,nyagwange_epidemiology_2022,KEN
220223_CoastalKenya_KenyaMedicalResearchInstitute_Apr,220223_CoastalKenya_KenyaMedicalResearchInstitute,Epidemiology of COVID-19 infections on routine polymerase chain reaction (PCR) and serology testing in Coastal Kenya,2022-02-23,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Kenya,,,"We conducted a retrospective analysis of surveillance data
obtained between 17th March 2020 and 30th June 2021 from the
Coastal part of Kenya, including Mombasa, Taita Taveta, Kilifi,
Kwale, Lamu and Tana River.",,2020-04-01,2020-04-30,Blood donors,All,Multiple groups,,,Time frame,Apr 2020,434,0.16399999999999998,,,,,,,,Unclear,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['High'],,Unclear,Yes,Yes,,Unclear,Yes,Yes,,James Nyagwange,Kenya Medical Research Institute,Not Unity-Aligned,https://wellcomeopenresearch.org/articles/7-69,2022-03-09,2022-07-16,Unverified,nyagwange_epidemiology_2022,KEN
220223_CoastalKenya_KenyaMedicalResearchInstitute_Nov,220223_CoastalKenya_KenyaMedicalResearchInstitute,Epidemiology of COVID-19 infections on routine polymerase chain reaction (PCR) and serology testing in Coastal Kenya,2022-02-23,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Kenya,,,"We conducted a retrospective analysis of surveillance data
obtained between 17th March 2020 and 30th June 2021 from the
Coastal part of Kenya, including Mombasa, Taita Taveta, Kilifi,
Kwale, Lamu and Tana River.",,2020-11-01,2020-11-15,Blood donors,All,Multiple groups,,,Time frame,Nov 2020,15,0.733,,,,,,,,Unclear,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['High'],,Unclear,Yes,Yes,,Unclear,Yes,Yes,,James Nyagwange,Kenya Medical Research Institute,Not Unity-Aligned,https://wellcomeopenresearch.org/articles/7-69,2022-03-09,2022-07-16,Unverified,nyagwange_epidemiology_2022,KEN
220223_CoastalKenya_KenyaMedicalResearchInstitute_Jun,220223_CoastalKenya_KenyaMedicalResearchInstitute,Epidemiology of COVID-19 infections on routine polymerase chain reaction (PCR) and serology testing in Coastal Kenya,2022-02-23,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Kenya,,,"We conducted a retrospective analysis of surveillance data
obtained between 17th March 2020 and 30th June 2021 from the
Coastal part of Kenya, including Mombasa, Taita Taveta, Kilifi,
Kwale, Lamu and Tana River.",,2020-06-01,2020-06-30,Blood donors,All,Multiple groups,,,Time frame,Jun 2020,1234,0.19,,,,,,,,Unclear,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['High'],,Unclear,Yes,Yes,,Unclear,Yes,Yes,,James Nyagwange,Kenya Medical Research Institute,Not Unity-Aligned,https://wellcomeopenresearch.org/articles/7-69,2022-03-09,2022-07-16,Unverified,nyagwange_epidemiology_2022,KEN
220223_CoastalKenya_KenyaMedicalResearchInstitute_Mar,220223_CoastalKenya_KenyaMedicalResearchInstitute,Epidemiology of COVID-19 infections on routine polymerase chain reaction (PCR) and serology testing in Coastal Kenya,2022-02-23,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Kenya,,,"We conducted a retrospective analysis of surveillance data
obtained between 17th March 2020 and 30th June 2021 from the
Coastal part of Kenya, including Mombasa, Taita Taveta, Kilifi,
Kwale, Lamu and Tana River.",,2020-03-17,2020-03-31,Blood donors,All,Multiple groups,,,Time frame,Mar 2020,12,0.083,,,,,,,,Unclear,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['High'],,Unclear,Yes,Yes,,Unclear,Yes,Yes,,James Nyagwange,Kenya Medical Research Institute,Not Unity-Aligned,https://wellcomeopenresearch.org/articles/7-69,2022-03-09,2022-07-16,Unverified,nyagwange_epidemiology_2022,KEN
220223_CoastalKenya_KenyaMedicalResearchInstitute_Sep,220223_CoastalKenya_KenyaMedicalResearchInstitute,Epidemiology of COVID-19 infections on routine polymerase chain reaction (PCR) and serology testing in Coastal Kenya,2022-02-23,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Kenya,,,"We conducted a retrospective analysis of surveillance data
obtained between 17th March 2020 and 30th June 2021 from the
Coastal part of Kenya, including Mombasa, Taita Taveta, Kilifi,
Kwale, Lamu and Tana River.",,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,,,Time frame,Sep 2020,106,0.27399999999999997,,,,,,,,Unclear,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.927,0.99,['High'],,Unclear,Yes,Yes,,Unclear,Yes,Yes,,James Nyagwange,Kenya Medical Research Institute,Not Unity-Aligned,https://wellcomeopenresearch.org/articles/7-69,2022-03-09,2022-07-16,Unverified,nyagwange_epidemiology_2022,KEN
220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Busia_20210415-20210521_OverallAdjusted,220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Busia_20210415-20210521,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: repeated cross-sectional surveys 2020-21,2022-03-06,Preprint,Local,Repeated cross-sectional study,Kenya,,Busia,"All women attending ANC for the first time, who provided a routine blood sample at their clinic visit, were included in the study. ","Women who did not provide a sample at their first antenatal care visit, or women attending their second or subsequent ANC visit, were excluded.",2021-04-15,2021-05-21,Pregnant or parturient women,Female,Adults (18-64 years),14.0,44.0,Primary Estimate,Test Adjusted,270,0.306,0.247,0.371,True,True,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.927,0.99,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,R Lucinde,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.03.22271860v1.full-text,2022-03-16,2022-07-16,Verified,lucinde_sero-surveillance_2022,KEN
220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Busia_20210415-20210521_OverallCrude,220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Busia_20210415-20210521,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: repeated cross-sectional surveys 2020-21,2022-03-06,Preprint,Local,Repeated cross-sectional study,Kenya,,Busia,"All women attending ANC for the first time, who provided a routine blood sample at their clinic visit, were included in the study. ","Women who did not provide a sample at their first antenatal care visit, or women attending their second or subsequent ANC visit, were excluded.",2021-04-15,2021-05-21,Pregnant or parturient women,Female,Adults (18-64 years),14.0,44.0,Analysis,Crude,270,0.2889,,,,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.927,0.99,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,R Lucinde,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.03.22271860v1.full-text,2022-03-16,2022-07-16,Verified,lucinde_sero-surveillance_2022,KEN
220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Busia_20210415-20210521_Age30-45,220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Busia_20210415-20210521,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: repeated cross-sectional surveys 2020-21,2022-03-06,Preprint,Local,Repeated cross-sectional study,Kenya,,Busia,"All women attending ANC for the first time, who provided a routine blood sample at their clinic visit, were included in the study. ","Women who did not provide a sample at their first antenatal care visit, or women attending their second or subsequent ANC visit, were excluded.",2021-04-15,2021-05-21,Pregnant or parturient women,Female,Adults (18-64 years),30.0,44.0,Age,30-45,7,0.2857,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.927,0.99,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,R Lucinde,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.03.22271860v1.full-text,2022-03-16,2022-07-16,Verified,lucinde_sero-surveillance_2022,KEN
220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Busia_20210415-20210521_Age17-29,220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Busia_20210415-20210521,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: repeated cross-sectional surveys 2020-21,2022-03-06,Preprint,Local,Repeated cross-sectional study,Kenya,,Busia,"All women attending ANC for the first time, who provided a routine blood sample at their clinic visit, were included in the study. ","Women who did not provide a sample at their first antenatal care visit, or women attending their second or subsequent ANC visit, were excluded.",2021-04-15,2021-05-21,Pregnant or parturient women,Female,Adults (18-64 years),17.0,29.0,Age,17-29,14,0.2143,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.927,0.99,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,R Lucinde,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.03.22271860v1.full-text,2022-03-16,2022-07-16,Verified,lucinde_sero-surveillance_2022,KEN
220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Busia_20210920-20211022_OverallAdjusted,220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Busia_20210920-20211022,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: repeated cross-sectional surveys 2020-21,2022-03-06,Preprint,Local,Repeated cross-sectional study,Kenya,,Busia,"All women attending ANC for the first time, who provided a routine blood sample at their clinic visit, were included in the study. ","Women who did not provide a sample at their first antenatal care visit, or women attending their second or subsequent ANC visit, were excluded.",2021-09-20,2021-10-22,Pregnant or parturient women,Female,Adults (18-64 years),14.0,44.0,Primary Estimate,Test Adjusted,297,0.7070000000000001,0.6409999999999999,0.774,True,True,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.927,0.99,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,R Lucinde,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.03.22271860v1.full-text,2022-03-16,2022-07-16,Verified,lucinde_sero-surveillance_2022,KEN
220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Busia_20210920-20211022_VaccinatedYES,220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Busia_20210920-20211022,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: repeated cross-sectional surveys 2020-21,2022-03-06,Preprint,Local,Repeated cross-sectional study,Kenya,,Busia,"All women attending ANC for the first time, who provided a routine blood sample at their clinic visit, were included in the study. ","Women who did not provide a sample at their first antenatal care visit, or women attending their second or subsequent ANC visit, were excluded.",2021-09-20,2021-10-22,Pregnant or parturient women,Female,Adults (18-64 years),14.0,44.0,COVID-19 vaccination status,,6,0.6667000000000001,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.927,0.99,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,R Lucinde,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.03.22271860v1.full-text,2022-03-16,2022-07-16,Verified,lucinde_sero-surveillance_2022,KEN
220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Busia_20210920-20211022_Age30-45,220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Busia_20210920-20211022,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: repeated cross-sectional surveys 2020-21,2022-03-06,Preprint,Local,Repeated cross-sectional study,Kenya,,Busia,"All women attending ANC for the first time, who provided a routine blood sample at their clinic visit, were included in the study. ","Women who did not provide a sample at their first antenatal care visit, or women attending their second or subsequent ANC visit, were excluded.",2021-09-20,2021-10-22,Pregnant or parturient women,Female,Adults (18-64 years),30.0,44.0,Age,30-45,84,0.6905,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.927,0.99,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,R Lucinde,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.03.22271860v1.full-text,2022-03-16,2022-07-16,Verified,lucinde_sero-surveillance_2022,KEN
220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Busia_20210920-20211022_VaccinatedNO,220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Busia_20210920-20211022,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: repeated cross-sectional surveys 2020-21,2022-03-06,Preprint,Local,Repeated cross-sectional study,Kenya,,Busia,"All women attending ANC for the first time, who provided a routine blood sample at their clinic visit, were included in the study. ","Women who did not provide a sample at their first antenatal care visit, or women attending their second or subsequent ANC visit, were excluded.",2021-09-20,2021-10-22,Pregnant or parturient women,Female,Adults (18-64 years),14.0,44.0,COVID-19 vaccination status,,288,0.6528,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.927,0.99,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,R Lucinde,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.03.22271860v1.full-text,2022-03-16,2022-07-16,Verified,lucinde_sero-surveillance_2022,KEN
220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Busia_20210920-20211022_Age17-29,220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Busia_20210920-20211022,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: repeated cross-sectional surveys 2020-21,2022-03-06,Preprint,Local,Repeated cross-sectional study,Kenya,,Busia,"All women attending ANC for the first time, who provided a routine blood sample at their clinic visit, were included in the study. ","Women who did not provide a sample at their first antenatal care visit, or women attending their second or subsequent ANC visit, were excluded.",2021-09-20,2021-10-22,Pregnant or parturient women,Female,Adults (18-64 years),17.0,29.0,Age,17-29,203,0.6305,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.927,0.99,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,R Lucinde,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.03.22271860v1.full-text,2022-03-16,2022-07-16,Verified,lucinde_sero-surveillance_2022,KEN
220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Busia_20210920-20211022_OverallCrude,220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Busia_20210920-20211022,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: repeated cross-sectional surveys 2020-21,2022-03-06,Preprint,Local,Repeated cross-sectional study,Kenya,,Busia,"All women attending ANC for the first time, who provided a routine blood sample at their clinic visit, were included in the study. ","Women who did not provide a sample at their first antenatal care visit, or women attending their second or subsequent ANC visit, were excluded.",2021-09-20,2021-10-22,Pregnant or parturient women,Female,Adults (18-64 years),14.0,44.0,Analysis,Crude,297,0.6566,,,,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.927,0.99,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,R Lucinde,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.03.22271860v1.full-text,2022-03-16,2022-07-16,Verified,lucinde_sero-surveillance_2022,KEN
220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_1NovDec2020_OverallAdjusted,220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_1NovDec2020,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: repeated cross-sectional surveys 2020-21,2022-03-06,Preprint,Local,Repeated cross-sectional study,Kenya,,Kilifi,"All women attending ANC for the first time, who provided a routine blood sample at their clinic visit, were included in the study. ","Women who did not provide a sample at their first antenatal care visit, or women attending their second or subsequent ANC visit, were excluded.",2020-11-01,2020-12-31,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,Test Adjusted,236,0.14,0.094,0.195,True,True,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.927,0.99,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Unclear,R Lucinde,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.03.22271860v1.full-text,2022-03-16,2022-07-16,Verified,lucinde_sero-surveillance_2022,KEN
220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_1NovDec2020_OverallCrude,220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_1NovDec2020,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: repeated cross-sectional surveys 2020-21,2022-03-06,Preprint,Local,Repeated cross-sectional study,Kenya,,Kilifi,"All women attending ANC for the first time, who provided a routine blood sample at their clinic visit, were included in the study. ","Women who did not provide a sample at their first antenatal care visit, or women attending their second or subsequent ANC visit, were excluded.",2020-11-01,2020-12-31,Pregnant or parturient women,Female,Adults (18-64 years),,,Analysis,Crude,236,0.1356,,,,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.927,0.99,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Unclear,R Lucinde,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.03.22271860v1.full-text,2022-03-16,2022-07-16,Verified,lucinde_sero-surveillance_2022,KEN
220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_2MarApr2021_OverallAdjusted,220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_2MarApr2021,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: repeated cross-sectional surveys 2020-21,2022-03-06,Preprint,Local,Repeated cross-sectional study,Kenya,,Kilifi,"All women attending ANC for the first time, who provided a routine blood sample at their clinic visit, were included in the study. ","Women who did not provide a sample at their first antenatal care visit, or women attending their second or subsequent ANC visit, were excluded.",2021-03-01,2021-04-30,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,Test Adjusted,260,0.222,0.167,0.281,True,True,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.927,0.99,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Unclear,R Lucinde,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.03.22271860v1.full-text,2022-03-16,2022-07-16,Verified,lucinde_sero-surveillance_2022,KEN
220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_2MarApr2021_OverallCrude,220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_2MarApr2021,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: repeated cross-sectional surveys 2020-21,2022-03-06,Preprint,Local,Repeated cross-sectional study,Kenya,,Kilifi,"All women attending ANC for the first time, who provided a routine blood sample at their clinic visit, were included in the study. ","Women who did not provide a sample at their first antenatal care visit, or women attending their second or subsequent ANC visit, were excluded.",2021-03-01,2021-04-30,Pregnant or parturient women,Female,Adults (18-64 years),,,Analysis,Crude,260,0.2115,,,,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.927,0.99,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Unclear,R Lucinde,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.03.22271860v1.full-text,2022-03-16,2022-07-16,Verified,lucinde_sero-surveillance_2022,KEN
220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_3MayJun2021_OverallAdjusted,220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_3MayJun2021,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: repeated cross-sectional surveys 2020-21,2022-03-06,Preprint,Local,Repeated cross-sectional study,Kenya,,Kilifi,"All women attending ANC for the first time, who provided a routine blood sample at their clinic visit, were included in the study. ","Women who did not provide a sample at their first antenatal care visit, or women attending their second or subsequent ANC visit, were excluded.",2021-05-01,2021-06-30,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,Test Adjusted,382,0.289,0.239,0.344,True,True,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.927,0.99,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Unclear,R Lucinde,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.03.22271860v1.full-text,2022-03-16,2022-07-16,Verified,lucinde_sero-surveillance_2022,KEN
220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_3MayJun2021_OverallCrude,220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_3MayJun2021,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: repeated cross-sectional surveys 2020-21,2022-03-06,Preprint,Local,Repeated cross-sectional study,Kenya,,Kilifi,"All women attending ANC for the first time, who provided a routine blood sample at their clinic visit, were included in the study. ","Women who did not provide a sample at their first antenatal care visit, or women attending their second or subsequent ANC visit, were excluded.",2021-05-01,2021-06-30,Pregnant or parturient women,Female,Adults (18-64 years),,,Analysis,Crude,382,0.2723,,,,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.927,0.99,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Unclear,R Lucinde,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.03.22271860v1.full-text,2022-03-16,2022-07-16,Verified,lucinde_sero-surveillance_2022,KEN
220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_4JulAug2021_OverallAdjusted,220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_4JulAug2021,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: repeated cross-sectional surveys 2020-21,2022-03-06,Preprint,Local,Repeated cross-sectional study,Kenya,,Kilifi,"All women attending ANC for the first time, who provided a routine blood sample at their clinic visit, were included in the study. ","Women who did not provide a sample at their first antenatal care visit, or women attending their second or subsequent ANC visit, were excluded.",2021-07-01,2021-08-31,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,Test Adjusted,260,0.612,0.544,0.684,True,True,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.927,0.99,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Unclear,R Lucinde,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.03.22271860v1.full-text,2022-03-16,2022-07-16,Verified,lucinde_sero-surveillance_2022,KEN
220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_4JulAug2021_OverallCrude,220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_4JulAug2021,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: repeated cross-sectional surveys 2020-21,2022-03-06,Preprint,Local,Repeated cross-sectional study,Kenya,,Kilifi,"All women attending ANC for the first time, who provided a routine blood sample at their clinic visit, were included in the study. ","Women who did not provide a sample at their first antenatal care visit, or women attending their second or subsequent ANC visit, were excluded.",2021-07-01,2021-08-31,Pregnant or parturient women,Female,Adults (18-64 years),,,Analysis,Crude,260,0.5692,,,,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.927,0.99,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Unclear,R Lucinde,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.03.22271860v1.full-text,2022-03-16,2022-07-16,Verified,lucinde_sero-surveillance_2022,KEN
220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_5SepOct2021_OverallAdjusted,220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_5SepOct2021,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: repeated cross-sectional surveys 2020-21,2022-03-06,Preprint,Local,Repeated cross-sectional study,Kenya,,Kilifi,"All women attending ANC for the first time, who provided a routine blood sample at their clinic visit, were included in the study. ","Women who did not provide a sample at their first antenatal care visit, or women attending their second or subsequent ANC visit, were excluded.",2021-09-01,2021-10-31,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,Test Adjusted,305,0.627,0.562,0.691,True,True,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.927,0.99,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Unclear,R Lucinde,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.03.22271860v1.full-text,2022-03-16,2022-07-16,Verified,lucinde_sero-surveillance_2022,KEN
220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_5SepOct2021_OverallCrude,220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Kilifi_5SepOct2021,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: repeated cross-sectional surveys 2020-21,2022-03-06,Preprint,Local,Repeated cross-sectional study,Kenya,,Kilifi,"All women attending ANC for the first time, who provided a routine blood sample at their clinic visit, were included in the study. ","Women who did not provide a sample at their first antenatal care visit, or women attending their second or subsequent ANC visit, were excluded.",2021-09-01,2021-10-31,Pregnant or parturient women,Female,Adults (18-64 years),,,Analysis,Crude,305,0.5836,,,,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.927,0.99,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Unclear,R Lucinde,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.03.22271860v1.full-text,2022-03-16,2022-07-16,Verified,lucinde_sero-surveillance_2022,KEN
220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_20210127-20210311_OverallAdjusted,220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_20210127-20210311,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: repeated cross-sectional surveys 2020-21,2022-03-06,Preprint,Local,Repeated cross-sectional study,Kenya,,Nairobi,"All women attending ANC for the first time, who provided a routine blood sample at their clinic visit, were included in the study. ","Women who did not provide a sample at their first antenatal care visit, or women attending their second or subsequent ANC visit, were excluded.",2021-01-27,2021-03-11,Pregnant or parturient women,Female,Adults (18-64 years),17.0,45.0,Primary Estimate,Test Adjusted,265,0.321,0.262,0.384,True,True,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.927,0.99,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,R Lucinde,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.03.22271860v1.full-text,2022-03-16,2022-07-16,Verified,lucinde_sero-surveillance_2022,KEN
220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_20210127-20210311_Age30-45,220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_20210127-20210311,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: repeated cross-sectional surveys 2020-21,2022-03-06,Preprint,Local,Repeated cross-sectional study,Kenya,,Nairobi,"All women attending ANC for the first time, who provided a routine blood sample at their clinic visit, were included in the study. ","Women who did not provide a sample at their first antenatal care visit, or women attending their second or subsequent ANC visit, were excluded.",2021-01-27,2021-03-11,Pregnant or parturient women,Female,Adults (18-64 years),30.0,45.0,Age,30-45,141,0.3333,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.927,0.99,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,R Lucinde,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.03.22271860v1.full-text,2022-03-16,2022-07-16,Verified,lucinde_sero-surveillance_2022,KEN
220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_20210127-20210311_Age17-29,220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_20210127-20210311,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: repeated cross-sectional surveys 2020-21,2022-03-06,Preprint,Local,Repeated cross-sectional study,Kenya,,Nairobi,"All women attending ANC for the first time, who provided a routine blood sample at their clinic visit, were included in the study. ","Women who did not provide a sample at their first antenatal care visit, or women attending their second or subsequent ANC visit, were excluded.",2021-01-27,2021-03-11,Pregnant or parturient women,Female,Adults (18-64 years),17.0,29.0,Age,17-29,101,0.2772,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.927,0.99,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,R Lucinde,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.03.22271860v1.full-text,2022-03-16,2022-07-16,Verified,lucinde_sero-surveillance_2022,KEN
220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_20210127-20210311_OverallCrude,220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_20210127-20210311,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: repeated cross-sectional surveys 2020-21,2022-03-06,Preprint,Local,Repeated cross-sectional study,Kenya,,Nairobi,"All women attending ANC for the first time, who provided a routine blood sample at their clinic visit, were included in the study. ","Women who did not provide a sample at their first antenatal care visit, or women attending their second or subsequent ANC visit, were excluded.",2021-01-27,2021-03-11,Pregnant or parturient women,Female,Adults (18-64 years),17.0,45.0,Analysis,Crude,265,0.3019,,,,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.927,0.99,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,R Lucinde,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.03.22271860v1.full-text,2022-03-16,2022-07-16,Verified,lucinde_sero-surveillance_2022,KEN
220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_20210907-20211019_OverallAdjusted,220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_20210907-20211019,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: repeated cross-sectional surveys 2020-21,2022-03-06,Preprint,Local,Repeated cross-sectional study,Kenya,,Nairobi,"All women attending ANC for the first time, who provided a routine blood sample at their clinic visit, were included in the study. ","Women who did not provide a sample at their first antenatal care visit, or women attending their second or subsequent ANC visit, were excluded.",2021-09-07,2021-10-19,Pregnant or parturient women,Female,Adults (18-64 years),17.0,45.0,Primary Estimate,Test Adjusted,245,0.8490000000000001,0.783,0.915,True,True,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.927,0.99,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,R Lucinde,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.03.22271860v1.full-text,2022-03-16,2022-07-16,Verified,lucinde_sero-surveillance_2022,KEN
220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_20210907-20211019_VaccineNO,220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_20210907-20211019,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: repeated cross-sectional surveys 2020-21,2022-03-06,Preprint,Local,Repeated cross-sectional study,Kenya,,Nairobi,"All women attending ANC for the first time, who provided a routine blood sample at their clinic visit, were included in the study. ","Women who did not provide a sample at their first antenatal care visit, or women attending their second or subsequent ANC visit, were excluded.",2021-09-07,2021-10-19,Pregnant or parturient women,Female,Adults (18-64 years),17.0,45.0,COVID-19 vaccination status,,214,0.7617,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.927,0.99,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,R Lucinde,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.03.22271860v1.full-text,2022-03-16,2022-07-16,Verified,lucinde_sero-surveillance_2022,KEN
220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_20210907-20211019_Age30-45,220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_20210907-20211019,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: repeated cross-sectional surveys 2020-21,2022-03-06,Preprint,Local,Repeated cross-sectional study,Kenya,,Nairobi,"All women attending ANC for the first time, who provided a routine blood sample at their clinic visit, were included in the study. ","Women who did not provide a sample at their first antenatal care visit, or women attending their second or subsequent ANC visit, were excluded.",2021-09-07,2021-10-19,Pregnant or parturient women,Female,Adults (18-64 years),30.0,45.0,Age,30-45,139,0.7698,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.927,0.99,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,R Lucinde,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.03.22271860v1.full-text,2022-03-16,2022-07-16,Verified,lucinde_sero-surveillance_2022,KEN
220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_20210907-20211019_Age17-29,220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_20210907-20211019,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: repeated cross-sectional surveys 2020-21,2022-03-06,Preprint,Local,Repeated cross-sectional study,Kenya,,Nairobi,"All women attending ANC for the first time, who provided a routine blood sample at their clinic visit, were included in the study. ","Women who did not provide a sample at their first antenatal care visit, or women attending their second or subsequent ANC visit, were excluded.",2021-09-07,2021-10-19,Pregnant or parturient women,Female,Adults (18-64 years),17.0,29.0,Age,17-29,101,0.8119,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.927,0.99,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,R Lucinde,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.03.22271860v1.full-text,2022-03-16,2022-07-16,Verified,lucinde_sero-surveillance_2022,KEN
220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_20210907-20211019_OverallCrude,220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_20210907-20211019,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: repeated cross-sectional surveys 2020-21,2022-03-06,Preprint,Local,Repeated cross-sectional study,Kenya,,Nairobi,"All women attending ANC for the first time, who provided a routine blood sample at their clinic visit, were included in the study. ","Women who did not provide a sample at their first antenatal care visit, or women attending their second or subsequent ANC visit, were excluded.",2021-09-07,2021-10-19,Pregnant or parturient women,Female,Adults (18-64 years),17.0,45.0,Analysis,Crude,245,0.7878000000000001,,,,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.927,0.99,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,R Lucinde,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.03.22271860v1.full-text,2022-03-16,2022-07-16,Verified,lucinde_sero-surveillance_2022,KEN
220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_20210907-20211019_VaccineYES,220306_Kenya_KEMRIWellcomeTrustResearchProgramme_Nairobi_20210907-20211019,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: repeated cross-sectional surveys 2020-21,2022-03-06,Preprint,Local,Repeated cross-sectional study,Kenya,,Nairobi,"All women attending ANC for the first time, who provided a routine blood sample at their clinic visit, were included in the study. ","Women who did not provide a sample at their first antenatal care visit, or women attending their second or subsequent ANC visit, were excluded.",2021-09-07,2021-10-19,Pregnant or parturient women,Female,Adults (18-64 years),17.0,45.0,COVID-19 vaccination status,,31,0.9677,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.927,0.99,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,R Lucinde,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.03.22271860v1.full-text,2022-03-16,2022-07-16,Verified,lucinde_sero-surveillance_2022,KEN
220315_Kenya_UniversityofWashington_Primary,220315_Kenya_UniversityofWashington,SARS-CoV-2 antibody correlates among PWID living with and without HIV in Kenya,2022-03-15,Presentation or Conference,Local,Cross-sectional survey ,Kenya,,,"we recruited PWID living with HIV and their injecting and/or sexual partners in Nairobi, Kilifi, and Mombasa counties at needle and syringe programs (NSP)",,2021-04-15,2021-07-15,Blood donors,All,Multiple groups,,,Primary Estimate,,1000,0.309,,,True,,,,True,Unclear,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,,TotalAntibody,,,,,['Moderate'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Shradha J. Doshi,University of Washington,Unity-Aligned,https://www.iasusa.org/tam/march-2022/,2022-06-15,2024-03-19,Verified,doshi_sars-cov-2_2022,KEN
220729_Kenya_JaramogiOginga OdingaUniversityofScienceandTechnology,220729_Kenya_JaramogiOginga OdingaUniversityofScienceandTechnology,High seroprevalence of Immunoglobulin G (IgG) and IgM antibodies to SARS-CoV-2 in asymptomatic and symptomatic individuals amidst vaccination roll-out in western Kenya,2022-07-29,Preprint,Regional,Cross-sectional survey ,Kenya,Kisumu County and Siaya County,,"""We  screened  and  recruited  individuals  presenting  to  Kisumu  and  Siaya  Counties  referral 89hospitals  for  routine  COVID-19  tests  in  western  Kenya  (Fig  1).  All  patients,  regardless  of 90COVID-19 symptoms were eligible for enrollment.""",,2021-12-15,2022-02-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,98,0.765,0.669,0.845,True,,,,True,Self-referral,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,"['IgG', 'IgM']",Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Shehu Shagari Awandu,Jaramogi Oginga Odinga University of Science and Technology,Not Unity-Aligned,10.1101/2022.07.27.22278095,2022-08-09,2024-03-01,Unverified,awandu_high_2022,KEN
220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Kilifi_PopAdjusted,220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Kilifi,"SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-June 2022",2022-10-11,Preprint,Local,Cross-sectional survey ,Kenya,,,""" Individuals were eligible to participate in the study if they were resident in the respective HDSS, had no contraindication for blood sample collection, and provided consent.""",,2022-02-15,2022-05-08,Household and community samples,All,Multiple groups,,,Primary Estimate,,852,0.691,0.658,0.723,True,,True,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,,0.93,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Eunice Wangeci Kagucia,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://doi.org/10.1101/2022.10.10.22280824,2022-10-17,2024-04-17,Verified,kagucia_sars-cov-2_2022,KEN
220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Kilifi_Sex_Female,220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Kilifi,"SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-June 2022",2022-10-11,Preprint,Local,Cross-sectional survey ,Kenya,,,""" Individuals were eligible to participate in the study if they were resident in the respective HDSS, had no contraindication for blood sample collection, and provided consent.""",,2022-02-15,2022-05-08,Household and community samples,Female,Multiple groups,,,Sex/Gender,,468,0.724,0.681,0.764,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,,0.93,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Eunice Wangeci Kagucia,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://doi.org/10.1101/2022.10.10.22280824,2022-10-17,2024-04-17,Verified,kagucia_sars-cov-2_2022,KEN
220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Kilifi_Age_<16,220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Kilifi,"SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-June 2022",2022-10-11,Preprint,Local,Cross-sectional survey ,Kenya,,,""" Individuals were eligible to participate in the study if they were resident in the respective HDSS, had no contraindication for blood sample collection, and provided consent.""",,2022-02-15,2022-05-08,Household and community samples,All,Children and Youth (0-17 years),,15.0,Age,<16,313,0.623,0.567,0.677,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,,0.93,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Eunice Wangeci Kagucia,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://doi.org/10.1101/2022.10.10.22280824,2022-10-17,2024-04-17,Verified,kagucia_sars-cov-2_2022,KEN
220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Kilifi_UnAdj,220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Kilifi,"SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-June 2022",2022-10-11,Preprint,Local,Cross-sectional survey ,Kenya,,,""" Individuals were eligible to participate in the study if they were resident in the respective HDSS, had no contraindication for blood sample collection, and provided consent.""",,2022-02-15,2022-05-08,Household and community samples,All,Multiple groups,,,Analysis,,852,0.7020000000000001,0.67,0.7320000000000001,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,,0.93,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Eunice Wangeci Kagucia,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://doi.org/10.1101/2022.10.10.22280824,2022-10-17,2024-04-17,Verified,kagucia_sars-cov-2_2022,KEN
220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Kilifi_Age_25-34,220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Kilifi,"SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-June 2022",2022-10-11,Preprint,Local,Cross-sectional survey ,Kenya,,,""" Individuals were eligible to participate in the study if they were resident in the respective HDSS, had no contraindication for blood sample collection, and provided consent.""",,2022-02-15,2022-05-08,Household and community samples,All,Adults (18-64 years),25.0,34.0,Age,25-34,100,0.72,0.621,0.805,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,,0.93,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Eunice Wangeci Kagucia,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://doi.org/10.1101/2022.10.10.22280824,2022-10-17,2024-04-17,Verified,kagucia_sars-cov-2_2022,KEN
220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Kilifi_Sex_Male,220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Kilifi,"SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-June 2022",2022-10-11,Preprint,Local,Cross-sectional survey ,Kenya,,,""" Individuals were eligible to participate in the study if they were resident in the respective HDSS, had no contraindication for blood sample collection, and provided consent.""",,2022-02-15,2022-05-08,Household and community samples,Male,Multiple groups,,,Sex/Gender,,384,0.674,0.625,0.721,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,,0.93,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Eunice Wangeci Kagucia,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://doi.org/10.1101/2022.10.10.22280824,2022-10-17,2024-04-17,Verified,kagucia_sars-cov-2_2022,KEN
220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Kilifi_Age_45-54,220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Kilifi,"SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-June 2022",2022-10-11,Preprint,Local,Cross-sectional survey ,Kenya,,,""" Individuals were eligible to participate in the study if they were resident in the respective HDSS, had no contraindication for blood sample collection, and provided consent.""",,2022-02-15,2022-05-08,Household and community samples,All,Adults (18-64 years),45.0,54.0,Age,45-54,102,0.775,0.681,0.851,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,,0.93,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Eunice Wangeci Kagucia,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://doi.org/10.1101/2022.10.10.22280824,2022-10-17,2024-04-17,Verified,kagucia_sars-cov-2_2022,KEN
220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Kilifi_Age_35-44,220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Kilifi,"SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-June 2022",2022-10-11,Preprint,Local,Cross-sectional survey ,Kenya,,,""" Individuals were eligible to participate in the study if they were resident in the respective HDSS, had no contraindication for blood sample collection, and provided consent.""",,2022-02-15,2022-05-08,Household and community samples,All,Adults (18-64 years),35.0,44.0,Age,35-44,100,0.75,0.653,0.831,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,,0.93,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Eunice Wangeci Kagucia,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://doi.org/10.1101/2022.10.10.22280824,2022-10-17,2024-04-17,Verified,kagucia_sars-cov-2_2022,KEN
220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Kilifi_Age_55-64,220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Kilifi,"SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-June 2022",2022-10-11,Preprint,Local,Cross-sectional survey ,Kenya,,,""" Individuals were eligible to participate in the study if they were resident in the respective HDSS, had no contraindication for blood sample collection, and provided consent.""",,2022-02-15,2022-05-08,Household and community samples,All,Adults (18-64 years),55.0,64.0,Age,55-64,101,0.752,0.657,0.833,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,,0.93,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Eunice Wangeci Kagucia,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://doi.org/10.1101/2022.10.10.22280824,2022-10-17,2024-04-17,Verified,kagucia_sars-cov-2_2022,KEN
220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Kilifi_Age_16-24,220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Kilifi,"SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-June 2022",2022-10-11,Preprint,Local,Cross-sectional survey ,Kenya,,,""" Individuals were eligible to participate in the study if they were resident in the respective HDSS, had no contraindication for blood sample collection, and provided consent.""",,2022-02-15,2022-05-08,Household and community samples,All,Multiple groups,16.0,24.0,Age,16-24,86,0.744,0.639,0.832,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,,0.93,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Eunice Wangeci Kagucia,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://doi.org/10.1101/2022.10.10.22280824,2022-10-17,2024-04-17,Verified,kagucia_sars-cov-2_2022,KEN
220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Kilifi_Age_>=65,220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Kilifi,"SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-June 2022",2022-10-11,Preprint,Local,Cross-sectional survey ,Kenya,,,""" Individuals were eligible to participate in the study if they were resident in the respective HDSS, had no contraindication for blood sample collection, and provided consent.""",,2022-02-15,2022-05-08,Household and community samples,All,Seniors (65+ years),65.0,,Age,,50,0.74,0.597,0.854,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,,0.93,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Eunice Wangeci Kagucia,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://doi.org/10.1101/2022.10.10.22280824,2022-10-17,2024-04-17,Verified,kagucia_sars-cov-2_2022,KEN
220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Nairobi_PopAdjusted,220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Nairobi,"SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-June 2022",2022-10-11,Preprint,Local,Cross-sectional survey ,Kenya,,,""" Individuals were eligible to participate in the study if
they were resident in the respective HDSS, had no contraindication for blood sample
collection, and provided consent.""",,2022-03-08,2022-06-22,Household and community samples,All,Multiple groups,,,Primary Estimate,,851,0.885,0.861,0.9059999999999999,True,,True,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,,0.93,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Eunice Wangeci Kagucia,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://doi.org/10.1101/2022.10.10.22280824,2022-10-17,2024-04-17,Verified,kagucia_sars-cov-2_2022,KEN
220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Nairobi_Age_>=65,220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Nairobi,"SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-June 2022",2022-10-11,Preprint,Local,Cross-sectional survey ,Kenya,,,""" Individuals were eligible to participate in the study if
they were resident in the respective HDSS, had no contraindication for blood sample
collection, and provided consent.""",,2022-03-08,2022-06-22,Household and community samples,All,Seniors (65+ years),65.0,,Age,,51,0.922,0.811,0.978,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,,0.93,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Eunice Wangeci Kagucia,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://doi.org/10.1101/2022.10.10.22280824,2022-10-17,2024-04-17,Verified,kagucia_sars-cov-2_2022,KEN
220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Nairobi_Age_55-64,220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Nairobi,"SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-June 2022",2022-10-11,Preprint,Local,Cross-sectional survey ,Kenya,,,""" Individuals were eligible to participate in the study if
they were resident in the respective HDSS, had no contraindication for blood sample
collection, and provided consent.""",,2022-03-08,2022-06-22,Household and community samples,All,Adults (18-64 years),55.0,64.0,Age,55-64,100,0.97,0.915,0.994,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,,0.93,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Eunice Wangeci Kagucia,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://doi.org/10.1101/2022.10.10.22280824,2022-10-17,2024-04-17,Verified,kagucia_sars-cov-2_2022,KEN
220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Nairobi_Sex_Male,220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Nairobi,"SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-June 2022",2022-10-11,Preprint,Local,Cross-sectional survey ,Kenya,,,""" Individuals were eligible to participate in the study if
they were resident in the respective HDSS, had no contraindication for blood sample
collection, and provided consent.""",,2022-03-08,2022-06-22,Household and community samples,Male,Multiple groups,,,Sex/Gender,,447,0.871,0.838,0.902,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,,0.93,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Eunice Wangeci Kagucia,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://doi.org/10.1101/2022.10.10.22280824,2022-10-17,2024-04-17,Verified,kagucia_sars-cov-2_2022,KEN
220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Nairobi_Age_45-54,220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Nairobi,"SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-June 2022",2022-10-11,Preprint,Local,Cross-sectional survey ,Kenya,,,""" Individuals were eligible to participate in the study if
they were resident in the respective HDSS, had no contraindication for blood sample
collection, and provided consent.""",,2022-03-08,2022-06-22,Household and community samples,All,Adults (18-64 years),45.0,54.0,Age,45-54,101,0.95,0.888,0.984,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,,0.93,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Eunice Wangeci Kagucia,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://doi.org/10.1101/2022.10.10.22280824,2022-10-17,2024-04-17,Verified,kagucia_sars-cov-2_2022,KEN
220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Nairobi_Age_35-44,220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Nairobi,"SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-June 2022",2022-10-11,Preprint,Local,Cross-sectional survey ,Kenya,,,""" Individuals were eligible to participate in the study if
they were resident in the respective HDSS, had no contraindication for blood sample
collection, and provided consent.""",,2022-03-08,2022-06-22,Household and community samples,All,Adults (18-64 years),35.0,44.0,Age,35-44,99,0.96,0.9,0.989,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,,0.93,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Eunice Wangeci Kagucia,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://doi.org/10.1101/2022.10.10.22280824,2022-10-17,2024-04-17,Verified,kagucia_sars-cov-2_2022,KEN
220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Nairobi_Age_<16,220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Nairobi,"SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-June 2022",2022-10-11,Preprint,Local,Cross-sectional survey ,Kenya,,,""" Individuals were eligible to participate in the study if
they were resident in the respective HDSS, had no contraindication for blood sample
collection, and provided consent.""",,2022-03-08,2022-06-22,Household and community samples,All,Children and Youth (0-17 years),,15.0,Age,<16,306,0.807,0.758,0.85,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,,0.93,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Eunice Wangeci Kagucia,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://doi.org/10.1101/2022.10.10.22280824,2022-10-17,2024-04-17,Verified,kagucia_sars-cov-2_2022,KEN
220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Nairobi_Unadj,220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Nairobi,"SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-June 2022",2022-10-11,Preprint,Local,Cross-sectional survey ,Kenya,,,""" Individuals were eligible to participate in the study if
they were resident in the respective HDSS, had no contraindication for blood sample
collection, and provided consent.""",,2022-03-08,2022-06-22,Household and community samples,All,Multiple groups,,,Analysis,,851,0.888,0.865,0.909,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,,0.93,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Eunice Wangeci Kagucia,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://doi.org/10.1101/2022.10.10.22280824,2022-10-17,2024-04-17,Verified,kagucia_sars-cov-2_2022,KEN
220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Nairobi_Age_25-34,220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Nairobi,"SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-June 2022",2022-10-11,Preprint,Local,Cross-sectional survey ,Kenya,,,""" Individuals were eligible to participate in the study if
they were resident in the respective HDSS, had no contraindication for blood sample
collection, and provided consent.""",,2022-03-08,2022-06-22,Household and community samples,All,Adults (18-64 years),25.0,34.0,Age,25-34,100,0.88,0.8,0.936,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,,0.93,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Eunice Wangeci Kagucia,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://doi.org/10.1101/2022.10.10.22280824,2022-10-17,2024-04-17,Verified,kagucia_sars-cov-2_2022,KEN
220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Nairobi_Sex_Female,220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Nairobi,"SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-June 2022",2022-10-11,Preprint,Local,Cross-sectional survey ,Kenya,,,""" Individuals were eligible to participate in the study if
they were resident in the respective HDSS, had no contraindication for blood sample
collection, and provided consent.""",,2022-03-08,2022-06-22,Household and community samples,Female,Multiple groups,,,Sex/Gender,,404,0.905,0.873,0.933,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,,0.93,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Eunice Wangeci Kagucia,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://doi.org/10.1101/2022.10.10.22280824,2022-10-17,2024-04-17,Verified,kagucia_sars-cov-2_2022,KEN
220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Nairobi_Age_16-24,220111_Kenya_KEMRI-WellcomeTrustResearchProgramme_Nairobi,"SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-June 2022",2022-10-11,Preprint,Local,Cross-sectional survey ,Kenya,,,""" Individuals were eligible to participate in the study if
they were resident in the respective HDSS, had no contraindication for blood sample
collection, and provided consent.""",,2022-03-08,2022-06-22,Household and community samples,All,Multiple groups,16.0,24.0,Age,16-24,94,0.915,0.839,0.963,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,,0.93,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Eunice Wangeci Kagucia,KEMRI-Wellcome Trust Research Programme,Unity-Aligned,https://doi.org/10.1101/2022.10.10.22280824,2022-10-17,2024-04-17,Verified,kagucia_sars-cov-2_2022,KEN
221017_ Nairobi_FredHutchinsonCancerCenter_overall,221017_ Nairobi_FredHutchinsonCancerCenter,Comparison of nucleocapsid and spike antibody ELISAs for determining SARS-CoV-2 seropositivity in Kenyan women and infants.,2022-10-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,Kenya,,Nairobi,"""Between December 2018 to March 2020, 211 pregnant women in their third trimester were recruited from Mathare North Health Centre in Nairobi; a subset of these women and their infants subsequently consented for SARS-CoV-2 testing. Women were eligible to enroll in the Linda Kizazi Study if aged 18-40 years, between 28-42 weeks’ gestation, planning to breastfeed, and had received ≥6 months of ART if living with HIV (LWHIV).""","""Mothers with planned Caesarean section, with serious medical conditions, or who were taking antimicrobial or immunosuppressive medication other than for HIV prophylaxis were not eligible for enrollment in the parent cohort.""",2020-01-01,2020-12-01,Household and community samples,All,Multiple groups,0.0,40.0,Primary Estimate,,352,0.134,,,True,,,,True,Sequential,"Mount Sinai ELISA,Platelia SARS-CoV-2 Total Ab assay","Mount Sinai Laboratory (MSL),Bio-rad",ELISA,Plasma,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],No,No,No,Yes,Yes,Yes,Yes,No,Unclear,Carolyn Fish,Fred Hutchinson Cancer Center,Unity-Aligned,https://dx.doi.org/10.1002/jmv.28221,2022-10-26,2024-04-17,Verified,fish_comparison_2022,KEN
221017_ Nairobi_FredHutchinsonCancerCenter_test_Platelia,221017_ Nairobi_FredHutchinsonCancerCenter,Comparison of nucleocapsid and spike antibody ELISAs for determining SARS-CoV-2 seropositivity in Kenyan women and infants.,2022-10-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,Kenya,,Nairobi,"""Between December 2018 to March 2020, 211 pregnant women in their third trimester were recruited from Mathare North Health Centre in Nairobi; a subset of these women and their infants subsequently consented for SARS-CoV-2 testing. Women were eligible to enroll in the Linda Kizazi Study if aged 18-40 years, between 28-42 weeks’ gestation, planning to breastfeed, and had received ≥6 months of ART if living with HIV (LWHIV).""","""Mothers with planned Caesarean section, with serious medical conditions, or who were taking antimicrobial or immunosuppressive medication other than for HIV prophylaxis were not eligible for enrollment in the parent cohort.""",2020-01-01,2020-12-01,Household and community samples,All,Multiple groups,0.0,40.0,Test used,,352,0.196,,,,,,,,Sequential,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.9490000000000001,0.9740000000000001,['High'],No,No,No,Yes,Yes,Yes,Yes,No,Unclear,Carolyn Fish,Fred Hutchinson Cancer Center,Unity-Aligned,https://dx.doi.org/10.1002/jmv.28221,2022-10-26,2024-04-17,Verified,fish_comparison_2022,KEN
221017_ Nairobi_FredHutchinsonCancerCenter_test_MountSinai,221017_ Nairobi_FredHutchinsonCancerCenter,Comparison of nucleocapsid and spike antibody ELISAs for determining SARS-CoV-2 seropositivity in Kenyan women and infants.,2022-10-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,Kenya,,Nairobi,"""Between December 2018 to March 2020, 211 pregnant women in their third trimester were recruited from Mathare North Health Centre in Nairobi; a subset of these women and their infants subsequently consented for SARS-CoV-2 testing. Women were eligible to enroll in the Linda Kizazi Study if aged 18-40 years, between 28-42 weeks’ gestation, planning to breastfeed, and had received ≥6 months of ART if living with HIV (LWHIV).""","""Mothers with planned Caesarean section, with serious medical conditions, or who were taking antimicrobial or immunosuppressive medication other than for HIV prophylaxis were not eligible for enrollment in the parent cohort.""",2020-01-01,2020-12-01,Household and community samples,All,Multiple groups,0.0,40.0,Test used,,352,0.145,,,,,,,,Sequential,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Plasma,IgG,Spike,Validated by manufacturers,0.9500000000000001,1.0,['High'],No,No,No,Yes,Yes,Yes,Yes,No,Unclear,Carolyn Fish,Fred Hutchinson Cancer Center,Unity-Aligned,https://dx.doi.org/10.1002/jmv.28221,2022-10-26,2024-04-17,Verified,fish_comparison_2022,KEN
221212_USA_RTIInternational_Kenya,221212_USA_RTIInternational_Kenya,"COVID-19 Antibody Positivity Over Time and Pregnancy Outcomes in Seven Low-and-Middle-Income Countries: A Prospective, Observational Study of the Global Network for Women's and Children's Health Research.",2022-12-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kenya,,,"""The COVID-19 antibody study, embedded within the MNHR, included a sub-set of women who were approached at delivery and enrolled. We collected a serum sample at or near delivery for each mother who was approached and consented.""", Women who did not consent to give blood for testing. Indeterminate results are excluded. ,2020-12-01,2020-12-31,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,1794,0.242,,,True,,,,True,Convenience,ELISA SARS-CoV-2 IgG Test System,Zeus,ELISA,Serum,IgG,"Nucleocapsid (N-protein), Spike",,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Robert L. Goldenberg,RTI International,Unity-Aligned,https://dx.doi.org/10.1111/1471-0528.17366,2022-12-24,2024-03-01,Unverified,goldenberg_covid-19_2022,KEN
221215_Kenya_IcahnSchoolofMedicine_Overall,221215_Kenya_IcahnSchoolofMedicine,SARS-CoV-2 Seroprevalence in Kenyan Youth living with HIV,2022-12-15,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Kenya,Western,"Eldoret, Kitale, Turbo, Webuye",Perinatally-infected youth living with HIV,,2021-02-15,2021-09-15,Representative patient population,All,Children and Youth (0-17 years),,,Primary Estimate,,241,0.29,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],,Unclear,No,No,,Unclear,Yes,No,,Mary Boyle,"Icahn School of Medicine at Mount Sinai, New York",Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac492.939,2023-02-09,2023-03-19,Unverified,boyle_1100_2022,KEN
221228_Kenya_WashingtonStateUniversity_adj,221228_Kenya_WashingtonStateUniversity,Near-Complete SARS-CoV-2 Seroprevalence among Rural and Urban Kenyans despite Significant Vaccine Hesitancy and Refusal.,2022-12-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kenya,,,"""We conducted a cross-sectional survey among residents of urban (Nairobi city) and rural (Kakamega) counties of Kenya (Figure 1) between 17 January and 24 February 2022...""
""Criteria for replacing selected households included households without a suitable respondent to grant consent, households whose head declined to grant consent, and if there was no household at the expected geocoordinates. Households without a competent adult or household head were revisited twice before being declared non-respondent. Replacement was carried out using randomly selected replacement households. Participants who were not home during the study visit were revisited within seven days during a time they were likely to be available.""",,2022-01-17,2022-02-24,Household and community samples,All,Multiple groups,,,Primary Estimate,,1537,0.902,0.886,0.912,True,,True,,True,Stratified probability,Wantai SARS-CoV-2 IgG ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.871,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Yes,Carolyne Nasimiyu,Washington State University,Unity-Aligned,https://dx.doi.org/10.3390/vaccines11010068,2023-02-08,2024-04-11,Verified,nasimiyuNearCompleteSARSCoV2Seroprevalence2023,KEN
221228_Kenya_WashingtonStateUniversity_unadj,221228_Kenya_WashingtonStateUniversity,Near-Complete SARS-CoV-2 Seroprevalence among Rural and Urban Kenyans despite Significant Vaccine Hesitancy and Refusal.,2022-12-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kenya,,,"""We conducted a cross-sectional survey among residents of urban (Nairobi city) and rural (Kakamega) counties of Kenya (Figure 1) between 17 January and 24 February 2022...""
""Criteria for replacing selected households included households without a suitable respondent to grant consent, households whose head declined to grant consent, and if there was no household at the expected geocoordinates. Households without a competent adult or household head were revisited twice before being declared non-respondent. Replacement was carried out using randomly selected replacement households. Participants who were not home during the study visit were revisited within seven days during a time they were likely to be available.""",,2022-01-17,2022-02-24,Household and community samples,All,Multiple groups,,,Analysis,,1537,0.91,0.894,0.923,,,,,,Stratified probability,Wantai SARS-CoV-2 IgG ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.871,['Moderate'],Yes,Yes,Yes,Yes,Yes,No,Yes,No,Yes,Carolyne Nasimiyu,Washington State University,Unity-Aligned,https://dx.doi.org/10.3390/vaccines11010068,2023-02-08,2024-04-11,Verified,nasimiyuNearCompleteSARSCoV2Seroprevalence2023,KEN
230223_Kenya_UniversityofWashington,230223_Kenya_UniversityofWashington,"SARS-CoV-2 antibody prevalence, correlates, and access to harm reduction services among people who inject drugs living with and without HIV and their partners in Kenya.",2023-02-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Kenya,Coast region,,"""Participants were men and women above the age of 18 years who were enrolled in a study of HIV and hepatitis C-assisted partner services among PWID (NIH R01DA043409) which has been described in detail elsewhere [13]. All participants had either injected drugs within the last year or been named as a sexual or injecting partner of a PLWH who had injected drugs within the last year.""",,2021-04-15,2021-07-15,Multiple populations,All,Multiple groups,18.0,74.0,Primary Estimate,,1000,0.309,,,True,,,,True,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),,0.974,0.949,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Shrada Doshi,University of Washington,Not Unity-Aligned,https://dx.doi.org/10.1186/s12954-023-00754-5,2023-03-20,2024-03-01,Unverified,doshi_sars-cov-2_2023,KEN
230704_Asembo_USCDCKenya_Round1_Overall_PopAdj,230704_Asembo_USCDCKenya_Round1,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Kenya,,Asembo,"Household members in Asembo, Siaya County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-03-12,2021-04-08,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,"Weighted by age, sex, and household clustering",935,0.26,0.224,0.3,True,,True,,True,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2023-07-31,2024-05-01,Verified,munywoki_heterogenous_2023,KEN
230704_Asembo_USCDCKenya_Round1_Age0-4,230704_Asembo_USCDCKenya_Round1,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Kenya,,Asembo,"Household members in Asembo, Siaya County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-03-12,2021-04-08,Household and community samples,All,Children and Youth (0-17 years),0.0,4.0,Age,0-4,79,0.177,0.1,0.279,,,,,,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2024-05-01,2024-05-01,Verified,munywoki_heterogenous_2023,KEN
230704_Asembo_USCDCKenya_Round1_Age10-19,230704_Asembo_USCDCKenya_Round1,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Kenya,,Asembo,"Household members in Asembo, Siaya County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-03-12,2021-04-08,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,273,0.293,0.24,0.351,,,,,,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2024-05-01,2024-05-01,Verified,munywoki_heterogenous_2023,KEN
230704_Asembo_USCDCKenya_Round1_Age60+,230704_Asembo_USCDCKenya_Round1,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Kenya,,Asembo,"Household members in Asembo, Siaya County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-03-12,2021-04-08,Household and community samples,All,Seniors (65+ years),60.0,,Age,60+,95,0.189,0.116,0.283,,,,,,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2024-05-01,2024-05-01,Verified,munywoki_heterogenous_2023,KEN
230704_Asembo_USCDCKenya_Round1_Age5-9,230704_Asembo_USCDCKenya_Round1,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Kenya,,Asembo,"Household members in Asembo, Siaya County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-03-12,2021-04-08,Household and community samples,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,145,0.138,0.086,0.205,,,,,,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2024-05-01,2024-05-01,Verified,munywoki_heterogenous_2023,KEN
230704_Asembo_USCDCKenya_Round1_Age20-29,230704_Asembo_USCDCKenya_Round1,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Kenya,,Asembo,"Household members in Asembo, Siaya County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-03-12,2021-04-08,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,97,0.278,0.192,0.379,,,,,,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2024-05-01,2024-05-01,Verified,munywoki_heterogenous_2023,KEN
230704_Asembo_USCDCKenya_Round1_Age40-49,230704_Asembo_USCDCKenya_Round1,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Kenya,,Asembo,"Household members in Asembo, Siaya County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-03-12,2021-04-08,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,78,0.256,0.164,0.368,,,,,,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2024-05-01,2024-05-01,Verified,munywoki_heterogenous_2023,KEN
230704_Asembo_USCDCKenya_Round1_Age50-59,230704_Asembo_USCDCKenya_Round1,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Kenya,,Asembo,"Household members in Asembo, Siaya County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-03-12,2021-04-08,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,58,0.259,0.153,0.39,,,,,,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2024-05-01,2024-05-01,Verified,munywoki_heterogenous_2023,KEN
230704_Asembo_USCDCKenya_Round1_Age30-39,230704_Asembo_USCDCKenya_Round1,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Kenya,,Asembo,"Household members in Asembo, Siaya County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-03-12,2021-04-08,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,110,0.364,0.274,0.461,,,,,,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2024-05-01,2024-05-01,Verified,munywoki_heterogenous_2023,KEN
230704_Asembo_USCDCKenya_Round2_Overall_PopAdj,230704_Asembo_USCDCKenya_Round2,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Prospective cohort,Kenya,,Asembo,"Household members in Asembo, Siaya County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-07-08,2021-08-04,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,"Weighted by age, sex, and household clustering",888,0.487,0.443,0.532,True,,True,,True,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2023-07-31,2024-05-01,Verified,munywoki_heterogenous_2023,KEN
230704_Asembo_USCDCKenya_Round2_Age50-59,230704_Asembo_USCDCKenya_Round2,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Prospective cohort,Kenya,,Asembo,"Household members in Asembo, Siaya County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-07-08,2021-08-04,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,64,0.484,0.358,0.613,,,,,,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2024-05-01,2024-05-01,Unverified,munywoki_heterogenous_2023,KEN
230704_Asembo_USCDCKenya_Round2_Age20-29,230704_Asembo_USCDCKenya_Round2,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Prospective cohort,Kenya,,Asembo,"Household members in Asembo, Siaya County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-07-08,2021-08-04,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,93,0.495,0.389,0.6,,,,,,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2024-05-01,2024-05-01,Unverified,munywoki_heterogenous_2023,KEN
230704_Asembo_USCDCKenya_Round2_Age5-9,230704_Asembo_USCDCKenya_Round2,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Prospective cohort,Kenya,,Asembo,"Household members in Asembo, Siaya County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-07-08,2021-08-04,Household and community samples,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,122,0.385,0.299,0.478,,,,,,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2024-05-01,2024-05-01,Unverified,munywoki_heterogenous_2023,KEN
230704_Asembo_USCDCKenya_Round2_Age40-49,230704_Asembo_USCDCKenya_Round2,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Prospective cohort,Kenya,,Asembo,"Household members in Asembo, Siaya County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-07-08,2021-08-04,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,72,0.472,0.353,0.594,,,,,,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2024-05-01,2024-05-01,Unverified,munywoki_heterogenous_2023,KEN
230704_Asembo_USCDCKenya_Round2_Age10-19,230704_Asembo_USCDCKenya_Round2,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Prospective cohort,Kenya,,Asembo,"Household members in Asembo, Siaya County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-07-08,2021-08-04,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,261,0.579,0.516,0.639,,,,,,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2024-05-01,2024-05-01,Unverified,munywoki_heterogenous_2023,KEN
230704_Asembo_USCDCKenya_Round2_Age30-39,230704_Asembo_USCDCKenya_Round2,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Prospective cohort,Kenya,,Asembo,"Household members in Asembo, Siaya County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-07-08,2021-08-04,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,114,0.561,0.465,0.654,,,,,,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2024-05-01,2024-05-01,Unverified,munywoki_heterogenous_2023,KEN
230704_Asembo_USCDCKenya_Round2_Age60+,230704_Asembo_USCDCKenya_Round2,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Prospective cohort,Kenya,,Asembo,"Household members in Asembo, Siaya County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-07-08,2021-08-04,Household and community samples,All,Seniors (65+ years),60.0,,Age,60+,94,0.479,0.375,0.584,,,,,,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2024-05-01,2024-05-01,Unverified,munywoki_heterogenous_2023,KEN
230704_Asembo_USCDCKenya_Round2_Age0-4,230704_Asembo_USCDCKenya_Round2,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Prospective cohort,Kenya,,Asembo,"Household members in Asembo, Siaya County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-07-08,2021-08-04,Household and community samples,All,Children and Youth (0-17 years),0.0,4.0,Age,0-4,68,0.324,0.215,0.448,,,,,,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2024-05-01,2024-05-01,Unverified,munywoki_heterogenous_2023,KEN
230704_Kibera_USCDCKenya_Round1_Overall_PopAdj,230704_Kibera_USCDCKenya_Round1,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Kenya,,Kibera,"Household members in Kibera, Nairobi County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-02-19,2021-03-28,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,"Weighted by age, sex, and household clustering",859,0.562,0.521,0.602,True,,True,,True,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2023-07-31,2024-05-01,Verified,munywoki_heterogenous_2023,KEN
230704_Kibera_USCDCKenya_Round1_Age0-4,230704_Kibera_USCDCKenya_Round1,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Kenya,,Kibera,"Household members in Kibera, Nairobi County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-02-19,2021-03-28,Household and community samples,All,Children and Youth (0-17 years),0.0,4.0,Age,0-4,73,0.315,0.211,0.434,,,,,,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2024-05-01,2024-05-01,Unverified,munywoki_heterogenous_2023,KEN
230704_Kibera_USCDCKenya_Round1_Age30-39,230704_Kibera_USCDCKenya_Round1,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Kenya,,Kibera,"Household members in Kibera, Nairobi County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-02-19,2021-03-28,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,119,0.664,0.572,0.748,,,,,,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2024-05-01,2024-05-01,Unverified,munywoki_heterogenous_2023,KEN
230704_Kibera_USCDCKenya_Round1_Age5-9,230704_Kibera_USCDCKenya_Round1,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Kenya,,Kibera,"Household members in Kibera, Nairobi County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-02-19,2021-03-28,Household and community samples,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,133,0.338,0.259,0.425,,,,,,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2024-05-01,2024-05-01,Unverified,munywoki_heterogenous_2023,KEN
230704_Kibera_USCDCKenya_Round1_Age50-59,230704_Kibera_USCDCKenya_Round1,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Kenya,,Kibera,"Household members in Kibera, Nairobi County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-02-19,2021-03-28,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,43,0.651,0.491,0.79,,,,,,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2024-05-01,2024-05-01,Unverified,munywoki_heterogenous_2023,KEN
230704_Kibera_USCDCKenya_Round1_Age40-49,230704_Kibera_USCDCKenya_Round1,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Kenya,,Kibera,"Household members in Kibera, Nairobi County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-02-19,2021-03-28,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,88,0.648,0.539,0.747,,,,,,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2024-05-01,2024-05-01,Unverified,munywoki_heterogenous_2023,KEN
230704_Kibera_USCDCKenya_Round1_Age60+,230704_Kibera_USCDCKenya_Round1,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Kenya,,Kibera,"Household members in Kibera, Nairobi County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-02-19,2021-03-28,Household and community samples,All,Seniors (65+ years),60.0,,Age,60+,13,0.615,0.316,0.861,,,,,,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2024-05-01,2024-05-01,Unverified,munywoki_heterogenous_2023,KEN
230704_Kibera_USCDCKenya_Round1_Age20-29,230704_Kibera_USCDCKenya_Round1,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Kenya,,Kibera,"Household members in Kibera, Nairobi County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-02-19,2021-03-28,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,140,0.643,0.558,0.722,,,,,,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2024-05-01,2024-05-01,Unverified,munywoki_heterogenous_2023,KEN
230704_Kibera_USCDCKenya_Round1_Age10-19,230704_Kibera_USCDCKenya_Round1,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Kenya,,Kibera,"Household members in Kibera, Nairobi County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-02-19,2021-03-28,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,250,0.592,0.528,0.654,,,,,,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2024-05-01,2024-05-01,Unverified,munywoki_heterogenous_2023,KEN
230704_Kibera_USCDCKenya_Round2_Overall_PopAdj,230704_Kibera_USCDCKenya_Round2,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Prospective cohort,Kenya,,Kibera,"Household members in Kibera, Nairobi County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-06-04,2021-07-04,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,"Weighted by age, sex, and household clustering",750,0.639,0.596,0.679,True,,True,,True,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2023-07-31,2024-05-01,Verified,munywoki_heterogenous_2023,KEN
230704_Kibera_USCDCKenya_Round2_Age20-29,230704_Kibera_USCDCKenya_Round2,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Prospective cohort,Kenya,,Kibera,"Household members in Kibera, Nairobi County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-06-04,2021-07-04,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,124,0.71,0.621,0.788,,,,,,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2024-05-01,2024-05-01,Unverified,munywoki_heterogenous_2023,KEN
230704_Kibera_USCDCKenya_Round2_Age5-9,230704_Kibera_USCDCKenya_Round2,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Prospective cohort,Kenya,,Kibera,"Household members in Kibera, Nairobi County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-06-04,2021-07-04,Household and community samples,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,110,0.518,0.421,0.614,,,,,,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2024-05-01,2024-05-01,Unverified,munywoki_heterogenous_2023,KEN
230704_Kibera_USCDCKenya_Round2_Age50-59,230704_Kibera_USCDCKenya_Round2,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Prospective cohort,Kenya,,Kibera,"Household members in Kibera, Nairobi County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-06-04,2021-07-04,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,36,0.639,0.462,0.792,,,,,,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2024-05-01,2024-05-01,Unverified,munywoki_heterogenous_2023,KEN
230704_Kibera_USCDCKenya_Round2_Age0-4,230704_Kibera_USCDCKenya_Round2,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Prospective cohort,Kenya,,Kibera,"Household members in Kibera, Nairobi County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-06-04,2021-07-04,Household and community samples,All,Children and Youth (0-17 years),0.0,4.0,Age,0-4,67,0.373,0.258,0.5,,,,,,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2024-05-01,2024-05-01,Unverified,munywoki_heterogenous_2023,KEN
230704_Kibera_USCDCKenya_Round2_Age30-39,230704_Kibera_USCDCKenya_Round2,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Prospective cohort,Kenya,,Kibera,"Household members in Kibera, Nairobi County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-06-04,2021-07-04,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,110,0.664,0.567,0.751,,,,,,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2024-05-01,2024-05-01,Unverified,munywoki_heterogenous_2023,KEN
230704_Kibera_USCDCKenya_Round2_Age60+,230704_Kibera_USCDCKenya_Round2,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Prospective cohort,Kenya,,Kibera,"Household members in Kibera, Nairobi County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-06-04,2021-07-04,Household and community samples,All,Seniors (65+ years),60.0,,Age,60+,17,0.706,0.44,0.897,,,,,,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2024-05-01,2024-05-01,Unverified,munywoki_heterogenous_2023,KEN
230704_Kibera_USCDCKenya_Round2_Age10-19,230704_Kibera_USCDCKenya_Round2,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Prospective cohort,Kenya,,Kibera,"Household members in Kibera, Nairobi County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-06-04,2021-07-04,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,201,0.711,0.644,0.773,,,,,,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2024-05-01,2024-05-01,Unverified,munywoki_heterogenous_2023,KEN
230704_Kibera_USCDCKenya_Round2_Age40-49,230704_Kibera_USCDCKenya_Round2,"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021",2023-07-04,Journal Article (Peer-Reviewed),Local,Prospective cohort,Kenya,,Kibera,"Household members in Kibera, Nairobi County, Kenya, who were part of the population-based infectious disease surveillance (PBIDS) platform.","Based on Figure 2:
- Household heads not available,
- out-migrated,
- declined consent,
- failed venipuncture.",2021-06-04,2021-07-04,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,85,0.729,0.622,0.82,,,,,,Simplified probability,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,Validated by manufacturers,0.92,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Patrick Munywoki,U.S. Centers for Disease Control and Prevention (CDC)-Kenya,Unity-Aligned,http://doi.org/10.12688/gatesopenres.14684.1,2024-05-01,2024-05-01,Unverified,munywoki_heterogenous_2023,KEN
230720_Kenya_JawaharlalNehruMedicalCollege_Overall,230720_Kenya_JawaharlalNehruMedicalCollege,COVID-19 symptoms and antibody positivity among unvaccinated pregnant women: An observational study in seven countries from the Global Network,2023-07-20,Journal Article (Peer-Reviewed),National,Prospective cohort,Kenya,,,staff (registry administrators [RAs]) identified pregnant women in their respective clusters,vaccinated pregnant women,2020-10-01,2022-06-30,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,2420,0.311,,,True,,,,True,Stratified non-probability,Not reported/ Unable to specify,,,Serum,,,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Avinash Kavi,Jawaharlal Nehru Medical College,Not Unity-Aligned,https://dx.doi.org/10.1111/1471-0528.17604,2023-08-22,2023-08-23,Unverified,kavi_covid-19_2023,KEN
211128_Prishtina_MunicipalityofPrishtina_Primary,211128_Prishtina_MunicipalityofPrishtina,Seroprevalence of anti-SARS-CoV-2 antibodies among municipal staff in the municipality of Prishtina,2021-11-28,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Kosovo,,Prishtina,"The target sample of the municipal survey, was consecutive and intended to
include all healthcare and administration workers of the municipality of Prishtina. The
sample selected for this study was only composed of municipal workers.",Health care workers,2020-10-01,2020-11-30,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,418,0.21050000000000002,,,True,,,,True,Convenience,"VIDAS® SARS-COV-2 IgG,Not reported/ Unable to specify","BioMérieux,NA",,,"['IgG', 'IgM']",,,,,['High'],,No,No,No,,Unclear,Yes,No,,Bujar Gashi,Municipality of Prishtina,Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph182312545,2021-12-07,2024-03-01,Unverified,gashi_seroprevalence_2021,XKX
220116_Prishtina_PrishtinaStarts_IgMorIgG_Overall,220116_Prishtina_PrishtinaStarts,Seroprevalence of anti-SARS-CoV-2 antibodies among staff at primary healthcare institutions in Prishtina.,2022-01-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Kosovo,,Prishtina,"""...survey targeted all healthcare and administration workers of the Municipality of Prishtina...""",,2020-10-14,2020-12-17,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,IgM or IgG,475,0.1747,,,True,,,,True,Entire sample,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,,,"['IgG', 'IgM']",,,,,['Moderate'],,Yes,No,No,,Yes,Yes,Yes,,Rrezart Halili,Prishtina Starts,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07038-6,2022-01-27,2024-03-01,Unverified,halili_seroprevalence_2022,XKX
201205_Kuwait_KuwaitUniversity_Overall_unadj,201205_Kuwait_KuwaitUniversity,Seroprevalence of SARS-CoV-2 in migrant workers in Kuwait,2020-12-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kuwait,,,"non-Kuwaiti migrant worker adult males over the age of 20 years, have been resident of Kuwait for a minimum of 6 months, and worked as cashiers, packers or cleaners.","exclusion criteria were inability to provide informed consent and worker with apparent COVID-19-like symptoms including temperature, cough and runny nose.",2020-05-23,2020-06-26,Essential non-healthcare workers,Male,Adults (18-64 years),20.0,,Primary Estimate,,525,0.381,0.34,0.423,True,,,,True,Stratified probability,Biozek Medical COVID-19 Rapid Test,Biozek,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.66,0.97,['High'],No,Yes,No,No,Unclear,Unclear,Yes,No,Unclear,Walid Q Alali,University of Kuwait,Not Unity-Aligned,https://dx.doi.org/10.1093/jtm/taaa223,2021-01-23,2024-03-01,Verified,alali_seroprevalence_2020,KWT
201205_Kuwait_KuwaitUniversity_>50_unadj,201205_Kuwait_KuwaitUniversity,Seroprevalence of SARS-CoV-2 in migrant workers in Kuwait,2020-12-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kuwait,,,"non-Kuwaiti migrant worker adult males over the age of 20 years, have been resident of Kuwait for a minimum of 6 months, and worked as cashiers, packers or cleaners.","exclusion criteria were inability to provide informed consent and worker with apparent COVID-19-like symptoms including temperature, cough and runny nose.",2020-05-23,2020-06-26,Essential non-healthcare workers,Male,Adults (18-64 years),51.0,,Age,>50,154,0.409,0.334,0.489,,,,,,Stratified probability,Biozek Medical COVID-19 Rapid Test,Biozek,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.66,0.97,['High'],No,Yes,No,No,Unclear,Unclear,Yes,No,Unclear,Walid Q Alali,University of Kuwait,Not Unity-Aligned,https://dx.doi.org/10.1093/jtm/taaa223,2021-01-23,2024-03-01,Verified,alali_seroprevalence_2020,KWT
201205_Kuwait_KuwaitUniversity_31-40_unadj,201205_Kuwait_KuwaitUniversity,Seroprevalence of SARS-CoV-2 in migrant workers in Kuwait,2020-12-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kuwait,,,"non-Kuwaiti migrant worker adult males over the age of 20 years, have been resident of Kuwait for a minimum of 6 months, and worked as cashiers, packers or cleaners.","exclusion criteria were inability to provide informed consent and worker with apparent COVID-19-like symptoms including temperature, cough and runny nose.",2020-05-23,2020-06-26,Essential non-healthcare workers,Male,Adults (18-64 years),31.0,40.0,Age,31-40,150,0.327,0.256,0.406,,,,,,Stratified probability,Biozek Medical COVID-19 Rapid Test,Biozek,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.66,0.97,['High'],No,Yes,No,No,Unclear,Unclear,Yes,No,Unclear,Walid Q Alali,University of Kuwait,Not Unity-Aligned,https://dx.doi.org/10.1093/jtm/taaa223,2021-01-23,2024-03-01,Verified,alali_seroprevalence_2020,KWT
201205_Kuwait_KuwaitUniversity_20-30_unadj,201205_Kuwait_KuwaitUniversity,Seroprevalence of SARS-CoV-2 in migrant workers in Kuwait,2020-12-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kuwait,,,"non-Kuwaiti migrant worker adult males over the age of 20 years, have been resident of Kuwait for a minimum of 6 months, and worked as cashiers, packers or cleaners.","exclusion criteria were inability to provide informed consent and worker with apparent COVID-19-like symptoms including temperature, cough and runny nose.",2020-05-23,2020-06-26,Essential non-healthcare workers,Male,Adults (18-64 years),20.0,30.0,Age,20-30,50,0.36,0.24,0.5,,,,,,Stratified probability,Biozek Medical COVID-19 Rapid Test,Biozek,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.66,0.97,['High'],No,Yes,No,No,Unclear,Unclear,Yes,No,Unclear,Walid Q Alali,University of Kuwait,Not Unity-Aligned,https://dx.doi.org/10.1093/jtm/taaa223,2021-01-23,2024-03-01,Verified,alali_seroprevalence_2020,KWT
201205_Kuwait_KuwaitUniversity_41-50_unadj,201205_Kuwait_KuwaitUniversity,Seroprevalence of SARS-CoV-2 in migrant workers in Kuwait,2020-12-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kuwait,,,"non-Kuwaiti migrant worker adult males over the age of 20 years, have been resident of Kuwait for a minimum of 6 months, and worked as cashiers, packers or cleaners.","exclusion criteria were inability to provide informed consent and worker with apparent COVID-19-like symptoms including temperature, cough and runny nose.",2020-05-23,2020-06-26,Essential non-healthcare workers,Male,Adults (18-64 years),41.0,50.0,Age,41-50,171,0.409,0.33799999999999997,0.485,,,,,,Stratified probability,Biozek Medical COVID-19 Rapid Test,Biozek,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.66,0.97,['High'],No,Yes,No,No,Unclear,Unclear,Yes,No,Unclear,Walid Q Alali,University of Kuwait,Not Unity-Aligned,https://dx.doi.org/10.1093/jtm/taaa223,2021-01-23,2024-03-01,Verified,alali_seroprevalence_2020,KWT
210513_Kuwait_KuwaitUniversity_Overall,210513_Kuwait_KuwaitUniversity,"Severe acute respiratory syndrome coronavirus 2 seroprevalence survey among 10,256 workers in Kuwait.",2021-05-03,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kuwait,"Ahmadi, Farwaniya, Hawali, Asma, Jahra, Mubarak Alkabeer","Jeleeb Al Shuyoukh, Mahboula","The migrant workers residing in areas under lockdown in Kuwait. All individuals who requested to be relocated outside of the
lockdown areas of Jeleeb al Shuyoukh and Mahboula were included. Next, we enrolled participants from Hawali, Asma, Jahra, and Mubarak Alkabeer governates.","The
exclusion criteria were age less than 18 years old.",2020-04-18,2020-05-10,Non-essential workers and unemployed persons,All,Adults (18-64 years),18.0,,Primary Estimate,,10256,0.059000000000000004,0.054000000000000006,0.063,True,,,,True,Simplified probability,Biozek Medical COVID-19 Rapid Test,Biozek,LFIA,Multiple Types,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Haya Altawalah,Institut Pasteur du Maroc,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcvp.2021.100017,2022-03-14,2024-03-01,Unverified,altawalah_severe_2021,KWT
210816_Kuwait_MinistryofHealth_primary,210816_Kuwait_MinistryofHealth,Factors associated with SARS-CoV-2 infection amongst healthcare workers in a COVID-19 designated hospital,2021-08-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kuwait,,,healthcare workers and hospital administrators over the age of 18 across all health districts in Kuwait ,Participants who reported that they were not active in their role during the pandemic period were excluded from the study,2020-08-15,2020-10-15,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,847,0.20500000000000002,,,True,,,,True,Convenience,LIAISON SARS-CoV-2 S1/S2 IgM,DiaSorin,CLIA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,SarahAl Youha,Ministry of Health,Not Unity-Aligned,http://dx.doi.org/10.1016/j.jiph.2021.08.012,2021-08-30,2024-03-01,Unverified,al_youha_factors_2021,KWT
230202_Kuwait_MinistryOfHealth_Overall,230202_Kuwait_MinistryOfHealth,Changing Patterns of SARS-CoV-2 Seroprevalence: A Snapshot among the General Population in Kuwait.,2023-02-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kuwait,,,"""Phase 1: Remaining blood (whole blood or serum) samples taken upon physician request (a convenience non-random collection), for any reason, at five general hospitals across Kuwait between was our target population. The blood samples represented a diverse range of patients (outpatient and inpatient) belonging to both genders and five age groups.""",,2020-09-01,2020-12-31,Residual sera,All,Multiple groups,,,Primary Estimate,,19453,0.2489,0.2429,0.255,True,,,,True,Stratified probability,LIAISON® SARS-CoV-2 TrimericS IgG,DiaSorin,CLIA,Plasma,IgG,Spike,Validated by manufacturers,0.987,0.995,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Wadha Alfouzan,Ministry of Health,Unity-Aligned,https://dx.doi.org/10.3390/vaccines11020336,2023-04-12,2024-04-22,Verified,alfouzan_changing_2023,KWT
230202_Kuwait_MinistryOfHealth_<15,230202_Kuwait_MinistryOfHealth,Changing Patterns of SARS-CoV-2 Seroprevalence: A Snapshot among the General Population in Kuwait.,2023-02-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kuwait,,,"""Phase 1: Remaining blood (whole blood or serum) samples taken upon physician request (a convenience non-random collection), for any reason, at five general hospitals across Kuwait between was our target population. The blood samples represented a diverse range of patients (outpatient and inpatient) belonging to both genders and five age groups.""",,2020-09-01,2020-12-31,Residual sera,All,Children and Youth (0-17 years),,15.0,Age,,328,0.23,0.209,0.253,,,,,,Stratified probability,LIAISON® SARS-CoV-2 TrimericS IgG,DiaSorin,CLIA,Plasma,IgG,Spike,Validated by manufacturers,0.987,0.995,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Wadha Alfouzan,Ministry of Health,Unity-Aligned,https://dx.doi.org/10.3390/vaccines11020336,2024-04-22,2024-04-22,Verified,alfouzan_changing_2023,KWT
230202_Kuwait_MinistryOfHealth_25-44,230202_Kuwait_MinistryOfHealth,Changing Patterns of SARS-CoV-2 Seroprevalence: A Snapshot among the General Population in Kuwait.,2023-02-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kuwait,,,"""Phase 1: Remaining blood (whole blood or serum) samples taken upon physician request (a convenience non-random collection), for any reason, at five general hospitals across Kuwait between was our target population. The blood samples represented a diverse range of patients (outpatient and inpatient) belonging to both genders and five age groups.""",,2020-09-01,2020-12-31,Residual sera,All,Adults (18-64 years),25.0,44.0,Age,,1736,0.26,0.249,0.27,,,,,,Stratified probability,LIAISON® SARS-CoV-2 TrimericS IgG,DiaSorin,CLIA,Plasma,IgG,Spike,Validated by manufacturers,0.987,0.995,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Wadha Alfouzan,Ministry of Health,Unity-Aligned,https://dx.doi.org/10.3390/vaccines11020336,2024-04-22,2024-04-22,Verified,alfouzan_changing_2023,KWT
230202_Kuwait_MinistryOfHealth_45-64,230202_Kuwait_MinistryOfHealth,Changing Patterns of SARS-CoV-2 Seroprevalence: A Snapshot among the General Population in Kuwait.,2023-02-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kuwait,,,"""Phase 1: Remaining blood (whole blood or serum) samples taken upon physician request (a convenience non-random collection), for any reason, at five general hospitals across Kuwait between was our target population. The blood samples represented a diverse range of patients (outpatient and inpatient) belonging to both genders and five age groups.""",,2020-09-01,2020-12-31,Residual sera,All,Adults (18-64 years),45.0,64.0,Age,,1619,0.3,0.284,0.308,,,,,,Stratified probability,LIAISON® SARS-CoV-2 TrimericS IgG,DiaSorin,CLIA,Plasma,IgG,Spike,Validated by manufacturers,0.987,0.995,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Wadha Alfouzan,Ministry of Health,Unity-Aligned,https://dx.doi.org/10.3390/vaccines11020336,2024-04-22,2024-04-22,Verified,alfouzan_changing_2023,KWT
230202_Kuwait_MinistryOfHealth_>65,230202_Kuwait_MinistryOfHealth,Changing Patterns of SARS-CoV-2 Seroprevalence: A Snapshot among the General Population in Kuwait.,2023-02-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kuwait,,,"""Phase 1: Remaining blood (whole blood or serum) samples taken upon physician request (a convenience non-random collection), for any reason, at five general hospitals across Kuwait between was our target population. The blood samples represented a diverse range of patients (outpatient and inpatient) belonging to both genders and five age groups.""",,2020-09-01,2020-12-31,Residual sera,All,Seniors (65+ years),65.0,,Age,,742,0.231,0.217,0.246,,,,,,Stratified probability,LIAISON® SARS-CoV-2 TrimericS IgG,DiaSorin,CLIA,Plasma,IgG,Spike,Validated by manufacturers,0.987,0.995,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Wadha Alfouzan,Ministry of Health,Unity-Aligned,https://dx.doi.org/10.3390/vaccines11020336,2024-04-22,2024-04-22,Verified,alfouzan_changing_2023,KWT
230202_Kuwait_MinistryOfHealth_15-24,230202_Kuwait_MinistryOfHealth,Changing Patterns of SARS-CoV-2 Seroprevalence: A Snapshot among the General Population in Kuwait.,2023-02-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Kuwait,,,"""Phase 1: Remaining blood (whole blood or serum) samples taken upon physician request (a convenience non-random collection), for any reason, at five general hospitals across Kuwait between was our target population. The blood samples represented a diverse range of patients (outpatient and inpatient) belonging to both genders and five age groups.""",,2020-09-01,2020-12-31,Residual sera,All,Adults (18-64 years),15.0,24.0,Age,,530,0.205,0.19,0.221,,,,,,Stratified probability,LIAISON® SARS-CoV-2 TrimericS IgG,DiaSorin,CLIA,Plasma,IgG,Spike,Validated by manufacturers,0.987,0.995,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Wadha Alfouzan,Ministry of Health,Unity-Aligned,https://dx.doi.org/10.3390/vaccines11020336,2024-04-22,2024-04-22,Verified,alfouzan_changing_2023,KWT
211209_Kyrgyzstan_SaintPetersburgPasteurInstitute_Overall,211209_Kyrgyzstan_SaintPetersburgPasteurInstitute,SARS-CoV-2 Herd Immunity of the Kyrgyz Population in 2021,2021-12-09,Preprint,National,Cross-sectional survey ,Kyrgyzstan,,,Kyrgyzstan residents. ,,2021-06-28,2021-07-03,Household and community samples,All,Multiple groups,1.0,,Primary Estimate,,9471,0.48700000000000004,0.47700000000000004,0.49700000000000005,True,,,,True,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anna Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1138128/v1,2021-12-15,2022-07-16,Verified,popova_sars-cov-2_2021-1,KGZ
211209_Kyrgyzstan_SaintPetersburgPasteurInstitute_VaccineEpiVacCorona,211209_Kyrgyzstan_SaintPetersburgPasteurInstitute,SARS-CoV-2 Herd Immunity of the Kyrgyz Population in 2021,2021-12-09,Preprint,National,Cross-sectional survey ,Kyrgyzstan,,,Kyrgyzstan residents. ,,2021-06-28,2021-07-03,Household and community samples,All,Multiple groups,1.0,,COVID-19 vaccination status,Vaccine EpiVacCorona,133,0.8270000000000001,0.752,0.887,,,,,,Simplified probability,Author designed (ELISA) - Unknown,,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anna Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1138128/v1,2021-12-15,2022-07-16,Verified,popova_sars-cov-2_2021-1,KGZ
211209_Kyrgyzstan_SaintPetersburgPasteurInstitute_Age18-29,211209_Kyrgyzstan_SaintPetersburgPasteurInstitute,SARS-CoV-2 Herd Immunity of the Kyrgyz Population in 2021,2021-12-09,Preprint,National,Cross-sectional survey ,Kyrgyzstan,,,Kyrgyzstan residents. ,,2021-06-28,2021-07-03,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,18-29,1447,0.37200000000000005,0.348,0.39799999999999996,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anna Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1138128/v1,2021-12-15,2022-07-16,Verified,popova_sars-cov-2_2021-1,KGZ
211209_Kyrgyzstan_SaintPetersburgPasteurInstitute_VaccineYES,211209_Kyrgyzstan_SaintPetersburgPasteurInstitute,SARS-CoV-2 Herd Immunity of the Kyrgyz Population in 2021,2021-12-09,Preprint,National,Cross-sectional survey ,Kyrgyzstan,,,Kyrgyzstan residents. ,,2021-06-28,2021-07-03,Household and community samples,All,Multiple groups,1.0,,COVID-19 vaccination status,,2395,0.91,0.898,0.9209999999999999,,,,,,Simplified probability,Author designed (ELISA) - Unknown,,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anna Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1138128/v1,2021-12-15,2022-07-16,Verified,popova_sars-cov-2_2021-1,KGZ
211209_Kyrgyzstan_SaintPetersburgPasteurInstitute_Age40-49,211209_Kyrgyzstan_SaintPetersburgPasteurInstitute,SARS-CoV-2 Herd Immunity of the Kyrgyz Population in 2021,2021-12-09,Preprint,National,Cross-sectional survey ,Kyrgyzstan,,,Kyrgyzstan residents. ,,2021-06-28,2021-07-03,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,,1681,0.507,0.483,0.531,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anna Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1138128/v1,2021-12-15,2022-07-16,Verified,popova_sars-cov-2_2021-1,KGZ
211209_Kyrgyzstan_SaintPetersburgPasteurInstitute_RegionTalas,211209_Kyrgyzstan_SaintPetersburgPasteurInstitute,SARS-CoV-2 Herd Immunity of the Kyrgyz Population in 2021,2021-12-09,Preprint,Regional,Cross-sectional survey ,Kyrgyzstan,Talas,,Kyrgyzstan residents. ,,2021-06-28,2021-07-03,Household and community samples,All,Multiple groups,1.0,,Geographical area,Talas Region,898,0.495,0.462,0.529,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anna Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1138128/v1,2021-12-15,2022-07-16,Verified,popova_sars-cov-2_2021-1,KGZ
211209_Kyrgyzstan_SaintPetersburgPasteurInstitute_RegionOsh,211209_Kyrgyzstan_SaintPetersburgPasteurInstitute,SARS-CoV-2 Herd Immunity of the Kyrgyz Population in 2021,2021-12-09,Preprint,Regional,Cross-sectional survey ,Kyrgyzstan,Osh,,Kyrgyzstan residents. ,,2021-06-28,2021-07-03,Household and community samples,All,Multiple groups,1.0,,Geographical area,Osh Region,1201,0.533,0.503,0.561,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anna Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1138128/v1,2021-12-15,2022-07-16,Verified,popova_sars-cov-2_2021-1,KGZ
211209_Kyrgyzstan_SaintPetersburgPasteurInstitute_RegionNaryn,211209_Kyrgyzstan_SaintPetersburgPasteurInstitute,SARS-CoV-2 Herd Immunity of the Kyrgyz Population in 2021,2021-12-09,Preprint,Regional,Cross-sectional survey ,Kyrgyzstan,Naryn,,Kyrgyzstan residents. ,,2021-06-28,2021-07-03,Household and community samples,All,Multiple groups,1.0,,Geographical area,Naryn Region,797,0.533,0.498,0.568,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anna Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1138128/v1,2021-12-15,2022-07-16,Verified,popova_sars-cov-2_2021-1,KGZ
211209_Kyrgyzstan_SaintPetersburgPasteurInstitute_Age30-39,211209_Kyrgyzstan_SaintPetersburgPasteurInstitute,SARS-CoV-2 Herd Immunity of the Kyrgyz Population in 2021,2021-12-09,Preprint,National,Cross-sectional survey ,Kyrgyzstan,,,Kyrgyzstan residents. ,,2021-06-28,2021-07-03,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,,1658,0.41100000000000003,0.38799999999999996,0.436,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anna Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1138128/v1,2021-12-15,2022-07-16,Verified,popova_sars-cov-2_2021-1,KGZ
211209_Kyrgyzstan_SaintPetersburgPasteurInstitute_VaccineNO,211209_Kyrgyzstan_SaintPetersburgPasteurInstitute,SARS-CoV-2 Herd Immunity of the Kyrgyz Population in 2021,2021-12-09,Preprint,National,Cross-sectional survey ,Kyrgyzstan,,,Kyrgyzstan residents. ,,2021-06-28,2021-07-03,Household and community samples,All,Multiple groups,1.0,,COVID-19 vaccination status,,7076,0.45049999999999996,,,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anna Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1138128/v1,2021-12-15,2022-07-16,Verified,popova_sars-cov-2_2021-1,KGZ
211209_Kyrgyzstan_SaintPetersburgPasteurInstitute_RegionIssyk-Kul,211209_Kyrgyzstan_SaintPetersburgPasteurInstitute,SARS-CoV-2 Herd Immunity of the Kyrgyz Population in 2021,2021-12-09,Preprint,Regional,Cross-sectional survey ,Kyrgyzstan,Issyk-Kul,,Kyrgyzstan residents. ,,2021-06-28,2021-07-03,Household and community samples,All,Multiple groups,1.0,,Geographical area,Issyk-Kul Region,817,0.528,0.493,0.562,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anna Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1138128/v1,2021-12-15,2022-07-16,Verified,popova_sars-cov-2_2021-1,KGZ
211209_Kyrgyzstan_SaintPetersburgPasteurInstitute_Age60-69,211209_Kyrgyzstan_SaintPetersburgPasteurInstitute,SARS-CoV-2 Herd Immunity of the Kyrgyz Population in 2021,2021-12-09,Preprint,National,Cross-sectional survey ,Kyrgyzstan,,,Kyrgyzstan residents. ,,2021-06-28,2021-07-03,Household and community samples,All,Seniors (65+ years),60.0,69.0,Age,,1437,0.5920000000000001,0.5660000000000001,0.617,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anna Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1138128/v1,2021-12-15,2022-07-16,Verified,popova_sars-cov-2_2021-1,KGZ
211209_Kyrgyzstan_SaintPetersburgPasteurInstitute_Age1-6,211209_Kyrgyzstan_SaintPetersburgPasteurInstitute,SARS-CoV-2 Herd Immunity of the Kyrgyz Population in 2021,2021-12-09,Preprint,National,Cross-sectional survey ,Kyrgyzstan,,,Kyrgyzstan residents. ,,2021-06-28,2021-07-03,Household and community samples,All,Children and Youth (0-17 years),1.0,6.0,Age,1-6,176,0.261,0.198,0.33299999999999996,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anna Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1138128/v1,2021-12-15,2022-07-16,Verified,popova_sars-cov-2_2021-1,KGZ
211209_Kyrgyzstan_SaintPetersburgPasteurInstitute_VaccineSputnik,211209_Kyrgyzstan_SaintPetersburgPasteurInstitute,SARS-CoV-2 Herd Immunity of the Kyrgyz Population in 2021,2021-12-09,Preprint,National,Cross-sectional survey ,Kyrgyzstan,,,Kyrgyzstan residents. ,,2021-06-28,2021-07-03,Household and community samples,All,Multiple groups,1.0,,COVID-19 vaccination status,Vaccine Sputnik,393,0.9059999999999999,0.873,0.9329999999999999,,,,,,Simplified probability,Author designed (ELISA) - Unknown,,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anna Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1138128/v1,2021-12-15,2022-07-16,Verified,popova_sars-cov-2_2021-1,KGZ
211209_Kyrgyzstan_SaintPetersburgPasteurInstitute_RegionBatken,211209_Kyrgyzstan_SaintPetersburgPasteurInstitute,SARS-CoV-2 Herd Immunity of the Kyrgyz Population in 2021,2021-12-09,Preprint,Regional,Cross-sectional survey ,Kyrgyzstan,Batken,,Kyrgyzstan residents. ,,2021-06-28,2021-07-03,Household and community samples,All,Multiple groups,1.0,,Geographical area,Batken Region,719,0.451,0.41500000000000004,0.489,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anna Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1138128/v1,2021-12-15,2022-07-16,Verified,popova_sars-cov-2_2021-1,KGZ
211209_Kyrgyzstan_SaintPetersburgPasteurInstitute_RegionJalal-Abad,211209_Kyrgyzstan_SaintPetersburgPasteurInstitute,SARS-CoV-2 Herd Immunity of the Kyrgyz Population in 2021,2021-12-09,Preprint,Regional,Cross-sectional survey ,Kyrgyzstan,Jalal-Abad,,Kyrgyzstan residents. ,,2021-06-28,2021-07-03,Household and community samples,All,Multiple groups,1.0,,Geographical area,Jalal-Abad Region,1598,0.49700000000000005,0.47100000000000003,0.52,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anna Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1138128/v1,2021-12-15,2022-07-16,Verified,popova_sars-cov-2_2021-1,KGZ
211209_Kyrgyzstan_SaintPetersburgPasteurInstitute_Age14-17,211209_Kyrgyzstan_SaintPetersburgPasteurInstitute,SARS-CoV-2 Herd Immunity of the Kyrgyz Population in 2021,2021-12-09,Preprint,National,Cross-sectional survey ,Kyrgyzstan,,,Kyrgyzstan residents. ,,2021-06-28,2021-07-03,Household and community samples,All,Children and Youth (0-17 years),14.0,17.0,Age,14-17,305,0.334,0.282,0.39,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anna Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1138128/v1,2021-12-15,2022-07-16,Verified,popova_sars-cov-2_2021-1,KGZ
211209_Kyrgyzstan_SaintPetersburgPasteurInstitute_Age50-59,211209_Kyrgyzstan_SaintPetersburgPasteurInstitute,SARS-CoV-2 Herd Immunity of the Kyrgyz Population in 2021,2021-12-09,Preprint,National,Cross-sectional survey ,Kyrgyzstan,,,Kyrgyzstan residents. ,,2021-06-28,2021-07-03,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,,1739,0.5910000000000001,0.568,0.614,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anna Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1138128/v1,2021-12-15,2022-07-16,Verified,popova_sars-cov-2_2021-1,KGZ
211209_Kyrgyzstan_SaintPetersburgPasteurInstitute_RegionChui,211209_Kyrgyzstan_SaintPetersburgPasteurInstitute,SARS-CoV-2 Herd Immunity of the Kyrgyz Population in 2021,2021-12-09,Preprint,Regional,Cross-sectional survey ,Kyrgyzstan,Chui,,Kyrgyzstan residents. ,,2021-06-28,2021-07-03,Household and community samples,All,Multiple groups,1.0,,Geographical area,Chui Region,816,0.513,0.479,0.5479999999999999,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anna Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1138128/v1,2021-12-15,2022-07-16,Verified,popova_sars-cov-2_2021-1,KGZ
211209_Kyrgyzstan_SaintPetersburgPasteurInstitute_Age70+,211209_Kyrgyzstan_SaintPetersburgPasteurInstitute,SARS-CoV-2 Herd Immunity of the Kyrgyz Population in 2021,2021-12-09,Preprint,National,Cross-sectional survey ,Kyrgyzstan,,,Kyrgyzstan residents. ,,2021-06-28,2021-07-03,Household and community samples,All,Seniors (65+ years),70.0,,Age,,716,0.557,0.52,0.594,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anna Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1138128/v1,2021-12-15,2022-07-16,Verified,popova_sars-cov-2_2021-1,KGZ
211209_Kyrgyzstan_SaintPetersburgPasteurInstitute_Age7-13,211209_Kyrgyzstan_SaintPetersburgPasteurInstitute,SARS-CoV-2 Herd Immunity of the Kyrgyz Population in 2021,2021-12-09,Preprint,National,Cross-sectional survey ,Kyrgyzstan,,,Kyrgyzstan residents. ,,2021-06-28,2021-07-03,Household and community samples,All,Children and Youth (0-17 years),7.0,13.0,Age,7-13,312,0.35600000000000004,0.303,0.41200000000000003,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anna Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1138128/v1,2021-12-15,2022-07-16,Verified,popova_sars-cov-2_2021-1,KGZ
211209_Kyrgyzstan_SaintPetersburgPasteurInstitute_VaccineSinoPharm,211209_Kyrgyzstan_SaintPetersburgPasteurInstitute,SARS-CoV-2 Herd Immunity of the Kyrgyz Population in 2021,2021-12-09,Preprint,National,Cross-sectional survey ,Kyrgyzstan,,,Kyrgyzstan residents. ,,2021-06-28,2021-07-03,Household and community samples,All,Multiple groups,1.0,,COVID-19 vaccination status,Vaccine SinoPharm,1869,0.9159999999999999,0.903,0.9279999999999999,,,,,,Simplified probability,Author designed (ELISA) - Unknown,,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anna Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1138128/v1,2021-12-15,2022-07-16,Verified,popova_sars-cov-2_2021-1,KGZ
210713_LaoPDR_InstitutPasteurDuLaos_GeneralCommunity_Primary_Adjusted,210713_LaoPDR_InstitutPasteurDuLaos_GeneralCommunity,"Low seroprevalence of COVID-19 in Lao PDR, late 2020",2021-07-13,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lao People's Democratic Republic,"Vientiane Prefecture, Oudomxay, Luangprabang, Savannakhet, Champassak",,"all inhabitants aged five and above were invited to participate (from 5 provinces: Vientiane Capital, two provinces in the North-Luang-Prabang, Oudomxay and two provinces in the South -Savanakhet and Champassak). If a designated village could not be reached due to obstacles such as inaccessibility during the rainy season, the nearest village accessible was selected as an alternative",,2020-08-12,2020-09-25,Household and community samples,All,Multiple groups,5.0,55.0,Primary Estimate,,2433,0.052000000000000005,0.042,0.065,True,,True,,,Stratified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,No,Unclear,Yes,No,Unclear,Siriphone Virachith,Institut Pasteur du Laos,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2021.100197,2021-07-28,2022-07-16,Verified,virachith_low_2021,LAO
210713_LaoPDR_InstitutPasteurDuLaos_GeneralCommunity_>60,210713_LaoPDR_InstitutPasteurDuLaos_GeneralCommunity,"Low seroprevalence of COVID-19 in Lao PDR, late 2020",2021-07-13,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lao People's Democratic Republic,"Vientiane Prefecture, Oudomxay, Luangprabang, Savannakhet, Champassak",,"all inhabitants aged five and above were invited to participate (from 5 provinces: Vientiane Capital, two provinces in the North-Luang-Prabang, Oudomxay and two provinces in the South -Savanakhet and Champassak). If a designated village could not be reached due to obstacles such as inaccessibility during the rainy season, the nearest village accessible was selected as an alternative",,2020-08-12,2020-09-25,Household and community samples,All,Multiple groups,60.0,,Age,>60 years old,351,0.08800000000000001,0.062000000000000006,0.12300000000000001,,,,,,Stratified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,No,Unclear,Yes,No,Unclear,Siriphone Virachith,Institut Pasteur du Laos,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2021.100197,2021-07-28,2022-07-16,Verified,virachith_low_2021,LAO
210713_LaoPDR_InstitutPasteurDuLaos_GeneralCommunity_males,210713_LaoPDR_InstitutPasteurDuLaos_GeneralCommunity,"Low seroprevalence of COVID-19 in Lao PDR, late 2020",2021-07-13,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lao People's Democratic Republic,"Vientiane Prefecture, Oudomxay, Luangprabang, Savannakhet, Champassak",,"all inhabitants aged five and above were invited to participate (from 5 provinces: Vientiane Capital, two provinces in the North-Luang-Prabang, Oudomxay and two provinces in the South -Savanakhet and Champassak). If a designated village could not be reached due to obstacles such as inaccessibility during the rainy season, the nearest village accessible was selected as an alternative",,2020-08-12,2020-09-25,Household and community samples,Male,Multiple groups,5.0,55.0,Sex/Gender,,1019,0.061,0.048,0.073,,,,,,Stratified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,No,Unclear,Yes,No,Unclear,Siriphone Virachith,Institut Pasteur du Laos,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2021.100197,2021-07-28,2022-07-16,Verified,virachith_low_2021,LAO
210713_LaoPDR_InstitutPasteurDuLaos_GeneralCommunity_Primary_Unadjusted,210713_LaoPDR_InstitutPasteurDuLaos_GeneralCommunity,"Low seroprevalence of COVID-19 in Lao PDR, late 2020",2021-07-13,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lao People's Democratic Republic,"Vientiane Prefecture, Oudomxay, Luangprabang, Savannakhet, Champassak",,"all inhabitants aged five and above were invited to participate (from 5 provinces: Vientiane Capital, two provinces in the North-Luang-Prabang, Oudomxay and two provinces in the South -Savanakhet and Champassak). If a designated village could not be reached due to obstacles such as inaccessibility during the rainy season, the nearest village accessible was selected as an alternative",,2020-08-12,2020-09-25,Household and community samples,All,Multiple groups,5.0,55.0,Analysis,,2433,0.054000000000000006,0.045,0.063,,,,,True,Stratified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,No,Unclear,Yes,No,Unclear,Siriphone Virachith,Institut Pasteur du Laos,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2021.100197,2021-09-29,2022-07-16,Verified,virachith_low_2021,LAO
210713_LaoPDR_InstitutPasteurDuLaos_GeneralCommunity_Females,210713_LaoPDR_InstitutPasteurDuLaos_GeneralCommunity,"Low seroprevalence of COVID-19 in Lao PDR, late 2020",2021-07-13,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lao People's Democratic Republic,"Vientiane Prefecture, Oudomxay, Luangprabang, Savannakhet, Champassak",,"all inhabitants aged five and above were invited to participate (from 5 provinces: Vientiane Capital, two provinces in the North-Luang-Prabang, Oudomxay and two provinces in the South -Savanakhet and Champassak). If a designated village could not be reached due to obstacles such as inaccessibility during the rainy season, the nearest village accessible was selected as an alternative",,2020-08-12,2020-09-25,Household and community samples,Female,Multiple groups,5.0,55.0,Sex/Gender,,1414,0.049,0.039,0.061,,,,,,Stratified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,No,Unclear,Yes,No,Unclear,Siriphone Virachith,Institut Pasteur du Laos,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2021.100197,2021-07-28,2022-07-16,Verified,virachith_low_2021,LAO
210713_LaoPDR_InstitutPasteurDuLaos_GeneralCommunity_<=18years,210713_LaoPDR_InstitutPasteurDuLaos_GeneralCommunity,"Low seroprevalence of COVID-19 in Lao PDR, late 2020",2021-07-13,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lao People's Democratic Republic,"Vientiane Prefecture, Oudomxay, Luangprabang, Savannakhet, Champassak",,"all inhabitants aged five and above were invited to participate (from 5 provinces: Vientiane Capital, two provinces in the North-Luang-Prabang, Oudomxay and two provinces in the South -Savanakhet and Champassak). If a designated village could not be reached due to obstacles such as inaccessibility during the rainy season, the nearest village accessible was selected as an alternative",,2020-08-12,2020-09-25,Household and community samples,All,Children and Youth (0-17 years),5.0,18.0,Age,=< 18 years of age,233,0.039,0.02,0.073,,,,,,Stratified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,No,Unclear,Yes,No,Unclear,Siriphone Virachith,Institut Pasteur du Laos,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2021.100197,2021-07-28,2022-07-16,Verified,virachith_low_2021,LAO
210713_LaoPDR_InstitutPasteurDuLaos_GeneralCommunity_41-60,210713_LaoPDR_InstitutPasteurDuLaos_GeneralCommunity,"Low seroprevalence of COVID-19 in Lao PDR, late 2020",2021-07-13,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lao People's Democratic Republic,"Vientiane Prefecture, Oudomxay, Luangprabang, Savannakhet, Champassak",,"all inhabitants aged five and above were invited to participate (from 5 provinces: Vientiane Capital, two provinces in the North-Luang-Prabang, Oudomxay and two provinces in the South -Savanakhet and Champassak). If a designated village could not be reached due to obstacles such as inaccessibility during the rainy season, the nearest village accessible was selected as an alternative",,2020-08-12,2020-09-25,Household and community samples,All,Adults (18-64 years),41.0,60.0,Age,41-60 years of age,1000,0.06,0.047,0.076,,,,,,Stratified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,No,Unclear,Yes,No,Unclear,Siriphone Virachith,Institut Pasteur du Laos,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2021.100197,2021-07-28,2022-07-16,Verified,virachith_low_2021,LAO
210713_LaoPDR_InstitutPasteurDuLaos_GeneralCommunity_Spike,210713_LaoPDR_InstitutPasteurDuLaos_GeneralCommunity,"Low seroprevalence of COVID-19 in Lao PDR, late 2020",2021-07-13,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lao People's Democratic Republic,"Vientiane Prefecture, Oudomxay, Luangprabang, Savannakhet, Champassak",,"all inhabitants aged five and above were invited to participate (from 5 provinces: Vientiane Capital, two provinces in the North-Luang-Prabang, Oudomxay and two provinces in the South -Savanakhet and Champassak). If a designated village could not be reached due to obstacles such as inaccessibility during the rainy season, the nearest village accessible was selected as an alternative",,2020-08-12,2020-09-25,Household and community samples,All,Multiple groups,5.0,55.0,Test used,,1061,0.018000000000000002,0.011000000000000001,0.027999999999999997,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,No,Unclear,Yes,No,Unclear,Siriphone Virachith,Institut Pasteur du Laos,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2021.100197,2021-07-28,2022-07-16,Verified,virachith_low_2021,LAO
210713_LaoPDR_InstitutPasteurDuLaos_GeneralCommunity_19-40,210713_LaoPDR_InstitutPasteurDuLaos_GeneralCommunity,"Low seroprevalence of COVID-19 in Lao PDR, late 2020",2021-07-13,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lao People's Democratic Republic,"Vientiane Prefecture, Oudomxay, Luangprabang, Savannakhet, Champassak",,"all inhabitants aged five and above were invited to participate (from 5 provinces: Vientiane Capital, two provinces in the North-Luang-Prabang, Oudomxay and two provinces in the South -Savanakhet and Champassak). If a designated village could not be reached due to obstacles such as inaccessibility during the rainy season, the nearest village accessible was selected as an alternative",,2020-08-12,2020-09-25,Household and community samples,All,Adults (18-64 years),19.0,40.0,Age,19-40 years of age,849,0.036000000000000004,0.026000000000000002,0.051,,,,,,Stratified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,No,Unclear,Yes,No,Unclear,Siriphone Virachith,Institut Pasteur du Laos,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2021.100197,2021-07-28,2022-07-16,Verified,virachith_low_2021,LAO
210713_LaoPDR_InstitutPasteurDuLaos_HCW_Primary_Adjusted,210713_LaoPDR_InstitutPasteurDuLaos_HCWs,"Low seroprevalence of COVID-19 in Lao PDR, late 2020",2021-07-13,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lao People's Democratic Republic,"Vientiane Prefecture, Oudomxay, Luangprabang, Savannakhet, Champassak",,"In Vientiane Capital, the survey focusing on healthcare workers was conducted in four central hospitals (three major public referral hospitals and one major military hospital) and in two district hospitals. In the four other provinces, only healthcare workers working in the provincial hospitals were included. All staff assigned to dedicated COVID-19 teams were invited to participate including clinical and non-clinical staff (e.g administrative staff, drivers, cleaners etc). In central and provincial hospitals, nurses, doctors and lab- technicians working in emergency departments (ER), outpatient departments (OPD), intensive care units (ICU), infectious disease departments, inpatient departments (IPD) and paediatric departments were randomly selected maintaining the nurses to doctors ratio in each department. In the two district hospitals, staff working in the OPD and ER were randomly selected",,2020-08-12,2020-09-25,Health care workers and caregivers,All,Adults (18-64 years),20.0,65.0,Primary Estimate,,666,0.0195,0.011000000000000001,0.033,True,,,,True,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,No,Unclear,Yes,No,Yes,Siriphone Virachith,Institut Pasteur du Laos,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2021.100197,2021-07-28,2022-07-16,Verified,virachith_low_2021,LAO
210713_LaoPDR_InstitutPasteurDuLaos_WildlifeContacts_Primary,210713_LaoPDR_InstitutPasteurDuLaos_WildlifeContacts,"Low seroprevalence of COVID-19 in Lao PDR, late 2020",2021-07-13,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Lao People's Democratic Republic,Vientiane Province,,"Four villages in Feung District, Vientiane province, were visited in September 2020. The villages were selected as they are locations where the profession of bat guano collecting - for selling as fertilizer –is common. Villagers who had contact with bats or other wildlife were informed about the study by the head of their village and invited to participate.",,2020-08-12,2020-09-25,Non-essential workers and unemployed persons,All,Multiple groups,17.0,86.0,Primary Estimate,,74,0.203,0.126,0.31,True,,,,True,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,,Nucleocapsid(N-protein),,,,['High'],Yes,No,No,Yes,No,Unclear,Yes,No,Unclear,Siriphone Virachith,Institut Pasteur du Laos,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2021.100197,2021-07-28,2022-07-16,Verified,virachith_low_2021,LAO
210107_Latvia_UniversityCollegeLondon_PaediatricHCW,210107_Latvia_UniversityCollegeLondon,Cross Sectional Prevalence of SARS-CoV-2 antibodies in Health Care Workers in Paediatric Facilities in Eight Countries,2021-01-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Latvia,,,"This was part of a larger study undertaken in HCWs in paediatric facilities in seven European sites and one South African site. Staff of all categories in each healthcare setting were invited to join the study, irrespective of symptoms or whether they suspected they had previously had COVID-19. ",,2020-05-19,2020-06-20,Health care workers and caregivers,All,Adults (18-64 years),20.0,73.0,Primary Estimate,,177,0.0,0.0,0.021400000000000002,True,,,,True,Convenience,"EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit,Meso Scale Discovery multiplex assay","Epitope Diagnostics, Inc.,Meso Scale Discovery",ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,No,No,Unclear,Yes,Yes,No,Unclear,D Goldblatt,University College London,Not Unity-Aligned,http://dx.doi.org/10.1016/j.jhin.2020.12.019,2021-03-13,2024-03-01,Verified,goldblatt_cross-sectional_2021,LVA
230210_Riga_RigaStradinsUniversity_Overall,230210_Riga_RigaStradinsUniversity,SARS-CoV-2 seroprevalence among children in Latvia: A cross-sectional study.,2023-02-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Latvia,,Riga,"""The eligibility criteria were age between 0 and 18 years and no indication of acute SARS-CoV-2 infection nor contact person status at the time of enrollment in the study.""","""The exclusion criteria were acute SARS-CoV-2 infection and noncompliance with the defined age category.""",2022-03-15,2022-07-15,Residual sera,All,Children and Youth (0-17 years),0.0,18.0,Primary Estimate,,200,0.865,0.818,0.912,True,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,"CLIA, CMIA",Serum,"IgG, IgM, IgA",Nucleocapsid (N-protein),Validated by manufacturers,,,['High'],,Yes,No,Yes,,Yes,Yes,Yes,,Krista Sapronova,Children Clinical University Hospital and Riga Stradins University,Not Unity-Aligned,https://dx.doi.org/10.1097/MD.0000000000032795,2023-03-07,2024-03-01,Unverified,sapronova_sars-cov-2_2023,LVA
220110_Lebanon_LebaneseUniversity_Overall_TestPopAdj,220110_Lebanon_LebaneseUniversity,SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey.,2022-01-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lebanon,"Beirut, Mount Lebanon, North Lebanon, Akkar, Baalbek El-Hermel, Bekaa, Nabatieh, and South Lebanon",,All residents who were deemed to be asymptomatic for SARS-CoV-2 infection at the time of data collection were eligible to participate. ,"The exclusion criteria included patients confirmed with SARS-CoV-2 infection, individuals under quarantine, and patients presenting symptoms suggestive of SARS-CoV-2 infection including cough, fever, body aches, and shortness of breath, as well as those who refused to give informed consent.",2020-12-07,2021-01-15,Household and community samples,All,Multiple groups,,,Primary Estimate,"Test and Population (age group, sex, geographic location) adjusted",2058,0.185,0.168,0.20199999999999999,True,True,True,,,Stratified probability,nCOVID-19 IgG & IgM POCT,Technogenetics,LFIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abbas Hoballah,Lebanese University,Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07031-z,2022-01-18,2023-08-15,Verified,hoballah_sars-cov-2_2022,LBN
220110_Lebanon_LebaneseUniversity_Overall_Crude,220110_Lebanon_LebaneseUniversity,SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey.,2022-01-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lebanon,"Beirut, Mount Lebanon, North Lebanon, Akkar, Baalbek El-Hermel, Bekaa, Nabatieh, and South Lebanon",,All residents who were deemed to be asymptomatic for SARS-CoV-2 infection at the time of data collection were eligible to participate. ,"The exclusion criteria included patients confirmed with SARS-CoV-2 infection, individuals under quarantine, and patients presenting symptoms suggestive of SARS-CoV-2 infection including cough, fever, body aches, and shortness of breath, as well as those who refused to give informed consent.",2020-12-07,2021-01-15,Household and community samples,All,Multiple groups,,,Analysis,"Population (age group, sex, geographic location) adjusted",2058,0.15990000000000001,,,,,,,,Stratified probability,nCOVID-19 IgG & IgM POCT,Technogenetics,LFIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abbas Hoballah,Lebanese University,Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07031-z,2022-05-17,2024-03-01,Verified,hoballah_sars-cov-2_2022,LBN
220110_Lebanon_LebaneseUniversity_Beirut_PopAdj,220110_Lebanon_LebaneseUniversity,SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey.,2022-01-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Lebanon,Beirut,,All residents who were deemed to be asymptomatic for SARS-CoV-2 infection at the time of data collection were eligible to participate. ,"The exclusion criteria included patients confirmed with SARS-CoV-2 infection, individuals under quarantine, and patients presenting symptoms suggestive of SARS-CoV-2 infection including cough, fever, body aches, and shortness of breath, as well as those who refused to give informed consent.",2020-12-07,2021-01-15,Household and community samples,All,Multiple groups,,,Geographical area,Beirut,162,0.10099999999999999,0.053,0.149,,,True,,,Stratified probability,nCOVID-19 IgG & IgM POCT,Technogenetics,LFIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abbas Hoballah,Lebanese University,Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07031-z,2022-01-18,2024-03-01,Verified,hoballah_sars-cov-2_2022,LBN
220110_Lebanon_LebaneseUniversity_Akkar_PopAdj,220110_Lebanon_LebaneseUniversity,SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey.,2022-01-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Lebanon,Akkar,,All residents who were deemed to be asymptomatic for SARS-CoV-2 infection at the time of data collection were eligible to participate. ,"The exclusion criteria included patients confirmed with SARS-CoV-2 infection, individuals under quarantine, and patients presenting symptoms suggestive of SARS-CoV-2 infection including cough, fever, body aches, and shortness of breath, as well as those who refused to give informed consent.",2020-12-07,2021-01-15,Household and community samples,All,Multiple groups,,,Geographical area,Akkar,119,0.11199999999999999,0.052000000000000005,0.172,,,True,,,Stratified probability,nCOVID-19 IgG & IgM POCT,Technogenetics,LFIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abbas Hoballah,Lebanese University,Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07031-z,2022-01-18,2024-03-01,Verified,hoballah_sars-cov-2_2022,LBN
220110_Lebanon_LebaneseUniversity_Female_PopAdj,220110_Lebanon_LebaneseUniversity,SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey.,2022-01-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lebanon,"Beirut, Mount Lebanon, North Lebanon, Akkar, Baalbek El-Hermel, Bekaa, Nabatieh, and South Lebanon",,All residents who were deemed to be asymptomatic for SARS-CoV-2 infection at the time of data collection were eligible to participate. ,"The exclusion criteria included patients confirmed with SARS-CoV-2 infection, individuals under quarantine, and patients presenting symptoms suggestive of SARS-CoV-2 infection including cough, fever, body aches, and shortness of breath, as well as those who refused to give informed consent.",2020-12-07,2021-01-15,Household and community samples,Female,Multiple groups,,,Sex/Gender,,851,0.16399999999999998,0.14,0.187,,,True,,,Stratified probability,nCOVID-19 IgG & IgM POCT,Technogenetics,LFIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abbas Hoballah,Lebanese University,Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07031-z,2022-01-18,2024-03-01,Verified,hoballah_sars-cov-2_2022,LBN
220110_Lebanon_LebaneseUniversity_20-29_PopAdj,220110_Lebanon_LebaneseUniversity,SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey.,2022-01-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lebanon,"Beirut, Mount Lebanon, North Lebanon, Akkar, Baalbek El-Hermel, Bekaa, Nabatieh, and South Lebanon",,All residents who were deemed to be asymptomatic for SARS-CoV-2 infection at the time of data collection were eligible to participate. ,"The exclusion criteria included patients confirmed with SARS-CoV-2 infection, individuals under quarantine, and patients presenting symptoms suggestive of SARS-CoV-2 infection including cough, fever, body aches, and shortness of breath, as well as those who refused to give informed consent.",2020-12-07,2021-01-15,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,403,0.122,0.092,0.152,,,True,,,Stratified probability,nCOVID-19 IgG & IgM POCT,Technogenetics,LFIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abbas Hoballah,Lebanese University,Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07031-z,2022-01-18,2024-03-01,Verified,hoballah_sars-cov-2_2022,LBN
220110_Lebanon_LebaneseUniversity_30-39_PopAdj,220110_Lebanon_LebaneseUniversity,SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey.,2022-01-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lebanon,"Beirut, Mount Lebanon, North Lebanon, Akkar, Baalbek El-Hermel, Bekaa, Nabatieh, and South Lebanon",,All residents who were deemed to be asymptomatic for SARS-CoV-2 infection at the time of data collection were eligible to participate. ,"The exclusion criteria included patients confirmed with SARS-CoV-2 infection, individuals under quarantine, and patients presenting symptoms suggestive of SARS-CoV-2 infection including cough, fever, body aches, and shortness of breath, as well as those who refused to give informed consent.",2020-12-07,2021-01-15,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,366,0.171,0.135,0.207,,,True,,,Stratified probability,nCOVID-19 IgG & IgM POCT,Technogenetics,LFIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abbas Hoballah,Lebanese University,Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07031-z,2022-01-18,2024-03-01,Verified,hoballah_sars-cov-2_2022,LBN
220110_Lebanon_LebaneseUniversity_50-59_PopAdj,220110_Lebanon_LebaneseUniversity,SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey.,2022-01-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lebanon,"Beirut, Mount Lebanon, North Lebanon, Akkar, Baalbek El-Hermel, Bekaa, Nabatieh, and South Lebanon",,All residents who were deemed to be asymptomatic for SARS-CoV-2 infection at the time of data collection were eligible to participate. ,"The exclusion criteria included patients confirmed with SARS-CoV-2 infection, individuals under quarantine, and patients presenting symptoms suggestive of SARS-CoV-2 infection including cough, fever, body aches, and shortness of breath, as well as those who refused to give informed consent.",2020-12-07,2021-01-15,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,320,0.157,0.11900000000000001,0.195,,,True,,,Stratified probability,nCOVID-19 IgG & IgM POCT,Technogenetics,LFIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abbas Hoballah,Lebanese University,Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07031-z,2022-01-18,2024-03-01,Verified,hoballah_sars-cov-2_2022,LBN
220110_Lebanon_LebaneseUniversity_Male_PopAdj,220110_Lebanon_LebaneseUniversity,SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey.,2022-01-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lebanon,"Beirut, Mount Lebanon, North Lebanon, Akkar, Baalbek El-Hermel, Bekaa, Nabatieh, and South Lebanon",,All residents who were deemed to be asymptomatic for SARS-CoV-2 infection at the time of data collection were eligible to participate. ,"The exclusion criteria included patients confirmed with SARS-CoV-2 infection, individuals under quarantine, and patients presenting symptoms suggestive of SARS-CoV-2 infection including cough, fever, body aches, and shortness of breath, as well as those who refused to give informed consent.",2020-12-07,2021-01-15,Household and community samples,Male,Multiple groups,,,Sex/Gender,,1207,0.156,0.136,0.17500000000000002,,,True,,,Stratified probability,nCOVID-19 IgG & IgM POCT,Technogenetics,LFIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abbas Hoballah,Lebanese University,Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07031-z,2022-01-18,2024-03-01,Verified,hoballah_sars-cov-2_2022,LBN
220110_Lebanon_LebaneseUniversity_40-49_PopAdj,220110_Lebanon_LebaneseUniversity,SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey.,2022-01-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lebanon,"Beirut, Mount Lebanon, North Lebanon, Akkar, Baalbek El-Hermel, Bekaa, Nabatieh, and South Lebanon",,All residents who were deemed to be asymptomatic for SARS-CoV-2 infection at the time of data collection were eligible to participate. ,"The exclusion criteria included patients confirmed with SARS-CoV-2 infection, individuals under quarantine, and patients presenting symptoms suggestive of SARS-CoV-2 infection including cough, fever, body aches, and shortness of breath, as well as those who refused to give informed consent.",2020-12-07,2021-01-15,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,360,0.19,0.152,0.228,,,True,,,Stratified probability,nCOVID-19 IgG & IgM POCT,Technogenetics,LFIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abbas Hoballah,Lebanese University,Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07031-z,2022-01-18,2024-03-01,Verified,hoballah_sars-cov-2_2022,LBN
220110_Lebanon_LebaneseUniversity_Bekaa_PopAdj,220110_Lebanon_LebaneseUniversity,SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey.,2022-01-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Lebanon,Bekaa,,All residents who were deemed to be asymptomatic for SARS-CoV-2 infection at the time of data collection were eligible to participate. ,"The exclusion criteria included patients confirmed with SARS-CoV-2 infection, individuals under quarantine, and patients presenting symptoms suggestive of SARS-CoV-2 infection including cough, fever, body aches, and shortness of breath, as well as those who refused to give informed consent.",2020-12-07,2021-01-15,Household and community samples,All,Multiple groups,,,Geographical area,Bekaa,143,0.18,0.115,0.245,,,True,,,Stratified probability,nCOVID-19 IgG & IgM POCT,Technogenetics,LFIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abbas Hoballah,Lebanese University,Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07031-z,2022-01-18,2024-03-01,Verified,hoballah_sars-cov-2_2022,LBN
220110_Lebanon_LebaneseUniversity_NorthLebanon_PopAdj,220110_Lebanon_LebaneseUniversity,SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey.,2022-01-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Lebanon,North Lebanon,,All residents who were deemed to be asymptomatic for SARS-CoV-2 infection at the time of data collection were eligible to participate. ,"The exclusion criteria included patients confirmed with SARS-CoV-2 infection, individuals under quarantine, and patients presenting symptoms suggestive of SARS-CoV-2 infection including cough, fever, body aches, and shortness of breath, as well as those who refused to give informed consent.",2020-12-07,2021-01-15,Household and community samples,All,Multiple groups,,,Geographical area,North Lebanon,163,0.182,0.122,0.242,,,True,,,Stratified probability,nCOVID-19 IgG & IgM POCT,Technogenetics,LFIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abbas Hoballah,Lebanese University,Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07031-z,2022-01-18,2024-03-01,Verified,hoballah_sars-cov-2_2022,LBN
220110_Lebanon_LebaneseUniversity_<=19_PopAdj,220110_Lebanon_LebaneseUniversity,SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey.,2022-01-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lebanon,"Beirut, Mount Lebanon, North Lebanon, Akkar, Baalbek El-Hermel, Bekaa, Nabatieh, and South Lebanon",,All residents who were deemed to be asymptomatic for SARS-CoV-2 infection at the time of data collection were eligible to participate. ,"The exclusion criteria included patients confirmed with SARS-CoV-2 infection, individuals under quarantine, and patients presenting symptoms suggestive of SARS-CoV-2 infection including cough, fever, body aches, and shortness of breath, as well as those who refused to give informed consent.",2020-12-07,2021-01-15,Household and community samples,All,Children and Youth (0-17 years),,19.0,Age,≤19,293,0.15,0.11199999999999999,0.188,,,True,,,Stratified probability,nCOVID-19 IgG & IgM POCT,Technogenetics,LFIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abbas Hoballah,Lebanese University,Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07031-z,2022-01-18,2024-03-01,Verified,hoballah_sars-cov-2_2022,LBN
220110_Lebanon_LebaneseUniversity_SouthLebanon_PopAdj,220110_Lebanon_LebaneseUniversity,SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey.,2022-01-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Lebanon,South Lebanon,,All residents who were deemed to be asymptomatic for SARS-CoV-2 infection at the time of data collection were eligible to participate. ,"The exclusion criteria included patients confirmed with SARS-CoV-2 infection, individuals under quarantine, and patients presenting symptoms suggestive of SARS-CoV-2 infection including cough, fever, body aches, and shortness of breath, as well as those who refused to give informed consent.",2020-12-07,2021-01-15,Household and community samples,All,Multiple groups,,,Geographical area,South Lebanon,269,0.126,0.095,0.157,,,True,,,Stratified probability,nCOVID-19 IgG & IgM POCT,Technogenetics,LFIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abbas Hoballah,Lebanese University,Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07031-z,2022-01-18,2024-03-01,Verified,hoballah_sars-cov-2_2022,LBN
220110_Lebanon_LebaneseUniversity_>=60_PopAdj,220110_Lebanon_LebaneseUniversity,SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey.,2022-01-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lebanon,"Beirut, Mount Lebanon, North Lebanon, Akkar, Baalbek El-Hermel, Bekaa, Nabatieh, and South Lebanon",,All residents who were deemed to be asymptomatic for SARS-CoV-2 infection at the time of data collection were eligible to participate. ,"The exclusion criteria included patients confirmed with SARS-CoV-2 infection, individuals under quarantine, and patients presenting symptoms suggestive of SARS-CoV-2 infection including cough, fever, body aches, and shortness of breath, as well as those who refused to give informed consent.",2020-12-07,2021-01-15,Household and community samples,All,Multiple groups,60.0,,Age,≥60,200,0.18600000000000003,0.135,0.237,,,True,,,Stratified probability,nCOVID-19 IgG & IgM POCT,Technogenetics,LFIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abbas Hoballah,Lebanese University,Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07031-z,2022-01-18,2024-03-01,Verified,hoballah_sars-cov-2_2022,LBN
220110_Lebanon_LebaneseUniversity_BaalbekEl-Hermel_PopAdj,220110_Lebanon_LebaneseUniversity,SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey.,2022-01-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Lebanon,Baalbek El-Hermel,,All residents who were deemed to be asymptomatic for SARS-CoV-2 infection at the time of data collection were eligible to participate. ,"The exclusion criteria included patients confirmed with SARS-CoV-2 infection, individuals under quarantine, and patients presenting symptoms suggestive of SARS-CoV-2 infection including cough, fever, body aches, and shortness of breath, as well as those who refused to give informed consent.",2020-12-07,2021-01-15,Household and community samples,All,Multiple groups,,,Geographical area,Baalbek El-Hermel,112,0.298,0.21,0.386,,,True,,,Stratified probability,nCOVID-19 IgG & IgM POCT,Technogenetics,LFIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abbas Hoballah,Lebanese University,Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07031-z,2022-01-18,2024-03-01,Verified,hoballah_sars-cov-2_2022,LBN
220110_Lebanon_LebaneseUniversity_Nabatieh_PopAdj,220110_Lebanon_LebaneseUniversity,SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey.,2022-01-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Lebanon,Nabatieh,,All residents who were deemed to be asymptomatic for SARS-CoV-2 infection at the time of data collection were eligible to participate. ,"The exclusion criteria included patients confirmed with SARS-CoV-2 infection, individuals under quarantine, and patients presenting symptoms suggestive of SARS-CoV-2 infection including cough, fever, body aches, and shortness of breath, as well as those who refused to give informed consent.",2020-12-07,2021-01-15,Household and community samples,All,Multiple groups,,,Geographical area,Nabatieh,165,0.061,0.022000000000000002,0.1,,,True,,,Stratified probability,nCOVID-19 IgG & IgM POCT,Technogenetics,LFIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abbas Hoballah,Lebanese University,Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07031-z,2022-01-18,2024-03-01,Verified,hoballah_sars-cov-2_2022,LBN
220110_Lebanon_LebaneseUniversity_MountLebanon_PopAdj,220110_Lebanon_LebaneseUniversity,SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey.,2022-01-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Lebanon,Mount Lebanon,,All residents who were deemed to be asymptomatic for SARS-CoV-2 infection at the time of data collection were eligible to participate. ,"The exclusion criteria included patients confirmed with SARS-CoV-2 infection, individuals under quarantine, and patients presenting symptoms suggestive of SARS-CoV-2 infection including cough, fever, body aches, and shortness of breath, as well as those who refused to give informed consent.",2020-12-07,2021-01-15,Household and community samples,All,Multiple groups,,,Geographical area,Mount Lebanon,925,0.18100000000000002,0.158,0.204,,,True,,,Stratified probability,nCOVID-19 IgG & IgM POCT,Technogenetics,LFIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abbas Hoballah,Lebanese University,Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07031-z,2022-01-18,2024-03-01,Verified,hoballah_sars-cov-2_2022,LBN
220110_Lebanon_LebaneseUniversity_Overall_PopAdj,220110_Lebanon_LebaneseUniversity,SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey.,2022-01-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lebanon,"Beirut, Mount Lebanon, North Lebanon, Akkar, Baalbek El-Hermel, Bekaa, Nabatieh, and South Lebanon",,All residents who were deemed to be asymptomatic for SARS-CoV-2 infection at the time of data collection were eligible to participate. ,"The exclusion criteria included patients confirmed with SARS-CoV-2 infection, individuals under quarantine, and patients presenting symptoms suggestive of SARS-CoV-2 infection including cough, fever, body aches, and shortness of breath, as well as those who refused to give informed consent.",2020-12-07,2021-01-15,Household and community samples,All,Multiple groups,,,Analysis,"Population (age group, sex, geographic location) adjusted",2058,0.159,0.14400000000000002,0.174,,,True,,True,Stratified probability,nCOVID-19 IgG & IgM POCT,Technogenetics,LFIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abbas Hoballah,Lebanese University,Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07031-z,2022-01-18,2024-03-01,Verified,hoballah_sars-cov-2_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_TestAdj_Overall,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lebanon,eight Lebanese governorates,138 Lebanese municipalities,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Multiple groups,15.0,74.0,Primary Estimate,Overall test adjusted,13755,0.24600000000000002,,,True,True,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9981000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2023-08-15,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_District_KouRa,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Lebanon,,,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Multiple groups,15.0,74.0,Geographical area,District: Kou ra,257,0.1479,0.105,0.1906,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998099999999999,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_District_Nabatiyeh,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Lebanon,,,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Multiple groups,15.0,74.0,Geographical area,District: Nabatiyeh,520,0.0981,0.073,0.12300000000000001,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9980999999999987,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_District_Beirut,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Lebanon,,,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Multiple groups,15.0,74.0,Geographical area,District: Beirut,1085,0.2627,0.2359,0.2884,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9981000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_District_Zahleh,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Lebanon,,,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Multiple groups,15.0,74.0,Geographical area,District: Zahleh,461,0.25379999999999997,0.2125,0.2928,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9980999999999981,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_District_Baabda,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Lebanon,,,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Multiple groups,15.0,74.0,Geographical area,District: Baabda,1416,0.26480000000000004,0.2422,0.2874,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9981000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_District_Rachiaya,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Lebanon,,,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Multiple groups,15.0,74.0,Geographical area,District: Rachiaya,98,0.31629999999999997,0.22440000000000002,0.3979,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9980999999999987,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_District_Refugees,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lebanon,,,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Multiple groups,15.0,74.0,Geographical area,District: Refugees camps,447,0.3669,0.3221,0.41159999999999997,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9980999999999985,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_District_Tripoli,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Lebanon,,,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Multiple groups,15.0,74.0,Geographical area,District: Tripoli,688,0.359,0.3226,0.39380000000000004,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9980999999999983,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_Age_70-74,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lebanon,eight Lebanese governorates,138 Lebanese municipalities,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Seniors (65+ years),70.0,74.0,Age,Age: 70-74,436,0.2064,0.1697,0.24309999999999998,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9981000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_District_ElMetn,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Lebanon,,,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Multiple groups,15.0,74.0,Geographical area,District: El Metn,1538,0.3628,0.3387,0.38680000000000003,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9980999999999994,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_Overall,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lebanon,eight Lebanese governorates,138 Lebanese municipalities,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Multiple groups,15.0,74.0,Analysis,Overall unadjusted,13755,0.2303,0.22350000000000003,0.2374,,,,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9981000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_Age_20-24,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lebanon,eight Lebanese governorates,138 Lebanese municipalities,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Adults (18-64 years),20.0,24.0,Age,Age: 20-24,1474,0.2612,0.23879999999999998,0.2836,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9981000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_District_Hermel,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Lebanon,,,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Multiple groups,15.0,74.0,Geographical area,District: Hermel,96,0.0417,0.010400000000000001,0.0833,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9980999999999993,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_Age_35-39,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lebanon,eight Lebanese governorates,138 Lebanese municipalities,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Adults (18-64 years),35.0,39.0,Age,Age: 35-39,1230,0.261,0.2366,0.2854,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9981000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_Age_25-29,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lebanon,eight Lebanese governorates,138 Lebanese municipalities,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Adults (18-64 years),25.0,29.0,Age,Age: 25-29,1258,0.24800000000000003,0.2241,0.27190000000000003,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9981000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_District_Sour,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Lebanon,,,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Multiple groups,15.0,74.0,Geographical area,District: Sour,634,0.1104,0.0867,0.1356,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9980999999999983,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_District_Jubail,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Lebanon,,,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Multiple groups,15.0,74.0,Geographical area,District: Jubail,398,0.0176,0.005,0.0301,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9980999999999991,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_Age_30-34,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lebanon,eight Lebanese governorates,138 Lebanese municipalities,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Adults (18-64 years),30.0,34.0,Age,Age: 30-34,1188,0.2374,0.21300000000000002,0.2618,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9981000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_Age_55-59,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lebanon,eight Lebanese governorates,138 Lebanese municipalities,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Adults (18-64 years),55.0,59.0,Age,Age: 55-59,1320,0.1917,0.1705,0.2121,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9981000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_District_WestBekaa,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Lebanon,,,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Multiple groups,15.0,74.0,Geographical area,District: West Bekaa,220,0.1818,0.1318,0.2318,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9980999999999982,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_Sex_Male,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lebanon,eight Lebanese governorates,138 Lebanese municipalities,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,Male,Multiple groups,15.0,74.0,Sex/Gender,,7200,0.21530000000000002,0.2057,0.22469999999999998,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9981000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_Age_65-69,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lebanon,eight Lebanese governorates,138 Lebanese municipalities,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Seniors (65+ years),65.0,69.0,Age,Age: 65-69,611,0.17350000000000002,0.14400000000000002,0.2029,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9981000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_District_BintJbayl,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Lebanon,,,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Multiple groups,15.0,74.0,Geographical area,District: Bint Jbayl,229,0.0349,0.0131,0.0611,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9981000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_District_MiniehDanieh,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Lebanon,,,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Multiple groups,15.0,74.0,Geographical area,District: Minieh-Danieh,351,0.4046,0.3504,0.4529,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9980999999999988,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_District_Jezzine,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Lebanon,,,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Multiple groups,15.0,74.0,Geographical area,District: Jezzine,97,0.0309,0.0,0.0721,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9980999999999992,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_District_Aley,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Lebanon,,,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Multiple groups,15.0,74.0,Geographical area,District: Aley,844,0.3531,0.3199,0.3839,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9981000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_District_Kasrouane,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Lebanon,,,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Multiple groups,15.0,74.0,Geographical area,District: Kasrouane,697,0.1277,0.1033,0.152,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998099999999999,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_Age_15-19,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lebanon,eight Lebanese governorates,138 Lebanese municipalities,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Children and Youth (0-17 years),15.0,19.0,Age,Age: 15-19,1250,0.2792,0.2544,0.304,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9981000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_District_Marjaayoun,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Lebanon,,,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Multiple groups,15.0,74.0,Geographical area,District: Marjaayoun,193,0.010400000000000001,0.0,0.0259,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9980999999999989,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_Sex_Female,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lebanon,eight Lebanese governorates,138 Lebanese municipalities,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,Female,Multiple groups,15.0,74.0,Sex/Gender,,6555,0.2468,0.2366,0.2575,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9981000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_District_Bcharre,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Lebanon,,,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Multiple groups,15.0,74.0,Geographical area,District: Bcharre,93,0.18280000000000002,0.1075,0.258,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9981000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_District_Chouf,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Lebanon,,,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Multiple groups,15.0,74.0,Geographical area,District: Chouf,745,0.22010000000000002,0.1906,0.2483,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9981000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_District_Zgharta,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Lebanon,,,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Multiple groups,15.0,74.0,Geographical area,District: Zgharta,236,0.2161,0.161,0.2669,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998099999999998,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_District_Saida,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Lebanon,,,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Multiple groups,15.0,74.0,Geographical area,District: Saida,791,0.054400000000000004,0.0391,0.0695,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9980999999999984,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_District_Baalbeck,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Lebanon,,,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Multiple groups,15.0,74.0,Geographical area,District: Baalbeck,596,0.2953,0.2583,0.3322,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9981000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_District_Akkar,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Lebanon,,,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Multiple groups,15.0,74.0,Geographical area,District: Akkar,806,0.1439,0.12029999999999999,0.16870000000000002,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9981000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_District_Hasbaya,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Lebanon,,,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Multiple groups,15.0,74.0,Geographical area,District: Hasbaya,78,0.6026,0.4743,0.6923,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9980999999999993,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_Age_45-49,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lebanon,eight Lebanese governorates,138 Lebanese municipalities,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Adults (18-64 years),45.0,49.0,Age,Age: 45-49,1318,0.23600000000000002,0.2132,0.25870000000000004,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9981000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_Age_60-64,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lebanon,eight Lebanese governorates,138 Lebanese municipalities,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Adults (18-64 years),60.0,64.0,Age,Age: 60-64,942,0.1688,0.1454,0.1932,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9981000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_District_Batroun,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Lebanon,,,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Multiple groups,15.0,74.0,Geographical area,District: Batroun,141,0.1773,0.1134,0.23399999999999999,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9981000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_Age_50-54,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lebanon,eight Lebanese governorates,138 Lebanese municipalities,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Adults (18-64 years),50.0,54.0,Age,Age: 50-54,1447,0.2129,0.1907,0.2343,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9981000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220129_Lebanon_LebaneseAmericanUniversityMedicalCentre_UnAdj_Age_40-44,220129_Lebanon_LebaneseAmericanUniversityMedicalCentre,Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study,2022-01-29,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lebanon,eight Lebanese governorates,138 Lebanese municipalities,"""The sample included male and female Lebanese and non-Lebanese residents, as well as Syrian and Palestinian refugees living in Lebanon, between 15 and 75 years of age.""","""Individuals of the same household, symptomatic individuals (for consistency and the safety of participants), individuals of extreme ages (< 15 and > 75 years old) due to sample acquiring difficulty, and vaccinated individuals were excluded.""

""congregate settings (e.g. nursing homes, prisons, same household, or same building) were avoided to decrease bias.""",2020-09-21,2021-04-08,Household and community samples,All,Adults (18-64 years),40.0,44.0,Age,Age: 40-44,1281,0.2279,0.2053,0.2514,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9981000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ahmad Mahdi,Lebanese American University Medical Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800496/,2022-06-29,2024-03-01,Unverified,mahdi_severe_2022,LBN
220521_Lebanon_HumanLink_Overall,220521_Lebanon_HumanLink,Prevalence and determinants of SARS-CoV-2 neutralizing antibodies in Lebanon.,2022-05-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lebanon,"Beirut, North, South, Akkar, Nabatiye, Bekaa, Baalbak-Hermel",,"subjects above 18 years of age were enrolled from seven governorates: Beirut, North, South, Akkar, Nabatiye, Bekaa, and Baalbak-Hermel",Exclusion criteria included unwillingness or inability to provide consent and comply with the study requirements. ,2020-10-15,2021-04-15,Multiple populations,All,Multiple groups,18.0,,Primary Estimate,,2783,0.589,,,True,,,,True,Convenience,Author designed (Neutralization Assay),,Neutralization,Serum,Neutralizing,Whole-virusantigen,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Omar Bahlawan,Human Link,Not Unity-Aligned,https://dx.doi.org/10.1007/s00705-022-05470-2,2022-06-04,2022-07-16,Unverified,bahlawan_prevalence_2022,LBN
230621_Lesotho_UniversityHospitalZurich,230621_Lesotho_UniversityHospitalZurich,Seroprofiling of antibodies against endemic human coronaviruses and SARS-CoV-2 in an HIV cohort in Lesotho: correlates of antibody response and seropositivity.,2023-06-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lesotho,,,,,2020-02-15,2021-07-15,Residual sera,All,Multiple groups,,,Primary Estimate,,3173,0.35,,,True,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Plasma,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Jennifer Brown,University Hospital Zurich,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiad197,2023-06-30,2023-07-04,Unverified,brownSeroprofilingAntibodiesEndemic2023,LSO
200526_AlzintanCity_Al-ZintanUniversity_GenPopulation,200526_AlzintanCity_Al-ZintanUniversity_1,Seroprevalence of antibodies against SARS-CoV-2 among public community and health-care workers in Alzintan City of Libya,2020-05-26,Preprint,Local,Cross-sectional survey ,Libya,Libya,Alzintan City,"Collection of samples were divided in two categories; random samples from public community and samples from health-care workers belonging to two Governmental hospitals and one private clinic 

The random samples were collected from patients visiting Obstetrics and Gynecology Centerand Blood Bank Center (Both are located in the same building) in Alzintan City for regular
medical checkup, laboratory analysis, blood donation and for MRI. ",,2020-04-02,2020-05-18,Multiple populations,All,Multiple groups,,,Primary Estimate,,142,0.042300000000000004,,,True,,,,True,Simplified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.8640000000000001,0.996,['High'],Yes,Yes,No,Yes,Yes,No,Yes,No,Yes,Abdulwahab Kammon,Al-Zintan University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.05.25.20109470v1,2020-05-30,2024-03-01,Verified,kammon_seroprevalence_2020,LBY
200526_AlzintanCity_Al-ZintanUniversity_GenPop_AgeOver40,200526_AlzintanCity_Al-ZintanUniversity_1,Seroprevalence of antibodies against SARS-CoV-2 among public community and health-care workers in Alzintan City of Libya,2020-05-26,Preprint,Local,Cross-sectional survey ,Libya,Libya,Alzintan City,"Collection of samples were divided in two categories; random samples from public community and samples from health-care workers belonging to two Governmental hospitals and one private clinic 

The random samples were collected from patients visiting Obstetrics and Gynecology Centerand Blood Bank Center (Both are located in the same building) in Alzintan City for regular
medical checkup, laboratory analysis, blood donation and for MRI. ",,2020-04-02,2020-05-18,Multiple populations,All,Multiple groups,41.0,,Age,>40,64,0.078,,,,,,,,Simplified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.8640000000000001,0.996,['High'],Yes,Yes,No,Yes,Yes,No,Yes,No,Yes,Abdulwahab Kammon,Al-Zintan University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.05.25.20109470v1,2020-08-14,2024-03-01,Verified,kammon_seroprevalence_2020,LBY
200526_AlzintanCity_Al-ZintanUniversity_GenPop_Age40orUnder,200526_AlzintanCity_Al-ZintanUniversity_1,Seroprevalence of antibodies against SARS-CoV-2 among public community and health-care workers in Alzintan City of Libya,2020-05-26,Preprint,Local,Cross-sectional survey ,Libya,Libya,Alzintan City,"Collection of samples were divided in two categories; random samples from public community and samples from health-care workers belonging to two Governmental hospitals and one private clinic 

The random samples were collected from patients visiting Obstetrics and Gynecology Centerand Blood Bank Center (Both are located in the same building) in Alzintan City for regular
medical checkup, laboratory analysis, blood donation and for MRI. ",,2020-04-02,2020-05-18,Multiple populations,All,Multiple groups,,40.0,Age,<=40,78,0.0128,,,,,,,,Simplified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.8640000000000001,0.996,['High'],Yes,Yes,No,Yes,Yes,No,Yes,No,Yes,Abdulwahab Kammon,Al-Zintan University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.05.25.20109470v1,2020-08-14,2024-03-01,Verified,kammon_seroprevalence_2020,LBY
200526_AlzintanCity_Al-ZintanUniversity_HealthCareWorkers,200526_AlzintanCity_Al-ZintanUniversity_2,Seroprevalence of antibodies against SARS-CoV-2 among public community and health-care workers in Alzintan City of Libya,2020-05-26,Preprint,Local,Cross-sectional survey ,Libya,Libya,Alzintan City,"Collection of samples were divided in two categories; random samples from public community and samples from health-care workers belonging to two Governmental hospitals and one private clinic 

The random samples were collected from patients visiting Obstetrics and Gynecology Centerand Blood Bank Center (Both are located in the same building) in Alzintan City for regular
medical checkup, laboratory analysis, blood donation and for MRI. ",,2020-04-02,2020-05-18,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,77,0.0,,,True,,,,True,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.8640000000000001,0.996,['High'],No,Yes,No,Yes,Yes,No,Yes,No,Yes,Abdulwahab Kammon,Al-Zintan University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.05.25.20109470v1,2020-05-30,2024-03-01,Verified,kammon_seroprevalence_2020,LBY
200526_AlzintanCity_Al-ZintanUniversity_HealthCare_AgeOver40,200526_AlzintanCity_Al-ZintanUniversity_2,Seroprevalence of antibodies against SARS-CoV-2 among public community and health-care workers in Alzintan City of Libya,2020-05-26,Preprint,Local,Cross-sectional survey ,Libya,Libya,Alzintan City,"Collection of samples were divided in two categories; random samples from public community and samples from health-care workers belonging to two Governmental hospitals and one private clinic 

The random samples were collected from patients visiting Obstetrics and Gynecology Centerand Blood Bank Center (Both are located in the same building) in Alzintan City for regular
medical checkup, laboratory analysis, blood donation and for MRI. ",,2020-04-02,2020-05-18,Health care workers and caregivers,All,Multiple groups,41.0,,Age,>40,18,0.0,,,,,,,,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.8640000000000001,0.996,['High'],No,Yes,No,Yes,Yes,No,Yes,No,Yes,Abdulwahab Kammon,Al-Zintan University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.05.25.20109470v1,2020-07-29,2024-03-01,Verified,kammon_seroprevalence_2020,LBY
200526_AlzintanCity_Al-ZintanUniversity_HealthCare_Age40orUnder,200526_AlzintanCity_Al-ZintanUniversity_2,Seroprevalence of antibodies against SARS-CoV-2 among public community and health-care workers in Alzintan City of Libya,2020-05-26,Preprint,Local,Cross-sectional survey ,Libya,Libya,Alzintan City,"Collection of samples were divided in two categories; random samples from public community and samples from health-care workers belonging to two Governmental hospitals and one private clinic 

The random samples were collected from patients visiting Obstetrics and Gynecology Centerand Blood Bank Center (Both are located in the same building) in Alzintan City for regular
medical checkup, laboratory analysis, blood donation and for MRI. ",,2020-04-02,2020-05-18,Health care workers and caregivers,All,Adults (18-64 years),,40.0,Age,<=40,59,0.0,,,,,,,,Stratified probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.8640000000000001,0.996,['High'],No,Yes,No,Yes,Yes,No,Yes,No,Yes,Abdulwahab Kammon,Al-Zintan University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.05.25.20109470v1,2020-07-29,2024-03-01,Verified,kammon_seroprevalence_2020,LBY
200929_Benghazi_TheCenterOfInfectiousDiseases-Benghazi_overall,200929_Benghazi_TheCenterOfInfectiousDiseases-Benghazi,Population-Based Random Survey for detection of COVID-19 Infection and Seroprevalence in Benghazi- Libya May/2020,2020-09-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Libya,,Benghazi,"individuals in Benghazi, including all geographical areas of Benghazi and all persons irrespective of their age, gender or nationality.",,2020-05-02,2020-05-07,Household and community samples,All,Multiple groups,,,Primary Estimate,,600,0.0,,,True,,,,True,Stratified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.8170000000000001,0.9670000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Amal A Elfakhri,The Center of Infectious Diseases- Benghazi,Not Unity-Aligned,https://preventive-medicine.imedpub.com/populationbased-random-survey-for-detection-of-covid19-infection-and-seroprevalence-in-benghazi-libya-may2020.pdf,2021-04-26,2022-07-16,Verified,elfakhri_population-based_2020,LBY
220727_Tobruk_UniversityOfTobruk,220727_Tobruk_UniversityOfTobruk,"Low SARS-CoV-2 antibodies in blood donors after the first 6 months of COVID-19 epidemic in the Tobruk region, eastern Libya.",2022-07-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Libya,,,"""The survey consisted of 200 healthy blood donors from the central blood bank in Tobruk, which is the main blood bank in the Tobruk region.""",,2021-01-15,2021-02-15,Blood donors,Male,Multiple groups,,,Primary Estimate,,200,0.04,,,True,,,,True,Unclear,Standard Q COVID-19 IgM/IgG Combo,SD Biosensor,,Whole Blood,"['IgG', 'IgM']",,,,,['High'],,Unclear,No,No,,Unclear,Yes,No,,Faisal Ismail,University of Tobruk,Not Unity-Aligned,https://dx.doi.org/10.1017/dmp.2022.180,2022-08-03,2022-08-03,Unverified,ismail_low_2022,LBY
201209_Liechtenstein_KantonsspitalGraubunden_Overall,201209_Liechtenstein_KantonsspitalGraubunden,Characterization of a Pan-Immunoglobulin Assay Quantifying Antibodies Directed against the Receptor Binding Domain of the SARS-CoV-2 S1-Subunit of the Spike Protein: A Population-Based Study.,2020-12-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Liechtenstein,,,"Contacts of COVID-19 patients that had tested negative by PCR, otherwise no known COVID-19",,2020-06-02,2020-10-06,Multiple populations,All,Multiple groups,,,Primary Estimate,Overall,1159,0.078,0.064,0.095,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Abbott Architect SARS-CoV-2 IgG,LIAISON SARS-CoV-2 S1/S2 IgM,Liaison SARS-CoV-2 S1/S2 IgG,Anti-SARS-CoV-2 ELISA IgA,Anti-SARS-CoV-2 ELISA IgG,EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit,EDI™ Novel Coronavirus COVID-19 IgM ELISA Kit,SGTi-flex COVID-19 IgM/IgG (manual)","Roche Diagnostics,Abbott Laboratories,DiaSorin,EUROIMMUN,Epitope Diagnostics, Inc.,Sugentech, Inc.",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],Unclear,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anna Schaffner,Kantonsspital Graunbunden,Not Unity-Aligned,https://dx.doi.org/10.3390/jcm9123989,2021-01-28,2024-03-01,Verified,schaffner_characterization_2020,LIE
210118_Lithuania_210118_Lithuania_LithuanianUniversityofHealthSciences_TestAdj,210118_Lithuania_LithuanianUniversityofHealthSciences,SARS-CoV-2 Seroprevalence in Lithuania: Results of National Population Survey,2021-01-18,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lithuania,"Vilnius County, Kaunas county, Klaipėda County, Tauragė County, Utena county
","Vilnius, Kaunas, Klaipėda
",Randomly selected adult participants (18 years and older) were asked by mail to visit a designated health care unit to undergo the SARS-CoV-2 antibodies test and fill in the questionnaire.,,2020-08-10,2020-09-10,Household and community samples,All,Multiple groups,18.0,92.0,Primary Estimate,Test Adjusted,3089,0.013999999999999999,0.0092,0.0199,True,True,,,,Simplified probability,AMP Rapid Test SARS-CoV-2 IgG/IgM,AMEDA Labordiagnostik GmbH,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.92,0.9940000000000001,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Kastytis Smigelskas, Lithuanian University of Health Sciences,Unity-Aligned,https://www.journals.vu.lt/AML/article/view/22344,2021-05-13,2023-08-15,Verified,smigelskas_sars-cov-2_2021,LTU
210118_Lithuania_210118_Lithuania_LithuanianUniversityofHealthSciences_18-64,210118_Lithuania_LithuanianUniversityofHealthSciences,SARS-CoV-2 Seroprevalence in Lithuania: Results of National Population Survey,2021-01-18,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lithuania,"Vilnius County, Kaunas county, Klaipėda County, Tauragė County, Utena county
","Vilnius, Kaunas, Klaipėda
",Randomly selected adult participants (18 years and older) were asked by mail to visit a designated health care unit to undergo the SARS-CoV-2 antibodies test and fill in the questionnaire.,,2020-08-10,2020-09-10,Household and community samples,All,Adults (18-64 years),18.0,64.0,Age,18-64 years,868,0.0138,,,,,,,,Simplified probability,AMP Rapid Test SARS-CoV-2 IgG/IgM,AMEDA Labordiagnostik GmbH,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.92,0.9940000000000001,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Kastytis Smigelskas, Lithuanian University of Health Sciences,Unity-Aligned,https://www.journals.vu.lt/AML/article/view/22344,2021-08-26,2024-03-01,Verified,smigelskas_sars-cov-2_2021,LTU
210118_Lithuania_210118_Lithuania_LithuanianUniversityofHealthSciences_Male,210118_Lithuania_LithuanianUniversityofHealthSciences,SARS-CoV-2 Seroprevalence in Lithuania: Results of National Population Survey,2021-01-18,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lithuania,"Vilnius County, Kaunas county, Klaipėda County, Tauragė County, Utena county
","Vilnius, Kaunas, Klaipėda
",Randomly selected adult participants (18 years and older) were asked by mail to visit a designated health care unit to undergo the SARS-CoV-2 antibodies test and fill in the questionnaire.,,2020-08-10,2020-09-10,Household and community samples,Male,Multiple groups,18.0,92.0,Sex/Gender,,1114,0.0117,,,,,,,,Simplified probability,AMP Rapid Test SARS-CoV-2 IgG/IgM,AMEDA Labordiagnostik GmbH,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.92,0.9940000000000001,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Kastytis Smigelskas, Lithuanian University of Health Sciences,Unity-Aligned,https://www.journals.vu.lt/AML/article/view/22344,2021-08-26,2024-03-01,Verified,smigelskas_sars-cov-2_2021,LTU
210118_Lithuania_210118_Lithuania_LithuanianUniversityofHealthSciences_Unadj,210118_Lithuania_LithuanianUniversityofHealthSciences,SARS-CoV-2 Seroprevalence in Lithuania: Results of National Population Survey,2021-01-18,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lithuania,"Vilnius County, Kaunas county, Klaipėda County, Tauragė County, Utena county
","Vilnius, Kaunas, Klaipėda
",Randomly selected adult participants (18 years and older) were asked by mail to visit a designated health care unit to undergo the SARS-CoV-2 antibodies test and fill in the questionnaire.,,2020-08-10,2020-09-10,Household and community samples,All,Multiple groups,18.0,92.0,Analysis,Unadjusted ,3089,0.0188,0.0146,0.0242,,,,,True,Simplified probability,AMP Rapid Test SARS-CoV-2 IgG/IgM,AMEDA Labordiagnostik GmbH,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.92,0.9940000000000001,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Kastytis Smigelskas, Lithuanian University of Health Sciences,Unity-Aligned,https://www.journals.vu.lt/AML/article/view/22344,2021-05-12,2024-03-01,Verified,smigelskas_sars-cov-2_2021,LTU
210118_Lithuania_210118_Lithuania_LithuanianUniversityofHealthSciences_Female,210118_Lithuania_LithuanianUniversityofHealthSciences,SARS-CoV-2 Seroprevalence in Lithuania: Results of National Population Survey,2021-01-18,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lithuania,"Vilnius County, Kaunas county, Klaipėda County, Tauragė County, Utena county","Vilnius, Kaunas, Klaipėda
",Randomly selected adult participants (18 years and older) were asked by mail to visit a designated health care unit to undergo the SARS-CoV-2 antibodies test and fill in the questionnaire.,,2020-08-10,2020-09-10,Household and community samples,Female,Multiple groups,18.0,92.0,Sex/Gender,,1973,0.022799999999999997,,,,,,,,Simplified probability,AMP Rapid Test SARS-CoV-2 IgG/IgM,AMEDA Labordiagnostik GmbH,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.92,0.9940000000000001,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Kastytis Smigelskas, Lithuanian University of Health Sciences,Unity-Aligned,https://www.journals.vu.lt/AML/article/view/22344,2021-08-26,2024-03-01,Verified,smigelskas_sars-cov-2_2021,LTU
210118_Lithuania_210118_Lithuania_LithuanianUniversityofHealthSciences_65+,210118_Lithuania_LithuanianUniversityofHealthSciences,SARS-CoV-2 Seroprevalence in Lithuania: Results of National Population Survey,2021-01-18,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Lithuania,"Vilnius County, Kaunas county, Klaipėda County, Tauragė County, Utena county
","Vilnius, Kaunas, Klaipėda
",Randomly selected adult participants (18 years and older) were asked by mail to visit a designated health care unit to undergo the SARS-CoV-2 antibodies test and fill in the questionnaire.,,2020-08-10,2020-09-10,Household and community samples,All,Seniors (65+ years),65.0,92.0,Age,65+ years,2218,0.0207,,,,,,,,Simplified probability,AMP Rapid Test SARS-CoV-2 IgG/IgM,AMEDA Labordiagnostik GmbH,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.92,0.9940000000000001,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Kastytis Smigelskas, Lithuanian University of Health Sciences,Unity-Aligned,https://www.journals.vu.lt/AML/article/view/22344,2021-08-26,2024-03-01,Verified,smigelskas_sars-cov-2_2021,LTU
210107_Lithuania_UniversityCollegeLondon_PaediatricHCW,210107_Lithuania_UniversityCollegeLondon,Cross Sectional Prevalence of SARS-CoV-2 antibodies in Health Care Workers in Paediatric Facilities in Eight Countries,2021-01-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Lithuania,,,"This was part of a larger study undertaken in HCWs in paediatric facilities in seven European sites and one South African site. Staff of all categories in each healthcare setting were invited to join the study, irrespective of symptoms or whether they suspected they had previously had COVID-19. ",,2020-06-01,2020-06-12,Health care workers and caregivers,All,Adults (18-64 years),22.0,70.0,Primary Estimate,,300,0.006600000000000001,0.0018,0.024,True,,,,True,Convenience,"EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit,Meso Scale Discovery multiplex assay","Epitope Diagnostics, Inc.,Meso Scale Discovery",ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,No,No,Unclear,Yes,Yes,No,Unclear,D Goldblatt,University College London,Not Unity-Aligned,http://dx.doi.org/10.1016/j.jhin.2020.12.019,2021-03-13,2024-03-01,Verified,goldblatt_cross-sectional_2021,LTU
210206_Kaunas_HospitalofLithuanianUniversityofHealthSciencesKaunoKlinikos_LFIA,210206_Kaunas_HospitalofLithuanianUniversityofHealthSciencesKaunoKlinikos,SARS-CoV-2 Seroprevalence in Healthcare Workers of Kaunas Hospitals during the First Wave of the COVID-19 Pandemic ,2021-02-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Lithuania,,Kaunas,"healthcare workers who had contact with patients having acute respiratory symptoms at Kaunas hospitals, including the HLUHS KK and KH LUHS",,2020-06-15,2020-09-21,Health care workers and caregivers,All,Multiple groups,21.0,74.0,Primary Estimate,Overall LFIA results,432,0.0116,,,True,,,,True,Convenience,AMP Rapid Test SARS-CoV-2 IgG/IgM,AMEDA Labordiagnostik GmbH,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.918,0.9640000000000001,['High'],No,No,No,Yes,No,Yes,Yes,No,Unclear,Laura Pereckaite,The Hospital of Lithuanian University of Health Sciences Kauno Klinikos,Not Unity-Aligned,https://dx.doi.org/10.3390/medicina57020148,2021-03-16,2024-03-01,Verified,pereckaite_sars-cov-2_2021,LTU
210212_Kaunas_LithuanianUniversityOfHealthSciences_HidradenitisSuppurativa,210212_Kaunas_LithuanianUniversityOfHealthScience,SARS-CoV-2 seroprevalence in patients with hidradenitis suppurativa in Lithuania,2021-02-12,Presentation or Conference,Local,Cross-sectional survey ,Lithuania,,Kaunas,Patients with hidradenitis suppurativa followed at ERN-Skin reference centre at the Hospital of Lithuanian University of Health Sciences,,2020-08-12,2020-12-30,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,26,0.077,0.0213,0.2414,True,,,,True,Convenience,"Anti-SARS-CoV-2 NCP ELISA (IgG),Anti-SARS-CoV-2 NCP ELISA (IGM)",EUROIMMUN,ELISA,Serum,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,No,,Vaiva Jariene,Lithuanian University of Health Sciences,Not Unity-Aligned,https://www.researchgate.net/publication/349992124_SARS-CoV-2_Seroprevalence_in_Patients_with_Hidradenitis_Suppurativa_in_Lithuania,2021-07-05,2024-03-01,Verified,jariene_sars-cov-2_2021,LTU
200518_Luxembourg_LuxembourgInstituteofHealth_GenPop_IgGPopAdj,200518_Luxembourg_LuxembourgInstituteofHealth,Prevalence of SARS-CoV-2 infection in the Luxembourgish population: the CON-VINCE study.,2020-05-18,Preprint,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Luxembourg,,,Resident of Luxembourg ,"Infection by Coronavirus with severe disease course requiring a hospital admission prior to the inclusion to the study, presence of fever and respiratory distress/cough at the time of inclusion not attributable to other known chronic disease, age > 79 years, individuals living across the borders",2020-04-15,2020-05-05,Household and community samples,All,Multiple groups,18.0,79.0,Primary Estimate,,1820,0.0209,0.013700000000000002,0.0282,True,,True,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.8570000000000001,0.978,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Chantal Snoeck,Luxembourg Institute of Health,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.05.11.20092916v1,2020-07-12,2024-03-01,Verified,snoeck_prevalence_nodate,LUX
210604_Madagascar_InstitutPasteurDeMadagascar_AntananarivoApril_Adj,210604_Madagascar_InstitutPasteurDeMadagascar_Antananarivo1April,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Antananarivo,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-04-01,2020-04-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Test/pop adjusted - bayesian model,157,0.0,0.0,0.0,True,True,True,,,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-16,2023-08-15,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_AntananarivoApril_Unadj,210604_Madagascar_InstitutPasteurDeMadagascar_Antananarivo1April,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Antananarivo,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-04-01,2020-04-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Analysis,unadjusted.,157,0.0,0.0,0.0,,,,,True,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-16,2024-03-01,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_AntananarivoAugust_Adj,210604_Madagascar_InstitutPasteurDeMadagascar_Antananarivo2August,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Antananarivo,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-08-01,2020-08-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Test/pop adjusted - bayesian model,432,0.413,0.41100000000000003,0.41500000000000004,True,True,True,,,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-16,2023-08-15,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_AntananarivoAugust_unAdj,210604_Madagascar_InstitutPasteurDeMadagascar_Antananarivo2August,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Antananarivo,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-08-01,2020-08-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Analysis,unadj,432,0.35200000000000004,0.308,0.39799999999999996,,,,,True,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-16,2024-03-01,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_AntananarivoJuly_Adj,210604_Madagascar_InstitutPasteurDeMadagascar_Antananarivo3July,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Antananarivo,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-07-01,2020-07-31,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Test/pop adjusted - bayesian model,428,0.354,0.35200000000000004,0.35600000000000004,True,True,True,,,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-16,2023-08-15,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_AntananarivoJuly_Unadj,210604_Madagascar_InstitutPasteurDeMadagascar_Antananarivo3July,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Antananarivo,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-07-01,2020-07-31,Blood donors,All,Adults (18-64 years),18.0,68.0,Analysis,unadjusted,428,0.29,0.249,0.334,,,,,True,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-16,2024-03-01,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_AntananarivoJune_Adj,210604_Madagascar_InstitutPasteurDeMadagascar_Antananarivo4June,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Antananarivo,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-06-01,2020-06-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Test/pop adjusted - bayesian model,308,0.027999999999999997,0.027000000000000003,0.028999999999999998,True,True,True,,,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-16,2023-08-15,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_AntananarivoJune_unAdj,210604_Madagascar_InstitutPasteurDeMadagascar_Antananarivo4June,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Antananarivo,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-06-01,2020-06-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Analysis,unadjusted,308,0.033,0.018000000000000002,0.059000000000000004,,,,,True,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-16,2024-03-01,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_AntananarivoMarch_Adj,210604_Madagascar_InstitutPasteurDeMadagascar_Antananarivo5March,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Antananarivo,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-03-01,2020-03-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Test/pop adjusted - bayesian model,496,0.0,0.0,0.0,True,True,True,,,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-16,2023-08-15,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_AntananarivoMarch_Unadj,210604_Madagascar_InstitutPasteurDeMadagascar_Antananarivo5March,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Antananarivo,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-03-01,2020-03-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Analysis,unadjusted.,496,0.008,0.003,0.021,,,,,True,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-16,2024-03-01,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_AntananarivoMay_Adj,210604_Madagascar_InstitutPasteurDeMadagascar_Antananarivo6May,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Antananarivo,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-05-01,2020-05-31,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Test/pop adjusted - bayesian model,598,0.0,0.0,0.0,True,True,True,,,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-16,2023-08-15,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_AntananarivoMay_Unadj,210604_Madagascar_InstitutPasteurDeMadagascar_Antananarivo6May,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Antananarivo,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-05-01,2020-05-31,Blood donors,All,Adults (18-64 years),18.0,68.0,Analysis,unadj,598,0.002,0.0,0.009000000000000001,,,,,True,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-16,2024-03-01,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_AntananarivoNovember_Adj,210604_Madagascar_InstitutPasteurDeMadagascar_Antananarivo7November,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Antananarivo,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-11-01,2020-11-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Test/pop adjusted - bayesian model,502,0.38,0.379,0.38200000000000006,True,True,True,,,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-16,2023-08-15,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_AntananarivoNovember_unAdj,210604_Madagascar_InstitutPasteurDeMadagascar_Antananarivo7November,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Antananarivo,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-11-01,2020-11-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Analysis,unadjusted,502,0.313,0.27399999999999997,0.355,,,,,True,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-16,2024-03-01,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_AntananarivoOctober_Adj,210604_Madagascar_InstitutPasteurDeMadagascar_Antananarivo8October,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Antananarivo,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-10-01,2020-10-31,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Test/pop adjusted - bayesian model,495,0.43200000000000005,0.43,0.434,True,True,True,,,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-16,2023-08-15,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_AntananarivoOctober_UnAdj,210604_Madagascar_InstitutPasteurDeMadagascar_Antananarivo8October,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Antananarivo,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-10-01,2020-10-31,Blood donors,All,Adults (18-64 years),18.0,68.0,Analysis,unadjusted,502,0.36,0.319,0.40299999999999997,,,,,True,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-16,2024-03-01,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_AntananarivoSeptember_Adj,210604_Madagascar_InstitutPasteurDeMadagascar_Antananarivo9September,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Antananarivo,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-09-01,2020-09-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Test/pop adjusted - bayesian model,481,0.435,0.433,0.438,True,True,True,,,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-16,2023-08-15,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_AntananarivoSeptember_unAdj,210604_Madagascar_InstitutPasteurDeMadagascar_Antananarivo9September,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Antananarivo,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-09-01,2020-09-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Analysis,unadjsuted,481,0.385,0.342,0.429,,,,,True,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-16,2024-03-01,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_FianarantsoaJune_Adj,210604_Madagascar_InstitutPasteurDeMadagascar_Fianarantsoa1June,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Fianarantsoa,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-06-01,2020-06-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Test/pop adjusted - bayesian model,129,0.0,0.0,0.0,True,True,True,,,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2023-08-15,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_FianarantsoaJune_unAdj,210604_Madagascar_InstitutPasteurDeMadagascar_Fianarantsoa1June,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Fianarantsoa,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-06-01,2020-06-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Analysis,unadj,129,0.008,0.001,0.043,,,,,True,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2024-03-01,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_FianarantsoaJuly_Adj,210604_Madagascar_InstitutPasteurDeMadagascar_Fianarantsoa2July,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Fianarantsoa,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-07-01,2020-07-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Test/pop adjusted - bayesian model,142,0.0,0.0,0.0,True,True,True,,,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2023-08-15,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_FianarantsoaJuly_unAdj,210604_Madagascar_InstitutPasteurDeMadagascar_Fianarantsoa2July,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Fianarantsoa,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-07-01,2020-07-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Analysis,unadjusted,142,0.0,0.0,0.0026000000000000003,,,,,True,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2024-03-01,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_FianarantsoaAugust_Adj,210604_Madagascar_InstitutPasteurDeMadagascar_Fianarantsoa3August,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Fianarantsoa,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-08-01,2020-08-31,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Test/pop adjusted - bayesian model,120,0.10400000000000001,0.102,0.106,True,True,True,,,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2023-08-15,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_FianarantsoaAugust_unAdj,210604_Madagascar_InstitutPasteurDeMadagascar_Fianarantsoa3August,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Fianarantsoa,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-08-01,2020-08-31,Blood donors,All,Adults (18-64 years),18.0,68.0,Analysis,unadjusted,120,0.092,0.052000000000000005,0.157,,,,,True,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2024-03-01,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_FianarantsoaSeptember_Adj,210604_Madagascar_InstitutPasteurDeMadagascar_Fianarantsoa4September,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Fianarantsoa,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-09-01,2020-09-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Test/pop adjusted - bayesian model,173,0.219,0.21600000000000003,0.22100000000000003,True,True,True,,,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2023-08-15,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_FianarantsoaSeptember_unAdj,210604_Madagascar_InstitutPasteurDeMadagascar_Fianarantsoa4September,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Fianarantsoa,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-09-01,2020-09-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Analysis,unadjusted,173,0.185,0.134,0.249,,,,,True,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2024-03-01,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_FianarantsoaOctober_Adj,210604_Madagascar_InstitutPasteurDeMadagascar_Fianarantsoa5October,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Fianarantsoa,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-10-01,2020-10-31,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Test/pop adjusted - bayesian model,152,0.187,0.185,0.189,True,True,True,,,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2023-08-15,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_FianarantsoaOctober_unAdj,210604_Madagascar_InstitutPasteurDeMadagascar_Fianarantsoa5October,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Fianarantsoa,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-10-01,2020-10-31,Blood donors,All,Adults (18-64 years),18.0,68.0,Analysis,unadjusted,152,0.151,0.10300000000000001,0.217,,,,,True,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2024-03-01,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_FianarantsoaNovember_Adj,210604_Madagascar_InstitutPasteurDeMadagascar_Fianarantsoa6November,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Fianarantsoa,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-11-01,2020-11-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Test/pop adjusted - bayesian model,172,0.162,0.16,0.16399999999999998,True,True,True,,,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2023-08-15,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_FianarantsoaNovember_unAdj,210604_Madagascar_InstitutPasteurDeMadagascar_Fianarantsoa6November,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Fianarantsoa,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-11-01,2020-11-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Analysis,unadjusted,172,0.128,0.086,0.18600000000000003,,,,,True,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2024-03-01,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_MahajangaJune_Adj,210604_Madagascar_InstitutPasteurDeMadagascar_Mahajanga1June,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Mahajanga,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-06-01,2020-06-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Test/pop adjusted - bayesian model,50,0.0,0.0,0.0,True,True,True,,,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2023-08-15,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_MahajangaJune_unAdj ,210604_Madagascar_InstitutPasteurDeMadagascar_Mahajanga1June,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Mahajanga,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-06-01,2020-06-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Analysis,unadjusted,50,0.0,0.0,0.071,,,,,True,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2024-03-01,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_MahajangaJuly_Adj,210604_Madagascar_InstitutPasteurDeMadagascar_Mahajanga2July,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Mahajanga,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-07-01,2020-07-31,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Test/pop adjusted - bayesian model,98,0.0,0.0,0.001,True,True,True,,,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2023-08-15,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_MahajangaJuly_unAdj,210604_Madagascar_InstitutPasteurDeMadagascar_Mahajanga2July,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Mahajanga,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-07-01,2020-07-31,Blood donors,All,Adults (18-64 years),18.0,68.0,Analysis,Test/pop adjusted - bayesian model,98,0.01,0.002,0.055999999999999994,,,,,True,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2024-03-01,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_MahajangaAugust_Adj,210604_Madagascar_InstitutPasteurDeMadagascar_Mahajanga3August,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Mahajanga,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-08-01,2020-08-31,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Test/pop adjusted - bayesian model,107,0.445,0.441,0.44799999999999995,True,True,True,,,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2023-08-15,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_MahajangaAugust_unAdj ,210604_Madagascar_InstitutPasteurDeMadagascar_Mahajanga3August,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Mahajanga,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-08-01,2020-08-31,Blood donors,All,Adults (18-64 years),18.0,68.0,Analysis,unadjusted,107,0.355,0.271,0.449,,,,,True,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2024-03-01,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_MahajangaSeptember_Adj ,210604_Madagascar_InstitutPasteurDeMadagascar_Mahajanga4September,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Mahajanga,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-09-01,2020-09-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Test/pop adjusted - bayesian model,53,0.26,0.259,0.261,True,True,True,,,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2023-08-15,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_MahajangaSeptember_unAdj ,210604_Madagascar_InstitutPasteurDeMadagascar_Mahajanga4September,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Mahajanga,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-09-01,2020-09-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Analysis,unadjusted,53,0.37700000000000006,0.259,0.512,,,,,True,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2024-03-01,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_MahajangaOctober_Adj,210604_Madagascar_InstitutPasteurDeMadagascar_Mahajanga5October,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Mahajanga,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-10-01,2020-10-31,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Test/pop adjusted - bayesian model,26,0.29600000000000004,0.289,0.302,True,True,True,,,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2022-07-16,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_MahajangaOctober_unAdj,210604_Madagascar_InstitutPasteurDeMadagascar_Mahajanga5October,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Mahajanga,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-10-01,2020-10-31,Blood donors,All,Adults (18-64 years),18.0,68.0,Analysis,unadjusted,26,0.269,0.13699999999999998,0.461,,,,,True,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2024-03-01,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_MahajangaNovember_Adj ,210604_Madagascar_InstitutPasteurDeMadagascar_Mahajanga6November,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Mahajanga,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-11-01,2020-11-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Test/pop adjusted - bayesian model,30,0.215,0.209,0.22,True,True,True,,,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2023-08-15,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_MahajangaNovember_unAdj,210604_Madagascar_InstitutPasteurDeMadagascar_Mahajanga6November,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Mahajanga,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-11-01,2020-11-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Analysis,unadjusted,30,0.167,0.073,0.336,,,,,True,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2024-03-01,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_ToamasinaJune_Adj,210604_Madagascar_InstitutPasteurDeMadagascar_Toamasina1June,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Toamasina,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-06-01,2020-06-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Test/pop adjusted - bayesian model,82,0.43700000000000006,0.43100000000000005,0.443,True,True,True,,,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-16,2023-08-15,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_ToamasinaJune_unAdj,210604_Madagascar_InstitutPasteurDeMadagascar_Toamasina1June,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Toamasina,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-06-01,2020-06-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Analysis,unadjusted,82,0.39,0.292,0.499,,,,,True,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-16,2024-03-01,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_ToamasinaJuly_Adj,210604_Madagascar_InstitutPasteurDeMadagascar_Toamasina2July,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Toamasina,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-07-01,2020-07-31,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Test/pop adjusted - bayesian model,182,0.512,0.508,0.516,True,True,True,,,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-16,2023-08-15,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_ToamasinaJuly_unAdj,210604_Madagascar_InstitutPasteurDeMadagascar_Toamasina2July,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Toamasina,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-07-01,2020-07-31,Blood donors,All,Adults (18-64 years),18.0,68.0,Analysis,analysis,182,0.434,0.364,0.507,,,,,True,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-16,2024-03-01,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_ToamasinaAugust_Adj,210604_Madagascar_InstitutPasteurDeMadagascar_Toamasina3August,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Toamasina,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-08-01,2020-08-31,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Test/pop adjusted - bayesian model,227,0.49200000000000005,0.489,0.495,True,True,True,,,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-16,2023-08-15,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_ToamasinaAugust_unAdj,210604_Madagascar_InstitutPasteurDeMadagascar_Toamasina3August,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Toamasina,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-08-01,2020-08-31,Blood donors,All,Adults (18-64 years),18.0,68.0,Analysis,unadjusted,227,0.401,0.33899999999999997,0.466,,,,,True,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-16,2024-03-01,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_ToamasinaSeptember_Adj,210604_Madagascar_InstitutPasteurDeMadagascar_Toamasina4September,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Toamasina,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-09-01,2020-09-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Test/pop adjusted - bayesian model,213,0.36200000000000004,0.359,0.365,True,True,True,,,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-16,2023-08-15,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_ToamasinaSeptember_unAdj,210604_Madagascar_InstitutPasteurDeMadagascar_Toamasina4September,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Toamasina,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-09-01,2020-09-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Analysis,unadjusted,213,0.29100000000000004,0.23399999999999999,0.355,,,,,True,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-16,2024-03-01,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_ToamasinaOctober_Adj,210604_Madagascar_InstitutPasteurDeMadagascar_Toamasina5October,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Toamasina,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-10-01,2020-10-31,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Test/pop adjusted - bayesian model,199,0.33,0.326,0.33299999999999996,True,True,True,,,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-16,2023-08-15,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_ToamasinaOctober_unAdj,210604_Madagascar_InstitutPasteurDeMadagascar_Toamasina5October,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Toamasina,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-10-01,2020-10-31,Blood donors,All,Adults (18-64 years),18.0,68.0,Analysis,unadjusted,199,0.261,0.20500000000000002,0.327,,,,,True,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-16,2024-03-01,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_ToamasinaNovember_Adj,210604_Madagascar_InstitutPasteurDeMadagascar_Toamasina6November,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Toamasina,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-11-01,2020-11-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Test/pop adjusted - bayesian model,282,0.233,0.231,0.23500000000000001,True,True,True,,,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-16,2023-08-15,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_ToamasinaNovember_unAdj,210604_Madagascar_InstitutPasteurDeMadagascar_Toamasina6November,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Toamasina,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-11-01,2020-11-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Analysis,unadjusted,282,0.184,0.14300000000000002,0.233,,,,,True,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-16,2024-03-01,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_ToliaraJune_Adj,210604_Madagascar_InstitutPasteurDeMadagascar_Toliara1June,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Toliara,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-06-01,2020-06-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Test/pop adjusted - bayesian model,87,0.0,0.0,0.001,True,True,True,,,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2023-08-15,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_ToliaraJune_unAdj,210604_Madagascar_InstitutPasteurDeMadagascar_Toliara1June,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Toliara,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-06-01,2020-06-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Analysis,unadjusted,87,0.012,0.002,0.062000000000000006,,,,,True,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2024-03-01,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_ToliaraJuly_Adj,210604_Madagascar_InstitutPasteurDeMadagascar_Toliara2July,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Toliara,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-07-01,2020-07-31,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Test/pop adjusted - bayesian model,147,0.0,0.0,0.0,True,True,True,,,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2023-08-15,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_ToliaraJuly_unAdj ,210604_Madagascar_InstitutPasteurDeMadagascar_Toliara2July,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Toliara,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-07-01,2020-07-31,Blood donors,All,Adults (18-64 years),18.0,68.0,Analysis,unadjusted,147,0.006999999999999999,0.001,0.038,,,,,True,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2024-03-01,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_ToliaraAugust_Adj,210604_Madagascar_InstitutPasteurDeMadagascar_Toliara3August,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Toliara,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-08-01,2020-08-31,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Test/pop adjusted - bayesian model,167,0.079,0.077,0.081,True,True,True,,,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2023-08-15,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_ToliaraAugust_unAdj,210604_Madagascar_InstitutPasteurDeMadagascar_Toliara3August,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Toliara,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-08-01,2020-08-31,Blood donors,All,Adults (18-64 years),18.0,68.0,Analysis,unadjusted,167,0.07200000000000001,0.042,0.121,,,,,True,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2024-03-01,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_ToliaraSeptember_Adj,210604_Madagascar_InstitutPasteurDeMadagascar_Toliara4September,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Toliara,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-09-01,2020-09-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Test/pop adjusted - bayesian model,185,0.242,0.239,0.244,True,True,True,,,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2023-08-15,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_ToliaraSeptember_unAdj,210604_Madagascar_InstitutPasteurDeMadagascar_Toliara4September,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Toliara,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-09-01,2020-09-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Analysis,unadjusted,185,0.20500000000000002,0.154,0.269,,,,,True,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2024-03-01,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_ToliaraOctober_Adj,210604_Madagascar_InstitutPasteurDeMadagascar_Toliara5October,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Toliara,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-10-01,2020-10-31,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Test/pop adjusted - bayesian model,139,0.277,0.273,0.28,True,True,True,,,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2023-08-15,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_ToliaraOctober_unAdj,210604_Madagascar_InstitutPasteurDeMadagascar_Toliara5October,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Toliara,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-10-01,2020-10-31,Blood donors,All,Adults (18-64 years),18.0,68.0,Analysis,unadjusted,139,0.223,0.162,0.299,,,,,True,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2024-03-01,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_ToliaraNovember_Adj,210604_Madagascar_InstitutPasteurDeMadagascar_Toliara6November,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Toliara,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-11-01,2020-11-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Test/pop adjusted - bayesian model,199,0.23500000000000001,0.23199999999999998,0.23800000000000002,True,True,True,,,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2023-08-15,Verified,schoenhals_sars-cov-2_2021,MDG
210604_Madagascar_InstitutPasteurDeMadagascar_ToliaraNovember_unAdj,210604_Madagascar_InstitutPasteurDeMadagascar_Toliara6November,SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic.,2021-06-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Madagascar,,Toliara,"Plasma or serum samples were collected in 5 out of 7 Regional Blood Transfusion Centres (RBTCs) of Madagascar for which it was possible to collect samples throughout the epidemic, and despite drastic travel restrictions.","Duplicates, and donors under the age of 18",2020-11-01,2020-11-30,Blood donors,All,Adults (18-64 years),18.0,68.0,Analysis,unadjusted,199,0.18100000000000002,0.134,0.24,,,,,True,Convenience,ID Screen,ID.Vet,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9259999999999999,0.996,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,,Matthieu Schoenhals,Institut Pasteur de Madagascar,Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103419,2021-06-17,2024-03-01,Verified,schoenhals_sars-cov-2_2021,MDG
211001_Antananarivo_InstitutPasteurdeMadagascar_7April2021_AntiRBD,211001_Antananarivo_InstitutPasteurdeMadagascar_April2021,Seroprevalence of ancestral and Beta SARS-CoV-2 antibodies in Malagasy blood donors,2021-09-14,Presentation or Conference,Local,Repeated cross-sectional study,Madagascar,, Antananarivo,Blood donors from the Regional Blood Transfusion Centre in Antananarivo,"NR
",2021-04-01,2021-04-30,Blood donors,All,Adults (18-64 years),18.0,61.0,Primary Estimate,Anti RBD,493,0.584,0.54,0.627,True,,,,True,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,0.9436,['High'],No,No,No,Yes,Unclear,Yes,Yes,No,,Solohery Razafimahatratra,Institut Pasteur de Madagascar,Unity-Aligned,http://dx.doi.org/10.1016/S2214-109X%2821%2900361-2,2021-09-22,2024-03-01,Unverified,razafimahatratra_seroprevalence_2021,MDG
211001_Antananarivo_InstitutPasteurdeMadagascar_7April2021_AntiN,211001_Antananarivo_InstitutPasteurdeMadagascar_April2021,Seroprevalence of ancestral and Beta SARS-CoV-2 antibodies in Malagasy blood donors,2021-09-14,Presentation or Conference,Local,Repeated cross-sectional study,Madagascar,, Antananarivo,Blood donors from the Regional Blood Transfusion Centre in Antananarivo,"NR
",2021-04-01,2021-04-30,Blood donors,All,Adults (18-64 years),18.0,61.0,Test used,Anti N,493,0.292,0.254,0.334,,,,,,Sequential,ID Screen,ID.Vet,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,No,,Solohery Razafimahatratra,Institut Pasteur de Madagascar,Unity-Aligned,http://dx.doi.org/10.1016/S2214-109X%2821%2900361-2,2021-12-09,2024-03-01,Unverified,razafimahatratra_seroprevalence_2021,MDG
211001_Antananarivo_InstitutPasteurdeMadagascar_3December2020,211001_Antananarivo_InstitutPasteurdeMadagascar_December2020,Seroprevalence of ancestral and Beta SARS-CoV-2 antibodies in Malagasy blood donors,2021-09-14,Presentation or Conference,Local,Repeated cross-sectional study,Madagascar,, Antananarivo,Blood donors from the Regional Blood Transfusion Centre in Antananarivo,"NR
",2020-12-01,2020-12-31,Blood donors,All,Adults (18-64 years),18.0,59.0,Primary Estimate,Anti N,177,0.22,0.166,0.287,True,,,,True,Sequential,ID Screen,ID.Vet,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,,Solohery Razafimahatratra,Institut Pasteur de Madagascar,Unity-Aligned,http://dx.doi.org/10.1016/S2214-109X%2821%2900361-2,2021-09-22,2024-03-01,Verified,razafimahatratra_seroprevalence_2021,MDG
211001_Antananarivo_InstitutPasteurdeMadagascar_5February2021_AntiRBD,211001_Antananarivo_InstitutPasteurdeMadagascar_February2021,Seroprevalence of ancestral and Beta SARS-CoV-2 antibodies in Malagasy blood donors,2021-09-14,Presentation or Conference,Local,Repeated cross-sectional study,Madagascar,, Antananarivo,Blood donors from the Regional Blood Transfusion Centre in Antananarivo,"NR
",2021-02-01,2021-02-28,Blood donors,All,Adults (18-64 years),18.0,62.0,Primary Estimate,Anti RBD,319,0.505,0.45,0.559,True,,,,True,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,0.9436,['High'],No,No,No,Yes,Unclear,Yes,Yes,No,,Solohery Razafimahatratra,Institut Pasteur de Madagascar,Unity-Aligned,http://dx.doi.org/10.1016/S2214-109X%2821%2900361-2,2021-09-22,2024-03-01,Unverified,razafimahatratra_seroprevalence_2021,MDG
211001_Antananarivo_InstitutPasteurdeMadagascar_5February2021_AntiN,211001_Antananarivo_InstitutPasteurdeMadagascar_February2021,Seroprevalence of ancestral and Beta SARS-CoV-2 antibodies in Malagasy blood donors,2021-09-14,Presentation or Conference,Local,Repeated cross-sectional study,Madagascar,, Antananarivo,Blood donors from the Regional Blood Transfusion Centre in Antananarivo,"NR
",2021-02-01,2021-02-28,Blood donors,All,Adults (18-64 years),18.0,62.0,Test used,Anti N,319,0.172,0.135,0.218,,,,,,Sequential,ID Screen,ID.Vet,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,No,,Solohery Razafimahatratra,Institut Pasteur de Madagascar,Unity-Aligned,http://dx.doi.org/10.1016/S2214-109X%2821%2900361-2,2021-12-09,2024-03-01,Unverified,razafimahatratra_seroprevalence_2021,MDG
211001_Antananarivo_InstitutPasteurdeMadagascar_4January2021_AntiRBD,211001_Antananarivo_InstitutPasteurdeMadagascar_January2021,Seroprevalence of ancestral and Beta SARS-CoV-2 antibodies in Malagasy blood donors,2021-09-14,Presentation or Conference,Local,Repeated cross-sectional study,Madagascar,, Antananarivo,Blood donors from the Regional Blood Transfusion Centre in Antananarivo,"NR
",2021-01-01,2021-01-31,Blood donors,All,Adults (18-64 years),18.0,62.0,Primary Estimate,Anti RBD,389,0.44700000000000006,0.399,0.49700000000000005,True,,,,True,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,0.9436,['High'],No,No,No,Yes,Unclear,Yes,Yes,No,,Solohery Razafimahatratra,Institut Pasteur de Madagascar,Unity-Aligned,http://dx.doi.org/10.1016/S2214-109X%2821%2900361-2,2021-09-22,2024-03-01,Verified,razafimahatratra_seroprevalence_2021,MDG
211001_Antananarivo_InstitutPasteurdeMadagascar_4January2021_AntiN,211001_Antananarivo_InstitutPasteurdeMadagascar_January2021,Seroprevalence of ancestral and Beta SARS-CoV-2 antibodies in Malagasy blood donors,2021-09-14,Presentation or Conference,Local,Repeated cross-sectional study,Madagascar,, Antananarivo,Blood donors from the Regional Blood Transfusion Centre in Antananarivo,"NR
",2021-01-01,2021-01-31,Blood donors,All,Adults (18-64 years),18.0,62.0,Test used,Anti N,389,0.17,0.136,0.21,,,,,,Sequential,ID Screen,ID.Vet,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,No,,Solohery Razafimahatratra,Institut Pasteur de Madagascar,Unity-Aligned,http://dx.doi.org/10.1016/S2214-109X%2821%2900361-2,2021-12-09,2024-03-01,Verified,razafimahatratra_seroprevalence_2021,MDG
211001_Antananarivo_InstitutPasteurdeMadagascar_6March2021_AntiRBD,211001_Antananarivo_InstitutPasteurdeMadagascar_March2021,Seroprevalence of ancestral and Beta SARS-CoV-2 antibodies in Malagasy blood donors,2021-09-14,Presentation or Conference,Local,Repeated cross-sectional study,Madagascar,, Antananarivo,Blood donors from the Regional Blood Transfusion Centre in Antananarivo,"NR
",2021-03-01,2021-03-31,Blood donors,All,Adults (18-64 years),18.0,61.0,Primary Estimate,Anti RBD,497,0.499,0.455,0.543,True,,,,True,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,0.9436,['High'],No,No,No,Yes,Unclear,Yes,Yes,No,,Solohery Razafimahatratra,Institut Pasteur de Madagascar,Unity-Aligned,http://dx.doi.org/10.1016/S2214-109X%2821%2900361-2,2021-09-21,2024-03-01,Verified,razafimahatratra_seroprevalence_2021,MDG
211001_Antananarivo_InstitutPasteurdeMadagascar_6March2021_AntiN,211001_Antananarivo_InstitutPasteurdeMadagascar_March2021,Seroprevalence of ancestral and Beta SARS-CoV-2 antibodies in Malagasy blood donors,2021-09-14,Presentation or Conference,Local,Repeated cross-sectional study,Madagascar,, Antananarivo,Blood donors from the Regional Blood Transfusion Centre in Antananarivo,"NR
",2021-03-01,2021-03-31,Blood donors,All,Adults (18-64 years),18.0,61.0,Test used,Anti N,497,0.159,0.129,0.19399999999999998,,,,,,Sequential,ID Screen,ID.Vet,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,No,,Solohery Razafimahatratra,Institut Pasteur de Madagascar,Unity-Aligned,http://dx.doi.org/10.1016/S2214-109X%2821%2900361-2,2021-12-09,2024-03-01,Verified,razafimahatratra_seroprevalence_2021,MDG
211001_Antananarivo_InstitutPasteurdeMadagascar_8May2021_AntiRBD,211001_Antananarivo_InstitutPasteurdeMadagascar_May2021,Seroprevalence of ancestral and Beta SARS-CoV-2 antibodies in Malagasy blood donors,2021-09-14,Presentation or Conference,Local,Repeated cross-sectional study,Madagascar,, Antananarivo,Blood donors from the Regional Blood Transfusion Centre in Antananarivo,,2021-05-01,2021-05-26,Blood donors,All,Adults (18-64 years),18.0,68.0,Primary Estimate,Anti RBD,500,0.648,0.561,0.726,True,,,,True,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,0.9436,['High'],No,No,No,Yes,Unclear,Yes,Yes,No,,Solohery Razafimahatratra,Institut Pasteur de Madagascar,Unity-Aligned,http://dx.doi.org/10.1016/S2214-109X%2821%2900361-2,2021-09-21,2024-03-01,Verified,razafimahatratra_seroprevalence_2021,MDG
211001_Antananarivo_InstitutPasteurdeMadagascar_8May2021_AntiN,211001_Antananarivo_InstitutPasteurdeMadagascar_May2021,Seroprevalence of ancestral and Beta SARS-CoV-2 antibodies in Malagasy blood donors,2021-09-14,Presentation or Conference,Local,Repeated cross-sectional study,Madagascar,, Antananarivo,Blood donors from the Regional Blood Transfusion Centre in Antananarivo,,2021-05-01,2021-05-26,Blood donors,All,Adults (18-64 years),18.0,68.0,Test used,Anti N,500,0.47600000000000003,0.433,0.52,,,,,,Sequential,ID Screen,ID.Vet,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,No,,Solohery Razafimahatratra,Institut Pasteur de Madagascar,Unity-Aligned,http://dx.doi.org/10.1016/S2214-109X%2821%2900361-2,2021-12-09,2024-03-01,Verified,razafimahatratra_seroprevalence_2021,MDG
211001_Antananarivo_InstitutPasteurdeMadagascar_2November2020,211001_Antananarivo_InstitutPasteurdeMadagascar_November2020,Seroprevalence of ancestral and Beta SARS-CoV-2 antibodies in Malagasy blood donors,2021-09-14,Presentation or Conference,Local,Repeated cross-sectional study,Madagascar,, Antananarivo,Blood donors from the Regional Blood Transfusion Centre in Antananarivo,"NR
",2020-11-01,2020-11-30,Blood donors,All,Adults (18-64 years),18.0,64.0,Primary Estimate,Anti N,503,0.312,0.273,0.354,True,,,,True,Sequential,ID Screen,ID.Vet,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,,Solohery Razafimahatratra,Institut Pasteur de Madagascar,Unity-Aligned,http://dx.doi.org/10.1016/S2214-109X%2821%2900361-2,2021-09-22,2024-03-01,Verified,razafimahatratra_seroprevalence_2021,MDG
211001_Antananarivo_InstitutPasteurdeMadagascar_1October2020,211001_Antananarivo_InstitutPasteurdeMadagascar_October2020,Seroprevalence of ancestral and Beta SARS-CoV-2 antibodies in Malagasy blood donors,2021-09-14,Presentation or Conference,Local,Repeated cross-sectional study,Madagascar,, Antananarivo,Blood donors from the Regional Blood Transfusion Centre in Antananarivo,"NR
",2020-10-01,2020-10-31,Blood donors,All,Adults (18-64 years),18.0,61.0,Primary Estimate,Anti N,497,0.358,0.317,0.401,True,,,,True,Sequential,ID Screen,ID.Vet,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,,Solohery Razafimahatratra,Institut Pasteur de Madagascar,Unity-Aligned,http://dx.doi.org/10.1016/S2214-109X%2821%2900361-2,2021-09-22,2024-03-01,Verified,razafimahatratra_seroprevalence_2021,MDG
220905_Germany_BernhardNochtInsituteForTropicalMedicine_Madagascar_Adj,220905_Germany_BernhardNochtInsituteForTropicalMedicine_Madagascar,"High seroprevalence of SARS-CoV-2 in Burkina-Faso, Ghana and Madagascar in 2021: a population-based study.",2022-09-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Madagascar,Fianarantsoa,Fianarantsoa,A minimum age of 10 years and a requirement of no existing health problems contraindicating blood sample collection were applied.,Households were excluded from analysis in the case of ID mismatches,2021-02-26,2021-06-18,Household and community samples,All,Multiple groups,10.0,,Primary Estimate,test and pop adjusted,674,0.41500000000000004,0.365,0.49,True,True,True,,,Stratified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Nicole S. Struck,Bernhard Nocht Insitute for Tropical Medicine,Not Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13918-y,2022-09-12,2022-09-12,Unverified,struck_high_2022,MDG
220905_Germany_BernhardNochtInsituteForTropicalMedicine_Madagascar_Crude,220905_Germany_BernhardNochtInsituteForTropicalMedicine_Madagascar,"High seroprevalence of SARS-CoV-2 in Burkina-Faso, Ghana and Madagascar in 2021: a population-based study.",2022-09-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Madagascar,Fianarantsoa,Fianarantsoa,A minimum age of 10 years and a requirement of no existing health problems contraindicating blood sample collection were applied.,Households were excluded from analysis in the case of ID mismatches,2021-02-26,2021-06-18,Household and community samples,All,Multiple groups,10.0,,Analysis,,674,0.375,,,,,,,True,Stratified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Nicole S. Struck,Bernhard Nocht Insitute for Tropical Medicine,Not Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13918-y,2022-09-12,2022-09-12,Unverified,struck_high_2022,MDG
230324_Ifanadiana_InstitutPasteurDeMadagascar_SpikeS2_Primary,230324_Ifanadiana_InstitutPasteurDeMadagascar,Morbidity and mortality burden of COVID-19 in rural Madagascar: results from a longitudinal cohort and nested seroprevalence study,2023-03-24,Preprint,Local,Cross-sectional survey ,Madagascar,Vatovavy,,"We integrated a nested seroprevalence study within a pre-existing longitudinal cohort conducted in a representative sample of 1600 households in Ifanadiana District, Madagascar.

We collected dried blood spots in about 6500 individuals of all ages.

Four waves of data collection have been conducted in 2014, 2016, 2018 and 2021, in which the original 1600 households were revisited. Any missing households (or those that declined to continue) were replaced with others from the same cluster using a predefined random replacement list.","Missing households (or those that declined to continue).

Data were visually inspected for outliers, and 134 individuals who had abnormally high values of antibodies (outside the range of mean + 3 sd) were removed.",2021-04-22,2021-06-20,Household and community samples,All,Multiple groups,0.0,100.0,Primary Estimate,Anti-spike S2,6496,0.438,0.409,0.467,True,,,,True,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Dried Blood,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Andres Garchitorena,Institut Pasteur de Madagascar,Unity-Aligned,http://doi.org/10.1101/2023.03.24.23287674,2023-05-07,2024-04-20,Verified,garchitorena_morbidity_2023,MDG
230324_Ifanadiana_InstitutPasteurDeMadagascar_NP,230324_Ifanadiana_InstitutPasteurDeMadagascar,Morbidity and mortality burden of COVID-19 in rural Madagascar: results from a longitudinal cohort and nested seroprevalence study,2023-03-24,Preprint,Local,Cross-sectional survey ,Madagascar,Vatovavy,,"We integrated a nested seroprevalence study within a pre-existing longitudinal cohort conducted in a representative sample of 1600 households in Ifanadiana District, Madagascar.

We collected dried blood spots in about 6500 individuals of all ages.

Four waves of data collection have been conducted in 2014, 2016, 2018 and 2021, in which the original 1600 households were revisited. Any missing households (or those that declined to continue) were replaced with others from the same cluster using a predefined random replacement list.","Missing households (or those that declined to continue).

Data were visually inspected for outliers, and 134 individuals who had abnormally high values of antibodies (outside the range of mean + 3 sd) were removed.",2021-04-22,2021-06-20,Household and community samples,All,Multiple groups,0.0,100.0,Test used,Anti-nucleocapsid protein (NP) ,6496,0.164,0.141,0.187,,,,,,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Dried Blood,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Andres Garchitorena,Institut Pasteur de Madagascar,Unity-Aligned,http://doi.org/10.1101/2023.03.24.23287674,2023-05-07,2024-04-20,Verified,garchitorena_morbidity_2023,MDG
200805_Blantyre_Malawi-Liverpool-WellcomeTrust_HCW_TestAdj,200805_Blantyre_Malawi-Liverpool-WellcomeTrust,High SARS-CoV-2 seroprevalence in health care workers but relatively low numbers of deaths in urban Malawi,2020-08-05,Preprint,National,Prospective cohort,Malawi,Southern Region Malawi,Blantyre,"Inclusion criteria for the study included being an HCW resident in Blantyre, aged between 18 and 65 years old, and otherwise symptomatic.",The exclusion criterion was withholding consent.,2020-05-22,2020-06-19,Health care workers and caregivers,All,Adults (18-64 years),20.0,64.0,Primary Estimate,Adjusted: test,500,0.12300000000000001,0.08199999999999999,0.165,True,True,,,True,Convenience,Omega diagnostics COVID-19 IgG ELISA,Generic Diagnostics Ltd,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.881,0.932,['High'],Yes,No,No,Yes,Yes,Unclear,Yes,Yes,Unclear,Marah Chibwana,Malawi-Liverpool-Wellcome Trust Clinical Research Programme,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.30.20164970v3.full.pdf,2020-08-08,2023-08-15,Verified,chibwana_high_2020,MWI
211119_Malawi_Malawi-Liverpool-WellcomeTrustClinicalResearchProgramme_Primary,211119_Malawi_Malawi-Liverpool-WellcomeTrustClinicalResearchProgramme,SARS-CoV-2 exposure in Malawian blood donors: an analysis of seroprevalence and variant dynamics between January 2020 and July 2021.,2021-11-19,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Malawi,,,HIV-seronegative individuals aged 15–65 years old who donated with the Malawi Blood Transfusion Service,"Donors meeting
the routine donor ineligibility criteria including age
below 15 or above 65 years; haemoglobin below 12.5 g/
dl; past medical history suggestive of human immunodeficiency virus (HIV), hepatitis, or syphilis; and past or
present history of renal, cardiovascular, central nervous
system, and metabolic disorders were excluded",2020-01-15,2021-07-15,Blood donors,All,Multiple groups,15.0,63.0,Primary Estimate,,5085,0.276,,,True,,,,True,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.97,0.98,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Jonathan Mandolo,Malawi-Liverpool-Wellcome Trust Clinical Research Programme,Unity-Aligned,https://dx.doi.org/10.1186/s12916-021-02187-y,2021-11-30,2024-03-01,Verified,mandolo_sars-cov-2_2021,MWI
211119_Malawi_Malawi-Liverpool-WellcomeTrustClinicalResearchProgramme_Female,211119_Malawi_Malawi-Liverpool-WellcomeTrustClinicalResearchProgramme,SARS-CoV-2 exposure in Malawian blood donors: an analysis of seroprevalence and variant dynamics between January 2020 and July 2021.,2021-11-19,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Malawi,,,HIV-seronegative individuals aged 15–65 years old who donated with the Malawi Blood Transfusion Service,"Donors meeting
the routine donor ineligibility criteria including age
below 15 or above 65 years; haemoglobin below 12.5 g/
dl; past medical history suggestive of human immunodeficiency virus (HIV), hepatitis, or syphilis; and past or
present history of renal, cardiovascular, central nervous
system, and metabolic disorders were excluded",2020-01-15,2021-07-15,Blood donors,Female,Multiple groups,,,Sex/Gender,,1393,0.292,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.97,0.98,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Jonathan Mandolo,Malawi-Liverpool-Wellcome Trust Clinical Research Programme,Unity-Aligned,https://dx.doi.org/10.1186/s12916-021-02187-y,2021-11-30,2024-03-01,Verified,mandolo_sars-cov-2_2021,MWI
211119_Malawi_Malawi-Liverpool-WellcomeTrustClinicalResearchProgramme_30-39,211119_Malawi_Malawi-Liverpool-WellcomeTrustClinicalResearchProgramme,SARS-CoV-2 exposure in Malawian blood donors: an analysis of seroprevalence and variant dynamics between January 2020 and July 2021.,2021-11-19,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Malawi,,,HIV-seronegative individuals aged 15–65 years old who donated with the Malawi Blood Transfusion Service,"Donors meeting
the routine donor ineligibility criteria including age
below 15 or above 65 years; haemoglobin below 12.5 g/
dl; past medical history suggestive of human immunodeficiency virus (HIV), hepatitis, or syphilis; and past or
present history of renal, cardiovascular, central nervous
system, and metabolic disorders were excluded",2020-01-15,2021-07-15,Blood donors,All,Adults (18-64 years),30.0,39.0,Age,30-39,1068,0.266,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.97,0.98,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Jonathan Mandolo,Malawi-Liverpool-Wellcome Trust Clinical Research Programme,Unity-Aligned,https://dx.doi.org/10.1186/s12916-021-02187-y,2021-11-30,2024-03-01,Verified,mandolo_sars-cov-2_2021,MWI
211119_Malawi_Malawi-Liverpool-WellcomeTrustClinicalResearchProgramme_Male,211119_Malawi_Malawi-Liverpool-WellcomeTrustClinicalResearchProgramme,SARS-CoV-2 exposure in Malawian blood donors: an analysis of seroprevalence and variant dynamics between January 2020 and July 2021.,2021-11-19,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Malawi,,,HIV-seronegative individuals aged 15–65 years old who donated with the Malawi Blood Transfusion Service,"Donors meeting
the routine donor ineligibility criteria including age
below 15 or above 65 years; haemoglobin below 12.5 g/
dl; past medical history suggestive of human immunodeficiency virus (HIV), hepatitis, or syphilis; and past or
present history of renal, cardiovascular, central nervous
system, and metabolic disorders were excluded",2020-01-15,2021-07-15,Blood donors,Male,Multiple groups,,,Sex/Gender,,3692,0.269,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.97,0.98,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Jonathan Mandolo,Malawi-Liverpool-Wellcome Trust Clinical Research Programme,Unity-Aligned,https://dx.doi.org/10.1186/s12916-021-02187-y,2021-11-30,2024-03-01,Verified,mandolo_sars-cov-2_2021,MWI
211119_Malawi_Malawi-Liverpool-WellcomeTrustClinicalResearchProgramme_40-49,211119_Malawi_Malawi-Liverpool-WellcomeTrustClinicalResearchProgramme,SARS-CoV-2 exposure in Malawian blood donors: an analysis of seroprevalence and variant dynamics between January 2020 and July 2021.,2021-11-19,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Malawi,,,HIV-seronegative individuals aged 15–65 years old who donated with the Malawi Blood Transfusion Service,"Donors meeting
the routine donor ineligibility criteria including age
below 15 or above 65 years; haemoglobin below 12.5 g/
dl; past medical history suggestive of human immunodeficiency virus (HIV), hepatitis, or syphilis; and past or
present history of renal, cardiovascular, central nervous
system, and metabolic disorders were excluded",2020-01-15,2021-07-15,Blood donors,All,Adults (18-64 years),40.0,49.0,Age,40-49,596,0.258,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.97,0.98,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Jonathan Mandolo,Malawi-Liverpool-Wellcome Trust Clinical Research Programme,Unity-Aligned,https://dx.doi.org/10.1186/s12916-021-02187-y,2021-11-30,2024-03-01,Verified,mandolo_sars-cov-2_2021,MWI
211119_Malawi_Malawi-Liverpool-WellcomeTrustClinicalResearchProgramme_15-19,211119_Malawi_Malawi-Liverpool-WellcomeTrustClinicalResearchProgramme,SARS-CoV-2 exposure in Malawian blood donors: an analysis of seroprevalence and variant dynamics between January 2020 and July 2021.,2021-11-19,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Malawi,,,HIV-seronegative individuals aged 15–65 years old who donated with the Malawi Blood Transfusion Service,"Donors meeting
the routine donor ineligibility criteria including age
below 15 or above 65 years; haemoglobin below 12.5 g/
dl; past medical history suggestive of human immunodeficiency virus (HIV), hepatitis, or syphilis; and past or
present history of renal, cardiovascular, central nervous
system, and metabolic disorders were excluded",2020-01-15,2021-07-15,Blood donors,All,Multiple groups,15.0,19.0,Age,15-19,912,0.29100000000000004,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.97,0.98,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Jonathan Mandolo,Malawi-Liverpool-Wellcome Trust Clinical Research Programme,Unity-Aligned,https://dx.doi.org/10.1186/s12916-021-02187-y,2021-11-30,2024-03-01,Verified,mandolo_sars-cov-2_2021,MWI
211119_Malawi_Malawi-Liverpool-WellcomeTrustClinicalResearchProgramme_50+,211119_Malawi_Malawi-Liverpool-WellcomeTrustClinicalResearchProgramme,SARS-CoV-2 exposure in Malawian blood donors: an analysis of seroprevalence and variant dynamics between January 2020 and July 2021.,2021-11-19,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Malawi,,,HIV-seronegative individuals aged 15–65 years old who donated with the Malawi Blood Transfusion Service,"Donors meeting
the routine donor ineligibility criteria including age
below 15 or above 65 years; haemoglobin below 12.5 g/
dl; past medical history suggestive of human immunodeficiency virus (HIV), hepatitis, or syphilis; and past or
present history of renal, cardiovascular, central nervous
system, and metabolic disorders were excluded",2020-01-15,2021-07-15,Blood donors,All,Adults (18-64 years),50.0,63.0,Age,50+,44,0.318,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.97,0.98,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Jonathan Mandolo,Malawi-Liverpool-Wellcome Trust Clinical Research Programme,Unity-Aligned,https://dx.doi.org/10.1186/s12916-021-02187-y,2021-11-30,2024-03-01,Verified,mandolo_sars-cov-2_2021,MWI
211119_Malawi_Malawi-Liverpool-WellcomeTrustClinicalResearchProgramme_20-29,211119_Malawi_Malawi-Liverpool-WellcomeTrustClinicalResearchProgramme,SARS-CoV-2 exposure in Malawian blood donors: an analysis of seroprevalence and variant dynamics between January 2020 and July 2021.,2021-11-19,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Malawi,,,HIV-seronegative individuals aged 15–65 years old who donated with the Malawi Blood Transfusion Service,"Donors meeting
the routine donor ineligibility criteria including age
below 15 or above 65 years; haemoglobin below 12.5 g/
dl; past medical history suggestive of human immunodeficiency virus (HIV), hepatitis, or syphilis; and past or
present history of renal, cardiovascular, central nervous
system, and metabolic disorders were excluded",2020-01-15,2021-07-15,Blood donors,All,Adults (18-64 years),20.0,29.0,Age,20-29,2465,0.277,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.97,0.98,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Jonathan Mandolo,Malawi-Liverpool-Wellcome Trust Clinical Research Programme,Unity-Aligned,https://dx.doi.org/10.1186/s12916-021-02187-y,2021-11-30,2024-03-01,Verified,mandolo_sars-cov-2_2021,MWI
211217_Lilongwe_UniversitatsmedizinBerlin,211217_Lilongwe_UniversitatsmedizinBerlin,SARS-CoV-2 prevalence and immunity: a hospital-based study from Malawi.,2021-12-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Malawi,Central Region,Lilongwe,"The study population included participants working or presenting at the facility. HCWs were defined as health care professionals, allied health workers and administration; non-HCWs were defined as patients, guardians, and relatives. Participants were selected through convenience sampling, aiming at an equal distribution of HCWs and non-HCWs.",Participants under 18 years and those who presented with contraindications to venipuncture or unwilling or unable to consent were excluded.,2020-08-24,2020-09-03,Multiple populations,All,Multiple groups,18.0,,Primary Estimate,,914,0.0799,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit","EUROIMMUN,GenScript",ELISA,Serum,"['IgG', 'Neutralizing']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,No,,No,Yes,No,,C Meinus,University of Malawi ,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.12.336,2022-01-12,2024-03-01,Unverified,meinus_sars-cov-2_2021,MWI
220803_Mzuzu_MzuzuUniversity,220803_Mzuzu_MzuzuUniversity,"Prevalence of Immunoglobulin (G (IgG) and M (IgM)) Against SARS-COV-2 and risk factors for positivity among Students at tertiary education institution, Malawi",2022-08-03,Preprint,Local,Cross-sectional survey ,Malawi,,Mzuzu,This pilot study was conducted to determine the SARS-CoV-2 Seroprevalence among students of Mzuzu University,"We excluded vaccinated, those with known and confirmed SARS CoV-2, refused to participate,
history of hospitalization, known to be on quarantine for being suspected to have been exposed to the
known Covid-19 patients",2022-03-01,2022-03-31,Students and Daycares,All,Multiple groups,,,Primary Estimate,,166,0.78,,,True,,,,True,Convenience,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9620000000000001,1.0,['High'],,No,No,Yes,,No,Yes,Yes,,Saul Eric Mwale,Mzuzu University,Not Unity-Aligned,https://assets.researchsquare.com/files/rs-1870665/v1/bacd0fb8-f35a-4ab7-a0a6-5671b4c46db8.pdf?c=1659971385,2022-08-25,2024-03-01,Unverified,saul_eric_mwale_prevalence_2022,MWI
220823_Malawi_PublicHealthInstituteofMalawi_TestAdj,220823_Malawi_PublicHealthInstituteofMalawi,"Omicron B.1.1.529 variant infections associated with severe disease are uncommon in a COVID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi",2022-08-23,Preprint,National,Cross-sectional survey ,Malawi,,,"Inclusion criteria included being aged ≥5 years, residing in the sampled household, providing informed written consent (or consent from parent/guardian and assent if aged 12 to 17 years), willing to provide the required samples, and having no recent history of nose bleeding.",,2021-12-27,2022-01-17,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,,4619,0.865,0.833,0.892,True,True,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Not reported/ Unable to specify","Beijing Wantai Biological,NA",ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.94,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Upendo Mseka,Public Health Institute of Malawi,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.08.22.22279060v1,2022-08-30,2024-04-09,Verified,mseka_omicron_2022,MWI
220823_Malawi_PublicHealthInstituteofMalawi_Dedza,220823_Malawi_PublicHealthInstituteofMalawi,"Omicron B.1.1.529 variant infections associated with severe disease are uncommon in a COVID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi",2022-08-23,Preprint,Local,Cross-sectional survey ,Malawi,,,"Inclusion criteria included being aged ≥5 years, residing in the sampled household, providing informed written consent (or consent from parent/guardian and assent if aged 12 to 17 years), willing to provide the required samples, and having no recent history of nose bleeding.",,2021-12-27,2022-01-17,Household and community samples,All,Multiple groups,,,Geographical area,Dedza,527,0.77,0.7320000000000001,0.8059999999999999,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Not reported/ Unable to specify","Beijing Wantai Biological,NA",ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.94,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Upendo Mseka,Public Health Institute of Malawi,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.08.22.22279060v1,2022-08-30,2024-04-09,Verified,mseka_omicron_2022,MWI
220823_Malawi_PublicHealthInstituteofMalawi_Unvaccinated,220823_Malawi_PublicHealthInstituteofMalawi,"Omicron B.1.1.529 variant infections associated with severe disease are uncommon in a COVID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi",2022-08-23,Preprint,National,Cross-sectional survey ,Malawi,,,"Inclusion criteria included being aged ≥5 years, residing in the sampled household, providing informed written consent (or consent from parent/guardian and assent if aged 12 to 17 years), willing to provide the required samples, and having no recent history of nose bleeding.",,2021-12-27,2022-01-17,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,Unvaccinated,3606,0.774,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Not reported/ Unable to specify","Beijing Wantai Biological,NA",ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.94,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Upendo Mseka,Public Health Institute of Malawi,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.08.22.22279060v1,2022-08-30,2024-04-09,Verified,mseka_omicron_2022,MWI
220823_Malawi_PublicHealthInstituteofMalawi_>50,220823_Malawi_PublicHealthInstituteofMalawi,"Omicron B.1.1.529 variant infections associated with severe disease are uncommon in a COVID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi",2022-08-23,Preprint,National,Cross-sectional survey ,Malawi,,,"Inclusion criteria included being aged ≥5 years, residing in the sampled household, providing informed written consent (or consent from parent/guardian and assent if aged 12 to 17 years), willing to provide the required samples, and having no recent history of nose bleeding.",,2021-12-27,2022-01-17,Household and community samples,All,Multiple groups,51.0,,Age,>50,1043,0.812,0.787,0.835,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Not reported/ Unable to specify","Beijing Wantai Biological,NA",ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.94,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Upendo Mseka,Public Health Institute of Malawi,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.08.22.22279060v1,2022-08-30,2024-04-09,Verified,mseka_omicron_2022,MWI
220823_Malawi_PublicHealthInstituteofMalawi_Male,220823_Malawi_PublicHealthInstituteofMalawi,"Omicron B.1.1.529 variant infections associated with severe disease are uncommon in a COVID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi",2022-08-23,Preprint,National,Cross-sectional survey ,Malawi,,,"Inclusion criteria included being aged ≥5 years, residing in the sampled household, providing informed written consent (or consent from parent/guardian and assent if aged 12 to 17 years), willing to provide the required samples, and having no recent history of nose bleeding.",,2021-12-27,2022-01-17,Household and community samples,Male,Multiple groups,,,Sex/Gender,Male,2002,0.7759999999999999,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Not reported/ Unable to specify","Beijing Wantai Biological,NA",ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.94,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Upendo Mseka,Public Health Institute of Malawi,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.08.22.22279060v1,2022-08-30,2024-04-09,Verified,mseka_omicron_2022,MWI
220823_Malawi_PublicHealthInstituteofMalawi_18-50,220823_Malawi_PublicHealthInstituteofMalawi,"Omicron B.1.1.529 variant infections associated with severe disease are uncommon in a COVID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi",2022-08-23,Preprint,National,Cross-sectional survey ,Malawi,,,"Inclusion criteria included being aged ≥5 years, residing in the sampled household, providing informed written consent (or consent from parent/guardian and assent if aged 12 to 17 years), willing to provide the required samples, and having no recent history of nose bleeding.",,2021-12-27,2022-01-17,Household and community samples,All,Adults (18-64 years),18.0,50.0,Age,18-50,2750,0.8220000000000001,0.807,0.836,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Not reported/ Unable to specify","Beijing Wantai Biological,NA",ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.94,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Upendo Mseka,Public Health Institute of Malawi,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.08.22.22279060v1,2022-08-30,2024-04-09,Verified,mseka_omicron_2022,MWI
220823_Malawi_PublicHealthInstituteofMalawi_Kasungu,220823_Malawi_PublicHealthInstituteofMalawi,"Omicron B.1.1.529 variant infections associated with severe disease are uncommon in a COVID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi",2022-08-23,Preprint,Local,Cross-sectional survey ,Malawi,,,"Inclusion criteria included being aged ≥5 years, residing in the sampled household, providing informed written consent (or consent from parent/guardian and assent if aged 12 to 17 years), willing to provide the required samples, and having no recent history of nose bleeding.",,2021-12-27,2022-01-17,Household and community samples,All,Multiple groups,,,Geographical area,Kasungu,645,0.753,0.718,0.7859999999999999,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Not reported/ Unable to specify","Beijing Wantai Biological,NA",ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.94,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Upendo Mseka,Public Health Institute of Malawi,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.08.22.22279060v1,2022-08-30,2024-04-09,Verified,mseka_omicron_2022,MWI
220823_Malawi_PublicHealthInstituteofMalawi_Dowa,220823_Malawi_PublicHealthInstituteofMalawi,"Omicron B.1.1.529 variant infections associated with severe disease are uncommon in a COVID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi",2022-08-23,Preprint,Local,Cross-sectional survey ,Malawi,,,"Inclusion criteria included being aged ≥5 years, residing in the sampled household, providing informed written consent (or consent from parent/guardian and assent if aged 12 to 17 years), willing to provide the required samples, and having no recent history of nose bleeding.",,2021-12-27,2022-01-17,Household and community samples,All,Multiple groups,,,Geographical area,Dowa,441,0.757,0.757,0.797,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Not reported/ Unable to specify","Beijing Wantai Biological,NA",ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.94,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Upendo Mseka,Public Health Institute of Malawi,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.08.22.22279060v1,2022-08-30,2024-04-09,Verified,mseka_omicron_2022,MWI
220823_Malawi_PublicHealthInstituteofMalawi_Vaccinated2Doses,220823_Malawi_PublicHealthInstituteofMalawi,"Omicron B.1.1.529 variant infections associated with severe disease are uncommon in a COVID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi",2022-08-23,Preprint,National,Cross-sectional survey ,Malawi,,,"Inclusion criteria included being aged ≥5 years, residing in the sampled household, providing informed written consent (or consent from parent/guardian and assent if aged 12 to 17 years), willing to provide the required samples, and having no recent history of nose bleeding.",,2021-12-27,2022-01-17,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,Vaccinated 2 Doses,492,0.965,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Not reported/ Unable to specify","Beijing Wantai Biological,NA",ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.94,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Upendo Mseka,Public Health Institute of Malawi,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.08.22.22279060v1,2022-08-30,2024-04-09,Verified,mseka_omicron_2022,MWI
220823_Malawi_PublicHealthInstituteofMalawi_Lilongwe,220823_Malawi_PublicHealthInstituteofMalawi,"Omicron B.1.1.529 variant infections associated with severe disease are uncommon in a COVID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi",2022-08-23,Preprint,Local,Cross-sectional survey ,Malawi,,,"Inclusion criteria included being aged ≥5 years, residing in the sampled household, providing informed written consent (or consent from parent/guardian and assent if aged 12 to 17 years), willing to provide the required samples, and having no recent history of nose bleeding.",,2021-12-27,2022-01-17,Household and community samples,All,Multiple groups,,,Geographical area,Lilongwe,1327,0.853,0.833,0.872,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Not reported/ Unable to specify","Beijing Wantai Biological,NA",ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.94,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Upendo Mseka,Public Health Institute of Malawi,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.08.22.22279060v1,2022-08-30,2024-04-09,Verified,mseka_omicron_2022,MWI
220823_Malawi_PublicHealthInstituteofMalawi_Machinga,220823_Malawi_PublicHealthInstituteofMalawi,"Omicron B.1.1.529 variant infections associated with severe disease are uncommon in a COVID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi",2022-08-23,Preprint,Local,Cross-sectional survey ,Malawi,,,"Inclusion criteria included being aged ≥5 years, residing in the sampled household, providing informed written consent (or consent from parent/guardian and assent if aged 12 to 17 years), willing to provide the required samples, and having no recent history of nose bleeding.",,2021-12-27,2022-01-17,Household and community samples,All,Multiple groups,,,Geographical area,Machinga,477,0.797,0.758,0.8320000000000001,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Not reported/ Unable to specify","Beijing Wantai Biological,NA",ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.94,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Upendo Mseka,Public Health Institute of Malawi,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.08.22.22279060v1,2022-08-30,2024-04-09,Verified,mseka_omicron_2022,MWI
220823_Malawi_PublicHealthInstituteofMalawi_13-17,220823_Malawi_PublicHealthInstituteofMalawi,"Omicron B.1.1.529 variant infections associated with severe disease are uncommon in a COVID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi",2022-08-23,Preprint,National,Cross-sectional survey ,Malawi,,,"Inclusion criteria included being aged ≥5 years, residing in the sampled household, providing informed written consent (or consent from parent/guardian and assent if aged 12 to 17 years), willing to provide the required samples, and having no recent history of nose bleeding.",,2021-12-27,2022-01-17,Household and community samples,All,Children and Youth (0-17 years),13.0,17.0,Age,13-17,230,0.778,0.7190000000000001,0.8300000000000001,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Not reported/ Unable to specify","Beijing Wantai Biological,NA",ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.94,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Upendo Mseka,Public Health Institute of Malawi,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.08.22.22279060v1,2022-08-30,2024-04-09,Verified,mseka_omicron_2022,MWI
220823_Malawi_PublicHealthInstituteofMalawi_Blantyre,220823_Malawi_PublicHealthInstituteofMalawi,"Omicron B.1.1.529 variant infections associated with severe disease are uncommon in a COVID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi",2022-08-23,Preprint,Local,Cross-sectional survey ,Malawi,,,"Inclusion criteria included being aged ≥5 years, residing in the sampled household, providing informed written consent (or consent from parent/guardian and assent if aged 12 to 17 years), willing to provide the required samples, and having no recent history of nose bleeding.",,2021-12-27,2022-01-17,Household and community samples,All,Multiple groups,,,Geographical area,Blantyre,768,0.883,0.858,0.905,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Not reported/ Unable to specify","Beijing Wantai Biological,NA",ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.94,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Upendo Mseka,Public Health Institute of Malawi,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.08.22.22279060v1,2022-08-30,2024-04-09,Verified,mseka_omicron_2022,MWI
220823_Malawi_PublicHealthInstituteofMalawi_Unadj,220823_Malawi_PublicHealthInstituteofMalawi,"Omicron B.1.1.529 variant infections associated with severe disease are uncommon in a COVID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi",2022-08-23,Preprint,National,Cross-sectional survey ,Malawi,,,"Inclusion criteria included being aged ≥5 years, residing in the sampled household, providing informed written consent (or consent from parent/guardian and assent if aged 12 to 17 years), willing to provide the required samples, and having no recent history of nose bleeding.",,2021-12-27,2022-01-17,Household and community samples,All,Multiple groups,5.0,,Analysis,,4619,0.813,0.8009999999999999,0.8240000000000001,,,,,True,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Not reported/ Unable to specify","Beijing Wantai Biological,NA",ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.94,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Upendo Mseka,Public Health Institute of Malawi,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.08.22.22279060v1,2022-08-30,2024-04-09,Verified,mseka_omicron_2022,MWI
220823_Malawi_PublicHealthInstituteofMalawi_Zomba,220823_Malawi_PublicHealthInstituteofMalawi,"Omicron B.1.1.529 variant infections associated with severe disease are uncommon in a COVID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi",2022-08-23,Preprint,Local,Cross-sectional survey ,Malawi,,,"Inclusion criteria included being aged ≥5 years, residing in the sampled household, providing informed written consent (or consent from parent/guardian and assent if aged 12 to 17 years), willing to provide the required samples, and having no recent history of nose bleeding.",,2021-12-27,2022-01-17,Household and community samples,All,Multiple groups,,,Geographical area,Zomba,434,0.779,0.737,0.8170000000000001,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Not reported/ Unable to specify","Beijing Wantai Biological,NA",ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.94,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Upendo Mseka,Public Health Institute of Malawi,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.08.22.22279060v1,2022-08-30,2024-04-09,Verified,mseka_omicron_2022,MWI
220823_Malawi_PublicHealthInstituteofMalawi_Female,220823_Malawi_PublicHealthInstituteofMalawi,"Omicron B.1.1.529 variant infections associated with severe disease are uncommon in a COVID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi",2022-08-23,Preprint,National,Cross-sectional survey ,Malawi,,,"Inclusion criteria included being aged ≥5 years, residing in the sampled household, providing informed written consent (or consent from parent/guardian and assent if aged 12 to 17 years), willing to provide the required samples, and having no recent history of nose bleeding.",,2021-12-27,2022-01-17,Household and community samples,Female,Multiple groups,,,Sex/Gender,Female,2617,0.841,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Not reported/ Unable to specify","Beijing Wantai Biological,NA",ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.94,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Upendo Mseka,Public Health Institute of Malawi,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.08.22.22279060v1,2022-08-30,2024-04-09,Verified,mseka_omicron_2022,MWI
220823_Malawi_PublicHealthInstituteofMalawi_<13,220823_Malawi_PublicHealthInstituteofMalawi,"Omicron B.1.1.529 variant infections associated with severe disease are uncommon in a COVID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi",2022-08-23,Preprint,National,Cross-sectional survey ,Malawi,,,"Inclusion criteria included being aged ≥5 years, residing in the sampled household, providing informed written consent (or consent from parent/guardian and assent if aged 12 to 17 years), willing to provide the required samples, and having no recent history of nose bleeding.",,2021-12-27,2022-01-17,Household and community samples,All,Multiple groups,14.0,,Age,>13,188,0.663,0.5910000000000001,0.73,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Not reported/ Unable to specify","Beijing Wantai Biological,NA",ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.94,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Upendo Mseka,Public Health Institute of Malawi,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.08.22.22279060v1,2022-08-30,2024-04-09,Verified,mseka_omicron_2022,MWI
220823_Malawi_PublicHealthInstituteofMalawi_Vaccinated1Dose,220823_Malawi_PublicHealthInstituteofMalawi,"Omicron B.1.1.529 variant infections associated with severe disease are uncommon in a COVID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi",2022-08-23,Preprint,National,Cross-sectional survey ,Malawi,,,"Inclusion criteria included being aged ≥5 years, residing in the sampled household, providing informed written consent (or consent from parent/guardian and assent if aged 12 to 17 years), willing to provide the required samples, and having no recent history of nose bleeding.",,2021-12-27,2022-01-17,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,Vaccinated 1 Dose,521,0.9390000000000001,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Not reported/ Unable to specify","Beijing Wantai Biological,NA",ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.94,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Upendo Mseka,Public Health Institute of Malawi,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.08.22.22279060v1,2022-08-30,2024-04-09,Verified,mseka_omicron_2022,MWI
220916_Blantyre_IstitutoSuperioreDiSanita_2020Feb-2021May_Overall,220916_Blantyre_IstitutoSuperioreDiSanita,Dynamics of SARS-CoV-2 exposure in Malawian infants between February 2020 and May 2021.,2022-09-16,Journal Article (Peer-Reviewed),Local,Prospective cohort,Malawi,,Blantyre,"""we present data from Malawian infants (from 6 weeks of age to 12 months), whose blood was collected between February 2020 and May 2021, during a longitudinal study aimed to define the health status of HIV-exposed and -unexposed infants.""

""The two cohorts of HIV-infected mothers and their infants (HIV-exposed uninfected, HEU) and HIV-negative women with their unexposed infants (HIV-unexposed uninfected, HUU) were followed with monthly visits from delivery until 12 months postpartum. All women (> 18 years of age) were enrolled during pregnancy, between 32 and 36 weeks of gestation, at three different antenatal Clinics: an urban site in Mandala, and two semi-urban sites in Chileka, and Machinjiri, all in the Blantyre area.""",,2020-02-01,2021-05-15,Perinatal,All,Children and Youth (0-17 years),0.0,1.0,Primary Estimate,Feb 2020 - May 2021,158,0.31,0.237,0.383,True,,,,True,Convenience,"Human Anti-IgG/A/M SARS-CoV-2 ELISA,COVID-SeroKlir, Kantaro Semi-Quantitative SARS-CoV-2 IgG Antibody Kit","The Binding Site,Kantaro Biosciences LLC",ELISA,Multiple Types,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],,No,No,Yes,,Unclear,Yes,No,,Silvia Baroncelli,Istituto Superiore di Sanità,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcvp.2022.100110,2022-09-28,2024-03-01,Unverified,baroncelli_dynamics_2022,MWI
221017_Malawi_USCDC_Community1,221017_Malawi_USCDC_Community1,"SARS-CoV-2 Prevalence in Malawi Based on Data from Survey of Communities and Health Workers in 5 High-Burden Districts, October 2020",2022-10-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Malawi,,,Survey of Communities and Health Workers,,2020-10-14,2020-12-08,Household and community samples,All,Multiple groups,,,Primary Estimate,,4261,0.078,0.063,0.096,True,,True,,True,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9670000000000001,0.975,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Joe Alex Theu,United States Centres for Disease Control,Unity-Aligned,https://dx.doi.org/10.3201/eid2813.212348,2022-12-22,2024-03-01,Unverified,theu_sars-cov-2_2022,MWI
221017_Malawi_USCDC_HCW2,221017_Malawi_USCDC_HCW2,"SARS-CoV-2 Prevalence in Malawi Based on Data from Survey of Communities and Health Workers in 5 High-Burden Districts, October 2020",2022-10-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Malawi,,,Survey of Communities and Health Workers,,2020-10-14,2020-12-08,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,970,0.09699999999999999,0.064,0.145,True,,True,,True,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.9670000000000001,0.975,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Joe Alex Theu,United States Centres for Disease Control,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2813.212348,2023-01-12,2024-03-01,Unverified,theu_sars-cov-2_2022,MWI
230706_Karonga_MalawiEpidemiologyAndInterventionResearchUnit_Survey1_PopAdj,230706_Karonga_MalawiEpidemiologyAndInterventionResearchUnit_Survey1,Characterising The Evolving SARS-CoV-2 Seroprevalence In Urban and Rural Malawi between February 2021 and April 2022: A Population-Based Cohort Study,2023-07-06,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Malawi,Northern Region,Karonga,"We conducted a prospective cohort study on randomly selected households from population-based cohorts operated by the Malawi Epidemiology and Intervention Research Unit (MEIRU): rural (Karonga Health and Demographic Surveillance Site (HDSS), Northern Region; population 51,000) and urban (Area 25, Lilongwe, Central Region; population 75,000) (Supplementary Figure 2).

Inclusion of participants of all ages ...",,2021-02-24,2021-06-08,Household and community samples,All,Multiple groups,,,Primary Estimate,Population-weighted,1005,0.263,0.207,0.321,True,,True,,True,Simplified probability,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.865,0.988,['Low'],,Yes,Yes,Yes,,Yes,Yes,No,,Louis Banda,Malawi Epidemiology and Intervention Research Unit,Unity-Aligned,https://dx.doi.org/10.2139/ssrn.4498429,2023-08-01,2024-03-01,Unverified,banda_characterising_2023,MWI
230706_Lilongwe_MalawiEpidemiologyAndInterventionResearchUnit_Survey1_PopAdj,230706_Lilongwe_MalawiEpidemiologyAndInterventionResearchUnit_Survey1,Characterising The Evolving SARS-CoV-2 Seroprevalence In Urban and Rural Malawi between February 2021 and April 2022: A Population-Based Cohort Study,2023-07-06,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Malawi,Central Region,Lilongwe,"We conducted a prospective cohort study on randomly selected households from population-based cohorts operated by the Malawi Epidemiology and Intervention Research Unit (MEIRU): rural (Karonga Health and Demographic Surveillance Site (HDSS), Northern Region; population 51,000) and urban (Area 25, Lilongwe, Central Region; population 75,000) (Supplementary Figure 2).

Inclusion of participants of all ages ...",,2021-02-24,2021-06-08,Household and community samples,All,Multiple groups,,,Primary Estimate,Population-weighted,1000,0.464,0.402,0.53,True,,True,,True,Simplified probability,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.865,0.988,['Low'],,Yes,Yes,Yes,,Yes,Yes,No,,Louis Banda,Malawi Epidemiology and Intervention Research Unit,Unity-Aligned,https://dx.doi.org/10.2139/ssrn.4498429,2023-08-01,2024-03-01,Unverified,banda_characterising_2023,MWI
20231028_Karonga_MalawiEpidemiologyInterventionResearchUnit_Survey1_Overall_PopAdj,20231028_Karonga_MalawiEpidemiologyInterventionResearchUnit_Survey1,Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study,2023-10-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Malawi,,Karonga,Informed consent,"NR
",2021-02-01,2022-04-01,Household and community samples,All,Multiple groups,,,Primary Estimate,,1001,0.263,0.207,0.321,True,True,True,,True,Stratified probability,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Serum,IgG,Spike,Validated by manufacturers,0.865,0.988,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Louis Banda,Malawi Epidemiology and Intervention Research Unit (MEIRU),Unity-Aligned,https://doi.org/10.1016/j.ijid.2023.10.020,2024-01-29,2024-02-01,Unverified,banda_characterising_2023,MWI
20231028_Karonga_MalawiEpidemiologyInterventionResearchUnit_Survey1_30plus_PopAdj,20231028_Karonga_MalawiEpidemiologyInterventionResearchUnit_Survey1,Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study,2023-10-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Malawi,,Karonga,Informed consent,"NR
",2021-02-01,2022-04-01,Household and community samples,All,Multiple groups,30.0,,Age,,348,0.36,0.316,0.401,True,True,True,,,Stratified probability,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Serum,IgG,Spike,Validated by manufacturers,0.865,0.988,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Louis Banda,Malawi Epidemiology and Intervention Research Unit (MEIRU),Unity-Aligned,https://doi.org/10.1016/j.ijid.2023.10.020,2024-01-29,2024-02-01,Unverified,banda_characterising_2023,MWI
20231028_Karonga_MalawiEpidemiologyInterventionResearchUnit_Survey1_Lessthan15_PopAdj,20231028_Karonga_MalawiEpidemiologyInterventionResearchUnit_Survey1,Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study,2023-10-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Malawi,,Karonga,Informed consent,"NR
",2021-02-01,2022-04-01,Household and community samples,All,Children and Youth (0-17 years),,15.0,Age,,372,0.141,0.088,0.204,True,True,True,,,Stratified probability,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Serum,IgG,Spike,Validated by manufacturers,0.865,0.988,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Louis Banda,Malawi Epidemiology and Intervention Research Unit (MEIRU),Unity-Aligned,https://doi.org/10.1016/j.ijid.2023.10.020,2024-01-29,2024-02-01,Unverified,banda_characterising_2023,MWI
20231028_Karonga_MalawiEpidemiologyInterventionResearchUnit_Survey1_30plus_PopUnAdj,20231028_Karonga_MalawiEpidemiologyInterventionResearchUnit_Survey1,Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study,2023-10-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Malawi,,Karonga,Informed consent,"NR
",2021-02-01,2022-04-01,Household and community samples,All,Multiple groups,30.0,,Age,,348,0.417,0.364,0.47,,True,,,,Stratified probability,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Serum,IgG,Spike,Validated by manufacturers,0.865,0.988,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Louis Banda,Malawi Epidemiology and Intervention Research Unit (MEIRU),Unity-Aligned,https://doi.org/10.1016/j.ijid.2023.10.020,2024-01-30,2024-02-01,Unverified,banda_characterising_2023,MWI
20231028_Karonga_MalawiEpidemiologyInterventionResearchUnit_Survey1_Overall_PopUnAdj,20231028_Karonga_MalawiEpidemiologyInterventionResearchUnit_Survey1,Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study,2023-10-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Malawi,,Karonga,Informed consent,"NR
",2021-02-01,2022-04-01,Household and community samples,All,Multiple groups,,,Age,,1001,0.336,0.306,0.366,,True,,,,Stratified probability,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Serum,IgG,Spike,Validated by manufacturers,0.865,0.988,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Louis Banda,Malawi Epidemiology and Intervention Research Unit (MEIRU),Unity-Aligned,https://doi.org/10.1016/j.ijid.2023.10.020,2024-01-30,2024-02-01,Unverified,banda_characterising_2023,MWI
20231028_Karonga_MalawiEpidemiologyInterventionResearchUnit_Survey1_15to29_PopAdj,20231028_Karonga_MalawiEpidemiologyInterventionResearchUnit_Survey1,Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study,2023-10-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Malawi,,Karonga,Informed consent,"NR
",2021-02-01,2022-04-01,Household and community samples,All,Multiple groups,15.0,29.0,Age,,281,0.358,0.254,0.46,,True,True,,,Stratified probability,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Serum,IgG,Spike,Validated by manufacturers,0.865,0.988,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Louis Banda,Malawi Epidemiology and Intervention Research Unit (MEIRU),Unity-Aligned,https://doi.org/10.1016/j.ijid.2023.10.020,2024-01-29,2024-02-01,Unverified,banda_characterising_2023,MWI
20231028_Karonga_MalawiEpidemiologyInterventionResearchUnit_Survey1_Lessthan15_PopUnAdj,20231028_Karonga_MalawiEpidemiologyInterventionResearchUnit_Survey1,Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study,2023-10-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Malawi,,Karonga,Informed consent,"NR
",2021-02-01,2022-04-01,Household and community samples,All,Children and Youth (0-17 years),,15.0,Age,,372,0.202,0.162,0.246,,True,,,,Stratified probability,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Serum,IgG,Spike,Validated by manufacturers,0.865,0.988,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Louis Banda,Malawi Epidemiology and Intervention Research Unit (MEIRU),Unity-Aligned,https://doi.org/10.1016/j.ijid.2023.10.020,2024-01-30,2024-02-01,Unverified,banda_characterising_2023,MWI
20231028_Karonga_MalawiEpidemiologyInterventionResearchUnit_Survey1_15to29_PopUnAdj,20231028_Karonga_MalawiEpidemiologyInterventionResearchUnit_Survey1,Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study,2023-10-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Malawi,,Karonga,Informed consent,"NR
",2021-02-01,2022-04-01,Household and community samples,All,Multiple groups,15.0,29.0,Age,,281,0.413,0.354,0.473,,True,,,,Stratified probability,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Serum,IgG,Spike,Validated by manufacturers,0.865,0.988,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Louis Banda,Malawi Epidemiology and Intervention Research Unit (MEIRU),Unity-Aligned,https://doi.org/10.1016/j.ijid.2023.10.020,2024-01-30,2024-02-01,Unverified,banda_characterising_2023,MWI
20231028_Karonga_MalawiEpidemiologyInterventionResearchUnit_Survey4_Overall_PopAdj,20231028_Karonga_MalawiEpidemiologyInterventionResearchUnit_Survey4,Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study,2023-10-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Malawi,,Karonga,Informed consent,"NR
",2021-02-01,2022-04-01,Household and community samples,All,Multiple groups,,,Primary Estimate,,886,0.893,0.854,0.922,True,True,True,,True,Stratified probability,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Serum,IgG,Spike,Validated by manufacturers,0.865,0.988,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Louis Banda,Malawi Epidemiology and Intervention Research Unit (MEIRU),Unity-Aligned,https://doi.org/10.1016/j.ijid.2023.10.020,2024-01-30,2024-02-01,Unverified,banda_characterising_2023,MWI
20231028_Karonga_MalawiEpidemiologyInterventionResearchUnit_Survey4_Lessthan15_PopAdj,20231028_Karonga_MalawiEpidemiologyInterventionResearchUnit_Survey4,Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study,2023-10-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Malawi,,Karonga,Informed consent,"NR
",2021-02-01,2022-04-01,Household and community samples,All,Children and Youth (0-17 years),,15.0,Age,,338,0.852,0.816,0.883,True,True,True,,,Stratified probability,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Serum,IgG,Spike,Validated by manufacturers,0.865,0.988,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Louis Banda,Malawi Epidemiology and Intervention Research Unit (MEIRU),Unity-Aligned,https://doi.org/10.1016/j.ijid.2023.10.020,2024-01-30,2024-02-01,Unverified,banda_characterising_2023,MWI
20231028_Karonga_MalawiEpidemiologyInterventionResearchUnit_Survey4_30plus_PopAdj,20231028_Karonga_MalawiEpidemiologyInterventionResearchUnit_Survey4,Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study,2023-10-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Malawi,,Karonga,Informed consent,"NR
",2021-02-01,2022-04-01,Household and community samples,All,Multiple groups,30.0,,Age,,314,0.899,0.83,0.943,True,True,True,,,Unclear,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Serum,IgG,Spike,Validated by manufacturers,0.865,0.988,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Louis Banda,Malawi Epidemiology and Intervention Research Unit (MEIRU),Unity-Aligned,https://doi.org/10.1016/j.ijid.2023.10.020,2024-01-30,2024-02-01,Unverified,banda_characterising_2023,MWI
20231028_Karonga_MalawiEpidemiologyInterventionResearchUnit_Survey4_15to29_PopAdj,20231028_Karonga_MalawiEpidemiologyInterventionResearchUnit_Survey4,Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study,2023-10-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Malawi,,Karonga,Informed consent,"NR
",2021-02-01,2022-04-01,Household and community samples,All,Multiple groups,15.0,29.0,Age,,234,0.954,0.907,0.982,True,True,True,,,Unclear,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Serum,IgG,Spike,Validated by manufacturers,0.865,0.988,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Louis Banda,Malawi Epidemiology and Intervention Research Unit (MEIRU),Unity-Aligned,https://doi.org/10.1016/j.ijid.2023.10.020,2024-01-30,2024-02-01,Unverified,banda_characterising_2023,MWI
20231028_Karonga_MalawiEpidemiologyInterventionResearchUnit_Survey4_30plus_PopUnAdj,20231028_Karonga_MalawiEpidemiologyInterventionResearchUnit_Survey4,Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study,2023-10-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Malawi,,Karonga,Informed consent,"NR
",2021-02-01,2022-04-01,Household and community samples,All,Multiple groups,30.0,,Age,,314,0.774,0.724,0.819,,,,,,Stratified probability,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Serum,IgG,Spike,Validated by manufacturers,0.865,0.988,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Louis Banda,Malawi Epidemiology and Intervention Research Unit (MEIRU),Unity-Aligned,https://doi.org/10.1016/j.ijid.2023.10.020,2024-01-30,2024-03-01,Unverified,banda_characterising_2023,MWI
20231028_Karonga_MalawiEpidemiologyInterventionResearchUnit_Survey4_15to29_PopUnAdj,20231028_Karonga_MalawiEpidemiologyInterventionResearchUnit_Survey4,Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study,2023-10-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Malawi,,Karonga,Informed consent,"NR
",2021-02-01,2022-04-01,Household and community samples,All,Multiple groups,15.0,29.0,Age,,234,0.833,0.779,0.879,,,,,,Stratified probability,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Serum,IgG,Spike,Validated by manufacturers,0.865,0.988,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Louis Banda,Malawi Epidemiology and Intervention Research Unit (MEIRU),Unity-Aligned,https://doi.org/10.1016/j.ijid.2023.10.020,2024-01-30,2024-03-01,Unverified,banda_characterising_2023,MWI
20231028_Karonga_MalawiEpidemiologyInterventionResearchUnit_Survey4_Lessthan15_PopUnAdj,20231028_Karonga_MalawiEpidemiologyInterventionResearchUnit_Survey4,Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study,2023-10-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Malawi,,Karonga,Informed consent,"NR
",2021-02-01,2022-04-01,Household and community samples,All,Children and Youth (0-17 years),,15.0,Age,,338,0.627,0.573,0.678,,,,,,Stratified probability,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Serum,IgG,Spike,Validated by manufacturers,0.865,0.988,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Louis Banda,Malawi Epidemiology and Intervention Research Unit (MEIRU),Unity-Aligned,https://doi.org/10.1016/j.ijid.2023.10.020,2024-01-30,2024-03-01,Unverified,banda_characterising_2023,MWI
20231028_Karonga_MalawiEpidemiologyInterventionResearchUnit_Survey4_Overall_PopUnAdj,20231028_Karonga_MalawiEpidemiologyInterventionResearchUnit_Survey4,Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study,2023-10-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Malawi,,Karonga,Informed consent,"NR
",2021-02-01,2022-04-01,Household and community samples,All,Multiple groups,,,Age,,886,0.734,0.703,0.763,,,,,,Stratified probability,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Serum,IgG,Spike,Validated by manufacturers,0.865,0.988,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Louis Banda,Malawi Epidemiology and Intervention Research Unit (MEIRU),Unity-Aligned,https://doi.org/10.1016/j.ijid.2023.10.020,2024-01-30,2024-03-01,Unverified,banda_characterising_2023,MWI
20231028_Lilongwe_MalawiEpidemiologyInterventionResearchUnit_Survey1_30plus_PopAdj,20231028_Lilongwe_MalawiEpidemiologyInterventionResearchUnit_Survey1,Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study,2023-10-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Malawi,,"Lilongwe
",Informed consent,"NR
",2021-02-01,2022-04-01,Household and community samples,All,Multiple groups,30.0,,Age,,395,0.599,0.555,0.641,True,True,True,,,Stratified probability,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Serum,IgG,Spike,Validated by manufacturers,0.865,0.988,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Louis Banda,Malawi Epidemiology and Intervention Research Unit (MEIRU),Unity-Aligned,https://doi.org/10.1016/j.ijid.2023.10.020,2024-01-31,2024-02-01,Unverified,banda_characterising_2023,MWI
20231028_Lilongwe_MalawiEpidemiologyInterventionResearchUnit_Survey1_Lessthan15_PopAdj,20231028_Lilongwe_MalawiEpidemiologyInterventionResearchUnit_Survey1,Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study,2023-10-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Malawi,,"Lilongwe
",Informed consent,"NR
",2021-02-01,2022-04-01,Household and community samples,All,Children and Youth (0-17 years),,15.0,Age,,276,0.243,0.174,0.332,True,True,True,,,Stratified probability,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Serum,IgG,Spike,Validated by manufacturers,0.865,0.988,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Louis Banda,Malawi Epidemiology and Intervention Research Unit (MEIRU),Unity-Aligned,https://doi.org/10.1016/j.ijid.2023.10.020,2024-01-31,2024-02-01,Unverified,banda_characterising_2023,MWI
20231028_Lilongwe_MalawiEpidemiologyInterventionResearchUnit_Survey1_15to29_PopAdj,20231028_Lilongwe_MalawiEpidemiologyInterventionResearchUnit_Survey1,Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study,2023-10-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Malawi,,"Lilongwe
",Informed consent,"NR
",2021-02-01,2022-04-01,Household and community samples,All,Multiple groups,15.0,29.0,Age,,277,0.593,0.485,0.702,True,True,True,,,Stratified probability,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Serum,IgG,Spike,Validated by manufacturers,0.865,0.988,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Louis Banda,Malawi Epidemiology and Intervention Research Unit (MEIRU),Unity-Aligned,https://doi.org/10.1016/j.ijid.2023.10.020,2024-01-31,2024-02-01,Unverified,banda_characterising_2023,MWI
20231028_Lilongwe_MalawiEpidemiologyInterventionResearchUnit_Survey1_Overall_PopAdj,20231028_Lilongwe_MalawiEpidemiologyInterventionResearchUnit_Survey1,Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study,2023-10-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Malawi,,"Lilongwe
",Informed consent,"NR
",2021-02-01,2022-04-01,Household and community samples,All,Multiple groups,,,Primary Estimate,,948,0.464,0.402,0.53,True,True,True,,True,Stratified probability,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Serum,IgG,Spike,Validated by manufacturers,0.865,0.988,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Louis Banda,Malawi Epidemiology and Intervention Research Unit (MEIRU),Unity-Aligned,https://doi.org/10.1016/j.ijid.2023.10.020,2024-01-31,2024-02-01,Unverified,banda_characterising_2023,MWI
20231028_Lilongwe_MalawiEpidemiologyInterventionResearchUnit_Survey1_Lessthan15_PopUnAdj,20231028_Lilongwe_MalawiEpidemiologyInterventionResearchUnit_Survey1,Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study,2023-10-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Malawi,,"Lilongwe
",Informed consent,"NR
",2021-02-01,2022-04-01,Household and community samples,All,Children and Youth (0-17 years),,15.0,Age,,276,0.301,0.247,0.359,,,,,,Stratified probability,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Serum,IgG,Spike,Validated by manufacturers,0.865,0.988,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Louis Banda,Malawi Epidemiology and Intervention Research Unit (MEIRU),Unity-Aligned,https://doi.org/10.1016/j.ijid.2023.10.020,2024-01-31,2024-03-01,Unverified,banda_characterising_2023,MWI
20231028_Lilongwe_MalawiEpidemiologyInterventionResearchUnit_Survey1_15to29_PopUnAdj,20231028_Lilongwe_MalawiEpidemiologyInterventionResearchUnit_Survey1,Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study,2023-10-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Malawi,,"Lilongwe
",Informed consent,"NR
",2021-02-01,2022-04-01,Household and community samples,All,Multiple groups,15.0,29.0,Age,,277,0.599,0.539,0.658,,,,,,Stratified probability,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Serum,IgG,Spike,Validated by manufacturers,0.865,0.988,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Louis Banda,Malawi Epidemiology and Intervention Research Unit (MEIRU),Unity-Aligned,https://doi.org/10.1016/j.ijid.2023.10.020,2024-01-31,2024-03-01,Unverified,banda_characterising_2023,MWI
20231028_Lilongwe_MalawiEpidemiologyInterventionResearchUnit_Survey1_30plus_PopUnAdj,20231028_Lilongwe_MalawiEpidemiologyInterventionResearchUnit_Survey1,Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study,2023-10-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Malawi,,"Lilongwe
",Informed consent,"NR
",2021-02-01,2022-04-01,Household and community samples,All,Multiple groups,30.0,,Age,,395,0.605,0.555,0.653,,,,,,Stratified probability,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Serum,IgG,Spike,Validated by manufacturers,0.865,0.988,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Louis Banda,Malawi Epidemiology and Intervention Research Unit (MEIRU),Unity-Aligned,https://doi.org/10.1016/j.ijid.2023.10.020,2024-01-31,2024-03-01,Unverified,banda_characterising_2023,MWI
20231028_Lilongwe_MalawiEpidemiologyInterventionResearchUnit_Survey1_Overall_PopUnAdj,20231028_Lilongwe_MalawiEpidemiologyInterventionResearchUnit_Survey1,Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study,2023-10-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Malawi,,"Lilongwe
",Informed consent,"NR
",2021-02-01,2022-04-01,Household and community samples,All,Multiple groups,,,Age,,948,0.515,0.482,0.547,,,,,,Stratified probability,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Serum,IgG,Spike,Validated by manufacturers,0.865,0.988,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Louis Banda,Malawi Epidemiology and Intervention Research Unit (MEIRU),Unity-Aligned,https://doi.org/10.1016/j.ijid.2023.10.020,2024-01-31,2024-03-01,Unverified,banda_characterising_2023,MWI
20231028_Lilongwe_MalawiEpidemiologyInterventionResearchUnit_Survey4_Lessthan15_PopAdj,20231028_Lilongwe_MalawiEpidemiologyInterventionResearchUnit_Survey4,Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study,2023-10-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Malawi,,"Lilongwe
",Informed consent,"NR
",2021-02-01,2022-04-01,Household and community samples,All,Children and Youth (0-17 years),,15.0,Age,,165,0.914,0.881,0.946,True,True,True,,,Stratified probability,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Serum,IgG,Spike,Validated by manufacturers,0.865,0.988,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Unclear,Louis Banda,Malawi Epidemiology and Intervention Research Unit (MEIRU),Unity-Aligned,https://doi.org/10.1016/j.ijid.2023.10.020,2024-01-31,2024-02-01,Unverified,banda_characterising_2023,MWI
20231028_Lilongwe_MalawiEpidemiologyInterventionResearchUnit_Survey4_30plus_PopAdj,20231028_Lilongwe_MalawiEpidemiologyInterventionResearchUnit_Survey4,Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study,2023-10-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Malawi,,"Lilongwe
",Informed consent,"NR
",2021-02-01,2022-04-01,Household and community samples,All,Multiple groups,30.0,,Age,,241,0.946,0.893,0.978,True,True,True,,,Stratified probability,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Serum,IgG,Spike,Validated by manufacturers,0.865,0.988,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Unclear,Louis Banda,Malawi Epidemiology and Intervention Research Unit (MEIRU),Unity-Aligned,https://doi.org/10.1016/j.ijid.2023.10.020,2024-01-31,2024-02-01,Unverified,banda_characterising_2023,MWI
20231028_Lilongwe_MalawiEpidemiologyInterventionResearchUnit_Survey4_15to29_PopAdj,20231028_Lilongwe_MalawiEpidemiologyInterventionResearchUnit_Survey4,Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study,2023-10-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Malawi,,"Lilongwe
",Informed consent,"NR
",2021-02-01,2022-04-01,Household and community samples,All,Multiple groups,15.0,29.0,Age,,125,0.967,0.913,0.99,True,True,True,,,Stratified probability,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Serum,IgG,Spike,Validated by manufacturers,0.865,0.988,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Unclear,Louis Banda,Malawi Epidemiology and Intervention Research Unit (MEIRU),Unity-Aligned,https://doi.org/10.1016/j.ijid.2023.10.020,2024-01-31,2024-02-01,Unverified,banda_characterising_2023,MWI
20231028_Lilongwe_MalawiEpidemiologyInterventionResearchUnit_Survey4_Overall_PopAdj,20231028_Lilongwe_MalawiEpidemiologyInterventionResearchUnit_Survey4,Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study,2023-10-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Malawi,,"Lilongwe
",Informed consent,"NR
",2021-02-01,2022-04-01,Household and community samples,All,Multiple groups,,,Primary Estimate,,531,0.939,0.906,0.965,True,True,True,,True,Stratified probability,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Serum,IgG,Spike,Validated by manufacturers,0.865,0.988,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Unclear,Louis Banda,Malawi Epidemiology and Intervention Research Unit (MEIRU),Unity-Aligned,https://doi.org/10.1016/j.ijid.2023.10.020,2024-01-31,2024-02-01,Unverified,banda_characterising_2023,MWI
20231028_Lilongwe_MalawiEpidemiologyInterventionResearchUnit_Survey4_Overall_PopUnAdj,20231028_Lilongwe_MalawiEpidemiologyInterventionResearchUnit_Survey4,Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study,2023-10-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Malawi,,"Lilongwe
",Informed consent,"NR
",2021-02-01,2022-04-01,Household and community samples,All,Multiple groups,,,Age,,531,0.808,0.772,0.841,,,,,,Stratified probability,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Serum,IgG,Spike,Validated by manufacturers,0.865,0.988,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Unclear,Louis Banda,Malawi Epidemiology and Intervention Research Unit (MEIRU),Unity-Aligned,https://doi.org/10.1016/j.ijid.2023.10.020,2024-01-31,2024-03-01,Unverified,banda_characterising_2023,MWI
20231028_Lilongwe_MalawiEpidemiologyInterventionResearchUnit_Survey4_15to29_PopUnAdj,20231028_Lilongwe_MalawiEpidemiologyInterventionResearchUnit_Survey4,Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study,2023-10-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Malawi,,"Lilongwe
",Informed consent,"NR
",2021-02-01,2022-04-01,Household and community samples,All,Multiple groups,15.0,29.0,Age,,125,0.872,0.8,0.925,,,,,,Stratified probability,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Serum,IgG,Spike,Validated by manufacturers,0.865,0.988,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Unclear,Louis Banda,Malawi Epidemiology and Intervention Research Unit (MEIRU),Unity-Aligned,https://doi.org/10.1016/j.ijid.2023.10.020,2024-01-31,2024-03-01,Unverified,banda_characterising_2023,MWI
20231028_Lilongwe_MalawiEpidemiologyInterventionResearchUnit_Survey4_30plus_PopUnAdj,20231028_Lilongwe_MalawiEpidemiologyInterventionResearchUnit_Survey4,Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study,2023-10-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Malawi,,"Lilongwe
",Informed consent,"NR
",2021-02-01,2022-04-01,Household and community samples,All,Multiple groups,30.0,,Age,,241,0.863,0.813,0.904,,,,,,Stratified probability,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Serum,IgG,Spike,Validated by manufacturers,0.865,0.988,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Unclear,Louis Banda,Malawi Epidemiology and Intervention Research Unit (MEIRU),Unity-Aligned,https://doi.org/10.1016/j.ijid.2023.10.020,2024-01-31,2024-03-01,Unverified,banda_characterising_2023,MWI
20231028_Lilongwe_MalawiEpidemiologyInterventionResearchUnit_Survey4_Lessthan15_PopUnAdj,20231028_Lilongwe_MalawiEpidemiologyInterventionResearchUnit_Survey4,Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study,2023-10-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Malawi,,"Lilongwe
",Informed consent,"NR
",2021-02-01,2022-04-01,Household and community samples,All,Children and Youth (0-17 years),,15.0,Age,,165,0.679,0.602,0.749,,,,,,Stratified probability,Mount Sinai ELISA,Mount Sinai Laboratory (MSL),ELISA,Serum,IgG,Spike,Validated by manufacturers,0.865,0.988,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Unclear,Louis Banda,Malawi Epidemiology and Intervention Research Unit (MEIRU),Unity-Aligned,https://doi.org/10.1016/j.ijid.2023.10.020,2024-01-31,2024-03-01,Unverified,banda_characterising_2023,MWI
200813_Selangor_UniversityMalaya_OverallPopAdj,200813_Selangor_UniversityMalaya,"Low postpandemic wave SARS-CoV-2 seroprevalence in Kuala Lumpur and Selangor, Malaysia",2020-08-13,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Malaysia,Selangor,Kuala Lumpur,We retrieved 816 serum samples sent for diagnostic testing for nonrespiratory infections (mainly dengue) and archived at −20°.,,2020-01-29,2020-06-06,Residual sera,All,Multiple groups,,,Primary Estimate,,588,0.004,0.0,0.009300000000000001,True,,True,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,,,['High'],No,No,No,No,Unclear,Unclear,Yes,No,Unclear,I Ching Sam,University Malaya,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.26426,2020-10-02,2022-07-16,Verified,sam_low_nodate,MYS
200813_Selangor_UniversityMalaya_Postwave,200813_Selangor_UniversityMalaya,"Low postpandemic wave SARS-CoV-2 seroprevalence in Kuala Lumpur and Selangor, Malaysia",2020-08-13,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Malaysia,Selangor,Kuala Lumpur,We retrieved 816 serum samples sent for diagnostic testing for nonrespiratory infections (mainly dengue) and archived at −20°.,,2020-04-15,2020-06-06,Residual sera,All,Multiple groups,,,Time frame,Post wave,261,0.004,0.0001,0.021,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,,,['High'],No,No,No,No,Unclear,Unclear,Yes,No,Unclear,I Ching Sam,University Malaya,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.26426,2020-10-02,2022-07-16,Verified,sam_low_nodate,MYS
200813_Selangor_UniversityMalaya_OverallUnadj,200813_Selangor_UniversityMalaya,"Low postpandemic wave SARS-CoV-2 seroprevalence in Kuala Lumpur and Selangor, Malaysia",2020-08-13,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Malaysia,Selangor,Kuala Lumpur,We retrieved 816 serum samples sent for diagnostic testing for nonrespiratory infections (mainly dengue) and archived at −20°.,,2020-01-29,2020-06-06,Residual sera,All,Multiple groups,,,Analysis,Unadjusted,588,0.005,0.001,0.015,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,,,['High'],No,No,No,No,Unclear,Unclear,Yes,No,Unclear,I Ching Sam,University Malaya,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.26426,2020-10-02,2022-07-16,Verified,sam_low_nodate,MYS
200813_Selangor_UniversityMalaya_Mainwave,200813_Selangor_UniversityMalaya,"Low postpandemic wave SARS-CoV-2 seroprevalence in Kuala Lumpur and Selangor, Malaysia",2020-08-13,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Malaysia,Selangor,Kuala Lumpur,We retrieved 816 serum samples sent for diagnostic testing for nonrespiratory infections (mainly dengue) and archived at −20°.,,2020-01-29,2020-04-14,Residual sera,All,Multiple groups,,,Time frame,Main wave,327,0.006,0.0007000000000000001,0.022000000000000002,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,,1.0,['High'],No,No,No,No,Unclear,Unclear,Yes,No,Unclear,I Ching Sam,University Malaya,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.26426,2020-10-02,2022-07-16,Verified,sam_low_nodate,MYS
210321_KlangValley_MalaysianMinistryofHealth_HCW,210321_KlangValley_MalaysianMinistryofHealth,Serology surveillance of SARS-CoV-2 antibodies among healthcare workers in COVID-19 designated facilities in Malaysia,2021-03-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Malaysia,Klang Valley,,"Participation in the study was voluntary. Healthcare workers
were invited by advertisement and/or internal announcement to
participate in the study. HCW from Kuala Lumpur Hospital, Sungai Buloh Hospital and the National Public Health Laboratory (NPHL). All participants must have at least 30 workdays prior to study enrollment, and were asymptomatic at the point of recruitment. HCW included nurses,  medical doctors,  laboratory technologists and others (drivers, clerks, assistant food technologists, dentists, physiotherapists, speech therapists, dental surgeon assistants, entomologist, research officer, science officer and pharmacist).",HCW who were previously confirmed with COVID-19 infection or listed as PUI for COVID-19 at the time of study recruitment were excluded from this study.,2020-04-13,2020-05-12,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,400,0.0,0.0,9.5e-05,True,,,,True,Self-referral,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,GenScript,Neutralization,Serum,,Spike,Multiple tests with diff validations or values derived from each type,0.913,1.0,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,No,Yuan Liang Woon,Malaysian Ministry of Health,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2021.100123,2021-04-18,2024-03-01,Verified,woon_serology_2021,MYS
211110_Malaysia_UniversityofMalaya_PopAdjusted,211110_Malaysia_UniversityofMalaya,"Changing predominant SARS-CoV-2 lineages drive successive COVID-19 waves in Malaysia, February 2020 to March 2021.",2021-11-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Malaysia,Selangor,Kuala Lumpur,residual serum samples from UMMC inpatients collected between December 2020 to April 2021 for diagnostic testing for nonrespiratory infections.,,2020-12-15,2021-04-15,Residual sera,All,Multiple groups,,,Primary Estimate,,653,0.03,,,True,,True,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,I-Ching Sam,University of Malaya,Unity-Aligned,https://dx.doi.org/10.1002/jmv.27441,2021-11-18,2024-03-01,Verified,sam_changing_2021,MYS
211110_Malaysia_UniversityofMalaya_Crude,211110_Malaysia_UniversityofMalaya,"Changing predominant SARS-CoV-2 lineages drive successive COVID-19 waves in Malaysia, February 2020 to March 2021.",2021-11-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Malaysia,Selangor,Kuala Lumpur,residual serum samples from UMMC inpatients collected between December 2020 to April 2021 for diagnostic testing for nonrespiratory infections.,,2020-12-15,2021-04-15,Residual sera,All,Multiple groups,,,Analysis,,653,0.040999999999999995,0.027000000000000003,0.06,,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,I-Ching Sam,University of Malaya,Unity-Aligned,https://dx.doi.org/10.1002/jmv.27441,2021-11-18,2024-03-01,Verified,sam_changing_2021,MYS
211110_Malaysia_UniversityofMalaya_Age0-9,211110_Malaysia_UniversityofMalaya,"Changing predominant SARS-CoV-2 lineages drive successive COVID-19 waves in Malaysia, February 2020 to March 2021.",2021-11-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Malaysia,Selangor,Kuala Lumpur,residual serum samples from UMMC inpatients collected between December 2020 to April 2021 for diagnostic testing for nonrespiratory infections.,,2020-12-15,2021-04-15,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,0-9,80,0.0,0.0,0.045,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,I-Ching Sam,University of Malaya,Unity-Aligned,https://dx.doi.org/10.1002/jmv.27441,2021-11-18,2024-03-01,Verified,sam_changing_2021,MYS
211110_Malaysia_UniversityofMalaya_Age10-19,211110_Malaysia_UniversityofMalaya,"Changing predominant SARS-CoV-2 lineages drive successive COVID-19 waves in Malaysia, February 2020 to March 2021.",2021-11-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Malaysia,Selangor,Kuala Lumpur,residual serum samples from UMMC inpatients collected between December 2020 to April 2021 for diagnostic testing for nonrespiratory infections.,,2020-12-15,2021-04-15,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,43,0.0,0.0,0.08199999999999999,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,I-Ching Sam,University of Malaya,Unity-Aligned,https://dx.doi.org/10.1002/jmv.27441,2021-11-18,2024-03-01,Verified,sam_changing_2021,MYS
211110_Malaysia_UniversityofMalaya_Age30-39,211110_Malaysia_UniversityofMalaya,"Changing predominant SARS-CoV-2 lineages drive successive COVID-19 waves in Malaysia, February 2020 to March 2021.",2021-11-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Malaysia,Selangor,Kuala Lumpur,residual serum samples from UMMC inpatients collected between December 2020 to April 2021 for diagnostic testing for nonrespiratory infections.,,2020-12-15,2021-04-15,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,,102,0.059000000000000004,0.022000000000000002,0.12400000000000001,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,I-Ching Sam,University of Malaya,Unity-Aligned,https://dx.doi.org/10.1002/jmv.27441,2021-11-18,2024-03-01,Verified,sam_changing_2021,MYS
211110_Malaysia_UniversityofMalaya_Age20-29,211110_Malaysia_UniversityofMalaya,"Changing predominant SARS-CoV-2 lineages drive successive COVID-19 waves in Malaysia, February 2020 to March 2021.",2021-11-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Malaysia,Selangor,Kuala Lumpur,residual serum samples from UMMC inpatients collected between December 2020 to April 2021 for diagnostic testing for nonrespiratory infections.,,2020-12-15,2021-04-15,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29,99,0.01,0.0003,0.055,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,I-Ching Sam,University of Malaya,Unity-Aligned,https://dx.doi.org/10.1002/jmv.27441,2021-11-18,2024-03-01,Verified,sam_changing_2021,MYS
211110_Malaysia_UniversityofMalaya_Age60-69,211110_Malaysia_UniversityofMalaya,"Changing predominant SARS-CoV-2 lineages drive successive COVID-19 waves in Malaysia, February 2020 to March 2021.",2021-11-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Malaysia,Selangor,Kuala Lumpur,residual serum samples from UMMC inpatients collected between December 2020 to April 2021 for diagnostic testing for nonrespiratory infections.,,2020-12-15,2021-04-15,Residual sera,All,Seniors (65+ years),60.0,69.0,Age,,78,0.10300000000000001,0.045,0.192,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,I-Ching Sam,University of Malaya,Unity-Aligned,https://dx.doi.org/10.1002/jmv.27441,2021-11-18,2024-03-01,Verified,sam_changing_2021,MYS
211110_Malaysia_UniversityofMalaya_Age70+,211110_Malaysia_UniversityofMalaya,"Changing predominant SARS-CoV-2 lineages drive successive COVID-19 waves in Malaysia, February 2020 to March 2021.",2021-11-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Malaysia,Selangor,Kuala Lumpur,residual serum samples from UMMC inpatients collected between December 2020 to April 2021 for diagnostic testing for nonrespiratory infections.,,2020-12-15,2021-04-15,Residual sera,All,Seniors (65+ years),70.0,,Age,,86,0.081,0.033,0.161,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,I-Ching Sam,University of Malaya,Unity-Aligned,https://dx.doi.org/10.1002/jmv.27441,2021-11-18,2024-03-01,Verified,sam_changing_2021,MYS
211110_Malaysia_UniversityofMalaya_Age40-49,211110_Malaysia_UniversityofMalaya,"Changing predominant SARS-CoV-2 lineages drive successive COVID-19 waves in Malaysia, February 2020 to March 2021.",2021-11-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Malaysia,Selangor,Kuala Lumpur,residual serum samples from UMMC inpatients collected between December 2020 to April 2021 for diagnostic testing for nonrespiratory infections.,,2020-12-15,2021-04-15,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,,84,0.048,0.013000000000000001,0.11800000000000001,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,I-Ching Sam,University of Malaya,Unity-Aligned,https://dx.doi.org/10.1002/jmv.27441,2021-11-18,2024-03-01,Verified,sam_changing_2021,MYS
211110_Malaysia_UniversityofMalaya_Age50-59,211110_Malaysia_UniversityofMalaya,"Changing predominant SARS-CoV-2 lineages drive successive COVID-19 waves in Malaysia, February 2020 to March 2021.",2021-11-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Malaysia,Selangor,Kuala Lumpur,residual serum samples from UMMC inpatients collected between December 2020 to April 2021 for diagnostic testing for nonrespiratory infections.,,2020-12-15,2021-04-15,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,,81,0.012,0.0003,0.067,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.995,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,I-Ching Sam,University of Malaya,Unity-Aligned,https://dx.doi.org/10.1002/jmv.27441,2021-11-18,2024-03-01,Verified,sam_changing_2021,MYS
220117_KlangValleyAndPerak_HealthyMalaysiaSociety_LocalWorkers_TestAndSeroReversionAdj,220117_KlangValleyAndPerak_HealthyMalaysiaSociety_LocalWorkers,Sero-Prevalence of Covid-19 among workers in Malaysia,2022-01-17,Preprint,Regional,Cross-sectional survey ,Malaysia,Klang Valley; and Perak,,"Workers ""who participated in ongoing studies on worksite-based screening and vaccination.""",,2021-07-15,2021-09-15,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,204,0.121,0.08,0.162,True,True,,,,Convenience,COVID-19 IgG/IgM ECO Test,ECO Diagnostica LTDA,LFIA,Whole Blood,,,Validated by independent authors/third party/non-developers,0.8300000000000001,0.96,['High'],,No,No,Yes,,Yes,Yes,Yes,,Noorliza Mohamad Noordin,Healthy Malaysia Society,Not Unity-Aligned,https://doi.org/10.1101/2022.01.16.22269388,2022-01-25,2023-08-15,Unverified,noordin_sero-prevalence_2022,MYS
220117_KlangValleyAndPerak_HealthyMalaysiaSociety_MigrantWorkers_TestAndSeroReversionAdj,220117_KlangValleyAndPerak_HealthyMalaysiaSociety_MigrantWorkers,Sero-Prevalence of Covid-19 among workers in Malaysia,2022-01-17,Preprint,Regional,Cross-sectional survey ,Malaysia,Klang Valley; and Perak,,"Workers ""who participated in ongoing studies on worksite-based screening and vaccination.""",,2021-07-15,2021-09-15,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,874,0.9990000000000001,0.9670000000000001,1.0,True,True,,,,Convenience,COVID-19 IgG/IgM ECO Test,ECO Diagnostica LTDA,LFIA,Whole Blood,,,Validated by independent authors/third party/non-developers,0.8300000000000001,0.96,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Noorliza Mohamad Noordin,Healthy Malaysia Society,Not Unity-Aligned,https://doi.org/10.1101/2022.01.16.22269388,2022-01-25,2023-08-15,Unverified,noordin_sero-prevalence_2022,MYS
220301_KlangValley_UniversitiTeknologiMARA_Spike,220301_KlangValley_UniversitiTeknologiMARA ,Seroprevalence of SARS-CoV-2 Antibodies Among Blood Donors in Malaysia During the Pre-Vaccination Period,2022-03-01,Presentation or Conference,Regional,Cross-sectional survey ,Malaysia,Klang Valley,,Blood donors in Klang Valley,,2021-02-15,2021-03-15,Blood donors,All,Adults (18-64 years),,,Primary Estimate,,806,0.045899999999999996,,,True,,,,True,Sequential,Wantai SARS-CoV-2 IgG ELISA,Beijing Wantai Biological,ELISA,Serum,,Spike,,,,['High'],No,No,Yes,No,No,Yes,Yes,No,,A.M.A. Shukri,Universiti Teknologi MARA,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.12.080,2022-03-14,2024-03-01,Verified,shukri_seroprevalence_2022,MYS
220301_KlangValley_UniversitiTeknologiMARA_Nucleocapsid,220301_KlangValley_UniversitiTeknologiMARA ,Seroprevalence of SARS-CoV-2 Antibodies Among Blood Donors in Malaysia During the Pre-Vaccination Period,2022-03-01,Presentation or Conference,Regional,Cross-sectional survey ,Malaysia,Klang Valley,,Blood donors in Klang Valley,,2021-02-15,2021-03-15,Blood donors,All,Adults (18-64 years),,,Test used,,806,0.031000000000000003,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,ELISA,Serum,,Nucleocapsid(N-protein),,,,['High'],No,No,Yes,No,No,Yes,Yes,No,,A.M.A. Shukri,Universiti Teknologi MARA,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.12.080,2022-05-12,2024-03-01,Verified,shukri_seroprevalence_2022,MYS
220602_UniversitiMalaysiaSabah_INTIInternationalUniversity_Overall,220602_UniversitiMalaysiaSabah_INTIInternationalUniversity,Seroprevalence of COVID-19 and Psychological Distress among Front Liners at the Universiti Malaysia Sabah Campus during the Third Wave of COVID-19,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Malaysia,Sabah,Kota Kinabalu,"This included university hospital staff, the security division, the student affairs department, and medical laboratory technologists.",,2020-12-15,2021-06-15,Multiple populations,All,Adults (18-64 years),,,Primary Estimate,IgG or IgM,168,0.0833,,,True,,,,True,Convenience,Standard Q COVID-19 IgM/IgG Combo,SD Biosensor,,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,1.0,,['High'],,No,No,Yes,,Unclear,Yes,No,,Mohd Hijazi,INTI International University,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph19116840,2022-06-16,2022-07-16,Unverified,hijazi_seroprevalence_2022,MYS
220602_UniversitiMalaysiaSabah_INTIInternationalUniversity_Age_30orless,220602_UniversitiMalaysiaSabah_INTIInternationalUniversity,Seroprevalence of COVID-19 and Psychological Distress among Front Liners at the Universiti Malaysia Sabah Campus during the Third Wave of COVID-19,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Malaysia,Sabah,Kota Kinabalu,"This included university hospital staff, the security division, the student affairs department, and medical laboratory technologists.",,2020-12-15,2021-06-15,Multiple populations,All,Adults (18-64 years),,30.0,Age,30-,37,0.08109999999999999,,,,,,,,Convenience,Standard Q COVID-19 IgM/IgG Combo,SD Biosensor,,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,1.0,,['High'],,No,No,Yes,,Unclear,Yes,No,,Mohd Hijazi,INTI International University,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph19116840,2022-06-16,2022-07-16,Unverified,hijazi_seroprevalence_2022,MYS
220602_UniversitiMalaysiaSabah_INTIInternationalUniversity_31+,220602_UniversitiMalaysiaSabah_INTIInternationalUniversity,Seroprevalence of COVID-19 and Psychological Distress among Front Liners at the Universiti Malaysia Sabah Campus during the Third Wave of COVID-19,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Malaysia,Sabah,Kota Kinabalu,"This included university hospital staff, the security division, the student affairs department, and medical laboratory technologists.",,2020-12-15,2021-06-15,Multiple populations,All,Adults (18-64 years),31.0,,Age,31+,131,0.084,,,,,,,,Convenience,Standard Q COVID-19 IgM/IgG Combo,SD Biosensor,,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,1.0,,['High'],,No,No,Yes,,Unclear,Yes,No,,Mohd Hijazi,INTI International University,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph19116840,2022-06-16,2022-07-16,Unverified,hijazi_seroprevalence_2022,MYS
220920_Malaysia_UniversitiSainsMalaysia_Overall,220920_Malaysia_UniversitiSainsMalaysia,Low Seroprevalence of SARS-CoV-2 among Healthcare Workers in Malaysia during the Third COVID-19 Wave: Prospective Study with Literature Survey on Infection Prevention and Control Measures.,2022-09-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Malaysia,Penang,Gelugor,USM HCWs who were aged above 18 years old and asymptomatic for influenza-like illness and had not received any COVID-19 vaccination were eligible to join this study. ,"HCWs who had acute respiratory illness symptoms (fever, cough, sore throat, conjunctivitis, shortness of breath, anosmia and myalgia) within 14 days before sampling were excluded from this study. ",2020-08-24,2021-03-09,Health care workers and caregivers,All,Multiple groups,18.0,,Primary Estimate,overall anti-N,617,0.0,,,True,,,,True,Self-referral,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Nik Mohd Noor Nik Zuraina,Universiti Sains Malaysia,Not Unity-Aligned,https://dx.doi.org/10.3390/healthcare10101810,2022-11-09,2024-03-01,Unverified,nikzuraina_low_2022,MYS
230101_Malaysia_UniversitiPutraMalaysia_Pre-Vaccination,230101_Malaysia_UniversitiPutraMalaysia_Pre-Vaccination,Humoral response to SARS-CoV-2 vaccines among healthcare workers in a tertiary hospital in Malaysia.,2023-01-01,Journal Article (Peer-Reviewed),Local,Prospective cohort,Malaysia,,,"""Participants were eligible for inclusion in the study if they were Malaysian, aged 18 years or more, worked at the study location and received two doses of COVID-19 vaccine at the study location. ""","""Participants were excluded if they were pregnant, planning to get pregnant, breast-feeding, was less than 2 weeks after surgery/vaccination/body piercing, diagnosed with acute diseases or malignancy, not vaccinated against COVID-19, or only received a single dose COVID-19 vaccination.""",2020-05-15,2021-06-15,Health care workers and caregivers,All,Adults (18-64 years),22.0,59.0,Primary Estimate,Primary estimate,666,0.022,,,True,,,,True,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.945,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Amrina Mohd Amin,Universiti Putra Malaysia,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/36715186/ ,2023-02-26,2024-03-01,Unverified,amrina_humoral_2023,MYS
211226_Male_MaldivesNationalUniversity_overall,211226_Male_MaldivesNationalUniversity,A sero-epidemiological study after two waves of the COVID-19 epidemic.,2021-12-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Maldives,,Male',The study population were the people living in Male’ at the time of survey. ,,2020-10-15,2020-11-16,Household and community samples,All,Multiple groups,,,Primary Estimate,,1940,0.134,,,True,,,,True,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Raheema Abdul-Raheem,Maldives National University,Unity-Aligned,https://apjai-journal.org/wp-content/uploads/2022/01/AP-040721-1177.pdf,2022-01-12,2024-03-01,Verified,abdul-raheem_sero-epidemiological_2021,MDV
211226_Male_MaldivesNationalUniversity_male,211226_Male_MaldivesNationalUniversity,A sero-epidemiological study after two waves of the COVID-19 epidemic.,2021-12-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Maldives,,Male',The study population were the people living in Male’ at the time of survey. ,,2020-10-15,2020-11-16,Household and community samples,Male,Multiple groups,,,Sex/Gender,,745,0.0913,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Raheema Abdul-Raheem,Maldives National University,Unity-Aligned,https://apjai-journal.org/wp-content/uploads/2022/01/AP-040721-1177.pdf,2022-01-12,2024-03-01,Verified,abdul-raheem_sero-epidemiological_2021,MDV
211226_Male_MaldivesNationalUniversity_female,211226_Male_MaldivesNationalUniversity,A sero-epidemiological study after two waves of the COVID-19 epidemic.,2021-12-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Maldives,,Male',The study population were the people living in Male’ at the time of survey. ,,2020-10-15,2020-11-16,Household and community samples,Female,Multiple groups,,,Sex/Gender,,718,0.0877,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Raheema Abdul-Raheem,Maldives National University,Unity-Aligned,https://apjai-journal.org/wp-content/uploads/2022/01/AP-040721-1177.pdf,2022-01-12,2024-03-01,Verified,abdul-raheem_sero-epidemiological_2021,MDV
211226_Male_MaldivesNationalUniversity_18-34,211226_Male_MaldivesNationalUniversity,A sero-epidemiological study after two waves of the COVID-19 epidemic.,2021-12-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Maldives,,Male',The study population were the people living in Male’ at the time of survey. ,,2020-10-15,2020-11-16,Household and community samples,All,Adults (18-64 years),18.0,34.0,Age,18-34,945,0.1386,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Raheema Abdul-Raheem,Maldives National University,Unity-Aligned,https://apjai-journal.org/wp-content/uploads/2022/01/AP-040721-1177.pdf,2022-01-12,2024-03-01,Verified,abdul-raheem_sero-epidemiological_2021,MDV
211226_Male_MaldivesNationalUniversity_35-59,211226_Male_MaldivesNationalUniversity,A sero-epidemiological study after two waves of the COVID-19 epidemic.,2021-12-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Maldives,,Male',The study population were the people living in Male’ at the time of survey. ,,2020-10-15,2020-11-16,Household and community samples,All,Adults (18-64 years),35.0,59.0,Age,35-39,451,0.1796,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Raheema Abdul-Raheem,Maldives National University,Unity-Aligned,https://apjai-journal.org/wp-content/uploads/2022/01/AP-040721-1177.pdf,2022-01-12,2024-03-01,Verified,abdul-raheem_sero-epidemiological_2021,MDV
211226_Male_MaldivesNationalUniversity_60+,211226_Male_MaldivesNationalUniversity,A sero-epidemiological study after two waves of the COVID-19 epidemic.,2021-12-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Maldives,,Male',The study population were the people living in Male’ at the time of survey. ,,2020-10-15,2020-11-16,Household and community samples,All,Multiple groups,60.0,,Age,>=60,77,0.2597,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Raheema Abdul-Raheem,Maldives National University,Unity-Aligned,https://apjai-journal.org/wp-content/uploads/2022/01/AP-040721-1177.pdf,2022-01-12,2024-03-01,Verified,abdul-raheem_sero-epidemiological_2021,MDV
211226_Male_MaldivesNationalUniversity_0-17,211226_Male_MaldivesNationalUniversity,A sero-epidemiological study after two waves of the COVID-19 epidemic.,2021-12-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Maldives,,Male',The study population were the people living in Male’ at the time of survey. ,,2020-10-15,2020-11-16,Household and community samples,All,Children and Youth (0-17 years),1.0,17.0,Age,0-17,410,0.0488,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Raheema Abdul-Raheem,Maldives National University,Unity-Aligned,https://apjai-journal.org/wp-content/uploads/2022/01/AP-040721-1177.pdf,2022-01-12,2024-03-01,Verified,abdul-raheem_sero-epidemiological_2021,MDV
210629_Mali_NationalInstitutesofHealth_1SotubaVisit1_OverallAdjusted,210629_Mali_NationalInstitutesofHealth_1SotubaVisit1,Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study,2021-06-29,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mali,Bamako,Bamako,"We assessed individuals aged 6 months or older from 3 communities in Mali for anti-SARS-CoV-2 antibodies.

...

Community members including those enrolled in existing malaria studies were invited to participate.",,2020-07-29,2020-10-16,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,587,0.19,0.142,0.23800000000000002,True,True,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.7390000000000001,0.9940000000000001,['Moderate'],Yes,No,No,Yes,Unclear,Unclear,Yes,Yes,Unclear,Issaka Sagara,National Institutes of Health,Unity-Aligned, https://doi.org/10.1093/cid/ciab589,2022-03-09,2022-07-16,Verified,sagara_rapidly_2021-2,MLI
210629_Mali_NationalInstitutesofHealth_1SotubaVisit1_Age18+,210629_Mali_NationalInstitutesofHealth_1SotubaVisit1,Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study,2021-06-29,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mali,Bamako,Bamako,"We assessed individuals aged 6 months or older from 3 communities in Mali for anti-SARS-CoV-2 antibodies.

...

Community members including those enrolled in existing malaria studies were invited to participate.",,2020-07-29,2020-10-16,Household and community samples,All,Multiple groups,18.0,,Age,,229,0.162,0.114,0.21,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.7390000000000001,0.9940000000000001,['Moderate'],Yes,No,No,Yes,Unclear,Unclear,Yes,Yes,Unclear,Issaka Sagara,National Institutes of Health,Unity-Aligned, https://doi.org/10.1093/cid/ciab589,2022-03-09,2022-07-16,Verified,sagara_rapidly_2021-2,MLI
210629_Mali_NationalInstitutesofHealth_1SotubaVisit1_Age<10,210629_Mali_NationalInstitutesofHealth_1SotubaVisit1,Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study,2021-06-29,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mali,Bamako,Bamako,"We assessed individuals aged 6 months or older from 3 communities in Mali for anti-SARS-CoV-2 antibodies.

...

Community members including those enrolled in existing malaria studies were invited to participate.",,2020-07-29,2020-10-16,Household and community samples,All,Children and Youth (0-17 years),0.0,9.0,Age,,202,0.107,0.063,0.151,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.7390000000000001,0.9940000000000001,['Moderate'],Yes,No,No,Yes,Unclear,Unclear,Yes,Yes,Unclear,Issaka Sagara,National Institutes of Health,Unity-Aligned, https://doi.org/10.1093/cid/ciab589,2022-03-09,2022-07-16,Verified,sagara_rapidly_2021-2,MLI
210629_Mali_NationalInstitutesofHealth_1SotubaVisit1_Age10-17,210629_Mali_NationalInstitutesofHealth_1SotubaVisit1,Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study,2021-06-29,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mali,Bamako,Bamako,"We assessed individuals aged 6 months or older from 3 communities in Mali for anti-SARS-CoV-2 antibodies.

...

Community members including those enrolled in existing malaria studies were invited to participate.",,2020-07-29,2020-10-16,Household and community samples,All,Children and Youth (0-17 years),10.0,17.0,Age,,163,0.11699999999999999,0.066,0.167,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.7390000000000001,0.9940000000000001,['Moderate'],Yes,No,No,Yes,Unclear,Unclear,Yes,Yes,Unclear,Issaka Sagara,National Institutes of Health,Unity-Aligned, https://doi.org/10.1093/cid/ciab589,2022-03-09,2022-07-16,Verified,sagara_rapidly_2021-2,MLI
210629_Mali_NationalInstitutesofHealth_1SotubaVisit1_OverallCrude,210629_Mali_NationalInstitutesofHealth_1SotubaVisit1,Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study,2021-06-29,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mali,Bamako,Bamako,"We assessed individuals aged 6 months or older from 3 communities in Mali for anti-SARS-CoV-2 antibodies.

...

Community members including those enrolled in existing malaria studies were invited to participate.",,2020-07-29,2020-10-16,Household and community samples,All,Multiple groups,0.0,,Analysis,,587,0.131,0.10400000000000001,0.159,,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.7390000000000001,0.9940000000000001,['Moderate'],Yes,No,No,Yes,Unclear,Unclear,Yes,Yes,Unclear,Issaka Sagara,National Institutes of Health,Unity-Aligned, https://doi.org/10.1093/cid/ciab589,2022-03-09,2022-07-16,Verified,sagara_rapidly_2021-2,MLI
210629_Mali_NationalInstitutesofHealth_1SotubaVisit2_OverallAdjusted,210629_Mali_NationalInstitutesofHealth_1SotubaVisit2,Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study,2021-06-29,Journal Article (Peer-Reviewed),Local,Prospective cohort,Mali,Bamako,Bamako,"We assessed individuals aged 6 months or older from 3 communities in Mali for anti-SARS-CoV-2 antibodies.

...

Community members including those enrolled in existing malaria studies were invited to participate.",,2020-12-21,2021-01-26,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,528,0.7040000000000001,0.568,0.841,True,True,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.7390000000000001,0.9940000000000001,['Moderate'],Yes,No,No,No,Unclear,Unclear,Yes,Yes,Unclear,Issaka Sagara,National Institutes of Health,Unity-Aligned, https://doi.org/10.1093/cid/ciab589,2022-03-09,2022-07-16,Verified,sagara_rapidly_2021-2,MLI
210629_Mali_NationalInstitutesofHealth_1SotubaVisit2_Age18+,210629_Mali_NationalInstitutesofHealth_1SotubaVisit2,Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study,2021-06-29,Journal Article (Peer-Reviewed),Local,Prospective cohort,Mali,Bamako,Bamako,"We assessed individuals aged 6 months or older from 3 communities in Mali for anti-SARS-CoV-2 antibodies.

...

Community members including those enrolled in existing malaria studies were invited to participate.",,2020-12-21,2021-01-26,Household and community samples,All,Multiple groups,18.0,,Age,,229,0.5720000000000001,0.504,0.64,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.7390000000000001,0.9940000000000001,['Moderate'],Yes,No,No,No,Unclear,Unclear,Yes,Yes,Unclear,Issaka Sagara,National Institutes of Health,Unity-Aligned, https://doi.org/10.1093/cid/ciab589,2022-03-09,2022-07-16,Verified,sagara_rapidly_2021-2,MLI
210629_Mali_NationalInstitutesofHealth_1SotubaVisit2_OverallCrude,210629_Mali_NationalInstitutesofHealth_1SotubaVisit2,Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study,2021-06-29,Journal Article (Peer-Reviewed),Local,Prospective cohort,Mali,Bamako,Bamako,"We assessed individuals aged 6 months or older from 3 communities in Mali for anti-SARS-CoV-2 antibodies.

...

Community members including those enrolled in existing malaria studies were invited to participate.",,2020-12-21,2021-01-26,Household and community samples,All,Multiple groups,0.0,,Analysis,,528,0.449,0.40700000000000003,0.49100000000000005,,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.7390000000000001,0.9940000000000001,['Moderate'],Yes,No,No,No,Unclear,Unclear,Yes,Yes,Unclear,Issaka Sagara,National Institutes of Health,Unity-Aligned, https://doi.org/10.1093/cid/ciab589,2022-03-09,2022-07-16,Verified,sagara_rapidly_2021-2,MLI
210629_Mali_NationalInstitutesofHealth_1SotubaVisit2_Age<10,210629_Mali_NationalInstitutesofHealth_1SotubaVisit2,Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study,2021-06-29,Journal Article (Peer-Reviewed),Local,Prospective cohort,Mali,Bamako,Bamako,"We assessed individuals aged 6 months or older from 3 communities in Mali for anti-SARS-CoV-2 antibodies.

...

Community members including those enrolled in existing malaria studies were invited to participate.",,2020-12-21,2021-01-26,Household and community samples,All,Children and Youth (0-17 years),0.0,9.0,Age,,202,0.29100000000000004,0.22399999999999998,0.35700000000000004,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.7390000000000001,0.9940000000000001,['Moderate'],Yes,No,No,No,Unclear,Unclear,Yes,Yes,Unclear,Issaka Sagara,National Institutes of Health,Unity-Aligned, https://doi.org/10.1093/cid/ciab589,2022-03-09,2022-07-16,Verified,sagara_rapidly_2021-2,MLI
210629_Mali_NationalInstitutesofHealth_1SotubaVisit2_Age10-17,210629_Mali_NationalInstitutesofHealth_1SotubaVisit2,Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study,2021-06-29,Journal Article (Peer-Reviewed),Local,Prospective cohort,Mali,Bamako,Bamako,"We assessed individuals aged 6 months or older from 3 communities in Mali for anti-SARS-CoV-2 antibodies.

...

Community members including those enrolled in existing malaria studies were invited to participate.",,2020-12-21,2021-01-26,Household and community samples,All,Children and Youth (0-17 years),10.0,17.0,Age,,163,0.473,0.394,0.552,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.7390000000000001,0.9940000000000001,['Moderate'],Yes,No,No,No,Unclear,Unclear,Yes,Yes,Unclear,Issaka Sagara,National Institutes of Health,Unity-Aligned, https://doi.org/10.1093/cid/ciab589,2022-03-09,2022-07-16,Verified,sagara_rapidly_2021-2,MLI
210629_Mali_NationalInstitutesofHealth_2BancoumanaVisit1_OverallAdjusted,210629_Mali_NationalInstitutesofHealth_2BancoumanaVisit1,Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study,2021-06-29,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mali,Koulikoro Region,Bancoumana,"We assessed individuals aged 6 months or older from 3 communities in Mali for anti-SARS-CoV-2 antibodies.

...

Community members including those enrolled in existing malaria studies were invited to participate.",,2020-07-29,2020-09-24,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,963,0.065,0.040999999999999995,0.09,True,True,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.7390000000000001,0.9940000000000001,['Moderate'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Issaka Sagara,National Institutes of Health,Unity-Aligned, https://doi.org/10.1093/cid/ciab589,2022-03-09,2022-07-16,Verified,sagara_rapidly_2021-2,MLI
210629_Mali_NationalInstitutesofHealth_2BancoumanaVisit1_Age18+,210629_Mali_NationalInstitutesofHealth_2BancoumanaVisit1,Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study,2021-06-29,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mali,Koulikoro Region,Bancoumana,"We assessed individuals aged 6 months or older from 3 communities in Mali for anti-SARS-CoV-2 antibodies.

...

Community members including those enrolled in existing malaria studies were invited to participate.",,2020-07-29,2020-09-24,Household and community samples,All,Multiple groups,18.0,,Age,,402,0.057,0.034,0.081,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.7390000000000001,0.9940000000000001,['Moderate'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Issaka Sagara,National Institutes of Health,Unity-Aligned, https://doi.org/10.1093/cid/ciab589,2022-03-09,2022-07-16,Verified,sagara_rapidly_2021-2,MLI
210629_Mali_NationalInstitutesofHealth_2BancoumanaVisit1_Age<10,210629_Mali_NationalInstitutesofHealth_2BancoumanaVisit1,Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study,2021-06-29,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mali,Koulikoro Region,Bancoumana,"We assessed individuals aged 6 months or older from 3 communities in Mali for anti-SARS-CoV-2 antibodies.

...

Community members including those enrolled in existing malaria studies were invited to participate.",,2020-07-29,2020-09-24,Household and community samples,All,Children and Youth (0-17 years),0.0,9.0,Age,,279,0.04,0.015,0.064,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.7390000000000001,0.9940000000000001,['Moderate'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Issaka Sagara,National Institutes of Health,Unity-Aligned, https://doi.org/10.1093/cid/ciab589,2022-03-09,2022-07-16,Verified,sagara_rapidly_2021-2,MLI
210629_Mali_NationalInstitutesofHealth_2BancoumanaVisit1_Age10-17,210629_Mali_NationalInstitutesofHealth_2BancoumanaVisit1,Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study,2021-06-29,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mali,Koulikoro Region,Bancoumana,"We assessed individuals aged 6 months or older from 3 communities in Mali for anti-SARS-CoV-2 antibodies.

...

Community members including those enrolled in existing malaria studies were invited to participate.",,2020-07-29,2020-09-24,Household and community samples,All,Children and Youth (0-17 years),10.0,17.0,Age,,284,0.06,0.031000000000000003,0.08800000000000001,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.7390000000000001,0.9940000000000001,['Moderate'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Issaka Sagara,National Institutes of Health,Unity-Aligned, https://doi.org/10.1093/cid/ciab589,2022-03-09,2022-07-16,Verified,sagara_rapidly_2021-2,MLI
210629_Mali_NationalInstitutesofHealth_2BancoumanaVisit1_OverallCrude,210629_Mali_NationalInstitutesofHealth_2BancoumanaVisit1,Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study,2021-06-29,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mali,Koulikoro Region,Bancoumana,"We assessed individuals aged 6 months or older from 3 communities in Mali for anti-SARS-CoV-2 antibodies.

...

Community members including those enrolled in existing malaria studies were invited to participate.",,2020-07-29,2020-09-24,Household and community samples,All,Multiple groups,0.0,,Analysis,,963,0.053,0.039,0.067,,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.7390000000000001,0.9940000000000001,['Moderate'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Issaka Sagara,National Institutes of Health,Unity-Aligned, https://doi.org/10.1093/cid/ciab589,2022-03-09,2022-07-16,Verified,sagara_rapidly_2021-2,MLI
210629_Mali_NationalInstitutesofHealth_2BancoumanaVisit2_OverallAdjusted,210629_Mali_NationalInstitutesofHealth_2BancoumanaVisit2,Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study,2021-06-29,Journal Article (Peer-Reviewed),Local,Prospective cohort,Mali,Koulikoro Region,Bancoumana,"We assessed individuals aged 6 months or older from 3 communities in Mali for anti-SARS-CoV-2 antibodies.

...

Community members including those enrolled in existing malaria studies were invited to participate.",,2020-12-28,2021-01-29,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,904,0.521,0.419,0.623,True,True,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.7390000000000001,0.9940000000000001,['Moderate'],Yes,No,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Issaka Sagara,National Institutes of Health,Unity-Aligned, https://doi.org/10.1093/cid/ciab589,2022-03-09,2022-07-16,Verified,sagara_rapidly_2021-2,MLI
210629_Mali_NationalInstitutesofHealth_2BancoumanaVisit2_OverallCrude,210629_Mali_NationalInstitutesofHealth_2BancoumanaVisit2,Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study,2021-06-29,Journal Article (Peer-Reviewed),Local,Prospective cohort,Mali,Koulikoro Region,Bancoumana,"We assessed individuals aged 6 months or older from 3 communities in Mali for anti-SARS-CoV-2 antibodies.

...

Community members including those enrolled in existing malaria studies were invited to participate.",,2020-12-28,2021-01-29,Household and community samples,All,Multiple groups,0.0,,Analysis,,904,0.355,0.324,0.386,,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.7390000000000001,0.9940000000000001,['Moderate'],Yes,No,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Issaka Sagara,National Institutes of Health,Unity-Aligned, https://doi.org/10.1093/cid/ciab589,2022-03-09,2022-07-16,Verified,sagara_rapidly_2021-2,MLI
210629_Mali_NationalInstitutesofHealth_2BancoumanaVisit2_Age10-17,210629_Mali_NationalInstitutesofHealth_2BancoumanaVisit2,Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study,2021-06-29,Journal Article (Peer-Reviewed),Local,Prospective cohort,Mali,Koulikoro Region,Bancoumana,"We assessed individuals aged 6 months or older from 3 communities in Mali for anti-SARS-CoV-2 antibodies.

...

Community members including those enrolled in existing malaria studies were invited to participate.",,2020-12-28,2021-01-29,Household and community samples,All,Children and Youth (0-17 years),10.0,17.0,Age,,284,0.36600000000000005,0.308,0.244,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.7390000000000001,0.9940000000000001,['Moderate'],Yes,No,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Issaka Sagara,National Institutes of Health,Unity-Aligned, https://doi.org/10.1093/cid/ciab589,2022-03-09,2022-07-16,Verified,sagara_rapidly_2021-2,MLI
210629_Mali_NationalInstitutesofHealth_2BancoumanaVisit2_Age18+,210629_Mali_NationalInstitutesofHealth_2BancoumanaVisit2,Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study,2021-06-29,Journal Article (Peer-Reviewed),Local,Prospective cohort,Mali,Koulikoro Region,Bancoumana,"We assessed individuals aged 6 months or older from 3 communities in Mali for anti-SARS-CoV-2 antibodies.

...

Community members including those enrolled in existing malaria studies were invited to participate.",,2020-12-28,2021-01-29,Household and community samples,All,Multiple groups,18.0,,Age,,402,0.42600000000000005,0.376,0.47600000000000003,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.7390000000000001,0.9940000000000001,['Moderate'],Yes,No,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Issaka Sagara,National Institutes of Health,Unity-Aligned, https://doi.org/10.1093/cid/ciab589,2022-03-09,2022-07-16,Verified,sagara_rapidly_2021-2,MLI
210629_Mali_NationalInstitutesofHealth_2BancoumanaVisit2_Age<10,210629_Mali_NationalInstitutesofHealth_2BancoumanaVisit2,Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study,2021-06-29,Journal Article (Peer-Reviewed),Local,Prospective cohort,Mali,Koulikoro Region,Bancoumana,"We assessed individuals aged 6 months or older from 3 communities in Mali for anti-SARS-CoV-2 antibodies.

...

Community members including those enrolled in existing malaria studies were invited to participate.",,2020-12-28,2021-01-29,Household and community samples,All,Children and Youth (0-17 years),0.0,9.0,Age,,279,0.242,0.19100000000000003,0.294,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.7390000000000001,0.9940000000000001,['Moderate'],Yes,No,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Issaka Sagara,National Institutes of Health,Unity-Aligned, https://doi.org/10.1093/cid/ciab589,2022-03-09,2022-07-16,Verified,sagara_rapidly_2021-2,MLI
210629_Mali_NationalInstitutesofHealth_3DoneguebougouVisit1_OverallAdjusted,210629_Mali_NationalInstitutesofHealth_3DoneguebougouVisit1,Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study,2021-06-29,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mali,Koulikoro Region,Doneguebougou,"We assessed individuals aged 6 months or older from 3 communities in Mali for anti-SARS-CoV-2 antibodies.

...

Community members including those enrolled in existing malaria studies were invited to participate.",,2020-07-28,2020-08-27,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,1109,0.05,0.027999999999999997,0.071,True,True,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.7390000000000001,0.9940000000000001,['Moderate'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Issaka Sagara,National Institutes of Health,Unity-Aligned, https://doi.org/10.1093/cid/ciab589,2022-03-09,2022-07-16,Verified,sagara_rapidly_2021-2,MLI
210629_Mali_NationalInstitutesofHealth_3DoneguebougouVisit1_Age<10,210629_Mali_NationalInstitutesofHealth_3DoneguebougouVisit1,Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study,2021-06-29,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mali,Koulikoro Region,Doneguebougou,"We assessed individuals aged 6 months or older from 3 communities in Mali for anti-SARS-CoV-2 antibodies.

...

Community members including those enrolled in existing malaria studies were invited to participate.",,2020-07-28,2020-08-27,Household and community samples,All,Children and Youth (0-17 years),0.0,9.0,Age,,356,0.031000000000000003,0.012,0.051,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.7390000000000001,0.9940000000000001,['Moderate'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Issaka Sagara,National Institutes of Health,Unity-Aligned, https://doi.org/10.1093/cid/ciab589,2022-03-09,2022-07-16,Verified,sagara_rapidly_2021-2,MLI
210629_Mali_NationalInstitutesofHealth_3DoneguebougouVisit1_Age18+,210629_Mali_NationalInstitutesofHealth_3DoneguebougouVisit1,Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study,2021-06-29,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mali,Koulikoro Region,Doneguebougou,"We assessed individuals aged 6 months or older from 3 communities in Mali for anti-SARS-CoV-2 antibodies.

...

Community members including those enrolled in existing malaria studies were invited to participate.",,2020-07-28,2020-08-27,Household and community samples,All,Multiple groups,18.0,,Age,,467,0.062000000000000006,0.04,0.085,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.7390000000000001,0.9940000000000001,['Moderate'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Issaka Sagara,National Institutes of Health,Unity-Aligned, https://doi.org/10.1093/cid/ciab589,2022-03-09,2022-07-16,Verified,sagara_rapidly_2021-2,MLI
210629_Mali_NationalInstitutesofHealth_3DoneguebougouVisit1_Age10-17,210629_Mali_NationalInstitutesofHealth_3DoneguebougouVisit1,Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study,2021-06-29,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mali,Koulikoro Region,Doneguebougou,"We assessed individuals aged 6 months or older from 3 communities in Mali for anti-SARS-CoV-2 antibodies.

...

Community members including those enrolled in existing malaria studies were invited to participate.",,2020-07-28,2020-08-27,Household and community samples,All,Children and Youth (0-17 years),10.0,17.0,Age,,290,0.017,0.0,0.035,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.7390000000000001,0.9940000000000001,['Moderate'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Issaka Sagara,National Institutes of Health,Unity-Aligned, https://doi.org/10.1093/cid/ciab589,2022-03-09,2022-07-16,Verified,sagara_rapidly_2021-2,MLI
210629_Mali_NationalInstitutesofHealth_3DoneguebougouVisit1_OverallCrude,210629_Mali_NationalInstitutesofHealth_3DoneguebougouVisit1,Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study,2021-06-29,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mali,Koulikoro Region,Doneguebougou,"We assessed individuals aged 6 months or older from 3 communities in Mali for anti-SARS-CoV-2 antibodies.

...

Community members including those enrolled in existing malaria studies were invited to participate.",,2020-07-28,2020-08-27,Household and community samples,All,Multiple groups,0.0,,Analysis,,1109,0.040999999999999995,0.028999999999999998,0.052000000000000005,,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.7390000000000001,0.9940000000000001,['Moderate'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Issaka Sagara,National Institutes of Health,Unity-Aligned, https://doi.org/10.1093/cid/ciab589,2022-03-09,2022-07-16,Verified,sagara_rapidly_2021-2,MLI
210629_Mali_NationalInstitutesofHealth_3DoneguebougouVisit2_OverallAdjusted,210629_Mali_NationalInstitutesofHealth_3DoneguebougouVisit2,Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study,2021-06-29,Journal Article (Peer-Reviewed),Local,Prospective cohort,Mali,Koulikoro Region,Doneguebougou,"We assessed individuals aged 6 months or older from 3 communities in Mali for anti-SARS-CoV-2 antibodies.

...

Community members including those enrolled in existing malaria studies were invited to participate.",,2020-12-14,2021-01-15,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,1088,0.35000000000000003,0.27899999999999997,0.42100000000000004,True,True,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.7390000000000001,0.9940000000000001,['Moderate'],Yes,No,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Issaka Sagara,National Institutes of Health,Unity-Aligned, https://doi.org/10.1093/cid/ciab589,2022-03-09,2022-07-16,Verified,sagara_rapidly_2021-2,MLI
210629_Mali_NationalInstitutesofHealth_3DoneguebougouVisit2_OverallCrude,210629_Mali_NationalInstitutesofHealth_3DoneguebougouVisit2,Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study,2021-06-29,Journal Article (Peer-Reviewed),Local,Prospective cohort,Mali,Koulikoro Region,Doneguebougou,"We assessed individuals aged 6 months or older from 3 communities in Mali for anti-SARS-CoV-2 antibodies.

...

Community members including those enrolled in existing malaria studies were invited to participate.",,2020-12-14,2021-01-15,Household and community samples,All,Multiple groups,0.0,,Analysis,,1088,0.258,0.23199999999999998,0.284,,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.7390000000000001,0.9940000000000001,['Moderate'],Yes,No,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Issaka Sagara,National Institutes of Health,Unity-Aligned, https://doi.org/10.1093/cid/ciab589,2022-03-09,2022-07-16,Verified,sagara_rapidly_2021-2,MLI
210629_Mali_NationalInstitutesofHealth_3DoneguebougouVisit2_Age10-17,210629_Mali_NationalInstitutesofHealth_3DoneguebougouVisit2,Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study,2021-06-29,Journal Article (Peer-Reviewed),Local,Prospective cohort,Mali,Koulikoro Region,Doneguebougou,"We assessed individuals aged 6 months or older from 3 communities in Mali for anti-SARS-CoV-2 antibodies.

...

Community members including those enrolled in existing malaria studies were invited to participate.",,2020-12-14,2021-01-15,Household and community samples,All,Children and Youth (0-17 years),10.0,17.0,Age,,290,0.28500000000000003,0.23199999999999998,0.337,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.7390000000000001,0.9940000000000001,['Moderate'],Yes,No,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Issaka Sagara,National Institutes of Health,Unity-Aligned, https://doi.org/10.1093/cid/ciab589,2022-03-09,2022-07-16,Verified,sagara_rapidly_2021-2,MLI
210629_Mali_NationalInstitutesofHealth_3DoneguebougouVisit2_Age18+,210629_Mali_NationalInstitutesofHealth_3DoneguebougouVisit2,Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study,2021-06-29,Journal Article (Peer-Reviewed),Local,Prospective cohort,Mali,Koulikoro Region,Doneguebougou,"We assessed individuals aged 6 months or older from 3 communities in Mali for anti-SARS-CoV-2 antibodies.

...

Community members including those enrolled in existing malaria studies were invited to participate.",,2020-12-14,2021-01-15,Household and community samples,All,Multiple groups,18.0,,Age,,467,0.34700000000000003,0.304,0.391,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.7390000000000001,0.9940000000000001,['Moderate'],Yes,No,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Issaka Sagara,National Institutes of Health,Unity-Aligned, https://doi.org/10.1093/cid/ciab589,2022-03-09,2022-07-16,Verified,sagara_rapidly_2021-2,MLI
210629_Mali_NationalInstitutesofHealth_3DoneguebougouVisit2_Age<10,210629_Mali_NationalInstitutesofHealth_3DoneguebougouVisit2,Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study,2021-06-29,Journal Article (Peer-Reviewed),Local,Prospective cohort,Mali,Koulikoro Region,Doneguebougou,"We assessed individuals aged 6 months or older from 3 communities in Mali for anti-SARS-CoV-2 antibodies.

...

Community members including those enrolled in existing malaria studies were invited to participate.",,2020-12-14,2021-01-15,Household and community samples,All,Children and Youth (0-17 years),0.0,9.0,Age,,356,0.122,0.08800000000000001,0.157,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.7390000000000001,0.9940000000000001,['Moderate'],Yes,No,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Issaka Sagara,National Institutes of Health,Unity-Aligned, https://doi.org/10.1093/cid/ciab589,2022-03-09,2022-07-16,Verified,sagara_rapidly_2021-2,MLI
220107_Bamako_UniversityOfBamako,220107_Bamako_UniversityOfBamako,"High SARS-CoV-2 Seroprevalence among Healthcare Workers in Bamako, Mali",2022-01-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mali,,Bamako,"HCWs were eligible to take part in the study if
they had no symptoms suggestive of COVID-19 on the day of enrollment and had no
positive PCR test for COVID-19 in the last three days before study enrollment. However,
participants were asked to report all symptoms experienced and PCR results in the past
3 months of study enrollment.
",,2020-11-15,2021-06-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,238,0.6176,,,True,,,,True,Convenience,SARS-CoV-2 IgG ELISA,Enzo Life Sciences,ELISA,Serum,IgG,Spike,Validated by manufacturers,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Anou M. Somboro,University Of Bamako,Not Unity-Aligned,https://dx.doi.org/10.3390/v14010102,2022-01-21,2022-07-16,Unverified,somboroHighSARSCoV2Seroprevalence2022,MLI
220216_Bamako_SorbonneUniversite_Overall,220216_Bamako_SorbonneUniversite,High SARS-CoV-2 Seroprevalence among Healthcare Workers in Bamako Referral Hospitals: A Prospective Multi-Site Cross-sectional Study (ANRS COV11),2022-02-16,Preprint,Local,Cross-sectional survey ,Mali,,Bamako,"HCW older than 18 years working in three referral
51 hospitals with a center for COVID-19 patient management in Bamako (Gabriel Toure
52 University Hospital, Dermatology Hospital of Bamako, and Mali Hospital). ",,2021-03-16,2021-07-15,Health care workers and caregivers,All,Adults (18-64 years),19.0,,Primary Estimate,,195,0.523,,,True,,,,True,Convenience,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,,0.9400000000000001,['High'],,No,No,Yes,,No,Yes,No,,Almoustapha Maiga,Sorbonne Universite,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2022.02.019,2022-02-28,2024-03-01,Unverified,maiga_high_2022,MLI
220616_Kita_UniversityCollegeLondon_Community_Overall,220616_Kita_UniversityCollegeLondon_Community,"SARS-CoV-2 infection and antibody seroprevalence in routine surveillance patients, healthcare workers and general population in Kita region, Mali: an observational study 2020–2021",2022-06-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mali,,Kita,"apparently healthy community residents in 16 villages in or near Kita town, Mali",,2020-12-01,2020-12-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,875,0.2766,,,True,,,,True,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.93,1.0,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Dagmar Alber,Tampere University,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-060367,2022-06-29,2024-03-31,Unverified,alber_sars-cov-2_2022,MLI
220616_Kita_UniversityCollegeLondon_Community_Male,220616_Kita_UniversityCollegeLondon_Community,"SARS-CoV-2 infection and antibody seroprevalence in routine surveillance patients, healthcare workers and general population in Kita region, Mali: an observational study 2020–2021",2022-06-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mali,,Kita,"apparently healthy community residents in 16 villages in or near Kita town, Mali",,2020-12-01,2020-12-31,Household and community samples,Male,Multiple groups,,,Sex/Gender,,330,0.297,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.93,1.0,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Dagmar Alber,Tampere University,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-060367,2022-06-29,2024-03-01,Unverified,alber_sars-cov-2_2022,MLI
220616_Kita_UniversityCollegeLondon_Community_Female,220616_Kita_UniversityCollegeLondon_Community,"SARS-CoV-2 infection and antibody seroprevalence in routine surveillance patients, healthcare workers and general population in Kita region, Mali: an observational study 2020–2021",2022-06-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mali,,Kita,"apparently healthy community residents in 16 villages in or near Kita town, Mali",,2020-12-01,2020-12-31,Household and community samples,Female,Multiple groups,,,Sex/Gender,,543,0.2615,,,,,,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.93,1.0,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Dagmar Alber,Tampere University,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-060367,2022-06-29,2024-03-01,Unverified,alber_sars-cov-2_2022,MLI
220803_Mali_NationalInstituteofAllergyandInfectiousDiseases_Visit2_overall,220803_Mali_NationalInstituteofAllergyandInfectiousDiseases_Visit2,"Recent malaria does not substantially impact COVID-19 antibody response or rates of symptomatic illness in communities with high malaria and COVID-19 transmission in Mali, West Africa",2022-08-03,Journal Article (Peer-Reviewed),National,Prospective cohort,Mali,,,"""Malian individuals participating in the longitudinal cohort COVID-19 serosurvey who also underwent intensive malaria surveillance in clinical trials of investigational malaria vaccines during the 2020 transmission season were included in this subgroup analysis""","""After excluding participants with asymptomatic infection ...""

""... seven were COVID-19 seropositive at visit 1 and were removed from the analysis as the time of COVID-19 seroconversion did not occur during the study period""",2020-12-15,2021-01-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,1314,0.298,,,True,,,,True,Sequential,Not reported/ Unable to specify,,ELISA,Plasma,,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,John Woodford,National Institute of Allergy and Infectious Diseases,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2022.959697,2022-08-30,2022-08-31,Unverified,woodfordRecentMalariaDoes2022,MLI
220803_Mali_NationalInstituteofAllergyandInfectiousDiseases_Visit2_children,220803_Mali_NationalInstituteofAllergyandInfectiousDiseases_Visit2,"Recent malaria does not substantially impact COVID-19 antibody response or rates of symptomatic illness in communities with high malaria and COVID-19 transmission in Mali, West Africa",2022-08-03,Journal Article (Peer-Reviewed),National,Prospective cohort,Mali,,,"""Malian individuals participating in the longitudinal cohort COVID-19 serosurvey who also underwent intensive malaria surveillance in clinical trials of investigational malaria vaccines during the 2020 transmission season were included in this subgroup analysis""","""After excluding participants with asymptomatic infection ...""

""... seven were COVID-19 seropositive at visit 1 and were removed from the analysis as the time of COVID-19 seroconversion did not occur during the study period""",2020-12-15,2021-01-15,Household and community samples,All,Multiple groups,,17.0,Age,<18,613,0.184,,,,,,,,Sequential,Not reported/ Unable to specify,,ELISA,Plasma,,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,John Woodford,National Institute of Allergy and Infectious Diseases,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2022.959697,2022-08-30,2022-08-31,Unverified,woodfordRecentMalariaDoes2022,MLI
220803_Mali_NationalInstituteofAllergyandInfectiousDiseases_Visit2_adult,220803_Mali_NationalInstituteofAllergyandInfectiousDiseases_Visit2,"Recent malaria does not substantially impact COVID-19 antibody response or rates of symptomatic illness in communities with high malaria and COVID-19 transmission in Mali, West Africa",2022-08-03,Journal Article (Peer-Reviewed),National,Prospective cohort,Mali,,,"""Malian individuals participating in the longitudinal cohort COVID-19 serosurvey who also underwent intensive malaria surveillance in clinical trials of investigational malaria vaccines during the 2020 transmission season were included in this subgroup analysis""","""After excluding participants with asymptomatic infection ...""

""... seven were COVID-19 seropositive at visit 1 and were removed from the analysis as the time of COVID-19 seroconversion did not occur during the study period""",2020-12-15,2021-01-15,Household and community samples,All,Multiple groups,18.0,,Age,=>18,701,0.39799999999999996,,,,,,,,Sequential,Not reported/ Unable to specify,,ELISA,Plasma,,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,John Woodford,National Institute of Allergy and Infectious Diseases,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2022.959697,2022-08-30,2022-08-31,Unverified,woodfordRecentMalariaDoes2022,MLI
220803_Mali_NationalInstituteofAllergyandInfectiousDiseases_Visit3_overall,220803_Mali_NationalInstituteofAllergyandInfectiousDiseases_Visit3,"Recent malaria does not substantially impact COVID-19 antibody response or rates of symptomatic illness in communities with high malaria and COVID-19 transmission in Mali, West Africa",2022-08-03,Journal Article (Peer-Reviewed),National,Prospective cohort,Mali,,,"""Malian individuals participating in the longitudinal cohort COVID-19 serosurvey who also underwent intensive malaria surveillance in clinical trials of investigational malaria vaccines during the 2020 transmission season were included in this subgroup analysis""","""After excluding participants with asymptomatic infection ...""

""... seven were COVID-19 seropositive at visit 1 and were removed from the analysis as the time of COVID-19 seroconversion did not occur during the study period""

"" Due to budget restrictions participants at the Bancoumana site did not undergo visit 3 follow up""

""Nine participants were removed from the visit 3 analysis due to intercurrent COVID-19 vaccination as serostatus due to natural infection could no longer be assessed. """,2021-07-01,2021-07-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,787,0.306,,,True,,,,True,Sequential,Not reported/ Unable to specify,,ELISA,Plasma,,Spike,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,John Woodford,National Institute of Allergy and Infectious Diseases,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2022.959697,2022-08-30,2022-08-31,Unverified,woodfordRecentMalariaDoes2022,MLI
220803_Mali_NationalInstituteofAllergyandInfectiousDiseases_Visit2_adult,220803_Mali_NationalInstituteofAllergyandInfectiousDiseases_Visit3,"Recent malaria does not substantially impact COVID-19 antibody response or rates of symptomatic illness in communities with high malaria and COVID-19 transmission in Mali, West Africa",2022-08-03,Journal Article (Peer-Reviewed),National,Prospective cohort,Mali,,,"""Malian individuals participating in the longitudinal cohort COVID-19 serosurvey who also underwent intensive malaria surveillance in clinical trials of investigational malaria vaccines during the 2020 transmission season were included in this subgroup analysis""","""After excluding participants with asymptomatic infection ...""

""... seven were COVID-19 seropositive at visit 1 and were removed from the analysis as the time of COVID-19 seroconversion did not occur during the study period""

"" Due to budget restrictions participants at the Bancoumana site did not undergo visit 3 follow up""

""Nine participants were removed from the visit 3 analysis due to intercurrent COVID-19 vaccination as serostatus due to natural infection could no longer be assessed. """,2021-07-01,2021-07-31,Household and community samples,All,Multiple groups,18.0,,Age,=>18,303,0.386,,,,,,,,Sequential,Not reported/ Unable to specify,,ELISA,Plasma,,Spike,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,John Woodford,National Institute of Allergy and Infectious Diseases,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2022.959697,2022-08-30,2022-08-31,Unverified,woodfordRecentMalariaDoes2022,MLI
220803_Mali_NationalInstituteofAllergyandInfectiousDiseases_Visit3_children,220803_Mali_NationalInstituteofAllergyandInfectiousDiseases_Visit3,"Recent malaria does not substantially impact COVID-19 antibody response or rates of symptomatic illness in communities with high malaria and COVID-19 transmission in Mali, West Africa",2022-08-03,Journal Article (Peer-Reviewed),National,Prospective cohort,Mali,,,"""Malian individuals participating in the longitudinal cohort COVID-19 serosurvey who also underwent intensive malaria surveillance in clinical trials of investigational malaria vaccines during the 2020 transmission season were included in this subgroup analysis""","""After excluding participants with asymptomatic infection ...""

""... seven were COVID-19 seropositive at visit 1 and were removed from the analysis as the time of COVID-19 seroconversion did not occur during the study period""

"" Due to budget restrictions participants at the Bancoumana site did not undergo visit 3 follow up""

""Nine participants were removed from the visit 3 analysis due to intercurrent COVID-19 vaccination as serostatus due to natural infection could no longer be assessed. """,2021-07-01,2021-07-31,Household and community samples,All,Multiple groups,,17.0,Age,<18,484,0.256,,,,,,,,Sequential,Not reported/ Unable to specify,,ELISA,Plasma,,Spike,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,John Woodford,National Institute of Allergy and Infectious Diseases,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2022.959697,2022-08-30,2022-08-31,Unverified,woodfordRecentMalariaDoes2022,MLI
230105_ Koutiala_MedecinsSansFrontières_overall,230105_ Koutiala_MedecinsSansFrontières,"Seroprevalence of anti-SARS-CoV-2 antibodies among blood donors from December 2020 to June 2021 in Koutiala district, Mali.",2023-01-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Mali,Sikasso,Koutiala,"""All persons between the ages of 18 and 60 years who had volunteered to donate blood, regardless of previous COVID-19 disease, and who met the blood donor selection criteria as established by MSF and the Ministry of Health (MOH) were included in the study after giving their consent.""","""9 were subsequently excluded from the analysis due to poor data quality""

""While initially excluded, patients with a positive malaria RDT test were included in the study from March 2021 onwards, """,2020-12-01,2021-06-30,Blood donors,All,Adults (18-64 years),18.0,60.0,Primary Estimate,Dec 2020 -June 2021,927,0.246,0.218,0.274,True,,,,True,Sequential,NG-Test® finger-prick test,NG Biotech Laboratoires,LFIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.937,0.992,['High'],No,No,Yes,No,No,No,Yes,Yes,Unclear,Fara Wagbo Temessadouno,Medecins Sans Frontières,Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0001316,2023-05-07,2024-04-12,Verified,temessadounoSeroprevalenceAntiSARSCoV2Antibodies2023,MLI
230105_ Koutiala_MedecinsSansFrontières_dec20,230105_ Koutiala_MedecinsSansFrontières,"Seroprevalence of anti-SARS-CoV-2 antibodies among blood donors from December 2020 to June 2021 in Koutiala district, Mali.",2023-01-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Mali,Sikasso,Koutiala,"""All persons between the ages of 18 and 60 years who had volunteered to donate blood, regardless of previous COVID-19 disease, and who met the blood donor selection criteria as established by MSF and the Ministry of Health (MOH) were included in the study after giving their consent.""","""9 were subsequently excluded from the analysis due to poor data quality""

""While initially excluded, patients with a positive malaria RDT test were included in the study from March 2021 onwards, """,2020-12-01,2020-12-31,Blood donors,All,Adults (18-64 years),18.0,60.0,Time frame,Dec 2020,76,0.3026,0.199,0.406,,,,,,Sequential,NG-Test® finger-prick test,NG Biotech Laboratoires,LFIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.937,0.992,['High'],No,No,Yes,No,No,No,Yes,Yes,Unclear,Fara Wagbo Temessadouno,Medecins Sans Frontières,Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0001316,2023-05-07,2024-04-12,Verified,temessadounoSeroprevalenceAntiSARSCoV2Antibodies2023,MLI
230105_ Koutiala_MedecinsSansFrontières_march21,230105_ Koutiala_MedecinsSansFrontières,"Seroprevalence of anti-SARS-CoV-2 antibodies among blood donors from December 2020 to June 2021 in Koutiala district, Mali.",2023-01-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Mali,Sikasso,Koutiala,"""All persons between the ages of 18 and 60 years who had volunteered to donate blood, regardless of previous COVID-19 disease, and who met the blood donor selection criteria as established by MSF and the Ministry of Health (MOH) were included in the study after giving their consent.""","""9 were subsequently excluded from the analysis due to poor data quality""

""While initially excluded, patients with a positive malaria RDT test were included in the study from March 2021 onwards, """,2021-03-01,2021-03-31,Blood donors,All,Adults (18-64 years),18.0,60.0,Time frame,March 2021,222,0.2117,0.158,0.265,,,,,,Sequential,NG-Test® finger-prick test,NG Biotech Laboratoires,LFIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.937,0.992,['High'],No,No,Yes,No,No,No,Yes,Yes,Unclear,Fara Wagbo Temessadouno,Medecins Sans Frontières,Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0001316,2023-05-07,2024-04-12,Verified,temessadounoSeroprevalenceAntiSARSCoV2Antibodies2023,MLI
230105_ Koutiala_MedecinsSansFrontières_may21,230105_ Koutiala_MedecinsSansFrontières,"Seroprevalence of anti-SARS-CoV-2 antibodies among blood donors from December 2020 to June 2021 in Koutiala district, Mali.",2023-01-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Mali,Sikasso,Koutiala,"""All persons between the ages of 18 and 60 years who had volunteered to donate blood, regardless of previous COVID-19 disease, and who met the blood donor selection criteria as established by MSF and the Ministry of Health (MOH) were included in the study after giving their consent.""","""9 were subsequently excluded from the analysis due to poor data quality""

""While initially excluded, patients with a positive malaria RDT test were included in the study from March 2021 onwards, """,2021-05-01,2021-05-31,Blood donors,All,Adults (18-64 years),18.0,60.0,Time frame,May 2021,88,0.25,0.159,0.341,,,,,,Sequential,NG-Test® finger-prick test,NG Biotech Laboratoires,LFIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.937,0.992,['High'],No,No,Yes,No,No,No,Yes,Yes,Unclear,Fara Wagbo Temessadouno,Medecins Sans Frontières,Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0001316,2023-05-07,2024-04-12,Verified,temessadounoSeroprevalenceAntiSARSCoV2Antibodies2023,MLI
230105_ Koutiala_MedecinsSansFrontières_feb21,230105_ Koutiala_MedecinsSansFrontières,"Seroprevalence of anti-SARS-CoV-2 antibodies among blood donors from December 2020 to June 2021 in Koutiala district, Mali.",2023-01-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Mali,Sikasso,Koutiala,"""All persons between the ages of 18 and 60 years who had volunteered to donate blood, regardless of previous COVID-19 disease, and who met the blood donor selection criteria as established by MSF and the Ministry of Health (MOH) were included in the study after giving their consent.""","""9 were subsequently excluded from the analysis due to poor data quality""

""While initially excluded, patients with a positive malaria RDT test were included in the study from March 2021 onwards, """,2021-02-01,2021-02-28,Blood donors,All,Adults (18-64 years),18.0,60.0,Time frame,Feb 2021,250,0.244,0.191,0.297,,,,,,Sequential,NG-Test® finger-prick test,NG Biotech Laboratoires,LFIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.937,0.992,['High'],No,No,Yes,No,No,No,Yes,Yes,Unclear,Fara Wagbo Temessadouno,Medecins Sans Frontières,Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0001316,2023-05-07,2024-04-12,Verified,temessadounoSeroprevalenceAntiSARSCoV2Antibodies2023,MLI
230105_ Koutiala_MedecinsSansFrontières_april21,230105_ Koutiala_MedecinsSansFrontières,"Seroprevalence of anti-SARS-CoV-2 antibodies among blood donors from December 2020 to June 2021 in Koutiala district, Mali.",2023-01-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Mali,Sikasso,Koutiala,"""All persons between the ages of 18 and 60 years who had volunteered to donate blood, regardless of previous COVID-19 disease, and who met the blood donor selection criteria as established by MSF and the Ministry of Health (MOH) were included in the study after giving their consent.""","""9 were subsequently excluded from the analysis due to poor data quality""

""While initially excluded, patients with a positive malaria RDT test were included in the study from March 2021 onwards, """,2021-04-01,2021-04-30,Blood donors,All,Adults (18-64 years),18.0,60.0,Time frame,April 2021,90,0.2667,0.174,0.359,,,,,,Sequential,NG-Test® finger-prick test,NG Biotech Laboratoires,LFIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.937,0.992,['High'],No,No,Yes,No,No,No,Yes,Yes,Unclear,Fara Wagbo Temessadouno,Medecins Sans Frontières,Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0001316,2023-05-07,2024-04-12,Verified,temessadounoSeroprevalenceAntiSARSCoV2Antibodies2023,MLI
230105_ Koutiala_MedecinsSansFrontières_jan21,230105_ Koutiala_MedecinsSansFrontières,"Seroprevalence of anti-SARS-CoV-2 antibodies among blood donors from December 2020 to June 2021 in Koutiala district, Mali.",2023-01-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Mali,Sikasso,Koutiala,"""All persons between the ages of 18 and 60 years who had volunteered to donate blood, regardless of previous COVID-19 disease, and who met the blood donor selection criteria as established by MSF and the Ministry of Health (MOH) were included in the study after giving their consent.""","""9 were subsequently excluded from the analysis due to poor data quality""

""While initially excluded, patients with a positive malaria RDT test were included in the study from March 2021 onwards, """,2021-01-01,2021-01-31,Blood donors,All,Adults (18-64 years),18.0,60.0,Time frame,Jan 2021,132,0.2576,0.181,0.334,,,,,,Sequential,NG-Test® finger-prick test,NG Biotech Laboratoires,LFIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.937,0.992,['High'],No,No,Yes,No,No,No,Yes,Yes,Unclear,Fara Wagbo Temessadouno,Medecins Sans Frontières,Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0001316,2023-05-07,2024-04-12,Verified,temessadounoSeroprevalenceAntiSARSCoV2Antibodies2023,MLI
230105_ Koutiala_MedecinsSansFrontières_june21,230105_ Koutiala_MedecinsSansFrontières,"Seroprevalence of anti-SARS-CoV-2 antibodies among blood donors from December 2020 to June 2021 in Koutiala district, Mali.",2023-01-05,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Mali,Sikasso,Koutiala,"""All persons between the ages of 18 and 60 years who had volunteered to donate blood, regardless of previous COVID-19 disease, and who met the blood donor selection criteria as established by MSF and the Ministry of Health (MOH) were included in the study after giving their consent.""","""9 were subsequently excluded from the analysis due to poor data quality""

""While initially excluded, patients with a positive malaria RDT test were included in the study from March 2021 onwards, """,2021-06-01,2021-06-30,Blood donors,All,Adults (18-64 years),18.0,60.0,Time frame,June 2021,69,0.2464,0.144,0.349,,,,,,Sequential,NG-Test® finger-prick test,NG Biotech Laboratoires,LFIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.937,0.992,['High'],No,No,Yes,No,No,No,Yes,Yes,Unclear,Fara Wagbo Temessadouno,Medecins Sans Frontières,Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0001316,2023-05-07,2024-04-12,Verified,temessadounoSeroprevalenceAntiSARSCoV2Antibodies2023,MLI
230420_Bamako_AixMarseilleUniversity_PopAdj_Overall,230420_Bamako_AixMarseilleUniversity,"SARS-CoV-2 seroprevalence and living conditions in Bamako (Mali): a cross-sectional multistage household survey after the first epidemic wave, 2020",2023-04-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mali,,Bamako,"After selecting houses in Bamako, Mali, with a multi-stage cluster sampling method, ""all household members in the age range willing to participate were recruited. The study was conducted among the general population aged ≥1 year old for the seroprevalence study, and ≥12 years old for the questionnaire survey.""","Individuals with missing IgG results were excluded from the seroprevalence analysis [but not IgM].

Out of 1526 participants, 2 did not provide samples, 170 had no interpretable test results for both IgG and IgM, and 27 inconclusive results due to a missing IgG and negative IgM results or inversely.",2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,1.0,100.0,Primary Estimate,Adjusted for population age and sex,1327,0.164,0.08,0.249,True,,True,,True,Stratified probability,"VIDAS® SARS-COV-2 IgG,VIDAS® SARS-COV-2 IgM",BioMérieux,"ELISA,ELISA",Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,,,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Yes,Mady Cissoko,Aix-Marseille University,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2022-067124,2023-05-25,2024-04-24,Verified,cissoko_sars-cov-2_2023,MLI
230510_Bamako_UniversityOfSciencesTechniquesAndTechnologiesOfBamako,230510_Bamako_UniversityOfSciencesTechniquesAndTechnologiesOfBamako,"Seroprevalence of SARS-CoV-2 antibodies in the general population of Bamako, Mali, and factors associated with infection: a population-based cross-sectional study",2023-05-10,Preprint,Local,Cross-sectional survey ,Mali,,,"The eligibility criteria were as follows: resident of the selected locality, regardless of age, and recent or previous SARS-CoV-2 infection.","Participants who refused to provide informed consent or assent, children under one year of age, persons temporarily living in Bamako, and those suffering from diseases (such as mental and hemorrhagic) were not included.",2022-09-01,2022-09-30,Household and community samples,All,Multiple groups,1.0,,Primary Estimate,,3601,0.98,,,True,,,,True,Stratified non-probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.739,0.994,['High'],Yes,No,Yes,Yes,No,Unclear,Yes,No,Unclear,Bourama Traore,"University of Sciences, Techniques and Technologies of Bamako",Unity-Aligned,https://doi.org/10.22541/au.168369884.49641985/v1,2023-05-31,2024-04-30,Verified,traore_seroprevalence_2023,MLI
210118_Nouakchott_CentreHospitalierNationalDeNouakchott_Overall,210118_Nouakchott_CentreHospitalierNationalDeNouakchott,Serological tests for SARS-CoV-2 in a health workers population in Nouakchott-Mauritania,2021-01-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mauritania,,Nouakchott,All types of healthcare workers working at the Centre Hospitalier National de Nouakchott,,2020-05-05,2020-05-27,Health care workers and caregivers,All,Adults (18-64 years),20.0,60.0,Primary Estimate,,835,0.0167,,,True,,,,True,Convenience,SARS-CoV-2 IgG/IgM Rapid Qualitative Test Kit,Xiamen Biotime Biotechnology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9640000000000001,0.9870000000000001,['High'],No,No,Yes,Yes,No,No,Yes,Yes,Unclear,Mohamed Lemine Ould Salem,Centre Hospitalier National de Nouakchott,Not Unity-Aligned,http://dx.doi.org/10.11604/pamj.2021.38.55.24259,2021-04-13,2024-03-01,Verified,salem_depistage_2021,MRT
201021_VeracruzCity_UniversidadVeracruzana_unadj,201021_VeracruzCity_UniversidadVeracruzana,Prevalence of SARS-CoV-2 IgG antibodies in a population from Veracruz (Southeastern Mexico),2020-10-21,Preprint,Local,Cross-sectional survey ,Mexico,Veracruz,Veracruz City,Adult patients (age>=18 years) that attended 2 ambulatory diagnostic private practice centers for testing,,2020-06-01,2020-07-31,Residual sera,All,Multiple groups,18.0,98.0,Primary Estimate,,2174,0.295,0.2759,0.3147,True,,,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Jose Maria Remes-Troche,Universidad Veracruzana,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.19.20215558v1,2021-01-17,2024-03-01,Verified,remes-troche_prevalence_2020,MEX
201021_VeracruzCity_UniversidadVeracruzana_<29_unadj,201021_VeracruzCity_UniversidadVeracruzana,Prevalence of SARS-CoV-2 IgG antibodies in a population from Veracruz (Southeastern Mexico),2020-10-21,Preprint,Local,Cross-sectional survey ,Mexico,,Veracruz City,Adult patients (age>=18 years) that attended 2 ambulatory diagnostic private practice centers for testing,,2020-06-01,2020-07-31,Residual sera,All,Adults (18-64 years),0.0,29.0,Age,<29,503,0.2286282306,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Jose Maria Remes-Troche,Universidad Veracruzana,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.19.20215558v1,2021-01-17,2024-03-01,Verified,remes-troche_prevalence_2020,MEX
201021_VeracruzCity_UniversidadVeracruzana_>70_unadj,201021_VeracruzCity_UniversidadVeracruzana,Prevalence of SARS-CoV-2 IgG antibodies in a population from Veracruz (Southeastern Mexico),2020-10-21,Preprint,Local,Cross-sectional survey ,Mexico,,Veracruz City,Adult patients (age>=18 years) that attended 2 ambulatory diagnostic private practice centers for testing,,2020-06-01,2020-07-31,Residual sera,All,Seniors (65+ years),71.0,98.0,Age,>70,98,0.2755102041,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Jose Maria Remes-Troche,Universidad Veracruzana,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.19.20215558v1,2021-01-17,2024-03-01,Verified,remes-troche_prevalence_2020,MEX
201021_VeracruzCity_UniversidadVeracruzana_30-39_unadj,201021_VeracruzCity_UniversidadVeracruzana,Prevalence of SARS-CoV-2 IgG antibodies in a population from Veracruz (Southeastern Mexico),2020-10-21,Preprint,Local,Cross-sectional survey ,Mexico,,Veracruz City,Adult patients (age>=18 years) that attended 2 ambulatory diagnostic private practice centers for testing,,2020-06-01,2020-07-31,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,554,0.3176895307,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Jose Maria Remes-Troche,Universidad Veracruzana,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.19.20215558v1,2021-01-17,2024-03-01,Verified,remes-troche_prevalence_2020,MEX
201021_VeracruzCity_UniversidadVeracruzana_60-69_unadj,201021_VeracruzCity_UniversidadVeracruzana,Prevalence of SARS-CoV-2 IgG antibodies in a population from Veracruz (Southeastern Mexico),2020-10-21,Preprint,Local,Cross-sectional survey ,Mexico,,Veracruz City,Adult patients (age>=18 years) that attended 2 ambulatory diagnostic private practice centers for testing,,2020-06-01,2020-07-31,Residual sera,All,Adults (18-64 years),60.0,69.0,Age,60-69,205,0.3756097561,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Jose Maria Remes-Troche,Universidad Veracruzana,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.19.20215558v1,2021-01-17,2024-03-01,Verified,remes-troche_prevalence_2020,MEX
201021_VeracruzCity_UniversidadVeracruzana_40-49_unadj,201021_VeracruzCity_UniversidadVeracruzana,Prevalence of SARS-CoV-2 IgG antibodies in a population from Veracruz (Southeastern Mexico),2020-10-21,Preprint,Local,Cross-sectional survey ,Mexico,,Veracruz City,Adult patients (age>=18 years) that attended 2 ambulatory diagnostic private practice centers for testing,,2020-06-01,2020-07-31,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,470,0.27872340430000003,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Jose Maria Remes-Troche,Universidad Veracruzana,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.19.20215558v1,2021-01-17,2024-03-01,Verified,remes-troche_prevalence_2020,MEX
201021_VeracruzCity_UniversidadVeracruzana_Female_unadj,201021_VeracruzCity_UniversidadVeracruzana,Prevalence of SARS-CoV-2 IgG antibodies in a population from Veracruz (Southeastern Mexico),2020-10-21,Preprint,Local,Cross-sectional survey ,Mexico,,Veracruz City,Adult patients (age>=18 years) that attended 2 ambulatory diagnostic private practice centers for testing,,2020-06-01,2020-07-31,Residual sera,Female,Multiple groups,18.0,98.0,Sex/Gender,Female,1165,0.27296137340000004,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Jose Maria Remes-Troche,Universidad Veracruzana,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.19.20215558v1,2021-01-17,2024-03-01,Verified,remes-troche_prevalence_2020,MEX
201021_VeracruzCity_UniversidadVeracruzana_50-59_unadj,201021_VeracruzCity_UniversidadVeracruzana,Prevalence of SARS-CoV-2 IgG antibodies in a population from Veracruz (Southeastern Mexico),2020-10-21,Preprint,Local,Cross-sectional survey ,Mexico,,Veracruz City,Adult patients (age>=18 years) that attended 2 ambulatory diagnostic private practice centers for testing,,2020-06-01,2020-07-31,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,344,0.3372093023,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Jose Maria Remes-Troche,Universidad Veracruzana,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.19.20215558v1,2021-01-17,2024-03-01,Verified,remes-troche_prevalence_2020,MEX
201021_VeracruzCity_UniversidadVeracruzana_Male_unadj,201021_VeracruzCity_UniversidadVeracruzana,Prevalence of SARS-CoV-2 IgG antibodies in a population from Veracruz (Southeastern Mexico),2020-10-21,Preprint,Local,Cross-sectional survey ,Mexico,,Veracruz City,Adult patients (age>=18 years) that attended 2 ambulatory diagnostic private practice centers for testing,,2020-06-01,2020-07-31,Residual sera,Male,Multiple groups,18.0,98.0,Sex/Gender,,1009,0.3211100099,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Jose Maria Remes-Troche,Universidad Veracruzana,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.19.20215558v1,2021-01-17,2024-03-01,Verified,remes-troche_prevalence_2020,MEX
201216_Mexico_GovernmentOfMexico_overall,201216_Mexico_GovernmentOfMexico,Secretaría de Salud presenta resultados preliminares de la Encuesta Nacional de Salud y Nutrición COVID-19,2020-12-16,News and Media,National,Cross-sectional survey ,Mexico,,,Individuals in Mexico,,2020-08-15,2020-11-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,7098,0.25,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,Secretaria de Salud ,Government of Mexico,Not Unity-Aligned,https://www.gob.mx/salud/prensa/255-secretaria-de-salud-presenta-resultados-preliminares-de-la-encuesta-nacional-de-salud-y-nutricion-covid-19?idiom=es,2021-06-06,2022-07-16,Verified,salud_255_2020,MEX
210415_Mexico_InstitutodeSaludparaelBienestar_Overall,210415_Mexico_InstitutodeSaludparaelBienestar,SARS-CoV-2 IgG Antibodies Seroprevalence and Sera Neutralizing Activity in MEXICO: A National Cross-Sectional Study during 2020.,2021-04-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Mexico,,,"""specimens were collected from 34 clinical laboratories (CLs; i.e., in each state’s main hospital) and 34 blood banks (BBs; i.e., in either the hospitals or unique to the respective states), across all 32 of the United Mexican States.""","The samples could come from any outpatient collection, excluding patients with fever
within the previous two weeks and/or patients with an acute respiratory infection",2020-02-10,2020-12-31,Residual sera,All,Multiple groups,0.0,100.0,Primary Estimate,Overall,24273,0.159,,,True,,,,True,Stratified non-probability,"Liaison SARS-CoV-2 S1/S2 IgG,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit","DiaSorin,GenScript",Multiple Types,Serum,"['IgG', 'Neutralizing']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,,Jose Munoz-Medina,Instituto de Salud para el Bienestar,Unity-Aligned,https://dx.doi.org/10.3390/microorganisms9040850,2021-05-19,2024-03-01,Verified,munoz-medina_sars-cov-2_2021,MEX
210415_Mexico_InstitutodeSaludparaelBienestar_Feb10-Feb27,210415_Mexico_InstitutodeSaludparaelBienestar,SARS-CoV-2 IgG Antibodies Seroprevalence and Sera Neutralizing Activity in MEXICO: A National Cross-Sectional Study during 2020.,2021-04-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Mexico,,,"""specimens were collected from 34 clinical laboratories (CLs; i.e., in each state’s main hospital) and 34 blood banks (BBs; i.e., in either the hospitals or unique to the respective states), across all 32 of the United Mexican States.""","The samples could come from any outpatient collection, excluding patients with fever
within the previous two weeks and/or patients with an acute respiratory infection",2020-02-10,2020-02-27,Residual sera,All,Multiple groups,0.0,100.0,Time frame,IgG S1/S2 from Feb 10-Feb 27 2020,1057,0.0378,,,,,,,,Stratified non-probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,,Jose Munoz-Medina,Instituto de Salud para el Bienestar,Unity-Aligned,https://dx.doi.org/10.3390/microorganisms9040850,2021-07-05,2024-03-01,Verified,munoz-medina_sars-cov-2_2021,MEX
210415_Mexico_InstitutodeSaludparaelBienestar_December,210415_Mexico_InstitutodeSaludparaelBienestar,SARS-CoV-2 IgG Antibodies Seroprevalence and Sera Neutralizing Activity in MEXICO: A National Cross-Sectional Study during 2020.,2021-04-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Mexico,,,"""specimens were collected from 34 clinical laboratories (CLs; i.e., in each state’s main hospital) and 34 blood banks (BBs; i.e., in either the hospitals or unique to the respective states), across all 32 of the United Mexican States.""","The samples could come from any outpatient collection, excluding patients with fever
within the previous two weeks and/or patients with an acute respiratory infection",2020-12-01,2020-12-31,Residual sera,All,Multiple groups,0.0,100.0,Time frame,December,5359,0.306,0.29300000000000004,0.318,,,,,,Stratified non-probability,"Liaison SARS-CoV-2 S1/S2 IgG,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit","DiaSorin,GenScript",Multiple Types,Serum,"['IgG', 'Neutralizing']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,,Jose Munoz-Medina,Instituto de Salud para el Bienestar,Unity-Aligned,https://dx.doi.org/10.3390/microorganisms9040850,2021-09-17,2024-03-01,Verified,munoz-medina_sars-cov-2_2021,MEX
210423_Monterrey_UniversidadAutónomaDeNuevoLeón,210423_Monterrey_UniversidadAutónomaDeNuevoLeón,Prevalence of antibodies against SARS-CoV-2 in hemodialysis patients.,2021-04-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mexico,Nuevo Leon,Monterrey,All patients in our HD unit were tested within the 10 days after the detection of 1 confirmed case by positive PCR test,,2020-05-22,2020-05-30,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,19.0,87.0,Primary Estimate,,154,0.11699999999999999,,,True,,,,True,Sequential,COVID-19 IgG/IgM Rapid Test Cassette,Healgen,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,,0.9011,0.9845999999999999,['High'],,No,No,Yes,,Yes,Yes,Yes,,Giovanna Yazmin Arteaga Muller,Universidad Autónoma de Nuevo León,Not Unity-Aligned,https://dx.doi.org/10.1007/s11255-021-02852-4,2021-05-20,2024-03-01,Unverified,arteaga-muller_prevalence_2021,MEX
210607_NuevoLeon_HealthServicesOfTheStateOfNuevoLeon_Overall,210607_NuevoLeon_HealthServicesOfTheStateOfNuevoLeon,"Prevalence of IgG antibodies induced by the SARS-COV-2 virus in asymptomatic adults in Nuevo Leon, Mexico",2021-06-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Nuevo Leon,,"Individuals≥18 years with no previous diagnosis or symptoms suggestive ofCOVID‐19 were consecutively screened in one of the busiest subway stations. Also,a search for eligible individuals was done from house‐to‐house, after selecting densely populated geographic sectors of each of the municipalities of the me-tropolitan area (n= 4495)",The sampling carried out in a subway station excluded vehicle users.,2020-08-15,2020-11-15,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,4495,0.271,0.258,0.284,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Edgar Rodriguez-Vidales,Health Services of the State of Nuevo Leon,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27131,2021-06-22,2024-03-01,Verified,rodriguezvidales_prevalence_2021,MEX
210607_NuevoLeon_HealthServicesOfTheStateOfNuevoLeon_Male,210607_NuevoLeon_HealthServicesOfTheStateOfNuevoLeon,"Prevalence of IgG antibodies induced by the SARS-COV-2 virus in asymptomatic adults in Nuevo Leon, Mexico",2021-06-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Nuevo Leon,,"Individuals≥18 years with no previous diagnosis or symptoms suggestive ofCOVID‐19 were consecutively screened in one of the busiest subway stations. Also,a search for eligible individuals was done from house‐to‐house, after selecting densely populated geographic sectors of each of the municipalities of the me-tropolitan area (n= 4495)",The sampling carried out in a subway station excluded vehicle users.,2020-08-15,2020-11-15,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,1632,0.28500000000000003,0.264,0.307,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Edgar Rodriguez-Vidales,Health Services of the State of Nuevo Leon,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27131,2021-10-01,2024-03-01,Verified,rodriguezvidales_prevalence_2021,MEX
210607_NuevoLeon_HealthServicesOfTheStateOfNuevoLeon_45-60,210607_NuevoLeon_HealthServicesOfTheStateOfNuevoLeon,"Prevalence of IgG antibodies induced by the SARS-COV-2 virus in asymptomatic adults in Nuevo Leon, Mexico",2021-06-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Nuevo Leon,,"Individuals≥18 years with no previous diagnosis or symptoms suggestive ofCOVID‐19 were consecutively screened in one of the busiest subway stations. Also,a search for eligible individuals was done from house‐to‐house, after selecting densely populated geographic sectors of each of the municipalities of the me-tropolitan area (n= 4495)",The sampling carried out in a subway station excluded vehicle users.,2020-08-15,2020-11-15,Household and community samples,All,Adults (18-64 years),45.0,60.0,Age,45-60,1456,0.28500000000000003,0.263,0.309,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Edgar Rodriguez-Vidales,Health Services of the State of Nuevo Leon,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27131,2021-10-01,2024-03-01,Verified,rodriguezvidales_prevalence_2021,MEX
210607_NuevoLeon_HealthServicesOfTheStateOfNuevoLeon_25-44,210607_NuevoLeon_HealthServicesOfTheStateOfNuevoLeon,"Prevalence of IgG antibodies induced by the SARS-COV-2 virus in asymptomatic adults in Nuevo Leon, Mexico",2021-06-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Nuevo Leon,,"Individuals≥18 years with no previous diagnosis or symptoms suggestive ofCOVID‐19 were consecutively screened in one of the busiest subway stations. Also,a search for eligible individuals was done from house‐to‐house, after selecting densely populated geographic sectors of each of the municipalities of the me-tropolitan area (n= 4495)",The sampling carried out in a subway station excluded vehicle users.,2020-08-15,2020-11-15,Household and community samples,All,Adults (18-64 years),25.0,44.0,Age,25-44,1809,0.275,0.255,0.29600000000000004,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Edgar Rodriguez-Vidales,Health Services of the State of Nuevo Leon,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27131,2021-10-01,2024-03-01,Verified,rodriguezvidales_prevalence_2021,MEX
210607_NuevoLeon_HealthServicesOfTheStateOfNuevoLeon_Female,210607_NuevoLeon_HealthServicesOfTheStateOfNuevoLeon,"Prevalence of IgG antibodies induced by the SARS-COV-2 virus in asymptomatic adults in Nuevo Leon, Mexico",2021-06-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Nuevo Leon,,"Individuals≥18 years with no previous diagnosis or symptoms suggestive ofCOVID‐19 were consecutively screened in one of the busiest subway stations. Also,a search for eligible individuals was done from house‐to‐house, after selecting densely populated geographic sectors of each of the municipalities of the me-tropolitan area (n= 4495)",The sampling carried out in a subway station excluded vehicle users.,2020-08-15,2020-11-15,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,2861,0.262,0.247,0.27899999999999997,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Edgar Rodriguez-Vidales,Health Services of the State of Nuevo Leon,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27131,2021-10-01,2024-03-01,Verified,rodriguezvidales_prevalence_2021,MEX
210607_NuevoLeon_HealthServicesOfTheStateOfNuevoLeon_61-64,210607_NuevoLeon_HealthServicesOfTheStateOfNuevoLeon,"Prevalence of IgG antibodies induced by the SARS-COV-2 virus in asymptomatic adults in Nuevo Leon, Mexico",2021-06-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Nuevo Leon,,"Individuals≥18 years with no previous diagnosis or symptoms suggestive ofCOVID‐19 were consecutively screened in one of the busiest subway stations. Also,a search for eligible individuals was done from house‐to‐house, after selecting densely populated geographic sectors of each of the municipalities of the me-tropolitan area (n= 4495)",The sampling carried out in a subway station excluded vehicle users.,2020-08-15,2020-11-15,Household and community samples,All,Adults (18-64 years),61.0,64.0,Age,61-64,264,0.25,0.20199999999999999,0.306,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Edgar Rodriguez-Vidales,Health Services of the State of Nuevo Leon,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27131,2021-10-01,2024-03-01,Verified,rodriguezvidales_prevalence_2021,MEX
210607_NuevoLeon_HealthServicesOfTheStateOfNuevoLeon_18-24,210607_NuevoLeon_HealthServicesOfTheStateOfNuevoLeon,"Prevalence of IgG antibodies induced by the SARS-COV-2 virus in asymptomatic adults in Nuevo Leon, Mexico",2021-06-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Nuevo Leon,,"Individuals≥18 years with no previous diagnosis or symptoms suggestive ofCOVID‐19 were consecutively screened in one of the busiest subway stations. Also,a search for eligible individuals was done from house‐to‐house, after selecting densely populated geographic sectors of each of the municipalities of the me-tropolitan area (n= 4495)",The sampling carried out in a subway station excluded vehicle users.,2020-08-15,2020-11-15,Household and community samples,All,Adults (18-64 years),18.0,24.0,Age,18-24,507,0.268,0.23199999999999998,0.308,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Edgar Rodriguez-Vidales,Health Services of the State of Nuevo Leon,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27131,2021-10-01,2024-03-01,Verified,rodriguezvidales_prevalence_2021,MEX
210607_NuevoLeon_HealthServicesOfTheStateOfNuevoLeon_65+,210607_NuevoLeon_HealthServicesOfTheStateOfNuevoLeon,"Prevalence of IgG antibodies induced by the SARS-COV-2 virus in asymptomatic adults in Nuevo Leon, Mexico",2021-06-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Nuevo Leon,,"Individuals≥18 years with no previous diagnosis or symptoms suggestive ofCOVID‐19 were consecutively screened in one of the busiest subway stations. Also,a search for eligible individuals was done from house‐to‐house, after selecting densely populated geographic sectors of each of the municipalities of the me-tropolitan area (n= 4495)",The sampling carried out in a subway station excluded vehicle users.,2020-08-15,2020-11-15,Household and community samples,All,Seniors (65+ years),65.0,,Age,65+,450,0.22,0.184,0.261,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Edgar Rodriguez-Vidales,Health Services of the State of Nuevo Leon,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27131,2021-10-01,2024-03-01,Verified,rodriguezvidales_prevalence_2021,MEX
210624_NuevoLeon_AutonomousUniversityofNuevoLeon_primary,210624_NuevoLeon_AutonomousUniversityofNuevoLeon,"Seroprevalence of Anti-SARS-CoV-2 Antibodies in Blood Donors from Nuevo Leon State, Mexico, during 2020: A Retrospective Cross-Sectional Evaluation.",2021-06-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Nuevo Leon,,"blood donors living in Nuevo Leon state, who attended two donation venues, the Blood Bank Center at the “Dr. Jose E. Gonzalez” University Hospital and the Blood Bank ofcthe Transfusion Center of the Secretariat of Health of Nuevo Leon state, Mexico.","Donors with risk factors for bloodtransmitted
diseases, recent disease, or who were deemed unhealthy during the physical examination were excluded.",2020-01-01,2020-12-15,Blood donors,All,Adults (18-64 years),18.0,65.0,Primary Estimate,,2068,0.053,,,True,True,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,,,0.9,1.0,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Natalia Martinez-Acu a,Autonomous University of Nuevo Leon,Unity-Aligned,https://dx.doi.org/10.3390/v13071225,2021-02-04,2023-07-04,Verified,martinez-acuña_seroprevalence_2021,MEX
210624_NuevoLeon_AutonomousUniversityofNuevoLeon_age_18to29,210624_NuevoLeon_AutonomousUniversityofNuevoLeon,"Seroprevalence of Anti-SARS-CoV-2 Antibodies in Blood Donors from Nuevo Leon State, Mexico, during 2020: A Retrospective Cross-Sectional Evaluation.",2021-06-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Nuevo Leon,,"blood donors living in Nuevo Leon state, who attended two donation venues, the Blood Bank Center at the “Dr. Jose E. Gonzalez” University Hospital and the Blood Bank ofcthe Transfusion Center of the Secretariat of Health of Nuevo Leon state, Mexico.","Donors with risk factors for bloodtransmitted
diseases, recent disease, or who were deemed unhealthy during the physical examination were excluded.",2020-01-01,2020-08-30,Blood donors,All,Adults (18-64 years),18.0,29.0,Age,18 to 29,695,0.0417,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,,,0.9,1.0,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Natalia Martinez-Acu a,Autonomous University of Nuevo Leon,Unity-Aligned,https://dx.doi.org/10.3390/v13071225,2021-02-04,2024-03-01,Verified,martinez-acuña_seroprevalence_2021,MEX
210624_NuevoLeon_AutonomousUniversityofNuevoLeon-sex_fem,210624_NuevoLeon_AutonomousUniversityofNuevoLeon,"Seroprevalence of Anti-SARS-CoV-2 Antibodies in Blood Donors from Nuevo Leon State, Mexico, during 2020: A Retrospective Cross-Sectional Evaluation.",2021-06-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Nuevo Leon,,"blood donors living in Nuevo Leon state, who attended two donation venues, the Blood Bank Center at the “Dr. Jose E. Gonzalez” University Hospital and the Blood Bank ofcthe Transfusion Center of the Secretariat of Health of Nuevo Leon state, Mexico.","Donors with risk factors for bloodtransmitted
diseases, recent disease, or who were deemed unhealthy during the physical examination were excluded.",2020-01-01,2020-12-15,Blood donors,Female,Adults (18-64 years),18.0,65.0,Sex/Gender,Female,495,0.0639,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,,,0.9,1.0,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Natalia Martinez-Acu a,Autonomous University of Nuevo Leon,Unity-Aligned,https://dx.doi.org/10.3390/v13071225,2021-02-04,2024-03-01,Verified,martinez-acuña_seroprevalence_2021,MEX
210624_NuevoLeon_AutonomousUniversityofNuevoLeon_analysis,210624_NuevoLeon_AutonomousUniversityofNuevoLeon,"Seroprevalence of Anti-SARS-CoV-2 Antibodies in Blood Donors from Nuevo Leon State, Mexico, during 2020: A Retrospective Cross-Sectional Evaluation.",2021-06-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Nuevo Leon,,"blood donors living in Nuevo Leon state, who attended two donation venues, the Blood Bank Center at the “Dr. Jose E. Gonzalez” University Hospital and the Blood Bank ofcthe Transfusion Center of the Secretariat of Health of Nuevo Leon state, Mexico.","Donors with risk factors for bloodtransmitted
diseases, recent disease, or who were deemed unhealthy during the physical examination were excluded.",2020-01-01,2020-12-15,Blood donors,All,Adults (18-64 years),18.0,65.0,Analysis,,2068,0.0478,,,,,,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,,,0.9,1.0,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Natalia Martinez-Acu a,Autonomous University of Nuevo Leon,Unity-Aligned,https://dx.doi.org/10.3390/v13071225,2021-07-12,2024-03-01,Verified,martinez-acuña_seroprevalence_2021,MEX
210624_NuevoLeon_AutonomousUniversityofNuevoLeon_sex_male,210624_NuevoLeon_AutonomousUniversityofNuevoLeon,"Seroprevalence of Anti-SARS-CoV-2 Antibodies in Blood Donors from Nuevo Leon State, Mexico, during 2020: A Retrospective Cross-Sectional Evaluation.",2021-06-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Nuevo Leon,,"blood donors living in Nuevo Leon state, who attended two donation venues, the Blood Bank Center at the “Dr. Jose E. Gonzalez” University Hospital and the Blood Bank ofcthe Transfusion Center of the Secretariat of Health of Nuevo Leon state, Mexico.","Donors with risk factors for bloodtransmitted
diseases, recent disease, or who were deemed unhealthy during the physical examination were excluded.",2020-01-01,2020-12-15,Blood donors,Male,Adults (18-64 years),18.0,65.0,Sex/Gender,,1436,0.0434,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,,,0.9,1.0,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Natalia Martinez-Acu a,Autonomous University of Nuevo Leon,Unity-Aligned,https://dx.doi.org/10.3390/v13071225,2021-02-04,2024-03-01,Verified,martinez-acuña_seroprevalence_2021,MEX
210624_NuevoLeon_AutonomousUniversityofNuevoLeon_age_30to49,210624_NuevoLeon_AutonomousUniversityofNuevoLeon,"Seroprevalence of Anti-SARS-CoV-2 Antibodies in Blood Donors from Nuevo Leon State, Mexico, during 2020: A Retrospective Cross-Sectional Evaluation.",2021-06-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Nuevo Leon,,"blood donors living in Nuevo Leon state, who attended two donation venues, the Blood Bank Center at the “Dr. Jose E. Gonzalez” University Hospital and the Blood Bank ofcthe Transfusion Center of the Secretariat of Health of Nuevo Leon state, Mexico.","Donors with risk factors for bloodtransmitted
diseases, recent disease, or who were deemed unhealthy during the physical examination were excluded.",2020-01-01,2020-08-30,Blood donors,All,Adults (18-64 years),30.0,49.0,Age,30 to 49,1050,0.038,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,,,0.9,1.0,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Natalia Martinez-Acu a,Autonomous University of Nuevo Leon,Unity-Aligned,https://dx.doi.org/10.3390/v13071225,2021-02-04,2024-03-01,Verified,martinez-acuña_seroprevalence_2021,MEX
210624_NuevoLeon_AutonomousUniversityofNuevoLeon_age_50to65,210624_NuevoLeon_AutonomousUniversityofNuevoLeon,"Seroprevalence of Anti-SARS-CoV-2 Antibodies in Blood Donors from Nuevo Leon State, Mexico, during 2020: A Retrospective Cross-Sectional Evaluation.",2021-06-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Nuevo Leon,,"blood donors living in Nuevo Leon state, who attended two donation venues, the Blood Bank Center at the “Dr. Jose E. Gonzalez” University Hospital and the Blood Bank ofcthe Transfusion Center of the Secretariat of Health of Nuevo Leon state, Mexico.","Donors with risk factors for bloodtransmitted
diseases, recent disease, or who were deemed unhealthy during the physical examination were excluded.",2020-01-01,2020-08-30,Blood donors,All,Adults (18-64 years),50.0,65.0,Age,50 to 65,186,0.043,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,,,0.9,1.0,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Natalia Martinez-Acu a,Autonomous University of Nuevo Leon,Unity-Aligned,https://dx.doi.org/10.3390/v13071225,2021-02-04,2024-03-01,Verified,martinez-acuña_seroprevalence_2021,MEX
210812_MexicoCity_InstitutoNacionaldeRehabilitacion_Overall,210812_MexicoCity_InstitutoNacionaldeRehabilitacion,"Serological prevalence of SARS-CoV-2 infection and associated factors in healthcare workers in a ""non-COVID"" hospital in Mexico City",2021-08-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mexico,,Mexico City,"We performed a cross-sectional study, having as study population the personnel that works in
our hospital, the Instituto Nacional de Rehabilitacion “Luis Guillermo Ibarra Ibarra”

Inclusion criteria were: being personnel working in the hospital, from any shift, and granting written informed consent.

The subjects in the sample were stratified in 10 groups according to their work activities: administrative; scientific research; medical personnel; nursing; stretcher-bearers and orderlies; technicians and laboratory personnel; therapists and patient counseling; janitorial; security; and food services. We
selected participants randomly from each of the 10 work group strata, according to the size of each work group",,2020-08-10,2020-09-09,Health care workers and caregivers,All,Multiple groups,17.0,77.0,Primary Estimate,,299,0.13,,,True,,,,True,Stratified probability,Anti-SARS-CoV-2 NCP ELISA (IgG),EUROIMMUN,ELISA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.946,0.998,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Esteban Cruz-Arenas,Nacional de Rehabilitacion hospital,Not Unity-Aligned,http://dx.doi.org/10.1371/journal.pone.0255916,2021-08-29,2024-03-01,Unverified,cruz-arenas_serological_2021,MEX
210812_MexicoCity_InstitutoNacionaldeRehabilitacion_30-44,210812_MexicoCity_InstitutoNacionaldeRehabilitacion,"Serological prevalence of SARS-CoV-2 infection and associated factors in healthcare workers in a ""non-COVID"" hospital in Mexico City",2021-08-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mexico,,Mexico City,"We performed a cross-sectional study, having as study population the personnel that works in
our hospital, the Instituto Nacional de Rehabilitacion “Luis Guillermo Ibarra Ibarra”

Inclusion criteria were: being personnel working in the hospital, from any shift, and granting written informed consent.

The subjects in the sample were stratified in 10 groups according to their work activities: administrative; scientific research; medical personnel; nursing; stretcher-bearers and orderlies; technicians and laboratory personnel; therapists and patient counseling; janitorial; security; and food services. We
selected participants randomly from each of the 10 work group strata, according to the size of each work group",,2020-08-10,2020-09-09,Health care workers and caregivers,All,Adults (18-64 years),30.0,44.0,Age,30-44,124,0.153,,,,,,,,Stratified probability,Anti-SARS-CoV-2 NCP ELISA (IgG),EUROIMMUN,ELISA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.946,0.998,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Esteban Cruz-Arenas,Nacional de Rehabilitacion hospital,Not Unity-Aligned,http://dx.doi.org/10.1371/journal.pone.0255916,2021-08-29,2024-03-01,Unverified,cruz-arenas_serological_2021,MEX
210812_MexicoCity_InstitutoNacionaldeRehabilitacion_60andover,210812_MexicoCity_InstitutoNacionaldeRehabilitacion,"Serological prevalence of SARS-CoV-2 infection and associated factors in healthcare workers in a ""non-COVID"" hospital in Mexico City",2021-08-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mexico,,Mexico City,"We performed a cross-sectional study, having as study population the personnel that works in
our hospital, the Instituto Nacional de Rehabilitacion “Luis Guillermo Ibarra Ibarra”

Inclusion criteria were: being personnel working in the hospital, from any shift, and granting written informed consent.

The subjects in the sample were stratified in 10 groups according to their work activities: administrative; scientific research; medical personnel; nursing; stretcher-bearers and orderlies; technicians and laboratory personnel; therapists and patient counseling; janitorial; security; and food services. We
selected participants randomly from each of the 10 work group strata, according to the size of each work group",,2020-08-10,2020-09-09,Health care workers and caregivers,All,Seniors (65+ years),60.0,77.0,Age,>=60,20,0.1,,,,,,,,Stratified probability,Anti-SARS-CoV-2 NCP ELISA (IgG),EUROIMMUN,ELISA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.946,0.998,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Esteban Cruz-Arenas,Nacional de Rehabilitacion hospital,Not Unity-Aligned,http://dx.doi.org/10.1371/journal.pone.0255916,2021-08-29,2024-03-01,Unverified,cruz-arenas_serological_2021,MEX
210812_MexicoCity_InstitutoNacionaldeRehabilitacion_45-59,210812_MexicoCity_InstitutoNacionaldeRehabilitacion,"Serological prevalence of SARS-CoV-2 infection and associated factors in healthcare workers in a ""non-COVID"" hospital in Mexico City",2021-08-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mexico,,Mexico City,"We performed a cross-sectional study, having as study population the personnel that works in
our hospital, the Instituto Nacional de Rehabilitacion “Luis Guillermo Ibarra Ibarra”

Inclusion criteria were: being personnel working in the hospital, from any shift, and granting written informed consent.

The subjects in the sample were stratified in 10 groups according to their work activities: administrative; scientific research; medical personnel; nursing; stretcher-bearers and orderlies; technicians and laboratory personnel; therapists and patient counseling; janitorial; security; and food services. We
selected participants randomly from each of the 10 work group strata, according to the size of each work group",,2020-08-10,2020-09-09,Health care workers and caregivers,All,Adults (18-64 years),45.0,59.0,Age,45-59,114,0.096,,,,,,,,Stratified probability,Anti-SARS-CoV-2 NCP ELISA (IgG),EUROIMMUN,ELISA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.946,0.998,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Esteban Cruz-Arenas,Nacional de Rehabilitacion hospital,Not Unity-Aligned,http://dx.doi.org/10.1371/journal.pone.0255916,2021-08-29,2024-03-01,Unverified,cruz-arenas_serological_2021,MEX
210812_MexicoCity_InstitutoNacionaldeRehabilitacion_under30,210812_MexicoCity_InstitutoNacionaldeRehabilitacion,"Serological prevalence of SARS-CoV-2 infection and associated factors in healthcare workers in a ""non-COVID"" hospital in Mexico City",2021-08-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mexico,,Mexico City,"We performed a cross-sectional study, having as study population the personnel that works in
our hospital, the Instituto Nacional de Rehabilitacion “Luis Guillermo Ibarra Ibarra”

Inclusion criteria were: being personnel working in the hospital, from any shift, and granting written informed consent.

The subjects in the sample were stratified in 10 groups according to their work activities: administrative; scientific research; medical personnel; nursing; stretcher-bearers and orderlies; technicians and laboratory personnel; therapists and patient counseling; janitorial; security; and food services. We
selected participants randomly from each of the 10 work group strata, according to the size of each work group",,2020-08-10,2020-09-09,Health care workers and caregivers,All,Adults (18-64 years),17.0,29.0,Age,<30,41,0.171,,,,,,,,Stratified probability,Anti-SARS-CoV-2 NCP ELISA (IgG),EUROIMMUN,ELISA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.946,0.998,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Esteban Cruz-Arenas,Nacional de Rehabilitacion hospital,Not Unity-Aligned,http://dx.doi.org/10.1371/journal.pone.0255916,2021-08-29,2024-03-01,Unverified,cruz-arenas_serological_2021,MEX
210819_CityofGuadalupe_UniversidadAutónomadeNuevoLeón_Overall,210819_CityofGuadalupe_UniversidadAutónomadeNuevoLeón,Prevalence and associated characteristics of anti-SARS-CoV-2 antibodies in Mexico 5 months after pandemic arrival.,2021-08-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mexico,Nuevo Leon,Guadalupe,"The participants were drawn from a complete database of 4,220 government employees who were voluntarily invited to participate in this serological survey",,2020-07-09,2020-07-23,Multiple populations,All,Multiple groups,,,Primary Estimate,,3268,0.059000000000000004,0.051,0.068,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Cristina Diaz‑Salazar,Universidad Autonoma de Nuevo Leon,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06550-5,2021-09-01,2024-03-01,Verified,diaz-salazar_prevalence_2021,MEX
210819_CityofGuadalupe_UniversidadAutónomadeNuevoLeón_50-65yrs,210819_CityofGuadalupe_UniversidadAutónomadeNuevoLeón,Prevalence and associated characteristics of anti-SARS-CoV-2 antibodies in Mexico 5 months after pandemic arrival.,2021-08-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mexico,Nuevo Leon,Guadalupe,"The participants were drawn from a complete database of 4,220 government employees who were voluntarily invited to participate in this serological survey",,2020-07-09,2020-07-23,Multiple populations,All,Multiple groups,50.0,65.0,Age,50-65,765,0.0458,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Cristina Diaz‑Salazar,Universidad Autonoma de Nuevo Leon,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06550-5,2021-09-01,2024-03-01,Verified,diaz-salazar_prevalence_2021,MEX
210819_CityofGuadalupe_UniversidadAutónomadeNuevoLeón_>65yrs,210819_CityofGuadalupe_UniversidadAutónomadeNuevoLeón,Prevalence and associated characteristics of anti-SARS-CoV-2 antibodies in Mexico 5 months after pandemic arrival.,2021-08-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mexico,Nuevo Leon,Guadalupe,"The participants were drawn from a complete database of 4,220 government employees who were voluntarily invited to participate in this serological survey",,2020-07-09,2020-07-23,Multiple populations,All,Seniors (65+ years),65.0,,Age,>65,48,0.0833,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Cristina Diaz‑Salazar,Universidad Autonoma de Nuevo Leon,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06550-5,2021-09-01,2024-03-01,Verified,diaz-salazar_prevalence_2021,MEX
210819_CityofGuadalupe_UniversidadAutónomadeNuevoLeón_18-34yrs,210819_CityofGuadalupe_UniversidadAutónomadeNuevoLeón,Prevalence and associated characteristics of anti-SARS-CoV-2 antibodies in Mexico 5 months after pandemic arrival.,2021-08-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mexico,Nuevo Leon,Guadalupe,"The participants were drawn from a complete database of 4,220 government employees who were voluntarily invited to participate in this serological survey",,2020-07-09,2020-07-23,Multiple populations,All,Children and Youth (0-17 years),18.0,34.0,Age,18-34,1127,0.060300000000000006,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Cristina Diaz‑Salazar,Universidad Autonoma de Nuevo Leon,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06550-5,2021-09-01,2024-03-01,Verified,diaz-salazar_prevalence_2021,MEX
210819_CityofGuadalupe_UniversidadAutónomadeNuevoLeón_35-49yrs,210819_CityofGuadalupe_UniversidadAutónomadeNuevoLeón,Prevalence and associated characteristics of anti-SARS-CoV-2 antibodies in Mexico 5 months after pandemic arrival.,2021-08-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mexico,Nuevo Leon,Guadalupe,"The participants were drawn from a complete database of 4,220 government employees who were voluntarily invited to participate in this serological survey",,2020-07-09,2020-07-23,Multiple populations,All,Adults (18-64 years),35.0,49.0,Age,35-49,1328,0.06480000000000001,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Cristina Diaz‑Salazar,Universidad Autonoma de Nuevo Leon,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06550-5,2021-09-01,2024-03-01,Verified,diaz-salazar_prevalence_2021,MEX
210916_MexicoCity_UniversidadNacionalAutónomaDeMéxico_Primary,210916_MexicoCity_UniversidadNacionalAutónomaDeMéxico,"SARS-CoV-2 Seroprevalence among the Health Care Staff of an Ophthalmological Reference Centre, a Cross Sectional Study.",2021-09-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mexico,,Mexico City,all HCWs at the Institute of Ophthalmology,,2020-09-21,2020-12-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,169,0.207,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,No,No,,Unclear,Yes,No,,Fatima Sofía Magana-Guerrero,Universidad Nacional Autónoma De México,Not Unity-Aligned,https://dx.doi.org/10.1080/09286586.2021.1974493,2021-09-28,2022-07-16,Unverified,magaña-guerrero_sars-cov-2_2021,MEX
211105_Mexico_InstitutoNacionaldeSaludPublica_Adolescent_Primary,211105_Mexico_InstitutoNacionaldeSaludPublica_Adolescent,Seroprevalence of SARS-CoV-2 in Mexican children and adolescents in primary and secondary education age,2021-11-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Mexico,,,"Within the households, all the children between 0-4 years old, and one individual from each group of age (5-9, 10-19, 20-34, 35-49, ≥50 years) with sampling simple random.

This study includes children ages 3-12.",,2020-08-15,2020-11-15,Household and community samples,All,Children and Youth (0-17 years),3.0,12.0,Primary Estimate,,944,0.187,0.149,0.225,True,True,True,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.92,0.995,['Low'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,No,Francisco Canto-Osorio,Instituto Nacional de Salud Públic,Unity-Aligned,https://saludpublica.mx/index.php/spm/article/view/12847,2021-12-01,2023-08-15,Verified,canto-osorio_seroprevalence_2021,MEX
211105_Mexico_InstitutoNacionaldeSaludPublica_Children_Primary,211105_Mexico_InstitutoNacionaldeSaludPublica_Children,Seroprevalence of SARS-CoV-2 in Mexican children and adolescents in primary and secondary education age,2021-11-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Mexico,,,"Within the households, all the children between 0-4 years old, and one individual from each group of age (5-9, 10-19, 20-34, 35-49, ≥50 years) with sampling simple random

This study include adolescents ages 13-19.",,2020-08-15,2020-11-15,Household and community samples,All,Children and Youth (0-17 years),13.0,19.0,Primary Estimate,,858,0.267,0.22100000000000003,0.313,True,True,True,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.92,0.995,['Low'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,No,Francisco Canto-Osorio,Instituto Nacional de Salud Públic,Unity-Aligned,https://saludpublica.mx/index.php/spm/article/view/12847,2021-12-01,2023-08-15,Verified,canto-osorio_seroprevalence_2021,MEX
211109_Nayarit_AutonomousUniversityofNayarit_overall,211109_Nayarit_AutonomousUniversityofNayarit,"Anti-SARS CoV-2 IgG levels in children from Nayarit, Mexico, as a biomarker of community immunity. Case study of 17 months after the COVID-19 pandemic",2021-11-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mexico,Nayarit,Ciudad de Tepic,children aged 6-12 years,,2021-06-28,2021-06-28,Household and community samples,All,Children and Youth (0-17 years),6.0,12.0,Primary Estimate,,134,0.17,,,True,,,,True,Convenience,Author designed (ELISA) -Unknown,,ELISA,Serum,IgG,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Gladys Alejandra Toledo-Ibarra,Autonomous University of Nayarit,Not Unity-Aligned,https://saludpublica.mx/index.php/spm/article/view/13128/12175,2021-12-01,2022-07-16,Unverified,toledo-ibarra_niveles_2021,MEX
211213_MexicoCity_INCMNSZ_Baseline,211213_MexicoCity_INCMNSZ_Baseline,SARS-CoV-2 Infection Rate in Patients With Cancer and Health Care Workers in a Chemoradiotherapy Unit During the Pandemic: A Prospective Cohort in Mexico.,2021-12-13,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mexico,,Mexico City,"Inclusion criteria were (1) patients age 18 years
or older, with a diagnosis of a solid malignant neoplasm
under active oncologic treatment in the chemotherapy and
radiotherapy unit, and (2) HCW of the unit including
physicians, nurses, technicians, and administrative staff.",Patients with hematologic malignancies were excluded.,2020-06-12,2020-08-14,Multiple populations,All,Multiple groups,18.0,,Primary Estimate,,119,0.016,,,True,,,,True,Unclear,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,Unclear,No,No,,Yes,Yes,Yes,,Monica Meneses-Medina,The National Institute of Medical Sciences and Nutrition Salvador Zubirán,Not Unity-Aligned,https://dx.doi.org/10.1200/GO.21.00207,2022-01-04,2024-03-01,Unverified,meneses-medina_sars-cov-2_2021,MEX
211213_MexicoCity_INCMNSZ_FollowUp,211213_MexicoCity_INCMNSZ_FollowUp,SARS-CoV-2 Infection Rate in Patients With Cancer and Health Care Workers in a Chemoradiotherapy Unit During the Pandemic: A Prospective Cohort in Mexico.,2021-12-13,Journal Article (Peer-Reviewed),Local,Prospective cohort,Mexico,,Mexico City,"Inclusion criteria were (1) patients age 18 years
or older, with a diagnosis of a solid malignant neoplasm
under active oncologic treatment in the chemotherapy and
radiotherapy unit, and (2) HCW of the unit including
physicians, nurses, technicians, and administrative staff.",Patients with hematologic malignancies were excluded.,2020-08-15,2020-09-30,Multiple populations,All,Multiple groups,18.0,,Primary Estimate,,97,0.07200000000000001,,,True,,,,True,Unclear,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,Unclear,No,No,,Yes,Yes,Yes,,Monica Meneses-Medina,The National Institute of Medical Sciences and Nutrition Salvador Zubirán,Not Unity-Aligned,https://dx.doi.org/10.1200/GO.21.00207,2022-01-04,2024-03-01,Unverified,meneses-medina_sars-cov-2_2021,MEX
220127_Campeche_UniversidadAutonomaCampeche_Overall,220127_Campeche_UniversidadAutonomaCampeche,Seroprevalence of SARS-CoV-2 antibodies in blood donors during the third wave of infection in Campeche Mexico,2022-01-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Campeche,," blood donors who attended Centro Estatal de la Transfusion Sanguínea de Campeche, Mexico during the period of August through September 2021",,2021-08-15,2021-09-15,Blood donors,All,Multiple groups,18.0,,Primary Estimate,Overall,479,0.691,,,True,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9400000000000001,1.0,['High'],No,No,No,Yes,No,Unclear,Yes,Yes,,Victor Monteon,Universidad Autonoma Campeche,Unity-Aligned,https://dx.doi.org/10.1016/j.transci.2022.103374,2022-02-09,2022-07-16,Verified,monteon_seroprevalence_2022,MEX
220127_Campeche_UniversidadAutonomaCampeche_Age_33-37,220127_Campeche_UniversidadAutonomaCampeche,Seroprevalence of SARS-CoV-2 antibodies in blood donors during the third wave of infection in Campeche Mexico,2022-01-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Campeche,," blood donors who attended Centro Estatal de la Transfusion Sanguínea de Campeche, Mexico during the period of August through September 2021",,2021-08-15,2021-09-15,Blood donors,All,Adults (18-64 years),33.0,37.0,Age,Age: 33-37,84,0.6667000000000001,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9400000000000001,1.0,['High'],No,No,No,Yes,No,Unclear,Yes,Yes,,Victor Monteon,Universidad Autonoma Campeche,Unity-Aligned,https://dx.doi.org/10.1016/j.transci.2022.103374,2022-02-09,2022-07-16,Verified,monteon_seroprevalence_2022,MEX
220127_Campeche_UniversidadAutonomaCampeche_Vaccinated,220127_Campeche_UniversidadAutonomaCampeche,Seroprevalence of SARS-CoV-2 antibodies in blood donors during the third wave of infection in Campeche Mexico,2022-01-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Campeche,," blood donors who attended Centro Estatal de la Transfusion Sanguínea de Campeche, Mexico during the period of August through September 2021",,2021-08-15,2021-09-15,Blood donors,All,Multiple groups,18.0,,COVID-19 vaccination status,Vaccinated,338,0.8018000000000001,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9400000000000001,1.0,['High'],No,No,No,Yes,No,Unclear,Yes,Yes,,Victor Monteon,Universidad Autonoma Campeche,Unity-Aligned,https://dx.doi.org/10.1016/j.transci.2022.103374,2022-02-09,2022-07-16,Verified,monteon_seroprevalence_2022,MEX
220127_Campeche_UniversidadAutonomaCampeche_Age_48-52,220127_Campeche_UniversidadAutonomaCampeche,Seroprevalence of SARS-CoV-2 antibodies in blood donors during the third wave of infection in Campeche Mexico,2022-01-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Campeche,," blood donors who attended Centro Estatal de la Transfusion Sanguínea de Campeche, Mexico during the period of August through September 2021",,2021-08-15,2021-09-15,Blood donors,All,Adults (18-64 years),48.0,52.0,Age,Age: 48-52,26,0.7692,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9400000000000001,1.0,['High'],No,No,No,Yes,No,Unclear,Yes,Yes,,Victor Monteon,Universidad Autonoma Campeche,Unity-Aligned,https://dx.doi.org/10.1016/j.transci.2022.103374,2022-02-09,2022-07-16,Verified,monteon_seroprevalence_2022,MEX
220127_Campeche_UniversidadAutonomaCampeche_Age_Above53,220127_Campeche_UniversidadAutonomaCampeche,Seroprevalence of SARS-CoV-2 antibodies in blood donors during the third wave of infection in Campeche Mexico,2022-01-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Campeche,," blood donors who attended Centro Estatal de la Transfusion Sanguínea de Campeche, Mexico during the period of August through September 2021",,2021-08-15,2021-09-15,Blood donors,All,Multiple groups,53.0,,Age,Age: >53,29,0.8621,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9400000000000001,1.0,['High'],No,No,No,Yes,No,Unclear,Yes,Yes,,Victor Monteon,Universidad Autonoma Campeche,Unity-Aligned,https://dx.doi.org/10.1016/j.transci.2022.103374,2022-02-09,2022-07-16,Verified,monteon_seroprevalence_2022,MEX
220127_Campeche_UniversidadAutonomaCampeche_Sex_Male,220127_Campeche_UniversidadAutonomaCampeche,Seroprevalence of SARS-CoV-2 antibodies in blood donors during the third wave of infection in Campeche Mexico,2022-01-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Campeche,," blood donors who attended Centro Estatal de la Transfusion Sanguínea de Campeche, Mexico during the period of August through September 2021",,2021-08-15,2021-09-15,Blood donors,Male,Multiple groups,18.0,,Sex/Gender,Sex: Male,398,0.6709,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9400000000000001,1.0,['High'],No,No,No,Yes,No,Unclear,Yes,Yes,,Victor Monteon,Universidad Autonoma Campeche,Unity-Aligned,https://dx.doi.org/10.1016/j.transci.2022.103374,2022-02-09,2022-07-16,Verified,monteon_seroprevalence_2022,MEX
220127_Campeche_UniversidadAutonomaCampeche_Unvaccinated,220127_Campeche_UniversidadAutonomaCampeche,Seroprevalence of SARS-CoV-2 antibodies in blood donors during the third wave of infection in Campeche Mexico,2022-01-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Campeche,," blood donors who attended Centro Estatal de la Transfusion Sanguínea de Campeche, Mexico during the period of August through September 2021",,2021-08-15,2021-09-15,Blood donors,All,Multiple groups,18.0,,COVID-19 vaccination status,Unvaccinated,141,0.4255,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9400000000000001,1.0,['High'],No,No,No,Yes,No,Unclear,Yes,Yes,,Victor Monteon,Universidad Autonoma Campeche,Unity-Aligned,https://dx.doi.org/10.1016/j.transci.2022.103374,2022-02-09,2022-07-16,Verified,monteon_seroprevalence_2022,MEX
220127_Campeche_UniversidadAutonomaCampeche_Age_18-22,220127_Campeche_UniversidadAutonomaCampeche,Seroprevalence of SARS-CoV-2 antibodies in blood donors during the third wave of infection in Campeche Mexico,2022-01-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Campeche,," blood donors who attended Centro Estatal de la Transfusion Sanguínea de Campeche, Mexico during the period of August through September 2021",,2021-08-15,2021-09-15,Blood donors,All,Adults (18-64 years),18.0,,Age,Age: 18-22,71,0.7042,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9400000000000001,1.0,['High'],No,No,No,Yes,No,Unclear,Yes,Yes,,Victor Monteon,Universidad Autonoma Campeche,Unity-Aligned,https://dx.doi.org/10.1016/j.transci.2022.103374,2022-02-09,2022-07-16,Verified,monteon_seroprevalence_2022,MEX
220127_Campeche_UniversidadAutonomaCampeche_Sex_Female,220127_Campeche_UniversidadAutonomaCampeche,Seroprevalence of SARS-CoV-2 antibodies in blood donors during the third wave of infection in Campeche Mexico,2022-01-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Campeche,," blood donors who attended Centro Estatal de la Transfusion Sanguínea de Campeche, Mexico during the period of August through September 2021",,2021-08-15,2021-09-15,Blood donors,Female,Multiple groups,18.0,,Sex/Gender,Sex: Female,81,0.7654000000000001,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9400000000000001,1.0,['High'],No,No,No,Yes,No,Unclear,Yes,Yes,,Victor Monteon,Universidad Autonoma Campeche,Unity-Aligned,https://dx.doi.org/10.1016/j.transci.2022.103374,2022-02-09,2022-07-16,Verified,monteon_seroprevalence_2022,MEX
220127_Campeche_UniversidadAutonomaCampeche_Age_38-42,220127_Campeche_UniversidadAutonomaCampeche,Seroprevalence of SARS-CoV-2 antibodies in blood donors during the third wave of infection in Campeche Mexico,2022-01-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Campeche,," blood donors who attended Centro Estatal de la Transfusion Sanguínea de Campeche, Mexico during the period of August through September 2021",,2021-08-15,2021-09-15,Blood donors,All,Adults (18-64 years),38.0,42.0,Age,Age: 38-42,50,0.84,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9400000000000001,1.0,['High'],No,No,No,Yes,No,Unclear,Yes,Yes,,Victor Monteon,Universidad Autonoma Campeche,Unity-Aligned,https://dx.doi.org/10.1016/j.transci.2022.103374,2022-02-09,2022-07-16,Verified,monteon_seroprevalence_2022,MEX
220127_Campeche_UniversidadAutonomaCampeche_Age_23-27,220127_Campeche_UniversidadAutonomaCampeche,Seroprevalence of SARS-CoV-2 antibodies in blood donors during the third wave of infection in Campeche Mexico,2022-01-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Campeche,," blood donors who attended Centro Estatal de la Transfusion Sanguínea de Campeche, Mexico during the period of August through September 2021",,2021-08-15,2021-09-15,Blood donors,All,Adults (18-64 years),23.0,27.0,Age,Age: 23-27,99,0.6667000000000001,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9400000000000001,1.0,['High'],No,No,No,Yes,No,Unclear,Yes,Yes,,Victor Monteon,Universidad Autonoma Campeche,Unity-Aligned,https://dx.doi.org/10.1016/j.transci.2022.103374,2022-02-09,2022-07-16,Verified,monteon_seroprevalence_2022,MEX
220127_Campeche_UniversidadAutonomaCampeche_Age_43-47,220127_Campeche_UniversidadAutonomaCampeche,Seroprevalence of SARS-CoV-2 antibodies in blood donors during the third wave of infection in Campeche Mexico,2022-01-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Campeche,," blood donors who attended Centro Estatal de la Transfusion Sanguínea de Campeche, Mexico during the period of August through September 2021",,2021-08-15,2021-09-15,Blood donors,All,Adults (18-64 years),43.0,47.0,Age,Age: 43-47,49,0.7143,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9400000000000001,1.0,['High'],No,No,No,Yes,No,Unclear,Yes,Yes,,Victor Monteon,Universidad Autonoma Campeche,Unity-Aligned,https://dx.doi.org/10.1016/j.transci.2022.103374,2022-02-09,2022-07-16,Verified,monteon_seroprevalence_2022,MEX
220127_Campeche_UniversidadAutonomaCampeche_Age_28-32,220127_Campeche_UniversidadAutonomaCampeche,Seroprevalence of SARS-CoV-2 antibodies in blood donors during the third wave of infection in Campeche Mexico,2022-01-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Campeche,," blood donors who attended Centro Estatal de la Transfusion Sanguínea de Campeche, Mexico during the period of August through September 2021",,2021-08-15,2021-09-15,Blood donors,All,Adults (18-64 years),28.0,32.0,Age,Age: 28-32,71,0.5211,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9400000000000001,1.0,['High'],No,No,No,Yes,No,Unclear,Yes,Yes,,Victor Monteon,Universidad Autonoma Campeche,Unity-Aligned,https://dx.doi.org/10.1016/j.transci.2022.103374,2022-02-09,2022-07-16,Verified,monteon_seroprevalence_2022,MEX
220201_Mexico_NationalInstituteofPublicHealth_Overall,220201_Mexico_NationalInstituteofPublicHealth,Nationally representative SARS-CoV-2 antibody prevalence estimates after the first epidemic wave in Mexico.,2022-02-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Mexico,,,"10,216 households were selected. At
each household, an adult family member was asked to respond to a household
questionnaire and a questionnaire on the use of health services and health status of
each family member.",,2020-08-15,2020-11-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,9463,0.249,0.222,0.267,True,True,,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9202,0.9952,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Ana Basto-Abreu,National Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1038/s41467-022-28232-9,2022-02-08,2023-08-15,Unverified,basto-abreu_nationally_2022,MEX
220201_Mexico_NationalInstituteofPublicHealth_>=60,220201_Mexico_NationalInstituteofPublicHealth,Nationally representative SARS-CoV-2 antibody prevalence estimates after the first epidemic wave in Mexico.,2022-02-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Mexico,,,"10,216 households were selected. At
each household, an adult family member was asked to respond to a household
questionnaire and a questionnaire on the use of health services and health status of
each family member.",,2020-08-15,2020-11-15,Household and community samples,All,Seniors (65+ years),60.0,,Age,>=60,1787,0.18600000000000003,0.154,0.20800000000000002,,True,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9202,0.9952,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Ana Basto-Abreu,National Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1038/s41467-022-28232-9,2022-02-08,2023-08-15,Unverified,basto-abreu_nationally_2022,MEX
220201_Mexico_NationalInstituteofPublicHealth_40-59,220201_Mexico_NationalInstituteofPublicHealth,Nationally representative SARS-CoV-2 antibody prevalence estimates after the first epidemic wave in Mexico.,2022-02-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Mexico,,,"10,216 households were selected. At
each household, an adult family member was asked to respond to a household
questionnaire and a questionnaire on the use of health services and health status of
each family member.",,2020-08-15,2020-11-15,Household and community samples,All,Adults (18-64 years),40.0,59.0,Age,40-59,2831,0.278,0.24600000000000002,0.302,,True,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9202,0.9952,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Ana Basto-Abreu,National Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1038/s41467-022-28232-9,2022-02-08,2023-08-15,Unverified,basto-abreu_nationally_2022,MEX
220201_Mexico_NationalInstituteofPublicHealth_20-39,220201_Mexico_NationalInstituteofPublicHealth,Nationally representative SARS-CoV-2 antibody prevalence estimates after the first epidemic wave in Mexico.,2022-02-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Mexico,,,"10,216 households were selected. At
each household, an adult family member was asked to respond to a household
questionnaire and a questionnaire on the use of health services and health status of
each family member.",,2020-08-15,2020-11-15,Household and community samples,All,Adults (18-64 years),20.0,39.0,Age,20-39,2954,0.27899999999999997,0.249,0.303,,True,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9202,0.9952,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Ana Basto-Abreu,National Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1038/s41467-022-28232-9,2022-02-08,2023-08-15,Unverified,basto-abreu_nationally_2022,MEX
220201_Mexico_NationalInstituteofPublicHealth_1-19,220201_Mexico_NationalInstituteofPublicHealth,Nationally representative SARS-CoV-2 antibody prevalence estimates after the first epidemic wave in Mexico.,2022-02-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Mexico,,,"10,216 households were selected. At
each household, an adult family member was asked to respond to a household
questionnaire and a questionnaire on the use of health services and health status of
each family member.",,2020-08-15,2020-11-15,Household and community samples,All,Children and Youth (0-17 years),1.0,19.0,Age,1-19,1891,0.225,0.19,0.253,,True,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9202,0.9952,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Ana Basto-Abreu,National Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1038/s41467-022-28232-9,2022-02-08,2023-08-15,Unverified,basto-abreu_nationally_2022,MEX
220201_Mexico_NationalInstituteofPublicHealth_Male,220201_Mexico_NationalInstituteofPublicHealth,Nationally representative SARS-CoV-2 antibody prevalence estimates after the first epidemic wave in Mexico.,2022-02-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Mexico,,,"10,216 households were selected. At
each household, an adult family member was asked to respond to a household
questionnaire and a questionnaire on the use of health services and health status of
each family member.",,2020-08-15,2020-11-15,Household and community samples,Male,Multiple groups,,,Sex/Gender,,3976,0.253,0.223,0.27399999999999997,,True,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9202,0.9952,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Ana Basto-Abreu,National Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1038/s41467-022-28232-9,2022-02-08,2023-08-15,Unverified,basto-abreu_nationally_2022,MEX
220201_Mexico_NationalInstituteofPublicHealth_Female,220201_Mexico_NationalInstituteofPublicHealth,Nationally representative SARS-CoV-2 antibody prevalence estimates after the first epidemic wave in Mexico.,2022-02-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Mexico,,,"10,216 households were selected. At
each household, an adult family member was asked to respond to a household
questionnaire and a questionnaire on the use of health services and health status of
each family member.",,2020-08-15,2020-11-15,Household and community samples,Female,Multiple groups,,,Sex/Gender,,5487,0.245,0.217,0.265,,True,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9202,0.9952,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Ana Basto-Abreu,National Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1038/s41467-022-28232-9,2022-02-08,2023-08-15,Unverified,basto-abreu_nationally_2022,MEX
220311_Tijuana_UniversityofCaliforniaSanFrancisco_2020NovDec,220311_Tijuana_UniversityofCaliforniaSanFrancisco_2020NovDec,"The impact of the COVID-19 pandemic among migrants in shelters in Tijuana, Baja California, Mexico.",2022-03-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mexico,Baja California,Tijuana,"We defined the inclusion criteria with the aim of enrolling the most vulnerable population of in-transit migrants and asylum seekers. Thus, we recruited persons either: (1) born in a Latin American or Caribbean country other than Mexico, who had been in Tijuana for ≤5 years or (2) born in a Mexican state other than Baja California (the state where Tijuana is located), who had arrived in Tijuana ≤1 year prior due to deportation from the US or internal displacement in Mexico. In addition, participants had to be >=18 years old, able to respond the survey questionnaire in Spanish, English or French and to provide written informed consent.",Older than 18 years of age,2021-02-15,2021-04-15,Persons experiencing homelessness,All,Adults (18-64 years),,,Primary Estimate,,84,0.46299999999999997,,,True,,,,True,Convenience,Author designed (type unknown),,,,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Ietza Bojorquez-Chapela,University of California San Francisco,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjgh-2021-007202,2022-03-22,2022-07-16,Unverified,bojorquez-chapela_impact_2022,MEX
220311_Tijuana_UniversityofCaliforniaSanFrancisco_2021FebApr,220311_Tijuana_UniversityofCaliforniaSanFrancisco_2021FebApr,"The impact of the COVID-19 pandemic among migrants in shelters in Tijuana, Baja California, Mexico.",2022-03-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mexico,Baja California,Tijuana,"We defined the inclusion criteria with the aim of enrolling the most vulnerable population of in-transit migrants and asylum seekers. Thus, we recruited persons either: (1) born in a Latin American or Caribbean country other than Mexico, who had been in Tijuana for ≤5 years or (2) born in a Mexican state other than Baja California (the state where Tijuana is located), who had arrived in Tijuana ≤1 year prior due to deportation from the US or internal displacement in Mexico. In addition, participants had to be >=18 years old, able to respond the survey questionnaire in Spanish, English or French and to provide written informed consent.",Older than 18 years of age,2020-11-15,2020-12-15,Persons experiencing homelessness,All,Adults (18-64 years),,,Primary Estimate,,397,0.545,,,True,,,,True,Convenience,Author designed (type unknown),,,,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Ietza Bojorquez-Chapela,University of California San Francisco,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjgh-2021-007202,2022-03-22,2022-07-16,Unverified,bojorquez-chapela_impact_2022,MEX
220317_MexicoCity_NationalInstituteofRespiratoryDiseases_Overall_TestAdj,220317_MexicoCity_NationalInstituteofRespiratoryDiseases,Seroepidemiology of SARS-CoV-2 in healthcare personnel working at the largest tertiary COVID-19 referral hospitals in Mexico City,2022-03-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,Mexico,Mexico City,Mexico City,"healthcare personnel (physicians and physicians in training (residents and fellows), nurses, laboratory technicians, researchers, graduate biomedical research students, and housekeeping, maintenance, laundry, security, kitchen, and administrative staff) working at the two largest, tertiary care, National Ministry of Health referral hospitals for COVID-19 in Mexico City: the National Institute of Respiratory Diseases (INER) and the National Institute of Medical Sciences and Nutrition Salvador Zubirán (INCMNSZ)",,2020-10-15,2021-06-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,883,0.335,,,True,True,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9792000000000001,0.9995,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Vanessa Davila-Conn,National Institute of Respiratory Diseases,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0264964,2022-04-06,2023-08-15,Unverified,davila-conn_seroepidemiology_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_Overall,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Mexico,"Aguascalientes,Baja California,Baja California Sur,Campeche,Chiapas,Chihuahua,Ciudad de México,Coahuila,Colima,Durango,Estado de México,Guanajuato,Guerrero,Hidalgo,Jalisco,Michoacán,Morelos,Nayarit,Nuevo León,Oaxaca,Puebla,Querétaro,Quintana Roo,San Luis Potosí,Sinaloa,Sonora,Tabasco,Tamaulipas,Tlaxcala,Veracruz,Yucatán,Zacatecas",,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Multiple groups,,,Primary Estimate,,522690,0.32799999999999996,0.321,0.335,True,,True,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_State_Durango,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Durango,,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Multiple groups,,,Geographical area,State: Durango,4930,0.342,0.309,0.375,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_Sex_Male,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Mexico,"Aguascalientes,Baja California,Baja California Sur,Campeche,Chiapas,Chihuahua,Ciudad de México,Coahuila,Colima,Durango,Estado de México,Guanajuato,Guerrero,Hidalgo,Jalisco,Michoacán,Morelos,Nayarit,Nuevo León,Oaxaca,Puebla,Querétaro,Quintana Roo,San Luis Potosí,Sinaloa,Sonora,Tabasco,Tamaulipas,Tlaxcala,Veracruz,Yucatán,Zacatecas",,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,Male,Multiple groups,,,Sex/Gender,Sex: Male,226069,0.33,0.321,0.33899999999999997,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_UnAdj_Overall,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Mexico,"Aguascalientes,Baja California,Baja California Sur,Campeche,Chiapas,Chihuahua,Ciudad de México,Coahuila,Colima,Durango,Estado de México,Guanajuato,Guerrero,Hidalgo,Jalisco,Michoacán,Morelos,Nayarit,Nuevo León,Oaxaca,Puebla,Querétaro,Quintana Roo,San Luis Potosí,Sinaloa,Sonora,Tabasco,Tamaulipas,Tlaxcala,Veracruz,Yucatán,Zacatecas",,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Multiple groups,,,Analysis,,522690,0.35710000000000003,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_State_Michoacan,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Michoacán,,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Multiple groups,,,Geographical area,State: Michoacán,12803,0.28600000000000003,0.27,0.303,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_UnAdj_Age_50-59,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Mexico,"Aguascalientes,Baja California,Baja California Sur,Campeche,Chiapas,Chihuahua,Ciudad de México,Coahuila,Colima,Durango,Estado de México,Guanajuato,Guerrero,Hidalgo,Jalisco,Michoacán,Morelos,Nayarit,Nuevo León,Oaxaca,Puebla,Querétaro,Quintana Roo,San Luis Potosí,Sinaloa,Sonora,Tabasco,Tamaulipas,Tlaxcala,Veracruz,Yucatán,Zacatecas",,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,Age: 50-59,91683,0.358,0.355,0.36100000000000004,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_State_SanLuisPotosi,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,San Luis Potosí,,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Multiple groups,,,Geographical area,State: San Luis Potosí,4461,0.305,0.273,0.336,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_State_NuevoLeon,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Nuevo León,,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Multiple groups,,,Geographical area,State: Nuevo León,35283,0.40700000000000003,0.394,0.42,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_State_BajaCaliforniaSur,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Baja California Sur,,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Multiple groups,,,Geographical area,State: Baja California Sur,1017,0.385,0.29100000000000004,0.48,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_State_BajaCalifornia,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Baja California,,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Multiple groups,,,Geographical area,State: Baja California,26484,0.34,0.32799999999999996,0.353,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_State_Nayarit,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Nayarit,,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Multiple groups,,,Geographical area,State: Nayarit,2532,0.237,0.19100000000000003,0.28300000000000003,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_State_Aguascalientes,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Aguascalientes,,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Multiple groups,,,Geographical area,State: Aguascalientes,3212,0.227,0.193,0.261,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_State_Tabasco,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Tabasco,,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Multiple groups,,,Geographical area,State: Tabasco,3889,0.513,0.46,0.5650000000000001,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_UnAdj_Age_60orMore,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Mexico,"Aguascalientes,Baja California,Baja California Sur,Campeche,Chiapas,Chihuahua,Ciudad de México,Coahuila,Colima,Durango,Estado de México,Guanajuato,Guerrero,Hidalgo,Jalisco,Michoacán,Morelos,Nayarit,Nuevo León,Oaxaca,Puebla,Querétaro,Quintana Roo,San Luis Potosí,Sinaloa,Sonora,Tabasco,Tamaulipas,Tlaxcala,Veracruz,Yucatán,Zacatecas",,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Seniors (65+ years),60.0,,Age,Age: ≥ 60,84443,0.289,0.28600000000000003,0.292,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_State_Jalisco,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Jalisco,,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Multiple groups,,,Geographical area,State: Jalisco,34796,0.308,0.297,0.318,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_UnAdj_Age_Under20,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Mexico,"Aguascalientes,Baja California,Baja California Sur,Campeche,Chiapas,Chihuahua,Ciudad de México,Coahuila,Colima,Durango,Estado de México,Guanajuato,Guerrero,Hidalgo,Jalisco,Michoacán,Morelos,Nayarit,Nuevo León,Oaxaca,Puebla,Querétaro,Quintana Roo,San Luis Potosí,Sinaloa,Sonora,Tabasco,Tamaulipas,Tlaxcala,Veracruz,Yucatán,Zacatecas",,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Children and Youth (0-17 years),,19.0,Age,Age: < 20,34797,0.33,0.325,0.335,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_State_Hidalgo,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Hidalgo,,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Multiple groups,,,Geographical area,State: Hidalgo,4513,0.35200000000000004,0.318,0.386,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_State_CiudadDeMexico,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Ciudad de México,,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Multiple groups,,,Geographical area,State: Ciudad de México,74345,0.359,0.35100000000000003,0.36700000000000005,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_State_Colima,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Colima,,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Multiple groups,,,Geographical area,State: Colima,2914,0.18100000000000002,0.145,0.21600000000000003,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_State_Guanajuato,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Guanajuato,,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Multiple groups,,,Geographical area,State: Guanajuato,24403,0.282,0.268,0.29600000000000004,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_State_Sonora,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Sonora,,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Multiple groups,,,Geographical area,State: Sonora,14565,0.395,0.374,0.41500000000000004,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_State_Morelos,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Morelos,,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Multiple groups,,,Geographical area,State: Morelos,2420,0.267,0.23,0.304,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_State_Oaxaca,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Oaxaca,,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Multiple groups,,,Geographical area,State: Oaxaca,1510,0.326,0.257,0.395,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_State_Coahuila,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Coahuila,,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Multiple groups,,,Geographical area,State: Coahuila,8924,0.38799999999999996,0.36600000000000005,0.409,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_State_Guerrero,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Guerrero,,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Multiple groups,,,Geographical area,State: Guerrero,1829,0.321,0.278,0.365,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_State_Tamaulipas,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Tamaulipas,,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Multiple groups,,,Geographical area,State: Tamaulipas,6923,0.373,0.34600000000000003,0.4,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_State_Zacatecas,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Zacatecas,,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Multiple groups,,,Geographical area,State: Zacatecas,2247,0.29100000000000004,0.25,0.332,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_Sex_Female,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Mexico,"Aguascalientes,Baja California,Baja California Sur,Campeche,Chiapas,Chihuahua,Ciudad de México,Coahuila,Colima,Durango,Estado de México,Guanajuato,Guerrero,Hidalgo,Jalisco,Michoacán,Morelos,Nayarit,Nuevo León,Oaxaca,Puebla,Querétaro,Quintana Roo,San Luis Potosí,Sinaloa,Sonora,Tabasco,Tamaulipas,Tlaxcala,Veracruz,Yucatán,Zacatecas",,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,Female,Multiple groups,,,Sex/Gender,Sex: Female,296621,0.326,0.316,0.337,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_State_Chihuahua,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Chihuahua,,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Multiple groups,,,Geographical area,State: Chihuahua,18814,0.41200000000000003,0.396,0.428,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_State_Queretaro,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Querétaro,,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Multiple groups,,,Geographical area,State: Querétaro,17653,0.239,0.226,0.252,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_State_QuintanaRoo,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Quintana Roo,,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Multiple groups,,,Geographical area,State: Quintana Roo,4551,0.35700000000000004,0.324,0.39,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_UnAdj_Age_30-39,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Mexico,"Aguascalientes,Baja California,Baja California Sur,Campeche,Chiapas,Chihuahua,Ciudad de México,Coahuila,Colima,Durango,Estado de México,Guanajuato,Guerrero,Hidalgo,Jalisco,Michoacán,Morelos,Nayarit,Nuevo León,Oaxaca,Puebla,Querétaro,Quintana Roo,San Luis Potosí,Sinaloa,Sonora,Tabasco,Tamaulipas,Tlaxcala,Veracruz,Yucatán,Zacatecas",,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,Age: 30-39,109828,0.385,0.383,0.38799999999999996,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_State_Sinaloa,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Sinaloa,,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Multiple groups,,,Geographical area,State: Sinaloa,60111,0.409,0.399,0.419,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_State_Puebla,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Puebla,,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Multiple groups,,,Geographical area,State: Puebla,18983,0.27399999999999997,0.259,0.29,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_State_Yucatan,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Yucatán,,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Multiple groups,,,Geographical area,State: Yucatán,1249,0.376,0.27399999999999997,0.478,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_State_Tlaxcala,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Tlaxcala,,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Multiple groups,,,Geographical area,State: Tlaxcala,1796,0.337,0.298,0.37700000000000006,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_State_Chiapas,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Chiapas,,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Multiple groups,,,Geographical area,State: Chiapas,3943,0.264,0.219,0.309,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_State_EstadoDeMexico,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Estado de México,,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Multiple groups,,,Geographical area,State: Estado de México,98813,0.349,0.342,0.35600000000000004,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_State_Veracruz,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Veracruz,,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Multiple groups,,,Geographical area,State: Veracruz,21679,0.32299999999999995,0.309,0.337,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_UnAdj_Age_40-49,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Mexico,"Aguascalientes,Baja California,Baja California Sur,Campeche,Chiapas,Chihuahua,Ciudad de México,Coahuila,Colima,Durango,Estado de México,Guanajuato,Guerrero,Hidalgo,Jalisco,Michoacán,Morelos,Nayarit,Nuevo León,Oaxaca,Puebla,Querétaro,Quintana Roo,San Luis Potosí,Sinaloa,Sonora,Tabasco,Tamaulipas,Tlaxcala,Veracruz,Yucatán,Zacatecas",,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,Age: 40-49,104108,0.38,0.37700000000000006,0.383,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_PopAdj_State_Campeche,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Campeche,,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Multiple groups,,,Geographical area,State: Campeche,1098,0.273,0.227,0.32,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220328_Mexico_SaludDignaAC_UnAdj_Age_20-29,220328_Mexico_SaludDignaAC,Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.,2022-03-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Mexico,"Aguascalientes,Baja California,Baja California Sur,Campeche,Chiapas,Chihuahua,Ciudad de México,Coahuila,Colima,Durango,Estado de México,Guanajuato,Guerrero,Hidalgo,Jalisco,Michoacán,Morelos,Nayarit,Nuevo León,Oaxaca,Puebla,Querétaro,Quintana Roo,San Luis Potosí,Sinaloa,Sonora,Tabasco,Tamaulipas,Tlaxcala,Veracruz,Yucatán,Zacatecas",,"Only people allowed to use their information, with serological results (positive or negative) and demographic information, were included in the analysis.",,2020-07-05,2020-12-31,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,Age: 20-29,97831,0.369,0.36600000000000005,0.373,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Miguel Fernández-Rojas,Salud Digna A.C.,Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-09395-3,2022-04-06,2022-07-16,Verified,fernandez-rojas_seroconversion_2022,MEX
220512_MexicoCity_GeneralHospitalofMexico_Overall,220512_MexicoCity_GeneralHospitalofMexico,High Incidence Rate of SARS-CoV-2 Infection in Health Care Workers at a Dedicated COVID-19 Hospital: Experiences of the Pandemic from a Large Mexican Hospital.,2022-05-12,Journal Article (Peer-Reviewed),Local,Prospective cohort,Mexico,,Mexico City,"We invited volunteers to participate in the study with no previous diagnosis of SARSCoV-2, evidenced by a negative quantitative PCR (qPCR) test in oropharyngeal swabs
and negative IgG antibodies against the virus, aged 18 years and above, and with no
previous COVID-19 vaccination.","Pregnancy or lactation, or concurring symptoms of COVID-19",2020-08-15,2021-01-15,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,109,0.5872,,,True,,,,True,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,No,,Unclear,Yes,No,,Nallely Bueno-Hernandez,General Hospital of Mexico,Not Unity-Aligned,https://dx.doi.org/10.3390/healthcare10050896,2022-06-09,2022-07-16,Unverified,bueno-hernandez_high_2022,MEX
220605_Sinaloa_UniversityofSinaloa_Neonates2,220605_Sinaloa_UniversityofSinaloa_Neonates2,Epidemiological and clinical characteristics of pregnant women and neonates with COVID-19 in Northwest Mexico,2022-06-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Sinaloa State,,"In this study, pregnant women and neonates from the Women’s Hospital located in Sinaloa state, Northwest Mexico, were collected from
August to December 2020",,2020-08-15,2020-12-15,Perinatal,Female,Children and Youth (0-17 years),,,Primary Estimate,,84,0.35700000000000004,,,True,,,,True,Unclear,Qualitative Elecsys Anti-SARS-CoV-2 Probe,Roche Diagnostics,CLIA,Whole Blood,IgG,,,,,['High'],,Unclear,No,No,,Unclear,Yes,No,,Nidia Leon-Sicairos,University of Sinaloa,Not Unity-Aligned,https://dx.doi.org/10.1111/aji.13583,2022-06-23,2022-07-16,Unverified,leonsicairos_epidemiological_2022,MEX
220605_Sinaloa_UniversityofSinaloa_PregnantWomen1,220605_Sinaloa_UniversityofSinaloa_PregnantWomen1,Epidemiological and clinical characteristics of pregnant women and neonates with COVID-19 in Northwest Mexico,2022-06-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Sinaloa State,,"In this study, pregnant women and neonates from the Women’s Hospital located in Sinaloa state, Northwest Mexico, were collected from
August to December 2020","Women who were not pregnant or those
with previous SARS-CoV-2 infection were excluded",2020-08-15,2020-12-15,Pregnant or parturient women,Female,Multiple groups,,,Primary Estimate,,116,0.11199999999999999,,,True,,,,True,Unclear,Qualitative Elecsys Anti-SARS-CoV-2 Probe,Roche Diagnostics,CLIA,Whole Blood,IgG,,,,,['High'],,Unclear,No,No,,Unclear,Yes,No,,Nidia Leon-Sicairos,University of Sinaloa,Not Unity-Aligned,https://dx.doi.org/10.1111/aji.13583,2022-06-21,2022-07-16,Unverified,leonsicairos_epidemiological_2022,MEX
220602_Mexico_InstitutoNacionaldeNeurologíayNeurocirugía_PandemicDonors,220602_Mexico_InstitutoNacionaldeNeurologíayNeurocirugía_PandemicDonors,Seric IgG anti-SARS-CoV-2 pre- and post- Covid-19 pandemic from Mexican asymptomatic subjects.,2022-06-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mexico,,,"""The pandemic samples were collected from October to December 2020  and  came  from  blood  donors  and  neurological  patients who came to the Clinical Laboratory for routine studies.  ""","""Patients with a previous diagnosis of Guillain-Barré syndrome (who could have an early-stage form of Covid-19) were excluded""",2020-10-01,2020-12-31,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,243,0.29600000000000004,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9440000000000001,0.963,['High'],,No,No,Yes,,Yes,Yes,No,,Lucinda Aguirre-Cruz,Instituto Nacional de Neurología y Neurocirugía,Unity-Aligned,https://dx.doi.org/10.21149/12930,2022-10-01,2024-03-01,Unverified,aguirre-cruz_seric_2022,MEX
220602_Mexico_InstitutoNacionaldeNeurologíayNeurocirugía_PandemicPatients,220602_Mexico_InstitutoNacionaldeNeurologíayNeurocirugía_PandemicPatients,Seric IgG anti-SARS-CoV-2 pre- and post- Covid-19 pandemic from Mexican asymptomatic subjects.,2022-06-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mexico,,,"""The pandemic samples were collected from October to December 2020  and  came  from  blood  donors  and  neurological  patients who came to the Clinical Laboratory for routine studies.  ""","""Patients with a previous diagnosis of Guillain-Barré syndrome (who could have an early-stage form of Covid-19) were excluded""",2020-10-01,2020-12-31,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,17.0,,Primary Estimate,,312,0.157,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9440000000000001,0.963,['High'],,No,No,Yes,,Yes,Yes,No,,Lucinda Aguirre-Cruz,Instituto Nacional de Neurología y Neurocirugía,Not Unity-Aligned,https://dx.doi.org/10.21149/12930,2022-10-01,2024-03-01,Unverified,aguirre-cruz_seric_2022,MEX
220602_Mexico_InstitutoNacionaldeNeurologíayNeurocirugía_Prepandemic,220602_Mexico_InstitutoNacionaldeNeurologíayNeurocirugía_Prepandemic,Seric IgG anti-SARS-CoV-2 pre- and post- Covid-19 pandemic from Mexican asymptomatic subjects.,2022-06-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mexico,,,"""The  pre-pandemic  samples  were  collected  from  January  2018 to December 2019 and came from the blood bank donor serum library,""","""Patients with a previous diagnosis of Guillain-Barré syndrome (who could have an early-stage form of Covid-19) were excluded""",2018-01-01,2019-12-31,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,538,0.006,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9440000000000001,0.963,['High'],,No,No,Yes,,Yes,Yes,No,,Lucinda Aguirre-Cruz,Instituto Nacional de Neurología y Neurocirugía,Unity-Aligned,https://dx.doi.org/10.21149/12930,2022-10-01,2024-03-01,Unverified,aguirre-cruz_seric_2022,MEX
220615_Merida_EmoryUniversity_Overall,220615_Merida_EmoryUniversity,"SARS-CoV-2 antibody prevalence in a pediatric cohort of unvaccinated children in Merida, Yucatan, Mexico.",2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mexico,Yucatan,Merida,"recruiting a cohort of children aged 2–15 years old in October 2020 as a part of the Targeted Indoor Residual Spraying (TIRS) trial in Me´rida.  The study enrolled 4,600 children distributed among 50 randomized clusters (5x5 city blocks) in Me´rida.",,2021-02-15,2021-06-15,Household and community samples,All,Children and Youth (0-17 years),2.0,15.0,Primary Estimate,anti IgG/IgM,1005,0.255,,,True,,,,True,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,No,No,No,Yes,No,Unclear,Guadalupe Ayora-Talavera,Emory University,Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0000354,2023-04-25,2024-03-01,Unverified,ayora-talavera_sars-cov-2_2022,MEX
220615_Merida_EmoryUniversity_antiG,220615_Merida_EmoryUniversity,"SARS-CoV-2 antibody prevalence in a pediatric cohort of unvaccinated children in Merida, Yucatan, Mexico.",2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mexico,Yucatan,Merida,"recruiting a cohort of children aged 2–15 years old in October 2020 as a part of the Targeted Indoor Residual Spraying (TIRS) trial in Me´rida.  The study enrolled 4,600 children distributed among 50 randomized clusters (5x5 city blocks) in Me´rida.",,2021-02-15,2021-06-15,Household and community samples,All,Children and Youth (0-17 years),2.0,15.0,Test used,anti IgG,1005,0.249,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,0.98,['Moderate'],Yes,Yes,Yes,No,No,No,Yes,No,Unclear,Guadalupe Ayora-Talavera,Emory University,Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0000354,2023-04-25,2024-03-01,Unverified,ayora-talavera_sars-cov-2_2022,MEX
220615_Merida_EmoryUniversity_antiM,220615_Merida_EmoryUniversity,"SARS-CoV-2 antibody prevalence in a pediatric cohort of unvaccinated children in Merida, Yucatan, Mexico.",2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mexico,Yucatan,Merida,"recruiting a cohort of children aged 2–15 years old in October 2020 as a part of the Targeted Indoor Residual Spraying (TIRS) trial in Me´rida.  The study enrolled 4,600 children distributed among 50 randomized clusters (5x5 city blocks) in Me´rida.",,2021-02-15,2021-06-15,Household and community samples,All,Children and Youth (0-17 years),2.0,15.0,Test used,anti IgM,1005,0.026,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Serum,IgM,Spike,Validated by independent authors/third party/non-developers,0.82,0.96,['Moderate'],Yes,Yes,Yes,No,No,No,Yes,No,Unclear,Guadalupe Ayora-Talavera,Emory University,Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0000354,2023-04-25,2024-03-01,Unverified,ayora-talavera_sars-cov-2_2022,MEX
220708_Mexico_InstitutoNacionaldeSaludPública_Overall,220708_Mexico_InstitutoNacionaldeSaludPública,Prevalence of anti-SARS-CoV-2 antibodies and associated factors in healthcare workers of a Mexican Covid-19 hospital,2022-07-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mexico,Morelos,,"""The inclusion criteria were people over 18 years of age working in the hospital, who agreed to sign the informed consent letter and answered a short questionnaire related to exposure and history of SARS-CoV-2 infection, and provided a venous blood sample.""","NR
",2021-01-14,2021-01-21,Health care workers and caregivers,All,Adults (18-64 years),20.0,69.0,Primary Estimate,,381,0.31,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)",EUROIMMUN,ELISA,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Yes,Yes,No,,Antonia Herrera-Ortiz,Instituto Nacional de Salud Pública,Not Unity-Aligned,https://dx.doi.org/10.21149/13677,2022-09-27,2024-03-01,Unverified,herrera-ortiz_prevalence_2022,MEX
220708_Mexico_InstitutoNacionaldeSaludPública_50to59,220708_Mexico_InstitutoNacionaldeSaludPública,Prevalence of anti-SARS-CoV-2 antibodies and associated factors in healthcare workers of a Mexican Covid-19 hospital,2022-07-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mexico,Morelos,,"""The inclusion criteria were people over 18 years of age working in the hospital, who agreed to sign the informed consent letter and answered a short questionnaire related to exposure and history of SARS-CoV-2 infection, and provided a venous blood sample.""","NR
",2021-01-14,2021-01-21,Health care workers and caregivers,All,Adults (18-64 years),50.0,59.0,Age,50-59,96,0.252,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)",EUROIMMUN,ELISA,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Yes,Yes,No,,Antonia Herrera-Ortiz,Instituto Nacional de Salud Pública,Not Unity-Aligned,https://dx.doi.org/10.21149/13677,2022-09-27,2024-03-01,Unverified,herrera-ortiz_prevalence_2022,MEX
220708_Mexico_InstitutoNacionaldeSaludPública_30to39,220708_Mexico_InstitutoNacionaldeSaludPública,Prevalence of anti-SARS-CoV-2 antibodies and associated factors in healthcare workers of a Mexican Covid-19 hospital,2022-07-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mexico,Morelos,,"""The inclusion criteria were people over 18 years of age working in the hospital, who agreed to sign the informed consent letter and answered a short questionnaire related to exposure and history of SARS-CoV-2 infection, and provided a venous blood sample.""","NR
",2021-01-14,2021-01-21,Health care workers and caregivers,All,Adults (18-64 years),30.0,39.0,Age,30-39,103,0.27,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)",EUROIMMUN,ELISA,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Yes,Yes,No,,Antonia Herrera-Ortiz,Instituto Nacional de Salud Pública,Not Unity-Aligned,https://dx.doi.org/10.21149/13677,2022-09-27,2024-03-01,Unverified,herrera-ortiz_prevalence_2022,MEX
220708_Mexico_InstitutoNacionaldeSaludPública_40to49,220708_Mexico_InstitutoNacionaldeSaludPública,Prevalence of anti-SARS-CoV-2 antibodies and associated factors in healthcare workers of a Mexican Covid-19 hospital,2022-07-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mexico,Morelos,,"""The inclusion criteria were people over 18 years of age working in the hospital, who agreed to sign the informed consent letter and answered a short questionnaire related to exposure and history of SARS-CoV-2 infection, and provided a venous blood sample.""","NR
",2021-01-14,2021-01-21,Health care workers and caregivers,All,Adults (18-64 years),40.0,49.0,Age,40-49,108,0.28300000000000003,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)",EUROIMMUN,ELISA,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Yes,Yes,No,,Antonia Herrera-Ortiz,Instituto Nacional de Salud Pública,Not Unity-Aligned,https://dx.doi.org/10.21149/13677,2022-09-27,2024-03-01,Unverified,herrera-ortiz_prevalence_2022,MEX
220708_Mexico_InstitutoNacionaldeSaludPública_60to69,220708_Mexico_InstitutoNacionaldeSaludPública,Prevalence of anti-SARS-CoV-2 antibodies and associated factors in healthcare workers of a Mexican Covid-19 hospital,2022-07-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mexico,Morelos,,"""The inclusion criteria were people over 18 years of age working in the hospital, who agreed to sign the informed consent letter and answered a short questionnaire related to exposure and history of SARS-CoV-2 infection, and provided a venous blood sample.""","NR
",2021-01-14,2021-01-21,Health care workers and caregivers,All,Adults (18-64 years),60.0,69.0,Age,60-69,19,0.05,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)",EUROIMMUN,ELISA,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Yes,Yes,No,,Antonia Herrera-Ortiz,Instituto Nacional de Salud Pública,Not Unity-Aligned,https://dx.doi.org/10.21149/13677,2022-09-27,2024-03-01,Unverified,herrera-ortiz_prevalence_2022,MEX
220708_Mexico_InstitutoNacionaldeSaludPública_20to29,220708_Mexico_InstitutoNacionaldeSaludPública,Prevalence of anti-SARS-CoV-2 antibodies and associated factors in healthcare workers of a Mexican Covid-19 hospital,2022-07-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mexico,Morelos,,"""The inclusion criteria were people over 18 years of age working in the hospital, who agreed to sign the informed consent letter and answered a short questionnaire related to exposure and history of SARS-CoV-2 infection, and provided a venous blood sample.""","NR
",2021-01-14,2021-01-21,Health care workers and caregivers,All,Adults (18-64 years),20.0,29.0,Age,20-29,55,0.14400000000000002,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)",EUROIMMUN,ELISA,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Yes,Yes,No,,Antonia Herrera-Ortiz,Instituto Nacional de Salud Pública,Not Unity-Aligned,https://dx.doi.org/10.21149/13677,2022-09-27,2024-03-01,Unverified,herrera-ortiz_prevalence_2022,MEX
220802_Baja_SecretariatofHealthofBajaCalifornia,220802_Baja_SecretariatofHealthofBajaCalifornia,"Prevalence of SARS-CoV-2 infection in Baja California, Mexico: Findings from a community-based survey in February 2021 in the Mexico-United States border.",2022-08-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,Baja California,,"""Survey inclusion criteria were: Spanish speakers residing in Baja California for at least six months, age five years or older""",,2021-02-01,2021-02-19,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,,1126,0.211,0.174,0.252,True,,True,,True,Convenience,Author designed (ELISA) - Unknown,,ELISA,Whole Blood,IgG,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Oscar Zazueta,Secretariat of Health of Baja California,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0000820,2023-05-03,2023-05-04,Unverified,zazueta_prevalence_2022,MEX
221117_Mexico_CarlosSlimFoundation,221117_Mexico_CarlosSlimFoundation,MIDO COVID: A digital public health strategy designed to tackle chronic disease and the COVID-19 pandemic in Mexico,2022-11-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Mexico,,,"""The study population comprised 58,277 workers of the Carso Group, ... MIDO COVID screening was applied to all asymptomatic individu- als in the workplace and non-pregnant women (pregnant women received normal standard of care as usual).""",,2020-06-26,2020-12-16,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,,58277,0.040999999999999995,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Hector Gallardo-Rinco,Carlos Slim Foundation ,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0277014,2022-12-08,2023-03-19,Unverified,gallardo-rincon_mido_2022,MEX
230413_Mexico_UniversidadAutónomaDeGuerrero_HCWs,230413_Mexico_UniversidadAutónomaDeGuerrero,Seroprevalence of IgG and Subclasses against the Nucleocapsid of SARS-CoV-2 in Health Workers.,2023-04-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mexico,,Guerrero,health workers of the general hospital “Dr. Raymundo Abarca Alarcón”.,,2021-01-01,2021-01-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,HCWs from the designated hospital,253,0.427,,,True,,,,True,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karen Cortes-Sarabia,Universidad Autónoma de Guerrero,Not Unity-Aligned,https://dx.doi.org/10.3390/v15040955,2023-05-29,2023-05-30,Unverified,cortés-sarabia_seroprevalence_2023,MEX
230809_StateofMexico_MexicanSocialSecurityInstitute_Overall,230809_StateofMexico_MexicanSocialSecurityInstitute,Association of Obesity with SARS-CoV-2 and Its Relationship with the Humoral Response Prior to Vaccination in the State of Mexico: A Cross-Sectional Study.,2023-08-09,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,State of Mexico,,"""The inclusion criteria of the participants were: adult participants with-out previous application of any vaccination scheme against COVID-19 and who agreed to sign the informed consent form. ""","""Exclusion criteria were the presence of signs or symptomsof respiratory disease, and refusal to sign the informed consent form""",2021-05-14,2021-07-27,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,980,0.4602,,,True,,,,True,Convenience,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,GenScript,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Daniel Montes-Herrera,Mexican Social Security Institute,Unity-Aligned,https://dx.doi.org/10.3390/diagnostics13162630,2023-09-20,2024-04-25,Verified,montes-herrera_association_2023,MEX
230809_StateofMexico_MexicanSocialSecurityInstitute_Age_40-49,230809_StateofMexico_MexicanSocialSecurityInstitute,Association of Obesity with SARS-CoV-2 and Its Relationship with the Humoral Response Prior to Vaccination in the State of Mexico: A Cross-Sectional Study.,2023-08-09,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,State of Mexico,,"""The inclusion criteria of the participants were: adult participants with-out previous application of any vaccination scheme against COVID-19 and who agreed to sign the informed consent form. ""","""Exclusion criteria were the presence of signs or symptomsof respiratory disease, and refusal to sign the informed consent form""",2021-05-14,2021-07-27,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49 years,127,0.3622,,,,,,,,Convenience,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,GenScript,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Daniel Montes-Herrera,Mexican Social Security Institute,Unity-Aligned,https://dx.doi.org/10.3390/diagnostics13162630,2024-04-25,2024-04-25,Verified,montes-herrera_association_2023,MEX
230809_StateofMexico_MexicanSocialSecurityInstitute_Age_60-100,230809_StateofMexico_MexicanSocialSecurityInstitute,Association of Obesity with SARS-CoV-2 and Its Relationship with the Humoral Response Prior to Vaccination in the State of Mexico: A Cross-Sectional Study.,2023-08-09,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,State of Mexico,,"""The inclusion criteria of the participants were: adult participants with-out previous application of any vaccination scheme against COVID-19 and who agreed to sign the informed consent form. ""","""Exclusion criteria were the presence of signs or symptomsof respiratory disease, and refusal to sign the informed consent form""",2021-05-14,2021-07-27,Household and community samples,All,Seniors (65+ years),60.0,100.0,Age,60-100 years,26,0.3846,,,,,,,,Convenience,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,GenScript,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Daniel Montes-Herrera,Mexican Social Security Institute,Unity-Aligned,https://dx.doi.org/10.3390/diagnostics13162630,2024-04-25,2024-04-25,Verified,montes-herrera_association_2023,MEX
230809_StateofMexico_MexicanSocialSecurityInstitute_Age_50-59,230809_StateofMexico_MexicanSocialSecurityInstitute,Association of Obesity with SARS-CoV-2 and Its Relationship with the Humoral Response Prior to Vaccination in the State of Mexico: A Cross-Sectional Study.,2023-08-09,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,State of Mexico,,"""The inclusion criteria of the participants were: adult participants with-out previous application of any vaccination scheme against COVID-19 and who agreed to sign the informed consent form. ""","""Exclusion criteria were the presence of signs or symptomsof respiratory disease, and refusal to sign the informed consent form""",2021-05-14,2021-07-27,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59 years,429,0.4872,,,,,,,,Convenience,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,GenScript,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Daniel Montes-Herrera,Mexican Social Security Institute,Unity-Aligned,https://dx.doi.org/10.3390/diagnostics13162630,2024-04-25,2024-04-25,Verified,montes-herrera_association_2023,MEX
230809_StateofMexico_MexicanSocialSecurityInstitute_Age_30-39,230809_StateofMexico_MexicanSocialSecurityInstitute,Association of Obesity with SARS-CoV-2 and Its Relationship with the Humoral Response Prior to Vaccination in the State of Mexico: A Cross-Sectional Study.,2023-08-09,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,State of Mexico,,"""The inclusion criteria of the participants were: adult participants with-out previous application of any vaccination scheme against COVID-19 and who agreed to sign the informed consent form. ""","""Exclusion criteria were the presence of signs or symptomsof respiratory disease, and refusal to sign the informed consent form""",2021-05-14,2021-07-27,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39 years,294,0.4898,,,,,,,,Convenience,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,GenScript,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Daniel Montes-Herrera,Mexican Social Security Institute,Unity-Aligned,https://dx.doi.org/10.3390/diagnostics13162630,2024-04-25,2024-04-25,Verified,montes-herrera_association_2023,MEX
230809_StateofMexico_MexicanSocialSecurityInstitute_Age_18-29,230809_StateofMexico_MexicanSocialSecurityInstitute,Association of Obesity with SARS-CoV-2 and Its Relationship with the Humoral Response Prior to Vaccination in the State of Mexico: A Cross-Sectional Study.,2023-08-09,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Mexico,State of Mexico,,"""The inclusion criteria of the participants were: adult participants with-out previous application of any vaccination scheme against COVID-19 and who agreed to sign the informed consent form. ""","""Exclusion criteria were the presence of signs or symptomsof respiratory disease, and refusal to sign the informed consent form""",2021-05-14,2021-07-27,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,18-29 years,64,0.4219,,,,,,,,Convenience,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,GenScript,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Daniel Montes-Herrera,Mexican Social Security Institute,Unity-Aligned,https://dx.doi.org/10.3390/diagnostics13162630,2024-04-25,2024-04-25,Verified,montes-herrera_association_2023,MEX
230824_Mexico_NationalInstituteofPublicHealth_AntiS_Adj,230824_Mexico_NationalInstituteofPublicHealth,SARS-CoV-2 seroprevalence and vaccine coverage from August to November 2021: A nationally representative survey in Mexico.,2023-08-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Mexico,,,this study belongs to the National Health and Nutrition Survey (ENSANUT) 2021,participants with unknown age or age was under one,2021-08-04,2021-11-11,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,Anti-S adjusted,7236,0.841,0.797,0.883,True,True,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Ana Basto-Abreu,National Institute of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.29038,2023-09-15,2023-09-16,Unverified,basto_abreu_sarscov2_2023,MEX
230824_Mexico_NationalInstituteofPublicHealth_AntiN_Adj,230824_Mexico_NationalInstituteofPublicHealth,SARS-CoV-2 seroprevalence and vaccine coverage from August to November 2021: A nationally representative survey in Mexico.,2023-08-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Mexico,,,this study belongs to the National Health and Nutrition Survey (ENSANUT) 2021,participants with unknown age or age was under one,2021-08-04,2021-11-11,Household and community samples,All,Multiple groups,18.0,,Test used,Anti-N adjusted,7236,0.592,0.562,0.622,,True,,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Dried Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Ana Basto-Abreu,National Institute of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.29038,2023-09-15,2023-09-16,Unverified,basto_abreu_sarscov2_2023,MEX
230824_Mexico_NationalInstituteofPublicHealth_AntiS_UnAdj,230824_Mexico_NationalInstituteofPublicHealth,SARS-CoV-2 seroprevalence and vaccine coverage from August to November 2021: A nationally representative survey in Mexico.,2023-08-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Mexico,,,this study belongs to the National Health and Nutrition Survey (ENSANUT) 2021,participants with unknown age or age was under one,2021-08-04,2021-11-11,Household and community samples,All,Multiple groups,18.0,,Analysis,Anti-S unadjusted,7236,0.762,0.746,0.788,,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Ana Basto-Abreu,National Institute of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.29038,2023-09-15,2023-09-16,Unverified,basto_abreu_sarscov2_2023,MEX
230824_Mexico_NationalInstituteofPublicHealth_AntiN_UnAdj,230824_Mexico_NationalInstituteofPublicHealth,SARS-CoV-2 seroprevalence and vaccine coverage from August to November 2021: A nationally representative survey in Mexico.,2023-08-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Mexico,,,this study belongs to the National Health and Nutrition Survey (ENSANUT) 2021,participants with unknown age or age was under one,2021-08-04,2021-11-11,Household and community samples,All,Multiple groups,18.0,,Analysis,Anti-N unadjusted,7236,0.547,0.527,0.567,,,,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Dried Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Ana Basto-Abreu,National Institute of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.29038,2023-09-15,2024-03-01,Unverified,basto_abreu_sarscov2_2023,MEX
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_1stRound_PopAdj_TotalAb_Overall,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_1stRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2020-10-13,2020-12-14,Household and community samples,All,Multiple groups,0.0,90.0,Primary Estimate,"Pop-adjusted, Wantai Total Ab",5000,0.015,0.012,0.02,True,,True,,True,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2023-05-06,2024-04-26,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_1stRound_PopAdj_TotalAb_Age70+,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_1stRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2020-10-13,2020-12-14,Household and community samples,All,Seniors (65+ years),70.0,90.0,Age,70+,99,0.0,0.0,0.0,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-26,2024-04-26,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_1stRound_UnAdj_TotalAb-NAbs,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_1stRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2020-10-13,2020-12-14,Household and community samples,All,Multiple groups,0.0,90.0,Test used,"Unadjusted, Wantai Total Ab + Wantai NAbs",5000,0.0,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Wantai SARS-CoV-2 NAbs ELISA kit","Beijing Wantai Biological,Beijing Wantai Biological Pharmacy Enterprise",ELISA,Serum,"['Neutralizing', 'TotalAntibody']",Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2023-05-07,2024-04-26,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_1stRound_PopAdj_TotalAb_Age50-59,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_1stRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2020-10-13,2020-12-14,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,468,0.013,0.005,0.037,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-26,2024-04-26,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_1stRound_PopAdj_TotalAb_Age10-14,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_1stRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2020-10-13,2020-12-14,Household and community samples,All,Children and Youth (0-17 years),10.0,14.0,Age,10-14,430,0.019,0.009,0.037,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-26,2024-04-26,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_1stRound_PopAdj_TotalAb_Age5-9,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_1stRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2020-10-13,2020-12-14,Household and community samples,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,562,0.007,0.003,0.015,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-26,2024-04-26,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_1stRound_PopAdj_TotalAb_Age60-69,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_1stRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2020-10-13,2020-12-14,Household and community samples,All,Multiple groups,60.0,69.0,Age,60-69,218,0.008,0.002,0.03,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-26,2024-04-26,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_1stRound_PopAdj_TotalAb_Age40-49,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_1stRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2020-10-13,2020-12-14,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,677,0.016,0.008,0.034,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-26,2024-04-26,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_1stRound_PopAdj_TotalAb_Age20-29,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_1stRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2020-10-13,2020-12-14,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,815,0.019,0.01,0.036,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-26,2024-04-26,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_1stRound_PopAdj_TotalAb_Age0-4,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_1stRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2020-10-13,2020-12-14,Household and community samples,All,Children and Youth (0-17 years),0.0,4.0,Age,0-4,580,0.013,0.005,0.032,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-26,2024-04-26,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_1stRound_PopAdj_TotalAb_Age15-19,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_1stRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2020-10-13,2020-12-14,Household and community samples,All,Children and Youth (0-17 years),15.0,19.0,Age,15-19,328,0.015,0.005,0.041,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-26,2024-04-26,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_1stRound_PopAdj_TotalAb_Age30-39,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_1stRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2020-10-13,2020-12-14,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,823,0.023,0.011,0.047,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-26,2024-04-26,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_2ndRound_PopAdj_TotalAb_Overall,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_2ndRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-01-18,2021-03-15,Household and community samples,All,Multiple groups,0.0,90.0,Primary Estimate,"Pop-adjusted, Wantai Total Ab",4524,0.015,0.011,0.021,True,,True,,True,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2023-05-07,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_2ndRound_PopAdj_TotalAb_Age10-14,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_2ndRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-01-18,2021-03-15,Household and community samples,All,Children and Youth (0-17 years),10.0,14.0,Age,10-14,420,0.021,0.01,0.044,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-26,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_2ndRound_PopAdj_TotalAb_Age60-69,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_2ndRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-01-18,2021-03-15,Household and community samples,All,Multiple groups,60.0,69.0,Age,60-69,215,0.018,0.005,0.067,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-26,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_2ndRound_PopAdj_TotalAb_Age0-4,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_2ndRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-01-18,2021-03-15,Household and community samples,All,Children and Youth (0-17 years),0.0,4.0,Age,0-4,356,0.003,0.001,0.015,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-26,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_2ndRound_PopAdj_TotalAb_Age5-9,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_2ndRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-01-18,2021-03-15,Household and community samples,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,545,0.01,0.003,0.034,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-26,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_2ndRound_PopAdj_TotalAb_Age15-19,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_2ndRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-01-18,2021-03-15,Household and community samples,All,Children and Youth (0-17 years),15.0,19.0,Age,15-19,287,0.018,0.006,0.056,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-26,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_2ndRound_PopAdj_TotalAb_Age50-59,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_2ndRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-01-18,2021-03-15,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,483,0.009,0.002,0.037,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-26,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_2ndRound_PopAdj_TotalAb_Age70+,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_2ndRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-01-18,2021-03-15,Household and community samples,All,Seniors (65+ years),70.0,90.0,Age,70+,104,0.011,0.002,0.062,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-26,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_2ndRound_UnAdj_TotalAb-NAbs,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_2ndRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-01-18,2021-03-15,Household and community samples,All,Multiple groups,0.0,90.0,Test used,"Unadjusted, Wantai Total Ab + Wantai NAbs",4524,0.0,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Wantai SARS-CoV-2 NAbs ELISA kit","Beijing Wantai Biological,Beijing Wantai Biological Pharmacy Enterprise",ELISA,Serum,"['Neutralizing', 'TotalAntibody']",Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2023-05-07,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_2ndRound_PopAdj_TotalAb_Age30-39,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_2ndRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-01-18,2021-03-15,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,776,0.028,0.016,0.048,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-26,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_2ndRound_PopAdj_TotalAb_Age20-29,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_2ndRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-01-18,2021-03-15,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,692,0.012,0.005,0.028,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-26,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_2ndRound_PopAdj_TotalAb_Age40-49,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_2ndRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-01-18,2021-03-15,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,646,0.016,0.009,0.027,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-26,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_3rdRound_PopAdj_TotalAb,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_3rdRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-05-24,2021-06-28,Household and community samples,All,Multiple groups,0.0,90.0,Primary Estimate,"Pop-adjusted, Wantai Total Ab",4255,0.51,0.476,0.544,True,,True,,True,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2023-05-07,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_3rdRound_UnAdj_TotalAb-NAbs_Overall,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_3rdRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-05-24,2021-06-28,Household and community samples,All,Multiple groups,0.0,90.0,Test used,"Unadjusted, Wantai Total Ab + Wantai NAbs",4255,0.316,,,,,True,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Wantai SARS-CoV-2 NAbs ELISA kit","Beijing Wantai Biological,Beijing Wantai Biological Pharmacy Enterprise",ELISA,Serum,"['Neutralizing', 'TotalAntibody']",Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2023-05-07,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_3rdRound_UnAdj_TotalAb-NAbs_Age15-19,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_3rdRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-05-24,2021-06-28,Household and community samples,All,Children and Youth (0-17 years),15.0,19.0,Age,15-19,270,0.449,0.384,0.515,,,True,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Wantai SARS-CoV-2 NAbs ELISA kit","Beijing Wantai Biological,Beijing Wantai Biological Pharmacy Enterprise",ELISA,Serum,"['Neutralizing', 'TotalAntibody']",Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-27,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_3rdRound_UnAdj_TotalAb-NAbs_Age5-9,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_3rdRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-05-24,2021-06-28,Household and community samples,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,494,0.126,0.088,0.175,,,True,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Wantai SARS-CoV-2 NAbs ELISA kit","Beijing Wantai Biological,Beijing Wantai Biological Pharmacy Enterprise",ELISA,Serum,"['Neutralizing', 'TotalAntibody']",Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-27,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_3rdRound_UnAdj_TotalAb-NAbs_Age60-69,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_3rdRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-05-24,2021-06-28,Household and community samples,All,Multiple groups,60.0,69.0,Age,60-69,211,0.609,0.497,0.711,,,True,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Wantai SARS-CoV-2 NAbs ELISA kit","Beijing Wantai Biological,Beijing Wantai Biological Pharmacy Enterprise",ELISA,Serum,"['Neutralizing', 'TotalAntibody']",Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-27,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_3rdRound_UnAdj_TotalAb-NAbs_Age20-29,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_3rdRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-05-24,2021-06-28,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,638,0.732,0.679,0.78,,,True,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Wantai SARS-CoV-2 NAbs ELISA kit","Beijing Wantai Biological,Beijing Wantai Biological Pharmacy Enterprise",ELISA,Serum,"['Neutralizing', 'TotalAntibody']",Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-27,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_3rdRound_UnAdj_TotalAb-NAbs_Age10-14,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_3rdRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-05-24,2021-06-28,Household and community samples,All,Children and Youth (0-17 years),10.0,14.0,Age,10-14,391,0.139,0.106,0.18,,,True,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Wantai SARS-CoV-2 NAbs ELISA kit","Beijing Wantai Biological,Beijing Wantai Biological Pharmacy Enterprise",ELISA,Serum,"['Neutralizing', 'TotalAntibody']",Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-27,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_3rdRound_UnAdj_TotalAb-NAbs_Age0-4,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_3rdRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-05-24,2021-06-28,Household and community samples,All,Children and Youth (0-17 years),0.0,4.0,Age,0-4,335,0.109,0.068,0.169,,,True,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Wantai SARS-CoV-2 NAbs ELISA kit","Beijing Wantai Biological,Beijing Wantai Biological Pharmacy Enterprise",ELISA,Serum,"['Neutralizing', 'TotalAntibody']",Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-27,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_3rdRound_UnAdj_TotalAb-NAbs_Age40-49,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_3rdRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-05-24,2021-06-28,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,609,0.749,0.696,0.795,,,True,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Wantai SARS-CoV-2 NAbs ELISA kit","Beijing Wantai Biological,Beijing Wantai Biological Pharmacy Enterprise",ELISA,Serum,"['Neutralizing', 'TotalAntibody']",Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-27,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_3rdRound_UnAdj_TotalAb-NAbs_Age50-59,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_3rdRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-05-24,2021-06-28,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,484,0.718,0.659,0.771,,,True,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Wantai SARS-CoV-2 NAbs ELISA kit","Beijing Wantai Biological,Beijing Wantai Biological Pharmacy Enterprise",ELISA,Serum,"['Neutralizing', 'TotalAntibody']",Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-27,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_3rdRound_UnAdj_TotalAb-NAbs_Age70+,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_3rdRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-05-24,2021-06-28,Household and community samples,All,Seniors (65+ years),70.0,90.0,Age,70+,97,0.427,0.319,0.542,,,True,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Wantai SARS-CoV-2 NAbs ELISA kit","Beijing Wantai Biological,Beijing Wantai Biological Pharmacy Enterprise",ELISA,Serum,"['Neutralizing', 'TotalAntibody']",Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-27,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_3rdRound_UnAdj_TotalAb-NAbs_Age30-39,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_3rdRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-05-24,2021-06-28,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,726,0.739,0.65,0.812,,,True,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Wantai SARS-CoV-2 NAbs ELISA kit","Beijing Wantai Biological,Beijing Wantai Biological Pharmacy Enterprise",ELISA,Serum,"['Neutralizing', 'TotalAntibody']",Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-27,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_4thRound_PopAdj_TotalAb,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_4thRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Prospective cohort,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-09-03,2021-12-09,Household and community samples,All,Multiple groups,0.0,90.0,Primary Estimate,"Pop-adjusted, Wantai Total Ab",4088,0.806,0.778,0.831,True,,True,,True,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2023-05-07,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_4thRound_UnAdj_TotalAb-NAbs_Overall,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_4thRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Prospective cohort,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-09-03,2021-12-09,Household and community samples,All,Multiple groups,0.0,90.0,Test used,"Unadjusted, Wantai Total Ab + Wantai NAbs",4088,0.702,,,,,True,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Wantai SARS-CoV-2 NAbs ELISA kit","Beijing Wantai Biological,Beijing Wantai Biological Pharmacy Enterprise",ELISA,Serum,"['Neutralizing', 'TotalAntibody']",Spike,,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2023-05-07,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_4thRound_UnAdj_TotalAb-NAbs_Age70+,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_4thRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Prospective cohort,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-09-03,2021-12-09,Household and community samples,All,Seniors (65+ years),70.0,90.0,Age,70+,104,0.854,0.744,0.921,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-27,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_4thRound_UnAdj_TotalAb-NAbs_Age5-9,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_4thRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Prospective cohort,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-09-03,2021-12-09,Household and community samples,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,504,0.43,0.342,0.523,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-27,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_4thRound_UnAdj_TotalAb-NAbs_Age15-19,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_4thRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Prospective cohort,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-09-03,2021-12-09,Household and community samples,All,Children and Youth (0-17 years),15.0,19.0,Age,15-19,294,0.941,0.888,0.969,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-27,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_4thRound_UnAdj_TotalAb-NAbs_Age50-59,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_4thRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Prospective cohort,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-09-03,2021-12-09,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,477,0.956,0.927,0.973,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-27,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_4thRound_UnAdj_TotalAb-NAbs_Age20-29,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_4thRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Prospective cohort,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-09-03,2021-12-09,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,558,0.951,0.906,0.975,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-27,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_4thRound_UnAdj_TotalAb-NAbs_Age0-4,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_4thRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Prospective cohort,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-09-03,2021-12-09,Household and community samples,All,Children and Youth (0-17 years),0.0,4.0,Age,0-4,192,0.397,0.288,0.518,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-27,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_4thRound_UnAdj_TotalAb-NAbs_Age40-49,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_4thRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Prospective cohort,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-09-03,2021-12-09,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,590,0.93,0.888,0.957,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-27,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_4thRound_UnAdj_TotalAb-NAbs_Age60-69,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_4thRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Prospective cohort,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-09-03,2021-12-09,Household and community samples,All,Multiple groups,60.0,69.0,Age,60-69,231,0.893,0.794,0.947,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-27,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_4thRound_UnAdj_TotalAb-NAbs_Age30-39,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_4thRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Prospective cohort,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-09-03,2021-12-09,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,740,0.942,0.91,0.963,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-27,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_4thRound_UnAdj_TotalAb-NAbs_Age10-14,230410_Mongolia_MongolianNationalUniversityOfMedicalSciences_4thRound,"SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study",2023-04-10,Journal Article (Peer-Reviewed),National,Prospective cohort,Mongolia,"Dornod, Khentii, Selenge, Umnugobi, Dornogobi, Bayankhongor, Bayan-Ulgii, Zavkhan
","Ulaanbaatar, Erdenet","We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling.

We used serology (infection or vaccination non-differentiating) in a large prospective population representative cohort.

Supplementary materials:
All individuals identified for recruitment into the investigation, irrespective of age, irrespective of acute or prior COVID-19 infection.","Supplementary materials:
Refusal to give informed consent, or contraindication to venipuncture. The confirmed cases only imported by international charter flight.

From reference 4 (https://doi.org/10.1016/j.lanwpc.2021.100317):
Participants in the following groups were considered ineligible
for enrolment: those who expressed voluntary refusal;
those contraindicated for venepuncture; and returnees
from international travel or known imported cases of
SARS-CoV-2. ",2021-09-03,2021-12-09,Household and community samples,All,Children and Youth (0-17 years),10.0,14.0,Age,10-14,398,0.626,0.561,0.688,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.99,0.99,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Battogtokh Chimeddorj,Mongolian National University of Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2023.100760,2024-04-27,2024-04-27,Verified,chimeddorj_sars-cov-2_2023,MNG
200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_CommercialEstablishments,200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_CommercialEstablishments3,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Nampula,2020-07-07,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Nampula,Nampula,,,2020-06-17,2020-06-30,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,Workers of commercial establishments,250,0.05,0.02,0.07,True,,,,True,Convenience,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Eduardo Samo Gudo,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-SARS-CoV-2-NAMPULA_vfinal.pdf,2021-07-12,2024-03-01,Verified,eduardo_samo_gudo_inquerito_2020,MOZ
200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Primary,200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Nampula,2020-07-07,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Nampula,Nampula,,,2020-06-17,2020-06-30,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,1769,0.05,0.04,0.06,True,,,,True,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,No,Yes,No,Unclear,Eduardo Samo Gudo,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-SARS-CoV-2-NAMPULA_vfinal.pdf,2021-05-21,2024-03-01,Verified,eduardo_samo_gudo_inquerito_2020,MOZ
200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Age35-59,200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Nampula,2020-07-07,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Nampula,Nampula,,,2020-06-17,2020-06-30,Household and community samples,All,Adults (18-64 years),35.0,59.0,Age,,385,0.05,,,,,,,,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,No,Yes,No,Unclear,Eduardo Samo Gudo,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-SARS-CoV-2-NAMPULA_vfinal.pdf,2021-07-12,2024-03-01,Verified,eduardo_samo_gudo_inquerito_2020,MOZ
200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Bairro_Muatala,200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Nampula,2020-07-07,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Nampula,Nampula,,,2020-06-17,2020-06-30,Household and community samples,All,Multiple groups,,,Geographical area,Muatala,174,0.05,,,,,,,,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,No,Yes,No,Unclear,Eduardo Samo Gudo,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-SARS-CoV-2-NAMPULA_vfinal.pdf,2021-07-12,2024-03-01,Verified,eduardo_samo_gudo_inquerito_2020,MOZ
200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Bairro_Namicopo,200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Nampula,2020-07-07,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Nampula,Nampula,,,2020-06-17,2020-06-30,Household and community samples,All,Multiple groups,,,Geographical area,Namicopo,90,0.03,,,,,,,,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,No,Yes,No,Unclear,Eduardo Samo Gudo,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-SARS-CoV-2-NAMPULA_vfinal.pdf,2021-07-12,2024-03-01,Verified,eduardo_samo_gudo_inquerito_2020,MOZ
200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Bairro_MutavaRex,200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Nampula,2020-07-07,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Nampula,Nampula,,,2020-06-17,2020-06-30,Household and community samples,All,Multiple groups,,,Geographical area,Mutava Rex,86,0.03,,,,,,,,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,No,Yes,No,Unclear,Eduardo Samo Gudo,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-SARS-CoV-2-NAMPULA_vfinal.pdf,2021-07-12,2024-03-01,Verified,eduardo_samo_gudo_inquerito_2020,MOZ
200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Age>60,200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Nampula,2020-07-07,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Nampula,Nampula,,,2020-06-17,2020-06-30,Household and community samples,All,Seniors (65+ years),60.0,,Age,,95,0.03,,,,,,,,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,No,Yes,No,Unclear,Eduardo Samo Gudo,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-SARS-CoV-2-NAMPULA_vfinal.pdf,2021-07-12,2024-03-01,Verified,eduardo_samo_gudo_inquerito_2020,MOZ
200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Age15-34,200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Nampula,2020-07-07,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Nampula,Nampula,,,2020-06-17,2020-06-30,Household and community samples,All,Adults (18-64 years),15.0,34.0,Age,,719,0.06,,,,,,,,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,No,Yes,No,Unclear,Eduardo Samo Gudo,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-SARS-CoV-2-NAMPULA_vfinal.pdf,2021-07-12,2024-03-01,Verified,eduardo_samo_gudo_inquerito_2020,MOZ
200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Bairro_Mutauanha,200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Nampula,2020-07-07,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Nampula,Nampula,,,2020-06-17,2020-06-30,Household and community samples,All,Multiple groups,,,Geographical area,Mutauanha,80,0.04,,,,,,,,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,No,Yes,No,Unclear,Eduardo Samo Gudo,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-SARS-CoV-2-NAMPULA_vfinal.pdf,2021-07-12,2024-03-01,Verified,eduardo_samo_gudo_inquerito_2020,MOZ
200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Age0-14,200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Nampula,2020-07-07,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Nampula,Nampula,,,2020-06-17,2020-06-30,Household and community samples,All,Children and Youth (0-17 years),0.0,14.0,Age,,461,0.03,,,,,,,,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,No,Yes,No,Unclear,Eduardo Samo Gudo,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-SARS-CoV-2-NAMPULA_vfinal.pdf,2021-07-12,2024-03-01,Verified,eduardo_samo_gudo_inquerito_2020,MOZ
200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Bairro_Marere,200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Nampula,2020-07-07,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Nampula,Nampula,,,2020-06-17,2020-06-30,Household and community samples,All,Multiple groups,,,Geographical area,Marere,72,0.03,,,,,,,,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,No,Yes,No,Unclear,Eduardo Samo Gudo,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-SARS-CoV-2-NAMPULA_vfinal.pdf,2021-07-12,2024-03-01,Verified,eduardo_samo_gudo_inquerito_2020,MOZ
200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Bairro_Carrupeia,200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Nampula,2020-07-07,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Nampula,Nampula,,,2020-06-17,2020-06-30,Household and community samples,All,Multiple groups,,,Geographical area,Carrupeia,83,0.04,,,,,,,,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,No,Yes,No,Unclear,Eduardo Samo Gudo,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-SARS-CoV-2-NAMPULA_vfinal.pdf,2021-07-12,2024-03-01,Verified,eduardo_samo_gudo_inquerito_2020,MOZ
200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Bairro_Napipine,200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Nampula,2020-07-07,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Nampula,Nampula,,,2020-06-17,2020-06-30,Household and community samples,All,Multiple groups,,,Geographical area,Napipine,95,0.03,,,,,,,,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,No,Yes,No,Unclear,Eduardo Samo Gudo,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-SARS-CoV-2-NAMPULA_vfinal.pdf,2021-07-12,2024-03-01,Verified,eduardo_samo_gudo_inquerito_2020,MOZ
200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Bairro_Muhala-Sede,200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Nampula,2020-07-07,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Nampula,Nampula,,,2020-06-17,2020-06-30,Household and community samples,All,Multiple groups,,,Geographical area,Muhala-Sede,125,0.06,,,,,,,,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,No,Yes,No,Unclear,Eduardo Samo Gudo,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-SARS-CoV-2-NAMPULA_vfinal.pdf,2021-07-12,2024-03-01,Verified,eduardo_samo_gudo_inquerito_2020,MOZ
200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Bairro_Murrapaniua,200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Nampula,2020-07-07,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Nampula,Nampula,,,2020-06-17,2020-06-30,Household and community samples,All,Multiple groups,,,Geographical area,Murrapaniua,91,0.05,,,,,,,,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,No,Yes,No,Unclear,Eduardo Samo Gudo,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-SARS-CoV-2-NAMPULA_vfinal.pdf,2021-07-12,2024-03-01,Verified,eduardo_samo_gudo_inquerito_2020,MOZ
200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Bairro_Muahivire,200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Nampula,2020-07-07,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Nampula,Nampula,,,2020-06-17,2020-06-30,Household and community samples,All,Multiple groups,,,Geographical area,Muahivire,144,0.01,,,,,,,,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,No,Yes,No,Unclear,Eduardo Samo Gudo,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-SARS-CoV-2-NAMPULA_vfinal.pdf,2021-07-12,2024-03-01,Verified,eduardo_samo_gudo_inquerito_2020,MOZ
200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Bairro_Central,200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Nampula,2020-07-07,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Nampula,Nampula,,,2020-06-17,2020-06-30,Household and community samples,All,Multiple groups,,,Geographical area,Central ,476,0.03,,,,,,,,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,No,Yes,No,Unclear,Eduardo Samo Gudo,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-SARS-CoV-2-NAMPULA_vfinal.pdf,2021-07-12,2024-03-01,Verified,eduardo_samo_gudo_inquerito_2020,MOZ
200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Bairro_Natikire,200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Nampula,2020-07-07,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Nampula,Nampula,,,2020-06-17,2020-06-30,Household and community samples,All,Multiple groups,,,Geographical area,Natikire,128,0.12,,,,,,,,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,No,Yes,No,Unclear,Eduardo Samo Gudo,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-SARS-CoV-2-NAMPULA_vfinal.pdf,2021-07-12,2024-03-01,Verified,eduardo_samo_gudo_inquerito_2020,MOZ
200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Bairro_Namutequeliua,200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Nampula,2020-07-07,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Nampula,Nampula,,,2020-06-17,2020-06-30,Household and community samples,All,Multiple groups,,,Geographical area,Namutequeliua,103,0.11,,,,,,,,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,No,Yes,No,Unclear,Eduardo Samo Gudo,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-SARS-CoV-2-NAMPULA_vfinal.pdf,2021-07-12,2024-03-01,Verified,eduardo_samo_gudo_inquerito_2020,MOZ
200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_HCW,200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_HCW5,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Nampula,2020-07-07,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Nampula,Nampula,,,2020-06-17,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,HCWs,1427,0.07,0.06,0.09,True,,,,True,Convenience,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,Yes,No,Unclear,No,Yes,No,Unclear,Eduardo Samo Gudo,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-SARS-CoV-2-NAMPULA_vfinal.pdf,2021-07-12,2024-03-01,Verified,eduardo_samo_gudo_inquerito_2020,MOZ
200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_MerchantsVendors,200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_MerchantsVendors7,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Nampula,2020-07-07,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Nampula,Nampula,,,2020-06-17,2020-06-30,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,Merchants and Vendors,1493,0.1,0.08,0.11,True,,,,True,Convenience,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,Yes,No,Unclear,No,Yes,No,Unclear,Eduardo Samo Gudo,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-SARS-CoV-2-NAMPULA_vfinal.pdf,2021-07-12,2024-03-01,Verified,eduardo_samo_gudo_inquerito_2020,MOZ
200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Police,200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Police4,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Nampula,2020-07-07,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Nampula,Nampula,,,2020-06-17,2020-06-30,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,Police forces,564,0.06,0.04,0.08,True,,,,True,Convenience,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Eduardo Samo Gudo,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-SARS-CoV-2-NAMPULA_vfinal.pdf,2021-07-12,2024-03-01,Verified,eduardo_samo_gudo_inquerito_2020,MOZ
200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Refugees,200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Refugees2,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Nampula,2020-07-07,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Nampula,Nampula,,,2020-06-17,2020-06-30,Persons experiencing homelessness,All,Multiple groups,,,Primary Estimate,Residents of a refugee center,221,0.06,0.02,0.08,True,,,,True,Convenience,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Eduardo Samo Gudo,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-SARS-CoV-2-NAMPULA_vfinal.pdf,2021-07-12,2024-03-01,Verified,eduardo_samo_gudo_inquerito_2020,MOZ
200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_TransportationWorkers,200701_NampulaCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_TransportationWorkers6,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Nampula,2020-07-07,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Nampula,Nampula,,,2020-06-17,2020-06-30,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,Workers in the transporation industry,554,0.03,0.01,0.04,True,,,,True,Convenience,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Eduardo Samo Gudo,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-SARS-CoV-2-NAMPULA_vfinal.pdf,2021-07-12,2024-03-01,Verified,eduardo_samo_gudo_inquerito_2020,MOZ
201727_Pemba_RepúblicaDeMoçambiqueMinistérioDaSaúde_CommercialEstablishments,201727_Pemba_RepúblicaDeMoçambiqueMinistérioDaSaúde_CommercialEstablishments6,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Pemba (InCOVID 2020),2020-07-27,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Cabo Delgado,Pemba,,,2020-07-06,2020-07-13,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,369,0.054000000000000006,,,True,,,,True,Convenience,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Paulo Arnaldo,República de Moçambique Ministério da Saúde,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/09/Inquerito-SARS-CoV-2-PEMBA_-RESULTADOS-PRELIMINARES_FINAL_3_27.07.2020.pdf,2021-06-25,2024-03-01,Verified,paulo_arnaldo_inquerito_2020,MOZ
201727_Pemba_RepúblicaDeMoçambiqueMinistérioDaSaúde_DefenseForces,201727_Pemba_RepúblicaDeMoçambiqueMinistérioDaSaúde_DefenseForces5,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Pemba (InCOVID 2020),2020-07-27,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Cabo Delgado,Pemba,,,2020-07-06,2020-07-13,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,513,0.037000000000000005,,,True,,,,True,Convenience,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Paulo Arnaldo,República de Moçambique Ministério da Saúde,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/09/Inquerito-SARS-CoV-2-PEMBA_-RESULTADOS-PRELIMINARES_FINAL_3_27.07.2020.pdf,2021-06-25,2024-03-01,Verified,paulo_arnaldo_inquerito_2020,MOZ
201727_Pemba_RepúblicaDeMoçambiqueMinistérioDaSaúde_DisplacedPeople,201727_Pemba_RepúblicaDeMoçambiqueMinistérioDaSaúde_DisplacedPeople8,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Pemba (InCOVID 2020),2020-07-27,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Cabo Delgado,Pemba,,,2020-07-06,2020-07-13,Persons experiencing homelessness,All,Multiple groups,,,Primary Estimate,,66,0.061,,,True,,,,True,Convenience,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Paulo Arnaldo,República de Moçambique Ministério da Saúde,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/09/Inquerito-SARS-CoV-2-PEMBA_-RESULTADOS-PRELIMINARES_FINAL_3_27.07.2020.pdf,2021-06-25,2024-03-01,Verified,paulo_arnaldo_inquerito_2020,MOZ
201727_Pemba_RepúblicaDeMoçambiqueMinistérioDaSaúde_Fishermen,201727_Pemba_RepúblicaDeMoçambiqueMinistérioDaSaúde_Fishermen7,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Pemba (InCOVID 2020),2020-07-27,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Cabo Delgado,Pemba,,,2020-07-06,2020-07-13,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,80,0.05,,,True,,,,True,Convenience,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Paulo Arnaldo,República de Moçambique Ministério da Saúde,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/09/Inquerito-SARS-CoV-2-PEMBA_-RESULTADOS-PRELIMINARES_FINAL_3_27.07.2020.pdf,2021-06-25,2024-03-01,Verified,paulo_arnaldo_inquerito_2020,MOZ
201727_Pemba_RepúblicaDeMoçambiqueMinistérioDaSaúde_Overall,201727_Pemba_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Pemba (InCOVID 2020),2020-07-27,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Cabo Delgado,Pemba,,,2020-07-06,2020-07-13,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,1360,0.025,,,True,,,,True,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Paulo Arnaldo,República de Moçambique Ministério da Saúde,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/09/Inquerito-SARS-CoV-2-PEMBA_-RESULTADOS-PRELIMINARES_FINAL_3_27.07.2020.pdf,2021-05-20,2024-03-01,Verified,paulo_arnaldo_inquerito_2020,MOZ
201727_Pemba_RepúblicaDeMoçambiqueMinistérioDaSaúde_Age35-59,201727_Pemba_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Pemba (InCOVID 2020),2020-07-27,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Cabo Delgado,Pemba,,,2020-07-06,2020-07-13,Household and community samples,All,Adults (18-64 years),35.0,59.0,Age,,232,0.03,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Paulo Arnaldo,República de Moçambique Ministério da Saúde,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/09/Inquerito-SARS-CoV-2-PEMBA_-RESULTADOS-PRELIMINARES_FINAL_3_27.07.2020.pdf,2021-06-25,2024-03-01,Verified,paulo_arnaldo_inquerito_2020,MOZ
201727_Pemba_RepúblicaDeMoçambiqueMinistérioDaSaúde_Age0-14,201727_Pemba_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Pemba (InCOVID 2020),2020-07-27,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Cabo Delgado,Pemba,,,2020-07-06,2020-07-13,Household and community samples,All,Children and Youth (0-17 years),0.0,14.0,Age,,404,0.017,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Paulo Arnaldo,República de Moçambique Ministério da Saúde,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/09/Inquerito-SARS-CoV-2-PEMBA_-RESULTADOS-PRELIMINARES_FINAL_3_27.07.2020.pdf,2021-06-25,2024-03-01,Verified,paulo_arnaldo_inquerito_2020,MOZ
201727_Pemba_RepúblicaDeMoçambiqueMinistérioDaSaúde_Age15-34,201727_Pemba_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Pemba (InCOVID 2020),2020-07-27,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Cabo Delgado,Pemba,,,2020-07-06,2020-07-13,Household and community samples,All,Adults (18-64 years),15.0,34.0,Age,,455,0.033,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Paulo Arnaldo,República de Moçambique Ministério da Saúde,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/09/Inquerito-SARS-CoV-2-PEMBA_-RESULTADOS-PRELIMINARES_FINAL_3_27.07.2020.pdf,2021-06-25,2024-03-01,Verified,paulo_arnaldo_inquerito_2020,MOZ
201727_Pemba_RepúblicaDeMoçambiqueMinistérioDaSaúde_Age60+,201727_Pemba_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Pemba (InCOVID 2020),2020-07-27,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Cabo Delgado,Pemba,,,2020-07-06,2020-07-13,Household and community samples,All,Seniors (65+ years),60.0,,Age,,62,0.032,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Paulo Arnaldo,República de Moçambique Ministério da Saúde,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/09/Inquerito-SARS-CoV-2-PEMBA_-RESULTADOS-PRELIMINARES_FINAL_3_27.07.2020.pdf,2021-06-25,2024-03-01,Verified,paulo_arnaldo_inquerito_2020,MOZ
201727_Pemba_RepúblicaDeMoçambiqueMinistérioDaSaúde_HealthProfessionals,201727_Pemba_RepúblicaDeMoçambiqueMinistérioDaSaúde_HealthProfessionals2,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Pemba (InCOVID 2020),2020-07-27,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Cabo Delgado,Pemba,,,2020-07-06,2020-07-13,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,506,0.055,,,True,,,,True,Convenience,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Paulo Arnaldo,República de Moçambique Ministério da Saúde,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/09/Inquerito-SARS-CoV-2-PEMBA_-RESULTADOS-PRELIMINARES_FINAL_3_27.07.2020.pdf,2021-06-25,2024-03-01,Verified,paulo_arnaldo_inquerito_2020,MOZ
201727_Pemba_RepúblicaDeMoçambiqueMinistérioDaSaúde_TransportationWorkers,201727_Pemba_RepúblicaDeMoçambiqueMinistérioDaSaúde_TransportationWorkers4,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Pemba (InCOVID 2020),2020-07-27,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Cabo Delgado,Pemba,,,2020-07-06,2020-07-13,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,248,0.048,,,True,,,,True,Convenience,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Paulo Arnaldo,República de Moçambique Ministério da Saúde,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/09/Inquerito-SARS-CoV-2-PEMBA_-RESULTADOS-PRELIMINARES_FINAL_3_27.07.2020.pdf,2021-06-25,2024-03-01,Verified,paulo_arnaldo_inquerito_2020,MOZ
201727_Pemba_RepúblicaDeMoçambiqueMinistérioDaSaúde_Vendors/Merchants,201727_Pemba_RepúblicaDeMoçambiqueMinistérioDaSaúde_Vendors/Merchants3,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Pemba (InCOVID 2020),2020-07-27,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Cabo Delgado,Pemba,,,2020-07-06,2020-07-13,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,928,0.065,,,True,,,,True,Convenience,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,Yes,No,Unclear,No,Yes,No,Unclear,Paulo Arnaldo,República de Moçambique Ministério da Saúde,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/09/Inquerito-SARS-CoV-2-PEMBA_-RESULTADOS-PRELIMINARES_FINAL_3_27.07.2020.pdf,2021-06-25,2024-03-01,Verified,paulo_arnaldo_inquerito_2020,MOZ
200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Airport&PortWorkers,200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Airport&PortWorkers5,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maputo (InCOVID 2020),2020-08-31,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,,Maputo,,,2020-08-03,2020-08-21,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,362,0.033100000000000004,,,True,,,,True,Convenience,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Edna Viegas,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/08/Inqu%C3%A9rito-SE-SARS-CoV-2_Cidade-de-Maputo_resultados_31Ago2020.pdf,2021-07-18,2024-03-01,Verified,edna_viegas_inquerito_2020,MOZ
200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_CommercialEstablishments,200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_CommercialEstablishments3,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maputo (InCOVID 2020),2020-08-31,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,,Maputo,,,2020-08-03,2020-08-21,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,595,0.0454,,,True,,,,True,Convenience,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Edna Viegas,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/08/Inqu%C3%A9rito-SE-SARS-CoV-2_Cidade-de-Maputo_resultados_31Ago2020.pdf,2021-07-18,2024-03-01,Verified,edna_viegas_inquerito_2020,MOZ
200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop,200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maputo (InCOVID 2020),2020-08-31,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,,Maputo,,,2020-08-03,2020-08-21,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,4717,0.0379,,,True,,,,True,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Edna Viegas,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/08/Inqu%C3%A9rito-SE-SARS-CoV-2_Cidade-de-Maputo_resultados_31Ago2020.pdf,2021-05-21,2024-03-01,Verified,edna_viegas_inquerito_2020,MOZ
200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Bairro_Nlhamankulu,200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maputo (InCOVID 2020),2020-08-31,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,,Maputo,,,2020-08-03,2020-08-21,Household and community samples,All,Multiple groups,0.0,,Geographical area,Bairro Nlhamankulu,784,0.0472,,,,,,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Edna Viegas,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/08/Inqu%C3%A9rito-SE-SARS-CoV-2_Cidade-de-Maputo_resultados_31Ago2020.pdf,2021-07-18,2024-03-01,Verified,edna_viegas_inquerito_2020,MOZ
200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Bairro_KaTembe,200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maputo (InCOVID 2020),2020-08-31,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,,Maputo,,,2020-08-03,2020-08-21,Household and community samples,All,Multiple groups,0.0,,Geographical area,Bairro KaTembe,402,0.044800000000000006,,,,,,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Edna Viegas,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/08/Inqu%C3%A9rito-SE-SARS-CoV-2_Cidade-de-Maputo_resultados_31Ago2020.pdf,2021-07-18,2024-03-01,Verified,edna_viegas_inquerito_2020,MOZ
200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Age60+,200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maputo (InCOVID 2020),2020-08-31,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,,Maputo,,,2020-08-03,2020-08-21,Household and community samples,All,Seniors (65+ years),60.0,,Age,,714,0.044800000000000006,,,,,,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Edna Viegas,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/08/Inqu%C3%A9rito-SE-SARS-CoV-2_Cidade-de-Maputo_resultados_31Ago2020.pdf,2021-07-18,2024-03-01,Verified,edna_viegas_inquerito_2020,MOZ
200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Age0-14,200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maputo (InCOVID 2020),2020-08-31,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,,Maputo,,,2020-08-03,2020-08-21,Household and community samples,All,Children and Youth (0-17 years),0.0,14.0,Age,,1168,0.0325,,,,,,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Edna Viegas,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/08/Inqu%C3%A9rito-SE-SARS-CoV-2_Cidade-de-Maputo_resultados_31Ago2020.pdf,2021-07-18,2024-03-01,Verified,edna_viegas_inquerito_2020,MOZ
200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Bairro_Kamaxakeni,200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maputo (InCOVID 2020),2020-08-31,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,,Maputo,,,2020-08-03,2020-08-21,Household and community samples,All,Multiple groups,0.0,,Geographical area,Bairro Kamaxakeni,865,0.0393,,,,,,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Edna Viegas,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/08/Inqu%C3%A9rito-SE-SARS-CoV-2_Cidade-de-Maputo_resultados_31Ago2020.pdf,2021-07-18,2024-03-01,Verified,edna_viegas_inquerito_2020,MOZ
200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Bairro_Kampfumo,200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maputo (InCOVID 2020),2020-08-31,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,,Maputo,,,2020-08-03,2020-08-21,Household and community samples,All,Multiple groups,0.0,,Geographical area,Bairro Kampfumo,653,0.030600000000000002,,,,,,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Edna Viegas,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/08/Inqu%C3%A9rito-SE-SARS-CoV-2_Cidade-de-Maputo_resultados_31Ago2020.pdf,2021-07-18,2024-03-01,Verified,edna_viegas_inquerito_2020,MOZ
200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Age35-59,200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maputo (InCOVID 2020),2020-08-31,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,,Maputo,,,2020-08-03,2020-08-21,Household and community samples,All,Adults (18-64 years),35.0,59.0,Age,,1253,0.030299999999999997,,,,,,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Edna Viegas,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/08/Inqu%C3%A9rito-SE-SARS-CoV-2_Cidade-de-Maputo_resultados_31Ago2020.pdf,2021-07-18,2024-03-01,Verified,edna_viegas_inquerito_2020,MOZ
200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Bairro_KaNyaka,200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maputo (InCOVID 2020),2020-08-31,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,,Maputo,,,2020-08-03,2020-08-21,Household and community samples,All,Multiple groups,0.0,,Geographical area,Bairro KaNyaka,237,0.0042,,,,,,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Edna Viegas,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/08/Inqu%C3%A9rito-SE-SARS-CoV-2_Cidade-de-Maputo_resultados_31Ago2020.pdf,2021-07-18,2024-03-01,Verified,edna_viegas_inquerito_2020,MOZ
200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Bairro_KaMavota,200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maputo (InCOVID 2020),2020-08-31,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,,Maputo,,,2020-08-03,2020-08-21,Household and community samples,All,Multiple groups,0.0,,Geographical area,Bairro KaMavota,916,0.032799999999999996,,,,,,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Edna Viegas,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/08/Inqu%C3%A9rito-SE-SARS-CoV-2_Cidade-de-Maputo_resultados_31Ago2020.pdf,2021-07-18,2024-03-01,Verified,edna_viegas_inquerito_2020,MOZ
200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Age15-34,200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maputo (InCOVID 2020),2020-08-31,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,,Maputo,,,2020-08-03,2020-08-21,Household and community samples,All,Adults (18-64 years),15.0,34.0,Age,,1537,0.0442,,,,,,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Edna Viegas,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/08/Inqu%C3%A9rito-SE-SARS-CoV-2_Cidade-de-Maputo_resultados_31Ago2020.pdf,2021-07-18,2024-03-01,Verified,edna_viegas_inquerito_2020,MOZ
200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Bairro_KaMubukwana,200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maputo (InCOVID 2020),2020-08-31,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,,Maputo,,,2020-08-03,2020-08-21,Household and community samples,All,Multiple groups,0.0,,Geographical area,Bairro KaMubukwana,860,0.0453,,,,,,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Edna Viegas,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/08/Inqu%C3%A9rito-SE-SARS-CoV-2_Cidade-de-Maputo_resultados_31Ago2020.pdf,2021-07-18,2024-03-01,Verified,edna_viegas_inquerito_2020,MOZ
200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_HCW,200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_HCW6,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maputo (InCOVID 2020),2020-08-31,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,,Maputo,,,2020-08-03,2020-08-21,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1443,0.0263,,,True,,,,True,Convenience,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,Yes,No,Unclear,No,Yes,No,Unclear,Edna Viegas,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/08/Inqu%C3%A9rito-SE-SARS-CoV-2_Cidade-de-Maputo_resultados_31Ago2020.pdf,2021-07-18,2024-03-01,Verified,edna_viegas_inquerito_2020,MOZ
200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_NursingHomeWorkers,200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_NursingHomeWorkers8,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maputo (InCOVID 2020),2020-08-31,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,,Maputo,,,2020-08-03,2020-08-21,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,85,0.0118,,,True,,,,True,Convenience,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Edna Viegas,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/08/Inqu%C3%A9rito-SE-SARS-CoV-2_Cidade-de-Maputo_resultados_31Ago2020.pdf,2021-07-18,2024-03-01,Verified,edna_viegas_inquerito_2020,MOZ
200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Police,200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Police4,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maputo (InCOVID 2020),2020-08-31,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,,Maputo,,,2020-08-03,2020-08-21,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,559,0.0394,,,True,,,,True,Convenience,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Edna Viegas,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/08/Inqu%C3%A9rito-SE-SARS-CoV-2_Cidade-de-Maputo_resultados_31Ago2020.pdf,2021-07-18,2024-03-01,Verified,edna_viegas_inquerito_2020,MOZ
200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_TransportationWorkers,200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_TransportationWorkers7,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maputo (InCOVID 2020),2020-08-31,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,,Maputo,,,2020-08-03,2020-08-21,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,623,0.0225,,,True,,,,True,Convenience,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,Yes,No,Unclear,No,Yes,No,Unclear,Edna Viegas,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/08/Inqu%C3%A9rito-SE-SARS-CoV-2_Cidade-de-Maputo_resultados_31Ago2020.pdf,2021-07-18,2024-03-01,Verified,edna_viegas_inquerito_2020,MOZ
200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_VendorsMerchants,200831_MaputoCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_VendorsMerchants2,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maputo (InCOVID 2020),2020-08-31,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,,Maputo,,,2020-08-03,2020-08-21,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,1246,0.052199999999999996,,,True,,,,True,Convenience,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,Yes,No,Unclear,No,Yes,No,Unclear,Edna Viegas,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/08/Inqu%C3%A9rito-SE-SARS-CoV-2_Cidade-de-Maputo_resultados_31Ago2020.pdf,2021-07-18,2024-03-01,Verified,edna_viegas_inquerito_2020,MOZ
200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_CommercialEstablishments,200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_CommercialEstablishment6,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Tete (InCOVID 2020),2020-09-24,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Tete,Tete,,,2020-08-31,2020-10-12,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,404,0.005,,,True,,,,True,Convenience,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/09/Inque%CC%81rito-SE-SARS-CoV-2_Cidade-de-Tete_resultados.pdf,2021-07-17,2024-03-01,Verified,mussagy_mahomed_inquerito_2020-1,MOZ
200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop,200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Tete (InCOVID 2020),2020-09-24,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Tete,Tete,,,2020-08-31,2020-10-12,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,1946,0.006999999999999999,,,True,,,,True,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/09/Inque%CC%81rito-SE-SARS-CoV-2_Cidade-de-Tete_resultados.pdf,2021-05-21,2024-03-01,Verified,mussagy_mahomed_inquerito_2020-1,MOZ
200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Bairro_Matundo,200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Tete (InCOVID 2020),2020-09-24,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Tete,Tete,,,2020-08-31,2020-10-12,Household and community samples,All,Multiple groups,0.0,,Geographical area,Matundo ,234,0.017,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/09/Inque%CC%81rito-SE-SARS-CoV-2_Cidade-de-Tete_resultados.pdf,2021-07-17,2024-03-01,Verified,mussagy_mahomed_inquerito_2020-1,MOZ
200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Age60+,200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Tete (InCOVID 2020),2020-09-24,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Tete,Tete,,,2020-08-31,2020-10-12,Household and community samples,All,Seniors (65+ years),60.0,,Age,,1946,0.006999999999999999,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/09/Inque%CC%81rito-SE-SARS-CoV-2_Cidade-de-Tete_resultados.pdf,2021-07-17,2024-03-01,Verified,mussagy_mahomed_inquerito_2020-1,MOZ
200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Bairro_SamoraMachel,200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Tete (InCOVID 2020),2020-09-24,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Tete,Tete,,,2020-08-31,2020-10-12,Household and community samples,All,Multiple groups,0.0,,Geographical area,Samora Machel,183,0.011000000000000001,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/09/Inque%CC%81rito-SE-SARS-CoV-2_Cidade-de-Tete_resultados.pdf,2021-07-17,2024-03-01,Verified,mussagy_mahomed_inquerito_2020-1,MOZ
200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Bairro_Chingodzi,200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Tete (InCOVID 2020),2020-09-24,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Tete,Tete,,,2020-08-31,2020-10-12,Household and community samples,All,Multiple groups,0.0,,Geographical area,Chingodzi,235,0.004,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/09/Inque%CC%81rito-SE-SARS-CoV-2_Cidade-de-Tete_resultados.pdf,2021-07-17,2024-03-01,Verified,mussagy_mahomed_inquerito_2020-1,MOZ
200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Age0-14,200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Tete (InCOVID 2020),2020-09-24,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Tete,Tete,,,2020-08-31,2020-10-12,Household and community samples,All,Children and Youth (0-17 years),0.0,14.0,Age,,1946,0.003,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/09/Inque%CC%81rito-SE-SARS-CoV-2_Cidade-de-Tete_resultados.pdf,2021-07-17,2024-03-01,Verified,mussagy_mahomed_inquerito_2020-1,MOZ
200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Bairro_FilipeSamuelMagaia,200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Tete (InCOVID 2020),2020-09-24,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Tete,Tete,,,2020-08-31,2020-10-12,Household and community samples,All,Multiple groups,0.0,,Geographical area,Filipe Samuel Magaia,193,0.0,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/09/Inque%CC%81rito-SE-SARS-CoV-2_Cidade-de-Tete_resultados.pdf,2021-07-17,2024-03-01,Verified,mussagy_mahomed_inquerito_2020-1,MOZ
200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Bairro_Degue,200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Tete (InCOVID 2020),2020-09-24,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Tete,Tete,,,2020-08-31,2020-10-12,Household and community samples,All,Multiple groups,0.0,,Geographical area,Degue,252,0.0,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/09/Inque%CC%81rito-SE-SARS-CoV-2_Cidade-de-Tete_resultados.pdf,2021-07-17,2024-03-01,Verified,mussagy_mahomed_inquerito_2020-1,MOZ
200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Age35-59,200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Tete (InCOVID 2020),2020-09-24,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Tete,Tete,,,2020-08-31,2020-10-12,Household and community samples,All,Adults (18-64 years),35.0,59.0,Age,,1946,0.008,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/09/Inque%CC%81rito-SE-SARS-CoV-2_Cidade-de-Tete_resultados.pdf,2021-07-17,2024-03-01,Verified,mussagy_mahomed_inquerito_2020-1,MOZ
200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Age15-34,200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Tete (InCOVID 2020),2020-09-24,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Tete,Tete,,,2020-08-31,2020-10-12,Household and community samples,All,Adults (18-64 years),15.0,34.0,Age,,1946,0.013999999999999999,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/09/Inque%CC%81rito-SE-SARS-CoV-2_Cidade-de-Tete_resultados.pdf,2021-07-17,2024-03-01,Verified,mussagy_mahomed_inquerito_2020-1,MOZ
200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Bairro_JosinaMachel,200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Tete (InCOVID 2020),2020-09-24,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Tete,Tete,,,2020-08-31,2020-10-12,Household and community samples,All,Multiple groups,0.0,,Geographical area,Josina Machel,256,0.008,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/09/Inque%CC%81rito-SE-SARS-CoV-2_Cidade-de-Tete_resultados.pdf,2021-07-17,2024-03-01,Verified,mussagy_mahomed_inquerito_2020-1,MOZ
200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Bairro_FranciscoManyanga,200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Tete (InCOVID 2020),2020-09-24,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Tete,Tete,,,2020-08-31,2020-10-12,Household and community samples,All,Multiple groups,0.0,,Geographical area,Francisco Manyanga,216,0.009000000000000001,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/09/Inque%CC%81rito-SE-SARS-CoV-2_Cidade-de-Tete_resultados.pdf,2021-07-17,2024-03-01,Verified,mussagy_mahomed_inquerito_2020-1,MOZ
200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Bairro_Mpadue,200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Tete (InCOVID 2020),2020-09-24,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Tete,Tete,,,2020-08-31,2020-10-12,Household and community samples,All,Multiple groups,0.0,,Geographical area,Mpadue,176,0.011000000000000001,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/09/Inque%CC%81rito-SE-SARS-CoV-2_Cidade-de-Tete_resultados.pdf,2021-07-17,2024-03-01,Verified,mussagy_mahomed_inquerito_2020-1,MOZ
200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Bairro_MateusSansaoMutemba,200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Tete (InCOVID 2020),2020-09-24,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Tete,Tete,,,2020-08-31,2020-10-12,Household and community samples,All,Multiple groups,0.0,,Geographical area,Mateus Sansao Mutemba,197,0.0,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/09/Inque%CC%81rito-SE-SARS-CoV-2_Cidade-de-Tete_resultados.pdf,2021-07-17,2024-03-01,Verified,mussagy_mahomed_inquerito_2020-1,MOZ
200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_HCW,200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_HCW5,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Tete (InCOVID 2020),2020-09-24,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Tete,Tete,,,2020-08-31,2020-10-12,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,569,0.006999999999999999,,,True,,,,True,Convenience,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/09/Inque%CC%81rito-SE-SARS-CoV-2_Cidade-de-Tete_resultados.pdf,2021-07-17,2024-03-01,Verified,mussagy_mahomed_inquerito_2020-1,MOZ
200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Police,200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_Police2,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Tete (InCOVID 2020),2020-09-24,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Tete,Tete,,,2020-08-31,2020-10-12,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,554,0.028999999999999998,,,True,,,,True,Convenience,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/09/Inque%CC%81rito-SE-SARS-CoV-2_Cidade-de-Tete_resultados.pdf,2021-07-17,2024-03-01,Verified,mussagy_mahomed_inquerito_2020-1,MOZ
200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_TransporationWorkers,200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_TransporationWorkers3,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Tete (InCOVID 2020),2020-09-24,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Tete,Tete,,,2020-08-31,2020-10-12,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,334,0.015,,,True,,,,True,Convenience,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/09/Inque%CC%81rito-SE-SARS-CoV-2_Cidade-de-Tete_resultados.pdf,2021-07-17,2024-03-01,Verified,mussagy_mahomed_inquerito_2020-1,MOZ
200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_VendorsMerchants,200924_TeteCity_RepúblicaDeMoçambiqueMinistérioDaSaúde_VendorsMerchants4,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Tete (InCOVID 2020),2020-09-24,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Tete,Tete,,,2020-08-31,2020-10-12,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,1556,0.008,,,True,,,,True,Convenience,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,Yes,No,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/09/Inque%CC%81rito-SE-SARS-CoV-2_Cidade-de-Tete_resultados.pdf,2021-07-17,2024-03-01,Verified,mussagy_mahomed_inquerito_2020-1,MOZ
201015_Beira_RepúblicaDeMoçambiqueMinistérioDaSaúde_CommercialEstablishments,201015_Beira_RepúblicaDeMoçambiqueMinistérioDaSaúde_CommercialEstablishment2,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Beira (InCOVID 2020),2020-10-15,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Sofala,Beira,,,2020-09-21,2020-10-02,Non-essential workers and unemployed persons,All,Multiple groups,,,Primary Estimate,Workers in commercial establishments ,188,0.069,,,True,,,,True,Convenience,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Nedio Mabunda,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/10/InCOVID-2020_-BEIRA_-RESULTADOS-PRELIMINARES.pdf,2021-07-09,2024-03-01,Verified,nedio_mabunda_inquerito_2020,MOZ
201015_Beira_RepúblicaDeMoçambiqueMinistérioDaSaúde_DefenceForces,201015_Beira_RepúblicaDeMoçambiqueMinistérioDaSaúde_DefenceForces3,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Beira (InCOVID 2020),2020-10-15,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Sofala,Beira,,,2020-09-21,2020-10-02,Essential non-healthcare workers,All,Multiple groups,,,Primary Estimate,Workers in Defence Forces,324,0.027999999999999997,,,True,,,,True,Convenience,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Nedio Mabunda,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/10/InCOVID-2020_-BEIRA_-RESULTADOS-PRELIMINARES.pdf,2021-07-09,2024-03-01,Verified,nedio_mabunda_inquerito_2020,MOZ
201015_Beira_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop,201015_Beira_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Beira (InCOVID 2020),2020-10-15,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Sofala,Beira,,,2020-09-21,2020-10-02,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,Genpop,4940,0.052000000000000005,,,True,,,,True,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Nedio Mabunda,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/10/InCOVID-2020_-BEIRA_-RESULTADOS-PRELIMINARES.pdf,2021-05-21,2024-03-01,Verified,nedio_mabunda_inquerito_2020,MOZ
201015_Beira_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Age35-59,201015_Beira_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Beira (InCOVID 2020),2020-10-15,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Sofala,Beira,,,2020-09-21,2020-10-02,Household and community samples,All,Adults (18-64 years),35.0,59.0,Age,Genpop,793,0.064,,,,,,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Nedio Mabunda,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/10/InCOVID-2020_-BEIRA_-RESULTADOS-PRELIMINARES.pdf,2021-07-09,2024-03-01,Verified,nedio_mabunda_inquerito_2020,MOZ
201015_Beira_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Age60+,201015_Beira_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Beira (InCOVID 2020),2020-10-15,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Sofala,Beira,,,2020-09-21,2020-10-02,Household and community samples,All,Seniors (65+ years),60.0,,Age,Genpop,236,0.034,,,,,,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Nedio Mabunda,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/10/InCOVID-2020_-BEIRA_-RESULTADOS-PRELIMINARES.pdf,2021-07-09,2024-03-01,Verified,nedio_mabunda_inquerito_2020,MOZ
201015_Beira_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Age15-34,201015_Beira_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Beira (InCOVID 2020),2020-10-15,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Sofala,Beira,,,2020-09-21,2020-10-02,Household and community samples,All,Adults (18-64 years),15.0,34.0,Age,Genpop,1679,0.068,,,,,,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Nedio Mabunda,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/10/InCOVID-2020_-BEIRA_-RESULTADOS-PRELIMINARES.pdf,2021-07-09,2024-03-01,Verified,nedio_mabunda_inquerito_2020,MOZ
201015_Beira_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Age0-14,201015_Beira_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Beira (InCOVID 2020),2020-10-15,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Sofala,Beira,,,2020-09-21,2020-10-02,Household and community samples,All,Children and Youth (0-17 years),0.0,14.0,Age,Genpop,1404,0.033,,,,,,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Nedio Mabunda,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/10/InCOVID-2020_-BEIRA_-RESULTADOS-PRELIMINARES.pdf,2021-07-09,2024-03-01,Verified,nedio_mabunda_inquerito_2020,MOZ
201015_Beira_RepúblicaDeMoçambiqueMinistérioDaSaúde_HCW,201015_Beira_RepúblicaDeMoçambiqueMinistérioDaSaúde_HCW4,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Beira (InCOVID 2020),2020-10-15,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Sofala,Beira,,,2020-09-21,2020-10-02,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,HCW,787,0.039,,,True,,,,True,Convenience,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),,,,['High'],Yes,No,Yes,No,Unclear,No,Yes,No,Unclear,Nedio Mabunda,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/10/InCOVID-2020_-BEIRA_-RESULTADOS-PRELIMINARES.pdf,2021-07-09,2024-03-01,Verified,nedio_mabunda_inquerito_2020,MOZ
201015_Beira_RepúblicaDeMoçambiqueMinistérioDaSaúde_TransportationWorkers,201015_Beira_RepúblicaDeMoçambiqueMinistérioDaSaúde_TransportationWorkers5,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Beira (InCOVID 2020),2020-10-15,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Sofala,Beira,,,2020-09-21,2020-10-02,Essential non-healthcare workers,All,Multiple groups,,,Primary Estimate,Transportation workers,473,0.087,,,True,,,,True,Convenience,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Nedio Mabunda,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/10/InCOVID-2020_-BEIRA_-RESULTADOS-PRELIMINARES.pdf,2021-07-09,2024-03-01,Verified,nedio_mabunda_inquerito_2020,MOZ
201015_Beira_RepúblicaDeMoçambiqueMinistérioDaSaúde_VendorsMerchants,201015_Beira_RepúblicaDeMoçambiqueMinistérioDaSaúde_VendorsMerchants6,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Beira (InCOVID 2020),2020-10-15,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Sofala,Beira,,,2020-09-21,2020-10-02,Non-essential workers and unemployed persons,All,Multiple groups,,,Primary Estimate,Vendors and Merchants,1585,0.083,,,True,,,,True,Convenience,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),,,,['High'],Yes,No,Yes,No,Unclear,No,Yes,No,Unclear,Nedio Mabunda,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/10/InCOVID-2020_-BEIRA_-RESULTADOS-PRELIMINARES.pdf,2021-07-09,2024-03-01,Verified,nedio_mabunda_inquerito_2020,MOZ
201019_Lichinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_CommercialEstablishments,201019_Lichinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_CommercialEstablishments6,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Lichinga (InCOVID 2020),2020-10-19,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Niassa,Lichinga,,,2020-09-28,2020-10-09,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,122,0.0,,,True,,,,True,Convenience,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Jeronimo Langa,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/10/Inquerito-SE-SARS-CoV-2-Lichinga_19-10-020.pdf,2021-07-17,2024-03-01,Verified,jeronimo_langa_inquerito_2020,MOZ
201019_Lichinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop,201019_Lichinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Lichinga (InCOVID 2020),2020-10-19,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Niassa,Lichinga,,,2020-09-28,2020-10-09,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,1635,0.003,,,True,,,,True,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Jeronimo Langa,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/10/Inquerito-SE-SARS-CoV-2-Lichinga_19-10-020.pdf,2021-05-21,2024-03-01,Verified,jeronimo_langa_inquerito_2020,MOZ
201019_Lichinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Age35-59,201019_Lichinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Lichinga (InCOVID 2020),2020-10-19,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Niassa,Lichinga,,,2020-09-28,2020-10-09,Household and community samples,All,Adults (18-64 years),35.0,59.0,Age,,397,0.003,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Jeronimo Langa,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/10/Inquerito-SE-SARS-CoV-2-Lichinga_19-10-020.pdf,2021-07-17,2024-03-01,Verified,jeronimo_langa_inquerito_2020,MOZ
201019_Lichinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Age60+,201019_Lichinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Lichinga (InCOVID 2020),2020-10-19,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Niassa,Lichinga,,,2020-09-28,2020-10-09,Household and community samples,All,Seniors (65+ years),60.0,,Age,,92,0.0,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Jeronimo Langa,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/10/Inquerito-SE-SARS-CoV-2-Lichinga_19-10-020.pdf,2021-07-17,2024-03-01,Verified,jeronimo_langa_inquerito_2020,MOZ
201019_Lichinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Age15-34,201019_Lichinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Lichinga (InCOVID 2020),2020-10-19,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Niassa,Lichinga,,,2020-09-28,2020-10-09,Household and community samples,All,Adults (18-64 years),15.0,34.0,Age,,618,0.005,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Jeronimo Langa,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/10/Inquerito-SE-SARS-CoV-2-Lichinga_19-10-020.pdf,2021-07-17,2024-03-01,Verified,jeronimo_langa_inquerito_2020,MOZ
201019_Lichinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Age0-14,201019_Lichinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Lichinga (InCOVID 2020),2020-10-19,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Niassa,Lichinga,,,2020-09-28,2020-10-09,Household and community samples,All,Children and Youth (0-17 years),0.0,14.0,Age,,528,0.002,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Jeronimo Langa,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/10/Inquerito-SE-SARS-CoV-2-Lichinga_19-10-020.pdf,2021-07-17,2024-03-01,Verified,jeronimo_langa_inquerito_2020,MOZ
201019_Lichinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_HCWs,201019_Lichinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_HCWs4,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Lichinga (InCOVID 2020),2020-10-19,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Niassa,Lichinga,,,2020-09-28,2020-10-09,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,454,0.018000000000000002,,,True,,,,True,Convenience,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Jeronimo Langa,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/10/Inquerito-SE-SARS-CoV-2-Lichinga_19-10-020.pdf,2021-07-17,2024-03-01,Verified,jeronimo_langa_inquerito_2020,MOZ
201019_Lichinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_PoliceForces,201019_Lichinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_PoliceForces5,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Lichinga (InCOVID 2020),2020-10-19,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Niassa,Lichinga,,,2020-09-28,2020-10-09,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,471,0.015,,,True,,,,True,Convenience,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Jeronimo Langa,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/10/Inquerito-SE-SARS-CoV-2-Lichinga_19-10-020.pdf,2021-07-17,2024-03-01,Verified,jeronimo_langa_inquerito_2020,MOZ
201019_Lichinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_TransporationWorkers,201019_Lichinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_TransportationWorkers3,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Lichinga (InCOVID 2020),2020-10-19,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Niassa,Lichinga,,,2020-09-28,2020-10-09,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,230,0.004,,,True,,,,True,Convenience,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Jeronimo Langa,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/10/Inquerito-SE-SARS-CoV-2-Lichinga_19-10-020.pdf,2021-07-17,2024-03-01,Verified,jeronimo_langa_inquerito_2020,MOZ
201019_Lichinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_VendorsMerchants,201019_Lichinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_VendorsMerchants2,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Lichinga (InCOVID 2020),2020-10-19,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Niassa,Lichinga,,,2020-09-28,2020-10-09,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,871,0.002,,,True,,,,True,Convenience,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,Yes,No,Unclear,No,Yes,No,Unclear,Jeronimo Langa,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/10/Inquerito-SE-SARS-CoV-2-Lichinga_19-10-020.pdf,2021-07-17,2024-03-01,Verified,jeronimo_langa_inquerito_2020,MOZ
201021_Matola_RepúblicaDeMoçambiqueMinistérioDaSaúde_CommercialEstablishments,201021_Matola_RepúblicaDeMoçambiqueMinistérioDaSaúde_CommercialEstablishments2,Inquérito Sero-epidemiológico de SARS-CoV-2 na Província de Maputo (InCOVID 2020),2020-10-21,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Maputo,Matolo,,,2020-09-14,2020-09-30,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,323,0.0588,,,True,,,,True,Convenience,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Ivalda Macicame,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/10/Inque%CC%81rito-Provincia-de-Maputo_resultados-preliminares_21Out2020-versao-final.pdf,2021-07-18,2024-03-01,Verified,ivalda_macicame_inquerito_2020,MOZ
201021_Matola_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop,201021_Matola_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Província de Maputo (InCOVID 2020),2020-10-21,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Maputo,Matolo,,,2020-09-14,2020-09-30,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,5394,0.0356,,,True,,,,True,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Ivalda Macicame,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/10/Inque%CC%81rito-Provincia-de-Maputo_resultados-preliminares_21Out2020-versao-final.pdf,2021-05-21,2024-03-01,Verified,ivalda_macicame_inquerito_2020,MOZ
201021_Matola_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Female,201021_Matola_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Província de Maputo (InCOVID 2020),2020-10-21,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Maputo,Matolo,,,2020-09-14,2020-09-30,Household and community samples,Female,Multiple groups,0.0,,Sex/Gender,,3238,0.038,,,,,,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Ivalda Macicame,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/10/Inque%CC%81rito-Provincia-de-Maputo_resultados-preliminares_21Out2020-versao-final.pdf,2021-07-18,2024-03-01,Verified,ivalda_macicame_inquerito_2020,MOZ
201021_Matola_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Age60+,201021_Matola_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Província de Maputo (InCOVID 2020),2020-10-21,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Maputo,Matolo,,,2020-09-14,2020-09-30,Household and community samples,All,Seniors (65+ years),60.0,,Age,,519,0.0385,,,,,,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Ivalda Macicame,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/10/Inque%CC%81rito-Provincia-de-Maputo_resultados-preliminares_21Out2020-versao-final.pdf,2021-07-18,2024-03-01,Verified,ivalda_macicame_inquerito_2020,MOZ
201021_Matola_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Age15-34,201021_Matola_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Província de Maputo (InCOVID 2020),2020-10-21,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Maputo,Matolo,,,2020-09-14,2020-09-30,Household and community samples,All,Adults (18-64 years),15.0,34.0,Age,,1946,0.0391,,,,,,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Ivalda Macicame,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/10/Inque%CC%81rito-Provincia-de-Maputo_resultados-preliminares_21Out2020-versao-final.pdf,2021-07-18,2024-03-01,Verified,ivalda_macicame_inquerito_2020,MOZ
201021_Matola_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Age0-14,201021_Matola_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Província de Maputo (InCOVID 2020),2020-10-21,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Maputo,Matolo,,,2020-09-14,2020-09-30,Household and community samples,All,Children and Youth (0-17 years),0.0,14.0,Age,,1661,0.0235,,,,,,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Ivalda Macicame,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/10/Inque%CC%81rito-Provincia-de-Maputo_resultados-preliminares_21Out2020-versao-final.pdf,2021-07-18,2024-03-01,Verified,ivalda_macicame_inquerito_2020,MOZ
201021_Matola_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Age35-59,201021_Matola_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Província de Maputo (InCOVID 2020),2020-10-21,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Maputo,Matolo,,,2020-09-14,2020-09-30,Household and community samples,All,Adults (18-64 years),35.0,59.0,Age,,1268,0.045,,,,,,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Ivalda Macicame,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/10/Inque%CC%81rito-Provincia-de-Maputo_resultados-preliminares_21Out2020-versao-final.pdf,2021-07-18,2024-03-01,Verified,ivalda_macicame_inquerito_2020,MOZ
201021_Matola_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Male,201021_Matola_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Província de Maputo (InCOVID 2020),2020-10-21,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Maputo,Matolo,,,2020-09-14,2020-09-30,Household and community samples,Male,Multiple groups,0.0,,Sex/Gender,,2156,0.032,,,,,,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Ivalda Macicame,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/10/Inque%CC%81rito-Provincia-de-Maputo_resultados-preliminares_21Out2020-versao-final.pdf,2021-07-18,2024-03-01,Verified,ivalda_macicame_inquerito_2020,MOZ
201021_Matola_RepúblicaDeMoçambiqueMinistérioDaSaúde_HCWs,201021_Matola_RepúblicaDeMoçambiqueMinistérioDaSaúde_HCW5,Inquérito Sero-epidemiológico de SARS-CoV-2 na Província de Maputo (InCOVID 2020),2020-10-21,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Maputo,Matolo,,,2020-09-14,2020-09-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,793,0.039,,,True,,,,True,Convenience,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,Yes,No,Unclear,No,Yes,No,Unclear,Ivalda Macicame,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/10/Inque%CC%81rito-Provincia-de-Maputo_resultados-preliminares_21Out2020-versao-final.pdf,2021-07-18,2024-03-01,Verified,ivalda_macicame_inquerito_2020,MOZ
201021_Matola_RepúblicaDeMoçambiqueMinistérioDaSaúde_PoliceForces,201021_Matola_RepúblicaDeMoçambiqueMinistérioDaSaúde_PoliceForces4,Inquérito Sero-epidemiológico de SARS-CoV-2 na Província de Maputo (InCOVID 2020),2020-10-21,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Maputo,Matolo,,,2020-09-14,2020-09-30,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,456,0.043899999999999995,,,True,,,,True,Convenience,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Ivalda Macicame,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/10/Inque%CC%81rito-Provincia-de-Maputo_resultados-preliminares_21Out2020-versao-final.pdf,2021-07-18,2024-03-01,Verified,ivalda_macicame_inquerito_2020,MOZ
201021_Matola_RepúblicaDeMoçambiqueMinistérioDaSaúde_TransportationWorkers,201021_Matola_RepúblicaDeMoçambiqueMinistérioDaSaúde_TransportationWorkers6,Inquérito Sero-epidemiológico de SARS-CoV-2 na Província de Maputo (InCOVID 2020),2020-10-21,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Maputo,Matolo,,,2020-09-14,2020-09-30,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,282,0.0319,,,True,,,,True,Convenience,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Ivalda Macicame,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/10/Inque%CC%81rito-Provincia-de-Maputo_resultados-preliminares_21Out2020-versao-final.pdf,2021-07-18,2024-03-01,Verified,ivalda_macicame_inquerito_2020,MOZ
201021_Matola_RepúblicaDeMoçambiqueMinistérioDaSaúde_VendorsMerchants,201021_Matola_RepúblicaDeMoçambiqueMinistérioDaSaúde_VendorsMerchants3,Inquérito Sero-epidemiológico de SARS-CoV-2 na Província de Maputo (InCOVID 2020),2020-10-21,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Maputo,Matolo,,,2020-09-14,2020-09-30,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,1288,0.0497,,,True,,,,True,Convenience,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,Yes,No,Unclear,No,Yes,No,Unclear,Ivalda Macicame,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/10/Inque%CC%81rito-Provincia-de-Maputo_resultados-preliminares_21Out2020-versao-final.pdf,2021-07-18,2024-03-01,Verified,ivalda_macicame_inquerito_2020,MOZ
201127_Chimoio_RepúblicaDeMoçambiqueMinistérioDaSaúde_CommercialEstablishments,201127_Chimoio_RepúblicaDeMoçambiqueMinistérioDaSaúde_CommercialEstablishments5,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Chimoio (InCOVID 2020),2020-11-27,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Manica Province,Chimoio,,,2020-11-02,2020-11-17,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,Workers in commercial establishments,172,0.047,,,True,,,,True,Convenience,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Arlete Mahumane,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/11/Inqueirito-SE-SARS-CoV-2-de-Cidade-de-Chimoio-Resultados-preliminares-27-Nov-2020-V_1.1_corrigido-I_JANI_FINAL1.pdf,2021-07-12,2024-03-01,Verified,arlete_mahumane_inquerito_2020,MOZ
201127_Chimoio_RepúblicaDeMoçambiqueMinistérioDaSaúde_DefenceForces,201127_Chimoio_RepúblicaDeMoçambiqueMinistérioDaSaúde_DefenceForces4,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Chimoio (InCOVID 2020),2020-11-27,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Manica Province,Chimoio,,,2020-11-02,2020-11-17,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,Defence and security forces,407,0.049,,,True,,,,True,Convenience,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Arlete Mahumane,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/11/Inqueirito-SE-SARS-CoV-2-de-Cidade-de-Chimoio-Resultados-preliminares-27-Nov-2020-V_1.1_corrigido-I_JANI_FINAL1.pdf,2021-07-12,2024-03-01,Verified,arlete_mahumane_inquerito_2020,MOZ
201127_Chimoio_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Primary,201127_Chimoio_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Chimoio (InCOVID 2020),2020-11-27,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Manica Province,Chimoio,,,2020-11-02,2020-11-17,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,9756,0.013999999999999999,,,True,,,,True,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Arlete Mahumane,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/11/Inqueirito-SE-SARS-CoV-2-de-Cidade-de-Chimoio-Resultados-preliminares-27-Nov-2020-V_1.1_corrigido-I_JANI_FINAL1.pdf,2021-05-20,2024-03-01,Verified,arlete_mahumane_inquerito_2020,MOZ
201127_Chimoio_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Age0-14,201127_Chimoio_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Chimoio (InCOVID 2020),2020-11-27,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Manica Province,Chimoio,,,2020-11-02,2020-11-17,Household and community samples,All,Children and Youth (0-17 years),0.0,14.0,Age,,3341,0.011000000000000001,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Arlete Mahumane,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/11/Inqueirito-SE-SARS-CoV-2-de-Cidade-de-Chimoio-Resultados-preliminares-27-Nov-2020-V_1.1_corrigido-I_JANI_FINAL1.pdf,2021-07-12,2024-03-01,Verified,arlete_mahumane_inquerito_2020,MOZ
201127_Chimoio_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Age15-34,201127_Chimoio_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Chimoio (InCOVID 2020),2020-11-27,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Manica Province,Chimoio,,,2020-11-02,2020-11-17,Household and community samples,All,Adults (18-64 years),15.0,34.0,Age,,4211,0.013999999999999999,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Arlete Mahumane,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/11/Inqueirito-SE-SARS-CoV-2-de-Cidade-de-Chimoio-Resultados-preliminares-27-Nov-2020-V_1.1_corrigido-I_JANI_FINAL1.pdf,2021-07-12,2024-03-01,Verified,arlete_mahumane_inquerito_2020,MOZ
201127_Chimoio_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Age35-59,201127_Chimoio_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Chimoio (InCOVID 2020),2020-11-27,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Manica Province,Chimoio,,,2020-11-02,2020-11-17,Household and community samples,All,Adults (18-64 years),35.0,59.0,Age,,1679,0.017,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Arlete Mahumane,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/11/Inqueirito-SE-SARS-CoV-2-de-Cidade-de-Chimoio-Resultados-preliminares-27-Nov-2020-V_1.1_corrigido-I_JANI_FINAL1.pdf,2021-07-12,2024-03-01,Verified,arlete_mahumane_inquerito_2020,MOZ
201127_Chimoio_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop_Age>60,201127_Chimoio_RepúblicaDeMoçambiqueMinistérioDaSaúde_Genpop1,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Chimoio (InCOVID 2020),2020-11-27,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Manica Province,Chimoio,,,2020-11-02,2020-11-17,Household and community samples,All,Seniors (65+ years),60.0,,Age,,508,0.02,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Arlete Mahumane,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/11/Inqueirito-SE-SARS-CoV-2-de-Cidade-de-Chimoio-Resultados-preliminares-27-Nov-2020-V_1.1_corrigido-I_JANI_FINAL1.pdf,2021-07-12,2024-03-01,Verified,arlete_mahumane_inquerito_2020,MOZ
201127_Chimoio_RepúblicaDeMoçambiqueMinistérioDaSaúde_HCW,201127_Chimoio_RepúblicaDeMoçambiqueMinistérioDaSaúde_HCW3,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Chimoio (InCOVID 2020),2020-11-27,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Manica Province,Chimoio,,,2020-11-02,2020-11-17,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,HCW,380,0.013000000000000001,,,True,,,,True,Convenience,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Arlete Mahumane,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/11/Inqueirito-SE-SARS-CoV-2-de-Cidade-de-Chimoio-Resultados-preliminares-27-Nov-2020-V_1.1_corrigido-I_JANI_FINAL1.pdf,2021-07-12,2024-03-01,Verified,arlete_mahumane_inquerito_2020,MOZ
201127_Chimoio_RepúblicaDeMoçambiqueMinistérioDaSaúde_TransportationWorkers,201127_Chimoio_RepúblicaDeMoçambiqueMinistérioDaSaúde_TransportationWorkers2,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Chimoio (InCOVID 2020),2020-11-27,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Manica Province,Chimoio,,,2020-11-02,2020-11-17,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,Workers in the Transporation industry,287,0.01,,,True,,,,True,Convenience,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Arlete Mahumane,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/11/Inqueirito-SE-SARS-CoV-2-de-Cidade-de-Chimoio-Resultados-preliminares-27-Nov-2020-V_1.1_corrigido-I_JANI_FINAL1.pdf,2021-07-12,2024-03-01,Verified,arlete_mahumane_inquerito_2020,MOZ
201127_Chimoio_RepúblicaDeMoçambiqueMinistérioDaSaúde_VendorsMerchants,201127_Chimoio_RepúblicaDeMoçambiqueMinistérioDaSaúde_VendorsMerchants6,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Chimoio (InCOVID 2020),2020-11-27,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Manica Province,Chimoio,,,2020-11-02,2020-11-17,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,Vendors and merchants,643,0.019,,,True,,,,True,Convenience,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,Yes,No,Unclear,No,Yes,No,Unclear,Arlete Mahumane,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/11/Inqueirito-SE-SARS-CoV-2-de-Cidade-de-Chimoio-Resultados-preliminares-27-Nov-2020-V_1.1_corrigido-I_JANI_FINAL1.pdf,2021-07-12,2024-03-01,Verified,arlete_mahumane_inquerito_2020,MOZ
201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Chokwe2_CommercialEstablishments,201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Chokwe2_CommercialEstablishments,Inquérito Sero-epidemiológico de SARS-CoV-2 nas Cidades de Xai-Xai e Chókwè (InCOVID 2020),2020-12-08,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Gaza,Chokwe,,,2020-11-16,2020-11-21,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,145,0.075,,,True,,,,True,Convenience,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Paulo Arnaldo,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/InCOVID-2020_-XAI-XAI-CHOKWE_-RESULTADOS-PRELIMINARES_08-12-2020.pdf,2021-07-24,2024-03-01,Verified,paulo_arnaldo_inquerito_2020-1,MOZ
201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Chokwe2_DefenceForces,201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Chokwe2_DefenceForces,Inquérito Sero-epidemiológico de SARS-CoV-2 nas Cidades de Xai-Xai e Chókwè (InCOVID 2020),2020-12-08,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Gaza,Chokwe,,,2020-11-16,2020-11-21,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,67,0.10400000000000001,,,True,,,,True,Convenience,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Paulo Arnaldo,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/InCOVID-2020_-XAI-XAI-CHOKWE_-RESULTADOS-PRELIMINARES_08-12-2020.pdf,2021-07-24,2024-03-01,Verified,paulo_arnaldo_inquerito_2020-1,MOZ
201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Chokwe2_Genpop_Primary,201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Chokwe2_Genpop,Inquérito Sero-epidemiológico de SARS-CoV-2 nas Cidades de Xai-Xai e Chókwè (InCOVID 2020),2020-12-08,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Gaza,Chokwe,,,2020-11-16,2020-11-21,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,2451,0.053,,,True,,,,True,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Paulo Arnaldo,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/InCOVID-2020_-XAI-XAI-CHOKWE_-RESULTADOS-PRELIMINARES_08-12-2020.pdf,2021-05-21,2024-03-01,Verified,paulo_arnaldo_inquerito_2020-1,MOZ
201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Chokwe2_Genpop_Age15-34,201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Chokwe2_Genpop,Inquérito Sero-epidemiológico de SARS-CoV-2 nas Cidades de Xai-Xai e Chókwè (InCOVID 2020),2020-12-08,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Gaza,Chokwe,,,2020-11-16,2020-11-21,Household and community samples,All,Adults (18-64 years),15.0,34.0,Age,,825,0.055999999999999994,,,,,,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Paulo Arnaldo,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/InCOVID-2020_-XAI-XAI-CHOKWE_-RESULTADOS-PRELIMINARES_08-12-2020.pdf,2021-07-24,2024-03-01,Verified,paulo_arnaldo_inquerito_2020-1,MOZ
201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Chokwe2_Genpop_Age60+,201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Chokwe2_Genpop,Inquérito Sero-epidemiológico de SARS-CoV-2 nas Cidades de Xai-Xai e Chókwè (InCOVID 2020),2020-12-08,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Gaza,Chokwe,,,2020-11-16,2020-11-21,Household and community samples,All,Seniors (65+ years),60.0,,Age,,184,0.033,,,,,,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Paulo Arnaldo,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/InCOVID-2020_-XAI-XAI-CHOKWE_-RESULTADOS-PRELIMINARES_08-12-2020.pdf,2021-07-24,2024-03-01,Verified,paulo_arnaldo_inquerito_2020-1,MOZ
201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Chokwe2_Genpop_Age35-59,201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Chokwe2_Genpop,Inquérito Sero-epidemiológico de SARS-CoV-2 nas Cidades de Xai-Xai e Chókwè (InCOVID 2020),2020-12-08,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Gaza,Chokwe,,,2020-11-16,2020-11-21,Household and community samples,All,Adults (18-64 years),35.0,59.0,Age,,432,0.046,,,,,,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Paulo Arnaldo,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/InCOVID-2020_-XAI-XAI-CHOKWE_-RESULTADOS-PRELIMINARES_08-12-2020.pdf,2021-07-24,2024-03-01,Verified,paulo_arnaldo_inquerito_2020-1,MOZ
201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Chokwe2_Genpop_Age0-14,201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Chokwe2_Genpop,Inquérito Sero-epidemiológico de SARS-CoV-2 nas Cidades de Xai-Xai e Chókwè (InCOVID 2020),2020-12-08,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Gaza,Chokwe,,,2020-11-16,2020-11-21,Household and community samples,All,Children and Youth (0-17 years),0.0,14.0,Age,,1010,0.055999999999999994,,,,,,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Paulo Arnaldo,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/InCOVID-2020_-XAI-XAI-CHOKWE_-RESULTADOS-PRELIMINARES_08-12-2020.pdf,2021-07-24,2024-03-01,Verified,paulo_arnaldo_inquerito_2020-1,MOZ
201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Chokwe2_HCWs,201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Chokwe2_HCWs,Inquérito Sero-epidemiológico de SARS-CoV-2 nas Cidades de Xai-Xai e Chókwè (InCOVID 2020),2020-12-08,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Gaza,Chokwe,,,2020-11-16,2020-11-21,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,165,0.10300000000000001,,,True,,,,True,Convenience,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Paulo Arnaldo,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/InCOVID-2020_-XAI-XAI-CHOKWE_-RESULTADOS-PRELIMINARES_08-12-2020.pdf,2021-07-24,2024-03-01,Verified,paulo_arnaldo_inquerito_2020-1,MOZ
201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Chokwe2_TransporationWorkers,201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Chokwe2_TransporationWorkers,Inquérito Sero-epidemiológico de SARS-CoV-2 nas Cidades de Xai-Xai e Chókwè (InCOVID 2020),2020-12-08,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Gaza,Chokwe,,,2020-11-16,2020-11-21,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,112,0.161,,,True,,,,True,Convenience,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Paulo Arnaldo,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/InCOVID-2020_-XAI-XAI-CHOKWE_-RESULTADOS-PRELIMINARES_08-12-2020.pdf,2021-07-24,2024-03-01,Verified,paulo_arnaldo_inquerito_2020-1,MOZ
201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Chokwe2_VendorsMerchants,201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Chokwe2_VendorsMerchants,Inquérito Sero-epidemiológico de SARS-CoV-2 nas Cidades de Xai-Xai e Chókwè (InCOVID 2020),2020-12-08,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Gaza,Chokwe,,,2020-11-16,2020-11-21,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,472,0.068,,,True,,,,True,Convenience,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Paulo Arnaldo,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/InCOVID-2020_-XAI-XAI-CHOKWE_-RESULTADOS-PRELIMINARES_08-12-2020.pdf,2021-07-24,2024-03-01,Verified,paulo_arnaldo_inquerito_2020-1,MOZ
201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Xai-Xai1_CommercialEstablishments,201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Xai-Xai1_CommercialEstablishments,Inquérito Sero-epidemiológico de SARS-CoV-2 nas Cidades de Xai-Xai e Chókwè (InCOVID 2020),2020-12-08,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Gaza,Xai-Xai,,,2020-11-02,2020-11-12,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,272,0.033,,,True,,,,True,Convenience,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Paulo Arnaldo,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/InCOVID-2020_-XAI-XAI-CHOKWE_-RESULTADOS-PRELIMINARES_08-12-2020.pdf,2021-07-24,2024-03-01,Verified,paulo_arnaldo_inquerito_2020-1,MOZ
201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Xai-Xai1_DefenceForces,201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Xai-Xai1_DefenceForces,Inquérito Sero-epidemiológico de SARS-CoV-2 nas Cidades de Xai-Xai e Chókwè (InCOVID 2020),2020-12-08,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Gaza,Xai-Xai,,,2020-11-02,2020-11-12,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,116,0.017,,,True,,,,True,Convenience,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Paulo Arnaldo,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/InCOVID-2020_-XAI-XAI-CHOKWE_-RESULTADOS-PRELIMINARES_08-12-2020.pdf,2021-07-24,2024-03-01,Verified,paulo_arnaldo_inquerito_2020-1,MOZ
201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Xai-Xai1_Genpop_Primary,201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Xai-Xai1_Genpop,Inquérito Sero-epidemiológico de SARS-CoV-2 nas Cidades de Xai-Xai e Chókwè (InCOVID 2020),2020-12-08,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Gaza,Xai-Xai,,,2020-11-02,2020-11-12,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,4932,0.037000000000000005,,,True,,,,True,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Paulo Arnaldo,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/InCOVID-2020_-XAI-XAI-CHOKWE_-RESULTADOS-PRELIMINARES_08-12-2020.pdf,2021-05-21,2024-03-01,Verified,paulo_arnaldo_inquerito_2020-1,MOZ
201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Xai-Xai1_Genpop_Age35-59,201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Xai-Xai1_Genpop,Inquérito Sero-epidemiológico de SARS-CoV-2 nas Cidades de Xai-Xai e Chókwè (InCOVID 2020),2020-12-08,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Gaza,Xai-Xai,,,2020-11-02,2020-11-12,Household and community samples,All,Adults (18-64 years),35.0,59.0,Age,,923,0.049,,,,,,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Paulo Arnaldo,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/InCOVID-2020_-XAI-XAI-CHOKWE_-RESULTADOS-PRELIMINARES_08-12-2020.pdf,2021-07-24,2024-03-01,Verified,paulo_arnaldo_inquerito_2020-1,MOZ
201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Xai-Xai1_Genpop_Age15-34,201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Xai-Xai1_Genpop,Inquérito Sero-epidemiológico de SARS-CoV-2 nas Cidades de Xai-Xai e Chókwè (InCOVID 2020),2020-12-08,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Gaza,Xai-Xai,,,2020-11-02,2020-11-12,Household and community samples,All,Adults (18-64 years),15.0,34.0,Age,,1834,0.04,,,,,,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Paulo Arnaldo,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/InCOVID-2020_-XAI-XAI-CHOKWE_-RESULTADOS-PRELIMINARES_08-12-2020.pdf,2021-07-24,2024-03-01,Verified,paulo_arnaldo_inquerito_2020-1,MOZ
201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Xai-Xai1_Genpop_Age60+,201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Xai-Xai1_Genpop,Inquérito Sero-epidemiológico de SARS-CoV-2 nas Cidades de Xai-Xai e Chókwè (InCOVID 2020),2020-12-08,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Gaza,Xai-Xai,,,2020-11-02,2020-11-12,Household and community samples,All,Seniors (65+ years),60.0,,Age,,403,0.047,,,,,,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Paulo Arnaldo,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/InCOVID-2020_-XAI-XAI-CHOKWE_-RESULTADOS-PRELIMINARES_08-12-2020.pdf,2021-07-24,2024-03-01,Verified,paulo_arnaldo_inquerito_2020-1,MOZ
201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Xai-Xai1_Genpop_Age0-14,201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Xai-Xai1_Genpop,Inquérito Sero-epidemiológico de SARS-CoV-2 nas Cidades de Xai-Xai e Chókwè (InCOVID 2020),2020-12-08,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Gaza,Xai-Xai,,,2020-11-02,2020-11-12,Household and community samples,All,Children and Youth (0-17 years),0.0,14.0,Age,,1772,0.025,,,,,,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Paulo Arnaldo,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/InCOVID-2020_-XAI-XAI-CHOKWE_-RESULTADOS-PRELIMINARES_08-12-2020.pdf,2021-07-24,2024-03-01,Verified,paulo_arnaldo_inquerito_2020-1,MOZ
201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Xai-Xai1_HCWs,201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Xai-Xai1_HCW,Inquérito Sero-epidemiológico de SARS-CoV-2 nas Cidades de Xai-Xai e Chókwè (InCOVID 2020),2020-12-08,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Gaza,Xai-Xai,,,2020-11-02,2020-11-12,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,281,0.057,,,True,,,,True,Convenience,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Paulo Arnaldo,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/InCOVID-2020_-XAI-XAI-CHOKWE_-RESULTADOS-PRELIMINARES_08-12-2020.pdf,2021-07-24,2024-03-01,Verified,paulo_arnaldo_inquerito_2020-1,MOZ
201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Xai-Xai1_TransporationWorkers,201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Xai-Xai1_TransportationWorkers,Inquérito Sero-epidemiológico de SARS-CoV-2 nas Cidades de Xai-Xai e Chókwè (InCOVID 2020),2020-12-08,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Gaza,Xai-Xai,,,2020-11-02,2020-11-12,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,209,0.038,,,True,,,,True,Convenience,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Paulo Arnaldo,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/InCOVID-2020_-XAI-XAI-CHOKWE_-RESULTADOS-PRELIMINARES_08-12-2020.pdf,2021-07-24,2024-03-01,Verified,paulo_arnaldo_inquerito_2020-1,MOZ
201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Xai-Xai1_VendorsMerchants,201208_Xai-Xai&Chokwe_RepúblicaDeMoçambiqueMinistérioDaSaúde_Xai-Xai1_VendorsMerchants,Inquérito Sero-epidemiológico de SARS-CoV-2 nas Cidades de Xai-Xai e Chókwè (InCOVID 2020),2020-12-08,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Gaza,Xai-Xai,,,2020-11-02,2020-11-12,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,460,0.059000000000000004,,,True,,,,True,Convenience,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Paulo Arnaldo,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/InCOVID-2020_-XAI-XAI-CHOKWE_-RESULTADOS-PRELIMINARES_08-12-2020.pdf,2021-07-24,2024-03-01,Verified,paulo_arnaldo_inquerito_2020-1,MOZ
201216_Mozambique_RepúblicaDeMoçambiqueMinistérioDaSaúde_Massinga2_CommercialEstablishments,201216_Maxixe&Massinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Massinga2_CommercialEstablishments,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maxixe e Vila de Massinga (InCOVID 2020),2020-12-16,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Inhambane,Massinga,,,2020-11-26,2020-12-03,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,128,0.109,,,True,,,,True,Convenience,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-de-SARS-CoV-2_Maxixe-e-Massinga.pdf,2021-07-24,2024-03-01,Verified,mussagy_mahomed_inquerito_2020,MOZ
201216_Mozambique_RepúblicaDeMoçambiqueMinistérioDaSaúde_Massinga2_DefenceForces,201216_Maxixe&Massinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Massinga2_DefenceForces,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maxixe e Vila de Massinga (InCOVID 2020),2020-12-16,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Inhambane,Massinga,,,2020-11-26,2020-12-03,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,116,0.18100000000000002,,,True,,,,True,Convenience,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-de-SARS-CoV-2_Maxixe-e-Massinga.pdf,2021-07-24,2024-03-01,Verified,mussagy_mahomed_inquerito_2020,MOZ
201216_Mozambique_RepúblicaDeMoçambiqueMinistérioDaSaúde_Massinga2_Genpop_Primary,201216_Maxixe&Massinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Massinga2_Genpop,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maxixe e Vila de Massinga (InCOVID 2020),2020-12-16,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Inhambane,Massinga,,,2020-11-26,2020-12-03,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,1577,0.07400000000000001,,,True,,,,True,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-de-SARS-CoV-2_Maxixe-e-Massinga.pdf,2021-05-21,2024-03-01,Verified,mussagy_mahomed_inquerito_2020,MOZ
201216_Mozambique_RepúblicaDeMoçambiqueMinistérioDaSaúde_Massinga2_Genpop_Age35-59,201216_Maxixe&Massinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Massinga2_Genpop,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maxixe e Vila de Massinga (InCOVID 2020),2020-12-16,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Inhambane,Massinga,,,2020-11-26,2020-12-03,Household and community samples,All,Adults (18-64 years),35.0,59.0,Age,,285,0.07400000000000001,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-de-SARS-CoV-2_Maxixe-e-Massinga.pdf,2021-07-24,2024-03-01,Verified,mussagy_mahomed_inquerito_2020,MOZ
201216_Mozambique_RepúblicaDeMoçambiqueMinistérioDaSaúde_Massinga2_Genpop_Age15-34,201216_Maxixe&Massinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Massinga2_Genpop,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maxixe e Vila de Massinga (InCOVID 2020),2020-12-16,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Inhambane,Massinga,,,2020-11-26,2020-12-03,Household and community samples,All,Adults (18-64 years),15.0,34.0,Age,,551,0.105,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-de-SARS-CoV-2_Maxixe-e-Massinga.pdf,2021-07-24,2024-03-01,Verified,mussagy_mahomed_inquerito_2020,MOZ
201216_Mozambique_RepúblicaDeMoçambiqueMinistérioDaSaúde_Massinga2_Genpop_Age60+,201216_Maxixe&Massinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Massinga2_Genpop,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maxixe e Vila de Massinga (InCOVID 2020),2020-12-16,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Inhambane,Massinga,,,2020-11-26,2020-12-03,Household and community samples,All,Seniors (65+ years),60.0,,Age,,111,0.073,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-de-SARS-CoV-2_Maxixe-e-Massinga.pdf,2021-07-24,2024-03-01,Verified,mussagy_mahomed_inquerito_2020,MOZ
201216_Mozambique_RepúblicaDeMoçambiqueMinistérioDaSaúde_Massinga2_Genpop_Age0-14,201216_Maxixe&Massinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Massinga2_Genpop,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maxixe e Vila de Massinga (InCOVID 2020),2020-12-16,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Inhambane,Massinga,,,2020-11-26,2020-12-03,Household and community samples,All,Children and Youth (0-17 years),0.0,14.0,Age,,630,0.049,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-de-SARS-CoV-2_Maxixe-e-Massinga.pdf,2021-07-24,2024-03-01,Verified,mussagy_mahomed_inquerito_2020,MOZ
201216_Mozambique_RepúblicaDeMoçambiqueMinistérioDaSaúde_Massinga2_HCW,201216_Maxixe&Massinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Massinga2_HCWs,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maxixe e Vila de Massinga (InCOVID 2020),2020-12-16,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Inhambane,Massinga,,,2020-11-26,2020-12-03,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,131,0.061,,,True,,,,True,Convenience,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-de-SARS-CoV-2_Maxixe-e-Massinga.pdf,2021-07-24,2024-03-01,Verified,mussagy_mahomed_inquerito_2020,MOZ
201216_Mozambique_RepúblicaDeMoçambiqueMinistérioDaSaúde_Massinga2_TransportationWorkers,201216_Maxixe&Massinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Massinga2_TransporationWorkers,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maxixe e Vila de Massinga (InCOVID 2020),2020-12-16,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Inhambane,Massinga,,,2020-11-26,2020-12-03,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,34,0.059000000000000004,,,True,,,,True,Convenience,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-de-SARS-CoV-2_Maxixe-e-Massinga.pdf,2021-07-24,2024-03-01,Verified,mussagy_mahomed_inquerito_2020,MOZ
201216_Mozambique_RepúblicaDeMoçambiqueMinistérioDaSaúde_Massinga2_Vendors/Merchants,201216_Maxixe&Massinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Massinga2_VendorsMerchants,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maxixe e Vila de Massinga (InCOVID 2020),2020-12-16,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Inhambane,Massinga,,,2020-11-26,2020-12-03,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,517,0.08900000000000001,,,True,,,,True,Convenience,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-de-SARS-CoV-2_Maxixe-e-Massinga.pdf,2021-07-24,2024-03-01,Verified,mussagy_mahomed_inquerito_2020,MOZ
201216_Maxixe&Massinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Maxixe1_CommercialEstablishments,201216_Maxixe&Massinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Maxixe1_CommercialEstablishments,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maxixe e Vila de Massinga (InCOVID 2020),2020-12-16,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Inhambane,Maxixe,,,2020-11-07,2020-11-21,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,255,0.035,,,True,,,,True,Convenience,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-de-SARS-CoV-2_Maxixe-e-Massinga.pdf,2021-07-24,2024-03-01,Verified,mussagy_mahomed_inquerito_2020,MOZ
201216_Maxixe&Massinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Maxixe1_DefenceForcesy,201216_Maxixe&Massinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Maxixe1_DefenceForces,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maxixe e Vila de Massinga (InCOVID 2020),2020-12-16,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Inhambane,Maxixe,,,2020-11-07,2020-11-21,Essential non-healthcare workers,All,Multiple groups,,,Primary Estimate,,174,0.092,,,True,,,,True,Convenience,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-de-SARS-CoV-2_Maxixe-e-Massinga.pdf,2021-07-24,2024-03-01,Verified,mussagy_mahomed_inquerito_2020,MOZ
201216_Maxixe&Massinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Maxixe1_Genpop_Primary,201216_Maxixe&Massinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Maxixe1_Genpop,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maxixe e Vila de Massinga (InCOVID 2020),2020-12-16,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Inhambane,Maxixe,,,2020-11-07,2020-11-21,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,3974,0.055,,,True,,,,True,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-de-SARS-CoV-2_Maxixe-e-Massinga.pdf,2021-05-21,2024-03-01,Verified,mussagy_mahomed_inquerito_2020,MOZ
201216_Maxixe&Massinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Maxixe1_Genpop_Age15-34,201216_Maxixe&Massinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Maxixe1_Genpop,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maxixe e Vila de Massinga (InCOVID 2020),2020-12-16,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Inhambane,Maxixe,,,2020-11-07,2020-11-21,Household and community samples,All,Adults (18-64 years),15.0,34.0,Age,,1204,0.06,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-de-SARS-CoV-2_Maxixe-e-Massinga.pdf,2021-07-24,2024-03-01,Verified,mussagy_mahomed_inquerito_2020,MOZ
201216_Maxixe&Massinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Maxixe1_Genpop_Age0-14,201216_Maxixe&Massinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Maxixe1_Genpop,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maxixe e Vila de Massinga (InCOVID 2020),2020-12-16,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Inhambane,Maxixe,,,2020-11-07,2020-11-21,Household and community samples,All,Children and Youth (0-17 years),0.0,14.0,Age,,1657,0.054000000000000006,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-de-SARS-CoV-2_Maxixe-e-Massinga.pdf,2021-07-24,2024-03-01,Verified,mussagy_mahomed_inquerito_2020,MOZ
201216_Maxixe&Massinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Maxixe1_Genpop_Age60+y,201216_Maxixe&Massinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Maxixe1_Genpop,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maxixe e Vila de Massinga (InCOVID 2020),2020-12-16,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Inhambane,Maxixe,,,2020-11-07,2020-11-21,Household and community samples,All,Seniors (65+ years),60.0,,Age,,342,0.044000000000000004,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-de-SARS-CoV-2_Maxixe-e-Massinga.pdf,2021-07-24,2024-03-01,Verified,mussagy_mahomed_inquerito_2020,MOZ
201216_Maxixe&Massinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Maxixe1_Genpop_Age35-59,201216_Maxixe&Massinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Maxixe1_Genpop,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maxixe e Vila de Massinga (InCOVID 2020),2020-12-16,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Inhambane,Maxixe,,,2020-11-07,2020-11-21,Household and community samples,All,Adults (18-64 years),35.0,59.0,Age,,771,0.055999999999999994,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-de-SARS-CoV-2_Maxixe-e-Massinga.pdf,2021-07-24,2024-03-01,Verified,mussagy_mahomed_inquerito_2020,MOZ
201216_Maxixe&Massinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Maxixe1_HCW,201216_Maxixe&Massinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Maxixe1_HCWs,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maxixe e Vila de Massinga (InCOVID 2020),2020-12-16,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Inhambane,Maxixe,,,2020-11-07,2020-11-21,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,342,0.02,,,True,,,,True,Convenience,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-de-SARS-CoV-2_Maxixe-e-Massinga.pdf,2021-07-24,2024-03-01,Verified,mussagy_mahomed_inquerito_2020,MOZ
201216_Maxixe&Massinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Maxixe1_TransportationWorkers,201216_Maxixe&Massinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Maxixe1_TransportationWorkers,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maxixe e Vila de Massinga (InCOVID 2020),2020-12-16,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Inhambane,Maxixe,,,2020-11-07,2020-11-21,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,153,0.046,,,True,,,,True,Convenience,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-de-SARS-CoV-2_Maxixe-e-Massinga.pdf,2021-07-24,2024-03-01,Verified,mussagy_mahomed_inquerito_2020,MOZ
201216_Maxixe&Massinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Maxixe1_VendorsMerchants,201216_Maxixe&Massinga_RepúblicaDeMoçambiqueMinistérioDaSaúde_Maxixe1_VendorsMerchants,Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maxixe e Vila de Massinga (InCOVID 2020),2020-12-16,Presentation or Conference,Local,Cross-sectional survey ,Mozambique,Inhambane,Maxixe,,,2020-11-07,2020-11-21,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,1001,0.045,,,True,,,,True,Convenience,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,Yes,No,Unclear,No,Yes,No,Unclear,Mussagy Mahomed,Republica de Mocambique Ministerio da Saude,Not Unity-Aligned,https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-de-SARS-CoV-2_Maxixe-e-Massinga.pdf,2021-07-24,2024-03-01,Verified,mussagy_mahomed_inquerito_2020,MOZ
220624_MaputoCity_InstitutoNacionaldeSaúde_GenPop_Overall_TestAdj_PopAdj,220624_MaputoCity_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Maputo,Maputo City,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-08-04,2020-08-24,Household and community samples,All,Multiple groups,0.0,,Analysis,Test and population adjusted,4719,0.021,0.012,0.033,True,True,True,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.833,0.98,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-07,2023-08-15,Unverified,arnaldo_prevalence_2022,MOZ
220624_MaputoCity_InstitutoNacionaldeSaúde_Age45-59_PopAdj,220624_MaputoCity_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Maputo,Maputo City,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-08-04,2020-08-24,Household and community samples,All,Adults (18-64 years),45.0,59.0,Age,Age 45-59,681,0.059000000000000004,0.036000000000000004,0.096,,,True,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.833,0.98,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-14,2024-03-01,Unverified,arnaldo_prevalence_2022,MOZ
220624_MaputoCity_InstitutoNacionaldeSaúde_Age25-34_PopAdj,220624_MaputoCity_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Maputo,Maputo City,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-08-04,2020-08-24,Household and community samples,All,Adults (18-64 years),25.0,34.0,Age,Age 25-34,665,0.057,0.036000000000000004,0.08800000000000001,,,True,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.833,0.98,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-14,2024-03-01,Unverified,arnaldo_prevalence_2022,MOZ
220624_MaputoCity_InstitutoNacionaldeSaúde_GenPop_Overall_PopAdj,220624_MaputoCity_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Maputo,Maputo City,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-08-04,2020-08-24,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,Crude prevalence was adjusted for population structure,4719,0.037000000000000005,0.028999999999999998,0.047,,,True,,True,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.833,0.98,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-07,2024-03-01,Unverified,arnaldo_prevalence_2022,MOZ
220624_MaputoCity_InstitutoNacionaldeSaúde_Age15-24_PopAdj,220624_MaputoCity_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Maputo,Maputo City,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-08-04,2020-08-24,Household and community samples,All,Multiple groups,15.0,24.0,Age,Age 15-24,862,0.025,0.016,0.038,,,True,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.833,0.98,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-14,2024-03-01,Unverified,arnaldo_prevalence_2022,MOZ
220624_MaputoCity_InstitutoNacionaldeSaúde_Age10-14_PopAdj,220624_MaputoCity_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Maputo,Maputo City,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-08-04,2020-08-24,Household and community samples,All,Children and Youth (0-17 years),10.0,14.0,Age,Age 10-14,450,0.054000000000000006,0.035,0.08199999999999999,,,True,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.833,0.98,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-14,2024-03-01,Unverified,arnaldo_prevalence_2022,MOZ
220624_MaputoCity_InstitutoNacionaldeSaúde_Age0-9_PopAdj,220624_MaputoCity_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Maputo,Maputo City,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-08-04,2020-08-24,Household and community samples,All,Children and Youth (0-17 years),0.0,9.0,Age,Age 0-9,766,0.021,0.012,0.036000000000000004,,,True,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.833,0.98,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-14,2024-03-01,Unverified,arnaldo_prevalence_2022,MOZ
220624_MaputoCity_InstitutoNacionaldeSaúde_GenPop_Males_PopAdj,220624_MaputoCity_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Maputo,Maputo City,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-08-04,2020-08-24,Household and community samples,Male,Multiple groups,0.0,,Sex/Gender,Crude prevalence was adjusted for population structure,1877,0.031000000000000003,0.022000000000000002,0.043,,,True,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.833,0.98,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-12,2024-03-01,Unverified,arnaldo_prevalence_2022,MOZ
220624_MaputoCity_InstitutoNacionaldeSaúde_Age35-44_PopAdj,220624_MaputoCity_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Maputo,Maputo City,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-08-04,2020-08-24,Household and community samples,All,Adults (18-64 years),35.0,44.0,Age,Age 35-44,559,0.016,0.006999999999999999,0.04,,,True,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.833,0.98,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-14,2024-03-01,Unverified,arnaldo_prevalence_2022,MOZ
220624_MaputoCity_InstitutoNacionaldeSaúde_AgeUnknown_UnAdj,220624_MaputoCity_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Maputo,Maputo City,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-08-04,2020-08-24,Household and community samples,All,Multiple groups,,,Age,Age unknown,79,0.076,,,,,,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.833,0.98,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-14,2024-03-01,Unverified,arnaldo_prevalence_2022,MOZ
220624_MaputoCity_InstitutoNacionaldeSaúde_Age60+_PopAdj,220624_MaputoCity_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Maputo,Maputo City,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-08-04,2020-08-24,Household and community samples,All,Multiple groups,60.0,,Age,Age 6,667,0.05,0.032,0.078,,,True,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.833,0.98,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-14,2024-03-01,Unverified,arnaldo_prevalence_2022,MOZ
220624_MaputoCity_InstitutoNacionaldeSaúde_GenPop_Females_PopAdj,220624_MaputoCity_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Maputo,Maputo City,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-08-04,2020-08-24,Household and community samples,Female,Multiple groups,0.0,,Sex/Gender,Crude prevalence was adjusted for population structure,2842,0.043,0.032,0.057,,,True,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.833,0.98,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-12,2024-03-01,Unverified,arnaldo_prevalence_2022,MOZ
220624_Pemba_InstitutoNacionaldeSaúde_GenPop_Overall_TestAdjPopAdj,220624_Pemba_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Cabo Delgado,Pemba,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-07-06,2020-07-13,Household and community samples,All,Multiple groups,0.0,,Analysis,Test and population adjusted,1358,0.03,0.01,0.066,True,True,True,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.867,0.9870000000000001,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-12,2023-08-15,Unverified,arnaldo_prevalence_2022,MOZ
220624_Pemba_InstitutoNacionaldeSaúde_GenPop_Males_PopAdj,220624_Pemba_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Cabo Delgado,Pemba,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-07-06,2020-07-13,Household and community samples,Male,Multiple groups,0.0,,Sex/Gender,Crude prevalence was adjusted for population structure,572,0.045,0.027999999999999997,0.071,,,True,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.867,0.9870000000000001,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-14,2024-03-01,Unverified,arnaldo_prevalence_2022,MOZ
220624_Pemba_InstitutoNacionaldeSaúde_Age60+_PopAdj,220624_Pemba_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Cabo Delgado,Pemba,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-07-06,2020-07-13,Household and community samples,All,Multiple groups,60.0,,Age,Age 60+,60,0.04,0.006999999999999999,0.20800000000000002,,,True,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.867,0.9870000000000001,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-14,2024-03-01,Unverified,arnaldo_prevalence_2022,MOZ
220624_Pemba_InstitutoNacionaldeSaúde_GenPop_Females_PopAdj,220624_Pemba_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Cabo Delgado,Pemba,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-07-06,2020-07-13,Household and community samples,Female,Multiple groups,0.0,,Sex/Gender,Crude prevalence was adjusted for population structure,786,0.033,0.013000000000000001,0.078,,,True,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.867,0.9870000000000001,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-14,2024-03-01,Unverified,arnaldo_prevalence_2022,MOZ
220624_Pemba_InstitutoNacionaldeSaúde_Age15-24_PopAdj,220624_Pemba_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Cabo Delgado,Pemba,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-07-06,2020-07-13,Household and community samples,All,Multiple groups,15.0,24.0,Age,Age 15-24,262,0.035,0.016,0.073,,,True,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.867,0.9870000000000001,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-14,2024-03-01,Unverified,arnaldo_prevalence_2022,MOZ
220624_Pemba_InstitutoNacionaldeSaúde_Age25-34_PopAdj,220624_Pemba_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Cabo Delgado,Pemba,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-07-06,2020-07-13,Household and community samples,All,Adults (18-64 years),25.0,34.0,Age,Age 25-34,195,0.026000000000000002,0.01,0.061,,,True,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.867,0.9870000000000001,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-14,2024-03-01,Unverified,arnaldo_prevalence_2022,MOZ
220624_Pemba_InstitutoNacionaldeSaúde_Age0-9_PopAdj,220624_Pemba_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Cabo Delgado,Pemba,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-07-06,2020-07-13,Household and community samples,All,Children and Youth (0-17 years),0.0,9.0,Age,Age 0-9,226,0.024,0.01,0.055,,,True,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.867,0.9870000000000001,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-14,2024-03-01,Unverified,arnaldo_prevalence_2022,MOZ
220624_Pemba_InstitutoNacionaldeSaúde_Age35-44_PopAdj,220624_Pemba_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Cabo Delgado,Pemba,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-07-06,2020-07-13,Household and community samples,All,Adults (18-64 years),35.0,44.0,Age,Age 35-44,126,0.033,0.008,0.125,,,True,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.867,0.9870000000000001,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-14,2024-03-01,Unverified,arnaldo_prevalence_2022,MOZ
220624_Pemba_InstitutoNacionaldeSaúde_GenPop_Overall_PopAdj,220624_Pemba_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Cabo Delgado,Pemba,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-07-06,2020-07-13,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,Crude prevalence was adjusted for population structure,1358,0.039,0.021,0.069,,,True,,True,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.867,0.9870000000000001,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-06,2024-03-01,Unverified,arnaldo_prevalence_2022,MOZ
220624_Pemba_InstitutoNacionaldeSaúde_Age45-59_PopAdj,220624_Pemba_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Cabo Delgado,Pemba,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-07-06,2020-07-13,Household and community samples,All,Adults (18-64 years),45.0,59.0,Age,Age 45-59,109,0.067,0.04,0.109,,,True,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.867,0.9870000000000001,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-14,2024-03-01,Unverified,arnaldo_prevalence_2022,MOZ
220624_Pemba_InstitutoNacionaldeSaúde_Age10-14_PopAdj,220624_Pemba_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Cabo Delgado,Pemba,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-07-06,2020-07-13,Household and community samples,All,Children and Youth (0-17 years),10.0,14.0,Age,Age 10-14,180,0.053,0.015,0.174,,,True,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.867,0.9870000000000001,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-14,2024-03-01,Unverified,arnaldo_prevalence_2022,MOZ
220624_Pemba_InstitutoNacionaldeSaúde_AgeUnknown_UnAdj,220624_Pemba_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Cabo Delgado,Pemba,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-07-06,2020-07-13,Household and community samples,All,Multiple groups,,,Age,Age unknown,200,0.015,,,,,,,,Stratified probability,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Qingdao Hightop Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.867,0.9870000000000001,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-14,2024-03-01,Unverified,arnaldo_prevalence_2022,MOZ
220624_Quelimane_InstitutoNacionaldeSaúde_GenPop_Overall_TestAdj_PopAdj,220624_Quelimane_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Zambezia,Quelimane,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-08-10,2020-08-21,Household and community samples,All,Multiple groups,0.0,,Analysis,Test and population adjusted,5066,0.009000000000000001,0.001,0.019,True,True,True,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.833,0.98,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-12,2023-08-15,Unverified,arnaldo_prevalence_2022,MOZ
220624_Quelimane_InstitutoNacionaldeSaúde_GenPop_Males_PopAdj,220624_Quelimane_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Zambezia,Quelimane,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-08-10,2020-08-21,Household and community samples,Male,Multiple groups,0.0,,Sex/Gender,Crude prevalence was adjusted for population structure,2170,0.027000000000000003,0.019,0.037000000000000005,,,True,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.833,0.98,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-14,2024-03-01,Unverified,arnaldo_prevalence_2022,MOZ
220624_Quelimane_InstitutoNacionaldeSaúde_Age15-24_PopAdj,220624_Quelimane_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Zambezia,Quelimane,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-08-10,2020-08-21,Household and community samples,All,Multiple groups,15.0,24.0,Age,Age 15-24,1155,0.04,0.027999999999999997,0.057,,,True,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.833,0.98,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-14,2024-03-01,Unverified,arnaldo_prevalence_2022,MOZ
220624_Quelimane_InstitutoNacionaldeSaúde_Age60+_PopAdj copy,220624_Quelimane_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Zambezia,Quelimane,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-08-10,2020-08-21,Household and community samples,All,Multiple groups,,,Age,Age unknown,681,0.021,,,,,,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.833,0.98,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-14,2024-03-01,Unverified,arnaldo_prevalence_2022,MOZ
220624_Quelimane_InstitutoNacionaldeSaúde_Age0-9_PopAdj,220624_Quelimane_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Zambezia,Quelimane,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-08-10,2020-08-21,Household and community samples,All,Children and Youth (0-17 years),0.0,9.0,Age,Age 0-9,885,0.027000000000000003,0.017,0.043,,,True,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.833,0.98,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-14,2024-03-01,Unverified,arnaldo_prevalence_2022,MOZ
220624_Quelimane_InstitutoNacionaldeSaúde_Age10-14_PopAdj,220624_Quelimane_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Zambezia,Quelimane,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-08-10,2020-08-21,Household and community samples,All,Children and Youth (0-17 years),10.0,14.0,Age,Age 10-14,487,0.027000000000000003,0.016,0.045,,,True,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.833,0.98,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-14,2024-03-01,Unverified,arnaldo_prevalence_2022,MOZ
220624_Quelimane_InstitutoNacionaldeSaúde_Age35-44_PopAdj,220624_Quelimane_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Zambezia,Quelimane,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-08-10,2020-08-21,Household and community samples,All,Adults (18-64 years),35.0,44.0,Age,Age 35-44,433,0.013999999999999999,0.006,0.034,,,True,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.833,0.98,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-14,2024-03-01,Unverified,arnaldo_prevalence_2022,MOZ
220624_Quelimane_InstitutoNacionaldeSaúde_GenPop_Females_PopAdj,220624_Quelimane_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Zambezia,Quelimane,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-08-10,2020-08-21,Household and community samples,Female,Multiple groups,0.0,,Sex/Gender,Crude prevalence was adjusted for population structure,2896,0.027999999999999997,0.021,0.037000000000000005,,,True,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.833,0.98,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-14,2024-03-01,Unverified,arnaldo_prevalence_2022,MOZ
220624_Quelimane_InstitutoNacionaldeSaúde_Age60+_PopAdj,220624_Quelimane_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Zambezia,Quelimane,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-08-10,2020-08-21,Household and community samples,All,Multiple groups,60.0,,Age,Age 60+,222,0.027999999999999997,0.011000000000000001,0.07,,,True,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.833,0.98,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-14,2024-03-01,Unverified,arnaldo_prevalence_2022,MOZ
220624_Quelimane_InstitutoNacionaldeSaúde_Age25-34_PopAdj,220624_Quelimane_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Zambezia,Quelimane,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-08-10,2020-08-21,Household and community samples,All,Adults (18-64 years),25.0,34.0,Age,Age 25-34,782,0.017,0.01,0.03,,,True,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.833,0.98,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-14,2024-03-01,Unverified,arnaldo_prevalence_2022,MOZ
220624_Quelimane_InstitutoNacionaldeSaúde_GenPop_Overall_PopAdj,220624_Quelimane_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Zambezia,Quelimane,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-08-10,2020-08-21,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,Crude prevalence was adjusted for population structure,5066,0.027000000000000003,0.021,0.035,,,True,,True,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.833,0.98,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-06,2024-03-01,Unverified,arnaldo_prevalence_2022,MOZ
220624_Quelimane_InstitutoNacionaldeSaúde_Age45-59_PopAdj,220624_Quelimane_InstitutoNacionaldeSaúde_GenPop,"Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020",2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Mozambique,Zambezia,Quelimane,,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""",2020-08-10,2020-08-21,Household and community samples,All,Adults (18-64 years),45.0,59.0,Age,Age 45-59,421,0.024,0.013000000000000001,0.045,,,True,,,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.833,0.98,['Moderate'],,Yes,Yes,Yes,,No,Yes,No,,Paulo Arnaldo,Instituto Nacional de Saúde,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac516,2022-07-14,2024-03-01,Unverified,arnaldo_prevalence_2022,MOZ
221024_Manhica_BarcelonaInstituteforGlobalHealth,221024_Manhica_BarcelonaInstituteforGlobalHealth,SARS-CoV-2 seropositivity and HIV viral load among Mozambican pregnant women.,2022-10-26,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Mozambique,Maputo Province,Manhica District,Mozambican HIV-infected pregnant women attending antenatal care clinic in Manhica district Hospital or Palmeira Health Post,,2019-11-15,2021-06-15,Pregnant or parturient women,All,Multiple groups,13.0,47.0,Primary Estimate,,397,0.113,0.084,0.149,True,,,,True,Convenience,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['High'],Yes,No,No,No,Yes,Yes,Yes,Yes,Unclear,Raquel Gonzalez,Barcelona Institute for Global Health,Unity-Aligned,https://dx.doi.org/10.1097/QAI.0000000000003120,2022-11-06,2024-03-15,Verified,gonzalez_sars-cov-2_2022,MOZ
231226_Maputo_InstitutoNacionaldeSaude_unadj,231226_Maputo_InstitutoNacionaldeSaude,"Mild and moderate COVID-19 during Alpha, Delta and Omikron pandemic waves in urban Maputo, Mozambique, December 2020-March 2022: a population-based surveillance study",2023-12-26,Preprint,Local,Prospective cohort,Mozambique,,Maputo,"Recruited households were embedded in the Health and Demographic Surveillance System of Polana Caniço, covering 15,393 residents. Participants had to be residents since ≥3 months, and included all ages.",,2020-12-15,2021-07-31,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,1412,0.213,,,True,,,,True,Simplified probability,Author designed (Multiplex),,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.96,0.99,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Brecht Ingelbeen,Instituto Nacional de Saúde,Unity-Aligned,https://doi.org/10.1101/2023.12.22.23300474,2024-05-14,2024-05-14,Unverified,ingelbeen_mild_2023,MOZ
231226_Maputo_InstitutoNacionaldeSaude_20-29,231226_Maputo_InstitutoNacionaldeSaude,"Mild and moderate COVID-19 during Alpha, Delta and Omikron pandemic waves in urban Maputo, Mozambique, December 2020-March 2022: a population-based surveillance study",2023-12-26,Preprint,Local,Prospective cohort,Mozambique,,Maputo,"Recruited households were embedded in the Health and Demographic Surveillance System of Polana Caniço, covering 15,393 residents. Participants had to be residents since ≥3 months, and included all ages.",,2020-12-15,2021-07-31,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,,161,0.173,,,,,,,,Simplified probability,Author designed (Multiplex),,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.96,0.9899999999999988,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Brecht Ingelbeen,Instituto Nacional de Saúde,Unity-Aligned,https://doi.org/10.1101/2023.12.22.23300474,2024-05-14,2024-05-14,Unverified,ingelbeen_mild_2023,MOZ
231226_Maputo_InstitutoNacionaldeSaude_mar2021,231226_Maputo_InstitutoNacionaldeSaude,"Mild and moderate COVID-19 during Alpha, Delta and Omikron pandemic waves in urban Maputo, Mozambique, December 2020-March 2022: a population-based surveillance study",2023-12-26,Preprint,Local,Prospective cohort,Mozambique,,Maputo,"Recruited households were embedded in the Health and Demographic Surveillance System of Polana Caniço, covering 15,393 residents. Participants had to be residents since ≥3 months, and included all ages.",,2021-03-01,2021-03-31,Household and community samples,All,Multiple groups,0.0,,Time frame,,526,0.116,,,,,,,,Simplified probability,Author designed (Multiplex),,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.96,0.99,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Brecht Ingelbeen,Instituto Nacional de Saúde,Unity-Aligned,https://doi.org/10.1101/2023.12.22.23300474,2024-05-14,2024-05-14,Unverified,ingelbeen_mild_2023,MOZ
231226_Maputo_InstitutoNacionaldeSaude_50-59,231226_Maputo_InstitutoNacionaldeSaude,"Mild and moderate COVID-19 during Alpha, Delta and Omikron pandemic waves in urban Maputo, Mozambique, December 2020-March 2022: a population-based surveillance study",2023-12-26,Preprint,Local,Prospective cohort,Mozambique,,Maputo,"Recruited households were embedded in the Health and Demographic Surveillance System of Polana Caniço, covering 15,393 residents. Participants had to be residents since ≥3 months, and included all ages.",,2020-12-15,2021-07-31,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,,240,0.225,,,,,,,,Simplified probability,Author designed (Multiplex),,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.96,0.9899999999999988,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Brecht Ingelbeen,Instituto Nacional de Saúde,Unity-Aligned,https://doi.org/10.1101/2023.12.22.23300474,2024-05-14,2024-05-14,Unverified,ingelbeen_mild_2023,MOZ
231226_Maputo_InstitutoNacionaldeSaude_60-69,231226_Maputo_InstitutoNacionaldeSaude,"Mild and moderate COVID-19 during Alpha, Delta and Omikron pandemic waves in urban Maputo, Mozambique, December 2020-March 2022: a population-based surveillance study",2023-12-26,Preprint,Local,Prospective cohort,Mozambique,,Maputo,"Recruited households were embedded in the Health and Demographic Surveillance System of Polana Caniço, covering 15,393 residents. Participants had to be residents since ≥3 months, and included all ages.",,2020-12-15,2021-07-31,Household and community samples,All,Seniors (65+ years),60.0,69.0,Age,,202,0.282,,,,,,,,Simplified probability,Author designed (Multiplex),,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.96,0.9899999999999987,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Brecht Ingelbeen,Instituto Nacional de Saúde,Unity-Aligned,https://doi.org/10.1101/2023.12.22.23300474,2024-05-14,2024-05-14,Unverified,ingelbeen_mild_2023,MOZ
231226_Maputo_InstitutoNacionaldeSaude_may2021,231226_Maputo_InstitutoNacionaldeSaude,"Mild and moderate COVID-19 during Alpha, Delta and Omikron pandemic waves in urban Maputo, Mozambique, December 2020-March 2022: a population-based surveillance study",2023-12-26,Preprint,Local,Prospective cohort,Mozambique,,Maputo,"Recruited households were embedded in the Health and Demographic Surveillance System of Polana Caniço, covering 15,393 residents. Participants had to be residents since ≥3 months, and included all ages.",,2021-05-01,2021-05-31,Household and community samples,All,Multiple groups,0.0,,Time frame,,247,0.267,,,,,,,,Simplified probability,Author designed (Multiplex),,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.96,0.9899999999999994,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Brecht Ingelbeen,Instituto Nacional de Saúde,Unity-Aligned,https://doi.org/10.1101/2023.12.22.23300474,2024-05-14,2024-05-14,Unverified,ingelbeen_mild_2023,MOZ
231226_Maputo_InstitutoNacionaldeSaude_10-19,231226_Maputo_InstitutoNacionaldeSaude,"Mild and moderate COVID-19 during Alpha, Delta and Omikron pandemic waves in urban Maputo, Mozambique, December 2020-March 2022: a population-based surveillance study",2023-12-26,Preprint,Local,Prospective cohort,Mozambique,,Maputo,"Recruited households were embedded in the Health and Demographic Surveillance System of Polana Caniço, covering 15,393 residents. Participants had to be residents since ≥3 months, and included all ages.",,2020-12-15,2021-07-31,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,,305,0.19,,,,,,,,Simplified probability,Author designed (Multiplex),,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.96,0.9899999999999989,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Brecht Ingelbeen,Instituto Nacional de Saúde,Unity-Aligned,https://doi.org/10.1101/2023.12.22.23300474,2024-05-14,2024-05-14,Unverified,ingelbeen_mild_2023,MOZ
231226_Maputo_InstitutoNacionaldeSaude_apr2021,231226_Maputo_InstitutoNacionaldeSaude,"Mild and moderate COVID-19 during Alpha, Delta and Omikron pandemic waves in urban Maputo, Mozambique, December 2020-March 2022: a population-based surveillance study",2023-12-26,Preprint,Local,Prospective cohort,Mozambique,,Maputo,"Recruited households were embedded in the Health and Demographic Surveillance System of Polana Caniço, covering 15,393 residents. Participants had to be residents since ≥3 months, and included all ages.",,2021-04-01,2021-04-30,Household and community samples,All,Multiple groups,0.0,,Time frame,,322,0.242,,,,,,,,Simplified probability,Author designed (Multiplex),,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.96,0.9899999999999997,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Brecht Ingelbeen,Instituto Nacional de Saúde,Unity-Aligned,https://doi.org/10.1101/2023.12.22.23300474,2024-05-14,2024-05-14,Unverified,ingelbeen_mild_2023,MOZ
231226_Maputo_InstitutoNacionaldeSaude_jun2021,231226_Maputo_InstitutoNacionaldeSaude,"Mild and moderate COVID-19 during Alpha, Delta and Omikron pandemic waves in urban Maputo, Mozambique, December 2020-March 2022: a population-based surveillance study",2023-12-26,Preprint,Local,Prospective cohort,Mozambique,,Maputo,"Recruited households were embedded in the Health and Demographic Surveillance System of Polana Caniço, covering 15,393 residents. Participants had to be residents since ≥3 months, and included all ages.",,2021-06-01,2021-06-30,Household and community samples,All,Multiple groups,0.0,,Time frame,,73,0.342,,,,,,,,Simplified probability,Author designed (Multiplex),,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.96,0.9899999999999993,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Brecht Ingelbeen,Instituto Nacional de Saúde,Unity-Aligned,https://doi.org/10.1101/2023.12.22.23300474,2024-05-14,2024-05-14,Unverified,ingelbeen_mild_2023,MOZ
231226_Maputo_InstitutoNacionaldeSaude_40-49,231226_Maputo_InstitutoNacionaldeSaude,"Mild and moderate COVID-19 during Alpha, Delta and Omikron pandemic waves in urban Maputo, Mozambique, December 2020-March 2022: a population-based surveillance study",2023-12-26,Preprint,Local,Prospective cohort,Mozambique,,Maputo,"Recruited households were embedded in the Health and Demographic Surveillance System of Polana Caniço, covering 15,393 residents. Participants had to be residents since ≥3 months, and included all ages.",,2020-12-15,2021-07-31,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,,68,0.221,,,,,,,,Simplified probability,Author designed (Multiplex),,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.96,0.9899999999999988,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Brecht Ingelbeen,Instituto Nacional de Saúde,Unity-Aligned,https://doi.org/10.1101/2023.12.22.23300474,2024-05-14,2024-05-14,Unverified,ingelbeen_mild_2023,MOZ
231226_Maputo_InstitutoNacionaldeSaude_dec2020,231226_Maputo_InstitutoNacionaldeSaude,"Mild and moderate COVID-19 during Alpha, Delta and Omikron pandemic waves in urban Maputo, Mozambique, December 2020-March 2022: a population-based surveillance study",2023-12-26,Preprint,Local,Prospective cohort,Mozambique,,Maputo,"Recruited households were embedded in the Health and Demographic Surveillance System of Polana Caniço, covering 15,393 residents. Participants had to be residents since ≥3 months, and included all ages.",,2020-12-15,2020-12-31,Household and community samples,All,Multiple groups,0.0,,Time frame,,124,0.048,,,,,,,,Simplified probability,Author designed (Multiplex),,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.96,0.99,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Brecht Ingelbeen,Instituto Nacional de Saúde,Unity-Aligned,https://doi.org/10.1101/2023.12.22.23300474,2024-05-14,2024-05-14,Unverified,ingelbeen_mild_2023,MOZ
231226_Maputo_InstitutoNacionaldeSaude_jul2021,231226_Maputo_InstitutoNacionaldeSaude,"Mild and moderate COVID-19 during Alpha, Delta and Omikron pandemic waves in urban Maputo, Mozambique, December 2020-March 2022: a population-based surveillance study",2023-12-26,Preprint,Local,Prospective cohort,Mozambique,,Maputo,"Recruited households were embedded in the Health and Demographic Surveillance System of Polana Caniço, covering 15,393 residents. Participants had to be residents since ≥3 months, and included all ages.",,2021-07-01,2021-07-31,Household and community samples,All,Multiple groups,0.0,,Time frame,,215,0.334,,,,,,,,Simplified probability,Author designed (Multiplex),,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.96,0.9899999999999992,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Brecht Ingelbeen,Instituto Nacional de Saúde,Unity-Aligned,https://doi.org/10.1101/2023.12.22.23300474,2024-05-14,2024-05-14,Unverified,ingelbeen_mild_2023,MOZ
231226_Maputo_InstitutoNacionaldeSaude_Sonly,231226_Maputo_InstitutoNacionaldeSaude,"Mild and moderate COVID-19 during Alpha, Delta and Omikron pandemic waves in urban Maputo, Mozambique, December 2020-March 2022: a population-based surveillance study",2023-12-26,Preprint,Local,Prospective cohort,Mozambique,,Maputo,"Recruited households were embedded in the Health and Demographic Surveillance System of Polana Caniço, covering 15,393 residents. Participants had to be residents since ≥3 months, and included all ages.",,2021-06-01,2021-06-30,Household and community samples,All,Multiple groups,0.0,,Test used,,215,0.465,,,,,,,,Simplified probability,Author designed (Multiplex),,Luminex,Dried Blood,IgG,Spike,Validated by developers,0.96,0.9899999999999985,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Brecht Ingelbeen,Instituto Nacional de Saúde,Unity-Aligned,https://doi.org/10.1101/2023.12.22.23300474,2024-05-14,2024-05-14,Unverified,ingelbeen_mild_2023,MOZ
231226_Maputo_InstitutoNacionaldeSaude_jan2021,231226_Maputo_InstitutoNacionaldeSaude,"Mild and moderate COVID-19 during Alpha, Delta and Omikron pandemic waves in urban Maputo, Mozambique, December 2020-March 2022: a population-based surveillance study",2023-12-26,Preprint,Local,Prospective cohort,Mozambique,,Maputo,"Recruited households were embedded in the Health and Demographic Surveillance System of Polana Caniço, covering 15,393 residents. Participants had to be residents since ≥3 months, and included all ages.",,2021-01-01,2021-01-31,Household and community samples,All,Multiple groups,0.0,,Time frame,,458,0.054,,,,,,,,Simplified probability,Author designed (Multiplex),,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.96,0.99,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Brecht Ingelbeen,Instituto Nacional de Saúde,Unity-Aligned,https://doi.org/10.1101/2023.12.22.23300474,2024-05-14,2024-05-14,Unverified,ingelbeen_mild_2023,MOZ
231226_Maputo_InstitutoNacionaldeSaude_0-9,231226_Maputo_InstitutoNacionaldeSaude,"Mild and moderate COVID-19 during Alpha, Delta and Omikron pandemic waves in urban Maputo, Mozambique, December 2020-March 2022: a population-based surveillance study",2023-12-26,Preprint,Local,Prospective cohort,Mozambique,,Maputo,"Recruited households were embedded in the Health and Demographic Surveillance System of Polana Caniço, covering 15,393 residents. Participants had to be residents since ≥3 months, and included all ages.",,2020-12-15,2021-07-31,Household and community samples,All,Children and Youth (0-17 years),0.0,9.0,Age,,223,0.156,,,,,,,,Simplified probability,Author designed (Multiplex),,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.96,0.989999999999999,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Brecht Ingelbeen,Instituto Nacional de Saúde,Unity-Aligned,https://doi.org/10.1101/2023.12.22.23300474,2024-05-14,2024-05-14,Unverified,ingelbeen_mild_2023,MOZ
231226_Maputo_InstitutoNacionaldeSaude_30-39,231226_Maputo_InstitutoNacionaldeSaude,"Mild and moderate COVID-19 during Alpha, Delta and Omikron pandemic waves in urban Maputo, Mozambique, December 2020-March 2022: a population-based surveillance study",2023-12-26,Preprint,Local,Prospective cohort,Mozambique,,Maputo,"Recruited households were embedded in the Health and Demographic Surveillance System of Polana Caniço, covering 15,393 residents. Participants had to be residents since ≥3 months, and included all ages.",,2020-12-15,2021-07-31,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,,114,0.122,,,,,,,,Simplified probability,Author designed (Multiplex),,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.96,0.9899999999999989,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Brecht Ingelbeen,Instituto Nacional de Saúde,Unity-Aligned,https://doi.org/10.1101/2023.12.22.23300474,2024-05-14,2024-05-14,Unverified,ingelbeen_mild_2023,MOZ
231226_Maputo_InstitutoNacionaldeSaude_feb2021,231226_Maputo_InstitutoNacionaldeSaude,"Mild and moderate COVID-19 during Alpha, Delta and Omikron pandemic waves in urban Maputo, Mozambique, December 2020-March 2022: a population-based surveillance study",2023-12-26,Preprint,Local,Prospective cohort,Mozambique,,Maputo,"Recruited households were embedded in the Health and Demographic Surveillance System of Polana Caniço, covering 15,393 residents. Participants had to be residents since ≥3 months, and included all ages.",,2021-02-01,2021-02-28,Household and community samples,All,Multiple groups,0.0,,Time frame,,225,0.089,,,,,,,,Simplified probability,Author designed (Multiplex),,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.96,0.99,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Brecht Ingelbeen,Instituto Nacional de Saúde,Unity-Aligned,https://doi.org/10.1101/2023.12.22.23300474,2024-05-14,2024-05-14,Unverified,ingelbeen_mild_2023,MOZ
231226_Maputo_InstitutoNacionaldeSaude_70+,231226_Maputo_InstitutoNacionaldeSaude,"Mild and moderate COVID-19 during Alpha, Delta and Omikron pandemic waves in urban Maputo, Mozambique, December 2020-March 2022: a population-based surveillance study",2023-12-26,Preprint,Local,Prospective cohort,Mozambique,,Maputo,"Recruited households were embedded in the Health and Demographic Surveillance System of Polana Caniço, covering 15,393 residents. Participants had to be residents since ≥3 months, and included all ages.",,2020-12-15,2021-07-31,Household and community samples,All,Seniors (65+ years),70.0,,Age,,93,0.279,,,,,,,,Simplified probability,Author designed (Multiplex),,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.96,0.9899999999999985,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Brecht Ingelbeen,Instituto Nacional de Saúde,Unity-Aligned,https://doi.org/10.1101/2023.12.22.23300474,2024-05-14,2024-05-14,Unverified,ingelbeen_mild_2023,MOZ
210404_Nepal_GovernmentOfNepal_overall_PopAdj,210404_Nepal_GovernmentOfNepal,ENHANCED SURVEILLANCE ON SERO-PREVALENCE OF SARS-COV-2 IN GENERAL POPULATION,2021-04-04,Institutional Report,National,Cross-sectional survey ,Nepal,,,The study population consisted of any person aged six (6) months or older and living in Nepal for a continuous period of at least 4 weeks prior to the first blood sampling date,"Exclusion criteria included refusal to give informed consent or contraindication to venepuncture. Additionally, to allow for enough time for exposure to infection and development of antibodies (IgM or IgG or other types), any person who had arrived in the country less than 4 weeks prior to the blood sample collection date was excluded.

The population under 6 months was excluded for operational difficulties in getting a blood sample and also because young infants have not been found to be significant source of COVID-19 infection.",2020-10-09,2020-10-22,Household and community samples,All,Multiple groups,,,Primary Estimate,,3040,0.14400000000000002,0.11800000000000001,0.17,True,,True,,True,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.975,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Government of Nepal,Government of Nepal,Unity-Aligned,https://mohp.gov.np/attachments/article/708/First%20Sero-prevalence_final_report_04-04-2021.pdf,2021-05-22,2024-03-01,Verified,government_of_nepal_enhanced_2021,NPL
210404_Nepal_GovernmentOfNepal_overall_Female,210404_Nepal_GovernmentOfNepal,ENHANCED SURVEILLANCE ON SERO-PREVALENCE OF SARS-COV-2 IN GENERAL POPULATION,2021-04-04,Institutional Report,National,Cross-sectional survey ,Nepal,,,The study population consisted of any person aged six (6) months or older and living in Nepal for a continuous period of at least 4 weeks prior to the first blood sampling date,"Exclusion criteria included refusal to give informed consent or contraindication to venepuncture. Additionally, to allow for enough time for exposure to infection and development of antibodies (IgM or IgG or other types), any person who had arrived in the country less than 4 weeks prior to the blood sample collection date was excluded.

The population under 6 months was excluded for operational difficulties in getting a blood sample and also because young infants have not been found to be significant source of COVID-19 infection.",2020-10-09,2020-10-22,Household and community samples,Female,Multiple groups,,,Sex/Gender,,1296,0.122,0.09,0.16399999999999998,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.975,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Government of Nepal,Government of Nepal,Unity-Aligned,https://mohp.gov.np/attachments/article/708/First%20Sero-prevalence_final_report_04-04-2021.pdf,2021-07-21,2024-03-01,Verified,government_of_nepal_enhanced_2021,NPL
210404_Nepal_GovernmentOfNepal_overall_84plus,210404_Nepal_GovernmentOfNepal,ENHANCED SURVEILLANCE ON SERO-PREVALENCE OF SARS-COV-2 IN GENERAL POPULATION,2021-04-04,Institutional Report,National,Cross-sectional survey ,Nepal,,,The study population consisted of any person aged six (6) months or older and living in Nepal for a continuous period of at least 4 weeks prior to the first blood sampling date,"Exclusion criteria included refusal to give informed consent or contraindication to venepuncture. Additionally, to allow for enough time for exposure to infection and development of antibodies (IgM or IgG or other types), any person who had arrived in the country less than 4 weeks prior to the blood sample collection date was excluded.

The population under 6 months was excluded for operational difficulties in getting a blood sample and also because young infants have not been found to be significant source of COVID-19 infection.",2020-10-09,2020-10-22,Household and community samples,All,Seniors (65+ years),,,Age,84+,25,0.021,0.002,0.153,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.975,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Government of Nepal,Government of Nepal,Unity-Aligned,https://mohp.gov.np/attachments/article/708/First%20Sero-prevalence_final_report_04-04-2021.pdf,2021-07-21,2024-03-01,Verified,government_of_nepal_enhanced_2021,NPL
210404_Nepal_GovernmentOfNepal_overall_2534,210404_Nepal_GovernmentOfNepal,ENHANCED SURVEILLANCE ON SERO-PREVALENCE OF SARS-COV-2 IN GENERAL POPULATION,2021-04-04,Institutional Report,National,Cross-sectional survey ,Nepal,,,The study population consisted of any person aged six (6) months or older and living in Nepal for a continuous period of at least 4 weeks prior to the first blood sampling date,"Exclusion criteria included refusal to give informed consent or contraindication to venepuncture. Additionally, to allow for enough time for exposure to infection and development of antibodies (IgM or IgG or other types), any person who had arrived in the country less than 4 weeks prior to the blood sample collection date was excluded.

The population under 6 months was excluded for operational difficulties in getting a blood sample and also because young infants have not been found to be significant source of COVID-19 infection.",2020-10-09,2020-10-22,Household and community samples,All,Adults (18-64 years),,,Age,25-34,463,0.139,0.105,0.18100000000000002,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.975,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Government of Nepal,Government of Nepal,Unity-Aligned,https://mohp.gov.np/attachments/article/708/First%20Sero-prevalence_final_report_04-04-2021.pdf,2021-07-21,2024-03-01,Verified,government_of_nepal_enhanced_2021,NPL
210404_Nepal_GovernmentOfNepal_overall_Male,210404_Nepal_GovernmentOfNepal,ENHANCED SURVEILLANCE ON SERO-PREVALENCE OF SARS-COV-2 IN GENERAL POPULATION,2021-04-04,Institutional Report,National,Cross-sectional survey ,Nepal,,,The study population consisted of any person aged six (6) months or older and living in Nepal for a continuous period of at least 4 weeks prior to the first blood sampling date,"Exclusion criteria included refusal to give informed consent or contraindication to venepuncture. Additionally, to allow for enough time for exposure to infection and development of antibodies (IgM or IgG or other types), any person who had arrived in the country less than 4 weeks prior to the blood sample collection date was excluded.

The population under 6 months was excluded for operational difficulties in getting a blood sample and also because young infants have not been found to be significant source of COVID-19 infection.",2020-10-09,2020-10-22,Household and community samples,Male,Multiple groups,,,Sex/Gender,,1744,0.158,0.13,0.19100000000000003,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.975,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Government of Nepal,Government of Nepal,Unity-Aligned,https://mohp.gov.np/attachments/article/708/First%20Sero-prevalence_final_report_04-04-2021.pdf,2021-07-21,2024-03-01,Verified,government_of_nepal_enhanced_2021,NPL
210404_Nepal_GovernmentOfNepal_overall_3544,210404_Nepal_GovernmentOfNepal,ENHANCED SURVEILLANCE ON SERO-PREVALENCE OF SARS-COV-2 IN GENERAL POPULATION,2021-04-04,Institutional Report,National,Cross-sectional survey ,Nepal,,,The study population consisted of any person aged six (6) months or older and living in Nepal for a continuous period of at least 4 weeks prior to the first blood sampling date,"Exclusion criteria included refusal to give informed consent or contraindication to venepuncture. Additionally, to allow for enough time for exposure to infection and development of antibodies (IgM or IgG or other types), any person who had arrived in the country less than 4 weeks prior to the blood sample collection date was excluded.

The population under 6 months was excluded for operational difficulties in getting a blood sample and also because young infants have not been found to be significant source of COVID-19 infection.",2020-10-09,2020-10-22,Household and community samples,All,Adults (18-64 years),,,Age,35-44,487,0.195,0.14400000000000002,0.259,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.975,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Government of Nepal,Government of Nepal,Unity-Aligned,https://mohp.gov.np/attachments/article/708/First%20Sero-prevalence_final_report_04-04-2021.pdf,2021-07-21,2024-03-01,Verified,government_of_nepal_enhanced_2021,NPL
210404_Nepal_GovernmentOfNepal_overall_6574,210404_Nepal_GovernmentOfNepal,ENHANCED SURVEILLANCE ON SERO-PREVALENCE OF SARS-COV-2 IN GENERAL POPULATION,2021-04-04,Institutional Report,National,Cross-sectional survey ,Nepal,,,The study population consisted of any person aged six (6) months or older and living in Nepal for a continuous period of at least 4 weeks prior to the first blood sampling date,"Exclusion criteria included refusal to give informed consent or contraindication to venepuncture. Additionally, to allow for enough time for exposure to infection and development of antibodies (IgM or IgG or other types), any person who had arrived in the country less than 4 weeks prior to the blood sample collection date was excluded.

The population under 6 months was excluded for operational difficulties in getting a blood sample and also because young infants have not been found to be significant source of COVID-19 infection.",2020-10-09,2020-10-22,Household and community samples,All,Seniors (65+ years),,,Age,65-74,208,0.162,0.10300000000000001,0.247,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.975,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Government of Nepal,Government of Nepal,Unity-Aligned,https://mohp.gov.np/attachments/article/708/First%20Sero-prevalence_final_report_04-04-2021.pdf,2021-07-21,2024-03-01,Verified,government_of_nepal_enhanced_2021,NPL
210404_Nepal_GovernmentOfNepal_overall_04,210404_Nepal_GovernmentOfNepal,ENHANCED SURVEILLANCE ON SERO-PREVALENCE OF SARS-COV-2 IN GENERAL POPULATION,2021-04-04,Institutional Report,National,Cross-sectional survey ,Nepal,,,The study population consisted of any person aged six (6) months or older and living in Nepal for a continuous period of at least 4 weeks prior to the first blood sampling date,"Exclusion criteria included refusal to give informed consent or contraindication to venepuncture. Additionally, to allow for enough time for exposure to infection and development of antibodies (IgM or IgG or other types), any person who had arrived in the country less than 4 weeks prior to the blood sample collection date was excluded.

The population under 6 months was excluded for operational difficulties in getting a blood sample and also because young infants have not been found to be significant source of COVID-19 infection.",2020-10-09,2020-10-22,Household and community samples,All,Children and Youth (0-17 years),,,Age,0-4,110,0.095,0.046,0.184,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.975,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Government of Nepal,Government of Nepal,Unity-Aligned,https://mohp.gov.np/attachments/article/708/First%20Sero-prevalence_final_report_04-04-2021.pdf,2021-07-21,2024-03-01,Verified,government_of_nepal_enhanced_2021,NPL
210404_Nepal_GovernmentOfNepal_overall_514,210404_Nepal_GovernmentOfNepal,ENHANCED SURVEILLANCE ON SERO-PREVALENCE OF SARS-COV-2 IN GENERAL POPULATION,2021-04-04,Institutional Report,National,Cross-sectional survey ,Nepal,,,The study population consisted of any person aged six (6) months or older and living in Nepal for a continuous period of at least 4 weeks prior to the first blood sampling date,"Exclusion criteria included refusal to give informed consent or contraindication to venepuncture. Additionally, to allow for enough time for exposure to infection and development of antibodies (IgM or IgG or other types), any person who had arrived in the country less than 4 weeks prior to the blood sample collection date was excluded.

The population under 6 months was excluded for operational difficulties in getting a blood sample and also because young infants have not been found to be significant source of COVID-19 infection.",2020-10-09,2020-10-22,Household and community samples,All,Children and Youth (0-17 years),,,Age,5-14,345,0.085,0.054000000000000006,0.133,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.975,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Government of Nepal,Government of Nepal,Unity-Aligned,https://mohp.gov.np/attachments/article/708/First%20Sero-prevalence_final_report_04-04-2021.pdf,2021-07-21,2024-03-01,Verified,government_of_nepal_enhanced_2021,NPL
210404_Nepal_GovernmentOfNepal_overall_1524,210404_Nepal_GovernmentOfNepal,ENHANCED SURVEILLANCE ON SERO-PREVALENCE OF SARS-COV-2 IN GENERAL POPULATION,2021-04-04,Institutional Report,National,Cross-sectional survey ,Nepal,,,The study population consisted of any person aged six (6) months or older and living in Nepal for a continuous period of at least 4 weeks prior to the first blood sampling date,"Exclusion criteria included refusal to give informed consent or contraindication to venepuncture. Additionally, to allow for enough time for exposure to infection and development of antibodies (IgM or IgG or other types), any person who had arrived in the country less than 4 weeks prior to the blood sample collection date was excluded.

The population under 6 months was excluded for operational difficulties in getting a blood sample and also because young infants have not been found to be significant source of COVID-19 infection.",2020-10-09,2020-10-22,Household and community samples,All,Multiple groups,,,Age,15-24,547,0.14300000000000002,0.10099999999999999,0.198,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.975,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Government of Nepal,Government of Nepal,Unity-Aligned,https://mohp.gov.np/attachments/article/708/First%20Sero-prevalence_final_report_04-04-2021.pdf,2021-07-21,2024-03-01,Verified,government_of_nepal_enhanced_2021,NPL
210404_Nepal_GovernmentOfNepal_overall_7584,210404_Nepal_GovernmentOfNepal,ENHANCED SURVEILLANCE ON SERO-PREVALENCE OF SARS-COV-2 IN GENERAL POPULATION,2021-04-04,Institutional Report,National,Cross-sectional survey ,Nepal,,,The study population consisted of any person aged six (6) months or older and living in Nepal for a continuous period of at least 4 weeks prior to the first blood sampling date,"Exclusion criteria included refusal to give informed consent or contraindication to venepuncture. Additionally, to allow for enough time for exposure to infection and development of antibodies (IgM or IgG or other types), any person who had arrived in the country less than 4 weeks prior to the blood sample collection date was excluded.

The population under 6 months was excluded for operational difficulties in getting a blood sample and also because young infants have not been found to be significant source of COVID-19 infection.",2020-10-09,2020-10-22,Household and community samples,All,Seniors (65+ years),,,Age,75-84,77,0.06,0.016,0.20500000000000002,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.975,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Government of Nepal,Government of Nepal,Unity-Aligned,https://mohp.gov.np/attachments/article/708/First%20Sero-prevalence_final_report_04-04-2021.pdf,2021-07-21,2024-03-01,Verified,government_of_nepal_enhanced_2021,NPL
210404_Nepal_GovernmentOfNepal_overall_5564,210404_Nepal_GovernmentOfNepal,ENHANCED SURVEILLANCE ON SERO-PREVALENCE OF SARS-COV-2 IN GENERAL POPULATION,2021-04-04,Institutional Report,National,Cross-sectional survey ,Nepal,,,The study population consisted of any person aged six (6) months or older and living in Nepal for a continuous period of at least 4 weeks prior to the first blood sampling date,"Exclusion criteria included refusal to give informed consent or contraindication to venepuncture. Additionally, to allow for enough time for exposure to infection and development of antibodies (IgM or IgG or other types), any person who had arrived in the country less than 4 weeks prior to the blood sample collection date was excluded.

The population under 6 months was excluded for operational difficulties in getting a blood sample and also because young infants have not been found to be significant source of COVID-19 infection.",2020-10-09,2020-10-22,Household and community samples,All,Adults (18-64 years),,,Age,55-64,350,0.17,0.12,0.23600000000000002,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.975,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Government of Nepal,Government of Nepal,Unity-Aligned,https://mohp.gov.np/attachments/article/708/First%20Sero-prevalence_final_report_04-04-2021.pdf,2021-07-21,2024-03-01,Verified,government_of_nepal_enhanced_2021,NPL
210404_Nepal_GovernmentOfNepal_overall_4554,210404_Nepal_GovernmentOfNepal,ENHANCED SURVEILLANCE ON SERO-PREVALENCE OF SARS-COV-2 IN GENERAL POPULATION,2021-04-04,Institutional Report,National,Cross-sectional survey ,Nepal,,,The study population consisted of any person aged six (6) months or older and living in Nepal for a continuous period of at least 4 weeks prior to the first blood sampling date,"Exclusion criteria included refusal to give informed consent or contraindication to venepuncture. Additionally, to allow for enough time for exposure to infection and development of antibodies (IgM or IgG or other types), any person who had arrived in the country less than 4 weeks prior to the blood sample collection date was excluded.

The population under 6 months was excluded for operational difficulties in getting a blood sample and also because young infants have not been found to be significant source of COVID-19 infection.",2020-10-09,2020-10-22,Household and community samples,All,Adults (18-64 years),,,Age,45-54,428,0.16,0.109,0.22899999999999998,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9670000000000001,0.975,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Government of Nepal,Government of Nepal,Unity-Aligned,https://mohp.gov.np/attachments/article/708/First%20Sero-prevalence_final_report_04-04-2021.pdf,2021-07-21,2024-03-01,Verified,government_of_nepal_enhanced_2021,NPL
210623_KathmanduValley_NepalHealthResearchCouncil_TestAdj,210623_KathmanduValley_NepalHealthResearchCouncil,"Seroprevalence of COVID-19 among health workers in the Kathmandu valley, Nepal (SEVID-KaV): a longitudinal cohort study",2021-06-23,Preprint,Regional,Cross-sectional survey ,Nepal,Bagmati Pradesh Province,Kathmandu Valley,"For each of the 20 clusters, we included the first 40 participants based on their order in the randomized sampling list, resulting in 800 records in our analytic sample",,2020-12-03,2020-12-25,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Test Adj,800,0.3899,0.2908,0.4391,True,True,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.893,0.9920000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Kiran Raj Pandey,Nepal Health Research Council,Not Unity-Aligned,10.21203/rs.3.rs-626260/v1,2021-07-05,2023-08-15,Unverified,kiranrajpandey2021b,NPL
210706_Kathmandu_ManmohanMemorialMedicalCollege_primary,210706_Kathmandu_ManmohanMemorialMedicalCollege,ANTI - SARS-CoV-2 ANTIBODY SCREENING IN HEALTH CARE WORKERS AND ITS CORRELATION WITH CLINICAL PRESENTATION,2021-07-06,Preprint,Local,Cross-sectional survey ,Nepal,,Kathmandu,Healthcare workers working at MMTH were conveniently selected for the study,HCWs who refused to give informed written consent (n=16) were excluded from the study,2020-11-15,2021-01-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,185,0.222,,,True,,,,True,Convenience,SARS-CoV-2 IgM/IgG Antibody Assay Kit,Zybio Inc.,Other,Serum,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,Suraj Aryal,Manmohan Memorial Medical College,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.01.21259884v1.full-text,2021-07-13,2024-03-01,Verified,aryal_anti_2021,NPL
210830_Nepal_MinistryofHealthandPopulation_Overall,210830_Nepal_MinistryofHealthandPopulation,"Over two-thirds population has Covid-19 antibodies, seroprevalence study shows",2021-08-30,News and Media,National,Cross-sectional survey ,Nepal,,,"Blood samples were collected from 76 districts (excluding Manang) on a random sampling basis between July 5 and August 14 (taken from updated post by the Kathmandu Post on Sep 3, 2021: https://tkpo.st/3gWTgRW)",,2021-07-05,2021-08-14,Household and community samples,All,Multiple groups,,,Primary Estimate,,13161,0.6859999999999999,,,True,,,,True,Simplified probability,Not reported/ Unable to specify,,,,,,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,Shuvam Dhungana,Ministry of Health and Population,Not Unity-Aligned,https://kathmandupost.com/health/2021/08/30/over-two-thirds-population-has-covid-19-antibodies-seroprevalence-study-shows,2021-09-07,2022-07-16,Verified,dhungana_over_2021,NPL
220201_Kathmandu_ManmohanMemorialMedicalCollegeAndTeachingHospital_Overall,220201_Kathmandu_ManmohanMemorialMedicalCollegeAndTeachingHospital,"Anti-SARS-CoV-2 Antibody Screening in Healthcare Workers and Its Correlation with Clinical Presentation in Tertiary Care Hospital, Kathmandu, Nepal, from November 2020 to January 2021.",2022-02-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Nepal,,Kathmandu,"""HCWs, including administrative staff working at MMTH [Manmohan Memorial Medical College and Teaching Hospital] at least 6 months before the sample collection date, were invited to participate in the study voluntarily. The study was conducted in all departments of the hospital.""","""HCWs who refused to give the informed written consent (n = 16) were excluded from the study.""",2020-11-15,2021-01-15,Health care workers and caregivers,All,Adults (18-64 years),20.0,,Primary Estimate,,185,0.22160000000000002,,,True,,,,True,Convenience,SARS-CoV-2 IgM/IgG Antibody Assay Kit,Zybio Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Suraj Aryal,Manmohan Memorial Medical College and Teaching Hospital,Not Unity-Aligned,https://dx.doi.org/10.1155/2022/8515051,2022-02-20,2024-03-01,Unverified,aryal_anti-sars-cov-2_2022,NPL
220201_Kathmandu_ManmohanMemorialMedicalCollegeAndTeachingHospital_Age_20–30,220201_Kathmandu_ManmohanMemorialMedicalCollegeAndTeachingHospital,"Anti-SARS-CoV-2 Antibody Screening in Healthcare Workers and Its Correlation with Clinical Presentation in Tertiary Care Hospital, Kathmandu, Nepal, from November 2020 to January 2021.",2022-02-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Nepal,,Kathmandu,"""HCWs, including administrative staff working at MMTH [Manmohan Memorial Medical College and Teaching Hospital] at least 6 months before the sample collection date, were invited to participate in the study voluntarily. The study was conducted in all departments of the hospital.""","""HCWs who refused to give the informed written consent (n = 16) were excluded from the study.""",2020-11-15,2021-01-15,Health care workers and caregivers,All,Adults (18-64 years),20.0,30.0,Age,Age: 20-30,115,0.2261,,,,,,,,Convenience,SARS-CoV-2 IgM/IgG Antibody Assay Kit,Zybio Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Suraj Aryal,Manmohan Memorial Medical College and Teaching Hospital,Not Unity-Aligned,https://dx.doi.org/10.1155/2022/8515051,2022-02-20,2024-03-01,Unverified,aryal_anti-sars-cov-2_2022,NPL
220201_Kathmandu_ManmohanMemorialMedicalCollegeAndTeachingHospital_Age_31–40,220201_Kathmandu_ManmohanMemorialMedicalCollegeAndTeachingHospital,"Anti-SARS-CoV-2 Antibody Screening in Healthcare Workers and Its Correlation with Clinical Presentation in Tertiary Care Hospital, Kathmandu, Nepal, from November 2020 to January 2021.",2022-02-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Nepal,,Kathmandu,"""HCWs, including administrative staff working at MMTH [Manmohan Memorial Medical College and Teaching Hospital] at least 6 months before the sample collection date, were invited to participate in the study voluntarily. The study was conducted in all departments of the hospital.""","""HCWs who refused to give the informed written consent (n = 16) were excluded from the study.""",2020-11-15,2021-01-15,Health care workers and caregivers,All,Adults (18-64 years),31.0,40.0,Age,Age: 31-40,46,0.2391,,,,,,,,Convenience,SARS-CoV-2 IgM/IgG Antibody Assay Kit,Zybio Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Suraj Aryal,Manmohan Memorial Medical College and Teaching Hospital,Not Unity-Aligned,https://dx.doi.org/10.1155/2022/8515051,2022-02-20,2024-03-01,Unverified,aryal_anti-sars-cov-2_2022,NPL
220201_Kathmandu_ManmohanMemorialMedicalCollegeAndTeachingHospital_Age_41–50,220201_Kathmandu_ManmohanMemorialMedicalCollegeAndTeachingHospital,"Anti-SARS-CoV-2 Antibody Screening in Healthcare Workers and Its Correlation with Clinical Presentation in Tertiary Care Hospital, Kathmandu, Nepal, from November 2020 to January 2021.",2022-02-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Nepal,,Kathmandu,"""HCWs, including administrative staff working at MMTH [Manmohan Memorial Medical College and Teaching Hospital] at least 6 months before the sample collection date, were invited to participate in the study voluntarily. The study was conducted in all departments of the hospital.""","""HCWs who refused to give the informed written consent (n = 16) were excluded from the study.""",2020-11-15,2021-01-15,Health care workers and caregivers,All,Adults (18-64 years),41.0,50.0,Age,Age: 41-50,19,0.15789999999999998,,,,,,,,Convenience,SARS-CoV-2 IgM/IgG Antibody Assay Kit,Zybio Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Suraj Aryal,Manmohan Memorial Medical College and Teaching Hospital,Not Unity-Aligned,https://dx.doi.org/10.1155/2022/8515051,2022-02-20,2024-03-01,Unverified,aryal_anti-sars-cov-2_2022,NPL
220201_Kathmandu_ManmohanMemorialMedicalCollegeAndTeachingHospital_Age_Above50,220201_Kathmandu_ManmohanMemorialMedicalCollegeAndTeachingHospital,"Anti-SARS-CoV-2 Antibody Screening in Healthcare Workers and Its Correlation with Clinical Presentation in Tertiary Care Hospital, Kathmandu, Nepal, from November 2020 to January 2021.",2022-02-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Nepal,,Kathmandu,"""HCWs, including administrative staff working at MMTH [Manmohan Memorial Medical College and Teaching Hospital] at least 6 months before the sample collection date, were invited to participate in the study voluntarily. The study was conducted in all departments of the hospital.""","""HCWs who refused to give the informed written consent (n = 16) were excluded from the study.""",2020-11-15,2021-01-15,Health care workers and caregivers,All,Adults (18-64 years),50.0,,Age,Age: Above 50,5,0.2,,,,,,,,Convenience,SARS-CoV-2 IgM/IgG Antibody Assay Kit,Zybio Inc.,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Suraj Aryal,Manmohan Memorial Medical College and Teaching Hospital,Not Unity-Aligned,https://dx.doi.org/10.1155/2022/8515051,2022-02-20,2024-03-01,Unverified,aryal_anti-sars-cov-2_2022,NPL
200824_Rotterdam_ErasmusMedicalCentre_1_March,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Multiple groups,,,Primary Estimate,,879,0.002,,,True,,,,True,Convenience,Author designed (IFA) - NON-MULTIPLEXED,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_Secto_Age1-2,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Children and Youth (0-17 years),1.0,2.0,Test used,Tested for Spike protein ectodomain proteins,75,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_Age1-2,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Children and Youth (0-17 years),1.0,2.0,Age,1-2,75,0.0,,,,,,,,Convenience,Author designed (IFA) - NON-MULTIPLEXED,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_N,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Multiple groups,,,Test used,Tested for Nucleocapsid proteins,879,0.005,,,,,,,,Convenience,Author designed (IFA) - NON-MULTIPLEXED,,,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_Secto_Age40-60,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Adults (18-64 years),40.0,60.0,Test used,Tested for Spike protein ectodomain proteins,134,0.015,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_S1_Age5-10,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Children and Youth (0-17 years),5.0,10.0,Test used,Tested for Spike-1 proteins,96,0.01,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_S1_Age60-80,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Seniors (65+ years),60.0,80.0,Test used,Tested for Spike-1 proteins,124,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_Secto_Age20-40,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Adults (18-64 years),20.0,40.0,Test used,Tested for Spike protein ectodomain proteins,131,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_S1_Age1-2,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Children and Youth (0-17 years),1.0,2.0,Test used,Tested for Spike-1 proteins,75,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_Age10-20,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Children and Youth (0-17 years),10.0,20.0,Age,10-20,131,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_N_Age60-80,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Seniors (65+ years),60.0,80.0,Test used,Tested for Nucleocapsid proteins,124,0.016,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_N_Age1-2,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Children and Youth (0-17 years),1.0,2.0,Test used,Tested for Nucleocapsid proteins,75,0.0,,,,,,,,Convenience,Author designed (IFA) - NON-MULTIPLEXED,,,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_Age40-60,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Adults (18-64 years),40.0,60.0,Age,40-60 ,134,0.006999999999999999,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_S1_Age20-40,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Adults (18-64 years),20.0,40.0,Test used,Tested for Spike-1 proteins,131,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_Age20-40,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Adults (18-64 years),20.0,40.0,Age,20-40,131,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_S1_Age40-60,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Adults (18-64 years),40.0,60.0,Test used,Tested for Spike-1 proteins,134,0.006999999999999999,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_N_Age10-20,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Children and Youth (0-17 years),10.0,20.0,Test used,Tested for Nucleocapsid proteins,131,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_Secto_Age80,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Seniors (65+ years),80.0,,Test used,Tested for Spike protein ectodomain proteins,105,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_S1_Age80,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Seniors (65+ years),80.0,,Test used,Tested for Spike-1 proteins,105,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_N_Age5-10,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Children and Youth (0-17 years),5.0,10.0,Test used,Tested for Nucleocapsid proteins,96,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_S1_Age6-12mo,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Children and Youth (0-17 years),0.0,1.0,Test used,Tested for Spike-1 proteins,41,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_Age80,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Seniors (65+ years),80.0,,Age,=>80,105,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_Age6-12mo,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Children and Youth (0-17 years),0.0,1.0,Age,0.5-1 ,41,0.0,,,,,,,,Convenience,Author designed (IFA) - NON-MULTIPLEXED,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_N_Age6-12mo,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Children and Youth (0-17 years),0.0,1.0,Test used,Tested for Nucleocapsid proteins,41,0.0,,,,,,,,Convenience,Author designed (IFA) - NON-MULTIPLEXED,,,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_S1,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Multiple groups,,,Test used,Tested for Spike-1 proteins,879,0.002,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_Secto_Age6-12mo,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Children and Youth (0-17 years),0.0,1.0,Test used,Tested for Spike protein ectodomain proteins,41,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_N_Age40-60,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Adults (18-64 years),40.0,60.0,Test used,Tested for Nucleocapsid proteins,134,0.006999999999999999,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_N_Age80,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Seniors (65+ years),80.0,,Test used,Tested for Nucleocapsid proteins,105,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_Age5-10,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Children and Youth (0-17 years),5.0,10.0,Age,5-10,96,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_S1_Age10-20,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Children and Youth (0-17 years),10.0,20.0,Test used,Tested for Spike-1 proteins,131,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_Age2-5,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Children and Youth (0-17 years),2.0,5.0,Age,2-5,42,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_Secto_Age2-5,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Children and Youth (0-17 years),2.0,5.0,Test used,Tested for Spike protein ectodomain proteins,42,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_N_Age20-40,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Adults (18-64 years),20.0,40.0,Test used,Tested for Nucleocapsid proteins,131,0.008,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_S1_Age2-5,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Children and Youth (0-17 years),2.0,5.0,Test used,Tested for Spike-1 proteins,42,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_Secto_Age10-20,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Children and Youth (0-17 years),10.0,20.0,Test used,Tested for Spike protein ectodomain proteins,131,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_Secto_Age60-80,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Seniors (65+ years),60.0,80.0,Test used,Tested for Spike protein ectodomain proteins,124,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_Age60-80,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Seniors (65+ years),60.0,80.0,Age,60-80,124,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_N_Age2-5,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Children and Youth (0-17 years),2.0,5.0,Test used,Tested for Nucleocapsid proteins,42,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_Secto,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Multiple groups,,,Test used,Tested for Spike protein ectodomain proteins,879,0.002,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T1_Secto_Age5-10,200824_Rotterdam_ErasmusMedicalCentre_1_March,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-03-02,2020-03-06,Residual sera,All,Children and Youth (0-17 years),5.0,10.0,Test used,Tested for Spike protein ectodomain proteins,96,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_2_April,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Multiple groups,,,Primary Estimate,,729,0.025,,,True,,,,True,Convenience,Author designed (IFA) - NON-MULTIPLEXED,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_S1_Age10-20,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Children and Youth (0-17 years),10.0,20.0,Test used,Tested for Spike-1 proteins,139,0.006999999999999999,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_S1_Age80,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Seniors (65+ years),80.0,,Test used,Tested for Spike-1 proteins,82,0.024,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_Secto,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Multiple groups,,,Test used,Tested for Spike protein ectodomain proteins,729,0.025,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_Secto_Age10-20,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Children and Youth (0-17 years),10.0,20.0,Test used,Tested for Spike protein ectodomain proteins,139,0.006999999999999999,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_Age20-40,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Adults (18-64 years),20.0,40.0,Age,Age 20-40 years,140,0.013999999999999999,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_Secto_Age60-80,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Seniors (65+ years),60.0,80.0,Test used,Tested for Spike protein ectodomain proteins,139,0.05,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_Age10-20,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Children and Youth (0-17 years),10.0,20.0,Age,Age 10-20 years,139,0.006999999999999999,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_Secto_Age5-10,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Children and Youth (0-17 years),5.0,10.0,Test used,Tested for Spike protein ectodomain proteins,34,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_Age1-2,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Children and Youth (0-17 years),1.0,2.0,Age,Age 1-2 years,14,0.0,,,,,,,,Convenience,Author designed (IFA) - NON-MULTIPLEXED,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_Age6-12mo,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Children and Youth (0-17 years),0.0,1.0,Age,Age 6-12 months,17,0.0,,,,,,,,Convenience,Author designed (IFA) - NON-MULTIPLEXED,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_S1_Age5-10,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Children and Youth (0-17 years),5.0,10.0,Test used,Tested for Spike-1 proteins,34,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_Age5-10,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Children and Youth (0-17 years),5.0,10.0,Age,Age 5-10 years,34,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_Secto_Age6-12mo,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Children and Youth (0-17 years),0.0,1.0,Test used,Tested for Spike protein ectodomain proteins,17,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_N_Age1-2,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Children and Youth (0-17 years),1.0,2.0,Test used,Tested for Nucleocapsid proteins,14,0.0,,,,,,,,Convenience,Author designed (IFA) - NON-MULTIPLEXED,,,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_Age2-5,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Children and Youth (0-17 years),2.0,5.0,Age,Age 2-5 years,24,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_N_Age6-12mo,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Children and Youth (0-17 years),0.0,1.0,Test used,Tested for Nucleocapsid proteins,17,0.0,,,,,,,,Convenience,Author designed (IFA) - NON-MULTIPLEXED,,,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_Secto_Age20-40,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Adults (18-64 years),20.0,40.0,Test used,Tested for Spike protein ectodomain proteins,140,0.021,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_S1_Age60-80,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Seniors (65+ years),60.0,80.0,Test used,Tested for Spike-1 proteins,139,0.05,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_N_Age10-20,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Children and Youth (0-17 years),10.0,20.0,Test used,Tested for Nucleocapsid proteins,139,0.006999999999999999,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_Secto_Age80,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Seniors (65+ years),80.0,,Test used,Tested for Spike protein ectodomain proteins,82,0.024,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_S1,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Multiple groups,,,Test used,Tested for Spike-1 proteins,729,0.025,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_Secto_Age1-2,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Children and Youth (0-17 years),1.0,2.0,Test used,Tested for Spike protein ectodomain proteins,14,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_Age60-80,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Seniors (65+ years),60.0,80.0,Age,Age 60-80 years,139,0.05,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_S1_Age20-40,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Adults (18-64 years),20.0,40.0,Test used,Tested for Spike-1 proteins,140,0.021,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_S1_Age1-2,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Children and Youth (0-17 years),1.0,2.0,Test used,Tested for Spike-1 proteins,14,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_N,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Multiple groups,,,Test used,Tested for Nucleocapsid proteins,729,0.028999999999999998,,,,,,,,Convenience,Author designed (IFA) - NON-MULTIPLEXED,,,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_S1_Age40-60,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Adults (18-64 years),40.0,60.0,Test used,Tested for Spike-1 proteins,140,0.036000000000000004,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_N_Age2-5,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Children and Youth (0-17 years),2.0,5.0,Test used,Tested for Nucleocapsid proteins,24,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_Age40-60,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Adults (18-64 years),40.0,60.0,Age,Age 40-60 years,140,0.036000000000000004,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_Age80,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Seniors (65+ years),80.0,,Age,Age 80+ years,82,0.024,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_Secto_Age2-5,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Children and Youth (0-17 years),2.0,5.0,Test used,Tested for Spike protein ectodomain proteins,24,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_S1_Age2-5,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Children and Youth (0-17 years),2.0,5.0,Test used,Tested for Spike-1 proteins,24,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_N_Age40-60,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Adults (18-64 years),40.0,60.0,Test used,Tested for Nucleocapsid proteins,140,0.036000000000000004,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_N_Age80,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Seniors (65+ years),80.0,,Test used,Tested for Nucleocapsid proteins,82,0.024,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_N_Age20-40,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Adults (18-64 years),20.0,40.0,Test used,Tested for Nucleocapsid proteins,140,0.028999999999999998,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_N_Age60-80,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Seniors (65+ years),60.0,80.0,Test used,Tested for Nucleocapsid proteins,139,0.065,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_Secto_Age40-60,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Adults (18-64 years),40.0,60.0,Test used,Tested for Spike protein ectodomain proteins,140,0.036000000000000004,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_N_Age5-10,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Children and Youth (0-17 years),5.0,10.0,Test used,Tested for Nucleocapsid proteins,34,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
200824_Rotterdam_ErasmusMedicalCentre_T2_S1_Age6-12mo,200824_Rotterdam_ErasmusMedicalCentre_2_April,"Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands",2020-08-24,Preprint,Local,Repeated cross-sectional study,Netherlands,,Rotterdam, Leftover lithium heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus medical center.," Samples from patients in which a SARS-CoV-2 PCR was
170 performed were excluded regardless of the result. ",2020-04-03,2020-04-07,Residual sera,All,Children and Youth (0-17 years),0.0,1.0,Test used,Tested for Spike-1 proteins,17,0.0,,,,,,,,Convenience,Author designed (ELISA) -Spike,,,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,Brenda Westerhuis,Erasmus Medical Centre,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.21.20177857v1,2020-10-19,2022-07-16,Verified,noauthor_homologous_nodate,NLD
201112_Netherlands_AmsterdamUMC_GenPop_Overall_1Test,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Netherlands,,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,All,Multiple groups,18.0,72.0,Primary Estimate,,7361,0.034,,,True,,,,True,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,Validated by independent authors/third party/non-developers,1.0,0.991,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2020-05-25,2024-03-01,Verified,slot_low_2020,NLD
201112_Netherlands_AmsterdamUMC_GenPop_31to40,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Netherlands,,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,All,Adults (18-64 years),31.0,40.0,Age,31-40,882,0.025,0.016,0.038,,,,,,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,Validated by independent authors/third party/non-developers,1.0,0.991,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2020-05-25,2024-03-01,Verified,slot_low_2020,NLD
201112_Netherlands_AmsterdamUMC_Amsterdam,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,Amsterdam,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,All,Multiple groups,18.0,72.0,Geographical area,Amsterdam,183,0.033,,,,,,,,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2021-03-04,2024-03-01,Verified,slot_low_2020,NLD
201112_Netherlands_AmsterdamUMC_HartvoorBrabant,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,Hart voor Brabant,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,All,Multiple groups,18.0,72.0,Geographical area,Hart voor Brabant,617,0.057999999999999996,,,,,,,,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2021-03-04,2024-03-01,Verified,slot_low_2020,NLD
201112_Netherlands_AmsterdamUMC_GenPop_60to72,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Netherlands,,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,All,Seniors (65+ years),60.0,72.0,Age,60-72,1742,0.027000000000000003,0.02,0.038,,,,,,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,Validated by independent authors/third party/non-developers,1.0,0.991,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2020-05-25,2024-03-01,Verified,slot_low_2020,NLD
201112_Netherlands_AmsterdamUMC_NoordenOostGelderland,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,Noord en Oost Gelderland,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,All,Multiple groups,18.0,72.0,Geographical area,Noord en Oost Gelderland,279,0.028999999999999998,,,,,,,,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2021-03-04,2024-03-01,Verified,slot_low_2020,NLD
201112_Netherlands_AmsterdamUMC_WestBrabant,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,West-Brabant,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,All,Multiple groups,18.0,72.0,Geographical area,West-Brabant,216,0.042,,,,,,,,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2021-03-04,2024-03-01,Verified,slot_low_2020,NLD
201112_Netherlands_AmsterdamUMC_Drenthe,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,Drenthe,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,All,Multiple groups,18.0,72.0,Geographical area,Drenthe,158,0.006,,,,,,,,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2021-03-04,2024-03-01,Verified,slot_low_2020,NLD
201112_Netherlands_AmsterdamUMC_Brabant-Zuid,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,Brabant-Zuid Oost,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,All,Multiple groups,18.0,72.0,Geographical area,Brabant-Zuid Oost,105,0.095,,,,,,,,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2021-03-04,2024-03-01,Verified,slot_low_2020,NLD
201112_Netherlands_AmsterdamUMC_Flevoland,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,Flevoland,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,All,Multiple groups,18.0,72.0,Geographical area,Flevoland,24,0.0,,,,,,,,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2021-03-04,2024-03-01,Verified,slot_low_2020,NLD
201112_Netherlands_AmsterdamUMC_Zeeland,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,Zeeland,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,All,Multiple groups,18.0,72.0,Geographical area,Zeeland,238,0.013000000000000001,,,,,,,,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2021-03-04,2024-03-01,Verified,slot_low_2020,NLD
201112_Netherlands_AmsterdamUMC_ZuidLimburg,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,Zuid Limburg,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,All,Multiple groups,18.0,72.0,Geographical area,Zuid Limburg,445,0.036000000000000004,,,,,,,,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2021-03-04,2024-03-01,Verified,slot_low_2020,NLD
201112_Netherlands_AmsterdamUMC_ZuidHollandZuid,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,Zuid Holland-Zuid,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,All,Multiple groups,18.0,72.0,Geographical area,Zuid Holland-Zuid,323,0.019,,,,,,,,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2021-03-04,2024-03-01,Verified,slot_low_2020,NLD
201112_Netherlands_AmsterdamUMC_GenPop_18to30,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Netherlands,,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,All,Adults (18-64 years),18.0,30.0,Age,18-30,1251,0.042,0.031000000000000003,0.054000000000000006,,,,,,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,Validated by independent authors/third party/non-developers,1.0,0.991,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2020-05-25,2024-03-01,Verified,slot_low_2020,NLD
201112_Netherlands_AmsterdamUMC_GenPop_Women,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Netherlands,,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,Female,Multiple groups,18.0,72.0,Sex/Gender,Female,3510,0.0273,,,,,,,,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,Validated by independent authors/third party/non-developers,1.0,0.991,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2020-07-05,2024-03-01,Verified,slot_low_2020,NLD
201112_Netherlands_AmsterdamUMC_HollandsNoorden,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,Hollands Noorden,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,All,Multiple groups,18.0,72.0,Geographical area,Hollands Noorden,340,0.024,,,,,,,,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2021-03-04,2024-03-01,Verified,slot_low_2020,NLD
201112_Netherlands_AmsterdamUMC_GenPop_51to60,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Netherlands,,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,All,Adults (18-64 years),51.0,60.0,Age,51-60,2131,0.023,0.017,0.03,,,,,,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,Validated by independent authors/third party/non-developers,1.0,0.991,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2020-05-25,2024-03-01,Verified,slot_low_2020,NLD
201112_Netherlands_AmsterdamUMC_GenPop_41to50,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Netherlands,,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,All,Adults (18-64 years),41.0,50.0,Age,41-50,1354,0.023,0.016,0.032,,,,,,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,Validated by independent authors/third party/non-developers,1.0,0.991,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2020-05-25,2024-03-01,Verified,slot_low_2020,NLD
201112_Netherlands_AmsterdamUMC_Gelderland-Zuid,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,Gelderland-Zuid,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,All,Multiple groups,18.0,72.0,Geographical area,Gelderland-Zuid,276,0.033,,,,,,,,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2021-03-04,2024-03-01,Verified,slot_low_2020,NLD
201112_Netherlands_AmsterdamUMC_Groningen,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,Groningen,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,All,Multiple groups,18.0,72.0,Geographical area,Groningen,221,0.019,,,,,,,,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2021-03-04,2024-03-01,Verified,slot_low_2020,NLD
201112_Netherlands_AmsterdamUMC_Haaglanden,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,Haaglanden,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,All,Multiple groups,18.0,72.0,Geographical area,Haaglanden,399,0.013000000000000001,,,,,,,,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2021-03-04,2024-03-01,Verified,slot_low_2020,NLD
201112_Netherlands_AmsterdamUMC_GooienVech,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,Gooi en Vechtstreek,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,All,Multiple groups,18.0,72.0,Geographical area,Gooi en Vechtstreek,26,0.0,,,,,,,,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2021-03-04,2024-03-01,Verified,slot_low_2020,NLD
201112_Netherlands_AmsterdamUMC_HollandsMidden,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,Hollands Midden,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,All,Multiple groups,18.0,72.0,Geographical area,Hollands Midden,657,0.015,,,,,,,,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2021-03-04,2024-03-01,Verified,slot_low_2020,NLD
201112_Netherlands_AmsterdamUMC_GelderlandMidden,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,Gelderland Midden,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,All,Multiple groups,18.0,72.0,Geographical area,Gelderland Midden,203,0.005,,,,,,,,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2021-03-04,2024-03-01,Verified,slot_low_2020,NLD
201112_Netherlands_AmsterdamUMC_NoordenMiddenLimburg,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,Noord en Midden Limburg,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,All,Multiple groups,18.0,72.0,Geographical area,Noord en Midden Limburg,277,0.069,,,,,,,,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2021-03-04,2024-03-01,Verified,slot_low_2020,NLD
201112_Netherlands_AmsterdamUMC_GenPop_Men,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Netherlands,,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,Male,Multiple groups,18.0,72.0,Sex/Gender,Male,3838,0.027000000000000003,,,,,,,,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,Validated by independent authors/third party/non-developers,1.0,0.991,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2020-07-05,2024-03-01,Verified,slot_low_2020,NLD
201112_Netherlands_AmsterdamUMC_Volksgenzondheid,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,Volksgezondheid Utrecht,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,All,Multiple groups,18.0,72.0,Geographical area,Volksgezondheid Utrecht,273,0.026000000000000002,,,,,,,,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2021-03-04,2024-03-01,Verified,slot_low_2020,NLD
201112_Netherlands_AmsterdamUMC_RotterdamRijnmond,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,Rotterdam-Rijnmond,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,All,Multiple groups,18.0,72.0,Geographical area,Rotterdam-Rijnmond,237,0.004,,,,,,,,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2021-03-04,2024-03-01,Verified,slot_low_2020,NLD
201112_Netherlands_AmsterdamUMC_Twente,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,Twente,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,All,Multiple groups,18.0,72.0,Geographical area,Twente,254,0.035,,,,,,,,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2021-03-04,2024-03-01,Verified,slot_low_2020,NLD
201112_Netherlands_AmsterdamUMC_Zaanstreek,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,Zaanstreek/Waterland,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,All,Multiple groups,18.0,72.0,Geographical area,Zaanstreek/Waterland,221,0.018000000000000002,,,,,,,,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2021-03-04,2024-03-01,Verified,slot_low_2020,NLD
201112_Netherlands_AmsterdamUMC_Kennemerland,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,Kennemenrland,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,All,Multiple groups,18.0,72.0,Geographical area,Kennemenrland,148,0.02,,,,,,,,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2021-03-04,2024-03-01,Verified,slot_low_2020,NLD
201112_Netherlands_AmsterdamUMC_Fryslan,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,Fryslan,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,All,Multiple groups,18.0,72.0,Geographical area,Fryslan,389,0.003,,,,,,,,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2021-03-04,2024-03-01,Verified,slot_low_2020,NLD
201112_Netherlands_AmsterdamUMC_IJsseland,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,IJsselland,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,All,Multiple groups,18.0,72.0,Geographical area,IJsselland,328,0.018000000000000002,,,,,,,,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2021-03-04,2024-03-01,Verified,slot_low_2020,NLD
201112_Netherlands_AmsterdamUMC_GenPop_Overall_ReTest,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Netherlands,,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,All,Multiple groups,18.0,72.0,Test used,Overall re-tested positive,7631,0.031000000000000003,,,,,,,,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2021-03-04,2024-03-01,Verified,slot_low_2020,NLD
201112_Netherlands_AmsterdamUMC_Utrecht,201112_Netherlands_AmsterdamUMC,Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.,2020-11-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,Utrecht,,"We studied plasma and serum samples of 7,361 adult blood plasma donors and 153 convalescent plasma donors from throughout the Netherlands, collected from 1 until 15 April 2020.  Subjects were enrolled in the study if they were accepted for routine donation, without further selection and in accordance with European laws and guidelines34,35. As a consequence, all subjects were healthy at the time of donation and had not reported health issues in the 2 weeks before donation. Subjects were defined by age (18–72 years), gender and zip code of the subject’s residence. ",donors who were ill and have not recovered at least two weeks before.,2020-04-01,2020-04-15,Blood donors,All,Multiple groups,18.0,72.0,Geographical area,Utrecht,514,0.035,,,,,,,,Sequential,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ed Slot,Amsterdam UMC,Unity-Aligned,https://www.nature.com/articles/s41467-020-19481-7,2021-03-04,2024-03-01,Verified,slot_low_2020,NLD
201128_Netherlands_CentreforInfectiousDiseaseControl_LowVaccineCoverage_overall,201128_Netherlands_CentreforInfectiousDiseaseControl_LowVaccineCoverage,Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave,2020-11-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Netherlands,,,Participants who had taken part in a large-scale nationwide serosurveillance study (PIENTER-3) in 2016/2017 from low vaccination coverage municipalities,,2020-03-31,2020-05-11,Household and community samples,All,Multiple groups,2.0,90.0,Primary Estimate,,570,0.028999999999999998,0.013999999999999999,0.063,True,True,True,,True,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.99,['Moderate'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,Unclear,Eric Vos,Centre for Infectious Disease Control,Not Unity-Aligned,https://dx.doi.org/10.1136/jech-2020-215678,2021-01-24,2022-07-16,Verified,vos_nationwide_2020,NLD
201128_Netherlands_CentreforInfectiousDiseaseControl_LowVaccineCoverage_age2-17,201128_Netherlands_CentreforInfectiousDiseaseControl_LowVaccineCoverage,Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave,2020-11-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Netherlands,,,Participants who had taken part in a large-scale nationwide serosurveillance study (PIENTER-3) in 2016/2017 from low vaccination coverage municipalities,,2020-03-31,2020-05-11,Household and community samples,All,Children and Youth (0-17 years),2.0,17.0,Age,2-17,93,0.0,,,,True,True,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.99,['Moderate'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,Unclear,Eric Vos,Centre for Infectious Disease Control,Not Unity-Aligned,https://dx.doi.org/10.1136/jech-2020-215678,2021-01-24,2022-07-16,Verified,vos_nationwide_2020,NLD
201128_Netherlands_CentreforInfectiousDiseaseControl_LowVaccineCoverage_female,201128_Netherlands_CentreforInfectiousDiseaseControl_LowVaccineCoverage,Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave,2020-11-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Netherlands,,,Participants who had taken part in a large-scale nationwide serosurveillance study (PIENTER-3) in 2016/2017 from low vaccination coverage municipalities,,2020-03-31,2020-05-11,Household and community samples,Female,Multiple groups,2.0,90.0,Sex/Gender,Female,337,0.019,0.006999999999999999,0.049,,True,True,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.99,['Moderate'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,Unclear,Eric Vos,Centre for Infectious Disease Control,Not Unity-Aligned,https://dx.doi.org/10.1136/jech-2020-215678,2021-01-24,2022-07-16,Verified,vos_nationwide_2020,NLD
201128_Netherlands_CentreforInfectiousDiseaseControl_LowVaccineCoverage_male,201128_Netherlands_CentreforInfectiousDiseaseControl_LowVaccineCoverage,Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave,2020-11-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Netherlands,,,Participants who had taken part in a large-scale nationwide serosurveillance study (PIENTER-3) in 2016/2017 from low vaccination coverage municipalities,,2020-03-31,2020-05-11,Household and community samples,Male,Multiple groups,2.0,90.0,Sex/Gender,,233,0.04,0.015,0.106,,True,True,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.99,['Moderate'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,Unclear,Eric Vos,Centre for Infectious Disease Control,Not Unity-Aligned,https://dx.doi.org/10.1136/jech-2020-215678,2021-01-24,2022-07-16,Verified,vos_nationwide_2020,NLD
201128_Netherlands_CentreforInfectiousDiseaseControl_LowVaccineCoverage_age18-39,201128_Netherlands_CentreforInfectiousDiseaseControl_LowVaccineCoverage,Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave,2020-11-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Netherlands,,,Participants who had taken part in a large-scale nationwide serosurveillance study (PIENTER-3) in 2016/2017 from low vaccination coverage municipalities,,2020-03-31,2020-05-11,Household and community samples,All,Adults (18-64 years),18.0,39.0,Age,18-39,196,0.068,0.03,0.146,,True,True,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.99,['Moderate'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,Unclear,Eric Vos,Centre for Infectious Disease Control,Not Unity-Aligned,https://dx.doi.org/10.1136/jech-2020-215678,2021-01-24,2022-07-16,Verified,vos_nationwide_2020,NLD
201128_Netherlands_CentreforInfectiousDiseaseControl_LowVaccineCoverage_age40-64,201128_Netherlands_CentreforInfectiousDiseaseControl_LowVaccineCoverage,Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave,2020-11-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Netherlands,,,Participants who had taken part in a large-scale nationwide serosurveillance study (PIENTER-3) in 2016/2017 from low vaccination coverage municipalities,,2020-03-31,2020-05-11,Household and community samples,All,Adults (18-64 years),40.0,64.0,Age,40-64,198,0.024,0.008,0.083,,True,True,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.99,['Moderate'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,Unclear,Eric Vos,Centre for Infectious Disease Control,Not Unity-Aligned,https://dx.doi.org/10.1136/jech-2020-215678,2021-01-24,2022-07-16,Verified,vos_nationwide_2020,NLD
201128_Netherlands_CentreforInfectiousDiseaseControl_LowVaccineCoverage_age65-90,201128_Netherlands_CentreforInfectiousDiseaseControl_LowVaccineCoverage,Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave,2020-11-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Netherlands,,,Participants who had taken part in a large-scale nationwide serosurveillance study (PIENTER-3) in 2016/2017 from low vaccination coverage municipalities,,2020-03-31,2020-05-11,Household and community samples,All,Seniors (65+ years),65.0,90.0,Age,65-90,83,0.01,0.001,0.07,,True,True,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.99,['Moderate'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,Unclear,Eric Vos,Centre for Infectious Disease Control,Not Unity-Aligned,https://dx.doi.org/10.1136/jech-2020-215678,2021-01-24,2022-07-16,Verified,vos_nationwide_2020,NLD
201128_Netherlands_CentreforInfectiousDiseaseControl_genpop_overall,201128_Netherlands_CentreforInfectiousDiseaseControl_genpop_overall,Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave,2020-11-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Netherlands,,,Participants who had taken part in a large-scale nationwide serosurveillance study (PIENTER-3) in 2016/2017,,2020-03-31,2020-05-11,Household and community samples,All,Multiple groups,2.0,90.0,Primary Estimate,,2637,0.027999999999999997,0.021,0.037000000000000005,True,True,True,,True,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.99,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Eric Vos,Centre for Infectious Disease Control,Not Unity-Aligned,https://dx.doi.org/10.1136/jech-2020-215678,2021-01-24,2022-07-16,Verified,vos_nationwide_2020,NLD
201128_Netherlands_CentreforInfectiousDiseaseControl_genpop_age2-17,201128_Netherlands_CentreforInfectiousDiseaseControl_genpop_overall,Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave,2020-11-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Netherlands,,,Participants who had taken part in a large-scale nationwide serosurveillance study (PIENTER-3) in 2016/2017,,2020-03-31,2020-05-11,Household and community samples,All,Children and Youth (0-17 years),2.0,17.0,Age,2-17,507,0.027010000000000003,0.006,0.049,,True,True,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.99,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Eric Vos,Centre for Infectious Disease Control,Not Unity-Aligned,https://dx.doi.org/10.1136/jech-2020-215678,2021-01-24,2022-07-16,Verified,vos_nationwide_2020,NLD
201128_Netherlands_CentreforInfectiousDiseaseControl_genpop_age18-39,201128_Netherlands_CentreforInfectiousDiseaseControl_genpop_overall,Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave,2020-11-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Netherlands,,,Participants who had taken part in a large-scale nationwide serosurveillance study (PIENTER-3) in 2016/2017,,2020-03-31,2020-05-11,Household and community samples,All,Adults (18-64 years),18.0,39.0,Age,18-39,735,0.049,0.032,0.075,,True,True,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.99,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Eric Vos,Centre for Infectious Disease Control,Not Unity-Aligned,https://dx.doi.org/10.1136/jech-2020-215678,2021-01-24,2022-07-16,Verified,vos_nationwide_2020,NLD
201128_Netherlands_CentreforInfectiousDiseaseControl_genpop_North,201128_Netherlands_CentreforInfectiousDiseaseControl_genpop_overall,Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave,2020-11-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Netherlands,,,Participants who had taken part in a large-scale nationwide serosurveillance study (PIENTER-3) in 2016/2017,,2020-03-31,2020-05-11,Household and community samples,All,Multiple groups,2.0,90.0,Geographical area,North Region,566,0.013000000000000001,0.004,0.032,,True,True,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.99,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Eric Vos,Centre for Infectious Disease Control,Not Unity-Aligned,https://dx.doi.org/10.1136/jech-2020-215678,2021-03-05,2022-07-16,Verified,vos_nationwide_2020,NLD
201128_Netherlands_CentreforInfectiousDiseaseControl_genpop_SouthWest,201128_Netherlands_CentreforInfectiousDiseaseControl_genpop_overall,Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave,2020-11-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Netherlands,,,Participants who had taken part in a large-scale nationwide serosurveillance study (PIENTER-3) in 2016/2017,,2020-03-31,2020-05-11,Household and community samples,All,Multiple groups,2.0,90.0,Geographical area,South West Region,468,0.03,0.015,0.053,,True,True,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.99,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Eric Vos,Centre for Infectious Disease Control,Not Unity-Aligned,https://dx.doi.org/10.1136/jech-2020-215678,2021-03-05,2022-07-16,Verified,vos_nationwide_2020,NLD
201128_Netherlands_CentreforInfectiousDiseaseControl_genpop_male,201128_Netherlands_CentreforInfectiousDiseaseControl_genpop_overall,Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave,2020-11-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Netherlands,,,Participants who had taken part in a large-scale nationwide serosurveillance study (PIENTER-3) in 2016/2017,,2020-03-31,2020-05-11,Household and community samples,Male,Multiple groups,2.0,90.0,Sex/Gender,,1184,0.028999999999999998,0.018000000000000002,0.045,,True,True,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.99,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Eric Vos,Centre for Infectious Disease Control,Not Unity-Aligned,https://dx.doi.org/10.1136/jech-2020-215678,2021-01-24,2022-07-16,Verified,vos_nationwide_2020,NLD
201128_Netherlands_CentreforInfectiousDiseaseControl_genpop_age65-90,201128_Netherlands_CentreforInfectiousDiseaseControl_genpop_overall,Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave,2020-11-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Netherlands,,,Participants who had taken part in a large-scale nationwide serosurveillance study (PIENTER-3) in 2016/2017,,2020-03-31,2020-05-11,Household and community samples,All,Seniors (65+ years),65.0,90.0,Age,65-90,476,0.025,0.012,0.051,,True,True,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.99,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Eric Vos,Centre for Infectious Disease Control,Not Unity-Aligned,https://dx.doi.org/10.1136/jech-2020-215678,2021-01-24,2022-07-16,Verified,vos_nationwide_2020,NLD
201128_Netherlands_CentreforInfectiousDiseaseControl_genpop_MidWest,201128_Netherlands_CentreforInfectiousDiseaseControl_genpop_overall,Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave,2020-11-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Netherlands,,,Participants who had taken part in a large-scale nationwide serosurveillance study (PIENTER-3) in 2016/2017,,2020-03-31,2020-05-11,Household and community samples,All,Multiple groups,2.0,90.0,Geographical area,Mid West Region,427,0.04,0.018000000000000002,0.08,,True,True,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.99,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Eric Vos,Centre for Infectious Disease Control,Not Unity-Aligned,https://dx.doi.org/10.1136/jech-2020-215678,2021-03-05,2022-07-16,Verified,vos_nationwide_2020,NLD
201128_Netherlands_CentreforInfectiousDiseaseControl_genpop_age40-64,201128_Netherlands_CentreforInfectiousDiseaseControl_genpop_overall,Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave,2020-11-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Netherlands,,,Participants who had taken part in a large-scale nationwide serosurveillance study (PIENTER-3) in 2016/2017,,2020-03-31,2020-05-11,Household and community samples,All,Adults (18-64 years),40.0,64.0,Age,40-64,919,0.019,0.012,0.032,,True,True,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.99,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Eric Vos,Centre for Infectious Disease Control,Not Unity-Aligned,https://dx.doi.org/10.1136/jech-2020-215678,2021-01-24,2022-07-16,Verified,vos_nationwide_2020,NLD
201128_Netherlands_CentreforInfectiousDiseaseControl_genpop_MidEast,201128_Netherlands_CentreforInfectiousDiseaseControl_genpop_overall,Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave,2020-11-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Netherlands,,,Participants who had taken part in a large-scale nationwide serosurveillance study (PIENTER-3) in 2016/2017,,2020-03-31,2020-05-11,Household and community samples,All,Multiple groups,2.0,90.0,Geographical area,Mid East Region,508,0.031000000000000003,0.013000000000000001,0.062000000000000006,,True,True,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.99,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Eric Vos,Centre for Infectious Disease Control,Not Unity-Aligned,https://dx.doi.org/10.1136/jech-2020-215678,2021-03-05,2022-07-16,Verified,vos_nationwide_2020,NLD
201128_Netherlands_CentreforInfectiousDiseaseControl_genpop_SouthEast,201128_Netherlands_CentreforInfectiousDiseaseControl_genpop_overall,Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave,2020-11-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Netherlands,,,Participants who had taken part in a large-scale nationwide serosurveillance study (PIENTER-3) in 2016/2017,,2020-03-31,2020-05-11,Household and community samples,All,Multiple groups,2.0,90.0,Geographical area,South East Region,668,0.027000000000000003,0.013999999999999999,0.047,,True,True,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.99,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Eric Vos,Centre for Infectious Disease Control,Not Unity-Aligned,https://dx.doi.org/10.1136/jech-2020-215678,2021-03-05,2022-07-16,Verified,vos_nationwide_2020,NLD
201128_Netherlands_CentreforInfectiousDiseaseControl_genpop_female,201128_Netherlands_CentreforInfectiousDiseaseControl_genpop_overall,Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave,2020-11-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Netherlands,,,Participants who had taken part in a large-scale nationwide serosurveillance study (PIENTER-3) in 2016/2017,,2020-03-31,2020-05-11,Household and community samples,Female,Multiple groups,2.0,90.0,Sex/Gender,Female,1453,0.027000000000000003,0.017,0.040999999999999995,,True,True,,,Stratified probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.99,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Eric Vos,Centre for Infectious Disease Control,Not Unity-Aligned,https://dx.doi.org/10.1136/jech-2020-215678,2021-01-24,2022-07-16,Verified,vos_nationwide_2020,NLD
210316_Netherlands_SanquinResearch_blooddonors,210316_Netherlands_SanquinResearch,Low awareness of past SARS-CoV-2 infection in healthy plasma donors,2021-03-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Netherlands,,,Individuals who donated plasma anywhere in the Netherlands between May 11th and 18th 2020 who consented (99.7%) to using leftovers of their donation for research were tested for SARS-CoV-2 antibodies. ,"Those who donated COVID-19 convalescent plasma were excluded, as they were recruited separately and are, thus, not representative of regular plasma donors.",2020-05-11,2020-05-18,Blood donors,All,Multiple groups,18.0,73.0,Primary Estimate,Blood donors,3676,0.065,,,True,,,,True,Entire sample,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,,,Validated by independent authors/third party/non-developers,0.9870000000000001,0.996,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Katj van den HUrk,Sanquin Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.xcrm.2021.100222,2021-05-10,2024-03-01,Verified,van_den_hurk_low_2021,NLD
210316_Netherlands_SanquinResearch_blooddonors_males,210316_Netherlands_SanquinResearch,Low awareness of past SARS-CoV-2 infection in healthy plasma donors,2021-03-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Netherlands,,,Individuals who donated plasma anywhere in the Netherlands between May 11th and 18th 2020 who consented (99.7%) to using leftovers of their donation for research were tested for SARS-CoV-2 antibodies. ,"Those who donated COVID-19 convalescent plasma were excluded, as they were recruited separately and are, thus, not representative of regular plasma donors.",2020-05-11,2020-05-18,Blood donors,Male,Multiple groups,18.0,73.0,Sex/Gender,Males,1892,0.0666,,,,,,,,Entire sample,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,,,Validated by independent authors/third party/non-developers,0.9870000000000001,0.996,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Katj van den HUrk,Sanquin Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.xcrm.2021.100222,2021-05-10,2024-03-01,Verified,van_den_hurk_low_2021,NLD
210316_Netherlands_SanquinResearch_blooddonors_females,210316_Netherlands_SanquinResearch,Low awareness of past SARS-CoV-2 infection in healthy plasma donors,2021-03-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Netherlands,,,Individuals who donated plasma anywhere in the Netherlands between May 11th and 18th 2020 who consented (99.7%) to using leftovers of their donation for research were tested for SARS-CoV-2 antibodies. ,"Those who donated COVID-19 convalescent plasma were excluded, as they were recruited separately and are, thus, not representative of regular plasma donors.",2020-05-11,2020-05-18,Blood donors,Female,Multiple groups,18.0,73.0,Sex/Gender,Females,1784,0.0633,,,,,,,,Entire sample,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,,,Validated by independent authors/third party/non-developers,0.9870000000000001,0.996,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Katj van den HUrk,Sanquin Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.xcrm.2021.100222,2021-05-10,2024-03-01,Verified,van_den_hurk_low_2021,NLD
210323_Budel_MaastrichtUniversity_Overall,210323_Budel_MaastrichtUniversity,[Experiences of (care) professionals during a COVID-19 outbreak and results of serological tests in the staff of a heavily affected nursing home.].,2021-03-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Netherlands,North Brabant,Budel,"Participants in the study were employees who worked in the MB nursing home in Budel between March 1, 2020 and May 31, 2020 (n=281). This concerned the care staff (helpers, care assistants, carers and nurses), practitioners (geriatric care specialists and paramedics), facility service staff and household service staff. All employees were invited to participate in the study, which consisted of completing a digital questionnaire, taking the serological test and participating in group interviews. Prior written permission was requested for this. Participation was voluntary and all participants could cancel their participation at any time.",,2020-06-04,2020-06-16,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,240,0.39170000000000005,,,True,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,,Serum,"['IgA', 'IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.961,0.98,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,Yes,Joyce Heffels,Maastricht University,Not Unity-Aligned,https://dx.doi.org/10.36613/tgg.1875-6832/2021.01.01,2021-06-08,2024-03-01,Verified,joyce_cf_heffels_ervaringen_2021,NLD
210430_Amsterdam_AmsterdamUniversityMedicalCenter,210430_Amsterdam_AmsterdamUniversityMedicalCenter,SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort.,2021-04-30,Journal Article (Peer-Reviewed),Local,Prospective cohort,Netherlands,North Holland,Amsterdam,"On July 31, 2020, all adult patients with a current diagnosis of MS who had visited the MS Center Amsterdam in the past 2 years were invited to participate.",,2020-07-31,2020-12-18,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),,,Primary Estimate,,546,0.11699999999999999,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,0.981,0.995,['High'],,No,No,Yes,,Unclear,Yes,Yes,,Zoe van Kempen,Amsterdam University Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1001/jamaneurol.2021.1364,2021-05-25,2022-07-16,Unverified,zoel.e.vankempenSARSCoV2AntibodiesAdult2021,NLD
210728_Amsterdam_AmsterdamUniversityMedicalCenters_COVIDCare3,210728_Amsterdam_AmsterdamUniversityMedicalCenters_COVIDCare3,Serologic Surveillance and Phylogenetic Analysis of SARS-CoV-2 Infection Among Hospital Health Care Workers.,2021-07-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Netherlands,,Amsterdam," HCWs working as nurses or physicians with bedside contacts with patients with COVID-19 on designated regular-care COVID-19 wards, emergency departments (EDs), or intensive care units (ICUs)",,2020-03-23,2020-06-25,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,439,0.132,0.099,0.16399999999999998,True,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,0.8520000000000001,0.993,['High'],No,No,No,Yes,Unclear,Yes,Yes,No,Unclear,Jonne Sikkens,Amsterdam University Medical Centers ,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.18554,2021-08-02,2024-03-01,Verified,sikkens_serologic_2021,NLD
210728_Amsterdam_AmsterdamUniversityMedicalCenters_NoPatientCare1,210728_Amsterdam_AmsterdamUniversityMedicalCenters_NoPatientCare1,Serologic Surveillance and Phylogenetic Analysis of SARS-CoV-2 Infection Among Hospital Health Care Workers.,2021-07-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Netherlands,,Amsterdam,HCWs not working in patient care.,,2020-03-23,2020-06-25,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,198,0.036000000000000004,0.009000000000000001,0.061,True,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,0.8520000000000001,0.993,['High'],No,No,No,Yes,Unclear,Yes,Yes,No,Unclear,Jonne Sikkens,Amsterdam University Medical Centers ,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.18554,2021-08-02,2024-03-01,Verified,sikkens_serologic_2021,NLD
210728_Amsterdam_AmsterdamUniversityMedicalCenters_NonCOVIDCare2,210728_Amsterdam_AmsterdamUniversityMedicalCenters_NonCOVIDCare2,Serologic Surveillance and Phylogenetic Analysis of SARS-CoV-2 Infection Among Hospital Health Care Workers.,2021-07-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Netherlands,,Amsterdam,HCWs working as nurses or physicians on wards designated for non–COVID-19 care,,2020-06-25,2020-06-25,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,164,0.067,0.027999999999999997,0.105,True,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,0.8520000000000001,0.993,['High'],No,No,No,Yes,Unclear,Yes,Yes,No,Unclear,Jonne Sikkens,Amsterdam University Medical Centers ,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.18554,2021-08-02,2024-03-01,Verified,sikkens_serologic_2021,NLD
210915_Netherlands_UniversityofAmsterdam_Wantai_Overall,210915_Netherlands_UniversityofAmsterdam,Saliva SARS-CoV-2 Antibody Prevalence in Children.,2021-09-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Netherlands,North Holland,Amsterdam,"""Inclusion criteria were children aged 0 to 18 years residing in the Netherlands who required blood testing or intravenous cannulation for any reason. Eligibility was irrespective of (suspected) acute or prior COVID-19 infection.""","""Children were excluded if sample collection of neither serum
nor saliva was sufficient.""",2020-04-12,2020-10-02,Residual sera,All,Children and Youth (0-17 years),,17.0,Primary Estimate,,487,0.0329,0.019,0.053,True,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.975,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Maya Keuning,University of Amsterdam,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00731-21,2021-09-22,2024-03-01,Verified,keuning_saliva_2021,NLD
210915_Netherlands_UniversityofAmsterdam_Wantai_Female,210915_Netherlands_UniversityofAmsterdam,Saliva SARS-CoV-2 Antibody Prevalence in Children.,2021-09-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Netherlands,North Holland,Amsterdam,"""Inclusion criteria were children aged 0 to 18 years residing in the Netherlands who required blood testing or intravenous cannulation for any reason. Eligibility was irrespective of (suspected) acute or prior COVID-19 infection.""","""Children were excluded if sample collection of neither serum
nor saliva was sufficient.""",2020-04-12,2020-10-02,Residual sera,Female,Children and Youth (0-17 years),,17.0,Sex/Gender,,252,0.039700000000000006,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.975,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Maya Keuning,University of Amsterdam,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00731-21,2021-10-28,2024-03-01,Verified,keuning_saliva_2021,NLD
210915_Netherlands_UniversityofAmsterdam_Luminex_Overall,210915_Netherlands_UniversityofAmsterdam,Saliva SARS-CoV-2 Antibody Prevalence in Children.,2021-09-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Netherlands,North Holland,Amsterdam,"""Inclusion criteria were children aged 0 to 18 years residing in the Netherlands who required blood testing or intravenous cannulation for any reason. Eligibility was irrespective of (suspected) acute or prior COVID-19 infection.""","""Children were excluded if sample collection of neither serum
nor saliva was sufficient.""",2020-04-12,2020-10-02,Residual sera,All,Children and Youth (0-17 years),,18.0,Test used,,509,0.067,,,,,,,,Convenience,Author designed (Luminex),,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Maya Keuning,University of Amsterdam,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00731-21,2021-09-22,2022-07-16,Verified,keuning_saliva_2021,NLD
210915_Netherlands_UniversityofAmsterdam_Wantai_Age<1,210915_Netherlands_UniversityofAmsterdam,Saliva SARS-CoV-2 Antibody Prevalence in Children.,2021-09-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Netherlands,North Holland,Amsterdam,"""Inclusion criteria were children aged 0 to 18 years residing in the Netherlands who required blood testing or intravenous cannulation for any reason. Eligibility was irrespective of (suspected) acute or prior COVID-19 infection.""","""Children were excluded if sample collection of neither serum
nor saliva was sufficient.""",2020-04-12,2020-10-02,Residual sera,All,Children and Youth (0-17 years),,1.0,Age,,34,0.0,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.975,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Maya Keuning,University of Amsterdam,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00731-21,2021-10-28,2024-03-01,Verified,keuning_saliva_2021,NLD
210915_Netherlands_UniversityofAmsterdam_Wantai_Age1-4,210915_Netherlands_UniversityofAmsterdam,Saliva SARS-CoV-2 Antibody Prevalence in Children.,2021-09-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Netherlands,North Holland,Amsterdam,"""Inclusion criteria were children aged 0 to 18 years residing in the Netherlands who required blood testing or intravenous cannulation for any reason. Eligibility was irrespective of (suspected) acute or prior COVID-19 infection.""","""Children were excluded if sample collection of neither serum
nor saliva was sufficient.""",2020-04-12,2020-10-02,Residual sera,All,Children and Youth (0-17 years),1.0,4.0,Age,1-4,64,0.015600000000000001,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.975,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Maya Keuning,University of Amsterdam,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00731-21,2021-10-28,2024-03-01,Verified,keuning_saliva_2021,NLD
210915_Netherlands_UniversityofAmsterdam_Wantai_Age5-9,210915_Netherlands_UniversityofAmsterdam,Saliva SARS-CoV-2 Antibody Prevalence in Children.,2021-09-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Netherlands,North Holland,Amsterdam,"""Inclusion criteria were children aged 0 to 18 years residing in the Netherlands who required blood testing or intravenous cannulation for any reason. Eligibility was irrespective of (suspected) acute or prior COVID-19 infection.""","""Children were excluded if sample collection of neither serum
nor saliva was sufficient.""",2020-04-12,2020-10-02,Residual sera,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,102,0.0294,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.975,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Maya Keuning,University of Amsterdam,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00731-21,2021-10-28,2024-03-01,Verified,keuning_saliva_2021,NLD
210915_Netherlands_UniversityofAmsterdam_Wantai_Age10-14,210915_Netherlands_UniversityofAmsterdam,Saliva SARS-CoV-2 Antibody Prevalence in Children.,2021-09-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Netherlands,North Holland,Amsterdam,"""Inclusion criteria were children aged 0 to 18 years residing in the Netherlands who required blood testing or intravenous cannulation for any reason. Eligibility was irrespective of (suspected) acute or prior COVID-19 infection.""","""Children were excluded if sample collection of neither serum
nor saliva was sufficient.""",2020-04-12,2020-10-02,Residual sera,All,Children and Youth (0-17 years),10.0,14.0,Age,10-14,145,0.0414,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.975,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Maya Keuning,University of Amsterdam,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00731-21,2021-10-28,2024-03-01,Verified,keuning_saliva_2021,NLD
210915_Netherlands_UniversityofAmsterdam_Wantai_Age15-17,210915_Netherlands_UniversityofAmsterdam,Saliva SARS-CoV-2 Antibody Prevalence in Children.,2021-09-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Netherlands,North Holland,Amsterdam,"""Inclusion criteria were children aged 0 to 18 years residing in the Netherlands who required blood testing or intravenous cannulation for any reason. Eligibility was irrespective of (suspected) acute or prior COVID-19 infection.""","""Children were excluded if sample collection of neither serum
nor saliva was sufficient.""",2020-04-12,2020-10-02,Residual sera,All,Children and Youth (0-17 years),15.0,17.0,Age,15-17,142,0.042300000000000004,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.975,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Maya Keuning,University of Amsterdam,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00731-21,2021-10-28,2024-03-01,Verified,keuning_saliva_2021,NLD
210915_Netherlands_UniversityofAmsterdam_Wantai_Male,210915_Netherlands_UniversityofAmsterdam,Saliva SARS-CoV-2 Antibody Prevalence in Children.,2021-09-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Netherlands,North Holland,Amsterdam,"""Inclusion criteria were children aged 0 to 18 years residing in the Netherlands who required blood testing or intravenous cannulation for any reason. Eligibility was irrespective of (suspected) acute or prior COVID-19 infection.""","""Children were excluded if sample collection of neither serum
nor saliva was sufficient.""",2020-04-12,2020-10-02,Residual sera,Male,Children and Youth (0-17 years),,17.0,Sex/Gender,,235,0.0255,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.975,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Maya Keuning,University of Amsterdam,Unity-Aligned,https://dx.doi.org/10.1128/Spectrum.00731-21,2021-10-28,2024-03-01,Verified,keuning_saliva_2021,NLD
211008_NorthBrabant_RegionalPublicHealthServiceofWestBrabant_Overall,211008_NorthBrabant_RegionalPublicHealthServiceofWestBrabant,SARS-CoV-2 antibodies in employees working in non-medical contact-intensive professions in the Netherlands: baseline data from the prospective COco-study.,2021-10-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,North Brabant,,"Participants were eligible when working as hospitality staff or hairdressers in this region (Breda, Roosendaal and surrounding municipalities) for ≥ 100 h during the 3 months before enrolment.","People were excluded if their age was < 18 years, if they were reluctant to venepuncture, incapacitated or unwilling to give informed consent, or a blood or plasma donor. The latter exclusion criteria was included since we are planning to compare seroprevalence in our cohort to seroprevalence in a matched cohort of blood and plasma donors in the region.",2020-06-01,2020-07-14,Non-essential workers and unemployed persons,All,Multiple groups,17.0,74.0,Primary Estimate,,497,0.113,,,True,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Whole Blood,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.96,0.99,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Dymphie Mioch,Regional Public Health Service of West-Brabant,Not Unity-Aligned,https://dx.doi.org/10.1016/j.pmedr.2021.101594,2021-10-19,2024-03-01,Unverified,mioch_sars-cov-2_2021,NLD
211008_NorthBrabant_RegionalPublicHealthServiceofWestBrabant_30-50,211008_NorthBrabant_RegionalPublicHealthServiceofWestBrabant,SARS-CoV-2 antibodies in employees working in non-medical contact-intensive professions in the Netherlands: baseline data from the prospective COco-study.,2021-10-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,North Brabant,,"Participants were eligible when working as hospitality staff or hairdressers in this region (Breda, Roosendaal and surrounding municipalities) for ≥ 100 h during the 3 months before enrolment.","People were excluded if their age was < 18 years, if they were reluctant to venepuncture, incapacitated or unwilling to give informed consent, or a blood or plasma donor. The latter exclusion criteria was included since we are planning to compare seroprevalence in our cohort to seroprevalence in a matched cohort of blood and plasma donors in the region.",2020-06-01,2020-07-14,Non-essential workers and unemployed persons,All,Adults (18-64 years),30.0,50.0,Age,30-50,214,0.107,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Whole Blood,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.96,0.99,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Dymphie Mioch,Regional Public Health Service of West-Brabant,Not Unity-Aligned,https://dx.doi.org/10.1016/j.pmedr.2021.101594,2021-10-19,2024-03-01,Unverified,mioch_sars-cov-2_2021,NLD
211008_NorthBrabant_RegionalPublicHealthServiceofWestBrabant_51-74,211008_NorthBrabant_RegionalPublicHealthServiceofWestBrabant,SARS-CoV-2 antibodies in employees working in non-medical contact-intensive professions in the Netherlands: baseline data from the prospective COco-study.,2021-10-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,North Brabant,,"Participants were eligible when working as hospitality staff or hairdressers in this region (Breda, Roosendaal and surrounding municipalities) for ≥ 100 h during the 3 months before enrolment.","People were excluded if their age was < 18 years, if they were reluctant to venepuncture, incapacitated or unwilling to give informed consent, or a blood or plasma donor. The latter exclusion criteria was included since we are planning to compare seroprevalence in our cohort to seroprevalence in a matched cohort of blood and plasma donors in the region.",2020-06-01,2020-07-14,Non-essential workers and unemployed persons,All,Multiple groups,51.0,74.0,Age,51-74,114,0.12300000000000001,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Whole Blood,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.96,0.99,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Dymphie Mioch,Regional Public Health Service of West-Brabant,Not Unity-Aligned,https://dx.doi.org/10.1016/j.pmedr.2021.101594,2021-10-19,2024-03-01,Unverified,mioch_sars-cov-2_2021,NLD
211008_NorthBrabant_RegionalPublicHealthServiceofWestBrabant_17-29,211008_NorthBrabant_RegionalPublicHealthServiceofWestBrabant,SARS-CoV-2 antibodies in employees working in non-medical contact-intensive professions in the Netherlands: baseline data from the prospective COco-study.,2021-10-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,North Brabant,,"Participants were eligible when working as hospitality staff or hairdressers in this region (Breda, Roosendaal and surrounding municipalities) for ≥ 100 h during the 3 months before enrolment.","People were excluded if their age was < 18 years, if they were reluctant to venepuncture, incapacitated or unwilling to give informed consent, or a blood or plasma donor. The latter exclusion criteria was included since we are planning to compare seroprevalence in our cohort to seroprevalence in a matched cohort of blood and plasma donors in the region.",2020-06-01,2020-07-14,Non-essential workers and unemployed persons,All,Adults (18-64 years),17.0,29.0,Age,17-29,169,0.11199999999999999,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Whole Blood,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.96,0.99,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Dymphie Mioch,Regional Public Health Service of West-Brabant,Not Unity-Aligned,https://dx.doi.org/10.1016/j.pmedr.2021.101594,2021-10-19,2024-03-01,Unverified,mioch_sars-cov-2_2021,NLD
211018_Venlo_VieCuriMedicalCentre_Overall,211018_Venlo_VieCuriMedicalCentre,SARS-CoV-2 seroprevalence in healthcare workers of a teaching hospital in a highly endemic region in the Netherlands after the first wave: A cross-sectional study,2021-10-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Netherlands,Limburg,Venlo,"All employees of the VieCuri Medical Centre. Only individuals employed by the hospital, interns and volunteers, at the moment of blood collection, were included.",,2020-06-22,2020-07-03,Health care workers and caregivers,All,Multiple groups,17.0,80.0,Primary Estimate,,2507,0.21100000000000002,,,True,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,,TotalAntibody,,Validated by independent authors/third party/non-developers,0.975,0.996,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Maud Bouwman,VieCuri Medical Centre,Not Unity-Aligned,http://dx.doi.org/10.1136/bmjopen-2021-051573,2021-11-04,2024-03-01,Unverified,bouwman_sars-cov-2_2021,NLD
211027_Amsterdam_AmsterdamUniversityMedicalCenters_HIVneg_MarApr2021,211027_Amsterdam_AmsterdamUniversityMedicalCenters_HIVneg_MarApr2021,People with HIV and suppressed viremia on ART are not at increased risk for acquiring SARS-CoV- 2 infection,2021-10-27,Presentation or Conference,Local,Prospective cohort,Netherlands,,Amsterdam,Consenting HIV-negative AGEhIV participants,,2021-03-01,2021-04-30,Multiple populations,All,Multiple groups,,,Primary Estimate,,288,0.122,,,True,,,,True,Convenience,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9820000000000001,['High'],,No,No,No,,Yes,Yes,Yes,,Myrthe L Verburgh,Amsterdam University Medical Centers,Not Unity-Aligned,http://dx.doi.org/10.1111/hiv.13183,2021-12-14,2024-03-01,Verified,verburgh_people_2021,NLD
211027_Amsterdam_AmsterdamUniversityMedicalCenters_HIVneg_SepOct2020,211027_Amsterdam_AmsterdamUniversityMedicalCenters_HIVneg_SepOct2020,People with HIV and suppressed viremia on ART are not at increased risk for acquiring SARS-CoV- 2 infection,2021-10-27,Presentation or Conference,Local,Prospective cohort,Netherlands,,Amsterdam,Consenting HIV-negative AGEhIV participants,,2020-09-01,2020-10-31,Multiple populations,All,Multiple groups,,,Primary Estimate,,312,0.067,,,True,,,,True,Convenience,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9820000000000001,['High'],Unclear,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Myrthe L Verburgh,Amsterdam University Medical Centers,Not Unity-Aligned,http://dx.doi.org/10.1111/hiv.13183,2021-12-14,2024-03-01,Verified,verburgh_people_2021,NLD
211027_Amsterdam_AmsterdamUniversityMedicalCenters_HIVpos_MarApr2021,211027_Amsterdam_AmsterdamUniversityMedicalCenters_HIVpos_MarApr2021,People with HIV and suppressed viremia on ART are not at increased risk for acquiring SARS-CoV- 2 infection,2021-10-27,Presentation or Conference,Local,Prospective cohort,Netherlands,,Amsterdam,Consenting HIV-positive AGEhIV participants,,2021-03-01,2021-04-30,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,202,0.129,,,True,,,,True,Convenience,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9820000000000001,['High'],Unclear,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Myrthe L Verburgh,Amsterdam University Medical Centers,Not Unity-Aligned,http://dx.doi.org/10.1111/hiv.13183,2021-12-14,2024-03-01,Verified,verburgh_people_2021,NLD
211027_Amsterdam_AmsterdamUniversityMedicalCenters_HIVpos_SepOct2020,211027_Amsterdam_AmsterdamUniversityMedicalCenters_HIVpos_SepOct2020,People with HIV and suppressed viremia on ART are not at increased risk for acquiring SARS-CoV- 2 infection,2021-10-27,Presentation or Conference,Local,Prospective cohort,Netherlands,,Amsterdam,Consenting HIV-positive AGEhIV participants,,2020-09-01,2020-10-31,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,236,0.055,,,True,,,,True,Convenience,INgezim COVID 19 DR,Eurofins Ingenasa,ELISA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9820000000000001,['High'],Unclear,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Myrthe L Verburgh,Amsterdam University Medical Centers,Not Unity-Aligned,http://dx.doi.org/10.1111/hiv.13183,2021-12-14,2024-03-01,Verified,verburgh_people_2021,NLD
211009_Rotterdam_FranciscusGasthuisandVlietland_Period1_Overall,211009_Rotterdam_FranciscusGasthuisandVlietland_Period1,Trends in SARS-CoV-2 seroprevalence amongst urban paediatric patients compared with a nationwide cohort in the Netherlands.,2021-12-01,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Netherlands,South Holland,Rotterdam,"residual plasma samples from consecutive paediatric patients (1 month-17 years of age) who visited our (outpatient) clinic or emergency room and underwent blood drawing for any medical reason after the first wave (period 1: July 19-September 19, 2020). If a child had multiple blood samples drawn during the inclusion period, the first blood sample was selected for analysis.","Children with known current COVID-19 related conditions (e.g., respiratory tract infection or multisystem inflammatory syndrome in children (MIS-C) with proven positive SARS-CoV-2 PCR and/or antibodies) were excluded from the analysis.",2020-07-19,2020-09-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,all children 0-17,209,0.040999999999999995,0.011000000000000001,0.071,True,,True,,True,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,,,,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,,I.L.M. Rotee,Franciscus Gasthuis & Vlietland,Unity-Aligned,https://dx.doi.org/10.1016/j.jcvp.2021.100045,2022-03-15,2024-03-01,Verified,rotee_trends_2021,NLD
211009_Rotterdam_FranciscusGasthuisandVlietland_Period2_Overall,211009_Rotterdam_FranciscusGasthuisandVlietland_Period2,Trends in SARS-CoV-2 seroprevalence amongst urban paediatric patients compared with a nationwide cohort in the Netherlands.,2021-12-01,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Netherlands,South Holland,Rotterdam,"residual plasma samples from consecutive paediatric patients (1 month-17 years of age) who visited our (outpatient) clinic or emergency room and underwent blood drawing for any medical reason during the second wave (period 2: October 19-December 19, 2020). If a child had multiple blood samples drawn during the inclusion period, the first blood sample was selected for analysis.","Children with known current COVID-19 related conditions (e.g., respiratory tract infection or multisystem inflammatory syndrome in children (MIS-C) with proven positive SARS-CoV-2 PCR and/or antibodies) were excluded from the analysis.",2020-10-19,2020-12-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,all children 0-17,240,0.138,0.09,0.187,True,,True,,True,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,,,,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,,I.L.M. Rotee, Franciscus Gasthuis & Vlietland,Unity-Aligned,https://dx.doi.org/10.1016/j.jcvp.2021.100045,2022-03-15,2024-03-01,Verified,rotee_trends_2021,NLD
211214_Amsterdam_UniversityofAmsterdam_Visit2,211214_Amsterdam_UniversityofAmsterdam_Visit2,"Differences in SARS-CoV-2 infections during the first and second wave of SARS-CoV-2 between six ethnic groups in Amsterdam, the Netherlands: A population-based longitudinal serological study.",2021-12-14,Journal Article (Peer-Reviewed),Local,Prospective cohort,Netherlands,North Holland,Amsterdam,"Members of the HELIUS multi-ethnic cohort study who ""filled in a questionnaire and underwent a phys-ical examination during which biological samples wereobtained""",,2020-11-23,2021-06-04,Household and community samples,All,Multiple groups,18.0,70.0,Primary Estimate,,2075,0.2361,,,True,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,,0.9400000000000001,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,No,Liza Coyer,University of Amsterdam,Unity-Aligned,https://dx.doi.org/10.1016/j.lanepe.2021.100284,2022-01-12,2024-03-01,Verified,coyer_differences_2022,NLD
211220_Amsterdam_AmsterdamInfectionandImmunityInstitute_Overall,211220_Amsterdam_AmsterdamInfectionandImmunityInstitute,Similar risk of SARS-CoV-2 infection and similar nucleocapsid antibody levels in people with well-controlled HIV and a comparable cohort of people without HIV.,2021-12-20,Journal Article (Peer-Reviewed),Local,Prospective cohort,Netherlands,North Holland,Amsterdam,"In August 2020, following the first SARS-CoV-2 epidemic wave in the Netherlands, all AGEhIV 
Cohort participants in active follow-up and residing in the Netherlands were asked to 
participate in a COVID-19 substudy, which includes five planned, six-monthly study visits 
between September 2020 and October 2022. During each visit, blood is obtained to assess 
SARS-CoV-2 humoral and cellular immune responses and participants complete a standardized 
study questionnaire. ",,2020-09-15,2021-04-15,Multiple populations,All,Multiple groups,53.0,,Primary Estimate,,563,0.10830000000000001,,,True,,,,True,Convenience,INgezim COVID 19 DR,Eurofins Ingenasa,,,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9820000000000001,['High'],No,No,No,Yes,No,Yes,Yes,Yes,Yes,Myrthe Verburgh,Amsterdam Infection and Immunity Institute,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab616,2022-01-09,2024-03-01,Verified,verburgh_similar_2021,NLD
211220_Amsterdam_AmsterdamInfectionandImmunityInstitute_Age53-59,211220_Amsterdam_AmsterdamInfectionandImmunityInstitute,Similar risk of SARS-CoV-2 infection and similar nucleocapsid antibody levels in people with well-controlled HIV and a comparable cohort of people without HIV.,2021-12-20,Journal Article (Peer-Reviewed),Local,Prospective cohort,Netherlands,North Holland,Amsterdam,"In August 2020, following the first SARS-CoV-2 epidemic wave in the Netherlands, all AGEhIV 
Cohort participants in active follow-up and residing in the Netherlands were asked to 
participate in a COVID-19 substudy, which includes five planned, six-monthly study visits 
between September 2020 and October 2022. During each visit, blood is obtained to assess 
SARS-CoV-2 humoral and cellular immune responses and participants complete a standardized 
study questionnaire. ",,2020-09-15,2021-04-15,Multiple populations,All,Adults (18-64 years),53.0,59.0,Age,53-59,246,0.1585,,,,,,,,Convenience,INgezim COVID 19 DR,Eurofins Ingenasa,,,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9820000000000001,['High'],No,No,No,Yes,No,Yes,Yes,Yes,Yes,Myrthe Verburgh,Amsterdam Infection and Immunity Institute,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab616,2022-01-09,2024-03-01,Verified,verburgh_similar_2021,NLD
211220_Amsterdam_AmsterdamInfectionandImmunityInstitute_Age60-64,211220_Amsterdam_AmsterdamInfectionandImmunityInstitute,Similar risk of SARS-CoV-2 infection and similar nucleocapsid antibody levels in people with well-controlled HIV and a comparable cohort of people without HIV.,2021-12-20,Journal Article (Peer-Reviewed),Local,Prospective cohort,Netherlands,North Holland,Amsterdam,"In August 2020, following the first SARS-CoV-2 epidemic wave in the Netherlands, all AGEhIV 
Cohort participants in active follow-up and residing in the Netherlands were asked to 
participate in a COVID-19 substudy, which includes five planned, six-monthly study visits 
between September 2020 and October 2022. During each visit, blood is obtained to assess 
SARS-CoV-2 humoral and cellular immune responses and participants complete a standardized 
study questionnaire. ",,2020-09-15,2021-04-15,Multiple populations,All,Adults (18-64 years),60.0,64.0,Age,60-64,143,0.1119,,,,,,,,Convenience,INgezim COVID 19 DR,Eurofins Ingenasa,,,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9820000000000001,['High'],No,No,No,Yes,No,Yes,Yes,Yes,Yes,Myrthe Verburgh,Amsterdam Infection and Immunity Institute,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab616,2022-01-09,2024-03-01,Verified,verburgh_similar_2021,NLD
211220_Amsterdam_AmsterdamInfectionandImmunityInstitute_Age70+,211220_Amsterdam_AmsterdamInfectionandImmunityInstitute,Similar risk of SARS-CoV-2 infection and similar nucleocapsid antibody levels in people with well-controlled HIV and a comparable cohort of people without HIV.,2021-12-20,Journal Article (Peer-Reviewed),Local,Prospective cohort,Netherlands,North Holland,Amsterdam,"In August 2020, following the first SARS-CoV-2 epidemic wave in the Netherlands, all AGEhIV 
Cohort participants in active follow-up and residing in the Netherlands were asked to 
participate in a COVID-19 substudy, which includes five planned, six-monthly study visits 
between September 2020 and October 2022. During each visit, blood is obtained to assess 
SARS-CoV-2 humoral and cellular immune responses and participants complete a standardized 
study questionnaire. ",,2020-09-15,2021-04-15,Multiple populations,All,Seniors (65+ years),70.0,,Age,70+,83,0.04820000000000001,,,,,,,,Convenience,INgezim COVID 19 DR,Eurofins Ingenasa,,,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9820000000000001,['High'],No,No,No,Yes,No,Yes,Yes,Yes,Yes,Myrthe Verburgh,Amsterdam Infection and Immunity Institute,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab616,2022-01-09,2024-03-01,Verified,verburgh_similar_2021,NLD
211220_Amsterdam_AmsterdamInfectionandImmunityInstitute_Age65-69,211220_Amsterdam_AmsterdamInfectionandImmunityInstitute,Similar risk of SARS-CoV-2 infection and similar nucleocapsid antibody levels in people with well-controlled HIV and a comparable cohort of people without HIV.,2021-12-20,Journal Article (Peer-Reviewed),Local,Prospective cohort,Netherlands,North Holland,Amsterdam,"In August 2020, following the first SARS-CoV-2 epidemic wave in the Netherlands, all AGEhIV 
Cohort participants in active follow-up and residing in the Netherlands were asked to 
participate in a COVID-19 substudy, which includes five planned, six-monthly study visits 
between September 2020 and October 2022. During each visit, blood is obtained to assess 
SARS-CoV-2 humoral and cellular immune responses and participants complete a standardized 
study questionnaire. ",,2020-09-15,2021-04-15,Multiple populations,All,Seniors (65+ years),65.0,69.0,Age,65-69,95,0.0526,,,,,,,,Convenience,INgezim COVID 19 DR,Eurofins Ingenasa,,,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9820000000000001,['High'],No,No,No,Yes,No,Yes,Yes,Yes,Yes,Myrthe Verburgh,Amsterdam Infection and Immunity Institute,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab616,2022-01-09,2024-03-01,Verified,verburgh_similar_2021,NLD
220106_Amsterdam_PublicHealthServiceofAmsterdam,220106_Amsterdam_PublicHealthServiceofAmsterdam,"SARS-CoV-2 antibody prevalence and correlates of six ethnic groups living in Amsterdam, the Netherlands: a population-based cross-sectional study, June-October 2020.",2022-01-06,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Netherlands,,Amsterdam,"""Individuals who participated in the HELIUS study, a multiethnic cohort study conducted in Amsterdam, the Netherlands, which focuses on cardiovascular disease, mental health, and infectious diseases"" ""HELIUS participants who were still in
follow-up and belonged to one of the six ethnic groups""
included in the substudy","""Excluding participants not belonging to one of the six ethnic groups included in the COVID-19 study""",2020-06-24,2020-10-09,Household and community samples,All,Multiple groups,18.0,70.0,Primary Estimate,,2483,0.0906,,,True,,,,True,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,,,,['Moderate'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Liza Coyer,University of Amsterdam,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-052752,2022-01-18,2024-03-01,Verified,coyer_sars-cov-2_2022,NLD
220810_Limburg_SouthLimburgPublicHealthService_Overall,220810_Limburg_SouthLimburgPublicHealthService,Sex and age differences in the proportion of experienced symptoms by SARS-CoV-2 serostatus in a community-based cross-sectional study.,2022-08-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,Limburg,,"""Only participants without confirmed SARS-CoV-2 infection were included (n = 9715, age range 18–90 years).""

""adults (18+ years) living in the southern Dutch region were eligible for participation"".

""Participants needed to understand, write and read the Dutch language, since materials were only available in Dutch.""

""Only participants with complete participation were included in the analysis, meaning donating a blood sample and filling out the questionnaire.""","""Participants with PCR confirmed SARSCoV-2 infection (n = 286) were excluded (seroprevalence of PCR confirmed participants: 80.1% (95% CI 75.4%–84.7%)).""",2020-10-28,2020-12-23,Household and community samples,All,Multiple groups,18.0,90.0,Primary Estimate,,9715,0.177,0.16899999999999998,0.185,True,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.9450000000000001,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Demi Pagen,South Limburg Public Health Service,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268822001339,2022-09-12,2024-03-01,Unverified,pagen_sex_2022,NLD
220810_Limburg_SouthLimburgPublicHealthService_SexOther,220810_Limburg_SouthLimburgPublicHealthService,Sex and age differences in the proportion of experienced symptoms by SARS-CoV-2 serostatus in a community-based cross-sectional study.,2022-08-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,Limburg,,"""Only participants without confirmed SARS-CoV-2 infection were included (n = 9715, age range 18–90 years).""

""adults (18+ years) living in the southern Dutch region were eligible for participation"".

""Participants needed to understand, write and read the Dutch language, since materials were only available in Dutch.""

""Only participants with complete participation were included in the analysis, meaning donating a blood sample and filling out the questionnaire.""","""Participants with PCR confirmed SARSCoV-2 infection (n = 286) were excluded (seroprevalence of PCR confirmed participants: 80.1% (95% CI 75.4%–84.7%)).""",2020-10-28,2020-12-23,Household and community samples,Other,Multiple groups,18.0,90.0,Sex/Gender,,4,0.5,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.9450000000000001,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Demi Pagen,South Limburg Public Health Service,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268822001339,2022-09-13,2024-03-01,Unverified,pagen_sex_2022,NLD
220810_Limburg_SouthLimburgPublicHealthService_Age18-60,220810_Limburg_SouthLimburgPublicHealthService,Sex and age differences in the proportion of experienced symptoms by SARS-CoV-2 serostatus in a community-based cross-sectional study.,2022-08-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,Limburg,,"""Only participants without confirmed SARS-CoV-2 infection were included (n = 9715, age range 18–90 years).""

""adults (18+ years) living in the southern Dutch region were eligible for participation"".

""Participants needed to understand, write and read the Dutch language, since materials were only available in Dutch.""

""Only participants with complete participation were included in the analysis, meaning donating a blood sample and filling out the questionnaire.""","""Participants with PCR confirmed SARSCoV-2 infection (n = 286) were excluded (seroprevalence of PCR confirmed participants: 80.1% (95% CI 75.4%–84.7%)).""",2020-10-28,2020-12-23,Household and community samples,All,Adults (18-64 years),18.0,59.0,Age,Age: 18–60,6825,0.17300000000000001,0.129,0.17300000000000001,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.9450000000000001,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Demi Pagen,South Limburg Public Health Service,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268822001339,2022-09-13,2024-03-01,Unverified,pagen_sex_2022,NLD
220810_Limburg_SouthLimburgPublicHealthService_Age60+,220810_Limburg_SouthLimburgPublicHealthService,Sex and age differences in the proportion of experienced symptoms by SARS-CoV-2 serostatus in a community-based cross-sectional study.,2022-08-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,Limburg,,"""Only participants without confirmed SARS-CoV-2 infection were included (n = 9715, age range 18–90 years).""

""adults (18+ years) living in the southern Dutch region were eligible for participation"".

""Participants needed to understand, write and read the Dutch language, since materials were only available in Dutch.""

""Only participants with complete participation were included in the analysis, meaning donating a blood sample and filling out the questionnaire.""","""Participants with PCR confirmed SARSCoV-2 infection (n = 286) were excluded (seroprevalence of PCR confirmed participants: 80.1% (95% CI 75.4%–84.7%)).""",2020-10-28,2020-12-23,Household and community samples,All,Seniors (65+ years),60.0,90.0,Age,Age: ≥60,2890,0.18600000000000003,0.135,0.225,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.9450000000000001,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Demi Pagen,South Limburg Public Health Service,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268822001339,2022-09-13,2024-03-01,Unverified,pagen_sex_2022,NLD
220810_Limburg_SouthLimburgPublicHealthService_SexFemale,220810_Limburg_SouthLimburgPublicHealthService,Sex and age differences in the proportion of experienced symptoms by SARS-CoV-2 serostatus in a community-based cross-sectional study.,2022-08-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,Limburg,,"""Only participants without confirmed SARS-CoV-2 infection were included (n = 9715, age range 18–90 years).""

""adults (18+ years) living in the southern Dutch region were eligible for participation"".

""Participants needed to understand, write and read the Dutch language, since materials were only available in Dutch.""

""Only participants with complete participation were included in the analysis, meaning donating a blood sample and filling out the questionnaire.""","""Participants with PCR confirmed SARSCoV-2 infection (n = 286) were excluded (seroprevalence of PCR confirmed participants: 80.1% (95% CI 75.4%–84.7%)).""",2020-10-28,2020-12-23,Household and community samples,Female,Multiple groups,18.0,90.0,Sex/Gender,,5643,0.18,0.17,0.19,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.9450000000000001,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Demi Pagen,South Limburg Public Health Service,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268822001339,2022-09-13,2024-03-01,Unverified,pagen_sex_2022,NLD
220810_Limburg_SouthLimburgPublicHealthService_SexMale,220810_Limburg_SouthLimburgPublicHealthService,Sex and age differences in the proportion of experienced symptoms by SARS-CoV-2 serostatus in a community-based cross-sectional study.,2022-08-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,Limburg,,"""Only participants without confirmed SARS-CoV-2 infection were included (n = 9715, age range 18–90 years).""

""adults (18+ years) living in the southern Dutch region were eligible for participation"".

""Participants needed to understand, write and read the Dutch language, since materials were only available in Dutch.""

""Only participants with complete participation were included in the analysis, meaning donating a blood sample and filling out the questionnaire.""","""Participants with PCR confirmed SARSCoV-2 infection (n = 286) were excluded (seroprevalence of PCR confirmed participants: 80.1% (95% CI 75.4%–84.7%)).""",2020-10-28,2020-12-23,Household and community samples,Male,Multiple groups,18.0,90.0,Sex/Gender,,4068,0.17300000000000001,0.161,0.184,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,,Validated by manufacturers,0.9450000000000001,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Demi Pagen,South Limburg Public Health Service,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268822001339,2022-09-13,2024-03-01,Unverified,pagen_sex_2022,NLD
220909_Netherlands_AmsterdamUniversityMedicalCenters,220909_Netherlands_AmsterdamUniversityMedicalCenters,Differences in systemic and mucosal SARS-CoV-2 antibody prevalence in a prospective cohort of Dutch children.,2022-09-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Netherlands,,,"For this cross-sectional study we simultaneously sampled
blood and saliva of children attending medical care at six
secondary and tertiary care hospitals in the North-West region
of the Netherlands during May 10th to October 15th 2021.",,2021-05-10,2021-10-15,Residual sera,All,Children and Youth (0-17 years),,18.0,Primary Estimate,,209,0.36,0.29,0.43,True,,,,True,Unclear,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.97,0.98,['High'],No,Unclear,No,No,No,Yes,Yes,Yes,Unclear,Maya W Keuning,Amsterdam University Medical Centers,Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2022.976382,2022-10-20,2024-04-10,Verified,keuning_differences_2022,NLD
221215_Netherland_BravisHospital_Overall,221215_Netherland_BravisHospital,"Prevalence, risk and severity of SARS-CoV-2 infections in psoriasis patients receiving conventional systemic, biologic or topical treatment during the COVID-19 pandemic: a cross-sectional cohort study (PsoCOVID)",2022-12-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Netherlands,,"Roosendaal, Nijmegen, Arnhem","The PsoCovid study is a multi-center cross-sectional cohort study of psoriasis patients who received psoriasis treatment between March 2020-October 2021 in 3 Dutch hospitals. 

Included were adults ≥18 years that received BT, ST or TT
between March 2020 until October 2021. Patients could be included irrespective of their vaccination history, because the vaccine-elicited antibodies that are measured are not directed against the SARS-CoV-2 N-antigen. ","Exclusion criteria were immunosuppressive or immunomodulatory treatment for indications other than psoriasis, or immunocompromised due to another reason than psoriasis treatment (e.g. receiving chemotherapy).",2021-04-12,2021-10-31,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,88.0,Primary Estimate,,482,0.064,,,True,,,,True,Convenience,"xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Wantai SARS-CoV-2 Total Ab ELISA","Luminex Corporation,Beijing Wantai Biological",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,K.V. Kwee,Bravis Hospital,Not Unity-Aligned,https://dx.doi.org/10.1080/09546634.2022.2161297,2023-01-10,2024-03-01,Unverified,kwee_prevalence_2022,NLD
220109_Netherlands_NationalInstituteforPublicHealthandtheEnvironment_antiNp,220109_Netherlands_NationalInstituteforPublicHealthandtheEnvironment,The effect of previous SARS-CoV-2 infection and COVID-19 vaccination on SARS-CoV-2 Omicron infection and relation with serological response - A prospective cohort study,2023-01-09,Preprint,National,Cross-sectional survey ,Netherlands,,,"VASCO participants were recruited through random mailings and (social) media campaigns and inclusion ran from May 2021 and December 2021. Community‐dwelling adults aged 18‐85 years were included, and persons 60‐85 years were oversampled.",Participants were excluded if they received more doses than possible according to the Dutch vaccination strategy.,2022-01-10,2022-09-01,Household and community samples,All,Multiple groups,18.0,85.0,Primary Estimate,self-reported positive anti-N test during follow up,43257,0.050800000000000005,,,True,,,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Brechje de Gier,National Institute for Public Health and the Environment,Unity-Aligned,10.1101/2023.01.09.23284334,2023-01-24,2024-04-18,Verified,degier_effect_2023,NLD
230725_Amsterdam_PublicHealthServiceOfAmsterdam_Staff_Overall,230725_Amsterdam_PublicHealthServiceOfAmsterdam_Staff,Low prevalence of current and past SARS-CoV-2 infections among visitors and staff members of homelessness services in Amsterdam at the end of the second wave of infections in the Netherlands.,2023-07-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Netherlands,,Amsterdam,"Inclusion criteria were being a visitor/resident or staff member from the homelessness service, being 18 years or older, being proficient in Dutch, English or Polish and being able to understand the study information.","Exclusion criteria were unable to hold an interview and/or provide informed consent or having severe COVID-19 related symptoms (including fever and shortness of breath), as perceived by the staff.",2021-05-03,2021-05-21,Non-essential workers and unemployed persons,All,Multiple groups,,,Primary Estimate,,53,0.113,0.043,0.23,True,,,,True,Convenience,Biozek Medical COVID-19 Rapid Test,Biozek,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.857,,['High'],,No,No,Yes,,Unclear,Yes,No,,Ellen Generaal,Public Health Service of Amsterdam,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0288610,2023-08-21,2024-03-01,Unverified,generaal_low_2023,NLD
230725_Amsterdam_PublicHealthServiceOfAmsterdam_Visitors_Overall,230725_Amsterdam_PublicHealthServiceOfAmsterdam_Visitors,Low prevalence of current and past SARS-CoV-2 infections among visitors and staff members of homelessness services in Amsterdam at the end of the second wave of infections in the Netherlands.,2023-07-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Netherlands,,Amsterdam,"Inclusion criteria were being a visitor/resident or staff member from the homelessness service, being 18 years or older, being proficient in Dutch, English or Polish and being able to understand the study information.","Exclusion criteria were unable to hold an interview and/or provide informed consent or having severe COVID-19 related symptoms (including fever and shortness of breath), as perceived by the staff.",2021-05-03,2021-05-21,Persons experiencing homelessness,All,Multiple groups,,,Primary Estimate,,134,0.03,0.008,0.075,True,,,,True,Convenience,Biozek Medical COVID-19 Rapid Test,Biozek,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.857,,['High'],,No,No,Yes,,Unclear,Yes,No,,Ellen Generaal,Public Health Service of Amsterdam,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0288610,2023-08-21,2024-03-01,Unverified,generaal_low_2023,NLD
230801_Netherlands_EmmaChildren’sHospital,230801_Netherlands_EmmaChildren’sHospital,Physical activity in lactating women influences SARS-CoV-2-specific antibodies in human milk.,2023-08-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Netherlands,,,"""In the current study, where we investigated the relationship between SARS-CoV-2 specific antibodies in serum/milk and physical activity, only the lactating women of the COVID MILK – POWER MILK who have had a previous SARS-CoV-2 infection were included.""","""From these participants, 11 participants had to be excluded due to missing human milk samples. """,2020-10-12,2021-02-24,Residual sera,Female,Adults (18-64 years),20.0,44.0,Primary Estimate,,2312,0.154,,,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,Serum,"['IgA', 'IgG']",Spike,,0.679,0.99,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Hannah G. Juncker,Emma Children’s Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.heliyon.2023.e19218,2023-09-21,2023-09-22,Unverified,junckerPhysicalActivityLactating2023,NLD
230802_Netherland_AmsterdamUMClocationVrijeUniversiteitAmsterdam_Overall,230802_Netherland_AmsterdamUMClocationVrijeUniversiteitAmsterdam,"Why not to pick your nose: Association between nose picking and SARS-CoV-2 incidence, a cohort study in hospital health care workers.",2023-08-02,Journal Article (Peer-Reviewed),Local,Prospective cohort,Netherlands,,Amsterdam,HCW working in the Amsterdam University Medical Centers,,2020-03-15,2020-10-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,HCWs working in the Amsterdam University Medical Centers,219,0.155,,,True,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.954,0.996,['High'],,No,No,Yes,,Yes,Yes,Yes,,A. H. Ayesha Lavell,Amsterdam UMC location Vrije Universiteit Amsterdam,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0288352,2023-08-22,2024-03-01,Unverified,lavell_why_2023,NLD
210419_NewZealand_UniversityOfAuckland_BloodDonors,210419_NewZealand_UniversityOfAuckland,Charting Elimination in the Pandemic: A SARS-CoV-2 Serosurvey of Blood Donors in New Zealand,2021-04-19,Preprint,National,Cross-sectional survey ,New Zealand,,,"Blood donors aged 16 to 88 years. 9,771 are blood donors and
35 are living tissue and stem cell donors. All donors must be free of illness and weigh >50 kg.",exclusions include illness within the previous 28 days as well as vCJD risk if domiciled in the UK between 1980-1996,2020-12-03,2021-01-06,Blood donors,All,Adults (18-64 years),16.0,88.0,Primary Estimate,,9806,0.0010299999999999999,0.0009,0.0012,True,True,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgG,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit","EUROIMMUN,GenScript",Multiple Types,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,0.8170000000000001,1.0,['Moderate'],No,No,Yes,Yes,Yes,No,Yes,Yes,Yes,Lauren Carlton,University of Auckland,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.04.12.21255282v1,2021-05-20,2023-08-15,Verified,carltonChartingEliminationPandemic2021,NZL
210419_NewZealand_UniversityOfAuckland_BloodDonors,210419_NewZealand_UniversityOfAuckland,Charting Elimination in the Pandemic: A SARS-CoV-2 Serosurvey of Blood Donors in New Zealand,2021-04-19,Preprint,National,Cross-sectional survey ,New Zealand,,,"Blood donors aged 16 to 88 years. 9,771 are blood donors and
35 are living tissue and stem cell donors. All donors must be free of illness and weigh >50 kg.",exclusions include illness within the previous 28 days as well as vCJD risk if domiciled in the UK between 1980-1996,2020-12-03,2021-01-06,Blood donors,All,Adults (18-64 years),16.0,88.0,Analysis,,9806,0.0018,,,,,,,True,Sequential,"Anti-SARS-CoV-2 ELISA IgG,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit","EUROIMMUN,GenScript",Multiple Types,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,0.8170000000000001,1.0,['Moderate'],No,No,Yes,Yes,Yes,No,Yes,Yes,Yes,Lauren Carlton,University of Auckland,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.04.12.21255282v1,2021-08-12,2024-03-01,Verified,carltonChartingEliminationPandemic2021,NZL
210518_NewZealand_SouthernCommunityLaboratories_MostAdj,210518_NewZealand_SouthernCommunityLaboratories,"SARS-CoV-2 antibodies in the Southern Region of New Zealand, 2020.",2021-05-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,New Zealand,Southern Region,,"The PCR-confirmed and probable cases, and their contacts were contacted for recruitment via the local public health unit. The remaining higher risk individuals (frontline healthcare workers,  tourism workers, or Queenstown residents) were recruited via posters and media (print, television, and social media).",,2020-06-04,2020-08-04,Contacts of COVID patients,All,Multiple groups,4.0,90.0,Primary Estimate,"Abbott and at least one other test, test adjusted",1127,0.008,0.004,0.015,True,True,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Wantai SARS-CoV-2 Total Ab ELISA,Anti-SARS-CoV-2 ELISA IgG,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Author designed (ELISA) -Spike","Abbott Laboratories,Beijing Wantai Biological,EUROIMMUN,GenScript,NA",Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Alyson Craigie,Southern Community Laboratories,Not Unity-Aligned,https://dx.doi.org/10.1016/j.pathol.2021.04.001,2021-06-20,2023-08-15,Verified,craigie_sars-cov-2_2021,NZL
210819_Managua_UniversityOfMichiganAnnArbor_Primary_PopAdj,210819_Managua_UniversityOfMichiganAnnArbor,Clinical spectrum of SARS-CoV-2 infection and protection from symptomatic re-infection,2021-08-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Nicaragua,,Managua,"The Household Influenza Cohort Study (HICS) began in 2017
and is an ongoing study in Managua, Nicaragua. HICS is a
community-based cohort in which participants are provided
with their primary care, are encouraged to report to the study
health center at the first indication of any illness, and are followed
for influenza infection and illness. 

Annual blood samples were collected in March 2020 or at enrollment, and midyear samples were collected during October–November 2020.",,2020-10-15,2020-11-15,Household and community samples,All,Multiple groups,0.0,96.0,Primary Estimate,,1995,0.5750000000000001,,,True,,True,,,Self-referral,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Hannah E. Maier,"University of Michigan, Ann Arbor ",Not Unity-Aligned,http://dx.doi.org/10.1093/cid/ciab717,2021-09-21,2022-07-16,Verified,maier_clinilcal_2021,NIC
210819_Managua_UniversityOfMichiganAnnArbor_Age30-59,210819_Managua_UniversityOfMichiganAnnArbor,Clinical spectrum of SARS-CoV-2 infection and protection from symptomatic re-infection,2021-08-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Nicaragua,,Managua,"The Household Influenza Cohort Study (HICS) began in 2017
and is an ongoing study in Managua, Nicaragua. HICS is a
community-based cohort in which participants are provided
with their primary care, are encouraged to report to the study
health center at the first indication of any illness, and are followed
for influenza infection and illness. 

Annual blood samples were collected in March 2020 or at enrollment, and midyear samples were collected during October–November 2020.",,2020-10-15,2020-11-15,Household and community samples,All,Adults (18-64 years),30.0,59.0,Age,age 30-59,565,0.6020000000000001,0.541,0.669,,,,,,Self-referral,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Hannah E. Maier,"University of Michigan, Ann Arbor ",Not Unity-Aligned,http://dx.doi.org/10.1093/cid/ciab717,2021-09-21,2022-07-16,Verified,maier_clinilcal_2021,NIC
210819_Managua_UniversityOfMichiganAnnArbor_Female,210819_Managua_UniversityOfMichiganAnnArbor,Clinical spectrum of SARS-CoV-2 infection and protection from symptomatic re-infection,2021-08-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Nicaragua,,Managua,"The Household Influenza Cohort Study (HICS) began in 2017
and is an ongoing study in Managua, Nicaragua. HICS is a
community-based cohort in which participants are provided
with their primary care, are encouraged to report to the study
health center at the first indication of any illness, and are followed
for influenza infection and illness. 

Annual blood samples were collected in March 2020 or at enrollment, and midyear samples were collected during October–November 2020.",,2020-10-15,2020-11-15,Household and community samples,Female,Multiple groups,0.0,96.0,Sex/Gender,,1231,0.593,0.552,0.638,,,,,,Self-referral,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Hannah E. Maier,"University of Michigan, Ann Arbor ",Not Unity-Aligned,http://dx.doi.org/10.1093/cid/ciab717,2021-09-21,2022-07-16,Verified,maier_clinilcal_2021,NIC
210819_Managua_UniversityOfMichiganAnnArbor_Male,210819_Managua_UniversityOfMichiganAnnArbor,Clinical spectrum of SARS-CoV-2 infection and protection from symptomatic re-infection,2021-08-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Nicaragua,,Managua,"The Household Influenza Cohort Study (HICS) began in 2017
and is an ongoing study in Managua, Nicaragua. HICS is a
community-based cohort in which participants are provided
with their primary care, are encouraged to report to the study
health center at the first indication of any illness, and are followed
for influenza infection and illness. 

Annual blood samples were collected in March 2020 or at enrollment, and midyear samples were collected during October–November 2020.",,2020-10-15,2020-11-15,Household and community samples,Male,Multiple groups,0.0,96.0,Sex/Gender,,764,0.526,0.47700000000000004,0.58,,,,,,Self-referral,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Hannah E. Maier,"University of Michigan, Ann Arbor ",Not Unity-Aligned,http://dx.doi.org/10.1093/cid/ciab717,2021-09-21,2022-07-16,Verified,maier_clinilcal_2021,NIC
210819_Managua_UniversityOfMichiganAnnArbor_Age60-96,210819_Managua_UniversityOfMichiganAnnArbor,Clinical spectrum of SARS-CoV-2 infection and protection from symptomatic re-infection,2021-08-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Nicaragua,,Managua,"The Household Influenza Cohort Study (HICS) began in 2017
and is an ongoing study in Managua, Nicaragua. HICS is a
community-based cohort in which participants are provided
with their primary care, are encouraged to report to the study
health center at the first indication of any illness, and are followed
for influenza infection and illness. 

Annual blood samples were collected in March 2020 or at enrollment, and midyear samples were collected during October–November 2020.",,2020-10-15,2020-11-15,Household and community samples,All,Seniors (65+ years),60.0,96.0,Age,age 60-96,113,0.619,0.49,0.783,,,,,,Self-referral,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Hannah E. Maier,"University of Michigan, Ann Arbor ",Not Unity-Aligned,http://dx.doi.org/10.1093/cid/ciab717,2021-09-21,2022-07-16,Verified,maier_clinilcal_2021,NIC
210819_Managua_UniversityOfMichiganAnnArbor_Age5-10,210819_Managua_UniversityOfMichiganAnnArbor,Clinical spectrum of SARS-CoV-2 infection and protection from symptomatic re-infection,2021-08-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Nicaragua,,Managua,"The Household Influenza Cohort Study (HICS) began in 2017
and is an ongoing study in Managua, Nicaragua. HICS is a
community-based cohort in which participants are provided
with their primary care, are encouraged to report to the study
health center at the first indication of any illness, and are followed
for influenza infection and illness. 

Annual blood samples were collected in March 2020 or at enrollment, and midyear samples were collected during October–November 2020.",,2020-10-15,2020-11-15,Household and community samples,All,Children and Youth (0-17 years),5.0,10.0,Age,age 5-10,431,0.506,0.443,0.578,,,,,,Self-referral,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Hannah E. Maier,"University of Michigan, Ann Arbor ",Not Unity-Aligned,http://dx.doi.org/10.1093/cid/ciab717,2021-09-21,2022-07-16,Verified,maier_clinilcal_2021,NIC
210819_Managua_UniversityOfMichiganAnnArbor_Age0-2,210819_Managua_UniversityOfMichiganAnnArbor,Clinical spectrum of SARS-CoV-2 infection and protection from symptomatic re-infection,2021-08-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Nicaragua,,Managua,"The Household Influenza Cohort Study (HICS) began in 2017
and is an ongoing study in Managua, Nicaragua. HICS is a
community-based cohort in which participants are provided
with their primary care, are encouraged to report to the study
health center at the first indication of any illness, and are followed
for influenza infection and illness. 

Annual blood samples were collected in March 2020 or at enrollment, and midyear samples were collected during October–November 2020.",,2020-10-15,2020-11-15,Household and community samples,All,Children and Youth (0-17 years),0.0,2.0,Age,age 0-2,89,0.47200000000000003,0.349,0.639,,,,,,Self-referral,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Hannah E. Maier,"University of Michigan, Ann Arbor ",Not Unity-Aligned,http://dx.doi.org/10.1093/cid/ciab717,2021-09-21,2022-07-16,Verified,maier_clinilcal_2021,NIC
210819_Managua_UniversityOfMichiganAnnArbor_Age18-29,210819_Managua_UniversityOfMichiganAnnArbor,Clinical spectrum of SARS-CoV-2 infection and protection from symptomatic re-infection,2021-08-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Nicaragua,,Managua,"The Household Influenza Cohort Study (HICS) began in 2017
and is an ongoing study in Managua, Nicaragua. HICS is a
community-based cohort in which participants are provided
with their primary care, are encouraged to report to the study
health center at the first indication of any illness, and are followed
for influenza infection and illness. 

Annual blood samples were collected in March 2020 or at enrollment, and midyear samples were collected during October–November 2020.",,2020-10-15,2020-11-15,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,age 18-29,291,0.605,0.522,0.701,,,,,,Self-referral,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Hannah E. Maier,"University of Michigan, Ann Arbor ",Not Unity-Aligned,http://dx.doi.org/10.1093/cid/ciab717,2021-09-21,2022-07-16,Verified,maier_clinilcal_2021,NIC
210819_Managua_UniversityOfMichiganAnnArbor_unAdj,210819_Managua_UniversityOfMichiganAnnArbor,Clinical spectrum of SARS-CoV-2 infection and protection from symptomatic re-infection,2021-08-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Nicaragua,,Managua,"The Household Influenza Cohort Study (HICS) began in 2017
and is an ongoing study in Managua, Nicaragua. HICS is a
community-based cohort in which participants are provided
with their primary care, are encouraged to report to the study
health center at the first indication of any illness, and are followed
for influenza infection and illness. 

Annual blood samples were collected in March 2020 or at enrollment, and midyear samples were collected during October–November 2020.",,2020-10-15,2020-11-15,Household and community samples,All,Multiple groups,0.0,96.0,Analysis,,1995,0.5670000000000001,,,,,,,True,Self-referral,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Hannah E. Maier,"University of Michigan, Ann Arbor ",Not Unity-Aligned,http://dx.doi.org/10.1093/cid/ciab717,2021-09-21,2022-07-16,Verified,maier_clinilcal_2021,NIC
210819_Managua_UniversityOfMichiganAnnArbor_Age3-4,210819_Managua_UniversityOfMichiganAnnArbor,Clinical spectrum of SARS-CoV-2 infection and protection from symptomatic re-infection,2021-08-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Nicaragua,,Managua,"The Household Influenza Cohort Study (HICS) began in 2017
and is an ongoing study in Managua, Nicaragua. HICS is a
community-based cohort in which participants are provided
with their primary care, are encouraged to report to the study
health center at the first indication of any illness, and are followed
for influenza infection and illness. 

Annual blood samples were collected in March 2020 or at enrollment, and midyear samples were collected during October–November 2020.",,2020-10-15,2020-11-15,Household and community samples,All,Children and Youth (0-17 years),3.0,4.0,Age,age 3-4,94,0.394,0.28500000000000003,0.543,,,,,,Self-referral,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Hannah E. Maier,"University of Michigan, Ann Arbor ",Not Unity-Aligned,http://dx.doi.org/10.1093/cid/ciab717,2021-09-21,2022-07-16,Verified,maier_clinilcal_2021,NIC
210819_Managua_UniversityOfMichiganAnnArbor_Age11-17,210819_Managua_UniversityOfMichiganAnnArbor,Clinical spectrum of SARS-CoV-2 infection and protection from symptomatic re-infection,2021-08-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Nicaragua,,Managua,"The Household Influenza Cohort Study (HICS) began in 2017
and is an ongoing study in Managua, Nicaragua. HICS is a
community-based cohort in which participants are provided
with their primary care, are encouraged to report to the study
health center at the first indication of any illness, and are followed
for influenza infection and illness. 

Annual blood samples were collected in March 2020 or at enrollment, and midyear samples were collected during October–November 2020.",,2020-10-15,2020-11-15,Household and community samples,All,Children and Youth (0-17 years),11.0,17.0,Age,age 11-17,412,0.604,0.534,0.684,,,,,,Self-referral,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Hannah E. Maier,"University of Michigan, Ann Arbor ",Not Unity-Aligned,http://dx.doi.org/10.1093/cid/ciab717,2021-09-21,2022-07-16,Verified,maier_clinilcal_2021,NIC
211020_Leon_NationalAutonomousUniversityofNicaraguaatLeon_FebMar2021_TestAdj,211020_Leon_NationalAutonomousUniversityofNicaraguaatLeon_FebMar2021,"Seroepidemiology of SARS-CoV-2 infections in an urban population-based cohort in Leon, Nicaragua",2021-10-20,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Nicaragua,, León,"Paticipants who were tested during the first time point, who were taken from The SAGE study, a population-based birth cohort
study in León, Nicaragua. ""Starting in July 2020, we contacted the household members of
350 cohort children (both adults and children) and offered participation in this study. We also offered participation in the study for
cohort children, including those who had reached 36 months of
age. Any interested household members were eligible to enrol,
and not all household members were required to enrol.""",,2021-02-15,2021-03-15,Household and community samples,All,Multiple groups,,,Primary Estimate,Test adjustment,1243,0.34700000000000003,0.312,0.38200000000000006,True,True,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9520000000000001,0.9670000000000001,['Moderate'],,No,Yes,No,,Unclear,Yes,Yes,,Fredman Gonzalez,The National Autonomous University of Nicaragua at León,Not Unity-Aligned,10.1017/s0950268821002144,2022-01-01,2022-07-16,Unverified,gonzalez_seroepidemiology_2021-1,NIC
211020_Leon_NationalAutonomousUniversityofNicaraguaatLeon_FebMar2021_Crude,211020_Leon_NationalAutonomousUniversityofNicaraguaatLeon_FebMar2021,"Seroepidemiology of SARS-CoV-2 infections in an urban population-based cohort in Leon, Nicaragua",2021-10-20,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Nicaragua,, León,"Paticipants who were tested during the first time point, who were taken from The SAGE study, a population-based birth cohort
study in León, Nicaragua. ""Starting in July 2020, we contacted the household members of
350 cohort children (both adults and children) and offered participation in this study. We also offered participation in the study for
cohort children, including those who had reached 36 months of
age. Any interested household members were eligible to enrol,
and not all household members were required to enrol.""",,2021-02-15,2021-03-15,Household and community samples,All,Multiple groups,,,Analysis,,1243,0.35200000000000004,,,,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9520000000000001,0.9670000000000001,['Moderate'],,No,Yes,No,,Unclear,Yes,Yes,,Fredman Gonzalez,The National Autonomous University of Nicaragua at León,Not Unity-Aligned,10.1017/s0950268821002144,2022-01-01,2022-07-16,Unverified,gonzalez_seroepidemiology_2021-1,NIC
211020_Leon_NationalAutonomousUniversityofNicaraguaatLeon_SepOct2020_TestAdj,211020_Leon_NationalAutonomousUniversityofNicaraguaatLeon_SepOct2020,"Seroepidemiology of SARS-CoV-2 infections in an urban population-based cohort in Leon, Nicaragua",2021-10-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Nicaragua,, León,"Participants of The Sapovirus-Associated Gastro-Enteritis (SAGE) study, a population-based birth cohort
study in León, Nicaragua. ""Starting in July 2020, we contacted the household members of
350 cohort children (both adults and children) and offered participation in this study. We also offered participation in the study for
cohort children, including those who had reached 36 months of
age. Any interested household members were eligible to enrol,
and not all household members were required to enrol.""",,2020-09-15,2020-10-15,Household and community samples,All,Multiple groups,,,Primary Estimate,Test adjustment,1243,0.268,0.233,0.30100000000000005,True,True,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9520000000000001,0.9670000000000001,['Moderate'],,No,Yes,No,,Unclear,Yes,Yes,,Fredman Gonzalez,The National Autonomous University of Nicaragua at León,Not Unity-Aligned,10.1017/s0950268821002144,2022-01-01,2022-07-16,Unverified,gonzalez_seroepidemiology_2021-1,NIC
211020_Leon_NationalAutonomousUniversityofNicaraguaatLeon_SepOct2020_Crude,211020_Leon_NationalAutonomousUniversityofNicaraguaatLeon_SepOct2020,"Seroepidemiology of SARS-CoV-2 infections in an urban population-based cohort in Leon, Nicaragua",2021-10-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Nicaragua,, León,"Participants of The Sapovirus-Associated Gastro-Enteritis (SAGE) study, a population-based birth cohort
study in León, Nicaragua. ""Starting in July 2020, we contacted the household members of
350 cohort children (both adults and children) and offered participation in this study. We also offered participation in the study for
cohort children, including those who had reached 36 months of
age. Any interested household members were eligible to enrol,
and not all household members were required to enrol.""",,2020-09-15,2020-10-15,Household and community samples,All,Multiple groups,,,Analysis,,1243,0.27899999999999997,,,,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9520000000000001,0.9670000000000001,['Moderate'],,No,Yes,No,,Unclear,Yes,Yes,,Fredman Gonzalez,The National Autonomous University of Nicaragua at León,Not Unity-Aligned,10.1017/s0950268821002144,2022-01-01,2022-07-16,Unverified,gonzalez_seroepidemiology_2021-1,NIC
220105_Managua_UniversityofMichigan,220105_Managua_UniversityofMichigan,Burden of SARS-CoV-2 and protection from symptomatic second infection in children.,2022-01-05,Preprint,Local,Prospective cohort,Nicaragua,Managua,Managua,"Participants were from the Nicaraguan Pediatric Influenza Cohort, the methods of which have been described in detail previously.23 Briefly, children aged 0-14 years were enrolled when visiting the Health Center Sócrates Flores Vivas (HCSFV), or through home visits, and followed until their 15th birthday or loss to follow-up.",,2020-03-01,2021-10-15,Household and community samples,All,Children and Youth (0-17 years),0.0,14.0,Primary Estimate,,1824,0.498,,,True,,,,,Unclear,Author designed (ELISA) -Spike,,ELISA,Serum,,Spike,,,,['High'],,Unclear,Yes,Yes,,Unclear,Yes,No,,John Kubale,University of Michigan,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.01.03.22268684v1.full-text,2022-01-18,2022-07-16,Unverified,kubale_burden_2022,NIC
220105_Nicaragua_MountAuburnHospital_Ages_40-59,220105_Nicaragua_MountAuburnHospital,SARS-CoV-2 prevalence at eight urban health clinics in Nicaragua: possible implications for the COVID-19 pandemic.,2022-01-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Nicaragua,,,"From 22 February to 19 March 2021, study staff at participating
health clinics recruited patients by inviting them to enrol in the study.
On the day of specimen collection, an investigator in charge of recruiting
volunteers invited patients attending routine check-ups or seeking care
for issues unrelated to COVID-19 to participate in the study. Study participation on application was random and voluntary. All patients were
eligible to participate.","Eight samples were
excluded because the consent signature was missing (n=5) or they were
from the same family (n=3) ",2021-02-22,2021-03-19,Household and community samples,All,Adults (18-64 years),40.0,59.0,Age,,156,0.42310000000000003,,,True,,,,True,Convenience,COVID-19 IgG/IgM Rapid Test,SafeCare Bio-Tech,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.91,0.96,['High'],,No,No,Yes,,No,Yes,No,,Jorge Huete-Perez,Mount Auburn Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijregi.2021.12.013,2022-06-28,2024-03-01,Unverified,huete-perez_sars-cov-2_2022,NIC
220105_Nicaragua_MountAuburnHospital_Ages_19-39,220105_Nicaragua_MountAuburnHospital,SARS-CoV-2 prevalence at eight urban health clinics in Nicaragua: possible implications for the COVID-19 pandemic.,2022-01-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Nicaragua,,,"From 22 February to 19 March 2021, study staff at participating
health clinics recruited patients by inviting them to enrol in the study.
On the day of specimen collection, an investigator in charge of recruiting
volunteers invited patients attending routine check-ups or seeking care
for issues unrelated to COVID-19 to participate in the study. Study participation on application was random and voluntary. All patients were
eligible to participate.","Eight samples were
excluded because the consent signature was missing (n=5) or they were
from the same family (n=3) ",2021-02-22,2021-03-19,Household and community samples,All,Adults (18-64 years),19.0,39.0,Age,,208,0.4375,,,True,,,,True,Convenience,COVID-19 IgG/IgM Rapid Test,SafeCare Bio-Tech,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.91,0.96,['High'],,No,No,Yes,,No,Yes,No,,Jorge Huete-Perez,Mount Auburn Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijregi.2021.12.013,2022-06-28,2024-03-01,Unverified,huete-perez_sars-cov-2_2022,NIC
220105_Nicaragua_MountAuburnHospital_Ages_60+,220105_Nicaragua_MountAuburnHospital,SARS-CoV-2 prevalence at eight urban health clinics in Nicaragua: possible implications for the COVID-19 pandemic.,2022-01-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Nicaragua,,,"From 22 February to 19 March 2021, study staff at participating
health clinics recruited patients by inviting them to enrol in the study.
On the day of specimen collection, an investigator in charge of recruiting
volunteers invited patients attending routine check-ups or seeking care
for issues unrelated to COVID-19 to participate in the study. Study participation on application was random and voluntary. All patients were
eligible to participate.","Eight samples were
excluded because the consent signature was missing (n=5) or they were
from the same family (n=3) ",2021-02-22,2021-03-19,Household and community samples,All,Seniors (65+ years),60.0,,Age,,60,0.3667,,,True,,,,True,Convenience,COVID-19 IgG/IgM Rapid Test,SafeCare Bio-Tech,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.91,0.96,['High'],,No,No,Yes,,No,Yes,No,,Jorge Huete-Perez,Mount Auburn Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijregi.2021.12.013,2022-06-28,2024-03-01,Unverified,huete-perez_sars-cov-2_2022,NIC
220105_Nicaragua_MountAuburnHospital_City_Managua,220105_Nicaragua_MountAuburnHospital,SARS-CoV-2 prevalence at eight urban health clinics in Nicaragua: possible implications for the COVID-19 pandemic.,2022-01-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Nicaragua,,Managua,"From 22 February to 19 March 2021, study staff at participating
health clinics recruited patients by inviting them to enrol in the study.
On the day of specimen collection, an investigator in charge of recruiting
volunteers invited patients attending routine check-ups or seeking care
for issues unrelated to COVID-19 to participate in the study. Study participation on application was random and voluntary. All patients were
eligible to participate.","Eight samples were
excluded because the consent signature was missing (n=5) or they were
from the same family (n=3) ",2021-02-22,2021-03-19,Household and community samples,All,Multiple groups,,,Geographical area,,451,0.3836,,,True,,,,True,Convenience,COVID-19 IgG/IgM Rapid Test,SafeCare Bio-Tech,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.91,0.96,['High'],,No,No,Yes,,No,Yes,No,,Jorge Huete-Perez,Mount Auburn Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijregi.2021.12.013,2022-06-28,2024-03-01,Unverified,huete-perez_sars-cov-2_2022,NIC
220105_Nicaragua_MountAuburnHospital_Sex_Male,220105_Nicaragua_MountAuburnHospital,SARS-CoV-2 prevalence at eight urban health clinics in Nicaragua: possible implications for the COVID-19 pandemic.,2022-01-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Nicaragua,,,"From 22 February to 19 March 2021, study staff at participating
health clinics recruited patients by inviting them to enrol in the study.
On the day of specimen collection, an investigator in charge of recruiting
volunteers invited patients attending routine check-ups or seeking care
for issues unrelated to COVID-19 to participate in the study. Study participation on application was random and voluntary. All patients were
eligible to participate.","Eight samples were
excluded because the consent signature was missing (n=5) or they were
from the same family (n=3) ",2021-02-22,2021-03-19,Household and community samples,Male,Multiple groups,,,Sex/Gender,,228,0.386,,,True,,,,True,Convenience,COVID-19 IgG/IgM Rapid Test,SafeCare Bio-Tech,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.91,0.96,['High'],,No,No,Yes,,No,Yes,No,,Jorge Huete-Perez,Mount Auburn Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijregi.2021.12.013,2022-06-28,2024-03-01,Unverified,huete-perez_sars-cov-2_2022,NIC
220105_Nicaragua_MountAuburnHospital_Ages_0-18,220105_Nicaragua_MountAuburnHospital,SARS-CoV-2 prevalence at eight urban health clinics in Nicaragua: possible implications for the COVID-19 pandemic.,2022-01-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Nicaragua,,,"From 22 February to 19 March 2021, study staff at participating
health clinics recruited patients by inviting them to enrol in the study.
On the day of specimen collection, an investigator in charge of recruiting
volunteers invited patients attending routine check-ups or seeking care
for issues unrelated to COVID-19 to participate in the study. Study participation on application was random and voluntary. All patients were
eligible to participate.","Eight samples were
excluded because the consent signature was missing (n=5) or they were
from the same family (n=3) ",2021-02-22,2021-03-19,Household and community samples,All,Children and Youth (0-17 years),0.0,18.0,Age,,78,0.15380000000000002,,,True,,,,True,Convenience,COVID-19 IgG/IgM Rapid Test,SafeCare Bio-Tech,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.91,0.96,['High'],,No,No,Yes,,No,Yes,No,,Jorge Huete-Perez,Mount Auburn Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijregi.2021.12.013,2022-06-28,2024-03-01,Unverified,huete-perez_sars-cov-2_2022,NIC
220105_Nicaragua_MountAuburnHospital_Sex_Female,220105_Nicaragua_MountAuburnHospital,SARS-CoV-2 prevalence at eight urban health clinics in Nicaragua: possible implications for the COVID-19 pandemic.,2022-01-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Nicaragua,,,"From 22 February to 19 March 2021, study staff at participating
health clinics recruited patients by inviting them to enrol in the study.
On the day of specimen collection, an investigator in charge of recruiting
volunteers invited patients attending routine check-ups or seeking care
for issues unrelated to COVID-19 to participate in the study. Study participation on application was random and voluntary. All patients were
eligible to participate.","Eight samples were
excluded because the consent signature was missing (n=5) or they were
from the same family (n=3) ",2021-02-22,2021-03-19,Household and community samples,Female,Multiple groups,,,Sex/Gender,,274,0.37590000000000007,,,True,,,,True,Convenience,COVID-19 IgG/IgM Rapid Test,SafeCare Bio-Tech,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.91,0.96,['High'],,No,No,Yes,,No,Yes,No,,Jorge Huete-Perez,Mount Auburn Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijregi.2021.12.013,2022-06-28,2024-03-01,Unverified,huete-perez_sars-cov-2_2022,NIC
220105_Nicaragua_MountAuburnHospital_CIty_Leon_Masaya,220105_Nicaragua_MountAuburnHospital,SARS-CoV-2 prevalence at eight urban health clinics in Nicaragua: possible implications for the COVID-19 pandemic.,2022-01-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Nicaragua,,"Leon, Masaya","From 22 February to 19 March 2021, study staff at participating
health clinics recruited patients by inviting them to enrol in the study.
On the day of specimen collection, an investigator in charge of recruiting
volunteers invited patients attending routine check-ups or seeking care
for issues unrelated to COVID-19 to participate in the study. Study participation on application was random and voluntary. All patients were
eligible to participate.","Eight samples were
excluded because the consent signature was missing (n=5) or they were
from the same family (n=3) ",2021-02-22,2021-03-19,Household and community samples,All,Multiple groups,,,Geographical area,,51,0.3529,,,True,,,,True,Convenience,COVID-19 IgG/IgM Rapid Test,SafeCare Bio-Tech,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.91,0.96,['High'],,No,No,Yes,,No,Yes,No,,Jorge Huete-Perez,Mount Auburn Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijregi.2021.12.013,2022-06-28,2024-03-01,Unverified,huete-perez_sars-cov-2_2022,NIC
220105_Nicaragua_MountAuburnHospital_Overall,220105_Nicaragua_MountAuburnHospital,SARS-CoV-2 prevalence at eight urban health clinics in Nicaragua: possible implications for the COVID-19 pandemic.,2022-01-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Nicaragua,,,"From 22 February to 19 March 2021, study staff at participating
health clinics recruited patients by inviting them to enrol in the study.
On the day of specimen collection, an investigator in charge of recruiting
volunteers invited patients attending routine check-ups or seeking care
for issues unrelated to COVID-19 to participate in the study. Study participation on application was random and voluntary. All patients were
eligible to participate.","Eight samples were
excluded because the consent signature was missing (n=5) or they were
from the same family (n=3) ",2021-02-22,2021-03-19,Household and community samples,All,Multiple groups,,,Primary Estimate,,502,0.38,,,True,,,,True,Convenience,COVID-19 IgG/IgM Rapid Test,SafeCare Bio-Tech,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.91,0.96,['High'],,No,No,Yes,,No,Yes,No,,Jorge Huete-Perez,Mount Auburn Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijregi.2021.12.013,2022-06-28,2024-03-01,Unverified,huete-perez_sars-cov-2_2022,NIC
220525_Managua_UniversityofMichigan_2020,220525_Managua_UniversityofMichigan_2020,SARS-CoV-2 and endemic coronaviruses: Comparing symptom presentation and severity of symptomatic illness among Nicaraguan children.,2022-05-25,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Nicaragua,,Managua,"""Children ages 0–14 years who live in District 2 of Managua, Nicaragua and within the catchment area of Health Center So ́crates Flores Vivas were eligible to participate. ""

""Participants included in this analysis were members of NPICS between 2011–2016 or March 2020 to September 2021.""",,2020-03-01,2021-09-30,Residual sera,All,Children and Youth (0-17 years),0.0,14.0,Primary Estimate,,1455,0.016,,,True,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Aaron Frutos,"University of Michigan
",Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0000414,2022-07-13,2022-07-25,Unverified,frutosSARSCoV2EndemicCoronaviruses2022,NIC
220525_Managua_ UniversityofMichigan_2021,220525_Managua_UniversityofMichigan_2021,SARS-CoV-2 and endemic coronaviruses: Comparing symptom presentation and severity of symptomatic illness among Nicaraguan children.,2022-05-25,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Nicaragua,,Managua,"""Children ages 0–14 years who live in District 2 of Managua, Nicaragua and within the catchment area of Health Center So ́crates Flores Vivas were eligible to participate. ""

""Participants included in this analysis were members of NPICS between 2011–2016 or March 2020 to September 2021.""",,2020-03-01,2021-09-30,Residual sera,All,Children and Youth (0-17 years),0.0,14.0,Primary Estimate,,1743,0.49,,,True,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Aaron Frutos,"University of Michigan
",Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0000414,2022-07-13,2022-07-25,Unverified,frutosSARSCoV2EndemicCoronaviruses2022,NIC
220627_Nicarugua_UniversityOfMichiganSchoolOfPublicHealth,220627_Nicarugua_UniversityOfMichiganSchoolOfPublicHealth,Association of SARS-CoV-2 Seropositivity and Symptomatic Reinfection in Children in Nicaragua.,2022-06-27,Journal Article (Peer-Reviewed),National,Prospective cohort,Nicaragua,,,"Participants were from the Nicaraguan Pediatric Influenza Cohort, the methods of which have been described in detail previously:

https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-015-1256-6
:
""The NPICS is conducted in District II of Managua, Nicaragua, at the Health Center Sócrates Flores Vivas (HCSFV). The district is adjacent to Lake Managua and includes neighborhoods ranging from low to middle class, including several areas classified as urban slums""",,2020-03-01,2021-10-15,Household and community samples,All,Children and Youth (0-17 years),0.0,14.0,Primary Estimate,,1824,0.498,0.47500000000000003,0.521,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,John Kubale,University of Michigan School of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.18794,2022-07-25,2022-07-25,Unverified,kubale_association_2022,NIC
221201_Nicaragua_UniversityOfMichigan_Primary,221201_Nicaragua_UniversityOfMichigan,SARS-CoV-2 infection-induced immunity and the duration of viral shedding: Results from a Nicaraguan household cohort study,2022-12-01,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Nicaragua,,Managua,previous blood samples from PCR positive individuals in a household survey,"""To assess seropositivity resulting from prior infection, individuals with
any vaccine dose ≥14 days prior to shedding onset were excluded for
primary analyses.""",2020-05-15,2022-03-15,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,745,0.595,,,True,,,,True,Convenience,Author designed (ELISA) - Unknown,,ELISA,Serum,,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Hannah E. Maier,University of Michigan,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.13074,2023-02-20,2023-03-22,Unverified,maier_sars-cov-2_2022,NIC
200724_Nigeria_JosephUkpoHospitalsandResearchInstitutes_HCWPatients_IgG_T1,200724_Nigeria_JosephUkpoHospitalsandResearchInstitutes,Prevalence of IgG and IgM antibodies to SARS-CoV-2 among clinic staff and patients,2020-07-24,Preprint,Local,Cross-sectional survey ,Nigeria,Cross River State,Calabar,"Participants were adults (>18 years of age) randomly sampled from volunteering staff and patients of
the UCTH, Nigeria, from 17
th June to 25th June 2020.",,2020-06-17,2020-06-24,Multiple populations,All,Adults (18-64 years),,,Primary Estimate,,66,0.26,,,True,,,,True,Unclear,COVID-19 IgG/IgM Rapid Test Cassette,Healgen,LFIA,Whole Blood,IgG,,,,,['High'],Unclear,Unclear,No,No,No,Yes,Yes,Yes,Unclear,Marcus Inyama Asuquo,Joseph Ukpo Hospitals and Research Institutes,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.02.20145441v2,2020-09-26,2024-03-01,Verified,asuquo_prevalence_2020,NGA
200805_Niger_IbrahimBadamasiBabangidaUniversity_IgG_GenPop_UnAdj,200805_Niger_IbrahimBadamasiBabangidaUniversity,Seroprevalence of COVID-19 in Niger State,2020-08-05,Preprint,Regional,Cross-sectional survey ,Nigeria,Niger State,,Residents in Niger State,,2020-06-26,2020-06-30,Household and community samples,All,Multiple groups,,,Primary Estimate,,185,0.2541,,,True,,,,True,Stratified probability,COVID-19 IgG and IgM Rapid Test,Cambridge Network,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,Yes,Yes,Yes,Yes,Unclear,Hussaini Majiya,Ibrahim Badamasi Babangida University,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.04.20168112v1.full.pdf,2020-10-14,2024-03-01,Verified,majiya_seroprevalence_2020,NGA
200805_Niger_IbrahimBadamasiBabangidaUniversity_IgG_Age42-53_UnAdj,200805_Niger_IbrahimBadamasiBabangidaUniversity,Seroprevalence of COVID-19 in Niger State,2020-08-05,Preprint,Regional,Cross-sectional survey ,Nigeria,Niger State,,Residents in Niger State,,2020-06-26,2020-06-30,Household and community samples,All,Adults (18-64 years),42.0,53.0,Age,42-53,37,0.32420000000000004,,,,,,,,Stratified probability,COVID-19 IgG and IgM Rapid Test,Cambridge Network,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,Yes,Yes,Yes,Yes,Unclear,Hussaini Majiya,Ibrahim Badamasi Babangida University,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.04.20168112v1.full.pdf,2020-10-14,2024-03-01,Verified,majiya_seroprevalence_2020,NGA
200805_Niger_IbrahimBadamasiBabangidaUniversity_Males_UnAdj,200805_Niger_IbrahimBadamasiBabangidaUniversity,Seroprevalence of COVID-19 in Niger State,2020-08-05,Preprint,Regional,Cross-sectional survey ,Nigeria,Niger State,,Residents in Niger State,,2020-06-26,2020-06-30,Household and community samples,Male,Multiple groups,,,Sex/Gender,Male,103,0.2718,,,,,,,,Stratified probability,COVID-19 IgG and IgM Rapid Test,Cambridge Network,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,Yes,Yes,Yes,Yes,Unclear,Hussaini Majiya,Ibrahim Badamasi Babangida University,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.04.20168112v1.full.pdf,2020-10-14,2024-03-01,Verified,majiya_seroprevalence_2020,NGA
200805_Niger_IbrahimBadamasiBabangidaUniversity_Females_UnAdj,200805_Niger_IbrahimBadamasiBabangidaUniversity,Seroprevalence of COVID-19 in Niger State,2020-08-05,Preprint,Regional,Cross-sectional survey ,Nigeria,Niger State,,Residents in Niger State,,2020-06-26,2020-06-30,Household and community samples,Female,Multiple groups,,,Sex/Gender,Female ,82,0.23170000000000002,,,,,,,,Stratified probability,COVID-19 IgG and IgM Rapid Test,Cambridge Network,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,Yes,Yes,Yes,Yes,Unclear,Hussaini Majiya,Ibrahim Badamasi Babangida University,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.04.20168112v1.full.pdf,2020-10-14,2024-03-01,Verified,majiya_seroprevalence_2020,NGA
200805_Niger_IbrahimBadamasiBabangidaUniversity_IgG_Age30-41_UnAdj,200805_Niger_IbrahimBadamasiBabangidaUniversity,Seroprevalence of COVID-19 in Niger State,2020-08-05,Preprint,Regional,Cross-sectional survey ,Nigeria,Niger State,,Residents in Niger State,,2020-06-26,2020-06-30,Household and community samples,All,Adults (18-64 years),30.0,41.0,Age,30-41,45,0.3333,,,,,,,,Stratified probability,COVID-19 IgG and IgM Rapid Test,Cambridge Network,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,Yes,Yes,Yes,Yes,Unclear,Hussaini Majiya,Ibrahim Badamasi Babangida University,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.04.20168112v1.full.pdf,2020-10-14,2024-03-01,Verified,majiya_seroprevalence_2020,NGA
200805_Niger_IbrahimBadamasiBabangidaUniversity_IgG_Age>66_UnAdj,200805_Niger_IbrahimBadamasiBabangidaUniversity,Seroprevalence of COVID-19 in Niger State,2020-08-05,Preprint,Regional,Cross-sectional survey ,Nigeria,Niger State,,Residents in Niger State,,2020-06-26,2020-06-30,Household and community samples,All,Seniors (65+ years),66.0,,Age,>=66,8,0.25,,,,,,,,Stratified probability,COVID-19 IgG and IgM Rapid Test,Cambridge Network,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,1.0,1.0,['Moderate'],Yes,Yes,No,No,Yes,Yes,Yes,Yes,Unclear,Hussaini Majiya,Ibrahim Badamasi Babangida University,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.04.20168112v1.full.pdf,2020-10-14,2024-03-01,Verified,majiya_seroprevalence_2020,NGA
210121_Abuja_MolecularPathologyInstituteEnugu,210121_Abuja_MolecularPathologyInstituteEnugu,Sero-pravelence of SARS CoV-2 IgM and IgG Antibodies Amongst Blood Donors in Nigeria,2021-01-21,Preprint,Local,Cross-sectional survey ,Nigeria,,"Abuja, Enugu","blood donors were drawn from blood donation
centers in the city of Abuja and Enugu located in the north central and south eastern part of Nigeria
respectively",,2020-08-01,2020-08-31,Blood donors,All,Adults (18-64 years),21.0,48.0,Primary Estimate,,113,0.42,0.34,0.52,True,,,,True,Convenience,NovaLisa® SARS-CoV-2 IgG/IgM,NovaTec Immundiagnostics GmbH,ELISA,Plasma,IgG,,Validated by manufacturers,1.0,1.0,['High'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,,Ijeoma Ifeorah,Molecular Pathology Institute,Unity-Aligned,https://www.researchsquare.com/article/rs-151037/v1,2021-05-21,2024-03-01,Unverified,noauthor_sero-pravelence_2021,NGA
210719_AnambraState_StateMinistryOfHealth_testadj,210719_AnambraState_StateMinistryOfHealth,"Population seroprevalence of SARS-CoV-2 antibodies in Anambra state, South-East, Nigeria",2021-07-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Nigeria,Anambra State,,"For each selected health facility , all clients (≥ one year of age) and health staff were eligible for the survey.",Clients and staff that declined consent were excluded from the study.,2020-12-08,2020-12-15,Household and community samples,All,Multiple groups,1.0,,Primary Estimate,,3142,0.1607,,,True,True,,,,Stratified probability,Realy-Tech 2019 nCOV/COVID-19 IgG/IgM Rapid Test,Hangzhou Realy Tech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.98,0.99,['Moderate'],No,Yes,Yes,Yes,No,No,Yes,Yes,Yes,OgoChukwu Vincent Okpala,Anambra State Ministry of Health,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S1201971221005968,2021-08-03,2023-08-15,Verified,okpala_population_2021,NGA
210719_AnambraState_StateMinistryOfHealth_70+,210719_AnambraState_StateMinistryOfHealth,"Population seroprevalence of SARS-CoV-2 antibodies in Anambra state, South-East, Nigeria",2021-07-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Nigeria,Anambra State,,"For each selected health facility , all clients (≥ one year of age) and health staff were eligible for the survey.",Clients and staff that declined consent were excluded from the study.,2020-12-08,2020-12-15,Household and community samples,All,Seniors (65+ years),70.0,,Age,>=70,134,0.22399999999999998,0.1564,0.3039,,,,,,Stratified probability,Realy-Tech 2019 nCOV/COVID-19 IgG/IgM Rapid Test,Hangzhou Realy Tech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.98,0.99,['Moderate'],No,Yes,Yes,Yes,No,No,Yes,Yes,Yes,OgoChukwu Vincent Okpala,Anambra State Ministry of Health,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S1201971221005968,2021-08-03,2024-03-01,Verified,okpala_population_2021,NGA
210719_AnambraState_StateMinistryOfHealth_Male,210719_AnambraState_StateMinistryOfHealth,"Population seroprevalence of SARS-CoV-2 antibodies in Anambra state, South-East, Nigeria",2021-07-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Nigeria,Anambra State,,"For each selected health facility , all clients (≥ one year of age) and health staff were eligible for the survey.",Clients and staff that declined consent were excluded from the study.,2020-12-08,2020-12-15,Household and community samples,Male,Multiple groups,1.0,,Sex/Gender,,1168,0.165,0.1444,0.18780000000000002,,,,,,Stratified probability,Realy-Tech 2019 nCOV/COVID-19 IgG/IgM Rapid Test,Hangzhou Realy Tech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.98,0.99,['Moderate'],No,Yes,Yes,Yes,No,No,Yes,Yes,Yes,OgoChukwu Vincent Okpala,Anambra State Ministry of Health,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S1201971221005968,2021-08-03,2024-03-01,Verified,okpala_population_2021,NGA
210719_AnambraState_StateMinistryOfHealth_10-19,210719_AnambraState_StateMinistryOfHealth,"Population seroprevalence of SARS-CoV-2 antibodies in Anambra state, South-East, Nigeria",2021-07-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Nigeria,Anambra State,,"For each selected health facility , all clients (≥ one year of age) and health staff were eligible for the survey.",Clients and staff that declined consent were excluded from the study.,2020-12-08,2020-12-15,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,523,0.155,0.12490000000000001,0.1888,,,,,,Stratified probability,Realy-Tech 2019 nCOV/COVID-19 IgG/IgM Rapid Test,Hangzhou Realy Tech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.98,0.99,['Moderate'],No,Yes,Yes,Yes,No,No,Yes,Yes,Yes,OgoChukwu Vincent Okpala,Anambra State Ministry of Health,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S1201971221005968,2021-09-08,2024-03-01,Verified,okpala_population_2021,NGA
210719_AnambraState_StateMinistryOfHealth_unadj,210719_AnambraState_StateMinistryOfHealth,"Population seroprevalence of SARS-CoV-2 antibodies in Anambra state, South-East, Nigeria",2021-07-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Nigeria,Anambra State,,"For each selected health facility , all clients (≥ one year of age) and health staff were eligible for the survey.",Clients and staff that declined consent were excluded from the study.,2020-12-08,2020-12-15,Household and community samples,All,Multiple groups,1.0,,Analysis,,3142,0.17600000000000002,0.16260000000000002,0.1898,,,,,True,Stratified probability,Realy-Tech 2019 nCOV/COVID-19 IgG/IgM Rapid Test,Hangzhou Realy Tech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.98,0.99,['Moderate'],No,Yes,Yes,Yes,No,No,Yes,Yes,Yes,OgoChukwu Vincent Okpala,Anambra State Ministry of Health,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S1201971221005968,2021-09-08,2024-03-01,Verified,okpala_population_2021,NGA
210719_AnambraState_StateMinistryOfHealth_50-59,210719_AnambraState_StateMinistryOfHealth,"Population seroprevalence of SARS-CoV-2 antibodies in Anambra state, South-East, Nigeria",2021-07-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Nigeria,Anambra State,,"For each selected health facility , all clients (≥ one year of age) and health staff were eligible for the survey.",Clients and staff that declined consent were excluded from the study.,2020-12-08,2020-12-15,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,268,0.22399999999999998,0.1754,0.2786,,,,,,Stratified probability,Realy-Tech 2019 nCOV/COVID-19 IgG/IgM Rapid Test,Hangzhou Realy Tech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.98,0.99,['Moderate'],No,Yes,Yes,Yes,No,No,Yes,Yes,Yes,OgoChukwu Vincent Okpala,Anambra State Ministry of Health,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S1201971221005968,2021-09-08,2024-03-01,Verified,okpala_population_2021,NGA
210719_AnambraState_StateMinistryOfHealth_1-9,210719_AnambraState_StateMinistryOfHealth,"Population seroprevalence of SARS-CoV-2 antibodies in Anambra state, South-East, Nigeria",2021-07-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Nigeria,Anambra State,,"For each selected health facility , all clients (≥ one year of age) and health staff were eligible for the survey.",Clients and staff that declined consent were excluded from the study.,2020-12-08,2020-12-15,Household and community samples,All,Children and Youth (0-17 years),1.0,9.0,Age,1-9,388,0.139,0.1063,0.1777,,,,,,Stratified probability,Realy-Tech 2019 nCOV/COVID-19 IgG/IgM Rapid Test,Hangzhou Realy Tech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.98,0.99,['Moderate'],No,Yes,Yes,Yes,No,No,Yes,Yes,Yes,OgoChukwu Vincent Okpala,Anambra State Ministry of Health,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S1201971221005968,2021-08-03,2024-03-01,Verified,okpala_population_2021,NGA
210719_AnambraState_StateMinistryOfHealth_60-69,210719_AnambraState_StateMinistryOfHealth,"Population seroprevalence of SARS-CoV-2 antibodies in Anambra state, South-East, Nigeria",2021-07-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Nigeria,Anambra State,,"For each selected health facility , all clients (≥ one year of age) and health staff were eligible for the survey.",Clients and staff that declined consent were excluded from the study.,2020-12-08,2020-12-15,Household and community samples,All,Multiple groups,60.0,69.0,Age,60-69,199,0.22100000000000003,0.1655,0.2852,,,,,,Stratified probability,Realy-Tech 2019 nCOV/COVID-19 IgG/IgM Rapid Test,Hangzhou Realy Tech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.98,0.99,['Moderate'],No,Yes,Yes,Yes,No,No,Yes,Yes,Yes,OgoChukwu Vincent Okpala,Anambra State Ministry of Health,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S1201971221005968,2021-09-08,2024-03-01,Verified,okpala_population_2021,NGA
210719_AnambraState_StateMinistryOfHealth_40-49,210719_AnambraState_StateMinistryOfHealth,"Population seroprevalence of SARS-CoV-2 antibodies in Anambra state, South-East, Nigeria",2021-07-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Nigeria,Anambra State,,"For each selected health facility , all clients (≥ one year of age) and health staff were eligible for the survey.",Clients and staff that declined consent were excluded from the study.,2020-12-08,2020-12-15,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,455,0.189,0.15410000000000001,0.2281,,,,,,Stratified probability,Realy-Tech 2019 nCOV/COVID-19 IgG/IgM Rapid Test,Hangzhou Realy Tech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.98,0.99,['Moderate'],No,Yes,Yes,Yes,No,No,Yes,Yes,Yes,OgoChukwu Vincent Okpala,Anambra State Ministry of Health,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S1201971221005968,2021-09-08,2024-03-01,Verified,okpala_population_2021,NGA
210719_AnambraState_StateMinistryOfHealth_Female,210719_AnambraState_StateMinistryOfHealth,"Population seroprevalence of SARS-CoV-2 antibodies in Anambra state, South-East, Nigeria",2021-07-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Nigeria,Anambra State,,"For each selected health facility , all clients (≥ one year of age) and health staff were eligible for the survey.",Clients and staff that declined consent were excluded from the study.,2020-12-08,2020-12-15,Household and community samples,Female,Multiple groups,1.0,,Sex/Gender,,1974,0.182,0.1656,0.20010000000000003,,,,,,Stratified probability,Realy-Tech 2019 nCOV/COVID-19 IgG/IgM Rapid Test,Hangzhou Realy Tech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.98,0.99,['Moderate'],No,Yes,Yes,Yes,No,No,Yes,Yes,Yes,OgoChukwu Vincent Okpala,Anambra State Ministry of Health,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S1201971221005968,2021-08-03,2024-03-01,Verified,okpala_population_2021,NGA
210719_AnambraState_StateMinistryOfHealth_30-39,210719_AnambraState_StateMinistryOfHealth,"Population seroprevalence of SARS-CoV-2 antibodies in Anambra state, South-East, Nigeria",2021-07-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Nigeria,Anambra State,,"For each selected health facility , all clients (≥ one year of age) and health staff were eligible for the survey.",Clients and staff that declined consent were excluded from the study.,2020-12-08,2020-12-15,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,527,0.167,0.1361,0.2016,,,,,,Stratified probability,Realy-Tech 2019 nCOV/COVID-19 IgG/IgM Rapid Test,Hangzhou Realy Tech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.98,0.99,['Moderate'],No,Yes,Yes,Yes,No,No,Yes,Yes,Yes,OgoChukwu Vincent Okpala,Anambra State Ministry of Health,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S1201971221005968,2021-09-08,2024-03-01,Verified,okpala_population_2021,NGA
210719_AnambraState_StateMinistryOfHealth_20-29,210719_AnambraState_StateMinistryOfHealth,"Population seroprevalence of SARS-CoV-2 antibodies in Anambra state, South-East, Nigeria",2021-07-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Nigeria,Anambra State,,"For each selected health facility , all clients (≥ one year of age) and health staff were eligible for the survey.",Clients and staff that declined consent were excluded from the study.,2020-12-08,2020-12-15,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,648,0.17,0.1416,0.2009,,,,,,Stratified probability,Realy-Tech 2019 nCOV/COVID-19 IgG/IgM Rapid Test,Hangzhou Realy Tech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.98,0.99,['Moderate'],No,Yes,Yes,Yes,No,No,Yes,Yes,Yes,OgoChukwu Vincent Okpala,Anambra State Ministry of Health,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S1201971221005968,2021-09-08,2024-03-01,Verified,okpala_population_2021,NGA
220617_Nigeria_NigerianInstituteofMedicalResearch,220617_Nigeria_NigerianInstituteofMedicalResearch,Seroprevalence of SARS-CoV-2 in four states of Nigeria in October 2020: A population-based household survey.,2022-06-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Nigeria,"Enugu, Gombe, Nasarawa, Lago",,Households - all individuals in household were eligible,,2020-10-01,2020-10-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,10628,0.182,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 NCP ELISA (IgG),xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay","Abbott Laboratories,EUROIMMUN,Luminex Corporation",Multiple Types,,IgG,"['Nucleocapsid (N-protein)', 'Spike, Nucleocapsid (N-protein)']",,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Rosemary Audu,Nigerian Institute of Medical Research,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0000363,2023-05-03,2024-03-01,Unverified,audu_seroprevalence_2022,NGA
220628_Kaduna_UniversityofGlasgow_Overall,220628_Kaduna_UniversityofGlasgow,"SARS-CoV-2 seroprevalence at urban and rural sites in Kaduna State, Nigeria, during October/November 2021, immediately prior to detection of the Omicron variant.",2022-06-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Nigeria,Kaduna,"Kaduna City, Kofar-Gayan","Participants attending hospital outpatient units for reasons not related to COVID-19. Samples were collected at Yusuf Dantsoho Memorial Hospital, Tudun-Wada, Kaduna City and Hajiya Gambo Suwaba General Hospital, Kofar-Gayan",Participants with learning disabilities were excluded from the study.,2021-10-11,2021-11-08,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,802,0.43700000000000006,,,True,,True,,True,Convenience,Biopanda COVID-19 IgM/IgG Rapid Test Kit,Biopanda,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.99,0.986,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Gloria Chechet,University of Glasgow,Unity-Aligned,https://dx.doi.org/10.1093/ije/dyac141,2022-07-06,2024-03-30,Verified,chechet_sars-cov-2_2022,NGA
220628_Kaduna_UniversityofGlasgow_0-9,220628_Kaduna_UniversityofGlasgow,"SARS-CoV-2 seroprevalence at urban and rural sites in Kaduna State, Nigeria, during October/November 2021, immediately prior to detection of the Omicron variant.",2022-06-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Nigeria,Kaduna,"Kaduna City, Kofar-Gayan","Participants attending hospital outpatient units for reasons not related to COVID-19. Samples were collected at Yusuf Dantsoho Memorial Hospital, Tudun-Wada, Kaduna City and Hajiya Gambo Suwaba General Hospital, Kofar-Gayan",Participants with learning disabilities were excluded from the study.,2021-10-11,2021-11-08,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,0-9,71,0.3099,,,,,,,,Convenience,Biopanda COVID-19 IgM/IgG Rapid Test Kit,Biopanda,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.99,0.986,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Gloria Chechet,University of Glasgow,Unity-Aligned,https://dx.doi.org/10.1093/ije/dyac141,2024-03-30,2024-03-30,Unverified,chechet_sars-cov-2_2022,NGA
220628_Kaduna_UniversityofGlasgow_10-19,220628_Kaduna_UniversityofGlasgow,"SARS-CoV-2 seroprevalence at urban and rural sites in Kaduna State, Nigeria, during October/November 2021, immediately prior to detection of the Omicron variant.",2022-06-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Nigeria,Kaduna,"Kaduna City, Kofar-Gayan","Participants attending hospital outpatient units for reasons not related to COVID-19. Samples were collected at Yusuf Dantsoho Memorial Hospital, Tudun-Wada, Kaduna City and Hajiya Gambo Suwaba General Hospital, Kofar-Gayan",Participants with learning disabilities were excluded from the study.,2021-10-11,2021-11-08,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,102,0.3922,,,,,,,,Convenience,Biopanda COVID-19 IgM/IgG Rapid Test Kit,Biopanda,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.99,0.986,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Gloria Chechet,University of Glasgow,Unity-Aligned,https://dx.doi.org/10.1093/ije/dyac141,2024-03-30,2024-03-30,Unverified,chechet_sars-cov-2_2022,NGA
220628_Kaduna_UniversityofGlasgow_Male,220628_Kaduna_UniversityofGlasgow,"SARS-CoV-2 seroprevalence at urban and rural sites in Kaduna State, Nigeria, during October/November 2021, immediately prior to detection of the Omicron variant.",2022-06-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Nigeria,Kaduna,"Kaduna City, Kofar-Gayan","Participants attending hospital outpatient units for reasons not related to COVID-19. Samples were collected at Yusuf Dantsoho Memorial Hospital, Tudun-Wada, Kaduna City and Hajiya Gambo Suwaba General Hospital, Kofar-Gayan",Participants with learning disabilities were excluded from the study.,2021-10-11,2021-11-08,Residual sera,Male,Multiple groups,,,Sex/Gender,Male,415,0.516,,,,,,,,Convenience,Biopanda COVID-19 IgM/IgG Rapid Test Kit,Biopanda,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.99,0.986,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Gloria Chechet,University of Glasgow,Unity-Aligned,https://dx.doi.org/10.1093/ije/dyac141,2022-07-06,2024-03-30,Verified,chechet_sars-cov-2_2022,NGA
220628_Kaduna_UniversityofGlasgow_Female,220628_Kaduna_UniversityofGlasgow,"SARS-CoV-2 seroprevalence at urban and rural sites in Kaduna State, Nigeria, during October/November 2021, immediately prior to detection of the Omicron variant.",2022-06-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Nigeria,Kaduna,"Kaduna City, Kofar-Gayan","Participants attending hospital outpatient units for reasons not related to COVID-19. Samples were collected at Yusuf Dantsoho Memorial Hospital, Tudun-Wada, Kaduna City and Hajiya Gambo Suwaba General Hospital, Kofar-Gayan",Participants with learning disabilities were excluded from the study.,2021-10-11,2021-11-08,Residual sera,Female,Multiple groups,,,Sex/Gender,Female,386,0.44,,,,,,,,Convenience,Biopanda COVID-19 IgM/IgG Rapid Test Kit,Biopanda,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.99,0.986,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Gloria Chechet,University of Glasgow,Unity-Aligned,https://dx.doi.org/10.1093/ije/dyac141,2022-07-06,2024-03-30,Verified,chechet_sars-cov-2_2022,NGA
220628_Kaduna_UniversityofGlasgow_>34,220628_Kaduna_UniversityofGlasgow,"SARS-CoV-2 seroprevalence at urban and rural sites in Kaduna State, Nigeria, during October/November 2021, immediately prior to detection of the Omicron variant.",2022-06-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Nigeria,Kaduna,"Kaduna City, Kofar-Gayan","Participants attending hospital outpatient units for reasons not related to COVID-19. Samples were collected at Yusuf Dantsoho Memorial Hospital, Tudun-Wada, Kaduna City and Hajiya Gambo Suwaba General Hospital, Kofar-Gayan",Participants with learning disabilities were excluded from the study.,2021-10-11,2021-11-08,Residual sera,All,Multiple groups,35.0,,Age,>34,197,0.5025,,,,,,,,Convenience,Biopanda COVID-19 IgM/IgG Rapid Test Kit,Biopanda,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.99,0.986,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Gloria Chechet,University of Glasgow,Unity-Aligned,https://dx.doi.org/10.1093/ije/dyac141,2024-03-30,2024-03-30,Unverified,chechet_sars-cov-2_2022,NGA
220628_Kaduna_UniversityofGlasgow_20-34,220628_Kaduna_UniversityofGlasgow,"SARS-CoV-2 seroprevalence at urban and rural sites in Kaduna State, Nigeria, during October/November 2021, immediately prior to detection of the Omicron variant.",2022-06-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Nigeria,Kaduna,"Kaduna City, Kofar-Gayan","Participants attending hospital outpatient units for reasons not related to COVID-19. Samples were collected at Yusuf Dantsoho Memorial Hospital, Tudun-Wada, Kaduna City and Hajiya Gambo Suwaba General Hospital, Kofar-Gayan",Participants with learning disabilities were excluded from the study.,2021-10-11,2021-11-08,Residual sera,All,Adults (18-64 years),20.0,34.0,Age,20-34,396,0.5455,,,,,,,,Convenience,Biopanda COVID-19 IgM/IgG Rapid Test Kit,Biopanda,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.99,0.986,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Gloria Chechet,University of Glasgow,Unity-Aligned,https://dx.doi.org/10.1093/ije/dyac141,2024-03-30,2024-03-30,Unverified,chechet_sars-cov-2_2022,NGA
221011_Nigeria_UniversityofIlorin_Primary,221011_Nigeria_UniversityofIlorin,SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria.,2022-10-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Nigeria,"Abuja, Kwara, Kaduna, Sokoto, Akwa-Ibom, Lagos, Ondo, Enugu, Imo, Borno, Yobe",,All individuals within sample frame,None,2021-06-29,2021-08-21,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,4904,0.789,,,True,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9670000000000001,0.975,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Olatunji Matthew Kolawole,Federal Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.36053,2022-10-19,2024-04-16,Verified,kolawole_sars_2022,NGA
221011_Nigeria_UniversityofIlorin_Age_65-69,221011_Nigeria_UniversityofIlorin,SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria.,2022-10-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Nigeria,"Abuja, Kwara, Kaduna, Sokoto, Akwa-Ibom, Lagos, Ondo, Enugu, Imo, Borno, Yobe",,All individuals within sample frame,None,2021-06-29,2021-08-21,Household and community samples,All,Seniors (65+ years),65.0,69.0,Age,65-69,51,0.7843000000000001,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9670000000000001,0.975,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Olatunji Matthew Kolawole,Federal Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.36053,2022-10-19,2024-04-16,Verified,kolawole_sars_2022,NGA
221011_Nigeria_UniversityofIlorin_Age_5-9,221011_Nigeria_UniversityofIlorin,SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria.,2022-10-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Nigeria,"Abuja, Kwara, Kaduna, Sokoto, Akwa-Ibom, Lagos, Ondo, Enugu, Imo, Borno, Yobe",,All individuals within sample frame,None,2021-06-29,2021-08-21,Household and community samples,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,323,0.6687000000000001,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9670000000000001,0.975,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Olatunji Matthew Kolawole,Federal Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.36053,2022-10-19,2024-04-16,Verified,kolawole_sars_2022,NGA
221011_Nigeria_UniversityofIlorin_Females,221011_Nigeria_UniversityofIlorin,SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria.,2022-10-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Nigeria,"Abuja, Kwara, Kaduna, Sokoto, Akwa-Ibom, Lagos, Ondo, Enugu, Imo, Borno, Yobe",,All individuals within sample frame,None,2021-06-29,2021-08-21,Household and community samples,Female,Multiple groups,0.0,,Sex/Gender,Female,3033,0.7959999999999999,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9670000000000001,0.975,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Olatunji Matthew Kolawole,Federal Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.36053,2022-10-19,2024-04-16,Verified,kolawole_sars_2022,NGA
221011_Nigeria_UniversityofIlorin_Age_35-39,221011_Nigeria_UniversityofIlorin,SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria.,2022-10-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Nigeria,"Abuja, Kwara, Kaduna, Sokoto, Akwa-Ibom, Lagos, Ondo, Enugu, Imo, Borno, Yobe",,All individuals within sample frame,None,2021-06-29,2021-08-21,Household and community samples,All,Adults (18-64 years),35.0,39.0,Age,35-39,406,0.8251000000000001,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9670000000000001,0.975,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Olatunji Matthew Kolawole,Federal Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.36053,2022-10-19,2024-04-16,Verified,kolawole_sars_2022,NGA
221011_Nigeria_UniversityofIlorin_Geography_Edo,221011_Nigeria_UniversityofIlorin,SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria.,2022-10-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Nigeria,Edo,,All individuals within sample frame,None,2021-06-29,2021-08-21,Household and community samples,All,Multiple groups,0.0,,Geographical area,Edo,416,0.74,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9670000000000001,0.975,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Olatunji Matthew Kolawole,Federal Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.36053,2022-10-19,2024-04-16,Verified,kolawole_sars_2022,NGA
221011_Nigeria_UniversityofIlorin_Geography_Borno,221011_Nigeria_UniversityofIlorin,SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria.,2022-10-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Nigeria,Borno,,All individuals within sample frame,None,2021-06-29,2021-08-21,Household and community samples,All,Multiple groups,0.0,,Geographical area,Borno,389,0.877,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9670000000000001,0.975,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Olatunji Matthew Kolawole,Federal Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.36053,2022-10-19,2024-04-16,Verified,kolawole_sars_2022,NGA
221011_Nigeria_UniversityofIlorin_Males,221011_Nigeria_UniversityofIlorin,SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria.,2022-10-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Nigeria,"Abuja, Kwara, Kaduna, Sokoto, Akwa-Ibom, Lagos, Ondo, Enugu, Imo, Borno, Yobe",,All individuals within sample frame,None,2021-06-29,2021-08-21,Household and community samples,Male,Multiple groups,0.0,,Sex/Gender,Male,1871,0.778,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9670000000000001,0.975,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Olatunji Matthew Kolawole,Federal Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.36053,2022-10-19,2024-04-16,Verified,kolawole_sars_2022,NGA
221011_Nigeria_UniversityofIlorin_Age_50-54,221011_Nigeria_UniversityofIlorin,SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria.,2022-10-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Nigeria,"Abuja, Kwara, Kaduna, Sokoto, Akwa-Ibom, Lagos, Ondo, Enugu, Imo, Borno, Yobe",,All individuals within sample frame,None,2021-06-29,2021-08-21,Household and community samples,All,Adults (18-64 years),50.0,54.0,Age,50-54,165,0.8484999999999999,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9670000000000001,0.975,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Olatunji Matthew Kolawole,Federal Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.36053,2022-10-19,2024-04-16,Verified,kolawole_sars_2022,NGA
221011_Nigeria_UniversityofIlorin_Geography_Akwa-Ibom,221011_Nigeria_UniversityofIlorin,SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria.,2022-10-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Nigeria,Akwa-Ibom,,All individuals within sample frame,None,2021-06-29,2021-08-21,Household and community samples,All,Multiple groups,0.0,,Geographical area,Akwa-Ibom,444,0.8109999999999999,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9670000000000001,0.975,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Olatunji Matthew Kolawole,Federal Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.36053,2022-10-19,2024-04-16,Verified,kolawole_sars_2022,NGA
221011_Nigeria_UniversityofIlorin_Geography_Abuja,221011_Nigeria_UniversityofIlorin,SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria.,2022-10-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Nigeria,Abuja,,All individuals within sample frame,None,2021-06-29,2021-08-21,Household and community samples,All,Multiple groups,0.0,,Geographical area,Abuja,401,0.758,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9670000000000001,0.975,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Olatunji Matthew Kolawole,Federal Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.36053,2022-10-19,2024-04-16,Verified,kolawole_sars_2022,NGA
221011_Nigeria_UniversityofIlorin_Age_45-49,221011_Nigeria_UniversityofIlorin,SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria.,2022-10-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Nigeria,"Abuja, Kwara, Kaduna, Sokoto, Akwa-Ibom, Lagos, Ondo, Enugu, Imo, Borno, Yobe",,All individuals within sample frame,None,2021-06-29,2021-08-21,Household and community samples,All,Adults (18-64 years),45.0,49.0,Age,45-49,237,0.8059000000000001,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9670000000000001,0.975,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Olatunji Matthew Kolawole,Federal Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.36053,2022-10-19,2024-04-16,Verified,kolawole_sars_2022,NGA
221011_Nigeria_UniversityofIlorin_Geography_Kaduna,221011_Nigeria_UniversityofIlorin,SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria.,2022-10-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Nigeria,Kaduna,,All individuals within sample frame,None,2021-06-29,2021-08-21,Household and community samples,All,Multiple groups,0.0,,Geographical area,Kaduna,410,0.768,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9670000000000001,0.975,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Olatunji Matthew Kolawole,Federal Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.36053,2022-10-19,2024-04-16,Verified,kolawole_sars_2022,NGA
221011_Nigeria_UniversityofIlorin_Age_20-24,221011_Nigeria_UniversityofIlorin,SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria.,2022-10-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Nigeria,"Abuja, Kwara, Kaduna, Sokoto, Akwa-Ibom, Lagos, Ondo, Enugu, Imo, Borno, Yobe",,All individuals within sample frame,None,2021-06-29,2021-08-21,Household and community samples,All,Adults (18-64 years),20.0,24.0,Age,20-24,498,0.8473999999999999,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9670000000000001,0.975,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Olatunji Matthew Kolawole,Federal Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.36053,2022-10-19,2024-04-16,Verified,kolawole_sars_2022,NGA
221011_Nigeria_UniversityofIlorin_Age_0-4,221011_Nigeria_UniversityofIlorin,SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria.,2022-10-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Nigeria,"Abuja, Kwara, Kaduna, Sokoto, Akwa-Ibom, Lagos, Ondo, Enugu, Imo, Borno, Yobe",,All individuals within sample frame,None,2021-06-29,2021-08-21,Household and community samples,All,Children and Youth (0-17 years),0.0,4.0,Age,0-4,318,0.5849000000000001,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9670000000000001,0.975,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Olatunji Matthew Kolawole,Federal Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.36053,2022-10-19,2024-04-16,Verified,kolawole_sars_2022,NGA
221011_Nigeria_UniversityofIlorin_Geography_Lagos,221011_Nigeria_UniversityofIlorin,SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria.,2022-10-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Nigeria,Lagos,,All individuals within sample frame,None,2021-06-29,2021-08-21,Household and community samples,All,Multiple groups,0.0,,Geographical area,Lagos,401,0.698,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9670000000000001,0.975,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Olatunji Matthew Kolawole,Federal Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.36053,2022-10-19,2024-04-16,Verified,kolawole_sars_2022,NGA
221011_Nigeria_UniversityofIlorin_Geography_Enugu,221011_Nigeria_UniversityofIlorin,SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria.,2022-10-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Nigeria,Enugu,,All individuals within sample frame,None,2021-06-29,2021-08-21,Household and community samples,All,Multiple groups,0.0,,Geographical area,Enugu,412,0.8590000000000001,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9670000000000001,0.975,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Olatunji Matthew Kolawole,Federal Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.36053,2022-10-19,2024-04-16,Verified,kolawole_sars_2022,NGA
221011_Nigeria_UniversityofIlorin_Age_60-64,221011_Nigeria_UniversityofIlorin,SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria.,2022-10-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Nigeria,"Abuja, Kwara, Kaduna, Sokoto, Akwa-Ibom, Lagos, Ondo, Enugu, Imo, Borno, Yobe",,All individuals within sample frame,None,2021-06-29,2021-08-21,Household and community samples,All,Adults (18-64 years),60.0,64.0,Age,60-64,89,0.7528,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9670000000000001,0.975,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Olatunji Matthew Kolawole,Federal Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.36053,2022-10-19,2024-04-16,Verified,kolawole_sars_2022,NGA
221011_Nigeria_UniversityofIlorin_Age_70+,221011_Nigeria_UniversityofIlorin,SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria.,2022-10-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Nigeria,"Abuja, Kwara, Kaduna, Sokoto, Akwa-Ibom, Lagos, Ondo, Enugu, Imo, Borno, Yobe",,All individuals within sample frame,None,2021-06-29,2021-08-21,Household and community samples,All,Seniors (65+ years),70.0,,Age,>=70,80,0.725,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9670000000000001,0.975,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Olatunji Matthew Kolawole,Federal Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.36053,2022-10-19,2024-04-16,Verified,kolawole_sars_2022,NGA
221011_Nigeria_UniversityofIlorin_Age_30-34,221011_Nigeria_UniversityofIlorin,SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria.,2022-10-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Nigeria,"Abuja, Kwara, Kaduna, Sokoto, Akwa-Ibom, Lagos, Ondo, Enugu, Imo, Borno, Yobe",,All individuals within sample frame,None,2021-06-29,2021-08-21,Household and community samples,All,Adults (18-64 years),30.0,34.0,Age,30-34,478,0.8222,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9670000000000001,0.975,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Olatunji Matthew Kolawole,Federal Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.36053,2022-10-19,2024-04-16,Verified,kolawole_sars_2022,NGA
221011_Nigeria_UniversityofIlorin_Geography_Sokoto,221011_Nigeria_UniversityofIlorin,SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria.,2022-10-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Nigeria,Sokoto,,All individuals within sample frame,None,2021-06-29,2021-08-21,Household and community samples,All,Multiple groups,0.0,,Geographical area,Sokoto,400,0.85,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9670000000000001,0.975,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Olatunji Matthew Kolawole,Federal Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.36053,2022-10-19,2024-04-16,Verified,kolawole_sars_2022,NGA
221011_Nigeria_UniversityofIlorin_Geography_Yobe,221011_Nigeria_UniversityofIlorin,SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria.,2022-10-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Nigeria,Yobe,,All individuals within sample frame,None,2021-06-29,2021-08-21,Household and community samples,All,Multiple groups,0.0,,Geographical area,Yobe,410,0.805,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9670000000000001,0.975,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Olatunji Matthew Kolawole,Federal Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.36053,2022-10-19,2024-04-16,Verified,kolawole_sars_2022,NGA
221011_Nigeria_UniversityofIlorin_Geography_Ondo,221011_Nigeria_UniversityofIlorin,SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria.,2022-10-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Nigeria,Ondo,,All individuals within sample frame,None,2021-06-29,2021-08-21,Household and community samples,All,Multiple groups,0.0,,Geographical area,Ondo,421,0.736,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9670000000000001,0.975,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Olatunji Matthew Kolawole,Federal Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.36053,2022-10-19,2024-04-16,Verified,kolawole_sars_2022,NGA
221011_Nigeria_UniversityofIlorin_Age_15-19,221011_Nigeria_UniversityofIlorin,SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria.,2022-10-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Nigeria,"Abuja, Kwara, Kaduna, Sokoto, Akwa-Ibom, Lagos, Ondo, Enugu, Imo, Borno, Yobe",,All individuals within sample frame,None,2021-06-29,2021-08-21,Household and community samples,All,Children and Youth (0-17 years),15.0,19.0,Age,15-19,737,0.8358,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9670000000000001,0.975,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Olatunji Matthew Kolawole,Federal Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.36053,2022-10-19,2024-04-16,Verified,kolawole_sars_2022,NGA
221011_Nigeria_UniversityofIlorin_Geography_Imo,221011_Nigeria_UniversityofIlorin,SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria.,2022-10-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Nigeria,Imo,,All individuals within sample frame,None,2021-06-29,2021-08-21,Household and community samples,All,Multiple groups,0.0,,Geographical area,Imo,400,0.8079999999999999,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9670000000000001,0.975,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Olatunji Matthew Kolawole,Federal Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.36053,2022-10-19,2024-04-16,Verified,kolawole_sars_2022,NGA
221011_Nigeria_UniversityofIlorin_Geography_Kwara,221011_Nigeria_UniversityofIlorin,SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria.,2022-10-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Nigeria,Kwara,,All individuals within sample frame,None,2021-06-29,2021-08-21,Household and community samples,All,Multiple groups,0.0,,Geographical area,Kwara,400,0.763,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9670000000000001,0.975,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Olatunji Matthew Kolawole,Federal Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.36053,2022-10-19,2024-04-16,Verified,kolawole_sars_2022,NGA
221011_Nigeria_UniversityofIlorin_Age_10-14,221011_Nigeria_UniversityofIlorin,SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria.,2022-10-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Nigeria,"Abuja, Kwara, Kaduna, Sokoto, Akwa-Ibom, Lagos, Ondo, Enugu, Imo, Borno, Yobe",,All individuals within sample frame,None,2021-06-29,2021-08-21,Household and community samples,All,Children and Youth (0-17 years),10.0,14.0,Age,10-14,596,0.755,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9670000000000001,0.975,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Olatunji Matthew Kolawole,Federal Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.36053,2022-10-19,2024-04-16,Verified,kolawole_sars_2022,NGA
221011_Nigeria_UniversityofIlorin_Age_40-44,221011_Nigeria_UniversityofIlorin,SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria.,2022-10-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Nigeria,"Abuja, Kwara, Kaduna, Sokoto, Akwa-Ibom, Lagos, Ondo, Enugu, Imo, Borno, Yobe",,All individuals within sample frame,None,2021-06-29,2021-08-21,Household and community samples,All,Adults (18-64 years),40.0,44.0,Age,40-44,309,0.8155,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9670000000000001,0.975,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Olatunji Matthew Kolawole,Federal Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.36053,2022-10-19,2024-04-16,Verified,kolawole_sars_2022,NGA
221011_Nigeria_UniversityofIlorin_Age_55-59,221011_Nigeria_UniversityofIlorin,SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria.,2022-10-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Nigeria,"Abuja, Kwara, Kaduna, Sokoto, Akwa-Ibom, Lagos, Ondo, Enugu, Imo, Borno, Yobe",,All individuals within sample frame,None,2021-06-29,2021-08-21,Household and community samples,All,Adults (18-64 years),55.0,59.0,Age,55-59,111,0.8108,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9670000000000001,0.975,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Olatunji Matthew Kolawole,Federal Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.36053,2022-10-19,2024-04-16,Verified,kolawole_sars_2022,NGA
221011_Nigeria_UniversityofIlorin_Age_25-29,221011_Nigeria_UniversityofIlorin,SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria.,2022-10-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Nigeria,"Abuja, Kwara, Kaduna, Sokoto, Akwa-Ibom, Lagos, Ondo, Enugu, Imo, Borno, Yobe",,All individuals within sample frame,None,2021-06-29,2021-08-21,Household and community samples,All,Adults (18-64 years),25.0,29.0,Age,25-29,506,0.8181999999999999,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9670000000000001,0.975,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Olatunji Matthew Kolawole,Federal Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.36053,2022-10-19,2024-04-16,Verified,kolawole_sars_2022,NGA
221017_Lagos_CITIID_Primary,221017_Lagos_CITIID,SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa,2022-10-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Nigeria,,Lagos,"""Health care workers (HCWs) and Health workers (HWs) at the Nigerian Institute of Medical Research (NIMR) and Federal Medical Centre, Ebute Metta, volunteering to be vaccinated with two doses of AZD1222 12 weeks apart were recruited to the study following signed informed consent.""",,2021-01-01,2021-01-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Anti-N or Anti-RBD,140,0.5929,,,True,,,,True,Convenience,Author designed (Luminex),,Luminex,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Adam Abdullahi,Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID),Not Unity-Aligned,https://doi.org/10.1038/s41467-022-33792-x,2022-10-25,2022-10-25,Unverified,abdullahi_sars-cov-2_2022-1,NGA
230117_Nigeria_UniversityofAbuja_baseline,230117_Nigeria_UniversityofAbuja_baseline,"Nigeria healthcare worker SARS-CoV-2 serology study: Results from a prospective, longitudinal cohort.",2023-01-17,Journal Article (Peer-Reviewed),National,Prospective cohort,Nigeria,,,"""Eligibility criteria included: 1) full-time employment as a health care worker to minimize losses to follow-up and 2) willingness and ability to provide informed con- sent. ""","NR
",2020-06-01,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,baseline: Jue 2020,490,0.31,0.27,0.35,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,Dried Blood,IgG,Spike,,,,['Missing'],,No,Yes,Yes,,Unclear,Yes,No,,Dike B. Ojji,University of Abuja,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0000549,2023-05-03,2023-05-09,Unverified,ojji_nigeria_2023,NGA
230117_Nigeria_UniversityofAbuja_month3,230117_Nigeria_UniversityofAbuja_month3,"Nigeria healthcare worker SARS-CoV-2 serology study: Results from a prospective, longitudinal cohort.",2023-01-17,Journal Article (Peer-Reviewed),National,Prospective cohort,Nigeria,,,"""Eligibility criteria included: 1) full-time employment as a health care worker to minimize losses to follow-up and 2) willingness and ability to provide informed con- sent. ""","NR
",2020-09-01,2020-09-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,3 month follow-up: September 2020,493,0.45,0.4,0.49,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,Dried Blood,IgG,Spike,,,,['Missing'],,No,Yes,Yes,,Unclear,Yes,No,,Dike B. Ojji,University of Abuja,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0000549,2023-05-03,2023-05-05,Unverified,ojji_nigeria_2023,NGA
230117_Nigeria_UniversityofAbuja_month6,230117_Nigeria_UniversityofAbuja_month6,"Nigeria healthcare worker SARS-CoV-2 serology study: Results from a prospective, longitudinal cohort.",2023-01-17,Journal Article (Peer-Reviewed),National,Prospective cohort,Nigeria,,,"""Eligibility criteria included: 1) full-time employment as a health care worker to minimize losses to follow-up and 2) willingness and ability to provide informed con- sent. ""","NR
",2020-12-01,2020-12-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,6 month follow-up: December 2020,489,0.7,0.66,0.74,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,Dried Blood,IgG,Spike,,,,['Missing'],,No,Yes,Yes,,Unclear,Yes,No,,Dike B. Ojji,University of Abuja,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0000549,2023-05-03,2023-05-04,Unverified,ojji_nigeria_2023,NGA
230619_Lagos_UniversityofLagos_GenPop,230619_Lagos_UniversityofLagos_GenPop,"High SARS-CoV-2 seroprevalence in Lagos, Nigeria with robust antibody and cellular immune responses.",2023-06-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Nigeria,,Lagos,"The Lagos State Vaccine study population included individuals from the general population from Agbowa, Amuwo, Ikorodu, Iwaya, and Oshodi, Lagos State, Nigeria, all of whom, at the time of enrollment (baseline), had no documented history of SARS-CoV-2 infection and were administered the first dose of the Oxford-AstraZeneca COVID-19 vaccine between March to April 2021 and the second dose 8 weeks later.",,2021-03-15,2021-07-15,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,,116,0.59,,,True,,,,True,Convenience,Not reported/ Unable to specify,,Other,Whole Blood,,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Sulaimon Akanmu,University of Lagos,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcvp.2023.100156,2023-07-29,2023-08-15,Unverified,akanmu_high_2023,NGA
230619_Lagos_UniversityofLagos_HCW,230619_Lagos_UniversityofLagos_HCW,"High SARS-CoV-2 seroprevalence in Lagos, Nigeria with robust antibody and cellular immune responses.",2023-06-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Nigeria,,Lagos,The HCW cohort was recruited from the Lagos University Teaching Hospital (LUTH),,2021-03-15,2021-10-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,134,0.7,,,True,,,,True,Convenience,Not reported/ Unable to specify,,Other,Whole Blood,,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Sulaimon Akanmu,University of Lagos,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcvp.2023.100156,2023-07-29,2023-08-15,Unverified,akanmu_high_2023,NGA
210531_Skopje_InstituteForTransfusionMedicine,210531_Skopje_InstituteForTransfusionMedicine,Seroprevalence of SARS-CoV-2 among blood donors,2021-05-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,North Macedonia,Skopje,Skopje,"every blood donor who met the usual donor selection criteria, as well as the additional criteria concerning the coronavirus pandemic, such as normal body temperature, no signs of infection, no recent contact etc.",,2020-11-15,2021-03-15,Blood donors,All,Multiple groups,,,Primary Estimate,overal,9773,0.25,,,True,,,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Tatjana Makarovska Bojadjieva, Institute for Transfusion Medicine,Unity-Aligned,http://dx.doi.org/10.1111/vox.13117,2021-07-01,2024-03-01,Verified,t_makarovska_bojadjieva_seroprevalence_2021,MKD
210531_Skopje_InstituteForTransfusionMedicine_HighCutoff,210531_Skopje_InstituteForTransfusionMedicine,Seroprevalence of SARS-CoV-2 among blood donors,2021-05-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,North Macedonia,Skopje,Skopje,"every blood donor who met the usual donor selection criteria, as well as the additional criteria concerning the coronavirus pandemic, such as normal body temperature, no signs of infection, no recent contact etc.",,2020-11-15,2021-03-15,Blood donors,All,Multiple groups,,,Test used,Index > 5 S/C,9773,0.083,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Tatjana Makarovska Bojadjieva, Institute for Transfusion Medicine,Unity-Aligned,http://dx.doi.org/10.1111/vox.13117,2021-07-01,2024-03-01,Verified,t_makarovska_bojadjieva_seroprevalence_2021,MKD
200615_Bergen_UniversityofBergen_HouseholdMembers,200615_Bergen_UniversityofBergen,Seroconversion in household members of COVID-19 outpatients,2020-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Norway,Western Norway,Bergen,"All suspected COVID-19 cases in the peak period between
Feb 28 and April 4 were referred to the Bergen municipality emergency room for centralised evaluation and testing according to a strict exposure likelihood algorithm. Both cases and household members were tested for specific antibodies to the receptor binding domain of SARS-CoV-2.",,2020-02-28,2020-04-04,Contacts of COVID patients,All,Multiple groups,,,Primary Estimate,,77,0.31170000000000003,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,,,['High'],Yes,No,No,No,Unclear,Unclear,Yes,No,Unclear,Rebecca Cox,University of Bergen,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295487/,2020-07-19,2022-07-16,Verified,cox_seroconversion_2021,NOR
201128_Bergen_UniversityofBergen_primaryest_HCW,201128_Bergen_UniversityofBergen,SARS-CoV-2-specific neutralizing antibody responses in Norwegian healthcare workers after the first wave of COVID-19 pandemic: a prospective cohort study.,2020-11-28,Journal Article (Peer-Reviewed),Local,Prospective cohort,Norway,Midhordland,Bergen,"Inclusion criteria were HCW with or without present/potential future exposure to COVID-19 patients, and working from 6 March to
9 April 2020","Exclusion criteria were HCW in quarantine or
RT-PCR confirmed SARS-CoV-2 infection at recruitment. ",2020-03-06,2020-04-09,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,HCW ,607,0.0527,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Mai Chi Trieu,University of Bergen,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiaa737,2021-01-29,2022-07-16,Verified,trieu_sars-cov-2specific_2020,NOR
210115_Norway_NorwegianArmedForcesJointMedicalServices_primary,210115_Norway_NorwegianArmedForcesJointMedicalServices,Severe acute respiratory syndrome coronavirus 2 prevalence in 1170 asymptomatic Norwegian conscripts,2021-01-15,Journal Article (Peer-Reviewed),National,Prospective cohort,Norway,,,"The study cohort included 1170 healthy conscripts (median age: 20 years, range 18-25), 798 men (68.2%) and 372 women (31.8%),who enrolled in military training between 19 and April 27, 2020.",,2020-04-19,2020-04-27,Essential non-healthcare workers,All,Adults (18-64 years),18.0,25.0,Primary Estimate,,1170,0.006999999999999999,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Einar Kristian Borud,Norwegian Armed Forces Joint Medical Services,Not Unity-Aligned,https://dx.doi.org/10.1002/hsr2.233,2021-02-27,2024-03-01,Verified,borud_severe_2021,NOR
210223_Lorenskog_AkershusUniversityHospital_Overall,210223_Lorenskog_AkershusUniversityHospital,Comparison of SARS-CoV-2 infections in healthcare workers with high and low exposures to Covid-19 patients in a Norwegian University Hospital,2021-02-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Norway,,Lorenskog,"HCWs were invited from five wards: Covid ward A(N=92), Covid ward B (N=75), ICU (N=148), an ortho-paedic  ward  (N=70)  and  the  Department  ofMicrobiology and Infection Control (N=51)",,2020-05-11,2020-06-11,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,360,0.033,,,True,,,,True,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","DiaSorin,Roche Diagnostics",CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,No,Yes,Nina Handal,Akershus University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.1885734,2021-03-23,2024-03-01,Verified,handal_comparison_2021,NOR
210326_Norway_ArcticUniversityOfNorway_PopAdj_TestAdj,210326_Norway_ArcticUniversityOfNorway,"Seroprevalence of antibodies against SARS-CoV-2 virus in the adult Norwegian population, winter 2020/2021: pre-vaccination period",2021-03-26,Preprint,National,Cross-sectional survey ,Norway,,,"16+ adults
To be eligible, individuals had to have a national identity number, known country of birth, a registered
address and a mobile phone number","Individuals living in prisons, nursing homes, or long-term
psychiatric institutions (all of whom represent approximately 1% of the national population over 16 years of age [12]) were not eligible for inclusion",2020-11-25,2021-02-15,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,"Overall, pop and test adj",27700,0.009000000000000001,0.006999999999999999,0.01,True,True,True,,,Stratified probability,"Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED","EUROIMMUN,NA",Multiple Types,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Erik Anda,Arctic University of Norway,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.23.21253730v1,2021-05-18,2023-08-15,Verified,anda_seroprevalence_2021,NOR
210326_Norway_ArcticUniversityOfNorway_Unadj,210326_Norway_ArcticUniversityOfNorway,"Seroprevalence of antibodies against SARS-CoV-2 virus in the adult Norwegian population, winter 2020/2021: pre-vaccination period",2021-03-26,Preprint,National,Cross-sectional survey ,Norway,,,"16+ adults
To be eligible, individuals had to have a national identity number, known country of birth, a registered
address and a mobile phone number","Individuals living in prisons, nursing homes, or long-term
psychiatric institutions (all of whom represent approximately 1% of the national population over 16 years of age [12]) were not eligible for inclusion",2020-11-25,2021-02-15,Household and community samples,All,Multiple groups,16.0,,Analysis,"Overall, unadj",27700,0.008,0.006999999999999999,0.01,,,,,True,Stratified probability,"Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED","EUROIMMUN,NA",Multiple Types,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Erik Anda,Arctic University of Norway,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.23.21253730v1,2021-07-30,2024-03-01,Verified,anda_seroprevalence_2021,NOR
210326_Norway_ArcticUniversityOfNorway_age16-19,210326_Norway_ArcticUniversityOfNorway,"Seroprevalence of antibodies against SARS-CoV-2 virus in the adult Norwegian population, winter 2020/2021: pre-vaccination period",2021-03-26,Preprint,National,Cross-sectional survey ,Norway,,,"16+ adults
To be eligible, individuals had to have a national identity number, known country of birth, a registered
address and a mobile phone number","Individuals living in prisons, nursing homes, or long-term
psychiatric institutions (all of whom represent approximately 1% of the national population over 16 years of age [12]) were not eligible for inclusion",2020-11-25,2021-02-15,Household and community samples,All,Adults (18-64 years),16.0,19.0,Age,age 16-19,868,0.018000000000000002,0.011000000000000001,0.03,,,,,,Stratified probability,"Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED","EUROIMMUN,NA",Multiple Types,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Erik Anda,Arctic University of Norway,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.23.21253730v1,2021-07-30,2024-03-01,Verified,anda_seroprevalence_2021,NOR
210326_Norway_ArcticUniversityOfNorway_age45-66,210326_Norway_ArcticUniversityOfNorway,"Seroprevalence of antibodies against SARS-CoV-2 virus in the adult Norwegian population, winter 2020/2021: pre-vaccination period",2021-03-26,Preprint,National,Cross-sectional survey ,Norway,,,"16+ adults
To be eligible, individuals had to have a national identity number, known country of birth, a registered
address and a mobile phone number","Individuals living in prisons, nursing homes, or long-term
psychiatric institutions (all of whom represent approximately 1% of the national population over 16 years of age [12]) were not eligible for inclusion",2020-11-25,2021-02-15,Household and community samples,All,Adults (18-64 years),45.0,66.0,Age,age 45-66,11206,0.008,0.006,0.01,,,,,,Stratified probability,"Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED","EUROIMMUN,NA",Multiple Types,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Erik Anda,Arctic University of Norway,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.23.21253730v1,2021-07-30,2024-03-01,Verified,anda_seroprevalence_2021,NOR
210326_Norway_ArcticUniversityOfNorway_age67-79,210326_Norway_ArcticUniversityOfNorway,"Seroprevalence of antibodies against SARS-CoV-2 virus in the adult Norwegian population, winter 2020/2021: pre-vaccination period",2021-03-26,Preprint,National,Cross-sectional survey ,Norway,,,"16+ adults
To be eligible, individuals had to have a national identity number, known country of birth, a registered
address and a mobile phone number","Individuals living in prisons, nursing homes, or long-term
psychiatric institutions (all of whom represent approximately 1% of the national population over 16 years of age [12]) were not eligible for inclusion",2020-11-25,2021-02-15,Household and community samples,All,Seniors (65+ years),67.0,79.0,Age,age 67-79,4655,0.006,0.004,0.009000000000000001,,,,,,Stratified probability,"Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED","EUROIMMUN,NA",Multiple Types,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Erik Anda,Arctic University of Norway,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.23.21253730v1,2021-07-30,2024-03-01,Verified,anda_seroprevalence_2021,NOR
210326_Norway_ArcticUniversityOfNorway_age20-44,210326_Norway_ArcticUniversityOfNorway,"Seroprevalence of antibodies against SARS-CoV-2 virus in the adult Norwegian population, winter 2020/2021: pre-vaccination period",2021-03-26,Preprint,National,Cross-sectional survey ,Norway,,,"16+ adults
To be eligible, individuals had to have a national identity number, known country of birth, a registered
address and a mobile phone number","Individuals living in prisons, nursing homes, or long-term
psychiatric institutions (all of whom represent approximately 1% of the national population over 16 years of age [12]) were not eligible for inclusion",2020-11-25,2021-02-15,Household and community samples,All,Adults (18-64 years),20.0,44.0,Age,age 20-44,10190,0.01,0.008,0.012,,,,,,Stratified probability,"Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED","EUROIMMUN,NA",Multiple Types,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Erik Anda,Arctic University of Norway,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.23.21253730v1,2021-07-30,2024-03-01,Verified,anda_seroprevalence_2021,NOR
210326_Norway_ArcticUniversityOfNorway_female,210326_Norway_ArcticUniversityOfNorway,"Seroprevalence of antibodies against SARS-CoV-2 virus in the adult Norwegian population, winter 2020/2021: pre-vaccination period",2021-03-26,Preprint,National,Cross-sectional survey ,Norway,,,"16+ adults
To be eligible, individuals had to have a national identity number, known country of birth, a registered
address and a mobile phone number","Individuals living in prisons, nursing homes, or long-term
psychiatric institutions (all of whom represent approximately 1% of the national population over 16 years of age [12]) were not eligible for inclusion",2020-11-25,2021-02-15,Household and community samples,Female,Multiple groups,16.0,,Sex/Gender,,15895,0.008,0.006999999999999999,0.01,,,,,,Stratified probability,"Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED","EUROIMMUN,NA",Multiple Types,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Erik Anda,Arctic University of Norway,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.23.21253730v1,2021-07-30,2024-03-01,Verified,anda_seroprevalence_2021,NOR
210326_Norway_ArcticUniversityOfNorway_age80+,210326_Norway_ArcticUniversityOfNorway,"Seroprevalence of antibodies against SARS-CoV-2 virus in the adult Norwegian population, winter 2020/2021: pre-vaccination period",2021-03-26,Preprint,National,Cross-sectional survey ,Norway,,,"16+ adults
To be eligible, individuals had to have a national identity number, known country of birth, a registered
address and a mobile phone number","Individuals living in prisons, nursing homes, or long-term
psychiatric institutions (all of whom represent approximately 1% of the national population over 16 years of age [12]) were not eligible for inclusion",2020-11-25,2021-02-15,Household and community samples,All,Seniors (65+ years),80.0,,Age,age 80+,781,0.004,0.001,0.012,,,,,,Stratified probability,"Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED","EUROIMMUN,NA",Multiple Types,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Erik Anda,Arctic University of Norway,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.23.21253730v1,2021-07-30,2024-03-01,Verified,anda_seroprevalence_2021,NOR
210326_Norway_ArcticUniversityOfNorway_male,210326_Norway_ArcticUniversityOfNorway,"Seroprevalence of antibodies against SARS-CoV-2 virus in the adult Norwegian population, winter 2020/2021: pre-vaccination period",2021-03-26,Preprint,National,Cross-sectional survey ,Norway,,,"16+ adults
To be eligible, individuals had to have a national identity number, known country of birth, a registered
address and a mobile phone number","Individuals living in prisons, nursing homes, or long-term
psychiatric institutions (all of whom represent approximately 1% of the national population over 16 years of age [12]) were not eligible for inclusion",2020-11-25,2021-02-15,Household and community samples,Male,Multiple groups,16.0,,Sex/Gender,,11793,0.009000000000000001,0.006999999999999999,0.01,,,,,,Stratified probability,"Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED","EUROIMMUN,NA",Multiple Types,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Erik Anda,Arctic University of Norway,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.23.21253730v1,2021-07-30,2024-03-01,Verified,anda_seroprevalence_2021,NOR
210331_Bergen_UniversityOfBergen_overall_unadj,210331_Bergen_UniversityOfBergen,"Attack rates amongst household members of outpatients with confirmed COVID-19 in Bergen, Norway: A case-ascertained study.",2021-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Norway,,Bergen,Household members of confirmed COVID-19 cases,"Households where a case resided alone or no household members were willing to participate in the study, were excluded from the analysis",2020-02-28,2020-04-04,Contacts of COVID patients,All,Multiple groups,,,Primary Estimate,,179,0.45,0.38,0.53,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],Yes,No,No,Yes,Yes,Unclear,Yes,No,Yes,Kanika Kuwelker,University of Bergen ,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanepe.2020.100014,2021-05-17,2022-07-16,Verified,kuwelker_attack_2021,NOR
211109_Norway_NorwegianInstituteofPublicHealth_Time1_PopTestAdj,211109_Norway_NorwegianInstituteofPublicHealth_Time1,Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic.,2021-11-09,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Norway,,,Residual sera from medical laboratories,,2020-04-19,2020-05-16,Residual sera,All,Multiple groups,,,Primary Estimate,,900,0.01,0.001,0.024,True,True,True,,,Convenience,Author designed (type unknown),,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.86,1.0,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.12932,2021-11-18,2022-07-16,Verified,tunheim_trends_2021,NOR
211109_Norway_NorwegianInstituteofPublicHealth_Time1_Unadj,211109_Norway_NorwegianInstituteofPublicHealth_Time1,Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic.,2021-11-09,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Norway,,,Residual sera from medical laboratories,,2020-04-19,2020-05-16,Residual sera,All,Multiple groups,,,Analysis,,900,0.011000000000000001,,,,,,,True,Convenience,Author designed (type unknown),,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.86,1.0,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.12932,2021-11-18,2022-07-16,Verified,tunheim_trends_2021,NOR
211109_Norway_NorwegianInstituteofPublicHealth_Time1_0-4,211109_Norway_NorwegianInstituteofPublicHealth_Time1,Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic.,2021-11-09,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Norway,,,Residual sera from medical laboratories,,2020-04-19,2020-05-16,Residual sera,All,Children and Youth (0-17 years),,,Age,0-4 years-old,41,0.0,,,,,,,,Convenience,Author designed (type unknown),,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.86,1.0,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.12932,2021-11-18,2022-07-16,Verified,tunheim_trends_2021,NOR
211109_Norway_NorwegianInstituteofPublicHealth_Time1_15-24,211109_Norway_NorwegianInstituteofPublicHealth_Time1,Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic.,2021-11-09,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Norway,,,Residual sera from medical laboratories,,2020-04-19,2020-05-16,Residual sera,All,Adults (18-64 years),,,Age,15-24 years-old,166,0.012,,,,,,,,Convenience,Author designed (type unknown),,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.86,1.0,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.12932,2021-11-18,2022-07-16,Verified,tunheim_trends_2021,NOR
211109_Norway_NorwegianInstituteofPublicHealth_Time1_Female,211109_Norway_NorwegianInstituteofPublicHealth_Time1,Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic.,2021-11-09,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Norway,,,Residual sera from medical laboratories,,2020-04-19,2020-05-16,Residual sera,Female,Multiple groups,,,Sex/Gender,,509,0.008,,,,,,,,Convenience,Author designed (type unknown),,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.86,1.0,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.12932,2021-11-18,2022-07-16,Verified,tunheim_trends_2021,NOR
211109_Norway_NorwegianInstituteofPublicHealth_Time1_Male,211109_Norway_NorwegianInstituteofPublicHealth_Time1,Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic.,2021-11-09,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Norway,,,Residual sera from medical laboratories,,2020-04-19,2020-05-16,Residual sera,Male,Multiple groups,,,Sex/Gender,,383,0.016,,,,,,,,Convenience,Author designed (type unknown),,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.86,1.0,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.12932,2021-11-18,2022-07-16,Verified,tunheim_trends_2021,NOR
211109_Norway_NorwegianInstituteofPublicHealth_Time1_25-59,211109_Norway_NorwegianInstituteofPublicHealth_Time1,Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic.,2021-11-09,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Norway,,,Residual sera from medical laboratories,,2020-04-19,2020-05-16,Residual sera,All,Adults (18-64 years),,,Age,25-59 years-old,372,0.011000000000000001,,,,,,,,Convenience,Author designed (type unknown),,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.86,1.0,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.12932,2021-11-18,2022-07-16,Verified,tunheim_trends_2021,NOR
211109_Norway_NorwegianInstituteofPublicHealth_Time1_5-14,211109_Norway_NorwegianInstituteofPublicHealth_Time1,Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic.,2021-11-09,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Norway,,,Residual sera from medical laboratories,,2020-04-19,2020-05-16,Residual sera,All,Children and Youth (0-17 years),,,Age,5-14 years-old,115,0.017,,,,,,,,Convenience,Author designed (type unknown),,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.86,1.0,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.12932,2021-11-18,2022-07-16,Verified,tunheim_trends_2021,NOR
211109_Norway_NorwegianInstituteofPublicHealth_Time1_>=60,211109_Norway_NorwegianInstituteofPublicHealth_Time1,Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic.,2021-11-09,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Norway,,,Residual sera from medical laboratories,,2020-04-19,2020-05-16,Residual sera,All,Seniors (65+ years),,,Age,>=60 years-old,206,0.01,,,,,,,,Convenience,Author designed (type unknown),,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.86,1.0,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.12932,2021-11-18,2022-07-16,Verified,tunheim_trends_2021,NOR
211109_Norway_NorwegianInstituteofPublicHealth_Time2_PopTestAdj,211109_Norway_NorwegianInstituteofPublicHealth_Time2,Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic.,2021-11-09,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Norway,,,Residual sera from medical laboratories," In the first sampling round, the laboratories were asked to avoid samples from individuals with suspected COVID-19",2020-07-19,2020-09-12,Residual sera,All,Multiple groups,,,Primary Estimate,,1812,0.006,0.002,0.012,True,True,True,,,Convenience,Author designed (type unknown),,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.86,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.12932,2021-11-18,2022-07-16,Verified,tunheim_trends_2021,NOR
211109_Norway_NorwegianInstituteofPublicHealth_Time2_25-59,211109_Norway_NorwegianInstituteofPublicHealth_Time2,Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic.,2021-11-09,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Norway,,,Residual sera from medical laboratories," In the first sampling round, the laboratories were asked to avoid samples from individuals with suspected COVID-19",2020-07-19,2020-09-12,Residual sera,All,Adults (18-64 years),,,Age,25-59 years-old,700,0.003,,,,,,,,Convenience,Author designed (type unknown),,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.86,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.12932,2021-11-18,2022-07-16,Verified,tunheim_trends_2021,NOR
211109_Norway_NorwegianInstituteofPublicHealth_Time2_15-24,211109_Norway_NorwegianInstituteofPublicHealth_Time2,Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic.,2021-11-09,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Norway,,,Residual sera from medical laboratories," In the first sampling round, the laboratories were asked to avoid samples from individuals with suspected COVID-19",2020-07-19,2020-09-12,Residual sera,All,Adults (18-64 years),,,Age,15-24 years-old,308,0.01,,,,,,,,Convenience,Author designed (type unknown),,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.86,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.12932,2021-11-18,2022-07-16,Verified,tunheim_trends_2021,NOR
211109_Norway_NorwegianInstituteofPublicHealth_Time2_Female,211109_Norway_NorwegianInstituteofPublicHealth_Time2,Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic.,2021-11-09,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Norway,,,Residual sera from medical laboratories," In the first sampling round, the laboratories were asked to avoid samples from individuals with suspected COVID-19",2020-07-19,2020-09-12,Residual sera,Female,Multiple groups,,,Sex/Gender,,1039,0.005,,,,,,,,Convenience,Author designed (type unknown),,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.86,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.12932,2021-11-18,2022-07-16,Verified,tunheim_trends_2021,NOR
211109_Norway_NorwegianInstituteofPublicHealth_Time2_>=60,211109_Norway_NorwegianInstituteofPublicHealth_Time2,Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic.,2021-11-09,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Norway,,,Residual sera from medical laboratories," In the first sampling round, the laboratories were asked to avoid samples from individuals with suspected COVID-19",2020-07-19,2020-09-12,Residual sera,All,Seniors (65+ years),,,Age,>=60 years-old,379,0.008,,,,,,,,Convenience,Author designed (type unknown),,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.86,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.12932,2021-11-18,2022-07-16,Verified,tunheim_trends_2021,NOR
211109_Norway_NorwegianInstituteofPublicHealth_Time2_Unadj,211109_Norway_NorwegianInstituteofPublicHealth_Time2,Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic.,2021-11-09,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Norway,,,Residual sera from medical laboratories," In the first sampling round, the laboratories were asked to avoid samples from individuals with suspected COVID-19",2020-07-19,2020-09-12,Residual sera,All,Multiple groups,,,Analysis,,1812,0.006,,,,,,,True,Convenience,Author designed (type unknown),,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.86,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.12932,2021-11-18,2022-07-16,Verified,tunheim_trends_2021,NOR
211109_Norway_NorwegianInstituteofPublicHealth_Time2_0-4,211109_Norway_NorwegianInstituteofPublicHealth_Time2,Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic.,2021-11-09,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Norway,,,Residual sera from medical laboratories," In the first sampling round, the laboratories were asked to avoid samples from individuals with suspected COVID-19",2020-07-19,2020-09-12,Residual sera,All,Children and Youth (0-17 years),,,Age,0-4 years-old,112,0.0,,,,,,,,Convenience,Author designed (type unknown),,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.86,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.12932,2021-11-18,2022-07-16,Verified,tunheim_trends_2021,NOR
211109_Norway_NorwegianInstituteofPublicHealth_Time2_5-14,211109_Norway_NorwegianInstituteofPublicHealth_Time2,Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic.,2021-11-09,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Norway,,,Residual sera from medical laboratories," In the first sampling round, the laboratories were asked to avoid samples from individuals with suspected COVID-19",2020-07-19,2020-09-12,Residual sera,All,Children and Youth (0-17 years),,,Age,5-14 years-old,312,0.01,,,,,,,,Convenience,Author designed (type unknown),,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.86,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.12932,2021-11-18,2022-07-16,Verified,tunheim_trends_2021,NOR
211109_Norway_NorwegianInstituteofPublicHealth_Time2_Male,211109_Norway_NorwegianInstituteofPublicHealth_Time2,Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic.,2021-11-09,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Norway,,,Residual sera from medical laboratories," In the first sampling round, the laboratories were asked to avoid samples from individuals with suspected COVID-19",2020-07-19,2020-09-12,Residual sera,Male,Multiple groups,,,Sex/Gender,,770,0.008,,,,,,,,Convenience,Author designed (type unknown),,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.86,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.12932,2021-11-18,2022-07-16,Verified,tunheim_trends_2021,NOR
211109_Norway_NorwegianInstituteofPublicHealth_Time3_PopTestAdj,211109_Norway_NorwegianInstituteofPublicHealth_Time3,Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic.,2021-11-09,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Norway,,,Residual sera from medical laboratories,,2020-12-27,2021-02-13,Residual sera,All,Multiple groups,,,Primary Estimate,,1912,0.032,0.023,0.042,True,True,True,,,Convenience,Author designed (type unknown),,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.96,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1111/irv.12932,2021-11-18,2022-07-16,Verified,tunheim_trends_2021,NOR
211109_Norway_NorwegianInstituteofPublicHealth_Time3_Male,211109_Norway_NorwegianInstituteofPublicHealth_Time3,Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic.,2021-11-09,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Norway,,,Residual sera from medical laboratories,,2020-12-27,2021-02-13,Residual sera,Male,Multiple groups,,,Sex/Gender,,827,0.044000000000000004,,,,,,,,Convenience,Author designed (type unknown),,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.96,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1111/irv.12932,2021-11-18,2022-07-16,Verified,tunheim_trends_2021,NOR
211109_Norway_NorwegianInstituteofPublicHealth_Time3_15-24,211109_Norway_NorwegianInstituteofPublicHealth_Time3,Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic.,2021-11-09,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Norway,,,Residual sera from medical laboratories,,2020-12-27,2021-02-13,Residual sera,All,Adults (18-64 years),,,Age,15-24 years-old,320,0.025,,,,,,,,Convenience,Author designed (type unknown),,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.96,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1111/irv.12932,2021-11-18,2022-07-16,Verified,tunheim_trends_2021,NOR
211109_Norway_NorwegianInstituteofPublicHealth_Time3_0-4,211109_Norway_NorwegianInstituteofPublicHealth_Time3,Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic.,2021-11-09,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Norway,,,Residual sera from medical laboratories,,2020-12-27,2021-02-13,Residual sera,All,Children and Youth (0-17 years),,,Age,0-4 years-old,158,0.057,,,,,,,,Convenience,Author designed (type unknown),,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.96,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1111/irv.12932,2021-11-18,2022-07-16,Verified,tunheim_trends_2021,NOR
211109_Norway_NorwegianInstituteofPublicHealth_Time3_>=60,211109_Norway_NorwegianInstituteofPublicHealth_Time3,Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic.,2021-11-09,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Norway,,,Residual sera from medical laboratories,,2020-12-27,2021-02-13,Residual sera,All,Seniors (65+ years),,,Age,>=60 years-old,391,0.038,,,,,,,,Convenience,Author designed (type unknown),,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.9599999999999996,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1111/irv.12932,2021-11-18,2022-07-16,Verified,tunheim_trends_2021,NOR
211109_Norway_NorwegianInstituteofPublicHealth_Time3_Unadj,211109_Norway_NorwegianInstituteofPublicHealth_Time3,Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic.,2021-11-09,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Norway,,,Residual sera from medical laboratories,,2020-12-27,2021-02-13,Residual sera,All,Multiple groups,,,Analysis,,1912,0.032,,,,,,,True,Convenience,Author designed (type unknown),,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.96,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1111/irv.12932,2021-11-18,2022-07-16,Verified,tunheim_trends_2021,NOR
211109_Norway_NorwegianInstituteofPublicHealth_Time3_Female,211109_Norway_NorwegianInstituteofPublicHealth_Time3,Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic.,2021-11-09,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Norway,,,Residual sera from medical laboratories,,2020-12-27,2021-02-13,Residual sera,Female,Multiple groups,,,Sex/Gender,,1077,0.023,,,,,,,,Convenience,Author designed (type unknown),,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.96,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1111/irv.12932,2021-11-18,2022-07-16,Verified,tunheim_trends_2021,NOR
211109_Norway_NorwegianInstituteofPublicHealth_Time3_25-59,211109_Norway_NorwegianInstituteofPublicHealth_Time3,Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic.,2021-11-09,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Norway,,,Residual sera from medical laboratories,,2020-12-27,2021-02-13,Residual sera,All,Adults (18-64 years),,,Age,25-59 years-old,708,0.021,,,,,,,,Convenience,Author designed (type unknown),,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.96,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1111/irv.12932,2021-11-18,2022-07-16,Verified,tunheim_trends_2021,NOR
211109_Norway_NorwegianInstituteofPublicHealth_Time3_5-14,211109_Norway_NorwegianInstituteofPublicHealth_Time3,Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic.,2021-11-09,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Norway,,,Residual sera from medical laboratories,,2020-12-27,2021-02-13,Residual sera,All,Children and Youth (0-17 years),,,Age,5-14 years-old,335,0.042,,,,,,,,Convenience,Author designed (type unknown),,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.96,0.998,['Moderate'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1111/irv.12932,2021-11-18,2022-07-16,Verified,tunheim_trends_2021,NOR
211109_Norway_NorwegianInstituteofPublicHealth_Time4_Primary,211109_Norway_NorwegianInstituteofPublicHealth_Time4,Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic.,2021-11-09,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Norway,,,Residual sera from medical laboratories,,2019-08-01,2019-08-31,Residual sera,All,Multiple groups,,,Primary Estimate,,216,0.0,,,True,,,,True,Convenience,Author designed (type unknown),,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],No,No,No,No,Unclear,Unclear,Yes,No,,Gro Tunheim,Norwegian Institute of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.12932,2021-11-18,2022-07-16,Verified,tunheim_trends_2021,NOR
211117_Norway_OsloUniversityHospital_KidneyTransplantRecipient,211117_Norway_OsloUniversityHospital_KidneyTransplantRecipient,Kidney Transplant Recipient Behavior During the Early COVID-19 Pandemic: A National Survey Study in Norway.,2021-11-17,Preprint,National,Prospective cohort,Norway,,,"All adult kidney transplant recipients (n = 3,596) with a functioning graft as of April 20th, 2020, and a signed informed consent stating that data in the Norwegian Renal Registry (NRR) may be used for research were considered eligible to participate in the study.",536 had reservation towards phone contact,2020-06-15,2020-10-31,Representative patient population,All,Multiple groups,,,Primary Estimate,,815,0.0,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Author designed (IFA) - MULTIPLEXED","Roche Diagnostics,NA",Multiple Types,,IgG,,Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Kjersti B. Blom,Oslo University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.xkme.2021.09.006,2021-12-01,2024-03-01,Unverified,blom_kidney_2021,NOR
220113_Lorenskog_UniversityofOslo_Overall_TestAdj,220113_Lorenskog_UniversityofOslo,Prevalence of antibodies against SARS-CoV-2 among pregnant women in Norway during the period December 2019 through December 2020.,2022-01-13,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Norway,Akershus,Lorenskog,"women who were in the first trimester of pregnancy during the period December 2019 through December 2020  in the catchment region of Akershus University Hospital, Norway",,2019-12-01,2020-12-31,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,Test adjustment,6520,0.017,,,True,True,,,,Sequential,"Elecsys® Anti‐SARS‐CoV‐2 (N),Liaison SARS-CoV-2 S1/S2 IgG","Roche Diagnostics,DiaSorin",CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,,Anne Eskild,University of Oslo,Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000073,2022-01-18,2023-08-15,Verified,eskild_prevalence_2022,NOR
220113_Lorenskog_UniversityofOslo_Jun2020_Crude,220113_Lorenskog_UniversityofOslo,Prevalence of antibodies against SARS-CoV-2 among pregnant women in Norway during the period December 2019 through December 2020.,2022-01-13,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Norway,Akershus,Lorenskog,"women who were in the first trimester of pregnancy during the period December 2019 through December 2020  in the catchment region of Akershus University Hospital, Norway",,2020-06-01,2020-06-30,Pregnant or parturient women,Female,Adults (18-64 years),,,Time frame,"June 2020, Unadjusted",521,0.013000000000000001,,,,,,,,Sequential,"Elecsys® Anti‐SARS‐CoV‐2 (N),Liaison SARS-CoV-2 S1/S2 IgG","Roche Diagnostics,DiaSorin",CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,,Anne Eskild,University of Oslo,Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000073,2022-01-18,2024-03-01,Verified,eskild_prevalence_2022,NOR
220113_Lorenskog_UniversityofOslo_Overall_Crude,220113_Lorenskog_UniversityofOslo,Prevalence of antibodies against SARS-CoV-2 among pregnant women in Norway during the period December 2019 through December 2020.,2022-01-13,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Norway,Akershus,Lorenskog,"women who were in the first trimester of pregnancy during the period December 2019 through December 2020  in the catchment region of Akershus University Hospital, Norway",,2019-12-01,2020-12-31,Pregnant or parturient women,Female,Adults (18-64 years),,,Analysis,Unadjusted,6520,0.015,,,,,,,True,Sequential,"Elecsys® Anti‐SARS‐CoV‐2 (N),Liaison SARS-CoV-2 S1/S2 IgG","Roche Diagnostics,DiaSorin",CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,,Anne Eskild,University of Oslo,Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000073,2022-01-18,2024-03-01,Verified,eskild_prevalence_2022,NOR
220113_Lorenskog_UniversityofOslo_Oct2020_Crude,220113_Lorenskog_UniversityofOslo,Prevalence of antibodies against SARS-CoV-2 among pregnant women in Norway during the period December 2019 through December 2020.,2022-01-13,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Norway,Akershus,Lorenskog,"women who were in the first trimester of pregnancy during the period December 2019 through December 2020  in the catchment region of Akershus University Hospital, Norway",,2020-10-01,2020-10-31,Pregnant or parturient women,Female,Adults (18-64 years),,,Time frame,"October 2020, Unadjusted",521,0.017,,,,,,,,Sequential,"Elecsys® Anti‐SARS‐CoV‐2 (N),Liaison SARS-CoV-2 S1/S2 IgG","Roche Diagnostics,DiaSorin",CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,,Anne Eskild,University of Oslo,Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000073,2022-01-18,2024-03-01,Verified,eskild_prevalence_2022,NOR
220113_Lorenskog_UniversityofOslo_Apr2020_Crude,220113_Lorenskog_UniversityofOslo,Prevalence of antibodies against SARS-CoV-2 among pregnant women in Norway during the period December 2019 through December 2020.,2022-01-13,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Norway,Akershus,Lorenskog,"women who were in the first trimester of pregnancy during the period December 2019 through December 2020  in the catchment region of Akershus University Hospital, Norway",,2020-04-01,2020-04-30,Pregnant or parturient women,Female,Adults (18-64 years),,,Time frame,"April 2020, Unadjusted",455,0.006999999999999999,,,,,,,,Sequential,"Elecsys® Anti‐SARS‐CoV‐2 (N),Liaison SARS-CoV-2 S1/S2 IgG","Roche Diagnostics,DiaSorin",CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,,Anne Eskild,University of Oslo,Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000073,2022-01-18,2024-03-01,Verified,eskild_prevalence_2022,NOR
220113_Lorenskog_UniversityofOslo_Nov2020_Crude,220113_Lorenskog_UniversityofOslo,Prevalence of antibodies against SARS-CoV-2 among pregnant women in Norway during the period December 2019 through December 2020.,2022-01-13,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Norway,Akershus,Lorenskog,"women who were in the first trimester of pregnancy during the period December 2019 through December 2020  in the catchment region of Akershus University Hospital, Norway",,2020-11-01,2020-11-30,Pregnant or parturient women,Female,Adults (18-64 years),,,Time frame,"November 2020, Unadjusted",511,0.031000000000000003,,,,,,,,Sequential,"Elecsys® Anti‐SARS‐CoV‐2 (N),Liaison SARS-CoV-2 S1/S2 IgG","Roche Diagnostics,DiaSorin",CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,,Anne Eskild,University of Oslo,Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000073,2022-01-18,2024-03-01,Verified,eskild_prevalence_2022,NOR
220113_Lorenskog_UniversityofOslo_Dec2020_Crude,220113_Lorenskog_UniversityofOslo,Prevalence of antibodies against SARS-CoV-2 among pregnant women in Norway during the period December 2019 through December 2020.,2022-01-13,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Norway,Akershus,Lorenskog,"women who were in the first trimester of pregnancy during the period December 2019 through December 2020  in the catchment region of Akershus University Hospital, Norway",,2020-12-01,2020-12-31,Pregnant or parturient women,Female,Adults (18-64 years),,,Time frame,"December 2020, Unadjusted",418,0.05,,,,,,,,Sequential,"Elecsys® Anti‐SARS‐CoV‐2 (N),Liaison SARS-CoV-2 S1/S2 IgG","Roche Diagnostics,DiaSorin",CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,,Anne Eskild,University of Oslo,Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000073,2022-01-18,2024-03-01,Verified,eskild_prevalence_2022,NOR
220113_Lorenskog_UniversityofOslo_May2020_Crude,220113_Lorenskog_UniversityofOslo,Prevalence of antibodies against SARS-CoV-2 among pregnant women in Norway during the period December 2019 through December 2020.,2022-01-13,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Norway,Akershus,Lorenskog,"women who were in the first trimester of pregnancy during the period December 2019 through December 2020  in the catchment region of Akershus University Hospital, Norway",,2020-05-01,2020-05-31,Pregnant or parturient women,Female,Adults (18-64 years),,,Time frame,"May 2020, Unadjusted",464,0.015,,,,,,,,Sequential,"Elecsys® Anti‐SARS‐CoV‐2 (N),Liaison SARS-CoV-2 S1/S2 IgG","Roche Diagnostics,DiaSorin",CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,,Anne Eskild,University of Oslo,Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000073,2022-01-18,2024-03-01,Verified,eskild_prevalence_2022,NOR
220113_Lorenskog_UniversityofOslo_Jul2020_Crude,220113_Lorenskog_UniversityofOslo,Prevalence of antibodies against SARS-CoV-2 among pregnant women in Norway during the period December 2019 through December 2020.,2022-01-13,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Norway,Akershus,Lorenskog,"women who were in the first trimester of pregnancy during the period December 2019 through December 2020  in the catchment region of Akershus University Hospital, Norway",,2020-07-01,2020-07-31,Pregnant or parturient women,Female,Adults (18-64 years),,,Time frame,"July 2020, Unadjusted",437,0.013999999999999999,,,,,,,,Sequential,"Elecsys® Anti‐SARS‐CoV‐2 (N),Liaison SARS-CoV-2 S1/S2 IgG","Roche Diagnostics,DiaSorin",CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,,Anne Eskild,University of Oslo,Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000073,2022-01-18,2024-03-01,Verified,eskild_prevalence_2022,NOR
220113_Lorenskog_UniversityofOslo_Aug2020_Crude,220113_Lorenskog_UniversityofOslo,Prevalence of antibodies against SARS-CoV-2 among pregnant women in Norway during the period December 2019 through December 2020.,2022-01-13,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Norway,Akershus,Lorenskog,"women who were in the first trimester of pregnancy during the period December 2019 through December 2020  in the catchment region of Akershus University Hospital, Norway",,2020-08-01,2020-08-31,Pregnant or parturient women,Female,Adults (18-64 years),,,Time frame,"August 2020, Unadjusted",541,0.018000000000000002,,,,,,,,Sequential,"Elecsys® Anti‐SARS‐CoV‐2 (N),Liaison SARS-CoV-2 S1/S2 IgG","Roche Diagnostics,DiaSorin",CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,,Anne Eskild,University of Oslo,Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000073,2022-01-18,2024-03-01,Verified,eskild_prevalence_2022,NOR
220113_Lorenskog_UniversityofOslo_Dec2019_Crude,220113_Lorenskog_UniversityofOslo,Prevalence of antibodies against SARS-CoV-2 among pregnant women in Norway during the period December 2019 through December 2020.,2022-01-13,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Norway,Akershus,Lorenskog,"women who were in the first trimester of pregnancy during the period December 2019 through December 2020  in the catchment region of Akershus University Hospital, Norway",,2019-12-01,2019-12-31,Pregnant or parturient women,Female,Adults (18-64 years),,,Time frame,"December 2019, Unadjusted",445,0.002,,,,,,,,Sequential,"Elecsys® Anti‐SARS‐CoV‐2 (N),Liaison SARS-CoV-2 S1/S2 IgG","Roche Diagnostics,DiaSorin",CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,,Anne Eskild,University of Oslo,Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000073,2022-01-18,2024-03-01,Verified,eskild_prevalence_2022,NOR
220113_Lorenskog_UniversityofOslo_Sep2020_Crude,220113_Lorenskog_UniversityofOslo,Prevalence of antibodies against SARS-CoV-2 among pregnant women in Norway during the period December 2019 through December 2020.,2022-01-13,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Norway,Akershus,Lorenskog,"women who were in the first trimester of pregnancy during the period December 2019 through December 2020  in the catchment region of Akershus University Hospital, Norway",,2020-09-01,2020-09-30,Pregnant or parturient women,Female,Adults (18-64 years),,,Time frame,"September 2020, Unadjusted",559,0.025,,,,,,,,Sequential,"Elecsys® Anti‐SARS‐CoV‐2 (N),Liaison SARS-CoV-2 S1/S2 IgG","Roche Diagnostics,DiaSorin",CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,,Anne Eskild,University of Oslo,Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000073,2022-01-18,2024-03-01,Verified,eskild_prevalence_2022,NOR
220113_Lorenskog_UniversityofOslo_Feb2020_Crude,220113_Lorenskog_UniversityofOslo,Prevalence of antibodies against SARS-CoV-2 among pregnant women in Norway during the period December 2019 through December 2020.,2022-01-13,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Norway,Akershus,Lorenskog,"women who were in the first trimester of pregnancy during the period December 2019 through December 2020  in the catchment region of Akershus University Hospital, Norway",,2020-02-01,2020-02-29,Pregnant or parturient women,Female,Adults (18-64 years),,,Time frame,"February 2020, Unadjusted",498,0.002,,,,,,,,Sequential,"Elecsys® Anti‐SARS‐CoV‐2 (N),Liaison SARS-CoV-2 S1/S2 IgG","Roche Diagnostics,DiaSorin",CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,,Anne Eskild,University of Oslo,Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000073,2022-01-18,2024-03-01,Verified,eskild_prevalence_2022,NOR
220113_Lorenskog_UniversityofOslo_Jan2020_Crude,220113_Lorenskog_UniversityofOslo,Prevalence of antibodies against SARS-CoV-2 among pregnant women in Norway during the period December 2019 through December 2020.,2022-01-13,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Norway,Akershus,Lorenskog,"women who were in the first trimester of pregnancy during the period December 2019 through December 2020  in the catchment region of Akershus University Hospital, Norway",,2020-01-01,2020-01-31,Pregnant or parturient women,Female,Adults (18-64 years),,,Time frame,"January 2020, Unadjusted",679,0.003,,,,,,,,Sequential,"Elecsys® Anti‐SARS‐CoV‐2 (N),Liaison SARS-CoV-2 S1/S2 IgG","Roche Diagnostics,DiaSorin",CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,,Anne Eskild,University of Oslo,Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000073,2022-01-18,2024-03-01,Verified,eskild_prevalence_2022,NOR
220113_Lorenskog_UniversityofOslo_Mar2020_Crude,220113_Lorenskog_UniversityofOslo,Prevalence of antibodies against SARS-CoV-2 among pregnant women in Norway during the period December 2019 through December 2020.,2022-01-13,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Norway,Akershus,Lorenskog,"women who were in the first trimester of pregnancy during the period December 2019 through December 2020  in the catchment region of Akershus University Hospital, Norway",,2020-03-01,2020-03-31,Pregnant or parturient women,Female,Adults (18-64 years),,,Time frame,"March 2020, Unadjusted",471,0.002,,,,,,,,Sequential,"Elecsys® Anti‐SARS‐CoV‐2 (N),Liaison SARS-CoV-2 S1/S2 IgG","Roche Diagnostics,DiaSorin",CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,,Anne Eskild,University of Oslo,Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000073,2022-01-18,2024-03-01,Verified,eskild_prevalence_2022,NOR
220331_Norway_TheArcticUniversityofNorway_Popadj,220331_Norway_TheArcticUniversityofNorway,"Seroprevalence of antibodies against SARS-CoV-2 in the adult population during the pre-vaccination period, Norway, winter 2020/21",2022-03-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Norway,,,"""To  be  eligible,  individuals  had  to  have  a  national  identity  number,  known  country  of  birth,  a  registered  Norwegian  address  and  a  mobile  phone  number""

16 or older","""individuals living in prisons, nursing homes, or  long-term  psychiatric  institutions  (all  of  whom  represent  ca  1%  of  the  national  population )  were  not  eligible  for  inclusion""

<16 were excluded",2020-11-15,2021-02-15,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,,27700,0.009000000000000001,0.006999999999999999,0.01,True,,True,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED","EUROIMMUN,NA",ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Erik Eik Anda,The Arctic University of Norway,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.13.2100376,2022-04-13,2024-03-01,Unverified,anda_seroprevalence_2022,NOR
220331_Norway_TheArcticUniversityofNorway_Sex_Female,220331_Norway_TheArcticUniversityofNorway,"Seroprevalence of antibodies against SARS-CoV-2 in the adult population during the pre-vaccination period, Norway, winter 2020/21",2022-03-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Norway,,,"""To  be  eligible,  individuals  had  to  have  a  national  identity  number,  known  country  of  birth,  a  registered  Norwegian  address  and  a  mobile  phone  number""

16 or older","""individuals living in prisons, nursing homes, or  long-term  psychiatric  institutions  (all  of  whom  represent  ca  1%  of  the  national  population )  were  not  eligible  for  inclusion""

<16 were excluded",2020-11-15,2021-02-15,Household and community samples,Female,Multiple groups,,,Sex/Gender,,15895,0.008,0.006,0.01,,,True,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED","EUROIMMUN,NA",ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Erik Eik Anda,The Arctic University of Norway,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.13.2100376,2022-04-17,2024-03-01,Unverified,anda_seroprevalence_2022,NOR
220331_Norway_TheArcticUniversityofNorway_Region_Viken,220331_Norway_TheArcticUniversityofNorway,"Seroprevalence of antibodies against SARS-CoV-2 in the adult population during the pre-vaccination period, Norway, winter 2020/21",2022-03-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Norway,,,"""To  be  eligible,  individuals  had  to  have  a  national  identity  number,  known  country  of  birth,  a  registered  Norwegian  address  and  a  mobile  phone  number""

16 or older","""individuals living in prisons, nursing homes, or  long-term  psychiatric  institutions  (all  of  whom  represent  ca  1%  of  the  national  population )  were  not  eligible  for  inclusion""

<16 were excluded",2020-11-15,2021-02-15,Household and community samples,All,Multiple groups,,,Geographical area,Viken,6714,0.01,0.006999999999999999,0.013000000000000001,,,True,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED","EUROIMMUN,NA",ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Erik Eik Anda,The Arctic University of Norway,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.13.2100376,2022-04-17,2024-03-01,Unverified,anda_seroprevalence_2022,NOR
220331_Norway_TheArcticUniversityofNorway_Region_VestfoldandTelemark,220331_Norway_TheArcticUniversityofNorway,"Seroprevalence of antibodies against SARS-CoV-2 in the adult population during the pre-vaccination period, Norway, winter 2020/21",2022-03-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Norway,,,"""To  be  eligible,  individuals  had  to  have  a  national  identity  number,  known  country  of  birth,  a  registered  Norwegian  address  and  a  mobile  phone  number""

16 or older","""individuals living in prisons, nursing homes, or  long-term  psychiatric  institutions  (all  of  whom  represent  ca  1%  of  the  national  population )  were  not  eligible  for  inclusion""

<16 were excluded",2020-11-15,2021-02-15,Household and community samples,All,Multiple groups,,,Geographical area,Vestfold and Telemark,2155,0.002,0.0,0.004,,,True,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED","EUROIMMUN,NA",ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Erik Eik Anda,The Arctic University of Norway,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.13.2100376,2022-04-17,2024-03-01,Unverified,anda_seroprevalence_2022,NOR
220331_Norway_TheArcticUniversityofNorway_Sex_Male,220331_Norway_TheArcticUniversityofNorway,"Seroprevalence of antibodies against SARS-CoV-2 in the adult population during the pre-vaccination period, Norway, winter 2020/21",2022-03-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Norway,,,"""To  be  eligible,  individuals  had  to  have  a  national  identity  number,  known  country  of  birth,  a  registered  Norwegian  address  and  a  mobile  phone  number""

16 or older","""individuals living in prisons, nursing homes, or  long-term  psychiatric  institutions  (all  of  whom  represent  ca  1%  of  the  national  population )  were  not  eligible  for  inclusion""

<16 were excluded",2020-11-15,2021-02-15,Household and community samples,Male,Multiple groups,,,Sex/Gender,,11793,0.009000000000000001,0.006999999999999999,0.011000000000000001,,,True,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED","EUROIMMUN,NA",ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Erik Eik Anda,The Arctic University of Norway,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.13.2100376,2022-04-17,2024-03-01,Unverified,anda_seroprevalence_2022,NOR
220331_Norway_TheArcticUniversityofNorway_Age_>=80,220331_Norway_TheArcticUniversityofNorway,"Seroprevalence of antibodies against SARS-CoV-2 in the adult population during the pre-vaccination period, Norway, winter 2020/21",2022-03-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Norway,,,"""To  be  eligible,  individuals  had  to  have  a  national  identity  number,  known  country  of  birth,  a  registered  Norwegian  address  and  a  mobile  phone  number""

16 or older","""individuals living in prisons, nursing homes, or  long-term  psychiatric  institutions  (all  of  whom  represent  ca  1%  of  the  national  population )  were  not  eligible  for  inclusion""

<16 were excluded",2020-11-15,2021-02-15,Household and community samples,All,Seniors (65+ years),80.0,80.0,Age,>= 80,781,0.004,0.0,0.009000000000000001,,,True,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED","EUROIMMUN,NA",ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Erik Eik Anda,The Arctic University of Norway,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.13.2100376,2022-04-17,2024-03-01,Unverified,anda_seroprevalence_2022,NOR
220331_Norway_TheArcticUniversityofNorway_Age_20-44,220331_Norway_TheArcticUniversityofNorway,"Seroprevalence of antibodies against SARS-CoV-2 in the adult population during the pre-vaccination period, Norway, winter 2020/21",2022-03-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Norway,,,"""To  be  eligible,  individuals  had  to  have  a  national  identity  number,  known  country  of  birth,  a  registered  Norwegian  address  and  a  mobile  phone  number""

16 or older","""individuals living in prisons, nursing homes, or  long-term  psychiatric  institutions  (all  of  whom  represent  ca  1%  of  the  national  population )  were  not  eligible  for  inclusion""

<16 were excluded",2020-11-15,2021-02-15,Household and community samples,All,Adults (18-64 years),20.0,44.0,Age,20-44,10190,0.01,0.008,0.012,,,True,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED","EUROIMMUN,NA",ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Erik Eik Anda,The Arctic University of Norway,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.13.2100376,2022-04-17,2024-03-01,Unverified,anda_seroprevalence_2022,NOR
220331_Norway_TheArcticUniversityofNorway_Region_Vestland,220331_Norway_TheArcticUniversityofNorway,"Seroprevalence of antibodies against SARS-CoV-2 in the adult population during the pre-vaccination period, Norway, winter 2020/21",2022-03-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Norway,,,"""To  be  eligible,  individuals  had  to  have  a  national  identity  number,  known  country  of  birth,  a  registered  Norwegian  address  and  a  mobile  phone  number""

16 or older","""individuals living in prisons, nursing homes, or  long-term  psychiatric  institutions  (all  of  whom  represent  ca  1%  of  the  national  population )  were  not  eligible  for  inclusion""

<16 were excluded",2020-11-15,2021-02-15,Household and community samples,All,Multiple groups,,,Geographical area,Vestland,3326,0.013999999999999999,0.009000000000000001,0.018000000000000002,,,True,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED","EUROIMMUN,NA",ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Erik Eik Anda,The Arctic University of Norway,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.13.2100376,2022-04-17,2024-03-01,Unverified,anda_seroprevalence_2022,NOR
220331_Norway_TheArcticUniversityofNorway_Region_Innlandet,220331_Norway_TheArcticUniversityofNorway,"Seroprevalence of antibodies against SARS-CoV-2 in the adult population during the pre-vaccination period, Norway, winter 2020/21",2022-03-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Norway,,,"""To  be  eligible,  individuals  had  to  have  a  national  identity  number,  known  country  of  birth,  a  registered  Norwegian  address  and  a  mobile  phone  number""

16 or older","""individuals living in prisons, nursing homes, or  long-term  psychiatric  institutions  (all  of  whom  represent  ca  1%  of  the  national  population )  were  not  eligible  for  inclusion""

<16 were excluded",2020-11-15,2021-02-15,Household and community samples,All,Multiple groups,,,Geographical area,Innlandet,1806,0.006,0.002,0.011000000000000001,,,True,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED","EUROIMMUN,NA",ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Erik Eik Anda,The Arctic University of Norway,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.13.2100376,2022-04-17,2024-03-01,Unverified,anda_seroprevalence_2022,NOR
220331_Norway_TheArcticUniversityofNorway_Region_Nordland,220331_Norway_TheArcticUniversityofNorway,"Seroprevalence of antibodies against SARS-CoV-2 in the adult population during the pre-vaccination period, Norway, winter 2020/21",2022-03-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Norway,,,"""To  be  eligible,  individuals  had  to  have  a  national  identity  number,  known  country  of  birth,  a  registered  Norwegian  address  and  a  mobile  phone  number""

16 or older","""individuals living in prisons, nursing homes, or  long-term  psychiatric  institutions  (all  of  whom  represent  ca  1%  of  the  national  population )  were  not  eligible  for  inclusion""

<16 were excluded",2020-11-15,2021-02-15,Household and community samples,All,Multiple groups,,,Geographical area,Nordland,1213,0.004,0.0,0.009000000000000001,,,True,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED","EUROIMMUN,NA",ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Erik Eik Anda,The Arctic University of Norway,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.13.2100376,2022-04-17,2024-03-01,Unverified,anda_seroprevalence_2022,NOR
220331_Norway_TheArcticUniversityofNorway_Age_16-19,220331_Norway_TheArcticUniversityofNorway,"Seroprevalence of antibodies against SARS-CoV-2 in the adult population during the pre-vaccination period, Norway, winter 2020/21",2022-03-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Norway,,,"""To  be  eligible,  individuals  had  to  have  a  national  identity  number,  known  country  of  birth,  a  registered  Norwegian  address  and  a  mobile  phone  number""

16 or older","""individuals living in prisons, nursing homes, or  long-term  psychiatric  institutions  (all  of  whom  represent  ca  1%  of  the  national  population )  were  not  eligible  for  inclusion""

<16 were excluded",2020-11-15,2021-02-15,Household and community samples,All,Multiple groups,16.0,19.0,Age,16-19,868,0.019,0.009000000000000001,0.028999999999999998,,,True,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED","EUROIMMUN,NA",ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Erik Eik Anda,The Arctic University of Norway,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.13.2100376,2022-04-17,2024-03-01,Unverified,anda_seroprevalence_2022,NOR
220331_Norway_TheArcticUniversityofNorway_Region_Agder,220331_Norway_TheArcticUniversityofNorway,"Seroprevalence of antibodies against SARS-CoV-2 in the adult population during the pre-vaccination period, Norway, winter 2020/21",2022-03-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Norway,,,"""To  be  eligible,  individuals  had  to  have  a  national  identity  number,  known  country  of  birth,  a  registered  Norwegian  address  and  a  mobile  phone  number""

16 or older","""individuals living in prisons, nursing homes, or  long-term  psychiatric  institutions  (all  of  whom  represent  ca  1%  of  the  national  population )  were  not  eligible  for  inclusion""

<16 were excluded",2020-11-15,2021-02-15,Household and community samples,All,Multiple groups,,,Geographical area,Agder,1362,0.006999999999999999,0.001,0.012,,,True,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED","EUROIMMUN,NA",ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Erik Eik Anda,The Arctic University of Norway,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.13.2100376,2022-04-17,2024-03-01,Unverified,anda_seroprevalence_2022,NOR
220331_Norway_TheArcticUniversityofNorway_Unadj,220331_Norway_TheArcticUniversityofNorway,"Seroprevalence of antibodies against SARS-CoV-2 in the adult population during the pre-vaccination period, Norway, winter 2020/21",2022-03-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Norway,,,"""To  be  eligible,  individuals  had  to  have  a  national  identity  number,  known  country  of  birth,  a  registered  Norwegian  address  and  a  mobile  phone  number""

16 or older","""individuals living in prisons, nursing homes, or  long-term  psychiatric  institutions  (all  of  whom  represent  ca  1%  of  the  national  population )  were  not  eligible  for  inclusion""

<16 were excluded",2020-11-15,2021-02-15,Household and community samples,All,Multiple groups,16.0,,Analysis,,27700,0.008,0.006999999999999999,0.01,,,True,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED","EUROIMMUN,NA",ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Erik Eik Anda,The Arctic University of Norway,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.13.2100376,2022-04-17,2024-03-01,Unverified,anda_seroprevalence_2022,NOR
220331_Norway_TheArcticUniversityofNorway_Age_45-66,220331_Norway_TheArcticUniversityofNorway,"Seroprevalence of antibodies against SARS-CoV-2 in the adult population during the pre-vaccination period, Norway, winter 2020/21",2022-03-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Norway,,,"""To  be  eligible,  individuals  had  to  have  a  national  identity  number,  known  country  of  birth,  a  registered  Norwegian  address  and  a  mobile  phone  number""

16 or older","""individuals living in prisons, nursing homes, or  long-term  psychiatric  institutions  (all  of  whom  represent  ca  1%  of  the  national  population )  were  not  eligible  for  inclusion""

<16 were excluded",2020-11-15,2021-02-15,Household and community samples,All,Adults (18-64 years),45.0,66.0,Age,45-66,11206,0.006999999999999999,0.006,0.009000000000000001,,,True,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED","EUROIMMUN,NA",ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Erik Eik Anda,The Arctic University of Norway,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.13.2100376,2022-04-17,2024-03-01,Unverified,anda_seroprevalence_2022,NOR
220331_Norway_TheArcticUniversityofNorway_Region_MoreandRomsdal,220331_Norway_TheArcticUniversityofNorway,"Seroprevalence of antibodies against SARS-CoV-2 in the adult population during the pre-vaccination period, Norway, winter 2020/21",2022-03-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Norway,,,"""To  be  eligible,  individuals  had  to  have  a  national  identity  number,  known  country  of  birth,  a  registered  Norwegian  address  and  a  mobile  phone  number""

16 or older","""individuals living in prisons, nursing homes, or  long-term  psychiatric  institutions  (all  of  whom  represent  ca  1%  of  the  national  population )  were  not  eligible  for  inclusion""

<16 were excluded",2020-11-15,2021-02-15,Household and community samples,All,Multiple groups,,,Geographical area,Møre and Romsdal,1256,0.0,0.0,0.001,,,True,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED","EUROIMMUN,NA",ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Erik Eik Anda,The Arctic University of Norway,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.13.2100376,2022-04-17,2024-03-01,Unverified,anda_seroprevalence_2022,NOR
220331_Norway_TheArcticUniversityofNorway_Region_Rogaland,220331_Norway_TheArcticUniversityofNorway,"Seroprevalence of antibodies against SARS-CoV-2 in the adult population during the pre-vaccination period, Norway, winter 2020/21",2022-03-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Norway,,,"""To  be  eligible,  individuals  had  to  have  a  national  identity  number,  known  country  of  birth,  a  registered  Norwegian  address  and  a  mobile  phone  number""

16 or older","""individuals living in prisons, nursing homes, or  long-term  psychiatric  institutions  (all  of  whom  represent  ca  1%  of  the  national  population )  were  not  eligible  for  inclusion""

<16 were excluded",2020-11-15,2021-02-15,Household and community samples,All,Multiple groups,,,Geographical area,Rogaland,2072,0.006999999999999999,0.003,0.012,,,True,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED","EUROIMMUN,NA",ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Erik Eik Anda,The Arctic University of Norway,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.13.2100376,2022-04-17,2024-03-01,Unverified,anda_seroprevalence_2022,NOR
220331_Norway_TheArcticUniversityofNorway_Age_67-79,220331_Norway_TheArcticUniversityofNorway,"Seroprevalence of antibodies against SARS-CoV-2 in the adult population during the pre-vaccination period, Norway, winter 2020/21",2022-03-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Norway,,,"""To  be  eligible,  individuals  had  to  have  a  national  identity  number,  known  country  of  birth,  a  registered  Norwegian  address  and  a  mobile  phone  number""

16 or older","""individuals living in prisons, nursing homes, or  long-term  psychiatric  institutions  (all  of  whom  represent  ca  1%  of  the  national  population )  were  not  eligible  for  inclusion""

<16 were excluded",2020-11-15,2021-02-15,Household and community samples,All,Seniors (65+ years),67.0,79.0,Age,67-79,4655,0.005,0.003,0.006999999999999999,,,True,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED","EUROIMMUN,NA",ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Erik Eik Anda,The Arctic University of Norway,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.13.2100376,2022-04-17,2024-03-01,Unverified,anda_seroprevalence_2022,NOR
220331_Norway_TheArcticUniversityofNorway_Region_Trondelag,220331_Norway_TheArcticUniversityofNorway,"Seroprevalence of antibodies against SARS-CoV-2 in the adult population during the pre-vaccination period, Norway, winter 2020/21",2022-03-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Norway,,,"""To  be  eligible,  individuals  had  to  have  a  national  identity  number,  known  country  of  birth,  a  registered  Norwegian  address  and  a  mobile  phone  number""

16 or older","""individuals living in prisons, nursing homes, or  long-term  psychiatric  institutions  (all  of  whom  represent  ca  1%  of  the  national  population )  were  not  eligible  for  inclusion""

<16 were excluded",2020-11-15,2021-02-15,Household and community samples,All,Multiple groups,,,Geographical area,Trøndelag,2314,0.004,0.0,0.008,,,True,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED","EUROIMMUN,NA",ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Erik Eik Anda,The Arctic University of Norway,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.13.2100376,2022-04-17,2024-03-01,Unverified,anda_seroprevalence_2022,NOR
220331_Norway_TheArcticUniversityofNorway_Region_Oslo,220331_Norway_TheArcticUniversityofNorway,"Seroprevalence of antibodies against SARS-CoV-2 in the adult population during the pre-vaccination period, Norway, winter 2020/21",2022-03-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Norway,,,"""To  be  eligible,  individuals  had  to  have  a  national  identity  number,  known  country  of  birth,  a  registered  Norwegian  address  and  a  mobile  phone  number""

16 or older","""individuals living in prisons, nursing homes, or  long-term  psychiatric  institutions  (all  of  whom  represent  ca  1%  of  the  national  population )  were  not  eligible  for  inclusion""

<16 were excluded",2020-11-15,2021-02-15,Household and community samples,All,Multiple groups,,,Geographical area,Oslo,3782,0.017,0.012,0.022000000000000002,,,True,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED","EUROIMMUN,NA",ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Erik Eik Anda,The Arctic University of Norway,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.13.2100376,2022-04-17,2024-03-01,Unverified,anda_seroprevalence_2022,NOR
220331_Norway_TheArcticUniversityofNorway_Region_TromsandFinnmark,220331_Norway_TheArcticUniversityofNorway,"Seroprevalence of antibodies against SARS-CoV-2 in the adult population during the pre-vaccination period, Norway, winter 2020/21",2022-03-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Norway,,,"""To  be  eligible,  individuals  had  to  have  a  national  identity  number,  known  country  of  birth,  a  registered  Norwegian  address  and  a  mobile  phone  number""

16 or older","""individuals living in prisons, nursing homes, or  long-term  psychiatric  institutions  (all  of  whom  represent  ca  1%  of  the  national  population )  were  not  eligible  for  inclusion""

<16 were excluded",2020-11-15,2021-02-15,Household and community samples,All,Multiple groups,,,Geographical area,Troms and Finnmark,1685,0.006999999999999999,0.002,0.011000000000000001,,,True,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - MULTIPLEXED","EUROIMMUN,NA",ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Erik Eik Anda,The Arctic University of Norway,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.13.2100376,2022-04-17,2024-03-01,Unverified,anda_seroprevalence_2022,NOR
220630_Norway_NorwegianInstituteofPublicHealth_Overall_PopTestAdj,220630_Norway_NorwegianInstituteofPublicHealth,"Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.",2022-06-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Norway,,,"Anonymized residual sera were collected between July 19 and September 12, 2021, by 17 laboratories across Norway", Three samples were excluded due to antibody profiles indicating previous treatment with immunoglobulins. Sera lacking information on county of residence were attributed to the county of the submitting laboratory.,2021-07-19,2021-09-12,Residual sera,All,Multiple groups,0.0,98.0,Primary Estimate,,1926,0.626,0.601,0.652,True,True,True,,,Sequential,Author designed (Multiplex),,Other,Serum,IgG,Spike,Validated by developers,0.97,0.997,['Moderate'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1111/irv.13024,2022-07-25,2022-07-25,Unverified,tunheim_prevalence_2022,NOR
220630_Norway_NorwegianInstituteofPublicHealth_County_VestfoldogTelemark_UnAdj,220630_Norway_NorwegianInstituteofPublicHealth,"Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.",2022-06-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Norway,Vestfold og Telemark,,"Anonymized residual sera were collected between July 19 and September 12, 2021, by 17 laboratories across Norway", Three samples were excluded due to antibody profiles indicating previous treatment with immunoglobulins. Sera lacking information on county of residence were attributed to the county of the submitting laboratory.,2021-07-19,2021-09-12,Residual sera,All,Multiple groups,0.0,98.0,Geographical area,Vestfold og Telemark,125,0.46399999999999997,0.374,0.555,,,,,,Sequential,Author designed (Multiplex),,Other,Serum,IgG,Spike,Validated by developers,0.97,0.997,['Moderate'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1111/irv.13024,2022-07-25,2022-07-25,Unverified,tunheim_prevalence_2022,NOR
220630_Norway_NorwegianInstituteofPublicHealth_Age_12–17_UnAdj,220630_Norway_NorwegianInstituteofPublicHealth,"Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.",2022-06-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Norway,,,"Anonymized residual sera were collected between July 19 and September 12, 2021, by 17 laboratories across Norway", Three samples were excluded due to antibody profiles indicating previous treatment with immunoglobulins. Sera lacking information on county of residence were attributed to the county of the submitting laboratory.,2021-07-19,2021-09-12,Residual sera,All,Children and Youth (0-17 years),12.0,17.0,Age,12–17,190,0.132,0.087,0.188,,,,,,Sequential,Author designed (Multiplex),,Other,Serum,IgG,Spike,Validated by developers,0.97,0.997,['Moderate'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1111/irv.13024,2022-07-25,2022-07-25,Unverified,tunheim_prevalence_2022,NOR
220630_Norway_NorwegianInstituteofPublicHealth_County_Oslo_UnAdj,220630_Norway_NorwegianInstituteofPublicHealth,"Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.",2022-06-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Norway,Oslo,,"Anonymized residual sera were collected between July 19 and September 12, 2021, by 17 laboratories across Norway", Three samples were excluded due to antibody profiles indicating previous treatment with immunoglobulins. Sera lacking information on county of residence were attributed to the county of the submitting laboratory.,2021-07-19,2021-09-12,Residual sera,All,Multiple groups,0.0,98.0,Geographical area,Oslo,115,0.617,0.522,0.706,,,,,,Sequential,Author designed (Multiplex),,Other,Serum,IgG,Spike,Validated by developers,0.97,0.997,['Moderate'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1111/irv.13024,2022-07-25,2022-07-25,Unverified,tunheim_prevalence_2022,NOR
220630_Norway_NorwegianInstituteofPublicHealth_County_Nordland_UnAdj,220630_Norway_NorwegianInstituteofPublicHealth,"Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.",2022-06-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Norway,Nordland,,"Anonymized residual sera were collected between July 19 and September 12, 2021, by 17 laboratories across Norway", Three samples were excluded due to antibody profiles indicating previous treatment with immunoglobulins. Sera lacking information on county of residence were attributed to the county of the submitting laboratory.,2021-07-19,2021-09-12,Residual sera,All,Multiple groups,0.0,98.0,Geographical area,Nordland,126,0.49200000000000005,0.402,0.583,,,,,,Sequential,Author designed (Multiplex),,Other,Serum,IgG,Spike,Validated by developers,0.97,0.997,['Moderate'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1111/irv.13024,2022-07-25,2022-07-25,Unverified,tunheim_prevalence_2022,NOR
220630_Norway_NorwegianInstituteofPublicHealth_Age_0–11_UnAdj,220630_Norway_NorwegianInstituteofPublicHealth,"Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.",2022-06-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Norway,,,"Anonymized residual sera were collected between July 19 and September 12, 2021, by 17 laboratories across Norway", Three samples were excluded due to antibody profiles indicating previous treatment with immunoglobulins. Sera lacking information on county of residence were attributed to the county of the submitting laboratory.,2021-07-19,2021-09-12,Residual sera,All,Children and Youth (0-17 years),0.0,11.0,Age,0–11,385,0.122,0.091,0.159,,,,,,Sequential,Author designed (Multiplex),,Other,Serum,IgG,Spike,Validated by developers,0.97,0.997,['Moderate'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1111/irv.13024,2022-07-25,2022-07-25,Unverified,tunheim_prevalence_2022,NOR
220630_Norway_NorwegianInstituteofPublicHealth_Overall_UnAdj,220630_Norway_NorwegianInstituteofPublicHealth,"Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.",2022-06-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Norway,,,"Anonymized residual sera were collected between July 19 and September 12, 2021, by 17 laboratories across Norway", Three samples were excluded due to antibody profiles indicating previous treatment with immunoglobulins. Sera lacking information on county of residence were attributed to the county of the submitting laboratory.,2021-07-19,2021-09-12,Residual sera,All,Multiple groups,0.0,98.0,Analysis,,1926,0.534,0.512,0.557,,,,,True,Sequential,Author designed (Multiplex),,Other,Serum,IgG,Spike,Validated by developers,0.97,0.997,['Moderate'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1111/irv.13024,2022-07-25,2022-07-25,Unverified,tunheim_prevalence_2022,NOR
220630_Norway_NorwegianInstituteofPublicHealth_County_Rogaland_UnAdj,220630_Norway_NorwegianInstituteofPublicHealth,"Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.",2022-06-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Norway,Rogaland,,"Anonymized residual sera were collected between July 19 and September 12, 2021, by 17 laboratories across Norway", Three samples were excluded due to antibody profiles indicating previous treatment with immunoglobulins. Sera lacking information on county of residence were attributed to the county of the submitting laboratory.,2021-07-19,2021-09-12,Residual sera,All,Multiple groups,0.0,98.0,Geographical area,Rogaland,123,0.618,0.526,0.7040000000000001,,,,,,Sequential,Author designed (Multiplex),,Other,Serum,IgG,Spike,Validated by developers,0.97,0.997,['Moderate'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1111/irv.13024,2022-07-25,2022-07-25,Unverified,tunheim_prevalence_2022,NOR
220630_Norway_NorwegianInstituteofPublicHealth_County_Innlandet_UnAdj,220630_Norway_NorwegianInstituteofPublicHealth,"Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.",2022-06-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Norway,Innlandet,,"Anonymized residual sera were collected between July 19 and September 12, 2021, by 17 laboratories across Norway", Three samples were excluded due to antibody profiles indicating previous treatment with immunoglobulins. Sera lacking information on county of residence were attributed to the county of the submitting laboratory.,2021-07-19,2021-09-12,Residual sera,All,Multiple groups,0.0,98.0,Geographical area,Innlandet,121,0.545,0.452,0.636,,,,,,Sequential,Author designed (Multiplex),,Other,Serum,IgG,Spike,Validated by developers,0.97,0.997,['Moderate'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1111/irv.13024,2022-07-25,2022-07-25,Unverified,tunheim_prevalence_2022,NOR
220630_Norway_NorwegianInstituteofPublicHealth_County_MøreogRomsdal_UnAdj,220630_Norway_NorwegianInstituteofPublicHealth,"Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.",2022-06-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Norway,Møre og Romsdal,,"Anonymized residual sera were collected between July 19 and September 12, 2021, by 17 laboratories across Norway", Three samples were excluded due to antibody profiles indicating previous treatment with immunoglobulins. Sera lacking information on county of residence were attributed to the county of the submitting laboratory.,2021-07-19,2021-09-12,Residual sera,All,Multiple groups,0.0,98.0,Geographical area,Møre og Romsdal,130,0.615,0.526,0.6990000000000001,,,,,,Sequential,Author designed (Multiplex),,Other,Serum,IgG,Spike,Validated by developers,0.97,0.997,['Moderate'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1111/irv.13024,2022-07-25,2022-07-25,Unverified,tunheim_prevalence_2022,NOR
220630_Norway_NorwegianInstituteofPublicHealth_County_Trøndelag_UnAdj,220630_Norway_NorwegianInstituteofPublicHealth,"Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.",2022-06-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Norway,Trøndelag,,"Anonymized residual sera were collected between July 19 and September 12, 2021, by 17 laboratories across Norway", Three samples were excluded due to antibody profiles indicating previous treatment with immunoglobulins. Sera lacking information on county of residence were attributed to the county of the submitting laboratory.,2021-07-19,2021-09-12,Residual sera,All,Multiple groups,0.0,98.0,Geographical area,Trøndelag,216,0.537,0.46799999999999997,0.605,,,,,,Sequential,Author designed (Multiplex),,Other,Serum,IgG,Spike,Validated by developers,0.97,0.997,['Moderate'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1111/irv.13024,2022-07-25,2022-07-25,Unverified,tunheim_prevalence_2022,NOR
220630_Norway_NorwegianInstituteofPublicHealth_Age_45–64_UnAdj,220630_Norway_NorwegianInstituteofPublicHealth,"Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.",2022-06-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Norway,,,"Anonymized residual sera were collected between July 19 and September 12, 2021, by 17 laboratories across Norway", Three samples were excluded due to antibody profiles indicating previous treatment with immunoglobulins. Sera lacking information on county of residence were attributed to the county of the submitting laboratory.,2021-07-19,2021-09-12,Residual sera,All,Adults (18-64 years),45.0,64.0,Age,45–64,327,0.789,0.741,0.8320000000000001,,,,,,Sequential,Author designed (Multiplex),,Other,Serum,IgG,Spike,Validated by developers,0.97,0.997,['Moderate'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1111/irv.13024,2022-07-25,2022-07-25,Unverified,tunheim_prevalence_2022,NOR
220630_Norway_NorwegianInstituteofPublicHealth_Sex_Female_UnAdj,220630_Norway_NorwegianInstituteofPublicHealth,"Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.",2022-06-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Norway,,,"Anonymized residual sera were collected between July 19 and September 12, 2021, by 17 laboratories across Norway", Three samples were excluded due to antibody profiles indicating previous treatment with immunoglobulins. Sera lacking information on county of residence were attributed to the county of the submitting laboratory.,2021-07-19,2021-09-12,Residual sera,Female,Multiple groups,0.0,98.0,Sex/Gender,,1061,0.554,0.523,0.5860000000000001,,,,,,Sequential,Author designed (Multiplex),,Other,Serum,IgG,Spike,Validated by developers,0.97,0.997,['Moderate'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1111/irv.13024,2022-07-25,2022-07-25,Unverified,tunheim_prevalence_2022,NOR
220630_Norway_NorwegianInstituteofPublicHealth_Sex_Male_UnAdj,220630_Norway_NorwegianInstituteofPublicHealth,"Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.",2022-06-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Norway,,,"Anonymized residual sera were collected between July 19 and September 12, 2021, by 17 laboratories across Norway", Three samples were excluded due to antibody profiles indicating previous treatment with immunoglobulins. Sera lacking information on county of residence were attributed to the county of the submitting laboratory.,2021-07-19,2021-09-12,Residual sera,Male,Multiple groups,0.0,98.0,Sex/Gender,,865,0.54,0.503,0.5770000000000001,,,,,,Sequential,Author designed (Multiplex),,Other,Serum,IgG,Spike,Validated by developers,0.97,0.997,['Moderate'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1111/irv.13024,2022-07-25,2022-07-25,Unverified,tunheim_prevalence_2022,NOR
220630_Norway_NorwegianInstituteofPublicHealth_Anti-N_UnAdj,220630_Norway_NorwegianInstituteofPublicHealth,"Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.",2022-06-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Norway,,,"Anonymized residual sera were collected between July 19 and September 12, 2021, by 17 laboratories across Norway", Three samples were excluded due to antibody profiles indicating previous treatment with immunoglobulins. Sera lacking information on county of residence were attributed to the county of the submitting laboratory.,2021-07-19,2021-09-12,Residual sera,All,Multiple groups,0.0,98.0,Test used,RBD and Nucleocapsid,1926,0.086,0.07400000000000001,0.099,,,,,,Sequential,Author designed (Multiplex),,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.9500000000000001,0.998,['Moderate'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1111/irv.13024,2022-07-25,2022-07-25,Unverified,tunheim_prevalence_2022,NOR
220630_Norway_NorwegianInstituteofPublicHealth_Age_≥65_UnAdj,220630_Norway_NorwegianInstituteofPublicHealth,"Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.",2022-06-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Norway,,,"Anonymized residual sera were collected between July 19 and September 12, 2021, by 17 laboratories across Norway", Three samples were excluded due to antibody profiles indicating previous treatment with immunoglobulins. Sera lacking information on county of residence were attributed to the county of the submitting laboratory.,2021-07-19,2021-09-12,Residual sera,All,Seniors (65+ years),65.0,,Age,≥65,309,0.835,0.789,0.875,,,,,,Sequential,Author designed (Multiplex),,Other,Serum,IgG,Spike,Validated by developers,0.97,0.997,['Moderate'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1111/irv.13024,2022-07-25,2022-07-25,Unverified,tunheim_prevalence_2022,NOR
220630_Norway_NorwegianInstituteofPublicHealth_County_Viken_UnAdj,220630_Norway_NorwegianInstituteofPublicHealth,"Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.",2022-06-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Norway,Viken,,"Anonymized residual sera were collected between July 19 and September 12, 2021, by 17 laboratories across Norway", Three samples were excluded due to antibody profiles indicating previous treatment with immunoglobulins. Sera lacking information on county of residence were attributed to the county of the submitting laboratory.,2021-07-19,2021-09-12,Residual sera,All,Multiple groups,0.0,98.0,Geographical area,Viken,390,0.569,0.518,0.619,,,,,,Sequential,Author designed (Multiplex),,Other,Serum,IgG,Spike,Validated by developers,0.97,0.997,['Moderate'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1111/irv.13024,2022-07-25,2022-07-25,Unverified,tunheim_prevalence_2022,NOR
220630_Norway_NorwegianInstituteofPublicHealth_County_Vestland_UnAdj,220630_Norway_NorwegianInstituteofPublicHealth,"Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.",2022-06-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Norway,Vestland,,"Anonymized residual sera were collected between July 19 and September 12, 2021, by 17 laboratories across Norway", Three samples were excluded due to antibody profiles indicating previous treatment with immunoglobulins. Sera lacking information on county of residence were attributed to the county of the submitting laboratory.,2021-07-19,2021-09-12,Residual sera,All,Multiple groups,0.0,98.0,Geographical area,Vestland,246,0.504,0.44,0.568,,,,,,Sequential,Author designed (Multiplex),,Other,Serum,IgG,Spike,Validated by developers,0.97,0.997,['Moderate'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1111/irv.13024,2022-07-25,2022-07-25,Unverified,tunheim_prevalence_2022,NOR
220630_Norway_NorwegianInstituteofPublicHealth_County_TromsogFinnmark_UnAdj,220630_Norway_NorwegianInstituteofPublicHealth,"Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.",2022-06-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Norway,Troms og Finnmark,,"Anonymized residual sera were collected between July 19 and September 12, 2021, by 17 laboratories across Norway", Three samples were excluded due to antibody profiles indicating previous treatment with immunoglobulins. Sera lacking information on county of residence were attributed to the county of the submitting laboratory.,2021-07-19,2021-09-12,Residual sera,All,Multiple groups,0.0,98.0,Geographical area,Troms og Finnmark,218,0.47200000000000003,0.405,0.541,,,,,,Sequential,Author designed (Multiplex),,Other,Serum,IgG,Spike,Validated by developers,0.97,0.997,['Moderate'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1111/irv.13024,2022-07-25,2022-07-25,Unverified,tunheim_prevalence_2022,NOR
220630_Norway_NorwegianInstituteofPublicHealth_Age_18–44_UnAdj,220630_Norway_NorwegianInstituteofPublicHealth,"Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.",2022-06-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Norway,,,"Anonymized residual sera were collected between July 19 and September 12, 2021, by 17 laboratories across Norway", Three samples were excluded due to antibody profiles indicating previous treatment with immunoglobulins. Sera lacking information on county of residence were attributed to the county of the submitting laboratory.,2021-07-19,2021-09-12,Residual sera,All,Adults (18-64 years),18.0,44.0,Age,18–44,715,0.617,0.58,0.653,,,,,,Sequential,Author designed (Multiplex),,Other,Serum,IgG,Spike,Validated by developers,0.97,0.997,['Moderate'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1111/irv.13024,2022-07-25,2022-07-25,Unverified,tunheim_prevalence_2022,NOR
220630_Norway_NorwegianInstituteofPublicHealth_County_Agder_UnAdj,220630_Norway_NorwegianInstituteofPublicHealth,"Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.",2022-06-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Norway,Agder,,"Anonymized residual sera were collected between July 19 and September 12, 2021, by 17 laboratories across Norway", Three samples were excluded due to antibody profiles indicating previous treatment with immunoglobulins. Sera lacking information on county of residence were attributed to the county of the submitting laboratory.,2021-07-19,2021-09-12,Residual sera,All,Multiple groups,0.0,98.0,Geographical area,Agder,113,0.44200000000000006,0.349,0.539,,,,,,Sequential,Author designed (Multiplex),,Other,Serum,IgG,Spike,Validated by developers,0.97,0.997,['Moderate'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,,Gro Tunheim,Norwegian Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.1111/irv.13024,2022-07-25,2022-07-25,Unverified,tunheim_prevalence_2022,NOR
220630_Oslo_NationalInstituteofOccupationalHealth_Baseline,220630_Oslo_NationalInstituteofOccupationalHealth_Baseline,"SARS-CoV-2 serological findings and exposure risk among employees in school and retail after first and second wave COVID-19 pandemic in Oslo, Norway: a cohort study.",2022-06-30,Journal Article (Peer-Reviewed),Local,Prospective cohort,Norway,,Oslo,"Eligible participants were workers either male or female,
age >18 years (18–70 years). ",Lack of consent,2020-05-18,2020-07-02,Essential non-healthcare workers,All,Multiple groups,18.0,70.0,Primary Estimate,,209,0.028700000000000003,,,True,,,,True,Convenience,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,,Serum,IgG,,,,,['High'],,No,No,No,,Yes,Yes,Yes,,Anne-Mari Moe,National Institute of Occupational Health,Not Unity-Aligned,https://dx.doi.org/10.13075/ijomeh.1896.01942,2022-07-13,2024-03-01,Unverified,moe_sars-cov-2_2022,NOR
220630_Oslo_NationalInstituteofOccupationalHealth_Followup,220630_Oslo_NationalInstituteofOccupationalHealth_Followup,"SARS-CoV-2 serological findings and exposure risk among employees in school and retail after first and second wave COVID-19 pandemic in Oslo, Norway: a cohort study.",2022-06-30,Journal Article (Peer-Reviewed),Local,Prospective cohort,Norway,,Oslo,"Eligible participants were workers either male or female,
age >18 years (18–70 years). ",Lack of consent,2021-01-07,2021-03-17,Essential non-healthcare workers,All,Multiple groups,18.0,70.0,Primary Estimate,,158,0.0696,,,True,,,,True,Convenience,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,,Serum,IgG,,,,,['High'],,No,No,No,,Yes,Yes,Yes,,Anne-Mari Moe,National Institute of Occupational Health,Not Unity-Aligned,https://dx.doi.org/10.13075/ijomeh.1896.01942,2022-07-13,2024-03-01,Unverified,moe_sars-cov-2_2022,NOR
230522_Oslo_OsloUniversityHospital,230522_Oslo_OsloUniversityHospital,Seroprevalence of SARS-CoV-2 and humoral immune responses to mRNA vaccines among people who use drugs - In the light of tailored mitigating strategies,2023-05-22,Preprint,Local,Prospective cohort,Norway,,Oslo,"The inclusion criteria were being a resident at one of the ASWS’ institutions for people with severe drug addictions or being a patient at the low-threshold clinic for OAT, and consenting to participate in the study. ","the exclusion criteria were not being able to consent, i.e. because of psychosis or heavy drug intoxication, and being under the age of 18. ",2020-11-01,2020-11-30,Persons experiencing homelessness,All,Multiple groups,18.0,,Primary Estimate,,99,0.96,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,[],[],,0.94,0.995,['High'],,No,No,Yes,,Unclear,Yes,Yes,,Linda Wusthoff,Oslo University Hospital,Not Unity-Aligned,https://doi.org/10.21203/rs.3.rs-2939683/v1,2023-06-30,2023-07-04,Unverified,wusthoff_seroprevalence_2023,NOR
230721_WesternNorway_UniversityOfBergen_Overall,230721_WesternNorway_UniversityOfBergen,Risk assessment and antibody responses to SARS-CoV-2 in healthcare workers,2023-07-21,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Norway,Western Norway,,"The inclusion criteria were HCWs working during the period 6 March 2020 to 9 December 2020 [at one of the four medical centres, including Bergen Municipality Emergency Room (city testing centre), and three hospitals (Haukeland University Hospital, Haraldsplass Deaconess Hospital, and Stavanger University Hospital)].","Exclusion criteria were HCWs who were absent from work due to quarantine or recent RT-PCR-confirmed SARSCoV-2 infection, therefore posing a risk for active viral shedding and transmission.",2020-03-06,2020-12-09,Health care workers and caregivers,All,Multiple groups,19.0,78.0,Primary Estimate,,1214,0.1,0.084,0.119,True,,,,True,Convenience,"Author designed (ELISA) -Unknown,Author designed (ELISA) -Spike",,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Amit Bansal,University of Bergen,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2023.1164326,2023-08-22,2023-08-23,Unverified,bansal_risk_2023,NOR
210427_Oman_Directorate-GeneralforDiseasesSurveillanceandControl_Primary,210427_Oman_Directorate-GeneralforDiseasesSurveillanceandControl,The role of supporting services in driving SARS-CoV-2 transmission within healthcare settings: a multicenter seroprevalence study.,2021-04-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Oman,"Al Dakhilia, North Batinah, and South Batinah goveronates",,"Involving workers in a healthcare setting from the three district COVID-19 management referral hospitals — Nizwa, Sohar, and Rustaq",,2020-09-14,2020-09-28,Health care workers and caregivers,All,Adults (18-64 years),20.0,,Primary Estimate,Overall HCW,1078,0.21,,,True,,,,True,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Amal Al Maani,Directorate-General for Diseases Surveillance and Control,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.04.071,2021-05-31,2024-03-01,Verified,al-maani_role_2021,OMN
210427_Oman_Directorate-GeneralforDiseasesSurveillanceandControl_Age60plus,210427_Oman_Directorate-GeneralforDiseasesSurveillanceandControl,The role of supporting services in driving SARS-CoV-2 transmission within healthcare settings: a multicenter seroprevalence study.,2021-04-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Oman,"Al Dakhilia, North Batinah, and South Batinah goveronates",,"Involving workers in a healthcare setting from the three district COVID-19 management referral hospitals — Nizwa, Sohar, and Rustaq",,2020-09-14,2020-09-28,Health care workers and caregivers,All,Adults (18-64 years),60.0,,Age,60-69,6,0.0,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Amal Al Maani,Directorate-General for Diseases Surveillance and Control,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.04.071,2021-08-09,2024-03-01,Verified,al-maani_role_2021,OMN
210427_Oman_Directorate-GeneralforDiseasesSurveillanceandControl_Age30to39,210427_Oman_Directorate-GeneralforDiseasesSurveillanceandControl,The role of supporting services in driving SARS-CoV-2 transmission within healthcare settings: a multicenter seroprevalence study.,2021-04-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Oman,"Al Dakhilia, North Batinah, and South Batinah goveronates",,"Involving workers in a healthcare setting from the three district COVID-19 management referral hospitals — Nizwa, Sohar, and Rustaq",,2020-09-14,2020-09-28,Health care workers and caregivers,All,Adults (18-64 years),30.0,39.0,Age,30-39,529,0.22,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Amal Al Maani,Directorate-General for Diseases Surveillance and Control,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.04.071,2021-08-09,2024-03-01,Verified,al-maani_role_2021,OMN
210427_Oman_Directorate-GeneralforDiseasesSurveillanceandControl_Age40to49,210427_Oman_Directorate-GeneralforDiseasesSurveillanceandControl,The role of supporting services in driving SARS-CoV-2 transmission within healthcare settings: a multicenter seroprevalence study.,2021-04-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Oman,"Al Dakhilia, North Batinah, and South Batinah goveronates",,"Involving workers in a healthcare setting from the three district COVID-19 management referral hospitals — Nizwa, Sohar, and Rustaq",,2020-09-14,2020-09-28,Health care workers and caregivers,All,Adults (18-64 years),40.0,49.0,Age,40-49,295,0.19,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Amal Al Maani,Directorate-General for Diseases Surveillance and Control,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.04.071,2021-08-09,2024-03-01,Verified,al-maani_role_2021,OMN
210427_Oman_Directorate-GeneralforDiseasesSurveillanceandControl_Age20to29,210427_Oman_Directorate-GeneralforDiseasesSurveillanceandControl,The role of supporting services in driving SARS-CoV-2 transmission within healthcare settings: a multicenter seroprevalence study.,2021-04-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Oman,"Al Dakhilia, North Batinah, and South Batinah goveronates",,"Involving workers in a healthcare setting from the three district COVID-19 management referral hospitals — Nizwa, Sohar, and Rustaq",,2020-09-14,2020-09-28,Health care workers and caregivers,All,Adults (18-64 years),20.0,29.0,Age,20-29,195,0.23,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Amal Al Maani,Directorate-General for Diseases Surveillance and Control,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.04.071,2021-08-09,2024-03-01,Verified,al-maani_role_2021,OMN
210427_Oman_Directorate-GeneralforDiseasesSurveillanceandControl_Age50to59,210427_Oman_Directorate-GeneralforDiseasesSurveillanceandControl,The role of supporting services in driving SARS-CoV-2 transmission within healthcare settings: a multicenter seroprevalence study.,2021-04-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Oman,"Al Dakhilia, North Batinah, and South Batinah goveronates",,"Involving workers in a healthcare setting from the three district COVID-19 management referral hospitals — Nizwa, Sohar, and Rustaq",,2020-09-14,2020-09-28,Health care workers and caregivers,All,Adults (18-64 years),50.0,59.0,Age,50-59,53,0.23,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Amal Al Maani,Directorate-General for Diseases Surveillance and Control,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.04.071,2021-08-09,2024-03-01,Verified,al-maani_role_2021,OMN
210915_Oman_ArmedForcesHospital_HCW_overall,210915_Oman_ArmedForcesHospital_HCW,Prevalence and persistence of SARS-CoV2 antibodies among healthcare workers in Oman.,2021-09-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Oman,,Muscat,"All HCWs, of different nationalities, working at the AFH were invited to participate in the study through an internal announcement. Subjects were asked to consent if they are willing to participate. All staff aged 20 years and above who have been working in the hospital since the January 2020 were included. ","Recently recruited (less than 3 months) medical and non-medical staff, as well as symptomatic HCWs at the time of conducting the study, were excluded.",2020-12-09,2020-12-24,Health care workers and caregivers,All,Adults (18-64 years),20.0,,Primary Estimate,,1111,0.336,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.988,0.9998,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Khalid Al-Naamani,Armed Forces Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jiph.2021.09.006,2021-11-02,2024-03-01,Unverified,al-naamani_prevalence_2021,OMN
210930_Oman_MinistryOfHealth_Cycle1_PrimaryEstimate,210930_Oman_MinistryOfHealth_Cycle1,SARS-COV-2 antibody seroprevalence in the general population of Oman: results from four successive nationwide seroepidemiological surveys.,2021-09-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Oman,,,General population of Oman,"In this study, current symptoms consistent with COVID-19 infection were excluded, as the participant would be directed to undergo PCR testing. Other exclusion criteria included age under 5 years old, contraindication to venipuncture, or lack of willingness to participate.
",2020-07-12,2020-07-23,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,General Population of Oman,4210,0.055,0.048,0.062000000000000006,True,,,,True,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Seif Al-Abri,Ministry of Health (Oman),Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.09.062,2021-10-14,2024-03-01,Verified,al-abri_sars-cov-2_2021,OMN
210930_Oman_MinistryOfHealth_Cycle1_15-30,210930_Oman_MinistryOfHealth_Cycle1,SARS-COV-2 antibody seroprevalence in the general population of Oman: results from four successive nationwide seroepidemiological surveys.,2021-09-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Oman,,,General population of Oman,"In this study, current symptoms consistent with COVID-19 infection were excluded, as the participant would be directed to undergo PCR testing. Other exclusion criteria included age under 5 years old, contraindication to venipuncture, or lack of willingness to participate.
",2020-07-12,2020-07-23,Household and community samples,All,Multiple groups,15.0,30.0,Age,,1243,0.055999999999999994,0.043,0.071,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Seif Al-Abri,Ministry of Health (Oman),Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.09.062,2021-10-15,2024-03-01,Verified,al-abri_sars-cov-2_2021,OMN
210930_Oman_MinistryOfHealth_Cycle1_Male,210930_Oman_MinistryOfHealth_Cycle1,SARS-COV-2 antibody seroprevalence in the general population of Oman: results from four successive nationwide seroepidemiological surveys.,2021-09-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Oman,,,General population of Oman,"In this study, current symptoms consistent with COVID-19 infection were excluded, as the participant would be directed to undergo PCR testing. Other exclusion criteria included age under 5 years old, contraindication to venipuncture, or lack of willingness to participate.
",2020-07-12,2020-07-23,Household and community samples,Male,Multiple groups,5.0,,Sex/Gender,,2577,0.063,0.053,0.07400000000000001,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Seif Al-Abri,Ministry of Health (Oman),Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.09.062,2021-10-15,2024-03-01,Verified,al-abri_sars-cov-2_2021,OMN
210930_Oman_MinistryOfHealth_Cycle1_50+,210930_Oman_MinistryOfHealth_Cycle1,SARS-COV-2 antibody seroprevalence in the general population of Oman: results from four successive nationwide seroepidemiological surveys.,2021-09-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Oman,,,General population of Oman,"In this study, current symptoms consistent with COVID-19 infection were excluded, as the participant would be directed to undergo PCR testing. Other exclusion criteria included age under 5 years old, contraindication to venipuncture, or lack of willingness to participate.
",2020-07-12,2020-07-23,Household and community samples,All,Multiple groups,50.0,,Age,,531,0.051,0.034,0.07400000000000001,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Seif Al-Abri,Ministry of Health (Oman),Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.09.062,2021-10-15,2024-03-01,Verified,al-abri_sars-cov-2_2021,OMN
210930_Oman_MinistryOfHealth_Cycle1_5-14,210930_Oman_MinistryOfHealth_Cycle1,SARS-COV-2 antibody seroprevalence in the general population of Oman: results from four successive nationwide seroepidemiological surveys.,2021-09-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Oman,,,General population of Oman,"In this study, current symptoms consistent with COVID-19 infection were excluded, as the participant would be directed to undergo PCR testing. Other exclusion criteria included age under 5 years old, contraindication to venipuncture, or lack of willingness to participate.
",2020-07-12,2020-07-23,Household and community samples,All,Children and Youth (0-17 years),5.0,14.0,Age,,707,0.034,0.023,0.051,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Seif Al-Abri,Ministry of Health (Oman),Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.09.062,2021-10-15,2024-03-01,Verified,al-abri_sars-cov-2_2021,OMN
210930_Oman_MinistryOfHealth_Cycle1_31-49,210930_Oman_MinistryOfHealth_Cycle1,SARS-COV-2 antibody seroprevalence in the general population of Oman: results from four successive nationwide seroepidemiological surveys.,2021-09-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Oman,,,General population of Oman,"In this study, current symptoms consistent with COVID-19 infection were excluded, as the participant would be directed to undergo PCR testing. Other exclusion criteria included age under 5 years old, contraindication to venipuncture, or lack of willingness to participate.
",2020-07-12,2020-07-23,Household and community samples,All,Adults (18-64 years),31.0,49.0,Age,,1729,0.063,0.052000000000000005,0.077,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Seif Al-Abri,Ministry of Health (Oman),Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.09.062,2021-10-15,2024-03-01,Verified,al-abri_sars-cov-2_2021,OMN
210930_Oman_MinistryOfHealth_Cycle1_Female,210930_Oman_MinistryOfHealth_Cycle1,SARS-COV-2 antibody seroprevalence in the general population of Oman: results from four successive nationwide seroepidemiological surveys.,2021-09-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Oman,,,General population of Oman,"In this study, current symptoms consistent with COVID-19 infection were excluded, as the participant would be directed to undergo PCR testing. Other exclusion criteria included age under 5 years old, contraindication to venipuncture, or lack of willingness to participate.
",2020-07-12,2020-07-23,Household and community samples,Female,Multiple groups,5.0,,Sex/Gender,,1633,0.04,0.032,0.051,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Seif Al-Abri,Ministry of Health (Oman),Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.09.062,2021-10-15,2024-03-01,Verified,al-abri_sars-cov-2_2021,OMN
210930_Oman_MinistryOfHealth_Cycle2_PrimaryEstimate,210930_Oman_MinistryOfHealth_Cycle2,SARS-COV-2 antibody seroprevalence in the general population of Oman: results from four successive nationwide seroepidemiological surveys.,2021-09-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Oman,,,General population of Oman,"In this study, current symptoms consistent with COVID-19 infection were excluded, as the participant would be directed to undergo PCR testing. Other exclusion criteria included age under 5 years old, contraindication to venipuncture, or lack of willingness to participate.
",2020-08-16,2020-08-27,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,General Population of Oman,4403,0.09699999999999999,0.085,0.11,True,,,,True,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Seif Al-Abri,Ministry of Health (Oman),Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.09.062,2021-10-14,2024-03-01,Verified,al-abri_sars-cov-2_2021,OMN
210930_Oman_MinistryOfHealth_Cycle2_5-14,210930_Oman_MinistryOfHealth_Cycle2,SARS-COV-2 antibody seroprevalence in the general population of Oman: results from four successive nationwide seroepidemiological surveys.,2021-09-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Oman,,,General population of Oman,"In this study, current symptoms consistent with COVID-19 infection were excluded, as the participant would be directed to undergo PCR testing. Other exclusion criteria included age under 5 years old, contraindication to venipuncture, or lack of willingness to participate.
",2020-08-16,2020-08-27,Household and community samples,All,Children and Youth (0-17 years),5.0,14.0,Age,,179,0.098,0.06,0.155,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Seif Al-Abri,Ministry of Health (Oman),Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.09.062,2021-10-15,2024-03-01,Verified,al-abri_sars-cov-2_2021,OMN
210930_Oman_MinistryOfHealth_Cycle2_15-30,210930_Oman_MinistryOfHealth_Cycle2,SARS-COV-2 antibody seroprevalence in the general population of Oman: results from four successive nationwide seroepidemiological surveys.,2021-09-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Oman,,,General population of Oman,"In this study, current symptoms consistent with COVID-19 infection were excluded, as the participant would be directed to undergo PCR testing. Other exclusion criteria included age under 5 years old, contraindication to venipuncture, or lack of willingness to participate.
",2020-08-16,2020-08-27,Household and community samples,All,Multiple groups,15.0,30.0,Age,,1443,0.114,0.098,0.132,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Seif Al-Abri,Ministry of Health (Oman),Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.09.062,2021-10-15,2024-03-01,Verified,al-abri_sars-cov-2_2021,OMN
210930_Oman_MinistryOfHealth_Cycle2_50+,210930_Oman_MinistryOfHealth_Cycle2,SARS-COV-2 antibody seroprevalence in the general population of Oman: results from four successive nationwide seroepidemiological surveys.,2021-09-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Oman,,,General population of Oman,"In this study, current symptoms consistent with COVID-19 infection were excluded, as the participant would be directed to undergo PCR testing. Other exclusion criteria included age under 5 years old, contraindication to venipuncture, or lack of willingness to participate.
",2020-08-16,2020-08-27,Household and community samples,All,Multiple groups,50.0,,Age,,465,0.075,0.054000000000000006,0.10400000000000001,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Seif Al-Abri,Ministry of Health (Oman),Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.09.062,2021-10-15,2024-03-01,Verified,al-abri_sars-cov-2_2021,OMN
210930_Oman_MinistryOfHealth_Cycle2_31-49,210930_Oman_MinistryOfHealth_Cycle2,SARS-COV-2 antibody seroprevalence in the general population of Oman: results from four successive nationwide seroepidemiological surveys.,2021-09-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Oman,,,General population of Oman,"In this study, current symptoms consistent with COVID-19 infection were excluded, as the participant would be directed to undergo PCR testing. Other exclusion criteria included age under 5 years old, contraindication to venipuncture, or lack of willingness to participate.
",2020-08-16,2020-08-27,Household and community samples,All,Adults (18-64 years),31.0,49.0,Age,,2316,0.092,0.081,0.105,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Seif Al-Abri,Ministry of Health (Oman),Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.09.062,2021-10-15,2024-03-01,Verified,al-abri_sars-cov-2_2021,OMN
210930_Oman_MinistryOfHealth_Cycle2_Female,210930_Oman_MinistryOfHealth_Cycle2,SARS-COV-2 antibody seroprevalence in the general population of Oman: results from four successive nationwide seroepidemiological surveys.,2021-09-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Oman,,,General population of Oman,"In this study, current symptoms consistent with COVID-19 infection were excluded, as the participant would be directed to undergo PCR testing. Other exclusion criteria included age under 5 years old, contraindication to venipuncture, or lack of willingness to participate.
",2020-08-16,2020-08-27,Household and community samples,Female,Multiple groups,5.0,,Sex/Gender,,1172,0.091,0.07,0.11800000000000001,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Seif Al-Abri,Ministry of Health (Oman),Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.09.062,2021-10-15,2024-03-01,Verified,al-abri_sars-cov-2_2021,OMN
210930_Oman_MinistryOfHealth_Cycle2_Male,210930_Oman_MinistryOfHealth_Cycle2,SARS-COV-2 antibody seroprevalence in the general population of Oman: results from four successive nationwide seroepidemiological surveys.,2021-09-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Oman,,,General population of Oman,"In this study, current symptoms consistent with COVID-19 infection were excluded, as the participant would be directed to undergo PCR testing. Other exclusion criteria included age under 5 years old, contraindication to venipuncture, or lack of willingness to participate.
",2020-08-16,2020-08-27,Household and community samples,Male,Multiple groups,5.0,,Sex/Gender,,3231,0.10099999999999999,0.09,0.114,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Seif Al-Abri,Ministry of Health (Oman),Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.09.062,2021-10-15,2024-03-01,Verified,al-abri_sars-cov-2_2021,OMN
210930_Oman_MinistryOfHealth_Cycle3_PrimaryEstimate,210930_Oman_MinistryOfHealth_Cycle3,SARS-COV-2 antibody seroprevalence in the general population of Oman: results from four successive nationwide seroepidemiological surveys.,2021-09-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Oman,,,General population of Oman,"In this study, current symptoms consistent with COVID-19 infection were excluded, as the participant would be directed to undergo PCR testing. Other exclusion criteria included age under 5 years old, contraindication to venipuncture, or lack of willingness to participate.
",2020-09-13,2020-09-24,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,General Population of Oman,4780,0.16399999999999998,0.145,0.184,True,,,,True,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Seif Al-Abri,Ministry of Health (Oman),Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.09.062,2021-10-14,2024-03-01,Verified,al-abri_sars-cov-2_2021,OMN
210930_Oman_MinistryOfHealth_Cycle3_Male,210930_Oman_MinistryOfHealth_Cycle3,SARS-COV-2 antibody seroprevalence in the general population of Oman: results from four successive nationwide seroepidemiological surveys.,2021-09-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Oman,,,General population of Oman,"In this study, current symptoms consistent with COVID-19 infection were excluded, as the participant would be directed to undergo PCR testing. Other exclusion criteria included age under 5 years old, contraindication to venipuncture, or lack of willingness to participate.
",2020-09-13,2020-09-24,Household and community samples,Male,Multiple groups,5.0,,Sex/Gender,,3366,0.163,0.14300000000000002,0.185,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Seif Al-Abri,Ministry of Health (Oman),Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.09.062,2021-10-15,2024-03-01,Verified,al-abri_sars-cov-2_2021,OMN
210930_Oman_MinistryOfHealth_Cycle3_15-30,210930_Oman_MinistryOfHealth_Cycle3,SARS-COV-2 antibody seroprevalence in the general population of Oman: results from four successive nationwide seroepidemiological surveys.,2021-09-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Oman,,,General population of Oman,"In this study, current symptoms consistent with COVID-19 infection were excluded, as the participant would be directed to undergo PCR testing. Other exclusion criteria included age under 5 years old, contraindication to venipuncture, or lack of willingness to participate.
",2020-09-13,2020-09-24,Household and community samples,All,Multiple groups,15.0,30.0,Age,,1403,0.18,0.161,0.20199999999999999,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Seif Al-Abri,Ministry of Health (Oman),Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.09.062,2021-10-15,2024-03-01,Verified,al-abri_sars-cov-2_2021,OMN
210930_Oman_MinistryOfHealth_Cycle3_5-14,210930_Oman_MinistryOfHealth_Cycle3,SARS-COV-2 antibody seroprevalence in the general population of Oman: results from four successive nationwide seroepidemiological surveys.,2021-09-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Oman,,,General population of Oman,"In this study, current symptoms consistent with COVID-19 infection were excluded, as the participant would be directed to undergo PCR testing. Other exclusion criteria included age under 5 years old, contraindication to venipuncture, or lack of willingness to participate.
",2020-09-13,2020-09-24,Household and community samples,All,Children and Youth (0-17 years),5.0,14.0,Age,,77,0.17,0.099,0.27399999999999997,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Seif Al-Abri,Ministry of Health (Oman),Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.09.062,2021-10-15,2024-03-01,Verified,al-abri_sars-cov-2_2021,OMN
210930_Oman_MinistryOfHealth_Cycle3_Female,210930_Oman_MinistryOfHealth_Cycle3,SARS-COV-2 antibody seroprevalence in the general population of Oman: results from four successive nationwide seroepidemiological surveys.,2021-09-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Oman,,,General population of Oman,"In this study, current symptoms consistent with COVID-19 infection were excluded, as the participant would be directed to undergo PCR testing. Other exclusion criteria included age under 5 years old, contraindication to venipuncture, or lack of willingness to participate.
",2020-09-13,2020-09-24,Household and community samples,Female,Multiple groups,5.0,,Sex/Gender,,1414,0.165,0.132,0.20500000000000002,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Seif Al-Abri,Ministry of Health (Oman),Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.09.062,2021-10-15,2024-03-01,Verified,al-abri_sars-cov-2_2021,OMN
210930_Oman_MinistryOfHealth_Cycle3_31-49,210930_Oman_MinistryOfHealth_Cycle3,SARS-COV-2 antibody seroprevalence in the general population of Oman: results from four successive nationwide seroepidemiological surveys.,2021-09-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Oman,,,General population of Oman,"In this study, current symptoms consistent with COVID-19 infection were excluded, as the participant would be directed to undergo PCR testing. Other exclusion criteria included age under 5 years old, contraindication to venipuncture, or lack of willingness to participate.
",2020-09-13,2020-09-24,Household and community samples,All,Adults (18-64 years),31.0,49.0,Age,,2726,0.156,0.142,0.17,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Seif Al-Abri,Ministry of Health (Oman),Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.09.062,2021-10-15,2024-03-01,Verified,al-abri_sars-cov-2_2021,OMN
210930_Oman_MinistryOfHealth_Cycle3_50+,210930_Oman_MinistryOfHealth_Cycle3,SARS-COV-2 antibody seroprevalence in the general population of Oman: results from four successive nationwide seroepidemiological surveys.,2021-09-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Oman,,,General population of Oman,"In this study, current symptoms consistent with COVID-19 infection were excluded, as the participant would be directed to undergo PCR testing. Other exclusion criteria included age under 5 years old, contraindication to venipuncture, or lack of willingness to participate.
",2020-09-13,2020-09-24,Household and community samples,All,Multiple groups,50.0,,Age,,574,0.149,0.121,0.18100000000000002,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Seif Al-Abri,Ministry of Health (Oman),Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.09.062,2021-10-15,2024-03-01,Verified,al-abri_sars-cov-2_2021,OMN
210930_Oman_MinistryOfHealth_Cycle4_PrimaryEstimate,210930_Oman_MinistryOfHealth_Cycle4,SARS-COV-2 antibody seroprevalence in the general population of Oman: results from four successive nationwide seroepidemiological surveys.,2021-09-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Oman,,,General population of Oman,"In this study, current symptoms consistent with COVID-19 infection were excluded, as the participant would be directed to undergo PCR testing. Other exclusion criteria included age under 5 years old, contraindication to venipuncture, or lack of willingness to participate.
",2020-11-08,2020-11-19,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,General Population of Oman,4064,0.22,0.196,0.24600000000000002,True,,,,True,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Seif Al-Abri,Ministry of Health (Oman),Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.09.062,2021-10-14,2024-03-01,Verified,al-abri_sars-cov-2_2021,OMN
210930_Oman_MinistryOfHealth_Cycle4_Male,210930_Oman_MinistryOfHealth_Cycle4,SARS-COV-2 antibody seroprevalence in the general population of Oman: results from four successive nationwide seroepidemiological surveys.,2021-09-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Oman,,,General population of Oman,"In this study, current symptoms consistent with COVID-19 infection were excluded, as the participant would be directed to undergo PCR testing. Other exclusion criteria included age under 5 years old, contraindication to venipuncture, or lack of willingness to participate.
",2020-11-08,2020-11-19,Household and community samples,Male,Multiple groups,5.0,,Sex/Gender,,2820,0.21600000000000003,0.192,0.242,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Seif Al-Abri,Ministry of Health (Oman),Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.09.062,2021-10-15,2024-03-01,Verified,al-abri_sars-cov-2_2021,OMN
210930_Oman_MinistryOfHealth_Cycle4_5-14,210930_Oman_MinistryOfHealth_Cycle4,SARS-COV-2 antibody seroprevalence in the general population of Oman: results from four successive nationwide seroepidemiological surveys.,2021-09-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Oman,,,General population of Oman,"In this study, current symptoms consistent with COVID-19 infection were excluded, as the participant would be directed to undergo PCR testing. Other exclusion criteria included age under 5 years old, contraindication to venipuncture, or lack of willingness to participate.
",2020-11-08,2020-11-19,Household and community samples,All,Children and Youth (0-17 years),5.0,14.0,Age,,57,0.23500000000000001,0.139,0.368,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Seif Al-Abri,Ministry of Health (Oman),Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.09.062,2021-10-15,2024-03-01,Verified,al-abri_sars-cov-2_2021,OMN
210930_Oman_MinistryOfHealth_Cycle4_50+,210930_Oman_MinistryOfHealth_Cycle4,SARS-COV-2 antibody seroprevalence in the general population of Oman: results from four successive nationwide seroepidemiological surveys.,2021-09-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Oman,,,General population of Oman,"In this study, current symptoms consistent with COVID-19 infection were excluded, as the participant would be directed to undergo PCR testing. Other exclusion criteria included age under 5 years old, contraindication to venipuncture, or lack of willingness to participate.
",2020-11-08,2020-11-19,Household and community samples,All,Multiple groups,50.0,,Age,,493,0.21,0.17600000000000002,0.24800000000000003,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Seif Al-Abri,Ministry of Health (Oman),Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.09.062,2021-10-15,2024-03-01,Verified,al-abri_sars-cov-2_2021,OMN
210930_Oman_MinistryOfHealth_Cycle4_Female,210930_Oman_MinistryOfHealth_Cycle4,SARS-COV-2 antibody seroprevalence in the general population of Oman: results from four successive nationwide seroepidemiological surveys.,2021-09-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Oman,,,General population of Oman,"In this study, current symptoms consistent with COVID-19 infection were excluded, as the participant would be directed to undergo PCR testing. Other exclusion criteria included age under 5 years old, contraindication to venipuncture, or lack of willingness to participate.
",2020-11-08,2020-11-19,Household and community samples,Female,Multiple groups,5.0,,Sex/Gender,,1244,0.226,0.18100000000000002,0.278,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Seif Al-Abri,Ministry of Health (Oman),Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.09.062,2021-10-15,2024-03-01,Verified,al-abri_sars-cov-2_2021,OMN
210930_Oman_MinistryOfHealth_Cycle4_31-49,210930_Oman_MinistryOfHealth_Cycle4,SARS-COV-2 antibody seroprevalence in the general population of Oman: results from four successive nationwide seroepidemiological surveys.,2021-09-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Oman,,,General population of Oman,"In this study, current symptoms consistent with COVID-19 infection were excluded, as the participant would be directed to undergo PCR testing. Other exclusion criteria included age under 5 years old, contraindication to venipuncture, or lack of willingness to participate.
",2020-11-08,2020-11-19,Household and community samples,All,Adults (18-64 years),31.0,49.0,Age,,2384,0.20199999999999999,0.18600000000000003,0.219,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Seif Al-Abri,Ministry of Health (Oman),Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.09.062,2021-10-15,2024-03-01,Verified,al-abri_sars-cov-2_2021,OMN
210930_Oman_MinistryOfHealth_Cycle4_15-30,210930_Oman_MinistryOfHealth_Cycle4,SARS-COV-2 antibody seroprevalence in the general population of Oman: results from four successive nationwide seroepidemiological surveys.,2021-09-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Oman,,,General population of Oman,"In this study, current symptoms consistent with COVID-19 infection were excluded, as the participant would be directed to undergo PCR testing. Other exclusion criteria included age under 5 years old, contraindication to venipuncture, or lack of willingness to participate.
",2020-11-08,2020-11-19,Household and community samples,All,Multiple groups,15.0,30.0,Age,,1130,0.242,0.218,0.268,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Seif Al-Abri,Ministry of Health (Oman),Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.09.062,2021-10-15,2024-03-01,Verified,al-abri_sars-cov-2_2021,OMN
220705_Muscat_RoyalHospital_Baseline,220705_Muscat_RoyalHospital_Baseline,Seroconversion of COVID-19 in Frontline Healthcare Workers in a Tertiary Care Hospital in Oman,2022-07-05,Journal Article (Peer-Reviewed),Local,Prospective cohort,Oman,,"Muscat
","The population studied was the frontline healthcare workers (HCWs), who were likely to be continuously exposed
to suspected/confirmed cases of SARS-CoV-2. This included emergency department (adult and pediatric), adult
critical care, COVID-19 isolation wards, infectious diseases specialists and infection control staff. All job
categories in those clinical areas were included in the study.",there were no exclusion criteria,2020-05-01,2020-05-31,Health care workers and caregivers,All,Adults (18-64 years),28.0,57.0,Primary Estimate,,328,0.012,,,True,,,,True,Convenience,Author designed (ELISA) -Unknown,,ELISA,Serum,IgG,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Amal Altai,The Royal Hospital,Not Unity-Aligned,https://dx.doi.org/10.5001/omj.2022.74,2022-08-19,2022-08-19,Unverified,altai_seroconversion_2022,OMN
220705_Muscat_RoyalHospital_Follow-up,220705_Muscat_RoyalHospital_Follow-up,Seroconversion of COVID-19 in Frontline Healthcare Workers in a Tertiary Care Hospital in Oman,2022-07-05,Journal Article (Peer-Reviewed),Local,Prospective cohort,Oman,,Muscat,"The population studied was the frontline healthcare workers (HCWs), who were likely to be continuously exposed
to suspected/confirmed cases of SARS-CoV-2. This included emergency department (adult and pediatric), adult
critical care, COVID-19 isolation wards, infectious diseases specialists and infection control staff. All job
categories in those clinical areas were included in the study.",there were no exclusion criteria,2020-08-01,2020-08-31,Health care workers and caregivers,All,Adults (18-64 years),28.0,57.0,Primary Estimate,,328,0.037000000000000005,,,True,,,,True,Convenience,Author designed (ELISA) -Unknown,,ELISA,Serum,IgG,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Amal Altai,The Royal Hospital,Not Unity-Aligned,https://dx.doi.org/10.5001/omj.2022.74,2022-08-19,2022-08-19,Unverified,altai_seroconversion_2022,OMN
200814_Pakistan_GetzPharma_Overall,200814_Pakistan_GetzPharma,"Sero-prevalence findings from metropoles in Pakistan: implications for assessing COVID-19 prevalence and case-fatality within a dense, urban working population",2020-08-14,Preprint,Regional,Cross-sectional survey ,Pakistan,,"Karachi, Lahore, Multan, Peshawar and Quetta","adult, working population aged 18-65 years, recruited from dense, urban workplaces including
factories, corporates, restaurants, media houses, schools, banks, healthcare providers in hospitals, and families
of positive cases in various metropoles of Pakistan",,2020-07-06,2020-07-06,Household and community samples,All,Adults (18-64 years),18.0,65.0,Primary Estimate,,24210,0.17500000000000002,,,True,,,,True,Simplified probability,IgG/IgM Test Kit (Colloidal gold),Getz Pharma,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['High'],,Yes,Yes,No,,Yes,Yes,Yes,,Wajiha Javed,Getz Pharma,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.13.20173914v1,2021-05-17,2024-03-01,Verified,javed_sero-prevalence_2020,PAK
200720_Lahore_ChughtaiInstituteofPathology_Overall,200720_Lahore_ChughtaiInstituteofPathology,"Frequency of COVID-19 IgG Antibodies among Special Police Squad Lahore, Pakistan",2020-08-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Pakistan,,Lahore,"A total of 154 policemen of Elite Security Unit of Punjab Police, Dolphin Force, were selected to participate in the study after their
written consent.","Squad members willing to participate in the study were enrolled; and those not willing to give the blood samples for research purpose, were excluded from the study. Squad officers who had any sign of acute respiratory infection were excluded from the study as they might be a risk to the team members of the laboratory taking samples",2020-05-20,2020-05-30,Essential non-healthcare workers,Male,Adults (18-64 years),,,Primary Estimate,,154,0.156,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,0.9677,0.99,['High'],Yes,No,No,No,No,Yes,Yes,Yes,Unclear,Omar Chughtai,Chughtai Institute of Pathology,Not Unity-Aligned,https://jcpsp.pk/article-detail/frequency-of-covid19-igg-antibodies-among-special-police-squad-lahore-pakistan,2020-10-03,2024-03-01,Verified,chughtai_frequency_2020,PAK
200824_Karachi_NationalInstituteofBloodDiseases&BoneMarrowTransplantation_Overall,200824_Karachi_NationalInstituteofBloodDiseases&BoneMarrowTransplantation,"Seroprevalence of SARS-CoV-2 antibodies among healthy blood donors in Karachi, Pakistan",2020-08-24,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Pakistan,Sindh,Karachi,"Voluntary/exchange blood donors who came at the National institute of blood diseases and bone marrow transplantation, Karachi, during the pandemic in May, June and July. Blood donors meeting the AABB 18th edition donor acceptance and deferral criteria were included. Consecutive blood donors donated were screened for standard serological panel of HbsAg, Anti-HCV, Anti-HIV and Syphilis using Cobas-411 analyser and Malaria. All seronegative donors were then screened for COVID serology using the same instrument.","Donors who had a history of COVID-19 infection, were excluded from the study. Any donors having close contact with other COVID-19 patients were also excluded. Furthermore, donors having positive screening for hepatitis B, hepatitis C, HIV, syphilis or malaria were also excluded",2020-05-15,2020-07-15,Blood donors,Male,Adults (18-64 years),,,Primary Estimate,,370,0.34600000000000003,,,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,,,['High'],No,No,No,No,No,Yes,Yes,Yes,,Amber Younas,National Institute of Blood Diseases & Bone Marrow Transplantation,Not Unity-Aligned,https://dx.doi.org/10.1016/j.transci.2020.102923,2020-10-20,2024-03-01,Verified,younas_seroprevalence_2020,PAK
200824_Karachi_NationalInstituteofBloodDiseases&BoneMarrowTransplantation_Overall_ELISA_IgG,200824_Karachi_NationalInstituteofBloodDiseases&BoneMarrowTransplantation,"Seroprevalence of SARS-CoV-2 antibodies among healthy blood donors in Karachi, Pakistan",2020-08-24,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Pakistan,,Karachi,"Voluntary/exchange blood donors who came at the National institute of blood diseases and bone marrow transplantation, Karachi, during the pandemic in May, June and July. Blood donors meeting the AABB 18th edition donor acceptance and deferral criteria were included. Consecutive blood donors donated were screened for standard serological panel of HbsAg, Anti-HCV, Anti-HIV and Syphilis using Cobas-411 analyser and Malaria. All seronegative donors were then screened for COVID serology using the same instrument.","Donors who had a history of COVID-19 infection, were excluded from the study. Any donors having close contact with other COVID-19 patients were also excluded. Furthermore, donors having positive screening for hepatitis B, hepatitis C, HIV, syphilis or malaria were also excluded",2020-05-15,2020-07-15,Blood donors,Male,Adults (18-64 years),,,Test used,,128,0.632,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,Multiple Types,Multiple Types,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,No,No,No,Yes,Yes,Yes,,Amber Younas,National Institute of Blood Diseases & Bone Marrow Transplantation,Not Unity-Aligned,https://dx.doi.org/10.1016/j.transci.2020.102923,2020-10-27,2024-03-01,Verified,younas_seroprevalence_2020,PAK
200824_Karachi_NationalInstituteofBloodDiseases&BoneMarrowTransplantation_JuneOverall,200824_Karachi_NationalInstituteofBloodDiseases&BoneMarrowTransplantation,"Seroprevalence of SARS-CoV-2 antibodies among healthy blood donors in Karachi, Pakistan",2020-08-24,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Pakistan,Sindh,Karachi,"Voluntary/exchange blood donors who came at the National institute of blood diseases and bone marrow transplantation, Karachi, during the pandemic in May, June and July. Blood donors meeting the AABB 18th edition donor acceptance and deferral criteria were included. Consecutive blood donors donated were screened for standard serological panel of HbsAg, Anti-HCV, Anti-HIV and Syphilis using Cobas-411 analyser and Malaria. All seronegative donors were then screened for COVID serology using the same instrument.","Donors who had a history of COVID-19 infection, were excluded from the study. Any donors having close contact with other COVID-19 patients were also excluded. Furthermore, donors having positive screening for hepatitis B, hepatitis C, HIV, syphilis or malaria were also excluded",2020-05-15,2020-07-15,Blood donors,Male,Adults (18-64 years),,,Time frame,Blood donors from the June cohort,70,0.214,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,Multiple Types,Multiple Types,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,,,['High'],No,No,No,No,No,Yes,Yes,Yes,,Amber Younas,National Institute of Blood Diseases & Bone Marrow Transplantation,Not Unity-Aligned,https://dx.doi.org/10.1016/j.transci.2020.102923,2020-10-20,2024-03-01,Verified,younas_seroprevalence_2020,PAK
200824_Karachi_NationalInstituteofBloodDiseases&BoneMarrowTransplantation_JulyOverall,200824_Karachi_NationalInstituteofBloodDiseases&BoneMarrowTransplantation,"Seroprevalence of SARS-CoV-2 antibodies among healthy blood donors in Karachi, Pakistan",2020-08-24,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Pakistan,Sindh,Karachi,"Voluntary/exchange blood donors who came at the National institute of blood diseases and bone marrow transplantation, Karachi, during the pandemic in May, June and July. Blood donors meeting the AABB 18th edition donor acceptance and deferral criteria were included. Consecutive blood donors donated were screened for standard serological panel of HbsAg, Anti-HCV, Anti-HIV and Syphilis using Cobas-411 analyser and Malaria. All seronegative donors were then screened for COVID serology using the same instrument.","Donors who had a history of COVID-19 infection, were excluded from the study. Any donors having close contact with other COVID-19 patients were also excluded. Furthermore, donors having positive screening for hepatitis B, hepatitis C, HIV, syphilis or malaria were also excluded",2020-05-15,2020-07-15,Blood donors,Male,Adults (18-64 years),,,Time frame,Blood donors from the July cohort,300,0.37700000000000006,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,Multiple Types,Multiple Types,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,,,['High'],No,No,No,No,No,Yes,Yes,Yes,,Amber Younas,National Institute of Blood Diseases & Bone Marrow Transplantation,Not Unity-Aligned,https://dx.doi.org/10.1016/j.transci.2020.102923,2020-10-20,2024-03-01,Verified,younas_seroprevalence_2020,PAK
200824_Karachi_NationalInstituteofBloodDiseases&BoneMarrowTransplantation_Overall_ELISA_IgM,200824_Karachi_NationalInstituteofBloodDiseases&BoneMarrowTransplantation,"Seroprevalence of SARS-CoV-2 antibodies among healthy blood donors in Karachi, Pakistan",2020-08-24,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Pakistan,,Karachi,"Voluntary/exchange blood donors who came at the National institute of blood diseases and bone marrow transplantation, Karachi, during the pandemic in May, June and July. Blood donors meeting the AABB 18th edition donor acceptance and deferral criteria were included. Consecutive blood donors donated were screened for standard serological panel of HbsAg, Anti-HCV, Anti-HIV and Syphilis using Cobas-411 analyser and Malaria. All seronegative donors were then screened for COVID serology using the same instrument.","Donors who had a history of COVID-19 infection, were excluded from the study. Any donors having close contact with other COVID-19 patients were also excluded. Furthermore, donors having positive screening for hepatitis B, hepatitis C, HIV, syphilis or malaria were also excluded",2020-05-15,2020-07-15,Blood donors,Male,Adults (18-64 years),,,Test used,,24,0.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,Multiple Types,Multiple Types,IgM,Nucleocapsid(N-protein),,,,['High'],No,No,No,No,No,Yes,Yes,Yes,,Amber Younas,National Institute of Blood Diseases & Bone Marrow Transplantation,Not Unity-Aligned,https://dx.doi.org/10.1016/j.transci.2020.102923,2020-10-27,2024-03-01,Verified,younas_seroprevalence_2020,PAK
200930_PeshawarCity_RiphahInternationalUniversity_Overall,200930_PeshawarCity_RiphahInternationalUniversity,"Seroprevalence and Risk Factors of SARS CoV-2 in Health Care Workers of Tertiary-Care Hospitals in the Province of Khyber Pakhtunkhwa, Pakistan",2020-09-30,Preprint,Local,Cross-sectional survey ,Pakistan,Khyber Pakhtunkhwa,Peshawar City,"included doctors, paramedics, nurses, medical technicians, laboratory and other staff of the hospitals",,2020-06-15,2020-06-29,Health care workers and caregivers,All,Adults (18-64 years),20.0,,Primary Estimate,Overall estimate,1011,0.307,0.278,0.336,True,,,,True,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,,Validated by manufacturers,0.988,1.0,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Mohsina Haq,Riphah International University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.29.20203125v1,2021-01-19,2024-03-01,Verified,haq_seroprevalence_2020,PAK
200930_PeshawarCity_RiphahInternationalUniversity_30-39,200930_PeshawarCity_RiphahInternationalUniversity,"Seroprevalence and Risk Factors of SARS CoV-2 in Health Care Workers of Tertiary-Care Hospitals in the Province of Khyber Pakhtunkhwa, Pakistan",2020-09-30,Preprint,Local,Cross-sectional survey ,Pakistan,Khyber Pakhtunkhwa,Peshawar City,"included doctors, paramedics, nurses, medical technicians, laboratory and other staff of the hospitals",,2020-06-15,2020-06-29,Health care workers and caregivers,All,Adults (18-64 years),30.0,39.0,Age,30-39,266,0.3383,0.281,0.39799999999999996,,,,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,,Validated by manufacturers,0.988,1.0,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Mohsina Haq,Riphah International University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.29.20203125v1,2021-01-19,2024-03-01,Verified,haq_seroprevalence_2020,PAK
200930_PeshawarCity_RiphahInternationalUniversity_60+,200930_PeshawarCity_RiphahInternationalUniversity,"Seroprevalence and Risk Factors of SARS CoV-2 in Health Care Workers of Tertiary-Care Hospitals in the Province of Khyber Pakhtunkhwa, Pakistan",2020-09-30,Preprint,Local,Cross-sectional survey ,Pakistan,Khyber Pakhtunkhwa,Peshawar City,"included doctors, paramedics, nurses, medical technicians, laboratory and other staff of the hospitals",,2020-06-15,2020-06-29,Health care workers and caregivers,All,Seniors (65+ years),60.0,,Age,60+,24,0.0417,,,,,,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,,Validated by manufacturers,0.988,1.0,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Mohsina Haq,Riphah International University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.29.20203125v1,2021-01-19,2024-03-01,Verified,haq_seroprevalence_2020,PAK
200930_PeshawarCity_RiphahInternationalUniversity_20-29,200930_PeshawarCity_RiphahInternationalUniversity,"Seroprevalence and Risk Factors of SARS CoV-2 in Health Care Workers of Tertiary-Care Hospitals in the Province of Khyber Pakhtunkhwa, Pakistan",2020-09-30,Preprint,Local,Cross-sectional survey ,Pakistan,Khyber Pakhtunkhwa,Peshawar City,"included doctors, paramedics, nurses, medical technicians, laboratory and other staff of the hospitals",,2020-06-15,2020-06-29,Health care workers and caregivers,All,Adults (18-64 years),20.0,29.0,Age,20-29,532,0.295,0.257,0.335,,,,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,,Validated by manufacturers,0.988,1.0,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Mohsina Haq,Riphah International University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.29.20203125v1,2021-01-19,2024-03-01,Verified,haq_seroprevalence_2020,PAK
200930_PeshawarCity_RiphahInternationalUniversity_40-49,200930_PeshawarCity_RiphahInternationalUniversity,"Seroprevalence and Risk Factors of SARS CoV-2 in Health Care Workers of Tertiary-Care Hospitals in the Province of Khyber Pakhtunkhwa, Pakistan",2020-09-30,Preprint,Local,Cross-sectional survey ,Pakistan,Khyber Pakhtunkhwa,Peshawar City,"included doctors, paramedics, nurses, medical technicians, laboratory and other staff of the hospitals",,2020-06-15,2020-06-29,Health care workers and caregivers,All,Adults (18-64 years),40.0,49.0,Age,40-49,127,0.315,0.23500000000000001,0.40299999999999997,,,,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,,Validated by manufacturers,0.988,1.0,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Mohsina Haq,Riphah International University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.29.20203125v1,2021-01-19,2024-03-01,Verified,haq_seroprevalence_2020,PAK
200930_PeshawarCity_RiphahInternationalUniversity_50-59,200930_PeshawarCity_RiphahInternationalUniversity,"Seroprevalence and Risk Factors of SARS CoV-2 in Health Care Workers of Tertiary-Care Hospitals in the Province of Khyber Pakhtunkhwa, Pakistan",2020-09-30,Preprint,Local,Cross-sectional survey ,Pakistan,Khyber Pakhtunkhwa,Peshawar City,"included doctors, paramedics, nurses, medical technicians, laboratory and other staff of the hospitals",,2020-06-15,2020-06-29,Health care workers and caregivers,All,Adults (18-64 years),50.0,59.0,Age,50-59,62,0.355,0.237,0.48600000000000004,,,,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,,Validated by manufacturers,0.988,1.0,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Mohsina Haq,Riphah International University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.29.20203125v1,2021-01-19,2024-03-01,Verified,haq_seroprevalence_2020,PAK
200930_Karachi_NationalInstituteOfBloodDiseasesAndBoneMarrowTransplantation,200930_Karachi_NationalInstituteOfBloodDiseasesAndBoneMarrowTransplantation,is karachi knocking at herd immunity? a possible reason for decline in sars-cov-2 infections,2020-09-30,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Pakistan,Sindh,Kararchi,The study included adult male and female participants from different segments of the population.,RT-PCR proven COVID-19 cases were excluded,2020-08-30,2020-09-12,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,,2404,0.55,,,True,,,,True,Convenience,Not reported/ Unable to specify,,CLIA,Whole Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Faiza Rezwan,National Institute of Blood Diseases and Bone Marrow Transplantation,Not Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3700931,2021-05-20,2022-07-16,Unverified,rezwan_is_2020,PAK
201109_ Peshawar_HayatabadMedicalComplex_Overall,201109_ Peshawar_HayatabadMedicalComplex,Does Working in a COVID-19 Receiving Health Facility Influence Seroprevalence to SARS-CoV-2?,2020-11-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Pakistan,Khyber Pakhtunkhwa,Peshawar,"HCW from two tertiary care hospitals in Peshawar, Pakistan","HCWs with conditions affecting immunity, such as HIV infection or the use of chemotherapeutic agents and steroids, were excluded from the study.",2020-07-13,2020-07-15,Health care workers and caregivers,All,Multiple groups,,79.0,Primary Estimate,,1011,0.30760000000000004,,,True,,,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,,"['IgG', 'IgM']",,Validated by manufacturers,0.87,1.0,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Yes,Mohammad Noor,Hayatabad Medical Complex,Not Unity-Aligned,https://dx.doi.org/10.7759/cureus.11389,2021-01-17,2024-03-01,Verified,noor_does_2020,PAK
201109_ Peshawar_HayatabadMedicalComplex_<=50,201109_ Peshawar_HayatabadMedicalComplex,Does Working in a COVID-19 Receiving Health Facility Influence Seroprevalence to SARS-CoV-2?,2020-11-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Pakistan,Khyber Pakhtunkhwa,Peshawar,"HCW from two tertiary care hospitals in Peshawar, Pakistan","HCWs with conditions affecting immunity, such as HIV infection or the use of chemotherapeutic agents and steroids, were excluded from the study.",2020-07-13,2020-07-15,Health care workers and caregivers,All,Multiple groups,,50.0,Age,<= 50 years of age,903,0.31120000000000003,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,,"['IgG', 'IgM']",,Validated by manufacturers,0.87,1.0,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Yes,Mohammad Noor,Hayatabad Medical Complex,Not Unity-Aligned,https://dx.doi.org/10.7759/cureus.11389,2021-01-17,2024-03-01,Verified,noor_does_2020,PAK
201109_ Peshawar_HayatabadMedicalComplex_>50,201109_ Peshawar_HayatabadMedicalComplex,Does Working in a COVID-19 Receiving Health Facility Influence Seroprevalence to SARS-CoV-2?,2020-11-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Pakistan,Khyber Pakhtunkhwa,Peshawar,"HCW from two tertiary care hospitals in Peshawar, Pakistan","HCWs with conditions affecting immunity, such as HIV infection or the use of chemotherapeutic agents and steroids, were excluded from the study.",2020-07-13,2020-07-15,Health care workers and caregivers,All,Multiple groups,51.0,70.0,Age,>50 years,108,0.2778,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,,"['IgG', 'IgM']",,Validated by manufacturers,0.87,1.0,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Yes,Mohammad Noor,Hayatabad Medical Complex,Not Unity-Aligned,https://dx.doi.org/10.7759/cureus.11389,2021-01-17,2024-03-01,Verified,noor_does_2020,PAK
210101_Pakistan_ColSultan’sLab_Overall,210101_Pakistan_ColSultan’sLab,A Single-centre Study of COVID-19 antibody,2021-01-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Pakistan,,,,,2020-06-13,2020-07-08,Residual sera,All,Multiple groups,,,Primary Estimate,,453,0.638,,,True,,,,True,Self-referral,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,,,,['High'],No,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Sidra Ghazanfer,Col Sultan’s Lab,Not Unity-Aligned,https://dx.doi.org/10.29271/jcpsp.2021.01.S55,2021-04-10,2024-03-01,Verified,ghazanfer_single-centre_2021,PAK
210103_Pakistan_LiaquatUniversity_primary,210103_Pakistan_LiaquatUniversity,Do COVID-19 Antibodies Provide Long-Term Protection?,2021-01-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Pakistan,,,outpatient department (OPD) of the Internal Medicine department at a tertiary care hospital ,,2020-06-15,2020-08-15,Residual sera,All,Multiple groups,,,Primary Estimate,,728,0.10800000000000001,,,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,Serum,,Spike,Validated by manufacturers,1.0,0.998,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,,Sheeba Ansari,Liaquat University,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854312/,2021-02-19,2023-07-04,Verified,ansari_covid-19_2021,PAK
210321_Karachi_AgaKhanUniversity_Phase1East_PopAdj_TestAdj,210321_Karachi_AgaKhanUniversity_Phase1East,"Serial population-based serosurveys for COVID-19 in two neighbourhoods of Karachi, Pakistan",2021-03-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Pakistan,Karachi,District East,all household members were eligible to participate regardless of their infectious status,"Facilities such as hospitals, care homes, educational institutions and prison were excluded. However, healthcare workers within a household were not excluded.",2020-04-15,2020-04-25,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,"Overall, test and population adjusted",500,0.004,0.0,0.013000000000000001,True,True,True,True,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,1.0,0.998,['Moderate'],Yes,Yes,No,No,Yes,Yes,Yes,Yes,No,Muhammed Imran Nisar,Aga Khan University,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.03.040,2021-05-17,2023-08-15,Verified,nisar_serial_2021,PAK
210321_Karachi_AgaKhanUniversity_Phase1East_Unadj,210321_Karachi_AgaKhanUniversity_Phase1East,"Serial population-based serosurveys for COVID-19 in two neighbourhoods of Karachi, Pakistan",2021-03-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Pakistan,Karachi,District East,all household members were eligible to participate regardless of their infectious status,"Facilities such as hospitals, care homes, educational institutions and prison were excluded. However, healthcare workers within a household were not excluded.",2020-04-15,2020-04-25,Household and community samples,All,Multiple groups,0.0,,Analysis,"Overall, test and population unadjusted",500,0.004,,,,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,1.0,0.998,['Moderate'],Yes,Yes,No,No,Yes,Yes,Yes,Yes,No,Muhammed Imran Nisar,Aga Khan University,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.03.040,2021-07-22,2024-03-01,Verified,nisar_serial_2021,PAK
210321_Karachi_AgaKhanUniversity_Phase1Malir_PopAdj_TestAdj,210321_Karachi_AgaKhanUniversity_Phase1Malir,"Serial population-based serosurveys for COVID-19 in two neighbourhoods of Karachi, Pakistan",2021-03-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Pakistan,Karachi,District Malir,all household members were eligible to participate regardless of their infectious status,"Facilities such as hospitals, care homes, educational institutions and prison were excluded. However, healthcare workers within a household were not excluded.",2020-04-15,2020-04-25,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,"Overall, test and population adjusted",500,0.002,0.0,0.006999999999999999,True,True,True,True,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,1.0,0.998,['Moderate'],Yes,Yes,No,No,Yes,Yes,Yes,Yes,No,Muhammed Imran Nisar,Aga Khan University,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.03.040,2021-05-17,2023-08-15,Verified,nisar_serial_2021,PAK
210321_Karachi_AgaKhanUniversity_Phase1Malir_Unadj,210321_Karachi_AgaKhanUniversity_Phase1Malir,"Serial population-based serosurveys for COVID-19 in two neighbourhoods of Karachi, Pakistan",2021-03-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Pakistan,Karachi,District Malir,all household members were eligible to participate regardless of their infectious status,"Facilities such as hospitals, care homes, educational institutions and prison were excluded. However, healthcare workers within a household were not excluded.",2020-04-15,2020-04-25,Household and community samples,All,Multiple groups,0.0,,Analysis,"Overall, test and population unadjusted",500,0.0,,,,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,1.0,0.998,['Moderate'],Yes,Yes,No,No,Yes,Yes,Yes,Yes,No,Muhammed Imran Nisar,Aga Khan University,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.03.040,2021-07-22,2024-03-01,Verified,nisar_serial_2021,PAK
210321_Karachi_AgaKhanUniversity_Phase2East_PopAdj_TestAdj,210321_Karachi_AgaKhanUniversity_Phase2East,"Serial population-based serosurveys for COVID-19 in two neighbourhoods of Karachi, Pakistan",2021-03-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Pakistan,Karachi,District East ,all household members were eligible to participate regardless of their infectious status,"Facilities such as hospitals, care homes, educational institutions and prison were excluded. However, healthcare workers within a household were not excluded.",2020-06-25,2020-07-11,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,"Overall, test and population adjusted",500,0.151,0.094,0.217,True,True,True,True,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,1.0,0.998,['Moderate'],Yes,Yes,No,No,Yes,Yes,Yes,Yes,No,Muhammed Imran Nisar,Aga Khan University,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.03.040,2021-05-17,2023-08-15,Verified,nisar_serial_2021,PAK
210321_Karachi_AgaKhanUniversity_Phase2East_Unadj,210321_Karachi_AgaKhanUniversity_Phase2East,"Serial population-based serosurveys for COVID-19 in two neighbourhoods of Karachi, Pakistan",2021-03-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Pakistan,Karachi,District East ,all household members were eligible to participate regardless of their infectious status,"Facilities such as hospitals, care homes, educational institutions and prison were excluded. However, healthcare workers within a household were not excluded.",2020-06-25,2020-07-11,Household and community samples,All,Multiple groups,0.0,,Analysis,"Overall, test and population unadjusted",500,0.2,,,,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,1.0,0.998,['Moderate'],Yes,Yes,No,No,Yes,Yes,Yes,Yes,No,Muhammed Imran Nisar,Aga Khan University,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.03.040,2021-07-22,2024-03-01,Verified,nisar_serial_2021,PAK
210321_Karachi_AgaKhanUniversity_Phase2Malir_PopAdj_TestAdj,210321_Karachi_AgaKhanUniversity_Phase2Malir,"Serial population-based serosurveys for COVID-19 in two neighbourhoods of Karachi, Pakistan",2021-03-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Pakistan,Karachi,District Malir,all household members were eligible to participate regardless of their infectious status,"Facilities such as hospitals, care homes, educational institutions and prison were excluded. However, healthcare workers within a household were not excluded.",2020-06-25,2020-07-11,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,"Overall, test and population adjusted",504,0.087,0.051,0.131,True,True,True,True,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,1.0,0.998,['Moderate'],Yes,Yes,No,No,Yes,Yes,Yes,Yes,No,Muhammed Imran Nisar,Aga Khan University,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.03.040,2021-05-17,2023-08-15,Verified,nisar_serial_2021,PAK
210321_Karachi_AgaKhanUniversity_Phase2Malir_Unadj,210321_Karachi_AgaKhanUniversity_Phase2Malir,"Serial population-based serosurveys for COVID-19 in two neighbourhoods of Karachi, Pakistan",2021-03-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Pakistan,Karachi,District Malir,all household members were eligible to participate regardless of their infectious status,"Facilities such as hospitals, care homes, educational institutions and prison were excluded. However, healthcare workers within a household were not excluded.",2020-06-25,2020-07-11,Household and community samples,All,Multiple groups,0.0,,Analysis,"Overall, test and population unadjusted",504,0.127,,,,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,1.0,0.998,['Moderate'],Yes,Yes,No,No,Yes,Yes,Yes,Yes,No,Muhammed Imran Nisar,Aga Khan University,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.03.040,2021-07-22,2024-03-01,Verified,nisar_serial_2021,PAK
210321_Karachi_AgaKhanUniversity_Phase3East_PopAdj_TestAdj,210321_Karachi_AgaKhanUniversity_Phase3East,"Serial population-based serosurveys for COVID-19 in two neighbourhoods of Karachi, Pakistan",2021-03-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Pakistan,Karachi,District East ,all household members were eligible to participate regardless of their infectious status,"Facilities such as hospitals, care homes, educational institutions and prison were excluded. However, healthcare workers within a household were not excluded.",2020-08-17,2020-08-22,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,"Overall, test and population adjusted",500,0.215,0.156,0.28,True,True,True,True,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,1.0,0.998,['Moderate'],Yes,Yes,No,No,Yes,Yes,Yes,Yes,No,Muhammed Imran Nisar,Aga Khan University,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.03.040,2021-05-17,2023-08-15,Verified,nisar_serial_2021,PAK
210321_Karachi_AgaKhanUniversity_Phase3East_Unadj,210321_Karachi_AgaKhanUniversity_Phase3East,"Serial population-based serosurveys for COVID-19 in two neighbourhoods of Karachi, Pakistan",2021-03-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Pakistan,Karachi,District East ,all household members were eligible to participate regardless of their infectious status,"Facilities such as hospitals, care homes, educational institutions and prison were excluded. However, healthcare workers within a household were not excluded.",2020-08-17,2020-08-22,Household and community samples,All,Multiple groups,0.0,,Analysis,"Overall, test and population unadjusted",500,0.24,,,,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,1.0,0.998,['Moderate'],Yes,Yes,No,No,Yes,Yes,Yes,Yes,No,Muhammed Imran Nisar,Aga Khan University,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.03.040,2021-07-22,2024-03-01,Verified,nisar_serial_2021,PAK
210321_Karachi_AgaKhanUniversity_Phase3Malir_PopAdj_TestAdj,210321_Karachi_AgaKhanUniversity_Phase3Malir,"Serial population-based serosurveys for COVID-19 in two neighbourhoods of Karachi, Pakistan",2021-03-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Pakistan,Karachi,District Malir,all household members were eligible to participate regardless of their infectious status,"Facilities such as hospitals, care homes, educational institutions and prison were excluded. However, healthcare workers within a household were not excluded.",2020-08-17,2020-08-22,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,"Overall, test and population adjusted",501,0.128,0.083,0.177,True,True,True,True,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,1.0,0.998,['Moderate'],Yes,Yes,No,No,Yes,Yes,Yes,Yes,No,Muhammed Imran Nisar,Aga Khan University,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.03.040,2021-05-17,2023-08-15,Verified,nisar_serial_2021,PAK
210321_Karachi_AgaKhanUniversity_Phase3Malir_Unadj,210321_Karachi_AgaKhanUniversity_Phase3Malir,"Serial population-based serosurveys for COVID-19 in two neighbourhoods of Karachi, Pakistan",2021-03-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Pakistan,Karachi,District Malir,all household members were eligible to participate regardless of their infectious status,"Facilities such as hospitals, care homes, educational institutions and prison were excluded. However, healthcare workers within a household were not excluded.",2020-08-17,2020-08-22,Household and community samples,All,Multiple groups,0.0,,Analysis,"Overall, test and population unadjusted",501,0.16,,,,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,1.0,0.998,['Moderate'],Yes,Yes,No,No,Yes,Yes,Yes,Yes,No,Muhammed Imran Nisar,Aga Khan University,Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.03.040,2021-07-22,2024-03-01,Verified,nisar_serial_2021,PAK
210421_Pakistan_MemorialCancerHospitalandResearchCenter_overall,210421_Pakistan_MemorialCancerHospitalandResearchCenter,Seroprevalence of SARS-CoV-2 Antibodies Among Health Care Personnel at a Health Care System in Pakistan,2021-04-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Pakistan,Punjab,Lahore,The Trust offered SARS-CoV-2 total antibody testing free of cost to employees. ,,2020-07-29,2020-07-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Healthcare workers,2162,0.396,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Salma Abbas,Shaukat Khanum Memorial Cancer Hospital and Research Centre,Not Unity-Aligned,https://dx.doi.org/10.1177/10105395211011010,2021-05-19,2024-03-01,Verified,abbas_seroprevalence_2021,PAK
210525_Pakistan_RiphahInternationalUniversity,210525_Pakistan_RiphahInternationalUniversity,SARS-CoV-2: big seroprevalence data from Pakistan-is herd immunity at hand?.,2021-05-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Pakistan,,,Residents in Pakistan,,2020-07-15,2020-07-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,15390,0.424,0.41500000000000004,0.4314,True,,,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.988,1.0,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Mohsina Haq,Riphah International University ,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01629-2,2021-06-07,2024-03-01,Verified,haq_sars-cov-2_2021,PAK
210525_Pakistan_RiphahInternationalUniversity_<=20,210525_Pakistan_RiphahInternationalUniversity,SARS-CoV-2: big seroprevalence data from Pakistan-is herd immunity at hand?.,2021-05-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Pakistan,,,Residents in Pakistan,,2020-07-15,2020-07-31,Household and community samples,All,Multiple groups,,20.0,Age,=<20 years old,1549,0.36700000000000005,0.342,0.391,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.988,1.0,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Mohsina Haq,Riphah International University ,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01629-2,2021-08-12,2024-03-01,Verified,haq_sars-cov-2_2021,PAK
210525_Pakistan_RiphahInternationalUniversity_21-40,210525_Pakistan_RiphahInternationalUniversity,SARS-CoV-2: big seroprevalence data from Pakistan-is herd immunity at hand?.,2021-05-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Pakistan,,,Residents in Pakistan,,2020-07-15,2020-07-31,Household and community samples,All,Adults (18-64 years),21.0,40.0,Age,21-40 years old,9348,0.423,0.413,0.433,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.988,1.0,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Mohsina Haq,Riphah International University ,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01629-2,2021-08-12,2024-03-01,Verified,haq_sars-cov-2_2021,PAK
210525_Pakistan_RiphahInternationalUniversity_Males,210525_Pakistan_RiphahInternationalUniversity,SARS-CoV-2: big seroprevalence data from Pakistan-is herd immunity at hand?.,2021-05-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Pakistan,,,Residents in Pakistan,,2020-07-15,2020-07-31,Household and community samples,Male,Multiple groups,,,Sex/Gender,,12280,0.428,0.419,0.43700000000000006,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.988,1.0,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Mohsina Haq,Riphah International University ,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01629-2,2021-08-12,2024-03-01,Verified,haq_sars-cov-2_2021,PAK
210525_Pakistan_RiphahInternationalUniversity_>60,210525_Pakistan_RiphahInternationalUniversity,SARS-CoV-2: big seroprevalence data from Pakistan-is herd immunity at hand?.,2021-05-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Pakistan,,,Residents in Pakistan,,2020-07-15,2020-07-31,Household and community samples,All,Seniors (65+ years),61.0,,Age,>60  years old,652,0.446,0.40700000000000003,0.485,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.988,1.0,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Mohsina Haq,Riphah International University ,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01629-2,2021-08-12,2024-03-01,Verified,haq_sars-cov-2_2021,PAK
210525_Pakistan_RiphahInternationalUniversity_41-60,210525_Pakistan_RiphahInternationalUniversity,SARS-CoV-2: big seroprevalence data from Pakistan-is herd immunity at hand?.,2021-05-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Pakistan,,,Residents in Pakistan,,2020-07-15,2020-07-31,Household and community samples,All,Adults (18-64 years),41.0,60.0,Age,41-60 years old,3841,0.443,0.42700000000000005,0.459,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.988,1.0,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Mohsina Haq,Riphah International University ,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01629-2,2021-08-12,2024-03-01,Verified,haq_sars-cov-2_2021,PAK
210525_Pakistan_RiphahInternationalUniversity_Females,210525_Pakistan_RiphahInternationalUniversity,SARS-CoV-2: big seroprevalence data from Pakistan-is herd immunity at hand?.,2021-05-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Pakistan,,,Residents in Pakistan,,2020-07-15,2020-07-31,Household and community samples,Female,Multiple groups,,,Sex/Gender,,3110,0.405,0.387,0.42200000000000004,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.988,1.0,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Mohsina Haq,Riphah International University ,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01629-2,2021-08-12,2024-03-01,Verified,haq_sars-cov-2_2021,PAK
210529_Pakistan_CombinedMilitaryHospitalKharianMedicalCollege,210529_Pakistan_CombinedMilitaryHospitalKharianMedicalCollege,Seroprevalence of COVID-19 and associated factors in a medical institution in Pakistan.,2021-05-29,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Pakistan,,,"In total, 442 participants were included in the study: 40 (9%) faculty members, 299 (67%) students, and 103 (23.3%) administrative/technical staff.",,2020-09-01,2020-09-30,Non-essential workers and unemployed persons,All,Multiple groups,,,Primary Estimate,,442,0.1696,,,True,,,,True,Convenience,Ichroma COVID-19 Ab Test,Boditech Med Inc.,LFIA,Whole Blood,IgG,,,0.958,0.9670000000000001,['High'],,No,No,No,,Yes,Yes,No,,Iffat Naiyar,Combined Military Hospital Kharian Medical College,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jtumed.2021.04.004,2021-06-17,2024-03-01,Unverified,iffatnaiyarSeroprevalenceCOVID19Associated2021,PAK
210816_Pakistan_ChughtaiInstituteofPathology_Primary,210816_Pakistan_ChughtaiInstituteofPathology,Seroprevalence of COVID-19 IgG antibodies among healthcare workers of Pakistan: a cross-sectional study assessing exposure to COVID-19 and identification of high-risk subgroups.,2021-08-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Pakistan,,,"A list of healthcare centres who were authorised to treat and diagnose patients with COVID-19 was issued by government officials of Pakistan and only the HCWs involved in providing services and care in these centres were approached for inclusion (doctors, nurses/para medical staff and medical laboratory technologists)","HCWs with no interaction with patients with COVID-19 (either direct contact or dealing with patient samples) or the workers who were not present on duty in the last one month from the date of commencement of study were excluded. Moreover, HCWs who were already involved in some clinical trials of COVID-19 were not involved in the study. HCWs showing active signs and symptoms compatible with COVID-19 were not involved in the study as they might be a risk to the team members of the laboratory taking samples.",2021-07-01,2021-07-20,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,15000,0.33,,,True,,,,True,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.996,0.9670000000000001,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Hijab Batool,Chughtai Institute of Pathology,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2020-046276,2021-08-24,2024-03-01,Unverified,batool_seroprevalence_2021,PAK
210927_Karachi_AgaKhanUniversityandHospital_primary,210927_Karachi_AgaKhanUniversityandHospital,Increasing IgG antibodies to SARS-CoV-2 in asymptomatic blood donors through the second COVID-19 wave in Karachi associated with exposure and immunity in the population,2021-09-27,Preprint,Local,Repeated cross-sectional study,Pakistan,,Karachi,"Blood donors who presented to the blood bank for donations were informed about the study and if they consented, they were recruited. Any individual who had no signs and symptoms of disease within the past four weeks was eligible for the study.",Any donor with a history of COVID-19 related symptoms or confirmed infection was excluded from enrollment as a blood donor.,2020-12-15,2021-02-14,Blood donors,All,Multiple groups,,,Primary Estimate,,558,0.534,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,,,['High'],No,No,No,Yes,No,Unclear,Yes,No,No,Muhammad Hasan,The Aga Khan University and Hospital,Not Unity-Aligned,https://www.researchsquare.com/article/rs-941908/v1,2021-10-13,2022-07-16,Verified,hasan_increasing_2021,PAK
210927_Karachi_AgaKhanUniversityandHospital_age_41-50,210927_Karachi_AgaKhanUniversityandHospital,Increasing IgG antibodies to SARS-CoV-2 in asymptomatic blood donors through the second COVID-19 wave in Karachi associated with exposure and immunity in the population,2021-09-27,Preprint,Local,Repeated cross-sectional study,Pakistan,,Karachi,"Blood donors who presented to the blood bank for donations were informed about the study and if they consented, they were recruited. Any individual who had no signs and symptoms of disease within the past four weeks was eligible for the study.",Any donor with a history of COVID-19 related symptoms or confirmed infection was excluded from enrollment as a blood donor.,2020-12-15,2021-02-14,Blood donors,All,Adults (18-64 years),,,Age,,38,0.474,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,,,['High'],No,No,No,Yes,No,Unclear,Yes,No,No,Muhammad Hasan,The Aga Khan University and Hospital,Not Unity-Aligned,https://www.researchsquare.com/article/rs-941908/v1,2021-10-13,2022-07-16,Verified,hasan_increasing_2021,PAK
210927_Karachi_AgaKhanUniversityandHospital_age_17-20,210927_Karachi_AgaKhanUniversityandHospital,Increasing IgG antibodies to SARS-CoV-2 in asymptomatic blood donors through the second COVID-19 wave in Karachi associated with exposure and immunity in the population,2021-09-27,Preprint,Local,Repeated cross-sectional study,Pakistan,,Karachi,"Blood donors who presented to the blood bank for donations were informed about the study and if they consented, they were recruited. Any individual who had no signs and symptoms of disease within the past four weeks was eligible for the study.",Any donor with a history of COVID-19 related symptoms or confirmed infection was excluded from enrollment as a blood donor.,2020-12-15,2021-02-14,Blood donors,All,Multiple groups,,,Age,,74,0.473,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,,,['High'],No,No,No,Yes,No,Unclear,Yes,No,No,Muhammad Hasan,The Aga Khan University and Hospital,Not Unity-Aligned,https://www.researchsquare.com/article/rs-941908/v1,2021-10-13,2022-07-16,Verified,hasan_increasing_2021,PAK
210927_Karachi_AgaKhanUniversityandHospital_age_31-40,210927_Karachi_AgaKhanUniversityandHospital,Increasing IgG antibodies to SARS-CoV-2 in asymptomatic blood donors through the second COVID-19 wave in Karachi associated with exposure and immunity in the population,2021-09-27,Preprint,Local,Repeated cross-sectional study,Pakistan,,Karachi,"Blood donors who presented to the blood bank for donations were informed about the study and if they consented, they were recruited. Any individual who had no signs and symptoms of disease within the past four weeks was eligible for the study.",Any donor with a history of COVID-19 related symptoms or confirmed infection was excluded from enrollment as a blood donor.,2020-12-15,2021-02-14,Blood donors,All,Adults (18-64 years),,,Age,,167,0.617,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,,,['High'],No,No,No,Yes,No,Unclear,Yes,No,No,Muhammad Hasan,The Aga Khan University and Hospital,Not Unity-Aligned,https://www.researchsquare.com/article/rs-941908/v1,2021-10-13,2022-07-16,Verified,hasan_increasing_2021,PAK
210927_Karachi_AgaKhanUniversityandHospital_Feb2021,210927_Karachi_AgaKhanUniversityandHospital,Increasing IgG antibodies to SARS-CoV-2 in asymptomatic blood donors through the second COVID-19 wave in Karachi associated with exposure and immunity in the population,2021-09-27,Preprint,Local,Repeated cross-sectional study,Pakistan,,Karachi,"Blood donors who presented to the blood bank for donations were informed about the study and if they consented, they were recruited. Any individual who had no signs and symptoms of disease within the past four weeks was eligible for the study.",Any donor with a history of COVID-19 related symptoms or confirmed infection was excluded from enrollment as a blood donor.,2021-02-01,2021-02-14,Blood donors,All,Multiple groups,,,Time frame,,236,0.525,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,,,['High'],No,No,No,Yes,No,Unclear,Yes,No,No,Muhammad Hasan,The Aga Khan University and Hospital,Not Unity-Aligned,https://www.researchsquare.com/article/rs-941908/v1,2021-10-13,2022-07-16,Verified,hasan_increasing_2021,PAK
210927_Karachi_AgaKhanUniversityandHospital_age_21-30,210927_Karachi_AgaKhanUniversityandHospital,Increasing IgG antibodies to SARS-CoV-2 in asymptomatic blood donors through the second COVID-19 wave in Karachi associated with exposure and immunity in the population,2021-09-27,Preprint,Local,Repeated cross-sectional study,Pakistan,,Karachi,"Blood donors who presented to the blood bank for donations were informed about the study and if they consented, they were recruited. Any individual who had no signs and symptoms of disease within the past four weeks was eligible for the study.",Any donor with a history of COVID-19 related symptoms or confirmed infection was excluded from enrollment as a blood donor.,2020-12-15,2021-02-14,Blood donors,All,Adults (18-64 years),,,Age,,275,0.513,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,,,['High'],No,No,No,Yes,No,Unclear,Yes,No,No,Muhammad Hasan,The Aga Khan University and Hospital,Not Unity-Aligned,https://www.researchsquare.com/article/rs-941908/v1,2021-10-13,2022-07-16,Verified,hasan_increasing_2021,PAK
210927_Karachi_AgaKhanUniversityandHospital_Dec2020,210927_Karachi_AgaKhanUniversityandHospital,Increasing IgG antibodies to SARS-CoV-2 in asymptomatic blood donors through the second COVID-19 wave in Karachi associated with exposure and immunity in the population,2021-09-27,Preprint,Local,Repeated cross-sectional study,Pakistan,,Karachi,"Blood donors who presented to the blood bank for donations were informed about the study and if they consented, they were recruited. Any individual who had no signs and symptoms of disease within the past four weeks was eligible for the study.",Any donor with a history of COVID-19 related symptoms or confirmed infection was excluded from enrollment as a blood donor.,2020-12-15,2020-12-31,Blood donors,All,Multiple groups,,,Time frame,,322,0.54,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,,,['High'],No,No,No,Yes,No,Unclear,Yes,No,No,Muhammad Hasan,The Aga Khan University and Hospital,Not Unity-Aligned,https://www.researchsquare.com/article/rs-941908/v1,2021-10-13,2022-07-16,Verified,hasan_increasing_2021,PAK
210927_Karachi_AgaKhanUniversityandHospital_age_51-60,210927_Karachi_AgaKhanUniversityandHospital,Increasing IgG antibodies to SARS-CoV-2 in asymptomatic blood donors through the second COVID-19 wave in Karachi associated with exposure and immunity in the population,2021-09-27,Preprint,Local,Repeated cross-sectional study,Pakistan,,Karachi,"Blood donors who presented to the blood bank for donations were informed about the study and if they consented, they were recruited. Any individual who had no signs and symptoms of disease within the past four weeks was eligible for the study.",Any donor with a history of COVID-19 related symptoms or confirmed infection was excluded from enrollment as a blood donor.,2020-12-15,2021-02-14,Blood donors,All,Adults (18-64 years),,,Age,,4,0.25,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,,,['High'],No,No,No,Yes,No,Unclear,Yes,No,No,Muhammad Hasan,The Aga Khan University and Hospital,Not Unity-Aligned,https://www.researchsquare.com/article/rs-941908/v1,2021-10-13,2022-07-16,Verified,hasan_increasing_2021,PAK
210929_Islamabad_NationalInstituteofHealth_Overall,210929_Islamabad_NationalInstituteofHealth,"Prevalence of SARS-CoV-2: An age-stratified, population-based, seroepidemiological survey in Islamabad, Pakistan",2021-09-29,Preprint,Local,Cross-sectional survey ,Pakistan,Islamabad Capital Territory,Islamabad,"Residents of households in both urban and rural administrative units of the district of Islamabad, Pakistan. A household was defined as “a dwelling with a 140 common kitchen or common opening onto a shared space.” All persons living in a household were included in the study for representation of all ages and genders.",,2020-06-01,2020-06-30,Household and community samples,All,Multiple groups,,,Primary Estimate,,6333,0.163,,,True,,,,True,Stratified probability,Panbio COVID-19 IgG/IgM rapid test device,Abbott Laboratories,CLIA,,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,No,Yes,No,Yes,Mirza Amir Baig,National Institute of Health,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.09.27.21264003v1.article-info,2021-10-05,2024-03-01,Verified,baig_prevalence_2021,PAK
211213_Sindh_ShaheedMohtarmaBenazirBhuttoMedicalUniversity_Primary,211213_Sindh_ShaheedMohtarmaBenazirBhuttoMedicalUniversity,"Seroprevalence of Anti-SARS-CoV-2 Antibodies in COVID-19 Patients in Hyderabad, Sindh",2021-12-13,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Pakistan,Sindh,Hyderabad,"The study involved patients visiting hospitals. The subjects included in the
study were never diagnosed with COVID-19 and
they do not have any COVID-19-related
symptoms such as fever or cough and live in
Hyderabad and adjoining areas.","All the
symptomatic and confirmed COVID-19 cases
were excluded from the study.",2020-08-01,2020-11-30,Residual sera,All,Adults (18-64 years),18.0,65.0,Primary Estimate,,1229,0.16760000000000003,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Shahzad Rasheed Qureshi,"Liaquat University of Medical and Health
Sciences ",Not Unity-Aligned,http://libraryaplos.com/xmlui/handle/123456789/8719,2022-01-10,2024-03-01,Unverified,qureshi_seroprevalence_2021,PAK
211213_Sindh_ShaheedMohtarmaBenazirBhuttoMedicalUniversity_46-65,211213_Sindh_ShaheedMohtarmaBenazirBhuttoMedicalUniversity,"Seroprevalence of Anti-SARS-CoV-2 Antibodies in COVID-19 Patients in Hyderabad, Sindh",2021-12-13,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Pakistan,Sindh,Hyderabad,"The study involved patients visiting hospitals. The subjects included in the
study were never diagnosed with COVID-19 and
they do not have any COVID-19-related
symptoms such as fever or cough and live in
Hyderabad and adjoining areas.","All the
symptomatic and confirmed COVID-19 cases
were excluded from the study.",2020-08-01,2020-11-30,Residual sera,All,Adults (18-64 years),46.0,65.0,Age,46-65,242,0.2231,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Shahzad Rasheed Qureshi,"Liaquat University of Medical and Health
Sciences ",Not Unity-Aligned,http://libraryaplos.com/xmlui/handle/123456789/8719,2022-01-10,2024-03-01,Unverified,qureshi_seroprevalence_2021,PAK
211213_Sindh_ShaheedMohtarmaBenazirBhuttoMedicalUniversity_18-25,211213_Sindh_ShaheedMohtarmaBenazirBhuttoMedicalUniversity,"Seroprevalence of Anti-SARS-CoV-2 Antibodies in COVID-19 Patients in Hyderabad, Sindh",2021-12-13,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Pakistan,Sindh,Hyderabad,"The study involved patients visiting hospitals. The subjects included in the
study were never diagnosed with COVID-19 and
they do not have any COVID-19-related
symptoms such as fever or cough and live in
Hyderabad and adjoining areas.","All the
symptomatic and confirmed COVID-19 cases
were excluded from the study.",2020-08-01,2020-11-30,Residual sera,All,Adults (18-64 years),18.0,25.0,Age,18-25,325,0.16,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Shahzad Rasheed Qureshi,"Liaquat University of Medical and Health
Sciences ",Not Unity-Aligned,http://libraryaplos.com/xmlui/handle/123456789/8719,2022-01-10,2024-03-01,Unverified,qureshi_seroprevalence_2021,PAK
211213_Sindh_ShaheedMohtarmaBenazirBhuttoMedicalUniversity_26-35,211213_Sindh_ShaheedMohtarmaBenazirBhuttoMedicalUniversity,"Seroprevalence of Anti-SARS-CoV-2 Antibodies in COVID-19 Patients in Hyderabad, Sindh",2021-12-13,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Pakistan,Sindh,Hyderabad,"The study involved patients visiting hospitals. The subjects included in the
study were never diagnosed with COVID-19 and
they do not have any COVID-19-related
symptoms such as fever or cough and live in
Hyderabad and adjoining areas.","All the
symptomatic and confirmed COVID-19 cases
were excluded from the study.",2020-08-01,2020-11-30,Residual sera,All,Adults (18-64 years),26.0,35.0,Age,26-35,423,0.1323,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Shahzad Rasheed Qureshi,"Liaquat University of Medical and Health
Sciences ",Not Unity-Aligned,http://libraryaplos.com/xmlui/handle/123456789/8719,2022-01-10,2024-03-01,Unverified,qureshi_seroprevalence_2021,PAK
211213_Sindh_ShaheedMohtarmaBenazirBhuttoMedicalUniversity_36-45,211213_Sindh_ShaheedMohtarmaBenazirBhuttoMedicalUniversity,"Seroprevalence of Anti-SARS-CoV-2 Antibodies in COVID-19 Patients in Hyderabad, Sindh",2021-12-13,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Pakistan,Sindh,Hyderabad,"The study involved patients visiting hospitals. The subjects included in the
study were never diagnosed with COVID-19 and
they do not have any COVID-19-related
symptoms such as fever or cough and live in
Hyderabad and adjoining areas.","All the
symptomatic and confirmed COVID-19 cases
were excluded from the study.",2020-08-01,2020-11-30,Residual sera,All,Adults (18-64 years),36.0,45.0,Age,36-45,239,0.1841,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Shahzad Rasheed Qureshi,"Liaquat University of Medical and Health
Sciences ",Not Unity-Aligned,http://libraryaplos.com/xmlui/handle/123456789/8719,2022-01-10,2024-03-01,Unverified,qureshi_seroprevalence_2021,PAK
220310_PeshawarCity_RiphahInternationalUniversity_OverallCrude,220310_PeshawarCity_RiphahInternationalUniversity,Identifying higher risk subgroups of health care workers for priority vaccination against COVID-19.,2022-03-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Pakistan,,Peshawar,"This was a multicentre cross-sectional study conducted in two major tertiary-care hospitals (Prime Foundation group of hospitals: Mercy Teaching Hospital and Kuwait Teaching Hospital), Peshawar city Pakistan. Participants of the study were selected from a list of HCWs through simple random sampling technique. A total number of 1000 HCWs were invited to participate (500 from Mercy Teaching Hospital and 500 from Kuwait Teaching Hospital). The sampling period was from 15 to 29 June 2020. The HCWs included doctors, nurses, paramedics and hospital support staff.",,2020-06-15,2020-06-29,Health care workers and caregivers,All,Adults (18-64 years),,60.0,Primary Estimate,,987,0.3141,0.28500000000000003,0.344,True,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,,Serum,,,Validated by manufacturers,0.1,0.988,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Mohsina Haq,Riphah International University,Not Unity-Aligned,https://dx.doi.org/10.1177/25151355221080724,2022-03-21,2022-07-16,Unverified,haq_identifying_2022,PAK
220310_PeshawarCity_RiphahInternationalUniversity_Age41-50,220310_PeshawarCity_RiphahInternationalUniversity,Identifying higher risk subgroups of health care workers for priority vaccination against COVID-19.,2022-03-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Pakistan,,Peshawar,"This was a multicentre cross-sectional study conducted in two major tertiary-care hospitals (Prime Foundation group of hospitals: Mercy Teaching Hospital and Kuwait Teaching Hospital), Peshawar city Pakistan. Participants of the study were selected from a list of HCWs through simple random sampling technique. A total number of 1000 HCWs were invited to participate (500 from Mercy Teaching Hospital and 500 from Kuwait Teaching Hospital). The sampling period was from 15 to 29 June 2020. The HCWs included doctors, nurses, paramedics and hospital support staff.",,2020-06-15,2020-06-29,Health care workers and caregivers,All,Adults (18-64 years),41.0,50.0,Age,41-50,136,0.3603,0.27899999999999997,0.44700000000000006,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,,Serum,,,Validated by manufacturers,0.1,0.988,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Mohsina Haq,Riphah International University,Not Unity-Aligned,https://dx.doi.org/10.1177/25151355221080724,2022-03-21,2022-07-16,Unverified,haq_identifying_2022,PAK
220310_PeshawarCity_RiphahInternationalUniversity_Age31-40,220310_PeshawarCity_RiphahInternationalUniversity,Identifying higher risk subgroups of health care workers for priority vaccination against COVID-19.,2022-03-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Pakistan,,Peshawar,"This was a multicentre cross-sectional study conducted in two major tertiary-care hospitals (Prime Foundation group of hospitals: Mercy Teaching Hospital and Kuwait Teaching Hospital), Peshawar city Pakistan. Participants of the study were selected from a list of HCWs through simple random sampling technique. A total number of 1000 HCWs were invited to participate (500 from Mercy Teaching Hospital and 500 from Kuwait Teaching Hospital). The sampling period was from 15 to 29 June 2020. The HCWs included doctors, nurses, paramedics and hospital support staff.",,2020-06-15,2020-06-29,Health care workers and caregivers,All,Adults (18-64 years),31.0,40.0,Age,31-40,266,0.3383,0.281,0.39799999999999996,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,,Serum,,,Validated by manufacturers,0.1,0.988,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Mohsina Haq,Riphah International University,Not Unity-Aligned,https://dx.doi.org/10.1177/25151355221080724,2022-03-21,2022-07-16,Unverified,haq_identifying_2022,PAK
220310_PeshawarCity_RiphahInternationalUniversity_Age51-60,220310_PeshawarCity_RiphahInternationalUniversity,Identifying higher risk subgroups of health care workers for priority vaccination against COVID-19.,2022-03-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Pakistan,,Peshawar,"This was a multicentre cross-sectional study conducted in two major tertiary-care hospitals (Prime Foundation group of hospitals: Mercy Teaching Hospital and Kuwait Teaching Hospital), Peshawar city Pakistan. Participants of the study were selected from a list of HCWs through simple random sampling technique. A total number of 1000 HCWs were invited to participate (500 from Mercy Teaching Hospital and 500 from Kuwait Teaching Hospital). The sampling period was from 15 to 29 June 2020. The HCWs included doctors, nurses, paramedics and hospital support staff.",,2020-06-15,2020-06-29,Health care workers and caregivers,All,Adults (18-64 years),51.0,60.0,Age,51-60,66,0.40909999999999996,0.289,0.537,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,,Serum,,,Validated by manufacturers,0.1,0.988,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Mohsina Haq,Riphah International University,Not Unity-Aligned,https://dx.doi.org/10.1177/25151355221080724,2022-03-21,2022-07-16,Unverified,haq_identifying_2022,PAK
220310_PeshawarCity_RiphahInternationalUniversity_Age21-30,220310_PeshawarCity_RiphahInternationalUniversity,Identifying higher risk subgroups of health care workers for priority vaccination against COVID-19.,2022-03-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Pakistan,,Peshawar,"This was a multicentre cross-sectional study conducted in two major tertiary-care hospitals (Prime Foundation group of hospitals: Mercy Teaching Hospital and Kuwait Teaching Hospital), Peshawar city Pakistan. Participants of the study were selected from a list of HCWs through simple random sampling technique. A total number of 1000 HCWs were invited to participate (500 from Mercy Teaching Hospital and 500 from Kuwait Teaching Hospital). The sampling period was from 15 to 29 June 2020. The HCWs included doctors, nurses, paramedics and hospital support staff.",,2020-06-15,2020-06-29,Health care workers and caregivers,All,Adults (18-64 years),21.0,30.0,Age,21-30,507,0.2821,0.242,0.321,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,,Serum,,,Validated by manufacturers,0.1,0.988,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Mohsina Haq,Riphah International University,Not Unity-Aligned,https://dx.doi.org/10.1177/25151355221080724,2022-03-21,2022-07-16,Unverified,haq_identifying_2022,PAK
220310_PeshawarCity_RiphahInternationalUniversity_Age<20,220310_PeshawarCity_RiphahInternationalUniversity,Identifying higher risk subgroups of health care workers for priority vaccination against COVID-19.,2022-03-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Pakistan,,Peshawar,"This was a multicentre cross-sectional study conducted in two major tertiary-care hospitals (Prime Foundation group of hospitals: Mercy Teaching Hospital and Kuwait Teaching Hospital), Peshawar city Pakistan. Participants of the study were selected from a list of HCWs through simple random sampling technique. A total number of 1000 HCWs were invited to participate (500 from Mercy Teaching Hospital and 500 from Kuwait Teaching Hospital). The sampling period was from 15 to 29 June 2020. The HCWs included doctors, nurses, paramedics and hospital support staff.",,2020-06-15,2020-06-29,Health care workers and caregivers,All,Adults (18-64 years),,20.0,Age,<20,12,0.0833,0.021,0.384,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,,Serum,,,Validated by manufacturers,0.1,0.988,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Mohsina Haq,Riphah International University,Not Unity-Aligned,https://dx.doi.org/10.1177/25151355221080724,2022-03-21,2022-07-16,Unverified,haq_identifying_2022,PAK
220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination_Overall,220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination,COVID-19 seroprevalence in Pakistan: a cross-sectional study,2022-04-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Pakistan,"Punjab, Sindh, Baluchistan, Khyber Pakhtunkhwa, Azad Jammu & Kashmir, Gilgit Baltistan",,"This was a nationwide study in the four provinces (Punjab, Sindh, Baluchistan and Khyber Pakhtunkhwa) and two regions (Azad Jammu & Kashmir (AJK) and Gilgit Baltistan (GB)) of Pakistan. Individuals of all ages and genders were eligible to participate.","exclusion criteria: contraindications to venipuncture however, no such case was encountered",2020-10-21,2020-11-08,Household and community samples,All,Multiple groups,,,Primary Estimate,,4998,0.0702,,,True,,,,True,Stratified probability,Novel Corona Virus (SARS-CoV-2) IgM/IgG Rapid Test Kit,Bioperfectus,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,0.9500000000000001,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Ahsan Ahmad,Ministry of National Health Services Regulations and Coordination,Unity-Aligned,https://bmjopen.bmj.com/content/12/4/e055381.abstract,2022-04-12,2024-03-01,Verified,ahmad_covid-19_2022,PAK
220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination_Age10-19,220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination,COVID-19 seroprevalence in Pakistan: a cross-sectional study,2022-04-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Pakistan,"Punjab, Sindh, Baluchistan, Khyber Pakhtunkhwa, Azad Jammu & Kashmir, Gilgit Baltistan",,"This was a nationwide study in the four provinces (Punjab, Sindh, Baluchistan and Khyber Pakhtunkhwa) and two regions (Azad Jammu & Kashmir (AJK) and Gilgit Baltistan (GB)) of Pakistan. Individuals of all ages and genders were eligible to participate.","exclusion criteria: contraindications to venipuncture however, no such case was encountered",2020-10-21,2020-11-08,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,1019,0.0451,,,,,,,,Stratified probability,Novel Corona Virus (SARS-CoV-2) IgM/IgG Rapid Test Kit,Bioperfectus,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,0.9500000000000001,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Ahsan Ahmad,Ministry of National Health Services Regulations and Coordination,Unity-Aligned,https://bmjopen.bmj.com/content/12/4/e055381.abstract,2022-04-12,2024-03-01,Verified,ahmad_covid-19_2022,PAK
220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination_DistrictRawalpindi,220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination,COVID-19 seroprevalence in Pakistan: a cross-sectional study,2022-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Pakistan,,,"This was a nationwide study in the four provinces (Punjab, Sindh, Baluchistan and Khyber Pakhtunkhwa) and two regions (Azad Jammu & Kashmir (AJK) and Gilgit Baltistan (GB)) of Pakistan. Individuals of all ages and genders were eligible to participate.","exclusion criteria: contraindications to venipuncture however, no such case was encountered",2020-10-21,2020-11-08,Household and community samples,All,Multiple groups,,,Geographical area,Rawalpindi,501,0.0679,,,,,,,,Stratified probability,Novel Corona Virus (SARS-CoV-2) IgM/IgG Rapid Test Kit,Bioperfectus,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,0.9500000000000001,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Ahsan Ahmad,Ministry of National Health Services Regulations and Coordination,Unity-Aligned,https://bmjopen.bmj.com/content/12/4/e055381.abstract,2022-04-12,2024-03-01,Verified,ahmad_covid-19_2022,PAK
220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination_Age60+,220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination,COVID-19 seroprevalence in Pakistan: a cross-sectional study,2022-04-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Pakistan,"Punjab, Sindh, Baluchistan, Khyber Pakhtunkhwa, Azad Jammu & Kashmir, Gilgit Baltistan",,"This was a nationwide study in the four provinces (Punjab, Sindh, Baluchistan and Khyber Pakhtunkhwa) and two regions (Azad Jammu & Kashmir (AJK) and Gilgit Baltistan (GB)) of Pakistan. Individuals of all ages and genders were eligible to participate.","exclusion criteria: contraindications to venipuncture however, no such case was encountered",2020-10-21,2020-11-08,Household and community samples,All,Seniors (65+ years),60.0,,Age,60+,975,0.08720000000000001,,,,,,,,Stratified probability,Novel Corona Virus (SARS-CoV-2) IgM/IgG Rapid Test Kit,Bioperfectus,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,0.9500000000000001,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Ahsan Ahmad,Ministry of National Health Services Regulations and Coordination,Unity-Aligned,https://bmjopen.bmj.com/content/12/4/e055381.abstract,2022-04-12,2024-03-01,Verified,ahmad_covid-19_2022,PAK
220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination_DistrictMuzaffarabad,220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination,COVID-19 seroprevalence in Pakistan: a cross-sectional study,2022-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Pakistan,,,"This was a nationwide study in the four provinces (Punjab, Sindh, Baluchistan and Khyber Pakhtunkhwa) and two regions (Azad Jammu & Kashmir (AJK) and Gilgit Baltistan (GB)) of Pakistan. Individuals of all ages and genders were eligible to participate.","exclusion criteria: contraindications to venipuncture however, no such case was encountered",2020-10-21,2020-11-08,Household and community samples,All,Multiple groups,,,Geographical area,Muzaffarabad,499,0.0782,,,,,,,,Stratified probability,Novel Corona Virus (SARS-CoV-2) IgM/IgG Rapid Test Kit,Bioperfectus,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,0.9500000000000001,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Ahsan Ahmad,Ministry of National Health Services Regulations and Coordination,Unity-Aligned,https://bmjopen.bmj.com/content/12/4/e055381.abstract,2022-04-12,2024-03-01,Verified,ahmad_covid-19_2022,PAK
220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination_DistrictAbbottabad,220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination,COVID-19 seroprevalence in Pakistan: a cross-sectional study,2022-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Pakistan,,,"This was a nationwide study in the four provinces (Punjab, Sindh, Baluchistan and Khyber Pakhtunkhwa) and two regions (Azad Jammu & Kashmir (AJK) and Gilgit Baltistan (GB)) of Pakistan. Individuals of all ages and genders were eligible to participate.","exclusion criteria: contraindications to venipuncture however, no such case was encountered",2020-10-21,2020-11-08,Household and community samples,All,Multiple groups,,,Geographical area,Abbottabad,502,0.0837,,,,,,,,Stratified probability,Novel Corona Virus (SARS-CoV-2) IgM/IgG Rapid Test Kit,Bioperfectus,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,0.9500000000000001,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Ahsan Ahmad,Ministry of National Health Services Regulations and Coordination,Unity-Aligned,https://bmjopen.bmj.com/content/12/4/e055381.abstract,2022-04-12,2024-03-01,Verified,ahmad_covid-19_2022,PAK
220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination_Age20-39,220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination,COVID-19 seroprevalence in Pakistan: a cross-sectional study,2022-04-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Pakistan,"Punjab, Sindh, Baluchistan, Khyber Pakhtunkhwa, Azad Jammu & Kashmir, Gilgit Baltistan",,"This was a nationwide study in the four provinces (Punjab, Sindh, Baluchistan and Khyber Pakhtunkhwa) and two regions (Azad Jammu & Kashmir (AJK) and Gilgit Baltistan (GB)) of Pakistan. Individuals of all ages and genders were eligible to participate.","exclusion criteria: contraindications to venipuncture however, no such case was encountered",2020-10-21,2020-11-08,Household and community samples,All,Adults (18-64 years),20.0,39.0,Age,20-39,1030,0.07769999999999999,,,,,,,,Stratified probability,Novel Corona Virus (SARS-CoV-2) IgM/IgG Rapid Test Kit,Bioperfectus,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,0.9500000000000001,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Ahsan Ahmad,Ministry of National Health Services Regulations and Coordination,Unity-Aligned,https://bmjopen.bmj.com/content/12/4/e055381.abstract,2022-04-12,2024-03-01,Verified,ahmad_covid-19_2022,PAK
220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination_SexMale,220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination,COVID-19 seroprevalence in Pakistan: a cross-sectional study,2022-04-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Pakistan,"Punjab, Sindh, Baluchistan, Khyber Pakhtunkhwa, Azad Jammu & Kashmir, Gilgit Baltistan",,"This was a nationwide study in the four provinces (Punjab, Sindh, Baluchistan and Khyber Pakhtunkhwa) and two regions (Azad Jammu & Kashmir (AJK) and Gilgit Baltistan (GB)) of Pakistan. Individuals of all ages and genders were eligible to participate.","exclusion criteria: contraindications to venipuncture however, no such case was encountered",2020-10-21,2020-11-08,Household and community samples,Male,Multiple groups,,,Sex/Gender,,2572,0.0692,,,,,,,,Stratified probability,Novel Corona Virus (SARS-CoV-2) IgM/IgG Rapid Test Kit,Bioperfectus,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,0.9500000000000001,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Ahsan Ahmad,Ministry of National Health Services Regulations and Coordination,Unity-Aligned,https://bmjopen.bmj.com/content/12/4/e055381.abstract,2022-04-12,2024-03-01,Verified,ahmad_covid-19_2022,PAK
220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination_DistrictSibbi,220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination,COVID-19 seroprevalence in Pakistan: a cross-sectional study,2022-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Pakistan,,,"This was a nationwide study in the four provinces (Punjab, Sindh, Baluchistan and Khyber Pakhtunkhwa) and two regions (Azad Jammu & Kashmir (AJK) and Gilgit Baltistan (GB)) of Pakistan. Individuals of all ages and genders were eligible to participate.","exclusion criteria: contraindications to venipuncture however, no such case was encountered",2020-10-21,2020-11-08,Household and community samples,All,Multiple groups,,,Geographical area,Sibbi,498,0.04820000000000001,,,,,,,,Stratified probability,Novel Corona Virus (SARS-CoV-2) IgM/IgG Rapid Test Kit,Bioperfectus,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,0.9500000000000001,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Ahsan Ahmad,Ministry of National Health Services Regulations and Coordination,Unity-Aligned,https://bmjopen.bmj.com/content/12/4/e055381.abstract,2022-04-12,2024-03-01,Verified,ahmad_covid-19_2022,PAK
220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination_DistrictLodhran,220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination,COVID-19 seroprevalence in Pakistan: a cross-sectional study,2022-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Pakistan,,,"This was a nationwide study in the four provinces (Punjab, Sindh, Baluchistan and Khyber Pakhtunkhwa) and two regions (Azad Jammu & Kashmir (AJK) and Gilgit Baltistan (GB)) of Pakistan. Individuals of all ages and genders were eligible to participate.","exclusion criteria: contraindications to venipuncture however, no such case was encountered",2020-10-21,2020-11-08,Household and community samples,All,Multiple groups,,,Geographical area,Lodhran,500,0.086,,,,,,,,Stratified probability,Novel Corona Virus (SARS-CoV-2) IgM/IgG Rapid Test Kit,Bioperfectus,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,0.9500000000000001,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Ahsan Ahmad,Ministry of National Health Services Regulations and Coordination,Unity-Aligned,https://bmjopen.bmj.com/content/12/4/e055381.abstract,2022-04-12,2024-03-01,Verified,ahmad_covid-19_2022,PAK
220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination_DistrictJacobabad,220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination,COVID-19 seroprevalence in Pakistan: a cross-sectional study,2022-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Pakistan,,,"This was a nationwide study in the four provinces (Punjab, Sindh, Baluchistan and Khyber Pakhtunkhwa) and two regions (Azad Jammu & Kashmir (AJK) and Gilgit Baltistan (GB)) of Pakistan. Individuals of all ages and genders were eligible to participate.","exclusion criteria: contraindications to venipuncture however, no such case was encountered",2020-10-21,2020-11-08,Household and community samples,All,Multiple groups,,,Geographical area,Jacobabad,499,0.0741,,,,,,,,Stratified probability,Novel Corona Virus (SARS-CoV-2) IgM/IgG Rapid Test Kit,Bioperfectus,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,0.9500000000000001,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Ahsan Ahmad,Ministry of National Health Services Regulations and Coordination,Unity-Aligned,https://bmjopen.bmj.com/content/12/4/e055381.abstract,2022-04-12,2024-03-01,Verified,ahmad_covid-19_2022,PAK
220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination_DistrictQuetta,220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination,COVID-19 seroprevalence in Pakistan: a cross-sectional study,2022-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Pakistan,,,"This was a nationwide study in the four provinces (Punjab, Sindh, Baluchistan and Khyber Pakhtunkhwa) and two regions (Azad Jammu & Kashmir (AJK) and Gilgit Baltistan (GB)) of Pakistan. Individuals of all ages and genders were eligible to participate.","exclusion criteria: contraindications to venipuncture however, no such case was encountered",2020-10-21,2020-11-08,Household and community samples,All,Multiple groups,,,Geographical area,Quetta,500,0.032,,,,,,,,Stratified probability,Novel Corona Virus (SARS-CoV-2) IgM/IgG Rapid Test Kit,Bioperfectus,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,0.9500000000000001,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Ahsan Ahmad,Ministry of National Health Services Regulations and Coordination,Unity-Aligned,https://bmjopen.bmj.com/content/12/4/e055381.abstract,2022-04-12,2024-03-01,Verified,ahmad_covid-19_2022,PAK
220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination_Age0-9,220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination,COVID-19 seroprevalence in Pakistan: a cross-sectional study,2022-04-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Pakistan,"Punjab, Sindh, Baluchistan, Khyber Pakhtunkhwa, Azad Jammu & Kashmir, Gilgit Baltistan",,"This was a nationwide study in the four provinces (Punjab, Sindh, Baluchistan and Khyber Pakhtunkhwa) and two regions (Azad Jammu & Kashmir (AJK) and Gilgit Baltistan (GB)) of Pakistan. Individuals of all ages and genders were eligible to participate.","exclusion criteria: contraindications to venipuncture however, no such case was encountered",2020-10-21,2020-11-08,Household and community samples,All,Children and Youth (0-17 years),,9.0,Age,0-9,973,0.0391,,,,,,,,Stratified probability,Novel Corona Virus (SARS-CoV-2) IgM/IgG Rapid Test Kit,Bioperfectus,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,0.9500000000000001,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Ahsan Ahmad,Ministry of National Health Services Regulations and Coordination,Unity-Aligned,https://bmjopen.bmj.com/content/12/4/e055381.abstract,2022-04-12,2024-03-01,Verified,ahmad_covid-19_2022,PAK
220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination_DistrictGhotki,220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination,COVID-19 seroprevalence in Pakistan: a cross-sectional study,2022-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Pakistan,,,"This was a nationwide study in the four provinces (Punjab, Sindh, Baluchistan and Khyber Pakhtunkhwa) and two regions (Azad Jammu & Kashmir (AJK) and Gilgit Baltistan (GB)) of Pakistan. Individuals of all ages and genders were eligible to participate.","exclusion criteria: contraindications to venipuncture however, no such case was encountered",2020-10-21,2020-11-08,Household and community samples,All,Multiple groups,,,Geographical area,Ghotki,498,0.0,,,,,,,,Stratified probability,Novel Corona Virus (SARS-CoV-2) IgM/IgG Rapid Test Kit,Bioperfectus,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,0.9500000000000001,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Ahsan Ahmad,Ministry of National Health Services Regulations and Coordination,Unity-Aligned,https://bmjopen.bmj.com/content/12/4/e055381.abstract,2022-04-12,2024-03-01,Verified,ahmad_covid-19_2022,PAK
220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination_SexFemale,220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination,COVID-19 seroprevalence in Pakistan: a cross-sectional study,2022-04-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Pakistan,"Punjab, Sindh, Baluchistan, Khyber Pakhtunkhwa, Azad Jammu & Kashmir, Gilgit Baltistan",,"This was a nationwide study in the four provinces (Punjab, Sindh, Baluchistan and Khyber Pakhtunkhwa) and two regions (Azad Jammu & Kashmir (AJK) and Gilgit Baltistan (GB)) of Pakistan. Individuals of all ages and genders were eligible to participate.","exclusion criteria: contraindications to venipuncture however, no such case was encountered",2020-10-21,2020-11-08,Household and community samples,Female,Multiple groups,,,Sex/Gender,,2426,0.0713,,,,,,,,Stratified probability,Novel Corona Virus (SARS-CoV-2) IgM/IgG Rapid Test Kit,Bioperfectus,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,0.9500000000000001,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Ahsan Ahmad,Ministry of National Health Services Regulations and Coordination,Unity-Aligned,https://bmjopen.bmj.com/content/12/4/e055381.abstract,2022-04-12,2024-03-01,Verified,ahmad_covid-19_2022,PAK
220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination_Age40-59,220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination,COVID-19 seroprevalence in Pakistan: a cross-sectional study,2022-04-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Pakistan,"Punjab, Sindh, Baluchistan, Khyber Pakhtunkhwa, Azad Jammu & Kashmir, Gilgit Baltistan",,"This was a nationwide study in the four provinces (Punjab, Sindh, Baluchistan and Khyber Pakhtunkhwa) and two regions (Azad Jammu & Kashmir (AJK) and Gilgit Baltistan (GB)) of Pakistan. Individuals of all ages and genders were eligible to participate.","exclusion criteria: contraindications to venipuncture however, no such case was encountered",2020-10-21,2020-11-08,Household and community samples,All,Adults (18-64 years),40.0,59.0,Age,40-59,1000,0.10099999999999999,,,,,,,,Stratified probability,Novel Corona Virus (SARS-CoV-2) IgM/IgG Rapid Test Kit,Bioperfectus,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,0.9500000000000001,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Ahsan Ahmad,Ministry of National Health Services Regulations and Coordination,Unity-Aligned,https://bmjopen.bmj.com/content/12/4/e055381.abstract,2022-04-12,2024-03-01,Verified,ahmad_covid-19_2022,PAK
220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination_DistrictMardan,220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination,COVID-19 seroprevalence in Pakistan: a cross-sectional study,2022-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Pakistan,,,"This was a nationwide study in the four provinces (Punjab, Sindh, Baluchistan and Khyber Pakhtunkhwa) and two regions (Azad Jammu & Kashmir (AJK) and Gilgit Baltistan (GB)) of Pakistan. Individuals of all ages and genders were eligible to participate.","exclusion criteria: contraindications to venipuncture however, no such case was encountered",2020-10-21,2020-11-08,Household and community samples,All,Multiple groups,,,Geographical area,Mardan,501,0.061900000000000004,,,,,,,,Stratified probability,Novel Corona Virus (SARS-CoV-2) IgM/IgG Rapid Test Kit,Bioperfectus,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,0.9500000000000001,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Ahsan Ahmad,Ministry of National Health Services Regulations and Coordination,Unity-Aligned,https://bmjopen.bmj.com/content/12/4/e055381.abstract,2022-04-12,2024-03-01,Verified,ahmad_covid-19_2022,PAK
220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination_DistrictGilgit,220406_Pakistan_MinistryofNationalHealthServicesRegulationsandCoordination,COVID-19 seroprevalence in Pakistan: a cross-sectional study,2022-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Pakistan,,,"This was a nationwide study in the four provinces (Punjab, Sindh, Baluchistan and Khyber Pakhtunkhwa) and two regions (Azad Jammu & Kashmir (AJK) and Gilgit Baltistan (GB)) of Pakistan. Individuals of all ages and genders were eligible to participate.","exclusion criteria: contraindications to venipuncture however, no such case was encountered",2020-10-21,2020-11-08,Household and community samples,All,Multiple groups,,,Geographical area,Gilgit,500,0.17,,,,,,,,Stratified probability,Novel Corona Virus (SARS-CoV-2) IgM/IgG Rapid Test Kit,Bioperfectus,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,0.9500000000000001,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Ahsan Ahmad,Ministry of National Health Services Regulations and Coordination,Unity-Aligned,https://bmjopen.bmj.com/content/12/4/e055381.abstract,2022-04-12,2024-03-01,Verified,ahmad_covid-19_2022,PAK
220520_Pakistan_GetzPharma_IgGorIgM,220520_Pakistan_GetzPharma,Seroprevalence and characteristics of Coronavirus Disease (COVID-19) in workers with non-specific disease symptoms,2022-05-20,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Pakistan,Sindh; Punjab; Khyber Pakhtunkhwa; Balochistan.,Karachi; Lahore; Multan; Peshawar; and Quetta.,"""Participants between 18 to 65 years of age were recruited during April-September 2020 from the workplaces, including factories, corporates, restaurants, media houses, schools, banks, and hospitals, located in Karachi, Lahore, Multan, Peshawar, and Quetta"".","""non-consenting individuals, PCR-positive at the time of screening, having past 14-days history of COVID-19 and COVID-19 vaccine trials’ participants were excluded.""",2020-04-15,2020-09-15,Multiple populations,All,Adults (18-64 years),18.0,65.0,Primary Estimate,IgG and/or IgM,17764,0.1582,,,True,,,,True,Convenience,IgG/IgM Test Kit (Colloidal gold),Getz Pharma,LFIA,Serum,"['IgG', 'IgM']",,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Wajiha Javed,Getz Pharma,Not Unity-Aligned,https://doi.org/10.1186/s12879-022-07461-9,2022-05-30,2024-03-01,Unverified,javed_seroprevalence_2022,PAK
220524_KhyberPakhtunkhwa_KhyberMedicalUniversity_SecondWave,220524_KhyberPakhtunkhwa_KhyberMedicalUniversity,"Comparison of SARS-CoV-2 antibodies seroprevalence during second and third waves of COVID-19 among healthy blood donors of Khyber Pakhtunkhwa, province of Pakistan",2022-05-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Pakistan,Khyber Pakhtunkhw,Peshawar,"- collected from Regional Blood Center(RBC) Peshawar, Pakistan
- data from the second wave (November 2020 to January 2020) and the third wave of Covid-19
- healthy blood donors",,2020-11-01,2021-01-01,Blood donors,All,Adults (18-64 years),18.0,60.0,Primary Estimate,,2100,0.56,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown)","Abbott Laboratories,Roche Diagnostics",CLIA,Whole Blood,,,Validated by manufacturers,,,['Missing'],,No,Yes,No,,Unclear,Yes,No,,M. Khan,Khyber Medical University,Not Unity-Aligned,https://dx.doi.org/10.1111/vox.13285,2022-07-06,2024-03-01,Unverified,ISBT2022Abstract2022a,PAK
220620_Peshawar_RegionalBloodCentre_Overall,220620_Peshawar_RegionalBloodCentre,"Seroprevalence of Sars-Cov-2 antibodies among eligible blood donors of Peshawar, Pakistan",2022-06-20,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Pakistan,Khyber Pakhtunkhwa,Peshawar,"""... confirm that the donors meet selection criteria following National Guidelines for Quality Control in Transfusion Medicine. The process aims to ensure that the donors are healthy and free of transmissible infectious diseases.""","""... hose who were not eligible [according to the the WHO and National Guidelines “Blood Donor Selection Criteria”] were excluded from the study.""",2020-11-15,2021-06-15,Residual sera,All,Multiple groups,18.0,,Primary Estimate,,4047,0.59,,,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,,Nucleocapsid(N-protein),,1.0,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Muhammad Nisar Khan,Regional Blood Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301020/,2022-08-03,2024-03-29,Verified,khanSeroprevalenceSarsCov2Antibodies2022,PAK
220620_Peshawar_RegionalBloodCentre_55plus,220620_Peshawar_RegionalBloodCentre,"Seroprevalence of Sars-Cov-2 antibodies among eligible blood donors of Peshawar, Pakistan",2022-06-20,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Pakistan,Khyber Pakhtunkhwa,Peshawar,"""... confirm that the donors meet selection criteria following National Guidelines for Quality Control in Transfusion Medicine. The process aims to ensure that the donors are healthy and free of transmissible infectious diseases.""","""... hose who were not eligible [according to the the WHO and National Guidelines “Blood Donor Selection Criteria”] were excluded from the study.""",2020-11-15,2021-06-15,Residual sera,All,Multiple groups,55.0,,Age,55+,7,0.429,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,,Nucleocapsid(N-protein),,1.0,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Muhammad Nisar Khan,Regional Blood Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301020/,2022-08-03,2024-03-29,Verified,khanSeroprevalenceSarsCov2Antibodies2022,PAK
220620_Peshawar_RegionalBloodCentre_Baseline,220620_Peshawar_RegionalBloodCentre,"Seroprevalence of Sars-Cov-2 antibodies among eligible blood donors of Peshawar, Pakistan",2022-06-20,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Pakistan,Khyber Pakhtunkhwa,Peshawar,"""... confirm that the donors meet selection criteria following National Guidelines for Quality Control in Transfusion Medicine. The process aims to ensure that the donors are healthy and free of transmissible infectious diseases.""","""... hose who were not eligible [according to the the WHO and National Guidelines “Blood Donor Selection Criteria”] were excluded from the study.""",2020-11-15,2020-12-15,Residual sera,All,Multiple groups,18.0,,Time frame,November-December 2020,382,0.454,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,,Nucleocapsid(N-protein),,1.0,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Muhammad Nisar Khan,Regional Blood Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301020/,2022-08-03,2024-03-29,Verified,khanSeroprevalenceSarsCov2Antibodies2022,PAK
220620_Peshawar_RegionalBloodCentre_25to34,220620_Peshawar_RegionalBloodCentre,"Seroprevalence of Sars-Cov-2 antibodies among eligible blood donors of Peshawar, Pakistan",2022-06-20,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Pakistan,Khyber Pakhtunkhwa,Peshawar,"""... confirm that the donors meet selection criteria following National Guidelines for Quality Control in Transfusion Medicine. The process aims to ensure that the donors are healthy and free of transmissible infectious diseases.""","""... hose who were not eligible [according to the the WHO and National Guidelines “Blood Donor Selection Criteria”] were excluded from the study.""",2020-11-15,2021-06-15,Residual sera,All,Adults (18-64 years),25.0,34.0,Age,25-34,1543,0.595,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,,Nucleocapsid(N-protein),,1.0,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Muhammad Nisar Khan,Regional Blood Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301020/,2022-08-03,2024-03-29,Verified,khanSeroprevalenceSarsCov2Antibodies2022,PAK
220620_Peshawar_RegionalBloodCentre_Wave2,220620_Peshawar_RegionalBloodCentre,"Seroprevalence of Sars-Cov-2 antibodies among eligible blood donors of Peshawar, Pakistan",2022-06-20,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Pakistan,Khyber Pakhtunkhwa,Peshawar,"""... confirm that the donors meet selection criteria following National Guidelines for Quality Control in Transfusion Medicine. The process aims to ensure that the donors are healthy and free of transmissible infectious diseases.""","""... hose who were not eligible [according to the the WHO and National Guidelines “Blood Donor Selection Criteria”] were excluded from the study.""",2021-01-15,2021-02-15,Residual sera,All,Multiple groups,18.0,,Time frame,January-February 2021,1765,0.56,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,,Nucleocapsid(N-protein),,1.0,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Muhammad Nisar Khan,Regional Blood Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301020/,2022-08-03,2024-03-29,Verified,khanSeroprevalenceSarsCov2Antibodies2022,PAK
220620_Peshawar_RegionalBloodCentre_35to44,220620_Peshawar_RegionalBloodCentre,"Seroprevalence of Sars-Cov-2 antibodies among eligible blood donors of Peshawar, Pakistan",2022-06-20,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Pakistan,Khyber Pakhtunkhwa,Peshawar,"""... confirm that the donors meet selection criteria following National Guidelines for Quality Control in Transfusion Medicine. The process aims to ensure that the donors are healthy and free of transmissible infectious diseases.""","""... hose who were not eligible [according to the the WHO and National Guidelines “Blood Donor Selection Criteria”] were excluded from the study.""",2020-11-15,2021-06-15,Residual sera,All,Adults (18-64 years),35.0,44.0,Age,35-44,604,0.596,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,,Nucleocapsid(N-protein),,1.0,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Muhammad Nisar Khan,Regional Blood Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301020/,2022-08-03,2024-03-29,Verified,khanSeroprevalenceSarsCov2Antibodies2022,PAK
220620_Peshawar_RegionalBloodCentre_Female,220620_Peshawar_RegionalBloodCentre,"Seroprevalence of Sars-Cov-2 antibodies among eligible blood donors of Peshawar, Pakistan",2022-06-20,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Pakistan,Khyber Pakhtunkhwa,Peshawar,"""... confirm that the donors meet selection criteria following National Guidelines for Quality Control in Transfusion Medicine. The process aims to ensure that the donors are healthy and free of transmissible infectious diseases.""","""... hose who were not eligible [according to the the WHO and National Guidelines “Blood Donor Selection Criteria”] were excluded from the study.""",2020-11-15,2021-06-15,Residual sera,Female,Multiple groups,18.0,,Sex/Gender,Female,47,0.277,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,,Nucleocapsid(N-protein),,1.0,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Muhammad Nisar Khan,Regional Blood Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301020/,2022-08-03,2024-03-29,Verified,khanSeroprevalenceSarsCov2Antibodies2022,PAK
220620_Peshawar_RegionalBloodCentre_45to54,220620_Peshawar_RegionalBloodCentre,"Seroprevalence of Sars-Cov-2 antibodies among eligible blood donors of Peshawar, Pakistan",2022-06-20,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Pakistan,Khyber Pakhtunkhwa,Peshawar,"""... confirm that the donors meet selection criteria following National Guidelines for Quality Control in Transfusion Medicine. The process aims to ensure that the donors are healthy and free of transmissible infectious diseases.""","""... hose who were not eligible [according to the the WHO and National Guidelines “Blood Donor Selection Criteria”] were excluded from the study.""",2020-11-15,2021-06-15,Residual sera,All,Adults (18-64 years),45.0,54.0,Age,45-54,97,0.649,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,,Nucleocapsid(N-protein),,1.0,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Muhammad Nisar Khan,Regional Blood Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301020/,2022-08-03,2024-03-29,Verified,khanSeroprevalenceSarsCov2Antibodies2022,PAK
220620_Peshawar_RegionalBloodCentre_Wave3,220620_Peshawar_RegionalBloodCentre,"Seroprevalence of Sars-Cov-2 antibodies among eligible blood donors of Peshawar, Pakistan",2022-06-20,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Pakistan,Khyber Pakhtunkhwa,Peshawar,"""... confirm that the donors meet selection criteria following National Guidelines for Quality Control in Transfusion Medicine. The process aims to ensure that the donors are healthy and free of transmissible infectious diseases.""","""... hose who were not eligible [according to the the WHO and National Guidelines “Blood Donor Selection Criteria”] were excluded from the study.""",2021-03-15,2021-06-15,Residual sera,All,Multiple groups,18.0,,Time frame,March-June 2021,1900,0.65,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,,Nucleocapsid(N-protein),,1.0,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Muhammad Nisar Khan,Regional Blood Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301020/,2022-08-03,2024-03-29,Verified,khanSeroprevalenceSarsCov2Antibodies2022,PAK
220620_Peshawar_RegionalBloodCentre_Male,220620_Peshawar_RegionalBloodCentre,"Seroprevalence of Sars-Cov-2 antibodies among eligible blood donors of Peshawar, Pakistan",2022-06-20,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Pakistan,Khyber Pakhtunkhwa,Peshawar,"""... confirm that the donors meet selection criteria following National Guidelines for Quality Control in Transfusion Medicine. The process aims to ensure that the donors are healthy and free of transmissible infectious diseases.""","""... hose who were not eligible [according to the the WHO and National Guidelines “Blood Donor Selection Criteria”] were excluded from the study.""",2020-11-15,2021-06-15,Residual sera,Male,Multiple groups,18.0,,Sex/Gender,Male,4000,0.595,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,,Nucleocapsid(N-protein),,1.0,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Muhammad Nisar Khan,Regional Blood Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301020/,2022-08-03,2024-03-29,Verified,khanSeroprevalenceSarsCov2Antibodies2022,PAK
220620_Peshawar_RegionalBloodCentre_18to24,220620_Peshawar_RegionalBloodCentre,"Seroprevalence of Sars-Cov-2 antibodies among eligible blood donors of Peshawar, Pakistan",2022-06-20,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Pakistan,Khyber Pakhtunkhwa,Peshawar,"""... confirm that the donors meet selection criteria following National Guidelines for Quality Control in Transfusion Medicine. The process aims to ensure that the donors are healthy and free of transmissible infectious diseases.""","""... hose who were not eligible [according to the the WHO and National Guidelines “Blood Donor Selection Criteria”] were excluded from the study.""",2020-11-15,2021-06-15,Residual sera,All,Adults (18-64 years),18.0,24.0,Age,18-24,1796,0.583,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,,Nucleocapsid(N-protein),,1.0,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Muhammad Nisar Khan,Regional Blood Centre,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301020/,2022-08-03,2024-03-29,Verified,khanSeroprevalenceSarsCov2Antibodies2022,PAK
20220824_Karachi_AgaKhanUniverstiy_Primary,20220824_Karachi_AgaKhanUniversity,IgG antibodies to SARS-CoV-2 in asymptomatic blood donors at two time points in Karachi.,2022-08-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Pakistan,Sindh,Karachi,Adult blood donors aged 18 years and over who presented to the blood bank for donations between December 2020 and February 2021," Any donor with a history of COVID-19 related symptoms or confirmed infection was excluded from enrollment as a blood donor. However, this exclusion criteria did not prevent recruitment of those who were asymptomatically or paucisymptomatically infected at the time of donation.",2020-12-15,2021-02-15,Blood donors,All,Adults (18-64 years),17.0,53.0,Primary Estimate,"A, B, AB, O",558,0.534,,,,,,,True,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Unknown",,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,1.0,0.9109999999999999,['High'],,No,No,Yes,,Unclear,Yes,No,,Muhammad Hasan,Aga Khan University Hospital ,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0271259,2022-09-23,2022-09-23,Unverified,hasan_igg_2022,PAK
220920_Peshawar_PeshawarDentalCollege_overall,220920_Peshawar_PeshawarDentalCollege,Prevalence of SARS-COV-2 Antibodies in Dental Healthcare Providers,2022-09-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Pakistan,Khyber Pakhtunkhwa,Peshawar,"""All the dental staffs working in the [Peshawar] dental college and hospital were included... The dental staff included senior faculty, trainees/medical officers, house officers, dental assistants, ancillary staff and administrative/support staff.""",,2020-01-01,2020-12-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,133,0.3308,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Shawana Iqbal,Peshawar Dental College,Not Unity-Aligned,https://dx.doi.org/10.53350/pjmhs22168335,2022-10-17,2022-10-20,Unverified,iqbalPrevalenceSARSCOV2Antibodies2022,PAK
220920_Peshawar_PeshawarDentalCollege_upto40,220920_Peshawar_PeshawarDentalCollege,Prevalence of SARS-COV-2 Antibodies in Dental Healthcare Providers,2022-09-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Pakistan,Khyber Pakhtunkhwa,Peshawar,"""All the dental staffs working in the [Peshawar] dental college and hospital were included... The dental staff included senior faculty, trainees/medical officers, house officers, dental assistants, ancillary staff and administrative/support staff.""",,2020-01-01,2020-12-31,Health care workers and caregivers,All,Adults (18-64 years),,40.0,Age,,123,0.3333,,,,,,,,Convenience,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Shawana Iqbal,Peshawar Dental College,Not Unity-Aligned,https://dx.doi.org/10.53350/pjmhs22168335,2022-10-17,2022-10-20,Unverified,iqbalPrevalenceSARSCOV2Antibodies2022,PAK
220920_Peshawar_PeshawarDentalCollege_40plus,220920_Peshawar_PeshawarDentalCollege,Prevalence of SARS-COV-2 Antibodies in Dental Healthcare Providers,2022-09-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Pakistan,Khyber Pakhtunkhwa,Peshawar,"""All the dental staffs working in the [Peshawar] dental college and hospital were included... The dental staff included senior faculty, trainees/medical officers, house officers, dental assistants, ancillary staff and administrative/support staff.""",,2020-01-01,2020-12-31,Health care workers and caregivers,All,Adults (18-64 years),40.0,,Age,,10,0.3,,,,,,,,Convenience,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Shawana Iqbal,Peshawar Dental College,Not Unity-Aligned,https://dx.doi.org/10.53350/pjmhs22168335,2022-10-17,2022-10-20,Unverified,iqbalPrevalenceSARSCOV2Antibodies2022,PAK
221212_USA_RTIInternational_Pakistan,221212_USA_RTIInternational_Pakistan,"COVID-19 Antibody Positivity Over Time and Pregnancy Outcomes in Seven Low-and-Middle-Income Countries: A Prospective, Observational Study of the Global Network for Women's and Children's Health Research.",2022-12-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Pakistan,,,"""The COVID-19 antibody study, embedded within the MNHR, included a sub-set of women who were approached at delivery and enrolled. We collected a serum sample at or near delivery for each mother who was approached and consented.""", Women who did not consent to give blood for testing. Indeterminate results are excluded. ,2020-10-01,2020-10-31,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,2031,0.20500000000000002,,,True,,,,True,Convenience,ELISA SARS-CoV-2 IgG Test System,Zeus,ELISA,Serum,IgG,"Nucleocapsid (N-protein), Spike",,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Robert L. Goldenberg,RTI International,Unity-Aligned,https://dx.doi.org/10.1111/1471-0528.17366,2022-12-24,2024-03-01,Unverified,goldenberg_covid-19_2022,PAK
221217_IbrahimHyderi_AgaKhanUniversity_Children_Baseline_Primary,221217_IbrahimHyderi_AgaKhanUniversity_Children_Baseline,Prevalence and risk factors of Severe Acute Respiratory Syndrome Coronavirus 2 infection in women and children in peri-urban communities in Pakistan: A prospective cohort study.,2022-12-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,Pakistan,,Karachi,"""All women and their children enrolled in the AMANHI biobank study who were residing in the study area at the time of the study were eligible to be part of this survey"" (From study). "" consented pregnant women, in their local or preferred languages, to undergo a screening ultrasound scan to date he pregnancies accurately. They enrolled women if the ul-
trasound-estimated gestational age of the pregnancy was
within the eligibility cut-offs (gestation 8 to <20 weeks).
Women were consented for the screening scan, follow-up
and biosample collection."" (From original study description of cohort""",,2021-03-15,2021-06-15,Household and community samples,All,Children and Youth (0-17 years),2.0,,Primary Estimate,,1097,0.184,0.161,0.207,True,True,,,True,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.885,1.0,['Moderate'],Yes,Unclear,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Nadia Ansari,Aga Khan University,Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.95955,2023-01-13,2024-04-10,Verified,ansari_prevalence_2022,PAK
221217_IbrahimHyderi_AgaKhanUniversity_Children_Baseline_Age37-48months,221217_IbrahimHyderi_AgaKhanUniversity_Children_Baseline,Prevalence and risk factors of Severe Acute Respiratory Syndrome Coronavirus 2 infection in women and children in peri-urban communities in Pakistan: A prospective cohort study.,2022-12-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,Pakistan,,Karachi,"""All women and their children enrolled in the AMANHI biobank study who were residing in the study area at the time of the study were eligible to be part of this survey"" (From study). "" consented pregnant women, in their local or preferred languages, to undergo a screening ultrasound scan to date he pregnancies accurately. They enrolled women if the ul-
trasound-estimated gestational age of the pregnancy was
within the eligibility cut-offs (gestation 8 to <20 weeks).
Women were consented for the screening scan, follow-up
and biosample collection."" (From original study description of cohort""",,2021-03-15,2021-06-15,Household and community samples,All,Children and Youth (0-17 years),3.0,4.0,Age,37-48 months,246,0.196,0.149,0.247,,True,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.885,1.0,['Moderate'],Yes,Unclear,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Nadia Ansari,Aga Khan University,Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.95955,2023-01-13,2024-04-10,Verified,ansari_prevalence_2022,PAK
221217_IbrahimHyderi_AgaKhanUniversity_Children_Baseline_Age24-36months,221217_IbrahimHyderi_AgaKhanUniversity_Children_Baseline,Prevalence and risk factors of Severe Acute Respiratory Syndrome Coronavirus 2 infection in women and children in peri-urban communities in Pakistan: A prospective cohort study.,2022-12-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,Pakistan,,Karachi,"""All women and their children enrolled in the AMANHI biobank study who were residing in the study area at the time of the study were eligible to be part of this survey"" (From study). "" consented pregnant women, in their local or preferred languages, to undergo a screening ultrasound scan to date he pregnancies accurately. They enrolled women if the ul-
trasound-estimated gestational age of the pregnancy was
within the eligibility cut-offs (gestation 8 to <20 weeks).
Women were consented for the screening scan, follow-up
and biosample collection."" (From original study description of cohort""",,2021-03-15,2021-06-15,Household and community samples,All,Children and Youth (0-17 years),2.0,3.0,Age,24-36 months,340,0.174,0.135,0.21600000000000003,,True,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.885,1.0,['Moderate'],Yes,Unclear,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Nadia Ansari,Aga Khan University,Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.95955,2023-01-13,2024-04-10,Verified,ansari_prevalence_2022,PAK
221217_IbrahimHyderi_AgaKhanUniversity_Children_Baseline_Age49+months,221217_IbrahimHyderi_AgaKhanUniversity_Children_Baseline,Prevalence and risk factors of Severe Acute Respiratory Syndrome Coronavirus 2 infection in women and children in peri-urban communities in Pakistan: A prospective cohort study.,2022-12-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,Pakistan,,Karachi,"""All women and their children enrolled in the AMANHI biobank study who were residing in the study area at the time of the study were eligible to be part of this survey"" (From study). "" consented pregnant women, in their local or preferred languages, to undergo a screening ultrasound scan to date he pregnancies accurately. They enrolled women if the ul-
trasound-estimated gestational age of the pregnancy was
within the eligibility cut-offs (gestation 8 to <20 weeks).
Women were consented for the screening scan, follow-up
and biosample collection."" (From original study description of cohort""",,2021-03-15,2021-06-15,Household and community samples,All,Children and Youth (0-17 years),4.0,,Age,49+ months,511,0.187,0.155,0.22100000000000003,,True,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.885,1.0,['Moderate'],Yes,Unclear,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Nadia Ansari,Aga Khan University,Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.95955,2023-01-13,2024-04-10,Verified,ansari_prevalence_2022,PAK
221217_IbrahimHyderi_AgaKhanUniversity_Children_Baseline_Males,221217_IbrahimHyderi_AgaKhanUniversity_Children_Baseline,Prevalence and risk factors of Severe Acute Respiratory Syndrome Coronavirus 2 infection in women and children in peri-urban communities in Pakistan: A prospective cohort study.,2022-12-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,Pakistan,,Karachi,"""All women and their children enrolled in the AMANHI biobank study who were residing in the study area at the time of the study were eligible to be part of this survey"" (From study). "" consented pregnant women, in their local or preferred languages, to undergo a screening ultrasound scan to date he pregnancies accurately. They enrolled women if the ul-
trasound-estimated gestational age of the pregnancy was
within the eligibility cut-offs (gestation 8 to <20 weeks).
Women were consented for the screening scan, follow-up
and biosample collection."" (From original study description of cohort""",,2021-03-15,2021-06-15,Household and community samples,Male,Children and Youth (0-17 years),2.0,,Sex/Gender,Males,565,0.171,0.139,0.20199999999999999,,True,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.885,1.0,['Moderate'],Yes,Unclear,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Nadia Ansari,Aga Khan University,Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.95955,2023-01-13,2024-04-10,Verified,ansari_prevalence_2022,PAK
221217_IbrahimHyderi_AgaKhanUniversity_Children_Baseline_Females,221217_IbrahimHyderi_AgaKhanUniversity_Children_Baseline,Prevalence and risk factors of Severe Acute Respiratory Syndrome Coronavirus 2 infection in women and children in peri-urban communities in Pakistan: A prospective cohort study.,2022-12-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,Pakistan,,Karachi,"""All women and their children enrolled in the AMANHI biobank study who were residing in the study area at the time of the study were eligible to be part of this survey"" (From study). "" consented pregnant women, in their local or preferred languages, to undergo a screening ultrasound scan to date he pregnancies accurately. They enrolled women if the ul-
trasound-estimated gestational age of the pregnancy was
within the eligibility cut-offs (gestation 8 to <20 weeks).
Women were consented for the screening scan, follow-up
and biosample collection."" (From original study description of cohort""",,2021-03-15,2021-06-15,Household and community samples,Female,Children and Youth (0-17 years),2.0,,Sex/Gender,Females,532,0.198,0.165,0.231,,True,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.885,1.0,['Moderate'],Yes,Unclear,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Nadia Ansari,Aga Khan University,Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.95955,2023-01-13,2024-04-10,Verified,ansari_prevalence_2022,PAK
221217_IbrahimHyderi_AgaKhanUniversity_Children_Follow-up_Primary,221217_IbrahimHyderi_AgaKhanUniversity_Children_Follow-up,Prevalence and risk factors of Severe Acute Respiratory Syndrome Coronavirus 2 infection in women and children in peri-urban communities in Pakistan: A prospective cohort study.,2022-12-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,Pakistan,,Karachi,"""All women and their children enrolled in the AMANHI biobank study who were residing in the study area at the time of the study were eligible to be part of this survey"" (From study). "" consented pregnant women, in their local or preferred languages, to undergo a screening ultrasound scan to date he pregnancies accurately. They enrolled women if the ul-
trasound-estimated gestational age of the pregnancy was
within the eligibility cut-offs (gestation 8 to <20 weeks).
Women were consented for the screening scan, follow-up
and biosample collection."" (From original study description of cohort""","Refused consent + Women who reported fever and cough or any three of the following symptoms viz fever, cough, sore throat, fatigue, headache, runny nose, loss of taste or smell, nausea, vomiting, and diarrhoea, were referred to the nearest COVID-19 diagnostic testing facility (not tested for ABs)",2021-09-15,2021-12-15,Household and community samples,All,Children and Youth (0-17 years),2.0,,Primary Estimate,,1063,0.574,0.543,0.603,True,True,,,True,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.885,1.0,['Moderate'],Yes,Unclear,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Nadia Ansari,Aga Khan University,Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.95955,2023-01-13,2024-04-10,Verified,ansari_prevalence_2022,PAK
221217_IbrahimHyderi_AgaKhanUniversity_Children_Follow-up_Age37-48months,221217_IbrahimHyderi_AgaKhanUniversity_Children_Follow-up,Prevalence and risk factors of Severe Acute Respiratory Syndrome Coronavirus 2 infection in women and children in peri-urban communities in Pakistan: A prospective cohort study.,2022-12-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,Pakistan,,Karachi,"""All women and their children enrolled in the AMANHI biobank study who were residing in the study area at the time of the study were eligible to be part of this survey"" (From study). "" consented pregnant women, in their local or preferred languages, to undergo a screening ultrasound scan to date he pregnancies accurately. They enrolled women if the ul-
trasound-estimated gestational age of the pregnancy was
within the eligibility cut-offs (gestation 8 to <20 weeks).
Women were consented for the screening scan, follow-up
and biosample collection."" (From original study description of cohort""","Refused consent + Women who reported fever and cough or any three of the following symptoms viz fever, cough, sore throat, fatigue, headache, runny nose, loss of taste or smell, nausea, vomiting, and diarrhoea, were referred to the nearest COVID-19 diagnostic testing facility (not tested for ABs)",2021-09-15,2021-12-15,Household and community samples,All,Children and Youth (0-17 years),3.0,4.0,Age,37-48 months,398,0.546,0.49600000000000005,0.594,,True,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.885,1.0,['Moderate'],Yes,Unclear,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Nadia Ansari,Aga Khan University,Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.95955,2023-01-13,2024-04-10,Verified,ansari_prevalence_2022,PAK
221217_IbrahimHyderi_AgaKhanUniversity_Children_Follow-up_Age49+months,221217_IbrahimHyderi_AgaKhanUniversity_Children_Follow-up,Prevalence and risk factors of Severe Acute Respiratory Syndrome Coronavirus 2 infection in women and children in peri-urban communities in Pakistan: A prospective cohort study.,2022-12-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,Pakistan,,Karachi,"""All women and their children enrolled in the AMANHI biobank study who were residing in the study area at the time of the study were eligible to be part of this survey"" (From study). "" consented pregnant women, in their local or preferred languages, to undergo a screening ultrasound scan to date he pregnancies accurately. They enrolled women if the ul-
trasound-estimated gestational age of the pregnancy was
within the eligibility cut-offs (gestation 8 to <20 weeks).
Women were consented for the screening scan, follow-up
and biosample collection."" (From original study description of cohort""","Refused consent + Women who reported fever and cough or any three of the following symptoms viz fever, cough, sore throat, fatigue, headache, runny nose, loss of taste or smell, nausea, vomiting, and diarrhoea, were referred to the nearest COVID-19 diagnostic testing facility (not tested for ABs)",2021-09-15,2021-12-15,Household and community samples,All,Children and Youth (0-17 years),4.0,,Age,49+ months,579,0.601,0.559,0.639,,True,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.885,1.0,['Moderate'],Yes,Unclear,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Nadia Ansari,Aga Khan University,Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.95955,2023-01-13,2024-04-10,Verified,ansari_prevalence_2022,PAK
221217_IbrahimHyderi_AgaKhanUniversity_Children_Follow-up_Males,221217_IbrahimHyderi_AgaKhanUniversity_Children_Follow-up,Prevalence and risk factors of Severe Acute Respiratory Syndrome Coronavirus 2 infection in women and children in peri-urban communities in Pakistan: A prospective cohort study.,2022-12-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,Pakistan,,Karachi,"""All women and their children enrolled in the AMANHI biobank study who were residing in the study area at the time of the study were eligible to be part of this survey"" (From study). "" consented pregnant women, in their local or preferred languages, to undergo a screening ultrasound scan to date he pregnancies accurately. They enrolled women if the ul-
trasound-estimated gestational age of the pregnancy was
within the eligibility cut-offs (gestation 8 to <20 weeks).
Women were consented for the screening scan, follow-up
and biosample collection."" (From original study description of cohort""","Refused consent + Women who reported fever and cough or any three of the following symptoms viz fever, cough, sore throat, fatigue, headache, runny nose, loss of taste or smell, nausea, vomiting, and diarrhoea, were referred to the nearest COVID-19 diagnostic testing facility (not tested for ABs)",2021-09-15,2021-12-15,Household and community samples,Male,Children and Youth (0-17 years),2.0,,Sex/Gender,Males,545,0.5710000000000001,0.528,0.61,,True,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.885,1.0,['Moderate'],Yes,Unclear,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Nadia Ansari,Aga Khan University,Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.95955,2023-01-13,2024-04-10,Verified,ansari_prevalence_2022,PAK
221217_IbrahimHyderi_AgaKhanUniversity_Children_Follow-up_Females,221217_IbrahimHyderi_AgaKhanUniversity_Children_Follow-up,Prevalence and risk factors of Severe Acute Respiratory Syndrome Coronavirus 2 infection in women and children in peri-urban communities in Pakistan: A prospective cohort study.,2022-12-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,Pakistan,,Karachi,"""All women and their children enrolled in the AMANHI biobank study who were residing in the study area at the time of the study were eligible to be part of this survey"" (From study). "" consented pregnant women, in their local or preferred languages, to undergo a screening ultrasound scan to date he pregnancies accurately. They enrolled women if the ul-
trasound-estimated gestational age of the pregnancy was
within the eligibility cut-offs (gestation 8 to <20 weeks).
Women were consented for the screening scan, follow-up
and biosample collection."" (From original study description of cohort""","Refused consent + Women who reported fever and cough or any three of the following symptoms viz fever, cough, sore throat, fatigue, headache, runny nose, loss of taste or smell, nausea, vomiting, and diarrhoea, were referred to the nearest COVID-19 diagnostic testing facility (not tested for ABs)",2021-09-15,2021-12-15,Household and community samples,Female,Children and Youth (0-17 years),2.0,,Sex/Gender,Females,518,0.5760000000000001,0.532,0.617,,True,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.885,1.0,['Moderate'],Yes,Unclear,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Nadia Ansari,Aga Khan University,Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.95955,2023-01-13,2024-04-10,Verified,ansari_prevalence_2022,PAK
221217_IbrahimHyderi_AgaKhanUniversity_Children_Follow-up_Age24-36months,221217_IbrahimHyderi_AgaKhanUniversity_Children_Follow-up,Prevalence and risk factors of Severe Acute Respiratory Syndrome Coronavirus 2 infection in women and children in peri-urban communities in Pakistan: A prospective cohort study.,2022-12-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,Pakistan,,Karachi,"""All women and their children enrolled in the AMANHI biobank study who were residing in the study area at the time of the study were eligible to be part of this survey"" (From study). "" consented pregnant women, in their local or preferred languages, to undergo a screening ultrasound scan to date he pregnancies accurately. They enrolled women if the ul-
trasound-estimated gestational age of the pregnancy was
within the eligibility cut-offs (gestation 8 to <20 weeks).
Women were consented for the screening scan, follow-up
and biosample collection."" (From original study description of cohort""","Refused consent + Women who reported fever and cough or any three of the following symptoms viz fever, cough, sore throat, fatigue, headache, runny nose, loss of taste or smell, nausea, vomiting, and diarrhoea, were referred to the nearest COVID-19 diagnostic testing facility (not tested for ABs)",2021-09-15,2021-12-15,Household and community samples,All,Children and Youth (0-17 years),2.0,3.0,Age,24-36 months,86,0.51,0.399,0.616,,True,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.885,1.0,['Moderate'],Yes,Unclear,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Nadia Ansari,Aga Khan University,Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.95955,2023-01-13,2024-04-10,Verified,ansari_prevalence_2022,PAK
221217_IbrahimHyderi_AgaKhanUniversity_Women_Baseline_Primary,221217_IbrahimHyderi_AgaKhanUniversity_Women_Baseline,Prevalence and risk factors of Severe Acute Respiratory Syndrome Coronavirus 2 infection in women and children in peri-urban communities in Pakistan: A prospective cohort study.,2022-12-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,Pakistan,,Karachi,"""All women and their children enrolled in the AMANHI biobank study who were residing in the study area at the time of the study were eligible to be part of this survey"" (From study). "" consented pregnant women, in their local or preferred languages, to undergo a screening ultrasound scan to date he pregnancies accurately. They enrolled women if the ul-
trasound-estimated gestational age of the pregnancy was
within the eligibility cut-offs (gestation 8 to <20 weeks).
Women were consented for the screening scan, follow-up
and biosample collection."" (From original study description of cohort""",,2021-03-15,2021-06-15,Pregnant or parturient women,Female,Adults (18-64 years),20.0,,Primary Estimate,,1414,0.45299999999999996,0.42600000000000005,0.479,True,True,,,True,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.885,1.0,['Moderate'],Yes,Unclear,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Nadia Ansari,Aga Khan University,Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.95955,2023-01-13,2024-04-10,Verified,ansari_prevalence_2022,PAK
221217_IbrahimHyderi_AgaKhanUniversity_Women_Baseline_Age40+,221217_IbrahimHyderi_AgaKhanUniversity_Women_Baseline,Prevalence and risk factors of Severe Acute Respiratory Syndrome Coronavirus 2 infection in women and children in peri-urban communities in Pakistan: A prospective cohort study.,2022-12-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,Pakistan,,Karachi,"""All women and their children enrolled in the AMANHI biobank study who were residing in the study area at the time of the study were eligible to be part of this survey"" (From study). "" consented pregnant women, in their local or preferred languages, to undergo a screening ultrasound scan to date he pregnancies accurately. They enrolled women if the ul-
trasound-estimated gestational age of the pregnancy was
within the eligibility cut-offs (gestation 8 to <20 weeks).
Women were consented for the screening scan, follow-up
and biosample collection."" (From original study description of cohort""",,2021-03-15,2021-06-15,Pregnant or parturient women,Female,Adults (18-64 years),40.0,,Age,40+,122,0.484,0.397,0.5710000000000001,,True,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.885,1.0,['Moderate'],Yes,Unclear,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Nadia Ansari,Aga Khan University,Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.95955,2023-01-13,2024-04-10,Verified,ansari_prevalence_2022,PAK
221217_IbrahimHyderi_AgaKhanUniversity_Women_Baseline_Age30-39,221217_IbrahimHyderi_AgaKhanUniversity_Women_Baseline,Prevalence and risk factors of Severe Acute Respiratory Syndrome Coronavirus 2 infection in women and children in peri-urban communities in Pakistan: A prospective cohort study.,2022-12-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,Pakistan,,Karachi,"""All women and their children enrolled in the AMANHI biobank study who were residing in the study area at the time of the study were eligible to be part of this survey"" (From study). "" consented pregnant women, in their local or preferred languages, to undergo a screening ultrasound scan to date he pregnancies accurately. They enrolled women if the ul-
trasound-estimated gestational age of the pregnancy was
within the eligibility cut-offs (gestation 8 to <20 weeks).
Women were consented for the screening scan, follow-up
and biosample collection."" (From original study description of cohort""",,2021-03-15,2021-06-15,Pregnant or parturient women,Female,Adults (18-64 years),30.0,39.0,Age,30-39,787,0.443,0.408,0.47700000000000004,,True,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.885,1.0,['Moderate'],Yes,Unclear,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Nadia Ansari,Aga Khan University,Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.95955,2023-01-13,2024-04-10,Verified,ansari_prevalence_2022,PAK
221217_IbrahimHyderi_AgaKhanUniversity_Women_Baseline_Age20-29,221217_IbrahimHyderi_AgaKhanUniversity_Women_Baseline,Prevalence and risk factors of Severe Acute Respiratory Syndrome Coronavirus 2 infection in women and children in peri-urban communities in Pakistan: A prospective cohort study.,2022-12-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,Pakistan,,Karachi,"""All women and their children enrolled in the AMANHI biobank study who were residing in the study area at the time of the study were eligible to be part of this survey"" (From study). "" consented pregnant women, in their local or preferred languages, to undergo a screening ultrasound scan to date he pregnancies accurately. They enrolled women if the ul-
trasound-estimated gestational age of the pregnancy was
within the eligibility cut-offs (gestation 8 to <20 weeks).
Women were consented for the screening scan, follow-up
and biosample collection."" (From original study description of cohort""",,2021-03-15,2021-06-15,Pregnant or parturient women,Female,Adults (18-64 years),20.0,29.0,Age,20-29,505,0.461,0.41500000000000004,0.504,,True,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.885,1.0,['Moderate'],Yes,Unclear,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Nadia Ansari,Aga Khan University,Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.95955,2023-01-13,2024-04-10,Verified,ansari_prevalence_2022,PAK
221217_IbrahimHyderi_AgaKhanUniversity_Women_Follow-up_Primary,221217_IbrahimHyderi_AgaKhanUniversity_Women_Follow-up,Prevalence and risk factors of Severe Acute Respiratory Syndrome Coronavirus 2 infection in women and children in peri-urban communities in Pakistan: A prospective cohort study.,2022-12-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,Pakistan,,Karachi,"""All women and their children enrolled in the AMANHI biobank study who were residing in the study area at the time of the study were eligible to be part of this survey"" (From study). "" consented pregnant women, in their local or preferred languages, to undergo a screening ultrasound scan to date he pregnancies accurately. They enrolled women if the ul-
trasound-estimated gestational age of the pregnancy was
within the eligibility cut-offs (gestation 8 to <20 weeks).
Women were consented for the screening scan, follow-up
and biosample collection."" (From original study description of cohort""","Refused consent + Women who reported fever and cough or any three of the following symptoms viz fever, cough, sore throat, fatigue, headache, runny nose, loss of taste or smell, nausea, vomiting, and diarrhoea, were referred to the nearest COVID-19 diagnostic testing facility (not tested for ABs)",2021-09-15,2021-12-15,Pregnant or parturient women,Female,Adults (18-64 years),20.0,,Primary Estimate,,1142,0.823,0.799,0.8440000000000001,True,True,,,True,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.885,1.0,['Moderate'],Yes,Unclear,Yes,No,Yes,Yes,Yes,Yes,Unclear,Nadia Ansari,Aga Khan University,Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.95955,2023-01-13,2024-04-10,Verified,ansari_prevalence_2022,PAK
221217_IbrahimHyderi_AgaKhanUniversity_Women_Follow-up_Age20-29,221217_IbrahimHyderi_AgaKhanUniversity_Women_Follow-up,Prevalence and risk factors of Severe Acute Respiratory Syndrome Coronavirus 2 infection in women and children in peri-urban communities in Pakistan: A prospective cohort study.,2022-12-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,Pakistan,,Karachi,"""All women and their children enrolled in the AMANHI biobank study who were residing in the study area at the time of the study were eligible to be part of this survey"" (From study). "" consented pregnant women, in their local or preferred languages, to undergo a screening ultrasound scan to date he pregnancies accurately. They enrolled women if the ul-
trasound-estimated gestational age of the pregnancy was
within the eligibility cut-offs (gestation 8 to <20 weeks).
Women were consented for the screening scan, follow-up
and biosample collection."" (From original study description of cohort""","Refused consent + Women who reported fever and cough or any three of the following symptoms viz fever, cough, sore throat, fatigue, headache, runny nose, loss of taste or smell, nausea, vomiting, and diarrhoea, were referred to the nearest COVID-19 diagnostic testing facility (not tested for ABs)",2021-09-15,2021-12-15,Pregnant or parturient women,Female,Adults (18-64 years),20.0,29.0,Age,20-29,408,0.833,0.793,0.867,,True,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.885,1.0,['Moderate'],Yes,Unclear,Yes,No,Yes,Yes,Yes,Yes,Unclear,Nadia Ansari,Aga Khan University,Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.95955,2023-01-13,2024-04-10,Verified,ansari_prevalence_2022,PAK
221217_IbrahimHyderi_AgaKhanUniversity_Women_Follow-up_Age40+,221217_IbrahimHyderi_AgaKhanUniversity_Women_Follow-up,Prevalence and risk factors of Severe Acute Respiratory Syndrome Coronavirus 2 infection in women and children in peri-urban communities in Pakistan: A prospective cohort study.,2022-12-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,Pakistan,,Karachi,"""All women and their children enrolled in the AMANHI biobank study who were residing in the study area at the time of the study were eligible to be part of this survey"" (From study). "" consented pregnant women, in their local or preferred languages, to undergo a screening ultrasound scan to date he pregnancies accurately. They enrolled women if the ul-
trasound-estimated gestational age of the pregnancy was
within the eligibility cut-offs (gestation 8 to <20 weeks).
Women were consented for the screening scan, follow-up
and biosample collection."" (From original study description of cohort""","Refused consent + Women who reported fever and cough or any three of the following symptoms viz fever, cough, sore throat, fatigue, headache, runny nose, loss of taste or smell, nausea, vomiting, and diarrhoea, were referred to the nearest COVID-19 diagnostic testing facility (not tested for ABs)",2021-09-15,2021-12-15,Pregnant or parturient women,Female,Adults (18-64 years),40.0,,Age,40+,110,0.865,0.792,0.9209999999999999,,True,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.885,1.0,['Moderate'],Yes,Unclear,Yes,No,Yes,Yes,Yes,Yes,Unclear,Nadia Ansari,Aga Khan University,Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.95955,2023-01-13,2024-04-10,Verified,ansari_prevalence_2022,PAK
221217_IbrahimHyderi_AgaKhanUniversity_Women_Follow-up_Age30-39,221217_IbrahimHyderi_AgaKhanUniversity_Women_Follow-up,Prevalence and risk factors of Severe Acute Respiratory Syndrome Coronavirus 2 infection in women and children in peri-urban communities in Pakistan: A prospective cohort study.,2022-12-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,Pakistan,,Karachi,"""All women and their children enrolled in the AMANHI biobank study who were residing in the study area at the time of the study were eligible to be part of this survey"" (From study). "" consented pregnant women, in their local or preferred languages, to undergo a screening ultrasound scan to date he pregnancies accurately. They enrolled women if the ul-
trasound-estimated gestational age of the pregnancy was
within the eligibility cut-offs (gestation 8 to <20 weeks).
Women were consented for the screening scan, follow-up
and biosample collection."" (From original study description of cohort""","Refused consent + Women who reported fever and cough or any three of the following symptoms viz fever, cough, sore throat, fatigue, headache, runny nose, loss of taste or smell, nausea, vomiting, and diarrhoea, were referred to the nearest COVID-19 diagnostic testing facility (not tested for ABs)",2021-09-15,2021-12-15,Pregnant or parturient women,Female,Adults (18-64 years),30.0,39.0,Age,30-39,624,0.804,0.7709999999999999,0.8340000000000001,,True,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.885,1.0,['Moderate'],Yes,Unclear,Yes,No,Yes,Yes,Yes,Yes,Unclear,Nadia Ansari,Aga Khan University,Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.95955,2023-01-13,2024-04-10,Verified,ansari_prevalence_2022,PAK
230215_Pakistan_DrZiauddinHospital_Primary,230215_Pakistan_DrZiauddinHospital,Point of Care Testing for SARS-COV-2 Antibodies before doing Endoscopy,2023-02-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,Pakistan,,Karachi,"""This prospective, cross-sectional study included patients requiring endoscopy procedure, who are asymptomatic for COVID-19 infection.","""Patients with a positive PCR for COVID-19 and those with symptoms
specific for COVID-19 i.e., fever, cough, Shortness of breath etc. were excluded from the study.""",2020-10-15,2021-04-15,Residual sera,All,Multiple groups,13.0,92.0,Primary Estimate,,207,0.115,,,True,,,,True,Sequential,Novel Coronavirus IgG/IgM test kit,Genrui Biotech,LFIA,,"['IgG', 'IgM']",,,,,['High'],,No,No,Yes,,No,Yes,No,,Abeer Altaf,Dr. Ziauddin Hospital,Not Unity-Aligned,https://dx.doi.org/10.12669/pjms.39.2.5659,2023-03-06,2024-03-01,Unverified,altaf_point_2023,PAK
230301_Baqai_BaqaiMedicalUniversity,230301_Baqai_BaqaiMedicalUniversity,IDF2022-0286 Presence of SARS-CoV-2 antibodies in asymptomatic type 1 diabetes; is there any association between glycemic control,2023-03-01,Presentation or Conference,Local,Cross-sectional survey ,Pakistan,Karachi,Baqai,Type 1 diabetes patients,,2021-06-15,2021-11-15,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),,,Primary Estimate,,300,0.19,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,[],[],,,,['High'],,No,No,Yes,,Unclear,Yes,No,,A. Fawwad,Baqai Medical University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.diabres.2023.110510,2023-10-05,2023-10-05,Unverified,fawwad_idf2022-0286_2023,PAK
230303_Karachi_DowInternationalMedicalCollege,230303_Karachi_DowInternationalMedicalCollege,"Seroprevalence of SARS-CoV-2 (COVID-19) antibodies in tertiary care hospital of Karachi, Pakistan",2023-03-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Pakistan,,Karachi,"""This cross-sectional observational study included
patients registered for anti-SARS-CoV-2 antibodies
investigation in the DDRRL from August to December
2020 ... All registered COVID-19 antibodies
cases of all ages and gender were included in this study. ""","""Duplicated samples or with missing information are excluded.""",2020-08-01,2020-12-31,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,5247,0.462,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),,1.0,0.995,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Ambreen Fatima,Dow International Medical Colleg,Not Unity-Aligned,https://www.rmj.org.pk/fulltext/27-1662180772.pdf,2023-04-05,2024-03-01,Unverified,fatimaSeroprevalenceSARSCoV2COVID192023,PAK
230720_Pakistan_JawaharlalNehruMedicalCollege_Overall,230720_Pakistan_JawaharlalNehruMedicalCollege,COVID-19 symptoms and antibody positivity among unvaccinated pregnant women: An observational study in seven countries from the Global Network,2023-07-20,Journal Article (Peer-Reviewed),National,Prospective cohort,Pakistan,,,staff (registry administrators [RAs]) identified pregnant women in their respective clusters,vaccinated pregnant women,2020-10-01,2022-06-30,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,2892,0.268,,,True,,,,True,Stratified non-probability,Not reported/ Unable to specify,,,Serum,,,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Avinash Kavi,Jawaharlal Nehru Medical College,Not Unity-Aligned,https://dx.doi.org/10.1111/1471-0528.17604,2023-08-22,2023-08-23,Unverified,kavi_covid-19_2023,PAK
230727_Karachi_AgaKhanUniversity_Dec2021_adj,230727_Karachi_AgaKhanUniversity_Dec2021,"Community-based seroprevalence of SARS CoV-2 in an urban district of Karachi, Pakistan",2023-07-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Pakistan,Karachi,,All household members were eligible to participate regardless of age and infection status in the District East of Karachi,,2021-12-01,2021-12-31,Household and community samples,All,Multiple groups,,,Analysis,,506,0.849,0.785,0.923,True,True,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Muhammad Imran Nisar,Aga Khan University,Not Unity-Aligned,https://www.joghr.org/article/84241-community-based-seroprevalence-of-sars-cov-2-in-an-urban-district-of-karachi-pakistan,2023-08-23,2023-08-25,Unverified,nisarCommunitybasedSeroprevalenceSARS2023,PAK
230727_Karachi_AgaKhanUniversity_Dec2021_unadj,230727_Karachi_AgaKhanUniversity_Dec2021,"Community-based seroprevalence of SARS CoV-2 in an urban district of Karachi, Pakistan",2023-07-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Pakistan,Karachi,,All household members were eligible to participate regardless of age and infection status in the District East of Karachi,,2021-12-01,2021-12-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,506,0.763,,,,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Muhammad Imran Nisar,Aga Khan University,Not Unity-Aligned,https://www.joghr.org/article/84241-community-based-seroprevalence-of-sars-cov-2-in-an-urban-district-of-karachi-pakistan,2023-08-23,2023-08-25,Unverified,nisarCommunitybasedSeroprevalenceSARS2023,PAK
230727_Karachi_AgaKhanUniversity_Feb2021_adj,230727_Karachi_AgaKhanUniversity_Feb2021,"Community-based seroprevalence of SARS CoV-2 in an urban district of Karachi, Pakistan",2023-07-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Pakistan,Karachi,,All household members were eligible to participate regardless of age and infection status in the District East of Karachi,,2021-02-01,2021-02-28,Household and community samples,All,Multiple groups,,,Analysis,,532,0.539,0.455,0.632,True,True,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Muhammad Imran Nisar,Aga Khan University,Not Unity-Aligned,https://www.joghr.org/article/84241-community-based-seroprevalence-of-sars-cov-2-in-an-urban-district-of-karachi-pakistan,2023-08-23,2023-08-25,Unverified,nisarCommunitybasedSeroprevalenceSARS2023,PAK
230727_Karachi_AgaKhanUniversity_Feb2021_unadj,230727_Karachi_AgaKhanUniversity_Feb2021,"Community-based seroprevalence of SARS CoV-2 in an urban district of Karachi, Pakistan",2023-07-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Pakistan,Karachi,,All household members were eligible to participate regardless of age and infection status in the District East of Karachi,,2021-02-01,2021-02-28,Household and community samples,All,Multiple groups,,,Primary Estimate,,532,0.474,,,,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Muhammad Imran Nisar,Aga Khan University,Not Unity-Aligned,https://www.joghr.org/article/84241-community-based-seroprevalence-of-sars-cov-2-in-an-urban-district-of-karachi-pakistan,2023-08-23,2023-08-25,Unverified,nisarCommunitybasedSeroprevalenceSARS2023,PAK
230727_Karachi_AgaKhanUniversity_Nov2020_adj,230727_Karachi_AgaKhanUniversity_Nov2020,"Community-based seroprevalence of SARS CoV-2 in an urban district of Karachi, Pakistan",2023-07-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Pakistan,Karachi,,All household members were eligible to participate regardless of age and infection status in the District East of Karachi,,2020-11-01,2020-11-30,Household and community samples,All,Multiple groups,,,Analysis,,500,0.24,0.18,0.31,True,True,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Muhammad Imran Nisar,Aga Khan University,Not Unity-Aligned,https://www.joghr.org/article/84241-community-based-seroprevalence-of-sars-cov-2-in-an-urban-district-of-karachi-pakistan,2023-08-23,2023-08-25,Unverified,nisarCommunitybasedSeroprevalenceSARS2023,PAK
230727_Karachi_AgaKhanUniversity_Nov2020_unadj,230727_Karachi_AgaKhanUniversity_Nov2020,"Community-based seroprevalence of SARS CoV-2 in an urban district of Karachi, Pakistan",2023-07-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Pakistan,Karachi,,All household members were eligible to participate regardless of age and infection status in the District East of Karachi,,2020-11-01,2020-11-30,Household and community samples,All,Multiple groups,,,Primary Estimate,,500,0.262,,,,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Muhammad Imran Nisar,Aga Khan University,Not Unity-Aligned,https://www.joghr.org/article/84241-community-based-seroprevalence-of-sars-cov-2-in-an-urban-district-of-karachi-pakistan,2023-08-23,2023-08-25,Unverified,nisarCommunitybasedSeroprevalenceSARS2023,PAK
210302_Panama_InstitutodeInvestigacionesCientíficasyServiciosdeAltaTecnología_BloodDonors,210302_Panama_InstitutodeInvestigacionesCientíficasyServiciosdeAltaTecnología_BloodDonors,Performance of a Point of Care Test for Detecting IgM and IgG Antibodies Against SARS-CoV-2 and Seroprevalence in Blood Donors and Health Care Workers in Panama,2021-03-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Panama,,"Panama City,
Colon","The inclusion criteria were being an adult over 18 years old and providing written informed consent. All study participants completed a clinical screening survey for COVID-19-related symptoms and consented to submit samples for screening of other infections. Only healthy blood donors (HD) that tested negative for other infectious diseases, including Chagas disease, HIV, HBV, HAV, and HTLV1, were invited to participate in our study.",The exclusion criteria comprised those with missing data and patients in intensive and semi-intensive care units.,2020-04-30,2020-07-07,Blood donors,All,Multiple groups,18.0,79.0,Primary Estimate,Primary,255,0.1333,,,True,,,,True,Convenience,Author designed (ELISA) - Nucleocapsid,,LFIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by developers,0.8701000000000001,0.9889,['High'],No,No,No,Yes,Unclear,Unclear,Yes,No,,Alcibiades Villarreal,"Instituto de Investigaciones Científicas y
Servicios de Alta Tecnología",Unity-Aligned,https://www.frontiersin.org/articles/10.3389/fmed.2021.616106/full,2021-04-07,2022-07-16,Verified,villarreal_performance_2021,PAN
210302_Panama_InstitutodeInvestigacionesCientíficasyServiciosdeAltaTecnología_BloodDonors_60-79yrs,210302_Panama_InstitutodeInvestigacionesCientíficasyServiciosdeAltaTecnología_BloodDonors,Performance of a Point of Care Test for Detecting IgM and IgG Antibodies Against SARS-CoV-2 and Seroprevalence in Blood Donors and Health Care Workers in Panama,2021-03-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Panama,,"Panama City,
Colon","The inclusion criteria were being an adult over 18 years old and providing written informed consent. All study participants completed a clinical screening survey for COVID-19-related symptoms and consented to submit samples for screening of other infections. Only healthy blood donors (HD) that tested negative for other infectious diseases, including Chagas disease, HIV, HBV, HAV, and HTLV1, were invited to participate in our study.",The exclusion criteria comprised those with missing data and patients in intensive and semi-intensive care units.,2020-04-30,2020-07-07,Blood donors,All,Multiple groups,60.0,79.0,Age,60-79 years,7,0.0,,,,,,,,Convenience,Author designed (ELISA) - Nucleocapsid,,LFIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by developers,0.8701000000000001,0.9889,['High'],No,No,No,Yes,Unclear,Unclear,Yes,No,,Alcibiades Villarreal,"Instituto de Investigaciones Científicas y
Servicios de Alta Tecnología",Unity-Aligned,https://www.frontiersin.org/articles/10.3389/fmed.2021.616106/full,2021-04-07,2022-07-16,Verified,villarreal_performance_2021,PAN
210302_Panama_InstitutodeInvestigacionesCientíficasyServiciosdeAltaTecnología_BloodDonors_20-39yrs,210302_Panama_InstitutodeInvestigacionesCientíficasyServiciosdeAltaTecnología_BloodDonors,Performance of a Point of Care Test for Detecting IgM and IgG Antibodies Against SARS-CoV-2 and Seroprevalence in Blood Donors and Health Care Workers in Panama,2021-03-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Panama,,"Panama City,
Colon","The inclusion criteria were being an adult over 18 years old and providing written informed consent. All study participants completed a clinical screening survey for COVID-19-related symptoms and consented to submit samples for screening of other infections. Only healthy blood donors (HD) that tested negative for other infectious diseases, including Chagas disease, HIV, HBV, HAV, and HTLV1, were invited to participate in our study.",The exclusion criteria comprised those with missing data and patients in intensive and semi-intensive care units.,2020-04-30,2020-07-07,Blood donors,All,Adults (18-64 years),20.0,39.0,Age,20-39 years,141,0.156,,,,,,,,Convenience,Author designed (ELISA) - Nucleocapsid,,LFIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by developers,0.8701000000000001,0.9889,['High'],No,No,No,Yes,Unclear,Unclear,Yes,No,,Alcibiades Villarreal,"Instituto de Investigaciones Científicas y
Servicios de Alta Tecnología",Unity-Aligned,https://www.frontiersin.org/articles/10.3389/fmed.2021.616106/full,2021-04-07,2022-07-16,Verified,villarreal_performance_2021,PAN
210302_Panama_InstitutodeInvestigacionesCientíficasyServiciosdeAltaTecnología_BloodDonors_<20yrs,210302_Panama_InstitutodeInvestigacionesCientíficasyServiciosdeAltaTecnología_BloodDonors,Performance of a Point of Care Test for Detecting IgM and IgG Antibodies Against SARS-CoV-2 and Seroprevalence in Blood Donors and Health Care Workers in Panama,2021-03-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Panama,,"Panama City, Colon","The inclusion criteria were being an adult over 18 years old and providing written informed consent. All study participants completed a clinical screening survey for COVID-19-related symptoms and consented to submit samples for screening of other infections. Only healthy blood donors (HD) that tested negative for other infectious diseases, including Chagas disease, HIV, HBV, HAV, and HTLV1, were invited to participate in our study.",The exclusion criteria comprised those with missing data and patients in intensive and semi-intensive care units.,2020-04-30,2020-07-07,Blood donors,All,Adults (18-64 years),18.0,19.0,Age,<20 years,7,0.1429,,,,,,,,Convenience,Author designed (ELISA) - Nucleocapsid,,LFIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by developers,0.8701000000000001,0.9889,['High'],No,No,No,Yes,Unclear,Unclear,Yes,No,,Alcibiades Villarreal,"Instituto de Investigaciones Científicas y
Servicios de Alta Tecnología",Unity-Aligned,https://www.frontiersin.org/articles/10.3389/fmed.2021.616106/full,2021-09-05,2022-07-16,Verified,villarreal_performance_2021,PAN
210302_Panama_InstitutodeInvestigacionesCientíficasyServiciosdeAltaTecnología_BloodDonors_Male,210302_Panama_InstitutodeInvestigacionesCientíficasyServiciosdeAltaTecnología_BloodDonors,Performance of a Point of Care Test for Detecting IgM and IgG Antibodies Against SARS-CoV-2 and Seroprevalence in Blood Donors and Health Care Workers in Panama,2021-03-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Panama,,"Panama City,
Colon","The inclusion criteria were being an adult over 18 years old and providing written informed consent. All study participants completed a clinical screening survey for COVID-19-related symptoms and consented to submit samples for screening of other infections. Only healthy blood donors (HD) that tested negative for other infectious diseases, including Chagas disease, HIV, HBV, HAV, and HTLV1, were invited to participate in our study.",The exclusion criteria comprised those with missing data and patients in intensive and semi-intensive care units.,2020-04-30,2020-07-07,Blood donors,Male,Multiple groups,18.0,79.0,Sex/Gender,Male,181,0.12710000000000002,,,,,,,,Convenience,Author designed (ELISA) - Nucleocapsid,,LFIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by developers,0.8701000000000001,0.9889,['High'],No,No,No,Yes,Unclear,Unclear,Yes,No,,Alcibiades Villarreal,"Instituto de Investigaciones Científicas y
Servicios de Alta Tecnología",Unity-Aligned,https://www.frontiersin.org/articles/10.3389/fmed.2021.616106/full,2021-04-07,2022-07-16,Verified,villarreal_performance_2021,PAN
210302_Panama_InstitutodeInvestigacionesCientíficasyServiciosdeAltaTecnología_BloodDonors_40-59yrs,210302_Panama_InstitutodeInvestigacionesCientíficasyServiciosdeAltaTecnología_BloodDonors,Performance of a Point of Care Test for Detecting IgM and IgG Antibodies Against SARS-CoV-2 and Seroprevalence in Blood Donors and Health Care Workers in Panama,2021-03-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Panama,,"Panama City,
Colon","The inclusion criteria were being an adult over 18 years old and providing written informed consent. All study participants completed a clinical screening survey for COVID-19-related symptoms and consented to submit samples for screening of other infections. Only healthy blood donors (HD) that tested negative for other infectious diseases, including Chagas disease, HIV, HBV, HAV, and HTLV1, were invited to participate in our study.",The exclusion criteria comprised those with missing data and patients in intensive and semi-intensive care units.,2020-04-30,2020-07-07,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,40-59 years,100,0.11,,,,,,,,Convenience,Author designed (ELISA) - Nucleocapsid,,LFIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by developers,0.8701000000000001,0.9889,['High'],No,No,No,Yes,Unclear,Unclear,Yes,No,,Alcibiades Villarreal,"Instituto de Investigaciones Científicas y
Servicios de Alta Tecnología",Unity-Aligned,https://www.frontiersin.org/articles/10.3389/fmed.2021.616106/full,2021-04-07,2022-07-16,Verified,villarreal_performance_2021,PAN
210302_Panama_InstitutodeInvestigacionesCientíficasyServiciosdeAltaTecnología_BloodDonors_Female,210302_Panama_InstitutodeInvestigacionesCientíficasyServiciosdeAltaTecnología_BloodDonors,Performance of a Point of Care Test for Detecting IgM and IgG Antibodies Against SARS-CoV-2 and Seroprevalence in Blood Donors and Health Care Workers in Panama,2021-03-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Panama,,"Panama City,
Colon","The inclusion criteria were being an adult over 18 years old and providing written informed consent. All study participants completed a clinical screening survey for COVID-19-related symptoms and consented to submit samples for screening of other infections. Only healthy blood donors (HD) that tested negative for other infectious diseases, including Chagas disease, HIV, HBV, HAV, and HTLV1, were invited to participate in our study.",The exclusion criteria comprised those with missing data and patients in intensive and semi-intensive care units.,2020-04-30,2020-07-07,Blood donors,Female,Multiple groups,18.0,79.0,Sex/Gender,Female,74,0.1486,,,,,,,,Convenience,Author designed (ELISA) - Nucleocapsid,,LFIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by developers,0.8701000000000001,0.9889,['High'],No,No,No,Yes,Unclear,Unclear,Yes,No,,Alcibiades Villarreal,"Instituto de Investigaciones Científicas y
Servicios de Alta Tecnología",Unity-Aligned,https://www.frontiersin.org/articles/10.3389/fmed.2021.616106/full,2021-04-07,2022-07-16,Verified,villarreal_performance_2021,PAN
210302_Panama_InstitutodeInvestigacionesCientíficasyServiciosdeAltaTecnología_HCWs,210302_Panama_InstitutodeInvestigacionesCientíficasyServiciosdeAltaTecnología_HCWs,Performance of a Point of Care Test for Detecting IgM and IgG Antibodies Against SARS-CoV-2 and Seroprevalence in Blood Donors and Health Care Workers in Panama,2021-03-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Panama,,"Panama City,
Colon","The inclusion criteria were being an adult over 18 years old and providing written informed consent. All study participants completed a clinical screening survey for COVID-19-related symptoms and consented to submit samples for screening of other infections. Only healthy blood donors (HD) that tested negative for other infectious diseases, including Chagas disease, HIV, HBV, HAV, and HTLV1, were invited to participate in our study.",The exclusion criteria comprised those with missing data and patients in intensive and semi-intensive care units.,2020-04-30,2020-07-07,Health care workers and caregivers,All,Multiple groups,18.0,79.0,Primary Estimate,Primary,351,0.1282,,,True,,,,True,Unclear,Author designed (ELISA) - Nucleocapsid,,LFIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by developers,0.8701000000000001,0.9889,['High'],Yes,Unclear,No,Yes,Unclear,Unclear,Yes,No,Unclear,Alcibiades Villarreal,"Instituto de Investigaciones Científicas y
Servicios de Alta Tecnología",Not Unity-Aligned,https://www.frontiersin.org/articles/10.3389/fmed.2021.616106/full,2021-04-07,2022-07-16,Verified,villarreal_performance_2021,PAN
210302_Panama_InstitutodeInvestigacionesCientíficasyServiciosdeAltaTecnología_HCWs_20-39yrs ,210302_Panama_InstitutodeInvestigacionesCientíficasyServiciosdeAltaTecnología_HCWs,Performance of a Point of Care Test for Detecting IgM and IgG Antibodies Against SARS-CoV-2 and Seroprevalence in Blood Donors and Health Care Workers in Panama,2021-03-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Panama,,"Panama City,
Colon","The inclusion criteria were being an adult over 18 years old and providing written informed consent. All study participants completed a clinical screening survey for COVID-19-related symptoms and consented to submit samples for screening of other infections. Only healthy blood donors (HD) that tested negative for other infectious diseases, including Chagas disease, HIV, HBV, HAV, and HTLV1, were invited to participate in our study.",The exclusion criteria comprised those with missing data and patients in intensive and semi-intensive care units.,2020-04-30,2020-07-07,Health care workers and caregivers,All,Adults (18-64 years),20.0,39.0,Age,20-39 years,198,0.11109999999999999,,,,,,,,Unclear,Author designed (ELISA) - Nucleocapsid,,LFIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by developers,0.8701000000000001,0.9889,['High'],Yes,Unclear,No,Yes,Unclear,Unclear,Yes,No,Unclear,Alcibiades Villarreal,"Instituto de Investigaciones Científicas y
Servicios de Alta Tecnología",Not Unity-Aligned,https://www.frontiersin.org/articles/10.3389/fmed.2021.616106/full,2021-04-07,2022-07-16,Verified,villarreal_performance_2021,PAN
210302_Panama_InstitutodeInvestigacionesCientíficasyServiciosdeAltaTecnología_HCWs_40-59yrs ,210302_Panama_InstitutodeInvestigacionesCientíficasyServiciosdeAltaTecnología_HCWs,Performance of a Point of Care Test for Detecting IgM and IgG Antibodies Against SARS-CoV-2 and Seroprevalence in Blood Donors and Health Care Workers in Panama,2021-03-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Panama,,"Panama City,
Colon","The inclusion criteria were being an adult over 18 years old and providing written informed consent. All study participants completed a clinical screening survey for COVID-19-related symptoms and consented to submit samples for screening of other infections. Only healthy blood donors (HD) that tested negative for other infectious diseases, including Chagas disease, HIV, HBV, HAV, and HTLV1, were invited to participate in our study.",The exclusion criteria comprised those with missing data and patients in intensive and semi-intensive care units.,2020-04-30,2020-07-07,Health care workers and caregivers,All,Adults (18-64 years),40.0,59.0,Age,40-59 years,137,0.1387,,,,,,,,Unclear,Author designed (ELISA) - Nucleocapsid,,LFIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by developers,0.8701000000000001,0.9889,['High'],Yes,Unclear,No,Yes,Unclear,Unclear,Yes,No,Unclear,Alcibiades Villarreal,"Instituto de Investigaciones Científicas y
Servicios de Alta Tecnología",Not Unity-Aligned,https://www.frontiersin.org/articles/10.3389/fmed.2021.616106/full,2021-04-07,2022-07-16,Verified,villarreal_performance_2021,PAN
210302_Panama_InstitutodeInvestigacionesCientíficasyServiciosdeAltaTecnología_HCWs_60-79yrs,210302_Panama_InstitutodeInvestigacionesCientíficasyServiciosdeAltaTecnología_HCWs,Performance of a Point of Care Test for Detecting IgM and IgG Antibodies Against SARS-CoV-2 and Seroprevalence in Blood Donors and Health Care Workers in Panama,2021-03-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Panama,,"Panama City,
Colon","The inclusion criteria were being an adult over 18 years old and providing written informed consent. All study participants completed a clinical screening survey for COVID-19-related symptoms and consented to submit samples for screening of other infections. Only healthy blood donors (HD) that tested negative for other infectious diseases, including Chagas disease, HIV, HBV, HAV, and HTLV1, were invited to participate in our study.",The exclusion criteria comprised those with missing data and patients in intensive and semi-intensive care units.,2020-04-30,2020-07-07,Health care workers and caregivers,All,Multiple groups,60.0,79.0,Age,60-79 years,19,0.21050000000000002,,,,,,,,Unclear,Author designed (ELISA) - Nucleocapsid,,LFIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by developers,0.8701000000000001,0.9889,['High'],Yes,Unclear,No,Yes,Unclear,Unclear,Yes,No,Unclear,Alcibiades Villarreal,"Instituto de Investigaciones Científicas y
Servicios de Alta Tecnología",Not Unity-Aligned,https://www.frontiersin.org/articles/10.3389/fmed.2021.616106/full,2021-04-07,2022-07-16,Verified,villarreal_performance_2021,PAN
201215_CiudaddelEste_MinisteriodeSaludPública_primary,201215_CiudaddelEste_MinisteriodeSaludPública,30% of those tested in the East had Covid,2020-12-15,News and Media,Local,Cross-sectional survey ,Paraguay,,Ciudad del Este,"Households in Ciudad del Este,",,2020-11-29,2020-12-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,1675,0.3,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['Moderate'],Yes,Unclear,Yes,No,No,Unclear,Yes,No,Yes,,Ministerio de Salud Pública,Not Unity-Aligned,https://www.ultimahora.com/el-30-testeados-el-este-tuvieron-covid-n2918654.html,2021-04-22,2022-07-16,Verified,noauthor_30_nodate,PRY
220615_Paraguay_MinisteriodeSaludPublicayBienestarSocial_Overall,220615_Paraguay_MinisteriodeSaludPublicayBienestarSocial,COVID 19 infection: age-stratified population-based cohort seroepidemiological study in Asuncion and Central,2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Paraguay,Central Department,Asunción,prospective cohort study in inhabitants of the health regions of Asunción and Center of Paraguay. ,,2020-12-22,2021-03-15,Household and community samples,All,Multiple groups,,,Primary Estimate,accumulative round 1-3,1699,0.269,0.24800000000000003,0.29100000000000004,True,,,,True,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.84,0.87,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Agueda Cabello,Ministerio de Salud Pública y Bienestar Social ,Unity-Aligned,https://dx.doi.org/10.4067/s0716-10182022000200238,2022-10-20,2024-04-17,Verified,cabello_covid_2022,PRY
220615_Paraguay_MinisteriodeSaludPublicayBienestarSocial_Age20to29,220615_Paraguay_MinisteriodeSaludPublicayBienestarSocial,COVID 19 infection: age-stratified population-based cohort seroepidemiological study in Asuncion and Central,2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Paraguay,Central Department,Asunción,prospective cohort study in inhabitants of the health regions of Asunción and Center of Paraguay. ,,2020-12-22,2021-03-15,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,age: 20-29,273,0.29300000000000004,,,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.84,0.87,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Agueda Cabello,Ministerio de Salud Pública y Bienestar Social ,Unity-Aligned,https://dx.doi.org/10.4067/s0716-10182022000200238,2022-10-20,2024-04-17,Verified,cabello_covid_2022,PRY
220615_Paraguay_MinisteriodeSaludPublicayBienestarSocial_Round2,220615_Paraguay_MinisteriodeSaludPublicayBienestarSocial,COVID 19 infection: age-stratified population-based cohort seroepidemiological study in Asuncion and Central,2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Paraguay,Central Department,Asunción,prospective cohort study in inhabitants of the health regions of Asunción and Center of Paraguay. ,,2021-01-12,2021-01-26,Household and community samples,All,Multiple groups,,,Time frame,round 2,898,0.193,0.168,0.22,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.84,0.87,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Agueda Cabello,Ministerio de Salud Pública y Bienestar Social ,Unity-Aligned,https://dx.doi.org/10.4067/s0716-10182022000200238,2022-10-20,2024-04-17,Verified,cabello_covid_2022,PRY
220615_Paraguay_MinisteriodeSaludPublicayBienestarSocial_AgeBelow5,220615_Paraguay_MinisteriodeSaludPublicayBienestarSocial,COVID 19 infection: age-stratified population-based cohort seroepidemiological study in Asuncion and Central,2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Paraguay,Central Department,Asunción,prospective cohort study in inhabitants of the health regions of Asunción and Center of Paraguay. ,,2020-12-22,2021-03-15,Household and community samples,All,Children and Youth (0-17 years),,5.0,Age,age: < 5,30,0.267,,,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.84,0.87,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Agueda Cabello,Ministerio de Salud Pública y Bienestar Social ,Unity-Aligned,https://dx.doi.org/10.4067/s0716-10182022000200238,2022-10-20,2024-04-17,Verified,cabello_covid_2022,PRY
220615_Paraguay_MinisteriodeSaludPublicayBienestarSocial_AgeOver60,220615_Paraguay_MinisteriodeSaludPublicayBienestarSocial,COVID 19 infection: age-stratified population-based cohort seroepidemiological study in Asuncion and Central,2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Paraguay,Central Department,Asunción,prospective cohort study in inhabitants of the health regions of Asunción and Center of Paraguay. ,,2020-12-22,2021-03-15,Household and community samples,All,Multiple groups,60.0,,Age,age: >= 60,379,0.24800000000000003,,,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.84,0.87,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Agueda Cabello,Ministerio de Salud Pública y Bienestar Social ,Unity-Aligned,https://dx.doi.org/10.4067/s0716-10182022000200238,2022-10-20,2024-04-17,Verified,cabello_covid_2022,PRY
220615_Paraguay_MinisteriodeSaludPublicayBienestarSocial_Age40to49,220615_Paraguay_MinisteriodeSaludPublicayBienestarSocial,COVID 19 infection: age-stratified population-based cohort seroepidemiological study in Asuncion and Central,2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Paraguay,Central Department,Asunción,prospective cohort study in inhabitants of the health regions of Asunción and Center of Paraguay. ,,2020-12-22,2021-03-15,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,age: 40-49,215,0.26,,,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.84,0.87,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Agueda Cabello,Ministerio de Salud Pública y Bienestar Social ,Unity-Aligned,https://dx.doi.org/10.4067/s0716-10182022000200238,2022-10-20,2024-04-17,Verified,cabello_covid_2022,PRY
220615_Paraguay_MinisteriodeSaludPublicayBienestarSocial_Round3,220615_Paraguay_MinisteriodeSaludPublicayBienestarSocial,COVID 19 infection: age-stratified population-based cohort seroepidemiological study in Asuncion and Central,2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Paraguay,Central Department,Asunción,prospective cohort study in inhabitants of the health regions of Asunción and Center of Paraguay. ,,2021-02-02,2021-03-15,Household and community samples,All,Multiple groups,,,Time frame,round 3,916,0.22399999999999998,0.198,0.255,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.84,0.87,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Agueda Cabello,Ministerio de Salud Pública y Bienestar Social ,Unity-Aligned,https://dx.doi.org/10.4067/s0716-10182022000200238,2022-10-20,2024-04-17,Verified,cabello_covid_2022,PRY
220615_Paraguay_MinisteriodeSaludPublicayBienestarSocial_Age15to19,220615_Paraguay_MinisteriodeSaludPublicayBienestarSocial,COVID 19 infection: age-stratified population-based cohort seroepidemiological study in Asuncion and Central,2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Paraguay,Central Department,Asunción,prospective cohort study in inhabitants of the health regions of Asunción and Center of Paraguay. ,,2020-12-22,2021-03-15,Household and community samples,All,Children and Youth (0-17 years),15.0,19.0,Age,age: 15-19,108,0.29600000000000004,,,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.84,0.87,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Agueda Cabello,Ministerio de Salud Pública y Bienestar Social ,Unity-Aligned,https://dx.doi.org/10.4067/s0716-10182022000200238,2022-10-20,2024-04-17,Verified,cabello_covid_2022,PRY
220615_Paraguay_MinisteriodeSaludPublicayBienestarSocial_Age5to14,220615_Paraguay_MinisteriodeSaludPublicayBienestarSocial,COVID 19 infection: age-stratified population-based cohort seroepidemiological study in Asuncion and Central,2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Paraguay,Central Department,Asunción,prospective cohort study in inhabitants of the health regions of Asunción and Center of Paraguay. ,,2020-12-22,2021-03-15,Household and community samples,All,Children and Youth (0-17 years),5.0,14.0,Age,age: 5-14,125,0.21600000000000003,,,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.84,0.87,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Agueda Cabello,Ministerio de Salud Pública y Bienestar Social ,Unity-Aligned,https://dx.doi.org/10.4067/s0716-10182022000200238,2022-10-20,2024-04-17,Verified,cabello_covid_2022,PRY
220615_Paraguay_MinisteriodeSaludPublicayBienestarSocial_Age50to59,220615_Paraguay_MinisteriodeSaludPublicayBienestarSocial,COVID 19 infection: age-stratified population-based cohort seroepidemiological study in Asuncion and Central,2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Paraguay,Central Department,Asunción,prospective cohort study in inhabitants of the health regions of Asunción and Center of Paraguay. ,,2020-12-22,2021-03-15,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,age: 50-59,238,0.24800000000000003,,,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.84,0.87,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Agueda Cabello,Ministerio de Salud Pública y Bienestar Social ,Unity-Aligned,https://dx.doi.org/10.4067/s0716-10182022000200238,2022-10-20,2024-04-17,Verified,cabello_covid_2022,PRY
220615_Paraguay_MinisteriodeSaludPublicayBienestarSocial_Age30to39,220615_Paraguay_MinisteriodeSaludPublicayBienestarSocial,COVID 19 infection: age-stratified population-based cohort seroepidemiological study in Asuncion and Central,2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Paraguay,Central Department,Asunción,prospective cohort study in inhabitants of the health regions of Asunción and Center of Paraguay. ,,2020-12-22,2021-03-15,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,age: 30-39,290,0.307,,,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.84,0.87,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Agueda Cabello,Ministerio de Salud Pública y Bienestar Social ,Unity-Aligned,https://dx.doi.org/10.4067/s0716-10182022000200238,2022-10-20,2024-04-17,Verified,cabello_covid_2022,PRY
220615_Paraguay_MinisteriodeSaludPublicayBienestarSocial_Round1,220615_Paraguay_MinisteriodeSaludPublicayBienestarSocial,COVID 19 infection: age-stratified population-based cohort seroepidemiological study in Asuncion and Central,2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Paraguay,Central Department,Asunción,prospective cohort study in inhabitants of the health regions of Asunción and Center of Paraguay. ,,2020-12-22,2021-01-05,Household and community samples,All,Multiple groups,,,Time frame,round 1,1313,0.21600000000000003,0.195,0.239,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.84,0.87,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Agueda Cabello,Ministerio de Salud Pública y Bienestar Social ,Unity-Aligned,https://dx.doi.org/10.4067/s0716-10182022000200238,2022-10-20,2024-04-17,Verified,cabello_covid_2022,PRY
221215_Paraguay_UniversidadDelPacífico_Children_IgM/IgG,221215_Paraguay_UniversidadDelPacífico_Children,SARS-CoV-2 seroprevalence in school children and teachers in Paraguay,2022-12-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Paraguay,,,cross-sectional study in primary school teachers and secondary schools in Asunción and the Central Department of Paraguayan.,,2021-10-25,2021-11-05,Students and Daycares,All,Children and Youth (0-17 years),5.0,18.0,Primary Estimate,IgG/IgM prevalence,966,0.377,,,True,,,,,Unclear,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Dried Blood,"['IgG', 'IgM']",Spike,Validated by manufacturers,,,['Moderate'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Margarita Samudio,Universidad del Pacífico,Not Unity-Aligned,https://dx.doi.org/10.4067/S0716-10182022000600675,2023-05-29,2024-03-01,Unverified,samudio_sars-cov-2_2022,PRY
221215_Paraguay_UniversidadDelPacífico_Teachers_IgM/IgG,221215_Paraguay_UniversidadDelPacífico_Teachers,SARS-CoV-2 seroprevalence in school children and teachers in Paraguay,2022-12-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Paraguay,,,"cross-sectional study in children, adolescents in Asunción and the Central Department of Paraguayan. All children were invited to participate in the study. adolescents between the ages of 5 and 18, who attended to selected schools",Children whose parents or legal guardians did not provide consent informed.,2021-10-25,2021-11-05,Non-essential workers and unemployed persons,All,Adults (18-64 years),18.0,,Primary Estimate,IgG/IgM prevalence,148,0.919,,,True,,,,,Unclear,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Dried Blood,"['IgG', 'IgM']",Spike,Validated by manufacturers,,,['High'],,Unclear,No,Yes,,Yes,Yes,Yes,,Margarita Samudio,Universidad del Pacífico,Not Unity-Aligned,https://dx.doi.org/10.4067/S0716-10182022000600675,2023-05-29,2024-03-01,Unverified,samudio_sars-cov-2_2022,PRY
230326_CiudadDelEste_MinisterioDeSaludPublica,230326_CiudadDelEste_MinisterioDeSaludPublica,"High Circulation of SARS-CoV-2 In Ciudad del Este District, Paraguay, 2020",2023-03-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Paraguay,Alto Paraná department,Ciudad del Este,Residents of the Ciudad del Este district of Alto Paraná department in Paraguay.,,2020-10-27,2020-11-21,Household and community samples,All,Multiple groups,,,Primary Estimate,,1978,0.2988,,,True,,,,True,Simplified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.84,0.87,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Agueda Cabello,Ministerio de Salud Pública,Unity-Aligned,https://revsaludpublica.sld.cu/index.php/spu/article/view/3850,2023-05-30,2024-04-23,Verified,cabello_high_2023,PRY
230326_CiudadDelEste_MinisterioDeSaludPublica_11-15,230326_CiudadDelEste_MinisterioDeSaludPublica,"High Circulation of SARS-CoV-2 In Ciudad del Este District, Paraguay, 2020",2023-03-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Paraguay,Alto Paraná department,Ciudad del Este,Residents of the Ciudad del Este district of Alto Paraná department in Paraguay.,,2020-10-27,2020-11-21,Household and community samples,All,Children and Youth (0-17 years),11.0,15.0,Age,11-15,127,0.307,,,,,,,,Simplified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.84,0.87,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Agueda Cabello,Ministerio de Salud Pública,Unity-Aligned,https://revsaludpublica.sld.cu/index.php/spu/article/view/3850,2024-04-23,2024-04-23,Verified,cabello_high_2023,PRY
230326_CiudadDelEste_MinisterioDeSaludPublica_>65,230326_CiudadDelEste_MinisterioDeSaludPublica,"High Circulation of SARS-CoV-2 In Ciudad del Este District, Paraguay, 2020",2023-03-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Paraguay,Alto Paraná department,Ciudad del Este,Residents of the Ciudad del Este district of Alto Paraná department in Paraguay.,,2020-10-27,2020-11-21,Household and community samples,All,Seniors (65+ years),65.0,,Age,>65,151,0.252,,,,,,,,Simplified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.84,0.87,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Agueda Cabello,Ministerio de Salud Pública,Unity-Aligned,https://revsaludpublica.sld.cu/index.php/spu/article/view/3850,2024-04-23,2024-04-23,Verified,cabello_high_2023,PRY
230326_CiudadDelEste_MinisterioDeSaludPublica_5-10,230326_CiudadDelEste_MinisterioDeSaludPublica,"High Circulation of SARS-CoV-2 In Ciudad del Este District, Paraguay, 2020",2023-03-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Paraguay,Alto Paraná department,Ciudad del Este,Residents of the Ciudad del Este district of Alto Paraná department in Paraguay.,,2020-10-27,2020-11-21,Household and community samples,All,Children and Youth (0-17 years),5.0,10.0,Age,5-10,785,0.274,,,,,,,,Simplified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.84,0.87,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Agueda Cabello,Ministerio de Salud Pública,Unity-Aligned,https://revsaludpublica.sld.cu/index.php/spu/article/view/3850,2024-04-23,2024-04-23,Verified,cabello_high_2023,PRY
230326_CiudadDelEste_MinisterioDeSaludPublica_16-35,230326_CiudadDelEste_MinisterioDeSaludPublica,"High Circulation of SARS-CoV-2 In Ciudad del Este District, Paraguay, 2020",2023-03-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Paraguay,Alto Paraná department,Ciudad del Este,Residents of the Ciudad del Este district of Alto Paraná department in Paraguay.,,2020-10-27,2020-11-21,Household and community samples,All,Adults (18-64 years),16.0,35.0,Age,16-35,761,0.288,,,,,,,,Simplified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.84,0.87,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Agueda Cabello,Ministerio de Salud Pública,Unity-Aligned,https://revsaludpublica.sld.cu/index.php/spu/article/view/3850,2024-04-23,2024-04-23,Verified,cabello_high_2023,PRY
230326_CiudadDelEste_MinisterioDeSaludPublica_<5,230326_CiudadDelEste_MinisterioDeSaludPublica,"High Circulation of SARS-CoV-2 In Ciudad del Este District, Paraguay, 2020",2023-03-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Paraguay,Alto Paraná department,Ciudad del Este,Residents of the Ciudad del Este district of Alto Paraná department in Paraguay.,,2020-10-27,2020-11-21,Household and community samples,All,Children and Youth (0-17 years),,5.0,Age,<5,1193,0.315,,,,,,,,Simplified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.84,0.87,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Agueda Cabello,Ministerio de Salud Pública,Unity-Aligned,https://revsaludpublica.sld.cu/index.php/spu/article/view/3850,2024-04-23,2024-04-23,Verified,cabello_high_2023,PRY
230326_CiudadDelEste_MinisterioDeSaludPublica_51-65,230326_CiudadDelEste_MinisterioDeSaludPublica,"High Circulation of SARS-CoV-2 In Ciudad del Este District, Paraguay, 2020",2023-03-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Paraguay,Alto Paraná department,Ciudad del Este,Residents of the Ciudad del Este district of Alto Paraná department in Paraguay.,,2020-10-27,2020-11-21,Household and community samples,All,Adults (18-64 years),51.0,65.0,Age,51-65,324,0.333,,,,,,,,Simplified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.84,0.87,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Agueda Cabello,Ministerio de Salud Pública,Unity-Aligned,https://revsaludpublica.sld.cu/index.php/spu/article/view/3850,2024-04-23,2024-04-23,Verified,cabello_high_2023,PRY
230326_CiudadDelEste_MinisterioDeSaludPublica_36-50,230326_CiudadDelEste_MinisterioDeSaludPublica,"High Circulation of SARS-CoV-2 In Ciudad del Este District, Paraguay, 2020",2023-03-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Paraguay,Alto Paraná department,Ciudad del Este,Residents of the Ciudad del Este district of Alto Paraná department in Paraguay.,,2020-10-27,2020-11-21,Household and community samples,All,Adults (18-64 years),36.0,50.0,Age,36-50,491,0.31,,,,,,,,Simplified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.84,0.87,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Agueda Cabello,Ministerio de Salud Pública,Unity-Aligned,https://revsaludpublica.sld.cu/index.php/spu/article/view/3850,2024-04-23,2024-04-23,Verified,cabello_high_2023,PRY
200726_Peru_NationalCenterforEpidemiology_Overall,200726_Peru_NationalCenterforEpidemiology,Minsa publishes technical data of the study that reveals that 25.3% of Lima and Callao acquired COVID-19,2020-07-27,News and Media,Local,Cross-sectional survey ,Peru,"Lima, Callao","Lima, Callao",Habitual residents  of any age in private homes in the metropolitan area of ​​Lima and Callao,"The population residing in collective dwellings (convents, boarding schools, hotels, etc.) were excluded.",2020-06-28,2020-07-09,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,3118,0.21600000000000003,0.187,0.24600000000000002,True,,,,True,Stratified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.4,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,Peruvian Government,"National Center for Epidemiology, Prevention and Control of Diseases",Not Unity-Aligned,https://gestion.pe/peru/coronavirus-peru-minsa-divulga-ficha-tecnica-del-estudio-que-revela-que-el-253-de-lima-y-callao-adquirio-el-covid-19-cuarentena-estado-de-emergencia-nndc-noticia/,2020-10-20,2022-07-16,Verified,noauthor_minsa_2020,PER
200808_Lima_NationalMaternalPerinatalInstitute_overall,200808_Lima_NationalMaternalPerinatalInstitute,SARS-COVID-19 antibodies in pregnant women at a level III hospital in Peru,2020-08-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Peru,Lima Province,Lima,"All pregnant women hospitalized between April
15 and May 15, 2020 participated in the study if
they fulfilled the following inclusion criteria: a)
hospital admission indicated by the specialist;
b) SARS-CoV-2 antibodies serological on admittance; c) having the SARS-CoV-2 antibodies serological test results.","Exclusion criteria were: a)
under-registration of the study variables in the
medical record; b) not having the results of the
serological tests requested for admission",2020-04-15,2020-05-15,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,overall pregnant women,2419,0.07,0.061,0.081,True,,,,True,Sequential,Not reported/ Unable to specify,,LFIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.976,0.988,['Moderate'],Yes,No,Yes,No,Yes,Unclear,Yes,Yes,,Enrique Guevara Rios,"National Maternal Perinatal
Institut",Unity-Aligned,http://www.scielo.org.pe/scielo.php?pid=S2304-51322020000300002&script=sci_abstract&tlng=en,2021-05-18,2022-07-16,Verified,guevara-rios_sars-covid-19_2020,PER
210901_LimaPeru_HospitalNacionalDocenteMadreNinoSanBartolome_primary,210901_LimaPeru_HospitalNacionalDocenteMadreNinoSanBartolome,"Gestation in times of COVID-19 pandemic. Hospital nacional docente Madre Nino San Bartolome, Lima, Peru",2020-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Peru,,Lima,all pregnant women who arrived at the obstetric emergency of Hospital San Bartolome,none reported,2020-04-15,2020-07-15,Pregnant or parturient women,Female,Adults (18-64 years),14.0,48.0,Primary Estimate,,1869,0.185,,,True,,,,True,Sequential,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,No,Yes,Unclear,Yes,No,Yes,Edy Martin Vera Loyola,Hospital Nacional Docente Madre Nino San Bartolome ,Not Unity-Aligned,http://www.spog.org.pe/web/revista/index.php/RPGO/article/download/2265/pdf,2021-06-06,2022-07-16,Verified,EdyMartinVera_Gestación2020,PER
210901_LimaPeru_HospitalNacionalDocenteMadreNinoSanBartolome_June,210901_LimaPeru_HospitalNacionalDocenteMadreNinoSanBartolome,"Gestation in times of COVID-19 pandemic. Hospital nacional docente Madre Nino San Bartolome, Lima, Peru",2020-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Peru,,Lima,all pregnant women who arrived at the obstetric emergency of Hospital San Bartolome,none reported,2020-06-01,2020-06-30,Pregnant or parturient women,Female,Adults (18-64 years),14.0,48.0,Time frame,June,475,0.253,,,,,,,,Sequential,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,No,Yes,Unclear,Yes,No,Yes,Edy Martin Vera Loyola,Hospital Nacional Docente Madre Nino San Bartolome ,Not Unity-Aligned,http://www.spog.org.pe/web/revista/index.php/RPGO/article/download/2265/pdf,2021-07-08,2022-07-16,Verified,EdyMartinVera_Gestación2020,PER
210901_LimaPeru_HospitalNacionalDocenteMadreNinoSanBartolome_July,210901_LimaPeru_HospitalNacionalDocenteMadreNinoSanBartolome,"Gestation in times of COVID-19 pandemic. Hospital nacional docente Madre Nino San Bartolome, Lima, Peru",2020-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Peru,,Lima,all pregnant women who arrived at the obstetric emergency of Hospital San Bartolome,none reported,2020-07-01,2020-07-15,Pregnant or parturient women,Female,Adults (18-64 years),14.0,48.0,Time frame,July,451,0.34299999999999997,,,,,,,,Sequential,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,No,Yes,Unclear,Yes,No,Yes,Edy Martin Vera Loyola,Hospital Nacional Docente Madre Nino San Bartolome ,Not Unity-Aligned,http://www.spog.org.pe/web/revista/index.php/RPGO/article/download/2265/pdf,2021-07-08,2022-07-16,Verified,EdyMartinVera_Gestación2020,PER
210901_LimaPeru_HospitalNacionalDocenteMadreNinoSanBartolome_April,210901_LimaPeru_HospitalNacionalDocenteMadreNinoSanBartolome,"Gestation in times of COVID-19 pandemic. Hospital nacional docente Madre Nino San Bartolome, Lima, Peru",2020-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Peru,,Lima,all pregnant women who arrived at the obstetric emergency of Hospital San Bartolome,none reported,2020-04-15,2020-04-30,Pregnant or parturient women,Female,Adults (18-64 years),14.0,48.0,Time frame,April,391,0.025,,,,,,,,Sequential,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,No,Yes,Unclear,Yes,No,Yes,Edy Martin Vera Loyola,Hospital Nacional Docente Madre Nino San Bartolome ,Not Unity-Aligned,http://www.spog.org.pe/web/revista/index.php/RPGO/article/download/2265/pdf,2021-07-08,2022-07-16,Verified,EdyMartinVera_Gestación2020,PER
210901_LimaPeru_HospitalNacionalDocenteMadreNinoSanBartolome_May,210901_LimaPeru_HospitalNacionalDocenteMadreNinoSanBartolome,"Gestation in times of COVID-19 pandemic. Hospital nacional docente Madre Nino San Bartolome, Lima, Peru",2020-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Peru,,Lima,all pregnant women who arrived at the obstetric emergency of Hospital San Bartolome,none reported,2020-05-01,2020-05-31,Pregnant or parturient women,Female,Adults (18-64 years),14.0,48.0,Time frame,May,552,0.10800000000000001,,,,,,,,Sequential,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,No,Yes,Unclear,Yes,No,Yes,Edy Martin Vera Loyola,Hospital Nacional Docente Madre Nino San Bartolome ,Not Unity-Aligned,http://www.spog.org.pe/web/revista/index.php/RPGO/article/download/2265/pdf,2021-07-08,2022-07-16,Verified,EdyMartinVera_Gestación2020,PER
200901_Loreto_HospitalRegionaldeLoreto_primary,200901_Loreto_HospitalRegionaldeLoreto,Seroprevalence of COVID-19 in workers in a hospital in the Peruvian Amazon,2020-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Peru,,Loreto,HCW in the Hospital Regional de Loreto,,2020-05-19,2020-06-06,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1147,0.583,,,True,,,,True,Convenience,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,Yes,Ricci Alonso Chafloque Vasquez,Hospital Regional de Loreto,Not Unity-Aligned,https://amp.cmp.org.pe/index.php/AMP/article/view/1050,2021-05-21,2022-07-16,Verified,chafloque-vasquez_seroprevalence_2020,PER
210120_Iquitos_DIRESA_1monthFollowUp_overall_adj,210120_Iquitos_DIRESA_1month,"Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Loreto, Peru",2021-01-20,Preprint,Local,Prospective cohort,Peru,Loreto,Iquitos,"We included in our study all the inhabitants of Iquitos, Loreto, Peru, since the arrival of COVID-19 to Peru (March 6 , 2020).","(a) institutionalized individuals at nursing homes, prisons, or boarding schools, (b) subjects receiving any pharmacological treatment proposed for COVID-19 (hydroxychloroquine, ivermectin, or azithromycin), (c) individuals with any contraindication for phlebotomy (cellulitis or abscess, venous fibrosis on palpation, presence of hematoma, vascular shunt or graft, or a vascular access device), and (d) health workers or individuals living with an active health worker.",2020-08-13,2020-08-18,Household and community samples,All,Multiple groups,0.0,89.0,Primary Estimate,,621,0.66,0.62,0.701,True,True,True,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.958,1.0,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Carlos Alvarez-Antonio,Universidad de Ingeniería y Tecnología,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.01.17.21249913v1,2021-02-12,2023-07-04,Verified,alvarez-antonio_seroprevalence_2021,PER
210120_Iquitos_DIRESA_1monthFollowUp_overall_unadj,210120_Iquitos_DIRESA_1month,"Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Loreto, Peru",2021-01-20,Preprint,Local,Prospective cohort,Peru,Loreto,Iquitos,"We included in our study all the inhabitants of Iquitos, Loreto, Peru, since the arrival of COVID-19 to Peru (March 6 , 2020).","(a) institutionalized individuals at nursing homes, prisons, or boarding schools, (b) subjects receiving any pharmacological treatment proposed for COVID-19 (hydroxychloroquine, ivermectin, or azithromycin), (c) individuals with any contraindication for phlebotomy (cellulitis or abscess, venous fibrosis on palpation, presence of hematoma, vascular shunt or graft, or a vascular access device), and (d) health workers or individuals living with an active health worker.",2020-08-13,2020-08-18,Household and community samples,All,Multiple groups,0.0,89.0,Analysis,,621,0.68,,,,,,,True,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.958,1.0,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Carlos Alvarez-Antonio,Universidad de Ingeniería y Tecnología,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.01.17.21249913v1,2021-02-12,2024-03-01,Verified,alvarez-antonio_seroprevalence_2021,PER
210120_Iquitos_DIRESA_baseline_overall_adj,210120_Iquitos_DIRESA_baseline,"Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Loreto, Peru",2021-01-20,Preprint,Local,Prospective cohort,Peru,Loreto,Iquitos,"We included in our study all the inhabitants of Iquitos, Loreto, Peru, since the arrival of COVID-19 to Peru (March 6 , 2020).","(a) institutionalized individuals at nursing homes, prisons, or boarding schools, (b) subjects receiving any pharmacological treatment proposed for COVID-19 (hydroxychloroquine, ivermectin, or azithromycin), (c) individuals with any contraindication for phlebotomy (cellulitis or abscess, venous fibrosis on palpation, presence of hematoma, vascular shunt or graft, or a vascular access device), and (d) health workers or individuals living with an active health worker.",2020-07-13,2020-07-18,Household and community samples,All,Multiple groups,0.0,89.0,Primary Estimate,,716,0.7000000000000001,0.67,0.7340000000000001,True,True,True,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.958,1.0,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Carlos Alvarez-Antonio,Universidad de Ingeniería y Tecnología,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.01.17.21249913v1,2021-02-12,2023-07-04,Verified,alvarez-antonio_seroprevalence_2021,PER
210120_Iquitos_DIRESA_baseline_overall_unadj,210120_Iquitos_DIRESA_baseline,"Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Loreto, Peru",2021-01-20,Preprint,Local,Prospective cohort,Peru,Loreto,Iquitos,"We included in our study all the inhabitants of Iquitos, Loreto, Peru, since the arrival of COVID-19 to Peru (March 6 , 2020).","(a) institutionalized individuals at nursing homes, prisons, or boarding schools, (b) subjects receiving any pharmacological treatment proposed for COVID-19 (hydroxychloroquine, ivermectin, or azithromycin), (c) individuals with any contraindication for phlebotomy (cellulitis or abscess, venous fibrosis on palpation, presence of hematoma, vascular shunt or graft, or a vascular access device), and (d) health workers or individuals living with an active health worker.",2020-07-13,2020-07-18,Household and community samples,All,Multiple groups,0.0,89.0,Analysis,,716,0.737,,,,,,,True,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.958,1.0,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Carlos Alvarez-Antonio,Universidad de Ingeniería y Tecnología,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.01.17.21249913v1,2021-02-12,2024-03-01,Verified,alvarez-antonio_seroprevalence_2021,PER
210312_Lima_InstitutoNacionalDeSalud_Overall,210312_Lima_InstitutoNacionalDeSalud,"Household transmission of SARS-CoV-2 (COVID-19) in Lima, Peru",2021-03-12,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Peru,,Lima,"As inclusion criteria, contacts with complete epidemiological records with IgG / IgM results were selected, carried out by personnel of the National Institute of Health of Peru (INS), included in the epidemiological surveillance of households","Those files that were not found in the search process, or that belong to people who do not cohabit in the primary case's home, were excluded. Therefore, this study is considered a census type.",2020-04-23,2020-05-02,Contacts of COVID patients,All,Multiple groups,,,Primary Estimate,,236,0.53,,,True,,,,True,Stratified non-probability,Coretests COVID-19 IgM/IgG Ab Test,Core Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.976,1.0,['High'],Yes,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,Yolanda Angulo Bazan,Instituto Nacional de Salud,Not Unity-Aligned,https://dx.doi.org/10.1590/0102-311X00238720,2021-05-11,2024-03-01,Verified,angulo-bazan_transmision_2021,PER
210331_Lima_PeruvianMinistryOfHealth_Overall_PopAdj_TestAdj,210331_Lima_PeruvianMinistryOfHealth,"SARS-CoV-2 prevalence associated to low socioeconomic status and overcrowding in an LMIC megacity: A population-based seroepidemiological survey in Lima, Peru",2021-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Peru,Lima and Callao,Lima metropolitan area,The target population was people of all ages and sex living in urban areas,"We excluded collective residences (e.g. military bar- racks, police stations, student residences, hospitals, hotels); and also individuals with health conditions where finger prick or nasopharyn- geal swab was contraindicated, under the influence of alcohol or drugs, or who did not agree to participate.",2020-06-28,2020-07-09,Household and community samples,All,Multiple groups,,,Primary Estimate,"Overall, adjusted for population and test",3212,0.20800000000000002,0.172,0.23500000000000001,True,True,True,,,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.9694,0.9623,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Mary F Reyes Vega,Peruvian Ministry of Health,Unity-Aligned,https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00081-X/fulltext#%20,2021-04-10,2023-08-15,Verified,reyes-vega_sars-cov-2_2021,PER
210331_Lima_PeruvianMinistryOfHealth_age30-59,210331_Lima_PeruvianMinistryOfHealth,"SARS-CoV-2 prevalence associated to low socioeconomic status and overcrowding in an LMIC megacity: A population-based seroepidemiological survey in Lima, Peru",2021-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Peru,Lima and Callao,Lima metropolitan area,The target population was people of all ages and sex living in urban areas,"We excluded collective residences (e.g. military bar- racks, police stations, student residences, hospitals, hotels); and also individuals with health conditions where finger prick or nasopharyn- geal swab was contraindicated, under the influence of alcohol or drugs, or who did not agree to participate.",2020-06-28,2020-07-09,Household and community samples,All,Multiple groups,,,Age,age 30-59,1303,0.185,0.17600000000000002,0.245,,True,True,,,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.9694,0.9623,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Mary F Reyes Vega,Peruvian Ministry of Health,Unity-Aligned,https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00081-X/fulltext#%20,2021-04-10,2023-08-15,Verified,reyes-vega_sars-cov-2_2021,PER
210331_Lima_PeruvianMinistryOfHealth_Male,210331_Lima_PeruvianMinistryOfHealth,"SARS-CoV-2 prevalence associated to low socioeconomic status and overcrowding in an LMIC megacity: A population-based seroepidemiological survey in Lima, Peru",2021-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Peru,Lima and Callao,Lima metropolitan area,The target population was people of all ages and sex living in urban areas,"We excluded collective residences (e.g. military bar- racks, police stations, student residences, hospitals, hotels); and also individuals with health conditions where finger prick or nasopharyn- geal swab was contraindicated, under the influence of alcohol or drugs, or who did not agree to participate.",2020-06-28,2020-07-09,Household and community samples,Male,Multiple groups,,,Sex/Gender,Male,1428,0.198,0.166,0.23500000000000001,,True,True,,,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.9694,0.9623,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Mary F Reyes Vega,Peruvian Ministry of Health,Unity-Aligned,https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00081-X/fulltext#%20,2021-04-10,2023-08-15,Verified,reyes-vega_sars-cov-2_2021,PER
210331_Lima_PeruvianMinistryOfHealth_Overall_PopAdj_TestUnadj,210331_Lima_PeruvianMinistryOfHealth,"SARS-CoV-2 prevalence associated to low socioeconomic status and overcrowding in an LMIC megacity: A population-based seroepidemiological survey in Lima, Peru",2021-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Peru,Lima and Callao,Lima metropolitan area,The target population was people of all ages and sex living in urban areas,"We excluded collective residences (e.g. military bar- racks, police stations, student residences, hospitals, hotels); and also individuals with health conditions where finger prick or nasopharyn- geal swab was contraindicated, under the influence of alcohol or drugs, or who did not agree to participate.",2020-06-28,2020-07-09,Household and community samples,All,Multiple groups,,,Analysis,"Overall, adjusted for population only",3212,0.214,0.18600000000000003,0.245,,,True,,True,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.9694,0.9623,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Mary F Reyes Vega,Peruvian Ministry of Health,Unity-Aligned,https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00081-X/fulltext#%20,2021-04-10,2024-03-01,Verified,reyes-vega_sars-cov-2_2021,PER
210331_Lima_PeruvianMinistryOfHealth_Female,210331_Lima_PeruvianMinistryOfHealth,"SARS-CoV-2 prevalence associated to low socioeconomic status and overcrowding in an LMIC megacity: A population-based seroepidemiological survey in Lima, Peru",2021-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Peru,Lima and Callao,Lima metropolitan area,The target population was people of all ages and sex living in urban areas,"We excluded collective residences (e.g. military bar- racks, police stations, student residences, hospitals, hotels); and also individuals with health conditions where finger prick or nasopharyn- geal swab was contraindicated, under the influence of alcohol or drugs, or who did not agree to participate.",2020-06-28,2020-07-09,Household and community samples,Female,Multiple groups,,,Sex/Gender,Female,1784,0.214,0.18300000000000002,0.24100000000000002,,True,True,,,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.9694,0.9623,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Mary F Reyes Vega,Peruvian Ministry of Health,Unity-Aligned,https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00081-X/fulltext#%20,2021-04-10,2023-08-15,Verified,reyes-vega_sars-cov-2_2021,PER
210331_Lima_PeruvianMinistryOfHealth_age12-17,210331_Lima_PeruvianMinistryOfHealth,"SARS-CoV-2 prevalence associated to low socioeconomic status and overcrowding in an LMIC megacity: A population-based seroepidemiological survey in Lima, Peru",2021-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Peru,Lima and Callao,Lima metropolitan area,The target population was people of all ages and sex living in urban areas,"We excluded collective residences (e.g. military bar- racks, police stations, student residences, hospitals, hotels); and also individuals with health conditions where finger prick or nasopharyn- geal swab was contraindicated, under the influence of alcohol or drugs, or who did not agree to participate.",2020-06-28,2020-07-09,Household and community samples,All,Multiple groups,,,Age,age 12-17,259,0.231,0.17,0.30100000000000005,,True,True,,,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.9694,0.9623,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Mary F Reyes Vega,Peruvian Ministry of Health,Unity-Aligned,https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00081-X/fulltext#%20,2021-04-10,2023-08-15,Verified,reyes-vega_sars-cov-2_2021,PER
210331_Lima_PeruvianMinistryOfHealth_age60+,210331_Lima_PeruvianMinistryOfHealth,"SARS-CoV-2 prevalence associated to low socioeconomic status and overcrowding in an LMIC megacity: A population-based seroepidemiological survey in Lima, Peru",2021-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Peru,Lima and Callao,Lima metropolitan area,The target population was people of all ages and sex living in urban areas,"We excluded collective residences (e.g. military bar- racks, police stations, student residences, hospitals, hotels); and also individuals with health conditions where finger prick or nasopharyn- geal swab was contraindicated, under the influence of alcohol or drugs, or who did not agree to participate.",2020-06-28,2020-07-09,Household and community samples,All,Multiple groups,,,Age,age 60+,621,0.146,0.134,0.20199999999999999,,True,True,,,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.9694,0.9623,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Mary F Reyes Vega,Peruvian Ministry of Health,Unity-Aligned,https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00081-X/fulltext#%20,2021-04-10,2023-08-15,Verified,reyes-vega_sars-cov-2_2021,PER
210331_Lima_PeruvianMinistryOfHealth_age0-11,210331_Lima_PeruvianMinistryOfHealth,"SARS-CoV-2 prevalence associated to low socioeconomic status and overcrowding in an LMIC megacity: A population-based seroepidemiological survey in Lima, Peru",2021-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Peru,Lima and Callao,Lima metropolitan area,The target population was people of all ages and sex living in urban areas,"We excluded collective residences (e.g. military bar- racks, police stations, student residences, hospitals, hotels); and also individuals with health conditions where finger prick or nasopharyn- geal swab was contraindicated, under the influence of alcohol or drugs, or who did not agree to participate.",2020-06-28,2020-07-09,Household and community samples,All,Multiple groups,,,Age,age 0-11,459,0.212,0.167,0.275,,True,True,,,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.9694,0.9623,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Mary F Reyes Vega,Peruvian Ministry of Health,Unity-Aligned,https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00081-X/fulltext#%20,2021-04-10,2023-08-15,Verified,reyes-vega_sars-cov-2_2021,PER
210331_Lima_PeruvianMinistryOfHealth_age18-29,210331_Lima_PeruvianMinistryOfHealth,"SARS-CoV-2 prevalence associated to low socioeconomic status and overcrowding in an LMIC megacity: A population-based seroepidemiological survey in Lima, Peru",2021-03-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Peru,Lima and Callao,Lima metropolitan area,The target population was people of all ages and sex living in urban areas,"We excluded collective residences (e.g. military bar- racks, police stations, student residences, hospitals, hotels); and also individuals with health conditions where finger prick or nasopharyn- geal swab was contraindicated, under the influence of alcohol or drugs, or who did not agree to participate.",2020-06-28,2020-07-09,Household and community samples,All,Multiple groups,,,Age,age 18-29,570,0.20600000000000002,0.17500000000000002,0.261,,True,True,,,Stratified probability,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.9694,0.9623,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Mary F Reyes Vega,Peruvian Ministry of Health,Unity-Aligned,https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00081-X/fulltext#%20,2021-04-10,2023-08-15,Verified,reyes-vega_sars-cov-2_2021,PER
210406_Lambayeque_UniversidadParticulardeChiclayo_PopTestAdj,210406_Lambayeque_UniversidadParticulardeChiclayo,"SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June-July 2020",2021-04-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Peru,Lambayeque Province,,Population of the Lambayeque region,People who had previously had a diagnosis of SARS-CoV-2 by RT-PCR or by serological test are excluded,2020-06-24,2020-07-10,Household and community samples,All,Multiple groups,9.0,,Primary Estimate,overall pop and test adj,2010,0.295,0.276,0.315,True,True,True,,,Stratified probability,Coretests COVID-19 IgM/IgG Ab Test,Core Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.66,0.97,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Cristian Diaz Velez,Universidad Particular de Chiclayo,Not Unity-Aligned,https://dx.doi.org/10.7717/peerj.11210,2021-05-19,2023-08-15,Verified,diaz-velez_sars-cov-2_2021,PER
210406_Lambayeque_UniversidadParticulardeChiclayo_PopTestAdj_Lambayeque,210406_Lambayeque_UniversidadParticulardeChiclayo,"SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June-July 2020",2021-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Peru,Lambayeque Province,Lambayeque,Population of the Lambayeque region,People who had previously had a diagnosis of SARS-CoV-2 by RT-PCR or by serological test are excluded,2020-06-24,2020-07-10,Household and community samples,All,Multiple groups,9.0,,Geographical area,Lambayeque,476,0.329,0.287,0.371,,True,True,,,Stratified probability,Coretests COVID-19 IgM/IgG Ab Test,Core Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.66,0.97,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Cristian Diaz Velez,Universidad Particular de Chiclayo,Not Unity-Aligned,https://dx.doi.org/10.7717/peerj.11210,2021-07-27,2023-08-15,Verified,diaz-velez_sars-cov-2_2021,PER
210406_Lambayeque_UniversidadParticulardeChiclayo_PopAdj,210406_Lambayeque_UniversidadParticulardeChiclayo,"SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June-July 2020",2021-04-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Peru,Lambayeque Province,,Population of the Lambayeque region,People who had previously had a diagnosis of SARS-CoV-2 by RT-PCR or by serological test are excluded,2020-06-24,2020-07-10,Household and community samples,All,Multiple groups,9.0,,Analysis,overall pop adj,2010,0.4215,0.38170000000000004,0.4651,,,True,,True,Stratified probability,Coretests COVID-19 IgM/IgG Ab Test,Core Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.66,0.97,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Cristian Diaz Velez,Universidad Particular de Chiclayo,Not Unity-Aligned,https://dx.doi.org/10.7717/peerj.11210,2021-05-19,2024-03-01,Verified,diaz-velez_sars-cov-2_2021,PER
210406_Lambayeque_UniversidadParticulardeChiclayo_PopTestAdj_41-50,210406_Lambayeque_UniversidadParticulardeChiclayo,"SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June-July 2020",2021-04-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Peru,Lambayeque Province,,Population of the Lambayeque region,People who had previously had a diagnosis of SARS-CoV-2 by RT-PCR or by serological test are excluded,2020-06-24,2020-07-10,Household and community samples,All,Adults (18-64 years),41.0,50.0,Age,41-50,353,0.311,0.265,0.36200000000000004,,True,True,,,Stratified probability,Coretests COVID-19 IgM/IgG Ab Test,Core Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.66,0.97,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Cristian Diaz Velez,Universidad Particular de Chiclayo,Not Unity-Aligned,https://dx.doi.org/10.7717/peerj.11210,2021-07-27,2023-08-15,Verified,diaz-velez_sars-cov-2_2021,PER
210406_Lambayeque_UniversidadParticulardeChiclayo_PopTestAdj_61-70,210406_Lambayeque_UniversidadParticulardeChiclayo,"SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June-July 2020",2021-04-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Peru,Lambayeque Province,,Population of the Lambayeque region,People who had previously had a diagnosis of SARS-CoV-2 by RT-PCR or by serological test are excluded,2020-06-24,2020-07-10,Household and community samples,All,Seniors (65+ years),61.0,70.0,Age,61-70,215,0.24600000000000002,0.192,0.308,,True,True,,,Stratified probability,Coretests COVID-19 IgM/IgG Ab Test,Core Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.66,0.97,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Cristian Diaz Velez,Universidad Particular de Chiclayo,Not Unity-Aligned,https://dx.doi.org/10.7717/peerj.11210,2021-07-27,2023-08-15,Verified,diaz-velez_sars-cov-2_2021,PER
210406_Lambayeque_UniversidadParticulardeChiclayo_PopTestAdj_Chiclayo,210406_Lambayeque_UniversidadParticulardeChiclayo,"SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June-July 2020",2021-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Peru,Lambayeque Province,Chiclayo,Population of the Lambayeque region,People who had previously had a diagnosis of SARS-CoV-2 by RT-PCR or by serological test are excluded,2020-06-24,2020-07-10,Household and community samples,All,Multiple groups,9.0,,Geographical area,Chiclayo,1371,0.292,0.269,0.316,,True,True,,,Stratified probability,Coretests COVID-19 IgM/IgG Ab Test,Core Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.66,0.97,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Cristian Diaz Velez,Universidad Particular de Chiclayo,Not Unity-Aligned,https://dx.doi.org/10.7717/peerj.11210,2021-07-27,2023-08-15,Verified,diaz-velez_sars-cov-2_2021,PER
210406_Lambayeque_UniversidadParticulardeChiclayo_PopTestAdj_71-80,210406_Lambayeque_UniversidadParticulardeChiclayo,"SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June-July 2020",2021-04-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Peru,Lambayeque Province,,Population of the Lambayeque region,People who had previously had a diagnosis of SARS-CoV-2 by RT-PCR or by serological test are excluded,2020-06-24,2020-07-10,Household and community samples,All,Seniors (65+ years),71.0,80.0,Age,71-80,129,0.203,0.142,0.282,,True,True,,,Stratified probability,Coretests COVID-19 IgM/IgG Ab Test,Core Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.66,0.97,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Cristian Diaz Velez,Universidad Particular de Chiclayo,Not Unity-Aligned,https://dx.doi.org/10.7717/peerj.11210,2021-07-27,2023-08-15,Verified,diaz-velez_sars-cov-2_2021,PER
210406_Lambayeque_UniversidadParticulardeChiclayo_PopTestAdj_9-20,210406_Lambayeque_UniversidadParticulardeChiclayo,"SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June-July 2020",2021-04-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Peru,Lambayeque Province,,Population of the Lambayeque region,People who had previously had a diagnosis of SARS-CoV-2 by RT-PCR or by serological test are excluded,2020-06-24,2020-07-10,Household and community samples,All,Children and Youth (0-17 years),9.0,20.0,Age,9-20,220,0.269,0.214,0.332,,True,True,,,Stratified probability,Coretests COVID-19 IgM/IgG Ab Test,Core Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.66,0.97,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Cristian Diaz Velez,Universidad Particular de Chiclayo,Not Unity-Aligned,https://dx.doi.org/10.7717/peerj.11210,2021-07-27,2023-08-15,Verified,diaz-velez_sars-cov-2_2021,PER
210406_Lambayeque_UniversidadParticulardeChiclayo_PopTestAdj_21-30,210406_Lambayeque_UniversidadParticulardeChiclayo,"SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June-July 2020",2021-04-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Peru,Lambayeque Province,,Population of the Lambayeque region,People who had previously had a diagnosis of SARS-CoV-2 by RT-PCR or by serological test are excluded,2020-06-24,2020-07-10,Household and community samples,All,Adults (18-64 years),21.0,30.0,Age,21-30,329,0.31,0.261,0.36100000000000004,,True,True,,,Stratified probability,Coretests COVID-19 IgM/IgG Ab Test,Core Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.66,0.97,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Cristian Diaz Velez,Universidad Particular de Chiclayo,Not Unity-Aligned,https://dx.doi.org/10.7717/peerj.11210,2021-07-27,2023-08-15,Verified,diaz-velez_sars-cov-2_2021,PER
210406_Lambayeque_UniversidadParticulardeChiclayo_PopTestAdj_31-40,210406_Lambayeque_UniversidadParticulardeChiclayo,"SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June-July 2020",2021-04-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Peru,Lambayeque Province,,Population of the Lambayeque region,People who had previously had a diagnosis of SARS-CoV-2 by RT-PCR or by serological test are excluded,2020-06-24,2020-07-10,Household and community samples,All,Adults (18-64 years),31.0,40.0,Age,31-40,394,0.349,0.303,0.39799999999999996,,True,True,,,Stratified probability,Coretests COVID-19 IgM/IgG Ab Test,Core Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.66,0.97,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Cristian Diaz Velez,Universidad Particular de Chiclayo,Not Unity-Aligned,https://dx.doi.org/10.7717/peerj.11210,2021-07-27,2023-08-15,Verified,diaz-velez_sars-cov-2_2021,PER
210406_Lambayeque_UniversidadParticulardeChiclayo_PopTestAdj_Ferreñafe,210406_Lambayeque_UniversidadParticulardeChiclayo,"SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June-July 2020",2021-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Peru,Lambayeque Province,Ferreñafe,Population of the Lambayeque region,People who had previously had a diagnosis of SARS-CoV-2 by RT-PCR or by serological test are excluded,2020-06-24,2020-07-10,Household and community samples,All,Multiple groups,9.0,,Geographical area,Ferreñafe,163,0.225,0.168,0.295,,True,True,,,Stratified probability,Coretests COVID-19 IgM/IgG Ab Test,Core Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.66,0.97,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Cristian Diaz Velez,Universidad Particular de Chiclayo,Not Unity-Aligned,https://dx.doi.org/10.7717/peerj.11210,2021-07-27,2023-08-15,Verified,diaz-velez_sars-cov-2_2021,PER
210406_Lambayeque_UniversidadParticulardeChiclayo_PopTestAdj_Female,210406_Lambayeque_UniversidadParticulardeChiclayo,"SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June-July 2020",2021-04-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Peru,Lambayeque Province,,Population of the Lambayeque region,People who had previously had a diagnosis of SARS-CoV-2 by RT-PCR or by serological test are excluded,2020-06-24,2020-07-10,Household and community samples,Female,Multiple groups,9.0,,Sex/Gender,Female,1061,0.28800000000000003,0.26,0.318,,True,True,,,Stratified probability,Coretests COVID-19 IgM/IgG Ab Test,Core Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.66,0.97,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Cristian Diaz Velez,Universidad Particular de Chiclayo,Not Unity-Aligned,https://dx.doi.org/10.7717/peerj.11210,2021-07-27,2023-08-15,Verified,diaz-velez_sars-cov-2_2021,PER
210406_Lambayeque_UniversidadParticulardeChiclayo_PopTestAdj_80+,210406_Lambayeque_UniversidadParticulardeChiclayo,"SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June-July 2020",2021-04-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Peru,Lambayeque Province,,Population of the Lambayeque region,People who had previously had a diagnosis of SARS-CoV-2 by RT-PCR or by serological test are excluded,2020-06-24,2020-07-10,Household and community samples,All,Seniors (65+ years),80.0,,Age,80+,55,0.22100000000000003,0.13,0.35100000000000003,,True,True,,,Stratified probability,Coretests COVID-19 IgM/IgG Ab Test,Core Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.66,0.97,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Cristian Diaz Velez,Universidad Particular de Chiclayo,Not Unity-Aligned,https://dx.doi.org/10.7717/peerj.11210,2021-07-27,2023-08-15,Verified,diaz-velez_sars-cov-2_2021,PER
210406_Lambayeque_UniversidadParticulardeChiclayo_PopTestAdj_51-60,210406_Lambayeque_UniversidadParticulardeChiclayo,"SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June-July 2020",2021-04-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Peru,Lambayeque Province,,Population of the Lambayeque region,People who had previously had a diagnosis of SARS-CoV-2 by RT-PCR or by serological test are excluded,2020-06-24,2020-07-10,Household and community samples,All,Adults (18-64 years),51.0,60.0,Age,51-60,315,0.298,0.25,0.35100000000000003,,True,True,,,Stratified probability,Coretests COVID-19 IgM/IgG Ab Test,Core Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.66,0.97,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Cristian Diaz Velez,Universidad Particular de Chiclayo,Not Unity-Aligned,https://dx.doi.org/10.7717/peerj.11210,2021-07-27,2023-08-15,Verified,diaz-velez_sars-cov-2_2021,PER
210406_Lambayeque_UniversidadParticulardeChiclayo_PopTestAdj_Male,210406_Lambayeque_UniversidadParticulardeChiclayo,"SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June-July 2020",2021-04-06,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Peru,Lambayeque Province,,Population of the Lambayeque region,People who had previously had a diagnosis of SARS-CoV-2 by RT-PCR or by serological test are excluded,2020-06-24,2020-07-10,Household and community samples,Male,Multiple groups,9.0,,Sex/Gender,Male ,949,0.30100000000000005,0.27399999999999997,0.33,,True,True,,,Stratified probability,Coretests COVID-19 IgM/IgG Ab Test,Core Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.66,0.97,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Cristian Diaz Velez,Universidad Particular de Chiclayo,Not Unity-Aligned,https://dx.doi.org/10.7717/peerj.11210,2021-07-27,2023-08-15,Verified,diaz-velez_sars-cov-2_2021,PER
210421_Lima_HarvardMedicalSchool_BusDepot2,210421_Lima_HarvardMedicalSchool_BusDepot2,"Prevalence of SARS-CoV-2 antibodies among market and city bus depot workers in Lima, Peru.",2021-04-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Peru,Lima Province,Lima,"The present work took place in the northern Lima health 
jurisdiction, which includes urban and peri-urban areas and informal human settlements; it is characterized by high rates of poverty",,2020-06-05,2020-07-18,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,477,0.3633,,,True,,,,True,Convenience,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,,,"['IgG', 'IgM']",,,0.9,0.99,['High'],,No,No,Yes,,No,Yes,Yes,,Marco Tovar,Harvard Medical School,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab323,2021-05-20,2024-03-01,Unverified,tovarPrevalenceSARSCoV2Antibodies2021,PER
210421_Lima_HarvardMedicalSchool_Market1,210421_Lima_HarvardMedicalSchool_Market1,"Prevalence of SARS-CoV-2 antibodies among market and city bus depot workers in Lima, Peru.",2021-04-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Peru,Lima Province,Lima,"The present work took place in the northern Lima health 
jurisdiction, which includes urban and peri-urban areas and informal human settlements; it is characterized by high rates of poverty",,2020-06-05,2020-07-18,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,1285,0.45,,,True,,,,True,Convenience,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,,,"['IgG', 'IgM']",,,0.9,0.99,['Moderate'],,No,Yes,Yes,,No,Yes,Yes,,Marco Tovar,Harvard Medical School,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab323,2021-05-20,2024-03-01,Unverified,tovarPrevalenceSARSCoV2Antibodies2021,PER
210701_LaRinconada_GrenobleAlpesUniversity_overall,210701_LaRinconada_GrenobleAlpesUniversity,High-Altitude Environment and COVID-19: SARS-CoV-2 Seropositivity in the Highest City in the World,2021-07-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Peru,Puno,La Riconanda,"all adult inhabitants of La Rinconada who freely reported for a medical check-up to a transient medical and research laboratory established in the mining cooperative building located in the main street of the town (Enserink, 2019) were enrolled in the study and subjected to a serologic COVID-19 test, after giving their written informed consent.",None,2020-10-11,2020-10-18,Household and community samples,All,Multiple groups,,,Primary Estimate,overall,159,0.484,0.405,0.564,True,,,,True,Sequential,COVID-PRESTO®,AAZ LMB,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,1.0,['High'],Yes,No,No,Yes,No,Unclear,Yes,Yes,Unclear,Benoit Champigneulle,Grenoble Alpes University,Unity-Aligned,http://dx.doi.org/10.1089/ham.2021.0020,2021-07-29,2024-03-01,Verified,champigneulle_high-altitude_2021,PER
210701_LaRinconada_GrenobleAlpesUniversity_Male,210701_LaRinconada_GrenobleAlpesUniversity,High-Altitude Environment and COVID-19: SARS-CoV-2 Seropositivity in the Highest City in the World,2021-07-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Peru,Puno,La Riconanda,"all adult inhabitants of La Rinconada who freely reported for a medical check-up to a transient medical and research laboratory established in the mining cooperative building located in the main street of the town (Enserink, 2019) were enrolled in the study and subjected to a serologic COVID-19 test, after giving their written informed consent.",None,2020-10-11,2020-10-18,Household and community samples,Male,Multiple groups,,,Sex/Gender,male,126,0.5,,,,,,,,Sequential,COVID-PRESTO®,AAZ LMB,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],Yes,No,No,Yes,No,Unclear,Yes,Yes,Unclear,Benoit Champigneulle,Grenoble Alpes University,Unity-Aligned,http://dx.doi.org/10.1089/ham.2021.0020,2021-07-29,2024-03-01,Verified,champigneulle_high-altitude_2021,PER
210701_LaRinconada_GrenobleAlpesUniversity_Female,210701_LaRinconada_GrenobleAlpesUniversity,High-Altitude Environment and COVID-19: SARS-CoV-2 Seropositivity in the Highest City in the World,2021-07-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Peru,Puno,La Riconanda,"all adult inhabitants of La Rinconada who freely reported for a medical check-up to a transient medical and research laboratory established in the mining cooperative building located in the main street of the town (Enserink, 2019) were enrolled in the study and subjected to a serologic COVID-19 test, after giving their written informed consent.",None,2020-10-11,2020-10-18,Household and community samples,Female,Multiple groups,,,Sex/Gender,female,33,0.4242,,,,,,,,Sequential,COVID-PRESTO®,AAZ LMB,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],Yes,No,No,Yes,No,Unclear,Yes,Yes,Unclear,Benoit Champigneulle,Grenoble Alpes University,Unity-Aligned,http://dx.doi.org/10.1089/ham.2021.0020,2021-07-29,2024-03-01,Verified,champigneulle_high-altitude_2021,PER
210920_Peru_UniversidadAndinadelCusco_OverallPopAdj,210920_Peru_UniversidadAndinadelCusco,SARS-CoV-2 seroprevalence in a high-altitude setting in Peru: Adult population-based cross-sectional study,2021-09-20,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Peru,Cusco Region,,"""People aged≥18 years old, who voluntarily agreed to participate in the study, signed theirinformed consent, accepted the telephone and serological follow-up, usual resident of thestudy area (≥6 months), and with the ability to understand the procedures were included.""

""We did not exclude people with acute symptoms or who had already given positive results to previous tests.""",,2020-09-12,2020-09-27,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,1924,0.331,0.30100000000000005,0.364,True,,True,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9670000000000001,0.986,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Charles Huamani,Universidad Andina del Cusco,Unity-Aligned,http://dx.doi.org/10.7717/peerj.12149,2021-10-05,2024-03-01,Verified,huamani_sars-cov-2_2021,PER
210920_Peru_UniversidadAndinadelCusco_40-59,210920_Peru_UniversidadAndinadelCusco,SARS-CoV-2 seroprevalence in a high-altitude setting in Peru: Adult population-based cross-sectional study,2021-09-20,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Peru,Cusco Region,,"""People aged≥18 years old, who voluntarily agreed to participate in the study, signed theirinformed consent, accepted the telephone and serological follow-up, usual resident of thestudy area (≥6 months), and with the ability to understand the procedures were included.""

""We did not exclude people with acute symptoms or who had already given positive results to previous tests.""",,2020-09-12,2020-09-27,Household and community samples,All,Adults (18-64 years),40.0,59.0,Age,40-59 yrs,702,0.358,0.318,0.402,,,True,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9670000000000001,0.986,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Charles Huamani,Universidad Andina del Cusco,Unity-Aligned,http://dx.doi.org/10.7717/peerj.12149,2021-10-07,2024-03-01,Verified,huamani_sars-cov-2_2021,PER
210920_Peru_UniversidadAndinadelCusco_18-40,210920_Peru_UniversidadAndinadelCusco,SARS-CoV-2 seroprevalence in a high-altitude setting in Peru: Adult population-based cross-sectional study,2021-09-20,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Peru,Cusco Region,,"""People aged≥18 years old, who voluntarily agreed to participate in the study, signed theirinformed consent, accepted the telephone and serological follow-up, usual resident of thestudy area (≥6 months), and with the ability to understand the procedures were included.""

""We did not exclude people with acute symptoms or who had already given positive results to previous tests.""",,2020-09-12,2020-09-27,Household and community samples,All,Adults (18-64 years),18.0,40.0,Age,18-40 yrs,876,0.348,0.31,0.391,,,True,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9670000000000001,0.986,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Charles Huamani,Universidad Andina del Cusco,Unity-Aligned,http://dx.doi.org/10.7717/peerj.12149,2021-10-07,2024-03-01,Verified,huamani_sars-cov-2_2021,PER
210920_Peru_UniversidadAndinadelCusco_>60,210920_Peru_UniversidadAndinadelCusco,SARS-CoV-2 seroprevalence in a high-altitude setting in Peru: Adult population-based cross-sectional study,2021-09-20,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Peru,Cusco Region,,"""People aged≥18 years old, who voluntarily agreed to participate in the study, signed theirinformed consent, accepted the telephone and serological follow-up, usual resident of thestudy area (≥6 months), and with the ability to understand the procedures were included.""

""We did not exclude people with acute symptoms or who had already given positive results to previous tests.""",,2020-09-12,2020-09-27,Household and community samples,All,Multiple groups,60.0,,Age,60+ yrs ,308,0.247,0.197,0.309,,,True,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9670000000000001,0.986,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Charles Huamani,Universidad Andina del Cusco,Unity-Aligned,http://dx.doi.org/10.7717/peerj.12149,2021-10-07,2024-03-01,Verified,huamani_sars-cov-2_2021,PER
210920_Peru_UniversidadAndinadelCusco_Female,210920_Peru_UniversidadAndinadelCusco,SARS-CoV-2 seroprevalence in a high-altitude setting in Peru: Adult population-based cross-sectional study,2021-09-20,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Peru,Cusco Region,,"""People aged≥18 years old, who voluntarily agreed to participate in the study, signed theirinformed consent, accepted the telephone and serological follow-up, usual resident of thestudy area (≥6 months), and with the ability to understand the procedures were included.""

""We did not exclude people with acute symptoms or who had already given positive results to previous tests.""",,2020-09-12,2020-09-27,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,1096,0.34600000000000003,0.312,0.383,,,True,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9670000000000001,0.986,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Charles Huamani,Universidad Andina del Cusco,Unity-Aligned,http://dx.doi.org/10.7717/peerj.12149,2021-10-07,2024-03-01,Verified,huamani_sars-cov-2_2021,PER
210920_Peru_UniversidadAndinadelCusco_Male,210920_Peru_UniversidadAndinadelCusco,SARS-CoV-2 seroprevalence in a high-altitude setting in Peru: Adult population-based cross-sectional study,2021-09-20,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Peru,Cusco Region,,"""People aged≥18 years old, who voluntarily agreed to participate in the study, signed theirinformed consent, accepted the telephone and serological follow-up, usual resident of thestudy area (≥6 months), and with the ability to understand the procedures were included.""

""We did not exclude people with acute symptoms or who had already given positive results to previous tests.""",,2020-09-12,2020-09-27,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,828,0.311,0.273,0.35200000000000004,,,True,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9670000000000001,0.986,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Charles Huamani,Universidad Andina del Cusco,Unity-Aligned,http://dx.doi.org/10.7717/peerj.12149,2021-10-07,2024-03-01,Verified,huamani_sars-cov-2_2021,PER
210920_Peru_UniversidadAndinadelCusco_OverallUnAdj,210920_Peru_UniversidadAndinadelCusco,SARS-CoV-2 seroprevalence in a high-altitude setting in Peru: Adult population-based cross-sectional study,2021-09-20,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Peru,Cusco Region,,"""People aged≥18 years old, who voluntarily agreed to participate in the study, signed theirinformed consent, accepted the telephone and serological follow-up, usual resident of thestudy area (≥6 months), and with the ability to understand the procedures were included.""

""We did not exclude people with acute symptoms or who had already given positive results to previous tests.""",,2020-09-12,2020-09-27,Household and community samples,All,Multiple groups,18.0,,Analysis,,1924,0.331,,,,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9670000000000001,0.986,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Charles Huamani,Universidad Andina del Cusco,Unity-Aligned,http://dx.doi.org/10.7717/peerj.12149,2021-10-07,2024-03-01,Verified,huamani_sars-cov-2_2021,PER
211023_Peru_GermanCentreforInfectionResearch_CLIAandNeutralization,211023_Peru_GermanCentreforInfectionResearch,"High SARS-CoV-2 seroprevalence in rural Peru, 2021; a cross-sectional population-based study",2021-10-23,Preprint,Regional,Cross-sectional survey ,Peru,San Martin,,"Residents of ""the rural region of San Martin, Peru""","""Exclusion criteria encompassed population residing in collective dwellings such as barracks, police stations, convents, boarding schools and hotels, used as temporary housing of unrelated people with unstable population dynamics, age ≤5 years, skin lesions in the venous puncture site, usage of alcohol or psychoactive drugs, not being permanent resident and not signing the informed consent.""",2021-03-01,2021-03-31,Household and community samples,All,Multiple groups,6.0,89.0,Primary Estimate,,563,0.5897,0.55,0.63,True,,,,True,Simplified probability,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,MAGLUMI 2019-nCoV IgM/IgG","GenScript,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd)",Multiple Types,Serum,"['IgG', 'Neutralizing']",Spike,,,,['High'],Yes,Yes,No,Yes,No,No,Yes,No,Unclear,Andres Moreira-Soto,German Centre for Infection Research,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.10.19.21265219v1.full-text,2021-11-04,2024-03-01,Verified,moreira-soto_high_2021,PER
211023_Peru_GermanCentreforInfectionResearch_CLIAonly,211023_Peru_GermanCentreforInfectionResearch,"High SARS-CoV-2 seroprevalence in rural Peru, 2021; a cross-sectional population-based study",2021-10-23,Preprint,Regional,Cross-sectional survey ,Peru,San Martin,,"Residents of ""the rural region of San Martin, Peru""","""Exclusion criteria encompassed population residing in collective dwellings such as barracks, police stations, convents, boarding schools and hotels, used as temporary housing of unrelated people with unstable population dynamics, age ≤5 years, skin lesions in the venous puncture site, usage of alcohol or psychoactive drugs, not being permanent resident and not signing the informed consent.""",2021-03-01,2021-03-31,Household and community samples,All,Multiple groups,6.0,89.0,Test used,,563,0.6359,,,,,,,,Simplified probability,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Serum,IgG,Spike,,,,['High'],Yes,Yes,No,Yes,No,No,Yes,No,Unclear,Andres Moreira-Soto,German Centre for Infection Research,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.10.19.21265219v1.full-text,2021-11-04,2024-03-01,Verified,moreira-soto_high_2021,PER
211204_Lima_CentersForDiseaseControlAndPrevention,211204_Lima_CentersForDiseaseControlAndPrevention,High Laboratory-confirmed SARS-CoV-2 Attack Rate in Lima Health Care Personnel during August 2020-March 2021 Suggests Role for Improved Infection Control,2021-12-04,Presentation or Conference,Local,Cross-sectional survey ,Peru,,Lima,"Healthcare workers serving the two selected acute care hospitals in Lima, Peru.",,2020-08-15,2021-03-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,667,0.3208,,,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,Serum,,,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Matthew Westercamp,Centers for Disease Control and Prevention,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab466.576,2022-03-22,2022-07-16,Unverified,westercamp_375_2021,PER
211215_Lima_InstitutoNacionalMaternoPerinatal,211215_Lima_InstitutoNacionalMaternoPerinatal,Clinical and epidemiological characterization in the follow-up of newborns with COVID-19: a descriptive study.,2021-12-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Peru,,Lima,All pregnant women admitted to Instituto Nacional Materno Perinatal,,2020-06-01,2020-09-30,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,4733,0.314,,,True,,,,True,Sequential,One Step COVID-19 Test,Celer Technologies Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],,No,Yes,No,,No,Yes,No,,Carmen Davila-Aliaga,Instituto Nacional Materno Perinatal,Not Unity-Aligned,https://dx.doi.org/10.5867/medwave.2021.11.002141,2021-12-23,2024-03-01,Unverified,davila-aliaga_caracterizacion_2021,PER
221227_SanJuandeLurigancho_VanderbiltUniversity_Baseline,221227_SanJuandeLurigancho_VanderbiltUniversity_Baseline,"SARS-CoV-2 infections in households in a peri-urban community of Lima, Peru: A prospective cohort study",2021-12-27,Journal Article (Peer-Reviewed),Local,Prospective cohort,Peru,Lima,Lima,"Households were eligible for participation if they included at least three consenting members—one person <18 years, one 18–50 years, and one >50 years old—who were available during weekday working hours to be visited at home or in a nearby working area and had no plans to moving out of the area within the planned study follow-up period.",,2020-12-09,2021-01-15,Household and community samples,All,Multiple groups,1.0,85.0,Primary Estimate,,128,0.46090000000000003,0.3725,0.5512,True,,,,True,Convenience,Standard Q COVID-19 IgM/IgG Combo,SD Biosensor,,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Claudio Lanata,Vanderbilt University,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.12952,2022-05-03,2022-07-16,Unverified,lanata_sars-cov-2_2022,PER
221227_SanJuandeLurigancho_VanderbiltUniversity_FollowUp,221227_SanJuandeLurigancho_VanderbiltUniversity_FollowUp,"SARS-CoV-2 infections in households in a peri-urban community of Lima, Peru: A prospective cohort study",2021-12-27,Journal Article (Peer-Reviewed),Local,Prospective cohort,Peru,Lima,Lima,"Households were eligible for participation if they included at least three consenting members—one person <18 years, one 18–50 years, and one >50 years old—who were available during weekday working hours to be visited at home or in a nearby working area and had no plans to moving out of the area within the planned study follow-up period.",,2021-01-15,2021-03-19,Household and community samples,All,Multiple groups,1.0,85.0,Primary Estimate,,111,0.5315,0.43450000000000005,0.6269,True,,,,True,Convenience,Standard Q COVID-19 IgM/IgG Combo,SD Biosensor,,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Claudio Lanata,Vanderbilt University,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.12952,2022-05-03,2022-07-16,Unverified,lanata_sars-cov-2_2022,PER
211223_Lima_UniversidadPeruanaCayetanoHeredia,211223_Lima_UniversidadPeruanaCayetanoHeredia,SARS-CoV-2 antibody status at time of delivery and the risk of preeclampsia,2022-01-01,Presentation or Conference,Local,Retrospective cohort,Peru,Lima,Lima,We conducted a retrospective cohort study of pregnant patients admitted to our institution from August 1st to September 30th 2020.,,2020-08-01,2020-09-30,Pregnant or parturient women,Female,Adults (18-64 years),18.0,,Primary Estimate,,440,0.375,,,True,,,,True,Convenience,Standard Q COVID-19 IgM/IgG Combo,SD Biosensor,,,"['IgG', 'IgM']",,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Arianna Portmann-Baracco,Universidad Peruana Cayetano Heredia,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ajog.2021.11.1178,2022-01-10,2022-07-16,Unverified,portmann-baracco_sars-cov-2_2022,PER
211223_Lima_UniversidadPeruanaCayetanoHeredia_Age>35,211223_Lima_UniversidadPeruanaCayetanoHeredia,SARS-CoV-2 antibody status at time of delivery and the risk of preeclampsia,2022-01-01,Presentation or Conference,Local,Retrospective cohort,Peru,Lima,Lima,We conducted a retrospective cohort study of pregnant patients admitted to our institution from August 1st to September 30th 2020.,,2020-08-01,2020-09-30,Pregnant or parturient women,Female,Adults (18-64 years),36.0,,Age,,52,0.40380000000000005,,,,,,,,Convenience,Standard Q COVID-19 IgM/IgG Combo,SD Biosensor,,,"['IgG', 'IgM']",,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Arianna Portmann-Baracco,Universidad Peruana Cayetano Heredia,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ajog.2021.11.1178,2022-01-10,2022-07-16,Unverified,portmann-baracco_sars-cov-2_2022,PER
211223_Lima_UniversidadPeruanaCayetanoHeredia_Age18-35,211223_Lima_UniversidadPeruanaCayetanoHeredia,SARS-CoV-2 antibody status at time of delivery and the risk of preeclampsia,2022-01-01,Presentation or Conference,Local,Retrospective cohort,Peru,Lima,Lima,We conducted a retrospective cohort study of pregnant patients admitted to our institution from August 1st to September 30th 2020.,,2020-08-01,2020-09-30,Pregnant or parturient women,Female,Adults (18-64 years),18.0,35.0,Age,,388,0.3711,,,,,,,,Convenience,Standard Q COVID-19 IgM/IgG Combo,SD Biosensor,,,"['IgG', 'IgM']",,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Arianna Portmann-Baracco,Universidad Peruana Cayetano Heredia,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ajog.2021.11.1178,2022-01-10,2022-07-16,Unverified,portmann-baracco_sars-cov-2_2022,PER
220119_Cantagallo_MINSA_Round1,220119_Cantagallo_MINSA_Round1,"COVID-19 outbreak in an urban indigenous community in Northern Lima, Peru",2022-01-19,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Peru,Lima,Cantagallo,"Members of the Shipibo-Konibo Community of Cantagallo, Peru. In first round, symptomatic people were screened or with a history of contact with a positive patient.",,2020-05-02,2020-05-02,Household and community samples,All,Multiple groups,,,Primary Estimate,,119,0.3361,,,True,,,,True,Convenience,Not reported/ Unable to specify,,LFIA,,"['IgG', 'IgM']",,,,,['High'],,No,No,No,,Unclear,Yes,No,,Luis Zavalaga,MINSA,Not Unity-Aligned,https://dx.doi.org/10.20453/RMH.V32I4.4120,2022-03-09,2022-07-16,Unverified,llanos_zavalaga_brote_2022,PER
220119_Cantagallo_MINSA_Round2,220119_Cantagallo_MINSA_Round2,"COVID-19 outbreak in an urban indigenous community in Northern Lima, Peru",2022-01-19,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Peru,Lima,Cantagallo,"Members of the Shipibo-Konibo Community of Cantagallo, Peru. ",,2020-05-12,2020-05-12,Household and community samples,All,Multiple groups,,,Primary Estimate,,475,0.7326,,,True,,,,True,Convenience,Not reported/ Unable to specify,,LFIA,,"['IgG', 'IgM']",,,,,['High'],,No,No,No,,Unclear,Yes,No,,Luis Zavalaga,MINSA,Not Unity-Aligned,https://dx.doi.org/10.20453/RMH.V32I4.4120,2022-03-09,2022-07-16,Unverified,llanos_zavalaga_brote_2022,PER
220119_Cantagallo_MINSA_Round3,220119_Cantagallo_MINSA_Round3,"COVID-19 outbreak in an urban indigenous community in Northern Lima, Peru",2022-01-19,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Peru,Lima,Cantagallo,"Members of the Shipibo-Konibo Community of Cantagallo, Peru. ",,2020-08-10,2020-08-10,Household and community samples,All,Multiple groups,,,Primary Estimate,,485,0.6804000000000001,,,True,,,,True,Convenience,Not reported/ Unable to specify,,LFIA,,"['IgG', 'IgM']",,,,,['High'],,No,No,No,,Unclear,Yes,No,,Luis Zavalaga,MINSA,Not Unity-Aligned,https://dx.doi.org/10.20453/RMH.V32I4.4120,2022-03-09,2022-07-16,Unverified,llanos_zavalaga_brote_2022,PER
220325_Pucallpa_NationalUniversityofJaén_IgGorIgM,220325_Pucallpa_NationalUniversityofJaén,Serological prevalence of antibodies to SARS-CoV-2 in a prison in the Peruvian Amazon,2022-03-25,Preprint,Local,Cross-sectional survey ,Peru,Coronel Portillo,Pucallpa,"inmates from the Penitentiary Center in Pucallpa, Peru",,2020-06-25,2020-07-24,Persons who are incarcerated,All,Adults (18-64 years),,,Primary Estimate,,325,0.5785,,,True,,,,True,Simplified probability,Not reported/ Unable to specify,,CLIA,Dried Blood,"['IgG', 'IgM']",,,,,['High'],,Yes,No,Yes,,Unclear,Yes,No,,Arturo Rafael-Heredia,National University of Jaén,Not Unity-Aligned,https://preprints.scielo.org/index.php/scielo/preprint/view/3828,2022-04-06,2022-07-16,Unverified,rafael-heredia_prevalencia_2022,PER
220408_Peru_UniversidadPeruanadeCienciasAplicadas_IgM,220408_Peru_UniversidadPeruanadeCienciasAplicadas,Detection of SARS-CoV-2 antibodies in febrile patients from an endemic region of dengue and chikungunya in Peru,2022-04-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Peru,Jaen,Jaen,"Patients are included if they attended outpatient clinics with acute febrile illness (axillary temperature greater than or equal to 38˚C in the previous 7 days) along with one or more of the following symptoms: headache, myalgias, arthralgias, retro-ocular pain, lumbar pain, arthritis, nausea, rash, vomiting, conjunctivitis, odynophagia, loss of appetite, among others.","Exclusion criteria included patients with an identifiable source of infection, such as acute upper respiratory tract infections, urinary tract infections, among others.",2020-04-15,2021-03-15,Representative patient population,All,Multiple groups,11.0,,Primary Estimate,,464,0.358,,,True,,,,True,Sequential,SARS-CoV-2 NP IgG/IgM ELISA Kit,ImmunoDiagnostics,ELISA,Serum,IgM,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.882,0.92,['High'],,No,No,Yes,,No,Yes,No,,Yordi Tarazona-Castro,Universidad Peruana de Ciencias Aplicadas,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0265820,2022-04-21,2024-03-01,Unverified,tarazona-Castro_detection_2022,PER
230424_Iquitos_UniversidadCientıficadelSur_Belen,230424_Iquitos_UniversidadCientıficadelSur,Dengue and COVID-19 Co-circulation in the Peruvian Amazon: A Population-Based Study.,2023-04-24,Journal Article (Peer-Reviewed),Local,Prospective cohort,Peru,,,"""All adults (18+ years) with a baseline sample in the COVID-19 cohort study who were residents of Iquitos, Loreto, Peru, after the arrival of COVID-19 to Peru (March 6, 2020) were eligible for enrollment. ""","""Exclusion criteria included 1) institutionalized individuals at nursing homes, prisons, or boarding schools; 2) individuals with any contraindication for phlebotomy (cellulitis or abscess, venous fibrosis on palpation, presence of hematoma, vascular shunt or graft, or a vascular access device); and 3) health workers or individuals living with an active health worker.""",2020-07-13,2020-07-18,Household and community samples,All,Adults (18-64 years),18.0,,Geographical area,,34,0.82,0.65,0.932,True,True,True,,True,Stratified non-probability,"OnSite COVID-19 IgG/IgM Rapid Test,Anti-SARS-CoV-2 ELISA IgG","CTK Biotech, Inc.,EUROIMMUN",LFIA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Pons,Universidad Cientıfica del Sur,Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.22-0539,2023-05-31,2024-04-27,Verified,ponsDengueCOVID19CoCirculation2023,PER
230424_Iquitos_UniversidadCientıficadelSur_Punchana,230424_Iquitos_UniversidadCientıficadelSur,Dengue and COVID-19 Co-circulation in the Peruvian Amazon: A Population-Based Study.,2023-04-24,Journal Article (Peer-Reviewed),Local,Prospective cohort,Peru,,,"""All adults (18+ years) with a baseline sample in the COVID-19 cohort study who were residents of Iquitos, Loreto, Peru, after the arrival of COVID-19 to Peru (March 6, 2020) were eligible for enrollment. ""","""Exclusion criteria included 1) institutionalized individuals at nursing homes, prisons, or boarding schools; 2) individuals with any contraindication for phlebotomy (cellulitis or abscess, venous fibrosis on palpation, presence of hematoma, vascular shunt or graft, or a vascular access device); and 3) health workers or individuals living with an active health worker.""",2020-07-13,2020-07-18,Household and community samples,All,Adults (18-64 years),18.0,,Geographical area,,59,0.78,0.64,0.88,True,True,True,,True,Stratified non-probability,"OnSite COVID-19 IgG/IgM Rapid Test,Anti-SARS-CoV-2 ELISA IgG","CTK Biotech, Inc.,EUROIMMUN",LFIA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Pons,Universidad Cientıfica del Sur,Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.22-0539,2023-05-31,2024-04-27,Verified,ponsDengueCOVID19CoCirculation2023,PER
230424_Iquitos_UniversidadCientıficadelSur_San Juan,230424_Iquitos_UniversidadCientıficadelSur,Dengue and COVID-19 Co-circulation in the Peruvian Amazon: A Population-Based Study.,2023-04-24,Journal Article (Peer-Reviewed),Local,Prospective cohort,Peru,,,"""All adults (18+ years) with a baseline sample in the COVID-19 cohort study who were residents of Iquitos, Loreto, Peru, after the arrival of COVID-19 to Peru (March 6, 2020) were eligible for enrollment. ""","""Exclusion criteria included 1) institutionalized individuals at nursing homes, prisons, or boarding schools; 2) individuals with any contraindication for phlebotomy (cellulitis or abscess, venous fibrosis on palpation, presence of hematoma, vascular shunt or graft, or a vascular access device); and 3) health workers or individuals living with an active health worker.""",2020-07-13,2020-07-18,Household and community samples,All,Adults (18-64 years),18.0,,Geographical area,,126,0.82,0.74,0.881,True,True,True,,True,Stratified non-probability,"OnSite COVID-19 IgG/IgM Rapid Test,Anti-SARS-CoV-2 ELISA IgG","CTK Biotech, Inc.,EUROIMMUN",LFIA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Pons,Universidad Cientıfica del Sur,Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.22-0539,2023-05-31,2024-04-27,Verified,ponsDengueCOVID19CoCirculation2023,PER
230424_Iquitos_UniversidadCientıficadelSur_Iquitos,230424_Iquitos_UniversidadCientıficadelSur,Dengue and COVID-19 Co-circulation in the Peruvian Amazon: A Population-Based Study.,2023-04-24,Journal Article (Peer-Reviewed),Local,Prospective cohort,Peru,,,"""All adults (18+ years) with a baseline sample in the COVID-19 cohort study who were residents of Iquitos, Loreto, Peru, after the arrival of COVID-19 to Peru (March 6, 2020) were eligible for enrollment. ""","""Exclusion criteria included 1) institutionalized individuals at nursing homes, prisons, or boarding schools; 2) individuals with any contraindication for phlebotomy (cellulitis or abscess, venous fibrosis on palpation, presence of hematoma, vascular shunt or graft, or a vascular access device); and 3) health workers or individuals living with an active health worker.""",2020-07-13,2020-07-18,Household and community samples,All,Adults (18-64 years),18.0,,Geographical area,,107,0.73,0.63,0.81,True,True,True,,True,Stratified non-probability,"OnSite COVID-19 IgG/IgM Rapid Test,Anti-SARS-CoV-2 ELISA IgG","CTK Biotech, Inc.,EUROIMMUN",LFIA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Pons,Universidad Cientıfica del Sur,Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.22-0539,2023-05-31,2024-04-27,Verified,ponsDengueCOVID19CoCirculation2023,PER
230424_Iquitos_UniversidadCientıficadelSur_overall,230424_Iquitos_UniversidadCientıficadelSur,Dengue and COVID-19 Co-circulation in the Peruvian Amazon: A Population-Based Study.,2023-04-24,Journal Article (Peer-Reviewed),Local,Prospective cohort,Peru,,"Iquitos
","""All adults (18+ years) with a baseline sample in the COVID-19 cohort study who were residents of Iquitos, Loreto, Peru, after the arrival of COVID-19 to Peru (March 6, 2020) were eligible for enrollment. ""","""Exclusion criteria included 1) institutionalized individuals at nursing homes, prisons, or boarding schools; 2) individuals with any contraindication for phlebotomy (cellulitis or abscess, venous fibrosis on palpation, presence of hematoma, vascular shunt or graft, or a vascular access device); and 3) health workers or individuals living with an active health worker.""",2020-07-13,2020-07-18,Household and community samples,All,Adults (18-64 years),18.0,,Primary Estimate,,326,0.78,0.73,0.826,True,True,True,,True,Stratified non-probability,"OnSite COVID-19 IgG/IgM Rapid Test,Anti-SARS-CoV-2 ELISA IgG","CTK Biotech, Inc.,EUROIMMUN",LFIA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Pons,Universidad Cientıfica del Sur,Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.22-0539,2023-05-31,2024-04-27,Verified,ponsDengueCOVID19CoCirculation2023,PER
230424_Iquitos_UniversidadCientıficadelSur_Age30-59,230424_Iquitos_UniversidadCientıficadelSur,Dengue and COVID-19 Co-circulation in the Peruvian Amazon: A Population-Based Study.,2023-04-24,Journal Article (Peer-Reviewed),Local,Prospective cohort,Peru,,"Iquitos
","""All adults (18+ years) with a baseline sample in the COVID-19 cohort study who were residents of Iquitos, Loreto, Peru, after the arrival of COVID-19 to Peru (March 6, 2020) were eligible for enrollment. ""","""Exclusion criteria included 1) institutionalized individuals at nursing homes, prisons, or boarding schools; 2) individuals with any contraindication for phlebotomy (cellulitis or abscess, venous fibrosis on palpation, presence of hematoma, vascular shunt or graft, or a vascular access device); and 3) health workers or individuals living with an active health worker.""",2020-07-13,2020-07-18,Household and community samples,All,Adults (18-64 years),30.0,59.0,Age,30-59,196,0.77,0.71,0.827,,True,True,,,Stratified non-probability,"OnSite COVID-19 IgG/IgM Rapid Test,Anti-SARS-CoV-2 ELISA IgG","CTK Biotech, Inc.,EUROIMMUN",LFIA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Pons,Universidad Cientıfica del Sur,Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.22-0539,2024-04-27,2024-04-27,Verified,ponsDengueCOVID19CoCirculation2023,PER
230424_Iquitos_UniversidadCientıficadelSur_Age18-29,230424_Iquitos_UniversidadCientıficadelSur,Dengue and COVID-19 Co-circulation in the Peruvian Amazon: A Population-Based Study.,2023-04-24,Journal Article (Peer-Reviewed),Local,Prospective cohort,Peru,,"Iquitos
","""All adults (18+ years) with a baseline sample in the COVID-19 cohort study who were residents of Iquitos, Loreto, Peru, after the arrival of COVID-19 to Peru (March 6, 2020) were eligible for enrollment. ""","""Exclusion criteria included 1) institutionalized individuals at nursing homes, prisons, or boarding schools; 2) individuals with any contraindication for phlebotomy (cellulitis or abscess, venous fibrosis on palpation, presence of hematoma, vascular shunt or graft, or a vascular access device); and 3) health workers or individuals living with an active health worker.""",2020-07-13,2020-07-18,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,18-29,88,0.81,0.71,0.883,,True,True,,,Stratified non-probability,"OnSite COVID-19 IgG/IgM Rapid Test,Anti-SARS-CoV-2 ELISA IgG","CTK Biotech, Inc.,EUROIMMUN",LFIA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Pons,Universidad Cientıfica del Sur,Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.22-0539,2024-04-27,2024-04-27,Verified,ponsDengueCOVID19CoCirculation2023,PER
230424_Iquitos_UniversidadCientıficadelSur_Age60+,230424_Iquitos_UniversidadCientıficadelSur,Dengue and COVID-19 Co-circulation in the Peruvian Amazon: A Population-Based Study.,2023-04-24,Journal Article (Peer-Reviewed),Local,Prospective cohort,Peru,,"Iquitos
","""All adults (18+ years) with a baseline sample in the COVID-19 cohort study who were residents of Iquitos, Loreto, Peru, after the arrival of COVID-19 to Peru (March 6, 2020) were eligible for enrollment. ""","""Exclusion criteria included 1) institutionalized individuals at nursing homes, prisons, or boarding schools; 2) individuals with any contraindication for phlebotomy (cellulitis or abscess, venous fibrosis on palpation, presence of hematoma, vascular shunt or graft, or a vascular access device); and 3) health workers or individuals living with an active health worker.""",2020-07-13,2020-07-18,Household and community samples,All,Seniors (65+ years),60.0,,Age,60+,42,0.86,0.71,0.946,,True,True,,,Stratified non-probability,"OnSite COVID-19 IgG/IgM Rapid Test,Anti-SARS-CoV-2 ELISA IgG","CTK Biotech, Inc.,EUROIMMUN",LFIA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Maria Pons,Universidad Cientıfica del Sur,Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.22-0539,2024-04-27,2024-04-27,Verified,ponsDengueCOVID19CoCirculation2023,PER
230628_PuertoPizarro_HospitalAmistadPeruCoreaSantaRosa_TestAdj_Overall,230628_PuertoPizarro_HospitalAmistadPeruCoreaSantaRosa,SARS-CoV-2 seroprevalence on the north coast of Peru: A cross-sectional study after the first wave.,2023-06-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Peru,Tumbes,Puerto Pizarro,"""A baseline census was conducted to collect data on households. After obtaining IC [informed consent] (13), non-medical field workers (trained by a team of epidemiologists LMMV, RGM, and PVB) performed a door-to-door survey of all individuals older than 2 years old.""

""Every person in one out of every four Puerto Pizarro homes (n = 742) was asked to take part in a systematic random sampling.""",Not signing the informed consent form.,2020-11-11,2020-11-30,Household and community samples,All,Multiple groups,2.0,,Primary Estimate,Adjusted for sensitivity (99.03%) and specificity (98.65%),1391,0.2472,,,True,True,,,,Simplified probability,Standard Q COVID-19 IgM/IgG Combo,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9903000000000001,0.9865,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Luz M. Moyano,Hospital Amistad Peru Corea Santa Rosa,Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0010794,2022-09-20,2023-07-28,Unverified,moyano_sars-cov-2_2023,PER
230628_PuertoPizarro_HospitalAmistadPeruCoreaSantaRosa_UnAdj_SexFemale,230628_PuertoPizarro_HospitalAmistadPeruCoreaSantaRosa,SARS-CoV-2 seroprevalence on the north coast of Peru: A cross-sectional study after the first wave.,2023-06-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Peru,Tumbes,Puerto Pizarro,"""A baseline census was conducted to collect data on households. After obtaining IC [informed consent] (13), non-medical field workers (trained by a team of epidemiologists LMMV, RGM, and PVB) performed a door-to-door survey of all individuals older than 2 years old.""

""Every person in one out of every four Puerto Pizarro homes (n = 742) was asked to take part in a systematic random sampling.""",Not signing the informed consent form.,2020-11-11,2020-11-30,Household and community samples,Female,Multiple groups,2.0,,Sex/Gender,,742,0.2871,,,,,,,,Simplified probability,Standard Q COVID-19 IgM/IgG Combo,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9903000000000001,0.9865,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Luz M. Moyano,Hospital Amistad Peru Corea Santa Rosa,Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0010794,2022-09-20,2023-07-28,Unverified,moyano_sars-cov-2_2023,PER
230628_PuertoPizarro_HospitalAmistadPeruCoreaSantaRosa_UnAdj_SexMale,230628_PuertoPizarro_HospitalAmistadPeruCoreaSantaRosa,SARS-CoV-2 seroprevalence on the north coast of Peru: A cross-sectional study after the first wave.,2023-06-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Peru,Tumbes,Puerto Pizarro,"""A baseline census was conducted to collect data on households. After obtaining IC [informed consent] (13), non-medical field workers (trained by a team of epidemiologists LMMV, RGM, and PVB) performed a door-to-door survey of all individuals older than 2 years old.""

""Every person in one out of every four Puerto Pizarro homes (n = 742) was asked to take part in a systematic random sampling.""",Not signing the informed consent form.,2020-11-11,2020-11-30,Household and community samples,Male,Multiple groups,2.0,,Sex/Gender,,649,0.22030000000000002,,,,,,,,Simplified probability,Standard Q COVID-19 IgM/IgG Combo,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9903000000000001,0.9865,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Luz M. Moyano,Hospital Amistad Peru Corea Santa Rosa,Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0010794,2022-09-20,2023-07-28,Unverified,moyano_sars-cov-2_2023,PER
230628_PuertoPizarro_HospitalAmistadPeruCoreaSantaRosa_UnAdj_Overall,230628_PuertoPizarro_HospitalAmistadPeruCoreaSantaRosa,SARS-CoV-2 seroprevalence on the north coast of Peru: A cross-sectional study after the first wave.,2023-06-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Peru,Tumbes,Puerto Pizarro,"""A baseline census was conducted to collect data on households. After obtaining IC [informed consent] (13), non-medical field workers (trained by a team of epidemiologists LMMV, RGM, and PVB) performed a door-to-door survey of all individuals older than 2 years old.""

""Every person in one out of every four Puerto Pizarro homes (n = 742) was asked to take part in a systematic random sampling.""",Not signing the informed consent form.,2020-11-11,2020-11-30,Household and community samples,All,Multiple groups,2.0,,Analysis,Unadjusted,1391,0.2559,,,,,,,True,Simplified probability,Standard Q COVID-19 IgM/IgG Combo,SD Biosensor,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9903000000000001,0.9865,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Luz M. Moyano,Hospital Amistad Peru Corea Santa Rosa,Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0010794,2022-09-20,2023-07-28,Unverified,moyano_sars-cov-2_2023,PER
220101_SanLazaroHospital_NagasakiUniversity_OverallTestAdjusted,220101_SanLazaroHospital_NagasakiUniversity,A call to protect non-clinical frontliners in the fight against COVID-19: evidence from a seroprevalence study in the Philippines.,2022-01-01,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Philippines,National Capital Region,Manila,"Employees of San Lazaro Hospital (SLH), a tertiary infectious disease referral hospital in Manila, Philippines.

From March 8 to April 24, 2021, we invited all HCW (around ∼1,200) in the hospital to be part of the study.",,2021-03-08,2021-04-24,Health care workers and caregivers,All,Multiple groups,21.0,,Primary Estimate,Test Adjusted,525,0.36,0.3,0.381,True,True,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Nimfa Putong,Nagasaki University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2021.100353,2022-01-18,2023-08-15,Unverified,putong_call_2022,PHL
220101_SanLazaroHospital_NagasakiUniversity_Age41-60,220101_SanLazaroHospital_NagasakiUniversity,A call to protect non-clinical frontliners in the fight against COVID-19: evidence from a seroprevalence study in the Philippines.,2022-01-01,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Philippines,National Capital Region,Manila,"Employees of San Lazaro Hospital (SLH), a tertiary infectious disease referral hospital in Manila, Philippines.

From March 8 to April 24, 2021, we invited all HCW (around ∼1,200) in the hospital to be part of the study.",,2021-03-08,2021-04-24,Health care workers and caregivers,All,Adults (18-64 years),41.0,60.0,Age,41-60,191,0.3665,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Nimfa Putong,Nagasaki University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2021.100353,2022-01-18,2024-03-01,Unverified,putong_call_2022,PHL
220101_SanLazaroHospital_NagasakiUniversity_Age>60,220101_SanLazaroHospital_NagasakiUniversity,A call to protect non-clinical frontliners in the fight against COVID-19: evidence from a seroprevalence study in the Philippines.,2022-01-01,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Philippines,National Capital Region,Manila,"Employees of San Lazaro Hospital (SLH), a tertiary infectious disease referral hospital in Manila, Philippines.

From March 8 to April 24, 2021, we invited all HCW (around ∼1,200) in the hospital to be part of the study.",,2021-03-08,2021-04-24,Health care workers and caregivers,All,Seniors (65+ years),61.0,,Age,,24,0.375,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Nimfa Putong,Nagasaki University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2021.100353,2022-01-18,2024-03-01,Unverified,putong_call_2022,PHL
220101_SanLazaroHospital_NagasakiUniversity_Age21-40,220101_SanLazaroHospital_NagasakiUniversity,A call to protect non-clinical frontliners in the fight against COVID-19: evidence from a seroprevalence study in the Philippines.,2022-01-01,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Philippines,National Capital Region,Manila,"Employees of San Lazaro Hospital (SLH), a tertiary infectious disease referral hospital in Manila, Philippines.

From March 8 to April 24, 2021, we invited all HCW (around ∼1,200) in the hospital to be part of the study.",,2021-03-08,2021-04-24,Health care workers and caregivers,All,Adults (18-64 years),21.0,40.0,Age,21-40,310,0.3194,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Nimfa Putong,Nagasaki University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2021.100353,2022-01-18,2024-03-01,Unverified,putong_call_2022,PHL
220427_Manila_AteneoDeManilaUniversity_Overall,220427_Manila_AteneoDeManilaUniversity,The prevalence of SARS-CoV-2 antibodies within the community of a private tertiary university in the Philippines: a serial cross sectional study,2022-04-27,Preprint,Local,Cross-sectional survey ,Philippines,,Manila,"""Participants of the study included faculty, administrators, professionals, staff, maintenance, security guards, affiliates, in-campus residents, and students of Ateneo de Manila University (AdMU).""

Ateneo de Manila University is a private tertiary academic university in Manila, the Philippines.",,2021-06-15,2021-12-15,Multiple populations,All,Multiple groups,20.0,87.0,Primary Estimate,,1318,0.478,,,True,,,,True,Convenience,Qualitative Elecsys Anti-SARS-CoV-2 Probe,Roche Diagnostics,LFIA,Whole Blood,IgG,,Validated by manufacturers,0.92,1.0,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Lourdes Bernadette Sumpaico-Tanchanco,Ateneo de Manila University,Not Unity-Aligned,https://dx.doi.org/10.1101/2022.04.25.22274280,2022-09-16,2022-09-23,Unverified,sumpaico-tanchanco_prevalence_2022,PHL
221011_Manila_NagasakiUniversity_Overall,221011_Manila_NagasakiUniversity,"SARS-CoV-2 seroprevalence and infection rate in Manila, Philippines prior to national vaccination program implementation: a repeated cross-sectional analysis.",2022-10-11,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Philippines,,Manila,"""New patients consulting at ABC [animal bite clinic] and/or their household contacts greater than 1 year of age were eligible for enrollment.""

""those who provided written informed consent were enrolled consecutively. There were no limitations on daily recruitment.""",,2020-05-29,2021-03-23,Residual sera,All,Multiple groups,1.0,,Primary Estimate,Periods 1 to 4 combined.,615,0.3935,,,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,TotalAntibody,,Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Greco Mark Malijan,Nagasaki University,Unity-Aligned,https://dx.doi.org/10.1186/s41182-022-00468-7,2022-10-20,2022-10-20,Unverified,malijan_sars-cov-2_2022,PHL
221011_Manila_NagasakiUniversity_SexFemale,221011_Manila_NagasakiUniversity,"SARS-CoV-2 seroprevalence and infection rate in Manila, Philippines prior to national vaccination program implementation: a repeated cross-sectional analysis.",2022-10-11,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Philippines,,Manila,"""New patients consulting at ABC [animal bite clinic] and/or their household contacts greater than 1 year of age were eligible for enrollment.""

""those who provided written informed consent were enrolled consecutively. There were no limitations on daily recruitment.""",,2020-05-29,2021-03-23,Residual sera,Female,Multiple groups,1.0,,Sex/Gender,,342,0.4094,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,TotalAntibody,,Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Greco Mark Malijan,Nagasaki University,Unity-Aligned,https://dx.doi.org/10.1186/s41182-022-00468-7,2022-10-20,2022-10-20,Unverified,malijan_sars-cov-2_2022,PHL
221011_Manila_NagasakiUniversity_Age40-49,221011_Manila_NagasakiUniversity,"SARS-CoV-2 seroprevalence and infection rate in Manila, Philippines prior to national vaccination program implementation: a repeated cross-sectional analysis.",2022-10-11,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Philippines,,Manila,"""New patients consulting at ABC [animal bite clinic] and/or their household contacts greater than 1 year of age were eligible for enrollment.""

""those who provided written informed consent were enrolled consecutively. There were no limitations on daily recruitment.""",,2020-05-29,2021-03-23,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,Age group: 40-49,114,0.386,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,TotalAntibody,,Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Greco Mark Malijan,Nagasaki University,Unity-Aligned,https://dx.doi.org/10.1186/s41182-022-00468-7,2022-10-20,2022-10-20,Unverified,malijan_sars-cov-2_2022,PHL
221011_Manila_NagasakiUniversity_Age18-39,221011_Manila_NagasakiUniversity,"SARS-CoV-2 seroprevalence and infection rate in Manila, Philippines prior to national vaccination program implementation: a repeated cross-sectional analysis.",2022-10-11,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Philippines,,Manila,"""New patients consulting at ABC [animal bite clinic] and/or their household contacts greater than 1 year of age were eligible for enrollment.""

""those who provided written informed consent were enrolled consecutively. There were no limitations on daily recruitment.""",,2020-05-29,2021-03-23,Residual sera,All,Adults (18-64 years),18.0,39.0,Age,Age group: 18-39,335,0.40299999999999997,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,TotalAntibody,,Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Greco Mark Malijan,Nagasaki University,Unity-Aligned,https://dx.doi.org/10.1186/s41182-022-00468-7,2022-10-20,2022-10-20,Unverified,malijan_sars-cov-2_2022,PHL
221011_Manila_NagasakiUniversity_Period3,221011_Manila_NagasakiUniversity,"SARS-CoV-2 seroprevalence and infection rate in Manila, Philippines prior to national vaccination program implementation: a repeated cross-sectional analysis.",2022-10-11,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Philippines,,Manila,"""New patients consulting at ABC [animal bite clinic] and/or their household contacts greater than 1 year of age were eligible for enrollment.""

""those who provided written informed consent were enrolled consecutively. There were no limitations on daily recruitment.""",,2020-12-01,2021-01-15,Residual sera,All,Multiple groups,1.0,,Time frame,Period 3 (1 Dec 2020 to 15 Jan 2021),174,0.46,0.384,0.537,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,TotalAntibody,,Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Greco Mark Malijan,Nagasaki University,Unity-Aligned,https://dx.doi.org/10.1186/s41182-022-00468-7,2022-10-20,2022-10-20,Unverified,malijan_sars-cov-2_2022,PHL
221011_Manila_NagasakiUniversity_Period1,221011_Manila_NagasakiUniversity,"SARS-CoV-2 seroprevalence and infection rate in Manila, Philippines prior to national vaccination program implementation: a repeated cross-sectional analysis.",2022-10-11,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Philippines,,Manila,"""New patients consulting at ABC [animal bite clinic] and/or their household contacts greater than 1 year of age were eligible for enrollment.""

""those who provided written informed consent were enrolled consecutively. There were no limitations on daily recruitment.""",,2020-05-29,2020-07-03,Residual sera,All,Multiple groups,1.0,,Time frame,Period 1 (29 May 2020 to 3 Jul 2020),115,0.113,0.065,0.18600000000000003,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,TotalAntibody,,Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Greco Mark Malijan,Nagasaki University,Unity-Aligned,https://dx.doi.org/10.1186/s41182-022-00468-7,2022-10-20,2022-10-20,Unverified,malijan_sars-cov-2_2022,PHL
221011_Manila_NagasakiUniversity_Period4,221011_Manila_NagasakiUniversity,"SARS-CoV-2 seroprevalence and infection rate in Manila, Philippines prior to national vaccination program implementation: a repeated cross-sectional analysis.",2022-10-11,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Philippines,,Manila,"""New patients consulting at ABC [animal bite clinic] and/or their household contacts greater than 1 year of age were eligible for enrollment.""

""those who provided written informed consent were enrolled consecutively. There were no limitations on daily recruitment.""",,2021-03-01,2021-03-23,Residual sera,All,Multiple groups,1.0,,Time frame,Period 4 (1 Mar 2021 to 23 Mar 2021),168,0.446,0.37,0.525,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,TotalAntibody,,Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Greco Mark Malijan,Nagasaki University,Unity-Aligned,https://dx.doi.org/10.1186/s41182-022-00468-7,2022-10-20,2022-10-20,Unverified,malijan_sars-cov-2_2022,PHL
221011_Manila_NagasakiUniversity_SexMale,221011_Manila_NagasakiUniversity,"SARS-CoV-2 seroprevalence and infection rate in Manila, Philippines prior to national vaccination program implementation: a repeated cross-sectional analysis.",2022-10-11,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Philippines,,Manila,"""New patients consulting at ABC [animal bite clinic] and/or their household contacts greater than 1 year of age were eligible for enrollment.""

""those who provided written informed consent were enrolled consecutively. There were no limitations on daily recruitment.""",,2020-05-29,2021-03-23,Residual sera,Male,Multiple groups,1.0,,Sex/Gender,,273,0.3736,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,TotalAntibody,,Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Greco Mark Malijan,Nagasaki University,Unity-Aligned,https://dx.doi.org/10.1186/s41182-022-00468-7,2022-10-20,2022-10-20,Unverified,malijan_sars-cov-2_2022,PHL
221011_Manila_NagasakiUniversity_Age50-59,221011_Manila_NagasakiUniversity,"SARS-CoV-2 seroprevalence and infection rate in Manila, Philippines prior to national vaccination program implementation: a repeated cross-sectional analysis.",2022-10-11,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Philippines,,Manila,"""New patients consulting at ABC [animal bite clinic] and/or their household contacts greater than 1 year of age were eligible for enrollment.""

""those who provided written informed consent were enrolled consecutively. There were no limitations on daily recruitment.""",,2020-05-29,2021-03-23,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,Age group: 50-59,80,0.3875,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,TotalAntibody,,Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Greco Mark Malijan,Nagasaki University,Unity-Aligned,https://dx.doi.org/10.1186/s41182-022-00468-7,2022-10-20,2022-10-20,Unverified,malijan_sars-cov-2_2022,PHL
221011_Manila_NagasakiUniversity_Period2,221011_Manila_NagasakiUniversity,"SARS-CoV-2 seroprevalence and infection rate in Manila, Philippines prior to national vaccination program implementation: a repeated cross-sectional analysis.",2022-10-11,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Philippines,,Manila,"""New patients consulting at ABC [animal bite clinic] and/or their household contacts greater than 1 year of age were eligible for enrollment.""

""those who provided written informed consent were enrolled consecutively. There were no limitations on daily recruitment.""",,2020-08-28,2020-09-25,Residual sera,All,Multiple groups,1.0,,Time frame,Period 2 (28 Aug 2020 to 25 Sep 2020),158,0.46799999999999997,0.389,0.549,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,TotalAntibody,,Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Greco Mark Malijan,Nagasaki University,Unity-Aligned,https://dx.doi.org/10.1186/s41182-022-00468-7,2022-10-20,2022-10-20,Unverified,malijan_sars-cov-2_2022,PHL
221011_Manila_NagasakiUniversity_AgeBelow18,221011_Manila_NagasakiUniversity,"SARS-CoV-2 seroprevalence and infection rate in Manila, Philippines prior to national vaccination program implementation: a repeated cross-sectional analysis.",2022-10-11,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Philippines,,Manila,"""New patients consulting at ABC [animal bite clinic] and/or their household contacts greater than 1 year of age were eligible for enrollment.""

""those who provided written informed consent were enrolled consecutively. There were no limitations on daily recruitment.""",,2020-05-29,2021-03-23,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Age,Age group: Below 18,57,0.42110000000000003,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,TotalAntibody,,Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Greco Mark Malijan,Nagasaki University,Unity-Aligned,https://dx.doi.org/10.1186/s41182-022-00468-7,2022-10-20,2022-10-20,Unverified,malijan_sars-cov-2_2022,PHL
221011_Manila_NagasakiUniversity_Age60andAbove,221011_Manila_NagasakiUniversity,"SARS-CoV-2 seroprevalence and infection rate in Manila, Philippines prior to national vaccination program implementation: a repeated cross-sectional analysis.",2022-10-11,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Philippines,,Manila,"""New patients consulting at ABC [animal bite clinic] and/or their household contacts greater than 1 year of age were eligible for enrollment.""

""those who provided written informed consent were enrolled consecutively. There were no limitations on daily recruitment.""",,2020-05-29,2021-03-23,Residual sera,All,Seniors (65+ years),60.0,,Age,Age group: 60 and above,29,0.2759,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,TotalAntibody,,Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Greco Mark Malijan,Nagasaki University,Unity-Aligned,https://dx.doi.org/10.1186/s41182-022-00468-7,2022-10-20,2022-10-20,Unverified,malijan_sars-cov-2_2022,PHL
221109_Bohol_Gov.CelestinoGallaresMemorialHospital,221109_Bohol_Gov.CelestinoGallaresMemorialHospital,"Clinico-Demographic Characteristics of Patients with SARS-CoV-2 Antibodies: A Single Tertiary Center Retrospective Study in Bohol, Philippines",2022-11-09,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Philippines,,Bohol,patients at Gov. Celestino Gallares Memorial Hospital,,2020-07-01,2021-05-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,4138,0.044500000000000005,,,True,,,,True,Unclear,Author designed (CLIA),,CLIA,,,,,,,['High'],,Unclear,Yes,No,,Unclear,Yes,No,,A L Salillas,Gov. Celestino Gallares Memorial Hospital,Not Unity-Aligned,https://dx.doi.org/10.1093/ajcp/aqac126.304,2023-02-10,2023-03-19,Unverified,salillas_clinico-demographic_2022,PHL
201011_Mazowieckie_MedicalUniversityofWarsaw_IgG_Overall,201011_Mazowieckie_MedicalUniversityofWarsaw,"Prevalence of current and past SARS-CoV-2 infections among police employees in Poland, june-july 2020",2020-10-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Poland,Mazowieckie Province,,police employees (police officers and civilian employees) from Mazowieckie Province in Poland,"The exclusion criteria include refusal to participate, lack of a signed informed consent, hospitalization, quarantine, leave, and secondment to work in another police unit that was not selected for the survey.",2020-06-22,2020-07-08,Essential non-healthcare workers,All,Multiple groups,20.0,,Primary Estimate,Overall IgG,5082,0.043,0.037000000000000005,0.049,True,,,,True,Stratified probability,COVID-19 ELISA IgG,Vircell S.L.,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.97,0.9400000000000001,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,No,Mariusz Gujski,Medical University of Warsaw,Not Unity-Aligned,http://dx.doi.org/10.3390/jcm9103245,2021-01-29,2024-03-01,Verified,gujski_prevalence_2020,POL
201011_Mazowieckie_MedicalUniversityofWarsaw_IgG_Age_60+,201011_Mazowieckie_MedicalUniversityofWarsaw,"Prevalence of current and past SARS-CoV-2 infections among police employees in Poland, june-july 2020",2020-10-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Poland,Mazowieckie Province,,police employees (police officers and civilian employees) from Mazowieckie Province in Poland,"The exclusion criteria include refusal to participate, lack of a signed informed consent, hospitalization, quarantine, leave, and secondment to work in another police unit that was not selected for the survey.",2020-06-22,2020-07-08,Essential non-healthcare workers,All,Seniors (65+ years),60.0,,Age,60+ years,141,0.085,,,,,,,,Stratified probability,COVID-19 ELISA IgG,Vircell S.L.,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.97,0.9400000000000001,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,No,Mariusz Gujski,Medical University of Warsaw,Not Unity-Aligned,http://dx.doi.org/10.3390/jcm9103245,2021-02-17,2024-03-01,Verified,gujski_prevalence_2020,POL
201011_Mazowieckie_MedicalUniversityofWarsaw_IgG_Age_45-59,201011_Mazowieckie_MedicalUniversityofWarsaw,"Prevalence of current and past SARS-CoV-2 infections among police employees in Poland, june-july 2020",2020-10-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Poland,Mazowieckie Province,,police employees (police officers and civilian employees) from Mazowieckie Province in Poland,"The exclusion criteria include refusal to participate, lack of a signed informed consent, hospitalization, quarantine, leave, and secondment to work in another police unit that was not selected for the survey.",2020-06-22,2020-07-08,Essential non-healthcare workers,All,Adults (18-64 years),45.0,59.0,Age,45-59 years,1254,0.04,,,,,,,,Stratified probability,COVID-19 ELISA IgG,Vircell S.L.,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.97,0.9400000000000001,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,No,Mariusz Gujski,Medical University of Warsaw,Not Unity-Aligned,http://dx.doi.org/10.3390/jcm9103245,2021-02-17,2024-03-01,Verified,gujski_prevalence_2020,POL
201011_Mazowieckie_MedicalUniversityofWarsaw_IgG_Age_20-29,201011_Mazowieckie_MedicalUniversityofWarsaw,"Prevalence of current and past SARS-CoV-2 infections among police employees in Poland, june-july 2020",2020-10-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Poland,Mazowieckie Province,,police employees (police officers and civilian employees) from Mazowieckie Province in Poland,"The exclusion criteria include refusal to participate, lack of a signed informed consent, hospitalization, quarantine, leave, and secondment to work in another police unit that was not selected for the survey.",2020-06-22,2020-07-08,Essential non-healthcare workers,All,Adults (18-64 years),20.0,29.0,Age,20-29 years,688,0.032,,,,,,,,Stratified probability,COVID-19 ELISA IgG,Vircell S.L.,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.97,0.9400000000000001,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,No,Mariusz Gujski,Medical University of Warsaw,Not Unity-Aligned,http://dx.doi.org/10.3390/jcm9103245,2021-02-17,2024-03-01,Verified,gujski_prevalence_2020,POL
201011_Mazowieckie_MedicalUniversityofWarsaw_IgG_Age_30-39,201011_Mazowieckie_MedicalUniversityofWarsaw,"Prevalence of current and past SARS-CoV-2 infections among police employees in Poland, june-july 2020",2020-10-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Poland,Mazowieckie Province,,police employees (police officers and civilian employees) from Mazowieckie Province in Poland,"The exclusion criteria include refusal to participate, lack of a signed informed consent, hospitalization, quarantine, leave, and secondment to work in another police unit that was not selected for the survey.",2020-06-22,2020-07-08,Essential non-healthcare workers,All,Adults (18-64 years),30.0,39.0,Age,30-39 years,2999,0.044000000000000004,,,,,,,,Stratified probability,COVID-19 ELISA IgG,Vircell S.L.,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.97,0.9400000000000001,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,No,Mariusz Gujski,Medical University of Warsaw,Not Unity-Aligned,http://dx.doi.org/10.3390/jcm9103245,2021-02-17,2024-03-01,Verified,gujski_prevalence_2020,POL
201222_Warsaw_CentralClinicalHospitalMSWiA,201222_Warsaw_CentralClinicalHospitalMSWiA,The prevalence of SARS-CoV-2 infection and the severity of the course of COVID-19 in patients with psoriasis treated with biologic therapy.,2020-12-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Poland,,Warsaw,All patients with moderate to severe psoriasis treated with biologics in the Dermatology Department of Central Clinical Hospital of Ministry of the Interior and Administration in Warsaw were enrolled into the study. ,,2020-04-01,2020-10-31,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),,,Primary Estimate,Primary,61,0.16390000000000002,,,True,,,,True,Sequential,"COVID-19 ELISA IgG,COVID-19 ELISA IgM/IgA",Vircell S.L.,ELISA,Serum,"['IgA', 'IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['High'],Yes,No,No,Yes,Yes,Yes,Yes,No,Yes,Piotr Ciechanowicz,Central ClinicalHospital MSWiA,Not Unity-Aligned,https://dx.doi.org/10.1080/09546634.2020.1861177,2021-03-07,2024-03-01,Verified,ciechanowicz_prevalence_2020,POL
210205_Poland_CentralClinicalHospital_HCWs_IgG,210205_Poland_CentralClinicalHospital_HCW,Inflammatory bowel disease is associated with higher seroprevalence rates of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),2021-02-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Poland,,,"The control group consisted of non-IBD health professionals – employees of the Central Clinical Hospital of the Ministry of the Interior and Administration in Warsaw (n=1036). To correctly compare IBD patients with non-IBD individuals, a propensity matching method was applied by using a logistic regression model (n=432).",,2020-05-01,2020-06-15,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,432,0.016,,,True,,,,True,Stratified non-probability,COVID-19 ELISA IgG,Vircell S.L.,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.85,0.98,['High'],,No,No,Yes,,No,Yes,No,,Michal Lodyga,Central Clinical Hospital of the Ministry of the Interior and Administration,Not Unity-Aligned,https://dx.doi.org/10.20452/pamw.15796,2021-02-23,2024-03-01,Verified,lodyga_inflammatory_2021,POL
210205_Poland_CentralClinicalHospital_IBDPatients_IgG,210205_Poland_CentralClinicalHospital_IBDPatients,Inflammatory bowel disease is associated with higher seroprevalence rates of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),2021-02-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Poland,,,"Three tertiary centers, recruiting patients from three different geographical areas in Poland – east-central (Warsaw), western (Poznan), and south-central (Lodz), participated in the study. All consecutive IBD patients visiting hospitals from 1st May to 15th June 2020, were included in the analysis. The visits were either due to the continuation of biological treatment or due to disease exacerbation.",,2020-05-01,2020-06-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,432,0.046,,,True,,,,True,Sequential,COVID-19 ELISA IgG,Vircell S.L.,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.88,0.99,['High'],No,No,No,Yes,Yes,No,Yes,No,,Michal Lodyga,Central Clinical Hospital of the Ministry of the Interior and Administration,Not Unity-Aligned,https://dx.doi.org/10.20452/pamw.15796,2021-02-23,2024-03-01,Verified,lodyga_inflammatory_2021,POL
210317_SilesianVoivodeship_JanKochanowskiUniversity,210317_SilesianVoivodeship_JanKochanowskiUniversity,Rapid serological tests for SARS-CoV-2 IgG/IgM - not worth attention?.,2021-03-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Poland,Silesian Voivodeship,,"asymptomatic employees in 2 companies located in the Silesian Voivodeship, Poland",,2020-05-15,2020-06-15,Non-essential workers and unemployed persons,All,Adults (18-64 years),18.0,65.0,Primary Estimate,Overall employee group,516,0.0194,,,True,,,,True,Convenience,2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,Nanjing Vazyme Medical Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],No,No,No,No,Unclear,No,Yes,No,No,Rafal Krygier, Jan Kochanowski University,Not Unity-Aligned,https://dx.doi.org/10.13075/ijomeh.1896.01756,2021-05-18,2024-02-29,Verified,krygier_rapid_2021,POL
210331_Poznań_PolishAcademyofSciences_Primary,210331_Poznań_PolishAcademyofSciences,"Prevalence of anti-SARS-CoV-2 antibodies in Poznan Poland, after the first wave of the COVID-19 pandemic",2021-03-31,Preprint,Local,Cross-sectional survey ,Poland,Greater Poland,Poznań,"We randomly selected and invited 1500 adult (over 18 years old) study participants from approximately 15,000 volunteers living in the Poznań metropolitan area",,2020-07-15,2020-09-15,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,Overall estimate,1500,0.009300000000000001,0.005600000000000001,0.015600000000000001,True,,,,True,Simplified probability,"Anti-SARS-CoV-2 ELISA IgG,anti-SARS-CoV-2 IgG immunoblot","EUROIMMUN,Polycheck",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Dagny Lorent,Polish Academy of Sciences,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.29.21254544v1.full,2021-05-14,2024-03-01,Verified,lorent_prevalence_2021,POL
210331_Poznań_PolishAcademyofSciences_50-65,210331_Poznań_PolishAcademyofSciences,"Prevalence of anti-SARS-CoV-2 antibodies in Poznan Poland, after the first wave of the COVID-19 pandemic",2021-03-31,Preprint,Local,Cross-sectional survey ,Poland,Greater Poland,Poznań,"We randomly selected and invited 1500 adult (over 18 years old) study participants from approximately 15,000 volunteers living in the Poznań metropolitan area",,2020-07-15,2020-09-15,Household and community samples,All,Adults (18-64 years),50.0,65.0,Age,50-65,194,0.0,0.0,0.0194,,,,,,Simplified probability,"Anti-SARS-CoV-2 ELISA IgG,anti-SARS-CoV-2 IgG immunoblot","EUROIMMUN,Polycheck",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Dagny Lorent,Polish Academy of Sciences,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.29.21254544v1.full,2021-07-30,2024-03-01,Verified,lorent_prevalence_2021,POL
210331_Poznań_PolishAcademyofSciences_Female,210331_Poznań_PolishAcademyofSciences,"Prevalence of anti-SARS-CoV-2 antibodies in Poznan Poland, after the first wave of the COVID-19 pandemic",2021-03-31,Preprint,Local,Cross-sectional survey ,Poland,Greater Poland,Poznań,"We randomly selected and invited 1500 adult (over 18 years old) study participants from approximately 15,000 volunteers living in the Poznań metropolitan area",,2020-07-15,2020-09-15,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,Female,896,0.0089,0.0045000000000000005,0.0175,,,,,,Simplified probability,"Anti-SARS-CoV-2 ELISA IgG,anti-SARS-CoV-2 IgG immunoblot","EUROIMMUN,Polycheck",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Dagny Lorent,Polish Academy of Sciences,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.29.21254544v1.full,2021-07-30,2024-03-01,Verified,lorent_prevalence_2021,POL
210331_Poznań_PolishAcademyofSciences_Male,210331_Poznań_PolishAcademyofSciences,"Prevalence of anti-SARS-CoV-2 antibodies in Poznan Poland, after the first wave of the COVID-19 pandemic",2021-03-31,Preprint,Local,Cross-sectional survey ,Poland,Greater Poland,Poznań,"We randomly selected and invited 1500 adult (over 18 years old) study participants from approximately 15,000 volunteers living in the Poznań metropolitan area",,2020-07-15,2020-09-15,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,Male,604,0.0099,0.0046,0.0215,,,,,,Simplified probability,"Anti-SARS-CoV-2 ELISA IgG,anti-SARS-CoV-2 IgG immunoblot","EUROIMMUN,Polycheck",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Dagny Lorent,Polish Academy of Sciences,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.29.21254544v1.full,2021-07-30,2024-03-01,Verified,lorent_prevalence_2021,POL
210331_Poznań_PolishAcademyofSciences_18-33,210331_Poznań_PolishAcademyofSciences,"Prevalence of anti-SARS-CoV-2 antibodies in Poznan Poland, after the first wave of the COVID-19 pandemic",2021-03-31,Preprint,Local,Cross-sectional survey ,Poland,Greater Poland,Poznań,"We randomly selected and invited 1500 adult (over 18 years old) study participants from approximately 15,000 volunteers living in the Poznań metropolitan area",,2020-07-15,2020-09-15,Household and community samples,All,Adults (18-64 years),18.0,33.0,Age,18-33,623,0.008,0.0034000000000000002,0.0187,,,,,,Simplified probability,"Anti-SARS-CoV-2 ELISA IgG,anti-SARS-CoV-2 IgG immunoblot","EUROIMMUN,Polycheck",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Dagny Lorent,Polish Academy of Sciences,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.29.21254544v1.full,2021-07-30,2024-03-01,Verified,lorent_prevalence_2021,POL
210331_Poznań_PolishAcademyofSciences_34-49,210331_Poznań_PolishAcademyofSciences,"Prevalence of anti-SARS-CoV-2 antibodies in Poznan Poland, after the first wave of the COVID-19 pandemic",2021-03-31,Preprint,Local,Cross-sectional survey ,Poland,Greater Poland,Poznań,"We randomly selected and invited 1500 adult (over 18 years old) study participants from approximately 15,000 volunteers living in the Poznań metropolitan area",,2020-07-15,2020-09-15,Household and community samples,All,Adults (18-64 years),34.0,49.0,Age,34-49,606,0.0116,0.005600000000000001,0.023700000000000002,,,,,,Simplified probability,"Anti-SARS-CoV-2 ELISA IgG,anti-SARS-CoV-2 IgG immunoblot","EUROIMMUN,Polycheck",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Dagny Lorent,Polish Academy of Sciences,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.29.21254544v1.full,2021-07-30,2024-03-01,Verified,lorent_prevalence_2021,POL
210331_Poznań_PolishAcademyofSciences_65+,210331_Poznań_PolishAcademyofSciences,"Prevalence of anti-SARS-CoV-2 antibodies in Poznan Poland, after the first wave of the COVID-19 pandemic",2021-03-31,Preprint,Local,Cross-sectional survey ,Poland,Greater Poland,Poznań,"We randomly selected and invited 1500 adult (over 18 years old) study participants from approximately 15,000 volunteers living in the Poznań metropolitan area",,2020-07-15,2020-09-15,Household and community samples,All,Seniors (65+ years),65.0,,Age,65+,77,0.026000000000000002,0.0046,0.08990000000000001,,,,,,Simplified probability,"Anti-SARS-CoV-2 ELISA IgG,anti-SARS-CoV-2 IgG immunoblot","EUROIMMUN,Polycheck",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Dagny Lorent,Polish Academy of Sciences,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.29.21254544v1.full,2021-07-30,2024-03-01,Verified,lorent_prevalence_2021,POL
210401_Warsaw_Children’sMemorialHealthInstitute_HCW,210401_Warsaw_Children’sMemorialHealthInstitute,Prevalence of IgG antibodies against SARS-CoV-2 among healthcare workers in a tertiary pediatric hospital in Poland,2021-04-01,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Poland,,Warsaw,"Testing was made available for all HCWs (including physicians, nurses, and other workers with direct patient contact, i.e. physical therapists, as well as workers without direct
patient contact, i.e. laboratory workers, pharmacists, administrative staff, maintenance staff,
etc.). All participants were asymptomatic at the time of serology testing. In particular, the study included participants who were previously symptomatic but had no symptoms for at
least 14 days.",,2020-07-01,2020-08-09,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1879,0.0085,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.99,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Beata Kasztelewicz,Children’s Memorial Health Institute,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0249550,2021-05-02,2024-03-01,Unverified,kasztelewicz_prevalence_2020,POL
210419_Lublin_MedicalUniversityofLublin_HealthyControls,210419_Lublin_MedicalUniversityofLublin_HealthyControls,Seroprevalence of Antibodies against SARS-CoV-2 in Children with Juvenile Idiopathic Arthritis a Case-Control Study.,2021-04-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Poland,Lublin Voivodeship,Lublin,healthy children of health workers.,"We excluded children taking medication affecting the immune system; reporting symptoms of infection in the last three months before the study; or patients with diagnosed chronic diseases, such as allergies, inflammatory, autoimmune, or oncological diseases. ",2020-06-01,2020-09-30,Household and community samples,All,Children and Youth (0-17 years),1.0,18.0,Primary Estimate,Healthy controls overall,32,0.063,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,0.919,['High'],No,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Violetta Opoka Winiarska ,Medical University of Lublin,Not Unity-Aligned,https://dx.doi.org/10.3390/jcm10081771,2021-05-19,2024-03-01,Verified,opoka-winiarska_seroprevalence_2021,POL
210419_Lublin_MedicalUniversityofLublin_JIA,210419_Lublin_MedicalUniversityofLublin_JIA,Seroprevalence of Antibodies against SARS-CoV-2 in Children with Juvenile Idiopathic Arthritis a Case-Control Study.,2021-04-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Poland,Lublin Voivodeship,Lublin,"The JIA group included children with oligoarthritis (n = 29), polyarthritis with positive rheumatoid factor (RF) (n = 5), polyarthritis with negative RF (n = 13) and psoriatic arthritis (n = 3), enthesitis-related arthritis (n = 10), and systemic arthritis (n = 2). "," Patients with JIA in remission without treatment were excluded from the study because, in this group, the disease activity (the indicator studied) was, by definition, low.",2020-06-01,2020-09-30,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),2.0,18.0,Primary Estimate,overall JIA patients ,62,0.048,,,True,,,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,0.919,['High'],No,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Violetta Opoka Winiarska ,Medical University of Lublin,Not Unity-Aligned,https://dx.doi.org/10.3390/jcm10081771,2021-05-19,2024-03-01,Verified,opoka-winiarska_seroprevalence_2021,POL
210420_Bytom1_UniversityofOpole,210420_Bytom1_UniversityofOpole,SARS-CoV-2 Antibody Screening in Healthcare Workers in Non-Infectious Hospitals in Two Different Regions of Southern Poland (Upper Silesia and Opole Voivodeships): A Prospective Cohort Study.,2021-04-20,Journal Article (Peer-Reviewed),Local,Prospective cohort,Poland,Silesian,Bytom,The remaining inclusion criteria for the study were for volunteers to have signed a form of informed consent to participate in a medical experiment project and to have enjoyed good or very good health status.,"The study excluded volunteers with a positive SARS-CoV-2 test by RT-PCR, with an active form of respiratory tract infection, ones with a CRP (C-reactive protein) result above the reference value, ones of generally poor health (subjective assessment of the subject), ones who had not agreed to participate in the study, those who had not completed the diagnostic questionnaire, ones who lacked continuity in professional activity within the period of 6 weeks prior to recruitment to the medical experiment, and volunteers under 18 years of age. We did not include volunteers who were RT-PCR positive in the analysis because 100% of (+) RT-PCR patients are IgG seropositive 10–19 days after infection [16,17]. Thus, we would have overestimated the numbers and we only wanted to screen active HCWs who did not know whether they had contracted SARS-CoV-2 infection (the social aspect of our study), especially since in addition to the scientific aspect of the result, the volunteers received a diagnostically reliable test result (double blood draw to avoid the risk of a serological window).",2020-07-15,2020-08-15,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,90,0.1,,,True,,,,True,Convenience,Anti-SARS-CoV-2 NCP ELISA (IgG),EUROIMMUN,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,0.99,['High'],,No,No,Yes,,Yes,Yes,Yes,,Rafal Jakub Buldak,University of Opole,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph18084376,2021-05-21,2024-03-01,Unverified,buldakSARSCoV2AntibodyScreening2021,POL
210420_MiasteczkoSlaskie2_UniversityofOpole,210420_MiasteczkoSlaskie2_UniversityofOpole,SARS-CoV-2 Antibody Screening in Healthcare Workers in Non-Infectious Hospitals in Two Different Regions of Southern Poland (Upper Silesia and Opole Voivodeships): A Prospective Cohort Study.,2021-04-20,Journal Article (Peer-Reviewed),Local,Prospective cohort,Poland,Silesian,Miasteczko Slaskie,The remaining inclusion criteria for the study were for volunteers to have signed a form of informed consent to participate in a medical experiment project and to have enjoyed good or very good health status.,"The study excluded volunteers with a positive SARS-CoV-2 test by RT-PCR, with an active form of respiratory tract infection, ones with a CRP (C-reactive protein) result above the reference value, ones of generally poor health (subjective assessment of the subject), ones who had not agreed to participate in the study, those who had not completed the diagnostic questionnaire, ones who lacked continuity in professional activity within the period of 6 weeks prior to recruitment to the medical experiment, and volunteers under 18 years of age. We did not include volunteers who were RT-PCR positive in the analysis because 100% of (+) RT-PCR patients are IgG seropositive 10–19 days after infection [16,17]. Thus, we would have overestimated the numbers and we only wanted to screen active HCWs who did not know whether they had contracted SARS-CoV-2 infection (the social aspect of our study), especially since in addition to the scientific aspect of the result, the volunteers received a diagnostically reliable test result (double blood draw to avoid the risk of a serological window).",2020-07-15,2020-08-15,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,25,0.04,,,True,,,,True,Convenience,Anti-SARS-CoV-2 NCP ELISA (IgG),EUROIMMUN,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,0.99,['High'],,No,No,Yes,,Yes,Yes,Yes,,Rafal Jakub Buldak,University of Opole,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph18084376,2021-05-21,2024-03-01,Unverified,buldakSARSCoV2AntibodyScreening2021,POL
210420_Opole3_UniversityofOpole,210420_Opole3_UniversityofOpole,SARS-CoV-2 Antibody Screening in Healthcare Workers in Non-Infectious Hospitals in Two Different Regions of Southern Poland (Upper Silesia and Opole Voivodeships): A Prospective Cohort Study.,2021-04-20,Journal Article (Peer-Reviewed),Local,Prospective cohort,Poland,Opole,Opole,The remaining inclusion criteria for the study were for volunteers to have signed a form of informed consent to participate in a medical experiment project and to have enjoyed good or very good health status.,"The study excluded volunteers with a positive SARS-CoV-2 test by RT-PCR, with an active form of respiratory tract infection, ones with a CRP (C-reactive protein) result above the reference value, ones of generally poor health (subjective assessment of the subject), ones who had not agreed to participate in the study, those who had not completed the diagnostic questionnaire, ones who lacked continuity in professional activity within the period of 6 weeks prior to recruitment to the medical experiment, and volunteers under 18 years of age. We did not include volunteers who were RT-PCR positive in the analysis because 100% of (+) RT-PCR patients are IgG seropositive 10–19 days after infection [16,17]. Thus, we would have overestimated the numbers and we only wanted to screen active HCWs who did not know whether they had contracted SARS-CoV-2 infection (the social aspect of our study), especially since in addition to the scientific aspect of the result, the volunteers received a diagnostically reliable test result (double blood draw to avoid the risk of a serological window).",2020-07-15,2020-08-15,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,84,0.011899999999999999,,,True,,,,True,Convenience,Anti-SARS-CoV-2 NCP ELISA (IgG),EUROIMMUN,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,0.99,['High'],,No,No,Yes,,Yes,Yes,Yes,,Rafal Jakub Buldak,University of Opole,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph18084376,2021-05-21,2024-03-01,Unverified,buldakSARSCoV2AntibodyScreening2021,POL
210415_Poland_MedicalUniversityOfSilesiaInKatowice_Overall,210421_Poland_MedicalUniversityOfSilesiaInKatowice,"Association between Influenza Vaccination and Positive SARS-CoV-2 IgG and IgM Tests in the General Population of Katowice Region, Poland.",2021-04-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Poland,Silesian Voivodeship,"Katowice, Gliwice, Sosnowiec","General population in the Silesian Voivodeship (Katowice, Gliwice, and Sosnowiec) with records at the central statistical office in Poland",,2020-10-15,2020-11-15,Household and community samples,All,Multiple groups,,,Primary Estimate,general population of the Silesian Voivodeship,5479,0.22899999999999998,,,True,,,,True,Self-referral,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA",EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Małgorzata Kowalska,Medical University of SilesiaIn Katowice,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines9050415,2021-05-28,2024-03-01,Verified,kowalska_association_2021,POL
210415_Poland_MedicalUniversityOfSilesiaInKatowice_Age_<65,210421_Poland_MedicalUniversityOfSilesiaInKatowice,"Association between Influenza Vaccination and Positive SARS-CoV-2 IgG and IgM Tests in the General Population of Katowice Region, Poland.",2021-04-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Poland,Silesian Voivodeship,"Katowice, Gliwice, Sosnowiec","General population in the Silesian Voivodeship (Katowice, Gliwice, and Sosnowiec) with records at the central statistical office in Poland",,2020-10-15,2020-11-15,Household and community samples,All,Adults (18-64 years),,,Age,,681,0.1439,,,,,,,,Self-referral,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,0.99,0.88,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Małgorzata Kowalska,Medical University of SilesiaIn Katowice,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines9050415,2021-06-05,2024-03-01,Verified,kowalska_association_2021,POL
210415_Poland_MedicalUniversityOfSilesiaInKatowice_Male,210421_Poland_MedicalUniversityOfSilesiaInKatowice,"Association between Influenza Vaccination and Positive SARS-CoV-2 IgG and IgM Tests in the General Population of Katowice Region, Poland.",2021-04-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Poland,Silesian Voivodeship,"Katowice, Gliwice, Sosnowiec","General population in the Silesian Voivodeship (Katowice, Gliwice, and Sosnowiec) with records at the central statistical office in Poland",,2020-10-15,2020-11-15,Household and community samples,Male,Multiple groups,,,Sex/Gender,,2287,0.1968,,,,,,,,Self-referral,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,0.99,0.88,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Małgorzata Kowalska,Medical University of SilesiaIn Katowice,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines9050415,2021-06-05,2024-03-01,Verified,kowalska_association_2021,POL
210415_Poland_MedicalUniversityOfSilesiaInKatowice_Age_65+,210421_Poland_MedicalUniversityOfSilesiaInKatowice,"Association between Influenza Vaccination and Positive SARS-CoV-2 IgG and IgM Tests in the General Population of Katowice Region, Poland.",2021-04-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Poland,Silesian Voivodeship,"Katowice, Gliwice, Sosnowiec","General population in the Silesian Voivodeship (Katowice, Gliwice, and Sosnowiec) with records at the central statistical office in Poland",,2020-10-15,2020-11-15,Household and community samples,All,Seniors (65+ years),,,Age,,4741,0.21920000000000003,,,,,,,,Self-referral,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,0.99,0.88,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Małgorzata Kowalska,Medical University of SilesiaIn Katowice,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines9050415,2021-06-05,2024-03-01,Verified,kowalska_association_2021,POL
210415_Poland_MedicalUniversityOfSilesiaInKatowice_Female,210421_Poland_MedicalUniversityOfSilesiaInKatowice,"Association between Influenza Vaccination and Positive SARS-CoV-2 IgG and IgM Tests in the General Population of Katowice Region, Poland.",2021-04-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Poland,Silesian Voivodeship,"Katowice, Gliwice, Sosnowiec","General population in the Silesian Voivodeship (Katowice, Gliwice, and Sosnowiec) with records at the central statistical office in Poland",,2020-10-15,2020-11-15,Household and community samples,Female,Multiple groups,,,Sex/Gender,,3192,0.21300000000000002,,,,,,,,Self-referral,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,0.99,0.88,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,No,,Małgorzata Kowalska,Medical University of SilesiaIn Katowice,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines9050415,2021-06-05,2024-03-01,Verified,kowalska_association_2021,POL
210527_Krakow_JagiellonianUniversityMedicalCollege_Primary,210527_Krakow_JagiellonianUniversityMedicalCollege,SARS-CoV-2 infection and seroconversion in pediatric patients on biological therapy for Crohn's disease: single tertiary center experience,2021-05-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Poland,,Kraskow,"All patients undergoing
biologic therapy with infliximab, adalimumab, or vedolizumab for
mild-to moderate CD",,2020-03-04,2021-03-03,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),2.0,19.0,Primary Estimate,,62,0.306,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Architect Anti-SARS-CoV-2 IgM",Abbott Laboratories,CLIA,Serum,"['IgG', 'IgM']",,,,,['High'],,No,No,Yes,,No,Yes,No,,Ruth Sladek,Jagiellonian University Medical College,Not Unity-Aligned,https://academic.oup.com/ecco-jcc/article/15/Supplement_1/S372/6286668,2021-11-24,2024-03-01,Unverified,sladek_p351_2021,POL
210608_Warsaw_CentralClinicalHospitalOfTheMinistryOfInterior,210608_Warsaw_CentralClinicalHospitalOfTheMinistryOfInterior,Dynamics of humoral response to coronavirus antigens among employees of COVID-dedicated hospital: an observational study.,2021-06-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Poland,Mazovia,Warsaw,Every employee of the Central Clinical Hospital of the Ministry of Interior and Administration in Warsaw who did at least one test for levels of anti-SARS-CoV-2 antibodies between 21st April 2020 and 20th July 2020,,2020-04-21,2020-07-20,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1572,0.227,,,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Radosław Rzeplinski,Central Clinical Hospital of the Ministry of Interior and Administration,Not Unity-Aligned,https://dx.doi.org/10.20452/pamw.16025,2021-06-19,2022-07-16,Unverified,rzeplinski_dynamics_2021,POL
210625_Wroclaw_RegionalSpecialistHospitalInWrocław_overall,210625_Wroclaw_RegionalSpecialistHospitalInWrocław,Hidden fraction of Polish population immune to SARS-CoV-2 in May 2021,2021-06-25,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Poland,Silesia,Wroclaw,"healthy individuals (over 17 years old), who had not been vaccinated against COVID-19 with any kind of vaccine, nor had they ever been diagnosed positively for SARS-CoV-2 infection",,2021-05-15,2021-05-22,Household and community samples,All,Multiple groups,17.0,,Primary Estimate,,501,0.5910000000000001,,,True,,,,True,Unclear,"Microblot-Array COVID-19 IgG,Microblot-Array COVID-19 IgA",TestLine Clinical Diagnostics,Other,Serum,"['IgA', 'IgG']","['Envelopeprotein', 'Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,Unclear,No,No,Yes,Unclear,Yes,No,Unclear,Wiktoria Budziar,Regional Specialist Hospital in Wrocław,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.06.22.21258711v1.full-text,2021-07-06,2022-07-16,Verified,budziar_hidden_2021,POL
210820_Poland_CentralClinicalHospitaloftheMinistryoftheInteriorandAdministration,210820_Poland_CentralClinicalHospitaloftheMinistryoftheInteriorandAdministration,Social distancing during covid-19 pandemic among inflammatory bowel disease patients,2021-08-20,Journal Article (Peer-Reviewed),National,Prospective cohort,Poland,"Masovian Voivodeship, Greater Poland Voivodeship, Łódź Voivodeship","Warsaw, Poznań, Łódź","Three tertiary centers, recruiting patients from three different geographical areas in Poland—East-central (Warsaw), western (Poznan), and south-central (Lodz)—participated in the study. The study included 473 patients with inflammatory bowel disease",,2020-05-01,2020-09-30,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,473,0.09300000000000001,,,True,,,,True,Unclear,COVID-19 ELISA IgG,Vircell S.L.,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.88,0.99,['High'],,Unclear,No,Yes,,No,Yes,No,,Michal Lodyga,Central Clinical Hospital of the Ministry of the Interior and Administration,Not Unity-Aligned,http://dx.doi.org/10.3390/jcm10163689,2021-08-31,2024-03-01,Unverified,lodyga_social_2021,POL
211109_Poland_SlaskiUniwersytetMedyczny_Primary,211109_Poland_SlaskiUniwersytetMedyczny,[Infection Fatality Rate (IFR) during the course of COVID-19 pandemic in Upper Silesia Metropolitan Area (Poland) in 2020].,2021-11-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Poland,,"Katowice, Gliwice and Sosnowiec","A group of 6,000 people was drawn. inhabitants of 3 cities (Katowice, Gliwice and Sosnowiec) including all age groups (1-94)",,2020-10-15,2020-11-15,Household and community samples,All,Multiple groups,1.0,94.0,Primary Estimate,,1167,0.114,0.095,0.132,True,,,,True,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,,IgG,,Validated by manufacturers,0.88,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,No,Jan Zejda,Slaski Uniwersytet Medyczny,Unity-Aligned,https://dx.doi.org/10.13075/mp.5893.01179,2021-11-18,2024-03-01,Verified,zejda_infection_2021,POL
211127_Bydgoszcz_NicolausCopernicusUniversity_OverallIgG,211127_Bydgoszcz_NicolausCopernicusUniversity,The differences in the level of anti-sars-cov-2 antibodies after mrna vaccine between convalescent and non-previously infected people disappear after the second dose-study in healthcare workers group in Poland,2021-11-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Poland,Kuyavian-Pomeranian,Bydgoszcz,"The study was conducted on 120 healthcare workers from Dr. Antoni Jurasz University
Hospital No. 1 in Bydgoszcz, which admitted the COVID-19 patients.

...

The volunteers who had contact
with patients (104; 86.7%) or with specimens collected from SARS-CoV-2 positive patients
(16; 13.3%) were included in the initial study group. The samples from volunteers were
collected between June and December 2020 in one-month intervals.",,2020-07-15,2020-12-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,IgG,120,0.0,,,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Joanna Kwiecinska-Pirog,Nicolaus Copernicus University,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines9121402,2022-01-04,2022-07-16,Unverified,kwiecinska-pirog_differences_2021,POL
211130_Lublin_MedicalUniversityofLublin_HC,211130_Lublin_MedicalUniversityofLublin_HC,The impact of asymptomatic SARS-CoV-2 infection in children with pediatric inflammatory diseases on selected clinical and laboratory parameters,2021-11-30,Presentation or Conference,Local,Prospective cohort,Poland,Lublin,Lublin,"healthy controls (HC) with a similar age distribution to the children with JIA.

The examination was performed during the routine visits to the University Children’s
Hospital in Lublin, blood samples were collected for further procedures, and disease activity was
determined according to the JADAS-71 scale.",Children with Juvenile idiopathic arthritis (JIA),2021-01-10,2021-05-30,Residual sera,All,Children and Youth (0-17 years),,16.0,Primary Estimate,,31,0.065,,,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgA,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Izabela Morawska,Medical University of Lublin,Not Unity-Aligned,https://dx.doi.org/10.1080/2331205X.2021.2002558,2022-01-18,2022-07-16,Unverified,morawska_impact_2021,POL
211130_Lublin_MedicalUniversityofLublin_JIA,211130_Lublin_MedicalUniversityofLublin_JIA,The impact of asymptomatic SARS-CoV-2 infection in children with pediatric inflammatory diseases on selected clinical and laboratory parameters,2021-11-30,Presentation or Conference,Local,Prospective cohort,Poland,Lublin,Lublin,"children diagnosed with JIA

The examination was performed during the routine visits to the University Children’s
Hospital in Lublin, blood samples were collected for further procedures, and disease activity was
determined according to the JADAS-71 scale.",,2021-01-10,2021-05-30,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),,16.0,Primary Estimate,,65,0.292,,,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgA,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Izabela Morawska,Medical University of Lublin,Not Unity-Aligned,https://dx.doi.org/10.1080/2331205X.2021.2002558,2022-01-18,2022-07-16,Unverified,morawska_impact_2021,POL
220110_Wrocław_WroclawMedicalUniversity,220110_Wrocław_WroclawMedicalUniversity,Two Doses of BNT162b2 mRNA Vaccine in Patients after Hematopoietic Stem Cell Transplantation: Humoral Response and Serological Conversion Predictors,2022-01-10,Journal Article (Peer-Reviewed),Local,Prospective cohort,Poland,Silesia,Wrocław,"Patients that have previously undergone hematologic stem cell transplantation (HSCT): autologous HCT (autoHCT) and 64 after allogeneic HCT (alloHCT) at least 3 months prior to the study. 

Patients after autologous transplant performed in 2020 and patients after alloHCT, regardless of the year when the procedure was performed; however, at least 3 months after HCT according to the recommendations.",,2021-03-15,2021-04-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,20.0,69.0,Primary Estimate,,93,0.25,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,Other,Multiple Types,IgG,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Maciej Majcherek ,Wroclaw Medical University ,Not Unity-Aligned,https://dx.doi.org/10.3390/cancers14020325,2022-01-19,2024-03-01,Unverified,majcherek_two_2022,POL
220210_Wroclaw_WroclawMedicalUniversity_AdministrativeWorkers,220210_Wroclaw_WroclawMedicalUniversity_AdministrativeWorkers,SARS-CoV-2 IgG Amongst Dental Workers During the COVID-19 Pandemic.,2022-02-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Poland,,Wroclaw,"""Healthy volunteers were considered to be individuals without any sig-
nificant illness relevant to the proposed study, for this reason
it has been considered − not undergoing any pulmonary
infections by probable COVID-19 background.""","Exclusion criteria were symptoms of respiratory disease such
as cough, fever, or dyspnoea or being under quarantine. ",2020-09-28,2020-11-19,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,20,0.05,,,True,,,,True,Convenience,COVID-19 (SARS-CoV-2) IgG ELISA (DECOV1901),Demeditec,ELISA,Serum,IgG,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Irena Dus-Ilnicka,Wroclaw Medical University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.identj.2022.02.003,2022-03-15,2022-07-16,Unverified,dus-ilnicka_sars-cov-2_2022,POL
220210_Wroclaw_WroclawMedicalUniversity_ChairsideAssistants,220210_Wroclaw_WroclawMedicalUniversity_ChairsideAssistants,SARS-CoV-2 IgG Amongst Dental Workers During the COVID-19 Pandemic.,2022-02-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Poland,,Wroclaw,"""Healthy volunteers were considered to be individuals without any sig-
nificant illness relevant to the proposed study, for this reason
it has been considered − not undergoing any pulmonary
infections by probable COVID-19 background.""","Exclusion criteria were symptoms of respiratory disease such
as cough, fever, or dyspnoea or being under quarantine. ",2020-09-28,2020-11-19,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,40,0.075,,,True,,,,True,Convenience,COVID-19 (SARS-CoV-2) IgG ELISA (DECOV1901),Demeditec,ELISA,Serum,IgG,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Irena Dus-Ilnicka,Wroclaw Medical University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.identj.2022.02.003,2022-03-15,2022-07-16,Unverified,dus-ilnicka_sars-cov-2_2022,POL
220210_Wroclaw_WroclawMedicalUniversity_Dentists,220210_Wroclaw_WroclawMedicalUniversity_Dentists,SARS-CoV-2 IgG Amongst Dental Workers During the COVID-19 Pandemic.,2022-02-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Poland,,Wroclaw,"""Healthy volunteers were considered to be individuals without any sig-
nificant illness relevant to the proposed study, for this reason
it has been considered − not undergoing any pulmonary
infections by probable COVID-19 background.""","Exclusion criteria were symptoms of respiratory disease such
as cough, fever, or dyspnoea or being under quarantine. ",2020-09-28,2020-11-19,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,67,0.06,,,True,,,,True,Convenience,COVID-19 (SARS-CoV-2) IgG ELISA (DECOV1901),Demeditec,ELISA,Serum,IgG,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Irena Dus-Ilnicka,Wroclaw Medical University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.identj.2022.02.003,2022-03-15,2022-07-16,Unverified,dus-ilnicka_sars-cov-2_2022,POL
220217_Lublin_MedicalUniversityofLublin_Dec2020_Overall,220217_Lublin_MedicalUniversityofLublin_Dec2020,SARS-CoV-2 Seroprevalence in Healthcare Workers before the Vaccination in Poland: Evolution from the First to the Second Pandemic Outbreak,2022-02-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,Poland,,Lublin,"All HCWs (including
physicians, nurses, and other workers with direct patient contact, i.e., physical therapists,
as well as workers without direct patient contact, i.e., laboratory workers, pharmacists,
administrative staff, maintenance staff, etc.) of Independent Public Teaching Hospital No. 1 in Lublin and of Regional Occupational Medicine Center (ROMC) in Lublin.","NR
",2020-12-04,2020-12-15,Health care workers and caregivers,All,Adults (18-64 years),21.0,69.0,Primary Estimate,,179,0.48,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA",EUROIMMUN,ELISA,Serum,"['IgA', 'IgG']",Spike,,,,['High'],,No,No,Yes,,Yes,Yes,No,,Izabela Korona-Głowniak,Medical University of Lublin,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph19042319,2022-03-02,2024-03-01,Unverified,korona-glowniak_sars-cov-2_2022,POL
220217_Lublin_MedicalUniversityofLublin_May2020_Overall,220217_Lublin_MedicalUniversityofLublin_May2020,SARS-CoV-2 Seroprevalence in Healthcare Workers before the Vaccination in Poland: Evolution from the First to the Second Pandemic Outbreak,2022-02-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,Poland,,Lublin,"All HCWs (including
physicians, nurses, and other workers with direct patient contact, i.e., physical therapists,
as well as workers without direct patient contact, i.e., laboratory workers, pharmacists,
administrative staff, maintenance staff, etc.) of Independent Public Teaching Hospital No. 1 in Lublin and of Regional Occupational Medicine Center (ROMC) in Lublin.","NR
",2020-05-05,2020-05-25,Health care workers and caregivers,All,Multiple groups,24.0,74.0,Primary Estimate,,208,0.07200000000000001,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA",EUROIMMUN,ELISA,Serum,"['IgA', 'IgG']",Spike,,,,['High'],,No,No,Yes,,Yes,Yes,No,,Izabela Korona-Głowniak,Medical University of Lublin,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph19042319,2022-03-02,2024-03-01,Unverified,korona-glowniak_sars-cov-2_2022,POL
220316_Zabrze_MedicalUniversityofSilesia_Overall,220316_Zabrze_MedicalUniversityofSilesia,Serologic Status According Severe Acute Respiratory Syndrome Coronavirus 2 in Patients After Orthotopic Heart Transplantation,2022-03-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Poland,Silesia,Zabrze,Consecutive adult patients admitted to the transplantation ward or transplantation ambulance,,2021-02-15,2021-09-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,371,0.736,,,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['High'],,No,No,Yes,,Yes,Yes,No,,Agnieszka Kuczaj,Medical University of Silesia,Not Unity-Aligned,https://dx.doi.org/10.1016/j.transproceed.2022.02.044,2022-04-21,2024-03-01,Unverified,kuczaj_serologic_2022,POL
220317_Poland_NationalResearchInstitute_Primary,220317_Poland_NationalResearchInstitute,Healthcare workers highly affected during the COVID-19 epidemic wave in Poland prior to vaccination availability: seroprevalence study.,2022-03-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Poland,"Pomorskie voivodeship, Mazowieckie voivodeship, Wielkopolskie voivodeship","Gdańsk, Wejherowo, Warsaw, Grójec, Krotoszyn","All HCW employed in the hospital at the time of the study, were eligible for the study, includ- ing medical doctors, nurses, midwives, rehabilitators, technicians, and receptionists – all could volunteer for participation. Other hospital staff with no or occasion- al contact with patients were also invited to participate in the study. ",25 (2.2%) were excluded due to inconsistent/indeterminate test results. ,2020-12-01,2020-12-23,Health care workers and caregivers,All,Multiple groups,0.0,74.0,Primary Estimate,adjusted,1040,0.252,0.226,0.27899999999999997,True,,,,True,Self-referral,"2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit,NovaLisa® SARS-CoV-2 IgG/IgM","Nanjing Vazyme Medical Technology Co. Ltd,NovaTec Immundiagnostics GmbH",Multiple Types,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Magdalena Rosiska,National Research Institute,Not Unity-Aligned,https://dx.doi.org/10.13075/mp.5893.01216,2022-03-29,2024-03-01,Unverified,rosinska_healthcare_2022,POL
220323_Wroclaw_RegionalSpecializedHospitalinWroclaw_Overall,220323_Wroclaw_RegionalSpecializedHospitalinWroclaw,Dynamics of anti-SARS-CoV-2 seroconversion in individual patients and at the population level,2022-03-23,Preprint,Local,Prospective cohort,Poland,Lower Silesian Voivodeship,Wroclaw,Participant in the cohort studied in May 2021 with a negative serology,"Participants who were affected by diagnosed COVID-19 between May and December 2021 were excluded.
Vaccinated.",2021-12-11,2021-12-11,Household and community samples,All,Multiple groups,17.0,,Primary Estimate,IgG,38,0.2895,,,True,,,,True,Convenience,Microblot-Array COVID-19 IgG,TestLine Clinical Diagnostics,,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Unclear,Yes,No,,Alina Szewczyk-Dabrowska,Regional Specialized Hospital in Wroclaw,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.20.22272651v1.full-text,2022-03-30,2022-07-16,Unverified,szewczyk-dabrowska_dynamics_2022,POL
220323_Wroclaw_RegionalSpecializedHospitalinWroclaw_NCP,220323_Wroclaw_RegionalSpecializedHospitalinWroclaw,Dynamics of anti-SARS-CoV-2 seroconversion in individual patients and at the population level,2022-03-23,Preprint,Local,Prospective cohort,Poland,Lower Silesian Voivodeship,Wroclaw,Participant in the cohort studied in May 2021 with a negative serology,"Participants who were affected by diagnosed COVID-19 between May and December 2021 were excluded.
Vaccinated.",2021-12-11,2021-12-11,Household and community samples,All,Multiple groups,17.0,,Test used,anti-NCP only,38,0.2632,,,,,,,,Convenience,Microblot-Array COVID-19 IgG,TestLine Clinical Diagnostics,,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,No,,Unclear,Yes,No,,Alina Szewczyk-Dabrowska,Regional Specialized Hospital in Wroclaw,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.20.22272651v1.full-text,2022-03-30,2022-07-16,Unverified,szewczyk-dabrowska_dynamics_2022,POL
220323_Wroclaw_RegionalSpecializedHospitalinWroclaw_RBD,220323_Wroclaw_RegionalSpecializedHospitalinWroclaw,Dynamics of anti-SARS-CoV-2 seroconversion in individual patients and at the population level,2022-03-23,Preprint,Local,Prospective cohort,Poland,Lower Silesian Voivodeship,Wroclaw,Participant in the cohort studied in May 2021 with a negative serology,"Participants who were affected by diagnosed COVID-19 between May and December 2021 were excluded.
Vaccinated.",2021-12-11,2021-12-11,Household and community samples,All,Multiple groups,17.0,,Test used,anti-RBD only,38,0.2632,,,,,,,,Convenience,Microblot-Array COVID-19 IgG,TestLine Clinical Diagnostics,,Serum,IgG,Spike,,,,['High'],,No,No,No,,Unclear,Yes,No,,Alina Szewczyk-Dabrowska,Regional Specialized Hospital in Wroclaw,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.20.22272651v1.full-text,2022-03-30,2022-07-16,Unverified,szewczyk-dabrowska_dynamics_2022,POL
220329_Krakow_UniversityHospitalinKrakow_Overall,220329_Krakow_UniversityHospitalinKrakow,The Seroprevalence of SARS-CoV-2 Antibodies among HealthCare Workers in University Hospital in Krakow before the Era of Vaccination,2022-03-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Poland,,Krakow,"(1) hospital employee or (2) fifth-year medical student, (3) voluntary consent to participate in the study.",The sole key exclusion criterion was refusal to participate in the study and receiving the COVID-19 vaccine no earlier than 4 days before the day of collecting the material (blood sample) for testing.,2021-01-04,2021-01-19,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,1221,0.4267,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.895,0.9906,['High'],,No,Yes,Yes,,Yes,Yes,No,,Barbara Zoltowska,University Hospital in Krakow,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph19074044,2022-04-05,2024-03-01,Unverified,zoltowska_seroprevalence_2022,POL
220329_Krakow_UniversityHospitalinKrakow_Age_18-36,220329_Krakow_UniversityHospitalinKrakow,The Seroprevalence of SARS-CoV-2 Antibodies among HealthCare Workers in University Hospital in Krakow before the Era of Vaccination,2022-03-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Poland,,Krakow,"(1) hospital employee or (2) fifth-year medical student, (3) voluntary consent to participate in the study.",The sole key exclusion criterion was refusal to participate in the study and receiving the COVID-19 vaccine no earlier than 4 days before the day of collecting the material (blood sample) for testing.,2021-01-04,2021-01-19,Health care workers and caregivers,All,Adults (18-64 years),18.0,36.0,Age,Age: 18-36 years,467,0.3812,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.895,0.9906,['High'],,No,Yes,Yes,,Yes,Yes,No,,Barbara Zoltowska,University Hospital in Krakow,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph19074044,2022-04-05,2024-03-01,Unverified,zoltowska_seroprevalence_2022,POL
220329_Krakow_UniversityHospitalinKrakow_Age_56orMore,220329_Krakow_UniversityHospitalinKrakow,The Seroprevalence of SARS-CoV-2 Antibodies among HealthCare Workers in University Hospital in Krakow before the Era of Vaccination,2022-03-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Poland,,Krakow,"(1) hospital employee or (2) fifth-year medical student, (3) voluntary consent to participate in the study.",The sole key exclusion criterion was refusal to participate in the study and receiving the COVID-19 vaccine no earlier than 4 days before the day of collecting the material (blood sample) for testing.,2021-01-04,2021-01-19,Health care workers and caregivers,All,Adults (18-64 years),56.0,,Age,Age: 56 or more,177,0.41240000000000004,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.895,0.9906,['High'],,No,Yes,Yes,,Yes,Yes,No,,Barbara Zoltowska,University Hospital in Krakow,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph19074044,2022-04-05,2024-03-01,Unverified,zoltowska_seroprevalence_2022,POL
220329_Krakow_UniversityHospitalinKrakow_Age_37-55,220329_Krakow_UniversityHospitalinKrakow,The Seroprevalence of SARS-CoV-2 Antibodies among HealthCare Workers in University Hospital in Krakow before the Era of Vaccination,2022-03-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Poland,,Krakow,"(1) hospital employee or (2) fifth-year medical student, (3) voluntary consent to participate in the study.",The sole key exclusion criterion was refusal to participate in the study and receiving the COVID-19 vaccine no earlier than 4 days before the day of collecting the material (blood sample) for testing.,2021-01-04,2021-01-19,Health care workers and caregivers,All,Adults (18-64 years),37.0,55.0,Age,Age: 37-55 years,577,0.4679,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.895,0.9906,['High'],,No,Yes,Yes,,Yes,Yes,No,,Barbara Zoltowska,University Hospital in Krakow,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph19074044,2022-04-05,2024-03-01,Unverified,zoltowska_seroprevalence_2022,POL
220405_Silesia_MedicalUniversityofSilesia,220405_Silesia_MedicalUniversityofSilesia,"[The frequency of positive results of serological tests against SARS-CoV-2 in healthcare workers in Upper Silesia Metropolitan Area, Poland].",2022-04-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Poland,Silesia,,Medical professionals from the Upper Silesia Metropolitan Area,,2020-10-15,2020-11-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,575,0.19100000000000003,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IGM)",EUROIMMUN,ELISA,Serum,"['IgG', 'IgM']",,,,,['High'],,No,No,Yes,,Yes,Yes,No,,Marek Wojczyk,Medical University of Silesia,Not Unity-Aligned,https://dx.doi.org/10.13075/mp.5893.01221,2022-04-13,2024-03-01,Unverified,wojczyk_frequency_2022,POL
220430_Poland_WroclawMedicalUniversity_Primary,220430_Poland_WroclawMedicalUniversity,Complete (Humoral and Cellular) Response to Vaccination against COVID-19 in a Group of Healthcare Workers-Assessment of Factors Affecting Immunogenicity,2022-04-30,Journal Article (Peer-Reviewed),Local,Prospective cohort,Poland,,,medical personnel from two hospitals,medical peronnel who did not receive full veccination,2020-11-15,2021-02-10,Health care workers and caregivers,All,Multiple groups,22.0,72.0,Primary Estimate,,344,0.34600000000000003,,,True,,,,True,Convenience,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,,IgG,Spike,Validated by manufacturers,0.932,0.998,['High'],,No,No,Yes,,Yes,Yes,Yes,,Ewa Morgiel,Wroclaw Medical University,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10050710,2022-06-05,2024-03-01,Unverified,morgiel_complete_2022,POL
220701_Bydgoszcz_VoivodeshipInfectiousObservationHospital,220701_Bydgoszcz_VoivodeshipInfectiousObservationHospital,The Seroprevalence of SARS-CoV-2 IgG Antibodies in Children Hospitalized for Reasons Other Than COVID-19,2022-07-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Poland,,Bydgoszcz,"Children aged 2 weeks to 18 years, hospitalized in the Department of Paediatrics, Infectious Diseases, and Hepatology in Bydgoszcz, Poland (The reasons for hospitalization were acute gastroenteritis, respiratory infections, hepatitis of various etiologies, infectious mononucleosis, chicken pox, and other infectious diseases. All study patients tested negative for SARS-CoV-2 antigen/nucleic acid.)",Children vaccinated against SARS-CoV-2 or hospitalized due to COVID-19 were excluded from the study.,2021-06-01,2022-04-30,Residual sera,All,Multiple groups,0.0,18.0,Primary Estimate,,686,0.5700000000000001,,,True,,,,True,Unclear,LIAISON® SARS-CoV-2 TrimericS IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['Moderate'],,Unclear,Yes,No,,Yes,Yes,Yes,,Justyna Franczak,Voivodeship Infectious Observation Hospital,Not Unity-Aligned,https://dx.doi.org/10.3390/jcm11133819,2022-07-12,2024-03-01,Unverified,franczak_seroprevalence_2022,POL
220719_Lodz_PolishMother'sMemorialHospital,220719_Lodz_PolishMother'sMemorialHospital,SARS-Cov-2 infection in patients with univentricular heart after fontan operation,2022-07-19,Presentation or Conference,Local,Cross-sectional survey ,Poland,,Lodz,"""all 38 Fontan patients admitted to Cardiology Department""",None described,2020-09-15,2021-05-15,Residual sera,All,Multiple groups,,,Primary Estimate,,38,0.55,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Anna Mazurek Kula,"Cardiology Department, Polish Mother’s Memorial Hospital Research Institute",Not Unity-Aligned,https://dx.doi.org/10.1017/S1047951122001950,2022-10-19,2022-10-19,Unverified,kula_sars-cov-2_2022,POL
220920_Poland_InstituteofBioorganicChemistryPolishAcademyofSciences_Wave1,220920_Poland_InstituteofBioorganicChemistryPolishAcademyofSciences,The Longitudinal Analysis on the Anti-SARS-CoV-2 Antibodies among Healthcare Workers in Poland-Before and after BNT126b2 mRNA COVID-19 Vaccination.,2022-09-20,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Poland,the Greater Poland Region,"Poznan, Wrzesnia","we included HCWs from the Department of Infectious Diseases and Child Neurology (DIDaCN), K. Jonscher’s Clinical Hospital, Poznan University of Medical Sciences, Poznan, and the Gynecology and ObstetricsWard (GaOW), District Hospital,Wrzesnia, in the study.",,2020-09-01,2020-09-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,"sep 2020, anti-S",90,0.0,0.0,0.0409,True,,,,True,Self-referral,"Anti-SARS-CoV-2 ELISA IgG,Author designed (ELISA) -Spike","EUROIMMUN,NA",ELISA,,IgG,Spike,,,,['High'],,No,No,No,,Unclear,Yes,No,,Dagny Lorent,Institute of Bioorganic Chemistry Polish Academy of Sciences,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10101576,2022-11-16,2024-03-01,Unverified,lorent_longitudinal_2022,POL
221102_Wroclaw_SilesianCenterOfOncology_Overall,221102_Wroclaw_SilesianCenterOfOncology,Antibody responses to sars-cov-2 vaccination/infection in hematological malignances and allogeneic hematopoietic stem cell transplantation patients - a single-center experience,2022-11-02,Presentation or Conference,Local,Cross-sectional survey ,Poland,,Wroclaw,"""83 patients of the Department of the Hematology and Transplant Center of the Lower Silesian Oncology Center in Wroclaw"".","""4 patients were excluded from antibody analysis due to short time post-vaccination (6-10 days)"".",2020-12-15,2021-09-15,Residual sera,All,Multiple groups,20.0,86.0,Primary Estimate,,83,0.46990000000000004,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,E. Jaskula,Silesian Center of Oncology,Not Unity-Aligned,https://dx.doi.org/10.1038/s41409-022-01798-0,2022-12-13,2023-03-22,Unverified,jaskula_antibody_2022,POL
221124_Bialystok_MedicalUniversityofBialystok_GroupVisit1_IgG-s_Primary,221124_Bialystok_MedicalUniversityofBialystok_GroupVisit1,Antibodies against SARS-CoV-2 S and N proteins in relapsing-remitting multiple sclerosis patients treated with disease-modifying therapies,2022-11-24,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Poland,,Bialystok,"""PwMS who had the relapsing-remitting course of disease
(RR PwMS) diagnosed according to the McDonald’s 2010 and
2017 criteria, and who were being treated with DMTs at the
Department of Neurology, MUB, were included in this study.""",,2020-05-15,2020-06-15,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),,,Primary Estimate,,186,0.032,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Joanna Kulikowska,Medical University of Bialystok,Not Unity-Aligned,https://dx.doi.org/10.5603/PJNNS.a2022.0067,2022-12-15,2024-03-01,Unverified,kulikowska_antibodies_2022,POL
221124_Bialystok_MedicalUniversityofBialystok_GroupVisit2_IgG-s_Primary,221124_Bialystok_MedicalUniversityofBialystok_GroupVisit2,Antibodies against SARS-CoV-2 S and N proteins in relapsing-remitting multiple sclerosis patients treated with disease-modifying therapies,2022-11-24,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Poland,,Bialystok,"""PwMS who had the relapsing-remitting course of disease
(RR PwMS) diagnosed according to the McDonald’s 2010 and
2017 criteria, and who were being treated with DMTs at the
Department of Neurology, MUB, were included in this study.""",,2021-05-15,2021-06-15,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),,,Primary Estimate,,88,0.713,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Joanna Kulikowska,Medical University of Bialystok,Not Unity-Aligned,https://dx.doi.org/10.5603/PJNNS.a2022.0067,2022-12-15,2024-03-01,Unverified,kulikowska_antibodies_2022,POL
230105_Krakow_JagiellonianUniversityMedicalCollege,230105_Krakow_JagiellonianUniversityMedicalCollege,"SARS-CoV-2 antibody response after mRNA vaccination in healthcare workers with and without previous COVID-19, a follow-up study from a university hospital in Poland during 6 months 2021",2023-01-05,Journal Article (Peer-Reviewed),Local,Prospective cohort,Poland,,Krakow,"""HCWs including nurses, paramedics, doctors, healthcare
technicians, administrative staff and students at the University
Hospital in Krakow, Poland, (UHK) were invited to participate in
the study""",,2021-01-01,2021-01-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,676,0.41100000000000003,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,"IgG, IgM, IgA",Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Izabella Owsianka,Jagiellonian University Medical College,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2022.1071204,2023-02-08,2024-03-01,Unverified,owsianka_sars-cov-2_2023,POL
230831_Poland_NIPHNIH–NRI_antiS,230831_Poland_NIPHNIH–NRI,"Reversed urban-rural gradient in COVID-19 seroprevalence and related factors in a nationally representative survey, Poland, 29 March to 14 May 2021.",2023-08-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Poland,,,"a nationwide sample of Polish adults (≥ 20 years-old) from each administrative region (voivodeship) and age category, in line with the World Health Organization (WHO)-Unity protocol:",Records with borderline laboratory results were excluded; Individuals refused to participate.,2021-03-19,2021-05-14,Household and community samples,All,Multiple groups,20.0,,Primary Estimate,overall unadjusted anti-S1 estimate,5892,0.544,,,True,,,,True,Stratified probability,Anti-SARS-CoV-2 QuantiVac ELISA ,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Michał Czerwinski,National Institute of Public Health NIH–National Research Institute,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2023.28.35.2200745,2023-09-20,2024-04-30,Verified,czerwinski_reversed_2023,POL
230831_Poland_NIPHNIH–NRI_antiN,230831_Poland_NIPHNIH–NRI,"Reversed urban-rural gradient in COVID-19 seroprevalence and related factors in a nationally representative survey, Poland, 29 March to 14 May 2021.",2023-08-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Poland,,,"a nationwide sample of Polish adults (≥ 20 years-old) from each administrative region (voivodeship) and age category, in line with the World Health Organization (WHO)-Unity protocol:",Records with borderline laboratory results were excluded; Individuals refused to participate.,2021-03-19,2021-05-14,Household and community samples,All,Multiple groups,20.0,,Test used,overall unadjusted anti-S1 estimate,5892,0.316,,,True,,,,True,Stratified probability,Anti-SARS-CoV-2 NCP ELISA (IgG),EUROIMMUN,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Michał Czerwinski,National Institute of Public Health NIH–National Research Institute,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2023.28.35.2200745,2023-09-20,2024-04-30,Verified,czerwinski_reversed_2023,POL
230831_Poland_NIPHNIH–NRI_Age_20-39,230831_Poland_NIPHNIH–NRI,"Reversed urban-rural gradient in COVID-19 seroprevalence and related factors in a nationally representative survey, Poland, 29 March to 14 May 2021.",2023-08-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Poland,,,"a nationwide sample of Polish adults (≥ 20 years-old) from each administrative region (voivodeship) and age category, in line with the World Health Organization (WHO)-Unity protocol:",Records with borderline laboratory results were excluded; Individuals refused to participate.,2021-03-19,2021-05-14,Household and community samples,All,Adults (18-64 years),20.0,39.0,Age,20-39 years,1392,0.291,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 NCP ELISA (IgG),EUROIMMUN,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Michał Czerwinski,National Institute of Public Health NIH–National Research Institute,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2023.28.35.2200745,2024-04-30,2024-04-30,Verified,czerwinski_reversed_2023,POL
230831_Poland_NIPHNIH–NRI_Age_70+,230831_Poland_NIPHNIH–NRI,"Reversed urban-rural gradient in COVID-19 seroprevalence and related factors in a nationally representative survey, Poland, 29 March to 14 May 2021.",2023-08-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Poland,,,"a nationwide sample of Polish adults (≥ 20 years-old) from each administrative region (voivodeship) and age category, in line with the World Health Organization (WHO)-Unity protocol:",Records with borderline laboratory results were excluded; Individuals refused to participate.,2021-03-19,2021-05-14,Household and community samples,All,Seniors (65+ years),70.0,,Age,70+ years,913,0.28,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 NCP ELISA (IgG),EUROIMMUN,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Michał Czerwinski,National Institute of Public Health NIH–National Research Institute,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2023.28.35.2200745,2024-04-30,2024-04-30,Verified,czerwinski_reversed_2023,POL
230831_Poland_NIPHNIH–NRI_Age_40-59,230831_Poland_NIPHNIH–NRI,"Reversed urban-rural gradient in COVID-19 seroprevalence and related factors in a nationally representative survey, Poland, 29 March to 14 May 2021.",2023-08-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Poland,,,"a nationwide sample of Polish adults (≥ 20 years-old) from each administrative region (voivodeship) and age category, in line with the World Health Organization (WHO)-Unity protocol:",Records with borderline laboratory results were excluded; Individuals refused to participate.,2021-03-19,2021-05-14,Household and community samples,All,Adults (18-64 years),40.0,59.0,Age,40-59 years,2163,0.329,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 NCP ELISA (IgG),EUROIMMUN,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Michał Czerwinski,National Institute of Public Health NIH–National Research Institute,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2023.28.35.2200745,2024-04-30,2024-04-30,Verified,czerwinski_reversed_2023,POL
230831_Poland_NIPHNIH–NRI_Age_60-69,230831_Poland_NIPHNIH–NRI,"Reversed urban-rural gradient in COVID-19 seroprevalence and related factors in a nationally representative survey, Poland, 29 March to 14 May 2021.",2023-08-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Poland,,,"a nationwide sample of Polish adults (≥ 20 years-old) from each administrative region (voivodeship) and age category, in line with the World Health Organization (WHO)-Unity protocol:",Records with borderline laboratory results were excluded; Individuals refused to participate.,2021-03-19,2021-05-14,Household and community samples,All,Seniors (65+ years),60.0,69.0,Age,60-69 years,1424,0.264,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 NCP ELISA (IgG),EUROIMMUN,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Michał Czerwinski,National Institute of Public Health NIH–National Research Institute,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2023.28.35.2200745,2024-04-30,2024-04-30,Verified,czerwinski_reversed_2023,POL
200902_Lisbon_UniversityofLisbon_Overall,200902_Lisbon_UniversityofLisbon,Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers,2020-09-02,Preprint,Local,Cross-sectional survey ,Portugal,Estremadura,Lisbon,"Employees/staff at the University of Lisbon, accross all divisions",,2020-05-13,2020-07-10,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,Staff at the University of Lisbon,2571,0.015,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.9474,0.98,['Moderate'],Yes,No,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Patricia Figueiredo Campos,University of Lisbon,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.30.20184309v1,2020-10-19,2022-07-16,Verified,figueiredo-campos_seroprevalence_2020,PRT
201021_UniversidadeDeLisboa_UniversidadeDeLisboa_overall,201021_UniversidadeDeLisboa_UniversidadeDeLisboa,Seroprevalence of anti‐SARS‐CoV‐2 antibodies in COVID‐19 patients and healthy volunteers up to 6 months post disease onset,2020-10-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Portugal,,Lisbon,"Employees at the University, accross all divisions",,2020-05-13,2020-07-10,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,2715,0.026000000000000002,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Patricia Figueiredo Campos,Universidade de Lisboa,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.1002/eji.202048970,2021-03-22,2022-07-16,Verified,figueiredocampos_seroprevalence_2020,PRT
201218_Lisbon_NovaUniversityofLisbon,201218_Lisbon_NOVAUniversityofLisbon,Evaluating SARS-CoV-2 Seroconversion Following Relieve of Confinement Measures,2020-12-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Portugal,Lisboa Region,Lisbon,NOVA university’s collaborators encompassing seven distinct schools and the rectorate,,2020-06-15,2020-06-30,Non-essential workers and unemployed persons,All,Multiple groups,17.0,76.0,Primary Estimate,IgG overall estimate,1636,0.0305,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9474,0.9953000000000001,['Moderate'],Yes,No,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Juliana Goncalves,NOVA University of Lisbon,Not Unity-Aligned,https://dx.doi.org/10.3389/fmed.2020.603996,2021-01-23,2022-07-16,Verified,goncalves_evaluating_2020,PRT
210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge_overall_TestAdj_PopAdj,210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge,Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19),2021-02-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Portugal,"Norte Region, Centro Region, Lisboa Region, Alentejo Region, Algarve Region, Madeira, Azores",,"The target population of the survey included residents in Portugal (mainland and Autonomous Regions) aged one year old (yo) and over. Participants were recruited among the visiting partner laboratories or public hospitals during the study period, for reasons unrelated to COVID-19 and with a medical prescription for a blood test that involved venipuncture.","Those unable to give their informed consent and those with conditions that could interfere with immune response, such as chronic liver disease, cancer in previ- ous five years, immunodeficiency, organ transplantation or transfusion in previous six months, were excluded.",2020-05-21,2020-07-08,Residual sera,All,Multiple groups,1.0,,Primary Estimate,,2301,0.017,0.0,0.033,True,True,True,,,Stratified non-probability,"Anti-SARS-CoV-2 ELISA IgG,Wantai SARS-CoV-2 IgM ELISA","EUROIMMUN,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Irina Kislaya, Instituto Nacional de Saúde Doutor Ricardo Jorge,Unity-Aligned,https://actamedicaportuguesa.com/revista/index.php/amp/article/view/15122,2021-03-11,2023-08-15,Verified,kislaya_seroprevalence_2021,PRT
210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge_Alentej,210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge,Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19),2021-02-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Portugal,Alentejo ,,"The target population of the survey included residents in Portugal (mainland and Autonomous Regions) aged one year old (yo) and over. Participants were recruited among the visiting partner laboratories or public hospitals during the study period, for reasons unrelated to COVID-19 and with a medical prescription for a blood test that involved venipuncture.","Those unable to give their informed consent and those with conditions that could interfere with immune response, such as chronic liver disease, cancer in previ- ous five years, immunodeficiency, organ transplantation or transfusion in previous six months, were excluded.",2020-05-21,2020-07-08,Residual sera,All,Multiple groups,1.0,,Geographical area,Alentejo ,266,0.012,0.003,0.04,,,True,,,Stratified non-probability,"Anti-SARS-CoV-2 ELISA IgG,Wantai SARS-CoV-2 IgM ELISA","EUROIMMUN,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Irina Kislaya, Instituto Nacional de Saúde Doutor Ricardo Jorge,Unity-Aligned,https://actamedicaportuguesa.com/revista/index.php/amp/article/view/15122,2021-03-11,2024-03-01,Verified,kislaya_seroprevalence_2021,PRT
210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge_Algarve,210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge,Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19),2021-02-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Portugal,Algarve ,,"The target population of the survey included residents in Portugal (mainland and Autonomous Regions) aged one year old (yo) and over. Participants were recruited among the visiting partner laboratories or public hospitals during the study period, for reasons unrelated to COVID-19 and with a medical prescription for a blood test that involved venipuncture.","Those unable to give their informed consent and those with conditions that could interfere with immune response, such as chronic liver disease, cancer in previ- ous five years, immunodeficiency, organ transplantation or transfusion in previous six months, were excluded.",2020-05-21,2020-07-08,Residual sera,All,Multiple groups,1.0,,Geographical area,Algarve ,351,0.022000000000000002,0.01,0.05,,,True,,,Stratified non-probability,"Anti-SARS-CoV-2 ELISA IgG,Wantai SARS-CoV-2 IgM ELISA","EUROIMMUN,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Irina Kislaya, Instituto Nacional de Saúde Doutor Ricardo Jorge,Unity-Aligned,https://actamedicaportuguesa.com/revista/index.php/amp/article/view/15122,2021-03-11,2024-03-01,Verified,kislaya_seroprevalence_2021,PRT
210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge_age60+,210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge,Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19),2021-02-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Portugal,"Norte Region, Centro Region, Lisboa Region, Alentejo Region, Algarve Region, Madeira, Azores",,"The target population of the survey included residents in Portugal (mainland and Autonomous Regions) aged one year old (yo) and over. Participants were recruited among the visiting partner laboratories or public hospitals during the study period, for reasons unrelated to COVID-19 and with a medical prescription for a blood test that involved venipuncture.","Those unable to give their informed consent and those with conditions that could interfere with immune response, such as chronic liver disease, cancer in previ- ous five years, immunodeficiency, organ transplantation or transfusion in previous six months, were excluded.",2020-05-21,2020-07-08,Residual sera,All,Seniors (65+ years),60.0,,Age,60+,664,0.028999999999999998,0.015,0.053,,,True,,,Stratified non-probability,"Anti-SARS-CoV-2 ELISA IgG,Wantai SARS-CoV-2 IgM ELISA","EUROIMMUN,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Irina Kislaya, Instituto Nacional de Saúde Doutor Ricardo Jorge,Unity-Aligned,https://actamedicaportuguesa.com/revista/index.php/amp/article/view/15122,2021-03-11,2024-03-01,Verified,kislaya_seroprevalence_2021,PRT
210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge_IgG,210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge,Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19),2021-02-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Portugal,"Norte Region, Centro Region, Lisboa Region, Alentejo Region, Algarve Region, Madeira, Azores",,"The target population of the survey included residents in Portugal (mainland and Autonomous Regions) aged one year old (yo) and over. Participants were recruited among the visiting partner laboratories or public hospitals during the study period, for reasons unrelated to COVID-19 and with a medical prescription for a blood test that involved venipuncture.","Those unable to give their informed consent and those with conditions that could interfere with immune response, such as chronic liver disease, cancer in previ- ous five years, immunodeficiency, organ transplantation or transfusion in previous six months, were excluded.",2020-05-21,2020-07-08,Residual sera,All,Multiple groups,1.0,,Test used,IgG - EUROIMMUN anti-SARS-CoV-2,2301,0.019,0.012,0.031000000000000003,,,True,,,Stratified non-probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,,Validated by manufacturers,0.9440000000000001,0.996,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Irina Kislaya, Instituto Nacional de Saúde Doutor Ricardo Jorge,Unity-Aligned,https://actamedicaportuguesa.com/revista/index.php/amp/article/view/15122,2021-03-11,2024-03-01,Verified,kislaya_seroprevalence_2021,PRT
210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge_Azores,210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge,Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19),2021-02-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Portugal,Azores ,,"The target population of the survey included residents in Portugal (mainland and Autonomous Regions) aged one year old (yo) and over. Participants were recruited among the visiting partner laboratories or public hospitals during the study period, for reasons unrelated to COVID-19 and with a medical prescription for a blood test that involved venipuncture.","Those unable to give their informed consent and those with conditions that could interfere with immune response, such as chronic liver disease, cancer in previ- ous five years, immunodeficiency, organ transplantation or transfusion in previous six months, were excluded.",2020-05-21,2020-07-08,Residual sera,All,Multiple groups,1.0,,Geographical area,Azores ,350,0.026000000000000002,0.013000000000000001,0.052000000000000005,,,True,,,Stratified non-probability,"Anti-SARS-CoV-2 ELISA IgG,Wantai SARS-CoV-2 IgM ELISA","EUROIMMUN,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Irina Kislaya, Instituto Nacional de Saúde Doutor Ricardo Jorge,Unity-Aligned,https://actamedicaportuguesa.com/revista/index.php/amp/article/view/15122,2021-03-11,2024-03-01,Verified,kislaya_seroprevalence_2021,PRT
210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge_IgM,210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge,Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19),2021-02-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Portugal,"Norte Region, Centro Region, Lisboa Region, Alentejo Region, Algarve Region, Madeira, Azores",,"The target population of the survey included residents in Portugal (mainland and Autonomous Regions) aged one year old (yo) and over. Participants were recruited among the visiting partner laboratories or public hospitals during the study period, for reasons unrelated to COVID-19 and with a medical prescription for a blood test that involved venipuncture.","Those unable to give their informed consent and those with conditions that could interfere with immune response, such as chronic liver disease, cancer in previ- ous five years, immunodeficiency, organ transplantation or transfusion in previous six months, were excluded.",2020-05-21,2020-07-08,Residual sera,All,Multiple groups,1.0,,Test used,IgM - Wantai SARS-CoV-2 ELISA,2301,0.019,0.011000000000000001,0.031000000000000003,,,True,,,Stratified non-probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,IgM,,Validated by manufacturers,0.861,0.9940000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Irina Kislaya, Instituto Nacional de Saúde Doutor Ricardo Jorge,Unity-Aligned,https://actamedicaportuguesa.com/revista/index.php/amp/article/view/15122,2021-03-11,2024-03-01,Verified,kislaya_seroprevalence_2021,PRT
210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge_North,210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge,Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19),2021-02-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Portugal,North ,,"The target population of the survey included residents in Portugal (mainland and Autonomous Regions) aged one year old (yo) and over. Participants were recruited among the visiting partner laboratories or public hospitals during the study period, for reasons unrelated to COVID-19 and with a medical prescription for a blood test that involved venipuncture.","Those unable to give their informed consent and those with conditions that could interfere with immune response, such as chronic liver disease, cancer in previ- ous five years, immunodeficiency, organ transplantation or transfusion in previous six months, were excluded.",2020-05-21,2020-07-08,Residual sera,All,Multiple groups,1.0,,Geographical area,North ,327,0.027999999999999997,0.013000000000000001,0.06,,,True,,,Stratified non-probability,"Anti-SARS-CoV-2 ELISA IgG,Wantai SARS-CoV-2 IgM ELISA","EUROIMMUN,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Irina Kislaya, Instituto Nacional de Saúde Doutor Ricardo Jorge,Unity-Aligned,https://actamedicaportuguesa.com/revista/index.php/amp/article/view/15122,2021-03-11,2024-03-01,Verified,kislaya_seroprevalence_2021,PRT
210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge_Center,210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge,Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19),2021-02-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Portugal,Centre,,"The target population of the survey included residents in Portugal (mainland and Autonomous Regions) aged one year old (yo) and over. Participants were recruited among the visiting partner laboratories or public hospitals during the study period, for reasons unrelated to COVID-19 and with a medical prescription for a blood test that involved venipuncture.","Those unable to give their informed consent and those with conditions that could interfere with immune response, such as chronic liver disease, cancer in previ- ous five years, immunodeficiency, organ transplantation or transfusion in previous six months, were excluded.",2020-05-21,2020-07-08,Residual sera,All,Multiple groups,1.0,,Geographical area,Centre,335,0.027000000000000003,0.013000000000000001,0.055,,,True,,,Stratified non-probability,"Anti-SARS-CoV-2 ELISA IgG,Wantai SARS-CoV-2 IgM ELISA","EUROIMMUN,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Irina Kislaya, Instituto Nacional de Saúde Doutor Ricardo Jorge,Unity-Aligned,https://actamedicaportuguesa.com/revista/index.php/amp/article/view/15122,2021-03-11,2024-03-01,Verified,kislaya_seroprevalence_2021,PRT
210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge_age40-59,210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge,Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19),2021-02-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Portugal,"Norte Region, Centro Region, Lisboa Region, Alentejo Region, Algarve Region, Madeira, Azores",,"The target population of the survey included residents in Portugal (mainland and Autonomous Regions) aged one year old (yo) and over. Participants were recruited among the visiting partner laboratories or public hospitals during the study period, for reasons unrelated to COVID-19 and with a medical prescription for a blood test that involved venipuncture.","Those unable to give their informed consent and those with conditions that could interfere with immune response, such as chronic liver disease, cancer in previ- ous five years, immunodeficiency, organ transplantation or transfusion in previous six months, were excluded.",2020-05-21,2020-07-08,Residual sera,All,Adults (18-64 years),40.0,59.0,Age,40-59,479,0.032,0.015,0.067,,,True,,,Stratified non-probability,"Anti-SARS-CoV-2 ELISA IgG,Wantai SARS-CoV-2 IgM ELISA","EUROIMMUN,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Irina Kislaya, Instituto Nacional de Saúde Doutor Ricardo Jorge,Unity-Aligned,https://actamedicaportuguesa.com/revista/index.php/amp/article/view/15122,2021-03-11,2024-03-01,Verified,kislaya_seroprevalence_2021,PRT
210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge_overall_PopAdj,210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge,Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19),2021-02-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Portugal,"Norte Region, Centro Region, Lisboa Region, Alentejo Region, Algarve Region, Madeira, Azores",,"The target population of the survey included residents in Portugal (mainland and Autonomous Regions) aged one year old (yo) and over. Participants were recruited among the visiting partner laboratories or public hospitals during the study period, for reasons unrelated to COVID-19 and with a medical prescription for a blood test that involved venipuncture.","Those unable to give their informed consent and those with conditions that could interfere with immune response, such as chronic liver disease, cancer in previ- ous five years, immunodeficiency, organ transplantation or transfusion in previous six months, were excluded.",2020-05-21,2020-07-08,Residual sera,All,Multiple groups,1.0,,Analysis,Pop adj but not test adj,2301,0.028999999999999998,0.02,0.042,,,True,,True,Stratified non-probability,"Anti-SARS-CoV-2 ELISA IgG,Wantai SARS-CoV-2 IgM ELISA","EUROIMMUN,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Irina Kislaya, Instituto Nacional de Saúde Doutor Ricardo Jorge,Unity-Aligned,https://actamedicaportuguesa.com/revista/index.php/amp/article/view/15122,2021-03-11,2024-03-01,Verified,kislaya_seroprevalence_2021,PRT
210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge_LisboaRegion,210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge,Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19),2021-02-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Portugal, Lisboa Region,,"The target population of the survey included residents in Portugal (mainland and Autonomous Regions) aged one year old (yo) and over. Participants were recruited among the visiting partner laboratories or public hospitals during the study period, for reasons unrelated to COVID-19 and with a medical prescription for a blood test that involved venipuncture.","Those unable to give their informed consent and those with conditions that could interfere with immune response, such as chronic liver disease, cancer in previ- ous five years, immunodeficiency, organ transplantation or transfusion in previous six months, were excluded.",2020-05-21,2020-07-08,Residual sera,All,Multiple groups,1.0,,Geographical area,Lisbon and Tagus Valley (Lisboa Region),343,0.035,0.019,0.063,,,True,,,Stratified non-probability,"Anti-SARS-CoV-2 ELISA IgG,Wantai SARS-CoV-2 IgM ELISA","EUROIMMUN,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Irina Kislaya, Instituto Nacional de Saúde Doutor Ricardo Jorge,Unity-Aligned,https://actamedicaportuguesa.com/revista/index.php/amp/article/view/15122,2021-03-11,2024-03-01,Verified,kislaya_seroprevalence_2021,PRT
210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge_Madeira,210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge,Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19),2021-02-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Portugal,Madeira ,,"The target population of the survey included residents in Portugal (mainland and Autonomous Regions) aged one year old (yo) and over. Participants were recruited among the visiting partner laboratories or public hospitals during the study period, for reasons unrelated to COVID-19 and with a medical prescription for a blood test that involved venipuncture.","Those unable to give their informed consent and those with conditions that could interfere with immune response, such as chronic liver disease, cancer in previ- ous five years, immunodeficiency, organ transplantation or transfusion in previous six months, were excluded.",2020-05-21,2020-07-08,Residual sera,All,Multiple groups,1.0,,Geographical area,Madeira ,329,0.016,0.006,0.039,,,True,,,Stratified non-probability,"Anti-SARS-CoV-2 ELISA IgG,Wantai SARS-CoV-2 IgM ELISA","EUROIMMUN,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Irina Kislaya, Instituto Nacional de Saúde Doutor Ricardo Jorge,Unity-Aligned,https://actamedicaportuguesa.com/revista/index.php/amp/article/view/15122,2021-03-11,2024-03-01,Verified,kislaya_seroprevalence_2021,PRT
210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge_female,210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge,Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19),2021-02-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Portugal,"Norte Region, Centro Region, Lisboa Region, Alentejo Region, Algarve Region, Madeira, Azores",,"The target population of the survey included residents in Portugal (mainland and Autonomous Regions) aged one year old (yo) and over. Participants were recruited among the visiting partner laboratories or public hospitals during the study period, for reasons unrelated to COVID-19 and with a medical prescription for a blood test that involved venipuncture.","Those unable to give their informed consent and those with conditions that could interfere with immune response, such as chronic liver disease, cancer in previ- ous five years, immunodeficiency, organ transplantation or transfusion in previous six months, were excluded.",2020-05-21,2020-07-08,Residual sera,Female,Multiple groups,1.0,,Sex/Gender,Female,1244,0.018000000000000002,0.009000000000000001,0.034,,,True,,,Stratified non-probability,"Anti-SARS-CoV-2 ELISA IgG,Wantai SARS-CoV-2 IgM ELISA","EUROIMMUN,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Irina Kislaya, Instituto Nacional de Saúde Doutor Ricardo Jorge,Unity-Aligned,https://actamedicaportuguesa.com/revista/index.php/amp/article/view/15122,2021-03-11,2024-03-01,Verified,kislaya_seroprevalence_2021,PRT
210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge_age1-9,210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge,Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19),2021-02-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Portugal,"Norte Region, Centro Region, Lisboa Region, Alentejo Region, Algarve Region, Madeira, Azores",,"The target population of the survey included residents in Portugal (mainland and Autonomous Regions) aged one year old (yo) and over. Participants were recruited among the visiting partner laboratories or public hospitals during the study period, for reasons unrelated to COVID-19 and with a medical prescription for a blood test that involved venipuncture.","Those unable to give their informed consent and those with conditions that could interfere with immune response, such as chronic liver disease, cancer in previ- ous five years, immunodeficiency, organ transplantation or transfusion in previous six months, were excluded.",2020-05-21,2020-07-08,Residual sera,All,Children and Youth (0-17 years),1.0,9.0,Age, 1-9,404,0.028999999999999998,0.013000000000000001,0.062000000000000006,,,True,,,Stratified non-probability,"Anti-SARS-CoV-2 ELISA IgG,Wantai SARS-CoV-2 IgM ELISA","EUROIMMUN,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Irina Kislaya, Instituto Nacional de Saúde Doutor Ricardo Jorge,Unity-Aligned,https://actamedicaportuguesa.com/revista/index.php/amp/article/view/15122,2021-03-11,2024-03-01,Verified,kislaya_seroprevalence_2021,PRT
210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge_age10-19,210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge,Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19),2021-02-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Portugal,"Norte Region, Centro Region, Lisboa Region, Alentejo Region, Algarve Region, Madeira, Azores",,"The target population of the survey included residents in Portugal (mainland and Autonomous Regions) aged one year old (yo) and over. Participants were recruited among the visiting partner laboratories or public hospitals during the study period, for reasons unrelated to COVID-19 and with a medical prescription for a blood test that involved venipuncture.","Those unable to give their informed consent and those with conditions that could interfere with immune response, such as chronic liver disease, cancer in previ- ous five years, immunodeficiency, organ transplantation or transfusion in previous six months, were excluded.",2020-05-21,2020-07-08,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age, 10-19,377,0.022000000000000002,0.008,0.055,,,True,,,Stratified non-probability,"Anti-SARS-CoV-2 ELISA IgG,Wantai SARS-CoV-2 IgM ELISA","EUROIMMUN,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Irina Kislaya, Instituto Nacional de Saúde Doutor Ricardo Jorge,Unity-Aligned,https://actamedicaportuguesa.com/revista/index.php/amp/article/view/15122,2021-03-11,2024-03-01,Verified,kislaya_seroprevalence_2021,PRT
210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge_male,210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge,Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19),2021-02-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Portugal,"Norte Region, Centro Region, Lisboa Region, Alentejo Region, Algarve Region, Madeira, Azores",,"The target population of the survey included residents in Portugal (mainland and Autonomous Regions) aged one year old (yo) and over. Participants were recruited among the visiting partner laboratories or public hospitals during the study period, for reasons unrelated to COVID-19 and with a medical prescription for a blood test that involved venipuncture.","Those unable to give their informed consent and those with conditions that could interfere with immune response, such as chronic liver disease, cancer in previ- ous five years, immunodeficiency, organ transplantation or transfusion in previous six months, were excluded.",2020-05-21,2020-07-08,Residual sera,Male,Multiple groups,1.0,,Sex/Gender,,1057,0.040999999999999995,0.026000000000000002,0.066,,,True,,,Stratified non-probability,"Anti-SARS-CoV-2 ELISA IgG,Wantai SARS-CoV-2 IgM ELISA","EUROIMMUN,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Irina Kislaya, Instituto Nacional de Saúde Doutor Ricardo Jorge,Unity-Aligned,https://actamedicaportuguesa.com/revista/index.php/amp/article/view/15122,2021-03-11,2024-03-01,Verified,kislaya_seroprevalence_2021,PRT
210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge_age20-39,210201_Portugal_InstitutoNacionalDeSaúdeDoutorRicardoJorge,Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19),2021-02-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Portugal,"Norte Region, Centro Region, Lisboa Region, Alentejo Region, Algarve Region, Madeira, Azores",,"The target population of the survey included residents in Portugal (mainland and Autonomous Regions) aged one year old (yo) and over. Participants were recruited among the visiting partner laboratories or public hospitals during the study period, for reasons unrelated to COVID-19 and with a medical prescription for a blood test that involved venipuncture.","Those unable to give their informed consent and those with conditions that could interfere with immune response, such as chronic liver disease, cancer in previ- ous five years, immunodeficiency, organ transplantation or transfusion in previous six months, were excluded.",2020-05-21,2020-07-08,Residual sera,All,Adults (18-64 years),20.0,39.0,Age,20-39,377,0.028999999999999998,0.012,0.07,,,True,,,Stratified non-probability,"Anti-SARS-CoV-2 ELISA IgG,Wantai SARS-CoV-2 IgM ELISA","EUROIMMUN,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Irina Kislaya, Instituto Nacional de Saúde Doutor Ricardo Jorge,Unity-Aligned,https://actamedicaportuguesa.com/revista/index.php/amp/article/view/15122,2021-03-11,2024-03-01,Verified,kislaya_seroprevalence_2021,PRT
210426_Portugal_DepartmentofEpidemiologyandInfectiousDiseasesoftheNationalInstitutesofHealth,210426_Portugal_DepartmentofEpidemiologyandInfectiousDiseasesoftheNationalInstitutesofHealth,The second national serological survey showed that 15.5% of the Portuguese population has antibodies against SARS-CoV-2,2021-04-26,News and Media,National,Cross-sectional survey ,Portugal,,,"The data for this second national serological survey comes from people over twelve months old who have been to the research hospital or laboratory for clinical testing.
",,2021-02-02,2021-03-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,8463,0.155,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],Unclear,No,Yes,No,Unclear,Unclear,Yes,No,Unclear,Pedro Simas,Department of Epidemiology and Infectious Diseases of the National Institutes of Health (INSA),Not Unity-Aligned,https://newsline.news/the-second-national-serological-survey-showed-that-15-5-of-the-portuguese-population-has-antibodies-against-sars-cov-2/,2021-05-17,2022-07-16,Verified,pedro_simas_second_2021,PRT
210428_Europe_SorbonneUniversité_3Centro,210428_Europe_SorbonneUniversité_3Centro,SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study.,2021-04-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Portugal,Região do Centro,,"Eligible individuals had to be older than 18 years and have a definite clinical diagnosis of rheumatoid arthritis, axial spondyloarthritis, systemic lupus erythematosus, Sjögren's syndrome, or giant cell arteritis diagnosed by experienced rheumatologists and fulfilling the respective international classification criteria.","Patients who refused to participate, did not speak or read the local language, or were unwilling to undergo routine blood collection during the study period were excluded. ",2020-07-07,2020-12-08,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,,Primary Estimate,,526,0.011000000000000001,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Liaison SARS-CoV-2 S1/S2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Siemens,DiaSorin,Beckman Coulter,Roche Diagnostics",,,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,Yes,Unclear,Unclear,No,No,Unclear,David Saadoun,Sorbonne Université,Not Unity-Aligned,https://dx.doi.org/10.1016/S2665-9913(21)00112-0,2021-05-30,2024-03-01,Verified,davidsaadounetal.SARSCoV2OutbreakImmunemediated2021,PRT
210616_Lisbon_ UniversidadeNOVAdeLisboa_primary,210616_Lisbon_ UniversidadeNOVAdeLisboa,Staff SARS-CoV-2 Seroprevalence and Mental Health as Key Factors in University Response to COVID-19 Pandemic.,2021-06-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Portugal,,Lisbon,"employees—professors, researchers,
and administrative and operational staff—of the nine schools
within NOVA University, plus those in the RUNL and SAS",,2020-06-15,2020-06-30,Non-essential workers and unemployed persons,All,Multiple groups,,,Primary Estimate,,1624,0.031000000000000003,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9474,0.9953000000000001,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,David G. Lopes, Universidade NOVA de Lisboa,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2021.689919,2021-07-15,2022-07-16,Unverified,lopes_staff_2021,PRT
210616_Lisbon_ UniversidadeNOVAdeLisboa_age_40-49,210616_Lisbon_ UniversidadeNOVAdeLisboa,Staff SARS-CoV-2 Seroprevalence and Mental Health as Key Factors in University Response to COVID-19 Pandemic.,2021-06-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Portugal,,Lisbon,"employees—professors, researchers,
and administrative and operational staff—of the nine schools
within NOVA University, plus those in the RUNL and SAS",,2020-06-15,2020-06-30,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Age,,413,0.028999999999999998,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9474,0.9953000000000001,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,David G. Lopes, Universidade NOVA de Lisboa,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2021.689919,2021-07-15,2022-07-16,Unverified,lopes_staff_2021,PRT
210616_Lisbon_ UniversidadeNOVAdeLisboa_age>60,210616_Lisbon_ UniversidadeNOVAdeLisboa,Staff SARS-CoV-2 Seroprevalence and Mental Health as Key Factors in University Response to COVID-19 Pandemic.,2021-06-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Portugal,,Lisbon,"employees—professors, researchers,
and administrative and operational staff—of the nine schools
within NOVA University, plus those in the RUNL and SAS",,2020-06-15,2020-06-30,Non-essential workers and unemployed persons,All,Multiple groups,,,Age,,160,0.019,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9474,0.9953000000000001,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,David G. Lopes, Universidade NOVA de Lisboa,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2021.689919,2021-07-15,2022-07-16,Unverified,lopes_staff_2021,PRT
210616_Lisbon_ UniversidadeNOVAdeLisboa_age_50-59,210616_Lisbon_ UniversidadeNOVAdeLisboa,Staff SARS-CoV-2 Seroprevalence and Mental Health as Key Factors in University Response to COVID-19 Pandemic.,2021-06-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Portugal,,Lisbon,"employees—professors, researchers,
and administrative and operational staff—of the nine schools
within NOVA University, plus those in the RUNL and SAS",,2020-06-15,2020-06-30,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Age,,309,0.028999999999999998,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9474,0.9953000000000001,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,David G. Lopes, Universidade NOVA de Lisboa,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2021.689919,2021-07-15,2022-07-16,Unverified,lopes_staff_2021,PRT
210616_Lisbon_ UniversidadeNOVAdeLisboa_age_<30,210616_Lisbon_ UniversidadeNOVAdeLisboa,Staff SARS-CoV-2 Seroprevalence and Mental Health as Key Factors in University Response to COVID-19 Pandemic.,2021-06-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Portugal,,Lisbon,"employees—professors, researchers,
and administrative and operational staff—of the nine schools
within NOVA University, plus those in the RUNL and SAS",,2020-06-15,2020-06-30,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Age,,296,0.037000000000000005,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9474,0.9953000000000001,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,David G. Lopes, Universidade NOVA de Lisboa,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2021.689919,2021-07-15,2022-07-16,Unverified,lopes_staff_2021,PRT
210616_Lisbon_ UniversidadeNOVAdeLisboa_age_30-39,210616_Lisbon_ UniversidadeNOVAdeLisboa,Staff SARS-CoV-2 Seroprevalence and Mental Health as Key Factors in University Response to COVID-19 Pandemic.,2021-06-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Portugal,,Lisbon,"employees—professors, researchers,
and administrative and operational staff—of the nine schools
within NOVA University, plus those in the RUNL and SAS",,2020-06-15,2020-06-30,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Age,,438,0.034,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9474,0.9953000000000001,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,David G. Lopes, Universidade NOVA de Lisboa,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2021.689919,2021-07-15,2022-07-16,Unverified,lopes_staff_2021,PRT
210621_Portugal_LosAlamosNationalLaboratory_overall_PopAdj_TestAdj,210621_Portugal_LosAlamosNationalLaboratory,Longitudinal SARS-CoV-2 seroprevalence in Portugal and antibody maintenance 12 months after the start of the COVID-19 pandemic,2021-06-21,Preprint,National,Cross-sectional survey ,Portugal,,,"Participants from a first seroprevalence study conducted in September 2020, from the general Portuguese population",Participants were excluded if they had any contraindication for phlebotomy. ,2021-03-01,2021-03-17,Household and community samples,All,Multiple groups,,,Primary Estimate,"Overal, population and test adjusted",2435,0.17300000000000001,0.158,0.188,True,True,True,,True,Stratified probability,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.981,0.9990000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Luisa Canto e Castro,Los Alamos National Laboratory,Unity-Aligned,https://europepmc.org/article/PPR/PPR359402,2021-07-02,2023-08-15,Verified,castro_longitudinal_2021,PRT
210621_Portugal_LosAlamosNationalLaboratory_overall_Age18-54,210621_Portugal_LosAlamosNationalLaboratory,Longitudinal SARS-CoV-2 seroprevalence in Portugal and antibody maintenance 12 months after the start of the COVID-19 pandemic,2021-06-21,Preprint,National,Cross-sectional survey ,Portugal,,,"Participants from a first seroprevalence study conducted in September 2020, from the general Portuguese population",Participants were excluded if they had any contraindication for phlebotomy. ,2021-03-01,2021-03-17,Household and community samples,All,Adults (18-64 years),,,Age,18-54,1138,0.20199999999999999,0.17800000000000002,0.22399999999999998,,True,True,,,Stratified probability,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.981,0.9990000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Luisa Canto e Castro,Los Alamos National Laboratory,Unity-Aligned,https://europepmc.org/article/PPR/PPR359402,2021-07-30,2023-08-15,Verified,castro_longitudinal_2021,PRT
210621_Portugal_LosAlamosNationalLaboratory_overall_Age55+,210621_Portugal_LosAlamosNationalLaboratory,Longitudinal SARS-CoV-2 seroprevalence in Portugal and antibody maintenance 12 months after the start of the COVID-19 pandemic,2021-06-21,Preprint,National,Cross-sectional survey ,Portugal,,,"Participants from a first seroprevalence study conducted in September 2020, from the general Portuguese population",Participants were excluded if they had any contraindication for phlebotomy. ,2021-03-01,2021-03-17,Household and community samples,All,Multiple groups,,,Age,55+,1033,0.142,0.121,0.163,,True,True,,,Stratified probability,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.981,0.9990000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Luisa Canto e Castro,Los Alamos National Laboratory,Unity-Aligned,https://europepmc.org/article/PPR/PPR359402,2021-07-30,2023-08-15,Verified,castro_longitudinal_2021,PRT
210621_Portugal_LosAlamosNationalLaboratory_overall_Age<18,210621_Portugal_LosAlamosNationalLaboratory,Longitudinal SARS-CoV-2 seroprevalence in Portugal and antibody maintenance 12 months after the start of the COVID-19 pandemic,2021-06-21,Preprint,National,Cross-sectional survey ,Portugal,,,"Participants from a first seroprevalence study conducted in September 2020, from the general Portuguese population",Participants were excluded if they had any contraindication for phlebotomy. ,2021-03-01,2021-03-17,Household and community samples,All,Children and Youth (0-17 years),,,Age,<18,264,0.15,0.11,0.196,,True,True,,,Stratified probability,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.981,0.9990000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Luisa Canto e Castro,Los Alamos National Laboratory,Unity-Aligned,https://europepmc.org/article/PPR/PPR359402,2021-07-30,2023-08-15,Verified,castro_longitudinal_2021,PRT
210621_Portugal_LosAlamosNationalLaboratory_Unvaccinated,210621_Portugal_LosAlamosNationalLaboratory,Longitudinal SARS-CoV-2 seroprevalence in Portugal and antibody maintenance 12 months after the start of the COVID-19 pandemic,2021-06-21,Preprint,National,Cross-sectional survey ,Portugal,,,"Participants from a first seroprevalence study conducted in September 2020, from the general Portuguese population",Participants were excluded if they had any contraindication for phlebotomy. ,2021-03-01,2021-03-17,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,Vaccinated no,2262,0.131,0.11800000000000001,0.146,,True,True,,,Stratified probability,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.981,0.9990000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Luisa Canto e Castro,Los Alamos National Laboratory,Unity-Aligned,https://europepmc.org/article/PPR/PPR359402,2021-07-30,2023-08-15,Verified,castro_longitudinal_2021,PRT
210630_Porto_UniversidadeDoPorto_primary,210630_Porto_UniversidadeDoPorto,"Prevalence of SARS-CoV-2 antibodies among workers of the public higher education institutions of Porto, Portugal: a cross-sectional study.",2021-06-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Portugal,Norte,Porto,,,2020-05-21,2020-07-31,Essential non-healthcare workers,All,Multiple groups,,,Primary Estimate,,4592,0.025,0.001,0.053,True,True,,,,Convenience,"Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Standard Q COVID-19 IgM/IgG Combo",SD Biosensor,Multiple Types,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,,,['High'],Yes,No,Yes,Yes,Unclear,Unclear,No,Yes,Unclear,Paula Meireles, Universidade do Porto,Not Unity-Aligned,https://dx.doi.org/10.1136/oemed-2021-107519,2021-07-06,2023-08-15,Verified,meireles_prevalence_2021-1,PRT
210630_Porto_UniversidadeDoPorto_adj_30-39,210630_Porto_UniversidadeDoPorto,"Prevalence of SARS-CoV-2 antibodies among workers of the public higher education institutions of Porto, Portugal: a cross-sectional study.",2021-06-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Portugal,Norte,Porto,,,2020-05-21,2020-07-31,Essential non-healthcare workers,All,Multiple groups,,,Age,30-39,1097,0.0116,0.0054,0.0252,,True,,,,Convenience,"Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Standard Q COVID-19 IgM/IgG Combo",SD Biosensor,Multiple Types,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,,,['High'],Yes,No,Yes,Yes,Unclear,Unclear,No,Yes,Unclear,Paula Meireles, Universidade do Porto,Not Unity-Aligned,https://dx.doi.org/10.1136/oemed-2021-107519,2021-07-09,2023-08-15,Verified,meireles_prevalence_2021-1,PRT
210630_Porto_UniversidadeDoPorto_adj_70+,210630_Porto_UniversidadeDoPorto,"Prevalence of SARS-CoV-2 antibodies among workers of the public higher education institutions of Porto, Portugal: a cross-sectional study.",2021-06-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Portugal,Norte,Porto,,,2020-05-21,2020-07-31,Essential non-healthcare workers,All,Multiple groups,,,Age,70+,38,0.0406,0.0101,0.1625,,True,,,,Convenience,"Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Standard Q COVID-19 IgM/IgG Combo",SD Biosensor,Multiple Types,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,,,['High'],Yes,No,Yes,Yes,Unclear,Unclear,No,Yes,Unclear,Paula Meireles, Universidade do Porto,Not Unity-Aligned,https://dx.doi.org/10.1136/oemed-2021-107519,2021-07-09,2023-08-15,Verified,meireles_prevalence_2021-1,PRT
210630_Porto_UniversidadeDoPorto_adj_50-59,210630_Porto_UniversidadeDoPorto,"Prevalence of SARS-CoV-2 antibodies among workers of the public higher education institutions of Porto, Portugal: a cross-sectional study.",2021-06-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Portugal,Norte,Porto,,,2020-05-21,2020-07-31,Essential non-healthcare workers,All,Multiple groups,,,Age,50-59,936,0.024100000000000003,0.011200000000000002,0.051500000000000004,,True,,,,Convenience,"Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Standard Q COVID-19 IgM/IgG Combo",SD Biosensor,Multiple Types,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,,,['High'],Yes,No,Yes,Yes,Unclear,Unclear,No,Yes,Unclear,Paula Meireles, Universidade do Porto,Not Unity-Aligned,https://dx.doi.org/10.1136/oemed-2021-107519,2021-07-09,2023-08-15,Verified,meireles_prevalence_2021-1,PRT
210630_Porto_UniversidadeDoPorto_unadj_<30,210630_Porto_UniversidadeDoPorto,"Prevalence of SARS-CoV-2 antibodies among workers of the public higher education institutions of Porto, Portugal: a cross-sectional study.",2021-06-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Portugal,Norte,Porto,,,2020-05-21,2020-07-31,Essential non-healthcare workers,All,Multiple groups,,,Age,<30,435,0.021,,,,,,,,Convenience,"Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Standard Q COVID-19 IgM/IgG Combo",SD Biosensor,Multiple Types,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,,,['High'],Yes,No,Yes,Yes,Unclear,Unclear,No,Yes,Unclear,Paula Meireles, Universidade do Porto,Not Unity-Aligned,https://dx.doi.org/10.1136/oemed-2021-107519,2021-07-09,2024-03-01,Verified,meireles_prevalence_2021-1,PRT
210630_Porto_UniversidadeDoPorto_adj_40-49,210630_Porto_UniversidadeDoPorto,"Prevalence of SARS-CoV-2 antibodies among workers of the public higher education institutions of Porto, Portugal: a cross-sectional study.",2021-06-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Portugal,Norte,Porto,,,2020-05-21,2020-07-31,Essential non-healthcare workers,All,Multiple groups,,,Age,40-49,1479,0.018000000000000002,0.0086,0.0374,,True,,,,Convenience,"Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Standard Q COVID-19 IgM/IgG Combo",SD Biosensor,Multiple Types,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,,,['High'],Yes,No,Yes,Yes,Unclear,Unclear,No,Yes,Unclear,Paula Meireles, Universidade do Porto,Not Unity-Aligned,https://dx.doi.org/10.1136/oemed-2021-107519,2021-07-09,2023-08-15,Verified,meireles_prevalence_2021-1,PRT
210630_Porto_UniversidadeDoPorto_adj_60-69,210630_Porto_UniversidadeDoPorto,"Prevalence of SARS-CoV-2 antibodies among workers of the public higher education institutions of Porto, Portugal: a cross-sectional study.",2021-06-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Portugal,Norte,Porto,,,2020-05-21,2020-07-31,Essential non-healthcare workers,All,Multiple groups,,,Age,60-69,505,0.027700000000000002,0.0124,0.061900000000000004,,True,,,,Convenience,"Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Standard Q COVID-19 IgM/IgG Combo",SD Biosensor,Multiple Types,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,,,['High'],Yes,No,Yes,Yes,Unclear,Unclear,No,Yes,Unclear,Paula Meireles, Universidade do Porto,Not Unity-Aligned,https://dx.doi.org/10.1136/oemed-2021-107519,2021-07-09,2023-08-15,Verified,meireles_prevalence_2021-1,PRT
210826_Portugal_LosAlamosNationalLaboratory_PopAdj_TestAdj,210826_Portugal_LosAlamosNationalLaboratory,"Prevalence of SARS-CoV-2 Antibodies after First 6 Months of COVID-19 Pandemic, Portugal",2021-08-26,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Portugal,,,Resident of Portugal,,2020-09-08,2020-10-14,Household and community samples,All,Multiple groups,,,Primary Estimate,,13398,0.022000000000000002,0.02,0.025,True,True,True,,,Convenience,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.981,0.9990000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Luisa Castro,Los Alamos National Laboratory,Unity-Aligned,https://wwwnc.cdc.gov/eid/article/27/11/21-0636_article,2021-09-29,2023-08-15,Verified,castro_early_2021,PRT
210826_Portugal_LosAlamosNationalLaboratory_Unadj,210826_Portugal_LosAlamosNationalLaboratory,"Prevalence of SARS-CoV-2 Antibodies after First 6 Months of COVID-19 Pandemic, Portugal",2021-08-26,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Portugal,,,Resident of Portugal,,2020-09-08,2020-10-14,Household and community samples,All,Multiple groups,,,Analysis,,13398,0.0221,,,,,,,True,Convenience,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.981,0.9990000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Luisa Castro,Los Alamos National Laboratory,Unity-Aligned,https://wwwnc.cdc.gov/eid/article/27/11/21-0636_article,2021-09-29,2024-03-01,Verified,castro_early_2021,PRT
210826_Portugal_LosAlamosNationalLaboratory_>=55,210826_Portugal_LosAlamosNationalLaboratory,"Prevalence of SARS-CoV-2 Antibodies after First 6 Months of COVID-19 Pandemic, Portugal",2021-08-26,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Portugal,,,Resident of Portugal,,2020-09-08,2020-10-14,Household and community samples,All,Multiple groups,55.0,,Age,>=55,4795,0.0198,,,,,,,,Convenience,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.981,0.9990000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Luisa Castro,Los Alamos National Laboratory,Unity-Aligned,https://wwwnc.cdc.gov/eid/article/27/11/21-0636_article,2021-09-29,2024-03-01,Verified,castro_early_2021,PRT
210826_Portugal_LosAlamosNationalLaboratory_18-54,210826_Portugal_LosAlamosNationalLaboratory,"Prevalence of SARS-CoV-2 Antibodies after First 6 Months of COVID-19 Pandemic, Portugal",2021-08-26,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Portugal,,,Resident of Portugal,,2020-09-08,2020-10-14,Household and community samples,All,Adults (18-64 years),18.0,54.0,Age,18-54,6495,0.0234,,,,,,,,Convenience,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.981,0.9990000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Luisa Castro,Los Alamos National Laboratory,Unity-Aligned,https://wwwnc.cdc.gov/eid/article/27/11/21-0636_article,2021-09-29,2024-03-01,Verified,castro_early_2021,PRT
210826_Portugal_LosAlamosNationalLaboratory_<18,210826_Portugal_LosAlamosNationalLaboratory,"Prevalence of SARS-CoV-2 Antibodies after First 6 Months of COVID-19 Pandemic, Portugal",2021-08-26,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Portugal,,,Resident of Portugal,,2020-09-08,2020-10-14,Household and community samples,All,Children and Youth (0-17 years),,17.0,Age,<18 ,2108,0.0232,,,,,,,,Convenience,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.981,0.9990000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Luisa Castro,Los Alamos National Laboratory,Unity-Aligned,https://wwwnc.cdc.gov/eid/article/27/11/21-0636_article,2021-09-29,2024-03-01,Verified,castro_early_2021,PRT
210826_Portugal_LosAlamosNationalLaboratory_Female,210826_Portugal_LosAlamosNationalLaboratory,"Prevalence of SARS-CoV-2 Antibodies after First 6 Months of COVID-19 Pandemic, Portugal",2021-08-26,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Portugal,,,Resident of Portugal,,2020-09-08,2020-10-14,Household and community samples,Female,Multiple groups,,,Sex/Gender,,7413,0.021,0.019,0.026000000000000002,,,True,,,Convenience,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.981,0.9990000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Luisa Castro,Los Alamos National Laboratory,Unity-Aligned,https://wwwnc.cdc.gov/eid/article/27/11/21-0636_article,2021-09-29,2024-03-01,Verified,castro_early_2021,PRT
210826_Portugal_LosAlamosNationalLaboratory_Male,210826_Portugal_LosAlamosNationalLaboratory,"Prevalence of SARS-CoV-2 Antibodies after First 6 Months of COVID-19 Pandemic, Portugal",2021-08-26,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Portugal,,,Resident of Portugal,,2020-09-08,2020-10-14,Household and community samples,Male,Multiple groups,,,Sex/Gender,,5985,0.023,0.02,0.027999999999999997,,,True,,,Convenience,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.981,0.9990000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Luisa Castro,Los Alamos National Laboratory,Unity-Aligned,https://wwwnc.cdc.gov/eid/article/27/11/21-0636_article,2021-09-29,2024-03-01,Verified,castro_early_2021,PRT
211012_NortheastPortugal_FernandoPessoaUniversity_Overall,211012_NortheastPortugal_FernandoPessoaUniversity,Pre-vaccination immune response to COVID-19 in a population in Northeast Portugal.,2021-10-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Portugal,,,"""unvaccinated participants (including diagnosed and undiagnosed individuals, with and without known virus exposure) that voluntarily sought the lab for testing.""",,2020-04-15,2021-02-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,358,0.30446927370000004,,,True,,,,True,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],Unclear,No,No,Yes,No,Yes,Yes,Yes,,Mary Duro,Fernando Pessoa University,Not Unity-Aligned,https://dx.doi.org/10.1007/s11845-021-02799-6,2021-10-18,2024-03-01,Verified,duro_pre-vaccination_2021,PRT
211018_Porto_UniversidadedoPorto,211018_Porto_UniversidadedoPorto,Incidence of SARS-CoV-2 infection in a cohort of workers from the University of Porto,2021-10-18,Preprint,Local,Cross-sectional survey ,Portugal,Porto District,Porto,All the workers of the U.Porto were invited to participate in two serological surveys using a point of care test for SARS-CoV-2 specific IgM and IgG antibodies.,,2020-11-27,2021-01-29,Non-essential workers and unemployed persons,All,Multiple groups,,,Primary Estimate,,1891,0.10682178739999999,,,True,,,,True,Self-referral,Standard Q COVID-19 IgM/IgG Combo,SD Biosensor,,,"['IgG', 'IgM']",,Validated by manufacturers,0.9450000000000001,0.9570000000000001,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Joana Costa,Universidade do Porto,Not Unity-Aligned,10.1101/2021.10.14.21264980,2021-10-28,2022-07-16,Unverified,costa_incidence_2021,PRT
211018_Porto_UniversidadedoPorto_Age_30-39,211018_Porto_UniversidadedoPorto,Incidence of SARS-CoV-2 infection in a cohort of workers from the University of Porto,2021-10-18,Preprint,Local,Cross-sectional survey ,Portugal,Porto District,Porto,All the workers of the U.Porto were invited to participate in two serological surveys using a point of care test for SARS-CoV-2 specific IgM and IgG antibodies.,,2020-11-27,2021-01-29,Non-essential workers and unemployed persons,All,Adults (18-64 years),30.0,39.0,Age,30-39,464,0.09698275862,,,,,,,,Self-referral,Standard Q COVID-19 IgM/IgG Combo,SD Biosensor,,,"['IgG', 'IgM']",,Validated by manufacturers,0.9450000000000001,0.9570000000000001,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Joana Costa,Universidade do Porto,Not Unity-Aligned,10.1101/2021.10.14.21264980,2021-10-28,2022-07-16,Unverified,costa_incidence_2021,PRT
211018_Porto_UniversidadedoPorto_Age_40-49,211018_Porto_UniversidadedoPorto,Incidence of SARS-CoV-2 infection in a cohort of workers from the University of Porto,2021-10-18,Preprint,Local,Cross-sectional survey ,Portugal,Porto District,Porto,All the workers of the U.Porto were invited to participate in two serological surveys using a point of care test for SARS-CoV-2 specific IgM and IgG antibodies.,,2020-11-27,2021-01-29,Non-essential workers and unemployed persons,All,Adults (18-64 years),40.0,49.0,Age,40-49,659,0.1001517451,,,,,,,,Self-referral,Standard Q COVID-19 IgM/IgG Combo,SD Biosensor,,,"['IgG', 'IgM']",,Validated by manufacturers,0.9450000000000001,0.9570000000000001,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Joana Costa,Universidade do Porto,Not Unity-Aligned,10.1101/2021.10.14.21264980,2021-10-28,2022-07-16,Unverified,costa_incidence_2021,PRT
211018_Porto_UniversidadedoPorto_Age_50-59,211018_Porto_UniversidadedoPorto,Incidence of SARS-CoV-2 infection in a cohort of workers from the University of Porto,2021-10-18,Preprint,Local,Cross-sectional survey ,Portugal,Porto District,Porto,All the workers of the U.Porto were invited to participate in two serological surveys using a point of care test for SARS-CoV-2 specific IgM and IgG antibodies.,,2020-11-27,2021-01-29,Non-essential workers and unemployed persons,All,Adults (18-64 years),50.0,59.0,Age,50-59,394,0.1294416244,,,,,,,,Self-referral,Standard Q COVID-19 IgM/IgG Combo,SD Biosensor,,,"['IgG', 'IgM']",,Validated by manufacturers,0.9450000000000001,0.9570000000000001,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Joana Costa,Universidade do Porto,Not Unity-Aligned,10.1101/2021.10.14.21264980,2021-10-28,2022-07-16,Unverified,costa_incidence_2021,PRT
211018_Porto_UniversidadedoPorto_Age_<30,211018_Porto_UniversidadedoPorto,Incidence of SARS-CoV-2 infection in a cohort of workers from the University of Porto,2021-10-18,Preprint,Local,Cross-sectional survey ,Portugal,Porto District,Porto,All the workers of the U.Porto were invited to participate in two serological surveys using a point of care test for SARS-CoV-2 specific IgM and IgG antibodies.,,2020-11-27,2021-01-29,Non-essential workers and unemployed persons,All,Multiple groups,,30.0,Age,<30,146,0.102739726,,,,,,,,Self-referral,Standard Q COVID-19 IgM/IgG Combo,SD Biosensor,,,"['IgG', 'IgM']",,Validated by manufacturers,0.9450000000000001,0.9570000000000001,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Joana Costa,Universidade do Porto,Not Unity-Aligned,10.1101/2021.10.14.21264980,2021-10-28,2022-07-16,Unverified,costa_incidence_2021,PRT
211018_Porto_UniversidadedoPorto_Age_>=60,211018_Porto_UniversidadedoPorto,Incidence of SARS-CoV-2 infection in a cohort of workers from the University of Porto,2021-10-18,Preprint,Local,Cross-sectional survey ,Portugal,Porto District,Porto,All the workers of the U.Porto were invited to participate in two serological surveys using a point of care test for SARS-CoV-2 specific IgM and IgG antibodies.,,2020-11-27,2021-01-29,Non-essential workers and unemployed persons,All,Multiple groups,60.0,,Age,>=60,226,0.10619469029999999,,,,,,,,Self-referral,Standard Q COVID-19 IgM/IgG Combo,SD Biosensor,,,"['IgG', 'IgM']",,Validated by manufacturers,0.9450000000000001,0.9570000000000001,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Joana Costa,Universidade do Porto,Not Unity-Aligned,10.1101/2021.10.14.21264980,2021-10-28,2022-07-16,Unverified,costa_incidence_2021,PRT
211130_SantaMariadaFeira_CHEDV,211130_SantaMariadaFeira_CHEDV,Maternal SARS-CoV-2 infection: What to expect in newborns,2021-11-30,Presentation or Conference,Local,Prospective cohort,Portugal,Norte,Santa Maria da Feira,newborns whose mothers were infected with COVID-19 during pregnancy.,,2020-04-01,2021-05-31,Perinatal,All,Children and Youth (0-17 years),0.0,1.0,Primary Estimate,,32,0.3125,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Unclear,Yes,No,,Rosario Cunha,Centro Hospitalar de Entre Douro e Vouga,Not Unity-Aligned,https://dx.doi.org/10.1080/2331205X.2021.2002558,2022-01-18,2022-07-16,Unverified,cunha_maternal_2021,PRT
211130_Porto_CentroHospitalarUniversitáriodeSãoJoão,211130_Porto_CentroHospitalarUniversitáriodeSãoJoão,New-onset type 1 diabetes in children during the COVID-19 pandemic-a Tertiary Centre Experience,2021-11-30,Presentation or Conference,Local,Retrospective cohort,Portugal,Norte,Porto,"""including patients with new-onset T1D, diagnosed and treated in our Unit, between March 1st and December 31st, 2020.""

The unit mentioned is the Department of Pediatrics, Centro Hospitalar Universitário de São João",,2020-03-01,2020-12-31,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),,,Primary Estimate,,19,0.0,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,Serum,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Laura Leite-Almeida,Centro Hospitalar Universitário de São João,Not Unity-Aligned,https://dx.doi.org/10.1080/2331205X.2021.2002558,2022-01-17,2022-07-16,Unverified,leite-almeida_new-onset_2021,PRT
211217_Portugal_NationalInstituteofHealth_Primary,211217_Portugal_NationalInstituteofHealth,National COVID-19 Serological Survey (3rd phase),2021-12-17,Institutional Report,National,Cross-sectional survey ,Portugal,,,"All individuals who went to one of the participating collection points were invited to participate. (laboratories or partner health units) during the study period, holders of a medical prescription for performing a clinical analysis that involved venipuncture.","Individuals unable to provide informed consent (those with physical or mental disability, dementia, or other health condition that affects the ability to understand study and questionnaire objectives). Although the occurrence of previous SARS-CoV-2 infection or the presence of signs and symptoms suggestive of COVID-19 were not considered grounds for exclusion, individuals whose reason for going to the laboratory or health unit was the prescription of a diagnostic test for COVID-19, in order to avoid preferential selection of participants at higher risk of SARS-CoV infection 2 on the date of recruitment.",2021-09-28,2021-11-19,Household and community samples,All,Multiple groups,1.0,,Primary Estimate,,4545,0.8640000000000001,0.8520000000000001,0.876,True,,True,,True,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,ISN COVID-19 Group,National Institute of Health,Unity-Aligned,http://repositorio.insa.pt/handle/10400.18/7828,2022-01-26,2024-03-01,Verified,isn_covid-19_group_national_2021,PRT
211217_Portugal_NationalInstituteofHealth_Center,211217_Portugal_NationalInstituteofHealth,National COVID-19 Serological Survey (3rd phase),2021-12-17,Institutional Report,National,Cross-sectional survey ,Portugal,,,"All individuals who went to one of the participating collection points were invited to participate. (laboratories or partner health units) during the study period, holders of a medical prescription for performing a clinical analysis that involved venipuncture.","Individuals unable to provide informed consent (those with physical or mental disability, dementia, or other health condition that affects the ability to understand study and questionnaire objectives). Although the occurrence of previous SARS-CoV-2 infection or the presence of signs and symptoms suggestive of COVID-19 were not considered grounds for exclusion, individuals whose reason for going to the laboratory or health unit was the prescription of a diagnostic test for COVID-19, in order to avoid preferential selection of participants at higher risk of SARS-CoV infection 2 on the date of recruitment.",2021-09-28,2021-11-19,Household and community samples,All,Multiple groups,,,Geographical area,Center (Centro),671,0.858,0.831,0.881,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,ISN COVID-19 Group,National Institute of Health,Unity-Aligned,http://repositorio.insa.pt/handle/10400.18/7828,2022-01-26,2024-03-01,Verified,isn_covid-19_group_national_2021,PRT
211217_Portugal_NationalInstituteofHealth_50-59,211217_Portugal_NationalInstituteofHealth,National COVID-19 Serological Survey (3rd phase),2021-12-17,Institutional Report,National,Cross-sectional survey ,Portugal,,,"All individuals who went to one of the participating collection points were invited to participate. (laboratories or partner health units) during the study period, holders of a medical prescription for performing a clinical analysis that involved venipuncture.","Individuals unable to provide informed consent (those with physical or mental disability, dementia, or other health condition that affects the ability to understand study and questionnaire objectives). Although the occurrence of previous SARS-CoV-2 infection or the presence of signs and symptoms suggestive of COVID-19 were not considered grounds for exclusion, individuals whose reason for going to the laboratory or health unit was the prescription of a diagnostic test for COVID-19, in order to avoid preferential selection of participants at higher risk of SARS-CoV infection 2 on the date of recruitment.",2021-09-28,2021-11-19,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,,568,0.965,0.941,0.98,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,ISN COVID-19 Group,National Institute of Health,Unity-Aligned,http://repositorio.insa.pt/handle/10400.18/7828,2022-01-26,2024-03-01,Verified,isn_covid-19_group_national_2021,PRT
211217_Portugal_NationalInstituteofHealth_Female,211217_Portugal_NationalInstituteofHealth,National COVID-19 Serological Survey (3rd phase),2021-12-17,Institutional Report,National,Cross-sectional survey ,Portugal,,,"All individuals who went to one of the participating collection points were invited to participate. (laboratories or partner health units) during the study period, holders of a medical prescription for performing a clinical analysis that involved venipuncture.","Individuals unable to provide informed consent (those with physical or mental disability, dementia, or other health condition that affects the ability to understand study and questionnaire objectives). Although the occurrence of previous SARS-CoV-2 infection or the presence of signs and symptoms suggestive of COVID-19 were not considered grounds for exclusion, individuals whose reason for going to the laboratory or health unit was the prescription of a diagnostic test for COVID-19, in order to avoid preferential selection of participants at higher risk of SARS-CoV infection 2 on the date of recruitment.",2021-09-28,2021-11-19,Household and community samples,Female,Multiple groups,,,Sex/Gender,,2498,0.883,0.867,0.8959999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,ISN COVID-19 Group,National Institute of Health,Unity-Aligned,http://repositorio.insa.pt/handle/10400.18/7828,2022-01-26,2024-03-01,Verified,isn_covid-19_group_national_2021,PRT
211217_Portugal_NationalInstituteofHealth_30-39,211217_Portugal_NationalInstituteofHealth,National COVID-19 Serological Survey (3rd phase),2021-12-17,Institutional Report,National,Cross-sectional survey ,Portugal,,,"All individuals who went to one of the participating collection points were invited to participate. (laboratories or partner health units) during the study period, holders of a medical prescription for performing a clinical analysis that involved venipuncture.","Individuals unable to provide informed consent (those with physical or mental disability, dementia, or other health condition that affects the ability to understand study and questionnaire objectives). Although the occurrence of previous SARS-CoV-2 infection or the presence of signs and symptoms suggestive of COVID-19 were not considered grounds for exclusion, individuals whose reason for going to the laboratory or health unit was the prescription of a diagnostic test for COVID-19, in order to avoid preferential selection of participants at higher risk of SARS-CoV infection 2 on the date of recruitment.",2021-09-28,2021-11-19,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,,549,0.946,0.919,0.9640000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,ISN COVID-19 Group,National Institute of Health,Unity-Aligned,http://repositorio.insa.pt/handle/10400.18/7828,2022-01-26,2024-03-01,Verified,isn_covid-19_group_national_2021,PRT
211217_Portugal_NationalInstituteofHealth_Alentejo,211217_Portugal_NationalInstituteofHealth,National COVID-19 Serological Survey (3rd phase),2021-12-17,Institutional Report,National,Cross-sectional survey ,Portugal,,,"All individuals who went to one of the participating collection points were invited to participate. (laboratories or partner health units) during the study period, holders of a medical prescription for performing a clinical analysis that involved venipuncture.","Individuals unable to provide informed consent (those with physical or mental disability, dementia, or other health condition that affects the ability to understand study and questionnaire objectives). Although the occurrence of previous SARS-CoV-2 infection or the presence of signs and symptoms suggestive of COVID-19 were not considered grounds for exclusion, individuals whose reason for going to the laboratory or health unit was the prescription of a diagnostic test for COVID-19, in order to avoid preferential selection of participants at higher risk of SARS-CoV infection 2 on the date of recruitment.",2021-09-28,2021-11-19,Household and community samples,All,Multiple groups,,,Geographical area,Alentejo,585,0.858,0.828,0.8840000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,ISN COVID-19 Group,National Institute of Health,Unity-Aligned,http://repositorio.insa.pt/handle/10400.18/7828,2022-01-26,2024-03-01,Verified,isn_covid-19_group_national_2021,PRT
211217_Portugal_NationalInstituteofHealth_1-9,211217_Portugal_NationalInstituteofHealth,National COVID-19 Serological Survey (3rd phase),2021-12-17,Institutional Report,National,Cross-sectional survey ,Portugal,,,"All individuals who went to one of the participating collection points were invited to participate. (laboratories or partner health units) during the study period, holders of a medical prescription for performing a clinical analysis that involved venipuncture.","Individuals unable to provide informed consent (those with physical or mental disability, dementia, or other health condition that affects the ability to understand study and questionnaire objectives). Although the occurrence of previous SARS-CoV-2 infection or the presence of signs and symptoms suggestive of COVID-19 were not considered grounds for exclusion, individuals whose reason for going to the laboratory or health unit was the prescription of a diagnostic test for COVID-19, in order to avoid preferential selection of participants at higher risk of SARS-CoV infection 2 on the date of recruitment.",2021-09-28,2021-11-19,Household and community samples,All,Children and Youth (0-17 years),1.0,9.0,Age,1-9,486,0.179,0.14,0.226,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,ISN COVID-19 Group,National Institute of Health,Unity-Aligned,http://repositorio.insa.pt/handle/10400.18/7828,2022-01-26,2024-03-01,Verified,isn_covid-19_group_national_2021,PRT
211217_Portugal_NationalInstituteofHealth_40-49,211217_Portugal_NationalInstituteofHealth,National COVID-19 Serological Survey (3rd phase),2021-12-17,Institutional Report,National,Cross-sectional survey ,Portugal,,,"All individuals who went to one of the participating collection points were invited to participate. (laboratories or partner health units) during the study period, holders of a medical prescription for performing a clinical analysis that involved venipuncture.","Individuals unable to provide informed consent (those with physical or mental disability, dementia, or other health condition that affects the ability to understand study and questionnaire objectives). Although the occurrence of previous SARS-CoV-2 infection or the presence of signs and symptoms suggestive of COVID-19 were not considered grounds for exclusion, individuals whose reason for going to the laboratory or health unit was the prescription of a diagnostic test for COVID-19, in order to avoid preferential selection of participants at higher risk of SARS-CoV infection 2 on the date of recruitment.",2021-09-28,2021-11-19,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,,579,0.943,0.912,0.9640000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,ISN COVID-19 Group,National Institute of Health,Unity-Aligned,http://repositorio.insa.pt/handle/10400.18/7828,2022-01-26,2024-03-01,Verified,isn_covid-19_group_national_2021,PRT
211217_Portugal_NationalInstituteofHealth_Madeira,211217_Portugal_NationalInstituteofHealth,National COVID-19 Serological Survey (3rd phase),2021-12-17,Institutional Report,National,Cross-sectional survey ,Portugal,,,"All individuals who went to one of the participating collection points were invited to participate. (laboratories or partner health units) during the study period, holders of a medical prescription for performing a clinical analysis that involved venipuncture.","Individuals unable to provide informed consent (those with physical or mental disability, dementia, or other health condition that affects the ability to understand study and questionnaire objectives). Although the occurrence of previous SARS-CoV-2 infection or the presence of signs and symptoms suggestive of COVID-19 were not considered grounds for exclusion, individuals whose reason for going to the laboratory or health unit was the prescription of a diagnostic test for COVID-19, in order to avoid preferential selection of participants at higher risk of SARS-CoV infection 2 on the date of recruitment.",2021-09-28,2021-11-19,Household and community samples,All,Multiple groups,,,Geographical area,Madeira ,431,0.863,0.7909999999999999,0.912,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,ISN COVID-19 Group,National Institute of Health,Unity-Aligned,http://repositorio.insa.pt/handle/10400.18/7828,2022-01-26,2024-03-01,Verified,isn_covid-19_group_national_2021,PRT
211217_Portugal_NationalInstituteofHealth_20-29,211217_Portugal_NationalInstituteofHealth,National COVID-19 Serological Survey (3rd phase),2021-12-17,Institutional Report,National,Cross-sectional survey ,Portugal,,,"All individuals who went to one of the participating collection points were invited to participate. (laboratories or partner health units) during the study period, holders of a medical prescription for performing a clinical analysis that involved venipuncture.","Individuals unable to provide informed consent (those with physical or mental disability, dementia, or other health condition that affects the ability to understand study and questionnaire objectives). Although the occurrence of previous SARS-CoV-2 infection or the presence of signs and symptoms suggestive of COVID-19 were not considered grounds for exclusion, individuals whose reason for going to the laboratory or health unit was the prescription of a diagnostic test for COVID-19, in order to avoid preferential selection of participants at higher risk of SARS-CoV infection 2 on the date of recruitment.",2021-09-28,2021-11-19,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,546,0.922,0.888,0.946,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,ISN COVID-19 Group,National Institute of Health,Unity-Aligned,http://repositorio.insa.pt/handle/10400.18/7828,2022-01-26,2024-03-01,Verified,isn_covid-19_group_national_2021,PRT
211217_Portugal_NationalInstituteofHealth_>=70,211217_Portugal_NationalInstituteofHealth,National COVID-19 Serological Survey (3rd phase),2021-12-17,Institutional Report,National,Cross-sectional survey ,Portugal,,,"All individuals who went to one of the participating collection points were invited to participate. (laboratories or partner health units) during the study period, holders of a medical prescription for performing a clinical analysis that involved venipuncture.","Individuals unable to provide informed consent (those with physical or mental disability, dementia, or other health condition that affects the ability to understand study and questionnaire objectives). Although the occurrence of previous SARS-CoV-2 infection or the presence of signs and symptoms suggestive of COVID-19 were not considered grounds for exclusion, individuals whose reason for going to the laboratory or health unit was the prescription of a diagnostic test for COVID-19, in order to avoid preferential selection of participants at higher risk of SARS-CoV infection 2 on the date of recruitment.",2021-09-28,2021-11-19,Household and community samples,All,Seniors (65+ years),70.0,,Age,,663,0.93,0.902,0.9500000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,ISN COVID-19 Group,National Institute of Health,Unity-Aligned,http://repositorio.insa.pt/handle/10400.18/7828,2022-01-26,2024-03-01,Verified,isn_covid-19_group_national_2021,PRT
211217_Portugal_NationalInstituteofHealth_Male,211217_Portugal_NationalInstituteofHealth,National COVID-19 Serological Survey (3rd phase),2021-12-17,Institutional Report,National,Cross-sectional survey ,Portugal,,,"All individuals who went to one of the participating collection points were invited to participate. (laboratories or partner health units) during the study period, holders of a medical prescription for performing a clinical analysis that involved venipuncture.","Individuals unable to provide informed consent (those with physical or mental disability, dementia, or other health condition that affects the ability to understand study and questionnaire objectives). Although the occurrence of previous SARS-CoV-2 infection or the presence of signs and symptoms suggestive of COVID-19 were not considered grounds for exclusion, individuals whose reason for going to the laboratory or health unit was the prescription of a diagnostic test for COVID-19, in order to avoid preferential selection of participants at higher risk of SARS-CoV infection 2 on the date of recruitment.",2021-09-28,2021-11-19,Household and community samples,Male,Multiple groups,,,Sex/Gender,,2047,0.8440000000000001,0.8240000000000001,0.8620000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,ISN COVID-19 Group,National Institute of Health,Unity-Aligned,http://repositorio.insa.pt/handle/10400.18/7828,2022-01-26,2024-03-01,Verified,isn_covid-19_group_national_2021,PRT
211217_Portugal_NationalInstituteofHealth_Acores,211217_Portugal_NationalInstituteofHealth,National COVID-19 Serological Survey (3rd phase),2021-12-17,Institutional Report,National,Cross-sectional survey ,Portugal,,,"All individuals who went to one of the participating collection points were invited to participate. (laboratories or partner health units) during the study period, holders of a medical prescription for performing a clinical analysis that involved venipuncture.","Individuals unable to provide informed consent (those with physical or mental disability, dementia, or other health condition that affects the ability to understand study and questionnaire objectives). Although the occurrence of previous SARS-CoV-2 infection or the presence of signs and symptoms suggestive of COVID-19 were not considered grounds for exclusion, individuals whose reason for going to the laboratory or health unit was the prescription of a diagnostic test for COVID-19, in order to avoid preferential selection of participants at higher risk of SARS-CoV infection 2 on the date of recruitment.",2021-09-28,2021-11-19,Household and community samples,All,Multiple groups,,,Geographical area,Açores,579,0.84,0.81,0.865,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,ISN COVID-19 Group,National Institute of Health,Unity-Aligned,http://repositorio.insa.pt/handle/10400.18/7828,2022-01-26,2024-03-01,Verified,isn_covid-19_group_national_2021,PRT
211217_Portugal_NationalInstituteofHealth_10-19,211217_Portugal_NationalInstituteofHealth,National COVID-19 Serological Survey (3rd phase),2021-12-17,Institutional Report,National,Cross-sectional survey ,Portugal,,,"All individuals who went to one of the participating collection points were invited to participate. (laboratories or partner health units) during the study period, holders of a medical prescription for performing a clinical analysis that involved venipuncture.","Individuals unable to provide informed consent (those with physical or mental disability, dementia, or other health condition that affects the ability to understand study and questionnaire objectives). Although the occurrence of previous SARS-CoV-2 infection or the presence of signs and symptoms suggestive of COVID-19 were not considered grounds for exclusion, individuals whose reason for going to the laboratory or health unit was the prescription of a diagnostic test for COVID-19, in order to avoid preferential selection of participants at higher risk of SARS-CoV infection 2 on the date of recruitment.",2021-09-28,2021-11-19,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,591,0.768,0.7240000000000001,0.8079999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,ISN COVID-19 Group,National Institute of Health,Unity-Aligned,http://repositorio.insa.pt/handle/10400.18/7828,2022-01-26,2024-03-01,Verified,isn_covid-19_group_national_2021,PRT
211217_Portugal_NationalInstituteofHealth_North,211217_Portugal_NationalInstituteofHealth,National COVID-19 Serological Survey (3rd phase),2021-12-17,Institutional Report,National,Cross-sectional survey ,Portugal,,,"All individuals who went to one of the participating collection points were invited to participate. (laboratories or partner health units) during the study period, holders of a medical prescription for performing a clinical analysis that involved venipuncture.","Individuals unable to provide informed consent (those with physical or mental disability, dementia, or other health condition that affects the ability to understand study and questionnaire objectives). Although the occurrence of previous SARS-CoV-2 infection or the presence of signs and symptoms suggestive of COVID-19 were not considered grounds for exclusion, individuals whose reason for going to the laboratory or health unit was the prescription of a diagnostic test for COVID-19, in order to avoid preferential selection of participants at higher risk of SARS-CoV infection 2 on the date of recruitment.",2021-09-28,2021-11-19,Household and community samples,All,Multiple groups,,,Geographical area,North (Norte),884,0.8840000000000001,0.863,0.902,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,ISN COVID-19 Group,National Institute of Health,Unity-Aligned,http://repositorio.insa.pt/handle/10400.18/7828,2022-01-26,2024-03-01,Verified,isn_covid-19_group_national_2021,PRT
211217_Portugal_NationalInstituteofHealth_LisbonandTagusValley,211217_Portugal_NationalInstituteofHealth,National COVID-19 Serological Survey (3rd phase),2021-12-17,Institutional Report,National,Cross-sectional survey ,Portugal,,,"All individuals who went to one of the participating collection points were invited to participate. (laboratories or partner health units) during the study period, holders of a medical prescription for performing a clinical analysis that involved venipuncture.","Individuals unable to provide informed consent (those with physical or mental disability, dementia, or other health condition that affects the ability to understand study and questionnaire objectives). Although the occurrence of previous SARS-CoV-2 infection or the presence of signs and symptoms suggestive of COVID-19 were not considered grounds for exclusion, individuals whose reason for going to the laboratory or health unit was the prescription of a diagnostic test for COVID-19, in order to avoid preferential selection of participants at higher risk of SARS-CoV infection 2 on the date of recruitment.",2021-09-28,2021-11-19,Household and community samples,All,Multiple groups,,,Geographical area,Lisbon and Tagus Valley (Lisboa e Vale do Tejo),815,0.858,0.833,0.88,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,ISN COVID-19 Group,National Institute of Health,Unity-Aligned,http://repositorio.insa.pt/handle/10400.18/7828,2022-01-26,2024-03-01,Verified,isn_covid-19_group_national_2021,PRT
211217_Portugal_NationalInstituteofHealth_60-69,211217_Portugal_NationalInstituteofHealth,National COVID-19 Serological Survey (3rd phase),2021-12-17,Institutional Report,National,Cross-sectional survey ,Portugal,,,"All individuals who went to one of the participating collection points were invited to participate. (laboratories or partner health units) during the study period, holders of a medical prescription for performing a clinical analysis that involved venipuncture.","Individuals unable to provide informed consent (those with physical or mental disability, dementia, or other health condition that affects the ability to understand study and questionnaire objectives). Although the occurrence of previous SARS-CoV-2 infection or the presence of signs and symptoms suggestive of COVID-19 were not considered grounds for exclusion, individuals whose reason for going to the laboratory or health unit was the prescription of a diagnostic test for COVID-19, in order to avoid preferential selection of participants at higher risk of SARS-CoV infection 2 on the date of recruitment.",2021-09-28,2021-11-19,Household and community samples,All,Adults (18-64 years),60.0,69.0,Age,,563,0.938,0.909,0.958,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,ISN COVID-19 Group,National Institute of Health,Unity-Aligned,http://repositorio.insa.pt/handle/10400.18/7828,2022-01-26,2024-03-01,Verified,isn_covid-19_group_national_2021,PRT
211217_Portugal_NationalInstituteofHealth_Algarve,211217_Portugal_NationalInstituteofHealth,National COVID-19 Serological Survey (3rd phase),2021-12-17,Institutional Report,National,Cross-sectional survey ,Portugal,,,"All individuals who went to one of the participating collection points were invited to participate. (laboratories or partner health units) during the study period, holders of a medical prescription for performing a clinical analysis that involved venipuncture.","Individuals unable to provide informed consent (those with physical or mental disability, dementia, or other health condition that affects the ability to understand study and questionnaire objectives). Although the occurrence of previous SARS-CoV-2 infection or the presence of signs and symptoms suggestive of COVID-19 were not considered grounds for exclusion, individuals whose reason for going to the laboratory or health unit was the prescription of a diagnostic test for COVID-19, in order to avoid preferential selection of participants at higher risk of SARS-CoV infection 2 on the date of recruitment.",2021-09-28,2021-11-19,Household and community samples,All,Multiple groups,,,Geographical area,Algarve ,580,0.802,0.7690000000000001,0.8320000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,ISN COVID-19 Group,National Institute of Health,Unity-Aligned,http://repositorio.insa.pt/handle/10400.18/7828,2022-01-26,2024-03-01,Verified,isn_covid-19_group_national_2021,PRT
220207_Porto_UniversidadedoPorto_Cohort_Primary,220207_Porto_UniversidadedoPorto_Cohort,"Incidence of SARS-CoV-2 infection in a cohort of workers from the University of Porto, Portugal.",2022-02-07,Journal Article (Peer-Reviewed),Local,Prospective cohort,Portugal,,Porto,Workers at the Universidade do Porto who provided written consent,,2020-05-21,2021-01-29,Non-essential workers and unemployed persons,All,Multiple groups,,,Primary Estimate,,1891,0.107,,,True,,,,True,Convenience,"Standard Q COVID-19 IgM/IgG Combo,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ",SD Biosensor,Multiple Types,,"['IgG', 'IgM']","['Notreported', 'Nucleocapsid(N-protein)']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,No,No,,Joana Costa,Universidade do Porto,Not Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2035429,2022-02-14,2024-03-01,Unverified,costa_incidence_2022,PRT
220207_Porto_UniversidadedoPorto_Cohort_Age_30–39,220207_Porto_UniversidadedoPorto_Cohort,"Incidence of SARS-CoV-2 infection in a cohort of workers from the University of Porto, Portugal.",2022-02-07,Journal Article (Peer-Reviewed),Local,Prospective cohort,Portugal,,Porto,Workers at the Universidade do Porto who provided written consent,,2020-05-21,2021-01-29,Non-essential workers and unemployed persons,All,Adults (18-64 years),30.0,39.0,Age,30-39,464,0.09699999999999999,,,,,,,,Convenience,"Standard Q COVID-19 IgM/IgG Combo,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ",SD Biosensor,Multiple Types,,"['IgG', 'IgM']","['Notreported', 'Nucleocapsid(N-protein)']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,No,No,,Joana Costa,Universidade do Porto,Not Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2035429,2022-02-14,2024-03-01,Unverified,costa_incidence_2022,PRT
220207_Porto_UniversidadedoPorto_Cohort_Age_50–59,220207_Porto_UniversidadedoPorto_Cohort,"Incidence of SARS-CoV-2 infection in a cohort of workers from the University of Porto, Portugal.",2022-02-07,Journal Article (Peer-Reviewed),Local,Prospective cohort,Portugal,,Porto,Workers at the Universidade do Porto who provided written consent,,2020-05-21,2021-01-29,Non-essential workers and unemployed persons,All,Adults (18-64 years),50.0,59.0,Age,50-59,394,0.129,,,,,,,,Convenience,"Standard Q COVID-19 IgM/IgG Combo,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ",SD Biosensor,Multiple Types,,"['IgG', 'IgM']","['Notreported', 'Nucleocapsid(N-protein)']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,No,No,,Joana Costa,Universidade do Porto,Not Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2035429,2022-02-14,2024-03-01,Unverified,costa_incidence_2022,PRT
220207_Porto_UniversidadedoPorto_Cohort_Age_40–49,220207_Porto_UniversidadedoPorto_Cohort,"Incidence of SARS-CoV-2 infection in a cohort of workers from the University of Porto, Portugal.",2022-02-07,Journal Article (Peer-Reviewed),Local,Prospective cohort,Portugal,,Porto,Workers at the Universidade do Porto who provided written consent,,2020-05-21,2021-01-29,Non-essential workers and unemployed persons,All,Adults (18-64 years),40.0,49.0,Age,40-49,659,0.1,,,,,,,,Convenience,"Standard Q COVID-19 IgM/IgG Combo,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ",SD Biosensor,Multiple Types,,"['IgG', 'IgM']","['Notreported', 'Nucleocapsid(N-protein)']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,No,No,,Joana Costa,Universidade do Porto,Not Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2035429,2022-02-14,2024-03-01,Unverified,costa_incidence_2022,PRT
220207_Porto_UniversidadedoPorto_Cohort_Age_<30,220207_Porto_UniversidadedoPorto_Cohort,"Incidence of SARS-CoV-2 infection in a cohort of workers from the University of Porto, Portugal.",2022-02-07,Journal Article (Peer-Reviewed),Local,Prospective cohort,Portugal,,Porto,Workers at the Universidade do Porto who provided written consent,,2020-05-21,2021-01-29,Non-essential workers and unemployed persons,All,Multiple groups,,29.0,Age,<30,146,0.10300000000000001,,,,,,,,Convenience,"Standard Q COVID-19 IgM/IgG Combo,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ",SD Biosensor,Multiple Types,,"['IgG', 'IgM']","['Notreported', 'Nucleocapsid(N-protein)']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,No,No,,Joana Costa,Universidade do Porto,Not Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2035429,2022-02-14,2024-03-01,Unverified,costa_incidence_2022,PRT
220207_Porto_UniversidadedoPorto_Cohort_Age_≥60,220207_Porto_UniversidadedoPorto_Cohort,"Incidence of SARS-CoV-2 infection in a cohort of workers from the University of Porto, Portugal.",2022-02-07,Journal Article (Peer-Reviewed),Local,Prospective cohort,Portugal,,Porto,Workers at the Universidade do Porto who provided written consent,,2020-05-21,2021-01-29,Non-essential workers and unemployed persons,All,Adults (18-64 years),60.0,,Age,>=60,226,0.106,,,,,,,,Convenience,"Standard Q COVID-19 IgM/IgG Combo,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ",SD Biosensor,Multiple Types,,"['IgG', 'IgM']","['Notreported', 'Nucleocapsid(N-protein)']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,No,No,,Joana Costa,Universidade do Porto,Not Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2035429,2022-02-14,2024-03-01,Unverified,costa_incidence_2022,PRT
220207_Porto_UniversidadedoPorto_FirstRound,220207_Porto_UniversidadedoPorto_FirstRound,"Incidence of SARS-CoV-2 infection in a cohort of workers from the University of Porto, Portugal.",2022-02-07,Journal Article (Peer-Reviewed),Local,Prospective cohort,Portugal,,Porto,Workers at the Universidade do Porto who provided written consent,,2020-05-21,2020-07-31,Non-essential workers and unemployed persons,All,Multiple groups,,,Primary Estimate,,3628,0.040999999999999995,,,True,,,,True,Convenience,"Standard Q COVID-19 IgM/IgG Combo,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ",SD Biosensor,Multiple Types,,"['IgG', 'IgM']","['Notreported', 'Nucleocapsid(N-protein)']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,No,,Unclear,No,No,,Joana Costa,Universidade do Porto,Not Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2035429,2022-02-14,2024-03-01,Unverified,costa_incidence_2022,PRT
220207_Porto_UniversidadedoPorto_SecondRound,220207_Porto_UniversidadedoPorto_SecondRound,"Incidence of SARS-CoV-2 infection in a cohort of workers from the University of Porto, Portugal.",2022-02-07,Journal Article (Peer-Reviewed),Local,Prospective cohort,Portugal,,Porto,Workers at the Universidade do Porto who provided written consent,,2020-11-27,2021-01-29,Non-essential workers and unemployed persons,All,Multiple groups,,,Primary Estimate,,2661,0.132,,,True,,,,True,Convenience,Standard Q COVID-19 IgM/IgG Combo,SD Biosensor,IFA,,"['IgG', 'IgM']",,Validated by manufacturers,0.9450000000000001,0.9570000000000001,['High'],,No,Yes,No,,Unclear,Yes,No,,Joana Costa,Universidade do Porto,Not Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2035429,2022-02-14,2022-07-16,Unverified,costa_incidence_2022,PRT
220207_PortoandMatosinhos_UniversityofPorto_Overall,220207_PortoandMatosinhos_UniversityofPorto,Seroprevalence of SARS-CoV-2 and assessment of epidemiologic determinants in Portuguese municipal workers.,2022-02-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Portugal,Norte,"Porto, Matosinhos","municipal employees (firefighters, municipal police officers, maintenance workers, administrative assistants, managers, engineers, and others) of 2 cities in Northern Portugal (Porto and Matosinhos).

The authors assessed those employees tested May 15–June 19, 2020, with all municipal employees being eligible for inclusion.",,2020-05-15,2020-06-19,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,1696,0.029500000000000002,0.021,0.037000000000000005,True,,,,True,Convenience,COVID-19 antibody rapid test,SureScreen Diagnostics,,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.966,0.997,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Nuno Ferreira,University of Porto,Not Unity-Aligned,https://dx.doi.org/10.13075/ijomeh.1896.01878,2022-02-18,2024-03-01,Unverified,ferreira_seroprevalence_2022,PRT
220221_Lisboa_HospitalDaLuzLisboa_Baseline_Overall,220221_Lisboa_HospitalDaLuzLisboa_Baseline,SARS-CoV-2 Antibody Seroprevalence in Patients With Cancer on Systemic Antineoplastic Treatment in the First Wave of the COVID-19 Pandemic in Portugal,2022-02-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Portugal,,Lisbon,"18 years old or older; ability to understand and sign a written informed consent; diagnosis, documented in the electronic medical record (EMR), of one or more solid or hematologic malignancies, regardless of the clinical or pathological staging; treatment with chemotherapy or immunotherapy (or its combination, with or without other concomitant therapies, including radiation therapy), administered on an outpatient basis, orally or intravenously; and SARS-CoV-2 RNA molecular detection test in a respiratory sample (oropharynx and deep nasopharynx) within a maximum of 30 days prior to study enrolment. ","Patients were excluded in case of a previous diagnosis of symptomatic COVID-19, presumed or confirmed, if signs or symptoms possibly related to SARS-CoV-2 infection were present in the previous 14 days, or if they were participating in a clinical trial.",2020-05-06,2020-05-20,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,100,0.0,,,True,,,,True,Convenience,"MAGLUMI 2019-nCoV IgM/IgG,Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Goncalo Fernandes,Hospital da Luz Lisboa,Not Unity-Aligned,https://www.cureus.com/articles/82283-sars-cov-2-antibody-seroprevalence-in-patients-with-cancer-on-systemic-antineoplastic-treatment-in-the-first-wave-of-the-covid-19-pandemic-in-portugal,2022-03-08,2024-03-01,Unverified,fernandes_sars-cov-2_2022-1,PRT
220221_Lisboa_HospitalDaLuzLisboa_Visit2_Overall,220221_Lisboa_HospitalDaLuzLisboa_Visit2,SARS-CoV-2 Antibody Seroprevalence in Patients With Cancer on Systemic Antineoplastic Treatment in the First Wave of the COVID-19 Pandemic in Portugal,2022-02-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Portugal,,Lisbon,"18 years old or older; ability to understand and sign a written informed consent; diagnosis, documented in the electronic medical record (EMR), of one or more solid or hematologic malignancies, regardless of the clinical or pathological staging; treatment with chemotherapy or immunotherapy (or its combination, with or without other concomitant therapies, including radiation therapy), administered on an outpatient basis, orally or intravenously; and SARS-CoV-2 RNA molecular detection test in a respiratory sample (oropharynx and deep nasopharynx) within a maximum of 30 days prior to study enrolment + met inclusion/followed up for second visit","Patients were excluded in case of a previous diagnosis of symptomatic COVID-19, presumed or confirmed, if signs or symptoms possibly related to SARS-CoV-2 infection were present in the previous 14 days, or if they were participating in a clinical trial.",2020-06-06,2020-07-14,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,72,0.0278,,,True,,,,True,Convenience,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Yes,Yes,Yes,,Goncalo Fernandes,Hospital da Luz Lisboa,Not Unity-Aligned,https://www.cureus.com/articles/82283-sars-cov-2-antibody-seroprevalence-in-patients-with-cancer-on-systemic-antineoplastic-treatment-in-the-first-wave-of-the-covid-19-pandemic-in-portugal,2022-03-08,2024-03-01,Unverified,fernandes_sars-cov-2_2022-1,PRT
220511_CentroHospitalareUniversitáriodeCoimbra_UniversityofCoimbra,220511_CentroHospitalareUniversitáriodeCoimbra_UniversityofCoimbra,Long term serological SARS-CoV-2 IgG kinetics following mRNA COVID-19 vaccine: real-world data from a large cohort of healthcare workers.,2022-05-11,Journal Article (Peer-Reviewed),Local,Prospective cohort,Portugal,Coimbra,Coimbra,"HCWs from the Centro Hospitalar e Universitário de Coimbra getting their first vaccine dose.
Only subjects with complete serological data at all time points were included in analyses (n = 2968).",HCWs with a previous diagnosis of SARS-CoV-2 were excluded from the first phase of vaccination.,2020-12-15,2021-03-04,Health care workers and caregivers,All,Adults (18-64 years),20.0,67.0,Primary Estimate,,2968,0.0212,,,True,,,,True,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9937,0.9954999999999999,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Joana Oliveira-Silva,University of Coimbra,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2022.05.026,2022-06-05,2024-03-01,Unverified,oliveira-silva_long-term_2022,PRT
220601_VilaNovadeGaia_OrdemdosMédicosPortugueses_Overall_PopAdj,220601_VilaNovadeGaia_OrdemdosMédicosPortugueses,SARS-CoV-2 Antibody Prevalence in the Portuguese Municipality of Vila Nova de Gaia after the First Wave of the Pandemic,2022-06-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Portugal,,,"The population under study included men and women between 18 and 74 years of age living in any of the 15 par- ishes of the municipality of Vila Nova de Gaia, Portugal.",Individuals with a previous diagnosis of COVID-19 (deter- mined by the RT-PCR diagnostic test) were excluded.,2020-06-23,2020-07-17,Household and community samples,All,Multiple groups,18.0,74.0,Primary Estimate,,2754,0.030299999999999997,0.023700000000000002,0.038700000000000005,True,,True,,True,Stratified non-probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,,Validated by manufacturers,0.9870000000000001,0.995,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Alvaro Carvalho,Ordem dos Médicos Portugueses,Not Unity-Aligned,https://dx.doi.org/10.20344/amp.17676,2022-07-25,2024-03-01,Unverified,de_carvalho_sars-cov-2_2022,PRT
220601_VilaNovadeGaia_OrdemdosMédicosPortugueses_Age_55+_PopAdj,220601_VilaNovadeGaia_OrdemdosMédicosPortugueses,SARS-CoV-2 Antibody Prevalence in the Portuguese Municipality of Vila Nova de Gaia after the First Wave of the Pandemic,2022-06-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Portugal,,,"The population under study included men and women between 18 and 74 years of age living in any of the 15 par- ishes of the municipality of Vila Nova de Gaia, Portugal.",Individuals with a previous diagnosis of COVID-19 (deter- mined by the RT-PCR diagnostic test) were excluded.,2020-06-23,2020-07-17,Household and community samples,All,Multiple groups,55.0,74.0,Age,55+,821,0.0374,0.025,0.0555,,,True,,,Stratified non-probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,,Validated by manufacturers,0.9870000000000001,0.995,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Alvaro Carvalho,Ordem dos Médicos Portugueses,Not Unity-Aligned,https://dx.doi.org/10.20344/amp.17676,2022-07-25,2024-03-01,Unverified,de_carvalho_sars-cov-2_2022,PRT
220601_VilaNovadeGaia_OrdemdosMédicosPortugueses_Age_18-34_PopAdj,220601_VilaNovadeGaia_OrdemdosMédicosPortugueses,SARS-CoV-2 Antibody Prevalence in the Portuguese Municipality of Vila Nova de Gaia after the First Wave of the Pandemic,2022-06-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Portugal,,,"The population under study included men and women between 18 and 74 years of age living in any of the 15 par- ishes of the municipality of Vila Nova de Gaia, Portugal.",Individuals with a previous diagnosis of COVID-19 (deter- mined by the RT-PCR diagnostic test) were excluded.,2020-06-23,2020-07-17,Household and community samples,All,Adults (18-64 years),18.0,34.0,Age,18-34,472,0.038900000000000004,0.0225,0.0663,,,True,,,Stratified non-probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,,Validated by manufacturers,0.9870000000000001,0.995,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Alvaro Carvalho,Ordem dos Médicos Portugueses,Not Unity-Aligned,https://dx.doi.org/10.20344/amp.17676,2022-07-25,2024-03-01,Unverified,de_carvalho_sars-cov-2_2022,PRT
220601_VilaNovadeGaia_OrdemdosMédicosPortugueses_Age_35-54_PopAdj,220601_VilaNovadeGaia_OrdemdosMédicosPortugueses,SARS-CoV-2 Antibody Prevalence in the Portuguese Municipality of Vila Nova de Gaia after the First Wave of the Pandemic,2022-06-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Portugal,,,"The population under study included men and women between 18 and 74 years of age living in any of the 15 par- ishes of the municipality of Vila Nova de Gaia, Portugal.",Individuals with a previous diagnosis of COVID-19 (deter- mined by the RT-PCR diagnostic test) were excluded.,2020-06-23,2020-07-17,Household and community samples,All,Adults (18-64 years),35.0,54.0,Age,35-54,1461,0.0233,0.016,0.0337,,,True,,,Stratified non-probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,,Validated by manufacturers,0.9870000000000001,0.995,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Alvaro Carvalho,Ordem dos Médicos Portugueses,Not Unity-Aligned,https://dx.doi.org/10.20344/amp.17676,2022-07-25,2024-03-01,Unverified,de_carvalho_sars-cov-2_2022,PRT
220601_VilaNovadeGaia_OrdemdosMédicosPortugueses_Sex_Male_PopAdj,220601_VilaNovadeGaia_OrdemdosMédicosPortugueses,SARS-CoV-2 Antibody Prevalence in the Portuguese Municipality of Vila Nova de Gaia after the First Wave of the Pandemic,2022-06-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Portugal,,,"The population under study included men and women between 18 and 74 years of age living in any of the 15 par- ishes of the municipality of Vila Nova de Gaia, Portugal.",Individuals with a previous diagnosis of COVID-19 (deter- mined by the RT-PCR diagnostic test) were excluded.,2020-06-23,2020-07-17,Household and community samples,Male,Multiple groups,18.0,74.0,Sex/Gender,,1013,0.028700000000000003,0.0192,0.042699999999999995,,,True,,,Stratified non-probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,,Validated by manufacturers,0.9870000000000001,0.995,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Alvaro Carvalho,Ordem dos Médicos Portugueses,Not Unity-Aligned,https://dx.doi.org/10.20344/amp.17676,2022-07-25,2024-03-01,Unverified,de_carvalho_sars-cov-2_2022,PRT
220601_VilaNovadeGaia_OrdemdosMédicosPortugueses_Sex_Female_PopAdj,220601_VilaNovadeGaia_OrdemdosMédicosPortugueses,SARS-CoV-2 Antibody Prevalence in the Portuguese Municipality of Vila Nova de Gaia after the First Wave of the Pandemic,2022-06-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Portugal,,,"The population under study included men and women between 18 and 74 years of age living in any of the 15 par- ishes of the municipality of Vila Nova de Gaia, Portugal.",Individuals with a previous diagnosis of COVID-19 (deter- mined by the RT-PCR diagnostic test) were excluded.,2020-06-23,2020-07-17,Household and community samples,Female,Multiple groups,18.0,74.0,Sex/Gender,,1741,0.031920000000000004,0.0235,0.0432,,,True,,,Stratified non-probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,,Validated by manufacturers,0.9870000000000001,0.995,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Alvaro Carvalho,Ordem dos Médicos Portugueses,Not Unity-Aligned,https://dx.doi.org/10.20344/amp.17676,2022-07-25,2024-03-01,Unverified,de_carvalho_sars-cov-2_2022,PRT
220617_Portugal_CentroHospitalareUniversitariodeSaoJoao_Overall,220617_Portugal_CentroHospitalareUniversitariodeSaoJoao,SARS-CoV-2 seroprevalence in healthcare workers: The experience of a Portuguese COVID-19 front-line hospital during the 1st pandemic wave,2022-06-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Portugal,,,"Centro Hospitalar
Universitário de São João (CHUSJ) professionals were evaluated",,2020-04-09,2020-05-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1027,0.027000000000000003,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N),BioPlex 2200 SARS-CoV-2 IgG Panel","EUROIMMUN,Abbott Laboratories,Roche Diagnostics,Bio-rad",Multiple Types,,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Angelica Ramos,Centro Hospitalar e Universitario de Sao Joao,Not Unity-Aligned,https://dx.doi.org/10.1097/j.pbj.0000000000000166,2022-07-13,2024-03-01,Unverified,ramos_sars-cov-2_2022,PRT
221020_UniversityofPorto_UniversityofPorto_Overall_TestAdj,221020_UniversityofPorto_UniversityofPorto,The SARS-CoV-2 Infection Among Students in the University of Porto: A Cross-Sectional Study.,2022-10-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Portugal,,Porto,"""All undergraduate and postgraduate students from the U.Porto were sent an email by the University communication office to invite them to perform a rapid serological test for SARS-CoV-2 specific immunoglobulin (Ig) M and IgG antibodies. Along with this email, an information leaflet was sent. Participation was voluntary, and students scheduled their appointment according to their convenience""",,2020-09-24,2020-12-15,Students and Daycares,All,Multiple groups,,,Primary Estimate,Test adjusted IgG + IgM,6512,0.079,0.049,0.111,True,True,,,True,Convenience,"Standard Q COVID-19 IgM/IgG Combo,Hightop COVID-19 IgM/IgG Ab Rapid Test Kit ,Not reported/ Unable to specify","SD Biosensor,Qingdao Hightop Biotech Co. Ltd ,NA",Multiple Types,Whole Blood,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,Yes,,Paula Meireles,University of Porto,Not Unity-Aligned,https://dx.doi.org/10.3389/ijph.2022.1604548,2022-11-14,2023-08-15,Unverified,meireles_sars-cov-2_2021_1,PRT
221026_Portugal_InstitutoNacionaldeSaúdeDoutorRicardoJorge_Overall_Anti-S,221026_Portugal_InstitutoNacionaldeSaúdeDoutorRicardoJorge,"SARS-CoV-2 Seroprevalence Following a Large-Scale Vaccination Campaign in Portugal: Results of the National Serological Survey, September - November 2021.",2022-10-26,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Portugal,,,"Portuguese resi- dents aged one year old or above. Individuals seeking routine blood tests for rea- sons unrelated to COVID-19 in the above-mentioned sites were invited to participate (38 private Clinical Pathology Laboratories and 36 public hospitals and primary health care units of the Por- tuguese National Health System, comprising a total of 305 data collection sites with nationwide geographical distribu- tion)",,2021-09-28,2021-11-19,Residual sera,All,Multiple groups,1.0,,Primary Estimate,,4545,0.864,,,True,,True,,True,Stratified non-probability,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Irina Kislaya,Instituto Nacional de Saúde Doutor Ricardo Jorge,Unity-Aligned,https://dx.doi.org/10.20344/amp.18528,2023-05-08,2024-03-01,Unverified,kislaya_sars-cov-2_2022-1,PRT
221026_Portugal_InstitutoNacionaldeSaúdeDoutorRicardoJorge_Age_40-49,221026_Portugal_InstitutoNacionaldeSaúdeDoutorRicardoJorge,"SARS-CoV-2 Seroprevalence Following a Large-Scale Vaccination Campaign in Portugal: Results of the National Serological Survey, September - November 2021.",2022-10-26,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Portugal,,,"Portuguese resi- dents aged one year old or above. Individuals seeking routine blood tests for rea- sons unrelated to COVID-19 in the above-mentioned sites were invited to participate (38 private Clinical Pathology Laboratories and 36 public hospitals and primary health care units of the Por- tuguese National Health System, comprising a total of 305 data collection sites with nationwide geographical distribu- tion)",,2021-09-28,2021-11-19,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49 years,579,0.153,,,,,,,,Stratified non-probability,Alinity i SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Irina Kislaya,Instituto Nacional de Saúde Doutor Ricardo Jorge,Unity-Aligned,https://dx.doi.org/10.20344/amp.18528,2024-04-30,2024-05-01,Verified,kislaya_sars-cov-2_2022-1,PRT
221026_Portugal_InstitutoNacionaldeSaúdeDoutorRicardoJorge_Overall_Anti-N,221026_Portugal_InstitutoNacionaldeSaúdeDoutorRicardoJorge,"SARS-CoV-2 Seroprevalence Following a Large-Scale Vaccination Campaign in Portugal: Results of the National Serological Survey, September - November 2021.",2022-10-26,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Portugal,,,"Portuguese resi- dents aged one year old or above. Individuals seeking routine blood tests for rea- sons unrelated to COVID-19 in the above-mentioned sites were invited to participate (38 private Clinical Pathology Laboratories and 36 public hospitals and primary health care units of the Por- tuguese National Health System, comprising a total of 305 data collection sites with nationwide geographical distribu- tion)",,2021-09-28,2021-11-19,Residual sera,All,Multiple groups,1.0,,Test used,,4545,0.075,,,,,True,,,Stratified non-probability,Alinity i SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Irina Kislaya,Instituto Nacional de Saúde Doutor Ricardo Jorge,Unity-Aligned,https://dx.doi.org/10.20344/amp.18528,2023-05-08,2024-05-01,Verified,kislaya_sars-cov-2_2022-1,PRT
221026_Portugal_InstitutoNacionaldeSaúdeDoutorRicardoJorge_Age_70+,221026_Portugal_InstitutoNacionaldeSaúdeDoutorRicardoJorge,"SARS-CoV-2 Seroprevalence Following a Large-Scale Vaccination Campaign in Portugal: Results of the National Serological Survey, September - November 2021.",2022-10-26,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Portugal,,,"Portuguese resi- dents aged one year old or above. Individuals seeking routine blood tests for rea- sons unrelated to COVID-19 in the above-mentioned sites were invited to participate (38 private Clinical Pathology Laboratories and 36 public hospitals and primary health care units of the Por- tuguese National Health System, comprising a total of 305 data collection sites with nationwide geographical distribu- tion)",,2021-09-28,2021-11-19,Residual sera,All,Seniors (65+ years),70.0,,Age,70+ years,663,0.165,,,,,,,,Stratified non-probability,Alinity i SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Irina Kislaya,Instituto Nacional de Saúde Doutor Ricardo Jorge,Unity-Aligned,https://dx.doi.org/10.20344/amp.18528,2024-04-30,2024-05-01,Verified,kislaya_sars-cov-2_2022-1,PRT
221026_Portugal_InstitutoNacionaldeSaúdeDoutorRicardoJorge_Age_1-9,221026_Portugal_InstitutoNacionaldeSaúdeDoutorRicardoJorge,"SARS-CoV-2 Seroprevalence Following a Large-Scale Vaccination Campaign in Portugal: Results of the National Serological Survey, September - November 2021.",2022-10-26,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Portugal,,,"Portuguese resi- dents aged one year old or above. Individuals seeking routine blood tests for rea- sons unrelated to COVID-19 in the above-mentioned sites were invited to participate (38 private Clinical Pathology Laboratories and 36 public hospitals and primary health care units of the Por- tuguese National Health System, comprising a total of 305 data collection sites with nationwide geographical distribu- tion)",,2021-09-28,2021-11-19,Residual sera,All,Children and Youth (0-17 years),1.0,9.0,Age,1-9 years,486,0.078,,,,,,,,Stratified non-probability,Alinity i SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Irina Kislaya,Instituto Nacional de Saúde Doutor Ricardo Jorge,Unity-Aligned,https://dx.doi.org/10.20344/amp.18528,2024-04-30,2024-05-01,Verified,kislaya_sars-cov-2_2022-1,PRT
221026_Portugal_InstitutoNacionaldeSaúdeDoutorRicardoJorge_Age_30-39,221026_Portugal_InstitutoNacionaldeSaúdeDoutorRicardoJorge,"SARS-CoV-2 Seroprevalence Following a Large-Scale Vaccination Campaign in Portugal: Results of the National Serological Survey, September - November 2021.",2022-10-26,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Portugal,,,"Portuguese resi- dents aged one year old or above. Individuals seeking routine blood tests for rea- sons unrelated to COVID-19 in the above-mentioned sites were invited to participate (38 private Clinical Pathology Laboratories and 36 public hospitals and primary health care units of the Por- tuguese National Health System, comprising a total of 305 data collection sites with nationwide geographical distribu- tion)",,2021-09-28,2021-11-19,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39 years,549,0.119,,,,,,,,Stratified non-probability,Alinity i SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Irina Kislaya,Instituto Nacional de Saúde Doutor Ricardo Jorge,Unity-Aligned,https://dx.doi.org/10.20344/amp.18528,2024-04-30,2024-05-01,Verified,kislaya_sars-cov-2_2022-1,PRT
221026_Portugal_InstitutoNacionaldeSaúdeDoutorRicardoJorge_Age_50-59,221026_Portugal_InstitutoNacionaldeSaúdeDoutorRicardoJorge,"SARS-CoV-2 Seroprevalence Following a Large-Scale Vaccination Campaign in Portugal: Results of the National Serological Survey, September - November 2021.",2022-10-26,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Portugal,,,"Portuguese resi- dents aged one year old or above. Individuals seeking routine blood tests for rea- sons unrelated to COVID-19 in the above-mentioned sites were invited to participate (38 private Clinical Pathology Laboratories and 36 public hospitals and primary health care units of the Por- tuguese National Health System, comprising a total of 305 data collection sites with nationwide geographical distribu- tion)",,2021-09-28,2021-11-19,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59 years,568,0.146,,,,,,,,Stratified non-probability,Alinity i SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Irina Kislaya,Instituto Nacional de Saúde Doutor Ricardo Jorge,Unity-Aligned,https://dx.doi.org/10.20344/amp.18528,2024-04-30,2024-05-01,Verified,kislaya_sars-cov-2_2022-1,PRT
221026_Portugal_InstitutoNacionaldeSaúdeDoutorRicardoJorge_Age_10-19,221026_Portugal_InstitutoNacionaldeSaúdeDoutorRicardoJorge,"SARS-CoV-2 Seroprevalence Following a Large-Scale Vaccination Campaign in Portugal: Results of the National Serological Survey, September - November 2021.",2022-10-26,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Portugal,,,"Portuguese resi- dents aged one year old or above. Individuals seeking routine blood tests for rea- sons unrelated to COVID-19 in the above-mentioned sites were invited to participate (38 private Clinical Pathology Laboratories and 36 public hospitals and primary health care units of the Por- tuguese National Health System, comprising a total of 305 data collection sites with nationwide geographical distribu- tion)",,2021-09-28,2021-11-19,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19 years,591,0.102,,,,,,,,Stratified non-probability,Alinity i SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Irina Kislaya,Instituto Nacional de Saúde Doutor Ricardo Jorge,Unity-Aligned,https://dx.doi.org/10.20344/amp.18528,2024-04-30,2024-05-01,Verified,kislaya_sars-cov-2_2022-1,PRT
221026_Portugal_InstitutoNacionaldeSaúdeDoutorRicardoJorge_Age_20-29,221026_Portugal_InstitutoNacionaldeSaúdeDoutorRicardoJorge,"SARS-CoV-2 Seroprevalence Following a Large-Scale Vaccination Campaign in Portugal: Results of the National Serological Survey, September - November 2021.",2022-10-26,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Portugal,,,"Portuguese resi- dents aged one year old or above. Individuals seeking routine blood tests for rea- sons unrelated to COVID-19 in the above-mentioned sites were invited to participate (38 private Clinical Pathology Laboratories and 36 public hospitals and primary health care units of the Por- tuguese National Health System, comprising a total of 305 data collection sites with nationwide geographical distribu- tion)",,2021-09-28,2021-11-19,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29 years,546,0.109,,,,,,,,Stratified non-probability,Alinity i SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Irina Kislaya,Instituto Nacional de Saúde Doutor Ricardo Jorge,Unity-Aligned,https://dx.doi.org/10.20344/amp.18528,2024-04-30,2024-05-01,Verified,kislaya_sars-cov-2_2022-1,PRT
221026_Portugal_InstitutoNacionaldeSaúdeDoutorRicardoJorge_Age_60-69,221026_Portugal_InstitutoNacionaldeSaúdeDoutorRicardoJorge,"SARS-CoV-2 Seroprevalence Following a Large-Scale Vaccination Campaign in Portugal: Results of the National Serological Survey, September - November 2021.",2022-10-26,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Portugal,,,"Portuguese resi- dents aged one year old or above. Individuals seeking routine blood tests for rea- sons unrelated to COVID-19 in the above-mentioned sites were invited to participate (38 private Clinical Pathology Laboratories and 36 public hospitals and primary health care units of the Por- tuguese National Health System, comprising a total of 305 data collection sites with nationwide geographical distribu- tion)",,2021-09-28,2021-11-19,Residual sera,All,Seniors (65+ years),60.0,69.0,Age,60-69 years,563,0.129,,,,,,,,Stratified non-probability,Alinity i SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Irina Kislaya,Instituto Nacional de Saúde Doutor Ricardo Jorge,Unity-Aligned,https://dx.doi.org/10.20344/amp.18528,2024-04-30,2024-05-01,Verified,kislaya_sars-cov-2_2022-1,PRT
230202_Portugal_InstitutoNacionaldeSaúdeDoutorRicardo,230202_Portugal_InstitutoNacionaldeSaúdeDoutorRicardo,"Seroprevalence of Specific SARS-CoV-2 Antibodies during Omicron BA.5 Wave, Portugal, April-June 2022.",2023-02-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Portugal,,,""" anonymized residual serum samples from persons who had undergone blood testing for reasons unrelated to COVID-19
in a nationwide network of participating clinical pathology laboratories and public hospitals"" ",,2022-04-27,2022-06-08,Residual sera,All,Multiple groups,,,Primary Estimate,,3825,0.958,0.95,0.964,True,,,,True,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Irina Kislaya,Instituto Nacional de Saúde Doutor Ricardo,Unity-Aligned,https://dx.doi.org/10.3201/eid2903.221546,2023-03-08,2024-04-06,Verified,kislaya_seroprevalence_nodate,PRT
230202_Portugal_InstitutoNacionaldeSaúdeDoutorRicardo_>69,230202_Portugal_InstitutoNacionaldeSaúdeDoutorRicardo,"Seroprevalence of Specific SARS-CoV-2 Antibodies during Omicron BA.5 Wave, Portugal, April-June 2022.",2023-02-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Portugal,,,""" anonymized residual serum samples from persons who had undergone blood testing for reasons unrelated to COVID-19
in a nationwide network of participating clinical pathology laboratories and public hospitals"" ",,2022-04-27,2022-06-08,Residual sera,All,Seniors (65+ years),70.0,,Age,>69,3825,0.972,0.948,0.986,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Irina Kislaya,Instituto Nacional de Saúde Doutor Ricardo,Unity-Aligned,https://dx.doi.org/10.3201/eid2903.221546,2024-04-06,2024-04-22,Verified,kislaya_seroprevalence_nodate,PRT
230202_Portugal_InstitutoNacionaldeSaúdeDoutorRicardo_50-59,230202_Portugal_InstitutoNacionaldeSaúdeDoutorRicardo,"Seroprevalence of Specific SARS-CoV-2 Antibodies during Omicron BA.5 Wave, Portugal, April-June 2022.",2023-02-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Portugal,,,""" anonymized residual serum samples from persons who had undergone blood testing for reasons unrelated to COVID-19
in a nationwide network of participating clinical pathology laboratories and public hospitals"" ",,2022-04-27,2022-06-08,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,3825,0.977,0.951,0.989,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Irina Kislaya,Instituto Nacional de Saúde Doutor Ricardo,Unity-Aligned,https://dx.doi.org/10.3201/eid2903.221546,2024-04-06,2024-04-22,Verified,kislaya_seroprevalence_nodate,PRT
230202_Portugal_InstitutoNacionaldeSaúdeDoutorRicardo_10-19,230202_Portugal_InstitutoNacionaldeSaúdeDoutorRicardo,"Seroprevalence of Specific SARS-CoV-2 Antibodies during Omicron BA.5 Wave, Portugal, April-June 2022.",2023-02-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Portugal,,,""" anonymized residual serum samples from persons who had undergone blood testing for reasons unrelated to COVID-19
in a nationwide network of participating clinical pathology laboratories and public hospitals"" ",,2022-04-27,2022-06-08,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,3825,0.962,0.937,0.977,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Irina Kislaya,Instituto Nacional de Saúde Doutor Ricardo,Unity-Aligned,https://dx.doi.org/10.3201/eid2903.221546,2024-04-06,2024-04-22,Verified,kislaya_seroprevalence_nodate,PRT
230202_Portugal_InstitutoNacionaldeSaúdeDoutorRicardo_0-4,230202_Portugal_InstitutoNacionaldeSaúdeDoutorRicardo,"Seroprevalence of Specific SARS-CoV-2 Antibodies during Omicron BA.5 Wave, Portugal, April-June 2022.",2023-02-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Portugal,,,""" anonymized residual serum samples from persons who had undergone blood testing for reasons unrelated to COVID-19
in a nationwide network of participating clinical pathology laboratories and public hospitals"" ",,2022-04-27,2022-06-08,Residual sera,All,Children and Youth (0-17 years),,4.0,Age,0-4,3825,0.762,0.696,0.817,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Irina Kislaya,Instituto Nacional de Saúde Doutor Ricardo,Unity-Aligned,https://dx.doi.org/10.3201/eid2903.221546,2024-04-06,2024-04-22,Verified,kislaya_seroprevalence_nodate,PRT
230202_Portugal_InstitutoNacionaldeSaúdeDoutorRicardo_30-39,230202_Portugal_InstitutoNacionaldeSaúdeDoutorRicardo,"Seroprevalence of Specific SARS-CoV-2 Antibodies during Omicron BA.5 Wave, Portugal, April-June 2022.",2023-02-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Portugal,,,""" anonymized residual serum samples from persons who had undergone blood testing for reasons unrelated to COVID-19
in a nationwide network of participating clinical pathology laboratories and public hospitals"" ",,2022-04-27,2022-06-08,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,3825,0.969,0.941,0.984,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Irina Kislaya,Instituto Nacional de Saúde Doutor Ricardo,Unity-Aligned,https://dx.doi.org/10.3201/eid2903.221546,2024-04-06,2024-04-22,Verified,kislaya_seroprevalence_nodate,PRT
230202_Portugal_InstitutoNacionaldeSaúdeDoutorRicardo_20-29,230202_Portugal_InstitutoNacionaldeSaúdeDoutorRicardo,"Seroprevalence of Specific SARS-CoV-2 Antibodies during Omicron BA.5 Wave, Portugal, April-June 2022.",2023-02-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Portugal,,,""" anonymized residual serum samples from persons who had undergone blood testing for reasons unrelated to COVID-19
in a nationwide network of participating clinical pathology laboratories and public hospitals"" ",,2022-04-27,2022-06-08,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29,3825,0.986,0.965,0.995,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Irina Kislaya,Instituto Nacional de Saúde Doutor Ricardo,Unity-Aligned,https://dx.doi.org/10.3201/eid2903.221546,2024-04-06,2024-04-22,Verified,kislaya_seroprevalence_nodate,PRT
230202_Portugal_InstitutoNacionaldeSaúdeDoutorRicardo_5-9,230202_Portugal_InstitutoNacionaldeSaúdeDoutorRicardo,"Seroprevalence of Specific SARS-CoV-2 Antibodies during Omicron BA.5 Wave, Portugal, April-June 2022.",2023-02-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Portugal,,,""" anonymized residual serum samples from persons who had undergone blood testing for reasons unrelated to COVID-19
in a nationwide network of participating clinical pathology laboratories and public hospitals"" ",,2022-04-27,2022-06-08,Residual sera,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,3825,0.787,0.721,0.841,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Irina Kislaya,Instituto Nacional de Saúde Doutor Ricardo,Unity-Aligned,https://dx.doi.org/10.3201/eid2903.221546,2024-04-06,2024-04-22,Verified,kislaya_seroprevalence_nodate,PRT
230202_Portugal_InstitutoNacionaldeSaúdeDoutorRicardo_60-69,230202_Portugal_InstitutoNacionaldeSaúdeDoutorRicardo,"Seroprevalence of Specific SARS-CoV-2 Antibodies during Omicron BA.5 Wave, Portugal, April-June 2022.",2023-02-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Portugal,,,""" anonymized residual serum samples from persons who had undergone blood testing for reasons unrelated to COVID-19
in a nationwide network of participating clinical pathology laboratories and public hospitals"" ",,2022-04-27,2022-06-08,Residual sera,All,Multiple groups,60.0,69.0,Age,60-69,3825,0.974,0.948,0.987,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Irina Kislaya,Instituto Nacional de Saúde Doutor Ricardo,Unity-Aligned,https://dx.doi.org/10.3201/eid2903.221546,2024-04-06,2024-04-22,Verified,kislaya_seroprevalence_nodate,PRT
230202_Portugal_InstitutoNacionaldeSaúdeDoutorRicardo_40-49,230202_Portugal_InstitutoNacionaldeSaúdeDoutorRicardo,"Seroprevalence of Specific SARS-CoV-2 Antibodies during Omicron BA.5 Wave, Portugal, April-June 2022.",2023-02-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Portugal,,,""" anonymized residual serum samples from persons who had undergone blood testing for reasons unrelated to COVID-19
in a nationwide network of participating clinical pathology laboratories and public hospitals"" ",,2022-04-27,2022-06-08,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,3825,0.977,0.953,0.989,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Irina Kislaya,Instituto Nacional de Saúde Doutor Ricardo,Unity-Aligned,https://dx.doi.org/10.3201/eid2903.221546,2024-04-06,2024-04-22,Verified,kislaya_seroprevalence_nodate,PRT
230202_Portugal_InstitutoNacionaldeSaúdeDoutorRicardo_Female,230202_Portugal_InstitutoNacionaldeSaúdeDoutorRicardo,"Seroprevalence of Specific SARS-CoV-2 Antibodies during Omicron BA.5 Wave, Portugal, April-June 2022.",2023-02-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Portugal,,,""" anonymized residual serum samples from persons who had undergone blood testing for reasons unrelated to COVID-19
in a nationwide network of participating clinical pathology laboratories and public hospitals"" ",,2022-04-27,2022-06-08,Residual sera,Female,Multiple groups,,,Sex/Gender,Female,3825,0.958,0.946,0.968,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Irina Kislaya,Instituto Nacional de Saúde Doutor Ricardo,Unity-Aligned,https://dx.doi.org/10.3201/eid2903.221546,2024-04-06,2024-04-22,Verified,kislaya_seroprevalence_nodate,PRT
230202_Portugal_InstitutoNacionaldeSaúdeDoutorRicardo_Male,230202_Portugal_InstitutoNacionaldeSaúdeDoutorRicardo,"Seroprevalence of Specific SARS-CoV-2 Antibodies during Omicron BA.5 Wave, Portugal, April-June 2022.",2023-02-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Portugal,,,""" anonymized residual serum samples from persons who had undergone blood testing for reasons unrelated to COVID-19
in a nationwide network of participating clinical pathology laboratories and public hospitals"" ",,2022-04-27,2022-06-08,Residual sera,Male,Multiple groups,,,Sex/Gender,Male,3825,0.957,0.946,0.966,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Irina Kislaya,Instituto Nacional de Saúde Doutor Ricardo,Unity-Aligned,https://dx.doi.org/10.3201/eid2903.221546,2024-04-06,2024-04-22,Verified,kislaya_seroprevalence_nodate,PRT
201123_PuertoRico_PuertoRicoPublicHealthTrust_Primary,201123_PuertoRico_PuertoRicoPublicHealthTrust,Resultados Primera Fase Proyecto CASPER - Primer Estudio de Seroprevalencia de COVID-19 en Puerto Rico,2020-11-23,Institutional Report,National,Cross-sectional survey ,Puerto Rico,,"Arecibo, Bayamón, Caguas, Fajardo,Mayagüez, Aguadilla, Metro / San Juan, Ponce","We conducted seven simultaneous CASPERs to collect representative data in each of the seven public health regions of Puerto Rico (Arecibo, Bayamon, Caguas, Fajardo, Mayagüez, Aguadilla, Metro / San Juan, Ponce).

A two-stage cluster sampling methodology was used to select a representative sample of households for interview and testing in each health region.","1,816 of 1,906 serum samples collected from 1,175 households were tested. In 76 samples the results were indeterminate and 14 specimens did not have enough volume to perform the test.",2020-11-20,2020-11-23,Household and community samples,All,Multiple groups,12.0,,Primary Estimate,,1816,0.027999999999999997,,,True,,,,True,Stratified probability,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,Yes,Puerto Rico Public Health Trust,Puerto Rico Public Health Trust,Not Unity-Aligned,https://sites.google.com/view/casperpr/análisis-y-resultados?authuser=0,2021-05-21,2022-07-16,Verified,puerto_rico_public_health_trust_resultados_2020,PRI
201124_Qatar_MinistryofPublicHealth_Overall_popadj,201124_Qatar_MinistryofPublicHealth,Seroprevalence of SARS-CoV-2 infection in the craft and manual worker population of Qatar,2020-11-24,Preprint,National,Cross-sectional survey ,Qatar,,,expatriate craft and manual workers,,2020-07-26,2020-09-09,Non-essential workers and unemployed persons,All,Multiple groups,18.0,80.0,Primary Estimate,Overall test adj,2641,0.5529999999999999,0.533,0.573,True,,True,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,,Validated by manufacturers,0.9500000000000001,0.998,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Mohamed H Al Thani,Ministry of Public Health,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.11.24.20237719v1,2021-01-23,2024-03-01,Verified,al-thani_seroprevalence_2020,QAT
210309_Qatar_HamadMedicalCorporation_CemetaryWorkers,210309_Qatar_HamadMedicalCorporation_CemetaryStaff,SARS-CoV-2 Infection in Mortuary and Cemetery Workers,2021-03-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Qatar,,,Those who agreed to provide blood samples for serologic samples ,Unavailable due to leave or other absence at multiple visits,2020-09-01,2020-09-01,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,Cemetary workers,64,0.34380000000000005,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,,,,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Moza Alishaq,Hamad Medical Corporation,Not Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.03.012,2021-04-16,2024-03-01,Verified,alishaq_sars-cov-2_2021,QAT
210309_Qatar_HamadMedicalCorporation_MortuaryWorkers,210309_Qatar_HamadMedicalCorporation_MortuaryWorkers,SARS-CoV-2 Infection in Mortuary and Cemetery Workers,2021-03-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Qatar,,,Those who agreed to provide blood samples for serologic samples ,Unavailable due to leave or other absence at multiple visits,2020-09-17,2020-09-17,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,Mortuary staff,32,0.25,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,,,,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Moza Alishaq,Hamad Medical Corporation,Not Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.03.012,2021-04-16,2024-03-01,Verified,alishaq_sars-cov-2_2021,QAT
210501_Qatar_CornellUniversity,210501_Qatar_CornellUniversity,"Herd
  Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in
  10 Communities, Qatar",2021-05-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Qatar,,,Voluntary participation from expatriate craft and manual workers (CMWs). ten CMW communities were selected for feasibility and/or given earlier random PCR testing campaigns or contact tracing that suggested substantial infection levels.,,2020-06-21,2020-09-09,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,4970,0.644,0.63,0.657,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,,Validated by manufacturers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Andrew Jeremijenko,Cornell University ,Not Unity-Aligned,https://wwwnc.cdc.gov/eid/article/27/5/20-4365_article,2021-05-23,2024-03-01,Unverified,jeremijenko_herd_2021,QAT
210502_Qatar_CornellUniversity_Primary,210502_Qatar_CornellUniversity,SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar.,2021-05-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Qatar,,,"craft and manual worker (CMW) who registered at the Qatar Red Crescent Society (QRCS), which is a main provider of primary health care for CMWs in the country.",,2020-07-26,2020-09-09,Essential non-healthcare workers,Male,Multiple groups,18.0,80.0,Primary Estimate,,2641,0.5529999999999999,0.533,0.573,True,,True,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,Validated by independent authors/third party/non-developers,,,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Mohamed Al-Thani,Cornell University,Not Unity-Aligned,https://academic.oup.com/ofid/article/8/8/ofab221/6261968,2021-09-07,2024-03-01,Unverified,al-thani_sars-cov-2_2021,QAT
210502_Qatar_CornellUniversity_Age30to39,210502_Qatar_CornellUniversity,SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar.,2021-05-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Qatar,,,"craft and manual worker (CMW) who registered at the Qatar Red Crescent Society (QRCS), which is a main provider of primary health care for CMWs in the country.",,2020-07-26,2020-09-09,Essential non-healthcare workers,Male,Adults (18-64 years),30.0,39.0,Age,Age 30-39,979,0.5750000000000001,,,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,Validated by independent authors/third party/non-developers,,,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Mohamed Al-Thani,Cornell University,Not Unity-Aligned,https://academic.oup.com/ofid/article/8/8/ofab221/6261968,2021-09-07,2024-03-01,Unverified,al-thani_sars-cov-2_2021,QAT
210502_Qatar_CornellUniversity_Age50to59,210502_Qatar_CornellUniversity,SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar.,2021-05-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Qatar,,,"craft and manual worker (CMW) who registered at the Qatar Red Crescent Society (QRCS), which is a main provider of primary health care for CMWs in the country.",,2020-07-26,2020-09-09,Essential non-healthcare workers,Male,Adults (18-64 years),50.0,59.0,Age,Age 50-59,265,0.549,,,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,Validated by independent authors/third party/non-developers,,,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Mohamed Al-Thani,Cornell University,Not Unity-Aligned,https://academic.oup.com/ofid/article/8/8/ofab221/6261968,2021-09-07,2024-03-01,Unverified,al-thani_sars-cov-2_2021,QAT
210502_Qatar_CornellUniversity_Age40to49,210502_Qatar_CornellUniversity,SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar.,2021-05-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Qatar,,,"craft and manual worker (CMW) who registered at the Qatar Red Crescent Society (QRCS), which is a main provider of primary health care for CMWs in the country.",,2020-07-26,2020-09-09,Essential non-healthcare workers,Male,Adults (18-64 years),40.0,49.0,Age,Age 40-49,553,0.544,,,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,Validated by independent authors/third party/non-developers,,,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Mohamed Al-Thani,Cornell University,Not Unity-Aligned,https://academic.oup.com/ofid/article/8/8/ofab221/6261968,2021-09-07,2024-03-01,Unverified,al-thani_sars-cov-2_2021,QAT
210502_Qatar_CornellUniversity_AgeUnder29,210502_Qatar_CornellUniversity,SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar.,2021-05-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Qatar,,,"craft and manual worker (CMW) who registered at the Qatar Red Crescent Society (QRCS), which is a main provider of primary health care for CMWs in the country.",,2020-07-26,2020-09-09,Essential non-healthcare workers,Male,Adults (18-64 years),18.0,29.0,Age,Age <29,753,0.532,,,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,Validated by independent authors/third party/non-developers,,,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Mohamed Al-Thani,Cornell University,Not Unity-Aligned,https://academic.oup.com/ofid/article/8/8/ofab221/6261968,2021-09-07,2024-03-01,Unverified,al-thani_sars-cov-2_2021,QAT
210502_Qatar_CornellUniversity_AgeOver60,210502_Qatar_CornellUniversity,SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar.,2021-05-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Qatar,,,"craft and manual worker (CMW) who registered at the Qatar Red Crescent Society (QRCS), which is a main provider of primary health care for CMWs in the country.",,2020-07-26,2020-09-09,Essential non-healthcare workers,Male,Seniors (65+ years),60.0,80.0,Age,Age >60,91,0.47600000000000003,,,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,Validated by independent authors/third party/non-developers,,,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Mohamed Al-Thani,Cornell University,Not Unity-Aligned,https://academic.oup.com/ofid/article/8/8/ofab221/6261968,2021-09-07,2024-03-01,Unverified,al-thani_sars-cov-2_2021,QAT
210523_Qatar_CornellUniversity_Overall_PopTestAdj,210523_Qatar_CornellUniversity,"SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals",2021-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Qatar,,,"The sample included residual blood specimens collected from individuals receiving routine and other clinical care at Hamad Medical Corporation (HMC), a main provider of healthcare to the urban population of this country and the nationally designated provider for Coronavirus Disease 2019 (COVID-19) healthcare needs.",,2020-05-12,2020-09-09,Residual sera,All,Multiple groups,,,Primary Estimate,,112941,0.14800000000000002,,,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,Validated by independent authors/third party/non-developers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Peter Coyle,Cornell University,Unity-Aligned,http://dx.doi.org/10.1016/j.isci.2021.102646,2021-11-11,2023-08-15,Verified,coyle_sars-cov-2_2021-1,QAT
210523_Qatar_CornellUniversity_Age_50-59_PopAdj,210523_Qatar_CornellUniversity,"SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals",2021-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Qatar,,,"The sample included residual blood specimens collected from individuals receiving routine and other clinical care at Hamad Medical Corporation (HMC), a main provider of healthcare to the urban population of this country and the nationally designated provider for Coronavirus Disease 2019 (COVID-19) healthcare needs.",,2020-05-12,2020-09-09,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,16363,0.179,,,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,Validated by independent authors/third party/non-developers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Peter Coyle,Cornell University,Unity-Aligned,http://dx.doi.org/10.1016/j.isci.2021.102646,2021-11-11,2024-03-01,Verified,coyle_sars-cov-2_2021-1,QAT
210523_Qatar_CornellUniversity_Age_10-19_PopAdj,210523_Qatar_CornellUniversity,"SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals",2021-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Qatar,,,"The sample included residual blood specimens collected from individuals receiving routine and other clinical care at Hamad Medical Corporation (HMC), a main provider of healthcare to the urban population of this country and the nationally designated provider for Coronavirus Disease 2019 (COVID-19) healthcare needs.",,2020-05-12,2020-09-09,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,5557,0.073,,,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,Validated by independent authors/third party/non-developers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Peter Coyle,Cornell University,Unity-Aligned,http://dx.doi.org/10.1016/j.isci.2021.102646,2021-11-11,2024-03-01,Verified,coyle_sars-cov-2_2021-1,QAT
210523_Qatar_CornellUniversity_Women_PopAdj,210523_Qatar_CornellUniversity,"SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals",2021-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Qatar,,,"The sample included residual blood specimens collected from individuals receiving routine and other clinical care at Hamad Medical Corporation (HMC), a main provider of healthcare to the urban population of this country and the nationally designated provider for Coronavirus Disease 2019 (COVID-19) healthcare needs.",,2020-05-12,2020-09-09,Residual sera,Female,Multiple groups,,,Sex/Gender,,54707,0.08,,,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,Validated by independent authors/third party/non-developers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Peter Coyle,Cornell University,Unity-Aligned,http://dx.doi.org/10.1016/j.isci.2021.102646,2021-11-11,2024-03-01,Verified,coyle_sars-cov-2_2021-1,QAT
210523_Qatar_CornellUniversity_Age_20-29_PopAdj,210523_Qatar_CornellUniversity,"SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals",2021-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Qatar,,,"The sample included residual blood specimens collected from individuals receiving routine and other clinical care at Hamad Medical Corporation (HMC), a main provider of healthcare to the urban population of this country and the nationally designated provider for Coronavirus Disease 2019 (COVID-19) healthcare needs.",,2020-05-12,2020-09-09,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29,19271,0.15,,,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,Validated by independent authors/third party/non-developers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Peter Coyle,Cornell University,Unity-Aligned,http://dx.doi.org/10.1016/j.isci.2021.102646,2021-11-11,2024-03-01,Verified,coyle_sars-cov-2_2021-1,QAT
210523_Qatar_CornellUniversity_Age_60-69_PopAdj,210523_Qatar_CornellUniversity,"SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals",2021-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Qatar,,,"The sample included residual blood specimens collected from individuals receiving routine and other clinical care at Hamad Medical Corporation (HMC), a main provider of healthcare to the urban population of this country and the nationally designated provider for Coronavirus Disease 2019 (COVID-19) healthcare needs.",,2020-05-12,2020-09-09,Residual sera,All,Seniors (65+ years),60.0,69.0,Age,60-69,8639,0.15,,,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,Validated by independent authors/third party/non-developers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Peter Coyle,Cornell University,Unity-Aligned,http://dx.doi.org/10.1016/j.isci.2021.102646,2021-11-11,2024-03-01,Verified,coyle_sars-cov-2_2021-1,QAT
210523_Qatar_CornellUniversity_Overall_PopAdj,210523_Qatar_CornellUniversity,"SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals",2021-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Qatar,,,"The sample included residual blood specimens collected from individuals receiving routine and other clinical care at Hamad Medical Corporation (HMC), a main provider of healthcare to the urban population of this country and the nationally designated provider for Coronavirus Disease 2019 (COVID-19) healthcare needs.",,2020-05-12,2020-09-09,Residual sera,All,Multiple groups,,,Analysis,,112941,0.133,0.131,0.136,,,True,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,Validated by independent authors/third party/non-developers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Peter Coyle,Cornell University,Unity-Aligned,http://dx.doi.org/10.1016/j.isci.2021.102646,2021-11-11,2024-03-01,Verified,coyle_sars-cov-2_2021-1,QAT
210523_Qatar_CornellUniversity_Age_<10_PopAdj,210523_Qatar_CornellUniversity,"SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals",2021-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Qatar,,,"The sample included residual blood specimens collected from individuals receiving routine and other clinical care at Hamad Medical Corporation (HMC), a main provider of healthcare to the urban population of this country and the nationally designated provider for Coronavirus Disease 2019 (COVID-19) healthcare needs.",,2020-05-12,2020-09-09,Residual sera,All,Children and Youth (0-17 years),,9.0,Age,<10,3384,0.071,,,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,Validated by independent authors/third party/non-developers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Peter Coyle,Cornell University,Unity-Aligned,http://dx.doi.org/10.1016/j.isci.2021.102646,2021-11-11,2024-03-01,Verified,coyle_sars-cov-2_2021-1,QAT
210523_Qatar_CornellUniversity_Men_PopAdj,210523_Qatar_CornellUniversity,"SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals",2021-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Qatar,,,"The sample included residual blood specimens collected from individuals receiving routine and other clinical care at Hamad Medical Corporation (HMC), a main provider of healthcare to the urban population of this country and the nationally designated provider for Coronavirus Disease 2019 (COVID-19) healthcare needs.",,2020-05-12,2020-09-09,Residual sera,Male,Multiple groups,,,Sex/Gender,,58234,0.18300000000000002,,,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,Validated by independent authors/third party/non-developers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Peter Coyle,Cornell University,Unity-Aligned,http://dx.doi.org/10.1016/j.isci.2021.102646,2021-11-11,2024-03-01,Verified,coyle_sars-cov-2_2021-1,QAT
210523_Qatar_CornellUniversity_Overall_UnAdj,210523_Qatar_CornellUniversity,"SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals",2021-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Qatar,,,"The sample included residual blood specimens collected from individuals receiving routine and other clinical care at Hamad Medical Corporation (HMC), a main provider of healthcare to the urban population of this country and the nationally designated provider for Coronavirus Disease 2019 (COVID-19) healthcare needs.",,2020-05-12,2020-09-09,Residual sera,All,Multiple groups,,,Analysis,,112941,0.167,0.165,0.16899999999999998,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,Validated by independent authors/third party/non-developers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Peter Coyle,Cornell University,Unity-Aligned,http://dx.doi.org/10.1016/j.isci.2021.102646,2021-11-11,2024-03-01,Verified,coyle_sars-cov-2_2021-1,QAT
210523_Qatar_CornellUniversity_Age_70-79_PopAdj,210523_Qatar_CornellUniversity,"SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals",2021-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Qatar,,,"The sample included residual blood specimens collected from individuals receiving routine and other clinical care at Hamad Medical Corporation (HMC), a main provider of healthcare to the urban population of this country and the nationally designated provider for Coronavirus Disease 2019 (COVID-19) healthcare needs.",,2020-05-12,2020-09-09,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,3192,0.105,,,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,Validated by independent authors/third party/non-developers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Peter Coyle,Cornell University,Unity-Aligned,http://dx.doi.org/10.1016/j.isci.2021.102646,2021-11-11,2024-03-01,Verified,coyle_sars-cov-2_2021-1,QAT
210523_Qatar_CornellUniversity_Age_80+_PopAdj,210523_Qatar_CornellUniversity,"SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals",2021-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Qatar,,,"The sample included residual blood specimens collected from individuals receiving routine and other clinical care at Hamad Medical Corporation (HMC), a main provider of healthcare to the urban population of this country and the nationally designated provider for Coronavirus Disease 2019 (COVID-19) healthcare needs.",,2020-05-12,2020-09-09,Residual sera,All,Seniors (65+ years),80.0,,Age,80+,1331,0.075,,,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,Validated by independent authors/third party/non-developers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Peter Coyle,Cornell University,Unity-Aligned,http://dx.doi.org/10.1016/j.isci.2021.102646,2021-11-11,2024-03-01,Verified,coyle_sars-cov-2_2021-1,QAT
210523_Qatar_CornellUniversity_Age_30-39_PopAdj,210523_Qatar_CornellUniversity,"SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals",2021-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Qatar,,,"The sample included residual blood specimens collected from individuals receiving routine and other clinical care at Hamad Medical Corporation (HMC), a main provider of healthcare to the urban population of this country and the nationally designated provider for Coronavirus Disease 2019 (COVID-19) healthcare needs.",,2020-05-12,2020-09-09,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,31622,0.168,,,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,Validated by independent authors/third party/non-developers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Peter Coyle,Cornell University,Unity-Aligned,http://dx.doi.org/10.1016/j.isci.2021.102646,2021-11-11,2024-03-01,Verified,coyle_sars-cov-2_2021-1,QAT
210523_Qatar_CornellUniversity_Age_40-49_PopAdj,210523_Qatar_CornellUniversity,"SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals",2021-05-23,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Qatar,,,"The sample included residual blood specimens collected from individuals receiving routine and other clinical care at Hamad Medical Corporation (HMC), a main provider of healthcare to the urban population of this country and the nationally designated provider for Coronavirus Disease 2019 (COVID-19) healthcare needs.",,2020-05-12,2020-09-09,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,23582,0.18100000000000002,,,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,Validated by independent authors/third party/non-developers,0.995,0.998,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Peter Coyle,Cornell University,Unity-Aligned,http://dx.doi.org/10.1016/j.isci.2021.102646,2021-11-11,2024-03-01,Verified,coyle_sars-cov-2_2021-1,QAT
210604_Qatar_CornellUniversity_Overall1,210604_Qatar_CornellUniversity,Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population.,2021-06-04,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Qatar,,,"craft and manual workers who took part in a larger seroprevalence study in Qatar (Al-Thani, M. H. et al. Seroprevalence of SARS-CoV-2 infection in the craft and manual worker population of Qatar. MedRxiv. https://doi.org/10.1101/2020.11.24.20237719 (2020).)",,2020-07-26,2020-09-09,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,Overall,394,0.465,0.41600000000000004,0.514,True,,,,True,Convenience,"Mindray CL-900i anti-SARS-CoV-2 IgG/IgM,VIDAS Multiparametric immunoassay system for medium throughput,Elecsys® Anti‐SARS‐CoV‐2 (N)","Shenzhen Mindray Bio-Medical Electronics Co.,Biomerieux,Roche Diagnostics",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,No,No,Unclear,Unclear,Yes,No,Unclear,Gheyath K Nasrallah,Cornell University,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-91235-x,2021-06-16,2024-03-01,Verified,nasrallah_analytic_2021,QAT
210930_Qatar_HamadMedicalCorporation_Primary,210930_Qatar_HamadMedicalCorporation,Prevalence and risk factors for SARS-CoV-2 infection and seroprevalence among clinical and non-clinical staff in a national healthcare system,2021-09-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Qatar,,,Serum antibody testing for SARS-CoV-2 antibodies was performed on those who requested it or were referred by their clinical care provider.,,2020-03-01,2020-10-31,Multiple populations,All,Multiple groups,,,Primary Estimate,,12126,0.177,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Moza Alishaq,Hamad Medical Corporation,Not Unity-Aligned,http://dx.doi.org/10.1371/journal.pone.0257845,2021-10-14,2024-03-01,Unverified,alishaq_prevalence_2021,QAT
211019_Qatar_PrimaryHealthCareCorporation_Timepoint1,211019_Qatar_PrimaryHealthCareCorporation_Timepoint1,Antibody Response to SARS-CoV-2: A Cohort Study in Qatar's Primary Care Settings,2021-10-19,Journal Article (Peer-Reviewed),National,Prospective cohort,Qatar,,,Individuals registered with a mobile number on PHCC electronic medical records and aged ≥10 years were eligible for inclusion.,"Individuals with difficulties related to mobility and communication, bleeding disorders, and mental disabilities were excluded.",2020-07-01,2020-07-31,Household and community samples,All,Multiple groups,10.0,,Primary Estimate,,943,0.12,,,True,,,,True,Stratified probability,Mindray CL-900i anti-SARS-CoV-2 IgG/IgM,Shenzhen Mindray Bio-Medical Electronics Co.,CLIA,Plasma,IgG,,,,,['Moderate'],No,Yes,Yes,Yes,Unclear,Unclear,Yes,No,No,Mohamed Syed,Primary Health Care Corporation (PHCC),Not Unity-Aligned,https://journals.sagepub.com/doi/full/10.1177/21501327211050569,2021-11-09,2022-07-16,Verified,syed_antibody_2021,QAT
211019_Qatar_PrimaryHealthCareCorporation_Timepoint2,211019_Qatar_PrimaryHealthCareCorporation_Timepoint2,Antibody Response to SARS-CoV-2: A Cohort Study in Qatar's Primary Care Settings,2021-10-19,Journal Article (Peer-Reviewed),National,Prospective cohort,Qatar,,,Individuals registered with a mobile number on PHCC electronic medical records and aged ≥10 years were eligible for inclusion.,"Individuals with difficulties related to mobility and communication, bleeding disorders, and mental disabilities were excluded.",2020-10-01,2020-10-31,Household and community samples,All,Multiple groups,10.0,,Primary Estimate,,943,0.172,,,True,,,,True,Stratified probability,Mindray CL-900i anti-SARS-CoV-2 IgG/IgM,Shenzhen Mindray Bio-Medical Electronics Co.,CLIA,Plasma,IgG,,,,,['Moderate'],No,Yes,Yes,Yes,Unclear,Unclear,Yes,No,No,Mohamed Syed,Primary Health Care Corporation (PHCC),Not Unity-Aligned,https://journals.sagepub.com/doi/full/10.1177/21501327211050569,2021-11-09,2022-07-16,Verified,syed_antibody_2021,QAT
211111_Qatar_HamadMedicalCorporation_SchoolEnd,211111_Qatar_HamadMedicalCorporation_SchoolEnd,SARS-CoV-2 PCR and antibody positivity among school staff at the beginning and end of the first school term.,2021-11-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Qatar,,,"""Based on convenient access, large number of staff, and widespread willingness to participate in the national screening program, we chose one school for analysis.

... baseline nasopharyngeal swab for SARS-CoV-2 PCR and blood for SARS-CoV-2 antibody testing at the beginning of the 2020–2021 school year were obtained on all available staff.""",,2020-12-16,2020-12-22,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,331,0.3172,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by developers,0.995,0.998,['High'],,No,No,No,,Yes,Yes,Yes,,Moza Alishaq,Hamad Medical Corporation,Not Unity-Aligned,https://dx.doi.org/10.1186/s12889-021-12134-4,2021-11-25,2024-03-01,Unverified,alishaq_sars-cov-2_2021-1,QAT
211111_Qatar_HamadMedicalCorporation_SchoolStart,211111_Qatar_HamadMedicalCorporation_SchoolStart,SARS-CoV-2 PCR and antibody positivity among school staff at the beginning and end of the first school term.,2021-11-11,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Qatar,,,"""Based on convenient access, large number of staff, and widespread willingness to participate in the national screening program, we chose one school for analysis.

... baseline nasopharyngeal swab for SARS-CoV-2 PCR and blood for SARS-CoV-2 antibody testing at the beginning of the 2020–2021 school year were obtained on all available staff.""",,2020-08-19,2020-08-25,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,376,0.3005,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by developers,0.995,0.998,['High'],,No,No,Yes,,Yes,Yes,Yes,,Moza Alishaq,Hamad Medical Corporation,Not Unity-Aligned,https://dx.doi.org/10.1186/s12889-021-12134-4,2021-11-25,2024-03-01,Unverified,alishaq_sars-cov-2_2021-1,QAT
220131_Qatar_CornellUniversity_RocheElecsys,220131_Qatar_CornellUniversity,Assessing the performance of a serological point-of-care test in measuring detectable antibodies against SARS-CoV-2.,2022-01-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Qatar,,,"serum specimens that were collected and then tested for SARS-CoV-2 antibodies between October 10–21, 2020, from individuals receiving routine or other clinical care at Hamad Medical Corporation (HMC).",,2020-10-10,2020-10-21,Residual sera,All,Multiple groups,,,Primary Estimate,Elecsys,709,0.7193,0.685,0.752,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.89,0.998,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,,Peter Coyle,Cornell University,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0262897,2022-02-10,2024-03-01,Verified,coyle_assessing_2022,QAT
220131_Qatar_CornellUniversity_BioMedomics,220131_Qatar_CornellUniversity,Assessing the performance of a serological point-of-care test in measuring detectable antibodies against SARS-CoV-2.,2022-01-31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Qatar,,,"serum specimens that were collected and then tested for SARS-CoV-2 antibodies between October 10–21, 2020, from individuals receiving routine or other clinical care at Hamad Medical Corporation (HMC).",,2020-10-10,2020-10-21,Residual sera,All,Multiple groups,,,Test used,BioMedomics,709,0.6347,0.598,0.67,,,,,,Convenience,COVID-19 IgM-IgG Dual Antibody Rapid Test,"BioMedomics, Inc.",LFIA,Serum,"['IgG', 'IgM']",Spike,,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,,Peter Coyle,Cornell University,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0262897,2022-02-10,2024-03-01,Verified,coyle_assessing_2022,QAT
220615_Qatar_PrimaryHealthCareCorporation_Primary,220615_Qatar_PrimaryHealthCareCorporation,SARS-CoV-2 seropositivity and subsequent infection risk: a prospective cohort study.,2022-06-15,Journal Article (Peer-Reviewed),National,Prospective cohort,Qatar,,,individuals aged 10 years and above registered with Qatar’s largest primary healthcare provider.,excluded individuals 2 weeks from the date of receiving the first dose.,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,10.0,,Primary Estimate,,2044,0.09050000000000001,,,True,,,,True,Simplified probability,Mindray CL-900i anti-SARS-CoV-2 IgG/IgM,Shenzhen Mindray Bio-Medical Electronics Co.,CLIA,Plasma,IgG,Spike,,,,['Moderate'],,Yes,Yes,No,,Unclear,Yes,No,,Mohamed Syed,Primary Health Care Corporation,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijregi.2022.02.005,2022-06-28,2022-07-16,Unverified,syed_sars-cov-2_2022,QAT
220721_Qatar_HamadMedicalCorporation_Restricted_Overall,220721_Qatar_HamadMedicalCorporation_Restricted,Seroprevalence of SARS-CoV-2 Infection Among Working Women and Impact of Workplace Restrictions,2022-07-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Qatar,,,"""working women who were restricted to working from home, working indoors, or temporarily furloughed (restricted group)"".

""The first group included female school staff and salon/spa workers"".",,2020-03-17,2020-09-10,Multiple populations,Female,Adults (18-64 years),,,Primary Estimate,,1636,0.0513,,,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,,,Validated by manufacturers,0.995,0.998,['High'],,No,Yes,No,,Unclear,Yes,Yes,,Moza Alishaq,Hamad Medical Corporation,Not Unity-Aligned,https://dx.doi.org/10.2147/IDR.S360241,2022-08-12,2022-08-26,Unverified,alishaq_seroprevalence_2022,QAT
200709_Korea_KoreaCentersforDiseaseControlandPrevention_Total,200709_Korea_KoreaCentersforDiseaseControlandPrevention,0.03% of Koreans developed coronavirus antibodies: KCDC,2020-07-09,News and Media,National,Cross-sectional survey ,Republic of Korea,Korea,,Participants of the National Nutrition Survey or individuals in a medical institution in Seoul,,2020-07-09,2020-07-09,Household and community samples,All,Multiple groups,,,Primary Estimate,,3055,0.0003,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],No,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,Ock Hyun-ju,Korea Centers for Disease Control and Prevention,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=http://www.koreaherald.com/view.php%3Fud%3D20200709000787&ct=ga&cd=CAAYEDIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNG8AlCeBcx2rR4FfgC726ll5TtgUw,2020-07-31,2023-12-13,Verified,ock_hyun-ju_003_2020,KOR
200716_Daegu_DaeguCatholicUniversityHospital_Overall,200716_Daegu_DaeguCatholicUniversityHospital,"IgG Seroprevalence of COVID-19 among Individuals without a History of the Coronavirus Disease Infection in Daegu, Korea.",2020-07-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,North Gyeongsang,Daegu," 1) subjects who were never diagnosed with COVID-19, 2) subjects who do not currently have any COVID-19-related symptom such as fever or cough, and 3) subjects who live in Daegu.",,2020-05-25,2020-06-05,Multiple populations,All,Multiple groups,18.0,82.0,Primary Estimate,,198,0.076,,,True,,,,True,Convenience,DIAKEY COVID-19 IgM/IgG Rapid Test Kit,Shin Jin Medics Inc,LFIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.92,['High'],No,No,No,Yes,Unclear,Yes,Yes,No,Unclear,Suk-Kyoon Song,Daegu Catholic University Hospital,Not Unity-Aligned,https://dx.doi.org/10.3346/jkms.2020.35.e269,2020-09-26,2024-03-01,Verified,song_igg_2020-1,KOR
200716_Daegu_DaeguCatholicUniversityHospital_age<40,200716_Daegu_DaeguCatholicUniversityHospital,"IgG Seroprevalence of COVID-19 among Individuals without a History of the Coronavirus Disease Infection in Daegu, Korea.",2020-07-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,North Gyeongsang,Daegu," 1) subjects who were never diagnosed with COVID-19, 2) subjects who do not currently have any COVID-19-related symptom such as fever or cough, and 3) subjects who live in Daegu.",,2020-05-25,2020-06-05,Multiple populations,All,Adults (18-64 years),18.0,82.0,Age,<40,43,0.047,,,,,,,,Convenience,DIAKEY COVID-19 IgM/IgG Rapid Test Kit,Shin Jin Medics Inc,LFIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.92,['High'],No,No,No,Yes,Unclear,Yes,Yes,No,Unclear,Suk-Kyoon Song,Daegu Catholic University Hospital,Not Unity-Aligned,https://dx.doi.org/10.3346/jkms.2020.35.e269,2020-09-26,2024-03-01,Verified,song_igg_2020-1,KOR
200716_Daegu_DaeguCatholicUniversityHospital_age40-59,200716_Daegu_DaeguCatholicUniversityHospital,"IgG Seroprevalence of COVID-19 among Individuals without a History of the Coronavirus Disease Infection in Daegu, Korea.",2020-07-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,North Gyeongsang,Daegu," 1) subjects who were never diagnosed with COVID-19, 2) subjects who do not currently have any COVID-19-related symptom such as fever or cough, and 3) subjects who live in Daegu.",,2020-05-25,2020-06-05,Multiple populations,All,Adults (18-64 years),18.0,82.0,Age,40-59,89,0.067,,,,,,,,Convenience,DIAKEY COVID-19 IgM/IgG Rapid Test Kit,Shin Jin Medics Inc,LFIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.92,['High'],No,No,No,Yes,Unclear,Yes,Yes,No,Unclear,Suk-Kyoon Song,Daegu Catholic University Hospital,Not Unity-Aligned,https://dx.doi.org/10.3346/jkms.2020.35.e269,2020-09-26,2024-03-01,Verified,song_igg_2020-1,KOR
200716_Daegu_DaeguCatholicUniversityHospital_age>60,200716_Daegu_DaeguCatholicUniversityHospital,"IgG Seroprevalence of COVID-19 among Individuals without a History of the Coronavirus Disease Infection in Daegu, Korea.",2020-07-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,North Gyeongsang,Daegu," 1) subjects who were never diagnosed with COVID-19, 2) subjects who do not currently have any COVID-19-related symptom such as fever or cough, and 3) subjects who live in Daegu.",,2020-05-25,2020-06-05,Multiple populations,All,Seniors (65+ years),18.0,82.0,Age,>60,66,0.106,,,,,,,,Convenience,DIAKEY COVID-19 IgM/IgG Rapid Test Kit,Shin Jin Medics Inc,LFIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,0.92,['High'],No,No,No,Yes,Unclear,Yes,Yes,No,Unclear,Suk-Kyoon Song,Daegu Catholic University Hospital,Not Unity-Aligned,https://dx.doi.org/10.3346/jkms.2020.35.e269,2020-09-26,2024-03-01,Verified,song_igg_2020-1,KOR
200824_Seoul_KoreaUniversity_Overall,200824_Seoul_KoreaUniversity,"Seroprevalence of Anti-SARS-CoV-2 Antibodies among Outpatients in Southwestern Seoul, Korea",2020-08-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,Seoul,The serum samples were used anonymously except for the information about sex and age. Serum samples from patients of different ages were collected to investigate the age-stratified seroprevalence of SARS-CoV-2.,Samples from patients with laboratory-confirmed COVID-19 were excluded from this study.,2020-05-25,2020-05-29,Residual sera,All,Multiple groups,0.0,92.0,Primary Estimate,,1500,0.0007000000000000001,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Ji Noh,Korea University,Not Unity-Aligned,https://jkms.org/DOIx.php?id=10.3346/jkms.2020.35.e311,2020-10-04,2024-03-01,Verified,noh_seroprevalence_2020,KOR
200824_Seoul_KoreaUniversity_0-19,200824_Seoul_KoreaUniversity,"Seroprevalence of Anti-SARS-CoV-2 Antibodies among Outpatients in Southwestern Seoul, Korea",2020-08-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,Seoul,The serum samples were used anonymously except for the information about sex and age. Serum samples from patients of different ages were collected to investigate the age-stratified seroprevalence of SARS-CoV-2.,Samples from patients with laboratory-confirmed COVID-19 were excluded from this study.,2020-05-25,2020-05-29,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Age,0-19 years,226,0.0,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Ji Noh,Korea University,Not Unity-Aligned,https://jkms.org/DOIx.php?id=10.3346/jkms.2020.35.e311,2020-10-04,2024-03-01,Verified,noh_seroprevalence_2020,KOR
200824_Seoul_KoreaUniversity_Male,200824_Seoul_KoreaUniversity,"Seroprevalence of Anti-SARS-CoV-2 Antibodies among Outpatients in Southwestern Seoul, Korea",2020-08-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,Seoul,The serum samples were used anonymously except for the information about sex and age. Serum samples from patients of different ages were collected to investigate the age-stratified seroprevalence of SARS-CoV-2.,Samples from patients with laboratory-confirmed COVID-19 were excluded from this study.,2020-05-25,2020-05-29,Residual sera,Male,Multiple groups,0.0,92.0,Sex/Gender,Males,730,0.0014000000000000002,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Ji Noh,Korea University,Not Unity-Aligned,https://jkms.org/DOIx.php?id=10.3346/jkms.2020.35.e311,2020-10-04,2024-03-01,Verified,noh_seroprevalence_2020,KOR
200824_Seoul_KoreaUniversity_Female,200824_Seoul_KoreaUniversity,"Seroprevalence of Anti-SARS-CoV-2 Antibodies among Outpatients in Southwestern Seoul, Korea",2020-08-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,Seoul,The serum samples were used anonymously except for the information about sex and age. Serum samples from patients of different ages were collected to investigate the age-stratified seroprevalence of SARS-CoV-2.,Samples from patients with laboratory-confirmed COVID-19 were excluded from this study.,2020-05-25,2020-05-29,Residual sera,Female,Multiple groups,0.0,92.0,Sex/Gender,Females,770,0.0,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Ji Noh,Korea University,Not Unity-Aligned,https://jkms.org/DOIx.php?id=10.3346/jkms.2020.35.e311,2020-10-04,2024-03-01,Verified,noh_seroprevalence_2020,KOR
200824_Seoul_KoreaUniversity_30-39,200824_Seoul_KoreaUniversity,"Seroprevalence of Anti-SARS-CoV-2 Antibodies among Outpatients in Southwestern Seoul, Korea",2020-08-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,Seoul,The serum samples were used anonymously except for the information about sex and age. Serum samples from patients of different ages were collected to investigate the age-stratified seroprevalence of SARS-CoV-2.,Samples from patients with laboratory-confirmed COVID-19 were excluded from this study.,2020-05-25,2020-05-29,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39 years,261,0.0038,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Ji Noh,Korea University,Not Unity-Aligned,https://jkms.org/DOIx.php?id=10.3346/jkms.2020.35.e311,2020-10-04,2024-03-01,Verified,noh_seroprevalence_2020,KOR
200824_Seoul_KoreaUniversity_>60,200824_Seoul_KoreaUniversity,"Seroprevalence of Anti-SARS-CoV-2 Antibodies among Outpatients in Southwestern Seoul, Korea",2020-08-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,Seoul,The serum samples were used anonymously except for the information about sex and age. Serum samples from patients of different ages were collected to investigate the age-stratified seroprevalence of SARS-CoV-2.,Samples from patients with laboratory-confirmed COVID-19 were excluded from this study.,2020-05-25,2020-05-29,Residual sera,All,Seniors (65+ years),60.0,,Age,>60 years,246,0.0,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Ji Noh,Korea University,Not Unity-Aligned,https://jkms.org/DOIx.php?id=10.3346/jkms.2020.35.e311,2020-10-04,2024-03-01,Verified,noh_seroprevalence_2020,KOR
200824_Seoul_KoreaUniversity_40-49,200824_Seoul_KoreaUniversity,"Seroprevalence of Anti-SARS-CoV-2 Antibodies among Outpatients in Southwestern Seoul, Korea",2020-08-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,Seoul,The serum samples were used anonymously except for the information about sex and age. Serum samples from patients of different ages were collected to investigate the age-stratified seroprevalence of SARS-CoV-2.,Samples from patients with laboratory-confirmed COVID-19 were excluded from this study.,2020-05-25,2020-05-29,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49 years,254,0.0,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Ji Noh,Korea University,Not Unity-Aligned,https://jkms.org/DOIx.php?id=10.3346/jkms.2020.35.e311,2020-10-04,2024-03-01,Verified,noh_seroprevalence_2020,KOR
200824_Seoul_KoreaUniversity_50-59,200824_Seoul_KoreaUniversity,"Seroprevalence of Anti-SARS-CoV-2 Antibodies among Outpatients in Southwestern Seoul, Korea",2020-08-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,Seoul,The serum samples were used anonymously except for the information about sex and age. Serum samples from patients of different ages were collected to investigate the age-stratified seroprevalence of SARS-CoV-2.,Samples from patients with laboratory-confirmed COVID-19 were excluded from this study.,2020-05-25,2020-05-29,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59 years,226,0.0,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Ji Noh,Korea University,Not Unity-Aligned,https://jkms.org/DOIx.php?id=10.3346/jkms.2020.35.e311,2020-10-04,2024-03-01,Verified,noh_seroprevalence_2020,KOR
200824_Seoul_KoreaUniversity_20-29,200824_Seoul_KoreaUniversity,"Seroprevalence of Anti-SARS-CoV-2 Antibodies among Outpatients in Southwestern Seoul, Korea",2020-08-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,Seoul,The serum samples were used anonymously except for the information about sex and age. Serum samples from patients of different ages were collected to investigate the age-stratified seroprevalence of SARS-CoV-2.,Samples from patients with laboratory-confirmed COVID-19 were excluded from this study.,2020-05-25,2020-05-29,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29 years,258,0.0,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Ji Noh,Korea University,Not Unity-Aligned,https://jkms.org/DOIx.php?id=10.3346/jkms.2020.35.e311,2020-10-04,2024-03-01,Verified,noh_seroprevalence_2020,KOR
201120_SouthKorea_SungkyunkwanUniversitySchoolofMedicine_DesHCW_ELISA1,201120_SouthKorea_SungkyunkwanUniversitySchoolofMedicine_DesHCW,Serologic Evaluation of Healthcare Workers Caring for COVID-19 Patients in the Republic of Korea.,2020-11-20,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Republic of Korea,,,"Healthcare workers who were designated to COVID-19 patient care were recruited to participate in this study, and those who agreed to undergo serum sampling were enrolled. 

Healthcare workers from six university hospitals: Samsung Medical Center (SMC), Chonnam National University Hospital (CNUH), Chonnam National University Bitgoeul Hospital (CNUBH), Kyungpook National University Hospital (KNUH), Keimyung University Dongsan Hospital (KUDH), and Keimyung University Daegu Dongsan Hospital (KUDDH). KNUH, KUDH, and KUDDH are located in Daegu city.",,2020-04-26,2020-05-09,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Follow up ELISA total Ab,309,0.0032,,,True,,,,True,Convenience,PCL COVID-19 Total Ab EIA test,Vitrex Medical,ELISA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9820000000000001,1.0,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Jae Hoon Ko,Sungkyunkwan University School of Medicine,Not Unity-Aligned,https://dx.doi.org/10.3389/fmicb.2020.587613,2021-02-24,2024-03-01,Verified,ko_serologic_2020,KOR
201120_SouthKorea_SungkyunkwanUniversitySchoolofMedicine_NonDesHCW_ELISA1,201120_SouthKorea_SungkyunkwanUniversitySchoolofMedicine_NonDesHCW,Serologic Evaluation of Healthcare Workers Caring for COVID-19 Patients in the Republic of Korea.,2020-11-20,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Republic of Korea,,,Health care workers not designated to COVID-19 patients were eligible,,2020-04-26,2020-05-09,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Follow up ELISA total Ab,123,0.0,,,True,,,,True,Convenience,PCL COVID-19 Total Ab EIA test,Vitrex Medical,ELISA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9820000000000001,1.0,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Jae Hoon Ko,Sungkyunkwan University School of Medicine,Not Unity-Aligned,https://dx.doi.org/10.3389/fmicb.2020.587613,2021-02-24,2024-03-01,Verified,ko_serologic_2020,KOR
201123_Korea_KoreaDiseaseControlAndPreventionAgency_military,201123_Korea_KoreaDiseaseControlAndPreventionAgency_Military,COVID-19 Serology Tests Still Show Low Antibody Rate of 0.07%,2020-11-23,News and Media,National,Cross-sectional survey ,Republic of Korea,,,Men enlisted for military service,,2020-08-15,2020-10-15,Essential non-healthcare workers,Male,Adults (18-64 years),18.0,,Primary Estimate,,6900,0.0036,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,KBS World,Korea Disease Control and Prevention Agency,Not Unity-Aligned,https://world.kbs.co.kr/service/news_view.htm?lang=e&Seq_Code=157801,2021-03-07,2022-07-16,Verified,noauthor_covid-19_nodate-1,KOR
201123_Korea_KoreaDiseaseControlAndPreventionAgency_genpop,201123_Korea_KoreaDiseaseControlAndPreventionAgency_genpop,COVID-19 Serology Tests Still Show Low Antibody Rate of 0.07%,2020-11-23,News and Media,National,Cross-sectional survey ,Republic of Korea,,,The general population (not specified),,2020-08-15,2020-10-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,1379,0.0022,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,KBS World,Korea Disease Control and Prevention Agency,Not Unity-Aligned,https://world.kbs.co.kr/service/news_view.htm?lang=e&Seq_Code=157801,2021-03-07,2022-07-16,Verified,noauthor_covid-19_nodate-1,KOR
210424_SouthKorea_KoreaAssociationofHealthPromotion_Primary,210424_SouthKorea_KoreaAssociationofHealthPromotion,"Nationwide
  seroprevalence of antibodies to SARS-CoV-2 in asymptomatic population in
  South Korea: a cross-sectional study",2021-04-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Republic of Korea,,"Seoul (Dongbu), Chuncheon, Chungju, Daegu (Dong-gu), Daegu (Buk-gu), Ulsan, Busan, Changwon, Kwangju, Jeonju, Daejeon, Suwon, Seoul (Kangnam), Incheon, Seoul (Seobu), Jeju ","We randomly selected subjects from 
health examinees (>18 years) who underwent health check-ups at 16 health promotion centres using stratification by region and sex. 
Required subjects were allocated to health promotion 
centres proportional to regional population size where 
centres were located and stratified randomisation underwent with regard to sex.","Subjects who had COVID-19-related symptoms or 
who had a history of return from abroad or contact 
with confirmed COVID-19 patients within 2 weeks were 
excluded",2020-09-24,2020-12-09,Residual sera,All,Multiple groups,18.0,86.0,Primary Estimate,,4085,0.0039000000000000003,0.002,0.0058,True,,,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Eun Hee Nah,Korea Association of Health Promotion,Unity-Aligned,https://bmjopen.bmj.com/content/11/4/e049837.abstract,2021-05-17,2024-03-01,Unverified,nah_nationwide_2021,KOR
210424_SouthKorea_KoreaAssociationofHealthPromotion_Males,210424_SouthKorea_KoreaAssociationofHealthPromotion,"Nationwide
  seroprevalence of antibodies to SARS-CoV-2 in asymptomatic population in
  South Korea: a cross-sectional study",2021-04-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Republic of Korea,,"Seoul (Dongbu), Chuncheon, Chungju, Daegu (Dong-gu), Daegu (Buk-gu), Ulsan, Busan, Changwon, Kwangju, Jeonju, Daejeon, Suwon, Seoul (Kangnam), Incheon, Seoul (Seobu), Jeju ","We randomly selected subjects from 
health examinees (>18 years) who underwent health check-ups at 16 health promotion centres using stratification by region and sex. 
Required subjects were allocated to health promotion 
centres proportional to regional population size where 
centres were located and stratified randomisation underwent with regard to sex.","Subjects who had COVID-19-related symptoms or 
who had a history of return from abroad or contact 
with confirmed COVID-19 patients within 2 weeks were 
excluded",2020-09-24,2020-12-09,Residual sera,Male,Multiple groups,18.0,,Sex/Gender,,2014,0.003,0.0006,0.0054,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Eun Hee Nah,Korea Association of Health Promotion,Unity-Aligned,https://bmjopen.bmj.com/content/11/4/e049837.abstract,2021-08-25,2024-03-01,Unverified,nah_nationwide_2021,KOR
210424_SouthKorea_KoreaAssociationofHealthPromotion_Females,210424_SouthKorea_KoreaAssociationofHealthPromotion,"Nationwide
  seroprevalence of antibodies to SARS-CoV-2 in asymptomatic population in
  South Korea: a cross-sectional study",2021-04-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Republic of Korea,,"Seoul (Dongbu), Chuncheon, Chungju, Daegu (Dong-gu), Daegu (Buk-gu), Ulsan, Busan, Changwon, Kwangju, Jeonju, Daejeon, Suwon, Seoul (Kangnam), Incheon, Seoul (Seobu), Jeju ","We randomly selected subjects from 
health examinees (>18 years) who underwent health check-ups at 16 health promotion centres using stratification by region and sex. 
Required subjects were allocated to health promotion 
centres proportional to regional population size where 
centres were located and stratified randomisation underwent with regard to sex.","Subjects who had COVID-19-related symptoms or 
who had a history of return from abroad or contact 
with confirmed COVID-19 patients within 2 weeks were 
excluded",2020-09-24,2020-12-09,Residual sera,Female,Multiple groups,18.0,,Sex/Gender,,2071,0.0048,0.0018,0.0078000000000000005,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Eun Hee Nah,Korea Association of Health Promotion,Unity-Aligned,https://bmjopen.bmj.com/content/11/4/e049837.abstract,2021-08-25,2024-03-01,Unverified,nah_nationwide_2021,KOR
210428_ChungbukProvince_ChungbukNationalUniversity_NonEpicenter_OverallAdj,210428_ChungbukProvince_ChungbukNationalUniversity_NonEpicenter,"Differences
  in seroprevalence between epicenter and non-epicenter areas of the COVID-19
  outbreak in South Korea",2021-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,Chungbuk Province,,"Excess outpatient sera were randomly selected daily (around 
130 serum samples per day) from Chungbuk National University Hospital (CBNUH) in Chungbuk Province, between May 1, 2020 and July 17, 2020.",,2020-05-01,2020-07-17,Residual sera,All,Multiple groups,,,Primary Estimate,,3981,0.0091,0.0069,0.0113,True,,True,,,Simplified probability,Author designed (IFA) - Unknown,,IFA,Serum,IgG,,,0.995,1.0,['Low'],No,Yes,Yes,No,Unclear,Unclear,Yes,Yes,,Hye Won Jeong,Chungbuk National University,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079228/,2021-05-17,2022-07-16,Verified,jeong_differences_2021,KOR
210428_ChungbukProvince_ChungbukNationalUniversity_NonEpicenter_0-9,210428_ChungbukProvince_ChungbukNationalUniversity_NonEpicenter,"Differences
  in seroprevalence between epicenter and non-epicenter areas of the COVID-19
  outbreak in South Korea",2021-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,Chungbuk Province,,"Excess outpatient sera were randomly selected daily (around 
130 serum samples per day) from Chungbuk National University Hospital (CBNUH) in Chungbuk Province, between May 1, 2020 and July 17, 2020.",,2020-05-01,2020-07-17,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,0-9,230,0.0043,0.0,0.0129,,,,,,Simplified probability,Author designed (IFA) - Unknown,,IFA,Serum,IgG,,,0.995,1.0,['Low'],No,Yes,Yes,No,Unclear,Unclear,Yes,Yes,,Hye Won Jeong,Chungbuk National University,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079228/,2021-09-08,2022-07-16,Verified,jeong_differences_2021,KOR
210428_ChungbukProvince_ChungbukNationalUniversity_NonEpicenter_70-79,210428_ChungbukProvince_ChungbukNationalUniversity_NonEpicenter,"Differences
  in seroprevalence between epicenter and non-epicenter areas of the COVID-19
  outbreak in South Korea",2021-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,Chungbuk Province,,"Excess outpatient sera were randomly selected daily (around 
130 serum samples per day) from Chungbuk National University Hospital (CBNUH) in Chungbuk Province, between May 1, 2020 and July 17, 2020.",,2020-05-01,2020-07-17,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,526,0.0076,0.0002,0.015,,,,,,Simplified probability,Author designed (IFA) - Unknown,,IFA,Serum,IgG,,,0.995,1.0,['Low'],No,Yes,Yes,No,Unclear,Unclear,Yes,Yes,,Hye Won Jeong,Chungbuk National University,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079228/,2021-09-08,2022-07-16,Verified,jeong_differences_2021,KOR
210428_ChungbukProvince_ChungbukNationalUniversity_NonEpicenter_60-69,210428_ChungbukProvince_ChungbukNationalUniversity_NonEpicenter,"Differences
  in seroprevalence between epicenter and non-epicenter areas of the COVID-19
  outbreak in South Korea",2021-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,Chungbuk Province,,"Excess outpatient sera were randomly selected daily (around 
130 serum samples per day) from Chungbuk National University Hospital (CBNUH) in Chungbuk Province, between May 1, 2020 and July 17, 2020.",,2020-05-01,2020-07-17,Residual sera,All,Multiple groups,60.0,69.0,Age,60-69,908,0.0055000000000000005,0.0007000000000000001,0.0103,,,,,,Simplified probability,Author designed (IFA) - Unknown,,IFA,Serum,IgG,,,0.995,1.0,['Low'],No,Yes,Yes,No,Unclear,Unclear,Yes,Yes,,Hye Won Jeong,Chungbuk National University,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079228/,2021-09-08,2022-07-16,Verified,jeong_differences_2021,KOR
210428_ChungbukProvince_ChungbukNationalUniversity_NonEpicenter_>80,210428_ChungbukProvince_ChungbukNationalUniversity_NonEpicenter,"Differences
  in seroprevalence between epicenter and non-epicenter areas of the COVID-19
  outbreak in South Korea",2021-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,Chungbuk Province,,"Excess outpatient sera were randomly selected daily (around 
130 serum samples per day) from Chungbuk National University Hospital (CBNUH) in Chungbuk Province, between May 1, 2020 and July 17, 2020.",,2020-05-01,2020-07-17,Residual sera,All,Seniors (65+ years),80.0,,Age,>80,238,0.0042,0.0,0.0124,,,,,,Simplified probability,Author designed (IFA) - Unknown,,IFA,Serum,IgG,,,0.995,1.0,['Low'],No,Yes,Yes,No,Unclear,Unclear,Yes,Yes,,Hye Won Jeong,Chungbuk National University,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079228/,2021-09-08,2022-07-16,Verified,jeong_differences_2021,KOR
210428_ChungbukProvince_ChungbukNationalUniversity_NonEpicenter_50-59,210428_ChungbukProvince_ChungbukNationalUniversity_NonEpicenter,"Differences
  in seroprevalence between epicenter and non-epicenter areas of the COVID-19
  outbreak in South Korea",2021-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,Chungbuk Province,,"Excess outpatient sera were randomly selected daily (around 
130 serum samples per day) from Chungbuk National University Hospital (CBNUH) in Chungbuk Province, between May 1, 2020 and July 17, 2020.",,2020-05-01,2020-07-17,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,874,0.0069,0.0014000000000000002,0.0123,,,,,,Simplified probability,Author designed (IFA) - Unknown,,IFA,Serum,IgG,,,0.995,1.0,['Low'],No,Yes,Yes,No,Unclear,Unclear,Yes,Yes,,Hye Won Jeong,Chungbuk National University,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079228/,2021-09-08,2022-07-16,Verified,jeong_differences_2021,KOR
210428_ChungbukProvince_ChungbukNationalUniversity_NonEpicenter_30-39,210428_ChungbukProvince_ChungbukNationalUniversity_NonEpicenter,"Differences
  in seroprevalence between epicenter and non-epicenter areas of the COVID-19
  outbreak in South Korea",2021-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,Chungbuk Province,,"Excess outpatient sera were randomly selected daily (around 
130 serum samples per day) from Chungbuk National University Hospital (CBNUH) in Chungbuk Province, between May 1, 2020 and July 17, 2020.",,2020-05-01,2020-07-17,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,306,0.0098,0.0,0.020800000000000003,,,,,,Simplified probability,Author designed (IFA) - Unknown,,IFA,Serum,IgG,,,0.995,1.0,['Low'],No,Yes,Yes,No,Unclear,Unclear,Yes,Yes,,Hye Won Jeong,Chungbuk National University,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079228/,2021-09-08,2022-07-16,Verified,jeong_differences_2021,KOR
210428_ChungbukProvince_ChungbukNationalUniversity_NonEpicenter_20-29,210428_ChungbukProvince_ChungbukNationalUniversity_NonEpicenter,"Differences
  in seroprevalence between epicenter and non-epicenter areas of the COVID-19
  outbreak in South Korea",2021-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,Chungbuk Province,,"Excess outpatient sera were randomly selected daily (around 
130 serum samples per day) from Chungbuk National University Hospital (CBNUH) in Chungbuk Province, between May 1, 2020 and July 17, 2020.",,2020-05-01,2020-07-17,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29,263,0.019,0.0025,0.0355,,,,,,Simplified probability,Author designed (IFA) - Unknown,,IFA,Serum,IgG,,,0.995,1.0,['Low'],No,Yes,Yes,No,Unclear,Unclear,Yes,Yes,,Hye Won Jeong,Chungbuk National University,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079228/,2021-09-08,2022-07-16,Verified,jeong_differences_2021,KOR
210428_ChungbukProvince_ChungbukNationalUniversity_NonEpicenter_OverallUnadj,210428_ChungbukProvince_ChungbukNationalUniversity_NonEpicenter,"Differences
  in seroprevalence between epicenter and non-epicenter areas of the COVID-19
  outbreak in South Korea",2021-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,Chungbuk Province,,"Excess outpatient sera were randomly selected daily (around 
130 serum samples per day) from Chungbuk National University Hospital (CBNUH) in Chungbuk Province, between May 1, 2020 and July 17, 2020.",,2020-05-01,2020-07-17,Residual sera,All,Multiple groups,,,Analysis,,3981,0.0083,0.0055000000000000005,0.0111,,,,,True,Simplified probability,Author designed (IFA) - Unknown,,IFA,Serum,IgG,,,0.995,1.0,['Low'],No,Yes,Yes,No,Unclear,Unclear,Yes,Yes,,Hye Won Jeong,Chungbuk National University,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079228/,2021-09-08,2022-07-16,Verified,jeong_differences_2021,KOR
210428_ChungbukProvince_ChungbukNationalUniversity_NonEpicenter_40-49,210428_ChungbukProvince_ChungbukNationalUniversity_NonEpicenter,"Differences
  in seroprevalence between epicenter and non-epicenter areas of the COVID-19
  outbreak in South Korea",2021-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,Chungbuk Province,,"Excess outpatient sera were randomly selected daily (around 
130 serum samples per day) from Chungbuk National University Hospital (CBNUH) in Chungbuk Province, between May 1, 2020 and July 17, 2020.",,2020-05-01,2020-07-17,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,491,0.0122,0.0025,0.0219,,,,,,Simplified probability,Author designed (IFA) - Unknown,,IFA,Serum,IgG,,,0.995,1.0,['Low'],No,Yes,Yes,No,Unclear,Unclear,Yes,Yes,,Hye Won Jeong,Chungbuk National University,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079228/,2021-09-08,2022-07-16,Verified,jeong_differences_2021,KOR
210428_ChungbukProvince_ChungbukNationalUniversity_NonEpicenter_10-19,210428_ChungbukProvince_ChungbukNationalUniversity_NonEpicenter,"Differences
  in seroprevalence between epicenter and non-epicenter areas of the COVID-19
  outbreak in South Korea",2021-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,Chungbuk Province,,"Excess outpatient sera were randomly selected daily (around 
130 serum samples per day) from Chungbuk National University Hospital (CBNUH) in Chungbuk Province, between May 1, 2020 and July 17, 2020.",,2020-05-01,2020-07-17,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,145,0.0138,0.0,0.032799999999999996,,,,,,Simplified probability,Author designed (IFA) - Unknown,,IFA,Serum,IgG,,,0.995,1.0,['Low'],No,Yes,Yes,No,Unclear,Unclear,Yes,Yes,,Hye Won Jeong,Chungbuk National University,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079228/,2021-09-08,2022-07-16,Verified,jeong_differences_2021,KOR
210428_DaeguCity_ChungbukNationalUniversity_Epicenter_OverallAdj,210428_DaeguCity_ChungbukNationalUniversity_Epicenter,"Differences
  in seroprevalence between epicenter and non-epicenter areas of the COVID-19
  outbreak in South Korea",2021-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,North Gyeongsang Province,Daegu,"Excess outpatient sera were randomly selected daily (around 
130 serum samples per day) from Kyungpook 
National University Hospital (KNUH) in Daegu City between May 1, 2020 and July 17, 2020.",,2020-05-01,2020-07-17,Residual sera,All,Multiple groups,,,Primary Estimate,,3268,0.012700000000000001,0.0101,0.015300000000000001,True,,True,,,Simplified probability,Author designed (IFA) - Unknown,,IFA,Serum,IgG,,Validated by developers,0.995,1.0,['Low'],No,Yes,Yes,No,Unclear,Unclear,Yes,Yes,,Hye Won Jeong,Chungbuk National University,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079228/,2021-05-17,2022-07-16,Verified,jeong_differences_2021,KOR
210428_DaeguCity_ChungbukNationalUniversity_Epicenter_OverallUnadj,210428_DaeguCity_ChungbukNationalUniversity_Epicenter,"Differences
  in seroprevalence between epicenter and non-epicenter areas of the COVID-19
  outbreak in South Korea",2021-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,North Gyeongsang Province,Daegu,"Excess outpatient sera were randomly selected daily (around 
130 serum samples per day) from Kyungpook 
National University Hospital (KNUH) in Daegu City between May 1, 2020 and July 17, 2020.",,2020-05-01,2020-07-17,Residual sera,All,Multiple groups,,,Analysis,,3268,0.0125,0.0087,0.016399999999999998,,,,,True,Simplified probability,Author designed (IFA) - Unknown,,IFA,Serum,IgG,,Validated by developers,0.995,1.0,['Low'],No,Yes,Yes,No,Unclear,Unclear,Yes,Yes,,Hye Won Jeong,Chungbuk National University,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079228/,2021-09-08,2022-07-16,Verified,jeong_differences_2021,KOR
210428_DaeguCity_ChungbukNationalUniversity_Epicenter_>80,210428_DaeguCity_ChungbukNationalUniversity_Epicenter,"Differences
  in seroprevalence between epicenter and non-epicenter areas of the COVID-19
  outbreak in South Korea",2021-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,North Gyeongsang Province,Daegu,"Excess outpatient sera were randomly selected daily (around 
130 serum samples per day) from Kyungpook 
National University Hospital (KNUH) in Daegu City between May 1, 2020 and July 17, 2020.",,2020-05-01,2020-07-17,Residual sera,All,Seniors (65+ years),80.0,,Age,>80,226,0.0088,0.0,0.0211,,,,,,Simplified probability,Author designed (IFA) - Unknown,,IFA,Serum,IgG,,Validated by developers,0.995,1.0,['Low'],No,Yes,Yes,No,Unclear,Unclear,Yes,Yes,,Hye Won Jeong,Chungbuk National University,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079228/,2021-09-08,2022-07-16,Verified,jeong_differences_2021,KOR
210428_DaeguCity_ChungbukNationalUniversity_Epicenter_0-9,210428_DaeguCity_ChungbukNationalUniversity_Epicenter,"Differences
  in seroprevalence between epicenter and non-epicenter areas of the COVID-19
  outbreak in South Korea",2021-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,North Gyeongsang Province,Daegu,"Excess outpatient sera were randomly selected daily (around 
130 serum samples per day) from Kyungpook 
National University Hospital (KNUH) in Daegu City between May 1, 2020 and July 17, 2020.",,2020-05-01,2020-07-17,Residual sera,All,Children and Youth (0-17 years),0.0,9.0,Age,0-9,56,0.0,0.0,0.0,,,,,,Simplified probability,Author designed (IFA) - Unknown,,IFA,Serum,IgG,,Validated by developers,0.995,1.0,['Low'],No,Yes,Yes,No,Unclear,Unclear,Yes,Yes,,Hye Won Jeong,Chungbuk National University,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079228/,2021-09-08,2022-07-16,Verified,jeong_differences_2021,KOR
210428_DaeguCity_ChungbukNationalUniversity_Epicenter_50-59,210428_DaeguCity_ChungbukNationalUniversity_Epicenter,"Differences
  in seroprevalence between epicenter and non-epicenter areas of the COVID-19
  outbreak in South Korea",2021-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,North Gyeongsang Province,Daegu,"Excess outpatient sera were randomly selected daily (around 
130 serum samples per day) from Kyungpook 
National University Hospital (KNUH) in Daegu City between May 1, 2020 and July 17, 2020.",,2020-05-01,2020-07-17,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,732,0.013700000000000002,0.0053,0.0221,,,,,,Simplified probability,Author designed (IFA) - Unknown,,IFA,Serum,IgG,,Validated by developers,0.995,1.0,['Low'],No,Yes,Yes,No,Unclear,Unclear,Yes,Yes,,Hye Won Jeong,Chungbuk National University,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079228/,2021-09-08,2022-07-16,Verified,jeong_differences_2021,KOR
210428_DaeguCity_ChungbukNationalUniversity_Epicenter_30-39,210428_DaeguCity_ChungbukNationalUniversity_Epicenter,"Differences
  in seroprevalence between epicenter and non-epicenter areas of the COVID-19
  outbreak in South Korea",2021-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,North Gyeongsang Province,Daegu,"Excess outpatient sera were randomly selected daily (around 
130 serum samples per day) from Kyungpook 
National University Hospital (KNUH) in Daegu City between May 1, 2020 and July 17, 2020.",,2020-05-01,2020-07-17,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,187,0.016,0.0,0.034100000000000005,,,,,,Simplified probability,Author designed (IFA) - Unknown,,IFA,Serum,IgG,,Validated by developers,0.995,1.0,['Low'],No,Yes,Yes,No,Unclear,Unclear,Yes,Yes,,Hye Won Jeong,Chungbuk National University,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079228/,2021-09-08,2022-07-16,Verified,jeong_differences_2021,KOR
210428_DaeguCity_ChungbukNationalUniversity_Epicenter_70-79,210428_DaeguCity_ChungbukNationalUniversity_Epicenter,"Differences
  in seroprevalence between epicenter and non-epicenter areas of the COVID-19
  outbreak in South Korea",2021-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,North Gyeongsang Province,Daegu,"Excess outpatient sera were randomly selected daily (around 
130 serum samples per day) from Kyungpook 
National University Hospital (KNUH) in Daegu City between May 1, 2020 and July 17, 2020.",,2020-05-01,2020-07-17,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,622,0.0177,0.0073,0.027999999999999997,,,,,,Simplified probability,Author designed (IFA) - Unknown,,IFA,Serum,IgG,,Validated by developers,0.995,1.0,['Low'],No,Yes,Yes,No,Unclear,Unclear,Yes,Yes,,Hye Won Jeong,Chungbuk National University,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079228/,2021-09-08,2022-07-16,Verified,jeong_differences_2021,KOR
210428_DaeguCity_ChungbukNationalUniversity_Epicenter_60-69,210428_DaeguCity_ChungbukNationalUniversity_Epicenter,"Differences
  in seroprevalence between epicenter and non-epicenter areas of the COVID-19
  outbreak in South Korea",2021-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,North Gyeongsang Province,Daegu,"Excess outpatient sera were randomly selected daily (around 
130 serum samples per day) from Kyungpook 
National University Hospital (KNUH) in Daegu City between May 1, 2020 and July 17, 2020.",,2020-05-01,2020-07-17,Residual sera,All,Multiple groups,60.0,69.0,Age,60-69,855,0.0129,0.0053,0.0204,,,,,,Simplified probability,Author designed (IFA) - Unknown,,IFA,Serum,IgG,,Validated by developers,0.995,1.0,['Low'],No,Yes,Yes,No,Unclear,Unclear,Yes,Yes,,Hye Won Jeong,Chungbuk National University,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079228/,2021-09-08,2022-07-16,Verified,jeong_differences_2021,KOR
210428_DaeguCity_ChungbukNationalUniversity_Epicenter_10-19,210428_DaeguCity_ChungbukNationalUniversity_Epicenter,"Differences
  in seroprevalence between epicenter and non-epicenter areas of the COVID-19
  outbreak in South Korea",2021-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,North Gyeongsang Province,Daegu,"Excess outpatient sera were randomly selected daily (around 
130 serum samples per day) from Kyungpook 
National University Hospital (KNUH) in Daegu City between May 1, 2020 and July 17, 2020.",,2020-05-01,2020-07-17,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,58,0.0172,0.0,0.0507,,,,,,Simplified probability,Author designed (IFA) - Unknown,,IFA,Serum,IgG,,Validated by developers,0.995,1.0,['Low'],No,Yes,Yes,No,Unclear,Unclear,Yes,Yes,,Hye Won Jeong,Chungbuk National University,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079228/,2021-09-08,2022-07-16,Verified,jeong_differences_2021,KOR
210428_DaeguCity_ChungbukNationalUniversity_Epicenter_20-29,210428_DaeguCity_ChungbukNationalUniversity_Epicenter,"Differences
  in seroprevalence between epicenter and non-epicenter areas of the COVID-19
  outbreak in South Korea",2021-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,North Gyeongsang Province,Daegu,"Excess outpatient sera were randomly selected daily (around 
130 serum samples per day) from Kyungpook 
National University Hospital (KNUH) in Daegu City between May 1, 2020 and July 17, 2020.",,2020-05-01,2020-07-17,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29,158,0.012700000000000001,0.0,0.0301,,,,,,Simplified probability,Author designed (IFA) - Unknown,,IFA,Serum,IgG,,Validated by developers,0.995,1.0,['Low'],No,Yes,Yes,No,Unclear,Unclear,Yes,Yes,,Hye Won Jeong,Chungbuk National University,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079228/,2021-09-08,2022-07-16,Verified,jeong_differences_2021,KOR
210428_DaeguCity_ChungbukNationalUniversity_Epicenter_40-49,210428_DaeguCity_ChungbukNationalUniversity_Epicenter,"Differences
  in seroprevalence between epicenter and non-epicenter areas of the COVID-19
  outbreak in South Korea",2021-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,North Gyeongsang Province,Daegu,"Excess outpatient sera were randomly selected daily (around 
130 serum samples per day) from Kyungpook 
National University Hospital (KNUH) in Daegu City between May 1, 2020 and July 17, 2020.",,2020-05-01,2020-07-17,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,374,0.0027,0.0,0.0079,,,,,,Simplified probability,Author designed (IFA) - Unknown,,IFA,Serum,IgG,,Validated by developers,0.995,1.0,['Low'],No,Yes,Yes,No,Unclear,Unclear,Yes,Yes,,Hye Won Jeong,Chungbuk National University,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079228/,2021-09-08,2022-07-16,Verified,jeong_differences_2021,KOR
210524_SouthKorea_KoreaDiseaseControlAndPreventionAgency_July1_overall,210524_SouthKorea_KoreaDiseaseControlAndPreventionAgency_July1,Seroprevalence of SARS-CoV-2 antibodies in South Korea.,2021-05-24,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Republic of Korea,,,Individuals who participated in the National Health and Nutrition Examination Survey,,2020-04-21,2020-06-16,Residual sera,All,Multiple groups,,,Primary Estimate,,1500,0.0,,,True,,,,True,Convenience,Author designed (Neutralization Assay),,Neutralization,Serum,Neutralizing,,Validated by independent authors/third party/non-developers,0.9329999999999999,0.971,['High'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Kwangmin Lee,Korea Disease Control and Prevention Agency,Unity-Aligned,https://dx.doi.org/10.1007/s42952-021-00131-7,2021-06-07,2022-07-16,Verified,lee_seroprevalence_2021,KOR
210524_SouthKorea_KoreaDiseaseControlAndPreventionAgency_November3_TestAdj,210524_SouthKorea_KoreaDiseaseControlAndPreventionAgency_November3,Seroprevalence of SARS-CoV-2 antibodies in South Korea.,2021-05-24,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Republic of Korea,,,Individuals who participated in the National Health and Nutrition Examination Survey,,2020-08-14,2020-10-31,Residual sera,All,Multiple groups,,,Primary Estimate,,1379,0.0062,,,True,True,,,,Convenience,Author designed (Neutralization Assay),,Neutralization,Serum,Neutralizing,,Validated by independent authors/third party/non-developers,0.9329999999999999,0.971,['High'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Kwangmin Lee,Korea Disease Control and Prevention Agency,Unity-Aligned,https://dx.doi.org/10.1007/s42952-021-00131-7,2021-06-07,2022-07-16,Verified,lee_seroprevalence_2021,KOR
210524_SouthKorea_KoreaDiseaseControlAndPreventionAgency_November3_Unadj,210524_SouthKorea_KoreaDiseaseControlAndPreventionAgency_November3,Seroprevalence of SARS-CoV-2 antibodies in South Korea.,2021-05-24,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Republic of Korea,,,Individuals who participated in the National Health and Nutrition Examination Survey,,2020-08-14,2020-10-31,Residual sera,All,Multiple groups,,,Analysis,,1379,0.0022,,,,,,,True,Convenience,Author designed (Neutralization Assay),,Neutralization,Serum,Neutralizing,,Validated by independent authors/third party/non-developers,0.9329999999999999,0.971,['High'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Kwangmin Lee,Korea Disease Control and Prevention Agency,Unity-Aligned,https://dx.doi.org/10.1007/s42952-021-00131-7,2021-06-07,2022-07-16,Verified,lee_seroprevalence_2021,KOR
210524_SouthKorea_KoreaDiseaseControlAndPreventionAgency_September2,210524_SouthKorea_KoreaDiseaseControlAndPreventionAgency_September2,Seroprevalence of SARS-CoV-2 antibodies in South Korea.,2021-05-24,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Republic of Korea,,,Individuals who participated in the National Health and Nutrition Examination Survey,,2020-06-10,2020-08-13,Residual sera,All,Multiple groups,,,Primary Estimate,,1440,0.0007000000000000001,,,True,,,,True,Convenience,Author designed (Neutralization Assay),,Neutralization,Serum,Neutralizing,,Validated by independent authors/third party/non-developers,0.9329999999999999,0.971,['High'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Kwangmin Lee,Korea Disease Control and Prevention Agency,Unity-Aligned,https://dx.doi.org/10.1007/s42952-021-00131-7,2021-06-07,2022-07-16,Verified,lee_seroprevalence_2021,KOR
210630_Hwaseong_DongtanSacredHeartHospital,210630_Hwaseong_DongtanSacredHeartHospital,Comparing Results of Five SARS-CoV-2 Antibody Assays Before and After the First Dose of ChAdOx1 nCoV-19 Vaccine among Health Care Workers.,2021-06-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,Gyeonggi,Hwaseong,"HCWs from two university hospitals >18 years of age, recieving AZ vaccines between March 4 and 12, 2021. ",Participants who recieved Pfizer-BioNTech or other vaccines aside from AstraZeneca,2021-03-04,2021-03-12,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Neutralizing assay - GenScript,298,0.0,,,True,,,,True,Convenience,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,GenScript,Neutralization,Serum,"['IgG', 'IgM', 'Neutralizing']",Spike,Validated by independent authors/third party/non-developers,0.9540000000000001,0.908,['High'],,No,No,Yes,,Yes,Yes,No,,Seri Jeong,Dongtan Sacred Heart Hospital,Not Unity-Aligned,https://dx.doi.org/10.1128/JCM.01105-21,2021-07-07,2024-03-01,Unverified,jeong_comparing_2021,KOR
211019_Daegu_KyungpookNationalUniversity_Overall,211019_Daegu_KyungpookNationalUniversity,"Prevalence of SARS-CoV-2 Antibody in 2,935 Healthcare Workers at 6 Major Hospitals, Daegu, Korea.",2021-10-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,Daegu,"Healthcare workers at 6 major hospitals in Daegu (Kyungpook National University Hospital, Daegu Fatima Hospital, Yeungnam University Medical Center, Keimyung University Dongsan Medical Center, Kyungpook National University Chilgok Hospital and Daegu Catholic University Medical Center), Korea",,2021-01-18,2021-02-26,Health care workers and caregivers,All,Multiple groups,20.0,,Primary Estimate,,2935,0.0040999999999999995,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Not reported/ Unable to specify,Abbott Architect SARS-CoV-2 IgG,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit","Roche Diagnostics,NA,Abbott Laboratories,GenScript",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Yu Kim,Kyungpook National University,Not Unity-Aligned,https://dx.doi.org/10.3346/jkms.2021.36.e294,2021-11-16,2024-03-01,Unverified,kim_prevalence_2021,KOR
211019_Daegu_KyungpookNationalUniversity_Age70+,211019_Daegu_KyungpookNationalUniversity,"Prevalence of SARS-CoV-2 Antibody in 2,935 Healthcare Workers at 6 Major Hospitals, Daegu, Korea.",2021-10-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,Daegu,"Healthcare workers at 6 major hospitals in Daegu (Kyungpook National University Hospital, Daegu Fatima Hospital, Yeungnam University Medical Center, Keimyung University Dongsan Medical Center, Kyungpook National University Chilgok Hospital and Daegu Catholic University Medical Center), Korea",,2021-01-18,2021-02-26,Health care workers and caregivers,All,Seniors (65+ years),70.0,,Age,,2,0.0,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Not reported/ Unable to specify,Abbott Architect SARS-CoV-2 IgG,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit","Roche Diagnostics,NA,Abbott Laboratories,GenScript",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Yu Kim,Kyungpook National University,Not Unity-Aligned,https://dx.doi.org/10.3346/jkms.2021.36.e294,2021-11-16,2024-03-01,Unverified,kim_prevalence_2021,KOR
211019_Daegu_KyungpookNationalUniversity_Age50-59,211019_Daegu_KyungpookNationalUniversity,"Prevalence of SARS-CoV-2 Antibody in 2,935 Healthcare Workers at 6 Major Hospitals, Daegu, Korea.",2021-10-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,Daegu,"Healthcare workers at 6 major hospitals in Daegu (Kyungpook National University Hospital, Daegu Fatima Hospital, Yeungnam University Medical Center, Keimyung University Dongsan Medical Center, Kyungpook National University Chilgok Hospital and Daegu Catholic University Medical Center), Korea",,2021-01-18,2021-02-26,Health care workers and caregivers,All,Adults (18-64 years),50.0,59.0,Age,,541,0.0055000000000000005,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Not reported/ Unable to specify,Abbott Architect SARS-CoV-2 IgG,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit","Roche Diagnostics,NA,Abbott Laboratories,GenScript",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Yu Kim,Kyungpook National University,Not Unity-Aligned,https://dx.doi.org/10.3346/jkms.2021.36.e294,2021-11-16,2024-03-01,Unverified,kim_prevalence_2021,KOR
211019_Daegu_KyungpookNationalUniversity_Age40-49,211019_Daegu_KyungpookNationalUniversity,"Prevalence of SARS-CoV-2 Antibody in 2,935 Healthcare Workers at 6 Major Hospitals, Daegu, Korea.",2021-10-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,Daegu,"Healthcare workers at 6 major hospitals in Daegu (Kyungpook National University Hospital, Daegu Fatima Hospital, Yeungnam University Medical Center, Keimyung University Dongsan Medical Center, Kyungpook National University Chilgok Hospital and Daegu Catholic University Medical Center), Korea",,2021-01-18,2021-02-26,Health care workers and caregivers,All,Adults (18-64 years),40.0,49.0,Age,,561,0.0036,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Not reported/ Unable to specify,Abbott Architect SARS-CoV-2 IgG,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit","Roche Diagnostics,NA,Abbott Laboratories,GenScript",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Yu Kim,Kyungpook National University,Not Unity-Aligned,https://dx.doi.org/10.3346/jkms.2021.36.e294,2021-11-16,2024-03-01,Unverified,kim_prevalence_2021,KOR
211019_Daegu_KyungpookNationalUniversity_Age60-69,211019_Daegu_KyungpookNationalUniversity,"Prevalence of SARS-CoV-2 Antibody in 2,935 Healthcare Workers at 6 Major Hospitals, Daegu, Korea.",2021-10-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,Daegu,"Healthcare workers at 6 major hospitals in Daegu (Kyungpook National University Hospital, Daegu Fatima Hospital, Yeungnam University Medical Center, Keimyung University Dongsan Medical Center, Kyungpook National University Chilgok Hospital and Daegu Catholic University Medical Center), Korea",,2021-01-18,2021-02-26,Health care workers and caregivers,All,Seniors (65+ years),60.0,69.0,Age,,145,0.0069,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Not reported/ Unable to specify,Abbott Architect SARS-CoV-2 IgG,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit","Roche Diagnostics,NA,Abbott Laboratories,GenScript",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Yu Kim,Kyungpook National University,Not Unity-Aligned,https://dx.doi.org/10.3346/jkms.2021.36.e294,2021-11-16,2024-03-01,Unverified,kim_prevalence_2021,KOR
211019_Daegu_KyungpookNationalUniversity_Age30-39,211019_Daegu_KyungpookNationalUniversity,"Prevalence of SARS-CoV-2 Antibody in 2,935 Healthcare Workers at 6 Major Hospitals, Daegu, Korea.",2021-10-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,Daegu,"Healthcare workers at 6 major hospitals in Daegu (Kyungpook National University Hospital, Daegu Fatima Hospital, Yeungnam University Medical Center, Keimyung University Dongsan Medical Center, Kyungpook National University Chilgok Hospital and Daegu Catholic University Medical Center), Korea",,2021-01-18,2021-02-26,Health care workers and caregivers,All,Adults (18-64 years),30.0,39.0,Age,,838,0.0024,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Not reported/ Unable to specify,Abbott Architect SARS-CoV-2 IgG,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit","Roche Diagnostics,NA,Abbott Laboratories,GenScript",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Yu Kim,Kyungpook National University,Not Unity-Aligned,https://dx.doi.org/10.3346/jkms.2021.36.e294,2021-11-16,2024-03-01,Unverified,kim_prevalence_2021,KOR
211019_Daegu_KyungpookNationalUniversity_Age20-29,211019_Daegu_KyungpookNationalUniversity,"Prevalence of SARS-CoV-2 Antibody in 2,935 Healthcare Workers at 6 Major Hospitals, Daegu, Korea.",2021-10-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,Daegu,"Healthcare workers at 6 major hospitals in Daegu (Kyungpook National University Hospital, Daegu Fatima Hospital, Yeungnam University Medical Center, Keimyung University Dongsan Medical Center, Kyungpook National University Chilgok Hospital and Daegu Catholic University Medical Center), Korea",,2021-01-18,2021-02-26,Health care workers and caregivers,All,Adults (18-64 years),20.0,29.0,Age,20-29,826,0.0048,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Not reported/ Unable to specify,Abbott Architect SARS-CoV-2 IgG,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit","Roche Diagnostics,NA,Abbott Laboratories,GenScript",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Yu Kim,Kyungpook National University,Not Unity-Aligned,https://dx.doi.org/10.3346/jkms.2021.36.e294,2021-11-16,2024-03-01,Unverified,kim_prevalence_2021,KOR
221230_Gyeonggi_HallymUniversityCollegeofMedicine_Overall,221230_Gyeonggi_HallymUniversityCollegeofMedicine,Seven-Month Analysis of Five SARS-CoV-2 Antibody Assay Results after ChAdOx1 nCoV-19 Vaccination: Significant Decrease in SARS-CoV-2 Antibody Titer.,2021-12-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Republic of Korea,Gyeonggi,,"The main inclusion criteria were as follows: older than 20 years of age, eligible for vaccination, and upon provision of informed consent, including the acknowledgement of the purpose and design of this study. ",,2021-03-01,2021-03-12,Health care workers and caregivers,All,Adults (18-64 years),22.0,60.0,Primary Estimate,Roche,228,0.0,,,True,,,,True,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,,,,['High'],,Unclear,No,Yes,,Yes,Yes,Yes,,Seri Jeong,Hallym University College of Medicine,Not Unity-Aligned,https://dx.doi.org/10.3390/diagnostics12010085,2022-02-02,2024-03-01,Unverified,jeong_seven-month_2022,KOR
220221_Korea_NationalInstituteofInfectiousDiseases_Overall,220221_Korea_NationalInstituteofInfectiousDiseases,Seroprevalence study of SARS-CoV-2 antibodies in community based on participants in the 2020 Korea National Health and Nutrition Examination Survey (KNHANES),2022-02-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Republic of Korea,,,"Participants of the Korea National Health and Nutrition Examination Survey (KNHANES) - a nationwide cross-sectional surveillance system that assesses the health and nutritional status of Koreans through health interviews, examinations, and nutrition surveys. KNHANES is conducted every year, and includes 10,000 individuals aged 1 year and above. However, the blood and urine samples, for the health examination are collected from participants aged 10 years and above.",,2020-04-24,2020-12-12,Residual sera,All,Multiple groups,,,Primary Estimate,,5284,0.0009,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,R-FIND COVID-19 ELISA,SGTi-flex COVID-19 IgM/IgG (manual),Author designed (Neutralization Assay)","Roche Diagnostics,Abbott Laboratories,Beckman Coulter,SG medical, Inc.,Sugentech, Inc.,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Ah-Ra Kim,National Institute of Infectious Diseases,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022028,2022-03-07,2024-03-01,Verified,kim_seroprevalence_2022,KOR
220221_Korea_NationalInstituteofInfectiousDiseases_Gangwon,220221_Korea_NationalInstituteofInfectiousDiseases,Seroprevalence study of SARS-CoV-2 antibodies in community based on participants in the 2020 Korea National Health and Nutrition Examination Survey (KNHANES),2022-02-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Republic of Korea,Gangwon,,"Participants of the Korea National Health and Nutrition Examination Survey (KNHANES) - a nationwide cross-sectional surveillance system that assesses the health and nutritional status of Koreans through health interviews, examinations, and nutrition surveys. KNHANES is conducted every year, and includes 10,000 individuals aged 1 year and above. However, the blood and urine samples, for the health examination are collected from participants aged 10 years and above.",,2020-04-24,2020-12-12,Residual sera,All,Multiple groups,,,Geographical area,Gangwon,211,0.0047,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,R-FIND COVID-19 ELISA,SGTi-flex COVID-19 IgM/IgG (manual),Author designed (Neutralization Assay)","Roche Diagnostics,Abbott Laboratories,Beckman Coulter,SG medical, Inc.,Sugentech, Inc.,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Ah-Ra Kim,National Institute of Infectious Diseases,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022028,2022-03-07,2024-03-01,Verified,kim_seroprevalence_2022,KOR
220221_Korea_NationalInstituteofInfectiousDiseases_Female,220221_Korea_NationalInstituteofInfectiousDiseases,Seroprevalence study of SARS-CoV-2 antibodies in community based on participants in the 2020 Korea National Health and Nutrition Examination Survey (KNHANES),2022-02-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Republic of Korea,,,"Participants of the Korea National Health and Nutrition Examination Survey (KNHANES) - a nationwide cross-sectional surveillance system that assesses the health and nutritional status of Koreans through health interviews, examinations, and nutrition surveys. KNHANES is conducted every year, and includes 10,000 individuals aged 1 year and above. However, the blood and urine samples, for the health examination are collected from participants aged 10 years and above.",,2020-04-24,2020-12-12,Residual sera,Female,Multiple groups,,,Sex/Gender,,2893,0.0007000000000000001,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,R-FIND COVID-19 ELISA,SGTi-flex COVID-19 IgM/IgG (manual),Author designed (Neutralization Assay)","Roche Diagnostics,Abbott Laboratories,Beckman Coulter,SG medical, Inc.,Sugentech, Inc.,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Ah-Ra Kim,National Institute of Infectious Diseases,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022028,2022-03-07,2024-03-01,Verified,kim_seroprevalence_2022,KOR
220221_Korea_NationalInstituteofInfectiousDiseases_SecondRound,220221_Korea_NationalInstituteofInfectiousDiseases,Seroprevalence study of SARS-CoV-2 antibodies in community based on participants in the 2020 Korea National Health and Nutrition Examination Survey (KNHANES),2022-02-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Republic of Korea,,,"Participants of the Korea National Health and Nutrition Examination Survey (KNHANES) - a nationwide cross-sectional surveillance system that assesses the health and nutritional status of Koreans through health interviews, examinations, and nutrition surveys. KNHANES is conducted every year, and includes 10,000 individuals aged 1 year and above. However, the blood and urine samples, for the health examination are collected from participants aged 10 years and above.",,2020-06-24,2020-08-13,Residual sera,All,Multiple groups,,,Time frame,Second collection period,1440,0.0007000000000000001,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,R-FIND COVID-19 ELISA,SGTi-flex COVID-19 IgM/IgG (manual),Author designed (Neutralization Assay)","Roche Diagnostics,Abbott Laboratories,Beckman Coulter,SG medical, Inc.,Sugentech, Inc.,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Ah-Ra Kim,National Institute of Infectious Diseases,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022028,2022-03-07,2024-03-01,Verified,kim_seroprevalence_2022,KOR
220221_Korea_NationalInstituteofInfectiousDiseases_FourthRound,220221_Korea_NationalInstituteofInfectiousDiseases,Seroprevalence study of SARS-CoV-2 antibodies in community based on participants in the 2020 Korea National Health and Nutrition Examination Survey (KNHANES),2022-02-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Republic of Korea,,,"Participants of the Korea National Health and Nutrition Examination Survey (KNHANES) - a nationwide cross-sectional surveillance system that assesses the health and nutritional status of Koreans through health interviews, examinations, and nutrition surveys. KNHANES is conducted every year, and includes 10,000 individuals aged 1 year and above. However, the blood and urine samples, for the health examination are collected from participants aged 10 years and above.",,2020-11-01,2020-12-12,Residual sera,All,Multiple groups,,,Time frame,Fourth collection period,910,0.0011,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,R-FIND COVID-19 ELISA,SGTi-flex COVID-19 IgM/IgG (manual),Author designed (Neutralization Assay)","Roche Diagnostics,Abbott Laboratories,Beckman Coulter,SG medical, Inc.,Sugentech, Inc.,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Ah-Ra Kim,National Institute of Infectious Diseases,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022028,2022-03-07,2024-03-01,Verified,kim_seroprevalence_2022,KOR
220221_Korea_NationalInstituteofInfectiousDiseases_10-19,220221_Korea_NationalInstituteofInfectiousDiseases,Seroprevalence study of SARS-CoV-2 antibodies in community based on participants in the 2020 Korea National Health and Nutrition Examination Survey (KNHANES),2022-02-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Republic of Korea,,,"Participants of the Korea National Health and Nutrition Examination Survey (KNHANES) - a nationwide cross-sectional surveillance system that assesses the health and nutritional status of Koreans through health interviews, examinations, and nutrition surveys. KNHANES is conducted every year, and includes 10,000 individuals aged 1 year and above. However, the blood and urine samples, for the health examination are collected from participants aged 10 years and above.",,2020-04-24,2020-12-12,Residual sera,All,Children and Youth (0-17 years),,,Age,10-19,499,0.0,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,R-FIND COVID-19 ELISA,SGTi-flex COVID-19 IgM/IgG (manual),Author designed (Neutralization Assay)","Roche Diagnostics,Abbott Laboratories,Beckman Coulter,SG medical, Inc.,Sugentech, Inc.,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Ah-Ra Kim,National Institute of Infectious Diseases,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022028,2022-03-07,2024-03-01,Verified,kim_seroprevalence_2022,KOR
220221_Korea_NationalInstituteofInfectiousDiseases_FirstRound,220221_Korea_NationalInstituteofInfectiousDiseases,Seroprevalence study of SARS-CoV-2 antibodies in community based on participants in the 2020 Korea National Health and Nutrition Examination Survey (KNHANES),2022-02-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Republic of Korea,,,"Participants of the Korea National Health and Nutrition Examination Survey (KNHANES) - a nationwide cross-sectional surveillance system that assesses the health and nutritional status of Koreans through health interviews, examinations, and nutrition surveys. KNHANES is conducted every year, and includes 10,000 individuals aged 1 year and above. However, the blood and urine samples, for the health examination are collected from participants aged 10 years and above.",,2020-04-24,2020-06-19,Residual sera,All,Multiple groups,,,Time frame,First collection period,1555,0.0,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,R-FIND COVID-19 ELISA,SGTi-flex COVID-19 IgM/IgG (manual),Author designed (Neutralization Assay)","Roche Diagnostics,Abbott Laboratories,Beckman Coulter,SG medical, Inc.,Sugentech, Inc.,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Ah-Ra Kim,National Institute of Infectious Diseases,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022028,2022-03-07,2024-03-01,Verified,kim_seroprevalence_2022,KOR
220221_Korea_NationalInstituteofInfectiousDiseases_Male,220221_Korea_NationalInstituteofInfectiousDiseases,Seroprevalence study of SARS-CoV-2 antibodies in community based on participants in the 2020 Korea National Health and Nutrition Examination Survey (KNHANES),2022-02-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Republic of Korea,,,"Participants of the Korea National Health and Nutrition Examination Survey (KNHANES) - a nationwide cross-sectional surveillance system that assesses the health and nutritional status of Koreans through health interviews, examinations, and nutrition surveys. KNHANES is conducted every year, and includes 10,000 individuals aged 1 year and above. However, the blood and urine samples, for the health examination are collected from participants aged 10 years and above.",,2020-04-24,2020-12-12,Residual sera,Male,Multiple groups,,,Sex/Gender,,2391,0.0013000000000000002,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,R-FIND COVID-19 ELISA,SGTi-flex COVID-19 IgM/IgG (manual),Author designed (Neutralization Assay)","Roche Diagnostics,Abbott Laboratories,Beckman Coulter,SG medical, Inc.,Sugentech, Inc.,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Ah-Ra Kim,National Institute of Infectious Diseases,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022028,2022-03-07,2024-03-01,Verified,kim_seroprevalence_2022,KOR
220221_Korea_NationalInstituteofInfectiousDiseases_Ulsan,220221_Korea_NationalInstituteofInfectiousDiseases,Seroprevalence study of SARS-CoV-2 antibodies in community based on participants in the 2020 Korea National Health and Nutrition Examination Survey (KNHANES),2022-02-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Republic of Korea,Ulsan,,"Participants of the Korea National Health and Nutrition Examination Survey (KNHANES) - a nationwide cross-sectional surveillance system that assesses the health and nutritional status of Koreans through health interviews, examinations, and nutrition surveys. KNHANES is conducted every year, and includes 10,000 individuals aged 1 year and above. However, the blood and urine samples, for the health examination are collected from participants aged 10 years and above.",,2020-04-24,2020-12-12,Residual sera,All,Multiple groups,,,Geographical area,Ulsan,94,0.0,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,R-FIND COVID-19 ELISA,SGTi-flex COVID-19 IgM/IgG (manual),Author designed (Neutralization Assay)","Roche Diagnostics,Abbott Laboratories,Beckman Coulter,SG medical, Inc.,Sugentech, Inc.,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Ah-Ra Kim,National Institute of Infectious Diseases,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022028,2022-03-07,2024-03-01,Verified,kim_seroprevalence_2022,KOR
220221_Korea_NationalInstituteofInfectiousDiseases_Sejong,220221_Korea_NationalInstituteofInfectiousDiseases,Seroprevalence study of SARS-CoV-2 antibodies in community based on participants in the 2020 Korea National Health and Nutrition Examination Survey (KNHANES),2022-02-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Republic of Korea,Sejong,,"Participants of the Korea National Health and Nutrition Examination Survey (KNHANES) - a nationwide cross-sectional surveillance system that assesses the health and nutritional status of Koreans through health interviews, examinations, and nutrition surveys. KNHANES is conducted every year, and includes 10,000 individuals aged 1 year and above. However, the blood and urine samples, for the health examination are collected from participants aged 10 years and above.",,2020-04-24,2020-12-12,Residual sera,All,Multiple groups,,,Geographical area,Sejong,84,0.0,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,R-FIND COVID-19 ELISA,SGTi-flex COVID-19 IgM/IgG (manual),Author designed (Neutralization Assay)","Roche Diagnostics,Abbott Laboratories,Beckman Coulter,SG medical, Inc.,Sugentech, Inc.,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Ah-Ra Kim,National Institute of Infectious Diseases,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022028,2022-03-07,2024-03-01,Verified,kim_seroprevalence_2022,KOR
220221_Korea_NationalInstituteofInfectiousDiseases_Gyeongsang,220221_Korea_NationalInstituteofInfectiousDiseases,Seroprevalence study of SARS-CoV-2 antibodies in community based on participants in the 2020 Korea National Health and Nutrition Examination Survey (KNHANES),2022-02-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Republic of Korea,Gyeongsang,,"Participants of the Korea National Health and Nutrition Examination Survey (KNHANES) - a nationwide cross-sectional surveillance system that assesses the health and nutritional status of Koreans through health interviews, examinations, and nutrition surveys. KNHANES is conducted every year, and includes 10,000 individuals aged 1 year and above. However, the blood and urine samples, for the health examination are collected from participants aged 10 years and above.",,2020-04-24,2020-12-12,Residual sera,All,Multiple groups,,,Geographical area,Gyeongsang,688,0.0,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,R-FIND COVID-19 ELISA,SGTi-flex COVID-19 IgM/IgG (manual),Author designed (Neutralization Assay)","Roche Diagnostics,Abbott Laboratories,Beckman Coulter,SG medical, Inc.,Sugentech, Inc.,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Ah-Ra Kim,National Institute of Infectious Diseases,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022028,2022-03-07,2024-03-01,Verified,kim_seroprevalence_2022,KOR
220221_Korea_NationalInstituteofInfectiousDiseases_Seoul,220221_Korea_NationalInstituteofInfectiousDiseases,Seroprevalence study of SARS-CoV-2 antibodies in community based on participants in the 2020 Korea National Health and Nutrition Examination Survey (KNHANES),2022-02-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Republic of Korea,Seoul,,"Participants of the Korea National Health and Nutrition Examination Survey (KNHANES) - a nationwide cross-sectional surveillance system that assesses the health and nutritional status of Koreans through health interviews, examinations, and nutrition surveys. KNHANES is conducted every year, and includes 10,000 individuals aged 1 year and above. However, the blood and urine samples, for the health examination are collected from participants aged 10 years and above.",,2020-04-24,2020-12-12,Residual sera,All,Multiple groups,,,Geographical area,Seoul,982,0.002,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,R-FIND COVID-19 ELISA,SGTi-flex COVID-19 IgM/IgG (manual),Author designed (Neutralization Assay)","Roche Diagnostics,Abbott Laboratories,Beckman Coulter,SG medical, Inc.,Sugentech, Inc.,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Ah-Ra Kim,National Institute of Infectious Diseases,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022028,2022-03-07,2024-03-01,Verified,kim_seroprevalence_2022,KOR
220221_Korea_NationalInstituteofInfectiousDiseases_≥70,220221_Korea_NationalInstituteofInfectiousDiseases,Seroprevalence study of SARS-CoV-2 antibodies in community based on participants in the 2020 Korea National Health and Nutrition Examination Survey (KNHANES),2022-02-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Republic of Korea,,,"Participants of the Korea National Health and Nutrition Examination Survey (KNHANES) - a nationwide cross-sectional surveillance system that assesses the health and nutritional status of Koreans through health interviews, examinations, and nutrition surveys. KNHANES is conducted every year, and includes 10,000 individuals aged 1 year and above. However, the blood and urine samples, for the health examination are collected from participants aged 10 years and above.",,2020-04-24,2020-12-12,Residual sera,All,Seniors (65+ years),,,Age,≥70,1003,0.0,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,R-FIND COVID-19 ELISA,SGTi-flex COVID-19 IgM/IgG (manual),Author designed (Neutralization Assay)","Roche Diagnostics,Abbott Laboratories,Beckman Coulter,SG medical, Inc.,Sugentech, Inc.,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Ah-Ra Kim,National Institute of Infectious Diseases,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022028,2022-03-07,2024-03-01,Verified,kim_seroprevalence_2022,KOR
220221_Korea_NationalInstituteofInfectiousDiseases_Jeju,220221_Korea_NationalInstituteofInfectiousDiseases,Seroprevalence study of SARS-CoV-2 antibodies in community based on participants in the 2020 Korea National Health and Nutrition Examination Survey (KNHANES),2022-02-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Republic of Korea,Jeju,,"Participants of the Korea National Health and Nutrition Examination Survey (KNHANES) - a nationwide cross-sectional surveillance system that assesses the health and nutritional status of Koreans through health interviews, examinations, and nutrition surveys. KNHANES is conducted every year, and includes 10,000 individuals aged 1 year and above. However, the blood and urine samples, for the health examination are collected from participants aged 10 years and above.",,2020-04-24,2020-12-12,Residual sera,All,Multiple groups,,,Geographical area,Jeju,130,0.0,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,R-FIND COVID-19 ELISA,SGTi-flex COVID-19 IgM/IgG (manual),Author designed (Neutralization Assay)","Roche Diagnostics,Abbott Laboratories,Beckman Coulter,SG medical, Inc.,Sugentech, Inc.,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Ah-Ra Kim,National Institute of Infectious Diseases,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022028,2022-03-07,2024-03-01,Verified,kim_seroprevalence_2022,KOR
220221_Korea_NationalInstituteofInfectiousDiseases_50-59,220221_Korea_NationalInstituteofInfectiousDiseases,Seroprevalence study of SARS-CoV-2 antibodies in community based on participants in the 2020 Korea National Health and Nutrition Examination Survey (KNHANES),2022-02-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Republic of Korea,,,"Participants of the Korea National Health and Nutrition Examination Survey (KNHANES) - a nationwide cross-sectional surveillance system that assesses the health and nutritional status of Koreans through health interviews, examinations, and nutrition surveys. KNHANES is conducted every year, and includes 10,000 individuals aged 1 year and above. However, the blood and urine samples, for the health examination are collected from participants aged 10 years and above.",,2020-04-24,2020-12-12,Residual sera,All,Adults (18-64 years),,,Age,50-59,871,0.0023,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,R-FIND COVID-19 ELISA,SGTi-flex COVID-19 IgM/IgG (manual),Author designed (Neutralization Assay)","Roche Diagnostics,Abbott Laboratories,Beckman Coulter,SG medical, Inc.,Sugentech, Inc.,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Ah-Ra Kim,National Institute of Infectious Diseases,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022028,2022-03-07,2024-03-01,Verified,kim_seroprevalence_2022,KOR
220221_Korea_NationalInstituteofInfectiousDiseases_20-29,220221_Korea_NationalInstituteofInfectiousDiseases,Seroprevalence study of SARS-CoV-2 antibodies in community based on participants in the 2020 Korea National Health and Nutrition Examination Survey (KNHANES),2022-02-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Republic of Korea,,,"Participants of the Korea National Health and Nutrition Examination Survey (KNHANES) - a nationwide cross-sectional surveillance system that assesses the health and nutritional status of Koreans through health interviews, examinations, and nutrition surveys. KNHANES is conducted every year, and includes 10,000 individuals aged 1 year and above. However, the blood and urine samples, for the health examination are collected from participants aged 10 years and above.",,2020-04-24,2020-12-12,Residual sera,All,Adults (18-64 years),,,Age,20-29,588,0.0,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,R-FIND COVID-19 ELISA,SGTi-flex COVID-19 IgM/IgG (manual),Author designed (Neutralization Assay)","Roche Diagnostics,Abbott Laboratories,Beckman Coulter,SG medical, Inc.,Sugentech, Inc.,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Ah-Ra Kim,National Institute of Infectious Diseases,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022028,2022-03-07,2024-03-01,Verified,kim_seroprevalence_2022,KOR
220221_Korea_NationalInstituteofInfectiousDiseases_Busan,220221_Korea_NationalInstituteofInfectiousDiseases,Seroprevalence study of SARS-CoV-2 antibodies in community based on participants in the 2020 Korea National Health and Nutrition Examination Survey (KNHANES),2022-02-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Republic of Korea,Busan,,"Participants of the Korea National Health and Nutrition Examination Survey (KNHANES) - a nationwide cross-sectional surveillance system that assesses the health and nutritional status of Koreans through health interviews, examinations, and nutrition surveys. KNHANES is conducted every year, and includes 10,000 individuals aged 1 year and above. However, the blood and urine samples, for the health examination are collected from participants aged 10 years and above.",,2020-04-24,2020-12-12,Residual sera,All,Multiple groups,,,Geographical area,Busan,307,0.0,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,R-FIND COVID-19 ELISA,SGTi-flex COVID-19 IgM/IgG (manual),Author designed (Neutralization Assay)","Roche Diagnostics,Abbott Laboratories,Beckman Coulter,SG medical, Inc.,Sugentech, Inc.,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Ah-Ra Kim,National Institute of Infectious Diseases,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022028,2022-03-07,2024-03-01,Verified,kim_seroprevalence_2022,KOR
220221_Korea_NationalInstituteofInfectiousDiseases_Gwangju,220221_Korea_NationalInstituteofInfectiousDiseases,Seroprevalence study of SARS-CoV-2 antibodies in community based on participants in the 2020 Korea National Health and Nutrition Examination Survey (KNHANES),2022-02-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Republic of Korea,Gwangju,,"Participants of the Korea National Health and Nutrition Examination Survey (KNHANES) - a nationwide cross-sectional surveillance system that assesses the health and nutritional status of Koreans through health interviews, examinations, and nutrition surveys. KNHANES is conducted every year, and includes 10,000 individuals aged 1 year and above. However, the blood and urine samples, for the health examination are collected from participants aged 10 years and above.",,2020-04-24,2020-12-12,Residual sera,All,Multiple groups,,,Geographical area,Gwangju,180,0.0,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,R-FIND COVID-19 ELISA,SGTi-flex COVID-19 IgM/IgG (manual),Author designed (Neutralization Assay)","Roche Diagnostics,Abbott Laboratories,Beckman Coulter,SG medical, Inc.,Sugentech, Inc.,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Ah-Ra Kim,National Institute of Infectious Diseases,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022028,2022-03-07,2024-03-01,Verified,kim_seroprevalence_2022,KOR
220221_Korea_NationalInstituteofInfectiousDiseases_60-69,220221_Korea_NationalInstituteofInfectiousDiseases,Seroprevalence study of SARS-CoV-2 antibodies in community based on participants in the 2020 Korea National Health and Nutrition Examination Survey (KNHANES),2022-02-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Republic of Korea,,,"Participants of the Korea National Health and Nutrition Examination Survey (KNHANES) - a nationwide cross-sectional surveillance system that assesses the health and nutritional status of Koreans through health interviews, examinations, and nutrition surveys. KNHANES is conducted every year, and includes 10,000 individuals aged 1 year and above. However, the blood and urine samples, for the health examination are collected from participants aged 10 years and above.",,2020-04-24,2020-12-12,Residual sera,All,Multiple groups,,,Age,60-69,919,0.0011,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,R-FIND COVID-19 ELISA,SGTi-flex COVID-19 IgM/IgG (manual),Author designed (Neutralization Assay)","Roche Diagnostics,Abbott Laboratories,Beckman Coulter,SG medical, Inc.,Sugentech, Inc.,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Ah-Ra Kim,National Institute of Infectious Diseases,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022028,2022-03-07,2024-03-01,Verified,kim_seroprevalence_2022,KOR
220221_Korea_NationalInstituteofInfectiousDiseases_SingleTestPositive,220221_Korea_NationalInstituteofInfectiousDiseases,Seroprevalence study of SARS-CoV-2 antibodies in community based on participants in the 2020 Korea National Health and Nutrition Examination Survey (KNHANES),2022-02-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Republic of Korea,,,"Participants of the Korea National Health and Nutrition Examination Survey (KNHANES) - a nationwide cross-sectional surveillance system that assesses the health and nutritional status of Koreans through health interviews, examinations, and nutrition surveys. KNHANES is conducted every year, and includes 10,000 individuals aged 1 year and above. However, the blood and urine samples, for the health examination are collected from participants aged 10 years and above.",,2020-04-24,2020-12-12,Residual sera,All,Multiple groups,,,Test used,,5284,0.0025,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.998,1.0,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Ah-Ra Kim,National Institute of Infectious Diseases,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022028,2022-06-05,2024-03-01,Verified,kim_seroprevalence_2022,KOR
220221_Korea_NationalInstituteofInfectiousDiseases_30-39,220221_Korea_NationalInstituteofInfectiousDiseases,Seroprevalence study of SARS-CoV-2 antibodies in community based on participants in the 2020 Korea National Health and Nutrition Examination Survey (KNHANES),2022-02-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Republic of Korea,,,"Participants of the Korea National Health and Nutrition Examination Survey (KNHANES) - a nationwide cross-sectional surveillance system that assesses the health and nutritional status of Koreans through health interviews, examinations, and nutrition surveys. KNHANES is conducted every year, and includes 10,000 individuals aged 1 year and above. However, the blood and urine samples, for the health examination are collected from participants aged 10 years and above.",,2020-04-24,2020-12-12,Residual sera,All,Adults (18-64 years),,,Age,30-39,612,0.0016,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,R-FIND COVID-19 ELISA,SGTi-flex COVID-19 IgM/IgG (manual),Author designed (Neutralization Assay)","Roche Diagnostics,Abbott Laboratories,Beckman Coulter,SG medical, Inc.,Sugentech, Inc.,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Ah-Ra Kim,National Institute of Infectious Diseases,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022028,2022-03-07,2024-03-01,Verified,kim_seroprevalence_2022,KOR
220221_Korea_NationalInstituteofInfectiousDiseases_Jeonra,220221_Korea_NationalInstituteofInfectiousDiseases,Seroprevalence study of SARS-CoV-2 antibodies in community based on participants in the 2020 Korea National Health and Nutrition Examination Survey (KNHANES),2022-02-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Republic of Korea,Jeonra,,"Participants of the Korea National Health and Nutrition Examination Survey (KNHANES) - a nationwide cross-sectional surveillance system that assesses the health and nutritional status of Koreans through health interviews, examinations, and nutrition surveys. KNHANES is conducted every year, and includes 10,000 individuals aged 1 year and above. However, the blood and urine samples, for the health examination are collected from participants aged 10 years and above.",,2020-04-24,2020-12-12,Residual sera,All,Multiple groups,,,Geographical area,Jeonra,292,0.0,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,R-FIND COVID-19 ELISA,SGTi-flex COVID-19 IgM/IgG (manual),Author designed (Neutralization Assay)","Roche Diagnostics,Abbott Laboratories,Beckman Coulter,SG medical, Inc.,Sugentech, Inc.,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Ah-Ra Kim,National Institute of Infectious Diseases,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022028,2022-03-07,2024-03-01,Verified,kim_seroprevalence_2022,KOR
220221_Korea_NationalInstituteofInfectiousDiseases_40-49,220221_Korea_NationalInstituteofInfectiousDiseases,Seroprevalence study of SARS-CoV-2 antibodies in community based on participants in the 2020 Korea National Health and Nutrition Examination Survey (KNHANES),2022-02-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Republic of Korea,,,"Participants of the Korea National Health and Nutrition Examination Survey (KNHANES) - a nationwide cross-sectional surveillance system that assesses the health and nutritional status of Koreans through health interviews, examinations, and nutrition surveys. KNHANES is conducted every year, and includes 10,000 individuals aged 1 year and above. However, the blood and urine samples, for the health examination are collected from participants aged 10 years and above.",,2020-04-24,2020-12-12,Residual sera,All,Adults (18-64 years),,,Age,40-49,792,0.0013000000000000002,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,R-FIND COVID-19 ELISA,SGTi-flex COVID-19 IgM/IgG (manual),Author designed (Neutralization Assay)","Roche Diagnostics,Abbott Laboratories,Beckman Coulter,SG medical, Inc.,Sugentech, Inc.,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Ah-Ra Kim,National Institute of Infectious Diseases,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022028,2022-03-07,2024-03-01,Verified,kim_seroprevalence_2022,KOR
220221_Korea_NationalInstituteofInfectiousDiseases_Daejeon,220221_Korea_NationalInstituteofInfectiousDiseases,Seroprevalence study of SARS-CoV-2 antibodies in community based on participants in the 2020 Korea National Health and Nutrition Examination Survey (KNHANES),2022-02-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Republic of Korea,Daejeon,,"Participants of the Korea National Health and Nutrition Examination Survey (KNHANES) - a nationwide cross-sectional surveillance system that assesses the health and nutritional status of Koreans through health interviews, examinations, and nutrition surveys. KNHANES is conducted every year, and includes 10,000 individuals aged 1 year and above. However, the blood and urine samples, for the health examination are collected from participants aged 10 years and above.",,2020-04-24,2020-12-12,Residual sera,All,Multiple groups,,,Geographical area,Daejeon,187,0.0,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,R-FIND COVID-19 ELISA,SGTi-flex COVID-19 IgM/IgG (manual),Author designed (Neutralization Assay)","Roche Diagnostics,Abbott Laboratories,Beckman Coulter,SG medical, Inc.,Sugentech, Inc.,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Ah-Ra Kim,National Institute of Infectious Diseases,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022028,2022-03-07,2024-03-01,Verified,kim_seroprevalence_2022,KOR
220221_Korea_NationalInstituteofInfectiousDiseases_Chungcheong,220221_Korea_NationalInstituteofInfectiousDiseases,Seroprevalence study of SARS-CoV-2 antibodies in community based on participants in the 2020 Korea National Health and Nutrition Examination Survey (KNHANES),2022-02-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Republic of Korea,Chungcheong,,"Participants of the Korea National Health and Nutrition Examination Survey (KNHANES) - a nationwide cross-sectional surveillance system that assesses the health and nutritional status of Koreans through health interviews, examinations, and nutrition surveys. KNHANES is conducted every year, and includes 10,000 individuals aged 1 year and above. However, the blood and urine samples, for the health examination are collected from participants aged 10 years and above.",,2020-04-24,2020-12-12,Residual sera,All,Multiple groups,,,Geographical area,Chungcheong,340,0.0,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,R-FIND COVID-19 ELISA,SGTi-flex COVID-19 IgM/IgG (manual),Author designed (Neutralization Assay)","Roche Diagnostics,Abbott Laboratories,Beckman Coulter,SG medical, Inc.,Sugentech, Inc.,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Ah-Ra Kim,National Institute of Infectious Diseases,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022028,2022-03-07,2024-03-01,Verified,kim_seroprevalence_2022,KOR
220221_Korea_NationalInstituteofInfectiousDiseases_ThirdRound,220221_Korea_NationalInstituteofInfectiousDiseases,Seroprevalence study of SARS-CoV-2 antibodies in community based on participants in the 2020 Korea National Health and Nutrition Examination Survey (KNHANES),2022-02-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Republic of Korea,,,"Participants of the Korea National Health and Nutrition Examination Survey (KNHANES) - a nationwide cross-sectional surveillance system that assesses the health and nutritional status of Koreans through health interviews, examinations, and nutrition surveys. KNHANES is conducted every year, and includes 10,000 individuals aged 1 year and above. However, the blood and urine samples, for the health examination are collected from participants aged 10 years and above.",,2020-08-14,2020-10-31,Residual sera,All,Multiple groups,,,Time frame,Third collection period,1379,0.0022,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,R-FIND COVID-19 ELISA,SGTi-flex COVID-19 IgM/IgG (manual),Author designed (Neutralization Assay)","Roche Diagnostics,Abbott Laboratories,Beckman Coulter,SG medical, Inc.,Sugentech, Inc.,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Ah-Ra Kim,National Institute of Infectious Diseases,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022028,2022-03-07,2024-03-01,Verified,kim_seroprevalence_2022,KOR
220221_Korea_NationalInstituteofInfectiousDiseases_Daegu,220221_Korea_NationalInstituteofInfectiousDiseases,Seroprevalence study of SARS-CoV-2 antibodies in community based on participants in the 2020 Korea National Health and Nutrition Examination Survey (KNHANES),2022-02-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Republic of Korea,Daegu,,"Participants of the Korea National Health and Nutrition Examination Survey (KNHANES) - a nationwide cross-sectional surveillance system that assesses the health and nutritional status of Koreans through health interviews, examinations, and nutrition surveys. KNHANES is conducted every year, and includes 10,000 individuals aged 1 year and above. However, the blood and urine samples, for the health examination are collected from participants aged 10 years and above.",,2020-04-24,2020-12-12,Residual sera,All,Multiple groups,,,Geographical area,Daegu,171,0.0,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,R-FIND COVID-19 ELISA,SGTi-flex COVID-19 IgM/IgG (manual),Author designed (Neutralization Assay)","Roche Diagnostics,Abbott Laboratories,Beckman Coulter,SG medical, Inc.,Sugentech, Inc.,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Ah-Ra Kim,National Institute of Infectious Diseases,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022028,2022-03-07,2024-03-01,Verified,kim_seroprevalence_2022,KOR
220221_Korea_NationalInstituteofInfectiousDiseases_Metropolitan,220221_Korea_NationalInstituteofInfectiousDiseases,Seroprevalence study of SARS-CoV-2 antibodies in community based on participants in the 2020 Korea National Health and Nutrition Examination Survey (KNHANES),2022-02-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Republic of Korea,"Gyeonggi, Incheon",,"Participants of the Korea National Health and Nutrition Examination Survey (KNHANES) - a nationwide cross-sectional surveillance system that assesses the health and nutritional status of Koreans through health interviews, examinations, and nutrition surveys. KNHANES is conducted every year, and includes 10,000 individuals aged 1 year and above. However, the blood and urine samples, for the health examination are collected from participants aged 10 years and above.",,2020-04-24,2020-12-12,Residual sera,All,Multiple groups,,,Geographical area,"Gyeonggi, Incheon",1618,0.0012,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Abbott Architect SARS-CoV-2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,R-FIND COVID-19 ELISA,SGTi-flex COVID-19 IgM/IgG (manual),Author designed (Neutralization Assay)","Roche Diagnostics,Abbott Laboratories,Beckman Coulter,SG medical, Inc.,Sugentech, Inc.,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Ah-Ra Kim,National Institute of Infectious Diseases,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022028,2022-03-07,2024-03-01,Verified,kim_seroprevalence_2022,KOR
220504_KoreanArmyTrainingCenter_InjeUniversity_Overall,220504_KoreanArmyTrainingCenter_InjeUniversity,"Comparison of the Prevalence of Antibodies to SARS-CoV-2 in 9954 Recruits in the Korean Army Training Center with the General Korean Population of Equivalent Age Between September and November, 2020.",2022-05-04,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Republic of Korea,,,"All of the participants were newly enlisted personnel at the Korean Army Training Center, Nonsan, Chungnam, Korea.
The study population was all adult men, who were enlisted due to mandatory draft, aged 18 or older.",,2020-09-01,2020-11-30,Essential non-healthcare workers,Male,Adults (18-64 years),18.0,,Primary Estimate,,9954,0.0031,,,True,,,,True,Simplified probability,"Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Abbott Architect SARS-CoV-2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,R-FIND COVID-19 ELISA,SGTi-flex COVID-19 IgM/IgG (manual),Author designed (Neutralization Assay)","Roche Diagnostics,Abbott Laboratories,Beckman Coulter,SG medical, Inc.,Sugentech, Inc.,NA",Multiple Types,Serum,"['IgG', 'IgM', 'Neutralizing']",,,,,['Moderate'],,Yes,Yes,No,,Unclear,Yes,No,,Kwang Mun,Armed Force Medical Science Research Institute,Not Unity-Aligned,https://dx.doi.org/10.12659/MSM.934926,2022-05-10,2024-03-01,Unverified,mun_comparison_2022,KOR
220906_Korea_TheCatholicUniversityofKorea,220906_Korea_TheCatholicUniversityofKorea,"The Seroprevalence of SARS-CoV-2 in Children During Early COVID-19 Pandemic in Korea: A Nationwide, Population-Based Study.",2022-09-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Republic of Korea,,,"""The study subjects were selected from 17 geographically different regions in Korea (including metropolitan cities and provinces). Leftover sera collected from children aged 0–18 years in Seegene Medical Foundation (Seoul, Korea), an independent reference laboratory""","""samples collected from provincial medical centers were excluded to reduce bias""",2020-12-24,2021-03-25,Household and community samples,All,Children and Youth (0-17 years),0.0,18.0,Primary Estimate,,1866,0.0011,,,True,,,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.998,0.995,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Jin Lee, The Catholic University of Korea,Unity-Aligned,https://dx.doi.org/10.3346/jkms.2022.37.e314,2022-11-22,2024-04-10,Verified,leeSeroprevalenceSARSCoV2Children2022,KOR
220923_Korea_KoreaCDC_Overall,220923_Korea_KoreaCDC,Community-based representative sample COVID-19 antibody positive rate survey (1st),2022-09-23,Institutional Report,National,Cross-sectional survey ,Republic of Korea,,,"households were targeted by 17 cities and provinces, 258 public health centers, 34 regional universities, and 291 cooperative medical institutions
",,2022-08-08,2022-09-06,Household and community samples,All,Multiple groups,,,Primary Estimate,positivity due to vaccination/ infection,9901,0.9938,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],,Unclear,Yes,No,,Unclear,Yes,No,,Korea Disease Control and Prevention Agency,Korea Centers for Disease Control and Prevention,Not Unity-Aligned,http://ncov.kdca.go.kr/tcmBoardView.do?contSeq=372996,2022-10-04,2022-10-04,Unverified,baek_corona_2022,KOR
220923_Korea_KoreaCDC_Infection,220923_Korea_KoreaCDC,Community-based representative sample COVID-19 antibody positive rate survey (1st),2022-09-23,Institutional Report,National,Cross-sectional survey ,Republic of Korea,,,"households were targeted by 17 cities and provinces, 258 public health centers, 34 regional universities, and 291 cooperative medical institutions
",,2022-08-08,2022-09-06,Household and community samples,All,Multiple groups,,,Test used,positivity due to infection,9901,0.3815,,,,,,,,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],,Unclear,Yes,No,,Unclear,Yes,No,,Korea Disease Control and Prevention Agency,Korea Centers for Disease Control and Prevention,Not Unity-Aligned,http://ncov.kdca.go.kr/tcmBoardView.do?contSeq=372996,2022-10-04,2022-10-04,Unverified,baek_corona_2022,KOR
220930_Seoul_SeoulNationalUniversity_overall_popadj,220930_Seoul_SeoulNationalUniversity,Seroprevalence of severe acute respiratory syndrome coronavirus 2 antibodies during the third wave of coronavirus disease in the Seoul metropolitan area of Korea,2022-09-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,"Gyeonggi-do, Seoul and Incheon","""5,002 residual sera samples from January 30 to March 3, 2021 from 265 medical facilities in Seoul, 346 in Kyunggi-do’ and 57 in Incheon""","""Among [the residual sera samples], 60 samples from tertiary institutions were excluded.""",2021-01-30,2021-03-03,Residual sera,All,Multiple groups,19.0,,Primary Estimate,,4942,0.0047,0.0031,0.007,True,,True,,True,Sequential,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Elecsys® Anti‐SARS‐CoV‐2 (S)","GenScript,Roche Diagnostics",Multiple Types,Serum,,Spike,,,,['Missing'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Kyuhyun Yoon,Seoul National University,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022085,2022-10-30,2024-04-15,Verified,yoonSeroprevalenceSevereAcute2022,KOR
220930_Seoul_SeoulNationalUniversity_Gyeonggi-do_popadj,220930_Seoul_SeoulNationalUniversity,Seroprevalence of severe acute respiratory syndrome coronavirus 2 antibodies during the third wave of coronavirus disease in the Seoul metropolitan area of Korea,2022-09-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,Gyeonggi-do,"""5,002 residual sera samples from January 30 to March 3, 2021 from 265 medical facilities in Seoul, 346 in Kyunggi-do’ and 57 in Incheon""","""Among [the residual sera samples], 60 samples from tertiary institutions were excluded.""",2021-01-30,2021-03-03,Residual sera,All,Multiple groups,19.0,,Geographical area,Gyeonggi-do,2882,0.0067,0.0045,0.0108,,,True,,,Sequential,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Elecsys® Anti‐SARS‐CoV‐2 (S)","GenScript,Roche Diagnostics",Multiple Types,Serum,,Spike,,,,['Missing'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Kyuhyun Yoon,Seoul National University,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022085,2022-10-30,2024-04-15,Verified,yoonSeroprevalenceSevereAcute2022,KOR
220930_Seoul_SeoulNationalUniversity_female_unadj,220930_Seoul_SeoulNationalUniversity,Seroprevalence of severe acute respiratory syndrome coronavirus 2 antibodies during the third wave of coronavirus disease in the Seoul metropolitan area of Korea,2022-09-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,"Gyeonggi-do, Seoul and Incheon","""5,002 residual sera samples from January 30 to March 3, 2021 from 265 medical facilities in Seoul, 346 in Kyunggi-do’ and 57 in Incheon""","""Among [the residual sera samples], 60 samples from tertiary institutions were excluded.""",2021-01-30,2021-03-03,Residual sera,Female,Multiple groups,19.0,,Sex/Gender,,2488,0.006,0.0037,0.0099,,,,,,Sequential,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Elecsys® Anti‐SARS‐CoV‐2 (S)","GenScript,Roche Diagnostics",Multiple Types,Serum,,Spike,,,,['Missing'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Kyuhyun Yoon,Seoul National University,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022085,2022-10-28,2024-04-15,Verified,yoonSeroprevalenceSevereAcute2022,KOR
220930_Seoul_SeoulNationalUniversity_70plus_unadj,220930_Seoul_SeoulNationalUniversity,Seroprevalence of severe acute respiratory syndrome coronavirus 2 antibodies during the third wave of coronavirus disease in the Seoul metropolitan area of Korea,2022-09-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,"Gyeonggi-do, Seoul and Incheon","""5,002 residual sera samples from January 30 to March 3, 2021 from 265 medical facilities in Seoul, 346 in Kyunggi-do’ and 57 in Incheon""","""Among [the residual sera samples], 60 samples from tertiary institutions were excluded.""",2021-01-30,2021-03-03,Residual sera,All,Seniors (65+ years),70.0,,Age,70+,549,0.0091,0.0039,0.0211,,,,,,Sequential,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Elecsys® Anti‐SARS‐CoV‐2 (S)","GenScript,Roche Diagnostics",Multiple Types,Serum,,Spike,,,,['Missing'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Kyuhyun Yoon,Seoul National University,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022085,2022-10-28,2024-04-15,Verified,yoonSeroprevalenceSevereAcute2022,KOR
220930_Seoul_SeoulNationalUniversity_male_unadj,220930_Seoul_SeoulNationalUniversity,Seroprevalence of severe acute respiratory syndrome coronavirus 2 antibodies during the third wave of coronavirus disease in the Seoul metropolitan area of Korea,2022-09-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,"Gyeonggi-do, Seoul and Incheon","""5,002 residual sera samples from January 30 to March 3, 2021 from 265 medical facilities in Seoul, 346 in Kyunggi-do’ and 57 in Incheon""","""Among [the residual sera samples], 60 samples from tertiary institutions were excluded.""",2021-01-30,2021-03-03,Residual sera,Male,Multiple groups,19.0,,Sex/Gender,,2454,0.0041,0.0022,0.0075,,,,,,Sequential,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Elecsys® Anti‐SARS‐CoV‐2 (S)","GenScript,Roche Diagnostics",Multiple Types,Serum,,Spike,,,,['Missing'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Kyuhyun Yoon,Seoul National University,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022085,2022-10-28,2024-04-15,Verified,yoonSeroprevalenceSevereAcute2022,KOR
220930_Seoul_SeoulNationalUniversity_40to49_popadj,220930_Seoul_SeoulNationalUniversity,Seroprevalence of severe acute respiratory syndrome coronavirus 2 antibodies during the third wave of coronavirus disease in the Seoul metropolitan area of Korea,2022-09-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,"Gyeonggi-do, Seoul and Incheon","""5,002 residual sera samples from January 30 to March 3, 2021 from 265 medical facilities in Seoul, 346 in Kyunggi-do’ and 57 in Incheon""","""Among [the residual sera samples], 60 samples from tertiary institutions were excluded.""",2021-01-30,2021-03-03,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,982,0.0018,0.0005,0.007,,,True,,,Sequential,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Elecsys® Anti‐SARS‐CoV‐2 (S)","GenScript,Roche Diagnostics",Multiple Types,Serum,,Spike,,,,['Missing'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Kyuhyun Yoon,Seoul National University,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022085,2022-10-30,2024-04-15,Verified,yoonSeroprevalenceSevereAcute2022,KOR
220930_Seoul_SeoulNationalUniversity_Seoul_unadj,220930_Seoul_SeoulNationalUniversity,Seroprevalence of severe acute respiratory syndrome coronavirus 2 antibodies during the third wave of coronavirus disease in the Seoul metropolitan area of Korea,2022-09-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,Seoul,"""5,002 residual sera samples from January 30 to March 3, 2021 from 265 medical facilities in Seoul, 346 in Kyunggi-do’ and 57 in Incheon""","""Among [the residual sera samples], 60 samples from tertiary institutions were excluded.""",2021-01-30,2021-03-03,Residual sera,All,Multiple groups,19.0,,Geographical area,Seoul,1681,0.003,0.0013,0.0069,,,,,,Sequential,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Elecsys® Anti‐SARS‐CoV‐2 (S)","GenScript,Roche Diagnostics",Multiple Types,Serum,,Spike,,,,['Missing'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Kyuhyun Yoon,Seoul National University,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022085,2022-10-28,2024-04-15,Verified,yoonSeroprevalenceSevereAcute2022,KOR
220930_Seoul_SeoulNationalUniversity_Gyeonggi-do_unadj,220930_Seoul_SeoulNationalUniversity,Seroprevalence of severe acute respiratory syndrome coronavirus 2 antibodies during the third wave of coronavirus disease in the Seoul metropolitan area of Korea,2022-09-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,Gyeonggi-do,"""5,002 residual sera samples from January 30 to March 3, 2021 from 265 medical facilities in Seoul, 346 in Kyunggi-do’ and 57 in Incheon""","""Among [the residual sera samples], 60 samples from tertiary institutions were excluded.""",2021-01-30,2021-03-03,Residual sera,All,Multiple groups,19.0,,Geographical area,Gyeonggi-do,2882,0.0069,0.0045,0.0107,,,,,,Sequential,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Elecsys® Anti‐SARS‐CoV‐2 (S)","GenScript,Roche Diagnostics",Multiple Types,Serum,,Spike,,,,['Missing'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Kyuhyun Yoon,Seoul National University,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022085,2022-10-28,2024-04-15,Verified,yoonSeroprevalenceSevereAcute2022,KOR
220930_Seoul_SeoulNationalUniversity_30to39_popadj,220930_Seoul_SeoulNationalUniversity,Seroprevalence of severe acute respiratory syndrome coronavirus 2 antibodies during the third wave of coronavirus disease in the Seoul metropolitan area of Korea,2022-09-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,"Gyeonggi-do, Seoul and Incheon","""5,002 residual sera samples from January 30 to March 3, 2021 from 265 medical facilities in Seoul, 346 in Kyunggi-do’ and 57 in Incheon""","""Among [the residual sera samples], 60 samples from tertiary institutions were excluded.""",2021-01-30,2021-03-03,Residual sera,All,Adults (18-64 years),30.0,3.0,Age,30-39,855,0.004,0.0014,0.011,,,True,,,Sequential,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Elecsys® Anti‐SARS‐CoV‐2 (S)","GenScript,Roche Diagnostics",Multiple Types,Serum,,Spike,,,,['Missing'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Kyuhyun Yoon,Seoul National University,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022085,2022-10-30,2024-04-15,Verified,yoonSeroprevalenceSevereAcute2022,KOR
220930_Seoul_SeoulNationalUniversity_40to49_unadj,220930_Seoul_SeoulNationalUniversity,Seroprevalence of severe acute respiratory syndrome coronavirus 2 antibodies during the third wave of coronavirus disease in the Seoul metropolitan area of Korea,2022-09-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,"Gyeonggi-do, Seoul and Incheon","""5,002 residual sera samples from January 30 to March 3, 2021 from 265 medical facilities in Seoul, 346 in Kyunggi-do’ and 57 in Incheon""","""Among [the residual sera samples], 60 samples from tertiary institutions were excluded.""",2021-01-30,2021-03-03,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,982,0.002,0.0006,0.0074,,,,,,Sequential,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Elecsys® Anti‐SARS‐CoV‐2 (S)","GenScript,Roche Diagnostics",Multiple Types,Serum,,Spike,,,,['Missing'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Kyuhyun Yoon,Seoul National University,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022085,2022-10-28,2024-04-15,Verified,yoonSeroprevalenceSevereAcute2022,KOR
220930_Seoul_SeoulNationalUniversity_50to59_unadj,220930_Seoul_SeoulNationalUniversity,Seroprevalence of severe acute respiratory syndrome coronavirus 2 antibodies during the third wave of coronavirus disease in the Seoul metropolitan area of Korea,2022-09-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,"Gyeonggi-do, Seoul and Incheon","""5,002 residual sera samples from January 30 to March 3, 2021 from 265 medical facilities in Seoul, 346 in Kyunggi-do’ and 57 in Incheon""","""Among [the residual sera samples], 60 samples from tertiary institutions were excluded.""",2021-01-30,2021-03-03,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,967,0.0072,0.0035,0.0149,,,,,,Sequential,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Elecsys® Anti‐SARS‐CoV‐2 (S)","GenScript,Roche Diagnostics",Multiple Types,Serum,,Spike,,,,['Missing'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Kyuhyun Yoon,Seoul National University,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022085,2022-10-28,2024-04-15,Verified,yoonSeroprevalenceSevereAcute2022,KOR
220930_Seoul_SeoulNationalUniversity_Incheon_unadj,220930_Seoul_SeoulNationalUniversity,Seroprevalence of severe acute respiratory syndrome coronavirus 2 antibodies during the third wave of coronavirus disease in the Seoul metropolitan area of Korea,2022-09-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,Incheon,"""5,002 residual sera samples from January 30 to March 3, 2021 from 265 medical facilities in Seoul, 346 in Kyunggi-do’ and 57 in Incheon""","""Among [the residual sera samples], 60 samples from tertiary institutions were excluded.""",2021-01-30,2021-03-03,Residual sera,All,Multiple groups,19.0,,Geographical area,Incheon,379,0.0,0.0,0.0,,,,,,Sequential,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Elecsys® Anti‐SARS‐CoV‐2 (S)","GenScript,Roche Diagnostics",Multiple Types,Serum,,Spike,,,,['Missing'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Kyuhyun Yoon,Seoul National University,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022085,2022-10-28,2024-04-15,Verified,yoonSeroprevalenceSevereAcute2022,KOR
220930_Seoul_SeoulNationalUniversity_female_popadj,220930_Seoul_SeoulNationalUniversity,Seroprevalence of severe acute respiratory syndrome coronavirus 2 antibodies during the third wave of coronavirus disease in the Seoul metropolitan area of Korea,2022-09-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,"Gyeonggi-do, Seoul and Incheon","""5,002 residual sera samples from January 30 to March 3, 2021 from 265 medical facilities in Seoul, 346 in Kyunggi-do’ and 57 in Incheon""","""Among [the residual sera samples], 60 samples from tertiary institutions were excluded.""",2021-01-30,2021-03-03,Residual sera,Female,Multiple groups,19.0,,Sex/Gender,,2488,0.0055,0.0033,0.0093,,,True,,,Sequential,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Elecsys® Anti‐SARS‐CoV‐2 (S)","GenScript,Roche Diagnostics",Multiple Types,Serum,,Spike,,,,['Missing'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Kyuhyun Yoon,Seoul National University,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022085,2022-10-30,2024-04-15,Verified,yoonSeroprevalenceSevereAcute2022,KOR
220930_Seoul_SeoulNationalUniversity_50to59_popadj,220930_Seoul_SeoulNationalUniversity,Seroprevalence of severe acute respiratory syndrome coronavirus 2 antibodies during the third wave of coronavirus disease in the Seoul metropolitan area of Korea,2022-09-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,"Gyeonggi-do, Seoul and Incheon","""5,002 residual sera samples from January 30 to March 3, 2021 from 265 medical facilities in Seoul, 346 in Kyunggi-do’ and 57 in Incheon""","""Among [the residual sera samples], 60 samples from tertiary institutions were excluded.""",2021-01-30,2021-03-03,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,967,0.0069,0.0033,0.0144,,,True,,,Sequential,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Elecsys® Anti‐SARS‐CoV‐2 (S)","GenScript,Roche Diagnostics",Multiple Types,Serum,,Spike,,,,['Missing'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Kyuhyun Yoon,Seoul National University,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022085,2022-10-30,2024-04-15,Verified,yoonSeroprevalenceSevereAcute2022,KOR
220930_Seoul_SeoulNationalUniversity_Incheon_popadj,220930_Seoul_SeoulNationalUniversity,Seroprevalence of severe acute respiratory syndrome coronavirus 2 antibodies during the third wave of coronavirus disease in the Seoul metropolitan area of Korea,2022-09-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,Incheon,"""5,002 residual sera samples from January 30 to March 3, 2021 from 265 medical facilities in Seoul, 346 in Kyunggi-do’ and 57 in Incheon""","""Among [the residual sera samples], 60 samples from tertiary institutions were excluded.""",2021-01-30,2021-03-03,Residual sera,All,Multiple groups,19.0,,Geographical area,Incheon,379,0.0,0.0,0.0,,,True,,,Sequential,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Elecsys® Anti‐SARS‐CoV‐2 (S)","GenScript,Roche Diagnostics",Multiple Types,Serum,,Spike,,,,['Missing'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Kyuhyun Yoon,Seoul National University,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022085,2022-10-30,2024-04-15,Verified,yoonSeroprevalenceSevereAcute2022,KOR
220930_Seoul_SeoulNationalUniversity_70plus_popadj,220930_Seoul_SeoulNationalUniversity,Seroprevalence of severe acute respiratory syndrome coronavirus 2 antibodies during the third wave of coronavirus disease in the Seoul metropolitan area of Korea,2022-09-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,"Gyeonggi-do, Seoul and Incheon","""5,002 residual sera samples from January 30 to March 3, 2021 from 265 medical facilities in Seoul, 346 in Kyunggi-do’ and 57 in Incheon""","""Among [the residual sera samples], 60 samples from tertiary institutions were excluded.""",2021-01-30,2021-03-03,Residual sera,All,Seniors (65+ years),70.0,,Age,70+,549,0.0079,0.0032,0.0195,,,True,,,Sequential,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Elecsys® Anti‐SARS‐CoV‐2 (S)","GenScript,Roche Diagnostics",Multiple Types,Serum,,Spike,,,,['Missing'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Kyuhyun Yoon,Seoul National University,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022085,2022-10-30,2024-04-15,Verified,yoonSeroprevalenceSevereAcute2022,KOR
220930_Seoul_SeoulNationalUniversity_60to69_unadj,220930_Seoul_SeoulNationalUniversity,Seroprevalence of severe acute respiratory syndrome coronavirus 2 antibodies during the third wave of coronavirus disease in the Seoul metropolitan area of Korea,2022-09-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,"Gyeonggi-do, Seoul and Incheon","""5,002 residual sera samples from January 30 to March 3, 2021 from 265 medical facilities in Seoul, 346 in Kyunggi-do’ and 57 in Incheon""","""Among [the residual sera samples], 60 samples from tertiary institutions were excluded.""",2021-01-30,2021-03-03,Residual sera,All,Multiple groups,60.0,69.0,Age,60-69,691,0.0058,0.0023,0.0148,,,,,,Sequential,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Elecsys® Anti‐SARS‐CoV‐2 (S)","GenScript,Roche Diagnostics",Multiple Types,Serum,,Spike,,,,['Missing'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Kyuhyun Yoon,Seoul National University,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022085,2022-10-28,2024-04-15,Verified,yoonSeroprevalenceSevereAcute2022,KOR
220930_Seoul_SeoulNationalUniversity_30to39_unadj,220930_Seoul_SeoulNationalUniversity,Seroprevalence of severe acute respiratory syndrome coronavirus 2 antibodies during the third wave of coronavirus disease in the Seoul metropolitan area of Korea,2022-09-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,"Gyeonggi-do, Seoul and Incheon","""5,002 residual sera samples from January 30 to March 3, 2021 from 265 medical facilities in Seoul, 346 in Kyunggi-do’ and 57 in Incheon""","""Among [the residual sera samples], 60 samples from tertiary institutions were excluded.""",2021-01-30,2021-03-03,Residual sera,All,Adults (18-64 years),30.0,3.0,Age,30-39,855,0.0047,0.0018,0.012,,,,,,Sequential,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Elecsys® Anti‐SARS‐CoV‐2 (S)","GenScript,Roche Diagnostics",Multiple Types,Serum,,Spike,,,,['Missing'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Kyuhyun Yoon,Seoul National University,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022085,2022-10-28,2024-04-15,Verified,yoonSeroprevalenceSevereAcute2022,KOR
220930_Seoul_SeoulNationalUniversity_overall_unadj,220930_Seoul_SeoulNationalUniversity,Seroprevalence of severe acute respiratory syndrome coronavirus 2 antibodies during the third wave of coronavirus disease in the Seoul metropolitan area of Korea,2022-09-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,"Gyeonggi-do, Seoul and Incheon","""5,002 residual sera samples from January 30 to March 3, 2021 from 265 medical facilities in Seoul, 346 in Kyunggi-do’ and 57 in Incheon""","""Among [the residual sera samples], 60 samples from tertiary institutions were excluded.""",2021-01-30,2021-03-03,Residual sera,All,Multiple groups,19.0,,Analysis,,4942,0.0051,0.0034,0.0075,,,,,,Sequential,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Elecsys® Anti‐SARS‐CoV‐2 (S)","GenScript,Roche Diagnostics",Multiple Types,Serum,,Spike,,,,['Missing'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Kyuhyun Yoon,Seoul National University,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022085,2022-10-28,2024-04-15,Verified,yoonSeroprevalenceSevereAcute2022,KOR
220930_Seoul_SeoulNationalUniversity_19to29_unadj,220930_Seoul_SeoulNationalUniversity,Seroprevalence of severe acute respiratory syndrome coronavirus 2 antibodies during the third wave of coronavirus disease in the Seoul metropolitan area of Korea,2022-09-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,"Gyeonggi-do, Seoul and Incheon","""5,002 residual sera samples from January 30 to March 3, 2021 from 265 medical facilities in Seoul, 346 in Kyunggi-do’ and 57 in Incheon""","""Among [the residual sera samples], 60 samples from tertiary institutions were excluded.""",2021-01-30,2021-03-03,Residual sera,All,Adults (18-64 years),19.0,29.0,Age,19-29,898,0.0033,0.0011,0.0098,,,,,,Sequential,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Elecsys® Anti‐SARS‐CoV‐2 (S)","GenScript,Roche Diagnostics",Multiple Types,Serum,,Spike,,,,['Missing'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Kyuhyun Yoon,Seoul National University,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022085,2022-10-28,2024-04-15,Verified,yoonSeroprevalenceSevereAcute2022,KOR
220930_Seoul_SeoulNationalUniversity_19to29_popadj,220930_Seoul_SeoulNationalUniversity,Seroprevalence of severe acute respiratory syndrome coronavirus 2 antibodies during the third wave of coronavirus disease in the Seoul metropolitan area of Korea,2022-09-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,"Gyeonggi-do, Seoul and Incheon","""5,002 residual sera samples from January 30 to March 3, 2021 from 265 medical facilities in Seoul, 346 in Kyunggi-do’ and 57 in Incheon""","""Among [the residual sera samples], 60 samples from tertiary institutions were excluded.""",2021-01-30,2021-03-03,Residual sera,All,Adults (18-64 years),19.0,29.0,Age,19-29,898,0.0029,0.0009,0.0092,,,True,,,Sequential,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Elecsys® Anti‐SARS‐CoV‐2 (S)","GenScript,Roche Diagnostics",Multiple Types,Serum,,Spike,,,,['Missing'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Kyuhyun Yoon,Seoul National University,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022085,2022-10-30,2024-04-15,Verified,yoonSeroprevalenceSevereAcute2022,KOR
220930_Seoul_SeoulNationalUniversity_60to69_popadj,220930_Seoul_SeoulNationalUniversity,Seroprevalence of severe acute respiratory syndrome coronavirus 2 antibodies during the third wave of coronavirus disease in the Seoul metropolitan area of Korea,2022-09-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,"Gyeonggi-do, Seoul and Incheon","""5,002 residual sera samples from January 30 to March 3, 2021 from 265 medical facilities in Seoul, 346 in Kyunggi-do’ and 57 in Incheon""","""Among [the residual sera samples], 60 samples from tertiary institutions were excluded.""",2021-01-30,2021-03-03,Residual sera,All,Multiple groups,60.0,69.0,Age,60-69,691,0.0061,0.0023,0.0156,,,True,,,Sequential,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Elecsys® Anti‐SARS‐CoV‐2 (S)","GenScript,Roche Diagnostics",Multiple Types,Serum,,Spike,,,,['Missing'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Kyuhyun Yoon,Seoul National University,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022085,2022-10-30,2024-04-15,Verified,yoonSeroprevalenceSevereAcute2022,KOR
220930_Seoul_SeoulNationalUniversity_male_popadj,220930_Seoul_SeoulNationalUniversity,Seroprevalence of severe acute respiratory syndrome coronavirus 2 antibodies during the third wave of coronavirus disease in the Seoul metropolitan area of Korea,2022-09-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,"Gyeonggi-do, Seoul and Incheon","""5,002 residual sera samples from January 30 to March 3, 2021 from 265 medical facilities in Seoul, 346 in Kyunggi-do’ and 57 in Incheon""","""Among [the residual sera samples], 60 samples from tertiary institutions were excluded.""",2021-01-30,2021-03-03,Residual sera,Male,Multiple groups,19.0,,Sex/Gender,,2454,0.0038,0.002,0.0071,,,True,,,Sequential,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Elecsys® Anti‐SARS‐CoV‐2 (S)","GenScript,Roche Diagnostics",Multiple Types,Serum,,Spike,,,,['Missing'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Kyuhyun Yoon,Seoul National University,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022085,2022-10-30,2024-04-15,Verified,yoonSeroprevalenceSevereAcute2022,KOR
220930_Seoul_SeoulNationalUniversity_Seoul_popadj,220930_Seoul_SeoulNationalUniversity,Seroprevalence of severe acute respiratory syndrome coronavirus 2 antibodies during the third wave of coronavirus disease in the Seoul metropolitan area of Korea,2022-09-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Republic of Korea,,Seoul,"""5,002 residual sera samples from January 30 to March 3, 2021 from 265 medical facilities in Seoul, 346 in Kyunggi-do’ and 57 in Incheon""","""Among [the residual sera samples], 60 samples from tertiary institutions were excluded.""",2021-01-30,2021-03-03,Residual sera,All,Multiple groups,19.0,,Geographical area,Seoul,1681,0.003,0.0013,0.0069,,,True,,,Sequential,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Elecsys® Anti‐SARS‐CoV‐2 (S)","GenScript,Roche Diagnostics",Multiple Types,Serum,,Spike,,,,['Missing'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Kyuhyun Yoon,Seoul National University,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2022085,2022-10-30,2024-04-15,Verified,yoonSeroprevalenceSevereAcute2022,KOR
230817_SouthKorea_AjouUniviersitySchoolofMedicine_overall,230817_SouthKorea_AjouUniviersitySchoolofMedicine,Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-Sero SMART): findings from national representative sample,2023-08-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Republic of Korea,,,""" In August 2022, a survey was conducted among 10,000 household members aged 5 years and older, in households selected through two stage probability random sampling""","""To account for participant access to blood collection sites, we have excluded PSUs located in isolated areas.""",2022-08-12,2022-09-05,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,,9945,0.976,0.972,0.979,True,,True,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.995,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Jina Han,Ajou Univiersity School of Medicine,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2023075,2023-09-20,2024-05-01,Verified,hanKoreaSeroprevalenceStudy1692198001,KOR
230817_SouthKorea_AjouUniviersitySchoolofMedicine_Jeonbuk,230817_SouthKorea_AjouUniviersitySchoolofMedicine,Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-Sero SMART): findings from national representative sample,2023-08-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Republic of Korea,Jeonbuk,,""" In August 2022, a survey was conducted among 10,000 household members aged 5 years and older, in households selected through two stage probability random sampling""","""To account for participant access to blood collection sites, we have excluded PSUs located in isolated areas.""",2022-08-12,2022-09-05,Household and community samples,All,Multiple groups,5.0,,Geographical area,,440,0.987,0.973,1.0,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.995,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Jina Han,Ajou Univiersity School of Medicine,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2023075,2023-09-20,2024-05-01,Verified,hanKoreaSeroprevalenceStudy1692198001,KOR
230817_SouthKorea_AjouUniviersitySchoolofMedicine_Gyeongnam  ,230817_SouthKorea_AjouUniviersitySchoolofMedicine,Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-Sero SMART): findings from national representative sample,2023-08-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Republic of Korea,Gyeongnam  ,,""" In August 2022, a survey was conducted among 10,000 household members aged 5 years and older, in households selected through two stage probability random sampling""","""To account for participant access to blood collection sites, we have excluded PSUs located in isolated areas.""",2022-08-12,2022-09-05,Household and community samples,All,Multiple groups,5.0,,Geographical area,,710,0.977,0.962,0.991,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.995,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Jina Han,Ajou Univiersity School of Medicine,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2023075,2023-09-20,2024-05-01,Verified,hanKoreaSeroprevalenceStudy1692198001,KOR
230817_SouthKorea_AjouUniviersitySchoolofMedicine_Age_50-59,230817_SouthKorea_AjouUniviersitySchoolofMedicine,Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-Sero SMART): findings from national representative sample,2023-08-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Republic of Korea,,,""" In August 2022, a survey was conducted among 10,000 household members aged 5 years and older, in households selected through two stage probability random sampling""","""To account for participant access to blood collection sites, we have excluded PSUs located in isolated areas.""",2022-08-12,2022-09-05,Household and community samples,All,Adults (18-64 years),5.0,,Age,50-59 years,1660,0.545,0.519,0.572,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.995,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Jina Han,Ajou Univiersity School of Medicine,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2023075,2024-05-01,2024-05-01,Verified,hanKoreaSeroprevalenceStudy1692198001,KOR
230817_SouthKorea_AjouUniviersitySchoolofMedicine_Daejeon,230817_SouthKorea_AjouUniviersitySchoolofMedicine,Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-Sero SMART): findings from national representative sample,2023-08-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Republic of Korea,Daejeon,,""" In August 2022, a survey was conducted among 10,000 household members aged 5 years and older, in households selected through two stage probability random sampling""","""To account for participant access to blood collection sites, we have excluded PSUs located in isolated areas.""",2022-08-12,2022-09-05,Household and community samples,All,Multiple groups,5.0,,Geographical area,,230,0.963,0.937,0.989,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.995,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Jina Han,Ajou Univiersity School of Medicine,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2023075,2023-09-20,2024-05-01,Verified,hanKoreaSeroprevalenceStudy1692198001,KOR
230817_SouthKorea_AjouUniviersitySchoolofMedicine_Seoul,230817_SouthKorea_AjouUniviersitySchoolofMedicine,Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-Sero SMART): findings from national representative sample,2023-08-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Republic of Korea,Seoul,,""" In August 2022, a survey was conducted among 10,000 household members aged 5 years and older, in households selected through two stage probability random sampling""","""To account for participant access to blood collection sites, we have excluded PSUs located in isolated areas.""",2022-08-12,2022-09-05,Household and community samples,All,Multiple groups,5.0,,Geographical area,,1399,0.985,0.978,0.992,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.995,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Jina Han,Ajou Univiersity School of Medicine,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2023075,2023-09-20,2024-05-01,Verified,hanKoreaSeroprevalenceStudy1692198001,KOR
230817_SouthKorea_AjouUniviersitySchoolofMedicine_Age_10-19,230817_SouthKorea_AjouUniviersitySchoolofMedicine,Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-Sero SMART): findings from national representative sample,2023-08-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Republic of Korea,,,""" In August 2022, a survey was conducted among 10,000 household members aged 5 years and older, in households selected through two stage probability random sampling""","""To account for participant access to blood collection sites, we have excluded PSUs located in isolated areas.""",2022-08-12,2022-09-05,Household and community samples,All,Children and Youth (0-17 years),5.0,,Age,10-19 years,757,0.693,0.658,0.728,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.995,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Jina Han,Ajou Univiersity School of Medicine,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2023075,2024-05-01,2024-05-01,Verified,hanKoreaSeroprevalenceStudy1692198001,KOR
230817_SouthKorea_AjouUniviersitySchoolofMedicine_Gangwon,230817_SouthKorea_AjouUniviersitySchoolofMedicine,Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-Sero SMART): findings from national representative sample,2023-08-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Republic of Korea,Gangwon,,""" In August 2022, a survey was conducted among 10,000 household members aged 5 years and older, in households selected through two stage probability random sampling""","""To account for participant access to blood collection sites, we have excluded PSUs located in isolated areas.""",2022-08-12,2022-09-05,Household and community samples,All,Multiple groups,5.0,,Geographical area,,495,0.984,0.971,0.998,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.995,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Jina Han,Ajou Univiersity School of Medicine,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2023075,2023-09-20,2024-05-01,Verified,hanKoreaSeroprevalenceStudy1692198001,KOR
230817_SouthKorea_AjouUniviersitySchoolofMedicine_Ulsan,230817_SouthKorea_AjouUniviersitySchoolofMedicine,Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-Sero SMART): findings from national representative sample,2023-08-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Republic of Korea,Ulsan,,""" In August 2022, a survey was conducted among 10,000 household members aged 5 years and older, in households selected through two stage probability random sampling""","""To account for participant access to blood collection sites, we have excluded PSUs located in isolated areas.""",2022-08-12,2022-09-05,Household and community samples,All,Multiple groups,5.0,,Geographical area,,192,0.947,0.91,0.983,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.995,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Jina Han,Ajou Univiersity School of Medicine,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2023075,2023-09-20,2024-05-01,Verified,hanKoreaSeroprevalenceStudy1692198001,KOR
230817_SouthKorea_AjouUniviersitySchoolofMedicine_Age_40-49,230817_SouthKorea_AjouUniviersitySchoolofMedicine,Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-Sero SMART): findings from national representative sample,2023-08-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Republic of Korea,,,""" In August 2022, a survey was conducted among 10,000 household members aged 5 years and older, in households selected through two stage probability random sampling""","""To account for participant access to blood collection sites, we have excluded PSUs located in isolated areas.""",2022-08-12,2022-09-05,Household and community samples,All,Adults (18-64 years),5.0,,Age,40-49 years,1337,0.597,0.568,0.626,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.995,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Jina Han,Ajou Univiersity School of Medicine,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2023075,2024-05-01,2024-05-01,Verified,hanKoreaSeroprevalenceStudy1692198001,KOR
230817_SouthKorea_AjouUniviersitySchoolofMedicine_Gyeonggi,230817_SouthKorea_AjouUniviersitySchoolofMedicine,Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-Sero SMART): findings from national representative sample,2023-08-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Republic of Korea,Gyeonggi,,""" In August 2022, a survey was conducted among 10,000 household members aged 5 years and older, in households selected through two stage probability random sampling""","""To account for participant access to blood collection sites, we have excluded PSUs located in isolated areas.""",2022-08-12,2022-09-05,Household and community samples,All,Multiple groups,5.0,,Geographical area,,2173,0.982,0.976,0.988,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.995,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Jina Han,Ajou Univiersity School of Medicine,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2023075,2023-09-20,2024-05-01,Verified,hanKoreaSeroprevalenceStudy1692198001,KOR
230817_SouthKorea_AjouUniviersitySchoolofMedicine_Jeju,230817_SouthKorea_AjouUniviersitySchoolofMedicine,Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-Sero SMART): findings from national representative sample,2023-08-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Republic of Korea,Jeju,,""" In August 2022, a survey was conducted among 10,000 household members aged 5 years and older, in households selected through two stage probability random sampling""","""To account for participant access to blood collection sites, we have excluded PSUs located in isolated areas.""",2022-08-12,2022-09-05,Household and community samples,All,Multiple groups,5.0,,Geographical area,,182,0.977,0.944,1.0,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.995,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Jina Han,Ajou Univiersity School of Medicine,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2023075,2023-09-20,2024-05-01,Verified,hanKoreaSeroprevalenceStudy1692198001,KOR
230817_SouthKorea_AjouUniviersitySchoolofMedicine_Age_70-79,230817_SouthKorea_AjouUniviersitySchoolofMedicine,Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-Sero SMART): findings from national representative sample,2023-08-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Republic of Korea,,,""" In August 2022, a survey was conducted among 10,000 household members aged 5 years and older, in households selected through two stage probability random sampling""","""To account for participant access to blood collection sites, we have excluded PSUs located in isolated areas.""",2022-08-12,2022-09-05,Household and community samples,All,Seniors (65+ years),5.0,,Age,70-79 years,1450,0.43,0.402,0.458,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.995,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Jina Han,Ajou Univiersity School of Medicine,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2023075,2024-05-01,2024-05-01,Verified,hanKoreaSeroprevalenceStudy1692198001,KOR
230817_SouthKorea_AjouUniviersitySchoolofMedicine_Jeonnam ,230817_SouthKorea_AjouUniviersitySchoolofMedicine,Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-Sero SMART): findings from national representative sample,2023-08-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Republic of Korea,Jeonnam ,,""" In August 2022, a survey was conducted among 10,000 household members aged 5 years and older, in households selected through two stage probability random sampling""","""To account for participant access to blood collection sites, we have excluded PSUs located in isolated areas.""",2022-08-12,2022-09-05,Household and community samples,All,Multiple groups,5.0,,Geographical area,,611,0.981,0.967,0.994,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.995,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Jina Han,Ajou Univiersity School of Medicine,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2023075,2023-09-20,2024-05-01,Verified,hanKoreaSeroprevalenceStudy1692198001,KOR
230817_SouthKorea_AjouUniviersitySchoolofMedicine_Gwangju,230817_SouthKorea_AjouUniviersitySchoolofMedicine,Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-Sero SMART): findings from national representative sample,2023-08-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Republic of Korea,Gwangju,,""" In August 2022, a survey was conducted among 10,000 household members aged 5 years and older, in households selected through two stage probability random sampling""","""To account for participant access to blood collection sites, we have excluded PSUs located in isolated areas.""",2022-08-12,2022-09-05,Household and community samples,All,Multiple groups,5.0,,Geographical area,,228,0.967,0.942,0.993,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.995,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Jina Han,Ajou Univiersity School of Medicine,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2023075,2023-09-20,2024-05-01,Verified,hanKoreaSeroprevalenceStudy1692198001,KOR
230817_SouthKorea_AjouUniviersitySchoolofMedicine_Age_60-69,230817_SouthKorea_AjouUniviersitySchoolofMedicine,Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-Sero SMART): findings from national representative sample,2023-08-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Republic of Korea,,,""" In August 2022, a survey was conducted among 10,000 household members aged 5 years and older, in households selected through two stage probability random sampling""","""To account for participant access to blood collection sites, we have excluded PSUs located in isolated areas.""",2022-08-12,2022-09-05,Household and community samples,All,Seniors (65+ years),5.0,,Age,60-69 years,1994,0.504,0.479,0.528,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.995,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Jina Han,Ajou Univiersity School of Medicine,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2023075,2024-05-01,2024-05-01,Verified,hanKoreaSeroprevalenceStudy1692198001,KOR
230817_SouthKorea_AjouUniviersitySchoolofMedicine_Age_5-9,230817_SouthKorea_AjouUniviersitySchoolofMedicine,Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-Sero SMART): findings from national representative sample,2023-08-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Republic of Korea,,,""" In August 2022, a survey was conducted among 10,000 household members aged 5 years and older, in households selected through two stage probability random sampling""","""To account for participant access to blood collection sites, we have excluded PSUs located in isolated areas.""",2022-08-12,2022-09-05,Household and community samples,All,Children and Youth (0-17 years),5.0,,Age,5-9 years,297,0.821,0.773,0.87,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.995,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Jina Han,Ajou Univiersity School of Medicine,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2023075,2024-05-01,2024-05-01,Verified,hanKoreaSeroprevalenceStudy1692198001,KOR
230817_SouthKorea_AjouUniviersitySchoolofMedicine_Incheon,230817_SouthKorea_AjouUniviersitySchoolofMedicine,Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-Sero SMART): findings from national representative sample,2023-08-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Republic of Korea,Incheon,,""" In August 2022, a survey was conducted among 10,000 household members aged 5 years and older, in households selected through two stage probability random sampling""","""To account for participant access to blood collection sites, we have excluded PSUs located in isolated areas.""",2022-08-12,2022-09-05,Household and community samples,All,Multiple groups,5.0,,Geographical area,,485,0.959,0.941,0.978,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.995,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Jina Han,Ajou Univiersity School of Medicine,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2023075,2023-09-20,2024-05-01,Verified,hanKoreaSeroprevalenceStudy1692198001,KOR
230817_SouthKorea_AjouUniviersitySchoolofMedicine_Busan,230817_SouthKorea_AjouUniviersitySchoolofMedicine,Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-Sero SMART): findings from national representative sample,2023-08-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Republic of Korea,Busan,,""" In August 2022, a survey was conducted among 10,000 household members aged 5 years and older, in households selected through two stage probability random sampling""","""To account for participant access to blood collection sites, we have excluded PSUs located in isolated areas.""",2022-08-12,2022-09-05,Household and community samples,All,Multiple groups,5.0,,Geographical area,,636,0.985,0.976,0.994,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.995,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Jina Han,Ajou Univiersity School of Medicine,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2023075,2023-09-20,2024-05-01,Verified,hanKoreaSeroprevalenceStudy1692198001,KOR
230817_SouthKorea_AjouUniviersitySchoolofMedicine_Chungnam,230817_SouthKorea_AjouUniviersitySchoolofMedicine,Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-Sero SMART): findings from national representative sample,2023-08-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Republic of Korea,Chungnam,,""" In August 2022, a survey was conducted among 10,000 household members aged 5 years and older, in households selected through two stage probability random sampling""","""To account for participant access to blood collection sites, we have excluded PSUs located in isolated areas.""",2022-08-12,2022-09-05,Household and community samples,All,Multiple groups,5.0,,Geographical area,,513,0.977,0.96,0.994,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.995,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Jina Han,Ajou Univiersity School of Medicine,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2023075,2023-09-20,2024-05-01,Verified,hanKoreaSeroprevalenceStudy1692198001,KOR
230817_SouthKorea_AjouUniviersitySchoolofMedicine_Age_80+,230817_SouthKorea_AjouUniviersitySchoolofMedicine,Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-Sero SMART): findings from national representative sample,2023-08-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Republic of Korea,,,""" In August 2022, a survey was conducted among 10,000 household members aged 5 years and older, in households selected through two stage probability random sampling""","""To account for participant access to blood collection sites, we have excluded PSUs located in isolated areas.""",2022-08-12,2022-09-05,Household and community samples,All,Seniors (65+ years),5.0,,Age,80+ years,629,0.312,0.272,0.352,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.995,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Jina Han,Ajou Univiersity School of Medicine,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2023075,2024-05-01,2024-05-01,Verified,hanKoreaSeroprevalenceStudy1692198001,KOR
230817_SouthKorea_AjouUniviersitySchoolofMedicine_Daegu,230817_SouthKorea_AjouUniviersitySchoolofMedicine,Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-Sero SMART): findings from national representative sample,2023-08-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Republic of Korea,Daegu,,""" In August 2022, a survey was conducted among 10,000 household members aged 5 years and older, in households selected through two stage probability random sampling""","""To account for participant access to blood collection sites, we have excluded PSUs located in isolated areas.""",2022-08-12,2022-09-05,Household and community samples,All,Multiple groups,5.0,,Geographical area,,382,0.936,0.908,0.963,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.995,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Jina Han,Ajou Univiersity School of Medicine,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2023075,2023-09-20,2024-05-01,Verified,hanKoreaSeroprevalenceStudy1692198001,KOR
230817_SouthKorea_AjouUniviersitySchoolofMedicine_Sejong,230817_SouthKorea_AjouUniviersitySchoolofMedicine,Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-Sero SMART): findings from national representative sample,2023-08-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Republic of Korea,Sejong,,""" In August 2022, a survey was conducted among 10,000 household members aged 5 years and older, in households selected through two stage probability random sampling""","""To account for participant access to blood collection sites, we have excluded PSUs located in isolated areas.""",2022-08-12,2022-09-05,Household and community samples,All,Multiple groups,5.0,,Geographical area,,100,0.995,0.984,1.0,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.995,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Jina Han,Ajou Univiersity School of Medicine,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2023075,2023-09-20,2024-05-01,Verified,hanKoreaSeroprevalenceStudy1692198001,KOR
230817_SouthKorea_AjouUniviersitySchoolofMedicine_Chungbuk,230817_SouthKorea_AjouUniviersitySchoolofMedicine,Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-Sero SMART): findings from national representative sample,2023-08-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Republic of Korea,Chungbuk,,""" In August 2022, a survey was conducted among 10,000 household members aged 5 years and older, in households selected through two stage probability random sampling""","""To account for participant access to blood collection sites, we have excluded PSUs located in isolated areas.""",2022-08-12,2022-09-05,Household and community samples,All,Multiple groups,5.0,,Geographical area,,431,0.965,0.944,0.986,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.995,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Jina Han,Ajou Univiersity School of Medicine,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2023075,2023-09-20,2024-05-01,Verified,hanKoreaSeroprevalenceStudy1692198001,KOR
230817_SouthKorea_AjouUniviersitySchoolofMedicine_Age_20-29,230817_SouthKorea_AjouUniviersitySchoolofMedicine,Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-Sero SMART): findings from national representative sample,2023-08-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Republic of Korea,,,""" In August 2022, a survey was conducted among 10,000 household members aged 5 years and older, in households selected through two stage probability random sampling""","""To account for participant access to blood collection sites, we have excluded PSUs located in isolated areas.""",2022-08-12,2022-09-05,Household and community samples,All,Adults (18-64 years),5.0,,Age,20-29 years,887,0.607,0.571,0.642,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.995,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Jina Han,Ajou Univiersity School of Medicine,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2023075,2024-05-01,2024-05-01,Verified,hanKoreaSeroprevalenceStudy1692198001,KOR
230817_SouthKorea_AjouUniviersitySchoolofMedicine_Gyeongbuk ,230817_SouthKorea_AjouUniviersitySchoolofMedicine,Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-Sero SMART): findings from national representative sample,2023-08-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Republic of Korea,Gyeongbuk ,,""" In August 2022, a survey was conducted among 10,000 household members aged 5 years and older, in households selected through two stage probability random sampling""","""To account for participant access to blood collection sites, we have excluded PSUs located in isolated areas.""",2022-08-12,2022-09-05,Household and community samples,All,Multiple groups,5.0,,Geographical area,,738,0.965,0.948,0.982,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.995,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Jina Han,Ajou Univiersity School of Medicine,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2023075,2023-09-20,2024-05-01,Verified,hanKoreaSeroprevalenceStudy1692198001,KOR
230817_SouthKorea_AjouUniviersitySchoolofMedicine_Age_30-39,230817_SouthKorea_AjouUniviersitySchoolofMedicine,Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-Sero SMART): findings from national representative sample,2023-08-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Republic of Korea,,,""" In August 2022, a survey was conducted among 10,000 household members aged 5 years and older, in households selected through two stage probability random sampling""","""To account for participant access to blood collection sites, we have excluded PSUs located in isolated areas.""",2022-08-12,2022-09-05,Household and community samples,All,Adults (18-64 years),5.0,,Age,30-39 years,934,0.615,0.581,0.649,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.995,0.998,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Jina Han,Ajou Univiersity School of Medicine,Unity-Aligned,https://dx.doi.org/10.4178/epih.e2023075,2024-05-01,2024-05-01,Verified,hanKoreaSeroprevalenceStudy1692198001,KOR
200424_Romania_MedLife_HCW,200424_Romania_MedLife,"Concluzii preliminare, studiu MedLife: “Cel mai probabil populatia nu are imunitate dobandita natural pentru COVID 19. Respectarea masurilor de protectie si extinderea testarii reprezinta sansa noastra de a functiona in siguranta si de a reporni economia""",2020-04-24,Institutional Report,National,Cross-sectional survey ,Romania,"Nord-Est, Sud-Est, Sud-Mutenia, Sud-Vest Oltenia, Vest, Nord-Vest, Centru, Bucuresti-Ilfov","Bucharest, Arad, Brasov, Sibiu, Piatra Neamt, Braila, Timisoara, Pitesti, Galati, Targoviste, Ploiesti","MedLife medical staff (doctors, nurses), as well as administration and reception staff.",,2020-03-24,2020-04-21,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,371,0.0296,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,MAGLUMI 2019-nCoV IgM/IgG,iFlash-SARS-CoV-2 IgM/IgG","Abbott Laboratories,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),Shenzhen Yhlo Biotech Co. Ltd",Multiple Types,Multiple Types,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,Unclear,Yes,No,Unclear,MedLife,MedLife,Not Unity-Aligned,https://www.medlife.ro/comunicat-de-presa/concluzii-preliminare-studiu-medlife-cel-mai-probabil-populatia-nu-are-imunitate-dobandita-natural-pentru-covid-19-respectarea-masurilor-de-protectie-si-extinderea-testarii-reprezinta-sansa-noastra-de-a-functiona-in-siguranta-si-de-a,2020-06-27,2024-03-01,Verified,medlife_concluzii_2020-1,ROU
210104_Romania_CarolDavilaUniversityofMedicineAndPharmacy_Overall_adj,210104_Romania_CarolDavilaUniversityofMedicineAndPharmacy,Serological Testing for COVID-19 in the Fertility Setting: The Lockdown Impact and Subsequent Dynamics Reflected in the Seroprevalence of Sars-Cov-2 Antibodies,2021-01-04,Preprint,Local,Prospective cohort,Romania,,Bucharest,Triage negative (pt or partner asymptomatic),Triage positive (pt or partner),2020-05-17,2020-12-01,Multiple populations,All,Adults (18-64 years),,,Primary Estimate,,546,0.06,,,True,,,,,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.907,0.986,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Corina Manolea,Carol Davila University of Medicine and Pharmacy,Not Unity-Aligned,https://www.preprints.org/manuscript/202101.0024/v1,2021-01-23,2024-03-01,Verified,manolea_serological_2021,ROU
210106_TimisCounty_VictorBabesUniversityofMedicineandPharmacy_Overall,210106_TimisCounty_VictorBabesUniversityofMedicineandPharmacy,Seroprevalence of SARS-CoV-2 antibodies In 2115 blood donors from Romania,2021-01-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Romania,,,Volunteer healthy blood donors residing in Timis County. All blood donors had to comply with the donation eligibility criteria set by the Romanian Ministry of Health.,"Individuals underwent a health screening procedure and in case of forehead temperature >37.3C on the day of donation, flu-like symptoms or close contact with suspected or confirmed coronavirus disease 2019 (COVID-19) cases 14 days before donation, they were excluded.",2020-07-08,2020-09-01,Blood donors,All,Adults (18-64 years),18.0,65.0,Primary Estimate,"Blood donors within Timis County, Romania",2115,0.0151,0.010700000000000001,0.0213,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",,Validated by manufacturers,1.0,0.9981000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Tudor Rares Olariu,Victor Babes University of Medicine and Pharmacy,Unity-Aligned,http://dx.doi.org/10.1016/j.cmi.2020.12.027,2021-03-18,2024-03-01,Verified,olariu_seroprevalence_2021,ROU
210106_TimisCounty_VictorBabesUniversityofMedicineandPharmacy_age50-65,210106_TimisCounty_VictorBabesUniversityofMedicineandPharmacy,Seroprevalence of SARS-CoV-2 antibodies In 2115 blood donors from Romania,2021-01-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Romania,,,Volunteer healthy blood donors residing in Timis County. All blood donors had to comply with the donation eligibility criteria set by the Romanian Ministry of Health.,"Individuals underwent a health screening procedure and in case of forehead temperature >37.3C on the day of donation, flu-like symptoms or close contact with suspected or confirmed coronavirus disease 2019 (COVID-19) cases 14 days before donation, they were excluded.",2020-07-08,2020-09-01,Blood donors,All,Adults (18-64 years),50.0,65.0,Age,"blood donors within Timis County, Romania aged 50-65",284,0.0282,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",,Validated by manufacturers,1.0,0.9981000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Tudor Rares Olariu,Victor Babes University of Medicine and Pharmacy,Unity-Aligned,http://dx.doi.org/10.1016/j.cmi.2020.12.027,2021-04-30,2024-03-01,Verified,olariu_seroprevalence_2021,ROU
210106_TimisCounty_VictorBabesUniversityofMedicineandPharmacy_age30-49,210106_TimisCounty_VictorBabesUniversityofMedicineandPharmacy,Seroprevalence of SARS-CoV-2 antibodies In 2115 blood donors from Romania,2021-01-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Romania,,,Volunteer healthy blood donors residing in Timis County. All blood donors had to comply with the donation eligibility criteria set by the Romanian Ministry of Health.,"Individuals underwent a health screening procedure and in case of forehead temperature >37.3C on the day of donation, flu-like symptoms or close contact with suspected or confirmed coronavirus disease 2019 (COVID-19) cases 14 days before donation, they were excluded.",2020-07-08,2020-09-01,Blood donors,All,Adults (18-64 years),30.0,49.0,Age,"blood donors within Timis County, Romania aged 30-49",1261,0.0095,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",,Validated by manufacturers,1.0,0.9981000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Tudor Rares Olariu,Victor Babes University of Medicine and Pharmacy,Unity-Aligned,http://dx.doi.org/10.1016/j.cmi.2020.12.027,2021-04-30,2024-03-01,Verified,olariu_seroprevalence_2021,ROU
210106_TimisCounty_VictorBabesUniversityofMedicineandPharmacy_age18-29,210106_TimisCounty_VictorBabesUniversityofMedicineandPharmacy,Seroprevalence of SARS-CoV-2 antibodies In 2115 blood donors from Romania,2021-01-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Romania,,,Volunteer healthy blood donors residing in Timis County. All blood donors had to comply with the donation eligibility criteria set by the Romanian Ministry of Health.,"Individuals underwent a health screening procedure and in case of forehead temperature >37.3C on the day of donation, flu-like symptoms or close contact with suspected or confirmed coronavirus disease 2019 (COVID-19) cases 14 days before donation, they were excluded.",2020-07-08,2020-09-01,Blood donors,All,Adults (18-64 years),18.0,29.0,Age,"blood donors within Timis County, Romania aged 18-29",570,0.0211,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",,Validated by manufacturers,1.0,0.9981000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Tudor Rares Olariu,Victor Babes University of Medicine and Pharmacy,Unity-Aligned,http://dx.doi.org/10.1016/j.cmi.2020.12.027,2021-04-30,2024-03-01,Verified,olariu_seroprevalence_2021,ROU
210106_TimisCounty_VictorBabesUniversityofMedicineandPharmacy_Female,210106_TimisCounty_VictorBabesUniversityofMedicineandPharmacy,Seroprevalence of SARS-CoV-2 antibodies In 2115 blood donors from Romania,2021-01-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Romania,,,Volunteer healthy blood donors residing in Timis County. All blood donors had to comply with the donation eligibility criteria set by the Romanian Ministry of Health.,"Individuals underwent a health screening procedure and in case of forehead temperature >37.3C on the day of donation, flu-like symptoms or close contact with suspected or confirmed coronavirus disease 2019 (COVID-19) cases 14 days before donation, they were excluded.",2020-07-08,2020-09-01,Blood donors,Female,Adults (18-64 years),,,Sex/Gender,"Female blood donors within Timis County, Romania",715,0.013999999999999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",,Validated by manufacturers,1.0,0.9981000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Tudor Rares Olariu,Victor Babes University of Medicine and Pharmacy,Unity-Aligned,http://dx.doi.org/10.1016/j.cmi.2020.12.027,2021-03-18,2024-03-01,Verified,olariu_seroprevalence_2021,ROU
210106_TimisCounty_VictorBabesUniversityofMedicineandPharmacy_Male,210106_TimisCounty_VictorBabesUniversityofMedicineandPharmacy,Seroprevalence of SARS-CoV-2 antibodies In 2115 blood donors from Romania,2021-01-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Romania,,,Volunteer healthy blood donors residing in Timis County. All blood donors had to comply with the donation eligibility criteria set by the Romanian Ministry of Health.,"Individuals underwent a health screening procedure and in case of forehead temperature >37.3C on the day of donation, flu-like symptoms or close contact with suspected or confirmed coronavirus disease 2019 (COVID-19) cases 14 days before donation, they were excluded.",2020-07-08,2020-09-01,Blood donors,Male,Adults (18-64 years),,,Sex/Gender,"Male blood donors within Timis County, Romania",1400,0.015700000000000002,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",,Validated by manufacturers,1.0,0.9981000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Tudor Rares Olariu,Victor Babes University of Medicine and Pharmacy,Unity-Aligned,http://dx.doi.org/10.1016/j.cmi.2020.12.027,2021-03-18,2024-03-01,Verified,olariu_seroprevalence_2021,ROU
210107_Romania_UniversityCollegeLondon_PaediatricHCW,210107_Romania_UniversityCollegeLondon,Cross Sectional Prevalence of SARS-CoV-2 antibodies in Health Care Workers in Paediatric Facilities in Eight Countries,2021-01-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Romania,,,"This was part of a larger study undertaken in HCWs in paediatric facilities in seven European sites and one South African site. Staff of all categories in each healthcare setting were invited to join the study, irrespective of symptoms or whether they suspected they had previously had COVID-19. ",,2020-05-14,2020-05-27,Health care workers and caregivers,All,Adults (18-64 years),21.0,65.0,Primary Estimate,,124,0.008100000000000001,0.0014000000000000002,0.043,True,,,,True,Convenience,"EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit,Meso Scale Discovery multiplex assay","Epitope Diagnostics, Inc.,Meso Scale Discovery",ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,No,No,Unclear,Yes,Yes,No,Unclear,D Goldblatt,University College London,Not Unity-Aligned,http://dx.doi.org/10.1016/j.jhin.2020.12.019,2021-03-13,2024-03-01,Verified,goldblatt_cross-sectional_2021,ROU
210727_Bucharest_CarolDavilaUniversityOfMedicineAndPharmacy_HCW_Unadj,210727_Bucharest_CarolDavilaUniversityOfMedicineAndPharmacy_HCWs,The prevalence of SARS-CoV-2 antibodies in triage-negative patients and staff of a fertility setting from lockdown release throughout 2020.,2021-07-27,Journal Article (Peer-Reviewed),Local,Prospective cohort,Romania,,Bucharest,,Excluded equivocal results,2020-05-17,2020-12-01,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Unadjusted,30,0.233,,,True,,,,True,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,LIAISON SARS-CoV-2 S1/S2 IgM",DiaSorin,CLIA,Serum,"['IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Yes,Yes,No,,Corina Manolea,Carol Davila University of Medicine and Pharmacy,Not Unity-Aligned,https://dx.doi.org/10.1093/hropen/hoab028,2021-08-03,2024-03-01,Unverified,manolea_prevalence_2021,ROU
210727_Bucharest_CarolDavilaUniversityOfMedicineAndPharmacy_Patients_Unadj,210727_Bucharest_CarolDavilaUniversityOfMedicineAndPharmacy_Patients,The prevalence of SARS-CoV-2 antibodies in triage-negative patients and staff of a fertility setting from lockdown release throughout 2020.,2021-07-27,Journal Article (Peer-Reviewed),Local,Prospective cohort,Romania,,Bucharest,"All patients eligible for undergoing ART treatments in a sizable pri-vate fertility unit in Bucharest, a 2 million people COVID-19 hotspotin Romania were offered the option of serological testing during theinitial stages of their treatment or molecular testing just before the fer-tility intervention",Excluded equivocal results,2020-05-17,2020-12-01,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),,,Primary Estimate,Unadjusted,516,0.068,,,True,,,,True,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,LIAISON SARS-CoV-2 S1/S2 IgM",DiaSorin,CLIA,Serum,"['IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Yes,Yes,No,,Corina Manolea,Carol Davila University of Medicine and Pharmacy,Not Unity-Aligned,https://dx.doi.org/10.1093/hropen/hoab028,2021-08-03,2024-03-01,Unverified,manolea_prevalence_2021,ROU
211226_Timisoara_VictorBabesUniversityOfMedicineAndPharmacy_Overall,211226_Timisoara_VictorBabesUniversityOfMedicineAndPharmacy,"SARS-CoV-2 Seroprevalence in Western Romania, March to June 2021",2021-12-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Romania,,,"""Individuals at least 18 years old were included.""

""No specific inclusion or exclusion criteria were used.""","""No specific inclusion or exclusion criteria were used.""",2021-03-10,2021-06-10,Residual sera,All,Multiple groups,18.0,91.0,Primary Estimate,,2443,0.456,0.4363,0.4758,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Tudor Rares Olariu,Victor Babes University of Medicine and Pharmacy,Not Unity-Aligned,https://dx.doi.org/10.3390/medicina58010035,2022-02-02,2024-03-01,Unverified,olariu_sars-cov-2_2021,ROU
211226_Timisoara_VictorBabesUniversityOfMedicineAndPharmacy_Sex_Male,211226_Timisoara_VictorBabesUniversityOfMedicineAndPharmacy,"SARS-CoV-2 Seroprevalence in Western Romania, March to June 2021",2021-12-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Romania,,,"""Individuals at least 18 years old were included.""

""No specific inclusion or exclusion criteria were used.""","""No specific inclusion or exclusion criteria were used.""",2021-03-10,2021-06-10,Residual sera,Male,Multiple groups,18.0,91.0,Sex/Gender,Sex: Male,848,0.4705,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Tudor Rares Olariu,Victor Babes University of Medicine and Pharmacy,Not Unity-Aligned,https://dx.doi.org/10.3390/medicina58010035,2022-02-02,2024-03-01,Unverified,olariu_sars-cov-2_2021,ROU
211226_Timisoara_VictorBabesUniversityOfMedicineAndPharmacy_Sex_Female,211226_Timisoara_VictorBabesUniversityOfMedicineAndPharmacy,"SARS-CoV-2 Seroprevalence in Western Romania, March to June 2021",2021-12-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Romania,,,"""Individuals at least 18 years old were included.""

""No specific inclusion or exclusion criteria were used.""","""No specific inclusion or exclusion criteria were used.""",2021-03-10,2021-06-10,Residual sera,Female,Multiple groups,18.0,91.0,Sex/Gender,Sex: Female,1595,0.4483,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Tudor Rares Olariu,Victor Babes University of Medicine and Pharmacy,Not Unity-Aligned,https://dx.doi.org/10.3390/medicina58010035,2022-02-02,2024-03-01,Unverified,olariu_sars-cov-2_2021,ROU
211226_Timisoara_VictorBabesUniversityOfMedicineAndPharmacy_Age_70–91,211226_Timisoara_VictorBabesUniversityOfMedicineAndPharmacy,"SARS-CoV-2 Seroprevalence in Western Romania, March to June 2021",2021-12-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Romania,,,"""Individuals at least 18 years old were included.""

""No specific inclusion or exclusion criteria were used.""","""No specific inclusion or exclusion criteria were used.""",2021-03-10,2021-06-10,Residual sera,All,Seniors (65+ years),70.0,91.0,Age,Age: 70–91,367,0.3079,0.2629,0.3569,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Tudor Rares Olariu,Victor Babes University of Medicine and Pharmacy,Not Unity-Aligned,https://dx.doi.org/10.3390/medicina58010035,2022-02-02,2024-03-01,Unverified,olariu_sars-cov-2_2021,ROU
211226_Timisoara_VictorBabesUniversityOfMedicineAndPharmacy_Age_50–69,211226_Timisoara_VictorBabesUniversityOfMedicineAndPharmacy,"SARS-CoV-2 Seroprevalence in Western Romania, March to June 2021",2021-12-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Romania,,,"""Individuals at least 18 years old were included.""

""No specific inclusion or exclusion criteria were used.""","""No specific inclusion or exclusion criteria were used.""",2021-03-10,2021-06-10,Residual sera,All,Multiple groups,50.0,69.0,Age,Age: 50–69,1043,0.4353,0.40549999999999997,0.4656,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Tudor Rares Olariu,Victor Babes University of Medicine and Pharmacy,Not Unity-Aligned,https://dx.doi.org/10.3390/medicina58010035,2022-02-02,2024-03-01,Unverified,olariu_sars-cov-2_2021,ROU
211226_Timisoara_VictorBabesUniversityOfMedicineAndPharmacy_Age_18–29,211226_Timisoara_VictorBabesUniversityOfMedicineAndPharmacy,"SARS-CoV-2 Seroprevalence in Western Romania, March to June 2021",2021-12-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Romania,,,"""Individuals at least 18 years old were included.""

""No specific inclusion or exclusion criteria were used.""","""No specific inclusion or exclusion criteria were used.""",2021-03-10,2021-06-10,Residual sera,All,Adults (18-64 years),18.0,29.0,Age,Age: 18–29,247,0.498,0.4339,0.5621,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Tudor Rares Olariu,Victor Babes University of Medicine and Pharmacy,Not Unity-Aligned,https://dx.doi.org/10.3390/medicina58010035,2022-02-02,2024-03-01,Unverified,olariu_sars-cov-2_2021,ROU
211226_Timisoara_VictorBabesUniversityOfMedicineAndPharmacy_Age_30–49,211226_Timisoara_VictorBabesUniversityOfMedicineAndPharmacy,"SARS-CoV-2 Seroprevalence in Western Romania, March to June 2021",2021-12-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Romania,,,"""Individuals at least 18 years old were included.""

""No specific inclusion or exclusion criteria were used.""","""No specific inclusion or exclusion criteria were used.""",2021-03-10,2021-06-10,Residual sera,All,Adults (18-64 years),30.0,49.0,Age,Age: 30–49,786,0.5394,0.5045000000000001,0.574,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Tudor Rares Olariu,Victor Babes University of Medicine and Pharmacy,Not Unity-Aligned,https://dx.doi.org/10.3390/medicina58010035,2022-02-02,2024-03-01,Unverified,olariu_sars-cov-2_2021,ROU
220211_TimisCounty_VictorBabesUniversityofMedicineandPharmacy_Overall,220211_TimisCounty_VictorBabesUniversityofMedicineandPharmacy,High SARS-CoV-2 seroprevalence in blood donors from Romania after the third COVID-19 pandemic wave,2022-02-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Romania,,,"Blood donor residents of Timis County who donated blood at the Regional Blood Transfusion Centre in Timisoara, Western Romania.
Donors had to have no symptoms of COVID-19.","Subjects with fever on the day of donation (forehead temperature > 37.3 °C), flulike symptoms 14 days before donation, and persons with a history of travel abroad or those who had close contact with suspected or confirmed COVID-19 cases 14 days before donation were not accepted. Individuals with anaemia, chronic hepatitis, liver cirrhosis, HIV, cancer, schizophrenia, epilepsy, asthma, diabetes type I were excluded from the blood donation procedure",2021-07-02,2021-09-02,Blood donors,All,Adults (18-64 years),18.0,64.0,Primary Estimate,,2395,0.4104,,,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9981000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Tudor Olariu,Victor Babes University of Medicine and Pharmacy,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2036811,2022-02-23,2024-03-01,Verified,olariu_high_2022,ROU
220211_TimisCounty_VictorBabesUniversityofMedicineandPharmacy_50-64,220211_TimisCounty_VictorBabesUniversityofMedicineandPharmacy,High SARS-CoV-2 seroprevalence in blood donors from Romania after the third COVID-19 pandemic wave,2022-02-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Romania,,,"Blood donor residents of Timis County who donated blood at the Regional Blood Transfusion Centre in Timisoara, Western Romania.
Donors had to have no symptoms of COVID-19.","Subjects with fever on the day of donation (forehead temperature > 37.3 °C), flulike symptoms 14 days before donation, and persons with a history of travel abroad or those who had close contact with suspected or confirmed COVID-19 cases 14 days before donation were not accepted. Individuals with anaemia, chronic hepatitis, liver cirrhosis, HIV, cancer, schizophrenia, epilepsy, asthma, diabetes type I were excluded from the blood donation procedure",2021-07-02,2021-09-02,Blood donors,All,Adults (18-64 years),50.0,64.0,Age,50-64,332,0.4217,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9981000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Tudor Olariu,Victor Babes University of Medicine and Pharmacy,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2036811,2022-02-23,2024-03-01,Verified,olariu_high_2022,ROU
220211_TimisCounty_VictorBabesUniversityofMedicineandPharmacy_Female,220211_TimisCounty_VictorBabesUniversityofMedicineandPharmacy,High SARS-CoV-2 seroprevalence in blood donors from Romania after the third COVID-19 pandemic wave,2022-02-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Romania,,,"Blood donor residents of Timis County who donated blood at the Regional Blood Transfusion Centre in Timisoara, Western Romania.
Donors had to have no symptoms of COVID-19.","Subjects with fever on the day of donation (forehead temperature > 37.3 °C), flulike symptoms 14 days before donation, and persons with a history of travel abroad or those who had close contact with suspected or confirmed COVID-19 cases 14 days before donation were not accepted. Individuals with anaemia, chronic hepatitis, liver cirrhosis, HIV, cancer, schizophrenia, epilepsy, asthma, diabetes type I were excluded from the blood donation procedure",2021-07-02,2021-09-02,Blood donors,Female,Adults (18-64 years),18.0,64.0,Sex/Gender,,947,0.4266,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9981000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Tudor Olariu,Victor Babes University of Medicine and Pharmacy,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2036811,2022-02-23,2024-03-01,Verified,olariu_high_2022,ROU
220211_TimisCounty_VictorBabesUniversityofMedicineandPharmacy_Male,220211_TimisCounty_VictorBabesUniversityofMedicineandPharmacy,High SARS-CoV-2 seroprevalence in blood donors from Romania after the third COVID-19 pandemic wave,2022-02-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Romania,,,"Blood donor residents of Timis County who donated blood at the Regional Blood Transfusion Centre in Timisoara, Western Romania.
Donors had to have no symptoms of COVID-19.","Subjects with fever on the day of donation (forehead temperature > 37.3 °C), flulike symptoms 14 days before donation, and persons with a history of travel abroad or those who had close contact with suspected or confirmed COVID-19 cases 14 days before donation were not accepted. Individuals with anaemia, chronic hepatitis, liver cirrhosis, HIV, cancer, schizophrenia, epilepsy, asthma, diabetes type I were excluded from the blood donation procedure",2021-07-02,2021-09-02,Blood donors,Male,Adults (18-64 years),18.0,64.0,Sex/Gender,,1448,0.39990000000000003,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9981000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Tudor Olariu,Victor Babes University of Medicine and Pharmacy,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2036811,2022-02-23,2024-03-01,Verified,olariu_high_2022,ROU
220211_TimisCounty_VictorBabesUniversityofMedicineandPharmacy_18-29,220211_TimisCounty_VictorBabesUniversityofMedicineandPharmacy,High SARS-CoV-2 seroprevalence in blood donors from Romania after the third COVID-19 pandemic wave,2022-02-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Romania,,,"Blood donor residents of Timis County who donated blood at the Regional Blood Transfusion Centre in Timisoara, Western Romania.
Donors had to have no symptoms of COVID-19.","Subjects with fever on the day of donation (forehead temperature > 37.3 °C), flulike symptoms 14 days before donation, and persons with a history of travel abroad or those who had close contact with suspected or confirmed COVID-19 cases 14 days before donation were not accepted. Individuals with anaemia, chronic hepatitis, liver cirrhosis, HIV, cancer, schizophrenia, epilepsy, asthma, diabetes type I were excluded from the blood donation procedure",2021-07-02,2021-09-02,Blood donors,All,Adults (18-64 years),18.0,29.0,Age,18-29,644,0.4068,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9981000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Tudor Olariu,Victor Babes University of Medicine and Pharmacy,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2036811,2022-02-23,2024-03-01,Verified,olariu_high_2022,ROU
220211_TimisCounty_VictorBabesUniversityofMedicineandPharmacy_30-49,220211_TimisCounty_VictorBabesUniversityofMedicineandPharmacy,High SARS-CoV-2 seroprevalence in blood donors from Romania after the third COVID-19 pandemic wave,2022-02-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Romania,,,"Blood donor residents of Timis County who donated blood at the Regional Blood Transfusion Centre in Timisoara, Western Romania.
Donors had to have no symptoms of COVID-19.","Subjects with fever on the day of donation (forehead temperature > 37.3 °C), flulike symptoms 14 days before donation, and persons with a history of travel abroad or those who had close contact with suspected or confirmed COVID-19 cases 14 days before donation were not accepted. Individuals with anaemia, chronic hepatitis, liver cirrhosis, HIV, cancer, schizophrenia, epilepsy, asthma, diabetes type I were excluded from the blood donation procedure",2021-07-02,2021-09-02,Blood donors,All,Adults (18-64 years),30.0,49.0,Age,30-49,1419,0.4094,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9981000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Tudor Olariu,Victor Babes University of Medicine and Pharmacy,Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2036811,2022-02-23,2024-03-01,Verified,olariu_high_2022,ROU
220406_TimisCounty_VictorBabesUniversityOfMedicineAndPharmacyTimisoara_Overall,220406_TimisCounty_VictorBabesUniversityOfMedicineAndPharmacyTimisoara,"SARS-CoV-2 Seroprevalence in Children from Western Romania, March to June 2021.",2022-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Romania,,Timisoara,"""Children were residents of Timis County (705,113 inhabitants), and were included in the study in the order in which they presented for routine laboratory investigations to Louis Turcanu and Bega Children’s Hospital Outpatient Clinics in Timisoara, Romania.""","""To exclude the possibility of maternal antibodies’ presence in children’s blood, infants younger than 1 year were not included in this study.""",2021-03-10,2021-06-10,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Primary Estimate,,379,0.467,,,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,,Tudor Olariu,Victor Babes University of Medicine and Pharmacy Timisoara,Unity-Aligned,https://dx.doi.org/10.1089/vbz.2022.0003,2022-04-13,2024-03-01,Verified,olariu_sars-cov-2_2022,ROU
220406_TimisCounty_VictorBabesUniversityOfMedicineAndPharmacyTimisoara_Age_1-5,220406_TimisCounty_VictorBabesUniversityOfMedicineAndPharmacyTimisoara,"SARS-CoV-2 Seroprevalence in Children from Western Romania, March to June 2021.",2022-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Romania,,Timisoara,"""Children were residents of Timis County (705,113 inhabitants), and were included in the study in the order in which they presented for routine laboratory investigations to Louis Turcanu and Bega Children’s Hospital Outpatient Clinics in Timisoara, Romania.""","""To exclude the possibility of maternal antibodies’ presence in children’s blood, infants younger than 1 year were not included in this study.""",2021-03-10,2021-06-10,Residual sera,All,Children and Youth (0-17 years),1.0,5.0,Age,Age: 1-5 (preschool),108,0.3981,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,,Tudor Olariu,Victor Babes University of Medicine and Pharmacy Timisoara,Unity-Aligned,https://dx.doi.org/10.1089/vbz.2022.0003,2022-04-14,2024-03-01,Verified,olariu_sars-cov-2_2022,ROU
220406_TimisCounty_VictorBabesUniversityOfMedicineAndPharmacyTimisoara_Age_6-11,220406_TimisCounty_VictorBabesUniversityOfMedicineAndPharmacyTimisoara,"SARS-CoV-2 Seroprevalence in Children from Western Romania, March to June 2021.",2022-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Romania,,Timisoara,"""Children were residents of Timis County (705,113 inhabitants), and were included in the study in the order in which they presented for routine laboratory investigations to Louis Turcanu and Bega Children’s Hospital Outpatient Clinics in Timisoara, Romania.""","""To exclude the possibility of maternal antibodies’ presence in children’s blood, infants younger than 1 year were not included in this study.""",2021-03-10,2021-06-10,Residual sera,All,Children and Youth (0-17 years),6.0,11.0,Age,Age: 6-11 (elementary school),133,0.4962,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,,Tudor Olariu,Victor Babes University of Medicine and Pharmacy Timisoara,Unity-Aligned,https://dx.doi.org/10.1089/vbz.2022.0003,2022-04-14,2024-03-01,Verified,olariu_sars-cov-2_2022,ROU
220406_TimisCounty_VictorBabesUniversityOfMedicineAndPharmacyTimisoara_Sex_Male,220406_TimisCounty_VictorBabesUniversityOfMedicineAndPharmacyTimisoara,"SARS-CoV-2 Seroprevalence in Children from Western Romania, March to June 2021.",2022-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Romania,,Timisoara,"""Children were residents of Timis County (705,113 inhabitants), and were included in the study in the order in which they presented for routine laboratory investigations to Louis Turcanu and Bega Children’s Hospital Outpatient Clinics in Timisoara, Romania.""","""To exclude the possibility of maternal antibodies’ presence in children’s blood, infants younger than 1 year were not included in this study.""",2021-03-10,2021-06-10,Residual sera,Male,Children and Youth (0-17 years),1.0,17.0,Sex/Gender,,189,0.4656,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,,Tudor Olariu,Victor Babes University of Medicine and Pharmacy Timisoara,Unity-Aligned,https://dx.doi.org/10.1089/vbz.2022.0003,2022-04-14,2024-03-01,Verified,olariu_sars-cov-2_2022,ROU
220406_TimisCounty_VictorBabesUniversityOfMedicineAndPharmacyTimisoara_Sex_female,220406_TimisCounty_VictorBabesUniversityOfMedicineAndPharmacyTimisoara,"SARS-CoV-2 Seroprevalence in Children from Western Romania, March to June 2021.",2022-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Romania,,Timisoara,"""Children were residents of Timis County (705,113 inhabitants), and were included in the study in the order in which they presented for routine laboratory investigations to Louis Turcanu and Bega Children’s Hospital Outpatient Clinics in Timisoara, Romania.""","""To exclude the possibility of maternal antibodies’ presence in children’s blood, infants younger than 1 year were not included in this study.""",2021-03-10,2021-06-10,Residual sera,Female,Children and Youth (0-17 years),1.0,17.0,Sex/Gender,,190,0.46840000000000004,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,,Tudor Olariu,Victor Babes University of Medicine and Pharmacy Timisoara,Unity-Aligned,https://dx.doi.org/10.1089/vbz.2022.0003,2022-04-14,2024-03-01,Verified,olariu_sars-cov-2_2022,ROU
220406_TimisCounty_VictorBabesUniversityOfMedicineAndPharmacyTimisoara_Age_12-17,220406_TimisCounty_VictorBabesUniversityOfMedicineAndPharmacyTimisoara,"SARS-CoV-2 Seroprevalence in Children from Western Romania, March to June 2021.",2022-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Romania,,Timisoara,"""Children were residents of Timis County (705,113 inhabitants), and were included in the study in the order in which they presented for routine laboratory investigations to Louis Turcanu and Bega Children’s Hospital Outpatient Clinics in Timisoara, Romania.""","""To exclude the possibility of maternal antibodies’ presence in children’s blood, infants younger than 1 year were not included in this study.""",2021-03-10,2021-06-10,Residual sera,All,Children and Youth (0-17 years),12.0,17.0,Age,Age: 12-17 (middle/high school),138,0.4928,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,,Tudor Olariu,Victor Babes University of Medicine and Pharmacy Timisoara,Unity-Aligned,https://dx.doi.org/10.1089/vbz.2022.0003,2022-04-14,2024-03-01,Verified,olariu_sars-cov-2_2022,ROU
230517_Bucharest_CarolDavilaUniversity,230517_Bucharest_CarolDavilaUniversity,SARS-CoV-2 Positive Serology and Islet Autoantibodies in Newly Diagnosed Pediatric Cases of Type 1 Diabetes Mellitus: A Single-Center Cohort Study,2023-05-17,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Romania,,Bucharest,we included patients newly diagnosed with T1DM at Marie Curie Emergency Children’s Hospital in Bucharest during a period of 13 months (1 April 202130 April 2022).,Patients with other types of diabetes were excluded.,2021-04-01,2022-04-30,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),,,Primary Estimate,,158,0.233,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Anca Andreea Boboc,Carol Davila University,Not Unity-Aligned,https://dx.doi.org/10.3390/ijms24108885,2023-06-27,2023-07-04,Unverified,boboc_sars-cov-2_2023,ROU
200611_Russia_NationalCouncilCombatingCoronavirus_GenPop,200611_Russia_NationalCouncilCombatingCoronavirus,1 in 7 Russians Have ‘Coronavirus Immunity’ – Official,2020-06-10,News and Media,National,Cross-sectional survey ,Russian Federation,,,People in 46 regions across Russia,,2020-06-10,2020-06-10,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,650000,0.14,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,0.9500000000000001,0.98,['Moderate'],Yes,Unclear,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Sergei Kiselyov,Russian National Council for Combating Coronavirus,Not Unity-Aligned,https://www.themoscowtimes.com/2020/06/10/1-in-7-russians-have-coronavirus-immunity-official-a70540 ; https://www.interfax.ru/russia/712617,2020-06-27,2023-12-13,Verified,kiselyov_1_2020-1,RUS
200626_Moscow_CityofMoscow,200626_Moscow_CityofMoscow,Large-scale antibody testing reveals that over 2 million Muscovites may already have contracted ...,2020-06-26,News and Media,Local,Cross-sectional survey ,Russian Federation,Central Russia,Moscow,Resident of Moscow,,2020-06-05,2020-06-18,Household and community samples,All,Multiple groups,,,Primary Estimate,,90000,0.19899999999999998,,,True,,,,True,Simplified probability,Not reported/ Unable to specify,,,,,,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,Jonny Tickle,City of Moscow,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.rt.com/russia/493055-moscow-mass-antibody-testing/&ct=ga&cd=CAEYESoUMTExMTExNDMxMTUyMzY3OTYzMDcyGjkwZGVhOTg5OTRlOTE4NTk6Y29tOmVuOlVT&usg=AFQjCNHh2eLjbkaY212mSAjMBempJCE7bA,2020-07-31,2022-07-16,Verified,tickle_large-scale_2020,RUS
200920_Leningrad_Saint-PetersburgPasteurResearchInstitute_Overall,200920_Leningrad_Saint-PetersburgPasteurResearchInstitute,Assessment of the Herd Immunity to SARS-CoV-2 among the Population of the Leningrad Region during the COVID-19 Epidemic,2020-09-16,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Russian Federation,Northwestern Federal District,,Members of the Leningrad general population,Active COVID-19 infection,2020-06-23,2020-06-26,Household and community samples,All,Multiple groups,1.0,,Primary Estimate,Overall gen pop,3130,0.207,,,True,,,,True,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Yes,Anna Popova,Saint-Petersburg Pasteur Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://journal.microbe.ru/jour/article/view/1371/1150#,2021-03-11,2022-07-16,Verified,popova_assessment_2020,RUS
200920_Leningrad_Saint-PetersburgPasteurResearchInstitute_50-59,200920_Leningrad_Saint-PetersburgPasteurResearchInstitute,Assessment of the Herd Immunity to SARS-CoV-2 among the Population of the Leningrad Region during the COVID-19 Epidemic,2020-09-16,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Russian Federation,Northwestern Federal District,,Members of the Leningrad general population,Active COVID-19 infection,2020-06-23,2020-06-26,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,480,0.177,,,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Yes,Anna Popova,Saint-Petersburg Pasteur Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://journal.microbe.ru/jour/article/view/1371/1150#,2021-03-11,2022-07-16,Verified,popova_assessment_2020,RUS
200920_Leningrad_Saint-PetersburgPasteurResearchInstitute_1-17,200920_Leningrad_Saint-PetersburgPasteurResearchInstitute,Assessment of the Herd Immunity to SARS-CoV-2 among the Population of the Leningrad Region during the COVID-19 Epidemic,2020-09-16,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Russian Federation,Northwestern Federal District,,Members of the Leningrad general population,Active COVID-19 infection,2020-06-23,2020-06-26,Household and community samples,All,Children and Youth (0-17 years),1.0,17.0,Age,1-17,401,0.269,,,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Yes,Anna Popova,Saint-Petersburg Pasteur Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://journal.microbe.ru/jour/article/view/1371/1150#,2021-03-11,2022-07-16,Verified,popova_assessment_2020,RUS
200920_Leningrad_Saint-PetersburgPasteurResearchInstitute_70+,200920_Leningrad_Saint-PetersburgPasteurResearchInstitute,Assessment of the Herd Immunity to SARS-CoV-2 among the Population of the Leningrad Region during the COVID-19 Epidemic,2020-09-16,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Russian Federation,Northwestern Federal District,,Members of the Leningrad general population,Active COVID-19 infection,2020-06-23,2020-06-26,Household and community samples,All,Seniors (65+ years),70.0,,Age,70+,379,0.29,,,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Yes,Anna Popova,Saint-Petersburg Pasteur Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://journal.microbe.ru/jour/article/view/1371/1150#,2021-03-11,2022-07-16,Verified,popova_assessment_2020,RUS
200920_Leningrad_Saint-PetersburgPasteurResearchInstitute_40-49,200920_Leningrad_Saint-PetersburgPasteurResearchInstitute,Assessment of the Herd Immunity to SARS-CoV-2 among the Population of the Leningrad Region during the COVID-19 Epidemic,2020-09-16,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Russian Federation,Northwestern Federal District,,Members of the Leningrad general population,Active COVID-19 infection,2020-06-23,2020-06-26,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,510,0.172,,,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Yes,Anna Popova,Saint-Petersburg Pasteur Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://journal.microbe.ru/jour/article/view/1371/1150#,2021-03-11,2022-07-16,Verified,popova_assessment_2020,RUS
200920_Leningrad_Saint-PetersburgPasteurResearchInstitute_18-29,200920_Leningrad_Saint-PetersburgPasteurResearchInstitute,Assessment of the Herd Immunity to SARS-CoV-2 among the Population of the Leningrad Region during the COVID-19 Epidemic,2020-09-16,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Russian Federation,Northwestern Federal District,,Members of the Leningrad general population,Active COVID-19 infection,2020-06-23,2020-06-26,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,18-29,464,0.177,,,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Yes,Anna Popova,Saint-Petersburg Pasteur Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://journal.microbe.ru/jour/article/view/1371/1150#,2021-03-11,2022-07-16,Verified,popova_assessment_2020,RUS
200920_Leningrad_Saint-PetersburgPasteurResearchInstitute_30-39,200920_Leningrad_Saint-PetersburgPasteurResearchInstitute,Assessment of the Herd Immunity to SARS-CoV-2 among the Population of the Leningrad Region during the COVID-19 Epidemic,2020-09-16,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Russian Federation,Northwestern Federal District,,Members of the Leningrad general population,Active COVID-19 infection,2020-06-23,2020-06-26,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,474,0.20500000000000002,,,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Yes,Anna Popova,Saint-Petersburg Pasteur Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://journal.microbe.ru/jour/article/view/1371/1150#,2021-03-11,2022-07-16,Verified,popova_assessment_2020,RUS
200920_Leningrad_Saint-PetersburgPasteurResearchInstitute_60-69,200920_Leningrad_Saint-PetersburgPasteurResearchInstitute,Assessment of the Herd Immunity to SARS-CoV-2 among the Population of the Leningrad Region during the COVID-19 Epidemic,2020-09-16,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Russian Federation,Northwestern Federal District,,Members of the Leningrad general population,Active COVID-19 infection,2020-06-23,2020-06-26,Household and community samples,All,Adults (18-64 years),60.0,69.0,Age,60-69,422,0.185,,,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Yes,Anna Popova,Saint-Petersburg Pasteur Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://journal.microbe.ru/jour/article/view/1371/1150#,2021-03-11,2022-07-16,Verified,popova_assessment_2020,RUS
200923_Saint-Petersburg_Saint-PetersburgPasteurResearchInstituteofEpidemiologyandMicrobiology_Overall,200923_Saint-Petersburg_Saint-PetersburgPasteurResearchInstituteofEpidemiologyandMicrobiology,Herd Immunity to SARS-CoV-2 among the Population in Saint-Petersburg during the COVID-19 Epidemic,2020-09-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,Saint-Petersburg,,The exclusion criterion was active COVID-19 infection at the time of the survey.,2020-06-15,2020-06-20,Household and community samples,All,Multiple groups,1.0,,Primary Estimate,Primary,2713,0.26,0.24300000000000002,0.277,True,,,,True,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Yes,Anna Popova,Saint-Petersburg Pasteur Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://journal.microbe.ru/jour/article/view/1372/1151,2021-03-20,2022-07-16,Verified,popova_herd_2020,RUS
200923_Saint-Petersburg_Saint-PetersburgPasteurResearchInstituteofEpidemiologyandMicrobiology_18-29yrs,200923_Saint-Petersburg_Saint-PetersburgPasteurResearchInstituteofEpidemiologyandMicrobiology,Herd Immunity to SARS-CoV-2 among the Population in Saint-Petersburg during the COVID-19 Epidemic,2020-09-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,Saint-Petersburg,,The exclusion criterion was active COVID-19 infection at the time of the survey.,2020-06-15,2020-06-20,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,20-29 years,390,0.21300000000000002,0.17300000000000001,0.257,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Yes,Anna Popova,Saint-Petersburg Pasteur Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://journal.microbe.ru/jour/article/view/1372/1151,2021-03-20,2022-07-16,Verified,popova_herd_2020,RUS
200923_Saint-Petersburg_Saint-PetersburgPasteurResearchInstituteofEpidemiologyandMicrobiology_1-6yrs,200923_Saint-Petersburg_Saint-PetersburgPasteurResearchInstituteofEpidemiologyandMicrobiology,Herd Immunity to SARS-CoV-2 among the Population in Saint-Petersburg during the COVID-19 Epidemic,2020-09-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,Saint-Petersburg,,The exclusion criterion was active COVID-19 infection at the time of the survey.,2020-06-15,2020-06-20,Household and community samples,All,Children and Youth (0-17 years),1.0,6.0,Age,1-6 years,106,0.311,0.225,0.40700000000000003,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Yes,Anna Popova,Saint-Petersburg Pasteur Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://journal.microbe.ru/jour/article/view/1372/1151,2021-03-20,2022-07-16,Verified,popova_herd_2020,RUS
200923_Saint-Petersburg_Saint-PetersburgPasteurResearchInstituteofEpidemiologyandMicrobiology_14-17yrs,200923_Saint-Petersburg_Saint-PetersburgPasteurResearchInstituteofEpidemiologyandMicrobiology,Herd Immunity to SARS-CoV-2 among the Population in Saint-Petersburg during the COVID-19 Epidemic,2020-09-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,Saint-Petersburg,,The exclusion criterion was active COVID-19 infection at the time of the survey.,2020-06-15,2020-06-20,Household and community samples,All,Children and Youth (0-17 years),14.0,17.0,Age,14-17 years,125,0.264,0.189,0.35000000000000003,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Yes,Anna Popova,Saint-Petersburg Pasteur Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://journal.microbe.ru/jour/article/view/1372/1151,2021-03-20,2022-07-16,Verified,popova_herd_2020,RUS
200923_Saint-Petersburg_Saint-PetersburgPasteurResearchInstituteofEpidemiologyandMicrobiology_60-69yrs ,200923_Saint-Petersburg_Saint-PetersburgPasteurResearchInstituteofEpidemiologyandMicrobiology,Herd Immunity to SARS-CoV-2 among the Population in Saint-Petersburg during the COVID-19 Epidemic,2020-09-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,Saint-Petersburg,,The exclusion criterion was active COVID-19 infection at the time of the survey.,2020-06-15,2020-06-20,Household and community samples,All,Adults (18-64 years),60.0,69.0,Age,60-69 years,442,0.29,0.24800000000000003,0.334,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Yes,Anna Popova,Saint-Petersburg Pasteur Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://journal.microbe.ru/jour/article/view/1372/1151,2021-03-20,2022-07-16,Verified,popova_herd_2020,RUS
200923_Saint-Petersburg_Saint-PetersburgPasteurResearchInstituteofEpidemiologyandMicrobiology_30-39yrs,200923_Saint-Petersburg_Saint-PetersburgPasteurResearchInstituteofEpidemiologyandMicrobiology,Herd Immunity to SARS-CoV-2 among the Population in Saint-Petersburg during the COVID-19 Epidemic,2020-09-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,Saint-Petersburg,,The exclusion criterion was active COVID-19 infection at the time of the survey.,2020-06-15,2020-06-20,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30 - 39 years,416,0.228,0.189,0.272,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Yes,Anna Popova,Saint-Petersburg Pasteur Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://journal.microbe.ru/jour/article/view/1372/1151,2021-03-20,2022-07-16,Verified,popova_herd_2020,RUS
200923_Saint-Petersburg_Saint-PetersburgPasteurResearchInstituteofEpidemiologyandMicrobiology_7-13yrs,200923_Saint-Petersburg_Saint-PetersburgPasteurResearchInstituteofEpidemiologyandMicrobiology,Herd Immunity to SARS-CoV-2 among the Population in Saint-Petersburg during the COVID-19 Epidemic,2020-09-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,Saint-Petersburg,,The exclusion criterion was active COVID-19 infection at the time of the survey.,2020-06-15,2020-06-20,Household and community samples,All,Children and Youth (0-17 years),7.0,13.0,Age,7-13 years,146,0.37700000000000006,0.298,0.461,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Yes,Anna Popova,Saint-Petersburg Pasteur Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://journal.microbe.ru/jour/article/view/1372/1151,2021-03-20,2022-07-16,Verified,popova_herd_2020,RUS
200923_Saint-Petersburg_Saint-PetersburgPasteurResearchInstituteofEpidemiologyandMicrobiology_>70yrs,200923_Saint-Petersburg_Saint-PetersburgPasteurResearchInstituteofEpidemiologyandMicrobiology,Herd Immunity to SARS-CoV-2 among the Population in Saint-Petersburg during the COVID-19 Epidemic,2020-09-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,Saint-Petersburg,,The exclusion criterion was active COVID-19 infection at the time of the survey.,2020-06-15,2020-06-20,Household and community samples,All,Seniors (65+ years),70.0,,Age,> 70 years,280,0.304,0.25,0.36100000000000004,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Yes,Anna Popova,Saint-Petersburg Pasteur Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://journal.microbe.ru/jour/article/view/1372/1151,2021-03-20,2022-07-16,Verified,popova_herd_2020,RUS
200923_Saint-Petersburg_Saint-PetersburgPasteurResearchInstituteofEpidemiologyandMicrobiology_40-49yrs,200923_Saint-Petersburg_Saint-PetersburgPasteurResearchInstituteofEpidemiologyandMicrobiology,Herd Immunity to SARS-CoV-2 among the Population in Saint-Petersburg during the COVID-19 Epidemic,2020-09-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,Saint-Petersburg,,The exclusion criterion was active COVID-19 infection at the time of the survey.,2020-06-15,2020-06-20,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49 years,395,0.223,0.18300000000000002,0.267,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Yes,Anna Popova,Saint-Petersburg Pasteur Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://journal.microbe.ru/jour/article/view/1372/1151,2021-03-20,2022-07-16,Verified,popova_herd_2020,RUS
200923_Saint-Petersburg_Saint-PetersburgPasteurResearchInstituteofEpidemiologyandMicrobiology_50-59yrs ,200923_Saint-Petersburg_Saint-PetersburgPasteurResearchInstituteofEpidemiologyandMicrobiology,Herd Immunity to SARS-CoV-2 among the Population in Saint-Petersburg during the COVID-19 Epidemic,2020-09-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,Saint-Petersburg,,The exclusion criterion was active COVID-19 infection at the time of the survey.,2020-06-15,2020-06-20,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59 years,413,0.254,0.21300000000000002,0.299,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Yes,Anna Popova,Saint-Petersburg Pasteur Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://journal.microbe.ru/jour/article/view/1372/1151,2021-03-20,2022-07-16,Verified,popova_herd_2020,RUS
201001_TyumenRegion_SaintPetersburgPasteurInstitute,201001_TyumenRegion_SaintPetersburgPasteurInstitute,Distribution of SARS-CоV-2 seroprevalence among residents of the Tyumen Region during the COVID-19 epidemic period,2020-10-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Tyumen region,,Volunteers for participation in the study were selected through questionnaire surveys and random sampling,The exclusion criterion was an active COVID-19 infection at the time of the survey.,2020-06-07,2020-06-20,Household and community samples,All,Multiple groups,1.0,,Primary Estimate,Primary,2758,0.245,0.22899999999999998,0.261,True,,,,True,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,No,Anna Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://microbiol.elpub.ru/jour/article/view/890/520,2021-03-20,2022-07-16,Verified,_distribution_2020,RUS
201001_TyumenRegion_SaintPetersburgPasteurInstitute_7-13yrs,201001_TyumenRegion_SaintPetersburgPasteurInstitute,Distribution of SARS-CоV-2 seroprevalence among residents of the Tyumen Region during the COVID-19 epidemic period,2020-10-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Tyumen region,,Volunteers for participation in the study were selected through questionnaire surveys and random sampling,The exclusion criterion was an active COVID-19 infection at the time of the survey.,2020-06-07,2020-06-20,Household and community samples,All,Children and Youth (0-17 years),7.0,13.0,Age,7-13 years,144,0.22899999999999998,0.16,0.298,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,No,Anna Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://microbiol.elpub.ru/jour/article/view/890/520,2021-03-20,2022-07-16,Verified,_distribution_2020,RUS
201001_TyumenRegion_SaintPetersburgPasteurInstitute_50-59yrs,201001_TyumenRegion_SaintPetersburgPasteurInstitute,Distribution of SARS-CоV-2 seroprevalence among residents of the Tyumen Region during the COVID-19 epidemic period,2020-10-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Tyumen region,,Volunteers for participation in the study were selected through questionnaire surveys and random sampling,The exclusion criterion was an active COVID-19 infection at the time of the survey.,2020-06-07,2020-06-20,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59 years,482,0.261,0.222,0.3,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,No,Anna Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://microbiol.elpub.ru/jour/article/view/890/520,2021-03-20,2022-07-16,Verified,_distribution_2020,RUS
201001_TyumenRegion_SaintPetersburgPasteurInstitute_>70yrs,201001_TyumenRegion_SaintPetersburgPasteurInstitute,Distribution of SARS-CоV-2 seroprevalence among residents of the Tyumen Region during the COVID-19 epidemic period,2020-10-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Tyumen region,,Volunteers for participation in the study were selected through questionnaire surveys and random sampling,The exclusion criterion was an active COVID-19 infection at the time of the survey.,2020-06-07,2020-06-20,Household and community samples,All,Seniors (65+ years),70.0,,Age,> 70 years,149,0.134,0.079,0.189,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,No,Anna Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://microbiol.elpub.ru/jour/article/view/890/520,2021-03-20,2022-07-16,Verified,_distribution_2020,RUS
201001_TyumenRegion_SaintPetersburgPasteurInstitute_60-69yrs,201001_TyumenRegion_SaintPetersburgPasteurInstitute,Distribution of SARS-CоV-2 seroprevalence among residents of the Tyumen Region during the COVID-19 epidemic period,2020-10-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Tyumen region,,Volunteers for participation in the study were selected through questionnaire surveys and random sampling,The exclusion criterion was an active COVID-19 infection at the time of the survey.,2020-06-07,2020-06-20,Household and community samples,All,Adults (18-64 years),60.0,69.0,Age,60-69 years,387,0.22,0.179,0.261,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,No,Anna Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://microbiol.elpub.ru/jour/article/view/890/520,2021-03-20,2022-07-16,Verified,_distribution_2020,RUS
201001_TyumenRegion_SaintPetersburgPasteurInstitute_14-17yrs,201001_TyumenRegion_SaintPetersburgPasteurInstitute,Distribution of SARS-CоV-2 seroprevalence among residents of the Tyumen Region during the COVID-19 epidemic period,2020-10-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Tyumen region,,Volunteers for participation in the study were selected through questionnaire surveys and random sampling,The exclusion criterion was an active COVID-19 infection at the time of the survey.,2020-06-07,2020-06-20,Household and community samples,All,Children and Youth (0-17 years),14.0,17.0,Age,14-17 years,137,0.255,0.192,0.318,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,No,Anna Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://microbiol.elpub.ru/jour/article/view/890/520,2021-03-20,2022-07-16,Verified,_distribution_2020,RUS
201001_TyumenRegion_SaintPetersburgPasteurInstitute_30-39yrs,201001_TyumenRegion_SaintPetersburgPasteurInstitute,Distribution of SARS-CоV-2 seroprevalence among residents of the Tyumen Region during the COVID-19 epidemic period,2020-10-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Tyumen region,,Volunteers for participation in the study were selected through questionnaire surveys and random sampling,The exclusion criterion was an active COVID-19 infection at the time of the survey.,2020-06-07,2020-06-20,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39 years,452,0.263,0.222,0.304,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,No,Anna Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://microbiol.elpub.ru/jour/article/view/890/520,2021-03-20,2022-07-16,Verified,_distribution_2020,RUS
201001_TyumenRegion_SaintPetersburgPasteurInstitute_40-49yrs,201001_TyumenRegion_SaintPetersburgPasteurInstitute,Distribution of SARS-CоV-2 seroprevalence among residents of the Tyumen Region during the COVID-19 epidemic period,2020-10-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Tyumen region,,Volunteers for participation in the study were selected through questionnaire surveys and random sampling,The exclusion criterion was an active COVID-19 infection at the time of the survey.,2020-06-07,2020-06-20,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49 years,447,0.242,0.20199999999999999,0.282,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,No,Anna Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://microbiol.elpub.ru/jour/article/view/890/520,2021-03-20,2022-07-16,Verified,_distribution_2020,RUS
201001_TyumenRegion_SaintPetersburgPasteurInstitute_1-6yrs,201001_TyumenRegion_SaintPetersburgPasteurInstitute,Distribution of SARS-CоV-2 seroprevalence among residents of the Tyumen Region during the COVID-19 epidemic period,2020-10-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Tyumen region,,Volunteers for participation in the study were selected through questionnaire surveys and random sampling,The exclusion criterion was an active COVID-19 infection at the time of the survey.,2020-06-07,2020-06-20,Household and community samples,All,Children and Youth (0-17 years),1.0,6.0,Age,1-6 yrs,75,0.34700000000000003,0.239,0.455,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,No,Anna Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://microbiol.elpub.ru/jour/article/view/890/520,2021-03-20,2022-07-16,Verified,_distribution_2020,RUS
201001_TyumenRegion_SaintPetersburgPasteurInstitute_18-29yrs,201001_TyumenRegion_SaintPetersburgPasteurInstitute,Distribution of SARS-CоV-2 seroprevalence among residents of the Tyumen Region during the COVID-19 epidemic period,2020-10-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Tyumen region,,Volunteers for participation in the study were selected through questionnaire surveys and random sampling,The exclusion criterion was an active COVID-19 infection at the time of the survey.,2020-06-07,2020-06-20,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,18-29 years,485,0.258,0.219,0.297,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,No,Anna Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://microbiol.elpub.ru/jour/article/view/890/520,2021-03-20,2022-07-16,Verified,_distribution_2020,RUS
201007_MinistryofHealthofRussianFederation_employees,201007_MinistryofHealthofRussianFederation_employees,Detection of antibodies to SARS-CoV-2 in healthcare professionals of the national center during the COVID-19 pandemic (April-June 2020),2020-10-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,Moscow,"employees of the FSBI National Medical Research Center for Obstetrics, Gynecology and Perinatology",,2020-04-15,2020-06-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Federal State Budgetary Institution employees,1589,0.08900000000000001,,,True,,,,True,Unclear,Author designed (ELISA) -Unknown,,ELISA,Serum,IgG,,,,,['High'],No,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,LV Krechetova,Ministry of Health of Russia,Not Unity-Aligned,http://dx.doi.org/10.18565/aig.2020.7.122-128,2021-01-16,2022-07-16,Verified,krechetova_detection_2020,RUS
201019_Irkutsk_SaintPetersburgPasteurResearchInstitute_Overall,201019_Irkutsk_SaintPetersburgPasteurResearchInstitute,Experience in Studying Seroprevalence to SARS-CoV-2 Virus in the Population of the Irkutsk Region during COVID-19 Outbreak,2020-10-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Irkutsk Region,,,The exclusion criterion is active COVID-19 infection at the time of the questionnaire.,2020-06-28,2020-07-19,Household and community samples,All,Multiple groups,1.0,,Primary Estimate,,2674,0.057999999999999996,0.0535,0.0625,True,,,,True,Simplified probability,Author designed (ELISA) -Unknown,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anna Popova,Saint-Petersburg Pasteur Research Institute,Not Unity-Aligned,https://journal.microbe.ru/jour/article/view/1370/1149,2021-03-14,2022-07-16,Verified,popova_experience_2020,RUS
201019_Irkutsk_SaintPetersburgPasteurResearchInstitute_14-17yrs,201019_Irkutsk_SaintPetersburgPasteurResearchInstitute,Experience in Studying Seroprevalence to SARS-CoV-2 Virus in the Population of the Irkutsk Region during COVID-19 Outbreak,2020-10-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Irkutsk Region,,,The exclusion criterion is active COVID-19 infection at the time of the questionnaire.,2020-06-28,2020-07-19,Household and community samples,All,Children and Youth (0-17 years),14.0,17.0,Age,14-17 years,94,0.138,0.10300000000000001,0.17300000000000001,,,,,,Simplified probability,Author designed (ELISA) -Unknown,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anna Popova,Saint-Petersburg Pasteur Research Institute,Not Unity-Aligned,https://journal.microbe.ru/jour/article/view/1370/1149,2021-03-14,2022-07-16,Verified,popova_experience_2020,RUS
201019_Irkutsk_SaintPetersburgPasteurResearchInstitute_50-59yrs,201019_Irkutsk_SaintPetersburgPasteurResearchInstitute,Experience in Studying Seroprevalence to SARS-CoV-2 Virus in the Population of the Irkutsk Region during COVID-19 Outbreak,2020-10-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Irkutsk Region,,,The exclusion criterion is active COVID-19 infection at the time of the questionnaire.,2020-06-28,2020-07-19,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59 years,386,0.044000000000000004,0.034,0.054000000000000006,,,,,,Simplified probability,Author designed (ELISA) -Unknown,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anna Popova,Saint-Petersburg Pasteur Research Institute,Not Unity-Aligned,https://journal.microbe.ru/jour/article/view/1370/1149,2021-03-14,2022-07-16,Verified,popova_experience_2020,RUS
201019_Irkutsk_SaintPetersburgPasteurResearchInstitute_1-6yrs,201019_Irkutsk_SaintPetersburgPasteurResearchInstitute,Experience in Studying Seroprevalence to SARS-CoV-2 Virus in the Population of the Irkutsk Region during COVID-19 Outbreak,2020-10-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Irkutsk Region,,,The exclusion criterion is active COVID-19 infection at the time of the questionnaire.,2020-06-28,2020-07-19,Household and community samples,All,Children and Youth (0-17 years),1.0,6.0,Age,1-6 years,102,0.11800000000000001,0.086,0.15,,,,,,Simplified probability,Author designed (ELISA) -Unknown,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anna Popova,Saint-Petersburg Pasteur Research Institute,Not Unity-Aligned,https://journal.microbe.ru/jour/article/view/1370/1149,2021-03-14,2022-07-16,Verified,popova_experience_2020,RUS
201019_Irkutsk_SaintPetersburgPasteurResearchInstitute_>70yrs,201019_Irkutsk_SaintPetersburgPasteurResearchInstitute,Experience in Studying Seroprevalence to SARS-CoV-2 Virus in the Population of the Irkutsk Region during COVID-19 Outbreak,2020-10-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Irkutsk Region,,,The exclusion criterion is active COVID-19 infection at the time of the questionnaire.,2020-06-28,2020-07-19,Household and community samples,All,Seniors (65+ years),70.0,,Age,Greater than 70 years,379,0.092,0.077,0.107,,,,,,Simplified probability,Author designed (ELISA) -Unknown,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anna Popova,Saint-Petersburg Pasteur Research Institute,Not Unity-Aligned,https://journal.microbe.ru/jour/article/view/1370/1149,2021-03-14,2022-07-16,Verified,popova_experience_2020,RUS
201019_Irkutsk_SaintPetersburgPasteurResearchInstitute_60-69yrs,201019_Irkutsk_SaintPetersburgPasteurResearchInstitute,Experience in Studying Seroprevalence to SARS-CoV-2 Virus in the Population of the Irkutsk Region during COVID-19 Outbreak,2020-10-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Irkutsk Region,,,The exclusion criterion is active COVID-19 infection at the time of the questionnaire.,2020-06-28,2020-07-19,Household and community samples,All,Adults (18-64 years),60.0,69.0,Age,60-69 years,390,0.036000000000000004,0.027000000000000003,0.045,,,,,,Simplified probability,Author designed (ELISA) -Unknown,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anna Popova,Saint-Petersburg Pasteur Research Institute,Not Unity-Aligned,https://journal.microbe.ru/jour/article/view/1370/1149,2021-03-14,2022-07-16,Verified,popova_experience_2020,RUS
201019_Irkutsk_SaintPetersburgPasteurResearchInstitute_7-13yrs,201019_Irkutsk_SaintPetersburgPasteurResearchInstitute,Experience in Studying Seroprevalence to SARS-CoV-2 Virus in the Population of the Irkutsk Region during COVID-19 Outbreak,2020-10-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Irkutsk Region,,,The exclusion criterion is active COVID-19 infection at the time of the questionnaire.,2020-06-28,2020-07-19,Household and community samples,All,Children and Youth (0-17 years),7.0,13.0,Age,7-13 years,191,0.031000000000000003,0.019,0.043,,,,,,Simplified probability,Author designed (ELISA) -Unknown,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anna Popova,Saint-Petersburg Pasteur Research Institute,Not Unity-Aligned,https://journal.microbe.ru/jour/article/view/1370/1149,2021-03-14,2022-07-16,Verified,popova_experience_2020,RUS
201019_Irkutsk_SaintPetersburgPasteurResearchInstitute_40-49yrs,201019_Irkutsk_SaintPetersburgPasteurResearchInstitute,Experience in Studying Seroprevalence to SARS-CoV-2 Virus in the Population of the Irkutsk Region during COVID-19 Outbreak,2020-10-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Irkutsk Region,,,The exclusion criterion is active COVID-19 infection at the time of the questionnaire.,2020-06-28,2020-07-19,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49 years,374,0.043,0.032,0.054000000000000006,,,,,,Simplified probability,Author designed (ELISA) -Unknown,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anna Popova,Saint-Petersburg Pasteur Research Institute,Not Unity-Aligned,https://journal.microbe.ru/jour/article/view/1370/1149,2021-03-14,2022-07-16,Verified,popova_experience_2020,RUS
201019_Irkutsk_SaintPetersburgPasteurResearchInstitute_30-39yrs,201019_Irkutsk_SaintPetersburgPasteurResearchInstitute,Experience in Studying Seroprevalence to SARS-CoV-2 Virus in the Population of the Irkutsk Region during COVID-19 Outbreak,2020-10-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Irkutsk Region,,,The exclusion criterion is active COVID-19 infection at the time of the questionnaire.,2020-06-28,2020-07-19,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39 years,373,0.04,0.03,0.05,,,,,,Simplified probability,Author designed (ELISA) -Unknown,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anna Popova,Saint-Petersburg Pasteur Research Institute,Not Unity-Aligned,https://journal.microbe.ru/jour/article/view/1370/1149,2021-03-14,2022-07-16,Verified,popova_experience_2020,RUS
201019_Irkutsk_SaintPetersburgPasteurResearchInstitute_18-29yrs,201019_Irkutsk_SaintPetersburgPasteurResearchInstitute,Experience in Studying Seroprevalence to SARS-CoV-2 Virus in the Population of the Irkutsk Region during COVID-19 Outbreak,2020-10-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Irkutsk Region,,,The exclusion criterion is active COVID-19 infection at the time of the questionnaire.,2020-06-28,2020-07-19,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,18-29 years,385,0.068,0.055,0.081,,,,,,Simplified probability,Author designed (ELISA) -Unknown,,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Anna Popova,Saint-Petersburg Pasteur Research Institute,Not Unity-Aligned,https://journal.microbe.ru/jour/article/view/1370/1149,2021-03-14,2022-07-16,Verified,popova_experience_2020,RUS
20201231_Moscow_MoscowResearchInstituteofEpidemiologyAndMicrobiology_Overall,20201231_Moscow_MoscowResearchInstituteofEpidemiologyAndMicrobiology,The structure of seroprevalence to the SARS-COV-2 virus among residents of the Moscow region during the period of epidemic incidence of COVID-19,2020-10-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Central Russia,Moscow Region,,exclusion criteria: there was an active COVID-19 infection at the time of the questionnaire rationing,2020-06-22,2020-07-11,Household and community samples,All,Multiple groups,1.0,,Primary Estimate,,2688,0.21,,,True,,,,True,Simplified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,A Popova,Moscow Research Insistute of Epidemiology and Microbiology named after V.I G.N Gabrichevsky,Not Unity-Aligned,http://dx.doi.org/10.20953/1729-9225-2020-4-17-26,2021-04-26,2022-07-16,Verified,popova_structure_2020,RUS
20201231_Moscow_MoscowResearchInstituteofEpidemiologyAndMicrobiology_7-13,20201231_Moscow_MoscowResearchInstituteofEpidemiologyAndMicrobiology,The structure of seroprevalence to the SARS-COV-2 virus among residents of the Moscow region during the period of epidemic incidence of COVID-19,2020-10-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Central Russia,Moscow Region,,exclusion criteria: there was an active COVID-19 infection at the time of the questionnaire rationing,2020-06-22,2020-07-11,Household and community samples,All,Children and Youth (0-17 years),7.0,13.0,Age,,185,0.24300000000000002,,,,,,,,Simplified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,A Popova,Moscow Research Insistute of Epidemiology and Microbiology named after V.I G.N Gabrichevsky,Not Unity-Aligned,http://dx.doi.org/10.20953/1729-9225-2020-4-17-26,2021-04-26,2022-07-16,Verified,popova_structure_2020,RUS
20201231_Moscow_MoscowResearchInstituteofEpidemiologyAndMicrobiology_70+,20201231_Moscow_MoscowResearchInstituteofEpidemiologyAndMicrobiology,The structure of seroprevalence to the SARS-COV-2 virus among residents of the Moscow region during the period of epidemic incidence of COVID-19,2020-10-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Central Russia,Moscow Region,,exclusion criteria: there was an active COVID-19 infection at the time of the questionnaire rationing,2020-06-22,2020-07-11,Household and community samples,All,Seniors (65+ years),70.0,,Age,,384,0.177,,,,,,,,Simplified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,A Popova,Moscow Research Insistute of Epidemiology and Microbiology named after V.I G.N Gabrichevsky,Not Unity-Aligned,http://dx.doi.org/10.20953/1729-9225-2020-4-17-26,2021-04-26,2022-07-16,Verified,popova_structure_2020,RUS
20201231_Moscow_MoscowResearchInstituteofEpidemiologyAndMicrobiology_14-17,20201231_Moscow_MoscowResearchInstituteofEpidemiologyAndMicrobiology,The structure of seroprevalence to the SARS-COV-2 virus among residents of the Moscow region during the period of epidemic incidence of COVID-19,2020-10-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Central Russia,Moscow Region,,exclusion criteria: there was an active COVID-19 infection at the time of the questionnaire rationing,2020-06-22,2020-07-11,Household and community samples,All,Children and Youth (0-17 years),14.0,17.0,Age,,88,0.307,,,,,,,,Simplified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,A Popova,Moscow Research Insistute of Epidemiology and Microbiology named after V.I G.N Gabrichevsky,Not Unity-Aligned,http://dx.doi.org/10.20953/1729-9225-2020-4-17-26,2021-04-26,2022-07-16,Verified,popova_structure_2020,RUS
20201231_Moscow_MoscowResearchInstituteofEpidemiologyAndMicrobiology_Males,20201231_Moscow_MoscowResearchInstituteofEpidemiologyAndMicrobiology,The structure of seroprevalence to the SARS-COV-2 virus among residents of the Moscow region during the period of epidemic incidence of COVID-19,2020-10-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Central Russia,Moscow Region,,exclusion criteria: there was an active COVID-19 infection at the time of the questionnaire rationing,2020-06-22,2020-07-11,Household and community samples,Male,Multiple groups,1.0,,Sex/Gender,,780,0.2,,,,,,,,Simplified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,A Popova,Moscow Research Insistute of Epidemiology and Microbiology named after V.I G.N Gabrichevsky,Not Unity-Aligned,http://dx.doi.org/10.20953/1729-9225-2020-4-17-26,2021-04-26,2022-07-16,Verified,popova_structure_2020,RUS
20201231_Moscow_MoscowResearchInstituteofEpidemiologyAndMicrobiology_60-69,20201231_Moscow_MoscowResearchInstituteofEpidemiologyAndMicrobiology,The structure of seroprevalence to the SARS-COV-2 virus among residents of the Moscow region during the period of epidemic incidence of COVID-19,2020-10-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Central Russia,Moscow Region,,exclusion criteria: there was an active COVID-19 infection at the time of the questionnaire rationing,2020-06-22,2020-07-11,Household and community samples,All,Adults (18-64 years),60.0,69.0,Age,,384,0.21100000000000002,,,,,,,,Simplified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,A Popova,Moscow Research Insistute of Epidemiology and Microbiology named after V.I G.N Gabrichevsky,Not Unity-Aligned,http://dx.doi.org/10.20953/1729-9225-2020-4-17-26,2021-04-26,2022-07-16,Verified,popova_structure_2020,RUS
20201231_Moscow_MoscowResearchInstituteofEpidemiologyAndMicrobiology_1-6yr,20201231_Moscow_MoscowResearchInstituteofEpidemiologyAndMicrobiology,The structure of seroprevalence to the SARS-COV-2 virus among residents of the Moscow region during the period of epidemic incidence of COVID-19,2020-10-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Central Russia,Moscow Region,,exclusion criteria: there was an active COVID-19 infection at the time of the questionnaire rationing,2020-06-22,2020-07-11,Household and community samples,All,Children and Youth (0-17 years),1.0,6.0,Age,,111,0.252,,,,,,,,Simplified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,A Popova,Moscow Research Insistute of Epidemiology and Microbiology named after V.I G.N Gabrichevsky,Not Unity-Aligned,http://dx.doi.org/10.20953/1729-9225-2020-4-17-26,2021-04-26,2022-07-16,Verified,popova_structure_2020,RUS
20201231_Moscow_MoscowResearchInstituteofEpidemiologyAndMicrobiology_30-39,20201231_Moscow_MoscowResearchInstituteofEpidemiologyAndMicrobiology,The structure of seroprevalence to the SARS-COV-2 virus among residents of the Moscow region during the period of epidemic incidence of COVID-19,2020-10-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Central Russia,Moscow Region,,exclusion criteria: there was an active COVID-19 infection at the time of the questionnaire rationing,2020-06-22,2020-07-11,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,,384,0.21600000000000003,,,,,,,,Simplified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,A Popova,Moscow Research Insistute of Epidemiology and Microbiology named after V.I G.N Gabrichevsky,Not Unity-Aligned,http://dx.doi.org/10.20953/1729-9225-2020-4-17-26,2021-04-26,2022-07-16,Verified,popova_structure_2020,RUS
20201231_Moscow_MoscowResearchInstituteofEpidemiologyAndMicrobiology_Females,20201231_Moscow_MoscowResearchInstituteofEpidemiologyAndMicrobiology,The structure of seroprevalence to the SARS-COV-2 virus among residents of the Moscow region during the period of epidemic incidence of COVID-19,2020-10-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Central Russia,Moscow Region,,exclusion criteria: there was an active COVID-19 infection at the time of the questionnaire rationing,2020-06-22,2020-07-11,Household and community samples,Female,Multiple groups,1.0,,Sex/Gender,,1908,0.214,,,,,,,,Simplified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,A Popova,Moscow Research Insistute of Epidemiology and Microbiology named after V.I G.N Gabrichevsky,Not Unity-Aligned,http://dx.doi.org/10.20953/1729-9225-2020-4-17-26,2021-04-26,2022-07-16,Verified,popova_structure_2020,RUS
20201231_Moscow_MoscowResearchInstituteofEpidemiologyAndMicrobiology_50-59,20201231_Moscow_MoscowResearchInstituteofEpidemiologyAndMicrobiology,The structure of seroprevalence to the SARS-COV-2 virus among residents of the Moscow region during the period of epidemic incidence of COVID-19,2020-10-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Central Russia,Moscow Region,,exclusion criteria: there was an active COVID-19 infection at the time of the questionnaire rationing,2020-06-22,2020-07-11,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,,384,0.22100000000000003,,,,,,,,Simplified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,A Popova,Moscow Research Insistute of Epidemiology and Microbiology named after V.I G.N Gabrichevsky,Not Unity-Aligned,http://dx.doi.org/10.20953/1729-9225-2020-4-17-26,2021-04-26,2022-07-16,Verified,popova_structure_2020,RUS
20201231_Moscow_MoscowResearchInstituteofEpidemiologyAndMicrobiology_40-49,20201231_Moscow_MoscowResearchInstituteofEpidemiologyAndMicrobiology,The structure of seroprevalence to the SARS-COV-2 virus among residents of the Moscow region during the period of epidemic incidence of COVID-19,2020-10-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Central Russia,Moscow Region,,exclusion criteria: there was an active COVID-19 infection at the time of the questionnaire rationing,2020-06-22,2020-07-11,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,,384,0.22100000000000003,,,,,,,,Simplified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,A Popova,Moscow Research Insistute of Epidemiology and Microbiology named after V.I G.N Gabrichevsky,Not Unity-Aligned,http://dx.doi.org/10.20953/1729-9225-2020-4-17-26,2021-04-26,2022-07-16,Verified,popova_structure_2020,RUS
20201231_Moscow_MoscowResearchInstituteofEpidemiologyAndMicrobiology_18-29,20201231_Moscow_MoscowResearchInstituteofEpidemiologyAndMicrobiology,The structure of seroprevalence to the SARS-COV-2 virus among residents of the Moscow region during the period of epidemic incidence of COVID-19,2020-10-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Central Russia,Moscow Region,,exclusion criteria: there was an active COVID-19 infection at the time of the questionnaire rationing,2020-06-22,2020-07-11,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,,384,0.16399999999999998,,,,,,,,Simplified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,A Popova,Moscow Research Insistute of Epidemiology and Microbiology named after V.I G.N Gabrichevsky,Not Unity-Aligned,http://dx.doi.org/10.20953/1729-9225-2020-4-17-26,2021-04-26,2022-07-16,Verified,popova_structure_2020,RUS
201021_RepublicOfTartarstan_SaintPetersburgPasteurInstitute_overall,201021_RepublicOfTartarstan_SaintPetersburgPasteurInstitute,Distribution of SARS-CоV-2 seroprevalence among residents of the Republic of Tatarstan during the COVID-19 epidemic period,2020-10-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Republic of Tartarstan,,population of the Republic of Tatarstan ,The exclusion criterion was active COVID-19 infection at the time of the survey.,2020-09-20,2020-09-27,Household and community samples,All,Multiple groups,1.0,,Primary Estimate,Overall gen pop,2946,0.313,,,True,,,,True,Simplified probability,Not reported/ Unable to specify,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Anna Yu Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://microbiol.elpub.ru/jour/article/view/940?locale=en_US,2021-05-18,2022-07-16,Verified,popovaDistributionSARSCoV2Seroprevalence2020,RUS
201021_RepublicOfTartarstan_SaintPetersburgPasteurInstitute_70+,201021_RepublicOfTartarstan_SaintPetersburgPasteurInstitute,Distribution of SARS-CоV-2 seroprevalence among residents of the Republic of Tatarstan during the COVID-19 epidemic period,2020-10-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Republic of Tartarstan,,population of the Republic of Tatarstan ,The exclusion criterion was active COVID-19 infection at the time of the survey.,2020-09-20,2020-09-27,Household and community samples,All,Seniors (65+ years),70.0,,Age,70+,387,0.24,,,,,,,,Simplified probability,Not reported/ Unable to specify,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Anna Yu Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://microbiol.elpub.ru/jour/article/view/940?locale=en_US,2021-06-03,2022-07-16,Verified,popovaDistributionSARSCoV2Seroprevalence2020,RUS
201021_RepublicOfTartarstan_SaintPetersburgPasteurInstitute_Male,201021_RepublicOfTartarstan_SaintPetersburgPasteurInstitute,Distribution of SARS-CоV-2 seroprevalence among residents of the Republic of Tatarstan during the COVID-19 epidemic period,2020-10-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Republic of Tartarstan,,population of the Republic of Tatarstan ,The exclusion criterion was active COVID-19 infection at the time of the survey.,2020-09-20,2020-09-27,Household and community samples,Male,Multiple groups,1.0,,Sex/Gender,Males,926,0.28500000000000003,,,,,,,,Simplified probability,Not reported/ Unable to specify,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Anna Yu Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://microbiol.elpub.ru/jour/article/view/940?locale=en_US,2021-06-03,2022-07-16,Verified,popovaDistributionSARSCoV2Seroprevalence2020,RUS
201021_RepublicOfTartarstan_SaintPetersburgPasteurInstitute_50-59,201021_RepublicOfTartarstan_SaintPetersburgPasteurInstitute,Distribution of SARS-CоV-2 seroprevalence among residents of the Republic of Tatarstan during the COVID-19 epidemic period,2020-10-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Republic of Tartarstan,,population of the Republic of Tatarstan ,The exclusion criterion was active COVID-19 infection at the time of the survey.,2020-09-20,2020-09-27,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,448,0.344,,,,,,,,Simplified probability,Not reported/ Unable to specify,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Anna Yu Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://microbiol.elpub.ru/jour/article/view/940?locale=en_US,2021-06-03,2022-07-16,Verified,popovaDistributionSARSCoV2Seroprevalence2020,RUS
201021_RepublicOfTartarstan_SaintPetersburgPasteurInstitute_1-6,201021_RepublicOfTartarstan_SaintPetersburgPasteurInstitute,Distribution of SARS-CоV-2 seroprevalence among residents of the Republic of Tatarstan during the COVID-19 epidemic period,2020-10-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Republic of Tartarstan,,population of the Republic of Tatarstan ,The exclusion criterion was active COVID-19 infection at the time of the survey.,2020-09-20,2020-09-27,Household and community samples,All,Children and Youth (0-17 years),1.0,6.0,Age,1-6 yrs,94,0.33,,,,,,,,Simplified probability,Not reported/ Unable to specify,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Anna Yu Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://microbiol.elpub.ru/jour/article/view/940?locale=en_US,2021-06-03,2022-07-16,Verified,popovaDistributionSARSCoV2Seroprevalence2020,RUS
201021_RepublicOfTartarstan_SaintPetersburgPasteurInstitute_60-69,201021_RepublicOfTartarstan_SaintPetersburgPasteurInstitute,Distribution of SARS-CоV-2 seroprevalence among residents of the Republic of Tatarstan during the COVID-19 epidemic period,2020-10-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Republic of Tartarstan,,population of the Republic of Tatarstan ,The exclusion criterion was active COVID-19 infection at the time of the survey.,2020-09-20,2020-09-27,Household and community samples,All,Multiple groups,60.0,69.0,Age,60-69,402,0.30100000000000005,,,,,,,,Simplified probability,Not reported/ Unable to specify,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Anna Yu Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://microbiol.elpub.ru/jour/article/view/940?locale=en_US,2021-06-03,2022-07-16,Verified,popovaDistributionSARSCoV2Seroprevalence2020,RUS
201021_RepublicOfTartarstan_SaintPetersburgPasteurInstitute_30-39,201021_RepublicOfTartarstan_SaintPetersburgPasteurInstitute,Distribution of SARS-CоV-2 seroprevalence among residents of the Republic of Tatarstan during the COVID-19 epidemic period,2020-10-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Republic of Tartarstan,,population of the Republic of Tatarstan ,The exclusion criterion was active COVID-19 infection at the time of the survey.,2020-09-20,2020-09-27,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39 yrs,448,0.306,,,,,,,,Simplified probability,Not reported/ Unable to specify,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Anna Yu Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://microbiol.elpub.ru/jour/article/view/940?locale=en_US,2021-06-03,2022-07-16,Verified,popovaDistributionSARSCoV2Seroprevalence2020,RUS
201021_RepublicOfTartarstan_SaintPetersburgPasteurInstitute_40-49,201021_RepublicOfTartarstan_SaintPetersburgPasteurInstitute,Distribution of SARS-CоV-2 seroprevalence among residents of the Republic of Tatarstan during the COVID-19 epidemic period,2020-10-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Republic of Tartarstan,,population of the Republic of Tatarstan ,The exclusion criterion was active COVID-19 infection at the time of the survey.,2020-09-20,2020-09-27,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,461,0.2842,,,,,,,,Simplified probability,Not reported/ Unable to specify,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Anna Yu Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://microbiol.elpub.ru/jour/article/view/940?locale=en_US,2021-06-03,2022-07-16,Verified,popovaDistributionSARSCoV2Seroprevalence2020,RUS
201021_RepublicOfTartarstan_SaintPetersburgPasteurInstitute_Female,201021_RepublicOfTartarstan_SaintPetersburgPasteurInstitute,Distribution of SARS-CоV-2 seroprevalence among residents of the Republic of Tatarstan during the COVID-19 epidemic period,2020-10-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Republic of Tartarstan,,population of the Republic of Tatarstan ,The exclusion criterion was active COVID-19 infection at the time of the survey.,2020-09-20,2020-09-27,Household and community samples,Female,Multiple groups,1.0,,Sex/Gender,female,2000,0.329,,,,,,,,Simplified probability,Not reported/ Unable to specify,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Anna Yu Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://microbiol.elpub.ru/jour/article/view/940?locale=en_US,2021-06-03,2022-07-16,Verified,popovaDistributionSARSCoV2Seroprevalence2020,RUS
201021_RepublicOfTartarstan_SaintPetersburgPasteurInstitute_18-29,201021_RepublicOfTartarstan_SaintPetersburgPasteurInstitute,Distribution of SARS-CоV-2 seroprevalence among residents of the Republic of Tatarstan during the COVID-19 epidemic period,2020-10-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Republic of Tartarstan,,population of the Republic of Tatarstan ,The exclusion criterion was active COVID-19 infection at the time of the survey.,2020-09-20,2020-09-27,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,18-29 yrs,400,0.3225,,,,,,,,Simplified probability,Not reported/ Unable to specify,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Anna Yu Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://microbiol.elpub.ru/jour/article/view/940?locale=en_US,2021-06-03,2022-07-16,Verified,popovaDistributionSARSCoV2Seroprevalence2020,RUS
201021_RepublicOfTartarstan_SaintPetersburgPasteurInstitute_7-13,201021_RepublicOfTartarstan_SaintPetersburgPasteurInstitute,Distribution of SARS-CоV-2 seroprevalence among residents of the Republic of Tatarstan during the COVID-19 epidemic period,2020-10-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Republic of Tartarstan,,population of the Republic of Tatarstan ,The exclusion criterion was active COVID-19 infection at the time of the survey.,2020-09-20,2020-09-27,Household and community samples,All,Children and Youth (0-17 years),7.0,13.0,Age,7-13 yrs,162,0.42,,,,,,,,Simplified probability,Not reported/ Unable to specify,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Anna Yu Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://microbiol.elpub.ru/jour/article/view/940?locale=en_US,2021-06-03,2022-07-16,Verified,popovaDistributionSARSCoV2Seroprevalence2020,RUS
201021_RepublicOfTartarstan_SaintPetersburgPasteurInstitute_14-17,201021_RepublicOfTartarstan_SaintPetersburgPasteurInstitute,Distribution of SARS-CоV-2 seroprevalence among residents of the Republic of Tatarstan during the COVID-19 epidemic period,2020-10-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Republic of Tartarstan,,population of the Republic of Tatarstan ,The exclusion criterion was active COVID-19 infection at the time of the survey.,2020-09-20,2020-09-27,Household and community samples,All,Children and Youth (0-17 years),14.0,17.0,Age,14-17,144,0.40299999999999997,,,,,,,,Simplified probability,Not reported/ Unable to specify,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Anna Yu Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://microbiol.elpub.ru/jour/article/view/940?locale=en_US,2021-06-03,2022-07-16,Verified,popovaDistributionSARSCoV2Seroprevalence2020,RUS
210101_MurmanskRegion_StPetersburgPasteurInstitute_Overall,210101_MurmanskRegion_StPetersburgPasteurInstitute,Humoral immunity to SARS-CoV-2 in the population of the Murmansk region against the background of the incidence of COVID-19,2021-01-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Murmansk Region,,,Active COVID-19 infection at the time of the survey,2020-08-03,2020-08-11,Household and community samples,All,Multiple groups,1.0,,Primary Estimate,,3117,0.312,0.304,0.32,True,,,,True,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,Yes,Yes,Yes,No,Unclear,Yes,No,Unclear,Anna Popova,St. Petersburg Pasteur Institute,Not Unity-Aligned,https://hiv.bmoc-spb.ru/jour/article/view/605#,2021-05-05,2022-07-16,Verified,popova_humoral_2021,RUS
210101_MurmanskRegion_StPetersburgPasteurInstitute_1-6yrs,210101_MurmanskRegion_StPetersburgPasteurInstitute,Humoral immunity to SARS-CoV-2 in the population of the Murmansk region against the background of the incidence of COVID-19,2021-01-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Murmansk Region,,,Active COVID-19 infection at the time of the survey,2020-08-03,2020-08-11,Household and community samples,All,Children and Youth (0-17 years),1.0,6.0,Age,1-6 yrs old,87,0.35600000000000004,0.305,0.40700000000000003,,,,,,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,Yes,Yes,Yes,No,Unclear,Yes,No,Unclear,Anna Popova,St. Petersburg Pasteur Institute,Not Unity-Aligned,https://hiv.bmoc-spb.ru/jour/article/view/605#,2021-05-05,2022-07-16,Verified,popova_humoral_2021,RUS
210101_MurmanskRegion_StPetersburgPasteurInstitute_7-13,210101_MurmanskRegion_StPetersburgPasteurInstitute,Humoral immunity to SARS-CoV-2 in the population of the Murmansk region against the background of the incidence of COVID-19,2021-01-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Murmansk Region,,,Active COVID-19 infection at the time of the survey,2020-08-03,2020-08-11,Household and community samples,All,Children and Youth (0-17 years),7.0,13.0,Age,7-13 years old,161,0.441,0.402,0.48,,,,,,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,Yes,Yes,Yes,No,Unclear,Yes,No,Unclear,Anna Popova,St. Petersburg Pasteur Institute,Not Unity-Aligned,https://hiv.bmoc-spb.ru/jour/article/view/605#,2021-05-05,2022-07-16,Verified,popova_humoral_2021,RUS
210101_MurmanskRegion_StPetersburgPasteurInstitute_female,210101_MurmanskRegion_StPetersburgPasteurInstitute,Humoral immunity to SARS-CoV-2 in the population of the Murmansk region against the background of the incidence of COVID-19,2021-01-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Murmansk Region,,,Active COVID-19 infection at the time of the survey,2020-08-03,2020-08-11,Household and community samples,Female,Multiple groups,1.0,,Sex/Gender,female,2255,0.723,,,,,,,,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,Yes,Yes,Yes,No,Unclear,Yes,No,Unclear,Anna Popova,St. Petersburg Pasteur Institute,Not Unity-Aligned,https://hiv.bmoc-spb.ru/jour/article/view/605#,2021-05-07,2022-07-16,Verified,popova_humoral_2021,RUS
210101_MurmanskRegion_StPetersburgPasteurInstitute_40-49,210101_MurmanskRegion_StPetersburgPasteurInstitute,Humoral immunity to SARS-CoV-2 in the population of the Murmansk region against the background of the incidence of COVID-19,2021-01-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Murmansk Region,,,Active COVID-19 infection at the time of the survey,2020-08-03,2020-08-11,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,510,0.34700000000000003,0.326,0.368,,,,,,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,Yes,Yes,Yes,No,Unclear,Yes,No,Unclear,Anna Popova,St. Petersburg Pasteur Institute,Not Unity-Aligned,https://hiv.bmoc-spb.ru/jour/article/view/605#,2021-05-05,2022-07-16,Verified,popova_humoral_2021,RUS
210101_MurmanskRegion_StPetersburgPasteurInstitute_14-17,210101_MurmanskRegion_StPetersburgPasteurInstitute,Humoral immunity to SARS-CoV-2 in the population of the Murmansk region against the background of the incidence of COVID-19,2021-01-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Murmansk Region,,,Active COVID-19 infection at the time of the survey,2020-08-03,2020-08-11,Household and community samples,All,Children and Youth (0-17 years),14.0,17.0,Age,14-17,130,0.3,0.26,0.34,,,,,,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,Yes,Yes,Yes,No,Unclear,Yes,No,Unclear,Anna Popova,St. Petersburg Pasteur Institute,Not Unity-Aligned,https://hiv.bmoc-spb.ru/jour/article/view/605#,2021-05-05,2022-07-16,Verified,popova_humoral_2021,RUS
210101_MurmanskRegion_StPetersburgPasteurInstitute_>=70,210101_MurmanskRegion_StPetersburgPasteurInstitute,Humoral immunity to SARS-CoV-2 in the population of the Murmansk region against the background of the incidence of COVID-19,2021-01-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Murmansk Region,,,Active COVID-19 infection at the time of the survey,2020-08-03,2020-08-11,Household and community samples,All,Seniors (65+ years),70.0,,Age,>=70,388,0.209,0.188,0.23,,,,,,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,Yes,Yes,Yes,No,Unclear,Yes,No,Unclear,Anna Popova,St. Petersburg Pasteur Institute,Not Unity-Aligned,https://hiv.bmoc-spb.ru/jour/article/view/605#,2021-05-05,2022-07-16,Verified,popova_humoral_2021,RUS
210101_MurmanskRegion_StPetersburgPasteurInstitute_50-59,210101_MurmanskRegion_StPetersburgPasteurInstitute,Humoral immunity to SARS-CoV-2 in the population of the Murmansk region against the background of the incidence of COVID-19,2021-01-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Murmansk Region,,,Active COVID-19 infection at the time of the survey,2020-08-03,2020-08-11,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,517,0.265,0.24600000000000002,0.284,,,,,,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,Yes,Yes,Yes,No,Unclear,Yes,No,Unclear,Anna Popova,St. Petersburg Pasteur Institute,Not Unity-Aligned,https://hiv.bmoc-spb.ru/jour/article/view/605#,2021-05-05,2022-07-16,Verified,popova_humoral_2021,RUS
210101_MurmanskRegion_StPetersburgPasteurInstitute_60-69,210101_MurmanskRegion_StPetersburgPasteurInstitute,Humoral immunity to SARS-CoV-2 in the population of the Murmansk region against the background of the incidence of COVID-19,2021-01-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Murmansk Region,,,Active COVID-19 infection at the time of the survey,2020-08-03,2020-08-11,Household and community samples,All,Multiple groups,60.0,69.0,Age,60-69,417,0.204,0.184,0.22399999999999998,,,,,,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,Yes,Yes,Yes,No,Unclear,Yes,No,Unclear,Anna Popova,St. Petersburg Pasteur Institute,Not Unity-Aligned,https://hiv.bmoc-spb.ru/jour/article/view/605#,2021-05-05,2022-07-16,Verified,popova_humoral_2021,RUS
210101_MurmanskRegion_StPetersburgPasteurInstitute_18-29,210101_MurmanskRegion_StPetersburgPasteurInstitute,Humoral immunity to SARS-CoV-2 in the population of the Murmansk region against the background of the incidence of COVID-19,2021-01-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Murmansk Region,,,Active COVID-19 infection at the time of the survey,2020-08-03,2020-08-11,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,18-29,429,0.371,0.348,0.394,,,,,,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,Yes,Yes,Yes,No,Unclear,Yes,No,Unclear,Anna Popova,St. Petersburg Pasteur Institute,Not Unity-Aligned,https://hiv.bmoc-spb.ru/jour/article/view/605#,2021-05-05,2022-07-16,Verified,popova_humoral_2021,RUS
210101_MurmanskRegion_StPetersburgPasteurInstitute_30-39,210101_MurmanskRegion_StPetersburgPasteurInstitute,Humoral immunity to SARS-CoV-2 in the population of the Murmansk region against the background of the incidence of COVID-19,2021-01-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Murmansk Region,,,Active COVID-19 infection at the time of the survey,2020-08-03,2020-08-11,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,478,0.402,0.38,0.424,,,,,,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,Yes,Yes,Yes,No,Unclear,Yes,No,Unclear,Anna Popova,St. Petersburg Pasteur Institute,Not Unity-Aligned,https://hiv.bmoc-spb.ru/jour/article/view/605#,2021-05-05,2022-07-16,Verified,popova_humoral_2021,RUS
210101_MurmanskRegion_StPetersburgPasteurInstitute_male,210101_MurmanskRegion_StPetersburgPasteurInstitute,Humoral immunity to SARS-CoV-2 in the population of the Murmansk region against the background of the incidence of COVID-19,2021-01-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Murmansk Region,,,Active COVID-19 infection at the time of the survey,2020-08-03,2020-08-11,Household and community samples,Male,Multiple groups,1.0,,Sex/Gender,male,862,0.277,,,,,,,,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,Yes,Yes,Yes,No,Unclear,Yes,No,Unclear,Anna Popova,St. Petersburg Pasteur Institute,Not Unity-Aligned,https://hiv.bmoc-spb.ru/jour/article/view/605#,2021-05-07,2022-07-16,Verified,popova_humoral_2021,RUS
210119_Kaliningrad_RussianAcademyOfSciences_overall,210119_Kaliningrad_RussianAcademyOfSciences,Herd immunity of sars-CoV-2 among the population of Kalinigrad region amid the COVID-19 epidemic,2021-01-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Kaliningrad Region,,"Individuals in Kaliningrad, Russia",The exclusion criterion was active COVID-19 infection at the time of the survey.,2020-08-03,2020-08-07,Household and community samples,All,Multiple groups,,,Primary Estimate,overall unadj,2939,0.502,0.4903,0.511,True,,,,True,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Unclear,A Yu Popova,The Russian Academy of Sciences ,Not Unity-Aligned,http://dx.doi.org/10.22625/2072-6732-2020-12-5-62-71,2021-03-25,2022-07-16,Verified,popova_herd_2021,RUS
210119_Kaliningrad_RussianAcademyOfSciences_female,210119_Kaliningrad_RussianAcademyOfSciences,Herd immunity of sars-CoV-2 among the population of Kalinigrad region amid the COVID-19 epidemic,2021-01-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Kaliningrad Region,,"Individuals in Kaliningrad, Russia",The exclusion criterion was active COVID-19 infection at the time of the survey.,2020-08-03,2020-08-07,Household and community samples,Female,Multiple groups,,,Sex/Gender,female,2011,0.511,0.5,0.522,,,,,,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Unclear,A Yu Popova,The Russian Academy of Sciences ,Not Unity-Aligned,http://dx.doi.org/10.22625/2072-6732-2020-12-5-62-71,2021-03-25,2022-07-16,Verified,popova_herd_2021,RUS
210119_Kaliningrad_RussianAcademyOfSciences_age70+,210119_Kaliningrad_RussianAcademyOfSciences,Herd immunity of sars-CoV-2 among the population of Kalinigrad region amid the COVID-19 epidemic,2021-01-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Kaliningrad Region,,"Individuals in Kaliningrad, Russia",The exclusion criterion was active COVID-19 infection at the time of the survey.,2020-08-03,2020-08-07,Household and community samples,All,Multiple groups,,,Age,age70+,316,0.434,0.406,0.462,,,,,,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Unclear,A Yu Popova,The Russian Academy of Sciences ,Not Unity-Aligned,http://dx.doi.org/10.22625/2072-6732-2020-12-5-62-71,2021-03-25,2022-07-16,Verified,popova_herd_2021,RUS
210119_Kaliningrad_RussianAcademyOfSciences_age7-13,210119_Kaliningrad_RussianAcademyOfSciences,Herd immunity of sars-CoV-2 among the population of Kalinigrad region amid the COVID-19 epidemic,2021-01-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Kaliningrad Region,,"Individuals in Kaliningrad, Russia",The exclusion criterion was active COVID-19 infection at the time of the survey.,2020-08-03,2020-08-07,Household and community samples,All,Multiple groups,,,Age,age7-13,146,0.623,0.583,0.663,,,,,,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Unclear,A Yu Popova,The Russian Academy of Sciences ,Not Unity-Aligned,http://dx.doi.org/10.22625/2072-6732-2020-12-5-62-71,2021-03-25,2022-07-16,Verified,popova_herd_2021,RUS
210119_Kaliningrad_RussianAcademyOfSciences_age14-17,210119_Kaliningrad_RussianAcademyOfSciences,Herd immunity of sars-CoV-2 among the population of Kalinigrad region amid the COVID-19 epidemic,2021-01-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Kaliningrad Region,,"Individuals in Kaliningrad, Russia",The exclusion criterion was active COVID-19 infection at the time of the survey.,2020-08-03,2020-08-07,Household and community samples,All,Multiple groups,,,Age,age14-17,115,0.7040000000000001,0.6609999999999999,0.747,,,,,,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Unclear,A Yu Popova,The Russian Academy of Sciences ,Not Unity-Aligned,http://dx.doi.org/10.22625/2072-6732-2020-12-5-62-71,2021-03-25,2022-07-16,Verified,popova_herd_2021,RUS
210119_Kaliningrad_RussianAcademyOfSciences_age30-39,210119_Kaliningrad_RussianAcademyOfSciences,Herd immunity of sars-CoV-2 among the population of Kalinigrad region amid the COVID-19 epidemic,2021-01-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Kaliningrad Region,,"Individuals in Kaliningrad, Russia",The exclusion criterion was active COVID-19 infection at the time of the survey.,2020-08-03,2020-08-07,Household and community samples,All,Multiple groups,,,Age,age30-39,465,0.473,0.45,0.49600000000000005,,,,,,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Unclear,A Yu Popova,The Russian Academy of Sciences ,Not Unity-Aligned,http://dx.doi.org/10.22625/2072-6732-2020-12-5-62-71,2021-03-25,2022-07-16,Verified,popova_herd_2021,RUS
210119_Kaliningrad_RussianAcademyOfSciences_age1-6,210119_Kaliningrad_RussianAcademyOfSciences,Herd immunity of sars-CoV-2 among the population of Kalinigrad region amid the COVID-19 epidemic,2021-01-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Kaliningrad Region,,"Individuals in Kaliningrad, Russia",The exclusion criterion was active COVID-19 infection at the time of the survey.,2020-08-03,2020-08-07,Household and community samples,All,Multiple groups,,,Age,age1-6,56,0.7140000000000001,0.654,0.774,,,,,,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Unclear,A Yu Popova,The Russian Academy of Sciences ,Not Unity-Aligned,http://dx.doi.org/10.22625/2072-6732-2020-12-5-62-71,2021-03-25,2022-07-16,Verified,popova_herd_2021,RUS
210119_Kaliningrad_RussianAcademyOfSciences_age60-69,210119_Kaliningrad_RussianAcademyOfSciences,Herd immunity of sars-CoV-2 among the population of Kalinigrad region amid the COVID-19 epidemic,2021-01-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Kaliningrad Region,,"Individuals in Kaliningrad, Russia",The exclusion criterion was active COVID-19 infection at the time of the survey.,2020-08-03,2020-08-07,Household and community samples,All,Multiple groups,,,Age,age60-69,465,0.46,0.43700000000000006,0.483,,,,,,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Unclear,A Yu Popova,The Russian Academy of Sciences ,Not Unity-Aligned,http://dx.doi.org/10.22625/2072-6732-2020-12-5-62-71,2021-03-25,2022-07-16,Verified,popova_herd_2021,RUS
210119_Kaliningrad_RussianAcademyOfSciences_male,210119_Kaliningrad_RussianAcademyOfSciences,Herd immunity of sars-CoV-2 among the population of Kalinigrad region amid the COVID-19 epidemic,2021-01-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Kaliningrad Region,,"Individuals in Kaliningrad, Russia",The exclusion criterion was active COVID-19 infection at the time of the survey.,2020-08-03,2020-08-07,Household and community samples,Male,Multiple groups,,,Sex/Gender,male,928,0.483,0.467,0.499,,,,,,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Unclear,A Yu Popova,The Russian Academy of Sciences ,Not Unity-Aligned,http://dx.doi.org/10.22625/2072-6732-2020-12-5-62-71,2021-03-25,2022-07-16,Verified,popova_herd_2021,RUS
210119_Kaliningrad_RussianAcademyOfSciences_age40-49,210119_Kaliningrad_RussianAcademyOfSciences,Herd immunity of sars-CoV-2 among the population of Kalinigrad region amid the COVID-19 epidemic,2021-01-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Kaliningrad Region,,"Individuals in Kaliningrad, Russia",The exclusion criterion was active COVID-19 infection at the time of the survey.,2020-08-03,2020-08-07,Household and community samples,All,Multiple groups,,,Age,age40-49,488,0.51,0.48700000000000004,0.533,,,,,,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Unclear,A Yu Popova,The Russian Academy of Sciences ,Not Unity-Aligned,http://dx.doi.org/10.22625/2072-6732-2020-12-5-62-71,2021-03-25,2022-07-16,Verified,popova_herd_2021,RUS
210119_Kaliningrad_RussianAcademyOfSciences_age50-59,210119_Kaliningrad_RussianAcademyOfSciences,Herd immunity of sars-CoV-2 among the population of Kalinigrad region amid the COVID-19 epidemic,2021-01-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Kaliningrad Region,,"Individuals in Kaliningrad, Russia",The exclusion criterion was active COVID-19 infection at the time of the survey.,2020-08-03,2020-08-07,Household and community samples,All,Multiple groups,,,Age,age50-59,493,0.44200000000000006,0.42,0.46399999999999997,,,,,,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Unclear,A Yu Popova,The Russian Academy of Sciences ,Not Unity-Aligned,http://dx.doi.org/10.22625/2072-6732-2020-12-5-62-71,2021-03-25,2022-07-16,Verified,popova_herd_2021,RUS
210119_Kaliningrad_RussianAcademyOfSciences_age18-29,210119_Kaliningrad_RussianAcademyOfSciences,Herd immunity of sars-CoV-2 among the population of Kalinigrad region amid the COVID-19 epidemic,2021-01-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Russian Federation,Kaliningrad Region,,"Individuals in Kaliningrad, Russia",The exclusion criterion was active COVID-19 infection at the time of the survey.,2020-08-03,2020-08-07,Household and community samples,All,Multiple groups,,,Age,age18-29,395,0.5700000000000001,0.545,0.595,,,,,,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Unclear,A Yu Popova,The Russian Academy of Sciences ,Not Unity-Aligned,http://dx.doi.org/10.22625/2072-6732-2020-12-5-62-71,2021-03-25,2022-07-16,Verified,popova_herd_2021,RUS
210205_Ekaterinburg_RussianAcademyOfSciences_overall,210205_Ekaterinburg_RussianAcademyOfSciences,SARS-CoV-2 Seropositivity among Dental Staff and the Role of Aspirating Systems.,2021-02-05,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Russian Federation,,Ekaterinburg,"The study included dentists or dental assistants from 3 dental clinics (2 private clinics and 1 government center) in Ekaterinburg (Russian Federation) serving for medical treatment during
the COVID-19 outbreak","HCWs aged >65 y, those with chronic diseases or immunological disorders, and pregnant women were not permitted to work during the pandemic based on the National Recommendations (Appendix) and were excluded from the study. ",2020-05-15,2020-08-15,Health care workers and caregivers,All,Adults (18-64 years),,65.0,Primary Estimate,,157,0.115,,,True,,,,True,Convenience,SARS- CoV-2-IgG-EIA-BEST and SARS-CoV-2- IgM-EIA-BEST ,Vector BEST,ELISA,Serum,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,No,Unclear,Yes,No,Unclear,M Sarapultseva,Russian Academy of Sciences,Not Unity-Aligned,https://dx.doi.org/10.1177/2380084421993099,2021-02-20,2022-07-16,Verified,sarapultseva_sars-cov-2_2021,RUS
201228_Moscow_SaintPetersburgPasteurInstitute_primary,201228_Moscow_SaintPetersburgPasteurInstitute,Collective immunity to SARS-COV-2 of moscow residents during the COVID-19 epidemic period,2021-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,Moscow,,"The exclusion criterion was active infection,
COVID-19 at the time of the survey",2020-07-01,2020-07-30,Household and community samples,All,Multiple groups,1.0,,Primary Estimate,,2688,0.22100000000000003,,,True,,,,True,Simplified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Popova A Yu,Saint-Petersburg Pasteur Institute,Not Unity-Aligned,http://dx.doi.org/10.20953/1729-9225-2020-4-8-16,2021-05-19,2022-07-16,Verified,federal_service_for_surveillance_on_consumer_rights_protection_and_human_wellbeing_moscow_russian_federation_collective_2020,RUS
201228_Moscow_SaintPetersburgPasteurInstitute_30-39,201228_Moscow_SaintPetersburgPasteurInstitute,Collective immunity to SARS-COV-2 of moscow residents during the COVID-19 epidemic period,2021-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,Moscow,,"The exclusion criterion was active infection,
COVID-19 at the time of the survey",2020-07-01,2020-07-30,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39 yrs old,384,0.167,,,,,,,,Simplified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Popova A Yu,Saint-Petersburg Pasteur Institute,Not Unity-Aligned,http://dx.doi.org/10.20953/1729-9225-2020-4-8-16,2021-06-03,2022-07-16,Verified,federal_service_for_surveillance_on_consumer_rights_protection_and_human_wellbeing_moscow_russian_federation_collective_2020,RUS
201228_Moscow_SaintPetersburgPasteurInstitute_1-6,201228_Moscow_SaintPetersburgPasteurInstitute,Collective immunity to SARS-COV-2 of moscow residents during the COVID-19 epidemic period,2021-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,Moscow,,"The exclusion criterion was active infection,
COVID-19 at the time of the survey",2020-07-01,2020-07-30,Household and community samples,All,Children and Youth (0-17 years),1.0,6.0,Age,1-6 years old,98,0.35700000000000004,,,,,,,,Simplified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Popova A Yu,Saint-Petersburg Pasteur Institute,Not Unity-Aligned,http://dx.doi.org/10.20953/1729-9225-2020-4-8-16,2021-06-03,2022-07-16,Verified,federal_service_for_surveillance_on_consumer_rights_protection_and_human_wellbeing_moscow_russian_federation_collective_2020,RUS
201228_Moscow_SaintPetersburgPasteurInstitute_18-29,201228_Moscow_SaintPetersburgPasteurInstitute,Collective immunity to SARS-COV-2 of moscow residents during the COVID-19 epidemic period,2021-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,Moscow,,"The exclusion criterion was active infection,
COVID-19 at the time of the survey",2020-07-01,2020-07-30,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,18-29 yrs old,384,0.159,,,,,,,,Simplified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Popova A Yu,Saint-Petersburg Pasteur Institute,Not Unity-Aligned,http://dx.doi.org/10.20953/1729-9225-2020-4-8-16,2021-06-03,2022-07-16,Verified,federal_service_for_surveillance_on_consumer_rights_protection_and_human_wellbeing_moscow_russian_federation_collective_2020,RUS
201228_Moscow_SaintPetersburgPasteurInstitute_50-59,201228_Moscow_SaintPetersburgPasteurInstitute,Collective immunity to SARS-COV-2 of moscow residents during the COVID-19 epidemic period,2021-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,Moscow,,"The exclusion criterion was active infection,
COVID-19 at the time of the survey",2020-07-01,2020-07-30,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,384,0.23199999999999998,,,,,,,,Simplified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Popova A Yu,Saint-Petersburg Pasteur Institute,Not Unity-Aligned,http://dx.doi.org/10.20953/1729-9225-2020-4-8-16,2021-06-03,2022-07-16,Verified,federal_service_for_surveillance_on_consumer_rights_protection_and_human_wellbeing_moscow_russian_federation_collective_2020,RUS
201228_Moscow_SaintPetersburgPasteurInstitute_40-49,201228_Moscow_SaintPetersburgPasteurInstitute,Collective immunity to SARS-COV-2 of moscow residents during the COVID-19 epidemic period,2021-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,Moscow,,"The exclusion criterion was active infection,
COVID-19 at the time of the survey",2020-07-01,2020-07-30,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49 years old,384,0.172,,,,,,,,Simplified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Popova A Yu,Saint-Petersburg Pasteur Institute,Not Unity-Aligned,http://dx.doi.org/10.20953/1729-9225-2020-4-8-16,2021-06-03,2022-07-16,Verified,federal_service_for_surveillance_on_consumer_rights_protection_and_human_wellbeing_moscow_russian_federation_collective_2020,RUS
201228_Moscow_SaintPetersburgPasteurInstitute_Female,201228_Moscow_SaintPetersburgPasteurInstitute,Collective immunity to SARS-COV-2 of moscow residents during the COVID-19 epidemic period,2021-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,Moscow,,"The exclusion criterion was active infection,
COVID-19 at the time of the survey",2020-07-01,2020-07-30,Household and community samples,Female,Multiple groups,1.0,,Sex/Gender,,1835,0.222,,,,,,,,Simplified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Popova A Yu,Saint-Petersburg Pasteur Institute,Not Unity-Aligned,http://dx.doi.org/10.20953/1729-9225-2020-4-8-16,2021-06-03,2022-07-16,Verified,federal_service_for_surveillance_on_consumer_rights_protection_and_human_wellbeing_moscow_russian_federation_collective_2020,RUS
201228_Moscow_SaintPetersburgPasteurInstitute_70+,201228_Moscow_SaintPetersburgPasteurInstitute,Collective immunity to SARS-COV-2 of moscow residents during the COVID-19 epidemic period,2021-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,Moscow,,"The exclusion criterion was active infection,
COVID-19 at the time of the survey",2020-07-01,2020-07-30,Household and community samples,All,Seniors (65+ years),70.0,,Age,70+,385,0.20500000000000002,,,,,,,,Simplified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Popova A Yu,Saint-Petersburg Pasteur Institute,Not Unity-Aligned,http://dx.doi.org/10.20953/1729-9225-2020-4-8-16,2021-06-03,2022-07-16,Verified,federal_service_for_surveillance_on_consumer_rights_protection_and_human_wellbeing_moscow_russian_federation_collective_2020,RUS
201228_Moscow_SaintPetersburgPasteurInstitute_7-13,201228_Moscow_SaintPetersburgPasteurInstitute,Collective immunity to SARS-COV-2 of moscow residents during the COVID-19 epidemic period,2021-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,Moscow,,"The exclusion criterion was active infection,
COVID-19 at the time of the survey",2020-07-01,2020-07-30,Household and community samples,All,Children and Youth (0-17 years),7.0,13.0,Age,7-13 years old,165,0.321,,,,,,,,Simplified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Popova A Yu,Saint-Petersburg Pasteur Institute,Not Unity-Aligned,http://dx.doi.org/10.20953/1729-9225-2020-4-8-16,2021-06-03,2022-07-16,Verified,federal_service_for_surveillance_on_consumer_rights_protection_and_human_wellbeing_moscow_russian_federation_collective_2020,RUS
201228_Moscow_SaintPetersburgPasteurInstitute_Male,201228_Moscow_SaintPetersburgPasteurInstitute,Collective immunity to SARS-COV-2 of moscow residents during the COVID-19 epidemic period,2021-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,Moscow,,"The exclusion criterion was active infection,
COVID-19 at the time of the survey",2020-07-01,2020-07-30,Household and community samples,Male,Multiple groups,1.0,,Sex/Gender,,853,0.22,,,,,,,,Simplified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Popova A Yu,Saint-Petersburg Pasteur Institute,Not Unity-Aligned,http://dx.doi.org/10.20953/1729-9225-2020-4-8-16,2021-06-03,2022-07-16,Verified,federal_service_for_surveillance_on_consumer_rights_protection_and_human_wellbeing_moscow_russian_federation_collective_2020,RUS
201228_Moscow_SaintPetersburgPasteurInstitute_14-17,201228_Moscow_SaintPetersburgPasteurInstitute,Collective immunity to SARS-COV-2 of moscow residents during the COVID-19 epidemic period,2021-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,Moscow,,"The exclusion criterion was active infection,
COVID-19 at the time of the survey",2020-07-01,2020-07-30,Household and community samples,All,Children and Youth (0-17 years),14.0,17.0,Age,14-17 ys old,121,0.446,,,,,,,,Simplified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Popova A Yu,Saint-Petersburg Pasteur Institute,Not Unity-Aligned,http://dx.doi.org/10.20953/1729-9225-2020-4-8-16,2021-06-03,2022-07-16,Verified,federal_service_for_surveillance_on_consumer_rights_protection_and_human_wellbeing_moscow_russian_federation_collective_2020,RUS
201228_Moscow_SaintPetersburgPasteurInstitute_60-69,201228_Moscow_SaintPetersburgPasteurInstitute,Collective immunity to SARS-COV-2 of moscow residents during the COVID-19 epidemic period,2021-04-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,Moscow,,"The exclusion criterion was active infection,
COVID-19 at the time of the survey",2020-07-01,2020-07-30,Household and community samples,All,Multiple groups,60.0,69.0,Age,60-69,383,0.245,,,,,,,,Simplified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Popova A Yu,Saint-Petersburg Pasteur Institute,Not Unity-Aligned,http://dx.doi.org/10.20953/1729-9225-2020-4-8-16,2021-06-03,2022-07-16,Verified,federal_service_for_surveillance_on_consumer_rights_protection_and_human_wellbeing_moscow_russian_federation_collective_2020,RUS
210504_Russia_FederalScientificResearchInstituteofEpidemiologyandMicrobiology_Phase1_1-6,210504_Russia_FederalScientificResearchInstituteofEpidemiologyandMicrobiology_Phase1_1-6,PECULIARITIES OF SARS-COV-2 NUCLEOCAPSID IN CHILDREN DURING THE COVID-19 EPIDEMIC OF 2020,2021-05-04,Journal Article (Peer-Reviewed),National,Prospective cohort,Russian Federation,,,Children aged 1-17 residing in one of the 26 tested Russian Federation states,The exclusion criterion was active infection. COVID-19 at the time of the survey.,2020-06-15,2020-08-15,Household and community samples,All,Children and Youth (0-17 years),1.0,6.0,Primary Estimate,,2577,0.225,0.14300000000000002,0.38200000000000006,True,,,,True,Stratified probability,Author designed (ELISA) -Unknown,,ELISA,Plasma,IgG,[],,,,['Moderate'],,Yes,Yes,No,,Unclear,Yes,No,,A.Y. Popova,Federal Scientific Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://dx.doi.org/10.24110/0031-403X-2021-100-3-97-106,2022-12-16,2023-03-19,Unverified,popova_peculiarities_2021,RUS
210504_Russia_FederalScientificResearchInstituteofEpidemiologyandMicrobiology_Phase1_14-17,210504_Russia_FederalScientificResearchInstituteofEpidemiologyandMicrobiology_Phase1_14-17,PECULIARITIES OF SARS-COV-2 NUCLEOCAPSID IN CHILDREN DURING THE COVID-19 EPIDEMIC OF 2020,2021-05-04,Journal Article (Peer-Reviewed),National,Prospective cohort,Russian Federation,,,Children aged 1-17 residing in one of the 26 tested Russian Federation states,The exclusion criterion was active infection. COVID-19 at the time of the survey.,2020-06-15,2020-08-15,Household and community samples,All,Children and Youth (0-17 years),14.0,17.0,Primary Estimate,,3277,0.226,0.134,0.39299999999999996,True,,,,True,Stratified probability,Author designed (ELISA) -Unknown,,ELISA,Plasma,IgG,[],,,,['Moderate'],,Yes,Yes,No,,Unclear,Yes,No,,A.Y. Popova,Federal Scientific Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://dx.doi.org/10.24110/0031-403X-2021-100-3-97-106,2022-12-16,2023-03-19,Unverified,popova_peculiarities_2021,RUS
210504_Russia_FederalScientificResearchInstituteofEpidemiologyandMicrobiology_Phase1_7-13,210504_Russia_FederalScientificResearchInstituteofEpidemiologyandMicrobiology_Phase1_7-13,PECULIARITIES OF SARS-COV-2 NUCLEOCAPSID IN CHILDREN DURING THE COVID-19 EPIDEMIC OF 2020,2021-05-04,Journal Article (Peer-Reviewed),National,Prospective cohort,Russian Federation,,,Children aged 1-17 residing in one of the 26 tested Russian Federation states,The exclusion criterion was active infection. COVID-19 at the time of the survey.,2020-06-15,2020-08-15,Household and community samples,All,Children and Youth (0-17 years),7.0,13.0,Primary Estimate,,2700,0.23199999999999998,0.14400000000000002,0.373,True,,,,True,Stratified probability,Author designed (ELISA) -Unknown,,ELISA,Plasma,IgG,[],,,,['Moderate'],,Yes,Yes,No,,Unclear,Yes,No,,A.Y. Popova,Federal Scientific Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://dx.doi.org/10.24110/0031-403X-2021-100-3-97-106,2022-12-16,2023-03-19,Unverified,popova_peculiarities_2021,RUS
210504_Russia_FederalScientificResearchInstituteofEpidemiologyandMicrobiology_Phase2,210504_Russia_FederalScientificResearchInstituteofEpidemiologyandMicrobiology_Phase2,PECULIARITIES OF SARS-COV-2 NUCLEOCAPSID IN CHILDREN DURING THE COVID-19 EPIDEMIC OF 2020,2021-05-04,Journal Article (Peer-Reviewed),National,Prospective cohort,Russian Federation,,,Children aged 1-17 residing in one of the 26 tested Russian Federation states,The exclusion criterion was active infection. COVID-19 at the time of the survey.,2020-09-15,2020-10-15,Household and community samples,All,Children and Youth (0-17 years),1.0,17.0,Primary Estimate,,4166,0.3718,,,True,,,,True,Stratified probability,Author designed (ELISA) -Unknown,,ELISA,Plasma,IgG,[],,,,['Moderate'],,Yes,Yes,No,,Unclear,Yes,No,,A.Y. Popova,Federal Scientific Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://dx.doi.org/10.24110/0031-403X-2021-100-3-97-106,2022-12-16,2023-03-19,Unverified,popova_peculiarities_2021,RUS
210504_Russia_FederalScientificResearchInstituteofEpidemiologyandMicrobiology_Phase3,210504_Russia_FederalScientificResearchInstituteofEpidemiologyandMicrobiology_Phase3,PECULIARITIES OF SARS-COV-2 NUCLEOCAPSID IN CHILDREN DURING THE COVID-19 EPIDEMIC OF 2020,2021-05-04,Journal Article (Peer-Reviewed),National,Prospective cohort,Russian Federation,,,Children aged 1-17 residing in one of the 26 tested Russian Federation states,The exclusion criterion was active infection. COVID-19 at the time of the survey.,2020-12-01,2020-12-31,Household and community samples,All,Children and Youth (0-17 years),1.0,17.0,Primary Estimate,,4838,0.4742,,,True,,,,True,Stratified probability,Author designed (ELISA) -Unknown,,ELISA,Plasma,IgG,[],,,,['Moderate'],,Yes,Yes,No,,Unclear,Yes,No,,A.Y. Popova,Federal Scientific Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://dx.doi.org/10.24110/0031-403X-2021-100-3-97-106,2022-12-16,2023-03-22,Unverified,popova_peculiarities_2021,RUS
210609_Chelyabinsk_SouthUralStateUniversity_HighRisk_testadj,210609_Chelyabinsk_SouthUralStateUniversity,"Seroprevalence of sars-cov-2 antibodies in symptomatic individuals is higher than in persons who are at increased risk exposure: The results of the single-center, prospective, cross-sectional study",2021-06-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,Chelyabinsk,"""A total of 1300 persons, who were at an increased risk of exposure to SARS-CoV-2 (i.e., healthcare workers, education staff, and supermarket employees), were invited to participate""","""This study excluded patients younger than 18 years with a history of coronary heart disease, pre-excitation syndromes, motor impairments (cerebral palsy and epilepsy), with pacemakers, drug addicts, and dialysis patients. One thousand and ninety-one persons were enrolled in the study and comprised the “high-risk” group; 209 persons did not agree to participate or did not attend the hospital for a scheduled appointment. Individuals were excluded from this group if they reported symptoms of COVID-19 or other acute respiratory virus infections on the day of the appointment.""",2020-09-28,2020-12-30,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,1091,0.1723,0.17170000000000002,0.1729,True,True,,,True,Unclear,SARS- CoV-2-IgG-EIA-BEST and SARS-CoV-2- IgM-EIA-BEST ,Vector BEST,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,,,['Moderate'],,Unclear,Yes,Yes,,Unclear,Yes,Yes,,Alexandr Zurochka,South Ural State University,Not Unity-Aligned,http://dx.doi.org/10.3390/vaccines9060627,2021-07-07,2022-07-16,Unverified,zurochka_seroprevalence_2021,RUS
210625_Ekaterinburg_DentalCollegeYamunanagar,210625_Ekaterinburg_DentalCollegeYamunanagar,Do aspirating systems have a role in preventing COVID-19 transmission among dental healthcare workers?.,2021-06-25,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Russian Federation,Ural,Ekaterinburg,The study included 157 HCWs who had direct contacts with the patients,"HCWs who are >65 years old, have other chronic diseases, have immunological concerns or are pregnant are not permitted to work according to Russian Federation guidelines, and hence were not part of the cohort. ",2020-05-15,2020-08-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,157,0.121,,,True,,,,True,Convenience,SARS- CoV-2-IgG-EIA-BEST and SARS-CoV-2- IgM-EIA-BEST ,Vector BEST,,,"['IgG', 'IgM']",,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Neeraj Gugnani,Dental College Yamunanagar,Not Unity-Aligned,https://dx.doi.org/10.1038/s41432-021-0171-5,2021-07-06,2022-07-16,Unverified,gugnaniAspiratingSystemsHave2021,RUS
210629_StPetersburg_Saint-PetersburgStateUniversityHospital_overall,210629_StPetersburg_Saint-PetersburgStateUniversityHospital,Long-term monitoring of the development and extinction of IgA and IgG responses to SARS-CoV-2 infection.,2021-06-29,Journal Article (Peer-Reviewed),Local,Prospective cohort,Russian Federation,,St. Petersburg,All study participants were office employees of a business company based in St. Petersburg (Russia),,2020-05-27,2021-03-19,Non-essential workers and unemployed persons,All,Adults (18-64 years),22.0,53.0,Primary Estimate,,180,0.15560000000000002,,,True,,,,True,Unclear,Anti-SARS-CoV-2 ELISA IgA,EUROIMMUN,ELISA,Serum,IgA,Spike,,,,['High'],Unclear,Unclear,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Andrei Ivanov,B.P.Konstantinov St Petersburg Nuclear Physics Institute,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27166,2021-07-06,2024-03-01,Verified,ivanov_long-term_nodate,RUS
210819_RussianFederation_StPetersburgPasteurInstitute_Overall,210819_RussianFederation_StPetersburgPasteurInstitute,Sars-cov-2 seroprevalence structure of the russian population during the covid-19 pandemic,2021-08-19,Journal Article (Peer-Reviewed),National,Prospective cohort,Russian Federation,,,people across 26 regions of Russia,"active COVID-19 infection at the time of the survey. also, as there could be no more than 30 from one organization, excluded participation in the study by organized groups (preschool institutions, schools, military units, etc.).",2020-06-15,2020-12-31,Household and community samples,All,Multiple groups,1.0,,Primary Estimate,Overall estimate (across 3 time periods),74158,0.192,0.189,0.195,True,,,,True,Unclear,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],,Unclear,Yes,No,,Unclear,Yes,No,,Anna Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,http://dx.doi.org/10.3390/v13081648,2021-08-31,2022-07-16,Unverified,popova_sars-cov-2_2021,RUS
210831_Novosibirsk_StPetersburgPasteurInstitute_Phase1_50-59,210831_Novosibirsk_StPetersburgPasteurInstitute_Phase1,Herd immunity to SARS-CoV-2 in the Novosibirsk Region population amid the COVID-19 pandemic,2021-08-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,"Kochenyevsky, Krasnozyersky, Moshkovsky, Novosibirsk, Elitny Village, Toguchinsky Districts",The selection of volunteers was carried out using the anke-using cloud technologiesand randomization by age and areaprinciples.,The exclusion criterion was the presencemanifest form of COVID-19 at the time of the questionnairevania,2020-06-28,2020-07-15,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59 years,409,0.076,0.052000000000000005,0.106,True,,,,True,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anna Popova,St Petersburg Pasteur Institute,Not Unity-Aligned,https://dx.doi.org/10.36233/0507-4088-54,2021-09-28,2022-07-16,Unverified,__2021-2,RUS
210831_Novosibirsk_StPetersburgPasteurInstitute_Phase1_Overall,210831_Novosibirsk_StPetersburgPasteurInstitute_Phase1,Herd immunity to SARS-CoV-2 in the Novosibirsk Region population amid the COVID-19 pandemic,2021-08-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,"Kochenyevsky, Krasnozyersky, Moshkovsky, Novosibirsk, Elitny Village, Toguchinsky Districts",The selection of volunteers was carried out using the anke-using cloud technologiesand randomization by age and areaprinciples.,The exclusion criterion was the presencemanifest form of COVID-19 at the time of the questionnairevania,2020-06-28,2020-07-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,2728,0.091,0.08,0.102,True,,,,True,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anna Popova,St Petersburg Pasteur Institute,Not Unity-Aligned,https://dx.doi.org/10.36233/0507-4088-54,2021-09-28,2022-07-16,Unverified,__2021-2,RUS
210831_Novosibirsk_StPetersburgPasteurInstitute_Phase1_7-13,210831_Novosibirsk_StPetersburgPasteurInstitute_Phase1,Herd immunity to SARS-CoV-2 in the Novosibirsk Region population amid the COVID-19 pandemic,2021-08-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,"Kochenyevsky, Krasnozyersky, Moshkovsky, Novosibirsk, Elitny Village, Toguchinsky Districts",The selection of volunteers was carried out using the anke-using cloud technologiesand randomization by age and areaprinciples.,The exclusion criterion was the presencemanifest form of COVID-19 at the time of the questionnairevania,2020-06-28,2020-07-15,Household and community samples,All,Children and Youth (0-17 years),7.0,13.0,Age,7-13 years,151,0.086,0.047,0.14300000000000002,True,,,,True,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anna Popova,St Petersburg Pasteur Institute,Not Unity-Aligned,https://dx.doi.org/10.36233/0507-4088-54,2021-09-28,2022-07-16,Unverified,__2021-2,RUS
210831_Novosibirsk_StPetersburgPasteurInstitute_Phase1_30-39,210831_Novosibirsk_StPetersburgPasteurInstitute_Phase1,Herd immunity to SARS-CoV-2 in the Novosibirsk Region population amid the COVID-19 pandemic,2021-08-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,"Kochenyevsky, Krasnozyersky, Moshkovsky, Novosibirsk, Elitny Village, Toguchinsky Districts",The selection of volunteers was carried out using the anke-using cloud technologiesand randomization by age and areaprinciples.,The exclusion criterion was the presencemanifest form of COVID-19 at the time of the questionnairevania,2020-06-28,2020-07-15,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39 years,388,0.049,0.03,0.08,True,,,,True,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anna Popova,St Petersburg Pasteur Institute,Not Unity-Aligned,https://dx.doi.org/10.36233/0507-4088-54,2021-09-28,2022-07-16,Unverified,__2021-2,RUS
210831_Novosibirsk_StPetersburgPasteurInstitute_Phase1_60-69,210831_Novosibirsk_StPetersburgPasteurInstitute_Phase1,Herd immunity to SARS-CoV-2 in the Novosibirsk Region population amid the COVID-19 pandemic,2021-08-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,"Kochenyevsky, Krasnozyersky, Moshkovsky, Novosibirsk, Elitny Village, Toguchinsky Districts",The selection of volunteers was carried out using the anke-using cloud technologiesand randomization by age and areaprinciples.,The exclusion criterion was the presencemanifest form of COVID-19 at the time of the questionnairevania,2020-06-28,2020-07-15,Household and community samples,All,Multiple groups,60.0,69.0,Age,60-69 years,376,0.08,0.054000000000000006,0.11199999999999999,True,,,,True,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anna Popova,St Petersburg Pasteur Institute,Not Unity-Aligned,https://dx.doi.org/10.36233/0507-4088-54,2021-09-28,2022-07-16,Unverified,__2021-2,RUS
210831_Novosibirsk_StPetersburgPasteurInstitute_Phase1_14-17,210831_Novosibirsk_StPetersburgPasteurInstitute_Phase1,Herd immunity to SARS-CoV-2 in the Novosibirsk Region population amid the COVID-19 pandemic,2021-08-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,"Kochenyevsky, Krasnozyersky, Moshkovsky, Novosibirsk, Elitny Village, Toguchinsky Districts",The selection of volunteers was carried out using the anke-using cloud technologiesand randomization by age and areaprinciples.,The exclusion criterion was the presencemanifest form of COVID-19 at the time of the questionnairevania,2020-06-28,2020-07-15,Household and community samples,All,Children and Youth (0-17 years),14.0,17.0,Age,14-17 years,182,0.17600000000000002,0.12300000000000001,0.239,True,,,,True,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anna Popova,St Petersburg Pasteur Institute,Not Unity-Aligned,https://dx.doi.org/10.36233/0507-4088-54,2021-09-28,2022-07-16,Unverified,__2021-2,RUS
210831_Novosibirsk_StPetersburgPasteurInstitute_Phase1_1-6,210831_Novosibirsk_StPetersburgPasteurInstitute_Phase1,Herd immunity to SARS-CoV-2 in the Novosibirsk Region population amid the COVID-19 pandemic,2021-08-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,"Kochenyevsky, Krasnozyersky, Moshkovsky, Novosibirsk, Elitny Village, Toguchinsky Districts",The selection of volunteers was carried out using the anke-using cloud technologiesand randomization by age and areaprinciples.,The exclusion criterion was the presencemanifest form of COVID-19 at the time of the questionnairevania,2020-06-28,2020-07-15,Household and community samples,All,Children and Youth (0-17 years),1.0,6.0,Age,1-6 years,55,0.109,0.040999999999999995,0.16899999999999998,True,,,,True,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anna Popova,St Petersburg Pasteur Institute,Not Unity-Aligned,https://dx.doi.org/10.36233/0507-4088-54,2021-09-28,2022-07-16,Unverified,__2021-2,RUS
210831_Novosibirsk_StPetersburgPasteurInstitute_Phase1_70+,210831_Novosibirsk_StPetersburgPasteurInstitute_Phase1,Herd immunity to SARS-CoV-2 in the Novosibirsk Region population amid the COVID-19 pandemic,2021-08-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,"Kochenyevsky, Krasnozyersky, Moshkovsky, Novosibirsk, Elitny Village, Toguchinsky Districts",The selection of volunteers was carried out using the anke-using cloud technologiesand randomization by age and areaprinciples.,The exclusion criterion was the presencemanifest form of COVID-19 at the time of the questionnairevania,2020-06-28,2020-07-15,Household and community samples,All,Seniors (65+ years),70.0,,Age,70+ years,377,0.14800000000000002,0.114,0.188,True,,,,True,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anna Popova,St Petersburg Pasteur Institute,Not Unity-Aligned,https://dx.doi.org/10.36233/0507-4088-54,2021-09-28,2022-07-16,Unverified,__2021-2,RUS
210831_Novosibirsk_StPetersburgPasteurInstitute_Phase1_18-29,210831_Novosibirsk_StPetersburgPasteurInstitute_Phase1,Herd immunity to SARS-CoV-2 in the Novosibirsk Region population amid the COVID-19 pandemic,2021-08-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,"Kochenyevsky, Krasnozyersky, Moshkovsky, Novosibirsk, Elitny Village, Toguchinsky Districts",The selection of volunteers was carried out using the anke-using cloud technologiesand randomization by age and areaprinciples.,The exclusion criterion was the presencemanifest form of COVID-19 at the time of the questionnairevania,2020-06-28,2020-07-15,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,18-29 years,399,0.055,0.035,0.08199999999999999,True,,,,True,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anna Popova,St Petersburg Pasteur Institute,Not Unity-Aligned,https://dx.doi.org/10.36233/0507-4088-54,2021-09-28,2022-07-16,Unverified,__2021-2,RUS
210831_Novosibirsk_StPetersburgPasteurInstitute_Phase1_40-49,210831_Novosibirsk_StPetersburgPasteurInstitute_Phase1,Herd immunity to SARS-CoV-2 in the Novosibirsk Region population amid the COVID-19 pandemic,2021-08-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,"Kochenyevsky, Krasnozyersky, Moshkovsky, Novosibirsk, Elitny Village, Toguchinsky Districts",The selection of volunteers was carried out using the anke-using cloud technologiesand randomization by age and areaprinciples.,The exclusion criterion was the presencemanifest form of COVID-19 at the time of the questionnairevania,2020-06-28,2020-07-15,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49 years,391,0.09699999999999999,0.07,0.131,True,,,,True,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anna Popova,St Petersburg Pasteur Institute,Not Unity-Aligned,https://dx.doi.org/10.36233/0507-4088-54,2021-09-28,2022-07-16,Unverified,__2021-2,RUS
210831_Novosibirsk_StPetersburgPasteurInstitute_Phase1_Female,210831_Novosibirsk_StPetersburgPasteurInstitute_Phase1,Herd immunity to SARS-CoV-2 in the Novosibirsk Region population amid the COVID-19 pandemic,2021-08-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,"Kochenyevsky, Krasnozyersky, Moshkovsky, Novosibirsk, Elitny Village, Toguchinsky Districts",The selection of volunteers was carried out using the anke-using cloud technologiesand randomization by age and areaprinciples.,The exclusion criterion was the presencemanifest form of COVID-19 at the time of the questionnairevania,2020-06-28,2020-07-15,Household and community samples,Female,Multiple groups,,,Sex/Gender,,1929,0.096,0.081,0.10099999999999999,,,,,,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anna Popova,St Petersburg Pasteur Institute,Not Unity-Aligned,https://dx.doi.org/10.36233/0507-4088-54,2021-09-28,2022-07-16,Unverified,__2021-2,RUS
210831_Novosibirsk_StPetersburgPasteurInstitute_Phase1_Male,210831_Novosibirsk_StPetersburgPasteurInstitute_Phase1,Herd immunity to SARS-CoV-2 in the Novosibirsk Region population amid the COVID-19 pandemic,2021-08-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,"Kochenyevsky, Krasnozyersky, Moshkovsky, Novosibirsk, Elitny Village, Toguchinsky Districts",The selection of volunteers was carried out using the anke-using cloud technologiesand randomization by age and areaprinciples.,The exclusion criterion was the presencemanifest form of COVID-19 at the time of the questionnairevania,2020-06-28,2020-07-15,Household and community samples,Male,Multiple groups,,,Sex/Gender,,803,0.078,0.061,0.099,,,,,,Stratified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anna Popova,St Petersburg Pasteur Institute,Not Unity-Aligned,https://dx.doi.org/10.36233/0507-4088-54,2021-09-28,2022-07-16,Unverified,__2021-2,RUS
210831_Novosibirsk_StPetersburgPasteurInstitute_Phase2-Stage1_Overall,210831_Novosibirsk_StPetersburgPasteurInstitute_Phase2-Stage1,Herd immunity to SARS-CoV-2 in the Novosibirsk Region population amid the COVID-19 pandemic,2021-08-31,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Russian Federation,,"Kochenyevsky, Krasnozyersky, Moshkovsky, Novosibirsk, Elitny Village, Toguchinsky Districts","The selection of volunteers was carried out using the anke-using cloud technologiesand randomization by age and areaprinciples.

From a cohort, formed in the 1st phase, a representative group was selectedvolunteers who agreed to participate in the 3-stagemonitoring seroprevalence",The exclusion criterion was the presencemanifest form of COVID-19 at the time of the questionnairevania,2020-06-28,2020-07-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,1637,0.07400000000000001,0.062000000000000006,0.08900000000000001,True,,,,True,Convenience,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Anna Popova,St Petersburg Pasteur Institute,Not Unity-Aligned,https://dx.doi.org/10.36233/0507-4088-54,2021-09-28,2022-07-16,Unverified,__2021-2,RUS
210831_Novosibirsk_StPetersburgPasteurInstitute_Phase2-Stage2_Overall,210831_Novosibirsk_StPetersburgPasteurInstitute_Phase2-Stage2,Herd immunity to SARS-CoV-2 in the Novosibirsk Region population amid the COVID-19 pandemic,2021-08-31,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Russian Federation,,"Kochenyevsky, Krasnozyersky, Moshkovsky, Novosibirsk, Elitny Village, Toguchinsky Districts","The selection of volunteers was carried out using the anke-using cloud technologiesand randomization by age and areaprinciples.

From a cohort, formed in the 1st phase, a representative group was selectedvolunteers who agreed to participate in the 3-stagemonitoring seroprevalence",The exclusion criterion was the presencemanifest form of COVID-19 at the time of the questionnairevania,2020-06-28,2020-07-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,1237,0.12400000000000001,0.106,0.14300000000000002,True,,,,True,Convenience,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Anna Popova,St Petersburg Pasteur Institute,Not Unity-Aligned,https://dx.doi.org/10.36233/0507-4088-54,2021-09-28,2022-07-16,Unverified,__2021-2,RUS
210831_Novosibirsk_StPetersburgPasteurInstitute_Phase2-Stage3_Overall,210831_Novosibirsk_StPetersburgPasteurInstitute_Phase2-Stage3,Herd immunity to SARS-CoV-2 in the Novosibirsk Region population amid the COVID-19 pandemic,2021-08-31,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Russian Federation,,"Kochenyevsky, Krasnozyersky, Moshkovsky, Novosibirsk, Elitny Village, Toguchinsky Districts","The selection of volunteers was carried out using the anke-using cloud technologiesand randomization by age and areaprinciples.

From a cohort, formed in the 1st phase, a representative group was selectedvolunteers who agreed to participate in the 3-stagemonitoring seroprevalence",The exclusion criterion was the presencemanifest form of COVID-19 at the time of the questionnairevania,2020-06-28,2020-07-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,1651,0.31,0.28800000000000003,0.33299999999999996,True,,,,True,Convenience,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Anna Popova,St Petersburg Pasteur Institute,Not Unity-Aligned,https://dx.doi.org/10.36233/0507-4088-54,2021-09-28,2022-07-16,Unverified,__2021-2,RUS
210928_Moscow_RussianFederation,210928_Moscow_RussianFederation,Seroprevalence of anti-sars-cov-2 antibodies among healthcare professionals in Moscow in april-december 2020,2021-09-28,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Russian Federation,Central Russia,Moscow,HCW of 74 healthcare institutions in Moscow,,2020-04-14,2020-12-31,Health care workers and caregivers,All,Multiple groups,18.0,,Primary Estimate,,24373,0.22100000000000003,,,True,,,,True,Unclear,SARS- CoV-2-IgG-EIA-BEST and SARS-CoV-2- IgM-EIA-BEST ,Vector BEST,ELISA,Serum,IgG,,,,,['High'],,Unclear,Yes,No,,Unclear,Yes,No,,Anna Popova,Russian Federation,Not Unity-Aligned,https://dx.doi.org/10.20953/1729-9225-2021-3-5-13,2022-01-23,2022-07-16,Unverified,popova_seroprevalence_2021,RUS
211101_Kazan_ScientificResearchInstitutesofRospotrebnadzor_HCW,211101_Kazan_ScientificResearchInstitutesofRospotrebnadzor_HCW,Study of features of humoral immune response to the new coronavirus infection covid-19 among healthcare workers,2021-10-31,Journal Article (Peer-Reviewed),Local,Prospective cohort,Russian Federation,Tatarstan,Kazan,medical workers from a multidisciplinary hospital in Kazan,,2020-06-30,2020-07-27,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,60,0.4667,,,True,,,,True,Simplified probability,SARS- CoV-2-IgG-EIA-BEST and SARS-CoV-2- IgM-EIA-BEST ,Vector BEST,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,Yes,No,No,,Unclear,Yes,No,,Irina Dmitrievna Reshetnikova,Scientific Research Institutes of Rospotrebnadzor,Not Unity-Aligned,https://dx.doi.org/10.15789/2220-7619-SOT-1587,2022-01-06,2022-07-16,Unverified,reshetnikova_study_2021,RUS
211101_Kazan_ScientificResearchInstitutesofRospotrebnadzor_nonHCW,211101_Kazan_ScientificResearchInstitutesofRospotrebnadzor_nonHCW,Study of features of humoral immune response to the new coronavirus infection covid-19 among healthcare workers,2021-10-31,Journal Article (Peer-Reviewed),Local,Prospective cohort,Russian Federation,Tatarstan,Kazan,"Translation: As a comparison group, a group of 60 non-medical workers (non-MR) was formed by random sampling, whose blood serum for IgG and IgM antibodies was tested in the dynamics of the disease twice with the same interval and in the same period as in MR.",,2020-06-30,2020-07-27,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,61,0.21309999999999998,,,True,,,,True,Simplified probability,SARS- CoV-2-IgG-EIA-BEST and SARS-CoV-2- IgM-EIA-BEST ,Vector BEST,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,Yes,No,No,,Unclear,Yes,No,,Irina Dmitrievna Reshetnikova,Scientific Research Institutes of Rospotrebnadzor,Not Unity-Aligned,https://dx.doi.org/10.15789/2220-7619-SOT-1587,2022-01-06,2022-07-16,Unverified,reshetnikova_study_2021,RUS
211227_Stavropol_StPetersburgResearchInstituteofEpidemiologyandMicrobiology_Round1_Overall,211227_Stavropol_StPetersburgResearchInstituteofEpidemiologyandMicrobiology_Round1,Characteristic of herd immunity among the population of Stavropol region amid the COVID-19 epidemic,2021-12-27,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Russian Federation,Stavropol Region,,,The exclusion criterion was active COVID-19 infection at the time of the questionnaire.,2020-06-06,2020-06-29,Household and community samples,All,Multiple groups,,,Primary Estimate,"Overall, unadj",2683,0.098,0.087,0.109,True,,,,True,Convenience,Author designed (ELISA) - Unknown,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,A Papova,Saint-Petersburg Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://dx.doi.org/10.22625/2072-6732-2021-13-4-79-89,2022-02-10,2022-07-16,Unverified,__2021-3,RUS
211227_Stavropol_StPetersburgResearchInstituteofEpidemiologyandMicrobiology_Round1_Age40-49,211227_Stavropol_StPetersburgResearchInstituteofEpidemiologyandMicrobiology_Round1,Characteristic of herd immunity among the population of Stavropol region amid the COVID-19 epidemic,2021-12-27,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Russian Federation,Stavropol Region,,,The exclusion criterion was active COVID-19 infection at the time of the questionnaire.,2020-06-06,2020-06-29,Household and community samples,All,Adults (18-64 years),,,Age,40-49,384,0.047,0.027999999999999997,0.073,,,,,,Convenience,Author designed (ELISA) - Unknown,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,A Papova,Saint-Petersburg Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://dx.doi.org/10.22625/2072-6732-2021-13-4-79-89,2022-02-10,2022-07-16,Unverified,__2021-3,RUS
211227_Stavropol_StPetersburgResearchInstituteofEpidemiologyandMicrobiology_Round1_Age50-59,211227_Stavropol_StPetersburgResearchInstituteofEpidemiologyandMicrobiology_Round1,Characteristic of herd immunity among the population of Stavropol region amid the COVID-19 epidemic,2021-12-27,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Russian Federation,Stavropol Region,,,The exclusion criterion was active COVID-19 infection at the time of the questionnaire.,2020-06-06,2020-06-29,Household and community samples,All,Adults (18-64 years),,,Age,50-59,383,0.086,0.06,0.11900000000000001,,,,,,Convenience,Author designed (ELISA) - Unknown,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,A Papova,Saint-Petersburg Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://dx.doi.org/10.22625/2072-6732-2021-13-4-79-89,2022-02-10,2022-07-16,Unverified,__2021-3,RUS
211227_Stavropol_StPetersburgResearchInstituteofEpidemiologyandMicrobiology_Round1_Age30-39,211227_Stavropol_StPetersburgResearchInstituteofEpidemiologyandMicrobiology_Round1,Characteristic of herd immunity among the population of Stavropol region amid the COVID-19 epidemic,2021-12-27,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Russian Federation,Stavropol Region,,,The exclusion criterion was active COVID-19 infection at the time of the questionnaire.,2020-06-06,2020-06-29,Household and community samples,All,Adults (18-64 years),,,Age,30-39,385,0.08,0.055,0.11199999999999999,,,,,,Convenience,Author designed (ELISA) - Unknown,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,A Papova,Saint-Petersburg Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://dx.doi.org/10.22625/2072-6732-2021-13-4-79-89,2022-02-10,2022-07-16,Unverified,__2021-3,RUS
211227_Stavropol_StPetersburgResearchInstituteofEpidemiologyandMicrobiology_Round1_Female,211227_Stavropol_StPetersburgResearchInstituteofEpidemiologyandMicrobiology_Round1,Characteristic of herd immunity among the population of Stavropol region amid the COVID-19 epidemic,2021-12-27,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Russian Federation,Stavropol Region,,,The exclusion criterion was active COVID-19 infection at the time of the questionnaire.,2020-06-06,2020-06-29,Household and community samples,Female,Multiple groups,,,Sex/Gender,female,1939,0.09300000000000001,0.08,0.10800000000000001,,,,,,Convenience,Author designed (ELISA) - Unknown,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,A Papova,Saint-Petersburg Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://dx.doi.org/10.22625/2072-6732-2021-13-4-79-89,2022-02-10,2022-07-16,Unverified,__2021-3,RUS
211227_Stavropol_StPetersburgResearchInstituteofEpidemiologyandMicrobiology_Round1_Age70+,211227_Stavropol_StPetersburgResearchInstituteofEpidemiologyandMicrobiology_Round1,Characteristic of herd immunity among the population of Stavropol region amid the COVID-19 epidemic,2021-12-27,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Russian Federation,Stavropol Region,,,The exclusion criterion was active COVID-19 infection at the time of the questionnaire.,2020-06-06,2020-06-29,Household and community samples,All,Seniors (65+ years),,,Age,70+,385,0.106,0.078,0.142,,,,,,Convenience,Author designed (ELISA) - Unknown,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,A Papova,Saint-Petersburg Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://dx.doi.org/10.22625/2072-6732-2021-13-4-79-89,2022-02-10,2022-07-16,Unverified,__2021-3,RUS
211227_Stavropol_StPetersburgResearchInstituteofEpidemiologyandMicrobiology_Round1_Age14-17,211227_Stavropol_StPetersburgResearchInstituteofEpidemiologyandMicrobiology_Round1,Characteristic of herd immunity among the population of Stavropol region amid the COVID-19 epidemic,2021-12-27,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Russian Federation,Stavropol Region,,,The exclusion criterion was active COVID-19 infection at the time of the questionnaire.,2020-06-06,2020-06-29,Household and community samples,All,Children and Youth (0-17 years),,,Age,14-17,101,0.099,0.049,0.17500000000000002,,,,,,Convenience,Author designed (ELISA) - Unknown,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,A Papova,Saint-Petersburg Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://dx.doi.org/10.22625/2072-6732-2021-13-4-79-89,2022-02-10,2022-07-16,Unverified,__2021-3,RUS
211227_Stavropol_StPetersburgResearchInstituteofEpidemiologyandMicrobiology_Round1_Age1-6,211227_Stavropol_StPetersburgResearchInstituteofEpidemiologyandMicrobiology_Round1,Characteristic of herd immunity among the population of Stavropol region amid the COVID-19 epidemic,2021-12-27,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Russian Federation,Stavropol Region,,,The exclusion criterion was active COVID-19 infection at the time of the questionnaire.,2020-06-06,2020-06-29,Household and community samples,All,Children and Youth (0-17 years),,,Age,1-6,130,0.192,0.129,0.271,,,,,,Convenience,Author designed (ELISA) - Unknown,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,A Papova,Saint-Petersburg Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://dx.doi.org/10.22625/2072-6732-2021-13-4-79-89,2022-02-10,2022-07-16,Unverified,__2021-3,RUS
211227_Stavropol_StPetersburgResearchInstituteofEpidemiologyandMicrobiology_Round1_Male,211227_Stavropol_StPetersburgResearchInstituteofEpidemiologyandMicrobiology_Round1,Characteristic of herd immunity among the population of Stavropol region amid the COVID-19 epidemic,2021-12-27,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Russian Federation,Stavropol Region,,,The exclusion criterion was active COVID-19 infection at the time of the questionnaire.,2020-06-06,2020-06-29,Household and community samples,Male,Multiple groups,,,Sex/Gender,male,748,0.10800000000000001,0.086,0.135,,,,,,Convenience,Author designed (ELISA) - Unknown,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,A Papova,Saint-Petersburg Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://dx.doi.org/10.22625/2072-6732-2021-13-4-79-89,2022-02-10,2022-07-16,Unverified,__2021-3,RUS
211227_Stavropol_StPetersburgResearchInstituteofEpidemiologyandMicrobiology_Round1_Age60-69,211227_Stavropol_StPetersburgResearchInstituteofEpidemiologyandMicrobiology_Round1,Characteristic of herd immunity among the population of Stavropol region amid the COVID-19 epidemic,2021-12-27,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Russian Federation,Stavropol Region,,,The exclusion criterion was active COVID-19 infection at the time of the questionnaire.,2020-06-06,2020-06-29,Household and community samples,All,Adults (18-64 years),,,Age,60-69,384,0.099,0.071,0.133,,,,,,Convenience,Author designed (ELISA) - Unknown,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,A Papova,Saint-Petersburg Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://dx.doi.org/10.22625/2072-6732-2021-13-4-79-89,2022-02-10,2022-07-16,Unverified,__2021-3,RUS
211227_Stavropol_StPetersburgResearchInstituteofEpidemiologyandMicrobiology_Round1_Age7-13,211227_Stavropol_StPetersburgResearchInstituteofEpidemiologyandMicrobiology_Round1,Characteristic of herd immunity among the population of Stavropol region amid the COVID-19 epidemic,2021-12-27,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Russian Federation,Stavropol Region,,,The exclusion criterion was active COVID-19 infection at the time of the questionnaire.,2020-06-06,2020-06-29,Household and community samples,All,Children and Youth (0-17 years),,,Age,7-13,152,0.197,0.13699999999999998,0.269,,,,,,Convenience,Author designed (ELISA) - Unknown,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,A Papova,Saint-Petersburg Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://dx.doi.org/10.22625/2072-6732-2021-13-4-79-89,2022-02-10,2022-07-16,Unverified,__2021-3,RUS
211227_Stavropol_StPetersburgResearchInstituteofEpidemiologyandMicrobiology_Round1_Age18-29,211227_Stavropol_StPetersburgResearchInstituteofEpidemiologyandMicrobiology_Round1,Characteristic of herd immunity among the population of Stavropol region amid the COVID-19 epidemic,2021-12-27,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Russian Federation,Stavropol Region,,,The exclusion criterion was active COVID-19 infection at the time of the questionnaire.,2020-06-06,2020-06-29,Household and community samples,All,Adults (18-64 years),,,Age,18-29,379,0.095,0.067,0.129,,,,,,Convenience,Author designed (ELISA) - Unknown,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,A Papova,Saint-Petersburg Research Institute of Epidemiology and Microbiology,Not Unity-Aligned,https://dx.doi.org/10.22625/2072-6732-2021-13-4-79-89,2022-02-10,2022-07-16,Unverified,__2021-3,RUS
211227_Krasnodar_KubanStateMedicalUniversity_Round1_Overall_NeutAssay,211227_Krasnodar_KubanStateMedicalUniversity_Round1,Dynamics of seroprevalence of anti-SARS-CoV-2 antibodies in non-vaccinated people,2021-12-27,Journal Article (Peer-Reviewed),Local,Prospective cohort,Russian Federation,Krasnodar Kai,Krasnodar,"Study was carried out at the CL laboratory in Krasnodar in a group of 806 unvaccinated people working in a relatively isolated team. Each subject was characterized by a negative PCR test for SARS-CoV-2 and the absence of clinical signs of COVID-19 at the time of blood serum sampling and in the previous
three months before that.",,2020-10-26,2020-12-30,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,,806,0.132,,,True,,,,True,Convenience,Access SARS-CoV-2 IgG Reagent Antibody Test,Beckman Coulter,Neutralization,Serum,IgG,Spike,,,,['High'],Unclear,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Vladimir Gorodin,Kuban State Medical University,Unity-Aligned,https://dx.doi.org/10.20953/1729-9225-2021-4-98-102,2022-04-21,2024-03-01,Unverified,kuban_state_medical_university_krasnodar_russian_federation_dynamics_2021,RUS
211227_Krasnodar_KubanStateMedicalUniversity_Round1_Overall_CLIA,211227_Krasnodar_KubanStateMedicalUniversity_Round1,Dynamics of seroprevalence of anti-SARS-CoV-2 antibodies in non-vaccinated people,2021-12-27,Journal Article (Peer-Reviewed),Local,Prospective cohort,Russian Federation,Krasnodar Kai,Krasnodar,"Study was carried out at the CL laboratory in Krasnodar in a group of 806 unvaccinated people working in a relatively isolated team. Each subject was characterized by a negative PCR test for SARS-CoV-2 and the absence of clinical signs of COVID-19 at the time of blood serum sampling and in the previous
three months before that.",,2020-10-26,2020-12-30,Household and community samples,All,Adults (18-64 years),,,Test used,,806,0.16,,,,,,,,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['High'],Unclear,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Vladimir Gorodin,Kuban State Medical University,Unity-Aligned,https://dx.doi.org/10.20953/1729-9225-2021-4-98-102,2022-04-21,2024-03-01,Unverified,kuban_state_medical_university_krasnodar_russian_federation_dynamics_2021,RUS
211227_Krasnodar_KubanStateMedicalUniversity_Round1_Overall_Male,211227_Krasnodar_KubanStateMedicalUniversity_Round1,Dynamics of seroprevalence of anti-SARS-CoV-2 antibodies in non-vaccinated people,2021-12-27,Journal Article (Peer-Reviewed),Local,Prospective cohort,Russian Federation,Krasnodar Kai,Krasnodar,"Study was carried out at the CL laboratory in Krasnodar in a group of 806 unvaccinated people working in a relatively isolated team. Each subject was characterized by a negative PCR test for SARS-CoV-2 and the absence of clinical signs of COVID-19 at the time of blood serum sampling and in the previous
three months before that.",,2020-10-26,2020-12-30,Household and community samples,Male,Adults (18-64 years),,,Sex/Gender,,615,0.11900000000000001,,,,,,,,Convenience,Access SARS-CoV-2 IgG Reagent Antibody Test,Beckman Coulter,Neutralization,Serum,IgG,Spike,,,,['High'],Unclear,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Vladimir Gorodin,Kuban State Medical University,Unity-Aligned,https://dx.doi.org/10.20953/1729-9225-2021-4-98-102,2022-06-03,2024-03-01,Unverified,kuban_state_medical_university_krasnodar_russian_federation_dynamics_2021,RUS
211227_Krasnodar_KubanStateMedicalUniversity_Round1_Overall_Female,211227_Krasnodar_KubanStateMedicalUniversity_Round1,Dynamics of seroprevalence of anti-SARS-CoV-2 antibodies in non-vaccinated people,2021-12-27,Journal Article (Peer-Reviewed),Local,Prospective cohort,Russian Federation,Krasnodar Kai,Krasnodar,"Study was carried out at the CL laboratory in Krasnodar in a group of 806 unvaccinated people working in a relatively isolated team. Each subject was characterized by a negative PCR test for SARS-CoV-2 and the absence of clinical signs of COVID-19 at the time of blood serum sampling and in the previous
three months before that.",,2020-10-26,2020-12-30,Household and community samples,Female,Adults (18-64 years),,,Sex/Gender,,191,0.17300000000000001,,,,,,,,Convenience,Access SARS-CoV-2 IgG Reagent Antibody Test,Beckman Coulter,Neutralization,Serum,IgG,Spike,,,,['High'],Unclear,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Vladimir Gorodin,Kuban State Medical University,Unity-Aligned,https://dx.doi.org/10.20953/1729-9225-2021-4-98-102,2022-06-03,2024-03-01,Unverified,kuban_state_medical_university_krasnodar_russian_federation_dynamics_2021,RUS
211227_Krasnodar_KubanStateMedicalUniversity_Round2_Overall_NeutAssay,211227_Krasnodar_KubanStateMedicalUniversity_Round2,Dynamics of seroprevalence of anti-SARS-CoV-2 antibodies in non-vaccinated people,2021-12-27,Journal Article (Peer-Reviewed),Local,Prospective cohort,Russian Federation,Krasnodar Kai,Krasnodar,"Study was carried out at the CL laboratory in Krasnodar in a group of 806 unvaccinated people working in a relatively isolated team. Each subject was characterized by a negative PCR test for SARS-CoV-2 and the absence of clinical signs of COVID-19 at the time of blood serum sampling and in the previous
three months before that.",Vaccinated,2020-10-26,2020-12-30,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,,806,0.355,,,True,,,,True,Convenience,Access SARS-CoV-2 IgG Reagent Antibody Test,Beckman Coulter,Neutralization,Serum,IgG,Spike,,,,['High'],Unclear,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Vladimir Gorodin,Kuban State Medical University,Not Unity-Aligned,https://dx.doi.org/10.20953/1729-9225-2021-4-98-102,2022-04-21,2024-03-01,Unverified,kuban_state_medical_university_krasnodar_russian_federation_dynamics_2021,RUS
211227_Krasnodar_KubanStateMedicalUniversity_Round2_Overall_Female,211227_Krasnodar_KubanStateMedicalUniversity_Round2,Dynamics of seroprevalence of anti-SARS-CoV-2 antibodies in non-vaccinated people,2021-12-27,Journal Article (Peer-Reviewed),Local,Prospective cohort,Russian Federation,Krasnodar Kai,Krasnodar,"Study was carried out at the CL laboratory in Krasnodar in a group of 806 unvaccinated people working in a relatively isolated team. Each subject was characterized by a negative PCR test for SARS-CoV-2 and the absence of clinical signs of COVID-19 at the time of blood serum sampling and in the previous
three months before that.",Vaccinated,2020-10-26,2020-12-30,Household and community samples,Female,Adults (18-64 years),,,Sex/Gender,,191,0.419,,,,,,,,Convenience,Access SARS-CoV-2 IgG Reagent Antibody Test,Beckman Coulter,Neutralization,Serum,IgG,Spike,,,,['High'],Unclear,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Vladimir Gorodin,Kuban State Medical University,Not Unity-Aligned,https://dx.doi.org/10.20953/1729-9225-2021-4-98-102,2022-06-03,2024-03-01,Unverified,kuban_state_medical_university_krasnodar_russian_federation_dynamics_2021,RUS
211227_Krasnodar_KubanStateMedicalUniversity_Round2_Overall_CLIA,211227_Krasnodar_KubanStateMedicalUniversity_Round2,Dynamics of seroprevalence of anti-SARS-CoV-2 antibodies in non-vaccinated people,2021-12-27,Journal Article (Peer-Reviewed),Local,Prospective cohort,Russian Federation,Krasnodar Kai,Krasnodar,"Study was carried out at the CL laboratory in Krasnodar in a group of 806 unvaccinated people working in a relatively isolated team. Each subject was characterized by a negative PCR test for SARS-CoV-2 and the absence of clinical signs of COVID-19 at the time of blood serum sampling and in the previous
three months before that.",Vaccinated,2020-10-26,2020-12-30,Household and community samples,All,Adults (18-64 years),,,Test used,,806,0.397,,,,,,,,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['High'],Unclear,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Vladimir Gorodin,Kuban State Medical University,Not Unity-Aligned,https://dx.doi.org/10.20953/1729-9225-2021-4-98-102,2022-04-21,2024-03-01,Unverified,kuban_state_medical_university_krasnodar_russian_federation_dynamics_2021,RUS
211227_Krasnodar_KubanStateMedicalUniversity_Round2_Overall_Male,211227_Krasnodar_KubanStateMedicalUniversity_Round2,Dynamics of seroprevalence of anti-SARS-CoV-2 antibodies in non-vaccinated people,2021-12-27,Journal Article (Peer-Reviewed),Local,Prospective cohort,Russian Federation,Krasnodar Kai,Krasnodar,"Study was carried out at the CL laboratory in Krasnodar in a group of 806 unvaccinated people working in a relatively isolated team. Each subject was characterized by a negative PCR test for SARS-CoV-2 and the absence of clinical signs of COVID-19 at the time of blood serum sampling and in the previous
three months before that.",Vaccinated,2020-10-26,2020-12-30,Household and community samples,Male,Adults (18-64 years),,,Sex/Gender,,615,0.335,,,,,,,,Convenience,Access SARS-CoV-2 IgG Reagent Antibody Test,Beckman Coulter,Neutralization,Serum,IgG,Spike,,,,['High'],Unclear,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Vladimir Gorodin,Kuban State Medical University,Not Unity-Aligned,https://dx.doi.org/10.20953/1729-9225-2021-4-98-102,2022-06-03,2024-03-01,Unverified,kuban_state_medical_university_krasnodar_russian_federation_dynamics_2021,RUS
220122_Arkhangelsk_LondonSchoolofHygieneandTropicalMedicine_TestAdj,220122_Arkhangelsk_LondonSchoolofHygieneandTropicalMedicine,"Seroprevalence of SARS-Cov-2 Antibodies in Adults, Arkhangelsk, Russia.",2022-01-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,Arkhangelsk,Adults 40–75 years of age who were residents of the city of Arkhangelsk in northwest Russia. We obtained participants for this study from persons who had taken part in the Know Your Heart study.,,2021-02-24,2021-05-28,Household and community samples,All,Multiple groups,40.0,75.0,Primary Estimate,Test adjusted,1067,0.726,0.642,0.831,True,True,,,,Convenience,SARS- CoV-2-IgG-EIA-BEST and SARS-CoV-2- IgM-EIA-BEST ,Vector BEST,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.89,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Ekaterina Krieger,London School of Hygiene & Tropical Medicine,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2802.211640,2022-01-31,2022-07-16,Unverified,krieger_seroprevalence_2022,RUS
220122_Arkhangelsk_LondonSchoolofHygieneandTropicalMedicine_55-64,220122_Arkhangelsk_LondonSchoolofHygieneandTropicalMedicine,"Seroprevalence of SARS-Cov-2 Antibodies in Adults, Arkhangelsk, Russia.",2022-01-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,Arkhangelsk,Adults 40–75 years of age who were residents of the city of Arkhangelsk in northwest Russia. We obtained participants for this study from persons who had taken part in the Know Your Heart study.,,2021-02-24,2021-05-28,Household and community samples,All,Adults (18-64 years),55.0,64.0,Age,55-64,360,0.61,,,,,,,,Convenience,SARS- CoV-2-IgG-EIA-BEST and SARS-CoV-2- IgM-EIA-BEST ,Vector BEST,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.89,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Ekaterina Krieger,London School of Hygiene & Tropical Medicine,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2802.211640,2022-01-31,2022-07-16,Unverified,krieger_seroprevalence_2022,RUS
220122_Arkhangelsk_LondonSchoolofHygieneandTropicalMedicine_Crude,220122_Arkhangelsk_LondonSchoolofHygieneandTropicalMedicine,"Seroprevalence of SARS-Cov-2 Antibodies in Adults, Arkhangelsk, Russia.",2022-01-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,Arkhangelsk,Adults 40–75 years of age who were residents of the city of Arkhangelsk in northwest Russia. We obtained participants for this study from persons who had taken part in the Know Your Heart study.,,2021-02-24,2021-05-28,Household and community samples,All,Multiple groups,40.0,75.0,Analysis,Crude estimate,1067,0.65,,,,,,,True,Convenience,SARS- CoV-2-IgG-EIA-BEST and SARS-CoV-2- IgM-EIA-BEST ,Vector BEST,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.89,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Ekaterina Krieger,London School of Hygiene & Tropical Medicine,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2802.211640,2022-01-31,2022-07-16,Unverified,krieger_seroprevalence_2022,RUS
220122_Arkhangelsk_LondonSchoolofHygieneandTropicalMedicine_Vac,220122_Arkhangelsk_LondonSchoolofHygieneandTropicalMedicine,"Seroprevalence of SARS-Cov-2 Antibodies in Adults, Arkhangelsk, Russia.",2022-01-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,Arkhangelsk,Adults 40–75 years of age who were residents of the city of Arkhangelsk in northwest Russia. We obtained participants for this study from persons who had taken part in the Know Your Heart study.,,2021-02-24,2021-05-28,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,,162,0.93,,,,,,,,Convenience,SARS- CoV-2-IgG-EIA-BEST and SARS-CoV-2- IgM-EIA-BEST ,Vector BEST,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.89,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Ekaterina Krieger,London School of Hygiene & Tropical Medicine,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2802.211640,2022-01-31,2022-07-16,Unverified,krieger_seroprevalence_2022,RUS
220122_Arkhangelsk_LondonSchoolofHygieneandTropicalMedicine_Unvac,220122_Arkhangelsk_LondonSchoolofHygieneandTropicalMedicine,"Seroprevalence of SARS-Cov-2 Antibodies in Adults, Arkhangelsk, Russia.",2022-01-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,Arkhangelsk,Adults 40–75 years of age who were residents of the city of Arkhangelsk in northwest Russia. We obtained participants for this study from persons who had taken part in the Know Your Heart study.,,2021-02-24,2021-05-28,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,,905,0.6,,,,,,,,Convenience,SARS- CoV-2-IgG-EIA-BEST and SARS-CoV-2- IgM-EIA-BEST ,Vector BEST,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.89,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Ekaterina Krieger,London School of Hygiene & Tropical Medicine,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2802.211640,2022-01-31,2022-07-16,Unverified,krieger_seroprevalence_2022,RUS
220122_Arkhangelsk_LondonSchoolofHygieneandTropicalMedicine_Female,220122_Arkhangelsk_LondonSchoolofHygieneandTropicalMedicine,"Seroprevalence of SARS-Cov-2 Antibodies in Adults, Arkhangelsk, Russia.",2022-01-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,Arkhangelsk,Adults 40–75 years of age who were residents of the city of Arkhangelsk in northwest Russia. We obtained participants for this study from persons who had taken part in the Know Your Heart study.,,2021-02-24,2021-05-28,Household and community samples,Female,Multiple groups,,,Sex/Gender,,634,0.64,,,,,,,,Convenience,SARS- CoV-2-IgG-EIA-BEST and SARS-CoV-2- IgM-EIA-BEST ,Vector BEST,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.89,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Ekaterina Krieger,London School of Hygiene & Tropical Medicine,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2802.211640,2022-01-31,2022-07-16,Unverified,krieger_seroprevalence_2022,RUS
220122_Arkhangelsk_LondonSchoolofHygieneandTropicalMedicine_Male,220122_Arkhangelsk_LondonSchoolofHygieneandTropicalMedicine,"Seroprevalence of SARS-Cov-2 Antibodies in Adults, Arkhangelsk, Russia.",2022-01-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,Arkhangelsk,Adults 40–75 years of age who were residents of the city of Arkhangelsk in northwest Russia. We obtained participants for this study from persons who had taken part in the Know Your Heart study.,,2021-02-24,2021-05-28,Household and community samples,Male,Multiple groups,,,Sex/Gender,,433,0.66,,,,,,,,Convenience,SARS- CoV-2-IgG-EIA-BEST and SARS-CoV-2- IgM-EIA-BEST ,Vector BEST,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.89,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Ekaterina Krieger,London School of Hygiene & Tropical Medicine,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2802.211640,2022-01-31,2022-07-16,Unverified,krieger_seroprevalence_2022,RUS
220122_Arkhangelsk_LondonSchoolofHygieneandTropicalMedicine_>=65,220122_Arkhangelsk_LondonSchoolofHygieneandTropicalMedicine,"Seroprevalence of SARS-Cov-2 Antibodies in Adults, Arkhangelsk, Russia.",2022-01-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,Arkhangelsk,Adults 40–75 years of age who were residents of the city of Arkhangelsk in northwest Russia. We obtained participants for this study from persons who had taken part in the Know Your Heart study.,,2021-02-24,2021-05-28,Household and community samples,All,Seniors (65+ years),65.0,75.0,Age,>=65,208,0.7000000000000001,,,,,,,,Convenience,SARS- CoV-2-IgG-EIA-BEST and SARS-CoV-2- IgM-EIA-BEST ,Vector BEST,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.89,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Ekaterina Krieger,London School of Hygiene & Tropical Medicine,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2802.211640,2022-01-31,2022-07-16,Unverified,krieger_seroprevalence_2022,RUS
220122_Arkhangelsk_LondonSchoolofHygieneandTropicalMedicine_40-54,220122_Arkhangelsk_LondonSchoolofHygieneandTropicalMedicine,"Seroprevalence of SARS-Cov-2 Antibodies in Adults, Arkhangelsk, Russia.",2022-01-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,Arkhangelsk,Adults 40–75 years of age who were residents of the city of Arkhangelsk in northwest Russia. We obtained participants for this study from persons who had taken part in the Know Your Heart study.,,2021-02-24,2021-05-28,Household and community samples,All,Adults (18-64 years),40.0,54.0,Age,40-54,499,0.65,,,,,,,,Convenience,SARS- CoV-2-IgG-EIA-BEST and SARS-CoV-2- IgM-EIA-BEST ,Vector BEST,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.89,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Ekaterina Krieger,London School of Hygiene & Tropical Medicine,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2802.211640,2022-01-31,2022-07-16,Unverified,krieger_seroprevalence_2022,RUS
220201_Moscow_InstituteofPreventiveMedicine_Overall,220201_Moscow_InstituteofPreventiveMedicine,Detection of anti-SARS-CoV-2 S1 RBD-specific antibodies prior to and during the pandemic in 2011-2021 and Covid-19 observational study in 2019-2021,2022-02-01,Preprint,Regional,Prospective cohort,Russian Federation,Central,Moscow,"The present observational study included subjects 18 years of age and older randomly selected from various cohorts previously recruited from 2011 to 2021 from the city of Moscow and Moscow Region at the National Research Center for Preventive Medicine, Ministry of Health Care of Russian Federation, Moscow, Russia.

Recent participants (N = 310; recruited in 2019 (N = 80), 2020 (N=132), and 2021 (N = 98)) were a part of a cohort for investigation of microcirculation (from August, 2019 to August, 2021)","The following exclusion criteria were used: any acute inflammation, including oral or dental; hematological diseases; left ventricular ejection fraction below 40%; diabetes mellitus; chronic kidney or liver failure; oncological diseases; mental illness; autoimmune diseases; any type of blood sugar-lowering therapy; any type of cholesterol-lowering therapy; pregnancy; and lactation. Patients with ischemic heart disease with an acute cardiovascular event less than 6 months before the enrollment were also excluded.",2019-08-01,2021-08-31,Residual sera,All,Multiple groups,18.0,,Primary Estimate,,310,0.2258,,,True,,,,True,Unclear,Anti-SARS-CoV-2 ELISA E111-IVD,Mediagnost,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9555,0.9836,['High'],,Unclear,No,No,,Unclear,Yes,Yes,,Nadezhda Gumanova,Institute of Preventive Medicine,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1308920/v1,2022-02-10,2022-09-27,Unverified,gumanova_detection_2022,RUS
220201_Moscow_InstituteofPreventiveMedicine_Time202001-202002,220201_Moscow_InstituteofPreventiveMedicine,Detection of anti-SARS-CoV-2 S1 RBD-specific antibodies prior to and during the pandemic in 2011-2021 and Covid-19 observational study in 2019-2021,2022-02-01,Preprint,Local,Prospective cohort,Russian Federation,Central,Moscow,"The present observational study included subjects 18 years of age and older randomly selected from various cohorts previously recruited from 2011 to 2021 from the city of Moscow and Moscow Region at the National Research Center for Preventive Medicine, Ministry of Health Care of Russian Federation, Moscow, Russia.

Recent participants (N = 310; recruited in 2019 (N = 80), 2020 (N=132), and 2021 (N = 98)) were a part of a cohort for investigation of microcirculation (from August, 2019 to August, 2021)","The following exclusion criteria were used: any acute inflammation, including oral or dental; hematological diseases; left ventricular ejection fraction below 40%; diabetes mellitus; chronic kidney or liver failure; oncological diseases; mental illness; autoimmune diseases; any type of blood sugar-lowering therapy; any type of cholesterol-lowering therapy; pregnancy; and lactation. Patients with ischemic heart disease with an acute cardiovascular event less than 6 months before the enrollment were also excluded.",2020-01-01,2020-02-29,Residual sera,All,Multiple groups,18.0,,Time frame,"January-February, 2020",32,0.063,,,,,,,,Unclear,Anti-SARS-CoV-2 ELISA E111-IVD,Mediagnost,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9555,0.9836,['High'],,Unclear,No,No,,Unclear,Yes,Yes,,Nadezhda Gumanova,Institute of Preventive Medicine,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1308920/v1,2022-02-10,2022-07-16,Unverified,gumanova_detection_2022,RUS
220201_Moscow_InstituteofPreventiveMedicine_Time202106,220201_Moscow_InstituteofPreventiveMedicine,Detection of anti-SARS-CoV-2 S1 RBD-specific antibodies prior to and during the pandemic in 2011-2021 and Covid-19 observational study in 2019-2021,2022-02-01,Preprint,Local,Prospective cohort,Russian Federation,Central,Moscow,"The present observational study included subjects 18 years of age and older randomly selected from various cohorts previously recruited from 2011 to 2021 from the city of Moscow and Moscow Region at the National Research Center for Preventive Medicine, Ministry of Health Care of Russian Federation, Moscow, Russia.

Recent participants (N = 310; recruited in 2019 (N = 80), 2020 (N=132), and 2021 (N = 98)) were a part of a cohort for investigation of microcirculation (from August, 2019 to August, 2021)","The following exclusion criteria were used: any acute inflammation, including oral or dental; hematological diseases; left ventricular ejection fraction below 40%; diabetes mellitus; chronic kidney or liver failure; oncological diseases; mental illness; autoimmune diseases; any type of blood sugar-lowering therapy; any type of cholesterol-lowering therapy; pregnancy; and lactation. Patients with ischemic heart disease with an acute cardiovascular event less than 6 months before the enrollment were also excluded.",2021-06-01,2021-06-30,Residual sera,All,Multiple groups,18.0,,Time frame,"June, 2021",14,0.643,,,,,,,,Unclear,Anti-SARS-CoV-2 ELISA E111-IVD,Mediagnost,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9555,0.9836,['High'],,Unclear,No,No,,Unclear,Yes,Yes,,Nadezhda Gumanova,Institute of Preventive Medicine,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1308920/v1,2022-02-10,2022-07-16,Unverified,gumanova_detection_2022,RUS
220201_Moscow_InstituteofPreventiveMedicine_VaccineNO,220201_Moscow_InstituteofPreventiveMedicine,Detection of anti-SARS-CoV-2 S1 RBD-specific antibodies prior to and during the pandemic in 2011-2021 and Covid-19 observational study in 2019-2021,2022-02-01,Preprint,Regional,Prospective cohort,Russian Federation,Central,Moscow,"The present observational study included subjects 18 years of age and older randomly selected from various cohorts previously recruited from 2011 to 2021 from the city of Moscow and Moscow Region at the National Research Center for Preventive Medicine, Ministry of Health Care of Russian Federation, Moscow, Russia.

Recent participants (N = 310; recruited in 2019 (N = 80), 2020 (N=132), and 2021 (N = 98)) were a part of a cohort for investigation of microcirculation (from August, 2019 to August, 2021)","The following exclusion criteria were used: any acute inflammation, including oral or dental; hematological diseases; left ventricular ejection fraction below 40%; diabetes mellitus; chronic kidney or liver failure; oncological diseases; mental illness; autoimmune diseases; any type of blood sugar-lowering therapy; any type of cholesterol-lowering therapy; pregnancy; and lactation. Patients with ischemic heart disease with an acute cardiovascular event less than 6 months before the enrollment were also excluded.",2020-09-01,2021-08-31,Residual sera,All,Multiple groups,18.0,,COVID-19 vaccination status,,97,0.2577,,,,,,,,Unclear,Anti-SARS-CoV-2 ELISA E111-IVD,Mediagnost,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9555,0.9836,['High'],,Unclear,No,No,,Unclear,Yes,Yes,,Nadezhda Gumanova,Institute of Preventive Medicine,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1308920/v1,2022-02-10,2022-09-27,Unverified,gumanova_detection_2022,RUS
220201_Moscow_InstituteofPreventiveMedicine_Time202108,220201_Moscow_InstituteofPreventiveMedicine,Detection of anti-SARS-CoV-2 S1 RBD-specific antibodies prior to and during the pandemic in 2011-2021 and Covid-19 observational study in 2019-2021,2022-02-01,Preprint,Regional,Prospective cohort,Russian Federation,Central,Moscow,"The present observational study included subjects 18 years of age and older randomly selected from various cohorts previously recruited from 2011 to 2021 from the city of Moscow and Moscow Region at the National Research Center for Preventive Medicine, Ministry of Health Care of Russian Federation, Moscow, Russia.

Recent participants (N = 310; recruited in 2019 (N = 80), 2020 (N=132), and 2021 (N = 98)) were a part of a cohort for investigation of microcirculation (from August, 2019 to August, 2021)","The following exclusion criteria were used: any acute inflammation, including oral or dental; hematological diseases; left ventricular ejection fraction below 40%; diabetes mellitus; chronic kidney or liver failure; oncological diseases; mental illness; autoimmune diseases; any type of blood sugar-lowering therapy; any type of cholesterol-lowering therapy; pregnancy; and lactation. Patients with ischemic heart disease with an acute cardiovascular event less than 6 months before the enrollment were also excluded.",2021-08-01,2021-08-31,Residual sera,All,Multiple groups,18.0,,Time frame,"August, 2021",3,0.75,,,,,,,,Unclear,Anti-SARS-CoV-2 ELISA E111-IVD,Mediagnost,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9555,0.9836,['High'],,Unclear,No,No,,Unclear,Yes,Yes,,Nadezhda Gumanova,Institute of Preventive Medicine,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1308920/v1,2022-02-10,2022-09-27,Unverified,gumanova_detection_2022,RUS
220201_Moscow_InstituteofPreventiveMedicine_Time202104,220201_Moscow_InstituteofPreventiveMedicine,Detection of anti-SARS-CoV-2 S1 RBD-specific antibodies prior to and during the pandemic in 2011-2021 and Covid-19 observational study in 2019-2021,2022-02-01,Preprint,Local,Prospective cohort,Russian Federation,Central,Moscow,"The present observational study included subjects 18 years of age and older randomly selected from various cohorts previously recruited from 2011 to 2021 from the city of Moscow and Moscow Region at the National Research Center for Preventive Medicine, Ministry of Health Care of Russian Federation, Moscow, Russia.

Recent participants (N = 310; recruited in 2019 (N = 80), 2020 (N=132), and 2021 (N = 98)) were a part of a cohort for investigation of microcirculation (from August, 2019 to August, 2021)","The following exclusion criteria were used: any acute inflammation, including oral or dental; hematological diseases; left ventricular ejection fraction below 40%; diabetes mellitus; chronic kidney or liver failure; oncological diseases; mental illness; autoimmune diseases; any type of blood sugar-lowering therapy; any type of cholesterol-lowering therapy; pregnancy; and lactation. Patients with ischemic heart disease with an acute cardiovascular event less than 6 months before the enrollment were also excluded.",2021-04-01,2021-04-30,Residual sera,All,Multiple groups,18.0,,Time frame,"April, 2021",22,0.545,,,,,,,,Unclear,Anti-SARS-CoV-2 ELISA E111-IVD,Mediagnost,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9555,0.9836,['High'],,Unclear,No,No,,Unclear,Yes,Yes,,Nadezhda Gumanova,Institute of Preventive Medicine,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1308920/v1,2022-02-10,2022-07-16,Unverified,gumanova_detection_2022,RUS
220201_Moscow_InstituteofPreventiveMedicine_Time201910-201912,220201_Moscow_InstituteofPreventiveMedicine,Detection of anti-SARS-CoV-2 S1 RBD-specific antibodies prior to and during the pandemic in 2011-2021 and Covid-19 observational study in 2019-2021,2022-02-01,Preprint,Local,Prospective cohort,Russian Federation,Central,Moscow,"The present observational study included subjects 18 years of age and older randomly selected from various cohorts previously recruited from 2011 to 2021 from the city of Moscow and Moscow Region at the National Research Center for Preventive Medicine, Ministry of Health Care of Russian Federation, Moscow, Russia.

Recent participants (N = 310; recruited in 2019 (N = 80), 2020 (N=132), and 2021 (N = 98)) were a part of a cohort for investigation of microcirculation (from August, 2019 to August, 2021)","The following exclusion criteria were used: any acute inflammation, including oral or dental; hematological diseases; left ventricular ejection fraction below 40%; diabetes mellitus; chronic kidney or liver failure; oncological diseases; mental illness; autoimmune diseases; any type of blood sugar-lowering therapy; any type of cholesterol-lowering therapy; pregnancy; and lactation. Patients with ischemic heart disease with an acute cardiovascular event less than 6 months before the enrollment were also excluded.",2019-10-01,2019-12-31,Residual sera,All,Multiple groups,18.0,,Time frame,"October-December, 2019",53,0.057,,,,,,,,Unclear,Anti-SARS-CoV-2 ELISA E111-IVD,Mediagnost,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9555,0.9836,['High'],,Unclear,No,No,,Unclear,Yes,Yes,,Nadezhda Gumanova,Institute of Preventive Medicine,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1308920/v1,2022-02-10,2022-07-16,Unverified,gumanova_detection_2022,RUS
220201_Moscow_InstituteofPreventiveMedicine_Time202105,220201_Moscow_InstituteofPreventiveMedicine,Detection of anti-SARS-CoV-2 S1 RBD-specific antibodies prior to and during the pandemic in 2011-2021 and Covid-19 observational study in 2019-2021,2022-02-01,Preprint,Local,Prospective cohort,Russian Federation,Central,Moscow,"The present observational study included subjects 18 years of age and older randomly selected from various cohorts previously recruited from 2011 to 2021 from the city of Moscow and Moscow Region at the National Research Center for Preventive Medicine, Ministry of Health Care of Russian Federation, Moscow, Russia.

Recent participants (N = 310; recruited in 2019 (N = 80), 2020 (N=132), and 2021 (N = 98)) were a part of a cohort for investigation of microcirculation (from August, 2019 to August, 2021)","The following exclusion criteria were used: any acute inflammation, including oral or dental; hematological diseases; left ventricular ejection fraction below 40%; diabetes mellitus; chronic kidney or liver failure; oncological diseases; mental illness; autoimmune diseases; any type of blood sugar-lowering therapy; any type of cholesterol-lowering therapy; pregnancy; and lactation. Patients with ischemic heart disease with an acute cardiovascular event less than 6 months before the enrollment were also excluded.",2021-05-01,2021-05-31,Residual sera,All,Multiple groups,18.0,,Time frame,"May, 2021",11,0.7270000000000001,,,,,,,,Unclear,Anti-SARS-CoV-2 ELISA E111-IVD,Mediagnost,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9555,0.9836,['High'],,Unclear,No,No,,Unclear,Yes,Yes,,Nadezhda Gumanova,Institute of Preventive Medicine,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1308920/v1,2022-02-10,2022-07-16,Unverified,gumanova_detection_2022,RUS
220201_Moscow_InstituteofPreventiveMedicine_Time202008-202009,220201_Moscow_InstituteofPreventiveMedicine,Detection of anti-SARS-CoV-2 S1 RBD-specific antibodies prior to and during the pandemic in 2011-2021 and Covid-19 observational study in 2019-2021,2022-02-01,Preprint,Local,Prospective cohort,Russian Federation,Central,Moscow,"The present observational study included subjects 18 years of age and older randomly selected from various cohorts previously recruited from 2011 to 2021 from the city of Moscow and Moscow Region at the National Research Center for Preventive Medicine, Ministry of Health Care of Russian Federation, Moscow, Russia.

Recent participants (N = 310; recruited in 2019 (N = 80), 2020 (N=132), and 2021 (N = 98)) were a part of a cohort for investigation of microcirculation (from August, 2019 to August, 2021)","The following exclusion criteria were used: any acute inflammation, including oral or dental; hematological diseases; left ventricular ejection fraction below 40%; diabetes mellitus; chronic kidney or liver failure; oncological diseases; mental illness; autoimmune diseases; any type of blood sugar-lowering therapy; any type of cholesterol-lowering therapy; pregnancy; and lactation. Patients with ischemic heart disease with an acute cardiovascular event less than 6 months before the enrollment were also excluded.",2020-08-01,2020-09-30,Residual sera,All,Multiple groups,18.0,,Time frame,"August-September, 2020",30,0.167,,,,,,,,Unclear,Anti-SARS-CoV-2 ELISA E111-IVD,Mediagnost,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9555,0.9836,['High'],,Unclear,No,No,,Unclear,Yes,Yes,,Nadezhda Gumanova,Institute of Preventive Medicine,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1308920/v1,2022-02-10,2022-07-16,Unverified,gumanova_detection_2022,RUS
220201_Moscow_InstituteofPreventiveMedicine_Time202101-202102,220201_Moscow_InstituteofPreventiveMedicine,Detection of anti-SARS-CoV-2 S1 RBD-specific antibodies prior to and during the pandemic in 2011-2021 and Covid-19 observational study in 2019-2021,2022-02-01,Preprint,Local,Prospective cohort,Russian Federation,Central,Moscow,"The present observational study included subjects 18 years of age and older randomly selected from various cohorts previously recruited from 2011 to 2021 from the city of Moscow and Moscow Region at the National Research Center for Preventive Medicine, Ministry of Health Care of Russian Federation, Moscow, Russia.

Recent participants (N = 310; recruited in 2019 (N = 80), 2020 (N=132), and 2021 (N = 98)) were a part of a cohort for investigation of microcirculation (from August, 2019 to August, 2021)","The following exclusion criteria were used: any acute inflammation, including oral or dental; hematological diseases; left ventricular ejection fraction below 40%; diabetes mellitus; chronic kidney or liver failure; oncological diseases; mental illness; autoimmune diseases; any type of blood sugar-lowering therapy; any type of cholesterol-lowering therapy; pregnancy; and lactation. Patients with ischemic heart disease with an acute cardiovascular event less than 6 months before the enrollment were also excluded.",2021-01-01,2021-02-28,Residual sera,All,Multiple groups,18.0,,Time frame,"January-February, 2021",8,0.25,,,,,,,,Unclear,Anti-SARS-CoV-2 ELISA E111-IVD,Mediagnost,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9555,0.9836,['High'],,Unclear,No,No,,Unclear,Yes,Yes,,Nadezhda Gumanova,Institute of Preventive Medicine,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1308920/v1,2022-02-10,2022-07-16,Unverified,gumanova_detection_2022,RUS
220201_Moscow_InstituteofPreventiveMedicine_Time202107,220201_Moscow_InstituteofPreventiveMedicine,Detection of anti-SARS-CoV-2 S1 RBD-specific antibodies prior to and during the pandemic in 2011-2021 and Covid-19 observational study in 2019-2021,2022-02-01,Preprint,Regional,Prospective cohort,Russian Federation,Central,Moscow,"The present observational study included subjects 18 years of age and older randomly selected from various cohorts previously recruited from 2011 to 2021 from the city of Moscow and Moscow Region at the National Research Center for Preventive Medicine, Ministry of Health Care of Russian Federation, Moscow, Russia.

Recent participants (N = 310; recruited in 2019 (N = 80), 2020 (N=132), and 2021 (N = 98)) were a part of a cohort for investigation of microcirculation (from August, 2019 to August, 2021)","The following exclusion criteria were used: any acute inflammation, including oral or dental; hematological diseases; left ventricular ejection fraction below 40%; diabetes mellitus; chronic kidney or liver failure; oncological diseases; mental illness; autoimmune diseases; any type of blood sugar-lowering therapy; any type of cholesterol-lowering therapy; pregnancy; and lactation. Patients with ischemic heart disease with an acute cardiovascular event less than 6 months before the enrollment were also excluded.",2021-07-01,2021-07-31,Residual sera,All,Multiple groups,18.0,,Time frame,"July, 2021",13,0.615,,,,,,,,Unclear,Anti-SARS-CoV-2 ELISA E111-IVD,Mediagnost,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9555,0.9836,['High'],,Unclear,No,No,,Unclear,Yes,Yes,,Nadezhda Gumanova,Institute of Preventive Medicine,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1308920/v1,2022-02-10,2022-09-27,Unverified,gumanova_detection_2022,RUS
220201_Moscow_InstituteofPreventiveMedicine_Time202010-202012,220201_Moscow_InstituteofPreventiveMedicine,Detection of anti-SARS-CoV-2 S1 RBD-specific antibodies prior to and during the pandemic in 2011-2021 and Covid-19 observational study in 2019-2021,2022-02-01,Preprint,Local,Prospective cohort,Russian Federation,Central,Moscow,"The present observational study included subjects 18 years of age and older randomly selected from various cohorts previously recruited from 2011 to 2021 from the city of Moscow and Moscow Region at the National Research Center for Preventive Medicine, Ministry of Health Care of Russian Federation, Moscow, Russia.

Recent participants (N = 310; recruited in 2019 (N = 80), 2020 (N=132), and 2021 (N = 98)) were a part of a cohort for investigation of microcirculation (from August, 2019 to August, 2021)","The following exclusion criteria were used: any acute inflammation, including oral or dental; hematological diseases; left ventricular ejection fraction below 40%; diabetes mellitus; chronic kidney or liver failure; oncological diseases; mental illness; autoimmune diseases; any type of blood sugar-lowering therapy; any type of cholesterol-lowering therapy; pregnancy; and lactation. Patients with ischemic heart disease with an acute cardiovascular event less than 6 months before the enrollment were also excluded.",2020-10-01,2020-12-31,Residual sera,All,Multiple groups,18.0,,Time frame,"October-December, 2020",19,0.158,,,,,,,,Unclear,Anti-SARS-CoV-2 ELISA E111-IVD,Mediagnost,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9555,0.9836,['High'],,Unclear,No,No,,Unclear,Yes,Yes,,Nadezhda Gumanova,Institute of Preventive Medicine,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1308920/v1,2022-02-10,2022-07-16,Unverified,gumanova_detection_2022,RUS
220201_Moscow_InstituteofPreventiveMedicine_Time202006-202007,220201_Moscow_InstituteofPreventiveMedicine,Detection of anti-SARS-CoV-2 S1 RBD-specific antibodies prior to and during the pandemic in 2011-2021 and Covid-19 observational study in 2019-2021,2022-02-01,Preprint,Local,Prospective cohort,Russian Federation,Central,Moscow,"The present observational study included subjects 18 years of age and older randomly selected from various cohorts previously recruited from 2011 to 2021 from the city of Moscow and Moscow Region at the National Research Center for Preventive Medicine, Ministry of Health Care of Russian Federation, Moscow, Russia.

Recent participants (N = 310; recruited in 2019 (N = 80), 2020 (N=132), and 2021 (N = 98)) were a part of a cohort for investigation of microcirculation (from August, 2019 to August, 2021)","The following exclusion criteria were used: any acute inflammation, including oral or dental; hematological diseases; left ventricular ejection fraction below 40%; diabetes mellitus; chronic kidney or liver failure; oncological diseases; mental illness; autoimmune diseases; any type of blood sugar-lowering therapy; any type of cholesterol-lowering therapy; pregnancy; and lactation. Patients with ischemic heart disease with an acute cardiovascular event less than 6 months before the enrollment were also excluded.",2020-06-01,2020-07-31,Residual sera,All,Multiple groups,18.0,,Time frame,"June-July, 2020",41,0.195,,,,,,,,Unclear,Anti-SARS-CoV-2 ELISA E111-IVD,Mediagnost,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9555,0.9836,['High'],,Unclear,No,No,,Unclear,Yes,Yes,,Nadezhda Gumanova,Institute of Preventive Medicine,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1308920/v1,2022-02-10,2022-07-16,Unverified,gumanova_detection_2022,RUS
220201_Moscow_InstituteofPreventiveMedicine_Time202103,220201_Moscow_InstituteofPreventiveMedicine,Detection of anti-SARS-CoV-2 S1 RBD-specific antibodies prior to and during the pandemic in 2011-2021 and Covid-19 observational study in 2019-2021,2022-02-01,Preprint,Local,Prospective cohort,Russian Federation,Central,Moscow,"The present observational study included subjects 18 years of age and older randomly selected from various cohorts previously recruited from 2011 to 2021 from the city of Moscow and Moscow Region at the National Research Center for Preventive Medicine, Ministry of Health Care of Russian Federation, Moscow, Russia.

Recent participants (N = 310; recruited in 2019 (N = 80), 2020 (N=132), and 2021 (N = 98)) were a part of a cohort for investigation of microcirculation (from August, 2019 to August, 2021)","The following exclusion criteria were used: any acute inflammation, including oral or dental; hematological diseases; left ventricular ejection fraction below 40%; diabetes mellitus; chronic kidney or liver failure; oncological diseases; mental illness; autoimmune diseases; any type of blood sugar-lowering therapy; any type of cholesterol-lowering therapy; pregnancy; and lactation. Patients with ischemic heart disease with an acute cardiovascular event less than 6 months before the enrollment were also excluded.",2021-03-01,2021-03-31,Residual sera,All,Multiple groups,18.0,,Time frame,"March 1, 2021",25,0.08,,,,,,,,Unclear,Anti-SARS-CoV-2 ELISA E111-IVD,Mediagnost,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9555,0.9836,['High'],,Unclear,No,No,,Unclear,Yes,Yes,,Nadezhda Gumanova,Institute of Preventive Medicine,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1308920/v1,2022-02-10,2022-07-16,Unverified,gumanova_detection_2022,RUS
220201_Moscow_InstituteofPreventiveMedicine_Time202003-202005,220201_Moscow_InstituteofPreventiveMedicine,Detection of anti-SARS-CoV-2 S1 RBD-specific antibodies prior to and during the pandemic in 2011-2021 and Covid-19 observational study in 2019-2021,2022-02-01,Preprint,Local,Prospective cohort,Russian Federation,Central,Moscow,"The present observational study included subjects 18 years of age and older randomly selected from various cohorts previously recruited from 2011 to 2021 from the city of Moscow and Moscow Region at the National Research Center for Preventive Medicine, Ministry of Health Care of Russian Federation, Moscow, Russia.

Recent participants (N = 310; recruited in 2019 (N = 80), 2020 (N=132), and 2021 (N = 98)) were a part of a cohort for investigation of microcirculation (from August, 2019 to August, 2021)","The following exclusion criteria were used: any acute inflammation, including oral or dental; hematological diseases; left ventricular ejection fraction below 40%; diabetes mellitus; chronic kidney or liver failure; oncological diseases; mental illness; autoimmune diseases; any type of blood sugar-lowering therapy; any type of cholesterol-lowering therapy; pregnancy; and lactation. Patients with ischemic heart disease with an acute cardiovascular event less than 6 months before the enrollment were also excluded.",2020-03-01,2020-05-31,Residual sera,All,Multiple groups,18.0,,Time frame,"March-May, 2020",11,0.273,,,,,,,,Unclear,Anti-SARS-CoV-2 ELISA E111-IVD,Mediagnost,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9555,0.9836,['High'],,Unclear,No,No,,Unclear,Yes,Yes,,Nadezhda Gumanova,Institute of Preventive Medicine,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1308920/v1,2022-02-10,2022-07-16,Unverified,gumanova_detection_2022,RUS
220201_Moscow_InstituteofPreventiveMedicine_VaccineYES,220201_Moscow_InstituteofPreventiveMedicine,Detection of anti-SARS-CoV-2 S1 RBD-specific antibodies prior to and during the pandemic in 2011-2021 and Covid-19 observational study in 2019-2021,2022-02-01,Preprint,Regional,Prospective cohort,Russian Federation,Central,Moscow,"The present observational study included subjects 18 years of age and older randomly selected from various cohorts previously recruited from 2011 to 2021 from the city of Moscow and Moscow Region at the National Research Center for Preventive Medicine, Ministry of Health Care of Russian Federation, Moscow, Russia.

Recent participants (N = 310; recruited in 2019 (N = 80), 2020 (N=132), and 2021 (N = 98)) were a part of a cohort for investigation of microcirculation (from August, 2019 to August, 2021)","The following exclusion criteria were used: any acute inflammation, including oral or dental; hematological diseases; left ventricular ejection fraction below 40%; diabetes mellitus; chronic kidney or liver failure; oncological diseases; mental illness; autoimmune diseases; any type of blood sugar-lowering therapy; any type of cholesterol-lowering therapy; pregnancy; and lactation. Patients with ischemic heart disease with an acute cardiovascular event less than 6 months before the enrollment were also excluded.",2020-09-01,2021-08-31,Residual sera,All,Multiple groups,18.0,,COVID-19 vaccination status,,137,0.2409,,,,,,,,Unclear,Anti-SARS-CoV-2 ELISA E111-IVD,Mediagnost,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9555,0.9836,['High'],,Unclear,No,No,,Unclear,Yes,Yes,,Nadezhda Gumanova,Institute of Preventive Medicine,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1308920/v1,2022-02-10,2022-09-27,Unverified,gumanova_detection_2022,RUS
220201_Moscow_InstituteofPreventiveMedicine_Time201908-201909,220201_Moscow_InstituteofPreventiveMedicine,Detection of anti-SARS-CoV-2 S1 RBD-specific antibodies prior to and during the pandemic in 2011-2021 and Covid-19 observational study in 2019-2021,2022-02-01,Preprint,Local,Prospective cohort,Russian Federation,Central,Moscow,"The present observational study included subjects 18 years of age and older randomly selected from various cohorts previously recruited from 2011 to 2021 from the city of Moscow and Moscow Region at the National Research Center for Preventive Medicine, Ministry of Health Care of Russian Federation, Moscow, Russia.

Recent participants (N = 310; recruited in 2019 (N = 80), 2020 (N=132), and 2021 (N = 98)) were a part of a cohort for investigation of microcirculation (from August, 2019 to August, 2021)","The following exclusion criteria were used: any acute inflammation, including oral or dental; hematological diseases; left ventricular ejection fraction below 40%; diabetes mellitus; chronic kidney or liver failure; oncological diseases; mental illness; autoimmune diseases; any type of blood sugar-lowering therapy; any type of cholesterol-lowering therapy; pregnancy; and lactation. Patients with ischemic heart disease with an acute cardiovascular event less than 6 months before the enrollment were also excluded.",2019-08-01,2019-09-30,Residual sera,All,Multiple groups,18.0,,Time frame,"August-September, 2019",27,0.037000000000000005,,,,,,,,Unclear,Anti-SARS-CoV-2 ELISA E111-IVD,Mediagnost,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9555,0.9836,['High'],,Unclear,No,No,,Unclear,Yes,Yes,,Nadezhda Gumanova,Institute of Preventive Medicine,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1308920/v1,2022-02-10,2022-07-16,Unverified,gumanova_detection_2022,RUS
220212_Moscow_RussianMedicalAcademyOfContinuousProfessionalEducation_2nd_Primary,220212_Moscow_RussianMedicalAcademyOfContinuousProfessionalEducation_2nd,Assessment of Diagnostic Specificity of Anti-SARS-CoV-2 Antibody Tests and Their Application for Monitoring of Seroconversion and Stability of Antiviral Antibody Response in Healthcare Workers in Moscow.,2022-02-12,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Russian Federation,,Moscow,"Study participants were employees of the Russian
Medical Academy of Continuous Education (RMANPO, Moscow, Russia) and included
medical personnel (except workers out of the red zone), teachers, students, technical
and administrative staff.",No inclusion/exclusion criteria for age and sex were applied.,2020-10-01,2021-01-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,June–September 2020,202,0.17800000000000002,,,True,,,True,,Unclear,SARS- CoV-2-IgG-EIA-BEST and SARS-CoV-2- IgM-EIA-BEST ,Vector BEST,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,0.985,['High'],,Unclear,No,No,,Unclear,Yes,No,,Vera S. Kichatova,Russian Medical Academy of Continuous Professional Education,Not Unity-Aligned,https://dx.doi.org/10.3390/microorganisms10020429,2022-03-09,2022-07-16,Unverified,kichatova_assessment_2022,RUS
220212_Moscow_RussianMedicalAcademyOfContinuousProfessionalEducation_After1st_Primary,220212_Moscow_RussianMedicalAcademyOfContinuousProfessionalEducation_After1st,Assessment of Diagnostic Specificity of Anti-SARS-CoV-2 Antibody Tests and Their Application for Monitoring of Seroconversion and Stability of Antiviral Antibody Response in Healthcare Workers in Moscow.,2022-02-12,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Russian Federation,,Moscow,"Study participants were employees of the Russian
Medical Academy of Continuous Education (RMANPO, Moscow, Russia) and included
medical personnel (except workers out of the red zone), teachers, students, technical
and administrative staff.",No inclusion/exclusion criteria for age and sex were applied.,2020-05-29,2020-09-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,October 2020–January 2021,202,0.272,,,True,,,True,,Unclear,SARS- CoV-2-IgG-EIA-BEST and SARS-CoV-2- IgM-EIA-BEST ,Vector BEST,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,0.985,['High'],,Unclear,No,No,,Unclear,Yes,No,,Vera S. Kichatova,Russian Medical Academy of Continuous Professional Education,Not Unity-Aligned,https://dx.doi.org/10.3390/microorganisms10020429,2022-03-09,2022-07-16,Unverified,kichatova_assessment_2022,RUS
220212_Moscow_RussianMedicalAcademyOfContinuousProfessionalEducation_After2nd_Primary,220212_Moscow_RussianMedicalAcademyOfContinuousProfessionalEducation_After2nd,Assessment of Diagnostic Specificity of Anti-SARS-CoV-2 Antibody Tests and Their Application for Monitoring of Seroconversion and Stability of Antiviral Antibody Response in Healthcare Workers in Moscow.,2022-02-12,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Russian Federation,,Moscow,"Study participants were employees of the Russian
Medical Academy of Continuous Education (RMANPO, Moscow, Russia) and included
medical personnel (except workers out of the red zone), teachers, students, technical
and administrative staff.",No inclusion/exclusion criteria for age and sex were applied.,2021-02-01,2021-05-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,February–June 2021,123,0.528,,,True,,,True,,Unclear,SARS- CoV-2-IgG-EIA-BEST and SARS-CoV-2- IgM-EIA-BEST ,Vector BEST,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,0.985,['High'],,Unclear,No,No,,Unclear,Yes,No,,Vera S. Kichatova,Russian Medical Academy of Continuous Professional Education,Not Unity-Aligned,https://dx.doi.org/10.3390/microorganisms10020429,2022-03-09,2022-07-16,Unverified,kichatova_assessment_2022,RUS
"221215_Saratov_RossiyskiyNauchno-Issledovatel'skiyProtivochumnyyInstitut""Mikrob""Rospotrebnadzora","""221215_Saratov_RossiyskiyNauchno-Issledovatel'skiyProtivochumnyyInstitut""""Mikrob""""Rospotrebnadzora""",ETIOLOGICAL PATTERN OF COMMUNITY-ACQUIRED PNEUMONIA RELATED TO THE NEW CORONAVIRUS INFECTION COVID-19 PANDEMIC IN THE SARATOV REGION,2022-02-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,Saratov Region,City of Saratov,Patients undergoing treatment for pneumonia in medical organizations in Saratov and the Saratov region from July to August 2020,,2020-06-23,2020-09-01,Residual sera,All,Multiple groups,,,Primary Estimate,,129,0.636,,,True,,,,True,Convenience,SARS- CoV-2-IgG-EIA-BEST and SARS-CoV-2- IgM-EIA-BEST ,Vector BEST,ELISA,Multiple Types,"['IgG', 'IgM']",,,,,['High'],,No,No,No,,Unclear,Yes,No,,Svetlana Portenko,Saratov City Clinical Hospital No. 10,Not Unity-Aligned,https://dx.doi.org/10.15789/2220-7619-EPO-1747,2022-06-04,2022-07-16,Unverified,portenko_etiological_2021,RUS
20220412_Moscow_MoscowInstituteofPhysicsandTechnology_Primary,20220412_Moscow_MoscowInstituteofPhysicsandTechnology,SARS-CoV-2-specific T cells and antibodies in COVID-19 protection: a prospective study.,2022-04-12,Preprint,Local,Cross-sectional survey ,Russian Federation,,"Moscow
",Individuals enrolled in the study were Moscow residents above 18 years old who voluntarily visited 5 Moscow city clinics for routine testing for COVID-19 antibodies and agreed to participate. No specific 6 inclusion or exclusion criteria were applied.,"The difference in these numbers resulted from cases in which the peripheral blood amount was not enough to perform both T cell assays, or from which samples 1 were excluded from the analysis because of failed controls.

Vaccinated participants were withdrawn from the study on the day of vaccination.

To avoid possible bias, we excluded from the analysis 175 individuals who had participated in the Sputnik V clinical trial and 81 individuals who were already infected at the moment of blood collection.",2020-10-15,2020-12-15,Blood donors,All,Multiple groups,15.0,89.0,Primary Estimate,IgG/IgM,5340,0.503,,,True,,,,True,Convenience,Mindray CL-900i anti-SARS-CoV-2 IgG/IgM,Shenzhen Mindray Bio-Medical Electronics Co.,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Ivan A. Molodtsov,Moscow Institute of Physics and Technology,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac278,2022-04-26,2022-07-16,Unverified,molodtsov_sars-cov-2_2022,RUS
220418_StPetersburg_SaintPetersburgPasteurInstitute_Stage1_antiRBD,220418_StPetersburg_SaintPetersburgPasteurInstitute_Stage1,Longitudinal Randomized Cohort Study of SARS-CoV-2 Antibody Seroprevalence in the St. Petersburg Population,2022-04-18,Preprint,Local,Prospective cohort,Russian Federation,Saint Petersburg,Saint Petersburg,Sampled from a previous cross-sectional study of 2713 volunteers in St. Petersburg. Had to have participated in all 5 stages of seromonitoring.,,2020-06-15,2020-06-20,Household and community samples,All,Multiple groups,,,Primary Estimate,,1000,0.038,0.027999999999999997,0.05,True,,,,True,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,,,,['High'],,Yes,Yes,No,,Unclear,Yes,No,,Viacheslav Smirnov,Saint Petersburg Pasteur Institute,Not Unity-Aligned,10.20944/preprints202204.0165.v1,2022-04-26,2022-07-16,Unverified,smirnov_longitudinal_2022,RUS
220418_StPetersburg_SaintPetersburgPasteurInstitute_Stage2_antiRBD,220418_StPetersburg_SaintPetersburgPasteurInstitute_Stage2,Longitudinal Randomized Cohort Study of SARS-CoV-2 Antibody Seroprevalence in the St. Petersburg Population,2022-04-18,Preprint,Local,Prospective cohort,Russian Federation,Saint Petersburg,Saint Petersburg,Sampled from a previous cross-sectional study of 2713 volunteers in St. Petersburg. Had to have participated in all 5 stages of seromonitoring.,,2020-08-31,2020-09-04,Household and community samples,All,Multiple groups,,,Primary Estimate,,1000,0.07,0.055999999999999994,0.085,True,,,,True,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,,,,['High'],,Yes,Yes,No,,Unclear,Yes,No,,Viacheslav Smirnov,Saint Petersburg Pasteur Institute,Not Unity-Aligned,10.20944/preprints202204.0165.v1,2022-04-27,2022-07-16,Unverified,smirnov_longitudinal_2022,RUS
220418_StPetersburg_SaintPetersburgPasteurInstitute_Stage3_antiN,220418_StPetersburg_SaintPetersburgPasteurInstitute_Stage3,Longitudinal Randomized Cohort Study of SARS-CoV-2 Antibody Seroprevalence in the St. Petersburg Population,2022-04-18,Preprint,Local,Prospective cohort,Russian Federation,Saint Petersburg,Saint Petersburg,Sampled from a previous cross-sectional study of 2713 volunteers in St. Petersburg. Had to have participated in all 5 stages of seromonitoring.,,2020-11-30,2020-12-11,Household and community samples,All,Multiple groups,,,Primary Estimate,,1000,0.171,0.15,0.193,True,,,,True,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],,Yes,Yes,No,,Unclear,Yes,No,,Viacheslav Smirnov,Saint Petersburg Pasteur Institute,Not Unity-Aligned,10.20944/preprints202204.0165.v1,2022-04-27,2022-07-16,Unverified,smirnov_longitudinal_2022,RUS
220418_StPetersburg_SaintPetersburgPasteurInstitute_Stage4_antiRBD,220418_StPetersburg_SaintPetersburgPasteurInstitute_Stage4,Longitudinal Randomized Cohort Study of SARS-CoV-2 Antibody Seroprevalence in the St. Petersburg Population,2022-04-18,Preprint,Local,Prospective cohort,Russian Federation,Saint Petersburg,Saint Petersburg,Sampled from a previous cross-sectional study of 2713 volunteers in St. Petersburg. Had to have participated in all 5 stages of seromonitoring.,,2021-03-01,2021-03-07,Household and community samples,All,Multiple groups,,,Primary Estimate,,1000,0.223,0.198,0.251,True,,,,True,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,,,,['High'],,Yes,Yes,No,,Unclear,Yes,No,,Viacheslav Smirnov,Saint Petersburg Pasteur Institute,Not Unity-Aligned,10.20944/preprints202204.0165.v1,2022-04-27,2022-07-16,Unverified,smirnov_longitudinal_2022,RUS
220418_StPetersburg_SaintPetersburgPasteurInstitute_Stage4_antiN,220418_StPetersburg_SaintPetersburgPasteurInstitute_Stage4,Longitudinal Randomized Cohort Study of SARS-CoV-2 Antibody Seroprevalence in the St. Petersburg Population,2022-04-18,Preprint,Local,Prospective cohort,Russian Federation,Saint Petersburg,Saint Petersburg,Sampled from a previous cross-sectional study of 2713 volunteers in St. Petersburg. Had to have participated in all 5 stages of seromonitoring.,,2021-03-01,2021-03-07,Household and community samples,All,Multiple groups,,,Test used,,1000,0.08199999999999999,0.066,0.10099999999999999,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],,Yes,Yes,No,,Unclear,Yes,No,,Viacheslav Smirnov,Saint Petersburg Pasteur Institute,Not Unity-Aligned,10.20944/preprints202204.0165.v1,2022-04-27,2022-07-16,Unverified,smirnov_longitudinal_2022,RUS
220418_StPetersburg_SaintPetersburgPasteurInstitute_Stage4_antiRBD_Unvacc,220418_StPetersburg_SaintPetersburgPasteurInstitute_Stage4,Longitudinal Randomized Cohort Study of SARS-CoV-2 Antibody Seroprevalence in the St. Petersburg Population,2022-04-18,Preprint,Local,Prospective cohort,Russian Federation,Saint Petersburg,Saint Petersburg,Sampled from a previous cross-sectional study of 2713 volunteers in St. Petersburg. Had to have participated in all 5 stages of seromonitoring.,,2021-03-01,2021-03-07,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,,869,0.17300000000000001,,,,,,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,,,,['High'],,Yes,Yes,No,,Unclear,Yes,No,,Viacheslav Smirnov,Saint Petersburg Pasteur Institute,Not Unity-Aligned,10.20944/preprints202204.0165.v1,2022-04-27,2022-07-16,Unverified,smirnov_longitudinal_2022,RUS
220418_StPetersburg_SaintPetersburgPasteurInstitute_Stage4_antiRBD_Vacc,220418_StPetersburg_SaintPetersburgPasteurInstitute_Stage4,Longitudinal Randomized Cohort Study of SARS-CoV-2 Antibody Seroprevalence in the St. Petersburg Population,2022-04-18,Preprint,Local,Prospective cohort,Russian Federation,Saint Petersburg,Saint Petersburg,Sampled from a previous cross-sectional study of 2713 volunteers in St. Petersburg. Had to have participated in all 5 stages of seromonitoring.,,2021-03-01,2021-03-07,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,,131,0.557,0.46799999999999997,0.644,,,,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,,,,['High'],,Yes,Yes,No,,Unclear,Yes,No,,Viacheslav Smirnov,Saint Petersburg Pasteur Institute,Not Unity-Aligned,10.20944/preprints202204.0165.v1,2022-04-27,2022-07-16,Unverified,smirnov_longitudinal_2022,RUS
220418_StPetersburg_SaintPetersburgPasteurInstitute_Stage4_antiRBD+N,220418_StPetersburg_SaintPetersburgPasteurInstitute_Stage4,Longitudinal Randomized Cohort Study of SARS-CoV-2 Antibody Seroprevalence in the St. Petersburg Population,2022-04-18,Preprint,Local,Prospective cohort,Russian Federation,Saint Petersburg,Saint Petersburg,Sampled from a previous cross-sectional study of 2713 volunteers in St. Petersburg. Had to have participated in all 5 stages of seromonitoring.,,2021-03-01,2021-03-07,Household and community samples,All,Multiple groups,,,Test used,,1000,0.381,0.35100000000000003,0.413,,,,,,Simplified probability,"Author designed (ELISA) - Nucleocapsid,Author designed (ELISA) -Spike",,ELISA,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,Yes,Yes,No,,Unclear,Yes,No,,Viacheslav Smirnov,Saint Petersburg Pasteur Institute,Not Unity-Aligned,10.20944/preprints202204.0165.v1,2022-04-27,2022-07-16,Unverified,smirnov_longitudinal_2022,RUS
220418_StPetersburg_SaintPetersburgPasteurInstitute_Stage5_antiRBD,220418_StPetersburg_SaintPetersburgPasteurInstitute_Stage5,Longitudinal Randomized Cohort Study of SARS-CoV-2 Antibody Seroprevalence in the St. Petersburg Population,2022-04-18,Preprint,Local,Prospective cohort,Russian Federation,Saint Petersburg,Saint Petersburg,Sampled from a previous cross-sectional study of 2713 volunteers in St. Petersburg. Had to have participated in all 5 stages of seromonitoring.,,2021-08-30,2021-09-03,Household and community samples,All,Multiple groups,,,Primary Estimate,,1000,0.40399999999999997,0.373,0.435,True,,,,True,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,,,,['High'],,Yes,Yes,No,,Unclear,Yes,No,,Viacheslav Smirnov,Saint Petersburg Pasteur Institute,Not Unity-Aligned,10.20944/preprints202204.0165.v1,2022-04-27,2022-07-16,Unverified,smirnov_longitudinal_2022,RUS
220418_StPetersburg_SaintPetersburgPasteurInstitute_Stage5_antiRBD_Unvacc,220418_StPetersburg_SaintPetersburgPasteurInstitute_Stage5,Longitudinal Randomized Cohort Study of SARS-CoV-2 Antibody Seroprevalence in the St. Petersburg Population,2022-04-18,Preprint,Local,Prospective cohort,Russian Federation,Saint Petersburg,Saint Petersburg,Sampled from a previous cross-sectional study of 2713 volunteers in St. Petersburg. Had to have participated in all 5 stages of seromonitoring.,,2021-08-30,2021-09-03,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,,419,0.34600000000000003,,,,,,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,,,,['High'],,Yes,Yes,No,,Unclear,Yes,No,,Viacheslav Smirnov,Saint Petersburg Pasteur Institute,Not Unity-Aligned,10.20944/preprints202204.0165.v1,2022-04-27,2022-07-16,Unverified,smirnov_longitudinal_2022,RUS
220418_StPetersburg_SaintPetersburgPasteurInstitute_Stage5_antiN,220418_StPetersburg_SaintPetersburgPasteurInstitute_Stage5,Longitudinal Randomized Cohort Study of SARS-CoV-2 Antibody Seroprevalence in the St. Petersburg Population,2022-04-18,Preprint,Local,Prospective cohort,Russian Federation,Saint Petersburg,Saint Petersburg,Sampled from a previous cross-sectional study of 2713 volunteers in St. Petersburg. Had to have participated in all 5 stages of seromonitoring.,,2021-08-30,2021-09-03,Household and community samples,All,Multiple groups,,,Test used,,1000,0.040999999999999995,0.03,0.055,,,,,,Simplified probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],,Yes,Yes,No,,Unclear,Yes,No,,Viacheslav Smirnov,Saint Petersburg Pasteur Institute,Not Unity-Aligned,10.20944/preprints202204.0165.v1,2022-04-27,2022-07-16,Unverified,smirnov_longitudinal_2022,RUS
220418_StPetersburg_SaintPetersburgPasteurInstitute_Stage5_antiRBD_Vacc,220418_StPetersburg_SaintPetersburgPasteurInstitute_Stage5,Longitudinal Randomized Cohort Study of SARS-CoV-2 Antibody Seroprevalence in the St. Petersburg Population,2022-04-18,Preprint,Local,Prospective cohort,Russian Federation,Saint Petersburg,Saint Petersburg,Sampled from a previous cross-sectional study of 2713 volunteers in St. Petersburg. Had to have participated in all 5 stages of seromonitoring.,,2021-08-30,2021-09-03,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,,419,0.618,0.569,0.664,,,,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,,,,['High'],,Yes,Yes,No,,Unclear,Yes,No,,Viacheslav Smirnov,Saint Petersburg Pasteur Institute,Not Unity-Aligned,10.20944/preprints202204.0165.v1,2022-04-27,2022-07-16,Unverified,smirnov_longitudinal_2022,RUS
220418_StPetersburg_SaintPetersburgPasteurInstitute_Stage5_antiRBD+N,220418_StPetersburg_SaintPetersburgPasteurInstitute_Stage5,Longitudinal Randomized Cohort Study of SARS-CoV-2 Antibody Seroprevalence in the St. Petersburg Population,2022-04-18,Preprint,Local,Prospective cohort,Russian Federation,Saint Petersburg,Saint Petersburg,Sampled from a previous cross-sectional study of 2713 volunteers in St. Petersburg. Had to have participated in all 5 stages of seromonitoring.,,2021-08-30,2021-09-03,Household and community samples,All,Multiple groups,,,Test used,,1000,0.379,0.349,0.41000000000000003,,,,,,Simplified probability,"Author designed (ELISA) - Nucleocapsid,Author designed (ELISA) -Spike",,ELISA,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,Yes,Yes,No,,Unclear,Yes,No,,Viacheslav Smirnov,Saint Petersburg Pasteur Institute,Not Unity-Aligned,10.20944/preprints202204.0165.v1,2022-04-27,2022-07-16,Unverified,smirnov_longitudinal_2022,RUS
220530_SaintPetersburg_SaintPetersburgStateUniversityHospital,220530_SaintPetersburg_SaintPetersburgStateUniversityHospital,"Prevalence and Dynamics of SARS-CoV-2 Antibodies in the Population of St. Petersburg, Russia.",2022-05-30,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Russian Federation,Northwestern Federal District,St. Petersburg,"The dataset was based on systematized information obtained from 
the Saint Petersburg State University Hospital laboratory 
database, inclusively summarizing the demographic factors, etiological categories of patients, results of SARSCoV-2 detection by real-time PCR, and serum IgA, IgM, 
and IgG antibodies for SARS-CoV-2, performed from May 
to November 2020.",,2020-05-15,2020-11-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,158283,0.167,,,True,,,,True,Sequential,"Anti-SARS-CoV-2 ELISA IgA,Architect Anti-SARS-CoV-2 IgM,SARS- CoV-2-IgG-EIA-BEST and SARS-CoV-2- IgM-EIA-BEST ,Author designed (ELISA) -Unknown,Not reported/ Unable to specify","EUROIMMUN,Abbott Laboratories,Vector BEST,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']",,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Ekaterina V Parshina,Saint Petersburg State University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1007/s44197-022-00041-9,2022-06-10,2024-03-01,Unverified,parshina_prevalence_2022,RUS
220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round1_Overall_PopTestAdj,220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round1,"COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.",2022-06-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Russian Federation,Northwestern Region,Saint Petersburg,Eligible individuals were adults residing in St. Petersburg older than 18 years and recruited using the random digit dialling (RDD) method,,2020-05-25,2020-06-28,Household and community samples,All,Multiple groups,,,Primary Estimate,,988,0.09699999999999999,0.077,0.11699999999999999,True,True,True,,,Simplified probability,CoronaPass total antibodies test,Genetico,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.92,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,No,Anton Barchuk,Smorodinova Research Institute of Influenza,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266945,2022-06-29,2023-08-15,Unverified,barchuk_covid-19_2022,RUS
220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round1_Sex_Male_UnAdj,220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round1,"COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.",2022-06-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Russian Federation,Northwestern Region,Saint Petersburg,Eligible individuals were adults residing in St. Petersburg older than 18 years and recruited using the random digit dialling (RDD) method,,2020-05-25,2020-06-28,Household and community samples,Male,Multiple groups,,,Sex/Gender,Male,365,0.125,0.08900000000000001,0.161,,,,,,Simplified probability,CoronaPass total antibodies test,Genetico,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.92,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,No,Anton Barchuk,Smorodinova Research Institute of Influenza,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266945,2022-06-29,2024-03-01,Unverified,barchuk_covid-19_2022,RUS
220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round1_Overall_PopAdj,220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round1,"COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.",2022-06-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Russian Federation,Northwestern Region,Saint Petersburg,Eligible individuals were adults residing in St. Petersburg older than 18 years and recruited using the random digit dialling (RDD) method,,2020-05-25,2020-06-28,Household and community samples,All,Multiple groups,,,Analysis,,988,0.08900000000000001,0.071,0.10800000000000001,,,True,,True,Simplified probability,CoronaPass total antibodies test,Genetico,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.92,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,No,Anton Barchuk,Smorodinova Research Institute of Influenza,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266945,2022-06-29,2024-03-01,Unverified,barchuk_covid-19_2022,RUS
220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round1_Age_65+_UnAdj,220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round1,"COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.",2022-06-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Russian Federation,Northwestern Region,Saint Petersburg,Eligible individuals were adults residing in St. Petersburg older than 18 years and recruited using the random digit dialling (RDD) method,,2020-05-25,2020-06-28,Household and community samples,All,Seniors (65+ years),65.0,,Age,65+,61,0.036000000000000004,0.0,0.084,,,,,,Simplified probability,CoronaPass total antibodies test,Genetico,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.92,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,No,Anton Barchuk,Smorodinova Research Institute of Influenza,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266945,2022-06-29,2024-03-01,Unverified,barchuk_covid-19_2022,RUS
220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round1_Age_35-49_UnAdj,220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round1,"COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.",2022-06-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Russian Federation,Northwestern Region,Saint Petersburg,Eligible individuals were adults residing in St. Petersburg older than 18 years and recruited using the random digit dialling (RDD) method,,2020-05-25,2020-06-28,Household and community samples,All,Adults (18-64 years),35.0,49.0,Age,35-49,341,0.092,0.06,0.125,,,,,,Simplified probability,CoronaPass total antibodies test,Genetico,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.92,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,No,Anton Barchuk,Smorodinova Research Institute of Influenza,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266945,2022-06-29,2024-03-01,Unverified,barchuk_covid-19_2022,RUS
220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round1_Sex_Female_UnAdj,220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round1,"COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.",2022-06-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Russian Federation,Northwestern Region,Saint Petersburg,Eligible individuals were adults residing in St. Petersburg older than 18 years and recruited using the random digit dialling (RDD) method,,2020-05-25,2020-06-28,Household and community samples,Female,Multiple groups,,,Sex/Gender,Female,623,0.11,0.084,0.136,,,,,,Simplified probability,CoronaPass total antibodies test,Genetico,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.92,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,No,Anton Barchuk,Smorodinova Research Institute of Influenza,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266945,2022-06-29,2024-03-01,Unverified,barchuk_covid-19_2022,RUS
220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round1_Age_50-64_UnAdj,220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round1,"COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.",2022-06-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Russian Federation,Northwestern Region,Saint Petersburg,Eligible individuals were adults residing in St. Petersburg older than 18 years and recruited using the random digit dialling (RDD) method,,2020-05-25,2020-06-28,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50-64,199,0.13699999999999998,0.086,0.187,,,,,,Simplified probability,CoronaPass total antibodies test,Genetico,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.92,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,No,Anton Barchuk,Smorodinova Research Institute of Influenza,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266945,2022-06-29,2024-03-01,Unverified,barchuk_covid-19_2022,RUS
220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round1_Age_18-34_UnAdj,220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round1,"COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.",2022-06-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Russian Federation,Northwestern Region,Saint Petersburg,Eligible individuals were adults residing in St. Petersburg older than 18 years and recruited using the random digit dialling (RDD) method,,2020-05-25,2020-06-28,Household and community samples,All,Adults (18-64 years),18.0,34.0,Age,18-34,387,0.138,0.102,0.174,,,,,,Simplified probability,CoronaPass total antibodies test,Genetico,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.92,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,No,Anton Barchuk,Smorodinova Research Institute of Influenza,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266945,2022-06-29,2024-03-01,Unverified,barchuk_covid-19_2022,RUS
220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round2_Overall_PopTestAdj,220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round2,"COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.",2022-06-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Russian Federation,Northwestern Region,Saint Petersburg,Eligible individuals were adults residing in St. Petersburg older than 18 years and recruited using the random digit dialling (RDD) method,,2020-07-20,2020-08-08,Household and community samples,All,Multiple groups,,,Primary Estimate,,474,0.133,0.099,0.166,True,True,True,,,Simplified probability,CoronaPass total antibodies test,Genetico,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.92,1.0,['Moderate'],Yes,Yes,No,Yes,Yes,No,Yes,Yes,No,Anton Barchuk,Smorodinova Research Institute of Influenza,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266945,2022-06-29,2023-08-15,Unverified,barchuk_covid-19_2022,RUS
220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round2_Sex_Male_UnAdj,220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round2,"COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.",2022-06-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Russian Federation,Northwestern Region,Saint Petersburg,Eligible individuals were adults residing in St. Petersburg older than 18 years and recruited using the random digit dialling (RDD) method,,2020-07-20,2020-08-08,Household and community samples,Male,Multiple groups,,,Sex/Gender,Male,174,0.162,0.105,0.22,,,,,,Simplified probability,CoronaPass total antibodies test,Genetico,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.92,1.0,['Moderate'],Yes,Yes,No,Yes,Yes,No,Yes,Yes,No,Anton Barchuk,Smorodinova Research Institute of Influenza,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266945,2022-06-29,2024-03-01,Unverified,barchuk_covid-19_2022,RUS
220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round2_Age_35-49_UnAdj,220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round2,"COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.",2022-06-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Russian Federation,Northwestern Region,Saint Petersburg,Eligible individuals were adults residing in St. Petersburg older than 18 years and recruited using the random digit dialling (RDD) method,,2020-07-20,2020-08-08,Household and community samples,All,Adults (18-64 years),35.0,49.0,Age,35-49,158,0.165,0.10400000000000001,0.226,,,,,,Simplified probability,CoronaPass total antibodies test,Genetico,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.92,1.0,['Moderate'],Yes,Yes,No,Yes,Yes,No,Yes,Yes,No,Anton Barchuk,Smorodinova Research Institute of Influenza,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266945,2022-06-29,2024-03-01,Unverified,barchuk_covid-19_2022,RUS
220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round2_Age_18-34_UnAdj,220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round2,"COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.",2022-06-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Russian Federation,Northwestern Region,Saint Petersburg,Eligible individuals were adults residing in St. Petersburg older than 18 years and recruited using the random digit dialling (RDD) method,,2020-07-20,2020-08-08,Household and community samples,All,Adults (18-64 years),18.0,34.0,Age,18-34,172,0.16399999999999998,0.106,0.222,,,,,,Simplified probability,CoronaPass total antibodies test,Genetico,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.92,1.0,['Moderate'],Yes,Yes,No,Yes,Yes,No,Yes,Yes,No,Anton Barchuk,Smorodinova Research Institute of Influenza,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266945,2022-06-29,2024-03-01,Unverified,barchuk_covid-19_2022,RUS
220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round2_Age_50-64_UnAdj,220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round2,"COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.",2022-06-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Russian Federation,Northwestern Region,Saint Petersburg,Eligible individuals were adults residing in St. Petersburg older than 18 years and recruited using the random digit dialling (RDD) method,,2020-07-20,2020-08-08,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50-64,116,0.20600000000000002,0.129,0.284,,,,,,Simplified probability,CoronaPass total antibodies test,Genetico,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.92,1.0,['Moderate'],Yes,Yes,No,Yes,Yes,No,Yes,Yes,No,Anton Barchuk,Smorodinova Research Institute of Influenza,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266945,2022-06-29,2024-03-01,Unverified,barchuk_covid-19_2022,RUS
220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round2_Age_65+_UnAdj,220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round2,"COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.",2022-06-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Russian Federation,Northwestern Region,Saint Petersburg,Eligible individuals were adults residing in St. Petersburg older than 18 years and recruited using the random digit dialling (RDD) method,,2020-07-20,2020-08-08,Household and community samples,All,Seniors (65+ years),65.0,,Age,65+,28,0.0,,,,,,,,Simplified probability,CoronaPass total antibodies test,Genetico,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.92,1.0,['Moderate'],Yes,Yes,No,Yes,Yes,No,Yes,Yes,No,Anton Barchuk,Smorodinova Research Institute of Influenza,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266945,2022-06-29,2024-03-01,Unverified,barchuk_covid-19_2022,RUS
220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round2_Overall_PopAdj,220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round2,"COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.",2022-06-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Russian Federation,Northwestern Region,Saint Petersburg,Eligible individuals were adults residing in St. Petersburg older than 18 years and recruited using the random digit dialling (RDD) method,,2020-07-20,2020-08-08,Household and community samples,All,Multiple groups,,,Analysis,,474,0.122,0.091,0.153,,,True,,True,Simplified probability,CoronaPass total antibodies test,Genetico,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.92,1.0,['Moderate'],Yes,Yes,No,Yes,Yes,No,Yes,Yes,No,Anton Barchuk,Smorodinova Research Institute of Influenza,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266945,2022-06-29,2024-03-01,Unverified,barchuk_covid-19_2022,RUS
220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round2_Sex_Female_UnAdj,220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round2,"COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.",2022-06-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Russian Federation,Northwestern Region,Saint Petersburg,Eligible individuals were adults residing in St. Petersburg older than 18 years and recruited using the random digit dialling (RDD) method,,2020-07-20,2020-08-08,Household and community samples,Female,Multiple groups,,,Sex/Gender,Female,300,0.167,0.122,0.21100000000000002,,,,,,Simplified probability,CoronaPass total antibodies test,Genetico,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.92,1.0,['Moderate'],Yes,Yes,No,Yes,Yes,No,Yes,Yes,No,Anton Barchuk,Smorodinova Research Institute of Influenza,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266945,2022-06-29,2024-03-01,Unverified,barchuk_covid-19_2022,RUS
220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round3_Overall_PopTestAdj,220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round3,"COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.",2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Russian Federation,Northwestern Region,Saint Petersburg,Eligible individuals were adults residing in St. Petersburg older than 18 years and recruited using the random digit dialling (RDD) method,,2020-10-12,2020-12-06,Household and community samples,All,Multiple groups,,,Primary Estimate,,1322,0.22899999999999998,0.203,0.255,True,True,True,,,Simplified probability,CoronaPass total antibodies test,Genetico,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.92,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,No,Anton Barchuk,Smorodinova Research Institute of Influenza,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266945,2022-06-29,2023-08-15,Unverified,barchuk_covid-19_2022,RUS
220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round3_Age_35-49_UnAdj,220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round3,"COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.",2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Russian Federation,Northwestern Region,Saint Petersburg,Eligible individuals were adults residing in St. Petersburg older than 18 years and recruited using the random digit dialling (RDD) method,,2020-10-12,2020-12-06,Household and community samples,All,Adults (18-64 years),35.0,49.0,Age,35-49,479,0.259,0.217,0.3,,,,,,Simplified probability,CoronaPass total antibodies test,Genetico,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.92,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,No,Anton Barchuk,Smorodinova Research Institute of Influenza,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266945,2022-06-29,2024-03-01,Unverified,barchuk_covid-19_2022,RUS
220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round3_Age_50-64_UnAdj,220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round3,"COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.",2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Russian Federation,Northwestern Region,Saint Petersburg,Eligible individuals were adults residing in St. Petersburg older than 18 years and recruited using the random digit dialling (RDD) method,,2020-10-12,2020-12-06,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50-64,267,0.281,0.22399999999999998,0.33799999999999997,,,,,,Simplified probability,CoronaPass total antibodies test,Genetico,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.92,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,No,Anton Barchuk,Smorodinova Research Institute of Influenza,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266945,2022-06-29,2024-03-01,Unverified,barchuk_covid-19_2022,RUS
220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round3_Sex_Female_UnAdj,220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round3,"COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.",2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Russian Federation,Northwestern Region,Saint Petersburg,Eligible individuals were adults residing in St. Petersburg older than 18 years and recruited using the random digit dialling (RDD) method,,2020-10-12,2020-12-06,Household and community samples,Female,Multiple groups,,,Sex/Gender,Female,874,0.239,0.209,0.269,,,,,,Simplified probability,CoronaPass total antibodies test,Genetico,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.92,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,No,Anton Barchuk,Smorodinova Research Institute of Influenza,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266945,2022-06-29,2024-03-01,Unverified,barchuk_covid-19_2022,RUS
220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round3_Sex_Male_UnAdj,220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round3,"COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.",2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Russian Federation,Northwestern Region,Saint Petersburg,Eligible individuals were adults residing in St. Petersburg older than 18 years and recruited using the random digit dialling (RDD) method,,2020-10-12,2020-12-06,Household and community samples,Male,Multiple groups,,,Sex/Gender,Male,448,0.27899999999999997,0.23500000000000001,0.32299999999999995,,,,,,Simplified probability,CoronaPass total antibodies test,Genetico,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.92,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,No,Anton Barchuk,Smorodinova Research Institute of Influenza,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266945,2022-06-29,2024-03-01,Unverified,barchuk_covid-19_2022,RUS
220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round3_Age_18-34_UnAdj,220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round3,"COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.",2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Russian Federation,Northwestern Region,Saint Petersburg,Eligible individuals were adults residing in St. Petersburg older than 18 years and recruited using the random digit dialling (RDD) method,,2020-10-12,2020-12-06,Household and community samples,All,Adults (18-64 years),18.0,34.0,Age,18-34,499,0.244,0.204,0.284,,,,,,Simplified probability,CoronaPass total antibodies test,Genetico,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.92,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,No,Anton Barchuk,Smorodinova Research Institute of Influenza,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266945,2022-06-29,2024-03-01,Unverified,barchuk_covid-19_2022,RUS
220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round3_Age_65+_UnAdj,220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round3,"COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.",2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Russian Federation,Northwestern Region,Saint Petersburg,Eligible individuals were adults residing in St. Petersburg older than 18 years and recruited using the random digit dialling (RDD) method,,2020-10-12,2020-12-06,Household and community samples,All,Seniors (65+ years),65.0,,Age,65+,77,0.16899999999999998,0.081,0.257,,,,,,Simplified probability,CoronaPass total antibodies test,Genetico,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.92,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,No,Anton Barchuk,Smorodinova Research Institute of Influenza,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266945,2022-06-29,2024-03-01,Unverified,barchuk_covid-19_2022,RUS
220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round3_Overall_PopAdj,220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round3,"COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.",2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Russian Federation,Northwestern Region,Saint Petersburg,Eligible individuals were adults residing in St. Petersburg older than 18 years and recruited using the random digit dialling (RDD) method,,2020-10-12,2020-12-06,Household and community samples,All,Multiple groups,,,Analysis,,1322,0.21,0.187,0.23399999999999999,,,True,,True,Simplified probability,CoronaPass total antibodies test,Genetico,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.92,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,No,Anton Barchuk,Smorodinova Research Institute of Influenza,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266945,2022-06-29,2024-03-01,Unverified,barchuk_covid-19_2022,RUS
220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round4_Overall_PopTestAdj,220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round4,"COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.",2022-06-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,Russian Federation,Northwestern Region,Saint Petersburg,Eligible individuals were adults residing in St. Petersburg older than 18 years and recruited using the random digit dialling (RDD) method,,2021-02-15,2021-04-04,Household and community samples,All,Multiple groups,,,Primary Estimate,,1140,0.439,0.397,0.48,True,True,True,,,Convenience,CoronaPass total antibodies test,Genetico,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.92,1.0,['High'],No,No,Yes,Yes,Yes,No,Yes,Yes,No,Anton Barchuk,Smorodinova Research Institute of Influenza,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266945,2022-06-29,2023-08-15,Unverified,barchuk_covid-19_2022,RUS
220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round4_Sex_Male_UnAdj,220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round4,"COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.",2022-06-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,Russian Federation,Northwestern Region,Saint Petersburg,Eligible individuals were adults residing in St. Petersburg older than 18 years and recruited using the random digit dialling (RDD) method,,2021-02-15,2021-04-04,Household and community samples,Male,Multiple groups,,,Sex/Gender,Male,393,0.653,0.6,0.705,,,,,,Convenience,CoronaPass total antibodies test,Genetico,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.92,1.0,['High'],No,No,Yes,Yes,Yes,No,Yes,Yes,No,Anton Barchuk,Smorodinova Research Institute of Influenza,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266945,2022-06-29,2024-03-01,Unverified,barchuk_covid-19_2022,RUS
220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round4_Sex_Female_UnAdj,220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round4,"COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.",2022-06-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,Russian Federation,Northwestern Region,Saint Petersburg,Eligible individuals were adults residing in St. Petersburg older than 18 years and recruited using the random digit dialling (RDD) method,,2021-02-15,2021-04-04,Household and community samples,Female,Multiple groups,,,Sex/Gender,Female,747,0.54,0.501,0.579,,,,,,Convenience,CoronaPass total antibodies test,Genetico,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.92,1.0,['High'],No,No,Yes,Yes,Yes,No,Yes,Yes,No,Anton Barchuk,Smorodinova Research Institute of Influenza,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266945,2022-06-29,2024-03-01,Unverified,barchuk_covid-19_2022,RUS
220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round4_Age_18-34_UnAdj,220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round4,"COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.",2022-06-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,Russian Federation,Northwestern Region,Saint Petersburg,Eligible individuals were adults residing in St. Petersburg older than 18 years and recruited using the random digit dialling (RDD) method,,2021-02-15,2021-04-04,Household and community samples,All,Adults (18-64 years),18.0,34.0,Age,18-34,391,0.517,0.46299999999999997,0.5710000000000001,,,,,,Convenience,CoronaPass total antibodies test,Genetico,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.92,1.0,['High'],No,No,Yes,Yes,Yes,No,Yes,Yes,No,Anton Barchuk,Smorodinova Research Institute of Influenza,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266945,2022-06-29,2024-03-01,Unverified,barchuk_covid-19_2022,RUS
220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round4_Age_35-49_UnAdj,220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round4,"COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.",2022-06-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,Russian Federation,Northwestern Region,Saint Petersburg,Eligible individuals were adults residing in St. Petersburg older than 18 years and recruited using the random digit dialling (RDD) method,,2021-02-15,2021-04-04,Household and community samples,All,Adults (18-64 years),35.0,49.0,Age,35-49,428,0.615,0.564,0.6659999999999999,,,,,,Convenience,CoronaPass total antibodies test,Genetico,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.92,1.0,['High'],No,No,Yes,Yes,Yes,No,Yes,Yes,No,Anton Barchuk,Smorodinova Research Institute of Influenza,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266945,2022-06-29,2024-03-01,Unverified,barchuk_covid-19_2022,RUS
220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round4_Age_65+_UnAdj,220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round4,"COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.",2022-06-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,Russian Federation,Northwestern Region,Saint Petersburg,Eligible individuals were adults residing in St. Petersburg older than 18 years and recruited using the random digit dialling (RDD) method,,2021-02-15,2021-04-04,Household and community samples,All,Seniors (65+ years),65.0,,Age,65+,64,0.425,0.295,0.555,,,,,,Convenience,CoronaPass total antibodies test,Genetico,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.92,1.0,['High'],No,No,Yes,Yes,Yes,No,Yes,Yes,No,Anton Barchuk,Smorodinova Research Institute of Influenza,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266945,2022-06-29,2024-03-01,Unverified,barchuk_covid-19_2022,RUS
220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round4_Overall_PopAdj,220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round4,"COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.",2022-06-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,Russian Federation,Northwestern Region,Saint Petersburg,Eligible individuals were adults residing in St. Petersburg older than 18 years and recruited using the random digit dialling (RDD) method,,2021-02-15,2021-04-04,Household and community samples,All,Multiple groups,,,Analysis,,1140,0.40399999999999997,0.365,0.44200000000000006,,,True,,True,Convenience,CoronaPass total antibodies test,Genetico,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.92,1.0,['High'],No,No,Yes,Yes,Yes,No,Yes,Yes,No,Anton Barchuk,Smorodinova Research Institute of Influenza,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266945,2022-06-29,2024-03-01,Unverified,barchuk_covid-19_2022,RUS
220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round4_Age_50-64_UnAdj,220615_StPetersburg_SmorodintsevResearchInstituteofInfluenza_Round4,"COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.",2022-06-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,Russian Federation,Northwestern Region,Saint Petersburg,Eligible individuals were adults residing in St. Petersburg older than 18 years and recruited using the random digit dialling (RDD) method,,2021-02-15,2021-04-04,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50-64,257,0.6509999999999999,0.5860000000000001,0.716,,,,,,Convenience,CoronaPass total antibodies test,Genetico,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.92,1.0,['High'],No,No,Yes,Yes,Yes,No,Yes,Yes,No,Anton Barchuk,Smorodinova Research Institute of Influenza,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266945,2022-06-29,2024-03-01,Unverified,barchuk_covid-19_2022,RUS
220617_Russia_PasteurInstituteofEpidemiologyandMicrobiology_Overall_NorSProtein,220617_Russia_PasteurInstituteofEpidemiologyandMicrobiology,SEROPREVALENCE OF ANTIBODIES TO SARS-CoV-2 IN CHILDREN AGAINST THE BACKGROUND OF THE COVID-19 EPIDEMIC IN THE RUSSIAN FEDERATION,2022-06-17,Journal Article (Peer-Reviewed),National,Prospective cohort,Russian Federation,"Astrakhan region, Belgorod region, Vladimir region
Irkutsk region, Krasnoyarsk region, Leningrad region, Moscow region, Nizhny Novgorod region, Novosibirsk region, Primorsky Krai, Republic of Crimea, Republic of Tatarstan, St. Petersburg, Saratov Region, Tula region, Khabarovsk region, Chelyabinsk region",,"Not included in this paper, but prior studies indicate children between 1-17 were recruited for the study among the 26 regions of the Russian Federation","Not included in this paper, but prior studies say known COVID-19 diagnosis was an exclusion criteria",2021-12-01,2021-12-31,Household and community samples,All,Children and Youth (0-17 years),1.0,17.0,Primary Estimate,Tested positive for either nucleocapsid or RBD of S protein,3667,0.823,,,True,,,,True,Simplified probability,ELISA anti-SARS-CoV reagent kit -2 IgG,FBSI State scientific center for applied microbiology and biotechnology,ELISA,Plasma,,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,Yes,Yes,No,,Unclear,Yes,No,,A.Y. Popova,Pasteur Institute,Not Unity-Aligned,https://dx.doi.org/10.24110/0031-403x-2022-101-3-85-97,2022-08-24,2022-08-24,Unverified,popova_serpencelessness_2022,RUS
220926_SaintPetersburg_S.M.KirovMilitaryMedicalAcademy_Females,220926_SaintPetersburg_S.M.KirovMilitaryMedicalAcademy_Females,Herd immunity to SARS-CoV-2 among adolescent students of the Russian Defense Ministry colleges of the city of Saint Petersburg,2022-09-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,St Petersburg,"""adolescent students of the Russian Defense Ministry colleges. Adolescents aged 11 to 17 years old from the male Russian MoD schools located in the city of Saint Petersburg,""

""written parental consent (or legal representative), in addition to signing provided by a parent (or legal representative) body) of children under 14 years of age and / or by the teenager himself 15–17 years old""",,2021-12-15,2022-05-15,Students and Daycares,Female,Children and Youth (0-17 years),11.0,16.0,Primary Estimate,,75,0.623,,,True,,,,True,Stratified non-probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,E.V. Kryukov,S.M. Kirov Military Medical Academy,Not Unity-Aligned,https://dx.doi.org/10.24110/0031-403X-2022-101-5-69-75,2022-11-17,2022-11-17,Unverified,kryukov_herd_2022,RUS
220926_SaintPetersburg_S.M.KirovMilitaryMedicalAcademy_Males,220926_SaintPetersburg_S.M.KirovMilitaryMedicalAcademy_Males,Herd immunity to SARS-CoV-2 among adolescent students of the Russian Defense Ministry colleges of the city of Saint Petersburg,2022-09-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,St Petersburg,"""adolescent students of the Russian Defense Ministry colleges. Adolescents aged 11 to 17 years old from the female Russian MoD schools located in the city of Saint Petersburg,""

""written parental consent (or legal representative), in addition to signing provided by a parent (or legal representative) body) of children under 14 years of age and / or by the teenager himself 15–17 years old""",,2021-12-15,2022-05-15,Students and Daycares,Male,Children and Youth (0-17 years),12.0,17.0,Primary Estimate,,153,0.6809999999999999,,,True,,,,True,Stratified non-probability,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,E.V. Kryukov,S.M. Kirov Military Medical Academy,Not Unity-Aligned,https://dx.doi.org/10.24110/0031-403X-2022-101-5-69-75,2022-11-17,2022-11-17,Unverified,kryukov_herd_2022,RUS
230101_Arkhangelsk_NorthernStateMedicalUniversity_2021Dec,230101_Arkhangelsk_NorthernStateMedicalUniversity_2021Dec,Humoral immunity to new coronavirus infection and vitamin D level in healthcare workers,2023-01-01,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Russian Federation,Arkhangelsk,,"Google translated:
""A cross-sectional study involving 170 medical workers with infectious diseases from divisions of the Arkhangelsk region providing medical care to patients with COVID-19 was conducted twice with an interval of 6 months: the first in May 2021, 1.5 years after the start of the COVID-19 pandemic, the second – in December 2021, 2 years after the start of the COVID-19 pandemic. The study included all medical workers who were at the workplace on the day of the survey and signed an informed consent (continuous sample).""",,2021-12-01,2021-12-31,Health care workers and caregivers,All,Multiple groups,21.0,81.0,Primary Estimate,,170,0.988,,,True,,,,True,Convenience,SARS- CoV-2-IgG-EIA-BEST and SARS-CoV-2- IgM-EIA-BEST ,Vector BEST,ELISA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,E.A. Krieger,Northern State Medical University,Not Unity-Aligned,https://dx.doi.org/10.22625/2072-6732-2023-15-2-93-104,2023-09-21,2023-09-22,Unverified,krieger_humoral_2023,RUS
230101_Arkhangelsk_NorthernStateMedicalUniversity_2021May,230101_Arkhangelsk_NorthernStateMedicalUniversity_2021May,Humoral immunity to new coronavirus infection and vitamin D level in healthcare workers,2023-01-01,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Russian Federation,Arkhangelsk,,"Google translated:
""A cross-sectional study involving 170 medical workers with infectious diseases from divisions of the Arkhangelsk region providing medical care to patients with COVID-19 was conducted twice with an interval of 6 months: the first in May 2021, 1.5 years after the start of the COVID-19 pandemic, the second – in December 2021, 2 years after the start of the COVID-19 pandemic. The study included all medical workers who were at the workplace on the day of the survey and signed an informed consent (continuous sample).""",,2021-05-01,2021-05-31,Health care workers and caregivers,All,Multiple groups,21.0,81.0,Primary Estimate,,170,0.912,,,True,,,,True,Convenience,SARS- CoV-2-IgG-EIA-BEST and SARS-CoV-2- IgM-EIA-BEST ,Vector BEST,ELISA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,E.A. Krieger,Northern State Medical University,Not Unity-Aligned,https://dx.doi.org/10.22625/2072-6732-2023-15-2-93-104,2023-09-18,2023-09-22,Unverified,krieger_humoral_2023,RUS
250315_Arkhangelsk_NorthernStateMedicalUniversity,250315_Arkhangelsk_NorthernStateMedicalUniversity,"COVID-19: seroprevalence and adherence to preventive measures in Arkhangelsk, Northwest Russia",2023-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Russian Federation,,Arkhangelsk,"The ESSE-RF study aimed to recruit a
sample that was representative of the population of
INFECTIOUS DISEASES 317
Russia. I"," The exclusions (N ¼ 122) were for the following reasons: 56 KYH participants had not consented to
be contacted with invitations to other studies, 61 had
died prior to the launch of ESSE-RF3 (4 of 61 deaths
were related to COVID-19), and 5 had become older
than the maximum age (74 years)",2021-02-24,2021-06-30,Household and community samples,All,Multiple groups,40.0,74.0,Primary Estimate,,1332,0.651,0.625,0.676,True,,,,True,Convenience,SARS- CoV-2-IgG-EIA-BEST and SARS-CoV-2- IgM-EIA-BEST ,Vector BEST,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.89,1.0,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Ekaterina Krieger,Northern State Medical University,Not Unity-Aligned,https://dx.doi.org/10.1080/23744235.2023.2179660,2023-04-11,2023-04-12,Unverified,krieger_covid-19_2023,RUS
200906_Madinah_KingFahadGeneralHospital_HCWs_Overall,200906_Madinah_KingFahadGeneralHospital,Enzyme-Linked Immunosorbent Assay for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) IgM/IgA and IgG Antibodies Among Healthcare Workers,2020-09-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,Hejaz,Madinah,Health care workers from five Madinah region-affiliated hospitals,,2020-04-18,2020-06-17,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,"N/A - overall estimate, IgG and/or IgM/IgA",330,0.24239999999999998,,,True,,,,True,Unclear,COVID-19 ELISA IgM/IgA,Vircell S.L.,ELISA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,Unclear,No,No,Unclear,No,Yes,No,Unclear,Suliman Alharbi,King Fahad General Hospital,Not Unity-Aligned,https://assets.cureus.com/uploads/original_article/pdf/39817/1599507536-20200907-8365-icotwh.pdf,2020-09-28,2024-03-01,Verified,alharbi_enzyme-linked_2020,SAU
201120_SaudiArabia_SaudiCDC_Overall,201120_SaudiArabia_SaudiCDC,Seroprevalence of SARS-CoV-2 (COVID-19) among healthcare workers in Saudi Arabia: comparing case and control hospitals.,2020-11-20,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Saudi Arabia,"Hail, Najran, Baha, Qassim, Norther Border, Jazan, Riyadh, Emirate of the Eastern Province, Aseer, Madinah, Makkah",,"The study included hospitals with more than 200 beds and the study was conducted between May 20th and 30th, 2020. Health workers
included physicians, nurses, pharmacists, respiratory therapists,
and administrative support who agree to participate in the study. The
HCWs were from departments at high risk to get exposed to COVID
19 cases: medicine, intensive care units, and emergency departments.","We excluded HCWs who were experiencing any suggestive
symptoms of COVID-19 at the time of enrolment.",2020-05-20,2020-05-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,HCWs overall,12621,0.0236,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Haleema Ali Alserehi,Saudi Center for Disease Prevention and Control,Not Unity-Aligned,https://dx.doi.org/10.1016/j.diagmicrobio.2020.115273,2021-01-23,2024-03-01,Verified,alserehi_seroprevalence_2020,SAU
201206_Al-Madinah_TaibahUniversity_Overall,201211_Al-Madinah_TaibahUniversity,The seroprevalence of SARS-CoV-2 IgG antibodies among asymptomatic blood donors in Saudi Arabia,2020-12-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Al-Madinah,"All eligible blood donors who were confirmed to be free from all viral infections, including hep B and C, HIV 1+2, and human T cell leukemia-lymphoma virus","Previously tested positive for SARS-CoV-2 infection, COVID-19 symptoms. Blood donors were excluded if they were diagnosed with existing diseases or presented with physically identifiable symptoms of any infection, including cough, sore throat, or fever.",2020-05-15,2020-07-15,Blood donors,Male,Adults (18-64 years),18.0,64.0,Primary Estimate,Blood donors,1212,0.1931,0.17120000000000002,0.2164,True,,,,True,Convenience,Author designed (ELISA) -Spike,,Multiple Types,Serum,IgG,Spike,Validated by manufacturers,,,['High'],No,No,Yes,No,Yes,Unclear,Yes,No,,Waleed H Mahallawi,Taibah University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.sjbs.2020.12.009,2021-02-17,2022-07-16,Verified,mahallawi_seroprevalence_2020,SAU
201206_Al-Madinah_TaibahUniversity_25-29,201211_Al-Madinah_TaibahUniversity,The seroprevalence of SARS-CoV-2 IgG antibodies among asymptomatic blood donors in Saudi Arabia,2020-12-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Al-Madinah,"All eligible blood donors who were confirmed to be free from all viral infections, including hep B and C, HIV 1+2, and human T cell leukemia-lymphoma virus","Previously tested positive for SARS-CoV-2 infection, COVID-19 symptoms. Blood donors were excluded if they were diagnosed with existing diseases or presented with physically identifiable symptoms of any infection, including cough, sore throat, or fever.",2020-05-15,2020-07-15,Blood donors,Male,Adults (18-64 years),25.0,29.0,Age,25-29 years of age,327,0.18960000000000002,,,,,,,,Convenience,Author designed (ELISA) -Spike,,Multiple Types,Serum,IgG,Spike,,,,['High'],No,No,Yes,No,Yes,Unclear,Yes,No,,Waleed H Mahallawi,Taibah University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.sjbs.2020.12.009,2021-02-17,2022-07-16,Verified,mahallawi_seroprevalence_2020,SAU
201206_Al-Madinah_TaibahUniversity_18-24,201211_Al-Madinah_TaibahUniversity,The seroprevalence of SARS-CoV-2 IgG antibodies among asymptomatic blood donors in Saudi Arabia,2020-12-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Al-Madinah,"All eligible blood donors who were confirmed to be free from all viral infections, including hep B and C, HIV 1+2, and human T cell leukemia-lymphoma virus","Previously tested positive for SARS-CoV-2 infection, COVID-19 symptoms. Blood donors were excluded if they were diagnosed with existing diseases or presented with physically identifiable symptoms of any infection, including cough, sore throat, or fever.",2020-05-15,2020-07-15,Blood donors,Male,Adults (18-64 years),18.0,24.0,Age,18-24 years of age,278,0.20140000000000002,,,,,,,,Convenience,Author designed (ELISA) -Spike,,Multiple Types,Serum,IgG,Spike,,,,['High'],No,No,Yes,No,Yes,Unclear,Yes,No,,Waleed H Mahallawi,Taibah University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.sjbs.2020.12.009,2021-02-17,2022-07-16,Verified,mahallawi_seroprevalence_2020,SAU
201206_Al-Madinah_TaibahUniversity_>=50,201211_Al-Madinah_TaibahUniversity,The seroprevalence of SARS-CoV-2 IgG antibodies among asymptomatic blood donors in Saudi Arabia,2020-12-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Al-Madinah,"All eligible blood donors who were confirmed to be free from all viral infections, including hep B and C, HIV 1+2, and human T cell leukemia-lymphoma virus","Previously tested positive for SARS-CoV-2 infection, COVID-19 symptoms. Blood donors were excluded if they were diagnosed with existing diseases or presented with physically identifiable symptoms of any infection, including cough, sore throat, or fever.",2020-05-15,2020-07-15,Blood donors,Male,Adults (18-64 years),50.0,64.0,Age,>= 50 y.o,59,0.16949999999999998,,,,,,,,Convenience,Author designed (ELISA) -Spike,,Multiple Types,Serum,IgG,Spike,,,,['High'],No,No,Yes,No,Yes,Unclear,Yes,No,,Waleed H Mahallawi,Taibah University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.sjbs.2020.12.009,2021-02-17,2022-07-16,Verified,mahallawi_seroprevalence_2020,SAU
201206_Al-Madinah_TaibahUniversity_30-34,201211_Al-Madinah_TaibahUniversity,The seroprevalence of SARS-CoV-2 IgG antibodies among asymptomatic blood donors in Saudi Arabia,2020-12-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Al-Madinah,"All eligible blood donors who were confirmed to be free from all viral infections, including hep B and C, HIV 1+2, and human T cell leukemia-lymphoma virus","Previously tested positive for SARS-CoV-2 infection, COVID-19 symptoms. Blood donors were excluded if they were diagnosed with existing diseases or presented with physically identifiable symptoms of any infection, including cough, sore throat, or fever.",2020-05-15,2020-07-15,Blood donors,Male,Adults (18-64 years),30.0,34.0,Age,30-34 years of age,209,0.21530000000000002,,,,,,,,Convenience,Author designed (ELISA) -Spike,,Multiple Types,Serum,IgG,Spike,,,,['High'],No,No,Yes,No,Yes,Unclear,Yes,No,,Waleed H Mahallawi,Taibah University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.sjbs.2020.12.009,2021-02-17,2022-07-16,Verified,mahallawi_seroprevalence_2020,SAU
201206_Al-Madinah_TaibahUniversity_45-49,201211_Al-Madinah_TaibahUniversity,The seroprevalence of SARS-CoV-2 IgG antibodies among asymptomatic blood donors in Saudi Arabia,2020-12-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Al-Madinah,"All eligible blood donors who were confirmed to be free from all viral infections, including hep B and C, HIV 1+2, and human T cell leukemia-lymphoma virus","Previously tested positive for SARS-CoV-2 infection, COVID-19 symptoms. Blood donors were excluded if they were diagnosed with existing diseases or presented with physically identifiable symptoms of any infection, including cough, sore throat, or fever.",2020-05-15,2020-07-15,Blood donors,Male,Adults (18-64 years),45.0,49.0,Age,45-49 y.o,67,0.209,,,,,,,,Convenience,Author designed (ELISA) -Spike,,Multiple Types,Serum,IgG,Spike,,,,['High'],No,No,Yes,No,Yes,Unclear,Yes,No,,Waleed H Mahallawi,Taibah University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.sjbs.2020.12.009,2021-02-17,2022-07-16,Verified,mahallawi_seroprevalence_2020,SAU
201206_Al-Madinah_TaibahUniversity_40-44,201211_Al-Madinah_TaibahUniversity,The seroprevalence of SARS-CoV-2 IgG antibodies among asymptomatic blood donors in Saudi Arabia,2020-12-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Al-Madinah,"All eligible blood donors who were confirmed to be free from all viral infections, including hep B and C, HIV 1+2, and human T cell leukemia-lymphoma virus","Previously tested positive for SARS-CoV-2 infection, COVID-19 symptoms. Blood donors were excluded if they were diagnosed with existing diseases or presented with physically identifiable symptoms of any infection, including cough, sore throat, or fever.",2020-05-15,2020-07-15,Blood donors,Male,Adults (18-64 years),40.0,44.0,Age,40-44 y.o,141,0.1844,,,,,,,,Convenience,Author designed (ELISA) -Spike,,Multiple Types,Serum,IgG,Spike,,,,['High'],No,No,Yes,No,Yes,Unclear,Yes,No,,Waleed H Mahallawi,Taibah University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.sjbs.2020.12.009,2021-02-17,2022-07-16,Verified,mahallawi_seroprevalence_2020,SAU
201206_Al-Madinah_TaibahUniversity_35-39,201211_Al-Madinah_TaibahUniversity,The seroprevalence of SARS-CoV-2 IgG antibodies among asymptomatic blood donors in Saudi Arabia,2020-12-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Al-Madinah,"All eligible blood donors who were confirmed to be free from all viral infections, including hep B and C, HIV 1+2, and human T cell leukemia-lymphoma virus","Previously tested positive for SARS-CoV-2 infection, COVID-19 symptoms. Blood donors were excluded if they were diagnosed with existing diseases or presented with physically identifiable symptoms of any infection, including cough, sore throat, or fever.",2020-05-15,2020-07-15,Blood donors,Male,Adults (18-64 years),35.0,39.0,Age,35-39 y.o,131,0.16030000000000003,,,,,,,,Convenience,Author designed (ELISA) -Spike,,Multiple Types,Serum,IgG,Spike,,,,['High'],No,No,Yes,No,Yes,Unclear,Yes,No,,Waleed H Mahallawi,Taibah University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.sjbs.2020.12.009,2021-02-17,2022-07-16,Verified,mahallawi_seroprevalence_2020,SAU
210105_Jeddah_KingAbdulazizUniversity_overall,210105_Jeddah_KingAbdulazizUniversity,Lack of Antibodies to SARS-CoV-2 among Blood Donors during COVID-19 Lockdown: A Study from Saudi Arabia,2021-01-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Jeddah,"All blood donors who visited KAUH, Jeddah, Saudi Arabia.",,2020-01-01,2020-05-31,Blood donors,All,Adults (18-64 years),,,Primary Estimate,,956,0.015,,,True,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,1.0,0.9840000000000001,['High'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Thamir Alandijany,King Abdulaziz University,Not Unity-Aligned,https://dx.doi.org/10.3390/healthcare9010051,2021-02-10,2022-07-16,Verified,alandijany_lack_2021,SAU
210112_Dammam_KingFahadSpecialistHospital_Overall,210112_Dammam_KingFahadSpecialistHospital,Detection of SARS-COV-2 Antibodies in Pediatric Kidney Transplant Patients,2021-01-12,Preprint,Local,Cross-sectional survey ,Saudi Arabia,Eastern Province,Dammam,"all pediatric kidney transplant patients <17 years of age who had an outpatient clinic visit or came to the hospital laboratory at King Fahad Specialist Hospital-Dammam for routine post-transplant
blood work between August 15
th 7 till October 12, 2020",,2020-08-15,2020-10-12,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,Overall,72,0.125,,,True,,,,True,Sequential,"Liaison SARS-CoV-2 S1/S2 IgG,Abbott Architect SARS-CoV-2 IgG","DiaSorin,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,No,,Alanoud Alshami,King Fahad Specialist Hospital,Not Unity-Aligned,https://assets.researchsquare.com/files/rs-140932/v1/a7cb2461-27b8-4eca-bf34-171b60bb1272.pdf,2021-02-05,2024-03-01,Verified,noauthor_detection_2021,SAU
210116_SaudiArabia_MinistryofHealth_overall,210116_SaudiArabia_MinistryofHealth,Seroprevalence of antibodies to SARS-CoV-2 among blood donors in the early month of the pandemic in Saudi Arabia,2021-01-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Saudi Arabia,,,"All blood donors, irrespective of their sociodemographic characteristics, who presented for blood donation at one of the 24 main blood banks in Saudi Arabia were included in the study. Participants were included in the study from 20 to 25 May 2020.","Blood donors with a contraindication for blood donation, those with a past or currently confirmed SARS- CoV-2 infection, and those who declined to give informed consent to participate in the study were excluded",2020-05-20,2020-05-25,Blood donors,All,Adults (18-64 years),17.0,70.0,Primary Estimate,,837,0.013999999999999999,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.998,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Ayman Banjar,Ministry of Health (Saudi Arabia),Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.01.028,2021-02-07,2024-03-01,Verified,banjar_seroprevalence_2021,SAU
210116_SaudiArabia_MinistryofHealth_age40-49,210116_SaudiArabia_MinistryofHealth,Seroprevalence of antibodies to SARS-CoV-2 among blood donors in the early month of the pandemic in Saudi Arabia,2021-01-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Saudi Arabia,,,"All blood donors, irrespective of their sociodemographic characteristics, who presented for blood donation at one of the 24 main blood banks in Saudi Arabia were included in the study. Participants were included in the study from 20 to 25 May 2020.","Blood donors with a contraindication for blood donation, those with a past or currently confirmed SARS- CoV-2 infection, and those who declined to give informed consent to participate in the study were excluded",2020-05-20,2020-05-25,Blood donors,All,Adults (18-64 years),40.0,49.0,Age,40-49,135,0.03,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.998,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Ayman Banjar,Ministry of Health (Saudi Arabia),Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.01.028,2021-02-07,2024-03-01,Verified,banjar_seroprevalence_2021,SAU
210116_SaudiArabia_MinistryofHealth_age70+,210116_SaudiArabia_MinistryofHealth,Seroprevalence of antibodies to SARS-CoV-2 among blood donors in the early month of the pandemic in Saudi Arabia,2021-01-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Saudi Arabia,,,"All blood donors, irrespective of their sociodemographic characteristics, who presented for blood donation at one of the 24 main blood banks in Saudi Arabia were included in the study. Participants were included in the study from 20 to 25 May 2020.","Blood donors with a contraindication for blood donation, those with a past or currently confirmed SARS- CoV-2 infection, and those who declined to give informed consent to participate in the study were excluded",2020-05-20,2020-05-25,Blood donors,All,Seniors (65+ years),70.0,70.0,Age,70+,1,0.0,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.998,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Ayman Banjar,Ministry of Health (Saudi Arabia),Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.01.028,2021-02-07,2024-03-01,Verified,banjar_seroprevalence_2021,SAU
210116_SaudiArabia_MinistryofHealth_age30-39,210116_SaudiArabia_MinistryofHealth,Seroprevalence of antibodies to SARS-CoV-2 among blood donors in the early month of the pandemic in Saudi Arabia,2021-01-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Saudi Arabia,,,"All blood donors, irrespective of their sociodemographic characteristics, who presented for blood donation at one of the 24 main blood banks in Saudi Arabia were included in the study. Participants were included in the study from 20 to 25 May 2020.","Blood donors with a contraindication for blood donation, those with a past or currently confirmed SARS- CoV-2 infection, and those who declined to give informed consent to participate in the study were excluded",2020-05-20,2020-05-25,Blood donors,All,Adults (18-64 years),30.0,39.0,Age,30-39,381,0.01,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.998,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Ayman Banjar,Ministry of Health (Saudi Arabia),Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.01.028,2021-02-07,2024-03-01,Verified,banjar_seroprevalence_2021,SAU
210116_SaudiArabia_MinistryofHealth_female,210116_SaudiArabia_MinistryofHealth,Seroprevalence of antibodies to SARS-CoV-2 among blood donors in the early month of the pandemic in Saudi Arabia,2021-01-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Saudi Arabia,,,"All blood donors, irrespective of their sociodemographic characteristics, who presented for blood donation at one of the 24 main blood banks in Saudi Arabia were included in the study. Participants were included in the study from 20 to 25 May 2020.","Blood donors with a contraindication for blood donation, those with a past or currently confirmed SARS- CoV-2 infection, and those who declined to give informed consent to participate in the study were excluded",2020-05-20,2020-05-25,Blood donors,Female,Adults (18-64 years),17.0,70.0,Sex/Gender,,32,0.0,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.998,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Ayman Banjar,Ministry of Health (Saudi Arabia),Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.01.028,2021-02-07,2024-03-01,Verified,banjar_seroprevalence_2021,SAU
210116_SaudiArabia_MinistryofHealth_age50-59,210116_SaudiArabia_MinistryofHealth,Seroprevalence of antibodies to SARS-CoV-2 among blood donors in the early month of the pandemic in Saudi Arabia,2021-01-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Saudi Arabia,,,"All blood donors, irrespective of their sociodemographic characteristics, who presented for blood donation at one of the 24 main blood banks in Saudi Arabia were included in the study. Participants were included in the study from 20 to 25 May 2020.","Blood donors with a contraindication for blood donation, those with a past or currently confirmed SARS- CoV-2 infection, and those who declined to give informed consent to participate in the study were excluded",2020-05-20,2020-05-25,Blood donors,All,Adults (18-64 years),50.0,59.0,Age,50-59,34,0.028999999999999998,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.998,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Ayman Banjar,Ministry of Health (Saudi Arabia),Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.01.028,2021-02-07,2024-03-01,Verified,banjar_seroprevalence_2021,SAU
210116_SaudiArabia_MinistryofHealth_age17-19,210116_SaudiArabia_MinistryofHealth,Seroprevalence of antibodies to SARS-CoV-2 among blood donors in the early month of the pandemic in Saudi Arabia,2021-01-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Saudi Arabia,,,"All blood donors, irrespective of their sociodemographic characteristics, who presented for blood donation at one of the 24 main blood banks in Saudi Arabia were included in the study. Participants were included in the study from 20 to 25 May 2020.","Blood donors with a contraindication for blood donation, those with a past or currently confirmed SARS- CoV-2 infection, and those who declined to give informed consent to participate in the study were excluded",2020-05-20,2020-05-25,Blood donors,All,Adults (18-64 years),17.0,19.0,Age,17-19,23,0.0,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.998,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Ayman Banjar,Ministry of Health (Saudi Arabia),Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.01.028,2021-02-07,2024-03-01,Verified,banjar_seroprevalence_2021,SAU
210116_SaudiArabia_MinistryofHealth_age60-69,210116_SaudiArabia_MinistryofHealth,Seroprevalence of antibodies to SARS-CoV-2 among blood donors in the early month of the pandemic in Saudi Arabia,2021-01-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Saudi Arabia,,,"All blood donors, irrespective of their sociodemographic characteristics, who presented for blood donation at one of the 24 main blood banks in Saudi Arabia were included in the study. Participants were included in the study from 20 to 25 May 2020.","Blood donors with a contraindication for blood donation, those with a past or currently confirmed SARS- CoV-2 infection, and those who declined to give informed consent to participate in the study were excluded",2020-05-20,2020-05-25,Blood donors,All,Seniors (65+ years),60.0,69.0,Age,60-69,2,0.0,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.998,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Ayman Banjar,Ministry of Health (Saudi Arabia),Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.01.028,2021-02-07,2024-03-01,Verified,banjar_seroprevalence_2021,SAU
210116_SaudiArabia_MinistryofHealth_age20-29,210116_SaudiArabia_MinistryofHealth,Seroprevalence of antibodies to SARS-CoV-2 among blood donors in the early month of the pandemic in Saudi Arabia,2021-01-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Saudi Arabia,,,"All blood donors, irrespective of their sociodemographic characteristics, who presented for blood donation at one of the 24 main blood banks in Saudi Arabia were included in the study. Participants were included in the study from 20 to 25 May 2020.","Blood donors with a contraindication for blood donation, those with a past or currently confirmed SARS- CoV-2 infection, and those who declined to give informed consent to participate in the study were excluded",2020-05-20,2020-05-25,Blood donors,All,Adults (18-64 years),20.0,29.0,Age,20-29,256,0.012,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.998,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Ayman Banjar,Ministry of Health (Saudi Arabia),Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.01.028,2021-02-07,2024-03-01,Verified,banjar_seroprevalence_2021,SAU
210116_SaudiArabia_MinistryofHealth_male,210116_SaudiArabia_MinistryofHealth,Seroprevalence of antibodies to SARS-CoV-2 among blood donors in the early month of the pandemic in Saudi Arabia,2021-01-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Saudi Arabia,,,"All blood donors, irrespective of their sociodemographic characteristics, who presented for blood donation at one of the 24 main blood banks in Saudi Arabia were included in the study. Participants were included in the study from 20 to 25 May 2020.","Blood donors with a contraindication for blood donation, those with a past or currently confirmed SARS- CoV-2 infection, and those who declined to give informed consent to participate in the study were excluded",2020-05-20,2020-05-25,Blood donors,Male,Adults (18-64 years),17.0,70.0,Sex/Gender,,796,0.015,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.998,0.995,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Ayman Banjar,Ministry of Health (Saudi Arabia),Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.01.028,2021-02-07,2024-03-01,Verified,banjar_seroprevalence_2021,SAU
210131_Riyadh_KingAbdullahInternationalMedicalResearchCenter_HCW_overall,210131_Riyadh_KingAbdullahInternationalMedicalResearchCenter_HCW,Nationwide Seroprevalence of SARS-CoV-2 in Saudi Arabia,2021-01-31,Preprint,Local,Cross-sectional survey ,Saudi Arabia,,Riyadh City,"To estimate the COVID-19 seroprevalence in HCWs in Riyadh city, a total of 400 samples were collected from health practitioners (doctors, nurses, and workers in hospital wards) from two of the main COVID-19 hospitals in Riyadh city; where high number of COVID-19 patients were admitted and treated. ",,2020-06-15,2020-11-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,400,0.075,0.0495,0.10160000000000001,True,,,,True,Unclear,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],No,Unclear,No,Yes,No,Unclear,Yes,No,Unclear,Naif Khalaf Alharbi,King Abdullah International Medical Research Center,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.01.28.21250598v1,2021-03-04,2022-07-16,Verified,alharbi_nationwide_2021,SAU
210131_SaudiArabia_KingAbdullahInternationalMedicalResearchCenter_genpop_overall,210131_SaudiArabia_KingAbdullahInternationalMedicalResearchCenter_genpop,Nationwide Seroprevalence of SARS-CoV-2 in Saudi Arabia,2021-01-31,Preprint,National,Cross-sectional survey ,Saudi Arabia,"Riyadh, Jazan, Qassim, Hail, Al-Ahsa, Makkah",,"11,272 samples were collected from six provinces of KSA; 5395 samples were collected from the blood donors and 5877 samples from the non-COVID-19 patients. The non- COVID-19 patients were defined as any person who is visiting a clinic or admitted at a hospital with samples collected for clinical biochemistry blood testing and confirmed to be negative for COVID-19 by RT-PCR.",,2020-06-15,2020-11-15,Multiple general populations,All,Multiple groups,,,Primary Estimate,,11275,0.109,0.10300000000000001,0.11599999999999999,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Author designed (ELISA) -Spike","EUROIMMUN,NA",ELISA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,No,Yes,Unclear,Yes,No,,Naif Khalaf Alharbi,King Abdullah International Medical Research Center,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.01.28.21250598v1,2021-03-04,2024-03-01,Verified,alharbi_nationwide_2021,SAU
210131_SaudiArabia_KingAbdullahInternationalMedicalResearchCenter_genpop_Makkah,210131_SaudiArabia_KingAbdullahInternationalMedicalResearchCenter_genpop,Nationwide Seroprevalence of SARS-CoV-2 in Saudi Arabia,2021-01-31,Preprint,Regional,Cross-sectional survey ,Saudi Arabia,Makkah,,"11,272 samples were collected from six provinces of KSA; 5395 samples were collected from the blood donors and 5877 samples from the non-COVID-19 patients. The non- COVID-19 patients were defined as any person who is visiting a clinic or admitted at a hospital with samples collected for clinical biochemistry blood testing and confirmed to be negative for COVID-19 by RT-PCR.",,2020-06-15,2020-11-15,Multiple general populations,All,Multiple groups,,,Geographical area,Makkah,1032,0.188,0.158,0.219,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Author designed (ELISA) -Spike","EUROIMMUN,NA",ELISA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,No,Yes,Unclear,Yes,No,,Naif Khalaf Alharbi,King Abdullah International Medical Research Center,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.01.28.21250598v1,2021-03-04,2024-03-01,Verified,alharbi_nationwide_2021,SAU
210131_SaudiArabia_KingAbdullahInternationalMedicalResearchCenter_genpop_Alahsa,210131_SaudiArabia_KingAbdullahInternationalMedicalResearchCenter_genpop,Nationwide Seroprevalence of SARS-CoV-2 in Saudi Arabia,2021-01-31,Preprint,Regional,Cross-sectional survey ,Saudi Arabia,Al-Ahsa ,,"11,272 samples were collected from six provinces of KSA; 5395 samples were collected from the blood donors and 5877 samples from the non-COVID-19 patients. The non- COVID-19 patients were defined as any person who is visiting a clinic or admitted at a hospital with samples collected for clinical biochemistry blood testing and confirmed to be negative for COVID-19 by RT-PCR.",,2020-06-15,2020-11-15,Multiple general populations,All,Multiple groups,,,Geographical area,Alasha,1874,0.147,0.127,0.166,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Author designed (ELISA) -Spike","EUROIMMUN,NA",ELISA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,No,Yes,Unclear,Yes,No,,Naif Khalaf Alharbi,King Abdullah International Medical Research Center,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.01.28.21250598v1,2021-03-04,2024-03-01,Verified,alharbi_nationwide_2021,SAU
210131_SaudiArabia_KingAbdullahInternationalMedicalResearchCenter_genpop_Jazan,210131_SaudiArabia_KingAbdullahInternationalMedicalResearchCenter_genpop,Nationwide Seroprevalence of SARS-CoV-2 in Saudi Arabia,2021-01-31,Preprint,Regional,Cross-sectional survey ,Saudi Arabia,Jazan,,"11,272 samples were collected from six provinces of KSA; 5395 samples were collected from the blood donors and 5877 samples from the non-COVID-19 patients. The non- COVID-19 patients were defined as any person who is visiting a clinic or admitted at a hospital with samples collected for clinical biochemistry blood testing and confirmed to be negative for COVID-19 by RT-PCR.",,2020-06-20,2020-06-20,Multiple general populations,All,Multiple groups,,,Geographical area,Jazan,640,0.016,0.006999999999999999,0.025,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Author designed (ELISA) -Spike","EUROIMMUN,NA",ELISA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,No,Yes,Unclear,Yes,No,,Naif Khalaf Alharbi,King Abdullah International Medical Research Center,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.01.28.21250598v1,2021-03-04,2024-03-01,Verified,alharbi_nationwide_2021,SAU
210131_SaudiArabia_KingAbdullahInternationalMedicalResearchCenter_genpop_Riyadh,210131_SaudiArabia_KingAbdullahInternationalMedicalResearchCenter_genpop,Nationwide Seroprevalence of SARS-CoV-2 in Saudi Arabia,2021-01-31,Preprint,Regional,Cross-sectional survey ,Saudi Arabia,Riyadh,,"11,272 samples were collected from six provinces of KSA; 5395 samples were collected from the blood donors and 5877 samples from the non-COVID-19 patients. The non- COVID-19 patients were defined as any person who is visiting a clinic or admitted at a hospital with samples collected for clinical biochemistry blood testing and confirmed to be negative for COVID-19 by RT-PCR.",,2020-06-20,2020-06-20,Multiple general populations,All,Multiple groups,,,Geographical area,Riyadh,4237,0.051,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Author designed (ELISA) -Spike","EUROIMMUN,NA",ELISA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,No,Yes,Unclear,Yes,No,,Naif Khalaf Alharbi,King Abdullah International Medical Research Center,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.01.28.21250598v1,2021-03-04,2024-03-01,Verified,alharbi_nationwide_2021,SAU
210131_SaudiArabia_KingAbdullahInternationalMedicalResearchCenter_genpop_Hail,210131_SaudiArabia_KingAbdullahInternationalMedicalResearchCenter_genpop,Nationwide Seroprevalence of SARS-CoV-2 in Saudi Arabia,2021-01-31,Preprint,Regional,Cross-sectional survey ,Saudi Arabia,Hail,,"11,272 samples were collected from six provinces of KSA; 5395 samples were collected from the blood donors and 5877 samples from the non-COVID-19 patients. The non- COVID-19 patients were defined as any person who is visiting a clinic or admitted at a hospital with samples collected for clinical biochemistry blood testing and confirmed to be negative for COVID-19 by RT-PCR.",,2020-07-15,2020-08-15,Multiple general populations,All,Multiple groups,,,Geographical area,Hail,460,0.209,0.18300000000000002,0.23500000000000001,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Author designed (ELISA) -Spike","EUROIMMUN,NA",ELISA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,No,Yes,Unclear,Yes,No,,Naif Khalaf Alharbi,King Abdullah International Medical Research Center,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.01.28.21250598v1,2021-03-04,2024-03-01,Verified,alharbi_nationwide_2021,SAU
210131_SaudiArabia_KingAbdullahInternationalMedicalResearchCenter_genpop_Qassim,210131_SaudiArabia_KingAbdullahInternationalMedicalResearchCenter_genpop,Nationwide Seroprevalence of SARS-CoV-2 in Saudi Arabia,2021-01-31,Preprint,Regional,Cross-sectional survey ,Saudi Arabia,Qassim,,"11,272 samples were collected from six provinces of KSA; 5395 samples were collected from the blood donors and 5877 samples from the non-COVID-19 patients. The non- COVID-19 patients were defined as any person who is visiting a clinic or admitted at a hospital with samples collected for clinical biochemistry blood testing and confirmed to be negative for COVID-19 by RT-PCR.",,2020-07-15,2020-08-15,Multiple general populations,All,Multiple groups,,,Geographical area,Qassim,3032,0.184,0.17,0.198,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Author designed (ELISA) -Spike","EUROIMMUN,NA",ELISA,Serum,IgG,Spike,,,,['High'],Yes,No,Yes,No,Yes,Unclear,Yes,No,,Naif Khalaf Alharbi,King Abdullah International Medical Research Center,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.01.28.21250598v1,2021-03-04,2024-03-01,Verified,alharbi_nationwide_2021,SAU
210213_Makkah_KingAbdulazizUniversity_HCW,210213_Makkah_KingAbdulazizUniversity,"Seroprevalence of Neutralizing Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) among Healthcare Workers in Makkah, Saudi Arabia",2021-02-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,Mecca Province,Makkah (Mecca),,,2020-06-01,2020-07-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,In House ELISA test & MN assay,204,0.063,,,True,,,,True,Convenience,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike",,Multiple Types,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,No,Unclear,Waleed Ahmed,King Abdulaziz University,Not Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S1018364721000276?via%3Dihub,2021-03-28,2022-07-16,Verified,ahmed_seroprevalence_2021,SAU
210628_Jeddah_KingAbdulazizUniversity,210628_Jeddah_KingAbdulazizUniversity,Prevalence of COVID-19 antibodies among operating room and critical care staff at a tertiary teaching hospital: A cross-sectional study.,2021-06-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,Mecca,Jeddah,"We included hospital employees working in the operating room and critical care units in King Abdulaziz University Hospital during the COVID-19 pandemic between August 9, 2020 and November 2, 2020. The sample comprised nurses, allied health personnel, and physicians, including trainees.",Did not provide blood sample,2020-08-09,2020-11-02,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Overall,319,0.122,,,True,,,,True,Convenience,"Author designed (Neutralization Assay),Author designed (ELISA) -Spike",,Multiple Types,Serum,"['IgG', 'Neutralizing']",,Validated by independent authors/third party/non-developers,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,No,Unclear,Sara Farsi,King Abdulaziz University,Not Unity-Aligned,https://dx.doi.org/10.15537/smj.2021.42.7.20210348,2021-07-07,2022-07-16,Verified,farsi_prevalence_2021,SAU
210720_Jeddah_KingAbdulazizUniversity_Overall,210720_Jeddah_KingAbdulazizUniversity,Seroprevalence of SARS-CoV-2 Binding and Neutralizing Antibodies in Healthcare Workers during the Epidemic Peak in Referral Hospitals and Quarantine Sites: Saudi Arabia,2021-07-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Jeddah,"This cross-sectional study was conducted from 29 June to 10 August 2020 in randomly selected HCWs from the 3 main referral hospitals in Jeddah as well as those working at 5quarantine sites established for COVID-19 patients. The population presented here wasdivided into medical and administration staff. Participants were adults older than 17 years,working at the included hospitals and quarantine sites during the specified period","thosewho reported absences from work for 30 days due to vacation or sabbatical during the studytime frame, or who volunteered in any COVID-19-related clinical trials were excluded.",2020-06-29,2020-08-10,Health care workers and caregivers,All,Adults (18-64 years),17.0,,Primary Estimate,,693,0.322,0.28800000000000003,0.358,True,,,,True,Convenience,"Author designed (Neutralization Assay),Author designed (ELISA) - MULTIPLEXED",,Multiple Types,Serum,"['IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Yes,Rowa Alhabbab,King Abdulaziz University,Not Unity-Aligned,10.3390/v13071413,2021-08-02,2022-07-16,Verified,alhabbab_seroprevalence_2021,SAU
210801_Riyadh_KingSaudUniversity_Primary,210801_Riyadh_KingSaudUniversity,"Risk factors and predictors that influence SARS-Cov-2 IgG positivity: A cross-sectional study of blood donors in Riyadh, Saudi Arabia.",2021-08-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Riyadh,"The inclusion criteria was based on the eligibility of blood donors who came to the blood bank at KSU. The blood bank eligibility criteria follows the American Association of Blood Banks (AABB)24 and Saudi Central Board for Accreditation of Healthcare Institutions (CBAHI) guidelines.25 Briefly, donors are required to be in good health, weigh more than 50 kg, not use any of the prohibited medications, and be free from any condition that may pose a risk of harm to themselves or the recipients of their blood products. Additional requirements were introduced in light of the SARS-CoV-2 pandemic, which include no history of SARS-CoV-2 diagnosis, related symptoms, or exposure in the 30 days before donation.",Donors were excluded if they did not sign an inform consent,2020-11-22,2020-12-17,Blood donors,All,Adults (18-64 years),18.0,62.0,Primary Estimate,,515,0.1223,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,,Validated by independent authors/third party/non-developers,1.0,0.996,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,,Mohammed F. Alosaimi,King Saud University,Not Unity-Aligned,https://dx.doi.org/10.15537/smj.2021.42.8.20210238,2021-08-10,2024-03-01,Verified,alosaimi_risk_2021,SAU
210801_Riyadh_KingSaudUniversity_Age50to69,210801_Riyadh_KingSaudUniversity,"Risk factors and predictors that influence SARS-Cov-2 IgG positivity: A cross-sectional study of blood donors in Riyadh, Saudi Arabia.",2021-08-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Riyadh,"The inclusion criteria was based on the eligibility of blood donors who came to the blood bank at KSU. The blood bank eligibility criteria follows the American Association of Blood Banks (AABB)24 and Saudi Central Board for Accreditation of Healthcare Institutions (CBAHI) guidelines.25 Briefly, donors are required to be in good health, weigh more than 50 kg, not use any of the prohibited medications, and be free from any condition that may pose a risk of harm to themselves or the recipients of their blood products. Additional requirements were introduced in light of the SARS-CoV-2 pandemic, which include no history of SARS-CoV-2 diagnosis, related symptoms, or exposure in the 30 days before donation.",Donors were excluded if they did not sign an inform consent,2020-11-22,2020-12-17,Blood donors,All,Adults (18-64 years),50.0,62.0,Age,50-69,18,0.2778,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,,Validated by independent authors/third party/non-developers,1.0,0.996,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,,Mohammed F. Alosaimi,King Saud University,Not Unity-Aligned,https://dx.doi.org/10.15537/smj.2021.42.8.20210238,2021-08-10,2024-03-01,Verified,alosaimi_risk_2021,SAU
210801_Riyadh_KingSaudUniversity_Male,210801_Riyadh_KingSaudUniversity,"Risk factors and predictors that influence SARS-Cov-2 IgG positivity: A cross-sectional study of blood donors in Riyadh, Saudi Arabia.",2021-08-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Riyadh,"The inclusion criteria was based on the eligibility of blood donors who came to the blood bank at KSU. The blood bank eligibility criteria follows the American Association of Blood Banks (AABB)24 and Saudi Central Board for Accreditation of Healthcare Institutions (CBAHI) guidelines.25 Briefly, donors are required to be in good health, weigh more than 50 kg, not use any of the prohibited medications, and be free from any condition that may pose a risk of harm to themselves or the recipients of their blood products. Additional requirements were introduced in light of the SARS-CoV-2 pandemic, which include no history of SARS-CoV-2 diagnosis, related symptoms, or exposure in the 30 days before donation.",Donors were excluded if they did not sign an inform consent,2020-11-22,2020-12-17,Blood donors,Male,Adults (18-64 years),18.0,62.0,Sex/Gender,,433,0.134,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,,Validated by independent authors/third party/non-developers,1.0,0.996,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,,Mohammed F. Alosaimi,King Saud University,Not Unity-Aligned,https://dx.doi.org/10.15537/smj.2021.42.8.20210238,2021-08-10,2024-03-01,Verified,alosaimi_risk_2021,SAU
210801_Riyadh_KingSaudUniversity_Female,210801_Riyadh_KingSaudUniversity,"Risk factors and predictors that influence SARS-Cov-2 IgG positivity: A cross-sectional study of blood donors in Riyadh, Saudi Arabia.",2021-08-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Riyadh,"The inclusion criteria was based on the eligibility of blood donors who came to the blood bank at KSU. The blood bank eligibility criteria follows the American Association of Blood Banks (AABB)24 and Saudi Central Board for Accreditation of Healthcare Institutions (CBAHI) guidelines.25 Briefly, donors are required to be in good health, weigh more than 50 kg, not use any of the prohibited medications, and be free from any condition that may pose a risk of harm to themselves or the recipients of their blood products. Additional requirements were introduced in light of the SARS-CoV-2 pandemic, which include no history of SARS-CoV-2 diagnosis, related symptoms, or exposure in the 30 days before donation.",Donors were excluded if they did not sign an inform consent,2020-11-22,2020-12-17,Blood donors,Female,Adults (18-64 years),18.0,62.0,Sex/Gender,,82,0.061,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,,Validated by independent authors/third party/non-developers,1.0,0.996,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,,Mohammed F. Alosaimi,King Saud University,Not Unity-Aligned,https://dx.doi.org/10.15537/smj.2021.42.8.20210238,2021-08-10,2024-03-01,Verified,alosaimi_risk_2021,SAU
210801_Riyadh_KingSaudUniversity_Age18to29,210801_Riyadh_KingSaudUniversity,"Risk factors and predictors that influence SARS-Cov-2 IgG positivity: A cross-sectional study of blood donors in Riyadh, Saudi Arabia.",2021-08-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Riyadh,"The inclusion criteria was based on the eligibility of blood donors who came to the blood bank at KSU. The blood bank eligibility criteria follows the American Association of Blood Banks (AABB)24 and Saudi Central Board for Accreditation of Healthcare Institutions (CBAHI) guidelines.25 Briefly, donors are required to be in good health, weigh more than 50 kg, not use any of the prohibited medications, and be free from any condition that may pose a risk of harm to themselves or the recipients of their blood products. Additional requirements were introduced in light of the SARS-CoV-2 pandemic, which include no history of SARS-CoV-2 diagnosis, related symptoms, or exposure in the 30 days before donation.",Donors were excluded if they did not sign an inform consent,2020-11-22,2020-12-17,Blood donors,All,Adults (18-64 years),18.0,29.0,Age,18-29,220,0.1227,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,,Validated by independent authors/third party/non-developers,1.0,0.996,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,,Mohammed F. Alosaimi,King Saud University,Not Unity-Aligned,https://dx.doi.org/10.15537/smj.2021.42.8.20210238,2021-08-10,2024-03-01,Verified,alosaimi_risk_2021,SAU
210801_Riyadh_KingSaudUniversity_Age30to49,210801_Riyadh_KingSaudUniversity,"Risk factors and predictors that influence SARS-Cov-2 IgG positivity: A cross-sectional study of blood donors in Riyadh, Saudi Arabia.",2021-08-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Riyadh,"The inclusion criteria was based on the eligibility of blood donors who came to the blood bank at KSU. The blood bank eligibility criteria follows the American Association of Blood Banks (AABB)24 and Saudi Central Board for Accreditation of Healthcare Institutions (CBAHI) guidelines.25 Briefly, donors are required to be in good health, weigh more than 50 kg, not use any of the prohibited medications, and be free from any condition that may pose a risk of harm to themselves or the recipients of their blood products. Additional requirements were introduced in light of the SARS-CoV-2 pandemic, which include no history of SARS-CoV-2 diagnosis, related symptoms, or exposure in the 30 days before donation.",Donors were excluded if they did not sign an inform consent,2020-11-22,2020-12-17,Blood donors,All,Adults (18-64 years),30.0,49.0,Age,30-49,213,0.14550000000000002,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,,Validated by independent authors/third party/non-developers,1.0,0.996,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,,Mohammed F. Alosaimi,King Saud University,Not Unity-Aligned,https://dx.doi.org/10.15537/smj.2021.42.8.20210238,2021-08-10,2024-03-01,Verified,alosaimi_risk_2021,SAU
210802_Riyadh_KingSaudUniversity_Primary,210802_Riyadh_KingSaudUniversity,Risk factors and predictors that influence SARS-Cov-2 IgG positivity,2021-08-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,Riyadh Province,Riyadh,"blood donors from the blood bank at King Saud University Medical City (KSUMC), Riyadh, Saudi Arabia",,2020-11-22,2020-12-17,Blood donors,All,Multiple groups,18.0,62.0,Primary Estimate,,515,0.1223,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Mohammed Alosaimi,King Saud University,Unity-Aligned,http://dx.doi.org/10.15537/SMJ.2021.42.8.20210238,2021-08-24,2024-03-01,Verified,alosaimi_risk_2021,SAU
210802_Riyadh_KingSaudUniversity_Age30-49,210802_Riyadh_KingSaudUniversity,Risk factors and predictors that influence SARS-Cov-2 IgG positivity,2021-08-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,Riyadh Province,Riyadh,"blood donors from the blood bank at King Saud University Medical City (KSUMC), Riyadh, Saudi Arabia",,2020-11-22,2020-12-17,Blood donors,All,Adults (18-64 years),30.0,49.0,Age,30-49,213,0.14550000000000002,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Mohammed Alosaimi,King Saud University,Unity-Aligned,http://dx.doi.org/10.15537/SMJ.2021.42.8.20210238,2021-08-24,2024-03-01,Verified,alosaimi_risk_2021,SAU
210802_Riyadh_KingSaudUniversity_Female,210802_Riyadh_KingSaudUniversity,Risk factors and predictors that influence SARS-Cov-2 IgG positivity,2021-08-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,Riyadh Province,Riyadh,"blood donors from the blood bank at King Saud University Medical City (KSUMC), Riyadh, Saudi Arabia",,2020-11-22,2020-12-17,Blood donors,Female,Multiple groups,,,Sex/Gender,,82,0.061,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Mohammed Alosaimi,King Saud University,Unity-Aligned,http://dx.doi.org/10.15537/SMJ.2021.42.8.20210238,2021-08-24,2024-03-01,Verified,alosaimi_risk_2021,SAU
210802_Riyadh_KingSaudUniversity_Male,210802_Riyadh_KingSaudUniversity,Risk factors and predictors that influence SARS-Cov-2 IgG positivity,2021-08-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,Riyadh Province,Riyadh,"blood donors from the blood bank at King Saud University Medical City (KSUMC), Riyadh, Saudi Arabia",,2020-11-22,2020-12-17,Blood donors,Male,Multiple groups,,,Sex/Gender,,433,0.134,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Mohammed Alosaimi,King Saud University,Unity-Aligned,http://dx.doi.org/10.15537/SMJ.2021.42.8.20210238,2021-08-24,2024-03-01,Verified,alosaimi_risk_2021,SAU
210802_Riyadh_KingSaudUniversity_Age50-69,210802_Riyadh_KingSaudUniversity,Risk factors and predictors that influence SARS-Cov-2 IgG positivity,2021-08-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,Riyadh Province,Riyadh,"blood donors from the blood bank at King Saud University Medical City (KSUMC), Riyadh, Saudi Arabia",,2020-11-22,2020-12-17,Blood donors,All,Multiple groups,50.0,69.0,Age,50-69,27,0.1852,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Mohammed Alosaimi,King Saud University,Unity-Aligned,http://dx.doi.org/10.15537/SMJ.2021.42.8.20210238,2021-08-24,2024-03-01,Verified,alosaimi_risk_2021,SAU
210802_Riyadh_KingSaudUniversity_Age18-29,210802_Riyadh_KingSaudUniversity,Risk factors and predictors that influence SARS-Cov-2 IgG positivity,2021-08-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,Riyadh Province,Riyadh,"blood donors from the blood bank at King Saud University Medical City (KSUMC), Riyadh, Saudi Arabia",,2020-11-22,2020-12-17,Blood donors,All,Adults (18-64 years),18.0,29.0,Age,18-29,275,0.09820000000000001,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Mohammed Alosaimi,King Saud University,Unity-Aligned,http://dx.doi.org/10.15537/SMJ.2021.42.8.20210238,2021-08-24,2024-03-01,Verified,alosaimi_risk_2021,SAU
210901_Riyadh_KingSaudbinAbdulazizUniversity,210901_Riyadh_KingSaudbinAbdulazizUniversity,Seroprevalence of SARS-CoV-2 among high-risk healthcare workers in a MERS-CoV endemic area.,2021-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,Riyadh Province,Riyadh City,"""This is a cross-sectional seroprevalence study enrolling 420high-risk HCWs who are working in three tertiary hospitals in Riyadh city""",,2020-07-01,2020-12-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,420,0.14800000000000002,0.115,0.185,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.9440000000000001,0.996,['High'],,No,No,Yes,,Yes,Yes,Yes,,Fayhan Alroqi,King Saudbin Abdulaziz University for Health Sciences,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jiph.2021.08.029,2021-09-13,2024-03-01,Unverified,alroqi_seroprevalence_2021,SAU
210922_Madinah_TaibahUniversity_children1_primary,210922_Madinah_TaibahUniversity_children1,"Assessment of SARS-CoV-2 anti-spike IgG antibody in women and children in Madinah, Saudi Arabia: A single-center study",2021-09-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,, Madinah,"Participants were recruited through the outpatient clinics in Madinah Maternity and Children’s Hospital, Saudi Arabia who were on follow-up during the time of conducting the study. The hospital receives children patients from birth up to 17 years.",We excluded any individuals with a positive infection history and those who received any COVID-19 vaccines.,2021-01-15,2021-04-15,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,,332,0.5872999999999999,,,True,,,,True,Convenience,SARS-CoV-2 Virus IgG Antibody Detection Kit (ELISA),BGI Genomics,ELISA,Plasma,IgG,Spike,Validated by manufacturers,0.9871,0.9838,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Waleed Mahallawi,Taibah University,Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph18199971,2021-10-05,2024-03-01,Verified,mahallawi_assessment_2021,SAU
210922_Madinah_TaibahUniversity_children1_male,210922_Madinah_TaibahUniversity_children1,"Assessment of SARS-CoV-2 anti-spike IgG antibody in women and children in Madinah, Saudi Arabia: A single-center study",2021-09-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,, Madinah,"Participants were recruited through the outpatient clinics in Madinah Maternity and Children’s Hospital, Saudi Arabia who were on follow-up during the time of conducting the study. The hospital receives children patients from birth up to 17 years.",We excluded any individuals with a positive infection history and those who received any COVID-19 vaccines.,2021-01-15,2021-04-15,Residual sera,Male,Children and Youth (0-17 years),0.0,17.0,Sex/Gender,,178,0.618,,,,,,,,Convenience,SARS-CoV-2 Virus IgG Antibody Detection Kit (ELISA),BGI Genomics,ELISA,Plasma,IgG,Spike,Validated by manufacturers,0.9871,0.9838,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Waleed Mahallawi,Taibah University,Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph18199971,2021-10-05,2024-03-01,Verified,mahallawi_assessment_2021,SAU
210922_Madinah_TaibahUniversity_children1_<=1year,210922_Madinah_TaibahUniversity_children1,"Assessment of SARS-CoV-2 anti-spike IgG antibody in women and children in Madinah, Saudi Arabia: A single-center study",2021-09-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,, Madinah,"Participants were recruited through the outpatient clinics in Madinah Maternity and Children’s Hospital, Saudi Arabia who were on follow-up during the time of conducting the study. The hospital receives children patients from birth up to 17 years.",We excluded any individuals with a positive infection history and those who received any COVID-19 vaccines.,2021-01-15,2021-04-15,Residual sera,All,Children and Youth (0-17 years),0.0,1.0,Age,<= 1 year old,75,0.6,,,,,,,,Convenience,SARS-CoV-2 Virus IgG Antibody Detection Kit (ELISA),BGI Genomics,ELISA,Plasma,IgG,Spike,Validated by manufacturers,0.9871,0.9838,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Waleed Mahallawi,Taibah University,Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph18199971,2021-10-05,2024-03-01,Verified,mahallawi_assessment_2021,SAU
210922_Madinah_TaibahUniversity_children1_female,210922_Madinah_TaibahUniversity_children1,"Assessment of SARS-CoV-2 anti-spike IgG antibody in women and children in Madinah, Saudi Arabia: A single-center study",2021-09-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,, Madinah,"Participants were recruited through the outpatient clinics in Madinah Maternity and Children’s Hospital, Saudi Arabia who were on follow-up during the time of conducting the study. The hospital receives children patients from birth up to 17 years.",We excluded any individuals with a positive infection history and those who received any COVID-19 vaccines.,2021-01-15,2021-04-15,Residual sera,Female,Children and Youth (0-17 years),0.0,17.0,Sex/Gender,,154,0.5519,,,,,,,,Convenience,SARS-CoV-2 Virus IgG Antibody Detection Kit (ELISA),BGI Genomics,ELISA,Plasma,IgG,Spike,Validated by manufacturers,0.9871,0.9838,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Waleed Mahallawi,Taibah University,Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph18199971,2021-10-05,2024-03-01,Verified,mahallawi_assessment_2021,SAU
210922_Madinah_TaibahUniversity_children1_newborn,210922_Madinah_TaibahUniversity_children1,"Assessment of SARS-CoV-2 anti-spike IgG antibody in women and children in Madinah, Saudi Arabia: A single-center study",2021-09-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,, Madinah,"Participants were recruited through the outpatient clinics in Madinah Maternity and Children’s Hospital, Saudi Arabia who were on follow-up during the time of conducting the study. The hospital receives children patients from birth up to 17 years.",We excluded any individuals with a positive infection history and those who received any COVID-19 vaccines.,2021-01-15,2021-04-15,Residual sera,All,Children and Youth (0-17 years),0.0,0.0,Age,Newborn (ages since born until 27 days),17,0.4706,,,,,,,,Convenience,SARS-CoV-2 Virus IgG Antibody Detection Kit (ELISA),BGI Genomics,ELISA,Plasma,IgG,Spike,Validated by manufacturers,0.9871,0.9838,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Waleed Mahallawi,Taibah University,Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph18199971,2021-10-05,2024-03-01,Verified,mahallawi_assessment_2021,SAU
210922_Madinah_TaibahUniversity_women2,210922_Madinah_TaibahUniversity_women2,"Assessment of SARS-CoV-2 anti-spike IgG antibody in women and children in Madinah, Saudi Arabia: A single-center study",2021-09-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,, Madinah,"Participants were recruited through the outpatient clinics in Madinah Maternity and Children’s Hospital, Saudi Arabia who were on follow-up during the time of conducting the study. ",We excluded any individuals with a positive infection history and those who received any COVID-19 vaccines.,2021-01-15,2021-04-15,Residual sera,Female,Adults (18-64 years),,,Primary Estimate,,247,0.502,,,True,,,,True,Convenience,SARS-CoV-2 Virus IgG Antibody Detection Kit (ELISA),BGI Genomics,ELISA,Plasma,IgG,Spike,Validated by manufacturers,0.9871,0.9838,['High'],No,No,No,No,No,Yes,Yes,Yes,,Waleed Mahallawi,Taibah University,Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph18199971,2021-10-05,2024-03-01,Verified,mahallawi_assessment_2021,SAU
211101_Riyadh_PrinceSultanMilitaryMedicalCity_Primary,211101_Riyadh_PrinceSultanMilitaryMedicalCity,"SARS-CoV-2 seroprevalence among healthcare workers from a tertiary care center in Riyadh, Saudi Arabia.",2021-11-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,,"We included only those HCWs who were registered in the human resources database as a hospital worker, asymptomatic adult of ≥14-years age, and agreed to give consent for a blood draw",excluded all those who have any symptoms of an active SARS-CoV-2 infection and external workers,2020-07-15,2020-08-15,Health care workers and caregivers,All,Adults (18-64 years),14.0,,Primary Estimate,,188,0.032,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Abeer M. Albaadani,Prince Sultan Military Medical City,Not Unity-Aligned,https://dx.doi.org/10.15537/smj.2021.42.11.20210391,2021-11-09,2024-03-01,Unverified,albaadani_sars-cov-2_2021,SAU
211123_Riyadh_KingFaisalHospitalAndResearchCentre,211123_Riyadh_KingFaisalHospitalAndResearchCentre,"Seroprevalence of SARS-CoV-2 antibodies in healthcare workers at a tertiary care hospital in Riyadh, Saudi Arabia.",2021-11-23,Journal Article (Peer-Reviewed),Local,Prospective cohort,Saudi Arabia,Riyadh Province,Riyadh,"Non-immunocompromised children were enrolled by random selection from a previous pediatric influenza cohort. Additional newborn infants aged ≤4 weeks were randomly selected and enrolled monthly, via home visits.",,2020-06-15,2020-12-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1076,0.24300000000000002,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.7190000000000001,0.9654,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Reem Almaghrabi,King Faisal Hospital and Research Centre,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijregi.2021.11.009,2022-06-28,2024-03-01,Unverified,almaghrabi_seroprevalence_2022,SAU
211126_Jazan_JazanUniversity_Primary,211126_Jazan_JazanUniversity,"Community-based seroprevalence of sars-cov-2 antibodies following the first wave of the covid-19 pandemic in jazan province, saudi arabia",2021-11-26,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Saudi Arabia,Jazan province,,"Individuals from all age groups were
included and gave informed consent to information that was provided to all participants,
or their legal guardians, before they were enrolled in the study.","Participants who refused to participate, pregnant women, and patients
with known chronic immunological diseases were excluded from this study.",2020-08-25,2020-12-30,Household and community samples,All,Multiple groups,1.0,75.0,Primary Estimate,,594,0.2575,0.212,0.3,True,,,,True,Self-referral,"COVID-19 ELISA IgG,Author designed (ELISA) -Spike","Vircell S.L.,NA",ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Abdulaziz Alhazmi,Jazan University,Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph182312451,2021-12-06,2024-03-01,Unverified,alhazmi_community-based_2021,SAU
211126_Jazan_JazanUniversity_Vircell,211126_Jazan_JazanUniversity,"Community-based seroprevalence of sars-cov-2 antibodies following the first wave of the covid-19 pandemic in jazan province, saudi arabia",2021-11-26,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Saudi Arabia,Jazan province,,"Individuals from all age groups were
included and gave informed consent to information that was provided to all participants,
or their legal guardians, before they were enrolled in the study.","Participants who refused to participate, pregnant women, and patients
with known chronic immunological diseases were excluded from this study.",2020-08-25,2020-12-30,Household and community samples,All,Multiple groups,1.0,75.0,Test used,Vircell ELISA kit,594,0.26,,,,,,,,Self-referral,COVID-19 ELISA IgG,Vircell S.L.,ELISA,Serum,IgG,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Abdulaziz Alhazmi,Jazan University,Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph182312451,2021-12-06,2024-03-01,Unverified,alhazmi_community-based_2021,SAU
211208_SaudiArabia_JohnsHopkinsAramcoHealthcare_Primary,211208_SaudiArabia_JohnsHopkinsAramcoHealthcare,High seroprevalence of SARS-CoV-2 among high-density communities in Saudi Arabia.,2021-12-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,,"A community-based serosurvey was carried out in three cities in Saudi Arabia. We asked the residents in these neighborhoods to participate voluntarily without any restrictions related to gender, age or nationality. In addition, we included those who
had prior positive SARS-CoV-2 PCR result, and had been
without symptoms for≥14 days, and also include those who
were never tested for SARS-CoV-2 and were asymptomatic.","We excluded symptomatic and those who were previously
labelled as COVID-19 cases and had not completed 14 days.",2020-08-01,2020-08-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,5629,0.502,0.488,0.515,True,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Sami Almudarra,Saudi Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01726-2,2021-12-13,2024-03-01,Unverified,almudarra_high_2021,SAU
211208_SaudiArabia_JohnsHopkinsAramcoHealthcare_<=17,211208_SaudiArabia_JohnsHopkinsAramcoHealthcare,High seroprevalence of SARS-CoV-2 among high-density communities in Saudi Arabia.,2021-12-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,,"A community-based serosurvey was carried out in three cities in Saudi Arabia. We asked the residents in these neighborhoods to participate voluntarily without any restrictions related to gender, age or nationality. In addition, we included those who
had prior positive SARS-CoV-2 PCR result, and had been
without symptoms for≥14 days, and also include those who
were never tested for SARS-CoV-2 and were asymptomatic.","We excluded symptomatic and those who were previously
labelled as COVID-19 cases and had not completed 14 days.",2020-08-01,2020-08-31,Household and community samples,All,Children and Youth (0-17 years),,,Age,<=17,239,0.523,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Sami Almudarra,Saudi Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01726-2,2021-12-13,2024-03-01,Unverified,almudarra_high_2021,SAU
211208_SaudiArabia_JohnsHopkinsAramcoHealthcare_35-54,211208_SaudiArabia_JohnsHopkinsAramcoHealthcare,High seroprevalence of SARS-CoV-2 among high-density communities in Saudi Arabia.,2021-12-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,,"A community-based serosurvey was carried out in three cities in Saudi Arabia. We asked the residents in these neighborhoods to participate voluntarily without any restrictions related to gender, age or nationality. In addition, we included those who
had prior positive SARS-CoV-2 PCR result, and had been
without symptoms for≥14 days, and also include those who
were never tested for SARS-CoV-2 and were asymptomatic.","We excluded symptomatic and those who were previously
labelled as COVID-19 cases and had not completed 14 days.",2020-08-01,2020-08-31,Household and community samples,All,Adults (18-64 years),,,Age,35-54,1720,0.5058,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Sami Almudarra,Saudi Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01726-2,2021-12-13,2024-03-01,Unverified,almudarra_high_2021,SAU
211208_SaudiArabia_JohnsHopkinsAramcoHealthcare_18-34,211208_SaudiArabia_JohnsHopkinsAramcoHealthcare,High seroprevalence of SARS-CoV-2 among high-density communities in Saudi Arabia.,2021-12-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,,"A community-based serosurvey was carried out in three cities in Saudi Arabia. We asked the residents in these neighborhoods to participate voluntarily without any restrictions related to gender, age or nationality. In addition, we included those who
had prior positive SARS-CoV-2 PCR result, and had been
without symptoms for≥14 days, and also include those who
were never tested for SARS-CoV-2 and were asymptomatic.","We excluded symptomatic and those who were previously
labelled as COVID-19 cases and had not completed 14 days.",2020-08-01,2020-08-31,Household and community samples,All,Adults (18-64 years),,,Age,18-34,2148,0.5568,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Sami Almudarra,Saudi Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01726-2,2021-12-13,2024-03-01,Unverified,almudarra_high_2021,SAU
211208_SaudiArabia_JohnsHopkinsAramcoHealthcare_Male,211208_SaudiArabia_JohnsHopkinsAramcoHealthcare,High seroprevalence of SARS-CoV-2 among high-density communities in Saudi Arabia.,2021-12-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,,"A community-based serosurvey was carried out in three cities in Saudi Arabia. We asked the residents in these neighborhoods to participate voluntarily without any restrictions related to gender, age or nationality. In addition, we included those who
had prior positive SARS-CoV-2 PCR result, and had been
without symptoms for≥14 days, and also include those who
were never tested for SARS-CoV-2 and were asymptomatic.","We excluded symptomatic and those who were previously
labelled as COVID-19 cases and had not completed 14 days.",2020-08-01,2020-08-31,Household and community samples,Male,Multiple groups,,,Sex/Gender,,161,0.4286,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Sami Almudarra,Saudi Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01726-2,2021-12-13,2024-03-01,Unverified,almudarra_high_2021,SAU
211208_SaudiArabia_JohnsHopkinsAramcoHealthcare_Female,211208_SaudiArabia_JohnsHopkinsAramcoHealthcare,High seroprevalence of SARS-CoV-2 among high-density communities in Saudi Arabia.,2021-12-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,,"A community-based serosurvey was carried out in three cities in Saudi Arabia. We asked the residents in these neighborhoods to participate voluntarily without any restrictions related to gender, age or nationality. In addition, we included those who
had prior positive SARS-CoV-2 PCR result, and had been
without symptoms for≥14 days, and also include those who
were never tested for SARS-CoV-2 and were asymptomatic.","We excluded symptomatic and those who were previously
labelled as COVID-19 cases and had not completed 14 days.",2020-08-01,2020-08-31,Household and community samples,Female,Multiple groups,,,Sex/Gender,,5468,0.504,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Sami Almudarra,Saudi Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01726-2,2021-12-13,2024-03-01,Unverified,almudarra_high_2021,SAU
211208_SaudiArabia_JohnsHopkinsAramcoHealthcare_>55,211208_SaudiArabia_JohnsHopkinsAramcoHealthcare,High seroprevalence of SARS-CoV-2 among high-density communities in Saudi Arabia.,2021-12-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,,"A community-based serosurvey was carried out in three cities in Saudi Arabia. We asked the residents in these neighborhoods to participate voluntarily without any restrictions related to gender, age or nationality. In addition, we included those who
had prior positive SARS-CoV-2 PCR result, and had been
without symptoms for≥14 days, and also include those who
were never tested for SARS-CoV-2 and were asymptomatic.","We excluded symptomatic and those who were previously
labelled as COVID-19 cases and had not completed 14 days.",2020-08-01,2020-08-31,Household and community samples,All,Multiple groups,,,Age,>55,261,0.47509999999999997,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Sami Almudarra,Saudi Ministry of Health,Unity-Aligned,https://dx.doi.org/10.1007/s15010-021-01726-2,2021-12-13,2024-03-01,Unverified,almudarra_high_2021,SAU
220131_Riyadh_KingSaudMedicalCity,220131_Riyadh_KingSaudMedicalCity ,SARS-CoV-2 antibody prevalence among healthcare workers: A cross-sectional study at a quaternary healthcare center in Saudi Arabia,2022-01-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Riyadh,"""Participation in  the  survey  was voluntary, and any HCW either a KSMC staff or an employee of a contracted company who serves at KSMC was eligible for the study.""","""HCWs who experienced any symptoms suggestive of COVID-19 at the time of enrollment were excluded from the study.""",2020-12-15,2020-12-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,3644,0.265,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Hala Amer,"""Prevention and Control of Infection Administration, King Saud Medical City""",Not Unity-Aligned,https://dx.doi.org/10.1016/j.jiph.2022.01.018,2022-02-22,2024-03-01,Unverified,amer_sars-cov-2_2022,SAU
220407_Madinah_TaibahUniversity_Overall,220407_Madinah_TaibahUniversity,Seroprevalence of SARS-Cov-2 IgG antibodies in patients at a single center in Saudi Arabia.,2022-04-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Madinah,"""Subjects were on follow-up visits to general walk-in clinics at the Medical Center of Taibah University, Madinah, Saudi Arabia.""","""Individuals were excluded if diagnosed previously with COVID-19 disease by RT-PCR, vaccinated (single or multiple doses, self-reported by the subjects) against COVID-19, or had experienced unusual symptoms within the previous two weeks. Additionally, those who were at close contact with confirmed SARS-CoV-2 infected patients and experienced symptoms of the COVID-19 disease were also excluded.""",2020-12-15,2021-04-30,Residual sera,All,Multiple groups,18.0,,Primary Estimate,,527,0.2353,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Waleed Mahallawi,Taibah University,Not Unity-Aligned,https://dx.doi.org/10.5144/0256-4947.2022.69,2022-04-12,2022-07-16,Unverified,mahallawi_seroprevalence_2022,SAU
220407_Madinah_TaibahUniversity_Sex_Male,220407_Madinah_TaibahUniversity,Seroprevalence of SARS-Cov-2 IgG antibodies in patients at a single center in Saudi Arabia.,2022-04-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Madinah,"""Subjects were on follow-up visits to general walk-in clinics at the Medical Center of Taibah University, Madinah, Saudi Arabia.""","""Individuals were excluded if diagnosed previously with COVID-19 disease by RT-PCR, vaccinated (single or multiple doses, self-reported by the subjects) against COVID-19, or had experienced unusual symptoms within the previous two weeks. Additionally, those who were at close contact with confirmed SARS-CoV-2 infected patients and experienced symptoms of the COVID-19 disease were also excluded.""",2020-12-15,2021-04-30,Residual sera,Male,Multiple groups,18.0,,Sex/Gender,,266,0.1617,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Waleed Mahallawi,Taibah University,Not Unity-Aligned,https://dx.doi.org/10.5144/0256-4947.2022.69,2022-04-14,2022-07-16,Unverified,mahallawi_seroprevalence_2022,SAU
220407_Madinah_TaibahUniversity_Age_18-29,220407_Madinah_TaibahUniversity,Seroprevalence of SARS-Cov-2 IgG antibodies in patients at a single center in Saudi Arabia.,2022-04-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Madinah,"""Subjects were on follow-up visits to general walk-in clinics at the Medical Center of Taibah University, Madinah, Saudi Arabia.""","""Individuals were excluded if diagnosed previously with COVID-19 disease by RT-PCR, vaccinated (single or multiple doses, self-reported by the subjects) against COVID-19, or had experienced unusual symptoms within the previous two weeks. Additionally, those who were at close contact with confirmed SARS-CoV-2 infected patients and experienced symptoms of the COVID-19 disease were also excluded.""",2020-12-15,2021-04-30,Residual sera,All,Adults (18-64 years),18.0,29.0,Age,Age: 18 to <30,201,0.1542,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Waleed Mahallawi,Taibah University,Not Unity-Aligned,https://dx.doi.org/10.5144/0256-4947.2022.69,2022-04-14,2022-07-16,Unverified,mahallawi_seroprevalence_2022,SAU
220407_Madinah_TaibahUniversity_Age_30-39,220407_Madinah_TaibahUniversity,Seroprevalence of SARS-Cov-2 IgG antibodies in patients at a single center in Saudi Arabia.,2022-04-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Madinah,"""Subjects were on follow-up visits to general walk-in clinics at the Medical Center of Taibah University, Madinah, Saudi Arabia.""","""Individuals were excluded if diagnosed previously with COVID-19 disease by RT-PCR, vaccinated (single or multiple doses, self-reported by the subjects) against COVID-19, or had experienced unusual symptoms within the previous two weeks. Additionally, those who were at close contact with confirmed SARS-CoV-2 infected patients and experienced symptoms of the COVID-19 disease were also excluded.""",2020-12-15,2021-04-30,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,Age: 30 to <40,168,0.2798,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Waleed Mahallawi,Taibah University,Not Unity-Aligned,https://dx.doi.org/10.5144/0256-4947.2022.69,2022-04-14,2022-07-16,Unverified,mahallawi_seroprevalence_2022,SAU
220407_Madinah_TaibahUniversity_Age_Above40,220407_Madinah_TaibahUniversity,Seroprevalence of SARS-Cov-2 IgG antibodies in patients at a single center in Saudi Arabia.,2022-04-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Madinah,"""Subjects were on follow-up visits to general walk-in clinics at the Medical Center of Taibah University, Madinah, Saudi Arabia.""","""Individuals were excluded if diagnosed previously with COVID-19 disease by RT-PCR, vaccinated (single or multiple doses, self-reported by the subjects) against COVID-19, or had experienced unusual symptoms within the previous two weeks. Additionally, those who were at close contact with confirmed SARS-CoV-2 infected patients and experienced symptoms of the COVID-19 disease were also excluded.""",2020-12-15,2021-04-30,Residual sera,All,Multiple groups,40.0,,Age,Age: ≥40,158,0.2911,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Waleed Mahallawi,Taibah University,Not Unity-Aligned,https://dx.doi.org/10.5144/0256-4947.2022.69,2022-04-14,2022-07-16,Unverified,mahallawi_seroprevalence_2022,SAU
220407_Madinah_TaibahUniversity_Sex_Female,220407_Madinah_TaibahUniversity,Seroprevalence of SARS-Cov-2 IgG antibodies in patients at a single center in Saudi Arabia.,2022-04-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Madinah,"""Subjects were on follow-up visits to general walk-in clinics at the Medical Center of Taibah University, Madinah, Saudi Arabia.""","""Individuals were excluded if diagnosed previously with COVID-19 disease by RT-PCR, vaccinated (single or multiple doses, self-reported by the subjects) against COVID-19, or had experienced unusual symptoms within the previous two weeks. Additionally, those who were at close contact with confirmed SARS-CoV-2 infected patients and experienced symptoms of the COVID-19 disease were also excluded.""",2020-12-15,2021-04-30,Residual sera,Female,Multiple groups,18.0,,Sex/Gender,,261,0.3103,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Waleed Mahallawi,Taibah University,Not Unity-Aligned,https://dx.doi.org/10.5144/0256-4947.2022.69,2022-04-14,2022-07-16,Unverified,mahallawi_seroprevalence_2022,SAU
220422_Riyadh_KingAbdullahInternationalMedicalResearchCenter_BloodDonors,220422_Riyadh_KingAbdullahInternationalMedicalResearchCenter_BloodDonors,"Seroprevalence of COVID-19 in Riyadh City during the early increase of COVID-19 infections in Saudi Arabia, June 2020.",2022-04-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,Riyadh Province,Riyadh City,"""The second cohort (n=350) was from healthy blood donors collected from the Blood Bank; the donors were routinely screened for SARS-CoV-19 by RT-PCR on nasopharyngeal swabs and confirmed negative. """,,2020-06-01,2020-06-16,Residual sera,All,Multiple groups,,,Primary Estimate,,350,0.06,,,True,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,No,No,,Unclear,Yes,No,,Mohammed Alenazi,King Abdullah International Medical Research Center,Not Unity-Aligned,https://dx.doi.org/10.1016/j.sjbs.2022.103282,2022-05-04,2022-07-16,Unverified,alenazi_seroprevalence_2022,SAU
220422_Riyadh_KingAbdullahInternationalMedicalResearchCenter_ResidualSera,220422_Riyadh_KingAbdullahInternationalMedicalResearchCenter_ResidualSera,"Seroprevalence of COVID-19 in Riyadh City during the early increase of COVID-19 infections in Saudi Arabia, June 2020.",2022-04-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,Riyadh Province,Riyadh City,""" The first cohort was residual serum samples from non-COVID patients (n=432) from the clinical Biochemistry
Lab. Non-COVID-19 patients were defined as any patients visiting hospitals for routine or emergency Biochemistry blood tests; these patients were required to do nasopharyngeal sample testing for SARS-CoV-2 RT-PCR. All patients were confirmed negative as documented in their medical records, and considered non-COVID-19 patients. """,,2020-06-01,2020-06-16,Residual sera,All,Multiple groups,,,Primary Estimate,,432,0.0925,,,True,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,No,No,,Unclear,Yes,No,,Mohammed Alenazi,King Abdullah International Medical Research Center,Not Unity-Aligned,https://dx.doi.org/10.1016/j.sjbs.2022.103282,2022-05-04,2022-07-16,Unverified,alenazi_seroprevalence_2022,SAU
220602_Abha_KingKhalidUniversity_HCW_ELISA_IgGIgM_Primary,220602_Abha_KingKhalidUniversity,COVID-19 among the Asymptomatic Healthcare Workers in the Tertiary Care Centers of the Southwestern Region of Saudi Arabia: Preventive and Protective Insights,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,'Asir,Abha,"Healthcare workers (including physicians, residents, medical
students, nurses, respiratory therapists, cleaners, cleaners’ supervisors,
medical engineers, administrators, housekeepers, laboratory radiology
specialists and laboratory specialists) working in Aseer Central Hospital. Participants were screened and tested for COVID-19 symptoms between October 2020 and February 2021. Individuals who were without symptoms and gave informed consent were included.",Individuals with COVID symptoms (not described in detail),2020-10-15,2021-02-15,Health care workers and caregivers,All,Adults (18-64 years),18.0,64.0,Primary Estimate,,186,0.1612,,,True,,,,True,Simplified probability,"COVID-19 ELISA IgG,COVID-19 ELISA IgM/IgA",Vircell S.L.,ELISA,Serum,"['IgG', 'IgM']",,,,,['High'],,Yes,No,Yes,,Yes,Yes,No,,Ahmed M. Al-Hakami,King Khalid University,Not Unity-Aligned,https://www.bahrainmedicalbulletin.com/JUNE_2022/BMB-22-204.pdf,2022-08-19,2024-03-01,Unverified,al-hakami_covid-19_2022,SAU
220808_Makkah_UmmAlQuraUniversity_Overall,220808_Makkah_UmmAlQuraUniversity,"High Seroprevalence of SARS-CoV-2 IgG and RNA among Asymptomatic Blood Donors in Makkah Region, Saudi Arabia.",2022-08-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Makkah,"blood donors at Makkah’s Central Blood Bank. All the study participants met the prerequisites for blood donation. Participants in this study were required to be free of COVID-19 symptoms and have never been infected
with SARS-CoV-2.","A blood donor was ruled out if he/she had been diagnosed with a
disease or showed outward signs of infections such as cough, sore throat, or fever. Hepatitis B and C, as well as human immunodeficiency virus (HIV) 1 and 2, were confirmed to be absent in all the participants.",2020-08-01,2020-12-30,Blood donors,All,Multiple groups,18.0,,Primary Estimate,,4368,0.515,,,True,,,,True,Unclear,SARS-CoV-2 Virus IgG Antibody Detection Kit (ELISA),BGI Genomics,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9378000000000001,0.9712000000000001,['Moderate'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Kamal H. Alzabeedi,Umm Al Qura University,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10081279,2022-09-07,2024-03-01,Unverified,high_alzabeedi_2022,SAU
220808_Makkah_UmmAlQuraUniversity_Age18to24,220808_Makkah_UmmAlQuraUniversity,"High Seroprevalence of SARS-CoV-2 IgG and RNA among Asymptomatic Blood Donors in Makkah Region, Saudi Arabia.",2022-08-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Makkah,"blood donors at Makkah’s Central Blood Bank. All the study participants met the prerequisites for blood donation. Participants in this study were required to be free of COVID-19 symptoms and have never been infected
with SARS-CoV-2.","A blood donor was ruled out if he/she had been diagnosed with a
disease or showed outward signs of infections such as cough, sore throat, or fever. Hepatitis B and C, as well as human immunodeficiency virus (HIV) 1 and 2, were confirmed to be absent in all the participants.",2020-08-01,2020-12-30,Blood donors,All,Adults (18-64 years),18.0,24.0,Age,age: 18-24,625,0.624,,,,,,,,Unclear,SARS-CoV-2 Virus IgG Antibody Detection Kit (ELISA),BGI Genomics,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9378000000000001,0.9712000000000001,['Moderate'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Kamal H. Alzabeedi,Umm Al Qura University,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10081279,2022-09-07,2024-03-01,Unverified,high_alzabeedi_2022,SAU
220808_Makkah_UmmAlQuraUniversity_Age40to44,220808_Makkah_UmmAlQuraUniversity,"High Seroprevalence of SARS-CoV-2 IgG and RNA among Asymptomatic Blood Donors in Makkah Region, Saudi Arabia.",2022-08-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Makkah,"blood donors at Makkah’s Central Blood Bank. All the study participants met the prerequisites for blood donation. Participants in this study were required to be free of COVID-19 symptoms and have never been infected
with SARS-CoV-2.","A blood donor was ruled out if he/she had been diagnosed with a
disease or showed outward signs of infections such as cough, sore throat, or fever. Hepatitis B and C, as well as human immunodeficiency virus (HIV) 1 and 2, were confirmed to be absent in all the participants.",2020-08-01,2020-12-30,Blood donors,All,Adults (18-64 years),40.0,44.0,Age,age: 40-44,521,0.484,,,,,,,,Unclear,SARS-CoV-2 Virus IgG Antibody Detection Kit (ELISA),BGI Genomics,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9378000000000001,0.9712000000000001,['Moderate'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Kamal H. Alzabeedi,Umm Al Qura University,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10081279,2022-09-07,2024-03-01,Unverified,high_alzabeedi_2022,SAU
220808_Makkah_UmmAlQuraUniversity_Age30to34,220808_Makkah_UmmAlQuraUniversity,"High Seroprevalence of SARS-CoV-2 IgG and RNA among Asymptomatic Blood Donors in Makkah Region, Saudi Arabia.",2022-08-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Makkah,"blood donors at Makkah’s Central Blood Bank. All the study participants met the prerequisites for blood donation. Participants in this study were required to be free of COVID-19 symptoms and have never been infected
with SARS-CoV-2.","A blood donor was ruled out if he/she had been diagnosed with a
disease or showed outward signs of infections such as cough, sore throat, or fever. Hepatitis B and C, as well as human immunodeficiency virus (HIV) 1 and 2, were confirmed to be absent in all the participants.",2020-08-01,2020-12-30,Blood donors,All,Adults (18-64 years),30.0,34.0,Age,age: 30-34,1024,0.47600000000000003,,,,,,,,Unclear,SARS-CoV-2 Virus IgG Antibody Detection Kit (ELISA),BGI Genomics,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9378000000000001,0.9712000000000001,['Moderate'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Kamal H. Alzabeedi,Umm Al Qura University,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10081279,2022-09-07,2024-03-01,Unverified,high_alzabeedi_2022,SAU
220808_Makkah_UmmAlQuraUniversity_AgeOver50,220808_Makkah_UmmAlQuraUniversity,"High Seroprevalence of SARS-CoV-2 IgG and RNA among Asymptomatic Blood Donors in Makkah Region, Saudi Arabia.",2022-08-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Makkah,"blood donors at Makkah’s Central Blood Bank. All the study participants met the prerequisites for blood donation. Participants in this study were required to be free of COVID-19 symptoms and have never been infected
with SARS-CoV-2.","A blood donor was ruled out if he/she had been diagnosed with a
disease or showed outward signs of infections such as cough, sore throat, or fever. Hepatitis B and C, as well as human immunodeficiency virus (HIV) 1 and 2, were confirmed to be absent in all the participants.",2020-08-01,2020-12-30,Blood donors,All,Multiple groups,,,Age,age: >=50,165,0.4,,,,,,,,Unclear,SARS-CoV-2 Virus IgG Antibody Detection Kit (ELISA),BGI Genomics,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9378000000000001,0.9712000000000001,['Moderate'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Kamal H. Alzabeedi,Umm Al Qura University,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10081279,2022-09-07,2024-03-01,Unverified,high_alzabeedi_2022,SAU
220808_Makkah_UmmAlQuraUniversity_Male,220808_Makkah_UmmAlQuraUniversity,"High Seroprevalence of SARS-CoV-2 IgG and RNA among Asymptomatic Blood Donors in Makkah Region, Saudi Arabia.",2022-08-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Makkah,"blood donors at Makkah’s Central Blood Bank. All the study participants met the prerequisites for blood donation. Participants in this study were required to be free of COVID-19 symptoms and have never been infected
with SARS-CoV-2.","A blood donor was ruled out if he/she had been diagnosed with a
disease or showed outward signs of infections such as cough, sore throat, or fever. Hepatitis B and C, as well as human immunodeficiency virus (HIV) 1 and 2, were confirmed to be absent in all the participants.",2020-08-01,2020-12-30,Blood donors,Male,Multiple groups,18.0,,Sex/Gender,,4339,0.518,,,,,,,,Unclear,SARS-CoV-2 Virus IgG Antibody Detection Kit (ELISA),BGI Genomics,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9378000000000001,0.9712000000000001,['Moderate'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Kamal H. Alzabeedi,Umm Al Qura University,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10081279,2022-09-07,2024-03-01,Unverified,high_alzabeedi_2022,SAU
220808_Makkah_UmmAlQuraUniversity_Age45to49,220808_Makkah_UmmAlQuraUniversity,"High Seroprevalence of SARS-CoV-2 IgG and RNA among Asymptomatic Blood Donors in Makkah Region, Saudi Arabia.",2022-08-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Makkah,"blood donors at Makkah’s Central Blood Bank. All the study participants met the prerequisites for blood donation. Participants in this study were required to be free of COVID-19 symptoms and have never been infected
with SARS-CoV-2.","A blood donor was ruled out if he/she had been diagnosed with a
disease or showed outward signs of infections such as cough, sore throat, or fever. Hepatitis B and C, as well as human immunodeficiency virus (HIV) 1 and 2, were confirmed to be absent in all the participants.",2020-08-01,2020-12-30,Blood donors,All,Adults (18-64 years),45.0,49.0,Age,age: 45-49,196,0.49,,,,,,,,Unclear,SARS-CoV-2 Virus IgG Antibody Detection Kit (ELISA),BGI Genomics,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9378000000000001,0.9712000000000001,['Moderate'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Kamal H. Alzabeedi,Umm Al Qura University,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10081279,2022-09-07,2024-03-01,Unverified,high_alzabeedi_2022,SAU
220808_Makkah_UmmAlQuraUniversity_Female,220808_Makkah_UmmAlQuraUniversity,"High Seroprevalence of SARS-CoV-2 IgG and RNA among Asymptomatic Blood Donors in Makkah Region, Saudi Arabia.",2022-08-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Makkah,"blood donors at Makkah’s Central Blood Bank. All the study participants met the prerequisites for blood donation. Participants in this study were required to be free of COVID-19 symptoms and have never been infected
with SARS-CoV-2.","A blood donor was ruled out if he/she had been diagnosed with a
disease or showed outward signs of infections such as cough, sore throat, or fever. Hepatitis B and C, as well as human immunodeficiency virus (HIV) 1 and 2, were confirmed to be absent in all the participants.",2020-08-01,2020-12-30,Blood donors,Female,Multiple groups,18.0,,Sex/Gender,,29,0.069,,,,,,,,Unclear,SARS-CoV-2 Virus IgG Antibody Detection Kit (ELISA),BGI Genomics,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9378000000000001,0.9712000000000001,['Moderate'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Kamal H. Alzabeedi,Umm Al Qura University,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10081279,2022-09-07,2024-03-01,Unverified,high_alzabeedi_2022,SAU
220808_Makkah_UmmAlQuraUniversity_Age25to29,220808_Makkah_UmmAlQuraUniversity,"High Seroprevalence of SARS-CoV-2 IgG and RNA among Asymptomatic Blood Donors in Makkah Region, Saudi Arabia.",2022-08-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Makkah,"blood donors at Makkah’s Central Blood Bank. All the study participants met the prerequisites for blood donation. Participants in this study were required to be free of COVID-19 symptoms and have never been infected
with SARS-CoV-2.","A blood donor was ruled out if he/she had been diagnosed with a
disease or showed outward signs of infections such as cough, sore throat, or fever. Hepatitis B and C, as well as human immunodeficiency virus (HIV) 1 and 2, were confirmed to be absent in all the participants.",2020-08-01,2020-12-30,Blood donors,All,Adults (18-64 years),25.0,29.0,Age,age: 25-29,987,0.594,,,,,,,,Unclear,SARS-CoV-2 Virus IgG Antibody Detection Kit (ELISA),BGI Genomics,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9378000000000001,0.9712000000000001,['Moderate'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Kamal H. Alzabeedi,Umm Al Qura University,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10081279,2022-09-07,2024-03-01,Unverified,high_alzabeedi_2022,SAU
220808_Makkah_UmmAlQuraUniversity_Age35to39,220808_Makkah_UmmAlQuraUniversity,"High Seroprevalence of SARS-CoV-2 IgG and RNA among Asymptomatic Blood Donors in Makkah Region, Saudi Arabia.",2022-08-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Makkah,"blood donors at Makkah’s Central Blood Bank. All the study participants met the prerequisites for blood donation. Participants in this study were required to be free of COVID-19 symptoms and have never been infected
with SARS-CoV-2.","A blood donor was ruled out if he/she had been diagnosed with a
disease or showed outward signs of infections such as cough, sore throat, or fever. Hepatitis B and C, as well as human immunodeficiency virus (HIV) 1 and 2, were confirmed to be absent in all the participants.",2020-08-01,2020-12-30,Blood donors,All,Adults (18-64 years),35.0,39.0,Age,age: 35-39,850,0.436,,,,,,,,Unclear,SARS-CoV-2 Virus IgG Antibody Detection Kit (ELISA),BGI Genomics,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9378000000000001,0.9712000000000001,['Moderate'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Kamal H. Alzabeedi,Umm Al Qura University,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10081279,2022-09-07,2024-03-01,Unverified,high_alzabeedi_2022,SAU
220810_Dhahran_JohnsHopkinsAramcoHealthcare,220810_Dhahran_JohnsHopkinsAramcoHealthcare,A Cohort Study of Seroprevalence of Antibodies Against SARS-CoV-2 Infection Among Healthcare Workers at a Tertiary Hospital in Saudi Arabia,2022-08-10,Journal Article (Peer-Reviewed),Local,Prospective cohort,Saudi Arabia,Eastern Province,Dhahran,"""healthcare workers at Johns Hopkins Aramco Healthcare (JHAH). JHAH is a tertiary hospital located in Dhahran"".",,2020-06-15,2021-04-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,682,0.1276,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Hayat Mushcab,Johns Hopkins Aramco Healthcare,Not Unity-Aligned,https://dx.doi.org/10.2147/IDR.S369755,2022-08-22,2024-03-01,Unverified,mushcab_cohort_2022,SAU
220812_Riyadh_KingFahadMedicalCity_Baseline,220812_Riyadh_KingFahadMedicalCity_Baseline,Seroprevalence and longevity of SARS-CoV-2 nucleocapsid antigen-IgG among health care workers in a large COVID-19 public hospital in Saudi Arabia: A prospective cohort study,2022-08-12,Journal Article (Peer-Reviewed),Local,Prospective cohort,Saudi Arabia,,Riyadh,"""All HCWs [at King Fahad Medical City] who could provide written informed consent were deemed eligible to be included in this study.""","""There were no exclusion criteria except for actively symptomatic employees.""",2020-06-15,2020-07-15,Health care workers and caregivers,All,Multiple groups,19.0,71.0,Primary Estimate,,2523,0.10800000000000001,0.096,0.121,True,,,,True,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.99,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Faisal Alasmari,King Fahad Medical City,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0272818,2022-08-23,2024-03-01,Unverified,alasmari_seroprevalence_2022,SAU
220818_Abha_KingKhalidUniversity_TestAdj_Overall,220818_Abha_KingKhalidUniversity,"Seroprevalence of SARS-CoV-2 among Children Visiting a Tertiary Hospital during the Prevaccination Period, Southwest Region, Saudi Arabia.",2022-08-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Abha,"""The children who needed a blood test for any reason were included in this study.""

""Inpatient, outpatient, and emergency department patients were included, based on two inclusion criteria: age less than 12 years of age and the need for a blood test for any reason.""","""Patients were excluded for having risk factors for ongoing SARS-CoV-2 infection (typical symptoms, recent positive nasopharyngeal swab, contact with confirmed or suspected cases, and traveling abroad) and/or immunodeficiency, either primary or secondary.""",2021-10-01,2021-11-30,Residual sera,All,Children and Youth (0-17 years),0.0,12.0,Primary Estimate,Test adjusted,413,0.33,0.28500000000000003,0.374,True,True,,,,Convenience,Diapro,Palex,ELISA,Serum,"['IgA', 'IgG', 'IgM']",,,,,['High'],,No,No,Yes,,No,Yes,Yes,,Ali Asseri,King Khalid University,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10081344,2022-09-07,2023-08-15,Unverified,asseri_seroprevalence_2022,SAU
220818_Abha_KingKhalidUniversity_UnAdj_SexFemale,220818_Abha_KingKhalidUniversity,"Seroprevalence of SARS-CoV-2 among Children Visiting a Tertiary Hospital during the Prevaccination Period, Southwest Region, Saudi Arabia.",2022-08-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Abha,"""The children who needed a blood test for any reason were included in this study.""

""Inpatient, outpatient, and emergency department patients were included, based on two inclusion criteria: age less than 12 years of age and the need for a blood test for any reason.""","""Patients were excluded for having risk factors for ongoing SARS-CoV-2 infection (typical symptoms, recent positive nasopharyngeal swab, contact with confirmed or suspected cases, and traveling abroad) and/or immunodeficiency, either primary or secondary.""",2021-10-01,2021-11-30,Residual sera,Female,Children and Youth (0-17 years),0.0,12.0,Sex/Gender,,170,0.33530000000000004,,,,,,,,Convenience,Diapro,Palex,ELISA,Serum,"['IgA', 'IgG', 'IgM']",,,,,['High'],,No,No,Yes,,No,Yes,Yes,,Ali Asseri,King Khalid University,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10081344,2022-09-07,2024-03-01,Unverified,asseri_seroprevalence_2022,SAU
220818_Abha_KingKhalidUniversity_UnAdj_AgeBelow1,220818_Abha_KingKhalidUniversity,"Seroprevalence of SARS-CoV-2 among Children Visiting a Tertiary Hospital during the Prevaccination Period, Southwest Region, Saudi Arabia.",2022-08-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Abha,"""The children who needed a blood test for any reason were included in this study.""

""Inpatient, outpatient, and emergency department patients were included, based on two inclusion criteria: age less than 12 years of age and the need for a blood test for any reason.""","""Patients were excluded for having risk factors for ongoing SARS-CoV-2 infection (typical symptoms, recent positive nasopharyngeal swab, contact with confirmed or suspected cases, and traveling abroad) and/or immunodeficiency, either primary or secondary.""",2021-10-01,2021-11-30,Residual sera,All,Children and Youth (0-17 years),0.0,1.0,Age,Age: <1,94,0.245,0.152,0.33799999999999997,,,,,,Convenience,Diapro,Palex,ELISA,Serum,"['IgA', 'IgG', 'IgM']",,,,,['High'],,No,No,Yes,,No,Yes,Yes,,Ali Asseri,King Khalid University,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10081344,2022-09-07,2024-03-01,Unverified,asseri_seroprevalence_2022,SAU
220818_Abha_KingKhalidUniversity_UnAdj_Overall,220818_Abha_KingKhalidUniversity,"Seroprevalence of SARS-CoV-2 among Children Visiting a Tertiary Hospital during the Prevaccination Period, Southwest Region, Saudi Arabia.",2022-08-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Abha,"""The children who needed a blood test for any reason were included in this study.""

""Inpatient, outpatient, and emergency department patients were included, based on two inclusion criteria: age less than 12 years of age and the need for a blood test for any reason.""","""Patients were excluded for having risk factors for ongoing SARS-CoV-2 infection (typical symptoms, recent positive nasopharyngeal swab, contact with confirmed or suspected cases, and traveling abroad) and/or immunodeficiency, either primary or secondary.""",2021-10-01,2021-11-30,Residual sera,All,Children and Youth (0-17 years),0.0,12.0,Analysis,Unadjusted,413,0.3075,,,,,,,True,Convenience,Diapro,Palex,ELISA,Serum,"['IgA', 'IgG', 'IgM']",,,,,['High'],,No,No,Yes,,No,Yes,Yes,,Ali Asseri,King Khalid University,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10081344,2022-09-07,2024-03-01,Unverified,asseri_seroprevalence_2022,SAU
220818_Abha_KingKhalidUniversity_UnAdj_AgeAbove5,220818_Abha_KingKhalidUniversity,"Seroprevalence of SARS-CoV-2 among Children Visiting a Tertiary Hospital during the Prevaccination Period, Southwest Region, Saudi Arabia.",2022-08-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Abha,"""The children who needed a blood test for any reason were included in this study.""

""Inpatient, outpatient, and emergency department patients were included, based on two inclusion criteria: age less than 12 years of age and the need for a blood test for any reason.""","""Patients were excluded for having risk factors for ongoing SARS-CoV-2 infection (typical symptoms, recent positive nasopharyngeal swab, contact with confirmed or suspected cases, and traveling abroad) and/or immunodeficiency, either primary or secondary.""",2021-10-01,2021-11-30,Residual sera,All,Children and Youth (0-17 years),5.0,12.0,Age,Age: >5,167,0.317,0.24600000000000002,0.387,,,,,,Convenience,Diapro,Palex,ELISA,Serum,"['IgA', 'IgG', 'IgM']",,,,,['High'],,No,No,Yes,,No,Yes,Yes,,Ali Asseri,King Khalid University,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10081344,2022-09-07,2024-03-01,Unverified,asseri_seroprevalence_2022,SAU
220818_Abha_KingKhalidUniversity_UnAdj_Age1-5,220818_Abha_KingKhalidUniversity,"Seroprevalence of SARS-CoV-2 among Children Visiting a Tertiary Hospital during the Prevaccination Period, Southwest Region, Saudi Arabia.",2022-08-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Abha,"""The children who needed a blood test for any reason were included in this study.""

""Inpatient, outpatient, and emergency department patients were included, based on two inclusion criteria: age less than 12 years of age and the need for a blood test for any reason.""","""Patients were excluded for having risk factors for ongoing SARS-CoV-2 infection (typical symptoms, recent positive nasopharyngeal swab, contact with confirmed or suspected cases, and traveling abroad) and/or immunodeficiency, either primary or secondary.""",2021-10-01,2021-11-30,Residual sera,All,Children and Youth (0-17 years),1.0,5.0,Age,Age: 1-5,152,0.336,0.254,0.40299999999999997,,,,,,Convenience,Diapro,Palex,ELISA,Serum,"['IgA', 'IgG', 'IgM']",,,,,['High'],,No,No,Yes,,No,Yes,Yes,,Ali Asseri,King Khalid University,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10081344,2022-09-07,2024-03-01,Unverified,asseri_seroprevalence_2022,SAU
220818_Abha_KingKhalidUniversity_UnAdj_SexMale,220818_Abha_KingKhalidUniversity,"Seroprevalence of SARS-CoV-2 among Children Visiting a Tertiary Hospital during the Prevaccination Period, Southwest Region, Saudi Arabia.",2022-08-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Abha,"""The children who needed a blood test for any reason were included in this study.""

""Inpatient, outpatient, and emergency department patients were included, based on two inclusion criteria: age less than 12 years of age and the need for a blood test for any reason.""","""Patients were excluded for having risk factors for ongoing SARS-CoV-2 infection (typical symptoms, recent positive nasopharyngeal swab, contact with confirmed or suspected cases, and traveling abroad) and/or immunodeficiency, either primary or secondary.""",2021-10-01,2021-11-30,Residual sera,Male,Children and Youth (0-17 years),0.0,12.0,Sex/Gender,,243,0.28809999999999997,,,,,,,,Convenience,Diapro,Palex,ELISA,Serum,"['IgA', 'IgG', 'IgM']",,,,,['High'],,No,No,Yes,,No,Yes,Yes,,Ali Asseri,King Khalid University,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10081344,2022-09-07,2024-03-01,Unverified,asseri_seroprevalence_2022,SAU
221211_SaudiArabia_KingSaudBinAbdulazizUniversity_Overall,221211_SaudiArabia_KingSaudBinAbdulazizUniversity,Community-Based Seroprevelance of SARS-CoV-2 in Saudi Arabia,2022-12-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Saudi Arabia,"Asir, Albaha, Najran, Jazan, Eastern Province, Makkah, Madinah",,"""The study was conducted in seven regions in Saudi Arabia: Asir, Albaha, Najran, Jazan, Eastern Province, Makkah, and Madinah regions. All districts from the selected regions were included.""

""Inclusion criteria included all individuals living in the same residential area (for the last six months) in the selected seven regions in Saudi Arabia, prior positive PCR result for COVID-19 and symptoms free for greater than or equal to 14 days, and never tested for COVID-19 and asymptomatic.""","""Those previously labeled as positive COVID-19 cases (in less than 14 days) were excluded.""",2020-07-15,2020-10-15,Household and community samples,All,Multiple groups,2.0,99.0,Primary Estimate,,14118,0.19100000000000003,,,True,,,,True,Stratified non-probability,Colloidal Gold IgM/IgG rapid assay kit,BGI Genomics,ELISA,Serum,"IgG, IgM",[],Validated by manufacturers,0.99,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Lujain Alassaf,King Saud Bin Abdulaziz University for Health Sciences,Not Unity-Aligned,https://dx.doi.org/10.7759/cureus.32419,2023-02-08,2023-03-19,Unverified,alassaf_community-based_2022,SAU
221222_Sakaka_JoufUniversity_IgG,221222_Sakaka_JoufUniversity,"High Seroprevalence of Anti-SARS-CoV-2 IgM/IgG among Inhabitants of Sakaka City, Aljouf, Saudi Arabia.",2022-12-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,Aljouf,Sakaka City,"Employees, workers, students, and staff of Jouf University, their relatives, and visitors to different city malls and the primary healthcare centers (through the collaboration of healthcare providers) were voluntarily recruited sequentially at their first appearance until the required sample size was met.",,2021-07-15,2021-10-15,Blood donors,All,Multiple groups,,,Primary Estimate,overall IgG estimate,400,0.5770000000000001,,,True,,,,True,Sequential,Colloidal gold immuno-chromatography LFIA cards,"SunLong Biotech Co., LTD, Hangzhou, China",LFIA,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Ahmed E. Taha,Jouf University,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines11010026,2023-02-06,2023-03-22,Unverified,taha_high_2022,SAU
221222_Sakaka_JoufUniversity_IgM,221222_Sakaka_JoufUniversity,"High Seroprevalence of Anti-SARS-CoV-2 IgM/IgG among Inhabitants of Sakaka City, Aljouf, Saudi Arabia.",2022-12-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,Aljouf,Sakaka City,"Employees, workers, students, and staff of Jouf University, their relatives, and visitors to different city malls and the primary healthcare centers (through the collaboration of healthcare providers) were voluntarily recruited sequentially at their first appearance until the required sample size was met.",,2021-07-15,2021-10-15,Blood donors,All,Multiple groups,,,Test used,overall IgM estimate,400,0.542,,,,,,,True,Sequential,Colloidal gold immuno-chromatography LFIA cards,"SunLong Biotech Co., LTD, Hangzhou, China",LFIA,Whole Blood,IgM,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Ahmed E. Taha,Jouf University,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines11010026,2023-02-06,2023-03-22,Unverified,taha_high_2022,SAU
230317_UniversityOfTabuk_Tabuk,230317_UniversityOfTabuk_Tabuk,"COVID-19: Establishing, implementing and assessment safety strategy, descriptive interventional study",2023-03-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Saudi Arabia,,Tabuk,Undergraduate students of applied medical sciences at the University of Tabuk who had physically attended (face to face) practical classes represented the study population,,2020-09-01,2020-12-31,Students and Daycares,All,Adults (18-64 years),,,Primary Estimate,,175,0.389,,,True,,,,True,Unclear,COVID-19 ELISA IgM/IgA,Vircell S.L.,ELISA,Serum,"['IgA', 'IgG']",Spike,,,,['High'],,Unclear,No,No,,No,Yes,No,,Tarig M. S. Alnour,University of Tabuk,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0283197,2023-04-12,2024-03-01,Unverified,alnour_covid-19_2023,SAU
230915_Riyadh_KingSaudMedicalCity_Overall,230915_Riyadh_KingSaudMedicalCity,Renin-angiotensin-system blockers and IgG antibodies in end-stage renal disease hemodialysis-receiving patients diagnosed with COVID-19 infection.,2023-09-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,Saudi Arabia,,Riyadh,All patients with ESRD receiving regular hemodialysis in our center were included in the study,Patients with insufficient data were excluded.,2020-11-15,2021-01-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,16.0,90.0,Primary Estimate,overall IgG estimated on the studied population,214,0.15,,,True,,,,True,Sequential,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Serum,IgG,Spike,Validated by manufacturers,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Sultan A. Almdallaleh,King Saud Medical City,Not Unity-Aligned,https://dx.doi.org/10.15537/smj.2023.44.9.20230129,2023-10-02,2024-03-01,Unverified,almdallaleh_renin-angiotensin-system-2023,SAU
210817_Senegal_UniversityGastonBerger_Primary,210817_Senegal_UniversityGastonBerger,Prevalence of SARS-CoV-2 Antibodies in Hemodialysis Patients in Senegal: A Multicenter Cross-Sectional Study,2021-08-17,Preprint,National,Cross-sectional survey ,Senegal,,,"Randomly sampled 10 dialysis units in eight regions of Senegal. Patients aged ≥ 18 years, on chronic hemodialysis for at least 3 months were included.",Patients who did not give their consent and those with a diagnosis of acute kidney injury were excluded.,2020-06-15,2020-09-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,,Primary Estimate,,303,0.212,0.167,0.261,True,,,,True,Simplified probability,COVID-19 IgG/IgM Rapid Test Cassette,Healgen,LFIA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Sidy Mohamed Seck,University Gaston Berger,Not Unity-Aligned,https://www.researchsquare.com/article/rs-660094/v1,2021-08-24,2024-03-01,Unverified,seck_prevalence_2021,SEN
211224_Senegal_InstitutDeRechercheEnSante_TestAdj_Overall,211224_Senegal_InstitutDeRechercheEnSante,Seroprevalence of SARS-CoV-2 IgG antibodies in a healthcare setting during the first pandemic wave in Senegal.,2021-12-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Senegal,,"Dakar , Thiès, Ziguinchor, Saint-Louis, Kaolack, Kolda, Touba, Tambacounda, Louga, Bounkiling","The seroprevalence rate of SARS-CoV-2 IgG
was assessed in 10 cities in Senegal by testing plasma from volunteers attending healthcare clinics for reasons
unrelated to coronavirus disease 2019",,2020-06-15,2020-10-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,3231,0.204,,,True,True,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Ambroise Ahouidi,Institut de Recherche en Sante,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702669/,2022-06-30,2023-08-15,Unverified,ahouidi_seroprevalence_2022,SEN
211224_Senegal_InstitutDeRechercheEnSante_TestAdj_Ages15-29,211224_Senegal_InstitutDeRechercheEnSante,Seroprevalence of SARS-CoV-2 IgG antibodies in a healthcare setting during the first pandemic wave in Senegal.,2021-12-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Senegal,,"Dakar , Thiès, Ziguinchor, Saint-Louis, Kaolack, Kolda, Touba, Tambacounda, Louga, Bounkiling","The seroprevalence rate of SARS-CoV-2 IgG
was assessed in 10 cities in Senegal by testing plasma from volunteers attending healthcare clinics for reasons
unrelated to coronavirus disease 2019",,2020-06-15,2020-10-15,Household and community samples,All,Multiple groups,15.0,29.0,Age,,1241,0.18600000000000003,,,,True,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Ambroise Ahouidi,Institut de Recherche en Sante,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702669/,2022-06-30,2023-08-15,Unverified,ahouidi_seroprevalence_2022,SEN
211224_Senegal_InstitutDeRechercheEnSante_TestAdj_Louga,211224_Senegal_InstitutDeRechercheEnSante,Seroprevalence of SARS-CoV-2 IgG antibodies in a healthcare setting during the first pandemic wave in Senegal.,2021-12-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Senegal,,Louga,"The seroprevalence rate of SARS-CoV-2 IgG
was assessed in 10 cities in Senegal by testing plasma from volunteers attending healthcare clinics for reasons
unrelated to coronavirus disease 2019",,2020-06-15,2020-10-15,Household and community samples,All,Multiple groups,,,Geographical area,,100,0.057,,,,True,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Ambroise Ahouidi,Institut de Recherche en Sante,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702669/,2022-06-30,2023-08-15,Unverified,ahouidi_seroprevalence_2022,SEN
211224_Senegal_InstitutDeRechercheEnSante_TestAdj_Ages30-44,211224_Senegal_InstitutDeRechercheEnSante,Seroprevalence of SARS-CoV-2 IgG antibodies in a healthcare setting during the first pandemic wave in Senegal.,2021-12-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Senegal,,"Dakar , Thiès, Ziguinchor, Saint-Louis, Kaolack, Kolda, Touba, Tambacounda, Louga, Bounkiling","The seroprevalence rate of SARS-CoV-2 IgG
was assessed in 10 cities in Senegal by testing plasma from volunteers attending healthcare clinics for reasons
unrelated to coronavirus disease 2019",,2020-06-15,2020-10-15,Household and community samples,All,Adults (18-64 years),30.0,44.0,Age,,955,0.16899999999999998,,,,True,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Ambroise Ahouidi,Institut de Recherche en Sante,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702669/,2022-06-30,2023-08-15,Unverified,ahouidi_seroprevalence_2022,SEN
211224_Senegal_InstitutDeRechercheEnSante_TestAdj_Saint-Louis,211224_Senegal_InstitutDeRechercheEnSante,Seroprevalence of SARS-CoV-2 IgG antibodies in a healthcare setting during the first pandemic wave in Senegal.,2021-12-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Senegal,,Saint-Louis,"The seroprevalence rate of SARS-CoV-2 IgG
was assessed in 10 cities in Senegal by testing plasma from volunteers attending healthcare clinics for reasons
unrelated to coronavirus disease 2019",,2020-06-15,2020-10-15,Household and community samples,All,Multiple groups,,,Geographical area,,396,0.19399999999999998,,,,True,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Ambroise Ahouidi,Institut de Recherche en Sante,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702669/,2022-06-30,2023-08-15,Unverified,ahouidi_seroprevalence_2022,SEN
211224_Senegal_InstitutDeRechercheEnSante_TestAdj_Dakar,211224_Senegal_InstitutDeRechercheEnSante,Seroprevalence of SARS-CoV-2 IgG antibodies in a healthcare setting during the first pandemic wave in Senegal.,2021-12-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Senegal,,Dakar,"The seroprevalence rate of SARS-CoV-2 IgG
was assessed in 10 cities in Senegal by testing plasma from volunteers attending healthcare clinics for reasons
unrelated to coronavirus disease 2019",,2020-06-15,2020-10-15,Household and community samples,All,Multiple groups,,,Geographical area,,852,0.20600000000000002,,,,True,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Ambroise Ahouidi,Institut de Recherche en Sante,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702669/,2022-06-30,2023-08-15,Unverified,ahouidi_seroprevalence_2022,SEN
211224_Senegal_InstitutDeRechercheEnSante_TestAdj_Touba,211224_Senegal_InstitutDeRechercheEnSante,Seroprevalence of SARS-CoV-2 IgG antibodies in a healthcare setting during the first pandemic wave in Senegal.,2021-12-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Senegal,,Touba,"The seroprevalence rate of SARS-CoV-2 IgG
was assessed in 10 cities in Senegal by testing plasma from volunteers attending healthcare clinics for reasons
unrelated to coronavirus disease 2019",,2020-06-15,2020-10-15,Household and community samples,All,Multiple groups,,,Geographical area,,395,0.167,,,,True,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Ambroise Ahouidi,Institut de Recherche en Sante,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702669/,2022-06-30,2023-08-15,Unverified,ahouidi_seroprevalence_2022,SEN
211224_Senegal_InstitutDeRechercheEnSante_TestAdj_Kolda,211224_Senegal_InstitutDeRechercheEnSante,Seroprevalence of SARS-CoV-2 IgG antibodies in a healthcare setting during the first pandemic wave in Senegal.,2021-12-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Senegal,,Kolda,"The seroprevalence rate of SARS-CoV-2 IgG
was assessed in 10 cities in Senegal by testing plasma from volunteers attending healthcare clinics for reasons
unrelated to coronavirus disease 2019",,2020-06-15,2020-10-15,Household and community samples,All,Multiple groups,,,Geographical area,,397,0.196,,,,True,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Ambroise Ahouidi,Institut de Recherche en Sante,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702669/,2022-06-30,2023-08-15,Unverified,ahouidi_seroprevalence_2022,SEN
211224_Senegal_InstitutDeRechercheEnSante_TestAdj_Ziguinchor,211224_Senegal_InstitutDeRechercheEnSante,Seroprevalence of SARS-CoV-2 IgG antibodies in a healthcare setting during the first pandemic wave in Senegal.,2021-12-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Senegal,,Ziguinchor,"The seroprevalence rate of SARS-CoV-2 IgG
was assessed in 10 cities in Senegal by testing plasma from volunteers attending healthcare clinics for reasons
unrelated to coronavirus disease 2019",,2020-06-15,2020-10-15,Household and community samples,All,Multiple groups,,,Geographical area,,372,0.41700000000000004,,,,True,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Ambroise Ahouidi,Institut de Recherche en Sante,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702669/,2022-06-30,2023-08-15,Unverified,ahouidi_seroprevalence_2022,SEN
211224_Senegal_InstitutDeRechercheEnSante_TestAdj_Thies,211224_Senegal_InstitutDeRechercheEnSante,Seroprevalence of SARS-CoV-2 IgG antibodies in a healthcare setting during the first pandemic wave in Senegal.,2021-12-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Senegal,,Thies,"The seroprevalence rate of SARS-CoV-2 IgG
was assessed in 10 cities in Senegal by testing plasma from volunteers attending healthcare clinics for reasons
unrelated to coronavirus disease 2019",,2020-06-15,2020-10-15,Household and community samples,All,Multiple groups,,,Geographical area,,191,0.18,,,,True,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Ambroise Ahouidi,Institut de Recherche en Sante,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702669/,2022-06-30,2023-08-15,Unverified,ahouidi_seroprevalence_2022,SEN
211224_Senegal_InstitutDeRechercheEnSante_TestAdj_Tambacounda,211224_Senegal_InstitutDeRechercheEnSante,Seroprevalence of SARS-CoV-2 IgG antibodies in a healthcare setting during the first pandemic wave in Senegal.,2021-12-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Senegal,,Tambacounda,"The seroprevalence rate of SARS-CoV-2 IgG
was assessed in 10 cities in Senegal by testing plasma from volunteers attending healthcare clinics for reasons
unrelated to coronavirus disease 2019",,2020-06-15,2020-10-15,Household and community samples,All,Multiple groups,,,Geographical area,,133,0.087,,,,True,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Ambroise Ahouidi,Institut de Recherche en Sante,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702669/,2022-06-30,2023-08-15,Unverified,ahouidi_seroprevalence_2022,SEN
211224_Senegal_InstitutDeRechercheEnSante_TestAdj_Ages60-74,211224_Senegal_InstitutDeRechercheEnSante,Seroprevalence of SARS-CoV-2 IgG antibodies in a healthcare setting during the first pandemic wave in Senegal.,2021-12-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Senegal,,"Dakar , Thiès, Ziguinchor, Saint-Louis, Kaolack, Kolda, Touba, Tambacounda, Louga, Bounkiling","The seroprevalence rate of SARS-CoV-2 IgG
was assessed in 10 cities in Senegal by testing plasma from volunteers attending healthcare clinics for reasons
unrelated to coronavirus disease 2019",,2020-06-15,2020-10-15,Household and community samples,All,Multiple groups,60.0,74.0,Age,,392,0.273,,,,True,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Ambroise Ahouidi,Institut de Recherche en Sante,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702669/,2022-06-30,2023-08-15,Unverified,ahouidi_seroprevalence_2022,SEN
211224_Senegal_InstitutDeRechercheEnSante_UnAdj_Overall,211224_Senegal_InstitutDeRechercheEnSante,Seroprevalence of SARS-CoV-2 IgG antibodies in a healthcare setting during the first pandemic wave in Senegal.,2021-12-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Senegal,,"Dakar , Thiès, Ziguinchor, Saint-Louis, Kaolack, Kolda, Touba, Tambacounda, Louga, Bounkiling","The seroprevalence rate of SARS-CoV-2 IgG
was assessed in 10 cities in Senegal by testing plasma from volunteers attending healthcare clinics for reasons
unrelated to coronavirus disease 2019",,2020-06-15,2020-10-15,Household and community samples,All,Multiple groups,,,Analysis,,3231,0.207,,,,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Ambroise Ahouidi,Institut de Recherche en Sante,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702669/,2022-06-30,2024-03-01,Unverified,ahouidi_seroprevalence_2022,SEN
211224_Senegal_InstitutDeRechercheEnSante_TestAdj_Ages0-14,211224_Senegal_InstitutDeRechercheEnSante,Seroprevalence of SARS-CoV-2 IgG antibodies in a healthcare setting during the first pandemic wave in Senegal.,2021-12-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Senegal,,"Dakar , Thiès, Ziguinchor, Saint-Louis, Kaolack, Kolda, Touba, Tambacounda, Louga, Bounkiling","The seroprevalence rate of SARS-CoV-2 IgG
was assessed in 10 cities in Senegal by testing plasma from volunteers attending healthcare clinics for reasons
unrelated to coronavirus disease 2019",,2020-06-15,2020-10-15,Household and community samples,All,Children and Youth (0-17 years),0.0,14.0,Age,,11,0.179,,,,True,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Ambroise Ahouidi,Institut de Recherche en Sante,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702669/,2022-06-30,2023-08-15,Unverified,ahouidi_seroprevalence_2022,SEN
211224_Senegal_InstitutDeRechercheEnSante_TestAdj_Kaolack,211224_Senegal_InstitutDeRechercheEnSante,Seroprevalence of SARS-CoV-2 IgG antibodies in a healthcare setting during the first pandemic wave in Senegal.,2021-12-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Senegal,,Kaolack,"The seroprevalence rate of SARS-CoV-2 IgG
was assessed in 10 cities in Senegal by testing plasma from volunteers attending healthcare clinics for reasons
unrelated to coronavirus disease 2019",,2020-06-15,2020-10-15,Household and community samples,All,Multiple groups,,,Geographical area,,269,0.142,,,,True,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Ambroise Ahouidi,Institut de Recherche en Sante,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702669/,2022-06-30,2023-08-15,Unverified,ahouidi_seroprevalence_2022,SEN
211224_Senegal_InstitutDeRechercheEnSante_TestAdj_Ages45-59,211224_Senegal_InstitutDeRechercheEnSante,Seroprevalence of SARS-CoV-2 IgG antibodies in a healthcare setting during the first pandemic wave in Senegal.,2021-12-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Senegal,,"Dakar , Thiès, Ziguinchor, Saint-Louis, Kaolack, Kolda, Touba, Tambacounda, Louga, Bounkiling","The seroprevalence rate of SARS-CoV-2 IgG
was assessed in 10 cities in Senegal by testing plasma from volunteers attending healthcare clinics for reasons
unrelated to coronavirus disease 2019",,2020-06-15,2020-10-15,Household and community samples,All,Adults (18-64 years),45.0,59.0,Age,,530,0.24,,,,True,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Ambroise Ahouidi,Institut de Recherche en Sante,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702669/,2022-06-30,2023-08-15,Unverified,ahouidi_seroprevalence_2022,SEN
211224_Senegal_InstitutDeRechercheEnSante_TestAdj_Bounkiling,211224_Senegal_InstitutDeRechercheEnSante,Seroprevalence of SARS-CoV-2 IgG antibodies in a healthcare setting during the first pandemic wave in Senegal.,2021-12-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Senegal,,Bounkiling,"The seroprevalence rate of SARS-CoV-2 IgG
was assessed in 10 cities in Senegal by testing plasma from volunteers attending healthcare clinics for reasons
unrelated to coronavirus disease 2019",,2020-06-15,2020-10-15,Household and community samples,All,Multiple groups,,,Geographical area,,126,0.11599999999999999,,,,True,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Ambroise Ahouidi,Institut de Recherche en Sante,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702669/,2022-06-30,2023-08-15,Unverified,ahouidi_seroprevalence_2022,SEN
211224_Senegal_InstitutDeRechercheEnSante_TestAdj_Ages75+,211224_Senegal_InstitutDeRechercheEnSante,Seroprevalence of SARS-CoV-2 IgG antibodies in a healthcare setting during the first pandemic wave in Senegal.,2021-12-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Senegal,,"Dakar , Thiès, Ziguinchor, Saint-Louis, Kaolack, Kolda, Touba, Tambacounda, Louga, Bounkiling","The seroprevalence rate of SARS-CoV-2 IgG
was assessed in 10 cities in Senegal by testing plasma from volunteers attending healthcare clinics for reasons
unrelated to coronavirus disease 2019",,2020-06-15,2020-10-15,Household and community samples,All,Seniors (65+ years),75.0,,Age,,102,0.29100000000000004,,,,True,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9963,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Ambroise Ahouidi,Institut de Recherche en Sante,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702669/,2022-06-30,2023-08-15,Unverified,ahouidi_seroprevalence_2022,SEN
220305_Senegal_InstitutPasteurdeDakar_OverallTestPopAdj,220305_Senegal_InstitutPasteurdeDakar,"Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020.",2022-03-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Senegal,,,Households in all areas of Senegal.,Hemolytic and under-filled blood samples were excluded from the serological analysis.,2020-10-25,2020-11-26,Household and community samples,All,Multiple groups,,,Primary Estimate,Test and Population Adjusted,1422,0.284,0.261,0.308,True,True,True,,,Simplified probability,"Omega diagnostics COVID-19 IgG ELISA,Wantai SARS-CoV-2 Total Ab ELISA","Generic Diagnostics Ltd,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Cheikh Talla,Institut Pasteur de Dakar,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897837/,2022-06-28,2023-08-15,Unverified,talla_seroprevalence_2022,SEN
220305_Senegal_InstitutPasteurdeDakar_AreaDakar,220305_Senegal_InstitutPasteurdeDakar,"Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020.",2022-03-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Senegal,Dakar,,Households in all areas of Senegal.,Hemolytic and under-filled blood samples were excluded from the serological analysis.,2020-10-25,2020-11-26,Household and community samples,All,Multiple groups,,,Geographical area,Dakar,295,0.434,0.37700000000000006,0.493,,,,,,Simplified probability,"Omega diagnostics COVID-19 IgG ELISA,Wantai SARS-CoV-2 Total Ab ELISA","Generic Diagnostics Ltd,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Cheikh Talla,Institut Pasteur de Dakar,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897837/,2022-06-28,2024-03-01,Unverified,talla_seroprevalence_2022,SEN
220305_Senegal_InstitutPasteurdeDakar_SexMale,220305_Senegal_InstitutPasteurdeDakar,"Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020.",2022-03-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Senegal,,,Households in all areas of Senegal.,Hemolytic and under-filled blood samples were excluded from the serological analysis.,2020-10-25,2020-11-26,Household and community samples,Male,Multiple groups,,,Sex/Gender,,596,0.265,0.23,0.302,,,,,,Simplified probability,"Omega diagnostics COVID-19 IgG ELISA,Wantai SARS-CoV-2 Total Ab ELISA","Generic Diagnostics Ltd,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Cheikh Talla,Institut Pasteur de Dakar,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897837/,2022-06-28,2024-03-01,Unverified,talla_seroprevalence_2022,SEN
220305_Senegal_InstitutPasteurdeDakar_Overall_Wantai,220305_Senegal_InstitutPasteurdeDakar,"Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020.",2022-03-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Senegal,,,Households in all areas of Senegal.,Hemolytic and under-filled blood samples were excluded from the serological analysis.,2020-10-25,2020-11-26,Household and community samples,All,Multiple groups,,,Test used,Wantai,1422,0.2475,,,,,,,,Simplified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.92,1.0,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Cheikh Talla,Institut Pasteur de Dakar,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897837/,2022-06-28,2024-03-01,Unverified,talla_seroprevalence_2022,SEN
220305_Senegal_InstitutPasteurdeDakar_AreaKedougou,220305_Senegal_InstitutPasteurdeDakar,"Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020.",2022-03-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Senegal,Kedougou,,Households in all areas of Senegal.,Hemolytic and under-filled blood samples were excluded from the serological analysis.,2020-10-25,2020-11-26,Household and community samples,All,Multiple groups,,,Geographical area,Kedougou,21,0.19,0.054000000000000006,0.419,,,,,,Simplified probability,"Omega diagnostics COVID-19 IgG ELISA,Wantai SARS-CoV-2 Total Ab ELISA","Generic Diagnostics Ltd,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Cheikh Talla,Institut Pasteur de Dakar,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897837/,2022-06-28,2024-03-01,Unverified,talla_seroprevalence_2022,SEN
220305_Senegal_InstitutPasteurdeDakar_AreaMatam,220305_Senegal_InstitutPasteurdeDakar,"Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020.",2022-03-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Senegal,Matam,,Households in all areas of Senegal.,Hemolytic and under-filled blood samples were excluded from the serological analysis.,2020-10-25,2020-11-26,Household and community samples,All,Multiple groups,,,Geographical area,Matam,45,0.111,0.037000000000000005,0.24100000000000002,,,,,,Simplified probability,"Omega diagnostics COVID-19 IgG ELISA,Wantai SARS-CoV-2 Total Ab ELISA","Generic Diagnostics Ltd,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Cheikh Talla,Institut Pasteur de Dakar,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897837/,2022-06-28,2024-03-01,Unverified,talla_seroprevalence_2022,SEN
220305_Senegal_InstitutPasteurdeDakar_AreaKaffrine,220305_Senegal_InstitutPasteurdeDakar,"Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020.",2022-03-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Senegal,Kaffrine,,Households in all areas of Senegal.,Hemolytic and under-filled blood samples were excluded from the serological analysis.,2020-10-25,2020-11-26,Household and community samples,All,Multiple groups,,,Geographical area,Kaffrine,79,0.266,0.17300000000000001,0.37700000000000006,,,,,,Simplified probability,"Omega diagnostics COVID-19 IgG ELISA,Wantai SARS-CoV-2 Total Ab ELISA","Generic Diagnostics Ltd,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Cheikh Talla,Institut Pasteur de Dakar,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897837/,2022-06-28,2024-03-01,Unverified,talla_seroprevalence_2022,SEN
220305_Senegal_InstitutPasteurdeDakar_SexFemale,220305_Senegal_InstitutPasteurdeDakar,"Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020.",2022-03-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Senegal,,,Households in all areas of Senegal.,Hemolytic and under-filled blood samples were excluded from the serological analysis.,2020-10-25,2020-11-26,Household and community samples,Female,Multiple groups,,,Sex/Gender,,850,0.276,0.247,0.308,,,,,,Simplified probability,"Omega diagnostics COVID-19 IgG ELISA,Wantai SARS-CoV-2 Total Ab ELISA","Generic Diagnostics Ltd,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Cheikh Talla,Institut Pasteur de Dakar,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897837/,2022-06-28,2024-03-01,Unverified,talla_seroprevalence_2022,SEN
220305_Senegal_InstitutPasteurdeDakar_AreaKaolack,220305_Senegal_InstitutPasteurdeDakar,"Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020.",2022-03-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Senegal,Kaolack,,Households in all areas of Senegal.,Hemolytic and under-filled blood samples were excluded from the serological analysis.,2020-10-25,2020-11-26,Household and community samples,All,Multiple groups,,,Geographical area,Kaolack,113,0.327,0.242,0.42200000000000004,,,,,,Simplified probability,"Omega diagnostics COVID-19 IgG ELISA,Wantai SARS-CoV-2 Total Ab ELISA","Generic Diagnostics Ltd,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Cheikh Talla,Institut Pasteur de Dakar,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897837/,2022-06-28,2024-03-01,Unverified,talla_seroprevalence_2022,SEN
220305_Senegal_InstitutPasteurdeDakar_Age16-30,220305_Senegal_InstitutPasteurdeDakar,"Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020.",2022-03-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Senegal,,,Households in all areas of Senegal.,Hemolytic and under-filled blood samples were excluded from the serological analysis.,2020-10-25,2020-11-26,Household and community samples,All,Adults (18-64 years),16.0,30.0,Age,16-30,337,0.368,0.316,0.42200000000000004,,,,,,Simplified probability,"Omega diagnostics COVID-19 IgG ELISA,Wantai SARS-CoV-2 Total Ab ELISA","Generic Diagnostics Ltd,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Cheikh Talla,Institut Pasteur de Dakar,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897837/,2022-06-28,2024-03-01,Unverified,talla_seroprevalence_2022,SEN
220305_Senegal_InstitutPasteurdeDakar_AreaZiguinchor,220305_Senegal_InstitutPasteurdeDakar,"Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020.",2022-03-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Senegal,Ziguinchor,,Households in all areas of Senegal.,Hemolytic and under-filled blood samples were excluded from the serological analysis.,2020-10-25,2020-11-26,Household and community samples,All,Multiple groups,,,Geographical area,Ziguinchor,50,0.56,0.413,0.7000000000000001,,,,,,Simplified probability,"Omega diagnostics COVID-19 IgG ELISA,Wantai SARS-CoV-2 Total Ab ELISA","Generic Diagnostics Ltd,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Cheikh Talla,Institut Pasteur de Dakar,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897837/,2022-06-28,2024-03-01,Unverified,talla_seroprevalence_2022,SEN
220305_Senegal_InstitutPasteurdeDakar_Overall_OMEGAandIDVet,220305_Senegal_InstitutPasteurdeDakar,"Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020.",2022-03-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Senegal,,,Households in all areas of Senegal.,Hemolytic and under-filled blood samples were excluded from the serological analysis.,2020-10-25,2020-11-26,Household and community samples,All,Multiple groups,,,Test used,OMEGA/IDVet,1422,0.1877,,,,,,,,Simplified probability,"Omega diagnostics COVID-19 IgG ELISA,ID Screen","Generic Diagnostics Ltd,ID.Vet",ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Cheikh Talla,Institut Pasteur de Dakar,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897837/,2022-06-28,2024-03-01,Unverified,talla_seroprevalence_2022,SEN
220305_Senegal_InstitutPasteurdeDakar_Age0-5,220305_Senegal_InstitutPasteurdeDakar,"Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020.",2022-03-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Senegal,,,Households in all areas of Senegal.,Hemolytic and under-filled blood samples were excluded from the serological analysis.,2020-10-25,2020-11-26,Household and community samples,All,Children and Youth (0-17 years),,5.0,Age,0-5,283,0.159,0.11800000000000001,0.207,,,,,,Simplified probability,"Omega diagnostics COVID-19 IgG ELISA,Wantai SARS-CoV-2 Total Ab ELISA","Generic Diagnostics Ltd,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Cheikh Talla,Institut Pasteur de Dakar,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897837/,2022-06-28,2024-03-01,Unverified,talla_seroprevalence_2022,SEN
220305_Senegal_InstitutPasteurdeDakar_AreaDiourbel,220305_Senegal_InstitutPasteurdeDakar,"Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020.",2022-03-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Senegal,Diourbel,,Households in all areas of Senegal.,Hemolytic and under-filled blood samples were excluded from the serological analysis.,2020-10-25,2020-11-26,Household and community samples,All,Multiple groups,,,Geographical area,Diourbel,117,0.188,0.122,0.271,,,,,,Simplified probability,"Omega diagnostics COVID-19 IgG ELISA,Wantai SARS-CoV-2 Total Ab ELISA","Generic Diagnostics Ltd,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Cheikh Talla,Institut Pasteur de Dakar,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897837/,2022-06-28,2024-03-01,Unverified,talla_seroprevalence_2022,SEN
220305_Senegal_InstitutPasteurdeDakar_Age61+,220305_Senegal_InstitutPasteurdeDakar,"Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020.",2022-03-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Senegal,,,Households in all areas of Senegal.,Hemolytic and under-filled blood samples were excluded from the serological analysis.,2020-10-25,2020-11-26,Household and community samples,All,Seniors (65+ years),61.0,,Age,61+,117,0.24800000000000003,0.17300000000000001,0.336,,,,,,Simplified probability,"Omega diagnostics COVID-19 IgG ELISA,Wantai SARS-CoV-2 Total Ab ELISA","Generic Diagnostics Ltd,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Cheikh Talla,Institut Pasteur de Dakar,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897837/,2022-06-28,2024-03-01,Unverified,talla_seroprevalence_2022,SEN
220305_Senegal_InstitutPasteurdeDakar_AreaTambacounda,220305_Senegal_InstitutPasteurdeDakar,"Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020.",2022-03-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Senegal,Tambacounda,,Households in all areas of Senegal.,Hemolytic and under-filled blood samples were excluded from the serological analysis.,2020-10-25,2020-11-26,Household and community samples,All,Multiple groups,,,Geographical area,Tambacounda,106,0.23600000000000002,0.159,0.32799999999999996,,,,,,Simplified probability,"Omega diagnostics COVID-19 IgG ELISA,Wantai SARS-CoV-2 Total Ab ELISA","Generic Diagnostics Ltd,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Cheikh Talla,Institut Pasteur de Dakar,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897837/,2022-06-28,2024-03-01,Unverified,talla_seroprevalence_2022,SEN
220305_Senegal_InstitutPasteurdeDakar_Age46-60,220305_Senegal_InstitutPasteurdeDakar,"Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020.",2022-03-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Senegal,,,Households in all areas of Senegal.,Hemolytic and under-filled blood samples were excluded from the serological analysis.,2020-10-25,2020-11-26,Household and community samples,All,Adults (18-64 years),46.0,60.0,Age,46-60,233,0.3,0.242,0.364,,,,,,Simplified probability,"Omega diagnostics COVID-19 IgG ELISA,Wantai SARS-CoV-2 Total Ab ELISA","Generic Diagnostics Ltd,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Cheikh Talla,Institut Pasteur de Dakar,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897837/,2022-06-28,2024-03-01,Unverified,talla_seroprevalence_2022,SEN
220305_Senegal_InstitutPasteurdeDakar_Age31-45,220305_Senegal_InstitutPasteurdeDakar,"Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020.",2022-03-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Senegal,,,Households in all areas of Senegal.,Hemolytic and under-filled blood samples were excluded from the serological analysis.,2020-10-25,2020-11-26,Household and community samples,All,Adults (18-64 years),31.0,45.0,Age,31-45,297,0.273,0.223,0.327,,,,,,Simplified probability,"Omega diagnostics COVID-19 IgG ELISA,Wantai SARS-CoV-2 Total Ab ELISA","Generic Diagnostics Ltd,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Cheikh Talla,Institut Pasteur de Dakar,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897837/,2022-06-28,2024-03-01,Unverified,talla_seroprevalence_2022,SEN
220305_Senegal_InstitutPasteurdeDakar_Age6-15,220305_Senegal_InstitutPasteurdeDakar,"Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020.",2022-03-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Senegal,,,Households in all areas of Senegal.,Hemolytic and under-filled blood samples were excluded from the serological analysis.,2020-10-25,2020-11-26,Household and community samples,All,Children and Youth (0-17 years),6.0,15.0,Age,6-15,179,0.24600000000000002,0.185,0.316,,,,,,Simplified probability,"Omega diagnostics COVID-19 IgG ELISA,Wantai SARS-CoV-2 Total Ab ELISA","Generic Diagnostics Ltd,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Cheikh Talla,Institut Pasteur de Dakar,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897837/,2022-06-28,2024-03-01,Unverified,talla_seroprevalence_2022,SEN
220305_Senegal_InstitutPasteurdeDakar_AreaLouga,220305_Senegal_InstitutPasteurdeDakar,"Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020.",2022-03-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Senegal,Louga,,Households in all areas of Senegal.,Hemolytic and under-filled blood samples were excluded from the serological analysis.,2020-10-25,2020-11-26,Household and community samples,All,Multiple groups,,,Geographical area,Louga,118,0.11,0.06,0.18100000000000002,,,,,,Simplified probability,"Omega diagnostics COVID-19 IgG ELISA,Wantai SARS-CoV-2 Total Ab ELISA","Generic Diagnostics Ltd,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Cheikh Talla,Institut Pasteur de Dakar,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897837/,2022-06-28,2024-03-01,Unverified,talla_seroprevalence_2022,SEN
220305_Senegal_InstitutPasteurdeDakar_OverallCrude,220305_Senegal_InstitutPasteurdeDakar,"Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020.",2022-03-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Senegal,,,Households in all areas of Senegal.,Hemolytic and under-filled blood samples were excluded from the serological analysis.,2020-10-25,2020-11-26,Household and community samples,All,Multiple groups,,,Analysis,Crude,1422,0.27899999999999997,0.257,0.304,,,,,True,Simplified probability,"Omega diagnostics COVID-19 IgG ELISA,Wantai SARS-CoV-2 Total Ab ELISA","Generic Diagnostics Ltd,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Cheikh Talla,Institut Pasteur de Dakar,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897837/,2022-06-28,2024-03-01,Unverified,talla_seroprevalence_2022,SEN
220305_Senegal_InstitutPasteurdeDakar_AreaThiès,220305_Senegal_InstitutPasteurdeDakar,"Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020.",2022-03-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Senegal,Thiès,,Households in all areas of Senegal.,Hemolytic and under-filled blood samples were excluded from the serological analysis.,2020-10-25,2020-11-26,Household and community samples,All,Multiple groups,,,Geographical area,Thiès,200,0.24,0.18300000000000002,0.305,,,,,,Simplified probability,"Omega diagnostics COVID-19 IgG ELISA,Wantai SARS-CoV-2 Total Ab ELISA","Generic Diagnostics Ltd,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Cheikh Talla,Institut Pasteur de Dakar,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897837/,2022-06-28,2024-03-01,Unverified,talla_seroprevalence_2022,SEN
220305_Senegal_InstitutPasteurdeDakar_AreaKolda,220305_Senegal_InstitutPasteurdeDakar,"Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020.",2022-03-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Senegal,Kolda,,Households in all areas of Senegal.,Hemolytic and under-filled blood samples were excluded from the serological analysis.,2020-10-25,2020-11-26,Household and community samples,All,Multiple groups,,,Geographical area,Kolda,52,0.231,0.125,0.368,,,,,,Simplified probability,"Omega diagnostics COVID-19 IgG ELISA,Wantai SARS-CoV-2 Total Ab ELISA","Generic Diagnostics Ltd,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Cheikh Talla,Institut Pasteur de Dakar,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897837/,2022-06-28,2024-03-01,Unverified,talla_seroprevalence_2022,SEN
220305_Senegal_InstitutPasteurdeDakar_AreaSaint-Louis,220305_Senegal_InstitutPasteurdeDakar,"Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020.",2022-03-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Senegal,Saint-Louis,,Households in all areas of Senegal.,Hemolytic and under-filled blood samples were excluded from the serological analysis.,2020-10-25,2020-11-26,Household and community samples,All,Multiple groups,,,Geographical area,Saint-Louis,94,0.16,0.092,0.25,,,,,,Simplified probability,"Omega diagnostics COVID-19 IgG ELISA,Wantai SARS-CoV-2 Total Ab ELISA","Generic Diagnostics Ltd,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Cheikh Talla,Institut Pasteur de Dakar,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897837/,2022-06-28,2024-03-01,Unverified,talla_seroprevalence_2022,SEN
220305_Senegal_InstitutPasteurdeDakar_AreaSédhiou,220305_Senegal_InstitutPasteurdeDakar,"Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020.",2022-03-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Senegal,Sédhiou,,Households in all areas of Senegal.,Hemolytic and under-filled blood samples were excluded from the serological analysis.,2020-10-25,2020-11-26,Household and community samples,All,Multiple groups,,,Geographical area,Sédhiou,57,0.474,0.34,0.61,,,,,,Simplified probability,"Omega diagnostics COVID-19 IgG ELISA,Wantai SARS-CoV-2 Total Ab ELISA","Generic Diagnostics Ltd,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Cheikh Talla,Institut Pasteur de Dakar,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897837/,2022-06-28,2024-03-01,Unverified,talla_seroprevalence_2022,SEN
220305_Senegal_InstitutPasteurdeDakar_AreaFatick,220305_Senegal_InstitutPasteurdeDakar,"Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020.",2022-03-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Senegal,Fatick,,Households in all areas of Senegal.,Hemolytic and under-filled blood samples were excluded from the serological analysis.,2020-10-25,2020-11-26,Household and community samples,All,Multiple groups,,,Geographical area,Fatick,75,0.17300000000000001,0.096,0.278,,,,,,Simplified probability,"Omega diagnostics COVID-19 IgG ELISA,Wantai SARS-CoV-2 Total Ab ELISA","Generic Diagnostics Ltd,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Cheikh Talla,Institut Pasteur de Dakar,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897837/,2022-06-28,2024-03-01,Unverified,talla_seroprevalence_2022,SEN
210709_Vojvodina_UniversityOfNoviSad_Unadj_April1_Overall,210709_Vojvodina_UniversityOfNoviSad_April1,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-04-17,2020-04-30,Household and community samples,All,Multiple groups,,,Primary Estimate,,1267,0.026000000000000002,0.018000000000000002,0.0363,True,,,,True,Stratified probability,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.873,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_Unadj_April1_65+,210709_Vojvodina_UniversityOfNoviSad_April1,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-04-17,2020-04-30,Household and community samples,All,Seniors (65+ years),65.0,,Age,65+,192,0.0313,0.011399999999999999,0.0664,,,,,,Stratified probability,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.873,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_Unadj_April1_Female,210709_Vojvodina_UniversityOfNoviSad_April1,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-04-17,2020-04-30,Household and community samples,Female,Multiple groups,,,Sex/Gender,,700,0.031400000000000004,0.0198,0.0472,,,,,,Stratified probability,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.873,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_Unadj_April1_Male,210709_Vojvodina_UniversityOfNoviSad_April1,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-04-17,2020-04-30,Household and community samples,Male,Multiple groups,,,Sex/Gender,,567,0.019,0.0094,0.0339,,,,,,Stratified probability,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.873,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_Unadj_April1_30-64,210709_Vojvodina_UniversityOfNoviSad_April1,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-04-17,2020-04-30,Household and community samples,All,Adults (18-64 years),30.0,64.0,Age,30-64,679,0.0339,0.0216,0.0504,,,,,,Stratified probability,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.873,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_Unadj_April1_5-14,210709_Vojvodina_UniversityOfNoviSad_April1,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-04-17,2020-04-30,Household and community samples,All,Children and Youth (0-17 years),5.0,14.0,Age,5-14,118,0.0169,0.002,0.059800000000000006,,,,,,Stratified probability,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.873,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_Unadj_April1_15-29,210709_Vojvodina_UniversityOfNoviSad_April1,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-04-17,2020-04-30,Household and community samples,All,Multiple groups,15.0,29.0,Age,15-29,226,0.0177,0.0048,0.0447,,,,,,Stratified probability,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.873,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_Unadj_April1_0-4,210709_Vojvodina_UniversityOfNoviSad_April1,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-04-17,2020-04-30,Household and community samples,All,Children and Youth (0-17 years),0.0,4.0,Age,0-4,52,0.0,,,,,,,,Stratified probability,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.873,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_Unadj_June3_Overall,210709_Vojvodina_UniversityOfNoviSad_June3,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-06-17,2020-06-30,Household and community samples,All,Multiple groups,,,Primary Estimate,,1014,0.0611,0.0472,0.07769999999999999,True,,,,True,Stratified probability,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8729999999999996,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_Unadj_June3_0-4,210709_Vojvodina_UniversityOfNoviSad_June3,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-06-17,2020-06-30,Household and community samples,All,Children and Youth (0-17 years),0.0,4.0,Age,0-4,32,0.0,,,,,,,,Stratified probability,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8729999999999996,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_Unadj_June3_15-29,210709_Vojvodina_UniversityOfNoviSad_June3,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-06-17,2020-06-30,Household and community samples,All,Multiple groups,15.0,29.0,Age,15-29,173,0.0636,0.0322,0.1109,,,,,,Stratified probability,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8729999999999996,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_Unadj_June3_Male,210709_Vojvodina_UniversityOfNoviSad_June3,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-06-17,2020-06-30,Household and community samples,Male,Multiple groups,,,Sex/Gender,,487,0.0458,0.028999999999999998,0.0683,,,,,,Stratified probability,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8729999999999996,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_Unadj_June3_Female,210709_Vojvodina_UniversityOfNoviSad_June3,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-06-17,2020-06-30,Household and community samples,Female,Multiple groups,,,Sex/Gender,,527,0.0608,0.042,0.08470000000000001,,,,,,Stratified probability,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8729999999999996,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_Unadj_June3_5-14,210709_Vojvodina_UniversityOfNoviSad_June3,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-06-17,2020-06-30,Household and community samples,All,Children and Youth (0-17 years),5.0,14.0,Age,5-14,67,0.029900000000000003,0.0037,0.1038,,,,,,Stratified probability,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8729999999999996,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_Unadj_June3_30-64,210709_Vojvodina_UniversityOfNoviSad_June3,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-06-17,2020-06-30,Household and community samples,All,Adults (18-64 years),30.0,64.0,Age,30-64,563,0.0693,0.0497,0.0935,,,,,,Stratified probability,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8729999999999996,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_Unadj_June3_65+,210709_Vojvodina_UniversityOfNoviSad_June3,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-06-17,2020-06-30,Household and community samples,All,Seniors (65+ years),65.0,,Age,65+,179,0.0559,0.0271,0.10039999999999999,,,,,,Stratified probability,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8729999999999996,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_Unadj_May2_Overall,210709_Vojvodina_UniversityOfNoviSad_May2,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-05-18,2020-05-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,1068,0.0393,0.0285,0.05280000000000001,True,,,,True,Stratified probability,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8729999999999996,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_Unadj_May2_65+,210709_Vojvodina_UniversityOfNoviSad_May2,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-05-18,2020-05-31,Household and community samples,All,Seniors (65+ years),65.0,,Age,65+,185,0.032400000000000005,0.012,0.0692,,,,,,Stratified probability,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8729999999999996,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_Unadj_May2_15-29,210709_Vojvodina_UniversityOfNoviSad_May2,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-05-18,2020-05-31,Household and community samples,All,Multiple groups,15.0,29.0,Age,15-29,177,0.0339,0.0125,0.0723,,,,,,Stratified probability,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8729999999999996,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_Unadj_May2_30-64,210709_Vojvodina_UniversityOfNoviSad_May2,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-05-18,2020-05-31,Household and community samples,All,Adults (18-64 years),30.0,64.0,Age,30-64,601,0.0466,0.031200000000000002,0.0666,,,,,,Stratified probability,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8729999999999996,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_Unadj_May2_0-4,210709_Vojvodina_UniversityOfNoviSad_May2,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-05-18,2020-05-31,Household and community samples,All,Children and Youth (0-17 years),0.0,4.0,Age,0-4,34,0.0,,,,,,,,Stratified probability,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8729999999999996,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_Unadj_May2_Male,210709_Vojvodina_UniversityOfNoviSad_May2,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-05-18,2020-05-31,Household and community samples,Male,Multiple groups,,,Sex/Gender,,480,0.0248,0.0128,0.043,,,,,,Stratified probability,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8729999999999996,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_Unadj_May2_5-14,210709_Vojvodina_UniversityOfNoviSad_May2,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-05-18,2020-05-31,Household and community samples,All,Children and Youth (0-17 years),5.0,14.0,Age,5-14,71,0.0282,0.0034000000000000002,0.0981,,,,,,Stratified probability,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8729999999999996,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_Unadj_May2_Female,210709_Vojvodina_UniversityOfNoviSad_May2,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-05-18,2020-05-31,Household and community samples,Female,Multiple groups,,,Sex/Gender,,588,0.0409,0.026400000000000003,0.0602,,,,,,Stratified probability,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8729999999999996,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_LFIA_September4_Overall,210709_Vojvodina_UniversityOfNoviSad_September4,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-09-17,2020-09-30,Household and community samples,All,Multiple groups,,,Primary Estimate,,1041,0.146,0.1251,0.1681,True,,,,True,Stratified probability,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8729999999999996,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_LFIA_September4_30-64,210709_Vojvodina_UniversityOfNoviSad_September4,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-09-17,2020-09-30,Household and community samples,All,Adults (18-64 years),30.0,64.0,Age,30-64,570,0.16140000000000002,0.13210000000000002,0.1942,,,,,,Stratified probability,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8729999999999996,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_MultipleTests_September4_Overall,210709_Vojvodina_UniversityOfNoviSad_September4,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-09-17,2020-09-30,Household and community samples,All,Multiple groups,,,Test used,,1041,0.16670000000000001,0.1445,0.1908,,,,,,Stratified probability,"recomLine SARS-CoV-2 IgG,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo)","Mikrogen GmbH,Innovita Biological Technology Co. Ltd",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_LFIA_September4_Male,210709_Vojvodina_UniversityOfNoviSad_September4,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-09-17,2020-09-30,Household and community samples,Male,Multiple groups,,,Sex/Gender,,458,0.1348,0.10490000000000001,0.16949999999999998,,,,,,Stratified probability,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8729999999999996,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_LFIA_September4_65+,210709_Vojvodina_UniversityOfNoviSad_September4,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-09-17,2020-09-30,Household and community samples,All,Seniors (65+ years),65.0,,Age,65+,192,0.09380000000000001,0.056600000000000004,0.1441,,,,,,Stratified probability,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8729999999999996,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_MultipleTests_September4_15-29,210709_Vojvodina_UniversityOfNoviSad_September4,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-09-17,2020-09-30,Household and community samples,All,Multiple groups,15.0,29.0,Age,15-29,173,0.21239999999999998,0.154,0.2809,,,,,,Stratified probability,"recomLine SARS-CoV-2 IgG,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo)","Mikrogen GmbH,Innovita Biological Technology Co. Ltd",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_MultipleTests_September4_Male,210709_Vojvodina_UniversityOfNoviSad_September4,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-09-17,2020-09-30,Household and community samples,Male,Multiple groups,,,Sex/Gender,,458,0.1515,0.1199,0.1877,,,,,,Stratified probability,"recomLine SARS-CoV-2 IgG,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo)","Mikrogen GmbH,Innovita Biological Technology Co. Ltd",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_MultipleTests_September4_65+,210709_Vojvodina_UniversityOfNoviSad_September4,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-09-17,2020-09-30,Household and community samples,All,Seniors (65+ years),65.0,,Age,65+,192,0.1342,0.0894,0.1907,,,,,,Stratified probability,"recomLine SARS-CoV-2 IgG,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo)","Mikrogen GmbH,Innovita Biological Technology Co. Ltd",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_LFIA_September4_0-4,210709_Vojvodina_UniversityOfNoviSad_September4,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-09-17,2020-09-30,Household and community samples,All,Children and Youth (0-17 years),0.0,4.0,Age,0-4,29,0.1034,0.021800000000000003,0.2735,,,,,,Stratified probability,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8729999999999996,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_MultipleTests_September4_Female,210709_Vojvodina_UniversityOfNoviSad_September4,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-09-17,2020-09-30,Household and community samples,Female,Multiple groups,,,Sex/Gender,,583,0.17260000000000003,0.1428,0.20579999999999998,,,,,,Stratified probability,"recomLine SARS-CoV-2 IgG,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo)","Mikrogen GmbH,Innovita Biological Technology Co. Ltd",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_MultipleTests_September4_0-4,210709_Vojvodina_UniversityOfNoviSad_September4,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-09-17,2020-09-30,Household and community samples,All,Children and Youth (0-17 years),0.0,4.0,Age,0-4,29,0.0792,0.012,0.2416,,,,,,Stratified probability,"recomLine SARS-CoV-2 IgG,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo)","Mikrogen GmbH,Innovita Biological Technology Co. Ltd",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_MultipleTests_September4_5-14,210709_Vojvodina_UniversityOfNoviSad_September4,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-09-17,2020-09-30,Household and community samples,All,Children and Youth (0-17 years),5.0,14.0,Age,5-14,77,0.1267,0.0618,0.22210000000000002,,,,,,Stratified probability,"recomLine SARS-CoV-2 IgG,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo)","Mikrogen GmbH,Innovita Biological Technology Co. Ltd",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_LFIA_September4_5-14,210709_Vojvodina_UniversityOfNoviSad_September4,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-09-17,2020-09-30,Household and community samples,All,Children and Youth (0-17 years),5.0,14.0,Age,5-14,77,0.12990000000000002,0.0641,0.2259,,,,,,Stratified probability,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8729999999999996,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_LFIA_September4_Female,210709_Vojvodina_UniversityOfNoviSad_September4,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-09-17,2020-09-30,Household and community samples,Female,Multiple groups,,,Sex/Gender,,583,0.1549,0.1265,0.1869,,,,,,Stratified probability,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8729999999999996,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_LFIA_September4_15-29,210709_Vojvodina_UniversityOfNoviSad_September4,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-09-17,2020-09-30,Household and community samples,All,Multiple groups,15.0,29.0,Age,15-29,173,0.16760000000000003,0.1152,0.2318,,,,,,Stratified probability,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8729999999999996,1.0,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
210709_Vojvodina_UniversityOfNoviSad_MultipleTests_September4_30-64,210709_Vojvodina_UniversityOfNoviSad_September4,Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.,2021-07-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Serbia,Vojvodina,,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.", Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.,2020-09-17,2020-09-30,Household and community samples,All,Adults (18-64 years),30.0,64.0,Age,30-64,570,0.1734,0.1432,0.207,,,,,,Stratified probability,"recomLine SARS-CoV-2 IgG,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo)","Mikrogen GmbH,Innovita Biological Technology Co. Ltd",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,Yes,Yes,Yes,Unclear,No,Yes,No,Unclear,Mioljub Ristic,University Of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254516,2021-07-21,2024-03-01,Verified,ristic_seroprevalence_2021,SRB
220324_UniversityOfBelgrade_Belgrade,220324_UniversityOfBelgrade_Belgrade,Workers: A Single-Center Experience,2022-03-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Serbia,,Belgrade,"All presently working HCWs were invited to participate
in the study without exclusion criteria","All presently working HCWs were invited to participate
in the study without exclusion criteria",2020-06-15,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,575,0.18300000000000002,,,True,,,,True,Convenience,Author designed (ELISA) -Unknown,,ELISA,Serum,IgG,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Marija Zdravkovic,University of Belgrade,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10040500,2022-04-22,2022-07-16,Unverified,zdravkovicCOVID19VaccinationWillingness2022,SRB
220525_Belgrade_UniversityofBelgrade_Overall_TestAdj,220525_Belgrade_UniversityofBelgrade,"Seroprevalence in health care workers during the later phase of the second wave: Results of three hospitals in Serbia, prior to vaccine administration",2022-05-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Serbia,Belgrade,Belgrade,"HCW working in three hospitals (Non-Covid Hosp, Emergency Center, and Covid Hospital)",HCW staff quarantined due to active symptoms or recent private contacts with ill persons without PPE were not included or diagnosed with COVID19 during sampling. ,2020-06-15,2020-10-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1580,0.168,,,True,True,,,True,Convenience,Author designed (ELISA) - MULTIPLEXED,,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,0.99,0.98,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,No,Ljiljana Markovic-Denic,University of Belgrade,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jiph.2022.05.009,2022-06-29,2022-07-16,Verified,markovic-denic_seroprevalence_2022,SRB
221216_Vojvodina_UniversityofNoviSad_Primary,221216_Vojvodina_UniversityofNoviSad,"Seroepidemiology of SARS-CoV-2 Virus in Healthcare Workers before Circulation of the Omicron Sublineages BA.4/BA.5 in Vojvodina, Serbia",2022-12-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Serbia,Vojvodina,,"people who worked in some of the government healthcare centers (primary, secondary, and tertiary) covering the entire territory of Vojvodina",the study participants were excluded if they reported symptoms of COVID-19 in the 14 days before sampling,2022-03-28,2022-06-10,Health care workers and caregivers,All,Multiple groups,20.0,80.0,Primary Estimate,,6936,0.9296,,,True,,,,True,Unclear,"Anti-SARS-CoV-2 QuantiVac ELISA ,LIAISON® SARS-CoV-2 TrimericS IgG","EUROIMMUN,DiaSorin",Multiple Types,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,Unclear,Yes,Yes,,Unclear,No,No,,Mioljub Ristic,University of Novi Sad,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10122168,2023-01-13,2024-03-01,Unverified,ristic_seroepidemiology_2022,SRB
211111_SierraLeone_HarvardMedicalSchool_WeightedOverall,211111_SierraLeone_HarvardMedicalSchool,"SARS-CoV-2 antibody prevalence in Sierra Leone, March 2021: a cross-sectional, nationally representative, age-stratified serosurvey",2021-11-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Sierra Leone,,,"We started by selecting individuals from the older strata in a systematic progression from house-to-house. In this method, the survey team would attempt to capture an individual of each sex in the older strata before progressing to younger strata. If there was not any individual available for the appointed age group, they would skip to the next younger age stratum and choose from that one.",,2021-03-01,2021-03-31,Household and community samples,All,Multiple groups,,,Primary Estimate,Weighted Overall,1893,0.027999999999999997,0.021,0.035,True,,True,,,Stratified probability,RightSign COVID-19 IgG/IgM Rapid Test Cassette,Hangzhou Biotest Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,1.0,1.0,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Mohamed Bailor Barrie,Harvard Medical School,Unity-Aligned,https://gh.bmj.com/content/6/11/e007271,2022-09-09,2024-03-01,Unverified,barrie_sars-cov-2_2021-1,SLE
211111_SierraLeone_HarvardMedicalSchool_PopAdj_20-39,211111_SierraLeone_HarvardMedicalSchool,"SARS-CoV-2 antibody prevalence in Sierra Leone, March 2021: a cross-sectional, nationally representative, age-stratified serosurvey",2021-11-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Sierra Leone,,,"We started by selecting individuals from the older strata in a systematic progression from house-to-house. In this method, the survey team would attempt to capture an individual of each sex in the older strata before progressing to younger strata. If there was not any individual available for the appointed age group, they would skip to the next younger age stratum and choose from that one.",,2021-03-01,2021-03-31,Household and community samples,All,Children and Youth (0-17 years),,,Age,20-39,384,0.026000000000000002,0.008,0.042,,,True,,,Stratified probability,RightSign COVID-19 IgG/IgM Rapid Test Cassette,Hangzhou Biotest Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,1.0,1.0,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Mohamed Bailor Barrie,Harvard Medical School,Unity-Aligned,https://gh.bmj.com/content/6/11/e007271,2022-09-09,2024-03-01,Unverified,barrie_sars-cov-2_2021-1,SLE
211111_SierraLeone_HarvardMedicalSchool_PopAdj_Female,211111_SierraLeone_HarvardMedicalSchool,"SARS-CoV-2 antibody prevalence in Sierra Leone, March 2021: a cross-sectional, nationally representative, age-stratified serosurvey",2021-11-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Sierra Leone,,,"We started by selecting individuals from the older strata in a systematic progression from house-to-house. In this method, the survey team would attempt to capture an individual of each sex in the older strata before progressing to younger strata. If there was not any individual available for the appointed age group, they would skip to the next younger age stratum and choose from that one.",,2021-03-01,2021-03-31,Household and community samples,Female,Multiple groups,,,Sex/Gender,Female,929,0.019,0.01,0.027999999999999997,,,True,,,Stratified probability,RightSign COVID-19 IgG/IgM Rapid Test Cassette,Hangzhou Biotest Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,1.0,1.0,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Mohamed Bailor Barrie,Harvard Medical School,Unity-Aligned,https://gh.bmj.com/content/6/11/e007271,2022-09-09,2024-03-01,Unverified,barrie_sars-cov-2_2021-1,SLE
211111_SierraLeone_HarvardMedicalSchool_PopAdj_40-59,211111_SierraLeone_HarvardMedicalSchool,"SARS-CoV-2 antibody prevalence in Sierra Leone, March 2021: a cross-sectional, nationally representative, age-stratified serosurvey",2021-11-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Sierra Leone,,,"We started by selecting individuals from the older strata in a systematic progression from house-to-house. In this method, the survey team would attempt to capture an individual of each sex in the older strata before progressing to younger strata. If there was not any individual available for the appointed age group, they would skip to the next younger age stratum and choose from that one.",,2021-03-01,2021-03-31,Household and community samples,All,Adults (18-64 years),,,Age,40-59,451,0.012,0.002,0.023,,,True,,,Stratified probability,RightSign COVID-19 IgG/IgM Rapid Test Cassette,Hangzhou Biotest Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,1.0,1.0,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Mohamed Bailor Barrie,Harvard Medical School,Unity-Aligned,https://gh.bmj.com/content/6/11/e007271,2022-09-09,2024-03-01,Unverified,barrie_sars-cov-2_2021-1,SLE
211111_SierraLeone_HarvardMedicalSchool_UnweightedOverall,211111_SierraLeone_HarvardMedicalSchool,"SARS-CoV-2 antibody prevalence in Sierra Leone, March 2021: a cross-sectional, nationally representative, age-stratified serosurvey",2021-11-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Sierra Leone,,,"We started by selecting individuals from the older strata in a systematic progression from house-to-house. In this method, the survey team would attempt to capture an individual of each sex in the older strata before progressing to younger strata. If there was not any individual available for the appointed age group, they would skip to the next younger age stratum and choose from that one.",,2021-03-01,2021-03-31,Household and community samples,All,Multiple groups,,,Analysis,Unweighted Overall,1893,0.026000000000000002,0.019,0.034,,,,,True,Stratified probability,RightSign COVID-19 IgG/IgM Rapid Test Cassette,Hangzhou Biotest Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,1.0,1.0,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Mohamed Bailor Barrie,Harvard Medical School,Unity-Aligned,https://gh.bmj.com/content/6/11/e007271,2022-09-09,2024-03-01,Unverified,barrie_sars-cov-2_2021-1,SLE
211111_SierraLeone_HarvardMedicalSchool_PopAdj_>60,211111_SierraLeone_HarvardMedicalSchool,"SARS-CoV-2 antibody prevalence in Sierra Leone, March 2021: a cross-sectional, nationally representative, age-stratified serosurvey",2021-11-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Sierra Leone,,,"We started by selecting individuals from the older strata in a systematic progression from house-to-house. In this method, the survey team would attempt to capture an individual of each sex in the older strata before progressing to younger strata. If there was not any individual available for the appointed age group, they would skip to the next younger age stratum and choose from that one.",,2021-03-01,2021-03-31,Household and community samples,All,Adults (18-64 years),,,Age,>60,359,0.044000000000000004,0.024,0.064,,,True,,,Stratified probability,RightSign COVID-19 IgG/IgM Rapid Test Cassette,Hangzhou Biotest Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,1.0,1.0,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Mohamed Bailor Barrie,Harvard Medical School,Unity-Aligned,https://gh.bmj.com/content/6/11/e007271,2022-09-09,2024-03-01,Unverified,barrie_sars-cov-2_2021-1,SLE
211111_SierraLeone_HarvardMedicalSchool_PopAdj_Male,211111_SierraLeone_HarvardMedicalSchool,"SARS-CoV-2 antibody prevalence in Sierra Leone, March 2021: a cross-sectional, nationally representative, age-stratified serosurvey",2021-11-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Sierra Leone,,,"We started by selecting individuals from the older strata in a systematic progression from house-to-house. In this method, the survey team would attempt to capture an individual of each sex in the older strata before progressing to younger strata. If there was not any individual available for the appointed age group, they would skip to the next younger age stratum and choose from that one.",,2021-03-01,2021-03-31,Household and community samples,Male,Multiple groups,,,Sex/Gender,Male,964,0.033,0.022000000000000002,0.045,,,True,,,Stratified probability,RightSign COVID-19 IgG/IgM Rapid Test Cassette,Hangzhou Biotest Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,1.0,1.0,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Mohamed Bailor Barrie,Harvard Medical School,Unity-Aligned,https://gh.bmj.com/content/6/11/e007271,2022-09-09,2024-03-01,Unverified,barrie_sars-cov-2_2021-1,SLE
211111_SierraLeone_HarvardMedicalSchool_PopAdj_10-19,211111_SierraLeone_HarvardMedicalSchool,"SARS-CoV-2 antibody prevalence in Sierra Leone, March 2021: a cross-sectional, nationally representative, age-stratified serosurvey",2021-11-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Sierra Leone,,,"We started by selecting individuals from the older strata in a systematic progression from house-to-house. In this method, the survey team would attempt to capture an individual of each sex in the older strata before progressing to younger strata. If there was not any individual available for the appointed age group, they would skip to the next younger age stratum and choose from that one.",,2021-03-01,2021-03-31,Household and community samples,All,Seniors (65+ years),,,Age,10-19,359,0.036000000000000004,0.016,0.055999999999999994,,,True,,,Stratified probability,RightSign COVID-19 IgG/IgM Rapid Test Cassette,Hangzhou Biotest Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,1.0,1.0,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Mohamed Bailor Barrie,Harvard Medical School,Unity-Aligned,https://gh.bmj.com/content/6/11/e007271,2022-09-09,2024-03-01,Unverified,barrie_sars-cov-2_2021-1,SLE
211111_SierraLeone_HarvardMedicalSchool_PopAdj_<10,211111_SierraLeone_HarvardMedicalSchool,"SARS-CoV-2 antibody prevalence in Sierra Leone, March 2021: a cross-sectional, nationally representative, age-stratified serosurvey",2021-11-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Sierra Leone,,,"We started by selecting individuals from the older strata in a systematic progression from house-to-house. In this method, the survey team would attempt to capture an individual of each sex in the older strata before progressing to younger strata. If there was not any individual available for the appointed age group, they would skip to the next younger age stratum and choose from that one.",,2021-03-01,2021-03-31,Household and community samples,All,Children and Youth (0-17 years),,,Age,<10,340,0.017,0.002,0.032,,,True,,,Stratified probability,RightSign COVID-19 IgG/IgM Rapid Test Cassette,Hangzhou Biotest Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,1.0,1.0,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Mohamed Bailor Barrie,Harvard Medical School,Unity-Aligned,https://gh.bmj.com/content/6/11/e007271,2022-09-09,2024-03-01,Unverified,barrie_sars-cov-2_2021-1,SLE
230329_Kambia_InstituteNationalResearchBiomedical_D0_Overall,230329_Kambia_InstituteNationalResearchBiomedical_D0,"Prevalence of immunoglobulin G and M to SARS-CoV-2 and other human coronaviruses in The Democratic Republic of Congo, Sierra Leone, and Uganda: A longitudinal study",2023-03-29,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Sierra Leone,,,"""staff working within primary healthcare facilities"".",,2021-03-01,2021-03-31,Health care workers and caregivers,All,Adults (18-64 years),20.0,68.0,Primary Estimate,RBD or NP; IgG or IgM,126,0.889,,,True,,,,True,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],,Yes,No,Yes,,Yes,Yes,Yes,,Bolarinde Lawal,Institute National Research biomedical,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2023.03.049,2023-03-31,2024-03-01,Unverified,lawal_prevalence_2023-1,SLE
230329_Kambia_InstituteNationalResearchBiomedical_M2_Overall,230329_Kambia_InstituteNationalResearchBiomedical_M2,"Prevalence of immunoglobulin G and M to SARS-CoV-2 and other human coronaviruses in The Democratic Republic of Congo, Sierra Leone, and Uganda: A longitudinal study",2023-03-29,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Sierra Leone,,,"""staff working within primary healthcare facilities"".",,2021-05-01,2021-05-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,RBD or NP; IgG or IgM,75,0.88,,,True,,,,True,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],,Yes,No,No,,Yes,Yes,Yes,,Bolarinde Lawal,Institute National Research biomedical,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2023.03.049,2023-03-31,2024-03-01,Unverified,lawal_prevalence_2023-1,SLE
230329_Kambia_InstituteNationalResearchBiomedical_M4_Overall,230329_Kambia_InstituteNationalResearchBiomedical_M4,"Prevalence of immunoglobulin G and M to SARS-CoV-2 and other human coronaviruses in The Democratic Republic of Congo, Sierra Leone, and Uganda: A longitudinal study",2023-03-29,Journal Article (Peer-Reviewed),Local,Prospective cohort,Sierra Leone,,,"""staff working within primary healthcare facilities"".",,2021-07-01,2021-07-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,RBD or NP; IgG or IgM,62,0.8226,,,True,,,,True,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],,Yes,No,No,,Yes,Yes,Yes,,Bolarinde Lawal,Institute National Research biomedical,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2023.03.049,2023-03-31,2024-03-01,Unverified,lawal_prevalence_2023-1,SLE
200429_Singapore_NCID_GeneralPopulation,200429_Singapore_NCID_GenPop1,Coronavirus: Community transmission in  S'pore very low,2020-04-29,News and Media,Local,Cross-sectional survey ,Singapore,,Singapore,,,2020-02-15,2020-04-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,774,0.0,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,Rei Kurohi,Singapore National Centre for Infectious Diseases,Not Unity-Aligned,https://www.straitstimes.com/singapore/health/coronavirus-community-transmission-in-spore-very-low-but-so-is-herd-immunity-says,2020-05-02,2022-07-16,Verified,kurohi_coronavirus_2020-1,SGP
200429_Singapore_Singapore_NCID_HCW,200429_Singapore_Singapore_NCID_HCW2,Coronavirus: Community transmission in  S'pore very low,2020-04-29,News and Media,Local,Cross-sectional survey ,Singapore,,Singapore,"Staff at National University Hospital, Tan Tock Seng Hospital, and NCID.",,2020-02-15,2020-04-15,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,1096,0.0,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,Rei Kurohi,Singapore National Centre for Infectious Diseases,Not Unity-Aligned,https://www.straitstimes.com/singapore/health/coronavirus-community-transmission-in-spore-very-low-but-so-is-herd-immunity-says,2020-05-02,2022-07-16,Verified,kurohi_coronavirus_2020-1,SGP
201102_Singapore_NationalCentreForInfectiousDiseases_overall,201102_Singapore_NationalCentreForInfectiousDiseases,SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study,2020-11-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Singapore,,,"All household, work, and social contacts of confirmed COVID-19 cases identified in Singapore between Jan 23 and April 3, 2020.","Contacts diagnosed with COVID-19 via symptom- based testing during quarantine were only asked to answer the risk factor questionnaire and were not approached for serology testing. We excluded individuals who were younger than 4 years, unable to answer the risk factor questionnaire because of inability to identify the index case that they were exposed to, and unable to travel to designated clinic locations for blood draw.",2020-01-23,2020-04-03,Contacts of COVID patients,All,Multiple groups,4.0,,Primary Estimate,,1150,0.038,,,True,,,,True,Entire sample,Author designed (Neutralization Assay),,Neutralization,Serum,Neutralizing,Spike,Validated by independent authors/third party/non-developers,0.9890000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Oon Tek Ng,"National Centre for Infectious Diseases, Singapore",Not Unity-Aligned,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30833-1/fulltext?dgcid=raven_jbs_etoc_email,2021-03-12,2022-07-16,Verified,ng_sars-cov-2_2021,SGP
210209_Singapore_MinistryOfHealthSingapore,210209_Singapore_MinistryOfHealthSingapore,Prevalence and Outcomes of SARS-CoV-2 Infection Among Migrant Workers in Singapore,2021-02-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Singapore,Singapore,Singapore,All migrant workers residing in a dormitory in purpose-build dormitories in Singapore. ,,2020-03-25,2020-07-25,Multiple populations,All,Adults (18-64 years),,,Primary Estimate,,135760,0.601,,,True,,,,True,Convenience,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Siemens,Abbott Laboratories,Roche Diagnostics",Multiple Types,,,,,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Iain Tan,Ministry of Health Singapore,Not Unity-Aligned,https://dx.doi.org/10.1001/jama.2020.24071,2021-03-06,2024-03-01,Verified,tan_prevalence_2021,SGP
210420_Singapore_NationalUniversityOfSingapore_Community_TestAdj,210420_Singapore_NationalUniversityOfSingapore_Community,Contrasting SARS-CoV-2 epidemics in Singapore: Cohort studies in migrant workers and the general population,2021-04-20,Preprint,National,Cross-sectional survey ,Singapore,,,Individuals taking part in the Singapore Population Health Studies  were eligible to take part in this study if they were Singapore Citizens or Permanent Residents aged >=21 years and had a stored serum sample collected prior to between January and August 2019 available for serological testing.,,2020-11-15,2020-12-15,Household and community samples,All,Multiple groups,23.0,83.0,Primary Estimate,,937,0.0016,8e-05,0.0072,True,True,,,,Convenience,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,GenScript,Neutralization,Serum,Neutralizing,,Validated by independent authors/third party/non-developers,0.8029999999999999,0.993,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear, Hannah E Clapham,National University of Singapore,Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3826194,2021-05-20,2023-08-15,Verified,clapham_contrasting_2021,SGP
210420_Singapore_NationalUniversityOfSingapore_Community_Unadj,210420_Singapore_NationalUniversityOfSingapore_Community,Contrasting SARS-CoV-2 epidemics in Singapore: Cohort studies in migrant workers and the general population,2021-04-20,Preprint,National,Cross-sectional survey ,Singapore,,,Individuals taking part in the Singapore Population Health Studies  were eligible to take part in this study if they were Singapore Citizens or Permanent Residents aged >=21 years and had a stored serum sample collected prior to between January and August 2019 available for serological testing.,,2020-11-15,2020-12-15,Household and community samples,All,Multiple groups,23.0,83.0,Analysis,,937,0.0021,,,,,,,True,Convenience,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,GenScript,Neutralization,Serum,Neutralizing,,Validated by independent authors/third party/non-developers,0.8029999999999999,0.993,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear, Hannah E Clapham,National University of Singapore,Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3826194,2021-05-20,2024-03-01,Verified,clapham_contrasting_2021,SGP
210420_Singapore_NationalUniversityOfSingapore_MigrantWorkers_TestAdj,210420_Singapore_NationalUniversityOfSingapore_MigrantWorkers,Contrasting SARS-CoV-2 epidemics in Singapore: Cohort studies in migrant workers and the general population,2021-04-20,Preprint,Local,Prospective cohort,Singapore,,,male residents of a migrant worker dormitory in Singapore,,2020-05-15,2020-06-15,Essential non-healthcare workers,Male,Adults (18-64 years),19.0,59.0,Primary Estimate,,478,0.638,0.579,0.703,True,True,,,,Simplified probability,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,GenScript,Neutralization,Serum,Neutralizing,,Validated by independent authors/third party/non-developers,0.8029999999999999,0.993,['High'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear, Hannah E Clapham,National University of Singapore,Not Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3826194,2021-05-20,2023-08-15,Verified,clapham_contrasting_2021,SGP
220216_Singapore_NationalUniversityofSingapore,220216_Singapore_NationalUniversityofSingapore,"Discrepant serological findings in SARS-CoV-2 PCR negative, hospitalised patients with fever and acute respiratory symptoms during the pandemic.",2022-02-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Singapore,Central Region of Singapore,Queenstown,Individuals hospitalized at the National University of Singapore for fever and respiratory symptoms and had a negative PCR test for COVID-19,"Patients who fulfilled the criteria (made by Singapore's Ministry of Health) for being a suspect case for COVID-19.Patients who did not undergo PCR testing, or tested PCR positive for COVID-19. ",2020-03-16,2020-06-19,Residual sera,All,Multiple groups,21.0,84.0,Primary Estimate,,51,0.156862745,,,True,,,,True,Convenience,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Elecsys® Anti‐SARS‐CoV‐2 (N)","GenScript,Roche Diagnostics",Multiple Types,Multiple Types,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,No,,Gail Cross,National University of Singapore,Not Unity-Aligned,https://dx.doi.org/10.1002/jmv.27656,2022-02-25,2024-03-01,Unverified,cross_discrepant_2022,SGP
211116_Bratislava_SlovakAcademyOfSciences,211116_Bratislava_SlovakAcademyOfSciences,Seroprevalence of SARS-CoV-2 IgG antibodies in the staff of the Slovak Academy of Sciences in response to COVID-19 and/or vaccination: situation in August 2021.,2021-11-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Slovakia,,Bratislava,"we performed a community-based crosssectional seroprevalence study in employees of the Slovak 
Academy of Sciences ",,2021-07-01,2021-08-15,Non-essential workers and unemployed persons,All,Multiple groups,,,Primary Estimate,,1928,0.8412999999999999,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.9440000000000001,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Ivana Kajanova,Slovak Academy Of Sciences,Not Unity-Aligned,https://dx.doi.org/10.4149/av_2021_407,2021-12-02,2024-03-01,Unverified,ivanakajanovaSeroprevalenceSARSCoV2IgG2021,SVK
220718_Trencin_SlovakAcademyofSciences_Overall,220718_Trencin_SlovakAcademyofSciences,Seroprevalence of SARS-CoV-2 antibodies in the county town of Slovakia - a pilot study from the Trencin city.,2022-07-18,Preprint,Local,Cross-sectional survey ,Slovakia,,Trencin,"All study participants had to meet the following inclusion criteria:
permanent residence in the city of Trencin; age 18 and over; consent to participate in the
study (signature of informed consent). ",,2022-01-20,2022-03-02,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,3013,0.7448,,,True,,,,True,Self-referral,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by manufacturers,0.9440000000000001,0.996,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Ivana Kajanova,Slovak Academy of Sciences,Not Unity-Aligned,https://dx.doi.org/10.4149/av_2022_301,2022-07-27,2024-03-01,Unverified,kajanova_seroprevalence_2022,SVK
210407_Slovenia_UniversityofLjubljana_FirstRound_GenPop_ElecsysTestAdj,210407_Slovenia_UniversityofLjubljana_FirstRound,"Seroprevalence of SARS-CoV-2 in Slovenia: results of two rounds of a nationwide population study on a probability-based sample, challenges and lessons learned",2021-04-07,Journal Article (Peer-Reviewed),National,Prospective cohort,Slovenia,,,"probability-based sample of the Slovenian population comprising data from 2.1 million people was selected from the Central Population Register (n = 3000). 
All participants provided written informed consent before enrolment and for individuals younger than 18 years a parent or legal guardian provided consent",,2020-04-20,2020-05-01,Household and community samples,All,Multiple groups,0.0,99.0,Primary Estimate,,1316,0.0087,0.004,0.0138,True,True,True,,,Simplified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,No,Mario Poljak ,University of Ljubljana,Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2021.03.009,2021-05-20,2023-08-15,Verified,poljak_seroprevalence_2021,SVN
210407_Slovenia_UniversityofLjubljana_FirstRound_GenPop_ELISATestUnadj,210407_Slovenia_UniversityofLjubljana_FirstRound,"Seroprevalence of SARS-CoV-2 in Slovenia: results of two rounds of a nationwide population study on a probability-based sample, challenges and lessons learned",2021-04-07,Journal Article (Peer-Reviewed),National,Prospective cohort,Slovenia,,,"probability-based sample of the Slovenian population comprising data from 2.1 million people was selected from the Central Population Register (n = 3000). 
All participants provided written informed consent before enrolment and for individuals younger than 18 years a parent or legal guardian provided consent",,2020-04-20,2020-05-01,Household and community samples,All,Multiple groups,0.0,99.0,Analysis,ELISA unadjusted,1316,0.0311,0.0223,0.040999999999999995,,,True,,True,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Multiple tests with diff validations or values derived from each type,0.9940000000000001,0.996,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,No,Mario Poljak ,University of Ljubljana,Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2021.03.009,2021-05-20,2024-03-01,Verified,poljak_seroprevalence_2021,SVN
210407_Slovenia_UniversityofLjubljana_SecondRound_Nov,210407_Slovenia_UniversityofLjubljana_SecondRound,"Seroprevalence of SARS-CoV-2 in Slovenia: results of two rounds of a nationwide population study on a probability-based sample, challenges and lessons learned",2021-04-07,Journal Article (Peer-Reviewed),National,Prospective cohort,Slovenia,,,"probability-based sample of the Slovenian population comprising data from 2.1 million people was selected from the Central Population Register (n = 3000). 
All participants provided written informed consent before enrolment and for individuals younger than 18 years a parent or legal guardian provided consent",,2020-10-17,2020-11-10,Household and community samples,All,Multiple groups,0.0,99.0,Primary Estimate,,1211,0.0429,0.0318,0.0547,True,,True,,True,Simplified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,No,No,Mario Poljak ,University of Ljubljana,Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2021.03.009,2021-08-05,2024-03-01,Verified,poljak_seroprevalence_2021,SVN
210407_Slovenia_UniversityofLjubljana_SecondRound_Nov_Age21to40,210407_Slovenia_UniversityofLjubljana_SecondRound,"Seroprevalence of SARS-CoV-2 in Slovenia: results of two rounds of a nationwide population study on a probability-based sample, challenges and lessons learned",2021-04-07,Journal Article (Peer-Reviewed),National,Prospective cohort,Slovenia,,,"probability-based sample of the Slovenian population comprising data from 2.1 million people was selected from the Central Population Register (n = 3000). 
All participants provided written informed consent before enrolment and for individuals younger than 18 years a parent or legal guardian provided consent",,2020-10-17,2020-11-10,Household and community samples,All,Adults (18-64 years),21.0,40.0,Age,21-40,1211,0.0601,0.0326,0.0897,,,True,,,Simplified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,No,No,Mario Poljak ,University of Ljubljana,Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2021.03.009,2021-08-05,2024-03-01,Verified,poljak_seroprevalence_2021,SVN
210407_Slovenia_UniversityofLjubljana_SecondRound_Nov_Age60plus,210407_Slovenia_UniversityofLjubljana_SecondRound,"Seroprevalence of SARS-CoV-2 in Slovenia: results of two rounds of a nationwide population study on a probability-based sample, challenges and lessons learned",2021-04-07,Journal Article (Peer-Reviewed),National,Prospective cohort,Slovenia,,,"probability-based sample of the Slovenian population comprising data from 2.1 million people was selected from the Central Population Register (n = 3000). 
All participants provided written informed consent before enrolment and for individuals younger than 18 years a parent or legal guardian provided consent",,2020-10-17,2020-11-10,Household and community samples,All,Seniors (65+ years),61.0,99.0,Age,60+,1211,0.020499999999999997,0.0074,0.0354,,,True,,,Simplified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,No,No,Mario Poljak ,University of Ljubljana,Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2021.03.009,2021-08-05,2024-03-01,Verified,poljak_seroprevalence_2021,SVN
210407_Slovenia_UniversityofLjubljana_SecondRound_Nov_Age0to20,210407_Slovenia_UniversityofLjubljana_SecondRound,"Seroprevalence of SARS-CoV-2 in Slovenia: results of two rounds of a nationwide population study on a probability-based sample, challenges and lessons learned",2021-04-07,Journal Article (Peer-Reviewed),National,Prospective cohort,Slovenia,,,"probability-based sample of the Slovenian population comprising data from 2.1 million people was selected from the Central Population Register (n = 3000). 
All participants provided written informed consent before enrolment and for individuals younger than 18 years a parent or legal guardian provided consent",,2020-10-17,2020-11-10,Household and community samples,All,Children and Youth (0-17 years),0.0,20.0,Age,0-20,1211,0.048600000000000004,0.019,0.0804,,,True,,,Simplified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,No,No,Mario Poljak ,University of Ljubljana,Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2021.03.009,2021-08-05,2024-03-01,Verified,poljak_seroprevalence_2021,SVN
210407_Slovenia_UniversityofLjubljana_SecondRound_Nov_Age41to60,210407_Slovenia_UniversityofLjubljana_SecondRound,"Seroprevalence of SARS-CoV-2 in Slovenia: results of two rounds of a nationwide population study on a probability-based sample, challenges and lessons learned",2021-04-07,Journal Article (Peer-Reviewed),National,Prospective cohort,Slovenia,,,"probability-based sample of the Slovenian population comprising data from 2.1 million people was selected from the Central Population Register (n = 3000). 
All participants provided written informed consent before enrolment and for individuals younger than 18 years a parent or legal guardian provided consent",,2020-10-17,2020-11-10,Household and community samples,All,Adults (18-64 years),41.0,60.0,Age,41-60,1211,0.0467,0.0273,0.0671,,,True,,,Simplified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,No,No,Mario Poljak ,University of Ljubljana,Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2021.03.009,2021-08-05,2024-03-01,Verified,poljak_seroprevalence_2021,SVN
220715_Slovenia_NationalInstituteofPublicHealth_Overall,220715_Slovenia_NationalInstituteofPublicHealth,Determinants of seropositivity for SARS-CoV-2 in hospital staff in the second wave of the pandemic in Slovenia.,2022-07-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Slovenia,,,"Nurses and clinicians currently employed at Novo Mesto
General Hospital (NMGH) in the south-east and Jesenice General Hospital (JGH) in the  north-west","The criteria for exclusion included
absence from the  workplace from March 1, 2020 (prolonged sick leave or maternity leave) or being a nursing/medical student.",2020-11-15,2020-12-15,Health care workers and caregivers,All,Adults (18-64 years),21.0,65.0,Primary Estimate,,813,0.204,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,1.0,0.9770000000000001,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Maja Socan,National Laboratory for Health,Not Unity-Aligned,https://dx.doi.org/10.13075/ijomeh.1896.01932,2022-07-27,2024-03-01,Unverified,socan_determinants_2022,SVN
230218_Ljubljana_NationalInstituteOfPublicHealth_Primary_AntiSorAntiN,230218_Ljubljana_NationalInstituteOfPublicHealth,Seroprevalence of Anti-SARS-CoV-2 Antibodies Following the Omicron BA.1 Wave.,2023-02-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Slovenia,,Ljubljana,"""For this cross-sectional, age-stratified seroprevalence study, a total of 2899 sera from persons aged 0–90 years were tested for anti-N and anti-S SARS-CoV-2 antibodies. The serum samples were convenient, non-random samples obtained from residual sera collected during routine laboratory testing at the National Laboratory of Health, Environment and Food (NLHEF).""",,2022-03-01,2022-06-06,Residual sera,All,Multiple groups,0.0,90.0,Primary Estimate,Anti-S or Anti-N positive,2899,0.8796,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 NCP ELISA (IgG)",EUROIMMUN,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],No,No,Yes,Yes,No,Yes,Yes,No,Unclear,Maja Socan,National Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/ijerph20043665,2023-04-11,2024-04-06,Verified,socan_seroprevalence_2023,SVN
230218_Ljubljana_NationalInstituteOfPublicHealth_AntiS_Female,230218_Ljubljana_NationalInstituteOfPublicHealth,Seroprevalence of Anti-SARS-CoV-2 Antibodies Following the Omicron BA.1 Wave.,2023-02-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Slovenia,,Ljubljana,"""For this cross-sectional, age-stratified seroprevalence study, a total of 2899 sera from persons aged 0–90 years were tested for anti-N and anti-S SARS-CoV-2 antibodies. The serum samples were convenient, non-random samples obtained from residual sera collected during routine laboratory testing at the National Laboratory of Health, Environment and Food (NLHEF).""",,2022-03-01,2022-06-06,Residual sera,Female,,,,Sex/Gender,Female,2227,0.837,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,No,Yes,Yes,No,Unclear,Maja Socan,National Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/ijerph20043665,2024-04-06,2024-04-06,Unverified,socan_seroprevalence_2023,SVN
230218_Ljubljana_NationalInstituteOfPublicHealth_AntiS_18-29,230218_Ljubljana_NationalInstituteOfPublicHealth,Seroprevalence of Anti-SARS-CoV-2 Antibodies Following the Omicron BA.1 Wave.,2023-02-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Slovenia,,Ljubljana,"""For this cross-sectional, age-stratified seroprevalence study, a total of 2899 sera from persons aged 0–90 years were tested for anti-N and anti-S SARS-CoV-2 antibodies. The serum samples were convenient, non-random samples obtained from residual sera collected during routine laboratory testing at the National Laboratory of Health, Environment and Food (NLHEF).""",,2022-03-01,2022-06-06,Residual sera,All,Adults (18-64 years),18.0,29.0,Age,18-29,748,0.814,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,No,Yes,Yes,No,Unclear,Maja Socan,National Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/ijerph20043665,2024-04-06,2024-04-06,Unverified,socan_seroprevalence_2023,SVN
230218_Ljubljana_NationalInstituteOfPublicHealth_AntiS_>69,230218_Ljubljana_NationalInstituteOfPublicHealth,Seroprevalence of Anti-SARS-CoV-2 Antibodies Following the Omicron BA.1 Wave.,2023-02-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Slovenia,,Ljubljana,"""For this cross-sectional, age-stratified seroprevalence study, a total of 2899 sera from persons aged 0–90 years were tested for anti-N and anti-S SARS-CoV-2 antibodies. The serum samples were convenient, non-random samples obtained from residual sera collected during routine laboratory testing at the National Laboratory of Health, Environment and Food (NLHEF).""",,2022-03-01,2022-06-06,Residual sera,All,Seniors (65+ years),70.0,,Age,>69,211,0.919,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,No,Yes,Yes,No,Unclear,Maja Socan,National Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/ijerph20043665,2024-04-06,2024-04-06,Unverified,socan_seroprevalence_2023,SVN
230218_Ljubljana_NationalInstituteOfPublicHealth_AntiS,230218_Ljubljana_NationalInstituteOfPublicHealth,Seroprevalence of Anti-SARS-CoV-2 Antibodies Following the Omicron BA.1 Wave.,2023-02-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Slovenia,,Ljubljana,"""For this cross-sectional, age-stratified seroprevalence study, a total of 2899 sera from persons aged 0–90 years were tested for anti-N and anti-S SARS-CoV-2 antibodies. The serum samples were convenient, non-random samples obtained from residual sera collected during routine laboratory testing at the National Laboratory of Health, Environment and Food (NLHEF).""",,2022-03-01,2022-06-06,Residual sera,All,Multiple groups,0.0,90.0,Test used,Anti-S positive,2899,0.8413,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,No,Yes,Yes,No,Unclear,Maja Socan,National Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/ijerph20043665,2023-04-11,2024-04-06,Verified,socan_seroprevalence_2023,SVN
230218_Ljubljana_NationalInstituteOfPublicHealth_AntiS_60-69,230218_Ljubljana_NationalInstituteOfPublicHealth,Seroprevalence of Anti-SARS-CoV-2 Antibodies Following the Omicron BA.1 Wave.,2023-02-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Slovenia,,Ljubljana,"""For this cross-sectional, age-stratified seroprevalence study, a total of 2899 sera from persons aged 0–90 years were tested for anti-N and anti-S SARS-CoV-2 antibodies. The serum samples were convenient, non-random samples obtained from residual sera collected during routine laboratory testing at the National Laboratory of Health, Environment and Food (NLHEF).""",,2022-03-01,2022-06-06,Residual sera,All,Multiple groups,60.0,69.0,Age,60-69,251,0.908,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,No,Yes,Yes,No,Unclear,Maja Socan,National Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/ijerph20043665,2024-04-06,2024-04-06,Unverified,socan_seroprevalence_2023,SVN
230218_Ljubljana_NationalInstituteOfPublicHealth_AntiN,230218_Ljubljana_NationalInstituteOfPublicHealth,Seroprevalence of Anti-SARS-CoV-2 Antibodies Following the Omicron BA.1 Wave.,2023-02-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Slovenia,,Ljubljana,"""For this cross-sectional, age-stratified seroprevalence study, a total of 2899 sera from persons aged 0–90 years were tested for anti-N and anti-S SARS-CoV-2 antibodies. The serum samples were convenient, non-random samples obtained from residual sera collected during routine laboratory testing at the National Laboratory of Health, Environment and Food (NLHEF).""",,2022-03-01,2022-06-06,Residual sera,All,Multiple groups,0.0,90.0,Test used,Anti-N positive,2899,0.486,,,,,,,,Convenience,Anti-SARS-CoV-2 NCP ELISA (IgG),EUROIMMUN,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['High'],No,No,Yes,Yes,No,Yes,Yes,No,Unclear,Maja Socan,National Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/ijerph20043665,2023-04-11,2024-04-06,Verified,socan_seroprevalence_2023,SVN
230218_Ljubljana_NationalInstituteOfPublicHealth_AntiS_Male,230218_Ljubljana_NationalInstituteOfPublicHealth,Seroprevalence of Anti-SARS-CoV-2 Antibodies Following the Omicron BA.1 Wave.,2023-02-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Slovenia,,Ljubljana,"""For this cross-sectional, age-stratified seroprevalence study, a total of 2899 sera from persons aged 0–90 years were tested for anti-N and anti-S SARS-CoV-2 antibodies. The serum samples were convenient, non-random samples obtained from residual sera collected during routine laboratory testing at the National Laboratory of Health, Environment and Food (NLHEF).""",,2022-03-01,2022-06-06,Residual sera,Male,,,,Sex/Gender,Male,672,0.854,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,No,Yes,Yes,No,Unclear,Maja Socan,National Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/ijerph20043665,2024-04-06,2024-04-06,Unverified,socan_seroprevalence_2023,SVN
230218_Ljubljana_NationalInstituteOfPublicHealth_AntiS_40-49,230218_Ljubljana_NationalInstituteOfPublicHealth,Seroprevalence of Anti-SARS-CoV-2 Antibodies Following the Omicron BA.1 Wave.,2023-02-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Slovenia,,Ljubljana,"""For this cross-sectional, age-stratified seroprevalence study, a total of 2899 sera from persons aged 0–90 years were tested for anti-N and anti-S SARS-CoV-2 antibodies. The serum samples were convenient, non-random samples obtained from residual sera collected during routine laboratory testing at the National Laboratory of Health, Environment and Food (NLHEF).""",,2022-03-01,2022-06-06,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,306,0.863,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,No,Yes,Yes,No,Unclear,Maja Socan,National Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/ijerph20043665,2024-04-06,2024-04-06,Unverified,socan_seroprevalence_2023,SVN
230218_Ljubljana_NationalInstituteOfPublicHealth_AntiS_50-59,230218_Ljubljana_NationalInstituteOfPublicHealth,Seroprevalence of Anti-SARS-CoV-2 Antibodies Following the Omicron BA.1 Wave.,2023-02-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Slovenia,,Ljubljana,"""For this cross-sectional, age-stratified seroprevalence study, a total of 2899 sera from persons aged 0–90 years were tested for anti-N and anti-S SARS-CoV-2 antibodies. The serum samples were convenient, non-random samples obtained from residual sera collected during routine laboratory testing at the National Laboratory of Health, Environment and Food (NLHEF).""",,2022-03-01,2022-06-06,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,327,0.899,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,No,Yes,Yes,No,Unclear,Maja Socan,National Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/ijerph20043665,2024-04-06,2024-04-06,Unverified,socan_seroprevalence_2023,SVN
230218_Ljubljana_NationalInstituteOfPublicHealth_AntiS_30-39,230218_Ljubljana_NationalInstituteOfPublicHealth,Seroprevalence of Anti-SARS-CoV-2 Antibodies Following the Omicron BA.1 Wave.,2023-02-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Slovenia,,Ljubljana,"""For this cross-sectional, age-stratified seroprevalence study, a total of 2899 sera from persons aged 0–90 years were tested for anti-N and anti-S SARS-CoV-2 antibodies. The serum samples were convenient, non-random samples obtained from residual sera collected during routine laboratory testing at the National Laboratory of Health, Environment and Food (NLHEF).""",,2022-03-01,2022-06-06,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,757,0.815,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,No,Yes,Yes,No,Unclear,Maja Socan,National Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/ijerph20043665,2024-04-06,2024-04-06,Unverified,socan_seroprevalence_2023,SVN
230218_Ljubljana_NationalInstituteOfPublicHealth_AntiS_0-17,230218_Ljubljana_NationalInstituteOfPublicHealth,Seroprevalence of Anti-SARS-CoV-2 Antibodies Following the Omicron BA.1 Wave.,2023-02-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Slovenia,,Ljubljana,"""For this cross-sectional, age-stratified seroprevalence study, a total of 2899 sera from persons aged 0–90 years were tested for anti-N and anti-S SARS-CoV-2 antibodies. The serum samples were convenient, non-random samples obtained from residual sera collected during routine laboratory testing at the National Laboratory of Health, Environment and Food (NLHEF).""",,2022-03-01,2022-06-06,Residual sera,All,Children and Youth (0-17 years),,17.0,Age,0-17,299,0.779,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,No,Yes,Yes,No,Unclear,Maja Socan,National Institute of Public Health,Unity-Aligned,https://dx.doi.org/10.3390/ijerph20043665,2024-04-06,2024-04-06,Unverified,socan_seroprevalence_2023,SVN
220130_Benadir_SIMADUniversity_Overall,220130_Benadir_SIMADUniversity,"Seroprevalence of Anti-SARS-CoV-2 Antibodies in Benadir Region, Somalia",2022-01-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Somalia,Benadir region,,"All individuals living in Benadir region aged ≥18 years were identified for potential
recruitment into the investigation; also individuals who didn’t receive the SARS-CoV-2
vaccine were recruited.","Individuals who refused to give informed consent, or from whom it was not obtainable,
were excluded from the study.",2021-05-19,2021-07-29,Household and community samples,All,Multiple groups,18.0,97.0,Primary Estimate,,2400,0.44799999999999995,,,True,,,,True,Stratified non-probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.8712000000000001,0.9974,['High'],,No,Yes,Yes,,No,Yes,No,,Mohamed Adam,SIMAD University,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10020220,2022-02-14,2024-03-01,Unverified,adam_seroprevalence_2022,SOM
220130_Benadir_SIMADUniversity_18-37,220130_Benadir_SIMADUniversity,"Seroprevalence of Anti-SARS-CoV-2 Antibodies in Benadir Region, Somalia",2022-01-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Somalia,Benadir region,,"All individuals living in Benadir region aged ≥18 years were identified for potential
recruitment into the investigation; also individuals who didn’t receive the SARS-CoV-2
vaccine were recruited.","Individuals who refused to give informed consent, or from whom it was not obtainable,
were excluded from the study.",2021-05-19,2021-07-29,Household and community samples,All,Adults (18-64 years),18.0,37.0,Age,18-37,1805,0.405,,,,,,,,Stratified non-probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.8712000000000001,0.9974,['High'],,No,Yes,Yes,,No,Yes,No,,Mohamed Adam,SIMAD University,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10020220,2022-02-14,2024-03-01,Unverified,adam_seroprevalence_2022,SOM
220130_Benadir_SIMADUniversity_Female,220130_Benadir_SIMADUniversity,"Seroprevalence of Anti-SARS-CoV-2 Antibodies in Benadir Region, Somalia",2022-01-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Somalia,Benadir region,,"All individuals living in Benadir region aged ≥18 years were identified for potential
recruitment into the investigation; also individuals who didn’t receive the SARS-CoV-2
vaccine were recruited.","Individuals who refused to give informed consent, or from whom it was not obtainable,
were excluded from the study.",2021-05-19,2021-07-29,Household and community samples,Female,Multiple groups,,,Sex/Gender,,1241,0.434,,,,,,,,Stratified non-probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.8712000000000001,0.9974,['High'],,No,Yes,Yes,,No,Yes,No,,Mohamed Adam,SIMAD University,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10020220,2022-02-14,2024-03-01,Unverified,adam_seroprevalence_2022,SOM
220130_Benadir_SIMADUniversity_78-97,220130_Benadir_SIMADUniversity,"Seroprevalence of Anti-SARS-CoV-2 Antibodies in Benadir Region, Somalia",2022-01-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Somalia,Benadir region,,"All individuals living in Benadir region aged ≥18 years were identified for potential
recruitment into the investigation; also individuals who didn’t receive the SARS-CoV-2
vaccine were recruited.","Individuals who refused to give informed consent, or from whom it was not obtainable,
were excluded from the study.",2021-05-19,2021-07-29,Household and community samples,All,Seniors (65+ years),78.0,97.0,Age,78-97,19,0.737,,,,,,,,Stratified non-probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.8712000000000001,0.9974,['High'],,No,Yes,Yes,,No,Yes,No,,Mohamed Adam,SIMAD University,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10020220,2022-02-14,2024-03-01,Unverified,adam_seroprevalence_2022,SOM
220130_Benadir_SIMADUniversity_38-57,220130_Benadir_SIMADUniversity,"Seroprevalence of Anti-SARS-CoV-2 Antibodies in Benadir Region, Somalia",2022-01-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Somalia,Benadir region,,"All individuals living in Benadir region aged ≥18 years were identified for potential
recruitment into the investigation; also individuals who didn’t receive the SARS-CoV-2
vaccine were recruited.","Individuals who refused to give informed consent, or from whom it was not obtainable,
were excluded from the study.",2021-05-19,2021-07-29,Household and community samples,All,Adults (18-64 years),38.0,57.0,Age,38-57,444,0.563,,,,,,,,Stratified non-probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.8712000000000001,0.9974,['High'],,No,Yes,Yes,,No,Yes,No,,Mohamed Adam,SIMAD University,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10020220,2022-02-14,2024-03-01,Unverified,adam_seroprevalence_2022,SOM
220130_Benadir_SIMADUniversity_58-77,220130_Benadir_SIMADUniversity,"Seroprevalence of Anti-SARS-CoV-2 Antibodies in Benadir Region, Somalia",2022-01-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Somalia,Benadir region,,"All individuals living in Benadir region aged ≥18 years were identified for potential
recruitment into the investigation; also individuals who didn’t receive the SARS-CoV-2
vaccine were recruited.","Individuals who refused to give informed consent, or from whom it was not obtainable,
were excluded from the study.",2021-05-19,2021-07-29,Household and community samples,All,Seniors (65+ years),58.0,77.0,Age,58-77,118,0.627,,,,,,,,Stratified non-probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.8712000000000001,0.9974,['High'],,No,Yes,Yes,,No,Yes,No,,Mohamed Adam,SIMAD University,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10020220,2022-02-14,2024-03-01,Unverified,adam_seroprevalence_2022,SOM
220130_Benadir_SIMADUniversity_Male,220130_Benadir_SIMADUniversity,"Seroprevalence of Anti-SARS-CoV-2 Antibodies in Benadir Region, Somalia",2022-01-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Somalia,Benadir region,,"All individuals living in Benadir region aged ≥18 years were identified for potential
recruitment into the investigation; also individuals who didn’t receive the SARS-CoV-2
vaccine were recruited.","Individuals who refused to give informed consent, or from whom it was not obtainable,
were excluded from the study.",2021-05-19,2021-07-29,Household and community samples,Male,Multiple groups,,,Sex/Gender,,1155,0.462,,,,,,,,Stratified non-probability,Finecare SARS-CoV-2 Antibody test,Guangzhou Wondfo Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.8712000000000001,0.9974,['High'],,No,Yes,Yes,,No,Yes,No,,Mohamed Adam,SIMAD University,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10020220,2022-02-14,2024-03-01,Unverified,adam_seroprevalence_2022,SOM
220609_Mogadishu_SIMADUniversity,220609_Mogadishu_SIMADUniversity,"Seroprevalence of SARS-CoV-2 virus antibodies and sociodemographic features of pregnant women in Mogadishu, Somalia: a cross-sectional survey study",2022-06-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Somalia,Banaadir,Mogadishu,"Pregnant women at the selected hospitals (major two referral hospitals for mother and child in the capital city of Mogadishu)

Women who indicated their informed consent and had no history of COVID-19 vaccination were included in the survey. ",Participants who did not consent to participate in the study + history of vaccination were excluded.,2021-07-31,2021-08-31,Pregnant or parturient women,All,Multiple groups,,,Primary Estimate,,477,0.36700000000000005,,,True,,,,True,Convenience,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.971,0.978,['High'],,No,No,No,,Yes,Yes,Yes,,Maryan Nur,SIMAD University,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-059617,2022-06-21,2024-03-01,Unverified,sh_nur_seroprevalence_2022,SOM
220915_Mogadishu_SIMADUniversity,220915_Mogadishu_SIMADUniversity,"Investigation of severe acute respiratory syndrome coronavirus 2 antibodies among the paediatric population in Mogadishu, Somalia.",2022-09-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Somalia,,Mogadishu,"""all the children attending the outpatient departments of the selected hospitals were included, regardless of their clinical status.""","""However, children with a history of COVID-19 infection were excluded.""",2021-07-26,2021-08-08,Residual sera,All,Children and Youth (0-17 years),,,Primary Estimate,,500,0.064,,,True,,,,True,Convenience,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Serum,"['IgG', 'IgM']",,,0.8712000000000001,0.9974,['High'],,No,No,Yes,,Yes,Yes,No,,Fartun Abdullahi H. Orey,SIMAD University,Not Unity-Aligned,https://dx.doi.org/10.1093/trstmh/trac088,2022-09-20,2024-03-01,Unverified,orey_investigation_2022,SOM
220915_Mogadishu_SIMADUniversity_Age_6-18,220915_Mogadishu_SIMADUniversity,"Investigation of severe acute respiratory syndrome coronavirus 2 antibodies among the paediatric population in Mogadishu, Somalia.",2022-09-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Somalia,,Mogadishu,"""all the children attending the outpatient departments of the selected hospitals were included, regardless of their clinical status.""","""However, children with a history of COVID-19 infection were excluded.""",2021-07-26,2021-08-08,Residual sera,All,Children and Youth (0-17 years),,,Age,6-18,125,0.14400000000000002,,,,,,,,Convenience,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Serum,"['IgG', 'IgM']",,,0.8712000000000001,0.9974,['High'],,No,No,Yes,,Yes,Yes,No,,Fartun Abdullahi H. Orey,SIMAD University,Not Unity-Aligned,https://dx.doi.org/10.1093/trstmh/trac088,2022-09-20,2024-03-01,Unverified,orey_investigation_2022,SOM
220915_Mogadishu_SIMADUniversity_Sex_Female,220915_Mogadishu_SIMADUniversity,"Investigation of severe acute respiratory syndrome coronavirus 2 antibodies among the paediatric population in Mogadishu, Somalia.",2022-09-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Somalia,,Mogadishu,"""all the children attending the outpatient departments of the selected hospitals were included, regardless of their clinical status.""","""However, children with a history of COVID-19 infection were excluded.""",2021-07-26,2021-08-08,Residual sera,Female,Children and Youth (0-17 years),,,Sex/Gender,,256,0.07400000000000001,,,,,,,,Convenience,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Serum,"['IgG', 'IgM']",,,0.8712000000000001,0.9974,['High'],,No,No,Yes,,Yes,Yes,No,,Fartun Abdullahi H. Orey,SIMAD University,Not Unity-Aligned,https://dx.doi.org/10.1093/trstmh/trac088,2022-09-20,2024-03-01,Unverified,orey_investigation_2022,SOM
220915_Mogadishu_SIMADUniversity_Age_<1,220915_Mogadishu_SIMADUniversity,"Investigation of severe acute respiratory syndrome coronavirus 2 antibodies among the paediatric population in Mogadishu, Somalia.",2022-09-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Somalia,,Mogadishu,"""all the children attending the outpatient departments of the selected hospitals were included, regardless of their clinical status.""","""However, children with a history of COVID-19 infection were excluded.""",2021-07-26,2021-08-08,Residual sera,All,Children and Youth (0-17 years),,,Age,,129,0.016,,,,,,,,Convenience,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Serum,"['IgG', 'IgM']",,,0.8712000000000001,0.9974,['High'],,No,No,Yes,,Yes,Yes,No,,Fartun Abdullahi H. Orey,SIMAD University,Not Unity-Aligned,https://dx.doi.org/10.1093/trstmh/trac088,2022-09-20,2024-03-01,Unverified,orey_investigation_2022,SOM
220915_Mogadishu_SIMADUniversity_Sex_Male,220915_Mogadishu_SIMADUniversity,"Investigation of severe acute respiratory syndrome coronavirus 2 antibodies among the paediatric population in Mogadishu, Somalia.",2022-09-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Somalia,,Mogadishu,"""all the children attending the outpatient departments of the selected hospitals were included, regardless of their clinical status.""","""However, children with a history of COVID-19 infection were excluded.""",2021-07-26,2021-08-08,Residual sera,Male,Children and Youth (0-17 years),,,Sex/Gender,,244,0.053,,,,,,,,Convenience,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Serum,"['IgG', 'IgM']",,,0.8712000000000001,0.9974,['High'],,No,No,Yes,,Yes,Yes,No,,Fartun Abdullahi H. Orey,SIMAD University,Not Unity-Aligned,https://dx.doi.org/10.1093/trstmh/trac088,2022-09-20,2024-03-01,Unverified,orey_investigation_2022,SOM
220915_Mogadishu_SIMADUniversity_Age_1-5,220915_Mogadishu_SIMADUniversity,"Investigation of severe acute respiratory syndrome coronavirus 2 antibodies among the paediatric population in Mogadishu, Somalia.",2022-09-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Somalia,,Mogadishu,"""all the children attending the outpatient departments of the selected hospitals were included, regardless of their clinical status.""","""However, children with a history of COVID-19 infection were excluded.""",2021-07-26,2021-08-08,Residual sera,All,Children and Youth (0-17 years),,,Age,1-5,246,0.049,,,,,,,,Convenience,OnSite COVID-19 IgG/IgM Rapid Test,"CTK Biotech, Inc.",LFIA,Serum,"['IgG', 'IgM']",,,0.8712000000000001,0.9974,['High'],,No,No,Yes,,Yes,Yes,No,,Fartun Abdullahi H. Orey,SIMAD University,Not Unity-Aligned,https://dx.doi.org/10.1093/trstmh/trac088,2022-09-20,2024-03-01,Unverified,orey_investigation_2022,SOM
230415_Somalia_FederalGovernmentOfSomalia_Overall,230415_Somalia_FederalGovernmentOfSomalia,Population-based sero-epidemiological investigation of SARS-CoV-2 infection in Somalia.,2023-04-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Somalia,"Somalia’s 18 administrative regions, including the Banadir Regional Administration and Somaliland",,"A convenience sample of participants was recruited from individuals attending outpatient and inpatient departments of public health facilities, or their accompanying family members.

We conducted this study in Somalia’s 18 administrative regions, including the Banadir Regional Administration and Somaliland, between March and July 2021.","excluded people attending respiratory disease clinics and, only one member per family was included.

Middle Juba was not included for security and operational reasons.

Individuals who were unwilling to participate (four p sons) were excluded.

Participants with missing data for a variable were excluded from the analysis for that variable.",2021-03-15,2021-07-15,Multiple general populations,All,Multiple groups,1.0,,Primary Estimate,Unweighted,2751,0.564,0.545,0.583,True,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.967,0.975,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Md Shajib Hossain,Federal Government of Somalia,Unity-Aligned,https://dx.doi.org/10.1016/j.jiph.2023.04.016,2023-05-29,2024-04-21,Verified,hossain_population-based_2023,SOM
230415_Somalia_FederalGovernmentOfSomalia_40-49yrs,230415_Somalia_FederalGovernmentOfSomalia,Population-based sero-epidemiological investigation of SARS-CoV-2 infection in Somalia.,2023-04-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Somalia,"Somalia’s 18 administrative regions, including the Banadir Regional Administration and Somaliland",,"A convenience sample of participants was recruited from individuals attending outpatient and inpatient departments of public health facilities, or their accompanying family members.

We conducted this study in Somalia’s 18 administrative regions, including the Banadir Regional Administration and Somaliland, between March and July 2021.","excluded people attending respiratory disease clinics and, only one member per family was included.

Middle Juba was not included for security and operational reasons.

Individuals who were unwilling to participate (four p sons) were excluded.

Participants with missing data for a variable were excluded from the analysis for that variable.",2021-03-15,2021-07-15,Multiple general populations,All,Adults (18-64 years),40.0,49.0,Age,40-49yrs,122,0.672,0.587,0.758,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.967,0.975,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Md Shajib Hossain,Federal Government of Somalia,Unity-Aligned,https://dx.doi.org/10.1016/j.jiph.2023.04.016,2024-04-21,2024-04-21,Verified,hossain_population-based_2023,SOM
230415_Somalia_FederalGovernmentOfSomalia_1-4yrs,230415_Somalia_FederalGovernmentOfSomalia,Population-based sero-epidemiological investigation of SARS-CoV-2 infection in Somalia.,2023-04-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Somalia,"Somalia’s 18 administrative regions, including the Banadir Regional Administration and Somaliland",,"A convenience sample of participants was recruited from individuals attending outpatient and inpatient departments of public health facilities, or their accompanying family members.

We conducted this study in Somalia’s 18 administrative regions, including the Banadir Regional Administration and Somaliland, between March and July 2021.","excluded people attending respiratory disease clinics and, only one member per family was included.

Middle Juba was not included for security and operational reasons.

Individuals who were unwilling to participate (four p sons) were excluded.

Participants with missing data for a variable were excluded from the analysis for that variable.",2021-03-15,2021-07-15,Multiple general populations,All,Children and Youth (0-17 years),1.0,4.0,Age,1-4yrs,325,0.458,0.403,0.514,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.967,0.975,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Md Shajib Hossain,Federal Government of Somalia,Unity-Aligned,https://dx.doi.org/10.1016/j.jiph.2023.04.016,2024-04-21,2024-04-21,Verified,hossain_population-based_2023,SOM
230415_Somalia_FederalGovernmentOfSomalia_10-19yrs,230415_Somalia_FederalGovernmentOfSomalia,Population-based sero-epidemiological investigation of SARS-CoV-2 infection in Somalia.,2023-04-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Somalia,"Somalia’s 18 administrative regions, including the Banadir Regional Administration and Somaliland",,"A convenience sample of participants was recruited from individuals attending outpatient and inpatient departments of public health facilities, or their accompanying family members.

We conducted this study in Somalia’s 18 administrative regions, including the Banadir Regional Administration and Somaliland, between March and July 2021.","excluded people attending respiratory disease clinics and, only one member per family was included.

Middle Juba was not included for security and operational reasons.

Individuals who were unwilling to participate (four p sons) were excluded.

Participants with missing data for a variable were excluded from the analysis for that variable.",2021-03-15,2021-07-15,Multiple general populations,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19yrs,615,0.582,0.543,0.622,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.967,0.975,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Md Shajib Hossain,Federal Government of Somalia,Unity-Aligned,https://dx.doi.org/10.1016/j.jiph.2023.04.016,2024-04-21,2024-04-21,Verified,hossain_population-based_2023,SOM
230415_Somalia_FederalGovernmentOfSomalia_50+yrs,230415_Somalia_FederalGovernmentOfSomalia,Population-based sero-epidemiological investigation of SARS-CoV-2 infection in Somalia.,2023-04-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Somalia,"Somalia’s 18 administrative regions, including the Banadir Regional Administration and Somaliland",,"A convenience sample of participants was recruited from individuals attending outpatient and inpatient departments of public health facilities, or their accompanying family members.

We conducted this study in Somalia’s 18 administrative regions, including the Banadir Regional Administration and Somaliland, between March and July 2021.","excluded people attending respiratory disease clinics and, only one member per family was included.

Middle Juba was not included for security and operational reasons.

Individuals who were unwilling to participate (four p sons) were excluded.

Participants with missing data for a variable were excluded from the analysis for that variable.",2021-03-15,2021-07-15,Multiple general populations,All,Multiple groups,50.0,,Age,50+yrs,302,0.63,0.573,0.686,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.967,0.975,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Md Shajib Hossain,Federal Government of Somalia,Unity-Aligned,https://dx.doi.org/10.1016/j.jiph.2023.04.016,2024-04-21,2024-04-21,Verified,hossain_population-based_2023,SOM
230415_Somalia_FederalGovernmentOfSomalia_20-29yrs,230415_Somalia_FederalGovernmentOfSomalia,Population-based sero-epidemiological investigation of SARS-CoV-2 infection in Somalia.,2023-04-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Somalia,"Somalia’s 18 administrative regions, including the Banadir Regional Administration and Somaliland",,"A convenience sample of participants was recruited from individuals attending outpatient and inpatient departments of public health facilities, or their accompanying family members.

We conducted this study in Somalia’s 18 administrative regions, including the Banadir Regional Administration and Somaliland, between March and July 2021.","excluded people attending respiratory disease clinics and, only one member per family was included.

Middle Juba was not included for security and operational reasons.

Individuals who were unwilling to participate (four p sons) were excluded.

Participants with missing data for a variable were excluded from the analysis for that variable.",2021-03-15,2021-07-15,Multiple general populations,All,Adults (18-64 years),20.0,29.0,Age,20-29yrs,482,0.634,0.589,0.678,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.967,0.975,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Md Shajib Hossain,Federal Government of Somalia,Unity-Aligned,https://dx.doi.org/10.1016/j.jiph.2023.04.016,2024-04-21,2024-04-21,Verified,hossain_population-based_2023,SOM
230415_Somalia_FederalGovernmentOfSomalia_5-9yrs,230415_Somalia_FederalGovernmentOfSomalia,Population-based sero-epidemiological investigation of SARS-CoV-2 infection in Somalia.,2023-04-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Somalia,"Somalia’s 18 administrative regions, including the Banadir Regional Administration and Somaliland",,"A convenience sample of participants was recruited from individuals attending outpatient and inpatient departments of public health facilities, or their accompanying family members.

We conducted this study in Somalia’s 18 administrative regions, including the Banadir Regional Administration and Somaliland, between March and July 2021.","excluded people attending respiratory disease clinics and, only one member per family was included.

Middle Juba was not included for security and operational reasons.

Individuals who were unwilling to participate (four p sons) were excluded.

Participants with missing data for a variable were excluded from the analysis for that variable.",2021-03-15,2021-07-15,Multiple general populations,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9yrs,278,0.5,0.44,0.56,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.967,0.975,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Md Shajib Hossain,Federal Government of Somalia,Unity-Aligned,https://dx.doi.org/10.1016/j.jiph.2023.04.016,2024-04-21,2024-04-21,Verified,hossain_population-based_2023,SOM
230415_Somalia_FederalGovernmentOfSomalia_30-39yrs,230415_Somalia_FederalGovernmentOfSomalia,Population-based sero-epidemiological investigation of SARS-CoV-2 infection in Somalia.,2023-04-15,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Somalia,"Somalia’s 18 administrative regions, including the Banadir Regional Administration and Somaliland",,"A convenience sample of participants was recruited from individuals attending outpatient and inpatient departments of public health facilities, or their accompanying family members.

We conducted this study in Somalia’s 18 administrative regions, including the Banadir Regional Administration and Somaliland, between March and July 2021.","excluded people attending respiratory disease clinics and, only one member per family was included.

Middle Juba was not included for security and operational reasons.

Individuals who were unwilling to participate (four p sons) were excluded.

Participants with missing data for a variable were excluded from the analysis for that variable.",2021-03-15,2021-07-15,Multiple general populations,All,Adults (18-64 years),30.0,39.0,Age,30-39yrs,294,0.655,0.599,0.711,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.967,0.975,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Md Shajib Hossain,Federal Government of Somalia,Unity-Aligned,https://dx.doi.org/10.1016/j.jiph.2023.04.016,2024-04-21,2024-04-21,Verified,hossain_population-based_2023,SOM
200928_CapeTown_UniversityofCapeTown_overall_testadj,200928_CapeTown_UniversityofCapeTown,SARS-CoV-2 Seroprevalence in the Cape Town Metropolitan sub-districts after the peak of infectons,2020-09-20,Institutional Report,Local,Cross-sectional survey ,South Africa,,Cape Town,"The sero-survey was conducted using residual serum and plasma from non-COVID-19 related, routine diagnostic samples over a 21-day period 3 weeks after the peak of lab-confirmed cases. The source of the residual samples was pregnant women who required blood grouping as part of standard antenatal care, and persons living with HIV (PLWHIV) who underwent routine annual viral load monitoring at public sector clinics",,2020-06-15,2020-08-07,Residual sera,All,Adults (18-64 years),,,Primary Estimate,,2791,0.446,0.42600000000000005,0.466,True,True,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.912,0.997,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Marvin Hsiao, University of Cape Town,Unity-Aligned,https://www.nicd.ac.za/wp-content/uploads/2020/09/COVID-19-Special-Public-Health-Surveillance-Bulletin_Issue-5.pdf,2021-03-03,2023-07-04,Verified,hsiao_sars-cov-2_2020,ZAF
200928_CapeTown_UniversityofCapeTown_male,200928_CapeTown_UniversityofCapeTown,SARS-CoV-2 Seroprevalence in the Cape Town Metropolitan sub-districts after the peak of infectons,2020-09-20,Institutional Report,Local,Cross-sectional survey ,South Africa,,Cape Town,"The sero-survey was conducted using residual serum and plasma from non-COVID-19 related, routine diagnostic samples over a 21-day period 3 weeks after the peak of lab-confirmed cases. The source of the residual samples was pregnant women who required blood grouping as part of standard antenatal care, and persons living with HIV (PLWHIV) who underwent routine annual viral load monitoring at public sector clinics",,2020-06-15,2020-08-07,Residual sera,Male,Adults (18-64 years),,,Sex/Gender,,518,0.32799999999999996,0.28800000000000003,0.369,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.912,0.997,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Marvin Hsiao, University of Cape Town,Unity-Aligned,https://www.nicd.ac.za/wp-content/uploads/2020/09/COVID-19-Special-Public-Health-Surveillance-Bulletin_Issue-5.pdf,2021-03-03,2024-03-01,Verified,hsiao_sars-cov-2_2020,ZAF
200928_CapeTown_UniversityofCapeTown_age20-50,200928_CapeTown_UniversityofCapeTown,SARS-CoV-2 Seroprevalence in the Cape Town Metropolitan sub-districts after the peak of infectons,2020-09-20,Institutional Report,Local,Cross-sectional survey ,South Africa,,Cape Town,"The sero-survey was conducted using residual serum and plasma from non-COVID-19 related, routine diagnostic samples over a 21-day period 3 weeks after the peak of lab-confirmed cases. The source of the residual samples was pregnant women who required blood grouping as part of standard antenatal care, and persons living with HIV (PLWHIV) who underwent routine annual viral load monitoring at public sector clinics",,2020-06-15,2020-08-07,Residual sera,All,Adults (18-64 years),20.0,50.0,Age,20-50,2349,0.41100000000000003,0.391,0.43100000000000005,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.912,0.997,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Marvin Hsiao, University of Cape Town,Unity-Aligned,https://www.nicd.ac.za/wp-content/uploads/2020/09/COVID-19-Special-Public-Health-Surveillance-Bulletin_Issue-5.pdf,2021-03-03,2024-03-01,Verified,hsiao_sars-cov-2_2020,ZAF
200928_CapeTown_UniversityofCapeTown_age<20,200928_CapeTown_UniversityofCapeTown,SARS-CoV-2 Seroprevalence in the Cape Town Metropolitan sub-districts after the peak of infectons,2020-09-20,Institutional Report,Local,Cross-sectional survey ,South Africa,,Cape Town,"The sero-survey was conducted using residual serum and plasma from non-COVID-19 related, routine diagnostic samples over a 21-day period 3 weeks after the peak of lab-confirmed cases. The source of the residual samples was pregnant women who required blood grouping as part of standard antenatal care, and persons living with HIV (PLWHIV) who underwent routine annual viral load monitoring at public sector clinics",,2020-06-15,2020-08-07,Residual sera,All,Adults (18-64 years),,19.0,Age,< 20 ,151,0.358,0.28,0.435,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.912,0.997,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Marvin Hsiao, University of Cape Town,Unity-Aligned,https://www.nicd.ac.za/wp-content/uploads/2020/09/COVID-19-Special-Public-Health-Surveillance-Bulletin_Issue-5.pdf,2021-03-03,2024-03-01,Verified,hsiao_sars-cov-2_2020,ZAF
200928_CapeTown_UniversityofCapeTown_female,200928_CapeTown_UniversityofCapeTown,SARS-CoV-2 Seroprevalence in the Cape Town Metropolitan sub-districts after the peak of infectons,2020-09-20,Institutional Report,Local,Cross-sectional survey ,South Africa,,Cape Town,"The sero-survey was conducted using residual serum and plasma from non-COVID-19 related, routine diagnostic samples over a 21-day period 3 weeks after the peak of lab-confirmed cases. The source of the residual samples was pregnant women who required blood grouping as part of standard antenatal care, and persons living with HIV (PLWHIV) who underwent routine annual viral load monitoring at public sector clinics",,2020-06-15,2020-08-07,Residual sera,Female,Adults (18-64 years),,,Sex/Gender,Female,2240,0.42100000000000004,0.401,0.44200000000000006,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.912,0.997,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Marvin Hsiao, University of Cape Town,Unity-Aligned,https://www.nicd.ac.za/wp-content/uploads/2020/09/COVID-19-Special-Public-Health-Surveillance-Bulletin_Issue-5.pdf,2021-03-03,2024-03-01,Verified,hsiao_sars-cov-2_2020,ZAF
200928_CapeTown_UniversityofCapeTown_age>50,200928_CapeTown_UniversityofCapeTown,SARS-CoV-2 Seroprevalence in the Cape Town Metropolitan sub-districts after the peak of infectons,2020-09-20,Institutional Report,Local,Cross-sectional survey ,South Africa,,Cape Town,"The sero-survey was conducted using residual serum and plasma from non-COVID-19 related, routine diagnostic samples over a 21-day period 3 weeks after the peak of lab-confirmed cases. The source of the residual samples was pregnant women who required blood grouping as part of standard antenatal care, and persons living with HIV (PLWHIV) who underwent routine annual viral load monitoring at public sector clinics",,2020-06-15,2020-08-07,Residual sera,All,Adults (18-64 years),51.0,,Age,>50,291,0.354,0.299,0.409,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.912,0.997,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Marvin Hsiao, University of Cape Town,Unity-Aligned,https://www.nicd.ac.za/wp-content/uploads/2020/09/COVID-19-Special-Public-Health-Surveillance-Bulletin_Issue-5.pdf,2021-03-03,2024-03-01,Verified,hsiao_sars-cov-2_2020,ZAF
200928_CapeTown_UniversityofCapeTown_overall_unadj,200928_CapeTown_UniversityofCapeTown,SARS-CoV-2 Seroprevalence in the Cape Town Metropolitan sub-districts after the peak of infectons,2020-09-20,Institutional Report,Local,Cross-sectional survey ,South Africa,,Cape Town,"The sero-survey was conducted using residual serum and plasma from non-COVID-19 related, routine diagnostic samples over a 21-day period 3 weeks after the peak of lab-confirmed cases. The source of the residual samples was pregnant women who required blood grouping as part of standard antenatal care, and persons living with HIV (PLWHIV) who underwent routine annual viral load monitoring at public sector clinics",,2020-06-15,2020-08-07,Residual sera,All,Adults (18-64 years),,,Analysis,,2791,0.402,0.384,0.42100000000000004,,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.912,0.997,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Marvin Hsiao, University of Cape Town,Unity-Aligned,https://www.nicd.ac.za/wp-content/uploads/2020/09/COVID-19-Special-Public-Health-Surveillance-Bulletin_Issue-5.pdf,2021-03-03,2024-03-01,Verified,hsiao_sars-cov-2_2020,ZAF
210107_CapeTown_UniversityCollegeLondon_PaediatricHCW,210107_CapeTown_UniversityCollegeLondon,Cross Sectional Prevalence of SARS-CoV-2 antibodies in Health Care Workers in Paediatric Facilities in Eight Countries,2021-01-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,South Africa,,Capetown,"This was part of a larger study undertaken in HCWs in paediatric facilities in seven European sites and one South African site. Staff of all categories in each healthcare setting were invited to join the study, irrespective of symptoms or whether they suspected they had previously had COVID-19. ",,2020-06-10,2020-08-17,Health care workers and caregivers,All,Adults (18-64 years),19.0,67.0,Primary Estimate,,222,0.1036,0.07,0.1507,True,,,,True,Convenience,"EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit,Meso Scale Discovery multiplex assay","Epitope Diagnostics, Inc.,Meso Scale Discovery",ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,No,No,Unclear,Yes,Yes,No,Unclear,D Goldblatt,University College London,Not Unity-Aligned,http://dx.doi.org/10.1016/j.jhin.2020.12.019,2021-03-13,2024-03-01,Verified,goldblatt_cross-sectional_2021,ZAF
210225_CapeTown_StellenboschUniversity_Overall,210225_CapeTown_StellenboschUniversity,"Higher SARS-CoV-2 seroprevalence in workers with lower socioeconomic status in Cape Town, South Africa",2021-02-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,South Africa,,Cape Town,"The workforce from which our volunteer sample was drawn included approximately 1200 workers either directly employed by the V&A Waterfront, by one of the various museums and attractions on site, or by one of the companies acting as service providers. The volunteers were contacted and scheduled through their internal business communications structures.",Volunteers were excluded if they had any symptoms of or known exposure to COVID-19 in the pre- vious 10 days. ,2020-08-17,2020-09-04,Essential non-healthcare workers,All,Adults (18-64 years),18.0,69.0,Primary Estimate,Employed at shopping and tourist destination,405,0.237,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,0.9854,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,No,Jane Shaw,Stellenbosch University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0247852,2021-03-27,2024-03-01,Verified,shaw_higher_2021,ZAF
210505_Johannesburg_UniversityoftheWitwatersrand,210505_Johannesburg_UniversityoftheWitwatersrand,SARS-CoV-2 infection among healthcare workers in South Africa: a longitudinal cohort study.,2021-05-05,Journal Article (Peer-Reviewed),Local,Prospective cohort,South Africa,Gauteng Province,Johannesburg,"We enrolled HCWs across five departments, including Internal Medicine (IM), Intensive Care,
Paediatrics, Obstetrics & Gynaecology, and the Vaccines and Infectious Diseases Analytics (VIDA)
research unit, at Chris Hani Baragwanath Academic Hospital (CHBAH) in South Africa",,2020-04-22,2020-09-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,HCWs,395,0.413,,,True,,,,True,Convenience,Author designed (Luminex),,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,No,Yes,Yes,Unclear,Yes,Yes,Unclear,Marta Nunes,University of the Witwatersrand,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab398,2021-05-29,2022-07-16,Verified,nunes_sars-cov-2_2021,ZAF
210706_SouthAfrica_SouthAfricanNationalBloodService_Overall_PopAdj,210706_SouthAfrica_SouthAfricanNationalBloodService,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in South Africa during the period January-May 2021,2021-07-06,Preprint,National,Cross-sectional survey ,South Africa,,,"All donors who underwent and passed routine screening through a self-administered questionnaire, one-on-one assessment and a mini-health screening by blood centre staff","Donors who did not meet the routine donor eligibility criteria were excluded from donation and therefore
from the study. Contact with persons infected by COVID-19, unresolved COVID-19 infection or
COVID-19-like symptoms in the preceding 14 days resulted in temporary deferral of potential donors",2021-01-15,2021-05-15,Blood donors,All,Multiple groups,15.0,69.0,Primary Estimate,overall 15-69,16762,0.474,0.462,0.48600000000000004,True,,True,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.995,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Marion Vermeulen,South African National Blood Service,Unity-Aligned,https://assets.researchsquare.com/files/rs-690372/v2_covered.pdf?c=1627923426,2021-07-13,2024-03-01,Verified,vermeulen_prevalence_2021,ZAF
210706_SouthAfrica_SouthAfricanNationalBloodService_Gauteng_PopAd,210706_SouthAfrica_SouthAfricanNationalBloodService,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in South Africa during the period January-May 2021,2021-07-06,Preprint,Regional,Cross-sectional survey ,South Africa,Gauteng,,"All donors who underwent and passed routine screening through a self-administered questionnaire, one-on-one assessment and a mini-health screening by blood centre staff","Donors who did not meet the routine donor eligibility criteria were excluded from donation and therefore
from the study. Contact with persons infected by COVID-19, unresolved COVID-19 infection or
COVID-19-like symptoms in the preceding 14 days resulted in temporary deferral of potential donors",2021-01-15,2021-05-15,Blood donors,All,Multiple groups,15.0,69.0,Geographical area,Gauteng,6202,0.438,0.423,0.454,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.995,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Marion Vermeulen,South African National Blood Service,Unity-Aligned,https://assets.researchsquare.com/files/rs-690372/v2_covered.pdf?c=1627923426,2021-07-13,2024-03-01,Verified,vermeulen_prevalence_2021,ZAF
210706_SouthAfrica_SouthAfricanNationalBloodService_NorthernCape_PopAdj,210706_SouthAfrica_SouthAfricanNationalBloodService,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in South Africa during the period January-May 2021,2021-07-06,Preprint,Regional,Cross-sectional survey ,South Africa,Northern Cape,,"All donors who underwent and passed routine screening through a self-administered questionnaire, one-on-one assessment and a mini-health screening by blood centre staff","Donors who did not meet the routine donor eligibility criteria were excluded from donation and therefore
from the study. Contact with persons infected by COVID-19, unresolved COVID-19 infection or
COVID-19-like symptoms in the preceding 14 days resulted in temporary deferral of potential donors",2021-01-15,2021-05-15,Blood donors,All,Multiple groups,15.0,69.0,Geographical area,Northern Cape,467,0.318,0.257,0.38,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.995,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Marion Vermeulen,South African National Blood Service,Unity-Aligned,https://assets.researchsquare.com/files/rs-690372/v2_covered.pdf?c=1627923426,2021-07-13,2024-03-01,Verified,vermeulen_prevalence_2021,ZAF
210706_SouthAfrica_SouthAfricanNationalBloodService_Mpumalanga_PopAdj,210706_SouthAfrica_SouthAfricanNationalBloodService,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in South Africa during the period January-May 2021,2021-07-06,Preprint,Regional,Cross-sectional survey ,South Africa,Mpumalanga,,"All donors who underwent and passed routine screening through a self-administered questionnaire, one-on-one assessment and a mini-health screening by blood centre staff","Donors who did not meet the routine donor eligibility criteria were excluded from donation and therefore
from the study. Contact with persons infected by COVID-19, unresolved COVID-19 infection or
COVID-19-like symptoms in the preceding 14 days resulted in temporary deferral of potential donors",2021-01-15,2021-05-15,Blood donors,All,Multiple groups,15.0,69.0,Geographical area,Mpumalanga,1695,0.47600000000000003,0.445,0.508,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.995,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Marion Vermeulen,South African National Blood Service,Unity-Aligned,https://assets.researchsquare.com/files/rs-690372/v2_covered.pdf?c=1627923426,2021-07-13,2024-03-01,Verified,vermeulen_prevalence_2021,ZAF
210706_SouthAfrica_SouthAfricanNationalBloodService_KwaZulu-Natal_PopAdj,210706_SouthAfrica_SouthAfricanNationalBloodService,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in South Africa during the period January-May 2021,2021-07-06,Preprint,Regional,Cross-sectional survey ,South Africa,KwaZulu Natal,,"All donors who underwent and passed routine screening through a self-administered questionnaire, one-on-one assessment and a mini-health screening by blood centre staff","Donors who did not meet the routine donor eligibility criteria were excluded from donation and therefore
from the study. Contact with persons infected by COVID-19, unresolved COVID-19 infection or
COVID-19-like symptoms in the preceding 14 days resulted in temporary deferral of potential donors",2021-01-15,2021-05-15,Blood donors,All,Multiple groups,15.0,69.0,Geographical area,KwaZulu-Natal,2107,0.521,0.49100000000000005,0.551,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.995,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Marion Vermeulen,South African National Blood Service,Unity-Aligned,https://assets.researchsquare.com/files/rs-690372/v2_covered.pdf?c=1627923426,2021-07-13,2024-03-01,Verified,vermeulen_prevalence_2021,ZAF
210706_SouthAfrica_SouthAfricanNationalBloodService_EasternCape_PopAdj,210706_SouthAfrica_SouthAfricanNationalBloodService,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in South Africa during the period January-May 2021,2021-07-06,Preprint,Regional,Cross-sectional survey ,South Africa,Eastern Cape,,"All donors who underwent and passed routine screening through a self-administered questionnaire, one-on-one assessment and a mini-health screening by blood centre staff","Donors who did not meet the routine donor eligibility criteria were excluded from donation and therefore
from the study. Contact with persons infected by COVID-19, unresolved COVID-19 infection or
COVID-19-like symptoms in the preceding 14 days resulted in temporary deferral of potential donors",2021-01-15,2021-05-15,Blood donors,All,Multiple groups,15.0,69.0,Geographical area,Eastern Cape,1465,0.625,0.588,0.659,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.995,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Marion Vermeulen,South African National Blood Service,Unity-Aligned,https://assets.researchsquare.com/files/rs-690372/v2_covered.pdf?c=1627923426,2021-07-13,2024-03-01,Verified,vermeulen_prevalence_2021,ZAF
210706_SouthAfrica_SouthAfricanNationalBloodService_FreeState_PopAdj,210706_SouthAfrica_SouthAfricanNationalBloodService,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in South Africa during the period January-May 2021,2021-07-06,Preprint,Regional,Cross-sectional survey ,South Africa,Free State,,"All donors who underwent and passed routine screening through a self-administered questionnaire, one-on-one assessment and a mini-health screening by blood centre staff","Donors who did not meet the routine donor eligibility criteria were excluded from donation and therefore
from the study. Contact with persons infected by COVID-19, unresolved COVID-19 infection or
COVID-19-like symptoms in the preceding 14 days resulted in temporary deferral of potential donors",2021-01-15,2021-05-15,Blood donors,All,Multiple groups,15.0,69.0,Geographical area,Free State,1082,0.478,0.428,0.53,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.995,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Marion Vermeulen,South African National Blood Service,Unity-Aligned,https://assets.researchsquare.com/files/rs-690372/v2_covered.pdf?c=1627923426,2021-07-13,2024-03-01,Verified,vermeulen_prevalence_2021,ZAF
210706_SouthAfrica_SouthAfricanNationalBloodService_WesternCape_PopAdj,210706_SouthAfrica_SouthAfricanNationalBloodService,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in South Africa during the period January-May 2021,2021-07-06,Preprint,Regional,Cross-sectional survey ,South Africa,Western Cape,,"All donors who underwent and passed routine screening through a self-administered questionnaire, one-on-one assessment and a mini-health screening by blood centre staff","Donors who did not meet the routine donor eligibility criteria were excluded from donation and therefore
from the study. Contact with persons infected by COVID-19, unresolved COVID-19 infection or
COVID-19-like symptoms in the preceding 14 days resulted in temporary deferral of potential donors",2021-01-15,2021-05-15,Blood donors,All,Multiple groups,15.0,69.0,Geographical area,Western Cape,2299,0.374,0.334,0.414,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.995,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Marion Vermeulen,South African National Blood Service,Unity-Aligned,https://assets.researchsquare.com/files/rs-690372/v2_covered.pdf?c=1627923426,2021-07-13,2024-03-01,Verified,vermeulen_prevalence_2021,ZAF
210706_SouthAfrica_SouthAfricanNationalBloodService_Limpopo_PopAdj,210706_SouthAfrica_SouthAfricanNationalBloodService,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in South Africa during the period January-May 2021,2021-07-06,Preprint,Regional,Cross-sectional survey ,South Africa,Limpopo,,"All donors who underwent and passed routine screening through a self-administered questionnaire, one-on-one assessment and a mini-health screening by blood centre staff","Donors who did not meet the routine donor eligibility criteria were excluded from donation and therefore
from the study. Contact with persons infected by COVID-19, unresolved COVID-19 infection or
COVID-19-like symptoms in the preceding 14 days resulted in temporary deferral of potential donors",2021-01-15,2021-05-15,Blood donors,All,Multiple groups,15.0,69.0,Geographical area,Limpopo,711,0.46299999999999997,0.413,0.512,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.995,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Marion Vermeulen,South African National Blood Service,Unity-Aligned,https://assets.researchsquare.com/files/rs-690372/v2_covered.pdf?c=1627923426,2021-07-13,2024-03-01,Verified,vermeulen_prevalence_2021,ZAF
210706_SouthAfrica_SouthAfricanNationalBloodService_Northwest_PopAdj,210706_SouthAfrica_SouthAfricanNationalBloodService,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in South Africa during the period January-May 2021,2021-07-06,Preprint,Regional,Cross-sectional survey ,South Africa,Northwest,,"All donors who underwent and passed routine screening through a self-administered questionnaire, one-on-one assessment and a mini-health screening by blood centre staff","Donors who did not meet the routine donor eligibility criteria were excluded from donation and therefore
from the study. Contact with persons infected by COVID-19, unresolved COVID-19 infection or
COVID-19-like symptoms in the preceding 14 days resulted in temporary deferral of potential donors",2021-01-15,2021-05-15,Blood donors,All,Multiple groups,15.0,69.0,Geographical area,Northwest,732,0.485,0.425,0.546,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.995,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Marion Vermeulen,South African National Blood Service,Unity-Aligned,https://assets.researchsquare.com/files/rs-690372/v2_covered.pdf?c=1627923426,2021-07-13,2024-03-01,Verified,vermeulen_prevalence_2021,ZAF
210706_SouthAfrica_SouthAfricanNationalBloodService_Female,210706_SouthAfrica_SouthAfricanNationalBloodService,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in South Africa during the period January-May 2021,2021-07-06,Preprint,National,Cross-sectional survey ,South Africa,,,"All donors who underwent and passed routine screening through a self-administered questionnaire, one-on-one assessment and a mini-health screening by blood centre staff","Donors who did not meet the routine donor eligibility criteria were excluded from donation and therefore
from the study. Contact with persons infected by COVID-19, unresolved COVID-19 infection or
COVID-19-like symptoms in the preceding 14 days resulted in temporary deferral of potential donors",2021-01-15,2021-05-15,Blood donors,Female,Multiple groups,15.0,69.0,Sex/Gender,Female,8178,0.314,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.995,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Marion Vermeulen,South African National Blood Service,Unity-Aligned,https://assets.researchsquare.com/files/rs-690372/v2_covered.pdf?c=1627923426,2021-08-18,2024-03-01,Verified,vermeulen_prevalence_2021,ZAF
210706_SouthAfrica_SouthAfricanNationalBloodService_Male,210706_SouthAfrica_SouthAfricanNationalBloodService,Prevalence of anti-SARS-CoV-2 antibodies among blood donors in South Africa during the period January-May 2021,2021-07-06,Preprint,National,Cross-sectional survey ,South Africa,,,"All donors who underwent and passed routine screening through a self-administered questionnaire, one-on-one assessment and a mini-health screening by blood centre staff","Donors who did not meet the routine donor eligibility criteria were excluded from donation and therefore
from the study. Contact with persons infected by COVID-19, unresolved COVID-19 infection or
COVID-19-like symptoms in the preceding 14 days resulted in temporary deferral of potential donors",2021-01-15,2021-05-15,Blood donors,Male,Multiple groups,15.0,69.0,Sex/Gender,Male,8584,0.294,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.995,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Marion Vermeulen,South African National Blood Service,Unity-Aligned,https://assets.researchsquare.com/files/rs-690372/v2_covered.pdf?c=1627923426,2021-08-18,2024-03-01,Verified,vermeulen_prevalence_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date1_Overall_Adj,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date1,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-07-20,2020-09-17,Household and community samples,All,Multiple groups,,,Primary Estimate,,445,0.01,0.0,0.02,True,True,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2023-08-15,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date1_Overall_Unadj,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date1,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-07-20,2020-09-17,Household and community samples,All,Multiple groups,,,Analysis,,445,0.011200000000000002,,,,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date1_Age_35-59,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date1,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-07-20,2020-09-17,Household and community samples,All,Adults (18-64 years),35.0,59.0,Age,35-59,76,0.013200000000000002,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date1_Age_≥60,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date1,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-07-20,2020-09-17,Household and community samples,All,Seniors (65+ years),60.0,,Age,≥60,40,0.025,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date1_Age_19-34,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date1,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-07-20,2020-09-17,Household and community samples,All,Adults (18-64 years),19.0,34.0,Age,19-34,87,0.0,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date1_Age_5-12,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date1,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-07-20,2020-09-17,Household and community samples,All,Children and Youth (0-17 years),5.0,12.0,Age,5-12,148,0.013500000000000002,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date1_Age_13-18,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date1,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-07-20,2020-09-17,Household and community samples,All,Children and Youth (0-17 years),13.0,18.0,Age,13-18,69,0.014499999999999999,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date1_Age_<5,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date1,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-07-20,2020-09-17,Household and community samples,All,Children and Youth (0-17 years),,4.0,Age,<5,25,0.0,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date2_Overall_Adj,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date2,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-09-21,2020-10-10,Household and community samples,All,Multiple groups,,,Primary Estimate,,494,0.05,0.0,0.02,True,True,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2023-08-15,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date2_Age_19-34,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date2,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-09-21,2020-10-10,Household and community samples,All,Adults (18-64 years),19.0,34.0,Age,19-34,88,0.056799999999999996,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date2_Age_13-18,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date2,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-09-21,2020-10-10,Household and community samples,All,Children and Youth (0-17 years),13.0,18.0,Age,13-18,72,0.0694,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date2_Age_5-12,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date2,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-09-21,2020-10-10,Household and community samples,All,Children and Youth (0-17 years),5.0,12.0,Age,5-12,169,0.0296,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date2_Age_35-59,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date2,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-09-21,2020-10-10,Household and community samples,All,Adults (18-64 years),35.0,59.0,Age,35-59,77,0.0649,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date2_Overall_Unadj,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date2,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-09-21,2020-10-10,Household and community samples,All,Multiple groups,,,Analysis,,494,0.0506,,,,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date2_Age_≥60,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date2,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-09-21,2020-10-10,Household and community samples,All,Seniors (65+ years),60.0,,Age,≥60,39,0.1026,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date2_Age_<5,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date2,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-09-21,2020-10-10,Household and community samples,All,Children and Youth (0-17 years),,4.0,Age,<5,49,0.0204,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date3_Overall_Adj,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date3,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-11-23,2020-12-12,Household and community samples,All,Multiple groups,,,Primary Estimate,,568,0.07,0.05,0.09,True,True,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2023-08-15,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date3_Overall_Unadj,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date3,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-11-23,2020-12-12,Household and community samples,All,Multiple groups,,,Analysis,,568,0.0722,,,,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date3_Age_13-18,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date3,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-11-23,2020-12-12,Household and community samples,All,Children and Youth (0-17 years),13.0,18.0,Age,13-18,80,0.1,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date3_Age_19-34,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date3,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-11-23,2020-12-12,Household and community samples,All,Adults (18-64 years),19.0,34.0,Age,19-34,91,0.1429,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date3_Age_5-12,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date3,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-11-23,2020-12-12,Household and community samples,All,Children and Youth (0-17 years),5.0,12.0,Age,5-12,195,0.0359,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date3_Age_35-59,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date3,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-11-23,2020-12-12,Household and community samples,All,Adults (18-64 years),35.0,59.0,Age,35-59,80,0.08750000000000001,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date3_Age_≥60,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date3,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-11-23,2020-12-12,Household and community samples,All,Seniors (65+ years),60.0,,Age,≥60,44,0.0909,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date3_Age_<5,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date3,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-11-23,2020-12-12,Household and community samples,All,Children and Youth (0-17 years),,4.0,Age,<5,78,0.0256,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date4_Overall_Adj,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date4,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-01-25,2021-02-20,Household and community samples,All,Multiple groups,,,Primary Estimate,,588,0.22,0.18,0.25,True,True,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2023-08-15,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date4_Age_35-59,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date4,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-01-25,2021-02-20,Household and community samples,All,Adults (18-64 years),35.0,59.0,Age,35-59,81,0.284,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date4_Age_19-34,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date4,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-01-25,2021-02-20,Household and community samples,All,Adults (18-64 years),19.0,34.0,Age,19-34,91,0.3626,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date4_Age_<5,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date4,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-01-25,2021-02-20,Household and community samples,All,Children and Youth (0-17 years),,4.0,Age,<5,87,0.16090000000000002,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date4_Age_13-18,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date4,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-01-25,2021-02-20,Household and community samples,All,Children and Youth (0-17 years),13.0,18.0,Age,13-18,82,0.2439,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date4_Age_≥60,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date4,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-01-25,2021-02-20,Household and community samples,All,Seniors (65+ years),60.0,,Age,≥60,45,0.1778,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date4_Age_5-12,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date4,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-01-25,2021-02-20,Household and community samples,All,Children and Youth (0-17 years),5.0,12.0,Age,5-12,202,0.1436,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date4_Overall_Unadj,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date4,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-01-25,2021-02-20,Household and community samples,All,Multiple groups,,,Analysis,,588,0.21600000000000003,,,,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date5_Overall_Adj,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date5,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-03-22,2021-04-11,Household and community samples,All,Multiple groups,,,Primary Estimate,,587,0.26,0.22,0.29,True,True,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2023-08-15,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date5_Age_<5,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date5,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-03-22,2021-04-11,Household and community samples,All,Children and Youth (0-17 years),,4.0,Age,<5,89,0.1685,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date5_Age_≥60,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date5,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-03-22,2021-04-11,Household and community samples,All,Seniors (65+ years),60.0,,Age,≥60,42,0.23809999999999998,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date5_Age_13-18,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date5,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-03-22,2021-04-11,Household and community samples,All,Children and Youth (0-17 years),13.0,18.0,Age,13-18,78,0.30770000000000003,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date5_Age_35-59,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date5,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-03-22,2021-04-11,Household and community samples,All,Adults (18-64 years),35.0,59.0,Age,35-59,82,0.3293,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date5_Overall_Unadj,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date5,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-03-22,2021-04-11,Household and community samples,All,Multiple groups,,,Analysis,,587,0.2555,,,,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date5_Age_19-34,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date5,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-03-22,2021-04-11,Household and community samples,All,Adults (18-64 years),19.0,34.0,Age,19-34,95,0.36840000000000006,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date5_Age_5-12,210903_SouthAfrica_UniversityoftheWitwatersrand_Rural_Date5,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-03-22,2021-04-11,Household and community samples,All,Children and Youth (0-17 years),5.0,12.0,Age,5-12,201,0.19399999999999998,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date1_Overall_Adj,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date1,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-07-20,2020-09-17,Household and community samples,All,Multiple groups,,,Primary Estimate,,505,0.15,0.12,0.18,True,True,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2023-08-15,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date1_Age_<5,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date1,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-07-20,2020-09-17,Household and community samples,All,Children and Youth (0-17 years),,4.0,Age,<5,45,0.0444,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date1_Age_13-18,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date1,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-07-20,2020-09-17,Household and community samples,All,Children and Youth (0-17 years),13.0,18.0,Age,13-18,75,0.18670000000000003,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date1_Overall_Unadj,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date1,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-07-20,2020-09-17,Household and community samples,All,Multiple groups,,,Analysis,,505,0.1446,,,,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date1_Age_35-59,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date1,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-07-20,2020-09-17,Household and community samples,All,Adults (18-64 years),35.0,59.0,Age,35-59,110,0.3,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date1_Age_≥60,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date1,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-07-20,2020-09-17,Household and community samples,All,Seniors (65+ years),60.0,,Age,≥60,57,0.0526,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date1_Age_5-12,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date1,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-07-20,2020-09-17,Household and community samples,All,Children and Youth (0-17 years),5.0,12.0,Age,5-12,116,0.09480000000000001,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date1_Age_19-34,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date1,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-07-20,2020-09-17,Household and community samples,All,Adults (18-64 years),19.0,34.0,Age,19-34,102,0.098,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date2_Overall_Adj,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date2,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-09-21,2020-10-10,Household and community samples,All,Multiple groups,,,Primary Estimate,,504,0.22,0.18,0.25,True,True,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2023-08-15,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date2_Age_13-18,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date2,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-09-21,2020-10-10,Household and community samples,All,Children and Youth (0-17 years),13.0,18.0,Age,13-18,75,0.25329999999999997,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date2_Age_19-34,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date2,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-09-21,2020-10-10,Household and community samples,All,Adults (18-64 years),19.0,34.0,Age,19-34,98,0.17350000000000002,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date2_Age_≥60,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date2,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-09-21,2020-10-10,Household and community samples,All,Seniors (65+ years),60.0,,Age,≥60,55,0.1091,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date2_Age_<5,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date2,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-09-21,2020-10-10,Household and community samples,All,Children and Youth (0-17 years),,4.0,Age,<5,50,0.1,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date2_Age_35-59,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date2,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-09-21,2020-10-10,Household and community samples,All,Adults (18-64 years),35.0,59.0,Age,35-59,110,0.40909999999999996,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date2_Age_5-12,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date2,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-09-21,2020-10-10,Household and community samples,All,Children and Youth (0-17 years),5.0,12.0,Age,5-12,116,0.1466,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date2_Overall_Unadj,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date2,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-09-21,2020-10-10,Household and community samples,All,Multiple groups,,,Analysis,,504,0.2163,,,,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date3_Overall_Adj,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date3,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-11-23,2020-12-12,Household and community samples,All,Multiple groups,,,Primary Estimate,,529,0.27,0.23,0.31,True,True,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2023-08-15,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date3_Age_5-12,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date3,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-11-23,2020-12-12,Household and community samples,All,Children and Youth (0-17 years),5.0,12.0,Age,5-12,125,0.192,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date3_Age_≥60,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date3,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-11-23,2020-12-12,Household and community samples,All,Seniors (65+ years),60.0,,Age,≥60,56,0.125,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date3_Age_19-34,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date3,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-11-23,2020-12-12,Household and community samples,All,Adults (18-64 years),19.0,34.0,Age,19-34,100,0.23,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date3_Age_<5,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date3,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-11-23,2020-12-12,Household and community samples,All,Children and Youth (0-17 years),,4.0,Age,<5,50,0.14,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date3_Age_35-59,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date3,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-11-23,2020-12-12,Household and community samples,All,Adults (18-64 years),35.0,59.0,Age,35-59,117,0.44439999999999996,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date3_Age_13-18,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date3,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-11-23,2020-12-12,Household and community samples,All,Children and Youth (0-17 years),13.0,18.0,Age,13-18,81,0.3704,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date3_Overall_Unadj,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date3,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2020-11-23,2020-12-12,Household and community samples,All,Multiple groups,,,Analysis,,529,0.27030000000000004,,,,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date4_Overall_Adj,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date4,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-01-25,2021-02-20,Household and community samples,All,Multiple groups,,,Primary Estimate,,510,0.36,0.32,0.4,True,True,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2023-08-15,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date4_Age_19-34,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date4,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-01-25,2021-02-20,Household and community samples,All,Adults (18-64 years),19.0,34.0,Age,19-34,99,0.2929,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date4_Age_35-59,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date4,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-01-25,2021-02-20,Household and community samples,All,Adults (18-64 years),35.0,59.0,Age,35-59,112,0.5446,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date4_Age_5-12,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date4,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-01-25,2021-02-20,Household and community samples,All,Children and Youth (0-17 years),5.0,12.0,Age,5-12,123,0.2602,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date4_Age_13-18,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date4,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-01-25,2021-02-20,Household and community samples,All,Children and Youth (0-17 years),13.0,18.0,Age,13-18,77,0.4545,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date4_Overall_Unadj,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date4,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-01-25,2021-02-20,Household and community samples,All,Multiple groups,,,Analysis,,510,0.35490000000000005,,,,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date4_Age_<5,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date4,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-01-25,2021-02-20,Household and community samples,All,Children and Youth (0-17 years),,4.0,Age,<5,44,0.1818,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date4_Age_≥60,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date4,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-01-25,2021-02-20,Household and community samples,All,Seniors (65+ years),60.0,,Age,≥60,55,0.2909,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date5_Overall_Adj,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date5,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-03-22,2021-04-11,Household and community samples,All,Multiple groups,,,Primary Estimate,,510,0.41000000000000003,0.37,0.45,True,True,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2023-08-15,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date5_Overall_Unadj,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date5,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-03-22,2021-04-11,Household and community samples,All,Multiple groups,,,Analysis,,510,0.4098,,,,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date5_Age_5-12,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date5,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-03-22,2021-04-11,Household and community samples,All,Children and Youth (0-17 years),5.0,12.0,Age,5-12,122,0.3115,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date5_Age_35-59,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date5,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-03-22,2021-04-11,Household and community samples,All,Adults (18-64 years),35.0,59.0,Age,35-59,111,0.5856,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date5_Age_≥60,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date5,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-03-22,2021-04-11,Household and community samples,All,Seniors (65+ years),60.0,,Age,≥60,53,0.3396,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date5_Age_<5,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date5,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-03-22,2021-04-11,Household and community samples,All,Children and Youth (0-17 years),,4.0,Age,<5,48,0.2708,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date5_Age_13-18,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date5,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-03-22,2021-04-11,Household and community samples,All,Children and Youth (0-17 years),13.0,18.0,Age,13-18,78,0.5256000000000001,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date5_Age_19-34,210903_SouthAfrica_UniversityoftheWitwatersrand_Urban_Date5,"SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.",2021-09-03,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"All households that previously participated in the PHIRST study from 2016-2018 in the urban site cohort were approached for enrolment (located in Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-03-22,2021-04-11,Household and community samples,All,Adults (18-64 years),19.0,34.0,Age,19-34,98,0.3469,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,Yes,No,No,No,Yes,Yes,Yes,Yes,Jackie Kleynhans,University of the Witwatersrand,Unity-Aligned,https://dx.doi.org/10.3201/eid2712.211465,2021-09-13,2024-03-01,Verified,kleynhans_sars-cov-2_2021,ZAF
211030_Gauteng_UniversityoftheWitwatersrand_Primary,211030_Gauteng_UniversityoftheWitwatersrand,"Estimated SARS-CoV-2 infection rate and fatality risk in Gauteng Province, South Africa: a population-based seroepidemiological survey.",2021-10-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Gauteng,,"All individuals residing in sampled households, irrespective of age, were eligible",,2020-11-04,2021-01-22,Household and community samples,All,Multiple groups,,,Primary Estimate,,5584,0.19100000000000003,0.18100000000000002,0.201,True,,,,True,Stratified probability,Author designed (Luminex),,,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,1.0,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Portia Chipo Mutevedzi,University of the Witwatersrand,Not Unity-Aligned,https://dx.doi.org/10.1093/ije/dyab217,2021-11-09,2022-11-11,Verified,mutevedzi_estimated_2021,ZAF
211030_Gauteng_UniversityoftheWitwatersrand_Nov2020,211030_Gauteng_UniversityoftheWitwatersrand,"Estimated SARS-CoV-2 infection rate and fatality risk in Gauteng Province, South Africa: a population-based seroepidemiological survey.",2021-10-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Gauteng,,"All individuals residing in sampled households, irrespective of age, were eligible",,2020-11-04,2021-01-22,Household and community samples,All,Multiple groups,,,Time frame,,1965,0.168,0.152,0.185,,,,,,Stratified probability,Author designed (Luminex),,,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,1.0,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Portia Chipo Mutevedzi,University of the Witwatersrand,Not Unity-Aligned,https://dx.doi.org/10.1093/ije/dyab217,2021-11-09,2022-11-11,Verified,mutevedzi_estimated_2021,ZAF
211030_Gauteng_UniversityoftheWitwatersrand_Dec2020,211030_Gauteng_UniversityoftheWitwatersrand,"Estimated SARS-CoV-2 infection rate and fatality risk in Gauteng Province, South Africa: a population-based seroepidemiological survey.",2021-10-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Gauteng,,"All individuals residing in sampled households, irrespective of age, were eligible",,2020-11-04,2021-01-22,Household and community samples,All,Multiple groups,,,Time frame,,1403,0.18,0.165,0.197,,,,,,Stratified probability,Author designed (Luminex),,,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,1.0,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Portia Chipo Mutevedzi,University of the Witwatersrand,Not Unity-Aligned,https://dx.doi.org/10.1093/ije/dyab217,2021-11-09,2022-11-11,Verified,mutevedzi_estimated_2021,ZAF
211030_Gauteng_UniversityoftheWitwatersrand_Male,211030_Gauteng_UniversityoftheWitwatersrand,"Estimated SARS-CoV-2 infection rate and fatality risk in Gauteng Province, South Africa: a population-based seroepidemiological survey.",2021-10-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Gauteng,,"All individuals residing in sampled households, irrespective of age, were eligible",,2020-11-04,2021-01-22,Household and community samples,Male,Multiple groups,,,Sex/Gender,,2244,0.16899999999999998,0.154,0.185,,,,,,Stratified probability,Author designed (Luminex),,,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,1.0,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Portia Chipo Mutevedzi,University of the Witwatersrand,Not Unity-Aligned,https://dx.doi.org/10.1093/ije/dyab217,2021-11-09,2022-11-11,Verified,mutevedzi_estimated_2021,ZAF
211030_Gauteng_UniversityoftheWitwatersrand_Female,211030_Gauteng_UniversityoftheWitwatersrand,"Estimated SARS-CoV-2 infection rate and fatality risk in Gauteng Province, South Africa: a population-based seroepidemiological survey.",2021-10-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Gauteng,,"All individuals residing in sampled households, irrespective of age, were eligible",,2020-11-04,2021-01-22,Household and community samples,Female,Multiple groups,,,Sex/Gender,,3331,0.20600000000000002,0.193,0.22,,,,,,Stratified probability,Author designed (Luminex),,,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,1.0,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Portia Chipo Mutevedzi,University of the Witwatersrand,Not Unity-Aligned,https://dx.doi.org/10.1093/ije/dyab217,2021-11-09,2022-11-11,Verified,mutevedzi_estimated_2021,ZAF
211030_Gauteng_UniversityoftheWitwatersrand_Jan2021,211030_Gauteng_UniversityoftheWitwatersrand,"Estimated SARS-CoV-2 infection rate and fatality risk in Gauteng Province, South Africa: a population-based seroepidemiological survey.",2021-10-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Gauteng,,"All individuals residing in sampled households, irrespective of age, were eligible",,2020-11-04,2021-01-22,Household and community samples,All,Multiple groups,,,Time frame,,2208,0.24100000000000002,0.219,0.264,,,,,,Stratified probability,Author designed (Luminex),,,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,1.0,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Portia Chipo Mutevedzi,University of the Witwatersrand,Not Unity-Aligned,https://dx.doi.org/10.1093/ije/dyab217,2021-11-09,2022-11-11,Verified,mutevedzi_estimated_2021,ZAF
211030_Gauteng_UniversityoftheWitwatersrand_45-60,211030_Gauteng_UniversityoftheWitwatersrand,"Estimated SARS-CoV-2 infection rate and fatality risk in Gauteng Province, South Africa: a population-based seroepidemiological survey.",2021-10-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Gauteng,,"All individuals residing in sampled households, irrespective of age, were eligible",,2020-11-04,2021-01-22,Household and community samples,All,Adults (18-64 years),46.0,60.0,Age,45-60 years-old,968,0.209,0.184,0.23500000000000001,,,,,,Stratified probability,Author designed (Luminex),,,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,1.0,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Portia Chipo Mutevedzi,University of the Witwatersrand,Not Unity-Aligned,https://dx.doi.org/10.1093/ije/dyab217,2021-11-09,2022-11-11,Verified,mutevedzi_estimated_2021,ZAF
211030_Gauteng_UniversityoftheWitwatersrand_>60,211030_Gauteng_UniversityoftheWitwatersrand,"Estimated SARS-CoV-2 infection rate and fatality risk in Gauteng Province, South Africa: a population-based seroepidemiological survey.",2021-10-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Gauteng,,"All individuals residing in sampled households, irrespective of age, were eligible",,2020-11-04,2021-01-22,Household and community samples,All,Multiple groups,61.0,,Age,>60 years-old,647,0.193,0.165,0.225,,,,,,Stratified probability,Author designed (Luminex),,,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,1.0,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Portia Chipo Mutevedzi,University of the Witwatersrand,Not Unity-Aligned,https://dx.doi.org/10.1093/ije/dyab217,2021-11-09,2022-11-11,Verified,mutevedzi_estimated_2021,ZAF
211030_Gauteng_UniversityoftheWitwatersrand_<5,211030_Gauteng_UniversityoftheWitwatersrand,"Estimated SARS-CoV-2 infection rate and fatality risk in Gauteng Province, South Africa: a population-based seroepidemiological survey.",2021-10-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Gauteng,,"All individuals residing in sampled households, irrespective of age, were eligible",,2020-11-04,2021-01-22,Household and community samples,All,Children and Youth (0-17 years),,4.0,Age,<5 years-old ,311,0.18,0.141,0.227,,,,,,Stratified probability,Author designed (Luminex),,,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,1.0,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Portia Chipo Mutevedzi,University of the Witwatersrand,Not Unity-Aligned,https://dx.doi.org/10.1093/ije/dyab217,2021-11-09,2022-11-11,Verified,mutevedzi_estimated_2021,ZAF
211030_Gauteng_UniversityoftheWitwatersrand_18-45,211030_Gauteng_UniversityoftheWitwatersrand,"Estimated SARS-CoV-2 infection rate and fatality risk in Gauteng Province, South Africa: a population-based seroepidemiological survey.",2021-10-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Gauteng,,"All individuals residing in sampled households, irrespective of age, were eligible",,2020-11-04,2021-01-22,Household and community samples,All,Adults (18-64 years),19.0,45.0,Age,18-45 years-old,2754,0.19100000000000003,0.177,0.20600000000000002,,,,,,Stratified probability,Author designed (Luminex),,,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,1.0,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Portia Chipo Mutevedzi,University of the Witwatersrand,Not Unity-Aligned,https://dx.doi.org/10.1093/ije/dyab217,2021-11-09,2022-11-11,Verified,mutevedzi_estimated_2021,ZAF
211030_Gauteng_UniversityoftheWitwatersrand_5-18,211030_Gauteng_UniversityoftheWitwatersrand,"Estimated SARS-CoV-2 infection rate and fatality risk in Gauteng Province, South Africa: a population-based seroepidemiological survey.",2021-10-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Gauteng,,"All individuals residing in sampled households, irrespective of age, were eligible",,2020-11-04,2021-01-22,Household and community samples,All,Children and Youth (0-17 years),5.0,18.0,Age,5-18 years-old,867,0.172,0.14800000000000002,0.198,,,,,,Stratified probability,Author designed (Luminex),,,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,1.0,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Portia Chipo Mutevedzi,University of the Witwatersrand,Not Unity-Aligned,https://dx.doi.org/10.1093/ije/dyab217,2021-11-09,2022-11-11,Verified,mutevedzi_estimated_2021,ZAF
211105_Gauteng_NationalHealthLaboratoryService_OverallFullAdjust,211105_Gauteng_NationalHealthLaboratoryService,"Sentinel seroprevalence of SARS-CoV-2 in Gauteng Province, South Africa, August- October 2020",2021-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"We selected remnant samples received at the chemistry departments at Charlotte Maxeke Johannesburg Academic Hospital, Chris Hani Baragwanath Academic Hospital and Helen Joseph Hospital for routine chemistry tests. Samples of adequate volume from hospital outpatient departments and PHC facilities, received from August to October 2020, were selected. Accompanying RT-PCR results for SARS-CoV-2, glycated haemoglobin (HbA1c), creatinine, HIV, viral load and CD4 T-cell count were included. These were linked to demographic information extracted from the Laboratory Information System. Specimens from individual patients were tested only once.",,2020-08-01,2020-10-31,Residual sera,All,Multiple groups,,,Primary Estimate,Test and Population Adjusted,6477,0.278,,,True,True,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jaya George,National Health Laboratory Service,Unity-Aligned,https://doi.org/10.7196/SAMJ.2021.v111i11.15669,2021-12-07,2023-08-15,Unverified,george_sentinel_2021-2,ZAF
211105_Gauteng_NationalHealthLaboratoryService_Johannesburg,211105_Gauteng_NationalHealthLaboratoryService,"Sentinel seroprevalence of SARS-CoV-2 in Gauteng Province, South Africa, August- October 2020",2021-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,Johannesburg,"We selected remnant samples received at the chemistry departments at Charlotte Maxeke Johannesburg Academic Hospital, Chris Hani Baragwanath Academic Hospital and Helen Joseph Hospital for routine chemistry tests. Samples of adequate volume from hospital outpatient departments and PHC facilities, received from August to October 2020, were selected. Accompanying RT-PCR results for SARS-CoV-2, glycated haemoglobin (HbA1c), creatinine, HIV, viral load and CD4 T-cell count were included. These were linked to demographic information extracted from the Laboratory Information System. Specimens from individual patients were tested only once.",,2020-08-01,2020-10-31,Residual sera,All,Multiple groups,,,Geographical area,Johannesburg,4393,0.27,0.254,0.28600000000000003,,True,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jaya George,National Health Laboratory Service,Unity-Aligned,https://doi.org/10.7196/SAMJ.2021.v111i11.15669,2021-12-07,2023-08-15,Unverified,george_sentinel_2021-2,ZAF
211105_Gauteng_NationalHealthLaboratoryService_Age80+,211105_Gauteng_NationalHealthLaboratoryService,"Sentinel seroprevalence of SARS-CoV-2 in Gauteng Province, South Africa, August- October 2020",2021-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"We selected remnant samples received at the chemistry departments at Charlotte Maxeke Johannesburg Academic Hospital, Chris Hani Baragwanath Academic Hospital and Helen Joseph Hospital for routine chemistry tests. Samples of adequate volume from hospital outpatient departments and PHC facilities, received from August to October 2020, were selected. Accompanying RT-PCR results for SARS-CoV-2, glycated haemoglobin (HbA1c), creatinine, HIV, viral load and CD4 T-cell count were included. These were linked to demographic information extracted from the Laboratory Information System. Specimens from individual patients were tested only once.",,2020-08-01,2020-10-31,Residual sera,All,Seniors (65+ years),,,Age,80+,109,0.22940000000000002,0.154,0.32,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jaya George,National Health Laboratory Service,Unity-Aligned,https://doi.org/10.7196/SAMJ.2021.v111i11.15669,2021-12-07,2024-03-01,Unverified,george_sentinel_2021-2,ZAF
211105_Gauteng_NationalHealthLaboratoryService_Age60-64,211105_Gauteng_NationalHealthLaboratoryService,"Sentinel seroprevalence of SARS-CoV-2 in Gauteng Province, South Africa, August- October 2020",2021-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"We selected remnant samples received at the chemistry departments at Charlotte Maxeke Johannesburg Academic Hospital, Chris Hani Baragwanath Academic Hospital and Helen Joseph Hospital for routine chemistry tests. Samples of adequate volume from hospital outpatient departments and PHC facilities, received from August to October 2020, were selected. Accompanying RT-PCR results for SARS-CoV-2, glycated haemoglobin (HbA1c), creatinine, HIV, viral load and CD4 T-cell count were included. These were linked to demographic information extracted from the Laboratory Information System. Specimens from individual patients were tested only once.",,2020-08-01,2020-10-31,Residual sera,All,Adults (18-64 years),,,Age,60-64,420,0.281,0.195,0.289,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jaya George,National Health Laboratory Service,Unity-Aligned,https://doi.org/10.7196/SAMJ.2021.v111i11.15669,2021-12-07,2024-03-01,Unverified,george_sentinel_2021-2,ZAF
211105_Gauteng_NationalHealthLaboratoryService_Age35-39,211105_Gauteng_NationalHealthLaboratoryService,"Sentinel seroprevalence of SARS-CoV-2 in Gauteng Province, South Africa, August- October 2020",2021-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"We selected remnant samples received at the chemistry departments at Charlotte Maxeke Johannesburg Academic Hospital, Chris Hani Baragwanath Academic Hospital and Helen Joseph Hospital for routine chemistry tests. Samples of adequate volume from hospital outpatient departments and PHC facilities, received from August to October 2020, were selected. Accompanying RT-PCR results for SARS-CoV-2, glycated haemoglobin (HbA1c), creatinine, HIV, viral load and CD4 T-cell count were included. These were linked to demographic information extracted from the Laboratory Information System. Specimens from individual patients were tested only once.",,2020-08-01,2020-10-31,Residual sera,All,Adults (18-64 years),,,Age,35-39,504,0.2956,0.256,0.33799999999999997,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jaya George,National Health Laboratory Service,Unity-Aligned,https://doi.org/10.7196/SAMJ.2021.v111i11.15669,2021-12-07,2024-03-01,Unverified,george_sentinel_2021-2,ZAF
211105_Gauteng_NationalHealthLaboratoryService_OverallCrude,211105_Gauteng_NationalHealthLaboratoryService,"Sentinel seroprevalence of SARS-CoV-2 in Gauteng Province, South Africa, August- October 2020",2021-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"We selected remnant samples received at the chemistry departments at Charlotte Maxeke Johannesburg Academic Hospital, Chris Hani Baragwanath Academic Hospital and Helen Joseph Hospital for routine chemistry tests. Samples of adequate volume from hospital outpatient departments and PHC facilities, received from August to October 2020, were selected. Accompanying RT-PCR results for SARS-CoV-2, glycated haemoglobin (HbA1c), creatinine, HIV, viral load and CD4 T-cell count were included. These were linked to demographic information extracted from the Laboratory Information System. Specimens from individual patients were tested only once.",,2020-08-01,2020-10-31,Residual sera,All,Multiple groups,,,Analysis,Crude,6477,0.2782,0.267,0.289,,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jaya George,National Health Laboratory Service,Unity-Aligned,https://doi.org/10.7196/SAMJ.2021.v111i11.15669,2021-12-07,2024-03-01,Unverified,george_sentinel_2021-2,ZAF
211105_Gauteng_NationalHealthLaboratoryService_Time2September,211105_Gauteng_NationalHealthLaboratoryService,"Sentinel seroprevalence of SARS-CoV-2 in Gauteng Province, South Africa, August- October 2020",2021-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"We selected remnant samples received at the chemistry departments at Charlotte Maxeke Johannesburg Academic Hospital, Chris Hani Baragwanath Academic Hospital and Helen Joseph Hospital for routine chemistry tests. Samples of adequate volume from hospital outpatient departments and PHC facilities, received from August to October 2020, were selected. Accompanying RT-PCR results for SARS-CoV-2, glycated haemoglobin (HbA1c), creatinine, HIV, viral load and CD4 T-cell count were included. These were linked to demographic information extracted from the Laboratory Information System. Specimens from individual patients were tested only once.",,2020-09-01,2020-09-30,Residual sera,All,Multiple groups,,,Time frame,September,3347,0.268,0.253,0.28300000000000003,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jaya George,National Health Laboratory Service,Unity-Aligned,https://doi.org/10.7196/SAMJ.2021.v111i11.15669,2021-12-07,2024-03-01,Unverified,george_sentinel_2021-2,ZAF
211105_Gauteng_NationalHealthLaboratoryService_Age15-19,211105_Gauteng_NationalHealthLaboratoryService,"Sentinel seroprevalence of SARS-CoV-2 in Gauteng Province, South Africa, August- October 2020",2021-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"We selected remnant samples received at the chemistry departments at Charlotte Maxeke Johannesburg Academic Hospital, Chris Hani Baragwanath Academic Hospital and Helen Joseph Hospital for routine chemistry tests. Samples of adequate volume from hospital outpatient departments and PHC facilities, received from August to October 2020, were selected. Accompanying RT-PCR results for SARS-CoV-2, glycated haemoglobin (HbA1c), creatinine, HIV, viral load and CD4 T-cell count were included. These were linked to demographic information extracted from the Laboratory Information System. Specimens from individual patients were tested only once.",,2020-08-01,2020-10-31,Residual sera,All,Children and Youth (0-17 years),,,Age,15-19,85,0.29410000000000003,0.2,0.40299999999999997,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jaya George,National Health Laboratory Service,Unity-Aligned,https://doi.org/10.7196/SAMJ.2021.v111i11.15669,2021-12-07,2024-03-01,Unverified,george_sentinel_2021-2,ZAF
211105_Gauteng_NationalHealthLaboratoryService_Time3October,211105_Gauteng_NationalHealthLaboratoryService,"Sentinel seroprevalence of SARS-CoV-2 in Gauteng Province, South Africa, August- October 2020",2021-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"We selected remnant samples received at the chemistry departments at Charlotte Maxeke Johannesburg Academic Hospital, Chris Hani Baragwanath Academic Hospital and Helen Joseph Hospital for routine chemistry tests. Samples of adequate volume from hospital outpatient departments and PHC facilities, received from August to October 2020, were selected. Accompanying RT-PCR results for SARS-CoV-2, glycated haemoglobin (HbA1c), creatinine, HIV, viral load and CD4 T-cell count were included. These were linked to demographic information extracted from the Laboratory Information System. Specimens from individual patients were tested only once.",,2020-10-01,2020-10-31,Residual sera,All,Multiple groups,,,Time frame,October,1664,0.28190000000000004,0.259,0.303,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jaya George,National Health Laboratory Service,Unity-Aligned,https://doi.org/10.7196/SAMJ.2021.v111i11.15669,2021-12-07,2024-03-01,Unverified,george_sentinel_2021-2,ZAF
211105_Gauteng_NationalHealthLaboratoryService_Age25-29,211105_Gauteng_NationalHealthLaboratoryService,"Sentinel seroprevalence of SARS-CoV-2 in Gauteng Province, South Africa, August- October 2020",2021-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"We selected remnant samples received at the chemistry departments at Charlotte Maxeke Johannesburg Academic Hospital, Chris Hani Baragwanath Academic Hospital and Helen Joseph Hospital for routine chemistry tests. Samples of adequate volume from hospital outpatient departments and PHC facilities, received from August to October 2020, were selected. Accompanying RT-PCR results for SARS-CoV-2, glycated haemoglobin (HbA1c), creatinine, HIV, viral load and CD4 T-cell count were included. These were linked to demographic information extracted from the Laboratory Information System. Specimens from individual patients were tested only once.",,2020-08-01,2020-10-31,Residual sera,All,Adults (18-64 years),,,Age,25-29,297,0.2761,0.226,0.331,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jaya George,National Health Laboratory Service,Unity-Aligned,https://doi.org/10.7196/SAMJ.2021.v111i11.15669,2021-12-07,2024-03-01,Unverified,george_sentinel_2021-2,ZAF
211105_Gauteng_NationalHealthLaboratoryService_Time1August,211105_Gauteng_NationalHealthLaboratoryService,"Sentinel seroprevalence of SARS-CoV-2 in Gauteng Province, South Africa, August- October 2020",2021-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"We selected remnant samples received at the chemistry departments at Charlotte Maxeke Johannesburg Academic Hospital, Chris Hani Baragwanath Academic Hospital and Helen Joseph Hospital for routine chemistry tests. Samples of adequate volume from hospital outpatient departments and PHC facilities, received from August to October 2020, were selected. Accompanying RT-PCR results for SARS-CoV-2, glycated haemoglobin (HbA1c), creatinine, HIV, viral load and CD4 T-cell count were included. These were linked to demographic information extracted from the Laboratory Information System. Specimens from individual patients were tested only once.",,2020-08-01,2020-08-31,Residual sera,All,Multiple groups,,,Time frame,August,1460,0.2986,0.275,0.32299999999999995,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jaya George,National Health Laboratory Service,Unity-Aligned,https://doi.org/10.7196/SAMJ.2021.v111i11.15669,2021-12-07,2024-03-01,Unverified,george_sentinel_2021-2,ZAF
211105_Gauteng_NationalHealthLaboratoryService_Age50-54,211105_Gauteng_NationalHealthLaboratoryService,"Sentinel seroprevalence of SARS-CoV-2 in Gauteng Province, South Africa, August- October 2020",2021-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"We selected remnant samples received at the chemistry departments at Charlotte Maxeke Johannesburg Academic Hospital, Chris Hani Baragwanath Academic Hospital and Helen Joseph Hospital for routine chemistry tests. Samples of adequate volume from hospital outpatient departments and PHC facilities, received from August to October 2020, were selected. Accompanying RT-PCR results for SARS-CoV-2, glycated haemoglobin (HbA1c), creatinine, HIV, viral load and CD4 T-cell count were included. These were linked to demographic information extracted from the Laboratory Information System. Specimens from individual patients were tested only once.",,2020-08-01,2020-10-31,Residual sera,All,Adults (18-64 years),,,Age,50-54,555,0.2721,0.23500000000000001,0.311,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jaya George,National Health Laboratory Service,Unity-Aligned,https://doi.org/10.7196/SAMJ.2021.v111i11.15669,2021-12-07,2024-03-01,Unverified,george_sentinel_2021-2,ZAF
211105_Gauteng_NationalHealthLaboratoryService_Age45-49,211105_Gauteng_NationalHealthLaboratoryService,"Sentinel seroprevalence of SARS-CoV-2 in Gauteng Province, South Africa, August- October 2020",2021-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"We selected remnant samples received at the chemistry departments at Charlotte Maxeke Johannesburg Academic Hospital, Chris Hani Baragwanath Academic Hospital and Helen Joseph Hospital for routine chemistry tests. Samples of adequate volume from hospital outpatient departments and PHC facilities, received from August to October 2020, were selected. Accompanying RT-PCR results for SARS-CoV-2, glycated haemoglobin (HbA1c), creatinine, HIV, viral load and CD4 T-cell count were included. These were linked to demographic information extracted from the Laboratory Information System. Specimens from individual patients were tested only once.",,2020-08-01,2020-10-31,Residual sera,All,Adults (18-64 years),,,Age,45-49,661,0.3056,0.271,0.342,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jaya George,National Health Laboratory Service,Unity-Aligned,https://doi.org/10.7196/SAMJ.2021.v111i11.15669,2021-12-07,2024-03-01,Unverified,george_sentinel_2021-2,ZAF
211105_Gauteng_NationalHealthLaboratoryService_Age10-14,211105_Gauteng_NationalHealthLaboratoryService,"Sentinel seroprevalence of SARS-CoV-2 in Gauteng Province, South Africa, August- October 2020",2021-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"We selected remnant samples received at the chemistry departments at Charlotte Maxeke Johannesburg Academic Hospital, Chris Hani Baragwanath Academic Hospital and Helen Joseph Hospital for routine chemistry tests. Samples of adequate volume from hospital outpatient departments and PHC facilities, received from August to October 2020, were selected. Accompanying RT-PCR results for SARS-CoV-2, glycated haemoglobin (HbA1c), creatinine, HIV, viral load and CD4 T-cell count were included. These were linked to demographic information extracted from the Laboratory Information System. Specimens from individual patients were tested only once.",,2020-08-01,2020-10-31,Residual sera,All,Children and Youth (0-17 years),,,Age,10-14,33,0.1818,0.07,0.355,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jaya George,National Health Laboratory Service,Unity-Aligned,https://doi.org/10.7196/SAMJ.2021.v111i11.15669,2021-12-07,2024-03-01,Unverified,george_sentinel_2021-2,ZAF
211105_Gauteng_NationalHealthLaboratoryService_Age40-44,211105_Gauteng_NationalHealthLaboratoryService,"Sentinel seroprevalence of SARS-CoV-2 in Gauteng Province, South Africa, August- October 2020",2021-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"We selected remnant samples received at the chemistry departments at Charlotte Maxeke Johannesburg Academic Hospital, Chris Hani Baragwanath Academic Hospital and Helen Joseph Hospital for routine chemistry tests. Samples of adequate volume from hospital outpatient departments and PHC facilities, received from August to October 2020, were selected. Accompanying RT-PCR results for SARS-CoV-2, glycated haemoglobin (HbA1c), creatinine, HIV, viral load and CD4 T-cell count were included. These were linked to demographic information extracted from the Laboratory Information System. Specimens from individual patients were tested only once.",,2020-08-01,2020-10-31,Residual sera,All,Adults (18-64 years),,,Age,40-44,662,0.2779,0.244,0.314,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jaya George,National Health Laboratory Service,Unity-Aligned,https://doi.org/10.7196/SAMJ.2021.v111i11.15669,2021-12-07,2024-03-01,Unverified,george_sentinel_2021-2,ZAF
211105_Gauteng_NationalHealthLaboratoryService_Age20-24,211105_Gauteng_NationalHealthLaboratoryService,"Sentinel seroprevalence of SARS-CoV-2 in Gauteng Province, South Africa, August- October 2020",2021-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"We selected remnant samples received at the chemistry departments at Charlotte Maxeke Johannesburg Academic Hospital, Chris Hani Baragwanath Academic Hospital and Helen Joseph Hospital for routine chemistry tests. Samples of adequate volume from hospital outpatient departments and PHC facilities, received from August to October 2020, were selected. Accompanying RT-PCR results for SARS-CoV-2, glycated haemoglobin (HbA1c), creatinine, HIV, viral load and CD4 T-cell count were included. These were linked to demographic information extracted from the Laboratory Information System. Specimens from individual patients were tested only once.",,2020-08-01,2020-10-31,Residual sera,All,Adults (18-64 years),,,Age,20-24,169,0.33140000000000003,0.261,0.408,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jaya George,National Health Laboratory Service,Unity-Aligned,https://doi.org/10.7196/SAMJ.2021.v111i11.15669,2021-12-07,2024-03-01,Unverified,george_sentinel_2021-2,ZAF
211105_Gauteng_NationalHealthLaboratoryService_Age5-9,211105_Gauteng_NationalHealthLaboratoryService,"Sentinel seroprevalence of SARS-CoV-2 in Gauteng Province, South Africa, August- October 2020",2021-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"We selected remnant samples received at the chemistry departments at Charlotte Maxeke Johannesburg Academic Hospital, Chris Hani Baragwanath Academic Hospital and Helen Joseph Hospital for routine chemistry tests. Samples of adequate volume from hospital outpatient departments and PHC facilities, received from August to October 2020, were selected. Accompanying RT-PCR results for SARS-CoV-2, glycated haemoglobin (HbA1c), creatinine, HIV, viral load and CD4 T-cell count were included. These were linked to demographic information extracted from the Laboratory Information System. Specimens from individual patients were tested only once.",,2020-08-01,2020-10-31,Residual sera,All,Children and Youth (0-17 years),,,Age,5-9,35,0.2286,0.10400000000000001,0.401,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jaya George,National Health Laboratory Service,Unity-Aligned,https://doi.org/10.7196/SAMJ.2021.v111i11.15669,2021-12-07,2024-03-01,Unverified,george_sentinel_2021-2,ZAF
211105_Gauteng_NationalHealthLaboratoryService_Age30-34,211105_Gauteng_NationalHealthLaboratoryService,"Sentinel seroprevalence of SARS-CoV-2 in Gauteng Province, South Africa, August- October 2020",2021-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"We selected remnant samples received at the chemistry departments at Charlotte Maxeke Johannesburg Academic Hospital, Chris Hani Baragwanath Academic Hospital and Helen Joseph Hospital for routine chemistry tests. Samples of adequate volume from hospital outpatient departments and PHC facilities, received from August to October 2020, were selected. Accompanying RT-PCR results for SARS-CoV-2, glycated haemoglobin (HbA1c), creatinine, HIV, viral load and CD4 T-cell count were included. These were linked to demographic information extracted from the Laboratory Information System. Specimens from individual patients were tested only once.",,2020-08-01,2020-10-31,Residual sera,All,Adults (18-64 years),,,Age,30-34,460,0.30870000000000003,0.267,0.353,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jaya George,National Health Laboratory Service,Unity-Aligned,https://doi.org/10.7196/SAMJ.2021.v111i11.15669,2021-12-07,2024-03-01,Unverified,george_sentinel_2021-2,ZAF
211105_Gauteng_NationalHealthLaboratoryService_Age0-4,211105_Gauteng_NationalHealthLaboratoryService,"Sentinel seroprevalence of SARS-CoV-2 in Gauteng Province, South Africa, August- October 2020",2021-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"We selected remnant samples received at the chemistry departments at Charlotte Maxeke Johannesburg Academic Hospital, Chris Hani Baragwanath Academic Hospital and Helen Joseph Hospital for routine chemistry tests. Samples of adequate volume from hospital outpatient departments and PHC facilities, received from August to October 2020, were selected. Accompanying RT-PCR results for SARS-CoV-2, glycated haemoglobin (HbA1c), creatinine, HIV, viral load and CD4 T-cell count were included. These were linked to demographic information extracted from the Laboratory Information System. Specimens from individual patients were tested only once.",,2020-08-01,2020-10-31,Residual sera,All,Children and Youth (0-17 years),,,Age,0-4,201,0.19399999999999998,0.142,0.256,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jaya George,National Health Laboratory Service,Unity-Aligned,https://doi.org/10.7196/SAMJ.2021.v111i11.15669,2021-12-07,2024-03-01,Unverified,george_sentinel_2021-2,ZAF
211105_Gauteng_NationalHealthLaboratoryService_Age65-69,211105_Gauteng_NationalHealthLaboratoryService,"Sentinel seroprevalence of SARS-CoV-2 in Gauteng Province, South Africa, August- October 2020",2021-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"We selected remnant samples received at the chemistry departments at Charlotte Maxeke Johannesburg Academic Hospital, Chris Hani Baragwanath Academic Hospital and Helen Joseph Hospital for routine chemistry tests. Samples of adequate volume from hospital outpatient departments and PHC facilities, received from August to October 2020, were selected. Accompanying RT-PCR results for SARS-CoV-2, glycated haemoglobin (HbA1c), creatinine, HIV, viral load and CD4 T-cell count were included. These were linked to demographic information extracted from the Laboratory Information System. Specimens from individual patients were tested only once.",,2020-08-01,2020-10-31,Residual sera,All,Seniors (65+ years),,,Age,65-69,342,0.2398,0.195,0.289,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jaya George,National Health Laboratory Service,Unity-Aligned,https://doi.org/10.7196/SAMJ.2021.v111i11.15669,2021-12-07,2024-03-01,Unverified,george_sentinel_2021-2,ZAF
211105_Gauteng_NationalHealthLaboratoryService_Age75-79,211105_Gauteng_NationalHealthLaboratoryService,"Sentinel seroprevalence of SARS-CoV-2 in Gauteng Province, South Africa, August- October 2020",2021-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"We selected remnant samples received at the chemistry departments at Charlotte Maxeke Johannesburg Academic Hospital, Chris Hani Baragwanath Academic Hospital and Helen Joseph Hospital for routine chemistry tests. Samples of adequate volume from hospital outpatient departments and PHC facilities, received from August to October 2020, were selected. Accompanying RT-PCR results for SARS-CoV-2, glycated haemoglobin (HbA1c), creatinine, HIV, viral load and CD4 T-cell count were included. These were linked to demographic information extracted from the Laboratory Information System. Specimens from individual patients were tested only once.",,2020-08-01,2020-10-31,Residual sera,All,Seniors (65+ years),,,Age,75-79,112,0.2411,0.165,0.331,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jaya George,National Health Laboratory Service,Unity-Aligned,https://doi.org/10.7196/SAMJ.2021.v111i11.15669,2021-12-07,2024-03-01,Unverified,george_sentinel_2021-2,ZAF
211105_Gauteng_NationalHealthLaboratoryService_Age70-74,211105_Gauteng_NationalHealthLaboratoryService,"Sentinel seroprevalence of SARS-CoV-2 in Gauteng Province, South Africa, August- October 2020",2021-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"We selected remnant samples received at the chemistry departments at Charlotte Maxeke Johannesburg Academic Hospital, Chris Hani Baragwanath Academic Hospital and Helen Joseph Hospital for routine chemistry tests. Samples of adequate volume from hospital outpatient departments and PHC facilities, received from August to October 2020, were selected. Accompanying RT-PCR results for SARS-CoV-2, glycated haemoglobin (HbA1c), creatinine, HIV, viral load and CD4 T-cell count were included. These were linked to demographic information extracted from the Laboratory Information System. Specimens from individual patients were tested only once.",,2020-08-01,2020-10-31,Residual sera,All,Seniors (65+ years),,,Age,70-74,230,0.2217,0.17,0.281,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jaya George,National Health Laboratory Service,Unity-Aligned,https://doi.org/10.7196/SAMJ.2021.v111i11.15669,2021-12-07,2024-03-01,Unverified,george_sentinel_2021-2,ZAF
211105_Gauteng_NationalHealthLaboratoryService_Age55-59,211105_Gauteng_NationalHealthLaboratoryService,"Sentinel seroprevalence of SARS-CoV-2 in Gauteng Province, South Africa, August- October 2020",2021-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"We selected remnant samples received at the chemistry departments at Charlotte Maxeke Johannesburg Academic Hospital, Chris Hani Baragwanath Academic Hospital and Helen Joseph Hospital for routine chemistry tests. Samples of adequate volume from hospital outpatient departments and PHC facilities, received from August to October 2020, were selected. Accompanying RT-PCR results for SARS-CoV-2, glycated haemoglobin (HbA1c), creatinine, HIV, viral load and CD4 T-cell count were included. These were linked to demographic information extracted from the Laboratory Information System. Specimens from individual patients were tested only once.",,2020-08-01,2020-10-31,Residual sera,All,Adults (18-64 years),,,Age,55-59,511,0.2701,0.23199999999999998,0.311,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jaya George,National Health Laboratory Service,Unity-Aligned,https://doi.org/10.7196/SAMJ.2021.v111i11.15669,2021-12-07,2024-03-01,Unverified,george_sentinel_2021-2,ZAF
211105_Gauteng_NationalHealthLaboratoryService_SexMale,211105_Gauteng_NationalHealthLaboratoryService,"Sentinel seroprevalence of SARS-CoV-2 in Gauteng Province, South Africa, August- October 2020",2021-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"We selected remnant samples received at the chemistry departments at Charlotte Maxeke Johannesburg Academic Hospital, Chris Hani Baragwanath Academic Hospital and Helen Joseph Hospital for routine chemistry tests. Samples of adequate volume from hospital outpatient departments and PHC facilities, received from August to October 2020, were selected. Accompanying RT-PCR results for SARS-CoV-2, glycated haemoglobin (HbA1c), creatinine, HIV, viral load and CD4 T-cell count were included. These were linked to demographic information extracted from the Laboratory Information System. Specimens from individual patients were tested only once.",,2020-08-01,2020-10-31,Residual sera,Male,Multiple groups,,,Sex/Gender,,3151,0.2615,0.24600000000000002,0.277,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jaya George,National Health Laboratory Service,Unity-Aligned,https://doi.org/10.7196/SAMJ.2021.v111i11.15669,2021-12-07,2024-03-01,Unverified,george_sentinel_2021-2,ZAF
211105_Gauteng_NationalHealthLaboratoryService_SexFemale,211105_Gauteng_NationalHealthLaboratoryService,"Sentinel seroprevalence of SARS-CoV-2 in Gauteng Province, South Africa, August- October 2020",2021-11-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"We selected remnant samples received at the chemistry departments at Charlotte Maxeke Johannesburg Academic Hospital, Chris Hani Baragwanath Academic Hospital and Helen Joseph Hospital for routine chemistry tests. Samples of adequate volume from hospital outpatient departments and PHC facilities, received from August to October 2020, were selected. Accompanying RT-PCR results for SARS-CoV-2, glycated haemoglobin (HbA1c), creatinine, HIV, viral load and CD4 T-cell count were included. These were linked to demographic information extracted from the Laboratory Information System. Specimens from individual patients were tested only once.",,2020-08-01,2020-10-31,Residual sera,Female,Multiple groups,,,Sex/Gender,,3234,0.2944,0.27899999999999997,0.31,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.93,0.99,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Jaya George,National Health Laboratory Service,Unity-Aligned,https://doi.org/10.7196/SAMJ.2021.v111i11.15669,2021-12-07,2024-03-01,Unverified,george_sentinel_2021-2,ZAF
220215_SouthAfrica_StellenboschUniversity,220215_SouthAfrica_StellenboschUniversity,Estimates of prevalence of anti-SARS-CoV-2 antibodies among blood donors in eight provinces of South Africa in November 2021,2022-02-15,Preprint,National,Cross-sectional survey ,South Africa,"Eastern Cape, Free state, Gauteng, Limpopo, Mpulanga, Northern Cape, North West, KwaZulu Natal",,consenting donors from all provinces except the Western Cape (which has its own separate blood service) presenting to donate blood to the South African National Blood Service (SANBS) from 8 to 12November 2021.,,2021-11-08,2021-11-12,Blood donors,All,Multiple groups,,,Primary Estimate,,3395,0.711,0.688,0.735,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,1.0,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Russel Cable,Stellenbosch University,Unity-Aligned,https://www.researchsquare.com/article/rs-1359658/v1,2022-02-24,2024-03-01,Unverified,cable_estimates_2022,ZAF
220215_SouthAfrica_NationalHealthLaboratoryService_Rural_Date6_OverallAdjusted,220215_SouthAfrica_NationalHealthLaboratoryService_Rural_Date6,"SARS-CoV-2 seroprevalence in a rural and urban community household cohort in South Africa, after the third wave, April-November 2021",2022-02-15,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"From previous instance of the study: Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-05-20,2021-06-09,Household and community samples,All,Multiple groups,,,Primary Estimate,Test Adjusted,579,0.26,0.23,0.3,True,True,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,Yes,No,No,,Yes,Yes,Yes,,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.10.22270772v1.full-text,2022-02-25,2023-08-15,Unverified,kleynhans_sars-cov-2_2022,ZAF
220215_SouthAfrica_NationalHealthLaboratoryService_Rural_Date6_OverallCrude,220215_SouthAfrica_NationalHealthLaboratoryService_Rural_Date6,"SARS-CoV-2 seroprevalence in a rural and urban community household cohort in South Africa, after the third wave, April-November 2021",2022-02-15,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"From previous instance of the study: Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-05-20,2021-06-09,Household and community samples,All,Multiple groups,,,Analysis,Crude,579,0.2608,,,,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,Yes,No,No,,Yes,Yes,Yes,,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.10.22270772v1.full-text,2022-02-25,2024-03-01,Unverified,kleynhans_sars-cov-2_2022,ZAF
220215_SouthAfrica_NationalHealthLaboratoryService_Rural_Date6_Age13-18,220215_SouthAfrica_NationalHealthLaboratoryService_Rural_Date6,"SARS-CoV-2 seroprevalence in a rural and urban community household cohort in South Africa, after the third wave, April-November 2021",2022-02-15,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"From previous instance of the study: Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-05-20,2021-06-09,Household and community samples,All,Children and Youth (0-17 years),13.0,18.0,Age,,75,0.32,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,Yes,No,No,,Yes,Yes,Yes,,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.10.22270772v1.full-text,2022-02-25,2024-03-01,Unverified,kleynhans_sars-cov-2_2022,ZAF
220215_SouthAfrica_NationalHealthLaboratoryService_Rural_Date6_Age<5,220215_SouthAfrica_NationalHealthLaboratoryService_Rural_Date6,"SARS-CoV-2 seroprevalence in a rural and urban community household cohort in South Africa, after the third wave, April-November 2021",2022-02-15,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"From previous instance of the study: Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-05-20,2021-06-09,Household and community samples,All,Children and Youth (0-17 years),,4.0,Age,,88,0.1591,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,Yes,No,No,,Yes,Yes,Yes,,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.10.22270772v1.full-text,2022-02-25,2024-03-01,Unverified,kleynhans_sars-cov-2_2022,ZAF
220215_SouthAfrica_NationalHealthLaboratoryService_Rural_Date6_Age35-59,220215_SouthAfrica_NationalHealthLaboratoryService_Rural_Date6,"SARS-CoV-2 seroprevalence in a rural and urban community household cohort in South Africa, after the third wave, April-November 2021",2022-02-15,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"From previous instance of the study: Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-05-20,2021-06-09,Household and community samples,All,Adults (18-64 years),35.0,59.0,Age,,84,0.3214,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,Yes,No,No,,Yes,Yes,Yes,,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.10.22270772v1.full-text,2022-02-25,2024-03-01,Unverified,kleynhans_sars-cov-2_2022,ZAF
220215_SouthAfrica_NationalHealthLaboratoryService_Rural_Date6_Age5-12,220215_SouthAfrica_NationalHealthLaboratoryService_Rural_Date6,"SARS-CoV-2 seroprevalence in a rural and urban community household cohort in South Africa, after the third wave, April-November 2021",2022-02-15,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"From previous instance of the study: Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-05-20,2021-06-09,Household and community samples,All,Children and Youth (0-17 years),5.0,12.0,Age,,202,0.2079,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,Yes,No,No,,Yes,Yes,Yes,,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.10.22270772v1.full-text,2022-02-25,2024-03-01,Unverified,kleynhans_sars-cov-2_2022,ZAF
220215_SouthAfrica_NationalHealthLaboratoryService_Rural_Date6_Age19-34,220215_SouthAfrica_NationalHealthLaboratoryService_Rural_Date6,"SARS-CoV-2 seroprevalence in a rural and urban community household cohort in South Africa, after the third wave, April-November 2021",2022-02-15,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"From previous instance of the study: Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-05-20,2021-06-09,Household and community samples,All,Adults (18-64 years),19.0,34.0,Age,,89,0.38200000000000006,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,Yes,No,No,,Yes,Yes,Yes,,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.10.22270772v1.full-text,2022-02-25,2024-03-01,Unverified,kleynhans_sars-cov-2_2022,ZAF
220215_SouthAfrica_NationalHealthLaboratoryService_Rural_Date6_Age>=60,220215_SouthAfrica_NationalHealthLaboratoryService_Rural_Date6,"SARS-CoV-2 seroprevalence in a rural and urban community household cohort in South Africa, after the third wave, April-November 2021",2022-02-15,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"From previous instance of the study: Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-05-20,2021-06-09,Household and community samples,All,Seniors (65+ years),60.0,,Age,>=60,41,0.2439,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,Yes,No,No,,Yes,Yes,Yes,,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.10.22270772v1.full-text,2022-02-25,2024-03-01,Unverified,kleynhans_sars-cov-2_2022,ZAF
220215_SouthAfrica_NationalHealthLaboratoryService_Urban_Date6_OverallAdjusted,220215_SouthAfrica_NationalHealthLaboratoryService_Urban_Date6,"SARS-CoV-2 seroprevalence in a rural and urban community household cohort in South Africa, after the third wave, April-November 2021",2022-02-15,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"From previous instance of the study: Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-05-20,2021-06-09,Household and community samples,All,Multiple groups,,,Primary Estimate,Test Adjusted,505,0.49,0.45,0.53,True,True,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,Yes,No,No,,Yes,Yes,Yes,,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.10.22270772v1.full-text,2022-02-25,2023-08-15,Unverified,kleynhans_sars-cov-2_2022,ZAF
220215_SouthAfrica_NationalHealthLaboratoryService_Urban_Date6_OverallCrude,220215_SouthAfrica_NationalHealthLaboratoryService_Urban_Date6,"SARS-CoV-2 seroprevalence in a rural and urban community household cohort in South Africa, after the third wave, April-November 2021",2022-02-15,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"From previous instance of the study: Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-05-20,2021-06-09,Household and community samples,All,Multiple groups,,,Analysis,Crude,505,0.4891,,,,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,Yes,No,No,,Yes,Yes,Yes,,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.10.22270772v1.full-text,2022-02-25,2024-03-01,Unverified,kleynhans_sars-cov-2_2022,ZAF
220215_SouthAfrica_NationalHealthLaboratoryService_Urban_Date6_Age<5,220215_SouthAfrica_NationalHealthLaboratoryService_Urban_Date6,"SARS-CoV-2 seroprevalence in a rural and urban community household cohort in South Africa, after the third wave, April-November 2021",2022-02-15,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"From previous instance of the study: Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-05-20,2021-06-09,Household and community samples,All,Children and Youth (0-17 years),,4.0,Age,,45,0.3111,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,Yes,No,No,,Yes,Yes,Yes,,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.10.22270772v1.full-text,2022-02-25,2024-03-01,Unverified,kleynhans_sars-cov-2_2022,ZAF
220215_SouthAfrica_NationalHealthLaboratoryService_Urban_Date6_Age35-59,220215_SouthAfrica_NationalHealthLaboratoryService_Urban_Date6,"SARS-CoV-2 seroprevalence in a rural and urban community household cohort in South Africa, after the third wave, April-November 2021",2022-02-15,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"From previous instance of the study: Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-05-20,2021-06-09,Household and community samples,All,Adults (18-64 years),35.0,59.0,Age,,111,0.6306,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,Yes,No,No,,Yes,Yes,Yes,,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.10.22270772v1.full-text,2022-02-25,2024-03-01,Unverified,kleynhans_sars-cov-2_2022,ZAF
220215_SouthAfrica_NationalHealthLaboratoryService_Urban_Date6_Age13-18,220215_SouthAfrica_NationalHealthLaboratoryService_Urban_Date6,"SARS-CoV-2 seroprevalence in a rural and urban community household cohort in South Africa, after the third wave, April-November 2021",2022-02-15,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"From previous instance of the study: Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-05-20,2021-06-09,Household and community samples,All,Children and Youth (0-17 years),13.0,18.0,Age,,77,0.5714,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,Yes,No,No,,Yes,Yes,Yes,,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.10.22270772v1.full-text,2022-02-25,2024-03-01,Unverified,kleynhans_sars-cov-2_2022,ZAF
220215_SouthAfrica_NationalHealthLaboratoryService_Urban_Date6_Age>=60,220215_SouthAfrica_NationalHealthLaboratoryService_Urban_Date6,"SARS-CoV-2 seroprevalence in a rural and urban community household cohort in South Africa, after the third wave, April-November 2021",2022-02-15,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"From previous instance of the study: Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-05-20,2021-06-09,Household and community samples,All,Seniors (65+ years),60.0,,Age,>=60,53,0.434,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,Yes,No,No,,Yes,Yes,Yes,,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.10.22270772v1.full-text,2022-02-25,2024-03-01,Unverified,kleynhans_sars-cov-2_2022,ZAF
220215_SouthAfrica_NationalHealthLaboratoryService_Urban_Date6_Age5-12,220215_SouthAfrica_NationalHealthLaboratoryService_Urban_Date6,"SARS-CoV-2 seroprevalence in a rural and urban community household cohort in South Africa, after the third wave, April-November 2021",2022-02-15,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"From previous instance of the study: Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-05-20,2021-06-09,Household and community samples,All,Children and Youth (0-17 years),5.0,12.0,Age,,125,0.41600000000000004,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,Yes,No,No,,Yes,Yes,Yes,,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.10.22270772v1.full-text,2022-02-25,2024-03-01,Unverified,kleynhans_sars-cov-2_2022,ZAF
220215_SouthAfrica_NationalHealthLaboratoryService_Urban_Date6_Age19-34,220215_SouthAfrica_NationalHealthLaboratoryService_Urban_Date6,"SARS-CoV-2 seroprevalence in a rural and urban community household cohort in South Africa, after the third wave, April-November 2021",2022-02-15,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,South Africa,North West Province,Matlosana Municipality,"From previous instance of the study: Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",,2021-05-20,2021-06-09,Household and community samples,All,Adults (18-64 years),19.0,34.0,Age,,94,0.4681,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],,Yes,No,No,,Yes,Yes,Yes,,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.02.10.22270772v1.full-text,2022-02-25,2024-03-01,Unverified,kleynhans_sars-cov-2_2022,ZAF
220223_GautengProvince_UniversityoftheWitwatersrand_Overall,220223_GautengProvince_UniversityoftheWitwatersrand,Population Immunity and Covid-19 Severity with Omicron Variant in South Africa,2022-02-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"Households living in Gauteng Province, South Africa.

This survey included households that had been sampled during the first seroprevalence survey (https://airtable.com/appFfYIupTrVQ0HJx/tbl9ldV2170ox2BWJ/viwlZGwcU1C56vqWE/reczDJte8eNh37Zze?blocks=hide), which was conducted from November 4, 2020, to January 22, 2021, and included an additional 10% households per cluster to accommodate for non-participation.

All individuals residing in sampled households, irrespective of age, were eligible.",,2021-10-22,2021-12-09,Household and community samples,All,Multiple groups,,,Primary Estimate,,7010,0.731,0.72,0.741,True,,,,True,Stratified probability,Author designed (Luminex),,,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Shabir Madhi,University of the Witwatersrand,Not Unity-Aligned,https://doi.org/10.1056/nejmoa2119658,2022-03-03,2022-07-16,Unverified,madhi_population_2022,ZAF
220223_GautengProvince_UniversityoftheWitwatersrand_AntiN,220223_GautengProvince_UniversityoftheWitwatersrand,Population Immunity and Covid-19 Severity with Omicron Variant in South Africa,2022-02-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"Households living in Gauteng Province, South Africa.

This survey included households that had been sampled during the first seroprevalence survey (https://airtable.com/appFfYIupTrVQ0HJx/tbl9ldV2170ox2BWJ/viwlZGwcU1C56vqWE/reczDJte8eNh37Zze?blocks=hide), which was conducted from November 4, 2020, to January 22, 2021, and included an additional 10% households per cluster to accommodate for non-participation.

All individuals residing in sampled households, irrespective of age, were eligible.",,2021-10-22,2021-12-09,Household and community samples,All,Multiple groups,,,Test used,Anti Nucleocapsid,7010,0.40700000000000003,0.395,0.418,,,,,,Stratified probability,Author designed (Luminex),,,Dried Blood,IgG,Nucleocapsid(N-protein),Validated by developers,0.85,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Shabir Madhi,University of the Witwatersrand,Not Unity-Aligned,https://doi.org/10.1056/nejmoa2119658,2022-03-04,2022-07-16,Unverified,madhi_population_2022,ZAF
220223_GautengProvince_UniversityoftheWitwatersrand_Sex_Female,220223_GautengProvince_UniversityoftheWitwatersrand,Population Immunity and Covid-19 Severity with Omicron Variant in South Africa,2022-02-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"Households living in Gauteng Province, South Africa.

This survey included households that had been sampled during the first seroprevalence survey (https://airtable.com/appFfYIupTrVQ0HJx/tbl9ldV2170ox2BWJ/viwlZGwcU1C56vqWE/reczDJte8eNh37Zze?blocks=hide), which was conducted from November 4, 2020, to January 22, 2021, and included an additional 10% households per cluster to accommodate for non-participation.

All individuals residing in sampled households, irrespective of age, were eligible.",,2021-10-22,2021-12-09,Household and community samples,Female,Multiple groups,,,Sex/Gender,,4065,0.7690000000000001,0.755,0.7809999999999999,,,,,,Stratified probability,Author designed (Luminex),,,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Shabir Madhi,University of the Witwatersrand,Not Unity-Aligned,https://doi.org/10.1056/nejmoa2119658,2022-03-04,2022-07-16,Unverified,madhi_population_2022,ZAF
220223_GautengProvince_UniversityoftheWitwatersrand_Age_12-17,220223_GautengProvince_UniversityoftheWitwatersrand,Population Immunity and Covid-19 Severity with Omicron Variant in South Africa,2022-02-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"Households living in Gauteng Province, South Africa.

This survey included households that had been sampled during the first seroprevalence survey (https://airtable.com/appFfYIupTrVQ0HJx/tbl9ldV2170ox2BWJ/viwlZGwcU1C56vqWE/reczDJte8eNh37Zze?blocks=hide), which was conducted from November 4, 2020, to January 22, 2021, and included an additional 10% households per cluster to accommodate for non-participation.

All individuals residing in sampled households, irrespective of age, were eligible.",,2021-10-22,2021-12-09,Household and community samples,All,Multiple groups,,,Age,Age: 12-17,622,0.738,0.7020000000000001,0.7709999999999999,,,,,,Stratified probability,Author designed (Luminex),,,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Shabir Madhi,University of the Witwatersrand,Not Unity-Aligned,https://doi.org/10.1056/nejmoa2119658,2022-03-04,2022-07-16,Unverified,madhi_population_2022,ZAF
220223_GautengProvince_UniversityoftheWitwatersrand_Age_18-50,220223_GautengProvince_UniversityoftheWitwatersrand,Population Immunity and Covid-19 Severity with Omicron Variant in South Africa,2022-02-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"Households living in Gauteng Province, South Africa.

This survey included households that had been sampled during the first seroprevalence survey (https://airtable.com/appFfYIupTrVQ0HJx/tbl9ldV2170ox2BWJ/viwlZGwcU1C56vqWE/reczDJte8eNh37Zze?blocks=hide), which was conducted from November 4, 2020, to January 22, 2021, and included an additional 10% households per cluster to accommodate for non-participation.

All individuals residing in sampled households, irrespective of age, were eligible.",,2021-10-22,2021-12-09,Household and community samples,All,Multiple groups,,,Age,Age: 18-50,4047,0.736,0.7220000000000001,0.7490000000000001,,,,,,Stratified probability,Author designed (Luminex),,,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Shabir Madhi,University of the Witwatersrand,Not Unity-Aligned,https://doi.org/10.1056/nejmoa2119658,2022-03-04,2022-07-16,Unverified,madhi_population_2022,ZAF
220223_GautengProvince_UniversityoftheWitwatersrand_AntiS,220223_GautengProvince_UniversityoftheWitwatersrand,Population Immunity and Covid-19 Severity with Omicron Variant in South Africa,2022-02-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"Households living in Gauteng Province, South Africa.

This survey included households that had been sampled during the first seroprevalence survey (https://airtable.com/appFfYIupTrVQ0HJx/tbl9ldV2170ox2BWJ/viwlZGwcU1C56vqWE/reczDJte8eNh37Zze?blocks=hide), which was conducted from November 4, 2020, to January 22, 2021, and included an additional 10% households per cluster to accommodate for non-participation.

All individuals residing in sampled households, irrespective of age, were eligible.",,2021-10-22,2021-12-09,Household and community samples,All,Multiple groups,,,Test used,Anti Spike,7010,0.7000000000000001,0.6890000000000001,0.71,,,,,,Stratified probability,Author designed (Luminex),,,Dried Blood,IgG,Spike,Validated by developers,1.0,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Shabir Madhi,University of the Witwatersrand,Not Unity-Aligned,https://doi.org/10.1056/nejmoa2119658,2022-03-04,2022-07-16,Unverified,madhi_population_2022,ZAF
220223_GautengProvince_UniversityoftheWitwatersrand_Age_<12,220223_GautengProvince_UniversityoftheWitwatersrand,Population Immunity and Covid-19 Severity with Omicron Variant in South Africa,2022-02-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"Households living in Gauteng Province, South Africa.

This survey included households that had been sampled during the first seroprevalence survey (https://airtable.com/appFfYIupTrVQ0HJx/tbl9ldV2170ox2BWJ/viwlZGwcU1C56vqWE/reczDJte8eNh37Zze?blocks=hide), which was conducted from November 4, 2020, to January 22, 2021, and included an additional 10% households per cluster to accommodate for non-participation.

All individuals residing in sampled households, irrespective of age, were eligible.",,2021-10-22,2021-12-09,Household and community samples,All,Multiple groups,,,Age,Age: <12,753,0.562,0.526,0.5970000000000001,,,,,,Stratified probability,Author designed (Luminex),,,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Shabir Madhi,University of the Witwatersrand,Not Unity-Aligned,https://doi.org/10.1056/nejmoa2119658,2022-03-04,2022-07-16,Unverified,madhi_population_2022,ZAF
220223_GautengProvince_UniversityoftheWitwatersrand_Unvaccinated,220223_GautengProvince_UniversityoftheWitwatersrand,Population Immunity and Covid-19 Severity with Omicron Variant in South Africa,2022-02-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"Households living in Gauteng Province, South Africa.

This survey included households that had been sampled during the first seroprevalence survey (https://airtable.com/appFfYIupTrVQ0HJx/tbl9ldV2170ox2BWJ/viwlZGwcU1C56vqWE/reczDJte8eNh37Zze?blocks=hide), which was conducted from November 4, 2020, to January 22, 2021, and included an additional 10% households per cluster to accommodate for non-participation.

All individuals residing in sampled households, irrespective of age, were eligible.",,2021-10-22,2021-12-09,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,,5691,0.684,0.672,0.696,,,,,,Stratified probability,Author designed (Luminex),,,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Shabir Madhi,University of the Witwatersrand,Not Unity-Aligned,https://doi.org/10.1056/nejmoa2119658,2022-03-04,2022-07-16,Unverified,madhi_population_2022,ZAF
220223_GautengProvince_UniversityoftheWitwatersrand_Age_>50,220223_GautengProvince_UniversityoftheWitwatersrand,Population Immunity and Covid-19 Severity with Omicron Variant in South Africa,2022-02-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"Households living in Gauteng Province, South Africa.

This survey included households that had been sampled during the first seroprevalence survey (https://airtable.com/appFfYIupTrVQ0HJx/tbl9ldV2170ox2BWJ/viwlZGwcU1C56vqWE/reczDJte8eNh37Zze?blocks=hide), which was conducted from November 4, 2020, to January 22, 2021, and included an additional 10% households per cluster to accommodate for non-participation.

All individuals residing in sampled households, irrespective of age, were eligible.",,2021-10-22,2021-12-09,Household and community samples,All,Multiple groups,,,Age,Age: >50,1588,0.797,0.7759999999999999,0.8150000000000001,,,,,,Stratified probability,Author designed (Luminex),,,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Shabir Madhi,University of the Witwatersrand,Not Unity-Aligned,https://doi.org/10.1056/nejmoa2119658,2022-03-04,2022-07-16,Unverified,madhi_population_2022,ZAF
220223_GautengProvince_UniversityoftheWitwatersrand_Sex_Male,220223_GautengProvince_UniversityoftheWitwatersrand,Population Immunity and Covid-19 Severity with Omicron Variant in South Africa,2022-02-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"Households living in Gauteng Province, South Africa.

This survey included households that had been sampled during the first seroprevalence survey (https://airtable.com/appFfYIupTrVQ0HJx/tbl9ldV2170ox2BWJ/viwlZGwcU1C56vqWE/reczDJte8eNh37Zze?blocks=hide), which was conducted from November 4, 2020, to January 22, 2021, and included an additional 10% households per cluster to accommodate for non-participation.

All individuals residing in sampled households, irrespective of age, were eligible.",,2021-10-22,2021-12-09,Household and community samples,Male,Multiple groups,,,Sex/Gender,,2941,0.679,0.662,0.696,,,,,,Stratified probability,Author designed (Luminex),,,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Shabir Madhi,University of the Witwatersrand,Not Unity-Aligned,https://doi.org/10.1056/nejmoa2119658,2022-03-04,2022-07-16,Unverified,madhi_population_2022,ZAF
220223_GautengProvince_UniversityoftheWitwatersrand_Vaccinated,220223_GautengProvince_UniversityoftheWitwatersrand,Population Immunity and Covid-19 Severity with Omicron Variant in South Africa,2022-02-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,"Households living in Gauteng Province, South Africa.

This survey included households that had been sampled during the first seroprevalence survey (https://airtable.com/appFfYIupTrVQ0HJx/tbl9ldV2170ox2BWJ/viwlZGwcU1C56vqWE/reczDJte8eNh37Zze?blocks=hide), which was conducted from November 4, 2020, to January 22, 2021, and included an additional 10% households per cluster to accommodate for non-participation.

All individuals residing in sampled households, irrespective of age, were eligible.",,2021-10-22,2021-12-09,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,,1319,0.9309999999999999,0.9159999999999999,0.943,,,,,,Stratified probability,Author designed (Luminex),,,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Shabir Madhi,University of the Witwatersrand,Not Unity-Aligned,https://doi.org/10.1056/nejmoa2119658,2022-03-04,2022-07-16,Unverified,madhi_population_2022,ZAF
220301_SouthAfrica_UniversityOfCapeTown,220301_SouthAfrica_UniversityOfCapeTown,Performance of SARS-CoV-2 antibody assays in a national serosurvey in South Africa,2022-03-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,South Africa,,,,,2021-04-15,2021-06-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,8146,0.06269999999999999,,,True,,,,True,Unclear,"Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown)","Abbott Laboratories,EUROIMMUN,Roche Diagnostics",CLIA,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,Unclear,Yes,No,,Unclear,Yes,No,,Sizulu Moyo,University of Cape Town,Not Unity-Aligned,https://www.iasusa.org/tam/march-2022/,2022-06-17,2024-03-01,Unverified,moyo_performance_2022,ZAF
220310_SouthAfrica_NationalHealthLaboratoryService_Overall,220310_SouthAfrica_NationalHealthLaboratoryService,Seroprevalence of SARS-CoV-2 after the second wave in South Africa in HIV-infected and uninfected persons: a cross-sectional household survey,2022-03-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,South Africa,"KwaZulu-Natal, North West Province, Western Cape","Pietermaritzburg, Klerksdorp, Mitchell's Plain","Residents of Mitchell’s Plain (Western Cape Province), Pietermaritzburg (KwaZulu-Natal Province), and Klerksdorp (North West Province) ",,2020-11-15,2021-04-15,Multiple general populations,All,Multiple groups,,,Primary Estimate,,7577,0.4523,0.43700000000000006,0.467,True,,,,True,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Elecsys® Anti‐SARS‐CoV‐2 (N)","Beijing Wantai Biological,Roche Diagnostics",ELISA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Nicole Wolter,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac198,2022-04-04,2024-03-01,Unverified,wolterSeroprevalenceSARSCoV2Second2022,ZAF
220310_SouthAfrica_NationalHealthLaboratoryService_Mar2021,220310_SouthAfrica_NationalHealthLaboratoryService,Seroprevalence of SARS-CoV-2 after the second wave in South Africa in HIV-infected and uninfected persons: a cross-sectional household survey,2022-03-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,South Africa,"KwaZulu-Natal, North West Province, Western Cape","Pietermaritzburg, Klerksdorp, Mitchell's Plain","Residents of Mitchell’s Plain (Western Cape Province), Pietermaritzburg (KwaZulu-Natal Province), and Klerksdorp (North West Province) ",,2021-03-11,2021-03-11,Multiple general populations,All,Multiple groups,,,Time frame,March 2021,3918,0.46,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Elecsys® Anti‐SARS‐CoV‐2 (N)","Beijing Wantai Biological,Roche Diagnostics",ELISA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Nicole Wolter,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac198,2022-04-04,2024-03-01,Unverified,wolterSeroprevalenceSARSCoV2Second2022,ZAF
220310_SouthAfrica_NationalHealthLaboratoryService_Age5-12,220310_SouthAfrica_NationalHealthLaboratoryService,Seroprevalence of SARS-CoV-2 after the second wave in South Africa in HIV-infected and uninfected persons: a cross-sectional household survey,2022-03-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,South Africa,"KwaZulu-Natal, North West Province, Western Cape","Pietermaritzburg, Klerksdorp, Mitchell's Plain","Residents of Mitchell’s Plain (Western Cape Province), Pietermaritzburg (KwaZulu-Natal Province), and Klerksdorp (North West Province) ",,2020-11-15,2021-04-15,Multiple general populations,All,Children and Youth (0-17 years),5.0,12.0,Age,,865,0.4023,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Elecsys® Anti‐SARS‐CoV‐2 (N)","Beijing Wantai Biological,Roche Diagnostics",ELISA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Nicole Wolter,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac198,2022-04-04,2024-03-01,Unverified,wolterSeroprevalenceSARSCoV2Second2022,ZAF
220310_SouthAfrica_NationalHealthLaboratoryService_SexFemale,220310_SouthAfrica_NationalHealthLaboratoryService,Seroprevalence of SARS-CoV-2 after the second wave in South Africa in HIV-infected and uninfected persons: a cross-sectional household survey,2022-03-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,South Africa,"KwaZulu-Natal, North West Province, Western Cape","Pietermaritzburg, Klerksdorp, Mitchell's Plain","Residents of Mitchell’s Plain (Western Cape Province), Pietermaritzburg (KwaZulu-Natal Province), and Klerksdorp (North West Province) ",,2020-11-15,2021-04-15,Multiple general populations,Female,Multiple groups,,,Sex/Gender,,4583,0.48350000000000004,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Elecsys® Anti‐SARS‐CoV‐2 (N)","Beijing Wantai Biological,Roche Diagnostics",ELISA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Nicole Wolter,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac198,2022-04-04,2024-03-01,Unverified,wolterSeroprevalenceSARSCoV2Second2022,ZAF
220310_SouthAfrica_NationalHealthLaboratoryService_AreaPietermaritzburg,220310_SouthAfrica_NationalHealthLaboratoryService,Seroprevalence of SARS-CoV-2 after the second wave in South Africa in HIV-infected and uninfected persons: a cross-sectional household survey,2022-03-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,"KwaZulu-Natal, North West Province, Western Cape",Pietermaritzburg,"Residents of Mitchell’s Plain (Western Cape Province), Pietermaritzburg (KwaZulu-Natal Province), and Klerksdorp (North West Province) ",,2020-11-15,2021-04-15,Multiple general populations,All,Multiple groups,,,Geographical area,Pietermaritzburg,2452,0.5024000000000001,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Elecsys® Anti‐SARS‐CoV‐2 (N)","Beijing Wantai Biological,Roche Diagnostics",ELISA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Nicole Wolter,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac198,2022-04-04,2024-03-01,Unverified,wolterSeroprevalenceSARSCoV2Second2022,ZAF
220310_SouthAfrica_NationalHealthLaboratoryService_Feb2021,220310_SouthAfrica_NationalHealthLaboratoryService,Seroprevalence of SARS-CoV-2 after the second wave in South Africa in HIV-infected and uninfected persons: a cross-sectional household survey,2022-03-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,South Africa,"KwaZulu-Natal, North West Province, Western Cape","Pietermaritzburg, Klerksdorp, Mitchell's Plain","Residents of Mitchell’s Plain (Western Cape Province), Pietermaritzburg (KwaZulu-Natal Province), and Klerksdorp (North West Province) ",,2021-02-01,2021-02-01,Multiple general populations,All,Multiple groups,,,Time frame,February 2021,907,0.443,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Elecsys® Anti‐SARS‐CoV‐2 (N)","Beijing Wantai Biological,Roche Diagnostics",ELISA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Nicole Wolter,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac198,2022-04-04,2024-03-01,Unverified,wolterSeroprevalenceSARSCoV2Second2022,ZAF
220310_SouthAfrica_NationalHealthLaboratoryService_Age13-18,220310_SouthAfrica_NationalHealthLaboratoryService,Seroprevalence of SARS-CoV-2 after the second wave in South Africa in HIV-infected and uninfected persons: a cross-sectional household survey,2022-03-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,South Africa,"KwaZulu-Natal, North West Province, Western Cape","Pietermaritzburg, Klerksdorp, Mitchell's Plain","Residents of Mitchell’s Plain (Western Cape Province), Pietermaritzburg (KwaZulu-Natal Province), and Klerksdorp (North West Province) ",,2020-11-15,2021-04-15,Multiple general populations,All,Children and Youth (0-17 years),13.0,18.0,Age,,810,0.4938,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Elecsys® Anti‐SARS‐CoV‐2 (N)","Beijing Wantai Biological,Roche Diagnostics",ELISA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Nicole Wolter,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac198,2022-04-04,2024-03-01,Unverified,wolterSeroprevalenceSARSCoV2Second2022,ZAF
220310_SouthAfrica_NationalHealthLaboratoryService_AreMitchellsPlain,220310_SouthAfrica_NationalHealthLaboratoryService,Seroprevalence of SARS-CoV-2 after the second wave in South Africa in HIV-infected and uninfected persons: a cross-sectional household survey,2022-03-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,"KwaZulu-Natal, North West Province, Western Cape",Mitchell's Plain,"Residents of Mitchell’s Plain (Western Cape Province), Pietermaritzburg (KwaZulu-Natal Province), and Klerksdorp (North West Province) ",,2020-11-15,2021-04-15,Multiple general populations,All,Multiple groups,,,Geographical area,Mitchell's Plain,2741,0.4546,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Elecsys® Anti‐SARS‐CoV‐2 (N)","Beijing Wantai Biological,Roche Diagnostics",ELISA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Nicole Wolter,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac198,2022-04-04,2024-03-01,Unverified,wolterSeroprevalenceSARSCoV2Second2022,ZAF
220310_SouthAfrica_NationalHealthLaboratoryService_Age25-39,220310_SouthAfrica_NationalHealthLaboratoryService,Seroprevalence of SARS-CoV-2 after the second wave in South Africa in HIV-infected and uninfected persons: a cross-sectional household survey,2022-03-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,South Africa,"KwaZulu-Natal, North West Province, Western Cape","Pietermaritzburg, Klerksdorp, Mitchell's Plain","Residents of Mitchell’s Plain (Western Cape Province), Pietermaritzburg (KwaZulu-Natal Province), and Klerksdorp (North West Province) ",,2020-11-15,2021-04-15,Multiple general populations,All,Adults (18-64 years),25.0,39.0,Age,25-39,2050,0.4941,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Elecsys® Anti‐SARS‐CoV‐2 (N)","Beijing Wantai Biological,Roche Diagnostics",ELISA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Nicole Wolter,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac198,2022-04-04,2024-03-01,Unverified,wolterSeroprevalenceSARSCoV2Second2022,ZAF
220310_SouthAfrica_NationalHealthLaboratoryService_SexMale,220310_SouthAfrica_NationalHealthLaboratoryService,Seroprevalence of SARS-CoV-2 after the second wave in South Africa in HIV-infected and uninfected persons: a cross-sectional household survey,2022-03-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,South Africa,"KwaZulu-Natal, North West Province, Western Cape","Pietermaritzburg, Klerksdorp, Mitchell's Plain","Residents of Mitchell’s Plain (Western Cape Province), Pietermaritzburg (KwaZulu-Natal Province), and Klerksdorp (North West Province) ",,2020-11-15,2021-04-15,Multiple general populations,Male,Multiple groups,,,Sex/Gender,,2993,0.4043,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Elecsys® Anti‐SARS‐CoV‐2 (N)","Beijing Wantai Biological,Roche Diagnostics",ELISA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Nicole Wolter,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac198,2022-04-04,2024-03-01,Unverified,wolterSeroprevalenceSARSCoV2Second2022,ZAF
220310_SouthAfrica_NationalHealthLaboratoryService_Age40-59,220310_SouthAfrica_NationalHealthLaboratoryService,Seroprevalence of SARS-CoV-2 after the second wave in South Africa in HIV-infected and uninfected persons: a cross-sectional household survey,2022-03-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,South Africa,"KwaZulu-Natal, North West Province, Western Cape","Pietermaritzburg, Klerksdorp, Mitchell's Plain","Residents of Mitchell’s Plain (Western Cape Province), Pietermaritzburg (KwaZulu-Natal Province), and Klerksdorp (North West Province) ",,2020-11-15,2021-04-15,Multiple general populations,All,Adults (18-64 years),40.0,59.0,Age,40-59,1981,0.44070000000000004,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Elecsys® Anti‐SARS‐CoV‐2 (N)","Beijing Wantai Biological,Roche Diagnostics",ELISA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Nicole Wolter,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac198,2022-04-04,2024-03-01,Unverified,wolterSeroprevalenceSARSCoV2Second2022,ZAF
220310_SouthAfrica_NationalHealthLaboratoryService_Apr2021,220310_SouthAfrica_NationalHealthLaboratoryService,Seroprevalence of SARS-CoV-2 after the second wave in South Africa in HIV-infected and uninfected persons: a cross-sectional household survey,2022-03-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,South Africa,"KwaZulu-Natal, North West Province, Western Cape","Pietermaritzburg, Klerksdorp, Mitchell's Plain","Residents of Mitchell’s Plain (Western Cape Province), Pietermaritzburg (KwaZulu-Natal Province), and Klerksdorp (North West Province) ",,2021-04-01,2021-04-30,Multiple general populations,All,Multiple groups,,,Time frame,April 2021,1849,0.47200000000000003,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Elecsys® Anti‐SARS‐CoV‐2 (N)","Beijing Wantai Biological,Roche Diagnostics",ELISA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Nicole Wolter,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac198,2022-04-04,2024-03-01,Unverified,wolterSeroprevalenceSARSCoV2Second2022,ZAF
220310_SouthAfrica_NationalHealthLaboratoryService_AreaKlerksdorp,220310_SouthAfrica_NationalHealthLaboratoryService,Seroprevalence of SARS-CoV-2 after the second wave in South Africa in HIV-infected and uninfected persons: a cross-sectional household survey,2022-03-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,"KwaZulu-Natal, North West Province, Western Cape",Klerksdrop,"Residents of Mitchell’s Plain (Western Cape Province), Pietermaritzburg (KwaZulu-Natal Province), and Klerksdorp (North West Province) ",,2020-11-15,2021-04-15,Multiple general populations,All,Multiple groups,,,Geographical area,Klerksdorp,2384,0.3981,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Elecsys® Anti‐SARS‐CoV‐2 (N)","Beijing Wantai Biological,Roche Diagnostics",ELISA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Nicole Wolter,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac198,2022-04-04,2024-03-01,Unverified,wolterSeroprevalenceSARSCoV2Second2022,ZAF
220310_SouthAfrica_NationalHealthLaboratoryService_Age60+,220310_SouthAfrica_NationalHealthLaboratoryService,Seroprevalence of SARS-CoV-2 after the second wave in South Africa in HIV-infected and uninfected persons: a cross-sectional household survey,2022-03-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,South Africa,"KwaZulu-Natal, North West Province, Western Cape","Pietermaritzburg, Klerksdorp, Mitchell's Plain","Residents of Mitchell’s Plain (Western Cape Province), Pietermaritzburg (KwaZulu-Natal Province), and Klerksdorp (North West Province) ",,2020-11-15,2021-04-15,Multiple general populations,All,Multiple groups,60.0,,Age,60+,1046,0.37,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Elecsys® Anti‐SARS‐CoV‐2 (N)","Beijing Wantai Biological,Roche Diagnostics",ELISA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Nicole Wolter,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac198,2022-04-04,2024-03-01,Unverified,wolterSeroprevalenceSARSCoV2Second2022,ZAF
220310_SouthAfrica_NationalHealthLaboratoryService_Dec2020,220310_SouthAfrica_NationalHealthLaboratoryService,Seroprevalence of SARS-CoV-2 after the second wave in South Africa in HIV-infected and uninfected persons: a cross-sectional household survey,2022-03-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,South Africa,"KwaZulu-Natal, North West Province, Western Cape","Pietermaritzburg, Klerksdorp, Mitchell's Plain","Residents of Mitchell’s Plain (Western Cape Province), Pietermaritzburg (KwaZulu-Natal Province), and Klerksdorp (North West Province) ",,2020-12-01,2020-12-31,Multiple general populations,All,Multiple groups,,,Time frame,December 2020,312,0.269,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Elecsys® Anti‐SARS‐CoV‐2 (N)","Beijing Wantai Biological,Roche Diagnostics",ELISA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Nicole Wolter,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac198,2022-04-04,2024-03-01,Unverified,wolterSeroprevalenceSARSCoV2Second2022,ZAF
220310_SouthAfrica_NationalHealthLaboratoryService_Nov2020,220310_SouthAfrica_NationalHealthLaboratoryService,Seroprevalence of SARS-CoV-2 after the second wave in South Africa in HIV-infected and uninfected persons: a cross-sectional household survey,2022-03-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,South Africa,"KwaZulu-Natal, North West Province, Western Cape","Pietermaritzburg, Klerksdorp, Mitchell's Plain","Residents of Mitchell’s Plain (Western Cape Province), Pietermaritzburg (KwaZulu-Natal Province), and Klerksdorp (North West Province) ",,2020-11-01,2020-11-30,Multiple general populations,All,Multiple groups,,,Time frame,November 2020,47,0.128,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Elecsys® Anti‐SARS‐CoV‐2 (N)","Beijing Wantai Biological,Roche Diagnostics",ELISA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Nicole Wolter,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac198,2022-04-04,2024-03-01,Unverified,wolterSeroprevalenceSARSCoV2Second2022,ZAF
220310_SouthAfrica_NationalHealthLaboratoryService_Age<5,220310_SouthAfrica_NationalHealthLaboratoryService,Seroprevalence of SARS-CoV-2 after the second wave in South Africa in HIV-infected and uninfected persons: a cross-sectional household survey,2022-03-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,South Africa,"KwaZulu-Natal, North West Province, Western Cape","Pietermaritzburg, Klerksdorp, Mitchell's Plain","Residents of Mitchell’s Plain (Western Cape Province), Pietermaritzburg (KwaZulu-Natal Province), and Klerksdorp (North West Province) ",,2020-11-15,2021-04-15,Multiple general populations,All,Children and Youth (0-17 years),,5.0,Age,,130,0.2462,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Elecsys® Anti‐SARS‐CoV‐2 (N)","Beijing Wantai Biological,Roche Diagnostics",ELISA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Nicole Wolter,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac198,2022-04-04,2024-03-01,Unverified,wolterSeroprevalenceSARSCoV2Second2022,ZAF
220310_SouthAfrica_NationalHealthLaboratoryService_Jan2021,220310_SouthAfrica_NationalHealthLaboratoryService,Seroprevalence of SARS-CoV-2 after the second wave in South Africa in HIV-infected and uninfected persons: a cross-sectional household survey,2022-03-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,South Africa,"KwaZulu-Natal, North West Province, Western Cape","Pietermaritzburg, Klerksdorp, Mitchell's Plain","Residents of Mitchell’s Plain (Western Cape Province), Pietermaritzburg (KwaZulu-Natal Province), and Klerksdorp (North West Province) ",,2021-01-01,2021-01-31,Multiple general populations,All,Multiple groups,,,Time frame,January 2021,544,0.48,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Elecsys® Anti‐SARS‐CoV‐2 (N)","Beijing Wantai Biological,Roche Diagnostics",ELISA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Nicole Wolter,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac198,2022-04-04,2024-03-01,Unverified,wolterSeroprevalenceSARSCoV2Second2022,ZAF
220310_SouthAfrica_NationalHealthLaboratoryService_Age19-24,220310_SouthAfrica_NationalHealthLaboratoryService,Seroprevalence of SARS-CoV-2 after the second wave in South Africa in HIV-infected and uninfected persons: a cross-sectional household survey,2022-03-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,South Africa,"KwaZulu-Natal, North West Province, Western Cape","Pietermaritzburg, Klerksdorp, Mitchell's Plain","Residents of Mitchell’s Plain (Western Cape Province), Pietermaritzburg (KwaZulu-Natal Province), and Klerksdorp (North West Province) ",,2020-11-15,2021-04-15,Multiple general populations,All,Adults (18-64 years),19.0,24.0,Age,19-24,695,0.39420000000000005,,,,,,,,Stratified probability,"Wantai SARS-CoV-2 Total Ab ELISA,Elecsys® Anti‐SARS‐CoV‐2 (N)","Beijing Wantai Biological,Roche Diagnostics",ELISA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Nicole Wolter,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac198,2022-04-04,2024-03-01,Unverified,wolterSeroprevalenceSARSCoV2Second2022,ZAF
220318_EasternCape_WalterSisuluUniversity_Primary,220318_EasternCape_WalterSisuluUniversity,"Cumulative incidence of SARS-CoV-2 and associated risk factors among healthcare workers: a cross-sectional study in the Eastern Cape, South Africa.",2022-03-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Eastern Cape,,"All categories of HCWs in the two hospitals (Cecilia Makiwane, Frere hospital) were eligible to participate in the study.",Eleven blood samples for SARS- CoV-2 IgG serology were missing or rejected by the labo- ratory and were excluded from the final analysis. Data for another three participants were excluded due to missing data on the main outcome measures.,2020-11-04,2020-12-18,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,1295,0.37700000000000006,,,True,,,,True,Stratified probability,Author designed (ELISA) - Nucleocapsid,,,Whole Blood,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,David Stead,Walter Sisulu University,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-058761,2022-03-29,2022-07-16,Unverified,stead_cumulative_2022,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD6_TestAdj,220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD6,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in 4 rural villages were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-05-20,2021-06-09,Household and community samples,All,Multiple groups,,,Primary Estimate,,579,0.26,0.23,0.3,True,True,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2023-08-15,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD6_0-4,220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD6,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in 4 rural villages were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-05-20,2021-06-09,Household and community samples,All,Children and Youth (0-17 years),0.0,4.0,Age,0-4,88,0.1591,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD6_Unadj,220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD6,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in 4 rural villages were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-05-20,2021-06-09,Household and community samples,All,Multiple groups,,,Analysis,,579,0.2608,,,,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD6_5-12,220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD6,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in 4 rural villages were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-05-20,2021-06-09,Household and community samples,All,Children and Youth (0-17 years),5.0,12.0,Age,5-12,202,0.2079,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD6_60+,220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD6,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in 4 rural villages were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-05-20,2021-06-09,Household and community samples,All,Multiple groups,60.0,,Age,60+,41,0.2439,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD6_19-34,220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD6,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in 4 rural villages were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-05-20,2021-06-09,Household and community samples,All,Adults (18-64 years),19.0,34.0,Age,19-34,89,0.38200000000000006,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD6_13-18,220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD6,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in 4 rural villages were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-05-20,2021-06-09,Household and community samples,All,Children and Youth (0-17 years),13.0,18.0,Age,13-18,75,0.32,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD6_35-59,220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD6,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in 4 rural villages were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-05-20,2021-06-09,Household and community samples,All,Adults (18-64 years),35.0,39.0,Age,35-59,84,0.3214,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD7_TestAdj,220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD7,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in 4 rural villages were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-07-19,2021-08-05,Household and community samples,All,Multiple groups,,,Primary Estimate,,578,0.39,0.35000000000000003,0.43,True,True,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2023-08-15,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD7_Unadj,220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD7,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in 4 rural villages were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-07-19,2021-08-05,Household and community samples,All,Multiple groups,,,Analysis,,578,0.3893,,,,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD7_35-59,220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD7,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in 4 rural villages were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-07-19,2021-08-05,Household and community samples,All,Adults (18-64 years),35.0,39.0,Age,35-59,82,0.4268,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD7_0-4,220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD7,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in 4 rural villages were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-07-19,2021-08-05,Household and community samples,All,Children and Youth (0-17 years),0.0,4.0,Age,0-4,90,0.2889,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD7_13-18,220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD7,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in 4 rural villages were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-07-19,2021-08-05,Household and community samples,All,Children and Youth (0-17 years),13.0,18.0,Age,13-18,77,0.5195000000000001,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD7_5-12,220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD7,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in 4 rural villages were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-07-19,2021-08-05,Household and community samples,All,Children and Youth (0-17 years),5.0,12.0,Age,5-12,202,0.3465,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD7_19-34,220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD7,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in 4 rural villages were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-07-19,2021-08-05,Household and community samples,All,Adults (18-64 years),19.0,34.0,Age,19-34,87,0.4598,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD7_60+,220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD7,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in 4 rural villages were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-07-19,2021-08-05,Household and community samples,All,Multiple groups,60.0,,Age,60+,40,0.35000000000000003,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD8_TestAdj,220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD8,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in 4 rural villages were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-09-13,2021-09-25,Household and community samples,All,Multiple groups,,,Primary Estimate,,548,0.59,0.55,0.64,True,True,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2023-08-15,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD8_Unadj,220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD8,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in 4 rural villages were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-09-13,2021-09-25,Household and community samples,All,Multiple groups,,,Analysis,,548,0.5931000000000001,,,,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD8_19-34,220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD8,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in 4 rural villages were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-09-13,2021-09-25,Household and community samples,All,Adults (18-64 years),19.0,34.0,Age,19-34,81,0.5926,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD8_60+,220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD8,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in 4 rural villages were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-09-13,2021-09-25,Household and community samples,All,Multiple groups,60.0,,Age,60+,37,0.4324,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD8_5-12,220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD8,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in 4 rural villages were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-09-13,2021-09-25,Household and community samples,All,Children and Youth (0-17 years),5.0,12.0,Age,5-12,200,0.6,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD8_13-18,220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD8,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in 4 rural villages were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-09-13,2021-09-25,Household and community samples,All,Children and Youth (0-17 years),13.0,18.0,Age,13-18,73,0.8081999999999999,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD8_0-4,220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD8,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in 4 rural villages were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-09-13,2021-09-25,Household and community samples,All,Children and Youth (0-17 years),0.0,4.0,Age,0-4,77,0.4286,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD8_35-59,220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD8,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in 4 rural villages were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-09-13,2021-09-25,Household and community samples,All,Adults (18-64 years),35.0,39.0,Age,35-59,80,0.6125,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD9_TestAdj,220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD9,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in 4 rural villages were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-11-15,2021-11-27,Household and community samples,All,Multiple groups,,,Primary Estimate,,550,0.6,0.56,0.64,True,True,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2023-08-15,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD9_19-34,220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD9,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in 4 rural villages were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-11-15,2021-11-27,Household and community samples,All,Adults (18-64 years),19.0,34.0,Age,19-34,80,0.5875,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD9_13-18,220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD9,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in 4 rural villages were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-11-15,2021-11-27,Household and community samples,All,Children and Youth (0-17 years),13.0,18.0,Age,13-18,71,0.8028000000000001,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD9_35-59,220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD9,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in 4 rural villages were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-11-15,2021-11-27,Household and community samples,All,Adults (18-64 years),35.0,39.0,Age,35-59,80,0.6125,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD9_0-4,220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD9,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in 4 rural villages were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-11-15,2021-11-27,Household and community samples,All,Children and Youth (0-17 years),0.0,4.0,Age,0-4,84,0.4286,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD9_Unadj,220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD9,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in 4 rural villages were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-11-15,2021-11-27,Household and community samples,All,Multiple groups,,,Analysis,,550,0.5982000000000001,,,,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD9_60+,220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD9,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in 4 rural villages were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-11-15,2021-11-27,Household and community samples,All,Multiple groups,60.0,,Age,60+,37,0.4865,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD9_5-12,220323_SouthAfrica_NationalHealthLaboratoryService_Rural_BD9,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,Mpumalanga Province,Bushbuckridge Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in 4 rural villages were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-11-15,2021-11-27,Household and community samples,All,Children and Youth (0-17 years),5.0,12.0,Age,5-12,198,0.6162,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD6_TestAdj,220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD6,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,North West Province,Matlosana Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in urban areas were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-05-20,2021-06-09,Household and community samples,All,Multiple groups,,,Primary Estimate,,505,0.49,0.45,0.53,True,True,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2023-08-15,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD6_13-18,220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD6,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,North West Province,Matlosana Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in urban areas were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-05-20,2021-06-09,Household and community samples,All,Children and Youth (0-17 years),13.0,18.0,Age,13-18,77,0.5714,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD6_5-12,220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD6,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,North West Province,Matlosana Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in urban areas were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-05-20,2021-06-09,Household and community samples,All,Children and Youth (0-17 years),5.0,12.0,Age,5-12,125,0.41600000000000004,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD6_19-34,220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD6,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,North West Province,Matlosana Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in urban areas were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-05-20,2021-06-09,Household and community samples,All,Adults (18-64 years),19.0,34.0,Age,19-34,94,0.4681,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD6_0-4,220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD6,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,North West Province,Matlosana Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in urban areas were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-05-20,2021-06-09,Household and community samples,All,Children and Youth (0-17 years),0.0,4.0,Age,0-4,45,0.3111,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD6_Unadj,220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD6,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,North West Province,Matlosana Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in urban areas were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-05-20,2021-06-09,Household and community samples,All,Multiple groups,,,Analysis,,505,0.4891,,,,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD6_60+,220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD6,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,North West Province,Matlosana Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in urban areas were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-05-20,2021-06-09,Household and community samples,All,Multiple groups,60.0,,Age,60+,53,0.434,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD6_35-59,220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD6,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,North West Province,Matlosana Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in urban areas were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-05-20,2021-06-09,Household and community samples,All,Adults (18-64 years),35.0,39.0,Age,35-59,111,0.6306,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD7_TestAdj,220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD7,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,North West Province,Matlosana Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in urban areas were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-07-19,2021-08-05,Household and community samples,All,Multiple groups,,,Primary Estimate,,499,0.56,0.51,0.6,True,True,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2023-08-15,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD7_5-12,220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD7,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,North West Province,Matlosana Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in urban areas were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-07-19,2021-08-05,Household and community samples,All,Children and Youth (0-17 years),5.0,12.0,Age,5-12,124,0.4839,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD7_60+,220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD7,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,North West Province,Matlosana Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in urban areas were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-07-19,2021-08-05,Household and community samples,All,Multiple groups,60.0,,Age,60+,52,0.6154000000000001,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD7_13-18,220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD7,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,North West Province,Matlosana Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in urban areas were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-07-19,2021-08-05,Household and community samples,All,Children and Youth (0-17 years),13.0,18.0,Age,13-18,74,0.6351,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD7_Unadj,220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD7,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,North West Province,Matlosana Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in urban areas were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-07-19,2021-08-05,Household and community samples,All,Multiple groups,,,Analysis,,499,0.5571,,,,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD7_19-34,220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD7,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,North West Province,Matlosana Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in urban areas were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-07-19,2021-08-05,Household and community samples,All,Adults (18-64 years),19.0,34.0,Age,19-34,96,0.5208,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD7_35-59,220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD7,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,North West Province,Matlosana Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in urban areas were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-07-19,2021-08-05,Household and community samples,All,Adults (18-64 years),35.0,39.0,Age,35-59,107,0.6542,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD7_0-4,220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD7,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,North West Province,Matlosana Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in urban areas were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-07-19,2021-08-05,Household and community samples,All,Children and Youth (0-17 years),0.0,4.0,Age,0-4,46,0.413,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD8_TestAdj,220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD8,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,North West Province,Matlosana Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in urban areas were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-09-13,2021-09-25,Household and community samples,All,Multiple groups,,,Primary Estimate,,493,0.6900000000000001,0.65,0.73,True,True,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2023-08-15,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD8_60+,220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD8,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,North West Province,Matlosana Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in urban areas were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-09-13,2021-09-25,Household and community samples,All,Multiple groups,60.0,,Age,60+,51,0.6470999999999999,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD8_5-12,220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD8,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,North West Province,Matlosana Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in urban areas were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-09-13,2021-09-25,Household and community samples,All,Children and Youth (0-17 years),5.0,12.0,Age,5-12,124,0.6048,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD8_0-4,220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD8,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,North West Province,Matlosana Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in urban areas were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-09-13,2021-09-25,Household and community samples,All,Children and Youth (0-17 years),0.0,4.0,Age,0-4,45,0.5556,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD8_35-59,220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD8,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,North West Province,Matlosana Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in urban areas were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-09-13,2021-09-25,Household and community samples,All,Adults (18-64 years),35.0,39.0,Age,35-59,104,0.7885,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD8_19-34,220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD8,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,North West Province,Matlosana Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in urban areas were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-09-13,2021-09-25,Household and community samples,All,Adults (18-64 years),19.0,34.0,Age,19-34,95,0.6842,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD8_Unadj,220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD8,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,North West Province,Matlosana Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in urban areas were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-09-13,2021-09-25,Household and community samples,All,Multiple groups,,,Analysis,,493,0.6876000000000001,,,,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD8_13-18,220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD8,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,North West Province,Matlosana Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in urban areas were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-09-13,2021-09-25,Household and community samples,All,Children and Youth (0-17 years),13.0,18.0,Age,13-18,74,0.7973,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD9_TestAdj,220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD9,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,North West Province,Matlosana Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in urban areas were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-11-15,2021-11-27,Household and community samples,All,Multiple groups,,,Primary Estimate,,479,0.7000000000000001,0.66,0.74,True,True,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2023-08-15,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD9_60+,220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD9,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,North West Province,Matlosana Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in urban areas were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-11-15,2021-11-27,Household and community samples,All,Multiple groups,60.0,,Age,60+,47,0.6383,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD9_Unadj,220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD9,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,North West Province,Matlosana Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in urban areas were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-11-15,2021-11-27,Household and community samples,All,Multiple groups,,,Analysis,,479,0.6994,,,,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD9_13-18,220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD9,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,North West Province,Matlosana Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in urban areas were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-11-15,2021-11-27,Household and community samples,All,Children and Youth (0-17 years),13.0,18.0,Age,13-18,72,0.8333,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD9_35-59,220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD9,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,North West Province,Matlosana Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in urban areas were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-11-15,2021-11-27,Household and community samples,All,Adults (18-64 years),35.0,39.0,Age,35-59,104,0.7885,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD9_0-4,220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD9,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,North West Province,Matlosana Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in urban areas were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-11-15,2021-11-27,Household and community samples,All,Children and Youth (0-17 years),0.0,4.0,Age,0-4,45,0.5333,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD9_19-34,220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD9,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,North West Province,Matlosana Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in urban areas were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-11-15,2021-11-27,Household and community samples,All,Adults (18-64 years),19.0,34.0,Age,19-34,88,0.7045,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD9_5-12,220323_SouthAfrica_NationalHealthLaboratoryService_Urban_BD9,"SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.",2022-03-23,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,South Africa,North West Province,Matlosana Municipality,"Members of the PHIRST/PHIRST-C cohorts: Households in urban areas were eligible if they had 3 or more household members (sharing at least 4 meals a week). All household members approached for inclusion, and eligible if >80% of members consented to be enrolled.",,2021-11-15,2021-11-27,Household and community samples,All,Children and Youth (0-17 years),5.0,12.0,Age,5-12,123,0.626,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Unclear,Jackie Kleynhans,National Health Laboratory Service,Unity-Aligned,https://dx.doi.org/10.3201/eid2805.220278,2022-03-31,2024-03-01,Verified,kleynhans_sars-cov-2_2022-1,ZAF
220331_SouthAfrica_HumanSciencesResearchCouncil,220331_SouthAfrica_HumanSciencesResearchCouncil,A national seroprevalence survey of SARS-CoV-2 antibodies in South Africa: 2020-2021,2022-03-31,Presentation or Conference,National,Repeated cross-sectional study,South Africa,,,Household-based population of those 12 and older,,2020-11-15,2021-06-15,Household and community samples,All,Multiple groups,12.0,,Primary Estimate,,13640,0.196,0.179,0.21300000000000002,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Not reported/ Unable to specify","EUROIMMUN,NA",Multiple Types,Whole Blood,,,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Leickness Simbayi,Human Sciences Research Council,Not Unity-Aligned,https://www.iasusa.org/tam/march-2022/,2022-06-15,2024-03-01,Unverified,simbayi_national_2022,ZAF
220413_Gugulethu_ICGEB_Primary,220413_Gugulethu_ICGEB,"SARS-CoV-2 Infection Is Associated with Uncontrolled HIV Viral Load in Non-Hospitalized HIV-Infected Patients from Gugulethu, South Africa",2022-04-13,Journal Article (Peer-Reviewed),Local,Prospective cohort,South Africa,Western Cape,Gugulethu,A cohort of 150 non-hospitalized adult HIV-infected patients presenting for routine HIV treatment at the Gugulethu Community Health Centre Antiretroviral clinic,Participants with missing data are excluded,2020-10-15,2021-06-15,Representative patient population,All,Adults (18-64 years),20.0,65.0,Primary Estimate,,150,0.7070000000000001,,,True,,,,True,Sequential,Author designed (ELISA) - Unknown,,ELISA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Humaira Lambarey,International Centre for Genetic Engineering and Biotechnology,Not Unity-Aligned,https://dx.doi.org/10.3390/v14061222,2022-06-27,2022-07-16,Unverified,lambarey_sars-cov-2_2022,ZAF
220526_SouthAfrica_StellenboschUniversity_Spike,220526_SouthAfrica_StellenboschUniversity,Estimates of prevalence of anti-SARS-CoV-2 antibodies among blood donors in South Africa in March 2022,2022-05-26,Preprint,National,Retrospective cohort,South Africa,,,"3395 residual specimens were randomly collected from consenting donors from all provinces presenting to donate blood at either of the South African Blood Services: the South African National Blood Service (SANBS), and the Western Cape Blood Service (WCBS) in mid-March 2022",,2022-03-08,2022-03-22,Blood donors,All,Multiple groups,,,Primary Estimate,Anti-Spike,3395,0.9720000000000001,0.965,0.98,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Validated by manufacturers,0.995,1.0,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Jeremy Bingham,Stellenbosch University,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-1687679/v2,2022-06-04,2024-03-01,Unverified,bingham_estimates_2022,ZAF
220526_SouthAfrica_StellenboschUniversity_SpikeAndNucleocapsid,220526_SouthAfrica_StellenboschUniversity,Estimates of prevalence of anti-SARS-CoV-2 antibodies among blood donors in South Africa in March 2022,2022-05-26,Preprint,National,Retrospective cohort,South Africa,,,"3395 residual specimens were randomly collected from consenting donors from all provinces presenting to donate blood at either of the South African Blood Services: the South African National Blood Service (SANBS), and the Western Cape Blood Service (WCBS) in mid-March 2022",,2022-03-08,2022-03-22,Blood donors,All,Multiple groups,,,Test used,Anti-Spike AND Anti-Nucleocapsid,3395,0.865,0.85,0.88,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.995,1.0,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Jeremy Bingham,Stellenbosch University,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-1687679/v2,2022-06-19,2024-03-01,Unverified,bingham_estimates_2022,ZAF
220526_SouthAfrica_StellenboschUniversity_Nucleocapsid,220526_SouthAfrica_StellenboschUniversity,Estimates of prevalence of anti-SARS-CoV-2 antibodies among blood donors in South Africa in March 2022,2022-05-26,Preprint,National,Retrospective cohort,South Africa,,,"3395 residual specimens were randomly collected from consenting donors from all provinces presenting to donate blood at either of the South African Blood Services: the South African National Blood Service (SANBS), and the Western Cape Blood Service (WCBS) in mid-March 2022",,2022-03-08,2022-03-22,Blood donors,All,Multiple groups,,,Test used,Anti-Nucleocapsid,3395,0.87,0.855,0.8840000000000001,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,1.0,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Jeremy Bingham,Stellenbosch University,Unity-Aligned,https://doi.org/10.21203/rs.3.rs-1687679/v2,2022-06-19,2024-03-01,Unverified,bingham_estimates_2022,ZAF
220531_Klerksdorp_UniversityofWitwatersrand_ThirdWave,220531_Klerksdorp_UniversityofWitwatersrand,"SARS-CoV-2 transmission, persistence of immunity, and estimates of Omicron’s impact in South African population cohorts",2022-05-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,South Africa,North West Province,Klerksdorp,"""222 randomly selected households were enrolled and followed up twice a week for SARS-CoV-2 real-time reverse transcription polymerase chain reaction (rRT-PCR) testing and symptom monitoring, and blood draws
were obtained every 2 months for SARS-CoV-2 serologic tests.""",,2021-08-01,2021-08-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,501,0.557,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['High'],,No,No,No,,Yes,Yes,Yes,,Kaiyuan Sun,University of Witwatersrand,Unity-Aligned,https://doi.org/10.1126/scitranslmed.abo7081,2022-06-10,2024-04-15,Unverified,sun_sars-cov-2_2022,ZAF
220531_Klerksdorp_UniversityofWitwatersrand_FirstWave,220531_Klerksdorp_UniversityofWitwatersrand,"SARS-CoV-2 transmission, persistence of immunity, and estimates of Omicron’s impact in South African population cohorts",2022-05-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,South Africa,North West Province,Klerksdorp,"""222 randomly selected households were enrolled and followed up twice a week for SARS-CoV-2 real-time reverse transcription polymerase chain reaction (rRT-PCR) testing and symptom monitoring, and blood draws
were obtained every 2 months for SARS-CoV-2 serologic tests.""",,2020-12-01,2021-12-31,Household and community samples,All,Multiple groups,,,Time frame,,530,0.27,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['High'],,No,No,No,,Yes,Yes,Yes,,Kaiyuan Sun,University of Witwatersrand,Unity-Aligned,https://doi.org/10.1126/scitranslmed.abo7081,2024-04-15,2024-04-15,Verified,sun_sars-cov-2_2022,ZAF
220531_Klerksdorp_UniversityofWitwatersrand_SecondWave,220531_Klerksdorp_UniversityofWitwatersrand,"SARS-CoV-2 transmission, persistence of immunity, and estimates of Omicron’s impact in South African population cohorts",2022-05-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,South Africa,North West Province,Klerksdorp,"""222 randomly selected households were enrolled and followed up twice a week for SARS-CoV-2 real-time reverse transcription polymerase chain reaction (rRT-PCR) testing and symptom monitoring, and blood draws
were obtained every 2 months for SARS-CoV-2 serologic tests.""",,2021-04-01,2021-04-30,Household and community samples,All,Multiple groups,,,Time frame,,514,0.403,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['High'],,No,No,No,,Yes,Yes,Yes,,Kaiyuan Sun,University of Witwatersrand,Unity-Aligned,https://doi.org/10.1126/scitranslmed.abo7081,2024-04-15,2024-04-15,Verified,sun_sars-cov-2_2022,ZAF
220715_Gauteng_UniversityOfTheWitwatersrand_Primary,220715_Gauteng_UniversityOfTheWitwatersrand,"SARS-CoV-2 infections during Omicron (BA.1) dominant wave and subsequent population immunity in Gauteng, South Africa",2022-07-15,Preprint,Regional,Repeated cross-sectional study,South Africa,Gauteng,,"A third cross-sectional population-based sero-survey in Gauteng, South Africa. We surveyed 3345 households, including 1052 (31.4%) enrolled in the previous survey. Dried blood spots were obtained from 7510 individuals, including 2420 (32.2%) with paired samples。

The sero-survey included households involved in the two earlier surveys. Nevertheless, based on availability and willingness to participate, the study design allowed for replacement households and different individuals within the same household which was previously involved to participate in the separate surveys. ","79 individuals (1.1%) out-migrated between the pre- and post-
Omicron wave; 37 individuals (0.5%) died between the pre- and post-Omicron wave; 726 individuals (10.4%) in inaccessible locations/households; 185 (2.4%) refused to participate; 102 (1.3%) specimens could not be linked to the individual questionnaire; 3 (0.04%) duplicate individuals",2022-03-01,2022-04-11,Household and community samples,All,Multiple groups,,,Primary Estimate,,7510,0.909,0.902,0.915,True,True,True,,,Stratified probability,Author designed (Luminex),,Other,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Shabir A. Madhi,University of the Witwatersrand ,Not Unity-Aligned,10.1101/2022.07.13.22277575,2022-07-25,2022-07-25,Unverified,madhi_sars-cov-2_2022,ZAF
220715_Gauteng_UniversityOfTheWitwatersrand_AgeOver50,220715_Gauteng_UniversityOfTheWitwatersrand,"SARS-CoV-2 infections during Omicron (BA.1) dominant wave and subsequent population immunity in Gauteng, South Africa",2022-07-15,Preprint,Regional,Repeated cross-sectional study,South Africa,Gauteng,,"A third cross-sectional population-based sero-survey in Gauteng, South Africa. We surveyed 3345 households, including 1052 (31.4%) enrolled in the previous survey. Dried blood spots were obtained from 7510 individuals, including 2420 (32.2%) with paired samples。

The sero-survey included households involved in the two earlier surveys. Nevertheless, based on availability and willingness to participate, the study design allowed for replacement households and different individuals within the same household which was previously involved to participate in the separate surveys. ","79 individuals (1.1%) out-migrated between the pre- and post-
Omicron wave; 37 individuals (0.5%) died between the pre- and post-Omicron wave; 726 individuals (10.4%) in inaccessible locations/households; 185 (2.4%) refused to participate; 102 (1.3%) specimens could not be linked to the individual questionnaire; 3 (0.04%) duplicate individuals",2022-03-01,2022-04-11,Household and community samples,All,Multiple groups,51.0,,Age,age: >50,1739,0.913,0.898,0.925,,True,True,,,Stratified probability,Author designed (Luminex),,Other,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Shabir A. Madhi,University of the Witwatersrand ,Not Unity-Aligned,10.1101/2022.07.13.22277575,2022-07-25,2022-11-11,Unverified,madhi_sars-cov-2_2022,ZAF
220715_Gauteng_UniversityOfTheWitwatersrand_AgeUnder12,220715_Gauteng_UniversityOfTheWitwatersrand,"SARS-CoV-2 infections during Omicron (BA.1) dominant wave and subsequent population immunity in Gauteng, South Africa",2022-07-15,Preprint,Regional,Repeated cross-sectional study,South Africa,Gauteng,,"A third cross-sectional population-based sero-survey in Gauteng, South Africa. We surveyed 3345 households, including 1052 (31.4%) enrolled in the previous survey. Dried blood spots were obtained from 7510 individuals, including 2420 (32.2%) with paired samples。

The sero-survey included households involved in the two earlier surveys. Nevertheless, based on availability and willingness to participate, the study design allowed for replacement households and different individuals within the same household which was previously involved to participate in the separate surveys. ","79 individuals (1.1%) out-migrated between the pre- and post-
Omicron wave; 37 individuals (0.5%) died between the pre- and post-Omicron wave; 726 individuals (10.4%) in inaccessible locations/households; 185 (2.4%) refused to participate; 102 (1.3%) specimens could not be linked to the individual questionnaire; 3 (0.04%) duplicate individuals",2022-03-01,2022-04-11,Household and community samples,All,Children and Youth (0-17 years),,11.0,Age,age: <12,584,0.841,0.809,0.868,,True,True,,,Stratified probability,Author designed (Luminex),,Other,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Shabir A. Madhi,University of the Witwatersrand ,Not Unity-Aligned,10.1101/2022.07.13.22277575,2022-07-25,2022-11-11,Unverified,madhi_sars-cov-2_2022,ZAF
220715_Gauteng_UniversityOfTheWitwatersrand_Vaccinated,220715_Gauteng_UniversityOfTheWitwatersrand,"SARS-CoV-2 infections during Omicron (BA.1) dominant wave and subsequent population immunity in Gauteng, South Africa",2022-07-15,Preprint,Regional,Repeated cross-sectional study,South Africa,Gauteng,,"A third cross-sectional population-based sero-survey in Gauteng, South Africa. We surveyed 3345 households, including 1052 (31.4%) enrolled in the previous survey. Dried blood spots were obtained from 7510 individuals, including 2420 (32.2%) with paired samples。

The sero-survey included households involved in the two earlier surveys. Nevertheless, based on availability and willingness to participate, the study design allowed for replacement households and different individuals within the same household which was previously involved to participate in the separate surveys. ","79 individuals (1.1%) out-migrated between the pre- and post-
Omicron wave; 37 individuals (0.5%) died between the pre- and post-Omicron wave; 726 individuals (10.4%) in inaccessible locations/households; 185 (2.4%) refused to participate; 102 (1.3%) specimens could not be linked to the individual questionnaire; 3 (0.04%) duplicate individuals",2022-03-01,2022-04-11,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,,1995,0.961,0.9520000000000001,0.9690000000000001,,True,True,,,Stratified probability,Author designed (Luminex),,Other,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Shabir A. Madhi,University of the Witwatersrand ,Not Unity-Aligned,10.1101/2022.07.13.22277575,2022-07-25,2022-11-11,Unverified,madhi_sars-cov-2_2022,ZAF
220715_Gauteng_UniversityOfTheWitwatersrand_Male,220715_Gauteng_UniversityOfTheWitwatersrand,"SARS-CoV-2 infections during Omicron (BA.1) dominant wave and subsequent population immunity in Gauteng, South Africa",2022-07-15,Preprint,Regional,Repeated cross-sectional study,South Africa,Gauteng,,"A third cross-sectional population-based sero-survey in Gauteng, South Africa. We surveyed 3345 households, including 1052 (31.4%) enrolled in the previous survey. Dried blood spots were obtained from 7510 individuals, including 2420 (32.2%) with paired samples。

The sero-survey included households involved in the two earlier surveys. Nevertheless, based on availability and willingness to participate, the study design allowed for replacement households and different individuals within the same household which was previously involved to participate in the separate surveys. ","79 individuals (1.1%) out-migrated between the pre- and post-
Omicron wave; 37 individuals (0.5%) died between the pre- and post-Omicron wave; 726 individuals (10.4%) in inaccessible locations/households; 185 (2.4%) refused to participate; 102 (1.3%) specimens could not be linked to the individual questionnaire; 3 (0.04%) duplicate individuals",2022-03-01,2022-04-11,Household and community samples,Male,Multiple groups,,,Sex/Gender,,3096,0.88,0.8690000000000001,0.891,,True,True,,,Stratified probability,Author designed (Luminex),,Other,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Shabir A. Madhi,University of the Witwatersrand ,Not Unity-Aligned,10.1101/2022.07.13.22277575,2022-07-25,2022-11-11,Unverified,madhi_sars-cov-2_2022,ZAF
220715_Gauteng_UniversityOfTheWitwatersrand_Analysis,220715_Gauteng_UniversityOfTheWitwatersrand,"SARS-CoV-2 infections during Omicron (BA.1) dominant wave and subsequent population immunity in Gauteng, South Africa",2022-07-15,Preprint,Regional,Repeated cross-sectional study,South Africa,Gauteng,,"A third cross-sectional population-based sero-survey in Gauteng, South Africa. We surveyed 3345 households, including 1052 (31.4%) enrolled in the previous survey. Dried blood spots were obtained from 7510 individuals, including 2420 (32.2%) with paired samples。

The sero-survey included households involved in the two earlier surveys. Nevertheless, based on availability and willingness to participate, the study design allowed for replacement households and different individuals within the same household which was previously involved to participate in the separate surveys. ","79 individuals (1.1%) out-migrated between the pre- and post-
Omicron wave; 37 individuals (0.5%) died between the pre- and post-Omicron wave; 726 individuals (10.4%) in inaccessible locations/households; 185 (2.4%) refused to participate; 102 (1.3%) specimens could not be linked to the individual questionnaire; 3 (0.04%) duplicate individuals",2022-03-01,2022-04-11,Household and community samples,All,Multiple groups,,,Analysis,,7510,0.9085,,,,,,,True,Stratified probability,Author designed (Luminex),,Other,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Shabir A. Madhi,University of the Witwatersrand ,Not Unity-Aligned,10.1101/2022.07.13.22277575,2022-07-25,2022-11-11,Unverified,madhi_sars-cov-2_2022,ZAF
220715_Gauteng_UniversityOfTheWitwatersrand_Age12to18,220715_Gauteng_UniversityOfTheWitwatersrand,"SARS-CoV-2 infections during Omicron (BA.1) dominant wave and subsequent population immunity in Gauteng, South Africa",2022-07-15,Preprint,Regional,Repeated cross-sectional study,South Africa,Gauteng,,"A third cross-sectional population-based sero-survey in Gauteng, South Africa. We surveyed 3345 households, including 1052 (31.4%) enrolled in the previous survey. Dried blood spots were obtained from 7510 individuals, including 2420 (32.2%) with paired samples。

The sero-survey included households involved in the two earlier surveys. Nevertheless, based on availability and willingness to participate, the study design allowed for replacement households and different individuals within the same household which was previously involved to participate in the separate surveys. ","79 individuals (1.1%) out-migrated between the pre- and post-
Omicron wave; 37 individuals (0.5%) died between the pre- and post-Omicron wave; 726 individuals (10.4%) in inaccessible locations/households; 185 (2.4%) refused to participate; 102 (1.3%) specimens could not be linked to the individual questionnaire; 3 (0.04%) duplicate individuals",2022-03-01,2022-04-11,Household and community samples,All,Children and Youth (0-17 years),12.0,18.0,Age,age: 12-18,553,0.946,0.924,0.9620000000000001,,True,True,,,Stratified probability,Author designed (Luminex),,Other,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Shabir A. Madhi,University of the Witwatersrand ,Not Unity-Aligned,10.1101/2022.07.13.22277575,2022-07-25,2022-11-11,Unverified,madhi_sars-cov-2_2022,ZAF
220715_Gauteng_UniversityOfTheWitwatersrand_NotVaccinated,220715_Gauteng_UniversityOfTheWitwatersrand,"SARS-CoV-2 infections during Omicron (BA.1) dominant wave and subsequent population immunity in Gauteng, South Africa",2022-07-15,Preprint,Regional,Repeated cross-sectional study,South Africa,Gauteng,,"A third cross-sectional population-based sero-survey in Gauteng, South Africa. We surveyed 3345 households, including 1052 (31.4%) enrolled in the previous survey. Dried blood spots were obtained from 7510 individuals, including 2420 (32.2%) with paired samples。

The sero-survey included households involved in the two earlier surveys. Nevertheless, based on availability and willingness to participate, the study design allowed for replacement households and different individuals within the same household which was previously involved to participate in the separate surveys. ","79 individuals (1.1%) out-migrated between the pre- and post-
Omicron wave; 37 individuals (0.5%) died between the pre- and post-Omicron wave; 726 individuals (10.4%) in inaccessible locations/households; 185 (2.4%) refused to participate; 102 (1.3%) specimens could not be linked to the individual questionnaire; 3 (0.04%) duplicate individuals",2022-03-01,2022-04-11,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,,4891,0.895,0.886,0.903,,True,True,,,Stratified probability,Author designed (Luminex),,Other,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Shabir A. Madhi,University of the Witwatersrand ,Not Unity-Aligned,10.1101/2022.07.13.22277575,2022-07-25,2022-11-11,Unverified,madhi_sars-cov-2_2022,ZAF
220715_Gauteng_UniversityOfTheWitwatersrand_Female,220715_Gauteng_UniversityOfTheWitwatersrand,"SARS-CoV-2 infections during Omicron (BA.1) dominant wave and subsequent population immunity in Gauteng, South Africa",2022-07-15,Preprint,Regional,Repeated cross-sectional study,South Africa,Gauteng,,"A third cross-sectional population-based sero-survey in Gauteng, South Africa. We surveyed 3345 households, including 1052 (31.4%) enrolled in the previous survey. Dried blood spots were obtained from 7510 individuals, including 2420 (32.2%) with paired samples。

The sero-survey included households involved in the two earlier surveys. Nevertheless, based on availability and willingness to participate, the study design allowed for replacement households and different individuals within the same household which was previously involved to participate in the separate surveys. ","79 individuals (1.1%) out-migrated between the pre- and post-
Omicron wave; 37 individuals (0.5%) died between the pre- and post-Omicron wave; 726 individuals (10.4%) in inaccessible locations/households; 185 (2.4%) refused to participate; 102 (1.3%) specimens could not be linked to the individual questionnaire; 3 (0.04%) duplicate individuals",2022-03-01,2022-04-11,Household and community samples,Female,Multiple groups,,,Sex/Gender,,4390,0.9279999999999999,0.92,0.9359999999999999,,True,True,,,Stratified probability,Author designed (Luminex),,Other,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Shabir A. Madhi,University of the Witwatersrand ,Not Unity-Aligned,10.1101/2022.07.13.22277575,2022-07-25,2022-11-11,Unverified,madhi_sars-cov-2_2022,ZAF
220715_Gauteng_UniversityOfTheWitwatersrand_Age19to50,220715_Gauteng_UniversityOfTheWitwatersrand,"SARS-CoV-2 infections during Omicron (BA.1) dominant wave and subsequent population immunity in Gauteng, South Africa",2022-07-15,Preprint,Regional,Repeated cross-sectional study,South Africa,Gauteng,,"A third cross-sectional population-based sero-survey in Gauteng, South Africa. We surveyed 3345 households, including 1052 (31.4%) enrolled in the previous survey. Dried blood spots were obtained from 7510 individuals, including 2420 (32.2%) with paired samples。

The sero-survey included households involved in the two earlier surveys. Nevertheless, based on availability and willingness to participate, the study design allowed for replacement households and different individuals within the same household which was previously involved to participate in the separate surveys. ","79 individuals (1.1%) out-migrated between the pre- and post-
Omicron wave; 37 individuals (0.5%) died between the pre- and post-Omicron wave; 726 individuals (10.4%) in inaccessible locations/households; 185 (2.4%) refused to participate; 102 (1.3%) specimens could not be linked to the individual questionnaire; 3 (0.04%) duplicate individuals",2022-03-01,2022-04-11,Household and community samples,All,Adults (18-64 years),19.0,50.0,Age,age: <18-50,4614,0.9109999999999999,0.903,0.919,,True,True,,,Stratified probability,Author designed (Luminex),,Other,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Shabir A. Madhi,University of the Witwatersrand ,Not Unity-Aligned,10.1101/2022.07.13.22277575,2022-07-25,2022-11-11,Unverified,madhi_sars-cov-2_2022,ZAF
220916_Drakenstein_UniversityCollegeLondon_Wave1,220916_Drakenstein_UniversityCollegeLondon_Wave1,Natural and hybrid immunity following four COVID-19 waves: A prospective cohort study of mothers in South Africa,2022-09-16,Journal Article (Peer-Reviewed),Local,Prospective cohort,South Africa,,Paarl,"""We studied participants in an established South African birth cohort, the Drakenstein Child Health Study (DCHS). Included sequential mothers attending follow-up visits with their children with blood sampling through all 4 waves of the pandemic."" ","Once vaccinated, a participant was excluded from calculation of
seroprevalence",2020-06-08,2020-08-30,Residual sera,Female,Adults (18-64 years),24.0,50.0,Primary Estimate,,339,0.519,,,True,,,,True,Convenience,Meso Scale Discovery multiplex assay,Meso Scale Discovery,Other,Serum,IgG,Spike,,0.903,0.9470000000000001,['High'],,No,No,No,,Unclear,Yes,No,,Heather J. Zar,University College London,Not Unity-Aligned,https://dx.doi.org/10.1016/j.eclinm.2022.101655,2022-10-01,2023-06-22,Unverified,zar_natural_2022-1,ZAF
220916_Drakenstein_UniversityCollegeLondon_Wave2,220916_Drakenstein_UniversityCollegeLondon_Wave2,Natural and hybrid immunity following four COVID-19 waves: A prospective cohort study of mothers in South Africa,2022-09-16,Journal Article (Peer-Reviewed),Local,Prospective cohort,South Africa,,Paarl,"""We studied participants in an established South African birth cohort, the Drakenstein Child Health Study (DCHS). Included sequential mothers attending follow-up visits with their children with blood sampling through all 4 waves of the pandemic."" ","Once vaccinated, a participant was excluded from calculation of
seroprevalence",2020-11-23,2021-02-07,Residual sera,Female,Adults (18-64 years),,,Primary Estimate,,337,0.742,,,True,,,,True,Convenience,Meso Scale Discovery multiplex assay,Meso Scale Discovery,Other,Serum,IgG,Spike,,0.903,0.9470000000000001,['High'],,No,No,No,,Unclear,Yes,No,,Heather J. Zar,University College London,Not Unity-Aligned,https://dx.doi.org/10.1016/j.eclinm.2022.101655,2022-10-02,2023-06-22,Unverified,zar_natural_2022-1,ZAF
220916_Drakenstein_UniversityCollegeLondon_Wave3,220916_Drakenstein_UniversityCollegeLondon_Wave3,Natural and hybrid immunity following four COVID-19 waves: A prospective cohort study of mothers in South Africa,2022-09-16,Journal Article (Peer-Reviewed),Local,Prospective cohort,South Africa,,Paarl,"""We studied participants in an established South African birth cohort, the Drakenstein Child Health Study (DCHS). Included sequential mothers attending follow-up visits with their children with blood sampling through all 4 waves of the pandemic."" ","Once vaccinated, a participant was excluded from calculation of
seroprevalence",2021-05-10,2021-09-19,Residual sera,Female,Adults (18-64 years),,,Primary Estimate,,244,0.898,,,True,,,,True,Convenience,Meso Scale Discovery multiplex assay,Meso Scale Discovery,Other,Serum,IgG,Spike,,0.903,0.9470000000000001,['High'],,No,No,No,,Unclear,Yes,No,,Heather J. Zar,University College London,Not Unity-Aligned,https://dx.doi.org/10.1016/j.eclinm.2022.101655,2022-10-02,2023-06-22,Unverified,zar_natural_2022-1,ZAF
220916_Drakenstein_UniversityCollegeLondon_Wave4,220916_Drakenstein_UniversityCollegeLondon_Wave4,Natural and hybrid immunity following four COVID-19 waves: A prospective cohort study of mothers in South Africa,2022-09-16,Journal Article (Peer-Reviewed),Local,Prospective cohort,South Africa,,Paarl,"""We studied participants in an established South African birth cohort, the Drakenstein Child Health Study (DCHS). Included sequential mothers attending follow-up visits with their children with blood sampling through all 4 waves of the pandemic."" ","Once vaccinated, a participant was excluded from calculation of
seroprevalence",2021-11-08,2022-01-23,Residual sera,Female,Adults (18-64 years),,,Primary Estimate,,185,0.973,,,True,,,,True,Convenience,Meso Scale Discovery multiplex assay,Meso Scale Discovery,Other,Serum,IgG,Spike,,0.903,0.9470000000000001,['High'],,No,No,No,,Unclear,Yes,No,,Heather J. Zar,University College London,Not Unity-Aligned,https://dx.doi.org/10.1016/j.eclinm.2022.101655,2022-10-02,2023-06-22,Unverified,zar_natural_2022-1,ZAF
220924_SouthAfrica_RobertKochInstitut_Overall,220924_SouthAfrica_RobertKochInstitut,"Multicountry study of SARS-CoV-2 and associated risk factors among healthcare workers in Cote d'Ivoire, Burkina Faso and South Africa.",2022-09-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,South Africa,,Pretoria,"""HCW participants were recruited on a voluntary basis. All staff, irrespective of symptoms or suspicion of previous COVID-19 infection, were invited to par- ticipate by their hospital administration through internal facility announcements. HCWs > 16 y of age and working during the period of the COVID-19 pandemic at the selected hospitals were eligible for inclusion. ""","""borderline or positive samples were excluded due to poor quality and quantity of the sample""",2021-03-23,2021-05-20,Health care workers and caregivers,All,Adults (18-64 years),16.0,,Primary Estimate,adjusted overall,212,0.39299999999999996,0.327,0.46299999999999997,True,True,,,True,Self-referral,"Anti-SARS-CoV-2 NCP ELISA (IgG),Author designed (Neutralization Assay)","EUROIMMUN,NA",Multiple Types,Serum,IgG,Nucleocapsid(N-protein),Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,Yes,,Sarah Kribi,Robert Koch Institut,Not Unity-Aligned,https://dx.doi.org/10.1093/trstmh/trac089,2022-10-04,2023-08-15,Unverified,kirbi_multicountry_2022,ZAF
221005_Johannesburg_UniversityOfTheWitwatersrand,221005_Johannesburg_UniversityOfTheWitwatersrand,"High prevalence of SARS-CoV-2 antibodies in pregnant women, after the second wave of infections in the inner city of Johannesburg, Gauteng Province, South Africa.",2022-11-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,South Africa,Gauteng Province,Johannesburg,Pregnant women attending antenatal care aged ≥12 years,acute illness or ;previously in covid-19 vaccine trial,2021-03-17,2021-06-09,Pregnant or parturient women,All,Multiple groups,,,Primary Estimate,,500,0.64,0.596,0.682,True,,,,True,Sequential,"Wantai SARS-CoV-2 Total Ab ELISA,Elecsys® Anti‐SARS‐CoV‐2 (N)","Beijing Wantai Biological,Roche Diagnostics",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],,No,Yes,No,,Yes,Yes,No,,Shobna Sawry,University of the Witwatersrand,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2022.10.036,2022-11-17,2024-03-01,Unverified,sawry_high_2022,ZAF
221205_CapeTown_UniversityofCapeTown,221205_CapeTown_UniversityofCapeTown,"Epidemiology and outcomes of SARS-CoV-2 infection associated with anti-nucleocapsid seropositivity in Cape Town, South Africa",2022-12-05,Preprint,Regional,Repeated cross-sectional study,South Africa,Western Cape,Cape Town,,,2020-08-17,2021-11-27,Multiple general populations,All,Multiple groups,,,Primary Estimate,,10339,0.5426056679,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.89,1.0,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,,Hannah Hussey,University of Cape Town,Unity-Aligned,10.1101/2022.12.01.22282927,2023-01-04,2024-04-19,Verified,hussey_epidemiology_2022,ZAF
221205_CapeTown_UniversityofCapeTown_Timeframe_Wave2,221205_CapeTown_UniversityofCapeTown,"Epidemiology and outcomes of SARS-CoV-2 infection associated with anti-nucleocapsid seropositivity in Cape Town, South Africa",2022-12-05,Preprint,Regional,Repeated cross-sectional study,South Africa,Western Cape,Cape Town,,,2021-02-08,2021-05-21,Multiple general populations,All,Multiple groups,,,Time frame,Wave 2,4148,0.5012054002,0.48600000000000004,0.5164,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.89,1.0,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,,Hannah Hussey,University of Cape Town,Unity-Aligned,10.1101/2022.12.01.22282927,2023-01-04,2024-04-19,Verified,hussey_epidemiology_2022,ZAF
221205_CapeTown_UniversityofCapeTown_Timeframe_Wave1,221205_CapeTown_UniversityofCapeTown,"Epidemiology and outcomes of SARS-CoV-2 infection associated with anti-nucleocapsid seropositivity in Cape Town, South Africa",2022-12-05,Preprint,Regional,Repeated cross-sectional study,South Africa,Western Cape,Cape Town,,,2020-08-17,2020-11-06,Multiple general populations,All,Multiple groups,,,Time frame,Wave 1,2327,0.3919209282,0.37229999999999996,0.4119,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.89,1.0,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,,Hannah Hussey,University of Cape Town,Unity-Aligned,10.1101/2022.12.01.22282927,2023-01-04,2024-04-19,Verified,hussey_epidemiology_2022,ZAF
221205_CapeTown_UniversityofCapeTown_Timeframe_Wave3,221205_CapeTown_UniversityofCapeTown,"Epidemiology and outcomes of SARS-CoV-2 infection associated with anti-nucleocapsid seropositivity in Cape Town, South Africa",2022-12-05,Preprint,Regional,Repeated cross-sectional study,South Africa,Western Cape,Cape Town,,,2021-09-20,2021-11-27,Multiple general populations,All,Multiple groups,,,Time frame,Wave 3,3863,0.6779704893,0.6631,0.6925,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.89,1.0,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,,Hannah Hussey,University of Cape Town,Unity-Aligned,10.1101/2022.12.01.22282927,2023-01-04,2024-04-19,Verified,hussey_epidemiology_2022,ZAF
230109_Pretoria_SteveBikoAcademicHospital_Overall,230109_Pretoria_SteveBikoAcademicHospital,The SARS-COV-2 Seroprevalence among Oncology Patients,2023-01-09,Journal Article (Peer-Reviewed),Local,Prospective cohort,South Africa,Gauteng Province,Pretoria,"""Cancer patients who are newly diagnosed or receiving treatment for solid tumours at the Radiation and Medical Oncology departments of SBAH were prospectively recruited for this study.""

""We used the single-prick COVID-19 IgG/IgM Rapid Test Cassettes to detect SARS-CoV-2 IgG/IgM antibodies in 760 patients with solid tumours who were asymptomatic and who had never tested positive for coronavirus disease 2019 (COVID-19).""",,2021-03-24,2022-03-30,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,92.0,Primary Estimate,,760,0.33159999999999995,,,True,,,,True,Convenience,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,"IgG, IgM",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,1.0,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Mankgopo Kgatle,Steve Biko Academic Hospital,Not Unity-Aligned,https://dx.doi.org/10.3390/jcm12020529,2023-02-10,2024-03-01,Unverified,kgatle_sars-cov-2_2023,ZAF
230221_Gauteng_UniversityoftheWitwatersrand_preBA1,230221_Gauteng_UniversityoftheWitwatersrand,"Sustained Low Incidence of Severe and Fatal COVID-19 Following Widespread Infection Induced Immunity after the Omicron (BA.1) Dominant in Gauteng, South Africa: An Observational Study.",2023-02-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,The sero-survey included households involved in the two earlier surveys. ,"Nevertheless, based on availability and willingness to participate, the study design allowed for replacement households and different individuals within the same household which was previously
involved to participate in the separate surveys.",2021-10-22,2021-12-09,Household and community samples,All,Multiple groups,,,Primary Estimate,,7010,0.731,0.72,0.741,True,,,,True,Simplified probability,Author designed (Luminex),,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Shabir A. Madhi ,University of the Witwatersrand,Not Unity-Aligned,https://dx.doi.org/10.3390/v15030597,2023-04-25,2023-04-26,Unverified,madhi_sustained_2023,ZAF
230221_Gauteng_UniversityoftheWitwatersrand_postBA1,230221_Gauteng_UniversityoftheWitwatersrand,"Sustained Low Incidence of Severe and Fatal COVID-19 Following Widespread Infection Induced Immunity after the Omicron (BA.1) Dominant in Gauteng, South Africa: An Observational Study.",2023-02-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,South Africa,Gauteng,,The sero-survey included households involved in the two earlier surveys. ,"Nevertheless, based on availability and willingness to participate, the study design allowed for replacement households and different individuals within the same household which was previously
involved to participate in the separate surveys.",2022-03-01,2022-04-11,Household and community samples,All,Multiple groups,,,Time frame,,7510,0.909,0.902,0.915,,,,,True,Simplified probability,Author designed (Luminex),,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Shabir A. Madhi ,University of the Witwatersrand,Not Unity-Aligned,https://dx.doi.org/10.3390/v15030597,2023-04-25,2023-04-26,Unverified,madhi_sustained_2023,ZAF
230523_SouthAfrica_UniversityofCapeTown,230523_SouthAfrica_UniversityofCapeTown,Distinct T cell functional profiles in SARS-CoV-2 seropositive and seronegative children associated with endemic human coronavirus cross-reactivity,2023-05-23,Preprint,Regional,Cross-sectional survey ,South Africa,Western Cape,"Cape Town, Cape Winelands","""71 children recruited in Cape Town, Western Cape, South Africa""","""The children included in this study had not received any SARS-CoV-2 vaccine prior to recruitment and no PCR- confirmed infection data were available""",2021-02-01,2021-05-20,Multiple populations,All,Children and Youth (0-17 years),,,Primary Estimate,,71,0.58,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Ntombi S. B. Benede,University of Cape Town,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2023.05.16.23290059v1,2023-06-28,2023-07-04,Unverified,benede_distinct_2023,ZAF
230629_KwaZuluNatal_UniversityOfKwaZuluNatal_Overall,230629_KwaZuluNatal_UniversityOfKwaZuluNatal,"Seroprevalence of SARS-CoV-2 immunoglobulin G in HIV-positive and HIV-negative individuals in KwaZulu-Natal, South Africa",2023-06-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,South Africa,KwaZulu-Natal,Durban,"This was a retrospective analysis of residual clinical blood specimens unrelated to coronavirus disease 2019 (COVID-19) submitted for diagnostic testing at Inkosi Albert Luthuli Central Hospital, Durban, from 10 November 2020 to 09 February 2021.

Sera and plasma specimens with sufficient volumes from the viral serology (HIV and hepatitis B enzyme-linked immunosorbent assay and HIV viral load laboratory sections) were selected for SARS-CoV-2 IgG testing.

Specimens from the same patient were tested once only.",Specimens with inadequate volumes (< 100 µL) were excluded.,2020-11-10,2021-02-09,Residual sera,All,Multiple groups,,,Primary Estimate,,8829,0.224,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.695,0.95,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,,Kerri-Lee Francois,University of KwaZulu-Natal,Unity-Aligned,https://dx.doi.org/10.4102/ajlm.v12i1.2065,2023-08-01,2024-04-24,Verified,francois_seroprevalence_2023,ZAF
230629_KwaZuluNatal_UniversityOfKwaZuluNatal_Age_10-19,230629_KwaZuluNatal_UniversityOfKwaZuluNatal,"Seroprevalence of SARS-CoV-2 immunoglobulin G in HIV-positive and HIV-negative individuals in KwaZulu-Natal, South Africa",2023-06-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,South Africa,KwaZulu-Natal,Durban,"This was a retrospective analysis of residual clinical blood specimens unrelated to coronavirus disease 2019 (COVID-19) submitted for diagnostic testing at Inkosi Albert Luthuli Central Hospital, Durban, from 10 November 2020 to 09 February 2021.

Sera and plasma specimens with sufficient volumes from the viral serology (HIV and hepatitis B enzyme-linked immunosorbent assay and HIV viral load laboratory sections) were selected for SARS-CoV-2 IgG testing.

Specimens from the same patient were tested once only.",Specimens with inadequate volumes (< 100 µL) were excluded.,2020-11-10,2021-02-09,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19 years,601,0.161,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.695,0.95,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,,Kerri-Lee Francois,University of KwaZulu-Natal,Unity-Aligned,https://dx.doi.org/10.4102/ajlm.v12i1.2065,2024-04-24,2024-04-24,Verified,francois_seroprevalence_2023,ZAF
230629_KwaZuluNatal_UniversityOfKwaZuluNatal_Age_60-69,230629_KwaZuluNatal_UniversityOfKwaZuluNatal,"Seroprevalence of SARS-CoV-2 immunoglobulin G in HIV-positive and HIV-negative individuals in KwaZulu-Natal, South Africa",2023-06-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,South Africa,KwaZulu-Natal,Durban,"This was a retrospective analysis of residual clinical blood specimens unrelated to coronavirus disease 2019 (COVID-19) submitted for diagnostic testing at Inkosi Albert Luthuli Central Hospital, Durban, from 10 November 2020 to 09 February 2021.

Sera and plasma specimens with sufficient volumes from the viral serology (HIV and hepatitis B enzyme-linked immunosorbent assay and HIV viral load laboratory sections) were selected for SARS-CoV-2 IgG testing.

Specimens from the same patient were tested once only.",Specimens with inadequate volumes (< 100 µL) were excluded.,2020-11-10,2021-02-09,Residual sera,All,Seniors (65+ years),60.0,69.0,Age,60-69 years,364,0.299,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.695,0.95,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,,Kerri-Lee Francois,University of KwaZulu-Natal,Unity-Aligned,https://dx.doi.org/10.4102/ajlm.v12i1.2065,2024-04-24,2024-04-24,Verified,francois_seroprevalence_2023,ZAF
230629_KwaZuluNatal_UniversityOfKwaZuluNatal_AgeUnknown,230629_KwaZuluNatal_UniversityOfKwaZuluNatal,"Seroprevalence of SARS-CoV-2 immunoglobulin G in HIV-positive and HIV-negative individuals in KwaZulu-Natal, South Africa",2023-06-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,South Africa,KwaZulu-Natal,Durban,"This was a retrospective analysis of residual clinical blood specimens unrelated to coronavirus disease 2019 (COVID-19) submitted for diagnostic testing at Inkosi Albert Luthuli Central Hospital, Durban, from 10 November 2020 to 09 February 2021.

Sera and plasma specimens with sufficient volumes from the viral serology (HIV and hepatitis B enzyme-linked immunosorbent assay and HIV viral load laboratory sections) were selected for SARS-CoV-2 IgG testing.

Specimens from the same patient were tested once only.",Specimens with inadequate volumes (< 100 µL) were excluded.,2020-11-10,2021-02-09,Residual sera,All,Multiple groups,,,Age,Age Unknown,95,0.232,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.695,0.95,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,,Kerri-Lee Francois,University of KwaZulu-Natal,Unity-Aligned,https://dx.doi.org/10.4102/ajlm.v12i1.2065,2024-04-24,2024-04-24,Verified,francois_seroprevalence_2023,ZAF
230629_KwaZuluNatal_UniversityOfKwaZuluNatal_Age_<10,230629_KwaZuluNatal_UniversityOfKwaZuluNatal,"Seroprevalence of SARS-CoV-2 immunoglobulin G in HIV-positive and HIV-negative individuals in KwaZulu-Natal, South Africa",2023-06-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,South Africa,KwaZulu-Natal,Durban,"This was a retrospective analysis of residual clinical blood specimens unrelated to coronavirus disease 2019 (COVID-19) submitted for diagnostic testing at Inkosi Albert Luthuli Central Hospital, Durban, from 10 November 2020 to 09 February 2021.

Sera and plasma specimens with sufficient volumes from the viral serology (HIV and hepatitis B enzyme-linked immunosorbent assay and HIV viral load laboratory sections) were selected for SARS-CoV-2 IgG testing.

Specimens from the same patient were tested once only.",Specimens with inadequate volumes (< 100 µL) were excluded.,2020-11-10,2021-02-09,Residual sera,All,Children and Youth (0-17 years),,9.0,Age,<10 years,390,0.1,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.695,0.95,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,,Kerri-Lee Francois,University of KwaZulu-Natal,Unity-Aligned,https://dx.doi.org/10.4102/ajlm.v12i1.2065,2024-04-24,2024-04-24,Verified,francois_seroprevalence_2023,ZAF
230629_KwaZuluNatal_UniversityOfKwaZuluNatal_Age_80+,230629_KwaZuluNatal_UniversityOfKwaZuluNatal,"Seroprevalence of SARS-CoV-2 immunoglobulin G in HIV-positive and HIV-negative individuals in KwaZulu-Natal, South Africa",2023-06-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,South Africa,KwaZulu-Natal,Durban,"This was a retrospective analysis of residual clinical blood specimens unrelated to coronavirus disease 2019 (COVID-19) submitted for diagnostic testing at Inkosi Albert Luthuli Central Hospital, Durban, from 10 November 2020 to 09 February 2021.

Sera and plasma specimens with sufficient volumes from the viral serology (HIV and hepatitis B enzyme-linked immunosorbent assay and HIV viral load laboratory sections) were selected for SARS-CoV-2 IgG testing.

Specimens from the same patient were tested once only.",Specimens with inadequate volumes (< 100 µL) were excluded.,2020-11-10,2021-02-09,Residual sera,All,Seniors (65+ years),80.0,,Age,80+ years,27,0.185,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.695,0.95,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,,Kerri-Lee Francois,University of KwaZulu-Natal,Unity-Aligned,https://dx.doi.org/10.4102/ajlm.v12i1.2065,2024-04-24,2024-04-24,Verified,francois_seroprevalence_2023,ZAF
230629_KwaZuluNatal_UniversityOfKwaZuluNatal_Age_40-49,230629_KwaZuluNatal_UniversityOfKwaZuluNatal,"Seroprevalence of SARS-CoV-2 immunoglobulin G in HIV-positive and HIV-negative individuals in KwaZulu-Natal, South Africa",2023-06-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,South Africa,KwaZulu-Natal,Durban,"This was a retrospective analysis of residual clinical blood specimens unrelated to coronavirus disease 2019 (COVID-19) submitted for diagnostic testing at Inkosi Albert Luthuli Central Hospital, Durban, from 10 November 2020 to 09 February 2021.

Sera and plasma specimens with sufficient volumes from the viral serology (HIV and hepatitis B enzyme-linked immunosorbent assay and HIV viral load laboratory sections) were selected for SARS-CoV-2 IgG testing.

Specimens from the same patient were tested once only.",Specimens with inadequate volumes (< 100 µL) were excluded.,2020-11-10,2021-02-09,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49 years,1665,0.218,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.695,0.95,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,,Kerri-Lee Francois,University of KwaZulu-Natal,Unity-Aligned,https://dx.doi.org/10.4102/ajlm.v12i1.2065,2024-04-24,2024-04-24,Verified,francois_seroprevalence_2023,ZAF
230629_KwaZuluNatal_UniversityOfKwaZuluNatal_Age_50-59,230629_KwaZuluNatal_UniversityOfKwaZuluNatal,"Seroprevalence of SARS-CoV-2 immunoglobulin G in HIV-positive and HIV-negative individuals in KwaZulu-Natal, South Africa",2023-06-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,South Africa,KwaZulu-Natal,Durban,"This was a retrospective analysis of residual clinical blood specimens unrelated to coronavirus disease 2019 (COVID-19) submitted for diagnostic testing at Inkosi Albert Luthuli Central Hospital, Durban, from 10 November 2020 to 09 February 2021.

Sera and plasma specimens with sufficient volumes from the viral serology (HIV and hepatitis B enzyme-linked immunosorbent assay and HIV viral load laboratory sections) were selected for SARS-CoV-2 IgG testing.

Specimens from the same patient were tested once only.",Specimens with inadequate volumes (< 100 µL) were excluded.,2020-11-10,2021-02-09,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59 years,893,0.27,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.695,0.95,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,,Kerri-Lee Francois,University of KwaZulu-Natal,Unity-Aligned,https://dx.doi.org/10.4102/ajlm.v12i1.2065,2024-04-24,2024-04-24,Verified,francois_seroprevalence_2023,ZAF
230629_KwaZuluNatal_UniversityOfKwaZuluNatal_Age_20-29,230629_KwaZuluNatal_UniversityOfKwaZuluNatal,"Seroprevalence of SARS-CoV-2 immunoglobulin G in HIV-positive and HIV-negative individuals in KwaZulu-Natal, South Africa",2023-06-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,South Africa,KwaZulu-Natal,Durban,"This was a retrospective analysis of residual clinical blood specimens unrelated to coronavirus disease 2019 (COVID-19) submitted for diagnostic testing at Inkosi Albert Luthuli Central Hospital, Durban, from 10 November 2020 to 09 February 2021.

Sera and plasma specimens with sufficient volumes from the viral serology (HIV and hepatitis B enzyme-linked immunosorbent assay and HIV viral load laboratory sections) were selected for SARS-CoV-2 IgG testing.

Specimens from the same patient were tested once only.",Specimens with inadequate volumes (< 100 µL) were excluded.,2020-11-10,2021-02-09,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29 years,1982,0.228,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.695,0.95,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,,Kerri-Lee Francois,University of KwaZulu-Natal,Unity-Aligned,https://dx.doi.org/10.4102/ajlm.v12i1.2065,2024-04-24,2024-04-24,Verified,francois_seroprevalence_2023,ZAF
230629_KwaZuluNatal_UniversityOfKwaZuluNatal_Age_30-39,230629_KwaZuluNatal_UniversityOfKwaZuluNatal,"Seroprevalence of SARS-CoV-2 immunoglobulin G in HIV-positive and HIV-negative individuals in KwaZulu-Natal, South Africa",2023-06-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,South Africa,KwaZulu-Natal,Durban,"This was a retrospective analysis of residual clinical blood specimens unrelated to coronavirus disease 2019 (COVID-19) submitted for diagnostic testing at Inkosi Albert Luthuli Central Hospital, Durban, from 10 November 2020 to 09 February 2021.

Sera and plasma specimens with sufficient volumes from the viral serology (HIV and hepatitis B enzyme-linked immunosorbent assay and HIV viral load laboratory sections) were selected for SARS-CoV-2 IgG testing.

Specimens from the same patient were tested once only.",Specimens with inadequate volumes (< 100 µL) were excluded.,2020-11-10,2021-02-09,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39 years,2677,0.225,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.695,0.95,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,,Kerri-Lee Francois,University of KwaZulu-Natal,Unity-Aligned,https://dx.doi.org/10.4102/ajlm.v12i1.2065,2024-04-24,2024-04-24,Verified,francois_seroprevalence_2023,ZAF
230629_KwaZuluNatal_UniversityOfKwaZuluNatal_Age_70-79,230629_KwaZuluNatal_UniversityOfKwaZuluNatal,"Seroprevalence of SARS-CoV-2 immunoglobulin G in HIV-positive and HIV-negative individuals in KwaZulu-Natal, South Africa",2023-06-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,South Africa,KwaZulu-Natal,Durban,"This was a retrospective analysis of residual clinical blood specimens unrelated to coronavirus disease 2019 (COVID-19) submitted for diagnostic testing at Inkosi Albert Luthuli Central Hospital, Durban, from 10 November 2020 to 09 February 2021.

Sera and plasma specimens with sufficient volumes from the viral serology (HIV and hepatitis B enzyme-linked immunosorbent assay and HIV viral load laboratory sections) were selected for SARS-CoV-2 IgG testing.

Specimens from the same patient were tested once only.",Specimens with inadequate volumes (< 100 µL) were excluded.,2020-11-10,2021-02-09,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79 years,135,0.348,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.695,0.95,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,,Kerri-Lee Francois,University of KwaZulu-Natal,Unity-Aligned,https://dx.doi.org/10.4102/ajlm.v12i1.2065,2024-04-24,2024-04-24,Verified,francois_seroprevalence_2023,ZAF
240202_Gugulethu_ICGEB_Overall,240202_Gugulethu_ICGEB,Reactivation of Latent Kaposi's Sarcoma-Associated Herpesvirus (KSHV) by SARS-CoV-2 in Non-Hospitalised HIV-Infected Patients,2024-02-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,South Africa,Western Cape,Gugulethu,"This study cohort consisted of 407 adult, non- hospitalised HIV-infected patients presenting for routine HIV treatment at the Gugulethu Community Health Centre Antiretroviral clinic, South Africa, a public-sector antiretroviral delivery site. Patients were selected for this study if their latest CD4 count was <350 cells/μL, according to their clinical files. ",,2023-01-01,2023-04-15,Representative patient population,All,Adults (18-64 years),,,Primary Estimate,,407,0.949,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Humaira Lambarey,International Centre for Genetic Engineering and Biotechnology (ICGEB),Not Unity-Aligned,10.2139/ssrn.4583146,2024-03-09,2024-03-10,Unverified,lambarey_reactivation_2023,ZAF
210427_Juba_WorldHealthOrganization_Overall_PopTestAdj,210427_Juba_WorldHealthOrganization,"Seroprevalence of severe acute respiratory syndrome coronavirus 2 IgG in Juba, South Sudan, 2020",2021-04-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,South Sudan,Central Equatoria,Juba,"We defined a household as a group of persons who slept under the same roof most nights and shared a cooking pot. Regardless of current or past COVID-19 illness, all household members were eligible for inclusion if they or their guardian provided written consent to participate and they were >1 year of age and had lived in the area >1 week before the survey. For households with >10 persons, only first-degree relatives of the head of household were eligible for study inclusion.  If multiple households lived in 1 shelter, we blindly drew from labeled papers to randomly select 1 household for inclusion.",,2020-08-10,2020-09-11,Household and community samples,All,Multiple groups,,,Primary Estimate,,2214,0.383,,,True,True,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.655,1.0,['Low'],Yes,Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Kirsten E Wiens,World Health Organization,Unity-Aligned,https://dx.doi.org/10.3201/eid2706.210568,2021-06-02,2022-07-16,Verified,wiens_early_2021,SSD
210427_Juba_WorldHealthOrganization_Age_1-4,210427_Juba_WorldHealthOrganization,"Seroprevalence of severe acute respiratory syndrome coronavirus 2 IgG in Juba, South Sudan, 2020",2021-04-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,South Sudan,Central Equatoria,Juba,"We defined a household as a group of persons who slept under the same roof most nights and shared a cooking pot. Regardless of current or past COVID-19 illness, all household members were eligible for inclusion if they or their guardian provided written consent to participate and they were >1 year of age and had lived in the area >1 week before the survey. For households with >10 persons, only first-degree relatives of the head of household were eligible for study inclusion.  If multiple households lived in 1 shelter, we blindly drew from labeled papers to randomly select 1 household for inclusion.",,2020-08-10,2020-09-11,Household and community samples,All,Children and Youth (0-17 years),1.0,4.0,Age,1-4,68,0.2941176471,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.655,1.0,['Low'],Yes,Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Kirsten E Wiens,World Health Organization,Unity-Aligned,https://dx.doi.org/10.3201/eid2706.210568,2021-08-19,2022-07-16,Verified,wiens_early_2021,SSD
210427_Juba_WorldHealthOrganization_Age_50-64,210427_Juba_WorldHealthOrganization,"Seroprevalence of severe acute respiratory syndrome coronavirus 2 IgG in Juba, South Sudan, 2020",2021-04-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,South Sudan,Central Equatoria,Juba,"We defined a household as a group of persons who slept under the same roof most nights and shared a cooking pot. Regardless of current or past COVID-19 illness, all household members were eligible for inclusion if they or their guardian provided written consent to participate and they were >1 year of age and had lived in the area >1 week before the survey. For households with >10 persons, only first-degree relatives of the head of household were eligible for study inclusion.  If multiple households lived in 1 shelter, we blindly drew from labeled papers to randomly select 1 household for inclusion.",,2020-08-10,2020-09-11,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50-64,120,0.25833333329999997,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.655,1.0,['Low'],Yes,Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Kirsten E Wiens,World Health Organization,Unity-Aligned,https://dx.doi.org/10.3201/eid2706.210568,2021-08-19,2022-07-16,Verified,wiens_early_2021,SSD
210427_Juba_WorldHealthOrganization_Male_UnAdj,210427_Juba_WorldHealthOrganization,"Seroprevalence of severe acute respiratory syndrome coronavirus 2 IgG in Juba, South Sudan, 2020",2021-04-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,South Sudan,Central Equatoria,Juba,"We defined a household as a group of persons who slept under the same roof most nights and shared a cooking pot. Regardless of current or past COVID-19 illness, all household members were eligible for inclusion if they or their guardian provided written consent to participate and they were >1 year of age and had lived in the area >1 week before the survey. For households with >10 persons, only first-degree relatives of the head of household were eligible for study inclusion.  If multiple households lived in 1 shelter, we blindly drew from labeled papers to randomly select 1 household for inclusion.",,2020-08-10,2020-09-11,Household and community samples,Male,Multiple groups,,,Sex/Gender,,691,0.21852387839999998,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.655,1.0,['Low'],Yes,Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Kirsten E Wiens,World Health Organization,Unity-Aligned,https://dx.doi.org/10.3201/eid2706.210568,2021-08-19,2022-07-16,Verified,wiens_early_2021,SSD
210427_Juba_WorldHealthOrganization_Age_65-84,210427_Juba_WorldHealthOrganization,"Seroprevalence of severe acute respiratory syndrome coronavirus 2 IgG in Juba, South Sudan, 2020",2021-04-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,South Sudan,Central Equatoria,Juba,"We defined a household as a group of persons who slept under the same roof most nights and shared a cooking pot. Regardless of current or past COVID-19 illness, all household members were eligible for inclusion if they or their guardian provided written consent to participate and they were >1 year of age and had lived in the area >1 week before the survey. For households with >10 persons, only first-degree relatives of the head of household were eligible for study inclusion.  If multiple households lived in 1 shelter, we blindly drew from labeled papers to randomly select 1 household for inclusion.",,2020-08-10,2020-09-11,Household and community samples,All,Seniors (65+ years),65.0,84.0,Age,65-84,75,0.22666666670000002,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.655,1.0,['Low'],Yes,Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Kirsten E Wiens,World Health Organization,Unity-Aligned,https://dx.doi.org/10.3201/eid2706.210568,2021-08-19,2022-07-16,Verified,wiens_early_2021,SSD
210427_Juba_WorldHealthOrganization_Age_20-29,210427_Juba_WorldHealthOrganization,"Seroprevalence of severe acute respiratory syndrome coronavirus 2 IgG in Juba, South Sudan, 2020",2021-04-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,South Sudan,Central Equatoria,Juba,"We defined a household as a group of persons who slept under the same roof most nights and shared a cooking pot. Regardless of current or past COVID-19 illness, all household members were eligible for inclusion if they or their guardian provided written consent to participate and they were >1 year of age and had lived in the area >1 week before the survey. For households with >10 persons, only first-degree relatives of the head of household were eligible for study inclusion.  If multiple households lived in 1 shelter, we blindly drew from labeled papers to randomly select 1 household for inclusion.",,2020-08-10,2020-09-11,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,459,0.1938997821,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.655,1.0,['Low'],Yes,Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Kirsten E Wiens,World Health Organization,Unity-Aligned,https://dx.doi.org/10.3201/eid2706.210568,2021-08-19,2022-07-16,Verified,wiens_early_2021,SSD
210427_Juba_WorldHealthOrganization_Age_30-39,210427_Juba_WorldHealthOrganization,"Seroprevalence of severe acute respiratory syndrome coronavirus 2 IgG in Juba, South Sudan, 2020",2021-04-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,South Sudan,Central Equatoria,Juba,"We defined a household as a group of persons who slept under the same roof most nights and shared a cooking pot. Regardless of current or past COVID-19 illness, all household members were eligible for inclusion if they or their guardian provided written consent to participate and they were >1 year of age and had lived in the area >1 week before the survey. For households with >10 persons, only first-degree relatives of the head of household were eligible for study inclusion.  If multiple households lived in 1 shelter, we blindly drew from labeled papers to randomly select 1 household for inclusion.",,2020-08-10,2020-09-11,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,307,0.1693811075,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.655,1.0,['Low'],Yes,Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Kirsten E Wiens,World Health Organization,Unity-Aligned,https://dx.doi.org/10.3201/eid2706.210568,2021-08-19,2022-07-16,Verified,wiens_early_2021,SSD
210427_Juba_WorldHealthOrganization_Age_10-19,210427_Juba_WorldHealthOrganization,"Seroprevalence of severe acute respiratory syndrome coronavirus 2 IgG in Juba, South Sudan, 2020",2021-04-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,South Sudan,Central Equatoria,Juba,"We defined a household as a group of persons who slept under the same roof most nights and shared a cooking pot. Regardless of current or past COVID-19 illness, all household members were eligible for inclusion if they or their guardian provided written consent to participate and they were >1 year of age and had lived in the area >1 week before the survey. For households with >10 persons, only first-degree relatives of the head of household were eligible for study inclusion.  If multiple households lived in 1 shelter, we blindly drew from labeled papers to randomly select 1 household for inclusion.",,2020-08-10,2020-09-11,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,448,0.27678571430000004,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.655,1.0,['Low'],Yes,Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Kirsten E Wiens,World Health Organization,Unity-Aligned,https://dx.doi.org/10.3201/eid2706.210568,2021-08-19,2022-07-16,Verified,wiens_early_2021,SSD
210427_Juba_WorldHealthOrganization_Age_5-9,210427_Juba_WorldHealthOrganization,"Seroprevalence of severe acute respiratory syndrome coronavirus 2 IgG in Juba, South Sudan, 2020",2021-04-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,South Sudan,Central Equatoria,Juba,"We defined a household as a group of persons who slept under the same roof most nights and shared a cooking pot. Regardless of current or past COVID-19 illness, all household members were eligible for inclusion if they or their guardian provided written consent to participate and they were >1 year of age and had lived in the area >1 week before the survey. For households with >10 persons, only first-degree relatives of the head of household were eligible for study inclusion.  If multiple households lived in 1 shelter, we blindly drew from labeled papers to randomly select 1 household for inclusion.",,2020-08-10,2020-09-11,Household and community samples,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,224,0.2321428571,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.655,1.0,['Low'],Yes,Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Kirsten E Wiens,World Health Organization,Unity-Aligned,https://dx.doi.org/10.3201/eid2706.210568,2021-08-19,2022-07-16,Verified,wiens_early_2021,SSD
210427_Juba_WorldHealthOrganization_Female_UnAdj,210427_Juba_WorldHealthOrganization,"Seroprevalence of severe acute respiratory syndrome coronavirus 2 IgG in Juba, South Sudan, 2020",2021-04-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,South Sudan,Central Equatoria,Juba,"We defined a household as a group of persons who slept under the same roof most nights and shared a cooking pot. Regardless of current or past COVID-19 illness, all household members were eligible for inclusion if they or their guardian provided written consent to participate and they were >1 year of age and had lived in the area >1 week before the survey. For households with >10 persons, only first-degree relatives of the head of household were eligible for study inclusion.  If multiple households lived in 1 shelter, we blindly drew from labeled papers to randomly select 1 household for inclusion.",,2020-08-10,2020-09-11,Household and community samples,Female,Multiple groups,,,Sex/Gender,,1149,0.22628372500000002,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.655,1.0,['Low'],Yes,Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Kirsten E Wiens,World Health Organization,Unity-Aligned,https://dx.doi.org/10.3201/eid2706.210568,2021-08-19,2022-07-16,Verified,wiens_early_2021,SSD
210427_Juba_WorldHealthOrganization_Age_40-49,210427_Juba_WorldHealthOrganization,"Seroprevalence of severe acute respiratory syndrome coronavirus 2 IgG in Juba, South Sudan, 2020",2021-04-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,South Sudan,Central Equatoria,Juba,"We defined a household as a group of persons who slept under the same roof most nights and shared a cooking pot. Regardless of current or past COVID-19 illness, all household members were eligible for inclusion if they or their guardian provided written consent to participate and they were >1 year of age and had lived in the area >1 week before the survey. For households with >10 persons, only first-degree relatives of the head of household were eligible for study inclusion.  If multiple households lived in 1 shelter, we blindly drew from labeled papers to randomly select 1 household for inclusion.",,2020-08-10,2020-09-11,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,139,0.1870503597,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.655,1.0,['Low'],Yes,Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Kirsten E Wiens,World Health Organization,Unity-Aligned,https://dx.doi.org/10.3201/eid2706.210568,2021-08-19,2022-07-16,Verified,wiens_early_2021,SSD
210427_Juba_WorldHealthOrganization_Overall_UnAdj,210427_Juba_WorldHealthOrganization,"Seroprevalence of severe acute respiratory syndrome coronavirus 2 IgG in Juba, South Sudan, 2020",2021-04-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,South Sudan,Central Equatoria,Juba,"We defined a household as a group of persons who slept under the same roof most nights and shared a cooking pot. Regardless of current or past COVID-19 illness, all household members were eligible for inclusion if they or their guardian provided written consent to participate and they were >1 year of age and had lived in the area >1 week before the survey. For households with >10 persons, only first-degree relatives of the head of household were eligible for study inclusion.  If multiple households lived in 1 shelter, we blindly drew from labeled papers to randomly select 1 household for inclusion.",,2020-08-10,2020-09-11,Household and community samples,All,Multiple groups,,,Analysis,,2214,0.223,,,,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.655,1.0,['Low'],Yes,Yes,Yes,No,No,Unclear,Yes,Yes,Yes,Kirsten E Wiens,World Health Organization,Unity-Aligned,https://dx.doi.org/10.3201/eid2706.210568,2021-06-01,2022-07-16,Verified,wiens_early_2021,SSD
200606_Leon_UniversidadedeLeon_HCWs,200606_Leon_GerenciadeAtenciónPrimariadelÁreadeSaluddeLeónSpain,Prevalence of SARS-CoV-2 infection in general practitioners and nurses in primary care and nursing homes in the Healthcare Area of Leon and associated factors,2020-06-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Léon,Léon,"General practitioners (GP) and primary care nurses in the
Healthcare Area of León, who worked in health centers or
nursing homes",,2020-04-01,2020-04-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,676,0.0592,,,,,,,True,Convenience,2019-nCoV IgG/IgM Rapid Test Cassette,Hanghzhou AllTest Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,No,Yes,No,Yes,Vicente Martin,"Gerencia de Atención Primaria del Área de Salud de León, Spain",Not Unity-Aligned,https://dx.doi.org/10.1016/j.semerg.2020.05.014,2020-07-30,2024-03-01,Verified,martin_prevalence_2020,ESP
200616_Madrid_UniversidadAutónomadeMadrid_TotalPop,200616_Madrid_UniversidadAutónomadeMadrid,"SARS-CoV-2 antibodies in adults in Madrid, Spain",2020-06-16,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Spain,Community of Madrid,Madrid,"university employees and their families, health care workers, social services personnel, and persons living in communities, religious or not",,2020-04-26,2020-05-16,Multiple populations,All,Multiple groups,18.0,89.0,Primary Estimate,,674,0.138,,,True,,,,True,Sequential,PCL COVID19 IgG/IgM Rapid Gold,Vitrex Medical,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Yes,Vicente Soriano, Universidad Autónoma de Madrid,Not Unity-Aligned,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa769/5858269,2020-06-18,2024-03-01,Verified,soriano_severe_2020,ESP
200617_TorrejonDeArdoz_MunicipalityOfTorrejonDeArdoz_IgGIgM,200617_TorrejonDeArdoz_MunicipalityOfTorrejonDeArdoz,"Los test serológicos de Torrejón de Ardoz arrojan un 20,18 % de personas con anticuerpos de coronavirus",2020-06-17,Institutional Report,Local,Cross-sectional survey ,Spain,,Torrejon de Ardoz,"104,299 people voluntarily participated from a target population of 139,452 inhabitants",,2020-05-29,2020-06-03,Household and community samples,All,Multiple groups,1.0,,Primary Estimate,IgG and IgM,104299,0.23070000000000002,,,True,,,,True,Entire sample,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,No,Yes,Unclear,Yes,No,Yes,Daniel Flores,Municipality of Torrejon de Ardoz,Not Unity-Aligned,https://www.rtve.es/noticias/20200617/test-serologicos-torrejon-ardoz-arrojan-2018-habitantes-tiene-anticuerpos-coronavirus/2018787.shtml,2020-10-08,2022-07-16,Verified,flores_coronavirus_2020,ESP
200606_Spain_InstitutodeSaludCarlosIII_primary,200606_Spain_InstitutodeSaludCarlosIII,ESTUDIO ENE-COVID: INFORME FINAL ESTUDIO NACIONAL DE SERO-EPIDEMIOLOGÍA DE LA INFECCIÓN POR SARS-COV-2 EN ESPAÑA,2020-07-06,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Spain,,,,,2020-06-08,2020-06-22,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,62167,0.052000000000000005,0.049,0.055,True,,True,,True,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,IgG,,Validated by manufacturers,0.97,1.0,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ministry of Health,Instituto de Salud Carlos III,Unity-Aligned,https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf,2021-06-21,2024-03-01,Unverified,ministerio_de_salud_estudio_2020-1,ESP
200708_Barcelona_UniversitatDeBarcelona_HCW_IgG/IgM/IgA,200708_Barcelona_UniversitatDeBarcelona,Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital,2020-07-08,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Spain,Catalonia,Barcelona,Inclusion criteria included being an adult (>17 years) worker at HCB registered at the Human Resources department. ,"Exclusion criteria included: a) absenteeism from workplace in the last 30 days (i.e. on vacation, sick leave, sabbatical), b) working exclusively outside the HCB or Maternity main buildings with no interaction with patients on a daily basis, c) retirement or endof-contract planned within one year after the recruitment date, and d) participating in COVID-19 clinical trials for preventive or treatment therapies. ",2020-03-28,2020-04-09,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,578,0.09300000000000001,0.071,0.12,True,,,,True,Simplified probability,Author designed (Luminex),,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.97,0.98,['Moderate'],Yes,Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Alberto Garcia Basteiro,Universitat de Barcelona ,Not Unity-Aligned,https://www.nature.com/articles/s41467-020-17318-x,2020-07-17,2022-07-16,Verified,garcia-basteiro_seroprevalence_2020,ESP
220709_Spain_IVIRMA_IgG,220709_Spain_IVIRMA,Is COVID-19 symptomatic triage enough? The limited value of serological testing,2020-07-09,Presentation or Conference,National,Cross-sectional survey ,Spain,,,Women attending one of 17 private fertility clinics belonging to IVIRMA group. ,Patients with symptoms of the virus or who had been in contact with someone suspected or confirmed to have been infected with SARS-CoV-2,2020-04-27,2020-05-19,Patients seeking care for non-COVID-19 reasons,Female,Adults (18-64 years),,,Primary Estimate,IgG,1549,0.0381,,,True,,,,True,Unclear,EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit,"Epitope Diagnostics, Inc.",ELISA,Plasma,IgG,,,,,['High'],,Unclear,Yes,No,,Yes,Yes,Yes,,C Gonzalez-Ravina,IVIRMA Global,Not Unity-Aligned,https://academic.oup.com/humrep/article/35/Supplement_1/i1/5867890?searchresult=1&login=true,2022-04-11,2024-03-01,Unverified,c_gonzalez-ravina_o-146_2020,ESP
200806_Valencia_HospitalClínicoUniversitario_HCWs_IgG_and_IgM,200806_Valencia_HospitalClínicoUniversitario,Caveats in interpreting SARS-CoV-2 IgM(+)/IgG(-)antibody profile in asymptomatic health care workers,2020-08-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Valencia,Valencia,"Asymptomatic health care workers at Hospital Clinico Universitario, Valencia",,2020-04-13,2020-04-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1153,0.035,,,True,,,,True,Unclear,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.956,0.96,['High'],No,Unclear,Yes,No,Unclear,Yes,Yes,No,Unclear,Arantxa Valdivia,Hospital Clínico Universitario,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.26400,2020-09-27,2024-03-01,Verified,valdivia_caveats_2020,ESP
200806_Barcelona_UniversitatdeBarcelona_PregnantWomen_Overall,200806_Barcelona_UniversitatdeBarcelona,Seroprevalence and presentation of SARS-CoV-2 in pregnancy,2020-08-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Barcelona,"pregnant women consecutively attending first trimester screening (ie, at 10–16 weeks of gestation; n=372) or delivery (n=502) from April 14 to May 5, 2020, at three university hospitals (ie, Hospital Sant Joan de Déu, Hospital Clínic, and Sant Pau) in Barcelona, Spain",,2020-04-14,2020-05-05,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,874,0.14,,,True,,,,True,Convenience,"COVID-19 ELISA IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total","Vircell S.L.,Ortho Clinical Diagnostics Inc.",,Serum,"['IgA', 'IgG', 'IgM']",,,,,['High'],No,No,Yes,No,No,No,Yes,No,,Francesca Crovetto,Universitat de Barcelona,Not Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31714-1/fulltext,2021-01-03,2024-03-01,Verified,crovetto_seroprevalence_2020,ESP
200810_Spain_CostadelSolHospital_HCW_IgGANDORIgM,200810_Spain_CostadelSolHospital_HCW,Search for asymptomatic carriers of SARS-CoV-2 in healthcare workers during the pandemic: a Spanish experience,2020-08-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Marbella,HCWs in a hospital involved in patient care,Workers who had been previously diagnosed with COVID-19 were excluded from the study,2020-04-15,2020-04-25,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,498,0.022000000000000002,,,True,,,,True,Convenience,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Serum,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,Yes,Yes,Yes,Yes,Yes,,Julian Olalla, Hospital Costa del Sol ,Not Unity-Aligned,http://dx.doi.org/10.1093/qjmed/hcaa238,2020-10-03,2024-03-01,Verified,olalla_search_2020,ESP
200828_CendeadeCizur_ISGlobal_primary,200828_CendeadeCizur_ISGlobal,"Coronavirus: New Seroprevalence Data for a Municipality in Navarra, Spain",2020-08-28,News and Media,Local,Cross-sectional survey ,Spain,Navarra,Cendea de Cizur,,,2020-06-01,2020-06-30,Household and community samples,All,Multiple groups,,,Primary Estimate,,728,0.079,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,"['IgA', 'IgG', 'IgM']",,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,Barcelona Institute for Global Health,ISGlobla,Not Unity-Aligned,https://www.isglobal.org/en_GB/-/coronavirus-nuevos-datos-de-seroprevalencia-para-un-municipio-en-navarra,2021-04-30,2022-07-16,Verified,noauthor_coronavirus_nodate,ESP
200831_Madrid_HospitalGeneralUniversitarioGregorioMaranon_Overall_UnAdj,200831_Madrid_HospitalGeneralUniversitarioGregorioMaranon,"Seroprevalence of SARS-CoV-2-specific antibodies in cancer outpatients in Madrid (Spain): A single center, prospective, cohort study and a review of available data",2020-08-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Community of Madrid,Torrejon de Ardoz,Oncology outpatients who attended the medical oncology consultation of the University Hospital of Torrejón,,2020-06-01,2020-06-19,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,22.0,88.0,Primary Estimate,,229,0.314,,,True,,,,True,Convenience,SARS-COV-2-IgG/IgM Test Cassette,Hangzhou Testsea Biotechnology Co. Ltd,,,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.96,1.0,['High'],No,No,No,Yes,No,Unclear,Yes,Yes,Unclear,Luis Cabezon-Gutierrez,Hospital General Universitario Gregorio Maranon,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ctrv.2020.102102,2020-10-20,2023-07-04,Verified,cabezon-gutierrez_seroprevalence_2020,ESP
200831_Madrid_HospitalGeneralUniversitarioGregorioMaranon_Age<50_UnAdj,200831_Madrid_HospitalGeneralUniversitarioGregorioMaranon,"Seroprevalence of SARS-CoV-2-specific antibodies in cancer outpatients in Madrid (Spain): A single center, prospective, cohort study and a review of available data",2020-08-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Community of Madrid,Torrejon de Ardoz,Oncology outpatients who attended the medical oncology consultation of the University Hospital of Torrejón,,2020-06-01,2020-06-19,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),,49.0,Age,Age <50,35,0.314,,,,,,,,Convenience,SARS-COV-2-IgG/IgM Test Cassette,Hangzhou Testsea Biotechnology Co. Ltd,,,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.96,1.0,['High'],No,No,No,Yes,No,Unclear,Yes,Yes,Unclear,Luis Cabezon-Gutierrez,Hospital General Universitario Gregorio Maranon,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ctrv.2020.102102,2020-10-20,2023-07-04,Verified,cabezon-gutierrez_seroprevalence_2020,ESP
200831_Madrid_HospitalGeneralUniversitarioGregorioMaranon_Age51-70_UnAdj,200831_Madrid_HospitalGeneralUniversitarioGregorioMaranon,"Seroprevalence of SARS-CoV-2-specific antibodies in cancer outpatients in Madrid (Spain): A single center, prospective, cohort study and a review of available data",2020-08-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Community of Madrid,Torrejon de Ardoz,Oncology outpatients who attended the medical oncology consultation of the University Hospital of Torrejón,,2020-06-01,2020-06-19,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,51.0,70.0,Age,Age 51-70,122,0.336,,,,,,,,Convenience,SARS-COV-2-IgG/IgM Test Cassette,Hangzhou Testsea Biotechnology Co. Ltd,,,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.96,1.0,['High'],No,No,No,Yes,No,Unclear,Yes,Yes,Unclear,Luis Cabezon-Gutierrez,Hospital General Universitario Gregorio Maranon,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ctrv.2020.102102,2020-10-20,2023-07-04,Verified,cabezon-gutierrez_seroprevalence_2020,ESP
200831_Madrid_HospitalGeneralUniversitarioGregorioMaranon_Age>70_UnAdj,200831_Madrid_HospitalGeneralUniversitarioGregorioMaranon,"Seroprevalence of SARS-CoV-2-specific antibodies in cancer outpatients in Madrid (Spain): A single center, prospective, cohort study and a review of available data",2020-08-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Community of Madrid,Torrejon de Ardoz,Oncology outpatients who attended the medical oncology consultation of the University Hospital of Torrejón,,2020-06-01,2020-06-19,Patients seeking care for non-COVID-19 reasons,All,Seniors (65+ years),71.0,,Age,Age >70,72,0.278,,,,,,,,Convenience,SARS-COV-2-IgG/IgM Test Cassette,Hangzhou Testsea Biotechnology Co. Ltd,,,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.96,1.0,['High'],No,No,No,Yes,No,Unclear,Yes,Yes,Unclear,Luis Cabezon-Gutierrez,Hospital General Universitario Gregorio Maranon,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ctrv.2020.102102,2020-10-20,2023-07-04,Verified,cabezon-gutierrez_seroprevalence_2020,ESP
201021_Spain_IVIRMA_Overall,201021_Spain_IVIRMA,RISK FACTOR ANALYSIS FOR SARS-COV-2 SEROPOSITIVITY WITHIN ASSISTED REPRODUCTIVE,2020-09-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Spain,,,"Asymptomatic individuals undergoing an assisted reproductive treatment. Before tested, a symptomatic triage had been carried out and only patients classified with a negative triage attended the clinic for further testing",Patients with a positive symptomatic triage ,2020-04-27,2020-06-26,Residual sera,All,Adults (18-64 years),,,Primary Estimate,Outpatients,6140,0.0068000000000000005,,,True,,,,True,Convenience,EDI™ Novel Coronavirus COVID-19 IgM ELISA Kit,"Epitope Diagnostics, Inc.",ELISA,Serum,IgM,,,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Nicolas Prados,IVIRMA Global Headquarters,Unity-Aligned,http://dx.doi.org/10.1016/j.fertnstert.2020.09.077,2021-01-08,2024-03-01,Verified,prados_risk_2020,ESP
200911_Barcelona_SardenyaPrimaryHealthCareCenter_Overall,200911_Barcelona_SardenyaPrimaryHealthCareCenter_Asymptomatic,Community seroprevalence of COVID-19 in probable and possible cases at primary health care centres in Spain,2020-09-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Catalonia,Barcelona,Individuals older than 1 registered at a primary health care center in Barcelona,"Institutionalized patients, terminally ill patients, suspected COVID-19 cases, patients who tested positive for COVID-19 prior to recruitment",2020-04-21,2020-04-24,Household and community samples,All,Multiple groups,1.0,94.0,Primary Estimate,Overall IgG and/or IgM,311,0.0547,0.0344,0.0858,True,,,,True,Stratified probability,"2019-nCoV IgG/IgM Antibody Detection Kit,COVID-19 antibody rapid test,Not reported/ Unable to specify","Zhuhai Livzon Diagnostics Inc,SureScreen Diagnostics,NA",LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,Yes,No,Yes,Yes,Unclear,Yes,No,No,Patricia Montenegro, Sardenya Primary Health Care Center,Not Unity-Aligned,http://dx.doi.org/10.1093/fampra/cmaa096,2021-01-08,2024-03-01,Verified,montenegro_community_2020,ESP
200911_Barcelona_SardenyaPrimaryHealthCareCenter_15-29,200911_Barcelona_SardenyaPrimaryHealthCareCenter_Asymptomatic,Community seroprevalence of COVID-19 in probable and possible cases at primary health care centres in Spain,2020-09-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Catalonia,Barcelona,Individuals older than 1 registered at a primary health care center in Barcelona,"Institutionalized patients, terminally ill patients, suspected COVID-19 cases, patients who tested positive for COVID-19 prior to recruitment",2020-04-21,2020-04-24,Household and community samples,All,Adults (18-64 years),15.0,29.0,Age,15-29,42,0.09519999999999999,,,,,,,,Stratified probability,"2019-nCoV IgG/IgM Antibody Detection Kit,COVID-19 antibody rapid test,Not reported/ Unable to specify","Zhuhai Livzon Diagnostics Inc,SureScreen Diagnostics,NA",LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,Yes,No,Yes,Yes,Unclear,Yes,No,No,Patricia Montenegro, Sardenya Primary Health Care Center,Not Unity-Aligned,http://dx.doi.org/10.1093/fampra/cmaa096,2021-01-08,2024-03-01,Verified,montenegro_community_2020,ESP
200911_Barcelona_SardenyaPrimaryHealthCareCenter_Men,200911_Barcelona_SardenyaPrimaryHealthCareCenter_Asymptomatic,Community seroprevalence of COVID-19 in probable and possible cases at primary health care centres in Spain,2020-09-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Catalonia,Barcelona,Individuals older than 1 registered at a primary health care center in Barcelona,"Institutionalized patients, terminally ill patients, suspected COVID-19 cases, patients who tested positive for COVID-19 prior to recruitment",2020-04-21,2020-04-24,Household and community samples,Male,Multiple groups,1.0,94.0,Sex/Gender,Male,140,0.042800000000000005,,,,,,,,Stratified probability,"2019-nCoV IgG/IgM Antibody Detection Kit,COVID-19 antibody rapid test,Not reported/ Unable to specify","Zhuhai Livzon Diagnostics Inc,SureScreen Diagnostics,NA",LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,Yes,No,Yes,Yes,Unclear,Yes,No,No,Patricia Montenegro, Sardenya Primary Health Care Center,Not Unity-Aligned,http://dx.doi.org/10.1093/fampra/cmaa096,2021-01-08,2024-03-01,Verified,montenegro_community_2020,ESP
200911_Barcelona_SardenyaPrimaryHealthCareCenter_Women,200911_Barcelona_SardenyaPrimaryHealthCareCenter_Asymptomatic,Community seroprevalence of COVID-19 in probable and possible cases at primary health care centres in Spain,2020-09-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Catalonia,Barcelona,Individuals older than 1 registered at a primary health care center in Barcelona,"Institutionalized patients, terminally ill patients, suspected COVID-19 cases, patients who tested positive for COVID-19 prior to recruitment",2020-04-21,2020-04-24,Household and community samples,Female,Multiple groups,1.0,94.0,Sex/Gender,Female,171,0.0643,,,,,,,,Stratified probability,"2019-nCoV IgG/IgM Antibody Detection Kit,COVID-19 antibody rapid test,Not reported/ Unable to specify","Zhuhai Livzon Diagnostics Inc,SureScreen Diagnostics,NA",LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,Yes,No,Yes,Yes,Unclear,Yes,No,No,Patricia Montenegro, Sardenya Primary Health Care Center,Not Unity-Aligned,http://dx.doi.org/10.1093/fampra/cmaa096,2021-01-08,2024-03-01,Verified,montenegro_community_2020,ESP
200911_Barcelona_SardenyaPrimaryHealthCareCenter_50-59,200911_Barcelona_SardenyaPrimaryHealthCareCenter_Asymptomatic,Community seroprevalence of COVID-19 in probable and possible cases at primary health care centres in Spain,2020-09-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Catalonia,Barcelona,Individuals older than 1 registered at a primary health care center in Barcelona,"Institutionalized patients, terminally ill patients, suspected COVID-19 cases, patients who tested positive for COVID-19 prior to recruitment",2020-04-21,2020-04-24,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,36,0.0556,,,,,,,,Stratified probability,"2019-nCoV IgG/IgM Antibody Detection Kit,COVID-19 antibody rapid test,Not reported/ Unable to specify","Zhuhai Livzon Diagnostics Inc,SureScreen Diagnostics,NA",LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,Yes,No,Yes,Yes,Unclear,Yes,No,No,Patricia Montenegro, Sardenya Primary Health Care Center,Not Unity-Aligned,http://dx.doi.org/10.1093/fampra/cmaa096,2021-01-08,2024-03-01,Verified,montenegro_community_2020,ESP
200911_Barcelona_SardenyaPrimaryHealthCareCenter_30-39,200911_Barcelona_SardenyaPrimaryHealthCareCenter_Asymptomatic,Community seroprevalence of COVID-19 in probable and possible cases at primary health care centres in Spain,2020-09-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Catalonia,Barcelona,Individuals older than 1 registered at a primary health care center in Barcelona,"Institutionalized patients, terminally ill patients, suspected COVID-19 cases, patients who tested positive for COVID-19 prior to recruitment",2020-04-21,2020-04-24,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,55,0.0182,,,,,,,,Stratified probability,"2019-nCoV IgG/IgM Antibody Detection Kit,COVID-19 antibody rapid test,Not reported/ Unable to specify","Zhuhai Livzon Diagnostics Inc,SureScreen Diagnostics,NA",LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,Yes,No,Yes,Yes,Unclear,Yes,No,No,Patricia Montenegro, Sardenya Primary Health Care Center,Not Unity-Aligned,http://dx.doi.org/10.1093/fampra/cmaa096,2021-01-08,2024-03-01,Verified,montenegro_community_2020,ESP
200911_Barcelona_SardenyaPrimaryHealthCareCenter_80+,200911_Barcelona_SardenyaPrimaryHealthCareCenter_Asymptomatic,Community seroprevalence of COVID-19 in probable and possible cases at primary health care centres in Spain,2020-09-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Catalonia,Barcelona,Individuals older than 1 registered at a primary health care center in Barcelona,"Institutionalized patients, terminally ill patients, suspected COVID-19 cases, patients who tested positive for COVID-19 prior to recruitment",2020-04-21,2020-04-24,Household and community samples,All,Seniors (65+ years),80.0,,Age,80+,17,0.1765,,,,,,,,Stratified probability,"2019-nCoV IgG/IgM Antibody Detection Kit,COVID-19 antibody rapid test,Not reported/ Unable to specify","Zhuhai Livzon Diagnostics Inc,SureScreen Diagnostics,NA",LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,Yes,No,Yes,Yes,Unclear,Yes,No,No,Patricia Montenegro, Sardenya Primary Health Care Center,Not Unity-Aligned,http://dx.doi.org/10.1093/fampra/cmaa096,2021-01-08,2024-03-01,Verified,montenegro_community_2020,ESP
200911_Barcelona_SardenyaPrimaryHealthCareCenter_60-69,200911_Barcelona_SardenyaPrimaryHealthCareCenter_Asymptomatic,Community seroprevalence of COVID-19 in probable and possible cases at primary health care centres in Spain,2020-09-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Catalonia,Barcelona,Individuals older than 1 registered at a primary health care center in Barcelona,"Institutionalized patients, terminally ill patients, suspected COVID-19 cases, patients who tested positive for COVID-19 prior to recruitment",2020-04-21,2020-04-24,Household and community samples,All,Adults (18-64 years),60.0,69.0,Age,60-69,34,0.0588,,,,,,,,Stratified probability,"2019-nCoV IgG/IgM Antibody Detection Kit,COVID-19 antibody rapid test,Not reported/ Unable to specify","Zhuhai Livzon Diagnostics Inc,SureScreen Diagnostics,NA",LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,Yes,No,Yes,Yes,Unclear,Yes,No,No,Patricia Montenegro, Sardenya Primary Health Care Center,Not Unity-Aligned,http://dx.doi.org/10.1093/fampra/cmaa096,2021-01-08,2024-03-01,Verified,montenegro_community_2020,ESP
200911_Barcelona_SardenyaPrimaryHealthCareCenter_70-79,200911_Barcelona_SardenyaPrimaryHealthCareCenter_Asymptomatic,Community seroprevalence of COVID-19 in probable and possible cases at primary health care centres in Spain,2020-09-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Catalonia,Barcelona,Individuals older than 1 registered at a primary health care center in Barcelona,"Institutionalized patients, terminally ill patients, suspected COVID-19 cases, patients who tested positive for COVID-19 prior to recruitment",2020-04-21,2020-04-24,Household and community samples,All,Seniors (65+ years),70.0,79.0,Age,70-79,31,0.0645,,,,,,,,Stratified probability,"2019-nCoV IgG/IgM Antibody Detection Kit,COVID-19 antibody rapid test,Not reported/ Unable to specify","Zhuhai Livzon Diagnostics Inc,SureScreen Diagnostics,NA",LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,Yes,No,Yes,Yes,Unclear,Yes,No,No,Patricia Montenegro, Sardenya Primary Health Care Center,Not Unity-Aligned,http://dx.doi.org/10.1093/fampra/cmaa096,2021-01-08,2024-03-01,Verified,montenegro_community_2020,ESP
200911_Barcelona_SardenyaPrimaryHealthCareCenter_0-14,200911_Barcelona_SardenyaPrimaryHealthCareCenter_Asymptomatic,Community seroprevalence of COVID-19 in probable and possible cases at primary health care centres in Spain,2020-09-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Catalonia,Barcelona,Individuals older than 1 registered at a primary health care center in Barcelona,"Institutionalized patients, terminally ill patients, suspected COVID-19 cases, patients who tested positive for COVID-19 prior to recruitment",2020-04-21,2020-04-24,Household and community samples,All,Children and Youth (0-17 years),0.0,14.0,Age,0-14,40,0.0,,,,,,,,Stratified probability,"2019-nCoV IgG/IgM Antibody Detection Kit,COVID-19 antibody rapid test,Not reported/ Unable to specify","Zhuhai Livzon Diagnostics Inc,SureScreen Diagnostics,NA",LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,Yes,No,Yes,Yes,Unclear,Yes,No,No,Patricia Montenegro, Sardenya Primary Health Care Center,Not Unity-Aligned,http://dx.doi.org/10.1093/fampra/cmaa096,2021-01-08,2024-03-01,Verified,montenegro_community_2020,ESP
200911_Barcelona_SardenyaPrimaryHealthCareCenter_40-49,200911_Barcelona_SardenyaPrimaryHealthCareCenter_Asymptomatic,Community seroprevalence of COVID-19 in probable and possible cases at primary health care centres in Spain,2020-09-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Catalonia,Barcelona,Individuals older than 1 registered at a primary health care center in Barcelona,"Institutionalized patients, terminally ill patients, suspected COVID-19 cases, patients who tested positive for COVID-19 prior to recruitment",2020-04-21,2020-04-24,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,56,0.0536,,,,,,,,Stratified probability,"2019-nCoV IgG/IgM Antibody Detection Kit,COVID-19 antibody rapid test,Not reported/ Unable to specify","Zhuhai Livzon Diagnostics Inc,SureScreen Diagnostics,NA",LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,Yes,No,Yes,Yes,Unclear,Yes,No,No,Patricia Montenegro, Sardenya Primary Health Care Center,Not Unity-Aligned,http://dx.doi.org/10.1093/fampra/cmaa096,2021-01-08,2024-03-01,Verified,montenegro_community_2020,ESP
200911_Santiago_HospitalClinicoUniversitariodeSantiagodeCompostela_Overall,200911_Santiago_HospitalClinicoUniversitariodeSantiagodeCompostela,Seroprevalence of SARS-CoV-2 Among Pediatric Healthcare Workers in Spain,2020-09-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Galicia,Santiago de Compostela,"We performed a sero-epidemiological survey on days+31,+32,and+33 after lockdown started, including all HCWs of thePediatric Department of the Hospital Clínico Universitario deSantiago de Compostela, namely, pediatricians, resident doctors,nurses, and administrative staff. Emergency Department andthe Pediatric Intensive Care Unit were considered the mostexposed areas.",,2020-04-14,2020-04-16,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,175,0.04,0.011000000000000001,0.069,True,,,,True,Convenience,Virusee Immunochromatographic Rapid Method,Genobio Pharmaceutical (Shanghai China),Other,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],Yes,No,No,No,Unclear,Unclear,Yes,No,Unclear,Ana Dacosta Urbieta,Hospital Clinico Universitario de Santiago de Compostela,Not Unity-Aligned,http://dx.doi.org/10.3389/fped.2020.00547,2021-01-05,2022-07-16,Verified,dacosta-urbieta_seroprevalence_2020,ESP
200918_Madrid_UniversityHospitalGregorioMarañón_Overall,200918_Madrid_UniversityHospitalGregorioMarañón,SARS-CoV-2 screening of asymptomatic women admitted for delivery must be performed with a combination of microbiological techniques: an observational study,2020-09-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,The first 100 women consecutively admitted for spontaneous delivery at the Department of Obstetrics and Gynecology of our institution.,Patients admitted for induction of labor or elective cesarean section were exclude,2020-05-06,2020-05-21,Pregnant or parturient women,Female,Adults (18-64 years),16.0,44.0,Primary Estimate,Overall estimate,100,0.13,,,True,,,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,No,No,No,Yes,Yes,Yes,Yes,Yes,Maria Vinuela,University Hospital Gregorio Marañón,Unity-Aligned,http://dx.doi.org/10.37201/req/088.2020,2020-11-12,2024-03-01,Verified,vinuela_sars-cov-2_2020,ESP
201014_Alicante_COVID-19GroupoftheInfectionsCommission,201014_Alicante_COVID-19GroupoftheInfectionsCommission,Sero-epidemiological study of SARS-CoV-2 infection among healthcare personnel in a healthcare department,2020-10-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Alacant,Alicante,Helath care professionals in a health department in Alicante General University Hospital,,2020-04-24,2020-05-08,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Overall IgG,4179,0.066,0.057999999999999996,0.073,True,,,,True,Unclear,Not reported/ Unable to specify,,ELISA,Serum,IgG,,,,,['High'],No,Unclear,Yes,No,No,Unclear,Yes,No,Yes,Paula Gras-Valenti,COVID-19 Group of the Infections Commission,Not Unity-Aligned,https://dx.doi.org/10.1016/j.eimc.2020.09.015,2021-01-29,2022-07-16,Verified,gras-valenti_estudio_2020,ESP
201024_Madrid_HospitalUniversitarioPrincipeDeAsturias_HCW_Overall,201024_Madrid_HospitalUniversitarioPrincipeDeAsturias,"SARS-CoV-2 infection among hospital workers of one of the most severely affected institutions in Madrid, Spain: a surveillance cross-sectional study",2020-10-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,"The study was performed in 2 periods. During the first period (March and April), PCR was performed in nasopharyngeal exudate for all hospital workers who presented symptoms of SARS-CoV-2 infection and were attended by the occupational health department. During the second period (May), all remaining workers were studied by serology (IgM and IgG antibodies), including asymptomatic workers and symptomatic workers that were negative by PCR.",Workers with a previously confirmed diagnosis via PCR were not tested.,2020-05-01,2020-05-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,2424,0.22399999999999998,,,True,,,,True,Convenience,2019-nCoV IgG/IgM Rapid Test Cassette,Hanghzhou AllTest Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.88,1.0,['High'],No,No,Yes,Yes,Unclear,No,Yes,No,Unclear,Felipe Perez Garcia ,Hospital Universitario Príncipe de Asturias,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2020.1303,2021-01-08,2024-03-01,Verified,perez-garcia_severe_2020,ESP
201029_Madrid_HospitalUniversitarioPríncipedeAsturias,201029_Madrid_HospitalUniversitarioPríncipedeAsturias,"Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection among hospital workers in a severely affected institution in Madrid, Spain: A surveillance cross-sectional study",2020-10-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,Workers at their hospital. ,vAll workers with a previously confirmed diagnosis of COVID-19 by PCR were not tested using serology,2020-05-01,2020-05-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,2424,0.22399999999999998,,,True,,,,True,Convenience,2019-nCoV IgG/IgM Rapid Test Cassette,Hanghzhou AllTest Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.88,1.0,['High'],Yes,No,Yes,No,Unclear,No,Yes,No,Yes,Felipe Perez Garcia,Hospital Universitario Príncipe de Asturias,Not Unity-Aligned,http://dx.doi.org/10.1017/ice.2020.1303,2021-08-02,2024-03-01,Verified,perez-garcia_severe_2021,ESP
201111_Barcelona_UniversityofBarcelona_HCW,201111_Barcelona_UniversityofBarcelona,SARS-CoV-2 Seroprevalence and Antibody Kinetics among Health Care Workers in a Spanish Hospital after 3 Months of Follow-up,2020-11-11,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Spain,,Barcelona,Inclusion criteria included being an adult (>17 years) worker at HCB. ,"Exclusion criteria included: (a) absenteeism from workplace in the last 30 days (i.e., on vacation, sick leave, sabbatical), (b) working exclusively outside the HCB or Maternity main buildings with no interaction with patients on a daily basis, (c) retirement or end-of-contract planned within one year after the recruitment date, and (d) participating in COVID-19 clinical trials for preventive or treatment therapies",2020-04-27,2020-05-06,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,565,0.145,,,True,,,,True,Simplified probability,Author designed (Luminex),,,Serum,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],Yes,Yes,No,Yes,Yes,Unclear,Yes,No,No,Gemma Moncunill,University of Barcelona,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiaa696,2021-01-20,2022-07-16,Verified,moncunill_sars-cov-2_2020-1,ESP
201112_Barcelona_UniversityHospitalSantJoandeDeu_HHC_primaryest,201112_Barcelona_UniversityHospitalSantJoandeDeu,"Susceptibility to Sars-COV-2 Infection Among Children And Adults: A Seroprevalence Study of Family Households in the Barcelona Metropolitan Region, Spain",2020-11-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Catalonia,Barcelona,families that included at least one first reported parent positive by SARS-CoV-2 Real-Time PCR and at least one child living in the same household,,2020-04-28,2020-06-03,Contacts of COVID patients,All,Multiple groups,,,Primary Estimate,Overall household contacts,1084,0.17989999999999998,,,True,,,,True,Convenience,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.833,,['High'],Yes,No,Yes,Yes,Unclear,No,Yes,No,Unclear,Pedro Brotons,University Hospital Sant Joan de Deu,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1721,2021-01-23,2024-03-01,Verified,brotons_susceptibility_2020,ESP
201112_Barcelona_UniversityHospitalSantJoandeDeu_HHC_children,201112_Barcelona_UniversityHospitalSantJoandeDeu,"Susceptibility to Sars-COV-2 Infection Among Children And Adults: A Seroprevalence Study of Family Households in the Barcelona Metropolitan Region, Spain",2020-11-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Catalonia,Barcelona,families that included at least one first reported parent positive by SARS-CoV-2 Real-Time PCR and at least one child living in the same household,,2020-04-28,2020-06-03,Contacts of COVID patients,All,Children and Youth (0-17 years),,15.0,Age,Children up to 15yrs,672,0.17600000000000002,0.14800000000000002,0.207,,,,,,Convenience,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.833,,['High'],Yes,No,Yes,Yes,Unclear,No,Yes,No,Unclear,Pedro Brotons,University Hospital Sant Joan de Deu,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1721,2021-01-23,2024-03-01,Verified,brotons_susceptibility_2020,ESP
201112_Barcelona_UniversityHospitalSantJoandeDeu_HHC_adults,201112_Barcelona_UniversityHospitalSantJoandeDeu,"Susceptibility to Sars-COV-2 Infection Among Children And Adults: A Seroprevalence Study of Family Households in the Barcelona Metropolitan Region, Spain",2020-11-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Catalonia,Barcelona,families that included at least one first reported parent positive by SARS-CoV-2 Real-Time PCR and at least one child living in the same household,,2020-04-28,2020-06-03,Contacts of COVID patients,All,Multiple groups,18.0,,Age,Adults from 18yrs,412,0.187,0.15,0.228,,,,,,Convenience,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Innovita Biological Technology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.833,,['High'],Yes,No,Yes,Yes,Unclear,No,Yes,No,Unclear,Pedro Brotons,University Hospital Sant Joan de Deu,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1721,2021-01-23,2024-03-01,Verified,brotons_susceptibility_2020,ESP
201026_Zaragoza_HospitalSanJuandeDios_HCW_primary,201026_Zaragoza_HospitalSanJuandeDios_HCW,[Prevalence of SARS-CoV-2 coronavirus infection in patients and professional staff at a medium or long-stay hospital in Spain],2020-11-13,Journal Article (Peer-Reviewed),Local,Prospective cohort,Spain,Aragon,Zaragoza,"HCW from the hospital, including those with direct contact with patients and those without. ",Patients with a confirmed COVID-19 diagnosis ,2020-03-20,2020-04-21,Health care workers and caregivers,All,Adults (18-64 years),19.0,64.0,Primary Estimate,HCWs,289,0.0588,,,True,,,,True,Convenience,Not reported/ Unable to specify,,LFIA,,"['IgG', 'IgM']",,Validated by developers,1.0,0.98,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,Unclear,Luis Antonio Moreno Borraz,Hospital San Juan de Dios,Not Unity-Aligned,https://dx.doi.org/10.1016/j.regg.2020.10.005,2021-01-27,2022-07-16,Verified,moreno_borraz_prevalencia_2020,ESP
201026_Zaragoza_HospitalSanJuandeDios_patients_primary,201026_Zaragoza_HospitalSanJuandeDios_Patients,[Prevalence of SARS-CoV-2 coronavirus infection in patients and professional staff at a medium or long-stay hospital in Spain],2020-11-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Aragon,Zaragoza,Outpatients and hospitalized patients requiring hemodialisis. ,Patients with a confirmed COVID-19 diagnosis ,2020-03-20,2020-04-21,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,36.0,97.0,Primary Estimate,patients on hemodialysis,229,0.0699,,,True,,,,True,Convenience,Not reported/ Unable to specify,,LFIA,,"['IgG', 'IgM']",,Validated by developers,1.0,0.98,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,Unclear,Luis Antonio Moreno Borraz,Hospital San Juan de Dios,Not Unity-Aligned,https://dx.doi.org/10.1016/j.regg.2020.10.005,2021-01-27,2022-07-16,Verified,moreno_borraz_prevalencia_2020,ESP
201120_Barcelona_UniversityHospitalSantJoanDeDeuBarcelona_Adults2,201120_Barcelona_UniversityHospitalSantJoanDeDeuBarcelona_Adults2,"Susceptibility to Severe Acute Respiratory Syndrome Coronavirus 2 Infection among Children and Adults: A Seroprevalence Study of Family Households in the Barcelona Metropolitan Region, Spain",2020-11-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Barcelona,"A total of 2412 families showed interest in participating in the 
study, of which 1359 met inclusion criteria. A total of 410 families documented a first RT-PCR–positive result for a household 
adult case, signed informed consents for participation, and were 
visited and tested using rapid LFA. Of them, 26 were excluded 
due to invalid LFA results in any family member, and 3 declined 
to answer the questionnaire and were also excluded. A  final 
number of 381 family households were selected.  

A total of 381 family households including 381 first-reported PCR-positive adult cases and 1084 contacts (672 children, 412 adults) were enrolled. ","A total of 2412 families showed interest in participating in the 
study, of which 1359 met inclusion criteria. A total of 410 families documented a first RT-PCR–positive result for a household 
adult case, signed informed consents for participation, and were 
visited and tested using rapid LFA. Of them, 26 were excluded 
due to invalid LFA results in any family member, and 3 declined 
to answer the questionnaire and were also excluded. A  final 
number of 381 family households were selected.

A total of 381 family households including 381 first-reported PCR-positive adult cases and 1084 contacts (672 children, 
412 adults) were enrolled. ",2020-04-28,2020-06-03,Household and community samples,All,Multiple groups,,,Primary Estimate,,412,0.187,0.15,0.228,True,,,,True,Convenience,"2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Abbott Architect SARS-CoV-2 IgG","Innovita Biological Technology Co. Ltd,Abbott Laboratories",ELISA,Serum,"['IgG', 'IgM']",,,,,['High'],,No,No,No,,No,Yes,No,,Pedro Brotons,University Hospital Sant Joan de Deu Barcelona,Not Unity-Aligned,http://dx.doi.org/10.1093/cid/ciaa1721,2021-07-20,2024-03-01,Unverified,brotonsSusceptibilitySevereAcute2020,ESP
201120_Barcelona_UniversityHospitalSantJoanDeDeuBarcelona_Children1,201120_Barcelona_UniversityHospitalSantJoanDeDeuBarcelona_Children1,"Susceptibility to Severe Acute Respiratory Syndrome Coronavirus 2 Infection among Children and Adults: A Seroprevalence Study of Family Households in the Barcelona Metropolitan Region, Spain",2020-11-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Barcelona,"A total of 2412 families showed interest in participating in the 
study, of which 1359 met inclusion criteria. A total of 410 families documented a first RT-PCR–positive result for a household 
adult case, signed informed consents for participation, and were 
visited and tested using rapid LFA. Of them, 26 were excluded 
due to invalid LFA results in any family member, and 3 declined 
to answer the questionnaire and were also excluded. A  final 
number of 381 family households were selected.  

A total of 381 family households including 381 first-reported PCR-positive adult cases and 1084 contacts (672 children, 412 adults) were enrolled. ","A total of 2412 families showed interest in participating in the 
study, of which 1359 met inclusion criteria. A total of 410 families documented a first RT-PCR–positive result for a household 
adult case, signed informed consents for participation, and were 
visited and tested using rapid LFA. Of them, 26 were excluded 
due to invalid LFA results in any family member, and 3 declined 
to answer the questionnaire and were also excluded. A  final 
number of 381 family households were selected.

A total of 381 family households including 381 first-reported PCR-positive adult cases and 1084 contacts (672 children, 
412 adults) were enrolled. ",2020-04-28,2020-06-03,Household and community samples,All,Multiple groups,,,Primary Estimate,,672,0.17600000000000002,0.14800000000000002,0.207,True,,,,True,Convenience,"2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo),Abbott Architect SARS-CoV-2 IgG","Innovita Biological Technology Co. Ltd,Abbott Laboratories",ELISA,Serum,"['IgG', 'IgM']",,,,,['High'],,No,Yes,No,,No,Yes,No,,Pedro Brotons,University Hospital Sant Joan de Deu Barcelona,Not Unity-Aligned,http://dx.doi.org/10.1093/cid/ciaa1721,2021-07-20,2024-03-01,Unverified,brotonsSusceptibilitySevereAcute2020,ESP
201125_Valencia_HospitalArnauDeVilanova_Overall,201125_Valencia_HospitalArnauDeVilanova,Impact of SARS-CoV-2 Infection on Patients with Cancer: Retrospective and Transversal Studies in Spanish Population,2020-11-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Valencia,Valencia,Cohort 2. Patients withconfirmed diagnosis of solid cancer treated at the outpatient medical oncology consultations withanticancer therapies between 2 May and 30 June 2020,,2020-05-02,2020-06-30,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,33.0,86.0,Primary Estimate,Primary estimate; All IgM and/or IgG positive,166,0.018000000000000002,,,True,,,,,Sequential,"Liaison SARS-CoV-2 S1/S2 IgG,Liason SARS-CoV-2 IgM test",DiaSorin,ELISA,Serum,"['IgG', 'IgM']",Spike,,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,No,Unclear,Javier Garde Noguera,"Hospital Arnau de Vilanova de Valencia, Spain",Not Unity-Aligned,https://dx.doi.org/10.3390/cancers12123513,2021-01-23,2024-03-01,Verified,garde-noguera_impact_2020-1,ESP
201130_Madrid_UniversidadComplutensedeMadrid_primary,201130_Madrid_UniversidadComplutensedeMadrid,Seroprevalence analysis of SARS-CoV-2 in pregnant women along the first pandemic outbreak and perinatal outcome,2020-11-30,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Spain,,Madrid,pregnant women with serologic analysis between February 28th to May 10th,,2020-02-28,2020-05-10,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,Pregnant women,769,0.11199999999999999,,,True,,,,True,Sequential,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,No,Yes,No,Yes,Unclear,Yes,No,,Cecilia Villalaın,The Universidad Complutense de Madrid,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0243029,2021-01-31,2022-07-16,Verified,villalain_seroprevalence_2020,ESP
201130_Madrid_UniversidadComplutensedeMadrid_timeframe_w13,201130_Madrid_UniversidadComplutensedeMadrid,Seroprevalence analysis of SARS-CoV-2 in pregnant women along the first pandemic outbreak and perinatal outcome,2020-11-30,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Spain,,Madrid,pregnant women with serologic analysis between February 28th to May 10th,,2020-03-23,2020-03-29,Pregnant or parturient women,Female,Adults (18-64 years),,,Time frame,Week 13,78,0.064,,,,,,,,Sequential,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,No,Yes,No,Yes,Unclear,Yes,No,,Cecilia Villalaın,The Universidad Complutense de Madrid,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0243029,2021-07-07,2022-07-16,Unverified,villalain_seroprevalence_2020,ESP
201130_Madrid_UniversidadComplutensedeMadrid_timeframe_w15,201130_Madrid_UniversidadComplutensedeMadrid,Seroprevalence analysis of SARS-CoV-2 in pregnant women along the first pandemic outbreak and perinatal outcome,2020-11-30,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Spain,,Madrid,pregnant women with serologic analysis between February 28th to May 10th,,2020-04-06,2020-04-12,Pregnant or parturient women,Female,Adults (18-64 years),,,Time frame,Week 15,53,0.113,,,,,,,,Sequential,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,No,Yes,No,Yes,Unclear,Yes,No,,Cecilia Villalaın,The Universidad Complutense de Madrid,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0243029,2021-07-07,2022-07-16,Unverified,villalain_seroprevalence_2020,ESP
201130_Madrid_UniversidadComplutensedeMadrid_timeframe_w19,201130_Madrid_UniversidadComplutensedeMadrid,Seroprevalence analysis of SARS-CoV-2 in pregnant women along the first pandemic outbreak and perinatal outcome,2020-11-30,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Spain,,Madrid,pregnant women with serologic analysis between February 28th to May 10th,,2020-05-04,2020-05-10,Pregnant or parturient women,Female,Adults (18-64 years),,,Time frame,Week 19,70,0.214,,,,,,,,Sequential,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,No,Yes,No,Yes,Unclear,Yes,No,,Cecilia Villalaın,The Universidad Complutense de Madrid,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0243029,2021-07-07,2022-07-16,Unverified,villalain_seroprevalence_2020,ESP
201130_Madrid_UniversidadComplutensedeMadrid_timeframe_w11,201130_Madrid_UniversidadComplutensedeMadrid,Seroprevalence analysis of SARS-CoV-2 in pregnant women along the first pandemic outbreak and perinatal outcome,2020-11-30,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Spain,,Madrid,pregnant women with serologic analysis between February 28th to May 10th,,2020-03-09,2020-03-15,Pregnant or parturient women,Female,Adults (18-64 years),,,Time frame,Week 11,75,0.027000000000000003,,,,,,,,Sequential,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,No,Yes,No,Yes,Unclear,Yes,No,,Cecilia Villalaın,The Universidad Complutense de Madrid,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0243029,2021-07-07,2022-07-16,Unverified,villalain_seroprevalence_2020,ESP
201130_Madrid_UniversidadComplutensedeMadrid_timeframe_w10,201130_Madrid_UniversidadComplutensedeMadrid,Seroprevalence analysis of SARS-CoV-2 in pregnant women along the first pandemic outbreak and perinatal outcome,2020-11-30,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Spain,,Madrid,pregnant women with serologic analysis between February 28th to May 10th,,2020-03-02,2020-03-08,Pregnant or parturient women,Female,Adults (18-64 years),,,Time frame,Week 10,84,0.0,,,,,,,,Sequential,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,No,Yes,No,Yes,Unclear,Yes,No,,Cecilia Villalaın,The Universidad Complutense de Madrid,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0243029,2021-07-07,2022-07-16,Unverified,villalain_seroprevalence_2020,ESP
201130_Madrid_UniversidadComplutensedeMadrid_timeframe_w14,201130_Madrid_UniversidadComplutensedeMadrid,Seroprevalence analysis of SARS-CoV-2 in pregnant women along the first pandemic outbreak and perinatal outcome,2020-11-30,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Spain,,Madrid,pregnant women with serologic analysis between February 28th to May 10th,,2020-03-30,2020-04-05,Pregnant or parturient women,Female,Adults (18-64 years),,,Time frame,Week 14,67,0.134,,,,,,,,Sequential,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,No,Yes,No,Yes,Unclear,Yes,No,,Cecilia Villalaın,The Universidad Complutense de Madrid,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0243029,2021-07-07,2022-07-16,Unverified,villalain_seroprevalence_2020,ESP
201130_Madrid_UniversidadComplutensedeMadrid_timeframe_w17,201130_Madrid_UniversidadComplutensedeMadrid,Seroprevalence analysis of SARS-CoV-2 in pregnant women along the first pandemic outbreak and perinatal outcome,2020-11-30,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Spain,,Madrid,pregnant women with serologic analysis between February 28th to May 10th,,2020-04-20,2020-04-26,Pregnant or parturient women,Female,Adults (18-64 years),,,Time frame,Week 17,91,0.154,,,,,,,,Sequential,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,No,Yes,No,Yes,Unclear,Yes,No,,Cecilia Villalaın,The Universidad Complutense de Madrid,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0243029,2021-07-07,2022-07-16,Unverified,villalain_seroprevalence_2020,ESP
201130_Madrid_UniversidadComplutensedeMadrid_timeframe_w12,201130_Madrid_UniversidadComplutensedeMadrid,Seroprevalence analysis of SARS-CoV-2 in pregnant women along the first pandemic outbreak and perinatal outcome,2020-11-30,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Spain,,Madrid,pregnant women with serologic analysis between February 28th to May 10th,,2020-03-16,2020-03-22,Pregnant or parturient women,Female,Adults (18-64 years),,,Time frame,Week 12,71,0.013999999999999999,,,,,,,,Sequential,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,No,Yes,No,Yes,Unclear,Yes,No,,Cecilia Villalaın,The Universidad Complutense de Madrid,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0243029,2021-07-07,2022-07-16,Unverified,villalain_seroprevalence_2020,ESP
201130_Madrid_UniversidadComplutensedeMadrid_timeframe_w16,201130_Madrid_UniversidadComplutensedeMadrid,Seroprevalence analysis of SARS-CoV-2 in pregnant women along the first pandemic outbreak and perinatal outcome,2020-11-30,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Spain,,Madrid,pregnant women with serologic analysis between February 28th to May 10th,,2020-04-13,2020-04-19,Pregnant or parturient women,Female,Adults (18-64 years),,,Time frame,Week 16,107,0.159,,,,,,,,Sequential,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,No,Yes,No,Yes,Unclear,Yes,No,,Cecilia Villalaın,The Universidad Complutense de Madrid,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0243029,2021-07-07,2022-07-16,Unverified,villalain_seroprevalence_2020,ESP
201130_Madrid_UniversidadComplutensedeMadrid_timeframe_w18,201130_Madrid_UniversidadComplutensedeMadrid,Seroprevalence analysis of SARS-CoV-2 in pregnant women along the first pandemic outbreak and perinatal outcome,2020-11-30,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Spain,,Madrid,pregnant women with serologic analysis between February 28th to May 10th,,2020-04-27,2020-05-03,Pregnant or parturient women,Female,Adults (18-64 years),,,Time frame,Week 18,73,0.233,,,,,,,,Sequential,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,No,Yes,No,Yes,Unclear,Yes,No,,Cecilia Villalaın,The Universidad Complutense de Madrid,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0243029,2021-07-07,2022-07-16,Unverified,villalain_seroprevalence_2020,ESP
201130_Spain_UniversityofZaragoza_unadj,201130_Spain_UniversityofZaragoza,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) universal screening in gravids during labor and delivery,2020-11-30,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Spain,,Madrid,women admitted for labor and delivery in a single hospital,,2020-03-31,2020-08-31,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,260,0.0692,,,True,,,,True,Sequential,"Biozek Medical COVID-19 Rapid Test,Abbott Architect SARS-CoV-2 IgG,COVID-19 ELISA IgG","Biozek,Abbott Laboratories,Vircell S.L.",Multiple Types,Serum,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,Unclear,Yes,No,Unclear,Ricardo Saviron Cornudella,University of Zaragoza,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ejogrb.2020.11.069,2021-01-23,2024-03-01,Verified,saviron-cornudella_severe_2020,ESP
201202_Tenerife_ QuironsaludTenerifeHospital_patients_primary,201202_Tenerife_QuironsaludTenerifeHospital,Pre-Procedural Antibody Testing for SARS-CoV-2 in routine endoscopic practice,2020-12-02,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Spain,Canary Islands,Tenerife," all patients with urgent and elective
endoscopic procedures carried out between April 27 and June 15, 2020",,2020-04-27,2020-06-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,Endoscopy patients,211,0.019,0.0007000000000000001,0.048,True,,,,True,Sequential,"Not reported/ Unable to specify,Elecsys® Anti‐SARS‐CoV‐2 (N)","NA,Roche Diagnostics",CLIA,Serum,TotalAntibody,,,,,['High'],Yes,No,No,Yes,Unclear,Unclear,Yes,No,Unclear,Alejandro Hernandez Camba, Quironsalud Tenerife Hospital,Not Unity-Aligned,https://dx.doi.org/10.17235/reed.2020.7434/2020,2021-01-31,2024-03-01,Verified,hernandez_camba_pre-procedural_2020,ESP
201218_Madrid_HospitalUniversitarioFundaciónAlcorcón_HCW_Overall,201218_Madrid_HospitalUniversitarioFundaciónAlcorcón,Hospital-Wide SARS-CoV-2 seroprevalence in health care workers in a Spanish teaching hospital,2020-12-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,All HCW were invited by the institutional email to attend an interview ,Patients with a positive nasopharyngeal swab test were sent home for quarantine or tothe ER for further clinical evaluation.,2020-04-14,2020-04-27,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,2590,0.316,,,True,,,,True,Convenience,Diapro,Palex,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.8890000000000001,0.918,['Moderate'],No,No,Yes,Yes,Unclear,No,Yes,No,Yes,Isabel Galan,Hospital Universitario Fundación Alcorcón,Not Unity-Aligned,https://dx.doi.org/10.1016/j.eimc.2020.11.015,2021-03-24,2024-03-01,Verified,galan_hospital-wide_2020,ESP
201221_Spain_HospitalClínicoUniversitarioLozanoBlesa,201221_Spain_HospitalClínicoUniversitarioLozanoBlesa,SARS-CoV-2 immunochromatographic IgM/IgG rapid test in pregnancy: a false friend?,2020-12-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Zaragoza,Zaragoza,pregnant women who were either at 36 weeks of gestation or had COVID-19 symptoms in the third trimester,,2020-04-27,2020-05-29,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,Pregnant women,169,0.0828,,,True,,,,True,Sequential,"Finecare SARS-CoV-2 Antibody test,Abbott Architect SARS-CoV-2 IgG,COVID-19 ELISA IgG","Guangzhou Wondfo Biotech Co. Ltd,Abbott Laboratories,Vircell S.L.",LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],No,No,No,No,No,Unclear,Yes,No,Unclear,M Fabre,Hospital Clínico Universitario Lozano Blesa,Not Unity-Aligned,https://dx.doi.org/10.1177/0004563220980495,2021-02-07,2024-03-01,Verified,fabre_sars-cov-2_2020,ESP
201228_Barcelona_InstitutCatalàdelaSalut_HCW_primary,201228_Barcelona_InstitutCatalàdelaSalut,"Seroprevalence of SARS-CoV-2 IgG Specific Antibodies among Healthcare Workers in the Northern Metropolitan Area of Barcelona, Spain, after the first pandemic wave",2020-12-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Barcelona,healthcare workers of the ICS-Northern Metropolitan Area of Barcelona,,2020-05-04,2020-05-22,Health care workers and caregivers,All,Multiple groups,18.0,,Primary Estimate,,7563,0.10300000000000001,,,True,,,,,Self-referral,"Liaison SARS-CoV-2 S1/S2 IgG,Abbott Architect SARS-CoV-2 IgG","DiaSorin,Abbott Laboratories",,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Jaume Barallat,Institut Català de la Salut,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0244348,2021-01-30,2024-03-01,Verified,fernandez-rivas_seroprevalence_2020,ESP
210112_Spain_HMHospitales_overall,210112_Spain_HMHospitales,Seroprevalence of SARS-CoV-2 antibodies in over 6000 healthcare workers in Spain,2021-01-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Spain,,,All employees registered at group HM (GHM) were invited to participate,,2020-04-15,2020-06-30,Health care workers and caregivers,All,Multiple groups,20.0,80.0,Primary Estimate,,6038,0.11,,,True,,,,True,Convenience,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Serum,IgG,,Validated by manufacturers,0.9120999999999999,0.9766,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jose Varona,HM Hospidales,Not Unity-Aligned,https://dx.doi.org/10.1093/ije/dyaa277,2021-02-06,2024-03-01,Unverified,varona_seroprevalence_2021,ESP
210114_Fuenlabrada_HospitalUniversitariodeFuenlabrada_HCW_IgG,210114_Fuenlabrada_HospitalUniversitariodeFuenlabrada,Impact of SARS-CoV-2 pandemic among health care workers in a secondary teaching hospital in Spain.,2021-01-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Fuenlabrada,"The cross-sectional study was carried out between April 14 and May 13, 2020 and included all HCW who came from different hospital services and belonged to all professional categories (administrative and auxiliary services staff, central services technicians, cleaning staff, clinic assistants, doctors, nurses and watchmen). All HCW were invited to participate, recruited from hospital Human Resources database (as of April 10, 2020) by the Occupational Health Service (OHS) and summoned by the Admission Service coordinated with the hospital’s Laboratory Medicine to perform the tests",,2020-04-14,2020-05-13,Health care workers and caregivers,All,Adults (18-64 years),18.0,65.0,Primary Estimate,,2439,0.16899999999999998,,,True,,,,True,Convenience,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Javier Fernandez,Hospital Universitario de Fuenlabrada,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0245001,2021-02-04,2024-03-01,Verified,garralda_fernandez_impact_2020,ESP
210119_Madrid_HospitalInfantilUniversitarioNiñoJesús,210119_Madrid_HospitalInfantilUniversitarioNiñoJesús,Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a pediatric monographic hospital in Madrid (Spain),2021-01-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Community of Madrid,Madrid,Workers at the Hospital Infantil Universitario Niño Jesús, Workers on sick leave and those who did not undergo serology were excluded,2020-04-13,2020-04-30,Health care workers and caregivers,All,Adults (18-64 years),20.0,68.0,Primary Estimate,Overall,1292,0.172,0.1516,0.1935,True,,,,True,Convenience,2019-nCoV IgG/IgM Rapid Test Cassette,Hanghzhou AllTest Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],No,No,Yes,No,Yes,No,Yes,No,Yes,Eva Escribano Ceruelo,Hospital Infantil Universitario Niño Jesús,Not Unity-Aligned,https://dx.doi.org/10.1016/j.eimc.2020.12.011,2021-03-16,2024-03-01,Verified,escribano_ceruelo_seroprevalencia_2021,ESP
210127_Madrid_UH-FundacionJimenezDiazUAM_primary,210127_Madrid_UH-FundacionJimenezDiazUAM,Clinical Features of Asymptomatic SARS-CoV-2 Infection in Hemodialysis Patients,2021-01-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Community of Madrid,Madrid,"In March 2020, the Hemodialysis Unit at UHFJD cared for 58 patients in the chronic hemodialysis program and the Fundación Renal Centro Santa Engracia for 142 patients (200 patients in total with age >18 years). Initially, patients in both units suspected of having an infection, that is, who presented clinical symptoms com- patible with COVID-19 or close contact with symptomatic indi- viduals, were tested for SARS-CoV-2 by nasopharyngeal swab PCR. Patients with positive results were transferred to the UHFJD hemodialysis unit. Eventually, only 5 patients on dialysis at UHFJD had not being tested. A total of 66 patients, of which 38 belonged to UHFJD and 28 to Fundación Renal Centro Santa Engracia, were tested for SARS-CoV-2 by PCR. ",,2020-03-01,2020-03-30,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,,Primary Estimate,,28,0.429,,,True,,,,True,Convenience,"COVID-19 ELISA IgG,COVID-19 ELISA IgM/IgA",Vircell S.L.,ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['High'],No,No,No,No,Unclear,No,Yes,No,,Maria Soledad Pizarro Sanchez,UH-Fundacion Jimenez Diaz UAM,Not Unity-Aligned,https://dx.doi.org/10.1159/000512535,2021-02-27,2024-03-01,Verified,pizarro-sanchez_clinical_2021,ESP
210318_Barcelona_UniversitatDeBarcelona_overall,210318_Barcelona_UniversitatDeBarcelona,Impact of SARS-CoV-2 Infection on Pregnancy Outcomes: A Population-Based Study,2021-02-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Barcelona,"Eligible women were all pregnant women from the catchment areas of three university hospitals (Hospital Sant Joan de Déu [HSJD], Hospital Clinic Barcelona [HCB], and Hospital de Sant Pau [HSP]) during the recruitment periods.",Women referred for a diagnosis of SARS-CoV-2 from outside the catchment areas of the participating centers were not eligible for the study,2020-03-15,2020-05-31,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,2225,0.141,,,True,,,,True,Sequential,"COVID-19 ELISA IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Author designed (Luminex)","Vircell S.L.,Ortho Clinical Diagnostics Inc.,NA",Multiple Types,,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,No,Yes,Yes,Yes,No,Unclear,Francesca Crovetto,Universitat de Barcelona,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab104,2021-03-18,2024-03-01,Unverified,crovetto_impact_2021,ESP
210209_Madrid_HospitalUniversitarioVirgendelRocio,210209_Madrid_HospitalUniversitarioVirgendelRocio,"High Rates of SARS-CoV-2 Family Transmission in Children of Healthcare Workers During the First Pandemic Wave in Madrid, Spain: Serologic Study",2021-02-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Community of Madrid,Madrid,Children of HCW who suffered a SARS-CoV-2 infection confirmed by either PCR or serology. Children who cohabited with their parents were included.,,2020-03-15,2020-05-15,Contacts of COVID patients,All,Children and Youth (0-17 years),,,Primary Estimate,,113,0.41600000000000004,,,True,,,,True,Convenience,COVID-19 ELISA IgG,Vircell S.L.,ELISA,Serum,IgG,,,,,['High'],No,No,No,Yes,No,No,Yes,No,Unclear,Ana Mendez Echevarria,Hospital Universitario Virgen del Rocio,Not Unity-Aligned,https://dx.doi.org/10.1097/INF.0000000000003088,2021-03-11,2024-03-01,Verified,mendez-echevarria_high_2021,ESP
210216_Alicante_UniversityofAlicante_overall_PopAdj_TestAdj,210216_Alicante_UniversityofAlicante,Seroprevalence study and cross-sectional survey on COVID-19 for a plan to reopen the university of alicante (Spain),2021-02-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Alicante,Alicante,Seroprevalence study and cross-sectional survey on COVID-19 for a plan to reopen the university of alicante (Spain),Seroprevalence study and cross-sectional survey on COVID-19 for a plan to reopen the university of alicante (Spain),2020-07-06,2020-07-22,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,"Ehe sample was selected from a representative random sample stratified by students, administrative staff, and faculty, and per academic program. ",1479,0.028900000000000002,0.0206,0.0373,True,True,True,,,Stratified probability,COVID-19 IgG/IgM Rapid Test Cassette,Cellex Inc.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.878,0.9990000000000001,['Low'],No,Yes,Yes,No,Yes,No,Yes,Yes,Yes,Jose Tuells,University of Alicante,Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph18041908,2021-03-27,2023-07-04,Verified,tuells_seroprevalence_2021,ESP
210223_Barcelona_UniversitatDeBarcelona_primary,210223_Barcelona_UniversitatDeBarcelona,Seven-month kinetics of SARS-CoV-2 antibodies and protective role of pre-existing antibodies to seasonal human coronaviruses on COVID-19,2021-02-23,Preprint,Local,Prospective cohort,Spain,,Barcelona,The study population included HCW at Hospital Clínic in Barcelona who delivered care and services directly or indirectly to patients,,2020-09-29,2020-10-20,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,507,0.16399999999999998,0.133,0.19899999999999998,True,,,,True,Simplified probability,Author designed (Luminex),,ELISA,Plasma,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.9578,1.0,['High'],No,Yes,No,Yes,Unclear,Unclear,Yes,Yes,Unclear,Natalia Ortega,Universitat de Barcelona ,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.22.21252150v1.full-text,2021-03-31,2022-07-16,Verified,ortega_seven-month_2021,ESP
210226_Mallorca_SonLlatzerUniversityHospital_overall,210226_Mallorca_SonLlatzerUniversityHospital,"Seroprevalence of SARS-CoV-2 antibody among healthcare workers in a university hospital in Mallorca, Spain, during the first wave of COVID-19 pandemic",2021-02-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,,the inclusion criteria required being registered in the human resources database as a hospital worker and giving consent for a blood draw and a nasopharyngeal swab.,All external workers who were not in this database and all participants with no serological results were excluded,2020-04-28,2020-06-11,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,2210,0.027999999999999997,0.025,0.031000000000000003,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9670000000000001,0.996,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Adrian Rodriguez,Son Llatzer University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.02.104,2021-04-02,2024-03-01,Verified,rodriguez_seroprevalence_2021,ESP
210301_Madrid_HospitalUniversitarioLaPaz_primary,210301_Madrid_HospitalUniversitarioLaPaz,Low rate of SARS-CoV-2 infection in picu workers caring for COVID-19 adults and children,2021-03-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,Pediatric Intensive Care Unit workers,,2020-03-15,2020-05-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,105,0.057,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],No,No,No,No,No,Unclear,Yes,No,Unclear,G Santos Simarro,Hospital Universitario La Paz,Not Unity-Aligned,http://dx.doi.org/10.1097/01.pcc.0000741352.50491.98,2021-05-22,2022-07-16,Verified,santos-simarro_p0754_2021,ESP
210309_Madrid_FundacionRenalInigoAlvarezDeToledo,210309_Madrid_FundacionRenalInigoAlvarezDeToledo,Rapid decline of anti-SARS-CoV-2 antibodies in patients on haemodialysis: the COVID-FRIAT study.,2021-03-09,Journal Article (Peer-Reviewed),Local,Prospective cohort,Spain,,Madrid,Non-COVID-19 patients,The only exclusion criterion was rejection to participate in the study. ,2020-03-01,2020-04-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,672,0.1502,,,True,,,,True,Convenience,COVID-19 ELISA IgM/IgA,Vircell S.L.,ELISA,Serum,"['IgA', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,0.88,0.99,['High'],,No,Yes,No,,No,Yes,No,,Roberto Alcazar Arroyo,Fundación Renal Íñigo Álvarez de Toledo,Not Unity-Aligned,https://dx.doi.org/10.1093/ckj/sfab048,2021-07-14,2024-03-01,Unverified,alcazar-arroyoRapidDeclineAntiSARSCoV22021,ESP
210316_Spain_HospitalUniversitarioPuertadeHierro_LymphomaPatients,210316_Spain_HospitalUniversitarioPuertadeHierro,Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel),2021-03-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Spain,,,patients diagnosed with lymphomas and followed up in the services of medical oncology at 7 different hospitals attached to the Oncological Group for the Treatment and Study of Lymphomas (GOTEL) in Spain,,2020-05-22,2020-06-11,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,17.0,89.0,Primary Estimate,,150,0.06,,,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,,IgG,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Fernando Franco,Hospital Universitario Puerta de Hierro,Not Unity-Aligned,https://dx.doi.org/10.3390/curroncol28020118,2021-04-23,2022-07-16,Unverified,franco_multicenter_2021,ESP
210305_Madrid_UNIRHealthSciencesSchoolandMedicalCentre_firstwave_primary,210305_Madrid_UNIRHealthSciencesSchoolandMedicalCentre_firstwave,"Main Differences Between the First and Second Waves of COVID-19 in Madrid, Spain.",2021-04-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,All consecutive individuals who attended during two trimesters in 2020 were examined retrospectively.,,2020-03-15,2020-06-30,Residual sera,All,Multiple groups,,,Primary Estimate,,968,0.126,,,True,,,,True,Sequential,PCL COVID19 IgG/IgM Rapid Gold,Vitrex Medical,LFIA,Whole Blood,,,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Vicente Soriano,UNIR Health Sciences School and Medical Centre,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.02.115,2021-05-18,2024-03-01,Verified,soriano_main_2021,ESP
210305_Madrid_UNIRHealthSciencesSchoolandMedicalCentre_secondwave_primary,210305_Madrid_UNIRHealthSciencesSchoolandMedicalCentre_secondwave,"Main Differences Between the First and Second Waves of COVID-19 in Madrid, Spain.",2021-04-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,All consecutive individuals who attended during two trimesters in 2020 were examined retrospectively.,,2020-09-15,2020-12-24,Residual sera,All,Multiple groups,,,Primary Estimate,,601,0.077,,,True,,,,True,Sequential,PCL COVID19 IgG/IgM Rapid Gold,Vitrex Medical,LFIA,Whole Blood,,,,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,,Vicente Soriano,UNIR Health Sciences School and Medical Centre,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.02.115,2021-05-18,2024-03-01,Verified,soriano_main_2021,ESP
210401_Madrid_HospitalUniversitarioRamonyCajal_HCW,210401_Madrid_HospitalUniversitarioRamonyCajal,SARS-CoV-2 Antibodies and utility of point of care testing in Health Care Workers from a Spanish University Hospital in Madrid,2021-04-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,"To avoid selection bias,  serology testing was offered to all staff working in the hospital (6747 HCW).",,2020-05-15,2020-06-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,5875,0.231,0.22100000000000003,0.24300000000000002,True,,,,True,Convenience,"2019-nCoV IgG/IgM Rapid Test Cassette,COVID-19 ELISA IgM/IgA","Hanghzhou AllTest Biotech Co. Ltd,Vircell S.L.",ELISA,Serum,IgG,,,,,['High'],,No,Yes,No,,No,Yes,No,,Mario Rodriguez Dominguez,Hospital Universitario Ramon y Cajal,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2021.03.018,2021-04-25,2024-03-01,Unverified,rodriguez-dominguez_severe_2021,ESP
210403_Majadahonda_HospitalUniversitarioPuertaDeHierro_overall_Unadj,210403_Majadahonda_HospitalUniversitarioPuertaDeHierro,Impact of COVID-19 pandemic on patients and health professionals of a radiation oncology department at a Spanish tertiary hospital,2021-04-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Municipality of Majadahonda,All staff of the department of Radiation Oncology,,2020-05-01,2020-05-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,50,0.12,,,True,,,,True,Convenience,"COVID-19 ELISA IgG,COVID-19 ELISA IgM/IgA",Vircell S.L.,ELISA,Serum,"['IgG', 'IgM']",,,,,['High'],No,No,No,No,Unclear,Yes,Yes,No,,Jesus Romero,Hospital Universitario Puerta de Hierro,Not Unity-Aligned,10.5603/RPOR.a2021.0036,2021-06-02,2024-03-01,Unverified,romero_impact_2021,ESP
210415_MadridZaragoza_GeneralUniversityHospital_pregnant,210415_MadridZaragoza_UniversityOfZaragoza,Screening of severe acute respiratory syndrome coronavirus-2 infection during labor and delivery using polymerase chain reaction and immunoglobulin testing,2021-04-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,NA & Zaragoza,Madrid & Zaragoza,A total of 1211 pregnant women admitted for labor and delivery or scheduled for labor induction or cesarean delivery were screened by PCR using nasopharyngeal swabs and testing IgG and IgM class antibodies. The inclusion criterion considered pregnancies over 23 weeks in gestations with spontaneous or induced labor. ,"Exclusion criteria corresponded to non-pregnant women, twin pregnancies, and neonatal or intrauterine deaths due to fetal malformations. Three patients with negative PCR, positive IgM and negative IgG were considered as possible false-positive cases and were excluded following the recommendations of the Spanish Ministry of Health Guidelines.",2020-03-31,2020-09-30,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,1211,0.0504,,,True,,,,True,Unclear,"Biozek Medical COVID-19 Rapid Test,Abbott Architect SARS-CoV-2 IgG,COVID-19 ELISA IgM/IgA","Biozek,Abbott Laboratories,Vircell S.L.",Multiple Types,Multiple Types,"['IgG', 'IgM']",,,,,['High'],Yes,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,Ricardo Saviron Cornudella,University of Zaragoza,Not Unity-Aligned,http://dx.doi.org/10.1016/j.lfs.2021.119200,2021-05-22,2024-03-01,Verified,saviron-cornudella_screening_2021,ESP
210420_Barcelona_CIBERESP,210420_Barcelona_CIBERESP,"Antibody Conversion rates to SARS-CoV-2 in Saliva from Children Attending Summer Schools in Barcelona, Spain",2021-04-20,Preprint,Local,Prospective cohort,Spain,,Barcelona,"A cohort of 1,905 children (age 0-14 years old) attending 22 Summer schools and 2 preschools, and adult staff working at the same facilities, located in 27 different venues in the
Barcelona metropolitan region, Spain, was followed up from June 29th to July 31st 2020.",,2020-06-29,2020-07-31,Students and Daycares,All,Multiple groups,0.0,,Primary Estimate,,1518,0.0322,,,True,,,,True,Convenience,Author designed (Luminex),,Multiple Types,Plasma,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Carlota Dobano,Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Públic,Not Unity-Aligned,10.1101/2021.04.20.440593,2021-05-23,2022-07-16,Unverified,dobano_antibody_2021,ESP
210428_Europe_SorbonneUniversité_4ComunidaddeMadrid,210428_Europe_SorbonneUniversité_4ComunidaddeMadrid,SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study.,2021-04-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,Comunidad de Madrid,,"Eligible individuals had to be older than 18 years and have a definite clinical diagnosis of rheumatoid arthritis, axial spondyloarthritis, systemic lupus erythematosus, Sjögren's syndrome, or giant cell arteritis diagnosed by experienced rheumatologists and fulfilling the respective international classification criteria.","Patients who refused to participate, did not speak or read the local language, or were unwilling to undergo routine blood collection during the study period were excluded. ",2020-07-07,2020-12-08,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,,Primary Estimate,,524,0.134,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Liaison SARS-CoV-2 S1/S2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Siemens,DiaSorin,Beckman Coulter,Roche Diagnostics",,,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,Yes,Unclear,Unclear,No,No,Unclear,David Saadoun,Sorbonne Université,Not Unity-Aligned,https://dx.doi.org/10.1016/S2665-9913(21)00112-0,2021-05-31,2024-03-01,Verified,davidsaadounetal.SARSCoV2OutbreakImmunemediated2021,ESP
210501_CastillaYLeon_CentroDeHemoterapiaYHemodonación,210501_CastillaYLeon_CentroDeHemoterapiaYHemodonación,"Sustained
  seroprevalence of anti SARS-CoV-2 total immunoglobulins in asymptomatic blood
  donors",2021-05-01,Preprint,National,Retrospective cohort,Spain,Castilla y Leon,,"A total of 12718 samples of 11444 donors over 18 years old were included from July 2019 to October 2020.

(The use of blood donor samples means we’re sampling mainly asymptomatic and recovered cases of COVID-19 (normal blood donation is allowed after 28 days following COVID-19 symptoms’ resolution)).","""We excluded convalescent plasma donors""",2019-07-15,2020-10-15,Blood donors,All,Multiple groups,18.0,75.0,Primary Estimate,,9886,0.06730000000000001,,,True,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,ELISA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Carmen Martin,Centro de Hemoterapia y Hemodonación de Castilla y León,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.04.28.21256242v1,2021-05-21,2024-03-01,Verified,martin_sustained_2021,ESP
210501_CastillaYLeon_CentroDeHemoterapiaYHemodonación_2019,210501_CastillaYLeon_CentroDeHemoterapiaYHemodonación,"Sustained
  seroprevalence of anti SARS-CoV-2 total immunoglobulins in asymptomatic blood
  donors",2021-05-01,Preprint,National,Retrospective cohort,Spain,Castilla y Leon,,"A total of 12718 samples of 11444 donors over 18 years old were included from July 2019 to October 2020.

(The use of blood donor samples means we’re sampling mainly asymptomatic and recovered cases of COVID-19 (normal blood donation is allowed after 28 days following COVID-19 symptoms’ resolution)).","""We excluded convalescent plasma donors""",2019-07-15,2019-10-31,Blood donors,All,Multiple groups,18.0,75.0,Time frame,,1142,0.0026000000000000003,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,ELISA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Carmen Martin,Centro de Hemoterapia y Hemodonación de Castilla y León,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.04.28.21256242v1,2021-06-30,2024-03-01,Verified,martin_sustained_2021,ESP
210501_CastillaYLeon_CentroDeHemoterapiaYHemodonación_2020,210501_CastillaYLeon_CentroDeHemoterapiaYHemodonación,"Sustained
  seroprevalence of anti SARS-CoV-2 total immunoglobulins in asymptomatic blood
  donors",2021-05-01,Preprint,National,Retrospective cohort,Spain,Castilla y Leon,,"A total of 12718 samples of 11444 donors over 18 years old were included from July 2019 to October 2020.

(The use of blood donor samples means we’re sampling mainly asymptomatic and recovered cases of COVID-19 (normal blood donation is allowed after 28 days following COVID-19 symptoms’ resolution)).","""We excluded convalescent plasma donors""",2020-01-01,2020-10-15,Blood donors,All,Multiple groups,18.0,75.0,Time frame,,9886,0.0665,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,ELISA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Carmen Martin,Centro de Hemoterapia y Hemodonación de Castilla y León,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.04.28.21256242v1,2021-06-30,2024-03-01,Verified,martin_sustained_2021,ESP
210504_Madrid_HospitalGeneralUniversitarioLaPaz_LongTermCareResidents1,210504_Madrid_HospitalGeneralUniversitarioLaPaz_LongTermCareResidents1,The Demography and Characteristic of SARS-CoV-2 Sero-positive Residents and Staff of Nursing Homes for Older Adults in the Community of Madrid: the SeroSOS Study.,2021-05-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,,"Nursing homes for older adults agreed to participate in the study, of which 66 were specificality devoted to the care of patients with mental or physical chronic disabilities. Resident of long term care centers registered in the Community of Madrid and who blood samples and clinical data was available for",,2020-07-07,2020-10-23,Assisted living and long-term care facilities,All,Seniors (65+ years),,,Primary Estimate,,9332,0.554,0.544,0.564,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Francisco Candel,Hospital General Universitario La Paz,Not Unity-Aligned,https://dx.doi.org/10.1093/ageing/afab096,2021-05-28,2024-03-01,Verified,candel_demography_2021,ESP
210504_Madrid_HospitalGeneralUniversitarioLaPaz_LongTermCareResidents1_Age85to90,210504_Madrid_HospitalGeneralUniversitarioLaPaz_LongTermCareResidents1,The Demography and Characteristic of SARS-CoV-2 Sero-positive Residents and Staff of Nursing Homes for Older Adults in the Community of Madrid: the SeroSOS Study.,2021-05-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,,"Nursing homes for older adults agreed to participate in the study, of which 66 were specificality devoted to the care of patients with mental or physical chronic disabilities. Resident of long term care centers registered in the Community of Madrid and who blood samples and clinical data was available for",,2020-07-07,2020-10-23,Assisted living and long-term care facilities,All,Seniors (65+ years),85.0,90.0,Age,85-90,2606,0.559,0.539,0.578,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Francisco Candel,Hospital General Universitario La Paz,Not Unity-Aligned,https://dx.doi.org/10.1093/ageing/afab096,2021-08-12,2024-03-01,Verified,candel_demography_2021,ESP
210504_Madrid_HospitalGeneralUniversitarioLaPaz_LongTermCareResidents1_Age90plus,210504_Madrid_HospitalGeneralUniversitarioLaPaz_LongTermCareResidents1,The Demography and Characteristic of SARS-CoV-2 Sero-positive Residents and Staff of Nursing Homes for Older Adults in the Community of Madrid: the SeroSOS Study.,2021-05-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,,"Nursing homes for older adults agreed to participate in the study, of which 66 were specificality devoted to the care of patients with mental or physical chronic disabilities. Resident of long term care centers registered in the Community of Madrid and who blood samples and clinical data was available for",,2020-07-07,2020-10-23,Assisted living and long-term care facilities,All,Seniors (65+ years),,,Age,>90,3590,0.547,0.531,0.564,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Francisco Candel,Hospital General Universitario La Paz,Not Unity-Aligned,https://dx.doi.org/10.1093/ageing/afab096,2021-08-12,2024-03-01,Verified,candel_demography_2021,ESP
210504_Madrid_HospitalGeneralUniversitarioLaPaz_LongTermCareResidents1_Age85minus,210504_Madrid_HospitalGeneralUniversitarioLaPaz_LongTermCareResidents1,The Demography and Characteristic of SARS-CoV-2 Sero-positive Residents and Staff of Nursing Homes for Older Adults in the Community of Madrid: the SeroSOS Study.,2021-05-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,,"Nursing homes for older adults agreed to participate in the study, of which 66 were specificality devoted to the care of patients with mental or physical chronic disabilities. Resident of long term care centers registered in the Community of Madrid and who blood samples and clinical data was available for",,2020-07-07,2020-10-23,Assisted living and long-term care facilities,All,Seniors (65+ years),,,Age,<85,3126,0.56,0.542,0.5770000000000001,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Francisco Candel,Hospital General Universitario La Paz,Not Unity-Aligned,https://dx.doi.org/10.1093/ageing/afab096,2021-08-12,2024-03-01,Verified,candel_demography_2021,ESP
210504_Madrid_HospitalGeneralUniversitarioLaPaz_LongTermCareWorkers2,210504_Madrid_HospitalGeneralUniversitarioLaPaz_LongTermCareWorkers2,The Demography and Characteristic of SARS-CoV-2 Sero-positive Residents and Staff of Nursing Homes for Older Adults in the Community of Madrid: the SeroSOS Study.,2021-05-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,,Workers in long term care centers registered in the Community of Madrid and who blood samples and clinical data was available for,,2020-07-07,2020-10-23,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,10614,0.315,0.306,0.324,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Francisco Candel,Hospital General Universitario La Paz,Not Unity-Aligned,https://dx.doi.org/10.1093/ageing/afab096,2021-05-28,2024-03-01,Verified,candel_demography_2021,ESP
210504_Madrid_HospitalGeneralUniversitarioLaPaz_LongTermCareWorkers_Age40to50,210504_Madrid_HospitalGeneralUniversitarioLaPaz_LongTermCareWorkers2,The Demography and Characteristic of SARS-CoV-2 Sero-positive Residents and Staff of Nursing Homes for Older Adults in the Community of Madrid: the SeroSOS Study.,2021-05-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,,Workers in long term care centers registered in the Community of Madrid and who blood samples and clinical data was available for,,2020-07-07,2020-10-23,Health care workers and caregivers,All,Adults (18-64 years),40.0,50.0,Age,40-50,2925,0.313,0.29600000000000004,0.33,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Francisco Candel,Hospital General Universitario La Paz,Not Unity-Aligned,https://dx.doi.org/10.1093/ageing/afab096,2021-08-12,2024-03-01,Verified,candel_demography_2021,ESP
210504_Madrid_HospitalGeneralUniversitarioLaPaz_LongTermCareWorkers_Age40minus,210504_Madrid_HospitalGeneralUniversitarioLaPaz_LongTermCareWorkers2,The Demography and Characteristic of SARS-CoV-2 Sero-positive Residents and Staff of Nursing Homes for Older Adults in the Community of Madrid: the SeroSOS Study.,2021-05-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,,Workers in long term care centers registered in the Community of Madrid and who blood samples and clinical data was available for,,2020-07-07,2020-10-23,Health care workers and caregivers,All,Adults (18-64 years),,,Age,<40,3185,0.267,0.252,0.28300000000000003,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Francisco Candel,Hospital General Universitario La Paz,Not Unity-Aligned,https://dx.doi.org/10.1093/ageing/afab096,2021-08-12,2024-03-01,Verified,candel_demography_2021,ESP
210504_Madrid_HospitalGeneralUniversitarioLaPaz_LongTermCareWorkers_Age50plus,210504_Madrid_HospitalGeneralUniversitarioLaPaz_LongTermCareWorkers2,The Demography and Characteristic of SARS-CoV-2 Sero-positive Residents and Staff of Nursing Homes for Older Adults in the Community of Madrid: the SeroSOS Study.,2021-05-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,,Workers in long term care centers registered in the Community of Madrid and who blood samples and clinical data was available for,,2020-07-07,2020-10-23,Health care workers and caregivers,All,Adults (18-64 years),,,Age,>50,4114,0.35100000000000003,0.336,0.36600000000000005,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Francisco Candel,Hospital General Universitario La Paz,Not Unity-Aligned,https://dx.doi.org/10.1093/ageing/afab096,2021-08-12,2024-03-01,Verified,candel_demography_2021,ESP
210507_Salamanca_UniversityofSalamanca,210507_Salamanca_UniversityofSalamanca,"Seroprevalence
  of SARS-CoV-2 Antibodies and Factors Associated with Seropositivity at the
  University of Salamanca: The DIANCUSAL Study",2021-05-07,Preprint,Local,Cross-sectional survey ,Spain,Province of Salamanca,Salamanca,"All USAL students, professors, and staff were invited to complete an anonymized questionnaire.",,2020-07-15,2020-10-15,Non-essential workers and unemployed persons,All,Multiple groups,17.0,76.0,Primary Estimate,,8197,0.0825,,,True,,,,True,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,Liason SARS-CoV-2 IgM test",DiaSorin,ELISA,Serum,"['IgG', 'IgM']",Spike,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Vicente Santiago Belen,University of Salamanca,Not Unity-Aligned,https://www.researchsquare.com/article/rs-489321/v1,2021-05-22,2024-03-01,Unverified,vicentesantiagobelenSeroprevalenceSARSCoV2Antibodies2021,ESP
210510_Cantabria_UniversityofCantabria_Overall,210510_Cantabria_UniversityofCantabria,Feasibility of large-scale population testing for SARS-CoV-2 detection by self-testing at home.,2021-05-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,Cantabria,,"The ETHON cohort compromises of 5,989 inhabitants from the region of Cantabria in northern Spain. Participants were selected through a random and representative sample by means of sampling by two-stage conglomerates with stratification according to economic status, housing area (rural/urban), and age, being representative of the general population.",,2020-04-27,2020-05-29,Household and community samples,All,Multiple groups,18.0,83.0,Primary Estimate,Overall,1022,0.031000000000000003,0.022000000000000002,0.044000000000000004,True,,,,True,Stratified probability,Lungene 2019-nCoV IgG/IgM Rapid Test,Hangzhou Clongene Biotech Co. Ltd ,LFIA,Multiple Types,IgG,,Validated by manufacturers,0.9740000000000001,0.9889,['Moderate'],,Yes,Yes,Yes,,No,Yes,Yes,,Paula Iruzubieta,University of Cantabria,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89236-x,2021-05-31,2024-03-01,Verified,iruzubieta_feasibility_2021,ESP
210510_Cantabria_UniversityofCantabria_65+,210510_Cantabria_UniversityofCantabria,Feasibility of large-scale population testing for SARS-CoV-2 detection by self-testing at home.,2021-05-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,Cantabria,,"The ETHON cohort compromises of 5,989 inhabitants from the region of Cantabria in northern Spain. Participants were selected through a random and representative sample by means of sampling by two-stage conglomerates with stratification according to economic status, housing area (rural/urban), and age, being representative of the general population.",,2020-04-27,2020-05-29,Household and community samples,All,Seniors (65+ years),65.0,83.0,Age,65+,280,0.0464,,,,,,,,Stratified probability,Lungene 2019-nCoV IgG/IgM Rapid Test,Hangzhou Clongene Biotech Co. Ltd ,LFIA,Multiple Types,IgG,,Validated by manufacturers,0.9740000000000001,0.9889,['Moderate'],,Yes,Yes,Yes,,No,Yes,Yes,,Paula Iruzubieta,University of Cantabria,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89236-x,2021-08-12,2024-03-01,Verified,iruzubieta_feasibility_2021,ESP
210510_Cantabria_UniversityofCantabria_Male,210510_Cantabria_UniversityofCantabria,Feasibility of large-scale population testing for SARS-CoV-2 detection by self-testing at home.,2021-05-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,Cantabria,,"The ETHON cohort compromises of 5,989 inhabitants from the region of Cantabria in northern Spain. Participants were selected through a random and representative sample by means of sampling by two-stage conglomerates with stratification according to economic status, housing area (rural/urban), and age, being representative of the general population.",,2020-04-27,2020-05-29,Household and community samples,Male,Multiple groups,18.0,83.0,Sex/Gender,Male,491,0.0244,,,,,,,,Stratified probability,Lungene 2019-nCoV IgG/IgM Rapid Test,Hangzhou Clongene Biotech Co. Ltd ,LFIA,Multiple Types,IgG,,Validated by manufacturers,0.9740000000000001,0.9889,['Moderate'],,Yes,Yes,Yes,,No,Yes,Yes,,Paula Iruzubieta,University of Cantabria,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89236-x,2021-08-12,2024-03-01,Verified,iruzubieta_feasibility_2021,ESP
210510_Cantabria_UniversityofCantabria_50-64,210510_Cantabria_UniversityofCantabria,Feasibility of large-scale population testing for SARS-CoV-2 detection by self-testing at home.,2021-05-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,Cantabria,,"The ETHON cohort compromises of 5,989 inhabitants from the region of Cantabria in northern Spain. Participants were selected through a random and representative sample by means of sampling by two-stage conglomerates with stratification according to economic status, housing area (rural/urban), and age, being representative of the general population.",,2020-04-27,2020-05-29,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50-64,274,0.032799999999999996,,,,,,,,Stratified probability,Lungene 2019-nCoV IgG/IgM Rapid Test,Hangzhou Clongene Biotech Co. Ltd ,LFIA,Multiple Types,IgG,,Validated by manufacturers,0.9740000000000001,0.9889,['Moderate'],,Yes,Yes,Yes,,No,Yes,Yes,,Paula Iruzubieta,University of Cantabria,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89236-x,2021-08-12,2024-03-01,Verified,iruzubieta_feasibility_2021,ESP
210510_Cantabria_UniversityofCantabria_18-49,210510_Cantabria_UniversityofCantabria,Feasibility of large-scale population testing for SARS-CoV-2 detection by self-testing at home.,2021-05-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,Cantabria,,"The ETHON cohort compromises of 5,989 inhabitants from the region of Cantabria in northern Spain. Participants were selected through a random and representative sample by means of sampling by two-stage conglomerates with stratification according to economic status, housing area (rural/urban), and age, being representative of the general population.",,2020-04-27,2020-05-29,Household and community samples,All,Adults (18-64 years),18.0,49.0,Age,18-49,468,0.0192,0.01,0.036000000000000004,,,,,,Stratified probability,Lungene 2019-nCoV IgG/IgM Rapid Test,Hangzhou Clongene Biotech Co. Ltd ,LFIA,Multiple Types,IgG,,Validated by manufacturers,0.9740000000000001,0.9889,['Moderate'],,Yes,Yes,Yes,,No,Yes,Yes,,Paula Iruzubieta,University of Cantabria,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89236-x,2021-08-12,2024-03-01,Verified,iruzubieta_feasibility_2021,ESP
210510_Cantabria_UniversityofCantabria_Female,210510_Cantabria_UniversityofCantabria,Feasibility of large-scale population testing for SARS-CoV-2 detection by self-testing at home.,2021-05-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,Cantabria,,"The ETHON cohort compromises of 5,989 inhabitants from the region of Cantabria in northern Spain. Participants were selected through a random and representative sample by means of sampling by two-stage conglomerates with stratification according to economic status, housing area (rural/urban), and age, being representative of the general population.",,2020-04-27,2020-05-29,Household and community samples,Female,Multiple groups,18.0,83.0,Sex/Gender,Female,531,0.0358,,,,,,,,Stratified probability,Lungene 2019-nCoV IgG/IgM Rapid Test,Hangzhou Clongene Biotech Co. Ltd ,LFIA,Multiple Types,IgG,,Validated by manufacturers,0.9740000000000001,0.9889,['Moderate'],,Yes,Yes,Yes,,No,Yes,Yes,,Paula Iruzubieta,University of Cantabria,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89236-x,2021-08-12,2024-03-01,Verified,iruzubieta_feasibility_2021,ESP
210514_Madrid_HospitalUniversitarioLaPaz,210514_Madrid_HospitalUniversitarioLaPaz,Clinical course and seroprevalence of COVID-19 in children with rheumatic diseases. Cross-sectional study from a reference centre in Spain,2021-05-14,Preprint,Local,Cross-sectional survey ,Spain,Madrid,Madrid,"Pediatric patients with rheumatic diseases in a
rheumatology unit of a reference hospital in Madrid, Spain",,2020-09-15,2021-02-15,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),,,Primary Estimate,,105,0.2,,,True,,,,True,Convenience,Not reported/ Unable to specify,,CLIA,Serum,IgG,,,,,['High'],Yes,No,No,Yes,No,Unclear,Yes,No,Unclear,Clara Udaondo ,Hospital Universitario La Paz,Not Unity-Aligned,https://www.researchsquare.com/article/rs-505561/v1,2021-05-28,2022-07-16,Verified,udaondo_clinical_2021,ESP
210526_HospitalUniversitarioFundacionJimenezDiaz_Madrid_hcw,210526_HospitalUniversitarioFundacionJimenezDiaz_Madrid,Serological study of healthcare workers in four different hospitals in Madrid (Spain) with no previous history of COVID-19.,2021-05-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,HCWs with no prior COVID-19 diagnosis (positive RT-PCR),,2020-04-06,2020-04-25,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,5995,0.162,,,True,,,,True,Convenience,Biozek Medical COVID-19 Rapid Test,Biozek,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Fabian Vazquez Rivas,Fundación Jiménez Díaz University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1136/oemed-2020-107001,2021-06-06,2024-03-01,Unverified,vazquez_rivas_serological_2021,ESP
210528_Spain_InstitutodeInvestigacionesBiomédicasdeMálaga_Overall,210528_Spain_InstitutodeInvestigacionesBiomédicasdeMálaga,Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients (p): SOLID study,2021-05-28,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Spain,,,Eligibility criteria was a diagnosis of any thoracic cancer. ,,2020-04-21,2020-06-03,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,1500,0.085,0.07200000000000001,0.10099999999999999,True,,,,True,Unclear,Not reported/ Unable to specify,,,,IgG,,,,,['High'],Yes,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,Mariano Provencio,Instituto de Investigaciones Biomédicas de Málaga (IBIMA),Not Unity-Aligned,https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.8531,2021-08-18,2022-07-16,Verified,provencio_seroprevalence_2021,ESP
210531_Madrid_CentroDeTransfusiónDeLaComunidadDeMadrid_overall,210531_Madrid_CentroDeTransfusiónDeLaComunidadDeMadrid,Anti SARS-CoV-2 antibodies prevalence in Madrid blood donors prior to first outbreak,2021-05-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,"blood donors that donate blood from January 1 to March 22, 2020",,2020-01-01,2020-03-22,Blood donors,All,Multiple groups,,,Primary Estimate,,2419,0.0008,,,True,,,,True,Sequential,MosaiQ COVID-19 Antibody Microarray,Quotient ,Other,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,,R. Alenda,Centro de Transfusión de la Comunidad de Madrid,Unity-Aligned,http://dx.doi.org/10.1111/vox.13117,2021-06-29,2024-03-01,Verified,alenda_p-216_2021,ESP
210531_Madrid_CentroDeTransfusiónDeLaComunidadDeMadrid_Jan26-31,210531_Madrid_CentroDeTransfusiónDeLaComunidadDeMadrid,Anti SARS-CoV-2 antibodies prevalence in Madrid blood donors prior to first outbreak,2021-05-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,"blood donors that donate blood from January 1 to March 22, 2020",,2020-01-26,2020-01-31,Blood donors,All,Multiple groups,,,Time frame,,172,0.0,,,,,,,,Sequential,MosaiQ COVID-19 Antibody Microarray,Quotient ,Other,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,,R. Alenda,Centro de Transfusión de la Comunidad de Madrid,Unity-Aligned,http://dx.doi.org/10.1111/vox.13117,2021-07-30,2024-03-01,Verified,alenda_p-216_2021,ESP
210531_Madrid_CentroDeTransfusiónDeLaComunidadDeMadrid_Mar-15-22,210531_Madrid_CentroDeTransfusiónDeLaComunidadDeMadrid,Anti SARS-CoV-2 antibodies prevalence in Madrid blood donors prior to first outbreak,2021-05-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,"blood donors that donate blood from January 1 to March 22, 2020",,2020-03-15,2020-03-22,Blood donors,All,Multiple groups,,,Time frame,,89,0.0,,,,,,,,Sequential,MosaiQ COVID-19 Antibody Microarray,Quotient ,Other,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,,R. Alenda,Centro de Transfusión de la Comunidad de Madrid,Unity-Aligned,http://dx.doi.org/10.1111/vox.13117,2021-07-30,2024-03-01,Verified,alenda_p-216_2021,ESP
210531_Madrid_CentroDeTransfusiónDeLaComunidadDeMadrid_Feb1-8,210531_Madrid_CentroDeTransfusiónDeLaComunidadDeMadrid,Anti SARS-CoV-2 antibodies prevalence in Madrid blood donors prior to first outbreak,2021-05-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,"blood donors that donate blood from January 1 to March 22, 2020",,2020-02-01,2020-02-08,Blood donors,All,Multiple groups,,,Time frame,,91,0.0,,,,,,,,Sequential,MosaiQ COVID-19 Antibody Microarray,Quotient ,Other,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,,R. Alenda,Centro de Transfusión de la Comunidad de Madrid,Unity-Aligned,http://dx.doi.org/10.1111/vox.13117,2021-07-30,2024-03-01,Verified,alenda_p-216_2021,ESP
210531_Madrid_CentroDeTransfusiónDeLaComunidadDeMadrid_Feb9-15,210531_Madrid_CentroDeTransfusiónDeLaComunidadDeMadrid,Anti SARS-CoV-2 antibodies prevalence in Madrid blood donors prior to first outbreak,2021-05-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,"blood donors that donate blood from January 1 to March 22, 2020",,2020-02-09,2020-02-15,Blood donors,All,Multiple groups,,,Time frame,,387,0.0,,,,,,,,Sequential,MosaiQ COVID-19 Antibody Microarray,Quotient ,Other,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,,R. Alenda,Centro de Transfusión de la Comunidad de Madrid,Unity-Aligned,http://dx.doi.org/10.1111/vox.13117,2021-07-30,2024-03-01,Verified,alenda_p-216_2021,ESP
210531_Madrid_CentroDeTransfusiónDeLaComunidadDeMadrid_March,210531_Madrid_CentroDeTransfusiónDeLaComunidadDeMadrid,Anti SARS-CoV-2 antibodies prevalence in Madrid blood donors prior to first outbreak,2021-05-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,"blood donors that donate blood from January 1 to March 22, 2020",,2020-03-01,2020-03-22,Blood donors,All,Multiple groups,,,Time frame,,548,0.0036,,,,,,,,Sequential,MosaiQ COVID-19 Antibody Microarray,Quotient ,Other,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,,R. Alenda,Centro de Transfusión de la Comunidad de Madrid,Unity-Aligned,http://dx.doi.org/10.1111/vox.13117,2021-07-30,2024-03-01,Verified,alenda_p-216_2021,ESP
210531_Madrid_CentroDeTransfusiónDeLaComunidadDeMadrid_Feb16-22,210531_Madrid_CentroDeTransfusiónDeLaComunidadDeMadrid,Anti SARS-CoV-2 antibodies prevalence in Madrid blood donors prior to first outbreak,2021-05-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,"blood donors that donate blood from January 1 to March 22, 2020",,2020-02-16,2020-02-22,Blood donors,All,Multiple groups,,,Time frame,,227,0.0,,,,,,,,Sequential,MosaiQ COVID-19 Antibody Microarray,Quotient ,Other,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,,R. Alenda,Centro de Transfusión de la Comunidad de Madrid,Unity-Aligned,http://dx.doi.org/10.1111/vox.13117,2021-07-30,2024-03-01,Verified,alenda_p-216_2021,ESP
210531_Madrid_CentroDeTransfusiónDeLaComunidadDeMadrid_Jan5-11,210531_Madrid_CentroDeTransfusiónDeLaComunidadDeMadrid,Anti SARS-CoV-2 antibodies prevalence in Madrid blood donors prior to first outbreak,2021-05-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,"blood donors that donate blood from January 1 to March 22, 2020",,2020-01-05,2020-01-11,Blood donors,All,Multiple groups,,,Time frame,,178,0.0,,,,,,,,Sequential,MosaiQ COVID-19 Antibody Microarray,Quotient ,Other,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,,R. Alenda,Centro de Transfusión de la Comunidad de Madrid,Unity-Aligned,http://dx.doi.org/10.1111/vox.13117,2021-07-30,2024-03-01,Verified,alenda_p-216_2021,ESP
210531_Madrid_CentroDeTransfusiónDeLaComunidadDeMadrid_Jan1-4,210531_Madrid_CentroDeTransfusiónDeLaComunidadDeMadrid,Anti SARS-CoV-2 antibodies prevalence in Madrid blood donors prior to first outbreak,2021-05-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,"blood donors that donate blood from January 1 to March 22, 2020",,2020-01-01,2020-01-04,Blood donors,All,Multiple groups,,,Time frame,,88,0.0,,,,,,,,Sequential,MosaiQ COVID-19 Antibody Microarray,Quotient ,Other,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,,R. Alenda,Centro de Transfusión de la Comunidad de Madrid,Unity-Aligned,http://dx.doi.org/10.1111/vox.13117,2021-07-30,2024-03-01,Verified,alenda_p-216_2021,ESP
210531_Madrid_CentroDeTransfusiónDeLaComunidadDeMadrid_January,210531_Madrid_CentroDeTransfusiónDeLaComunidadDeMadrid,Anti SARS-CoV-2 antibodies prevalence in Madrid blood donors prior to first outbreak,2021-05-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,"blood donors that donate blood from January 1 to March 22, 2020",,2020-01-01,2020-01-31,Blood donors,All,Multiple groups,,,Time frame,,800,0.0,,,,,,,,Sequential,MosaiQ COVID-19 Antibody Microarray,Quotient ,Other,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,,R. Alenda,Centro de Transfusión de la Comunidad de Madrid,Unity-Aligned,http://dx.doi.org/10.1111/vox.13117,2021-07-30,2024-03-01,Verified,alenda_p-216_2021,ESP
210531_Madrid_CentroDeTransfusiónDeLaComunidadDeMadrid_Feb23-29,210531_Madrid_CentroDeTransfusiónDeLaComunidadDeMadrid,Anti SARS-CoV-2 antibodies prevalence in Madrid blood donors prior to first outbreak,2021-05-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,"blood donors that donate blood from January 1 to March 22, 2020",,2020-02-23,2020-02-29,Blood donors,All,Multiple groups,,,Time frame,,366,0.0,,,,,,,,Sequential,MosaiQ COVID-19 Antibody Microarray,Quotient ,Other,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,,R. Alenda,Centro de Transfusión de la Comunidad de Madrid,Unity-Aligned,http://dx.doi.org/10.1111/vox.13117,2021-07-30,2024-03-01,Verified,alenda_p-216_2021,ESP
210531_Madrid_CentroDeTransfusiónDeLaComunidadDeMadrid_Mar8-14,210531_Madrid_CentroDeTransfusiónDeLaComunidadDeMadrid,Anti SARS-CoV-2 antibodies prevalence in Madrid blood donors prior to first outbreak,2021-05-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,"blood donors that donate blood from January 1 to March 22, 2020",,2020-03-08,2020-03-14,Blood donors,All,Multiple groups,,,Time frame,,183,0.005,,,,,,,,Sequential,MosaiQ COVID-19 Antibody Microarray,Quotient ,Other,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,,R. Alenda,Centro de Transfusión de la Comunidad de Madrid,Unity-Aligned,http://dx.doi.org/10.1111/vox.13117,2021-07-30,2024-03-01,Verified,alenda_p-216_2021,ESP
210531_Madrid_CentroDeTransfusiónDeLaComunidadDeMadrid_February,210531_Madrid_CentroDeTransfusiónDeLaComunidadDeMadrid,Anti SARS-CoV-2 antibodies prevalence in Madrid blood donors prior to first outbreak,2021-05-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,"blood donors that donate blood from January 1 to March 22, 2020",,2020-02-01,2020-02-29,Blood donors,All,Multiple groups,,,Time frame,,1071,0.0,,,,,,,,Sequential,MosaiQ COVID-19 Antibody Microarray,Quotient ,Other,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,,R. Alenda,Centro de Transfusión de la Comunidad de Madrid,Unity-Aligned,http://dx.doi.org/10.1111/vox.13117,2021-07-30,2024-03-01,Verified,alenda_p-216_2021,ESP
210531_Madrid_CentroDeTransfusiónDeLaComunidadDeMadrid_Jan19-25,210531_Madrid_CentroDeTransfusiónDeLaComunidadDeMadrid,Anti SARS-CoV-2 antibodies prevalence in Madrid blood donors prior to first outbreak,2021-05-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,"blood donors that donate blood from January 1 to March 22, 2020",,2020-01-19,2020-01-25,Blood donors,All,Multiple groups,,,Time frame,,179,0.0,,,,,,,,Sequential,MosaiQ COVID-19 Antibody Microarray,Quotient ,Other,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,,R. Alenda,Centro de Transfusión de la Comunidad de Madrid,Unity-Aligned,http://dx.doi.org/10.1111/vox.13117,2021-07-30,2024-03-01,Verified,alenda_p-216_2021,ESP
210531_Madrid_CentroDeTransfusiónDeLaComunidadDeMadrid_Mar1-7,210531_Madrid_CentroDeTransfusiónDeLaComunidadDeMadrid,Anti SARS-CoV-2 antibodies prevalence in Madrid blood donors prior to first outbreak,2021-05-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,"blood donors that donate blood from January 1 to March 22, 2020",,2020-03-01,2020-03-07,Blood donors,All,Multiple groups,,,Time frame,,276,0.004,,,,,,,,Sequential,MosaiQ COVID-19 Antibody Microarray,Quotient ,Other,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,,R. Alenda,Centro de Transfusión de la Comunidad de Madrid,Unity-Aligned,http://dx.doi.org/10.1111/vox.13117,2021-07-30,2024-03-01,Verified,alenda_p-216_2021,ESP
210531_Madrid_CentroDeTransfusiónDeLaComunidadDeMadrid_Jan12-18,210531_Madrid_CentroDeTransfusiónDeLaComunidadDeMadrid,Anti SARS-CoV-2 antibodies prevalence in Madrid blood donors prior to first outbreak,2021-05-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,"blood donors that donate blood from January 1 to March 22, 2020",,2020-01-12,2020-01-18,Blood donors,All,Multiple groups,,,Time frame,,183,0.0,,,,,,,,Sequential,MosaiQ COVID-19 Antibody Microarray,Quotient ,Other,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,,R. Alenda,Centro de Transfusión de la Comunidad de Madrid,Unity-Aligned,http://dx.doi.org/10.1111/vox.13117,2021-07-30,2024-03-01,Verified,alenda_p-216_2021,ESP
210614_Barcelona_HospitalUniversitariValld’Hebron,210614_Barcelona_HospitalUniversitariValld’Hebron,Low seroprevalence of SARS-CoV-2 antibodies in a liver transplant cohort.,2021-06-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Province of Barcelona,Barcelona,"""We performed a cross-sectional analysis  from  May  10th  to  October  26th  2020  of  all  adult  (>18  years  of  age)  liver transplant recipients  that  underwent  a  routine  laboratory  test  for  the  outpatient  clinic  follow-up at the Hospital Universitari Vall d’Hebron (Barcelona).""","""There were no exclusion criteria.""",2020-05-10,2020-10-26,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),18.0,,Primary Estimate,Liver-transplant recipients,294,0.031000000000000003,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Liaison SARS-CoV-2 S1/S2 IgG","Roche Diagnostics,DiaSorin",CLIA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],No,No,No,Yes,Yes,Yes,Yes,No,Yes,Isabel Campos-Varela,Hospital Universitari Vall d’Hebron,Not Unity-Aligned,https://dx.doi.org/10.1111/tri.13946,2021-06-20,2024-03-01,Verified,camposvarela_low_2021,ESP
210617_Barcelona_UniversitatDeBarcelona_Overall_PopAdj,210617_Barcelona_UniversitatDeBarcelona,Prevalence of SARS-CoV-2 Infection at the University of Barcelona during the Third COVID-19 Pandemic Wave in Spain,2021-06-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Catalonia,Barcelona,"Open to all UB members: students, administrative and service staff, faculty members and clinical faculty members. 

""This was a cross-sectional study conducted among UB members between 14 December 2020 and 25 February 2021...UB members were contacted by the information in the most recent census""","Non-UB member (i.e. not a student, faculty member, or administrative staff)",2020-12-14,2021-02-25,Multiple populations,All,Adults (18-64 years),,,Primary Estimate,,2775,0.1416,,,True,,True,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,No,Sebastian Videla,Universitat de Barcelona,Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph18126526,2021-07-01,2024-03-01,Verified,videla_prevalence_2021,ESP
210622_Madrid_HospitalCentralDeLaDefensaGomezUlla,210622_Madrid_HospitalCentralDeLaDefensaGomezUlla,"SARS-COV-2 Infection and Specific Antibody Detection on Health Care Workers from a Military Hospital in Madrid, Spain.",2021-06-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,The workforce of the hospital is composed of both military and civilian staff. Study participants were recruited from the entire hospital employees.,"Since there was no information on the working activity of some subject, 27 workers were not included in any group",2020-04-27,2020-06-10,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,2781,0.162,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Multiple Types,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Maria Simon Sacristan,Hospital Central de la Defensa Gómez Ulla,Not Unity-Aligned,https://dx.doi.org/10.1007/s00284-021-02541-6,2021-07-06,2024-03-01,Unverified,simonsacristanSARSCOV2InfectionSpecific2021,ESP
210626_Spain_HospitalGregorioMaranon_popadj,210626_Spain_HospitalGregorioMaranon,Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort.,2021-06-26,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Spain,,,"In this cross-sectional study, we determined antibodies against SARS-CoV-2 in plasma
samples consecutively collected from April 1, 2020, to September 30, 2020, from PWH
recruited in the Cohort of the Spanish HIV Research Network (CoRIS). CoRIS is a prospective cohort of PWH older than 13 years, naive to antiretroviral therapy (ART) at study entry, seen for the first time from January 1, 2004, in 46 participating centres from 13 of 17 Regions in Spain",,2020-04-01,2020-09-30,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),18.0,,Primary Estimate,,1076,0.081,0.065,0.1,True,,True,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Plasma,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Juan Berenguer,Hospital Gregorio Maranon,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2021.06.023,2021-07-07,2024-03-01,Verified,berenguer_prevalence_2021-1,ESP
210806_Barcelona_InstitutdeRecercaSantJoandeDéu,210806_Barcelona_InstitutdeRecercaSantJoandeDéu,COVID-19 in children and young adults with moderate/severe inborn errors of immunity in a high burden area in pre-vaccine era.,2021-08-06,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Spain,Catalonia,Barcelona,Patients with moderate/severe IEI aged 0–21 years old with signed informed consent,,2020-06-01,2020-06-30,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),0.0,21.0,Primary Estimate,,65,0.107,0.07,0.13,True,,,,True,Convenience,Author designed (Luminex),,,Plasma,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Angela Deya-Martinez,Institut de Recerca Sant Joan de Déu,Not Unity-Aligned,https://dx.doi.org/10.1016/j.clim.2021.108821,2021-08-25,2022-07-16,Unverified,deya-martinez_covid-19_2021,ESP
210817_Seville_HospitalUniversitarioVirgendeValme_HIV,210817_Seville_HospitalUniversitarioVirgendeValme_HIV,Incidence of and factors associated with SARS-CoV-2 infection among people living with HIV in Southern Spain after one year of pandemic.,2021-08-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,Spain,Andalusia,Seville,"Patients were enrolled in the study if 1) they had attended as outpatients our Unit from August 1st
,
2019 to February 8th, 2020; 2) had two subsequent evaluations from February 9th, 2020 to March 4th
,
2021. SARS-CoV-2 infections were diagnosed by PCR, antigen detection or serology. ",,2020-02-09,2021-03-04,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,HIV positive,707,0.075,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,,Validated by manufacturers,0.995,0.998,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Marta Fernandez-Fuertes,Hospital Universitario Virgen de Valme,Not Unity-Aligned,https://dx.doi.org/10.1111/tbed.14293,2021-08-25,2024-03-01,Unverified,fernandez-fuertes_incidence_2021,ESP
210823_Madrid_HospitalUniversitarioPuertadeHierroMajadahonda_HCW,210823_Madrid_HospitalUniversitarioPuertadeHierroMajadahonda,SARS-COV-2 seroprevalence among all healthcare workers in a tertiary hospital in Spain.,2021-08-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Communidad de Madrid,Madrid,all HCW at the University Hospital Puerta de Hierro Majadahonda,,2020-04-24,2020-05-08,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Healthcare workers,4324,0.166,0.155,0.177,True,,,,True,Convenience,"COVID-19 ELISA IgM/IgA,COVID-19 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Vircell S.L.,Roche Diagnostics",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Mireia Cantero,Hospital Universitario Puerta de Hierro Majadahonda,Not Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.1963468,2021-08-31,2024-03-01,Unverified,cantero_sars-cov-2_2021,ESP
210826_Borriana_PublicHealthCenterOfCastellon_PrimaryIgG,210826_Borriana_PublicHealthCenterOfCastellon,Mass gathering events and COVID-19 transmission in Borriana (Spain): A retrospective cohort study,2021-08-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Castellon,Borriana,Representative household sample + random sample of people who attended a mass gathering event,The 74 cases that presented the onset of symptoms or a positive test obtained before March 6 or after March 31 were therefore excluded since their illness onset (before the MGEs or more than three weeks after the last MGE) could not be related to the studied MGEs. (MGE = mass gathering events),2020-06-23,2020-06-27,Household and community samples,All,Multiple groups,,,Primary Estimate,,997,0.51,,,True,,,,True,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),COVID-19 IgG/IgM Rapid Test Cassette","Roche Diagnostics,Healgen",Multiple Types,Serum,IgG,"['Notreported', 'Nucleocapsid(N-protein)']",,,,['High'],Yes,Yes,Yes,No,Yes,Unclear,No,No,Yes,Salvador Domenech Montoliu,Public Health Center of Castellon,Not Unity-Aligned,http://dx.doi.org/10.1371/journal.pone.0256747,2021-09-07,2024-03-01,Verified,domenech-montoliu_mass_2021,ESP
211002_Madrid_HospitalLaPaz_Overall,211002_Madrid_HospitalLaPaz,Serum prevalence of SARS-COv2 antibodies in patients with inflammatory bowel disease before vaccination,2021-10-02,Presentation or Conference,Local,Cross-sectional survey ,Spain,Community of Madrid,Madrid,patients diagnosed with IBD followed in a Hospital La Paz unit. Patients with scheduled on-site visits to the unit were included.,,2021-02-26,2021-03-26,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,338,0.1864,,,True,,,,True,Convenience,Author designed (ELISA) - Unknown,,ELISA,,IgG,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,M. Hernandez Perez,Hospital La Paz,Not Unity-Aligned,http://dx.doi.org/10.1002/ueg2.12144,2021-11-09,2022-07-16,Unverified,hernandez_perez_serum_2021,ESP
211021_Spain_AlcalaUniversity_AdminStaff_Overall,211021_Spain_AlcalaUniversity_AdminStaff,"High Seroprevalence Against SARS-CoV-2 Among Faculty of Medicine and Health Sciences Personnel and Students of the University of Alcala, Spain: Contributing Factors.",2021-10-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,"Community of Madrid, Community of Castilla-La Mancha","Madrid, Guadalajara",administrative officers (AO) at the University of Alcala (UAH),,2020-06-08,2020-06-16,Essential non-healthcare workers,All,Multiple groups,,,Primary Estimate,,66,0.136,,,True,,,,True,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),COVID-19 VIRCLIA IgG MONOTEST","Siemens,Vircell S.L.",CLIA,Serum,"['IgA', 'IgG', 'IgM']",,,,,['Moderate'],,Yes,Yes,No,,Yes,Yes,No,,Ramon Perez-Tanoira,Alcala University,Not Unity-Aligned,https://dx.doi.org/10.2147/IJGM.S332803,2021-11-08,2024-03-01,Unverified,perez-tanoira_high_2021,ESP
211021_Spain_AlcalaUniversity_Students_Overall,211021_Spain_AlcalaUniversity_Students,"High Seroprevalence Against SARS-CoV-2 Among Faculty of Medicine and Health Sciences Personnel and Students of the University of Alcala, Spain: Contributing Factors.",2021-10-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,"Community of Madrid, Community of Castilla-La Mancha","Madrid, Guadalajara","University of Alcala (UAH) members in the Communities of Madrid and Castilla-La Mancha, Spain - students of the FMHS for Physical Activity and Sports Sciences (PASS), Nursing-Alcalá, and the Guadalajara campus, Physiotherapy and Medicine",,2020-06-08,2020-06-16,Students and Daycares,All,Adults (18-64 years),,,Primary Estimate,,507,0.172,,,True,,,,True,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),COVID-19 VIRCLIA IgG MONOTEST","Siemens,Vircell S.L.",CLIA,Serum,"['IgA', 'IgG', 'IgM']",,,,,['Moderate'],,Yes,Yes,No,,Yes,Yes,No,,Ramon Perez-Tanoira,Alcala University,Not Unity-Aligned,https://dx.doi.org/10.2147/IJGM.S332803,2021-11-04,2024-03-01,Unverified,perez-tanoira_high_2021,ESP
211021_Spain_AlcalaUniversity_TeachingStaff_Overall,211021_Spain_AlcalaUniversity_TeachingStaff,"High Seroprevalence Against SARS-CoV-2 Among Faculty of Medicine and Health Sciences Personnel and Students of the University of Alcala, Spain: Contributing Factors.",2021-10-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,"Community of Madrid, Community of Castilla-La Mancha","Madrid, Guadalajara",teaching and research staff (TRS) at the University of Alcala (UAH),,2020-06-08,2020-06-16,Essential non-healthcare workers,All,Multiple groups,,,Primary Estimate,,132,0.258,,,True,,,,True,Stratified probability,"Atellica® IM SARS-CoV-2 Total (COV2T),COVID-19 VIRCLIA IgG MONOTEST","Siemens,Vircell S.L.",CLIA,Serum,"['IgA', 'IgG', 'IgM']",,,,,['Moderate'],,Yes,Yes,No,,Yes,Yes,No,,Ramon Perez-Tanoira,Alcala University,Not Unity-Aligned,https://dx.doi.org/10.2147/IJGM.S332803,2021-11-08,2024-03-01,Unverified,perez-tanoira_high_2021,ESP
211022_AlcaladeHenares_HospitalUniversitarioPríncipedeAsturias_primary,211022_AlcaladeHenares_HospitalUniversitarioPríncipedeAsturias,[SARS-CoV-2 seroprevalence among workers in a hospital in Madrid.].,2021-10-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Madrid,Alcala de Henares,All hospital workersthey were invited to participate in this study.,,2020-05-01,2020-07-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1339,0.2263,,,True,,,,True,Convenience,"2019-nCoV IgG/IgM Rapid Test Cassette,Atellica® IM SARS-CoV-2 Total (COV2T),COVID-19 VIRCLIA IgG MONOTEST","Hanghzhou AllTest Biotech Co. Ltd,Siemens,Vircell S.L.",Multiple Types,Multiple Types,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Felipe Perez Garcia,Hospital Universitario Príncipede Asturias,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/34675168/,2021-11-02,2024-03-01,Unverified,perez-garcia_sars-cov-2_2021,ESP
211103_Catalonia_BarcelonaInstituteForGlobalHealth_adolescents_unadj,211103_Catalonia_BarcelonaInstituteForGlobalHealth_adolescents,Infection induced SARS-CoV-2 seroprevalence and heterogeneity of antibody responses in a general population cohort study in Catalonia Spain.,2021-11-03,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,Catalonia,,"The COVICAT study includes participants from different pre-existing ongoing population-based cohorts in Catalonia and was developed following the COVID-19 pandemic. Eligible participants were from three adult population-based cohorts (GCAT, Genomes for life52; MCC-Spain, population controls from Catalunya53; and ECRHS, European Community Respiratory Health Survey54), two mother–child cohorts [INMA-Sabadell, (INfancia y Medio Ambiente)55 children born in 2005–2007 and their mothers; BiSC, Barcelona Life Study Cohort pregnant women recruited immediately before and during the pandemic] and two small general population cohorts in special populations (Urban Training, older persons; and LeRAgs, rural population)",,2020-06-30,2020-11-15,Household and community samples,All,Children and Youth (0-17 years),13.0,15.0,Primary Estimate,,260,0.115,,,True,,,,True,Convenience,Author designed (Multiplex),,CLIA,,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.9578,1.0,['High'],Yes,No,No,No,Unclear,Unclear,Yes,Yes,Unclear,Marianna Karachaliou,Barcelona Institute For Global Health,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-00807-4,2021-11-12,2022-07-16,Verified,karachaliou_infection_2021,ESP
211103_Catalonia_BarcelonaInstituteForGlobalHealth_adults_popadj,211103_Catalonia_BarcelonaInstituteForGlobalHealth_adults,Infection induced SARS-CoV-2 seroprevalence and heterogeneity of antibody responses in a general population cohort study in Catalonia Spain.,2021-11-03,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,Catalonia,,"The COVICAT study includes participants from different pre-existing ongoing population-based cohorts in Catalonia and was developed following the COVID-19 pandemic. Eligible participants were from three adult population-based cohorts (GCAT, Genomes for life52; MCC-Spain, population controls from Catalunya53; and ECRHS, European Community Respiratory Health Survey54), two mother–child cohorts [INMA-Sabadell, (INfancia y Medio Ambiente)55 children born in 2005–2007 and their mothers; BiSC, Barcelona Life Study Cohort pregnant women recruited immediately before and during the pandemic] and two small general population cohorts in special populations (Urban Training, older persons; and LeRAgs, rural population)",,2020-06-30,2020-11-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,4740,0.153,,,True,,True,,True,Convenience,Author designed (Multiplex),,CLIA,,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.9578,1.0,['Moderate'],Yes,No,Yes,No,Unclear,Unclear,Yes,Yes,No,Marianna Karachaliou,Barcelona Institute For Global Health,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-00807-4,2021-11-10,2022-07-16,Verified,karachaliou_infection_2021,ESP
211103_Madrid_LaPazUniversityHospitalInstituteforHealthResearch_Overall_Testadj,211103_Madrid_LaPazUniversityHospitalInstituteforHealthResearch,SARS-CoV-2 IgG seropositivity in a cohort of 449 non-hospitalized individuals during Spanish COVID-19 lockdown.,2021-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Community of Madrid,Madrid,"To be included in the study, participants needed to fulfil at least one of the following inclusion criteria: 1) symptoms compatible with COVID-19 (fever, headache, dry cough, odynophagia, asthenia, myalgia, ageusia, anosmia, dyspnoea, gastrointestinal (diarrhoea, vomiting), cutaneous manifestations (defined as urticaria, erythema or flaky dermatitis-like lesions) and/or a pneumonia diagnosis at least 14 days before testing to abide by the quarantine rules established by the sanitary authorities; 2) contact with a confirmed COVID-19 case based on a positive RT-PCR of such contact; and 3) employment as an essential worker (those allowed to keep working during the lockdown under strict accreditation by the institutional employer). It is important to stress that the government order SND/344/2020 defined these criteria as the only ones that allowed us to perform diagnostic testing for COVID-1948 at the time when the participants were recruited for this study. Furthermore, none of the participants required hospitalization as an additional inclusion criterion.","The exclusion criteria included refusal to participate, an unsigned informed consent form, or failure to obtain or complete the questionnaire for study records.",2020-04-15,2020-06-15,Multiple populations,All,Multiple groups,,,Primary Estimate,,449,0.3369,0.2927,0.3821,True,True,,,,Convenience,REAL COVID19 Rapid test cassette,Durviz S.L.,LFIA,Serum,IgG,,Validated by manufacturers,1.0,0.98,['High'],,No,No,Yes,,Yes,Yes,Yes,,Patricia Torres Martinez,La Paz University Hospital Institute for Health Research,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-00990-4,2021-11-10,2023-08-15,Unverified,martinez_sars-cov-2_2021,ESP
211103_Madrid_LaPazUniversityHospitalInstituteforHealthResearch_60-69,211103_Madrid_LaPazUniversityHospitalInstituteforHealthResearch,SARS-CoV-2 IgG seropositivity in a cohort of 449 non-hospitalized individuals during Spanish COVID-19 lockdown.,2021-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Community of Madrid,Madrid,"To be included in the study, participants needed to fulfil at least one of the following inclusion criteria: 1) symptoms compatible with COVID-19 (fever, headache, dry cough, odynophagia, asthenia, myalgia, ageusia, anosmia, dyspnoea, gastrointestinal (diarrhoea, vomiting), cutaneous manifestations (defined as urticaria, erythema or flaky dermatitis-like lesions) and/or a pneumonia diagnosis at least 14 days before testing to abide by the quarantine rules established by the sanitary authorities; 2) contact with a confirmed COVID-19 case based on a positive RT-PCR of such contact; and 3) employment as an essential worker (those allowed to keep working during the lockdown under strict accreditation by the institutional employer). It is important to stress that the government order SND/344/2020 defined these criteria as the only ones that allowed us to perform diagnostic testing for COVID-1948 at the time when the participants were recruited for this study. Furthermore, none of the participants required hospitalization as an additional inclusion criterion.","The exclusion criteria included refusal to participate, an unsigned informed consent form, or failure to obtain or complete the questionnaire for study records.",2020-04-15,2020-06-15,Multiple populations,All,Multiple groups,60.0,69.0,Age,60-69,64,0.4219,0.2994,0.5518,,True,,,,Convenience,REAL COVID19 Rapid test cassette,Durviz S.L.,LFIA,Serum,IgG,,Validated by manufacturers,1.0,0.98,['High'],,No,No,Yes,,Yes,Yes,Yes,,Patricia Torres Martinez,La Paz University Hospital Institute for Health Research,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-00990-4,2021-11-10,2023-08-15,Unverified,martinez_sars-cov-2_2021,ESP
211103_Madrid_LaPazUniversityHospitalInstituteforHealthResearch_20-29,211103_Madrid_LaPazUniversityHospitalInstituteforHealthResearch,SARS-CoV-2 IgG seropositivity in a cohort of 449 non-hospitalized individuals during Spanish COVID-19 lockdown.,2021-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Community of Madrid,Madrid,"To be included in the study, participants needed to fulfil at least one of the following inclusion criteria: 1) symptoms compatible with COVID-19 (fever, headache, dry cough, odynophagia, asthenia, myalgia, ageusia, anosmia, dyspnoea, gastrointestinal (diarrhoea, vomiting), cutaneous manifestations (defined as urticaria, erythema or flaky dermatitis-like lesions) and/or a pneumonia diagnosis at least 14 days before testing to abide by the quarantine rules established by the sanitary authorities; 2) contact with a confirmed COVID-19 case based on a positive RT-PCR of such contact; and 3) employment as an essential worker (those allowed to keep working during the lockdown under strict accreditation by the institutional employer). It is important to stress that the government order SND/344/2020 defined these criteria as the only ones that allowed us to perform diagnostic testing for COVID-1948 at the time when the participants were recruited for this study. Furthermore, none of the participants required hospitalization as an additional inclusion criterion.","The exclusion criteria included refusal to participate, an unsigned informed consent form, or failure to obtain or complete the questionnaire for study records.",2020-04-15,2020-06-15,Multiple populations,All,Adults (18-64 years),20.0,29.0,Age,20-29,38,0.3421,0.1963,0.5365,,True,,,,Convenience,REAL COVID19 Rapid test cassette,Durviz S.L.,LFIA,Serum,IgG,,Validated by manufacturers,1.0,0.98,['High'],,No,No,Yes,,Yes,Yes,Yes,,Patricia Torres Martinez,La Paz University Hospital Institute for Health Research,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-00990-4,2021-11-10,2023-08-15,Unverified,martinez_sars-cov-2_2021,ESP
211103_Madrid_LaPazUniversityHospitalInstituteforHealthResearch_<20,211103_Madrid_LaPazUniversityHospitalInstituteforHealthResearch,SARS-CoV-2 IgG seropositivity in a cohort of 449 non-hospitalized individuals during Spanish COVID-19 lockdown.,2021-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Community of Madrid,Madrid,"To be included in the study, participants needed to fulfil at least one of the following inclusion criteria: 1) symptoms compatible with COVID-19 (fever, headache, dry cough, odynophagia, asthenia, myalgia, ageusia, anosmia, dyspnoea, gastrointestinal (diarrhoea, vomiting), cutaneous manifestations (defined as urticaria, erythema or flaky dermatitis-like lesions) and/or a pneumonia diagnosis at least 14 days before testing to abide by the quarantine rules established by the sanitary authorities; 2) contact with a confirmed COVID-19 case based on a positive RT-PCR of such contact; and 3) employment as an essential worker (those allowed to keep working during the lockdown under strict accreditation by the institutional employer). It is important to stress that the government order SND/344/2020 defined these criteria as the only ones that allowed us to perform diagnostic testing for COVID-1948 at the time when the participants were recruited for this study. Furthermore, none of the participants required hospitalization as an additional inclusion criterion.","The exclusion criteria included refusal to participate, an unsigned informed consent form, or failure to obtain or complete the questionnaire for study records.",2020-04-15,2020-06-15,Multiple populations,All,Multiple groups,,20.0,Age,<20,14,0.4286,0.1766,0.7114,,True,,,,Convenience,REAL COVID19 Rapid test cassette,Durviz S.L.,LFIA,Serum,IgG,,Validated by manufacturers,1.0,0.98,['High'],,No,No,Yes,,Yes,Yes,Yes,,Patricia Torres Martinez,La Paz University Hospital Institute for Health Research,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-00990-4,2021-11-10,2023-08-15,Unverified,martinez_sars-cov-2_2021,ESP
211103_Madrid_LaPazUniversityHospitalInstituteforHealthResearch_Over70,211103_Madrid_LaPazUniversityHospitalInstituteforHealthResearch,SARS-CoV-2 IgG seropositivity in a cohort of 449 non-hospitalized individuals during Spanish COVID-19 lockdown.,2021-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Community of Madrid,Madrid,"To be included in the study, participants needed to fulfil at least one of the following inclusion criteria: 1) symptoms compatible with COVID-19 (fever, headache, dry cough, odynophagia, asthenia, myalgia, ageusia, anosmia, dyspnoea, gastrointestinal (diarrhoea, vomiting), cutaneous manifestations (defined as urticaria, erythema or flaky dermatitis-like lesions) and/or a pneumonia diagnosis at least 14 days before testing to abide by the quarantine rules established by the sanitary authorities; 2) contact with a confirmed COVID-19 case based on a positive RT-PCR of such contact; and 3) employment as an essential worker (those allowed to keep working during the lockdown under strict accreditation by the institutional employer). It is important to stress that the government order SND/344/2020 defined these criteria as the only ones that allowed us to perform diagnostic testing for COVID-1948 at the time when the participants were recruited for this study. Furthermore, none of the participants required hospitalization as an additional inclusion criterion.","The exclusion criteria included refusal to participate, an unsigned informed consent form, or failure to obtain or complete the questionnaire for study records.",2020-04-15,2020-06-15,Multiple populations,All,Seniors (65+ years),70.0,,Age,≥70,21,0.3333,0.1459,0.5697,,True,,,,Convenience,REAL COVID19 Rapid test cassette,Durviz S.L.,LFIA,Serum,IgG,,Validated by manufacturers,1.0,0.98,['High'],,No,No,Yes,,Yes,Yes,Yes,,Patricia Torres Martinez,La Paz University Hospital Institute for Health Research,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-00990-4,2021-11-10,2023-08-15,Unverified,martinez_sars-cov-2_2021,ESP
211103_Madrid_LaPazUniversityHospitalInstituteforHealthResearch_50-59,211103_Madrid_LaPazUniversityHospitalInstituteforHealthResearch,SARS-CoV-2 IgG seropositivity in a cohort of 449 non-hospitalized individuals during Spanish COVID-19 lockdown.,2021-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Community of Madrid,Madrid,"To be included in the study, participants needed to fulfil at least one of the following inclusion criteria: 1) symptoms compatible with COVID-19 (fever, headache, dry cough, odynophagia, asthenia, myalgia, ageusia, anosmia, dyspnoea, gastrointestinal (diarrhoea, vomiting), cutaneous manifestations (defined as urticaria, erythema or flaky dermatitis-like lesions) and/or a pneumonia diagnosis at least 14 days before testing to abide by the quarantine rules established by the sanitary authorities; 2) contact with a confirmed COVID-19 case based on a positive RT-PCR of such contact; and 3) employment as an essential worker (those allowed to keep working during the lockdown under strict accreditation by the institutional employer). It is important to stress that the government order SND/344/2020 defined these criteria as the only ones that allowed us to perform diagnostic testing for COVID-1948 at the time when the participants were recruited for this study. Furthermore, none of the participants required hospitalization as an additional inclusion criterion.","The exclusion criteria included refusal to participate, an unsigned informed consent form, or failure to obtain or complete the questionnaire for study records.",2020-04-15,2020-06-15,Multiple populations,All,Adults (18-64 years),50.0,59.0,Age,50-59,88,0.3636,0.2631,0.4731,,True,,,,Convenience,REAL COVID19 Rapid test cassette,Durviz S.L.,LFIA,Serum,IgG,,Validated by manufacturers,1.0,0.98,['High'],,No,No,Yes,,Yes,Yes,Yes,,Patricia Torres Martinez,La Paz University Hospital Institute for Health Research,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-00990-4,2021-11-10,2023-08-15,Unverified,martinez_sars-cov-2_2021,ESP
211103_Madrid_LaPazUniversityHospitalInstituteforHealthResearch_30-39,211103_Madrid_LaPazUniversityHospitalInstituteforHealthResearch,SARS-CoV-2 IgG seropositivity in a cohort of 449 non-hospitalized individuals during Spanish COVID-19 lockdown.,2021-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Community of Madrid,Madrid,"To be included in the study, participants needed to fulfil at least one of the following inclusion criteria: 1) symptoms compatible with COVID-19 (fever, headache, dry cough, odynophagia, asthenia, myalgia, ageusia, anosmia, dyspnoea, gastrointestinal (diarrhoea, vomiting), cutaneous manifestations (defined as urticaria, erythema or flaky dermatitis-like lesions) and/or a pneumonia diagnosis at least 14 days before testing to abide by the quarantine rules established by the sanitary authorities; 2) contact with a confirmed COVID-19 case based on a positive RT-PCR of such contact; and 3) employment as an essential worker (those allowed to keep working during the lockdown under strict accreditation by the institutional employer). It is important to stress that the government order SND/344/2020 defined these criteria as the only ones that allowed us to perform diagnostic testing for COVID-1948 at the time when the participants were recruited for this study. Furthermore, none of the participants required hospitalization as an additional inclusion criterion.","The exclusion criteria included refusal to participate, an unsigned informed consent form, or failure to obtain or complete the questionnaire for study records.",2020-04-15,2020-06-15,Multiple populations,All,Adults (18-64 years),30.0,39.0,Age,30-39,111,0.2432,0.1668,0.33380000000000004,,True,,,,Convenience,REAL COVID19 Rapid test cassette,Durviz S.L.,LFIA,Serum,IgG,,Validated by manufacturers,1.0,0.98,['High'],,No,No,Yes,,Yes,Yes,Yes,,Patricia Torres Martinez,La Paz University Hospital Institute for Health Research,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-00990-4,2021-11-10,2023-08-15,Unverified,martinez_sars-cov-2_2021,ESP
211103_Madrid_LaPazUniversityHospitalInstituteforHealthResearch_40-49,211103_Madrid_LaPazUniversityHospitalInstituteforHealthResearch,SARS-CoV-2 IgG seropositivity in a cohort of 449 non-hospitalized individuals during Spanish COVID-19 lockdown.,2021-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Community of Madrid,Madrid,"To be included in the study, participants needed to fulfil at least one of the following inclusion criteria: 1) symptoms compatible with COVID-19 (fever, headache, dry cough, odynophagia, asthenia, myalgia, ageusia, anosmia, dyspnoea, gastrointestinal (diarrhoea, vomiting), cutaneous manifestations (defined as urticaria, erythema or flaky dermatitis-like lesions) and/or a pneumonia diagnosis at least 14 days before testing to abide by the quarantine rules established by the sanitary authorities; 2) contact with a confirmed COVID-19 case based on a positive RT-PCR of such contact; and 3) employment as an essential worker (those allowed to keep working during the lockdown under strict accreditation by the institutional employer). It is important to stress that the government order SND/344/2020 defined these criteria as the only ones that allowed us to perform diagnostic testing for COVID-1948 at the time when the participants were recruited for this study. Furthermore, none of the participants required hospitalization as an additional inclusion criterion.","The exclusion criteria included refusal to participate, an unsigned informed consent form, or failure to obtain or complete the questionnaire for study records.",2020-04-15,2020-06-15,Multiple populations,All,Adults (18-64 years),40.0,49.0,Age,40-49,113,0.33630000000000004,0.25010000000000004,0.43119999999999997,,True,,,,Convenience,REAL COVID19 Rapid test cassette,Durviz S.L.,LFIA,Serum,IgG,,Validated by manufacturers,1.0,0.98,['High'],,No,No,Yes,,Yes,Yes,Yes,,Patricia Torres Martinez,La Paz University Hospital Institute for Health Research,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-00990-4,2021-11-10,2023-08-15,Unverified,martinez_sars-cov-2_2021,ESP
211117_Catalonia_BarcelonaInstituteforGlobalHealth_Overall,211117_Catalonia_BarcelonaInstituteforGlobalHealth,"Ambient Air Pollution in Relation to SARS-CoV-2 Infection, Antibody Response, and COVID-19 Disease: A Cohort Study in Catalonia, Spain (COVICAT Study).",2021-11-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,Catalonia,,"Members of five existing cohorts:

"" The largest cohort is the Genomes for Life (GCAT) cohort. We included four additional smaller cohorts that enrich the study with populations of older ages and rural residences [the Multi Case-Control (MCC)–Spain study, the European Community Respiratory Health Survey (ECRHS), the Urban Training cohort, and the Acute Kidney Injury in Agricultural Workers in Spain: Risk Factors and Long Term Effects (LeRAgs) cohorts].""",,2020-05-17,2020-11-15,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,,4103,0.1811,,,True,,,,True,Convenience,Author designed (Luminex),,Luminex,Plasma,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.9578,1.0,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Yes,Manolis Kogevinas,Barcelona Institute for Global Health,Unity-Aligned,https://dx.doi.org/10.1289/EHP9726,2021-11-24,2022-07-16,Verified,kogevinas_ambient_2021,ESP
211117_Catalonia_BarcelonaInstituteforGlobalHealth_Overall_IgGonly,211117_Catalonia_BarcelonaInstituteforGlobalHealth,"Ambient Air Pollution in Relation to SARS-CoV-2 Infection, Antibody Response, and COVID-19 Disease: A Cohort Study in Catalonia, Spain (COVICAT Study).",2021-11-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,Catalonia,,"Members of five existing cohorts:

"" The largest cohort is the Genomes for Life (GCAT) cohort. We included four additional smaller cohorts that enrich the study with populations of older ages and rural residences [the Multi Case-Control (MCC)–Spain study, the European Community Respiratory Health Survey (ECRHS), the Urban Training cohort, and the Acute Kidney Injury in Agricultural Workers in Spain: Risk Factors and Long Term Effects (LeRAgs) cohorts].""",,2020-05-17,2020-11-15,Household and community samples,All,Adults (18-64 years),,,Test used,IgG only,4103,0.091,,,,,,,,Convenience,Author designed (Luminex),,Luminex,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Yes,Manolis Kogevinas,Barcelona Institute for Global Health,Unity-Aligned,https://dx.doi.org/10.1289/EHP9726,2021-11-24,2022-07-16,Verified,kogevinas_ambient_2021,ESP
211117_Catalonia_BarcelonaInstituteforGlobalHealth_Overall_IgMonly,211117_Catalonia_BarcelonaInstituteforGlobalHealth,"Ambient Air Pollution in Relation to SARS-CoV-2 Infection, Antibody Response, and COVID-19 Disease: A Cohort Study in Catalonia, Spain (COVICAT Study).",2021-11-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,Catalonia,,"Members of five existing cohorts:

"" The largest cohort is the Genomes for Life (GCAT) cohort. We included four additional smaller cohorts that enrich the study with populations of older ages and rural residences [the Multi Case-Control (MCC)–Spain study, the European Community Respiratory Health Survey (ECRHS), the Urban Training cohort, and the Acute Kidney Injury in Agricultural Workers in Spain: Risk Factors and Long Term Effects (LeRAgs) cohorts].""",,2020-05-17,2020-11-15,Household and community samples,All,Adults (18-64 years),,,Test used,IgM only,4103,0.037000000000000005,,,,,,,,Convenience,Author designed (Luminex),,Luminex,Plasma,IgM,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Yes,Manolis Kogevinas,Barcelona Institute for Global Health,Unity-Aligned,https://dx.doi.org/10.1289/EHP9726,2021-11-24,2022-07-16,Verified,kogevinas_ambient_2021,ESP
211117_Catalonia_BarcelonaInstituteforGlobalHealth_SexMale,211117_Catalonia_BarcelonaInstituteforGlobalHealth,"Ambient Air Pollution in Relation to SARS-CoV-2 Infection, Antibody Response, and COVID-19 Disease: A Cohort Study in Catalonia, Spain (COVICAT Study).",2021-11-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,Catalonia,,"Members of five existing cohorts:

"" The largest cohort is the Genomes for Life (GCAT) cohort. We included four additional smaller cohorts that enrich the study with populations of older ages and rural residences [the Multi Case-Control (MCC)–Spain study, the European Community Respiratory Health Survey (ECRHS), the Urban Training cohort, and the Acute Kidney Injury in Agricultural Workers in Spain: Risk Factors and Long Term Effects (LeRAgs) cohorts].""",,2020-05-17,2020-11-15,Household and community samples,Male,Adults (18-64 years),,,Sex/Gender,,4103,0.0756,,,,,,,,Convenience,Author designed (Luminex),,Luminex,Plasma,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.9578,1.0,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Yes,Manolis Kogevinas,Barcelona Institute for Global Health,Unity-Aligned,https://dx.doi.org/10.1289/EHP9726,2021-11-24,2022-07-16,Verified,kogevinas_ambient_2021,ESP
211117_Catalonia_BarcelonaInstituteforGlobalHealth_SexFemale,211117_Catalonia_BarcelonaInstituteforGlobalHealth,"Ambient Air Pollution in Relation to SARS-CoV-2 Infection, Antibody Response, and COVID-19 Disease: A Cohort Study in Catalonia, Spain (COVICAT Study).",2021-11-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,Catalonia,,"Members of five existing cohorts:

"" The largest cohort is the Genomes for Life (GCAT) cohort. We included four additional smaller cohorts that enrich the study with populations of older ages and rural residences [the Multi Case-Control (MCC)–Spain study, the European Community Respiratory Health Survey (ECRHS), the Urban Training cohort, and the Acute Kidney Injury in Agricultural Workers in Spain: Risk Factors and Long Term Effects (LeRAgs) cohorts].""",,2020-05-17,2020-11-15,Household and community samples,Female,Adults (18-64 years),,,Sex/Gender,,4103,0.10550000000000001,,,,,,,,Convenience,Author designed (Luminex),,Luminex,Plasma,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.9578,1.0,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Yes,Manolis Kogevinas,Barcelona Institute for Global Health,Unity-Aligned,https://dx.doi.org/10.1289/EHP9726,2021-11-24,2022-07-16,Verified,kogevinas_ambient_2021,ESP
211117_Catalonia_BarcelonaInstituteforGlobalHealth_Overall_IgAonly,211117_Catalonia_BarcelonaInstituteforGlobalHealth,"Ambient Air Pollution in Relation to SARS-CoV-2 Infection, Antibody Response, and COVID-19 Disease: A Cohort Study in Catalonia, Spain (COVICAT Study).",2021-11-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,Catalonia,,"Members of five existing cohorts:

"" The largest cohort is the Genomes for Life (GCAT) cohort. We included four additional smaller cohorts that enrich the study with populations of older ages and rural residences [the Multi Case-Control (MCC)–Spain study, the European Community Respiratory Health Survey (ECRHS), the Urban Training cohort, and the Acute Kidney Injury in Agricultural Workers in Spain: Risk Factors and Long Term Effects (LeRAgs) cohorts].""",,2020-05-17,2020-11-15,Household and community samples,All,Adults (18-64 years),,,Test used,IgA only,4103,0.147,,,,,,,,Convenience,Author designed (Luminex),,Luminex,Plasma,IgA,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Yes,Manolis Kogevinas,Barcelona Institute for Global Health,Unity-Aligned,https://dx.doi.org/10.1289/EHP9726,2021-11-24,2022-07-16,Verified,kogevinas_ambient_2021,ESP
220117_GranCanaria_InstitutoUniversitariodeInvestigacionesBiomédicasySanitarias,220117_GranCanaria_InstitutoUniversitariodeInvestigacionesBiomédicasySanitarias,"Role of the SARS-CoV-2 virus in the appearance of new onset type 1 diabetes mellitus in children in Gran Canaria, Spain",2022-01-17,Journal Article (Peer-Reviewed),Regional,Retrospective cohort,Spain,Las Palmas,Gran Canaria,Children with new onset T1DM between October 2020 and August 2021 who consented for the study and seroprevalence assessment,Previous PCR-confirmed COVID-19 diagnosis,2020-10-15,2021-08-15,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),0.0,13.0,Primary Estimate,,33,0.0303030303,,,True,,,,True,Entire sample,Not reported/ Unable to specify,,,,IgG,Nucleocapsid(N-protein),,,,['High'],,Yes,No,No,,Unclear,Yes,No,,Yeray Novoa-Medina,Instituto Universitario de Investigaciones Biomédicas y Sanitarias (IUIBS),Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/35026884/,2022-01-23,2022-07-16,Unverified,novoa-medina_role_2022,ESP
220204_Catalonia_TransfusionSafetyLaboratory_16May-3Jun_TestAdj,220204_Catalonia_TransfusionSafetyLaboratory_16May-3Jun,SARS-CoV-2 seroprevalence in blood donors before and after the first wave in Catalonia (Spain).,2022-02-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,"The 4 provinces inside Catalonia (Barcelona, Tarragona, Girona, and Lleida).",,"""Catalan blood donor population aged 18 to 70""",,2020-05-16,2020-06-03,Blood donors,All,Multiple groups,18.0,70.0,Primary Estimate,,3867,0.0542,0.0447,0.06480000000000001,True,True,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgG,Wantai SARS-CoV-2 Total Ab ELISA","EUROIMMUN,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'TotalAntibody']",Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,No,,No,Yes,Yes,,Maria Piron,Transfusion Safety Laboratory,Not Unity-Aligned,https://dx.doi.org/10.2450/2022.0232-21,2022-02-25,2023-08-15,Unverified,piron_sars-cov-2_2022,ESP
220204_Catalonia_TransfusionSafetyLaboratory_16May-3Jun_UnAdj,220204_Catalonia_TransfusionSafetyLaboratory_16May-3Jun,SARS-CoV-2 seroprevalence in blood donors before and after the first wave in Catalonia (Spain).,2022-02-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,"The 4 provinces inside Catalonia (Barcelona, Tarragona, Girona, and Lleida).",,"""Catalan blood donor population aged 18 to 70""",,2020-05-16,2020-06-03,Blood donors,All,Multiple groups,18.0,70.0,Analysis,,3867,0.0533,0.0466,0.0608,,,,,True,Sequential,"Anti-SARS-CoV-2 ELISA IgG,Wantai SARS-CoV-2 Total Ab ELISA","EUROIMMUN,Beijing Wantai Biological",ELISA,Serum,"['IgG', 'TotalAntibody']",Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,Yes,No,,No,Yes,Yes,,Maria Piron,Transfusion Safety Laboratory,Not Unity-Aligned,https://dx.doi.org/10.2450/2022.0232-21,2022-02-25,2024-03-01,Unverified,piron_sars-cov-2_2022,ESP
220204_Catalonia_TransfusionSafetyLaboratory_24Feb-9Mar_TestAdj,220204_Catalonia_TransfusionSafetyLaboratory_24Feb-9Mar,SARS-CoV-2 seroprevalence in blood donors before and after the first wave in Catalonia (Spain).,2022-02-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,"The 4 provinces inside Catalonia (Barcelona, Tarragona, Girona, and Lleida).",,"""Catalan blood donor population aged 18 to 70""",,2020-02-24,2020-03-09,Blood donors,All,Multiple groups,18.0,70.0,Primary Estimate,,10170,0.0,,,True,True,,,,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9500000000000001,0.995,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Maria Piron,Transfusion Safety Laboratory,Unity-Aligned,https://dx.doi.org/10.2450/2022.0232-21,2022-02-25,2023-08-15,Unverified,piron_sars-cov-2_2022,ESP
220204_Catalonia_TransfusionSafetyLaboratory_24Feb-9Mar_UnAdj,220204_Catalonia_TransfusionSafetyLaboratory_24Feb-9Mar,SARS-CoV-2 seroprevalence in blood donors before and after the first wave in Catalonia (Spain).,2022-02-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,"The 4 provinces inside Catalonia (Barcelona, Tarragona, Girona, and Lleida).",,"""Catalan blood donor population aged 18 to 70""",,2020-02-24,2020-03-09,Blood donors,All,Multiple groups,18.0,70.0,Analysis,,10170,0.0027,0.0018,0.0039000000000000003,,,,,True,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9500000000000001,0.995,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Maria Piron,Transfusion Safety Laboratory,Unity-Aligned,https://dx.doi.org/10.2450/2022.0232-21,2022-02-25,2024-03-01,Unverified,piron_sars-cov-2_2022,ESP
220204_Catalonia_TransfusionSafetyLaboratory_4Jun-17Jun_TestAdj,220204_Catalonia_TransfusionSafetyLaboratory_4Jun-17Jun,SARS-CoV-2 seroprevalence in blood donors before and after the first wave in Catalonia (Spain).,2022-02-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,"The 4 provinces inside Catalonia (Barcelona, Tarragona, Girona, and Lleida).",,"""Catalan blood donor population aged 18 to 70""",,2020-06-04,2020-06-17,Blood donors,All,Multiple groups,18.0,70.0,Primary Estimate,,2962,0.0565,0.0481,0.066,True,True,,,,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9500000000000001,0.995,['High'],,No,Yes,No,,Yes,Yes,Yes,,Maria Piron,Transfusion Safety Laboratory,Unity-Aligned,https://dx.doi.org/10.2450/2022.0232-21,2022-02-25,2023-08-15,Unverified,piron_sars-cov-2_2022,ESP
220204_Catalonia_TransfusionSafetyLaboratory_4Jun-17Jun_UnAdj,220204_Catalonia_TransfusionSafetyLaboratory_4Jun-17Jun,SARS-CoV-2 seroprevalence in blood donors before and after the first wave in Catalonia (Spain).,2022-02-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,"The 4 provinces inside Catalonia (Barcelona, Tarragona, Girona, and Lleida).",,"""Catalan blood donor population aged 18 to 70""",,2020-06-04,2020-06-17,Blood donors,All,Multiple groups,18.0,70.0,Analysis,,2962,0.0584,0.050499999999999996,0.0674,,,,,True,Sequential,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9500000000000001,0.995,['High'],,No,Yes,No,,Yes,Yes,Yes,,Maria Piron,Transfusion Safety Laboratory,Unity-Aligned,https://dx.doi.org/10.2450/2022.0232-21,2022-02-25,2024-03-01,Unverified,piron_sars-cov-2_2022,ESP
220209_Madrid_CityofMadrid_Overall,220209_Madrid_CityofMadrid,[SARS-CoV-2 seroprevalence study in patients undergoing addiction treatment in Madrid.].,2022-02-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,"People, diagnosed with
SUD, who were undergoing treatment in one of the
eight facilities ((Arganzuela, Hortaleza, Latina, San Blas, Tetuán,
Vallecas and Villaverde) and in the Madroño Mobile
Unit). The inclusion criteria
were being over 18 years of age, presenting a diagnosis
of SUD and following up on a device.","The exclusion
criteria were not meeting any of the three previous
criteria, or meeting them, not signing the informed
consent.",2020-06-15,2020-10-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,71.0,Primary Estimate,,473,0.051,,,True,,,,True,Convenience,COVID-19 IgG IgM Antibody Rapid Test Kit (Colloidal Gold),JOYSBIO,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9400000000000001,0.97,['High'],,No,No,Yes,,No,Yes,Yes,,Jose Olalla,City of Madrid,Not Unity-Aligned,https://www.sanidad.gob.es/biblioPublic/publicaciones/recursos_propios/resp/revista_cdrom/VOL96/ORIGINALES/RS96C_202202014.pdf,2022-02-14,2024-03-01,Unverified,diaz_olalla_sars-cov-2_2022,ESP
220302_Madrid_UniversidadReyJuanCarlos_Residents,220302_Madrid_UniversidadReyJuanCarlos_Residents,Humoral and Cellular Response after mRNA Vaccination in Nursing Homes: Influence of Age and of History of COVID-19.,2022-03-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,"Nursing homes that were under follow-up by the Supporting Unit for Residencies
(SUR) in the northern area of the Community of Madrid were offered the opportunity to
participate. All residents in nursing
homes were tested for their serological response to SARS-CoV-2 prior to the initiation of
the vaccination campaign.",,2020-07-15,2020-10-15,Assisted living and long-term care facilities,All,Seniors (65+ years),,,Primary Estimate,,1218,0.5,,,True,,,,True,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jesus San Roman,Universidad Rey Juan Carlos,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10030383,2022-04-04,2024-03-01,Unverified,san_roman_humoral_2022,ESP
220302_Madrid_UniversidadReyJuanCarlos_Staff,220302_Madrid_UniversidadReyJuanCarlos_Staff,Humoral and Cellular Response after mRNA Vaccination in Nursing Homes: Influence of Age and of History of COVID-19.,2022-03-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,"Nursing homes that were under follow-up by the Supporting Unit for Residencies
(SUR) in the northern area of the Community of Madrid were offered the opportunity to
participate. All workers in nursing
homes were tested for their serological response to SARS-CoV-2 prior to the initiation of
the vaccination campaign.",,2020-07-15,2020-10-15,Assisted living and long-term care facilities,All,Adults (18-64 years),,,Primary Estimate,,755,0.359,,,True,,,,True,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Spike,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jesus San Roman,Universidad Rey Juan Carlos,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10030383,2022-04-04,2024-03-01,Unverified,san_roman_humoral_2022,ESP
220309_Barcelona_HospitaldelaSantaCreuiSantPau_Overall,220309_Barcelona_HospitaldelaSantaCreuiSantPau,"First-trimester SARS-CoV-2 infection: clinical presentation, inflammatory markers and obstetric outcomes.",2022-03-09,Journal Article (Peer-Reviewed),Local,Prospective cohort,Spain,,Barcelona,Pregnant women with a singleton pregnancy who had a first-trimester blood sampling for aneuploidy screening were invited to participate at the time of first-trimester ultrasound,"Exclusion criteria were undetermined results at all SARS-CoV-2 serology tests, fetal major structural malformations, chromosomal or genetic abnormalities, and miscarriages before first-trimester ultrasound",2020-03-01,2020-05-31,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,817,0.152,,,True,,,,True,Sequential,"COVID-19 VIRCLIA IgG MONOTEST,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay","Vircell S.L.,Ortho Clinical Diagnostics Inc.,Luminex Corporation",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Cristina Trilla,Hospital de la Santa Creu i Sant Pau,Not Unity-Aligned,https://dx.doi.org/10.1159/000523974,2022-03-15,2024-03-01,Unverified,trilla_first-trimester_2022,ESP
220311_Spain_InstitutodeSaludCarlosIII_AntiRBD,220311_Spain_InstitutodeSaludCarlosIII,Evolution of antibodies against SARS-CoV-2 over seven months: Experience of the nationwide seroprevalence ENE-COVID study in Spain.,2022-03-11,Journal Article (Peer-Reviewed),National,Prospective cohort,Spain,,,Samples from all participants in the ENE-COVID study who agreed to donate a blood sample (ENE-COVID is a nationwide population-based longitudinal seroepidemiologic study in Spain),,2020-11-16,2020-11-29,Household and community samples,All,Multiple groups,,,Primary Estimate,Anti-S (RBD) target (Beckman CLIA),5827,0.054000000000000006,0.048,0.06,True,,,,True,Simplified probability,Access SARS-CoV-2 IgG Reagent Antibody Test,Beckman Coulter,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.988,1.0,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Mayte Perez-Olmeda,Instituto de Salud Carlos III,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S138665322200066X,2022-03-30,2024-03-01,Verified,perez-olmeda_evolution_2022,ESP
220311_Spain_InstitutodeSaludCarlosIII_AntiN copy,220311_Spain_InstitutodeSaludCarlosIII,Evolution of antibodies against SARS-CoV-2 over seven months: Experience of the nationwide seroprevalence ENE-COVID study in Spain.,2022-03-11,Journal Article (Peer-Reviewed),National,Prospective cohort,Spain,,,Samples from all participants in the ENE-COVID study who agreed to donate a blood sample (ENE-COVID is a nationwide population-based longitudinal seroepidemiologic study in Spain),,2020-11-16,2020-11-29,Household and community samples,All,Multiple groups,,,Test used,Anti-S (RBD) and Anti-N,5827,0.043,0.037000000000000005,0.048,,,,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test","Abbott Laboratories,Beckman Coulter",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Mayte Perez-Olmeda,Instituto de Salud Carlos III,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S138665322200066X,2022-05-30,2024-03-01,Verified,perez-olmeda_evolution_2022,ESP
220311_Spain_InstitutodeSaludCarlosIII_AntiN,220311_Spain_InstitutodeSaludCarlosIII,Evolution of antibodies against SARS-CoV-2 over seven months: Experience of the nationwide seroprevalence ENE-COVID study in Spain.,2022-03-11,Journal Article (Peer-Reviewed),National,Prospective cohort,Spain,,,Samples from all participants in the ENE-COVID study who agreed to donate a blood sample (ENE-COVID is a nationwide population-based longitudinal seroepidemiologic study in Spain),,2020-11-16,2020-11-29,Household and community samples,All,Multiple groups,,,Test used,Anti-N target (Abbott CMIA),5827,0.055,0.049,0.061,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.897,1.0,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Mayte Perez-Olmeda,Instituto de Salud Carlos III,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S138665322200066X,2022-03-30,2024-03-01,Verified,perez-olmeda_evolution_2022,ESP
220408_Spain_Osakidetza_Patients,220408_Spain_Osakidetza,COVID-19 among assisted reproduction patients in Spain. What should we do to stop the spread of infection,2022-04-08,Presentation or Conference,Local,Cross-sectional survey ,Spain,Biscay,,Observational study involving infertility patients and staff members of an AR center.,,2020-05-04,2020-05-18,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),,,Primary Estimate,,189,0.011000000000000001,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['Missing'],,No,No,No,,Unclear,Yes,No,,Barrenetxea Ziarrusta G,Osakidetza,Not Unity-Aligned,https://academic.oup.com/humrep/article/35/Supplement_1/i1/5867890?searchresult=1&login=true,2022-04-11,2022-07-16,Unverified,barrenetxeacovid-19_2022,ESP
220411_Madrid_HospitalGeneralUniversitarioGregorioMaranon_Residents_Overall,220411_Madrid_HospitalGeneralUniversitarioGregorioMaranon_Residents,"High incidence of COVID-19 at nursing homes in Madrid, Spain, despite preventive measures",2022-04-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,All surviving residents and health care workers who consented to participate in the present study were included.,,2020-04-18,2020-06-20,Assisted living and long-term care facilities,All,Seniors (65+ years),,,Primary Estimate,residents,942,0.706,,,True,,,,True,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Pilar Escribano,Hospital General Universitario Gregorio Maranon,Not Unity-Aligned,https://dx.doi.org/10.37201/req/008.2022,2022-04-21,2024-03-01,Unverified,escribano_high_2022,ESP
220411_Madrid_HospitalGeneralUniversitarioGregorioMaranon_Staff_Overall,220411_Madrid_HospitalGeneralUniversitarioGregorioMaranon_Staff,"High incidence of COVID-19 at nursing homes in Madrid, Spain, despite preventive measures",2022-04-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,All surviving residents and health care workers who consented to participate in the present study were included.,"NR
",2020-04-18,2020-06-20,Assisted living and long-term care facilities,All,Adults (18-64 years),,,Primary Estimate,staff,846,0.47000000000000003,,,True,,,,True,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Pilar Escribano,Hospital General Universitario Gregorio Maranon,Not Unity-Aligned,https://dx.doi.org/10.37201/req/008.2022,2022-04-21,2024-03-01,Unverified,escribano_high_2022,ESP
20220418_Catalonia_InstitutodeSaludGlobalBarcelona_Primary,20220418_Catalonia_InstitutodeSaludGlobalBarcelona,"SARS-CoV-2 infection, vaccination and antibody response trajectories in adults: a cohort study in Catalonia",2022-04-18,Preprint,Regional,Prospective cohort,Spain,Catalonia,,"This analysis uses data longitudinally collected during the COVID-19 pandemic among participants of the Genomes for life (GCAT) cohort in Catalonia. The GCAT cohort includes mainly middle-aged participants who are residents in Catalonia, and their recruitment started in 2014 (11).","We excluded only people vaccinated with Janssen COVID-19 vaccine
because they were few and eligible only for one dose at that time.",2021-05-26,2021-07-21,Blood donors,All,Multiple groups,43.0,72.0,Primary Estimate,any vaccination status,1076,0.9256505576,,,True,,,,True,Convenience,Author designed (Multiplex),,Other,,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9578,1.0,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,No,Marianna Karachaliou,Instituto de Salud Global Barcelona,Unity-Aligned,doi.org/10.21203/rs.3.rs-1536936/v1,2022-04-26,2022-07-16,Unverified,karachaliou_sars-cov-2_2022,ESP
20220418_Catalonia_InstitutodeSaludGlobalBarcelona_PartialVaccination,20220418_Catalonia_InstitutodeSaludGlobalBarcelona,"SARS-CoV-2 infection, vaccination and antibody response trajectories in adults: a cohort study in Catalonia",2022-04-18,Preprint,Regional,Prospective cohort,Spain,Catalonia,,"This analysis uses data longitudinally collected during the COVID-19 pandemic among participants of the Genomes for life (GCAT) cohort in Catalonia. The GCAT cohort includes mainly middle-aged participants who are residents in Catalonia, and their recruitment started in 2014 (11).","We excluded only people vaccinated with Janssen COVID-19 vaccine
because they were few and eligible only for one dose at that time.",2021-05-26,2021-07-21,Blood donors,All,Multiple groups,43.0,72.0,COVID-19 vaccination status,,257,0.9805447471,,,,,,,,Convenience,Author designed (Multiplex),,Other,,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.9578,1.0,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,No,Marianna Karachaliou,Instituto de Salud Global Barcelona,Unity-Aligned,doi.org/10.21203/rs.3.rs-1536936/v1,2022-04-26,2022-07-16,Unverified,karachaliou_sars-cov-2_2022,ESP
20220418_Catalonia_InstitutodeSaludGlobalBarcelona_FullyVaccination,20220418_Catalonia_InstitutodeSaludGlobalBarcelona,"SARS-CoV-2 infection, vaccination and antibody response trajectories in adults: a cohort study in Catalonia",2022-04-18,Preprint,Regional,Prospective cohort,Spain,Catalonia,,"This analysis uses data longitudinally collected during the COVID-19 pandemic among participants of the Genomes for life (GCAT) cohort in Catalonia. The GCAT cohort includes mainly middle-aged participants who are residents in Catalonia, and their recruitment started in 2014 (11).","We excluded only people vaccinated with Janssen COVID-19 vaccine
because they were few and eligible only for one dose at that time.",2021-05-26,2021-07-21,Blood donors,All,Multiple groups,43.0,72.0,COVID-19 vaccination status,,677,0.9955686854,,,,,,,,Convenience,Author designed (Multiplex),,Other,,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.9578,1.0,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,No,Marianna Karachaliou,Instituto de Salud Global Barcelona,Unity-Aligned,doi.org/10.21203/rs.3.rs-1536936/v1,2022-04-26,2022-07-16,Unverified,karachaliou_sars-cov-2_2022,ESP
20220418_Catalonia_InstitutodeSaludGlobalBarcelona_AntiS,20220418_Catalonia_InstitutodeSaludGlobalBarcelona,"SARS-CoV-2 infection, vaccination and antibody response trajectories in adults: a cohort study in Catalonia",2022-04-18,Preprint,Regional,Prospective cohort,Spain,Catalonia,,"This analysis uses data longitudinally collected during the COVID-19 pandemic among participants of the Genomes for life (GCAT) cohort in Catalonia. The GCAT cohort includes mainly middle-aged participants who are residents in Catalonia, and their recruitment started in 2014 (11).","We excluded only people vaccinated with Janssen COVID-19 vaccine
because they were few and eligible only for one dose at that time.",2021-05-26,2021-07-21,Blood donors,All,Multiple groups,43.0,72.0,Test used,overall anti-S,1076,0.8559479554000001,,,,,,,,Convenience,Author designed (Multiplex),,Other,,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.9578,1.0,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,No,Marianna Karachaliou,Instituto de Salud Global Barcelona,Unity-Aligned,doi.org/10.21203/rs.3.rs-1536936/v1,2022-04-26,2022-07-16,Unverified,karachaliou_sars-cov-2_2022,ESP
20220418_Catalonia_InstitutodeSaludGlobalBarcelona_NoVaccination,20220418_Catalonia_InstitutodeSaludGlobalBarcelona,"SARS-CoV-2 infection, vaccination and antibody response trajectories in adults: a cohort study in Catalonia",2022-04-18,Preprint,Regional,Prospective cohort,Spain,Catalonia,,"This analysis uses data longitudinally collected during the COVID-19 pandemic among participants of the Genomes for life (GCAT) cohort in Catalonia. The GCAT cohort includes mainly middle-aged participants who are residents in Catalonia, and their recruitment started in 2014 (11).","We excluded only people vaccinated with Janssen COVID-19 vaccine
because they were few and eligible only for one dose at that time.",2021-05-26,2021-07-21,Blood donors,All,Multiple groups,43.0,72.0,COVID-19 vaccination status,,83,0.843373494,,,,,,,,Convenience,Author designed (Multiplex),,Other,,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.9578,1.0,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,No,Marianna Karachaliou,Instituto de Salud Global Barcelona,Unity-Aligned,doi.org/10.21203/rs.3.rs-1536936/v1,2022-04-26,2022-07-16,Unverified,karachaliou_sars-cov-2_2022,ESP
20220418_Catalonia_InstitutodeSaludGlobalBarcelona_AntiN,20220418_Catalonia_InstitutodeSaludGlobalBarcelona,"SARS-CoV-2 infection, vaccination and antibody response trajectories in adults: a cohort study in Catalonia",2022-04-18,Preprint,Regional,Prospective cohort,Spain,Catalonia,,"This analysis uses data longitudinally collected during the COVID-19 pandemic among participants of the Genomes for life (GCAT) cohort in Catalonia. The GCAT cohort includes mainly middle-aged participants who are residents in Catalonia, and their recruitment started in 2014 (11).","We excluded only people vaccinated with Janssen COVID-19 vaccine
because they were few and eligible only for one dose at that time.",2021-05-26,2021-07-21,Blood donors,All,Multiple groups,43.0,72.0,Test used,overall anti-N,1076,0.07342007435,,,,,,,,Convenience,Author designed (Multiplex),,Other,,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by developers,0.9578,1.0,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,No,Marianna Karachaliou,Instituto de Salud Global Barcelona,Unity-Aligned,doi.org/10.21203/rs.3.rs-1536936/v1,2022-04-26,2022-07-16,Unverified,karachaliou_sars-cov-2_2022,ESP
220421_Catalonia_HospitalUniversitarideBellvitge,220421_Catalonia_HospitalUniversitarideBellvitge,"COVID-19 among workers of a comprehensive cancer centre between first and second epidemic waves (2020): a seroprevalence study in Catalonia, Spain",2022-04-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,"Catalonia Region (Four provinces: Barcelona, Girona, Lleida, and Tarragona)",,"""HCW  delivering  care  and  services  to  patients  (directly  or  indirectly)  and  support  staff, including those who do not deliver care but work in other tasks within the hospital.""

""The  inclusion  criteria  were:  (1)  to  be  an  active  worker  during  the  epidemic  period,  (1  February  2020–26  June  2020)  and  (2)  to  be  aged ≥18  years. """,Age < 18,2020-05-21,2020-06-26,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1235,0.0891,0.07440000000000001,0.1063,True,,,,True,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,Abbott Architect SARS-CoV-2 IgG","DiaSorin,Abbott Laboratories",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Yes,Yes,No,,Paula Peremiquel-Trillas,Hospital Universitari de Bellvitge,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-056637,2022-05-04,2024-03-01,Unverified,peremiquel-trillas_covid-19_2022,ESP
220429_HospitalUniversitarioArnaudeVilanova_IRBLleida_Overall,220429_HospitalUniversitarioArnaudeVilanova_IRBLleida,Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies,2022-04-29,Journal Article (Peer-Reviewed),Local,Prospective cohort,Spain,Lleida,Lleida,"All patients diagnosed with MS treated with any DMT in the MS unit in the Hospital Universitario Arnau de Vilanova, Lleida, Spain study were included.",,2020-03-15,2020-09-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,259,0.2046,,,True,,,,True,Convenience,"COVID-19 IgG – ELISA,COVID-19 IgM – ELISA,COVID-19 IgA – ELISA",Diagnostic Bioprobes,ELISA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Agustin Sancho-Saldana,IRB Leida,Not Unity-Aligned,https://dx.doi.org/10.3390/jcm11092509,2022-05-09,2022-07-16,Unverified,sancho-saldana_seroprevalence_2022,ESP
210430_Madrid_LaPazUniversityHospital,210430_Madrid_LaPazUniversityHospital,Clinical course and seroprevalence of COVID-19 in children with rheumatic diseases-cross-sectional study from a reference centre in Spain,2022-04-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Community of Madrid,Madrid,"All paediatric patients being treated for any rheumatic disease at the rheumatology unit at a reference hospital in Madrid, Spain",Absence of informed consent,2020-09-15,2021-02-15,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),,,Primary Estimate,,105,0.2,,,True,,,,True,Convenience,COVID-19 VIRCLIA IgG MONOTEST,Vircell S.L.,CLIA,Serum,IgG,,,,,['High'],No,No,No,Yes,No,Yes,Yes,Yes,No,Clara Udaondo,La Paz University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1007/s10067-022-06186-z,2022-05-09,2024-03-01,Verified,udaondo_clinical_2022,ESP
220527_ArgandaDelRey_ComplutenseUniversityofMadrid,220527_ArgandaDelRey_ComplutenseUniversityofMadrid,"Seroprevalence of anti-SARS-CoV-2 IgG antibodies: relationship with COVID-19 diagnosis, symptoms, smoking, and method of transmission.",2022-05-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Madrid,Arganda del Rey,"Individuals residing in the selected households were contacted by telephone and informed of the objective and characteristics of the study. 

The inclusion criteria for the study were: (1) being registered in the town of Arganda del Rey; (2) being older than 1 year of age; (3) having knowledge of the Spanish language.",,2021-01-18,2021-03-18,Household and community samples,All,Multiple groups,1.0,,Primary Estimate,,13560,0.242,,,True,,,,True,Simplified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Serum,IgG,Spike,Validated by manufacturers,0.9720000000000001,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Kora-Mareen Buhler,Complutense University of Madrid,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137247/,2022-06-29,2024-03-24,Verified,buhler_seroprevalence_2022,ESP
220602_Catalonia_InstitutCataladeLaSalut_Stage1_OverallCrude,220602_Catalonia_InstitutCataladeLaSalut_Stage1,Prevalence of SARS-CoV-2 antibodies and risk factors in the pandemic epicentre of Catalonia,2022-06-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Spain,Catalonia,Vilanova del Camí,"The inclusion criteria for serology were being a resident in the municipality of Vilanova del Camí, being older than 1 year and accepting the informed consent.",The only exclusion criterion was the presence of symptoms compatible with an active COVID-19 infection.,2020-10-01,2020-10-31,Household and community samples,All,Multiple groups,1.0,,Primary Estimate,,691,0.1216,,,True,,,,True,Convenience,COVID-19 IgG/IgM Rapid Test Kit,Salofa Oy,,,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.937,0.9990000000000001,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Sandra Moreno,Institut Catala de La Salut,Unity-Aligned,https://doi.org/10.1038/s41598-022-13290-2,2022-06-08,2024-03-23,Verified,moreno_prevalence_2022-1,ESP
220602_Catalonia_InstitutCataladeLaSalut_Stage1_SexFemale,220602_Catalonia_InstitutCataladeLaSalut_Stage1,Prevalence of SARS-CoV-2 antibodies and risk factors in the pandemic epicentre of Catalonia,2022-06-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Spain,Catalonia,Vilanova del Camí,"The inclusion criteria for serology were being a resident in the municipality of Vilanova del Camí, being older than 1 year and accepting the informed consent.",The only exclusion criterion was the presence of symptoms compatible with an active COVID-19 infection.,2020-10-01,2020-10-31,Household and community samples,Female,Multiple groups,1.0,,Sex/Gender,Female,417,0.11750000000000001,,,,,,,,Convenience,COVID-19 IgG/IgM Rapid Test Kit,Salofa Oy,,,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.937,0.9990000000000001,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Sandra Moreno,Institut Catala de La Salut,Unity-Aligned,https://doi.org/10.1038/s41598-022-13290-2,2022-06-08,2024-03-23,Verified,moreno_prevalence_2022-1,ESP
220602_Catalonia_InstitutCataladeLaSalut_Stage1_Age60+,220602_Catalonia_InstitutCataladeLaSalut_Stage1,Prevalence of SARS-CoV-2 antibodies and risk factors in the pandemic epicentre of Catalonia,2022-06-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Spain,Catalonia,Vilanova del Camí,"The inclusion criteria for serology were being a resident in the municipality of Vilanova del Camí, being older than 1 year and accepting the informed consent.",The only exclusion criterion was the presence of symptoms compatible with an active COVID-19 infection.,2020-10-01,2020-10-31,Household and community samples,All,Seniors (65+ years),60.0,,Age,60+,217,0.13820000000000002,,,,,,,,Convenience,COVID-19 IgG/IgM Rapid Test Kit,Salofa Oy,,,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.937,0.9990000000000001,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Sandra Moreno,Institut Catala de La Salut,Unity-Aligned,https://doi.org/10.1038/s41598-022-13290-2,2022-06-08,2024-03-23,Verified,moreno_prevalence_2022-1,ESP
220602_Catalonia_InstitutCataladeLaSalut_Stage1_Age1-20,220602_Catalonia_InstitutCataladeLaSalut_Stage1,Prevalence of SARS-CoV-2 antibodies and risk factors in the pandemic epicentre of Catalonia,2022-06-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Spain,Catalonia,Vilanova del Camí,"The inclusion criteria for serology were being a resident in the municipality of Vilanova del Camí, being older than 1 year and accepting the informed consent.",The only exclusion criterion was the presence of symptoms compatible with an active COVID-19 infection.,2020-10-01,2020-10-31,Household and community samples,All,Adults (18-64 years),1.0,20.0,Age,1-20,97,0.1134,,,,,,,,Convenience,COVID-19 IgG/IgM Rapid Test Kit,Salofa Oy,,,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.937,0.9990000000000001,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Sandra Moreno,Institut Catala de La Salut,Unity-Aligned,https://doi.org/10.1038/s41598-022-13290-2,2022-06-08,2024-03-23,Verified,moreno_prevalence_2022-1,ESP
220602_Catalonia_InstitutCataladeLaSalut_Stage1_Age40-59,220602_Catalonia_InstitutCataladeLaSalut_Stage1,Prevalence of SARS-CoV-2 antibodies and risk factors in the pandemic epicentre of Catalonia,2022-06-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Spain,Catalonia,Vilanova del Camí,"The inclusion criteria for serology were being a resident in the municipality of Vilanova del Camí, being older than 1 year and accepting the informed consent.",The only exclusion criterion was the presence of symptoms compatible with an active COVID-19 infection.,2020-10-01,2020-10-31,Household and community samples,All,Adults (18-64 years),40.0,59.0,Age,40-59,248,0.1048,,,,,,,,Convenience,COVID-19 IgG/IgM Rapid Test Kit,Salofa Oy,,,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.937,0.9990000000000001,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Sandra Moreno,Institut Catala de La Salut,Unity-Aligned,https://doi.org/10.1038/s41598-022-13290-2,2022-06-08,2024-03-23,Verified,moreno_prevalence_2022-1,ESP
220602_Catalonia_InstitutCataladeLaSalut_Stage1_Age20-39,220602_Catalonia_InstitutCataladeLaSalut_Stage1,Prevalence of SARS-CoV-2 antibodies and risk factors in the pandemic epicentre of Catalonia,2022-06-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Spain,Catalonia,Vilanova del Camí,"The inclusion criteria for serology were being a resident in the municipality of Vilanova del Camí, being older than 1 year and accepting the informed consent.",The only exclusion criterion was the presence of symptoms compatible with an active COVID-19 infection.,2020-10-01,2020-10-31,Household and community samples,All,Adults (18-64 years),20.0,39.0,Age,20-39,129,0.1318,,,,,,,,Convenience,COVID-19 IgG/IgM Rapid Test Kit,Salofa Oy,,,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.937,0.9990000000000001,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Sandra Moreno,Institut Catala de La Salut,Unity-Aligned,https://doi.org/10.1038/s41598-022-13290-2,2022-06-08,2024-03-23,Verified,moreno_prevalence_2022-1,ESP
220602_Catalonia_InstitutCataladeLaSalut_Stage1_SexMale,220602_Catalonia_InstitutCataladeLaSalut_Stage1,Prevalence of SARS-CoV-2 antibodies and risk factors in the pandemic epicentre of Catalonia,2022-06-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Spain,Catalonia,Vilanova del Camí,"The inclusion criteria for serology were being a resident in the municipality of Vilanova del Camí, being older than 1 year and accepting the informed consent.",The only exclusion criterion was the presence of symptoms compatible with an active COVID-19 infection.,2020-10-01,2020-10-31,Household and community samples,Male,Multiple groups,1.0,,Sex/Gender,Male,274,0.1277,,,,,,,,Convenience,COVID-19 IgG/IgM Rapid Test Kit,Salofa Oy,,,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.937,0.9990000000000001,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Sandra Moreno,Institut Catala de La Salut,Unity-Aligned,https://doi.org/10.1038/s41598-022-13290-2,2022-06-08,2024-03-23,Verified,moreno_prevalence_2022-1,ESP
220602_Catalonia_InstitutCataladeLaSalut_Stage2_OverallCrude,220602_Catalonia_InstitutCataladeLaSalut_Stage2,Prevalence of SARS-CoV-2 antibodies and risk factors in the pandemic epicentre of Catalonia,2022-06-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Spain,Catalonia,Vilanova del Camí,"The inclusion criteria for serology were being a resident in the municipality of Vilanova del Camí, being older than 1 year and accepting the informed consent.",The only exclusion criterion was the presence of symptoms compatible with an active COVID-19 infection.,2020-12-01,2020-12-31,Household and community samples,All,Multiple groups,1.0,,Primary Estimate,,1479,0.08380000000000001,,,True,,,,True,Convenience,COVID-19 IgG/IgM Rapid Test Kit,Salofa Oy,,,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.937,0.9990000000000001,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Sandra Moreno,Institut Catala de La Salut,Unity-Aligned,https://doi.org/10.1038/s41598-022-13290-2,2022-06-08,2024-03-23,Verified,moreno_prevalence_2022-1,ESP
220602_Catalonia_InstitutCataladeLaSalut_Stage2_Age60+,220602_Catalonia_InstitutCataladeLaSalut_Stage2,Prevalence of SARS-CoV-2 antibodies and risk factors in the pandemic epicentre of Catalonia,2022-06-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Spain,Catalonia,Vilanova del Camí,"The inclusion criteria for serology were being a resident in the municipality of Vilanova del Camí, being older than 1 year and accepting the informed consent.",The only exclusion criterion was the presence of symptoms compatible with an active COVID-19 infection.,2020-12-01,2020-12-31,Household and community samples,All,Seniors (65+ years),60.0,,Age,60+,453,0.1236,,,,,,,,Convenience,COVID-19 IgG/IgM Rapid Test Kit,Salofa Oy,,,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.937,0.9990000000000001,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Sandra Moreno,Institut Catala de La Salut,Unity-Aligned,https://doi.org/10.1038/s41598-022-13290-2,2022-06-08,2024-03-23,Verified,moreno_prevalence_2022-1,ESP
220602_Catalonia_InstitutCataladeLaSalut_Stage2_Age40-59,220602_Catalonia_InstitutCataladeLaSalut_Stage2,Prevalence of SARS-CoV-2 antibodies and risk factors in the pandemic epicentre of Catalonia,2022-06-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Spain,Catalonia,Vilanova del Camí,"The inclusion criteria for serology were being a resident in the municipality of Vilanova del Camí, being older than 1 year and accepting the informed consent.",The only exclusion criterion was the presence of symptoms compatible with an active COVID-19 infection.,2020-12-01,2020-12-31,Household and community samples,All,Adults (18-64 years),40.0,59.0,Age,40-59,594,0.0707,,,,,,,,Convenience,COVID-19 IgG/IgM Rapid Test Kit,Salofa Oy,,,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.937,0.9990000000000001,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Sandra Moreno,Institut Catala de La Salut,Unity-Aligned,https://doi.org/10.1038/s41598-022-13290-2,2022-06-08,2024-03-23,Verified,moreno_prevalence_2022-1,ESP
220602_Catalonia_InstitutCataladeLaSalut_Stage2_Age1-20,220602_Catalonia_InstitutCataladeLaSalut_Stage2,Prevalence of SARS-CoV-2 antibodies and risk factors in the pandemic epicentre of Catalonia,2022-06-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Spain,Catalonia,Vilanova del Camí,"The inclusion criteria for serology were being a resident in the municipality of Vilanova del Camí, being older than 1 year and accepting the informed consent.",The only exclusion criterion was the presence of symptoms compatible with an active COVID-19 infection.,2020-12-01,2020-12-31,Household and community samples,All,Adults (18-64 years),1.0,20.0,Age,1-20,158,0.0633,,,,,,,,Convenience,COVID-19 IgG/IgM Rapid Test Kit,Salofa Oy,,,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.937,0.9990000000000001,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Sandra Moreno,Institut Catala de La Salut,Unity-Aligned,https://doi.org/10.1038/s41598-022-13290-2,2022-06-08,2024-03-23,Verified,moreno_prevalence_2022-1,ESP
220602_Catalonia_InstitutCataladeLaSalut_Stage2_SexFemale,220602_Catalonia_InstitutCataladeLaSalut_Stage2,Prevalence of SARS-CoV-2 antibodies and risk factors in the pandemic epicentre of Catalonia,2022-06-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Spain,Catalonia,Vilanova del Camí,"The inclusion criteria for serology were being a resident in the municipality of Vilanova del Camí, being older than 1 year and accepting the informed consent.",The only exclusion criterion was the presence of symptoms compatible with an active COVID-19 infection.,2020-12-01,2020-12-31,Household and community samples,Female,Multiple groups,1.0,,Sex/Gender,Female,864,0.0799,,,,,,,,Convenience,COVID-19 IgG/IgM Rapid Test Kit,Salofa Oy,,,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.937,0.9990000000000001,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Sandra Moreno,Institut Catala de La Salut,Unity-Aligned,https://doi.org/10.1038/s41598-022-13290-2,2022-06-08,2024-03-23,Verified,moreno_prevalence_2022-1,ESP
220602_Catalonia_InstitutCataladeLaSalut_Stage2_Age20-39,220602_Catalonia_InstitutCataladeLaSalut_Stage2,Prevalence of SARS-CoV-2 antibodies and risk factors in the pandemic epicentre of Catalonia,2022-06-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Spain,Catalonia,Vilanova del Camí,"The inclusion criteria for serology were being a resident in the municipality of Vilanova del Camí, being older than 1 year and accepting the informed consent.",The only exclusion criterion was the presence of symptoms compatible with an active COVID-19 infection.,2020-12-01,2020-12-31,Household and community samples,All,Adults (18-64 years),20.0,39.0,Age,20-39,274,0.0584,,,,,,,,Convenience,COVID-19 IgG/IgM Rapid Test Kit,Salofa Oy,,,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.937,0.9990000000000001,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Sandra Moreno,Institut Catala de La Salut,Unity-Aligned,https://doi.org/10.1038/s41598-022-13290-2,2022-06-08,2024-03-23,Verified,moreno_prevalence_2022-1,ESP
220602_Catalonia_InstitutCataladeLaSalut_Stage2_SexMale,220602_Catalonia_InstitutCataladeLaSalut_Stage2,Prevalence of SARS-CoV-2 antibodies and risk factors in the pandemic epicentre of Catalonia,2022-06-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Spain,Catalonia,Vilanova del Camí,"The inclusion criteria for serology were being a resident in the municipality of Vilanova del Camí, being older than 1 year and accepting the informed consent.",The only exclusion criterion was the presence of symptoms compatible with an active COVID-19 infection.,2020-12-01,2020-12-31,Household and community samples,Male,Multiple groups,1.0,,Sex/Gender,Male,615,0.0894,,,,,,,,Convenience,COVID-19 IgG/IgM Rapid Test Kit,Salofa Oy,,,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.937,0.9990000000000001,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Sandra Moreno,Institut Catala de La Salut,Unity-Aligned,https://doi.org/10.1038/s41598-022-13290-2,2022-06-08,2024-03-23,Verified,moreno_prevalence_2022-1,ESP
220610_Madrid_HospitalUniversitarioRamonyCajal_Overall,220610_Madrid_HospitalUniversitarioRamonyCajal,Risk of SARS-CoV-2 Reinfections in a Prospective Inception Cohort Study: Impact of COVID-19 Vaccination,2022-06-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,"""This inception cohort study included 4943 individuals working during the first surge of COVID-19, starting in March 2020, at a tertiary university hospital [Hospital Universitario Ramón y Cajal] in Madrid, Spain.""",,2020-04-15,2020-05-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,4943,0.214,,,True,,,,True,Convenience,"COVID-19 ELISA IgG,COVID-19 ELISA IgM/IgA",Vircell S.L.,ELISA,Serum,"['IgA', 'IgG', 'IgM']","['Notreported', 'Nucleocapsid(N-protein)']",,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Jose Casado,Hospital Universitario Ramón y Cajal,Not Unity-Aligned,https://dx.doi.org/10.3390/jcm11123352,2022-06-21,2024-03-01,Unverified,casado_risk_2022,ESP
220613_HospitalUniversitarioRamónYCajal_Madrid,220613_HospitalUniversitarioRamónYCajal_Madrid,Low Positivity Rate of Anti-SARS-CoV-2 IgG in Unvaccinated Patients With Rheumatic Diseases Treated With Rituximab.,2022-06-13,Journal Article (Peer-Reviewed),Local,Prospective cohort,Spain,,Madrid,"Patients aged >16 years, regardless of previous COVID-19
history, were included.","Patients with an RMD treated with targeted
synthetic disease-modifying antirheumatic drugs (tsDMARDs) or
biological tsDMARDS (bDMARDs),rather than rituximab or TNF inhibitor were excluded",2020-04-15,2020-12-22,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,152,0.257,,,True,,,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Multiple Types,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Antia Garcia-Fernandez,Hospital Universitario Ramón y Cajal,Not Unity-Aligned,https://dx.doi.org/10.1097/RHU.0000000000001876,2022-06-24,2024-03-01,Unverified,garcia-fernandez_low_2022,ESP
220624_Barcelona_GermansTriasiPujolHospital,220624_Barcelona_GermansTriasiPujolHospital,Follow Up of the Humoral Response in Healthcare Workers after the Administration of Two Dose of the Anti SARS-CoV-2 Vaccines-Effectiveness in Delta Variant Breakthrough Infections,2022-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,Catalonia,Barcelona,""" all HCWs of the ICS-Northern Metropolitan Area of Barcelona (n= 9315) were offered to have serum testing""",,2021-06-01,2021-08-31,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,5000,0.9804,,,True,,,,True,Convenience,LIAISON® SARS-CoV-2 TrimericS IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Gema Fernandez-Rivas,Germans Trias i Pujol Hospital,Not Unity-Aligned,https://dx.doi.org/10.3390/v14071385,2022-07-13,2024-03-01,Unverified,fernandez-rivas_follow_2022,ESP
220624_Spain_EmiratesSpecialityHospitalDubai,220624_Spain_EmiratesSpecialityHospitalDubai,The impact of COVID-19 lockdown on children with recurrent wheezing and asthma in Spain,2022-06-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Spain,,,Children with recurring wheezing and asthma. Children younger than 16 yearsfollowed in the Pediatric Pulmonology Departments of the HM Hospitals from Madrid and Barcelona during the 2 months following the announcement of lockdown in Spain.,,2020-07-01,2020-07-31,Residual sera,All,Children and Youth (0-17 years),0.0,16.0,Primary Estimate,,233,0.073,,,True,,,,True,Convenience,Diapro,Palex,ELISA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,No,Yes,No,,Zarife Perez,Emirates Speciality Hospital Dubai,Not Unity-Aligned,https://dx.doi.org/10.1111/jpc.16068,2022-07-12,2024-03-01,Unverified,daoud_perez_impact_2022,ESP
220719_Valencia_INCLIVAHealthResearchInstitute_Age_20-34,220719_Valencia_INCLIVAHealthResearchInstitute,Cumulative incidence of SARS-CoV-2 infection in the general population of the Valencian Community (Spain) after the surge of the Omicron BA.1 variant,2022-07-19,Preprint,Local,Cross-sectional survey ,Spain,,Valencia,"The current cross-sectional, region-wide, population-based study was conducted in the primary care zones (PCZ) of the Valencia Health System )",,2022-04-01,2022-04-30,Household and community samples,All,Multiple groups,,,Age,,150,0.973,0.9470000000000001,0.9990000000000001,True,,,,True,Convenience,Author designed (CLIA),,CLIA,Serum,,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Jorge Camacho,INCLIVA Health Research Institute,Not Unity-Aligned,10.1101/2022.07.19.22277747,2022-07-28,2022-07-28,Unverified,camacho_cumulative_2022,ESP
220719_Valencia_INCLIVAHealthResearchInstitute_Age_0-9,220719_Valencia_INCLIVAHealthResearchInstitute,Cumulative incidence of SARS-CoV-2 infection in the general population of the Valencian Community (Spain) after the surge of the Omicron BA.1 variant,2022-07-19,Preprint,Local,Cross-sectional survey ,Spain,,Valencia,"The current cross-sectional, region-wide, population-based study was conducted in the primary care zones (PCZ) of the Valencia Health System )",,2022-04-01,2022-04-30,Household and community samples,All,Multiple groups,,,Age,,40,0.8,0.67,0.93,True,,,,True,Convenience,Author designed (CLIA),,CLIA,Serum,,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Jorge Camacho,INCLIVA Health Research Institute,Not Unity-Aligned,10.1101/2022.07.19.22277747,2022-07-28,2022-07-28,Unverified,camacho_cumulative_2022,ESP
220719_Valencia_INCLIVAHealthResearchInstitute_Age_65-79,220719_Valencia_INCLIVAHealthResearchInstitute,Cumulative incidence of SARS-CoV-2 infection in the general population of the Valencian Community (Spain) after the surge of the Omicron BA.1 variant,2022-07-19,Preprint,Local,Cross-sectional survey ,Spain,,Valencia,"The current cross-sectional, region-wide, population-based study was conducted in the primary care zones (PCZ) of the Valencia Health System )",,2022-04-01,2022-04-30,Household and community samples,All,Multiple groups,,,Age,,159,0.9870000000000001,0.97,1.0,True,,,,True,Convenience,Author designed (CLIA),,CLIA,Serum,,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Jorge Camacho,INCLIVA Health Research Institute,Not Unity-Aligned,10.1101/2022.07.19.22277747,2022-07-28,2022-07-28,Unverified,camacho_cumulative_2022,ESP
220719_Valencia_INCLIVAHealthResearchInstitute_Age_35-49,220719_Valencia_INCLIVAHealthResearchInstitute,Cumulative incidence of SARS-CoV-2 infection in the general population of the Valencian Community (Spain) after the surge of the Omicron BA.1 variant,2022-07-19,Preprint,Local,Cross-sectional survey ,Spain,,Valencia,"The current cross-sectional, region-wide, population-based study was conducted in the primary care zones (PCZ) of the Valencia Health System )",,2022-04-01,2022-04-30,Household and community samples,All,Multiple groups,,,Age,,181,0.983,0.965,1.0,True,,,,True,Convenience,Author designed (CLIA),,CLIA,Serum,,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Jorge Camacho,INCLIVA Health Research Institute,Not Unity-Aligned,10.1101/2022.07.19.22277747,2022-07-28,2022-07-28,Unverified,camacho_cumulative_2022,ESP
220719_Valencia_INCLIVAHealthResearchInstitute_Overall_PopAdj,220719_Valencia_INCLIVAHealthResearchInstitute,Cumulative incidence of SARS-CoV-2 infection in the general population of the Valencian Community (Spain) after the surge of the Omicron BA.1 variant,2022-07-19,Preprint,Local,Cross-sectional survey ,Spain,,Valencia,"The current cross-sectional, region-wide, population-based study was conducted in the primary care zones (PCZ) of the Valencia Health System )",,2022-04-01,2022-04-30,Household and community samples,All,Multiple groups,,,Primary Estimate,,931,0.9670000000000001,0.9550000000000001,0.978,True,,,,,Convenience,Author designed (CLIA),,CLIA,Serum,,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Jorge Camacho,INCLIVA Health Research Institute,Not Unity-Aligned,10.1101/2022.07.19.22277747,2022-07-28,2022-07-29,Unverified,camacho_cumulative_2022,ESP
220719_Valencia_INCLIVAHealthResearchInstitute_Age_50-64,220719_Valencia_INCLIVAHealthResearchInstitute,Cumulative incidence of SARS-CoV-2 infection in the general population of the Valencian Community (Spain) after the surge of the Omicron BA.1 variant,2022-07-19,Preprint,Local,Cross-sectional survey ,Spain,,Valencia,"The current cross-sectional, region-wide, population-based study was conducted in the primary care zones (PCZ) of the Valencia Health System )",,2022-04-01,2022-04-30,Household and community samples,All,Multiple groups,,,Age,,173,0.983,0.963,1.0,True,,,,True,Convenience,Author designed (CLIA),,CLIA,Serum,,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Jorge Camacho,INCLIVA Health Research Institute,Not Unity-Aligned,10.1101/2022.07.19.22277747,2022-07-28,2022-07-28,Unverified,camacho_cumulative_2022,ESP
220719_Valencia_INCLIVAHealthResearchInstitute_Age_10-19,220719_Valencia_INCLIVAHealthResearchInstitute,Cumulative incidence of SARS-CoV-2 infection in the general population of the Valencian Community (Spain) after the surge of the Omicron BA.1 variant,2022-07-19,Preprint,Local,Cross-sectional survey ,Spain,,Valencia,"The current cross-sectional, region-wide, population-based study was conducted in the primary care zones (PCZ) of the Valencia Health System )",,2022-04-01,2022-04-30,Household and community samples,All,Multiple groups,,,Age,,87,0.988,0.966,1.0,True,,,,True,Convenience,Author designed (CLIA),,CLIA,Serum,,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Jorge Camacho,INCLIVA Health Research Institute,Not Unity-Aligned,10.1101/2022.07.19.22277747,2022-07-28,2022-07-28,Unverified,camacho_cumulative_2022,ESP
220719_Valencia_INCLIVAHealthResearchInstitute_Age_80+,220719_Valencia_INCLIVAHealthResearchInstitute,Cumulative incidence of SARS-CoV-2 infection in the general population of the Valencian Community (Spain) after the surge of the Omicron BA.1 variant,2022-07-19,Preprint,Local,Cross-sectional survey ,Spain,,Valencia,"The current cross-sectional, region-wide, population-based study was conducted in the primary care zones (PCZ) of the Valencia Health System )",,2022-04-01,2022-04-30,Household and community samples,All,Multiple groups,,,Age,,141,0.9720000000000001,0.943,0.9990000000000001,True,,,,True,Convenience,Author designed (CLIA),,CLIA,Serum,,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Jorge Camacho,INCLIVA Health Research Institute,Not Unity-Aligned,10.1101/2022.07.19.22277747,2022-07-28,2022-07-28,Unverified,camacho_cumulative_2022,ESP
220719_Valencia_INCLIVAHealthResearchInstitute_Overall_UnAdj,220719_Valencia_INCLIVAHealthResearchInstitute,Cumulative incidence of SARS-CoV-2 infection in the general population of the Valencian Community (Spain) after the surge of the Omicron BA.1 variant,2022-07-19,Preprint,Local,Cross-sectional survey ,Spain,,Valencia,"The current cross-sectional, region-wide, population-based study was conducted in the primary care zones (PCZ) of the Valencia Health System )",,2022-04-01,2022-04-30,Household and community samples,All,Multiple groups,,,Analysis,,931,0.973,0.963,0.9840000000000001,,,,,True,Convenience,Author designed (CLIA),,CLIA,Serum,,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Jorge Camacho,INCLIVA Health Research Institute,Not Unity-Aligned,10.1101/2022.07.19.22277747,2022-07-28,2022-07-28,Unverified,camacho_cumulative_2022,ESP
220726_Spain_DiputaciónDeAlbacete_Employees,220726_Spain_DiputaciónDeAlbacete_Employees,Efficiency of Diagnostic Test for SARS-CoV-2 in a Nursing Home.,2022-07-26,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Spain,Castilla-la Mancha,Albacete,"""Being an employee of the social health center and signing an informed consent""","""Refusal to participating in the study and/or signing of the informed consent""",2020-06-15,2020-12-18,Health care workers and caregivers,All,Multiple groups,23.0,69.0,Primary Estimate,,255,0.24,,,True,,,,True,Unclear,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,,Multiple Types,IgG,Spike,,,,['High'],,Unclear,No,Yes,,Yes,Yes,Yes,,Sergio Salmeron,"Universidad de Castilla-La Mancha, ",Not Unity-Aligned,https://dx.doi.org/10.3390/geriatrics7040078,2022-08-05,2024-03-01,Unverified,salmeron_efficiency_2022,ESP
220726_Spain_DiputaciónDeAlbacete_Residents,220726_Spain_DiputaciónDeAlbacete_Residents,Efficiency of Diagnostic Test for SARS-CoV-2 in a Nursing Home.,2022-07-26,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Spain,Castilla-la Mancha,Albacete,"""Being a resident of the social health center and signing an informed consent""","""Refusal to participating in the study and/or signing of the informed consent""",2020-06-15,2020-12-18,Assisted living and long-term care facilities,All,Multiple groups,56.0,99.0,Primary Estimate,,107,0.514,,,True,,,,True,Unclear,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,,Multiple Types,IgG,Spike,,,,['High'],,Unclear,No,Yes,,Yes,Yes,Yes,,Sergio Salmeron,"Universidad de Castilla-La Mancha, ",Not Unity-Aligned,https://dx.doi.org/10.3390/geriatrics7040078,2022-08-05,2024-03-01,Unverified,salmeron_efficiency_2022,ESP
220818_Navarre_NavarreInstituteForHealthResearch_AntiS_Overall,220818_Navarre_NavarreInstituteForHealthResearch,"Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022",2022-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,Navarre,,"""The study included a sample of 1,461 people from the population of Navarre aged 5 years and older.""

""A sample of primary healthcare facilities (35/57) voluntarily recruited patients aged 5 years and older whose physicians requested a blood test for reasons unrelated to SARS-CoV-2 infection"".","""Patients with clinical manifestations of COVID-19 or close contact with a COVID-19 case in the previous 10 days, healthcare workers, nursing home residents and people not resident in the region were excluded.""",2022-04-26,2022-06-03,Residual sera,All,Multiple groups,5.0,,Primary Estimate,Anti-S Overall,1461,0.9274,,,True,,,,True,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,,Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Jesus Castilla,Navarre Institute for Health Research,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.33.2200619,2022-09-01,2024-03-01,Unverified,castilla_seroprevalence_2022,ESP
220818_Navarre_NavarreInstituteForHealthResearch_AntiS_Age18-29,220818_Navarre_NavarreInstituteForHealthResearch,"Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022",2022-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,Navarre,,"""The study included a sample of 1,461 people from the population of Navarre aged 5 years and older.""

""A sample of primary healthcare facilities (35/57) voluntarily recruited patients aged 5 years and older whose physicians requested a blood test for reasons unrelated to SARS-CoV-2 infection"".","""Patients with clinical manifestations of COVID-19 or close contact with a COVID-19 case in the previous 10 days, healthcare workers, nursing home residents and people not resident in the region were excluded.""",2022-04-26,2022-06-03,Residual sera,All,Adults (18-64 years),18.0,29.0,Age,Age: 18-29,153,0.9477,,,,,,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,,Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Jesus Castilla,Navarre Institute for Health Research,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.33.2200619,2022-09-01,2024-03-01,Unverified,castilla_seroprevalence_2022,ESP
220818_Navarre_NavarreInstituteForHealthResearch_AntiS_Age40-49,220818_Navarre_NavarreInstituteForHealthResearch,"Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022",2022-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,Navarre,,"""The study included a sample of 1,461 people from the population of Navarre aged 5 years and older.""

""A sample of primary healthcare facilities (35/57) voluntarily recruited patients aged 5 years and older whose physicians requested a blood test for reasons unrelated to SARS-CoV-2 infection"".","""Patients with clinical manifestations of COVID-19 or close contact with a COVID-19 case in the previous 10 days, healthcare workers, nursing home residents and people not resident in the region were excluded.""",2022-04-26,2022-06-03,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,Age: 40-49,208,0.9470999999999999,,,,,,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,,Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Jesus Castilla,Navarre Institute for Health Research,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.33.2200619,2022-09-01,2024-03-01,Unverified,castilla_seroprevalence_2022,ESP
220818_Navarre_NavarreInstituteForHealthResearch_AntiS_Age70-79,220818_Navarre_NavarreInstituteForHealthResearch,"Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022",2022-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,Navarre,,"""The study included a sample of 1,461 people from the population of Navarre aged 5 years and older.""

""A sample of primary healthcare facilities (35/57) voluntarily recruited patients aged 5 years and older whose physicians requested a blood test for reasons unrelated to SARS-CoV-2 infection"".","""Patients with clinical manifestations of COVID-19 or close contact with a COVID-19 case in the previous 10 days, healthcare workers, nursing home residents and people not resident in the region were excluded.""",2022-04-26,2022-06-03,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,Age: 70-79,201,0.9501999999999999,,,,,,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,,Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Jesus Castilla,Navarre Institute for Health Research,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.33.2200619,2022-09-01,2024-03-01,Unverified,castilla_seroprevalence_2022,ESP
220818_Navarre_NavarreInstituteForHealthResearch_AntiS_SexMale,220818_Navarre_NavarreInstituteForHealthResearch,"Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022",2022-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,Navarre,,"""The study included a sample of 1,461 people from the population of Navarre aged 5 years and older.""

""A sample of primary healthcare facilities (35/57) voluntarily recruited patients aged 5 years and older whose physicians requested a blood test for reasons unrelated to SARS-CoV-2 infection"".","""Patients with clinical manifestations of COVID-19 or close contact with a COVID-19 case in the previous 10 days, healthcare workers, nursing home residents and people not resident in the region were excluded.""",2022-04-26,2022-06-03,Residual sera,Male,Multiple groups,5.0,,Sex/Gender,,665,0.9263,,,,,,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,,Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Jesus Castilla,Navarre Institute for Health Research,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.33.2200619,2022-09-01,2024-03-01,Unverified,castilla_seroprevalence_2022,ESP
220818_Navarre_NavarreInstituteForHealthResearch_AntiS_Vaccinated,220818_Navarre_NavarreInstituteForHealthResearch,"Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022",2022-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,Navarre,,"""The study included a sample of 1,461 people from the population of Navarre aged 5 years and older.""

""A sample of primary healthcare facilities (35/57) voluntarily recruited patients aged 5 years and older whose physicians requested a blood test for reasons unrelated to SARS-CoV-2 infection"".","""Patients with clinical manifestations of COVID-19 or close contact with a COVID-19 case in the previous 10 days, healthcare workers, nursing home residents and people not resident in the region were excluded.""",2022-04-26,2022-06-03,Residual sera,All,Multiple groups,5.0,,COVID-19 vaccination status,,1335,0.9745,,,,,,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,,Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Jesus Castilla,Navarre Institute for Health Research,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.33.2200619,2022-09-01,2024-03-01,Unverified,castilla_seroprevalence_2022,ESP
220818_Navarre_NavarreInstituteForHealthResearch_AntiS_Age60-69,220818_Navarre_NavarreInstituteForHealthResearch,"Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022",2022-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,Navarre,,"""The study included a sample of 1,461 people from the population of Navarre aged 5 years and older.""

""A sample of primary healthcare facilities (35/57) voluntarily recruited patients aged 5 years and older whose physicians requested a blood test for reasons unrelated to SARS-CoV-2 infection"".","""Patients with clinical manifestations of COVID-19 or close contact with a COVID-19 case in the previous 10 days, healthcare workers, nursing home residents and people not resident in the region were excluded.""",2022-04-26,2022-06-03,Residual sera,All,Seniors (65+ years),60.0,69.0,Age,Age: 60-69,234,0.9487000000000001,,,,,,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,,Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Jesus Castilla,Navarre Institute for Health Research,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.33.2200619,2022-09-01,2024-03-01,Unverified,castilla_seroprevalence_2022,ESP
220818_Navarre_NavarreInstituteForHealthResearch_AntiS_Age50-59,220818_Navarre_NavarreInstituteForHealthResearch,"Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022",2022-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,Navarre,,"""The study included a sample of 1,461 people from the population of Navarre aged 5 years and older.""

""A sample of primary healthcare facilities (35/57) voluntarily recruited patients aged 5 years and older whose physicians requested a blood test for reasons unrelated to SARS-CoV-2 infection"".","""Patients with clinical manifestations of COVID-19 or close contact with a COVID-19 case in the previous 10 days, healthcare workers, nursing home residents and people not resident in the region were excluded.""",2022-04-26,2022-06-03,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,Age: 50-59,252,0.9562999999999999,,,,,,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,,Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Jesus Castilla,Navarre Institute for Health Research,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.33.2200619,2022-09-01,2024-03-01,Unverified,castilla_seroprevalence_2022,ESP
220818_Navarre_NavarreInstituteForHealthResearch_AntiS_Age80+,220818_Navarre_NavarreInstituteForHealthResearch,"Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022",2022-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,Navarre,,"""The study included a sample of 1,461 people from the population of Navarre aged 5 years and older.""

""A sample of primary healthcare facilities (35/57) voluntarily recruited patients aged 5 years and older whose physicians requested a blood test for reasons unrelated to SARS-CoV-2 infection"".","""Patients with clinical manifestations of COVID-19 or close contact with a COVID-19 case in the previous 10 days, healthcare workers, nursing home residents and people not resident in the region were excluded.""",2022-04-26,2022-06-03,Residual sera,All,Seniors (65+ years),80.0,,Age,Age: ≥80,96,0.9375,,,,,,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,,Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Jesus Castilla,Navarre Institute for Health Research,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.33.2200619,2022-09-01,2024-03-01,Unverified,castilla_seroprevalence_2022,ESP
220818_Navarre_NavarreInstituteForHealthResearch_AntiN_Overall,220818_Navarre_NavarreInstituteForHealthResearch,"Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022",2022-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,Navarre,,"""The study included a sample of 1,461 people from the population of Navarre aged 5 years and older.""

""A sample of primary healthcare facilities (35/57) voluntarily recruited patients aged 5 years and older whose physicians requested a blood test for reasons unrelated to SARS-CoV-2 infection"".","""Patients with clinical manifestations of COVID-19 or close contact with a COVID-19 case in the previous 10 days, healthcare workers, nursing home residents and people not resident in the region were excluded.""",2022-04-26,2022-06-03,Residual sera,All,Multiple groups,5.0,,Test used,Anti-N,1461,0.5886,,,,,,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Jesus Castilla,Navarre Institute for Health Research,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.33.2200619,2022-09-01,2024-03-01,Unverified,castilla_seroprevalence_2022,ESP
220818_Navarre_NavarreInstituteForHealthResearch_AntiS_Unvaccinated,220818_Navarre_NavarreInstituteForHealthResearch,"Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022",2022-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,Navarre,,"""The study included a sample of 1,461 people from the population of Navarre aged 5 years and older.""

""A sample of primary healthcare facilities (35/57) voluntarily recruited patients aged 5 years and older whose physicians requested a blood test for reasons unrelated to SARS-CoV-2 infection"".","""Patients with clinical manifestations of COVID-19 or close contact with a COVID-19 case in the previous 10 days, healthcare workers, nursing home residents and people not resident in the region were excluded.""",2022-04-26,2022-06-03,Residual sera,All,Multiple groups,5.0,,COVID-19 vaccination status,,107,0.3925,,,,,,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,,Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Jesus Castilla,Navarre Institute for Health Research,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.33.2200619,2022-09-01,2024-03-01,Unverified,castilla_seroprevalence_2022,ESP
220818_Navarre_NavarreInstituteForHealthResearch_AntiS_Age30-39,220818_Navarre_NavarreInstituteForHealthResearch,"Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022",2022-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,Navarre,,"""The study included a sample of 1,461 people from the population of Navarre aged 5 years and older.""

""A sample of primary healthcare facilities (35/57) voluntarily recruited patients aged 5 years and older whose physicians requested a blood test for reasons unrelated to SARS-CoV-2 infection"".","""Patients with clinical manifestations of COVID-19 or close contact with a COVID-19 case in the previous 10 days, healthcare workers, nursing home residents and people not resident in the region were excluded.""",2022-04-26,2022-06-03,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,Age: 30-39,136,0.9338,,,,,,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,,Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Jesus Castilla,Navarre Institute for Health Research,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.33.2200619,2022-09-01,2024-03-01,Unverified,castilla_seroprevalence_2022,ESP
220818_Navarre_NavarreInstituteForHealthResearch_AntiS_SexFemale,220818_Navarre_NavarreInstituteForHealthResearch,"Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022",2022-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,Navarre,,"""The study included a sample of 1,461 people from the population of Navarre aged 5 years and older.""

""A sample of primary healthcare facilities (35/57) voluntarily recruited patients aged 5 years and older whose physicians requested a blood test for reasons unrelated to SARS-CoV-2 infection"".","""Patients with clinical manifestations of COVID-19 or close contact with a COVID-19 case in the previous 10 days, healthcare workers, nursing home residents and people not resident in the region were excluded.""",2022-04-26,2022-06-03,Residual sera,Female,Multiple groups,5.0,,Sex/Gender,,796,0.9284,,,,,,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,,Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Jesus Castilla,Navarre Institute for Health Research,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.33.2200619,2022-09-01,2024-03-01,Unverified,castilla_seroprevalence_2022,ESP
220818_Navarre_NavarreInstituteForHealthResearch_AntiS_Age5-17,220818_Navarre_NavarreInstituteForHealthResearch,"Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022",2022-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,Navarre,,"""The study included a sample of 1,461 people from the population of Navarre aged 5 years and older.""

""A sample of primary healthcare facilities (35/57) voluntarily recruited patients aged 5 years and older whose physicians requested a blood test for reasons unrelated to SARS-CoV-2 infection"".","""Patients with clinical manifestations of COVID-19 or close contact with a COVID-19 case in the previous 10 days, healthcare workers, nursing home residents and people not resident in the region were excluded.""",2022-04-26,2022-06-03,Residual sera,All,Children and Youth (0-17 years),5.0,17.0,Age,Age: 5-17,181,0.7845000000000001,,,,,,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,,Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Jesus Castilla,Navarre Institute for Health Research,Not Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2022.27.33.2200619,2022-09-01,2024-03-01,Unverified,castilla_seroprevalence_2022,ESP
220826_Spain_InstitutodeSaludCarlosIII_Overall,220826_Spain_InstitutodeSaludCarlosIII,Evolution of COVID-19 Spread in the Cohort of LaLiga Football (Soccer) Professionals between May 2020 and April 2021,2022-08-26,Preprint,National,Cross-sectional survey ,Spain,,"
","""We studied a cohort formed by a football professional PLY and STF from 20 clubs in first division and 22 in second division. The football PLY are men between 18-40 years. STF are mostly men between 18-65 years.""",,2020-05-05,2021-04-22,Non-essential workers and unemployed persons,All,Multiple groups,,,Primary Estimate,,142,0.2958,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Anti-SARS-CoV-2 ELISA IgG","Abbott Laboratories,DiaSorin,EUROIMMUN",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Unclear,Yes,No,,Marina Penuelas,Instituto de Salud Carlos III (ISCIII),Not Unity-Aligned,10.20944/preprints202208.0437.v1,2022-09-07,2024-03-01,Unverified,peñuelasEvolutionCOVID19Spread2022,ESP
220914_Sevilla_UniversidaddeCordoba_Adults_Time1,220914_Sevilla_UniversidaddeCordoba_Adults_Time1,SARS-CoV-2 Seroprevalence Study in Pediatric Patients and Health Care Workers Using Multiplex Antibody Immunoassays.,2022-09-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Sevilla,"""adults (n = 190) consisting of
HCW (n = 95) from HUVR, and their family contacts (n = 95) who agreed to participate in
the study""",,2020-04-01,2020-04-30,Multiple populations,All,Children and Youth (0-17 years),,15.0,Primary Estimate,,190,0.1937,,,True,,,,True,Convenience,"COVID-19 ELISA IgM/IgA,Author designed (Luminex)","Vircell S.L.,NA",ELISA,Plasma,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Esther Prados de la Torre,Universidad de Córdoba,Not Unity-Aligned,https://dx.doi.org/10.3390/v14092039,2022-10-17,2024-03-01,Unverified,prados_de_la_torre_sars-cov-2_2022,ESP
220914_Sevilla_UniversidaddeCordoba_Adults_Time2,220914_Sevilla_UniversidaddeCordoba_Adults_Time2,SARS-CoV-2 Seroprevalence Study in Pediatric Patients and Health Care Workers Using Multiplex Antibody Immunoassays.,2022-09-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Sevilla,"""adults (n = 190) consisting of
HCW (n = 95) from HUVR, and their family contacts (n = 95) who agreed to participate in
the study""",,2020-06-01,2020-06-30,Multiple populations,All,Children and Youth (0-17 years),,15.0,Primary Estimate,,172,0.18600000000000003,,,True,,,,True,Convenience,"COVID-19 ELISA IgM/IgA,Author designed (Luminex)","Vircell S.L.,NA",ELISA,Plasma,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Unclear,Yes,No,,Esther Prados de la Torre,Universidad de Córdoba,Not Unity-Aligned,https://dx.doi.org/10.3390/v14092039,2022-10-17,2024-03-01,Unverified,prados_de_la_torre_sars-cov-2_2022,ESP
220914_Sevilla_UniversidaddeCordoba_Children,220914_Sevilla_UniversidaddeCordoba_Children,SARS-CoV-2 Seroprevalence Study in Pediatric Patients and Health Care Workers Using Multiplex Antibody Immunoassays.,2022-09-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Sevilla,"""children < 16 years old attending the participating center
with either clinical symptoms compatible with a possible SARS-CoV-2 infection (n = 41) or close contact with a patient diagnosed with SARS-CoV-2 infection by polymerase chain reaction (PCR) and/or antigen testing (n = 16), and in whom the need to take a blood sample was anticipated based on medical reasons""",,2020-04-01,2021-09-08,Multiple populations,All,Children and Youth (0-17 years),,15.0,Primary Estimate,,57,0.5439,,,True,,,,True,Convenience,"COVID-19 ELISA IgM/IgA,Author designed (Luminex)","Vircell S.L.,NA",ELISA,Plasma,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Esther Prados de la Torre,Universidad de Córdoba,Not Unity-Aligned,https://dx.doi.org/10.3390/v14092039,2022-10-17,2024-03-01,Unverified,prados_de_la_torre_sars-cov-2_2022,ESP
220928_Asturias_CentroDeSaludLaviada_Period1,220928_Asturias_CentroDeSaludLaviada_Period1,"Variation in SARS-CoV-2 seroprevalence in children in the region of Asturias, Northern Spain.",2022-09-28,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Spain,Asturias,,"""Children aged between two days and 14 years that needed a
blood sample at the time of recruitment or that voluntarily
agreed on being part of the study, were eligible to participate.""",""" four were excluded because they
did not sign the informed consent.""",2020-07-15,2020-09-15,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),,14.0,Primary Estimate,,195,0.015,0.003,0.043,True,,,,True,Convenience,"LIAISON® SARS-CoV-2 TrimericS IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","DiaSorin,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,No,,Unclear,Yes,No,,Elisa Garcia‑Garcia,Centro De Salud Laviada,Not Unity-Aligned,https://dx.doi.org/10.1007/s12519-022-00617-2,2022-10-07,2024-03-01,Unverified,garcia-garcia_variation_2022,ESP
220928_Asturias_CentroDeSaludLaviada_Period1_Age_10-14,220928_Asturias_CentroDeSaludLaviada_Period1,"Variation in SARS-CoV-2 seroprevalence in children in the region of Asturias, Northern Spain.",2022-09-28,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Spain,Asturias,,"""Children aged between two days and 14 years that needed a
blood sample at the time of recruitment or that voluntarily
agreed on being part of the study, were eligible to participate.""",""" four were excluded because they
did not sign the informed consent.""",2020-07-15,2020-09-15,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),10.0,14.0,Age,10-14,95,0.032,0.006,0.086,,,,,,Convenience,"LIAISON® SARS-CoV-2 TrimericS IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","DiaSorin,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,No,,Unclear,Yes,No,,Elisa Garcia‑Garcia,Centro De Salud Laviada,Not Unity-Aligned,https://dx.doi.org/10.1007/s12519-022-00617-2,2022-10-07,2024-03-01,Unverified,garcia-garcia_variation_2022,ESP
220928_Asturias_CentroDeSaludLaviada_Period1_Age_5-9,220928_Asturias_CentroDeSaludLaviada_Period1,"Variation in SARS-CoV-2 seroprevalence in children in the region of Asturias, Northern Spain.",2022-09-28,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Spain,Asturias,,"""Children aged between two days and 14 years that needed a
blood sample at the time of recruitment or that voluntarily
agreed on being part of the study, were eligible to participate.""",""" four were excluded because they
did not sign the informed consent.""",2020-07-15,2020-09-15,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,63,0.0,0.0,0.057,,,,,,Convenience,"LIAISON® SARS-CoV-2 TrimericS IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","DiaSorin,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,No,,Unclear,Yes,No,,Elisa Garcia‑Garcia,Centro De Salud Laviada,Not Unity-Aligned,https://dx.doi.org/10.1007/s12519-022-00617-2,2022-10-07,2024-03-01,Unverified,garcia-garcia_variation_2022,ESP
220928_Asturias_CentroDeSaludLaviada_Period1_Age_0-4,220928_Asturias_CentroDeSaludLaviada_Period1,"Variation in SARS-CoV-2 seroprevalence in children in the region of Asturias, Northern Spain.",2022-09-28,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Spain,Asturias,,"""Children aged between two days and 14 years that needed a
blood sample at the time of recruitment or that voluntarily
agreed on being part of the study, were eligible to participate.""",""" four were excluded because they
did not sign the informed consent.""",2020-07-15,2020-09-15,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),0.0,4.0,Age,0-4,37,0.0,0.0,0.09300000000000001,,,,,,Convenience,"LIAISON® SARS-CoV-2 TrimericS IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","DiaSorin,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,No,,Unclear,Yes,No,,Elisa Garcia‑Garcia,Centro De Salud Laviada,Not Unity-Aligned,https://dx.doi.org/10.1007/s12519-022-00617-2,2022-10-07,2024-03-01,Unverified,garcia-garcia_variation_2022,ESP
220928_Asturias_CentroDeSaludLaviada_Period2,220928_Asturias_CentroDeSaludLaviada_Period2,"Variation in SARS-CoV-2 seroprevalence in children in the region of Asturias, Northern Spain.",2022-09-28,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Spain,Asturias,,"""Children aged between two days and 14 years that needed a
blood sample at the time of recruitment or that voluntarily
agreed on being part of the study, were eligible to participate.""",""" four were excluded because they
did not sign the informed consent.""",2021-01-15,2021-03-15,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),,14.0,Primary Estimate,,176,0.091,0.046,0.127,True,,,,True,Convenience,"LIAISON® SARS-CoV-2 TrimericS IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","DiaSorin,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,No,,Unclear,Yes,No,,Elisa Garcia‑Garcia,Centro De Salud Laviada,Not Unity-Aligned,https://dx.doi.org/10.1007/s12519-022-00617-2,2022-10-07,2024-03-01,Unverified,garcia-garcia_variation_2022,ESP
220928_Asturias_CentroDeSaludLaviada_Period2_Age_10-14,220928_Asturias_CentroDeSaludLaviada_Period2,"Variation in SARS-CoV-2 seroprevalence in children in the region of Asturias, Northern Spain.",2022-09-28,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Spain,Asturias,,"""Children aged between two days and 14 years that needed a
blood sample at the time of recruitment or that voluntarily
agreed on being part of the study, were eligible to participate.""",""" four were excluded because they
did not sign the informed consent.""",2021-01-15,2021-03-15,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),10.0,14.0,Age,10-14,91,0.08800000000000001,0.036000000000000004,0.153,,,,,,Convenience,"LIAISON® SARS-CoV-2 TrimericS IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","DiaSorin,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,No,,Unclear,Yes,No,,Elisa Garcia‑Garcia,Centro De Salud Laviada,Not Unity-Aligned,https://dx.doi.org/10.1007/s12519-022-00617-2,2022-10-07,2024-03-01,Unverified,garcia-garcia_variation_2022,ESP
220928_Asturias_CentroDeSaludLaviada_Period2_Age_0-4,220928_Asturias_CentroDeSaludLaviada_Period2,"Variation in SARS-CoV-2 seroprevalence in children in the region of Asturias, Northern Spain.",2022-09-28,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Spain,Asturias,,"""Children aged between two days and 14 years that needed a
blood sample at the time of recruitment or that voluntarily
agreed on being part of the study, were eligible to participate.""",""" four were excluded because they
did not sign the informed consent.""",2021-01-15,2021-03-15,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),0.0,4.0,Age,0-4,32,0.125,0.028999999999999998,0.24800000000000003,,,,,,Convenience,"LIAISON® SARS-CoV-2 TrimericS IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","DiaSorin,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,No,,Unclear,Yes,No,,Elisa Garcia‑Garcia,Centro De Salud Laviada,Not Unity-Aligned,https://dx.doi.org/10.1007/s12519-022-00617-2,2022-10-07,2024-03-01,Unverified,garcia-garcia_variation_2022,ESP
220928_Asturias_CentroDeSaludLaviada_Period2_Age_5-9,220928_Asturias_CentroDeSaludLaviada_Period2,"Variation in SARS-CoV-2 seroprevalence in children in the region of Asturias, Northern Spain.",2022-09-28,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Spain,Asturias,,"""Children aged between two days and 14 years that needed a
blood sample at the time of recruitment or that voluntarily
agreed on being part of the study, were eligible to participate.""",""" four were excluded because they
did not sign the informed consent.""",2021-01-15,2021-03-15,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,53,0.076,0.018000000000000002,0.155,,,,,,Convenience,"LIAISON® SARS-CoV-2 TrimericS IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","DiaSorin,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,No,,Unclear,Yes,No,,Elisa Garcia‑Garcia,Centro De Salud Laviada,Not Unity-Aligned,https://dx.doi.org/10.1007/s12519-022-00617-2,2022-10-07,2024-03-01,Unverified,garcia-garcia_variation_2022,ESP
220928_Asturias_CentroDeSaludLaviada_Period3,220928_Asturias_CentroDeSaludLaviada_Period3,"Variation in SARS-CoV-2 seroprevalence in children in the region of Asturias, Northern Spain.",2022-09-28,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Spain,Asturias,,"""Children aged between two days and 14 years that needed a
blood sample at the time of recruitment or that voluntarily
agreed on being part of the study, were eligible to participate.""",""" four were excluded because they
did not sign the informed consent.""",2021-07-15,2021-09-15,Residual sera,All,Children and Youth (0-17 years),,14.0,Primary Estimate,,169,0.166,0.095,0.196,True,,,,True,Convenience,"LIAISON® SARS-CoV-2 TrimericS IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","DiaSorin,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,No,,Unclear,Yes,No,,Elisa Garcia‑Garcia,Centro De Salud Laviada,Not Unity-Aligned,https://dx.doi.org/10.1007/s12519-022-00617-2,2022-10-07,2024-03-01,Unverified,garcia-garcia_variation_2022,ESP
220928_Asturias_CentroDeSaludLaviada_Period3_Age_5-9,220928_Asturias_CentroDeSaludLaviada_Period3,"Variation in SARS-CoV-2 seroprevalence in children in the region of Asturias, Northern Spain.",2022-09-28,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Spain,Asturias,,"""Children aged between two days and 14 years that needed a
blood sample at the time of recruitment or that voluntarily
agreed on being part of the study, were eligible to participate.""",""" four were excluded because they
did not sign the informed consent.""",2021-07-15,2021-09-15,Residual sera,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,52,0.135,0.046,0.21600000000000003,,,,,,Convenience,"LIAISON® SARS-CoV-2 TrimericS IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","DiaSorin,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,No,,Unclear,Yes,No,,Elisa Garcia‑Garcia,Centro De Salud Laviada,Not Unity-Aligned,https://dx.doi.org/10.1007/s12519-022-00617-2,2022-10-07,2024-03-01,Unverified,garcia-garcia_variation_2022,ESP
220928_Asturias_CentroDeSaludLaviada_Period3_Age_0-4,220928_Asturias_CentroDeSaludLaviada_Period3,"Variation in SARS-CoV-2 seroprevalence in children in the region of Asturias, Northern Spain.",2022-09-28,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Spain,Asturias,,"""Children aged between two days and 14 years that needed a
blood sample at the time of recruitment or that voluntarily
agreed on being part of the study, were eligible to participate.""",""" four were excluded because they
did not sign the informed consent.""",2021-07-15,2021-09-15,Residual sera,All,Children and Youth (0-17 years),0.0,4.0,Age,0-4,29,0.31,0.114,0.402,,,,,,Convenience,"LIAISON® SARS-CoV-2 TrimericS IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","DiaSorin,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,No,,Unclear,Yes,No,,Elisa Garcia‑Garcia,Centro De Salud Laviada,Not Unity-Aligned,https://dx.doi.org/10.1007/s12519-022-00617-2,2022-10-07,2024-03-01,Unverified,garcia-garcia_variation_2022,ESP
220928_Asturias_CentroDeSaludLaviada_Period3_Age_10-14,220928_Asturias_CentroDeSaludLaviada_Period3,"Variation in SARS-CoV-2 seroprevalence in children in the region of Asturias, Northern Spain.",2022-09-28,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Spain,Asturias,,"""Children aged between two days and 14 years that needed a
blood sample at the time of recruitment or that voluntarily
agreed on being part of the study, were eligible to participate.""",""" four were excluded because they
did not sign the informed consent.""",2021-07-15,2021-09-15,Residual sera,All,Children and Youth (0-17 years),10.0,14.0,Age,10-14,88,0.136,0.064,0.20199999999999999,,,,,,Convenience,"LIAISON® SARS-CoV-2 TrimericS IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","DiaSorin,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,No,,Unclear,Yes,No,,Elisa Garcia‑Garcia,Centro De Salud Laviada,Not Unity-Aligned,https://dx.doi.org/10.1007/s12519-022-00617-2,2022-10-07,2024-03-01,Unverified,garcia-garcia_variation_2022,ESP
221020_Madrid_AlfonsoXElSabioUniversity,221020_Madrid_AlfonsoXElSabioUniversity,Seroprevalence of SARS-CoV-2 in a Fully Operative Dentistry Academic Center in Madrid (Spain) During the De-escalation Phase of the COVID-19 Pandemic. Are Our Dentists at Greater Risk?.,2022-10-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,"""The study evaluated the seroprevalence for SARS-CoV-2 in
the staff (administrative and dental personnel) of a University Dental Clinic (The Dental Center for Innovation and Advanced Specialties, Universidad Alfonso X el Sabio) located in Madrid (Spain), which serves approximately 40,000 patients per year. The group of dentists included professionals from the areas of oral surgery, orthodontics, endodontics,
and paediatric dentistry.""",,2020-05-11,2020-06-05,Health care workers and caregivers,All,Multiple groups,23.0,70.0,Primary Estimate,,195,0.2,,,True,,,,True,Convenience,"Author designed (type unknown),Sienna™ 2019-nCoV IgG/IgM Rapid Test Cassette","NA,T&D Diagnostics",Multiple Types,Multiple Types,"['IgG', 'IgM']",,,,,['High'],,No,No,Yes,,Unclear,No,No,,Patricia Cintora  ,Alfonso X El Sabio University,Not Unity-Aligned,https://dx.doi.org/10.3290/j.ohpd.b3464887,2022-10-26,2022-10-28,Unverified,cintora_seroprevalence_2022,ESP
221117_Catalonia_GovernmentOfCatalonia_Staff_PopAdj,221117_Catalonia_GovernmentOfCatalonia_Staff,The COVID-19 Sentinel Schools Network of Catalonia (CSSNC) project: Associated factors to prevalence and incidence of SARS-CoV-2 infection in educational settings during the 2020-2021 academic year,2022-11-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Spain,Catalonia,,"""In this study, were included 2,007 students and 520 school staff (teaching and non-teaching staff, such as extracurricular education instructors and administrative personal) who previously signed the informed consent, from seven schools all over Catalonia.""

""The cross-sectional component included students aged 3–19 from preschool (3–5 yearold), elementary school (7–10 year-old), middle school (12–15 year-old), high school (16–17 year-old) and vocational training (17–19 year-old) and school staff.""","""For at risk of infection we excluded individuals with RT-PCR or RAT positive result in the previous 60 days before started the cohort.""",2021-02-22,2021-03-22,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,pop adjusted estimate,520,0.226,0.19,0.267,True,,True,,,Convenience,Not reported/ Unable to specify,,LFIA,,"['IgG', 'IgM']",[],Validated by manufacturers,0.9720000000000001,0.8790000000000001,['High'],,No,No,Yes,,Unclear,Yes,No,,Fabiana Ganem,Government of Catalonia,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0277764,2022-12-13,2023-03-19,Unverified,ganem_covid-19_2022,ESP
221117_Catalonia_GovernmentOfCatalonia_Students_PopAdj,221117_Catalonia_GovernmentOfCatalonia_Students,The COVID-19 Sentinel Schools Network of Catalonia (CSSNC) project: Associated factors to prevalence and incidence of SARS-CoV-2 infection in educational settings during the 2020-2021 academic year,2022-11-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Spain,Catalonia,,"""In this study, were included 2,007 students and 520 school staff (teaching and non-teaching staff, such as extracurricular education instructors and administrative personal) who previously signed the informed consent, from seven schools all over Catalonia.""

""The cross-sectional component included students aged 3–19 from preschool (3–5 yearold), elementary school (7–10 year-old), middle school (12–15 year-old), high school (16–17 year-old) and vocational training (17–19 year-old) and school staff.""","""For at risk of infection we excluded individuals with RT-PCR or RAT positive result in the previous 60 days before started the cohort.""",2021-02-22,2021-03-22,Students and Daycares,All,Children and Youth (0-17 years),3.0,19.0,Primary Estimate,pop adjusted estimate,2007,0.152,0.135,0.17,True,,True,,,Convenience,Not reported/ Unable to specify,,LFIA,,"['IgG', 'IgM']",[],Validated by manufacturers,0.9720000000000001,0.8790000000000001,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Fabiana Ganem,Government of Catalonia,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0277764,2022-12-13,2023-03-19,Unverified,ganem_covid-19_2022,ESP
221123_Madrid_LaPazUniversityHospital,221123_Madrid_LaPazUniversityHospital,Humoral and cellular immune responses to Pfizer-BioNTech BNT162b2 SARS-CoV-2 vaccine in adolescents with liver transplantation: Single center experience,2022-11-23,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Spain,,Madrid,"""Our cohort included 33 adolescents and young-adult liver transplanted patients (age 11-21 years, median 16) in the long- term follow-up (9.9 ± 5.7 years, median 12) from La Paz University Hospital, Madrid (Spain). ""","""Before sample extraction, one patient was infected with SARS-CoV-2 and, consequently, was excluded from the study""
",,2021-05-15,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),11.0,21.0,Primary Estimate,,32,0.063,,,True,,,,True,Convenience,EliA SARS-CoV-2-Sp1 IgG Test,Thermo Fisher Scientific,ELISA,Plasma,IgG,Spike,,,,['High'],,No,No,No,,Unclear,Yes,No,,Elena Sanchez-Zapardiel,La Paz University Hospital,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2022.1049188,2023-01-06,2023-03-19,Unverified,sánchez-zapardielHumoralCellularImmune2022,ESP
230109_Barcelona_UniversitatdeBarcelona_Month0,230109_Barcelona_UniversitatdeBarcelona,RBD-Based ELISA and Luminex Predict Anti-SARS-CoV-2 Surrogate-Neutralizing Activity in Two Longitudinal Cohorts of German and Spanish Health Care Workers.,2023-01-09,Journal Article (Peer-Reviewed),Local,Prospective cohort,Spain,,Barcelona,"A total of 578 randomly selected HCW were recruited during the first wave of the COVID-19 pandemic in spring 2020 in the Hospital Clínic de Barcelona in Spain within the SEROCOV
study.",,2020-04-01,2020-04-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,month 0 test result using Luminex,580,0.138,,,True,,,,True,Simplified probability,Author designed (Luminex),,Luminex,Plasma,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.9578,1.0,['Moderate'],,Yes,No,Yes,,Unclear,Yes,Yes,,Ruth Aguilar,"Universitat de Barcelona, Technical University of Munich",Not Unity-Aligned,https://dx.doi.org/10.1128/spectrum.03165-22,2023-01-24,2023-03-19,Unverified,aguilar_rbd-based_2023,ESP
230127_Madrid_AlcorcónFoundationUniversityHospital,230127_Madrid_AlcorcónFoundationUniversityHospital,Seroprevalence of SARS-CoV2 Infections in Health Care Personnel in a Long-Term Care Institution After the First Wave of the Pandemic: A Cross-Sectional Study.,2023-01-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,HCWs at Virgen de la Poveda Hospital,,2020-04-30,2020-05-19,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,580,0.2845,,,True,,,,True,Convenience,Biozek Medical COVID-19 Rapid Test,Biozek,LFIA,,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.923,0.99,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Luis Alfredo Bautista Balbas,Alcorcón Foundation University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1177/21650799221135587,2023-03-10,2024-03-01,Unverified,balbas_seroprevalence_2023,ESP
230301_Asturias_CentrodeSaludLaviada_Round1,230301_Asturias_CentrodeSaludLaviada,Household Transmission of SARS-CoV-2 and Long-term Immunity in Children: A Prospective Study in Northern Spain.,2023-03-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,Asturias,,"""from public hospitals and primary healthcare centers. Children, between 2 days and 14 years old who required a blood sample at the time of recruitment or voluntarily agreed to participate in the study,""","""4 were excluded because they did not sign the informed consent""",2020-07-15,2020-09-15,Residual sera,All,Children and Youth (0-17 years),0.0,14.0,Primary Estimate,July to September 2020,195,0.018,0.004,0.051,True,True,,,True,Convenience,"LIAISON® SARS-CoV-2 TrimericS IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","DiaSorin,Roche Diagnostics",CLIA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Elisa Garcia-Garcia,Centro de Salud Laviada,Not Unity-Aligned,https://dx.doi.org/10.1097/INF.0000000000003790,2023-03-10,2023-03-19,Unverified,garcía-garcía_hohusehold_2023,ESP
230301_Asturias_CentrodeSaludLaviada_Round3,230301_Asturias_CentrodeSaludLaviada,Household Transmission of SARS-CoV-2 and Long-term Immunity in Children: A Prospective Study in Northern Spain.,2023-03-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,Asturias,,"""from public hospitals and primary healthcare centers. Children, between 2 days and 14 years old who required a blood sample at the time of recruitment or voluntarily agreed to participate in the study,""","""4 were excluded because they did not sign the informed consent""",2021-07-15,2021-09-15,Residual sera,All,Children and Youth (0-17 years),0.0,14.0,Time frame,July to September 2021,169,0.195,0.112,0.231,,True,,,True,Convenience,"LIAISON® SARS-CoV-2 TrimericS IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","DiaSorin,Roche Diagnostics",CLIA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Elisa Garcia-Garcia,Centro de Salud Laviada,Not Unity-Aligned,https://dx.doi.org/10.1097/INF.0000000000003790,2023-03-10,2023-03-19,Unverified,garcía-garcía_hohusehold_2023,ESP
230301_Asturias_CentrodeSaludLaviada_Round2,230301_Asturias_CentrodeSaludLaviada,Household Transmission of SARS-CoV-2 and Long-term Immunity in Children: A Prospective Study in Northern Spain.,2023-03-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Spain,Asturias,,"""from public hospitals and primary healthcare centers. Children, between 2 days and 14 years old who required a blood sample at the time of recruitment or voluntarily agreed to participate in the study,""","""4 were excluded because they did not sign the informed consent""",2021-01-15,2021-03-15,Residual sera,All,Children and Youth (0-17 years),0.0,14.0,Time frame,January to March 2021,176,0.107,0.054,0.149,,True,,,True,Convenience,"LIAISON® SARS-CoV-2 TrimericS IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","DiaSorin,Roche Diagnostics",CLIA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Elisa Garcia-Garcia,Centro de Salud Laviada,Not Unity-Aligned,https://dx.doi.org/10.1097/INF.0000000000003790,2023-03-10,2023-03-19,Unverified,garcía-garcía_hohusehold_2023,ESP
230308_Spain_UniversitatdeBarcelona,230308_Spain_UniversitatdeBarcelona,"Seroprevalence and socioeconomic impact of the first SARS-CoV-2 infection wave in a small town in Navarre, Spain.",2023-03-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Cizur,"""The inclusion criterion was being a resident of the municipality of Cendea de Cizur who signed-up for the survey. ""","""Exclusion criteria were: (i) being absent from the household at the time of the visit, (ii) not answering the phone after five attempts in at least two different days at different daytimes. """,2020-06-12,2020-06-19,Household and community samples,All,Multiple groups,,,Primary Estimate,,728,0.079,0.073,0.086,True,,,,True,Convenience,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Plasma,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.83,0.95,['Missing'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Unclear,Marta Ribes,Universitat de Barcelona,Unity-Aligned,https://dx.doi.org/10.1038/s41598-023-30542-x,2023-04-03,2024-03-28,Verified,ribesSeroprevalenceSocioeconomicImpact2023,ESP
230308_Spain_UniversitatdeBarcelona_0-10,230308_Spain_UniversitatdeBarcelona,"Seroprevalence and socioeconomic impact of the first SARS-CoV-2 infection wave in a small town in Navarre, Spain.",2023-03-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Cizur,"""The inclusion criterion was being a resident of the municipality of Cendea de Cizur who signed-up for the survey. ""","""Exclusion criteria were: (i) being absent from the household at the time of the visit, (ii) not answering the phone after five attempts in at least two different days at different daytimes. """,2020-06-12,2020-06-19,Household and community samples,All,Children and Youth (0-17 years),,10.0,Age,0-10,142,0.021,0.015,0.03,,,,,,Convenience,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Plasma,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.83,0.95,['Missing'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Unclear,Marta Ribes,Universitat de Barcelona,Unity-Aligned,https://dx.doi.org/10.1038/s41598-023-30542-x,2024-03-28,2024-03-28,Verified,ribesSeroprevalenceSocioeconomicImpact2023,ESP
230308_Spain_UniversitatdeBarcelona_21-50,230308_Spain_UniversitatdeBarcelona,"Seroprevalence and socioeconomic impact of the first SARS-CoV-2 infection wave in a small town in Navarre, Spain.",2023-03-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Cizur,"""The inclusion criterion was being a resident of the municipality of Cendea de Cizur who signed-up for the survey. ""","""Exclusion criteria were: (i) being absent from the household at the time of the visit, (ii) not answering the phone after five attempts in at least two different days at different daytimes. """,2020-06-12,2020-06-19,Household and community samples,All,Adults (18-64 years),21.0,30.0,Age,21-50,177,0.079,0.067,0.092,,,,,,Convenience,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Plasma,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.83,0.95,['Missing'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Unclear,Marta Ribes,Universitat de Barcelona,Unity-Aligned,https://dx.doi.org/10.1038/s41598-023-30542-x,2024-03-28,2024-03-28,Verified,ribesSeroprevalenceSocioeconomicImpact2023,ESP
230308_Spain_UniversitatdeBarcelona_51-65,230308_Spain_UniversitatdeBarcelona,"Seroprevalence and socioeconomic impact of the first SARS-CoV-2 infection wave in a small town in Navarre, Spain.",2023-03-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Cizur,"""The inclusion criterion was being a resident of the municipality of Cendea de Cizur who signed-up for the survey. ""","""Exclusion criteria were: (i) being absent from the household at the time of the visit, (ii) not answering the phone after five attempts in at least two different days at different daytimes. """,2020-06-12,2020-06-19,Household and community samples,All,Adults (18-64 years),51.0,65.0,Age,51-65,157,0.089,0.076,0.092,,,,,,Convenience,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Plasma,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.83,0.95,['Missing'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Unclear,Marta Ribes,Universitat de Barcelona,Unity-Aligned,https://dx.doi.org/10.1038/s41598-023-30542-x,2024-03-28,2024-03-28,Verified,ribesSeroprevalenceSocioeconomicImpact2023,ESP
230308_Spain_UniversitatdeBarcelona_11-20,230308_Spain_UniversitatdeBarcelona,"Seroprevalence and socioeconomic impact of the first SARS-CoV-2 infection wave in a small town in Navarre, Spain.",2023-03-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Cizur,"""The inclusion criterion was being a resident of the municipality of Cendea de Cizur who signed-up for the survey. ""","""Exclusion criteria were: (i) being absent from the household at the time of the visit, (ii) not answering the phone after five attempts in at least two different days at different daytimes. """,2020-06-12,2020-06-19,Household and community samples,All,Multiple groups,11.0,20.0,Age,11-20,159,0.113,0.099,0.13,,,,,,Convenience,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Plasma,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.83,0.95,['Missing'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Unclear,Marta Ribes,Universitat de Barcelona,Unity-Aligned,https://dx.doi.org/10.1038/s41598-023-30542-x,2024-03-28,2024-03-28,Verified,ribesSeroprevalenceSocioeconomicImpact2023,ESP
230308_Spain_UniversitatdeBarcelona_>65,230308_Spain_UniversitatdeBarcelona,"Seroprevalence and socioeconomic impact of the first SARS-CoV-2 infection wave in a small town in Navarre, Spain.",2023-03-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Cizur,"""The inclusion criterion was being a resident of the municipality of Cendea de Cizur who signed-up for the survey. ""","""Exclusion criteria were: (i) being absent from the household at the time of the visit, (ii) not answering the phone after five attempts in at least two different days at different daytimes. """,2020-06-12,2020-06-19,Household and community samples,All,Seniors (65+ years),66.0,,Age,>65,93,0.075,0.06,0.093,,,,,,Convenience,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Plasma,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.83,0.95,['Missing'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,Unclear,Marta Ribes,Universitat de Barcelona,Unity-Aligned,https://dx.doi.org/10.1038/s41598-023-30542-x,2024-03-28,2024-03-28,Verified,ribesSeroprevalenceSocioeconomicImpact2023,ESP
230309_Spain_InstitutodeSaludCarlosIII_Primary,230309_Spain_InstitutodeSaludCarlosIII,SARS-CoV-2 Infection During the First and Second Pandemic Waves in Spain: the ENE-COVID Study,2023-03-09,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Spain,,,None listed - sounds like everyone sampled was eligible?,None listed,2020-04-27,2020-06-22,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,68287,0.06,0.057,0.064,True,,,,True,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.82,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Beatriz Perez-Gomez ,Instituto de Salud Carlos III,Unity-Aligned,https://dx.doi.org/10.2105/AJPH.2023.307233,2023-04-03,2024-04-12,Verified,perez-gomez_sars-cov-2_2023,ESP
230309_Spain_InstitutodeSaludCarlosIII_0-19,230309_Spain_InstitutodeSaludCarlosIII,SARS-CoV-2 Infection During the First and Second Pandemic Waves in Spain: the ENE-COVID Study,2023-03-09,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Spain,,,None listed - sounds like everyone sampled was eligible?,None listed,2020-04-27,2020-06-22,Household and community samples,All,Children and Youth (0-17 years),0.0,19.0,Age,0-19,12581,0.04,0.035,0.045,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.82,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Beatriz Perez-Gomez ,Instituto de Salud Carlos III,Unity-Aligned,https://dx.doi.org/10.2105/AJPH.2023.307233,2024-04-12,2024-04-12,Verified,perez-gomez_sars-cov-2_2023,ESP
230309_Spain_InstitutodeSaludCarlosIII_50-64,230309_Spain_InstitutodeSaludCarlosIII,SARS-CoV-2 Infection During the First and Second Pandemic Waves in Spain: the ENE-COVID Study,2023-03-09,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Spain,,,None listed - sounds like everyone sampled was eligible?,None listed,2020-04-27,2020-06-22,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50-64,16799,0.072,0.066,0.078,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.82,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Beatriz Perez-Gomez ,Instituto de Salud Carlos III,Unity-Aligned,https://dx.doi.org/10.2105/AJPH.2023.307233,2024-04-12,2024-04-12,Verified,perez-gomez_sars-cov-2_2023,ESP
230309_Spain_InstitutodeSaludCarlosIII_35-49,230309_Spain_InstitutodeSaludCarlosIII,SARS-CoV-2 Infection During the First and Second Pandemic Waves in Spain: the ENE-COVID Study,2023-03-09,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Spain,,,None listed - sounds like everyone sampled was eligible?,None listed,2020-04-27,2020-06-22,Household and community samples,All,Adults (18-64 years),35.0,49.0,Age,35-49,16051,0.064,0.058,0.07,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.82,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Beatriz Perez-Gomez ,Instituto de Salud Carlos III,Unity-Aligned,https://dx.doi.org/10.2105/AJPH.2023.307233,2024-04-12,2024-04-12,Verified,perez-gomez_sars-cov-2_2023,ESP
230309_Spain_InstitutodeSaludCarlosIII_65+,230309_Spain_InstitutodeSaludCarlosIII,SARS-CoV-2 Infection During the First and Second Pandemic Waves in Spain: the ENE-COVID Study,2023-03-09,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Spain,,,None listed - sounds like everyone sampled was eligible?,None listed,2020-04-27,2020-06-22,Household and community samples,All,Seniors (65+ years),65.0,,Age,65+,13304,0.073,0.066,0.08,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.82,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Beatriz Perez-Gomez ,Instituto de Salud Carlos III,Unity-Aligned,https://dx.doi.org/10.2105/AJPH.2023.307233,2024-04-12,2024-04-12,Verified,perez-gomez_sars-cov-2_2023,ESP
230309_Spain_InstitutodeSaludCarlosIII_20-34,230309_Spain_InstitutodeSaludCarlosIII,SARS-CoV-2 Infection During the First and Second Pandemic Waves in Spain: the ENE-COVID Study,2023-03-09,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Spain,,,None listed - sounds like everyone sampled was eligible?,None listed,2020-04-27,2020-06-22,Household and community samples,All,Adults (18-64 years),20.0,34.0,Age,20-34,9552,0.051,0.044,0.058,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.82,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Beatriz Perez-Gomez ,Instituto de Salud Carlos III,Unity-Aligned,https://dx.doi.org/10.2105/AJPH.2023.307233,2024-04-12,2024-04-12,Verified,perez-gomez_sars-cov-2_2023,ESP
230423_Madrid_OrganismoAutónomoMadridSalud_Primary,230423_Madrid_OrganismoAutónomoMadridSalud,SARS-CoV-2 Infection in Patients With or at Risk for Sexually Transmitted Infections: Incidence and Associated Factors in a Sexual Health Clinic.,2023-04-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,"Observational cross-sectional study that included all those patients older than 18 years attended in the STI monographic consultation (for study or screening, regardless of the presence or not of STI symptoms), not vaccinated against COVID-19, who signed a consent for their inclusion in the period from March 10 to April 21, 2021.",refused to participate,2021-03-10,2021-04-21,Blood donors,All,Adults (18-64 years),18.0,,Primary Estimate,unadjusted overall estimate,512,0.242,,,True,,,,True,Sequential,COVID-19 IgG IgM Antibody Rapid Test Kit (Colloidal Gold),JOYSBIO,LFIA,Dried Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.924,0.944,['Moderate'],,No,Yes,Yes,,No,Yes,No,,A. Martin-Gorgojo,Organismo Autónomo Madrid Salud,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ad.2023.04.017,2023-05-29,2024-03-01,Unverified,martin-gorgojo_infección_2023,ESP
230229_Madrid_LaPazUniversityHospital,230229_Madrid_LaPazUniversityHospital,Seroprevalence of ANTI-SARS-CoV-2 antibodies in patients with inflammatory bowel disease,2023-04-29,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Spain,,Madrid,"""Patients with IBD under follow-up in our unit and with scheduled on-site visits were included""","""Patients who had received any dose of COVID-19 vaccine were not included. """,2021-02-26,2021-03-26,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),,,Primary Estimate,,392,0.1765,,,True,,,,True,Convenience,"Atellica® IM SARS-CoV-2 Total (COV2T),COVID-19 VIRCLIA IgG MONOTEST","Siemens,Vircell S.L.",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Yes,Yes,No,,M. D. Martin-Arranz,La Paz University Hospital,Not Unity-Aligned,https://www.nature.com/articles/s41598-023-33402-w,2023-05-31,2024-03-01,Unverified,martin-arranzSeroprevalenceANTISARSCoV2Antibodies2023,ESP
230518_Valencia_FISABIO_Overall,230518_Valencia_FISABIO,Seroprevalence of antibodies against SARS-CoV-2 in the Valencian Community (Spain) as of October 2022,2023-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Valencia,"Cross-sectional, region-wide, population-based study using
residual blood samples, conducted in randomly selected primary
care centers (PCC)",,2022-10-01,2022-10-31,Residual sera,All,Multiple groups,,,Primary Estimate,,785,0.984,0.975,0.993,True,,True,,True,Sequential,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,"CLIA, CMIA,CLIA, CMIA",,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,No,Yes,Anibal Garcia-Sempere,Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO),Unity-Aligned,https://dx.doi.org/10.1016/j.gaceta.2023.102312,2023-07-29,2024-05-01,Verified,garcia-sempere_seroprevalence_2023,ESP
230518_Valencia_FISABIO_Age_0-9,230518_Valencia_FISABIO,Seroprevalence of antibodies against SARS-CoV-2 in the Valencian Community (Spain) as of October 2022,2023-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Valencia,"Cross-sectional, region-wide, population-based study using
residual blood samples, conducted in randomly selected primary
care centers (PCC)",,2022-10-01,2022-10-31,Residual sera,All,Children and Youth (0-17 years),,,Age,0-9 years,56,0.911,0.804,0.97,,,,,,Sequential,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,"CLIA, CMIA,CLIA, CMIA",,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,No,Yes,Anibal Garcia-Sempere,Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO),Unity-Aligned,https://dx.doi.org/10.1016/j.gaceta.2023.102312,2024-05-01,2024-05-01,Verified,garcia-sempere_seroprevalence_2023,ESP
230518_Valencia_FISABIO_Age_10-19,230518_Valencia_FISABIO,Seroprevalence of antibodies against SARS-CoV-2 in the Valencian Community (Spain) as of October 2022,2023-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Valencia,"Cross-sectional, region-wide, population-based study using
residual blood samples, conducted in randomly selected primary
care centers (PCC)",,2022-10-01,2022-10-31,Residual sera,All,Children and Youth (0-17 years),,,Age,10-19 years,59,1.0,0.939,1.0,,,,,,Sequential,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,"CLIA, CMIA,CLIA, CMIA",,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,No,Yes,Anibal Garcia-Sempere,Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO),Unity-Aligned,https://dx.doi.org/10.1016/j.gaceta.2023.102312,2024-05-01,2024-05-01,Verified,garcia-sempere_seroprevalence_2023,ESP
230518_Valencia_FISABIO_Age_80+,230518_Valencia_FISABIO,Seroprevalence of antibodies against SARS-CoV-2 in the Valencian Community (Spain) as of October 2022,2023-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Valencia,"Cross-sectional, region-wide, population-based study using
residual blood samples, conducted in randomly selected primary
care centers (PCC)",,2022-10-01,2022-10-31,Residual sera,All,Seniors (65+ years),,,Age,80+ years,111,0.982,0.936,0.998,,,,,,Sequential,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,"CLIA, CMIA,CLIA, CMIA",,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,No,Yes,Anibal Garcia-Sempere,Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO),Unity-Aligned,https://dx.doi.org/10.1016/j.gaceta.2023.102312,2024-05-01,2024-05-01,Verified,garcia-sempere_seroprevalence_2023,ESP
230518_Valencia_FISABIO_Age_65-79,230518_Valencia_FISABIO,Seroprevalence of antibodies against SARS-CoV-2 in the Valencian Community (Spain) as of October 2022,2023-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Valencia,"Cross-sectional, region-wide, population-based study using
residual blood samples, conducted in randomly selected primary
care centers (PCC)",,2022-10-01,2022-10-31,Residual sera,All,Seniors (65+ years),,,Age,65-79 years,140,0.979,0.939,0.996,,,,,,Sequential,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,"CLIA, CMIA,CLIA, CMIA",,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,No,Yes,Anibal Garcia-Sempere,Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO),Unity-Aligned,https://dx.doi.org/10.1016/j.gaceta.2023.102312,2024-05-01,2024-05-01,Verified,garcia-sempere_seroprevalence_2023,ESP
230518_Valencia_FISABIO_Age_50-64,230518_Valencia_FISABIO,Seroprevalence of antibodies against SARS-CoV-2 in the Valencian Community (Spain) as of October 2022,2023-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Valencia,"Cross-sectional, region-wide, population-based study using
residual blood samples, conducted in randomly selected primary
care centers (PCC)",,2022-10-01,2022-10-31,Residual sera,All,Adults (18-64 years),,,Age,50-64 years,156,1.0,0.977,1.0,,,,,,Sequential,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,"CLIA, CMIA,CLIA, CMIA",,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,No,Yes,Anibal Garcia-Sempere,Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO),Unity-Aligned,https://dx.doi.org/10.1016/j.gaceta.2023.102312,2024-05-01,2024-05-01,Verified,garcia-sempere_seroprevalence_2023,ESP
230518_Valencia_FISABIO_Age_35-49,230518_Valencia_FISABIO,Seroprevalence of antibodies against SARS-CoV-2 in the Valencian Community (Spain) as of October 2022,2023-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Valencia,"Cross-sectional, region-wide, population-based study using
residual blood samples, conducted in randomly selected primary
care centers (PCC)",,2022-10-01,2022-10-31,Residual sera,All,Adults (18-64 years),,,Age,35-49 years,145,0.986,0.951,0.998,,,,,,Sequential,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,"CLIA, CMIA,CLIA, CMIA",,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,No,Yes,Anibal Garcia-Sempere,Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO),Unity-Aligned,https://dx.doi.org/10.1016/j.gaceta.2023.102312,2024-05-01,2024-05-01,Verified,garcia-sempere_seroprevalence_2023,ESP
230518_Valencia_FISABIO_Age_20-34,230518_Valencia_FISABIO,Seroprevalence of antibodies against SARS-CoV-2 in the Valencian Community (Spain) as of October 2022,2023-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Valencia,"Cross-sectional, region-wide, population-based study using
residual blood samples, conducted in randomly selected primary
care centers (PCC)",,2022-10-01,2022-10-31,Residual sera,All,Adults (18-64 years),,,Age,20-34 years,118,0.992,0.954,0.999,,,,,,Sequential,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,"CLIA, CMIA,CLIA, CMIA",,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,No,Yes,Anibal Garcia-Sempere,Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO),Unity-Aligned,https://dx.doi.org/10.1016/j.gaceta.2023.102312,2024-05-01,2024-05-01,Verified,garcia-sempere_seroprevalence_2023,ESP
230613_Catalonia_ConsorciSanitaridelMaresme_baseline,230613_Catalonia_ConsorciSanitaridelMaresme_baseline,Prevalence and risk factors of SARS-CoV-2 antibody responses among healthcare workers (June 2020-November 2021).,2023-06-13,Journal Article (Peer-Reviewed),Local,Prospective cohort,Spain,,Catalonia,"""This observational and prospective study followed the cohort of all 2455 active CSdM workers from June 2020 to November 2021. """,,2020-06-01,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1962,0.118,0.104,0.132,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),COVID-19 ELISA IgM/IgA","Roche Diagnostics,Vircell S.L.",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.995,['High'],,No,Yes,Yes,,No,Yes,Yes,,Maria Pilar Barrufet,Consorci Sanitari del Maresme,Not Unity-Aligned,https://dx.doi.org/10.1093/eurpub/ckad093,2023-06-29,2024-03-01,Unverified,barrufetPrevalenceRiskFactors2023,ESP
230613_Catalonia_ConsorciSanitaridelMaresme_fu1,230613_Catalonia_ConsorciSanitaridelMaresme_fu1,Prevalence and risk factors of SARS-CoV-2 antibody responses among healthcare workers (June 2020-November 2021).,2023-06-13,Journal Article (Peer-Reviewed),Local,Prospective cohort,Spain,,Catalonia,"""This observational and prospective study followed the cohort of all 2455 active CSdM workers from June 2020 to November 2021. """,,2020-10-01,2020-10-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1937,0.14,0.124,0.156,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),COVID-19 ELISA IgM/IgA","Roche Diagnostics,Vircell S.L.",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.995,['High'],,No,Yes,No,,No,Yes,Yes,,Maria Pilar Barrufet,Consorci Sanitari del Maresme,Not Unity-Aligned,https://dx.doi.org/10.1093/eurpub/ckad093,2023-06-29,2024-03-01,Unverified,barrufetPrevalenceRiskFactors2023,ESP
230613_Catalonia_ConsorciSanitaridelMaresme_fu2,230613_Catalonia_ConsorciSanitaridelMaresme_fu2,Prevalence and risk factors of SARS-CoV-2 antibody responses among healthcare workers (June 2020-November 2021).,2023-06-13,Journal Article (Peer-Reviewed),Local,Prospective cohort,Spain,,Catalonia,"""This observational and prospective study followed the cohort of all 2455 active CSdM workers from June 2020 to November 2021. """,,2021-04-01,2021-04-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1980,0.273,0.253,0.293,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),COVID-19 ELISA IgM/IgA","Roche Diagnostics,Vircell S.L.",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.995,['High'],,No,Yes,No,,No,Yes,Yes,,Maria Pilar Barrufet,Consorci Sanitari del Maresme,Not Unity-Aligned,https://dx.doi.org/10.1093/eurpub/ckad093,2023-06-29,2024-03-01,Unverified,barrufetPrevalenceRiskFactors2023,ESP
230613_Catalonia_ConsorciSanitaridelMaresme_fu3,230613_Catalonia_ConsorciSanitaridelMaresme_fu3,Prevalence and risk factors of SARS-CoV-2 antibody responses among healthcare workers (June 2020-November 2021).,2023-06-13,Journal Article (Peer-Reviewed),Local,Prospective cohort,Spain,,Catalonia,"""This observational and prospective study followed the cohort of all 2455 active CSdM workers from June 2020 to November 2021. """,,2021-11-01,2021-11-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1777,0.284,0.262,0.305,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),COVID-19 ELISA IgM/IgA","Roche Diagnostics,Vircell S.L.",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.995,['High'],,No,Yes,No,,No,Yes,Yes,,Maria Pilar Barrufet,Consorci Sanitari del Maresme,Not Unity-Aligned,https://dx.doi.org/10.1093/eurpub/ckad093,2023-06-29,2024-03-01,Unverified,barrufetPrevalenceRiskFactors2023,ESP
230808_Madrid_HospitalUniversitarioDeTorrejon,230808_Madrid_HospitalUniversitarioDeTorrejon,PRECORSE study: Seroprevalence of severe acute respiratory syndrome coronavirus 2 in the first trimester of pregnancy during the first wave of the COVID-19 pandemic and subsequent pregnancy complications-A cohort study.,2023-08-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Spain,,Madrid,"archived first-trimester antenatal blood samples of 707 consecutive pregnant women between January 1 and May 15, 2020, in Madrid, Spain.",,2020-01-01,2020-05-15,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,707,0.082,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,Serum,"['IgA', 'IgG', 'IgM']",,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Adriana Aquise,Hospital Universitario de Torrejón,Not Unity-Aligned,https://dx.doi.org/10.1002/ijgo.15027,2023-08-21,2023-08-22,Unverified,aquise_precorse_2023,ESP
211108_Colombo_UniversityofSriJayewardenepura,211108_Colombo_UniversityofSriJayewardenepura,"Transmission dynamics, clinical characteristics and sero-surveillance in the COVID-19 outbreak in a population dense area of Colombo, Sri Lanka April- May 2020.",2021-11-08,Journal Article (Peer-Reviewed),Local,Prospective cohort,Sri Lanka,,Colombo,"""all close contacts and all non-close contacts"" of index case",,2020-04-15,2020-05-19,Contacts of COVID patients,All,Multiple groups,,,Primary Estimate,,2633,0.0338,,,True,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Whole Blood,TotalAntibody,,Validated by independent authors/third party/non-developers,,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Chandima Jeewandara,University of Sri Jayewardenepura,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0257548,2021-11-17,2024-03-01,Unverified,jeewandara_transmission_2021,LKA
211112_Colombo_UniversityofSriJayewardenepura_Overall,211112_Colombo_UniversityofSriJayewardenepura,"Seroprevalence of SARS-CoV-2 Infection in the Colombo Municipality Region, Sri Lanka",2021-11-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Sri Lanka,Western Province,Colombo,Residents of any of the six districts of the Colombo Municipal Region.,"Unclear if this is an exclusion criteria or simply an observation:
""None of the participants had any symptoms at the time of obtaining blood samples and were not previously diagnosed as been infected with the SARS-CoV-2 virus.""",2021-01-15,2021-01-31,Household and community samples,All,Multiple groups,10.0,86.0,Primary Estimate,,2547,0.2446,,,True,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.98,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Chandima Jeewandara,University of Sri Jayewardenepura,Not Unity-Aligned,https://www.frontiersin.org/articles/10.3389/fpubh.2021.724398/full,2021-12-14,2024-03-01,Unverified,jeewandara_seroprevalence_2021,LKA
211112_Colombo_UniversityofSriJayewardenepura_SexFemale,211112_Colombo_UniversityofSriJayewardenepura,"Seroprevalence of SARS-CoV-2 Infection in the Colombo Municipality Region, Sri Lanka",2021-11-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Sri Lanka,Western Province,Colombo,Residents of any of the six districts of the Colombo Municipal Region.,"Unclear if this is an exclusion criteria or simply an observation:
""None of the participants had any symptoms at the time of obtaining blood samples and were not previously diagnosed as been infected with the SARS-CoV-2 virus.""",2021-01-15,2021-01-31,Household and community samples,Female,Multiple groups,10.0,86.0,Sex/Gender,,976,0.29710000000000003,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.98,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Chandima Jeewandara,University of Sri Jayewardenepura,Not Unity-Aligned,https://www.frontiersin.org/articles/10.3389/fpubh.2021.724398/full,2021-12-14,2024-03-01,Unverified,jeewandara_seroprevalence_2021,LKA
211112_Colombo_UniversityofSriJayewardenepura_Age31-40,211112_Colombo_UniversityofSriJayewardenepura,"Seroprevalence of SARS-CoV-2 Infection in the Colombo Municipality Region, Sri Lanka",2021-11-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Sri Lanka,Western Province,Colombo,Residents of any of the six districts of the Colombo Municipal Region.,"Unclear if this is an exclusion criteria or simply an observation:
""None of the participants had any symptoms at the time of obtaining blood samples and were not previously diagnosed as been infected with the SARS-CoV-2 virus.""",2021-01-15,2021-01-31,Household and community samples,All,Adults (18-64 years),31.0,40.0,Age,31-40,461,0.2256,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.98,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Chandima Jeewandara,University of Sri Jayewardenepura,Not Unity-Aligned,https://www.frontiersin.org/articles/10.3389/fpubh.2021.724398/full,2021-12-14,2024-03-01,Unverified,jeewandara_seroprevalence_2021,LKA
211112_Colombo_UniversityofSriJayewardenepura_Age10-20,211112_Colombo_UniversityofSriJayewardenepura,"Seroprevalence of SARS-CoV-2 Infection in the Colombo Municipality Region, Sri Lanka",2021-11-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Sri Lanka,Western Province,Colombo,Residents of any of the six districts of the Colombo Municipal Region.,"Unclear if this is an exclusion criteria or simply an observation:
""None of the participants had any symptoms at the time of obtaining blood samples and were not previously diagnosed as been infected with the SARS-CoV-2 virus.""",2021-01-15,2021-01-31,Household and community samples,All,Children and Youth (0-17 years),10.0,20.0,Age,,191,0.3403,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.98,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Chandima Jeewandara,University of Sri Jayewardenepura,Not Unity-Aligned,https://www.frontiersin.org/articles/10.3389/fpubh.2021.724398/full,2021-12-14,2024-03-01,Unverified,jeewandara_seroprevalence_2021,LKA
211112_Colombo_UniversityofSriJayewardenepura_Age41-50,211112_Colombo_UniversityofSriJayewardenepura,"Seroprevalence of SARS-CoV-2 Infection in the Colombo Municipality Region, Sri Lanka",2021-11-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Sri Lanka,Western Province,Colombo,Residents of any of the six districts of the Colombo Municipal Region.,"Unclear if this is an exclusion criteria or simply an observation:
""None of the participants had any symptoms at the time of obtaining blood samples and were not previously diagnosed as been infected with the SARS-CoV-2 virus.""",2021-01-15,2021-01-31,Household and community samples,All,Adults (18-64 years),41.0,50.0,Age,41-50,484,0.2583,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.98,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Chandima Jeewandara,University of Sri Jayewardenepura,Not Unity-Aligned,https://www.frontiersin.org/articles/10.3389/fpubh.2021.724398/full,2021-12-14,2024-03-01,Unverified,jeewandara_seroprevalence_2021,LKA
211112_Colombo_UniversityofSriJayewardenepura_SexMale,211112_Colombo_UniversityofSriJayewardenepura,"Seroprevalence of SARS-CoV-2 Infection in the Colombo Municipality Region, Sri Lanka",2021-11-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Sri Lanka,Western Province,Colombo,Residents of any of the six districts of the Colombo Municipal Region.,"Unclear if this is an exclusion criteria or simply an observation:
""None of the participants had any symptoms at the time of obtaining blood samples and were not previously diagnosed as been infected with the SARS-CoV-2 virus.""",2021-01-15,2021-01-31,Household and community samples,Male,Multiple groups,10.0,86.0,Sex/Gender,,1571,0.212,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.98,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Chandima Jeewandara,University of Sri Jayewardenepura,Not Unity-Aligned,https://www.frontiersin.org/articles/10.3389/fpubh.2021.724398/full,2021-12-14,2024-03-01,Unverified,jeewandara_seroprevalence_2021,LKA
211112_Colombo_UniversityofSriJayewardenepura_Age51-60,211112_Colombo_UniversityofSriJayewardenepura,"Seroprevalence of SARS-CoV-2 Infection in the Colombo Municipality Region, Sri Lanka",2021-11-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Sri Lanka,Western Province,Colombo,Residents of any of the six districts of the Colombo Municipal Region.,"Unclear if this is an exclusion criteria or simply an observation:
""None of the participants had any symptoms at the time of obtaining blood samples and were not previously diagnosed as been infected with the SARS-CoV-2 virus.""",2021-01-15,2021-01-31,Household and community samples,All,Adults (18-64 years),51.0,60.0,Age,51-60,507,0.2544,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.98,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Chandima Jeewandara,University of Sri Jayewardenepura,Not Unity-Aligned,https://www.frontiersin.org/articles/10.3389/fpubh.2021.724398/full,2021-12-14,2024-03-01,Unverified,jeewandara_seroprevalence_2021,LKA
211112_Colombo_UniversityofSriJayewardenepura_Age71+,211112_Colombo_UniversityofSriJayewardenepura,"Seroprevalence of SARS-CoV-2 Infection in the Colombo Municipality Region, Sri Lanka",2021-11-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Sri Lanka,Western Province,Colombo,Residents of any of the six districts of the Colombo Municipal Region.,"Unclear if this is an exclusion criteria or simply an observation:
""None of the participants had any symptoms at the time of obtaining blood samples and were not previously diagnosed as been infected with the SARS-CoV-2 virus.""",2021-01-15,2021-01-31,Household and community samples,All,Seniors (65+ years),71.0,86.0,Age,71+,163,0.1718,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.98,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Chandima Jeewandara,University of Sri Jayewardenepura,Not Unity-Aligned,https://www.frontiersin.org/articles/10.3389/fpubh.2021.724398/full,2021-12-14,2024-03-01,Unverified,jeewandara_seroprevalence_2021,LKA
211112_Colombo_UniversityofSriJayewardenepura_Age21-30,211112_Colombo_UniversityofSriJayewardenepura,"Seroprevalence of SARS-CoV-2 Infection in the Colombo Municipality Region, Sri Lanka",2021-11-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Sri Lanka,Western Province,Colombo,Residents of any of the six districts of the Colombo Municipal Region.,"Unclear if this is an exclusion criteria or simply an observation:
""None of the participants had any symptoms at the time of obtaining blood samples and were not previously diagnosed as been infected with the SARS-CoV-2 virus.""",2021-01-15,2021-01-31,Household and community samples,All,Adults (18-64 years),21.0,30.0,Age,21-30,448,0.18530000000000002,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.98,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Chandima Jeewandara,University of Sri Jayewardenepura,Not Unity-Aligned,https://www.frontiersin.org/articles/10.3389/fpubh.2021.724398/full,2021-12-14,2024-03-01,Unverified,jeewandara_seroprevalence_2021,LKA
211112_Colombo_UniversityofSriJayewardenepura_Age61-70,211112_Colombo_UniversityofSriJayewardenepura,"Seroprevalence of SARS-CoV-2 Infection in the Colombo Municipality Region, Sri Lanka",2021-11-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Sri Lanka,Western Province,Colombo,Residents of any of the six districts of the Colombo Municipal Region.,"Unclear if this is an exclusion criteria or simply an observation:
""None of the participants had any symptoms at the time of obtaining blood samples and were not previously diagnosed as been infected with the SARS-CoV-2 virus.""",2021-01-15,2021-01-31,Household and community samples,All,Seniors (65+ years),61.0,70.0,Age,61-70,293,0.3038,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.98,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Chandima Jeewandara,University of Sri Jayewardenepura,Not Unity-Aligned,https://www.frontiersin.org/articles/10.3389/fpubh.2021.724398/full,2021-12-14,2024-03-01,Unverified,jeewandara_seroprevalence_2021,LKA
230919_Tirupati_SVIMSUniversity,230919_Tirupati_SVIMSUniversity,"Persistence of SARS-CoV-2 IgG and Its Avidity Compared with Neutralizing Antibodies among Health Care Workers in a Tertiary Care Hospital, South India – a One Year Follow Up Study",2023-09-19,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Sri Lanka,,Tirupati,HCWs at virus research and diagnostic laboratory,,2021-07-15,2021-09-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1001,0.778,,,True,,,,True,Convenience,COVID KAVACH (KAWACH) IgG Microlisa (Microwell ELISA),J. Mitra & Co. Pvt. Ltd,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Anagoni Srikar,SVIMS University,Not Unity-Aligned,10.20944/preprints202309.1211.v1,2023-10-05,2024-03-01,Unverified,srikar_persistence_2023,LKA
201023_Khartoum_FederalMinistryofHealthSudan,201023_Khartoum_FederalMinistryofHealthSudan,Sudan FETP Conducts Targeted Testing for COVID-19 in Khartoum State,2020-10-23,News and Media,Regional,Cross-sectional survey ,Sudan,Khartoum,,,,2020-05-22,2020-07-05,Household and community samples,All,Multiple groups,,,Primary Estimate,,967,0.18300000000000002,,,True,,,,True,Unclear,Not reported/ Unable to specify,,LFIA,Whole Blood,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,William McCollum,Federal Ministry of Health (MOH) in Sudan,Not Unity-Aligned,https://www.tephinet.org/sudan-fetp-conducts-targeted-testing-for-covid-19-in-khartoum-state,2021-05-02,2022-07-16,Verified,noauthor_sudan_nodate,SDN
220501_GreaterOmdurman_MédecinsSansFrontières_TestAdjusted,220501_GreaterOmdurman_MédecinsSansFrontières,"SARS-CoV-2 Antibody Prevalence and Population-Based Death Rates, Greater Omdurman, Sudan",2022-05-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Sudan,Khartoum State,Omdurman,"""The second was a nested SARS-CoV-2 antibody prevalence survey; all the members of a subset of the household, regardless of age, were invited to participate in the seroprevalence study.""",,2021-03-01,2021-04-10,Household and community samples,All,Multiple groups,,,Analysis,,2375,0.546,0.514,0.578,True,True,,,,Stratified probability,"Standard Q COVID-19 IgM/IgG Combo,Anti-SARS-CoV-2 ELISA IgG","SD Biosensor,EUROIMMUN",LFIA,Dried Blood,"['IgG', 'IgM']",,Validated by manufacturers,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Yes,Wendelin Moser,Médecins Sans Frontières,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2805.211951,2022-05-03,2023-08-15,Verified,moser_sars-cov-2_2022,SDN
220501_GreaterOmdurman_MédecinsSansFrontières_Age50+,220501_GreaterOmdurman_MédecinsSansFrontières,"SARS-CoV-2 Antibody Prevalence and Population-Based Death Rates, Greater Omdurman, Sudan",2022-05-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Sudan,Khartoum State,Omdurman,"""The second was a nested SARS-CoV-2 antibody prevalence survey; all the members of a subset of the household, regardless of age, were invited to participate in the seroprevalence study.""",,2021-03-01,2021-04-10,Household and community samples,All,Multiple groups,50.0,,Age,,319,0.502,0.44700000000000006,0.556,,,,,,Stratified probability,Standard Q COVID-19 IgM/IgG Combo,SD Biosensor,LFIA,Dried Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9690000000000001,0.9620000000000001,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Yes,Wendelin Moser,Médecins Sans Frontières,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2805.211951,2022-05-03,2022-07-16,Verified,moser_sars-cov-2_2022,SDN
220501_GreaterOmdurman_MédecinsSansFrontières_Age<=4,220501_GreaterOmdurman_MédecinsSansFrontières,"SARS-CoV-2 Antibody Prevalence and Population-Based Death Rates, Greater Omdurman, Sudan",2022-05-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Sudan,Khartoum State,Omdurman,"""The second was a nested SARS-CoV-2 antibody prevalence survey; all the members of a subset of the household, regardless of age, were invited to participate in the seroprevalence study.""",,2021-03-01,2021-04-10,Household and community samples,All,Multiple groups,,4.0,Age,,299,0.187,0.147,0.23500000000000001,,,,,,Stratified probability,Standard Q COVID-19 IgM/IgG Combo,SD Biosensor,LFIA,Dried Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9690000000000001,0.9620000000000001,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Yes,Wendelin Moser,Médecins Sans Frontières,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2805.211951,2022-05-03,2022-07-16,Verified,moser_sars-cov-2_2022,SDN
220501_GreaterOmdurman_MédecinsSansFrontières_Age20-34,220501_GreaterOmdurman_MédecinsSansFrontières,"SARS-CoV-2 Antibody Prevalence and Population-Based Death Rates, Greater Omdurman, Sudan",2022-05-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Sudan,Khartoum State,Omdurman,"""The second was a nested SARS-CoV-2 antibody prevalence survey; all the members of a subset of the household, regardless of age, were invited to participate in the seroprevalence study.""",,2021-03-01,2021-04-10,Household and community samples,All,Multiple groups,20.0,34.0,Age,,629,0.355,0.318,0.39299999999999996,,,,,,Stratified probability,Standard Q COVID-19 IgM/IgG Combo,SD Biosensor,LFIA,Dried Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9690000000000001,0.9620000000000001,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Yes,Wendelin Moser,Médecins Sans Frontières,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2805.211951,2022-05-03,2022-07-16,Verified,moser_sars-cov-2_2022,SDN
220501_GreaterOmdurman_MédecinsSansFrontières_Age35-49,220501_GreaterOmdurman_MédecinsSansFrontières,"SARS-CoV-2 Antibody Prevalence and Population-Based Death Rates, Greater Omdurman, Sudan",2022-05-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Sudan,Khartoum State,Omdurman,"""The second was a nested SARS-CoV-2 antibody prevalence survey; all the members of a subset of the household, regardless of age, were invited to participate in the seroprevalence study.""",,2021-03-01,2021-04-10,Household and community samples,All,Multiple groups,35.0,49.0,Age,,342,0.395,0.344,0.44700000000000006,,,,,,Stratified probability,Standard Q COVID-19 IgM/IgG Combo,SD Biosensor,LFIA,Dried Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9690000000000001,0.9620000000000001,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Yes,Wendelin Moser,Médecins Sans Frontières,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2805.211951,2022-05-03,2022-07-16,Verified,moser_sars-cov-2_2022,SDN
220501_GreaterOmdurman_MédecinsSansFrontières_Overall,220501_GreaterOmdurman_MédecinsSansFrontières,"SARS-CoV-2 Antibody Prevalence and Population-Based Death Rates, Greater Omdurman, Sudan",2022-05-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Sudan,Khartoum State,Omdurman,"""The second was a nested SARS-CoV-2 antibody prevalence survey; all the members of a subset of the household, regardless of age, were invited to participate in the seroprevalence study.""",,2021-03-01,2021-04-10,Household and community samples,All,Multiple groups,,,Primary Estimate,,2374,0.34299999999999997,0.324,0.36200000000000004,,,,,True,Stratified probability,Standard Q COVID-19 IgM/IgG Combo,SD Biosensor,LFIA,Dried Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9690000000000001,0.9620000000000001,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Yes,Wendelin Moser,Médecins Sans Frontières,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2805.211951,2022-05-03,2022-07-16,Verified,moser_sars-cov-2_2022,SDN
220501_GreaterOmdurman_MédecinsSansFrontières_Age5-19,220501_GreaterOmdurman_MédecinsSansFrontières,"SARS-CoV-2 Antibody Prevalence and Population-Based Death Rates, Greater Omdurman, Sudan",2022-05-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Sudan,Khartoum State,Omdurman,"""The second was a nested SARS-CoV-2 antibody prevalence survey; all the members of a subset of the household, regardless of age, were invited to participate in the seroprevalence study.""",,2021-03-01,2021-04-10,Household and community samples,All,Multiple groups,5.0,19.0,Age,,786,0.306,0.275,0.33899999999999997,,,,,,Stratified probability,Standard Q COVID-19 IgM/IgG Combo,SD Biosensor,LFIA,Dried Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9690000000000001,0.9620000000000001,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Yes,Wendelin Moser,Médecins Sans Frontières,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2805.211951,2022-05-03,2022-07-16,Verified,moser_sars-cov-2_2022,SDN
200617_Norbotten_UmeaUniversity_overall,200617_Norbotten_UmeaUniversity,"The seroprevalence of covid-19 antibodies in Norrbotten County, Sweden",2020-06-17,Institutional Report,Regional,Cross-sectional survey ,Sweden,Norbotten,"Piteå, Luleå/Boden, Gällivare, Kalix, Kiruna",Age 20-80 living in all municipalities of Norbotten,,2020-05-25,2020-06-05,Household and community samples,All,Multiple groups,20.0,80.0,Primary Estimate,overall,425,0.019,0.008,0.037000000000000005,True,,,,True,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG","Abbott Laboratories,EUROIMMUN",Multiple Types,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['High'],Yes,Yes,No,Yes,No,No,Yes,No,Yes,Mats Eliasson,Umea University,Not Unity-Aligned,https://web.archive.org/web/20200623000020/https://www.norrbotten.se/publika/lg/kom/Corona/Rapport%20-%20förekomst%20av%20antikroppar/Förekomst%20av%20antikroppar%20mot%20covid-19%20i%20Norrbottens%20befolkning%20maj%202020%20-%20Region%20Norrbotten%20rapport%20200618.pdf,2021-05-21,2024-03-01,Verified,mats_eliasson_forekomst_2020,SWE
200617_Norbotten_UmeaUniversity_male,200617_Norbotten_UmeaUniversity,"The seroprevalence of covid-19 antibodies in Norrbotten County, Sweden",2020-06-17,Institutional Report,Regional,Cross-sectional survey ,Sweden,Norbotten,"Piteå, Luleå/Boden, Gällivare, Kalix, Kiruna",Age 20-80 living in all municipalities of Norbotten,,2020-05-25,2020-06-05,Household and community samples,Male,Multiple groups,20.0,80.0,Sex/Gender,,221,0.018000000000000002,0.005,0.046,,,,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG","Abbott Laboratories,EUROIMMUN",Multiple Types,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['High'],Yes,Yes,No,Yes,No,No,Yes,No,Yes,Mats Eliasson,Umea University,Not Unity-Aligned,https://web.archive.org/web/20200623000020/https://www.norrbotten.se/publika/lg/kom/Corona/Rapport%20-%20förekomst%20av%20antikroppar/Förekomst%20av%20antikroppar%20mot%20covid-19%20i%20Norrbottens%20befolkning%20maj%202020%20-%20Region%20Norrbotten%20rapport%20200618.pdf,2021-06-09,2024-03-01,Verified,mats_eliasson_forekomst_2020,SWE
200617_Norbotten_UmeaUniversity_age65+,200617_Norbotten_UmeaUniversity,"The seroprevalence of covid-19 antibodies in Norrbotten County, Sweden",2020-06-17,Institutional Report,Regional,Cross-sectional survey ,Sweden,Norbotten,"Piteå, Luleå/Boden, Gällivare, Kalix, Kiruna",Age 20-80 living in all municipalities of Norbotten,,2020-05-25,2020-06-05,Household and community samples,All,Seniors (65+ years),65.0,80.0,Age,age 65+,96,0.021,0.003,0.073,,,,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG","Abbott Laboratories,EUROIMMUN",Multiple Types,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['High'],Yes,Yes,No,Yes,No,No,Yes,No,Yes,Mats Eliasson,Umea University,Not Unity-Aligned,https://web.archive.org/web/20200623000020/https://www.norrbotten.se/publika/lg/kom/Corona/Rapport%20-%20förekomst%20av%20antikroppar/Förekomst%20av%20antikroppar%20mot%20covid-19%20i%20Norrbottens%20befolkning%20maj%202020%20-%20Region%20Norrbotten%20rapport%20200618.pdf,2021-06-09,2024-03-01,Verified,mats_eliasson_forekomst_2020,SWE
200617_Norbotten_UmeaUniversity_age30-64,200617_Norbotten_UmeaUniversity,"The seroprevalence of covid-19 antibodies in Norrbotten County, Sweden",2020-06-17,Institutional Report,Regional,Cross-sectional survey ,Sweden,Norbotten,"Piteå, Luleå/Boden, Gällivare, Kalix, Kiruna",Age 20-80 living in all municipalities of Norbotten,,2020-05-25,2020-06-05,Household and community samples,All,Adults (18-64 years),30.0,64.0,Age,age 30-64,268,0.006999999999999999,0.001,0.027000000000000003,,,,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG","Abbott Laboratories,EUROIMMUN",Multiple Types,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['High'],Yes,Yes,No,Yes,No,No,Yes,No,Yes,Mats Eliasson,Umea University,Not Unity-Aligned,https://web.archive.org/web/20200623000020/https://www.norrbotten.se/publika/lg/kom/Corona/Rapport%20-%20förekomst%20av%20antikroppar/Förekomst%20av%20antikroppar%20mot%20covid-19%20i%20Norrbottens%20befolkning%20maj%202020%20-%20Region%20Norrbotten%20rapport%20200618.pdf,2021-06-09,2024-03-01,Verified,mats_eliasson_forekomst_2020,SWE
200617_Norbotten_UmeaUniversity_age20-29,200617_Norbotten_UmeaUniversity,"The seroprevalence of covid-19 antibodies in Norrbotten County, Sweden",2020-06-17,Institutional Report,Regional,Cross-sectional survey ,Sweden,Norbotten,"Piteå, Luleå/Boden, Gällivare, Kalix, Kiruna",Age 20-80 living in all municipalities of Norbotten,,2020-05-25,2020-06-05,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,age 20-29,61,0.066,0.018000000000000002,0.159,,,,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG","Abbott Laboratories,EUROIMMUN",Multiple Types,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['High'],Yes,Yes,No,Yes,No,No,Yes,No,Yes,Mats Eliasson,Umea University,Not Unity-Aligned,https://web.archive.org/web/20200623000020/https://www.norrbotten.se/publika/lg/kom/Corona/Rapport%20-%20förekomst%20av%20antikroppar/Förekomst%20av%20antikroppar%20mot%20covid-19%20i%20Norrbottens%20befolkning%20maj%202020%20-%20Region%20Norrbotten%20rapport%20200618.pdf,2021-06-09,2024-03-01,Verified,mats_eliasson_forekomst_2020,SWE
200617_Norbotten_UmeaUniversity_female,200617_Norbotten_UmeaUniversity,"The seroprevalence of covid-19 antibodies in Norrbotten County, Sweden",2020-06-17,Institutional Report,Regional,Cross-sectional survey ,Sweden,Norbotten,"Piteå, Luleå/Boden, Gällivare, Kalix, Kiruna",Age 20-80 living in all municipalities of Norbotten,,2020-05-25,2020-06-05,Household and community samples,Female,Multiple groups,20.0,80.0,Sex/Gender,,204,0.02,0.005,0.049,,,,,,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG","Abbott Laboratories,EUROIMMUN",Multiple Types,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['High'],Yes,Yes,No,Yes,No,No,Yes,No,Yes,Mats Eliasson,Umea University,Not Unity-Aligned,https://web.archive.org/web/20200623000020/https://www.norrbotten.se/publika/lg/kom/Corona/Rapport%20-%20förekomst%20av%20antikroppar/Förekomst%20av%20antikroppar%20mot%20covid-19%20i%20Norrbottens%20befolkning%20maj%202020%20-%20Region%20Norrbotten%20rapport%20200618.pdf,2021-06-09,2024-03-01,Verified,mats_eliasson_forekomst_2020,SWE
200618_Sweden_SwedishPublicHealthAgency_Outpatients_Week17_Overall,200618_Sweden_SwedishPublicHealthAgency_Outpatients_1_week17,Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 1),2020-06-18,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Every week April 20 to June 12 gatherabout 1200 samples in, with 400 samples each from individuals 0-19 years, 20-64 years as well65-95 years.",,2020-04-20,2020-04-26,Residual sera,All,Multiple groups,0.0,95.0,Primary Estimate,,1200,0.053,0.038,0.071,True,True,True,,True,Stratified non-probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2020-10-24,2022-07-16,Verified,swedish_public_health_agency_pavisning_2020,SWE
200618_Sweden_SwedishPublicHealthAgency_Outpatients_Week17_Age20t064,200618_Sweden_SwedishPublicHealthAgency_Outpatients_1_week17,Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 1),2020-06-18,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Every week April 20 to June 12 gatherabout 1200 samples in, with 400 samples each from individuals 0-19 years, 20-64 years as well65-95 years.",,2020-04-20,2020-04-26,Residual sera,All,Adults (18-64 years),20.0,64.0,Age,20-64,400,0.07,0.045700000000000005,0.0998,,True,True,,,Stratified non-probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2020-10-25,2022-07-16,Verified,swedish_public_health_agency_pavisning_2020,SWE
200618_Sweden_SwedishPublicHealthAgency_Outpatients_Week17_Age65to95,200618_Sweden_SwedishPublicHealthAgency_Outpatients_1_week17,Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 1),2020-06-18,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Every week April 20 to June 12 gatherabout 1200 samples in, with 400 samples each from individuals 0-19 years, 20-64 years as well65-95 years.",,2020-04-20,2020-04-26,Residual sera,All,Seniors (65+ years),65.0,95.0,Age,65-95,400,0.047,0.0276,0.0732,,True,True,,,Stratified non-probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2020-10-25,2022-07-16,Verified,swedish_public_health_agency_pavisning_2020,SWE
200618_Sweden_SwedishPublicHealthAgency_Outpatients_Week17_Age0to19,200618_Sweden_SwedishPublicHealthAgency_Outpatients_1_week17,Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 1),2020-06-18,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Every week April 20 to June 12 gatherabout 1200 samples in, with 400 samples each from individuals 0-19 years, 20-64 years as well65-95 years.",,2020-04-20,2020-04-26,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Age,0-19,400,0.016,0.0033000000000000004,0.0358,,True,True,,,Stratified non-probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2020-10-25,2022-07-16,Verified,swedish_public_health_agency_pavisning_2020,SWE
200618_Sweden_SwedishPublicHealthAgency_Outpatients_Week18_Overall,200618_Sweden_SwedishPublicHealthAgency_Outpatients_2_week18,Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 1),2020-06-18,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Every week April 20 to June 12 gatherabout 1200 samples in, with 400 samples each from individuals 0-19 years, 20-64 years as well65-95 years.",,2020-04-27,2020-05-03,Residual sera,All,Multiple groups,0.0,95.0,Primary Estimate,,1200,0.04,0.0271,0.0567,True,True,True,,True,Stratified non-probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2020-10-25,2022-07-16,Verified,swedish_public_health_agency_pavisning_2020,SWE
200618_Sweden_SwedishPublicHealthAgency_Outpatients_Week18_Age0to19,200618_Sweden_SwedishPublicHealthAgency_Outpatients_2_week18,Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 1),2020-06-18,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Every week April 20 to June 12 gatherabout 1200 samples in, with 400 samples each from individuals 0-19 years, 20-64 years as well65-95 years.",,2020-04-27,2020-05-03,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Age,0-19,400,0.027999999999999997,0.0117,0.0501,,True,True,,,Stratified non-probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2020-10-25,2022-07-16,Verified,swedish_public_health_agency_pavisning_2020,SWE
200618_Sweden_SwedishPublicHealthAgency_Outpatients_Week18_Age65to95,200618_Sweden_SwedishPublicHealthAgency_Outpatients_2_week18,Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 1),2020-06-18,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Every week April 20 to June 12 gatherabout 1200 samples in, with 400 samples each from individuals 0-19 years, 20-64 years as well65-95 years.",,2020-04-27,2020-05-03,Residual sera,All,Seniors (65+ years),65.0,95.0,Age,65-95,400,0.017,0.0042,0.0366,,True,True,,,Stratified non-probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2020-10-25,2022-07-16,Verified,swedish_public_health_agency_pavisning_2020,SWE
200618_Sweden_SwedishPublicHealthAgency_Outpatients_Week18_Age20to64,200618_Sweden_SwedishPublicHealthAgency_Outpatients_2_week18,Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 1),2020-06-18,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Every week April 20 to June 12 gatherabout 1200 samples in, with 400 samples each from individuals 0-19 years, 20-64 years as well65-95 years.",,2020-04-27,2020-05-03,Residual sera,All,Adults (18-64 years),20.0,64.0,Age,20-64,400,0.053,0.032,0.0805,,True,True,,,Stratified non-probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2020-10-25,2022-07-16,Verified,swedish_public_health_agency_pavisning_2020,SWE
200618_Sweden_SwedishPublicHealthAgency_Outpatients_Week19_Overall,200618_Sweden_SwedishPublicHealthAgency_Outpatients_3_week19,Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 1),2020-06-18,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Every week April 20 to June 12 gatherabout 1200 samples in, with 400 samples each from individuals 0-19 years, 20-64 years as well65-95 years.",,2020-05-04,2020-05-10,Residual sera,All,Multiple groups,0.0,95.0,Primary Estimate,,1200,0.039,0.026099999999999998,0.0542,True,True,True,,True,Stratified non-probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2020-10-25,2022-07-16,Verified,swedish_public_health_agency_pavisning_2020,SWE
200618_Sweden_SwedishPublicHealthAgency_Outpatients_Week19_Age65to95,200618_Sweden_SwedishPublicHealthAgency_Outpatients_3_week19,Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 1),2020-06-18,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Every week April 20 to June 12 gatherabout 1200 samples in, with 400 samples each from individuals 0-19 years, 20-64 years as well65-95 years.",,2020-05-04,2020-05-10,Residual sera,All,Seniors (65+ years),65.0,95.0,Age,65-95,400,0.024,0.009300000000000001,0.045899999999999996,,True,True,,,Stratified non-probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2020-10-25,2022-07-16,Verified,swedish_public_health_agency_pavisning_2020,SWE
200618_Sweden_SwedishPublicHealthAgency_Outpatients_Week19_Age20to64,200618_Sweden_SwedishPublicHealthAgency_Outpatients_3_week19,Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 1),2020-06-18,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Every week April 20 to June 12 gatherabout 1200 samples in, with 400 samples each from individuals 0-19 years, 20-64 years as well65-95 years.",,2020-05-04,2020-05-10,Residual sera,All,Adults (18-64 years),20.0,64.0,Age,20-64,400,0.046,0.0267,0.07200000000000001,,True,True,,,Stratified non-probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2020-10-25,2022-07-16,Verified,swedish_public_health_agency_pavisning_2020,SWE
200618_Sweden_SwedishPublicHealthAgency_Outpatients_Week19_Age0to19,200618_Sweden_SwedishPublicHealthAgency_Outpatients_3_week19,Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 1),2020-06-18,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Every week April 20 to June 12 gatherabout 1200 samples in, with 400 samples each from individuals 0-19 years, 20-64 years as well65-95 years.",,2020-05-04,2020-05-10,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Age,0-19,400,0.032,0.015300000000000001,0.054400000000000004,,True,True,,,Stratified non-probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2020-10-25,2022-07-16,Verified,swedish_public_health_agency_pavisning_2020,SWE
200618_Sweden_SwedishPublicHealthAgency_Outpatients_Week20_Overall,200618_Sweden_SwedishPublicHealthAgency_Outpatients_4_week20,Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 1),2020-06-18,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Every week April 20 to June 12 gatherabout 1200 samples in, with 400 samples each from individuals 0-19 years, 20-64 years as well65-95 years.",,2020-05-11,2020-05-17,Residual sera,All,Multiple groups,0.0,95.0,Primary Estimate,,1200,0.045,0.030699999999999998,0.061500000000000006,True,True,True,,True,Stratified non-probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2020-10-25,2022-07-16,Verified,swedish_public_health_agency_pavisning_2020,SWE
200618_Sweden_SwedishPublicHealthAgency_Outpatients_Week20_Age65to95,200618_Sweden_SwedishPublicHealthAgency_Outpatients_4_week20,Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 1),2020-06-18,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Every week April 20 to June 12 gatherabout 1200 samples in, with 400 samples each from individuals 0-19 years, 20-64 years as well65-95 years.",,2020-05-11,2020-05-17,Residual sera,All,Seniors (65+ years),65.0,95.0,Age,65-95,400,0.019,0.0039000000000000003,0.04190000000000001,,True,True,,,Stratified non-probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2020-10-25,2022-07-16,Verified,swedish_public_health_agency_pavisning_2020,SWE
200618_Sweden_SwedishPublicHealthAgency_Outpatients_Week20_Age0to19,200618_Sweden_SwedishPublicHealthAgency_Outpatients_4_week20,Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 1),2020-06-18,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Every week April 20 to June 12 gatherabout 1200 samples in, with 400 samples each from individuals 0-19 years, 20-64 years as well65-95 years.",,2020-05-11,2020-05-17,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Age,0-19,400,0.048,0.027999999999999997,0.073,,True,True,,,Stratified non-probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2020-10-25,2022-07-16,Verified,swedish_public_health_agency_pavisning_2020,SWE
200618_Sweden_SwedishPublicHealthAgency_Outpatients_Week20_Age20to64,200618_Sweden_SwedishPublicHealthAgency_Outpatients_4_week20,Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 1),2020-06-18,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Every week April 20 to June 12 gatherabout 1200 samples in, with 400 samples each from individuals 0-19 years, 20-64 years as well65-95 years.",,2020-05-11,2020-05-17,Residual sera,All,Adults (18-64 years),20.0,64.0,Age,20-64,400,0.052000000000000005,0.0304,0.08,,True,True,,,Stratified non-probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2020-10-25,2022-07-16,Verified,swedish_public_health_agency_pavisning_2020,SWE
200618_Sweden_SwedishPublicHealthAgency_Outpatients_Week21_Overall,200618_Sweden_SwedishPublicHealthAgency_Outpatients_5_week21,Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 1),2020-06-18,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Every week April 20 to June 12 gatherabout 1200 samples in, with 400 samples each from individuals 0-19 years, 20-64 years as well65-95 years.",,2020-05-18,2020-05-24,Residual sera,All,Multiple groups,0.0,95.0,Primary Estimate,,1200,0.052000000000000005,0.0367,0.07,True,True,True,,True,Stratified non-probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2020-10-25,2022-07-16,Verified,swedish_public_health_agency_pavisning_2020,SWE
200618_Sweden_SwedishPublicHealthAgency_Outpatients_Week21_Age20to64,200618_Sweden_SwedishPublicHealthAgency_Outpatients_5_week21,Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 1),2020-06-18,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Every week April 20 to June 12 gatherabout 1200 samples in, with 400 samples each from individuals 0-19 years, 20-64 years as well65-95 years.",,2020-05-18,2020-05-24,Residual sera,All,Adults (18-64 years),20.0,64.0,Age,20-64,400,0.065,0.0414,0.0959,,True,True,,,Stratified non-probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2020-10-25,2022-07-16,Verified,swedish_public_health_agency_pavisning_2020,SWE
200618_Sweden_SwedishPublicHealthAgency_Outpatients_Week21_Age65to95,200618_Sweden_SwedishPublicHealthAgency_Outpatients_5_week21,Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 1),2020-06-18,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Every week April 20 to June 12 gatherabout 1200 samples in, with 400 samples each from individuals 0-19 years, 20-64 years as well65-95 years.",,2020-05-18,2020-05-24,Residual sera,All,Seniors (65+ years),65.0,95.0,Age,65-95,400,0.025,0.0088,0.049100000000000005,,True,True,,,Stratified non-probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2020-10-25,2022-07-16,Verified,swedish_public_health_agency_pavisning_2020,SWE
200618_Sweden_SwedishPublicHealthAgency_Outpatients_Week21_Age0to19,200618_Sweden_SwedishPublicHealthAgency_Outpatients_5_week21,Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 1),2020-06-18,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Every week April 20 to June 12 gatherabout 1200 samples in, with 400 samples each from individuals 0-19 years, 20-64 years as well65-95 years.",,2020-05-18,2020-05-24,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Age,0-19,400,0.04,0.0223,0.0631,,True,True,,,Stratified non-probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2020-10-25,2022-07-16,Verified,swedish_public_health_agency_pavisning_2020,SWE
200618_Sweden_SwedishPublicHealthAgency_Outpatients_Week22_Overall,200618_Sweden_SwedishPublicHealthAgency_Outpatients_6_week22,Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 1),2020-06-18,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Every week April 20 to June 12 gatherabout 1200 samples in, with 400 samples each from individuals 0-19 years, 20-64 years as well65-95 years.",,2020-05-25,2020-05-31,Residual sera,All,Multiple groups,0.0,95.0,Primary Estimate,,1200,0.057,0.0398,0.0772,True,True,True,,True,Stratified non-probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2020-10-25,2022-07-16,Verified,swedish_public_health_agency_pavisning_2020,SWE
200618_Sweden_SwedishPublicHealthAgency_Outpatients_Week22_Age20to64,200618_Sweden_SwedishPublicHealthAgency_Outpatients_6_week22,Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 1),2020-06-18,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Every week April 20 to June 12 gatherabout 1200 samples in, with 400 samples each from individuals 0-19 years, 20-64 years as well65-95 years.",,2020-05-25,2020-05-31,Residual sera,All,Adults (18-64 years),20.0,64.0,Age,20-64,400,0.076,0.048600000000000004,0.11019999999999999,,True,True,,,Stratified non-probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2020-10-25,2022-07-16,Verified,swedish_public_health_agency_pavisning_2020,SWE
200618_Sweden_SwedishPublicHealthAgency_Outpatients_Week22_Age65to95,200618_Sweden_SwedishPublicHealthAgency_Outpatients_6_week22,Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 1),2020-06-18,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Every week April 20 to June 12 gatherabout 1200 samples in, with 400 samples each from individuals 0-19 years, 20-64 years as well65-95 years.",,2020-05-25,2020-05-31,Residual sera,All,Seniors (65+ years),65.0,95.0,Age,65-95,400,0.018000000000000002,0.0028000000000000004,0.04190000000000001,,True,True,,,Stratified non-probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2020-10-25,2022-07-16,Verified,swedish_public_health_agency_pavisning_2020,SWE
200618_Sweden_SwedishPublicHealthAgency_Outpatients_Week22_Age0to19,200618_Sweden_SwedishPublicHealthAgency_Outpatients_6_week22,Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 1),2020-06-18,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Every week April 20 to June 12 gatherabout 1200 samples in, with 400 samples each from individuals 0-19 years, 20-64 years as well65-95 years.",,2020-05-25,2020-05-31,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Age,0-19,400,0.040999999999999995,0.022000000000000002,0.0669,,True,True,,,Stratified non-probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2020-10-25,2022-07-16,Verified,swedish_public_health_agency_pavisning_2020,SWE
200618_Sweden_SwedishPublicHealthAgency_Outpatients_Week23_Overall,200618_Sweden_SwedishPublicHealthAgency_Outpatients_7_week23,Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 1),2020-06-18,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Every week April 20 to June 12 gatherabout 1200 samples in, with 400 samples each from individuals 0-19 years, 20-64 years as well65-95 years.",,2020-06-01,2020-06-07,Residual sera,All,Multiple groups,0.0,95.0,Primary Estimate,,1200,0.068,0.0507,0.08800000000000001,True,True,True,,True,Stratified non-probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2020-10-25,2022-07-16,Verified,swedish_public_health_agency_pavisning_2020,SWE
200618_Sweden_SwedishPublicHealthAgency_Outpatients_Week23_Age20to64,200618_Sweden_SwedishPublicHealthAgency_Outpatients_7_week23,Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 1),2020-06-18,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Every week April 20 to June 12 gatherabout 1200 samples in, with 400 samples each from individuals 0-19 years, 20-64 years as well65-95 years.",,2020-06-01,2020-06-07,Residual sera,All,Adults (18-64 years),20.0,64.0,Age,20-64,400,0.094,0.0694,0.127,,True,True,,,Stratified non-probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2020-10-25,2022-07-16,Verified,swedish_public_health_agency_pavisning_2020,SWE
200618_Sweden_SwedishPublicHealthAgency_Outpatients_Week23_Age0to19,200618_Sweden_SwedishPublicHealthAgency_Outpatients_7_week23,Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 1),2020-06-18,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Every week April 20 to June 12 gatherabout 1200 samples in, with 400 samples each from individuals 0-19 years, 20-64 years as well65-95 years.",,2020-06-01,2020-06-07,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Age,0-19,400,0.039,0.023700000000000002,0.0622,,True,True,,,Stratified non-probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2020-10-25,2022-07-16,Verified,swedish_public_health_agency_pavisning_2020,SWE
200618_Sweden_SwedishPublicHealthAgency_Outpatients_Week23_Age65to95,200618_Sweden_SwedishPublicHealthAgency_Outpatients_7_week23,Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 1),2020-06-18,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Every week April 20 to June 12 gatherabout 1200 samples in, with 400 samples each from individuals 0-19 years, 20-64 years as well65-95 years.",,2020-06-01,2020-06-07,Residual sera,All,Seniors (65+ years),65.0,95.0,Age,65-95,400,0.023,0.0070999999999999995,0.0467,,True,True,,,Stratified non-probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2020-10-25,2022-07-16,Verified,swedish_public_health_agency_pavisning_2020,SWE
200618_Sweden_SwedishPublicHealthAgency_Outpatients_Week24_Overall,200618_Sweden_SwedishPublicHealthAgency_Outpatients_8_week24,Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 1),2020-06-18,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Every week April 20 to June 12 gatherabout 1200 samples in, with 400 samples each from individuals 0-19 years, 20-64 years as well65-95 years.",,2020-06-08,2020-06-14,Residual sera,All,Multiple groups,0.0,95.0,Primary Estimate,,1200,0.052000000000000005,0.0374,0.0706,True,True,True,,True,Stratified non-probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2020-10-25,2022-07-16,Verified,swedish_public_health_agency_pavisning_2020,SWE
200618_Sweden_SwedishPublicHealthAgency_Outpatients_Week24_Age65to95,200618_Sweden_SwedishPublicHealthAgency_Outpatients_8_week24,Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 1),2020-06-18,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Every week April 20 to June 12 gatherabout 1200 samples in, with 400 samples each from individuals 0-19 years, 20-64 years as well65-95 years.",,2020-06-08,2020-06-14,Residual sera,All,Seniors (65+ years),65.0,95.0,Age,65-95,400,0.015,0.0015,0.0369,,True,True,,,Stratified non-probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2020-10-25,2022-07-16,Verified,swedish_public_health_agency_pavisning_2020,SWE
200618_Sweden_SwedishPublicHealthAgency_Outpatients_Week24_Age0to19,200618_Sweden_SwedishPublicHealthAgency_Outpatients_8_week24,Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 1),2020-06-18,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Every week April 20 to June 12 gatherabout 1200 samples in, with 400 samples each from individuals 0-19 years, 20-64 years as well65-95 years.",,2020-06-08,2020-06-14,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Age,0-19,400,0.053,0.0326,0.0784,,True,True,,,Stratified non-probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2020-10-25,2022-07-16,Verified,swedish_public_health_agency_pavisning_2020,SWE
200618_Sweden_SwedishPublicHealthAgency_Outpatients_Week24_Age20to64,200618_Sweden_SwedishPublicHealthAgency_Outpatients_8_week24,Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 1),2020-06-18,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Every week April 20 to June 12 gatherabout 1200 samples in, with 400 samples each from individuals 0-19 years, 20-64 years as well65-95 years.",,2020-06-08,2020-06-14,Residual sera,All,Adults (18-64 years),20.0,64.0,Age,20-64,400,0.065,0.040999999999999995,0.0949,,True,True,,,Stratified non-probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2020-10-25,2022-07-16,Verified,swedish_public_health_agency_pavisning_2020,SWE
200716_Stockholm_RegionStockholm,200716_Stockholm_RegionStockholm,16 juli: Lägesrapport om arbetet med det nya coronaviruset,2020-07-16,Institutional Report,Local,Repeated cross-sectional study,Sweden,Uppland,Stockholm,Any resident wanting an antibody test. The tests are free of charge for the county's residents.,,2020-06-15,2020-07-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,149616,0.17600000000000002,,,True,,,,True,Self-referral,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,No,Yes,No,Unclear,Unclear,Yes,No,Unclear,Stockholm Region,Sweden Public Health Authority,Not Unity-Aligned,https://www.sll.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2020/07/16-juli-lagesrapport-om-arbetet-med-det-nya-coronaviruset/,2020-10-25,2022-07-16,Verified,stockholm_region_16_2020,SWE
200720_Uppsala_UppsalaUniversity_Total,200720_Uppsala_UppsalaUniversity,Work at inpatient care units is  associated with an increased risk of SARS-CoV-2 infection; a cross-sectional study of 8679 healthcare workers in Sweden.,2020-07-20,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Sweden,Uppsala,,Study subjects were to be above the age of 18 and without symptoms of airway infection for at least seven days. ,,2020-05-27,2020-06-25,Health care workers and caregivers,All,Multiple groups,18.0,85.0,Primary Estimate,,8679,0.066,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Anna-Karin Lidstrom,Uppsala University ,Not Unity-Aligned,https://dx.doi.org/10.1080/03009734.2020.1793039,2020-07-31,2024-03-01,Verified,lidstrom_work_2020-1,SWE
200723_Sweden_Werlabs_GenPop,200723_Sweden_Werlabs,14% of coronavirus antibody tests positive in Sweden in July,2020-07-23,News and Media,Local,Cross-sectional survey ,Sweden,"Skåne, Västra Götaland, Uppland","Stockholm, Gothenburg, Malmo","Residents of Malmo, Gothenburg, and Stockholm.",,2020-07-01,2020-07-22,Household and community samples,All,Multiple groups,,,Primary Estimate,,83000,0.14400000000000002,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Local,Werlabs,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.thelocal.se/20200723/14-of-antibody-tests-positive-in-sweden&ct=ga&cd=CAAYBzIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNHl1If-XI0aCeB5tGakbaJvFktByQ,2020-08-02,2022-07-16,Verified,the_local_se_14_2020,SWE
200723_Sweden_Werlabs_GenPop_Gothenburg,200723_Sweden_Werlabs,14% of coronavirus antibody tests positive in Sweden in July,2020-07-23,News and Media,Local,Cross-sectional survey ,Sweden,,Gothenburg,"Residents of Malmo, Gothenburg, and Stockholm.",,2020-07-01,2020-07-22,Household and community samples,All,Multiple groups,,,Geographical area,Gothenburg,2200,0.151,,,,,,,,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Local,Werlabs,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.thelocal.se/20200723/14-of-antibody-tests-positive-in-sweden&ct=ga&cd=CAAYBzIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNHl1If-XI0aCeB5tGakbaJvFktByQ,2020-08-02,2022-07-16,Verified,the_local_se_14_2020,SWE
200723_Sweden_Werlabs_GenPop_Malmo,200723_Sweden_Werlabs,14% of coronavirus antibody tests positive in Sweden in July,2020-07-23,News and Media,Local,Cross-sectional survey ,Sweden,,Malmo,"Residents of Malmo, Gothenburg, and Stockholm.",,2020-07-01,2020-07-22,Household and community samples,All,Multiple groups,,,Geographical area,Malmo ,800,0.08,,,,,,,,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Local,Werlabs,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.thelocal.se/20200723/14-of-antibody-tests-positive-in-sweden&ct=ga&cd=CAAYBzIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNHl1If-XI0aCeB5tGakbaJvFktByQ,2020-08-02,2022-07-16,Verified,the_local_se_14_2020,SWE
200723_Sweden_Werlabs_GenPop_Stolkholm,200723_Sweden_Werlabs,14% of coronavirus antibody tests positive in Sweden in July,2020-07-23,News and Media,Local,Cross-sectional survey ,Sweden,Uppland,Stockholm,"Residents of Malmo, Gothenburg, and Stockholm.",,2020-07-01,2020-07-22,Household and community samples,All,Multiple groups,,,Geographical area,Stockholm,80000,0.14400000000000002,,,,,,,,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Local,Werlabs,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.thelocal.se/20200723/14-of-antibody-tests-positive-in-sweden&ct=ga&cd=CAAYBzIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNHl1If-XI0aCeB5tGakbaJvFktByQ,2020-08-02,2022-07-16,Verified,the_local_se_14_2020,SWE
200805_Stockholm_UppsalaUniversity_CaregiversOverall_IgGORIgM,200805_Stockholm_UppsalaUniversity,High seroprevalence of SARS-CoV-2 in elderly care employees in Sweden,2020-08-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Sweden,,Stockholm,"Employees from 22 different elderly care homes in Stockholm, Swede",,2020-04-01,2020-04-20,Health care workers and caregivers,All,Adults (18-64 years),18.0,65.0,Primary Estimate,,1005,0.22899999999999998,0.204,0.257,True,,,,True,Convenience,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Johanna Lindahl,Uppsala University ,Not Unity-Aligned,https://dx.doi.org/10.1080/20008686.2020.1789036,2020-10-14,2024-03-01,Verified,lindahl_high_2020-1,SWE
200811_Stockholm_UppsalaUniversity_Djurgårdsstaden_TotalAbpositive,200811_Stockholm_UppsalaUniversity_1_djurg,"Pronounced difference in Covid-19 antibody prevalence indicates cluster transmission in Stockholm, Sweden.",2020-08-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Sweden,"Södermanland, Uppland",Stockholm,"In the present study, we selected two areas in Stockholm with different socio-economic conditions: Norra Djurgårdsstaden (NDS), a new area located
in the north-eastern inner city part of Stockholm, recently
built with a mainly middle- to high-income population,
and Tensta, a lower income highly segregated suburban
area in northern Stockholm, built in the late 1960´s. Randomly selected individuals were tested at local
temporary testing sites (June 17–18, 2020) using
a COVID-19 IgG/IgM rapid test (Zhejiang Orient
Gene Biotech Co Ltd, Huzhou, Zhejiang, China),
which has been described and evaluated previously",,2020-06-17,2020-06-18,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,,123,0.040999999999999995,0.006,0.076,True,,,,True,Simplified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,1.0,0.9550000000000001,['High'],Yes,Yes,No,Yes,Unclear,Yes,Yes,No,Unclear,Ake Lundkvist,Uppsala University ,Unity-Aligned,https://dx.doi.org/10.1080/20008686.2020.1806505,2020-10-16,2024-03-01,Verified,lundkvist_pronounced_2020-1,SWE
200811_Stockholm_UppsalaUniversity_Tensta_TotalAbPositive,200811_Stockholm_UppsalaUniversity_2_tensta,"Pronounced difference in Covid-19 antibody prevalence indicates cluster transmission in Stockholm, Sweden.",2020-08-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Sweden,"Södermanland, Uppland",Stockholm,"In the present study, we selected two
areas in Stockholm with different socio-economic conditions: Norra Djurgårdsstaden (NDS), a new area located
in the north-eastern inner city part of Stockholm, recently
built with a mainly middle- to high-income population,
and Tensta, a lower income highly segregated suburban
area in northern Stockholm, built in the late 1960´s. Randomly selected individuals were tested at local
temporary testing sites (June 17–18, 2020) using
a COVID-19 IgG/IgM rapid test (Zhejiang Orient
Gene Biotech Co Ltd, Huzhou, Zhejiang, China),
which has been described and evaluated previously",,2020-06-17,2020-06-18,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,,90,0.3,0.203,0.397,True,,,,True,Simplified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,1.0,0.9550000000000001,['High'],Yes,Yes,No,Yes,Unclear,Yes,Yes,No,Unclear,Ake Lundkvist,Uppsala University ,Unity-Aligned,https://dx.doi.org/10.1080/20008686.2020.1806505,2020-10-16,2024-03-01,Verified,lundkvist_pronounced_2020-1,SWE
200925_Stockholm_TheStockholmRegion,200925_Stockholm_TheStockholmRegion,25 september: Lägesrapport om arbetet med det nya coronaviruset,2020-09-25,Institutional Report,Local,Cross-sectional survey ,Sweden,,Stockholm,,,2020-06-15,2020-09-20,Household and community samples,All,Multiple groups,,,Primary Estimate,,483345,0.152,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Stockholm Region,The Stockholm Region,Not Unity-Aligned,https://www.sll.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2020/09/25-september-lagesrapport-om-arbetet-med-det-nya-coronaviruset/,2021-09-11,2022-07-16,Verified,the_stockholm_region_25_2020,SWE
200929_Stockholm_TheStockholmRegion,200929_Stockholm_TheStockholmRegion,29 september: Lägesrapport om covid-19,2020-09-29,Institutional Report,Local,Cross-sectional survey ,Sweden,,Stockholm,,,2020-09-21,2020-09-27,Household and community samples,All,Multiple groups,,,Primary Estimate,,9648,0.14300000000000002,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Stockholm Region,The Stockholm Region,Not Unity-Aligned,https://www.sll.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2020/09/29-september-lagesrapport-om-covid-19/,2021-09-11,2022-07-16,Verified,the_stockholm_region_29_2020,SWE
201006_Stockholm_TheStockholmRegion,201006_Stockholm_TheStockholmRegion,6 oktober: Lägesrapport om covid-19,2020-10-06,Institutional Report,Local,Cross-sectional survey ,Sweden,,Stockholm,,,2020-09-28,2020-10-04,Household and community samples,All,Multiple groups,,,Primary Estimate,,11670,0.154,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Stockholm Region,The Stockholm Region,Not Unity-Aligned,https://www.sll.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2020/10/6-oktober-lagesrapport-om-covid-19/,2021-09-13,2022-07-16,Verified,the_stockholm_region_6_2020,SWE
201008_Stockholm_DanderydHospital,201008_Stockholm_DanderydHospital,"SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden",2020-10-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Sweden,Sodermanland,Stockholm,Participants were eligible to participate in the study irrespective of whether they had had symptoms since the COVID-19 outbreak onset or not. There were no exclusion criteria,,2020-04-14,2020-05-08,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,2149,0.19100000000000003,,,True,,,,True,Convenience,Author designed (ELISA) - MULTIPLEXED,,,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.9920000000000001,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,No,Ann Sofie Rudberg,Danderyd Hospital,Not Unity-Aligned,http://dx.doi.org/10.1038/s41467-020-18848-0,2020-12-10,2022-07-16,Verified,rudberg_sars-cov-2_2020,SWE
201013_Stockholm_TheStockholmRegion,201013_Stockholm_TheStockholmRegion,13 oktober: Lägesrapport om covid-19,2020-10-13,Institutional Report,Local,Cross-sectional survey ,Sweden,,Stockholm,,,2020-10-05,2020-10-11,Household and community samples,All,Multiple groups,,,Primary Estimate,,11065,0.152,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Stockholm Region,The Stockholm Region,Not Unity-Aligned,https://www.sll.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2020/10/13-oktober-lagesrapport-om-covid-19/,2021-09-27,2022-07-16,Verified,the_stockholm_region_13_2020,SWE
201020_Stockholm_TheStockholmRegion,201020_Stockholm_TheStockholmRegion,20 oktober: Lägesrapport om covid-19,2020-10-20,Institutional Report,Local,Cross-sectional survey ,Sweden,,Stockholm,,,2020-10-12,2020-10-18,Household and community samples,All,Multiple groups,,,Primary Estimate,,10297,0.154,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Stockholm Region,The Stockholm Region,Not Unity-Aligned,https://www.sll.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2020/10/20-oktober-lagesrapport-om-covid-19/,2021-09-27,2022-07-16,Verified,the_stockholm_region_20_2020,SWE
201027_Stockholm_TheStockholmRegion,201027_Stockholm_TheStockholmRegion,27 oktober: Lägesrapport om covid-19,2020-10-27,Institutional Report,Local,Cross-sectional survey ,Sweden,,Stockholm,,,2020-10-19,2020-10-25,Household and community samples,All,Multiple groups,,,Primary Estimate,,8941,0.20600000000000002,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Stockholm Region,The Stockholm Region,Not Unity-Aligned,https://www.sll.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2020/10/27-oktober-lagesrapport-om-covid-19/,2021-09-27,2022-07-16,Verified,the_stockholm_region_27_2020,SWE
211103_Stockholm_TheStockholmRegion,201103_Stockholm_TheStockholmRegion,3 november: Lägesrapport om covid-19,2020-11-03,Institutional Report,Local,Cross-sectional survey ,Sweden,,Stockholm,,,2020-10-26,2020-11-01,Household and community samples,All,Multiple groups,,,Primary Estimate,,9580,0.217,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Stockholm Region,The Stockholm Region,Not Unity-Aligned,https://www.sll.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2020/11/3-november-lagesrapport-om-covid-19/,2021-09-27,2022-07-16,Verified,the_stockholm_region_3_2020,SWE
201110_Stockholm_TheStockholmRegion,201110_Stockholm_TheStockholmRegion,10 november: Lägesrapport om covid-19,2020-11-10,Institutional Report,Local,Cross-sectional survey ,Sweden,,Stockholm,,,2020-11-02,2020-11-08,Household and community samples,All,Multiple groups,,,Primary Estimate,,11500,0.259,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Stockholm Region,The Stockholm Region,Not Unity-Aligned,https://www.sll.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2020/11/10-november-lagesrapport-om-covid-19/,2021-10-04,2022-07-16,Verified,the_stockholm_region_10_2020,SWE
201117_Stockholm_TheStockholmRegion,201117_Stockholm_TheStockholmRegion,17 november: Lägesrapport om covid-19,2020-11-17,Institutional Report,Local,Cross-sectional survey ,Sweden,,Stockholm,,,2020-11-09,2020-11-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,13273,0.278,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Stockholm Region,The Stockholm Region,Not Unity-Aligned,https://www.sll.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2020/11/17-november-lagesrapport-om-covid-19/,2021-10-04,2022-07-16,Verified,the_stockholm_region_17_2020,SWE
201124_Stockholm_TheStockholmRegion,201124_Stockholm_TheStockholmRegion,24 november: Lägesrapport om covid-19,2020-11-24,Institutional Report,Local,Cross-sectional survey ,Sweden,,Stockholm,,,2020-11-16,2020-11-22,Household and community samples,All,Multiple groups,,,Primary Estimate,,15474,0.314,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Stockholm Region,The Stockholm Region,Not Unity-Aligned,https://www.sll.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2020/11/24-november-lagesrapport-om-covid-19/,2021-10-04,2022-07-16,Verified,the_stockholm_region_24_2020,SWE
201124_Vasteras_HospitalofVastmanland_HCW,201124_Vasteras_HospitalofVastmanland,Low rate of COVID-19 seroconversion in health-care workers at a Department of Infectious Diseases in Sweden during the later phase of the first wave; a prospective longitudinal seroepidemiological study.,2020-11-24,Journal Article (Peer-Reviewed),Local,Prospective cohort,Sweden,,Vasteras,"All HCWs presently working at the Department of Infectious Diseases of the Hospital of V€astmanland, V€asterås, Sweden, both clinical and administrative staff, were eligible to participate in the study. Participants who were relocated to another department were allowed to continue in the study. New employees who started working at the department during the study period were eligible to participate.",,2020-05-04,2020-08-19,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,131,0.1908,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9990000000000001,['High'],Yes,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,Mulki Rashid Abdi,The Hospital of Vastmanland ,Not Unity-Aligned,https://dx.doi.org/10.1080/23744235.2020.1849787,2021-02-23,2024-03-01,Verified,rashid-abdi_low_2020,SWE
201201_Stockholm_TheStockholmRegion,201201_Stockholm_TheStockholmRegion,1 december: Lägesrapport om covid-19,2020-12-01,Institutional Report,Local,Cross-sectional survey ,Sweden,,Stockholm,,,2020-11-23,2020-11-29,Household and community samples,All,Multiple groups,,,Primary Estimate,,16389,0.336,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Stockholm Region,The Stockholm Region,Not Unity-Aligned,https://www.sll.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2020/12/1-december-lagesrapport-om-covid-19/,2021-10-04,2022-07-16,Verified,the_stockholm_region_1_2020,SWE
201208_Stockholm_TheStockholmRegion,201208_Stockholm_TheStockholmRegion,8 december: Lägesrapport om covid-19,2020-12-08,Institutional Report,Local,Cross-sectional survey ,Sweden,,Stockholm,,,2020-11-30,2020-12-06,Household and community samples,All,Multiple groups,,,Primary Estimate,,16943,0.36700000000000005,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Stockholm Region,The Stockholm Region,Not Unity-Aligned,https://www.sll.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2020/12/8-december-lagesrapport-om-covid-19/,2021-10-04,2022-07-16,Verified,the_stockholm_region_8_2020,SWE
201215_Stockholm_TheStockholmRegion,201215_Stockholm_TheStockholmRegion,15 december: Lägesrapport om covid-19,2020-12-15,Institutional Report,Local,Cross-sectional survey ,Sweden,,Stockholm,,,2020-12-07,2020-12-13,Household and community samples,All,Multiple groups,,,Primary Estimate,,20466,0.39,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Stockholm Region,The Stockholm Region,Not Unity-Aligned,https://www.sll.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2020/12/15-december-lagesrapport-om-covid-19/,2021-10-14,2022-07-16,Verified,the_stockholm_region_15_2020,SWE
201222_Stockholm_TheStockholmRegion,201222_Stockholm_TheStockholmRegion,22 december: Lägesrapport om covid-19,2020-12-22,Institutional Report,Local,Cross-sectional survey ,Sweden,,Stockholm,,,2020-12-14,2020-12-20,Household and community samples,All,Multiple groups,,,Primary Estimate,,23466,0.381,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Stockholm Region,The Stockholm Region,Not Unity-Aligned,https://www.sll.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2020/12/22-december-lagesrapport-om-covid-19/,2021-10-14,2022-07-16,Verified,the_stockholm_region_22_2020,SWE
201222_Stockholm_KarolinskaUniversityHospital_LTCFstaff_primary,201222_Stockholm_KarolinskaUniversityHospital,"SARS-CoV-2 infections among personnel providing home care services for the elderly in Stockholm, Sweden",2020-12-22,Preprint,Local,Cross-sectional survey ,Sweden,,Stockholm,"Employees that were on duty from five different elderly home care service companies
(n=438) in the region of Stockholm were invited to participate in the study",,2020-05-11,2020-06-17,Assisted living and long-term care facilities,All,Multiple groups,,,Primary Estimate,LTCF employees,403,0.201,,,True,,,,True,Convenience,Author designed (Luminex),,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.9920000000000001,0.998,['High'],No,No,No,Yes,No,Unclear,Yes,Yes,Yes,Sadaf Sakina Hassan,Karolinska University Hospital,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.12.18.20248511v1,2021-02-02,2022-07-16,Verified,hassan_sars-cov-2_2020-1,SWE
201229_Stockholm_TheStockholmRegion,201229_Stockholm_TheStockholmRegion,29 december: Lägesrapport om covid-19,2020-12-29,Institutional Report,Local,Cross-sectional survey ,Sweden,,Stockholm,,,2020-12-21,2020-12-27,Household and community samples,All,Multiple groups,,,Primary Estimate,,17624,0.378,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Stockholm Region,The Stockholm Region,Not Unity-Aligned,https://www.sll.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2020/12/29-december-lagesrapport-om-covid-19/,2021-10-14,2022-07-16,Verified,the_stockholm_region_29_2020-1,SWE
210105_Stockholm_TheStockholmRegion,210105_Stockholm_TheStockholmRegion,5 januari: Lägesrapport om covid-19,2021-01-05,Institutional Report,Local,Cross-sectional survey ,Sweden,,Stockholm,,,2020-12-28,2021-01-03,Household and community samples,All,Multiple groups,,,Primary Estimate,,15061,0.424,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Stockholm Region,The Stockholm Region,Not Unity-Aligned,https://www.sll.se/verksamhet/halsa-och-vard/nyheter-lagesrapporter-covid-19/2021/01/5-januari-lagesrapport-om-covid-19/,2021-10-18,2022-07-16,Verified,the_stockholm_region_5_2021,SWE
210112_Stockholm_TheStockholmRegion,210112_Stockholm_TheStockholmRegion,12 januari: Lägesrapport om covid-19,2021-01-12,Institutional Report,Local,Cross-sectional survey ,Sweden,,Stockholm,,,2021-01-04,2021-01-10,Household and community samples,All,Multiple groups,,,Primary Estimate,,10378,0.428,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Stockholm Region,The Stockholm Region,Not Unity-Aligned,https://www.sll.se/verksamhet/halsa-och-vard/nyheter-lagesrapporter-covid-19/2021/01/12-januari-lagesrapport-om-covid-19/,2021-10-18,2022-07-16,Verified,the_stockholm_region_12_2021,SWE
210119_Stockholm_TheStockholmRegion,210119_Stockholm_TheStockholmRegion,19 januari: Lägesrapport om covid-19,2021-01-19,Institutional Report,Local,Cross-sectional survey ,Sweden,,Stockholm,,,2021-01-11,2021-01-17,Household and community samples,All,Multiple groups,,,Primary Estimate,,18544,0.45299999999999996,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Stockholm Region,The Stockholm Region,Not Unity-Aligned,https://www.sll.se/verksamhet/halsa-och-vard/nyheter-lagesrapporter-covid-19/2021/01/19-januari-lagesrapport-om-covid-19/,2021-10-18,2022-07-16,Verified,the_stockholm_region_19_2021,SWE
210121_Sweden_CopenhagenUniversityHospital_Sweden,210121_Sweden_CopenhagenUniversityHospital,Prevalence of SARS-CoV-2 IgG/IgM antibodies among Danish and Swedish Falck emergency and non-emergency healthcare workers,2021-01-21,Journal Article (Peer-Reviewed),National,Prospective cohort,Sweden,,,Participants were included on account of being Falck employees.,,2020-06-22,2020-08-10,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1248,0.083,,,True,,,,True,Convenience,"2019-nCoV IgG/IgM Antibody Detection Kit,Finecare SARS-CoV-2 Antibody test,Wondfo SARS-CoV-2 Antibody Test","Zhuhai Livzon Diagnostics Inc,Guangzhou Wondfo Biotech Co. Ltd",LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Jannie Laursen,Copenhagen University Hospital,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph18030923,2021-02-25,2024-03-01,Verified,laursen_prevalence_2021,SWE
210121_Sweden_CopenhagenUniversityHospital_Sweden_<40yo,210121_Sweden_CopenhagenUniversityHospital,Prevalence of SARS-CoV-2 IgG/IgM antibodies among Danish and Swedish Falck emergency and non-emergency healthcare workers,2021-01-21,Journal Article (Peer-Reviewed),National,Prospective cohort,Sweden,,,Participants were included on account of being Falck employees.,,2020-06-22,2020-08-10,Health care workers and caregivers,All,Adults (18-64 years),,39.0,Age,<40,374,0.09,,,,,,,,Convenience,"2019-nCoV IgG/IgM Antibody Detection Kit,Finecare SARS-CoV-2 Antibody test,Wondfo SARS-CoV-2 Antibody Test","Zhuhai Livzon Diagnostics Inc,Guangzhou Wondfo Biotech Co. Ltd",LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Jannie Laursen,Copenhagen University Hospital,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph18030923,2021-02-25,2024-03-01,Verified,laursen_prevalence_2021,SWE
210121_Sweden_CopenhagenUniversityHospital_Sweden_60+,210121_Sweden_CopenhagenUniversityHospital,Prevalence of SARS-CoV-2 IgG/IgM antibodies among Danish and Swedish Falck emergency and non-emergency healthcare workers,2021-01-21,Journal Article (Peer-Reviewed),National,Prospective cohort,Sweden,,,Participants were included on account of being Falck employees.,,2020-06-22,2020-08-10,Health care workers and caregivers,All,Seniors (65+ years),60.0,,Age,60+ yo,187,0.054000000000000006,,,,,,,,Convenience,"2019-nCoV IgG/IgM Antibody Detection Kit,Finecare SARS-CoV-2 Antibody test,Wondfo SARS-CoV-2 Antibody Test","Zhuhai Livzon Diagnostics Inc,Guangzhou Wondfo Biotech Co. Ltd",LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Jannie Laursen,Copenhagen University Hospital,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph18030923,2021-02-25,2024-03-01,Verified,laursen_prevalence_2021,SWE
210121_Sweden_CopenhagenUniversityHospital_Sweden_40-60,210121_Sweden_CopenhagenUniversityHospital,Prevalence of SARS-CoV-2 IgG/IgM antibodies among Danish and Swedish Falck emergency and non-emergency healthcare workers,2021-01-21,Journal Article (Peer-Reviewed),National,Prospective cohort,Sweden,,,Participants were included on account of being Falck employees.,,2020-06-22,2020-08-10,Health care workers and caregivers,All,Adults (18-64 years),40.0,60.0,Age,40-60yo,687,0.08800000000000001,,,,,,,,Convenience,"2019-nCoV IgG/IgM Antibody Detection Kit,Finecare SARS-CoV-2 Antibody test,Wondfo SARS-CoV-2 Antibody Test","Zhuhai Livzon Diagnostics Inc,Guangzhou Wondfo Biotech Co. Ltd",LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Jannie Laursen,Copenhagen University Hospital,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph18030923,2021-02-25,2024-03-01,Verified,laursen_prevalence_2021,SWE
210126_Stockholm_TheStockholmRegion,210126_Stockholm_TheStockholmRegion,26 januari: Lägesrapport om covid-19,2021-01-26,Institutional Report,Local,Cross-sectional survey ,Sweden,,Stockholm,,,2021-01-18,2021-01-24,Household and community samples,All,Multiple groups,,,Primary Estimate,,15498,0.444,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Stockholm Region,The Stockholm Region,Not Unity-Aligned,https://www.sll.se/verksamhet/halsa-och-vard/nyheter-lagesrapporter-covid-19/2021/01/26-januari-lagesrapport-om-covid-19/,2021-10-18,2022-07-16,Verified,the_stockholm_region_26_2021,SWE
210129_Stockholm_KarolinskaInstitutet_HCW,210129_Stockholm_KarolinskaInstitutet,Risk of SARS-CoV-2 exposure among hospital healthcare workers in relation to patient contact and type of care,2021-01-29,Preprint,Local,Cross-sectional survey ,Sweden,Uppland,Stockholm,All HCW at Stockholm South General Hospital (Södersjukhuset) invited to participate ,,2020-05-11,2020-06-11,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Overall HCW,3981,0.177,,,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.9920000000000001,0.998,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Yes,Susanna Klevebro,Karolinska Institutet,Not Unity-Aligned,https://doi.org/10.1101/2021.01.28.21250664,2021-02-21,2022-07-16,Verified,klevebro_risk_2021,SWE
210202_Stockholm_TheStockholmRegion,210202_Stockholm_TheStockholmRegion,2 februari: Lägesrapport om covid-19,2021-02-02,Institutional Report,Local,Cross-sectional survey ,Sweden,,Stockholm,,,2021-01-25,2021-01-31,Household and community samples,All,Multiple groups,,,Primary Estimate,,11749,0.457,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Stockholm Region,The Stockholm Region,Not Unity-Aligned,https://www.sll.se/verksamhet/halsa-och-vard/nyheter-lagesrapporter-covid-19/2021/02/2-februari-lagesrapport-om-covid-19/,2021-10-18,2022-07-16,Verified,the_stockholm_region_2_2021,SWE
210209_Stockholm_TheStockholmRegion,210209_Stockholm_TheStockholmRegion,9 februari: Lägesrapport om covid-19,2021-02-09,Institutional Report,Local,Cross-sectional survey ,Sweden,,Stockholm,,,2021-02-01,2021-02-07,Household and community samples,All,Multiple groups,,,Primary Estimate,,11175,0.44700000000000006,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Stockholm Region,The Stockholm Region,Not Unity-Aligned,https://www.regionstockholm.se/verksamhet/halsa-och-vard/nyheter-lagesrapporter-covid-19/2021/02/9-februari-lagesrapport-om-covid-19/,2021-11-22,2022-07-16,Verified,the_stockholm_region_9_2021,SWE
210216_Stockholm_TheStockholmRegion,210216_Stockholm_TheStockholmRegion,16 februari: Lägesrapport om covid-19,2021-02-16,Institutional Report,Local,Cross-sectional survey ,Sweden,,Stockholm,,,2021-02-08,2021-02-14,Household and community samples,All,Multiple groups,,,Primary Estimate,,8108,0.425,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Stockholm Region,The Stockholm Region,Not Unity-Aligned,https://www.regionstockholm.se/verksamhet/halsa-och-vard/nyheter-lagesrapporter-covid-19/2021/02/16-februari-lagesrapport-om-covid-19/,2021-11-22,2022-07-16,Verified,the_stockholm_region_16_2021,SWE
210223_Stockholm_TheStockholmRegion,210223_Stockholm_TheStockholmRegion,23 februari: Lägesrapport om covid-19,2021-02-23,Institutional Report,Local,Cross-sectional survey ,Sweden,,Stockholm,,,2021-02-15,2021-02-21,Household and community samples,All,Multiple groups,,,Primary Estimate,,9024,0.424,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Stockholm Region,The Stockholm Region,Not Unity-Aligned,https://www.regionstockholm.se/verksamhet/halsa-och-vard/nyheter-lagesrapporter-covid-19/2021/02/23-februari-lagesrapport-om-covid-19/,2021-11-22,2022-07-16,Verified,the_stockholm_region_23_2021,SWE
210302_Stockholm_TheStockholmRegion,210302_Stockholm_TheStockholmRegion,2 mars: Lägesrapport om covid-19,2021-03-02,Institutional Report,Local,Cross-sectional survey ,Sweden,,Stockholm,,,2021-02-22,2021-02-28,Household and community samples,All,Multiple groups,,,Primary Estimate,,12605,0.409,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Stockholm Region,The Stockholm Region,Not Unity-Aligned,https://www.regionstockholm.se/verksamhet/halsa-och-vard/nyheter-lagesrapporter-covid-19/2021/03/2-mars-lagesrapport-om-covid-19/,2021-11-22,2022-07-16,Verified,the_stockholm_region_2_2021-1,SWE
210305_Stockholm_Västerås_primary,210305_Stockholm_Västerås,No findings of SARS-CoV-2 in conjunctival swabs from patients at an emergency outpatient ophthalmological healthcare facility in a Swedish county hospital: a cross-sectional study,2021-03-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Sweden,,Stockholm,"All staff at the department of ophthalmology, Region Västmanland Sweden, were informed about the study and asked to participate. ",,2020-06-04,2020-06-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,70,0.043,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['High'],No,No,No,No,Unclear,Yes,Yes,Yes,Yes,Elisabet Granstam,Västerås,Not Unity-Aligned,https://bmjophth.bmj.com/content/6/1/e000616,2021-05-20,2024-03-01,Verified,granstam_no_2021,SWE
210309_Stockholm_TheStockholmRegion,210309_Stockholm_TheStockholmRegion,9 mars: Lägesrapport om covid-19,2021-03-09,Institutional Report,Local,Cross-sectional survey ,Sweden,,Stockholm,,,2021-03-01,2021-03-07,Household and community samples,All,Multiple groups,,,Primary Estimate,,9237,0.395,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Stockholm Region,The Stockholm Region,Not Unity-Aligned,https://www.regionstockholm.se/verksamhet/halsa-och-vard/nyheter-lagesrapporter-covid-19/2021/03/9-mars-lagesrapport-om-covid-19/,2021-11-22,2022-07-16,Verified,the_stockholm_region_9_2021-1,SWE
210309_SkåneRegion_LundUniversity_HCWs,210309_SkåneRegion_LundUniversity_HCWs,Association between SARS-CoV-2 and exposure risks in health care workers and university employees - a cross-sectional study,2021-03-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Sweden,Skåne Region,,,Those working in units with known outbreaks. ,2020-09-08,2020-11-10,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,271,0.059000000000000004,,,True,,,,True,Convenience,ZetaGene COVID-19 Antibody Test IgM/IgG,ZetaGene Ltd.,,Serum,IgG,,,,,['High'],No,No,No,Yes,No,Yes,Yes,Yes,No,David Nygren,Lund University,Not Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.1892819,2021-04-01,2024-03-01,Verified,nygren_association_2021,SWE
210309_SkåneRegion_LundUniversity_UniversityEmployees,210309_SkåneRegion_LundUniversity_UniversityEmployees,Association between SARS-CoV-2 and exposure risks in health care workers and university employees - a cross-sectional study,2021-03-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Sweden,Skåne Region,Lund,,Those working in units with known outbreaks. ,2020-09-08,2020-11-10,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,192,0.06,,,True,,,,True,Convenience,ZetaGene COVID-19 Antibody Test IgM/IgG,ZetaGene Ltd.,,Serum,IgG,,,,,['High'],No,No,No,Yes,No,Yes,Yes,Yes,No,David Nygren,Lund University,Not Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.1892819,2021-04-01,2024-03-01,Verified,nygren_association_2021,SWE
210316_Stockholm_TheStockholmRegion,210316_Stockholm_TheStockholmRegion,16 mars: Lägesrapport om covid-19,2021-03-16,Institutional Report,Local,Cross-sectional survey ,Sweden,,Stockholm,,,2021-03-08,2021-03-14,Household and community samples,All,Multiple groups,,,Primary Estimate,,9769,0.39799999999999996,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Stockholm Region,The Stockholm Region,Not Unity-Aligned,https://www.regionstockholm.se/verksamhet/halsa-och-vard/nyheter-lagesrapporter-covid-19/2021/03/16-mars-lagesrapport-om-covid-19/,2021-11-22,2022-07-16,Verified,the_stockholm_region_16_2021-1,SWE
210317_Sweden_TheSwedishPublicHealthAgency_BloodDonors_overall,210317_Sweden_TheSwedishPublicHealthAgency_BloodDonors,Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 2) ,2021-03-17,Institutional Report,National,Repeated cross-sectional study,Sweden,"Regions of: Jämtland-Härjedalen, Jönköping, Kalmar,
Skåne, Stockholm, Uppsala, Västerbotten, Västra Götaland and Örebro",,"Blood donors in nine regions of Sweden (Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten, Västra Götaland and Örebro)",,2020-11-23,2020-12-04,Blood donors,All,Multiple groups,,,Primary Estimate,,3183,0.07,0.0575,0.0848,True,True,True,,True,Convenience,,Sci LifeLab / KTH,ELISA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,0.9890000000000001,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Swedish Public Health Agency,The Swedish Public Health Agency (Folkhälsomyndigheten),Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/376f9021a4c84da08de18ac597284f0c/pavisning-antikroppar-genomgangen-covid-19-blodgivare-delrapport-2.pdf,2021-05-03,2022-07-16,Verified,swedish_public_health_agency_pavisning_2021,SWE
210323_Stockholm_TheStockholmRegion,210323_Stockholm_TheStockholmRegion,23 mars: Lägesrapport om covid-19,2021-03-23,Institutional Report,Local,Cross-sectional survey ,Sweden,,Stockholm,,,2021-03-15,2021-03-21,Household and community samples,All,Multiple groups,,,Primary Estimate,,9040,0.40399999999999997,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Stockholm Region,The Stockholm Region,Not Unity-Aligned,https://www.regionstockholm.se/verksamhet/halsa-och-vard/nyheter-lagesrapporter-covid-19/2021/03/23-mars-lagesrapport-om-covid-19/,2021-11-22,2022-07-16,Verified,the_stockholm_region_23_2021-1,SWE
210330_Stockholm_TheStockholmRegion,210330_Stockholm_TheStockholmRegion,30 mars: Lägesrapport om covid-19,2021-03-30,Institutional Report,Local,Cross-sectional survey ,Sweden,,Stockholm,,,2021-03-22,2021-03-28,Household and community samples,All,Multiple groups,,,Primary Estimate,,10146,0.409,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Stockholm Region,The Stockholm Region,Not Unity-Aligned,https://www.regionstockholm.se/verksamhet/halsa-och-vard/nyheter-lagesrapporter-covid-19/2021/03/30-mars-lagesrapport-om-covid-19/,2021-11-22,2022-07-16,Verified,the_stockholm_region_30_2021,SWE
210406_Stockholm_TheStockholmRegion,210406_Stockholm_TheStockholmRegion,6 april: Lägesrapport om covid-19,2021-04-06,Institutional Report,Local,Cross-sectional survey ,Sweden,,Stockholm,,,2021-03-29,2021-04-04,Household and community samples,All,Multiple groups,,,Primary Estimate,,10419,0.42700000000000005,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Stockholm Region,The Stockholm Region,Not Unity-Aligned,https://www.regionstockholm.se/verksamhet/halsa-och-vard/nyheter-lagesrapporter-covid-19/2021/04/6-april-lagesrapport-om-covid-19/,2021-11-22,2022-07-16,Verified,the_stockholm_region_6_2021,SWE
210412_Stockholm_KarolinskaInstitutet_hcw,210412_Stockholm_KarolinskaInstitutet,"SARS-CoV-2 infections amongst personnel providing home care services for older persons in Stockholm, Sweden",2021-04-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Sweden,Södermanland and Uppland,Stockholm,Employees who were on duty from five different home care service companies for older persons (n = 438) in the region of Stockholm were invited to participate in the study during the period 11 May–17 June 2020. ,,2020-05-11,2020-06-17,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,403,0.201,,,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.9920000000000001,0.998,['High'],Unclear,No,No,No,Unclear,Unclear,Yes,Yes,Yes,S Hassan,Karolinska Institutet,Not Unity-Aligned,https://dx.doi.org/10.1111/joim.13274,2021-05-02,2022-07-16,Verified,hassan_sarscov2_2021,SWE
210413_Stockholm_TheStockholmRegion,210413_Stockholm_TheStockholmRegion,13 april: Lägesrapport om covid-19,2021-04-13,Institutional Report,Local,Cross-sectional survey ,Sweden,,Stockholm,,,2021-04-05,2021-04-11,Household and community samples,All,Multiple groups,,,Primary Estimate,,2084,0.509,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Stockholm Region,The Stockholm Region,Not Unity-Aligned,https://www.regionstockholm.se/verksamhet/halsa-och-vard/nyheter-lagesrapporter-covid-19/2021/04/13-april-lagesrapport-om-covid-19/,2021-12-01,2022-07-16,Verified,the_stockholm_region_13_2021,SWE
210420_Stockholm_TheStockholmRegion,210420_Stockholm_TheStockholmRegion,20 april: Lägesrapport om covid-19,2021-04-20,Institutional Report,Local,Cross-sectional survey ,Sweden,,Stockholm,,,2021-04-12,2021-04-18,Household and community samples,All,Multiple groups,,,Primary Estimate,,868,0.5760000000000001,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Stockholm Region,The Stockholm Region,Not Unity-Aligned,https://www.regionstockholm.se/verksamhet/halsa-och-vard/nyheter-lagesrapporter-covid-19/2021/04/mall-lagesrapport-med-tabell/,2021-12-01,2022-07-16,Verified,the_stockholm_region_20_2021,SWE
210427_Stockholm_TheStockholmRegion,210427_Stockholm_TheStockholmRegion,27 april: Lägesrapport om covid-19,2021-04-27,Institutional Report,Local,Cross-sectional survey ,Sweden,,Stockholm,,,2021-04-19,2021-04-25,Household and community samples,All,Multiple groups,,,Primary Estimate,,953,0.615,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,The Stockholm Region,The Stockholm Region,Not Unity-Aligned,https://www.regionstockholm.se/verksamhet/halsa-och-vard/nyheter-lagesrapporter-covid-19/2021/04/27-april-Lagesrapport-om-ovid-19/,2021-12-01,2022-07-16,Verified,the_stockholm_region_27_2021,SWE
210427_Sweden_SwedishPublicHealthAgency_Outpatients_10_Week48-49_Overall,210427_Sweden_SwedishPublicHealthAgency_Outpatients_10_Week48-49,Påvisning av antikroppar efter genomgången covid-19 i blodprov från öppenvården (Delrapport 1) ,2021-04-27,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Weekly April 20 to June 12, 2020about 1200 samples were collected, with 400 samples each from individuals 0-19 years, 20-64 years and 65-95 years. For the later collections, the number of samples collected is adjustedto provide better estimation based on estimated seroprevalence in each age group(a total of approximately 4500 samples per collection period) and the collection period is extended totwo weeks.",,2020-11-23,2020-12-04,Residual sera,All,Multiple groups,0.0,95.0,Primary Estimate,,4500,0.079,0.0679,0.0919,True,True,True,,True,Stratified probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Low'],,Yes,Yes,No,,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2021-06-08,2022-07-16,Unverified,swedish_public_health_agency_pavisning_2021-1,SWE
210427_Sweden_SwedishPublicHealthAgency_Outpatients_11_Week9-10_2021_Overall,210427_Sweden_SwedishPublicHealthAgency_Outpatients_11_Week9-10_2021,Påvisning av antikroppar efter genomgången covid-19 i blodprov från öppenvården (Delrapport 1) ,2021-04-27,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jönköping, Kalmar, Skåne,Stockholm, Uppsala, Västerbotten, Västra Götaland, Örebo",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Weekly April 20 to June 12, 2020about 1200 samples were collected, with 400 samples each from individuals 0-19 years, 20-64 years and 65-95 years. For the later collections, the number of samples collected is adjustedto provide better estimation based on estimated seroprevalence in each age group(a total of approximately 4500 samples per collection period) and the collection period is extended totwo weeks.",,2021-03-01,2021-03-12,Residual sera,All,Multiple groups,0.0,95.0,Primary Estimate,,4749,0.207,0.1941,0.2208,True,True,True,,True,Stratified probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Low'],,Yes,Yes,No,,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2021-06-08,2022-07-16,Unverified,swedish_public_health_agency_pavisning_2021-1,SWE
210427_Sweden_SwedishPublicHealthAgency_Outpatients_9_Week42-43_Overall,210427_Sweden_SwedishPublicHealthAgency_Outpatients_9_Week42-43,Påvisning av antikroppar efter genomgången covid-19 i blodprov från öppenvården (Delrapport 1) ,2021-04-27,Institutional Report,National,Repeated cross-sectional study,Sweden,"Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro",,"The samples collected are leftover material from blood samples taken in outpatient careon a medical indication other than covid-19. Weekly April 20 to June 12, 2020about 1200 samples were collected, with 400 samples each from individuals 0-19 years, 20-64 years and 65-95 years. For the later collections, the number of samples collected is adjustedto provide better estimation based on estimated seroprevalence in each age group(a total of approximately 4500 samples per collection period) and the collection period is extended totwo weeks.",,2020-10-12,2020-10-23,Residual sera,All,Multiple groups,0.0,95.0,Primary Estimate,,4500,0.067,0.0567,0.0779,True,True,True,,True,Stratified probability,,Sci LifeLab / KTH,ELISA,Multiple Types,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9940000000000001,,['Low'],,Yes,Yes,No,,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf,2021-06-08,2022-07-16,Unverified,swedish_public_health_agency_pavisning_2021-1,SWE
210507_Stockholm_KarolinskaUniversityHospital,210507_Stockholm_KarolinskaUniversityHospital,SARS-CoV-2 Infections Among Healthcare Workers Outside Hospitals,2021-05-07,Preprint,Local,Cross-sectional survey ,Sweden,Uppland,Stockholm,"Healthcare providers in Stockholm, Sweden, were asked to invite their employees to a study of past or present SARS-CoV-2 infections in the healthcare setting. Healthcare staff on duty (hence without any disease symptoms) were eligible. To be included in the study, each study subject needed to provide a written informed consent form. For each unit included in the study, there needed to be an approval by the operations manager.","Staff members were excluded if they were absent from work or had an incomplete consent form. Samples (throat swabs or blood samples) were excluded if they were invalid or absent. If both samples were invalid or absent, the individual was excluded.",2020-06-01,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,839,0.12,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,0.9920000000000001,0.998,['Moderate'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Yes,Maria Froberg,Karolinska University Hospital,Not Unity-Aligned,https://www.researchsquare.com/article/rs-493146/v1,2021-05-29,2022-07-16,Verified,froberg_sars-cov-2_2021,SWE
210511_SkåneUniversityHospital_LundUniversity_HCW,210511_SkåneUniversityHospital_LundUniversity,Post-outbreak serological screening for SARS-CoV-2 infection in healthcare workers at a Swedish University Hospital,2021-05-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Sweden,,Lund,"HCWs who had been tested with RT-PCR for SARS-CoV-2 during an outbreak at Skåne University Hospital in May–June 2020,",,2020-08-01,2020-08-22,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,107,0.355,,,True,,,,True,Convenience,ZetaGene COVID-19 Antibody Test IgM/IgG,ZetaGene Ltd.,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9500000000000001,0.97,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Yes,Rasmus Strand,Lund University,Not Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.1925739,2021-05-31,2024-03-01,Verified,Strand_post-outbreak_2021,SWE
210518_Stockholm_KarolinskaInstitutet,210518_Stockholm_KarolinskaInstitutet,"Seropositivity in blood donors and pregnant women during the first year of SARS-CoV-2 transmission in Stockholm, Sweden",2021-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Sweden,Uppland,Stockholm,"Anonymized samples (n = 5,100 total) from blood donors (n = 100/sampling week) and pregnant women (n = 100/sampling week) were randomly selected from their respective pools through the Department of Clinical Microbiology, Karolinska University Hospital (KUH). Pregnant women were sampled as part of routine screening for infectious diseases during the first trimester of pregnancy. Blood donors are required to be over 50kg, over the age of 18, and  healthy for a minimum of two weeks before a donation and all participants reported symptom-free at sample collection",No study participant was analysed more than once over the course of the study.,2020-03-14,2021-02-28,Multiple general populations,All,Adults (18-64 years),18.0,,Primary Estimate,,5100,0.192,0.151,0.244,True,True,,,True,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,,,['Moderate'],No,Yes,Yes,No,Unclear,Unclear,Yes,Yes,No,Xaquin Castro Dopico,Karolinska Institutet,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/full/10.1111/joim.13304,2021-05-28,2022-07-16,Verified,dopico_seropositivity_2021,SWE
210614_Gothenburg_TheSwedishPublicHealthAgency_Primary,210614_Gothenburg_TheSwedishPublicHealthAgency,Förekomsten av antikroppar mot SARS-CoV-2 bland äldre i Göteborg 1-16 mars 2021,2021-06-14,Institutional Report,Local,Cross-sectional survey ,Sweden,,Gothenburg,"The selection of participants was based on the H70 study's selection of 75-76-year-olds born in 1944. A total of 1,269 people were offered to perform an antibody test against SARS-CoV-2. Of 1,269, 724 people (response rate 58 percent) were sampled and 719 of these also answered a questionnaire sent out. ","Participants with a so-called gray area result were thus excluded from the analysis and in addition, participants who stated that they had been vaccinated against covid-19 were excluded if they also lacked antibodies to the N protein",2021-03-01,2021-03-16,Blood donors,All,Seniors (65+ years),75.0,76.0,Primary Estimate,,724,0.069,0.053,0.09,True,True,,,True,Self-referral,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Swedish Public Health Agency,"The Public Health Agency of Sweden, University of Gothenburg, Sahlgrenska University Hospital and Region Västra Götaland",Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/eee8b4f90ef24a18b2a65865341710e1/forekomsten-antikroppar-sars-cov-2-aldre-goteborg.pdf,2021-08-10,2023-08-15,Unverified,swedish_förekomsten_2021-2,SWE
210614_Gothenburg_TheSwedishPublicHealthAgency_Female,210614_Gothenburg_TheSwedishPublicHealthAgency,Förekomsten av antikroppar mot SARS-CoV-2 bland äldre i Göteborg 1-16 mars 2021,2021-06-14,Institutional Report,Local,Cross-sectional survey ,Sweden,,Gothenburg,"The selection of participants was based on the H70 study's selection of 75-76-year-olds born in 1944. A total of 1,269 people were offered to perform an antibody test against SARS-CoV-2. Of 1,269, 724 people (response rate 58 percent) were sampled and 719 of these also answered a questionnaire sent out. ","Participants with a so-called gray area result were thus excluded from the analysis and in addition, participants who stated that they had been vaccinated against covid-19 were excluded if they also lacked antibodies to the N protein",2021-03-01,2021-03-16,Blood donors,Female,Seniors (65+ years),75.0,76.0,Sex/Gender,,403,0.062000000000000006,0.042,0.09,,True,,,,Self-referral,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Swedish Public Health Agency,"The Public Health Agency of Sweden, University of Gothenburg, Sahlgrenska University Hospital and Region Västra Götaland",Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/eee8b4f90ef24a18b2a65865341710e1/forekomsten-antikroppar-sars-cov-2-aldre-goteborg.pdf,2021-08-10,2023-08-15,Unverified,swedish_förekomsten_2021-2,SWE
210614_Gothenburg_TheSwedishPublicHealthAgency_Male,210614_Gothenburg_TheSwedishPublicHealthAgency,Förekomsten av antikroppar mot SARS-CoV-2 bland äldre i Göteborg 1-16 mars 2021,2021-06-14,Institutional Report,Local,Cross-sectional survey ,Sweden,,Gothenburg,"The selection of participants was based on the H70 study's selection of 75-76-year-olds born in 1944. A total of 1,269 people were offered to perform an antibody test against SARS-CoV-2. Of 1,269, 724 people (response rate 58 percent) were sampled and 719 of these also answered a questionnaire sent out. ","Participants with a so-called gray area result were thus excluded from the analysis and in addition, participants who stated that they had been vaccinated against covid-19 were excluded if they also lacked antibodies to the N protein",2021-03-01,2021-03-16,Blood donors,Male,Seniors (65+ years),75.0,76.0,Sex/Gender,,321,0.078,0.053,0.11199999999999999,,True,,,,Self-referral,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Swedish Public Health Agency,"The Public Health Agency of Sweden, University of Gothenburg, Sahlgrenska University Hospital and Region Västra Götaland",Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/eee8b4f90ef24a18b2a65865341710e1/forekomsten-antikroppar-sars-cov-2-aldre-goteborg.pdf,2021-08-10,2023-08-15,Unverified,swedish_förekomsten_2021-2,SWE
210614_Gothenburg_TheSwedishPublicHealthAgency_Vaccinated,210614_Gothenburg_TheSwedishPublicHealthAgency,Förekomsten av antikroppar mot SARS-CoV-2 bland äldre i Göteborg 1-16 mars 2021,2021-06-14,Institutional Report,Local,Cross-sectional survey ,Sweden,,Gothenburg,"The selection of participants was based on the H70 study's selection of 75-76-year-olds born in 1944. A total of 1,269 people were offered to perform an antibody test against SARS-CoV-2. Of 1,269, 724 people (response rate 58 percent) were sampled and 719 of these also answered a questionnaire sent out. ","Participants with a so-called gray area result were thus excluded from the analysis and in addition, participants who stated that they had been vaccinated against covid-19 were excluded if they also lacked antibodies to the N protein",2021-03-01,2021-03-16,Blood donors,All,Seniors (65+ years),75.0,76.0,COVID-19 vaccination status,Vaccinated yes,12,0.833,,,,,,,,Self-referral,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ",Abbott Laboratories,CLIA,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Swedish Public Health Agency,"The Public Health Agency of Sweden, University of Gothenburg, Sahlgrenska University Hospital and Region Västra Götaland",Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/eee8b4f90ef24a18b2a65865341710e1/forekomsten-antikroppar-sars-cov-2-aldre-goteborg.pdf,2021-08-10,2024-03-01,Unverified,swedish_förekomsten_2021-2,SWE
210617_Stockholm_KTHRoyalInstituteofTechnology,210617_Stockholm_KTHRoyalInstituteofTechnology,Multianalyte serology in home-sampled blood enables an unbiased assessment of the immune response against SARS-CoV-2.,2021-06-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Sweden,,Stolkholm,2000 randomly selected inhabitants (20–74 years old) from the population register in metropolitan Stockholm (Table S3) during April 2020.,,2020-04-15,2020-05-15,Household and community samples,All,Multiple groups,20.0,74.0,Primary Estimate,,878,0.125,0.10300000000000001,0.147,True,,,,True,Simplified probability,Author designed (Luminex),,ELISA,Dried Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,0.96,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,No,Niclas Roxhed,KTH Royal Institute of Technology,Not Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23893-4,2021-07-06,2022-07-16,Verified,menezes_high_2021,SWE
210618_Sweden_PublicHealthAgencyOfSweden,210618_Sweden_PublicHealthAgencyOfSweden,Stable IgG-antibody levels in patients with mild SARS-CoV-2 infection,2021-06-18,Preprint,National,Prospective cohort,Sweden,,,Non-cases were defined as study participants with no reported laboratory-confirmed SARS-CoV-2 infection (i.e. rRT-PCR test) as per recording in the SmiNet database up to the serum sampling date.,"Of 484 participants, 15 were excluded due to incomplete personal identification number, missing serum samples, or if serum sampling had occurred within 14 days of disease onset.",2020-10-30,2020-12-08,Household and community samples,All,Multiple groups,,,Primary Estimate,,324,0.086,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,0.997,1.0,['High'],,No,No,No,,Unclear,Yes,Yes,,Thomas Akerlund,Public Health Agency of Sweden,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.06.16.21258960v1.full-text,2021-06-30,2022-07-16,Unverified,akerlundStableIgGantibodyLevels2021,SWE
210719_Sweden_SwedishPublicHealthAgency_Outpatients_2022Week34-36_Overall,210719_Sweden_SwedishPublicHealthAgency_Outpatients_2022Week34-36,Påvisning av antikroppar mot SARS-CoV-2 i blodprov från öppenvården,2021-07-19,Institutional Report,National,Repeated cross-sectional study,Sweden,,"Jämtland Härjedalen, Kalmar, Skåne, Stockholm, Uppsala (0-19 years only), Västra Götaland and Örebro","In 2022, during the period 28 February to 20 March (weeks 9-11), child samples (0-19 years) were collected from seven regions: Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västra Götaland and Örebro. During the period 22 August to 11 September, samples were collected in seven regions: Jämtland Härjedalen, Kalmar, Skåne, Stockholm, Uppsala (0-19 years only), Västra Götaland and Örebro. The collection in Västra Götaland took place in Gothenburg.

The samples collected are leftover material from blood samples taken in outpatient care for a medical indication other than covid-19.",,2022-08-22,2022-09-11,Residual sera,All,Multiple groups,0.0,95.0,Primary Estimate,,3068,0.9420000000000001,0.9272,0.9554,True,True,True,,True,Stratified non-probability,,Sci LifeLab / KTH,ELISA,,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.9890000000000001,0.9940000000000001,['Moderate'],Yes,No,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Swedish Public Health Agency,Swedish Public Health Agency,Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-mot-sars-cov-2-blodprov-oppenvarden.pdf,2023-01-10,2023-03-19,Unverified,sweden_public_health_agency_pavisning_2021-1,SWE
210719_Sweden_SwedishPublicHealthAgency_Outpatients_Week21-22_Primary,210719_Sweden_SwedishPublicHealthAgency_Outpatients_Week21-22,Påvisning av antikroppar mot SARS-CoV-2 i blodprov från öppenvården,2021-07-19,Institutional Report,National,Repeated cross-sectional study,Sweden,,"Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten, Västra Götalandoch Örebro","The samples collected are leftover material from blood samples taken in outpatient care for a medical indication other than covid-19. Every week, April 20 to June 12, 2020, approximately 1,200 samples were collected, with 400 samples each from individuals 0-19 years, 20-64 years and 65-95 years.",,2021-05-24,2021-06-04,Residual sera,All,Multiple groups,0.0,95.0,Primary Estimate,,3949,0.522,0.5037,0.5405,True,True,True,,True,Stratified non-probability,,Sci LifeLab / KTH,ELISA,,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.9890000000000001,0.9940000000000001,['Moderate'],Yes,No,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Swedish Public Health Agency,Swedish Public Health Agency,Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-mot-sars-cov-2-blodprov-oppenvarden.pdf,2021-09-14,2023-01-10,Verified,sweden_public_health_agency_pavisning_2021-1,SWE
210719_Sweden_SwedishPublicHealthAgency_Outpatients_Week21-22_age20-65,210719_Sweden_SwedishPublicHealthAgency_Outpatients_Week21-22,Påvisning av antikroppar mot SARS-CoV-2 i blodprov från öppenvården,2021-07-19,Institutional Report,National,Repeated cross-sectional study,Sweden,,"Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten, Västra Götalandoch Örebro","The samples collected are leftover material from blood samples taken in outpatient care for a medical indication other than covid-19. Every week, April 20 to June 12, 2020, approximately 1,200 samples were collected, with 400 samples each from individuals 0-19 years, 20-64 years and 65-95 years.",,2021-05-24,2021-06-04,Residual sera,All,Adults (18-64 years),20.0,65.0,Age,20-65,3949,0.52,0.48119999999999996,0.5483,,True,True,,,Stratified non-probability,,Sci LifeLab / KTH,ELISA,,,Spike,Validated by independent authors/third party/non-developers,0.9890000000000001,0.9940000000000001,['Moderate'],Yes,No,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Swedish Public Health Agency,Swedish Public Health Agency,Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-mot-sars-cov-2-blodprov-oppenvarden.pdf,2021-09-16,2022-07-16,Verified,sweden_public_health_agency_pavisning_2021-1,SWE
210719_Sweden_SwedishPublicHealthAgency_Outpatients_Week21-22_age65-95,210719_Sweden_SwedishPublicHealthAgency_Outpatients_Week21-22,Påvisning av antikroppar mot SARS-CoV-2 i blodprov från öppenvården,2021-07-19,Institutional Report,National,Repeated cross-sectional study,Sweden,,"Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten, Västra Götalandoch Örebro","The samples collected are leftover material from blood samples taken in outpatient care for a medical indication other than covid-19. Every week, April 20 to June 12, 2020, approximately 1,200 samples were collected, with 400 samples each from individuals 0-19 years, 20-64 years and 65-95 years.",,2021-05-24,2021-06-04,Residual sera,All,Seniors (65+ years),65.0,95.0,Age,65-95,3949,0.85,0.8247,0.8725,,True,True,,,Stratified non-probability,,Sci LifeLab / KTH,ELISA,,,Spike,Validated by independent authors/third party/non-developers,0.9890000000000001,0.9940000000000001,['Moderate'],Yes,No,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Swedish Public Health Agency,Swedish Public Health Agency,Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-mot-sars-cov-2-blodprov-oppenvarden.pdf,2021-09-16,2022-07-16,Verified,sweden_public_health_agency_pavisning_2021-1,SWE
210719_Sweden_SwedishPublicHealthAgency_Outpatients_Week21-22_age0-19,210719_Sweden_SwedishPublicHealthAgency_Outpatients_Week21-22,Påvisning av antikroppar mot SARS-CoV-2 i blodprov från öppenvården,2021-07-19,Institutional Report,National,Repeated cross-sectional study,Sweden,,"Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten, Västra Götalandoch Örebro","The samples collected are leftover material from blood samples taken in outpatient care for a medical indication other than covid-19. Every week, April 20 to June 12, 2020, approximately 1,200 samples were collected, with 400 samples each from individuals 0-19 years, 20-64 years and 65-95 years.",,2021-05-24,2021-06-04,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Age,0-19,3949,0.277,0.2539,0.3004,,True,True,,,Stratified non-probability,,Sci LifeLab / KTH,ELISA,,,Spike,Validated by independent authors/third party/non-developers,0.9890000000000001,0.9940000000000001,['Moderate'],Yes,No,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Swedish Public Health Agency,Swedish Public Health Agency,Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-mot-sars-cov-2-blodprov-oppenvarden.pdf,2021-09-16,2022-07-16,Verified,sweden_public_health_agency_pavisning_2021-1,SWE
210719_Sweden_SwedishPublicHealthAgency_Outpatients_Week38-39_Overall,210719_Sweden_SwedishPublicHealthAgency_Outpatients_Week38-39,Påvisning av antikroppar mot SARS-CoV-2 i blodprov från öppenvården,2021-07-19,Institutional Report,National,Repeated cross-sectional study,Sweden,,"Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten, Västra Götaland and Örebro","Samples were collected from Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten, Västra Götaland and Örebro. The collection of samples aged 20-95 years in Västra Götaland took place in Trollhättan. Uppsala only collected samples from children (0-19 years).

The samples collected are leftover material from blood samples taken in outpatient care for a medical indication other than covid-19.
Each week from April 20 to June 12, 2020, approximately 1200 samples were collected, with 400 samples each from individuals aged 0-19 years, 20-64 years and 65-95 years. For the following collections, the number of samples was adjusted upwards to provide a better estimate of antibody prevalence in each age group, and the collection periods were extended to two or three weeks.",,2021-09-20,2021-10-03,Residual sera,All,Multiple groups,0.0,95.0,Primary Estimate,,2959,0.756,0.7382,0.7729,True,True,True,,True,Stratified non-probability,,Sci LifeLab / KTH,ELISA,,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.9890000000000001,0.9940000000000001,['Moderate'],Yes,No,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Swedish Public Health Agency,Swedish Public Health Agency,Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-mot-sars-cov-2-blodprov-oppenvarden.pdf,2023-01-10,2023-03-19,Unverified,sweden_public_health_agency_pavisning_2021-1,SWE
210719_Sweden_SwedishPublicHealthAgency_Outpatients_Week47-48_Overall,210719_Sweden_SwedishPublicHealthAgency_Outpatients_Week47-48,Påvisning av antikroppar mot SARS-CoV-2 i blodprov från öppenvården,2021-07-19,Institutional Report,National,Repeated cross-sectional study,Sweden,,"Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten, Västra Götaland and Örebro","Samples were collected from Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten, Västra Götaland and Örebro. The collection of samples aged 20-95 years in Västra Götaland took place in Trollhättan. Uppsala only collected samples from children (0-19 years).

The samples collected are leftover material from blood samples taken in outpatient care for a medical indication other than covid-19.
Each week from April 20 to June 12, 2020, approximately 1200 samples were collected, with 400 samples each from individuals aged 0-19 years, 20-64 years and 65-95 years. For the following collections, the number of samples was adjusted upwards to provide a better estimate of antibody prevalence in each age group, and the collection periods were extended to two or three weeks.",,2021-11-22,2021-12-05,Residual sera,All,Multiple groups,0.0,95.0,Primary Estimate,,2844,0.8340000000000001,0.8148000000000001,0.8523999999999999,True,True,True,,True,Stratified non-probability,,Sci LifeLab / KTH,ELISA,,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.9890000000000001,0.9940000000000001,['Moderate'],Yes,No,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Swedish Public Health Agency,Swedish Public Health Agency,Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-mot-sars-cov-2-blodprov-oppenvarden.pdf,2023-01-10,2023-03-19,Unverified,sweden_public_health_agency_pavisning_2021-1,SWE
200720_Sweden_TheSwedishPublicHealthAgency_Primary,210720_Sweden_TheSwedishPublicHealthAgency,"Förekomsten av antikroppar mot SARS-CoV-2 i Sverige, 26 april – 9 maj 2021",2021-07-20,Institutional Report,National,Cross-sectional survey ,Sweden,,,"All participants in the Health Report's web panel 2020 were invited to participate. The health report panel then consisted of approximately 4,500 randomly selected participants aged 2–90 years who are representative of Sweden in terms of age, region and gender.",266 participants did not submit their sample and 146 samples where the serological analysis did not obtain an evaluable result that was excluded. Samples received by the laboratory earlier than 27 April or later than 12 May were excluded.,2021-04-26,2021-05-09,Blood donors,All,Multiple groups,3.0,90.0,Primary Estimate,,2860,0.32799999999999996,0.306,0.35100000000000003,True,True,True,,True,Self-referral,Author designed (ELISA) -Spike,,ELISA,,IgG,Spike,Validated by developers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Swedish Public Health Agency,The Swedish Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/45eafde72689438a8a21efa93a5591a4/forekomsten-antikroppar-mot-sars-cov-2.pdf,2021-07-28,2022-07-16,Unverified,swedish_forekomsten_2021,SWE
200720_Sweden_TheSwedishPublicHealthAgency_Age2064,210720_Sweden_TheSwedishPublicHealthAgency,"Förekomsten av antikroppar mot SARS-CoV-2 i Sverige, 26 april – 9 maj 2021",2021-07-20,Institutional Report,National,Cross-sectional survey ,Sweden,,,"All participants in the Health Report's web panel 2020 were invited to participate. The health report panel then consisted of approximately 4,500 randomly selected participants aged 2–90 years who are representative of Sweden in terms of age, region and gender.",266 participants did not submit their sample and 146 samples where the serological analysis did not obtain an evaluable result that was excluded. Samples received by the laboratory earlier than 27 April or later than 12 May were excluded.,2021-04-26,2021-05-09,Blood donors,All,Adults (18-64 years),20.0,64.0,Age,20-64,1619,0.251,0.226,0.277,,True,True,,,Self-referral,Author designed (ELISA) -Spike,,ELISA,,IgG,Spike,Validated by developers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Swedish Public Health Agency,The Swedish Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/45eafde72689438a8a21efa93a5591a4/forekomsten-antikroppar-mot-sars-cov-2.pdf,2021-07-28,2022-07-16,Unverified,swedish_forekomsten_2021,SWE
200720_Sweden_TheSwedishPublicHealthAgency_Age1119,210720_Sweden_TheSwedishPublicHealthAgency,"Förekomsten av antikroppar mot SARS-CoV-2 i Sverige, 26 april – 9 maj 2021",2021-07-20,Institutional Report,National,Cross-sectional survey ,Sweden,,,"All participants in the Health Report's web panel 2020 were invited to participate. The health report panel then consisted of approximately 4,500 randomly selected participants aged 2–90 years who are representative of Sweden in terms of age, region and gender.",266 participants did not submit their sample and 146 samples where the serological analysis did not obtain an evaluable result that was excluded. Samples received by the laboratory earlier than 27 April or later than 12 May were excluded.,2021-04-26,2021-05-09,Blood donors,All,Children and Youth (0-17 years),11.0,19.0,Age,11-19,219,0.304,0.23600000000000002,0.38,,True,True,,,Self-referral,Author designed (ELISA) -Spike,,ELISA,,IgG,Spike,Validated by developers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Swedish Public Health Agency,The Swedish Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/45eafde72689438a8a21efa93a5591a4/forekomsten-antikroppar-mot-sars-cov-2.pdf,2021-07-28,2022-07-16,Unverified,swedish_forekomsten_2021,SWE
200720_Sweden_TheSwedishPublicHealthAgency_Age010,210720_Sweden_TheSwedishPublicHealthAgency,"Förekomsten av antikroppar mot SARS-CoV-2 i Sverige, 26 april – 9 maj 2021",2021-07-20,Institutional Report,National,Cross-sectional survey ,Sweden,,,"All participants in the Health Report's web panel 2020 were invited to participate. The health report panel then consisted of approximately 4,500 randomly selected participants aged 2–90 years who are representative of Sweden in terms of age, region and gender.",266 participants did not submit their sample and 146 samples where the serological analysis did not obtain an evaluable result that was excluded. Samples received by the laboratory earlier than 27 April or later than 12 May were excluded.,2021-04-26,2021-05-09,Blood donors,All,Children and Youth (0-17 years),0.0,10.0,Age,0-10 ,170,0.19100000000000003,0.10300000000000001,0.309,,True,True,,,Self-referral,Author designed (ELISA) -Spike,,ELISA,,IgG,Spike,Validated by developers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Swedish Public Health Agency,The Swedish Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/45eafde72689438a8a21efa93a5591a4/forekomsten-antikroppar-mot-sars-cov-2.pdf,2021-07-28,2022-07-16,Unverified,swedish_forekomsten_2021,SWE
200720_Sweden_TheSwedishPublicHealthAgency_Vaccinated,210720_Sweden_TheSwedishPublicHealthAgency,"Förekomsten av antikroppar mot SARS-CoV-2 i Sverige, 26 april – 9 maj 2021",2021-07-20,Institutional Report,National,Cross-sectional survey ,Sweden,,,"All participants in the Health Report's web panel 2020 were invited to participate. The health report panel then consisted of approximately 4,500 randomly selected participants aged 2–90 years who are representative of Sweden in terms of age, region and gender.",266 participants did not submit their sample and 146 samples where the serological analysis did not obtain an evaluable result that was excluded. Samples received by the laboratory earlier than 27 April or later than 12 May were excluded.,2021-04-26,2021-05-09,Blood donors,All,Multiple groups,3.0,90.0,COVID-19 vaccination status,Vaccinated yes,1867,0.201,0.17600000000000002,0.227,,True,True,,,Self-referral,Author designed (ELISA) -Spike,,ELISA,,IgG,Spike,Validated by developers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Swedish Public Health Agency,The Swedish Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/45eafde72689438a8a21efa93a5591a4/forekomsten-antikroppar-mot-sars-cov-2.pdf,2021-07-28,2022-07-16,Unverified,swedish_forekomsten_2021,SWE
200720_Sweden_TheSwedishPublicHealthAgency_Male,210720_Sweden_TheSwedishPublicHealthAgency,"Förekomsten av antikroppar mot SARS-CoV-2 i Sverige, 26 april – 9 maj 2021",2021-07-20,Institutional Report,National,Cross-sectional survey ,Sweden,,,"All participants in the Health Report's web panel 2020 were invited to participate. The health report panel then consisted of approximately 4,500 randomly selected participants aged 2–90 years who are representative of Sweden in terms of age, region and gender.",266 participants did not submit their sample and 146 samples where the serological analysis did not obtain an evaluable result that was excluded. Samples received by the laboratory earlier than 27 April or later than 12 May were excluded.,2021-04-26,2021-05-09,Blood donors,Male,Multiple groups,3.0,90.0,Sex/Gender,,1284,0.314,0.281,0.35000000000000003,,True,True,,,Self-referral,Author designed (ELISA) -Spike,,ELISA,,IgG,Spike,Validated by developers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Swedish Public Health Agency,The Swedish Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/45eafde72689438a8a21efa93a5591a4/forekomsten-antikroppar-mot-sars-cov-2.pdf,2021-07-28,2022-07-16,Unverified,swedish_forekomsten_2021,SWE
210720_Sweden_TheSwedishPublicHealthAgency_Age65plus,210720_Sweden_TheSwedishPublicHealthAgency,"Förekomsten av antikroppar mot SARS-CoV-2 i Sverige, 26 april – 9 maj 2021",2021-07-20,Institutional Report,National,Cross-sectional survey ,Sweden,,,"All participants in the Health Report's web panel 2020 were invited to participate. The health report panel then consisted of approximately 4,500 randomly selected participants aged 2–90 years who are representative of Sweden in terms of age, region and gender.",266 participants did not submit their sample and 146 samples where the serological analysis did not obtain an evaluable result that was excluded. Samples received by the laboratory earlier than 27 April or later than 12 May were excluded.,2021-04-26,2021-05-09,Blood donors,All,Seniors (65+ years),65.0,90.0,Age,65+,852,0.635,0.599,0.67,,True,True,,,Self-referral,Author designed (ELISA) -Spike,,ELISA,,IgG,Spike,Validated by developers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Swedish Public Health Agency,The Swedish Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/45eafde72689438a8a21efa93a5591a4/forekomsten-antikroppar-mot-sars-cov-2.pdf,2021-07-28,2022-07-16,Unverified,swedish_forekomsten_2021,SWE
200720_Sweden_TheSwedishPublicHealthAgency_Female,210720_Sweden_TheSwedishPublicHealthAgency,"Förekomsten av antikroppar mot SARS-CoV-2 i Sverige, 26 april – 9 maj 2021",2021-07-20,Institutional Report,National,Cross-sectional survey ,Sweden,,,"All participants in the Health Report's web panel 2020 were invited to participate. The health report panel then consisted of approximately 4,500 randomly selected participants aged 2–90 years who are representative of Sweden in terms of age, region and gender.",266 participants did not submit their sample and 146 samples where the serological analysis did not obtain an evaluable result that was excluded. Samples received by the laboratory earlier than 27 April or later than 12 May were excluded.,2021-04-26,2021-05-09,Blood donors,Female,Multiple groups,3.0,90.0,Sex/Gender,,1576,0.342,0.315,0.371,,True,True,,,Self-referral,Author designed (ELISA) -Spike,,ELISA,,IgG,Spike,Validated by developers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Swedish Public Health Agency,The Swedish Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/45eafde72689438a8a21efa93a5591a4/forekomsten-antikroppar-mot-sars-cov-2.pdf,2021-07-28,2022-07-16,Unverified,swedish_forekomsten_2021,SWE
210728_Stockholm_TheSwedishPublicHealthAgency,210728_Stockholm_TheSwedishPublicHealthAgency,"Undersökning av immunologiskt svar mot SARS-CoV-2 hos barn, unga och skolpersonal",2021-07-28,Institutional Report,Local,Cross-sectional survey ,Sweden,"Södermanland, Uppland",Stockholm,"This was preceded by information to requested classes, including obtaining consent from those who wished to participate and from guardians for all children under 18 years of age.

Only staff included in this extraction",,2020-11-15,2020-12-15,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,49,0.36700000000000005,,,True,,,,True,Unclear,Wantai SARS-CoV-2 IgG ELISA,Beijing Wantai Biological,ELISA,Serum,,,,,,['High'],,Unclear,No,No,,No,Yes,No,,Swedish Public Health Agency,The Swedish Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/publicerat-material/publikationsarkiv/u/undersokning-av-immunologiskt-svar-mot-sars-cov-2-hos-barn-unga-och-skolpersonal/,2021-09-15,2024-03-01,Unverified,noauthor_undersokning_nodate,SWE
210805_Varmland_CentreforClinicalResearchandEducation_primary,210805_Varmland_CentreforClinicalResearchandEducation,Higher rate of SARS-CoV-2 IgG seropositivity in hospital-based healthcare workers compared to elderly care staff in a Swedish low-prevalence region: a cross-sectional study.,2021-08-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Sweden,Varmland,,"All healthcare staff, including support staff, in hospitals, general practice, home care, and nursing homes were offered a serological test",There were no exclusion criteria,2020-06-20,2020-10-12,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,4955,0.057,,,True,,True,,True,Entire sample,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.97,0.995,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Lukas Frans Ocias,Centre for Clinical Research and Education of Varmland,Not Unity-Aligned,https://dx.doi.org/10.1080/23744235.2021.1959949,2021-08-10,2024-03-01,Unverified,ocias_higher_2021,SWE
210821_Stockholm_KarolinskaUniversityHospital_Overall,210821_Stockholm_KarolinskaUniversityHospital,Differences in risk for SARS-CoV-2 infection among healthcare workers,2021-08-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Sweden,Sodermanland and Uppland,Stockholm,We invited all employees currently at work at the Karolinska University Hospital in Stockholm,participants not formally employed (e.g. medical students) and subjects with invalid tests,2020-04-23,2020-06-24,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,12928,0.115,,,True,,,,True,Convenience,Author designed (Luminex),,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.9940000000000001,0.991,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Klara Miriam Elfstrom,Karolinska University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.pmedr.2021.101518,2021-09-13,2022-07-16,Verified,elfstrom_differences_2021-1,SWE
210827_Linkoping_LinkopingUniversity_Overall,210827_Linkoping_LinkopingUniversity,"SARS-CoV-2 Antibody Isotypes in Systemic Lupus Erythematosus Patients Prior to Vaccination: Associations With Disease Activity, Antinuclear Antibodies, and Immunomodulatory Drugs During the First Year of the Pandemic",2021-08-27,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Sweden,Ostergotland,Linkoping,"Patients had to have established SLE with a regular physical visit to the Rheumatology unit at Linköping University Hospital, Sweden, from March 2020 to January 2021. All patients fulfilled the 1982 American College of Rheumatology (ACR) and/or the 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for SLE and had previously been included in the prospective follow-up program KLURING (a Swedish acronym for Clinical LUpus Register In North-eastern Gothia) at the Department of Rheumatology, Linköping University Hospital",,2020-03-15,2021-01-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,20.0,90.0,Primary Estimate,,100,0.36,,,True,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Johanna Sjowall,Linkoping University,Not Unity-Aligned,https://www.frontiersin.org/articles/10.3389/fimmu.2021.724047/full,2021-09-07,2022-07-16,Unverified,sjowall_sars-cov-2_2021,SWE
211023_Sweden_KarolinskaInstitutet_Overall,211023_Sweden_KarolinskaInstitutet,SARS-CoV-2 specific B- and T-cell immunity in a population-based study of young Swedish adults.,2021-10-23,Journal Article (Peer-Reviewed),National,Prospective cohort,Sweden,,,"""includes participants from the prospective birth cohort BAMSE, which originally included 4089 newborns between 1994-1996.""",Vaccinated subjects were excluded,2020-10-06,2021-06-23,Household and community samples,All,Adults (18-64 years),24.0,27.0,Primary Estimate,,977,0.284,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Sophia Bjorkander,Karolinska Institutet,Not Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S0091674921016262,2021-11-03,2022-07-16,Unverified,bjorkander_sars-cov-2_2021,SWE
211023_Sweden_KarolinskaInstitutet_Male,211023_Sweden_KarolinskaInstitutet,SARS-CoV-2 specific B- and T-cell immunity in a population-based study of young Swedish adults.,2021-10-23,Journal Article (Peer-Reviewed),National,Prospective cohort,Sweden,,,"""includes participants from the prospective birth cohort BAMSE, which originally included 4089 newborns between 1994-1996.""",Vaccinated subjects were excluded,2020-10-06,2021-06-23,Household and community samples,Male,Adults (18-64 years),24.0,27.0,Sex/Gender,,605,0.2926,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Sophia Bjorkander,Karolinska Institutet,Not Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S0091674921016262,2021-11-03,2022-07-16,Unverified,bjorkander_sars-cov-2_2021,SWE
211023_Sweden_KarolinskaInstitutet_Female,211023_Sweden_KarolinskaInstitutet,SARS-CoV-2 specific B- and T-cell immunity in a population-based study of young Swedish adults.,2021-10-23,Journal Article (Peer-Reviewed),National,Prospective cohort,Sweden,,,"""includes participants from the prospective birth cohort BAMSE, which originally included 4089 newborns between 1994-1996.""",Vaccinated subjects were excluded,2020-10-06,2021-06-23,Household and community samples,Female,Adults (18-64 years),24.0,27.0,Sex/Gender,,371,0.2695,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Sophia Bjorkander,Karolinska Institutet,Not Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S0091674921016262,2021-11-03,2022-07-16,Unverified,bjorkander_sars-cov-2_2021,SWE
2101028_Sweden_SwedishPublicHealthAgency_BloodDoner_Week21-22,2101028_Sweden_SwedishPublicHealthAgency_BloodDoner_Week21-22,Påvisning av antikroppar mot SARS-CoV-2 hos blodgivare,2021-10-28,Institutional Report,National,Repeated cross-sectional study,Sweden,,,"samples from blood doners were collected from eight regions. Samples were collected from Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten, Västra Götaland and Örebro.",,2021-05-24,2021-06-04,Blood donors,All,Multiple groups,,,Primary Estimate,,3009,0.519,0.4953,0.5436,True,True,True,,True,Self-referral,,Sci LifeLab / KTH,,,,,Validated by independent authors/third party/non-developers,,,['Moderate'],,No,Yes,No,,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/376f9021a4c84da08de18ac597284f0c/pavisning-antikroppar-mot-sars-cov-2-blodgivare.pdf,2021-11-04,2022-07-16,Unverified,sweden_public_health_agency_pavisning_2021-2,SWE
2101028_Sweden_SwedishPublicHealthAgency_BloodDoner_Week38-39,2101028_Sweden_SwedishPublicHealthAgency_BloodDoner_Week38-39,Påvisning av antikroppar mot SARS-CoV-2 hos blodgivare,2021-10-28,Institutional Report,National,Repeated cross-sectional study,Sweden,,,"samples from blood doners were collected from eight regions. Samples were collected from Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten, Västra Götaland and Örebro.",,2021-09-20,2021-10-03,Blood donors,All,Multiple groups,,,Primary Estimate,,402,0.968,0.9446,0.9849,True,True,True,,True,Self-referral,,Sci LifeLab / KTH,,,,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],,No,No,No,,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/376f9021a4c84da08de18ac597284f0c/pavisning-antikroppar-mot-sars-cov-2-blodgivare.pdf,2021-11-04,2022-07-16,Unverified,sweden_public_health_agency_pavisning_2021-2,SWE
2101028_Sweden_SwedishPublicHealthAgency_BloodDoner_Week9-10,2101028_Sweden_SwedishPublicHealthAgency_BloodDoner_Week9-10,Påvisning av antikroppar mot SARS-CoV-2 hos blodgivare,2021-10-28,Institutional Report,National,Repeated cross-sectional study,Sweden,,,"samples from blood doners were collected from eight regions. Samples were collected from Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten, Västra Götaland and Örebro.",,2021-03-01,2021-03-12,Blood donors,All,Multiple groups,,,Primary Estimate,,3067,0.22399999999999998,0.20320000000000002,0.24489999999999998,True,True,True,,True,Self-referral,,Sci LifeLab / KTH,,,,,Validated by independent authors/third party/non-developers,,,['Moderate'],,No,Yes,No,,Unclear,Yes,Yes,,Swedish Public Health Agency,Sweden Public Health Agency,Not Unity-Aligned,https://www.folkhalsomyndigheten.se/contentassets/376f9021a4c84da08de18ac597284f0c/pavisning-antikroppar-mot-sars-cov-2-blodgivare.pdf,2021-11-04,2022-07-16,Unverified,sweden_public_health_agency_pavisning_2021-2,SWE
2101028_Sweden_SwedishPublicHealthAgency_Outpatients_Week38-39_Primary,211028_Sweden_SwedishPublicHealthAgency_Outpatients_Week38-39,Påvisning av antikroppar mot SARS-CoV-2 i blodprov från öppenvården,2021-10-28,Institutional Report,National,Repeated cross-sectional study,Sweden,,,The samples collected are leftover material from blood samples taken in outpatient care for a medical indication other than covid-19 ...  Week 38-39 2021 a total of 2959 samples are collected,,2021-09-20,2021-10-03,Residual sera,All,Multiple groups,0.0,95.0,Primary Estimate,,2959,0.756,0.7382,0.7729,True,True,True,,True,Convenience,,Sci LifeLab / KTH,ELISA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.9890000000000001,0.9940000000000001,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Swedish Public Health Agency,Swedish Public Health Agency,Unity-Aligned,https://www.folkhalsomyndigheten.se/publicerat-material/publikationsarkiv/p/pavisning-av-antikroppar-efter-genomgangen-covid-19-i-blodprov-fran-oppenvarden-delrapport-1/,2021-11-04,2022-07-16,Verified,sweden_public_health_agency_pavisning_2021-3,SWE
211102_Sweden_UniversityofGothenburg_BloodDonorsTP2_N+S,211102_Sweden_UniversityofGothenburg_BloodDonorsTP2,"Longitudinal Follow Up of Immune Responses to SARS-CoV-2 in Health Care Workers in Sweden With Several Different Commercial IgG-Assays, Measurement of Neutralizing Antibodies and CD4+ T-Cell Responses.",2021-11-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Sweden,,Gothenburg,,,2020-05-11,2020-05-21,Blood donors,All,Adults (18-64 years),20.0,69.0,Primary Estimate,N+S,111,0.036000000000000004,,,True,,,,True,Unclear,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,Unclear,No,Yes,No,Unclear,Yes,No,Unclear,Emelie Marklund,University of Gothenburg,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2021.750448,2022-01-04,2022-07-16,Verified,marklund_longitudinal_2021,SWE
211102_Sweden_UniversityofGothenburg_BloodDonorsTP2_Nonly,211102_Sweden_UniversityofGothenburg_BloodDonorsTP2,"Longitudinal Follow Up of Immune Responses to SARS-CoV-2 in Health Care Workers in Sweden With Several Different Commercial IgG-Assays, Measurement of Neutralizing Antibodies and CD4+ T-Cell Responses.",2021-11-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Sweden,,Gothenburg,,,2020-05-11,2020-05-21,Blood donors,All,Adults (18-64 years),20.0,69.0,Test used,N,111,0.027000000000000003,,,,,,,,Unclear,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,Unclear,No,Yes,No,Unclear,Yes,No,Unclear,Emelie Marklund,University of Gothenburg,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2021.750448,2022-01-04,2024-03-01,Verified,marklund_longitudinal_2021,SWE
211102_Sweden_UniversityofGothenburg_BloodDonorsTP4_N+S,211102_Sweden_UniversityofGothenburg_BloodDonorsTP4,"Longitudinal Follow Up of Immune Responses to SARS-CoV-2 in Health Care Workers in Sweden With Several Different Commercial IgG-Assays, Measurement of Neutralizing Antibodies and CD4+ T-Cell Responses.",2021-11-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Sweden,,Gothenburg,,,2020-09-21,2020-10-08,Blood donors,All,Multiple groups,21.0,74.0,Primary Estimate,N+S,181,0.0497,,,True,,,,True,Unclear,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,Unclear,No,Yes,No,Unclear,Yes,No,Unclear,Emelie Marklund,University of Gothenburg,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2021.750448,2022-01-04,2022-07-16,Verified,marklund_longitudinal_2021,SWE
211102_Sweden_UniversityofGothenburg_BloodDonorsTP4_S1/S2,211102_Sweden_UniversityofGothenburg_BloodDonorsTP4,"Longitudinal Follow Up of Immune Responses to SARS-CoV-2 in Health Care Workers in Sweden With Several Different Commercial IgG-Assays, Measurement of Neutralizing Antibodies and CD4+ T-Cell Responses.",2021-11-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Sweden,,Gothenburg,,,2020-09-21,2020-10-08,Blood donors,All,Multiple groups,21.0,74.0,Test used,S1/S2,181,0.0718,,,,,,,,Unclear,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['High'],No,Unclear,No,Yes,No,Unclear,Yes,No,Unclear,Emelie Marklund,University of Gothenburg,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2021.750448,2022-01-04,2024-03-01,Verified,marklund_longitudinal_2021,SWE
211102_Sweden_UniversityofGothenburg_BloodDonorsTP4_Nonly,211102_Sweden_UniversityofGothenburg_BloodDonorsTP4,"Longitudinal Follow Up of Immune Responses to SARS-CoV-2 in Health Care Workers in Sweden With Several Different Commercial IgG-Assays, Measurement of Neutralizing Antibodies and CD4+ T-Cell Responses.",2021-11-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Sweden,,Gothenburg,,,2020-09-21,2020-10-08,Blood donors,All,Multiple groups,21.0,74.0,Test used,N,181,0.033100000000000004,,,,,,,,Unclear,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,Unclear,No,Yes,No,Unclear,Yes,No,Unclear,Emelie Marklund,University of Gothenburg,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2021.750448,2022-01-04,2024-03-01,Verified,marklund_longitudinal_2021,SWE
211102_Sweden_UniversityofGothenburg_BloodDonorsTP5_N+S,211102_Sweden_UniversityofGothenburg_BloodDonorsTP5,"Longitudinal Follow Up of Immune Responses to SARS-CoV-2 in Health Care Workers in Sweden With Several Different Commercial IgG-Assays, Measurement of Neutralizing Antibodies and CD4+ T-Cell Responses.",2021-11-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Sweden,,Gothenburg,,,2021-01-12,2021-01-29,Blood donors,All,Multiple groups,23.0,75.0,Primary Estimate,N+S,253,0.1186,,,True,,,,True,Unclear,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,Unclear,No,Yes,No,Unclear,Yes,No,Unclear,Emelie Marklund,University of Gothenburg,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2021.750448,2021-12-02,2022-07-16,Verified,marklund_longitudinal_2021,SWE
211102_Sweden_UniversityofGothenburg_BloodDonorsTP5_Nonly,211102_Sweden_UniversityofGothenburg_BloodDonorsTP5,"Longitudinal Follow Up of Immune Responses to SARS-CoV-2 in Health Care Workers in Sweden With Several Different Commercial IgG-Assays, Measurement of Neutralizing Antibodies and CD4+ T-Cell Responses.",2021-11-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Sweden,,Gothenburg,,,2021-01-12,2021-01-29,Blood donors,All,Multiple groups,23.0,75.0,Test used,N,253,0.09880000000000001,,,,,,,,Unclear,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,Unclear,No,Yes,No,Unclear,Yes,No,Unclear,Emelie Marklund,University of Gothenburg,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2021.750448,2021-12-02,2024-03-01,Verified,marklund_longitudinal_2021,SWE
211102_Sweden_UniversityofGothenburg_BloodDonorsTP5_RBD,211102_Sweden_UniversityofGothenburg_BloodDonorsTP5,"Longitudinal Follow Up of Immune Responses to SARS-CoV-2 in Health Care Workers in Sweden With Several Different Commercial IgG-Assays, Measurement of Neutralizing Antibodies and CD4+ T-Cell Responses.",2021-11-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Sweden,,Gothenburg,,,2021-01-12,2021-01-29,Blood donors,All,Multiple groups,23.0,75.0,Test used,RBD,253,0.18969999999999998,,,,,,,,Unclear,AdviseDX SARS-CoV-2 anti-IgG II assay,Abbott Laboratories,CLIA,Serum,IgG,Spike,,,,['High'],No,Unclear,No,Yes,No,Unclear,Yes,No,Unclear,Emelie Marklund,University of Gothenburg,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2021.750448,2021-12-02,2024-03-01,Verified,marklund_longitudinal_2021,SWE
211102_Sweden_UniversityofGothenburg_HCWsTP1_N+S,211102_Sweden_UniversityofGothenburg_HCWsTP1,"Longitudinal Follow Up of Immune Responses to SARS-CoV-2 in Health Care Workers in Sweden With Several Different Commercial IgG-Assays, Measurement of Neutralizing Antibodies and CD4+ T-Cell Responses.",2021-11-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Sweden,,Gothenburg,"All HCWs (doctors, nurses, nurse assistants and administrative staff) at the Department of Infectious Diseases, Sahlgrenska University Hospital, Gothenburg, Sweden were eligible for participation",,2020-03-17,2020-03-25,Health care workers and caregivers,All,Adults (18-64 years),20.0,69.0,Primary Estimate,N+S,110,0.0,,,True,,,,True,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,Yes,No,Unclear,Yes,No,Unclear,Emelie Marklund,University of Gothenburg,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2021.750448,2022-01-04,2022-07-16,Verified,marklund_longitudinal_2021,SWE
211102_Sweden_UniversityofGothenburg_HCWsTP2_N+S,211102_Sweden_UniversityofGothenburg_HCWsTP2,"Longitudinal Follow Up of Immune Responses to SARS-CoV-2 in Health Care Workers in Sweden With Several Different Commercial IgG-Assays, Measurement of Neutralizing Antibodies and CD4+ T-Cell Responses.",2021-11-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Sweden,,Gothenburg,"All HCWs (doctors, nurses, nurse assistants and administrative staff) at the Department of Infectious Diseases, Sahlgrenska University Hospital, Gothenburg, Sweden were eligible for participation",,2020-05-11,2020-05-21,Health care workers and caregivers,All,Adults (18-64 years),20.0,69.0,Primary Estimate,N+S,110,0.0636,,,True,,,,True,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,Yes,No,Unclear,Yes,No,Unclear,Emelie Marklund,University of Gothenburg,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2021.750448,2022-01-04,2022-07-16,Verified,marklund_longitudinal_2021,SWE
211102_Sweden_UniversityofGothenburg_HCWsTP3_N+S,211102_Sweden_UniversityofGothenburg_HCWsTP3,"Longitudinal Follow Up of Immune Responses to SARS-CoV-2 in Health Care Workers in Sweden With Several Different Commercial IgG-Assays, Measurement of Neutralizing Antibodies and CD4+ T-Cell Responses.",2021-11-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Sweden,,Gothenburg,"All HCWs (doctors, nurses, nurse assistants and administrative staff) at the Department of Infectious Diseases, Sahlgrenska University Hospital, Gothenburg, Sweden were eligible for participation",,2020-06-08,2020-06-18,Health care workers and caregivers,All,Multiple groups,22.0,76.0,Primary Estimate,N+S,80,0.1125,,,True,,,,True,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,Yes,No,Unclear,Yes,No,Unclear,Emelie Marklund,University of Gothenburg,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2021.750448,2022-01-04,2022-07-16,Verified,marklund_longitudinal_2021,SWE
211102_Sweden_UniversityofGothenburg_HCWsTP4_N+S,211102_Sweden_UniversityofGothenburg_HCWsTP4,"Longitudinal Follow Up of Immune Responses to SARS-CoV-2 in Health Care Workers in Sweden With Several Different Commercial IgG-Assays, Measurement of Neutralizing Antibodies and CD4+ T-Cell Responses.",2021-11-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Sweden,,Gothenburg,"All HCWs (doctors, nurses, nurse assistants and administrative staff) at the Department of Infectious Diseases, Sahlgrenska University Hospital, Gothenburg, Sweden were eligible for participation",,2020-09-21,2020-10-08,Health care workers and caregivers,All,Multiple groups,20.0,76.0,Primary Estimate,N+S,190,0.1632,,,True,,,,True,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,Yes,No,Unclear,Yes,No,Unclear,Emelie Marklund,University of Gothenburg,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2021.750448,2022-01-04,2022-07-16,Verified,marklund_longitudinal_2021,SWE
211102_Sweden_UniversityofGothenburg_HCWsTP5_N+S,211102_Sweden_UniversityofGothenburg_HCWsTP5,"Longitudinal Follow Up of Immune Responses to SARS-CoV-2 in Health Care Workers in Sweden With Several Different Commercial IgG-Assays, Measurement of Neutralizing Antibodies and CD4+ T-Cell Responses.",2021-11-02,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Sweden,,Gothenburg,"All HCWs (doctors, nurses, nurse assistants and administrative staff) at the Department of Infectious Diseases, Sahlgrenska University Hospital, Gothenburg, Sweden were eligible for participation",,2021-01-12,2021-01-29,Health care workers and caregivers,All,Multiple groups,22.0,79.0,Primary Estimate,N+S,280,0.2929,,,True,,,,True,Convenience,iFlash-SARS-CoV-2 IgM/IgG,Shenzhen Yhlo Biotech Co. Ltd,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,Yes,No,Unclear,Yes,No,Unclear,Emelie Marklund,University of Gothenburg,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2021.750448,2021-12-02,2022-07-16,Verified,marklund_longitudinal_2021,SWE
220330_Sweden_UppsalaUniversity,220330_Sweden_UppsalaUniversity,Lung function before and after COVID-19 in young adults: A population-based study.,2022-03-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Sweden,,,"""The examined population comes from the BAMSE (Barn, Allergi, Milj€o, Stockholm, Epidemiologi) cohort, a Swedish population-based birth cohort
that initially included 4089 children followed since infancy (1994-1996).For this investigation, the data analyzed were from an examination performed
when the cohort members were 22 to 24 years of age (2016-2019)""

""The COVID-19 examination was done in 2 phases, the first of which was
conducted a web-based questionnaire open from August to November 2020 ... Thereafter,
1453 of the participants responding in the first phase were invited participate in to the second phase, which was conducted from October 2020 to June 2021,
which consisted of a questionnaire and a clinical examination that included lung function assessment and measurements of antibodies against SARSCoV-2 (n =1028).""","""After exclusion of participants with missing prebronchodilatory spirometry data from the pre–COVID-19 or COVID-19 examination, insufficient blood samples, or vaccination against SARS-CoV-2, a total of 853 participants remained""",2020-10-15,2021-06-15,Household and community samples,All,Adults (18-64 years),26.0,30.0,Primary Estimate,,850,0.2849,,,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Ida Mogensen,Uppsala University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jacig.2022.03.001,2023-02-08,2023-03-19,Unverified,mogensenLungFunctionCOVID192022,SWE
220525_Sweden_UppsalaUniversityHospital_Overall,220525_Sweden_UppsalaUniversityHospital,COVID-19 seroprevalence and clinical picture in Swedish pediatric oncology and hematology patients.,2022-05-25,Journal Article (Peer-Reviewed),National,Prospective cohort,Sweden,,,"Oncology and hematology patients treated or on follow-up at the Department of Children’s Oncology and Hematology, Uppsala University Children’s Hospital (Sweden), were invited to participate","NR
",2020-06-15,2021-09-07,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),0.0,18.0,Primary Estimate,,136,0.33,0.25,0.41000000000000003,True,,,,True,Convenience,Author designed (Luminex),,,Serum,"['IgG', 'IgM']",Spike,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Emil Sundberg,Uppsala University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1002/pbc.29773,2022-06-02,2022-07-16,Unverified,sundberg_covid19_2022,SWE
220609_Västerås_VästmanlandsHospital,220609_Västerås_VästmanlandsHospital,Long-lasting T-cell response to SARS-CoV-2 antigens after vaccination-a prospective cohort study of HCWs working with COVID-19 patients,2022-06-09,Journal Article (Peer-Reviewed),Local,Prospective cohort,Sweden,Västmanland,Västerås,HCWs at an Infectious Diseases Department caring for COVID-19 patients,,2020-11-15,2021-11-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,69,0.1884,,,True,,,,True,Unclear,"Abbott Architect SARS-CoV-2 IgG,AdviseDX SARS-CoV-2 anti-IgG II assay",Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,Unclear,No,Yes,,Yes,Yes,No,,Anders Krifors,Västmanlands Hospital,Not Unity-Aligned,https://dx.doi.org/10.1080/23744235.2022.2142662,2022-12-15,2024-03-01,Unverified,krifors_long-lasting_2022,SWE
220625_Sweden_PublicHealthAgencyofSweden,220625_Sweden_PublicHealthAgencyofSweden,"Seroprevalence of SARS-CoV-2 in Sweden, April 26 to May 9, 2021",2022-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Sweden,,,General population; participation by minors less than 16 years of age was by informed consent of the respective caretaker and minors 16–17 years of age by informed consent by both themselves and respective caretaker. ,,2021-04-26,2021-05-09,Household and community samples,All,Multiple groups,3.0,90.0,Primary Estimate,,2860,0.326,0.303,0.349,True,,True,,True,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Jessica Beser,Public Health Agency of Sweden,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-15183-w,2022-07-07,2022-07-16,Unverified,beser_seroprevalence_2022,SWE
220625_Sweden_PublicHealthAgencyofSweden_Age_20-64,220625_Sweden_PublicHealthAgencyofSweden,"Seroprevalence of SARS-CoV-2 in Sweden, April 26 to May 9, 2021",2022-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Sweden,,,General population; participation by minors less than 16 years of age was by informed consent of the respective caretaker and minors 16–17 years of age by informed consent by both themselves and respective caretaker. ,,2021-04-26,2021-05-09,Household and community samples,All,Adults (18-64 years),20.0,64.0,Age,,1619,0.24800000000000003,0.22,0.278,,,True,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Jessica Beser,Public Health Agency of Sweden,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-15183-w,2022-07-07,2022-07-16,Unverified,beser_seroprevalence_2022,SWE
220625_Sweden_PublicHealthAgencyofSweden_Sex_Male,220625_Sweden_PublicHealthAgencyofSweden,"Seroprevalence of SARS-CoV-2 in Sweden, April 26 to May 9, 2021",2022-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Sweden,,,General population; participation by minors less than 16 years of age was by informed consent of the respective caretaker and minors 16–17 years of age by informed consent by both themselves and respective caretaker. ,,2021-04-26,2021-05-09,Household and community samples,Male,Multiple groups,,,Sex/Gender,,1284,0.304,0.27,0.34,,,True,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Jessica Beser,Public Health Agency of Sweden,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-15183-w,2022-07-07,2022-07-16,Unverified,beser_seroprevalence_2022,SWE
220625_Sweden_PublicHealthAgencyofSweden_Sex_Female,220625_Sweden_PublicHealthAgencyofSweden,"Seroprevalence of SARS-CoV-2 in Sweden, April 26 to May 9, 2021",2022-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Sweden,,,General population; participation by minors less than 16 years of age was by informed consent of the respective caretaker and minors 16–17 years of age by informed consent by both themselves and respective caretaker. ,,2021-04-26,2021-05-09,Household and community samples,Female,Multiple groups,,,Sex/Gender,,1576,0.34700000000000003,0.317,0.379,,,True,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Jessica Beser,Public Health Agency of Sweden,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-15183-w,2022-07-07,2022-07-16,Unverified,beser_seroprevalence_2022,SWE
220625_Sweden_PublicHealthAgencyofSweden_Age_0-10,220625_Sweden_PublicHealthAgencyofSweden,"Seroprevalence of SARS-CoV-2 in Sweden, April 26 to May 9, 2021",2022-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Sweden,,,General population; participation by minors less than 16 years of age was by informed consent of the respective caretaker and minors 16–17 years of age by informed consent by both themselves and respective caretaker. ,,2021-04-26,2021-05-09,Household and community samples,All,Children and Youth (0-17 years),0.0,10.0,Age,,170,0.20500000000000002,0.12,0.314,,,True,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Jessica Beser,Public Health Agency of Sweden,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-15183-w,2022-07-07,2022-07-16,Unverified,beser_seroprevalence_2022,SWE
220625_Sweden_PublicHealthAgencyofSweden_Age_11-19,220625_Sweden_PublicHealthAgencyofSweden,"Seroprevalence of SARS-CoV-2 in Sweden, April 26 to May 9, 2021",2022-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Sweden,,,General population; participation by minors less than 16 years of age was by informed consent of the respective caretaker and minors 16–17 years of age by informed consent by both themselves and respective caretaker. ,,2021-04-26,2021-05-09,Household and community samples,All,Children and Youth (0-17 years),11.0,19.0,Age,,219,0.305,0.23600000000000002,0.38200000000000006,,,True,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Jessica Beser,Public Health Agency of Sweden,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-15183-w,2022-07-07,2022-07-16,Unverified,beser_seroprevalence_2022,SWE
220625_Sweden_PublicHealthAgencyofSweden_Age_>65,220625_Sweden_PublicHealthAgencyofSweden,"Seroprevalence of SARS-CoV-2 in Sweden, April 26 to May 9, 2021",2022-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Sweden,,,General population; participation by minors less than 16 years of age was by informed consent of the respective caretaker and minors 16–17 years of age by informed consent by both themselves and respective caretaker. ,,2021-04-26,2021-05-09,Household and community samples,All,Seniors (65+ years),65.0,,Age,,852,0.622,0.5860000000000001,0.658,,,True,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Jessica Beser,Public Health Agency of Sweden,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-15183-w,2022-07-07,2022-07-16,Unverified,beser_seroprevalence_2022,SWE
220630_Stockholm_FolktandvardenStockholm,220630_Stockholm_FolktandvardenStockholm,Prevalence of ongoing or previous SARS-CoV-2 infection among dental personnel - the Swedish experience,2022-06-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Sweden,,Stockholm,Employees randomly selected at Public Dental Service,"""Subjects who were sick, had respiratory symptoms on the day of testing, or had a suspected COVID-19 infection less than five days prior to the day of testing, were excluded""",2020-06-01,2020-06-15,Health care workers and caregivers,All,Adults (18-64 years),25.0,67.0,Primary Estimate,,341,0.10300000000000001,,,True,,,,True,Convenience,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Lars Fredriksson,Folktandvården Stockholm,Not Unity-Aligned,https://dx.doi.org/10.1080/00016357.2022.2095023,2022-07-13,2024-03-01,Unverified,fredriksson_prevalence_2022,SWE
220901_Sweden_UppsalaUniversity_Patients_Overall,220901_Sweden_UppsalaUniversity_Patients,1427P The role of anxiety and self-isolation in seropositivity for COVID-19 in actively treated cancer patients in Sweden,2022-09-01,Presentation or Conference,Local,Prospective cohort,Sweden,,Uppsala,"solid malignancy (SM) n=475, hematological malignancy (HM) n=147 patients",,2020-03-01,2020-08-01,Representative patient population,All,Multiple groups,,,Primary Estimate,,622,0.09550000000000002,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],,Unclear,Yes,No,,Unclear,Yes,No,,B. Ginman,Uppsala University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annonc.2022.07.1530,2022-09-26,2022-09-26,Unverified,ginman_role_2022,SWE
220901_Sweden_UppsalaUniversity_Staff_Overall,220901_Sweden_UppsalaUniversity_Staff,1427P The role of anxiety and self-isolation in seropositivity for COVID-19 in actively treated cancer patients in Sweden,2022-09-01,Presentation or Conference,Local,Prospective cohort,Sweden,,Uppsala,cancer care staff,,2020-03-01,2020-08-01,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,358,0.162,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],,Unclear,No,No,,Unclear,Yes,No,,B. Ginman,Uppsala University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annonc.2022.07.1530,2022-09-26,2022-09-26,Unverified,ginman_role_2022,SWE
220929_Stockholm_ChalmersUniversityofTechnology_Overall,220929_Stockholm_ChalmersUniversityofTechnology,Seroprevalence of SARS-CoV-2 antibodies among public transport workers in Sweden.,2022-09-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Sweden,Södermanland and Uppland,Stockholm,"""All employees at three bus depots in central Stockholm (n = 1385) were invited to participate in the study.""","Individuals who had received at least one dose of vaccine, or individuals who had unclear vaccination status",2021-04-26,2021-05-07,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,262,0.49600000000000005,,,True,,,,True,Convenience,Author designed (Luminex),,Luminex,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.997,0.9940000000000001,['High'],,No,No,Yes,,Unclear,Yes,Yes,,Anna Sjors Dahlman,Stockholm University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jth.2022.101508,2022-10-14,2022-10-14,Unverified,sjors_dahlman_seroprevalence_2022,SWE
230504_Sweden_PublicHealthAgencyOfSweden_Mar2022_PopTestAdj,230504_Sweden_PublicHealthAgencyOfSweden_Mar2022,"High Prevalence of SARS-CoV-2 Omicron Infection Despite High Seroprevalence, Sweden, 2022",2023-05-04,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Sweden,,,"Participants were invited from a nationwide probability-based web panel (5,6). Participants received material for sampling and instructions on how to perform self-sampling at home.",,2022-03-21,2022-03-25,Household and community samples,All,Multiple groups,2.0,96.0,Primary Estimate,Pop and test adjusted,2587,0.933,0.915,0.948,True,True,True,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.992,0.993,['Low'],Yes,Yes,Yes,No,No,Unclear,Yes,Yes,No,Ramona Groenheit,Public Health Agency of Sweden,Unity-Aligned,https://wwwnc.cdc.gov/eid/article/29/6/22-1862_article,2023-05-19,2023-05-25,Unverified,groenheit_high_2023,SWE
230504_Sweden_PublicHealthAgencyOfSweden_Mar2022_UnAdj,230504_Sweden_PublicHealthAgencyOfSweden_Mar2022,"High Prevalence of SARS-CoV-2 Omicron Infection Despite High Seroprevalence, Sweden, 2022",2023-05-04,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Sweden,,,"Participants were invited from a nationwide probability-based web panel (5,6). Participants received material for sampling and instructions on how to perform self-sampling at home.",,2022-03-21,2022-03-25,Household and community samples,All,Multiple groups,2.0,96.0,Analysis,Unadjusted,2587,0.9764,,,,,,,True,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.992,0.993,['Low'],Yes,Yes,Yes,No,No,Unclear,Yes,Yes,No,Ramona Groenheit,Public Health Agency of Sweden,Unity-Aligned,https://wwwnc.cdc.gov/eid/article/29/6/22-1862_article,2023-05-24,2023-05-25,Unverified,groenheit_high_2023,SWE
230504_Sweden_PublicHealthAgencyOfSweden_Sep2022_PopTestAdj,230504_Sweden_PublicHealthAgencyOfSweden_Sep2022,"High Prevalence of SARS-CoV-2 Omicron Infection Despite High Seroprevalence, Sweden, 2022",2023-05-04,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Sweden,,,"Participants were invited from a nationwide probability-based web panel (5,6). Participants received material for sampling and instructions on how to perform self-sampling at home.",,2022-09-26,2022-09-29,Household and community samples,All,Multiple groups,2.0,94.0,Primary Estimate,Pop and test adjusted,1554,0.931,0.892,0.96,True,True,True,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.992,0.993,['Low'],Yes,Yes,Yes,No,No,Unclear,Yes,Yes,No,Ramona Groenheit,Public Health Agency of Sweden,Unity-Aligned,https://wwwnc.cdc.gov/eid/article/29/6/22-1862_article,2023-05-24,2023-05-25,Unverified,groenheit_high_2023,SWE
230504_Sweden_PublicHealthAgencyOfSweden_Sep2022_UnAdj,230504_Sweden_PublicHealthAgencyOfSweden_Sep2022,"High Prevalence of SARS-CoV-2 Omicron Infection Despite High Seroprevalence, Sweden, 2022",2023-05-04,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Sweden,,,"Participants were invited from a nationwide probability-based web panel (5,6). Participants received material for sampling and instructions on how to perform self-sampling at home.",,2022-09-26,2022-09-29,Household and community samples,All,Multiple groups,2.0,94.0,Analysis,Unadjusted,1554,0.9807,,,,,,,True,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,0.992,0.993,['Low'],Yes,Yes,Yes,No,No,Unclear,Yes,Yes,No,Ramona Groenheit,Public Health Agency of Sweden,Unity-Aligned,https://wwwnc.cdc.gov/eid/article/29/6/22-1862_article,2023-05-24,2023-05-25,Unverified,groenheit_high_2023,SWE
230718_Sweden_LinkopingUniversity_May2021,230718_Sweden_LinkopingUniversity,"High seroprevalence of SARS-CoV-2 antibodies in healthcare workers in COVID-19 wards indicates an occupational hazard-a prospective cohort study during the first year of the COVID-19 pandemic in Kalmar County, Sweden",2023-07-18,Journal Article (Peer-Reviewed),Local,Prospective cohort,Sweden, Kalmar County,,"""The study population consisted of healthcare personnelfrom various wards in Kalmar County hospital and health-care personnel from two selected residential care facilities.""",,2021-05-01,2021-05-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,263,0.95,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,"CLIA, CMIA",Serum,IgG,Spike,,,,['High'],,No,No,No,,Yes,Yes,Yes,,Viktor Hultqvist,Linkoping University,Not Unity-Aligned,https://dx.doi.org/10.1111/apm.13343,2023-08-23,2024-03-01,Unverified,hultqvist_high_2023,SWE
230920_Uppsala_UppsalaUniversity,230920_Uppsala_UppsalaUniversity,Strict self-isolation did not protect Swedish cancer patients on active treatment from the risk of becoming seropositive for SARS-CoV-2.,2023-09-20,Journal Article (Peer-Reviewed),Local,Prospective cohort,Sweden,,Uppsala,"Eligible patients for the study were identified using planned appointments for any form of active antitumoral treatment (chemotherapy, monoclonal antibodies, tyrosine kinase inhibitors, immunotherapy – BCL2-inhibitors, PD1/PDL1-inhibitors, CDK4/6-inhibitors, BRAF/MEK-inhibitors) found through electronic medical records. Patients undergoing active treatment between 1 April 2020 and 1 August 2020 were offered study participation",,2020-04-01,2021-03-30,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,475,0.105,,,True,,,,True,Convenience,Author designed (Luminex),,,Serum,"['IgG', 'IgM']",,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Beatrice Ginman,Uppsala University,Not Unity-Aligned,https://dx.doi.org/10.1080/0284186X.2023.2257873,2023-10-20,2023-10-24,Unverified,beatrice_ginman_simon_pahnke_strict_202,SWE
200611_Geneva_UniversityofLausanne_genpop,200611_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study",2020-06-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,,"Eligible individuals were aged 20–74 years, identified through an annual residential list established by the local government and provided informed consent. Participants only eligible to participate once.","Individuals who were permanent residents of institutions (eg, prisons and care homes) were excluded. ",2020-04-06,2020-05-09,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,,2766,0.0781,,,True,,,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Silvia Stringhini,Geneva University Hospitals,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31304-0/fulltext#seccestitle10,2020-07-16,2024-03-01,Verified,stringhini_seroprevalence_2020,CHE
200611_Geneva_UniversityofLausanne_Week 5_TestPopAdj,200611_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study",2020-06-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,,"Eligible individuals were aged 20–74 years, identified through an annual residential list established by the local government and provided informed consent. Participants only eligible to participate once.","Individuals who were permanent residents of institutions (eg, prisons and care homes) were excluded. ",2020-05-04,2020-05-09,Household and community samples,All,Multiple groups,5.0,,Time frame,Week 5,775,0.10800000000000001,0.08199999999999999,0.139,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Silvia Stringhini,Geneva University Hospitals,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31304-0/fulltext#seccestitle10,2020-08-10,2023-07-04,Verified,stringhini_seroprevalence_2020,CHE
200611_Geneva_UniversityofLausanne_Week1_Unadj,200611_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study",2020-06-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,,"Eligible individuals were aged 20–74 years, identified through an annual residential list established by the local government and provided informed consent. Participants only eligible to participate once.","Individuals who were permanent residents of institutions (eg, prisons and care homes) were excluded. ",2020-04-06,2020-04-12,Household and community samples,All,Multiple groups,5.0,,Time frame,Week 1,341,0.035,,,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Silvia Stringhini,Geneva University Hospitals,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31304-0/fulltext#seccestitle10,2020-07-23,2024-03-01,Verified,stringhini_seroprevalence_2020,CHE
200611_Geneva_UniversityofLausanne_females,200611_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study",2020-06-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,Geneva,"Eligible individuals were aged 20–74 years, identified through an annual residential list established by the local government and provided informed consent. Participants only eligible to participate once.","Individuals who were permanent residents of institutions (eg, prisons and care homes) were excluded. ",2020-04-06,2020-05-09,Household and community samples,Female,Multiple groups,5.0,,Sex/Gender,Female,1454,0.069,,,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Silvia Stringhini,Geneva University Hospitals,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31304-0/fulltext#seccestitle10,2020-07-16,2024-03-01,Verified,stringhini_seroprevalence_2020,CHE
200611_Geneva_UniversityofLausanne_50-64,200611_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study",2020-06-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,Geneva,"Eligible individuals were aged 20–74 years, identified through an annual residential list established by the local government and provided informed consent. Participants only eligible to participate once.","Individuals who were permanent residents of institutions (eg, prisons and care homes) were excluded. ",2020-04-06,2020-05-09,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50-64,846,0.07400000000000001,,,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Silvia Stringhini,Geneva University Hospitals,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31304-0/fulltext#seccestitle10,2020-07-16,2024-03-01,Verified,stringhini_seroprevalence_2020,CHE
200611_Geneva_UniversityofLausanne_Week3_TestPopAdj,200611_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study",2020-06-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,,"Eligible individuals were aged 20–74 years, identified through an annual residential list established by the local government and provided informed consent. Participants only eligible to participate once.","Individuals who were permanent residents of institutions (eg, prisons and care homes) were excluded. ",2020-04-20,2020-04-26,Household and community samples,All,Multiple groups,5.0,,Time frame,Week 3,577,0.109,0.079,0.14400000000000002,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Silvia Stringhini,Geneva University Hospitals,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31304-0/fulltext#seccestitle10,2020-08-10,2023-07-04,Verified,stringhini_seroprevalence_2020,CHE
200611_Geneva_UniversityofLausanne_Week4_TestPopAdj,200611_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study",2020-06-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,,"Eligible individuals were aged 20–74 years, identified through an annual residential list established by the local government and provided informed consent. Participants only eligible to participate once.","Individuals who were permanent residents of institutions (eg, prisons and care homes) were excluded. ",2020-04-27,2020-05-03,Household and community samples,All,Multiple groups,5.0,,Time frame,Week 4,604,0.066,0.043,0.094,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Silvia Stringhini,Geneva University Hospitals,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31304-0/fulltext#seccestitle10,2020-08-10,2023-07-04,Verified,stringhini_seroprevalence_2020,CHE
200611_Geneva_UniversityofLausanne_>=65,200611_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study",2020-06-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,Geneva,"Eligible individuals were aged 20–74 years, identified through an annual residential list established by the local government and provided informed consent. Participants only eligible to participate once.","Individuals who were permanent residents of institutions (eg, prisons and care homes) were excluded. ",2020-04-06,2020-05-09,Household and community samples,All,Seniors (65+ years),65.0,,Age,=>65 ,369,0.040999999999999995,,,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Silvia Stringhini,Geneva University Hospitals,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31304-0/fulltext#seccestitle10,2020-06-12,2024-03-01,Verified,stringhini_seroprevalence_2020,CHE
200611_Geneva_UniversityofLausanne_Week 5_Unadj,200611_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study",2020-06-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,,"Eligible individuals were aged 20–74 years, identified through an annual residential list established by the local government and provided informed consent. Participants only eligible to participate once.","Individuals who were permanent residents of institutions (eg, prisons and care homes) were excluded. ",2020-05-04,2020-05-09,Household and community samples,All,Multiple groups,5.0,,Time frame,Week 5,775,0.106,,,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Silvia Stringhini,Geneva University Hospitals,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31304-0/fulltext#seccestitle10,2020-07-23,2024-03-01,Verified,stringhini_seroprevalence_2020,CHE
200611_Geneva_UniversityofLausanne_Week2_Unadj,200611_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study",2020-06-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,,"Eligible individuals were aged 20–74 years, identified through an annual residential list established by the local government and provided informed consent. Participants only eligible to participate once.","Individuals who were permanent residents of institutions (eg, prisons and care homes) were excluded. ",2020-04-13,2020-04-19,Household and community samples,All,Multiple groups,5.0,,Time frame,Week 2,469,0.06,,,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Silvia Stringhini,Geneva University Hospitals,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31304-0/fulltext#seccestitle10,2020-07-23,2024-03-01,Verified,stringhini_seroprevalence_2020,CHE
200611_Geneva_UniversityofLausanne_Week4_Unadj,200611_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study",2020-06-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,,"Eligible individuals were aged 20–74 years, identified through an annual residential list established by the local government and provided informed consent. Participants only eligible to participate once.","Individuals who were permanent residents of institutions (eg, prisons and care homes) were excluded. ",2020-04-27,2020-05-03,Household and community samples,All,Multiple groups,5.0,,Time frame,Week 4,604,0.06,,,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Silvia Stringhini,Geneva University Hospitals,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31304-0/fulltext#seccestitle10,2020-07-23,2024-03-01,Verified,stringhini_seroprevalence_2020,CHE
200611_Geneva_UniversityofLausanne_5-9,200611_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study",2020-06-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,Geneva,"Eligible individuals were aged 20–74 years, identified through an annual residential list established by the local government and provided informed consent. Participants only eligible to participate once.","Individuals who were permanent residents of institutions (eg, prisons and care homes) were excluded. ",2020-04-06,2020-05-09,Household and community samples,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,123,0.008,,,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Silvia Stringhini,Geneva University Hospitals,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31304-0/fulltext#seccestitle10,2020-06-12,2024-03-01,Verified,stringhini_seroprevalence_2020,CHE
200611_Geneva_UniversityofLausanne_20-49,200611_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study",2020-06-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,Geneva,"Eligible individuals were aged 20–74 years, identified through an annual residential list established by the local government and provided informed consent. Participants only eligible to participate once.","Individuals who were permanent residents of institutions (eg, prisons and care homes) were excluded. ",2020-04-06,2020-05-09,Household and community samples,All,Adults (18-64 years),20.0,49.0,Age,20-49,1096,0.099,,,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Silvia Stringhini,Geneva University Hospitals,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31304-0/fulltext#seccestitle10,2020-06-12,2024-03-01,Verified,stringhini_seroprevalence_2020,CHE
200611_Geneva_UniversityofLausanne_Week1_TestPopAdj,200611_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study",2020-06-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,,"Eligible individuals were aged 20–74 years, identified through an annual residential list established by the local government and provided informed consent. Participants only eligible to participate once.","Individuals who were permanent residents of institutions (eg, prisons and care homes) were excluded. ",2020-04-06,2020-04-12,Household and community samples,All,Multiple groups,5.0,,Time frame,Week 1,341,0.048,0.024,0.08,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Silvia Stringhini,Geneva University Hospitals,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31304-0/fulltext#seccestitle10,2020-08-10,2023-07-04,Verified,stringhini_seroprevalence_2020,CHE
200611_Geneva_UniversityofLausanne_Week2_TestPopAdj,200611_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study",2020-06-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,,"Eligible individuals were aged 20–74 years, identified through an annual residential list established by the local government and provided informed consent. Participants only eligible to participate once.","Individuals who were permanent residents of institutions (eg, prisons and care homes) were excluded. ",2020-04-13,2020-04-19,Household and community samples,All,Multiple groups,5.0,,Time frame,Week 2,469,0.085,0.059000000000000004,0.114,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Silvia Stringhini,Geneva University Hospitals,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31304-0/fulltext#seccestitle10,2020-08-10,2023-07-04,Verified,stringhini_seroprevalence_2020,CHE
200611_Geneva_UniversityofLausanne_10-19,200611_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study",2020-06-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,Geneva,"Eligible individuals were aged 20–74 years, identified through an annual residential list established by the local government and provided informed consent. Participants only eligible to participate once.","Individuals who were permanent residents of institutions (eg, prisons and care homes) were excluded. ",2020-04-06,2020-05-09,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,332,0.096,,,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Silvia Stringhini,Geneva University Hospitals,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31304-0/fulltext#seccestitle10,2020-06-12,2024-03-01,Verified,stringhini_seroprevalence_2020,CHE
200611_Geneva_UniversityofLausanne_Week3_Unadj,200611_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study",2020-06-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,,"Eligible individuals were aged 20–74 years, identified through an annual residential list established by the local government and provided informed consent. Participants only eligible to participate once.","Individuals who were permanent residents of institutions (eg, prisons and care homes) were excluded. ",2020-04-20,2020-04-26,Household and community samples,All,Multiple groups,5.0,,Time frame,Week 3,577,0.106,,,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Silvia Stringhini,Geneva University Hospitals,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31304-0/fulltext#seccestitle10,2020-07-23,2024-03-01,Verified,stringhini_seroprevalence_2020,CHE
200611_Geneva_UniversityofLausanne_males,200611_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study",2020-06-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,Geneva,"Eligible individuals were aged 20–74 years, identified through an annual residential list established by the local government and provided informed consent. Participants only eligible to participate once.","Individuals who were permanent residents of institutions (eg, prisons and care homes) were excluded. ",2020-04-06,2020-05-09,Household and community samples,Male,Multiple groups,5.0,,Sex/Gender,Male,1312,0.09,,,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,No,Silvia Stringhini,Geneva University Hospitals,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31304-0/fulltext#seccestitle10,2020-07-16,2024-03-01,Verified,stringhini_seroprevalence_2020,CHE
200807_Zurich_UniversityofZurich_BDSCohort_AprilQDA,200807_Zurich_UniversityofZurich_BDS_AprilQDA,Early peak and rapid decline of SARS-CoV-2 seroprevalence in a Swiss metropolitan region,2020-08-07,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Zurich,Zurich,"""Healthy individuals donating blood to local blood
banks (BDS)."" After one month, another sample from the same individual would be included if the patient visits the hospital and if blood is sent to the Institute of Clinical Chemistry.",,2020-04-01,2020-04-30,Blood donors,All,Adults (18-64 years),,,Primary Estimate,,1469,0.012,0.006999999999999999,,True,,,,True,Sequential,Author designed (ELISA) - MULTIPLEXED,,ELISA,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Marc Emmenegger,University of Zurich,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.05.31.20118554v4,2020-09-27,2022-07-16,Verified,emmenegger_early_2020,CHE
200807_Zurich_UniversityofZurich_BDSCohort_earlyJulyQDA,200807_Zurich_UniversityofZurich_BDS_earlyJulyQDA,Early peak and rapid decline of SARS-CoV-2 seroprevalence in a Swiss metropolitan region,2020-08-07,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Zurich,Zurich,"""Healthy individuals donating blood to local blood
banks (BDS).""",,2020-07-01,2020-07-15,Blood donors,All,Adults (18-64 years),,,Primary Estimate,,1067,0.006999999999999999,0.003,0.012,True,,,,True,Sequential,Author designed (ELISA) - MULTIPLEXED,,ELISA,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Marc Emmenegger,University of Zurich,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.05.31.20118554v4,2020-09-27,2022-07-16,Verified,emmenegger_early_2020,CHE
200807_Zurich_UniversityofZurich_USZCohort_AprilQDA,200807_Zurich_UniversityofZurich_USZ_AprilQDA,Early peak and rapid decline of SARS-CoV-2 seroprevalence in a Swiss metropolitan region,2020-08-07,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Zurich,Zurich,"Unselected patients coming
345 from all clinical departments of USZ (University Hospital Zurich). ",,2020-04-01,2020-04-30,Residual sera,All,Adults (18-64 years),,,Primary Estimate,,4275,0.013999999999999999,0.01,0.017,True,,,,True,Sequential,Author designed (ELISA) - MULTIPLEXED,,ELISA,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Marc Emmenegger,University of Zurich,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.05.31.20118554v4,2020-09-27,2022-07-16,Verified,emmenegger_early_2020,CHE
200807_Zurich_UniversityofZurich_USZCohort_MarchQDA,200807_Zurich_UniversityofZurich_USZ_MarchQDA,Early peak and rapid decline of SARS-CoV-2 seroprevalence in a Swiss metropolitan region,2020-08-07,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Zurich,Zurich,"Unselected patients coming
345 from all clinical departments of USZ (University Hospital Zurich). ",,2020-03-15,2020-03-31,Residual sera,All,Adults (18-64 years),,,Primary Estimate,,3806,0.003,0.001,0.005,True,,,,True,Sequential,Author designed (ELISA) - MULTIPLEXED,,ELISA,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Marc Emmenegger,University of Zurich,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.05.31.20118554v4,2020-09-27,2022-07-16,Verified,emmenegger_early_2020,CHE
200807_Zurich_UniversityofZurich_USZCohort_May-JulyAveQDA,200807_Zurich_UniversityofZurich_USZ_May-JulyAveQD,Early peak and rapid decline of SARS-CoV-2 seroprevalence in a Swiss metropolitan region,2020-08-07,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Zurich,Zurich,"Unselected patients coming
345 from all clinical departments of USZ (University Hospital Zurich). ",,2020-05-15,2020-07-15,Residual sera,All,Adults (18-64 years),,,Primary Estimate,,12831,0.009000000000000001,,,True,,,,True,Sequential,Author designed (ELISA) - MULTIPLEXED,,ELISA,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,1.0,1.0,['High'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,,Marc Emmenegger,University of Zurich,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.05.31.20118554v4,2020-09-27,2022-07-16,Verified,emmenegger_early_2020,CHE
200929_Ticino_InstituteofPublicHealth_primary,200929_Ticino_InstituteofPublicHealth,"Corona Immunitas Ticino, the first results are in",2020-09-29,News and Media,Local,Cross-sectional survey ,Switzerland,,,people in Ticino aged between 5 and 104 years were randomly selected by the Federal Statistical Office and progressively invited to participate in the Corona Immunitas Ticino study,,2020-07-01,2020-07-31,Household and community samples,All,Adults (18-64 years),20.0,64.0,Primary Estimate,,647,0.11,,,True,,,,True,Simplified probability,Author designed (ELISA) - Unknown,,,,,,,,,['High'],Unclear,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,Universita della Svizzera Italiana,The Institute of Public Health on the Università della Svizzera italiana,Not Unity-Aligned,https://www.biomed.usi.ch/en/feeds/8913,2021-04-23,2022-07-16,Verified,noauthor_corona_nodate,CHE
201008_StGallen_CantonalHospitalStGallen_hcw,201008_StGallen_CantonalHospitalStGallen,Prevalence of SARS-CoV-2 Antibodies among Swiss Hospital Workers - Results of a Prospective Cohort Study,2020-10-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,St. Gallen,St. Gallen,Hospital workers (≥16 years) from 2 tertiary-care hospitals (Cantonal Hospital St Gallen and the Children’s Hospital of Eastern Switzerland) ,<16 years,2020-03-19,2020-04-03,Health care workers and caregivers,All,Adults (18-64 years),16.0,,Primary Estimate,,1012,0.009881,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N),SGTi-flex COVID-19 IgM/IgG (manual)","Abbott Laboratories,Roche Diagnostics,Sugentech, Inc.",Multiple Types,Serum,IgG,,,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Phillipp Kohler,Cantonal Hospital St. Gallen,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2020.1244,2021-01-17,2024-03-01,Verified,kohler_prevalence_2020,CHE
201103_Vaud_UniversityofLausanne_CloseContacts2_Luminex,201103_Vaud_UniversityofLausanne_CloseContacts2,Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies,2020-11-03,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Vaud,,177 were sampled from contacts of RT-PCR-positive subjects,,2020-05-04,2020-06-27,Contacts of COVID patients,All,Multiple groups,1.0,90.0,Primary Estimate,Luminex Assay (Assay 1 L/S),177,0.36200000000000004,,,,,,,,Unclear,Author designed (Luminex),,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.97,1.0,['High'],Yes,Unclear,No,No,Unclear,Unclear,Yes,Yes,Unclear,Craig Fenwick,Lausanne University Hospital and University of Lausanne,Not Unity-Aligned,http://dx.doi.org/10.1128/JVI.01828-20,2021-01-23,2022-07-16,Verified,fenwick_changes_2020,CHE
201103_Vaud_UniversityofLausanne_GenPop1_Roche,201103_Vaud_UniversityofLausanne_GenPop1,Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies,2020-11-03,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Vaud,,"311 were randomly selected subjects in the general population. In the latter group, the addresses of subjects recruited were randomly selected by the Swiss Federal Office of Statistics from the population registry of the canton of Vaud in Switzerland",,2020-05-04,2020-06-27,Household and community samples,All,Multiple groups,1.0,90.0,Test used,Roche (assay 6 C/N),311,0.039,,,True,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.93,1.0,['Moderate'],Yes,Yes,No,No,Unclear,Unclear,Yes,Yes,Unclear,Craig Fenwick,Lausanne University Hospital and University of Lausanne,Unity-Aligned,http://dx.doi.org/10.1128/JVI.01828-20,2021-01-23,2024-03-01,Verified,fenwick_changes_2020,CHE
201103_Vaud_UniversityofLausanne_GenPop1_Euroimmun,201103_Vaud_UniversityofLausanne_GenPop1,Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies,2020-11-03,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Vaud,,"311 were randomly selected subjects in the general population. In the latter group, the addresses of subjects recruited were randomly selected by the Swiss Federal Office of Statistics from the population registry of the canton of Vaud in Switzerland",,2020-05-04,2020-06-27,Household and community samples,All,Multiple groups,1.0,90.0,Test used,Euroimmun (Assay 3 C/S1 Mono),311,0.042,,,,,,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.86,0.97,['Moderate'],Yes,Yes,No,No,Unclear,Unclear,Yes,Yes,Unclear,Craig Fenwick,Lausanne University Hospital and University of Lausanne,Unity-Aligned,http://dx.doi.org/10.1128/JVI.01828-20,2021-01-23,2024-03-01,Verified,fenwick_changes_2020,CHE
201103_Vaud_UniversityofLausanne_GenPop1_Snibe,201103_Vaud_UniversityofLausanne_GenPop1,Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies,2020-11-03,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Vaud,,"311 were randomly selected subjects in the general population. In the latter group, the addresses of subjects recruited were randomly selected by the Swiss Federal Office of Statistics from the population registry of the canton of Vaud in Switzerland",,2020-05-04,2020-06-27,Household and community samples,All,Multiple groups,1.0,90.0,Test used,Snibe (Assay 5 C/N),311,0.035,,,,,,,,Simplified probability,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.9,1.0,['Moderate'],Yes,Yes,No,No,Unclear,Unclear,Yes,Yes,Unclear,Craig Fenwick,Lausanne University Hospital and University of Lausanne,Unity-Aligned,http://dx.doi.org/10.1128/JVI.01828-20,2021-01-23,2024-03-01,Verified,fenwick_changes_2020,CHE
201103_Vaud_UniversityofLausanne_GenPop1_Luminex,201103_Vaud_UniversityofLausanne_GenPop1,Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies,2020-11-03,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Vaud,,"311 were randomly selected subjects in the general population. In the latter group, the addresses of subjects recruited were randomly selected by the Swiss Federal Office of Statistics from the population registry of the canton of Vaud in Switzerland",,2020-05-04,2020-06-27,Household and community samples,All,Multiple groups,1.0,90.0,Primary Estimate,Luminex Assay (Assay 1 L/S),311,0.064,,,,,,,,Simplified probability,Author designed (Luminex),,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.97,1.0,['Moderate'],Yes,Yes,No,No,Unclear,Unclear,Yes,Yes,Unclear,Craig Fenwick,Lausanne University Hospital and University of Lausanne,Unity-Aligned,http://dx.doi.org/10.1128/JVI.01828-20,2021-01-23,2022-07-16,Verified,fenwick_changes_2020,CHE
201103_Vaud_UniversityofLausanne_GenPop1_EpitopeDiagnostics,201103_Vaud_UniversityofLausanne_GenPop1,Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies,2020-11-03,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Vaud,,"311 were randomly selected subjects in the general population. In the latter group, the addresses of subjects recruited were randomly selected by the Swiss Federal Office of Statistics from the population registry of the canton of Vaud in Switzerland",,2020-05-04,2020-06-27,Household and community samples,All,Multiple groups,1.0,90.0,Test used,Epitope Diagnostics (Assay 4 C/N),311,0.045,,,,,,,,Simplified probability,EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit,"Epitope Diagnostics, Inc.",ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.89,0.98,['Moderate'],Yes,Yes,No,No,Unclear,Unclear,Yes,Yes,Unclear,Craig Fenwick,Lausanne University Hospital and University of Lausanne,Unity-Aligned,http://dx.doi.org/10.1128/JVI.01828-20,2021-01-23,2024-03-01,Verified,fenwick_changes_2020,CHE
201103_Vaud_UniversityofLausanne_GenPop1_Diasorin,201103_Vaud_UniversityofLausanne_GenPop1,Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies,2020-11-03,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Vaud,,"311 were randomly selected subjects in the general population. In the latter group, the addresses of subjects recruited were randomly selected by the Swiss Federal Office of Statistics from the population registry of the canton of Vaud in Switzerland",,2020-05-04,2020-06-27,Household and community samples,All,Multiple groups,1.0,90.0,Test used,Diasorin (Assay 2 C/S1 Mono),311,0.045,,,,,,,,Simplified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,1.0,['Moderate'],Yes,Yes,No,No,Unclear,Unclear,Yes,Yes,Unclear,Craig Fenwick,Lausanne University Hospital and University of Lausanne,Unity-Aligned,http://dx.doi.org/10.1128/JVI.01828-20,2021-01-23,2024-03-01,Verified,fenwick_changes_2020,CHE
201108_Geneva_GenevaUniversityHospital_Overall,201108_Geneva_GenevaUniversityHospital,Prevalence of IgG against SARS-CoV-2 and evaluation of a rapid MEDsan IgG test in children seeking medical care,2020-11-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Switzerland,,Geneva,"All patients younger than 16  years with blood collected at
Geneva University Hospitals between 1 and 30 April, and
for whom leftover ethylenediaminetetraacetic acid (EDTA)
plasma was available, were eligible, with the exception of neonates.",Neonates,2020-04-01,2020-04-30,Residual sera,All,Children and Youth (0-17 years),,16.0,Primary Estimate,,208,0.087,,,True,,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgG,Author designed (IFA) - NON-MULTIPLEXED","EUROIMMUN,NA",Multiple Types,Plasma,IgG,Spike,,,,['High'],No,No,No,Yes,Unclear,Unclear,Yes,No,,Klara Posfay Barbe,Geneva University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1702,2021-01-17,2024-03-01,Verified,posfay-barbe_prevalence_2020,CHE
201108_Geneva_GenevaUniversityHospital_ELISA,201108_Geneva_GenevaUniversityHospital,Prevalence of IgG against SARS-CoV-2 and evaluation of a rapid MEDsan IgG test in children seeking medical care,2020-11-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Switzerland,,Geneva,"All patients younger than 16  years with blood collected at
Geneva University Hospitals between 1 and 30 April, and
for whom leftover ethylenediaminetetraacetic acid (EDTA)
plasma was available, were eligible, with the exception of neonates.",Neonates,2020-04-01,2020-04-30,Residual sera,All,Children and Youth (0-17 years),,16.0,Test used,EuroImmun ELISA,208,0.091,,,,,,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Plasma,IgG,Spike,,,,['High'],No,No,No,Yes,Unclear,Unclear,Yes,No,,Klara Posfay Barbe,Geneva University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1702,2021-02-23,2024-03-01,Verified,posfay-barbe_prevalence_2020,CHE
201108_Geneva_GenevaUniversityHospital_RapidDiagnosticTest,201108_Geneva_GenevaUniversityHospital,Prevalence of IgG against SARS-CoV-2 and evaluation of a rapid MEDsan IgG test in children seeking medical care,2020-11-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Switzerland,,Geneva,"All patients younger than 16  years with blood collected at
Geneva University Hospitals between 1 and 30 April, and
for whom leftover ethylenediaminetetraacetic acid (EDTA)
plasma was available, were eligible, with the exception of neonates.",Neonates,2020-04-01,2020-04-30,Residual sera,All,Children and Youth (0-17 years),,16.0,Test used,Rapid Diagnostic Test,208,0.125,,,,,,,,Sequential,COVID-19 IgG RDT ,MEDsan GmbH,Other,Plasma,IgG,,,,,['High'],No,No,No,Yes,Unclear,Unclear,Yes,No,,Klara Posfay Barbe,Geneva University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1702,2021-02-23,2024-03-01,Verified,posfay-barbe_prevalence_2020,CHE
201108_Geneva_GenevaUniversityHospital_RIFAssay,201108_Geneva_GenevaUniversityHospital,Prevalence of IgG against SARS-CoV-2 and evaluation of a rapid MEDsan IgG test in children seeking medical care,2020-11-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Switzerland,,Geneva,"All patients younger than 16  years with blood collected at
Geneva University Hospitals between 1 and 30 April, and
for whom leftover ethylenediaminetetraacetic acid (EDTA)
plasma was available, were eligible, with the exception of neonates.",Neonates,2020-04-01,2020-04-30,Residual sera,All,Children and Youth (0-17 years),,16.0,Test used,Recombinant immunofluorescence assay,208,0.087,,,,,,,,Sequential,Author designed (IFA) - NON-MULTIPLEXED,,CLIA,Plasma,IgG,Spike,,,,['High'],No,No,No,Yes,Unclear,Unclear,Yes,No,,Klara Posfay Barbe,Geneva University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1702,2021-02-23,2022-07-16,Verified,posfay-barbe_prevalence_2020,CHE
201130_Fribourg_UniversitéDeFribourg_overall,201130_Fribourg_UniversitéDeFribourg,Corona Immunitas Fribourg Immunté de la population Episode 1/2020,2020-11-30,Institutional Report,Regional,Cross-sectional survey ,Switzerland,Canton of Fribourg,,the adult population aged 20 and over in the canton of Fribourg.,,2020-07-08,2020-10-14,Household and community samples,All,Multiple groups,20.0,,Primary Estimate,,418,0.08,0.04,0.12,True,True,True,,True,Simplified probability,Author designed (Luminex),,Luminex,,"['IgA', 'IgG']",Spike,Validated by developers,0.966,0.997,['Moderate'],Yes,Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Daniela Anker,Université de Fribourg,Unity-Aligned,https://www.unifr.ch/med/imf/fr/assets/public/images/COVID-19/2020-PopHealthLab-Corona-Immunitas-E1.pdf,2021-03-13,2022-07-16,Verified,anker_corona_2020,CHE
201130_Fribourg_UniversitéDeFribourg_male,201130_Fribourg_UniversitéDeFribourg,Corona Immunitas Fribourg Immunté de la population Episode 1/2020,2020-11-30,Institutional Report,Regional,Cross-sectional survey ,Switzerland,Canton of Fribourg,,the adult population aged 20 and over in the canton of Fribourg.,,2020-07-08,2020-10-14,Household and community samples,Male,Multiple groups,20.0,,Sex/Gender,,192,0.09,0.04,0.15,,True,True,,,Simplified probability,Author designed (Luminex),,Luminex,,"['IgA', 'IgG']",Spike,Validated by developers,0.966,0.997,['Moderate'],Yes,Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Daniela Anker,Université de Fribourg,Unity-Aligned,https://www.unifr.ch/med/imf/fr/assets/public/images/COVID-19/2020-PopHealthLab-Corona-Immunitas-E1.pdf,2021-03-13,2022-07-16,Verified,anker_corona_2020,CHE
201130_Fribourg_UniversitéDeFribourg_age20-64,201130_Fribourg_UniversitéDeFribourg,Corona Immunitas Fribourg Immunté de la population Episode 1/2020,2020-11-30,Institutional Report,Regional,Cross-sectional survey ,Switzerland,Canton of Fribourg,,the adult population aged 20 and over in the canton of Fribourg.,,2020-07-08,2020-10-14,Household and community samples,All,Adults (18-64 years),20.0,64.0,Age,20-64,227,0.08,0.04,0.12,,True,True,,,Simplified probability,Author designed (Luminex),,Luminex,,"['IgA', 'IgG']",Spike,Validated by developers,0.966,0.997,['Moderate'],Yes,Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Daniela Anker,Université de Fribourg,Unity-Aligned,https://www.unifr.ch/med/imf/fr/assets/public/images/COVID-19/2020-PopHealthLab-Corona-Immunitas-E1.pdf,2021-03-13,2022-07-16,Verified,anker_corona_2020,CHE
201130_Fribourg_UniversitéDeFribourg_age65+,201130_Fribourg_UniversitéDeFribourg,Corona Immunitas Fribourg Immunté de la population Episode 1/2020,2020-11-30,Institutional Report,Regional,Cross-sectional survey ,Switzerland,Canton of Fribourg,,the adult population aged 20 and over in the canton of Fribourg.,,2020-07-08,2020-10-14,Household and community samples,All,Seniors (65+ years),65.0,,Age,65+,191,0.05,0.02,0.1,,True,True,,,Simplified probability,Author designed (Luminex),,Luminex,,"['IgA', 'IgG']",Spike,Validated by developers,0.966,0.997,['Moderate'],Yes,Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Daniela Anker,Université de Fribourg,Unity-Aligned,https://www.unifr.ch/med/imf/fr/assets/public/images/COVID-19/2020-PopHealthLab-Corona-Immunitas-E1.pdf,2021-03-13,2022-07-16,Verified,anker_corona_2020,CHE
201130_Fribourg_UniversitéDeFribourg_female,201130_Fribourg_UniversitéDeFribourg,Corona Immunitas Fribourg Immunté de la population Episode 1/2020,2020-11-30,Institutional Report,Regional,Cross-sectional survey ,Switzerland,Canton of Fribourg,,the adult population aged 20 and over in the canton of Fribourg.,,2020-07-08,2020-10-14,Household and community samples,Female,Adults (18-64 years),20.0,64.0,Sex/Gender,Female,226,0.07,0.03,0.11,,True,True,,,Simplified probability,Author designed (Luminex),,Luminex,,"['IgA', 'IgG']",Spike,Validated by developers,0.966,0.997,['Moderate'],Yes,Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Daniela Anker,Université de Fribourg,Unity-Aligned,https://www.unifr.ch/med/imf/fr/assets/public/images/COVID-19/2020-PopHealthLab-Corona-Immunitas-E1.pdf,2021-03-13,2022-07-16,Verified,anker_corona_2020,CHE
201207_Ticino_UniversitaDellaSvizzeraItaliana,201207_Ticino_UniversitaDellaSvizzeraItaliana,Risk assessment and seroprevalence of SARS-CoV-2 infection in healthcare workers of COVID-19 and non-COVID-19 hospitals in Southern Switzerland.,2020-12-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Canton of Ticino,,"The only eligibility criterion was to be employed at one of the hos-pitals facilities in Ticino, including the administrative and other sup-port staff who were considered HCWs for the purpose of the study,and were provided with PPE from March 15, 2020, onward.",,2020-04-16,2020-04-30,Health care workers and caregivers,All,Multiple groups,16.0,,Primary Estimate,,4726,0.096,,,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,Validated by developers,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Luca Piccoli,Università della Svizzera italiana,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanepe.2020.100013,2021-07-07,2022-07-16,Unverified,PICCOLI2021100013,CHE
210201_Geneva_GenevaUniversityHospitals_overall_adj,210201_Geneva_GenevaUniversityHospitals,Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak,2021-02-01,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,,Geneva,"we repeated a representative serosurvey of the Geneva population using a stratified random sample (based on age, sex, and education level) of individuals aged 18–64 years from our previous study and an independent random sample of individuals aged 0–18 years and 65 years and older who were identified from resident registers of the Swiss Federal Office of Statistics.

This is the inclusion criteria from the previous study: The SEROCoV-POP study is a population-based study of former participants of the Bus Santé study and their household members. The Bus Santé study is a yearly representative stratified sample of 500 men and 500 women from the general population of the canton of Geneva. Eligible individuals were aged 20–74 years, identified through an annual residential list established by the local government.7 Individuals who were permanent residents of institutions (eg, prisons and care homes) were excluded.",,2020-11-23,2020-12-23,Household and community samples,All,Multiple groups,0.0,96.0,Primary Estimate,,4000,0.21100000000000002,0.192,0.231,True,True,True,True,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Silvia Stringhini,Geneva University Hospitals,Unity-Aligned,https://dx.doi.org/10.1016/S1473-3099(21)00054-2,2021-02-28,2023-08-15,Verified,stringhini_seroprevalence_2021,CHE
210201_Geneva_GenevaUniversityHospitals_overall_unadj,210201_Geneva_GenevaUniversityHospitals,Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak,2021-02-01,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,,Geneva,"we repeated a representative serosurvey of the Geneva population using a stratified random sample (based on age, sex, and education level) of individuals aged 18–64 years from our previous study and an independent random sample of individuals aged 0–18 years and 65 years and older who were identified from resident registers of the Swiss Federal Office of Statistics.

This is the inclusion criteria from the previous study: The SEROCoV-POP study is a population-based study of former participants of the Bus Santé study and their household members. The Bus Santé study is a yearly representative stratified sample of 500 men and 500 women from the general population of the canton of Geneva. Eligible individuals were aged 20–74 years, identified through an annual residential list established by the local government.7 Individuals who were permanent residents of institutions (eg, prisons and care homes) were excluded.",,2020-11-23,2020-12-23,Household and community samples,All,Multiple groups,0.0,96.0,Analysis,,4000,0.20500000000000002,,,,,,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Silvia Stringhini,Geneva University Hospitals,Unity-Aligned,https://dx.doi.org/10.1016/S1473-3099(21)00054-2,2021-02-28,2024-03-01,Verified,stringhini_seroprevalence_2021,CHE
210201_Geneva_GenevaUniversityHospitals_age65-74,210201_Geneva_GenevaUniversityHospitals,Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak,2021-02-01,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,,Geneva,"we repeated a representative serosurvey of the Geneva population using a stratified random sample (based on age, sex, and education level) of individuals aged 18–64 years from our previous study and an independent random sample of individuals aged 0–18 years and 65 years and older who were identified from resident registers of the Swiss Federal Office of Statistics.

This is the inclusion criteria from the previous study: The SEROCoV-POP study is a population-based study of former participants of the Bus Santé study and their household members. The Bus Santé study is a yearly representative stratified sample of 500 men and 500 women from the general population of the canton of Geneva. Eligible individuals were aged 20–74 years, identified through an annual residential list established by the local government.7 Individuals who were permanent residents of institutions (eg, prisons and care homes) were excluded.",,2020-11-23,2020-12-23,Household and community samples,All,Seniors (65+ years),65.0,74.0,Age,65-74,276,0.149,0.109,0.195,,True,True,True,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Silvia Stringhini,Geneva University Hospitals,Unity-Aligned,https://dx.doi.org/10.1016/S1473-3099(21)00054-2,2021-02-28,2023-08-15,Verified,stringhini_seroprevalence_2021,CHE
210201_Geneva_GenevaUniversityHospitals_age0-5,210201_Geneva_GenevaUniversityHospitals,Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak,2021-02-01,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,,Geneva,"we repeated a representative serosurvey of the Geneva population using a stratified random sample (based on age, sex, and education level) of individuals aged 18–64 years from our previous study and an independent random sample of individuals aged 0–18 years and 65 years and older who were identified from resident registers of the Swiss Federal Office of Statistics.

This is the inclusion criteria from the previous study: The SEROCoV-POP study is a population-based study of former participants of the Bus Santé study and their household members. The Bus Santé study is a yearly representative stratified sample of 500 men and 500 women from the general population of the canton of Geneva. Eligible individuals were aged 20–74 years, identified through an annual residential list established by the local government.7 Individuals who were permanent residents of institutions (eg, prisons and care homes) were excluded.",,2020-11-23,2020-12-23,Household and community samples,All,Children and Youth (0-17 years),0.0,5.0,Age,0-5,219,0.149,0.107,0.196,,True,True,True,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Silvia Stringhini,Geneva University Hospitals,Unity-Aligned,https://dx.doi.org/10.1016/S1473-3099(21)00054-2,2021-02-28,2023-08-15,Verified,stringhini_seroprevalence_2021,CHE
210201_Geneva_GenevaUniversityHospitals_age50-64,210201_Geneva_GenevaUniversityHospitals,Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak,2021-02-01,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,,Geneva,"we repeated a representative serosurvey of the Geneva population using a stratified random sample (based on age, sex, and education level) of individuals aged 18–64 years from our previous study and an independent random sample of individuals aged 0–18 years and 65 years and older who were identified from resident registers of the Swiss Federal Office of Statistics.

This is the inclusion criteria from the previous study: The SEROCoV-POP study is a population-based study of former participants of the Bus Santé study and their household members. The Bus Santé study is a yearly representative stratified sample of 500 men and 500 women from the general population of the canton of Geneva. Eligible individuals were aged 20–74 years, identified through an annual residential list established by the local government.7 Individuals who were permanent residents of institutions (eg, prisons and care homes) were excluded.",,2020-11-23,2020-12-23,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50-64,729,0.212,0.18100000000000002,0.24600000000000002,,True,True,True,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Silvia Stringhini,Geneva University Hospitals,Unity-Aligned,https://dx.doi.org/10.1016/S1473-3099(21)00054-2,2021-02-28,2023-08-15,Verified,stringhini_seroprevalence_2021,CHE
210201_Geneva_GenevaUniversityHospitals_age18-24,210201_Geneva_GenevaUniversityHospitals,Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak,2021-02-01,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,,Geneva,"we repeated a representative serosurvey of the Geneva population using a stratified random sample (based on age, sex, and education level) of individuals aged 18–64 years from our previous study and an independent random sample of individuals aged 0–18 years and 65 years and older who were identified from resident registers of the Swiss Federal Office of Statistics.

This is the inclusion criteria from the previous study: The SEROCoV-POP study is a population-based study of former participants of the Bus Santé study and their household members. The Bus Santé study is a yearly representative stratified sample of 500 men and 500 women from the general population of the canton of Geneva. Eligible individuals were aged 20–74 years, identified through an annual residential list established by the local government.7 Individuals who were permanent residents of institutions (eg, prisons and care homes) were excluded.",,2020-11-23,2020-12-23,Household and community samples,All,Adults (18-64 years),18.0,24.0,Age,18-24,206,0.254,0.198,0.315,,True,True,True,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Silvia Stringhini,Geneva University Hospitals,Unity-Aligned,https://dx.doi.org/10.1016/S1473-3099(21)00054-2,2021-02-28,2023-08-15,Verified,stringhini_seroprevalence_2021,CHE
210201_Geneva_GenevaUniversityHospitals_age35-49,210201_Geneva_GenevaUniversityHospitals,Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak,2021-02-01,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,,Geneva,"we repeated a representative serosurvey of the Geneva population using a stratified random sample (based on age, sex, and education level) of individuals aged 18–64 years from our previous study and an independent random sample of individuals aged 0–18 years and 65 years and older who were identified from resident registers of the Swiss Federal Office of Statistics.

This is the inclusion criteria from the previous study: The SEROCoV-POP study is a population-based study of former participants of the Bus Santé study and their household members. The Bus Santé study is a yearly representative stratified sample of 500 men and 500 women from the general population of the canton of Geneva. Eligible individuals were aged 20–74 years, identified through an annual residential list established by the local government.7 Individuals who were permanent residents of institutions (eg, prisons and care homes) were excluded.",,2020-11-23,2020-12-23,Household and community samples,All,Adults (18-64 years),35.0,49.0,Age,35-49,1237,0.23600000000000002,0.20800000000000002,0.264,,True,True,True,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Silvia Stringhini,Geneva University Hospitals,Unity-Aligned,https://dx.doi.org/10.1016/S1473-3099(21)00054-2,2021-02-28,2023-08-15,Verified,stringhini_seroprevalence_2021,CHE
210201_Geneva_GenevaUniversityHospitals_female,210201_Geneva_GenevaUniversityHospitals,Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak,2021-02-01,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,,Geneva,"we repeated a representative serosurvey of the Geneva population using a stratified random sample (based on age, sex, and education level) of individuals aged 18–64 years from our previous study and an independent random sample of individuals aged 0–18 years and 65 years and older who were identified from resident registers of the Swiss Federal Office of Statistics.

This is the inclusion criteria from the previous study: The SEROCoV-POP study is a population-based study of former participants of the Bus Santé study and their household members. The Bus Santé study is a yearly representative stratified sample of 500 men and 500 women from the general population of the canton of Geneva. Eligible individuals were aged 20–74 years, identified through an annual residential list established by the local government.7 Individuals who were permanent residents of institutions (eg, prisons and care homes) were excluded.",,2020-11-23,2020-12-23,Household and community samples,Female,Multiple groups,0.0,96.0,Sex/Gender,,2134,0.204,0.18300000000000002,0.225,,True,True,True,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Silvia Stringhini,Geneva University Hospitals,Unity-Aligned,https://dx.doi.org/10.1016/S1473-3099(21)00054-2,2021-02-28,2023-08-15,Verified,stringhini_seroprevalence_2021,CHE
210201_Geneva_GenevaUniversityHospitals_age6-11,210201_Geneva_GenevaUniversityHospitals,Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak,2021-02-01,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,,Geneva,"we repeated a representative serosurvey of the Geneva population using a stratified random sample (based on age, sex, and education level) of individuals aged 18–64 years from our previous study and an independent random sample of individuals aged 0–18 years and 65 years and older who were identified from resident registers of the Swiss Federal Office of Statistics.

This is the inclusion criteria from the previous study: The SEROCoV-POP study is a population-based study of former participants of the Bus Santé study and their household members. The Bus Santé study is a yearly representative stratified sample of 500 men and 500 women from the general population of the canton of Geneva. Eligible individuals were aged 20–74 years, identified through an annual residential list established by the local government.7 Individuals who were permanent residents of institutions (eg, prisons and care homes) were excluded.",,2020-11-23,2020-12-23,Household and community samples,All,Children and Youth (0-17 years),6.0,11.0,Age,6-11,395,0.228,0.187,0.271,,True,True,True,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Silvia Stringhini,Geneva University Hospitals,Unity-Aligned,https://dx.doi.org/10.1016/S1473-3099(21)00054-2,2021-02-28,2023-08-15,Verified,stringhini_seroprevalence_2021,CHE
210201_Geneva_GenevaUniversityHospitals_male,210201_Geneva_GenevaUniversityHospitals,Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak,2021-02-01,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,,Geneva,"we repeated a representative serosurvey of the Geneva population using a stratified random sample (based on age, sex, and education level) of individuals aged 18–64 years from our previous study and an independent random sample of individuals aged 0–18 years and 65 years and older who were identified from resident registers of the Swiss Federal Office of Statistics.

This is the inclusion criteria from the previous study: The SEROCoV-POP study is a population-based study of former participants of the Bus Santé study and their household members. The Bus Santé study is a yearly representative stratified sample of 500 men and 500 women from the general population of the canton of Geneva. Eligible individuals were aged 20–74 years, identified through an annual residential list established by the local government.7 Individuals who were permanent residents of institutions (eg, prisons and care homes) were excluded.",,2020-11-23,2020-12-23,Household and community samples,Male,Multiple groups,0.0,96.0,Sex/Gender,,1866,0.219,0.196,0.24300000000000002,,True,True,True,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Silvia Stringhini,Geneva University Hospitals,Unity-Aligned,https://dx.doi.org/10.1016/S1473-3099(21)00054-2,2021-02-28,2023-08-15,Verified,stringhini_seroprevalence_2021,CHE
210201_Geneva_GenevaUniversityHospitals_age25-34,210201_Geneva_GenevaUniversityHospitals,Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak,2021-02-01,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,,Geneva,"we repeated a representative serosurvey of the Geneva population using a stratified random sample (based on age, sex, and education level) of individuals aged 18–64 years from our previous study and an independent random sample of individuals aged 0–18 years and 65 years and older who were identified from resident registers of the Swiss Federal Office of Statistics.

This is the inclusion criteria from the previous study: The SEROCoV-POP study is a population-based study of former participants of the Bus Santé study and their household members. The Bus Santé study is a yearly representative stratified sample of 500 men and 500 women from the general population of the canton of Geneva. Eligible individuals were aged 20–74 years, identified through an annual residential list established by the local government.7 Individuals who were permanent residents of institutions (eg, prisons and care homes) were excluded.",,2020-11-23,2020-12-23,Household and community samples,All,Adults (18-64 years),25.0,34.0,Age,25-34,336,0.259,0.218,0.302,,True,True,True,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Silvia Stringhini,Geneva University Hospitals,Unity-Aligned,https://dx.doi.org/10.1016/S1473-3099(21)00054-2,2021-02-28,2023-08-15,Verified,stringhini_seroprevalence_2021,CHE
210201_Geneva_GenevaUniversityHospitals_age75+,210201_Geneva_GenevaUniversityHospitals,Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak,2021-02-01,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,,Geneva,"we repeated a representative serosurvey of the Geneva population using a stratified random sample (based on age, sex, and education level) of individuals aged 18–64 years from our previous study and an independent random sample of individuals aged 0–18 years and 65 years and older who were identified from resident registers of the Swiss Federal Office of Statistics.

This is the inclusion criteria from the previous study: The SEROCoV-POP study is a population-based study of former participants of the Bus Santé study and their household members. The Bus Santé study is a yearly representative stratified sample of 500 men and 500 women from the general population of the canton of Geneva. Eligible individuals were aged 20–74 years, identified through an annual residential list established by the local government.7 Individuals who were permanent residents of institutions (eg, prisons and care homes) were excluded.",,2020-11-23,2020-12-23,Household and community samples,All,Seniors (65+ years),75.0,96.0,Age,75+,202,0.09300000000000001,0.055,0.13699999999999998,,True,True,True,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Silvia Stringhini,Geneva University Hospitals,Unity-Aligned,https://dx.doi.org/10.1016/S1473-3099(21)00054-2,2021-02-28,2023-08-15,Verified,stringhini_seroprevalence_2021,CHE
210201_Geneva_GenevaUniversityHospitals_age12-17,210201_Geneva_GenevaUniversityHospitals,Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak,2021-02-01,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,,Geneva,"we repeated a representative serosurvey of the Geneva population using a stratified random sample (based on age, sex, and education level) of individuals aged 18–64 years from our previous study and an independent random sample of individuals aged 0–18 years and 65 years and older who were identified from resident registers of the Swiss Federal Office of Statistics.

This is the inclusion criteria from the previous study: The SEROCoV-POP study is a population-based study of former participants of the Bus Santé study and their household members. The Bus Santé study is a yearly representative stratified sample of 500 men and 500 women from the general population of the canton of Geneva. Eligible individuals were aged 20–74 years, identified through an annual residential list established by the local government.7 Individuals who were permanent residents of institutions (eg, prisons and care homes) were excluded.",,2020-11-23,2020-12-23,Household and community samples,All,Children and Youth (0-17 years),12.0,17.0,Age,12-17,400,0.23600000000000002,0.196,0.28,,True,True,True,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Spike,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Silvia Stringhini,Geneva University Hospitals,Unity-Aligned,https://dx.doi.org/10.1016/S1473-3099(21)00054-2,2021-02-28,2023-08-15,Verified,stringhini_seroprevalence_2021,CHE
210203_Ticino_UniversitàdellaSvizzeraitaliana_primary,210203_Ticino_UniversitàdellaSvizzeraitaliana,Corona Immunitas Ticino: together to react - here are the results of the  second phase of serological tests,2021-02-03,News and Media,Regional,Cross-sectional survey ,Switzerland,Ticino,,"Children, adolescents and the elderly (aged 65 or over).",,2020-11-01,2021-01-13,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,,1463,0.16,,,True,,,,True,Simplified probability,Not reported/ Unable to specify,,,,,,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,Institute of Public Health of the Universita della Svizzera italiana,Università della Svizzera italiana,Not Unity-Aligned,https://www.biomed.usi.ch/it/feeds/9035,2021-05-18,2022-07-16,Verified,noauthor_corona_nodate-1,CHE
20210226_Zurich_UniversityofZurich_carehomeworkers,20210226_Zurich_UniversityofZurich,Zurich studies on the seroprevalence of home and home staff as well as on the immune response and long-term consequences in those who tested positive for corona,2021-02-26,Institutional Report,Regional,Cross-sectional survey ,Switzerland,Canton of Zurich,,Retirement and nursing homes as well as Spitex organizations whose employees were particularly exposed in spring 2020 were selected. This means that they either worked in homes with residents infected with SARS-CoV-2 or in communities with a particularly large number of infected residents. ,,2020-09-09,2020-10-23,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,employees in retirement and nursing homes,296,0.149,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Canton Zurich,University of Zurich,Not Unity-Aligned,https://www.zh.ch/de/news-uebersicht/medienmitteilungen/2021/02/zuercher-studien-zu-seropraevalenz-von-spitex--und-heimpersonal-sowie-zu-immunantwort-und-langzeitfolgen-bei-corona-positiv-getesteten.html,2021-05-10,2022-07-16,Unverified,canton_zurich_zurcher_2021,CHE
20210226_Zurich_UniversityofZurich_spitexworkers,20210226_Zurich_UniversityofZurich_spitexworkers,Zurich studies on the seroprevalence of home and home staff as well as on the immune response and long-term consequences in those who tested positive for corona,2021-02-26,Institutional Report,Regional,Cross-sectional survey ,Switzerland,Canton of Zurich,,Retirement and nursing homes as well as Spitex organizations whose employees were particularly exposed in spring 2020 were selected. This means that they either worked in homes with residents infected with SARS-CoV-2 or in communities with a particularly large number of infected residents. ,,2020-09-09,2020-10-23,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,home care employees,131,0.038,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Canton Zurich,University of Zurich,Not Unity-Aligned,https://www.zh.ch/de/news-uebersicht/medienmitteilungen/2021/02/zuercher-studien-zu-seropraevalenz-von-spitex--und-heimpersonal-sowie-zu-immunantwort-und-langzeitfolgen-bei-corona-positiv-getesteten.html,2021-05-10,2022-07-16,Unverified,canton_zurich_zurcher_2021,CHE
210317_Zurich_UniversityofZurich_OverallAdj ,210317_Zurich_UniversityofZurich,"Clustering and longitudinal change in SARS-CoV-2 seroprevalence in school children in the canton of Zurich, Switzerland: prospective cohort study of 55 schools",2021-03-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Canton of Zurich,,"lower school level (grades 1 and 2; children aged 6-9 years); middle school level (grades 4 and 5; children aged 9-13 years); and upper school level (grades 7 and 8; children aged 12-16 years) in Zurich, Switzerland",Major exclusion criterion was suspected or confirmed SARS-CoV-2 infection in the given child during the testing (precluding the attendance of the testing at school).,2020-06-16,2020-11-19,Students and Daycares,All,Children and Youth (0-17 years),6.0,16.0,Primary Estimate,Pop adj and test adj,2776,0.078,0.062000000000000006,0.095,True,True,True,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.943,0.99,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Agne Ulyte,University of Zurich,Not Unity-Aligned,https://www.bmj.com/content/372/bmj.n616,2021-04-06,2022-07-16,Unverified,ulyte_clustering_2021,CHE
210319_Geneva_GenevaUniversityHospitals_HospitalEmployees,210319_Geneva_GenevaUniversityHospitals,SARS-CoV-2 seroconversion and occupational exposure of employees at a Swiss university hospital: a large longitudinal cohort study,2021-03-19,Journal Article (Peer-Reviewed),Local,Prospective cohort,Switzerland,,Geneva,"employees working at Geneva University Hospitals (HUG), regardless of their prior symptoms or documentation of SARS-CoV-2 infection",Employees unable to provide consent or for whom serum samples were not collected were excluded,2020-03-30,2020-06-12,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,3421,0.079,0.07,0.08800000000000001,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,Roche Diagnostics",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Yes,Yes,No,,Romain Martischang,Geneva University Hospitals,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2021.117,2021-04-23,2024-03-01,Unverified,martischang_severe_2021,CHE
210326_Vaud_UniversityofLausanne_CloseContactsOutsideHousehold2_Overall_ClusterAdj,210326_Vaud_UniversityofLausanne_CloseContactsOutsideHousehold2,"Prevalence of SARS-CoV-2 in Household Members and Other Close Contacts of COVID-19 Cases: A Serologic Study in Canton of Vaud, Switzerland.",2021-03-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Vaud,," all confirmed cases from week 1 were invited to participate in the study (n = 13), along with their close contacts identified by contact tracing (n = 117). Additionally, all cases aged between 6 months and 19 years (n = 66) and a random sample of noninstitutionalized cases aged ≥20 years (n = 368) who were tested positive during weeks 2–5 (from March 5 to April 1, 2020) were invited to take part in the study. 

Overall, this resulted in the solicitation of 447 confirmed cases (hereafter called index cases) and 137 close contacts not belonging to the households of the index cases. Moreover, index case participants were asked to invite all their household mem- bers aged ≥6 months to take part in the study. 
",,2020-05-04,2020-06-27,Contacts of COVID patients,All,Multiple groups,9.0,85.0,Primary Estimate,,69,0.19,0.1,0.332,True,,,True,,Simplified probability,Author designed (Luminex),,Other,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.9920000000000001,['Moderate'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,No,Julien Dupraz,University of Lausanne,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab149,2021-08-05,2022-07-16,Verified,dupraz_prevalence_2021,CHE
210326_Vaud_UniversityofLausanne_CloseContactsOutsideHousehold2_Age_40-65,210326_Vaud_UniversityofLausanne_CloseContactsOutsideHousehold2,"Prevalence of SARS-CoV-2 in Household Members and Other Close Contacts of COVID-19 Cases: A Serologic Study in Canton of Vaud, Switzerland.",2021-03-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Vaud,," all confirmed cases from week 1 were invited to participate in the study (n = 13), along with their close contacts identified by contact tracing (n = 117). Additionally, all cases aged between 6 months and 19 years (n = 66) and a random sample of noninstitutionalized cases aged ≥20 years (n = 368) who were tested positive during weeks 2–5 (from March 5 to April 1, 2020) were invited to take part in the study. 

Overall, this resulted in the solicitation of 447 confirmed cases (hereafter called index cases) and 137 close contacts not belonging to the households of the index cases. Moreover, index case participants were asked to invite all their household mem- bers aged ≥6 months to take part in the study. 
",,2020-05-04,2020-06-27,Contacts of COVID patients,All,Adults (18-64 years),40.0,65.0,Age,40-65,38,0.184,,,,,,,,Simplified probability,Author designed (Luminex),,Other,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.9920000000000001,['Moderate'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,No,Julien Dupraz,University of Lausanne,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab149,2021-08-05,2022-07-16,Verified,dupraz_prevalence_2021,CHE
210326_Vaud_UniversityofLausanne_CloseContactsOutsideHousehold2_Age_75+,210326_Vaud_UniversityofLausanne_CloseContactsOutsideHousehold2,"Prevalence of SARS-CoV-2 in Household Members and Other Close Contacts of COVID-19 Cases: A Serologic Study in Canton of Vaud, Switzerland.",2021-03-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Vaud,," all confirmed cases from week 1 were invited to participate in the study (n = 13), along with their close contacts identified by contact tracing (n = 117). Additionally, all cases aged between 6 months and 19 years (n = 66) and a random sample of noninstitutionalized cases aged ≥20 years (n = 368) who were tested positive during weeks 2–5 (from March 5 to April 1, 2020) were invited to take part in the study. 

Overall, this resulted in the solicitation of 447 confirmed cases (hereafter called index cases) and 137 close contacts not belonging to the households of the index cases. Moreover, index case participants were asked to invite all their household mem- bers aged ≥6 months to take part in the study. 
",,2020-05-04,2020-06-27,Contacts of COVID patients,All,Seniors (65+ years),75.0,,Age,75+,1,0.0,,,,,,,,Simplified probability,Author designed (Luminex),,Other,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.9920000000000001,['Moderate'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,No,Julien Dupraz,University of Lausanne,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab149,2021-08-05,2022-07-16,Verified,dupraz_prevalence_2021,CHE
210326_Vaud_UniversityofLausanne_CloseContactsOutsideHousehold2_Age_10-15,210326_Vaud_UniversityofLausanne_CloseContactsOutsideHousehold2,"Prevalence of SARS-CoV-2 in Household Members and Other Close Contacts of COVID-19 Cases: A Serologic Study in Canton of Vaud, Switzerland.",2021-03-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Vaud,," all confirmed cases from week 1 were invited to participate in the study (n = 13), along with their close contacts identified by contact tracing (n = 117). Additionally, all cases aged between 6 months and 19 years (n = 66) and a random sample of noninstitutionalized cases aged ≥20 years (n = 368) who were tested positive during weeks 2–5 (from March 5 to April 1, 2020) were invited to take part in the study. 

Overall, this resulted in the solicitation of 447 confirmed cases (hereafter called index cases) and 137 close contacts not belonging to the households of the index cases. Moreover, index case participants were asked to invite all their household mem- bers aged ≥6 months to take part in the study. 
",,2020-05-04,2020-06-27,Contacts of COVID patients,All,Children and Youth (0-17 years),10.0,15.0,Age,10-15,3,0.0,,,,,,,,Simplified probability,Author designed (Luminex),,Other,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.9920000000000001,['Moderate'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,No,Julien Dupraz,University of Lausanne,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab149,2021-08-05,2022-07-16,Verified,dupraz_prevalence_2021,CHE
210326_Vaud_UniversityofLausanne_CloseContactsOutsideHousehold2_Age_20-40,210326_Vaud_UniversityofLausanne_CloseContactsOutsideHousehold2,"Prevalence of SARS-CoV-2 in Household Members and Other Close Contacts of COVID-19 Cases: A Serologic Study in Canton of Vaud, Switzerland.",2021-03-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Vaud,," all confirmed cases from week 1 were invited to participate in the study (n = 13), along with their close contacts identified by contact tracing (n = 117). Additionally, all cases aged between 6 months and 19 years (n = 66) and a random sample of noninstitutionalized cases aged ≥20 years (n = 368) who were tested positive during weeks 2–5 (from March 5 to April 1, 2020) were invited to take part in the study. 

Overall, this resulted in the solicitation of 447 confirmed cases (hereafter called index cases) and 137 close contacts not belonging to the households of the index cases. Moreover, index case participants were asked to invite all their household mem- bers aged ≥6 months to take part in the study. 
",,2020-05-04,2020-06-27,Contacts of COVID patients,All,Adults (18-64 years),20.0,40.0,Age,20-40,15,0.2,,,,,,,,Simplified probability,Author designed (Luminex),,Other,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.9920000000000001,['Moderate'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,No,Julien Dupraz,University of Lausanne,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab149,2021-08-05,2022-07-16,Verified,dupraz_prevalence_2021,CHE
210326_Vaud_UniversityofLausanne_CloseContactsOutsideHousehold2_Age_65-75,210326_Vaud_UniversityofLausanne_CloseContactsOutsideHousehold2,"Prevalence of SARS-CoV-2 in Household Members and Other Close Contacts of COVID-19 Cases: A Serologic Study in Canton of Vaud, Switzerland.",2021-03-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Vaud,," all confirmed cases from week 1 were invited to participate in the study (n = 13), along with their close contacts identified by contact tracing (n = 117). Additionally, all cases aged between 6 months and 19 years (n = 66) and a random sample of noninstitutionalized cases aged ≥20 years (n = 368) who were tested positive during weeks 2–5 (from March 5 to April 1, 2020) were invited to take part in the study. 

Overall, this resulted in the solicitation of 447 confirmed cases (hereafter called index cases) and 137 close contacts not belonging to the households of the index cases. Moreover, index case participants were asked to invite all their household mem- bers aged ≥6 months to take part in the study. 
",,2020-05-04,2020-06-27,Contacts of COVID patients,All,Seniors (65+ years),65.0,75.0,Age,65-75,9,0.222,,,,,,,,Simplified probability,Author designed (Luminex),,Other,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.9920000000000001,['Moderate'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,No,Julien Dupraz,University of Lausanne,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab149,2021-08-05,2022-07-16,Verified,dupraz_prevalence_2021,CHE
210326_Vaud_UniversityofLausanne_CloseContactsOutsideHousehold2_Age_5-10,210326_Vaud_UniversityofLausanne_CloseContactsOutsideHousehold2,"Prevalence of SARS-CoV-2 in Household Members and Other Close Contacts of COVID-19 Cases: A Serologic Study in Canton of Vaud, Switzerland.",2021-03-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Vaud,," all confirmed cases from week 1 were invited to participate in the study (n = 13), along with their close contacts identified by contact tracing (n = 117). Additionally, all cases aged between 6 months and 19 years (n = 66) and a random sample of noninstitutionalized cases aged ≥20 years (n = 368) who were tested positive during weeks 2–5 (from March 5 to April 1, 2020) were invited to take part in the study. 

Overall, this resulted in the solicitation of 447 confirmed cases (hereafter called index cases) and 137 close contacts not belonging to the households of the index cases. Moreover, index case participants were asked to invite all their household mem- bers aged ≥6 months to take part in the study. 
",,2020-05-04,2020-06-27,Contacts of COVID patients,All,Children and Youth (0-17 years),5.0,10.0,Age,5-10,1,0.0,,,,,,,,Simplified probability,Author designed (Luminex),,Other,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.9920000000000001,['Moderate'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,No,Julien Dupraz,University of Lausanne,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab149,2021-08-05,2022-07-16,Verified,dupraz_prevalence_2021,CHE
210326_Vaud_UniversityofLausanne_CloseContactsOutsideHousehold2_Age_15-20,210326_Vaud_UniversityofLausanne_CloseContactsOutsideHousehold2,"Prevalence of SARS-CoV-2 in Household Members and Other Close Contacts of COVID-19 Cases: A Serologic Study in Canton of Vaud, Switzerland.",2021-03-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Vaud,," all confirmed cases from week 1 were invited to participate in the study (n = 13), along with their close contacts identified by contact tracing (n = 117). Additionally, all cases aged between 6 months and 19 years (n = 66) and a random sample of noninstitutionalized cases aged ≥20 years (n = 368) who were tested positive during weeks 2–5 (from March 5 to April 1, 2020) were invited to take part in the study. 

Overall, this resulted in the solicitation of 447 confirmed cases (hereafter called index cases) and 137 close contacts not belonging to the households of the index cases. Moreover, index case participants were asked to invite all their household mem- bers aged ≥6 months to take part in the study. 
",,2020-05-04,2020-06-27,Contacts of COVID patients,All,Multiple groups,15.0,20.0,Age,15-20,2,0.0,,,,,,,,Simplified probability,Author designed (Luminex),,Other,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.9920000000000001,['Moderate'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,No,Julien Dupraz,University of Lausanne,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab149,2021-08-05,2022-07-16,Verified,dupraz_prevalence_2021,CHE
210326_Vaud_UniversityofLausanne_Household1_Overall_ClusterAdj,210326_Vaud_UniversityofLausanne_Household1,"Prevalence of SARS-CoV-2 in Household Members and Other Close Contacts of COVID-19 Cases: A Serologic Study in Canton of Vaud, Switzerland.",2021-03-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Vaud,," all confirmed cases from week 1 were invited to participate in the study (n = 13), along with their close contacts identified by contact tracing (n = 117). Additionally, all cases aged between 6 months and 19 years (n = 66) and a random sample of noninstitutionalized cases aged ≥20 years (n = 368) who were tested positive during weeks 2–5 (from March 5 to April 1, 2020) were invited to take part in the study. 

Overall, this resulted in the solicitation of 447 confirmed cases (hereafter called index cases) and 137 close contacts not belonging to the households of the index cases. Moreover, index case participants were asked to invite all their household mem- bers aged ≥6 months to take part in the study. 
",,2020-05-04,2020-06-27,Contacts of COVID patients,All,Multiple groups,1.0,87.0,Primary Estimate,,302,0.5720000000000001,0.495,0.643,True,,,True,,Simplified probability,Author designed (Luminex),,Other,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.9920000000000001,['Moderate'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,Yes,Julien Dupraz,University of Lausanne,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab149,2021-08-05,2022-07-16,Verified,dupraz_prevalence_2021,CHE
210326_Vaud_UniversityofLausanne_Household1_Age_0.5-5,210326_Vaud_UniversityofLausanne_Household1,"Prevalence of SARS-CoV-2 in Household Members and Other Close Contacts of COVID-19 Cases: A Serologic Study in Canton of Vaud, Switzerland.",2021-03-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Vaud,," all confirmed cases from week 1 were invited to participate in the study (n = 13), along with their close contacts identified by contact tracing (n = 117). Additionally, all cases aged between 6 months and 19 years (n = 66) and a random sample of noninstitutionalized cases aged ≥20 years (n = 368) who were tested positive during weeks 2–5 (from March 5 to April 1, 2020) were invited to take part in the study. 

Overall, this resulted in the solicitation of 447 confirmed cases (hereafter called index cases) and 137 close contacts not belonging to the households of the index cases. Moreover, index case participants were asked to invite all their household mem- bers aged ≥6 months to take part in the study. 
",,2020-05-04,2020-06-27,Contacts of COVID patients,All,Children and Youth (0-17 years),0.0,5.0,Age,0.5-5,11,0.455,,,,,,,,Simplified probability,Author designed (Luminex),,Other,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.9920000000000001,['Moderate'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,Yes,Julien Dupraz,University of Lausanne,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab149,2021-08-05,2022-07-16,Verified,dupraz_prevalence_2021,CHE
210326_Vaud_UniversityofLausanne_Household1_Age_5-10,210326_Vaud_UniversityofLausanne_Household1,"Prevalence of SARS-CoV-2 in Household Members and Other Close Contacts of COVID-19 Cases: A Serologic Study in Canton of Vaud, Switzerland.",2021-03-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Vaud,," all confirmed cases from week 1 were invited to participate in the study (n = 13), along with their close contacts identified by contact tracing (n = 117). Additionally, all cases aged between 6 months and 19 years (n = 66) and a random sample of noninstitutionalized cases aged ≥20 years (n = 368) who were tested positive during weeks 2–5 (from March 5 to April 1, 2020) were invited to take part in the study. 

Overall, this resulted in the solicitation of 447 confirmed cases (hereafter called index cases) and 137 close contacts not belonging to the households of the index cases. Moreover, index case participants were asked to invite all their household mem- bers aged ≥6 months to take part in the study. 
",,2020-05-04,2020-06-27,Contacts of COVID patients,All,Children and Youth (0-17 years),5.0,10.0,Age,5-10,22,0.546,,,,,,,,Simplified probability,Author designed (Luminex),,Other,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.9920000000000001,['Moderate'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,Yes,Julien Dupraz,University of Lausanne,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab149,2021-08-05,2022-07-16,Verified,dupraz_prevalence_2021,CHE
210326_Vaud_UniversityofLausanne_Household1_Age_15-20,210326_Vaud_UniversityofLausanne_Household1,"Prevalence of SARS-CoV-2 in Household Members and Other Close Contacts of COVID-19 Cases: A Serologic Study in Canton of Vaud, Switzerland.",2021-03-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Vaud,," all confirmed cases from week 1 were invited to participate in the study (n = 13), along with their close contacts identified by contact tracing (n = 117). Additionally, all cases aged between 6 months and 19 years (n = 66) and a random sample of noninstitutionalized cases aged ≥20 years (n = 368) who were tested positive during weeks 2–5 (from March 5 to April 1, 2020) were invited to take part in the study. 

Overall, this resulted in the solicitation of 447 confirmed cases (hereafter called index cases) and 137 close contacts not belonging to the households of the index cases. Moreover, index case participants were asked to invite all their household mem- bers aged ≥6 months to take part in the study. 
",,2020-05-04,2020-06-27,Contacts of COVID patients,All,Children and Youth (0-17 years),15.0,20.0,Age,15-20,19,0.474,,,,,,,,Simplified probability,Author designed (Luminex),,Other,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.9920000000000001,['Moderate'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,Yes,Julien Dupraz,University of Lausanne,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab149,2021-08-05,2022-07-16,Verified,dupraz_prevalence_2021,CHE
210326_Vaud_UniversityofLausanne_Household1_Age_20-40,210326_Vaud_UniversityofLausanne_Household1,"Prevalence of SARS-CoV-2 in Household Members and Other Close Contacts of COVID-19 Cases: A Serologic Study in Canton of Vaud, Switzerland.",2021-03-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Vaud,," all confirmed cases from week 1 were invited to participate in the study (n = 13), along with their close contacts identified by contact tracing (n = 117). Additionally, all cases aged between 6 months and 19 years (n = 66) and a random sample of noninstitutionalized cases aged ≥20 years (n = 368) who were tested positive during weeks 2–5 (from March 5 to April 1, 2020) were invited to take part in the study. 

Overall, this resulted in the solicitation of 447 confirmed cases (hereafter called index cases) and 137 close contacts not belonging to the households of the index cases. Moreover, index case participants were asked to invite all their household mem- bers aged ≥6 months to take part in the study. 
",,2020-05-04,2020-06-27,Contacts of COVID patients,All,Adults (18-64 years),20.0,40.0,Age,20-40,76,0.48700000000000004,,,,,,,,Simplified probability,Author designed (Luminex),,Other,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.9920000000000001,['Moderate'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,Yes,Julien Dupraz,University of Lausanne,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab149,2021-08-05,2022-07-16,Verified,dupraz_prevalence_2021,CHE
210326_Vaud_UniversityofLausanne_Household1_Age_65-75,210326_Vaud_UniversityofLausanne_Household1,"Prevalence of SARS-CoV-2 in Household Members and Other Close Contacts of COVID-19 Cases: A Serologic Study in Canton of Vaud, Switzerland.",2021-03-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Vaud,," all confirmed cases from week 1 were invited to participate in the study (n = 13), along with their close contacts identified by contact tracing (n = 117). Additionally, all cases aged between 6 months and 19 years (n = 66) and a random sample of noninstitutionalized cases aged ≥20 years (n = 368) who were tested positive during weeks 2–5 (from March 5 to April 1, 2020) were invited to take part in the study. 

Overall, this resulted in the solicitation of 447 confirmed cases (hereafter called index cases) and 137 close contacts not belonging to the households of the index cases. Moreover, index case participants were asked to invite all their household mem- bers aged ≥6 months to take part in the study. 
",,2020-05-04,2020-06-27,Contacts of COVID patients,All,Seniors (65+ years),65.0,75.0,Age,65-75,14,0.8570000000000001,,,,,,,,Simplified probability,Author designed (Luminex),,Other,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.9920000000000001,['Moderate'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,Yes,Julien Dupraz,University of Lausanne,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab149,2021-08-05,2022-07-16,Verified,dupraz_prevalence_2021,CHE
210326_Vaud_UniversityofLausanne_Household1_Age_40-65,210326_Vaud_UniversityofLausanne_Household1,"Prevalence of SARS-CoV-2 in Household Members and Other Close Contacts of COVID-19 Cases: A Serologic Study in Canton of Vaud, Switzerland.",2021-03-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Vaud,," all confirmed cases from week 1 were invited to participate in the study (n = 13), along with their close contacts identified by contact tracing (n = 117). Additionally, all cases aged between 6 months and 19 years (n = 66) and a random sample of noninstitutionalized cases aged ≥20 years (n = 368) who were tested positive during weeks 2–5 (from March 5 to April 1, 2020) were invited to take part in the study. 

Overall, this resulted in the solicitation of 447 confirmed cases (hereafter called index cases) and 137 close contacts not belonging to the households of the index cases. Moreover, index case participants were asked to invite all their household mem- bers aged ≥6 months to take part in the study. 
",,2020-05-04,2020-06-27,Contacts of COVID patients,All,Adults (18-64 years),40.0,65.0,Age,40-65,116,0.517,,,,,,,,Simplified probability,Author designed (Luminex),,Other,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.9920000000000001,['Moderate'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,Yes,Julien Dupraz,University of Lausanne,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab149,2021-08-05,2022-07-16,Verified,dupraz_prevalence_2021,CHE
210326_Vaud_UniversityofLausanne_Household1_Age_75+,210326_Vaud_UniversityofLausanne_Household1,"Prevalence of SARS-CoV-2 in Household Members and Other Close Contacts of COVID-19 Cases: A Serologic Study in Canton of Vaud, Switzerland.",2021-03-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Vaud,," all confirmed cases from week 1 were invited to participate in the study (n = 13), along with their close contacts identified by contact tracing (n = 117). Additionally, all cases aged between 6 months and 19 years (n = 66) and a random sample of noninstitutionalized cases aged ≥20 years (n = 368) who were tested positive during weeks 2–5 (from March 5 to April 1, 2020) were invited to take part in the study. 

Overall, this resulted in the solicitation of 447 confirmed cases (hereafter called index cases) and 137 close contacts not belonging to the households of the index cases. Moreover, index case participants were asked to invite all their household mem- bers aged ≥6 months to take part in the study. 
",,2020-05-04,2020-06-27,Contacts of COVID patients,All,Seniors (65+ years),75.0,,Age,75+,12,0.833,,,,,,,,Simplified probability,Author designed (Luminex),,Other,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.9920000000000001,['Moderate'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,Yes,Julien Dupraz,University of Lausanne,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab149,2021-08-05,2022-07-16,Verified,dupraz_prevalence_2021,CHE
210326_Vaud_UniversityofLausanne_Household1_Age_10-15,210326_Vaud_UniversityofLausanne_Household1,"Prevalence of SARS-CoV-2 in Household Members and Other Close Contacts of COVID-19 Cases: A Serologic Study in Canton of Vaud, Switzerland.",2021-03-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Vaud,," all confirmed cases from week 1 were invited to participate in the study (n = 13), along with their close contacts identified by contact tracing (n = 117). Additionally, all cases aged between 6 months and 19 years (n = 66) and a random sample of noninstitutionalized cases aged ≥20 years (n = 368) who were tested positive during weeks 2–5 (from March 5 to April 1, 2020) were invited to take part in the study. 

Overall, this resulted in the solicitation of 447 confirmed cases (hereafter called index cases) and 137 close contacts not belonging to the households of the index cases. Moreover, index case participants were asked to invite all their household mem- bers aged ≥6 months to take part in the study. 
",,2020-05-04,2020-06-27,Contacts of COVID patients,All,Children and Youth (0-17 years),10.0,15.0,Age,10-15,32,0.469,,,,,,,,Simplified probability,Author designed (Luminex),,Other,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9670000000000001,0.9920000000000001,['Moderate'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,Yes,Julien Dupraz,University of Lausanne,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab149,2021-08-05,2022-07-16,Verified,dupraz_prevalence_2021,CHE
210115_Neuchatel_EcoleSuisseDeSantéPublique_PhaseII_overall,210115_Neuchatel_EcoleSuisseDeSantéPublique_PhaseII,RÉSULTATS DE L'ÉTUDE - CORONA IMMUNITAS,2021-03-31,News and Media,Regional,Repeated cross-sectional study,Switzerland,Canton of Neuchâtel ,,Individuals in Neuchâtel 20 and over,"This result includes a small number of people who have already received one or two doses of the vaccine before taking the blood test. Excluding these people, the figure is 21.3%",2020-08-21,2020-10-29,Household and community samples,All,Multiple groups,20.0,,Primary Estimate,,381,0.049,0.023799999999999998,0.08140000000000001,True,True,True,,,Stratified probability,Author designed (Luminex),,ELISA,Serum,"['IgA', 'IgG']",Spike,Validated by developers,0.966,0.997,['Moderate'],Yes,Yes,No,No,Unclear,Unclear,Yes,Yes,No,Republique et Canton de Neuchatel,École suisse de santé publique,Not Unity-Aligned,https://www.ne.ch/autorites/DFS/SCSP/medecin-cantonal/maladies-vaccinations/coronaimmunitas/Pages/R%c3%a9sultats-de-l'%c3%a9tude.aspx,2021-04-27,2022-07-16,Verified,republique_et_canton_de_neuchatel_resultats_nodate,CHE
210115_Neuchatel_EcoleSuisseDeSantéPublique_PhaseII_unadj,210115_Neuchatel_EcoleSuisseDeSantéPublique_PhaseII,RÉSULTATS DE L'ÉTUDE - CORONA IMMUNITAS,2021-03-31,News and Media,Regional,Repeated cross-sectional study,Switzerland,Canton of Neuchâtel ,,Individuals in Neuchâtel 20 and over,"This result includes a small number of people who have already received one or two doses of the vaccine before taking the blood test. Excluding these people, the figure is 21.3%",2020-08-21,2020-10-29,Household and community samples,All,Multiple groups,20.0,,Analysis,,381,0.057699999999999994,,,,,,,True,Stratified probability,Author designed (Luminex),,ELISA,Serum,"['IgA', 'IgG']",Spike,Validated by developers,0.966,0.997,['Moderate'],Yes,Yes,No,No,Unclear,Unclear,Yes,Yes,No,Republique et Canton de Neuchatel,École suisse de santé publique,Not Unity-Aligned,https://www.ne.ch/autorites/DFS/SCSP/medecin-cantonal/maladies-vaccinations/coronaimmunitas/Pages/R%c3%a9sultats-de-l'%c3%a9tude.aspx,2021-07-16,2022-07-16,Verified,republique_et_canton_de_neuchatel_resultats_nodate,CHE
210115_Neuchatel_EcoleSuisseDeSantéPublique_PhaseIII,210115_Neuchatel_EcoleSuisseDeSantéPublique_PhaseIII,RÉSULTATS DE L'ÉTUDE - CORONA IMMUNITAS,2021-03-31,News and Media,Regional,Repeated cross-sectional study,Switzerland,Canton of Neuchâtel ,,Individuals in Neuchâtel 20 and over,"This result includes a small number of people who have already received one or two doses of the vaccine before taking the blood test. Excluding these people, the figure is 21.3%",2020-12-23,2021-03-17,Household and community samples,All,Multiple groups,20.0,,Primary Estimate,,559,0.22,0.179,0.263,True,True,True,,,Stratified probability,Author designed (Luminex),,ELISA,Serum,"['IgA', 'IgG']",Spike,Validated by developers,0.966,0.997,['Moderate'],Yes,Yes,No,No,Yes,Unclear,Yes,Yes,No,Republique et Canton de Neuchatel,École suisse de santé publique,Not Unity-Aligned,https://www.ne.ch/autorites/DFS/SCSP/medecin-cantonal/maladies-vaccinations/coronaimmunitas/Pages/R%c3%a9sultats-de-l'%c3%a9tude.aspx,2021-04-27,2022-07-16,Verified,republique_et_canton_de_neuchatel_resultats_nodate,CHE
210115_Neuchatel_EcoleSuisseDeSantéPublique_PhaseIII_unadj,210115_Neuchatel_EcoleSuisseDeSantéPublique_PhaseIII,RÉSULTATS DE L'ÉTUDE - CORONA IMMUNITAS,2021-03-31,News and Media,Regional,Repeated cross-sectional study,Switzerland,Canton of Neuchâtel ,,Individuals in Neuchâtel 20 and over,"This result includes a small number of people who have already received one or two doses of the vaccine before taking the blood test. Excluding these people, the figure is 21.3%",2020-12-23,2021-03-17,Household and community samples,All,Multiple groups,20.0,,Analysis,,559,0.22719999999999999,,,,,,,True,Stratified probability,Author designed (Luminex),,ELISA,Serum,"['IgA', 'IgG']",Spike,Validated by developers,0.966,0.997,['Moderate'],Yes,Yes,No,No,Yes,Unclear,Yes,Yes,No,Republique et Canton de Neuchatel,École suisse de santé publique,Not Unity-Aligned,https://www.ne.ch/autorites/DFS/SCSP/medecin-cantonal/maladies-vaccinations/coronaimmunitas/Pages/R%c3%a9sultats-de-l'%c3%a9tude.aspx,2021-07-16,2022-07-16,Unverified,republique_et_canton_de_neuchatel_resultats_nodate,CHE
210419_Fribourg_UniversitédeFribourg_Overall_TestPopAdj,210419_Fribourg_UniversitédeFribourg,Corona Immunitas Fribourg Immunité de la population Episode 2/2021,2021-04-01,Institutional Report,Regional,Cross-sectional survey ,Switzerland,Canton of Fribourg,,The general population aged 20 and above in Fribourg ,,2020-11-30,2021-02-05,Household and community samples,All,Multiple groups,20.0,,Primary Estimate,Population and test adjusted,449,0.19,0.15,0.23,True,True,True,,True,Simplified probability,Author designed (Luminex),,ELISA,Serum,IgG,Spike,Validated by developers,0.966,0.997,['Moderate'],Yes,Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Emna El May,Université de Fribourg,Unity-Aligned,https://www.unifr.ch/med/imf/fr/assets/public/images/COVID-19/2021-PopHealthLab-Corona-Immunitas-E2.pdf,2021-04-19,2022-07-16,Verified,el_may_corona_2021,CHE
210419_Fribourg_UniversitédeFribourg_male,210419_Fribourg_UniversitédeFribourg,Corona Immunitas Fribourg Immunité de la population Episode 2/2021,2021-04-01,Institutional Report,Regional,Cross-sectional survey ,Switzerland,Canton of Fribourg,,The general population aged 20 and above in Fribourg ,,2020-11-30,2021-02-05,Household and community samples,Male,Multiple groups,20.0,,Sex/Gender,,204,0.19,,,,True,True,,,Simplified probability,Author designed (Luminex),,ELISA,Serum,IgG,Spike,Validated by developers,0.966,0.997,['Moderate'],Yes,Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Emna El May,Université de Fribourg,Unity-Aligned,https://www.unifr.ch/med/imf/fr/assets/public/images/COVID-19/2021-PopHealthLab-Corona-Immunitas-E2.pdf,2021-04-19,2022-07-16,Verified,el_may_corona_2021,CHE
210419_Fribourg_UniversitédeFribourg_Overall_Crude,210419_Fribourg_UniversitédeFribourg,Corona Immunitas Fribourg Immunité de la population Episode 2/2021,2021-04-01,Institutional Report,Regional,Cross-sectional survey ,Switzerland,Canton of Fribourg,,The general population aged 20 and above in Fribourg ,,2020-11-30,2021-02-05,Household and community samples,All,Multiple groups,20.0,,Analysis,Crude estimate,449,0.2049,,,,,,,,Simplified probability,Author designed (Luminex),,ELISA,Serum,IgG,Spike,Validated by developers,0.966,0.997,['Moderate'],Yes,Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Emna El May,Université de Fribourg,Unity-Aligned,https://www.unifr.ch/med/imf/fr/assets/public/images/COVID-19/2021-PopHealthLab-Corona-Immunitas-E2.pdf,2021-09-15,2022-07-16,Verified,el_may_corona_2021,CHE
210419_Fribourg_UniversitédeFribourg_female,210419_Fribourg_UniversitédeFribourg,Corona Immunitas Fribourg Immunité de la population Episode 2/2021,2021-04-01,Institutional Report,Regional,Cross-sectional survey ,Switzerland,Canton of Fribourg,,The general population aged 20 and above in Fribourg ,,2020-11-30,2021-02-05,Household and community samples,Female,Multiple groups,20.0,,Sex/Gender,,245,0.18,,,,True,True,,,Simplified probability,Author designed (Luminex),,ELISA,Serum,IgG,Spike,Validated by developers,0.966,0.997,['Moderate'],Yes,Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Emna El May,Université de Fribourg,Unity-Aligned,https://www.unifr.ch/med/imf/fr/assets/public/images/COVID-19/2021-PopHealthLab-Corona-Immunitas-E2.pdf,2021-04-19,2022-07-16,Verified,el_may_corona_2021,CHE
210419_Fribourg_UniversitédeFribourg_age65+,210419_Fribourg_UniversitédeFribourg,Corona Immunitas Fribourg Immunité de la population Episode 2/2021,2021-04-01,Institutional Report,Regional,Cross-sectional survey ,Switzerland,Canton of Fribourg,,The general population aged 20 and above in Fribourg ,,2020-11-30,2021-02-05,Household and community samples,All,Seniors (65+ years),65.0,,Age,age 65+,147,0.22,,,,True,True,,,Simplified probability,Author designed (Luminex),,ELISA,Serum,IgG,Spike,Validated by developers,0.966,0.997,['Moderate'],Yes,Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Emna El May,Université de Fribourg,Unity-Aligned,https://www.unifr.ch/med/imf/fr/assets/public/images/COVID-19/2021-PopHealthLab-Corona-Immunitas-E2.pdf,2021-04-19,2022-07-16,Verified,el_may_corona_2021,CHE
210419_Fribourg_UniversitédeFribourg_age20-64,210419_Fribourg_UniversitédeFribourg,Corona Immunitas Fribourg Immunité de la population Episode 2/2021,2021-04-01,Institutional Report,Regional,Cross-sectional survey ,Switzerland,Canton of Fribourg,,The general population aged 20 and above in Fribourg ,,2020-11-30,2021-02-05,Household and community samples,All,Adults (18-64 years),20.0,64.0,Age,age 20-64,302,0.18,,,,True,True,,,Simplified probability,Author designed (Luminex),,ELISA,Serum,IgG,Spike,Validated by developers,0.966,0.997,['Moderate'],Yes,Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Emna El May,Université de Fribourg,Unity-Aligned,https://www.unifr.ch/med/imf/fr/assets/public/images/COVID-19/2021-PopHealthLab-Corona-Immunitas-E2.pdf,2021-04-19,2022-07-16,Verified,el_may_corona_2021,CHE
210402_Switzerland_UniversitàdellaSvizzeraItaliana_overall,210402_Switzerland_UniversitàdellaSvizzeraItaliana,Seroprevalence of anti-SARS-CoV-2 IgG among adolescents at military fitness-for-duty evaluation,2021-04-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Southern Switzerland ,,Male citizens 18-19 years of age. Women willing to be part of the army are also invited.,,2020-07-15,2020-12-15,Household and community samples,All,Adults (18-64 years),18.0,19.0,Primary Estimate,,301,0.033,,,True,,,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,No,Elena Giuliano,Università della Svizzera Italiana,Unity-Aligned,https://dx.doi.org/10.1136/bmjmilitary-2021-001828,2021-04-24,2024-03-01,Verified,giuliano_seroprevalence_2021,CHE
210412_ValMesolcina_UniversitàdellaSvizzeraItaliana_HCW,210412_ValMesolcina_UniversitàdellaSvizzeraItaliana_HCW,SARS-CoV-2 Ig G among Healthcare Workers and the General Population.,2021-04-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Switzerland,Grisons,,"healthcare workers active in long-term care facilities, outpatient clinics, homecare or ambulance services of the valley were asked to participate through the heads of the healthcare structures or services.","Healthcare workers directly involved in the management of COVID19 inpatients were not included, because no institution responsible for the care of this condition is present in Val Mesolcina. ",2020-05-15,2020-05-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Overall HCWs,289,0.159,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Gregorio Milani ,Università della Svizzera Italiana,Not Unity-Aligned,https://dx.doi.org/10.3390/pathogens10040465,2021-05-19,2024-03-01,Verified,milani_sars-cov-2_2021,CHE
210412_ValMesolcina_UniversitàdellaSvizzeraItaliana__Genpop,210412_ValMesolcina_UniversitàdellaSvizzeraItaliana__Genpop,SARS-CoV-2 Ig G among Healthcare Workers and the General Population.,2021-04-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Switzerland,Grisons,,"All subjects of the Swiss Longitudinal Cohort Study, a prospective investigation involving 488 subjects representative of the general population of the valley [21], were invited to participate the study by mail",,2020-05-15,2020-05-31,Household and community samples,All,Multiple groups,,,Primary Estimate,Gen pop overall ,423,0.026000000000000002,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],Unclear,No,No,Yes,Unclear,Yes,Yes,Yes,Yes,Gregorio Milani ,Università della Svizzera Italiana,Unity-Aligned,https://dx.doi.org/10.3390/pathogens10040465,2021-05-19,2024-03-01,Verified,milani_sars-cov-2_2021,CHE
210412_ValMesolcina_UniversitàdellaSvizzeraItaliana__Female,210412_ValMesolcina_UniversitàdellaSvizzeraItaliana__Genpop,SARS-CoV-2 Ig G among Healthcare Workers and the General Population.,2021-04-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Switzerland,Grisons,,"All subjects of the Swiss Longitudinal Cohort Study, a prospective investigation involving 488 subjects representative of the general population of the valley [21], were invited to participate the study by mail",,2020-05-15,2020-05-31,Household and community samples,Female,Multiple groups,,,Sex/Gender,Female,235,0.034,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],Unclear,No,No,Yes,Unclear,Yes,Yes,Yes,Yes,Gregorio Milani ,Università della Svizzera Italiana,Unity-Aligned,https://dx.doi.org/10.3390/pathogens10040465,2021-08-13,2024-03-01,Verified,milani_sars-cov-2_2021,CHE
210412_ValMesolcina_UniversitàdellaSvizzeraItaliana__Male,210412_ValMesolcina_UniversitàdellaSvizzeraItaliana__Genpop,SARS-CoV-2 Ig G among Healthcare Workers and the General Population.,2021-04-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Switzerland,Grisons,,"All subjects of the Swiss Longitudinal Cohort Study, a prospective investigation involving 488 subjects representative of the general population of the valley [21], were invited to participate the study by mail",,2020-05-15,2020-05-31,Household and community samples,Male,Multiple groups,,,Sex/Gender,Male ,188,0.016,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],Unclear,No,No,Yes,Unclear,Yes,Yes,Yes,Yes,Gregorio Milani ,Università della Svizzera Italiana,Unity-Aligned,https://dx.doi.org/10.3390/pathogens10040465,2021-08-13,2024-03-01,Verified,milani_sars-cov-2_2021,CHE
210521_Zurich_UniversityofZurich_Overall,210521_Zurich_UniversityofZurich,Long-term symptoms after SARS-CoV-2 infection in school children: population-based cohort with 6-months follow-up. Short Report,2021-05-21,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Canton of Zurich,,"""Overall, 1355 of 2503 children with a serology result in October/November 2020 and follow up questionnaire in March-May 2021 were included.""","""Children who were seronegative in October/November 2020 and seroconverted or were not retested in March/April 2021 were excluded from the analysis (n=256).""

The study design of this preprint article is described elsewhere [reference 6] (https://doi.org/10.1136/bmj.n616). There, it is mentioned that:

""A major exclusion criterion was suspected or confirmed SARS-CoV-2 infection on the testing day, which precluded the child attending school and therefore being tested at school.""

""Serological results were unavailable if venous blood could not be obtained during venipuncture or previously enrolled participants declined venipuncture during testing.""",2020-10-26,2020-11-19,Students and Daycares,All,Children and Youth (0-17 years),6.0,16.0,Primary Estimate,,1355,0.0804,,,True,,,,True,Stratified probability,Author designed (Luminex),,,,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.943,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Thomas Radtke,University of Zurich,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.05.16.21257255v2,2021-06-06,2022-07-16,Unverified,Radtke_long-term_2021,CHE
210521_Zurich_UniversityofZurich_Age_12-16,210521_Zurich_UniversityofZurich,Long-term symptoms after SARS-CoV-2 infection in school children: population-based cohort with 6-months follow-up. Short Report,2021-05-21,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Canton of Zurich,,"""Overall, 1355 of 2503 children with a serology result in October/November 2020 and follow up questionnaire in March-May 2021 were included.""","""Children who were seronegative in October/November 2020 and seroconverted or were not retested in March/April 2021 were excluded from the analysis (n=256).""

The study design of this preprint article is described elsewhere [reference 6] (https://doi.org/10.1136/bmj.n616). There, it is mentioned that:

""A major exclusion criterion was suspected or confirmed SARS-CoV-2 infection on the testing day, which precluded the child attending school and therefore being tested at school.""

""Serological results were unavailable if venous blood could not be obtained during venipuncture or previously enrolled participants declined venipuncture during testing.""",2020-10-26,2020-11-19,Students and Daycares,All,Children and Youth (0-17 years),12.0,16.0,Age,Age: 12-16,586,0.0734,,,,,,,,Stratified probability,Author designed (Luminex),,,,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.943,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Thomas Radtke,University of Zurich,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.05.16.21257255v2,2022-02-17,2022-07-16,Unverified,Radtke_long-term_2021,CHE
210521_Zurich_UniversityofZurich_Age_6-11,210521_Zurich_UniversityofZurich,Long-term symptoms after SARS-CoV-2 infection in school children: population-based cohort with 6-months follow-up. Short Report,2021-05-21,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Canton of Zurich,,"""Overall, 1355 of 2503 children with a serology result in October/November 2020 and follow up questionnaire in March-May 2021 were included.""","""Children who were seronegative in October/November 2020 and seroconverted or were not retested in March/April 2021 were excluded from the analysis (n=256).""

The study design of this preprint article is described elsewhere [reference 6] (https://doi.org/10.1136/bmj.n616). There, it is mentioned that:

""A major exclusion criterion was suspected or confirmed SARS-CoV-2 infection on the testing day, which precluded the child attending school and therefore being tested at school.""

""Serological results were unavailable if venous blood could not be obtained during venipuncture or previously enrolled participants declined venipuncture during testing.""",2020-10-26,2020-11-19,Students and Daycares,All,Children and Youth (0-17 years),6.0,11.0,Age,Age: 6-11,769,0.0858,,,,,,,,Stratified probability,Author designed (Luminex),,,,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.943,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Thomas Radtke,University of Zurich,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.05.16.21257255v2,2022-02-17,2022-07-16,Unverified,Radtke_long-term_2021,CHE
210608_Geneva_UniversityOfGeneva_overall,210608_Geneva_UniversityOfGeneva,"Large variation in anti-SARS-CoV-2 antibody prevalence among essential workers in Geneva, Switzerland",2021-06-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Canton of Geneva,,Essential workers in Geneva from participating facilities.  Facilities were eligible for participation if they were located in the canton of Geneva and had remained mostly operational with on-site staff activity during the lockdown.,Inndividuals outside the target age range (18-65),2020-05-18,2020-09-18,Essential non-healthcare workers,All,Adults (18-64 years),18.0,65.0,Primary Estimate,,10513,0.098,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Silvia Stringhini,The University of Geneva,Not Unity-Aligned,http://dx.doi.org/10.1038/s41467-021-23796-4,2021-06-30,2024-03-01,Unverified,stringhini_large_2021,CHE
210621_Geneva_GenevaUniversityHospitals_overall,210621_Geneva_GenevaUniversityHospitals,Vulnerable patients forgo health care during the first wave of the Covid-19 pandemic,2021-06-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Switzerland,,Geneva,"""Participants were eligible for study participation if 1) they were aged 18 years or older, 2) had an outpatient visit in one of the following divisions of the HUG: cardiology, endocrinology, geriatrics (age ≥ 60 years), immunology, infectious diseases (HIV clinic), primary care (migrant health program and mobile outpatient community care center), nephrology, neurology, oncology, pneumology, and rheumatology, and 3) had a chronic health condition (except for patients from the migrant health program and mobile outpatient community care center).""",,2020-06-01,2020-06-30,Residual sera,All,Multiple groups,18.0,,Primary Estimate,,1167,0.059000000000000004,0.047,0.07400000000000001,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Stephanie Baggio,Geneva University Hospitals,Unity-Aligned,http://dx.doi.org/10.1016/j.ypmed.2021.106696,2021-07-07,2024-03-01,Verified,baggio_vulnerable_2021,CHE
210705_Lausanne_UniversityOfLausanne_Overall,210705_Lausanne_UniversityOfLausanne,SARS-CoV-2 seroprevalence in healthcare workers of a Swiss tertiary care centre at the end of the first wave: a cross-sectional study.,2021-07-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Switzerland,,Lausanne,Health care workers at the tertiary care university centre in Lausanne,"""Exclusion criteria were age under 18 years, symptoms within the 14 days prior to sampling (corresponding to the median time-window of seroconversion and participation in an alternative serological population study in the Canton of Vaud (SerocoViD). """,2020-05-18,2020-06-12,Health care workers and caregivers,All,Multiple groups,18.0,,Primary Estimate,,1874,0.1,0.087,0.115,True,,,,True,Stratified non-probability,Author designed (Luminex),,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.97,0.98,['High'],,No,Yes,No,,Unclear,Yes,Yes,,Sylvain Meylan,Lausanne University Hospital and University of Lausanne,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-049232,2021-07-13,2022-07-16,Unverified,meylan_sars-cov-2_2021,CHE
210706_Geneva_JohnsHopkinsBloombergSchoolofPublicHealth_RocheS1_Baseline_Overall,210706_Geneva_JohnsHopkinsBloombergSchoolofPublicHealth_Baseline,Persistence of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance,2021-07-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Switzerland,,Geneva,"Participants of the SEROCoV-POP and SEROCoV-WORK+ serosurveys who were seronegative on the Euroimmun anti-S1 test (EI-negative) at their first study visit (referred to as baseline, between April and July 2020) with a similar sex ratio and age range who returned for a second visit in November 2020 (referred to as follow-up). From the SEROCoV-POP cohort the selection of EI-negative was done randomly whereas from the SEROCoV-WORK+ cohort, participants having declared a positive RT-PCR against
SARS-CoV-2 before baseline serology were given priority for invitation.

Participants for this study were recruited from two previous serosurveys in the canton of Geneva, one population-based between April and June 2020 (SEROCoV-POP), and one focusing on essential workers between May and September 2020 (SEROCoV-WORK+). Participants of SEROCoV-POP were recruited by email and postal mail from the study population of a yearly health survey of a representative of the population of canton Geneva, and invited to bring members of their household aged 5
years and older. Participants of SEROCoV-WORK+ consisted of employees recruited on a voluntary basis from a selection of eligible facilities in the canton of Geneva which remained operational during the spring 2020 lockdown. Invitees to the two studies who were in quarantine or isolation, or experiencing COVID-19-related symptoms during the study recruitment period were ineligible for participation.","In SEROCoV-POP and SEROCoV-WORK+, tnvitees to the two studies who were in quarantine or isolation, or experiencing COVID-19-related symptoms during the study recruitment period were ineligible for participation.",2020-04-15,2020-07-15,Multiple populations,All,Multiple groups,,,Primary Estimate,,187,0.12300000000000001,,,True,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,,,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Javier Perez Saez,Johns Hopkins Bloomberg School of Public Health,Not Unity-Aligned,https://doi.org/10.1016/j.cmi.2021.06.040,2021-09-15,2024-03-01,Unverified,perez-saez_persistence_2021-1,CHE
210706_Geneva_JohnsHopkinsBloombergSchoolofPublicHealth_RocheS1_Baseline_17-65,210706_Geneva_JohnsHopkinsBloombergSchoolofPublicHealth_Baseline,Persistence of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance,2021-07-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Switzerland,,Geneva,"Participants of the SEROCoV-POP and SEROCoV-WORK+ serosurveys who were seronegative on the Euroimmun anti-S1 test (EI-negative) at their first study visit (referred to as baseline, between April and July 2020) with a similar sex ratio and age range who returned for a second visit in November 2020 (referred to as follow-up). From the SEROCoV-POP cohort the selection of EI-negative was done randomly whereas from the SEROCoV-WORK+ cohort, participants having declared a positive RT-PCR against
SARS-CoV-2 before baseline serology were given priority for invitation.

Participants for this study were recruited from two previous serosurveys in the canton of Geneva, one population-based between April and June 2020 (SEROCoV-POP), and one focusing on essential workers between May and September 2020 (SEROCoV-WORK+). Participants of SEROCoV-POP were recruited by email and postal mail from the study population of a yearly health survey of a representative of the population of canton Geneva, and invited to bring members of their household aged 5
years and older. Participants of SEROCoV-WORK+ consisted of employees recruited on a voluntary basis from a selection of eligible facilities in the canton of Geneva which remained operational during the spring 2020 lockdown. Invitees to the two studies who were in quarantine or isolation, or experiencing COVID-19-related symptoms during the study recruitment period were ineligible for participation.","In SEROCoV-POP and SEROCoV-WORK+, tnvitees to the two studies who were in quarantine or isolation, or experiencing COVID-19-related symptoms during the study recruitment period were ineligible for participation.",2020-04-15,2020-07-15,Multiple populations,All,Multiple groups,,,Age,"Baseline, 17-65",183,0.11480000000000001,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,,,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Javier Perez Saez,Johns Hopkins Bloomberg School of Public Health,Not Unity-Aligned,https://doi.org/10.1016/j.cmi.2021.06.040,2021-09-15,2024-03-01,Unverified,perez-saez_persistence_2021-1,CHE
210706_Geneva_JohnsHopkinsBloombergSchoolofPublicHealth_RocheS1_Baseline_65+,210706_Geneva_JohnsHopkinsBloombergSchoolofPublicHealth_Baseline,Persistence of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance,2021-07-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Switzerland,,Geneva,"Participants of the SEROCoV-POP and SEROCoV-WORK+ serosurveys who were seronegative on the Euroimmun anti-S1 test (EI-negative) at their first study visit (referred to as baseline, between April and July 2020) with a similar sex ratio and age range who returned for a second visit in November 2020 (referred to as follow-up). From the SEROCoV-POP cohort the selection of EI-negative was done randomly whereas from the SEROCoV-WORK+ cohort, participants having declared a positive RT-PCR against
SARS-CoV-2 before baseline serology were given priority for invitation.

Participants for this study were recruited from two previous serosurveys in the canton of Geneva, one population-based between April and June 2020 (SEROCoV-POP), and one focusing on essential workers between May and September 2020 (SEROCoV-WORK+). Participants of SEROCoV-POP were recruited by email and postal mail from the study population of a yearly health survey of a representative of the population of canton Geneva, and invited to bring members of their household aged 5
years and older. Participants of SEROCoV-WORK+ consisted of employees recruited on a voluntary basis from a selection of eligible facilities in the canton of Geneva which remained operational during the spring 2020 lockdown. Invitees to the two studies who were in quarantine or isolation, or experiencing COVID-19-related symptoms during the study recruitment period were ineligible for participation.","In SEROCoV-POP and SEROCoV-WORK+, tnvitees to the two studies who were in quarantine or isolation, or experiencing COVID-19-related symptoms during the study recruitment period were ineligible for participation.",2020-04-15,2020-07-15,Multiple populations,All,Multiple groups,,,Age,"Baseline, 65+",4,0.5,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,,,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Javier Perez Saez,Johns Hopkins Bloomberg School of Public Health,Not Unity-Aligned,https://doi.org/10.1016/j.cmi.2021.06.040,2021-09-15,2024-03-01,Unverified,perez-saez_persistence_2021-1,CHE
210706_Geneva_JohnsHopkinsBloombergSchoolofPublicHealth_RocheS1_FollowUp_Overall,210706_Geneva_JohnsHopkinsBloombergSchoolofPublicHealth_FollowUp,Persistence of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance,2021-07-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Switzerland,,Geneva,"Participants of the SEROCoV-POP and SEROCoV-WORK+ serosurveys who were seronegative on the Euroimmun anti-S1 test (EI-negative) at their first study visit (referred to as baseline, between April and July 2020) with a similar sex ratio and age range who returned for a second visit in November 2020 (referred to as follow-up). From the SEROCoV-POP cohort the selection of EI-negative was done randomly whereas from the SEROCoV-WORK+ cohort, participants having declared a positive RT-PCR against
SARS-CoV-2 before baseline serology were given priority for invitation.

Participants for this study were recruited from two previous serosurveys in the canton of Geneva, one population-based between April and June 2020 (SEROCoV-POP), and one focusing on essential workers between May and September 2020 (SEROCoV-WORK+). Participants of SEROCoV-POP were recruited by email and postal mail from the study population of a yearly health survey of a representative of the population of canton Geneva, and invited to bring members of their household aged 5
years and older. Participants of SEROCoV-WORK+ consisted of employees recruited on a voluntary basis from a selection of eligible facilities in the canton of Geneva which remained operational during the spring 2020 lockdown. Invitees to the two studies who were in quarantine or isolation, or experiencing COVID-19-related symptoms during the study recruitment period were ineligible for participation.","In SEROCoV-POP and SEROCoV-WORK+, tnvitees to the two studies who were in quarantine or isolation, or experiencing COVID-19-related symptoms during the study recruitment period were ineligible for participation.",2020-11-01,2020-11-30,Multiple populations,All,Multiple groups,,,Primary Estimate,,187,0.2727,,,True,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,,,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Javier Perez Saez,Johns Hopkins Bloomberg School of Public Health,Not Unity-Aligned,https://doi.org/10.1016/j.cmi.2021.06.040,2021-09-15,2024-03-01,Unverified,perez-saez_persistence_2021-1,CHE
210706_Geneva_JohnsHopkinsBloombergSchoolofPublicHealth_RocheS1_FollowUp_65+,210706_Geneva_JohnsHopkinsBloombergSchoolofPublicHealth_FollowUp,Persistence of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance,2021-07-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Switzerland,,Geneva,"Participants of the SEROCoV-POP and SEROCoV-WORK+ serosurveys who were seronegative on the Euroimmun anti-S1 test (EI-negative) at their first study visit (referred to as baseline, between April and July 2020) with a similar sex ratio and age range who returned for a second visit in November 2020 (referred to as follow-up). From the SEROCoV-POP cohort the selection of EI-negative was done randomly whereas from the SEROCoV-WORK+ cohort, participants having declared a positive RT-PCR against
SARS-CoV-2 before baseline serology were given priority for invitation.

Participants for this study were recruited from two previous serosurveys in the canton of Geneva, one population-based between April and June 2020 (SEROCoV-POP), and one focusing on essential workers between May and September 2020 (SEROCoV-WORK+). Participants of SEROCoV-POP were recruited by email and postal mail from the study population of a yearly health survey of a representative of the population of canton Geneva, and invited to bring members of their household aged 5
years and older. Participants of SEROCoV-WORK+ consisted of employees recruited on a voluntary basis from a selection of eligible facilities in the canton of Geneva which remained operational during the spring 2020 lockdown. Invitees to the two studies who were in quarantine or isolation, or experiencing COVID-19-related symptoms during the study recruitment period were ineligible for participation.","In SEROCoV-POP and SEROCoV-WORK+, tnvitees to the two studies who were in quarantine or isolation, or experiencing COVID-19-related symptoms during the study recruitment period were ineligible for participation.",2020-11-01,2020-11-30,Multiple populations,All,Multiple groups,,,Age,"Follow up, 65+",4,0.5,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,,,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Javier Perez Saez,Johns Hopkins Bloomberg School of Public Health,Not Unity-Aligned,https://doi.org/10.1016/j.cmi.2021.06.040,2021-09-15,2024-03-01,Unverified,perez-saez_persistence_2021-1,CHE
210706_Geneva_JohnsHopkinsBloombergSchoolofPublicHealth_RocheS1_FollowUp_17-65,210706_Geneva_JohnsHopkinsBloombergSchoolofPublicHealth_FollowUp,Persistence of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance,2021-07-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Switzerland,,Geneva,"Participants of the SEROCoV-POP and SEROCoV-WORK+ serosurveys who were seronegative on the Euroimmun anti-S1 test (EI-negative) at their first study visit (referred to as baseline, between April and July 2020) with a similar sex ratio and age range who returned for a second visit in November 2020 (referred to as follow-up). From the SEROCoV-POP cohort the selection of EI-negative was done randomly whereas from the SEROCoV-WORK+ cohort, participants having declared a positive RT-PCR against
SARS-CoV-2 before baseline serology were given priority for invitation.

Participants for this study were recruited from two previous serosurveys in the canton of Geneva, one population-based between April and June 2020 (SEROCoV-POP), and one focusing on essential workers between May and September 2020 (SEROCoV-WORK+). Participants of SEROCoV-POP were recruited by email and postal mail from the study population of a yearly health survey of a representative of the population of canton Geneva, and invited to bring members of their household aged 5
years and older. Participants of SEROCoV-WORK+ consisted of employees recruited on a voluntary basis from a selection of eligible facilities in the canton of Geneva which remained operational during the spring 2020 lockdown. Invitees to the two studies who were in quarantine or isolation, or experiencing COVID-19-related symptoms during the study recruitment period were ineligible for participation.","In SEROCoV-POP and SEROCoV-WORK+, tnvitees to the two studies who were in quarantine or isolation, or experiencing COVID-19-related symptoms during the study recruitment period were ineligible for participation.",2020-11-01,2020-11-30,Multiple populations,All,Multiple groups,,,Age,"Follow up, 17-65",183,0.26780000000000004,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,,,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Javier Perez Saez,Johns Hopkins Bloomberg School of Public Health,Not Unity-Aligned,https://doi.org/10.1016/j.cmi.2021.06.040,2021-09-15,2024-03-01,Unverified,perez-saez_persistence_2021-1,CHE
210719_Zurich_UniversityofZurich_T3_overallTestPopAdj,210719_Zurich_UniversityofZurich_T3,Evolution of SARS-CoV-2 seroprevalence and clusters in school children from June 2020 to April 2021 reflect community transmission: prospective cohort study Ciao Corona,2021-07-19,Preprint,Local,Prospective cohort,Switzerland,,Zurich,"We randomly selected classes within participating schools, stratified by school level: grades 1 to 2 in lower level (attended by 6 to 9-year-old-children), grades 4 to 5 in middle level (attended by 9 to 13-year-old children) and grades 7 to 8 in upper school level (attended by 12 to 16-year-old-children). Invited grades were selected to ensure that the same cohort of children will remain in the classes until April 2021 (children in grades 3, 6 and 9 often change the class and school in the next year). For this reason, in mixed classes with children from multiple grades, only children in grades 1 and 5 were eligible. Children and adolescents (hereafter referred to as children) of the selected classes were invited at each testing round, regardless of their participation in the previous round.",Major exclusion criterion was suspected or confirmed SARS-CoV-2 infection in the given child during the testing (precluding the attendance of the testing at school). Children dropped out of the study if they moved to a non-participating school.,2021-03-15,2021-04-16,Students and Daycares,All,Children and Youth (0-17 years),7.0,17.0,Primary Estimate,"Ever seropositive at t3, pop test adj",2450,0.16399999999999998,0.121,0.195,True,True,True,,,Simplified probability,Author designed (Luminex),,Other,Plasma,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.9820000000000001,0.9940000000000001,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Agne Ulyte,University of Zurich,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.19.21260644v1.full-text,2021-07-29,2024-02-02,Unverified,ulyte_evolution_2021,CHE
210726_Zurich_UniversityofZurich_Adults_Overall,210726_Zurich_UniversityofZurich_Adults,"Variation in SARS-CoV-2 seroprevalence across districts, schools and classes: baseline measurements from a cohort of primary and secondary school children in Switzerland.",2021-07-26,Journal Article (Peer-Reviewed),Local,Prospective cohort,Switzerland,Zurich,Zurich,Adults in Zurich in the same region in June–July 2020,,2020-06-16,2020-07-09,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,,857,0.036000000000000004,0.017,0.054000000000000006,True,True,True,,True,Simplified probability,Author designed (Luminex),,ELISA,Serum,"['IgA', 'IgG']",Spike,Validated by developers,0.983,0.9840000000000001,['Low'],Yes,Yes,Yes,No,Yes,Unclear,Yes,Yes,Unclear,Agne Ulyte,University of Zurich,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2020-047483,2021-08-03,2022-07-16,Verified,ulyte_variation_2021,CHE
210726_Zurich_UniversityofZurich_Children_PopTestAdj,210726_Zurich_UniversityofZurich_Children,"Variation in SARS-CoV-2 seroprevalence across districts, schools and classes: baseline measurements from a cohort of primary and secondary school children in Switzerland.",2021-07-26,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Switzerland,Canton of Zurich,Zurich,"School children grades 1-2, 4-5, and 7-8 (ages 6-16) in Zurich","""As we were only able to test the children at schools, a major exclusion criterion was a suspected or confirmed infection with SARS-CoV-2 in the given child on the testing date, precluding attendance of school.""
Invited grades and classes were selected to
ensure that the same cohort of children within the class can be followed until April 2021. Therefore, grades 1–2, 4–5 and 7–8 (but not grades 3, 6 and 9) were included, as they normally stay in the same school and class for the next school-year.",2020-06-16,2020-07-09,Students and Daycares,All,Children and Youth (0-17 years),6.0,16.0,Primary Estimate,Weighted overall estimate,2484,0.027999999999999997,0.015,0.040999999999999995,True,True,True,,,Stratified probability,Author designed (Luminex),,ELISA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.9329999999999999,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Agne Ulyte,University of Zurich,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2020-047483,2021-08-03,2022-07-16,Verified,ulyte_variation_2021,CHE
210813_Geneva_GenevaUniversityHospital_Primary,210813_Geneva_GenevaUniversityHospital,"Seroprevalence of anti-SARS-CoV-2 antibodies six months into the vaccination campaign in Geneva, Switzerland",2021-08-13,Preprint,Local,Prospective cohort,Switzerland,,Geneva,"The study sample was built from a combination of newly recruited individuals, randomly selected from official population registers provided by the Swiss Federal Statistics Office, and participants from previous population-representative seroprevalence surveys.",,2021-06-01,2021-07-07,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,3355,0.299,0.28,0.319,True,True,True,True,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Silvia Stringhini,Geneva University Hospital ,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.12.21261929v1,2021-08-24,2023-08-15,Verified,stringhini_seroprevalence_2021,CHE
210813_Geneva_GenevaUniversityHospital_Age0to5,210813_Geneva_GenevaUniversityHospital,"Seroprevalence of anti-SARS-CoV-2 antibodies six months into the vaccination campaign in Geneva, Switzerland",2021-08-13,Preprint,Local,Prospective cohort,Switzerland,,Geneva,"The study sample was built from a combination of newly recruited individuals, randomly selected from official population registers provided by the Swiss Federal Statistics Office, and participants from previous population-representative seroprevalence surveys.",,2021-06-01,2021-07-07,Household and community samples,All,Children and Youth (0-17 years),0.0,5.0,Age,0-5,150,0.20800000000000002,0.155,0.267,,True,True,True,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Silvia Stringhini,Geneva University Hospital ,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.12.21261929v1,2021-08-24,2023-08-15,Verified,stringhini_seroprevalence_2021,CHE
210813_Geneva_GenevaUniversityHospital_Age35to49,210813_Geneva_GenevaUniversityHospital,"Seroprevalence of anti-SARS-CoV-2 antibodies six months into the vaccination campaign in Geneva, Switzerland",2021-08-13,Preprint,Local,Prospective cohort,Switzerland,,Geneva,"The study sample was built from a combination of newly recruited individuals, randomly selected from official population registers provided by the Swiss Federal Statistics Office, and participants from previous population-representative seroprevalence surveys.",,2021-06-01,2021-07-07,Household and community samples,All,Adults (18-64 years),35.0,49.0,Age,35-49,805,0.322,0.287,0.359,,True,True,True,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Silvia Stringhini,Geneva University Hospital ,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.12.21261929v1,2021-08-24,2023-08-15,Verified,stringhini_seroprevalence_2021,CHE
210813_Geneva_GenevaUniversityHospital_Age6to11,210813_Geneva_GenevaUniversityHospital,"Seroprevalence of anti-SARS-CoV-2 antibodies six months into the vaccination campaign in Geneva, Switzerland",2021-08-13,Preprint,Local,Prospective cohort,Switzerland,,Geneva,"The study sample was built from a combination of newly recruited individuals, randomly selected from official population registers provided by the Swiss Federal Statistics Office, and participants from previous population-representative seroprevalence surveys.",,2021-06-01,2021-07-07,Household and community samples,All,Children and Youth (0-17 years),6.0,11.0,Age,6-11,281,0.314,0.267,0.364,,True,True,True,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Silvia Stringhini,Geneva University Hospital ,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.12.21261929v1,2021-08-24,2023-08-15,Verified,stringhini_seroprevalence_2021,CHE
210813_Geneva_GenevaUniversityHospital_Female,210813_Geneva_GenevaUniversityHospital,"Seroprevalence of anti-SARS-CoV-2 antibodies six months into the vaccination campaign in Geneva, Switzerland",2021-08-13,Preprint,Local,Prospective cohort,Switzerland,,Geneva,"The study sample was built from a combination of newly recruited individuals, randomly selected from official population registers provided by the Swiss Federal Statistics Office, and participants from previous population-representative seroprevalence surveys.",,2021-06-01,2021-07-07,Household and community samples,Female,Multiple groups,0.0,,Sex/Gender,,1814,0.295,0.272,0.319,,True,True,True,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Silvia Stringhini,Geneva University Hospital ,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.12.21261929v1,2021-08-24,2023-08-15,Verified,stringhini_seroprevalence_2021,CHE
210813_Geneva_GenevaUniversityHospital_Age50to64,210813_Geneva_GenevaUniversityHospital,"Seroprevalence of anti-SARS-CoV-2 antibodies six months into the vaccination campaign in Geneva, Switzerland",2021-08-13,Preprint,Local,Prospective cohort,Switzerland,,Geneva,"The study sample was built from a combination of newly recruited individuals, randomly selected from official population registers provided by the Swiss Federal Statistics Office, and participants from previous population-representative seroprevalence surveys.",,2021-06-01,2021-07-07,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50-64,732,0.298,0.265,0.334,,True,True,True,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Silvia Stringhini,Geneva University Hospital ,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.12.21261929v1,2021-08-24,2023-08-15,Verified,stringhini_seroprevalence_2021,CHE
210813_Geneva_GenevaUniversityHospital_AgeOver75,210813_Geneva_GenevaUniversityHospital,"Seroprevalence of anti-SARS-CoV-2 antibodies six months into the vaccination campaign in Geneva, Switzerland",2021-08-13,Preprint,Local,Prospective cohort,Switzerland,,Geneva,"The study sample was built from a combination of newly recruited individuals, randomly selected from official population registers provided by the Swiss Federal Statistics Office, and participants from previous population-representative seroprevalence surveys.",,2021-06-01,2021-07-07,Household and community samples,All,Seniors (65+ years),75.0,,Age,>=75,242,0.162,0.11800000000000001,0.21100000000000002,,True,True,True,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Silvia Stringhini,Geneva University Hospital ,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.12.21261929v1,2021-08-24,2023-08-15,Verified,stringhini_seroprevalence_2021,CHE
210813_Geneva_GenevaUniversityHospital_Age12to17,210813_Geneva_GenevaUniversityHospital,"Seroprevalence of anti-SARS-CoV-2 antibodies six months into the vaccination campaign in Geneva, Switzerland",2021-08-13,Preprint,Local,Prospective cohort,Switzerland,,Geneva,"The study sample was built from a combination of newly recruited individuals, randomly selected from official population registers provided by the Swiss Federal Statistics Office, and participants from previous population-representative seroprevalence surveys.",,2021-06-01,2021-07-07,Household and community samples,All,Children and Youth (0-17 years),12.0,17.0,Age,12-17,266,0.37700000000000006,0.325,0.43100000000000005,,True,True,True,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Silvia Stringhini,Geneva University Hospital ,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.12.21261929v1,2021-08-24,2023-08-15,Verified,stringhini_seroprevalence_2021,CHE
210813_Geneva_GenevaUniversityHospital_UnAdj,210813_Geneva_GenevaUniversityHospital,"Seroprevalence of anti-SARS-CoV-2 antibodies six months into the vaccination campaign in Geneva, Switzerland",2021-08-13,Preprint,Local,Prospective cohort,Switzerland,,Geneva,"The study sample was built from a combination of newly recruited individuals, randomly selected from official population registers provided by the Swiss Federal Statistics Office, and participants from previous population-representative seroprevalence surveys.",,2021-06-01,2021-07-07,Household and community samples,All,Multiple groups,0.0,,Analysis,,3355,0.27,,,,,,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.998,0.991,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Silvia Stringhini,Geneva University Hospital ,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.12.21261929v1,2021-08-24,2024-03-01,Unverified,stringhini_seroprevalence_2021,CHE
210813_Geneva_GenevaUniversityHospital_Age65to74,210813_Geneva_GenevaUniversityHospital,"Seroprevalence of anti-SARS-CoV-2 antibodies six months into the vaccination campaign in Geneva, Switzerland",2021-08-13,Preprint,Local,Prospective cohort,Switzerland,,Geneva,"The study sample was built from a combination of newly recruited individuals, randomly selected from official population registers provided by the Swiss Federal Statistics Office, and participants from previous population-representative seroprevalence surveys.",,2021-06-01,2021-07-07,Household and community samples,All,Seniors (65+ years),65.0,74.0,Age,65-74,207,0.225,0.17,0.284,,True,True,True,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Silvia Stringhini,Geneva University Hospital ,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.12.21261929v1,2021-08-24,2023-08-15,Verified,stringhini_seroprevalence_2021,CHE
210813_Geneva_GenevaUniversityHospital_Age18to24,210813_Geneva_GenevaUniversityHospital,"Seroprevalence of anti-SARS-CoV-2 antibodies six months into the vaccination campaign in Geneva, Switzerland",2021-08-13,Preprint,Local,Prospective cohort,Switzerland,,Geneva,"The study sample was built from a combination of newly recruited individuals, randomly selected from official population registers provided by the Swiss Federal Statistics Office, and participants from previous population-representative seroprevalence surveys.",,2021-06-01,2021-07-07,Household and community samples,All,Adults (18-64 years),18.0,24.0,Age,18-24,300,0.418,0.363,0.47500000000000003,,True,True,True,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Silvia Stringhini,Geneva University Hospital ,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.12.21261929v1,2021-08-24,2023-08-15,Verified,stringhini_seroprevalence_2021,CHE
210813_Geneva_GenevaUniversityHospital_Male,210813_Geneva_GenevaUniversityHospital,"Seroprevalence of anti-SARS-CoV-2 antibodies six months into the vaccination campaign in Geneva, Switzerland",2021-08-13,Preprint,Local,Prospective cohort,Switzerland,,Geneva,"The study sample was built from a combination of newly recruited individuals, randomly selected from official population registers provided by the Swiss Federal Statistics Office, and participants from previous population-representative seroprevalence surveys.",,2021-06-01,2021-07-07,Household and community samples,Male,Multiple groups,0.0,,Sex/Gender,,1541,0.304,0.28,0.33,,True,True,True,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Silvia Stringhini,Geneva University Hospital ,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.12.21261929v1,2021-08-24,2023-08-15,Verified,stringhini_seroprevalence_2021,CHE
210813_Geneva_GenevaUniversityHospital_Age25to34,210813_Geneva_GenevaUniversityHospital,"Seroprevalence of anti-SARS-CoV-2 antibodies six months into the vaccination campaign in Geneva, Switzerland",2021-08-13,Preprint,Local,Prospective cohort,Switzerland,,Geneva,"The study sample was built from a combination of newly recruited individuals, randomly selected from official population registers provided by the Swiss Federal Statistics Office, and participants from previous population-representative seroprevalence surveys.",,2021-06-01,2021-07-07,Household and community samples,All,Adults (18-64 years),25.0,34.0,Age,25-34,372,0.319,0.278,0.36200000000000004,,True,True,True,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Silvia Stringhini,Geneva University Hospital ,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.12.21261929v1,2021-08-24,2023-08-15,Verified,stringhini_seroprevalence_2021,CHE
210820_Solothurn_UniversityofBern_Primary,210820_Solothurn_UniversityofBern,Seroprevalence of SARS-CoV-2 in healthcare workers from outpatient facilities and retirement or nursing homes in a Swiss canton.,2021-08-20,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Switzerland,Canton of Solothurn,,"The cohort consisted of healthcare workers with a
minimum workload of ≥50% who worked in the outpatient clinic at a hospital, medical practice, retirement or nursing home, or in home care, who were at least 18 years old and had contact with patients before and during the first SARSCoV-2 epidemic wave from 1 January to 30 June 2020. Persons in close contact from the same household as the HCW who tested positive for SARS-CoV-2
by serology, were also invited to participate in this study.",,2020-06-01,2020-07-01,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,357,0.034,0.017,0.057999999999999996,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Yes,Yes,No,,Kathrin Zurcher,University of Bern,Not Unity-Aligned,https://dx.doi.org/10.4414/SMW.2021.w30021,2021-09-15,2024-03-01,Unverified,noauthor_seroprevalence_2021-5,CHE
210901_Switzerland_KantonsspitalStGallen,210901_Switzerland_KantonsspitalStGallen,"Anti-S1 antibodies after vaccination with anti SARS-CoV-2 mRNA vaccines in patients with rheumatoid arthritis differ in magnitude and kinetics from healthy controls: Results from a prospective, observational controlled study",2021-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Switzerland,St. Gallen,St. Gallen,Patients with rheumatoid arthritis,,2021-01-10,2021-03-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,77,0.0519,,,True,,,,True,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,,Nucleocapsid(N-protein),,,,['High'],,Unclear,No,No,,Yes,Yes,Yes,,Andrea Rubbert-Roth,Kantonsspital St. Gallen,Not Unity-Aligned,https://smw.ch/article/doi/SMW.2021.w30056,2021-09-29,2024-03-01,Unverified,rubbert-roth_anti-s1_2021,CHE
210903_Grisons_CantonalHospitalGrisons,210903_Grisons_CantonalHospitalGrisons,Seroconversion for SARS-COV-2 in health care workers after the first and the second wave of COVID-19 in the canton of Grisons in Switzerland,2021-09-03,Presentation or Conference,Regional,Cross-sectional survey ,Switzerland,Canton of Grisons,,"""HCW from 13 health care institutions were recruited.""",,2020-06-01,2021-01-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,5109,0.09300000000000001,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Katarzyna Szajek,Cantonal Hospital Grisons,Not Unity-Aligned,https://aricjournal.biomedcentral.com/track/pdf/10.1186/s13756-021-00974-z.pdf,2021-09-29,2024-03-01,Unverified,noauthor_abstracts_2021,CHE
211014_Switzerland_CantonalHospitalStGallen_Overall,211014_Switzerland_CantonalHospitalStGallen,Impact of baseline SARS-CoV-2 antibody status on syndromic surveillance and the risk of subsequent COVID-19-a prospective multicenter cohort study.,2021-10-14,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,,,Any hospital employee aged 16 years or older (across 23 healthcare institutions in Northern and Eastern Switzerland) with or without patient contact was eligible for the study.,"Participants were then prospectively followed and reminded by email and/or SMS to complete weekly web-based questionnaires. Questionnaires submitted within 2 weeks from baseline serology were excluded from the analysis in order to avoid the detection of symptoms or NPS results associated with episodes, which had started before baseline.",2020-06-22,2020-10-20,Health care workers and caregivers,All,Multiple groups,16.0,,Primary Estimate,,4812,0.03,,,True,,,,True,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.877,1.0,['Moderate'],,Unclear,Yes,Yes,,Yes,Yes,No,,Philipp Kohler,Cantonal Hospital St. Gallen,Not Unity-Aligned,https://dx.doi.org/10.1186/s12916-021-02144-9,2021-10-27,2024-03-01,Unverified,kohler_impact_2021-1,CHE
211019_Geneva_GenevaUniversityHospitals_Overall_Adjusted,211019_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 IgG antibodies, risk factors for infection and associated symptoms in Geneva, Switzerland: a population-based study",2021-10-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Canton of Geneva,,"SEROCoV-POP is a population-based repeated cross-sectional observational seroprevalence study. We recruited participants between 6 April and 30 June 2020. The recruitment strategy and serological data collection have previously been described in detail [4]. Briefly, participants were invited progressively by email and postal mail from the study population of a yearly health survey called Bus Santé [19], which is representative of the 20–74-year-old population of canton Geneva. Participants were invited to bring members of their household aged 5 years and older. ",,2020-04-06,2020-06-30,Household and community samples,All,Multiple groups,5.0,94.0,Primary Estimate,"adjusted for test, sex, and household clustering",8344,0.078,0.068,0.08900000000000001,True,True,True,True,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,1.0,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,No,Aude Richard,Geneva University Hospitals,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.12.16.20248180v1.full-text,2021-11-17,2023-08-15,Verified,richard_seroprevalence_2021,CHE
211019_Geneva_GenevaUniversityHospitals_18-49,211019_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 IgG antibodies, risk factors for infection and associated symptoms in Geneva, Switzerland: a population-based study",2021-10-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Canton of Geneva,,"SEROCoV-POP is a population-based repeated cross-sectional observational seroprevalence study. We recruited participants between 6 April and 30 June 2020. The recruitment strategy and serological data collection have previously been described in detail [4]. Briefly, participants were invited progressively by email and postal mail from the study population of a yearly health survey called Bus Santé [19], which is representative of the 20–74-year-old population of canton Geneva. Participants were invited to bring members of their household aged 5 years and older. ",,2020-04-06,2020-06-30,Household and community samples,All,Adults (18-64 years),18.0,49.0,Age,18-49,3108,0.09,,,,,,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,1.0,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,No,Aude Richard,Geneva University Hospitals,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.12.16.20248180v1.full-text,2021-11-17,2024-03-01,Verified,richard_seroprevalence_2021,CHE
211019_Geneva_GenevaUniversityHospitals_2May,211019_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 IgG antibodies, risk factors for infection and associated symptoms in Geneva, Switzerland: a population-based study",2021-10-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Canton of Geneva,,"SEROCoV-POP is a population-based repeated cross-sectional observational seroprevalence study. We recruited participants between 6 April and 30 June 2020. The recruitment strategy and serological data collection have previously been described in detail [4]. Briefly, participants were invited progressively by email and postal mail from the study population of a yearly health survey called Bus Santé [19], which is representative of the 20–74-year-old population of canton Geneva. Participants were invited to bring members of their household aged 5 years and older. ",,2020-05-01,2020-05-31,Household and community samples,All,Multiple groups,5.0,94.0,Time frame,May 2020,2996,0.081,0.07200000000000001,0.091,,,,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,1.0,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,No,Aude Richard,Geneva University Hospitals,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.12.16.20248180v1.full-text,2022-01-21,2024-03-01,Verified,richard_seroprevalence_2021,CHE
211019_Geneva_GenevaUniversityHospitals_Male,211019_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 IgG antibodies, risk factors for infection and associated symptoms in Geneva, Switzerland: a population-based study",2021-10-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Canton of Geneva,,"SEROCoV-POP is a population-based repeated cross-sectional observational seroprevalence study. We recruited participants between 6 April and 30 June 2020. The recruitment strategy and serological data collection have previously been described in detail [4]. Briefly, participants were invited progressively by email and postal mail from the study population of a yearly health survey called Bus Santé [19], which is representative of the 20–74-year-old population of canton Geneva. Participants were invited to bring members of their household aged 5 years and older. ",,2020-04-06,2020-06-30,Household and community samples,Male,Multiple groups,,,Sex/Gender,,3879,0.079,,,,,,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,1.0,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,No,Aude Richard,Geneva University Hospitals,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.12.16.20248180v1.full-text,2021-11-17,2024-03-01,Verified,richard_seroprevalence_2021,CHE
211019_Geneva_GenevaUniversityHospitals_3June,211019_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 IgG antibodies, risk factors for infection and associated symptoms in Geneva, Switzerland: a population-based study",2021-10-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Canton of Geneva,,"SEROCoV-POP is a population-based repeated cross-sectional observational seroprevalence study. We recruited participants between 6 April and 30 June 2020. The recruitment strategy and serological data collection have previously been described in detail [4]. Briefly, participants were invited progressively by email and postal mail from the study population of a yearly health survey called Bus Santé [19], which is representative of the 20–74-year-old population of canton Geneva. Participants were invited to bring members of their household aged 5 years and older. ",,2020-06-01,2020-06-30,Household and community samples,All,Multiple groups,5.0,94.0,Time frame,June 2020,3407,0.063,0.055999999999999994,0.07200000000000001,,,,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,1.0,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,No,Aude Richard,Geneva University Hospitals,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.12.16.20248180v1.full-text,2022-01-21,2024-03-01,Verified,richard_seroprevalence_2021,CHE
211019_Geneva_GenevaUniversityHospitals_Female,211019_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 IgG antibodies, risk factors for infection and associated symptoms in Geneva, Switzerland: a population-based study",2021-10-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Canton of Geneva,,"SEROCoV-POP is a population-based repeated cross-sectional observational seroprevalence study. We recruited participants between 6 April and 30 June 2020. The recruitment strategy and serological data collection have previously been described in detail [4]. Briefly, participants were invited progressively by email and postal mail from the study population of a yearly health survey called Bus Santé [19], which is representative of the 20–74-year-old population of canton Geneva. Participants were invited to bring members of their household aged 5 years and older. ",,2020-04-06,2020-06-30,Household and community samples,Female,Multiple groups,,,Sex/Gender,,4465,0.064,,,,,,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,1.0,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,No,Aude Richard,Geneva University Hospitals,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.12.16.20248180v1.full-text,2021-11-17,2024-03-01,Verified,richard_seroprevalence_2021,CHE
211019_Geneva_GenevaUniversityHospitals_Overall_Unadjusted,211019_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 IgG antibodies, risk factors for infection and associated symptoms in Geneva, Switzerland: a population-based study",2021-10-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Canton of Geneva,,"SEROCoV-POP is a population-based repeated cross-sectional observational seroprevalence study. We recruited participants between 6 April and 30 June 2020. The recruitment strategy and serological data collection have previously been described in detail [4]. Briefly, participants were invited progressively by email and postal mail from the study population of a yearly health survey called Bus Santé [19], which is representative of the 20–74-year-old population of canton Geneva. Participants were invited to bring members of their household aged 5 years and older. ",,2020-04-06,2020-06-30,Household and community samples,All,Multiple groups,5.0,94.0,Analysis,,8344,0.0707,,,,,,,True,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,1.0,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,No,Aude Richard,Geneva University Hospitals,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.12.16.20248180v1.full-text,2021-11-17,2024-03-01,Verified,richard_seroprevalence_2021,CHE
211019_Geneva_GenevaUniversityHospitals_<10,211019_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 IgG antibodies, risk factors for infection and associated symptoms in Geneva, Switzerland: a population-based study",2021-10-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Canton of Geneva,,"SEROCoV-POP is a population-based repeated cross-sectional observational seroprevalence study. We recruited participants between 6 April and 30 June 2020. The recruitment strategy and serological data collection have previously been described in detail [4]. Briefly, participants were invited progressively by email and postal mail from the study population of a yearly health survey called Bus Santé [19], which is representative of the 20–74-year-old population of canton Geneva. Participants were invited to bring members of their household aged 5 years and older. ",,2020-04-06,2020-06-30,Household and community samples,All,Children and Youth (0-17 years),5.0,10.0,Age,<10,274,0.033,,,,,,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,1.0,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,No,Aude Richard,Geneva University Hospitals,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.12.16.20248180v1.full-text,2021-11-17,2024-03-01,Verified,richard_seroprevalence_2021,CHE
211019_Geneva_GenevaUniversityHospitals_10-17,211019_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 IgG antibodies, risk factors for infection and associated symptoms in Geneva, Switzerland: a population-based study",2021-10-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Canton of Geneva,,"SEROCoV-POP is a population-based repeated cross-sectional observational seroprevalence study. We recruited participants between 6 April and 30 June 2020. The recruitment strategy and serological data collection have previously been described in detail [4]. Briefly, participants were invited progressively by email and postal mail from the study population of a yearly health survey called Bus Santé [19], which is representative of the 20–74-year-old population of canton Geneva. Participants were invited to bring members of their household aged 5 years and older. ",,2020-04-06,2020-06-30,Household and community samples,All,Children and Youth (0-17 years),10.0,17.0,Age,10-17,628,0.08,,,,,,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,1.0,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,No,Aude Richard,Geneva University Hospitals,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.12.16.20248180v1.full-text,2021-11-17,2024-03-01,Verified,richard_seroprevalence_2021,CHE
211019_Geneva_GenevaUniversityHospitals_≥75,211019_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 IgG antibodies, risk factors for infection and associated symptoms in Geneva, Switzerland: a population-based study",2021-10-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Canton of Geneva,,"SEROCoV-POP is a population-based repeated cross-sectional observational seroprevalence study. We recruited participants between 6 April and 30 June 2020. The recruitment strategy and serological data collection have previously been described in detail [4]. Briefly, participants were invited progressively by email and postal mail from the study population of a yearly health survey called Bus Santé [19], which is representative of the 20–74-year-old population of canton Geneva. Participants were invited to bring members of their household aged 5 years and older. ",,2020-04-06,2020-06-30,Household and community samples,All,Seniors (65+ years),75.0,94.0,Age,≥75,444,0.038,,,,,,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,1.0,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,No,Aude Richard,Geneva University Hospitals,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.12.16.20248180v1.full-text,2021-11-17,2024-03-01,Verified,richard_seroprevalence_2021,CHE
211019_Geneva_GenevaUniversityHospitals_65-74,211019_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 IgG antibodies, risk factors for infection and associated symptoms in Geneva, Switzerland: a population-based study",2021-10-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Canton of Geneva,,"SEROCoV-POP is a population-based repeated cross-sectional observational seroprevalence study. We recruited participants between 6 April and 30 June 2020. The recruitment strategy and serological data collection have previously been described in detail [4]. Briefly, participants were invited progressively by email and postal mail from the study population of a yearly health survey called Bus Santé [19], which is representative of the 20–74-year-old population of canton Geneva. Participants were invited to bring members of their household aged 5 years and older. ",,2020-04-06,2020-06-30,Household and community samples,All,Seniors (65+ years),65.0,74.0,Age,65-74,1196,0.047,,,,,,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,1.0,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,No,Aude Richard,Geneva University Hospitals,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.12.16.20248180v1.full-text,2021-11-17,2024-03-01,Verified,richard_seroprevalence_2021,CHE
211019_Geneva_GenevaUniversityHospitals_50-64,211019_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 IgG antibodies, risk factors for infection and associated symptoms in Geneva, Switzerland: a population-based study",2021-10-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Canton of Geneva,,"SEROCoV-POP is a population-based repeated cross-sectional observational seroprevalence study. We recruited participants between 6 April and 30 June 2020. The recruitment strategy and serological data collection have previously been described in detail [4]. Briefly, participants were invited progressively by email and postal mail from the study population of a yearly health survey called Bus Santé [19], which is representative of the 20–74-year-old population of canton Geneva. Participants were invited to bring members of their household aged 5 years and older. ",,2020-04-06,2020-06-30,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50-64,2694,0.067,,,,,,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,1.0,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,No,Aude Richard,Geneva University Hospitals,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.12.16.20248180v1.full-text,2021-11-17,2024-03-01,Verified,richard_seroprevalence_2021,CHE
211019_Geneva_GenevaUniversityHospitals_1April,211019_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 IgG antibodies, risk factors for infection and associated symptoms in Geneva, Switzerland: a population-based study",2021-10-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Canton of Geneva,,"SEROCoV-POP is a population-based repeated cross-sectional observational seroprevalence study. We recruited participants between 6 April and 30 June 2020. The recruitment strategy and serological data collection have previously been described in detail [4]. Briefly, participants were invited progressively by email and postal mail from the study population of a yearly health survey called Bus Santé [19], which is representative of the 20–74-year-old population of canton Geneva. Participants were invited to bring members of their household aged 5 years and older. ",,2020-04-06,2020-04-30,Household and community samples,All,Multiple groups,5.0,94.0,Time frame,April 2020,1939,0.067,0.057,0.079,,,,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,1.0,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,No,Aude Richard,Geneva University Hospitals,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.12.16.20248180v1.full-text,2022-01-21,2024-03-01,Verified,richard_seroprevalence_2021,CHE
211020_Vaud_UniversityofLausanne_Center1,211020_Vaud_UniversityofLausanne_Center1,Prevalence of SARS-CoV-2 and associated risk factors among asylum seekers living in centres,2021-10-20,Presentation or Conference,Regional,Cross-sectional survey ,Switzerland,Vaud,,All migrants living in two asylum centres were invited to participate.,,2020-05-15,2020-06-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,82,0.13,0.03,0.14,True,,,,True,Convenience,Not reported/ Unable to specify,,,,"['IgA', 'IgG']",Spike,,,,['High'],,No,No,No,,Unclear,Yes,No,,K Morisod,University of Lausanne,Not Unity-Aligned,https://academic.oup.com/eurpub/article/31/Supplement_3/ckab164.250/6405568?login=true,2022-01-19,2022-07-16,Unverified,morisod_prevalence_2021,CHE
211020_Vaud_UniversityofLausanne_Center2,211020_Vaud_UniversityofLausanne_Center2,Prevalence of SARS-CoV-2 and associated risk factors among asylum seekers living in centres,2021-10-20,Presentation or Conference,Regional,Cross-sectional survey ,Switzerland,Vaud,,All migrants living in two asylum centres were invited to participate.,,2020-05-15,2020-06-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,42,0.5,0.34,0.65,True,,,,True,Convenience,Not reported/ Unable to specify,,,,"['IgA', 'IgG']",Spike,,,,['High'],,No,No,No,,Unclear,Yes,No,,K Morisod,University of Lausanne,Not Unity-Aligned,https://academic.oup.com/eurpub/article/31/Supplement_3/ckab164.250/6405568?login=true,2022-01-19,2022-07-16,Unverified,morisod_prevalence_2021,CHE
211022_Switzerland_CantonalHospitalStGallen,211022_Switzerland_CantonalHospitalStGallen,Symptoms compatible with long-COVID in healthcare workers with and without SARS-CoV-2 infection – results of a prospective multicenter cohort,2021-10-22,Preprint,National,Cross-sectional survey ,Switzerland,,,"""Hospital employees from 23 healthcare institutions located in Northern and Eastern Switzerland were eligible""",Participants vaccinated in the week before the long-COVID questionnaire were excluded. ,2021-01-15,2021-02-15,Health care workers and caregivers,All,Multiple groups,16.0,72.0,Primary Estimate,,3334,0.2034,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.88,0.99,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Carol Strahm,Cantonal Hospital St Gallen,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.10.19.21265187v1.full-text,2021-11-04,2024-03-01,Unverified,strahm_symptoms_2021,CHE
211110_CantonofFribourg_UniversityofFribourg_Overall_Adj,211110_CantonofFribourg_UniversityofFribourg,Corona Immunitas Fribourg Immunité de la population Episode 3/2021,2021-11-10,Institutional Report,Regional,Cross-sectional survey ,Switzerland,Fribourg,,"A random
sample of the adult population aged 20 and over
in the canton of Fribourg.",,2021-05-20,2021-08-13,Household and community samples,All,Multiple groups,,,Primary Estimate,,504,0.74,0.6900000000000001,0.79,True,True,True,,,Simplified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,,IgG,Spike,Validated by independent authors/third party/non-developers,0.966,0.997,['High'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,No,Emna El May,Swiss School of Public Health,Unity-Aligned,https://zenodo.org/record/5665477,2022-03-09,2022-07-16,Verified,el_may_emna_corona_2021,CHE
211110_CantonofFribourg_UniversityofFribourg_Women,211110_CantonofFribourg_UniversityofFribourg,Corona Immunitas Fribourg Immunité de la population Episode 3/2021,2021-11-10,Institutional Report,Regional,Cross-sectional survey ,Switzerland,Fribourg,,"A random
sample of the adult population aged 20 and over
in the canton of Fribourg.",,2021-05-20,2021-08-13,Household and community samples,Female,Multiple groups,,,Sex/Gender,,277,0.72,,,,True,True,,,Simplified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,,IgG,Spike,Validated by independent authors/third party/non-developers,0.966,0.997,['High'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,No,Emna El May,Swiss School of Public Health,Unity-Aligned,https://zenodo.org/record/5665477,2022-03-09,2022-07-16,Verified,el_may_emna_corona_2021,CHE
211110_CantonofFribourg_UniversityofFribourg_Overall_Unadj,211110_CantonofFribourg_UniversityofFribourg,Corona Immunitas Fribourg Immunité de la population Episode 3/2021,2021-11-10,Institutional Report,Regional,Cross-sectional survey ,Switzerland,Fribourg,,"A random
sample of the adult population aged 20 and over
in the canton of Fribourg.",,2021-05-20,2021-08-13,Household and community samples,All,Multiple groups,,,Analysis,,504,0.78,,,,,,,True,Simplified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,,IgG,Spike,Validated by independent authors/third party/non-developers,0.966,0.997,['High'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,No,Emna El May,Swiss School of Public Health,Unity-Aligned,https://zenodo.org/record/5665477,2022-06-01,2022-07-16,Verified,el_may_emna_corona_2021,CHE
211110_CantonofFribourg_UniversityofFribourg_Vaccinated,211110_CantonofFribourg_UniversityofFribourg,Corona Immunitas Fribourg Immunité de la population Episode 3/2021,2021-11-10,Institutional Report,Regional,Cross-sectional survey ,Switzerland,Fribourg,,"A random
sample of the adult population aged 20 and over
in the canton of Fribourg.",,2021-05-20,2021-08-13,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,,316,0.99,,,,,,,,Simplified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,,IgG,Spike,Validated by independent authors/third party/non-developers,0.966,0.997,['High'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,No,Emna El May,Swiss School of Public Health,Unity-Aligned,https://zenodo.org/record/5665477,2022-03-09,2022-07-16,Verified,el_may_emna_corona_2021,CHE
211110_CantonofFribourg_UniversityofFribourg_Men,211110_CantonofFribourg_UniversityofFribourg,Corona Immunitas Fribourg Immunité de la population Episode 3/2021,2021-11-10,Institutional Report,Regional,Cross-sectional survey ,Switzerland,Fribourg,,"A random
sample of the adult population aged 20 and over
in the canton of Fribourg.",,2021-05-20,2021-08-13,Household and community samples,Male,Multiple groups,,,Sex/Gender,,227,0.75,,,,True,True,,,Simplified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,,IgG,Spike,Validated by independent authors/third party/non-developers,0.966,0.997,['High'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,No,Emna El May,Swiss School of Public Health,Unity-Aligned,https://zenodo.org/record/5665477,2022-03-09,2022-07-16,Verified,el_may_emna_corona_2021,CHE
211110_CantonofFribourg_UniversityofFribourg_65+,211110_CantonofFribourg_UniversityofFribourg,Corona Immunitas Fribourg Immunité de la population Episode 3/2021,2021-11-10,Institutional Report,Regional,Cross-sectional survey ,Switzerland,Fribourg,,"A random
sample of the adult population aged 20 and over
in the canton of Fribourg.",,2021-05-20,2021-08-13,Household and community samples,All,Seniors (65+ years),,,Age,65+,243,0.91,0.86,0.9400000000000001,,True,True,,,Simplified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,,IgG,Spike,Validated by independent authors/third party/non-developers,0.966,0.997,['High'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,No,Emna El May,Swiss School of Public Health,Unity-Aligned,https://zenodo.org/record/5665477,2022-03-09,2022-07-16,Verified,el_may_emna_corona_2021,CHE
211110_CantonofFribourg_UniversityofFribourg_20-64,211110_CantonofFribourg_UniversityofFribourg,Corona Immunitas Fribourg Immunité de la population Episode 3/2021,2021-11-10,Institutional Report,Regional,Cross-sectional survey ,Switzerland,Fribourg,,"A random
sample of the adult population aged 20 and over
in the canton of Fribourg.",,2021-05-20,2021-08-13,Household and community samples,All,Adults (18-64 years),,,Age,20-64,261,0.6900000000000001,0.63,0.75,,True,True,,,Simplified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,,IgG,Spike,Validated by independent authors/third party/non-developers,0.966,0.997,['High'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,No,Emna El May,Swiss School of Public Health,Unity-Aligned,https://zenodo.org/record/5665477,2022-03-09,2022-07-16,Verified,el_may_emna_corona_2021,CHE
211110_CantonofFribourg_UniversityofFribourg_Unvaccinated,211110_CantonofFribourg_UniversityofFribourg,Corona Immunitas Fribourg Immunité de la population Episode 3/2021,2021-11-10,Institutional Report,Regional,Cross-sectional survey ,Switzerland,Fribourg,,"A random
sample of the adult population aged 20 and over
in the canton of Fribourg.",,2021-05-20,2021-08-13,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,,186,0.43,,,,,,,,Simplified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,,IgG,Spike,Validated by independent authors/third party/non-developers,0.966,0.997,['High'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,No,Emna El May,Swiss School of Public Health,Unity-Aligned,https://zenodo.org/record/5665477,2022-03-09,2022-07-16,Verified,el_may_emna_corona_2021,CHE
211112_Zurich_UniversityofZurich_T1,211112_Zurich_UniversityofZurich_T1,Evolution of SARS-CoV-2 seroprevalence and clusters in school children from June 2020 to April 2021: prospective cohort study Ciao Corona.,2021-11-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Zurich,,"From cited protocol study:

Children and adolescents residing in Switzerland and attending a selected public or private, primary or secondary school (approximate age 6–16 years) in the canton of Zurich are eligible for the study

 School grades 1–2, 4–5, and 7–8 are included

In age-mixed learning classes in primary schools, only grades 1 and 5 are included as children in other grades potentially change the class after the summer break. Detailed inclusion and exclusion criteria are provided in the online data supplement.

Ulyte A, Radtke T, Abela IA, Haile SR, Braun J, Jung R Seroprevalence and immunity of SARS-CoV-2 infection in children and adolescents in schools in Switzerland: design for a longitudinal, school-based prospective cohort study [Internet]. Int J Public Health. 2020 Dec;65(9):1549–57. [cited 2021 Jan 17] Available from: https://pubmed.ncbi.nlm.nih.gov/33063141/ ","From cited protocol study:

Main exclusion criteria for schools are small school size (< 40 children in a selected school level), and for participants—suspected or confirmed infection with SARS-CoV-2 during testing.

grades 3, 6, and 9 grades are excluded as these students may move to another school after the summer break, and follow-up would be compromised.

Ulyte A, Radtke T, Abela IA, Haile SR, Braun J, Jung R Seroprevalence and immunity of SARS-CoV-2 infection in children and adolescents in schools in Switzerland: design for a longitudinal, school-based prospective cohort study [Internet]. Int J Public Health. 2020 Dec;65(9):1549–57. [cited 2021 Jan 17] Available from: https://pubmed.ncbi.nlm.nih.gov/33063141/ ",2020-06-16,2020-07-09,Students and Daycares,All,Children and Youth (0-17 years),7.0,17.0,Primary Estimate,,2601,0.015,0.006,0.026000000000000002,True,,,,True,Stratified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Plasma,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.9820000000000001,0.9940000000000001,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,Yes,No,Agne Ulyte,University of Zurich,Not Unity-Aligned,https://dx.doi.org/10.4414/smw.2021.w30092,2021-12-02,2022-07-16,Unverified,ulyte_evolution_2021-1,CHE
211112_Zurich_UniversityofZurich_T2,211112_Zurich_UniversityofZurich_T2,Evolution of SARS-CoV-2 seroprevalence and clusters in school children from June 2020 to April 2021: prospective cohort study Ciao Corona.,2021-11-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Zurich,,"From cited protocol study:

Children and adolescents residing in Switzerland and attending a selected public or private, primary or secondary school (approximate age 6–16 years) in the canton of Zurich are eligible for the study

 School grades 1–2, 4–5, and 7–8 are included

In age-mixed learning classes in primary schools, only grades 1 and 5 are included as children in other grades potentially change the class after the summer break. Detailed inclusion and exclusion criteria are provided in the online data supplement.

Ulyte A, Radtke T, Abela IA, Haile SR, Braun J, Jung R Seroprevalence and immunity of SARS-CoV-2 infection in children and adolescents in schools in Switzerland: design for a longitudinal, school-based prospective cohort study [Internet]. Int J Public Health. 2020 Dec;65(9):1549–57. [cited 2021 Jan 17] Available from: https://pubmed.ncbi.nlm.nih.gov/33063141/ ","From cited protocol study:

Main exclusion criteria for schools are small school size (< 40 children in a selected school level), and for participants—suspected or confirmed infection with SARS-CoV-2 during testing.

grades 3, 6, and 9 grades are excluded as these students may move to another school after the summer break, and follow-up would be compromised.

Ulyte A, Radtke T, Abela IA, Haile SR, Braun J, Jung R Seroprevalence and immunity of SARS-CoV-2 infection in children and adolescents in schools in Switzerland: design for a longitudinal, school-based prospective cohort study [Internet]. Int J Public Health. 2020 Dec;65(9):1549–57. [cited 2021 Jan 17] Available from: https://pubmed.ncbi.nlm.nih.gov/33063141/ ",2020-10-26,2020-11-19,Students and Daycares,All,Children and Youth (0-17 years),7.0,17.0,Primary Estimate,,1965,0.066,0.04,0.08900000000000001,True,,,,True,Stratified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Plasma,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.9820000000000001,0.9940000000000001,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,Yes,No,Agne Ulyte,University of Zurich,Not Unity-Aligned,https://dx.doi.org/10.4414/smw.2021.w30092,2021-12-02,2022-07-16,Unverified,ulyte_evolution_2021-1,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase1_OverallAdjusted,211228_Ticino_Ufficiodelmedicocantonale_Phase1,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2020-05-11,2020-06-28,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,,934,0.09,0.071,0.11199999999999999,True,True,,,,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2023-08-15,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase1_OverallCrude,211228_Ticino_Ufficiodelmedicocantonale_Phase1,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2020-05-11,2020-06-28,Household and community samples,All,Multiple groups,5.0,,Analysis,,934,0.09640000000000001,,,,,,,True,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2024-03-01,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase1_Age20-49,211228_Ticino_Ufficiodelmedicocantonale_Phase1,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2020-05-11,2020-06-28,Household and community samples,All,Adults (18-64 years),20.0,49.0,Age,20-49,355,0.08449999999999999,,,,,,,,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2024-03-01,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase1_SexFemale,211228_Ticino_Ufficiodelmedicocantonale_Phase1,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2020-05-11,2020-06-28,Household and community samples,Female,Multiple groups,5.0,,Sex/Gender,,495,0.0949,,,,,,,,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2024-03-01,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase1_Age65+,211228_Ticino_Ufficiodelmedicocantonale_Phase1,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2020-05-11,2020-06-28,Household and community samples,All,Seniors (65+ years),65.0,,Age,,174,0.1034,,,,,,,,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2024-03-01,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase1_SexMale,211228_Ticino_Ufficiodelmedicocantonale_Phase1,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2020-05-11,2020-06-28,Household and community samples,Male,Multiple groups,5.0,,Sex/Gender,,439,0.09789999999999999,,,,,,,,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2024-03-01,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase1_Age50-64,211228_Ticino_Ufficiodelmedicocantonale_Phase1,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2020-05-11,2020-06-28,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50-64,255,0.1137,,,,,,,,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2024-03-01,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase1_Age10-19,211228_Ticino_Ufficiodelmedicocantonale_Phase1,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2020-05-11,2020-06-28,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,102,0.098,,,,,,,,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2024-03-01,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase1_Age5-9,211228_Ticino_Ufficiodelmedicocantonale_Phase1,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2020-05-11,2020-06-28,Household and community samples,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,48,0.0625,,,,,,,,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2024-03-01,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase2_OverallAdjusted,211228_Ticino_Ufficiodelmedicocantonale_Phase2,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2020-08-03,2020-08-03,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,,905,0.084,0.065,0.105,True,True,,,,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2023-08-15,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase2_SexMale,211228_Ticino_Ufficiodelmedicocantonale_Phase2,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2020-08-03,2020-08-03,Household and community samples,Male,Multiple groups,5.0,,Sex/Gender,,424,0.1038,,,,,,,,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2024-03-01,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase2_SexFemale,211228_Ticino_Ufficiodelmedicocantonale_Phase2,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2020-08-03,2020-08-03,Household and community samples,Female,Multiple groups,5.0,,Sex/Gender,,481,0.07690000000000001,,,,,,,,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2024-03-01,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase2_Age20-49,211228_Ticino_Ufficiodelmedicocantonale_Phase2,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2020-08-03,2020-08-03,Household and community samples,All,Adults (18-64 years),20.0,49.0,Age,20-49,340,0.0882,,,,,,,,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2024-03-01,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase2_OverallCrude,211228_Ticino_Ufficiodelmedicocantonale_Phase2,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2020-08-03,2020-08-03,Household and community samples,All,Multiple groups,5.0,,Analysis,,905,0.0895,,,,,,,True,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2024-03-01,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase2_Age10-19,211228_Ticino_Ufficiodelmedicocantonale_Phase2,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2020-08-03,2020-08-03,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,98,0.061200000000000004,,,,,,,,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2024-03-01,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase2_Age65+,211228_Ticino_Ufficiodelmedicocantonale_Phase2,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2020-08-03,2020-08-03,Household and community samples,All,Seniors (65+ years),65.0,,Age,,174,0.0977,,,,,,,,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2024-03-01,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase2_Age50-64,211228_Ticino_Ufficiodelmedicocantonale_Phase2,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2020-08-03,2020-08-03,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50-64,247,0.1012,,,,,,,,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2024-03-01,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase2_Age5-9,211228_Ticino_Ufficiodelmedicocantonale_Phase2,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2020-08-03,2020-08-03,Household and community samples,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,46,0.0652,,,,,,,,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2024-03-01,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase3_OverallAdjusted,211228_Ticino_Ufficiodelmedicocantonale_Phase3,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2020-11-02,2020-12-27,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,,870,0.141,0.11699999999999999,0.168,True,True,,,,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,No,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2023-08-15,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase3_Age50-64,211228_Ticino_Ufficiodelmedicocantonale_Phase3,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2020-11-02,2020-12-27,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50-64,243,0.1564,,,,,,,,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,No,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2024-03-01,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase3_OverallCrude,211228_Ticino_Ufficiodelmedicocantonale_Phase3,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2020-11-02,2020-12-27,Household and community samples,All,Multiple groups,5.0,,Analysis,,870,0.1437,,,,,,,True,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,No,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2024-03-01,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase3_Age65+,211228_Ticino_Ufficiodelmedicocantonale_Phase3,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2020-11-02,2020-12-27,Household and community samples,All,Seniors (65+ years),65.0,,Age,,184,0.1359,,,,,,,,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,No,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2024-03-01,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase3_SexFemale,211228_Ticino_Ufficiodelmedicocantonale_Phase3,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2020-11-02,2020-12-27,Household and community samples,Female,Multiple groups,5.0,,Sex/Gender,,465,0.1419,,,,,,,,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,No,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2024-03-01,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase3_Age10-19,211228_Ticino_Ufficiodelmedicocantonale_Phase3,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2020-11-02,2020-12-27,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,93,0.129,,,,,,,,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,No,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2024-03-01,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase3_Age5-9,211228_Ticino_Ufficiodelmedicocantonale_Phase3,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2020-11-02,2020-12-27,Household and community samples,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,33,0.12119999999999999,,,,,,,,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,No,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2024-03-01,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase3_Age20-49,211228_Ticino_Ufficiodelmedicocantonale_Phase3,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2020-11-02,2020-12-27,Household and community samples,All,Adults (18-64 years),20.0,49.0,Age,20-49,317,0.1451,,,,,,,,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,No,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2024-03-01,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase3_SexMale,211228_Ticino_Ufficiodelmedicocantonale_Phase3,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2020-11-02,2020-12-27,Household and community samples,Male,Multiple groups,5.0,,Sex/Gender,,405,0.1457,,,,,,,,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,No,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2024-03-01,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase4_OverallAdjusted,211228_Ticino_Ufficiodelmedicocantonale_Phase4,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2021-05-03,2021-06-13,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,,722,0.223,0.192,0.257,True,,,,,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,No,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2024-03-01,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase4_Age65+,211228_Ticino_Ufficiodelmedicocantonale_Phase4,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2021-05-03,2021-06-13,Household and community samples,All,Seniors (65+ years),65.0,,Age,,160,0.225,,,,,,,,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,No,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2024-03-01,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase4_OverallCrude,211228_Ticino_Ufficiodelmedicocantonale_Phase4,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2021-05-03,2021-06-13,Household and community samples,All,Multiple groups,5.0,,Analysis,,722,0.22440000000000002,,,,,,,True,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,No,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2024-03-01,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase4_SexMale,211228_Ticino_Ufficiodelmedicocantonale_Phase4,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2021-05-03,2021-06-13,Household and community samples,Male,Multiple groups,5.0,,Sex/Gender,,329,0.23399999999999999,,,,,,,,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,No,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2024-03-01,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase4_SexFemale,211228_Ticino_Ufficiodelmedicocantonale_Phase4,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2021-05-03,2021-06-13,Household and community samples,Female,Multiple groups,5.0,,Sex/Gender,,393,0.2163,,,,,,,,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,No,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2024-03-01,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase4_Age5-9,211228_Ticino_Ufficiodelmedicocantonale_Phase4,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2021-05-03,2021-06-13,Household and community samples,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,25,0.28,,,,,,,,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,No,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2024-03-01,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase4_Age10-19,211228_Ticino_Ufficiodelmedicocantonale_Phase4,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2021-05-03,2021-06-13,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,75,0.25329999999999997,,,,,,,,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,No,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2024-03-01,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase4_Age50-64,211228_Ticino_Ufficiodelmedicocantonale_Phase4,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2021-05-03,2021-06-13,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50-64,210,0.2286,,,,,,,,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,No,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2024-03-01,Verified,beretta_seroprevalence_2021,CHE
211228_Ticino_Ufficiodelmedicocantonale_Phase4_Age20-49,211228_Ticino_Ufficiodelmedicocantonale_Phase4,"Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.",2021-12-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Ticino,,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.",Aged younger than 5 years old,2021-05-03,2021-06-13,Household and community samples,All,Adults (18-64 years),20.0,49.0,Age,20-49,252,0.20629999999999998,,,,,,,,Stratified probability,Rapid Test SARS-CoV-2 IgM/IgG Gold,Technogenetics,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.951,0.9890000000000001,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,No,Ottavio Beretta,Ufficio del medico cantonale,Unity-Aligned,https://smw.ch/article/doi/smw.2021.w30116,2022-01-09,2024-03-01,Verified,beretta_seroprevalence_2021,CHE
220105_Bern_InselspitalUniversityHospital_ELISA_S1,220105_Bern_InselspitalUniversityHospital,Serological testing for SARS-CoV-2 antibodies in clinical practice: a comparative diagnostic accuracy study.,2022-01-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Switzerland,,Bern,"Two groups of individuals representing distinct target populations were included between April and November 2020 (Figure 1): (a) consecutive inpatients with suspected SARSCoV-2 infection (ill patients at risk for complications), and (b) healthcare workers at Inselspital (healthy individuals tested for surveillance measures). The inclusion criteria for inpatients were: (1) hospitalization in Inselspital, (2) tested at least once for SARSCoV-2 by real-time polymerase chain reaction (RT-PCR; nasopharyngeal swab), (3) aged 18 or older, and (4) signed informed consent. Only inpatients with more than 4 days of residual sample material were considered. The inclusion criteria for healthcare workers
were: (1) medical staff at Inselspital since February 2020, (2) aged 18 or older, and (3) signed informed consent.",,2020-04-15,2020-11-15,Multiple populations,All,Multiple groups,,,Primary Estimate,ELISA Anti-S1 IgG Euroimmun,3658,0.0629,,,True,,,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by developers,0.8620000000000001,0.9820000000000001,['High'],,No,Yes,Yes,,Yes,Yes,No,,Michael P Horn,Inselspital University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1111/all.15206,2022-01-09,2024-03-01,Unverified,horn_serological_2022,CHE
220110_Grisons_ CantonalHospitalGrisons_Baseline1_Overall,220110_Grisons_ CantonalHospitalGrisons_Baseline1,Healthcare institutions' recommendation regarding the use of FFP-2 masks and SARS-CoV-2 seropositivity among healthcare workers: a multicenter longitudinal cohort study.,2022-01-10,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Switzerland,Canton of Grisons,,"We performed a multicenter prospective cohort study including 13 HCI caring for patients with COVID-19 in the canton of Grisons, Switzerland. The selected HCI consisted of one referral center (provincial hospital; 330 bed medical center with integrated intensive care unit), nine small primary care hospitals (average bed capacity: 33 beds), two rehabilitation centers (average bed capac- ity: 108 beds) and one psychiatric clinic (capacity of 240 beds). We invited all health care employees (≥ 16 years of age) in the selected HCI to participate in the study.",,2020-06-08,2020-08-13,Health care workers and caregivers,All,Adults (18-64 years),16.0,,Primary Estimate,,2794,0.035,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Katarzyna Szajek, Cantonal Hospital of Grisons,Not Unity-Aligned,https://dx.doi.org/10.1186/s13756-021-01047-x,2022-01-18,2024-03-01,Unverified,szajek_healthcare_2022-1,CHE
220110_Grisons_ CantonalHospitalGrisons_Followup2_Overall,220110_Grisons_ CantonalHospitalGrisons_Followup2,Healthcare institutions' recommendation regarding the use of FFP-2 masks and SARS-CoV-2 seropositivity among healthcare workers: a multicenter longitudinal cohort study.,2022-01-10,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Switzerland,Canton of Grisons,,"We performed a multicenter prospective cohort study including 13 HCI caring for patients with COVID-19 in the canton of Grisons, Switzerland. The selected HCI consisted of one referral center (provincial hospital; 330 bed medical center with integrated intensive care unit), nine small primary care hospitals (average bed capacity: 33 beds), two rehabilitation centers (average bed capac- ity: 108 beds) and one psychiatric clinic (capacity of 240 beds). We invited all health care employees (≥ 16 years of age) in the selected HCI to participate in the study.",,2021-01-04,2021-02-19,Health care workers and caregivers,All,Adults (18-64 years),16.0,,Primary Estimate,,2315,0.162,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Katarzyna Szajek, Cantonal Hospital of Grisons,Not Unity-Aligned,https://dx.doi.org/10.1186/s13756-021-01047-x,2022-01-18,2024-03-01,Unverified,szajek_healthcare_2022-1,CHE
220112_Zurich_UniversityofZurich_OAT,220112_Zurich_UniversityofZurich_OAT,High SARS-CoV-2 seroprevalence but no severe course of COVID-19 disease among people on opioid agonist treatment in Zurich: a cross-sectional study. ,2022-01-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Switzerland,,Zurich,"""Recruitment took place at the outpatient clinic called Arud Centre for Addiction Medicine in Switzerland, located in Zurich. Arud takes care of around 2500 patients with any kind of addiction disorder. A total 1014 patients were in OAT during the recruitment period and
therefore eligible for the study",,2020-07-01,2020-10-16,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,72.0,Primary Estimate,,122,0.098,0.051,0.172,True,,,,True,Convenience,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,,Whole Blood,"['IgA', 'IgG']",Spike,,0.966,0.997,['High'],Yes,No,No,Yes,No,Unclear,Yes,Yes,Unclear,Philip Bruggmann,University of Zurich,Not Unity-Aligned,https://smw.ch/article/doi/smw.2022.w30122,2022-01-18,2022-07-16,Verified,bruggmann_high_2022,CHE
220128_Zurich_UniversityofZurich_T1Children_testadj,220128_Zurich_UniversityofZurich_T1Children,"SARS-CoV-2 seroprevalence in children, parents and school personnel from June 2020 to April 2021: cohort study of 55 schools in Switzerland",2022-01-28,Preprint,Regional,Repeated cross-sectional study,Switzerland,Zurich,,"""Within participating schools, children from randomly
selected classes, all school personnel and parents of participating children were invited.""","""We excluded vaccinated adults (n=123) and those eligible for vaccination but with unclear vaccination status (n=215) from the main analysis.""",2020-06-15,2020-07-15,Students and Daycares,All,Children and Youth (0-17 years),6.0,16.0,Primary Estimate,,2473,0.044000000000000004,0.021,0.062000000000000006,True,True,,,,Convenience,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,,Serum,,Spike,Validated by independent authors/third party/non-developers,0.983,0.9840000000000001,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Agne Ulyte,University of Switzerland,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.01.25.22269827v1.full-text,2022-02-08,2022-07-16,Unverified,ulyte_sars-cov-2_2022,CHE
220128_Zurich_UniversityofZurich_T1Parents_testadj,220128_Zurich_UniversityofZurich_T1Parents,"SARS-CoV-2 seroprevalence in children, parents and school personnel from June 2020 to April 2021: cohort study of 55 schools in Switzerland",2022-01-28,Preprint,Regional,Repeated cross-sectional study,Switzerland,Zurich,,"""Within participating schools, children from randomly
selected classes, all school personnel and parents of participating children were invited.""","""We excluded vaccinated adults (n=123) and those eligible for vaccination but with unclear vaccination status (n=215) from the main analysis.""",2020-08-15,2020-09-15,Household and community samples,All,Multiple groups,25.0,69.0,Primary Estimate,,2045,0.057999999999999996,0.035,0.078,True,True,,,,Convenience,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,,Serum,,Spike,Validated by independent authors/third party/non-developers,0.983,0.9840000000000001,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Agne Ulyte,University of Switzerland,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.01.25.22269827v1.full-text,2022-02-08,2022-07-16,Unverified,ulyte_sars-cov-2_2022,CHE
220128_Zurich_UniversityofZurich_T1Parents_unadj,220128_Zurich_UniversityofZurich_T1Parents,"SARS-CoV-2 seroprevalence in children, parents and school personnel from June 2020 to April 2021: cohort study of 55 schools in Switzerland",2022-01-28,Preprint,Regional,Repeated cross-sectional study,Switzerland,Zurich,,"""Within participating schools, children from randomly
selected classes, all school personnel and parents of participating children were invited.""","""We excluded vaccinated adults (n=123) and those eligible for vaccination but with unclear vaccination status (n=215) from the main analysis.""",2020-08-15,2020-09-15,Household and community samples,All,Multiple groups,25.0,69.0,Analysis,,2045,0.07200000000000001,,,,,,,True,Convenience,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,,Serum,,Spike,Validated by independent authors/third party/non-developers,0.983,0.9840000000000001,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Agne Ulyte,University of Switzerland,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.01.25.22269827v1.full-text,2022-02-08,2022-07-16,Unverified,ulyte_sars-cov-2_2022,CHE
"220128_Zurich_UniversityofZurich_T1Personnel_testadj
",220128_Zurich_UniversityofZurich_T1Personnel,"SARS-CoV-2 seroprevalence in children, parents and school personnel from June 2020 to April 2021: cohort study of 55 schools in Switzerland",2022-01-28,Preprint,Regional,Repeated cross-sectional study,Switzerland,Zurich,,"""Within participating schools, children from randomly
selected classes, all school personnel and parents of participating children were invited.""","""We excluded vaccinated adults (n=123) and those eligible for vaccination but with unclear vaccination status (n=215) from the main analysis.""",2020-08-15,2020-09-15,Essential non-healthcare workers,All,Multiple groups,15.0,76.0,Primary Estimate,,1608,0.046,0.023,0.067,True,True,,,,Convenience,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,,Serum,,Spike,Validated by independent authors/third party/non-developers,0.983,0.9840000000000001,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Agne Ulyte,University of Switzerland,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.01.25.22269827v1.full-text,2022-02-08,2022-07-16,Unverified,ulyte_sars-cov-2_2022,CHE
220128_Zurich_UniversityofZurich_T3Children_testadj,220128_Zurich_UniversityofZurich_T3Children,"SARS-CoV-2 seroprevalence in children, parents and school personnel from June 2020 to April 2021: cohort study of 55 schools in Switzerland",2022-01-28,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Zurich,,"""Within participating schools, children from randomly
selected classes, all school personnel and parents of participating children were invited.""","""We excluded vaccinated adults (n=123) and those eligible for vaccination but with unclear vaccination status (n=215) from the main analysis.""",2021-03-15,2021-04-15,Students and Daycares,All,Children and Youth (0-17 years),7.0,17.0,Primary Estimate,,2450,0.18100000000000002,0.157,0.207,True,True,,,,Convenience,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,,Serum,,Spike,Validated by independent authors/third party/non-developers,0.983,0.9840000000000001,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Agne Ulyte,University of Switzerland,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.01.25.22269827v1.full-text,2022-02-08,2022-10-14,Unverified,ulyte_sars-cov-2_2022,CHE
220128_Zurich_UniversityofZurich_T3Children_Lower,220128_Zurich_UniversityofZurich_T3Children,"SARS-CoV-2 seroprevalence in children, parents and school personnel from June 2020 to April 2021: cohort study of 55 schools in Switzerland",2022-01-28,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Zurich,,"""Within participating schools, children from randomly
selected classes, all school personnel and parents of participating children were invited.""","""We excluded vaccinated adults (n=123) and those eligible for vaccination but with unclear vaccination status (n=215) from the main analysis.""",2021-03-15,2021-04-15,Students and Daycares,All,Children and Youth (0-17 years),7.0,9.0,Age,Lower school level,768,0.18100000000000002,0.147,0.217,,,,,,Convenience,Author designed (type unknown),,,Serum,,Spike,Validated by independent authors/third party/non-developers,0.983,0.9840000000000001,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Agne Ulyte,University of Switzerland,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.01.25.22269827v1.full-text,2022-02-24,2022-10-14,Unverified,ulyte_sars-cov-2_2022,CHE
220128_Zurich_UniversityofZurich_T3Children_Upper,220128_Zurich_UniversityofZurich_T3Children,"SARS-CoV-2 seroprevalence in children, parents and school personnel from June 2020 to April 2021: cohort study of 55 schools in Switzerland",2022-01-28,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Zurich,,"""Within participating schools, children from randomly
selected classes, all school personnel and parents of participating children were invited.""","""We excluded vaccinated adults (n=123) and those eligible for vaccination but with unclear vaccination status (n=215) from the main analysis.""",2021-03-15,2021-04-15,Students and Daycares,All,Children and Youth (0-17 years),12.0,17.0,Age,Upper school level,837,0.16,0.127,0.193,,,,,,Convenience,Author designed (type unknown),,,Serum,,Spike,Validated by independent authors/third party/non-developers,0.983,0.9840000000000001,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Agne Ulyte,University of Switzerland,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.01.25.22269827v1.full-text,2022-02-24,2022-10-14,Unverified,ulyte_sars-cov-2_2022,CHE
220128_Zurich_UniversityofZurich_T3Children_Middle,220128_Zurich_UniversityofZurich_T3Children,"SARS-CoV-2 seroprevalence in children, parents and school personnel from June 2020 to April 2021: cohort study of 55 schools in Switzerland",2022-01-28,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Zurich,,"""Within participating schools, children from randomly
selected classes, all school personnel and parents of participating children were invited.""","""We excluded vaccinated adults (n=123) and those eligible for vaccination but with unclear vaccination status (n=215) from the main analysis.""",2021-03-15,2021-04-15,Students and Daycares,All,Children and Youth (0-17 years),9.0,13.0,Age,Middle school level,845,0.203,0.16899999999999998,0.239,,,,,,Convenience,Author designed (type unknown),,,Serum,,Spike,Validated by independent authors/third party/non-developers,0.983,0.9840000000000001,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Agne Ulyte,University of Switzerland,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.01.25.22269827v1.full-text,2022-02-24,2022-10-14,Unverified,ulyte_sars-cov-2_2022,CHE
"220128_Zurich_UniversityofZurich_T3Parents_testadj
",220128_Zurich_UniversityofZurich_T3Parents,"SARS-CoV-2 seroprevalence in children, parents and school personnel from June 2020 to April 2021: cohort study of 55 schools in Switzerland",2022-01-28,Preprint,Regional,Repeated cross-sectional study,Switzerland,Zurich,,"""Within participating schools, children from randomly
selected classes, all school personnel and parents of participating children were invited.""","""We excluded vaccinated adults (n=123) and those eligible for vaccination but with unclear vaccination status (n=215) from the main analysis.""",2021-03-15,2021-04-15,Household and community samples,All,Multiple groups,29.0,72.0,Primary Estimate,,1545,0.209,0.18,0.239,True,True,,,,Convenience,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,,Serum,,Spike,Validated by independent authors/third party/non-developers,0.983,0.9840000000000001,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Agne Ulyte,University of Switzerland,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.01.25.22269827v1.full-text,2022-02-08,2022-10-14,Unverified,ulyte_sars-cov-2_2022,CHE
220128_Zurich_UniversityofZurich_T3Parents_unadj,220128_Zurich_UniversityofZurich_T3Parents,"SARS-CoV-2 seroprevalence in children, parents and school personnel from June 2020 to April 2021: cohort study of 55 schools in Switzerland",2022-01-28,Preprint,Regional,Repeated cross-sectional study,Switzerland,Zurich,,"""Within participating schools, children from randomly
selected classes, all school personnel and parents of participating children were invited.""","""We excluded vaccinated adults (n=123) and those eligible for vaccination but with unclear vaccination status (n=215) from the main analysis.""",2021-03-15,2021-04-15,Household and community samples,All,Multiple groups,29.0,72.0,Analysis,,1545,0.22399999999999998,,,,,,,True,Convenience,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,,Serum,,Spike,Validated by independent authors/third party/non-developers,0.983,0.9840000000000001,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Agne Ulyte,University of Switzerland,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.01.25.22269827v1.full-text,2022-02-08,2022-10-14,Unverified,ulyte_sars-cov-2_2022,CHE
220128_Zurich_UniversityofZurich_T3Personnel_testadj,220128_Zurich_UniversityofZurich_T3Personnel,"SARS-CoV-2 seroprevalence in children, parents and school personnel from June 2020 to April 2021: cohort study of 55 schools in Switzerland",2022-01-28,Preprint,Regional,Repeated cross-sectional study,Switzerland,Zurich,,"""Within participating schools, children from randomly
selected classes, all school personnel and parents of participating children were invited.""","""We excluded vaccinated adults (n=123) and those eligible for vaccination but with unclear vaccination status (n=215) from the main analysis.""",2021-03-15,2021-04-15,Essential non-healthcare workers,All,Multiple groups,15.0,77.0,Primary Estimate,,1435,0.16899999999999998,0.141,0.198,True,,,,,Convenience,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,,Serum,,Spike,Validated by independent authors/third party/non-developers,0.983,0.9840000000000001,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Agne Ulyte,University of Switzerland,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.01.25.22269827v1.full-text,2022-02-08,2022-10-14,Unverified,ulyte_sars-cov-2_2022,CHE
220128_Switzerland_CantonalHospitalStGallen_Overall,220128_Switzerland_CantonalHospitalStGallen,Symptoms compatible with long-COVID in healthcare workers with and without SARS-CoV-2 infection - results of a prospective multicenter cohort.,2022-01-28,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Switzerland,"Northern Switzerland, Eastern Switzerland",,"Hospital employees from 23 healthcare institutions located in Northern and Eastern Switzerland were eligible; study enrolment took palce in July and August 2020.

And from cited study: ""Acute care hospitals, rehabilitation clinics, and geriatric and psychiatric clinics were asked to participate. Employees aged 16 years or older were invited to enrol into the study via institutional webpages. Employees registered online and provided electronic consent.""

https://pubmed.ncbi.nlm.nih.gov/34020033/""","Participants vaccinated in the week before the long-COVID questionnaire were
excluded.",2021-01-15,2021-02-15,Health care workers and caregivers,All,Adults (18-64 years),16.0,,Primary Estimate,,3334,0.2352,,,True,,,,True,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.88,0.99,['Moderate'],,Unclear,Yes,Yes,,Yes,Yes,No,,Carol Strahm,Cantonal Hospital St Gallen,Not Unity-Aligned,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac054/6516835,2022-02-10,2024-03-01,Unverified,strahm_symptoms_2022,CHE
220216_Geneva_CantonalHospitalStGallen_Baseline,220216_Geneva_CantonalHospitalStGallen,Safety Evaluation of a Medical Congress Held During the COVID-19 Pandemic-A Prospective Cohort.,2022-02-16,Journal Article (Peer-Reviewed),Local,Prospective cohort,Switzerland,,Geneva,"Congress attendees (including participants, industry representatives and congress staff) >16 years old.
For study inclusion, oral informed consent was obtained from participants.",,2020-09-02,2020-09-04,Multiple populations,All,Multiple groups,,,Primary Estimate,,168,0.0298,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Dried Blood,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Yes,Yes,No,,Johannes Sumer,Cantonal Hospital St. Gallen,Not Unity-Aligned,https://dx.doi.org/10.3389/ijph.2022.1604147,2022-03-16,2024-03-01,Unverified,sumer_safety_2022,CHE
220316_Zurich_UniversityOfZurich_GeneralPop_Overall_TestPopAdj,220316_Zurich_UniversityOfZurich_GeneralPop,"Seroprevalence of SARS-CoV-2 antibodies, associated factors, experiences and attitudes of nursing home and home healthcare employees in Switzerland",2022-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Canton of Zurich,,"From https://doi.org/10.1007/s00038-020-01494-0:

The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.","From https://doi.org/10.1007/s00038-020-01494-0:

Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.",2020-06-17,2020-09-14,Household and community samples,All,Adults (18-64 years),20.0,64.0,Primary Estimate,,472,0.035,0.015,0.059000000000000004,True,True,True,,,Simplified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,,"['IgA', 'IgG']",Spike,Validated by manufacturers,0.966,0.997,['Moderate'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,Unclear,Erin West,University of Zurich,Unity-Aligned,https://doi.org/10.1186/s12879-022-07222-8,2022-03-24,2022-07-16,Verified,west_seroprevalence_2022,CHE
220316_Zurich_UniversityOfZurich_GeneralPop_Overall_UnAdj,220316_Zurich_UniversityOfZurich_GeneralPop,"Seroprevalence of SARS-CoV-2 antibodies, associated factors, experiences and attitudes of nursing home and home healthcare employees in Switzerland",2022-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Canton of Zurich,,"From https://doi.org/10.1007/s00038-020-01494-0:

The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.","From https://doi.org/10.1007/s00038-020-01494-0:

Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.",2020-06-17,2020-09-14,Household and community samples,All,Adults (18-64 years),20.0,64.0,Analysis,,472,0.0403,,,,,,,True,Simplified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,,"['IgA', 'IgG']",Spike,Validated by manufacturers,0.966,0.997,['Moderate'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,Unclear,Erin West,University of Zurich,Unity-Aligned,https://doi.org/10.1186/s12879-022-07222-8,2022-03-24,2022-07-16,Verified,west_seroprevalence_2022,CHE
220316_Zurich_UniversityOfZurich_GeneralPop_Sex_Male,220316_Zurich_UniversityOfZurich_GeneralPop,"Seroprevalence of SARS-CoV-2 antibodies, associated factors, experiences and attitudes of nursing home and home healthcare employees in Switzerland",2022-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Canton of Zurich,,"From https://doi.org/10.1007/s00038-020-01494-0:

The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.","From https://doi.org/10.1007/s00038-020-01494-0:

Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.",2020-06-17,2020-09-14,Household and community samples,Male,Adults (18-64 years),20.0,64.0,Sex/Gender,,226,0.053,,,,,,,,Simplified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,,"['IgA', 'IgG']",Spike,Validated by manufacturers,0.966,0.997,['Moderate'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,Unclear,Erin West,University of Zurich,Unity-Aligned,https://doi.org/10.1186/s12879-022-07222-8,2022-03-24,2022-07-16,Verified,west_seroprevalence_2022,CHE
220316_Zurich_UniversityOfZurich_GeneralPop_Sex_Female,220316_Zurich_UniversityOfZurich_GeneralPop,"Seroprevalence of SARS-CoV-2 antibodies, associated factors, experiences and attitudes of nursing home and home healthcare employees in Switzerland",2022-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Canton of Zurich,,"From https://doi.org/10.1007/s00038-020-01494-0:

The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.","From https://doi.org/10.1007/s00038-020-01494-0:

Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.",2020-06-17,2020-09-14,Household and community samples,Female,Adults (18-64 years),20.0,64.0,Sex/Gender,,246,0.027999999999999997,,,,,,,,Simplified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,,"['IgA', 'IgG']",Spike,Validated by manufacturers,0.966,0.997,['Moderate'],Yes,Yes,No,Yes,Unclear,Unclear,Yes,Yes,Unclear,Erin West,University of Zurich,Unity-Aligned,https://doi.org/10.1186/s12879-022-07222-8,2022-03-24,2022-07-16,Verified,west_seroprevalence_2022,CHE
220316_Zurich_UniversityOfZurich_HomeHealthcare_Overall,220316_Zurich_UniversityOfZurich_HomeHealthcare,"Seroprevalence of SARS-CoV-2 antibodies, associated factors, experiences and attitudes of nursing home and home healthcare employees in Switzerland",2022-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Canton of Zurich,,"The current sub-study targeted employees of selected nursing homes and home healthcare organizations (Spitex) in the canton of Zurich who were possibly exposed to SARS-CoV-2 at their work given there were positively tested nursing home residents or inhabitants of the communities, respectively, during the first wave in Switzerland between February and May/June 2020. The at home healthcare organizations, namely Spitex organizations in the Canton of Zurich (www.spitexzh.ch), are trained staff that provide care and support to people at home.",,2020-09-21,2020-10-23,Assisted living and long-term care facilities,All,Adults (18-64 years),,,Primary Estimate,,131,0.038,0.013999999999999999,0.091,True,,,,True,Simplified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,,,"['IgA', 'IgG']",Spike,Validated by manufacturers,0.966,0.997,['High'],No,Yes,No,Yes,Unclear,Unclear,Yes,Yes,No,Erin West,University of Zurich,Not Unity-Aligned,https://doi.org/10.1186/s12879-022-07222-8,2022-03-24,2022-07-16,Verified,west_seroprevalence_2022,CHE
220316_Zurich_UniversityOfZurich_NursingHomes_Overall,220316_Zurich_UniversityOfZurich_NursingHomes,"Seroprevalence of SARS-CoV-2 antibodies, associated factors, experiences and attitudes of nursing home and home healthcare employees in Switzerland",2022-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Canton of Zurich,,"The current sub-study targeted employees of selected nursing homes and home healthcare organizations (Spitex) in the canton of Zurich who were possibly exposed to SARS-CoV-2 at their work given there were positively tested nursing home residents or inhabitants of the communities, respectively, during the first wave in Switzerland between February and May/June 2020.",,2020-09-21,2020-10-23,Assisted living and long-term care facilities,All,Adults (18-64 years),,,Primary Estimate,,296,0.149,0.111,0.196,True,,,,True,Convenience,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,,,"['IgA', 'IgG']",Spike,Validated by manufacturers,0.966,0.997,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,No,Erin West,University of Zurich,Not Unity-Aligned,https://doi.org/10.1186/s12879-022-07222-8,2022-03-24,2022-07-16,Verified,west_seroprevalence_2022,CHE
220524_Switzerland_FribourgHospitalHFR_Primary,220524_Switzerland_FribourgHospitalHFR,"Seroprevalence of SARS-CoV-2 antibodies and associated risk factors in children less than 6 years of age in the canton of Fribourg, Switzerland (COVPED study): a population-based cross-sectional study",2022-05-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Fribourg,,"Inclusion criteria were (a) consultation at any of the participating sites regardless of the purpose or complaint, (b) age less than 6 years, (c) primary residence in the canton of Fri- bourg, (d) no previous participation in the study. The ex- clusion criterion was no language knowledge in German or French. All children full filling the inclusion criteria were offered participation, including healthy and sick children","2 were excluded because they were above 6 years of age, 8 because informed consent was not obtained and 3 because of an insufficient blood sample.
The exclusion criterion was no language knowledge in German or French",2021-01-11,2021-03-14,Residual sera,All,Children and Youth (0-17 years),0.0,6.0,Primary Estimate,,871,0.207,0.18,0.23,True,,,,True,Convenience,Author designed (Luminex),,Other,Serum,IgG,Spike,Validated by developers,0.966,0.9920000000000001,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,No,Paola A. Rouge Elton,Fribourg Hospital HFR,Unity-Aligned,https://dx.doi.org/10.4414/smw.2022.w30173,2022-07-06,2024-02-18,Unverified,elton_seroprevalence_2022,CHE
220524_Switzerland_FribourgHospitalHFR_Age12to23Mth,220524_Switzerland_FribourgHospitalHFR,"Seroprevalence of SARS-CoV-2 antibodies and associated risk factors in children less than 6 years of age in the canton of Fribourg, Switzerland (COVPED study): a population-based cross-sectional study",2022-05-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Fribourg,,"Inclusion criteria were (a) consultation at any of the participating sites regardless of the purpose or complaint, (b) age less than 6 years, (c) primary residence in the canton of Fri- bourg, (d) no previous participation in the study. The ex- clusion criterion was no language knowledge in German or French. All children full filling the inclusion criteria were offered participation, including healthy and sick children","2 were excluded because they were above 6 years of age, 8 because informed consent was not obtained and 3 because of an insufficient blood sample.
The exclusion criterion was no language knowledge in German or French",2021-01-11,2021-03-14,Residual sera,All,Children and Youth (0-17 years),1.0,2.0,Age,12 - 23 months,192,0.24,0.18,0.3,,,,,,Convenience,Author designed (Luminex),,Other,Serum,IgG,Spike,Validated by developers,0.966,0.9920000000000001,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,No,Paola A. Rouge Elton,Fribourg Hospital HFR,Unity-Aligned,https://dx.doi.org/10.4414/smw.2022.w30173,2022-07-06,2024-02-18,Unverified,elton_seroprevalence_2022,CHE
220524_Switzerland_FribourgHospitalHFR_Age36to47Mth,220524_Switzerland_FribourgHospitalHFR,"Seroprevalence of SARS-CoV-2 antibodies and associated risk factors in children less than 6 years of age in the canton of Fribourg, Switzerland (COVPED study): a population-based cross-sectional study",2022-05-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Fribourg,,"Inclusion criteria were (a) consultation at any of the participating sites regardless of the purpose or complaint, (b) age less than 6 years, (c) primary residence in the canton of Fri- bourg, (d) no previous participation in the study. The ex- clusion criterion was no language knowledge in German or French. All children full filling the inclusion criteria were offered participation, including healthy and sick children","2 were excluded because they were above 6 years of age, 8 because informed consent was not obtained and 3 because of an insufficient blood sample.
The exclusion criterion was no language knowledge in German or French",2021-01-11,2021-03-14,Residual sera,All,Children and Youth (0-17 years),3.0,4.0,Age,36 - 47 months,159,0.214,,,,,,,,Convenience,Author designed (Luminex),,Other,Serum,IgG,Spike,Validated by developers,0.966,0.9920000000000001,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,No,Paola A. Rouge Elton,Fribourg Hospital HFR,Unity-Aligned,https://dx.doi.org/10.4414/smw.2022.w30173,2022-07-06,2022-07-29,Unverified,elton_seroprevalence_2022,CHE
220524_Switzerland_FribourgHospitalHFR_Age3to11Mth,220524_Switzerland_FribourgHospitalHFR,"Seroprevalence of SARS-CoV-2 antibodies and associated risk factors in children less than 6 years of age in the canton of Fribourg, Switzerland (COVPED study): a population-based cross-sectional study",2022-05-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Fribourg,,"Inclusion criteria were (a) consultation at any of the participating sites regardless of the purpose or complaint, (b) age less than 6 years, (c) primary residence in the canton of Fri- bourg, (d) no previous participation in the study. The ex- clusion criterion was no language knowledge in German or French. All children full filling the inclusion criteria were offered participation, including healthy and sick children","2 were excluded because they were above 6 years of age, 8 because informed consent was not obtained and 3 because of an insufficient blood sample.
The exclusion criterion was no language knowledge in German or French",2021-01-11,2021-03-14,Residual sera,All,Children and Youth (0-17 years),0.0,1.0,Age,3.1 - 11 months,96,0.20800000000000002,0.13,0.29,,,,,,Convenience,Author designed (Luminex),,Other,Serum,IgG,Spike,Validated by developers,0.966,0.9920000000000001,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,No,Paola A. Rouge Elton,Fribourg Hospital HFR,Unity-Aligned,https://dx.doi.org/10.4414/smw.2022.w30173,2022-07-06,2024-02-18,Unverified,elton_seroprevalence_2022,CHE
220524_Switzerland_FribourgHospitalHFR_Age24to35Mth,220524_Switzerland_FribourgHospitalHFR,"Seroprevalence of SARS-CoV-2 antibodies and associated risk factors in children less than 6 years of age in the canton of Fribourg, Switzerland (COVPED study): a population-based cross-sectional study",2022-05-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Fribourg,,"Inclusion criteria were (a) consultation at any of the participating sites regardless of the purpose or complaint, (b) age less than 6 years, (c) primary residence in the canton of Fri- bourg, (d) no previous participation in the study. The ex- clusion criterion was no language knowledge in German or French. All children full filling the inclusion criteria were offered participation, including healthy and sick children","2 were excluded because they were above 6 years of age, 8 because informed consent was not obtained and 3 because of an insufficient blood sample.
The exclusion criterion was no language knowledge in German or French",2021-01-11,2021-03-14,Residual sera,All,Children and Youth (0-17 years),2.0,3.0,Age,24 - 35 months,146,0.185,,,,,,,,Convenience,Author designed (Luminex),,Other,Serum,IgG,Spike,Validated by developers,0.966,0.9920000000000001,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,No,Paola A. Rouge Elton,Fribourg Hospital HFR,Unity-Aligned,https://dx.doi.org/10.4414/smw.2022.w30173,2022-07-06,2022-07-29,Unverified,elton_seroprevalence_2022,CHE
220524_Switzerland_FribourgHospitalHFR_Female,220524_Switzerland_FribourgHospitalHFR,"Seroprevalence of SARS-CoV-2 antibodies and associated risk factors in children less than 6 years of age in the canton of Fribourg, Switzerland (COVPED study): a population-based cross-sectional study",2022-05-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Fribourg,,"Inclusion criteria were (a) consultation at any of the participating sites regardless of the purpose or complaint, (b) age less than 6 years, (c) primary residence in the canton of Fri- bourg, (d) no previous participation in the study. The ex- clusion criterion was no language knowledge in German or French. All children full filling the inclusion criteria were offered participation, including healthy and sick children","2 were excluded because they were above 6 years of age, 8 because informed consent was not obtained and 3 because of an insufficient blood sample.
The exclusion criterion was no language knowledge in German or French",2021-01-11,2021-03-14,Residual sera,Female,Children and Youth (0-17 years),0.0,6.0,Sex/Gender,,412,0.17500000000000002,,,,,,,,Convenience,Author designed (Luminex),,Other,Serum,IgG,Spike,Validated by developers,0.966,0.9920000000000001,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,No,Paola A. Rouge Elton,Fribourg Hospital HFR,Unity-Aligned,https://dx.doi.org/10.4414/smw.2022.w30173,2022-07-06,2022-07-29,Unverified,elton_seroprevalence_2022,CHE
220524_Switzerland_FribourgHospitalHFR_Ag48to59Mth,220524_Switzerland_FribourgHospitalHFR,"Seroprevalence of SARS-CoV-2 antibodies and associated risk factors in children less than 6 years of age in the canton of Fribourg, Switzerland (COVPED study): a population-based cross-sectional study",2022-05-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Fribourg,,"Inclusion criteria were (a) consultation at any of the participating sites regardless of the purpose or complaint, (b) age less than 6 years, (c) primary residence in the canton of Fri- bourg, (d) no previous participation in the study. The ex- clusion criterion was no language knowledge in German or French. All children full filling the inclusion criteria were offered participation, including healthy and sick children","2 were excluded because they were above 6 years of age, 8 because informed consent was not obtained and 3 because of an insufficient blood sample.
The exclusion criterion was no language knowledge in German or French",2021-01-11,2021-03-14,Residual sera,All,Children and Youth (0-17 years),4.0,5.0,Age,48 - 59 months,130,0.16899999999999998,,,,,,,,Convenience,Author designed (Luminex),,Other,Serum,IgG,Spike,Validated by developers,0.966,0.9920000000000001,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,No,Paola A. Rouge Elton,Fribourg Hospital HFR,Unity-Aligned,https://dx.doi.org/10.4414/smw.2022.w30173,2022-07-06,2022-07-29,Unverified,elton_seroprevalence_2022,CHE
220524_Switzerland_FribourgHospitalHFR_AgeLess3Mth,220524_Switzerland_FribourgHospitalHFR,"Seroprevalence of SARS-CoV-2 antibodies and associated risk factors in children less than 6 years of age in the canton of Fribourg, Switzerland (COVPED study): a population-based cross-sectional study",2022-05-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Fribourg,,"Inclusion criteria were (a) consultation at any of the participating sites regardless of the purpose or complaint, (b) age less than 6 years, (c) primary residence in the canton of Fri- bourg, (d) no previous participation in the study. The ex- clusion criterion was no language knowledge in German or French. All children full filling the inclusion criteria were offered participation, including healthy and sick children","2 were excluded because they were above 6 years of age, 8 because informed consent was not obtained and 3 because of an insufficient blood sample.
The exclusion criterion was no language knowledge in German or French",2021-01-11,2021-03-14,Residual sera,All,Children and Youth (0-17 years),0.0,1.0,Age,<= 3 months,22,0.364,0.18,0.6,,,,,,Convenience,Author designed (Luminex),,Other,Serum,IgG,Spike,Validated by developers,0.966,0.9920000000000001,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,No,Paola A. Rouge Elton,Fribourg Hospital HFR,Unity-Aligned,https://dx.doi.org/10.4414/smw.2022.w30173,2022-07-06,2024-02-18,Unverified,elton_seroprevalence_2022,CHE
220524_Switzerland_FribourgHospitalHFR_Age60to71Mth,220524_Switzerland_FribourgHospitalHFR,"Seroprevalence of SARS-CoV-2 antibodies and associated risk factors in children less than 6 years of age in the canton of Fribourg, Switzerland (COVPED study): a population-based cross-sectional study",2022-05-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Fribourg,,"Inclusion criteria were (a) consultation at any of the participating sites regardless of the purpose or complaint, (b) age less than 6 years, (c) primary residence in the canton of Fri- bourg, (d) no previous participation in the study. The ex- clusion criterion was no language knowledge in German or French. All children full filling the inclusion criteria were offered participation, including healthy and sick children","2 were excluded because they were above 6 years of age, 8 because informed consent was not obtained and 3 because of an insufficient blood sample.
The exclusion criterion was no language knowledge in German or French",2021-01-11,2021-03-14,Residual sera,All,Children and Youth (0-17 years),5.0,6.0,Age,60 - 71 months,126,0.18300000000000002,,,,,,,,Convenience,Author designed (Luminex),,Other,Serum,IgG,Spike,Validated by developers,0.966,0.9920000000000001,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,No,Paola A. Rouge Elton,Fribourg Hospital HFR,Unity-Aligned,https://dx.doi.org/10.4414/smw.2022.w30173,2022-07-06,2022-07-29,Unverified,elton_seroprevalence_2022,CHE
220524_Switzerland_FribourgHospitalHFR_Male,220524_Switzerland_FribourgHospitalHFR,"Seroprevalence of SARS-CoV-2 antibodies and associated risk factors in children less than 6 years of age in the canton of Fribourg, Switzerland (COVPED study): a population-based cross-sectional study",2022-05-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Fribourg,,"Inclusion criteria were (a) consultation at any of the participating sites regardless of the purpose or complaint, (b) age less than 6 years, (c) primary residence in the canton of Fri- bourg, (d) no previous participation in the study. The ex- clusion criterion was no language knowledge in German or French. All children full filling the inclusion criteria were offered participation, including healthy and sick children","2 were excluded because they were above 6 years of age, 8 because informed consent was not obtained and 3 because of an insufficient blood sample.
The exclusion criterion was no language knowledge in German or French",2021-01-11,2021-03-14,Residual sera,Male,Children and Youth (0-17 years),0.0,6.0,Sex/Gender,,459,0.23500000000000001,,,,,,,,Convenience,Author designed (Luminex),,Other,Serum,IgG,Spike,Validated by developers,0.966,0.9920000000000001,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,No,Paola A. Rouge Elton,Fribourg Hospital HFR,Unity-Aligned,https://dx.doi.org/10.4414/smw.2022.w30173,2022-07-06,2022-07-29,Unverified,elton_seroprevalence_2022,CHE
220527_CantonTicino_OspedaleSanGiovanni,220527_CantonTicino_OspedaleSanGiovanni,SARS-CoV-2 seroprevalence in subjects aged 0-16 years in Canton Ticino: preliminary results,2022-05-27,Journal Article (Peer-Reviewed),Regional,Retrospective cohort,Switzerland,Canton Ticino,,"Patients admitted from October 30,
2019 to outpatient clinics, and the emergency department and inpatient
ward of the Pediatric Institute of Southern Switzerland of Bellinzona were
enrolled",,2019-10-30,2021-09-15,Household and community samples,All,Children and Youth (0-17 years),,,Primary Estimate,,506,0.10400000000000001,,,True,,,,True,Sequential,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Mazzara C,Ospedale San Giovanni,Not Unity-Aligned,https://doi.org/10.4414/smw.2022.w30203,2022-07-26,2022-07-27,Unverified,mazzara_sars-cov-2_2022,CHE
220606_Bern_UniversityofBern_3Month,220606_Bern_UniversityofBern_3Month,Serosurveillance after a COVID-19 vaccine campaign in a Swiss police cohort.,2022-06-06,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Switzerland,Bern,,"employees of the Cantonal Police Bern, aged 18-65 years)",,2021-02-09,2021-03-09,Essential non-healthcare workers,All,Adults (18-64 years),18.0,65.0,Primary Estimate,,978,0.129,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,,,Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Parham Sendi,University of Bern,Not Unity-Aligned,https://dx.doi.org/10.1002/iid3.640,2022-07-29,2024-03-01,Unverified,sendi_serosurveillance_2022,CHE
220606_Bern_UniversityofBern_6Month,220606_Bern_UniversityofBern_6Month,Serosurveillance after a COVID-19 vaccine campaign in a Swiss police cohort.,2022-06-06,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Switzerland,Bern,,"employees of the Cantonal Police Bern, aged 18-65 years)",,2021-04-15,2021-05-15,Essential non-healthcare workers,All,Adults (18-64 years),18.0,65.0,Primary Estimate,,997,0.14400000000000002,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,,,Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Parham Sendi,University of Bern,Not Unity-Aligned,https://dx.doi.org/10.1002/iid3.640,2022-07-29,2024-03-01,Unverified,sendi_serosurveillance_2022,CHE
220606_Bern_UniversityofBern_Baseline,220606_Bern_UniversityofBern_Baseline,Serosurveillance after a COVID-19 vaccine campaign in a Swiss police cohort.,2022-06-06,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Switzerland,Bern,,"employees of the Cantonal Police Bern, aged 18-65 years)",,2021-02-09,2021-03-09,Essential non-healthcare workers,All,Adults (18-64 years),18.0,65.0,Primary Estimate,,982,0.153,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,,,Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Parham Sendi,University of Bern,Not Unity-Aligned,https://dx.doi.org/10.1002/iid3.640,2022-07-29,2024-03-01,Unverified,sendi_serosurveillance_2022,CHE
220620_Switzerland_Children’sHospitalofEasternSwitzerland_Overall,220620_Switzerland_Children’sHospitalofEasternSwitzerland,Is living in a household with children associated with SARS-CoV-2 seropositivity in adults? Results from the Swiss national seroprevalence study Corona Immunitas.,2022-06-20,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Switzerland,"Basle-City, Basle-Country, Berne, Fribourg, Grisons, Lucerne, Neuchatel, St. Gallen, Ticino, Vaud, Zurich",,"For this analysis, only working-age participants aged 18–64 years were included.","Excluded from this registry are
diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short term residence permit, and elderly people in nursing homes. ",2020-10-18,2021-02-15,Household and community samples,All,Adults (18-64 years),18.0,64.0,Primary Estimate,,2393,0.17300000000000001,,,True,,,,True,Simplified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,"['IgA', 'IgG']",Spike,Validated by independent authors/third party/non-developers,0.966,0.997,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Jacob Blankenberger,Children’s Hospital of Eastern Switzerland,Unity-Aligned,https://dx.doi.org/10.1186/s12916-022-02431-z,2022-06-27,2024-03-30,Verified,blankenberger_is_2022,CHE
220620_Switzerland_Children’sHospitalofEasternSwitzerland_Unvaccinated,220620_Switzerland_Children’sHospitalofEasternSwitzerland,Is living in a household with children associated with SARS-CoV-2 seropositivity in adults? Results from the Swiss national seroprevalence study Corona Immunitas.,2022-06-20,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Switzerland,"Basle-City, Basle-Country, Berne, Fribourg, Grisons, Lucerne, Neuchatel, St. Gallen, Ticino, Vaud, Zurich",,"For this analysis, only working-age participants aged 18–64 years were included.","Excluded from this registry are
diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short term residence permit, and elderly people in nursing homes. ",2020-10-18,2021-02-15,Household and community samples,All,Adults (18-64 years),18.0,64.0,COVID-19 vaccination status,,2380,0.171,,,,,,,,Simplified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,"['IgA', 'IgG']",Spike,Validated by independent authors/third party/non-developers,0.966,0.997,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Jacob Blankenberger,Children’s Hospital of Eastern Switzerland,Unity-Aligned,https://dx.doi.org/10.1186/s12916-022-02431-z,2022-06-27,2024-03-30,Verified,blankenberger_is_2022,CHE
220620_Switzerland_Children’sHospitalofEasternSwitzerland_Vaccinated,220620_Switzerland_Children’sHospitalofEasternSwitzerland,Is living in a household with children associated with SARS-CoV-2 seropositivity in adults? Results from the Swiss national seroprevalence study Corona Immunitas.,2022-06-20,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Switzerland,"Basle-City, Basle-Country, Berne, Fribourg, Grisons, Lucerne, Neuchatel, St. Gallen, Ticino, Vaud, Zurich",,"For this analysis, only working-age participants aged 18–64 years were included.","Excluded from this registry are
diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short term residence permit, and elderly people in nursing homes. ",2020-10-18,2021-02-15,Household and community samples,All,Adults (18-64 years),18.0,64.0,COVID-19 vaccination status,,13,0.385,,,,,,,,Simplified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,"['IgA', 'IgG']",Spike,Validated by independent authors/third party/non-developers,0.966,0.997,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Jacob Blankenberger,Children’s Hospital of Eastern Switzerland,Unity-Aligned,https://dx.doi.org/10.1186/s12916-022-02431-z,2022-06-27,2024-03-30,Verified,blankenberger_is_2022,CHE
220620_Switzerland_Children’sHospitalofEasternSwitzerland_Female,220620_Switzerland_Children’sHospitalofEasternSwitzerland,Is living in a household with children associated with SARS-CoV-2 seropositivity in adults? Results from the Swiss national seroprevalence study Corona Immunitas.,2022-06-20,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Switzerland,"Basle-City, Basle-Country, Berne, Fribourg, Grisons, Lucerne, Neuchatel, St. Gallen, Ticino, Vaud, Zurich",,"For this analysis, only working-age participants aged 18–64 years were included.","Excluded from this registry are
diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short term residence permit, and elderly people in nursing homes. ",2020-10-18,2021-02-15,Household and community samples,Female,Adults (18-64 years),18.0,64.0,Sex/Gender,,1274,0.166,,,,,,,,Simplified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,"['IgA', 'IgG']",Spike,Validated by independent authors/third party/non-developers,0.966,0.997,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Jacob Blankenberger,Children’s Hospital of Eastern Switzerland,Unity-Aligned,https://dx.doi.org/10.1186/s12916-022-02431-z,2022-06-27,2024-03-30,Verified,blankenberger_is_2022,CHE
220620_Switzerland_Children’sHospitalofEasternSwitzerland_Male,220620_Switzerland_Children’sHospitalofEasternSwitzerland,Is living in a household with children associated with SARS-CoV-2 seropositivity in adults? Results from the Swiss national seroprevalence study Corona Immunitas.,2022-06-20,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Switzerland,"Basle-City, Basle-Country, Berne, Fribourg, Grisons, Lucerne, Neuchatel, St. Gallen, Ticino, Vaud, Zurich",,"For this analysis, only working-age participants aged 18–64 years were included.","Excluded from this registry are
diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short term residence permit, and elderly people in nursing homes. ",2020-10-18,2021-02-15,Household and community samples,Male,Adults (18-64 years),18.0,64.0,Sex/Gender,,1119,0.18100000000000002,,,,,,,,Simplified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,"['IgA', 'IgG']",Spike,Validated by independent authors/third party/non-developers,0.966,0.997,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Jacob Blankenberger,Children’s Hospital of Eastern Switzerland,Unity-Aligned,https://dx.doi.org/10.1186/s12916-022-02431-z,2022-06-27,2024-03-30,Verified,blankenberger_is_2022,CHE
220729_Geneva_GenevaUniversityHospitals_Any,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,,Geneva,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,2521,0.938,0.9309999999999999,0.9450000000000001,True,True,True,,True,Simplified probability,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2023-08-15,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_antiS,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,,Geneva,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,All,Multiple groups,0.0,,Test used,,2521,0.9690000000000001,,,,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2024-03-01,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_antiN,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,,Geneva,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,All,Multiple groups,0.0,,Test used,,2521,0.7000000000000001,,,,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2024-03-01,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_antiN_AgeOver75,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,All,Seniors (65+ years),75.0,,Test used,age: >= 75,174,0.408,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2024-03-01,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_antiS_Age50to64,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,,Geneva,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,All,Adults (18-64 years),50.0,64.0,Test used,age: 50-64,400,0.968,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2024-03-01,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_Any_AgeOver75,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,All,Seniors (65+ years),75.0,,Age,age: >= 75,174,0.9670000000000001,0.9620000000000001,0.971,,True,True,,,Simplified probability,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2023-08-15,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_antiS_Age0to5,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,,Geneva,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,All,Children and Youth (0-17 years),0.0,5.0,Test used,age: 0-5,144,0.778,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2024-03-01,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_Any_Age25to34,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,All,Adults (18-64 years),25.0,34.0,Age,age: 25-34,267,0.9490000000000001,0.937,0.9590000000000001,,True,True,,,Simplified probability,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2023-08-15,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_Any_Age18to24,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,All,Adults (18-64 years),18.0,24.0,Age,age: 18-24,169,0.9500000000000001,0.93,0.9690000000000001,,True,True,,,Simplified probability,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2023-08-15,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_antiN_Male,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,,Geneva,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,Male,Multiple groups,0.0,,Test used,,1129,0.6859999999999999,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2024-03-01,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_antiS_Age18to24,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,,Geneva,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,All,Adults (18-64 years),18.0,24.0,Test used,age: 18-24,169,1.0,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2024-03-01,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_antiN_Age18to24,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,All,Adults (18-64 years),18.0,24.0,Test used,age: 18-24,169,0.799,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2024-03-01,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_Any_Male,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,,Geneva,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,Male,Multiple groups,0.0,,Sex/Gender,,1129,0.9329999999999999,0.924,0.9420000000000001,,True,True,,,Simplified probability,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2023-08-15,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_Any_Age35to49,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,All,Adults (18-64 years),35.0,49.0,Age,age: 35-49,787,0.9500000000000001,0.9420000000000001,0.9570000000000001,,True,True,,,Simplified probability,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2023-08-15,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_Any_Age6to11,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,All,Children and Youth (0-17 years),6.0,11.0,Age,age: 6-11,242,0.91,0.871,0.9440000000000001,,True,True,,,Simplified probability,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2023-08-15,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_Any_Age50to64,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,age: 50-64,400,0.9540000000000001,0.9470000000000001,0.961,,True,True,,,Simplified probability,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2023-08-15,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_antiS_Male,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,,Geneva,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,Male,Multiple groups,0.0,,Test used,,1129,0.965,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2024-03-01,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_antiN_Age50to64,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,All,Adults (18-64 years),50.0,64.0,Test used,age: 50-64,400,0.635,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2024-03-01,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_antiS_Age6to11,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,,Geneva,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,All,Children and Youth (0-17 years),6.0,11.0,Test used,age: 6-11,242,0.9550000000000001,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2024-03-01,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_antiN_Age6to11,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,All,Children and Youth (0-17 years),6.0,11.0,Test used,age: 6-11,242,0.897,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2024-03-01,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_Any_Age0to5,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,All,Children and Youth (0-17 years),0.0,5.0,Age,age: 0-5,144,0.772,0.703,0.833,,True,True,,,Simplified probability,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2023-08-15,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_antiN_Age12to17,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,All,Children and Youth (0-17 years),12.0,17.0,Test used,age: 12-17,155,0.813,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2024-03-01,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_antiS_AgeOver75,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,,Geneva,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,All,Seniors (65+ years),75.0,,Test used,age: >= 75,174,0.966,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2024-03-01,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_antiS_Age25to34,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,,Geneva,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,All,Adults (18-64 years),25.0,34.0,Test used,age: 25-34,267,0.985,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2024-03-01,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_Any_Female,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,,Geneva,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,Female,Multiple groups,0.0,,Sex/Gender,,1392,0.9420000000000001,0.934,0.9500000000000001,,True,True,,,Simplified probability,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2023-08-15,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_antiN_Age25to34,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,All,Adults (18-64 years),25.0,34.0,Test used,age: 25-34,267,0.783,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2024-03-01,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_antiN_Female,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,,Geneva,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,Female,Multiple groups,0.0,,Test used,,1392,0.711,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2024-03-01,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_antiS_Age35to49,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,,Geneva,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,All,Adults (18-64 years),35.0,49.0,Test used,age: 35-49,787,0.991,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2024-03-01,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_antiS_Age12to17,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,,Geneva,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,All,Children and Youth (0-17 years),12.0,17.0,Test used,age: 12-17,155,0.9870000000000001,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2024-03-01,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_antiS_Female,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,,Geneva,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,Female,Multiple groups,0.0,,Test used,,1392,0.971,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2024-03-01,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_antiN_Age35to49,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,All,Adults (18-64 years),35.0,49.0,Test used,age: 35-49,787,0.7040000000000001,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2024-03-01,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_antiN_Age0to5,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,All,Children and Youth (0-17 years),0.0,5.0,Test used,age: 0-5,144,0.743,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2024-03-01,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_antiS_Age65to74,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,,Geneva,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,All,Seniors (65+ years),65.0,74.0,Test used,age: 65-74,183,0.978,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2024-03-01,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_Any_Age12to17,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,All,Children and Youth (0-17 years),12.0,17.0,Age,age: 12-17,155,0.934,0.903,0.961,,True,True,,,Simplified probability,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2023-08-15,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_Any_Age65to74,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,All,Seniors (65+ years),65.0,74.0,Age,age: 65-74,183,0.951,0.943,0.9590000000000001,,True,True,,,Simplified probability,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2023-08-15,Unverified,zaballa_seroprevalence_2022,CHE
220729_Geneva_GenevaUniversityHospitals_antiN_Age65to74,220729_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland",2022-07-29,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Geneva,,"participants from a random sample of individuals aged ≥6 months provided by the cantonal population registry (Office cantonal de la population et des migrations), and from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys. Children and teenagers (<18 years) were invited to participate with members of their household.",sing data:* 17 index participants excluded from all analysis + 12 index participants excluded from neutralizing antibodies analysis* 12 household member participants excluded from global seroprevalence analysis,2022-04-29,2022-06-09,Household and community samples,All,Seniors (65+ years),65.0,74.0,Test used,age: 65-74,183,0.503,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,10.1101/2022.07.27.22278126,2022-08-10,2024-03-01,Unverified,zaballa_seroprevalence_2022,CHE
220803_Switzerland_UniversityOfLausanne,220803_Switzerland_UniversityOfLausanne,SARS-CoV-2 seroprevalence in hospital healthcare workers in Western Switzerland at the end of the second pandemic wave.,2022-08-03,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Switzerland,,,"A prospective observational study was proposed to all employees of the EHC, Morges, Switzerland (n=1800)",Persons vaccinated against SARS-CoV-2 were excluded,2021-02-15,2021-03-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,594,0.45299999999999996,0.41200000000000003,0.493,True,,,,True,Convenience,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.981,0.9920000000000001,['High'],,No,No,Yes,,Yes,Yes,Yes,,Damien Jacot,University of Lausanne,Not Unity-Aligned,https://dx.doi.org/10.1099/jmm.0.001558,2022-08-14,2024-03-01,Unverified,jacot_sars-cov-2_2022,CHE
220804_Ticino_UniversityOfZurich_AntiS_PopTestAdj_Overall,220804_Ticino_UniversityOfZurich,"Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022",2022-08-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Canton of Ticino,,"""For phase five, we randomly selected individuals from the general population in north-eastern (canton of Zurich) and southern Switzerland (canton of Ticino)"".

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-03-01,2022-03-31,Household and community samples,All,Multiple groups,16.0,99.0,Primary Estimate,Anti-spike; Pop and test adjusted,850,0.975,0.958,0.99,True,True,True,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.99,0.98,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Rebecca Amati,University of Zurich,Unity-Aligned,https://doi.org/10.2807/1560-7917.ES.2022.27.31.2200561,2022-08-16,2022-08-17,Unverified,amati_functional_2022,CHE
220804_Ticino_UniversityOfZurich_nAB_WildType_UnaAdj_Overall,220804_Ticino_UniversityOfZurich,"Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022",2022-08-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Canton of Ticino,,"""For phase five, we randomly selected individuals from the general population in north-eastern (canton of Zurich) and southern Switzerland (canton of Ticino)"".

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-03-01,2022-03-31,Household and community samples,All,Multiple groups,16.0,99.0,Test used,Neutralization against Wild type,850,0.9259000000000001,,,,,,,,Stratified probability,Author designed (Neutralization Assay),,Neutralization,Serum,Neutralizing,Spike,Validated by developers,0.9670000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Rebecca Amati,University of Zurich,Unity-Aligned,https://doi.org/10.2807/1560-7917.ES.2022.27.31.2200561,2022-08-16,2022-08-17,Unverified,amati_functional_2022,CHE
220804_Ticino_UniversityOfZurich_nAB_Delta_UnaAdj_Overall,220804_Ticino_UniversityOfZurich,"Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022",2022-08-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Canton of Ticino,,"""For phase five, we randomly selected individuals from the general population in north-eastern (canton of Zurich) and southern Switzerland (canton of Ticino)"".

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-03-01,2022-03-31,Household and community samples,All,Multiple groups,16.0,99.0,Test used,Neutralization against Delta,850,0.9106000000000001,,,,,,,,Stratified probability,Author designed (Neutralization Assay),,Neutralization,Serum,Neutralizing,Spike,Validated by developers,0.9670000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Rebecca Amati,University of Zurich,Unity-Aligned,https://doi.org/10.2807/1560-7917.ES.2022.27.31.2200561,2022-08-16,2022-08-17,Unverified,amati_functional_2022,CHE
220804_Ticino_UniversityOfZurich_AntiS_UnaAdj_Age30-44,220804_Ticino_UniversityOfZurich,"Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022",2022-08-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Canton of Ticino,,"""For phase five, we randomly selected individuals from the general population in north-eastern (canton of Zurich) and southern Switzerland (canton of Ticino)"".

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-03-01,2022-03-31,Household and community samples,All,Multiple groups,30.0,44.0,Age,Age: 30-44 years,208,0.9712000000000001,,,,,,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.99,0.98,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Rebecca Amati,University of Zurich,Unity-Aligned,https://doi.org/10.2807/1560-7917.ES.2022.27.31.2200561,2022-08-16,2022-08-17,Unverified,amati_functional_2022,CHE
220804_Ticino_UniversityOfZurich_AntiS_UnaAdj_Overall,220804_Ticino_UniversityOfZurich,"Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022",2022-08-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Canton of Ticino,,"""For phase five, we randomly selected individuals from the general population in north-eastern (canton of Zurich) and southern Switzerland (canton of Ticino)"".

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-03-01,2022-03-31,Household and community samples,All,Multiple groups,16.0,99.0,Analysis,Anti-spike; Unadjusted,850,0.9671,,,,,,,True,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.99,0.98,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Rebecca Amati,University of Zurich,Unity-Aligned,https://doi.org/10.2807/1560-7917.ES.2022.27.31.2200561,2022-08-16,2022-10-29,Unverified,amati_functional_2022,CHE
220804_Ticino_UniversityOfZurich_AntiS_UnaAdj_Age65+,220804_Ticino_UniversityOfZurich,"Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022",2022-08-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Canton of Ticino,,"""For phase five, we randomly selected individuals from the general population in north-eastern (canton of Zurich) and southern Switzerland (canton of Ticino)"".

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-03-01,2022-03-31,Household and community samples,All,Multiple groups,65.0,99.0,Age,Age: ≥65 years,204,0.9559000000000001,,,,,,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.99,0.98,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Rebecca Amati,University of Zurich,Unity-Aligned,https://doi.org/10.2807/1560-7917.ES.2022.27.31.2200561,2022-08-16,2022-08-17,Unverified,amati_functional_2022,CHE
220804_Ticino_UniversityOfZurich_AntiN_UnaAdj_Overall,220804_Ticino_UniversityOfZurich,"Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022",2022-08-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Canton of Ticino,,"""For phase five, we randomly selected individuals from the general population in north-eastern (canton of Zurich) and southern Switzerland (canton of Ticino)"".

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-03-01,2022-03-31,Household and community samples,All,Multiple groups,16.0,99.0,Test used,Anti-nucleocapsid,850,0.2706,,,,,,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Nucleocapsid(N-protein),Validated by developers,0.99,0.98,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Rebecca Amati,University of Zurich,Unity-Aligned,https://doi.org/10.2807/1560-7917.ES.2022.27.31.2200561,2022-08-16,2022-10-29,Unverified,amati_functional_2022,CHE
220804_Ticino_UniversityOfZurich_nAB_Omicron_UnaAdj_Overall,220804_Ticino_UniversityOfZurich,"Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022",2022-08-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Canton of Ticino,,"""For phase five, we randomly selected individuals from the general population in north-eastern (canton of Zurich) and southern Switzerland (canton of Ticino)"".

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-03-01,2022-03-31,Household and community samples,All,Multiple groups,16.0,99.0,Test used,Neutralization against Omicron,850,0.8729000000000001,,,,,,,,Stratified probability,Author designed (Neutralization Assay),,Neutralization,Serum,Neutralizing,Spike,Validated by developers,0.9670000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Rebecca Amati,University of Zurich,Unity-Aligned,https://doi.org/10.2807/1560-7917.ES.2022.27.31.2200561,2022-08-16,2022-10-29,Unverified,amati_functional_2022,CHE
220804_Ticino_UniversityOfZurich_AntiS_UnaAdj_Age45-64,220804_Ticino_UniversityOfZurich,"Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022",2022-08-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Canton of Ticino,,"""For phase five, we randomly selected individuals from the general population in north-eastern (canton of Zurich) and southern Switzerland (canton of Ticino)"".

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-03-01,2022-03-31,Household and community samples,All,Multiple groups,45.0,64.0,Age,Age: 45-64 years,262,0.9656,,,,,,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.99,0.98,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Rebecca Amati,University of Zurich,Unity-Aligned,https://doi.org/10.2807/1560-7917.ES.2022.27.31.2200561,2022-08-16,2022-08-17,Unverified,amati_functional_2022,CHE
220804_Ticino_UniversityOfZurich_AntiS_UnaAdj_Age16-29,220804_Ticino_UniversityOfZurich,"Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022",2022-08-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Canton of Ticino,,"""For phase five, we randomly selected individuals from the general population in north-eastern (canton of Zurich) and southern Switzerland (canton of Ticino)"".

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-03-01,2022-03-31,Household and community samples,All,Multiple groups,16.0,29.0,Age,Age: 16-29 years,176,0.9773000000000001,,,,,,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.99,0.98,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Rebecca Amati,University of Zurich,Unity-Aligned,https://doi.org/10.2807/1560-7917.ES.2022.27.31.2200561,2022-08-16,2022-08-17,Unverified,amati_functional_2022,CHE
220804_Zurich_UniversityOfZurich_AntiS_PopTestAdj_Overall,220804_Zurich_UniversityOfZurich,"Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022",2022-08-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Canton of Zurich,,"""For phase five, we randomly selected individuals from the general population in north-eastern (canton of Zurich) and southern Switzerland (canton of Ticino)"".

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-03-01,2022-03-31,Household and community samples,All,Multiple groups,16.0,99.0,Primary Estimate,Anti-spike; Pop and test adjusted,1044,0.988,0.9790000000000001,0.995,True,True,True,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.99,0.98,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Rebecca Amati,University of Zurich,Unity-Aligned,https://doi.org/10.2807/1560-7917.ES.2022.27.31.2200561,2022-08-16,2022-08-17,Unverified,amati_functional_2022,CHE
220804_Zurich_UniversityOfZurich_AntiN_UnaAdj_Overall,220804_Zurich_UniversityOfZurich,"Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022",2022-08-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Canton of Zurich,,"""For phase five, we randomly selected individuals from the general population in north-eastern (canton of Zurich) and southern Switzerland (canton of Ticino)"".

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-03-01,2022-03-31,Household and community samples,All,Multiple groups,16.0,99.0,Test used,Anti-nucleocapsid,1044,0.228,,,,,,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Nucleocapsid(N-protein),Validated by developers,0.99,0.98,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Rebecca Amati,University of Zurich,Unity-Aligned,https://doi.org/10.2807/1560-7917.ES.2022.27.31.2200561,2022-08-16,2022-10-29,Unverified,amati_functional_2022,CHE
220804_Zurich_UniversityOfZurich_nAB_WildType_UnaAdj_Overall,220804_Zurich_UniversityOfZurich,"Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022",2022-08-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Canton of Zurich,,"""For phase five, we randomly selected individuals from the general population in north-eastern (canton of Zurich) and southern Switzerland (canton of Ticino)"".

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-03-01,2022-03-31,Household and community samples,All,Multiple groups,16.0,99.0,Test used,Neutralization against Wild type,1044,0.9540000000000001,,,,,,,,Stratified probability,Author designed (Neutralization Assay),,Neutralization,Serum,Neutralizing,Spike,Validated by developers,0.9670000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Rebecca Amati,University of Zurich,Unity-Aligned,https://doi.org/10.2807/1560-7917.ES.2022.27.31.2200561,2022-08-16,2022-08-17,Unverified,amati_functional_2022,CHE
220804_Zurich_UniversityOfZurich_AntiS_UnaAdj_Age45-64,220804_Zurich_UniversityOfZurich,"Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022",2022-08-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Canton of Zurich,,"""For phase five, we randomly selected individuals from the general population in north-eastern (canton of Zurich) and southern Switzerland (canton of Ticino)"".

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-03-01,2022-03-31,Household and community samples,All,Multiple groups,45.0,64.0,Age,Age: 45-64 years,326,0.9847,,,,,,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.99,0.98,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Rebecca Amati,University of Zurich,Unity-Aligned,https://doi.org/10.2807/1560-7917.ES.2022.27.31.2200561,2022-08-16,2022-08-17,Unverified,amati_functional_2022,CHE
220804_Zurich_UniversityOfZurich_AntiS_UnaAdj_Age16-29,220804_Zurich_UniversityOfZurich,"Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022",2022-08-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Canton of Zurich,,"""For phase five, we randomly selected individuals from the general population in north-eastern (canton of Zurich) and southern Switzerland (canton of Ticino)"".

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-03-01,2022-03-31,Household and community samples,All,Multiple groups,16.0,29.0,Age,Age: 16-29 years,183,0.9781000000000001,,,,,,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.99,0.98,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Rebecca Amati,University of Zurich,Unity-Aligned,https://doi.org/10.2807/1560-7917.ES.2022.27.31.2200561,2022-08-16,2022-08-17,Unverified,amati_functional_2022,CHE
220804_Zurich_UniversityOfZurich_nAB_Omicron_UnaAdj_Overall,220804_Zurich_UniversityOfZurich,"Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022",2022-08-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Canton of Zurich,,"""For phase five, we randomly selected individuals from the general population in north-eastern (canton of Zurich) and southern Switzerland (canton of Ticino)"".

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-03-01,2022-03-31,Household and community samples,All,Multiple groups,16.0,99.0,Test used,Neutralization against Omicron,1044,0.8946,,,,,,,,Stratified probability,Author designed (Neutralization Assay),,Neutralization,Serum,Neutralizing,Spike,Validated by developers,0.9670000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Rebecca Amati,University of Zurich,Unity-Aligned,https://doi.org/10.2807/1560-7917.ES.2022.27.31.2200561,2022-08-16,2022-10-29,Unverified,amati_functional_2022,CHE
220804_Zurich_UniversityOfZurich_AntiS_UnaAdj_Overall,220804_Zurich_UniversityOfZurich,"Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022",2022-08-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Canton of Zurich,,"""For phase five, we randomly selected individuals from the general population in north-eastern (canton of Zurich) and southern Switzerland (canton of Ticino)"".

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-03-01,2022-03-31,Household and community samples,All,Multiple groups,16.0,99.0,Analysis,Anti-spike; Unadjusted,1044,0.9837,,,,,,,True,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.99,0.98,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Rebecca Amati,University of Zurich,Unity-Aligned,https://doi.org/10.2807/1560-7917.ES.2022.27.31.2200561,2022-08-16,2022-10-29,Unverified,amati_functional_2022,CHE
220804_Zurich_UniversityOfZurich_AntiS_UnaAdj_Age30-44,220804_Zurich_UniversityOfZurich,"Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022",2022-08-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Canton of Zurich,,"""For phase five, we randomly selected individuals from the general population in north-eastern (canton of Zurich) and southern Switzerland (canton of Ticino)"".

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-03-01,2022-03-31,Household and community samples,All,Multiple groups,30.0,44.0,Age,Age: 30-44 years,260,0.9884999999999999,,,,,,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.99,0.98,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Rebecca Amati,University of Zurich,Unity-Aligned,https://doi.org/10.2807/1560-7917.ES.2022.27.31.2200561,2022-08-16,2022-08-17,Unverified,amati_functional_2022,CHE
220804_Zurich_UniversityOfZurich_nAB_Delta_UnaAdj_Overall,220804_Zurich_UniversityOfZurich,"Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022",2022-08-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Canton of Zurich,,"""For phase five, we randomly selected individuals from the general population in north-eastern (canton of Zurich) and southern Switzerland (canton of Ticino)"".

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-03-01,2022-03-31,Household and community samples,All,Multiple groups,16.0,99.0,Test used,Neutralization against Delta,1044,0.9368000000000001,,,,,,,,Stratified probability,Author designed (Neutralization Assay),,Neutralization,Serum,Neutralizing,Spike,Validated by developers,0.9670000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Rebecca Amati,University of Zurich,Unity-Aligned,https://doi.org/10.2807/1560-7917.ES.2022.27.31.2200561,2022-08-16,2022-08-17,Unverified,amati_functional_2022,CHE
220804_Zurich_UniversityOfZurich_AntiS_UnaAdj_Age65+,220804_Zurich_UniversityOfZurich,"Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022",2022-08-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Canton of Zurich,,"""For phase five, we randomly selected individuals from the general population in north-eastern (canton of Zurich) and southern Switzerland (canton of Ticino)"".

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-03-01,2022-03-31,Household and community samples,All,Multiple groups,65.0,99.0,Age,Age: ≥65 years,275,0.9818000000000001,,,,,,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.99,0.98,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Rebecca Amati,University of Zurich,Unity-Aligned,https://doi.org/10.2807/1560-7917.ES.2022.27.31.2200561,2022-08-16,2022-08-17,Unverified,amati_functional_2022,CHE
220825_CantonofVaud_UniversityofLausanne_Baseline_Primary,220825_CantonofVaud_UniversityofLausanne_Baseline,"Adherence to Coronavirus Disease 2019 Preventive Measures in a Representative Sample of the Population of the Canton of Vaud, Switzerland",2022-08-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Canton of Vaud,,"""participants were selected from the official population registries by the Federal Office of Statistics, using a Poisson sampling, while stratifying by age groups: 15–19 years, 20–39 years, 40–64 years, 65–74 years, 75 years and more.""","""Exclusion criteria included institutionalized individuals, individuals without their capacity of giving consent, diplomats and asylum seekers. """,2020-05-03,2020-07-07,Household and community samples,All,Multiple groups,15.0,,Primary Estimate,,494,0.105,,,True,,,,True,Simplified probability,Author designed (Luminex),,ELISA,Multiple Types,"['IgA', 'IgG']",Spike,Validated by developers,,,['High'],,Yes,No,Yes,,Unclear,Yes,No,,Audrey Butty,University of Lausanne,Not Unity-Aligned,https://doi.org/10.3389/ijph.2022.1605048,2022-09-22,2022-09-22,Unverified,butty_adherence_2022,CHE
220825_CantonofVaud_UniversityofLausanne_Follow-up_Primary,220825_CantonofVaud_UniversityofLausanne_Follow-up,"Adherence to Coronavirus Disease 2019 Preventive Measures in a Representative Sample of the Population of the Canton of Vaud, Switzerland",2022-08-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Canton of Vaud,,"""participants were selected from the official population registries by the Federal Office of Statistics, using a Poisson sampling, while stratifying by age groups: 15–19 years, 20–39 years, 40–64 years, 65–74 years, 75 years and more.""","""Exclusion criteria included institutionalized individuals, individuals without their capacity of giving consent, diplomats and asylum seekers. """,2020-10-20,2020-12-12,Household and community samples,All,Multiple groups,15.0,,Primary Estimate,,410,0.16899999999999998,,,True,,,,True,Simplified probability,Author designed (Luminex),,ELISA,Multiple Types,"['IgA', 'IgG']",Spike,Validated by developers,,,['High'],,Yes,No,Yes,,Unclear,Yes,No,,Audrey Butty,University of Lausanne,Not Unity-Aligned,https://doi.org/10.3389/ijph.2022.1605048,2022-09-22,2022-09-22,Unverified,butty_adherence_2022,CHE
220825_Switzerland_UniversityOfZurich,220825_Switzerland_UniversityOfZurich,"Persistence, prevalence, and polymorphism of sequelae after COVID-19 in unvaccinated, young adults of the Swiss Armed Forces: a longitudinal, cohort study (LoCoMo).",2022-08-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Switzerland,,,"""Eligible participants were personnel of the Swiss Armed Forces (SAF) who were aged 18–30 years with a positive or negative RT-PCR test for SARS-CoV-2 during their service between March 1, 2020, and Dec 31, 2020.""

Serology results is only reported for RT-PCR negative (recent or non-recent) participants.","""Exclusion criteria were being unwilling or unavailable to participate in the study testing day in Zürich, Switzerland.""

""After check-in and a saliva SARS-CoV-2 rapid antigen test (COVID-19 Antigen Detection Kit [Colloidal Gold]; Zhuhai Lituo Biotechnology, Zhuhai, China) to exclude concurrent SARS-CoV-2 infection, participants answered baseline questions"".",2021-05-20,2021-11-26,Essential non-healthcare workers,All,Adults (18-64 years),18.0,30.0,Primary Estimate,,297,0.1549,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Jeremy Deuel,University of Zurich,Not Unity-Aligned,https://dx.doi.org/10.1016/S1473-3099(22)00449-2,2022-09-08,2024-03-01,Unverified,deuel_persistence_2022,CHE
220903_Bern_UniversityofBern_12Months,220903_Bern_UniversityofBern_12Months,The disease burden of Delta and Omicron variants of SARS-CoV-2 in a Predominantly Vaccinated and healthy cohort.,2022-09-03,Journal Article (Peer-Reviewed),Local,Prospective cohort,Switzerland,,Bern,"Employees of the Cantonal Police Bern, aged 18-65 years",,2022-03-01,2022-04-30,Essential non-healthcare workers,All,Adults (18-64 years),18.0,65.0,Primary Estimate,,967,0.516,0.485,0.547,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Qualitative Elecsys Anti-SARS-CoV-2 Probe",Roche Diagnostics,CLIA,Serum,IgG,Spike,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Parham Sendi,University of Bern,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2022.08.019,2022-09-20,2024-03-01,Unverified,sendi_disease_2022,CHE
220903_Bern_UniversityofBern_9Months,220903_Bern_UniversityofBern_9Months,The disease burden of Delta and Omicron variants of SARS-CoV-2 in a Predominantly Vaccinated and healthy cohort.,2022-09-03,Journal Article (Peer-Reviewed),Local,Prospective cohort,Switzerland,,Bern,"Employees of the Cantonal Police Bern, aged 18-65 years",,2021-12-01,2021-12-31,Essential non-healthcare workers,All,Adults (18-64 years),18.0,65.0,Primary Estimate,,985,0.19100000000000003,0.167,0.215,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Qualitative Elecsys Anti-SARS-CoV-2 Probe",Roche Diagnostics,CLIA,Serum,IgG,Spike,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Parham Sendi,University of Bern,Not Unity-Aligned,https://dx.doi.org/10.1016/j.cmi.2022.08.019,2022-09-20,2024-03-01,Unverified,sendi_disease_2022,CHE
220912_CantonofVaud_UniversityofLausanne_Overall_Primary,220912_CantonofVaud_UniversityofLausanne,"SARS-COV-2 SEROPREVALENCE IN EMPLOYEES OF FOUR ESSENTIAL NON-HEALTHCARE SECTORS AT MODERATE/HIGH RISK OF EXPOSURE TO CORONAVIRUS INFECTION: DATA FROM THE ""FIRST WAVE"".",2022-09-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Canton of Vaud,,"""Study participants were bus-drivers of a public transport company and employees of the following workplaces: five stores of a food supermarket company, a mail-sorting center of a postal service and four sites of a laundry operating in the healthcare sector. These workplaces are at moderate to high risk of SARS-CoV-2 exposure according to WHO (30). Notably, WHO classification defined a “medium exposure risk” for jobs/tasks with close, frequent contact with the general public and a “high exposure risk” for jobs/tasks with close contact with people more likely to have COVID-19, as well as contact with objects and surfaces possibly contaminated with the virus (30)""","-working from home
-COVID-19 suspected
- blood collection failure
-incapacity to answer",2020-03-01,2020-04-30,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,428,0.159,,,True,,,,True,Simplified probability,Author designed (Luminex),,ELISA,Whole Blood,"['IgA', 'IgG']",Spike,Validated by developers,,,['High'],,Yes,No,Yes,,Unclear,Yes,No,,Guilia Belloni,University of Lausanne,Not Unity-Aligned,https://dx.doi.org/10.1097/JOM.0000000000002690,2022-09-18,2022-09-22,Unverified,belloni_sars-cov-2_2022,CHE
220916_Switzerland_UniversityofFribourg_overall,220916_Switzerland_UniversityofFribourg,SARS-CoV-2 infection among employees working from home and on site: An occupational study in Switzerland,2022-09-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Switzerland,,Lausanne; Romont,"""employees from two Nestlé sites in Switzerland, a research center (Lausanne, n = 920) and a factory (Romont, n = 390).""
 
""All employees aged 18 years and older working at the two specific sites were invited""

",,2020-12-08,2021-02-11,Non-essential workers and unemployed persons,All,Adults (18-64 years),18.0,65.0,Primary Estimate,,425,0.16,,,True,,,,True,Convenience,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.966,0.997,['High'],,No,No,Yes,,Unclear,Yes,Yes,,Alexia Schmid,University of Fribourg,Not Unity-Aligned,https://doi.org/10.3389/fpubh.2022.980482,2022-09-22,2022-09-23,Verified,schmidSARSCoV2InfectionEmployees2022,CHE
220916_Switzerland_UniversityofFribourg_35to49,220916_Switzerland_UniversityofFribourg,SARS-CoV-2 infection among employees working from home and on site: An occupational study in Switzerland,2022-09-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Switzerland,,Lausanne; Romont,"""employees from two Nestlé sites in Switzerland, a research center (Lausanne, n = 920) and a factory (Romont, n = 390).""
 
""All employees aged 18 years and older working at the two specific sites were invited""

",,2020-12-08,2021-02-11,Non-essential workers and unemployed persons,All,Adults (18-64 years),35.0,49.0,Age,35-59,214,0.12,,,,,,,,Convenience,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.966,0.997,['High'],,No,No,Yes,,Unclear,Yes,Yes,,Alexia Schmid,University of Fribourg,Not Unity-Aligned,https://doi.org/10.3389/fpubh.2022.980482,2022-09-22,2022-09-23,Verified,schmidSARSCoV2InfectionEmployees2022,CHE
220916_Switzerland_UniversityofFribourg_50to65,220916_Switzerland_UniversityofFribourg,SARS-CoV-2 infection among employees working from home and on site: An occupational study in Switzerland,2022-09-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Switzerland,,Lausanne; Romont,"""employees from two Nestlé sites in Switzerland, a research center (Lausanne, n = 920) and a factory (Romont, n = 390).""
 
""All employees aged 18 years and older working at the two specific sites were invited""

",,2020-12-08,2021-02-11,Non-essential workers and unemployed persons,All,Adults (18-64 years),50.0,65.0,Age,50-65,108,0.16,,,,,,,,Convenience,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.966,0.997,['High'],,No,No,Yes,,Unclear,Yes,Yes,,Alexia Schmid,University of Fribourg,Not Unity-Aligned,https://doi.org/10.3389/fpubh.2022.980482,2022-09-22,2022-09-23,Verified,schmidSARSCoV2InfectionEmployees2022,CHE
220916_Switzerland_UniversityofFribourg_18to34,220916_Switzerland_UniversityofFribourg,SARS-CoV-2 infection among employees working from home and on site: An occupational study in Switzerland,2022-09-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Switzerland,,Lausanne; Romont,"""employees from two Nestlé sites in Switzerland, a research center (Lausanne, n = 920) and a factory (Romont, n = 390).""
 
""All employees aged 18 years and older working at the two specific sites were invited""

",,2020-12-08,2021-02-11,Non-essential workers and unemployed persons,All,Adults (18-64 years),18.0,34.0,Age,18-34,103,0.23,,,,,,,,Convenience,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.966,0.997,['High'],,No,No,Yes,,Unclear,Yes,Yes,,Alexia Schmid,University of Fribourg,Not Unity-Aligned,https://doi.org/10.3389/fpubh.2022.980482,2022-09-22,2022-09-23,Verified,schmidSARSCoV2InfectionEmployees2022,CHE
220923_CantonOfGeneva_GenevaUniversityHospitals_Overall,220923_CantonOfGeneva_GenevaUniversityHospitals,"Socio-economic determinants of SARS-CoV-2 infection: Results from a population-based cross-sectional serosurvey in Geneva, Switzerland",2022-09-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Canton of Geneva,,"""Data was obtained from a population-based serosurvey of adults in Geneva and their household members"".

""We limited our sample to adults aged 18 years and older"".",,2020-11-23,2020-12-23,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2899,0.2046,,,True,,,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.988,0.9998,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Hugo-Alejandro Santa-Ramirez,Geneva University Hospitals,Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.874252,2022-10-19,2024-04-10,Verified,santa-ramirez_socio-economic_2022-1,CHE
221017_Ticino_UniversityOfZurich_AntiS_PopTestAdj_Overall,221017_Ticino_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study,2022-10-17,Preprint,Regional,Prospective cohort,Switzerland,Canton of Ticino,,"""In phase five, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in phase six. For cross-sectional analyses in phase six, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud)."" --> the current study reports seroprevalence results only for phase 6.

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-06-01,2022-06-25,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,Anti-spike; Pop and test adjusted,739,0.983,0.9690000000000001,0.993,True,True,True,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.97,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Anja Frei,University of Zurich,Unity-Aligned,https://doi.org/10.1101/2022.10.14.22281076,2022-10-26,2024-04-24,Verified,frei_development_2022,CHE
221017_Ticino_UniversityOfZurich_AntiS_UnAdj_Age45-64,221017_Ticino_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study,2022-10-17,Preprint,Regional,Prospective cohort,Switzerland,Canton of Ticino,,"""In phase five, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in phase six. For cross-sectional analyses in phase six, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud)."" --> the current study reports seroprevalence results only for phase 6.

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-06-01,2022-06-25,Household and community samples,All,Adults (18-64 years),45.0,64.0,Age,Age: 45-64 years,241,0.9751000000000001,,,,,,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.97,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Anja Frei,University of Zurich,Unity-Aligned,https://doi.org/10.1101/2022.10.14.22281076,2022-10-27,2024-04-24,Verified,frei_development_2022,CHE
221017_Ticino_UniversityOfZurich_nAB_Delta_UnAdj_Overall,221017_Ticino_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study,2022-10-17,Preprint,Regional,Prospective cohort,Switzerland,Canton of Ticino,,"""In phase five, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in phase six. For cross-sectional analyses in phase six, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud)."" --> the current study reports seroprevalence results only for phase 6.

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-06-01,2022-06-25,Household and community samples,All,Multiple groups,16.0,,Test used,Neutralization against Delta,739,0.9066,,,,,,,,Stratified probability,Author designed (Neutralization Assay),,Neutralization,Serum,Neutralizing,Spike,Validated by developers,0.9670000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Anja Frei,University of Zurich,Unity-Aligned,https://doi.org/10.1101/2022.10.14.22281076,2022-10-27,2024-04-24,Verified,frei_development_2022,CHE
221017_Ticino_UniversityOfZurich_AntiS_UnAdj_Age30-44,221017_Ticino_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study,2022-10-17,Preprint,Regional,Prospective cohort,Switzerland,Canton of Ticino,,"""In phase five, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in phase six. For cross-sectional analyses in phase six, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud)."" --> the current study reports seroprevalence results only for phase 6.

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-06-01,2022-06-25,Household and community samples,All,Adults (18-64 years),30.0,44.0,Age,Age: 30-44 years,186,0.9892000000000001,,,,,,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.97,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Anja Frei,University of Zurich,Unity-Aligned,https://doi.org/10.1101/2022.10.14.22281076,2022-10-27,2024-04-24,Verified,frei_development_2022,CHE
221017_Ticino_UniversityOfZurich_AntiS_UnAdj_Overall,221017_Ticino_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study,2022-10-17,Preprint,Regional,Prospective cohort,Switzerland,Canton of Ticino,,"""In phase five, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in phase six. For cross-sectional analyses in phase six, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud)."" --> the current study reports seroprevalence results only for phase 6.

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-06-01,2022-06-25,Household and community samples,All,Multiple groups,16.0,,Analysis,Anti-spike; Unadjusted,739,0.9783000000000001,,,,,,,True,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.97,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Anja Frei,University of Zurich,Unity-Aligned,https://doi.org/10.1101/2022.10.14.22281076,2022-10-27,2024-04-24,Verified,frei_development_2022,CHE
221017_Ticino_UniversityOfZurich_nAB_Omicron_UnAdj_Overall,221017_Ticino_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study,2022-10-17,Preprint,Regional,Prospective cohort,Switzerland,Canton of Ticino,,"""In phase five, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in phase six. For cross-sectional analyses in phase six, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud)."" --> the current study reports seroprevalence results only for phase 6.

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-06-01,2022-06-25,Household and community samples,All,Multiple groups,16.0,,Test used,Neutralization against Omicron,739,0.843,,,,,,,,Stratified probability,Author designed (Neutralization Assay),,Neutralization,Serum,Neutralizing,Spike,Validated by developers,0.9670000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Anja Frei,University of Zurich,Unity-Aligned,https://doi.org/10.1101/2022.10.14.22281076,2022-10-27,2024-04-24,Verified,frei_development_2022,CHE
221017_Ticino_UniversityOfZurich_AntiS_UnAdj_Vaccinated,221017_Ticino_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study,2022-10-17,Preprint,Regional,Prospective cohort,Switzerland,Canton of Ticino,,"""In phase five, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in phase six. For cross-sectional analyses in phase six, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud)."" --> the current study reports seroprevalence results only for phase 6.

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-06-01,2022-06-25,Household and community samples,All,Multiple groups,16.0,,COVID-19 vaccination status,COVID Vaccinated,664,1.0,,,,,,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.97,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Anja Frei,University of Zurich,Unity-Aligned,https://doi.org/10.1101/2022.10.14.22281076,2022-10-27,2024-04-24,Verified,frei_development_2022,CHE
221017_Ticino_UniversityOfZurich_AntiS_UnAdj_Age65+,221017_Ticino_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study,2022-10-17,Preprint,Regional,Prospective cohort,Switzerland,Canton of Ticino,,"""In phase five, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in phase six. For cross-sectional analyses in phase six, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud)."" --> the current study reports seroprevalence results only for phase 6.

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-06-01,2022-06-25,Household and community samples,All,Seniors (65+ years),65.0,,Age,Age: ≥65 years,184,0.9783000000000001,,,,,,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.97,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Anja Frei,University of Zurich,Unity-Aligned,https://doi.org/10.1101/2022.10.14.22281076,2022-10-27,2024-04-24,Verified,frei_development_2022,CHE
221017_Ticino_UniversityOfZurich_AntiS_UnAdj_Age16-29,221017_Ticino_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study,2022-10-17,Preprint,Regional,Prospective cohort,Switzerland,Canton of Ticino,,"""In phase five, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in phase six. For cross-sectional analyses in phase six, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud)."" --> the current study reports seroprevalence results only for phase 6.

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-06-01,2022-06-25,Household and community samples,All,Adults (18-64 years),16.0,29.0,Age,Age: 16-29 years,128,0.9688,,,,,,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.97,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Anja Frei,University of Zurich,Unity-Aligned,https://doi.org/10.1101/2022.10.14.22281076,2022-10-27,2024-04-24,Verified,frei_development_2022,CHE
221017_Ticino_UniversityOfZurich_nAB_WildType_UnAdj_Overall,221017_Ticino_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study,2022-10-17,Preprint,Regional,Prospective cohort,Switzerland,Canton of Ticino,,"""In phase five, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in phase six. For cross-sectional analyses in phase six, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud)."" --> the current study reports seroprevalence results only for phase 6.

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-06-01,2022-06-25,Household and community samples,All,Multiple groups,16.0,,Test used,Neutralization against Wild type,739,0.9309999999999999,,,,,,,,Stratified probability,Author designed (Neutralization Assay),,Neutralization,Serum,Neutralizing,Spike,Validated by developers,0.9670000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Anja Frei,University of Zurich,Unity-Aligned,https://doi.org/10.1101/2022.10.14.22281076,2022-10-27,2024-04-24,Verified,frei_development_2022,CHE
221017_Ticino_UniversityOfZurich_AntiS_UnAdj_Unvaccinated,221017_Ticino_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study,2022-10-17,Preprint,Regional,Prospective cohort,Switzerland,Canton of Ticino,,"""In phase five, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in phase six. For cross-sectional analyses in phase six, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud)."" --> the current study reports seroprevalence results only for phase 6.

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-06-01,2022-06-25,Household and community samples,All,Multiple groups,16.0,,COVID-19 vaccination status,COVID Unvaccinated,75,0.7867000000000001,,,,,,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.97,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Anja Frei,University of Zurich,Unity-Aligned,https://doi.org/10.1101/2022.10.14.22281076,2022-10-27,2024-04-24,Verified,frei_development_2022,CHE
221017_Vaud_UniversityOfZurich_AntiS_PopTestAdj_Overall,221017_Vaud_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study,2022-10-17,Preprint,Regional,Prospective cohort,Switzerland,Canton of Vaud,,"""In phase five, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in phase six. For cross-sectional analyses in phase six, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud)."" --> the current study reports seroprevalence results only for phase 6.

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-05-30,2022-07-02,Household and community samples,All,Multiple groups,15.0,,Primary Estimate,Anti-spike; Pop and test adjusted,850,0.9840000000000001,0.973,0.993,True,True,True,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.97,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Anja Frei,University of Zurich,Unity-Aligned,https://doi.org/10.1101/2022.10.14.22281076,2022-10-26,2024-04-24,Verified,frei_development_2022,CHE
221017_Vaud_UniversityOfZurich_AntiS_UnAdj_Overall,221017_Vaud_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study,2022-10-17,Preprint,Regional,Prospective cohort,Switzerland,Canton of Vaud,,"""In phase five, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in phase six. For cross-sectional analyses in phase six, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud)."" --> the current study reports seroprevalence results only for phase 6.

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-05-30,2022-07-02,Household and community samples,All,Multiple groups,15.0,,Analysis,Anti-spike; Unadjusted,850,0.9823999999999999,,,,,,,True,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.97,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Anja Frei,University of Zurich,Unity-Aligned,https://doi.org/10.1101/2022.10.14.22281076,2022-10-27,2024-04-24,Verified,frei_development_2022,CHE
221017_Vaud_UniversityOfZurich_AntiS_UnAdj_Age15-29,221017_Vaud_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study,2022-10-17,Preprint,Regional,Prospective cohort,Switzerland,Canton of Vaud,,"""In phase five, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in phase six. For cross-sectional analyses in phase six, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud)."" --> the current study reports seroprevalence results only for phase 6.

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-05-30,2022-07-02,Household and community samples,All,Adults (18-64 years),15.0,29.0,Age,Age: 15-29 years,107,1.0,,,,,,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.97,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Anja Frei,University of Zurich,Unity-Aligned,https://doi.org/10.1101/2022.10.14.22281076,2022-10-27,2024-04-24,Verified,frei_development_2022,CHE
221017_Vaud_UniversityOfZurich_nAB_WildType_UnAdj_Overall,221017_Vaud_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study,2022-10-17,Preprint,Regional,Prospective cohort,Switzerland,Canton of Vaud,,"""In phase five, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in phase six. For cross-sectional analyses in phase six, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud)."" --> the current study reports seroprevalence results only for phase 6.

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-05-30,2022-07-02,Household and community samples,All,Multiple groups,15.0,,Test used,Neutralization against Wild type,850,0.9388,,,,,,,,Stratified probability,Author designed (Neutralization Assay),,Neutralization,Serum,Neutralizing,Spike,Validated by developers,0.9670000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Anja Frei,University of Zurich,Unity-Aligned,https://doi.org/10.1101/2022.10.14.22281076,2022-10-27,2024-04-24,Verified,frei_development_2022,CHE
221017_Vaud_UniversityOfZurich_AntiS_UnAdj_Age30-44,221017_Vaud_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study,2022-10-17,Preprint,Regional,Prospective cohort,Switzerland,Canton of Vaud,,"""In phase five, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in phase six. For cross-sectional analyses in phase six, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud)."" --> the current study reports seroprevalence results only for phase 6.

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-05-30,2022-07-02,Household and community samples,All,Adults (18-64 years),30.0,44.0,Age,Age: 30-44 years,183,0.9836,,,,,,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.97,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Anja Frei,University of Zurich,Unity-Aligned,https://doi.org/10.1101/2022.10.14.22281076,2022-10-27,2024-04-24,Verified,frei_development_2022,CHE
221017_Vaud_UniversityOfZurich_nAB_Omicron_UnAdj_Overall,221017_Vaud_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study,2022-10-17,Preprint,Regional,Prospective cohort,Switzerland,Canton of Vaud,,"""In phase five, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in phase six. For cross-sectional analyses in phase six, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud)."" --> the current study reports seroprevalence results only for phase 6.

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-05-30,2022-07-02,Household and community samples,All,Multiple groups,15.0,,Test used,Neutralization against Omicron,850,0.8694,,,,,,,,Stratified probability,Author designed (Neutralization Assay),,Neutralization,Serum,Neutralizing,Spike,Validated by developers,0.9670000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Anja Frei,University of Zurich,Unity-Aligned,https://doi.org/10.1101/2022.10.14.22281076,2022-10-27,2024-04-24,Verified,frei_development_2022,CHE
221017_Vaud_UniversityOfZurich_AntiS_UnAdj_Unvaccinated,221017_Vaud_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study,2022-10-17,Preprint,Regional,Prospective cohort,Switzerland,Canton of Vaud,,"""In phase five, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in phase six. For cross-sectional analyses in phase six, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud)."" --> the current study reports seroprevalence results only for phase 6.

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-05-30,2022-07-02,Household and community samples,All,Multiple groups,15.0,,COVID-19 vaccination status,COVID Unvaccinated,76,0.8158,,,,,,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.97,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Anja Frei,University of Zurich,Unity-Aligned,https://doi.org/10.1101/2022.10.14.22281076,2022-10-27,2024-04-24,Verified,frei_development_2022,CHE
221017_Vaud_UniversityOfZurich_AntiS_UnAdj_Age45-64,221017_Vaud_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study,2022-10-17,Preprint,Regional,Prospective cohort,Switzerland,Canton of Vaud,,"""In phase five, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in phase six. For cross-sectional analyses in phase six, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud)."" --> the current study reports seroprevalence results only for phase 6.

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-05-30,2022-07-02,Household and community samples,All,Adults (18-64 years),45.0,64.0,Age,Age: 45-64 years,275,0.9673,,,,,,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.97,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Anja Frei,University of Zurich,Unity-Aligned,https://doi.org/10.1101/2022.10.14.22281076,2022-10-27,2024-04-24,Verified,frei_development_2022,CHE
221017_Vaud_UniversityOfZurich_AntiS_UnAdj_Age65+,221017_Vaud_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study,2022-10-17,Preprint,Regional,Prospective cohort,Switzerland,Canton of Vaud,,"""In phase five, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in phase six. For cross-sectional analyses in phase six, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud)."" --> the current study reports seroprevalence results only for phase 6.

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-05-30,2022-07-02,Household and community samples,All,Seniors (65+ years),65.0,,Age,Age: ≥65 years,285,0.9895,,,,,,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.97,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Anja Frei,University of Zurich,Unity-Aligned,https://doi.org/10.1101/2022.10.14.22281076,2022-10-27,2024-04-24,Verified,frei_development_2022,CHE
221017_Vaud_UniversityOfZurich_nAB_Delta_UnAdj_Overall,221017_Vaud_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study,2022-10-17,Preprint,Regional,Prospective cohort,Switzerland,Canton of Vaud,,"""In phase five, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in phase six. For cross-sectional analyses in phase six, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud)."" --> the current study reports seroprevalence results only for phase 6.

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-05-30,2022-07-02,Household and community samples,All,Multiple groups,15.0,,Test used,Neutralization against Delta,850,0.9176000000000001,,,,,,,,Stratified probability,Author designed (Neutralization Assay),,Neutralization,Serum,Neutralizing,Spike,Validated by developers,0.9670000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Anja Frei,University of Zurich,Unity-Aligned,https://doi.org/10.1101/2022.10.14.22281076,2022-10-27,2024-04-24,Verified,frei_development_2022,CHE
221017_Vaud_UniversityOfZurich_AntiS_UnAdj_Vaccinated,221017_Vaud_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study,2022-10-17,Preprint,Regional,Prospective cohort,Switzerland,Canton of Vaud,,"""In phase five, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in phase six. For cross-sectional analyses in phase six, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud)."" --> the current study reports seroprevalence results only for phase 6.

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-05-30,2022-07-02,Household and community samples,All,Multiple groups,15.0,,COVID-19 vaccination status,COVID Vaccinated,774,0.9987,,,,,,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.97,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Anja Frei,University of Zurich,Unity-Aligned,https://doi.org/10.1101/2022.10.14.22281076,2022-10-27,2024-04-24,Verified,frei_development_2022,CHE
221017_Zurich_UniversityOfZurich_AntiS_PopTestAdj_Overall,221017_Zurich_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study,2022-10-17,Preprint,Regional,Prospective cohort,Switzerland,Canton of Zurich,,"""In phase five, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in phase six. For cross-sectional analyses in phase six, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud)."" --> the current study reports seroprevalence results only for phase 6.

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-06-02,2022-07-11,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,Anti-spike; Pop and test adjusted,964,0.9890000000000001,0.98,0.995,True,True,True,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.97,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Anja Frei,University of Zurich,Unity-Aligned,https://doi.org/10.1101/2022.10.14.22281076,2022-10-26,2024-04-24,Verified,frei_development_2022,CHE
221017_Zurich_UniversityOfZurich_AntiS_UnAdj_Age16-29,221017_Zurich_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study,2022-10-17,Preprint,Regional,Prospective cohort,Switzerland,Canton of Zurich,,"""In phase five, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in phase six. For cross-sectional analyses in phase six, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud)."" --> the current study reports seroprevalence results only for phase 6.

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-06-07,2022-07-08,Household and community samples,All,Adults (18-64 years),16.0,29.0,Age,Age: 16-29 years,156,0.9872,,,,,,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.97,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Anja Frei,University of Zurich,Unity-Aligned,https://doi.org/10.1101/2022.10.14.22281076,2022-10-27,2024-04-24,Verified,frei_development_2022,CHE
221017_Zurich_UniversityOfZurich_nAB_WildType_UnAdj_Overall,221017_Zurich_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study,2022-10-17,Preprint,Regional,Prospective cohort,Switzerland,Canton of Zurich,,"""In phase five, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in phase six. For cross-sectional analyses in phase six, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud)."" --> the current study reports seroprevalence results only for phase 6.

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-06-02,2022-07-11,Household and community samples,All,Multiple groups,16.0,,Test used,Neutralization against Wild type,964,0.9544,,,,,,,,Stratified probability,Author designed (Neutralization Assay),,Neutralization,Serum,Neutralizing,Spike,Validated by developers,0.9670000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Anja Frei,University of Zurich,Unity-Aligned,https://doi.org/10.1101/2022.10.14.22281076,2022-10-27,2024-04-24,Verified,frei_development_2022,CHE
221017_Zurich_UniversityOfZurich_AntiS_UnAdj_Overall,221017_Zurich_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study,2022-10-17,Preprint,Regional,Prospective cohort,Switzerland,Canton of Zurich,,"""In phase five, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in phase six. For cross-sectional analyses in phase six, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud)."" --> the current study reports seroprevalence results only for phase 6.

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-06-02,2022-07-11,Household and community samples,All,Multiple groups,16.0,,Analysis,Anti-spike; Unadjusted,964,0.9895999999999999,,,,,,,True,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.97,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Anja Frei,University of Zurich,Unity-Aligned,https://doi.org/10.1101/2022.10.14.22281076,2022-10-27,2024-04-24,Verified,frei_development_2022,CHE
221017_Zurich_UniversityOfZurich_AntiS_UnAdj_Age65+,221017_Zurich_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study,2022-10-17,Preprint,Regional,Prospective cohort,Switzerland,Canton of Zurich,,"""In phase five, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in phase six. For cross-sectional analyses in phase six, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud)."" --> the current study reports seroprevalence results only for phase 6.

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-06-07,2022-07-11,Household and community samples,All,Seniors (65+ years),65.0,,Age,Age: ≥65 years,267,0.9888,,,,,,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.97,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Anja Frei,University of Zurich,Unity-Aligned,https://doi.org/10.1101/2022.10.14.22281076,2022-10-27,2024-04-24,Verified,frei_development_2022,CHE
221017_Zurich_UniversityOfZurich_nAB_Omicron_UnAdj_Overall,221017_Zurich_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study,2022-10-17,Preprint,Regional,Prospective cohort,Switzerland,Canton of Zurich,,"""In phase five, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in phase six. For cross-sectional analyses in phase six, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud)."" --> the current study reports seroprevalence results only for phase 6.

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-06-02,2022-07-11,Household and community samples,All,Multiple groups,16.0,,Test used,Neutralization against Omicron,964,0.8361000000000001,,,,,,,,Stratified probability,Author designed (Neutralization Assay),,Neutralization,Serum,Neutralizing,Spike,Validated by developers,0.9670000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Anja Frei,University of Zurich,Unity-Aligned,https://doi.org/10.1101/2022.10.14.22281076,2022-10-27,2024-04-24,Verified,frei_development_2022,CHE
221017_Zurich_UniversityOfZurich_AntiS_UnAdj_Age45-64,221017_Zurich_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study,2022-10-17,Preprint,Regional,Prospective cohort,Switzerland,Canton of Zurich,,"""In phase five, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in phase six. For cross-sectional analyses in phase six, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud)."" --> the current study reports seroprevalence results only for phase 6.

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-06-02,2022-07-11,Household and community samples,All,Adults (18-64 years),45.0,64.0,Age,Age: 45-64 years,306,0.9934999999999999,,,,,,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.97,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Anja Frei,University of Zurich,Unity-Aligned,https://doi.org/10.1101/2022.10.14.22281076,2022-10-27,2024-04-24,Verified,frei_development_2022,CHE
221017_Zurich_UniversityOfZurich_AntiS_UnAdj_Age30-44,221017_Zurich_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study,2022-10-17,Preprint,Regional,Prospective cohort,Switzerland,Canton of Zurich,,"""In phase five, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in phase six. For cross-sectional analyses in phase six, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud)."" --> the current study reports seroprevalence results only for phase 6.

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-06-07,2022-07-11,Household and community samples,All,Adults (18-64 years),30.0,44.0,Age,Age: 30-44 years,235,0.9872,,,,,,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.97,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Anja Frei,University of Zurich,Unity-Aligned,https://doi.org/10.1101/2022.10.14.22281076,2022-10-27,2024-04-24,Verified,frei_development_2022,CHE
221017_Zurich_UniversityOfZurich_AntiS_UnAdj_Unvaccinated,221017_Zurich_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study,2022-10-17,Preprint,Regional,Prospective cohort,Switzerland,Canton of Zurich,,"""In phase five, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in phase six. For cross-sectional analyses in phase six, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud)."" --> the current study reports seroprevalence results only for phase 6.

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-06-02,2022-07-11,Household and community samples,All,Multiple groups,16.0,,COVID-19 vaccination status,COVID Unvaccinated,63,0.8412999999999999,,,,,,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.97,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Anja Frei,University of Zurich,Unity-Aligned,https://doi.org/10.1101/2022.10.14.22281076,2022-10-27,2024-04-24,Verified,frei_development_2022,CHE
221017_Zurich_UniversityOfZurich_nAB_Delta_UnAdj_Overall,221017_Zurich_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study,2022-10-17,Preprint,Regional,Prospective cohort,Switzerland,Canton of Zurich,,"""In phase five, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in phase six. For cross-sectional analyses in phase six, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud)."" --> the current study reports seroprevalence results only for phase 6.

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-06-02,2022-07-11,Household and community samples,All,Multiple groups,16.0,,Test used,Neutralization against Delta,964,0.9004000000000001,,,,,,,,Stratified probability,Author designed (Neutralization Assay),,Neutralization,Serum,Neutralizing,Spike,Validated by developers,0.9670000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Anja Frei,University of Zurich,Unity-Aligned,https://doi.org/10.1101/2022.10.14.22281076,2022-10-27,2024-04-24,Verified,frei_development_2022,CHE
221017_Zurich_UniversityOfZurich_AntiS_UnAdj_Vaccinated,221017_Zurich_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study,2022-10-17,Preprint,Regional,Prospective cohort,Switzerland,Canton of Zurich,,"""In phase five, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in phase six. For cross-sectional analyses in phase six, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud)."" --> the current study reports seroprevalence results only for phase 6.

Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""The inclusion criteria for the random sampling are residency in one of the participating Cantons. ‘‘Vulnerable to COVID-19 persons’’ (detailed below) are included. For inclusion in the data collection, individuals with a suspected or confirmed acute SARS-CoV-2 infection are postponed for a visit to 48 h after disappearance of symptoms or 21 days after a positive SARS-CoV-2 reverse transcription polymerase chain reaction test (RT-PCR) result.""","Based on the complete Methods published in https://doi.org/10.1007/s00038-020-01494-0:
""Excluded from the residential registry of the FSO are diplomats, persons with a foreign address in the registry, persons in asylum procedure, persons with a short-term residence permit, and elderly people in nursing homes.""",2022-06-02,2022-07-11,Household and community samples,All,Multiple groups,16.0,,COVID-19 vaccination status,COVID Vaccinated,901,1.0,,,,,,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by developers,0.97,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Anja Frei,University of Zurich,Unity-Aligned,https://doi.org/10.1101/2022.10.14.22281076,2022-10-27,2024-04-24,Verified,frei_development_2022,CHE
221021_Switzerland_UniversityOfLausanne_Overall,221021_Switzerland_UniversityOfLausanne,Oxidative Potential in Exhaled Air (OPEA) as a Tool for Predicting Certain Respiratory Disorders in the General Adult Population: Cross-Sectional Analysis Nested in the Swiss Health Study.,2022-10-21,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Switzerland,Vaud Canton,,"The SHeS involved Swiss residents in the Berne and Vaud Counties, aged 20 to 69. this study was restricted to SHeS participants residing in Vaud County","The exclusion criteria were as followed: (1) Not being capable of understanding the study information (e.g., language, psycho-cognitive impairment etc.); (2) unable to respond to the questions (e.g., language, psycho-cognitive or motor impairment etc.); (3) institutionalized persons (e.g., in prisons, nursing homes, etc.); (4) not a Swiss national residing in Switzerland and not a resident according to the definition: B/C/L/F/N or FDFA’s permit holders (minimum permit duration of 12 months); (5) unable to participate in most examinations for medical reasons; (6) unable to attend the visit at the study center for medical reasons; and (7) the unavailability of OPEA measurement.",2020-10-01,2021-12-31,Household and community samples,All,Multiple groups,20.0,71.0,Primary Estimate,,224,0.22760000000000002,,,True,,,,True,Convenience,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.966,0.997,['High'],Yes,No,No,Yes,No,Unclear,Yes,Yes,Unclear,Irina Guseva Canu,University of Lausanne,Unity-Aligned,https://dx.doi.org/10.3390/antiox11102079,2022-11-09,2024-04-17,Verified,guseva_oxidative_2022,CHE
221024_Puplinge_GenevaUniversityHospitals_Prisoners_Overall,221024_Puplinge_GenevaUniversityHospitals_Prisoners,SARS-CoV-2 seroprevalence study after the first wave among persons living and working in an overcrowded Swiss prison,2022-10-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Switzerland,Canton of Geneva,Puplinge,"People living in detention at Champ-Dollon prison in Puplinge, canton of Geneva, Switzerland, incarcerated either before the beginning of the pandemic (1 March 2020) or after. ",,2020-06-01,2020-06-30,Persons who are incarcerated,Male,Adults (18-64 years),,67.0,Primary Estimate,,177,0.0282,,,True,,,,True,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],,Yes,No,No,,Yes,Yes,Yes,,Laurent Getaz,Geneva University Hospitals,Not Unity-Aligned,https://dx.doi.org/10.1108/IJPH-01-2022-0002,2022-11-03,2024-03-01,Unverified,getaz_sars-cov-2_2022,CHE
221024_Puplinge_GenevaUniversityHospitals_Staff_Overall,221024_Puplinge_GenevaUniversityHospitals_Staff,SARS-CoV-2 seroprevalence study after the first wave among persons living and working in an overcrowded Swiss prison,2022-10-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Switzerland,Canton of Geneva,Puplinge,"Prison staff, including prison healthcare workers, at Champ-Dollon prison in Puplinge, canton of Geneva, Switzerland.",,2020-06-01,2020-06-30,Multiple populations,All,Adults (18-64 years),,,Primary Estimate,,227,0.048,0.027000000000000003,0.086,True,,,,True,Entire sample,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['High'],,Yes,No,No,,Yes,Yes,Yes,,Laurent Getaz,Geneva University Hospitals,Not Unity-Aligned,https://dx.doi.org/10.1108/IJPH-01-2022-0002,2022-11-03,2024-03-01,Unverified,getaz_sars-cov-2_2022,CHE
221115_Morges_UniversityofLausanne_Visit1,221115_Morges_UniversityofLausanne,SARS-CoV-2 neutralizing antibody response in vaccinated and non-vaccinated hospital healthcare workers with or without history of infection.,2022-11-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,Switzerland,,Morges,"""Participants over 18 years old were included on a voluntary basis after written informed consent at one of the following study visits: March 2021, June 2021, September 2021, and February 2022. """,,2021-03-01,2021-03-31,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,"March, 2021",587,0.4532,,,True,,,,True,Self-referral,Author designed (Luminex),,Luminex,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Damien Jacot,University of Lausanne,Not Unity-Aligned,https://dx.doi.org/10.1016/j.micinf.2022.105077,2022-12-15,2023-03-22,Unverified,jacot_sars-cov-2_2022-1,CHE
221121_Geneva_GenevaUniversityHospitals_Overall,221121_Geneva_GenevaUniversityHospitals,Persistent symptoms after SARS-CoV-2 infection in children: a cross-sectional population-based serological study.,2022-11-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Geneva,,"As per the study protocol, randomly selected children and adolescents
aged between 6 months and 17 years were invited to participate
with their family members.",Children were younger than 2 years. and participants with missing data were excluded.,2021-06-01,2021-07-07,Household and community samples,All,Children and Youth (0-17 years),2.0,17.0,Primary Estimate,,660,0.313,,,True,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.998,0.991,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Roxane Dumont,Geneva University Hospitals,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2022-063504,2022-12-07,2024-03-01,Unverified,dumont_persistent_2022,CHE
221121_Geneva_GenevaUniversityHospitals_Age2to5,221121_Geneva_GenevaUniversityHospitals,Persistent symptoms after SARS-CoV-2 infection in children: a cross-sectional population-based serological study.,2022-11-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Geneva,,"As per the study protocol, randomly selected children and adolescents
aged between 6 months and 17 years were invited to participate
with their family members.",Children were younger than 2 years. and participants with missing data were excluded.,2021-06-01,2021-07-07,Household and community samples,All,Children and Youth (0-17 years),2.0,5.0,Age,age: 2-5,147,0.197,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.998,0.991,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Roxane Dumont,Geneva University Hospitals,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2022-063504,2022-12-07,2024-03-01,Unverified,dumont_persistent_2022,CHE
221121_Geneva_GenevaUniversityHospitals_Male,221121_Geneva_GenevaUniversityHospitals,Persistent symptoms after SARS-CoV-2 infection in children: a cross-sectional population-based serological study.,2022-11-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Geneva,,"As per the study protocol, randomly selected children and adolescents
aged between 6 months and 17 years were invited to participate
with their family members.",Children were younger than 2 years. and participants with missing data were excluded.,2021-06-01,2021-07-07,Household and community samples,Male,Children and Youth (0-17 years),2.0,17.0,Sex/Gender,,334,0.329,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.998,0.991,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Roxane Dumont,Geneva University Hospitals,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2022-063504,2022-12-07,2024-03-01,Unverified,dumont_persistent_2022,CHE
221121_Geneva_GenevaUniversityHospitals_Age12to17,221121_Geneva_GenevaUniversityHospitals,Persistent symptoms after SARS-CoV-2 infection in children: a cross-sectional population-based serological study.,2022-11-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Geneva,,"As per the study protocol, randomly selected children and adolescents
aged between 6 months and 17 years were invited to participate
with their family members.",Children were younger than 2 years. and participants with missing data were excluded.,2021-06-01,2021-07-07,Household and community samples,All,Children and Youth (0-17 years),12.0,17.0,Age,age: 12-17,242,0.359,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.998,0.991,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Roxane Dumont,Geneva University Hospitals,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2022-063504,2022-12-07,2024-03-01,Unverified,dumont_persistent_2022,CHE
221121_Geneva_GenevaUniversityHospitals_Age6to11,221121_Geneva_GenevaUniversityHospitals,Persistent symptoms after SARS-CoV-2 infection in children: a cross-sectional population-based serological study.,2022-11-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Geneva,,"As per the study protocol, randomly selected children and adolescents
aged between 6 months and 17 years were invited to participate
with their family members.",Children were younger than 2 years. and participants with missing data were excluded.,2021-06-01,2021-07-07,Household and community samples,All,Children and Youth (0-17 years),6.0,11.0,Age,age: 6-11,271,0.336,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.998,0.991,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Roxane Dumont,Geneva University Hospitals,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2022-063504,2022-12-07,2024-03-01,Unverified,dumont_persistent_2022,CHE
221121_Geneva_GenevaUniversityHospitals_Female,221121_Geneva_GenevaUniversityHospitals,Persistent symptoms after SARS-CoV-2 infection in children: a cross-sectional population-based serological study.,2022-11-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Geneva,,"As per the study protocol, randomly selected children and adolescents
aged between 6 months and 17 years were invited to participate
with their family members.",Children were younger than 2 years. and participants with missing data were excluded.,2021-06-01,2021-07-07,Household and community samples,Female,Children and Youth (0-17 years),2.0,17.0,Sex/Gender,,326,0.297,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.998,0.991,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Roxane Dumont,Geneva University Hospitals,Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2022-063504,2022-12-07,2024-03-01,Unverified,dumont_persistent_2022,CHE
221129_Geneva_GenevaUniversityHospitals,221129_Geneva_GenevaUniversityHospitals,A population-based serological study of post-COVID syndrome prevalence and risk factors in children and adolescents.,2022-11-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Genève canton,Geneva,"""Children from the SEROCoV-KIDS cohort study (State of Geneva, Switzerland), aged 6 months to 17 years""","""Individuals with post-COVID syndrome after Omicron infection (these participants include those reporting post-COVID symptoms who would have had their infection prior to these dates, and thus prior to the Omicron surge)""; ""Children for whom we failed to take a blood sample were excluded from this analysis""",2021-12-15,2022-02-15,Household and community samples,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,,1034,0.5512572530000001,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.998,0.991,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,No,Roxane Dumont,Geneva University Hospitals,Unity-Aligned,https://dx.doi.org/10.1038/s41467-022-34616-8,2022-12-16,2024-04-23,Verified,dumont_population-based_2022,CHE
221129_Geneva_GenevaUniversityHospitals_Sex_Male,221129_Geneva_GenevaUniversityHospitals,A population-based serological study of post-COVID syndrome prevalence and risk factors in children and adolescents.,2022-11-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Genève canton,Geneva,"""Children from the SEROCoV-KIDS cohort study (State of Geneva, Switzerland), aged 6 months to 17 years""","""Individuals with post-COVID syndrome after Omicron infection (these participants include those reporting post-COVID symptoms who would have had their infection prior to these dates, and thus prior to the Omicron surge)""; ""Children for whom we failed to take a blood sample were excluded from this analysis""",2021-12-15,2022-02-15,Household and community samples,Male,Children and Youth (0-17 years),0.0,17.0,Sex/Gender,,505,0.5801980198,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.998,0.991,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,No,Roxane Dumont,Geneva University Hospitals,Unity-Aligned,https://dx.doi.org/10.1038/s41467-022-34616-8,2022-12-16,2024-04-23,Verified,dumont_population-based_2022,CHE
221129_Geneva_GenevaUniversityHospitals_Age_6-11,221129_Geneva_GenevaUniversityHospitals,A population-based serological study of post-COVID syndrome prevalence and risk factors in children and adolescents.,2022-11-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Genève canton,Geneva,"""Children from the SEROCoV-KIDS cohort study (State of Geneva, Switzerland), aged 6 months to 17 years""","""Individuals with post-COVID syndrome after Omicron infection (these participants include those reporting post-COVID symptoms who would have had their infection prior to these dates, and thus prior to the Omicron surge)""; ""Children for whom we failed to take a blood sample were excluded from this analysis""",2021-12-15,2022-02-15,Household and community samples,All,Children and Youth (0-17 years),6.0,11.0,Age,6-11,445,0.6,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.998,0.991,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,No,Roxane Dumont,Geneva University Hospitals,Unity-Aligned,https://dx.doi.org/10.1038/s41467-022-34616-8,2022-12-16,2024-04-23,Verified,dumont_population-based_2022,CHE
221129_Geneva_GenevaUniversityHospitals_Age_0-5,221129_Geneva_GenevaUniversityHospitals,A population-based serological study of post-COVID syndrome prevalence and risk factors in children and adolescents.,2022-11-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Genève canton,Geneva,"""Children from the SEROCoV-KIDS cohort study (State of Geneva, Switzerland), aged 6 months to 17 years""","""Individuals with post-COVID syndrome after Omicron infection (these participants include those reporting post-COVID symptoms who would have had their infection prior to these dates, and thus prior to the Omicron surge)""; ""Children for whom we failed to take a blood sample were excluded from this analysis""",2021-12-15,2022-02-15,Household and community samples,All,Children and Youth (0-17 years),0.0,5.0,Age,0-5,160,0.5,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.998,0.991,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,No,Roxane Dumont,Geneva University Hospitals,Unity-Aligned,https://dx.doi.org/10.1038/s41467-022-34616-8,2022-12-16,2024-04-23,Verified,dumont_population-based_2022,CHE
221129_Geneva_GenevaUniversityHospitals_Age_12-17,221129_Geneva_GenevaUniversityHospitals,A population-based serological study of post-COVID syndrome prevalence and risk factors in children and adolescents.,2022-11-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Genève canton,Geneva,"""Children from the SEROCoV-KIDS cohort study (State of Geneva, Switzerland), aged 6 months to 17 years""","""Individuals with post-COVID syndrome after Omicron infection (these participants include those reporting post-COVID symptoms who would have had their infection prior to these dates, and thus prior to the Omicron surge)""; ""Children for whom we failed to take a blood sample were excluded from this analysis""",2021-12-15,2022-02-15,Household and community samples,All,Children and Youth (0-17 years),12.0,17.0,Age,12-17,429,0.5198135198,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.998,0.991,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,No,Roxane Dumont,Geneva University Hospitals,Unity-Aligned,https://dx.doi.org/10.1038/s41467-022-34616-8,2022-12-16,2024-04-23,Verified,dumont_population-based_2022,CHE
221129_Geneva_GenevaUniversityHospitals_Sex_Female,221129_Geneva_GenevaUniversityHospitals,A population-based serological study of post-COVID syndrome prevalence and risk factors in children and adolescents.,2022-11-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Genève canton,Geneva,"""Children from the SEROCoV-KIDS cohort study (State of Geneva, Switzerland), aged 6 months to 17 years""","""Individuals with post-COVID syndrome after Omicron infection (these participants include those reporting post-COVID symptoms who would have had their infection prior to these dates, and thus prior to the Omicron surge)""; ""Children for whom we failed to take a blood sample were excluded from this analysis""",2021-12-15,2022-02-15,Household and community samples,Female,Children and Youth (0-17 years),0.0,17.0,Sex/Gender,,528,0.5227272727,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.998,0.991,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,No,Roxane Dumont,Geneva University Hospitals,Unity-Aligned,https://dx.doi.org/10.1038/s41467-022-34616-8,2022-12-16,2024-04-23,Verified,dumont_population-based_2022,CHE
221201_Geneva_GenevaUniversityHospitals,221201_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: A population-based study",2022-12-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Genève canton,Geneva,"""Individuals aged ≥6 months provided by the Geneva cantonal population registry (Office cantonal de la population et des migrations)"" OR individuals ""from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys (appendix 7)."" Note: randomly selected returning participants under age 18 were excluded. ","Hospitalized, in bad health conditions, not in Geneva during the whole study. Randomly selected returning participants <18 age. ",2022-04-29,2022-06-09,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,2521,0.938,0.9309999999999999,0.9450000000000001,True,True,True,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,No,No,Yes,Yes,Yes,No,María-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,https://doi.org/10.1016/j.lanepe.2022.100547,2022-12-16,2023-03-19,Unverified,zaballa_seroprevalence_2022-1,CHE
221201_Geneva_GenevaUniversityHospitals_Age_>=75,221201_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: A population-based study",2022-12-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Genève canton,Geneva,"""Individuals aged ≥6 months provided by the Geneva cantonal population registry (Office cantonal de la population et des migrations)"" OR individuals ""from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys (appendix 7)."" Note: randomly selected returning participants under age 18 were excluded. ","Hospitalized, in bad health conditions, not in Geneva during the whole study. Randomly selected returning participants <18 age. ",2022-04-29,2022-06-09,Household and community samples,All,Seniors (65+ years),75.0,,Age,>=75,174,0.9670000000000001,0.9620000000000001,0.971,,True,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,No,No,Yes,Yes,Yes,No,María-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,https://doi.org/10.1016/j.lanepe.2022.100547,2022-12-16,2023-03-19,Unverified,zaballa_seroprevalence_2022-1,CHE
221201_Geneva_GenevaUniversityHospitals_Age_65-74,221201_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: A population-based study",2022-12-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Genève canton,Geneva,"""Individuals aged ≥6 months provided by the Geneva cantonal population registry (Office cantonal de la population et des migrations)"" OR individuals ""from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys (appendix 7)."" Note: randomly selected returning participants under age 18 were excluded. ","Hospitalized, in bad health conditions, not in Geneva during the whole study. Randomly selected returning participants <18 age. ",2022-04-29,2022-06-09,Household and community samples,All,Seniors (65+ years),65.0,74.0,Age,65-74,183,0.951,0.943,0.9590000000000001,,True,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,No,No,Yes,Yes,Yes,No,María-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,https://doi.org/10.1016/j.lanepe.2022.100547,2022-12-16,2023-03-19,Unverified,zaballa_seroprevalence_2022-1,CHE
221201_Geneva_GenevaUniversityHospitals_Age_25-34,221201_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: A population-based study",2022-12-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Genève canton,Geneva,"""Individuals aged ≥6 months provided by the Geneva cantonal population registry (Office cantonal de la population et des migrations)"" OR individuals ""from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys (appendix 7)."" Note: randomly selected returning participants under age 18 were excluded. ","Hospitalized, in bad health conditions, not in Geneva during the whole study. Randomly selected returning participants <18 age. ",2022-04-29,2022-06-09,Household and community samples,All,Adults (18-64 years),25.0,34.0,Age,25-34,267,0.9490000000000001,0.937,0.9590000000000001,,True,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,No,No,Yes,Yes,Yes,No,María-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,https://doi.org/10.1016/j.lanepe.2022.100547,2022-12-16,2023-03-19,Unverified,zaballa_seroprevalence_2022-1,CHE
221201_Geneva_GenevaUniversityHospitals_Age_50-64,221201_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: A population-based study",2022-12-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Genève canton,Geneva,"""Individuals aged ≥6 months provided by the Geneva cantonal population registry (Office cantonal de la population et des migrations)"" OR individuals ""from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys (appendix 7)."" Note: randomly selected returning participants under age 18 were excluded. ","Hospitalized, in bad health conditions, not in Geneva during the whole study. Randomly selected returning participants <18 age. ",2022-04-29,2022-06-09,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50-64,400,0.9540000000000001,0.9470000000000001,0.961,,True,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,No,No,Yes,Yes,Yes,No,María-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,https://doi.org/10.1016/j.lanepe.2022.100547,2022-12-16,2023-03-19,Unverified,zaballa_seroprevalence_2022-1,CHE
221201_Geneva_GenevaUniversityHospitals_Age_35-49,221201_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: A population-based study",2022-12-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Genève canton,Geneva,"""Individuals aged ≥6 months provided by the Geneva cantonal population registry (Office cantonal de la population et des migrations)"" OR individuals ""from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys (appendix 7)."" Note: randomly selected returning participants under age 18 were excluded. ","Hospitalized, in bad health conditions, not in Geneva during the whole study. Randomly selected returning participants <18 age. ",2022-04-29,2022-06-09,Household and community samples,All,Adults (18-64 years),35.0,49.0,Age,35-49,787,0.9500000000000001,0.9420000000000001,0.9570000000000001,,True,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,No,No,Yes,Yes,Yes,No,María-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,https://doi.org/10.1016/j.lanepe.2022.100547,2022-12-16,2023-03-19,Unverified,zaballa_seroprevalence_2022-1,CHE
221201_Geneva_GenevaUniversityHospitals_Sex_Female,221201_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: A population-based study",2022-12-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Genève canton,Geneva,"""Individuals aged ≥6 months provided by the Geneva cantonal population registry (Office cantonal de la population et des migrations)"" OR individuals ""from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys (appendix 7)."" Note: randomly selected returning participants under age 18 were excluded. ","Hospitalized, in bad health conditions, not in Geneva during the whole study. Randomly selected returning participants <18 age. ",2022-04-29,2022-06-09,Household and community samples,Female,Multiple groups,0.0,,Sex/Gender,,1392,0.9420000000000001,0.934,0.9500000000000001,,True,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,No,No,Yes,Yes,Yes,No,María-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,https://doi.org/10.1016/j.lanepe.2022.100547,2022-12-16,2023-03-19,Unverified,zaballa_seroprevalence_2022-1,CHE
221201_Geneva_GenevaUniversityHospitals_Sex_Male,221201_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: A population-based study",2022-12-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Genève canton,Geneva,"""Individuals aged ≥6 months provided by the Geneva cantonal population registry (Office cantonal de la population et des migrations)"" OR individuals ""from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys (appendix 7)."" Note: randomly selected returning participants under age 18 were excluded. ","Hospitalized, in bad health conditions, not in Geneva during the whole study. Randomly selected returning participants <18 age. ",2022-04-29,2022-06-09,Household and community samples,Male,Multiple groups,0.0,,Sex/Gender,,1129,0.9329999999999999,0.924,0.9420000000000001,,True,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,No,No,Yes,Yes,Yes,No,María-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,https://doi.org/10.1016/j.lanepe.2022.100547,2022-12-16,2023-03-19,Unverified,zaballa_seroprevalence_2022-1,CHE
221201_Geneva_GenevaUniversityHospitals_Age_0-5,221201_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: A population-based study",2022-12-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Genève canton,Geneva,"""Individuals aged ≥6 months provided by the Geneva cantonal population registry (Office cantonal de la population et des migrations)"" OR individuals ""from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys (appendix 7)."" Note: randomly selected returning participants under age 18 were excluded. ","Hospitalized, in bad health conditions, not in Geneva during the whole study. Randomly selected returning participants <18 age. ",2022-04-29,2022-06-09,Household and community samples,All,Children and Youth (0-17 years),0.0,5.0,Age,0-5,144,0.772,0.703,0.833,,True,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,No,No,Yes,Yes,Yes,No,María-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,https://doi.org/10.1016/j.lanepe.2022.100547,2022-12-16,2023-03-19,Unverified,zaballa_seroprevalence_2022-1,CHE
221201_Geneva_GenevaUniversityHospitals_Age_18-24,221201_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: A population-based study",2022-12-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Genève canton,Geneva,"""Individuals aged ≥6 months provided by the Geneva cantonal population registry (Office cantonal de la population et des migrations)"" OR individuals ""from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys (appendix 7)."" Note: randomly selected returning participants under age 18 were excluded. ","Hospitalized, in bad health conditions, not in Geneva during the whole study. Randomly selected returning participants <18 age. ",2022-04-29,2022-06-09,Household and community samples,All,Adults (18-64 years),18.0,24.0,Age,18-24,169,0.9500000000000001,0.93,0.9690000000000001,,True,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,No,No,Yes,Yes,Yes,No,María-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,https://doi.org/10.1016/j.lanepe.2022.100547,2022-12-16,2023-03-19,Unverified,zaballa_seroprevalence_2022-1,CHE
221201_Geneva_GenevaUniversityHospitals_Age_12-17,221201_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: A population-based study",2022-12-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Genève canton,Geneva,"""Individuals aged ≥6 months provided by the Geneva cantonal population registry (Office cantonal de la population et des migrations)"" OR individuals ""from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys (appendix 7)."" Note: randomly selected returning participants under age 18 were excluded. ","Hospitalized, in bad health conditions, not in Geneva during the whole study. Randomly selected returning participants <18 age. ",2022-04-29,2022-06-09,Household and community samples,All,Children and Youth (0-17 years),12.0,17.0,Age,12-17,155,0.934,0.903,0.961,,True,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,No,No,Yes,Yes,Yes,No,María-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,https://doi.org/10.1016/j.lanepe.2022.100547,2022-12-16,2023-03-19,Unverified,zaballa_seroprevalence_2022-1,CHE
221201_Geneva_GenevaUniversityHospitals_Age_6-11,221201_Geneva_GenevaUniversityHospitals,"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: A population-based study",2022-12-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Genève canton,Geneva,"""Individuals aged ≥6 months provided by the Geneva cantonal population registry (Office cantonal de la population et des migrations)"" OR individuals ""from an age- and sex-stratified random sample of adults who participated in at least one of our previous serosurveys (appendix 7)."" Note: randomly selected returning participants under age 18 were excluded. ","Hospitalized, in bad health conditions, not in Geneva during the whole study. Randomly selected returning participants <18 age. ",2022-04-29,2022-06-09,Household and community samples,All,Children and Youth (0-17 years),6.0,11.0,Age,6-11,242,0.91,0.871,0.9440000000000001,,True,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,TotalAntibody,Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,No,No,Yes,Yes,Yes,No,María-Eugenia Zaballa,Geneva University Hospitals,Unity-Aligned,https://doi.org/10.1016/j.lanepe.2022.100547,2022-12-16,2023-03-19,Unverified,zaballa_seroprevalence_2022-1,CHE
230103_Zurich_UniversityofZurich_BDS,230103_Zurich_UniversityofZurich_BDS,Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region.,2023-01-03,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Switzerland,Canton of Zurich,,Blood donors in Zurich,,2019-12-01,2020-12-31,Blood donors,All,Adults (18-64 years),,,Primary Estimate,,16291,0.04,0.031000000000000003,0.051,True,,True,,True,Sequential,Author designed (type unknown),,Other,Serum,IgG,Spike,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Marc Emmenegger,University of Zurich,Not Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.105928,2023-02-10,2023-03-19,Unverified,emmenegger_continuous_2023,CHE
230103_Zurich_UniversityofZurich_USZ,230103_Zurich_UniversityofZurich_USZ,Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region.,2023-01-03,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Switzerland,Canton of Zurich,,University Hospital of Zurich patients,,2019-12-01,2020-12-31,Residual sera,All,Adults (18-64 years),,,Primary Estimate,,37745,0.063,0.055,0.07200000000000001,True,,,,True,Convenience,Author designed (type unknown),,Other,Serum,IgG,Spike,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Marc Emmenegger,University of Zurich,Not Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2023.105928,2023-02-10,2023-03-19,Unverified,emmenegger_continuous_2023,CHE
230112_Ticino_UniversitaDellaSvizzeraItaliana,230112_Ticino_UniversitaDellaSvizzeraItaliana,Prevalence and association of frailty with SARS-CoV-2 infection in older adults in Southern Switzerland-Findings from the Corona Immunitas Ticino Study,2023-01-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Canton Ticino,,"""In September 2020, we recruited a random sample of community-dwelling older adults (65 +) in the Corona Immunitas Ticino prospective cohort study (CIT)"".

""For this study on frailty, we considered 874 older adults aged 65 years and older, who agreed to participate in September and November 2020, provided informed consent and responded to the baseline questionnaire.""","""Of these, we excluded 114 participants due to missing values for the computation of the FI"".

""To test whether frailty was associated with SARS-CoV-2 infection, we further excluded 179 participants who did not perform or lacked a valid serological test result, resulting in sub-sample of 481 participants.""",2020-11-15,2021-01-15,Household and community samples,All,Seniors (65+ years),65.0,,Primary Estimate,,481,0.11230000000000001,,,True,,,,True,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,"other, CLIA",Serum,"IgG, IgA",Spike,,,,['High'],,Yes,No,No,,Unclear,Yes,No,,Miao Jiang,Università della Svizzera italiana,Not Unity-Aligned,https://dx.doi.org/10.1186/s12877-023-03730-7,2023-01-23,2023-03-19,Unverified,jiang_prevalence_2023,CHE
230115_Switzerland_UniversityofLausanne_Overall,230115_Switzerland_UniversityofLausanne,"SARS-CoV-2 Seroprevalence in Employees of Four Essential Non-Health Care Sectors at Moderate/High Risk of Exposure to Coronavirus Infection: Data from the ""first Wave""",2023-01-15,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Canton of Vaud,,"This cross-sectional study was conducted among workers of four companies operating in essential sectors in the Canton of Vaud, Switzerland. Study participants were bus drivers of a public transport company and employees of the following workplaces: five stores of a food supermarket company, a mail-sorting center of a postal service, and four sites of a laundry operating in the health care sector.",We excluded 27 employees who reported entirely working from home from the seroprevalence analyses because they were not at a higher risk of occupational SARS-CoV-2 exposure than the general population. The final study population of 428 employees was “participants working on site”. ,2020-05-25,2020-07-07,Essential non-healthcare workers,All,Multiple groups,,,Primary Estimate,overall IgG+IgA sero-prevalence in essential workers.,428,0.159,0.126,0.197,True,,,,True,Self-referral,Author designed (Luminex),,Luminex,,"['IgA', 'IgG']",Spike,Validated by developers,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Giulia Belloni,University of Lausanne,Not Unity-Aligned,https://dx.doi.org/10.1097/JOM.0000000000002690,2023-02-06,2023-03-19,Unverified,belloni_sars-cov-2_2023,CHE
220130_Zurich_UniversityOfZurich_T4_PopTestAdj_Overall,220130_Zurich_UniversityOfZurich_T4,Heterogeneous evolution of SARS-CoV-2 seroprevalence in school-age children: Results from the school-based cohort study Ciao Corona in November-December 2021 in the canton of Zurich.,2023-01-30,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Switzerland,Canton of Zürich,,"""As described elsewhere, 23 public and private primary schools in the canton of Zurich were randomly selected in May 2020, and the geographically closest secondary school was also invited.""

""In the fourth round of testing, from November to December 2021, some schools declined to continue, reducing the total number of schools included from 55 to 43.""","The main exclusion criterion was having a suspected or confirmed SARS-CoV-2 infection at the time of testing, which precluded attendance at school.",2021-11-15,2021-12-14,Students and Daycares,All,Children and Youth (0-17 years),7.0,17.0,Primary Estimate,,1875,0.46399999999999997,0.42600000000000005,0.509,True,True,True,,True,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,"['IgA', 'IgG']",Spike,Validated by manufacturers,0.9400000000000001,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Sarah Haile,University of Zurich,Not Unity-Aligned,https://dx.doi.org/10.57187/smw.2023.40035,2022-10-14,2023-03-10,Unverified,heterogeneous_haile_2023,CHE
220130_Zurich_UniversityOfZurich_T4_PopTestAdj_Age13-17,220130_Zurich_UniversityOfZurich_T4,Heterogeneous evolution of SARS-CoV-2 seroprevalence in school-age children: Results from the school-based cohort study Ciao Corona in November-December 2021 in the canton of Zurich.,2023-01-30,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Switzerland,Canton of Zürich,,"""As described elsewhere, 23 public and private primary schools in the canton of Zurich were randomly selected in May 2020, and the geographically closest secondary school was also invited.""

""In the fourth round of testing, from November to December 2021, some schools declined to continue, reducing the total number of schools included from 55 to 43.""","The main exclusion criterion was having a suspected or confirmed SARS-CoV-2 infection at the time of testing, which precluded attendance at school.",2021-11-15,2021-12-14,Students and Daycares,All,Children and Youth (0-17 years),13.0,17.0,Age,Age group: 13-17 (secondary school; grades 7-9),825,0.758,0.696,0.8240000000000001,,True,True,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,"['IgA', 'IgG']",Spike,Validated by manufacturers,0.9400000000000001,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Sarah Haile,University of Zurich,Not Unity-Aligned,https://dx.doi.org/10.57187/smw.2023.40035,2022-10-14,2023-03-10,Unverified,heterogeneous_haile_2023,CHE
220130_Zurich_UniversityOfZurich_T4_PopTestAdj_Age7-12,220130_Zurich_UniversityOfZurich_T4,Heterogeneous evolution of SARS-CoV-2 seroprevalence in school-age children: Results from the school-based cohort study Ciao Corona in November-December 2021 in the canton of Zurich.,2023-01-30,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Switzerland,Canton of Zürich,,"""As described elsewhere, 23 public and private primary schools in the canton of Zurich were randomly selected in May 2020, and the geographically closest secondary school was also invited.""

""In the fourth round of testing, from November to December 2021, some schools declined to continue, reducing the total number of schools included from 55 to 43.""","The main exclusion criterion was having a suspected or confirmed SARS-CoV-2 infection at the time of testing, which precluded attendance at school.",2021-11-15,2021-12-14,Students and Daycares,All,Children and Youth (0-17 years),7.0,12.0,Age,Age group: 7-12 (primary school; grades 1-6),1050,0.315,0.271,0.36100000000000004,,True,True,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,"['IgA', 'IgG']",Spike,Validated by manufacturers,0.9400000000000001,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Sarah Haile,University of Zurich,Not Unity-Aligned,https://dx.doi.org/10.57187/smw.2023.40035,2022-10-14,2023-03-10,Unverified,heterogeneous_haile_2023,CHE
220130_Zurich_UniversityOfZurich_T2_PopTestAdj_Overall,230130_Zurich_UniversityOfZurich_T2,Heterogeneous evolution of SARS-CoV-2 seroprevalence in school-age children: Results from the school-based cohort study Ciao Corona in November-December 2021 in the canton of Zurich.,2023-01-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Canton of Zürich,,"As described elsewhere,22 primary schools in the canton of Zurich were randomly selected in May 2020, and the geographically closest secondary school was also invited. The 55 participating schools were distributed in each of the 12 geographic districts proportional to the population size. Within participating schools, classes were randomly selected, stratified by school level: lower level (grades 1-2, age 6-9), middle level (grades 4-5, age 9-12), and upper level (grades 7-8, age 12-16. The aim was to invite at least 3 classes, with at least 40 children in each school level at a school. The invited sample is representative of the school-age population in the canton of Zurich.","The main exclusion criterion was having a suspected or confirmed SARS-CoV-2 infection at the time of testing, which precluded attendance at school.",2020-10-26,2020-11-19,Students and Daycares,All,Children and Youth (0-17 years),7.0,17.0,Primary Estimate,,2500,0.055999999999999994,0.035,0.076,True,True,True,,True,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,"['IgA', 'IgG']",Spike,Validated by manufacturers,0.9400000000000001,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Sarah Haile,University of Zurich,Not Unity-Aligned,https://dx.doi.org/10.57187/smw.2023.40035,2022-06-07,2023-03-10,Unverified,heterogeneous_haile_2023,CHE
220130_Zurich_UniversityOfZurich_T2_PopTestAdj_Age7-12,230130_Zurich_UniversityOfZurich_T2,Heterogeneous evolution of SARS-CoV-2 seroprevalence in school-age children: Results from the school-based cohort study Ciao Corona in November-December 2021 in the canton of Zurich.,2023-01-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Canton of Zürich,,"As described elsewhere,22 primary schools in the canton of Zurich were randomly selected in May 2020, and the geographically closest secondary school was also invited. The 55 participating schools were distributed in each of the 12 geographic districts proportional to the population size. Within participating schools, classes were randomly selected, stratified by school level: lower level (grades 1-2, age 6-9), middle level (grades 4-5, age 9-12), and upper level (grades 7-8, age 12-16. The aim was to invite at least 3 classes, with at least 40 children in each school level at a school. The invited sample is representative of the school-age population in the canton of Zurich.","The main exclusion criterion was having a suspected or confirmed SARS-CoV-2 infection at the time of testing, which precluded attendance at school.",2020-10-26,2020-11-19,Students and Daycares,All,Children and Youth (0-17 years),7.0,12.0,Age,Age group: 7-12 (primary school; grades 1-6),1594,0.055,0.034,0.078,,True,True,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,"['IgA', 'IgG']",Spike,Validated by manufacturers,0.9400000000000001,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Sarah Haile,University of Zurich,Not Unity-Aligned,https://dx.doi.org/10.57187/smw.2023.40035,2022-10-14,2023-03-10,Unverified,heterogeneous_haile_2023,CHE
220130_Zurich_UniversityOfZurich_T2_PopTestAdj_Age13-17,230130_Zurich_UniversityOfZurich_T2,Heterogeneous evolution of SARS-CoV-2 seroprevalence in school-age children: Results from the school-based cohort study Ciao Corona in November-December 2021 in the canton of Zurich.,2023-01-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Canton of Zürich,,"As described elsewhere,22 primary schools in the canton of Zurich were randomly selected in May 2020, and the geographically closest secondary school was also invited. The 55 participating schools were distributed in each of the 12 geographic districts proportional to the population size. Within participating schools, classes were randomly selected, stratified by school level: lower level (grades 1-2, age 6-9), middle level (grades 4-5, age 9-12), and upper level (grades 7-8, age 12-16. The aim was to invite at least 3 classes, with at least 40 children in each school level at a school. The invited sample is representative of the school-age population in the canton of Zurich.","The main exclusion criterion was having a suspected or confirmed SARS-CoV-2 infection at the time of testing, which precluded attendance at school.",2020-10-26,2020-11-19,Students and Daycares,All,Children and Youth (0-17 years),13.0,17.0,Age,Age group: 13-17 (secondary school; grades 7-9),906,0.055999999999999994,0.027999999999999997,0.087,,True,True,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Serum,"['IgA', 'IgG']",Spike,Validated by manufacturers,0.9400000000000001,0.9920000000000001,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Sarah Haile,University of Zurich,Not Unity-Aligned,https://dx.doi.org/10.57187/smw.2023.40035,2022-10-14,2023-03-10,Unverified,heterogeneous_haile_2023,CHE
230219_Ticino_UniversitadellaSvizzeraitaliana_Serosurvey1,230219_Ticino_UniversitadellaSvizzeraitaliana_Serosurvey1,"Trajectories of Seroprevalence and Neutralizing Activity of Antibodies against SARS-CoV-2 in Southern Switzerland between July 2020 and July 2021: An Ongoing, Prospective Population-Based Cohort Study.",2023-02-19,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Switzerland,Ticino Canton,,"""Corona Immunitas Ticino” is a population-based cohort study of a representativesample of community-dwelling residents of Ticino (southern Switzerland) aged five years and older""",NR ,2020-07-15,2020-07-31,Household and community samples,All,Adults (18-64 years),20.0,64.0,Primary Estimate,,646,0.078,0.054,0.104,True,True,True,,True,Convenience,Author designed (Luminex),,Luminex,,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Rebecca Amati,Università della Svizzera italiana,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph20043703,2023-04-06,2023-04-11,Unverified,amati_trajectories_2023,CHE
230219_Ticino_UniversitadellaSvizzeraitaliana_Serosurvey2,230219_Ticino_UniversitadellaSvizzeraitaliana_Serosurvey2,"Trajectories of Seroprevalence and Neutralizing Activity of Antibodies against SARS-CoV-2 in Southern Switzerland between July 2020 and July 2021: An Ongoing, Prospective Population-Based Cohort Study.",2023-02-19,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Switzerland,Ticino Canton,,"""Corona Immunitas Ticino” is a population-based cohort study of a representativesample of community-dwelling residents of Ticino (southern Switzerland) aged five years and older""",NR ,2020-11-16,2020-12-15,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,,1457,0.202,0.164,0.244,True,True,True,,True,Convenience,Author designed (Luminex),,Luminex,,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Rebecca Amati,Università della Svizzera italiana,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph20043703,2023-04-06,2023-04-11,Unverified,amati_trajectories_2023,CHE
230219_Ticino_UniversitadellaSvizzeraitaliana_Serosurvey3,230219_Ticino_UniversitadellaSvizzeraitaliana_Serosurvey3,"Trajectories of Seroprevalence and Neutralizing Activity of Antibodies against SARS-CoV-2 in Southern Switzerland between July 2020 and July 2021: An Ongoing, Prospective Population-Based Cohort Study.",2023-02-19,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Switzerland,Ticino Canton,,"""Corona Immunitas Ticino” is a population-based cohort study of a representativesample of community-dwelling residents of Ticino (southern Switzerland) aged five years and older""",NR ,2021-06-01,2021-07-15,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,,885,0.725,0.691,0.764,True,True,True,,True,Convenience,Author designed (Luminex),,Luminex,,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Rebecca Amati,Università della Svizzera italiana,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph20043703,2023-04-06,2023-04-11,Unverified,amati_trajectories_2023,CHE
230304_Switzerland_UniversityOfFribourg_Period1_Overall_PopTestAdj,230304_Switzerland_UniversityOfFribourg_Period1,Seroprevalence trends of anti-SARS-CoV-2 antibodies and associated risk factors: a population-based study.,2023-03-04,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Switzerland,"Basel-Landschaft, Basel-Stadt, Bern, Fribourg, Grisons, Lucerne, Neuchâtel, Saint Gallen, Ticino, Vaud, Zurich",,"""This study is part of Corona Immunitas [16]. Repeated population-based serological studies were conducted in different regions of Switzerland.""

""We included 13,291 participants (in period 1 n = 3402, in period 2 n = 5611, and in period 3 n = 4278) aged 20 and older from 11 Swiss cantons (Additional file1: Fig. S1).""","Based on Figure S2:
- participants under 20 years of age;
- participants with missing serology data.
""For the second objective of this study, we excluded participants who completed the questionnaire more than 30 days before or after having provided the blood sample for the serology test. The reason for this exclusion was to avoid a possible mismatch between serology results and information reported in the questionnaires (preventive behaviours, health status and socioeconomic status). For the same reason, we also excluded participants who provided information on vaccination status more than 11 days before or after providing the blood sample for the serology test.""",2020-05-01,2020-10-31,Household and community samples,All,Multiple groups,20.0,,Primary Estimate,National level,3402,0.037,0.021,0.049,True,True,True,,True,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,"other, CLIA",Serum,IgG,Spike,Validated by developers,0.966,0.997,['Low'],Yes,Yes,Yes,Yes,No,Unclear,Yes,Yes,No,Stefano Tancredi,University of Fribourg,Unity-Aligned,https://dx.doi.org/10.1007/s15010-023-02011-0,2023-04-11,2024-04-12,Verified,tancredi_seroprevalence_2023,CHE
230304_Switzerland_UniversityOfFribourg_Period1_65+,230304_Switzerland_UniversityOfFribourg_Period1,Seroprevalence trends of anti-SARS-CoV-2 antibodies and associated risk factors: a population-based study.,2023-03-04,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Switzerland,"Basel-Landschaft, Basel-Stadt, Bern, Fribourg, Grisons, Lucerne, Neuchâtel, Saint Gallen, Ticino, Vaud, Zurich",,"""This study is part of Corona Immunitas [16]. Repeated population-based serological studies were conducted in different regions of Switzerland.""

""We included 13,291 participants (in period 1 n = 3402, in period 2 n = 5611, and in period 3 n = 4278) aged 20 and older from 11 Swiss cantons (Additional file1: Fig. S1).""","Based on Figure S2:
- participants under 20 years of age;
- participants with missing serology data.
""For the second objective of this study, we excluded participants who completed the questionnaire more than 30 days before or after having provided the blood sample for the serology test. The reason for this exclusion was to avoid a possible mismatch between serology results and information reported in the questionnaires (preventive behaviours, health status and socioeconomic status). For the same reason, we also excluded participants who provided information on vaccination status more than 11 days before or after providing the blood sample for the serology test.""",2020-05-01,2020-10-31,Household and community samples,All,Seniors (65+ years),65.0,,Age,65+,1097,0.023,0.007,0.039,,,True,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,"other, CLIA",Serum,IgG,Spike,Validated by developers,0.966,0.997,['Low'],Yes,Yes,Yes,Yes,No,Unclear,Yes,Yes,No,Stefano Tancredi,University of Fribourg,Unity-Aligned,https://dx.doi.org/10.1007/s15010-023-02011-0,2024-04-12,2024-04-12,Verified,tancredi_seroprevalence_2023,CHE
230304_Switzerland_UniversityOfFribourg_Period1_20-64,230304_Switzerland_UniversityOfFribourg_Period1,Seroprevalence trends of anti-SARS-CoV-2 antibodies and associated risk factors: a population-based study.,2023-03-04,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Switzerland,"Basel-Landschaft, Basel-Stadt, Bern, Fribourg, Grisons, Lucerne, Neuchâtel, Saint Gallen, Ticino, Vaud, Zurich",,"""This study is part of Corona Immunitas [16]. Repeated population-based serological studies were conducted in different regions of Switzerland.""

""We included 13,291 participants (in period 1 n = 3402, in period 2 n = 5611, and in period 3 n = 4278) aged 20 and older from 11 Swiss cantons (Additional file1: Fig. S1).""","Based on Figure S2:
- participants under 20 years of age;
- participants with missing serology data.
""For the second objective of this study, we excluded participants who completed the questionnaire more than 30 days before or after having provided the blood sample for the serology test. The reason for this exclusion was to avoid a possible mismatch between serology results and information reported in the questionnaires (preventive behaviours, health status and socioeconomic status). For the same reason, we also excluded participants who provided information on vaccination status more than 11 days before or after providing the blood sample for the serology test.""",2020-05-01,2020-10-31,Household and community samples,All,Adults (18-64 years),20.0,64.0,Age,20-64,2305,0.041,0.025,0.055,,,True,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,"other, CLIA",Serum,IgG,Spike,Validated by developers,0.966,0.997,['Low'],Yes,Yes,Yes,Yes,No,Unclear,Yes,Yes,No,Stefano Tancredi,University of Fribourg,Unity-Aligned,https://dx.doi.org/10.1007/s15010-023-02011-0,2024-04-12,2024-04-12,Verified,tancredi_seroprevalence_2023,CHE
230304_Switzerland_UniversityOfFribourg_Period2_Overall_PopTestAdj,230304_Switzerland_UniversityOfFribourg_Period2,Seroprevalence trends of anti-SARS-CoV-2 antibodies and associated risk factors: a population-based study.,2023-03-04,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Switzerland,"Basel-Landschaft, Basel-Stadt, Bern, Fribourg, Grisons, Lucerne, Neuchâtel, Saint Gallen, Ticino, Vaud, Zurich",,"""This study is part of Corona Immunitas [16]. Repeated population-based serological studies were conducted in different regions of Switzerland.""

""We included 13,291 participants (in period 1 n = 3402, in period 2 n = 5611, and in period 3 n = 4278) aged 20 and older from 11 Swiss cantons (Additional file1: Fig. S1).""","Based on Figure S2:
- participants under 20 years of age;
- participants with missing serology data.
""For the second objective of this study, we excluded participants who completed the questionnaire more than 30 days before or after having provided the blood sample for the serology test. The reason for this exclusion was to avoid a possible mismatch between serology results and information reported in the questionnaires (preventive behaviours, health status and socioeconomic status). For the same reason, we also excluded participants who provided information on vaccination status more than 11 days before or after providing the blood sample for the serology test.""",2020-11-01,2021-05-15,Household and community samples,All,Multiple groups,20.0,,Primary Estimate,National level,5611,0.162,0.144,0.175,True,True,True,,True,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,"other, CLIA",Serum,IgG,Spike,Validated by developers,0.966,0.997,['Low'],Yes,Yes,Yes,Yes,No,Unclear,Yes,Yes,No,Stefano Tancredi,University of Fribourg,Unity-Aligned,https://dx.doi.org/10.1007/s15010-023-02011-0,2023-04-12,2024-04-12,Verified,tancredi_seroprevalence_2023,CHE
230304_Switzerland_UniversityOfFribourg_Period2_65+,230304_Switzerland_UniversityOfFribourg_Period2,Seroprevalence trends of anti-SARS-CoV-2 antibodies and associated risk factors: a population-based study.,2023-03-04,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Switzerland,"Basel-Landschaft, Basel-Stadt, Bern, Fribourg, Grisons, Lucerne, Neuchâtel, Saint Gallen, Ticino, Vaud, Zurich",,"""This study is part of Corona Immunitas [16]. Repeated population-based serological studies were conducted in different regions of Switzerland.""

""We included 13,291 participants (in period 1 n = 3402, in period 2 n = 5611, and in period 3 n = 4278) aged 20 and older from 11 Swiss cantons (Additional file1: Fig. S1).""","Based on Figure S2:
- participants under 20 years of age;
- participants with missing serology data.
""For the second objective of this study, we excluded participants who completed the questionnaire more than 30 days before or after having provided the blood sample for the serology test. The reason for this exclusion was to avoid a possible mismatch between serology results and information reported in the questionnaires (preventive behaviours, health status and socioeconomic status). For the same reason, we also excluded participants who provided information on vaccination status more than 11 days before or after providing the blood sample for the serology test.""",2020-11-01,2021-05-15,Household and community samples,All,Seniors (65+ years),65.0,,Age,65+,2450,0.171,0.15,0.19,,,True,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,"other, CLIA",Serum,IgG,Spike,Validated by developers,0.966,0.997,['Low'],Yes,Yes,Yes,Yes,No,Unclear,Yes,Yes,No,Stefano Tancredi,University of Fribourg,Unity-Aligned,https://dx.doi.org/10.1007/s15010-023-02011-0,2024-04-12,2024-04-12,Verified,tancredi_seroprevalence_2023,CHE
230304_Switzerland_UniversityOfFribourg_Period2_20-64,230304_Switzerland_UniversityOfFribourg_Period2,Seroprevalence trends of anti-SARS-CoV-2 antibodies and associated risk factors: a population-based study.,2023-03-04,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Switzerland,"Basel-Landschaft, Basel-Stadt, Bern, Fribourg, Grisons, Lucerne, Neuchâtel, Saint Gallen, Ticino, Vaud, Zurich",,"""This study is part of Corona Immunitas [16]. Repeated population-based serological studies were conducted in different regions of Switzerland.""

""We included 13,291 participants (in period 1 n = 3402, in period 2 n = 5611, and in period 3 n = 4278) aged 20 and older from 11 Swiss cantons (Additional file1: Fig. S1).""","Based on Figure S2:
- participants under 20 years of age;
- participants with missing serology data.
""For the second objective of this study, we excluded participants who completed the questionnaire more than 30 days before or after having provided the blood sample for the serology test. The reason for this exclusion was to avoid a possible mismatch between serology results and information reported in the questionnaires (preventive behaviours, health status and socioeconomic status). For the same reason, we also excluded participants who provided information on vaccination status more than 11 days before or after providing the blood sample for the serology test.""",2020-11-01,2021-05-15,Household and community samples,All,Adults (18-64 years),20.0,64.0,Age,20-64,3160,0.158,0.139,0.174,,,True,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,"other, CLIA",Serum,IgG,Spike,Validated by developers,0.966,0.997,['Low'],Yes,Yes,Yes,Yes,No,Unclear,Yes,Yes,No,Stefano Tancredi,University of Fribourg,Unity-Aligned,https://dx.doi.org/10.1007/s15010-023-02011-0,2024-04-12,2024-04-12,Verified,tancredi_seroprevalence_2023,CHE
230304_Switzerland_UniversityOfFribourg_Period3_Overall_PopTestAdj,230304_Switzerland_UniversityOfFribourg_Period3,Seroprevalence trends of anti-SARS-CoV-2 antibodies and associated risk factors: a population-based study.,2023-03-04,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Switzerland,"Basel-Landschaft, Basel-Stadt, Bern, Fribourg, Grisons, Lucerne, Neuchâtel, Saint Gallen, Ticino, Vaud, Zurich",,"""This study is part of Corona Immunitas [16]. Repeated population-based serological studies were conducted in different regions of Switzerland.""

""We included 13,291 participants (in period 1 n = 3402, in period 2 n = 5611, and in period 3 n = 4278) aged 20 and older from 11 Swiss cantons (Additional file1: Fig. S1).""","Based on Figure S2:
- participants under 20 years of age;
- participants with missing serology data.
""For the second objective of this study, we excluded participants who completed the questionnaire more than 30 days before or after having provided the blood sample for the serology test. The reason for this exclusion was to avoid a possible mismatch between serology results and information reported in the questionnaires (preventive behaviours, health status and socioeconomic status). For the same reason, we also excluded participants who provided information on vaccination status more than 11 days before or after providing the blood sample for the serology test.""",2021-05-16,2021-09-30,Household and community samples,All,Multiple groups,20.0,,Primary Estimate,National level,4278,0.72,0.703,0.738,True,True,True,,True,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,"other, CLIA",Serum,IgG,Spike,Validated by developers,0.966,0.997,['Low'],Yes,Yes,Yes,Yes,No,Unclear,Yes,Yes,No,Stefano Tancredi,University of Fribourg,Unity-Aligned,https://dx.doi.org/10.1007/s15010-023-02011-0,2023-04-12,2024-04-12,Verified,tancredi_seroprevalence_2023,CHE
230304_Switzerland_UniversityOfFribourg_Period3_20-64,230304_Switzerland_UniversityOfFribourg_Period3,Seroprevalence trends of anti-SARS-CoV-2 antibodies and associated risk factors: a population-based study.,2023-03-04,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Switzerland,"Basel-Landschaft, Basel-Stadt, Bern, Fribourg, Grisons, Lucerne, Neuchâtel, Saint Gallen, Ticino, Vaud, Zurich",,"""This study is part of Corona Immunitas [16]. Repeated population-based serological studies were conducted in different regions of Switzerland.""

""We included 13,291 participants (in period 1 n = 3402, in period 2 n = 5611, and in period 3 n = 4278) aged 20 and older from 11 Swiss cantons (Additional file1: Fig. S1).""","Based on Figure S2:
- participants under 20 years of age;
- participants with missing serology data.
""For the second objective of this study, we excluded participants who completed the questionnaire more than 30 days before or after having provided the blood sample for the serology test. The reason for this exclusion was to avoid a possible mismatch between serology results and information reported in the questionnaires (preventive behaviours, health status and socioeconomic status). For the same reason, we also excluded participants who provided information on vaccination status more than 11 days before or after providing the blood sample for the serology test.""",2021-05-16,2021-09-30,Household and community samples,All,Adults (18-64 years),20.0,64.0,Age,20-64,2585,0.659,0.638,0.681,,,True,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,"other, CLIA",Serum,IgG,Spike,Validated by developers,0.966,0.997,['Low'],Yes,Yes,Yes,Yes,No,Unclear,Yes,Yes,No,Stefano Tancredi,University of Fribourg,Unity-Aligned,https://dx.doi.org/10.1007/s15010-023-02011-0,2024-04-12,2024-04-12,Verified,tancredi_seroprevalence_2023,CHE
230304_Switzerland_UniversityOfFribourg_Period3_65+,230304_Switzerland_UniversityOfFribourg_Period3,Seroprevalence trends of anti-SARS-CoV-2 antibodies and associated risk factors: a population-based study.,2023-03-04,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Switzerland,"Basel-Landschaft, Basel-Stadt, Bern, Fribourg, Grisons, Lucerne, Neuchâtel, Saint Gallen, Ticino, Vaud, Zurich",,"""This study is part of Corona Immunitas [16]. Repeated population-based serological studies were conducted in different regions of Switzerland.""

""We included 13,291 participants (in period 1 n = 3402, in period 2 n = 5611, and in period 3 n = 4278) aged 20 and older from 11 Swiss cantons (Additional file1: Fig. S1).""","Based on Figure S2:
- participants under 20 years of age;
- participants with missing serology data.
""For the second objective of this study, we excluded participants who completed the questionnaire more than 30 days before or after having provided the blood sample for the serology test. The reason for this exclusion was to avoid a possible mismatch between serology results and information reported in the questionnaires (preventive behaviours, health status and socioeconomic status). For the same reason, we also excluded participants who provided information on vaccination status more than 11 days before or after providing the blood sample for the serology test.""",2021-05-16,2021-09-30,Household and community samples,All,Seniors (65+ years),65.0,,Age,65+,1693,0.92,0.902,0.942,,,True,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,"other, CLIA",Serum,IgG,Spike,Validated by developers,0.966,0.997,['Low'],Yes,Yes,Yes,Yes,No,Unclear,Yes,Yes,No,Stefano Tancredi,University of Fribourg,Unity-Aligned,https://dx.doi.org/10.1007/s15010-023-02011-0,2024-04-12,2024-04-12,Verified,tancredi_seroprevalence_2023,CHE
230311_ Vaud_CenterforPrimaryCareandPublicHealth,230311_ Vaud_CenterforPrimaryCareandPublicHealth,"Prevalence of SARS-CoV-2 infection and associated risk factors among asylum seekers living in asylum centres: A cross-sectional serologic study in Canton of Vaud, Switzerland.",2023-03-11,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Vaud,,"""conducted in two asylum centres (Centre 1 and Centre 2) in the canton of Vaud ... The two centres are accommodation centres for people who have applied for asylum in Switzerland and whose application is either pending, provisionally accepted, accepted or rejected. We considered all residents of these centres as asylum seekers and refugees.""",,2020-05-04,2020-06-27,Residual sera,All,Multiple groups,,,Primary Estimate,,124,0.258,,,True,,,,True,Convenience,Not reported/ Unable to specify,,Luminex,Serum,"['IgA', 'IgG']",,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Kevin Morisod,Center for Primary Care and Public Health,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jmh.2023.100175,2023-04-03,2023-04-12,Unverified,morisod_prevalence_2023,CHE
230321_Switzerland_UniversityofNottingham,230321_Switzerland_UniversityofNottingham,Association between serologically confirmed COVID-19 infection and cognitive functioning in community dwelling older adults.,2023-03-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Switzerland,,Zurich,"""This study used data from the Corona Immunitas study (42) from the Canton of Zurich, Switzerland. Randomly selected individuals from the general population were invited to take part in the study via letter or email. Individuals aged ≥65 years who agreed to participate in Corona Immunitas were asked to take part also in an additional study focusing on cognition (SwissDEM). To this additional study 657 individuals, who self-reported lack of diagnosis of dementia, participated and comprised the current study sample. """,,2020-10-15,2021-05-15,Household and community samples,All,Seniors (65+ years),65.0,,Primary Estimate,,657,0.0563,,,True,,,,True,Convenience,Not reported/ Unable to specify,,Luminex,Whole Blood,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Sabatini Serena,University of Nottingham,Not Unity-Aligned,https://dx.doi.org/10.3389/fneur.2023.1093852,2023-05-03,2023-05-09,Unverified,serena_association_2023,CHE
230417_CantonOfVaud_UniversityOfLausanne_CloseContacts,230417_CantonOfVaud_UniversityOfLausanne_CloseContacts,Association of plasma zinc levels with anti-SARS-CoV-2 IgG and IgA seropositivity in the general population: A case-control study.,2023-04-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Canton of Vaud,,"Participants were eligible for inclusion in the survey and blood sample reuse if they were aged 14 years or older, resided in the Canton of Vaud.","excluded if they could not give their informed consent. The study flowchart is shown in Fig. 1: study participants with missing data on variables of interest were excluded (IgG and IgA serostatus, age, gender, anthropometric data, smoking status, Zn, Se, Cu, 25(OH)D 3and CRP plasma levels).",2020-05-15,2020-06-15,Contacts of COVID patients,All,Multiple groups,,,Primary Estimate,,286,0.4895,,,True,,,,True,Convenience,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Plasma,"['IgA', 'IgG']",Spike,Validated by developers,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Antoine Equey,University of Lausanne,Not Unity-Aligned,https://dx.doi.org/10.1016/j.clnu.2023.04.007,2023-05-30,2023-05-31,Unverified,equey_association_2023,CHE
230417_CantonOfVaud_UniversityOfLausanne_GeneralPop,230417_CantonOfVaud_UniversityOfLausanne_GeneralPop,Association of plasma zinc levels with anti-SARS-CoV-2 IgG and IgA seropositivity in the general population: A case-control study.,2023-04-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Switzerland,Canton of Vaud,,"Participants were eligible for inclusion in the survey and blood sample reuse if they were aged 14 years or older, resided in the Canton of Vaud.","excluded if they could not give their informed consent. The study flowchart is shown in Fig. 1: study participants with missing data on variables of interest were excluded (IgG and IgA serostatus, age, gender, anthropometric data, smoking status, Zn, Se, Cu, 25(OH)D 3and CRP plasma levels).",2020-05-15,2020-06-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,473,0.0888,,,True,,,,True,Simplified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Plasma,"['IgA', 'IgG']",Spike,Validated by developers,,,['High'],,Yes,No,No,,Unclear,Yes,No,,Antoine Equey,University of Lausanne,Not Unity-Aligned,https://dx.doi.org/10.1016/j.clnu.2023.04.007,2023-05-30,2023-05-31,Unverified,equey_association_2023,CHE
230504_CantonOfZurich_UniversityOfZurich_Baseline_NAb-Omicron_Overall,230504_CantonOfZurich_UniversityOfZurich_Baseline,"Longitudinal Humoral and Cell-Mediated Immune Responses in a Population-Based Cohort in Zurich, Switzerland from March to June 2022 - Evidence for Protection against Omicron SARS-CoV-2 Infection by Neutralizing Antibodies and Spike-specific T cells",2023-05-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Canton of Zurich,,"Individuals aged 16 + residing in the canton of Zurich, Switzerland were randomly selected by age-stratified intervals from a population registry and invited to participate.",,2022-03-01,2022-03-31,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,Neutralizing antibodies against Omicron,1044,0.895,,,True,,,,True,Stratified probability,Author designed (Neutralization Assay),,Neutralization,Plasma,Neutralizing,Spike,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Kyra Denise Zens,University of Zurich,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2023.04.407,2023-05-31,2023-05-31,Unverified,zens_longitudinal_2023,CHE
230504_CantonOfZurich_UniversityOfZurich_Baseline_AntiN,230504_CantonOfZurich_UniversityOfZurich_Baseline,"Longitudinal Humoral and Cell-Mediated Immune Responses in a Population-Based Cohort in Zurich, Switzerland from March to June 2022 - Evidence for Protection against Omicron SARS-CoV-2 Infection by Neutralizing Antibodies and Spike-specific T cells",2023-05-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Canton of Zurich,,"Individuals aged 16 + residing in the canton of Zurich, Switzerland were randomly selected by age-stratified intervals from a population registry and invited to participate.",,2022-03-01,2022-03-31,Household and community samples,All,Multiple groups,16.0,,Test used,Anti-nucleocapsid,1044,0.232,,,,,,,,Stratified probability,BioPlex 2200 SARS-CoV-2 IgG Panel,Bio-rad,Luminex,Plasma,IgG,Nucleocapsid(N-protein),Validated by developers,0.97,0.99,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Kyra Denise Zens,University of Zurich,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2023.04.407,2023-05-31,2024-03-01,Unverified,zens_longitudinal_2023,CHE
230504_CantonOfZurich_UniversityOfZurich_Baseline_AntiS,230504_CantonOfZurich_UniversityOfZurich_Baseline,"Longitudinal Humoral and Cell-Mediated Immune Responses in a Population-Based Cohort in Zurich, Switzerland from March to June 2022 - Evidence for Protection against Omicron SARS-CoV-2 Infection by Neutralizing Antibodies and Spike-specific T cells",2023-05-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Canton of Zurich,,"Individuals aged 16 + residing in the canton of Zurich, Switzerland were randomly selected by age-stratified intervals from a population registry and invited to participate.",,2022-03-01,2022-03-31,Household and community samples,All,Multiple groups,16.0,,Test used,Anti-spike,1044,0.984,,,,,,,,Stratified probability,BioPlex 2200 SARS-CoV-2 IgG Panel,Bio-rad,Luminex,Plasma,IgG,Spike,Validated by developers,0.97,0.99,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Kyra Denise Zens,University of Zurich,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2023.04.407,2023-05-31,2024-03-01,Unverified,zens_longitudinal_2023,CHE
230504_CantonOfZurich_UniversityOfZurich_Baseline_NAb-WT,230504_CantonOfZurich_UniversityOfZurich_Baseline,"Longitudinal Humoral and Cell-Mediated Immune Responses in a Population-Based Cohort in Zurich, Switzerland from March to June 2022 - Evidence for Protection against Omicron SARS-CoV-2 Infection by Neutralizing Antibodies and Spike-specific T cells",2023-05-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Canton of Zurich,,"Individuals aged 16 + residing in the canton of Zurich, Switzerland were randomly selected by age-stratified intervals from a population registry and invited to participate.",,2022-03-01,2022-03-31,Household and community samples,All,Multiple groups,16.0,,Test used,Neutralizing antibodies against Wild Type,1044,0.968,,,,,,,,Stratified probability,Author designed (Neutralization Assay),,Neutralization,Plasma,Neutralizing,Spike,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Kyra Denise Zens,University of Zurich,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2023.04.407,2023-05-31,2023-05-31,Unverified,zens_longitudinal_2023,CHE
230504_CantonOfZurich_UniversityOfZurich_Baseline_NAb-Delta,230504_CantonOfZurich_UniversityOfZurich_Baseline,"Longitudinal Humoral and Cell-Mediated Immune Responses in a Population-Based Cohort in Zurich, Switzerland from March to June 2022 - Evidence for Protection against Omicron SARS-CoV-2 Infection by Neutralizing Antibodies and Spike-specific T cells",2023-05-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,Switzerland,Canton of Zurich,,"Individuals aged 16 + residing in the canton of Zurich, Switzerland were randomly selected by age-stratified intervals from a population registry and invited to participate.",,2022-03-01,2022-03-31,Household and community samples,All,Multiple groups,16.0,,Test used,Neutralizing antibodies against Delta,1044,0.937,,,,,,,,Stratified probability,Author designed (Neutralization Assay),,Neutralization,Plasma,Neutralizing,Spike,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Kyra Denise Zens,University of Zurich,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2023.04.407,2023-05-31,2023-05-31,Unverified,zens_longitudinal_2023,CHE
230504_CantonOfZurich_UniversityOfZurich_Followup_AntiS_Overall,230504_CantonOfZurich_UniversityOfZurich_Followup,"Longitudinal Humoral and Cell-Mediated Immune Responses in a Population-Based Cohort in Zurich, Switzerland from March to June 2022 - Evidence for Protection against Omicron SARS-CoV-2 Infection by Neutralizing Antibodies and Spike-specific T cells",2023-05-04,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Switzerland,Canton of Zurich,,"Individuals aged 16 + residing in the canton of Zurich, Switzerland were randomly selected by age-stratified intervals from a population registry and invited to participate.",,2022-06-07,2022-07-11,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,Anti-spike,964,0.988,,,True,,,,True,Stratified probability,BioPlex 2200 SARS-CoV-2 IgG Panel,Bio-rad,Luminex,Plasma,IgG,Spike,Validated by developers,0.97,0.99,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Kyra Denise Zens,University of Zurich,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2023.04.407,2023-05-31,2024-03-01,Unverified,zens_longitudinal_2023,CHE
230504_CantonOfZurich_UniversityOfZurich_Followup_AntiN,230504_CantonOfZurich_UniversityOfZurich_Followup,"Longitudinal Humoral and Cell-Mediated Immune Responses in a Population-Based Cohort in Zurich, Switzerland from March to June 2022 - Evidence for Protection against Omicron SARS-CoV-2 Infection by Neutralizing Antibodies and Spike-specific T cells",2023-05-04,Journal Article (Peer-Reviewed),Regional,Prospective cohort,Switzerland,Canton of Zurich,,"Individuals aged 16 + residing in the canton of Zurich, Switzerland were randomly selected by age-stratified intervals from a population registry and invited to participate.",,2022-06-07,2022-07-11,Household and community samples,All,Multiple groups,16.0,,Test used,Anti-nucleocapsid,964,0.367,,,,,,,,Stratified probability,BioPlex 2200 SARS-CoV-2 IgG Panel,Bio-rad,Luminex,Plasma,IgG,Nucleocapsid(N-protein),Validated by developers,0.97,0.99,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Kyra Denise Zens,University of Zurich,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2023.04.407,2023-05-31,2024-03-01,Unverified,zens_longitudinal_2023,CHE
230510_Switzerland_UniversityofGeneva,230510_Switzerland_UniversityofGeneva,Impact of SARS-CoV2 infection on anti-apolipoprotein A-1 IgG response in inflammatory rheumatic diseases,2023-05-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Switzerland,,,"""This is a nested cohort study from a prospective, longitudinal, cohort of IRDs patients, the Swiss Clinical Quality Management registry """,,2020-11-08,2021-02-02,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,368,0.0326,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.988,1.0,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Celine Lamacchia,University of Geneva,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2023.1154058,2023-06-29,2024-03-01,Unverified,lamacchiaImpactSARSCoV2Infection2023,CHE
230510_Zurich_UniversityofZurich_T1,230510_Zurich_UniversityofZurich,Persistent humoral immunity in children and adolescents throughout the COVID-19 pandemic (June 2020 to July 2022): a prospective school-based cohort study (Ciao Corona) in Switzerland,2023-05-10,Preprint,Regional,Repeated cross-sectional study,Switzerland,Canton of Zurich,,"""Randomly selected primary schools in canton of Zurich""

""All children and adolescents in the randomly
134 selected classes were eligible to participate in any of the testing rounds, irrespective of
135 whether they participated at baseline""",,2020-06-15,2020-07-15,Students and Daycares,All,Children and Youth (0-17 years),6.0,14.0,Primary Estimate,,2373,0.025,,,True,,,,True,Convenience,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Alessia Raineri,University of Zurich,Not Unity-Aligned,10.1101/2023.05.08.23289517,2023-05-31,2023-06-02,Unverified,raineri_persistent_2023,CHE
230628_Switzerland_CantonalHospitalStGallen,230628_Switzerland_CantonalHospitalStGallen,Evaluation of Self-Collected Dried Blood Spots for Detection of Sars-Cov-2 Nucleocapsid Antibodies Shows Low Sensitivity,2023-06-28,Preprint,Local,Prospective cohort,Switzerland,,,Health care workers (HCW) from two tertiary-care hospitals in Eastern Switzerland,,2020-03-15,2020-09-15,Health care workers and caregivers,All,Adults (18-64 years),17.0,65.0,Primary Estimate,,792,0.044,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,"CLIA, CMIA,CLIA, CMIA",Whole Blood,,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Yes,Yes,No,,Tamara Dorr,Cantonal Hospital St. Gallen,Not Unity-Aligned,10.2139/ssrn.4489649,2023-07-29,2024-03-01,Unverified,dorr_evaluation_2023,CHE
230705_Switzerland_UniversityOfZurich_Vaccinated,230705_Switzerland_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of Omicron infections.,2023-07-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Switzerland,"cantons of Ticino, Zurich, Vaud",,"For cross-sectional analyses in Phase 6, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud).",Participants who were immunologically naı¨ve (n¼25) or were missing relevant data to determine their immune status (n¼8) have been excluded.,2022-05-30,2022-07-11,Household and community samples,All,Multiple groups,16.0,,COVID-19 vaccination status,vaccinated OR vaccinated/infected individuals,2339,0.994,,,True,,True,,True,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,,IgG,Spike,Validated by manufacturers,0.97,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Anja Frei,University of Zurich,Unity-Aligned,https://dx.doi.org/10.1093/ije/dyad098,2023-07-28,2024-05-01,Verified,frei_development_2023,CHE
230705_Switzerland_UniversityOfZurich_antiS,230705_Switzerland_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of Omicron infections.,2023-07-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Switzerland,"cantons of Ticino, Zurich, Vaud",,"For cross-sectional analyses in Phase 6, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud).",Participants who were immunologically naı¨ve (n¼25) or were missing relevant data to determine their immune status (n¼8) have been excluded.,2022-05-30,2022-07-11,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,,2553,0.974,,,,,,,,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,,IgG,Spike,Validated by manufacturers,0.97,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Anja Frei,University of Zurich,Unity-Aligned,https://dx.doi.org/10.1093/ije/dyad098,2023-07-28,2024-05-01,Verified,frei_development_2023,CHE
230705_Switzerland_UniversityOfZurich_antiN,230705_Switzerland_UniversityOfZurich,Development of hybrid immunity during a period of high incidence of Omicron infections.,2023-07-05,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Switzerland,"cantons of Ticino, Zurich, Vaud",,"For cross-sectional analyses in Phase 6, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud).",Participants who were immunologically naı¨ve (n¼25) or were missing relevant data to determine their immune status (n¼8) have been excluded.,2022-05-30,2022-07-11,Household and community samples,All,Multiple groups,16.0,,Test used,,2553,0.17,,,,,True,,True,Stratified probability,Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS) ,Swiss Federal Institute of Technology,Luminex,,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.97,0.99,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Anja Frei,University of Zurich,Unity-Aligned,https://dx.doi.org/10.1093/ije/dyad098,2023-07-28,2024-05-01,Verified,frei_development_2023,CHE
210913_Syria_ArabInternationalUniversity_Overall,210913_Syria_ArabInternationalUniversity,"Seropositivity of anti-SARS-CoV-2 IgG antibodies among asymptomatic and pauci-symptomatic students and staff at the Arab International University, Syria: a snapshot after a year of pandemic",2021-09-13,Preprint,Local,Cross-sectional survey ,Syrian Arab Republic,Daraa Governorate,Ghabaghib,All AIU students and staff were invited to voluntarily participate in the study by filling out and submitting the self-administered anonymous survey including the informed consent.,"Respondents who reported COVID-19-specific symptoms including anosmia, ageusia, dyspnea, and/or thoracalgia; pulmonary infiltrates; oxygen therapy; and/or positive SARS-CoV-2-specific antibodies and/or RT-qPCR tests as well as those who were already vaccinated against SARS-CoV-2 were excluded from antibody testing.",2021-02-17,2021-03-31,Household and community samples,All,Multiple groups,19.0,74.0,Primary Estimate,,94,0.6383,,,True,,,,True,Convenience,COVID-19 ELISA IgG,Vircell S.L.,ELISA,Whole Blood,IgG,,,,,['High'],No,No,No,No,Unclear,No,Yes,No,No,Wafika Zarzour,Arab International University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-885678/v1,2021-09-21,2024-03-01,Verified,zarzour_seropositivity_2021,SYR
210913_Syria_ArabInternationalUniversity_Female,210913_Syria_ArabInternationalUniversity,"Seropositivity of anti-SARS-CoV-2 IgG antibodies among asymptomatic and pauci-symptomatic students and staff at the Arab International University, Syria: a snapshot after a year of pandemic",2021-09-13,Preprint,Local,Cross-sectional survey ,Syrian Arab Republic,Daraa Governorate,Ghabaghib,All AIU students and staff were invited to voluntarily participate in the study by filling out and submitting the self-administered anonymous survey including the informed consent.,"Respondents who reported COVID-19-specific symptoms including anosmia, ageusia, dyspnea, and/or thoracalgia; pulmonary infiltrates; oxygen therapy; and/or positive SARS-CoV-2-specific antibodies and/or RT-qPCR tests as well as those who were already vaccinated against SARS-CoV-2 were excluded from antibody testing.",2021-02-17,2021-03-31,Household and community samples,Female,Multiple groups,,,Sex/Gender,,65,0.6615000000000001,,,,,,,,Convenience,COVID-19 ELISA IgG,Vircell S.L.,ELISA,Whole Blood,IgG,,,,,['High'],No,No,No,No,Unclear,No,Yes,No,No,Wafika Zarzour,Arab International University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-885678/v1,2021-09-22,2024-03-01,Verified,zarzour_seropositivity_2021,SYR
210913_Syria_ArabInternationalUniversity_Male,210913_Syria_ArabInternationalUniversity,"Seropositivity of anti-SARS-CoV-2 IgG antibodies among asymptomatic and pauci-symptomatic students and staff at the Arab International University, Syria: a snapshot after a year of pandemic",2021-09-13,Preprint,Local,Cross-sectional survey ,Syrian Arab Republic,Daraa Governorate,Ghabaghib,All AIU students and staff were invited to voluntarily participate in the study by filling out and submitting the self-administered anonymous survey including the informed consent.,"Respondents who reported COVID-19-specific symptoms including anosmia, ageusia, dyspnea, and/or thoracalgia; pulmonary infiltrates; oxygen therapy; and/or positive SARS-CoV-2-specific antibodies and/or RT-qPCR tests as well as those who were already vaccinated against SARS-CoV-2 were excluded from antibody testing.",2021-02-17,2021-03-31,Household and community samples,Male,Multiple groups,,,Sex/Gender,,29,0.5861999999999999,,,,,,,,Convenience,COVID-19 ELISA IgG,Vircell S.L.,ELISA,Whole Blood,IgG,,,,,['High'],No,No,No,No,Unclear,No,Yes,No,No,Wafika Zarzour,Arab International University,Not Unity-Aligned,https://www.researchsquare.com/article/rs-885678/v1,2021-09-22,2024-03-01,Verified,zarzour_seropositivity_2021,SYR
230206_Tajikistan_SaintPetersburgPasteurInstitute_AntiNorAntiS_Primary,230206_Tajikistan_SaintPetersburgPasteurInstitute,Achievement of maximal SARS-CoV-2 collective immunity among the Tajik population by March 2022,2023-02-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Tajikistan,,"Dushanbe, Khujand, Bokhtar, Vahdad, Hisor, Istaravshan, Isfara, Kulob, Panjakent, Tursunzade","""population of the Republic of Tajikistan ... in ten areas, including three cities (Dushanbe, Khujand, Bokhtar) and seven districts (Vahdad, Hisor, Istaravshan, Isfara, Kulob, Panjakent, Tursunzade).""","""Grounds for non-inclusion in the study were: the refusal of subsequent laboratory testing; or the presence of manifest COVID-19 at the time of questionnaire completion.""

""After exclusion of eight non-valid samples ..."".",2022-03-14,2022-03-18,Household and community samples,All,Multiple groups,1.0,,Primary Estimate,Anti-N or Anti-S,3674,0.992,0.989,0.994,True,,,,True,Stratified non-probability,"Author designed (ELISA) - Nucleocapsid,Author designed (ELISA) -Spike",,ELISA,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,A.Yu. Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://dx.doi.org/10.15789/1563-0625-AOM-2630,2023-05-04,2023-05-05,Unverified,popova_achievement_2023,TJK
230206_Tajikistan_SaintPetersburgPasteurInstitute_AntiNandAntiS,230206_Tajikistan_SaintPetersburgPasteurInstitute,Achievement of maximal SARS-CoV-2 collective immunity among the Tajik population by March 2022,2023-02-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Tajikistan,,"Dushanbe, Khujand, Bokhtar, Vahdad, Hisor, Istaravshan, Isfara, Kulob, Panjakent, Tursunzade","""population of the Republic of Tajikistan ... in ten areas, including three cities (Dushanbe, Khujand, Bokhtar) and seven districts (Vahdad, Hisor, Istaravshan, Isfara, Kulob, Panjakent, Tursunzade).""","""Grounds for non-inclusion in the study were: the refusal of subsequent laboratory testing; or the presence of manifest COVID-19 at the time of questionnaire completion.""

""After exclusion of eight non-valid samples ..."".",2022-03-14,2022-03-18,Household and community samples,All,Multiple groups,1.0,,Test used,Anti-N and Anti-S,3674,0.892,0.882,0.902,,,,,,Stratified non-probability,"Author designed (ELISA) - Nucleocapsid,Author designed (ELISA) -Spike",,ELISA,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,A.Yu. Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://dx.doi.org/10.15789/1563-0625-AOM-2630,2023-05-04,2023-05-05,Unverified,popova_achievement_2023,TJK
230206_Tajikistan_SaintPetersburgPasteurInstitute_AntiN,230206_Tajikistan_SaintPetersburgPasteurInstitute,Achievement of maximal SARS-CoV-2 collective immunity among the Tajik population by March 2022,2023-02-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Tajikistan,,"Dushanbe, Khujand, Bokhtar, Vahdad, Hisor, Istaravshan, Isfara, Kulob, Panjakent, Tursunzade","""population of the Republic of Tajikistan ... in ten areas, including three cities (Dushanbe, Khujand, Bokhtar) and seven districts (Vahdad, Hisor, Istaravshan, Isfara, Kulob, Panjakent, Tursunzade).""","""Grounds for non-inclusion in the study were: the refusal of subsequent laboratory testing; or the presence of manifest COVID-19 at the time of questionnaire completion.""

""After exclusion of eight non-valid samples ..."".",2022-03-14,2022-03-18,Household and community samples,All,Multiple groups,1.0,,Test used,Anti-N,3674,0.909,0.899,0.918,,,,,,Stratified non-probability,Author designed (ELISA) - Nucleocapsid,,ELISA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,A.Yu. Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://dx.doi.org/10.15789/1563-0625-AOM-2630,2023-05-04,2023-05-05,Unverified,popova_achievement_2023,TJK
230206_Tajikistan_SaintPetersburgPasteurInstitute_AntiS,230206_Tajikistan_SaintPetersburgPasteurInstitute,Achievement of maximal SARS-CoV-2 collective immunity among the Tajik population by March 2022,2023-02-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Tajikistan,,"Dushanbe, Khujand, Bokhtar, Vahdad, Hisor, Istaravshan, Isfara, Kulob, Panjakent, Tursunzade","""population of the Republic of Tajikistan ... in ten areas, including three cities (Dushanbe, Khujand, Bokhtar) and seven districts (Vahdad, Hisor, Istaravshan, Isfara, Kulob, Panjakent, Tursunzade).""","""Grounds for non-inclusion in the study were: the refusal of subsequent laboratory testing; or the presence of manifest COVID-19 at the time of questionnaire completion.""

""After exclusion of eight non-valid samples ..."".",2022-03-14,2022-03-18,Household and community samples,All,Multiple groups,1.0,,Test used,Anti-S,3674,0.975,0.97,0.98,,,,,,Stratified non-probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,Validated by developers,1.0,0.98,['High'],,No,Yes,Yes,,Unclear,Yes,No,,A.Yu. Popova,Saint Petersburg Pasteur Institute,Not Unity-Aligned,https://dx.doi.org/10.15789/1563-0625-AOM-2630,2023-05-04,2023-05-05,Unverified,popova_achievement_2023,TJK
210401_Ranong_ChulalongkornUniversity,210401_Ranong_ChulalongkornUniversity,Seroprevalence of hospital staff in a province with zero COVID-19 cases,2021-04-01,Journal Article (Peer-Reviewed),Local,Prospective cohort,Thailand,Ranong,,"All 844 healthcare workers including the physician, nurse, medical assistance, medical technician, and non-medical officers of the largest public hospital in Ranong province that reported zero cumulative PCR-confirmed COVID-19 cases during the entire study period (17th April to 17th May 2020), were invited to participate in this study",,2020-04-17,2020-05-17,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,IgG OR IgM,844,0.008,0.004,0.017,True,,,,True,Convenience,Baiya Rapid COVID-19 IgG/IgM Test Kit,Baiya Phytopharm,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.941,0.98,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Tanawin Nopsopon,Chulalongkorn University,Not Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0238088,2021-04-05,2024-03-01,Unverified,nopsopon_seroprevalence_2021,THA
210714_Thailand_MinistryOfPublicHealthThailand_Overall,210714_Thailand_MinistryOfPublicHealthThailand,Sero-surveillance for SARS-CoV-2 infection among healthcare providers in four hospitals in Thailand one year after the first community outbreak.,2021-07-14,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Thailand,"Eastern, Western, Central Thailand",,"Have treated COVID-19 cases, are providing direct healthcare services, are 18+, worked >30 hrs/week, have potential occupational risks to SARS-CoV-2 infection, care for >=1 patients per day. ",Those employed <1 year or acutely ill with COVID-19. ,2021-01-18,2021-03-05,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,600,0.002,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 NCP ELISA (IgG),Anti-SARS-CoV-2 ELISA IgG",EUROIMMUN,ELISA,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Wanitchaya Kittikraisak,"Ministry of Public Health, Thailand",Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254563,2021-07-19,2024-03-01,Unverified,kittikraisak_sero-surveillance_2021,THA
210720_Bangkok_ChulalongkornUniversity,210720_Bangkok_ChulalongkornUniversity,Potential applications of the rapid COVID-19 antibody test kit screening in comparison to the RT-PCR in patients and personnel at the Department of Obstetrics and Gynecology,2021-07-20,Preprint,Local,Cross-sectional survey ,Thailand,,Bangkok,pregnant and patients admitted to the hospital for an operative procedure participated in the study,Participants were excluded when they denied or could not complete both the rapid test and RT-PCR testing.,2020-08-15,2021-01-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,210,0.0095,,,True,,,,True,Unclear,Baiya Rapid COVID-19 IgG/IgM Test Kit,Baiya Phytopharm,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.8865999999999999,0.9063,['High'],,Unclear,No,No,,Yes,Yes,No,,Amarin Narkwichean,Chulalongkorn University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.16.21259725v1.full-text,2021-08-04,2024-03-01,Unverified,narkwicheanPotentialApplicationsRapid2021,THA
211029_Thailand_ChulalongkornUniversity_overall_popadj,211029_Thailand_ChulalongkornUniversity,COVID-19 seroprevalence among hospital staff and preprocedural patients in Thai community hospitals: a cross-sectional study.,2021-10-29,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Thailand,"Northern Region, Northeastern Region, Central Region, Eastern Region, Southern Region",,"From 8 April to 26 June 2020, hospital staff and patients who needed procedural treatment or operation visiting the hospital during the recruiting period and did not meet the national nasopharyngeal PCR testing criteria in 244 hospitals (215 community hospitals and 29 general hospitals) from all regions of Thailand were recruited for antibody testing in their community hospital. Hospitals included in the study came from a national survey about willingness to use antibody testing for COVID-19 screening.",Participants with active symptoms meeting national criteria for nasopharyngeal PCR testing were quarantined and excluded.,2020-04-06,2020-06-26,Multiple populations,All,Adults (18-64 years),,,Primary Estimate,,857,0.063,,,True,,True,,,Convenience,Baiya Rapid COVID-19 IgG/IgM Test Kit,Baiya Phytopharm,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.941,0.98,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Tanawin Nopsopon,Chulalongkorn University,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2020-046676,2021-11-10,2024-03-01,Unverified,nopsopon_covid-19_2021,THA
220121_Thailand_MahidolUniversity_AtRiskOccupations_Overall,220121_Thailand_MahidolUniversity_AtRiskOccupations,Seroprevalence of anti-SARS coronavirus 2 antibodies in Thai adults during the first three epidemic waves,2022-01-21,Preprint,Regional,Cross-sectional survey ,Thailand,"Chiang Mai, Bangkok",Bangkok,"People at risk due to their occupations (airport drivers, public transport drivers, and workers in entertainment venues (e.g., pubs, bars, and massage parlors)). Age older than 18.",,2020-05-14,2021-05-21,Non-essential workers and unemployed persons,All,Multiple groups,18.0,,Primary Estimate,,1641,0.0018,,,True,,,,True,Unclear,"Author designed (Neutralization Assay),Abbott Architect SARS-CoV-2 IgG,Author designed (Indirect immunofluorescence assay) - Unknown","NA,Abbott Laboratories",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,Unclear,Yes,No,,Unclear,Yes,No,,Hatairat Lerdsamra,Mahidol University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.01.18.22269501v1.full-text,2022-02-01,2024-03-01,Unverified,lerdsamran_seroprevalence_2022,THA
220121_Thailand_MahidolUniversity_HealthPersonnel_Overall,220121_Thailand_MahidolUniversity_HealthPersonnel,Seroprevalence of anti-SARS coronavirus 2 antibodies in Thai adults during the first three epidemic waves,2022-01-21,Preprint,Regional,Cross-sectional survey ,Thailand,"Chiang Mai, Bangkok",Bangkok,People at risk due to their occupations (health personnel). Age older than 18.,,2020-05-14,2021-05-21,Health care workers and caregivers,All,Multiple groups,18.0,,Primary Estimate,,472,0.0,,,True,,,,True,Unclear,"Author designed (Neutralization Assay),Abbott Architect SARS-CoV-2 IgG,Author designed (Indirect immunofluorescence assay) - Unknown","NA,Abbott Laboratories",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,Unclear,No,No,,Yes,Yes,No,,Hatairat Lerdsamra,Mahidol University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.01.18.22269501v1.full-text,2022-02-01,2024-03-01,Unverified,lerdsamran_seroprevalence_2022,THA
220121_Thailand_MahidolUniversity_SharedEnvironmentCOVID_Overall,220121_Thailand_MahidolUniversity_SharedEnvironmentCOVID,Seroprevalence of anti-SARS coronavirus 2 antibodies in Thai adults during the first three epidemic waves,2022-01-21,Preprint,Regional,Cross-sectional survey ,Thailand,"Chiang Mai, Bangkok",Bangkok,People at risk due to sharing workplaces or communities with COVID-19 patients. Age older than 18.,,2020-01-15,2021-05-21,Contacts of COVID patients,All,Multiple groups,18.0,,Primary Estimate,,1856,0.0204,0.0144,0.0281,True,,,,True,Unclear,"Author designed (Neutralization Assay),Abbott Architect SARS-CoV-2 IgG,Author designed (Indirect immunofluorescence assay) - Unknown","NA,Abbott Laboratories",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,Unclear,Yes,No,,Unclear,Yes,No,,Hatairat Lerdsamra,Mahidol University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.01.18.22269501v1.full-text,2022-02-01,2024-03-01,Unverified,lerdsamran_seroprevalence_2022,THA
220121_Thailand_MahidolUniversity_TravelersQuarantine_Overall,220121_Thailand_MahidolUniversity_TravelersQuarantine,Seroprevalence of anti-SARS coronavirus 2 antibodies in Thai adults during the first three epidemic waves,2022-01-21,Preprint,Regional,Cross-sectional survey ,Thailand,"Chiang Mai, Bangkok",Bangkok,"Thai citizens in state quarantines, when arrived Thailand after extended duties in countries with known SARS-CoV-2 outbreak. Age older than 18.",,2020-05-14,2021-05-21,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,553,0.28,0.2379,0.32799999999999996,True,,,,True,Unclear,"Author designed (Neutralization Assay),Abbott Architect SARS-CoV-2 IgG,Author designed (Indirect immunofluorescence assay) - Unknown","NA,Abbott Laboratories",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,Unclear,No,No,,Unclear,Yes,No,,Hatairat Lerdsamra,Mahidol University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.01.18.22269501v1.full-text,2022-02-01,2024-03-01,Unverified,lerdsamran_seroprevalence_2022,THA
220202_Thailand_ChiangMaiUniversity_Overall,220202_Thailand_ChiangMaiUniversity,"Prevalences of SARS-CoV-2 RNA and anti-SARS-CoV-2 among at-risk populations in Chiang Mai and Lamphun provinces, Thailand, during November 2020-January 2021.",2022-02-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Thailand,Chiang Mai and Lamphun,,"People living in Chiang Mai and Lamphun provinces, Thailand. The populations were targeted at individuals with risk exposure to SARS-CoV-2 infection presenting no or mild symptoms and had a difficulty to
access the COVID-19 testing.",Healthcare workers who were already supported for COVID19 testing by the government were excluded. ,2020-11-15,2021-01-15,Household and community samples,All,Multiple groups,17.0,85.0,Primary Estimate,,1651,0.009000000000000001,0.005,0.013999999999999999,True,,,,True,Unclear,"Not reported/ Unable to specify,2019-nCoV IgG Rapid Test,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Acro Biotech COVID-19 IgM/IgG Rapid POC test","NA,Innovita Biological Technology Co. Ltd,SD Biosensor,ACRO Biotech Inc",LFIA,Plasma,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,,,['High'],,Unclear,Yes,Yes,,Unclear,Yes,No,,Siriluk Takalay,Chiang Mai University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0263127,2022-02-07,2024-03-01,Unverified,takalay_prevalences_2022,THA
220202_Thailand_ChiangMaiUniversity_ChiangMai,220202_Thailand_ChiangMaiUniversity,"Prevalences of SARS-CoV-2 RNA and anti-SARS-CoV-2 among at-risk populations in Chiang Mai and Lamphun provinces, Thailand, during November 2020-January 2021.",2022-02-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Thailand,"Chiang Mai
",,"People living in Chiang Mai and Lamphun provinces, Thailand. The populations were targeted at individuals with risk exposure to SARS-CoV-2 infection presenting no or mild symptoms and had a difficulty to
access the COVID-19 testing.",Healthcare workers who were already supported for COVID19 testing by the government were excluded. ,2020-11-15,2021-01-15,Household and community samples,All,Multiple groups,,,Geographical area,Chiang Mai province,1161,0.0086,,,,,,,,Unclear,"Not reported/ Unable to specify,2019-nCoV IgG Rapid Test,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Acro Biotech COVID-19 IgM/IgG Rapid POC test","NA,Innovita Biological Technology Co. Ltd,SD Biosensor,ACRO Biotech Inc",LFIA,Plasma,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,,,['High'],,Unclear,Yes,Yes,,Unclear,Yes,No,,Siriluk Takalay,Chiang Mai University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0263127,2022-02-07,2024-03-01,Unverified,takalay_prevalences_2022,THA
220202_Thailand_ChiangMaiUniversity_41-50,220202_Thailand_ChiangMaiUniversity,"Prevalences of SARS-CoV-2 RNA and anti-SARS-CoV-2 among at-risk populations in Chiang Mai and Lamphun provinces, Thailand, during November 2020-January 2021.",2022-02-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Thailand,Chiang Mai and Lamphun,,"People living in Chiang Mai and Lamphun provinces, Thailand. The populations were targeted at individuals with risk exposure to SARS-CoV-2 infection presenting no or mild symptoms and had a difficulty to
access the COVID-19 testing.",Healthcare workers who were already supported for COVID19 testing by the government were excluded. ,2020-11-15,2021-01-15,Household and community samples,All,Adults (18-64 years),41.0,50.0,Age,41-50,333,0.009000000000000001,,,,,,,,Unclear,"Not reported/ Unable to specify,2019-nCoV IgG Rapid Test,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Acro Biotech COVID-19 IgM/IgG Rapid POC test","NA,Innovita Biological Technology Co. Ltd,SD Biosensor,ACRO Biotech Inc",LFIA,Plasma,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,,,['High'],,Unclear,Yes,Yes,,Unclear,Yes,No,,Siriluk Takalay,Chiang Mai University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0263127,2022-02-07,2024-03-01,Unverified,takalay_prevalences_2022,THA
220202_Thailand_ChiangMaiUniversity_OtherProvs,220202_Thailand_ChiangMaiUniversity,"Prevalences of SARS-CoV-2 RNA and anti-SARS-CoV-2 among at-risk populations in Chiang Mai and Lamphun provinces, Thailand, during November 2020-January 2021.",2022-02-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Thailand,Other provinces aside from Chiang Mai and Lamphun,,"People living in Chiang Mai and Lamphun provinces, Thailand. The populations were targeted at individuals with risk exposure to SARS-CoV-2 infection presenting no or mild symptoms and had a difficulty to
access the COVID-19 testing.",Healthcare workers who were already supported for COVID19 testing by the government were excluded. ,2020-11-15,2021-01-15,Household and community samples,All,Multiple groups,,,Geographical area,Other provinces,23,0.0435,,,,,,,,Unclear,"Not reported/ Unable to specify,2019-nCoV IgG Rapid Test,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Acro Biotech COVID-19 IgM/IgG Rapid POC test","NA,Innovita Biological Technology Co. Ltd,SD Biosensor,ACRO Biotech Inc",LFIA,Plasma,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,,,['High'],,Unclear,Yes,Yes,,Unclear,Yes,No,,Siriluk Takalay,Chiang Mai University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0263127,2022-02-07,2024-03-01,Unverified,takalay_prevalences_2022,THA
220202_Thailand_ChiangMaiUniversity_Female,220202_Thailand_ChiangMaiUniversity,"Prevalences of SARS-CoV-2 RNA and anti-SARS-CoV-2 among at-risk populations in Chiang Mai and Lamphun provinces, Thailand, during November 2020-January 2021.",2022-02-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Thailand,Chiang Mai and Lamphun,,"People living in Chiang Mai and Lamphun provinces, Thailand. The populations were targeted at individuals with risk exposure to SARS-CoV-2 infection presenting no or mild symptoms and had a difficulty to
access the COVID-19 testing.",Healthcare workers who were already supported for COVID19 testing by the government were excluded. ,2020-11-15,2021-01-15,Household and community samples,Female,Multiple groups,,,Sex/Gender,,852,0.0094,,,,,,,,Unclear,"Not reported/ Unable to specify,2019-nCoV IgG Rapid Test,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Acro Biotech COVID-19 IgM/IgG Rapid POC test","NA,Innovita Biological Technology Co. Ltd,SD Biosensor,ACRO Biotech Inc",LFIA,Plasma,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,,,['High'],,Unclear,Yes,Yes,,Unclear,Yes,No,,Siriluk Takalay,Chiang Mai University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0263127,2022-02-07,2024-03-01,Unverified,takalay_prevalences_2022,THA
220202_Thailand_ChiangMaiUniversity_>50,220202_Thailand_ChiangMaiUniversity,"Prevalences of SARS-CoV-2 RNA and anti-SARS-CoV-2 among at-risk populations in Chiang Mai and Lamphun provinces, Thailand, during November 2020-January 2021.",2022-02-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Thailand,Chiang Mai and Lamphun,,"People living in Chiang Mai and Lamphun provinces, Thailand. The populations were targeted at individuals with risk exposure to SARS-CoV-2 infection presenting no or mild symptoms and had a difficulty to
access the COVID-19 testing.",Healthcare workers who were already supported for COVID19 testing by the government were excluded. ,2020-11-15,2021-01-15,Household and community samples,All,Multiple groups,51.0,85.0,Age,>50,218,0.0183,,,,,,,,Unclear,"Not reported/ Unable to specify,2019-nCoV IgG Rapid Test,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Acro Biotech COVID-19 IgM/IgG Rapid POC test","NA,Innovita Biological Technology Co. Ltd,SD Biosensor,ACRO Biotech Inc",LFIA,Plasma,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,,,['High'],,Unclear,Yes,Yes,,Unclear,Yes,No,,Siriluk Takalay,Chiang Mai University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0263127,2022-02-07,2024-03-01,Unverified,takalay_prevalences_2022,THA
220202_Thailand_ChiangMaiUniversity_Lamphun,220202_Thailand_ChiangMaiUniversity,"Prevalences of SARS-CoV-2 RNA and anti-SARS-CoV-2 among at-risk populations in Chiang Mai and Lamphun provinces, Thailand, during November 2020-January 2021.",2022-02-02,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Thailand,Lamphun,,"People living in Chiang Mai and Lamphun provinces, Thailand. The populations were targeted at individuals with risk exposure to SARS-CoV-2 infection presenting no or mild symptoms and had a difficulty to
access the COVID-19 testing.",Healthcare workers who were already supported for COVID19 testing by the government were excluded. ,2020-11-15,2021-01-15,Household and community samples,All,Multiple groups,,,Geographical area,Lamphun province,417,0.0048,,,,,,,,Unclear,"Not reported/ Unable to specify,2019-nCoV IgG Rapid Test,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Acro Biotech COVID-19 IgM/IgG Rapid POC test","NA,Innovita Biological Technology Co. Ltd,SD Biosensor,ACRO Biotech Inc",LFIA,Plasma,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,,,['High'],,Unclear,Yes,Yes,,Unclear,Yes,No,,Siriluk Takalay,Chiang Mai University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0263127,2022-02-07,2024-03-01,Unverified,takalay_prevalences_2022,THA
220202_Thailand_ChiangMaiUniversity_Male,220202_Thailand_ChiangMaiUniversity,"Prevalences of SARS-CoV-2 RNA and anti-SARS-CoV-2 among at-risk populations in Chiang Mai and Lamphun provinces, Thailand, during November 2020-January 2021.",2022-02-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Thailand,Chiang Mai and Lamphun,,"People living in Chiang Mai and Lamphun provinces, Thailand. The populations were targeted at individuals with risk exposure to SARS-CoV-2 infection presenting no or mild symptoms and had a difficulty to
access the COVID-19 testing.",Healthcare workers who were already supported for COVID19 testing by the government were excluded. ,2020-11-15,2021-01-15,Household and community samples,Male,Multiple groups,,,Sex/Gender,,791,0.0063,,,,,,,,Unclear,"Not reported/ Unable to specify,2019-nCoV IgG Rapid Test,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Acro Biotech COVID-19 IgM/IgG Rapid POC test","NA,Innovita Biological Technology Co. Ltd,SD Biosensor,ACRO Biotech Inc",LFIA,Plasma,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,,,['High'],,Unclear,Yes,Yes,,Unclear,Yes,No,,Siriluk Takalay,Chiang Mai University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0263127,2022-02-07,2024-03-01,Unverified,takalay_prevalences_2022,THA
220202_Thailand_ChiangMaiUniversity_<=30,220202_Thailand_ChiangMaiUniversity,"Prevalences of SARS-CoV-2 RNA and anti-SARS-CoV-2 among at-risk populations in Chiang Mai and Lamphun provinces, Thailand, during November 2020-January 2021.",2022-02-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Thailand,Chiang Mai and Lamphun,,"People living in Chiang Mai and Lamphun provinces, Thailand. The populations were targeted at individuals with risk exposure to SARS-CoV-2 infection presenting no or mild symptoms and had a difficulty to
access the COVID-19 testing.",Healthcare workers who were already supported for COVID19 testing by the government were excluded. ,2020-11-15,2021-01-15,Household and community samples,All,Adults (18-64 years),17.0,30.0,Age,<=30,609,0.0033000000000000004,,,,,,,,Unclear,"Not reported/ Unable to specify,2019-nCoV IgG Rapid Test,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Acro Biotech COVID-19 IgM/IgG Rapid POC test","NA,Innovita Biological Technology Co. Ltd,SD Biosensor,ACRO Biotech Inc",LFIA,Plasma,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,,,['High'],,Unclear,Yes,Yes,,Unclear,Yes,No,,Siriluk Takalay,Chiang Mai University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0263127,2022-02-07,2024-03-01,Unverified,takalay_prevalences_2022,THA
220202_Thailand_ChiangMaiUniversity_31-40,220202_Thailand_ChiangMaiUniversity,"Prevalences of SARS-CoV-2 RNA and anti-SARS-CoV-2 among at-risk populations in Chiang Mai and Lamphun provinces, Thailand, during November 2020-January 2021.",2022-02-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Thailand,Chiang Mai and Lamphun,,"People living in Chiang Mai and Lamphun provinces, Thailand. The populations were targeted at individuals with risk exposure to SARS-CoV-2 infection presenting no or mild symptoms and had a difficulty to
access the COVID-19 testing.",Healthcare workers who were already supported for COVID19 testing by the government were excluded. ,2020-11-15,2021-01-15,Household and community samples,All,Adults (18-64 years),31.0,40.0,Age,31-40,491,0.0102,,,,,,,,Unclear,"Not reported/ Unable to specify,2019-nCoV IgG Rapid Test,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,Acro Biotech COVID-19 IgM/IgG Rapid POC test","NA,Innovita Biological Technology Co. Ltd,SD Biosensor,ACRO Biotech Inc",LFIA,Plasma,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,,,['High'],,Unclear,Yes,Yes,,Unclear,Yes,No,,Siriluk Takalay,Chiang Mai University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0263127,2022-02-07,2024-03-01,Unverified,takalay_prevalences_2022,THA
220415_MahasarakhamUniversity_Mahasarakham_HCW2,220415_MahasarakhamUniversity_Mahasarakham_HCW2,SARS-CoV-2 IgG Seroprevalence Detected by Chemiluminescence Immunoassay among Healthcare Personnel and Patients in a Province with a Low Incidence Rate of COVID-19 during the First Wave of COVID-19 in Thailand,2022-04-15,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Thailand,Mahasarakham Province,,"We conducted cross-sectional serologic testing for SARS-CoV-2 antibodies among HCPs and patients in Suddhavej Hospital, Mahasarakham University.",We excluded cases with a previously diagnosed COVID-19 infection.,2020-02-20,2020-04-30,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,112,0.009000000000000001,0.000226,0.049,True,,,,True,Convenience,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9120999999999999,0.9733,['High'],,No,No,Yes,,Yes,Yes,Yes,,Samadhi Patamatamkul,Mahasarakham University,Not Unity-Aligned,https://dx.doi.org/10.1097/IPC.0000000000001150,2022-04-22,2024-03-01,Unverified,patamatamkulSARSCoV2IgGSeroprevalence2022,THA
220415_MahasarakhamUniversity_Mahasarakham_Patients1,220415_MahasarakhamUniversity_Mahasarakham_Patients1,SARS-CoV-2 IgG Seroprevalence Detected by Chemiluminescence Immunoassay among Healthcare Personnel and Patients in a Province with a Low Incidence Rate of COVID-19 during the First Wave of COVID-19 in Thailand,2022-04-15,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Thailand,Mahasarakham Province,,"We conducted cross-sectional serologic testing for SARS-CoV-2 antibodies among HCPs and patients in Suddhavej Hospital, Mahasarakham University.",We excluded cases with a previously diagnosed COVID-19 infection.,2020-02-20,2020-04-30,Multiple populations,All,Multiple groups,,,Primary Estimate,,78,0.026000000000000002,0.003,0.09,True,,,,True,Sequential,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Samadhi Patamatamkul,Mahasarakham University,Not Unity-Aligned,https://dx.doi.org/10.1097/IPC.0000000000001150,2022-04-22,2024-03-01,Unverified,patamatamkulSARSCoV2IgGSeroprevalence2022,THA
220427_Thailand_MahidolUniversity_AtRiskOccupation_Primary,220427_Thailand_MahidolUniversity_AtRiskOccupation,Seroprevalence of anti-SARS-CoV-2 antibodies in Thai adults during the first three epidemic waves.,2022-04-27,Journal Article (Peer-Reviewed),Local,Prospective cohort,Thailand,,"Bangkok, Chiang Mai","people at risk due to their occupations (health personnel, airport officers, public transport drivers, and workers in entertainment venues (e.g., pubs, bars, and massage
parlors))",,2020-05-15,2021-05-17,Multiple populations,All,Multiple groups,18.0,76.0,Primary Estimate,Overall,2113,0.0014000000000000002,0.0003,0.0042,True,,,,True,Unclear,"Author designed (Neutralization Assay),Abbott Architect SARS-CoV-2 IgG,Author designed (IFA) - MULTIPLEXED","NA,Abbott Laboratories",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Missing'],,Unclear,Yes,Yes,,Yes,Yes,No,,Hatairat Lerdsamran,Mahidol University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0263316,2022-05-03,2024-03-01,Unverified,lerdsamran_seroprevalence_2022-1,THA
220427_Thailand_MahidolUniversity_CloseContact_Primary,220427_Thailand_MahidolUniversity_CloseContact,Seroprevalence of anti-SARS-CoV-2 antibodies in Thai adults during the first three epidemic waves.,2022-04-27,Journal Article (Peer-Reviewed),Local,Prospective cohort,Thailand,,"Bangkok, Chiang Mai",people at risk due to sharing workplaces or communities with COVID-19 patients.,,2020-05-14,2021-05-21,Contacts of COVID patients,All,Multiple groups,18.0,90.0,Primary Estimate,Overall,1856,0.0204,0.0144,0.0281,True,,,,True,Unclear,"Author designed (Neutralization Assay),Abbott Architect SARS-CoV-2 IgG,Author designed (IFA) - MULTIPLEXED","NA,Abbott Laboratories",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Missing'],,Unclear,Yes,No,,Yes,Yes,No,,Hatairat Lerdsamran,Mahidol University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0263316,2022-05-03,2024-03-01,Unverified,lerdsamran_seroprevalence_2022-1,THA
220427_Thailand_MahidolUniversity_ReturnedWorkers_Primary,220427_Thailand_MahidolUniversity_ReturnedWorkers,Seroprevalence of anti-SARS-CoV-2 antibodies in Thai adults during the first three epidemic waves.,2022-04-27,Journal Article (Peer-Reviewed),Local,Prospective cohort,Thailand,,"Bangkok, Chiang Mai","Thai citizens in state quarantines, who had arrived in Thailand after extended periods of work in countries with known SARS-CoV-2 outbreaks.",,2020-05-17,2020-10-12,Multiple populations,All,Adults (18-64 years),,,Primary Estimate,Overall,553,0.28,0.2379,0.32799999999999996,True,,,,True,Unclear,"Author designed (Neutralization Assay),Abbott Architect SARS-CoV-2 IgG,Author designed (IFA) - MULTIPLEXED","NA,Abbott Laboratories",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Missing'],,Unclear,No,Yes,,Yes,Yes,No,,Hatairat Lerdsamran,Mahidol University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0263316,2022-05-03,2024-03-01,Unverified,lerdsamran_seroprevalence_2022-1,THA
220525_Mahasarakham_MahasarakhamUniversity,220525_Mahasarakham_MahasarakhamUniversity,Safety and Efficacy of Cataract Surgery Under a Local Infection Control Protocol Before and During a COVID-19 Wave in Thailand for Healthcare Workers and Patients: A Prospective Cohort from a Secondary Center.,2022-06-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Thailand,Maha Sarakham Province,Mahasarakham,"""32 HCWs who worked in the ophthalmology outpatient clinic, inpatient ophthalmology ward, and operating room""",,2020-07-01,2021-03-31,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,,27,0.0,,,True,,,,True,Convenience,"MAGLUMI 2019-nCoV IgM/IgG,Elecsys® Anti‐SARS‐CoV‐2 (S)","Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),Roche Diagnostics",Multiple Types,Serum,"['IgG', 'IgM']",,,,,['High'],,No,No,No,,Unclear,No,No,,Ploysai Rujkorakarn,Mahasarakham University,Not Unity-Aligned,https://dx.doi.org/10.2147/OPTH.S366353,2022-06-24,2024-03-01,Unverified,rujkorakarn_safety_2022,THA
221106_Bangkok_ChulabhornRoyalAcademy_Caregivers,221106_Bangkok_ChulabhornRoyalAcademy_Caregivers,SARS-CoV-2 seroprevalence among cancer patients and household caregivers in a cancer hospital: Cross-sectional survey after the second COVID-19 wave in Thailand.,2022-11-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Thailand,Central Thailand,Bangkok,"""Matched caregivers who had lived in the same households as patients for the past month were tested""",,2021-03-04,2021-05-31,Residual sera,All,Adults (18-64 years),,,Primary Estimate,,200,0.01,,,True,,,,True,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,,,Nucleocapsid(N-protein),,,,['High'],No,Unclear,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Teerapat Ungtrakul,Chulabhorn Royal Academy,Unity-Aligned,https://dx.doi.org/10.1016/j.puhip.2022.100341,2022-12-04,2024-03-01,Unverified,ungtrakul_sars-cov-2_2022,THA
221106_Bangkok_ChulabhornRoyalAcademy_Patients,221106_Bangkok_ChulabhornRoyalAcademy_Patients,SARS-CoV-2 seroprevalence among cancer patients and household caregivers in a cancer hospital: Cross-sectional survey after the second COVID-19 wave in Thailand.,2022-11-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Thailand,Central Thailand,Bangkok,"""Cancer patients at the Chulabhorn Hospital, a tertiary cancer hospital in Bangkok, Thailand""",,2021-03-04,2021-05-31,Residual sera,All,Adults (18-64 years),,,Primary Estimate,,200,0.0,,,True,,,,True,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,,,Nucleocapsid(N-protein),,,,['High'],No,Unclear,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Teerapat Ungtrakul,Chulabhorn Royal Academy,Unity-Aligned,https://dx.doi.org/10.1016/j.puhip.2022.100341,2022-12-04,2024-03-01,Unverified,ungtrakul_sars-cov-2_2022,THA
221205_Bangkok_ChulalongkornUniversity,221205_Bangkok_ChulalongkornUniversity,"SARS-CoV-2 infection- induced seroprevalence among children and associated risk factors during pre- and omicron-dominant wave, from January 2021 through November 2022, Thailand: Longitudinal study",2022-12-05,Preprint,Local,Cross-sectional survey ,Thailand,,Bangkok,"""This study analyzed the serum samples from children who were followed-up in the longitudinal serological study of pertussis vaccine immunity at the Center of Excellence in Clinical Virology, Chulalongkorn Memorial Hospital, Bangkok, Thailand, from January 1, 2021
115 through November 9, 2022.""",""" However, the exclusion criteria were parents who did not want to disclose vaccination and infection history, and children who previously received any dose of the inactivated COVID-19 vaccine, because such individuals could elicit anti-N IgG from the inactivated vaccine.""",2021-01-15,2021-12-15,Household and community samples,All,Children and Youth (0-17 years),5.0,7.0,Primary Estimate,,438,0.27399999999999997,0.157,0.40299999999999997,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,SARS-CoV-2 IgG II Quant ,Qualitative Elecsys Anti-SARS-CoV-2 Probe","Abbott Laboratories,Roche Diagnostics","CLIA, CMIA,CLIA, CMIA,CLIA",Serum,IgG,"['Nucleocapsid (N-protein)', 'Spike']",,,,['High'],,No,No,No,,Unclear,Yes,No,,Nungruthai Suntronwong,Chulalongkorn University,Not Unity-Aligned,10.1101/2022.12.01.22283006,2022-12-27,2024-03-01,Unverified,suntronwong_sars-cov-2_2022,THA
221216_Thailand_MinistryOfPublicHealth_Overall,221216_Thailand_MinistryOfPublicHealth,SARS-CoV-2 Seroprevalence in Unvaccinated Adults in Thailand in November 2021,2022-12-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Thailand,,,"""We approached subjects who visited COVID-19 vaccination centers regarding participation in this project. Enrolled subjects had to be aged between 18 and 60 years old, with no history of COVID-19 illness or vaccination. After providing written informed consent, the participants were bled and interviewed"".",,2021-11-15,2021-12-15,Household and community samples,All,Adults (18-64 years),18.0,60.0,Primary Estimate,,26717,0.013999999999999999,0.0124,0.0152,True,,,,True,Stratified non-probability,"Author designed (ELISA) -Spike,SARS-CoV-2 IgG II Quant ","NA,Abbott Laboratories","ELISA,CLIA, CMIA",Serum,IgG,Spike,Validated by developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Surakameth Mahasirimongkol,Ministry of Public Health,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10122169,2023-01-11,2024-03-01,Unverified,mahasirimongkol_sars-cov-2_2022,THA
221216_Thailand_MinistryOfPublicHealth_Age28-37,221216_Thailand_MinistryOfPublicHealth,SARS-CoV-2 Seroprevalence in Unvaccinated Adults in Thailand in November 2021,2022-12-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Thailand,,,"""We approached subjects who visited COVID-19 vaccination centers regarding participation in this project. Enrolled subjects had to be aged between 18 and 60 years old, with no history of COVID-19 illness or vaccination. After providing written informed consent, the participants were bled and interviewed"".",,2021-11-15,2021-12-15,Household and community samples,All,Adults (18-64 years),28.0,37.0,Age,Age: 28-37,5186,0.016,0.0126,0.0196,,,,,,Stratified non-probability,"Author designed (ELISA) -Spike,SARS-CoV-2 IgG II Quant ","NA,Abbott Laboratories","ELISA,CLIA, CMIA",Serum,IgG,Spike,Validated by developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Surakameth Mahasirimongkol,Ministry of Public Health,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10122169,2023-01-11,2024-03-01,Unverified,mahasirimongkol_sars-cov-2_2022,THA
221216_Thailand_MinistryOfPublicHealth_Age18-27,221216_Thailand_MinistryOfPublicHealth,SARS-CoV-2 Seroprevalence in Unvaccinated Adults in Thailand in November 2021,2022-12-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Thailand,,,"""We approached subjects who visited COVID-19 vaccination centers regarding participation in this project. Enrolled subjects had to be aged between 18 and 60 years old, with no history of COVID-19 illness or vaccination. After providing written informed consent, the participants were bled and interviewed"".",,2021-11-15,2021-12-15,Household and community samples,All,Adults (18-64 years),18.0,27.0,Age,Age: 18-27,8150,0.012,0.001,0.015,,,,,,Stratified non-probability,"Author designed (ELISA) -Spike,SARS-CoV-2 IgG II Quant ","NA,Abbott Laboratories","ELISA,CLIA, CMIA",Serum,IgG,Spike,Validated by developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Surakameth Mahasirimongkol,Ministry of Public Health,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10122169,2023-01-11,2024-03-01,Unverified,mahasirimongkol_sars-cov-2_2022,THA
221216_Thailand_MinistryOfPublicHealth_Age48-57,221216_Thailand_MinistryOfPublicHealth,SARS-CoV-2 Seroprevalence in Unvaccinated Adults in Thailand in November 2021,2022-12-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Thailand,,,"""We approached subjects who visited COVID-19 vaccination centers regarding participation in this project. Enrolled subjects had to be aged between 18 and 60 years old, with no history of COVID-19 illness or vaccination. After providing written informed consent, the participants were bled and interviewed"".",,2021-11-15,2021-12-15,Household and community samples,All,Adults (18-64 years),48.0,57.0,Age,Age: 48-57,6127,0.012,0.0091,0.0146,,,,,,Stratified non-probability,"Author designed (ELISA) -Spike,SARS-CoV-2 IgG II Quant ","NA,Abbott Laboratories","ELISA,CLIA, CMIA",Serum,IgG,Spike,Validated by developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Surakameth Mahasirimongkol,Ministry of Public Health,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10122169,2023-01-11,2024-03-01,Unverified,mahasirimongkol_sars-cov-2_2022,THA
221216_Thailand_MinistryOfPublicHealth_SexFemale,221216_Thailand_MinistryOfPublicHealth,SARS-CoV-2 Seroprevalence in Unvaccinated Adults in Thailand in November 2021,2022-12-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Thailand,,,"""We approached subjects who visited COVID-19 vaccination centers regarding participation in this project. Enrolled subjects had to be aged between 18 and 60 years old, with no history of COVID-19 illness or vaccination. After providing written informed consent, the participants were bled and interviewed"".",,2021-11-15,2021-12-15,Household and community samples,Female,Adults (18-64 years),18.0,60.0,Sex/Gender,Female,13873,0.016,0.0138,0.018000000000000002,,,,,,Stratified non-probability,"Author designed (ELISA) -Spike,SARS-CoV-2 IgG II Quant ","NA,Abbott Laboratories","ELISA,CLIA, CMIA",Serum,IgG,Spike,Validated by developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Surakameth Mahasirimongkol,Ministry of Public Health,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10122169,2023-01-11,2024-03-01,Unverified,mahasirimongkol_sars-cov-2_2022,THA
221216_Thailand_MinistryOfPublicHealth_Age38-47,221216_Thailand_MinistryOfPublicHealth,SARS-CoV-2 Seroprevalence in Unvaccinated Adults in Thailand in November 2021,2022-12-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Thailand,,,"""We approached subjects who visited COVID-19 vaccination centers regarding participation in this project. Enrolled subjects had to be aged between 18 and 60 years old, with no history of COVID-19 illness or vaccination. After providing written informed consent, the participants were bled and interviewed"".",,2021-11-15,2021-12-15,Household and community samples,All,Adults (18-64 years),38.0,47.0,Age,Age: 38-47,5146,0.015,0.0122,0.0191,,,,,,Stratified non-probability,"Author designed (ELISA) -Spike,SARS-CoV-2 IgG II Quant ","NA,Abbott Laboratories","ELISA,CLIA, CMIA",Serum,IgG,Spike,Validated by developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Surakameth Mahasirimongkol,Ministry of Public Health,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10122169,2023-01-11,2024-03-01,Unverified,mahasirimongkol_sars-cov-2_2022,THA
221216_Thailand_MinistryOfPublicHealth_Age58+,221216_Thailand_MinistryOfPublicHealth,SARS-CoV-2 Seroprevalence in Unvaccinated Adults in Thailand in November 2021,2022-12-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Thailand,,,"""We approached subjects who visited COVID-19 vaccination centers regarding participation in this project. Enrolled subjects had to be aged between 18 and 60 years old, with no history of COVID-19 illness or vaccination. After providing written informed consent, the participants were bled and interviewed"".",,2021-11-15,2021-12-15,Household and community samples,All,Adults (18-64 years),58.0,60.0,Age,Age: ≥58,2100,0.016,0.0108,0.0219,,,,,,Stratified non-probability,"Author designed (ELISA) -Spike,SARS-CoV-2 IgG II Quant ","NA,Abbott Laboratories","ELISA,CLIA, CMIA",Serum,IgG,Spike,Validated by developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Surakameth Mahasirimongkol,Ministry of Public Health,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10122169,2023-01-11,2024-03-01,Unverified,mahasirimongkol_sars-cov-2_2022,THA
221216_Thailand_MinistryOfPublicHealth_SexMale,221216_Thailand_MinistryOfPublicHealth,SARS-CoV-2 Seroprevalence in Unvaccinated Adults in Thailand in November 2021,2022-12-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Thailand,,,"""We approached subjects who visited COVID-19 vaccination centers regarding participation in this project. Enrolled subjects had to be aged between 18 and 60 years old, with no history of COVID-19 illness or vaccination. After providing written informed consent, the participants were bled and interviewed"".",,2021-11-15,2021-12-15,Household and community samples,Male,Adults (18-64 years),18.0,60.0,Sex/Gender,Male,12844,0.012,0.0098,0.013500000000000002,,,,,,Stratified non-probability,"Author designed (ELISA) -Spike,SARS-CoV-2 IgG II Quant ","NA,Abbott Laboratories","ELISA,CLIA, CMIA",Serum,IgG,Spike,Validated by developers,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Surakameth Mahasirimongkol,Ministry of Public Health,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10122169,2023-01-11,2024-03-01,Unverified,mahasirimongkol_sars-cov-2_2022,THA
230315_Chonburi_ChulalongkornUniversity_GeneralPop_Overall,230315_Chonburi_ChulalongkornUniversity_GeneralPop,"Seroprevalence of SARS-CoV-2 anti-nucleocapsid total Ig, anti-RBD IgG antibodies, and infection in Thailand: A cross-sectional survey from October 2022 to January 2023",2023-03-15,Preprint,Regional,Cross-sectional survey ,Thailand,Chonburi,,"""The inclusion criteria were age between the ages of newborn and 80 years; no immunological disorders such as immunocompetent, malignancy, or severe hematologic disorder; and no history of other chronic diseases.""","""Those who had congenital defects, chronic diseases, or any disease posed a risk of venipuncture or other blood disorders were excluded.""",2022-10-15,2023-01-15,Household and community samples,All,Multiple groups,0.0,79.0,Primary Estimate,Anti-RBS IgG,1193,0.964,,,True,,,,True,Stratified probability,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,"CLIA, CMIA",Serum,IgG,Spike,,,,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,,Jira Chansaenroj,Chulalongkorn University,Unity-Aligned,http://doi.org/10.21203/rs.3.rs-2646719/v1,2023-04-04,2024-03-09,Unverified,chansaenroj_seroprevalence_2023,THA
230315_Chonburi_ChulalongkornUniversity_HCWs_Overall,230315_Chonburi_ChulalongkornUniversity_HCWs,"Seroprevalence of SARS-CoV-2 anti-nucleocapsid total Ig, anti-RBD IgG antibodies, and infection in Thailand: A cross-sectional survey from October 2022 to January 2023",2023-03-15,Preprint,Regional,Cross-sectional survey ,Thailand,Chonburi,,"""The inclusion criteria were age between the ages of newborn and 80 years; no immunological disorders such as immunocompetent, malignancy, or severe hematologic disorder; and no history of other chronic diseases.""","""Those who had congenital defects, chronic diseases, or any disease posed a risk of venipuncture or other blood disorders were excluded.""",2022-10-15,2023-01-15,Health care workers and caregivers,All,Multiple groups,0.0,79.0,Primary Estimate,Anti-RBS IgG,266,1.0,,,True,,,,True,Stratified probability,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,"CLIA, CMIA",Serum,IgG,Spike,,,,['Moderate'],,Yes,No,No,,Yes,Yes,Yes,,Jira Chansaenroj,Chulalongkorn University,Not Unity-Aligned,http://doi.org/10.21203/rs.3.rs-2646719/v1,2023-04-04,2024-03-09,Unverified,chansaenroj_seroprevalence_2023,THA
230427_Bangkok_ChulalongkornUniversity_Omicron,230427_Bangkok_ChulalongkornUniversity_Omicron,"SARS-CoV-2 infection- induced seroprevalence among children and associated risk factors during the pre- and omicron-dominant wave, from January 2021 through December 2022, Thailand: A longitudinal study.",2023-04-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Thailand,,Bangkok,"""The inclusion criteria were healthy children who were followed-up in an
immunogenicity cohort study between 2015 and 2022""","""The exclusion criteria were parents who did not want to disclose the vaccination status and infection history and children who previously received any dose of the inactivated COVID-19 vaccine, because such individuals could elicit the anti-N IgG response from the inactivated
vaccine""",2022-01-15,2022-12-15,Residual sera,All,Children and Youth (0-17 years),5.0,7.0,Primary Estimate,,201,0.488,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (S),SARS-CoV-2 IgG II Quant ","Abbott Laboratories,Roche Diagnostics",Multiple Types,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Nungruthai Suntronwong,Chulalongkorn University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0279147,2023-05-31,2024-03-01,Unverified,suntronwong_sars-cov-2_2023,THA
230427_Bangkok_ChulalongkornUniversity_Preomicron,230427_Bangkok_ChulalongkornUniversity_Preomicron,"SARS-CoV-2 infection- induced seroprevalence among children and associated risk factors during the pre- and omicron-dominant wave, from January 2021 through December 2022, Thailand: A longitudinal study.",2023-04-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Thailand,,Bangkok,"""The inclusion criteria were healthy children who were followed-up in an
immunogenicity cohort study between 2015 and 2022""","""The exclusion criteria were parents who did not want to disclose the vaccination status and infection history and children who previously received any dose of the inactivated COVID-19 vaccine, because such individuals could elicit the anti-N IgG response from the inactivated
vaccine""",2021-01-15,2021-12-15,Residual sera,All,Children and Youth (0-17 years),5.0,7.0,Primary Estimate,,241,0.091,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (S),SARS-CoV-2 IgG II Quant ","Abbott Laboratories,Roche Diagnostics",Multiple Types,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Nungruthai Suntronwong,Chulalongkorn University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0279147,2023-05-31,2024-03-01,Unverified,suntronwong_sars-cov-2_2023,THA
230519_Bangkok_MinistryofPublicHealthThailand_Overall,230519_Bangkok_MinistryofPublicHealthThailand,"Seroprevalence of anti-SARS-CoV-2 antibodies and associated factors among household contacts of COVID-19 confirmed cases in Bangkok, Thailand.",2023-05-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Thailand,,Bangkok,close contacts of COVID-19 patients,"Exclusion criteria include refusal of informed consent, individuals unable to travel to the study site or declined to participate in any process of the study. Any individuals with a history of bleeding disorders, acute or chronic conditions that would limit the ability of individuals to participate in the study will also be excluded.",2021-01-12,2021-08-10,Household and community samples,All,Multiple groups,,,Primary Estimate,,452,0.2942,,,True,,,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Kamolthip Atsawawaranunt,"Ministry of Public Health ,Thailand",Unity-Aligned,https://dx.doi.org/10.1016/j.heliyon.2023.e16501,2023-06-22,2024-04-30,Verified,atsawawaranunt_seroprevalence_2023,THA
230519_Bangkok_MinistryofPublicHealthThailand_Age18-39,230519_Bangkok_MinistryofPublicHealthThailand,"Seroprevalence of anti-SARS-CoV-2 antibodies and associated factors among household contacts of COVID-19 confirmed cases in Bangkok, Thailand.",2023-05-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Thailand,,Bangkok,close contacts of COVID-19 patients,"Exclusion criteria include refusal of informed consent, individuals unable to travel to the study site or declined to participate in any process of the study. Any individuals with a history of bleeding disorders, acute or chronic conditions that would limit the ability of individuals to participate in the study will also be excluded.",2021-01-12,2021-08-10,Household and community samples,All,Adults (18-64 years),18.0,39.0,Age,18-39,293,0.2287,,,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Kamolthip Atsawawaranunt,"Ministry of Public Health ,Thailand",Unity-Aligned,https://dx.doi.org/10.1016/j.heliyon.2023.e16501,2024-04-30,2024-04-30,Verified,atsawawaranunt_seroprevalence_2023,THA
230519_Bangkok_MinistryofPublicHealthThailand_Age5-17,230519_Bangkok_MinistryofPublicHealthThailand,"Seroprevalence of anti-SARS-CoV-2 antibodies and associated factors among household contacts of COVID-19 confirmed cases in Bangkok, Thailand.",2023-05-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Thailand,,Bangkok,close contacts of COVID-19 patients,"Exclusion criteria include refusal of informed consent, individuals unable to travel to the study site or declined to participate in any process of the study. Any individuals with a history of bleeding disorders, acute or chronic conditions that would limit the ability of individuals to participate in the study will also be excluded.",2021-01-12,2021-08-10,Household and community samples,All,Children and Youth (0-17 years),5.0,17.0,Age,5-17,22,0.2727,,,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Kamolthip Atsawawaranunt,"Ministry of Public Health ,Thailand",Unity-Aligned,https://dx.doi.org/10.1016/j.heliyon.2023.e16501,2024-04-30,2024-04-30,Verified,atsawawaranunt_seroprevalence_2023,THA
230519_Bangkok_MinistryofPublicHealthThailand_Age60+,230519_Bangkok_MinistryofPublicHealthThailand,"Seroprevalence of anti-SARS-CoV-2 antibodies and associated factors among household contacts of COVID-19 confirmed cases in Bangkok, Thailand.",2023-05-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Thailand,,Bangkok,close contacts of COVID-19 patients,"Exclusion criteria include refusal of informed consent, individuals unable to travel to the study site or declined to participate in any process of the study. Any individuals with a history of bleeding disorders, acute or chronic conditions that would limit the ability of individuals to participate in the study will also be excluded.",2021-01-12,2021-08-10,Household and community samples,All,Seniors (65+ years),60.0,,Age,60+,27,0.5926,,,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Kamolthip Atsawawaranunt,"Ministry of Public Health ,Thailand",Unity-Aligned,https://dx.doi.org/10.1016/j.heliyon.2023.e16501,2024-04-30,2024-04-30,Verified,atsawawaranunt_seroprevalence_2023,THA
230519_Bangkok_MinistryofPublicHealthThailand_Age40-59,230519_Bangkok_MinistryofPublicHealthThailand,"Seroprevalence of anti-SARS-CoV-2 antibodies and associated factors among household contacts of COVID-19 confirmed cases in Bangkok, Thailand.",2023-05-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Thailand,,Bangkok,close contacts of COVID-19 patients,"Exclusion criteria include refusal of informed consent, individuals unable to travel to the study site or declined to participate in any process of the study. Any individuals with a history of bleeding disorders, acute or chronic conditions that would limit the ability of individuals to participate in the study will also be excluded.",2021-01-12,2021-08-10,Household and community samples,All,Adults (18-64 years),40.0,59.0,Age,40-59,110,0.4,,,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Kamolthip Atsawawaranunt,"Ministry of Public Health ,Thailand",Unity-Aligned,https://dx.doi.org/10.1016/j.heliyon.2023.e16501,2024-04-30,2024-04-30,Verified,atsawawaranunt_seroprevalence_2023,THA
220328_Dili_CharlesDarwinUniversity_Baseline_Overall,220328_Dili_CharlesDarwinUniversity_Baseline,"Serological surveillance of healthcare workers to evaluate natural infection- and vaccine-derived immunity to SARS-CoV-2 during an outbreak in Dili, Timor-Leste",2022-03-28,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Timor-Leste,Dili,Dili,All individuals working in patient-facing and/or clinical sample-processing roles at any of these facilities were eligible,,2021-04-07,2021-05-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,324,0.17300000000000001,,,True,,,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Paul Arkell,Charles Darwin University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2022.03.043,2022-04-12,2024-03-01,Unverified,arkell_serological_2022,TLS
220328_Dili_CharlesDarwinUniversity_FollowUp_Overall,220328_Dili_CharlesDarwinUniversity_FollowUp,"Serological surveillance of healthcare workers to evaluate natural infection- and vaccine-derived immunity to SARS-CoV-2 during an outbreak in Dili, Timor-Leste",2022-03-28,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Timor-Leste,Dili,Dili,All individuals working in patient-facing and/or clinical sample-processing roles at any of these facilities were eligible,,2021-07-09,2021-09-08,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,157,0.943,,,True,,,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Paul Arkell,Charles Darwin University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2022.03.043,2022-04-12,2024-03-01,Unverified,arkell_serological_2022,TLS
200807_Lome_UniversiteDeLome_Overall,200807_Lome_UniversiteDeLome,Prevalence of SARS-CoV-2 among high-risk populations in Lome (Togo) in 2020,2020-08-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Togo,,Lome,Participants were eligible to participate in the study if the following four criteria were fulfilled: (i) ≥ 18 years of age; (ii) working in one of the five sectors; (iii) having been regularly present at the workstation for the past 30 days; (iv) living in Lomé for the past 3 months.,,2020-04-23,2020-05-08,Non-essential workers and unemployed persons,All,Adults (18-64 years),18.0,,Primary Estimate,,955,0.009000000000000001,0.004,0.018000000000000002,True,,,,True,Convenience,Lungene 2019-nCoV IgG/IgM Rapid Test,Hangzhou Clongene Biotech Co. Ltd ,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.7709999999999999,0.9540000000000001,['High'],Yes,No,Yes,Yes,Unclear,No,Yes,No,Unclear,Wemboo Halatoko,Universite de Lome,Not Unity-Aligned,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0242124,2020-09-23,2024-03-01,Verified,halatoko_prevalence_2020,TGO
220615_Lome_UniveristyofLome_Overall,220615_Lome_UniversityofLome,"Prevalence of Malaria and Covid-19 in Febrile Patients in Lome, Togo in 2020.",2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Togo,,"Lomé
","Inclusion criteria were: (a) consulting in one of the three participating health facilities; (b) being at least 10 years old, regardless of sex; (c) having febrile syndrome with high suspicion of malaria; and (d) giving an informed consent,
signed by adults or, in the case of children, by their guardians or parents.

The three health facilities were: the community health center of Legbassito (CHC Legbassito), the Hospital of Bè, and the teaching hospital “Centre Hospitalier Universitaire Campus” (CHU Campus)",,2020-09-01,2020-10-31,Representative patient population,All,Multiple groups,10.0,,Primary Estimate,,243,0.057999999999999996,,,True,,,,True,Convenience,CLUNGENE SARS-COV-2 VIRUS (COVID-19) IgG/IgM Rapid Test Cassette lateral flow immunoassay,CLUNGENE,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.77,0.9500000000000001,['High'],,No,No,Yes,,Yes,Yes,No,,Ameyo Monique Dorkenoo,University of Lomé,Unity-Aligned,https://dx.doi.org/10.1007/s11686-022-00586-6,2022-07-20,2024-03-23,Verified,dorkenooPrevalenceMalariaCovid192022,TGO
220615_Lome_UniveristyofLome_10to19,220615_Lome_UniversityofLome,"Prevalence of Malaria and Covid-19 in Febrile Patients in Lome, Togo in 2020.",2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Togo,,"Lomé
","Inclusion criteria were: (a) consulting in one of the three participating health facilities; (b) being at least 10 years old, regardless of sex; (c) having febrile syndrome with high suspicion of malaria; and (d) giving an informed consent,
signed by adults or, in the case of children, by their guardians or parents.

The three health facilities were: the community health center of Legbassito (CHC Legbassito), the Hospital of Bè, and the teaching hospital “Centre Hospitalier Universitaire Campus” (CHU Campus)",,2020-09-01,2020-10-31,Representative patient population,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,68,0.11800000000000001,,,,,,,,Convenience,CLUNGENE SARS-COV-2 VIRUS (COVID-19) IgG/IgM Rapid Test Cassette lateral flow immunoassay,CLUNGENE,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.77,0.9500000000000001,['High'],,No,No,Yes,,Yes,Yes,No,,Ameyo Monique Dorkenoo,University of Lomé,Unity-Aligned,https://dx.doi.org/10.1007/s11686-022-00586-6,2022-07-20,2024-03-23,Verified,dorkenooPrevalenceMalariaCovid192022,TGO
220615_Lome_UniveristyofLome_40to49,220615_Lome_UniversityofLome,"Prevalence of Malaria and Covid-19 in Febrile Patients in Lome, Togo in 2020.",2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Togo,,"Lomé
","Inclusion criteria were: (a) consulting in one of the three participating health facilities; (b) being at least 10 years old, regardless of sex; (c) having febrile syndrome with high suspicion of malaria; and (d) giving an informed consent,
signed by adults or, in the case of children, by their guardians or parents.

The three health facilities were: the community health center of Legbassito (CHC Legbassito), the Hospital of Bè, and the teaching hospital “Centre Hospitalier Universitaire Campus” (CHU Campus)",,2020-09-01,2020-10-31,Representative patient population,All,Adults (18-64 years),40.0,49.0,Age,40-49,40,0.025,,,,,,,,Convenience,CLUNGENE SARS-COV-2 VIRUS (COVID-19) IgG/IgM Rapid Test Cassette lateral flow immunoassay,CLUNGENE,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.77,0.9500000000000001,['High'],,No,No,Yes,,Yes,Yes,No,,Ameyo Monique Dorkenoo,University of Lomé,Unity-Aligned,https://dx.doi.org/10.1007/s11686-022-00586-6,2022-07-20,2024-03-23,Verified,dorkenooPrevalenceMalariaCovid192022,TGO
220615_Lome_UniveristyofLome_30to39,220615_Lome_UniversityofLome,"Prevalence of Malaria and Covid-19 in Febrile Patients in Lome, Togo in 2020.",2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Togo,,"Lomé
","Inclusion criteria were: (a) consulting in one of the three participating health facilities; (b) being at least 10 years old, regardless of sex; (c) having febrile syndrome with high suspicion of malaria; and (d) giving an informed consent,
signed by adults or, in the case of children, by their guardians or parents.

The three health facilities were: the community health center of Legbassito (CHC Legbassito), the Hospital of Bè, and the teaching hospital “Centre Hospitalier Universitaire Campus” (CHU Campus)",,2020-09-01,2020-10-31,Representative patient population,All,Adults (18-64 years),30.0,39.0,Age,30-39,42,0.071,,,,,,,,Convenience,CLUNGENE SARS-COV-2 VIRUS (COVID-19) IgG/IgM Rapid Test Cassette lateral flow immunoassay,CLUNGENE,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.77,0.9500000000000001,['High'],,No,No,Yes,,Yes,Yes,No,,Ameyo Monique Dorkenoo,University of Lomé,Unity-Aligned,https://dx.doi.org/10.1007/s11686-022-00586-6,2022-07-20,2024-03-23,Verified,dorkenooPrevalenceMalariaCovid192022,TGO
220615_Lome_UniveristyofLome_50plus,220615_Lome_UniversityofLome,"Prevalence of Malaria and Covid-19 in Febrile Patients in Lome, Togo in 2020.",2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Togo,,"Lomé
","Inclusion criteria were: (a) consulting in one of the three participating health facilities; (b) being at least 10 years old, regardless of sex; (c) having febrile syndrome with high suspicion of malaria; and (d) giving an informed consent,
signed by adults or, in the case of children, by their guardians or parents.

The three health facilities were: the community health center of Legbassito (CHC Legbassito), the Hospital of Bè, and the teaching hospital “Centre Hospitalier Universitaire Campus” (CHU Campus)",,2020-09-01,2020-10-31,Representative patient population,All,Multiple groups,50.0,,Age,>50,31,0.0,,,,,,,,Convenience,CLUNGENE SARS-COV-2 VIRUS (COVID-19) IgG/IgM Rapid Test Cassette lateral flow immunoassay,CLUNGENE,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.77,0.9500000000000001,['High'],,No,No,Yes,,Yes,Yes,No,,Ameyo Monique Dorkenoo,University of Lomé,Unity-Aligned,https://dx.doi.org/10.1007/s11686-022-00586-6,2022-07-20,2024-03-23,Verified,dorkenooPrevalenceMalariaCovid192022,TGO
220615_Lome_UniveristyofLome_Female,220615_Lome_UniversityofLome,"Prevalence of Malaria and Covid-19 in Febrile Patients in Lome, Togo in 2020.",2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Togo,,"Lomé
","Inclusion criteria were: (a) consulting in one of the three participating health facilities; (b) being at least 10 years old, regardless of sex; (c) having febrile syndrome with high suspicion of malaria; and (d) giving an informed consent,
signed by adults or, in the case of children, by their guardians or parents.

The three health facilities were: the community health center of Legbassito (CHC Legbassito), the Hospital of Bè, and the teaching hospital “Centre Hospitalier Universitaire Campus” (CHU Campus)",,2020-09-01,2020-10-31,Representative patient population,Female,Multiple groups,10.0,,Sex/Gender,Female,150,0.06,,,,,,,,Convenience,CLUNGENE SARS-COV-2 VIRUS (COVID-19) IgG/IgM Rapid Test Cassette lateral flow immunoassay,CLUNGENE,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.77,0.9500000000000001,['High'],,No,No,Yes,,Yes,Yes,No,,Ameyo Monique Dorkenoo,University of Lomé,Unity-Aligned,https://dx.doi.org/10.1007/s11686-022-00586-6,2022-07-20,2024-03-23,Verified,dorkenooPrevalenceMalariaCovid192022,TGO
220615_Lome_UniveristyofLome_Male,220615_Lome_UniversityofLome,"Prevalence of Malaria and Covid-19 in Febrile Patients in Lome, Togo in 2020.",2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Togo,,"Lomé
","Inclusion criteria were: (a) consulting in one of the three participating health facilities; (b) being at least 10 years old, regardless of sex; (c) having febrile syndrome with high suspicion of malaria; and (d) giving an informed consent,
signed by adults or, in the case of children, by their guardians or parents.

The three health facilities were: the community health center of Legbassito (CHC Legbassito), the Hospital of Bè, and the teaching hospital “Centre Hospitalier Universitaire Campus” (CHU Campus)",,2020-09-01,2020-10-31,Representative patient population,Male,Multiple groups,10.0,,Sex/Gender,Male,93,0.054000000000000006,,,,,,,,Convenience,CLUNGENE SARS-COV-2 VIRUS (COVID-19) IgG/IgM Rapid Test Cassette lateral flow immunoassay,CLUNGENE,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.77,0.9500000000000001,['High'],,No,No,Yes,,Yes,Yes,No,,Ameyo Monique Dorkenoo,University of Lomé,Unity-Aligned,https://dx.doi.org/10.1007/s11686-022-00586-6,2022-07-20,2024-03-23,Verified,dorkenooPrevalenceMalariaCovid192022,TGO
220615_Lome_UniveristyofLome_20to29,220615_Lome_UniversityofLome,"Prevalence of Malaria and Covid-19 in Febrile Patients in Lome, Togo in 2020.",2022-06-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Togo,,"Lomé
","Inclusion criteria were: (a) consulting in one of the three participating health facilities; (b) being at least 10 years old, regardless of sex; (c) having febrile syndrome with high suspicion of malaria; and (d) giving an informed consent,
signed by adults or, in the case of children, by their guardians or parents.

The three health facilities were: the community health center of Legbassito (CHC Legbassito), the Hospital of Bè, and the teaching hospital “Centre Hospitalier Universitaire Campus” (CHU Campus)",,2020-09-01,2020-10-31,Representative patient population,All,Adults (18-64 years),20.0,29.0,Age,20-29,62,0.032,,,,,,,,Convenience,CLUNGENE SARS-COV-2 VIRUS (COVID-19) IgG/IgM Rapid Test Cassette lateral flow immunoassay,CLUNGENE,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.77,0.9500000000000001,['High'],,No,No,Yes,,Yes,Yes,No,,Ameyo Monique Dorkenoo,University of Lomé,Unity-Aligned,https://dx.doi.org/10.1007/s11686-022-00586-6,2022-07-20,2024-03-23,Verified,dorkenooPrevalenceMalariaCovid192022,TGO
220929_Lomé_UniversityofLomé_Anti-S_All_Primary,220929_Lomé_UniversityofLomé,"High SARS-CoV-2 seroprevalence among street adolescents in Lom√©, Togo, 2021",2022-09-29,Preprint,Local,Cross-sectional survey ,Togo,Maritime Region,Lomé,"""All adolescents aged between 13- and 19-years old living in the street were eligible for inclusion following informed consent. """,Outside eligible age group,2021-06-26,2021-07-03,Persons experiencing homelessness,All,Multiple groups,13.0,19.0,Primary Estimate,,299,0.635,0.578,0.6900000000000001,True,,,,True,Entire sample,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Spike,,,,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Arnold Junior Sadio,"Paris Cité University and Sorbonne Paris Nord University, IAME",Not Unity-Aligned,10.21203/rs.3.rs-2072529/v1,2022-10-06,2024-03-01,Unverified,sadio_high_2022,TGO
220929_Lomé_UniversityofLomé_Anti-N_Ages15-19,220929_Lomé_UniversityofLomé,"High SARS-CoV-2 seroprevalence among street adolescents in Lom√©, Togo, 2021",2022-09-29,Preprint,Local,Cross-sectional survey ,Togo,Maritime Region,Lomé,"""All adolescents aged between 13- and 19-years old living in the street were eligible for inclusion following informed consent. """,Outside eligible age group,2021-06-26,2021-07-03,Persons experiencing homelessness,All,Multiple groups,15.0,19.0,Age,Ages 15-19,194,0.438,0.368,0.511,,,,,,Entire sample,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Arnold Junior Sadio,"Paris Cité University and Sorbonne Paris Nord University, IAME",Not Unity-Aligned,10.21203/rs.3.rs-2072529/v1,2022-10-06,2024-03-01,Unverified,sadio_high_2022,TGO
220929_Lomé_UniversityofLomé_Anti-S_Ages10-14,220929_Lomé_UniversityofLomé,"High SARS-CoV-2 seroprevalence among street adolescents in Lom√©, Togo, 2021",2022-09-29,Preprint,Local,Cross-sectional survey ,Togo,Maritime Region,Lomé,"""All adolescents aged between 13- and 19-years old living in the street were eligible for inclusion following informed consent. """,Outside eligible age group,2021-06-26,2021-07-03,Persons experiencing homelessness,All,Children and Youth (0-17 years),,14.0,Age,10-14,105,0.6,0.5,0.693,,,,,,Entire sample,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Spike,,,,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Arnold Junior Sadio,"Paris Cité University and Sorbonne Paris Nord University, IAME",Not Unity-Aligned,10.21203/rs.3.rs-2072529/v1,2022-10-06,2024-03-01,Unverified,sadio_high_2022,TGO
220929_Lomé_UniversityofLomé_Anti-N_Ages10-14,220929_Lomé_UniversityofLomé,"High SARS-CoV-2 seroprevalence among street adolescents in Lom√©, Togo, 2021",2022-09-29,Preprint,Local,Cross-sectional survey ,Togo,Maritime Region,Lomé,"""All adolescents aged between 13- and 19-years old living in the street were eligible for inclusion following informed consent. """,Outside eligible age group,2021-06-26,2021-07-03,Persons experiencing homelessness,All,Children and Youth (0-17 years),,14.0,Age,,105,0.381,0.289,0.48100000000000004,,,,,,Entire sample,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Arnold Junior Sadio,"Paris Cité University and Sorbonne Paris Nord University, IAME",Not Unity-Aligned,10.21203/rs.3.rs-2072529/v1,2022-10-06,2024-03-01,Unverified,sadio_high_2022,TGO
220929_Lomé_UniversityofLomé_Anti-S_Ages15-19,220929_Lomé_UniversityofLomé,"High SARS-CoV-2 seroprevalence among street adolescents in Lom√©, Togo, 2021",2022-09-29,Preprint,Local,Cross-sectional survey ,Togo,Maritime Region,Lomé,"""All adolescents aged between 13- and 19-years old living in the street were eligible for inclusion following informed consent. """,Outside eligible age group,2021-06-26,2021-07-03,Persons experiencing homelessness,All,Multiple groups,15.0,19.0,Age,15-19,194,0.655,0.583,0.72,,,,,,Entire sample,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Spike,,,,['Moderate'],,Yes,No,Yes,,Yes,Yes,Yes,,Arnold Junior Sadio,"Paris Cité University and Sorbonne Paris Nord University, IAME",Not Unity-Aligned,10.21203/rs.3.rs-2072529/v1,2022-10-06,2024-03-01,Unverified,sadio_high_2022,TGO
221208_Togo_ResearchInstituteForSustainableDevelopment_PopTestAdj,221208_Togo_ResearchInstituteForSustainableDevelopment,"SARS-CoV-2 antibody seroprevalence in Togo: a national cross-sectional household survey, May–June, 2021",2022-12-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Togo,"Maritime, Plateaux, Centrale, Savanes","Grand Lome, Kara","Subjects were included if they met the following criteria: i) they were 5 years of age or older, ii) they resided in a randomly selected household, iii) they gave free and informed consent to participate in the study and to
provide a blood sample. For minors under the age of 18, in addition to the subject’s assent, consent from the legal guardian was required.",,2021-05-05,2021-06-30,Household and community samples,All,Multiple groups,6.0,99.0,Primary Estimate,,7593,0.655,0.643,0.6659999999999999,True,True,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.9436,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yao Konu,Research Institute for Sustainable Development,Unity-Aligned,https://doi.org/10.1186/s12889-022-14794-2,2024-03-30,2024-03-31,Verified,konu_sars-cov-2_2022-1,TGO
221208_Togo_ResearchInstituteForSustainableDevelopment_PopAdj,221208_Togo_ResearchInstituteForSustainableDevelopment,"SARS-CoV-2 antibody seroprevalence in Togo: a national cross-sectional household survey, May–June, 2021",2022-12-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Togo,"Maritime, Plateaux, Centrale, Savanes","Grand Lome, Kara","Subjects were included if they met the following criteria: i) they were 5 years of age or older, ii) they resided in a randomly selected household, iii) they gave free and informed consent to participate in the study and to
provide a blood sample. For minors under the age of 18, in addition to the subject’s assent, consent from the legal guardian was required.",,2021-05-05,2021-06-30,Household and community samples,All,Multiple groups,6.0,99.0,Analysis,,7593,0.618,0.6070000000000001,0.629,,,True,,True,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.9436,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yao Konu,Research Institute for Sustainable Development,Unity-Aligned,https://doi.org/10.1186/s12889-022-14794-2,2024-03-30,2024-03-31,Verified,konu_sars-cov-2_2022-1,TGO
221208_Togo_ResearchInstituteForSustainableDevelopment_Female,221208_Togo_ResearchInstituteForSustainableDevelopment,"SARS-CoV-2 antibody seroprevalence in Togo: a national cross-sectional household survey, May–June, 2021",2022-12-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Togo,"Maritime, Plateaux, Centrale, Savanes","Grand Lome, Kara","Subjects were included if they met the following criteria: i) they were 5 years of age or older, ii) they resided in a randomly selected household, iii) they gave free and informed consent to participate in the study and to
provide a blood sample. For minors under the age of 18, in addition to the subject’s assent, consent from the legal guardian was required.",,2021-05-05,2021-06-30,Household and community samples,Female,Multiple groups,6.0,99.0,Sex/Gender,Female,4164,0.611,0.595,0.626,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.9436,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yao Konu,Research Institute for Sustainable Development,Unity-Aligned,https://doi.org/10.1186/s12889-022-14794-2,2024-03-30,2024-03-31,Verified,konu_sars-cov-2_2022-1,TGO
221208_Togo_ResearchInstituteForSustainableDevelopment_>70,221208_Togo_ResearchInstituteForSustainableDevelopment,"SARS-CoV-2 antibody seroprevalence in Togo: a national cross-sectional household survey, May–June, 2021",2022-12-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Togo,"Maritime, Plateaux, Centrale, Savanes","Grand Lome, Kara","Subjects were included if they met the following criteria: i) they were 5 years of age or older, ii) they resided in a randomly selected household, iii) they gave free and informed consent to participate in the study and to
provide a blood sample. For minors under the age of 18, in addition to the subject’s assent, consent from the legal guardian was required.",,2021-05-05,2021-06-30,Household and community samples,All,Seniors (65+ years),71.0,99.0,Age,>70,227,0.601,0.5750000000000001,0.627,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.9436,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yao Konu,Research Institute for Sustainable Development,Unity-Aligned,https://doi.org/10.1186/s12889-022-14794-2,2024-03-30,2024-03-31,Verified,konu_sars-cov-2_2022-1,TGO
221208_Togo_ResearchInstituteForSustainableDevelopment_<10,221208_Togo_ResearchInstituteForSustainableDevelopment,"SARS-CoV-2 antibody seroprevalence in Togo: a national cross-sectional household survey, May–June, 2021",2022-12-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Togo,"Maritime, Plateaux, Centrale, Savanes","Grand Lome, Kara","Subjects were included if they met the following criteria: i) they were 5 years of age or older, ii) they resided in a randomly selected household, iii) they gave free and informed consent to participate in the study and to
provide a blood sample. For minors under the age of 18, in addition to the subject’s assent, consent from the legal guardian was required.",,2021-05-05,2021-06-30,Household and community samples,All,Children and Youth (0-17 years),6.0,9.0,Age,<10,937,0.47200000000000003,0.44,0.504,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.9436,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yao Konu,Research Institute for Sustainable Development,Unity-Aligned,https://doi.org/10.1186/s12889-022-14794-2,2024-03-30,2024-03-31,Verified,konu_sars-cov-2_2022-1,TGO
221208_Togo_ResearchInstituteForSustainableDevelopment_Unvaccinated,221208_Togo_ResearchInstituteForSustainableDevelopment,"SARS-CoV-2 antibody seroprevalence in Togo: a national cross-sectional household survey, May–June, 2021",2022-12-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Togo,"Maritime, Plateaux, Centrale, Savanes","Grand Lome, Kara","Subjects were included if they met the following criteria: i) they were 5 years of age or older, ii) they resided in a randomly selected household, iii) they gave free and informed consent to participate in the study and to
provide a blood sample. For minors under the age of 18, in addition to the subject’s assent, consent from the legal guardian was required.",,2021-05-05,2021-06-30,Household and community samples,All,Multiple groups,6.0,99.0,COVID-19 vaccination status,Unvaccinate,4924,0.616,0.5910000000000001,0.63,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.9436,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yao Konu,Research Institute for Sustainable Development,Unity-Aligned,https://doi.org/10.1186/s12889-022-14794-2,2024-03-30,2024-03-31,Verified,konu_sars-cov-2_2022-1,TGO
221208_Togo_ResearchInstituteForSustainableDevelopment_Vaccinated,221208_Togo_ResearchInstituteForSustainableDevelopment,"SARS-CoV-2 antibody seroprevalence in Togo: a national cross-sectional household survey, May–June, 2021",2022-12-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Togo,"Maritime, Plateaux, Centrale, Savanes","Grand Lome, Kara","Subjects were included if they met the following criteria: i) they were 5 years of age or older, ii) they resided in a randomly selected household, iii) they gave free and informed consent to participate in the study and to
provide a blood sample. For minors under the age of 18, in addition to the subject’s assent, consent from the legal guardian was required.",,2021-05-05,2021-06-30,Household and community samples,All,Multiple groups,6.0,99.0,COVID-19 vaccination status,Vaccinated,1316,0.8170000000000001,0.795,0.838,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.9436,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yao Konu,Research Institute for Sustainable Development,Unity-Aligned,https://doi.org/10.1186/s12889-022-14794-2,2024-03-30,2024-03-31,Verified,konu_sars-cov-2_2022-1,TGO
221208_Togo_ResearchInstituteForSustainableDevelopment_30-39,221208_Togo_ResearchInstituteForSustainableDevelopment,"SARS-CoV-2 antibody seroprevalence in Togo: a national cross-sectional household survey, May–June, 2021",2022-12-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Togo,"Maritime, Plateaux, Centrale, Savanes","Grand Lome, Kara","Subjects were included if they met the following criteria: i) they were 5 years of age or older, ii) they resided in a randomly selected household, iii) they gave free and informed consent to participate in the study and to
provide a blood sample. For minors under the age of 18, in addition to the subject’s assent, consent from the legal guardian was required.",,2021-05-05,2021-06-30,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,1640,0.698,0.668,0.7290000000000001,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.9436,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yao Konu,Research Institute for Sustainable Development,Unity-Aligned,https://doi.org/10.1186/s12889-022-14794-2,2024-03-30,2024-03-31,Verified,konu_sars-cov-2_2022-1,TGO
221208_Togo_ResearchInstituteForSustainableDevelopment_50-59,221208_Togo_ResearchInstituteForSustainableDevelopment,"SARS-CoV-2 antibody seroprevalence in Togo: a national cross-sectional household survey, May–June, 2021",2022-12-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Togo,"Maritime, Plateaux, Centrale, Savanes","Grand Lome, Kara","Subjects were included if they met the following criteria: i) they were 5 years of age or older, ii) they resided in a randomly selected household, iii) they gave free and informed consent to participate in the study and to
provide a blood sample. For minors under the age of 18, in addition to the subject’s assent, consent from the legal guardian was required.",,2021-05-05,2021-06-30,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,767,0.657,0.605,0.7090000000000001,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.9436,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yao Konu,Research Institute for Sustainable Development,Unity-Aligned,https://doi.org/10.1186/s12889-022-14794-2,2024-03-30,2024-03-31,Verified,konu_sars-cov-2_2022-1,TGO
221208_Togo_ResearchInstituteForSustainableDevelopment_40-49,221208_Togo_ResearchInstituteForSustainableDevelopment,"SARS-CoV-2 antibody seroprevalence in Togo: a national cross-sectional household survey, May–June, 2021",2022-12-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Togo,"Maritime, Plateaux, Centrale, Savanes","Grand Lome, Kara","Subjects were included if they met the following criteria: i) they were 5 years of age or older, ii) they resided in a randomly selected household, iii) they gave free and informed consent to participate in the study and to
provide a blood sample. For minors under the age of 18, in addition to the subject’s assent, consent from the legal guardian was required.",,2021-05-05,2021-06-30,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,1153,0.677,0.639,0.715,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.9436,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yao Konu,Research Institute for Sustainable Development,Unity-Aligned,https://doi.org/10.1186/s12889-022-14794-2,2024-03-30,2024-03-31,Verified,konu_sars-cov-2_2022-1,TGO
221208_Togo_ResearchInstituteForSustainableDevelopment_10-14,221208_Togo_ResearchInstituteForSustainableDevelopment,"SARS-CoV-2 antibody seroprevalence in Togo: a national cross-sectional household survey, May–June, 2021",2022-12-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Togo,"Maritime, Plateaux, Centrale, Savanes","Grand Lome, Kara","Subjects were included if they met the following criteria: i) they were 5 years of age or older, ii) they resided in a randomly selected household, iii) they gave free and informed consent to participate in the study and to
provide a blood sample. For minors under the age of 18, in addition to the subject’s assent, consent from the legal guardian was required.",,2021-05-05,2021-06-30,Household and community samples,All,Children and Youth (0-17 years),10.0,14.0,Age,10-14,738,0.56,0.528,0.5920000000000001,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.9436,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yao Konu,Research Institute for Sustainable Development,Unity-Aligned,https://doi.org/10.1186/s12889-022-14794-2,2024-03-30,2024-03-31,Verified,konu_sars-cov-2_2022-1,TGO
221208_Togo_ResearchInstituteForSustainableDevelopment_Male,221208_Togo_ResearchInstituteForSustainableDevelopment,"SARS-CoV-2 antibody seroprevalence in Togo: a national cross-sectional household survey, May–June, 2021",2022-12-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Togo,"Maritime, Plateaux, Centrale, Savanes","Grand Lome, Kara","Subjects were included if they met the following criteria: i) they were 5 years of age or older, ii) they resided in a randomly selected household, iii) they gave free and informed consent to participate in the study and to
provide a blood sample. For minors under the age of 18, in addition to the subject’s assent, consent from the legal guardian was required.",,2021-05-05,2021-06-30,Household and community samples,Male,Multiple groups,6.0,99.0,Sex/Gender,Male,3429,0.625,0.61,0.64,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.9436,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yao Konu,Research Institute for Sustainable Development,Unity-Aligned,https://doi.org/10.1186/s12889-022-14794-2,2024-03-30,2024-03-31,Verified,konu_sars-cov-2_2022-1,TGO
221208_Togo_ResearchInstituteForSustainableDevelopment_60-70,221208_Togo_ResearchInstituteForSustainableDevelopment,"SARS-CoV-2 antibody seroprevalence in Togo: a national cross-sectional household survey, May–June, 2021",2022-12-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Togo,"Maritime, Plateaux, Centrale, Savanes","Grand Lome, Kara","Subjects were included if they met the following criteria: i) they were 5 years of age or older, ii) they resided in a randomly selected household, iii) they gave free and informed consent to participate in the study and to
provide a blood sample. For minors under the age of 18, in addition to the subject’s assent, consent from the legal guardian was required.",,2021-05-05,2021-06-30,Household and community samples,All,Seniors (65+ years),60.0,70.0,Age,60-69,382,0.669,0.64,0.698,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.9436,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yao Konu,Research Institute for Sustainable Development,Unity-Aligned,https://doi.org/10.1186/s12889-022-14794-2,2024-03-30,2024-03-31,Verified,konu_sars-cov-2_2022-1,TGO
221208_Togo_ResearchInstituteForSustainableDevelopment_20-29,221208_Togo_ResearchInstituteForSustainableDevelopment,"SARS-CoV-2 antibody seroprevalence in Togo: a national cross-sectional household survey, May–June, 2021",2022-12-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Togo,"Maritime, Plateaux, Centrale, Savanes","Grand Lome, Kara","Subjects were included if they met the following criteria: i) they were 5 years of age or older, ii) they resided in a randomly selected household, iii) they gave free and informed consent to participate in the study and to
provide a blood sample. For minors under the age of 18, in addition to the subject’s assent, consent from the legal guardian was required.",,2021-05-05,2021-06-30,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,1266,0.634,0.606,0.662,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.9436,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yao Konu,Research Institute for Sustainable Development,Unity-Aligned,https://doi.org/10.1186/s12889-022-14794-2,2024-03-30,2024-03-31,Verified,konu_sars-cov-2_2022-1,TGO
221208_Togo_ResearchInstituteForSustainableDevelopment_15-19,221208_Togo_ResearchInstituteForSustainableDevelopment,"SARS-CoV-2 antibody seroprevalence in Togo: a national cross-sectional household survey, May–June, 2021",2022-12-08,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Togo,"Maritime, Plateaux, Centrale, Savanes","Grand Lome, Kara","Subjects were included if they met the following criteria: i) they were 5 years of age or older, ii) they resided in a randomly selected household, iii) they gave free and informed consent to participate in the study and to
provide a blood sample. For minors under the age of 18, in addition to the subject’s assent, consent from the legal guardian was required.",,2021-05-05,2021-06-30,Household and community samples,All,Children and Youth (0-17 years),15.0,19.0,Age,15-19,483,0.6609999999999999,0.626,0.6950000000000001,,,True,,,Stratified probability,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Plasma,TotalAntibody,Spike,Validated by manufacturers,0.9436,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yao Konu,Research Institute for Sustainable Development,Unity-Aligned,https://doi.org/10.1186/s12889-022-14794-2,2024-03-30,2024-03-31,Verified,konu_sars-cov-2_2022-1,TGO
230403_Lomé_UniversityofLomé_overall,230403_Lomé_UniversityofLomé,"High SARS-CoV-2 seroprevalence among street adolescents in Lome, Togo, 2021.",2023-04-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Togo,,Lome,"""All adolescents aged between 13- and 19-years old liv- ing in the street were eligible for inclusion following informed consent. """,,2021-06-26,2021-07-03,Persons experiencing homelessness,All,Children and Youth (0-17 years),10.0,19.0,Primary Estimate,,299,0.635,0.578,0.69,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.99,1.0,['High'],,No,No,Yes,,Yes,Yes,Yes,,Arnold Junior Sadio,University of Lomé,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-023-08167-2,2023-05-03,2024-03-01,Unverified,sadioHighSARSCoV2Seroprevalence2023,TGO
20220204_Tunis_UniversityofTunisElManar_AntiSAdj,220204_Tunis_UniversityofTunisElManar,COVID-19 in Tunisia (North Africa): Seroprevalence of SARS-CoV-2 in the general population of the capital city Tunis,2022-02-04,Preprint,Local,Cross-sectional survey ,Tunisia,,Tunis,The study included all persons who were permanent residents in the selected houses and who gave their consent to participate to the study.,We excluded the households in which at least one member refused to participate to the survey or refused blood sampling and those for which it was not possible to include all members after three visits of the investigators.,2021-03-15,2021-04-15,Household and community samples,All,Multiple groups,0.0,100.0,Primary Estimate,Anti-S Adj,1676,0.251,0.222,0.284,True,True,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.93,0.9500000000000001,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Ines Cherif,University of Tunis El Manar,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1317280/v2,2022-02-18,2022-07-16,Unverified,cherif_covid-19_2022,TUN
20220204_Tunis_UniversityofTunisElManar_Male,220204_Tunis_UniversityofTunisElManar,COVID-19 in Tunisia (North Africa): Seroprevalence of SARS-CoV-2 in the general population of the capital city Tunis,2022-02-04,Preprint,Local,Cross-sectional survey ,Tunisia,,Tunis,The study included all persons who were permanent residents in the selected houses and who gave their consent to participate to the study.,We excluded the households in which at least one member refused to participate to the survey or refused blood sampling and those for which it was not possible to include all members after three visits of the investigators.,2021-03-15,2021-04-15,Household and community samples,Male,Multiple groups,0.0,100.0,Sex/Gender,,628,0.39799999999999996,0.334,0.465,,True,True,,,Stratified probability,"Author designed (ELISA) - Nucleocapsid,Author designed (ELISA) -Spike",,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Ines Cherif,University of Tunis El Manar,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1317280/v2,2022-02-18,2022-07-16,Unverified,cherif_covid-19_2022,TUN
20220204_Tunis_UniversityofTunisElManar_Age0to9,220204_Tunis_UniversityofTunisElManar,COVID-19 in Tunisia (North Africa): Seroprevalence of SARS-CoV-2 in the general population of the capital city Tunis,2022-02-04,Preprint,Local,Cross-sectional survey ,Tunisia,,Tunis,The study included all persons who were permanent residents in the selected houses and who gave their consent to participate to the study.,We excluded the households in which at least one member refused to participate to the survey or refused blood sampling and those for which it was not possible to include all members after three visits of the investigators.,2021-03-15,2021-04-15,Household and community samples,All,Children and Youth (0-17 years),0.0,9.0,Age,,82,0.511,0.35200000000000004,0.668,,True,True,,,Stratified probability,"Author designed (ELISA) - Nucleocapsid,Author designed (ELISA) -Spike",,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Ines Cherif,University of Tunis El Manar,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1317280/v2,2022-02-18,2022-07-16,Unverified,cherif_covid-19_2022,TUN
20220204_Tunis_UniversityofTunisElManar_AgeOver60,220204_Tunis_UniversityofTunisElManar,COVID-19 in Tunisia (North Africa): Seroprevalence of SARS-CoV-2 in the general population of the capital city Tunis,2022-02-04,Preprint,Local,Cross-sectional survey ,Tunisia,,Tunis,The study included all persons who were permanent residents in the selected houses and who gave their consent to participate to the study.,We excluded the households in which at least one member refused to participate to the survey or refused blood sampling and those for which it was not possible to include all members after three visits of the investigators.,2021-03-15,2021-04-15,Household and community samples,All,Seniors (65+ years),60.0,100.0,Age,,424,0.37,0.326,0.41700000000000004,,True,True,,,Stratified probability,"Author designed (ELISA) - Nucleocapsid,Author designed (ELISA) -Spike",,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Ines Cherif,University of Tunis El Manar,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1317280/v2,2022-02-18,2022-07-16,Unverified,cherif_covid-19_2022,TUN
20220204_Tunis_UniversityofTunisElManar_Age10to19,220204_Tunis_UniversityofTunisElManar,COVID-19 in Tunisia (North Africa): Seroprevalence of SARS-CoV-2 in the general population of the capital city Tunis,2022-02-04,Preprint,Local,Cross-sectional survey ,Tunisia,,Tunis,The study included all persons who were permanent residents in the selected houses and who gave their consent to participate to the study.,We excluded the households in which at least one member refused to participate to the survey or refused blood sampling and those for which it was not possible to include all members after three visits of the investigators.,2021-03-15,2021-04-15,Household and community samples,All,Multiple groups,10.0,19.0,Age,,211,0.46,0.39,0.532,,True,True,,,Stratified probability,"Author designed (ELISA) - Nucleocapsid,Author designed (ELISA) -Spike",,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Ines Cherif,University of Tunis El Manar,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1317280/v2,2022-02-18,2022-07-16,Unverified,cherif_covid-19_2022,TUN
20220204_Tunis_UniversityofTunisElManar_Age40to49,220204_Tunis_UniversityofTunisElManar,COVID-19 in Tunisia (North Africa): Seroprevalence of SARS-CoV-2 in the general population of the capital city Tunis,2022-02-04,Preprint,Local,Cross-sectional survey ,Tunisia,,Tunis,The study included all persons who were permanent residents in the selected houses and who gave their consent to participate to the study.,We excluded the households in which at least one member refused to participate to the survey or refused blood sampling and those for which it was not possible to include all members after three visits of the investigators.,2021-03-15,2021-04-15,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,,273,0.374,0.318,0.43200000000000005,,True,True,,,Stratified probability,"Author designed (ELISA) - Nucleocapsid,Author designed (ELISA) -Spike",,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Ines Cherif,University of Tunis El Manar,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1317280/v2,2022-02-18,2022-07-16,Unverified,cherif_covid-19_2022,TUN
20220204_Tunis_UniversityofTunisElManar_Age30to39,220204_Tunis_UniversityofTunisElManar,COVID-19 in Tunisia (North Africa): Seroprevalence of SARS-CoV-2 in the general population of the capital city Tunis,2022-02-04,Preprint,Local,Cross-sectional survey ,Tunisia,,Tunis,The study included all persons who were permanent residents in the selected houses and who gave their consent to participate to the study.,We excluded the households in which at least one member refused to participate to the survey or refused blood sampling and those for which it was not possible to include all members after three visits of the investigators.,2021-03-15,2021-04-15,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,,228,0.322,0.264,0.386,,True,True,,,Stratified probability,"Author designed (ELISA) - Nucleocapsid,Author designed (ELISA) -Spike",,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Ines Cherif,University of Tunis El Manar,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1317280/v2,2022-02-18,2022-07-16,Unverified,cherif_covid-19_2022,TUN
20220204_Tunis_UniversityofTunisElManar_Age20to29,220204_Tunis_UniversityofTunisElManar,COVID-19 in Tunisia (North Africa): Seroprevalence of SARS-CoV-2 in the general population of the capital city Tunis,2022-02-04,Preprint,Local,Cross-sectional survey ,Tunisia,,Tunis,The study included all persons who were permanent residents in the selected houses and who gave their consent to participate to the study.,We excluded the households in which at least one member refused to participate to the survey or refused blood sampling and those for which it was not possible to include all members after three visits of the investigators.,2021-03-15,2021-04-15,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,,182,0.27399999999999997,0.214,0.344,,True,True,,,Stratified probability,"Author designed (ELISA) - Nucleocapsid,Author designed (ELISA) -Spike",,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Ines Cherif,University of Tunis El Manar,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1317280/v2,2022-02-18,2022-07-16,Unverified,cherif_covid-19_2022,TUN
20220204_Tunis_UniversityofTunisElManar_AntiSUnadj,220204_Tunis_UniversityofTunisElManar,COVID-19 in Tunisia (North Africa): Seroprevalence of SARS-CoV-2 in the general population of the capital city Tunis,2022-02-04,Preprint,Local,Cross-sectional survey ,Tunisia,,Tunis,The study included all persons who were permanent residents in the selected houses and who gave their consent to participate to the study.,We excluded the households in which at least one member refused to participate to the survey or refused blood sampling and those for which it was not possible to include all members after three visits of the investigators.,2021-03-15,2021-04-15,Household and community samples,All,Multiple groups,0.0,100.0,Analysis,Anti-S Unadj,1676,0.309,0.287,0.331,,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.93,0.9500000000000001,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Ines Cherif,University of Tunis El Manar,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1317280/v2,2022-02-18,2022-07-16,Unverified,cherif_covid-19_2022,TUN
20220204_Tunis_UniversityofTunisElManar_Age50to59,220204_Tunis_UniversityofTunisElManar,COVID-19 in Tunisia (North Africa): Seroprevalence of SARS-CoV-2 in the general population of the capital city Tunis,2022-02-04,Preprint,Local,Cross-sectional survey ,Tunisia,,Tunis,The study included all persons who were permanent residents in the selected houses and who gave their consent to participate to the study.,We excluded the households in which at least one member refused to participate to the survey or refused blood sampling and those for which it was not possible to include all members after three visits of the investigators.,2021-03-15,2021-04-15,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,,276,0.391,0.336,0.45,,True,True,,,Stratified probability,"Author designed (ELISA) - Nucleocapsid,Author designed (ELISA) -Spike",,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Ines Cherif,University of Tunis El Manar,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1317280/v2,2022-02-18,2022-07-16,Unverified,cherif_covid-19_2022,TUN
20220204_Tunis_UniversityofTunisElManar_Female,220204_Tunis_UniversityofTunisElManar,COVID-19 in Tunisia (North Africa): Seroprevalence of SARS-CoV-2 in the general population of the capital city Tunis,2022-02-04,Preprint,Local,Cross-sectional survey ,Tunisia,,Tunis,The study included all persons who were permanent residents in the selected houses and who gave their consent to participate to the study.,We excluded the households in which at least one member refused to participate to the survey or refused blood sampling and those for which it was not possible to include all members after three visits of the investigators.,2021-03-15,2021-04-15,Household and community samples,Female,Multiple groups,0.0,100.0,Sex/Gender,,1048,0.369,0.33299999999999996,0.40700000000000003,,True,True,,,Stratified probability,"Author designed (ELISA) - Nucleocapsid,Author designed (ELISA) -Spike",,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Ines Cherif,University of Tunis El Manar,Not Unity-Aligned,https://www.researchsquare.com/article/rs-1317280/v2,2022-02-18,2022-07-16,Unverified,cherif_covid-19_2022,TUN
230120_Tunisia_UniversityofTunisElManar,230120_Tunisia_UniversityofTunisElManar,Incidence and risk factors of SARS-CoV-2 infection among workers in a public health laboratory in Tunisia,2023-01-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Tunisia,Tunis,,"""workers at the Institut Pasteur de Tunis (IPT)""

""who had not received the COVID-19 vaccine were invited to participate in the survey""","""36 who had received the COVID-19 vaccine were excluded""",2021-03-22,2021-04-02,Health care workers and caregivers,All,Adults (18-64 years),20.0,,Primary Estimate,,428,0.329,0.287,0.374,True,True,,,True,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.9500000000000001,0.93,['High'],,No,No,Yes,,Unclear,Yes,Yes,,Ghassen Kharroubi,University of Tunis El Manar,Not Unity-Aligned,https://dx.doi.org/10.1007/s00705-022-05636-y,2023-02-08,2023-03-19,Unverified,kharroubiIncidenceRiskFactors2023,TUN
230612_Tunisia_NationalObservatoryofNewandEmergingDiseases_overall_adjusted,230612_Tunisia_NationalObservatoryofNewandEmergingDiseases,"Baseline Seroprevalence of SARS-CoV-2 Specific Antibodies in Hot Spot Areas of Great Tunis, up to 3 Months Post Disease Onset in Tunisia.",2023-07-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Tunisia,Great Tunis,,"""All persons present at the time of the survey in their household, irrespective of their COVID-19 status including children and have given their informed consent, were asked to participate in the study""","""Subjects who refused to give informed consent or to be sampled, or had any contraindication to capillary puncture were not included in this study.""",2020-04-01,2020-04-30,Household and community samples,All,Multiple groups,,,Test used,Adjusted seroprevalence for performances of test used,1049,0.008,0.0,0.022,True,True,,,,Convenience,Leccurate SARS-CoV-2 Antibody Rapid Test Kit (Colloidal Gold Immunochromatography),Beijing Lepu Medical Technology,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.657,0.657,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Sonia Dhaouadi,National Observatory of New and Emerging Diseases,Unity-Aligned,https://dx.doi.org/10.3390/epidemiologia4020020,2023-08-01,2024-04-29,Verified,dhaouadiBaselineSeroprevalenceSARSCoV22023,TUN
230612_Tunisia_NationalObservatoryofNewandEmergingDiseases_Ben Arous,230612_Tunisia_NationalObservatoryofNewandEmergingDiseases,"Baseline Seroprevalence of SARS-CoV-2 Specific Antibodies in Hot Spot Areas of Great Tunis, up to 3 Months Post Disease Onset in Tunisia.",2023-07-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Tunisia,Great Tunis,Ben Arous,"""All persons present at the time of the survey in their household, irrespective of their COVID-19 status including children and have given their informed consent, were asked to participate in the study""","""Subjects who refused to give informed consent or to be sampled, or had any contraindication to capillary puncture were not included in this study.""",2020-04-01,2020-04-30,Household and community samples,All,Multiple groups,,,Geographical area,Ben Arous,244,0.041,0.02,0.073,,,,,,Convenience,Leccurate SARS-CoV-2 Antibody Rapid Test Kit (Colloidal Gold Immunochromatography),Beijing Lepu Medical Technology,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.657,0.657,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Sonia Dhaouadi,National Observatory of New and Emerging Diseases,Unity-Aligned,https://dx.doi.org/10.3390/epidemiologia4020020,2023-08-01,2024-04-29,Verified,dhaouadiBaselineSeroprevalenceSARSCoV22023,TUN
230612_Tunisia_NationalObservatoryofNewandEmergingDiseases_Ariana,230612_Tunisia_NationalObservatoryofNewandEmergingDiseases,"Baseline Seroprevalence of SARS-CoV-2 Specific Antibodies in Hot Spot Areas of Great Tunis, up to 3 Months Post Disease Onset in Tunisia.",2023-07-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Tunisia,Great Tunis,Ariana,"""All persons present at the time of the survey in their household, irrespective of their COVID-19 status including children and have given their informed consent, were asked to participate in the study""","""Subjects who refused to give informed consent or to be sampled, or had any contraindication to capillary puncture were not included in this study.""",2020-04-01,2020-04-30,Household and community samples,All,Multiple groups,,,Geographical area,Ariana,208,0.048,0.023,0.087,,,,,,Convenience,Leccurate SARS-CoV-2 Antibody Rapid Test Kit (Colloidal Gold Immunochromatography),Beijing Lepu Medical Technology,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.657,0.657,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Sonia Dhaouadi,National Observatory of New and Emerging Diseases,Unity-Aligned,https://dx.doi.org/10.3390/epidemiologia4020020,2023-08-01,2024-04-29,Verified,dhaouadiBaselineSeroprevalenceSARSCoV22023,TUN
230612_Tunisia_NationalObservatoryofNewandEmergingDiseases_GreatTunis,230612_Tunisia_NationalObservatoryofNewandEmergingDiseases,"Baseline Seroprevalence of SARS-CoV-2 Specific Antibodies in Hot Spot Areas of Great Tunis, up to 3 Months Post Disease Onset in Tunisia.",2023-07-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Tunisia,Great Tunis,,"""All persons present at the time of the survey in their household, irrespective of their COVID-19 status including children and have given their informed consent, were asked to participate in the study""","""Subjects who refused to give informed consent or to be sampled, or had any contraindication to capillary puncture were not included in this study.""",2020-04-01,2020-04-30,Household and community samples,All,Multiple groups,,,Geographical area,Great Tunis,1049,0.025,0.016,0.036,,,,,,Convenience,Leccurate SARS-CoV-2 Antibody Rapid Test Kit (Colloidal Gold Immunochromatography),Beijing Lepu Medical Technology,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.657,0.657,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Sonia Dhaouadi,National Observatory of New and Emerging Diseases,Unity-Aligned,https://dx.doi.org/10.3390/epidemiologia4020020,2023-08-01,2024-04-29,Verified,dhaouadiBaselineSeroprevalenceSARSCoV22023,TUN
230612_Tunisia_NationalObservatoryofNewandEmergingDiseases_Tunis,230612_Tunisia_NationalObservatoryofNewandEmergingDiseases,"Baseline Seroprevalence of SARS-CoV-2 Specific Antibodies in Hot Spot Areas of Great Tunis, up to 3 Months Post Disease Onset in Tunisia.",2023-07-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Tunisia,Great Tunis,Tunis,"""All persons present at the time of the survey in their household, irrespective of their COVID-19 status including children and have given their informed consent, were asked to participate in the study""","""Subjects who refused to give informed consent or to be sampled, or had any contraindication to capillary puncture were not included in this study.""",2020-04-01,2020-04-30,Household and community samples,All,Multiple groups,,,Geographical area,Tunis,294,0.017,0.005,0.039,,,,,,Convenience,Leccurate SARS-CoV-2 Antibody Rapid Test Kit (Colloidal Gold Immunochromatography),Beijing Lepu Medical Technology,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.657,0.657,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Sonia Dhaouadi,National Observatory of New and Emerging Diseases,Unity-Aligned,https://dx.doi.org/10.3390/epidemiologia4020020,2023-08-01,2024-04-29,Verified,dhaouadiBaselineSeroprevalenceSARSCoV22023,TUN
230612_Tunisia_NationalObservatoryofNewandEmergingDiseases_Manouba,230612_Tunisia_NationalObservatoryofNewandEmergingDiseases,"Baseline Seroprevalence of SARS-CoV-2 Specific Antibodies in Hot Spot Areas of Great Tunis, up to 3 Months Post Disease Onset in Tunisia.",2023-07-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Tunisia,Great Tunis,Manouba,"""All persons present at the time of the survey in their household, irrespective of their COVID-19 status including children and have given their informed consent, were asked to participate in the study""","""Subjects who refused to give informed consent or to be sampled, or had any contraindication to capillary puncture were not included in this study.""",2020-04-01,2020-04-30,Household and community samples,All,Multiple groups,,,Geographical area,Manouba,333,0.003,0.0001,0.018,,,,,,Convenience,Leccurate SARS-CoV-2 Antibody Rapid Test Kit (Colloidal Gold Immunochromatography),Beijing Lepu Medical Technology,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.657,0.657,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Sonia Dhaouadi,National Observatory of New and Emerging Diseases,Unity-Aligned,https://dx.doi.org/10.3390/epidemiologia4020020,2023-08-01,2024-04-29,Verified,dhaouadiBaselineSeroprevalenceSARSCoV22023,TUN
230612_Tunisia_NationalObservatoryofNewandEmergingDiseases_overall_unadjusted,230612_Tunisia_NationalObservatoryofNewandEmergingDiseases,"Baseline Seroprevalence of SARS-CoV-2 Specific Antibodies in Hot Spot Areas of Great Tunis, up to 3 Months Post Disease Onset in Tunisia.",2023-07-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Tunisia,Great Tunis,,"""All persons present at the time of the survey in their household, irrespective of their COVID-19 status including children and have given their informed consent, were asked to participate in the study""","""Subjects who refused to give informed consent or to be sampled, or had any contraindication to capillary puncture were not included in this study.""",2020-04-01,2020-04-30,Household and community samples,All,Multiple groups,,,Primary Estimate,,1049,0.025,0.016,0.036,,,,,True,Convenience,Leccurate SARS-CoV-2 Antibody Rapid Test Kit (Colloidal Gold Immunochromatography),Beijing Lepu Medical Technology,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.657,0.657,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Sonia Dhaouadi,National Observatory of New and Emerging Diseases,Unity-Aligned,https://dx.doi.org/10.3390/epidemiologia4020020,2023-08-01,2024-04-29,Verified,dhaouadiBaselineSeroprevalenceSARSCoV22023,TUN
210920_Serdivan_SakaryaUniversity,210920_Serdivan_SakaryaUniversity,COVID-19 prevalence and oncologic outcomes of asymptomatic patients with active cancer who received chemotherapy,2021-01-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Turkey,Sakarya,Serdivan,"All patients with active cancer
who were followed-up and treated at the Medical Oncology Department between 7th April 2020 and 30th
May 2020 were eligible for enrolment to study. Only
patients who were receiving intravenous systemic
chemotherapy were selected.",". Patients
with hematological malignancies and lymphoma
were excluded from the study. ",2020-04-07,2020-05-30,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),,,Primary Estimate,Cancer patients,198,0.035,,,True,,,,True,Unclear,Not reported/ Unable to specify,,CLIA,Serum,"['IgG', 'IgM']",,,,,['High'],Yes,Unclear,No,Yes,Yes,Unclear,Yes,No,Unclear,Cemil Bilir,Sakarya University ,Not Unity-Aligned,http://dx.doi.org/10.19193/0393-6384_2021_1_103,2021-03-27,2022-07-16,Verified,bilir_covid-19_2021,TUR
210303_Turkey_UniversityofHealthSciences_Overall,210303_Turkey_UniversityofHealthSciences,Seroprevalence of Coronavirus Disease 2019 (COVID-19) Among Health Care Workers from Three Pandemic Hospitals of Turkey,2021-03-03,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Turkey,Marmara,Istanbul and Kocaeli,All HCWs at the three sampled hospitals,,2020-05-30,2020-06-06,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,813,0.027000000000000003,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Gizem Alkurt,University of Health Sciences,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0247865,2021-04-17,2024-03-01,Verified,alkurt_seroprevalence_2020,TUR
210310_Ankara_HacettepeUniversity_Overall,210310_Ankara_HacettepeUniversity,"SARS-CoV-2
  Seroprevalence Among Healthcare Workers: Retrospective Analysis of the Data
  From A University Hospital in Turkey",2021-03-10,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Turkey,Central Anatolia,Ankara,healthcare workers in our hospital who have participated extensively in the monitoring of COVID-19 patients,,2020-03-24,2020-09-10,Health care workers and caregivers,All,Adults (18-64 years),23.0,65.0,Primary Estimate,Overall HCWs,774,0.07400000000000001,,,True,,,,True,Unclear,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,,,,['High'],Yes,Unclear,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Adem Ozdemir,Hacettepe University,Not Unity-Aligned,http://www.mikrobiyolbul.org/linkout.aspx?pmid=33882653,2021-05-17,2022-07-16,Verified,ozdemir_retrospective_2021,TUR
210427_Turkey_SakaryaUniversity_Overall,210427_Turkey_SakaryaUniversity,Novel coronavirus seropositivity and related factors among healthcare workers at a university hospital during the prevaccination period: a cross-sectional study.,2021-04-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Turkey,,,"""All HCWs working on four campuses were informed about the antibody screening to be performed at the hospital. A list of all HCWs was made, and each were given an appointment for
blood sample collection. The appointments were determined by giving priority to the campuses and clinics where COVID-19 patients were treated. Antibody test results of 2988 HCWs whose blood samples were taken from among 3620 HCWs were evaluated. In this cross-sectional type of research, 82.5% of the participants were reached.""",,2020-05-01,2020-05-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,2988,0.0361,,,True,,,,True,Entire sample,COVID-19 IgM/IgG Total Antibody Rapid Test,Beijing Hotgen Biotech Co. Ltd China,Other,Serum,"['IgG', 'IgM']",,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Yes,Aziz Ogutlu,Sakarya University,Not Unity-Aligned,https://dx.doi.org/10.1186/s12941-021-00436-9,2021-05-25,2022-07-16,Verified,ogutlu_novel_2021,TUR
210522_Adana_AdanaDr.TurgutNoyanTeachingandResearchHospital,210522_Adana_AdanaDr.TurgutNoyanTeachingandResearchHospital,Antibody Screening and Risk Assessment of Healthcare Professionals in the COVID-19 Pandemic,2021-05-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Turkey,Mediterranean Region,Adana, healthcare professionals serving in various units of our hospital,,2020-05-18,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),19.0,61.0,Primary Estimate,,572,0.037000000000000005,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Hatice Hale GUMUS,Adana Dr. Turgut Noyan Teaching and Research Hospital,Not Unity-Aligned,http://mikrobiyolbul.org/managete/fu_folder/2021-03/357-373%20Hatice%20Hale%20Gumus.pdf,2021-08-02,2024-03-01,Unverified,gumus_antibody_2021,TUR
210523_Istanbul_KocUniversity,210523_Istanbul_KocUniversity,Predictors of SARS CoV-2 Infection Among Healthcare Workers: The Impact of Community-Hospital Gradient,2021-05-23,Preprint,Regional,Cross-sectional survey ,Turkey,Marmara,Istanbul,,Declined or withdrew consent,2020-05-01,2020-12-31,Health care workers and caregivers,All,Adults (18-64 years),18.0,66.0,Primary Estimate,,1732,0.15,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Fatihan Pınarlık,Koc University,Not Unity-Aligned,10.1101/2021.05.20.21257518,2021-06-07,2024-03-01,Unverified,pinarlik_predictors_2021,TUR
210706_Ankara_EtlikZübeydeHanımWomen'sHealthCareTrainingandResearchHospital_MiscarriagePatients,210706_Ankara_EtlikZübeydeHanımWomen'sHealthCareTrainingandResearchHospital_MiscarriagePatients,Did the SARS-CoV-2 effect pregnancy complications?,2021-07-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Turkey,,Ankara,,,2020-06-01,2020-07-31,Pregnant or parturient women,All,Adults (18-64 years),16.0,30.0,Primary Estimate,,230,0.0,,,True,,,,True,Sequential,COVID-19 IgG/IgM Rapid Test Device,Assure Tech. (Hangzhou) Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Ozge Yucel Celik,"Etlik Zübeyde Hanim Women's Health Care, Training, and Research Hospital",Unity-Aligned,https://dx.doi.org/10.5603/GP.a2021.0134,2021-07-19,2024-03-01,Verified,celik_did_2021,TUR
210706_Ankara_EtlikZübeydeHanımWomen'sHealthCareTrainingandResearchHospital_PROMPatients,210706_Ankara_EtlikZübeydeHanımWomen'sHealthCareTrainingandResearchHospital_PROMPatients,Did the SARS-CoV-2 effect pregnancy complications?,2021-07-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Turkey,,Ankara,pregnant women who were admitted for term PROM and miscarriage without viral symptoms,"Patients over 45 and those with the following conditions were excluded from the study: current pregnancy with previous miscarriage, multiple miscarriages, specified infectious disease, diabetes, obesity (BMI ≥ 35), thyroid disease, thrombophilia, teratogen drug use, pregnancy trauma, uterine anomaly, and known chromosomal and/or structural anomalies",2020-06-01,2020-07-31,Pregnant or parturient women,All,Adults (18-64 years),16.0,43.0,Primary Estimate,,205,0.029300000000000003,,,True,,,,True,Sequential,COVID-19 IgG/IgM Rapid Test Device,Assure Tech. (Hangzhou) Co. Ltd,LFIA,Serum,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Ozge Yucel Celik,"Etlik Zübeyde Hanim Women's Health Care, Training, and Research Hospital",Unity-Aligned,https://dx.doi.org/10.5603/GP.a2021.0134,2021-07-19,2024-03-01,Verified,celik_did_2021,TUR
210707_Istanbul_FlorenceNightingaleHospital_primary,210707_Istanbul_FlorenceNightingaleHospital,Interventional pain management during sars-cov-2 pandemic,2021-07-07,Journal Article (Peer-Reviewed),Local,Prospective cohort,Turkey,Marmara,Istanbul,"participants undergoing
interventions for pain management (epidural injection,
epidural neuroplasty, peripheral nerve and sympathetic
ganglion block, and radiofrequency interventions for nonmalignant pain; celiac-splanchnic impar ganglion neurolysis
and epidural-spinal port catheter implantation for malignant
pain) ",,2020-03-20,2020-06-20,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,83,0.036000000000000004,,,True,,,,True,Convenience,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Savas Comlek,Florence Nightingale Hospital,Not Unity-Aligned,http://dx.doi.org/10.22514/sv.2021.008,2021-07-28,2024-03-01,Unverified,noauthor_interventional_2021,TUR
210927_Turkey_HacettepeUniversity_Primary,210927_Turkey_HacettepeUniversity,SARS-CoV-2 seropositivity among pediatric health care personnel just after the first peak of pandemic: A nationwide surveillance,2021-09-27,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Turkey,"Middle Anatolia region
Marmara region
Aegean region
East Anatolia region
South-east Anatolian region
Black Sea region
Mediterranean region",,"Healthcare personnel at each study hospital were eligible if they regularly had direct or indirect contact with pediatric patients with COVID-19 disease, who were cared in ED (emergency department), intensive care unit (ICU), and inpatient and outpatient COVID-19 units",,2020-05-25,2020-06-10,Health care workers and caregivers,All,Adults (18-64 years),19.0,67.0,Primary Estimate,,4927,0.061,,,True,,,,True,Convenience,COVID-19 IgG/IgM Rapid Test Device,Assure Tech. (Hangzhou) Co. Ltd,LFIA,,"['IgG', 'IgM']",,Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Pembe Derin Oygar,Hacettepe University,Not Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2021.09.054,2021-11-04,2024-03-01,Unverified,oygar_sars-cov-2_2021,TUR
210930_Konya_NecmettinErbakanUniversityMeramFacultyofMedicine_Primary,210930_Konya_NecmettinErbakanUniversityMeramFacultyofMedicine,COVID-19 seroprevalance in a university hospital health workers,2021-09-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Turkey,,Konya,Necmettin Erbakan University Meram Faculty of Medicine health staff working at the hospital,,2020-06-01,2020-11-30,Health care workers and caregivers,All,Adults (18-64 years),22.0,67.0,Primary Estimate,,741,0.17,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,COVID-19 ELISA IgG","EUROIMMUN,Vircell S.L.",ELISA,Serum,IgG,,,,,['High'],,No,Yes,Yes,,Yes,Yes,No,,Gokce Kader Arslan,Necmettin Erbakan University Meram Faculty of Medicine,Not Unity-Aligned,http://dx.doi.org/10.5578/FLORA.20219706,2021-10-27,2024-03-01,Unverified,arslan_covid-19_2021,TUR
211030_Turkey_BiruniUniversity_AirCrew,211030_Turkey_BiruniUniversity_AirCrew,COVID-19 seroconversion in the aircrew from Turkey.,2021-10-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Turkey,Marmara,Istanbul,"patients attending the outpatient clinics at Biruni University Medical Faculty Hospital between December 1, 2020 and January 13, 2021 were examined from the patients’ files.

only patients older than 18 years of age","At the beginning of the study, the patients with pregnancy; below eighteen years; chronic heart failure; chronic kidney and liver diseases; alcoholism; malignancy; connective tissue diseases; neurologic and psychiatric problems (Parkinson's disease, bipolar disorder, depression); using steroids or immunosuppressives drugs; immunosuppressive illness were not included to the study.",2020-12-01,2021-01-13,Essential non-healthcare workers,All,Adults (18-64 years),18.0,,Primary Estimate,,313,0.46,,,True,,,,True,Unclear,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,Unclear,Yes,Yes,,Unclear,Yes,No,,Mehmet Islamoglu,Biruni University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.tmaid.2021.102190,2021-11-15,2022-07-16,Unverified,islamoglu_covid-19_2021,TUR
211030_Turkey_BiruniUniversity_HCW,211030_Turkey_BiruniUniversity_HCW,COVID-19 seroconversion in the aircrew from Turkey.,2021-10-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Turkey,Marmara,Istanbul,"patients attending the outpatient clinics at Biruni University Medical Faculty Hospital between December 1, 2020 and January 13, 2021 were examined from the patients’ files.

only patients older than 18 years of age","At the beginning of the study, the patients with pregnancy; below eighteen years; chronic heart failure; chronic kidney and liver diseases; alcoholism; malignancy; connective tissue diseases; neurologic and psychiatric problems (Parkinson's disease, bipolar disorder, depression); using steroids or immunosuppressives drugs; immunosuppressive illness were not included to the study.",2020-12-01,2021-01-13,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,451,0.41000000000000003,,,True,,,,True,Unclear,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,Unclear,Yes,Yes,,Unclear,Yes,No,,Mehmet Islamoglu,Biruni University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.tmaid.2021.102190,2021-11-15,2022-07-16,Unverified,islamoglu_covid-19_2021,TUR
211030_Turkey_BiruniUniversity_Other,211030_Turkey_BiruniUniversity_Other,COVID-19 seroconversion in the aircrew from Turkey.,2021-10-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Turkey,Marmara,Istanbul,"patients attending the outpatient clinics at Biruni University Medical Faculty Hospital between December 1, 2020 and January 13, 2021 were examined from the patients’ files.

only patients older than 18 years of age","At the beginning of the study, the patients with pregnancy; below eighteen years; chronic heart failure; chronic kidney and liver diseases; alcoholism; malignancy; connective tissue diseases; neurologic and psychiatric problems (Parkinson's disease, bipolar disorder, depression); using steroids or immunosuppressives drugs; immunosuppressive illness were not included to the study.",2020-12-01,2021-01-13,Residual sera,All,Adults (18-64 years),18.0,,Primary Estimate,,4258,0.353,,,True,,,,True,Unclear,Author designed (IFA) - MULTIPLEXED,,IFA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,Unclear,Yes,Yes,,Unclear,Yes,No,,Mehmet Islamoglu,Biruni University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.tmaid.2021.102190,2021-11-15,2022-07-16,Unverified,islamoglu_covid-19_2021,TUR
211108_Istanbul_UmraniyeTrainingandResearchHospital,211108_Istanbul_UmraniyeTrainingandResearchHospital,Clinical course of COVID-19 in children with rheumatic disease under biologic therapy,2021-11-08,Presentation or Conference,Local,Cross-sectional survey ,Turkey,Marmara,Istanbul,"Patients with pediatric rheumatic disease treated with bDMARDs who were evaluated at
the regular outpatient clinic follow-up or by telemedicine",,2020-04-01,2020-12-01,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),,,Primary Estimate,,436,0.0046,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Ferhat Demir,"Umraniye Training and Research
Hospital",Not Unity-Aligned,https://dx.doi.org/10.1186/s12969-021-00632-z,2022-01-02,2022-07-16,Unverified,demir_clinical_2021,TUR
220119_Istanbul_IstanbulUniversity_Overall,220119_Istanbul_IstanbulUniversity,Asymptomatic SARS-CoV-2 seropositivity: patients with childhood-onset rheumatic diseases versus healthy children.,2022-01-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Turkey,Marmara,Istanbul,"Those who remained asymptomatic for the last 5 months were called via phone, and their answers were verified. Patients diagnosed with FMF, JIA, and jSLE before the age of 18 and currently being under 21 and healthy individuals under 18 are included in the study.

Children who were previously admitted to our hospital due to a non-specific and transient complaint before the date of the first COVID-19 case were seen in our country and without any diagnosed underlying disease were established as the control group.",COVID-19 symptoms within the last 5 months,2020-08-15,2020-10-15,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),,21.0,Primary Estimate,IgG and/or IgA,149,0.1275,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgA,Anti-SARS-CoV-2 ELISA IgG",EUROIMMUN,ELISA,Serum,"['IgA', 'IgG']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Yes,Yes,No,,Fatih Haslak,Istanbul University,Not Unity-Aligned,https://dx.doi.org/10.1007/s10067-022-06067-5,2022-01-26,2024-03-01,Unverified,haslak_asymptomatic_2022,TUR
220208_Ankara_HacettepeUniversity_Overall,220208_Ankara_HacettepeUniversity,Seroprevalence of SARS-CoV-2 Antibodies and Associated Factors in Healthcare Workers before the Era of Vaccination at a Tertiary Care Hospital in Turkey,2022-02-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Turkey,Ankara,Ankara,"HCWs who worked at Hacettepe University Hospitals (including physicians, nurses, lab technicians, medical students, etc.)",,2020-10-15,2020-10-18,Health care workers and caregivers,All,Adults (18-64 years),18.0,65.0,Primary Estimate,,1974,0.19,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA",EUROIMMUN,ELISA,Serum,"['IgA', 'IgG']",Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,No,,Meliha Sonmezer,Hacettepe University,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10020258,2022-02-23,2024-03-01,Unverified,sonmezer_seroprevalence_2022,TUR
220315_Ankara_AnkaraCItyHospital_overall,220315_Ankara_AnkaraCItyHospital,Investigating Whether the Severity of SARS-CoV-2 Infection Is Higher in Liver Transplant Recipients: A Single-Center Experience.,2022-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Turkey,,Ankary,All patients were older than 18 years of age and had previously undergone LT. Included patients were those who underwent serum COVID-19 immunoglobulin M (IgM) and immunoglobulin G (IgG) antibody tests.,,2020-09-15,2021-03-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,91,0.30770000000000003,,,True,,,,True,Convenience,"ADVIA Centaur Immunoassay System,Atellica® IM SARS-CoV-2 Total (COV2T)",Siemens,CLIA,Serum,"['IgG', 'IgM']",Spike,,,,['High'],,No,No,No,,Unclear,Yes,No,,Dilara Gokce,Ankara City Hospital,Not Unity-Aligned,https://dx.doi.org/10.6002/ect.2021.0494,2022-03-24,2024-03-01,Unverified,turan_gokce_investigating_2022,TUR
220622_Trabzon_KaradenizTechnicalUniversity_Controls,220622_Trabzon_KaradenizTechnicalUniversity_Controls,SARS-COV-2 antibodies in children with chronic disease who were followed in pediatric gastroenterology outpatient clinic,2022-06-22,Presentation or Conference,Local,Cross-sectional survey ,Turkey,,Trabzon,"""A control group without any known chronic disease were randomly selected from outpatient clinic (n=48).""",,2021-01-15,2021-02-15,Residual sera,All,Children and Youth (0-17 years),,,Primary Estimate,,48,0.22920000000000001,,,True,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,,,Spike,,,,['High'],,Yes,No,No,,Yes,Yes,Yes,,G. Kaya,Karadeniz Technical University,Unity-Aligned,https://dx.doi.org/10.1097/MPG.0000000000003446,2022-08-11,2024-03-01,Unverified,kaya_sars-cov-2_2022,TUR
220622_Trabzon_KaradenizTechnicalUniversity_Patients,220622_Trabzon_KaradenizTechnicalUniversity_Patients,SARS-COV-2 antibodies in children with chronic disease who were followed in pediatric gastroenterology outpatient clinic,2022-06-22,Presentation or Conference,Local,Cross-sectional survey ,Turkey,,Trabzon,"""All the patients who were admitted to outpatient’s clinic during the study period with chronic diseases (definite diagnosis) were included into the study (n=141).""",,2021-01-15,2021-02-15,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),,,Primary Estimate,,141,0.2553,,,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,,,Spike,,,,['High'],,No,No,No,,Yes,Yes,Yes,,G. Kaya,Karadeniz Technical University,Not Unity-Aligned,https://dx.doi.org/10.1097/MPG.0000000000003446,2022-08-11,2024-03-01,Unverified,kaya_sars-cov-2_2022,TUR
220712_Turkey_DokuzEylulUniversity_Overall,220712_Turkey_DokuzEylulUniversity,Evaluation of SARS-CoV-2 antibody persistence and viral spread in stool: a long-term care experience before COVID-19 vaccination.,2022-07-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Turkey,,,"This prospective cross-sectional study was conducted in
Narlidere Nursing Home Elderly Care and Rehabilitation
Center. We planned to assess staf and elderly individuals
residing at our nation’s highest-capacity residential and
nursing home.",,2020-12-15,2021-01-15,Multiple populations,All,Multiple groups,22.0,102.0,Primary Estimate,,888,0.292,,,True,,,,True,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Multiple Types,IgG,Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Oya Eren‑Kutsoylu,Dokuz Eylul University,Not Unity-Aligned,https://dx.doi.org/10.1007/s11845-022-03095-7,2022-07-19,2024-03-01,Unverified,eren-kutsoylu_evaluation_2022,TUR
221011_Trabzon_KaradenizTechnicalUniversity_Overall,221011_Trabzon_KaradenizTechnicalUniversity,Evaluation of Asymptomatic Covid Infection in Children with Pediatric Hemato-Oncologic Disease.,2022-10-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Turkey,,Trabzon,"""The study included patients aged 2 to 20 years, who were under follow-up for pediatric hemato-oncologic disease between 01.02.2021 and 01.06.2021 in the pediatric hematology-oncology department of Karadeniz Technical University (KTU) Faculty of Medicine.""",,2021-02-01,2021-06-01,Residual sera,All,Children and Youth (0-17 years),2.0,20.0,Primary Estimate,,107,0.224,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,TotalAntibody,Spike,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Aysenur Bahadir,Karadeniz Technical University,Not Unity-Aligned,https://dx.doi.org/10.1007/s12288-022-01565-7,2023-04-25,2023-04-26,Unverified,bahadir_evaluation_2023,TUR
221020_Istanbul_HealthScienceUniversity,221020_Istanbul_HealthScienceUniversity,Does the severity of diabetic ketoacidosis in children with type 1 diabetes change during the COVID-19 pandemic? A single-center experience from a pediatric intensive care unit.,2022-10-20,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Turkey,Istanbul,,"""We retrospectively evaluated children aged from 1 month to 18 years old, diagnosed with DKA, and followed up at Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital PICU between April 2020 and De- cember 2021. The diagnosis of DKA was made according to the criteria of the American Diabetes Association.""","""Children with nonketotic hyperglycemia and additional comorbidities were excluded from the study. """,2020-04-15,2021-12-15,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),0.0,18.0,Primary Estimate,,55,0.036000000000000004,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Fatih Varol,Health Science University,Not Unity-Aligned,https://dx.doi.org/10.14744/nci.2022.09634,2022-12-08,2023-03-19,Unverified,varolDoesSeverityDiabetic2022,TUR
221027_Eskisehir_EskisehirOsmangaziUniversity_HCWs_Overall,221027_Eskisehir_EskisehirOsmangaziUniversity_HCWs,"Evaluation of hemodialysis patients and hemodialysis health workers with COVID-19 IgM and IgG antibody test; a multicenter study from Eskisehir, Turkiye.",2022-10-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Turkey,,Eskisehir,"""patients over the age of 18 years who are on standard HD treatment and the medical professionals (doctors, nurses, and auxiliary staff ) working at the same HD center.""","""who were not willing to participate in the study were excluded from the study.""",2020-09-01,2020-10-01,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,134,0.0,,,True,,,,True,Self-referral,ABT COVID-19 Rapid IgG-IgM Diagnostic Test,A.B.T. Biotechnology,CGIA/RDT,,"IgG, IgM",[],Validated by manufacturers,,0.98,['High'],,No,No,Yes,,Unclear,Yes,No,,Sultan Ozkurt,Eskisehir Osmangazi University,Not Unity-Aligned,https://dx.doi.org/10.14744/nci.2021.62447,2022-12-15,2023-08-15,Unverified,ozkurt_evaluation_2022,TUR
221027_Eskisehir_EskisehirOsmangaziUniversity_Patients_Overall,221027_Eskisehir_EskisehirOsmangaziUniversity_Patients,"Evaluation of hemodialysis patients and hemodialysis health workers with COVID-19 IgM and IgG antibody test; a multicenter study from Eskisehir, Turkiye.",2022-10-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Turkey,,Eskisehir,"""patients over the age of 18 years who are on standard HD treatment and the medical professionals (doctors, nurses, and auxiliary staff ) working at the same HD center.""","""who were not willing to participate in the study were excluded from the study.""",2020-09-01,2020-10-01,Residual sera,All,Multiple groups,18.0,,Primary Estimate,,633,0.0236,,,True,,,,True,Self-referral,ABT COVID-19 Rapid IgG-IgM Diagnostic Test,A.B.T. Biotechnology,CGIA/RDT,,"IgG, IgM",[],Validated by manufacturers,,0.98,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Sultan Ozkurt,Eskisehir Osmangazi University,Not Unity-Aligned,https://dx.doi.org/10.14744/nci.2021.62447,2022-12-15,2023-08-15,Unverified,ozkurt_evaluation_2022,TUR
221222_Samsum_UniversityCollegeDublinp,221222_Samsum_UniversityCollegeDublin,A prevalence study of COVID-19 among healthcare workers in a pandemic hospital in the Samsun province of Turkey,2022-12-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Turkey,,Samsum,HCWs in Samsun Training and Research hospital. A convenience sampling approach was utilised whereby hospital workers were approached with information about the study and asked if they would like to participate.,,2020-12-22,2020-12-25,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,176,0.153,0.10400000000000001,0.215,True,,,,True,Convenience,Lifotronic electrochemiluminescence immunoassay,Lifotronic,CLIA,,"IgG, IgM",[],Validated by manufacturers,0.925,0.9400000000000001,['High'],,No,No,Yes,,No,Yes,No,,Mehmet Hakan Taskin,University College Dublin,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0279067,2023-01-12,2024-03-01,Unverified,taskin_prevalence_2022,TUR
230916_AegeanRegion_UniversityOfHealthSciencesDrBehcetUzChildrensHospital,230916_AegeanRegion_UniversityOfHealthSciencesDrBehcetUzChildrensHospital,A hidden burden of disease in a specific group: Evaluation of COVID-19 seroconversion rates in pediatric patients with leukemia.,2023-09-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Turkey,Aegean Region,,"The study included all pediatric patients diagnosed with leukemia between September 22 and December 31, 2021.",,2021-09-22,2021-12-31,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),,,Primary Estimate,,54,0.3333,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Miray Yılmaz Çelebi,University of Health Sciences Dr. Behçet Uz Children's Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ajic.2023.09.006,2023-10-26,2024-03-01,Unverified,celebi_hidden_2023,TUR
220221_RakaiRegion_RakaiHealthSciencesProgram_HCWs_TestAdj,220221_RakaiRegion_RakaiHealthSciencesProgram_HCWs,"Severe Acute Respiratory Syndrome Coronavirus-2 seroprevalence in South-Central Uganda, during 2019-2021.",2022-02-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Uganda,"Kyotera district, Lyantonde district, Masaka district, Rakai district.",,"At the selected health facilities, all available, willing HCW were recruited into the study.",,2020-11-30,2021-01-08,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,753,0.267,0.23500000000000001,0.298,True,True,,,,Convenience,"CoronaCHEK COVID-19 IgG/IgM Rapid Test Cassette,Architect Anti-SARS-CoV-2 IgM","Hangzhou Biotest Biotech Co Ltd,Abbott Laboratories",Multiple Types,Plasma,"['IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Charles Ssuuna,Rakai Health Sciences Program,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07161-4,2022-03-03,2023-08-15,Unverified,ssuuna_severe_2022,UGA
220221_RakaiRegion_RakaiHealthSciencesProgram_HCWs_Age_25-34,220221_RakaiRegion_RakaiHealthSciencesProgram_HCWs,"Severe Acute Respiratory Syndrome Coronavirus-2 seroprevalence in South-Central Uganda, during 2019-2021.",2022-02-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Uganda,"Kyotera district, Lyantonde district, Masaka district, Rakai district.",,"At the selected health facilities, all available, willing HCW were recruited into the study.",,2020-11-30,2021-01-08,Health care workers and caregivers,All,Adults (18-64 years),25.0,34.0,Age,Age: 25-34,238,0.2395,,,,,,,,Convenience,"CoronaCHEK COVID-19 IgG/IgM Rapid Test Cassette,Architect Anti-SARS-CoV-2 IgM","Hangzhou Biotest Biotech Co Ltd,Abbott Laboratories",Multiple Types,Plasma,"['IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Charles Ssuuna,Rakai Health Sciences Program,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07161-4,2022-03-07,2024-03-01,Unverified,ssuuna_severe_2022,UGA
220221_RakaiRegion_RakaiHealthSciencesProgram_HCWs_Age_18-24,220221_RakaiRegion_RakaiHealthSciencesProgram_HCWs,"Severe Acute Respiratory Syndrome Coronavirus-2 seroprevalence in South-Central Uganda, during 2019-2021.",2022-02-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Uganda,"Kyotera district, Lyantonde district, Masaka district, Rakai district.",,"At the selected health facilities, all available, willing HCW were recruited into the study.",,2020-11-30,2021-01-08,Health care workers and caregivers,All,Adults (18-64 years),18.0,24.0,Age,Age: 18-24,188,0.17550000000000002,,,,,,,,Convenience,"CoronaCHEK COVID-19 IgG/IgM Rapid Test Cassette,Architect Anti-SARS-CoV-2 IgM","Hangzhou Biotest Biotech Co Ltd,Abbott Laboratories",Multiple Types,Plasma,"['IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Charles Ssuuna,Rakai Health Sciences Program,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07161-4,2022-03-07,2024-03-01,Unverified,ssuuna_severe_2022,UGA
220221_RakaiRegion_RakaiHealthSciencesProgram_HCWs_Age_45-54,220221_RakaiRegion_RakaiHealthSciencesProgram_HCWs,"Severe Acute Respiratory Syndrome Coronavirus-2 seroprevalence in South-Central Uganda, during 2019-2021.",2022-02-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Uganda,"Kyotera district, Lyantonde district, Masaka district, Rakai district.",,"At the selected health facilities, all available, willing HCW were recruited into the study.",,2020-11-30,2021-01-08,Health care workers and caregivers,All,Adults (18-64 years),45.0,54.0,Age,Age: 45-54,84,0.25,,,,,,,,Convenience,"CoronaCHEK COVID-19 IgG/IgM Rapid Test Cassette,Architect Anti-SARS-CoV-2 IgM","Hangzhou Biotest Biotech Co Ltd,Abbott Laboratories",Multiple Types,Plasma,"['IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Charles Ssuuna,Rakai Health Sciences Program,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07161-4,2022-03-07,2024-03-01,Unverified,ssuuna_severe_2022,UGA
220221_RakaiRegion_RakaiHealthSciencesProgram_HCWs_Age_55+,220221_RakaiRegion_RakaiHealthSciencesProgram_HCWs,"Severe Acute Respiratory Syndrome Coronavirus-2 seroprevalence in South-Central Uganda, during 2019-2021.",2022-02-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Uganda,"Kyotera district, Lyantonde district, Masaka district, Rakai district.",,"At the selected health facilities, all available, willing HCW were recruited into the study.",,2020-11-30,2021-01-08,Health care workers and caregivers,All,Adults (18-64 years),55.0,,Age,Age: 55+,50,0.18,,,,,,,,Convenience,"CoronaCHEK COVID-19 IgG/IgM Rapid Test Cassette,Architect Anti-SARS-CoV-2 IgM","Hangzhou Biotest Biotech Co Ltd,Abbott Laboratories",Multiple Types,Plasma,"['IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Charles Ssuuna,Rakai Health Sciences Program,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07161-4,2022-03-07,2024-03-01,Unverified,ssuuna_severe_2022,UGA
220221_RakaiRegion_RakaiHealthSciencesProgram_HCWs_Age_35-44,220221_RakaiRegion_RakaiHealthSciencesProgram_HCWs,"Severe Acute Respiratory Syndrome Coronavirus-2 seroprevalence in South-Central Uganda, during 2019-2021.",2022-02-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Uganda,"Kyotera district, Lyantonde district, Masaka district, Rakai district.",,"At the selected health facilities, all available, willing HCW were recruited into the study.",,2020-11-30,2021-01-08,Health care workers and caregivers,All,Adults (18-64 years),35.0,44.0,Age,Age: 35-44,193,0.2021,,,,,,,,Convenience,"CoronaCHEK COVID-19 IgG/IgM Rapid Test Cassette,Architect Anti-SARS-CoV-2 IgM","Hangzhou Biotest Biotech Co Ltd,Abbott Laboratories",Multiple Types,Plasma,"['IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Charles Ssuuna,Rakai Health Sciences Program,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07161-4,2022-03-07,2024-03-01,Unverified,ssuuna_severe_2022,UGA
220221_RakaiRegion_RakaiHealthSciencesProgram_PreOfficialCOVID_TestAdj,220221_RakaiRegion_RakaiHealthSciencesProgram_PreOfficialCOVID,"Severe Acute Respiratory Syndrome Coronavirus-2 seroprevalence in South-Central Uganda, during 2019-2021.",2022-02-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Uganda,"Kyotera district, Lyantonde district, Masaka district, Rakai district.",,"These samples are routinely collected and stored primarily for surveillance of HIV, as well as genetic studies of interest in future.",,2019-10-15,2020-03-18,Residual sera,All,Multiple groups,,,Primary Estimate,,636,0.023,0.012,0.035,True,True,,,,Unclear,"CoronaCHEK COVID-19 IgG/IgM Rapid Test Cassette,Architect Anti-SARS-CoV-2 IgM","Hangzhou Biotest Biotech Co Ltd,Abbott Laboratories",Multiple Types,Plasma,"['IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,Unclear,Yes,No,,Unclear,Yes,Yes,,Charles Ssuuna,Rakai Health Sciences Program,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07161-4,2022-03-03,2023-08-15,Unverified,ssuuna_severe_2022,UGA
220221_RakaiRegion_RakaiHealthSciencesProgram_PreOfficialCOVID_UnAdj,220221_RakaiRegion_RakaiHealthSciencesProgram_PreOfficialCOVID,"Severe Acute Respiratory Syndrome Coronavirus-2 seroprevalence in South-Central Uganda, during 2019-2021.",2022-02-21,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Uganda,"Kyotera district, Lyantonde district, Masaka district, Rakai district.",,"These samples are routinely collected and stored primarily for surveillance of HIV, as well as genetic studies of interest in future.",,2019-10-15,2020-03-18,Residual sera,All,Multiple groups,,,Analysis,,636,0.0173,,,,,,,True,Unclear,"CoronaCHEK COVID-19 IgG/IgM Rapid Test Cassette,Architect Anti-SARS-CoV-2 IgM","Hangzhou Biotest Biotech Co Ltd,Abbott Laboratories",Multiple Types,Plasma,"['IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,Unclear,Yes,No,,Unclear,Yes,Yes,,Charles Ssuuna,Rakai Health Sciences Program,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07161-4,2022-03-07,2024-03-01,Unverified,ssuuna_severe_2022,UGA
220331_Uganda_MakerereUniversity_Primary,220331_Uganda_MakerereUniversity,CROSS-SPECIES TRANSMISSION OF COVID-19 AT ANIMAL-HUMAN INTERFACE: A ONE HEALTH APPROACH FOR IMPROVED DISEASE SURVEILLANCE AND CONTROL IN UGANDA,2022-03-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Uganda,Amuru and Kyotera Districts,,"A formula by Killip et al (2004) was used to select 12 households per parish; and three members from each household were purposely targeted, that is, the husband, wife, and youngest child.","Participants who had known contact with confirmed COVID-19 cases, untamed animals and homesteads without domestic animals were not considered.",2020-07-15,2020-12-15,Household and community samples,All,Multiple groups,10.0,,Primary Estimate,IgG,72,0.319,,,True,,,,True,Stratified non-probability,immunochromatographic antibody test kit ,Astel diagnostics® ,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9329999999999999,0.9,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Jesca Lukanga Nakavuma,Makerere University,Not Unity-Aligned,https://doi.org/10.22541/au.164873468.80238886/v1,2022-04-05,2022-07-16,Unverified,nakavuma_cross-species_2022,UGA
220331_Uganda_MakerereUniversity_AgeOver50,220331_Uganda_MakerereUniversity,CROSS-SPECIES TRANSMISSION OF COVID-19 AT ANIMAL-HUMAN INTERFACE: A ONE HEALTH APPROACH FOR IMPROVED DISEASE SURVEILLANCE AND CONTROL IN UGANDA,2022-03-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Uganda,Amuru and Kyotera Districts,,"A formula by Killip et al (2004) was used to select 12 households per parish; and three members from each household were purposely targeted, that is, the husband, wife, and youngest child.","Participants who had known contact with confirmed COVID-19 cases, untamed animals and homesteads without domestic animals were not considered.",2020-07-15,2020-12-15,Household and community samples,All,Multiple groups,50.0,50.0,Age,Age: >= 50,17,0.294,,,,,,,,Stratified non-probability,immunochromatographic antibody test kit ,Astel diagnostics® ,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9329999999999999,0.9,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Jesca Lukanga Nakavuma,Makerere University,Not Unity-Aligned,https://doi.org/10.22541/au.164873468.80238886/v1,2022-04-05,2022-07-16,Unverified,nakavuma_cross-species_2022,UGA
220331_Uganda_MakerereUniversity_Age30to49,220331_Uganda_MakerereUniversity,CROSS-SPECIES TRANSMISSION OF COVID-19 AT ANIMAL-HUMAN INTERFACE: A ONE HEALTH APPROACH FOR IMPROVED DISEASE SURVEILLANCE AND CONTROL IN UGANDA,2022-03-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Uganda,Amuru and Kyotera Districts,,"A formula by Killip et al (2004) was used to select 12 households per parish; and three members from each household were purposely targeted, that is, the husband, wife, and youngest child.","Participants who had known contact with confirmed COVID-19 cases, untamed animals and homesteads without domestic animals were not considered.",2020-07-15,2020-12-15,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,Age: 30-49,20,0.4,,,,,,,,Stratified non-probability,immunochromatographic antibody test kit ,Astel diagnostics® ,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9329999999999999,0.9,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Jesca Lukanga Nakavuma,Makerere University,Not Unity-Aligned,https://doi.org/10.22541/au.164873468.80238886/v1,2022-04-05,2022-07-16,Unverified,nakavuma_cross-species_2022,UGA
220331_Uganda_MakerereUniversity_Female,220331_Uganda_MakerereUniversity,CROSS-SPECIES TRANSMISSION OF COVID-19 AT ANIMAL-HUMAN INTERFACE: A ONE HEALTH APPROACH FOR IMPROVED DISEASE SURVEILLANCE AND CONTROL IN UGANDA,2022-03-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Uganda,Amuru and Kyotera Districts,,"A formula by Killip et al (2004) was used to select 12 households per parish; and three members from each household were purposely targeted, that is, the husband, wife, and youngest child.","Participants who had known contact with confirmed COVID-19 cases, untamed animals and homesteads without domestic animals were not considered.",2020-07-15,2020-12-15,Household and community samples,Female,Multiple groups,10.0,,Sex/Gender,,36,0.47200000000000003,,,,,,,,Stratified non-probability,immunochromatographic antibody test kit ,Astel diagnostics® ,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9329999999999999,0.9,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Jesca Lukanga Nakavuma,Makerere University,Not Unity-Aligned,https://doi.org/10.22541/au.164873468.80238886/v1,2022-04-05,2022-07-16,Unverified,nakavuma_cross-species_2022,UGA
220331_Uganda_MakerereUniversity_Age10to29,220331_Uganda_MakerereUniversity,CROSS-SPECIES TRANSMISSION OF COVID-19 AT ANIMAL-HUMAN INTERFACE: A ONE HEALTH APPROACH FOR IMPROVED DISEASE SURVEILLANCE AND CONTROL IN UGANDA,2022-03-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Uganda,Amuru and Kyotera Districts,,"A formula by Killip et al (2004) was used to select 12 households per parish; and three members from each household were purposely targeted, that is, the husband, wife, and youngest child.","Participants who had known contact with confirmed COVID-19 cases, untamed animals and homesteads without domestic animals were not considered.",2020-07-15,2020-12-15,Household and community samples,All,Multiple groups,10.0,29.0,Age,Age: 10-29,35,0.28600000000000003,,,,,,,,Stratified non-probability,immunochromatographic antibody test kit ,Astel diagnostics® ,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9329999999999999,0.9,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Jesca Lukanga Nakavuma,Makerere University,Not Unity-Aligned,https://doi.org/10.22541/au.164873468.80238886/v1,2022-04-05,2022-07-16,Unverified,nakavuma_cross-species_2022,UGA
220331_Uganda_MakerereUniversity_Male,220331_Uganda_MakerereUniversity,CROSS-SPECIES TRANSMISSION OF COVID-19 AT ANIMAL-HUMAN INTERFACE: A ONE HEALTH APPROACH FOR IMPROVED DISEASE SURVEILLANCE AND CONTROL IN UGANDA,2022-03-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Uganda,Amuru and Kyotera Districts,,"A formula by Killip et al (2004) was used to select 12 households per parish; and three members from each household were purposely targeted, that is, the husband, wife, and youngest child.","Participants who had known contact with confirmed COVID-19 cases, untamed animals and homesteads without domestic animals were not considered.",2020-07-15,2020-12-15,Household and community samples,Male,Multiple groups,10.0,,Sex/Gender,,36,0.167,,,,,,,,Stratified non-probability,immunochromatographic antibody test kit ,Astel diagnostics® ,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9329999999999999,0.9,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Jesca Lukanga Nakavuma,Makerere University,Not Unity-Aligned,https://doi.org/10.22541/au.164873468.80238886/v1,2022-04-05,2022-07-16,Unverified,nakavuma_cross-species_2022,UGA
220921_Uganda_UCSF_Round1_PopTestAdj,220921_Uganda_UCSF_Round1,Reconstructing the SARS-CoV-2 epidemic in eastern Uganda through longitudinal serosurveillance in a malaria cohort.,2022-09-21,Preprint,Local,Prospective cohort,Uganda,,,Participants from the 80 households enrolled in the cohort were encouraged to come to a dedicated study clinic open 7 days per week for all medical care which they received free of charge.,,2020-10-12,2020-11-25,Household and community samples,All,Multiple groups,,,Primary Estimate,round 1,245,0.256,0.196,0.32,True,True,True,,,Convenience,Author designed (Multiplex),,Luminex,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.929,1.0,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,Jessica Briggs,University of California San Francisco,Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280170,2022-10-04,2023-03-19,Verified,briggs_reconstructing_2022,UGA
220921_Uganda_UCSF_Round1_AgeOver16,220921_Uganda_UCSF_Round1,Reconstructing the SARS-CoV-2 epidemic in eastern Uganda through longitudinal serosurveillance in a malaria cohort.,2022-09-21,Preprint,Local,Prospective cohort,Uganda,,,Participants from the 80 households enrolled in the cohort were encouraged to come to a dedicated study clinic open 7 days per week for all medical care which they received free of charge.,,2020-10-12,2020-11-25,Household and community samples,All,Multiple groups,16.0,,Age,"round 1, age: > 16",87,0.287,,,,,,,,Convenience,Author designed (Multiplex),,Luminex,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.929,1.0,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,Jessica Briggs,University of California San Francisco,Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280170,2022-10-04,2022-11-25,Verified,briggs_reconstructing_2022,UGA
220921_Uganda_UCSF_Round1_AgeUnder5,220921_Uganda_UCSF_Round1,Reconstructing the SARS-CoV-2 epidemic in eastern Uganda through longitudinal serosurveillance in a malaria cohort.,2022-09-21,Preprint,Local,Prospective cohort,Uganda,,,Participants from the 80 households enrolled in the cohort were encouraged to come to a dedicated study clinic open 7 days per week for all medical care which they received free of charge.,,2020-10-12,2020-11-25,Household and community samples,All,Children and Youth (0-17 years),0.0,5.0,Age,"round 1, age: < 5",89,0.157,,,,,,,,Convenience,Author designed (Multiplex),,Luminex,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.929,1.0,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,Jessica Briggs,University of California San Francisco,Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280170,2022-10-04,2022-11-25,Verified,briggs_reconstructing_2022,UGA
220921_Uganda_UCSF_Round1_Age5to15,220921_Uganda_UCSF_Round1,Reconstructing the SARS-CoV-2 epidemic in eastern Uganda through longitudinal serosurveillance in a malaria cohort.,2022-09-21,Preprint,Local,Prospective cohort,Uganda,,,Participants from the 80 households enrolled in the cohort were encouraged to come to a dedicated study clinic open 7 days per week for all medical care which they received free of charge.,,2020-10-12,2020-11-25,Household and community samples,All,Children and Youth (0-17 years),5.0,15.0,Age,"round 1, age: 5-15",69,0.217,,,,,,,,Convenience,Author designed (Multiplex),,Luminex,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.929,1.0,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,Jessica Briggs,University of California San Francisco,Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280170,2022-10-04,2022-11-25,Verified,briggs_reconstructing_2022,UGA
220921_Uganda_UCSF_Round1_UnAdj,220921_Uganda_UCSF_Round1,Reconstructing the SARS-CoV-2 epidemic in eastern Uganda through longitudinal serosurveillance in a malaria cohort.,2022-09-21,Preprint,Local,Prospective cohort,Uganda,,,Participants from the 80 households enrolled in the cohort were encouraged to come to a dedicated study clinic open 7 days per week for all medical care which they received free of charge.,,2020-10-12,2020-11-25,Household and community samples,All,Multiple groups,,,Analysis,round 1,245,0.22,,,,,,,True,Convenience,Author designed (Multiplex),,Luminex,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.929,1.0,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,Jessica Briggs,University of California San Francisco,Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280170,2022-11-25,2023-03-19,Verified,briggs_reconstructing_2022,UGA
220921_Uganda_UCSF_Round2_PopTestAdj,220921_Uganda_UCSF_Round2,Reconstructing the SARS-CoV-2 epidemic in eastern Uganda through longitudinal serosurveillance in a malaria cohort.,2022-09-21,Preprint,Local,Prospective cohort,Uganda,,,Participants from the 80 households enrolled in the cohort were encouraged to come to a dedicated study clinic open 7 days per week for all medical care which they received free of charge.,,2021-03-02,2021-04-28,Household and community samples,All,Multiple groups,,,Primary Estimate,round 2,414,0.43700000000000006,0.386,0.488,True,True,True,,,Convenience,Author designed (Multiplex),,Luminex,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.929,1.0,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,Jessica Briggs,University of California San Francisco,Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280170,2022-10-04,2023-03-19,Verified,briggs_reconstructing_2022,UGA
220921_Uganda_UCSF_Round2_AgeUnder5,220921_Uganda_UCSF_Round2,Reconstructing the SARS-CoV-2 epidemic in eastern Uganda through longitudinal serosurveillance in a malaria cohort.,2022-09-21,Preprint,Local,Prospective cohort,Uganda,,,Participants from the 80 households enrolled in the cohort were encouraged to come to a dedicated study clinic open 7 days per week for all medical care which they received free of charge.,,2021-03-02,2021-04-28,Household and community samples,All,Children and Youth (0-17 years),0.0,5.0,Age,"round 2, age: < 5",134,0.2611940299,,,,,,,,Convenience,Author designed (Multiplex),,Luminex,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.929,1.0,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,Jessica Briggs,University of California San Francisco,Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280170,2022-11-25,2023-03-19,Verified,briggs_reconstructing_2022,UGA
220921_Uganda_UCSF_Round2_UnAdj,220921_Uganda_UCSF_Round2,Reconstructing the SARS-CoV-2 epidemic in eastern Uganda through longitudinal serosurveillance in a malaria cohort.,2022-09-21,Preprint,Local,Prospective cohort,Uganda,,,Participants from the 80 households enrolled in the cohort were encouraged to come to a dedicated study clinic open 7 days per week for all medical care which they received free of charge.,,2021-03-02,2021-04-28,Household and community samples,All,Multiple groups,,,Analysis,round 2,414,0.379,,,,,,,True,Convenience,Author designed (Multiplex),,Luminex,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.929,1.0,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,Jessica Briggs,University of California San Francisco,Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280170,2022-11-25,2023-03-19,Verified,briggs_reconstructing_2022,UGA
220921_Uganda_UCSF_Round3_PopTestAdj,220921_Uganda_UCSF_Round3,Reconstructing the SARS-CoV-2 epidemic in eastern Uganda through longitudinal serosurveillance in a malaria cohort.,2022-09-21,Preprint,Local,Prospective cohort,Uganda,,,Participants from the 80 households enrolled in the cohort were encouraged to come to a dedicated study clinic open 7 days per week for all medical care which they received free of charge.,,2021-08-02,2021-09-29,Household and community samples,All,Multiple groups,,,Primary Estimate,round 3,434,0.677,0.625,0.726,True,True,True,,,Convenience,Author designed (Multiplex),,Luminex,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.929,1.0,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,Jessica Briggs,University of California San Francisco,Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280170,2022-10-04,2023-03-19,Verified,briggs_reconstructing_2022,UGA
220921_Uganda_UCSF_Round3_AgeUnder5,220921_Uganda_UCSF_Round3,Reconstructing the SARS-CoV-2 epidemic in eastern Uganda through longitudinal serosurveillance in a malaria cohort.,2022-09-21,Preprint,Local,Prospective cohort,Uganda,,,Participants from the 80 households enrolled in the cohort were encouraged to come to a dedicated study clinic open 7 days per week for all medical care which they received free of charge.,,2021-08-02,2021-09-29,Household and community samples,All,Children and Youth (0-17 years),0.0,5.0,Age,"round 3, age: < 5",129,0.5271317829000001,,,,,,,,Convenience,Author designed (Multiplex),,Luminex,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.929,1.0,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,Jessica Briggs,University of California San Francisco,Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280170,2022-11-25,2023-03-22,Verified,briggs_reconstructing_2022,UGA
220921_Uganda_UCSF_Round3_UnAdj,220921_Uganda_UCSF_Round3,Reconstructing the SARS-CoV-2 epidemic in eastern Uganda through longitudinal serosurveillance in a malaria cohort.,2022-09-21,Preprint,Local,Prospective cohort,Uganda,,,Participants from the 80 households enrolled in the cohort were encouraged to come to a dedicated study clinic open 7 days per week for all medical care which they received free of charge.,,2021-08-02,2021-09-29,Household and community samples,All,Multiple groups,,,Analysis,round 3,434,0.599,,,,,,,True,Convenience,Author designed (Multiplex),,Luminex,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.929,1.0,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,Jessica Briggs,University of California San Francisco,Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280170,2022-11-25,2023-03-22,Verified,briggs_reconstructing_2022,UGA
220921_Uganda_UCSF_Round4_PopTestAdj,220921_Uganda_UCSF_Round4,Reconstructing the SARS-CoV-2 epidemic in eastern Uganda through longitudinal serosurveillance in a malaria cohort.,2022-09-21,Preprint,Local,Prospective cohort,Uganda,,,Participants from the 80 households enrolled in the cohort were encouraged to come to a dedicated study clinic open 7 days per week for all medical care which they received free of charge.,,2022-02-01,2022-03-29,Household and community samples,All,Multiple groups,,,Primary Estimate,round 4,390,0.96,0.934,0.9790000000000001,True,True,True,,True,Convenience,Author designed (Multiplex),,Luminex,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.929,1.0,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,Jessica Briggs,University of California San Francisco,Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280170,2022-10-04,2023-03-19,Verified,briggs_reconstructing_2022,UGA
220921_Uganda_UCSF_Round4_Vaccinated,220921_Uganda_UCSF_Round4,Reconstructing the SARS-CoV-2 epidemic in eastern Uganda through longitudinal serosurveillance in a malaria cohort.,2022-09-21,Preprint,Local,Prospective cohort,Uganda,,,Participants from the 80 households enrolled in the cohort were encouraged to come to a dedicated study clinic open 7 days per week for all medical care which they received free of charge.,,2022-02-01,2022-03-29,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,"round 4, vaccinated",245,0.89,,,,,,,,Convenience,Author designed (Multiplex),,Luminex,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.929,1.0,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,Jessica Briggs,University of California San Francisco,Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280170,2022-10-04,2022-11-25,Verified,briggs_reconstructing_2022,UGA
220921_Uganda_UCSF_Round4_AgeUnder5,220921_Uganda_UCSF_Round4,Reconstructing the SARS-CoV-2 epidemic in eastern Uganda through longitudinal serosurveillance in a malaria cohort.,2022-09-21,Preprint,Local,Prospective cohort,Uganda,,,Participants from the 80 households enrolled in the cohort were encouraged to come to a dedicated study clinic open 7 days per week for all medical care which they received free of charge.,,2022-02-01,2022-03-29,Household and community samples,All,Children and Youth (0-17 years),0.0,5.0,Age,"round 4, age: < 5",139,0.8273381295000001,,,,,,,,Convenience,Author designed (Multiplex),,Luminex,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.929,1.0,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,Jessica Briggs,University of California San Francisco,Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280170,2022-11-25,2023-03-19,Verified,briggs_reconstructing_2022,UGA
220921_Uganda_UCSF_Round4_UnAdj,220921_Uganda_UCSF_Round4,Reconstructing the SARS-CoV-2 epidemic in eastern Uganda through longitudinal serosurveillance in a malaria cohort.,2022-09-21,Preprint,Local,Prospective cohort,Uganda,,,Participants from the 80 households enrolled in the cohort were encouraged to come to a dedicated study clinic open 7 days per week for all medical care which they received free of charge.,,2022-02-01,2022-03-29,Household and community samples,All,Multiple groups,,,Analysis,round 4,390,0.91,,,,,,,,Convenience,Author designed (Multiplex),,Luminex,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.929,1.0,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,Jessica Briggs,University of California San Francisco,Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280170,2022-11-25,2023-03-19,Verified,briggs_reconstructing_2022,UGA
220921_Uganda_UCSF_Round4_Unvaccinated,220921_Uganda_UCSF_Round4,Reconstructing the SARS-CoV-2 epidemic in eastern Uganda through longitudinal serosurveillance in a malaria cohort.,2022-09-21,Preprint,Local,Prospective cohort,Uganda,,,Participants from the 80 households enrolled in the cohort were encouraged to come to a dedicated study clinic open 7 days per week for all medical care which they received free of charge.,,2022-02-01,2022-03-29,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,"round 4, unvaccinated",145,0.9450000000000001,,,,,,,,Convenience,Author designed (Multiplex),,Luminex,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.9289999999999998,1.0,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Yes,Jessica Briggs,University of California San Francisco,Unity-Aligned,https://dx.doi.org/10.1101/2022.09.20.22280170,2022-10-04,2022-11-25,Verified,briggs_reconstructing_2022,UGA
230213_Uganda_UniversityofCaliforniaSanFrancisco_round1_popadj,230213_Uganda_UniversityofCaliforniaSanFrancisco_round1,"Seroprevalence of Antibodies to SARS-CoV-2 in Rural Households in Eastern Uganda, 2020-2022.",2023-02-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Uganda, Tororo and Busia districts,,"""This cohort study was conducted within the Program for Resistance, Immunology, Surveillance, and Modeling of Malaria in Uganda (PRISM) Border Cohort study in the Tororo and Busia districts of Uganda""","""Individuals who had received SARS-CoV-2 vaccination by a serosurvey round are removed from the attack rate estimation""",2020-10-12,2020-11-25,Household and community samples,All,Children and Youth (0-17 years),,,Primary Estimate,,245,0.256,0.196,0.32,True,True,True,,,Unclear,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.981,0.992,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Jessica Briggs,University of California San Francisco,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.55978,2023-03-05,2023-03-19,Unverified,briggsSeroprevalenceAntibodiesSARSCoV22023,UGA
230213_Uganda_UniversityofCaliforniaSanFrancisco_round1_popunadj,230213_Uganda_UniversityofCaliforniaSanFrancisco_round1,"Seroprevalence of Antibodies to SARS-CoV-2 in Rural Households in Eastern Uganda, 2020-2022.",2023-02-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Uganda, Tororo and Busia districts,,"""This cohort study was conducted within the Program for Resistance, Immunology, Surveillance, and Modeling of Malaria in Uganda (PRISM) Border Cohort study in the Tororo and Busia districts of Uganda""","""Individuals who had received SARS-CoV-2 vaccination by a serosurvey round are removed from the attack rate estimation""",2020-10-12,2020-11-25,Household and community samples,All,Children and Youth (0-17 years),,,Analysis,,245,0.22,,,,,,,True,Unclear,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.981,0.992,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Jessica Briggs,University of California San Francisco,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.55978,2023-03-05,2024-03-01,Unverified,briggsSeroprevalenceAntibodiesSARSCoV22023,UGA
230213_Uganda_UniversityofCaliforniaSanFrancisco_round2_popadj,230213_Uganda_UniversityofCaliforniaSanFrancisco_round2,"Seroprevalence of Antibodies to SARS-CoV-2 in Rural Households in Eastern Uganda, 2020-2022.",2023-02-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Uganda, Tororo and Busia districts,,"""This cohort study was conducted within the Program for Resistance, Immunology, Surveillance, and Modeling of Malaria in Uganda (PRISM) Border Cohort study in the Tororo and Busia districts of Uganda""","""Individuals who had received SARS-CoV-2 vaccination by a serosurvey round are removed from the attack rate estimation""",2021-03-02,2021-04-28,Household and community samples,All,Children and Youth (0-17 years),,,Primary Estimate,,414,0.437,0.386,0.488,True,True,True,,,Unclear,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.981,0.992,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Jessica Briggs,University of California San Francisco,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.55978,2023-03-05,2023-03-19,Unverified,briggsSeroprevalenceAntibodiesSARSCoV22023,UGA
230213_Uganda_UniversityofCaliforniaSanFrancisco_round2_popunadj,230213_Uganda_UniversityofCaliforniaSanFrancisco_round2,"Seroprevalence of Antibodies to SARS-CoV-2 in Rural Households in Eastern Uganda, 2020-2022.",2023-02-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Uganda, Tororo and Busia districts,,"""This cohort study was conducted within the Program for Resistance, Immunology, Surveillance, and Modeling of Malaria in Uganda (PRISM) Border Cohort study in the Tororo and Busia districts of Uganda""","""Individuals who had received SARS-CoV-2 vaccination by a serosurvey round are removed from the attack rate estimation""",2021-03-02,2021-04-28,Household and community samples,All,Children and Youth (0-17 years),,,Analysis,,414,0.379,,,,,,,True,Unclear,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.981,0.992,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Jessica Briggs,University of California San Francisco,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.55978,2023-03-05,2024-03-01,Unverified,briggsSeroprevalenceAntibodiesSARSCoV22023,UGA
230213_Uganda_UniversityofCaliforniaSanFrancisco_round3_popadj,230213_Uganda_UniversityofCaliforniaSanFrancisco_round3,"Seroprevalence of Antibodies to SARS-CoV-2 in Rural Households in Eastern Uganda, 2020-2022.",2023-02-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Uganda, Tororo and Busia districts,,"""This cohort study was conducted within the Program for Resistance, Immunology, Surveillance, and Modeling of Malaria in Uganda (PRISM) Border Cohort study in the Tororo and Busia districts of Uganda""","""Individuals who had received SARS-CoV-2 vaccination by a serosurvey round are removed from the attack rate estimation""",2021-08-02,2021-09-29,Household and community samples,All,Children and Youth (0-17 years),,,Primary Estimate,,434,0.677,0.625,0.726,True,True,True,,,Unclear,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.981,0.992,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Jessica Briggs,University of California San Francisco,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.55978,2023-03-05,2023-03-19,Unverified,briggsSeroprevalenceAntibodiesSARSCoV22023,UGA
230213_Uganda_UniversityofCaliforniaSanFrancisco_round3_popunadj,230213_Uganda_UniversityofCaliforniaSanFrancisco_round3,"Seroprevalence of Antibodies to SARS-CoV-2 in Rural Households in Eastern Uganda, 2020-2022.",2023-02-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Uganda, Tororo and Busia districts,,"""This cohort study was conducted within the Program for Resistance, Immunology, Surveillance, and Modeling of Malaria in Uganda (PRISM) Border Cohort study in the Tororo and Busia districts of Uganda""","""Individuals who had received SARS-CoV-2 vaccination by a serosurvey round are removed from the attack rate estimation""",2021-08-02,2021-09-29,Household and community samples,All,Children and Youth (0-17 years),,,Analysis,,434,0.5991,,,,,,,True,Unclear,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.981,0.992,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Jessica Briggs,University of California San Francisco,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.55978,2023-03-05,2024-03-01,Unverified,briggsSeroprevalenceAntibodiesSARSCoV22023,UGA
230213_Uganda_UniversityofCaliforniaSanFrancisco_round4_popadj,230213_Uganda_UniversityofCaliforniaSanFrancisco_round4,"Seroprevalence of Antibodies to SARS-CoV-2 in Rural Households in Eastern Uganda, 2020-2022.",2023-02-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Uganda, Tororo and Busia districts,,"""This cohort study was conducted within the Program for Resistance, Immunology, Surveillance, and Modeling of Malaria in Uganda (PRISM) Border Cohort study in the Tororo and Busia districts of Uganda""","""Individuals who had received SARS-CoV-2 vaccination by a serosurvey round are removed from the attack rate estimation""",2022-02-01,2022-03-29,Household and community samples,All,Children and Youth (0-17 years),,,Primary Estimate,,390,0.96,0.934,0.979,True,True,True,,,Unclear,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.981,0.992,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Jessica Briggs,University of California San Francisco,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.55978,2023-03-05,2023-03-19,Unverified,briggsSeroprevalenceAntibodiesSARSCoV22023,UGA
230213_Uganda_UniversityofCaliforniaSanFrancisco_round4_popunadj,230213_Uganda_UniversityofCaliforniaSanFrancisco_round4,"Seroprevalence of Antibodies to SARS-CoV-2 in Rural Households in Eastern Uganda, 2020-2022.",2023-02-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,Uganda, Tororo and Busia districts,,"""This cohort study was conducted within the Program for Resistance, Immunology, Surveillance, and Modeling of Malaria in Uganda (PRISM) Border Cohort study in the Tororo and Busia districts of Uganda""","""Individuals who had received SARS-CoV-2 vaccination by a serosurvey round are removed from the attack rate estimation""",2022-02-01,2022-03-29,Household and community samples,All,Children and Youth (0-17 years),,,Analysis,,390,0.91,,,,,,,True,Unclear,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.981,0.992,['High'],No,Unclear,No,Yes,No,Yes,Yes,Yes,Unclear,Jessica Briggs,University of California San Francisco,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.55978,2023-03-05,2024-03-01,Unverified,briggsSeroprevalenceAntibodiesSARSCoV22023,UGA
230222_Kampala_NationalInstituteofAllergyandInfectiousDiseases_Jan-Apr2022,230222_Kampala_NationalInstituteofAllergyandInfectiousDiseases,SARS-CoV-2 SEROPREVALENCE AMONG UGANDAN BLOOD DONORS: 2019-2022,2023-02-22,Presentation or Conference,Local,Repeated cross-sectional study,Uganda,,Kampala,Blood donor samples and participants in a clinical trial,,2022-01-15,2022-04-15,Multiple populations,All,Adults (18-64 years),16.0,,Primary Estimate,,5393,0.825,,,True,,,,True,Convenience,V-PLEX SARS-CoV-2 Panel 2 (ACE2) Kit,Meso Scale Diagnostics,CLIA,Serum,Neutralizing,"Spike, Nucleocapsid (N-protein), Multiplex",,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Swetha Ashokkumar,National Institute of Allergy and Infectious Diseases,Not Unity-Aligned,https://www.croiconference.org/abstract/sars-cov-2-seroprevalence-among-ugandan-blood-donors-2019-2022/,2023-06-01,2024-03-01,Unverified,ashokkumar_sars-cov-2_2023,UGA
230329_Masaka_InstituteNationalResearchBiomedical_D0_Overall,230329_Masaka_InstituteNationalResearchBiomedical_D0,"Prevalence of immunoglobulin G and M to SARS-CoV-2 and other human coronaviruses in The Democratic Republic of Congo, Sierra Leone, and Uganda: A longitudinal study",2023-03-29,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Uganda,,,"""staff working within primary healthcare facilities"".",,2021-07-01,2021-07-31,Health care workers and caregivers,All,Multiple groups,18.0,74.0,Primary Estimate,RBD or NP; IgG or IgM,213,0.892,,,True,,,,True,Convenience,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Bolarinde Lawal,Institute National Research biomedical,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2023.03.049,2023-03-31,2024-03-01,Unverified,lawal_prevalence_2023-1,UGA
230329_Masaka_InstituteNationalResearchBiomedical_M2_Overall,230329_Masaka_InstituteNationalResearchBiomedical_M2,"Prevalence of immunoglobulin G and M to SARS-CoV-2 and other human coronaviruses in The Democratic Republic of Congo, Sierra Leone, and Uganda: A longitudinal study",2023-03-29,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Uganda,,,"""staff working within primary healthcare facilities"".",,2021-09-01,2021-09-30,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,RBD or NP; IgG or IgM,141,0.837,,,True,,,,True,Convenience,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],,No,No,No,,Yes,Yes,Yes,,Bolarinde Lawal,Institute National Research biomedical,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2023.03.049,2023-03-31,2024-03-01,Unverified,lawal_prevalence_2023-1,UGA
230329_Masaka_InstituteNationalResearchBiomedical_M4_Overall,230329_Masaka_InstituteNationalResearchBiomedical_M4,"Prevalence of immunoglobulin G and M to SARS-CoV-2 and other human coronaviruses in The Democratic Republic of Congo, Sierra Leone, and Uganda: A longitudinal study",2023-03-29,Journal Article (Peer-Reviewed),Local,Prospective cohort,Uganda,,,"""staff working within primary healthcare facilities"".",,2021-11-01,2021-11-30,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,RBD or NP; IgG or IgM,98,0.929,,,True,,,,True,Convenience,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],,No,No,No,,Yes,Yes,Yes,,Bolarinde Lawal,Institute National Research biomedical,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2023.03.049,2023-03-31,2024-03-01,Unverified,lawal_prevalence_2023-1,UGA
231531_Uganda_JohnsHopkinsUniversity_Overall,231531_Uganda_JohnsHopkinsUniversity,SARS-CoV-2 seroprevalence among blood donors in Uganda: 2019-2022.,2023-05-31,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Uganda,,,"Samples were collected as a part of the Mirasol Evaluation of Reduction in Infections Trial (MERIT), a randomized clinical trial located in Uganda investigating the effect of a riboflavin plus UV light pathogen reduction technology on the incidence of transfusion transmitted infections
(TTIs).",,2021-11-15,2021-12-15,Blood donors,All,Multiple groups,,,Primary Estimate,Anti S/N,1876,0.563,,,True,,,,,Convenience,Meso Scale Discovery multiplex assay,Meso Scale Discovery,Other,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Evan M. Bloch,Johns Hopkins University,Not Unity-Aligned,https://dx.doi.org/10.1111/trf.17449,2023-06-22,2023-07-04,Unverified,bloch_sars-cov-2_2023,UGA
231531_Uganda_JohnsHopkinsUniversity_Hoima,231531_Uganda_JohnsHopkinsUniversity,SARS-CoV-2 seroprevalence among blood donors in Uganda: 2019-2022.,2023-05-31,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Uganda,,Hoima,"Samples were collected as a part of the Mirasol Evaluation of Reduction in Infections Trial (MERIT), a randomized clinical trial located in Uganda investigating the effect of a riboflavin plus UV light pathogen reduction technology on the incidence of transfusion transmitted infections
(TTIs).",,2021-11-15,2021-12-15,Blood donors,All,Multiple groups,,,Geographical area,Anti S/N at Hoima,174,0.477,,,,,,,,Convenience,Meso Scale Discovery multiplex assay,Meso Scale Discovery,Other,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Evan M. Bloch,Johns Hopkins University,Not Unity-Aligned,https://dx.doi.org/10.1111/trf.17449,2023-06-22,2023-07-03,Unverified,bloch_sars-cov-2_2023,UGA
231531_Uganda_JohnsHopkinsUniversity_AntiS,231531_Uganda_JohnsHopkinsUniversity,SARS-CoV-2 seroprevalence among blood donors in Uganda: 2019-2022.,2023-05-31,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Uganda,,,"Samples were collected as a part of the Mirasol Evaluation of Reduction in Infections Trial (MERIT), a randomized clinical trial located in Uganda investigating the effect of a riboflavin plus UV light pathogen reduction technology on the incidence of transfusion transmitted infections
(TTIs).",,2021-11-15,2021-12-15,Blood donors,All,Multiple groups,,,Test used,,1876,0.846,,,,,,,True,Convenience,Meso Scale Discovery multiplex assay,Meso Scale Discovery,Other,,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Evan M. Bloch,Johns Hopkins University,Not Unity-Aligned,https://dx.doi.org/10.1111/trf.17449,2023-06-22,2023-07-04,Unverified,bloch_sars-cov-2_2023,UGA
231531_Uganda_JohnsHopkinsUniversity_Jinja,231531_Uganda_JohnsHopkinsUniversity,SARS-CoV-2 seroprevalence among blood donors in Uganda: 2019-2022.,2023-05-31,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Uganda,,Jinja,"Samples were collected as a part of the Mirasol Evaluation of Reduction in Infections Trial (MERIT), a randomized clinical trial located in Uganda investigating the effect of a riboflavin plus UV light pathogen reduction technology on the incidence of transfusion transmitted infections
(TTIs).",,2021-11-15,2021-12-15,Blood donors,All,Multiple groups,,,Geographical area,Anti S/N at Jinja,119,0.479,,,,,,,,Convenience,Meso Scale Discovery multiplex assay,Meso Scale Discovery,Other,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Evan M. Bloch,Johns Hopkins University,Not Unity-Aligned,https://dx.doi.org/10.1111/trf.17449,2023-06-22,2023-07-04,Unverified,bloch_sars-cov-2_2023,UGA
231531_Uganda_JohnsHopkinsUniversity_Masaka,231531_Uganda_JohnsHopkinsUniversity,SARS-CoV-2 seroprevalence among blood donors in Uganda: 2019-2022.,2023-05-31,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Uganda,,Masaka,"Samples were collected as a part of the Mirasol Evaluation of Reduction in Infections Trial (MERIT), a randomized clinical trial located in Uganda investigating the effect of a riboflavin plus UV light pathogen reduction technology on the incidence of transfusion transmitted infections
(TTIs).",,2021-11-15,2021-12-15,Blood donors,All,Multiple groups,,,Geographical area,Anti S/N at Masaka,338,0.544,,,,,,,,Convenience,Meso Scale Discovery multiplex assay,Meso Scale Discovery,Other,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Evan M. Bloch,Johns Hopkins University,Not Unity-Aligned,https://dx.doi.org/10.1111/trf.17449,2023-06-22,2023-07-04,Unverified,bloch_sars-cov-2_2023,UGA
231531_Uganda_JohnsHopkinsUniversity_Kampala,231531_Uganda_JohnsHopkinsUniversity,SARS-CoV-2 seroprevalence among blood donors in Uganda: 2019-2022.,2023-05-31,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Uganda,,Kampala,"Samples were collected as a part of the Mirasol Evaluation of Reduction in Infections Trial (MERIT), a randomized clinical trial located in Uganda investigating the effect of a riboflavin plus UV light pathogen reduction technology on the incidence of transfusion transmitted infections
(TTIs).",,2021-11-15,2021-12-15,Blood donors,All,Multiple groups,,,Geographical area,Anti S/N at Kampala,1245,0.588,,,,,,,,Convenience,Meso Scale Discovery multiplex assay,Meso Scale Discovery,Other,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Evan M. Bloch,Johns Hopkins University,Not Unity-Aligned,https://dx.doi.org/10.1111/trf.17449,2023-06-22,2023-07-04,Unverified,bloch_sars-cov-2_2023,UGA
231531_Uganda_JohnsHopkinsUniversity_AntiN,231531_Uganda_JohnsHopkinsUniversity,SARS-CoV-2 seroprevalence among blood donors in Uganda: 2019-2022.,2023-05-31,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,Uganda,,,"Samples were collected as a part of the Mirasol Evaluation of Reduction in Infections Trial (MERIT), a randomized clinical trial located in Uganda investigating the effect of a riboflavin plus UV light pathogen reduction technology on the incidence of transfusion transmitted infections
(TTIs).",,2021-11-15,2021-12-15,Blood donors,All,Multiple groups,,,Test used,,1876,0.453,,,,,,,True,Convenience,Meso Scale Discovery multiplex assay,Meso Scale Discovery,Other,,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Evan M. Bloch,Johns Hopkins University,Not Unity-Aligned,https://dx.doi.org/10.1111/trf.17449,2023-06-22,2023-07-04,Unverified,bloch_sars-cov-2_2023,UGA
210501_Poltava_UkranianMedicalStomatologicalAcademy_IgG2,210501_Poltava_UkranianMedicalStomatologicalAcademy_IgG2,"EPIDEMIOLOGICAL DATA ON THE DETECTION OF IMMUNOGLOBULINS OF CLASS IGM, IGG TO SARS-COV-2 AMONG POPULATION OF POLTAVA REGION.",2021-05-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ukraine,Poltava Oblast,Poltava,,,2020-07-15,2020-12-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,468,0.47700000000000004,,,True,,,,True,Self-referral,EQUI SARS-CoV-2 IgG,EKVITESTLAB LLC,ELISA,Serum,IgG,,,,,['High'],No,No,No,No,No,Unclear,Yes,No,Unclear,Alla Marchenko,Ukranian Medical Stomatological Academy,Not Unity-Aligned,https://wiadlek.pl/wp-content/uploads/archive/2021/WLek202105116.pdf,2021-06-21,2022-07-16,Verified,marchenko_epidemiological_2021,UKR
210501_Poltava_UkranianMedicalStomatologicalAcademy_IgM1,210501_Poltava_UkranianMedicalStomatologicalAcademy_IgM1,"EPIDEMIOLOGICAL DATA ON THE DETECTION OF IMMUNOGLOBULINS OF CLASS IGM, IGG TO SARS-COV-2 AMONG POPULATION OF POLTAVA REGION.",2021-05-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Ukraine,Poltava Oblast,Poltava,,,2020-07-15,2020-12-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,2375,0.057,,,True,,,,True,Self-referral, EQUI SARS-CoV-2 IgM,EKVITESTLAB LLC,ELISA,Serum,IgG,,,,,['High'],No,No,Yes,No,No,Unclear,Yes,No,Unclear,Alla Marchenko,Ukranian Medical Stomatological Academy,Not Unity-Aligned,https://wiadlek.pl/wp-content/uploads/archive/2021/WLek202105116.pdf,2021-06-21,2022-07-16,Verified,marchenko_epidemiological_2021,UKR
210424_EmirateofAbuDhabi_AbuDhabiPublicHealthCenter_Households_TestAdj.,210424_EmirateofAbuDhabi_AbuDhabiPublicHealthCenter_Households1,"Seroprevalence of COVID-19 infection in the Emirate of Abu Dhabi, United Arab Emirates: a population-based cross-sectional study",2021-04-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United Arab Emirates,Emirate of Abu Dhabi,"Abu Dhabi, Al Ain, Al Dhafra","We separately surveyed cluster samples of households and of labour camps from three regions in the Emirate of Abu Dhabi (Abu Dhabi, Al Ain and Al Dhafra), considering that labour-camp workers exhibit different socio-demographic characteristics compared with the household population.

If a household was unwilling to participate in the study or if the household doorbell was not answered, the next household was selected instead. All residents in the sampled households were invited to participate in the study, irrespective of age or prior COVID-19 infection.",The exclusion criteria included the refusal to provide informed consent or contraindication to venipuncture.,2020-07-19,2020-08-14,Household and community samples,All,Multiple groups,,,Primary Estimate,test adj.,8831,0.10400000000000001,0.095,0.114,True,True,,,,Stratified probability,"Liaison SARS-CoV-2 S1/S2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","DiaSorin,Roche Diagnostics",CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9740000000000001,0.985,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Ahmed R Alsuwaidi,Abu Dhabi Public Health Center,Unity-Aligned,https://academic.oup.com/ije/advance-article/doi/10.1093/ije/dyab077/6248207,2021-05-14,2023-08-15,Unverified,alsuwaidi_seroprevalence_2021,ARE
210424_EmirateofAbuDhabi_AbuDhabiPublicHealthCenter_Households_UnAdj.,210424_EmirateofAbuDhabi_AbuDhabiPublicHealthCenter_Households1,"Seroprevalence of COVID-19 infection in the Emirate of Abu Dhabi, United Arab Emirates: a population-based cross-sectional study",2021-04-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United Arab Emirates,Emirate of Abu Dhabi,"Abu Dhabi, Al Ain, Al Dhafra","We separately surveyed cluster samples of households and of labour camps from three regions in the Emirate of Abu Dhabi (Abu Dhabi, Al Ain and Al Dhafra), considering that labour-camp workers exhibit different socio-demographic characteristics compared with the household population.

If a household was unwilling to participate in the study or if the household doorbell was not answered, the next household was selected instead. All residents in the sampled households were invited to participate in the study, irrespective of age or prior COVID-19 infection.",The exclusion criteria included the refusal to provide informed consent or contraindication to venipuncture.,2020-07-19,2020-08-14,Household and community samples,All,Multiple groups,,,Analysis,,8831,0.113,,,,,,,True,Stratified probability,"Liaison SARS-CoV-2 S1/S2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","DiaSorin,Roche Diagnostics",CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9740000000000001,0.985,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Ahmed R Alsuwaidi,Abu Dhabi Public Health Center,Unity-Aligned,https://academic.oup.com/ije/advance-article/doi/10.1093/ije/dyab077/6248207,2021-05-17,2024-03-01,Unverified,alsuwaidi_seroprevalence_2021,ARE
210424_EmirateofAbuDhabi_AbuDhabiPublicHealthCenter_LabourCamps_TestAdj.,210424_EmirateofAbuDhabi_AbuDhabiPublicHealthCenter_LabourCamps2,"Seroprevalence of COVID-19 infection in the Emirate of Abu Dhabi, United Arab Emirates: a population-based cross-sectional study",2021-04-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United Arab Emirates,Emirate of Abu Dhabi,"Abu Dhabi, Al Ain, Al Dhafra","We separately surveyed cluster samples of households and of labour camps from three regions in the Emirate of Abu Dhabi (Abu Dhabi, Al Ain and Al Dhafra), considering that labour-camp workers exhibit different socio-demographic characteristics compared with the household population.

A list of labour- camp workers present during the study visit was ordered alphabetically by last name. If one of the selected workers was unable to participate in the study, another worker listed after or before the first worker was selected instead",Camps with fewer than five workers were excluded.,2020-07-19,2020-08-14,Essential non-healthcare workers,All,Multiple groups,,,Primary Estimate,test adj.,4855,0.6859999999999999,0.617,0.747,True,True,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9740000000000001,0.985,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Ahmed R Alsuwaidi,Abu Dhabi Public Health Center,Not Unity-Aligned,https://academic.oup.com/ije/advance-article/doi/10.1093/ije/dyab077/6248207,2021-05-14,2023-08-15,Unverified,alsuwaidi_seroprevalence_2021,ARE
210709_Dubai_DubaiHealthAuthority_Overall,210709_Dubai_DubaiHealthAuthority,Seroprevalence of IgG Anti-SARS-CoV-2 among Voluntary Blood Donors in Dubai: Demographic and Risk Factors,2021-07-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Arab Emirates,,Dubai,Blood donors in Dubai,"-Travel outside Emirates in last 28 days
-History of acute symptoms of upper or lower respiratory illness
-close contact with a person under investigation for COVID-19
-Positive PCR test deferred for three months
-Cared for, lived with, or otherwise had close contact with individuals diagnosed or suspected of having COVID-19 in the 28 days prior to donating
-Been diagnosed with COVID-19 or who are suspected to have COVID-19 and who had symptomatic disease or had a positive diagnostic test for SARS-CoV-2 but never developed symptoms were deferred for 28 days after complete resolution of symptoms or the date of the positive diagnostic test, whichever is longer
- Individuals who tested positive for Ab but had never had symptoms or a diagnostic test were allowed to donate",2020-08-15,2020-12-15,Blood donors,All,Adults (18-64 years),17.0,65.0,Primary Estimate,Overal,1418,0.135,,,True,,,,True,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9677,0.9963,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,,May Raouf,Dubai Health Authority,Unity-Aligned,http://dx.doi.org/10.1159/000517456,2021-08-17,2024-03-01,Unverified,raouf_seroprevalence_2021,ARE
210709_Dubai_DubaiHealthAuthority_Female,210709_Dubai_DubaiHealthAuthority,Seroprevalence of IgG Anti-SARS-CoV-2 among Voluntary Blood Donors in Dubai: Demographic and Risk Factors,2021-07-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Arab Emirates,,Dubai,Blood donors in Dubai,"-Travel outside Emirates in last 28 days
-History of acute symptoms of upper or lower respiratory illness
-close contact with a person under investigation for COVID-19
-Positive PCR test deferred for three months
-Cared for, lived with, or otherwise had close contact with individuals diagnosed or suspected of having COVID-19 in the 28 days prior to donating
-Been diagnosed with COVID-19 or who are suspected to have COVID-19 and who had symptomatic disease or had a positive diagnostic test for SARS-CoV-2 but never developed symptoms were deferred for 28 days after complete resolution of symptoms or the date of the positive diagnostic test, whichever is longer
- Individuals who tested positive for Ab but had never had symptoms or a diagnostic test were allowed to donate",2020-08-15,2020-12-15,Blood donors,Female,Adults (18-64 years),17.0,65.0,Sex/Gender,Female,156,0.0513,,,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9677,0.9963,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,,May Raouf,Dubai Health Authority,Unity-Aligned,http://dx.doi.org/10.1159/000517456,2021-08-17,2024-03-01,Unverified,raouf_seroprevalence_2021,ARE
210709_Dubai_DubaiHealthAuthority_Male,210709_Dubai_DubaiHealthAuthority,Seroprevalence of IgG Anti-SARS-CoV-2 among Voluntary Blood Donors in Dubai: Demographic and Risk Factors,2021-07-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Arab Emirates,,Dubai,Blood donors in Dubai,"-Travel outside Emirates in last 28 days
-History of acute symptoms of upper or lower respiratory illness
-close contact with a person under investigation for COVID-19
-Positive PCR test deferred for three months
-Cared for, lived with, or otherwise had close contact with individuals diagnosed or suspected of having COVID-19 in the 28 days prior to donating
-Been diagnosed with COVID-19 or who are suspected to have COVID-19 and who had symptomatic disease or had a positive diagnostic test for SARS-CoV-2 but never developed symptoms were deferred for 28 days after complete resolution of symptoms or the date of the positive diagnostic test, whichever is longer
- Individuals who tested positive for Ab but had never had symptoms or a diagnostic test were allowed to donate",2020-08-15,2020-12-15,Blood donors,Male,Adults (18-64 years),17.0,65.0,Sex/Gender,Male,1262,0.1458,,,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9677,0.9963,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,,May Raouf,Dubai Health Authority,Unity-Aligned,http://dx.doi.org/10.1159/000517456,2021-08-17,2024-03-01,Unverified,raouf_seroprevalence_2021,ARE
210709_Dubai_DubaiHealthAuthority_46-65,210709_Dubai_DubaiHealthAuthority,Seroprevalence of IgG Anti-SARS-CoV-2 among Voluntary Blood Donors in Dubai: Demographic and Risk Factors,2021-07-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Arab Emirates,,Dubai,Blood donors in Dubai,"-Travel outside Emirates in last 28 days
-History of acute symptoms of upper or lower respiratory illness
-close contact with a person under investigation for COVID-19
-Positive PCR test deferred for three months
-Cared for, lived with, or otherwise had close contact with individuals diagnosed or suspected of having COVID-19 in the 28 days prior to donating
-Been diagnosed with COVID-19 or who are suspected to have COVID-19 and who had symptomatic disease or had a positive diagnostic test for SARS-CoV-2 but never developed symptoms were deferred for 28 days after complete resolution of symptoms or the date of the positive diagnostic test, whichever is longer
- Individuals who tested positive for Ab but had never had symptoms or a diagnostic test were allowed to donate",2020-08-15,2020-12-15,Blood donors,All,Adults (18-64 years),46.0,65.0,Age,46-65,243,0.1152,,,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9677,0.9963,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,,May Raouf,Dubai Health Authority,Unity-Aligned,http://dx.doi.org/10.1159/000517456,2021-08-17,2024-03-01,Unverified,raouf_seroprevalence_2021,ARE
210709_Dubai_DubaiHealthAuthority_17-35,210709_Dubai_DubaiHealthAuthority,Seroprevalence of IgG Anti-SARS-CoV-2 among Voluntary Blood Donors in Dubai: Demographic and Risk Factors,2021-07-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Arab Emirates,,Dubai,Blood donors in Dubai,"-Travel outside Emirates in last 28 days
-History of acute symptoms of upper or lower respiratory illness
-close contact with a person under investigation for COVID-19
-Positive PCR test deferred for three months
-Cared for, lived with, or otherwise had close contact with individuals diagnosed or suspected of having COVID-19 in the 28 days prior to donating
-Been diagnosed with COVID-19 or who are suspected to have COVID-19 and who had symptomatic disease or had a positive diagnostic test for SARS-CoV-2 but never developed symptoms were deferred for 28 days after complete resolution of symptoms or the date of the positive diagnostic test, whichever is longer
- Individuals who tested positive for Ab but had never had symptoms or a diagnostic test were allowed to donate",2020-08-15,2020-12-15,Blood donors,All,Adults (18-64 years),17.0,35.0,Age,17-35,690,0.1478,,,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9677,0.9963,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,,May Raouf,Dubai Health Authority,Unity-Aligned,http://dx.doi.org/10.1159/000517456,2021-08-17,2024-03-01,Unverified,raouf_seroprevalence_2021,ARE
210709_Dubai_DubaiHealthAuthority_36-45,210709_Dubai_DubaiHealthAuthority,Seroprevalence of IgG Anti-SARS-CoV-2 among Voluntary Blood Donors in Dubai: Demographic and Risk Factors,2021-07-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Arab Emirates,,Dubai,Blood donors in Dubai,"-Travel outside Emirates in last 28 days
-History of acute symptoms of upper or lower respiratory illness
-close contact with a person under investigation for COVID-19
-Positive PCR test deferred for three months
-Cared for, lived with, or otherwise had close contact with individuals diagnosed or suspected of having COVID-19 in the 28 days prior to donating
-Been diagnosed with COVID-19 or who are suspected to have COVID-19 and who had symptomatic disease or had a positive diagnostic test for SARS-CoV-2 but never developed symptoms were deferred for 28 days after complete resolution of symptoms or the date of the positive diagnostic test, whichever is longer
- Individuals who tested positive for Ab but had never had symptoms or a diagnostic test were allowed to donate",2020-08-15,2020-12-15,Blood donors,All,Adults (18-64 years),36.0,45.0,Age,36-45,485,0.1278,,,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9677,0.9963,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,,May Raouf,Dubai Health Authority,Unity-Aligned,http://dx.doi.org/10.1159/000517456,2021-08-17,2024-03-01,Unverified,raouf_seroprevalence_2021,ARE
210927_AbuDhabi_SEHAAbuDhabiHealthServicesCompany,210927_AbuDhabi_SEHAAbuDhabiHealthServicesCompany,An Analysis Of Antibody Responses And Clinical Sequalae Of The Sinopharm HB02 COVID19 Vaccine In Dialysis Patients In The UAE.,2021-09-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Arab Emirates,,Abu Dhabi,"he inclusion criteria for vaccination (and therefore inclusion for the study) (issued by theDepartment of Health, Abu Dhabi) were 18 years old and above;hemodynamically stable at the time of vaccination; and controlledchronic disease/s including autoimmune disease","The exclusion criteria were anyone with history of moderate to severe COVID19 infection needing oxygen during admission; known to be pregnant(based on clinical history and/or pregnancy test); previous severe allergic reaction to vaccination; recent history of convulsion, epilepsy,encephalopathy, or severe coagulation dysfunction; receiving any live attenuated vaccine within 1 month before this vaccination or other vaccines types within 14 days before this vaccination; recent history of Guillain Barre Syndrome (GBS) or transverse myelitis; uncontrolled 2HOLTET AL. symptomatic autoimmune disease, immunocompromised conditions,active cancer or in remission for less than 6 months, or inability or refusal to give informed consent
",2021-01-25,2021-03-30,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,446,0.17,,,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Stephen Holt,SEHA Abu Dhabi Health Services Company,Not Unity-Aligned,https://dx.doi.org/10.1111/nep.13980,2021-10-06,2024-03-01,Unverified,holt_analysis_2021,ARE
200520_England_RutherfordHealth_HCW_IgG,200520_England_RutherfordHealth,Serological prevalence of antibodies to SARS CoV-2 amongst cancer centre staff,2020-05-20,Preprint,Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,"Reading, Newport, Liverpool, Bedlington",staff on site at 4 cancer locations,,2020-04-14,2020-04-24,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,161,0.0124,,,True,,,,True,Convenience,SGTi-flex COVID-19 IgM/IgG (manual),"Sugentech, Inc.",LFIA,Whole Blood,IgG,,Validated by manufacturers,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Karol Sikora,Rutherford Health,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.05.16.20099408v1.full.pdf+html,2020-05-21,2024-03-01,Verified,sikora_serological_2020,GBR
200617_Gibraltar_GibraltarGovernment_HCW,200617_Gibraltar_GibraltarGovernment,"After in-house GHA screening programme, Govt rethinks its plans for anti-body tests",2020-06-17,News and Media,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Gibraltar,,Gibraltar Health Authority staff ,,2020-06-03,2020-06-17,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1247,0.013999999999999999,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,IgG,,,,,['High'],Yes,No,Yes,No,Unclear,Unclear,Yes,No,Unclear,Priya Gulraj,Gibraltar Government ,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.chronicle.gi/after-in-house-gha-screening-programme-govt-rethinks-its-plans-for-anti-body-tests/&ct=ga&cd=CAAYBjIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNHWZarBh_XNDZ6O6KvR5YUdioFyGg,2020-06-23,2022-07-16,Verified,gulraj_after_2020,GBR
200626_UK_OfficeforNationalStatistics_May_June2020_England_Genpop,200626_UK_OfficeforNationalStatistics_May_2020_England,Coronavirus (COVID-19) Infection Survey: May_June 2020,2020-06-25,Institutional Report,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"Only England is included in this pilot phase of the study. Discussions are underway with the devolved administrations in Scotland, Wales and Northern Ireland to include the whole of the UK in the main study. Only private households, otherwise known as the target population in this bulletin, are included in the sample. People in care homes, other communal establishments and hospitals are not included. We are initially conducting a pilot survey of households in England, working with the University of Oxford, IQVIA and UK Biocentre Milton Keynes to collect and analyse the samples. At the start of the pilot study, 20,000 households were invited to take part, with the aim of collecting data from around 10,000 households. To take part, invited households opted in to the survey by contacting a company called IQVIA, working on behalf of the ONS, to arrange a visit. Adults over 15 years of age from around 2,000 households will provide a blood sample taken by a trained nurse, phlebotomist or healthcare assistant. The sample for this initial survey has been drawn from households in which someone has already participated in an Office for National Statistics (ONS) survey and has consented to be approached for future research. Households cannot request to be part of the survey; this ensures the sample is representative of the wider population. While the pilot is based on a nationally representative survey sample, some individuals in the original ONS survey samples will have dropped out, while others will not have responded to the pilot. Blood samples are taken only from those aged 16 years and over","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2020-05-08,2020-06-04,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,,1575,0.063,0.045,0.087,True,,True,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office of National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/december2020,2021-03-12,2022-07-16,Verified,steel_coronavirus_2020-2,GBR
200707_NorthWestEngland_SalfordRoyalNHSFoundationTrust_HCW,200707_NorthWestEngland_SalfordRoyalNHSFoundationTrust,SARS-CoV-2 antibody screening in healthcare workers in a tertiary centre in North West England,2020-07-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,HCWs from renal and biochemistry department,,2020-05-04,2020-05-06,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,281,0.06,,,True,,,,True,Convenience,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Multiple Types,IgG,,,,,['High'],Yes,No,No,No,No,Yes,Yes,Yes,Unclear,Dimitrios Poulikakos,Salford Royal NHS Foundation Trust,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338856/,2020-07-20,2024-03-01,Verified,poulikakos_sars-cov-2_2020,GBR
200709_England_PHE_BloodDonor_GenPop_Overall_TestPopAdj_Week19to22,200709_England_PHE_BloodDonor_Week19to22,PHE England week 28 ,2020-07-09,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report updated results from the testing of samples provided by health blood donors aged 17-69 years, supplied by the NHS Blood and Transplant (NHS BT collection) are summarized.  Donor samples from different geographic regions (approximately 1000 samples per region) in England are tested each week. The results presented here are based on testing using the Euroimmun assay for samples collected between weeks 13-26.",,2020-05-04,2020-05-31,Blood donors,All,Adults (18-64 years),17.0,69.0,Primary Estimate,,7686,0.083,0.075,0.092,True,True,True,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-18,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200603_England_PHE_BloodDonor_GenPop_Southwest_TestPopAdj_Week21,200709_England_PHE_BloodDonor_Week19to22,PHE England week 28 ,2020-07-09,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report updated results from the testing of samples provided by health blood donors aged 17-69 years, supplied by the NHS Blood and Transplant (NHS BT collection) are summarized.  Donor samples from different geographic regions (approximately 1000 samples per region) in England are tested each week. The results presented here are based on testing using the Euroimmun assay for samples collected between weeks 13-26.",,2020-05-21,2020-05-22,Blood donors,All,Adults (18-64 years),17.0,69.0,Geographical area,Southwest of England ,1050,0.04,0.025,0.057,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200709_England_PHE_BloodDonor_GenPop_London_TestPopAdj_Week18,200709_England_PHE_BloodDonor_Week19to22,PHE England week 28 ,2020-07-09,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,London,"In this week’s report updated results from the testing of samples provided by health blood donors aged 17-69 years, supplied by the NHS Blood and Transplant (NHS BT collection) are summarized.  Donor samples from different geographic regions (approximately 1000 samples per region) in England are tested each week. The results presented here are based on testing using the Euroimmun assay for samples collected between weeks 13-26.",,2020-05-01,2020-05-03,Blood donors,All,Adults (18-64 years),17.0,69.0,Geographical area,London,974,0.15,0.12300000000000001,0.18,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200702_England_PHE_BloodDonor_GenPop_East_TestPopAdj_Week19,200709_England_PHE_BloodDonor_Week19to22,PHE England week 28 ,2020-07-09,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report updated results from the testing of samples provided by health blood donors aged 17-69 years, supplied by the NHS Blood and Transplant (NHS BT collection) are summarized.  Donor samples from different geographic regions (approximately 1000 samples per region) in England are tested each week. The results presented here are based on testing using the Euroimmun assay for samples collected between weeks 13-26.",,2020-05-07,2020-05-10,Blood donors,All,Adults (18-64 years),17.0,69.0,Geographical area,East of England ,1015,0.08800000000000001,0.067,0.11199999999999999,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200717_England_PHE_BloodDonor_GenPop_Overall_TestPopAdj_Week20to23,200709_England_PHE_BloodDonor_Week19to22,PHE England week 28 ,2020-07-09,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report updated results from the testing of samples provided by health blood donors aged 17-69 years, supplied by the NHS Blood and Transplant (NHS BT collection) are summarized.  Donor samples from different geographic regions (approximately 1000 samples per region) in England are tested each week. The results presented here are based on testing using the Euroimmun assay for samples collected between weeks 13-26.",,2020-05-13,2020-06-07,Blood donors,All,Adults (18-64 years),17.0,69.0,Time frame,,7777,0.08199999999999999,0.07400000000000001,0.09,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-18,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200717_England_PHE_BloodDonor_GenPop_East_TestPopAdj_Week22,200709_England_PHE_BloodDonor_Week19to22,PHE England week 28 ,2020-07-09,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report updated results from the testing of samples provided by health blood donors aged 17-69 years, supplied by the NHS Blood and Transplant (NHS BT collection) are summarized.  Donor samples from different geographic regions (approximately 1000 samples per region) in England are tested each week. The results presented here are based on testing using the Euroimmun assay for samples collected between weeks 13-26.",,2020-05-28,2020-05-29,Blood donors,All,Adults (18-64 years),17.0,69.0,Geographical area,East of England ,1100,0.052000000000000005,0.036000000000000004,0.07,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-06-28,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200624_England_PHE_BloodDonor_GenPop_Midlands_TestPopAdj_Week20,200709_England_PHE_BloodDonor_Week19to22,PHE England week 28 ,2020-07-09,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report updated results from the testing of samples provided by health blood donors aged 17-69 years, supplied by the NHS Blood and Transplant (NHS BT collection) are summarized.  Donor samples from different geographic regions (approximately 1000 samples per region) in England are tested each week. The results presented here are based on testing using the Euroimmun assay for samples collected between weeks 13-26.",,2020-05-14,2020-05-15,Blood donors,All,Adults (18-64 years),17.0,69.0,Geographical area,Midlands of England ,870,0.06,0.040999999999999995,0.081,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200702_England_PHE_BloodDonor_GenPop_Northeast_TestPopAdj_Week20,200709_England_PHE_BloodDonor_Week19to22,PHE England week 28 ,2020-07-09,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report updated results from the testing of samples provided by health blood donors aged 17-69 years, supplied by the NHS Blood and Transplant (NHS BT collection) are summarized.  Donor samples from different geographic regions (approximately 1000 samples per region) in England are tested each week. The results presented here are based on testing using the Euroimmun assay for samples collected between weeks 13-26.",,2020-05-13,2020-05-14,Blood donors,All,Adults (18-64 years),17.0,69.0,Geographical area,Northeast of England ,1014,0.071,0.053,0.09300000000000001,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200610_England_PHE_BloodDonor_GenPop_Southeast_TestPopAdj_Week22,200709_England_PHE_BloodDonor_Week19to22,PHE England week 28 ,2020-07-09,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report updated results from the testing of samples provided by health blood donors aged 17-69 years, supplied by the NHS Blood and Transplant (NHS BT collection) are summarized.  Donor samples from different geographic regions (approximately 1000 samples per region) in England are tested each week. The results presented here are based on testing using the Euroimmun assay for samples collected between weeks 13-26.",,2020-05-28,2020-05-29,Blood donors,All,Adults (18-64 years),17.0,69.0,Geographical area,Southeast of England ,832,0.047,0.028999999999999998,0.067,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200709_England_PHE_BloodDonor_GenPop_London_TestPopAdj_Week21,200709_England_PHE_BloodDonor_Week19to22,PHE England week 28 ,2020-07-09,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,London,"In this week’s report updated results from the testing of samples provided by health blood donors aged 17-69 years, supplied by the NHS Blood and Transplant (NHS BT collection) are summarized.  Donor samples from different geographic regions (approximately 1000 samples per region) in England are tested each week. The results presented here are based on testing using the Euroimmun assay for samples collected between weeks 13-26.",,2020-05-21,2020-05-22,Blood donors,All,Adults (18-64 years),17.0,69.0,Geographical area,London,797,0.157,0.128,0.19100000000000003,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200702_England_PHE_BloodDonor_GenPop_Overall_TestPopAdj_Week18to21,200709_England_PHE_BloodDonor_Week19to22,PHE England week 28 ,2020-07-09,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report updated results from the testing of samples provided by health blood donors aged 17-69 years, supplied by the NHS Blood and Transplant (NHS BT collection) are summarized.  Donor samples from different geographic regions (approximately 1000 samples per region) in England are tested each week. The results presented here are based on testing using the Euroimmun assay for samples collected between weeks 13-26.",,2020-04-30,2020-05-22,Blood donors,All,Adults (18-64 years),17.0,69.0,Time frame,,7694,0.086,0.078,0.094,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200717_England_PHE_BloodDonor_GenPop_Northwest_TestPopAdj_Week19,200709_England_PHE_BloodDonor_Week19to22,PHE England week 28 ,2020-07-09,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report updated results from the testing of samples provided by health blood donors aged 17-69 years, supplied by the NHS Blood and Transplant (NHS BT collection) are summarized.  Donor samples from different geographic regions (approximately 1000 samples per region) in England are tested each week. The results presented here are based on testing using the Euroimmun assay for samples collected between weeks 13-26.",,2020-05-06,2020-05-08,Blood donors,All,Adults (18-64 years),17.0,69.0,Geographical area,Northwest of England ,1008,0.10800000000000001,0.085,0.134,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-18,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200709_England_PHE_BloodDonor_GenPop_Overall_TestPopAdj_Week23to27,200709_England_PHE_BloodDonor_Week23to27,PHE England week 28 ,2020-07-09,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report updated results from the testing of samples provided by health blood donors aged 17-69 years, supplied by the NHS Blood and Transplant (NHS BT collection) are summarized.  Donor samples from different geographic regions (approximately 1000 samples per region) in England are tested each week. The results presented here are based on testing using the Euroimmun assay for samples collected between weeks 13-26.",,2020-06-01,2020-06-28,Blood donors,All,Multiple groups,17.0,69.0,Primary Estimate,,10318,0.07200000000000001,0.066,0.078,True,True,True,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-18,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200702_England_PHE_BloodDonor_GenPop_Overall_TestPopAdj_Week22to26,200709_England_PHE_BloodDonor_Week23to27,PHE England week 28 ,2020-07-09,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report updated results from the testing of samples provided by health blood donors aged 17-69 years, supplied by the NHS Blood and Transplant (NHS BT collection) are summarized.  Donor samples from different geographic regions (approximately 1000 samples per region) in England are tested each week. The results presented here are based on testing using the Euroimmun assay for samples collected between weeks 13-26.",,2020-05-28,2020-06-22,Blood donors,All,Adults (18-64 years),17.0,69.0,Time frame,,12302,0.086,0.078,0.091,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200709_England_PHE_BloodDonor_GenPop_London_TestPopAdj_Week23to24,200709_England_PHE_BloodDonor_Week23to27,PHE England week 28 ,2020-07-09,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,London,"In this week’s report updated results from the testing of samples provided by health blood donors aged 17-69 years, supplied by the NHS Blood and Transplant (NHS BT collection) are summarized.  Donor samples from different geographic regions (approximately 1000 samples per region) in England are tested each week. The results presented here are based on testing using the Euroimmun assay for samples collected between weeks 13-26.",,2020-06-05,2020-06-08,Blood donors,All,Adults (18-64 years),17.0,69.0,Geographical area,London,1094,0.15,0.125,0.179,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200709_England_PHE_BloodDonor_GenPop_Northwest_TestPopAdj_Week23,200709_England_PHE_BloodDonor_Week23to27,PHE England week 28 ,2020-07-09,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report updated results from the testing of samples provided by health blood donors aged 17-69 years, supplied by the NHS Blood and Transplant (NHS BT collection) are summarized.  Donor samples from different geographic regions (approximately 1000 samples per region) in England are tested each week. The results presented here are based on testing using the Euroimmun assay for samples collected between weeks 13-26.",,2020-06-04,2020-06-06,Blood donors,All,Adults (18-64 years),17.0,69.0,Geographical area,Northwest of England ,1020,0.09,0.069,0.114,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200717_England_PHE_BloodDonor_GenPop_East_TestPopAdj_Week27,200709_England_PHE_BloodDonor_Week23to27,PHE England week 28 ,2020-07-09,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report updated results from the testing of samples provided by health blood donors aged 17-69 years, supplied by the NHS Blood and Transplant (NHS BT collection) are summarized.  Donor samples from different geographic regions (approximately 1000 samples per region) in England are tested each week. The results presented here are based on testing using the Euroimmun assay for samples collected between weeks 13-26.",,2020-06-26,2020-06-29,Blood donors,All,Multiple groups,17.0,69.0,Geographical area,East of England ,994,0.05,0.033,0.069,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-18,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200717_England_PHE_BloodDonor_GenPop_London_TestPopAdj_Week25to26,200709_England_PHE_BloodDonor_Week23to27,PHE England week 28 ,2020-07-09,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,London,"In this week’s report updated results from the testing of samples provided by health blood donors aged 17-69 years, supplied by the NHS Blood and Transplant (NHS BT collection) are summarized.  Donor samples from different geographic regions (approximately 1000 samples per region) in England are tested each week. The results presented here are based on testing using the Euroimmun assay for samples collected between weeks 13-26.",,2020-06-19,2020-06-22,Blood donors,All,Multiple groups,17.0,69.0,Geographical area,London,911,0.133,0.107,0.162,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-18,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200731_England_PHE_BloodDonor_GenPop_Age30to39_PopAdj_Week26to30,200709_England_PHE_BloodDonor_Week23to27,PHE England week 28 ,2020-07-09,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report updated results from the testing of samples provided by health blood donors aged 17-69 years, supplied by the NHS Blood and Transplant (NHS BT collection) are summarized.  Donor samples from different geographic regions (approximately 1000 samples per region) in England are tested each week. The results presented here are based on testing using the Euroimmun assay for samples collected between weeks 13-26.",,2020-06-22,2020-07-20,Blood donors,All,Adults (18-64 years),30.0,39.0,Age,30 to 39,1865,0.053,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200702_England_PHE_BloodDonor_GenPop_Southwest_TestPopAdj_Week25to26,200709_England_PHE_BloodDonor_Week23to27,PHE England week 28 ,2020-07-09,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report updated results from the testing of samples provided by health blood donors aged 17-69 years, supplied by the NHS Blood and Transplant (NHS BT collection) are summarized.  Donor samples from different geographic regions (approximately 1000 samples per region) in England are tested each week. The results presented here are based on testing using the Euroimmun assay for samples collected between weeks 13-26.",,2020-06-19,2020-06-22,Blood donors,All,Multiple groups,17.0,69.0,Geographical area,Southwest of England ,1012,0.037000000000000005,0.022000000000000002,0.054000000000000006,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200717_England_PHE_BloodDonor_GenPop_Southeast_TestPopAdj_Week26to27,200709_England_PHE_BloodDonor_Week23to27,PHE England week 28 ,2020-07-09,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report updated results from the testing of samples provided by health blood donors aged 17-69 years, supplied by the NHS Blood and Transplant (NHS BT collection) are summarized.  Donor samples from different geographic regions (approximately 1000 samples per region) in England are tested each week. The results presented here are based on testing using the Euroimmun assay for samples collected between weeks 13-26.",,2020-06-26,2020-06-29,Blood donors,All,Multiple groups,17.0,69.0,Geographical area,Southeast of England ,1014,0.046,0.03,0.064,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-18,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200624_England_PHE_BloodDonor_GenPop_Midlands_PopAdj_Week24to25,200709_England_PHE_BloodDonor_Week23to27,PHE England week 28 ,2020-07-09,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report updated results from the testing of samples provided by health blood donors aged 17-69 years, supplied by the NHS Blood and Transplant (NHS BT collection) are summarized.  Donor samples from different geographic regions (approximately 1000 samples per region) in England are tested each week. The results presented here are based on testing using the Euroimmun assay for samples collected between weeks 13-26.",,2020-06-11,2020-06-16,Blood donors,All,Multiple groups,17.0,69.0,Geographical area,Midlands of England ,1124,0.07400000000000001,0.055999999999999994,0.095,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200702_England_PHE_BloodDonor_GenPop_Northeast_TestPopAdj_Week24,200709_England_PHE_BloodDonor_Week23to27,PHE England week 28 ,2020-07-09,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report updated results from the testing of samples provided by health blood donors aged 17-69 years, supplied by the NHS Blood and Transplant (NHS BT collection) are summarized.  Donor samples from different geographic regions (approximately 1000 samples per region) in England are tested each week. The results presented here are based on testing using the Euroimmun assay for samples collected between weeks 13-26.",,2020-06-10,2020-06-12,Blood donors,All,Multiple groups,17.0,69.0,Geographical area,Northeast of England ,1056,0.065,0.047,0.085,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-06-28,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200723_England_PHE_BloodDonor_GenPop_Overall_TestPopAdj_Week21to24,200709_England_PHE_BloodDonor_Week23to27,PHE England week 28 ,2020-07-09,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report updated results from the testing of samples provided by health blood donors aged 17-69 years, supplied by the NHS Blood and Transplant (NHS BT collection) are summarized.  Donor samples from different geographic regions (approximately 1000 samples per region) in England are tested each week. The results presented here are based on testing using the Euroimmun assay for samples collected between weeks 13-26.",,2020-05-22,2020-06-08,Blood donors,All,Adults (18-64 years),17.0,69.0,Time frame,,5893,0.08199999999999999,0.07400000000000001,0.09,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200709_England_PHE_BloodDonor_GenPop_Southeast_TestPopAdj_Week22to27,200709_England_PHE_BloodDonor_Week23to27,PHE England week 28 ,2020-07-09,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report updated results from the testing of samples provided by health blood donors aged 17-69 years, supplied by the NHS Blood and Transplant (NHS BT collection) are summarized.  Donor samples from different geographic regions (approximately 1000 samples per region) in England are tested each week. The results presented here are based on testing using the Euroimmun assay for samples collected between weeks 13-26.",,2020-06-01,2020-06-28,Blood donors,All,Multiple groups,17.0,69.0,Geographical area,Southeast of England ,1846,0.044000000000000004,0.025,0.064,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200731_England_PHE_BloodDonor_GenPop_Age17to29_PopAdj_Week26to30,200709_England_PHE_BloodDonor_Week23to27,PHE England week 28 ,2020-07-09,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report updated results from the testing of samples provided by health blood donors aged 17-69 years, supplied by the NHS Blood and Transplant (NHS BT collection) are summarized.  Donor samples from different geographic regions (approximately 1000 samples per region) in England are tested each week. The results presented here are based on testing using the Euroimmun assay for samples collected between weeks 13-26.",,2020-06-22,2020-07-20,Blood donors,All,Adults (18-64 years),17.0,29.0,Age,17 to 29  ,1525,0.077,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200717_England_PHE_BloodDonor_GenPop_Overall_TestPopAdj_Week24to28,200709_England_PHE_BloodDonor_Week23to27,PHE England week 28 ,2020-07-09,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report updated results from the testing of samples provided by health blood donors aged 17-69 years, supplied by the NHS Blood and Transplant (NHS BT collection) are summarized.  Donor samples from different geographic regions (approximately 1000 samples per region) in England are tested each week. The results presented here are based on testing using the Euroimmun assay for samples collected between weeks 13-26.",,2020-06-08,2020-07-06,Blood donors,All,Multiple groups,17.0,69.0,Time frame,,11385,0.071,0.065,0.078,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-18,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200709_London_UniversityCollegeLondonHospitals_HCW,200709_London_UniversityCollegeLondonHospitals,Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers,2020-07-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,London,"HCWs who were asymptomatic at time of enrolment and working in one of five clinical areas: Accident and Emergency (A&E), acute medical admissions (AMU), COVID-19 cohort wards, Intensive Care Unit (ICU) and haematology wards",,2020-03-26,2020-04-08,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,181,0.45299999999999996,,,True,,,,True,Convenience,"Author designed (IFA) - NON-MULTIPLEXED,Author designed (ELISA) -Spike",,Multiple Types,Serum,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],Yes,No,No,Yes,Yes,Unclear,Yes,No,Unclear,Catherine Houlihan,University College London Hospitals,Not Unity-Aligned,https://dx.doi.org/10.1016/S0140-6736(20)31484-7,2020-07-29,2022-07-16,Verified,houlihan_pandemic_2020,GBR
200709_London_UniversityCollegeLondonHospitals_HCWPositive2x_Age50+,200709_London_UniversityCollegeLondonHospitals,Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers,2020-07-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,London,"HCWs who were asymptomatic at time of enrolment and working in one of five clinical areas: Accident and Emergency (A&E), acute medical admissions (AMU), COVID-19 cohort wards, Intensive Care Unit (ICU) and haematology wards",,2020-03-26,2020-04-08,Health care workers and caregivers,All,Multiple groups,50.0,,Age,>=50,30,0.16670000000000001,,,,,,,,Convenience,"Author designed (IFA) - NON-MULTIPLEXED,Author designed (ELISA) -Spike",,Multiple Types,Serum,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],Yes,No,No,Yes,Yes,Unclear,Yes,No,Unclear,Catherine Houlihan,University College London Hospitals,Not Unity-Aligned,https://dx.doi.org/10.1016/S0140-6736(20)31484-7,2020-07-30,2022-07-16,Verified,houlihan_pandemic_2020,GBR
200709_London_UniversityCollegeLondonHospitals_HCWsPositive2x_Age30-39,200709_London_UniversityCollegeLondonHospitals,Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers,2020-07-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,London,"HCWs who were asymptomatic at time of enrolment and working in one of five clinical areas: Accident and Emergency (A&E), acute medical admissions (AMU), COVID-19 cohort wards, Intensive Care Unit (ICU) and haematology wards",,2020-03-26,2020-04-08,Health care workers and caregivers,All,Adults (18-64 years),30.0,39.0,Age,30-39,70,0.24280000000000002,,,,,,,,Convenience,"Author designed (IFA) - NON-MULTIPLEXED,Author designed (ELISA) -Spike",,Multiple Types,Serum,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],Yes,No,No,Yes,Yes,Unclear,Yes,No,Unclear,Catherine Houlihan,University College London Hospitals,Not Unity-Aligned,https://dx.doi.org/10.1016/S0140-6736(20)31484-7,2020-07-30,2022-07-16,Verified,houlihan_pandemic_2020,GBR
200709_London_UniversityCollegeLondonHospitals_HCWsPositive2x_Age<30,200709_London_UniversityCollegeLondonHospitals,Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers,2020-07-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,London,"HCWs who were asymptomatic at time of enrolment and working in one of five clinical areas: Accident and Emergency (A&E), acute medical admissions (AMU), COVID-19 cohort wards, Intensive Care Unit (ICU) and haematology wards",,2020-03-26,2020-04-08,Health care workers and caregivers,All,Adults (18-64 years),18.0,30.0,Age,<30,57,0.31579999999999997,,,,,,,,Convenience,"Author designed (IFA) - NON-MULTIPLEXED,Author designed (ELISA) -Spike",,Multiple Types,Serum,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],Yes,No,No,Yes,Yes,Unclear,Yes,No,Unclear,Catherine Houlihan,University College London Hospitals,Not Unity-Aligned,https://dx.doi.org/10.1016/S0140-6736(20)31484-7,2020-07-30,2022-07-16,Verified,houlihan_pandemic_2020,GBR
200709_London_UniversityCollegeLondonHospitals_HCWPositive2x_Age40-49,200709_London_UniversityCollegeLondonHospitals,Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers,2020-07-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,London,"HCWs who were asymptomatic at time of enrolment and working in one of five clinical areas: Accident and Emergency (A&E), acute medical admissions (AMU), COVID-19 cohort wards, Intensive Care Unit (ICU) and haematology wards",,2020-03-26,2020-04-08,Health care workers and caregivers,All,Adults (18-64 years),40.0,49.0,Age,40-49,40,0.15,,,,,,,,Convenience,"Author designed (IFA) - NON-MULTIPLEXED,Author designed (ELISA) -Spike",,Multiple Types,Serum,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],Yes,No,No,Yes,Yes,Unclear,Yes,No,Unclear,Catherine Houlihan,University College London Hospitals,Not Unity-Aligned,https://dx.doi.org/10.1016/S0140-6736(20)31484-7,2020-07-30,2022-07-16,Verified,houlihan_pandemic_2020,GBR
200724_UK_ChelseaandWestminsterHospital_HCW,200724_UK_ChelseaandWestminsterHospital,Point-of-care serological assays for delayed SARS-CoV-2 case identification among health-care workers in the UK: a prospective multicentre cohort study,2020-07-24,Journal Article (Peer-Reviewed),Local,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,London,"Health-care workers were eligible for serological testing if they had delivered direct clinical care to SARS-CoV-2- positive inpatients in cohort areas or isolation rooms involving aerosol-generating procedures; and had experienced mild to moderate symptoms matching the Public Health England (PHE) case definition7 for SARS-CoV-2 infection, including fever or cough, or both, with breathlessness or anosmia, or both, with onset at least 14 days before testing. Health-care workers were recruited to the asymptomatic cohort if they had satisfied inclusion criteria as above but had not experienced any PHE-defined COVID-19 symptoms since Dec 1, 2019",,2020-04-08,2020-06-12,Health care workers and caregivers,All,Multiple groups,20.0,72.0,Primary Estimate,,504,0.106,0.076,0.136,True,,,,True,Convenience,"OnSite COVID-19 IgG/IgM Rapid Test,Not reported/ Unable to specify,Abbott Architect SARS-CoV-2 IgG","CTK Biotech, Inc.,NA,Abbott Laboratories",Multiple Types,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,Yes,Yes,No,Unclear,Yes,No,No,Scott Pallett,Chelsea and Westminster Hospital NHS Trust,Not Unity-Aligned,https://dx.doi.org/10.1016/S2213-2600(20)30315-5,2020-10-28,2024-03-01,Verified,pallett_pointofcare_2020,GBR
200725_UK_TheQueenElizabethHospital_HealthCareWorkers_UnAdj,200725_UK_TheQueenElizabethHospital,COVID-19 Serology in Oncology Staff Study: Understanding SARS-CoV-2 in the Oncology Workforce.,2020-07-25,Journal Article (Peer-Reviewed),Local,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,King's Lynn,Healthcare workers from the oncology department at the Queen Elizabeth Hospital in Kings Lynn were recruited.,,2020-06-01,2020-06-07,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,70,0.214,,,True,,,,True,Unclear,Author designed (Luminex),,Other,,IgG,,,,,['High'],Yes,Unclear,No,No,Unclear,Unclear,Yes,No,Yes,D M Favara,The Queen Elizabeth Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.clon.2020.07.015,2020-09-29,2022-07-16,Verified,favara_covid-19_2020,GBR
200730_London_ImperialCollegeLondon_Overall,200730_London_ImperialCollegeLondon,High Prevalence of Asymptomatic COVID-19 Infection in Hemodialysis Patients Detected Using Serologic Screening.,2020-07-30,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,England,London,"In total, 376 patients receiving ICHD within two units affiliated with Imperial College Renal and Transplant Centre between April 27 and May 7, 2020 were included. Clinical and routine pathology
data were obtained from electronic records and dialysis records. All pathology data from each patient were analyzed over a 12-week period from February 24, 2020.",,2020-04-27,2020-05-07,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,55.0,77.0,Primary Estimate,,356,0.36200000000000004,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9390000000000001,1.0,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,Candice Clarke,Imperial College London,Not Unity-Aligned,https://dx.doi.org/10.1681/ASN.2020060827,2020-11-03,2024-03-01,Verified,clarke_high_2020,GBR
200726_UK_OfficeforNationalStatistics_June_July2020_England_Genpop,200726_UK_OfficeforNationalStatistics_June_2020_England,Coronavirus (COVID-19) Infection Survey: June_July 2020,2020-07-31,Institutional Report,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"Only England is included in this pilot phase of the study. Discussions are underway with the devolved administrations in Scotland, Wales and Northern Ireland to include the whole of the UK in the main study. Only private households, otherwise known as the target population in this bulletin, are included in the sample. People in care homes, other communal establishments and hospitals are not included. We are initially conducting a pilot survey of households in England, working with the University of Oxford, IQVIA and UK Biocentre Milton Keynes to collect and analyse the samples. At the start of the pilot study, 20,000 households were invited to take part, with the aim of collecting data from around 10,000 households. To take part, invited households opted in to the survey by contacting a company called IQVIA, working on behalf of the ONS, to arrange a visit. Adults over 15 years of age from around 2,000 households will provide a blood sample taken by a trained nurse, phlebotomist or healthcare assistant. The sample for this initial survey has been drawn from households in which someone has already participated in an Office for National Statistics (ONS) survey and has consented to be approached for future research. Households cannot request to be part of the survey; this ensures the sample is representative of the wider population. While the pilot is based on a nationally representative survey sample, some individuals in the original ONS survey samples will have dropped out, while others will not have responded to the pilot. Blood samples are taken only from those aged 16 years and over","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2020-06-05,2020-07-02,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,,2392,0.0418,,,True,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office of National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/december2020,2021-03-12,2022-07-16,Verified,steel_coronavirus_2020-2,GBR
200729_London_WhittingtonHealthNHSTrust_Overall,200729_London_WhittingtonHealthNHSTrust,Seroprevalence of SARS-CoV-2 antibodies in healthcare workers at a London NHS Trust,2020-08-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,London,All Whittington Health employees were eligible regardless of job or whether they had expe- rienced a COVID-19–like illness,,2020-05-15,2020-06-05,Health care workers and caregivers,All,Multiple groups,18.0,73.0,Primary Estimate,,2004,0.316,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,0.998,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,No,Joseph Grant,Whittington Health NHS Trust,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2020.402,2020-10-05,2024-03-01,Verified,grant_seroprevalence_2020-1,GBR
200807_England_PHE_BloodDonor_GenPop_Overall_TestPopAdj_Week27to31,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-06-29,2020-07-28,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,9388,0.059000000000000004,0.053,0.065,True,True,True,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200807_England_PHE_BloodDonor_GenPop_Age50to59_PopAdj_Week27to31,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-06-29,2020-07-28,Blood donors,All,Adults (18-64 years),50.0,59.0,Age,50 to 59,2233,0.065,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200702_England_PHE_BloodDonor_GenPop_Northeast_TestPopAdj_Week28,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-08,2020-07-09,Blood donors,All,Multiple groups,17.0,,Geographical area,Northeast of England ,1021,0.047,0.031000000000000003,0.066,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-08-15,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200814_England_PHE_BloodDonor_GenPop_Age30to39_PopAdj_Week28to31,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-06,2020-08-02,Blood donors,All,Adults (18-64 years),30.0,39.0,Age,30 to 39,1718,0.053,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200717_England_PHE_BloodDonor_GenPop_Midlands_PopAdj_Week28to29,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-10,2020-07-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Midlands of England ,1066,0.065,0.047,0.086,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-08-15,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200717_England_PHE_BloodDonor_GenPop_Northwest_TestPopAdj_Week31,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-29,2020-07-31,Blood donors,All,Multiple groups,17.0,,Geographical area,Northwest of England ,1032,0.07200000000000001,0.054000000000000006,0.094,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200717_England_PHE_BloodDonor_GenPop_London_TestPopAdj_Week31,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,London,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-30,2020-08-02,Blood donors,All,Multiple groups,17.0,,Geographical area,London,1004,0.087,0.066,0.11,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200821_England_PHE_BloodDonor_GenPop_Age50to59_PopAdj_Week29to32,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-13,2020-08-07,Blood donors,All,Adults (18-64 years),50.0,59.0,Age,50 to 59,1995,0.054000000000000006,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200821_England_PHE_BloodDonor_GenPop_Age70to84_PopAdj_Week29to32,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-13,2020-08-07,Blood donors,All,Seniors (65+ years),70.0,84.0,Age,70 to 84,467,0.013999999999999999,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200821_England_PHE_BloodDonor_GenPop_Age30to39_PopAdj_Week29to32,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-13,2020-08-07,Blood donors,All,Adults (18-64 years),30.0,39.0,Age,30 to 39,1711,0.065,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200814_England_PHE_BloodDonor_GenPop_Age50to59_PopAdj_Week28to31,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-06,2020-08-02,Blood donors,All,Adults (18-64 years),50.0,59.0,Age,50 to 59,2063,0.057999999999999996,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200821_England_PHE_BloodDonor_GenPop_Age40to49_PopAdj_Week29to32,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-13,2020-08-07,Blood donors,All,Adults (18-64 years),40.0,49.0,Age,40 to 49,1556,0.054000000000000006,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200717_England_PHE_BloodDonor_GenPop_Southeast_TestPopAdj_Week30,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-24,2020-07-24,Blood donors,All,Multiple groups,17.0,,Geographical area,Southeast of England ,1018,0.036000000000000004,0.022000000000000002,0.053,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200731_England_PHE_BloodDonor_GenPop_Age70to84_PopAdj_Week26to30,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-06-22,2020-07-20,Blood donors,All,Seniors (65+ years),70.0,84.0,Age,70 to 84,479,0.028999999999999998,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200731_England_PHE_BloodDonor_GenPop_Age50to59_PopAdj_Week26to30,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-06-22,2020-07-20,Blood donors,All,Adults (18-64 years),50.0,59.0,Age,50 to 59,2147,0.07,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200807_England_PHE_BloodDonor_GenPop_Age30to39_PopAdj_Week27to31,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-06-29,2020-07-28,Blood donors,All,Adults (18-64 years),30.0,39.0,Age,30 to 39,1822,0.051,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200731_England_PHE_BloodDonor_GenPop_Age60to69_PopAdj_Week26to30,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-06-22,2020-07-20,Blood donors,All,Adults (18-64 years),60.0,69.0,Age,60 to 69,1455,0.044000000000000004,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200717_England_PHE_BloodDonor_GenPop_East_TestPopAdj_Week30_31,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-25,2020-07-28,Blood donors,All,Multiple groups,17.0,,Geographical area,East of England ,1076,0.066,0.048,0.086,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.99,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200807_England_PHE_BloodDonor_GenPop_Age40to49_PopAdj_Week27to31,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-06-29,2020-07-28,Blood donors,All,Adults (18-64 years),40.0,49.0,Age,40 to 49,1765,0.057999999999999996,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200821_England_PHE_BloodDonor_GenPop_Overall_TestPopAdj_Week29to32,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-13,2020-08-07,Blood donors,All,Multiple groups,17.0,,Time frame,,8538,0.054000000000000006,0.048,0.06,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200814_England_PHE_BloodDonor_GenPop_Age60to69_PopAdj_Week28to31,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-06,2020-08-02,Blood donors,All,Adults (18-64 years),60.0,69.0,Age,60 to 69,1409,0.046,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200717_England_PHE_BloodDonor_GenPop_Northwest_TestPopAdj_Week27,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-01,2020-07-03,Blood donors,All,Multiple groups,17.0,,Geographical area,Northwest of England ,1014,0.083,0.063,0.106,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-18,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200807_England_PHE_BloodDonor_GenPop_Age70to84_PopAdj_Week27to31,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-06-29,2020-07-28,Blood donors,All,Seniors (65+ years),70.0,84.0,Age,70 to 84,536,0.026000000000000002,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200723_England_PHE_BloodDonor_GenPop_Overall_TestPopAdj_Week30,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-13,2020-07-21,Blood donors,All,Multiple groups,17.0,,Time frame,,11351,0.068,0.062000000000000006,0.075,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200807_England_PHE_BloodDonor_GenPop_Age60to69_PopAdj_Week27to31,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-06-29,2020-07-28,Blood donors,All,Adults (18-64 years),60.0,69.0,Age,60 to 69,1519,0.047,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200814_England_PHE_BloodDonor_GenPop_Age17to29_PopAdj_Week28to31,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-06,2020-08-02,Blood donors,All,Adults (18-64 years),17.0,29.0,Age,17 to 29 ,1399,0.08199999999999999,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200821_England_PHE_BloodDonor_GenPop_Age60to69_PopAdj_Week29to32,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-13,2020-08-07,Blood donors,All,Adults (18-64 years),60.0,69.0,Age,60 to 69,1422,0.037000000000000005,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200814_England_PHE_BloodDonor_GenPop_Age70to84_PopAdj_Week28to31,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-06,2020-08-02,Blood donors,All,Seniors (65+ years),70.0,84.0,Age,70 to 84,494,0.017,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200717_England_PHE_BloodDonor_GenPop_London_TestPopAdj_Week29to30,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,London,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-17,2020-07-20,Blood donors,All,Multiple groups,17.0,,Geographical area,London,1064,0.08900000000000001,0.069,0.113,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200702_England_PHE_BloodDonor_GenPop_Southwest_TestPopAdj_Week29to30,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-17,2020-07-20,Blood donors,All,Multiple groups,17.0,,Geographical area,Southwest of England ,1052,0.019,0.006,0.034,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200731_England_PHE_BloodDonor_GenPop_Age40to49_PopAdj_Week26to30,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-06-22,2020-07-20,Blood donors,All,Adults (18-64 years),40.0,49.0,Age,40 to 49,1749,0.06,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200821_England_PHE_BloodDonor_GenPop_Age17to29_PopAdj_Week29to32,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-13,2020-08-07,Blood donors,All,Adults (18-64 years),17.0,29.0,Age,17 to 29 ,1387,0.07200000000000001,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200807_England_PHE_BloodDonor_GenPop_Age17to29_PopAdj_Week27to31,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-06-29,2020-07-28,Blood donors,All,Adults (18-64 years),17.0,29.0,Age,17 to 29 ,1513,0.075,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200717_England_PHE_BloodDonor_GenPop_London_TestPopAdj_Week27to28,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,London,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-03,2020-07-06,Blood donors,All,Multiple groups,17.0,,Geographical area,London,1079,0.099,0.078,0.12300000000000001,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-18,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200814_England_PHE_BloodDonor_GenPop_Age40to49_PopAdj_Week28to31,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-06,2020-08-02,Blood donors,All,Adults (18-64 years),40.0,49.0,Age,40 to 49,1574,0.057,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200731_England_PHE_BloodDonor_GenPop_Overall_TestPopAdj_Week26to30,200807_England_PHE_BloodDonors_Week27to31,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-06-22,2020-07-20,Blood donors,All,Multiple groups,17.0,,Time frame,,9220,0.061,0.055,0.067,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200807_England_PHE_RCGP_GenPop_TestPopAdj_Overall_euroimmun,200807_England_PHE_RCGPCollection_Summary,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Data from samples collected from patients aged 65 years and older attending for routine blood tests at
one of the Royal College of General Practitioners Research and Surveillance Centre network of practices
(RCGP-RSC).",,2020-03-16,2020-06-30,Residual sera,All,Seniors (65+ years),65.0,110.0,Primary Estimate,,6000,0.039,,,True,True,True,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200807_England_PHE_RCGP_GenPop_TestPopAdj_80+_June,200807_England_PHE_RCGPCollection_Summary,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Data from samples collected from patients aged 65 years and older attending for routine blood tests at
one of the Royal College of General Practitioners Research and Surveillance Centre network of practices
(RCGP-RSC).",,2020-06-01,2020-06-30,Residual sera,All,Seniors (65+ years),80.0,110.0,Age,>=80,551,0.05,,,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-18,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200807_England_PHE_RCGP_GenPop_TestPopAdj_70_74_May,200807_England_PHE_RCGPCollection_Summary,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Data from samples collected from patients aged 65 years and older attending for routine blood tests at
one of the Royal College of General Practitioners Research and Surveillance Centre network of practices
(RCGP-RSC).",,2020-05-01,2020-05-30,Residual sera,All,Seniors (65+ years),70.0,74.0,Age,70-74 ,625,0.038,,,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-18,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200918_England_PHE_RCGPCollection_Euroim_June_Age70to74,200807_England_PHE_RCGPCollection_Summary,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Data from samples collected from patients aged 65 years and older attending for routine blood tests at
one of the Royal College of General Practitioners Research and Surveillance Centre network of practices
(RCGP-RSC).",,2020-06-01,2020-06-30,Residual sera,All,Seniors (65+ years),70.0,74.0,Age,70-74 ,657,0.023,,,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200807_England_PHE_RCGP_GenPop_TestPopAdj_65_69_May,200807_England_PHE_RCGPCollection_Summary,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Data from samples collected from patients aged 65 years and older attending for routine blood tests at
one of the Royal College of General Practitioners Research and Surveillance Centre network of practices
(RCGP-RSC).",,2020-05-01,2020-05-30,Residual sera,All,Seniors (65+ years),65.0,69.0,Age,65-69 ,506,0.036000000000000004,,,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-18,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200807_England_PHE_RCGP_GenPop_TestPopAdj_75_79_May,200807_England_PHE_RCGPCollection_Summary,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Data from samples collected from patients aged 65 years and older attending for routine blood tests at
one of the Royal College of General Practitioners Research and Surveillance Centre network of practices
(RCGP-RSC).",,2020-05-01,2020-05-30,Residual sera,All,Seniors (65+ years),75.0,79.0,Age,75-79,510,0.023,,,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-18,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200918_England_PHE_RCGPCollection_Euroim_June_Age80+,200807_England_PHE_RCGPCollection_Summary,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Data from samples collected from patients aged 65 years and older attending for routine blood tests at
one of the Royal College of General Practitioners Research and Surveillance Centre network of practices
(RCGP-RSC).",,2020-06-01,2020-06-30,Residual sera,All,Seniors (65+ years),80.0,100.0,Age,>=80,496,0.051,,,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200807_England_PHE_RCGP_GenPop_TestPopAdj_70_74_June,200807_England_PHE_RCGPCollection_Summary,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Data from samples collected from patients aged 65 years and older attending for routine blood tests at
one of the Royal College of General Practitioners Research and Surveillance Centre network of practices
(RCGP-RSC).",,2020-06-01,2020-06-30,Residual sera,All,Seniors (65+ years),70.0,74.0,Age,70-74 ,614,0.02,,,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-18,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200918_England_PHE_RCGPCollection_Euroim_June_Age65to69,200807_England_PHE_RCGPCollection_Summary,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Data from samples collected from patients aged 65 years and older attending for routine blood tests at
one of the Royal College of General Practitioners Research and Surveillance Centre network of practices
(RCGP-RSC).",,2020-06-01,2020-06-30,Residual sera,All,Seniors (65+ years),65.0,69.0,Age,65-69 ,462,0.027999999999999997,,,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200918_England_PHE_RCGPCollection_Summary_Euroim_June,200807_England_PHE_RCGPCollection_Summary,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Data from samples collected from patients aged 65 years and older attending for routine blood tests at
one of the Royal College of General Practitioners Research and Surveillance Centre network of practices
(RCGP-RSC).",,2020-06-01,2020-06-30,Residual sera,All,Seniors (65+ years),65.0,100.0,Test used,,2185,0.027999999999999997,0.018000000000000002,0.040999999999999995,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200918_England_PHE_RCGPCollection_Euroim_June_Age75to79,200807_England_PHE_RCGPCollection_Summary,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Data from samples collected from patients aged 65 years and older attending for routine blood tests at
one of the Royal College of General Practitioners Research and Surveillance Centre network of practices
(RCGP-RSC).",,2020-06-01,2020-06-30,Residual sera,All,Seniors (65+ years),75.0,79.0,Age,75-79,538,0.032,,,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200807_England_PHE_RCGP_GenPop_TestPopAdj_65_69_June,200807_England_PHE_RCGPCollection_Summary,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Data from samples collected from patients aged 65 years and older attending for routine blood tests at
one of the Royal College of General Practitioners Research and Surveillance Centre network of practices
(RCGP-RSC).",,2020-06-01,2020-06-30,Residual sera,All,Seniors (65+ years),65.0,69.0,Age,65-69 ,421,0.031000000000000003,,,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-18,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200807_England_PHE_RCGP_GenPop_TestPopAdj_75_79_June,200807_England_PHE_RCGPCollection_Summary,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Data from samples collected from patients aged 65 years and older attending for routine blood tests at
one of the Royal College of General Practitioners Research and Surveillance Centre network of practices
(RCGP-RSC).",,2020-06-01,2020-06-30,Residual sera,All,Seniors (65+ years),75.0,79.0,Age,75-79,495,0.028999999999999998,,,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-18,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200807_England_PHE_RCGP_GenPop_TestPopAdj_80+_May,200807_England_PHE_RCGPCollection_Summary,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Data from samples collected from patients aged 65 years and older attending for routine blood tests at
one of the Royal College of General Practitioners Research and Surveillance Centre network of practices
(RCGP-RSC).",,2020-05-01,2020-05-30,Residual sera,All,Seniors (65+ years),80.0,110.0,Age,>=80,567,0.044000000000000004,,,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-18,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200807_England_PHE_RCGP_GenPop_TestPopAdj_Overall_abbott,200807_England_PHE_RCGPCollection_Summary,PHE England week 32,2020-08-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Data from samples collected from patients aged 65 years and older attending for routine blood tests at
one of the Royal College of General Practitioners Research and Surveillance Centre network of practices
(RCGP-RSC).",,2020-03-16,2020-06-30,Residual sera,All,Seniors (65+ years),65.0,110.0,Test used,Abbott,6000,0.031000000000000003,,,,True,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-18,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200808_UK_PortlandHospitalforWomenandChildren_HCW,200808_London_PortlandHospitalforWomenandChildren,SARS-CoV-2-specific antibody detection in healthcare workers in a UK maternity Hospital: Correlation with SARS-CoV-2 RT-PCR results,2020-08-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,London,HCWs swabbed for SARS-CoV-2 between May 6 and 28,,2020-05-15,2020-05-28,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,190,0.22,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9690000000000001,0.9990000000000001,['High'],No,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Asma Khalil,St George’s University of London,Not Unity-Aligned,http://dx.doi.org/10.1093/cid/ciaa893,2020-10-03,2024-03-01,Verified,khalil_sars-cov-2-specific_2020,GBR
200810_London_UniversityCollegeLondon_Total,200810_London_UniversityCollegeLondon,A cross-sectional study of immune seroconversion to SARS-CoV-2 in front-line maternity health professionals,2020-08-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,London,"Midwives, anaesthetists, or obstetricians working on labour or postnatal care wards",History of SARS-CoV-2 infection diagnosed by PCR from nasopharyngeal swabs. Staff working in non-patients facing roles. ,2020-05-11,2020-06-05,Health care workers and caregivers,All,Multiple groups,21.0,66.0,Primary Estimate,,200,0.145,0.099,0.201,True,,,,True,Unclear,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],Yes,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,S Bampoe,University College London,Not Unity-Aligned,https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/full/10.1111/anae.15229,2020-10-04,2024-03-01,Verified,bampoe_cross-sectional_2020-1,GBR
200821_England_PHE_SeroepiUnitPaedsSurvey_Under20_TestAdj_FebMarch,200821_England_PHE_SeroepiUnitPaedsSurvey_1_FebMarch,PHE England week 34,2020-08-21,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,Residual sera from children and young adults under 30 years from participating NHS and PHE laboratories across England (SEU and paediatric hospital collections).,,2020-02-01,2020-03-31,Residual sera,All,Children and Youth (0-17 years),1.0,19.0,Primary Estimate,,443,0.008,0.0,0.025,True,True,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9570000000000001,0.991,['High'],Yes,Yes,No,No,Yes,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-18,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200821_England_PHE_SeroepiUnitPaedsSurvey_Under20_Unadj_FebMarch,200821_England_PHE_SeroepiUnitPaedsSurvey_1_FebMarch,PHE England week 34,2020-08-21,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,Residual sera from children and young adults under 30 years from participating NHS and PHE laboratories across England (SEU and paediatric hospital collections).,,2020-02-01,2020-03-31,Residual sera,All,Children and Youth (0-17 years),1.0,19.0,Analysis,Unadjusted,443,0.049,0.018000000000000002,0.08800000000000001,,,,,True,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9570000000000001,0.991,['High'],Yes,Yes,No,No,Yes,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200821_England_PHE_SeroepiUnitPaedsSurvey_Under20_TestAdj_April,200821_England_PHE_SeroepiUnitPaedsSurvey_2_April,PHE England week 34,2020-08-21,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,Residual sera from children and young adults under 30 years from participating NHS and PHE laboratories across England (SEU and paediatric hospital collections).,,2020-04-01,2020-04-30,Residual sera,All,Children and Youth (0-17 years),1.0,19.0,Primary Estimate,,647,0.061,0.040999999999999995,0.084,True,True,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9570000000000001,0.991,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200821_England_PHE_SeroepiUnitPaedsSurvey_Under20_Unadj_April,200821_England_PHE_SeroepiUnitPaedsSurvey_2_April,PHE England week 34,2020-08-21,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,Residual sera from children and young adults under 30 years from participating NHS and PHE laboratories across England (SEU and paediatric hospital collections).,,2020-04-01,2020-04-30,Residual sera,All,Children and Youth (0-17 years),1.0,19.0,Analysis,Unadjusted,647,0.066,0.049,0.08800000000000001,,,,,True,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9570000000000001,0.991,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200821_England_PHE_WhatsTheStory_TestAdj_FebMarch,200821_England_PHE_WhatsTheStory_Summary_1_FebMarch,PHE England week 34,2020-08-21,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Samples collected from healthy individuals under 25 years through a NIHR funded study, ‘What’s the STORY’. “What’s the Story” is a representative household survey that collects sera from healthy children and adolescents under the age of 25 years in England.",,2020-02-01,2020-03-31,Household and community samples,All,Children and Youth (0-17 years),1.0,19.0,Primary Estimate,,106,0.005,0.0,0.036000000000000004,True,True,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9570000000000001,0.991,['Moderate'],Yes,Yes,No,No,Yes,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-18,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200821_England_PHE_WhatsTheStory_Unadj_FebMarch,200821_England_PHE_WhatsTheStory_Summary_1_FebMarch,PHE England week 34,2020-08-21,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Samples collected from healthy individuals under 25 years through a NIHR funded study, ‘What’s the STORY’. “What’s the Story” is a representative household survey that collects sera from healthy children and adolescents under the age of 25 years in England.",,2020-02-01,2020-03-31,Household and community samples,All,Children and Youth (0-17 years),1.0,19.0,Analysis,Adjusted: test,106,0.013999999999999999,0.006,0.043,,,,,True,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9570000000000001,0.991,['Moderate'],Yes,Yes,No,No,Yes,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200821_England_PHE_WhatsTheStory_TestAdj_April,200821_England_PHE_WhatsTheStory_Summary_2_April,PHE England week 34,2020-08-21,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Samples collected from healthy individuals under 25 years through a NIHR funded study, ‘What’s the STORY’. “What’s the Story” is a representative household survey that collects sera from healthy children and adolescents under the age of 25 years in England.",,2020-04-01,2020-04-30,Household and community samples,All,Children and Youth (0-17 years),1.0,19.0,Primary Estimate,,201,0.038,0.012,0.075,True,True,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9570000000000001,0.991,['Moderate'],Yes,Yes,No,No,Yes,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200821_England_PHE_WhatsTheStory_Unadj_April,200821_England_PHE_WhatsTheStory_Summary_2_April,PHE England week 34,2020-08-21,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Samples collected from healthy individuals under 25 years through a NIHR funded study, ‘What’s the STORY’. “What’s the Story” is a representative household survey that collects sera from healthy children and adolescents under the age of 25 years in England.",,2020-04-01,2020-04-30,Household and community samples,All,Children and Youth (0-17 years),1.0,19.0,Analysis,Adjusted: test,201,0.045,0.021,0.08,,,,,True,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9570000000000001,0.991,['Moderate'],Yes,Yes,No,No,Yes,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200826_London_ImperialCollegeLondon_LTC,200826_London_ImperialCollegeLondon,High rates of SARS-CoV-2 seropositivity in nursing home residents,2020-08-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Greater London,London,Residents of four london nursing homes,,2020-06-01,2020-06-30,Assisted living and long-term care facilities,All,Seniors (65+ years),,,Primary Estimate,,241,0.718,0.66,0.77,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9390000000000001,1.0,['High'],No,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Neil Graham,Imperial College London,Not Unity-Aligned,https://www.journalofinfection.com/article/S0163-4453(20)30574-0/fulltext,2021-01-23,2024-03-01,Verified,nsn_high_2020,GBR
200826_UK_OfficeforNationalStatistics_July_August2020_England_genpop,200826_UK_OfficeforNationalStatistics_August2020_England,Coronavirus (COVID-19) Infection Survey: July_August2020,2020-08-28,Institutional Report,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2020-07-31,2020-08-27,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,,6189,0.055999999999999994,0.047,0.065,True,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office of National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/december2020,2021-03-12,2022-07-16,Verified,steel_coronavirus_2020-2,GBR
200826_UK_OfficeforNationalStatistics_July_020_England_genpop,200826_UK_OfficeforNationalStatistics_July_2020_England,Coronavirus (COVID-19) Infection Survey: July_August2020,2020-08-28,Institutional Report,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2020-07-03,2020-07-30,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,,3236,0.065,0.052000000000000005,0.081,True,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office of National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/december2020,2021-03-12,2022-07-16,Verified,steel_coronavirus_2020-2,GBR
200717_England_PHE_BloodDonor_GenPop_London_TestPopAdj_Week13,200828_England_PHE_BloodDonors_summary_1_Week13,PHE England week 35,2020-08-28,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,London,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-03-26,2020-03-27,Blood donors,All,Adults (18-64 years),17.0,69.0,Primary Estimate,,757,0.026000000000000002,0.011000000000000001,0.044000000000000004,True,True,True,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-18,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200617_England_PHE_BloodDonor_GenPop_Midlands_TestPopAdj_Week14,200828_England_PHE_BloodDonors_summary_2_Week14,PHE England week 35,2020-08-28,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-04-02,2020-04-03,Blood donors,All,Adults (18-64 years),17.0,69.0,Primary Estimate,Midlands of England ,916,0.024,0.01,0.04,True,True,True,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200709_England_PHE_BloodDonor_GenPop_London_TestPopAdj_Week15to16,200828_England_PHE_BloodDonors_summary_3_Week15to16,PHE England week 35,2020-08-28,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,London,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-04-09,2020-04-13,Blood donors,All,Adults (18-64 years),17.0,69.0,Primary Estimate,,1085,0.111,0.08900000000000001,0.136,True,True,True,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200527_England_PHE_BloodDonor_GenPop_Northeast_TestPopAdj_Week16,200828_England_PHE_BloodDonors_summary_4_week16,PHE England week 35,2020-08-28,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-04-14,2020-04-16,Blood donors,All,Adults (18-64 years),17.0,69.0,Primary Estimate,,1017,0.046,0.03,0.064,True,True,True,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.79,0.99,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200527_England_PHE_BloodDonor_GenPop_Northwest_TestPopAdj_Week16to17,200828_England_PHE_BloodDonors_summary_5_week16to17,PHE England week 35,2020-08-28,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-04-15,2020-04-20,Blood donors,All,Adults (18-64 years),17.0,69.0,Primary Estimate,,936,0.062000000000000006,0.044000000000000004,0.084,True,True,True,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.79,0.99,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200617_England_PHE_BloodDonor_GenPop_Midlands_TestPopAdj_Week17_Mid,200828_England_PHE_BloodDonors_summary_6_week17_Mid,PHE England week 35,2020-08-28,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-04-23,2020-04-24,Blood donors,All,Adults (18-64 years),17.0,69.0,Primary Estimate,,1043,0.073,0.054000000000000006,0.094,True,True,True,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200603_England_PHE_BloodDonor_GenPop_Southwest_TestPopAdj_Week17_South,200828_England_PHE_BloodDonors_summary_7_week17_South,PHE England week 35,2020-08-28,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-04-24,2020-04-26,Blood donors,All,Adults (18-64 years),17.0,69.0,Primary Estimate,,865,0.05,0.032,0.07,True,True,True,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200904_England_PHE_BloodDonors_Overall_TestPopAdj_Week31to35,200911_England_PHE_BloodDonors_summary_14_week31to35,PHE England week 37,2020-09-11,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-27,2020-08-30,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,8764,0.053,0.048,0.057999999999999996,True,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-23,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200702_England_PHE_BloodDonor_GenPop_Southwest_TestPopAdj_Week33,200911_England_PHE_BloodDonors_summary_14_week31to35,PHE England week 37,2020-09-11,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-08-13,2020-08-14,Blood donors,All,Multiple groups,17.0,,Geographical area,Southwest of England ,1026,0.028999999999999998,0.015,0.044000000000000004,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200918_England_PHE_BloodDonor_GenPop_Age40to49_PopAdj_Week33to36,200911_England_PHE_BloodDonors_summary_14_week31to35,PHE England week 37,2020-09-11,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-08-16,2020-09-06,Blood donors,All,Adults (18-64 years),40.0,49.0,Age,40 to 49,1490,0.049,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200918_England_PHE_BloodDonor_GenPop_Age70to84_PopAdj_Week33to36,200911_England_PHE_BloodDonors_summary_14_week31to35,PHE England week 37,2020-09-11,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-08-16,2020-09-06,Blood donors,All,Seniors (65+ years),70.0,84.0,Age,70 to 84,369,0.032,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200918_England_PHE_BloodDonors_Summary15_Week33to36,200911_England_PHE_BloodDonors_summary_14_week31to35,PHE England week 37,2020-09-11,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-08-13,2020-09-06,Blood donors,All,Multiple groups,17.0,,Time frame,,7899,0.055,0.049,0.061,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-23,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200911_England_PHE_BloodDonor_GenPop_Age17to29_PopAdj_Week31to35,200911_England_PHE_BloodDonors_summary_14_week31to35,PHE England week 37,2020-09-11,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-27,2020-08-30,Blood donors,All,Adults (18-64 years),17.0,29.0,Age,17 to 29 ,1330,0.078,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200904_England_PHE_BloodDonor_GenPop_Age60to69_PopAdj_Week30to33,200911_England_PHE_BloodDonors_summary_14_week31to35,PHE England week 37,2020-09-11,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-20,2020-08-16,Blood donors,All,Adults (18-64 years),60.0,69.0,Age,60 to 69,1482,0.034,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200911_England_PHE_BloodDonor_GenPop_Age30to39_PopAdj_Week31to35,200911_England_PHE_BloodDonors_summary_14_week31to35,PHE England week 37,2020-09-11,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-27,2020-08-30,Blood donors,All,Adults (18-64 years),30.0,39.0,Age,30 to 39,1574,0.071,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200918_England_PHE_BloodDonors_SouthEast_TestPopAdj_Week34,200911_England_PHE_BloodDonors_summary_14_week31to35,PHE England week 37,2020-09-11,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-08-17,2020-08-23,Blood donors,All,Multiple groups,17.0,,Geographical area,Southeast of England ,1000,0.037000000000000005,0.022000000000000002,0.054000000000000006,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200821_England_PHE_BloodDonor_GenPop_Midlands_PopAdj_Week32,200911_England_PHE_BloodDonors_summary_14_week31to35,PHE England week 37,2020-09-11,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-08-06,2020-08-07,Blood donors,All,Multiple groups,17.0,,Geographical area,Midlands of England ,1016,0.068,0.049,0.08900000000000001,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200911_England_PHE_BloodDonor_GenPop_Age70to84_PopAdj_Week31to35,200911_England_PHE_BloodDonors_summary_14_week31to35,PHE England week 37,2020-09-11,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-27,2020-08-30,Blood donors,All,Seniors (65+ years),70.0,84.0,Age,70 to 84,381,0.036000000000000004,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200904_England_PHE_BloodDonors_East_TestPopAdj_Week34to35,200911_England_PHE_BloodDonors_summary_14_week31to35,PHE England week 37,2020-09-11,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-08-17,2020-08-30,Blood donors,All,Multiple groups,17.0,,Geographical area,East of England ,1000,0.044000000000000004,0.027999999999999997,0.063,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200904_England_PHE_BloodDonor_GenPop_Age40to49_PopAdj_Week30to33,200911_England_PHE_BloodDonors_summary_14_week31to35,PHE England week 37,2020-09-11,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-20,2020-08-16,Blood donors,All,Adults (18-64 years),40.0,49.0,Age,40 to 49,1608,0.048,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200918_England_PHE_BloodDonor_GenPop_Age60to69_PopAdj_Week33to36,200911_England_PHE_BloodDonors_summary_14_week31to35,PHE England week 37,2020-09-11,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-08-16,2020-09-06,Blood donors,All,Adults (18-64 years),60.0,69.0,Age,60 to 69,1256,0.039,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200717_England_PHE_BloodDonor_GenPop_London_TestPopAdj_Week33,200911_England_PHE_BloodDonors_summary_14_week31to35,PHE England week 37,2020-09-11,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,London,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-08-13,2020-08-16,Blood donors,All,Multiple groups,17.0,,Geographical area,London,1011,0.08199999999999999,0.062000000000000006,0.105,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200904_England_PHE_BloodDonor_GenPop_Age50to59_PopAdj_Week30to33,200911_England_PHE_BloodDonors_summary_14_week31to35,PHE England week 37,2020-09-11,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-20,2020-08-16,Blood donors,All,Adults (18-64 years),50.0,59.0,Age,50 to 59,2026,0.055999999999999994,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200925_England_PHE_BloodDonors_London_week35,200911_England_PHE_BloodDonors_summary_14_week31to35,PHE England week 37,2020-09-11,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Greater London,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-08-24,2020-08-30,Blood donors,All,Multiple groups,17.0,,Geographical area,London,1000,0.10800000000000001,0.086,0.134,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200904_England_PHE_BloodDonors_SouthEast_TestPopAdj_Week33,200911_England_PHE_BloodDonors_summary_14_week31to35,PHE England week 37,2020-09-11,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-08-10,2020-08-16,Blood donors,All,Multiple groups,17.0,,Geographical area,Southeast of England ,1000,0.037000000000000005,0.022000000000000002,0.054000000000000006,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200904_England_PHE_BloodDonor_GenPop_Age30to39_PopAdj_Week30to33,200911_England_PHE_BloodDonors_summary_14_week31to35,PHE England week 37,2020-09-11,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-20,2020-08-16,Blood donors,All,Adults (18-64 years),30.0,39.0,Age,30 to 39,1724,0.063,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200918_England_PHE_BloodDonor_GenPop_Age17to29_PopAdj_Week33to36,200911_England_PHE_BloodDonors_summary_14_week31to35,PHE England week 37,2020-09-11,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-08-16,2020-09-06,Blood donors,All,Adults (18-64 years),17.0,29.0,Age,17 to 29 ,1335,0.07200000000000001,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200828_England_PHE_BloodDonor_GenPop_Overall_TestPopAdj_Week30to33,200911_England_PHE_BloodDonors_summary_14_week31to35,PHE England week 37,2020-09-11,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-20,2020-08-16,Blood donors,All,Multiple groups,17.0,,Time frame,,8940,0.055,0.049,0.061,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200717_England_PHE_BloodDonor_GenPop_Northwest_TestPopAdj_Week35,200911_England_PHE_BloodDonors_summary_14_week31to35,PHE England week 37,2020-09-11,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-08-24,2020-08-30,Blood donors,All,Multiple groups,17.0,,Geographical area,Northwest of England ,1000,0.068,0.047,0.092,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200918_England_PHE_BloodDonor_GenPop_Age50to59_PopAdj_Week33to36,200911_England_PHE_BloodDonors_summary_14_week31to35,PHE England week 37,2020-09-11,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-08-16,2020-09-06,Blood donors,All,Adults (18-64 years),50.0,59.0,Age,50 to 59,1881,0.055,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200911_England_PHE_BloodDonor_GenPop_Age40to49_PopAdj_Week31to35,200911_England_PHE_BloodDonors_summary_14_week31to35,PHE England week 37,2020-09-11,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-27,2020-08-30,Blood donors,All,Adults (18-64 years),40.0,49.0,Age,40 to 49,1481,0.040999999999999995,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200821_England_PHE_BloodDonor_GenPop_Northeast_PopAdj_Week32,200911_England_PHE_BloodDonors_summary_14_week31to35,PHE England week 37,2020-09-11,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-08-05,2020-08-06,Blood donors,All,Multiple groups,17.0,,Geographical area,Northeast of England ,994,0.05,0.033,0.069,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200904_England_PHE_BloodDonor_GenPop_Age17to29_PopAdj_Week30to33,200911_England_PHE_BloodDonors_summary_14_week31to35,PHE England week 37,2020-09-11,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-20,2020-08-16,Blood donors,All,Adults (18-64 years),17.0,29.0,Age,17 to 29 ,1463,0.076,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200904_England_PHE_BloodDonors_Overall_PopAdj_Week31to35,200911_England_PHE_BloodDonors_summary_14_week31to35,PHE England week 37,2020-09-11,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-27,2020-08-30,Blood donors,All,Multiple groups,17.0,,Analysis,,8764,0.052000000000000005,0.047,0.06,,,True,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200918_England_PHE_BloodDonor_GenPop_Age30to39_PopAdj_Week33to36,200911_England_PHE_BloodDonors_summary_14_week31to35,PHE England week 37,2020-09-11,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-08-16,2020-09-06,Blood donors,All,Adults (18-64 years),30.0,39.0,Age,30 to 39,1568,0.069,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200911_England_PHE_BloodDonor_GenPop_Age50to59_PopAdj_Week31to35,200911_England_PHE_BloodDonors_summary_14_week31to35,PHE England week 37,2020-09-11,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-27,2020-08-30,Blood donors,All,Adults (18-64 years),50.0,59.0,Age,50 to 59,1810,0.054000000000000006,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200911_England_PHE_BloodDonor_GenPop_Age60to69_PopAdj_Week31to35,200911_England_PHE_BloodDonors_summary_14_week31to35,PHE England week 37,2020-09-11,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-27,2020-08-30,Blood donors,All,Adults (18-64 years),60.0,69.0,Age,60 to 69,1281,0.036000000000000004,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200904_England_PHE_BloodDonor_GenPop_Age70to84_PopAdj_Week30to33,200911_England_PHE_BloodDonors_summary_14_week31to35,PHE England week 37,2020-09-11,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors supplied
by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from two different
geographic regions (approximately 1000 samples per region) in England are tested each week. Results
from testing donor samples from adults aged 17-69 years have been presented to date; however, recently
an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore
data from the most recent sampling periods included in this week’s report include donors in this older age
group. ",,2020-07-20,2020-08-16,Blood donors,All,Seniors (65+ years),70.0,84.0,Age,70 to 84,461,0.021,,,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200821_England_PHE_SeroepiUnitPaedsSurvey_Under20_TestAdj_May,200911_England_PHE_SeroepiUnitPaedsSurvey_5_MayAug,PHE England week 37,2020-09-11,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,Residual sera from children and young adults under 30 years from participating NHS and PHE laboratories across England (SEU and paediatric hospital collections).,,2020-05-01,2020-05-31,Residual sera,All,Children and Youth (0-17 years),1.0,19.0,Primary Estimate,,1061,0.073,0.055999999999999994,0.092,True,True,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9570000000000001,0.991,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-19,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200911_England_PHE_SeroepiUnitPaedsSurvey_5_May,200911_England_PHE_SeroepiUnitPaedsSurvey_5_MayAug,PHE England week 37,2020-09-11,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,Residual sera from children and young adults under 30 years from participating NHS and PHE laboratories across England (SEU and paediatric hospital collections).,,2020-05-01,2020-05-31,Residual sera,All,Multiple groups,0.0,29.0,Time frame,,1177,0.078,0.057999999999999996,0.102,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9570000000000001,0.991,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200821_England_PHE_SeroepiUnitPaedsSurvey_Under20_Unadj_May,200911_England_PHE_SeroepiUnitPaedsSurvey_5_MayAug,PHE England week 37,2020-09-11,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,Residual sera from children and young adults under 30 years from participating NHS and PHE laboratories across England (SEU and paediatric hospital collections).,,2020-05-01,2020-05-31,Residual sera,All,Children and Youth (0-17 years),1.0,19.0,Analysis,Unadjusted,1061,0.078,0.063,0.096,,,,,True,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9570000000000001,0.991,['Moderate'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200911_England_PHE_WhatsTheStory_Summary_5_May_August,200911_England_PHE_WhatsTheStory_Summary_5_May_August,PHE England week 37,2020-09-11,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Samples collected from healthy individuals under 25 years through a NIHR funded study, ‘What’s the STORY’. “What’s the Story” is a representative household survey that collects sera from healthy children and adolescents under the age of 25 years in England.",,2020-05-01,2020-08-05,Household and community samples,All,Children and Youth (0-17 years),1.0,24.0,Primary Estimate,,568,0.052000000000000005,0.032,0.078,True,,True,,True,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9570000000000001,0.991,['Moderate'],Yes,Yes,No,No,Yes,Yes,Yes,Yes,Yes,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-23,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200821_England_PHE_WhatsTheStory_TestAdj_May,200911_England_PHE_WhatsTheStory_Summary_5_May_August,PHE England week 37,2020-09-11,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Samples collected from healthy individuals under 25 years through a NIHR funded study, ‘What’s the STORY’. “What’s the Story” is a representative household survey that collects sera from healthy children and adolescents under the age of 25 years in England.",,2020-05-01,2020-05-31,Household and community samples,All,Children and Youth (0-17 years),1.0,19.0,Time frame,,143,0.019,0.0,0.057999999999999996,,True,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9570000000000001,0.991,['Moderate'],Yes,Yes,No,No,Yes,Yes,Yes,Yes,Yes,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-19,2024-02-01,Verified,public_health_england_national_2020-17,GBR
200821_England_PHE_WhatsTheStory_Unadj__June_August,200911_England_PHE_WhatsTheStory_Summary_5_May_August,PHE England week 37,2020-09-11,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Samples collected from healthy individuals under 25 years through a NIHR funded study, ‘What’s the STORY’. “What’s the Story” is a representative household survey that collects sera from healthy children and adolescents under the age of 25 years in England.",,2020-06-01,2020-08-02,Household and community samples,All,Children and Youth (0-17 years),1.0,19.0,Time frame,Adjusted: test,285,0.049,0.027999999999999997,0.078,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9570000000000001,0.991,['Moderate'],Yes,Yes,No,No,Yes,Yes,Yes,Yes,Yes,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-18,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200821_England_PHE_WhatsTheStory_TestAdj_June_August,200911_England_PHE_WhatsTheStory_Summary_5_May_August,PHE England week 37,2020-09-11,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Samples collected from healthy individuals under 25 years through a NIHR funded study, ‘What’s the STORY’. “What’s the Story” is a representative household survey that collects sera from healthy children and adolescents under the age of 25 years in England.",,2020-06-01,2020-08-02,Household and community samples,All,Children and Youth (0-17 years),1.0,19.0,Time frame,,285,0.042,0.019,0.073,,True,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9570000000000001,0.991,['Moderate'],Yes,Yes,No,No,Yes,Yes,Yes,Yes,Yes,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-18,2024-02-01,Verified,public_health_england_national_2020-17,GBR
200821_England_PHE_WhatsTheStory_Unadj_May,200911_England_PHE_WhatsTheStory_Summary_5_May_August,PHE England week 37,2020-09-11,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Samples collected from healthy individuals under 25 years through a NIHR funded study, ‘What’s the STORY’. “What’s the Story” is a representative household survey that collects sera from healthy children and adolescents under the age of 25 years in England.",,2020-05-01,2020-05-31,Household and community samples,All,Children and Youth (0-17 years),1.0,19.0,Analysis,Adjusted: test,143,0.027000000000000003,0.01,0.064,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9570000000000001,0.991,['Moderate'],Yes,Yes,No,No,Yes,Yes,Yes,Yes,Yes,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-07-19,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200911_England_PHE_WhatsTheStory_Summary_5_May_August_Age11to19,200911_England_PHE_WhatsTheStory_Summary_5_May_August,PHE England week 37,2020-09-11,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Samples collected from healthy individuals under 25 years through a NIHR funded study, ‘What’s the STORY’. “What’s the Story” is a representative household survey that collects sera from healthy children and adolescents under the age of 25 years in England.",,2020-05-01,2020-08-05,Household and community samples,All,Children and Youth (0-17 years),11.0,19.0,Age,11-19,248,0.059000000000000004,,,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9570000000000001,0.991,['Moderate'],Yes,Yes,No,No,Yes,Yes,Yes,Yes,Yes,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200911_England_PHE_WhatsTheStory_Summary_5_May_August_Age20to29,200911_England_PHE_WhatsTheStory_Summary_5_May_August,PHE England week 37,2020-09-11,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Samples collected from healthy individuals under 25 years through a NIHR funded study, ‘What’s the STORY’. “What’s the Story” is a representative household survey that collects sera from healthy children and adolescents under the age of 25 years in England.",,2020-05-01,2020-08-05,Household and community samples,All,Children and Youth (0-17 years),1.0,24.0,Age,20-29,102,0.095,,,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9570000000000001,0.991,['Moderate'],Yes,Yes,No,No,Yes,Yes,Yes,Yes,Yes,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200911_England_PHE_WhatsTheStory_Summary_5_May_August_Age5to10,200911_England_PHE_WhatsTheStory_Summary_5_May_August,PHE England week 37,2020-09-11,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Samples collected from healthy individuals under 25 years through a NIHR funded study, ‘What’s the STORY’. “What’s the Story” is a representative household survey that collects sera from healthy children and adolescents under the age of 25 years in England.",,2020-05-01,2020-08-05,Household and community samples,All,Children and Youth (0-17 years),5.0,10.0,Age,5-10,163,0.037000000000000005,,,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9570000000000001,0.991,['Moderate'],Yes,Yes,No,No,Yes,Yes,Yes,Yes,Yes,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200911_England_PHE_WhatsTheStory_Summary_5_May_August_Age1to4,200911_England_PHE_WhatsTheStory_Summary_5_May_August,PHE England week 37,2020-09-11,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Samples collected from healthy individuals under 25 years through a NIHR funded study, ‘What’s the STORY’. “What’s the Story” is a representative household survey that collects sera from healthy children and adolescents under the age of 25 years in England.",,2020-05-01,2020-08-05,Household and community samples,All,Children and Youth (0-17 years),1.0,4.0,Age,1-4,55,0.036000000000000004,,,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9570000000000001,0.991,['Moderate'],Yes,Yes,No,No,Yes,Yes,Yes,Yes,Yes,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200911_Birmingham_UniversityHospitalsBirminghamNHSFoundationTrust_Overall,200911_Birmingham_UniversityHospitalsBirminghamNHSFoundationTrust,SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional study,2020-09-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,Birmingham,"asymptomatic healthcare workers at UHBFT was undertaken, recruiting 545 individuals who were at work over the course of 24hours between 24 and 25 April 2020",Individuals were excluded if they reported symptoms of COVID-19 on the day. Individuals self-isolating at home due to personal symptomatic illnesses or illnesses in household contacts in the previous 2 weeks were indirectly excluded from the study,2020-04-24,2020-04-25,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Overall seroprevalence HCWs,516,0.244,,,True,,,,True,Self-referral,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,1.0,0.978,['High'],Yes,No,No,Yes,Yes,Unclear,Yes,Yes,Unclear,Adrian Shields,University Hospitals Birmingham NHS Foundation Trust,Not Unity-Aligned,http://dx.doi.org/10.1136/thoraxjnl-2020-215414,2020-11-03,2022-07-16,Verified,shields_sars-cov-2_2020-1,GBR
200920_EasternUK_CambridgeUniversityHospitalsNHSFoundationTrust_Day1Luminex,200920_EasternUK_CambridgeUniversityHospitalsNHSFoundationTrust,SARS-CoV-2 antigen and antibody prevalence among UK staff working with cancer patients during the COVID-19 pandemic,2020-09-20,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,East of England,,staff involved in treating cancer patients in non-surgical oncology departments at three UK secondary care hospitals in the Eastern Region,"Staff were excluded if they had not been working during the pandemic peak from March–June 2020, or were not patient-facing, primarily within a dedicated SARS-CoV-2 in-patient ward",2020-06-15,2020-06-15,Health care workers and caregivers,All,Adults (18-64 years),19.0,66.0,Primary Estimate,Overall Luminex test Day1,434,0.184,,,True,,,,True,Convenience,Author designed (Luminex),,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.84,1.0,['High'],Yes,No,No,Yes,Unclear,Unclear,Yes,No,Unclear,David Favara,Cambridge University Hospitals NHS Foundation Trust,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.18.20197590v1,2021-01-14,2022-07-16,Verified,favara_sars-cov-2_2020,GBR
200922_Gateshead_NHSFoundationTrust_Overall,200922_Gateshead_NHSFoundationTrust,Exposure of hospital healthcare workers to the novel coronavirus (SARS-CoV-2),2020-09-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,Gateshead,"Our NHS Trust at Gateshead, UK started offering the COVID-19
antibody test to all staff from 28 May 2020. All staff within our
organisation were offered the choice of having the COVID-19
antibody test on a voluntary first-come, first-served basis",,2020-05-28,2020-06-08,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,2521,0.19399999999999998,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,"['IgG', 'IgM']",,,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,No,Salman Razvi,Gateshead Health NHS Foundation Trust,Not Unity-Aligned,https://dx.doi.org/10.7861/clinmed.2020-0566,2020-10-14,2024-03-01,Verified,razvi_exposure_2020,GBR
200926_UK_OfficeforNationalStatistics_August_Sept2020_Wales_Genpop,200926_UK_OfficeforNationalStatistics_August_Sept2020_Wales,Coronavirus (COVID-19) Infection Survey: August_September2020,2020-09-25,Institutional Report,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Wales,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2020-08-28,2020-09-24,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,,236,0.047,0.02,0.092,True,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Moderate'],,Yes,No,No,,Unclear,Yes,Yes,,Office for National Statistics,Office of National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/december2020,2021-03-12,2024-02-01,Verified,steel_coronavirus_2020-2,GBR
200926_UK_OfficeforNationalStatistics_August_Sept2020_England_genpop,200926_UK_OfficeforNationalStatistics_September_2020_England,Coronavirus (COVID-19) Infection Survey: August_September2020,2020-09-25,Institutional Report,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2020-08-28,2020-09-24,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,,8742,0.057999999999999996,0.051,0.065,True,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office of National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/december2020,2021-03-12,2022-07-16,Verified,steel_coronavirus_2020-2,GBR
200930_Scotland_PublicHealthScotland_1ResidualSera_Overall_UnAdj,200930_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 Sept 2020,2020-09-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Data from blood donation clinics,,2020-04-20,2020-08-09,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,9802,0.048867578050000006,,,True,,,,True,Stratified non-probability,Not reported/ Unable to specify,,,Serum,,,,0.875,0.986,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/30-september-2020/,2021-04-22,2022-07-16,Verified,andrew_mcauley_enhanced_2020-1,GBR
200930_Scotland_PublicHealthScotland_1ResidualSera_May18-June14,200930_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 Sept 2020,2020-09-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Data from blood donation clinics,,2020-05-18,2020-06-14,Residual sera,All,Multiple groups,,,Time frame,May 18-June14,2172,0.034,0.018000000000000002,0.05,,True,,,,Stratified non-probability,Not reported/ Unable to specify,,,Serum,,,,0.875,0.986,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/30-september-2020/,2021-04-22,2022-07-16,Verified,andrew_mcauley_enhanced_2020-1,GBR
200930_Scotland_PublicHealthScotland_1ResidualSera_May18-May24,200930_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 Sept 2020,2020-09-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Data from blood donation clinics,,2020-05-18,2020-05-24,Residual sera,All,Multiple groups,,,Time frame,May 18-24,547,0.019,0.001,0.04,,True,,,,Stratified non-probability,Not reported/ Unable to specify,,,Serum,,,,0.875,0.986,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/30-september-2020/,2021-04-22,2022-07-16,Verified,andrew_mcauley_enhanced_2020-1,GBR
200930_Scotland_PublicHealthScotland_1ResidualSera_June8-June14,200930_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 Sept 2020,2020-09-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Data from blood donation clinics,,2020-06-08,2020-06-14,Residual sera,All,Multiple groups,,,Time frame,June 8-14,554,0.052000000000000005,0.027999999999999997,0.081,,True,,,,Stratified non-probability,Not reported/ Unable to specify,,,Serum,,,,0.875,0.986,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/30-september-2020/,2021-04-22,2022-07-16,Verified,andrew_mcauley_enhanced_2020-1,GBR
200930_Scotland_PublicHealthScotland_1ResidualSera_June1-June7,200930_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 Sept 2020,2020-09-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Data from blood donation clinics,,2020-06-01,2020-06-07,Residual sera,All,Multiple groups,,,Time frame,June 1-7,544,0.037000000000000005,0.013999999999999999,0.063,,True,,,,Stratified non-probability,Not reported/ Unable to specify,,,Serum,,,,0.875,0.986,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/30-september-2020/,2021-04-22,2022-07-16,Verified,andrew_mcauley_enhanced_2020-1,GBR
200930_Scotland_PublicHealthScotland_1ResidualSera_Apr20-Apr26,200930_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 Sept 2020,2020-09-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Data from blood donation clinics,,2020-04-20,2020-04-20,Residual sera,All,Multiple groups,,,Time frame,April 20-26,443,0.068,0.039,0.102,,True,,,,Stratified non-probability,Not reported/ Unable to specify,,,Serum,,,,0.875,0.986,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/30-september-2020/,2021-04-22,2022-07-16,Verified,andrew_mcauley_enhanced_2020-1,GBR
200930_Scotland_PublicHealthScotland_1ResidualSera_0-19,200930_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 Sept 2020,2020-09-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Data from blood donation clinics,,2020-04-20,2020-08-09,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Age,0-19,2341,0.05510465613,,,,,,,,Stratified non-probability,Not reported/ Unable to specify,,,Serum,,,,0.875,0.986,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/30-september-2020/,2021-04-22,2022-07-16,Verified,andrew_mcauley_enhanced_2020-1,GBR
200930_Scotland_PublicHealthScotland_1ResidualSera_Male,200930_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 Sept 2020,2020-09-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Data from blood donation clinics,,2020-04-20,2020-08-09,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,Male,4852,0.04760923331,,,,,,,,Stratified non-probability,Not reported/ Unable to specify,,,Serum,,,,0.875,0.986,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/30-september-2020/,2021-04-22,2022-07-16,Verified,andrew_mcauley_enhanced_2020-1,GBR
200930_Scotland_PublicHealthScotland_1ResidualSera_July20-July26,200930_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 Sept 2020,2020-09-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Data from blood donation clinics,,2020-07-20,2020-07-26,Residual sera,All,Multiple groups,,,Time frame,July 20-26,728,0.04,0.019,0.064,,True,,,,Stratified non-probability,Not reported/ Unable to specify,,,Serum,,,,0.875,0.986,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/30-september-2020/,2021-04-22,2022-07-16,Verified,andrew_mcauley_enhanced_2020-1,GBR
200930_Scotland_PublicHealthScotland_1ResidualSera_40-59,200930_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 Sept 2020,2020-09-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Data from blood donation clinics,,2020-04-20,2020-08-09,Residual sera,All,Adults (18-64 years),40.0,59.0,Age,40-59,2171,0.0561953017,,,,,,,,Stratified non-probability,Not reported/ Unable to specify,,,Serum,,,,0.875,0.986,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/30-september-2020/,2021-04-22,2022-07-16,Verified,andrew_mcauley_enhanced_2020-1,GBR
200930_Scotland_PublicHealthScotland_1ResidualSera_May4-May10,200930_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 Sept 2020,2020-09-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Data from blood donation clinics,,2020-05-04,2020-05-10,Residual sera,All,Multiple groups,,,Time frame,May 4-10,530,0.031000000000000003,0.009000000000000001,0.057,,True,,,,Stratified non-probability,Not reported/ Unable to specify,,,Serum,,,,0.875,0.986,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/30-september-2020/,2021-04-22,2022-07-16,Verified,andrew_mcauley_enhanced_2020-1,GBR
200930_Scotland_PublicHealthScotland_1ResidualSera_June15-June21,200930_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 Sept 2020,2020-09-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Data from blood donation clinics,,2020-06-15,2020-06-20,Residual sera,All,Multiple groups,,,Time frame,June 15-June21,656,0.043,0.021,0.069,,True,,,,Stratified non-probability,Not reported/ Unable to specify,,,Serum,,,,0.875,0.986,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/30-september-2020/,2021-04-22,2022-07-16,Verified,andrew_mcauley_enhanced_2020-1,GBR
200930_Scotland_PublicHealthScotland_1ResidualSera_July27-August2,200930_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 Sept 2020,2020-09-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Data from blood donation clinics,,2020-07-27,2020-08-02,Residual sera,All,Multiple groups,,,Time frame,July 27-Aug 2,725,0.035,0.015,0.059000000000000004,,True,,,,Stratified non-probability,Not reported/ Unable to specify,,,Serum,,,,0.875,0.986,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/30-september-2020/,2021-04-22,2022-07-16,Verified,andrew_mcauley_enhanced_2020-1,GBR
200930_Scotland_PublicHealthScotland_1ResidualSera_June29-July5,200930_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 Sept 2020,2020-09-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Data from blood donation clinics,,2020-06-29,2020-07-05,Residual sera,All,Multiple groups,,,Time frame,June 29-July 5,697,0.039,0.018000000000000002,0.064,,True,,,,Stratified non-probability,Not reported/ Unable to specify,,,Serum,,,,0.875,0.986,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/30-september-2020/,2021-04-22,2022-07-16,Verified,andrew_mcauley_enhanced_2020-1,GBR
200930_Scotland_PublicHealthScotland_1ResidualSera_60+,200930_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 Sept 2020,2020-09-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Data from blood donation clinics,,2020-04-20,2020-08-09,Residual sera,All,Seniors (65+ years),60.0,,Age,60+,2883,0.045091918140000006,,,,,,,,Stratified non-probability,Not reported/ Unable to specify,,,Serum,,,,0.875,0.986,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/30-september-2020/,2021-04-22,2022-07-16,Verified,andrew_mcauley_enhanced_2020-1,GBR
200930_Scotland_PublicHealthScotland_1ResidualSera_Apr27-May3,200930_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 Sept 2020,2020-09-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Data from blood donation clinics,,2020-04-27,2020-05-20,Residual sera,All,Multiple groups,,,Time frame,April 27 - May 3,545,0.043,0.019,0.07,,True,,,,Stratified non-probability,Not reported/ Unable to specify,,,Serum,,,,0.875,0.986,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/30-september-2020/,2021-04-22,2022-07-16,Verified,andrew_mcauley_enhanced_2020-1,GBR
200930_Scotland_PublicHealthScotland_1ResidualSera_July13-August9,200930_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 Sept 2020,2020-09-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Data from blood donation clinics,,2020-07-13,2020-08-09,Residual sera,All,Multiple groups,0.0,,Time frame,July13-August9,2882,0.037000000000000005,0.022000000000000002,0.052000000000000005,,True,,,,Stratified non-probability,Not reported/ Unable to specify,,,Serum,,,,0.875,0.986,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/30-september-2020/,2021-04-22,2022-07-16,Verified,andrew_mcauley_enhanced_2020-1,GBR
200930_Scotland_PublicHealthScotland_1ResidualSera_20-39,200930_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 Sept 2020,2020-09-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Data from blood donation clinics,,2020-04-20,2020-08-09,Residual sera,All,Adults (18-64 years),20.0,39.0,Age,20-39,2407,0.040714582469999996,,,,,,,,Stratified non-probability,Not reported/ Unable to specify,,,Serum,,,,0.875,0.986,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/30-september-2020/,2021-04-22,2022-07-16,Verified,andrew_mcauley_enhanced_2020-1,GBR
200930_Scotland_PublicHealthScotland_1ResidualSera_July13-July19,200930_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 Sept 2020,2020-09-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Data from blood donation clinics,,2020-07-13,2020-07-19,Residual sera,All,Multiple groups,,,Time frame,July 13-19,726,0.045,0.023,0.069,,True,,,,Stratified non-probability,Not reported/ Unable to specify,,,Serum,,,,0.875,0.986,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/30-september-2020/,2021-04-22,2022-07-16,Verified,andrew_mcauley_enhanced_2020-1,GBR
200930_Scotland_PublicHealthScotland_1ResidualSera_August3-August9,200930_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 Sept 2020,2020-09-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Data from blood donation clinics,,2020-08-03,2020-08-09,Residual sera,All,Multiple groups,,,Time frame,August 3- 9,703,0.027000000000000003,0.006999999999999999,0.049,,True,,,,Stratified non-probability,Not reported/ Unable to specify,,,Serum,,,,0.875,0.986,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/30-september-2020/,2021-04-22,2022-07-16,Verified,andrew_mcauley_enhanced_2020-1,GBR
200930_Scotland_PublicHealthScotland_1ResidualSera_May25-May30,200930_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 Sept 2020,2020-09-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Data from blood donation clinics,,2020-05-25,2020-05-30,Residual sera,All,Multiple groups,,,Time frame,May 25- May 30,527,0.028999999999999998,0.008,0.055,,True,,,,Stratified non-probability,Not reported/ Unable to specify,,,Serum,,,,0.875,0.986,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/30-september-2020/,2021-04-22,2022-07-16,Verified,andrew_mcauley_enhanced_2020-1,GBR
200930_Scotland_PublicHealthScotland_1ResidualSera_Female,200930_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 Sept 2020,2020-09-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Data from blood donation clinics,,2020-04-20,2020-08-09,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,Female,4950,0.050101010099999996,,,,,,,,Stratified non-probability,Not reported/ Unable to specify,,,Serum,,,,0.875,0.986,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/30-september-2020/,2021-04-22,2022-07-16,Verified,andrew_mcauley_enhanced_2020-1,GBR
200930_Scotland_PublicHealthScotland_1ResidualSera_June15-July12,200930_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 Sept 2020,2020-09-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Data from blood donation clinics,,2020-06-15,2020-07-12,Residual sera,All,Multiple groups,,,Time frame,June15-July12,2709,0.039,0.023,0.054000000000000006,,True,,,,Stratified non-probability,Not reported/ Unable to specify,,,Serum,,,,0.875,0.986,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/30-september-2020/,2021-04-22,2022-07-16,Verified,andrew_mcauley_enhanced_2020-1,GBR
200930_Scotland_PublicHealthScotland_1ResidualSera_April20-May17,200930_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 Sept 2020,2020-09-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Data from blood donation clinics,,2020-04-20,2020-05-17,Residual sera,All,Multiple groups,,,Time frame,April 20-May 17,2039,0.040999999999999995,0.024,0.057,,True,,,,Stratified non-probability,Not reported/ Unable to specify,,,Serum,,,,0.875,0.986,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/30-september-2020/,2021-04-22,2022-07-16,Verified,andrew_mcauley_enhanced_2020-1,GBR
200930_Scotland_PublicHealthScotland_1ResidualSera_May11-May17,200930_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 Sept 2020,2020-09-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Data from blood donation clinics,,2020-05-11,2020-05-17,Residual sera,All,Multiple groups,,,Time frame,May 11-17,521,0.026000000000000002,0.005,0.05,,True,,,,Stratified non-probability,Not reported/ Unable to specify,,,Serum,,,,0.875,0.986,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/30-september-2020/,2021-04-22,2022-07-16,Verified,andrew_mcauley_enhanced_2020-1,GBR
200930_Scotland_PublicHealthScotland_1ResidualSera_July6-July12,200930_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 Sept 2020,2020-09-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Data from blood donation clinics,,2020-07-06,2020-07-12,Residual sera,All,Multiple groups,,,Time frame,July 6-12,693,0.024,0.005,0.046,,True,,,,Stratified non-probability,Not reported/ Unable to specify,,,Serum,,,,0.875,0.986,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/30-september-2020/,2021-04-22,2022-07-16,Verified,andrew_mcauley_enhanced_2020-1,GBR
200930_Scotland_PublicHealthScotland_1ResidualSera_June22-June28,200930_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 Sept 2020,2020-09-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Data from blood donation clinics,,2020-06-22,2020-06-28,Residual sera,All,Multiple groups,,,Time frame,June 22-June28,663,0.049,0.026000000000000002,0.075,,True,,,,Stratified non-probability,Not reported/ Unable to specify,,,Serum,,,,0.875,0.986,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/30-september-2020/,2021-04-22,2022-07-16,Verified,andrew_mcauley_enhanced_2020-1,GBR
200930_Scotland_PublicHealthScotland_2BloodDonors_Overall_TestAdj,200930_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 Sept 2020,2020-09-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Data from blood donation clinics,,2020-06-29,2020-08-09,Blood donors,All,Multiple groups,0.0,,Primary Estimate,,3220,0.031000000000000003,0.025,0.038,True,True,,,True,Sequential,Not reported/ Unable to specify,,,Serum,,,,0.875,0.986,['High'],No,No,Yes,No,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/30-september-2020/,2020-10-25,2022-07-16,Verified,andrew_mcauley_enhanced_2020-1,GBR
200930_Scotland_PublicHealthScotland_2BloodDonors_July27-August2,200930_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 Sept 2020,2020-09-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Data from blood donation clinics,,2020-07-27,2020-08-02,Blood donors,All,Multiple groups,0.0,,Time frame,July 27-Aug2,498,0.046,0.027999999999999997,0.068,,True,,,,Sequential,Not reported/ Unable to specify,,,Serum,,,,0.875,0.986,['High'],No,No,Yes,No,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/30-september-2020/,2020-10-25,2022-07-16,Verified,andrew_mcauley_enhanced_2020-1,GBR
200930_Scotland_PublicHealthScotland_2BloodDonors_July6-July12,200930_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 Sept 2020,2020-09-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Data from blood donation clinics,,2020-07-06,2020-07-12,Blood donors,All,Multiple groups,0.0,,Time frame,July 6- July 12,747,0.026000000000000002,0.013999999999999999,0.040999999999999995,,True,,,,Sequential,Not reported/ Unable to specify,,,Serum,,,,0.875,0.986,['High'],No,No,Yes,No,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/30-september-2020/,2020-10-25,2022-07-16,Verified,andrew_mcauley_enhanced_2020-1,GBR
200930_Scotland_PublicHealthScotland_2BloodDonors_July13-July19,200930_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 Sept 2020,2020-09-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Data from blood donation clinics,,2020-07-13,2020-07-19,Blood donors,All,Multiple groups,0.0,,Time frame,July 13-19,502,0.027000000000000003,0.013000000000000001,0.046,,True,,,,Sequential,Not reported/ Unable to specify,,,Serum,,,,0.875,0.986,['High'],No,No,Yes,No,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/30-september-2020/,2020-10-25,2022-07-16,Verified,andrew_mcauley_enhanced_2020-1,GBR
200930_Scotland_PublicHealthScotland_2BloodDonors_August3-August9,200930_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 Sept 2020,2020-09-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Data from blood donation clinics,,2020-08-03,2020-08-09,Blood donors,All,Multiple groups,0.0,,Time frame,August 3-August 9,496,0.023,0.01,0.042,,True,,,,Sequential,Not reported/ Unable to specify,,,Serum,,,,0.875,0.986,['High'],No,No,Yes,No,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/30-september-2020/,2020-10-25,2022-07-16,Verified,andrew_mcauley_enhanced_2020-1,GBR
200930_Scotland_PublicHealthScotland_2BloodDonors_July20-July26,200930_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 Sept 2020,2020-09-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Data from blood donation clinics,,2020-07-20,2020-07-26,Blood donors,All,Multiple groups,0.0,,Time frame,July 20-26,498,0.021,0.008,0.039,,True,,,,Sequential,Not reported/ Unable to specify,,,Serum,,,,0.875,0.986,['High'],No,No,Yes,No,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/30-september-2020/,2020-10-25,2022-07-16,Verified,andrew_mcauley_enhanced_2020-1,GBR
200930_Scotland_PublicHealthScotland_2BloodDonors_June29-July5,200930_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 Sept 2020,2020-09-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Data from blood donation clinics,,2020-06-29,2020-07-05,Blood donors,All,Multiple groups,0.0,,Time frame,June 29 - July 5,479,0.018000000000000002,0.006,0.035,,True,,,,Sequential,Not reported/ Unable to specify,,,Serum,,,,0.875,0.986,['High'],No,No,Yes,No,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/30-september-2020/,2020-10-25,2022-07-16,Verified,andrew_mcauley_enhanced_2020-1,GBR
201002_England_PHE_BloodDonors_Summary_Final,201002_England_PHE_BloodDonors_Summary17_Final,PHE England week 40,2020-10-02,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples from the following sources are included:
Healthy adult blood donors aged 17 years and older, supplied by the NHS Blood and Transplant (NHS BT collection) between weeks 13 -38. Donor samples from two different geographic regions (approximately 1000 samples per region) in England are tested each week. From week 26, an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore data from the most recent sam-pling periods include donors in this older age group.",,2020-08-24,2020-09-18,Blood donors,All,Multiple groups,17.0,,Primary Estimate,,8230,0.061,0.054000000000000006,0.068,True,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-23,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200918_England_PHE_BloodDonor_GenPop_Midlands_TestPopAdj_Week35to36,201002_England_PHE_BloodDonors_Summary17_Final,PHE England week 40,2020-10-02,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples from the following sources are included:
Healthy adult blood donors aged 17 years and older, supplied by the NHS Blood and Transplant (NHS BT collection) between weeks 13 -38. Donor samples from two different geographic regions (approximately 1000 samples per region) in England are tested each week. From week 26, an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore data from the most recent sam-pling periods include donors in this older age group.",,2020-08-24,2020-09-06,Blood donors,All,Multiple groups,17.0,,Geographical area,Midlands of England ,1000,0.068,0.049,0.08900000000000001,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200918_England_PHE_BloodDonor_GenPop_Northeast_TestPopAdj_Week36,201002_England_PHE_BloodDonors_Summary17_Final,PHE England week 40,2020-10-02,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples from the following sources are included:
Healthy adult blood donors aged 17 years and older, supplied by the NHS Blood and Transplant (NHS BT collection) between weeks 13 -38. Donor samples from two different geographic regions (approximately 1000 samples per region) in England are tested each week. From week 26, an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore data from the most recent sam-pling periods include donors in this older age group.",,2020-08-31,2020-09-06,Blood donors,All,Multiple groups,17.0,,Geographical area,Northeast of England ,1000,0.039,0.024,0.057,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200925_England_PHE_BloodDonor_GenPop_Southwest_TestPopAdj_Week37,201002_England_PHE_BloodDonors_Summary17_Final,PHE England week 40,2020-10-02,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples from the following sources are included:
Healthy adult blood donors aged 17 years and older, supplied by the NHS Blood and Transplant (NHS BT collection) between weeks 13 -38. Donor samples from two different geographic regions (approximately 1000 samples per region) in England are tested each week. From week 26, an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore data from the most recent sam-pling periods include donors in this older age group.",,2020-09-07,2020-09-13,Blood donors,All,Multiple groups,17.0,,Geographical area,Southwest of England ,1000,0.035,0.021,0.052000000000000005,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200918_England_PHE_BloodDonors_Summary15_Week33to36_unadj,201002_England_PHE_BloodDonors_Summary17_Final,PHE England week 40,2020-10-02,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples from the following sources are included:
Healthy adult blood donors aged 17 years and older, supplied by the NHS Blood and Transplant (NHS BT collection) between weeks 13 -38. Donor samples from two different geographic regions (approximately 1000 samples per region) in England are tested each week. From week 26, an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore data from the most recent sam-pling periods include donors in this older age group.",,2020-08-13,2020-09-06,Blood donors,All,Multiple groups,17.0,,Analysis,,7899,0.057999999999999996,0.051,0.064,,,True,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200925_England_PHE_BloodDonors_Summary_week34to37,201002_England_PHE_BloodDonors_Summary17_Final,PHE England week 40,2020-10-02,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples from the following sources are included:
Healthy adult blood donors aged 17 years and older, supplied by the NHS Blood and Transplant (NHS BT collection) between weeks 13 -38. Donor samples from two different geographic regions (approximately 1000 samples per region) in England are tested each week. From week 26, an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore data from the most recent sam-pling periods include donors in this older age group.",,2020-08-19,2020-09-13,Blood donors,All,Multiple groups,17.0,,Time frame,,7888,0.061,0.054000000000000006,0.068,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-23,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200925_England_PHE_BloodDonors_London_week37,201002_England_PHE_BloodDonors_Summary17_Final,PHE England week 40,2020-10-02,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Greater London,,"In this week’s report the results from testing samples from the following sources are included:
Healthy adult blood donors aged 17 years and older, supplied by the NHS Blood and Transplant (NHS BT collection) between weeks 13 -38. Donor samples from two different geographic regions (approximately 1000 samples per region) in England are tested each week. From week 26, an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore data from the most recent sam-pling periods include donors in this older age group.",,2020-09-07,2020-09-13,Blood donors,All,Multiple groups,17.0,,Geographical area,London,1000,0.10800000000000001,0.086,0.134,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200918_England_PHE_BloodDonors_SouthEast_TestPopAdj_Week38,201002_England_PHE_BloodDonors_Summary17_Final,PHE England week 40,2020-10-02,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples from the following sources are included:
Healthy adult blood donors aged 17 years and older, supplied by the NHS Blood and Transplant (NHS BT collection) between weeks 13 -38. Donor samples from two different geographic regions (approximately 1000 samples per region) in England are tested each week. From week 26, an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore data from the most recent sam-pling periods include donors in this older age group.",,2020-09-14,2020-09-20,Blood donors,All,Multiple groups,17.0,,Geographical area,Southeast of England ,1000,0.027999999999999997,0.013999999999999999,0.045,,True,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2023-07-04,Verified,public_health_england_national_2020-17,GBR
200925_England_PHE_BloodDonors_Summary_week34to37_unadj,201002_England_PHE_BloodDonors_Summary17_Final,PHE England week 40,2020-10-02,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples from the following sources are included:
Healthy adult blood donors aged 17 years and older, supplied by the NHS Blood and Transplant (NHS BT collection) between weeks 13 -38. Donor samples from two different geographic regions (approximately 1000 samples per region) in England are tested each week. From week 26, an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore data from the most recent sam-pling periods include donors in this older age group.",,2020-08-19,2020-09-13,Blood donors,All,Multiple groups,17.0,,Test used,,7888,0.055999999999999994,0.051,0.062000000000000006,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
201002_England_PHE_BloodDonors_Summary_Final_Unadj,201002_England_PHE_BloodDonors_Summary17_Final,PHE England week 40,2020-10-02,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples from the following sources are included:
Healthy adult blood donors aged 17 years and older, supplied by the NHS Blood and Transplant (NHS BT collection) between weeks 13 -38. Donor samples from two different geographic regions (approximately 1000 samples per region) in England are tested each week. From week 26, an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore data from the most recent sam-pling periods include donors in this older age group.",,2020-08-24,2020-09-18,Blood donors,All,Multiple groups,17.0,,Analysis,,8230,0.057,0.052000000000000005,0.063,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8300000000000001,0.993,['Low'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
201002_England_PHE_RCGP_Collection_Summary_Final_week25to33_abbott,201002_England_PHE_RCGP_Collection_Summary_Final,PHE England week 40,2020-10-02,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors aged 17 years and older, supplied by the NHS Blood and Transplant (NHS BT collection) between weeks 13 -37 are summarised. Donor samples from two different geographic regions (approximately 1000 samples per region) in England are tested each week. Since week 26, an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore data from recent sampling periods include donors in this older age group",,2020-06-15,2020-08-16,Residual sera,All,Seniors (65+ years),65.0,100.0,Primary Estimate,,4315,0.065,0.055,0.076,True,,True,,True,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9570000000000001,0.991,['Low'],No,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-23,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200918_England_PHE_RCGPCollection_Euroim_July_Aug_Age80+,201002_England_PHE_RCGP_Collection_Summary_Final,PHE England week 40,2020-10-02,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors aged 17 years and older, supplied by the NHS Blood and Transplant (NHS BT collection) between weeks 13 -37 are summarised. Donor samples from two different geographic regions (approximately 1000 samples per region) in England are tested each week. Since week 26, an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore data from recent sampling periods include donors in this older age group",,2020-07-01,2020-08-14,Residual sera,All,Seniors (65+ years),80.0,100.0,Age,>=80,538,0.027000000000000003,,,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Low'],No,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
201002_England_PHE_RCGP_Collection_Summary_Final_week25to33_Euroimm,201002_England_PHE_RCGP_Collection_Summary_Final,PHE England week 40,2020-10-02,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors aged 17 years and older, supplied by the NHS Blood and Transplant (NHS BT collection) between weeks 13 -37 are summarised. Donor samples from two different geographic regions (approximately 1000 samples per region) in England are tested each week. Since week 26, an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore data from recent sampling periods include donors in this older age group",,2020-06-15,2020-08-16,Residual sera,All,Seniors (65+ years),65.0,100.0,Test used,,3860,0.059000000000000004,0.049,0.07,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Low'],No,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200918_England_PHE_RCGPCollection_Euroim_July_Aug_Age65to69,201002_England_PHE_RCGP_Collection_Summary_Final,PHE England week 40,2020-10-02,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors aged 17 years and older, supplied by the NHS Blood and Transplant (NHS BT collection) between weeks 13 -37 are summarised. Donor samples from two different geographic regions (approximately 1000 samples per region) in England are tested each week. Since week 26, an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore data from recent sampling periods include donors in this older age group",,2020-07-01,2020-08-14,Residual sera,All,Seniors (65+ years),65.0,69.0,Age,65-69 ,478,0.045,,,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Low'],No,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-23,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200918_England_PHE_RCGPCollection_Summary_Abbott_June,201002_England_PHE_RCGP_Collection_Summary_Final,PHE England week 40,2020-10-02,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors aged 17 years and older, supplied by the NHS Blood and Transplant (NHS BT collection) between weeks 13 -37 are summarised. Donor samples from two different geographic regions (approximately 1000 samples per region) in England are tested each week. Since week 26, an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore data from recent sampling periods include donors in this older age group",,2020-06-01,2020-06-30,Residual sera,All,Seniors (65+ years),65.0,100.0,Time frame,,2185,0.023,0.014499999999999999,0.033,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9570000000000001,0.991,['Low'],No,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200918_England_PHE_RCGPCollection_Summary_Euroim_July_Aug,201002_England_PHE_RCGP_Collection_Summary_Final,PHE England week 40,2020-10-02,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors aged 17 years and older, supplied by the NHS Blood and Transplant (NHS BT collection) between weeks 13 -37 are summarised. Donor samples from two different geographic regions (approximately 1000 samples per region) in England are tested each week. Since week 26, an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore data from recent sampling periods include donors in this older age group",,2020-07-01,2020-08-14,Residual sera,All,Seniors (65+ years),65.0,100.0,Test used,,2153,0.031000000000000003,0.022000000000000002,0.042,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Low'],No,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200918_England_PHE_RCGPCollection_Summary_Abbott_July_Aug,201002_England_PHE_RCGP_Collection_Summary_Final,PHE England week 40,2020-10-02,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors aged 17 years and older, supplied by the NHS Blood and Transplant (NHS BT collection) between weeks 13 -37 are summarised. Donor samples from two different geographic regions (approximately 1000 samples per region) in England are tested each week. Since week 26, an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore data from recent sampling periods include donors in this older age group",,2020-07-01,2020-08-14,Residual sera,All,Seniors (65+ years),65.0,100.0,Time frame,,2153,0.034,0.025,0.045,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9570000000000001,0.991,['Low'],No,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200918_England_PHE_RCGPCollection_Euroim_July_Aug_Age75to79,201002_England_PHE_RCGP_Collection_Summary_Final,PHE England week 40,2020-10-02,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors aged 17 years and older, supplied by the NHS Blood and Transplant (NHS BT collection) between weeks 13 -37 are summarised. Donor samples from two different geographic regions (approximately 1000 samples per region) in England are tested each week. Since week 26, an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore data from recent sampling periods include donors in this older age group",,2020-07-01,2020-08-14,Residual sera,All,Seniors (65+ years),75.0,79.0,Age,75-79,515,0.038,,,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Low'],No,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200918_England_PHE_RCGPCollection_Euroim_July_Aug_Age70to74,201002_England_PHE_RCGP_Collection_Summary_Final,PHE England week 40,2020-10-02,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors aged 17 years and older, supplied by the NHS Blood and Transplant (NHS BT collection) between weeks 13 -37 are summarised. Donor samples from two different geographic regions (approximately 1000 samples per region) in England are tested each week. Since week 26, an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore data from recent sampling periods include donors in this older age group",,2020-07-01,2020-08-14,Residual sera,All,Seniors (65+ years),70.0,74.0,Age,70-74 ,654,0.025,,,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Low'],No,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
201002_England_PHE_SeroepiUnitPaedsSurvey_6_Final_week25to33_Abbott,201002_England_PHE_SeroepiUnitPaedsSurvey_6_FebSept_Final,PHE England week 40,2020-10-02,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors aged 17 years and older, supplied by the NHS Blood and Transplant (NHS BT collection) between weeks 13 -37 are summarised. Donor samples from two different geographic regions (approximately 1000 samples per region) in England are tested each week. Since week 26, an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore data from recent sampling periods include donors in this older age group",,2020-06-15,2020-08-16,Residual sera,All,Multiple groups,0.0,29.0,Primary Estimate,,1212,0.052000000000000005,0.039,0.07,True,,True,,True,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9570000000000001,0.991,['Low'],No,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-23,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200821_England_PHE_SeroepiUnitPaedsSurvey_Under20_TestAdj_JuneAug,201002_England_PHE_SeroepiUnitPaedsSurvey_6_FebSept_Final,PHE England week 40,2020-10-02,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors aged 17 years and older, supplied by the NHS Blood and Transplant (NHS BT collection) between weeks 13 -37 are summarised. Donor samples from two different geographic regions (approximately 1000 samples per region) in England are tested each week. Since week 26, an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore data from recent sampling periods include donors in this older age group",,2020-06-01,2020-08-02,Residual sera,All,Children and Youth (0-17 years),1.0,19.0,Time frame,,2062,0.024,0.013000000000000001,0.034,,True,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9570000000000001,0.991,['Low'],No,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-18,2024-02-01,Verified,public_health_england_national_2020-17,GBR
200911_England_PHE_SeroepiUnitPaedsSurvey_5_MayAug_Age1to4,201002_England_PHE_SeroepiUnitPaedsSurvey_6_FebSept_Final,PHE England week 40,2020-10-02,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors aged 17 years and older, supplied by the NHS Blood and Transplant (NHS BT collection) between weeks 13 -37 are summarised. Donor samples from two different geographic regions (approximately 1000 samples per region) in England are tested each week. Since week 26, an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore data from recent sampling periods include donors in this older age group",,2020-05-01,2020-08-02,Residual sera,All,Children and Youth (0-17 years),1.0,4.0,Age,1-4,509,0.055,,,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9570000000000001,0.991,['Low'],No,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200911_England_PHE_SeroepiUnitPaedsSurvey_5_MayAug_Age5to10,201002_England_PHE_SeroepiUnitPaedsSurvey_6_FebSept_Final,PHE England week 40,2020-10-02,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors aged 17 years and older, supplied by the NHS Blood and Transplant (NHS BT collection) between weeks 13 -37 are summarised. Donor samples from two different geographic regions (approximately 1000 samples per region) in England are tested each week. Since week 26, an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore data from recent sampling periods include donors in this older age group",,2020-05-01,2020-08-02,Residual sera,All,Children and Youth (0-17 years),5.0,10.0,Age,5-10,790,0.065,,,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9570000000000001,0.991,['Low'],No,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200821_England_PHE_SeroepiUnitPaedsSurvey_Under20_Unadj_JuneAug,201002_England_PHE_SeroepiUnitPaedsSurvey_6_FebSept_Final,PHE England week 40,2020-10-02,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors aged 17 years and older, supplied by the NHS Blood and Transplant (NHS BT collection) between weeks 13 -37 are summarised. Donor samples from two different geographic regions (approximately 1000 samples per region) in England are tested each week. Since week 26, an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore data from recent sampling periods include donors in this older age group",,2020-06-01,2020-08-02,Residual sera,All,Children and Youth (0-17 years),1.0,19.0,Analysis,Unadjusted,2062,0.032,0.024,0.04,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9570000000000001,0.991,['Low'],No,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2020-10-18,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200911_England_PHE_SeroepiUnitPaedsSurvey_5_JuneJuly,201002_England_PHE_SeroepiUnitPaedsSurvey_6_FebSept_Final,PHE England week 40,2020-10-02,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors aged 17 years and older, supplied by the NHS Blood and Transplant (NHS BT collection) between weeks 13 -37 are summarised. Donor samples from two different geographic regions (approximately 1000 samples per region) in England are tested each week. Since week 26, an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore data from recent sampling periods include donors in this older age group",,2020-06-01,2020-08-02,Residual sera,All,Multiple groups,0.0,29.0,Time frame,,2158,0.057999999999999996,0.037000000000000005,0.085,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9570000000000001,0.991,['Low'],No,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
201002_England_PHE_SeroepiUnitPaedsSurvey_6_Final_week25to33_Euroimm,201002_England_PHE_SeroepiUnitPaedsSurvey_6_FebSept_Final,PHE England week 40,2020-10-02,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors aged 17 years and older, supplied by the NHS Blood and Transplant (NHS BT collection) between weeks 13 -37 are summarised. Donor samples from two different geographic regions (approximately 1000 samples per region) in England are tested each week. Since week 26, an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore data from recent sampling periods include donors in this older age group",,2020-06-15,2020-08-16,Residual sera,All,Multiple groups,0.0,29.0,Test used,,968,0.045,0.033,0.063,,,True,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Low'],No,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200911_England_PHE_SeroepiUnitPaedsSurvey_5_MayAug_Age11to19,201002_England_PHE_SeroepiUnitPaedsSurvey_6_FebSept_Final,PHE England week 40,2020-10-02,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors aged 17 years and older, supplied by the NHS Blood and Transplant (NHS BT collection) between weeks 13 -37 are summarised. Donor samples from two different geographic regions (approximately 1000 samples per region) in England are tested each week. Since week 26, an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore data from recent sampling periods include donors in this older age group",,2020-05-01,2020-08-02,Residual sera,All,Children and Youth (0-17 years),11.0,19.0,Age,11-19,1739,0.066,,,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9570000000000001,0.991,['Low'],No,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200911_England_PHE_SeroepiUnitPaedsSurvey_5_MayAug,201002_England_PHE_SeroepiUnitPaedsSurvey_6_FebSept_Final,PHE England week 40,2020-10-02,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors aged 17 years and older, supplied by the NHS Blood and Transplant (NHS BT collection) between weeks 13 -37 are summarised. Donor samples from two different geographic regions (approximately 1000 samples per region) in England are tested each week. Since week 26, an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore data from recent sampling periods include donors in this older age group",,2020-05-01,2020-08-02,Residual sera,All,Multiple groups,0.0,29.0,Time frame,,3335,0.06,0.046,0.078,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9570000000000001,0.991,['Low'],No,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-23,2024-03-01,Verified,public_health_england_national_2020-17,GBR
200911_England_PHE_SeroepiUnitPaedsSurvey_5_MayAug_Age20to29,201002_England_PHE_SeroepiUnitPaedsSurvey_6_FebSept_Final,PHE England week 40,2020-10-02,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"In this week’s report the results from testing samples provided by healthy adult blood donors aged 17 years and older, supplied by the NHS Blood and Transplant (NHS BT collection) between weeks 13 -37 are summarised. Donor samples from two different geographic regions (approximately 1000 samples per region) in England are tested each week. Since week 26, an exclusion of donors aged 70 years and older donating throughout lockdown was lifted, and therefore data from recent sampling periods include donors in this older age group",,2020-05-01,2020-08-02,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29,297,0.07200000000000001,,,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9570000000000001,0.991,['Low'],No,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Public Health England,Public Health England,Unity-Aligned,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,2021-01-31,2024-03-01,Verified,public_health_england_national_2020-17,GBR
201004_SEEngland_King’sCollegeLondon,201004_SEEngland_King’sCollegeLondon,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,2020-10-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,South East England,,"Members of TwinsUK cohort, residence within an 80-mile radius of the cohort headquarters St Thomas’ Hospital in Central London, active use of the COVID symptom study app, and availability for visit between 27th April and 2nd June 2020.","The exclusion criterion (for safety reasons) was report of recent symptoms indicating potential COVID-19 at the time of the study or within 14 days prior, which participants were required to confirm
via telephone consultation. ",2020-04-27,2020-06-02,Household and community samples,All,Multiple groups,19.0,86.0,Primary Estimate,,431,0.12,0.091,0.152,True,,,,True,Convenience,Author designed (ELISA) - MULTIPLEXED,,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.9,1.0,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,No,Philippa M Wells,King’s College London,Unity-Aligned,http://dx.doi.org/10.1016/j.jinf.2020.10.011,2020-09-28,2022-07-16,Verified,wells_estimates_2020,GBR
201021_London_BartsHealthNHSTrust_primary,201021_London_BartsHealthNHSTrust,COVID-19 prevalence and seroconversion in an urban hemodialysis unit in the United Kingdom,2020-10-21,Journal Article (Peer-Reviewed),Local,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,,London,in center hemodialysis (ICHD) patients at the tertiary center renal unit within Barts Health NHS Trust,,2020-05-01,2020-06-04,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,1253,0.18,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,"['IgG', 'IgM']",,,,,['High'],Yes,No,Yes,No,No,Yes,Yes,Yes,Unclear,Kieran McCafferty,Barts Health NHS Trust ,Not Unity-Aligned,http://dx.doi.org/10.1111/hdi.12883,2021-02-24,2024-03-01,Verified,mccafferty_covid-19_2020,GBR
201022_Scotland_UniversityOfOxford_overall,201022_Scotland_UniversityOfOxford,Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020.,2020-10-22,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Scotland,,"We analysed six batches of 500 plasma samples col- lected on 17 March, 21–23 March, 5–6 April, 18–20 April, 2–4 May and 16–18 May from Scotland. Each batch was sampled from a range of health boards across Scotland, with the coverage varying between batches.",children under 16 years are not permitted to donate blood,2020-03-17,2020-05-18,Blood donors,All,Adults (18-64 years),,,Primary Estimate,,3500,0.0317,,,True,,,,True,Simplified probability,Author designed (Neutralization Assay),,Neutralization,Serum,Neutralizing,Spike,Validated by developers,0.9400000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,No,Unclear,Yes,Yes,,Craig P Thompson,University of Oxford,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2020.25.42.2000685,2021-02-06,2022-07-16,Verified,thompson_detection_2020,GBR
201022_Scotland_UniversityOfOxford_geoGreaterGlasgow_April18-20,201022_Scotland_UniversityOfOxford,Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020.,2020-10-22,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Scotland,,"We analysed six batches of 500 plasma samples col- lected on 17 March, 21–23 March, 5–6 April, 18–20 April, 2–4 May and 16–18 May from Scotland. Each batch was sampled from a range of health boards across Scotland, with the coverage varying between batches.",children under 16 years are not permitted to donate blood,2020-04-18,2020-04-20,Blood donors,All,Adults (18-64 years),,,Geographical area,Greater Glasgow ,490,0.054000000000000006,0.032,0.079,,,,,,Simplified probability,Author designed (Neutralization Assay),,Neutralization,Serum,Neutralizing,Spike,Validated by developers,0.9400000000000001,1.0,['Moderate'],No,Yes,Yes,Yes,No,Unclear,Yes,Yes,,Craig P Thompson,University of Oxford,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2020.25.42.2000685,2021-02-06,2022-07-16,Verified,thompson_detection_2020,GBR
201022_Oxford_UniversityOfOxford_unadj,201022_Oxford_UniversityOfOxford,"SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020.",2020-10-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,Oxford,pregnant women in their first trimester of pregnancy whose antenatal serum samples had been taken,". We excluded samples for which no EPR record was available, and those with a missing postcode, generating a final dataset of 1,000 consecutive samples with supporting clinical metadata",2020-04-14,2020-06-15,Pregnant or parturient women,Female,Adults (18-64 years),17.0,48.0,Primary Estimate,Pregnant/parturient women,1000,0.053,0.04,0.069,True,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.991,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Unclear,Yes,Yes,Yes,Sheila F Lumley,University of Oxford,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2020.25.41.2001721,2021-01-21,2022-07-16,Verified,lumley_sars-cov-2_2020,GBR
201022_Oxford_UniversityOfOxford_neutralizing_unadj,201022_Oxford_UniversityOfOxford,"SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020.",2020-10-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,Oxford,pregnant women in their first trimester of pregnancy whose antenatal serum samples had been taken,". We excluded samples for which no EPR record was available, and those with a missing postcode, generating a final dataset of 1,000 consecutive samples with supporting clinical metadata",2020-04-14,2020-06-15,Pregnant or parturient women,Female,Adults (18-64 years),17.0,48.0,Test used,Pregnant/parturient women,1000,0.039,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9411,1.0,['Moderate'],Yes,No,Yes,No,Unclear,Unclear,Yes,Yes,Yes,Sheila F Lumley,University of Oxford,Unity-Aligned,https://dx.doi.org/10.2807/1560-7917.ES.2020.25.41.2001721,2021-02-23,2022-07-16,Verified,lumley_sars-cov-2_2020,GBR
201026_UK_OfficeforNationalStatistics_Sept_Oct2020_England_Genpop,201026_UK_OfficeforNationalStatistics_Oct2020_England,Coronavirus (COVID-19) Infection Survey: September_October2020,2020-10-23,Institutional Report,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2020-09-25,2020-10-22,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,,15687,0.069,0.064,0.075,True,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office of National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/december2020,2021-03-12,2022-07-16,Verified,steel_coronavirus_2020-2,GBR
201026_UK_OfficeforNationalStatistics_Sept_Oct2020_NorthernIreland_genpop,201026_UK_OfficeforNationalStatistics_Sept_Oct2020_NorthernIreland,Coronavirus (COVID-19) Infection Survey: September_October2020,2020-10-23,Institutional Report,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Northern Ireland,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2020-09-25,2020-10-22,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,,249,0.027999999999999997,0.012,0.055,True,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Moderate'],Yes,Yes,No,No,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office of National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/december2020,2021-03-12,2022-07-16,Verified,steel_coronavirus_2020-2,GBR
201026_UK_OfficeforNationalStatistics_Sept_Oct2020_Scotland_Genpop,201026_UK_OfficeforNationalStatistics_Sept_Oct2020_Scotland,Coronavirus (COVID-19) Infection Survey: September_October2020,2020-10-23,Institutional Report,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,"Scotland
",,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2020-09-25,2020-10-22,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,,383,0.068,0.043,0.102,True,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Moderate'],Yes,Yes,No,No,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office of National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/december2020,2021-03-12,2022-07-16,Verified,steel_coronavirus_2020-2,GBR
201026_UK_OfficeforNationalStatistics_Sept_Oct2020_Wales_Genpop,201026_UK_OfficeforNationalStatistics_Sept_Oct2020_Wales,Coronavirus (COVID-19) Infection Survey: September_October2020,2020-10-23,Institutional Report,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Wales,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2020-09-25,2020-10-22,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,,473,0.047,0.028999999999999998,0.073,True,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Moderate'],,Yes,No,No,,Unclear,Yes,Yes,,Office for National Statistics,Office of National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/december2020,2021-03-12,2024-02-01,Verified,steel_coronavirus_2020-2,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod1_TotalAdj,201027_England_ImperialCollegeLondon_SamplingPeriod1,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-06-20,2020-07-13,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,Primary estimate,99908,0.0596,0.057800000000000004,0.061399999999999996,True,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod1_75+,201027_England_ImperialCollegeLondon_SamplingPeriod1,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-06-20,2020-07-13,Household and community samples,All,Seniors (65+ years),75.0,,Age,75+ years,6410,0.033100000000000004,0.0286,0.0379,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod1_18-24,201027_England_ImperialCollegeLondon_SamplingPeriod1,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-06-20,2020-07-13,Household and community samples,All,Adults (18-64 years),18.0,24.0,Age,18-24 years,6499,0.0786,0.0726,0.085,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod1_EastofEngland,201027_England_ImperialCollegeLondon_SamplingPeriod1,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,East of England,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-06-20,2020-07-13,Household and community samples,All,Multiple groups,18.0,,Geographical area,East of England,14433,0.0509,0.045899999999999996,0.0563,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod1_WestMidlands,201027_England_ImperialCollegeLondon_SamplingPeriod1,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,West Midlands,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-06-20,2020-07-13,Household and community samples,All,Multiple groups,18.0,,Geographical area,West Midlands,9620,0.0582,0.05280000000000001,0.064,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod1_55-64,201027_England_ImperialCollegeLondon_SamplingPeriod1,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-06-20,2020-07-13,Household and community samples,All,Adults (18-64 years),55.0,64.0,Age,55-64 years,20404,0.0592,0.0546,0.064,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod1_TotalUnAdj,201027_England_ImperialCollegeLondon_SamplingPeriod1,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-06-20,2020-07-13,Household and community samples,All,Multiple groups,18.0,,Analysis,Total participants - unadjusted,99908,0.0555,0.0541,0.056900000000000006,,,,,True,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod1_EastMidlands,201027_England_ImperialCollegeLondon_SamplingPeriod1,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,East Midlands,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-06-20,2020-07-13,Household and community samples,All,Multiple groups,18.0,,Geographical area,East Midlands,12684,0.042300000000000004,0.0371,0.048,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod1_45-54,201027_England_ImperialCollegeLondon_SamplingPeriod1,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-06-20,2020-07-13,Household and community samples,All,Adults (18-64 years),45.0,54.0,Age,45-54 years,20634,0.0641,0.059800000000000006,0.0687,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod1_NorthWest ,201027_England_ImperialCollegeLondon_SamplingPeriod1,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,North West England,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-06-20,2020-07-13,Household and community samples,All,Multiple groups,18.0,,Geographical area,NorthWest region,11996,0.0665,0.061399999999999996,0.0719,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod1_YorkshireandtheHumber,201027_England_ImperialCollegeLondon_SamplingPeriod1,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Yorkshire and the Humber,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-06-20,2020-07-13,Household and community samples,All,Multiple groups,18.0,,Geographical area,Yorkshire and the Humber,6519,0.0395,0.0346,0.044800000000000006,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod1_Other,201027_England_ImperialCollegeLondon_SamplingPeriod1,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-06-20,2020-07-13,Household and community samples,All,Multiple groups,18.0,,Race,Other ethnicity,762,0.12279999999999999,0.10210000000000001,0.1466,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod1_White,201027_England_ImperialCollegeLondon_SamplingPeriod1,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-06-20,2020-07-13,Household and community samples,All,Multiple groups,18.0,,Race,White ethnicity,92737,0.0501,0.0483,0.0519,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod1_SouthWest,201027_England_ImperialCollegeLondon_SamplingPeriod1,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,South West,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-06-20,2020-07-13,Household and community samples,All,Multiple groups,18.0,,Geographical area,SouthWest region,9556,0.0279,0.023700000000000002,0.0325,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod1_SouthEast,201027_England_ImperialCollegeLondon_SamplingPeriod1,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,South East England,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-06-20,2020-07-13,Household and community samples,All,Multiple groups,18.0,,Geographical area,SouthEast region,21979,0.0392,0.0354,0.0432,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod1_Black,201027_England_ImperialCollegeLondon_SamplingPeriod1,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-06-20,2020-07-13,Household and community samples,All,Multiple groups,18.0,,Race,Black ethnicity,900,0.1734,0.1575,0.1905,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod1_Male,201027_England_ImperialCollegeLondon_SamplingPeriod1,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-06-20,2020-07-13,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,Male ,43825,0.0617,0.0591,0.0644,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod1_35-44,201027_England_ImperialCollegeLondon_SamplingPeriod1,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-06-20,2020-07-13,Household and community samples,All,Adults (18-64 years),35.0,44.0,Age,35-44 years,17052,0.0609,0.0565,0.06559999999999999,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod1_25-34,201027_England_ImperialCollegeLondon_SamplingPeriod1,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-06-20,2020-07-13,Household and community samples,All,Adults (18-64 years),25.0,34.0,Age,25-34 years,13366,0.07830000000000001,0.0735,0.08320000000000001,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod1_Female,201027_England_ImperialCollegeLondon_SamplingPeriod1,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-06-20,2020-07-13,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,Female ,56083,0.0575,0.055,0.0601,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod1_65-74,201027_England_ImperialCollegeLondon_SamplingPeriod1,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-06-20,2020-07-13,Household and community samples,All,Seniors (65+ years),65.0,74.0,Age,65-74 years,15543,0.0316,0.0276,0.0359,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod1_Asian,201027_England_ImperialCollegeLondon_SamplingPeriod1,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-06-20,2020-07-13,Household and community samples,All,Multiple groups,18.0,,Race,Asian ethnicity,3658,0.1186,0.1099,0.1277,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod1_Mixed,201027_England_ImperialCollegeLondon_SamplingPeriod1,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-06-20,2020-07-13,Household and community samples,All,Multiple groups,18.0,,Race,People with mixed ethnicity,1347,0.0892,0.0709,0.11080000000000001,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod1_London,201027_England_ImperialCollegeLondon_SamplingPeriod1,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Greater London,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-06-20,2020-07-13,Household and community samples,All,Multiple groups,18.0,,Geographical area,London,9547,0.12960000000000002,0.1234,0.1359,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod1_NorthEast,201027_England_ImperialCollegeLondon_SamplingPeriod1,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,North East England,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-06-20,2020-07-13,Household and community samples,All,Multiple groups,18.0,,Geographical area,NorthEast region,3574,0.050300000000000004,0.043,0.058499999999999996,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod2_TotalAdj,201027_England_ImperialCollegeLondon_SamplingPeriod2,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-07-31,2020-08-13,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,Primary estimate,105829,0.0483,0.0467,0.05,True,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod2_Male ,201027_England_ImperialCollegeLondon_SamplingPeriod2,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-07-31,2020-08-13,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,Male ,46269,0.0487,0.0464,0.051100000000000007,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-22,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod2_75+ ,201027_England_ImperialCollegeLondon_SamplingPeriod2,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-07-31,2020-08-13,Household and community samples,All,Seniors (65+ years),75.0,,Age,75+ years,7689,0.0161,0.0126,0.02,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-22,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod2_Female ,201027_England_ImperialCollegeLondon_SamplingPeriod2,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-07-31,2020-08-13,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,Female ,59560,0.0479,0.045700000000000005,0.050300000000000004,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-22,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod2_Black,201027_England_ImperialCollegeLondon_SamplingPeriod2,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-07-31,2020-08-13,Household and community samples,All,Multiple groups,18.0,,Race,Black ethnicity,936,0.1192,0.10560000000000001,0.1342,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod2_55-64 ,201027_England_ImperialCollegeLondon_SamplingPeriod2,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-07-31,2020-08-13,Household and community samples,All,Adults (18-64 years),55.0,64.0,Age,55-64 years,21840,0.047,0.043,0.0514,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-22,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod2_NorthWest ,201027_England_ImperialCollegeLondon_SamplingPeriod2,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,North West England,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-07-31,2020-08-13,Household and community samples,All,Multiple groups,18.0,,Geographical area,NorthWest region,12995,0.0525,0.048,0.05740000000000001,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod2_TotalUnAdj,201027_England_ImperialCollegeLondon_SamplingPeriod2,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-07-31,2020-08-13,Household and community samples,All,Multiple groups,18.0,,Analysis,"Total participants, unadjusted ",105829,0.0472,0.045899999999999996,0.048499999999999995,,,,,True,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod2_YorkshireandtheHumber,201027_England_ImperialCollegeLondon_SamplingPeriod2,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Yorkshire and the Humber,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-07-31,2020-08-13,Household and community samples,All,Multiple groups,18.0,,Geographical area,Yorkshire and the Humber,7391,0.039700000000000006,0.035,0.0449,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod2_London ,201027_England_ImperialCollegeLondon_SamplingPeriod2,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Greater London,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-07-31,2020-08-13,Household and community samples,All,Multiple groups,18.0,,Geographical area,London,9872,0.09380000000000001,0.0886,0.0993,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-22,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod2_Other ,201027_England_ImperialCollegeLondon_SamplingPeriod2,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-07-31,2020-08-13,Household and community samples,All,Multiple groups,18.0,,Race,Other ethnicity,939,0.0825,0.065,0.1033,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod2_White,201027_England_ImperialCollegeLondon_SamplingPeriod2,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-07-31,2020-08-13,Household and community samples,All,Multiple groups,18.0,,Race,White ethnicity,98003,0.0405,0.038900000000000004,0.0422,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod2_SouthWest ,201027_England_ImperialCollegeLondon_SamplingPeriod2,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,South West,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-07-31,2020-08-13,Household and community samples,All,Multiple groups,18.0,,Geographical area,SouthWest region,9976,0.0128,0.0095,0.0165,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-22,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod2_NorthEast,201027_England_ImperialCollegeLondon_SamplingPeriod2,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,North East England,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-07-31,2020-08-13,Household and community samples,All,Multiple groups,18.0,,Geographical area,NorthEast region,4027,0.0434,0.0366,0.051,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod2_35-44 ,201027_England_ImperialCollegeLondon_SamplingPeriod2,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-07-31,2020-08-13,Household and community samples,All,Adults (18-64 years),35.0,44.0,Age,35-44 years,17130,0.0512,0.0471,0.0555,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-22,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod2_SouthEast ,201027_England_ImperialCollegeLondon_SamplingPeriod2,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,South East England,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-07-31,2020-08-13,Household and community samples,All,Multiple groups,18.0,,Geographical area,SouthEast region,22632,0.0309,0.0275,0.0345,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-22,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod2_EastMidlands ,201027_England_ImperialCollegeLondon_SamplingPeriod2,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,East Midlands,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-07-31,2020-08-13,Household and community samples,All,Multiple groups,18.0,,Geographical area,East Midlands,13685,0.0337,0.028999999999999998,0.038900000000000004,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-22,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod2_Mixed ,201027_England_ImperialCollegeLondon_SamplingPeriod2,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-07-31,2020-08-13,Household and community samples,All,Multiple groups,18.0,,Race,People with mixed ethnicity,1308,0.061900000000000004,0.0466,0.0805,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod2_WestMidlands ,201027_England_ImperialCollegeLondon_SamplingPeriod2,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,West Midlands,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-07-31,2020-08-13,Household and community samples,All,Multiple groups,18.0,,Geographical area,West Midlands,10062,0.0697,0.0641,0.0757,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-22,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod2_45-54 ,201027_England_ImperialCollegeLondon_SamplingPeriod2,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-07-31,2020-08-13,Household and community samples,All,Adults (18-64 years),45.0,54.0,Age,45-54 years,21487,0.05480000000000001,0.050800000000000005,0.059000000000000004,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-22,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod2_EastofEngland ,201027_England_ImperialCollegeLondon_SamplingPeriod2,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,East of England,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-07-31,2020-08-13,Household and community samples,All,Multiple groups,18.0,,Geographical area,East of England,15189,0.0402,0.0358,0.045,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-22,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod2_25-34 ,201027_England_ImperialCollegeLondon_SamplingPeriod2,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-07-31,2020-08-13,Household and community samples,All,Adults (18-64 years),25.0,34.0,Age,25-34 years,13573,0.0588,0.0547,0.0632,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-22,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod2_65-74 ,201027_England_ImperialCollegeLondon_SamplingPeriod2,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-07-31,2020-08-13,Household and community samples,All,Seniors (65+ years),65.0,74.0,Age,65-74 years,17617,0.027400000000000004,0.023700000000000002,0.031400000000000004,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-22,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod2_18-24,201027_England_ImperialCollegeLondon_SamplingPeriod2,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-07-31,2020-08-13,Household and community samples,All,Adults (18-64 years),18.0,24.0,Age,18-24 years,6493,0.0731,0.0675,0.079,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-22,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod2_Asian,201027_England_ImperialCollegeLondon_SamplingPeriod2,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-07-31,2020-08-13,Household and community samples,All,Multiple groups,18.0,,Race,Asian ethnicity,3930,0.11230000000000001,0.10400000000000001,0.121,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod3_TotalAdj,201027_England_ImperialCollegeLondon_SamplingPeriod3,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-09-15,2020-09-28,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,Primary estimate,159367,0.0438,0.0425,0.0451,True,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod3_18-24 ,201027_England_ImperialCollegeLondon_SamplingPeriod3,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-09-15,2020-09-28,Household and community samples,All,Adults (18-64 years),18.0,24.0,Age,18-24 years,8763,0.067,0.0625,0.0717,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-22,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod3_45-54 ,201027_England_ImperialCollegeLondon_SamplingPeriod3,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-09-15,2020-09-28,Household and community samples,All,Adults (18-64 years),45.0,54.0,Age,45-54 years,32403,0.0496,0.04650000000000001,0.0529,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-22,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod3_Male ,201027_England_ImperialCollegeLondon_SamplingPeriod3,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-09-15,2020-09-28,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,Male ,69421,0.0437,0.04190000000000001,0.045599999999999995,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-22,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod3_35-44  ,201027_England_ImperialCollegeLondon_SamplingPeriod3,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-09-15,2020-09-28,Household and community samples,All,Adults (18-64 years),35.0,44.0,Age,35-44 years,26687,0.046,0.042800000000000005,0.049400000000000006,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-22,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod3_65-74 ,201027_England_ImperialCollegeLondon_SamplingPeriod3,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-09-15,2020-09-28,Household and community samples,All,Seniors (65+ years),65.0,74.0,Age,65-74 years,26542,0.0225,0.0196,0.0256,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-22,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod3_SouthWest ,201027_England_ImperialCollegeLondon_SamplingPeriod3,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,South West,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-09-15,2020-09-28,Household and community samples,All,Multiple groups,18.0,,Geographical area,SouthWest region,15176,0.016200000000000003,0.0134,0.0194,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-22,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod3_TotalUnAdj,201027_England_ImperialCollegeLondon_SamplingPeriod3,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-09-15,2020-09-28,Household and community samples,All,Multiple groups,18.0,,Analysis,"Total participants, unadjusted",159367,0.0442,0.0432,0.0452,,,,,True,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod3_NorthEast ,201027_England_ImperialCollegeLondon_SamplingPeriod3,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,North East England,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-09-15,2020-09-28,Household and community samples,All,Multiple groups,18.0,,Geographical area,NorthEast region,6327,0.038700000000000005,0.0333,0.0446,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod3_Black,201027_England_ImperialCollegeLondon_SamplingPeriod3,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-09-15,2020-09-28,Household and community samples,All,Multiple groups,18.0,,Race,Black ethnicity,1304,0.1377,0.12560000000000002,0.1506,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod3_EastMidlands,201027_England_ImperialCollegeLondon_SamplingPeriod3,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,East Midlands,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-09-15,2020-09-28,Household and community samples,All,Multiple groups,18.0,,Geographical area,East Midlands,20469,0.0311,0.0273,0.0352,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-22,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod3_NorthWest ,201027_England_ImperialCollegeLondon_SamplingPeriod3,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,North West England,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-09-15,2020-09-28,Household and community samples,All,Multiple groups,18.0,,Geographical area,NorthWest region,18616,0.045,0.0415,0.0487,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod3_YorkshireandtheHumber ,201027_England_ImperialCollegeLondon_SamplingPeriod3,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Yorkshire and the Humber,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-09-15,2020-09-28,Household and community samples,All,Multiple groups,18.0,,Geographical area,Yorkshire and the Humber,10594,0.0337,0.0301,0.037700000000000004,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod3_25-34 ,201027_England_ImperialCollegeLondon_SamplingPeriod3,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-09-15,2020-09-28,Household and community samples,All,Adults (18-64 years),25.0,34.0,Age,25-34 years,20212,0.051500000000000004,0.0483,0.054900000000000004,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-22,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod3_Asian,201027_England_ImperialCollegeLondon_SamplingPeriod3,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-09-15,2020-09-28,Household and community samples,All,Multiple groups,18.0,,Race,Asian ethnicity,5518,0.09699999999999999,0.0906,0.1038,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod3_SouthEast ,201027_England_ImperialCollegeLondon_SamplingPeriod3,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,South East England,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-09-15,2020-09-28,Household and community samples,All,Multiple groups,18.0,,Geographical area,SouthEast region,34738,0.0301,0.027400000000000004,0.033,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-22,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod3_London ,201027_England_ImperialCollegeLondon_SamplingPeriod3,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Greater London,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-09-15,2020-09-28,Household and community samples,All,Multiple groups,18.0,,Geographical area,London,15227,0.09460000000000002,0.09029999999999999,0.09910000000000001,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-22,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod3_Mixed ,201027_England_ImperialCollegeLondon_SamplingPeriod3,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-09-15,2020-09-28,Household and community samples,All,Multiple groups,18.0,,Race,People with mixed ethnicity,1865,0.056900000000000006,0.0446,0.0716,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod3_WestMidlands ,201027_England_ImperialCollegeLondon_SamplingPeriod3,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,West Midlands,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-09-15,2020-09-28,Household and community samples,All,Multiple groups,18.0,,Geographical area,West Midlands,15046,0.0477,0.0437,0.0519,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-22,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod3_75+ ,201027_England_ImperialCollegeLondon_SamplingPeriod3,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-09-15,2020-09-28,Household and community samples,All,Seniors (65+ years),75.0,,Age,75+ years,11890,0.0201,0.017,0.0234,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-22,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod3_Other ,201027_England_ImperialCollegeLondon_SamplingPeriod3,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-09-15,2020-09-28,Household and community samples,All,Multiple groups,18.0,,Race,Other ethnicity,1393,0.0825,0.0677,0.09949999999999999,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod3_Female,201027_England_ImperialCollegeLondon_SamplingPeriod3,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-09-15,2020-09-28,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,Female ,89944,0.043899999999999995,0.0421,0.045700000000000005,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-22,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod3_EastofEngland ,201027_England_ImperialCollegeLondon_SamplingPeriod3,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,East of England,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-09-15,2020-09-28,Household and community samples,All,Multiple groups,18.0,,Geographical area,East of England,23174,0.0369,0.0334,0.04070000000000001,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-22,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod3_55-64 ,201027_England_ImperialCollegeLondon_SamplingPeriod3,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-09-15,2020-09-28,Household and community samples,All,Adults (18-64 years),55.0,64.0,Age,55-64 years,32870,0.0433,0.0401,0.0467,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-22,2022-07-16,Verified,ward_declining_2020,GBR
201027_England_ImperialCollegeLondon_SamplingPeriod3_White,201027_England_ImperialCollegeLondon_SamplingPeriod3,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",2020-10-27,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"Invitations were sent to named individuals randomly selected from the NHS patient list which includes anyone registered with a General Practitioner in England and covers almost the entire
population.",,2020-09-15,2020-09-28,Household and community samples,All,Multiple groups,18.0,,Race,White ethnicity,148227,0.0363,0.035,0.0376,,True,True,,,Simplified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,2021-01-21,2022-07-16,Verified,ward_declining_2020,GBR
201103_London_PHE_LTCStaff,201103_London_PHE,Seropositivity and risk factors for SARS-CoV-2 infection in staff working in care homes during the COVID-19 pandemic,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Greater London,London,Staff at one of four London care homes,,2020-06-03,2020-06-30,Health care workers and caregivers,All,Multiple groups,0.0,,Primary Estimate,Staff,327,0.47100000000000003,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),,0.9390000000000001,1.0,['High'],No,No,No,Yes,No,Yes,Yes,Yes,Unclear,Thomas Rowland,Public Health England,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2020.10.035,2021-01-23,2024-03-01,Verified,rowland_seropositivity_2020,GBR
201103_London_PHE_LTCStaff_40-59,201103_London_PHE,Seropositivity and risk factors for SARS-CoV-2 infection in staff working in care homes during the COVID-19 pandemic,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Greater London,London,Staff at one of four London care homes,,2020-06-03,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),40.0,59.0,Age,40-59,149,0.557,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),,0.9390000000000001,1.0,['High'],No,No,No,Yes,No,Yes,Yes,Yes,Unclear,Thomas Rowland,Public Health England,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2020.10.035,2021-02-27,2024-03-01,Verified,rowland_seropositivity_2020,GBR
201103_London_PHE_LTCStaff_60+,201103_London_PHE,Seropositivity and risk factors for SARS-CoV-2 infection in staff working in care homes during the COVID-19 pandemic,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Greater London,London,Staff at one of four London care homes,,2020-06-03,2020-06-30,Health care workers and caregivers,All,Seniors (65+ years),60.0,,Age,60+,36,0.444,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),,0.9390000000000001,1.0,['High'],No,No,No,Yes,No,Yes,Yes,Yes,Unclear,Thomas Rowland,Public Health England,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2020.10.035,2021-02-27,2024-03-01,Verified,rowland_seropositivity_2020,GBR
201103_London_PHE_LTCStaff_0-39,201103_London_PHE,Seropositivity and risk factors for SARS-CoV-2 infection in staff working in care homes during the COVID-19 pandemic,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Greater London,London,Staff at one of four London care homes,,2020-06-03,2020-06-30,Health care workers and caregivers,All,Multiple groups,0.0,39.0,Age,0-39,142,0.387,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),,0.9390000000000001,1.0,['High'],No,No,No,Yes,No,Yes,Yes,Yes,Unclear,Thomas Rowland,Public Health England,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2020.10.035,2021-02-27,2024-03-01,Verified,rowland_seropositivity_2020,GBR
201105_London_ImperialCollegeLondon,201105_London_ImperialCollegeLondon,Prevalence of SARS-CoV-2 infection in patients with chronic myeloidleukemia,2020-11-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,London, patients (pts) with chronic myeloid leukemia (CML); ,,2020-06-01,2020-07-27,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),18.0,92.0,Primary Estimate,,161,0.11199999999999999,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,Other,,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.948,,['High'],Yes,No,No,Yes,Yes,Unclear,Yes,No,Unclear,Simone Claudiani,Imperial College London,Not Unity-Aligned,http://dx.doi.org/10.1182/blood-2020-142454,2021-04-04,2022-07-16,Verified,claudiani_prevalence_2020,GBR
201109_UK_WatfordGeneralHospital_ACU,201109_UK_WatfordGeneralHospital_ACU,Prevalence of COVID-19 Among Typical Ambulatory Care Patients in a District General Hospital in the United Kingdom.,2020-11-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,Watford,"Patients admitted to the acute care unit with acute stable chest pain, acute shortness of breath with suspected pulmonary embolism, suspected acute coronary syndrome, national early warning score less than 2. ","Patients with COVID-19-like symptoms, e.g., fever, cough, sore throat, and loss of taste and smell, known positive Covid-19 PCR, abnormal chest X-ray, or waiting for Covid-19 swab.",2020-03-27,2020-06-08,Residual sera,All,Multiple groups,29.0,78.0,Primary Estimate,Acute care unit,443,0.0158,,,True,,,,True,Sequential,Not reported/ Unable to specify,,,,,,,,,['High'],No,No,No,Yes,Yes,Unclear,Yes,No,,Muhammad Arif,Watford General Hospital,Not Unity-Aligned,https://dx.doi.org/10.7759/cureus.11398,2021-01-23,2022-07-16,Verified,arif_prevalence_2020,GBR
201012_UnitedKingdom_RoyalBelfastHospitalForSickChildren,201012_UnitedKingdom_RoyalBelfastHospitalForSickChildren,Seroprevalence of SARS-CoV-2 antibodies in children: a prospective multicentre cohort study,2020-11-10,Journal Article (Peer-Reviewed),National,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,"Ireland, Wales, Scotland, England","Belfast, Cardiff, Glasgow, London, Manchester","Children of healthcare workers, aged between 2 years and 15
years at the time of recruitment, were eligible to participate. A
‘healthcare worker’ was defined as an NHS employee","Children were excluded if they were receiving antibiotics, had been admitted to hospital within the last 7 days, were
receiving oral immunosuppressive treatment or if ever diagnosed with a malignancy",2020-04-16,2020-07-03,Family of essential workers,All,Children and Youth (0-17 years),2.0,15.0,Primary Estimate,,992,0.069,0.054000000000000006,0.086,True,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,DiaSorin,Roche Diagnostics",,Multiple Types,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Thomas Waterfield,Royal Belfast Hospital for Sick Children,Not Unity-Aligned,https://dx.doi.org/10.1136/archdischild-2020-320558,2021-01-17,2024-03-01,Verified,waterfield_seroprevalence_2020,GBR
201012_UnitedKingdom_RoyalBelfastHospitalForSickChildren_age10+,201012_UnitedKingdom_RoyalBelfastHospitalForSickChildren,Seroprevalence of SARS-CoV-2 antibodies in children: a prospective multicentre cohort study,2020-11-10,Journal Article (Peer-Reviewed),National,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,"Ireland, Wales, Scotland, England","Belfast, Cardiff, Glasgow, London, Manchester","Children of healthcare workers, aged between 2 years and 15
years at the time of recruitment, were eligible to participate. A
‘healthcare worker’ was defined as an NHS employee","Children were excluded if they were receiving antibiotics, had been admitted to hospital within the last 7 days, were
receiving oral immunosuppressive treatment or if ever diagnosed with a malignancy",2020-04-16,2020-07-03,Family of essential workers,All,Children and Youth (0-17 years),10.0,15.0,Age,=>10,508,0.0709,,,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,DiaSorin,Roche Diagnostics",,Multiple Types,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Thomas Waterfield,Royal Belfast Hospital for Sick Children,Not Unity-Aligned,https://dx.doi.org/10.1136/archdischild-2020-320558,2021-03-06,2024-03-01,Verified,waterfield_seroprevalence_2020,GBR
201012_UnitedKingdom_RoyalBelfastHospitalForSickChildren_age<10,201012_UnitedKingdom_RoyalBelfastHospitalForSickChildren,Seroprevalence of SARS-CoV-2 antibodies in children: a prospective multicentre cohort study,2020-11-10,Journal Article (Peer-Reviewed),National,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,"Ireland, Wales, Scotland, England","Belfast, Cardiff, Glasgow, London, Manchester","Children of healthcare workers, aged between 2 years and 15
years at the time of recruitment, were eligible to participate. A
‘healthcare worker’ was defined as an NHS employee","Children were excluded if they were receiving antibiotics, had been admitted to hospital within the last 7 days, were
receiving oral immunosuppressive treatment or if ever diagnosed with a malignancy",2020-04-16,2020-07-03,Family of essential workers,All,Children and Youth (0-17 years),2.0,9.0,Age,<10,484,0.0661,,,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,DiaSorin,Roche Diagnostics",,Multiple Types,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Thomas Waterfield,Royal Belfast Hospital for Sick Children,Not Unity-Aligned,https://dx.doi.org/10.1136/archdischild-2020-320558,2021-03-06,2024-03-01,Verified,waterfield_seroprevalence_2020,GBR
201113_London_ImperialCollegeLondon_KidneyTransplantPatients,201113_London_ImperialCollegeLondon,Identification of Patient Characteristics Associated With SARS-CoV-2 Infection and Outcome in Kidney Transplant Patients Using Serological Screening,2020-11-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Greater London,London,"From a cohort of 1725 patients transplanted at our center between October 2005 and March 2020, we pro- spectively screened 855 consecutive kidney transplant patients who attended the transplant phlebotomy service at Imperial College Renal and Transplant Centre (ICTRC) London between June 1 to July 3, 2020, for SARS-CoV-2 antibodies. 822 of these patients had no previously confirmed infection with RT-PCR (subgroup analysis performed)

",,2020-06-01,2020-07-03,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),43.0,64.0,Primary Estimate,Overall,855,0.10400000000000001,0.085,0.126,True,,,,True,Sequential,"Abbott Architect SARS-CoV-2 IgG,Coronavirus Antibody Rapid Test","Abbott Laboratories,Fortress Diagnostics",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Michelle Willicombe,Imperial College London,Not Unity-Aligned,https://dx.doi.org/10.1097/TP.0000000000003526,2021-01-16,2024-03-01,Verified,willicombe_identification_2021,GBR
201116_Leicester_UniversityofLeicester_HCW,201116_Leicester_UniversityofLeicester,Demographic and occupational determinants of anti-SARS-CoV-2 IgG seropositivity in hospital staff,2020-11-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,East Midlands,Leicester,"All 16011 staff employed at University Hospitals of Leicester (UHL) were offered antibody testing. Included all staff members who provided a blood sample for anti-SARS-CoV-2 IgG testing between 29 May 2020 and 13 July 2020. This included doctors, nurses/midwives/HCAs, AHPs, pharmacy, administrative/executive/managerial, radiographers, healthcare scientist, estates and other staff in the hospital
","Those who were symptomatic or had a positive PCR assay for SARS-CoV-2 within the previous three weeks were advised not to volunteer to give a blood sample for antibody testing.

Of the 11769 who had antibody testing, 35 were excluded as antibody results were reported as invalid.

Of the 11734 who had valid antibody results, 1072 were excluded due to missing data (ethnicity, gender, job, specialty, population density).


",2020-05-29,2020-07-13,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,10662,0.1077,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.935,1.0,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Christopher Martin,University of Leicester,Not Unity-Aligned,https://dx.doi.org/10.1093/pubmed/fdaa199,2021-02-13,2024-03-01,Verified,martin_demographic_2020,GBR
201117_UK_ImmunisationAndCountermeasuresDivision_ChildrenOfHCW,201117_UK_ImmunisationAndCountermeasuresDivision,Secondary attack rate and family clustering of SARS-CoV-2 infection in children of healthcare workers with confirmed COVID-19,2020-11-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,"Belfast, Cardiff, Glasgow, London, Manchester","Study recruited children of healthcare workers in five UK cities from May 2020. For the London cohort, public health and National Health Service (NHS) hospital staff were informed of the study by email during May 2020 and, after parents provided written consent and completed a short questionnaire, a nasal swab and venous blood sample was taken",,2020-05-01,2020-05-31,Contacts of COVID patients,All,Children and Youth (0-17 years),,15.0,Primary Estimate,,44,0.36200000000000004,0.09,0.634,True,,,True,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,Shamez Ladhani,Immunisation and Countermeasures Division,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1737,2021-01-22,2024-03-01,Verified,ladhani_secondary_2020,GBR
201119_UK_QueensUniversityBelfast_adj,201119_UK_QueensUniversityBelfast,Kinetics and seroprevalence of SARS-CoV-2 antibodies in children,2020-11-19,Journal Article (Peer-Reviewed),National,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,,"Belfast, Cardiff, Glasgow, London, Manchester",Children between ages of 2-15,,2020-06-26,2020-08-15,Family of essential workers,All,Children and Youth (0-17 years),2.0,15.0,Primary Estimate,,849,0.0766,0.0605,0.09640000000000001,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Liaison SARS-CoV-2 S1/S2 IgG","Roche Diagnostics,DiaSorin",Multiple Types,,"['IgG', 'TotalAntibody']",Spike,,,,['Moderate'],Yes,No,Yes,No,Unclear,Unclear,Yes,No,Unclear,Cathal Roarty,Queens University Belfast,Not Unity-Aligned,https://dx.doi.org/10.1016/S1473-3099(20)30884-7,2021-01-23,2024-03-01,Verified,roarty_kinetics_2020,GBR
201124_Scotland_PublicHealthScotland_overall,201124_Scotland_PublicHealthScotland,Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic.,2020-11-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Residual blood samples, originally collected for other diagnostic purposes in primary care settings, were obtained from regional biochemistry laboratories in six participating regional health authority areas (‘National Health Service (NHS) Boards’): Greater Glasgow and Clyde, Grampian, Highland, Lanarkshire, Lothian and Tayside.",,2020-04-20,2020-06-21,Residual sera,All,Multiple groups,,,Primary Estimate,,4744,0.043,0.042,0.045,True,True,,,True,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,,,IgG,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,E Dickson,Public Health Scotland,Unity-Aligned,https://dx.doi.org/10.1016/j.puhe.2020.11.014,2021-02-06,2024-02-02,Verified,dickson_enhanced_2020,GBR
201126_UK_OfficeforNationalStatistics_Oct_Nov2020_England_genpop,201126_UK_OfficeforNationalStatistics_Nov2020_England,Coronavirus (COVID-19) Infection Survey: October_November2020,2020-11-26,Institutional Report,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2020-10-23,2020-11-19,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,,15834,0.087,0.081,0.094,True,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office of National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/december2020,2021-03-12,2022-07-16,Verified,steel_coronavirus_2020-2,GBR
201126_UK_OfficeforNationalStatistics_Oct_Nov2020 _Scotland_Genpop,201126_UK_OfficeforNationalStatistics_Oct_Nov2020 _Scotland,Coronavirus (COVID-19) Infection Survey: October_November2020,2020-11-26,Institutional Report,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,"Scotland
",,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2020-10-23,2020-11-19,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,,397,0.078,0.05,0.11699999999999999,True,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Moderate'],Yes,Yes,No,No,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office of National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/december2020,2021-03-12,2022-07-16,Verified,steel_coronavirus_2020-2,GBR
201126_UK_OfficeforNationalStatistics_Oct_Nov2020_NorthernIreland_Genpop,201126_UK_OfficeforNationalStatistics_Oct_Nov2020_NorthernIreland,Coronavirus (COVID-19) Infection Survey: October_November2020,2020-11-26,Institutional Report,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Northern Ireland,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2020-10-23,2020-11-19,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,,333,0.035,0.016,0.064,True,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Moderate'],Yes,Yes,No,No,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office of National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/december2020,2021-03-12,2022-07-16,Verified,steel_coronavirus_2020-2,GBR
201126_UK_OfficeforNationalStatistics_Oct_Nov2020_Wales_genpop,201126_UK_OfficeforNationalStatistics_Oct_Nov2020_Wales,Coronavirus (COVID-19) Infection Survey: October_November2020,2020-11-26,Institutional Report,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Wales,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2020-10-23,2020-11-19,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,,497,0.061,0.04,0.09,True,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Moderate'],,Yes,No,No,,Unclear,Yes,Yes,,Office for National Statistics,Office of National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/december2020,2021-03-12,2024-02-01,Verified,steel_coronavirus_2020-2,GBR
201130_Bristol_NorthBristolNHSTrust_hcw,201130_Bristol_NorthBristolNHSTrust,Seroprevalence of SARS-CoV-2 IgG in healthcare workers and other staff at North Bristol NHS Trust: a sociodemographic analysis,2020-11-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,"Bristol, South Gloucestershire, North Somerset",HCWs and support staff at North Bristol NHS Trust,,2020-01-15,2020-06-15,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,Healthcare workers and support staff ,6858,0.09300000000000001,,,True,,,,True,Self-referral,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",CLIA,,"['IgG', 'IgM']",,,,,['High'],Yes,No,Yes,Yes,Unclear,Unclear,No,No,No,Christopher Jones,North Bristol NHS Trust,Not Unity-Aligned,https://www.journalofinfection.com/article/S0163-4453(20)30755-6/fulltext,2021-01-31,2024-03-01,Verified,jones_sars-cov-2_2020,GBR
201207_London_King'sCollegeLondon_overall,201207_London_King’sCollegeLondon,"Indicators of COVID-19 status in a cohort study of university staff and post-graduate research students, including results from home antibody testing",2020-12-07,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,England,London,"eligible participants were current staff or postgraduate research (PGR) students residing in the UK (for
antibody testing).",,2020-06-01,2020-06-30,Non-essential workers and unemployed persons,All,Multiple groups,18.0,,Primary Estimate,Students and staff,1882,0.066,0.055999999999999994,0.078,True,,,,True,Convenience,COVID-19 antibody rapid test,SureScreen Diagnostics,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.89,1.0,['High'],No,No,Yes,Yes,No,Yes,Yes,No,No,Katrina Davis,King's College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.12.07.20245183v1.full,2021-01-29,2024-03-01,Verified,davis_indicators_2020,GBR
201211_London_RichmondPharmacologyLtd,201211_London_RichmondPharmacologyLtd,Why the SARS-CoV-2 antibody test results may be misleading: insights from a longitudinal analysis of COVID-19,2020-12-11,Preprint,Local,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,London,"Staff members, and visitors and trial participants participating in other clinical trials",,2020-03-19,2020-12-02,Multiple populations,All,Multiple groups,3.0,89.0,Primary Estimate,Overall IgG,6061,0.064,,,True,,,,True,Unclear,Not reported/ Unable to specify,,Other,Whole Blood,IgG,,,,,['High'],No,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,Jorg Taubel,Richmond Pharmacology Ltd,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.12.08.20245894v2,2021-02-04,2022-07-16,Verified,taubel_why_2020,GBR
201212_Europe_UniversityOfGlasgow_UK1,201212_Europe_UniversityOfGlasgow_UK1,SARS-Cov-2 viral and serological screening of staff in 31 European fertility units.,2020-12-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"all staff members recommencing work at the Fertility Partnership, including clinical and head office staf",,2020-04-15,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,311,0.0675,0.0446,0.10099999999999999,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,,Scott M Nelson,University of Glasgow,Not Unity-Aligned,https://dx.doi.org/10.1093/hropen/hoaa056,2021-06-07,2024-03-01,Verified,nelson_sars-cov-2_2020,GBR
201214_UnitedKingdom_UniversityOfSouthamptonSchoolOfMedicine,201214_UnitedKingdom_UniversityOfSouthamptonSchoolOfMedicine,"Investigations, actions and learning from an outbreak of SARS-CoV-2 infection among healthcare workers in the United Kingdom.",2020-12-14,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"These were obtained from the staff members who 
consented to the investigation (HCWs of NHS elective healthcare facility)",,2020-05-13,2020-05-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,135,0.13,,,True,,,,True,Convenience,Liason SARS-CoV-2 IgM test,DiaSorin,CLIA,Serum,IgG,Spike,,,,['High'],,No,No,No,,Yes,Yes,Yes,,Kordo Saeed,University of Southampton School of Medicine,Not Unity-Aligned,https://dx.doi.org/10.1177/1757177420976798,2021-08-04,2024-03-01,Unverified,saeedInvestigationsActionsLearning2020,GBR
201215_Leicester_UniversityHospitalsofLeicesterNHSTrust,201215_Leicester_UniversityHospitalsofLeicesterNHSTrust,Seroprevalence of SARS-CoV-2 IgG antibodies in the current COVID-19 pandemic amongst co-workers at a UK renal transplant centre,2020-12-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,Leicester ,All staff in the renal transplant department was offered testing for COVID-19 IgG antibodies from 29/05/2020 until the 03/08/2020,,2020-05-29,2020-08-03,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Overall estimate,200,0.12,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,,Validated by independent authors/third party/non-developers,0.927,1.0,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,John Black,University Hospitals of Leicester NHS Trust,Not Unity-Aligned,https://dx.doi.org/10.1111/tri.13791,2021-01-27,2024-03-01,Verified,black_seroprevalence_nodate,GBR
201221_London_PublicHealthEngland_overall_unadj,201221_London_PublicHealthEngland,Cross sectional investigation of a COVID-19 outbreak at a London Army barracks: Neutralising antibodies and virus isolation.,2020-12-21,Journal Article (Peer-Reviewed),Local,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,,London,"All individuals (soldiers, their family members and civilians at the Army barracks) who sign a consent form, are aged over 18 and do not suffer from bleeding disorders.",Individuals who do not provide a signed consent form and individuals who lack capacity to give consent.,2020-05-05,2020-05-05,Multiple populations,All,Adults (18-64 years),,,Primary Estimate,,193,0.13,,,True,,,,True,Convenience,Author designed (ELISA) -Unknown,,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,,,['High'],Yes,No,No,No,Yes,Unclear,Yes,No,No,Hannah Taylor,Public Health England,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanepe.2020.100015,2021-05-17,2022-07-16,Verified,taylor_cross_2021,GBR
201222_Newcastle_Newcastle-upon-TyneHospitalsNHSTrust,201222_Newcastle_Newcastle-upon-TyneHospitalsNHSTrust,"SARS-CoV-2 testing of 11,884 healthcare workers at an acute NHS hospital trust in England: a retrospective analysis",2020-12-22,Preprint,Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England ,Newcastle-Upon-Tyne,all HCWs irrespective of role and/or prior PCR testing,,2020-05-29,2020-07-06,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Overall,11103,0.084,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Aidan Hanrath,Newcastle-upon-Tyne Hospitals NHS Trust,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.12.22.20242362v1,2021-02-02,2024-03-01,Verified,hanrath_sars-cov-2_2020,GBR
201223_Oxford_OxfordUniversityHospitals_HCW_Spike,201223_Oxford_OxfordUniversityHospitals,Antibody status and incidence of SARS-CoV-2 infection in health care workers,2020-12-23,Journal Article (Peer-Reviewed),Local,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,,,"All symptomatic and asymptomatic staff working at four teaching hospitals in Oxfordshire, United Kingdom. ",,2020-04-23,2020-11-30,Health care workers and caregivers,All,Multiple groups,16.0,86.0,Primary Estimate,Spike IgG assay,12541,0.1008,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.991,0.99,['Moderate'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Sheila Lumley,Oxford University Hospitals,Not Unity-Aligned,https://dx.doi.org/10.1056/NEJMoa2034545,2021-01-23,2022-07-16,Verified,lumley_antibody_2020,GBR
201223_Scotland_PublicHealthScotland_1ResidualSera_Overall_PopAdj_TestAdj,201223_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 Dec 2020,2020-12-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2020-10-26,2020-11-29,Residual sera,All,Multiple groups,,,Primary Estimate,"Overall, test and pop adjusted",3638,0.06820000000000001,0.05740000000000001,0.07740000000000001,True,True,True,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-december-2020/,2021-10-24,2022-07-16,Verified,public_health_scotland_enhanced_2020,GBR
201223_Scotland_PublicHealthScotland_1ResidualSera_Male_Unadj,201223_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 Dec 2020,2020-12-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2020-10-26,2020-11-29,Residual sera,Male,Multiple groups,,,Sex/Gender,"Males, unadj",1802,0.081,,,,,,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-december-2020/,2021-10-24,2022-07-16,Verified,public_health_scotland_enhanced_2020,GBR
201223_Scotland_PublicHealthScotland_1ResidualSera_Age_00 - 19_Unadj,201223_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 Dec 2020,2020-12-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2020-10-26,2020-11-29,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Age,"00 - 19, unadj",939,0.099,,,,,,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-december-2020/,2021-10-24,2022-07-16,Verified,public_health_scotland_enhanced_2020,GBR
201223_Scotland_PublicHealthScotland_1ResidualSera_Age_70+_Unadj,201223_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 Dec 2020,2020-12-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2020-10-26,2020-11-29,Residual sera,All,Seniors (65+ years),70.0,,Age,"70+, unadj",523,0.0707,,,,,,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-december-2020/,2021-10-24,2022-07-16,Verified,public_health_scotland_enhanced_2020,GBR
201223_Scotland_PublicHealthScotland_1ResidualSera_Overall_Unadj,201223_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 Dec 2020,2020-12-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2020-10-26,2020-11-29,Residual sera,All,Multiple groups,,,Analysis,"Overall, unadj",3638,0.0723,,,,,,,True,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-december-2020/,2021-10-24,2022-07-16,Verified,public_health_scotland_enhanced_2020,GBR
201223_Scotland_PublicHealthScotland_1ResidualSera_Age_20 - 39_Unadj,201223_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 Dec 2020,2020-12-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2020-10-26,2020-11-29,Residual sera,All,Adults (18-64 years),20.0,39.0,Age,"20 - 39, unadj",875,0.06860000000000001,,,,,,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-december-2020/,2021-10-24,2022-07-16,Verified,public_health_scotland_enhanced_2020,GBR
201223_Scotland_PublicHealthScotland_1ResidualSera_Age_60 - 69_Unadj,201223_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 Dec 2020,2020-12-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2020-10-26,2020-11-29,Residual sera,All,Seniors (65+ years),60.0,69.0,Age,"60 - 69, unadj",509,0.055,,,,,,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-december-2020/,2021-10-24,2022-07-16,Verified,public_health_scotland_enhanced_2020,GBR
201223_Scotland_PublicHealthScotland_1ResidualSera_Female_Unadj,201223_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 Dec 2020,2020-12-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2020-10-26,2020-11-29,Residual sera,Female,Multiple groups,,,Sex/Gender,"Females, unadj",1836,0.0637,,,,,,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-december-2020/,2021-10-24,2022-07-16,Verified,public_health_scotland_enhanced_2020,GBR
201223_Scotland_PublicHealthScotland_1ResidualSera_Age_40 - 59_Unadj,201223_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 Dec 2020,2020-12-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2020-10-26,2020-11-29,Residual sera,All,Adults (18-64 years),40.0,59.0,Age,"40 - 59, unadj",792,0.056799999999999996,,,,,,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-december-2020/,2021-10-24,2022-07-16,Verified,public_health_scotland_enhanced_2020,GBR
201223_Scotland_PublicHealthScotland_2BloodDonors_Overall_PopAdj_TestAdj,201223_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 Dec 2020,2020-12-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2020-10-26,2020-11-29,Blood donors,All,Multiple groups,,,Primary Estimate,"Overall, test and pop adjusted",2499,0.0626,0.0455,0.0889,True,True,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-december-2020/,2021-10-24,2023-08-15,Verified,public_health_scotland_enhanced_2020,GBR
201223_Scotland_PublicHealthScotland_2BloodDonors_Age_00-39_Unadj,201223_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 Dec 2020,2020-12-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2020-10-26,2020-11-29,Blood donors,All,Multiple groups,0.0,39.0,Age,"00 - 39, unadj",806,0.045899999999999996,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-december-2020/,2021-10-24,2024-03-01,Verified,public_health_scotland_enhanced_2020,GBR
201223_Scotland_PublicHealthScotland_2BloodDonors_Male_Unadj,201223_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 Dec 2020,2020-12-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2020-10-26,2020-11-29,Blood donors,Male,Multiple groups,,,Sex/Gender,"Males, unadj",1094,0.0402,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-december-2020/,2021-10-24,2024-03-01,Verified,public_health_scotland_enhanced_2020,GBR
201223_Scotland_PublicHealthScotland_2BloodDonors_Age_60+_Unadj,201223_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 Dec 2020,2020-12-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2020-10-26,2020-11-29,Blood donors,All,Seniors (65+ years),60.0,,Age,"60+, unadj",604,0.0348,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-december-2020/,2021-10-24,2024-03-01,Verified,public_health_scotland_enhanced_2020,GBR
201223_Scotland_PublicHealthScotland_2BloodDonors_Female_Unadj,201223_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 Dec 2020,2020-12-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2020-10-26,2020-11-29,Blood donors,Female,Multiple groups,,,Sex/Gender,"Females, unadj",1405,0.042699999999999995,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-december-2020/,2021-10-24,2024-03-01,Verified,public_health_scotland_enhanced_2020,GBR
201223_Scotland_PublicHealthScotland_2BloodDonors_Age_40-59_Unadj,201223_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 Dec 2020,2020-12-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2020-10-26,2020-11-29,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,"40 - 59, unadj",1089,0.0422,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-december-2020/,2021-10-24,2024-03-01,Verified,public_health_scotland_enhanced_2020,GBR
201223_Scotland_PublicHealthScotland_2BloodDonors_Overall_Unadj,201223_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 Dec 2020,2020-12-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2020-10-26,2020-11-29,Blood donors,All,Multiple groups,,,Analysis,Overall Unadj,2499,0.041600000000000005,,,,,,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-december-2020/,2021-10-24,2024-03-01,Verified,public_health_scotland_enhanced_2020,GBR
201226_UK_OfficeforNationalStatistics_Nov_Dec2020_England_genpop,201226_UK_OfficeforNationalStatistics_Nov_Dec2020_England,Coronavirus (COVID-19) Infection Survey: November_December 2020,2020-12-24,Institutional Report,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2020-11-20,2020-12-17,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,,21684,0.10099999999999999,0.096,0.106,True,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office of National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/december2020,2021-03-12,2022-07-16,Verified,steel_coronavirus_2020-2,GBR
201226_UK_OfficeforNationalStatistics_Nov_Dec2020_NortherIreland_genpop,201226_UK_OfficeforNationalStatistics_Nov_Dec2020_NorthernIreland,Coronavirus (COVID-19) Infection Survey: November_December 2020,2020-12-24,Institutional Report,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Northern Ireland,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2020-11-20,2020-12-17,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,,248,0.037000000000000005,0.017,0.071,True,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Moderate'],Yes,Yes,No,No,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office of National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/december2020,2021-03-12,2022-07-16,Verified,steel_coronavirus_2020-2,GBR
201226_UK_OfficeforNationalStatistics_Nov_Dec2020_Scotland_genpop,201226_UK_OfficeforNationalStatistics_Nov_Dec2020_Scotland,Coronavirus (COVID-19) Infection Survey: November_December 2020,2020-12-24,Institutional Report,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2020-11-20,2020-12-17,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,,1034,0.059000000000000004,0.044000000000000004,0.076,True,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office of National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/december2020,2021-03-12,2022-07-16,Verified,steel_coronavirus_2020-2,GBR
201226_UK_OfficeforNationalStatistics_Nov_Dec2020_Wales_genpop,201226_UK_OfficeforNationalStatistics_Nov_Dec2020_Wales,Coronavirus (COVID-19) Infection Survey: November_December 2020,2020-12-24,Institutional Report,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Wales,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2020-11-20,2020-12-17,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,,631,0.07200000000000001,0.051,0.099,True,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Moderate'],,Yes,Yes,No,,Unclear,Yes,Yes,,Office for National Statistics,Office of National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/december2020,2021-03-12,2022-07-16,Verified,steel_coronavirus_2020-2,GBR
201226_Scotland_UniversityofGlasgow_overall_unaj,201226_Scotland_UniversityofGlasgow,Severe Acute Respiratory Syndrome Coronavirus 2 Serosurveillance in a Patient Population Reveals Differences in Virus Exposure and Antibody-Mediated Immunity According to Host Demography and Healthcare Setting,2020-12-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Scotland,Greater Glasgow area,Random residual biochemistry serum samples from primary (general practices) and secondary (hospitals) healthcare settings were collected by the NHSGGC Biorepository between 16 March and 24 May 2020.,,2020-03-16,2020-05-24,Residual sera,All,Multiple groups,18.0,,Analysis,Overall Unadjusted using ELISA assays,6635,0.0781,0.0717,0.0848,True,,,,True,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9531000000000001,0.9720000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Ellen C Hughes,University of Glasgow,Unity-Aligned,http://dx.doi.org/10.1093/infdis/jiaa788,2021-05-23,2022-07-16,Verified,hughes_severe_2021,GBR
201226_Scotland_UniversityofGlasgow_female_unadj,201226_Scotland_UniversityofGlasgow,Severe Acute Respiratory Syndrome Coronavirus 2 Serosurveillance in a Patient Population Reveals Differences in Virus Exposure and Antibody-Mediated Immunity According to Host Demography and Healthcare Setting,2020-12-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Scotland,Greater Glasgow area,Random residual biochemistry serum samples from primary (general practices) and secondary (hospitals) healthcare settings were collected by the NHSGGC Biorepository between 16 March and 24 May 2020.,,2020-03-16,2020-05-24,Residual sera,Female,Multiple groups,18.0,,Sex/Gender,"Female, unadjusted, ELISA assays",3543,0.0672,0.0592,0.0759,,,,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9531000000000001,0.9720000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Ellen C Hughes,University of Glasgow,Unity-Aligned,http://dx.doi.org/10.1093/infdis/jiaa788,2021-05-23,2022-07-16,Verified,hughes_severe_2021,GBR
201226_Scotland_UniversityofGlasgow_age75+_unadj ,201226_Scotland_UniversityofGlasgow,Severe Acute Respiratory Syndrome Coronavirus 2 Serosurveillance in a Patient Population Reveals Differences in Virus Exposure and Antibody-Mediated Immunity According to Host Demography and Healthcare Setting,2020-12-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Scotland,Greater Glasgow area,Random residual biochemistry serum samples from primary (general practices) and secondary (hospitals) healthcare settings were collected by the NHSGGC Biorepository between 16 March and 24 May 2020.,,2020-03-16,2020-05-24,Residual sera,All,Seniors (65+ years),75.0,,Age,"Age 75+ unadjusted, ELISA assays",1527,0.0884,0.0746,0.1038,,,,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9531000000000001,0.9720000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Ellen C Hughes,University of Glasgow,Unity-Aligned,http://dx.doi.org/10.1093/infdis/jiaa788,2021-06-14,2022-07-16,Verified,hughes_severe_2021,GBR
201226_Scotland_UniversityofGlasgow_age18-44_unadj ,201226_Scotland_UniversityofGlasgow,Severe Acute Respiratory Syndrome Coronavirus 2 Serosurveillance in a Patient Population Reveals Differences in Virus Exposure and Antibody-Mediated Immunity According to Host Demography and Healthcare Setting,2020-12-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Scotland,Greater Glasgow area,Random residual biochemistry serum samples from primary (general practices) and secondary (hospitals) healthcare settings were collected by the NHSGGC Biorepository between 16 March and 24 May 2020.,,2020-03-16,2020-05-24,Residual sera,All,Adults (18-64 years),18.0,44.0,Age,"Age 18-44 unadjusted, ELISA assays",1662,0.050499999999999996,0.0405,0.0622,,,,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9531000000000001,0.9720000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Ellen C Hughes,University of Glasgow,Unity-Aligned,http://dx.doi.org/10.1093/infdis/jiaa788,2021-06-14,2022-07-16,Verified,hughes_severe_2021,GBR
201226_Scotland_UniversityofGlasgow_age65-74_unadj,201226_Scotland_UniversityofGlasgow,Severe Acute Respiratory Syndrome Coronavirus 2 Serosurveillance in a Patient Population Reveals Differences in Virus Exposure and Antibody-Mediated Immunity According to Host Demography and Healthcare Setting,2020-12-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Scotland,Greater Glasgow area,Random residual biochemistry serum samples from primary (general practices) and secondary (hospitals) healthcare settings were collected by the NHSGGC Biorepository between 16 March and 24 May 2020.,,2020-03-16,2020-05-24,Residual sera,All,Seniors (65+ years),65.0,74.0,Age,"Age 65-74 unadjusted, ELISA assays",1244,0.0748,0.0608,0.0908,,,,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9531000000000001,0.9720000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Ellen C Hughes,University of Glasgow,Unity-Aligned,http://dx.doi.org/10.1093/infdis/jiaa788,2021-06-14,2022-07-16,Verified,hughes_severe_2021,GBR
201226_Scotland_UniversityofGlasgow_overall_adj ,201226_Scotland_UniversityofGlasgow,Severe Acute Respiratory Syndrome Coronavirus 2 Serosurveillance in a Patient Population Reveals Differences in Virus Exposure and Antibody-Mediated Immunity According to Host Demography and Healthcare Setting,2020-12-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Scotland,Greater Glasgow area,Random residual biochemistry serum samples from primary (general practices) and secondary (hospitals) healthcare settings were collected by the NHSGGC Biorepository between 16 March and 24 May 2020.,,2020-03-16,2020-05-24,Residual sera,All,Multiple groups,18.0,,Primary Estimate,Overall Adjusted for test and population using ELISA assays,6635,0.0529,0.0013000000000000002,0.151,,True,True,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9531000000000001,0.9720000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Ellen C Hughes,University of Glasgow,Unity-Aligned,http://dx.doi.org/10.1093/infdis/jiaa788,2021-06-14,2022-07-16,Verified,hughes_severe_2021,GBR
201226_Scotland_UniversityofGlasgow_male_unadj,201226_Scotland_UniversityofGlasgow,Severe Acute Respiratory Syndrome Coronavirus 2 Serosurveillance in a Patient Population Reveals Differences in Virus Exposure and Antibody-Mediated Immunity According to Host Demography and Healthcare Setting,2020-12-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Scotland,Greater Glasgow area,Random residual biochemistry serum samples from primary (general practices) and secondary (hospitals) healthcare settings were collected by the NHSGGC Biorepository between 16 March and 24 May 2020.,,2020-03-16,2020-05-24,Residual sera,Male,Multiple groups,18.0,,Sex/Gender,"Male, unadjusted, ELISA assays",3092,0.0906,0.08070000000000001,0.1012,,,,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9531000000000001,0.9720000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Ellen C Hughes,University of Glasgow,Unity-Aligned,http://dx.doi.org/10.1093/infdis/jiaa788,2021-05-23,2022-07-16,Verified,hughes_severe_2021,GBR
201226_Scotland_UniversityofGlasgow_age45-64_unadj ,201226_Scotland_UniversityofGlasgow,Severe Acute Respiratory Syndrome Coronavirus 2 Serosurveillance in a Patient Population Reveals Differences in Virus Exposure and Antibody-Mediated Immunity According to Host Demography and Healthcare Setting,2020-12-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Scotland,Greater Glasgow area,Random residual biochemistry serum samples from primary (general practices) and secondary (hospitals) healthcare settings were collected by the NHSGGC Biorepository between 16 March and 24 May 2020.,,2020-03-16,2020-05-24,Residual sera,All,Adults (18-64 years),45.0,64.0,Age,"Age 45-64 unadjusted, ELISA assays",2202,0.0936,0.0817,0.10650000000000001,,,,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9531000000000001,0.9720000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Ellen C Hughes,University of Glasgow,Unity-Aligned,http://dx.doi.org/10.1093/infdis/jiaa788,2021-06-14,2022-07-16,Verified,hughes_severe_2021,GBR
201226_Scotland_UniversityofGlasgow_Neutralization_unadj,201226_Scotland_UniversityofGlasgow,Severe Acute Respiratory Syndrome Coronavirus 2 Serosurveillance in a Patient Population Reveals Differences in Virus Exposure and Antibody-Mediated Immunity According to Host Demography and Healthcare Setting,2020-12-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Scotland,Greater Glasgow area,Random residual biochemistry serum samples from primary (general practices) and secondary (hospitals) healthcare settings were collected by the NHSGGC Biorepository between 16 March and 24 May 2020.,,2020-03-24,2020-04-24,Residual sera,All,Multiple groups,18.0,,Test used,Neutralizaton assay,1974,0.0679,,,,,,,,Simplified probability,Author designed (Neutralization Assay),,Neutralization,Serum,Neutralizing,,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Ellen C Hughes,University of Glasgow,Unity-Aligned,http://dx.doi.org/10.1093/infdis/jiaa788,2021-06-14,2022-07-16,Verified,hughes_severe_2021,GBR
210101_London_LewishamGreenwichNHSTrust_HCW_Overall,210101_London_LewishamGreenwichNHSTrust,Prevalence and socio-demographic factors of SARS-CoV-2 antibody in multi-ethnic healthcare workers,2021-01-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,"Lewisham, Greenwich ",Employees of Lewisham and greenwich NHS Trust ,,2020-05-27,2020-06-24,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,healthcare workers,6212,0.26,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.99,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Mehool Patel,Lewisham and greenwich NHS Trust ,Not Unity-Aligned,https://dx.doi.org/10.7861/clinmed.2020-0619,2021-03-01,2024-03-01,Verified,patel_prevalence_2021,GBR
210106_UnitedKingdom_OxfordUniversity,210106_UnitedKingdom_OxfordUniversity,"The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers",2021-01-06,Journal Article (Peer-Reviewed),National,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,,,"Oxford University Hospitals (OUH) offers both symptomatic and asymptomatic SARS-CoV-2 testing programs to staff at its 4 teaching hospitals in Oxfordshire, UK.",,2020-04-23,2020-10-20,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,3217,0.16,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,ELISA,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Sheila F Lumley,Oxford University,Not Unity-Aligned,https://academic.oup.com/cid/article/73/3/e699/6064824,2021-10-14,2024-03-01,Unverified,lumleyDurationDynamicsDeterminants2021,GBR
210115_UK_UKBiobank_Overall,210115_UK_UKBiobank,UK Biobank SARS-CoV-2 Serology Study,2021-01-15,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,"England, Scotland, Wales",,,,2020-05-27,2020-12-04,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,18893,0.08992699999999999,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,UK Biobank,UK Biobank,Not Unity-Aligned,https://www.ukbiobank.ac.uk/media/x0nd5sul/ukb_serologystudy_report_revised_6months_jan21.pdf,2021-03-19,2022-07-16,Unverified,uk_biobank_uk_2021,GBR
210115_UK_UKBiobank_Region_NorthEast ,210115_UK_UKBiobank,UK Biobank SARS-CoV-2 Serology Study,2021-01-15,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,England,,,,2020-05-27,2020-12-04,Household and community samples,All,Multiple groups,18.0,,Geographical area,North East ,780,0.07200000000000001,0.055,0.092,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,UK Biobank,UK Biobank,Not Unity-Aligned,https://www.ukbiobank.ac.uk/media/x0nd5sul/ukb_serologystudy_report_revised_6months_jan21.pdf,2021-03-19,2022-07-16,Unverified,uk_biobank_uk_2021,GBR
210115_UK_UKBiobank_Region_London ,210115_UK_UKBiobank,UK Biobank SARS-CoV-2 Serology Study,2021-01-15,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,England,,,,2020-05-27,2020-12-04,Household and community samples,All,Multiple groups,18.0,,Geographical area,London ,5633,0.12400000000000001,0.115,0.133,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,UK Biobank,UK Biobank,Not Unity-Aligned,https://www.ukbiobank.ac.uk/media/x0nd5sul/ukb_serologystudy_report_revised_6months_jan21.pdf,2021-03-19,2022-07-16,Unverified,uk_biobank_uk_2021,GBR
210115_UK_UKBiobank_Age_60-69,210115_UK_UKBiobank,UK Biobank SARS-CoV-2 Serology Study,2021-01-15,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,"England, Scotland, Wales",,,,2020-05-27,2020-12-04,Household and community samples,All,Adults (18-64 years),18.0,,Age,60-69,3882,0.078,0.07,0.087,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,UK Biobank,UK Biobank,Not Unity-Aligned,https://www.ukbiobank.ac.uk/media/x0nd5sul/ukb_serologystudy_report_revised_6months_jan21.pdf,2021-03-19,2022-07-16,Unverified,uk_biobank_uk_2021,GBR
210115_UK_UKBiobank_White,210115_UK_UKBiobank,UK Biobank SARS-CoV-2 Serology Study,2021-01-15,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,"England, Scotland, Wales",,,,2020-05-27,2020-12-04,Household and community samples,All,Multiple groups,18.0,,Race,White,16479,0.084,0.081,0.08900000000000001,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,UK Biobank,UK Biobank,Not Unity-Aligned,https://www.ukbiobank.ac.uk/media/x0nd5sul/ukb_serologystudy_report_revised_6months_jan21.pdf,2021-03-19,2022-07-16,Unverified,uk_biobank_uk_2021,GBR
210115_UK_UKBiobank_Region_NorthWest ,210115_UK_UKBiobank,UK Biobank SARS-CoV-2 Serology Study,2021-01-15,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,England,,,,2020-05-27,2020-12-04,Household and community samples,All,Multiple groups,18.0,,Geographical area,North West ,2037,0.094,0.08199999999999999,0.10800000000000001,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,UK Biobank,UK Biobank,Not Unity-Aligned,https://www.ukbiobank.ac.uk/media/x0nd5sul/ukb_serologystudy_report_revised_6months_jan21.pdf,2021-03-19,2022-07-16,Unverified,uk_biobank_uk_2021,GBR
210115_UK_UKBiobank_Other,210115_UK_UKBiobank,UK Biobank SARS-CoV-2 Serology Study,2021-01-15,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,"England, Scotland, Wales",,,,2020-05-27,2020-12-04,Household and community samples,All,Multiple groups,18.0,,Race,Other,523,0.105,0.08,0.135,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,UK Biobank,UK Biobank,Not Unity-Aligned,https://www.ukbiobank.ac.uk/media/x0nd5sul/ukb_serologystudy_report_revised_6months_jan21.pdf,2021-03-19,2022-07-16,Unverified,uk_biobank_uk_2021,GBR
210115_UK_UKBiobank_Chinese,210115_UK_UKBiobank,UK Biobank SARS-CoV-2 Serology Study,2021-01-15,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,"England, Scotland, Wales",,,,2020-05-27,2020-12-04,Household and community samples,All,Multiple groups,18.0,,Race,Chinese,146,0.075,0.038,0.131,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,UK Biobank,UK Biobank,Not Unity-Aligned,https://www.ukbiobank.ac.uk/media/x0nd5sul/ukb_serologystudy_report_revised_6months_jan21.pdf,2021-03-19,2022-07-16,Unverified,uk_biobank_uk_2021,GBR
210115_UK_UKBiobank_Age_50-59,210115_UK_UKBiobank,UK Biobank SARS-CoV-2 Serology Study,2021-01-15,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,"England, Scotland, Wales",,,,2020-05-27,2020-12-04,Household and community samples,All,Adults (18-64 years),18.0,,Age,50-59,3722,0.096,0.09,0.106,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,UK Biobank,UK Biobank,Not Unity-Aligned,https://www.ukbiobank.ac.uk/media/x0nd5sul/ukb_serologystudy_report_revised_6months_jan21.pdf,2021-03-19,2022-07-16,Unverified,uk_biobank_uk_2021,GBR
210115_UK_UKBiobank_Region_Wales,210115_UK_UKBiobank,UK Biobank SARS-CoV-2 Serology Study,2021-01-15,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,Wales,,,,2020-05-27,2020-12-04,Household and community samples,All,Multiple groups,18.0,,Geographical area,Wales,742,0.059000000000000004,0.043,0.079,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,UK Biobank,UK Biobank,Not Unity-Aligned,https://www.ukbiobank.ac.uk/media/x0nd5sul/ukb_serologystudy_report_revised_6months_jan21.pdf,2021-03-19,2022-07-16,Unverified,uk_biobank_uk_2021,GBR
210115_UK_UKBiobank_Region_Scotland ,210115_UK_UKBiobank,UK Biobank SARS-CoV-2 Serology Study,2021-01-15,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,Scotland ,,,,2020-05-27,2020-12-04,Household and community samples,All,Multiple groups,18.0,,Geographical area,Scotland ,1168,0.055,0.042,0.069,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,UK Biobank,UK Biobank,Not Unity-Aligned,https://www.ukbiobank.ac.uk/media/x0nd5sul/ukb_serologystudy_report_revised_6months_jan21.pdf,2021-03-19,2022-07-16,Unverified,uk_biobank_uk_2021,GBR
210115_UK_UKBiobank_Black,210115_UK_UKBiobank,UK Biobank SARS-CoV-2 Serology Study,2021-01-15,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,"England, Scotland, Wales",,,,2020-05-27,2020-12-04,Household and community samples,All,Multiple groups,18.0,,Race,Black,466,0.163,0.131,0.2,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,UK Biobank,UK Biobank,Not Unity-Aligned,https://www.ukbiobank.ac.uk/media/x0nd5sul/ukb_serologystudy_report_revised_6months_jan21.pdf,2021-03-19,2022-07-16,Unverified,uk_biobank_uk_2021,GBR
210115_UK_UKBiobank_Women,210115_UK_UKBiobank,UK Biobank SARS-CoV-2 Serology Study,2021-01-15,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,"England, Scotland, Wales",,,,2020-05-27,2020-12-04,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,Women,10673,0.092,0.086,0.09699999999999999,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,UK Biobank,UK Biobank,Not Unity-Aligned,https://www.ukbiobank.ac.uk/media/x0nd5sul/ukb_serologystudy_report_revised_6months_jan21.pdf,2021-03-19,2022-07-16,Unverified,uk_biobank_uk_2021,GBR
210115_UK_UKBiobank_Age_30-39,210115_UK_UKBiobank,UK Biobank SARS-CoV-2 Serology Study,2021-01-15,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,"England, Scotland, Wales",,,,2020-05-27,2020-12-04,Household and community samples,All,Adults (18-64 years),18.0,,Age,30-39,2898,0.099,0.08800000000000001,0.11,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,UK Biobank,UK Biobank,Not Unity-Aligned,https://www.ukbiobank.ac.uk/media/x0nd5sul/ukb_serologystudy_report_revised_6months_jan21.pdf,2021-03-19,2022-07-16,Unverified,uk_biobank_uk_2021,GBR
210115_UK_UKBiobank_Region_SouthEast ,210115_UK_UKBiobank,UK Biobank SARS-CoV-2 Serology Study,2021-01-15,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,England,,,,2020-05-27,2020-12-04,Household and community samples,All,Multiple groups,18.0,,Geographical area,South East ,2441,0.075,0.065,0.087,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,UK Biobank,UK Biobank,Not Unity-Aligned,https://www.ukbiobank.ac.uk/media/x0nd5sul/ukb_serologystudy_report_revised_6months_jan21.pdf,2021-03-19,2022-07-16,Unverified,uk_biobank_uk_2021,GBR
210115_UK_UKBiobank_Mixed,210115_UK_UKBiobank,UK Biobank SARS-CoV-2 Serology Study,2021-01-15,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,"England, Scotland, Wales",,,,2020-05-27,2020-12-04,Household and community samples,All,Multiple groups,18.0,,Race,Mixed,708,0.11199999999999999,0.08900000000000001,0.13699999999999998,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,UK Biobank,UK Biobank,Not Unity-Aligned,https://www.ukbiobank.ac.uk/media/x0nd5sul/ukb_serologystudy_report_revised_6months_jan21.pdf,2021-03-19,2022-07-16,Unverified,uk_biobank_uk_2021,GBR
210115_UK_UKBiobank_Age_40-49,210115_UK_UKBiobank,UK Biobank SARS-CoV-2 Serology Study,2021-01-15,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,"England, Scotland, Wales",,,,2020-05-27,2020-12-04,Household and community samples,All,Adults (18-64 years),18.0,,Age,40-49,2343,0.08900000000000001,0.078,0.10099999999999999,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,UK Biobank,UK Biobank,Not Unity-Aligned,https://www.ukbiobank.ac.uk/media/x0nd5sul/ukb_serologystudy_report_revised_6months_jan21.pdf,2021-03-19,2022-07-16,Unverified,uk_biobank_uk_2021,GBR
210115_UK_UKBiobank_Men,210115_UK_UKBiobank,UK Biobank SARS-CoV-2 Serology Study,2021-01-15,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,"England, Scotland, Wales",,,,2020-05-27,2020-12-04,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,Men,8220,0.08800000000000001,0.08199999999999999,0.094,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,UK Biobank,UK Biobank,Not Unity-Aligned,https://www.ukbiobank.ac.uk/media/x0nd5sul/ukb_serologystudy_report_revised_6months_jan21.pdf,2021-03-19,2022-07-16,Unverified,uk_biobank_uk_2021,GBR
210115_UK_UKBiobank_South Asian ,210115_UK_UKBiobank,UK Biobank SARS-CoV-2 Serology Study,2021-01-15,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,"England, Scotland, Wales",,,,2020-05-27,2020-12-04,Household and community samples,All,Multiple groups,18.0,,Race,South Asian ,532,0.139,0.111,0.171,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,UK Biobank,UK Biobank,Not Unity-Aligned,https://www.ukbiobank.ac.uk/media/x0nd5sul/ukb_serologystudy_report_revised_6months_jan21.pdf,2021-03-19,2022-07-16,Unverified,uk_biobank_uk_2021,GBR
210115_UK_UKBiobank_Region_SouthWest ,210115_UK_UKBiobank,UK Biobank SARS-CoV-2 Serology Study,2021-01-15,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,England,,,,2020-05-27,2020-12-04,Household and community samples,All,Multiple groups,18.0,,Geographical area,South West ,1302,0.057999999999999996,0.046,0.07200000000000001,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,UK Biobank,UK Biobank,Not Unity-Aligned,https://www.ukbiobank.ac.uk/media/x0nd5sul/ukb_serologystudy_report_revised_6months_jan21.pdf,2021-03-19,2022-07-16,Unverified,uk_biobank_uk_2021,GBR
210115_UK_UKBiobank_Age_70+,210115_UK_UKBiobank,UK Biobank SARS-CoV-2 Serology Study,2021-01-15,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,"England, Scotland, Wales",,,,2020-05-27,2020-12-04,Household and community samples,All,Seniors (65+ years),18.0,,Age,70+,3998,0.067,0.059000000000000004,0.075,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,UK Biobank,UK Biobank,Not Unity-Aligned,https://www.ukbiobank.ac.uk/media/x0nd5sul/ukb_serologystudy_report_revised_6months_jan21.pdf,2021-03-19,2022-07-16,Unverified,uk_biobank_uk_2021,GBR
210115_UK_UKBiobank_Age_<30,210115_UK_UKBiobank,UK Biobank SARS-CoV-2 Serology Study,2021-01-15,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,"England, Scotland, Wales",,,,2020-05-27,2020-12-04,Household and community samples,All,Multiple groups,18.0,,Age,<30,2050,0.135,0.12,0.15,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,UK Biobank,UK Biobank,Not Unity-Aligned,https://www.ukbiobank.ac.uk/media/x0nd5sul/ukb_serologystudy_report_revised_6months_jan21.pdf,2021-03-19,2022-07-16,Unverified,uk_biobank_uk_2021,GBR
210115_UK_UKBiobank_Region_WestMidlands ,210115_UK_UKBiobank,UK Biobank SARS-CoV-2 Serology Study,2021-01-15,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,England,,,,2020-05-27,2020-12-04,Household and community samples,All,Multiple groups,18.0,,Geographical area,West Midlands ,1301,0.09699999999999999,0.081,0.114,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,UK Biobank,UK Biobank,Not Unity-Aligned,https://www.ukbiobank.ac.uk/media/x0nd5sul/ukb_serologystudy_report_revised_6months_jan21.pdf,2021-03-19,2022-07-16,Unverified,uk_biobank_uk_2021,GBR
210115_UK_UKBiobank_Region_EastEngland ,210115_UK_UKBiobank,UK Biobank SARS-CoV-2 Serology Study,2021-01-15,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,England,,,,2020-05-27,2020-12-04,Household and community samples,All,Multiple groups,18.0,,Geographical area,East of England ,889,0.07,0.054000000000000006,0.08900000000000001,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,UK Biobank,UK Biobank,Not Unity-Aligned,https://www.ukbiobank.ac.uk/media/x0nd5sul/ukb_serologystudy_report_revised_6months_jan21.pdf,2021-03-19,2022-07-16,Unverified,uk_biobank_uk_2021,GBR
210115_UK_UKBiobank_Region_EastMidlands ,210115_UK_UKBiobank,UK Biobank SARS-CoV-2 Serology Study,2021-01-15,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,England,,,,2020-05-27,2020-12-04,Household and community samples,All,Multiple groups,18.0,,Geographical area,East Midlands ,1133,0.071,0.057,0.08800000000000001,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,UK Biobank,UK Biobank,Not Unity-Aligned,https://www.ukbiobank.ac.uk/media/x0nd5sul/ukb_serologystudy_report_revised_6months_jan21.pdf,2021-03-19,2022-07-16,Unverified,uk_biobank_uk_2021,GBR
210115_UK_UKBiobank_Region_Yorkshire ,210115_UK_UKBiobank,UK Biobank SARS-CoV-2 Serology Study,2021-01-15,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,England,,,,2020-05-27,2020-12-04,Household and community samples,All,Multiple groups,18.0,,Geographical area,Yorkshire ,1467,0.08,0.066,0.095,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,UK Biobank,UK Biobank,Not Unity-Aligned,https://www.ukbiobank.ac.uk/media/x0nd5sul/ukb_serologystudy_report_revised_6months_jan21.pdf,2021-03-19,2022-07-16,Unverified,uk_biobank_uk_2021,GBR
210119_Lacashire_PublicHealthEngland_overall,210119_Lacashire_PublicHealthEngland,Use of dried blood spot samples for SARS-CoV-2 antibody detection using the Roche Elecsys high throughput immunoassay,2021-01-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,Lacashire,"volunteers were key workers who had been working on site during the pandemic, and who were neither experiencing any COVID-19 compatible symptoms, currently or within the former seven days.",,2020-06-03,2020-06-04,Essential non-healthcare workers,All,Adults (18-64 years),18.0,,Primary Estimate,,195,0.092,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Plasma,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,No,Ranya Mulchandani,Public Health England,Not Unity-Aligned,http://dx.doi.org/10.1016/j.jcv.2021.104739,2021-03-25,2024-03-01,Verified,mulchandani_use_2021,GBR
210111_UK_PublicHealthEngland_Round1_overall,210111_UK_PublicHealthEngland_Round1,"Prospective Active National Surveillance of Preschools and Primary Schools for SARS-CoV-2 Infection and Transmission in England, June 2020",2021-01-20,Preprint,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"For the blood sampling arm, schools were approached in five regions where a paediatric investigation team could be assembled: North London, East London, Oxford, Derby and Manchester. Headteachers in participating schools sent the study information pack to staff and parents and asked them to return a signed consent form with a completed questionnaire before the sampling day.",,2020-06-01,2020-06-15,Multiple populations,All,Multiple groups,4.0,,Primary Estimate,,2198,0.136,0.12400000000000001,0.151,True,,,,True,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,, Shamez Ladhani,Public Health England,Not Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3764198,2021-02-11,2024-03-01,Verified,ladhani_prospective_2021,GBR
210111_UK_PublicHealthEngland_Round2_overall ,210111_UK_PublicHealthEngland_Round2,"Prospective Active National Surveillance of Preschools and Primary Schools for SARS-CoV-2 Infection and Transmission in England, June 2020",2021-01-20,Preprint,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"For the blood sampling arm, schools were approached in five regions where a paediatric investigation team could be assembled: North London, East London, Oxford, Derby and Manchester. Headteachers in participating schools sent the study information pack to staff and parents and asked them to return a signed consent form with a completed questionnaire before the sampling day.",,2020-07-07,2020-07-21,Household and community samples,All,Multiple groups,4.0,,Primary Estimate,,1431,0.121,0.105,0.139,True,,,,True,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,No,,Yes,Yes,Yes,, Shamez Ladhani,Public Health England,Not Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3764198,2021-02-11,2024-03-01,Verified,ladhani_prospective_2021,GBR
210111_UK_PublicHealthEngland_Round3_overall,210111_UK_PublicHealthEngland_Round3,"Prospective Active National Surveillance of Preschools and Primary Schools for SARS-CoV-2 Infection and Transmission in England, June 2020",2021-01-20,Preprint,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"For the blood sampling arm, schools were approached in five regions where a paediatric investigation team could be assembled: North London, East London, Oxford, Derby and Manchester. Headteachers in participating schools sent the study information pack to staff and parents and asked them to return a signed consent form with a completed questionnaire before the sampling day.",,2020-11-17,2020-11-30,Household and community samples,All,Multiple groups,4.0,,Primary Estimate,,1216,0.10400000000000001,0.08800000000000001,0.12300000000000001,True,,,,True,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear, Shamez Ladhani,Public Health England,Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3764198,2021-02-11,2024-03-01,Verified,ladhani_prospective_2021,GBR
210123_London_KingsCollegeLondon_overall,210123_London_KingsCollegeLondon,The King’s College London Coronavirus Health and Experiences of Colleagues at King’s Study: SARS-CoV-2 antibody response in an occupational sample,2021-01-23,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,,London,postgraduate research students and current members of staff at King's College London ,,2020-06-15,2020-07-15,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,1882,0.066,,,True,,,,True,Convenience,COVID-19 antibody rapid test,SureScreen Diagnostics,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Daniel Leightley,,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.10.20191841v3,2021-03-27,2024-03-01,Unverified,leightley_kings_2021-1,GBR
210107_London_UniversityCollegeLondon_June_PaediatricHCW,210107_London_UniversityCollegeLondon_June,Cross Sectional Prevalence of SARS-CoV-2 antibodies in Health Care Workers in Paediatric Facilities in Eight Countries,2021-01-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,London,"This was part of a larger study undertaken in HCWs in paediatric facilities in seven European sites and one South African site. Staff of all categories in each healthcare setting were invited to join the study, irrespective of symptoms or whether they suspected they had previously had COVID-19. ",,2020-06-01,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),19.0,78.0,Primary Estimate,,1134,0.1693,0.1486,0.19219999999999998,True,,,,True,Convenience,"EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit,Meso Scale Discovery multiplex assay","Epitope Diagnostics, Inc.,Meso Scale Discovery",ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,Unclear,D Goldblatt,University College London,Not Unity-Aligned,http://dx.doi.org/10.1016/j.jhin.2020.12.019,2021-03-13,2024-03-01,Verified,goldblatt_cross-sectional_2021,GBR
210107_London_UniversityCollegeLondon_May_PaediatricHCW,210107_London_UniversityCollegeLondon_May,Cross Sectional Prevalence of SARS-CoV-2 antibodies in Health Care Workers in Paediatric Facilities in Eight Countries,2021-01-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,London,"This was part of a larger study undertaken in HCWs in paediatric facilities in seven European sites and one South African site. Staff of all categories in each healthcare setting were invited to join the study, irrespective of symptoms or whether they suspected they had previously had COVID-19. ",,2020-05-01,2020-05-31,Health care workers and caregivers,All,Adults (18-64 years),19.0,69.0,Primary Estimate,,1754,0.1534,0.1373,0.171,True,,,,True,Convenience,"EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit,Meso Scale Discovery multiplex assay","Epitope Diagnostics, Inc.,Meso Scale Discovery",ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,Unclear,D Goldblatt,University College London,Not Unity-Aligned,http://dx.doi.org/10.1016/j.jhin.2020.12.019,2021-03-13,2024-03-01,Unverified,goldblatt_cross-sectional_2021,GBR
210127_Scotland_PublicHealthScotland_1ResidualSera_overall_adj,210127_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 27 Jan 2021,2021-01-27,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2020-11-30,2021-01-03,Residual sera,All,Multiple groups,,,Primary Estimate,"Overall, test and pop adjusted",3485,0.096,0.084,0.10800000000000001,True,True,True,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-27-january-2021/,2021-10-26,2022-07-16,Verified,public_health_scotland_enhanced_2021-4,GBR
210127_Scotland_PublicHealthScotland_1ResidualSera_40-59,210127_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 27 Jan 2021,2021-01-27,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2020-11-30,2021-01-03,Residual sera,All,Adults (18-64 years),40.0,59.0,Age,"40 - 59, unadj",760,0.1,,,,,,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-27-january-2021/,2021-10-26,2022-07-16,Verified,public_health_scotland_enhanced_2021-4,GBR
210127_Scotland_PublicHealthScotland_1ResidualSera_female,210127_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 27 Jan 2021,2021-01-27,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2020-11-30,2021-01-03,Residual sera,Female,Multiple groups,,,Sex/Gender,"Females, unadj",1757,0.1024,,,,,,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-27-january-2021/,2021-10-26,2022-07-16,Verified,public_health_scotland_enhanced_2021-4,GBR
210127_Scotland_PublicHealthScotland_1ResidualSera_0-19,210127_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 27 Jan 2021,2021-01-27,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2020-11-30,2021-01-03,Residual sera,All,Children and Youth (0-17 years),,19.0,Age,"00 - 19, unadj",854,0.1112,,,,,,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-27-january-2021/,2021-10-26,2022-07-16,Verified,public_health_scotland_enhanced_2021-4,GBR
210127_Scotland_PublicHealthScotland_1ResidualSera_overall_unadj,210127_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 27 Jan 2021,2021-01-27,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2020-11-30,2021-01-03,Residual sera,All,Multiple groups,,,Analysis,"Overall, unadj",3485,0.0958,,,,,,,True,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-27-january-2021/,2021-10-26,2022-07-16,Verified,public_health_scotland_enhanced_2021-4,GBR
210127_Scotland_PublicHealthScotland_1ResidualSera_70+,210127_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 27 Jan 2021,2021-01-27,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2020-11-30,2021-01-03,Residual sera,All,Seniors (65+ years),70.0,,Age,"70+, unadj",506,0.0889,,,,,,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-27-january-2021/,2021-10-26,2022-07-16,Verified,public_health_scotland_enhanced_2021-4,GBR
210127_Scotland_PublicHealthScotland_1ResidualSera_male,210127_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 27 Jan 2021,2021-01-27,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2020-11-30,2021-01-03,Residual sera,Male,Multiple groups,,,Sex/Gender,"Males, unadj",1728,0.0891,,,,,,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-27-january-2021/,2021-10-26,2022-07-16,Verified,public_health_scotland_enhanced_2021-4,GBR
210127_Scotland_PublicHealthScotland_1ResidualSera_20-39,210127_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 27 Jan 2021,2021-01-27,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2020-11-30,2021-01-03,Residual sera,All,Adults (18-64 years),20.0,39.0,Age,"20 - 39, unadj",873,0.08710000000000001,,,,,,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-27-january-2021/,2021-10-26,2022-07-16,Verified,public_health_scotland_enhanced_2021-4,GBR
210127_Scotland_PublicHealthScotland_1ResidualSera_60-69,210127_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 27 Jan 2021,2021-01-27,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2020-11-30,2021-01-03,Residual sera,All,Seniors (65+ years),60.0,69.0,Age,"60 - 69, unadj",492,0.08539999999999999,,,,,,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-27-january-2021/,2021-10-26,2022-07-16,Verified,public_health_scotland_enhanced_2021-4,GBR
210127_Scotland_PublicHealthScotland_2BloodDonors_overall_adj,210127_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 27 Jan 2021,2021-01-27,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2020-11-30,2021-01-03,Blood donors,All,Multiple groups,,,Primary Estimate,"Overall, test and pop adjusted",2499,0.059000000000000004,0.044000000000000004,0.071,True,True,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-27-january-2021/,2021-10-26,2023-08-15,Verified,public_health_scotland_enhanced_2021-4,GBR
210127_Scotland_PublicHealthScotland_2BloodDonors_40-59,210127_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 27 Jan 2021,2021-01-27,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2020-11-30,2021-01-03,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,"40 - 59, unadj",1147,0.0401,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-27-january-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-4,GBR
210127_Scotland_PublicHealthScotland_2BloodDonors_males,210127_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 27 Jan 2021,2021-01-27,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2020-11-30,2021-01-03,Blood donors,Male,Multiple groups,,,Sex/Gender,"Males, unadj",1138,0.0325,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-27-january-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-4,GBR
210127_Scotland_PublicHealthScotland_2BloodDonors_0-39,210127_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 27 Jan 2021,2021-01-27,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2020-11-30,2021-01-03,Blood donors,All,Multiple groups,,39.0,Age,"00 - 39, unadj",789,0.0558,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-27-january-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-4,GBR
210127_Scotland_PublicHealthScotland_2BloodDonors_females,210127_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 27 Jan 2021,2021-01-27,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2020-11-30,2021-01-03,Blood donors,Female,Multiple groups,,,Sex/Gender,"Females, unadj",1361,0.0507,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-27-january-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-4,GBR
210127_Scotland_PublicHealthScotland_2BloodDonors_overall_unadj,210127_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 27 Jan 2021,2021-01-27,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2020-11-30,2021-01-03,Blood donors,All,Multiple groups,,,Analysis,Overall Unadj,2499,0.0424,,,,,,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-27-january-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-4,GBR
210127_Scotland_PublicHealthScotland_2BloodDonors_60+,210127_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 27 Jan 2021,2021-01-27,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2020-11-30,2021-01-03,Blood donors,All,Seniors (65+ years),60.0,,Age,"60+, unadj",563,0.028399999999999998,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-27-january-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-4,GBR
210127_Scotland_PublicHealthScotland_3PregnantWomen_Overall_PopAdj_TestAdj,210127_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 27 Jan 2021,2021-01-27,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2020-11-30,2021-01-03,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,"Overall, test and pop adjusted",3052,0.057999999999999996,0.05,0.068,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-27-january-2021/,2021-10-29,2023-08-15,Verified,public_health_scotland_enhanced_2021-4,GBR
210127_Scotland_PublicHealthScotland_3PregnantWomen_Age_30 - 39,210127_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 27 Jan 2021,2021-01-27,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2020-11-30,2021-01-03,Pregnant or parturient women,Female,Adults (18-64 years),30.0,39.0,Age,age 30-39,1689,0.0409,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-27-january-2021/,2021-10-29,2024-03-01,Verified,public_health_scotland_enhanced_2021-4,GBR
210127_Scotland_PublicHealthScotland_3PregnantWomen_Age_00 - 19,210127_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 27 Jan 2021,2021-01-27,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2020-11-30,2021-01-03,Pregnant or parturient women,Female,Children and Youth (0-17 years),0.0,19.0,Age,age 0-19,74,0.0405,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-27-january-2021/,2021-10-29,2024-03-01,Verified,public_health_scotland_enhanced_2021-4,GBR
210127_Scotland_PublicHealthScotland_3PregnantWomen_Overall_Unadj,210127_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 27 Jan 2021,2021-01-27,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2020-11-30,2021-01-03,Pregnant or parturient women,Female,Adults (18-64 years),,,Analysis,"Overall, unadj",3052,0.0534,,,,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-27-january-2021/,2021-10-29,2024-03-01,Verified,public_health_scotland_enhanced_2021-4,GBR
210127_Scotland_PublicHealthScotland_3PregnantWomen_Age_40+,210127_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 27 Jan 2021,2021-01-27,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2020-11-30,2021-01-03,Pregnant or parturient women,Female,Adults (18-64 years),40.0,,Age,age 40+,88,0.034100000000000005,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-27-january-2021/,2021-10-29,2024-03-01,Verified,public_health_scotland_enhanced_2021-4,GBR
210127_Scotland_PublicHealthScotland_3PregnantWomen_Age_20 - 29,210127_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 27 Jan 2021,2021-01-27,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2020-11-30,2021-01-03,Pregnant or parturient women,Female,Adults (18-64 years),20.0,29.0,Age,age 20-29,1201,0.0733,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-27-january-2021/,2021-10-29,2024-03-01,Verified,public_health_scotland_enhanced_2021-4,GBR
210127_UK_UniversityCollegeLondon_overall,210127_UK_UniversityCollegeLondon,Longitudinal Assessment of Symptoms and Risk of SARS-CoV-2 Infection in Healthcare Workers Across 5 Hospitals to Understand Ethnic Differences in Infection Risk,2021-01-27,Preprint,Regional,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,"Nottingham, London","Asymptomatic HCWs attending work. Nurses, doctors, allied health professionals and other frontline health-care workers were recruited in Nottingham and London, with additional staff from other workforce groups in London.",,2020-03-23,2020-07-10,Health care workers and caregivers,All,Adults (18-64 years),18.0,69.0,Primary Estimate,overall,1364,0.19941,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N),Author designed (ELISA) - MULTIPLEXED","EUROIMMUN,Roche Diagnostics,NA",ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Ana Valdes,University College London,Not Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3754805,2021-03-17,2024-03-01,Verified,valdes_longitudinal_2021,GBR
210127_London_King'sCollegeLondon_September_PostgradStudents&Staff,210127_London_King'sCollegeLondon,The King’s College London Coronavirus Health and Experiences of Colleagues at King’s Study: SARS-CoV-2 antibody response in a higher education sample,2021-01-27,Preprint,Local,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,,London,"cohort of postgraduate research students and members of staff at King’s College London, a large Russell Group University in London, UK

A current KCL staff member or PGR student

Aged 18 and over at time of participation

Able and willing to give informed consent to participate in the survey

Able to understand and communicate in written English and use a web browser

Be willing and able to conduct home antibody testing with a supplied rapid Immunoassay Test Cassette

Supply a UK address for delivery of the testing kits

Agree to informing the research team of the results of the testing kit",did not return a valid antibody test result ,2020-09-01,2020-09-30,Essential non-healthcare workers,All,Adults (18-64 years),18.0,,Primary Estimate,September,1675,0.054000000000000006,,,True,,,,True,Convenience,COVID-19 antibody rapid test,SureScreen Diagnostics,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Daniel Leightley,King's College London,Not Unity-Aligned,https://doi.org/10.1101/2021.01.26.21249744,2021-03-21,2024-03-01,Verified,leightley_kings_2021,GBR
210126_UK_OfficeforNationalStatistics_Dec_Jan20_21_England_Genpop,210126_UK_OfficeforNationalStatistics_Dec_Jan20_21_England,Coronavirus (COVID-19) Infection Survey: December_January2021,2021-01-29,Institutional Report,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2020-12-18,2021-01-14,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,,24150,0.153,0.147,0.159,True,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office of National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/december2020,2021-03-12,2022-07-16,Verified,steel_coronavirus_2020-2,GBR
210126_UK_OfficeforNationalStatistics_Dec_Jan20_21_NortherIreland_genpop,210126_UK_OfficeforNationalStatistics_Dec_Jan20_21_NorthernIreland,Coronavirus (COVID-19) Infection Survey: December_January2021,2021-01-29,Institutional Report,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Northern Ireland,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2020-12-18,2021-01-14,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,,313,0.12,0.078,0.174,True,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Moderate'],Yes,Yes,No,No,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office of National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/december2020,2021-03-12,2022-07-16,Verified,steel_coronavirus_2020-2,GBR
210126_UK_OfficeforNationalStatistics_Dec_Jan20_21_Scotland_genpop,210126_UK_OfficeforNationalStatistics_Dec_Jan20_21_Scotland,Coronavirus (COVID-19) Infection Survey: December_January2021,2021-01-29,Institutional Report,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,"Scotland
",,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2020-12-18,2021-01-14,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,,1832,0.107,0.091,0.12400000000000001,True,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office of National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/december2020,2021-03-12,2022-07-16,Verified,steel_coronavirus_2020-2,GBR
210126_UK_OfficeforNationalStatistics_Dec_Jan20_21_Wales_genpop,210126_UK_OfficeforNationalStatistics_Dec_Jan20_21_Wales,Coronavirus (COVID-19) Infection Survey: December_January2021,2021-01-29,Institutional Report,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Wales,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2020-12-18,2021-01-14,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,,732,0.115,0.086,0.149,True,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Moderate'],,Yes,Yes,No,,Unclear,Yes,Yes,,Office for National Statistics,Office of National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/december2020,2021-03-12,2022-07-16,Verified,steel_coronavirus_2020-2,GBR
210202_UK_SalfordRoyalNHS_primary,210202_UK_SalfordRoyalNHS,Investigating the Utility of COVID-19 Antibody Testing in End-Stage Renal Disease Patients Receiving Haemodialysis: A Cohort Study in the United Kingdom,2021-02-02,Preprint,Local,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,,,Patients who tested negative for SARS-CoV-2 on rRT-PCR were recruited to the epidemiological arm of Salford Kidney Study (SKS)SKS is a prospective observational study in the United Kingdom which has recruited chronic kidney disease patients since the year 2002. The ethical approval of SKS has been extended to include dialysis patients (both HD and peritoneal dialysis (PD)) since 2016. All adult patients who have provided informed consent are recruited to the SKS.,,2020-03-15,2020-10-30,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,237,0.051,,,True,,,,True,Convenience,"MAGLUMI 2019-nCoV IgM/IgG,ADVIA Centaur Immunoassay System","Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),Siemens",CLIA,Serum,IgG,,,,,['High'],No,No,No,Yes,Unclear,Unclear,No,No,No,Olivia Wickens,Salford Royal NHS ,Not Unity-Aligned,https://www.researchsquare.com/article/rs-154513/v1,2021-03-26,2024-03-01,Verified,wickens_investigating_2021,GBR
210203_England_TheUniversityofNottingham_HCW_primary,210203_England_TheUniversityofNottingham_HCW,SARS-CoV-2 transmission from the healthcare setting into the home: a prospective longitudinal cohort study,2021-02-03,Preprint,Local,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,East Midlands,,"patient-facing healthcare professionals
were recruited from the Queen’s Medical Centre and City Hospital located in Nottingham.  ",,2020-04-24,2020-07-10,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,633,0.18,,,True,,,,True,Convenience,Author designed (ELISA) - MULTIPLEXED,,ELISA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Simon Craxford,The University of Nottingham,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.01.21250950v1,2021-02-17,2022-07-16,Unverified,craxford_sars-cov-2_2021,GBR
210203_England_TheUniversityofNottingham_HHC_primary,210203_England_TheUniversityofNottingham_HHC,SARS-CoV-2 transmission from the healthcare setting into the home: a prospective longitudinal cohort study,2021-02-03,Preprint,Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"study participants were invited to bring their household contacts
(aged over 18) for a single blood sample",,2020-09-01,2020-09-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,178,0.073,,,True,,,,True,Convenience,Author designed (ELISA) - MULTIPLEXED,,ELISA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Simon Craxford,The University of Nottingham,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.01.21250950v1,2021-02-17,2022-07-16,Unverified,craxford_sars-cov-2_2021,GBR
210210_London_KingsCollegeLondon,210210_London_KingsCollegeLondon,Indicators of past COVID-19 infection status: Findings from a large occupational cohort of staff and postgraduate research students from a UK university,2021-02-10,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,England,London,eligible participants were current staff or PGRs residing in the UK (for antibody testing),,2020-06-01,2020-06-30,Multiple populations,All,Adults (18-64 years),18.0,,Primary Estimate,,1882,0.07,,,True,,,,True,Convenience,COVID-19 antibody rapid test,SureScreen Diagnostics,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.9400000000000001,0.963,['High'],No,No,Yes,Yes,No,Yes,Yes,No,No,Katrina Davis,King's College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.12.07.20245183v2,2021-04-05,2024-03-01,Verified,davis_indicators_2021,GBR
210211_UnitedKingdom_ImperialCollegeNHSTrust_GlomerularDiseasePatients,210211_UnitedKingdom_ImperialCollegeNHSTrust,Serological screening for COVID-19 in patients with glomerular disease,2021-02-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,London,"Patients at the Committee of Imperial College Healthcare NHS Trust (ICHNT) were offered serological screening for prior infection. The ICHNT cares for approximately 1500 patients with primary GN, vasculitis and systemic lupus erythematosus.","excludes those who did not consent for testing, and those receiving renal replacement therapy (HD, PD or renal transplant).",2020-05-19,2020-07-21,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,493,0.077,,,True,,,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Tabitha Turner Stokes,Imperial College Healthcare NHS Trust,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ekir.2021.02.006,2021-04-02,2024-03-01,Verified,turner-stokes_serologic_2021,GBR
210212_London_UniversityofOxford_Overall,210212_London_UniversityofOxford,Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic,2021-02-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,London,Sera from patients attending for maintenance infliximab or vedolizumab infusions between April and June 2020 at Royal London Hospital,,2020-04-15,2020-06-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,236,0.08470000000000001,,,True,,,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,,,,,['High'],No,No,No,No,Unclear,Yes,Yes,Yes,,Colleen GC McGregor,University of Oxford,Not Unity-Aligned,https://dx.doi.org/10.1136/gutjnl-2021-324116,2021-04-19,2024-03-01,Verified,mcgregor_maintenance_2021,GBR
210212_London_UniversityofOxford_Adults,210212_London_UniversityofOxford,Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic,2021-02-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,London,Sera from patients attending for maintenance infliximab or vedolizumab infusions between April and June 2020 at Royal London Hospital,,2020-04-15,2020-06-15,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),,,Age,,180,0.07200000000000001,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,,,,,['High'],No,No,No,No,Unclear,Yes,Yes,Yes,,Colleen GC McGregor,University of Oxford,Not Unity-Aligned,https://dx.doi.org/10.1136/gutjnl-2021-324116,2021-03-27,2024-03-01,Verified,mcgregor_maintenance_2021,GBR
210212_London_UniversityofOxford_Pediatrics,210212_London_UniversityofOxford,Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic,2021-02-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,London,Sera from patients attending for maintenance infliximab or vedolizumab infusions between April and June 2020 at Royal London Hospital,,2020-04-15,2020-06-15,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),,,Age,,56,0.125,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,,,,,['High'],No,No,No,No,Unclear,Yes,Yes,Yes,,Colleen GC McGregor,University of Oxford,Not Unity-Aligned,https://dx.doi.org/10.1136/gutjnl-2021-324116,2021-03-27,2024-03-01,Verified,mcgregor_maintenance_2021,GBR
210212_Oxford_UniversityofOxford,210212_Oxford_UniversityofOxford,Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic,2021-02-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,Oxford,Sera from patients attending for maintenance infliximab or vedolizumab infusions between April and June 2020 at the John Radcliffe Hospital ,,2020-04-15,2020-06-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,404,0.03,,,True,,,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,,,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,,Colleen GC McGregor,University of Oxford,Not Unity-Aligned,https://dx.doi.org/10.1136/gutjnl-2021-324116,2021-03-27,2024-03-01,Verified,mcgregor_maintenance_2021,GBR
210212_London_RoyalFreeHospital,210212_London_RoyalFreeHospital,Transmission of infection among health care personnel performing surgical tracheostomies on COVID-19 patients,2021-02-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,London,"Staff who were involved in surgical tracheostomies for invasively ventilated adultpatients managed in the ICU as COVID-19 cases (CT consistentwith COVID-19 and/or a positive COVID-19 RT-PCR test), and had serologic testing. ",The exclusion criteria were staff who did not consent for completing the questionnaire and HCP who tested positive for COVID-19 prior to the start of the study. Emergency procedures were excluded.,2020-03-26,2020-06-24,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,43,0.18600000000000003,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],No,Unclear,No,No,Unclear,Unclear,Yes,No,Unclear,Natarajan Angamuthu,Royal Free Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.surge.2021.01.007,2021-04-10,2022-07-16,Verified,noauthor_transmission_2021,GBR
210219_England_PHE_UniversityStudents_Overall,210219_England_PHE_UniversityStudents,"Seroprevalence of SARS-CoV-2 Antibodies in University Students: Cross-sectional Study, December 2020, England",2021-02-19,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"students attending the following five universities across England: Leeds Beckett University, Newcastle University, University of Manchester, Oxford Brookes University and Reading University. University students aged 25 years or under who were enrolled with the university during the 2020/2021 academic year were invited to participate. Students were eligible to participate irrespective of whether they had prior confirmed COVID-19 or COVID-19 related symptoms.
","excluded students who were confirmed PCR positive in the last 90 days. Excluded if outside age range. Excluded if no returned sample or no unique identifier with returned sample, or insufficient sample",2020-12-02,2020-12-11,Students and Daycares,All,Adults (18-64 years),17.0,25.0,Primary Estimate,Overall,2905,0.17800000000000002,0.165,0.193,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Not reported/ Unable to specify","Abbott Laboratories,NA",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Amoolya Vusirikala,Public Health England,Not Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3787684,2021-03-15,2024-03-01,Verified,vusirikala_seroprevalence_2021,GBR
210219_England_PHE_UniversityStudents_17-19,210219_England_PHE_UniversityStudents,"Seroprevalence of SARS-CoV-2 Antibodies in University Students: Cross-sectional Study, December 2020, England",2021-02-19,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"students attending the following five universities across England: Leeds Beckett University, Newcastle University, University of Manchester, Oxford Brookes University and Reading University. University students aged 25 years or under who were enrolled with the university during the 2020/2021 academic year were invited to participate. Students were eligible to participate irrespective of whether they had prior confirmed COVID-19 or COVID-19 related symptoms.
","excluded students who were confirmed PCR positive in the last 90 days. Excluded if outside age range. Excluded if no returned sample or no unique identifier with returned sample, or insufficient sample",2020-12-02,2020-12-11,Students and Daycares,All,Adults (18-64 years),17.0,19.0,Age,17-19,892,0.29300000000000004,,,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Not reported/ Unable to specify","Abbott Laboratories,NA",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Amoolya Vusirikala,Public Health England,Not Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3787684,2021-03-15,2024-03-01,Verified,vusirikala_seroprevalence_2021,GBR
210219_England_PHE_UniversityStudents_20-22,210219_England_PHE_UniversityStudents,"Seroprevalence of SARS-CoV-2 Antibodies in University Students: Cross-sectional Study, December 2020, England",2021-02-19,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"students attending the following five universities across England: Leeds Beckett University, Newcastle University, University of Manchester, Oxford Brookes University and Reading University. University students aged 25 years or under who were enrolled with the university during the 2020/2021 academic year were invited to participate. Students were eligible to participate irrespective of whether they had prior confirmed COVID-19 or COVID-19 related symptoms.
","excluded students who were confirmed PCR positive in the last 90 days. Excluded if outside age range. Excluded if no returned sample or no unique identifier with returned sample, or insufficient sample",2020-12-02,2020-12-11,Students and Daycares,All,Adults (18-64 years),20.0,22.0,Age,20-22,1739,0.133,,,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Not reported/ Unable to specify","Abbott Laboratories,NA",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Amoolya Vusirikala,Public Health England,Not Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3787684,2021-03-15,2024-03-01,Verified,vusirikala_seroprevalence_2021,GBR
210219_England_PHE_UniversityStudents_23-25,210219_England_PHE_UniversityStudents,"Seroprevalence of SARS-CoV-2 Antibodies in University Students: Cross-sectional Study, December 2020, England",2021-02-19,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"students attending the following five universities across England: Leeds Beckett University, Newcastle University, University of Manchester, Oxford Brookes University and Reading University. University students aged 25 years or under who were enrolled with the university during the 2020/2021 academic year were invited to participate. Students were eligible to participate irrespective of whether they had prior confirmed COVID-19 or COVID-19 related symptoms.
","excluded students who were confirmed PCR positive in the last 90 days. Excluded if outside age range. Excluded if no returned sample or no unique identifier with returned sample, or insufficient sample",2020-12-02,2020-12-11,Students and Daycares,All,Adults (18-64 years),23.0,25.0,Age,23-25,274,0.095,,,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Not reported/ Unable to specify","Abbott Laboratories,NA",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Amoolya Vusirikala,Public Health England,Not Unity-Aligned,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3787684,2021-03-15,2024-03-01,Verified,vusirikala_seroprevalence_2021,GBR
210225_England_ImperialCollegeLondon_Round4_overall_adj,210225_England_ImperialCollegeLondon_Round4,REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England,2021-02-25,Institutional Report,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,adult population 18 years and older in England registered with a General Practitioner in England ,,2020-10-27,2020-11-10,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,161537,0.0556,0.0543,0.0571,True,True,True,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London ,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.26.21252512v1,2021-03-24,2022-07-16,Verified,ward_react-2_2021,GBR
210225_England_ImperialCollegeLondon_Round4_overall_unadj ,210225_England_ImperialCollegeLondon_Round4,REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England,2021-02-25,Institutional Report,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,adult population 18 years and older in England registered with a General Practitioner in England ,,2020-10-27,2020-11-10,Household and community samples,All,Multiple groups,18.0,,Analysis,,161537,0.052199999999999996,0.051100000000000007,0.0533,,,,,True,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,Yes,No,Helen Ward,Imperial College London ,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.26.21252512v1,2021-03-24,2022-07-16,Verified,ward_react-2_2021,GBR
210225_England_ImperialCollegeLondon_Round5_overall_Primary,210225_England_ImperialCollegeLondon_Round5,REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England,2021-02-25,Institutional Report,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-01-25,2021-02-08,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,Test and pop adjusted,155172,0.139,0.13699999999999998,0.141,True,True,True,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Helen Ward,Imperial College London ,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.26.21252512v1,2021-06-18,2022-07-16,Verified,ward_react-2_2021,GBR
210225_England_ImperialCollegeLondon_Round22_unvaccinatedNorth West,210225_England_ImperialCollegeLondon_Round5,REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England,2021-02-25,Institutional Report,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-01-25,2021-02-08,Household and community samples,All,Multiple groups,18.0,,Geographical area,North West,15992,0.11699999999999999,0.11199999999999999,0.12300000000000001,,,True,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Helen Ward,Imperial College London ,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.26.21252512v1,2021-03-24,2022-07-16,Verified,ward_react-2_2021,GBR
210225_England_ImperialCollegeLondon_Round5_unvaccinated_male,210225_England_ImperialCollegeLondon_Round5,REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England,2021-02-25,Institutional Report,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-01-25,2021-02-08,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,male,61985,0.091,0.08800000000000001,0.09300000000000001,,,True,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Helen Ward,Imperial College London ,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.26.21252512v1,2021-03-24,2022-07-16,Verified,ward_react-2_2021,GBR
210225_England_ImperialCollegeLondon_Round5_unvaccinated_18-29yrs,210225_England_ImperialCollegeLondon_Round5,REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England,2021-02-25,Institutional Report,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-01-25,2021-02-08,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,18-29,16790,0.145,0.14,0.15,,,True,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Helen Ward,Imperial College London ,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.26.21252512v1,2021-03-24,2022-07-16,Verified,ward_react-2_2021,GBR
210225_England_ImperialCollegeLondon_Round5_overall_unadj,210225_England_ImperialCollegeLondon_Round5,REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England,2021-02-25,Institutional Report,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-01-25,2021-02-08,Household and community samples,All,Multiple groups,18.0,,Analysis,_overall_unadj,155172,0.1107,0.1092,0.11230000000000001,,,,,True,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Helen Ward,Imperial College London ,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.26.21252512v1,2021-03-24,2022-07-16,Verified,ward_react-2_2021,GBR
210225_England_ImperialCollegeLondon_Round5_unvaccinated_30-39yrs,210225_England_ImperialCollegeLondon_Round5,REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England,2021-02-25,Institutional Report,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-01-25,2021-02-08,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,22427,0.099,0.095,0.10400000000000001,,,True,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Helen Ward,Imperial College London ,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.26.21252512v1,2021-03-24,2022-07-16,Verified,ward_react-2_2021,GBR
210225_England_ImperialCollegeLondon_Round26_unvaccinatedYorkshire and The Humber ,210225_England_ImperialCollegeLondon_Round5,REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England,2021-02-25,Institutional Report,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-01-25,2021-02-08,Household and community samples,All,Multiple groups,18.0,,Geographical area,Yorkshire and The Humber ,9081,0.08800000000000001,0.08199999999999999,0.094,,,True,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Helen Ward,Imperial College London ,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.26.21252512v1,2021-03-24,2022-07-16,Verified,ward_react-2_2021,GBR
210225_England_ImperialCollegeLondon_Round19_unvaccinatedEast of England ,210225_England_ImperialCollegeLondon_Round5,REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England,2021-02-25,Institutional Report,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-01-25,2021-02-08,Household and community samples,All,Multiple groups,18.0,,Geographical area,East of England ,19567,0.083,0.078,0.08900000000000001,,,True,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Helen Ward,Imperial College London ,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.26.21252512v1,2021-03-24,2022-07-16,Verified,ward_react-2_2021,GBR
210225_England_ImperialCollegeLondon_Round24_unvaccinatedSouth West,210225_England_ImperialCollegeLondon_Round5,REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England,2021-02-25,Institutional Report,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-01-25,2021-02-08,Household and community samples,All,Multiple groups,18.0,,Geographical area,South West,13870,0.048,0.044000000000000004,0.053,,,True,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Helen Ward,Imperial College London ,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.26.21252512v1,2021-03-24,2022-07-16,Verified,ward_react-2_2021,GBR
210225_England_ImperialCollegeLondon_Round21_unvaccinatedNorth East,210225_England_ImperialCollegeLondon_Round5,REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England,2021-02-25,Institutional Report,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-01-25,2021-02-08,Household and community samples,All,Multiple groups,18.0,,Geographical area,North East,5050,0.09,0.08199999999999999,0.098,,,True,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Helen Ward,Imperial College London ,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.26.21252512v1,2021-03-24,2022-07-16,Verified,ward_react-2_2021,GBR
210225_England_ImperialCollegeLondon_Round5_unvaccinated,210225_England_ImperialCollegeLondon_Round5,REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England,2021-02-25,Institutional Report,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-01-25,2021-02-08,Household and community samples,All,Multiple groups,18.0,,COVID-19 vaccination status,Vaccinated no,136733,0.0978,0.0959,0.0998,,True,True,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Helen Ward,Imperial College London ,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.26.21252512v1,2021-03-24,2022-07-16,Verified,ward_react-2_2021,GBR
210225_England_ImperialCollegeLondon_Round5_unvaccinated_40-49yrs,210225_England_ImperialCollegeLondon_Round5,REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England,2021-02-25,Institutional Report,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-01-25,2021-02-08,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,26486,0.096,0.092,0.10099999999999999,,,True,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Helen Ward,Imperial College London ,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.26.21252512v1,2021-03-24,2022-07-16,Verified,ward_react-2_2021,GBR
210225_England_ImperialCollegeLondon_Round5_unvaccinated_80+yrs,210225_England_ImperialCollegeLondon_Round5,REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England,2021-02-25,Institutional Report,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-01-25,2021-02-08,Household and community samples,All,Seniors (65+ years),80.0,,Age,80+,219,0.10300000000000001,0.07400000000000001,0.141,,,True,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Helen Ward,Imperial College London ,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.26.21252512v1,2021-03-24,2022-07-16,Verified,ward_react-2_2021,GBR
210225_England_ImperialCollegeLondon_Round5_unvaccinated_female,210225_England_ImperialCollegeLondon_Round5,REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England,2021-02-25,Institutional Report,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-01-25,2021-02-08,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,female,75106,0.105,0.102,0.10800000000000001,,,True,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Helen Ward,Imperial College London ,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.26.21252512v1,2021-03-24,2022-07-16,Verified,ward_react-2_2021,GBR
210225_England_ImperialCollegeLondon_Round18_unvaccinatedEast Midlands ,210225_England_ImperialCollegeLondon_Round5,REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England,2021-02-25,Institutional Report,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-01-25,2021-02-08,Household and community samples,All,Multiple groups,18.0,,Geographical area,East Midlands ,17914,0.078,0.073,0.085,,,True,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Helen Ward,Imperial College London ,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.26.21252512v1,2021-03-24,2022-07-16,Verified,ward_react-2_2021,GBR
210225_England_ImperialCollegeLondon_Round5_unvaccinated_50-59yrs,210225_England_ImperialCollegeLondon_Round5,REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England,2021-02-25,Institutional Report,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-01-25,2021-02-08,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,31341,0.091,0.087,0.096,,,True,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Helen Ward,Imperial College London ,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.26.21252512v1,2021-03-24,2022-07-16,Verified,ward_react-2_2021,GBR
210225_England_ImperialCollegeLondon_Round5_vaccinated,210225_England_ImperialCollegeLondon_Round5,REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England,2021-02-25,Institutional Report,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-01-25,2021-02-08,Household and community samples,All,Multiple groups,18.0,,COVID-19 vaccination status,Vaccinated yes,18305,0.37920000000000004,0.3718,0.3866,,True,True,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Helen Ward,Imperial College London ,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.26.21252512v1,2021-03-24,2022-07-16,Verified,ward_react-2_2021,GBR
210225_England_ImperialCollegeLondon_Round23_unvaccinatedSouth East,210225_England_ImperialCollegeLondon_Round5,REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England,2021-02-25,Institutional Report,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-01-25,2021-02-08,Household and community samples,All,Multiple groups,18.0,,Geographical area,South East,30279,0.07400000000000001,0.07,0.078,,,True,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Helen Ward,Imperial College London ,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.26.21252512v1,2021-03-24,2022-07-16,Verified,ward_react-2_2021,GBR
210225_England_ImperialCollegeLondon_Round5_unvaccinated_70-79yrs,210225_England_ImperialCollegeLondon_Round5,REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England,2021-02-25,Institutional Report,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-01-25,2021-02-08,Household and community samples,All,Seniors (65+ years),70.0,79.0,Age,70-79,11957,0.045,0.040999999999999995,0.051,,,True,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Helen Ward,Imperial College London ,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.26.21252512v1,2021-03-24,2022-07-16,Verified,ward_react-2_2021,GBR
210225_England_ImperialCollegeLondon_Round5_unvaccinated_60-69yrs,210225_England_ImperialCollegeLondon_Round5,REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England,2021-02-25,Institutional Report,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-01-25,2021-02-08,Household and community samples,All,Multiple groups,60.0,69.0,Age,60-69,27875,0.069,0.065,0.073,,,True,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Helen Ward,Imperial College London ,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.26.21252512v1,2021-03-24,2022-07-16,Verified,ward_react-2_2021,GBR
210225_England_ImperialCollegeLondon_Round25_unvaccinatedWest Midlands,210225_England_ImperialCollegeLondon_Round5,REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England,2021-02-25,Institutional Report,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-01-25,2021-02-08,Household and community samples,All,Multiple groups,18.0,,Geographical area,West Midlands,13058,0.10300000000000001,0.09699999999999999,0.109,,,True,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Helen Ward,Imperial College London ,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.26.21252512v1,2021-03-24,2022-07-16,Verified,ward_react-2_2021,GBR
210225_England_ImperialCollegeLondon_Round20_unvaccinatedLondon,210225_England_ImperialCollegeLondon_Round5,REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England,2021-02-25,Institutional Report,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-01-25,2021-02-08,Household and community samples,All,Multiple groups,18.0,,Geographical area,London,12284,0.16899999999999998,0.163,0.17500000000000002,,,True,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Helen Ward,Imperial College London ,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.26.21252512v1,2021-03-24,2022-07-16,Verified,ward_react-2_2021,GBR
210226_WestMidlands_BirminghamCommunityHealthcareTrust_Baseline,210226_WestMidlands_BirminghamCommunityHealthcareTrust,Longitudinal protection following natural SARS-CoV-2 infection and early vaccine responses: insights from a cohort of community based dental health care professionals,2021-02-26,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,,,Registered general dental practitioners (GDPs) in the West Midlands area,,2020-06-01,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Dental care professionals,1507,0.163,,,True,,,,True,Convenience,Human Anti-IgG/A/M SARS-CoV-2 ELISA,The Binding Site,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.986,0.983,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Adrian Shields,Birmingham Community Healthcare Trust,Not Unity-Aligned,10.1101/2021.02.24.21252368,2021-04-15,2022-07-16,Verified,shields_longitudinal_2021,GBR
210301_England_OfficeForNationalStatistics_StudentsPrimary3,210301_England_OfficeForNationalStatistics_StudentsPrimary3,"COVID-19 Schools Infection Survey Round 2, England: antibody data, December 2020",2021-03-01,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,England,,"Within primary schools, all pupils were eligible to participate","The following schools were excluded from the sampling frame:

-special schools, independent schools, pupil referral units and further education colleges

-schools taking part in other school-based COVID-19 studies

",2020-12-02,2020-12-10,Students and Daycares,All,Children and Youth (0-17 years),,,Primary Estimate,,2152,0.09050000000000001,0.0733,0.11,,,True,,,Stratified probability,Not reported/ Unable to specify,,Other,,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.8,0.99,['Moderate'],,Yes,Yes,No,,Unclear,Yes,No,,Office for National Statistics ,Office for National Statistics,Not Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/covid19schoolsinfectionsurveyround4england/antibodydatamarch2021,2021-07-14,2022-07-16,Unverified,office_for_national_statistics_covid-19_2021-1,GBR
210301_England_OfficeForNationalStatistics_StudentsSecondary4,210301_England_OfficeForNationalStatistics_StudentsSecondary4,"COVID-19 Schools Infection Survey Round 2, England: antibody data, December 2020",2021-03-01,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,England,,"Because of the larger number of pupils in secondary schools, eligibility was restricted to two consecutive year groups in each secondary school. Year groups in secondary schools were chosen at random and in equal proportions across the schools and local authorities.","The following schools were excluded from the sampling frame:

-special schools, independent schools, pupil referral units and further education colleges

-schools taking part in other school-based COVID-19 studies

",2020-12-02,2020-12-10,Students and Daycares,All,Children and Youth (0-17 years),,,Primary Estimate,,3280,0.1345,0.1167,0.154,,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,Validated by independent authors/third party/non-developers,0.9720000000000001,0.998,['Missing'],,Yes,Yes,No,,Yes,Yes,Yes,,Office for National Statistics ,Office for National Statistics,Not Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/covid19schoolsinfectionsurveyround4england/antibodydatamarch2021,2021-07-14,2024-03-01,Unverified,office_for_national_statistics_covid-19_2021-1,GBR
210301_London_King’sCollegeHospital_primary,210301_London_King’sCollegeHospital,Severe Acute Respiratory Syndrome Coronavirus-2 Infections in Critical Care Staff: Beware the Risks Beyond the Bedside,2021-03-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,London,"All staff working in the critical care units at King’s
College Hospital, London, were invited to participate. ",,2020-04-22,2020-04-24,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,625,0.21,,,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,Serum,TotalAntibody,Spike,,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Kat El Bouzidi,King’s College Hospital,Not Unity-Aligned,https://dx.doi.org/10.1097/CCM.0000000000004878,2021-03-19,2022-07-16,Verified,el_bouzidi_severe_2021,GBR
210302_London_UniversityCollegeLondon_HCW_Overall,210302_London_UniversityCollegeLondon,Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS-CoV-2 infection,2021-03-02,Journal Article (Peer-Reviewed),Local,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,London,"Briefly, hospital healthcare workers (HCWs) self-declared fit to attend work were recruited to an observational cohort study consisting of questionnaires and biological sample collection at baseline and over 16 weekly-follow-up visits.",,2020-03-23,2020-08-17,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,729,0.215,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,Roche Diagnostics",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Yes,Yes,No,,Charlotte Manisty,University College London,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ebiom.2021.103259,2021-04-12,2024-03-01,Unverified,manisty_time_2021,GBR
210303_London_NorthMiddlesexUniversityHospitalNHSTrust_Overall,210303_London_NorthMiddlesexUniversityHospitalNHSTrust,Disproportionate impact of SARS-CoV-2 on ethnic minority and frontline healthcare workers: A cross-sectional seroprevalence survey at a North London hospital,2021-03-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,London,MUNH staff,,2020-06-04,2020-07-03,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,3285,0.35700000000000004,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,Yes,Emily Martin,North Middlesex University Hospital NHS Trust,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.02.027,2021-03-31,2022-07-16,Verified,martyn_disproportionate_2021,GBR
210303_Scotland_PublicHealthScotland_1ResidualSera_overall_adj,210303_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 03 March 2021,2021-03-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-01-04,2021-02-07,Residual sera,All,Multiple groups,,,Primary Estimate,"Overall, test and pop adjusted",3606,0.125,0.11199999999999999,0.138,True,True,True,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-march-2021/,2021-10-26,2022-07-16,Verified,public_health_scotland_enhanced_2021-8,GBR
210303_Scotland_PublicHealthScotland_1ResidualSera_male,210303_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 03 March 2021,2021-03-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-01-04,2021-02-07,Residual sera,Male,Multiple groups,,,Sex/Gender,"Males, unadj",1777,0.10470000000000002,,,,,,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-march-2021/,2021-10-26,2022-07-16,Verified,public_health_scotland_enhanced_2021-8,GBR
210303_Scotland_PublicHealthScotland_1ResidualSera_0-19,210303_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 03 March 2021,2021-03-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-01-04,2021-02-07,Residual sera,All,Children and Youth (0-17 years),,19.0,Age,"00 - 19, unadj",891,0.12789999999999999,,,,,,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-march-2021/,2021-10-26,2022-07-16,Verified,public_health_scotland_enhanced_2021-8,GBR
210303_Scotland_PublicHealthScotland_1ResidualSera_overall_unadj,210303_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 03 March 2021,2021-03-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-01-04,2021-02-07,Residual sera,All,Multiple groups,,,Analysis,"Overall, unadj",3606,0.1162,,,,,,,True,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-march-2021/,2021-10-26,2022-07-16,Verified,public_health_scotland_enhanced_2021-8,GBR
210303_Scotland_PublicHealthScotland_1ResidualSera_60-69,210303_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 03 March 2021,2021-03-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-01-04,2021-02-07,Residual sera,All,Seniors (65+ years),60.0,69.0,Age,"60 - 69, unadj",512,0.0898,,,,,,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-march-2021/,2021-10-26,2022-07-16,Verified,public_health_scotland_enhanced_2021-8,GBR
210303_Scotland_PublicHealthScotland_1ResidualSera_female,210303_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 03 March 2021,2021-03-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-01-04,2021-02-07,Residual sera,Female,Multiple groups,,,Sex/Gender,"Females, unadj",1829,0.1274,,,,,,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-march-2021/,2021-10-26,2022-07-16,Verified,public_health_scotland_enhanced_2021-8,GBR
210303_Scotland_PublicHealthScotland_1ResidualSera_70+,210303_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 03 March 2021,2021-03-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-01-04,2021-02-07,Residual sera,All,Seniors (65+ years),70.0,,Age,"70+, unadj",532,0.08460000000000001,,,,,,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-march-2021/,2021-10-26,2022-07-16,Verified,public_health_scotland_enhanced_2021-8,GBR
210303_Scotland_PublicHealthScotland_1ResidualSera_40-59,210303_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 03 March 2021,2021-03-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-01-04,2021-02-07,Residual sera,All,Adults (18-64 years),40.0,59.0,Age,"40 - 59, unadj",784,0.1429,,,,,,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-march-2021/,2021-10-26,2022-07-16,Verified,public_health_scotland_enhanced_2021-8,GBR
210303_Scotland_PublicHealthScotland_1ResidualSera_20-39,210303_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 03 March 2021,2021-03-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-01-04,2021-02-07,Residual sera,All,Adults (18-64 years),20.0,39.0,Age,"20 - 39, unadj",887,0.115,,,,,,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-march-2021/,2021-10-26,2022-07-16,Verified,public_health_scotland_enhanced_2021-8,GBR
210303_Scotland_PublicHealthScotland_2BloodDonors_overall_adj,210303_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 03 March 2021,2021-03-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-01-04,2021-02-07,Blood donors,All,Multiple groups,,,Primary Estimate,"Overall, test and pop adjusted",2497,0.152,0.134,0.17600000000000002,True,True,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-march-2021/,2021-10-26,2023-08-15,Verified,public_health_scotland_enhanced_2021-8,GBR
210303_Scotland_PublicHealthScotland_2BloodDonors_females,210303_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 03 March 2021,2021-03-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-01-04,2021-02-07,Blood donors,Female,Multiple groups,,,Sex/Gender,"Females, unadj",1328,0.1521,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-march-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-8,GBR
210303_Scotland_PublicHealthScotland_2BloodDonors_0-39,210303_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 03 March 2021,2021-03-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-01-04,2021-02-07,Blood donors,All,Multiple groups,,39.0,Age,"00 - 39, unadj",881,0.1464,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-march-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-8,GBR
210303_Scotland_PublicHealthScotland_2BloodDonors_males,210303_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 03 March 2021,2021-03-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-01-04,2021-02-07,Blood donors,Male,Multiple groups,,,Sex/Gender,"Males, unadj",1169,0.0864,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-march-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-8,GBR
210303_Scotland_PublicHealthScotland_2BloodDonors_overall_unadj,210303_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 03 March 2021,2021-03-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-01-04,2021-02-07,Blood donors,All,Multiple groups,,,Analysis,Overall Unadj,2497,0.1213,,,,,,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-march-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-8,GBR
210303_Scotland_PublicHealthScotland_2BloodDonors_40-59,210303_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 03 March 2021,2021-03-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-01-04,2021-02-07,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,"40 - 59, unadj",1148,0.12539999999999998,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-march-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-8,GBR
210303_Scotland_PublicHealthScotland_2BloodDonors_60+,210303_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 03 March 2021,2021-03-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-01-04,2021-02-07,Blood donors,All,Seniors (65+ years),60.0,,Age,"60+, unadj",468,0.0641,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-march-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-8,GBR
210303_Scotland_PublicHealthScotland_3PregnantWomen_Overall_PopAdj_TestAdj,210303_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 03 March 2021,2021-03-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-01-04,2021-02-07,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,"Overall, test and pop adjusted",3478,0.075,0.066,0.085,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-march-2021/,2021-10-29,2023-08-15,Verified,public_health_scotland_enhanced_2021-8,GBR
210303_Scotland_PublicHealthScotland_3PregnantWomen_Age_40+,210303_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 03 March 2021,2021-03-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-01-04,2021-02-07,Pregnant or parturient women,Female,Adults (18-64 years),40.0,,Age,age 40+,115,0.052199999999999996,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-march-2021/,2021-10-29,2024-03-01,Verified,public_health_scotland_enhanced_2021-8,GBR
210303_Scotland_PublicHealthScotland_3PregnantWomen_Age_20 - 29,210303_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 03 March 2021,2021-03-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-01-04,2021-02-07,Pregnant or parturient women,Female,Adults (18-64 years),20.0,29.0,Age,age 20-29,1378,0.0747,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-march-2021/,2021-10-29,2024-03-01,Verified,public_health_scotland_enhanced_2021-8,GBR
210303_Scotland_PublicHealthScotland_3PregnantWomen_Overall_Unadj,210303_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 03 March 2021,2021-03-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-01-04,2021-02-07,Pregnant or parturient women,Female,Adults (18-64 years),,,Analysis,"Overall, unadj",3478,0.0693,,,,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-march-2021/,2021-10-29,2024-03-01,Verified,public_health_scotland_enhanced_2021-8,GBR
210303_Scotland_PublicHealthScotland_3PregnantWomen_Age_00 - 19,210303_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 03 March 2021,2021-03-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-01-04,2021-02-07,Pregnant or parturient women,Female,Children and Youth (0-17 years),0.0,19.0,Age,age 0-19,68,0.0735,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-march-2021/,2021-10-29,2024-03-01,Verified,public_health_scotland_enhanced_2021-8,GBR
210303_Scotland_PublicHealthScotland_3PregnantWomen_Age_30 - 39,210303_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 03 March 2021,2021-03-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-01-04,2021-02-07,Pregnant or parturient women,Female,Adults (18-64 years),30.0,39.0,Age,age 30-39,1917,0.06620000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-march-2021/,2021-10-29,2024-03-01,Verified,public_health_scotland_enhanced_2021-8,GBR
210316_Sussex_UniversityofSussex_AbbottWSHT,210316_Sussex_UniversityofSussex_AbbottWSHT,Real-world experience of SARS-CoV-2 antibody assays in UK healthcare workers,2021-03-16,Journal Article (Peer-Reviewed),Local,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,West Sussex,"All antibody, SARS-CoV-2 polymerase chain reaction (PCR) viral nasopharyngeal throat swab and survey data from staff offered SARS-CoV-2 antibody testing via BSUH and WSHT were included",,2020-05-19,2020-10-20,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,12388,0.0789,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['High'],No,No,Yes,No,No,Yes,Yes,Yes,Unclear,Alyss Robinson,University of Sussex,Not Unity-Aligned,https://dx.doi.org/10.7861/clinmed.2020.1007,2021-04-15,2024-03-01,Verified,robinson_real-world_2021,GBR
210316_Sussex_UniversityofSussex_RocheBSUH,210316_Sussex_UniversityofSussex_RocheBSUH,Real-world experience of SARS-CoV-2 antibody assays in UK healthcare workers,2021-03-16,Journal Article (Peer-Reviewed),Local,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,Brighton and Sussex,"All antibody, SARS-CoV-2 polymerase chain reaction (PCR) viral nasopharyngeal throat swab and survey data from staff offered SARS-CoV-2 antibody testing via BSUH and WSHT were included",,2020-05-19,2020-09-29,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,14473,0.12990000000000002,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],No,No,Yes,No,No,Yes,Yes,Yes,Unclear,Alyss Robinson,University of Sussex,Not Unity-Aligned,https://dx.doi.org/10.7861/clinmed.2020.1007,2021-04-15,2024-03-01,Verified,robinson_real-world_2021,GBR
210316_Lancashire_LancashireTeachingHospitalsNHSTrust_OverallHCW,210316_Lancashire_LancashireTeachingHospitalsNHSTrust,Seroprevalence of SARS-CoV-2 infection in healthcare workers in a large teaching hospital in the North West of England: a period prevalence survey,2021-03-16,Journal Article (Peer-Reviewed),Local,Retrospective cohort,United Kingdom of Great Britain and Northern Ireland,England,"Chorley, Preston, South Ribble","All staff, regardless of role, who were tested for SARS-CoV-2 antibodies between May 29 and July 4 2020. ",Staff with incomplete data,2020-05-29,2020-07-04,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Overall,4474,0.174,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.92,1.0,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Robert Shorten ,Lancashire Teaching Hospitals NHS Foundation Trust,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2020-045384,2021-04-21,2024-03-01,Verified,shorten_seroprevalence_2021,GBR
210417_Leicestershire_UniversityofLeicester_Diasorin+Siemens,210417_Leicestershire_UniversityofLeicester,Retrospective serosurveillance for anti-SARS-CoV-2 immunoglobulin during a time of low prevalence: A cautionary tale,2021-03-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"samples were from patients undergoing viral serological screening in Leicestershire, England",,2019-10-01,2020-03-31,Residual sera,All,Multiple groups,0.0,95.0,Primary Estimate,Diasorin confirmed by Siemens assay,428,0.0,,,True,,,,True,Simplified probability,"Liaison SARS-CoV-2 S1/S2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T)","DiaSorin,Siemens",Multiple Types,Serum,"['IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],Unclear,Yes,No,No,Yes,Yes,Yes,No,,Paul William Bird,University of Leicester,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.03.007,2021-04-16,2024-03-01,Unverified,bird_retrospective_2021,GBR
210417_Leicestershire_UniversityofLeicester_DiasorinOnly,210417_Leicestershire_UniversityofLeicester,Retrospective serosurveillance for anti-SARS-CoV-2 immunoglobulin during a time of low prevalence: A cautionary tale,2021-03-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"samples were from patients undergoing viral serological screening in Leicestershire, England",,2019-10-01,2020-03-31,Residual sera,All,Multiple groups,0.0,95.0,Test used,Diasorin assay alone,428,0.023,,,,,,,,Simplified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9500000000000001,0.986,['High'],Unclear,Yes,No,No,Yes,Yes,Yes,No,,Paul William Bird,University of Leicester,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.03.007,2021-04-16,2024-03-01,Unverified,bird_retrospective_2021,GBR
210322_TheUnitedKingdom_RoyalDevonAndExeterNHSFoundationTrust_Overall,210322_TheUnitedKingdom_RoyalDevonAndExeterNHSFoundationTrust,Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab,2021-03-22,Journal Article (Peer-Reviewed),National,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,,,"The eligibility criteria were:1. Age 5 years and over.2. Diagnosis of IBD.3. Current  treatment  with  infliximab  or  vedolizumab  for  6  weeks or more, with at least one dose of drug received in the past 16 weeks",Patients were excluded if they had participate in a SARS-CoV-2 vaccine trial.,2020-09-22,2020-12-23,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,5.0,,Primary Estimate,,6935,0.043,0.038,0.048,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Nicholas Kennedy,Royal Devon and Exeter NHS Foundation Trust,Not Unity-Aligned,https://dx.doi.org/10.1136/gutjnl-2021-324388,2021-04-09,2024-03-01,Verified,kennedy_anti-sars-cov-2_2021,GBR
210322_England_PublicHealthEnglandColindale_Overall,210322_England_PublicHealthEnglandColindale,Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers,2021-03-22,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,England,"London, Wythenshawe, Porton","Office/lab staff, and sometimes family and friends (depending on location)",,2020-03-23,2020-11-18,Multiple populations,All,Adults (18-64 years),18.0,71.0,Primary Estimate,"Those who were ""confirmed positive"" (ie testing positive in at least 2 assays)",2246,0.11800000000000001,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S),Author designed (ELISA) -Spike","EUROIMMUN,Abbott Laboratories,Roche Diagnostics,NA",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,No,,Yes,Yes,No,,Robert Harris,Public Health England Colindale ,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.03.015,2021-05-13,2024-03-01,Unverified,harris_serological_2021,GBR
210323_Surrey_RoyalHollowayUniversityofLondon,210323_Surrey_RoyalHollowayUniversityofLondon,SARS-CoV-2 antibody seroprevalence in NHS healthcare workers in a large double-sited UK hospital,2021-03-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,Chertsey,"All adult staff (≥18 years old) from Ashford and St Peters Hospital
(ASPH), Surrey, UK were invited",,2020-10-15,2020-11-15,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,3119,0.19649999999999998,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.8250000000000001,0.9500000000000001,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Gie Ken Dror,Royal Holloway University of London,Not Unity-Aligned,https://dx.doi.org/10.7861/clinmed.2020-1096,2021-04-17,2024-03-01,Verified,ken-dror_sars-cov-2_2021,GBR
210324_London_ImperialCollegeLondon_Overall,210324_London_ImperialCollegeLondon,Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection,2021-03-24,Journal Article (Peer-Reviewed),Local,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,London,Patients receiving ICHD within 2 units affiliated with Imperial College Renal and Transplant Centre were included,,2020-02-24,2021-01-01,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,55.0,77.0,Primary Estimate,Overall (follow-up cohort),301,0.42857142857142855,,,True,,,,True,Unclear,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,Unclear,No,No,Unclear,Yes,Yes,Yes,Unclear,Candice L Clarke,Imperial College London,Not Unity-Aligned,https://dx.doi.org/10.1016/j.kint.2021.03.009,2021-05-23,2024-03-01,Verified,clarke_longevity_2021-1,GBR
210316_UK_OfficeForNationalStatistics_England_overall,210316_UK_OfficeForNationalStatistics_England,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,,34623,0.34600000000000003,0.34,0.353,True,,True,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-05-23,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_England_AgeOver80,210316_UK_OfficeForNationalStatistics_England,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,All,Seniors (65+ years),80.0,,Age,Age: >=80,1516,0.757,0.73,0.782,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-09-17,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_England_Age50to69,210316_UK_OfficeForNationalStatistics_England,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,All,Multiple groups,50.0,69.0,Age,Age: 50-69,13921,0.298,0.289,0.308,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-09-17,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_England_Age25to34,210316_UK_OfficeForNationalStatistics_England,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,All,Adults (18-64 years),25.0,34.0,Age,Age: 25-34,3278,0.277,0.26,0.295,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-09-17,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_England_Age16to24,210316_UK_OfficeForNationalStatistics_England,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,All,Multiple groups,16.0,24.0,Age,Age: 16-24,1821,0.32,0.297,0.34299999999999997,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-09-17,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_England_Age75to79,210316_UK_OfficeForNationalStatistics_England,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,All,Seniors (65+ years),75.0,79.0,Age,Age: 75-79,2275,0.688,0.665,0.71,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-09-17,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_England_Male,210316_UK_OfficeForNationalStatistics_England,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,Male,Multiple groups,16.0,,Sex/Gender,,18674,0.376,0.36700000000000005,0.384,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-09-17,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_England_Age35to49,210316_UK_OfficeForNationalStatistics_England,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,All,Adults (18-64 years),35.0,49.0,Age,Age: 35-49,7919,0.27399999999999997,0.262,0.287,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-09-17,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_England_Age70to74,210316_UK_OfficeForNationalStatistics_England,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,All,Seniors (65+ years),70.0,74.0,Age,Age: 70-74,3893,0.547,0.529,0.5650000000000001,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-09-17,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_England_Female,210316_UK_OfficeForNationalStatistics_England,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,Female,Multiple groups,16.0,,Sex/Gender,,15949,0.316,0.307,0.325,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-09-17,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_NorthernIreland_overall,210316_UK_OfficeForNationalStatistics_NorthernIreland,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Northern Ireland,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,,632,0.312,0.273,0.35200000000000004,True,,True,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-05-23,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_NorthernIreland_Age16to24,210316_UK_OfficeForNationalStatistics_NorthernIreland,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Northern Ireland,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,All,Multiple groups,16.0,24.0,Age,Age: 16-24,41,0.32,0.18,0.48700000000000004,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-09-17,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_NorthernIreland_Age35to49,210316_UK_OfficeForNationalStatistics_NorthernIreland,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Northern Ireland,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,All,Adults (18-64 years),35.0,49.0,Age,Age: 35-49,136,0.24300000000000002,0.172,0.326,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-09-17,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_NorthernIreland_Age50to69,210316_UK_OfficeForNationalStatistics_NorthernIreland,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Northern Ireland,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,All,Multiple groups,50.0,69.0,Age,Age: 50-69,274,0.34500000000000003,0.28800000000000003,0.406,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-09-17,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_NorthernIreland_Female,210316_UK_OfficeForNationalStatistics_NorthernIreland,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Northern Ireland,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,Female,Multiple groups,16.0,,Sex/Gender,,295,0.28500000000000003,0.231,0.344,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-09-17,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_NorthernIreland_Male,210316_UK_OfficeForNationalStatistics_NorthernIreland,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Northern Ireland,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,Male,Multiple groups,16.0,,Sex/Gender,,337,0.33799999999999997,0.28300000000000003,0.396,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-09-17,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_NorthernIreland_AgeOver70,210316_UK_OfficeForNationalStatistics_NorthernIreland,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Northern Ireland,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,All,Seniors (65+ years),70.0,,Age,Age: >=70,113,0.444,0.34700000000000003,0.543,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-09-17,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_NorthernIreland_Age25to34,210316_UK_OfficeForNationalStatistics_NorthernIreland,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Northern Ireland,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,All,Adults (18-64 years),25.0,34.0,Age,Age: 25-34,68,0.22899999999999998,0.13699999999999998,0.34500000000000003,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-09-17,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_Scotland_overall,210316_UK_OfficeForNationalStatistics_Scotland,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,"Scotland
",,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,,2737,0.223,0.20600000000000002,0.24100000000000002,True,,True,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-05-23,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_Scotland_Age70to74,210316_UK_OfficeForNationalStatistics_Scotland,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,"Scotland
",,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,All,Seniors (65+ years),70.0,74.0,Age,Age: 70-74,321,0.389,0.331,0.449,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-09-17,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_Scotland_Female,210316_UK_OfficeForNationalStatistics_Scotland,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,"Scotland
",,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,Female,Multiple groups,16.0,,Sex/Gender,,1248,0.193,0.16899999999999998,0.219,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-09-17,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_Scotland_Age25to34,210316_UK_OfficeForNationalStatistics_Scotland,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,"Scotland
",,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,All,Adults (18-64 years),25.0,34.0,Age,Age: 25-34,236,0.14800000000000002,0.105,0.2,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-09-17,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_Scotland_Age16to24,210316_UK_OfficeForNationalStatistics_Scotland,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,"Scotland
",,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,All,Multiple groups,16.0,24.0,Age,Age: 16-24,141,0.193,0.129,0.272,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-09-17,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_Scotland_Age50to69,210316_UK_OfficeForNationalStatistics_Scotland,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,"Scotland
",,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,All,Multiple groups,50.0,69.0,Age,Age: 50-69,1210,0.21100000000000002,0.187,0.237,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-09-17,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_Scotland_Age75to79,210316_UK_OfficeForNationalStatistics_Scotland,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,"Scotland
",,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,All,Seniors (65+ years),75.0,79.0,Age,Age: 75-79,165,0.39799999999999996,0.317,0.48200000000000004,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-09-17,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_Scotland_Male,210316_UK_OfficeForNationalStatistics_Scotland,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,"Scotland
",,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,Male,Multiple groups,16.0,,Sex/Gender,,1489,0.251,0.226,0.277,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-09-17,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_Scotland_AgeOver80,210316_UK_OfficeForNationalStatistics_Scotland,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,"Scotland
",,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,All,Seniors (65+ years),80.0,,Age,Age: >=80,106,0.609,0.503,0.708,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-09-17,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_Scotland_Age35to49,210316_UK_OfficeForNationalStatistics_Scotland,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,"Scotland
",,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,All,Adults (18-64 years),35.0,49.0,Age,Age: 35-49,558,0.158,0.127,0.19399999999999998,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-09-17,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_Wales_overall,210316_UK_OfficeForNationalStatistics_Wales,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Wales,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,All,Multiple groups,16.0,,Primary Estimate,,1224,0.305,0.275,0.336,True,,True,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-05-23,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_Wales_Male,210316_UK_OfficeForNationalStatistics_Wales,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Wales,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,Male,Multiple groups,16.0,,Sex/Gender,,642,0.35200000000000004,0.308,0.399,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-09-17,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_Wales_Age16to24,210316_UK_OfficeForNationalStatistics_Wales,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Wales,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,All,Multiple groups,16.0,24.0,Age,Age: 16-24,43,0.2,0.087,0.364,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-09-17,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_Wales_Age70to74,210316_UK_OfficeForNationalStatistics_Wales,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Wales,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,All,Seniors (65+ years),70.0,74.0,Age,Age: 70-74,169,0.47100000000000003,0.391,0.552,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-09-17,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_Wales_Female,210316_UK_OfficeForNationalStatistics_Wales,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Wales,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,Female,Multiple groups,16.0,,Sex/Gender,,582,0.255,0.21600000000000003,0.297,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-09-17,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_Wales_AgeOver80,210316_UK_OfficeForNationalStatistics_Wales,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Wales,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,All,Seniors (65+ years),80.0,,Age,Age: >=80,45,0.622,0.45799999999999996,0.767,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-09-17,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_Wales_Age25to34,210316_UK_OfficeForNationalStatistics_Wales,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Wales,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,All,Adults (18-64 years),25.0,34.0,Age,Age: 25-34,106,0.26,0.17600000000000002,0.36,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-09-17,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_Wales_Age35to49,210316_UK_OfficeForNationalStatistics_Wales,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Wales,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,All,Adults (18-64 years),35.0,49.0,Age,Age: 35-49,236,0.253,0.197,0.316,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-09-17,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_Wales_Age50to69,210316_UK_OfficeForNationalStatistics_Wales,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Wales,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,All,Multiple groups,50.0,69.0,Age,Age: 50-69,534,0.27399999999999997,0.23500000000000001,0.316,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-09-17,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210316_UK_OfficeForNationalStatistics_Wales_Age75to79,210316_UK_OfficeForNationalStatistics_Wales,Coronavirus (COVID-19) antibody and vaccination data for the UK_Feb4-March3,2021-03-30,Institutional Report,Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Wales,,"Only private households are included in the sample.  To capture data about people who have had COVID-19 but have since recovered, we aim to ask adults aged 16 years or older from around 10% of enrolled households to also give a sample of blood, which will be taken by a trained nurse, phlebotomist or healthcare assistant.","People living in care homes, other communal establishments and hospitals are not included. We do not take blood from anyone in a household where someone has symptoms compatible with COVID -19 infection, or is currently self-isolating or shielding, to make sure that study staff always stay at least two metres away from them.",2021-02-04,2021-03-03,Household and community samples,All,Seniors (65+ years),75.0,79.0,Age,Age: 75-79,91,0.5820000000000001,0.469,0.6890000000000001,,,True,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.99,0.991,['Low'],Yes,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Office for National Statistics,Office For National Statistics,Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk/2021,2021-09-17,2022-07-16,Verified,office_for_national_statistics_coronavirus_2021-4,GBR
210401_London_PublicHealthEngland_Overall,210401_London_PublicHealthEngland,"Persistence of SARS-CoV-2 N-Antibody Response in Healthcare Workers, London, UK",2021-04-01,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,,London,,,2020-03-30,2020-07-21,Health care workers and caregivers,All,Multiple groups,15.0,,Primary Estimate,Primary,1069,0.29,0.26,0.32,True,,,,True,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,,,['Moderate'],Yes,Unclear,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Madhumita Shrotri,Public Health England,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2704.204554,2021-04-11,2024-03-01,Verified,shrotri_persistence_2021,GBR
210407_Scotland_PublicHealthScotland_1ResidualSera_overall_adj,210407_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 07 April 2021,2021-04-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-02-08,2021-03-14,Residual sera,All,Multiple groups,,,Primary Estimate,"Overall, test and pop adjusted",3436,0.237,0.22100000000000003,0.255,True,True,True,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-7-april-2021/,2021-10-26,2022-07-16,Verified,public_health_scotland_enhanced_2021-12,GBR
210407_Scotland_PublicHealthScotland_1ResidualSera_20-39,210407_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 07 April 2021,2021-04-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-02-08,2021-03-14,Residual sera,All,Adults (18-64 years),20.0,39.0,Age,"20 - 39, unadj",851,0.18920000000000003,,,,,,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-7-april-2021/,2021-10-26,2022-07-16,Verified,public_health_scotland_enhanced_2021-12,GBR
210407_Scotland_PublicHealthScotland_1ResidualSera_male,210407_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 07 April 2021,2021-04-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-02-08,2021-03-14,Residual sera,Male,Multiple groups,,,Sex/Gender,"Males, unadj",1702,0.2056,,,,,,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-7-april-2021/,2021-10-26,2022-07-16,Unverified,public_health_scotland_enhanced_2021-12,GBR
210407_Scotland_PublicHealthScotland_1ResidualSera_60-69,210407_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 07 April 2021,2021-04-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-02-08,2021-03-14,Residual sera,All,Seniors (65+ years),60.0,69.0,Age,"60 - 69, unadj",468,0.2393,,,,,,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-7-april-2021/,2021-10-26,2022-07-16,Verified,public_health_scotland_enhanced_2021-12,GBR
210407_Scotland_PublicHealthScotland_1ResidualSera_overall_unadj,210407_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 07 April 2021,2021-04-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-02-08,2021-03-14,Residual sera,All,Multiple groups,,,Analysis,"Overall, unadj",3436,0.2218,,,,,,,True,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-7-april-2021/,2021-10-26,2022-07-16,Verified,public_health_scotland_enhanced_2021-12,GBR
210407_Scotland_PublicHealthScotland_1ResidualSera_40-59,210407_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 07 April 2021,2021-04-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-02-08,2021-03-14,Residual sera,All,Adults (18-64 years),40.0,59.0,Age,"40 - 59, unadj",741,0.1905,,,,,,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-7-april-2021/,2021-10-26,2022-07-16,Verified,public_health_scotland_enhanced_2021-12,GBR
210407_Scotland_PublicHealthScotland_1ResidualSera_70+,210407_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 07 April 2021,2021-04-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-02-08,2021-03-14,Residual sera,All,Seniors (65+ years),70.0,,Age,"70+, unadj",517,0.3985,,,,,,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-7-april-2021/,2021-10-26,2022-07-16,Verified,public_health_scotland_enhanced_2021-12,GBR
210407_Scotland_PublicHealthScotland_1ResidualSera_female,210407_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 07 April 2021,2021-04-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-02-08,2021-03-14,Residual sera,Female,Multiple groups,,,Sex/Gender,"Females, unadj",1734,0.23760000000000003,,,,,,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-7-april-2021/,2021-10-26,2022-07-16,Verified,public_health_scotland_enhanced_2021-12,GBR
210407_Scotland_PublicHealthScotland_1ResidualSera_0-19,210407_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 07 April 2021,2021-04-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-02-08,2021-03-14,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Age,"00 - 19, unadj",859,0.1641,,,,,,,,Stratified probability,Not reported/ Unable to specify,,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.875,0.986,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,,Public Health Scotland,Public Health Scotland,Not Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-7-april-2021/,2021-10-26,2022-07-16,Verified,public_health_scotland_enhanced_2021-12,GBR
210407_Scotland_PublicHealthScotland_2BloodDonors_overall_adj,210407_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 07 April 2021,2021-04-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-02-08,2021-03-14,Blood donors,All,Multiple groups,,,Primary Estimate,"Overall, test and pop adjusted",2492,0.252,0.225,0.27899999999999997,True,True,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-7-april-2021/,2021-10-26,2023-08-15,Verified,public_health_scotland_enhanced_2021-12,GBR
210407_Scotland_PublicHealthScotland_2BloodDonors_overall_unadj,210407_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 07 April 2021,2021-04-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-02-08,2021-03-14,Blood donors,All,Multiple groups,,,Analysis,Overall Unadj,2492,0.2215,,,,,,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-7-april-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-12,GBR
210407_Scotland_PublicHealthScotland_2BloodDonors_0-39,210407_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 07 April 2021,2021-04-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-02-08,2021-03-14,Blood donors,All,Multiple groups,0.0,39.0,Age,"00 - 39, unadj",887,0.21760000000000002,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-7-april-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-12,GBR
210407_Scotland_PublicHealthScotland_2BloodDonors_40-59,210407_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 07 April 2021,2021-04-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-02-08,2021-03-14,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,"40 - 59, unadj",1051,0.1827,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-7-april-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-12,GBR
210407_Scotland_PublicHealthScotland_2BloodDonors_60+,210407_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 07 April 2021,2021-04-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-02-08,2021-03-14,Blood donors,All,Seniors (65+ years),60.0,,Age,"60+, unadj",554,0.3014,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-7-april-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-12,GBR
210407_Scotland_PublicHealthScotland_2BloodDonors_males,210407_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 07 April 2021,2021-04-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-02-08,2021-03-14,Blood donors,Male,Multiple groups,,,Sex/Gender,"Males, unadj",1125,0.1705,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-7-april-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-12,GBR
210407_Scotland_PublicHealthScotland_2BloodDonors_females,210407_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 07 April 2021,2021-04-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-02-08,2021-03-14,Blood donors,Female,Multiple groups,,,Sex/Gender,"Females, unadj",1366,0.2635,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-7-april-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-12,GBR
210407_Scotland_PublicHealthScotland_3PregnantWomen_overall_adj,210407_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 07 April 2021,2021-04-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-02-08,2021-03-14,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,"Overall, test and pop adjusted",3355,0.096,0.085,0.107,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-7-april-2021/,2021-10-26,2023-08-15,Verified,public_health_scotland_enhanced_2021-12,GBR
210407_Scotland_PublicHealthScotland_3PregnantWomen_40+,210407_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 07 April 2021,2021-04-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-02-08,2021-03-14,Pregnant or parturient women,Female,Adults (18-64 years),40.0,,Age,age 40+,107,0.0374,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-7-april-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-12,GBR
210407_Scotland_PublicHealthScotland_3PregnantWomen_30-39,210407_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 07 April 2021,2021-04-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-02-08,2021-03-14,Pregnant or parturient women,Female,Adults (18-64 years),30.0,39.0,Age,age 30-39,1772,0.0818,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-7-april-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-12,GBR
210407_Scotland_PublicHealthScotland_3PregnantWomen_20-29,210407_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 07 April 2021,2021-04-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-02-08,2021-03-14,Pregnant or parturient women,Female,Adults (18-64 years),20.0,29.0,Age,age 20-29,1389,0.1015,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-7-april-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-12,GBR
210407_Scotland_PublicHealthScotland_3PregnantWomen_0-19,210407_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 07 April 2021,2021-04-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-02-08,2021-03-14,Pregnant or parturient women,Female,Children and Youth (0-17 years),0.0,19.0,Age,age 0-19,87,0.092,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-7-april-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-12,GBR
210407_Scotland_PublicHealthScotland_3PregnantWomen_overall_unadj,210407_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 07 April 2021,2021-04-07,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-02-08,2021-03-14,Pregnant or parturient women,Female,Adults (18-64 years),,,Analysis,"Overall, unadj",3355,0.0888,,,,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-7-april-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-12,GBR
210408_London_St.Thomas’NHSFoundationTrust_Primary,210408_London_St.Thomas’NHSFoundationTrust,IgG SARS-CoV-2 antibodies persist at least for 10 months in patients on hemodialysis.,2021-04-08,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,,London,,,2020-07-01,2020-07-31,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,Guy’s and St. Thomas’ NHS Foundation Trust patients on hemodialysis.,681,0.1865,,,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,,Serum,IgG,Spike,Validated by manufacturers,0.9740000000000001,,['Moderate'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Caroline Dudreuilh,St. Thomas’ NHS Foundation Trust,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ekir.2021.03.900,2021-05-22,2024-03-01,Verified,dudreuilh_igg_2021,GBR
210409_England_PublicHealthEngland,210409_England_PublicHealthEngland,"SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN).",2021-04-09,Journal Article (Peer-Reviewed),National,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,,,"All health-care workers, support staff, and administrative staff working at hospital sites participating in SIREN, who could provide written informed consent and anticipated remaining engaged in follow-up for 12 months were eligible to join SIREN.","Participants were excluded from this analysis if they had
no PCR tests after enrolment, enrolled after Dec 31, 2020,
or had insufficient PCR and antibody data to complete
cohort assignment.",2020-06-18,2020-12-31,Health care workers and caregivers,All,Multiple groups,18.0,85.0,Primary Estimate,HCWs across the National Health Service (NHS) in the UK.,25661,0.2943,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,Serum,,,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Victoria Jane Hall,Public Health England,Not Unity-Aligned,https://dx.doi.org/10.1016/S0140-6736(21)00675-9,2021-05-22,2022-07-16,Verified, hall_sars-cov-2_2021,GBR
210421_London_DMGDental-MaterialGesellschaftmbH_overall_unadj,210421_London_DMGDental-MaterialGesellschaftmbH,COVID-19 testing in a UK dental practice - results of a pilot study.,2021-04-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,London,Patient-facing personnel of a dental private practice,,2020-05-01,2020-05-31,Health care workers and caregivers,All,Adults (18-64 years),22.0,58.0,Primary Estimate,,14,0.2143,,,True,,,,True,Convenience,COVID-19 antibody rapid test,SureScreen Diagnostics,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],No,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Linda Greenwall,DMG Dental-Material Gesellschaft mbH,Not Unity-Aligned,https://dx.doi.org/10.1038/s41415-021-2849-7,2021-05-20,2024-03-01,Verified,greenwall_covid-19_2021,GBR
210423_Blackpool_NHSFoundationTrust_primaryAbbott,210423_Blackpool_NHSFoundationTrust,"EXPRESS: Comparison of four high throughput, automated immunoassays for the detection of SARS-CoV-2 antibodies.",2021-04-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,Blackpool,"These samples were from patients
who attended their local general practice and required a serum sample to be collected as
part of their routine care",,2020-08-01,2020-08-31,Residual sera,All,Multiple groups,13.0,94.0,Primary Estimate,Abbott Architect IgG,225,0.053,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,,Jane Oakey,NHS Foundation Trust ,Unity-Aligned,https://dx.doi.org/10.1177/00045632211015711,2021-05-20,2024-03-01,Verified,oakey_express_2021,GBR
210423_Blackpool_NHSFoundationTrust_BeckmanCoulter,210423_Blackpool_NHSFoundationTrust,"EXPRESS: Comparison of four high throughput, automated immunoassays for the detection of SARS-CoV-2 antibodies.",2021-04-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,Blackpool,"These samples were from patients
who attended their local general practice and required a serum sample to be collected as
part of their routine care",,2020-08-01,2020-08-31,Residual sera,All,Multiple groups,13.0,94.0,Test used,Beckman Coulter IgG Access,225,0.057999999999999996,,,,,,,,Convenience,Access SARS-CoV-2 IgG Reagent Antibody Test,Beckman Coulter,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,1.0,,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,,Jane Oakey,NHS Foundation Trust ,Unity-Aligned,https://dx.doi.org/10.1177/00045632211015711,2021-08-05,2024-03-01,Verified,oakey_express_2021,GBR
210423_Blackpool_NHSFoundationTrust_Roche,210423_Blackpool_NHSFoundationTrust,"EXPRESS: Comparison of four high throughput, automated immunoassays for the detection of SARS-CoV-2 antibodies.",2021-04-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,Blackpool,"These samples were from patients
who attended their local general practice and required a serum sample to be collected as
part of their routine care",,2020-08-01,2020-08-31,Residual sera,All,Multiple groups,13.0,94.0,Test used,Roche Elecsys Total Ab,225,0.049,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9620000000000001,,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,,Jane Oakey,NHS Foundation Trust ,Unity-Aligned,https://dx.doi.org/10.1177/00045632211015711,2021-08-05,2024-03-01,Verified,oakey_express_2021,GBR
210423_Blackpool_NHSFoundationTrust_Siemens,210423_Blackpool_NHSFoundationTrust,"EXPRESS: Comparison of four high throughput, automated immunoassays for the detection of SARS-CoV-2 antibodies.",2021-04-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,Blackpool,"These samples were from patients
who attended their local general practice and required a serum sample to be collected as
part of their routine care",,2020-08-01,2020-08-31,Residual sera,All,Multiple groups,13.0,94.0,Test used,Siemens ADVIA Centaur,225,0.053,,,,,,,,Convenience,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.923,,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,,Jane Oakey,NHS Foundation Trust ,Unity-Aligned,https://dx.doi.org/10.1177/00045632211015711,2021-08-05,2024-03-01,Verified,oakey_express_2021,GBR
210426_England_CambridgeUniversityHospitalsNHS,210426_England_CambridgeUniversityHospitalsNHS,SARS-CoV-2 Infection and Antibody Seroprevalence among UK Healthcare Professionals Working with Cancer Patients during the First Wave of the COVID-19 Pandemic,2021-04-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"CPs (which included patient-facingadministrative staff, such as clinic receptionists, health-care assistants and ward clerks) had to be working withinthe oncology department ward or outpatient setting andnot primarily within a dedicated SARS-CoV-2 inpatientward. HCPs who returned to work after self-isolating due toSARS-CoV-2 symptoms or exposure to a potentially affectedhousehold member (as per UK Government rules) wereeligible to participate.",HCPs were excluded if they had not been workingduring the pandemic peak from March to June 2020 or werenot patient facing. ,2020-06-15,2020-07-15,Health care workers and caregivers,All,Adults (18-64 years),19.0,66.0,Primary Estimate,,434,0.078,,,True,,,,True,Convenience,Abbexa COVID-19 IgG/IgM Rapid Test Kit,Abbexa,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.985,0.9794,['High'],,No,No,Yes,,No,Yes,Yes,,DM Favara,Cambridge University Hospitals NHS Foundation Trust,Not Unity-Aligned,https://dx.doi.org/10.1016/j.clon.2021.04.005,2021-05-27,2024-03-01,Unverified,favara_sars-cov-2_2021,GBR
210427_EastLondon_QueenMaryUniversityofLondon,210427_EastLondon_QueenMaryUniversityofLondon,"Disparities of SARS-CoV-2 Nucleoprotein-Specific IgG in Healthcare Workers in East London, UK.",2021-04-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,London,"Participant inclusion criteria
1. Aged 18 years or older
2. Known to have been infected with SARS-CoV-2, or who have not been infected with SARS-CoV-2
3. Agrees to complete all aspects of the study","Participant exclusion criteria
1. Belongs to a study group that has been filled
2. Has already participated in this study on a previous occasion
3. Is enrolled in a study to evaluate a new drug
4. Unable or unwilling to provide informed consent
5. Is a vulnerable person as deemed unfit for the study by the Principal Investigator",2020-06-15,2020-08-15,Health care workers and caregivers,All,Multiple groups,18.0,,Primary Estimate,Healthcare workers,2001,0.253,,,True,,,,True,Convenience,"Panbio COVID-19 IgG/IgM rapid test device,Abbott Architect SARS-CoV-2 IgG",Abbott Laboratories,,Multiple Types,"['IgG', 'IgM']",Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,No,,Yes,Yes,No,,Naheed Choudhry,Queen Mary University of London,Not Unity-Aligned,https://dx.doi.org/10.3389/fmed.2021.642723,2021-06-01,2024-03-01,Unverified,naheedchoudhryDisparitiesSARSCoV2NucleoproteinSpecific2021,GBR
210428_Europe_SorbonneUniversité_6London,210428_Europe_SorbonneUniversité_6London,SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study.,2021-04-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,London,London,"Eligible individuals had to be older than 18 years and have a definite clinical diagnosis of rheumatoid arthritis, axial spondyloarthritis, systemic lupus erythematosus, Sjögren's syndrome, or giant cell arteritis diagnosed by experienced rheumatologists and fulfilling the respective international classification criteria.","Patients who refused to participate, did not speak or read the local language, or were unwilling to undergo routine blood collection during the study period were excluded. ",2020-06-07,2020-12-08,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,,Primary Estimate,,239,0.146,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Liaison SARS-CoV-2 S1/S2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Siemens,DiaSorin,Beckman Coulter,Roche Diagnostics",,,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,Yes,Unclear,Unclear,No,No,Unclear,David Saadoun,Sorbonne Université,Not Unity-Aligned,https://dx.doi.org/10.1016/S2665-9913(21)00112-0,2021-05-31,2024-03-01,Verified,davidsaadounetal.SARSCoV2OutbreakImmunemediated2021,GBR
210502_England_ImperialCollegeLondon_TestPopAdj,210502_England_ImperialCollegeLondon,"Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adults.",2021-05-02,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"We  included non-overlapping community samples from the adult population 18 years and older, using a self-administered questionnaire and LFIA test at home. Invitations were sent to named individuals randomly selected from the National Health Service (NHS) patient list which includes anyone registered with a General Practitioner (primary care physician) in England, covering almost the entire population.",,2020-06-20,2020-09-28,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,"adjusted for test performance and weighted at national level for age, sex, region, ethnicity and deprivation to the adult population of England",365104,0.049400000000000006,0.048499999999999995,0.050300000000000004,True,True,True,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Helen Ward,Imperial College London,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanepe.2021.100098,2021-06-08,2022-07-16,Unverified,Ward_Prevalence_2021,GBR
210502_England_ImperialCollegeLondon_unadj,210502_England_ImperialCollegeLondon,"Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adults.",2021-05-02,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"We  included non-overlapping community samples from the adult population 18 years and older, using a self-administered questionnaire and LFIA test at home. Invitations were sent to named individuals randomly selected from the National Health Service (NHS) patient list which includes anyone registered with a General Practitioner (primary care physician) in England, covering almost the entire population.",,2020-06-20,2020-09-28,Household and community samples,All,Multiple groups,18.0,,Analysis,,365104,0.0481,0.0475,0.0488,,,,,True,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Helen Ward,Imperial College London,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanepe.2021.100098,2021-06-08,2022-07-16,Unverified,Ward_Prevalence_2021,GBR
210510_UK_PublicHealthEngland_Primary_RocheS,210510_UK_PublicHealthEngland,"Impact of COVID-19 vaccination program on seroprevalence in blood donors in England, 2021",2021-05-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,blood donors samples were available during the most recent 4-week period 22nd February-21st March 2021,,2021-02-22,2021-03-21,Blood donors,All,Multiple groups,17.0,84.0,Primary Estimate,primary estimtes using Roche S assay,7720,0.46399999999999997,0.454,0.47500000000000003,True,,True,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,,,Spike,Validated by independent authors/third party/non-developers,0.97,0.998,['Moderate'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Heather J Whitaker,Public Health England,Unity-Aligned,http://dx.doi.org/10.1016/j.jinf.2021.04.037,2021-06-05,2024-03-01,Verified,Whitaker_impact_2021,GBR
210510_UK_PublicHealthEngland_Primary_RocheN,210510_UK_PublicHealthEngland,"Impact of COVID-19 vaccination program on seroprevalence in blood donors in England, 2021",2021-05-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,blood donors samples were available during the most recent 4-week period 22nd February-21st March 2021,,2021-02-22,2021-03-21,Blood donors,All,Multiple groups,17.0,84.0,Test used,primary estimtes using Roche N assay,7717,0.145,0.13699999999999998,0.154,,,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.97,0.998,['Moderate'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Heather J Whitaker,Public Health England,Unity-Aligned,http://dx.doi.org/10.1016/j.jinf.2021.04.037,2021-06-05,2024-03-01,Verified,Whitaker_impact_2021,GBR
210512_Scotland_PublicHealthScotland_1ResidualSera_Overall_PopAdj_TestAdj,210512_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 12 May 2021,2021-05-12,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-04-12,2021-04-18,Residual sera,All,Multiple groups,,,Primary Estimate,"Overall, test and pop adjusted",708,0.438,0.402,0.474,True,True,True,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-12-may-2021/,2021-10-26,2023-08-15,Verified,public_health_scotland_enhanced_2021-16,GBR
210512_Scotland_PublicHealthScotland_1ResidualSera_Age_20 - 39_Unadj,210512_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 12 May 2021,2021-05-12,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-04-12,2021-04-18,Residual sera,All,Adults (18-64 years),20.0,39.0,Age,"20 - 39, unadj",178,0.38200000000000006,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-12-may-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-16,GBR
210512_Scotland_PublicHealthScotland_1ResidualSera_Age_60 - 69_Unadj,210512_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 12 May 2021,2021-05-12,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-04-12,2021-04-18,Residual sera,All,Seniors (65+ years),60.0,69.0,Age,"60 - 69, unadj",108,0.6759000000000001,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-12-may-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-16,GBR
210512_Scotland_PublicHealthScotland_1ResidualSera_Overall_Unadj,210512_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 12 May 2021,2021-05-12,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-04-12,2021-04-18,Residual sera,All,Multiple groups,,,Analysis,"Overall, unadj",708,0.428,,,,,,,True,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-12-may-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-16,GBR
210512_Scotland_PublicHealthScotland_1ResidualSera_Female_Unadj,210512_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 12 May 2021,2021-05-12,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-04-12,2021-04-18,Residual sera,Female,Multiple groups,,,Sex/Gender,"Females, unadj",354,0.44070000000000004,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-12-may-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-16,GBR
210512_Scotland_PublicHealthScotland_1ResidualSera_Age_40 - 59_Unadj,210512_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 12 May 2021,2021-05-12,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-04-12,2021-04-18,Residual sera,All,Adults (18-64 years),40.0,59.0,Age,"40 - 59, unadj",159,0.40880000000000005,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-12-may-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-16,GBR
210512_Scotland_PublicHealthScotland_1ResidualSera_Male_Unadj,210512_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 12 May 2021,2021-05-12,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-04-12,2021-04-18,Residual sera,Male,Multiple groups,,,Sex/Gender,"Males, unadj",354,0.4153,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-12-may-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-16,GBR
210512_Scotland_PublicHealthScotland_1ResidualSera_Age_00 - 19_Unadj,210512_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 12 May 2021,2021-05-12,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-04-12,2021-04-18,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Age,"00 - 19, unadj",167,0.2096,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-12-may-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-16,GBR
210512_Scotland_PublicHealthScotland_1ResidualSera_Age_70+_Unadj,210512_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 12 May 2021,2021-05-12,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-04-12,2021-04-18,Residual sera,All,Seniors (65+ years),70.0,,Age,"70+, unadj",96,0.6458,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-12-may-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-16,GBR
210512_Scotland_PublicHealthScotland_2BloodDonors_Overall_PopAdj_TestAdj,210512_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 12 May 2021,2021-05-12,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-03-15,2021-04-18,Blood donors,All,Multiple groups,,,Primary Estimate,"Overall, test and pop adjusted",2493,0.466,0.44,0.489,True,True,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-12-may-2021/,2021-10-26,2023-08-15,Verified,public_health_scotland_enhanced_2021-16,GBR
210512_Scotland_PublicHealthScotland_2BloodDonors_Female_Unadj,210512_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 12 May 2021,2021-05-12,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-03-15,2021-04-18,Blood donors,Female,Multiple groups,,,Sex/Gender,"Females, unadj",1448,0.4171,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-12-may-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-16,GBR
210512_Scotland_PublicHealthScotland_2BloodDonors_Male_Unadj,210512_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 12 May 2021,2021-05-12,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-03-15,2021-04-18,Blood donors,Male,Multiple groups,,,Sex/Gender,"Males, unadj",1045,0.36840000000000006,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-12-may-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-16,GBR
210512_Scotland_PublicHealthScotland_2BloodDonors_Age_00 - 39_Unadj,210512_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 12 May 2021,2021-05-12,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-03-15,2021-04-18,Blood donors,All,Multiple groups,0.0,39.0,Age,"00 - 39, unadj",933,0.2519,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-12-may-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-16,GBR
210512_Scotland_PublicHealthScotland_2BloodDonors_Age_40 - 59_Unadj,210512_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 12 May 2021,2021-05-12,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-03-15,2021-04-18,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,"40 - 59, unadj",1022,0.3532,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-12-may-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-16,GBR
210512_Scotland_PublicHealthScotland_2BloodDonors_Age_60+_Unadj,210512_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 12 May 2021,2021-05-12,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-03-15,2021-04-18,Blood donors,All,Seniors (65+ years),60.0,,Age,"60+, unadj",538,0.7305,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-12-may-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-16,GBR
210512_Scotland_PublicHealthScotland_2BloodDonors_Overall_Unadj,210512_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 12 May 2021,2021-05-12,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-03-15,2021-04-18,Blood donors,All,Multiple groups,,,Analysis,Overall Unadj,2493,0.39670000000000005,,,,,,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-12-may-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-16,GBR
210512_Scotland_PublicHealthScotland_3PregnantWomen_overall_adj,210512_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 12 May 2021,2021-05-12,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-03-15,2021-04-18,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,"Overall, test and pop adjusted",3326,0.125,0.11199999999999999,0.138,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-12-may-2021/,2021-10-26,2023-08-15,Verified,public_health_scotland_enhanced_2021-16,GBR
210512_Scotland_PublicHealthScotland_3PregnantWomen_30-39,210512_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 12 May 2021,2021-05-12,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-03-15,2021-04-18,Pregnant or parturient women,Female,Adults (18-64 years),30.0,39.0,Age,age 30-39,1840,0.1,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-12-may-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-16,GBR
210512_Scotland_PublicHealthScotland_3PregnantWomen_overall_unadj,210512_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 12 May 2021,2021-05-12,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-03-15,2021-04-18,Pregnant or parturient women,Female,Adults (18-64 years),,,Analysis,"Overall, unadj",3326,0.114,,,,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-12-may-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-16,GBR
210512_Scotland_PublicHealthScotland_3PregnantWomen_20-29,210512_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 12 May 2021,2021-05-12,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-03-15,2021-04-18,Pregnant or parturient women,Female,Adults (18-64 years),20.0,29.0,Age,age 20-29,1293,0.1323,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-12-may-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-16,GBR
210512_Scotland_PublicHealthScotland_3PregnantWomen_0-19,210512_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 12 May 2021,2021-05-12,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-03-15,2021-04-18,Pregnant or parturient women,Female,Children and Youth (0-17 years),0.0,19.0,Age,age 0-19,67,0.1642,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-12-may-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-16,GBR
210512_Scotland_PublicHealthScotland_3PregnantWomen_40+,210512_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 12 May 2021,2021-05-12,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-03-15,2021-04-18,Pregnant or parturient women,Female,Adults (18-64 years),40.0,,Age,age 40+,126,0.1032,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-12-may-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-16,GBR
210522_UK_UniversityCollegeLondon_overall,210522_UK_UniversityCollegeLondon,Household overcrowding and risk of SARS-CoV-2: analysis of the Virus Watch prospective community cohort study in England and Wales,2021-05-22,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England and Wales,,"18+ 
Individuals were included in this analysis if they underwent antibody testing between 1st February 2021 and 3rd May 2021 and completed the February 2021 monthly survey. ",,2021-02-01,2021-05-03,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,10330,0.08199999999999999,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Robert W Aldridge,University College London,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.05.10.21256912v2,2021-05-27,2024-03-01,Verified,aldridge_household_2021,GBR
210522_UK_UniversityCollegeLondon_Male,210522_UK_UniversityCollegeLondon,Household overcrowding and risk of SARS-CoV-2: analysis of the Virus Watch prospective community cohort study in England and Wales,2021-05-22,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England and Wales,,"18+ 
Individuals were included in this analysis if they underwent antibody testing between 1st February 2021 and 3rd May 2021 and completed the February 2021 monthly survey. ",,2021-02-01,2021-05-03,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,4438,0.079,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Robert W Aldridge,University College London,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.05.10.21256912v2,2021-08-12,2024-03-01,Verified,aldridge_household_2021,GBR
210522_UK_UniversityCollegeLondon_25-44,210522_UK_UniversityCollegeLondon,Household overcrowding and risk of SARS-CoV-2: analysis of the Virus Watch prospective community cohort study in England and Wales,2021-05-22,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England and Wales,,"18+ 
Individuals were included in this analysis if they underwent antibody testing between 1st February 2021 and 3rd May 2021 and completed the February 2021 monthly survey. ",,2021-02-01,2021-05-03,Household and community samples,All,Adults (18-64 years),25.0,44.0,Age,25-44,1106,0.14,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Robert W Aldridge,University College London,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.05.10.21256912v2,2021-08-12,2024-03-01,Verified,aldridge_household_2021,GBR
210522_UK_UniversityCollegeLondon_45-64,210522_UK_UniversityCollegeLondon,Household overcrowding and risk of SARS-CoV-2: analysis of the Virus Watch prospective community cohort study in England and Wales,2021-05-22,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England and Wales,,"18+ 
Individuals were included in this analysis if they underwent antibody testing between 1st February 2021 and 3rd May 2021 and completed the February 2021 monthly survey. ",,2021-02-01,2021-05-03,Household and community samples,All,Adults (18-64 years),45.0,64.0,Age,45-64,4053,0.099,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Robert W Aldridge,University College London,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.05.10.21256912v2,2021-08-12,2024-03-01,Verified,aldridge_household_2021,GBR
210522_UK_UniversityCollegeLondon_18-24,210522_UK_UniversityCollegeLondon,Household overcrowding and risk of SARS-CoV-2: analysis of the Virus Watch prospective community cohort study in England and Wales,2021-05-22,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England and Wales,,"18+ 
Individuals were included in this analysis if they underwent antibody testing between 1st February 2021 and 3rd May 2021 and completed the February 2021 monthly survey. ",,2021-02-01,2021-05-03,Household and community samples,All,Adults (18-64 years),18.0,24.0,Age,16-24,156,0.15,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Robert W Aldridge,University College London,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.05.10.21256912v2,2021-08-12,2024-03-01,Verified,aldridge_household_2021,GBR
210522_UK_UniversityCollegeLondon_>65,210522_UK_UniversityCollegeLondon,Household overcrowding and risk of SARS-CoV-2: analysis of the Virus Watch prospective community cohort study in England and Wales,2021-05-22,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England and Wales,,"18+ 
Individuals were included in this analysis if they underwent antibody testing between 1st February 2021 and 3rd May 2021 and completed the February 2021 monthly survey. ",,2021-02-01,2021-05-03,Household and community samples,All,Seniors (65+ years),65.0,,Age,,5015,0.053,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Robert W Aldridge,University College London,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.05.10.21256912v2,2021-08-12,2024-03-01,Verified,aldridge_household_2021,GBR
210522_UK_UniversityCollegeLondon_Female,210522_UK_UniversityCollegeLondon,Household overcrowding and risk of SARS-CoV-2: analysis of the Virus Watch prospective community cohort study in England and Wales,2021-05-22,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England and Wales,,"18+ 
Individuals were included in this analysis if they underwent antibody testing between 1st February 2021 and 3rd May 2021 and completed the February 2021 monthly survey. ",,2021-02-01,2021-05-03,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,5876,0.084,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Robert W Aldridge,University College London,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.05.10.21256912v2,2021-08-12,2024-03-01,Verified,aldridge_household_2021,GBR
210522_UK_UniversityCollegeLondon_MissingSex,210522_UK_UniversityCollegeLondon,Household overcrowding and risk of SARS-CoV-2: analysis of the Virus Watch prospective community cohort study in England and Wales,2021-05-22,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England and Wales,,"18+ 
Individuals were included in this analysis if they underwent antibody testing between 1st February 2021 and 3rd May 2021 and completed the February 2021 monthly survey. ",,2021-02-01,2021-05-03,Household and community samples,Other,Multiple groups,18.0,,Sex/Gender,,16,0.12,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Robert W Aldridge,University College London,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.05.10.21256912v2,2021-08-12,2024-03-01,Verified,aldridge_household_2021,GBR
210525_London_PublicHealthEngland_Week18_Euroimmun_Primary ,210525_London_PublicHealthEngland_Week18,"Seroprevalence of SARS-CoV-2 among Blood Donors and Changes after Introduction of Public Health and Social Measures, London, UK.",2021-05-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,London,,"Blood donors are healthy persons who are excluded from donating if they experienced any acute illness for >2 weeks before donating blood. In addition, specific donor exclusion criteria for coronavirus have been introduced (14 days postinfection at the time of the study, which was extended to 28 days starting June 8)",2020-05-01,2020-05-03,Blood donors,All,Multiple groups,17.0,69.0,Primary Estimate,Euroimmun ELISA,974,0.149,0.121,0.18,True,True,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Gayatri Amirthalingam,Public Health England,Unity-Aligned,https://dx.doi.org/10.3201/eid2707.203167,2021-07-01,2023-08-15,Verified,amirthalingam_seroprevalence_2021,GBR
210525_London_PublicHealthEngland_Week18_Euroimmun_17-29 ,210525_London_PublicHealthEngland_Week18,"Seroprevalence of SARS-CoV-2 among Blood Donors and Changes after Introduction of Public Health and Social Measures, London, UK.",2021-05-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,London,,"Blood donors are healthy persons who are excluded from donating if they experienced any acute illness for >2 weeks before donating blood. In addition, specific donor exclusion criteria for coronavirus have been introduced (14 days postinfection at the time of the study, which was extended to 28 days starting June 8)",2020-05-01,2020-05-03,Blood donors,All,Adults (18-64 years),17.0,29.0,Age,Euroimmun ELISA,226,0.13699999999999998,0.095,0.189,,,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Gayatri Amirthalingam,Public Health England,Unity-Aligned,https://dx.doi.org/10.3201/eid2707.203167,2021-07-01,2024-03-01,Verified,amirthalingam_seroprevalence_2021,GBR
210525_London_PublicHealthEngland_Week18_Abbott,210525_London_PublicHealthEngland_Week18,"Seroprevalence of SARS-CoV-2 among Blood Donors and Changes after Introduction of Public Health and Social Measures, London, UK.",2021-05-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,London,,"Blood donors are healthy persons who are excluded from donating if they experienced any acute illness for >2 weeks before donating blood. In addition, specific donor exclusion criteria for coronavirus have been introduced (14 days postinfection at the time of the study, which was extended to 28 days starting June 8)",2020-05-01,2020-05-03,Blood donors,All,Multiple groups,17.0,69.0,Test used,Abbott CLIA,973,0.12300000000000001,0.10300000000000001,0.146,,,True,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.914,0.98,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Gayatri Amirthalingam,Public Health England,Unity-Aligned,https://dx.doi.org/10.3201/eid2707.203167,2021-06-30,2024-03-01,Verified,amirthalingam_seroprevalence_2021,GBR
210525_London_PublicHealthEngland_Week18_Euroimmun_Female  ,210525_London_PublicHealthEngland_Week18,"Seroprevalence of SARS-CoV-2 among Blood Donors and Changes after Introduction of Public Health and Social Measures, London, UK.",2021-05-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,London,,"Blood donors are healthy persons who are excluded from donating if they experienced any acute illness for >2 weeks before donating blood. In addition, specific donor exclusion criteria for coronavirus have been introduced (14 days postinfection at the time of the study, which was extended to 28 days starting June 8)",2020-05-01,2020-05-03,Blood donors,Female,Multiple groups,17.0,69.0,Sex/Gender,Euroimmun ELISA,524,0.1202,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Gayatri Amirthalingam,Public Health England,Unity-Aligned,https://dx.doi.org/10.3201/eid2707.203167,2021-07-01,2024-03-01,Verified,amirthalingam_seroprevalence_2021,GBR
210525_London_PublicHealthEngland_Week18_Euroimmun_Testunadj ,210525_London_PublicHealthEngland_Week18,"Seroprevalence of SARS-CoV-2 among Blood Donors and Changes after Introduction of Public Health and Social Measures, London, UK.",2021-05-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,London,,"Blood donors are healthy persons who are excluded from donating if they experienced any acute illness for >2 weeks before donating blood. In addition, specific donor exclusion criteria for coronavirus have been introduced (14 days postinfection at the time of the study, which was extended to 28 days starting June 8)",2020-05-01,2020-05-03,Blood donors,All,Multiple groups,17.0,69.0,Analysis,Euroimmun ELISA,974,0.13,0.11,0.153,,,True,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Gayatri Amirthalingam,Public Health England,Unity-Aligned,https://dx.doi.org/10.3201/eid2707.203167,2021-07-01,2024-03-01,Verified,amirthalingam_seroprevalence_2021,GBR
210525_London_PublicHealthEngland_Week18_Inhouse,210525_London_PublicHealthEngland_Week18,"Seroprevalence of SARS-CoV-2 among Blood Donors and Changes after Introduction of Public Health and Social Measures, London, UK.",2021-05-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,London,,"Blood donors are healthy persons who are excluded from donating if they experienced any acute illness for >2 weeks before donating blood. In addition, specific donor exclusion criteria for coronavirus have been introduced (14 days postinfection at the time of the study, which was extended to 28 days starting June 8)",2020-05-01,2020-05-03,Blood donors,All,Multiple groups,17.0,69.0,Test used,Inhouse ELISA,964,0.141,0.12,0.165,,,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.925,0.98,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Gayatri Amirthalingam,Public Health England,Unity-Aligned,https://dx.doi.org/10.3201/eid2707.203167,2021-06-30,2022-07-16,Verified,amirthalingam_seroprevalence_2021,GBR
210525_London_PublicHealthEngland_Week18_Euroimmun_40-49  ,210525_London_PublicHealthEngland_Week18,"Seroprevalence of SARS-CoV-2 among Blood Donors and Changes after Introduction of Public Health and Social Measures, London, UK.",2021-05-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,London,,"Blood donors are healthy persons who are excluded from donating if they experienced any acute illness for >2 weeks before donating blood. In addition, specific donor exclusion criteria for coronavirus have been introduced (14 days postinfection at the time of the study, which was extended to 28 days starting June 8)",2020-05-01,2020-05-03,Blood donors,All,Adults (18-64 years),40.0,49.0,Age,Euroimmun ELISA,196,0.13699999999999998,0.09300000000000001,0.19399999999999998,,,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Gayatri Amirthalingam,Public Health England,Unity-Aligned,https://dx.doi.org/10.3201/eid2707.203167,2021-07-01,2024-03-01,Verified,amirthalingam_seroprevalence_2021,GBR
210525_London_PublicHealthEngland_Week18_Euroimmun_60-69  ,210525_London_PublicHealthEngland_Week18,"Seroprevalence of SARS-CoV-2 among Blood Donors and Changes after Introduction of Public Health and Social Measures, London, UK.",2021-05-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,London,,"Blood donors are healthy persons who are excluded from donating if they experienced any acute illness for >2 weeks before donating blood. In addition, specific donor exclusion criteria for coronavirus have been introduced (14 days postinfection at the time of the study, which was extended to 28 days starting June 8)",2020-05-01,2020-05-03,Blood donors,All,Seniors (65+ years),60.0,69.0,Age,Euroimmun ELISA,105,0.105,0.053,0.18,,,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Gayatri Amirthalingam,Public Health England,Unity-Aligned,https://dx.doi.org/10.3201/eid2707.203167,2021-07-01,2024-03-01,Verified,amirthalingam_seroprevalence_2021,GBR
210525_London_PublicHealthEngland_Week18_Euroimmun_50-59 ,210525_London_PublicHealthEngland_Week18,"Seroprevalence of SARS-CoV-2 among Blood Donors and Changes after Introduction of Public Health and Social Measures, London, UK.",2021-05-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,London,,"Blood donors are healthy persons who are excluded from donating if they experienced any acute illness for >2 weeks before donating blood. In addition, specific donor exclusion criteria for coronavirus have been introduced (14 days postinfection at the time of the study, which was extended to 28 days starting June 8)",2020-05-01,2020-05-03,Blood donors,All,Adults (18-64 years),50.0,59.0,Age,Euroimmun ELISA,187,0.091,0.054000000000000006,0.142,,,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Gayatri Amirthalingam,Public Health England,Unity-Aligned,https://dx.doi.org/10.3201/eid2707.203167,2021-07-01,2024-03-01,Verified,amirthalingam_seroprevalence_2021,GBR
210525_London_PublicHealthEngland_Week18_Euroimmun_Male ,210525_London_PublicHealthEngland_Week18,"Seroprevalence of SARS-CoV-2 among Blood Donors and Changes after Introduction of Public Health and Social Measures, London, UK.",2021-05-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,London,,"Blood donors are healthy persons who are excluded from donating if they experienced any acute illness for >2 weeks before donating blood. In addition, specific donor exclusion criteria for coronavirus have been introduced (14 days postinfection at the time of the study, which was extended to 28 days starting June 8)",2020-05-01,2020-05-03,Blood donors,Male,Multiple groups,17.0,69.0,Sex/Gender,Euroimmun ELISA,447,0.1387,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Gayatri Amirthalingam,Public Health England,Unity-Aligned,https://dx.doi.org/10.3201/eid2707.203167,2021-07-01,2024-03-01,Verified,amirthalingam_seroprevalence_2021,GBR
210525_London_PublicHealthEngland_Week18_Euroimmun_30-39  ,210525_London_PublicHealthEngland_Week18,"Seroprevalence of SARS-CoV-2 among Blood Donors and Changes after Introduction of Public Health and Social Measures, London, UK.",2021-05-25,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,London,,"Blood donors are healthy persons who are excluded from donating if they experienced any acute illness for >2 weeks before donating blood. In addition, specific donor exclusion criteria for coronavirus have been introduced (14 days postinfection at the time of the study, which was extended to 28 days starting June 8)",2020-05-01,2020-05-03,Blood donors,All,Adults (18-64 years),30.0,39.0,Age,Euroimmun ELISA,257,0.152,0.11,0.20199999999999999,,,True,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.8250000000000001,0.991,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Gayatri Amirthalingam,Public Health England,Unity-Aligned,https://dx.doi.org/10.3201/eid2707.203167,2021-07-01,2024-03-01,Verified,amirthalingam_seroprevalence_2021,GBR
210527_England_OfficeForNationalStatistics_StaffPrimary1_overall,210527_England_OfficeForNationalStatistics_StaffPrimary1,"COVID-19 Schools Infection Survey Round 4, England: antibody data, March 2021",2021-05-27,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,England,,"Within the selected schools, primary and secondary, all staff were eligible and invited to participate in the study. ","The following schools were excluded from the sampling frame:

-special schools, independent schools, pupil referral units and further education colleges

-schools taking part in other school-based COVID-19 studies

",2021-03-15,2021-03-31,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,1132,0.2152,0.1754,0.2594,True,,True,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,Validated by independent authors/third party/non-developers,0.9720000000000001,0.998,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Office for National Statistics ,Office for National Statistics,Not Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/covid19schoolsinfectionsurveyround4england/antibodydatamarch2021,2021-07-14,2024-03-01,Unverified,office_for_national_statistics_covid-19_2021,GBR
210527_England_OfficeForNationalStatistics_StaffSecondary2_overall,210527_England_OfficeForNationalStatistics_StaffSecondary2,"COVID-19 Schools Infection Survey Round 4, England: antibody data, March 2021",2021-05-27,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,England,,"Within the selected schools, primary and secondary, all staff were eligible and invited to participate in the study. ","The following schools were excluded from the sampling frame:

-special schools, independent schools, pupil referral units and further education colleges

-schools taking part in other school-based COVID-19 studies

",2021-03-15,2021-03-31,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,2159,0.18660000000000002,0.16469999999999999,0.21,True,,True,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,Validated by independent authors/third party/non-developers,0.9720000000000001,0.998,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Office for National Statistics ,Office for National Statistics,Not Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/covid19schoolsinfectionsurveyround4england/antibodydatamarch2021,2021-07-14,2024-03-01,Unverified,office_for_national_statistics_covid-19_2021,GBR
210601_England_UniversityCollegeLondon_residents_primary,210601_England_UniversityCollegeLondon_residents,Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study,2021-06-01,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,,LTCFs that provided care to adults aged older than 65 years and were owned by the FSHCG were eligible for participation and were identified by FSHCG. Staff and residents were eligible for inclusion in the analysis of risk of reinfection if they had a valid pseudo-identifier (enabling linkage of antibody test results to PCR tests); they lived or worked in a LTCF owned by FSHCG; they had at least one PCR test result during the analysis period; and they had at least one antibody test during the study period.,"We excluded staff members older than 65 years and residents aged younger than 65 years to minimise the risk that staff were misclassified as residents and residents were misclassified as staff members, and to enable assessment of immune response to SARS-CoV-2 in the two age groups (≥65 years vs ≤65 years).",2020-10-01,2021-02-01,Assisted living and long-term care facilities,All,Seniors (65+ years),65.0,103.0,Primary Estimate,,682,0.33,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria Krutikov,University College London,Not Unity-Aligned,https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(21)00093-3/fulltext,2021-07-28,2024-03-01,Verified,krutikov_incidence_2021-1,GBR
210601_England_UniversityCollegeLondon_staff_primary,210601_England_UniversityCollegeLondon_staff,Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study,2021-06-01,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,,LTCFs that provided care to adults aged older than 65 years and were owned by the FSHCG were eligible for participation and were identified by FSHCG. Staff and residents were eligible for inclusion in the analysis of risk of reinfection if they had a valid pseudo-identifier (enabling linkage of antibody test results to PCR tests); they lived or worked in a LTCF owned by FSHCG; they had at least one PCR test result during the analysis period; and they had at least one antibody test during the study period.,"We excluded staff members older than 65 years and residents aged younger than 65 years to minimise the risk that staff were misclassified as residents and residents were misclassified as staff members, and to enable assessment of immune response to SARS-CoV-2 in the two age groups (≥65 years vs ≤65 years).",2020-10-01,2021-02-01,Health care workers and caregivers,All,Adults (18-64 years),18.0,65.0,Primary Estimate,,1429,0.29,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Maria Krutikov,University College London,Not Unity-Aligned,https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(21)00093-3/fulltext,2021-07-28,2024-03-01,Verified,krutikov_incidence_2021-1,GBR
210316_England_PublicHealthEngland_Round1_Staff_Primary,210316_England_PublicHealthEngland_Round1_Staff,"SARS-CoV-2 infection and transmission in primary schools in England in June-December, 2020 (sKIDs): an active, prospective surveillance study.",2021-06-01,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,,Staff in participating primary schools,test positive in the first 2 rounds of serosurvey,2020-06-01,2020-06-19,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,1379,0.151,0.11900000000000001,0.189,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,Unclear,Shamez Ladhani,Public Health England,Not Unity-Aligned,https://dx.doi.org/10.1016/S2352-4642(21)00061-4,2021-07-22,2024-03-01,Verified,ladhani_sars-cov-2_2021,GBR
210316_England_PublicHealthEngland_Round1_Students_Primary,210316_England_PublicHealthEngland_Round1_Students,"SARS-CoV-2 infection and transmission in primary schools in England in June-December, 2020 (sKIDs): an active, prospective surveillance study.",2021-06-01,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,,Students in participating school's whose parents consented ,test positive in the first 2 rounds of serosurvey,2020-06-01,2020-06-19,Students and Daycares,All,Children and Youth (0-17 years),,,Primary Estimate,,816,0.11199999999999999,0.079,0.151,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Shamez Ladhani,Public Health England,Not Unity-Aligned,https://dx.doi.org/10.1016/S2352-4642(21)00061-4,2021-07-22,2024-03-01,Verified,ladhani_sars-cov-2_2021,GBR
210316_England_PublicHealthEngland_Round1_Students_Age10plus,210316_England_PublicHealthEngland_Round1_Students,"SARS-CoV-2 infection and transmission in primary schools in England in June-December, 2020 (sKIDs): an active, prospective surveillance study.",2021-06-01,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,,Students in participating school's whose parents consented ,test positive in the first 2 rounds of serosurvey,2020-06-01,2020-06-19,Students and Daycares,All,Children and Youth (0-17 years),,,Age,,274,0.109,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Shamez Ladhani,Public Health England,Not Unity-Aligned,https://dx.doi.org/10.1016/S2352-4642(21)00061-4,2021-07-22,2024-03-01,Verified,ladhani_sars-cov-2_2021,GBR
210316_England_PublicHealthEngland_Round1_Students_Age46,210316_England_PublicHealthEngland_Round1_Students,"SARS-CoV-2 infection and transmission in primary schools in England in June-December, 2020 (sKIDs): an active, prospective surveillance study.",2021-06-01,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,,Students in participating school's whose parents consented ,test positive in the first 2 rounds of serosurvey,2020-06-01,2020-06-19,Students and Daycares,All,Children and Youth (0-17 years),,,Age,,322,0.084,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Shamez Ladhani,Public Health England,Not Unity-Aligned,https://dx.doi.org/10.1016/S2352-4642(21)00061-4,2021-07-22,2024-03-01,Verified,ladhani_sars-cov-2_2021,GBR
210316_England_PublicHealthEngland_Round1_Students_Age79,210316_England_PublicHealthEngland_Round1_Students,"SARS-CoV-2 infection and transmission in primary schools in England in June-December, 2020 (sKIDs): an active, prospective surveillance study.",2021-06-01,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,,Students in participating school's whose parents consented ,test positive in the first 2 rounds of serosurvey,2020-06-01,2020-06-19,Students and Daycares,All,Children and Youth (0-17 years),,,Age,,220,0.155,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Shamez Ladhani,Public Health England,Not Unity-Aligned,https://dx.doi.org/10.1016/S2352-4642(21)00061-4,2021-07-22,2024-03-01,Unverified,ladhani_sars-cov-2_2021,GBR
210602_UK_dental_UniversityBirmingham,210602_UK_dental_UniversityBirmingham,COVID-19: Seroprevalence and Vaccine Responses in UK Dental Care Professionals.,2021-06-02,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,West midlands,,"Registered general dental practitioners (GDPs) in
the West Midlands area ",,2020-05-01,2020-05-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1507,0.163,,,True,,,,True,Convenience,,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by manufacturers,0.986,0.983,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,A M Shields,University of Birmingham,Not Unity-Aligned,https://dx.doi.org/10.1177/00220345211020270,2021-06-07,2021-10-05,Unverified,Shields_covid-19_2021,GBR
210602_UK_dental_UniversityBirmingham_Follow-up,210602_UK_dental_UniversityBirmingham_Follow-up,COVID-19: Seroprevalence and Vaccine Responses in UK Dental Care Professionals.,2021-06-02,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,West midlands,,"Registered general dental practitioners (GDPs) in
the West Midlands area that completed the baseline assessment 6 months prior. This follow-up samples includes unvaccinated and vaccinated individuals",,2021-01-01,2021-01-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,944,0.514,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.986,0.983,['Moderate'],,No,Yes,No,,Unclear,Yes,Yes,,A M Shields,University of Birmingham,Not Unity-Aligned,https://dx.doi.org/10.1177/00220345211020270,2021-06-07,2022-07-16,Unverified,Shields_covid-19_2021,GBR
210607_EastScotland_UniversityofDundee_Control2,210607_EastScotland_UniversityofDundee_Control2,The protective effect of sars-cov-2 antibodies in scottish healthcare workers,2021-06-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Scotland,Dundee,"A random selection of blood samples taken at NHS Tayside General Practice Surgeries were tested, covering the same time period as the HCW study cohort. Samples were age and sex matched to the Scottish population demographics",,2020-05-28,2020-09-02,Residual sera,All,Multiple groups,,,Primary Estimate,,231,0.048,,,True,,,,True,Sequential,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.9500000000000001,,['High'],Yes,No,No,No,Yes,Yes,Yes,Yes,Unclear,Hani Abo-Leyah,University of Dundee,Unity-Aligned,http://dx.doi.org/10.1183/23120541.00080-2021,2021-06-21,2024-03-01,Verified,abo-leyah_protective_2021,GBR
210607_EastScotland_UniversityofDundee_HCW1,210607_EastScotland_UniversityofDundee_HCW1,The protective effect of sars-cov-2 antibodies in scottish healthcare workers,2021-06-07,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Scotland,Dundee,"employment as a health or social care worker, and age >16 years","Participants were excluded if they had any contraindication to venepuncture, symptoms consistent with current SARS-CoV-2 infection at the time of enrolment, or had tested positive for SARS-CoV-2 in the preceding 14 days.

",2020-05-28,2020-09-02,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,2063,0.145,,,True,,,,True,Convenience,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.9500000000000001,,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Hani Abo-Leyah,University of Dundee,Not Unity-Aligned,http://dx.doi.org/10.1183/23120541.00080-2021,2021-06-21,2024-03-01,Verified,abo-leyah_protective_2021,GBR
210616_Scotland_PublicHealthScotland_1ResidualSera_Overall_PopAdj_TestAdj,210616_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 16 Jun 2021,2021-06-16,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-04-19,2021-05-23,Residual sera,All,Multiple groups,,,Primary Estimate,"Overall, test and pop adjusted",3589,0.48610000000000003,0.4696,0.503,True,True,True,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-16-june-2021/,2021-10-26,2023-08-15,Verified,public_health_scotland_enhanced_2021-20,GBR
210616_Scotland_PublicHealthScotland_1ResidualSera_Female_Unadj,210616_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 16 Jun 2021,2021-06-16,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-04-19,2021-05-23,Residual sera,Female,Multiple groups,,,Sex/Gender,"Females, unadj",1806,0.495,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-16-june-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-20,GBR
210616_Scotland_PublicHealthScotland_1ResidualSera_Overall_Unadj,210616_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 16 Jun 2021,2021-06-16,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-04-19,2021-05-23,Residual sera,All,Multiple groups,,,Analysis,"Overall, unadj",3589,0.47509999999999997,,,,,,,True,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-16-june-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-20,GBR
210616_Scotland_PublicHealthScotland_1ResidualSera_April19-25,210616_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 16 Jun 2021,2021-06-16,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-04-19,2021-04-25,Residual sera,All,Multiple groups,,,Time frame,Sampling April 18-24,713,0.425,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-16-june-2021/,2021-07-27,2024-03-01,Verified,public_health_scotland_enhanced_2021-20,GBR
210616_Scotland_PublicHealthScotland_1ResidualSera_Age_00-19_Unadj,210616_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 16 Jun 2021,2021-06-16,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-04-19,2021-05-23,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Age,"00 - 19, unadj",906,0.19090000000000001,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-16-june-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-20,GBR
210616_Scotland_PublicHealthScotland_1ResidualSera_Male_Unadj,210616_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 16 Jun 2021,2021-06-16,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-04-19,2021-05-23,Residual sera,Male,Multiple groups,,,Sex/Gender,"Males, unadj",1783,0.4549,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-16-june-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-20,GBR
210616_Scotland_PublicHealthScotland_1ResidualSera_May3-9,210616_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 16 Jun 2021,2021-06-16,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-05-03,2021-05-09,Residual sera,All,Multiple groups,,,Time frame,Sampling May 2-8,713,0.4755,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-16-june-2021/,2021-07-27,2024-03-01,Verified,public_health_scotland_enhanced_2021-20,GBR
210616_Scotland_PublicHealthScotland_1ResidualSera_April26-May2,210616_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 16 Jun 2021,2021-06-16,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-04-26,2021-05-02,Residual sera,All,Multiple groups,,,Time frame,Sampling April 25-May 1,728,0.4464,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-16-june-2021/,2021-07-27,2024-03-01,Verified,public_health_scotland_enhanced_2021-20,GBR
210616_Scotland_PublicHealthScotland_1ResidualSera_Age_70+_Unadj,210616_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 16 Jun 2021,2021-06-16,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-04-19,2021-05-23,Residual sera,All,Seniors (65+ years),70.0,,Age,"70+, unadj",515,0.8078000000000001,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-16-june-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-20,GBR
210616_Scotland_PublicHealthScotland_1ResidualSera_Age_60-69_Unadj,210616_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 16 Jun 2021,2021-06-16,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-04-19,2021-05-23,Residual sera,All,Seniors (65+ years),60.0,69.0,Age,"60 - 69, unadj",518,0.7123999999999999,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-16-june-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-20,GBR
210616_Scotland_PublicHealthScotland_1ResidualSera_Age_20-39_Unadj,210616_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 16 Jun 2021,2021-06-16,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-04-19,2021-05-23,Residual sera,All,Adults (18-64 years),20.0,39.0,Age,"20 - 39, unadj",873,0.3608,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-16-june-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-20,GBR
210616_Scotland_PublicHealthScotland_1ResidualSera_Age_40-59_Unadj,210616_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 16 Jun 2021,2021-06-16,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-04-19,2021-05-23,Residual sera,All,Adults (18-64 years),40.0,59.0,Age,"40 - 59, unadj",777,0.556,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-16-june-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-20,GBR
210616_Scotland_PublicHealthScotland_2BloodDonors_Overall_PopAdj_TestAdj,210616_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 16 Jun 2021,2021-06-16,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-04-19,2021-05-23,Blood donors,All,Multiple groups,,,Primary Estimate,"Overall, test and pop adj",2494,0.6631999999999999,0.638,0.684,True,True,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-16-june-2021/,2021-10-26,2023-08-15,Verified,public_health_scotland_enhanced_2021-20,GBR
210616_Scotland_PublicHealthScotland_2BloodDonors_Age_60+_Unadj,210616_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 16 Jun 2021,2021-06-16,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-04-19,2021-05-23,Blood donors,All,Seniors (65+ years),60.0,,Age,"60+, unadj",532,0.8553000000000001,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-16-june-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-20,GBR
210616_Scotland_PublicHealthScotland_2BloodDonors_Male_Unadj,210616_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 16 Jun 2021,2021-06-16,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-04-19,2021-05-23,Blood donors,Male,Multiple groups,,,Sex/Gender,"Males, unadj",1088,0.5809000000000001,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-16-june-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-20,GBR
210616_Scotland_PublicHealthScotland_2BloodDonors_Age_00 - 39_Unadj,210616_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 16 Jun 2021,2021-06-16,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-04-19,2021-05-23,Blood donors,All,Multiple groups,0.0,39.0,Age,"00 - 39, unadj",975,0.37229999999999996,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-16-june-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-20,GBR
210616_Scotland_PublicHealthScotland_2BloodDonors_Female_Unadj,210616_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 16 Jun 2021,2021-06-16,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-04-19,2021-05-23,Blood donors,Female,Multiple groups,,,Sex/Gender,"Females, unadj",1406,0.5939,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-16-june-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-20,GBR
210616_Scotland_PublicHealthScotland_2BloodDonors_Age_40 - 59_Unadj,210616_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 16 Jun 2021,2021-06-16,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-04-19,2021-05-23,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,"40 - 59, unadj",987,0.6575,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-16-june-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-20,GBR
210616_Scotland_PublicHealthScotland_2BloodDonors_Overall_Unadj,210616_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 16 Jun 2021,2021-06-16,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-04-19,2021-05-23,Blood donors,All,Multiple groups,,,Analysis,Overall Unadj,2494,0.5882000000000001,,,,,,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-16-june-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-20,GBR
210616_Scotland_PublicHealthScotland_3PregnantWomen_Overall_PopAdj_TestAdj,210616_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 16 Jun 2021,2021-06-16,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-04-19,2021-05-23,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,"Overall, test and pop adjusted",3333,0.1084,0.0969,0.12,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-16-june-2021/,2021-10-26,2023-08-15,Verified,public_health_scotland_enhanced_2021-20,GBR
210616_Scotland_PublicHealthScotland_3PregnantWomen_Age_00 - 19,210616_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 16 Jun 2021,2021-06-16,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-04-19,2021-05-23,Pregnant or parturient women,Female,Children and Youth (0-17 years),0.0,19.0,Age,age 0-19,63,0.07940000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-16-june-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-20,GBR
210616_Scotland_PublicHealthScotland_3PregnantWomen_Age_30 - 39,210616_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 16 Jun 2021,2021-06-16,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-04-19,2021-05-23,Pregnant or parturient women,Female,Adults (18-64 years),30.0,39.0,Age,age 30-39,1865,0.0949,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-16-june-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-20,GBR
210616_Scotland_PublicHealthScotland_3PregnantWomen_Age_20 - 29,210616_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 16 Jun 2021,2021-06-16,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-04-19,2021-05-23,Pregnant or parturient women,Female,Adults (18-64 years),20.0,29.0,Age,age 20-29,1301,0.113,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-16-june-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-20,GBR
210616_Scotland_PublicHealthScotland_3PregnantWomen_Overall_Unadj,210616_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 16 Jun 2021,2021-06-16,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-04-19,2021-05-23,Pregnant or parturient women,Female,Adults (18-64 years),,,Analysis,"Overall, unadj",3333,0.1002,,,,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-16-june-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-20,GBR
210616_Scotland_PublicHealthScotland_3PregnantWomen_Age_40+,210616_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 16 Jun 2021,2021-06-16,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-04-19,2021-05-23,Pregnant or parturient women,Female,Adults (18-64 years),40.0,,Age,age 40+,104,0.0481,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-16-june-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-20,GBR
210622_London_LondonSchoolOfHygieneAndTropicalMedicine_HCWs,210622_London_LondonSchoolOfHygieneAndTropicalMedicine,Association between SARS-CoV-2 exposure and antibody status among healthcare workers in two London hospitals: a cross-sectional study,2021-06-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,London,"The inclusion criteria were as follows: 1) having worked at either (or both) of Chelsea and West-minster Hospital and West Middlesex Hospital between 1March 2020 and 30 June 20202) in line with Public Health England (PHE) guidance, during the first three weeks of the study, only HCWs who had symptoms matching the PHE case definition for SARS-CoV-2infection (onset at least 14 days earlier) were eligible for testing .3) for the remaining five weeks of the study, testing became open to all HCW in the two hospitals",,2020-05-04,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,615,0.40700000000000003,,,True,,,,True,Convenience,"2019-nCoV IgG/IgM Antibody Detection Kit,OnSite COVID-19 IgG/IgM Rapid Test,COVID-19 IgG/IgM Rapid Test,VivaDiag COVID-19 IgM/IgG Rapid Test","Zhuhai Livzon Diagnostics Inc,CTK Biotech, Inc.,Zhejiang Orient Gene Biotech,VivaChek Biotech (Hangzhou) Co. Ltd",LFIA,Whole Blood,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,,,['High'],Yes,No,Yes,Yes,Unclear,Unclear,No,No,No,Admire Murongazvombo,London School Of Hygiene And Tropical Medicine,Not Unity-Aligned,http://dx.doi.org/10.1016/j.infpip.2021.100157,2021-07-28,2024-03-01,Verified,murongazvombo_association_2021,GBR
210525_Scotland_NHSLothian,210525_Scotland_NHSLothian,Comparison of SARS-CoV-2 serological assays for use in epidemiological surveillance in Scotland.,2021-06-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Scotland,,,,2020-04-27,2020-08-03,Household and community samples,All,Multiple groups,,,Primary Estimate,,355,0.045,,,True,,,,True,Sequential,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N),Liaison SARS-CoV-2 S1/S2 IgG,Atellica® IM SARS-CoV-2 Total (COV2T),Anti-SARS-CoV-2 ELISA IgG","Abbott Laboratories,Roche Diagnostics,DiaSorin,Siemens,EUROIMMUN",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],,No,No,No,,Unclear,Yes,No,,Lindsay McDonald,NHS Lothian,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcvp.2021.100028,2022-03-18,2024-03-01,Unverified,mcdonaldComparisonSARSCoV2Serological2021,GBR
210626_Leicester_UniversityOfLeicester,210626_Leicester_UniversityOfLeicester,Retrospective SARS-CoV-2 IgG screening during the first wave (March-June 2020) of the COVID-19 pandemic in the UK.,2021-06-26,Journal Article (Peer-Reviewed),Local,Retrospective cohort,United Kingdom of Great Britain and Northern Ireland,England,Leicester,"To examine the prevalence of these undiagnosed, mildly or asymptomatic SARS-CoV-2 infections, we ran a search of 22 124 serum samples collected between 16th March and the 3rd June. Archived serum samples stored in chronological order were selected randomly (selecting every 17th sample to cover the time period and to keep within the limits of kits available for testing) ",,2020-03-16,2020-06-03,Household and community samples,All,Multiple groups,0.0,99.0,Primary Estimate,overall,1779,0.1135,,,True,,,,True,Simplified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.97,0.9890000000000001,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Paul William Bird,University of Leicester,Unity-Aligned,https://dx.doi.org/10.1002/jmv.27162,2021-07-07,2024-03-01,Verified,bird_retrospective_2021-2,GBR
210701_England_OfficeForNationalStatistics_Round5_StaffPrimary1_overall,210701_England_OfficeForNationalStatistics_Round5_StaffPrimary1,"COVID-19 Schools Infection Survey, England: Round 5, England: May 2021",2021-07-01,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,England,,"Within the selected schools, primary and secondary, all staff were eligible and invited to participate in the study. ","The following schools were excluded from the sampling frame:

-special schools, independent schools, pupil referral units and further education colleges

-schools taking part in other school-based COVID-19 studies

",2021-05-05,2021-05-21,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,1023,0.24370000000000003,0.1975,0.2947,True,,True,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,Validated by independent authors/third party/non-developers,0.9720000000000001,0.998,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Office for National Statistics,Office for National Statistics,Not Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/covid19schoolsinfectionsurveyengland/round5englandmay2021,2021-07-29,2024-03-01,Unverified,office_for_national_statistics_covid-19_2021-2,GBR
210701_England_OfficeForNationalStatistics_Round5_StaffSecondary2_overall,210701_England_OfficeForNationalStatistics_Round5_StaffSecondary2,"COVID-19 Schools Infection Survey, England: Round 5, England: May 2021",2021-07-01,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,England,,"Within the selected schools, primary and secondary, all staff were eligible and invited to participate in the study. ","The following schools were excluded from the sampling frame:

-special schools, independent schools, pupil referral units and further education colleges

-schools taking part in other school-based COVID-19 studies

",2021-05-05,2021-05-21,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,1902,0.21789999999999998,0.1942,0.24300000000000002,True,,True,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,Validated by independent authors/third party/non-developers,0.9720000000000001,0.998,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Office for National Statistics,Office for National Statistics,Not Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/covid19schoolsinfectionsurveyengland/round5englandmay2021,2021-07-29,2024-03-01,Unverified,office_for_national_statistics_covid-19_2021-2,GBR
210706_London_LondonSchoolofHygiene&TropicalMedicine,210706_London_LondonSchoolofHygiene&TropicalMedicine,SARS-CoV-2 seroprevalence in a strictly-Orthodox Jewish community in the UK: A retrospective cohort study,2021-07-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,London,Members of a strictly Orthodox Jewish communit,,2020-10-19,2020-12-07,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,Overall cluster adjusted,1242,0.643,0.616,0.67,True,,,True,True,Simplified probability,Not reported/ Unable to specify,,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9620000000000001,0.9740000000000001,['Moderate'],No,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Yes,Katherine Gaskell,London School of Hygiene & Tropical Medicine,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8291041/,2021-08-04,2022-07-16,Verified,gaskell_sars-cov-2_2021,GBR
210713_England_DepartmentofHealthandSocialCare,210713_England_DepartmentofHealthandSocialCare,National cross-sectional survey of 1.14 million NHS staff SARS-CoV-2 serology tests: a comparison of NHS staff with regional community seroconversion rates.,2021-07-13,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"""all NHS staff who wanted it as part of the COVID-19 response""","""primary care samples were excluded.""",2020-05-26,2020-08-31,Health care workers and caregivers,All,Adults (18-64 years),18.0,65.0,Primary Estimate,overall ,1146310,0.163,0.162,0.16399999999999998,True,,,,True,Convenience,Not reported/ Unable to specify,,Multiple Types,Serum,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,No,Unclear,Unclear,Yes,No,Yes,Cordelia Coltart,Department of Health and Social Care,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-049703,2021-07-21,2022-07-16,Unverified,coltart_national_2021,GBR
210718_England_ImperialCollegeLondon_Round6,210718_England_ImperialCollegeLondon_Round6,"Vaccine uptake and SARS-CoV-2 antibody prevalence among 207,337 adults during May 2021 in England: REACT-2 study",2021-07-18,Preprint,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-05-12,2021-05-25,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,207337,0.611,0.609,0.614,True,True,True,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.14.21260497v1,2021-08-04,2022-07-16,Unverified,ward_vaccine_2021,GBR
210718_England_ImperialCollegeLondon_Round6_UnVaccinated,210718_England_ImperialCollegeLondon_Round6,"Vaccine uptake and SARS-CoV-2 antibody prevalence among 207,337 adults during May 2021 in England: REACT-2 study",2021-07-18,Preprint,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-05-12,2021-05-25,Household and community samples,All,Multiple groups,18.0,,COVID-19 vaccination status,Vaccinated no,18552,0.136,0.131,0.141,,,,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.14.21260497v1,2021-08-04,2022-07-16,Unverified,ward_vaccine_2021,GBR
210718_England_ImperialCollegeLondon_Round6_45-54yrs,210718_England_ImperialCollegeLondon_Round6,"Vaccine uptake and SARS-CoV-2 antibody prevalence among 207,337 adults during May 2021 in England: REACT-2 study",2021-07-18,Preprint,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-05-12,2021-05-25,Household and community samples,All,Adults (18-64 years),45.0,54.0,Age,45-54 years,17520,0.951,0.9490000000000001,0.953,,,True,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.14.21260497v1,2021-08-04,2022-07-16,Unverified,ward_vaccine_2021,GBR
210718_England_ImperialCollegeLondon_Round6_74yrs,210718_England_ImperialCollegeLondon_Round6,"Vaccine uptake and SARS-CoV-2 antibody prevalence among 207,337 adults during May 2021 in England: REACT-2 study",2021-07-18,Preprint,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-05-12,2021-05-25,Household and community samples,All,Seniors (65+ years),74.0,,Age,74 years,7314,0.9920000000000001,0.991,0.993,,,True,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.14.21260497v1,2021-08-04,2022-07-16,Unverified,ward_vaccine_2021,GBR
210718_England_ImperialCollegeLondon_Round6_18-24yrs,210718_England_ImperialCollegeLondon_Round6,"Vaccine uptake and SARS-CoV-2 antibody prevalence among 207,337 adults during May 2021 in England: REACT-2 study",2021-07-18,Preprint,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-05-12,2021-05-25,Household and community samples,All,Adults (18-64 years),18.0,24.0,Age,18-24 years,4718,0.251,0.245,0.256,,,True,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.14.21260497v1,2021-08-04,2022-07-16,Unverified,ward_vaccine_2021,GBR
210718_England_ImperialCollegeLondon_Round6_Female,210718_England_ImperialCollegeLondon_Round6,"Vaccine uptake and SARS-CoV-2 antibody prevalence among 207,337 adults during May 2021 in England: REACT-2 study",2021-07-18,Preprint,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-05-12,2021-05-25,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,116130,0.753,0.75,0.755,,,True,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.14.21260497v1,2021-08-04,2022-07-16,Unverified,ward_vaccine_2021,GBR
210718_England_ImperialCollegeLondon_Round6_65-74yrs,210718_England_ImperialCollegeLondon_Round6,"Vaccine uptake and SARS-CoV-2 antibody prevalence among 207,337 adults during May 2021 in England: REACT-2 study",2021-07-18,Preprint,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-05-12,2021-05-25,Household and community samples,All,Seniors (65+ years),65.0,74.0,Age,65-74 years,71265,0.991,0.99,0.9920000000000001,,,True,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.14.21260497v1,2021-08-04,2022-07-16,Unverified,ward_vaccine_2021,GBR
210718_England_ImperialCollegeLondon_Round6_Male,210718_England_ImperialCollegeLondon_Round6,"Vaccine uptake and SARS-CoV-2 antibody prevalence among 207,337 adults during May 2021 in England: REACT-2 study",2021-07-18,Preprint,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-05-12,2021-05-25,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,90370,0.703,0.7000000000000001,0.706,,,True,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.14.21260497v1,2021-08-04,2022-07-16,Unverified,ward_vaccine_2021,GBR
210718_England_ImperialCollegeLondon_Round6_55-64yrs,210718_England_ImperialCollegeLondon_Round6,"Vaccine uptake and SARS-CoV-2 antibody prevalence among 207,337 adults during May 2021 in England: REACT-2 study",2021-07-18,Preprint,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-05-12,2021-05-25,Household and community samples,All,Adults (18-64 years),55.0,64.0,Age,55-64 years,80537,0.98,0.9790000000000001,0.9820000000000001,,,True,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.14.21260497v1,2021-08-04,2022-07-16,Unverified,ward_vaccine_2021,GBR
210718_England_ImperialCollegeLondon_Round6_35-44yrs,210718_England_ImperialCollegeLondon_Round6,"Vaccine uptake and SARS-CoV-2 antibody prevalence among 207,337 adults during May 2021 in England: REACT-2 study",2021-07-18,Preprint,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-05-12,2021-05-25,Household and community samples,All,Adults (18-64 years),35.0,44.0,Age,35-44 years,14144,0.633,0.628,0.638,,,True,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.14.21260497v1,2021-08-04,2022-07-16,Unverified,ward_vaccine_2021,GBR
210718_England_ImperialCollegeLondon_Round6_25-34yrs,210718_England_ImperialCollegeLondon_Round6,"Vaccine uptake and SARS-CoV-2 antibody prevalence among 207,337 adults during May 2021 in England: REACT-2 study",2021-07-18,Preprint,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-05-12,2021-05-25,Household and community samples,All,Adults (18-64 years),25.0,34.0,Age,25-34 years,11006,0.332,0.32799999999999996,0.337,,,True,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.14.21260497v1,2021-08-04,2022-07-16,Unverified,ward_vaccine_2021,GBR
210718_England_ImperialCollegeLondon_Round6_Vaccinated,210718_England_ImperialCollegeLondon_Round6,"Vaccine uptake and SARS-CoV-2 antibody prevalence among 207,337 adults during May 2021 in England: REACT-2 study",2021-07-18,Preprint,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-05-12,2021-05-25,Household and community samples,All,Multiple groups,18.0,,COVID-19 vaccination status,Vaccinated yes,187952,0.66,0.658,0.662,,,,,,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.14.21260497v1,2021-08-04,2022-07-16,Unverified,ward_vaccine_2021,GBR
210718_England_ImperialCollegeLondon_Round6_Popadj,210718_England_ImperialCollegeLondon_Round6,"Vaccine uptake and SARS-CoV-2 antibody prevalence among 207,337 adults during May 2021 in England: REACT-2 study",2021-07-18,Preprint,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,,,"adult population 18 years and older in England registered with a General Practitioner in England, including vaccinated and unvaccinated individuals",,2021-05-12,2021-05-25,Household and community samples,All,Multiple groups,18.0,,Analysis,,207337,0.7290000000000001,0.7270000000000001,0.73,,,True,,True,Stratified probability,Coronavirus Antibody Rapid Test,Fortress Diagnostics,LFIA,Whole Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.8440000000000001,0.986,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Helen Ward,Imperial College London,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.14.21260497v1,2021-08-04,2022-07-16,Unverified,ward_vaccine_2021,GBR
210721_Scotland_PublicHealthScotland_1ResidualSera_overall_adj,210721_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 21 July 2021 ,2021-07-21,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-05-24,2021-06-27,Residual sera,All,Multiple groups,,,Primary Estimate,"Overall, test and pop adjusted",3554,0.614,0.5970000000000001,0.629,True,True,True,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-21-july-2021/,2021-11-03,2023-08-15,Verified,public_health_scotland_enhanced_2021-23,GBR
210721_Scotland_PublicHealthScotland_1ResidualSera_40-59,210721_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 21 July 2021 ,2021-07-21,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-05-24,2021-06-27,Residual sera,All,Adults (18-64 years),40.0,59.0,Age,"40 - 59, unadj",788,0.7449,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-21-july-2021/,2021-11-03,2024-03-01,Verified,public_health_scotland_enhanced_2021-23,GBR
210721_Scotland_PublicHealthScotland_1ResidualSera_female,210721_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 21 July 2021 ,2021-07-21,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-05-24,2021-06-27,Residual sera,Female,Multiple groups,,,Sex/Gender,"Females, unadj",1784,0.6099,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-21-july-2021/,2021-11-03,2024-03-01,Verified,public_health_scotland_enhanced_2021-23,GBR
210721_Scotland_PublicHealthScotland_1ResidualSera_60-69,210721_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 21 July 2021 ,2021-07-21,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-05-24,2021-06-27,Residual sera,All,Seniors (65+ years),60.0,69.0,Age,"60 - 69, unadj",467,0.8908,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-21-july-2021/,2021-11-03,2024-03-01,Verified,public_health_scotland_enhanced_2021-23,GBR
210721_Scotland_PublicHealthScotland_1ResidualSera_0-19,210721_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 21 July 2021 ,2021-07-21,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-05-24,2021-06-27,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Age,"00 - 19, unadj",884,0.2353,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-21-july-2021/,2021-11-03,2024-03-01,Verified,public_health_scotland_enhanced_2021-23,GBR
210721_Scotland_PublicHealthScotland_1ResidualSera_overall_unadj,210721_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 21 July 2021 ,2021-07-21,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-05-24,2021-06-27,Residual sera,All,Multiple groups,,,Analysis,"Overall, unadj",3554,0.5926,,,,,,,True,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-21-july-2021/,2021-11-03,2024-03-01,Verified,public_health_scotland_enhanced_2021-23,GBR
210721_Scotland_PublicHealthScotland_1ResidualSera_male,210721_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 21 July 2021 ,2021-07-21,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-05-24,2021-06-27,Residual sera,Male,Multiple groups,,,Sex/Gender,"Males, unadj",1770,0.5751,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-21-july-2021/,2021-11-03,2024-03-01,Verified,public_health_scotland_enhanced_2021-23,GBR
210721_Scotland_PublicHealthScotland_1ResidualSera_70+,210721_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 21 July 2021 ,2021-07-21,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-05-24,2021-06-27,Residual sera,All,Seniors (65+ years),70.0,,Age,"70+, unadj",535,0.8617,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-21-july-2021/,2021-11-03,2024-03-01,Verified,public_health_scotland_enhanced_2021-23,GBR
210721_Scotland_PublicHealthScotland_1ResidualSera_20-39,210721_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 21 July 2021 ,2021-07-21,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-05-24,2021-06-27,Residual sera,All,Adults (18-64 years),20.0,39.0,Age,"20 - 39, unadj",880,0.4932,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-21-july-2021/,2021-11-03,2024-03-01,Verified,public_health_scotland_enhanced_2021-23,GBR
210721_Scotland_PublicHealthScotland_2BloodDonors_overall_adj,210721_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 21 July 2021 ,2021-07-21,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-05-24,2021-06-27,Blood donors,All,Multiple groups,,,Primary Estimate,"Overall, test and pop adjusted",2494,0.818,0.798,0.84,True,True,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-21-july-2021/,2021-11-03,2023-08-15,Verified,public_health_scotland_enhanced_2021-23,GBR
210721_Scotland_PublicHealthScotland_2BloodDonors_40-59,210721_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 21 July 2021 ,2021-07-21,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-05-24,2021-06-27,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,"40 - 59, unadj",1031,0.87,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-21-july-2021/,2021-11-03,2024-03-01,Verified,public_health_scotland_enhanced_2021-23,GBR
210721_Scotland_PublicHealthScotland_2BloodDonors_females,210721_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 21 July 2021 ,2021-07-21,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-05-24,2021-06-27,Blood donors,Female,Multiple groups,,,Sex/Gender,"Females, unadj",1383,0.773,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-21-july-2021/,2021-11-03,2024-03-01,Verified,public_health_scotland_enhanced_2021-23,GBR
210721_Scotland_PublicHealthScotland_2BloodDonors_males,210721_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 21 July 2021 ,2021-07-21,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-05-24,2021-06-27,Blood donors,Male,Multiple groups,,,Sex/Gender,"Males, unadj",1111,0.7615000000000001,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-21-july-2021/,2021-11-03,2024-03-01,Verified,public_health_scotland_enhanced_2021-23,GBR
210721_Scotland_PublicHealthScotland_2BloodDonors_0-39,210721_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 21 July 2021 ,2021-07-21,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-05-24,2021-06-27,Blood donors,All,Multiple groups,0.0,39.0,Age,"00 - 39, unadj",920,0.5391,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-21-july-2021/,2021-11-03,2024-03-01,Verified,public_health_scotland_enhanced_2021-23,GBR
210721_Scotland_PublicHealthScotland_2BloodDonors_60+,210721_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 21 July 2021 ,2021-07-21,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-05-24,2021-06-27,Blood donors,All,Seniors (65+ years),60.0,,Age,"60+, unadj",543,0.9612999999999999,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-21-july-2021/,2021-11-03,2024-03-01,Verified,public_health_scotland_enhanced_2021-23,GBR
210721_Scotland_PublicHealthScotland_2BloodDonors_overall_unadj,210721_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 21 July 2021 ,2021-07-21,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-05-24,2021-06-27,Blood donors,All,Multiple groups,,,Analysis,Overall Unadj,2494,0.7678,,,,,,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-21-july-2021/,2021-11-03,2024-03-01,Verified,public_health_scotland_enhanced_2021-23,GBR
210721_Scotland_PublicHealthScotland_3PregnantWomen_overall_adj,210721_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 21 July 2021 ,2021-07-21,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymized and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-05-24,2021-06-27,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,"Overall, test and pop adjusted",3052,0.121,0.10800000000000001,0.135,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-21-july-2021/,2021-11-03,2023-08-15,Verified,public_health_scotland_enhanced_2021-23,GBR
210721_Scotland_PublicHealthScotland_3PregnantWomen_0-19,210721_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 21 July 2021 ,2021-07-21,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymized and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-05-24,2021-06-27,Pregnant or parturient women,Female,Children and Youth (0-17 years),0.0,19.0,Age,age 0-19,73,0.1507,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-21-july-2021/,2021-11-03,2024-03-01,Verified,public_health_scotland_enhanced_2021-23,GBR
210721_Scotland_PublicHealthScotland_3PregnantWomen_20-29,210721_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 21 July 2021 ,2021-07-21,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymized and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-05-24,2021-06-27,Pregnant or parturient women,Female,Adults (18-64 years),20.0,29.0,Age,age 20-29,1238,0.1276,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-21-july-2021/,2021-11-03,2024-03-01,Verified,public_health_scotland_enhanced_2021-23,GBR
210721_Scotland_PublicHealthScotland_3PregnantWomen_30-39,210721_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 21 July 2021 ,2021-07-21,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymized and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-05-24,2021-06-27,Pregnant or parturient women,Female,Adults (18-64 years),30.0,39.0,Age,age 30-39,1606,0.0978,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-21-july-2021/,2021-11-03,2024-03-01,Verified,public_health_scotland_enhanced_2021-23,GBR
210721_Scotland_PublicHealthScotland_3PregnantWomen_overall_unadj,210721_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 21 July 2021 ,2021-07-21,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymized and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-05-24,2021-06-27,Pregnant or parturient women,Female,Adults (18-64 years),,,Analysis,"Overall, unadj",3052,0.11170000000000001,,,,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-21-july-2021/,2021-11-03,2024-03-01,Verified,public_health_scotland_enhanced_2021-23,GBR
210721_Scotland_PublicHealthScotland_3PregnantWomen_40+,210721_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 21 July 2021 ,2021-07-21,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymized and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-05-24,2021-06-27,Pregnant or parturient women,Female,Adults (18-64 years),40.0,,Age,age 40+,135,0.11109999999999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-21-july-2021/,2021-11-03,2024-03-01,Verified,public_health_scotland_enhanced_2021-23,GBR
210808_Birmingham_UniversityHospitalsBirmingham_primary,210808_Birmingham_UniversityHospitalsBirmingham,Hemodialysis Patients Make Long-Lived Antibodies against SARS-CoV-2 that May Be Associated with Reduced Reinfection.,2021-08-02,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,,Birmingham,Patients on hemodialisis,,2020-03-15,2020-07-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,990,0.259,,,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Gemma D. Banham,University Hospitals Birmingham,Not Unity-Aligned,https://dx.doi.org/10.1681/ASN.2021020188,2021-08-17,2022-07-16,Verified,banham_hemodialysis_2021,GBR
210804_Cambridge_RoyalPapworthHospitalNHSTrust_HCW,210804_Cambridge_RoyalPapworthHospitalNHSTrust,Critical Care Workers Have Lower Seroprevalence of SARS-CoV-2 IgG Compared with Non-patient Facing Staff in First Wave of COVID19.,2021-08-04,Journal Article (Peer-Reviewed),Local,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,Cambridge,"Staff  from  Royal  Papworth  Hospital  NHS  Foundation  Trust  (RPH)  were  recruited  through  staff  email  over  the course of 2 months: 20th April 2020-10th June 2020, as  part  of  a  prospective  study  to  establish  seropreva-lence  and  immune  correlates  of  protective  immunity  to SARS-CoV-2. ",,2020-04-20,2020-06-10,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,498,0.14,,,True,,,,True,Convenience,Author designed (Luminex),,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.97,1.0,['High'],,No,No,Yes,,Unclear,Yes,Yes,,Helen Baxendale,Cambridge University Hospitals NHS Foundation Trust,Not Unity-Aligned,https://dx.doi.org/10.2478/jccm-2021-0018,2021-11-10,2022-07-16,Unverified,baxendale_critical_2021,GBR
210811_England_OfficeForNationalStatistics_Round6_StaffPrimary,210811_England_OfficeForNationalStatistics_Round6_StaffPrimary1,"COVID-19 Schools Infection Survey, England: Round 6, June 2021",2021-08-11,Institutional Report,National,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,,"Within the selected schools, primary and secondary, all staff were eligible and invited to participate in the study. ","The following schools were excluded from the sampling frame:

-special schools, independent schools, pupil referral units and further education colleges

-schools taking part in other school-based COVID-19 studies

",2021-06-14,2021-07-06,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,832,0.2516,0.1973,0.3122,True,,True,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,Validated by independent authors/third party/non-developers,0.9720000000000001,0.998,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Office for National Statistics,Office for National Statistics,Not Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/covid19schoolsinfectionsurveyengland/round6june2021,2021-09-01,2024-03-01,Unverified,office_for_national_statistics_covid-19_2021-3,GBR
210811_England_OfficeForNationalStatistics_Round6_StaffSecondary,210811_England_OfficeForNationalStatistics_Round6_StaffSecondary2,"COVID-19 Schools Infection Survey, England: Round 6, June 2021",2021-08-11,Institutional Report,National,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,,"Within the selected schools, primary and secondary, all staff were eligible and invited to participate in the study. ","The following schools were excluded from the sampling frame:

-special schools, independent schools, pupil referral units and further education colleges

-schools taking part in other school-based COVID-19 studies

",2021-06-14,2021-07-06,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,1574,0.2336,0.2066,0.2622,True,,True,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,Validated by independent authors/third party/non-developers,0.9720000000000001,0.998,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Office for National Statistics,Office for National Statistics,Not Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/covid19schoolsinfectionsurveyengland/round6june2021,2021-09-01,2024-03-01,Unverified,office_for_national_statistics_covid-19_2021-3,GBR
210811_England_OfficeForNationalStatistics_Round6_StudentsPrimary3_PopAdj_TestAdj,210811_England_OfficeForNationalStatistics_Round6_StudentsPrimary3,"COVID-19 Schools Infection Survey, England: Round 6, June 2021",2021-08-11,Institutional Report,National,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,,"Within primary schools, all pupils were eligible to participate","The following schools were excluded from the sampling frame:

-special schools, independent schools, pupil referral units and further education colleges

-schools taking part in other school-based COVID-19 studies

",2021-06-14,2021-07-06,Students and Daycares,All,Children and Youth (0-17 years),,,Primary Estimate,,3798,0.1125,0.0893,0.139,True,True,True,,,Stratified probability,Not reported/ Unable to specify,,Other,,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.8,0.99,['Low'],,Yes,Yes,No,,Unclear,Yes,Yes,,Office for National Statistics,Office for National Statistics,Not Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/covid19schoolsinfectionsurveyengland/round6june2021,2021-11-10,2022-07-16,Unverified,office_for_national_statistics_covid-19_2021-3,GBR
210811_England_OfficeForNationalStatistics_Round6_StudentsSecondary4_TestAdj_PopAdj,210811_England_OfficeForNationalStatistics_Round6_StudentsSecondary4,"COVID-19 Schools Infection Survey, England: Round 6, June 2021",2021-08-11,Institutional Report,National,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,,"because of the larger number of pupils in secondary schools, eligibility was restricted to two consecutive year groups in each secondary school. Year groups in secondary schools were chosen at random and in equal proportions across the schools and local authorities. Low response however, in Rounds 1 and 2, has led to a decision to widen eligibility to pupils in all year groups (except Year 11) within secondary schools from Round 4 onwards. In Round 6, 63 out of the 80 participating secondary schools had extended participation to other year groups.

Pupils from Year 11 are not eligible for enrolment. It was deemed that this study would be too disruptive for these pupils during their final year of secondary school.","The following schools were excluded from the sampling frame:

-special schools, independent schools, pupil referral units and further education colleges

-schools taking part in other school-based COVID-19 studies

",2021-06-14,2021-07-06,Students and Daycares,All,Children and Youth (0-17 years),,,Primary Estimate,,6927,0.1295,0.1162,0.1437,True,True,True,,,Stratified probability,Not reported/ Unable to specify,,Other,,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.8,0.99,['Low'],,Yes,Yes,No,,Unclear,Yes,Yes,,Office for National Statistics,Office for National Statistics,Not Unity-Aligned,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/covid19schoolsinfectionsurveyengland/round6june2021,2021-11-10,2022-07-16,Unverified,office_for_national_statistics_covid-19_2021-3,GBR
210819_England_UniversityofBirmingham_Overall,210819_England_UniversityofBirmingham,Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study.,2021-08-19,Journal Article (Peer-Reviewed),National,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,,"participants of the VIVALDI study (prospective cohort study looking at residents and staff in long-term care facilities in England, which provide care to adults ≥65). Staff and residents were eligible for inclusion if it was possible to link them to a pseudoidentifier in the COVID-19 Data Store (established as part of the national pandemic response), which enabled linkage to vaccination records. Only participants who had undergone their first dose of vaccination and two rounds of blood sampling (before and after vaccination) could be included",Those who had had both doses of vaccine before the second round of sampling were excluded from this study. Samples from individuals who were negative for anti-nucleocapsid IgG antibodies in their pre-vaccination sample but positive when tested a second time were considered likely to have had natural SARS-CoV-2 infection between testing rounds and were therefore excluded.,2020-12-11,2020-12-18,Assisted living and long-term care facilities,All,Adults (18-64 years),,,Primary Estimate,Estimate during phase 1 (pre-vaccine),124,0.24,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Gokhan Tut,University of Birmingham,Not Unity-Aligned,https://dx.doi.org/10.1016/S2666-7568(21)00168-9,2021-08-31,2024-03-01,Unverified,tut_profile_2021,GBR
210825_Scotland_PublicHealthScotland_1ResidualSera_overall_adj,210825_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 25 August 2021 ,2021-08-25,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-06-28,2021-08-01,Residual sera,All,Multiple groups,,,Primary Estimate,"Overall, test and pop adjusted",3427,0.7290000000000001,0.7140000000000001,0.7440000000000001,True,True,True,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-25-august-2021/,2021-10-26,2023-08-15,Verified,public_health_scotland_enhanced_2021-25,GBR
210825_Scotland_PublicHealthScotland_1ResidualSera_0-19,210825_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 25 August 2021 ,2021-08-25,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-06-28,2021-08-01,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Age,"00 - 19, unadj",857,0.3361,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-25-august-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-25,GBR
210825_Scotland_PublicHealthScotland_1ResidualSera_40-59,210825_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 25 August 2021 ,2021-08-25,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-06-28,2021-08-01,Residual sera,All,Adults (18-64 years),40.0,59.0,Age,"40 - 59, unadj",747,0.8501000000000001,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-25-august-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-25,GBR
210825_Scotland_PublicHealthScotland_1ResidualSera_male,210825_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 25 August 2021 ,2021-08-25,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-06-28,2021-08-01,Residual sera,Male,Multiple groups,,,Sex/Gender,"Males, unadj",1702,0.6939000000000001,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-25-august-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-25,GBR
210825_Scotland_PublicHealthScotland_1ResidualSera_female,210825_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 25 August 2021 ,2021-08-25,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-06-28,2021-08-01,Residual sera,Female,Multiple groups,,,Sex/Gender,"Females, unadj",1725,0.6939000000000001,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-25-august-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-25,GBR
210825_Scotland_PublicHealthScotland_1ResidualSera_20-39,210825_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 25 August 2021 ,2021-08-25,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-06-28,2021-08-01,Residual sera,All,Adults (18-64 years),20.0,39.0,Age,"20 - 39, unadj",833,0.7467,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-25-august-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-25,GBR
210825_Scotland_PublicHealthScotland_1ResidualSera_60-69,210825_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 25 August 2021 ,2021-08-25,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-06-28,2021-08-01,Residual sera,All,Seniors (65+ years),60.0,69.0,Age,"60 - 69, unadj",467,0.8929,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-25-august-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-25,GBR
210825_Scotland_PublicHealthScotland_1ResidualSera_overall_unadj,210825_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 25 August 2021 ,2021-08-25,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-06-28,2021-08-01,Residual sera,All,Multiple groups,,,Analysis,"Overall, unadj",3427,0.6939000000000001,,,,,,,True,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-25-august-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-25,GBR
210825_Scotland_PublicHealthScotland_1ResidualSera_70+,210825_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 25 August 2021 ,2021-08-25,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-06-28,2021-08-01,Residual sera,All,Seniors (65+ years),70.0,,Age,"70+, unadj",523,0.7954000000000001,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-25-august-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-25,GBR
210825_Scotland_PublicHealthScotland_2BloodDonors_overall_adj,210825_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 25 August 2021 ,2021-08-25,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-06-28,2021-08-01,Blood donors,All,Multiple groups,,,Primary Estimate,"Overall, test and pop adjusted",2493,0.995,0.9840000000000001,1.0,True,True,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-25-august-2021/,2021-10-26,2023-08-15,Verified,public_health_scotland_enhanced_2021-25,GBR
210825_Scotland_PublicHealthScotland_2BloodDonors_males,210825_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 25 August 2021 ,2021-08-25,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-06-28,2021-08-01,Blood donors,Male,Multiple groups,,,Sex/Gender,"Males, unadj",1134,0.9392,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-25-august-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-25,GBR
210825_Scotland_PublicHealthScotland_2BloodDonors_0-39,210825_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 25 August 2021 ,2021-08-25,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-06-28,2021-08-01,Blood donors,All,Multiple groups,0.0,39.0,Age,"00 - 39, unadj",835,0.903,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-25-august-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-25,GBR
210825_Scotland_PublicHealthScotland_2BloodDonors_60+,210825_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 25 August 2021 ,2021-08-25,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-06-28,2021-08-01,Blood donors,All,Seniors (65+ years),60.0,,Age,"60+, unadj",600,0.9683,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-25-august-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-25,GBR
210825_Scotland_PublicHealthScotland_2BloodDonors_overall_unadj,210825_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 25 August 2021 ,2021-08-25,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-06-28,2021-08-01,Blood donors,All,Multiple groups,,,Analysis,Overall Unadj,2493,0.9422,,,,,,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-25-august-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-25,GBR
210825_Scotland_PublicHealthScotland_2BloodDonors_females,210825_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 25 August 2021 ,2021-08-25,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-06-28,2021-08-01,Blood donors,Female,Multiple groups,,,Sex/Gender,"Females, unadj",1359,0.9448000000000001,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-25-august-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-25,GBR
210825_Scotland_PublicHealthScotland_2BloodDonors_40-59,210825_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 25 August 2021 ,2021-08-25,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing. Approximately 600 samples are collected each week from across Scotland.",,2021-06-28,2021-08-01,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,"40 - 59, unadj",1058,0.9584,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-25-august-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-25,GBR
210825_Scotland_PublicHealthScotland_3PregnantWomen_overall_adj,210825_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 25 August 2021 ,2021-08-25,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-06-28,2021-08-01,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,"Overall, test and pop adjusted",2990,0.138,0.12400000000000001,0.152,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-25-august-2021/,2021-10-26,2023-08-15,Verified,public_health_scotland_enhanced_2021-25,GBR
210825_Scotland_PublicHealthScotland_3PregnantWomen_30-39,210825_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 25 August 2021 ,2021-08-25,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-06-28,2021-08-01,Pregnant or parturient women,Female,Adults (18-64 years),30.0,39.0,Age,age 30-39,1598,0.1183,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-25-august-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-25,GBR
210825_Scotland_PublicHealthScotland_3PregnantWomen_20-29,210825_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 25 August 2021 ,2021-08-25,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-06-28,2021-08-01,Pregnant or parturient women,Female,Adults (18-64 years),20.0,29.0,Age,age 20-29,1213,0.136,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-25-august-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-25,GBR
210825_Scotland_PublicHealthScotland_3PregnantWomen_0-19,210825_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 25 August 2021 ,2021-08-25,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-06-28,2021-08-01,Pregnant or parturient women,Female,Children and Youth (0-17 years),0.0,19.0,Age,age 0-19,75,0.16,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-25-august-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-25,GBR
210825_Scotland_PublicHealthScotland_3PregnantWomen_40+,210825_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 25 August 2021 ,2021-08-25,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-06-28,2021-08-01,Pregnant or parturient women,Female,Adults (18-64 years),40.0,,Age,age 40+,104,0.13460000000000003,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-25-august-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-25,GBR
210825_Scotland_PublicHealthScotland_3PregnantWomen_overall_unadj,210825_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 25 August 2021 ,2021-08-25,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) ,,2021-06-28,2021-08-01,Pregnant or parturient women,Female,Adults (18-64 years),,,Analysis,"Overall, unadj",2990,0.12710000000000002,,,,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-25-august-2021/,2021-10-26,2024-03-01,Verified,public_health_scotland_enhanced_2021-25,GBR
210221_UnitedKingdom_RoyalDevonAndExeterNHSFoundationTrust,210221_UnitedKingdom_RoyalDevonAndExeterNHSFoundationTrust,Adalimumab and infliximab impair SARS-CoV-2 antibody responses: results from a therapeutic drug monitoring study in 11422 biologic-treated patients.,2021-09-02,Journal Article (Peer-Reviewed),National,Retrospective cohort,United Kingdom of Great Britain and Northern Ireland,,,Patient in UK with immune-mediated inflammatory disease,"insufficient demographic or clinical information, insufficient volume, or haemolysis",2020-01-29,2020-09-30,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,13509,0.031000000000000003,,,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.995,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Neil Chanchlani,Royal Devon And Exeter NHS Foundation Trust,Not Unity-Aligned,https://dx.doi.org/10.1093/ecco-jcc/jjab153,2021-09-08,2024-03-01,Unverified,Adalimumab and infliximab impair SARS-CoV-2 antibody responses: results from a therapeutic drug monitoring study in 11422 biologic-treated patients,GBR
210910_SouthWales_PublicHealthWales,210910_SouthWales_PublicHealthWales,The protective effect of previous COVID-19 infection in a high-prevalence hospital setting.,2021-09-10,Journal Article (Peer-Reviewed),Regional,Retrospective cohort,United Kingdom of Great Britain and Northern Ireland,Wales,,"Cohort inclusion: Individuals were included if they worked on a ward during a
period of high prevalence (an outbreak ward) and had close clinical contact with patients.

Antibody testing inclusion: Healthcare workers working on all sites were invited to have antibody testing carried out. Testing was voluntary but uptake was
high.",Cohort exclusion: No COVID-19 cohort wards were included.,2020-06-02,2020-07-07,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,276,0.38799999999999996,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 NCP ELISA (IgG),Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,Roche Diagnostics",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,,,['High'],,No,No,Yes,,Unclear,No,No,,Favian Narrainen,Public Health Wales Microbiology,Not Unity-Aligned,https://dx.doi.org/10.7861/clinmed.2021-0225,2021-09-23,2024-03-01,Unverified,narrainen_protective_2021,GBR
210920_Dublin_UniversityCollegeDublin_overall,210920_Dublin_UniversityCollegeDublin,Immunological assessment of SARS-CoV-2 infection in pregnancy from diagnosis to delivery: A multicentre prospective study.,2021-09-20,Journal Article (Peer-Reviewed),Local,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,Ireland,Dublin,Inpatient and outpatient clinics; asymptomatic pregnant women,Excluded if they had symptoms suggestive of active and/or recent infection (within 14 days),2020-05-04,2020-05-15,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,598,0.0167,0.008,0.031000000000000003,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Roche Diagnostics",Multiple Types,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,No,Yes,Kate Glennon,University College Dublin,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0253090,2021-09-27,2024-03-01,Verified,glennon_immunological_2021,GBR
210920_Dublin_UniversityCollegeDublin_AbbottAlinity,210920_Dublin_UniversityCollegeDublin,Immunological assessment of SARS-CoV-2 infection in pregnancy from diagnosis to delivery: A multicentre prospective study.,2021-09-20,Journal Article (Peer-Reviewed),Local,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,Ireland,Dublin,Inpatient and outpatient clinics; asymptomatic pregnant women,Excluded if they had symptoms suggestive of active and/or recent infection (within 14 days),2020-05-04,2020-05-15,Pregnant or parturient women,Female,Adults (18-64 years),,,Test used,Abbott/Alinity tests,598,0.0167,,,,,,,,Convenience,SARS-CoV-2 IgG II Quant ,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,No,Yes,Kate Glennon,University College Dublin,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0253090,2021-09-27,2024-03-01,Verified,glennon_immunological_2021,GBR
210920_Dublin_UniversityCollegeDublin_Roche,210920_Dublin_UniversityCollegeDublin,Immunological assessment of SARS-CoV-2 infection in pregnancy from diagnosis to delivery: A multicentre prospective study.,2021-09-20,Journal Article (Peer-Reviewed),Local,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,Ireland,Dublin,Inpatient and outpatient clinics; asymptomatic pregnant women,Excluded if they had symptoms suggestive of active and/or recent infection (within 14 days),2020-05-04,2020-05-15,Pregnant or parturient women,Female,Adults (18-64 years),,,Test used,Roche test,598,0.0201,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,No,Yes,Kate Glennon,University College Dublin,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0253090,2021-09-27,2024-03-01,Verified,glennon_immunological_2021,GBR
210929_England_PublicHealthEngland_Overall,210929_England_PublicHealthEngland_Students,"Antibody persistence and neutralising activity in primary school students and staff: Prospective active surveillance, June to December 2020, England.",2021-09-29,Journal Article (Peer-Reviewed),National,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,,"Briefly, 131 primary schools were recruited and included 46schools involved in swabbing with blood sampling at three time-points: following partial reopening of schools on 01 June 2020(1
19 June 2020) and end of the summer term (3
23 July 2020)",,2020-06-01,2020-07-23,Students and Daycares,All,Multiple groups,,,Primary Estimate,,2179,0.14,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Georgina Ireland,Public Health England,Not Unity-Aligned,https://dx.doi.org/10.1016/j.eclinm.2021.101150,2021-10-12,2024-03-01,Unverified,ireland_antibody_2021,GBR
210930_UnitedKingdom_QueensUniversityBelfast_Round1_overall,210930_UnitedKingdom_QueensUniversityBelfast_Round1,Seroprevalence and kinetics of SARS-CoV-2 antibodies in children in the UK: A prospective multicentre cohort study,2021-09-30,Journal Article (Peer-Reviewed),National,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,"England, Northern Ireland, Wales, Scotland","London, Belfast, Cardiff, Glasgow, Manchester",Children of healthcare workers were recruited from five UK centres,Of the 1002 included 15 were excluded from analysis due to unsuccessful phlebotomy. ,2020-04-16,2020-04-30,Family of essential workers,All,Children and Youth (0-17 years),,,Primary Estimate,,992,0.0776,0.0626,0.0959,True,,,,True,Unclear,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,,Multiple Types,,,,,,['High'],,Unclear,Yes,No,,Unclear,Yes,No,,Cathal Roarty,Queens University Belfast,Not Unity-Aligned,http://dx.doi.org/10.1136/archdischild-2021-rcpch.65,2021-11-10,2024-03-01,Unverified,roarty_553_2021,GBR
210930_UnitedKingdom_QueensUniversityBelfast_Round2_overall,210930_UnitedKingdom_QueensUniversityBelfast_Round2,Seroprevalence and kinetics of SARS-CoV-2 antibodies in children in the UK: A prospective multicentre cohort study,2021-09-30,Journal Article (Peer-Reviewed),National,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,"England, Northern Ireland, Wales, Scotland","London, Belfast, Cardiff, Glasgow, Manchester",Children of healthcare workers were recruited from five UK centres,Of the 1002 included 15 were excluded from analysis due to unsuccessful phlebotomy. ,2020-06-16,2020-06-30,Family of essential workers,All,Children and Youth (0-17 years),,,Primary Estimate,,849,0.0766,0.0605,0.09640000000000001,True,,,,True,Unclear,"Liaison SARS-CoV-2 S1/S2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (S)","DiaSorin,Roche Diagnostics",,Multiple Types,,,,,,['Moderate'],,Unclear,Yes,No,,Unclear,Yes,No,,Cathal Roarty,Queens University Belfast,Not Unity-Aligned,http://dx.doi.org/10.1136/archdischild-2021-rcpch.65,2021-11-10,2024-03-01,Unverified,roarty_553_2021,GBR
211030_UnitedKingdom_QueensUniversityBelfast,211030_UnitedKingdom_QueensUniversityBelfast,Symptoms of SARS-CoV-2 infection in the UK paediatric population,2021-09-30,Presentation or Conference,Regional,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,"Northern Ireland, Scotland, Wales, England","Belfast, Glasgow, Cardiff, Manchester,
London",Healthy children of NHS healthcare workers.,"experienced severe symptoms
requiring hospital admission.",2020-04-16,2020-07-03,Household and community samples,All,Children and Youth (0-17 years),2.0,16.0,Primary Estimate,,992,0.06849999999999999,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown)","Abbott Laboratories,DiaSorin,Roche Diagnostics",CLIA,Multiple Types,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,No,Unclear,Yes,No,Unclear,Claire McGinn,Queens University Belfast,Not Unity-Aligned,http://dx.doi.org/10.1136/archdischild-2021-rcpch.135,2021-11-10,2024-03-01,Verified,mcginn_675_2021,GBR
211020_Avon_UniversityOfBristol_G0_Overall,211020_Avon_UniversityOfBristol_G0,"The Avon Longitudinal Study of Parents and Children - A resource for COVID-19 research: Antibody testing results, April – June 2021",2021-10-20,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,,,"Women from the cohort of original pregnant women, the fathers/partners of these women (G0) in the ALSPAC cohort.

Participants who met any of the following criteria were invited to complete the second antibody test (Figure 1): 1) Participants who answered that they were happy to be contacted about future research projects involving testing or taking of biological samples as part of the second COVID-19 ALSPAC questionnaire; 2) Participants who completed either the first or fourth COVID-19 questionnaire, but not the second; or 3) Participants who were not invited to complete any of the previous ALSPAC COVID-19 questionnaires, but had recently provided an up-to-date email address to the ALSPAC administration team. Participants were not contacted if our administrative database records indicated that they were deceased, had withdrawn from the study, had declined further contact or had declined to complete questionnaires.","Participants were asked a screening question about their coagulation disorders; any participant who reported an increased risk of bleeding was told that they would not be able to take part. Participants were also asked to verify their date of birth and current postcode, the latter to ensure the blood sample collection kit was sent to the correct address and meant we could exclude participants living outside of the UK.",2021-04-08,2021-06-28,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,,2555,0.9640000000000001,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.988,0.9998,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,No,Daniel Major-Smith,University of Bristol,Unity-Aligned,https://wellcomeopenresearch.org/articles/6-283,2021-10-26,2024-03-01,Verified,major-smith_avon_2021,GBR
211020_Avon_UniversityOfBristol_G0_SexMale,211020_Avon_UniversityOfBristol_G0,"The Avon Longitudinal Study of Parents and Children - A resource for COVID-19 research: Antibody testing results, April – June 2021",2021-10-20,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,,,"Women from the cohort of original pregnant women, the fathers/partners of these women (G0) in the ALSPAC cohort.

Participants who met any of the following criteria were invited to complete the second antibody test (Figure 1): 1) Participants who answered that they were happy to be contacted about future research projects involving testing or taking of biological samples as part of the second COVID-19 ALSPAC questionnaire; 2) Participants who completed either the first or fourth COVID-19 questionnaire, but not the second; or 3) Participants who were not invited to complete any of the previous ALSPAC COVID-19 questionnaires, but had recently provided an up-to-date email address to the ALSPAC administration team. Participants were not contacted if our administrative database records indicated that they were deceased, had withdrawn from the study, had declined further contact or had declined to complete questionnaires.","Participants were asked a screening question about their coagulation disorders; any participant who reported an increased risk of bleeding was told that they would not be able to take part. Participants were also asked to verify their date of birth and current postcode, the latter to ensure the blood sample collection kit was sent to the correct address and meant we could exclude participants living outside of the UK.",2021-04-08,2021-06-28,Household and community samples,Male,Adults (18-64 years),,,Sex/Gender,,641,0.961,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.988,0.9998,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,No,Daniel Major-Smith,University of Bristol,Unity-Aligned,https://wellcomeopenresearch.org/articles/6-283,2021-10-26,2024-03-01,Verified,major-smith_avon_2021,GBR
211020_Avon_UniversityOfBristol_G0_SexFemale,211020_Avon_UniversityOfBristol_G0,"The Avon Longitudinal Study of Parents and Children - A resource for COVID-19 research: Antibody testing results, April – June 2021",2021-10-20,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,,,"Women from the cohort of original pregnant women, the fathers/partners of these women (G0) in the ALSPAC cohort.

Participants who met any of the following criteria were invited to complete the second antibody test (Figure 1): 1) Participants who answered that they were happy to be contacted about future research projects involving testing or taking of biological samples as part of the second COVID-19 ALSPAC questionnaire; 2) Participants who completed either the first or fourth COVID-19 questionnaire, but not the second; or 3) Participants who were not invited to complete any of the previous ALSPAC COVID-19 questionnaires, but had recently provided an up-to-date email address to the ALSPAC administration team. Participants were not contacted if our administrative database records indicated that they were deceased, had withdrawn from the study, had declined further contact or had declined to complete questionnaires.","Participants were asked a screening question about their coagulation disorders; any participant who reported an increased risk of bleeding was told that they would not be able to take part. Participants were also asked to verify their date of birth and current postcode, the latter to ensure the blood sample collection kit was sent to the correct address and meant we could exclude participants living outside of the UK.",2021-04-08,2021-06-28,Household and community samples,Female,Adults (18-64 years),,,Sex/Gender,,1914,0.965,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.988,0.9998,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,No,Daniel Major-Smith,University of Bristol,Unity-Aligned,https://wellcomeopenresearch.org/articles/6-283,2021-10-26,2024-03-01,Verified,major-smith_avon_2021,GBR
211020_Avon_UniversityOfBristol_G0_SandNpositive,211020_Avon_UniversityOfBristol_G0,"The Avon Longitudinal Study of Parents and Children - A resource for COVID-19 research: Antibody testing results, April – June 2021",2021-10-20,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,,,"Women from the cohort of original pregnant women, the fathers/partners of these women (G0) in the ALSPAC cohort.

Participants who met any of the following criteria were invited to complete the second antibody test (Figure 1): 1) Participants who answered that they were happy to be contacted about future research projects involving testing or taking of biological samples as part of the second COVID-19 ALSPAC questionnaire; 2) Participants who completed either the first or fourth COVID-19 questionnaire, but not the second; or 3) Participants who were not invited to complete any of the previous ALSPAC COVID-19 questionnaires, but had recently provided an up-to-date email address to the ALSPAC administration team. Participants were not contacted if our administrative database records indicated that they were deceased, had withdrawn from the study, had declined further contact or had declined to complete questionnaires.","Participants were asked a screening question about their coagulation disorders; any participant who reported an increased risk of bleeding was told that they would not be able to take part. Participants were also asked to verify their date of birth and current postcode, the latter to ensure the blood sample collection kit was sent to the correct address and meant we could exclude participants living outside of the UK.",2021-04-08,2021-06-28,Household and community samples,All,Adults (18-64 years),,,Test used,S and N positive,2055,0.12,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,No,Daniel Major-Smith,University of Bristol,Unity-Aligned,https://wellcomeopenresearch.org/articles/6-283,2021-11-03,2024-03-01,Verified,major-smith_avon_2021,GBR
211020_Avon_UniversityOfBristol_G1_Overall,211020_Avon_UniversityOfBristol_G1,"The Avon Longitudinal Study of Parents and Children - A resource for COVID-19 research: Antibody testing results, April – June 2021",2021-10-20,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,,,"Members of  the cohort of index children (G1) in the ALSPAC cohort.

Participants who met any of the following criteria were invited to complete the second antibody test (Figure 1): 1) Participants who answered that they were happy to be contacted about future research projects involving testing or taking of biological samples as part of the second COVID-19 ALSPAC questionnaire; 2) Participants who completed either the first or fourth COVID-19 questionnaire, but not the second; or 3) Participants who were not invited to complete any of the previous ALSPAC COVID-19 questionnaires, but had recently provided an up-to-date email address to the ALSPAC administration team. Participants were not contacted if our administrative database records indicated that they were deceased, had withdrawn from the study, had declined further contact or had declined to complete questionnaires.","Participants were asked a screening question about their coagulation disorders; any participant who reported an increased risk of bleeding was told that they would not be able to take part. Participants were also asked to verify their date of birth and current postcode, the latter to ensure the blood sample collection kit was sent to the correct address and meant we could exclude participants living outside of the UK.",2021-04-08,2021-06-28,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,,1686,0.4205,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.988,0.9998,['High'],,No,Yes,No,,Yes,Yes,Yes,,Daniel Major-Smith,University of Bristol,Unity-Aligned,https://wellcomeopenresearch.org/articles/6-283,2021-10-26,2024-03-01,Verified,major-smith_avon_2021,GBR
211020_Avon_UniversityOfBristol_G1_SandNpositive,211020_Avon_UniversityOfBristol_G1,"The Avon Longitudinal Study of Parents and Children - A resource for COVID-19 research: Antibody testing results, April – June 2021",2021-10-20,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,,,"Members of  the cohort of index children (G1) in the ALSPAC cohort.

Participants who met any of the following criteria were invited to complete the second antibody test (Figure 1): 1) Participants who answered that they were happy to be contacted about future research projects involving testing or taking of biological samples as part of the second COVID-19 ALSPAC questionnaire; 2) Participants who completed either the first or fourth COVID-19 questionnaire, but not the second; or 3) Participants who were not invited to complete any of the previous ALSPAC COVID-19 questionnaires, but had recently provided an up-to-date email address to the ALSPAC administration team. Participants were not contacted if our administrative database records indicated that they were deceased, had withdrawn from the study, had declined further contact or had declined to complete questionnaires.","Participants were asked a screening question about their coagulation disorders; any participant who reported an increased risk of bleeding was told that they would not be able to take part. Participants were also asked to verify their date of birth and current postcode, the latter to ensure the blood sample collection kit was sent to the correct address and meant we could exclude participants living outside of the UK.",2021-04-08,2021-06-28,Household and community samples,All,Adults (18-64 years),,,Test used,S and N positive,1667,0.145,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Daniel Major-Smith,University of Bristol,Unity-Aligned,https://wellcomeopenresearch.org/articles/6-283,2021-10-27,2024-03-01,Verified,major-smith_avon_2021,GBR
211020_Avon_UniversityOfBristol_G1_SexMale,211020_Avon_UniversityOfBristol_G1,"The Avon Longitudinal Study of Parents and Children - A resource for COVID-19 research: Antibody testing results, April – June 2021",2021-10-20,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,,,"Members of  the cohort of index children (G1) in the ALSPAC cohort.

Participants who met any of the following criteria were invited to complete the second antibody test (Figure 1): 1) Participants who answered that they were happy to be contacted about future research projects involving testing or taking of biological samples as part of the second COVID-19 ALSPAC questionnaire; 2) Participants who completed either the first or fourth COVID-19 questionnaire, but not the second; or 3) Participants who were not invited to complete any of the previous ALSPAC COVID-19 questionnaires, but had recently provided an up-to-date email address to the ALSPAC administration team. Participants were not contacted if our administrative database records indicated that they were deceased, had withdrawn from the study, had declined further contact or had declined to complete questionnaires.","Participants were asked a screening question about their coagulation disorders; any participant who reported an increased risk of bleeding was told that they would not be able to take part. Participants were also asked to verify their date of birth and current postcode, the latter to ensure the blood sample collection kit was sent to the correct address and meant we could exclude participants living outside of the UK.",2021-04-08,2021-06-28,Household and community samples,Male,Adults (18-64 years),,,Sex/Gender,,497,0.3521,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.988,0.9998,['High'],,No,Yes,No,,Yes,Yes,Yes,,Daniel Major-Smith,University of Bristol,Unity-Aligned,https://wellcomeopenresearch.org/articles/6-283,2021-10-26,2024-03-01,Verified,major-smith_avon_2021,GBR
211020_Avon_UniversityOfBristol_G1_Time1_April,211020_Avon_UniversityOfBristol_G1,"The Avon Longitudinal Study of Parents and Children - A resource for COVID-19 research: Antibody testing results, April – June 2021",2021-10-20,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,,,"Members of  the cohort of index children (G1) in the ALSPAC cohort.

Participants who met any of the following criteria were invited to complete the second antibody test (Figure 1): 1) Participants who answered that they were happy to be contacted about future research projects involving testing or taking of biological samples as part of the second COVID-19 ALSPAC questionnaire; 2) Participants who completed either the first or fourth COVID-19 questionnaire, but not the second; or 3) Participants who were not invited to complete any of the previous ALSPAC COVID-19 questionnaires, but had recently provided an up-to-date email address to the ALSPAC administration team. Participants were not contacted if our administrative database records indicated that they were deceased, had withdrawn from the study, had declined further contact or had declined to complete questionnaires.","Participants were asked a screening question about their coagulation disorders; any participant who reported an increased risk of bleeding was told that they would not be able to take part. Participants were also asked to verify their date of birth and current postcode, the latter to ensure the blood sample collection kit was sent to the correct address and meant we could exclude participants living outside of the UK.",2021-04-08,2021-04-30,Household and community samples,All,Adults (18-64 years),,,Time frame,April,1620,0.4228,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.988,0.9998,['High'],,No,Yes,No,,Yes,Yes,Yes,,Daniel Major-Smith,University of Bristol,Unity-Aligned,https://wellcomeopenresearch.org/articles/6-283,2021-10-26,2024-03-01,Verified,major-smith_avon_2021,GBR
211020_Avon_UniversityOfBristol_G1_SexFemale,211020_Avon_UniversityOfBristol_G1,"The Avon Longitudinal Study of Parents and Children - A resource for COVID-19 research: Antibody testing results, April – June 2021",2021-10-20,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,,,"Members of  the cohort of index children (G1) in the ALSPAC cohort.

Participants who met any of the following criteria were invited to complete the second antibody test (Figure 1): 1) Participants who answered that they were happy to be contacted about future research projects involving testing or taking of biological samples as part of the second COVID-19 ALSPAC questionnaire; 2) Participants who completed either the first or fourth COVID-19 questionnaire, but not the second; or 3) Participants who were not invited to complete any of the previous ALSPAC COVID-19 questionnaires, but had recently provided an up-to-date email address to the ALSPAC administration team. Participants were not contacted if our administrative database records indicated that they were deceased, had withdrawn from the study, had declined further contact or had declined to complete questionnaires.","Participants were asked a screening question about their coagulation disorders; any participant who reported an increased risk of bleeding was told that they would not be able to take part. Participants were also asked to verify their date of birth and current postcode, the latter to ensure the blood sample collection kit was sent to the correct address and meant we could exclude participants living outside of the UK.",2021-04-08,2021-06-28,Household and community samples,Female,Adults (18-64 years),,,Sex/Gender,,1189,0.4491,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.988,0.9998,['High'],,No,Yes,No,,Yes,Yes,Yes,,Daniel Major-Smith,University of Bristol,Unity-Aligned,https://wellcomeopenresearch.org/articles/6-283,2021-10-26,2024-03-01,Verified,major-smith_avon_2021,GBR
211020_Avon_UniversityOfBristol_G1_Time2_May/June,211020_Avon_UniversityOfBristol_G1,"The Avon Longitudinal Study of Parents and Children - A resource for COVID-19 research: Antibody testing results, April – June 2021",2021-10-20,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,,,"Members of  the cohort of index children (G1) in the ALSPAC cohort.

Participants who met any of the following criteria were invited to complete the second antibody test (Figure 1): 1) Participants who answered that they were happy to be contacted about future research projects involving testing or taking of biological samples as part of the second COVID-19 ALSPAC questionnaire; 2) Participants who completed either the first or fourth COVID-19 questionnaire, but not the second; or 3) Participants who were not invited to complete any of the previous ALSPAC COVID-19 questionnaires, but had recently provided an up-to-date email address to the ALSPAC administration team. Participants were not contacted if our administrative database records indicated that they were deceased, had withdrawn from the study, had declined further contact or had declined to complete questionnaires.","Participants were asked a screening question about their coagulation disorders; any participant who reported an increased risk of bleeding was told that they would not be able to take part. Participants were also asked to verify their date of birth and current postcode, the latter to ensure the blood sample collection kit was sent to the correct address and meant we could exclude participants living outside of the UK.",2021-05-01,2021-06-28,Household and community samples,All,Adults (18-64 years),,,Time frame,May/June,66,0.3636,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.988,0.9998,['High'],,No,Yes,No,,Yes,Yes,Yes,,Daniel Major-Smith,University of Bristol,Unity-Aligned,https://wellcomeopenresearch.org/articles/6-283,2021-10-26,2024-03-01,Verified,major-smith_avon_2021,GBR
211025_Ynysmaerdy _CardiffUniversity,211025_Ynysmaerdy _CardiffUniversity,A cluster of children with facial nerve palsy in a high prevalence area for COVID-19.,2021-10-25,Journal Article (Peer-Reviewed),Local,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,South Wales, Ynysmaerdy,Children with FNP (facial nerve palsy),,2020-06-15,2020-10-15,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),0.0,15.0,Primary Estimate,,5,0.0,,,True,,,,True,Entire sample,Not reported/ Unable to specify,,,,,,,,,['High'],No,Yes,No,No,No,Unclear,Yes,No,Unclear,David Barron,Cardiff University,Not Unity-Aligned,https://dx.doi.org/10.1186/s12887-021-02831-9,2021-11-02,2022-07-16,Verified,barron_cluster_2021,GBR
211103_Scotland_PublicHealthScotland_1ResidualSera_Overall_PopAdj_TestAdj,211103_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 3 Nov 2021,2021-11-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-09-06,2021-10-10,Residual sera,All,Multiple groups,,,Primary Estimate,"Overall, test and pop adjusted",3132,0.7759999999999999,0.7590000000000001,0.793,True,True,True,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-november-2021/,2021-11-10,2023-08-15,Verified,public_health_scotland_enhanced_2021-40,GBR
211103_Scotland_PublicHealthScotland_1ResidualSera_Age_70+_Unadj,211103_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 3 Nov 2021,2021-11-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-09-06,2021-10-10,Residual sera,All,Seniors (65+ years),70.0,,Age,70+_Unadj,524,0.7195,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-november-2021/,2021-11-10,2024-03-01,Verified,public_health_scotland_enhanced_2021-40,GBR
211103_Scotland_PublicHealthScotland_1ResidualSera_Female_Unadj,211103_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 3 Nov 2021,2021-11-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-09-06,2021-10-10,Residual sera,Female,Multiple groups,,,Sex/Gender,"Females, unadj",1566,0.7458,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-november-2021/,2021-11-10,2024-03-01,Verified,public_health_scotland_enhanced_2021-40,GBR
211103_Scotland_PublicHealthScotland_1ResidualSera_Age_00 - 19_Unadj,211103_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 3 Nov 2021,2021-11-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-09-06,2021-10-10,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Age,00 - 19_Unadj,778,0.5424,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-november-2021/,2021-11-10,2024-03-01,Verified,public_health_scotland_enhanced_2021-40,GBR
211103_Scotland_PublicHealthScotland_1ResidualSera_Age_20 - 39_Unadj,211103_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 3 Nov 2021,2021-11-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-09-06,2021-10-10,Residual sera,All,Adults (18-64 years),20.0,39.0,Age,20 - 39_Unadj,771,0.8470000000000001,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-november-2021/,2021-11-10,2024-03-01,Verified,public_health_scotland_enhanced_2021-40,GBR
211103_Scotland_PublicHealthScotland_1ResidualSera_Age_60 - 69_Unadj,211103_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 3 Nov 2021,2021-11-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-09-06,2021-10-10,Residual sera,All,Seniors (65+ years),60.0,69.0,Age,60 - 69_Unadj,402,0.8259000000000001,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-november-2021/,2021-11-10,2024-03-01,Verified,public_health_scotland_enhanced_2021-40,GBR
211103_Scotland_PublicHealthScotland_1ResidualSera_Overall_Unadj,211103_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 3 Nov 2021,2021-11-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-09-06,2021-10-10,Residual sera,All,Multiple groups,,,Analysis,"Overall, unadj",3132,0.7433,,,,,,,True,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-november-2021/,2021-11-10,2024-03-01,Verified,public_health_scotland_enhanced_2021-40,GBR
211103_Scotland_PublicHealthScotland_1ResidualSera_Male_Unadj,211103_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 3 Nov 2021,2021-11-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-09-06,2021-10-10,Residual sera,Male,Multiple groups,,,Sex/Gender,"Males, unadj",1566,0.7406999999999999,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-november-2021/,2021-11-10,2024-03-01,Verified,public_health_scotland_enhanced_2021-40,GBR
211103_Scotland_PublicHealthScotland_1ResidualSera_Age_40 - 59_Unadj,211103_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 3 Nov 2021,2021-11-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-09-06,2021-10-10,Residual sera,All,Adults (18-64 years),40.0,59.0,Age,40 - 59_Unadj,657,0.828,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-november-2021/,2021-11-10,2024-03-01,Verified,public_health_scotland_enhanced_2021-40,GBR
211103_Scotland_PublicHealthScotland_2BloodDonors_Overall_PopAdj_TestAdj,211103_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 3 Nov 2021,2021-11-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2021-09-06,2021-10-10,Blood donors,All,Multiple groups,,,Primary Estimate,"Overall, test and pop adjusted",2494,0.997,0.993,1.0,True,True,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-november-2021/,2021-11-10,2023-08-15,Verified,public_health_scotland_enhanced_2021-40,GBR
211103_Scotland_PublicHealthScotland_2BloodDonors_Age_40 - 59_Unadj,211103_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 3 Nov 2021,2021-11-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2021-09-06,2021-10-10,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,"40 - 59, unadj",1093,0.9689,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-november-2021/,2021-11-10,2024-03-01,Verified,public_health_scotland_enhanced_2021-40,GBR
211103_Scotland_PublicHealthScotland_2BloodDonors_Age_60+_Unadj,211103_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 3 Nov 2021,2021-11-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2021-09-06,2021-10-10,Blood donors,All,Seniors (65+ years),60.0,,Age,"60+, unadj",625,0.9168000000000001,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-november-2021/,2021-11-10,2024-03-01,Verified,public_health_scotland_enhanced_2021-40,GBR
211103_Scotland_PublicHealthScotland_2BloodDonors_Male_Unadj,211103_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 3 Nov 2021,2021-11-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2021-09-06,2021-10-10,Blood donors,Male,Multiple groups,,,Sex/Gender,"Males, unadj",1149,0.9487000000000001,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-november-2021/,2021-11-10,2024-03-01,Verified,public_health_scotland_enhanced_2021-40,GBR
211103_Scotland_PublicHealthScotland_2BloodDonors_Female_Unadj,211103_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 3 Nov 2021,2021-11-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2021-09-06,2021-10-10,Blood donors,Female,Multiple groups,,,Sex/Gender,"Females, unadj",1345,0.9561000000000001,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-november-2021/,2021-11-10,2024-03-01,Verified,public_health_scotland_enhanced_2021-40,GBR
211103_Scotland_PublicHealthScotland_2BloodDonors_Overall_Unadj,211103_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 3 Nov 2021,2021-11-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2021-09-06,2021-10-10,Blood donors,All,Multiple groups,,,Analysis,Overall Unadj,2494,0.9527,,,,,,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-november-2021/,2021-11-10,2024-03-01,Verified,public_health_scotland_enhanced_2021-40,GBR
211103_Scotland_PublicHealthScotland_2BloodDonors_Age_00 - 39_Unadj,211103_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 3 Nov 2021,2021-11-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2021-09-06,2021-10-10,Blood donors,All,Multiple groups,0.0,39.0,Age,"00 - 39, unadj",776,0.9588,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-november-2021/,2021-11-10,2024-03-01,Verified,public_health_scotland_enhanced_2021-40,GBR
211103_Scotland_PublicHealthScotland_3PregnantWomen_Overall_PopAdj_TestAdj,211103_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 3 Nov 2021,2021-11-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2021-09-06,2021-10-10,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,"Overall, test and pop adjusted",3023,0.197,0.18,0.21300000000000002,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-november-2021/,2021-11-10,2023-08-15,Verified,public_health_scotland_enhanced_2021-40,GBR
211103_Scotland_PublicHealthScotland_3PregnantWomen_Age_20 - 29_Unadj,211103_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 3 Nov 2021,2021-11-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2021-09-06,2021-10-10,Pregnant or parturient women,Female,Adults (18-64 years),,,Age,age 20-29,1211,0.2114,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-november-2021/,2021-11-10,2024-03-01,Verified,public_health_scotland_enhanced_2021-40,GBR
211103_Scotland_PublicHealthScotland_3PregnantWomen_Age_00 - 19_Unadj,211103_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 3 Nov 2021,2021-11-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2021-09-06,2021-10-10,Pregnant or parturient women,Female,Children and Youth (0-17 years),,,Age,age 0-19,68,0.25,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-november-2021/,2021-11-10,2024-03-01,Verified,public_health_scotland_enhanced_2021-40,GBR
211103_Scotland_PublicHealthScotland_3PregnantWomen_Overall_Unadj,211103_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 3 Nov 2021,2021-11-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2021-09-06,2021-10-10,Pregnant or parturient women,Female,Adults (18-64 years),,,Analysis,"Overall, unadj",3023,0.1809,,,,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-november-2021/,2021-11-10,2024-03-01,Verified,public_health_scotland_enhanced_2021-40,GBR
211103_Scotland_PublicHealthScotland_3PregnantWomen_Age_40+_Unadj,211103_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 3 Nov 2021,2021-11-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2021-09-06,2021-10-10,Pregnant or parturient women,Female,Adults (18-64 years),,,Age,age 40+,91,0.0989,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-november-2021/,2021-11-10,2024-03-01,Verified,public_health_scotland_enhanced_2021-40,GBR
211103_Scotland_PublicHealthScotland_3PregnantWomen_Age_30 - 39_Unadj,211103_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 3 Nov 2021,2021-11-03,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2021-09-06,2021-10-10,Pregnant or parturient women,Female,Adults (18-64 years),,,Age,age 30-39,1653,0.16030000000000003,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-november-2021/,2021-11-10,2024-03-01,Verified,public_health_scotland_enhanced_2021-40,GBR
211114_UnitedKingdom_UniversityHospitalSouthamptonNHSTrust,211114_UnitedKingdom_UniversityHospitalSouthamptonNHSTrust,Immunocompromised children and young people are at no increased risk of severe COVID-19,2021-11-14,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,Immunocompromised pediatric patients in the UK,,2021-02-15,2021-03-15,Residual sera,All,Multiple groups,0.0,19.0,Primary Estimate,,478,0.0983263598,,,True,,,,True,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Harry Chappell,University Hospital Southampton NHS Trust,Not Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S016344532100548X,2022-02-17,2022-07-16,Unverified,chappell_immunocompromised_2022-1,GBR
211130_England_UKHSA_2020NovDec_Overall_AdjustedS,211130_England_UKHSA_2020NovDec,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2020-11-01,2020-12-31,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Primary Estimate,"S-positive, Population Adjusted",711,0.14800000000000002,0.11199999999999999,0.198,True,,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-23,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2020NovDec_Age1–4,211130_England_UKHSA_2020NovDec,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2020-11-01,2020-12-31,Residual sera,All,Children and Youth (0-17 years),1.0,4.0,Age,1-4,124,0.1048,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2020NovDec_Age12–15,211130_England_UKHSA_2020NovDec,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2020-11-01,2020-12-31,Residual sera,All,Children and Youth (0-17 years),12.0,15.0,Age,12-15,225,0.11109999999999999,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2020NovDec_RegionSouthWest,211130_England_UKHSA_2020NovDec,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,South West,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2020-11-01,2020-12-31,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Geographical area,South West,35,0.0857,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2020NovDec_RegionMidlands,211130_England_UKHSA_2020NovDec,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Midlands,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2020-11-01,2020-12-31,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Geographical area,Midlands,20,0.15,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2020NovDec_Overall_AdjustedN,211130_England_UKHSA_2020NovDec,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2020-11-01,2020-12-31,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Test used,"N-positive, Population Adjusted",712,0.141,0.106,0.19,,,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.8390000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-23,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2020NovDec_RegionLondon,211130_England_UKHSA_2020NovDec,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,London,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2020-11-01,2020-12-31,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Geographical area,London,61,0.3279,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2020NovDec_Age16–17,211130_England_UKHSA_2020NovDec,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2020-11-01,2020-12-31,Residual sera,All,Children and Youth (0-17 years),16.0,17.0,Age,16-17,103,0.1359,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2020NovDec_Age5–11,211130_England_UKHSA_2020NovDec,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2020-11-01,2020-12-31,Residual sera,All,Children and Youth (0-17 years),5.0,11.0,Age,5-11,259,0.16219999999999998,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2020NovDec_RegionNorthWest,211130_England_UKHSA_2020NovDec,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,North West,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2020-11-01,2020-12-31,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Geographical area,North West,199,0.1608,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2020NovDec_RegionNorthEast,211130_England_UKHSA_2020NovDec,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,North East,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2020-11-01,2020-12-31,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Geographical area,North East,206,0.1456,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2020NovDec_Overall_Crude,211130_England_UKHSA_2020NovDec,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2020-11-01,2020-12-31,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Analysis,"S-positive, Crude",711,0.1322,,,,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2020SepOct_Overall_AdjustedS,211130_England_UKHSA_2020SepOct,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2020-09-01,2020-10-31,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Primary Estimate,"S-positive, Population Adjusted",119,0.076,0.032,0.182,True,,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['High'],No,No,No,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-23,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2020SepOct_Overall_AdjustedN,211130_England_UKHSA_2020SepOct,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2020-09-01,2020-10-31,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Test used,"N-positive, Population Adjusted",120,0.063,0.022000000000000002,0.17,,,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.8390000000000001,1.0,['High'],No,No,No,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-23,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2020SepOct_Age5–11,211130_England_UKHSA_2020SepOct,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2020-09-01,2020-10-31,Residual sera,All,Children and Youth (0-17 years),5.0,11.0,Age,5-11,42,0.0714,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['High'],No,No,No,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2020SepOct_Age16–17,211130_England_UKHSA_2020SepOct,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2020-09-01,2020-10-31,Residual sera,All,Children and Youth (0-17 years),16.0,17.0,Age,16-17,16,0.0625,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['High'],No,No,No,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2020SepOct_Age1–4,211130_England_UKHSA_2020SepOct,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2020-09-01,2020-10-31,Residual sera,All,Children and Youth (0-17 years),1.0,4.0,Age,1-4,26,0.0,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['High'],No,No,No,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2020SepOct_RegionNorthWest,211130_England_UKHSA_2020SepOct,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,North West,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2020-09-01,2020-10-31,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Geographical area,North West,27,0.11109999999999999,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['High'],No,No,No,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2020SepOct_RegionSouthWest,211130_England_UKHSA_2020SepOct,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,South West,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2020-09-01,2020-10-31,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Geographical area,South West,13,0.0,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['High'],No,No,No,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2020SepOct_RegionLondon,211130_England_UKHSA_2020SepOct,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,London,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2020-09-01,2020-10-31,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Geographical area,London,14,0.2143,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['High'],No,No,No,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2020SepOct_RegionNorthEast,211130_England_UKHSA_2020SepOct,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,North East,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2020-09-01,2020-10-31,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Geographical area,North East,63,0.0317,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['High'],No,No,No,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2020SepOct_Overall_Crude,211130_England_UKHSA_2020SepOct,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2020-09-01,2020-10-31,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Analysis,"S-positive, Crude",119,0.0672,,,,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['High'],No,No,No,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2020SepOct_Age12–15,211130_England_UKHSA_2020SepOct,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2020-09-01,2020-10-31,Residual sera,All,Children and Youth (0-17 years),12.0,15.0,Age,12-15,35,0.1143,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['High'],No,No,No,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021JanFeb_Overall_AdjustedS,211130_England_UKHSA_2021JanFeb,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-01-01,2021-02-28,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Primary Estimate,"S-positive, Population Adjusted",970,0.233,0.184,0.295,True,,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-23,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021JanFeb_RegionMidlands,211130_England_UKHSA_2021JanFeb,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Midlands,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-01-01,2021-02-28,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Geographical area,Midlands,22,0.4545,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021JanFeb_Age12–15,211130_England_UKHSA_2021JanFeb,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-01-01,2021-02-28,Residual sera,All,Children and Youth (0-17 years),12.0,15.0,Age,12-15,298,0.2349,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021JanFeb_Age5–11,211130_England_UKHSA_2021JanFeb,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-01-01,2021-02-28,Residual sera,All,Children and Youth (0-17 years),5.0,11.0,Age,5-11,340,0.2,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021JanFeb_Overall_AdjustedN,211130_England_UKHSA_2021JanFeb,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-01-01,2021-02-28,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Test used,"N-positive, Population Adjusted",975,0.22100000000000003,0.17300000000000001,0.28300000000000003,,,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.8390000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-23,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021JanFeb_RegionSouthWest,211130_England_UKHSA_2021JanFeb,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,South West,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-01-01,2021-02-28,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Geographical area,South West,66,0.030299999999999997,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021JanFeb_Age16–17,211130_England_UKHSA_2021JanFeb,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-01-01,2021-02-28,Residual sera,All,Children and Youth (0-17 years),16.0,17.0,Age,16-17,142,0.2183,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021JanFeb_Age1–4,211130_England_UKHSA_2021JanFeb,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-01-01,2021-02-28,Residual sera,All,Children and Youth (0-17 years),1.0,4.0,Age,1-4,190,0.1684,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021JanFeb_RegionLondon,211130_England_UKHSA_2021JanFeb,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,London,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-01-01,2021-02-28,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Geographical area,London,88,0.3636,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021JanFeb_RegionNorthEast,211130_England_UKHSA_2021JanFeb,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,North East,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-01-01,2021-02-28,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Geographical area,North East,412,0.1796,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021JanFeb_Overall_Crude,211130_England_UKHSA_2021JanFeb,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-01-01,2021-02-28,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Analysis,"S-positive, Crude",970,0.2072,,,,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021JanFeb_RegionNorthWest,211130_England_UKHSA_2021JanFeb,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,North West,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-01-01,2021-02-28,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Geographical area,North West,288,0.2604,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021JulAug_Overall_AdjustedS,211130_England_UKHSA_2021JulAug,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-07-01,2021-08-31,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Primary Estimate,"S-positive, Population Adjusted",685,0.264,0.201,0.353,True,,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-23,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021JulAug_Overall_Crude,211130_England_UKHSA_2021JulAug,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-07-01,2021-08-31,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Analysis,"S-positive, Crude",685,0.2949,,,,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021JulAug_RegionLondon,211130_England_UKHSA_2021JulAug,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,London,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-07-01,2021-08-31,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Geographical area,London,161,0.5031,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021JulAug_Age12–15,211130_England_UKHSA_2021JulAug,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-07-01,2021-08-31,Residual sera,All,Children and Youth (0-17 years),12.0,15.0,Age,12-15,293,0.3345,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021JulAug_RegionSouthWest,211130_England_UKHSA_2021JulAug,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,South West,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-07-01,2021-08-31,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Geographical area,South West,45,0.0667,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021JulAug_Age5–11,211130_England_UKHSA_2021JulAug,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-07-01,2021-08-31,Residual sera,All,Children and Youth (0-17 years),5.0,11.0,Age,5-11,167,0.2335,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021JulAug_Age16–17,211130_England_UKHSA_2021JulAug,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-07-01,2021-08-31,Residual sera,All,Children and Youth (0-17 years),16.0,17.0,Age,16-17,87,0.41380000000000006,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021JulAug_RegionNorthWest,211130_England_UKHSA_2021JulAug,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,North West,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-07-01,2021-08-31,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Geographical area,North West,12,0.25,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021JulAug_RegionMidlands,211130_England_UKHSA_2021JulAug,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Midlands,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-07-01,2021-08-31,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Geographical area,Midlands,111,0.3153,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021JulAug_Age1–4,211130_England_UKHSA_2021JulAug,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-07-01,2021-08-31,Residual sera,All,Children and Youth (0-17 years),1.0,4.0,Age,1-4,138,0.2101,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021JulAug_Overall_AdjustedN,211130_England_UKHSA_2021JulAug,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-07-01,2021-08-31,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Test used,"N-positive, Population Adjusted",685,0.222,0.165,0.314,,,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.8390000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-23,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021JulAug_RegionNorthEast,211130_England_UKHSA_2021JulAug,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,North East,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-07-01,2021-08-31,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Geographical area,North East,354,0.226,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021MarApr_Overall_AdjustedS,211130_England_UKHSA_2021MarApr,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-03-01,2021-04-30,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Primary Estimate,"S-positive, Population Adjusted",925,0.315,0.253,0.391,True,,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-23,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021MarApr_Overall_Crude,211130_England_UKHSA_2021MarApr,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-03-01,2021-04-30,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Analysis,"S-positive, Crude",925,0.3114,,,,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021MarApr_RegionSouthWest,211130_England_UKHSA_2021MarApr,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,South West,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-03-01,2021-04-30,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Geographical area,South West,35,0.1143,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021MarApr_RegionNorthEast,211130_England_UKHSA_2021MarApr,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,North East,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-03-01,2021-04-30,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Geographical area,North East,489,0.2331,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021MarApr_Age12–15,211130_England_UKHSA_2021MarApr,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-03-01,2021-04-30,Residual sera,All,Children and Youth (0-17 years),12.0,15.0,Age,12-15,329,0.32520000000000004,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021MarApr_Age5–11,211130_England_UKHSA_2021MarApr,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-03-01,2021-04-30,Residual sera,All,Children and Youth (0-17 years),5.0,11.0,Age,5-11,315,0.2762,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021MarApr_RegionMidlands,211130_England_UKHSA_2021MarApr,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Midlands,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-03-01,2021-04-30,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Geographical area,Midlands,20,0.45,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021MarApr_Age1–4,211130_England_UKHSA_2021MarApr,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-03-01,2021-04-30,Residual sera,All,Children and Youth (0-17 years),1.0,4.0,Age,1-4,178,0.2978,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021MarApr_Overall_AdjustedN,211130_England_UKHSA_2021MarApr,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-03-01,2021-04-30,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Test used,"N-positive, Population Adjusted",930,0.257,0.201,0.33,,,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.8390000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-23,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021MarApr_Age16–17,211130_England_UKHSA_2021MarApr,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-03-01,2021-04-30,Residual sera,All,Children and Youth (0-17 years),16.0,17.0,Age,16-17,103,0.3981,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021MarApr_RegionLondon,211130_England_UKHSA_2021MarApr,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,London,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-03-01,2021-04-30,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Geographical area,London,102,0.402,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021MarApr_RegionNorthWest,211130_England_UKHSA_2021MarApr,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,North West,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-03-01,2021-04-30,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Geographical area,North West,267,0.44189999999999996,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021MayJun_Overall_AdjustedS,211130_England_UKHSA_2021MayJun,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-05-01,2021-06-30,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Primary Estimate,"S-positive, Population Adjusted",1186,0.275,0.207,0.37200000000000005,True,,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-23,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021MayJun_Overall_AdjustedN,211130_England_UKHSA_2021MayJun,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-05-01,2021-06-30,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Test used,"N-positive, Population Adjusted",1187,0.218,0.161,0.311,,,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.8390000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-23,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021MayJun_RegionNorthEast,211130_England_UKHSA_2021MayJun,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,North East,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-05-01,2021-06-30,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Geographical area,North East,511,0.2446,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021MayJun_Age5–11,211130_England_UKHSA_2021MayJun,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-05-01,2021-06-30,Residual sera,All,Children and Youth (0-17 years),5.0,11.0,Age,5-11,284,0.2676,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021MayJun_RegionSouthWest,211130_England_UKHSA_2021MayJun,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,South West,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-05-01,2021-06-30,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Geographical area,South West,171,0.0877,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021MayJun_Overall_Crude,211130_England_UKHSA_2021MayJun,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-05-01,2021-06-30,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Analysis,"S-positive, Crude",1186,0.2766,,,,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021MayJun_RegionNorthWest,211130_England_UKHSA_2021MayJun,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,North West,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-05-01,2021-06-30,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Geographical area,North West,276,0.3152,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021MayJun_Age1–4,211130_England_UKHSA_2021MayJun,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-05-01,2021-06-30,Residual sera,All,Children and Youth (0-17 years),1.0,4.0,Age,1-4,196,0.2194,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021MayJun_Age12–15,211130_England_UKHSA_2021MayJun,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-05-01,2021-06-30,Residual sera,All,Children and Youth (0-17 years),12.0,15.0,Age,12-15,537,0.2831,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021MayJun_RegionMidlands,211130_England_UKHSA_2021MayJun,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Midlands,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-05-01,2021-06-30,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Geographical area,Midlands,16,0.3125,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021MayJun_RegionLondon,211130_England_UKHSA_2021MayJun,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,London,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-05-01,2021-06-30,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Geographical area,London,211,0.455,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021MayJun_Age16–17,211130_England_UKHSA_2021MayJun,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-05-01,2021-06-30,Residual sera,All,Children and Youth (0-17 years),16.0,17.0,Age,16-17,169,0.3373,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021SepOct_Overall_AdjustedS,211130_England_UKHSA_2021SepOct,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-09-01,2021-10-31,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Primary Estimate,"S-positive, Population Adjusted",600,0.461,0.383,0.536,True,,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-23,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021SepOct_RegionMidlands,211130_England_UKHSA_2021SepOct,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Midlands,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-09-01,2021-10-31,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Geographical area,Midlands,87,0.5977,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021SepOct_Age16–17,211130_England_UKHSA_2021SepOct,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-09-01,2021-10-31,Residual sera,All,Children and Youth (0-17 years),16.0,17.0,Age,16-17,83,0.7952,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021SepOct_Age5–11,211130_England_UKHSA_2021SepOct,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-09-01,2021-10-31,Residual sera,All,Children and Youth (0-17 years),5.0,11.0,Age,5-11,114,0.3246,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021SepOct_RegionNorthEast,211130_England_UKHSA_2021SepOct,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,North East,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-09-01,2021-10-31,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Geographical area,North East,316,0.5032,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021SepOct_RegionNorthWest,211130_England_UKHSA_2021SepOct,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,North West,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-09-01,2021-10-31,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Geographical area,North West,55,0.6727,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021SepOct_RegionLondon,211130_England_UKHSA_2021SepOct,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,London,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-09-01,2021-10-31,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Geographical area,London,63,0.619,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021SepOct_Overall_Crude,211130_England_UKHSA_2021SepOct,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-09-01,2021-10-31,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Analysis,"S-positive, Crude",600,0.545,,,,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021SepOct_RegionSouthWest,211130_England_UKHSA_2021SepOct,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,South West,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-09-01,2021-10-31,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Geographical area,South West,76,0.5132,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021SepOct_Age1–4,211130_England_UKHSA_2021SepOct,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-09-01,2021-10-31,Residual sera,All,Children and Youth (0-17 years),1.0,4.0,Age,1-4,92,0.4565,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021SepOct_Age12–15,211130_England_UKHSA_2021SepOct,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-09-01,2021-10-31,Residual sera,All,Children and Youth (0-17 years),12.0,15.0,Age,12-15,311,0.5852,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.9550000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-15,2024-03-01,Verified,oeser_large_2021,GBR
211130_England_UKHSA_2021SepOct_Overall_AdjustedN,211130_England_UKHSA_2021SepOct,Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.,2021-11-30,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Here we present results from residual serum samples collected from children aged one to 17 years in England from September 2020 to October 2021.

Overall, a total of 26 hospital trusts have participated in the main SEU collection since the start of the pan- demic with an average of 200 samples from children aged one to 17 years tested each month. In addition, a targeted paediatric collection from 18 hospitals across England providing paediatric services was established, with approximately 500 paediatric sam- ples collected each month. ",,2021-09-01,2021-10-31,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Test used,"N-positive, Population Adjusted",600,0.335,0.268,0.409,,,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.8390000000000001,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Clarissa Oeser,"UK Health Security Agency (UKHSA, formerly PHE)",Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2021.11.019,2021-12-23,2024-03-01,Verified,oeser_large_2021,GBR
211201_GreaterLondon_PublicHealthEngland_Residents,211201_GreaterLondon_PublicHealthEngland_Residents,Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England.,2021-12-01,Journal Article (Peer-Reviewed),Local,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,London,"All residents and staff were offered SARS-CoV-2 antibody testing more than 4 weeks after timepoint T0 (timepoint T1; weeks 20–30, 2020)","""no exclusion criteria.""",2020-05-11,2020-07-26,Assisted living and long-term care facilities,All,Seniors (65+ years),40.0,,Primary Estimate,,459,0.5773,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Author designed (ELISA) - MULTIPLEXED,Author designed (ELISA) -Spike","Abbott Laboratories,NA",,Serum,"['IgG', 'Notreported']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Yes,Yes,No,,Anna Jeffery-Smith,Public Health England,Not Unity-Aligned,https://dx.doi.org/10.1016/S2666-7568(21)00253-1,2021-12-14,2024-03-01,Unverified,jeffery-smith_reinfection_2021,GBR
211201_GreaterLondon_PublicHealthEngland_Staff,211201_GreaterLondon_PublicHealthEngland_Staff,Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England.,2021-12-01,Journal Article (Peer-Reviewed),Local,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,London,"All residents and staff were offered SARS-CoV-2 antibody testing more than 4 weeks after timepoint T0 (timepoint T1; weeks 20–30, 2020)","""no exclusion criteria.""",2020-05-11,2020-07-26,Assisted living and long-term care facilities,All,Adults (18-64 years),16.0,,Primary Estimate,,712,0.4958,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Author designed (ELISA) - MULTIPLEXED,Author designed (ELISA) -Spike","Abbott Laboratories,NA",,Serum,"['IgG', 'Notreported']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Anna Jeffery-Smith,Public Health England,Not Unity-Aligned,https://dx.doi.org/10.1016/S2666-7568(21)00253-1,2021-12-14,2024-03-01,Unverified,jeffery-smith_reinfection_2021,GBR
211208_Scotland_PublicHealthScotland_1ResidualSera_Overall_PopAdj_TestAdj,211208_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 December 2021,2021-12-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-10-11,2021-11-14,Residual sera,All,Multiple groups,,,Primary Estimate,"Overall, test and pop adjusted",2882,0.805,0.7859999999999999,0.8200000000000001,True,True,True,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-december-2021/,2021-12-15,2023-08-15,Verified,public_health_scotland_enhanced_2021,GBR
211208_Scotland_PublicHealthScotland_1ResidualSera_Age_00 - 19_Unadj,211208_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 December 2021,2021-12-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-10-11,2021-11-14,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Age,00 - 19_Unadj,732,0.6995,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-december-2021/,2021-12-15,2024-03-01,Verified,public_health_scotland_enhanced_2021,GBR
211208_Scotland_PublicHealthScotland_1ResidualSera_Age_60 - 69_Unadj,211208_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 December 2021,2021-12-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-10-11,2021-11-14,Residual sera,All,Seniors (65+ years),60.0,69.0,Age,60 - 69_Unadj,334,0.7635,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-december-2021/,2021-12-15,2024-03-01,Verified,public_health_scotland_enhanced_2021,GBR
211208_Scotland_PublicHealthScotland_1ResidualSera_Male_Unadj,211208_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 December 2021,2021-12-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-10-11,2021-11-14,Residual sera,Male,Multiple groups,,,Sex/Gender,"Males, unadj",1429,0.7676999999999999,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-december-2021/,2021-12-15,2024-03-01,Verified,public_health_scotland_enhanced_2021,GBR
211208_Scotland_PublicHealthScotland_1ResidualSera_Female_Unadj,211208_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 December 2021,2021-12-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-10-11,2021-11-14,Residual sera,Female,Multiple groups,,,Sex/Gender,"Females, unadj",1453,0.7942,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-december-2021/,2021-12-15,2024-03-01,Verified,public_health_scotland_enhanced_2021,GBR
211208_Scotland_PublicHealthScotland_1ResidualSera_Age_40 - 59_Unadj,211208_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 December 2021,2021-12-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-10-11,2021-11-14,Residual sera,All,Adults (18-64 years),40.0,59.0,Age,40 - 59_Unadj,605,0.8,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-december-2021/,2021-12-15,2024-03-01,Verified,public_health_scotland_enhanced_2021,GBR
211208_Scotland_PublicHealthScotland_1ResidualSera_Overall_Unadj,211208_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 December 2021,2021-12-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-10-11,2021-11-14,Residual sera,All,Multiple groups,,,Analysis,"Overall, unadj",2882,0.7811,,,,,,,True,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-december-2021/,2021-12-15,2024-03-01,Verified,public_health_scotland_enhanced_2021,GBR
211208_Scotland_PublicHealthScotland_1ResidualSera_Age_70+_Unadj,211208_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 December 2021,2021-12-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-10-11,2021-11-14,Residual sera,All,Seniors (65+ years),70.0,,Age,70+_Unadj,507,0.783,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-december-2021/,2021-12-15,2024-03-01,Verified,public_health_scotland_enhanced_2021,GBR
211208_Scotland_PublicHealthScotland_1ResidualSera_Age_20 - 39_Unadj,211208_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 December 2021,2021-12-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-10-11,2021-11-14,Residual sera,All,Adults (18-64 years),20.0,39.0,Age,20 - 39_Unadj,704,0.8565,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-december-2021/,2021-12-15,2024-03-01,Verified,public_health_scotland_enhanced_2021,GBR
211208_Scotland_PublicHealthScotland_2BloodDonors_Overall_PopAdj_TestAdj,211208_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 December 2021,2021-12-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2021-10-11,2021-11-14,Blood donors,All,Multiple groups,,,Primary Estimate,"Overall, test and pop adjusted",2496,0.998,0.9940000000000001,1.0,True,True,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-december-2021/,2021-12-15,2023-08-15,Verified,public_health_scotland_enhanced_2021,GBR
211208_Scotland_PublicHealthScotland_2BloodDonors_Age_00 - 39_Unadj,211208_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 December 2021,2021-12-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2021-10-11,2021-11-14,Blood donors,All,Multiple groups,0.0,39.0,Age,"00 - 39, unadj",852,0.9671,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-december-2021/,2021-12-15,2024-03-01,Verified,public_health_scotland_enhanced_2021,GBR
211208_Scotland_PublicHealthScotland_2BloodDonors_Male_Unadj,211208_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 December 2021,2021-12-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2021-10-11,2021-11-14,Blood donors,Male,Multiple groups,,,Sex/Gender,"Males, unadj",1183,0.9383,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-december-2021/,2021-12-15,2024-03-01,Verified,public_health_scotland_enhanced_2021,GBR
211208_Scotland_PublicHealthScotland_2BloodDonors_Age_40 - 59_Unadj,211208_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 December 2021,2021-12-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2021-10-11,2021-11-14,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,"40 - 59, unadj",1102,0.9374,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-december-2021/,2021-12-15,2024-03-01,Verified,public_health_scotland_enhanced_2021,GBR
211208_Scotland_PublicHealthScotland_2BloodDonors_Female_Unadj,211208_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 December 2021,2021-12-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2021-10-11,2021-11-14,Blood donors,Female,Multiple groups,,,Sex/Gender,"Females, unadj",1313,0.9490000000000001,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-december-2021/,2021-12-15,2024-03-01,Verified,public_health_scotland_enhanced_2021,GBR
211208_Scotland_PublicHealthScotland_2BloodDonors_Overall_Unadj,211208_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 December 2021,2021-12-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2021-10-11,2021-11-14,Blood donors,All,Multiple groups,,,Analysis,Overall Unadj,2496,0.9439000000000001,,,,,,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-december-2021/,2021-12-15,2024-03-01,Verified,public_health_scotland_enhanced_2021,GBR
211208_Scotland_PublicHealthScotland_2BloodDonors_Age_60+_Unadj,211208_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 December 2021,2021-12-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2021-10-11,2021-11-14,Blood donors,All,Seniors (65+ years),60.0,,Age,"60+, unadj",542,0.9207,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-december-2021/,2021-12-15,2024-03-01,Verified,public_health_scotland_enhanced_2021,GBR
211208_Scotland_PublicHealthScotland_3PregnantWomen_Overall_Anti-S_Unadj,211208_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 December 2021,2021-12-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2021-10-11,2021-11-14,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,"Overall, anti-S, unadjusted",2890,0.8616,,,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-december-2021/,2021-12-15,2024-03-01,Verified,public_health_scotland_enhanced_2021,GBR
211208_Scotland_PublicHealthScotland_3PregnantWomen_Age_20 - 29_Unadj,211208_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 December 2021,2021-12-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2021-10-11,2021-11-14,Pregnant or parturient women,Female,Adults (18-64 years),20.0,29.0,Age,age 20-29,1115,0.8151999999999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-december-2021/,2021-12-15,2024-03-01,Verified,public_health_scotland_enhanced_2021,GBR
211208_Scotland_PublicHealthScotland_3PregnantWomen_Age_40+_Unadj,211208_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 December 2021,2021-12-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2021-10-11,2021-11-14,Pregnant or parturient women,Female,Adults (18-64 years),40.0,,Age,age 40+,122,0.9098,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-december-2021/,2021-12-15,2024-03-01,Verified,public_health_scotland_enhanced_2021,GBR
211208_Scotland_PublicHealthScotland_3PregnantWomen_Age_30 - 39_Unadj,211208_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 December 2021,2021-12-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2021-10-11,2021-11-14,Pregnant or parturient women,Female,Adults (18-64 years),30.0,39.0,Age,age 30-39,1596,0.8959999999999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-december-2021/,2021-12-15,2024-03-01,Verified,public_health_scotland_enhanced_2021,GBR
211208_Scotland_PublicHealthScotland_3PregnantWomen_Age_00 - 19_Unadj,211208_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 December 2021,2021-12-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2021-10-11,2021-11-14,Pregnant or parturient women,Female,Children and Youth (0-17 years),0.0,19.0,Age,age 0-19,57,0.7018000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.923,1.0,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-december-2021/,2021-12-15,2024-03-01,Verified,public_health_scotland_enhanced_2021,GBR
211208_Scotland_PublicHealthScotland_3PregnantWomen_Overall_AntiS+AntiN_Unadj,211208_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 December 2021,2021-12-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2021-10-11,2021-11-14,Pregnant or parturient women,Female,Adults (18-64 years),,,Test used,"Overall, anti-S AND anti-N, unadj",2890,0.21309999999999998,,,,,,,,Sequential,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-december-2021/,2021-12-15,2024-03-01,Verified,public_health_scotland_enhanced_2021,GBR
211211_England_UKHealthSecurityAgency_Round1_Staff_S,211211_England_UKHealthSecurityAgency_Staff_Round1,"Emergence of the Delta Variant and risk of SARS-CoV-2 infection in secondary school students and staff: prospective surveillance in 18 schools, England",2021-12-11,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,England,"Derbyshire, West London, East London, Greater Manchester, Hertfordshire and Birmingham","The study involved testing secondary school students and staff for SARS-CoV-2 infection and antibodies at the start (Round 1: 22 September-17 October 2020) and end (Round 2: 3-17 December 2020) of the autumn term of the 2020/21 academic year, when the schools reopened in March (Round 3: 23 March-21 April 2021) and at the end of the academic year (Round 4: 20 May-14 July 2021).

Secondary schools were approached in areas where a paediatric investigation team could be assembled: Derbyshire, West London, East London, Greater Manchester, Hertfordshire and Birmingham.",,2020-09-22,2020-10-17,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,staff roche-S,861,0.161,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,,,,['Moderate'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Shamez N. Ladhani,The UK Health Security Agency,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.12.10.21267583v1.full-text,2021-12-25,2024-03-01,Verified,ladhani_emergence_2021,GBR
211211_England_UKHealthSecurityAgency_Round2_Staff_S,211211_England_UKHealthSecurityAgency_Staff_Round2,"Emergence of the Delta Variant and risk of SARS-CoV-2 infection in secondary school students and staff: prospective surveillance in 18 schools, England",2021-12-11,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,England,"Derbyshire, West London, East London, Greater Manchester, Hertfordshire and Birmingham","The study involved testing secondary school students and staff for SARS-CoV-2 infection and antibodies at the start (Round 1: 22 September-17 October 2020) and end (Round 2: 3-17 December 2020) of the autumn term of the 2020/21 academic year, when the schools reopened in March (Round 3: 23 March-21 April 2021) and at the end of the academic year (Round 4: 20 May-14 July 2021).

Secondary schools were approached in areas where a paediatric investigation team could be assembled: Derbyshire, West London, East London, Greater Manchester, Hertfordshire and Birmingham.",,2020-12-03,2020-12-17,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,staff roche-S,873,0.219,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,,,,['Moderate'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Shamez N. Ladhani,The UK Health Security Agency,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.12.10.21267583v1.full-text,2021-12-25,2024-03-01,Verified,ladhani_emergence_2021,GBR
211211_England_UKHealthSecurityAgency_Round3_Staff_S,211211_England_UKHealthSecurityAgency_Staff_Round3,"Emergence of the Delta Variant and risk of SARS-CoV-2 infection in secondary school students and staff: prospective surveillance in 18 schools, England",2021-12-11,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,England,"Derbyshire, West London, East London, Greater Manchester, Hertfordshire and Birmingham","The study involved testing secondary school students and staff for SARS-CoV-2 infection and antibodies at the start (Round 1: 22 September-17 October 2020) and end (Round 2: 3-17 December 2020) of the autumn term of the 2020/21 academic year, when the schools reopened in March (Round 3: 23 March-21 April 2021) and at the end of the academic year (Round 4: 20 May-14 July 2021).

Secondary schools were approached in areas where a paediatric investigation team could be assembled: Derbyshire, West London, East London, Greater Manchester, Hertfordshire and Birmingham.",,2021-03-21,2021-04-21,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,staff roche-S,773,0.598,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,,,,['Moderate'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Shamez N. Ladhani,The UK Health Security Agency,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.12.10.21267583v1.full-text,2021-12-25,2024-03-01,Verified,ladhani_emergence_2021,GBR
211211_England_UKHealthSecurityAgency_Round4_Staff_S,211211_England_UKHealthSecurityAgency_Staff_Round4,"Emergence of the Delta Variant and risk of SARS-CoV-2 infection in secondary school students and staff: prospective surveillance in 18 schools, England",2021-12-11,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,England,"Derbyshire, West London, East London, Greater Manchester, Hertfordshire and Birmingham","The study involved testing secondary school students and staff for SARS-CoV-2 infection and antibodies at the start (Round 1: 22 September-17 October 2020) and end (Round 2: 3-17 December 2020) of the autumn term of the 2020/21 academic year, when the schools reopened in March (Round 3: 23 March-21 April 2021) and at the end of the academic year (Round 4: 20 May-14 July 2021).

Secondary schools were approached in areas where a paediatric investigation team could be assembled: Derbyshire, West London, East London, Greater Manchester, Hertfordshire and Birmingham.",,2021-05-20,2021-07-14,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,staff roche-S,639,0.978,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,,,,['Moderate'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Shamez N. Ladhani,The UK Health Security Agency,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.12.10.21267583v1.full-text,2021-12-25,2024-03-01,Verified,ladhani_emergence_2021,GBR
211211_England_UKHealthSecurityAgency_Round1_Students_S,211211_England_UKHealthSecurityAgency_Students_Round1,"Emergence of the Delta Variant and risk of SARS-CoV-2 infection in secondary school students and staff: prospective surveillance in 18 schools, England",2021-12-11,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,England,"Derbyshire, West London, East London, Greater Manchester, Hertfordshire and Birmingham","The study involved testing secondary school students and staff for SARS-CoV-2 infection and antibodies at the start (Round 1: 22 September-17 October 2020) and end (Round 2: 3-17 December 2020) of the autumn term of the 2020/21 academic year, when the schools reopened in March (Round 3: 23 March-21 April 2021) and at the end of the academic year (Round 4: 20 May-14 July 2021).

Secondary schools were approached in areas where a paediatric investigation team could be assembled: Derbyshire, West London, East London, Greater Manchester, Hertfordshire and Birmingham.",,2020-09-22,2020-10-17,Students and Daycares,All,Children and Youth (0-17 years),,,Primary Estimate,students roche-S,894,0.17600000000000002,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,,,,['Moderate'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Shamez N. Ladhani,The UK Health Security Agency,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.12.10.21267583v1.full-text,2021-12-25,2024-03-01,Verified,ladhani_emergence_2021,GBR
211211_England_UKHealthSecurityAgency_Round2_Students_S,211211_England_UKHealthSecurityAgency_Students_Round2,"Emergence of the Delta Variant and risk of SARS-CoV-2 infection in secondary school students and staff: prospective surveillance in 18 schools, England",2021-12-11,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,England,"Derbyshire, West London, East London, Greater Manchester, Hertfordshire and Birmingham","The study involved testing secondary school students and staff for SARS-CoV-2 infection and antibodies at the start (Round 1: 22 September-17 October 2020) and end (Round 2: 3-17 December 2020) of the autumn term of the 2020/21 academic year, when the schools reopened in March (Round 3: 23 March-21 April 2021) and at the end of the academic year (Round 4: 20 May-14 July 2021).

Secondary schools were approached in areas where a paediatric investigation team could be assembled: Derbyshire, West London, East London, Greater Manchester, Hertfordshire and Birmingham.",,2020-12-03,2020-12-17,Students and Daycares,All,Children and Youth (0-17 years),,,Primary Estimate,students roche-S,893,0.231,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,,,,['Moderate'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Shamez N. Ladhani,The UK Health Security Agency,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.12.10.21267583v1.full-text,2021-12-25,2024-03-01,Verified,ladhani_emergence_2021,GBR
211211_England_UKHealthSecurityAgency_Round3_Students_S,211211_England_UKHealthSecurityAgency_Students_Round3,"Emergence of the Delta Variant and risk of SARS-CoV-2 infection in secondary school students and staff: prospective surveillance in 18 schools, England",2021-12-11,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,England,"Derbyshire, West London, East London, Greater Manchester, Hertfordshire and Birmingham","The study involved testing secondary school students and staff for SARS-CoV-2 infection and antibodies at the start (Round 1: 22 September-17 October 2020) and end (Round 2: 3-17 December 2020) of the autumn term of the 2020/21 academic year, when the schools reopened in March (Round 3: 23 March-21 April 2021) and at the end of the academic year (Round 4: 20 May-14 July 2021).

Secondary schools were approached in areas where a paediatric investigation team could be assembled: Derbyshire, West London, East London, Greater Manchester, Hertfordshire and Birmingham.",,2021-03-21,2021-04-21,Students and Daycares,All,Children and Youth (0-17 years),,,Primary Estimate,students roche-S,1030,0.39299999999999996,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,,,,['Moderate'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Shamez N. Ladhani,The UK Health Security Agency,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.12.10.21267583v1.full-text,2021-12-25,2024-03-01,Verified,ladhani_emergence_2021,GBR
211211_England_UKHealthSecurityAgency_Round4_Students_S,211211_England_UKHealthSecurityAgency_Students_Round4 ,"Emergence of the Delta Variant and risk of SARS-CoV-2 infection in secondary school students and staff: prospective surveillance in 18 schools, England",2021-12-11,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,England,"Derbyshire, West London, East London, Greater Manchester, Hertfordshire and Birmingham","The study involved testing secondary school students and staff for SARS-CoV-2 infection and antibodies at the start (Round 1: 22 September-17 October 2020) and end (Round 2: 3-17 December 2020) of the autumn term of the 2020/21 academic year, when the schools reopened in March (Round 3: 23 March-21 April 2021) and at the end of the academic year (Round 4: 20 May-14 July 2021).

Secondary schools were approached in areas where a paediatric investigation team could be assembled: Derbyshire, West London, East London, Greater Manchester, Hertfordshire and Birmingham.",,2021-05-20,2021-07-14,Students and Daycares,All,Children and Youth (0-17 years),,,Primary Estimate,students roche-S,655,0.414,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,,,,['Moderate'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Shamez N. Ladhani,The UK Health Security Agency,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.12.10.21267583v1.full-text,2021-12-25,2024-03-01,Verified,ladhani_emergence_2021,GBR
220101_England_UCLInstituteOfHealthInformatics_Primary,220101_England_UCLInstituteOfHealthInformatics,Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England.,2022-01-01,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,,"In brief, eligible LTCFs were identified by the provider or the National Institute for Health Research Clinical Research Network. Residents and staff within selected LTCFs were offered participation in the study",We excluded staff older than 65 years and residents younger than 65 years. An age threshold of 65 was used to differentiate between staff and residents in cases in which the role of the participant was unknown (n=672).,2020-06-01,2021-04-30,Multiple general populations,All,Multiple groups,,,Primary Estimate,,4722,0.28800000000000003,,,True,,,,True,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Maria Krutikov,UCL Institute of Health Informatics,Not Unity-Aligned,https://dx.doi.org/10.1016/S2666-7568(21)00282-8,2022-01-08,2024-03-01,Unverified,krutikov_prevalence_2022,GBR
220101_England_UCLInstituteOfHealthInformatics_Aug1Sept30_2020,220101_England_UCLInstituteOfHealthInformatics,Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England.,2022-01-01,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,,"In brief, eligible LTCFs were identified by the provider or the National Institute for Health Research Clinical Research Network. Residents and staff within selected LTCFs were offered participation in the study",We excluded staff older than 65 years and residents younger than 65 years. An age threshold of 65 was used to differentiate between staff and residents in cases in which the role of the participant was unknown (n=672).,2020-08-01,2020-09-30,Multiple general populations,All,Multiple groups,65.0,,Time frame,"
Aug 1–Sept 30, 2020 
",1794,0.264,0.22,0.315,,,True,,,Self-referral,"Abbott Architect SARS-CoV-2 IgG,Meso Scale Discovery multiplex assay","Abbott Laboratories,Meso Scale Discovery",,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Maria Krutikov,UCL Institute of Health Informatics,Not Unity-Aligned,https://dx.doi.org/10.1016/S2666-7568(21)00282-8,2022-01-08,2024-03-01,Unverified,krutikov_prevalence_2022,GBR
220101_England_UCLInstituteOfHealthInformatics_Dec1_2020Jan31_2021,220101_England_UCLInstituteOfHealthInformatics,Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England.,2022-01-01,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,,"In brief, eligible LTCFs were identified by the provider or the National Institute for Health Research Clinical Research Network. Residents and staff within selected LTCFs were offered participation in the study",We excluded staff older than 65 years and residents younger than 65 years. An age threshold of 65 was used to differentiate between staff and residents in cases in which the role of the participant was unknown (n=672).,2020-12-01,2021-01-31,Multiple general populations,All,Multiple groups,65.0,,Time frame,"Dec 1, 2020, to Jan 31, 2021",1136,0.174,0.136,0.22,,,True,,,Self-referral,"Abbott Architect SARS-CoV-2 IgG,Meso Scale Discovery multiplex assay","Abbott Laboratories,Meso Scale Discovery",,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Maria Krutikov,UCL Institute of Health Informatics,Not Unity-Aligned,https://dx.doi.org/10.1016/S2666-7568(21)00282-8,2022-01-08,2024-03-01,Unverified,krutikov_prevalence_2022,GBR
220101_England_UCLInstituteOfHealthInformatics_Feb1_28_2021,220101_England_UCLInstituteOfHealthInformatics,Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England.,2022-01-01,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,,"In brief, eligible LTCFs were identified by the provider or the National Institute for Health Research Clinical Research Network. Residents and staff within selected LTCFs were offered participation in the study",We excluded staff older than 65 years and residents younger than 65 years. An age threshold of 65 was used to differentiate between staff and residents in cases in which the role of the participant was unknown (n=672).,2021-02-01,2021-02-28,Multiple general populations,All,Multiple groups,65.0,,Time frame,"Feb 1–28, 2021",920,0.22,0.172,0.276,,,True,,,Self-referral,"Abbott Architect SARS-CoV-2 IgG,Meso Scale Discovery multiplex assay","Abbott Laboratories,Meso Scale Discovery",,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Maria Krutikov,UCL Institute of Health Informatics,Not Unity-Aligned,https://dx.doi.org/10.1016/S2666-7568(21)00282-8,2022-01-08,2024-03-01,Unverified,krutikov_prevalence_2022,GBR
220101_England_UCLInstituteOfHealthInformatics_March1April30_2021,220101_England_UCLInstituteOfHealthInformatics,Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England.,2022-01-01,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,,"In brief, eligible LTCFs were identified by the provider or the National Institute for Health Research Clinical Research Network. Residents and staff within selected LTCFs were offered participation in the study",We excluded staff older than 65 years and residents younger than 65 years. An age threshold of 65 was used to differentiate between staff and residents in cases in which the role of the participant was unknown (n=672).,2021-03-01,2021-04-30,Multiple general populations,All,Multiple groups,65.0,,Time frame,"
March 1–April 30, 2021 
",2064,0.261,0.219,0.307,,,True,,,Self-referral,"Abbott Architect SARS-CoV-2 IgG,Meso Scale Discovery multiplex assay","Abbott Laboratories,Meso Scale Discovery",,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Maria Krutikov,UCL Institute of Health Informatics,Not Unity-Aligned,https://dx.doi.org/10.1016/S2666-7568(21)00282-8,2022-01-08,2024-03-01,Unverified,krutikov_prevalence_2022,GBR
220101_England_UCLInstituteOfHealthInformatics_June1July 31_2020,220101_England_UCLInstituteOfHealthInformatics,Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England.,2022-01-01,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,,"In brief, eligible LTCFs were identified by the provider or the National Institute for Health Research Clinical Research Network. Residents and staff within selected LTCFs were offered participation in the study",We excluded staff older than 65 years and residents younger than 65 years. An age threshold of 65 was used to differentiate between staff and residents in cases in which the role of the participant was unknown (n=672).,2020-06-01,2020-07-31,Multiple general populations,All,Multiple groups,65.0,,Time frame,"
June 1–July 31, 2020 
",2225,0.306,0.254,0.364,,,True,,,Self-referral,"Abbott Architect SARS-CoV-2 IgG,Meso Scale Discovery multiplex assay","Abbott Laboratories,Meso Scale Discovery",,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Maria Krutikov,UCL Institute of Health Informatics,Not Unity-Aligned,https://dx.doi.org/10.1016/S2666-7568(21)00282-8,2022-01-08,2024-03-01,Unverified,krutikov_prevalence_2022,GBR
220101_England_UCLInstituteOfHealthInformatics_Female,220101_England_UCLInstituteOfHealthInformatics,Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England.,2022-01-01,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,,"In brief, eligible LTCFs were identified by the provider or the National Institute for Health Research Clinical Research Network. Residents and staff within selected LTCFs were offered participation in the study",We excluded staff older than 65 years and residents younger than 65 years. An age threshold of 65 was used to differentiate between staff and residents in cases in which the role of the participant was unknown (n=672).,2020-06-01,2021-04-30,Multiple general populations,Female,Multiple groups,,,Sex/Gender,,3892,0.289,,,,,,,,Self-referral,"Abbott Architect SARS-CoV-2 IgG,Meso Scale Discovery multiplex assay","Abbott Laboratories,Meso Scale Discovery",,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Maria Krutikov,UCL Institute of Health Informatics,Not Unity-Aligned,https://dx.doi.org/10.1016/S2666-7568(21)00282-8,2022-01-08,2024-03-01,Unverified,krutikov_prevalence_2022,GBR
220101_England_UCLInstituteOfHealthInformatics_Male,220101_England_UCLInstituteOfHealthInformatics,Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England.,2022-01-01,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,,"In brief, eligible LTCFs were identified by the provider or the National Institute for Health Research Clinical Research Network. Residents and staff within selected LTCFs were offered participation in the study",We excluded staff older than 65 years and residents younger than 65 years. An age threshold of 65 was used to differentiate between staff and residents in cases in which the role of the participant was unknown (n=672).,2020-06-01,2021-04-30,Multiple general populations,Male,Multiple groups,,,Sex/Gender,,828,0.28600000000000003,,,,,,,,Self-referral,"Abbott Architect SARS-CoV-2 IgG,Meso Scale Discovery multiplex assay","Abbott Laboratories,Meso Scale Discovery",,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Maria Krutikov,UCL Institute of Health Informatics,Not Unity-Aligned,https://dx.doi.org/10.1016/S2666-7568(21)00282-8,2022-01-08,2024-03-01,Unverified,krutikov_prevalence_2022,GBR
220101_England_UCLInstituteOfHealthInformatics_Oct1Nov30_2020,220101_England_UCLInstituteOfHealthInformatics,Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England.,2022-01-01,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,,"In brief, eligible LTCFs were identified by the provider or the National Institute for Health Research Clinical Research Network. Residents and staff within selected LTCFs were offered participation in the study",We excluded staff older than 65 years and residents younger than 65 years. An age threshold of 65 was used to differentiate between staff and residents in cases in which the role of the participant was unknown (n=672).,2020-10-01,2020-11-30,Multiple general populations,All,Multiple groups,65.0,,Time frame,"Oct 1–Nov 30, 2020",1349,0.265,0.215,0.322,,,True,,,Self-referral,"Abbott Architect SARS-CoV-2 IgG,Meso Scale Discovery multiplex assay","Abbott Laboratories,Meso Scale Discovery",,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Maria Krutikov,UCL Institute of Health Informatics,Not Unity-Aligned,https://dx.doi.org/10.1016/S2666-7568(21)00282-8,2022-01-08,2024-03-01,Unverified,krutikov_prevalence_2022,GBR
220119_Scotland_PublicHealthScotland_1ResidualSeraOverall_PopAdj_TestAdj,220119_Scotland_PublicHealthScotland_1ResidualSera,"Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 19 January, 2022",2022-01-19,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-11-15,2021-12-19,Residual sera,All,Multiple groups,,,Primary Estimate,"Overall, test and pop adjusted",2815,0.8740000000000001,0.8570000000000001,0.887,True,True,True,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-19-january-2022/,2022-01-25,2023-08-15,Verified,public_health_scotland_enhanced_2022,GBR
220119_Scotland_PublicHealthScotland_1ResidualSera_Age_20 - 39_Unadj,220119_Scotland_PublicHealthScotland_1ResidualSera,"Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 19 January, 2022",2022-01-19,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-11-15,2021-12-19,Residual sera,All,Adults (18-64 years),20.0,39.0,Age,20 - 39_Unadj,710,0.8704000000000001,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-19-january-2022/,2022-01-25,2024-03-01,Verified,public_health_scotland_enhanced_2022,GBR
220119_Scotland_PublicHealthScotland_1ResidualSeraOverall_Unadj,220119_Scotland_PublicHealthScotland_1ResidualSera,"Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 19 January, 2022",2022-01-19,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-11-15,2021-12-19,Residual sera,All,Multiple groups,,,Analysis,"Overall, unadj",2815,0.8526,,,,,,,True,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-19-january-2022/,2022-01-25,2024-03-01,Verified,public_health_scotland_enhanced_2022,GBR
220119_Scotland_PublicHealthScotland_1ResidualSera_Age_60 - 69_Unadj,220119_Scotland_PublicHealthScotland_1ResidualSera,"Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 19 January, 2022",2022-01-19,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-11-15,2021-12-19,Residual sera,All,Seniors (65+ years),60.0,69.0,Age,60 - 69_Unadj,316,0.9146,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-19-january-2022/,2022-01-25,2024-03-01,Verified,public_health_scotland_enhanced_2022,GBR
220119_Scotland_PublicHealthScotland_1ResidualSera_Age_00 - 19_Unadj,220119_Scotland_PublicHealthScotland_1ResidualSera,"Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 19 January, 2022",2022-01-19,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-11-15,2021-12-19,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Age,00 - 19_Unadj,682,0.7331000000000001,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-19-january-2022/,2022-01-25,2024-03-01,Verified,public_health_scotland_enhanced_2022,GBR
220119_Scotland_PublicHealthScotland_1ResidualSera_Age_40 - 59_Unadj,220119_Scotland_PublicHealthScotland_1ResidualSera,"Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 19 January, 2022",2022-01-19,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-11-15,2021-12-19,Residual sera,All,Adults (18-64 years),40.0,59.0,Age,40 - 59_Unadj,585,0.8444,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-19-january-2022/,2022-01-25,2024-03-01,Verified,public_health_scotland_enhanced_2022,GBR
220119_Scotland_PublicHealthScotland_1ResidualSeraFemale_Unadj,220119_Scotland_PublicHealthScotland_1ResidualSera,"Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 19 January, 2022",2022-01-19,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-11-15,2021-12-19,Residual sera,Female,Multiple groups,,,Sex/Gender,"Females, unadj",1289,0.9697,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-19-january-2022/,2022-01-25,2024-03-01,Verified,public_health_scotland_enhanced_2022,GBR
220119_Scotland_PublicHealthScotland_1ResidualSera_Age_70+_Unadj,220119_Scotland_PublicHealthScotland_1ResidualSera,"Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 19 January, 2022",2022-01-19,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-11-15,2021-12-19,Residual sera,All,Seniors (65+ years),70.0,,Age,70+_Unadj,682,0.7317,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-19-january-2022/,2022-01-25,2024-03-01,Verified,public_health_scotland_enhanced_2022,GBR
220119_Scotland_PublicHealthScotland_1ResidualSeraMale_Unadj,220119_Scotland_PublicHealthScotland_1ResidualSera,"Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 19 January, 2022",2022-01-19,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-11-15,2021-12-19,Residual sera,Male,Multiple groups,,,Sex/Gender,"Males, unadj",1204,0.9568000000000001,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-19-january-2022/,2022-01-25,2024-03-01,Verified,public_health_scotland_enhanced_2022,GBR
220119_Scotland_PublicHealthScotland_2BloodDonors_Overall_PopAdj_TestAdj,220119_Scotland_PublicHealthScotland_2BloodDonors,"Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 19 January, 2022",2022-01-19,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2021-11-15,2021-12-19,Blood donors,All,Multiple groups,,,Primary Estimate,"Overall, test and pop adjusted",2493,1.0,0.9990000000000001,1.0,True,True,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-19-january-2022/,2022-01-26,2023-08-15,Verified,public_health_scotland_enhanced_2022,GBR
220119_Scotland_PublicHealthScotland_2BloodDonors_Age_00 - 39_Unadj,220119_Scotland_PublicHealthScotland_2BloodDonors,"Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 19 January, 2022",2022-01-19,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2021-11-15,2021-12-19,Blood donors,All,Multiple groups,0.0,39.0,Age,"00 - 39, unadj",819,0.9695,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-19-january-2022/,2022-01-25,2024-03-01,Verified,public_health_scotland_enhanced_2022,GBR
220119_Scotland_PublicHealthScotland_2BloodDonors_Age_60+_Unadj,220119_Scotland_PublicHealthScotland_2BloodDonors,"Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 19 January, 2022",2022-01-19,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2021-11-15,2021-12-19,Blood donors,All,Seniors (65+ years),60.0,,Age,"60+, unadj",574,0.9756,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-19-january-2022/,2022-01-26,2024-03-01,Verified,public_health_scotland_enhanced_2022,GBR
220119_Scotland_PublicHealthScotland_2BloodDonors_Age_40 - 59_Unadj,220119_Scotland_PublicHealthScotland_2BloodDonors,"Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 19 January, 2022",2022-01-19,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2021-11-15,2021-12-19,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,"40 - 59, unadj",1100,0.9527,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-19-january-2022/,2022-01-26,2024-03-01,Verified,public_health_scotland_enhanced_2022,GBR
220119_Scotland_PublicHealthScotland_2BloodDonors_Overall_Unadj,220119_Scotland_PublicHealthScotland_2BloodDonors,"Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 19 January, 2022",2022-01-19,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2021-11-15,2021-12-19,Blood donors,All,Multiple groups,,,Analysis,Overall Unadj,2493,0.9634999999999999,,,,,,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-19-january-2022/,2022-01-26,2024-03-01,Verified,public_health_scotland_enhanced_2022,GBR
220119_Scotland_PublicHealthScotland_2BloodDonors_Female_Unadj,220119_Scotland_PublicHealthScotland_2BloodDonors,"Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 19 January, 2022",2022-01-19,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2021-11-15,2021-12-19,Blood donors,Female,Multiple groups,,,Sex/Gender,"Females, unadj",1289,0.9697,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-19-january-2022/,2022-01-26,2024-03-01,Verified,public_health_scotland_enhanced_2022,GBR
220119_Scotland_PublicHealthScotland_2BloodDonors_Male_Unadj,220119_Scotland_PublicHealthScotland_2BloodDonors,"Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 19 January, 2022",2022-01-19,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2021-11-15,2021-12-19,Blood donors,Male,Multiple groups,,,Sex/Gender,"Males, unadj",1204,0.9568000000000001,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-19-january-2022/,2022-01-26,2024-03-01,Verified,public_health_scotland_enhanced_2022,GBR
220119_Scotland_PublicHealthScotland_3PregnantWomen_Overall_Unadj,220119_Scotland_PublicHealthScotland_3PregnantWomen,"Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 19 January, 2022",2022-01-19,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2021-11-15,2021-12-19,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,"Overall, anti-S, unadjusted",3060,0.8725,,,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-19-january-2022/,2022-01-26,2024-03-01,Verified,public_health_scotland_enhanced_2022,GBR
220119_Scotland_PublicHealthScotland_3PregnantWomen_Age_30 - 39_Unadj,220119_Scotland_PublicHealthScotland_3PregnantWomen,"Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 19 January, 2022",2022-01-19,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2021-11-15,2021-12-19,Pregnant or parturient women,Female,Adults (18-64 years),30.0,39.0,Age,age 30-39,1714,0.8956000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-19-january-2022/,2022-01-26,2024-03-01,Verified,public_health_scotland_enhanced_2022,GBR
220119_Scotland_PublicHealthScotland_3PregnantWomen_Age_00 - 19_Unadj,220119_Scotland_PublicHealthScotland_3PregnantWomen,"Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 19 January, 2022",2022-01-19,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2021-11-15,2021-12-19,Pregnant or parturient women,Female,Children and Youth (0-17 years),0.0,19.0,Age,age 0-19,48,0.7083,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-19-january-2022/,2022-01-25,2024-03-01,Verified,public_health_scotland_enhanced_2022,GBR
220119_Scotland_PublicHealthScotland_3PregnantWomen_Age_20 - 29_Unadj,220119_Scotland_PublicHealthScotland_3PregnantWomen,"Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 19 January, 2022",2022-01-19,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2021-11-15,2021-12-19,Pregnant or parturient women,Female,Adults (18-64 years),20.0,29.0,Age,age 20-29,1189,0.8461,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-19-january-2022/,2022-01-26,2024-03-01,Verified,public_health_scotland_enhanced_2022,GBR
220119_Scotland_PublicHealthScotland_3PregnantWomen_Age_40+_Unadj,220119_Scotland_PublicHealthScotland_3PregnantWomen,"Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 19 January, 2022",2022-01-19,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2021-11-15,2021-12-19,Pregnant or parturient women,Female,Adults (18-64 years),40.0,,Age,age 40+,109,0.8715999999999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-19-january-2022/,2022-01-26,2024-03-01,Verified,public_health_scotland_enhanced_2022,GBR
220119_Scotland_PublicHealthScotland_3PregnantWomen_AntiS_AntiN,220119_Scotland_PublicHealthScotland_3PregnantWomen,"Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 19 January, 2022",2022-01-19,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2021-11-15,2021-12-19,Pregnant or parturient women,Female,Adults (18-64 years),,,Test used,"Overall, anti-S AND anti-N, unadj",3060,0.23170000000000002,,,,,,,,Sequential,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-19-january-2022/,2022-01-26,2024-03-01,Verified,public_health_scotland_enhanced_2022,GBR
220121_Oxford_UniversityOfOxford,220121_Oxford_UniversityOfOxford,"Trans-continental analysis of over, 2000 inflammatory bowel disease patients implicates geography, disease type, and exposure to immunosuppression as drivers of SARS-CoV-2 seroprevalence: Data from the ICARUS-IBD consortium",2022-01-21,Presentation or Conference,Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,Oxford,IBD patients prior to vaccination,,2020-05-26,2021-09-24,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,344,0.0669,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Atellica® IM SARS-CoV-2 Total (COV2T)","Roche Diagnostics,Siemens",,Serum,TotalAntibody,Spike,,,,['High'],,No,No,No,,Unclear,No,No,,S Y Wong,University of Oxford,Not Unity-Aligned,https://dx.doi.org/10.1093/ecco-jcc/jjab232.469,2022-03-08,2024-03-01,Unverified,wong_p342_2022,GBR
220124_SouthWales_PublicHealthWales_Overall,220124_SouthWales_PublicHealthWales,SARS-CoV-2 sero-prevalence in the workforces of three large workplaces in South Wales: a sero-epidemiological study.,2022-01-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,South Wales,,"Three separate large (non-NHS) workplaces were identifed within the boundaries of Cwm Taf Morgannwg University Health Board and approached to participate in the proposed sero-prevalence project. These were a food factory (not a meat processing plant), a non-food factory and a call centre. All the people working at the three workplaces were eligible to participate in the study, including
those who had previously tested positive for COVID-19.",,2020-09-01,2020-10-31,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,991,0.07,,,True,,,,True,Convenience,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.96,0.9550000000000001,['High'],,No,Yes,Yes,,Yes,Yes,No,,Alice Puchades,Public Health Wales,Not Unity-Aligned,https://dx.doi.org/10.1186/s12889-021-12478-x,2022-02-03,2024-03-01,Unverified,puchades_sars-cov-2_2022,GBR
220216_England_UKHealthSecurityAgency_PrimaryStaff,220216_England_UKHealthSecurityAgency_PrimaryStaff,"Secondary attack rates in primary and secondary school bubbles following a confirmed case: Active, prospective national surveillance, November to December 2020, England.",2022-02-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Primary school students, secondary school students, and primary school staff from 14 bubbles were recruited from seven schools, including 11 bubbles in four primary schools where a positive case had been detected.",PCR positive,2020-11-17,2020-12-15,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,16,0.0,,,True,,,,True,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Saliva,IgG,Nucleocapsid(N-protein),Validated by developers,0.75,0.99,['High'],,No,No,No,,Unclear,Yes,No,,Annabel Powell,UK Health Security Agency,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0262515,2022-02-23,2022-07-16,Unverified,powell_secondary_2022,GBR
220216_England_UKHealthSecurityAgency_PrimaryStudents,220216_England_UKHealthSecurityAgency_PrimaryStudents,"Secondary attack rates in primary and secondary school bubbles following a confirmed case: Active, prospective national surveillance, November to December 2020, England.",2022-02-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Primary school students, secondary school students, and primary school staff from 14 bubbles were recruited from seven schools, including 11 bubbles in four primary schools where a positive case had been detected.",PCR positive,2020-11-17,2020-12-15,Students and Daycares,All,Children and Youth (0-17 years),,,Primary Estimate,,60,0.0833,,,True,,,,True,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Saliva,IgG,Nucleocapsid(N-protein),Validated by developers,0.75,0.99,['High'],,No,No,No,,Unclear,Yes,No,,Annabel Powell,UK Health Security Agency,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0262515,2022-02-23,2022-07-16,Unverified,powell_secondary_2022,GBR
220216_England_UKHealthSecurityAgency_SecondaryStudents,220216_England_UKHealthSecurityAgency_SecondaryStudents,"Secondary attack rates in primary and secondary school bubbles following a confirmed case: Active, prospective national surveillance, November to December 2020, England.",2022-02-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,England,,"Primary school students, secondary school students, and primary school staff from 14 bubbles were recruited from seven schools, including 11 bubbles in four primary schools where a positive case had been detected.",PCR positive,2020-11-17,2020-12-15,Students and Daycares,All,Children and Youth (0-17 years),,18.0,Primary Estimate,,106,0.038,,,True,,,,True,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Saliva,IgG,Nucleocapsid(N-protein),Validated by developers,0.75,0.99,['High'],,No,No,No,,Unclear,Yes,No,,Annabel Powell,UK Health Security Agency,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0262515,2022-02-23,2022-07-16,Unverified,powell_secondary_2022,GBR
220222_UnitedKingdom_QueenMaryUniversityofLondon_Overall,220222_UnitedKingdom_QueenMaryUniversityofLondon,Determinants of pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK).,2022-02-22,Journal Article (Peer-Reviewed),National,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,"England, Scotland, Wales, and Northern Ireland",,"This antibody study is an add-on study to the COVIDENCE UK study - COVIDENCE UK is a prospective, longitudinal, population-based observational study of COVID-19 in the UK population (www.qmul.ac.uk/covidence). Inclusion criteria for COVIDENCE UK were age 16 years or older and UK residence at enrolment. COVIDENCE UK launched on May 1, 2020.

Antibody study included included all participants who enrolled in the study between May 1 and November 2, 2020, partaking in serology testing who were not vaccinated against COVID-19 or who provided their dried blood spot sample on or before the date of their first COVID-19 vaccination.",No exclusion criteria for COVIDENCE UK cohort.,2020-05-01,2020-11-02,Household and community samples,All,Multiple groups,,,Primary Estimate,,11130,0.152,,,True,,,,True,Self-referral,Human Anti-IgG/A/M SARS-CoV-2 ELISA,The Binding Site,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.986,0.983,['High'],Unclear,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Mohammad Talaei,Queen Mary University of London,Not Unity-Aligned,https://dx.doi.org/10.1186/s12916-022-02286-4,2022-03-08,2022-08-24,Verified,talaei_determinants_2022,GBR
220223_Scotland_PublicHealthScotland_1ResidualSera_Overall_PopAdj_TestAdj,220223_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 February 2022,2022-02-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-12-20,2022-01-23,Residual sera,All,Multiple groups,,,Primary Estimate,"Overall, test and pop adjusted",2863,0.915,0.905,0.93,True,True,True,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-february-2022/,2022-03-08,2023-08-15,Verified,public_health_scotland_enhanced_2022-1,GBR
220223_Scotland_PublicHealthScotland_1ResidualSera_Age_40 - 59_Unadj,220223_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 February 2022,2022-02-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-12-20,2022-01-23,Residual sera,All,Adults (18-64 years),40.0,59.0,Age,40 - 59_Unadj,595,0.9294,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-february-2022/,2022-03-08,2024-03-01,Verified,public_health_scotland_enhanced_2022-1,GBR
220223_Scotland_PublicHealthScotland_1ResidualSera_Male_Unadj,220223_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 February 2022,2022-02-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-12-20,2022-01-23,Residual sera,Male,Multiple groups,,,Sex/Gender,"Males, unadj",1427,0.8788,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-february-2022/,2022-03-08,2024-03-01,Verified,public_health_scotland_enhanced_2022-1,GBR
220223_Scotland_PublicHealthScotland_1ResidualSera_Age_00 - 19_Unadj,220223_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 February 2022,2022-02-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-12-20,2022-01-23,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Age,00 - 19_Unadj,732,0.7801,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-february-2022/,2022-03-08,2024-03-01,Verified,public_health_scotland_enhanced_2022-1,GBR
220223_Scotland_PublicHealthScotland_1ResidualSera_Age_70+_Unadj,220223_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 February 2022,2022-02-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-12-20,2022-01-23,Residual sera,All,Seniors (65+ years),70.0,,Age,70+_Unadj,495,0.9636,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-february-2022/,2022-03-08,2024-03-01,Verified,public_health_scotland_enhanced_2022-1,GBR
220223_Scotland_PublicHealthScotland_1ResidualSera_Female_Unadj,220223_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 February 2022,2022-02-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-12-20,2022-01-23,Residual sera,Female,Multiple groups,,,Sex/Gender,"Females, unadj",1436,0.8997,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-february-2022/,2022-03-08,2024-03-01,Verified,public_health_scotland_enhanced_2022-1,GBR
220223_Scotland_PublicHealthScotland_1ResidualSera_Age_20 - 39_Unadj,220223_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 February 2022,2022-02-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-12-20,2022-01-23,Residual sera,All,Adults (18-64 years),20.0,39.0,Age,20 - 39_Unadj,690,0.8841,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-february-2022/,2022-03-08,2024-03-01,Verified,public_health_scotland_enhanced_2022-1,GBR
220223_Scotland_PublicHealthScotland_1ResidualSera_Age_60 - 69_Unadj,220223_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 February 2022,2022-02-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-12-20,2022-01-23,Residual sera,All,Seniors (65+ years),60.0,69.0,Age,60 - 69_Unadj,351,0.9544,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-february-2022/,2022-03-08,2024-03-01,Verified,public_health_scotland_enhanced_2022-1,GBR
220223_Scotland_PublicHealthScotland_1ResidualSera_Overall_Unadj,220223_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 February 2022,2022-02-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2021-12-20,2022-01-23,Residual sera,All,Multiple groups,,,Analysis,"Overall, unadj",2863,0.8893000000000001,,,,,,,True,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-february-2022/,2022-03-08,2024-03-01,Verified,public_health_scotland_enhanced_2022-1,GBR
220223_Scotland_PublicHealthScotland_2BloodDonors_Overall_PopAdj_TestAdj,220223_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 February 2022,2022-02-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2021-12-20,2022-01-23,Blood donors,All,Multiple groups,,,Primary Estimate,"Overall, test and pop adjusted",2499,1.0,0.998,1.0,True,True,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-february-2022/,2022-03-08,2023-08-15,Verified,public_health_scotland_enhanced_2022-1,GBR
220223_Scotland_PublicHealthScotland_2BloodDonors_Age_40 - 59_Unadj,220223_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 February 2022,2022-02-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2021-12-20,2022-01-23,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,"40 - 59, unadj",1190,0.9849,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-february-2022/,2022-03-08,2024-03-01,Verified,public_health_scotland_enhanced_2022-1,GBR
220223_Scotland_PublicHealthScotland_2BloodDonors_Overall_Unadj,220223_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 February 2022,2022-02-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2021-12-20,2022-01-23,Blood donors,All,Multiple groups,,,Analysis,Overall Unadj,2499,0.9872,,,,,,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-february-2022/,2022-03-08,2024-03-01,Verified,public_health_scotland_enhanced_2022-1,GBR
220223_Scotland_PublicHealthScotland_2BloodDonors_Female_Unadj,220223_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 February 2022,2022-02-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2021-12-20,2022-01-23,Blood donors,Female,Multiple groups,,,Sex/Gender,"Females, unadj",1290,0.9876,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-february-2022/,2022-03-08,2024-03-01,Verified,public_health_scotland_enhanced_2022-1,GBR
220223_Scotland_PublicHealthScotland_2BloodDonors_Age_60+_Unadj,220223_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 February 2022,2022-02-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2021-12-20,2022-01-23,Blood donors,All,Seniors (65+ years),60.0,,Age,"60+, unadj",586,0.9915,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-february-2022/,2022-03-08,2024-03-01,Verified,public_health_scotland_enhanced_2022-1,GBR
220223_Scotland_PublicHealthScotland_2BloodDonors_Male_Unadj,220223_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 February 2022,2022-02-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2021-12-20,2022-01-23,Blood donors,Male,Multiple groups,,,Sex/Gender,"Males, unadj",1209,0.9868000000000001,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-february-2022/,2022-03-08,2024-03-01,Verified,public_health_scotland_enhanced_2022-1,GBR
220223_Scotland_PublicHealthScotland_2BloodDonors_Age_00 - 39_Unadj,220223_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 February 2022,2022-02-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2021-12-20,2022-01-23,Blood donors,All,Multiple groups,0.0,39.0,Age,"00 - 39, unadj",723,0.9876,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-february-2022/,2022-03-08,2024-03-01,Verified,public_health_scotland_enhanced_2022-1,GBR
220223_Scotland_PublicHealthScotland_3PregnantWomen_Overall_Unadj,220223_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 February 2022,2022-02-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2021-12-20,2022-01-23,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,"Overall, anti-S, unadjusted",2914,0.9101,,,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['High'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-february-2022/,2022-03-08,2024-03-01,Verified,public_health_scotland_enhanced_2022-1,GBR
220223_Scotland_PublicHealthScotland_3PregnantWomen_Age_40+_Unadj,220223_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 February 2022,2022-02-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2021-12-20,2022-01-23,Pregnant or parturient women,Female,Adults (18-64 years),40.0,,Age,age 40+,108,0.9074,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['High'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-february-2022/,2022-03-08,2024-03-01,Verified,public_health_scotland_enhanced_2022-1,GBR
220223_Scotland_PublicHealthScotland_3PregnantWomen_Age_20 - 29_Unadj,220223_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 February 2022,2022-02-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2021-12-20,2022-01-23,Pregnant or parturient women,Female,Adults (18-64 years),20.0,29.0,Age,age 20-29,1130,0.8929,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['High'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-february-2022/,2022-03-08,2024-03-01,Verified,public_health_scotland_enhanced_2022-1,GBR
220223_Scotland_PublicHealthScotland_3PregnantWomen_AntiS_AntiN,220223_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 February 2022,2022-02-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2021-12-20,2022-01-23,Pregnant or parturient women,Female,Adults (18-64 years),,,Test used,"Overall, anti-S AND anti-N, unadj",2914,0.2852,,,,,,,,Sequential,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['High'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-february-2022/,2022-03-08,2024-03-01,Verified,public_health_scotland_enhanced_2022-1,GBR
220223_Scotland_PublicHealthScotland_3PregnantWomen_Age_30 - 39_Unadj,220223_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 February 2022,2022-02-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2021-12-20,2022-01-23,Pregnant or parturient women,Female,Adults (18-64 years),30.0,39.0,Age,age 30-39,1617,0.9289000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['High'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-february-2022/,2022-03-08,2024-03-01,Verified,public_health_scotland_enhanced_2022-1,GBR
"220223_Scotland_PublicHealthScotland_3PregnantWomen_Age_00 - 19_Unadj
",220223_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 23 February 2022,2022-02-23,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2021-12-20,2022-01-23,Pregnant or parturient women,Female,Children and Youth (0-17 years),0.0,19.0,Age,age 0-19,59,0.7288,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['High'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-23-february-2022/,2022-03-08,2024-03-01,Verified,public_health_scotland_enhanced_2022-1,GBR
220303_NorthernIreland_UlsterUniversity,220303_NorthernIreland_UlsterUniversity,IgG antibody production and persistence to 6 months following SARS-CoV-2 vaccination: A Northern Ireland observational study.,2022-03-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,Northern Ireland,Belfast,"patients scheduled to receive the OAZ COVID-19 vaccine ...  at a GP clinic in Belfast, Northern Ireland.

Participants were eligible for the study if they were over 18 years of age and could attend a blood sample clinic at the time of their first or second vaccination.","Exclusion criteria included anyone with a blood disorder or contraindication to giving a blood sample, or anyone currently exhibiting symptoms of COVID-19.

For the purposes of this extraction, previously PCR positive patients were excluded.

",2021-03-01,2021-03-31,Household and community samples,All,Multiple groups,24.0,89.0,Primary Estimate,,80,0.1125,,,True,,,,True,Convenience,UK-RTC AbC-19 Rapid Test, Abingdon Health,LFIA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.9758,0.9959,['High'],,No,No,No,,Yes,Yes,Yes,,Louise Robertson,Ulster University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.vaccine.2022.02.087,2022-04-06,2024-03-01,Unverified,robertson_igg_2022,GBR
220310_Sheffield_SheffieldTeachingHospitalsNHSFoundationTrust_Baseline1_TestAdj,220310_Sheffield_SheffieldTeachingHospitalsNHSFoundationTrust_Baseline1,Risk factors for SARS-CoV-2 seroprevalence following the first pandemic wave in UK healthcare workers in a large NHS Foundation Trust,2022-03-10,Journal Article (Peer-Reviewed),Local,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,Sheffield,"From 13–18 May 2020, all contactable STH staff (n=17,757) were invited to take part in the COVID-19 Humoral ImmunE RespOnses in front-line HCWs (HERO) study by email and intranet alert.",,2020-05-15,2020-06-12,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1275,0.231,0.141,0.33299999999999996,True,True,,,True,Convenience,Author designed (ELISA) - MULTIPLEXED,,ELISA,Serum,"['IgA', 'IgG']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.9947,0.9956,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Hayley Colton,Sheffield Teaching Hospitals NHS Foundation Trust,Not Unity-Aligned,https://wellcomeopenresearch.org/articles/6-220/v2,2022-04-07,2022-07-16,Unverified,colton_risk_2022,GBR
220310_Sheffield_SheffieldTeachingHospitalsNHSFoundationTrust_Follow-up2_UnAdj,220310_Sheffield_SheffieldTeachingHospitalsNHSFoundationTrust_Follow-up2,Risk factors for SARS-CoV-2 seroprevalence following the first pandemic wave in UK healthcare workers in a large NHS Foundation Trust,2022-03-10,Journal Article (Peer-Reviewed),Local,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,England,Sheffield,"From 13–18 May 2020, all contactable STH staff (n=17,757) were invited to take part in the COVID-19 Humoral ImmunE RespOnses in front-line HCWs (HERO) study by email and intranet alert.",,2020-06-15,2020-07-10,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1166,0.2727,,,True,,,,True,Convenience,Author designed (ELISA) - MULTIPLEXED,,ELISA,Serum,"['IgA', 'IgG']","['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.9947,0.9956,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Hayley Colton,Sheffield Teaching Hospitals NHS Foundation Trust,Not Unity-Aligned,https://wellcomeopenresearch.org/articles/6-220/v2,2022-04-07,2022-07-16,Unverified,colton_risk_2022,GBR
220330_Scotland_PublicHealthScotland_1ResidualSera_1Overall_PopAdj_TestAdj,220330_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 March 2022,2022-03-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-01-24,2022-02-27,Residual sera,All,Multiple groups,,,Primary Estimate,"Overall, test and pop adjusted",2884,0.9336,0.9279999999999999,0.9470000000000001,True,True,True,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-30-march-2022/,2022-04-04,2023-08-15,Verified,public_health_scotland_enhanced_2022-2,GBR
220330_Scotland_PublicHealthScotland_1ResidualSera_1Age_20 - 39_Unadj,220330_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 March 2022,2022-03-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-01-24,2022-02-27,Residual sera,All,Adults (18-64 years),20.0,39.0,Age,20 - 39_Unadj,707,0.8982,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-30-march-2022/,2022-04-04,2024-03-01,Verified,public_health_scotland_enhanced_2022-2,GBR
220330_Scotland_PublicHealthScotland_1ResidualSera_1Female_Unadj,220330_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 March 2022,2022-03-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-01-24,2022-02-27,Residual sera,Female,Multiple groups,,,Sex/Gender,"Females, unadj",1440,0.9222,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-30-march-2022/,2022-04-04,2024-03-01,Verified,public_health_scotland_enhanced_2022-2,GBR
220330_Scotland_PublicHealthScotland_1ResidualSera_1Age_70+_Unadj,220330_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 March 2022,2022-03-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-01-24,2022-02-27,Residual sera,All,Seniors (65+ years),70.0,,Age,70+_Unadj,499,0.986,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-30-march-2022/,2022-04-04,2024-03-01,Verified,public_health_scotland_enhanced_2022-2,GBR
220330_Scotland_PublicHealthScotland_1ResidualSera_1Age_00 - 19_Unadj,220330_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 March 2022,2022-03-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-01-24,2022-02-27,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Age,00 - 19_Unadj,734,0.812,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-30-march-2022/,2022-04-04,2024-03-01,Verified,public_health_scotland_enhanced_2022-2,GBR
220330_Scotland_PublicHealthScotland_1ResidualSera_1Age_40 - 59_Unadj,220330_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 March 2022,2022-03-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-01-24,2022-02-27,Residual sera,All,Adults (18-64 years),40.0,59.0,Age,40 - 59_Unadj,591,0.9323,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-30-march-2022/,2022-04-04,2024-03-01,Verified,public_health_scotland_enhanced_2022-2,GBR
220330_Scotland_PublicHealthScotland_1ResidualSera_1Male_Unadj,220330_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 March 2022,2022-03-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-01-24,2022-02-27,Residual sera,Male,Multiple groups,,,Sex/Gender,"Males, unadj",1444,0.8926999999999999,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-30-march-2022/,2022-04-04,2024-03-01,Verified,public_health_scotland_enhanced_2022-2,GBR
220330_Scotland_PublicHealthScotland_1ResidualSera_1Overall_Unadj,220330_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 March 2022,2022-03-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-01-24,2022-02-27,Residual sera,All,Multiple groups,,,Analysis,"Overall, unadj",2884,0.9074,,,,,,,True,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-30-march-2022/,2022-04-04,2024-03-01,Verified,public_health_scotland_enhanced_2022-2,GBR
220330_Scotland_PublicHealthScotland_1ResidualSera_1Age_60 - 69_Unadj,220330_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 March 2022,2022-03-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-01-24,2022-02-27,Residual sera,All,Seniors (65+ years),60.0,69.0,Age,60 - 69_Unadj,353,0.9717,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-30-march-2022/,2022-04-04,2024-03-01,Verified,public_health_scotland_enhanced_2022-2,GBR
220330_Scotland_PublicHealthScotland_2BloodDonors_Overall_PopAdj_TestAdj,220330_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 March 2022,2022-03-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2022-01-24,2022-02-27,Blood donors,All,Multiple groups,,,Primary Estimate,"Overall, test and pop adjusted",2499,1.0,0.996,1.0,True,True,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-30-march-2022/,2022-04-04,2023-08-15,Verified,public_health_scotland_enhanced_2022-2,GBR
220330_Scotland_PublicHealthScotland_2BloodDonors_Overall_Unadj,220330_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 March 2022,2022-03-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2022-01-24,2022-02-27,Blood donors,All,Multiple groups,,,Analysis,Overall Unadj,2499,0.986,,,,,,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-30-march-2022/,2022-04-04,2024-03-01,Verified,public_health_scotland_enhanced_2022-2,GBR
220330_Scotland_PublicHealthScotland_2BloodDonors_Female_Unadj,220330_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 March 2022,2022-03-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2022-01-24,2022-02-27,Blood donors,Female,Multiple groups,,,Sex/Gender,"Females, unadj",1300,0.9869,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-30-march-2022/,2022-04-04,2024-03-01,Verified,public_health_scotland_enhanced_2022-2,GBR
220330_Scotland_PublicHealthScotland_2BloodDonors_Age_60+_Unadj,220330_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 March 2022,2022-03-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2022-01-24,2022-02-27,Blood donors,All,Seniors (65+ years),60.0,,Age,"60+, unadj",554,0.9945999999999999,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-30-march-2022/,2022-04-04,2024-03-01,Verified,public_health_scotland_enhanced_2022-2,GBR
220330_Scotland_PublicHealthScotland_2BloodDonors_Age_00 - 39_Unadj,220330_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 March 2022,2022-03-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2022-01-24,2022-02-27,Blood donors,All,Multiple groups,0.0,39.0,Age,"00 - 39, unadj",845,0.9787,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-30-march-2022/,2022-04-04,2024-03-01,Verified,public_health_scotland_enhanced_2022-2,GBR
220330_Scotland_PublicHealthScotland_2BloodDonors_Male_Unadj,220330_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 March 2022,2022-03-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2022-01-24,2022-02-27,Blood donors,Male,Multiple groups,,,Sex/Gender,"Males, unadj",1199,0.985,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-30-march-2022/,2022-04-04,2024-03-01,Verified,public_health_scotland_enhanced_2022-2,GBR
220330_Scotland_PublicHealthScotland_2BloodDonors_Age_40 - 59_Unadj,220330_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 March 2022,2022-03-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2022-01-24,2022-02-27,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,"40 - 59, unadj",1100,0.9873000000000001,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-30-march-2022/,2022-04-04,2024-03-01,Verified,public_health_scotland_enhanced_2022-2,GBR
220330_Scotland_PublicHealthScotland_3PregnantWomen_3Overall_PopAdj_TestAdj,220330_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 March 2022,2022-03-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2022-01-24,2022-02-27,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,"Overall, anti-S, pop and test adjusted ",3217,0.943,0.932,0.958,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-30-march-2022/,2022-04-04,2023-08-15,Verified,public_health_scotland_enhanced_2022-2,GBR
220330_Scotland_PublicHealthScotland_3PregnantWomen_Age_20 - 29_Unadj,220330_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 March 2022,2022-03-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2022-01-24,2022-02-27,Pregnant or parturient women,Female,Adults (18-64 years),20.0,29.0,Age,age 20-29,1202,0.9118,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-30-march-2022/,2022-04-04,2024-03-01,Verified,public_health_scotland_enhanced_2022-2,GBR
220330_Scotland_PublicHealthScotland_3PregnantWomen_AntiS_AntiN,220330_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 March 2022,2022-03-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2022-01-24,2022-02-27,Pregnant or parturient women,Female,Adults (18-64 years),,,Test used,"Overall, anti-S AND anti-N, unadj",3217,0.42960000000000004,,,,,,,,Sequential,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-30-march-2022/,2022-04-04,2024-03-01,Verified,public_health_scotland_enhanced_2022-2,GBR
220330_Scotland_PublicHealthScotland_3PregnantWomen_Age_00 - 19_Unadj,220330_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 March 2022,2022-03-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2022-01-24,2022-02-27,Pregnant or parturient women,Female,Children and Youth (0-17 years),0.0,19.0,Age,age 0-19,84,0.8333,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-30-march-2022/,2022-04-04,2024-03-01,Verified,public_health_scotland_enhanced_2022-2,GBR
220330_Scotland_PublicHealthScotland_3PregnantWomen_3Overall_Unadj,220330_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 March 2022,2022-03-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2022-01-24,2022-02-27,Pregnant or parturient women,Female,Adults (18-64 years),,,Analysis,"Overall, anti-S, unadjusted",3217,0.9397,,,,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-30-march-2022/,2022-04-04,2024-03-01,Verified,public_health_scotland_enhanced_2022-2,GBR
220330_Scotland_PublicHealthScotland_3PregnantWomen_Age_30 - 39_Unadj,220330_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 March 2022,2022-03-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2022-01-24,2022-02-27,Pregnant or parturient women,Female,Adults (18-64 years),30.0,39.0,Age,age 30-39,1828,0.9606,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-30-march-2022/,2022-04-04,2024-03-01,Verified,public_health_scotland_enhanced_2022-2,GBR
220330_Scotland_PublicHealthScotland_3PregnantWomen_Age_40+_Unadj,220330_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 30 March 2022,2022-03-30,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2022-01-24,2022-02-27,Pregnant or parturient women,Female,Adults (18-64 years),40.0,,Age,age 40+,103,0.9806,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],No,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-30-march-2022/,2022-04-04,2024-03-01,Verified,public_health_scotland_enhanced_2022-2,GBR
220408_UKHealthSecurityAgency_England_July-August(2)_Euroimmun,220408_England_UKHealthSecurityAgency_July-August(2),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-07-01,2020-08-31,Residual sera,All,Multiple groups,18.0,100.0,Primary Estimate,,5781,0.052000000000000005,0.045,0.061,True,,True,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-04-22,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_July-August(2)_18-29,220408_England_UKHealthSecurityAgency_July-August(2),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-07-01,2020-08-31,Residual sera,All,Adults (18-64 years),18.0,29.0,Age,18-29,360,0.067,,,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_July-August(2)_40-49,220408_England_UKHealthSecurityAgency_July-August(2),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-07-01,2020-08-31,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,673,0.05,,,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_July-August(2)_NorthEast&Yorkshire,220408_England_UKHealthSecurityAgency_July-August(2),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-07-01,2020-08-31,Residual sera,All,Multiple groups,18.0,100.0,Geographical area,North East & Yorkshire,1037,0.031000000000000003,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_July-August(2)_60-69,220408_England_UKHealthSecurityAgency_July-August(2),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-07-01,2020-08-31,Residual sera,All,Adults (18-64 years),60.0,69.0,Age,60-69,1051,0.057,,,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_July-August(2)_London,220408_England_UKHealthSecurityAgency_July-August(2),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-07-01,2020-08-31,Residual sera,All,Multiple groups,18.0,100.0,Geographical area,London,612,0.11800000000000001,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_July-August(2)_70-79,220408_England_UKHealthSecurityAgency_July-August(2),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-07-01,2020-08-31,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,1490,0.031000000000000003,,,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_July-August(2)_80+,220408_England_UKHealthSecurityAgency_July-August(2),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-07-01,2020-08-31,Residual sera,All,Seniors (65+ years),80.0,100.0,Age,80+,621,0.03,,,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_July-August(2)_SouthWest,220408_England_UKHealthSecurityAgency_July-August(2),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-07-01,2020-08-31,Residual sera,All,Multiple groups,18.0,100.0,Geographical area,South West,1421,0.034,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_July-August(2)_30-39,220408_England_UKHealthSecurityAgency_July-August(2),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-07-01,2020-08-31,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,520,0.054000000000000006,,,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_July-August(2)_Midlands,220408_England_UKHealthSecurityAgency_July-August(2),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-07-01,2020-08-31,Residual sera,All,Multiple groups,18.0,100.0,Geographical area,Midlands,766,0.048,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_July-August(2)_SouthEast,220408_England_UKHealthSecurityAgency_July-August(2),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-07-01,2020-08-31,Residual sera,All,Multiple groups,18.0,100.0,Geographical area,South East,868,0.037000000000000005,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_July-August(2)_NorthWest,220408_England_UKHealthSecurityAgency_July-August(2),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-07-01,2020-08-31,Residual sera,All,Multiple groups,18.0,100.0,Geographical area,North West,906,0.045,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_July-August(2)_Roche,220408_England_UKHealthSecurityAgency_July-August(2),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-07-01,2020-08-31,Residual sera,All,Multiple groups,18.0,100.0,Test used,,3572,0.063,0.054000000000000006,0.07400000000000001,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.8390000000000001,1.0,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-04-22,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_July-August(2)_50-59,220408_England_UKHealthSecurityAgency_July-August(2),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-07-01,2020-08-31,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,1066,0.037000000000000005,,,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_July-August(2)_Abbott,220408_England_UKHealthSecurityAgency_July-August(2),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-07-01,2020-08-31,Residual sera,All,Multiple groups,18.0,100.0,Test used,,5767,0.059000000000000004,0.051,0.067,,,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,1.0,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-04-22,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_May-June(1)_Euroimmun,220408_England_UKHealthSecurityAgency_May-June(1),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-05-01,2020-06-30,Residual sera,All,Multiple groups,18.0,100.0,Primary Estimate,,5455,0.040999999999999995,0.031000000000000003,0.053,True,,True,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-04-22,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_May-June(1)_NorthWest,220408_England_UKHealthSecurityAgency_May-June(1),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-05-01,2020-06-30,Residual sera,All,Multiple groups,18.0,100.0,Geographical area,North West,859,0.043,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_May-June(1)_Abbott,220408_England_UKHealthSecurityAgency_May-June(1),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-05-01,2020-06-30,Residual sera,All,Multiple groups,18.0,100.0,Test used,,9870,0.062000000000000006,0.054000000000000006,0.07,,,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,1.0,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-04-22,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_May-June(1)_40-49,220408_England_UKHealthSecurityAgency_May-June(1),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-05-01,2020-06-30,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,224,0.061,,,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_May-June(1)_London,220408_England_UKHealthSecurityAgency_May-June(1),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-05-01,2020-06-30,Residual sera,All,Multiple groups,18.0,100.0,Geographical area,London,228,0.055,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_May-June(1)_18-29,220408_England_UKHealthSecurityAgency_May-June(1),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-05-01,2020-06-30,Residual sera,All,Adults (18-64 years),18.0,29.0,Age,18-29,104,0.031000000000000003,,,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_May-June(1)_SouthWest,220408_England_UKHealthSecurityAgency_May-June(1),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-05-01,2020-06-30,Residual sera,All,Multiple groups,18.0,100.0,Geographical area,South West,1761,0.023,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_May-June(1)_30-39,220408_England_UKHealthSecurityAgency_May-June(1),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-05-01,2020-06-30,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,178,0.045,,,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_May-June(1)_SouthEast,220408_England_UKHealthSecurityAgency_May-June(1),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-05-01,2020-06-30,Residual sera,All,Multiple groups,18.0,100.0,Geographical area,South East,887,0.037000000000000005,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_May-June(1)_70-79,220408_England_UKHealthSecurityAgency_May-June(1),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-05-01,2020-06-30,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,2317,0.027000000000000003,,,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_May-June(1)_Midlands,220408_England_UKHealthSecurityAgency_May-June(1),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-05-01,2020-06-30,Residual sera,All,Multiple groups,18.0,100.0,Geographical area,Midlands,625,0.048,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_May-June(1)_80+,220408_England_UKHealthSecurityAgency_May-June(1),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-05-01,2020-06-30,Residual sera,All,Seniors (65+ years),80.0,100.0,Age,80+,1073,0.04,,,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_May-June(1)_NorthEast&Yorkshire,220408_England_UKHealthSecurityAgency_May-June(1),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-05-01,2020-06-30,Residual sera,All,Multiple groups,18.0,100.0,Geographical area,North East & Yorkshire,888,0.032,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_May-June(1)_60-69,220408_England_UKHealthSecurityAgency_May-June(1),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-05-01,2020-06-30,Residual sera,All,Adults (18-64 years),60.0,69.0,Age,60-69,1203,0.033,,,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_May-June(1)_50-59,220408_England_UKHealthSecurityAgency_May-June(1),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-05-01,2020-06-30,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,356,0.037000000000000005,,,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_Nov-Dec(4)_Euroimmun,220408_England_UKHealthSecurityAgency_Nov-Dec(4),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-11-01,2020-12-31,Residual sera,All,Multiple groups,18.0,100.0,Primary Estimate,,4934,0.066,0.057,0.076,True,,True,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-04-22,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_Nov-Dec(4)_NorthWest,220408_England_UKHealthSecurityAgency_Nov-Dec(4),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-11-01,2020-12-31,Residual sera,All,Multiple groups,18.0,100.0,Geographical area,North West,987,0.07,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_Nov-Dec(4)_80+,220408_England_UKHealthSecurityAgency_Nov-Dec(4),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-11-01,2020-12-31,Residual sera,All,Seniors (65+ years),80.0,100.0,Age,80+,541,0.047,,,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_Nov-Dec(4)_Midlands,220408_England_UKHealthSecurityAgency_Nov-Dec(4),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-11-01,2020-12-31,Residual sera,All,Multiple groups,18.0,100.0,Geographical area,Midlands,817,0.045,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_Nov-Dec(4)_18-29,220408_England_UKHealthSecurityAgency_Nov-Dec(4),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-11-01,2020-12-31,Residual sera,All,Adults (18-64 years),18.0,29.0,Age,18-29,231,0.076,,,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_Nov-Dec(4)_London,220408_England_UKHealthSecurityAgency_Nov-Dec(4),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-11-01,2020-12-31,Residual sera,All,Multiple groups,18.0,100.0,Geographical area,London,449,0.152,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_Nov-Dec(4)_SouthWest,220408_England_UKHealthSecurityAgency_Nov-Dec(4),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-11-01,2020-12-31,Residual sera,All,Multiple groups,18.0,100.0,Geographical area,South West,947,0.037000000000000005,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_Nov-Dec(4)_30-39,220408_England_UKHealthSecurityAgency_Nov-Dec(4),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-11-01,2020-12-31,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,376,0.077,,,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_Nov-Dec(4)_60-69,220408_England_UKHealthSecurityAgency_Nov-Dec(4),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-11-01,2020-12-31,Residual sera,All,Adults (18-64 years),60.0,69.0,Age,60-69,1025,0.063,,,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_Nov-Dec(4)_40-49,220408_England_UKHealthSecurityAgency_Nov-Dec(4),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-11-01,2020-12-31,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,563,0.062000000000000006,,,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_Nov-Dec(4)_70-79,220408_England_UKHealthSecurityAgency_Nov-Dec(4),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-11-01,2020-12-31,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,1267,0.040999999999999995,,,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_Nov-Dec(4)_50-59,220408_England_UKHealthSecurityAgency_Nov-Dec(4),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-11-01,2020-12-31,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,931,0.068,,,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_Nov-Dec(4)_Roche,220408_England_UKHealthSecurityAgency_Nov-Dec(4),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-11-01,2020-12-31,Residual sera,All,Multiple groups,18.0,100.0,Test used,,4236,0.08900000000000001,0.078,0.102,,,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.8390000000000001,1.0,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-04-22,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_Nov-Dec(4)_SouthEast,220408_England_UKHealthSecurityAgency_Nov-Dec(4),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-11-01,2020-12-31,Residual sera,All,Multiple groups,18.0,100.0,Geographical area,South East,540,0.048,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_Nov-Dec(4)_NorthEast&Yorkshire,220408_England_UKHealthSecurityAgency_Nov-Dec(4),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-11-01,2020-12-31,Residual sera,All,Multiple groups,18.0,100.0,Geographical area,North East & Yorkshire,964,0.053,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_Sept-Oct(3)_Euroimmun,220408_England_UKHealthSecurityAgency_Sept-Oct(3),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-09-01,2020-10-01,Residual sera,All,Multiple groups,18.0,100.0,Primary Estimate,,5478,0.055,0.048,0.064,True,,True,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-04-22,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_Sept-Oct(3)_SouthWest,220408_England_UKHealthSecurityAgency_Sept-Oct(3),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-09-01,2020-10-31,Residual sera,All,Multiple groups,18.0,100.0,Geographical area,South West,1025,0.027000000000000003,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_Sept-Oct(3)_30-39,220408_England_UKHealthSecurityAgency_Sept-Oct(3),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-09-01,2020-10-31,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,523,0.055,,,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_Sept-Oct(3)_70-79,220408_England_UKHealthSecurityAgency_Sept-Oct(3),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-09-01,2020-10-31,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,1237,0.040999999999999995,,,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_Sept-Oct(3)_NorthEast&Yorkshire,220408_England_UKHealthSecurityAgency_Sept-Oct(3),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-09-01,2020-10-31,Residual sera,All,Multiple groups,18.0,100.0,Geographical area,North East & Yorkshire,1140,0.035,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_Sept-Oct(3)_80+,220408_England_UKHealthSecurityAgency_Sept-Oct(3),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-09-01,2020-10-31,Residual sera,All,Seniors (65+ years),80.0,100.0,Age,80+,560,0.048,,,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_Sept-Oct(3)_18-29,220408_England_UKHealthSecurityAgency_Sept-Oct(3),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-09-01,2020-10-31,Residual sera,All,Adults (18-64 years),18.0,29.0,Age,18-29,396,0.062000000000000006,,,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_Sept-Oct(3)_SouthEast,220408_England_UKHealthSecurityAgency_Sept-Oct(3),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-09-01,2020-10-31,Residual sera,All,Multiple groups,18.0,100.0,Geographical area,South East,697,0.037000000000000005,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_Sept-Oct(3)_40-49,220408_England_UKHealthSecurityAgency_Sept-Oct(3),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-09-01,2020-10-31,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,668,0.055,,,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_Sept-Oct(3)_60-69,220408_England_UKHealthSecurityAgency_Sept-Oct(3),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-09-01,2020-10-31,Residual sera,All,Adults (18-64 years),60.0,69.0,Age,60-69,1052,0.047,,,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_Sept-Oct(3)_Abbott,220408_England_UKHealthSecurityAgency_Sept-Oct(3),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-09-01,2020-10-01,Residual sera,All,Multiple groups,18.0,100.0,Test used,,4781,0.05,0.043,0.059000000000000004,,,True,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.927,1.0,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-04-22,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_Sept-Oct(3)_NorthWest,220408_England_UKHealthSecurityAgency_Sept-Oct(3),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-09-01,2020-10-31,Residual sera,All,Multiple groups,18.0,100.0,Geographical area,North West,985,0.046,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_Sept-Oct(3)_50-59,220408_England_UKHealthSecurityAgency_Sept-Oct(3),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-09-01,2020-10-31,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,1042,0.062000000000000006,,,,,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_Sept-Oct(3)_London,220408_England_UKHealthSecurityAgency_Sept-Oct(3),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-09-01,2020-10-31,Residual sera,All,Multiple groups,18.0,100.0,Geographical area,London,624,0.138,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220408_UKHealthSecurityAgency_England_Sept-Oct(3)_Midlands,220408_England_UKHealthSecurityAgency_Sept-Oct(3),Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network,2022-04-08,Preprint,National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,"The study population comprises individuals registered at practices throughout England, where 212 
practices provided blood sera samples as part of the Oxford-RCGP RSC sentinel network","We excluded samples that were collected in March and April, from unknown locations, or from 
patients aged <18 years. Patients who have explicitly opted out of data sharing are
excluded from the analysis.",2020-09-01,2020-10-31,Residual sera,All,Multiple groups,18.0,100.0,Geographical area,Midlands,910,0.04,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.72,0.99,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,,Heather Whitaker,UK Health Security Agency,Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.04.016,2022-05-28,2024-03-01,Verified,whitakerSociodemographicDisparitiesCOVID19,GBR
220421_GreatBritain_UniversityCollegeLondon_Overall,220421_GreatBritain_UniversityCollegeLondon,"Occupation, work-related contact and SARS-CoV-2 anti-nucleocapsid serological status: findings from the Virus Watch prospective cohort study",2022-04-21,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,"England, Wales",,"Participants in the current study were a subset of the Virus Watch
Study cohort. Participants in the present study comprised of adults (≥18
years) who conducted monthly antibody testing in addition to
completing the main study surveys. Participants were eligible for
inclusion in the present study if:
1. They self-reported their occupation upon study registration.
2. They had a valid antibody test result conducted between 01
February 2021 and 08 June 2021.
3. They responded to the February 2021 monthly survey regarding features of work during the pandemic.","Not in employment, <18 years old",2021-02-01,2021-06-08,Household and community samples,All,Multiple groups,,,Primary Estimate,,3775,0.121,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,TotalAntibody,Nucleocapsid(N-protein),,,,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Sarah Beale,University College London,Unity-Aligned,https://dx.doi.org/10.1136/oemed-2021-107920,2022-05-04,2024-03-01,Verified,beale_occupation_2022,GBR
220504_Scotland_PublicHealthScotland_1ResidualSera_Overall_PopAdj_TestAdj,220504_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 4 May 2022,2022-05-04,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-02-28,2022-04-03,Residual sera,All,Multiple groups,,,Primary Estimate,"Overall, test and pop adjusted",2885,0.948,0.9450000000000001,0.961,True,True,True,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-4-may-2022/,2022-05-15,2023-08-15,Verified,scotland_enhanced_2022-3,GBR
220504_Scotland_PublicHealthScotland_1ResidualSera_Age_60 - 69_Unadj,220504_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 4 May 2022,2022-05-04,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-02-28,2022-04-03,Residual sera,All,Seniors (65+ years),60.0,69.0,Age,60 - 69_Unadj,327,0.9755,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-4-may-2022/,2022-05-15,2024-03-01,Verified,scotland_enhanced_2022-3,GBR
220504_Scotland_PublicHealthScotland_1ResidualSera_Age_20 - 39_Unadj,220504_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 4 May 2022,2022-05-04,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-02-28,2022-04-03,Residual sera,All,Adults (18-64 years),20.0,39.0,Age,20 - 39_Unadj,701,0.9087000000000001,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-4-may-2022/,2022-05-15,2024-03-01,Verified,scotland_enhanced_2022-3,GBR
220504_Scotland_PublicHealthScotland_1ResidualSera_Age_00 - 19_Unadj,220504_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 4 May 2022,2022-05-04,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-02-28,2022-04-03,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Age,00 - 19_Unadj,735,0.8354,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-4-may-2022/,2022-05-15,2024-03-01,Verified,scotland_enhanced_2022-3,GBR
220504_Scotland_PublicHealthScotland_1ResidualSera_Age_40 - 59_Unadj,220504_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 4 May 2022,2022-05-04,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-02-28,2022-04-03,Residual sera,All,Adults (18-64 years),40.0,59.0,Age,40 - 59_Unadj,600,0.9433,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-4-may-2022/,2022-05-15,2024-03-01,Verified,scotland_enhanced_2022-3,GBR
220504_Scotland_PublicHealthScotland_1ResidualSera_Female_Unadj,220504_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 4 May 2022,2022-05-04,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-02-28,2022-04-03,Residual sera,Female,Multiple groups,,,Sex/Gender,"Females, unadj",1448,0.9329999999999999,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-4-may-2022/,2022-05-15,2024-03-01,Verified,scotland_enhanced_2022-3,GBR
220504_Scotland_PublicHealthScotland_1ResidualSera_Overall_Unadj,220504_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 4 May 2022,2022-05-04,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-02-28,2022-04-03,Residual sera,All,Multiple groups,,,Analysis,"Overall, unadj",2885,0.9185,,,,,,,True,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-4-may-2022/,2022-05-15,2024-03-01,Verified,scotland_enhanced_2022-3,GBR
220504_Scotland_PublicHealthScotland_1ResidualSera_Age_70+_Unadj,220504_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 4 May 2022,2022-05-04,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-02-28,2022-04-03,Residual sera,All,Seniors (65+ years),70.0,,Age,70+_Unadj,522,0.9847,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-4-may-2022/,2022-05-15,2024-03-01,Verified,scotland_enhanced_2022-3,GBR
220504_Scotland_PublicHealthScotland_1ResidualSera_Male_Unadj,220504_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 4 May 2022,2022-05-04,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-02-28,2022-04-03,Residual sera,Male,Multiple groups,,,Sex/Gender,"Males, unadj",1437,0.904,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-4-may-2022/,2022-05-15,2024-03-01,Verified,scotland_enhanced_2022-3,GBR
220504_Scotland_PublicHealthScotland_2BloodDonors_Overall_PopAdj_TestAdj,220504_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 4 May 2022,2022-05-04,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2022-02-28,2022-04-03,Blood donors,All,Multiple groups,,,Primary Estimate,"Overall, test and pop adjusted",2499,1.0,0.997,1.0,True,True,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-4-may-2022/,2022-05-15,2023-08-15,Verified,scotland_enhanced_2022-3,GBR
220504_Scotland_PublicHealthScotland_2BloodDonors_Male_Unadj,220504_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 4 May 2022,2022-05-04,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2022-02-28,2022-04-03,Blood donors,Male,Multiple groups,,,Sex/Gender,"Males, unadj",1094,0.9872,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-4-may-2022/,2022-05-15,2024-03-01,Verified,scotland_enhanced_2022-3,GBR
220504_Scotland_PublicHealthScotland_2BloodDonors_Age_60+_Unadj,220504_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 4 May 2022,2022-05-04,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2022-02-28,2022-04-03,Blood donors,All,Seniors (65+ years),60.0,,Age,"60+, unadj",593,0.9916,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-4-may-2022/,2022-05-15,2024-03-01,Verified,scotland_enhanced_2022-3,GBR
220504_Scotland_PublicHealthScotland_2BloodDonors_Age_00 - 39_Unadj,220504_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 4 May 2022,2022-05-04,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2022-02-28,2022-04-03,Blood donors,All,Multiple groups,0.0,39.0,Age,"00 - 39, unadj",837,0.9856999999999999,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-4-may-2022/,2022-05-15,2024-03-01,Verified,scotland_enhanced_2022-3,GBR
220504_Scotland_PublicHealthScotland_2BloodDonors_Overall_Unadj,220504_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 4 May 2022,2022-05-04,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2022-02-28,2022-04-03,Blood donors,All,Multiple groups,,,Analysis,Overall Unadj,2499,0.9864,,,,,,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-4-may-2022/,2022-05-15,2024-03-01,Verified,scotland_enhanced_2022-3,GBR
220504_Scotland_PublicHealthScotland_2BloodDonors_Female_Unadj,220504_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 4 May 2022,2022-05-04,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2022-02-28,2022-04-03,Blood donors,Female,Multiple groups,,,Sex/Gender,"Females, unadj",1405,0.9858,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-4-may-2022/,2022-05-15,2024-03-01,Verified,scotland_enhanced_2022-3,GBR
220504_Scotland_PublicHealthScotland_2BloodDonors_Age_40 - 59_Unadj,220504_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 4 May 2022,2022-05-04,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2022-02-28,2022-04-03,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,"40 - 59, unadj",1069,0.9841,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-4-may-2022/,2022-05-15,2024-03-01,Verified,scotland_enhanced_2022-3,GBR
220504_Scotland_PublicHealthScotland_3PregnantWomen_Overall_PopAdj_TestAdj,220504_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 4 May 2022,2022-05-04,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2022-02-28,2022-04-03,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,"Overall, anti-S, pop and test adjusted ",3181,0.9540000000000001,0.9440000000000001,0.9690000000000001,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-4-may-2022/,2022-05-15,2023-08-15,Verified,scotland_enhanced_2022-3,GBR
220504_Scotland_PublicHealthScotland_3PregnantWomen_AntiS_AntiN,220504_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 4 May 2022,2022-05-04,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2022-02-28,2022-04-03,Pregnant or parturient women,Female,Adults (18-64 years),,,Test used,"Overall, anti-S AND anti-N, unadj",3181,0.5285,,,,,,,,Sequential,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-4-may-2022/,2022-05-15,2024-03-01,Verified,scotland_enhanced_2022-3,GBR
220504_Scotland_PublicHealthScotland_3PregnantWomen_Age_40+_Unadj,220504_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 4 May 2022,2022-05-04,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2022-02-28,2022-04-03,Pregnant or parturient women,Female,Adults (18-64 years),40.0,,Age,age 40+,113,0.9204000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-4-may-2022/,2022-05-15,2024-03-01,Verified,scotland_enhanced_2022-3,GBR
220504_Scotland_PublicHealthScotland_3PregnantWomen_Age_00 - 19_Unadj,220504_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 4 May 2022,2022-05-04,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2022-02-28,2022-04-03,Pregnant or parturient women,Female,Children and Youth (0-17 years),0.0,19.0,Age,age 0-19,69,0.9275,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-4-may-2022/,2022-05-15,2024-03-01,Verified,scotland_enhanced_2022-3,GBR
220504_Scotland_PublicHealthScotland_3PregnantWomen_Age_30 - 39_Unadj,220504_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 4 May 2022,2022-05-04,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2022-02-28,2022-04-03,Pregnant or parturient women,Female,Adults (18-64 years),30.0,39.0,Age,age 30-39,1737,0.9626000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-4-may-2022/,2022-05-15,2024-03-01,Verified,scotland_enhanced_2022-3,GBR
220504_Scotland_PublicHealthScotland_3PregnantWomen_Overall_Unadj,220504_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 4 May 2022,2022-05-04,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2022-02-28,2022-04-03,Pregnant or parturient women,Female,Adults (18-64 years),,,Analysis,"Overall, anti-S, unadjusted",3181,0.9497,,,,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-4-may-2022/,2022-05-15,2024-03-01,Verified,scotland_enhanced_2022-3,GBR
220504_Scotland_PublicHealthScotland_3PregnantWomen_Age_20 - 29_Unadj,220504_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 4 May 2022,2022-05-04,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2022-02-28,2022-04-03,Pregnant or parturient women,Female,Adults (18-64 years),20.0,29.0,Age,age 20-29,1262,0.9358,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-4-may-2022/,2022-05-15,2024-03-01,Verified,scotland_enhanced_2022-3,GBR
220608_Scotland_PublicHealthScotland_1ResidualSera_Overall_PopAdj_TestAdj,220608_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 June 2022,2022-06-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-04-04,2022-05-08,Residual sera,All,Multiple groups,,,Primary Estimate,"Overall, test and pop adjusted",2886,0.9477,0.9447,0.9609000000000001,True,True,True,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-june-2022/,2022-06-22,2024-05-01,Verified,scotland_enhanced_2022-4,GBR
220608_Scotland_PublicHealthScotland_1ResidualSera_Age_00 - 19_Unadj,220608_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 June 2022,2022-06-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-04-04,2022-05-08,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Age,00 - 19_Unadj,735,0.8354,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-june-2022/,2022-06-22,2024-05-01,Verified,scotland_enhanced_2022-4,GBR
220608_Scotland_PublicHealthScotland_1ResidualSera_Age_70+_Unadj,220608_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 June 2022,2022-06-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-04-04,2022-05-08,Residual sera,All,Seniors (65+ years),70.0,,Age,70+_Unadj,522,0.9847,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-june-2022/,2022-06-22,2024-05-01,Verified,scotland_enhanced_2022-4,GBR
220608_Scotland_PublicHealthScotland_1ResidualSera_Overall_Unadj,220608_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 June 2022,2022-06-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-04-04,2022-05-08,Residual sera,All,Multiple groups,,,Analysis,"Overall, unadj",2886,0.9186,,,,,,,True,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-june-2022/,2022-06-22,2024-05-01,Verified,scotland_enhanced_2022-4,GBR
220608_Scotland_PublicHealthScotland_1ResidualSera_Female_Unadj,220608_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 June 2022,2022-06-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-04-04,2022-05-08,Residual sera,Female,Multiple groups,,,Sex/Gender,"Females, unadj",1448,0.9329999999999999,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-june-2022/,2022-06-22,2024-05-01,Verified,scotland_enhanced_2022-4,GBR
220608_Scotland_PublicHealthScotland_1ResidualSera_Age_40 - 59_Unadj,220608_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 June 2022,2022-06-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-04-04,2022-05-08,Residual sera,All,Adults (18-64 years),40.0,59.0,Age,40 - 59_Unadj,601,0.9434,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-june-2022/,2022-06-22,2024-05-01,Verified,scotland_enhanced_2022-4,GBR
220608_Scotland_PublicHealthScotland_1ResidualSera_Age_20 - 39_Unadj,220608_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 June 2022,2022-06-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-04-04,2022-05-08,Residual sera,All,Adults (18-64 years),20.0,39.0,Age,20 - 39_Unadj,701,0.9087000000000001,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-june-2022/,2022-06-22,2024-05-01,Verified,scotland_enhanced_2022-4,GBR
220608_Scotland_PublicHealthScotland_1ResidualSera_Age_60 - 69_Unadj,220608_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 June 2022,2022-06-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-04-04,2022-05-08,Residual sera,All,Seniors (65+ years),60.0,69.0,Age,60 - 69_Unadj,327,0.9755,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-june-2022/,2022-06-22,2024-05-01,Verified,scotland_enhanced_2022-4,GBR
220608_Scotland_PublicHealthScotland_1ResidualSera_Male_Unadj,220608_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 June 2022,2022-06-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-04-04,2022-05-08,Residual sera,Male,Multiple groups,,,Sex/Gender,"Males, unadj",1438,0.904,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-june-2022/,2022-06-22,2024-05-01,Verified,scotland_enhanced_2022-4,GBR
220608_Scotland_PublicHealthScotland_2BloodDonors_Overall_PopAdj_TestAdj,220608_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 June 2022,2022-06-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2022-04-04,2022-05-08,Blood donors,All,Multiple groups,,,Primary Estimate,"Overall, test and pop adjusted",2499,1.0,0.9975,1.0,True,True,True,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-june-2022/,2022-06-22,2024-05-01,Verified,scotland_enhanced_2022-4,GBR
220608_Scotland_PublicHealthScotland_2BloodDonors_Overall_Unadj,220608_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 June 2022,2022-06-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2022-04-04,2022-05-08,Blood donors,All,Multiple groups,,,Analysis,Overall Unadj,2499,0.9864,,,,,,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-june-2022/,2022-06-22,2024-05-01,Verified,scotland_enhanced_2022-4,GBR
220608_Scotland_PublicHealthScotland_2BloodDonors_Age_40 - 59_Unadj,220608_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 June 2022,2022-06-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2022-04-04,2022-05-08,Blood donors,All,Adults (18-64 years),40.0,59.0,Age,"40 - 59, unadj",1069,0.9841,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-june-2022/,2022-06-22,2024-05-01,Verified,scotland_enhanced_2022-4,GBR
220608_Scotland_PublicHealthScotland_2BloodDonors_Age_60+_Unadj,220608_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 June 2022,2022-06-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2022-04-04,2022-05-08,Blood donors,All,Seniors (65+ years),60.0,,Age,"60+, unadj",593,0.9916,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-june-2022/,2022-06-22,2024-05-01,Verified,scotland_enhanced_2022-4,GBR
220608_Scotland_PublicHealthScotland_2BloodDonors_Male_Unadj,220608_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 June 2022,2022-06-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2022-04-04,2022-05-08,Blood donors,Male,Multiple groups,,,Sex/Gender,"Males, unadj",1094,0.9872,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-june-2022/,2022-06-22,2024-05-01,Verified,scotland_enhanced_2022-4,GBR
220608_Scotland_PublicHealthScotland_2BloodDonors_Female_Unadj,220608_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 June 2022,2022-06-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2022-04-04,2022-05-08,Blood donors,Female,Multiple groups,,,Sex/Gender,"Females, unadj",1405,0.9858,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-june-2022/,2022-06-22,2024-05-01,Verified,scotland_enhanced_2022-4,GBR
220727_Scotland_PublicHealthScotland_2BloodDonors_Age_00 - 39_Unadj,220608_Scotland_PublicHealthScotland_2BloodDonors,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 June 2022,2022-06-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,Samples originally collected from blood donors have been retrieved and tested by the Scottish National Blood Transfusion Service (SNBTS) since week commencing 29 June 2020.,,2022-04-04,2022-05-08,Blood donors,All,Multiple groups,0.0,39.0,Age,"00 - 39, unadj",837,0.9856999999999999,,,,,,,,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.84,1.0,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-june-2022/,2022-06-22,2024-05-01,Verified,scotland_enhanced_2022-4,GBR
220608_Scotland_PublicHealthScotland_3PregnantWomen_Overall_PopAdj_TestAdj,220608_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 June 2022,2022-06-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2022-04-04,2022-05-08,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,"Overall, anti-S, pop and test adjusted ",3181,0.9543,0.9440999999999999,0.9686,True,True,True,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-june-2022/,2022-06-22,2024-05-01,Verified,scotland_enhanced_2022-4,GBR
220608_Scotland_PublicHealthScotland_3PregnantWomen_Overall_Unadj,220608_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 June 2022,2022-06-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2022-04-04,2022-05-08,Pregnant or parturient women,Female,Adults (18-64 years),,,Analysis,"Overall, anti-S, unadjusted",3181,0.9497,,,,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-june-2022/,2022-06-22,2024-05-01,Verified,scotland_enhanced_2022-4,GBR
220608_Scotland_PublicHealthScotland_3PregnantWomen_Age_40+_Unadj,220608_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 June 2022,2022-06-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2022-04-04,2022-05-08,Pregnant or parturient women,Female,Adults (18-64 years),40.0,,Age,age 40+,113,0.9204000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-june-2022/,2022-06-22,2024-05-01,Verified,scotland_enhanced_2022-4,GBR
220608_Scotland_PublicHealthScotland_3PregnantWomen_Age_00 - 19_Unadj,220608_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 June 2022,2022-06-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2022-04-04,2022-05-08,Pregnant or parturient women,Female,Children and Youth (0-17 years),0.0,19.0,Age,age 0-19,69,0.9275,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-june-2022/,2022-06-22,2024-05-01,Verified,scotland_enhanced_2022-4,GBR
220608_Scotland_PublicHealthScotland_3PregnantWomen_Age_20 - 29_Unadj,220608_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 June 2022,2022-06-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2022-04-04,2022-05-08,Pregnant or parturient women,Female,Adults (18-64 years),20.0,29.0,Age,age 20-29,1262,0.9358,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-june-2022/,2022-06-22,2024-05-01,Verified,scotland_enhanced_2022-4,GBR
220608_Scotland_PublicHealthScotland_3PregnantWomen_AntiS_AntiN,220608_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 June 2022,2022-06-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2022-04-04,2022-05-08,Pregnant or parturient women,Female,Adults (18-64 years),,,Test used,"Overall, anti-S AND anti-N, unadj",3181,0.5285,,,,,,,,Sequential,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-june-2022/,2022-06-22,2024-05-01,Verified,scotland_enhanced_2022-4,GBR
220608_Scotland_PublicHealthScotland_3PregnantWomen_Age_30 - 39_Unadj,220608_Scotland_PublicHealthScotland_3PregnantWomen,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 8 June 2022,2022-06-08,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Samples originally collected from pregnant women at their antenatal booking appointment (approximately week 12 of pregnancy) and sent for Down’s Syndrome screening at the Western General Hospital, Edinburgh, have been anonymised and sent to NHS Lanarkshire for testing.",,2022-04-04,2022-05-08,Pregnant or parturient women,Female,Adults (18-64 years),30.0,39.0,Age,age 30-39,1737,0.9626000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.923,1.0,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-8-june-2022/,2022-06-22,2024-05-01,Verified,scotland_enhanced_2022-4,GBR
220623_England_UniversityofOxford_period1,220623_England_UniversityofOxford_period1,"Community seroprevalence of SARS-CoV-2 in children and adolescents in England, 2019-2021.",2022-06-23,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,,Bradford; Bristol; Imperial; Leeds; Manchester; Newcastle; Nottingham; Oxford; Plymouth; Sheffield; Southhampton; St Georges London; West Suffolk,"""We conducted a community-based cross- sectional seroprevalence study in participants aged
0–18 years old recruiting from seven regions in England between October 2019 and June 2021""","""Participants reported to be vaccinated before their visit were excluded from all analyses""",2019-10-01,2020-03-31,Household and community samples,All,Children and Youth (0-17 years),0.0,18.0,Primary Estimate,,2540,0.05,,,True,,True,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],,No,Yes,No,,Yes,Yes,No,,Helen Ratcliffe,University of Oxford,Not Unity-Aligned,https://dx.doi.org/10.1136/archdischild-2022-324375,2022-07-27,2024-03-01,Unverified,ratcliffeCommunitySeroprevalenceSARSCoV22022,GBR
220623_England_UniversityofOxford_period2,220623_England_UniversityofOxford_period2,"Community seroprevalence of SARS-CoV-2 in children and adolescents in England, 2019-2021.",2022-06-23,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,,Bradford; Bristol; Imperial; Leeds; Manchester; Newcastle; Nottingham; Oxford; Plymouth; Sheffield; Southhampton; St Georges London; West Suffolk,"""We conducted a community-based cross- sectional seroprevalence study in participants aged
0–18 years old recruiting from seven regions in England between October 2019 and June 2021""","""Participants reported to be vaccinated before their visit were excluded from all analyses""",2020-04-01,2020-05-31,Household and community samples,All,Children and Youth (0-17 years),0.0,18.0,Primary Estimate,,2540,0.135,,,True,,True,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],,No,Yes,No,,Yes,Yes,No,,Helen Ratcliffe,University of Oxford,Not Unity-Aligned,https://dx.doi.org/10.1136/archdischild-2022-324375,2022-07-27,2024-03-01,Unverified,ratcliffeCommunitySeroprevalenceSARSCoV22022,GBR
220623_England_UniversityofOxford_period3,220623_England_UniversityofOxford_period3,"Community seroprevalence of SARS-CoV-2 in children and adolescents in England, 2019-2021.",2022-06-23,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,,Bradford; Bristol; Imperial; Leeds; Manchester; Newcastle; Nottingham; Oxford; Plymouth; Sheffield; Southhampton; St Georges London; West Suffolk,"""We conducted a community-based cross- sectional seroprevalence study in participants aged
0–18 years old recruiting from seven regions in England between October 2019 and June 2021""","""Participants reported to be vaccinated before their visit were excluded from all analyses""",2020-06-01,2020-08-31,Household and community samples,All,Children and Youth (0-17 years),0.0,18.0,Primary Estimate,,2540,0.20800000000000002,,,True,,True,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],,No,Yes,No,,Yes,Yes,No,,Helen Ratcliffe,University of Oxford,Not Unity-Aligned,https://dx.doi.org/10.1136/archdischild-2022-324375,2022-07-27,2024-03-01,Unverified,ratcliffeCommunitySeroprevalenceSARSCoV22022,GBR
220623_England_UniversityofOxford_period4,220623_England_UniversityofOxford_period4,"Community seroprevalence of SARS-CoV-2 in children and adolescents in England, 2019-2021.",2022-06-23,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,,Bradford; Bristol; Imperial; Leeds; Manchester; Newcastle; Nottingham; Oxford; Plymouth; Sheffield; Southhampton; St Georges London; West Suffolk,"""We conducted a community-based cross- sectional seroprevalence study in participants aged
0–18 years old recruiting from seven regions in England between October 2019 and June 2021""","""Participants reported to be vaccinated before their visit were excluded from all analyses""",2020-09-01,2020-12-31,Household and community samples,All,Children and Youth (0-17 years),0.0,18.0,Primary Estimate,,2540,0.187,,,True,,True,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],,No,Yes,No,,Yes,Yes,No,,Helen Ratcliffe,University of Oxford,Not Unity-Aligned,https://dx.doi.org/10.1136/archdischild-2022-324375,2022-07-27,2024-03-01,Unverified,ratcliffeCommunitySeroprevalenceSARSCoV22022,GBR
220623_England_UniversityofOxford_period5,220623_England_UniversityofOxford_period5,"Community seroprevalence of SARS-CoV-2 in children and adolescents in England, 2019-2021.",2022-06-23,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,,Bradford; Bristol; Imperial; Leeds; Manchester; Newcastle; Nottingham; Oxford; Plymouth; Sheffield; Southhampton; St Georges London; West Suffolk,"""We conducted a community-based cross- sectional seroprevalence study in participants aged
0–18 years old recruiting from seven regions in England between October 2019 and June 2021""","""Participants reported to be vaccinated before their visit were excluded from all analyses""",2021-01-01,2021-03-31,Household and community samples,All,Children and Youth (0-17 years),0.0,18.0,Primary Estimate,,2540,0.311,,,True,,True,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],,No,Yes,No,,Yes,Yes,No,,Helen Ratcliffe,University of Oxford,Not Unity-Aligned,https://dx.doi.org/10.1136/archdischild-2022-324375,2022-07-27,2024-03-01,Unverified,ratcliffeCommunitySeroprevalenceSARSCoV22022,GBR
220623_England_UniversityofOxford_period6,220623_England_UniversityofOxford_period6,"Community seroprevalence of SARS-CoV-2 in children and adolescents in England, 2019-2021.",2022-06-23,Journal Article (Peer-Reviewed),National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,,Bradford; Bristol; Imperial; Leeds; Manchester; Newcastle; Nottingham; Oxford; Plymouth; Sheffield; Southhampton; St Georges London; West Suffolk,"""We conducted a community-based cross- sectional seroprevalence study in participants aged
0–18 years old recruiting from seven regions in England between October 2019 and June 2021""","""Participants reported to be vaccinated before their visit were excluded from all analyses""",2021-04-01,2021-06-30,Household and community samples,All,Children and Youth (0-17 years),0.0,18.0,Primary Estimate,,2540,0.107,,,True,,True,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],,No,Yes,No,,Yes,Yes,No,,Helen Ratcliffe,University of Oxford,Not Unity-Aligned,https://dx.doi.org/10.1136/archdischild-2022-324375,2022-07-27,2024-03-01,Unverified,ratcliffeCommunitySeroprevalenceSARSCoV22022,GBR
220713_Scotland_PublicHealthScotland_1ResidualSera_Overall_PopAdj_TestAdj,220713_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 13 July 2022,2022-07-13,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-06-06,2022-07-10,Residual sera,All,Multiple groups,0.0,,Primary Estimate,"Overall, test and pop adjusted",2544,0.9550000000000001,0.9500000000000001,0.97,True,True,True,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-13-july-2022/,2022-08-08,2023-08-15,Verified,scotland_enhanced_2022-5,GBR
220713_Scotland_PublicHealthScotland_1ResidualSera_Age_20-39_Unadj,220713_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 13 July 2022,2022-07-13,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-06-06,2022-07-10,Residual sera,All,Adults (18-64 years),20.0,39.0,Age,"20-39, unadj",622,0.9259999999999999,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-13-july-2022/,2022-08-08,2024-03-01,Verified,scotland_enhanced_2022-5,GBR
220713_Scotland_PublicHealthScotland_1ResidualSera_Female_Unadj,220713_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 13 July 2022,2022-07-13,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-06-06,2022-07-10,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,"Female, unadj",1276,0.9420000000000001,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-13-july-2022/,2022-08-08,2024-03-01,Verified,scotland_enhanced_2022-5,GBR
220713_Scotland_PublicHealthScotland_1ResidualSera_Age_00-19_Unadj,220713_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 13 July 2022,2022-07-13,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-06-06,2022-07-10,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Age,"0-19, unadj",651,0.8618000000000001,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-13-july-2022/,2022-08-08,2024-03-01,Verified,scotland_enhanced_2022-5,GBR
220713_Scotland_PublicHealthScotland_1ResidualSera_Age_70+_Unadj,220713_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 13 July 2022,2022-07-13,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-06-06,2022-07-10,Residual sera,All,Seniors (65+ years),70.0,,Age,"70+, unadj",457,0.9759000000000001,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-13-july-2022/,2022-08-08,2024-03-01,Verified,scotland_enhanced_2022-5,GBR
220713_Scotland_PublicHealthScotland_1ResidualSera_Age_40-59_Unadj,220713_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 13 July 2022,2022-07-13,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-06-06,2022-07-10,Residual sera,All,Adults (18-64 years),40.0,59.0,Age,"40-59, unadj",540,0.9407,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-13-july-2022/,2022-08-08,2024-03-01,Verified,scotland_enhanced_2022-5,GBR
220713_Scotland_PublicHealthScotland_1ResidualSera_Overall_Unadj,220713_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 13 July 2022,2022-07-13,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-06-06,2022-07-10,Residual sera,All,Multiple groups,0.0,,Analysis,"Overall, unadj",2544,0.9261,,,,,,,True,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-13-july-2022/,2022-08-08,2024-03-01,Verified,scotland_enhanced_2022-5,GBR
220713_Scotland_PublicHealthScotland_1ResidualSera_Male_Unadj,220713_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 13 July 2022,2022-07-13,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-06-06,2022-07-10,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,"Male, unadj",1268,0.9101,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-13-july-2022/,2022-08-08,2024-03-01,Verified,scotland_enhanced_2022-5,GBR
220713_Scotland_PublicHealthScotland_1ResidualSera_Age_60-69_Unadj,220713_Scotland_PublicHealthScotland_1ResidualSera,Enhanced Surveillance of COVID-19 in Scotland - Population-based seroprevalence surveillance 13 July 2022,2022-07-13,Institutional Report,National,Repeated cross-sectional study,United Kingdom of Great Britain and Northern Ireland,Scotland,,"Since week commencing 20 April 2020, blood samples, originally collected for other clinical reasons in community healthcare settings, have been obtained from regional biochemistry and immunology laboratories across Scotland.",,2022-06-06,2022-07-10,Residual sera,All,Seniors (65+ years),60.0,69.0,Age,"60-69, unadj",274,0.9672000000000001,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,Spike,Validated by independent authors/third party/non-developers,0.973,0.996,['Low'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Public Health Scotland,Public Health Scotland,Unity-Aligned,https://www.publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-13-july-2022/,2022-08-08,2024-03-01,Verified,scotland_enhanced_2022-5,GBR
220801_England_ImperialCollegeLondon_Overall,220801_England_ImperialCollegeLondon,Validity of self-testing at home with rapid SARS-CoV-2 antibody detection by lateral flow immunoassay,2022-08-01,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,aged 18 or over from the National Health Service (NHS) patient list,missing or invalid self-LFIA result,2021-07-01,2021-08-10,Household and community samples,All,Multiple groups,,,Primary Estimate,,3758,0.9640000000000001,0.9570000000000001,0.97,True,,,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.985,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Christina Atchison,Imperial College London,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.06.08.22276154v1.full-text,2022-07-01,2024-04-02,Verified,atchison_validity_2022,GBR
220801_England_ImperialCollegeLondon_Age_35-44,220801_England_ImperialCollegeLondon,Validity of self-testing at home with rapid SARS-CoV-2 antibody detection by lateral flow immunoassay,2022-08-01,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,aged 18 or over from the National Health Service (NHS) patient list,missing or invalid self-LFIA result,2021-07-01,2021-08-10,Household and community samples,All,Adults (18-64 years),35.0,44.0,Age,35-44,430,0.9670000000000001,0.946,0.981,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.985,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Christina Atchison,Imperial College London,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.06.08.22276154v1.full-text,2022-07-01,2024-04-02,Verified,atchison_validity_2022,GBR
220801_England_ImperialCollegeLondon_Age_18-24,220801_England_ImperialCollegeLondon,Validity of self-testing at home with rapid SARS-CoV-2 antibody detection by lateral flow immunoassay,2022-08-01,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,aged 18 or over from the National Health Service (NHS) patient list,missing or invalid self-LFIA result,2021-07-01,2021-08-10,Household and community samples,All,Adults (18-64 years),18.0,24.0,Age,18-24,385,0.958,0.9329999999999999,0.9740000000000001,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.985,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Christina Atchison,Imperial College London,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.06.08.22276154v1.full-text,2022-07-01,2024-04-02,Verified,atchison_validity_2022,GBR
220801_England_ImperialCollegeLondon_Unvaccinated,220801_England_ImperialCollegeLondon,Validity of self-testing at home with rapid SARS-CoV-2 antibody detection by lateral flow immunoassay,2022-08-01,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,aged 18 or over from the National Health Service (NHS) patient list,missing or invalid self-LFIA result,2021-07-01,2021-08-10,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,0 doses,466,0.779,0.7390000000000001,0.8140000000000001,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.985,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Christina Atchison,Imperial College London,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.06.08.22276154v1.full-text,2022-07-01,2024-04-02,Verified,atchison_validity_2022,GBR
220801_England_ImperialCollegeLondon_Age_45-54,220801_England_ImperialCollegeLondon,Validity of self-testing at home with rapid SARS-CoV-2 antibody detection by lateral flow immunoassay,2022-08-01,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,aged 18 or over from the National Health Service (NHS) patient list,missing or invalid self-LFIA result,2021-07-01,2021-08-10,Household and community samples,All,Adults (18-64 years),45.0,54.0,Age,45-54,163,0.9329999999999999,0.882,0.9620000000000001,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.985,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Christina Atchison,Imperial College London,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.06.08.22276154v1.full-text,2022-07-01,2024-04-02,Verified,atchison_validity_2022,GBR
220801_England_ImperialCollegeLondon_Age_75+,220801_England_ImperialCollegeLondon,Validity of self-testing at home with rapid SARS-CoV-2 antibody detection by lateral flow immunoassay,2022-08-01,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,aged 18 or over from the National Health Service (NHS) patient list,missing or invalid self-LFIA result,2021-07-01,2021-08-10,Household and community samples,All,Seniors (65+ years),75.0,,Age,75+,156,0.9870000000000001,0.9490000000000001,1.0,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.985,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Christina Atchison,Imperial College London,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.06.08.22276154v1.full-text,2022-07-01,2024-04-02,Verified,atchison_validity_2022,GBR
220801_England_ImperialCollegeLondon_Sex_Male,220801_England_ImperialCollegeLondon,Validity of self-testing at home with rapid SARS-CoV-2 antibody detection by lateral flow immunoassay,2022-08-01,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,aged 18 or over from the National Health Service (NHS) patient list,missing or invalid self-LFIA result,2021-07-01,2021-08-10,Household and community samples,Male,Multiple groups,,,Sex/Gender,Male,1483,0.9640000000000001,0.953,0.973,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.985,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Christina Atchison,Imperial College London,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.06.08.22276154v1.full-text,2022-07-01,2024-04-02,Verified,atchison_validity_2022,GBR
220801_England_ImperialCollegeLondon_Age_65-74,220801_England_ImperialCollegeLondon,Validity of self-testing at home with rapid SARS-CoV-2 antibody detection by lateral flow immunoassay,2022-08-01,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,aged 18 or over from the National Health Service (NHS) patient list,missing or invalid self-LFIA result,2021-07-01,2021-08-10,Household and community samples,All,Seniors (65+ years),65.0,74.0,Age,65-74,1292,0.983,0.9740000000000001,0.9890000000000001,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.985,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Christina Atchison,Imperial College London,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.06.08.22276154v1.full-text,2022-07-01,2024-04-02,Verified,atchison_validity_2022,GBR
220801_England_ImperialCollegeLondon_Age_55-64,220801_England_ImperialCollegeLondon,Validity of self-testing at home with rapid SARS-CoV-2 antibody detection by lateral flow immunoassay,2022-08-01,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,aged 18 or over from the National Health Service (NHS) patient list,missing or invalid self-LFIA result,2021-07-01,2021-08-10,Household and community samples,All,Adults (18-64 years),55.0,64.0,Age,55-64,628,0.943,0.9209999999999999,0.958,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.985,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Christina Atchison,Imperial College London,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.06.08.22276154v1.full-text,2022-07-01,2024-04-02,Verified,atchison_validity_2022,GBR
220801_England_ImperialCollegeLondon_Age_25-34,220801_England_ImperialCollegeLondon,Validity of self-testing at home with rapid SARS-CoV-2 antibody detection by lateral flow immunoassay,2022-08-01,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,aged 18 or over from the National Health Service (NHS) patient list,missing or invalid self-LFIA result,2021-07-01,2021-08-10,Household and community samples,All,Adults (18-64 years),25.0,34.0,Age,25-34,704,0.9500000000000001,0.9309999999999999,0.9640000000000001,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.985,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Christina Atchison,Imperial College London,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.06.08.22276154v1.full-text,2022-07-01,2024-04-02,Verified,atchison_validity_2022,GBR
220801_England_ImperialCollegeLondon_Sex_Female,220801_England_ImperialCollegeLondon,Validity of self-testing at home with rapid SARS-CoV-2 antibody detection by lateral flow immunoassay,2022-08-01,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,aged 18 or over from the National Health Service (NHS) patient list,missing or invalid self-LFIA result,2021-07-01,2021-08-10,Household and community samples,Female,Multiple groups,,,Sex/Gender,Female,2275,0.9640000000000001,0.9550000000000001,0.97,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.985,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Christina Atchison,Imperial College London,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.06.08.22276154v1.full-text,2022-07-01,2024-04-02,Verified,atchison_validity_2022,GBR
220801_England_ImperialCollegeLondon_Vaccinated,220801_England_ImperialCollegeLondon,Validity of self-testing at home with rapid SARS-CoV-2 antibody detection by lateral flow immunoassay,2022-08-01,Preprint,Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,aged 18 or over from the National Health Service (NHS) patient list,missing or invalid self-LFIA result,2021-07-01,2021-08-10,Household and community samples,All,Multiple groups,,,COVID-19 vaccination status,1-2 doses,3292,0.98997,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.985,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Christina Atchison,Imperial College London,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.06.08.22276154v1.full-text,2022-07-01,2024-04-02,Verified,atchison_validity_2022,GBR
220806_WestMidlands_TheRoyalWolverhamptonNHSTrust_Overall,220806_WestMidlands_TheRoyalWolverhamptonNHSTrust,COVID-19 seroprevalence after the first UK wave of the pandemic and its association with the physical and mental wellbeing of secondary care healthcare workers,2022-08-06,Journal Article (Peer-Reviewed),Local,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,,,"All HCWs from the Royal Wolverhampton NHS Trust which included both clinical and non-clinical staff (support
staff and estates teams included) were invited to participate","126 were excluded as we were unable to
match data with their antibody status",2020-06-17,2020-07-30,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,1082,0.276,,,True,,,,True,Convenience,Not reported/ Unable to specify,,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9270999999999999,0.9973000000000001,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Sonika Sethi,The Royal Wolverhampton NHS Trust,Not Unity-Aligned,https://dx.doi.org/10.1016/j.bbih.2022.100492,2022-09-06,2022-09-06,Unverified,sethi_covid-19_2022,GBR
220809_London_KingsCollegeLondon_Primary,220809_London_KingsCollegeLondon,Indicators of recent COVID-19 infection status: findings from a large occupational cohort of staff and postgraduate research students from a UK university.,2022-08-09,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United Kingdom of Great Britain and Northern Ireland,England,London,"""All KCL CHECK participants who consented to follow-up and gave a valid UK address were sent a test kit.""

""Included were staff and postgraduate research students at a large London university who volunteered for the study and were living in the UK in June 2020.""

""Participants were included in this analysis if they returned a valid antibody test result by 13th July 2020.""","""Participants residing outside the UK in June 2020 were excluded for logistical reasons.""

""Excluded were those who did not return a valid antibody test result.""",2020-06-17,2020-07-13,Multiple populations,All,Multiple groups,18.0,,Primary Estimate,,1882,0.0659,0.06,0.08,True,,,,True,Convenience,COVID-19 antibody rapid test,SureScreen Diagnostics,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.9400000000000001,0.97,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Katrina Davis,King’s College London,Not Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13889-0,2022-08-17,2024-03-01,Unverified,davis_indicators_2022,GBR
220817_Harlow_PrincessAlexandraHospital_Overall,220817_Harlow_PrincessAlexandraHospital,333 A sudden increase in children with newly diagnosed Type 1 Diabetes mellitus T1DM during the peak of the COVID-19 pandemic – Is there an association?,2022-08-17,Presentation or Conference,Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,Harlow,"Children presenting with new onset Type 1 diabetes in Princess Alexandra Hospital NHS Trust (PAH), District General Hospital, Harlow, Essex UK.",,2020-04-29,2020-06-06,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),1.0,14.0,Primary Estimate,,10,0.1,,,True,,,,True,Convenience,Qualitative Elecsys Anti-SARS-CoV-2 Probe,Roche Diagnostics,,,IgG,,Validated by manufacturers,0.97,,['High'],,No,No,Yes,,Unclear,Yes,No,,Abirami Namasivayam,Princess Alexandra Hospital,Not Unity-Aligned,https://dx.doi.org/10.1136/archdischild-2022-rcpch.433,2022-10-19,2022-10-21,Unverified,namasivayam_333_2022,GBR
220824_England_UKHealthSecurityAgency_PrimaryStaff_Round1_Overall,220824_England_UKHealthSecurityAgency_PrimaryStaff_Round1,Epidemiology of SARS-CoV-2 infection among staff and students in a cohort of English primary and secondary schools during 2020-2021.,2022-08-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"All students from 4 years of age and all staff in primary schools were eligible to join the study from the start (November 2020). For secondary students, in the first term (November-December 2020), only those from two systematically selected consecutive year-groups were eligible in any one school: years 7 and 8 (ages 11–13); 9 and 10 (ages 13–15); or years 12 and 13 (ages 16–18) were randomly selected to participate in each school. In January 2021, the offer of enrolment was expanded to all students in secondary schools, except those from year 11 who, following guidance from the Department for Education, were not invited to participate throughout the year to limit disruption to learning during their final examination year.",,2020-11-08,2020-11-21,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,1034,0.1151,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Tanya Abramsky,UK Health Security Agency,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanepe.2022.100471,2022-09-23,2024-03-01,Unverified,hargreaves_epidemiology_2022,GBR
220824_England_UKHealthSecurityAgency_PrimaryStaff_Round2_Overall,220824_England_UKHealthSecurityAgency_PrimaryStaff_Round2,Epidemiology of SARS-CoV-2 infection among staff and students in a cohort of English primary and secondary schools during 2020-2021.,2022-08-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"All students from 4 years of age and all staff in primary schools were eligible to join the study from the start (November 2020). For secondary students, in the first term (November-December 2020), only those from two systematically selected consecutive year-groups were eligible in any one school: years 7 and 8 (ages 11–13); 9 and 10 (ages 13–15); or years 12 and 13 (ages 16–18) were randomly selected to participate in each school. In January 2021, the offer of enrolment was expanded to all students in secondary schools, except those from year 11 who, following guidance from the Department for Education, were not invited to participate throughout the year to limit disruption to learning during their final examination year.",,2020-11-22,2020-12-05,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,1013,0.1362,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Tanya Abramsky,UK Health Security Agency,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanepe.2022.100471,2022-09-23,2024-03-01,Unverified,hargreaves_epidemiology_2022,GBR
220824_England_UKHealthSecurityAgency_PrimaryStaff_Round3_Overall,220824_England_UKHealthSecurityAgency_PrimaryStaff_Round3,Epidemiology of SARS-CoV-2 infection among staff and students in a cohort of English primary and secondary schools during 2020-2021.,2022-08-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"All students from 4 years of age and all staff in primary schools were eligible to join the study from the start (November 2020). For secondary students, in the first term (November-December 2020), only those from two systematically selected consecutive year-groups were eligible in any one school: years 7 and 8 (ages 11–13); 9 and 10 (ages 13–15); or years 12 and 13 (ages 16–18) were randomly selected to participate in each school. In January 2021, the offer of enrolment was expanded to all students in secondary schools, except those from year 11 who, following guidance from the Department for Education, were not invited to participate throughout the year to limit disruption to learning during their final examination year.",,2021-01-30,2021-02-07,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,66,0.2576,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,,Nucleocapsid(N-protein),,,,['High'],,No,No,No,,Yes,Yes,Yes,,Tanya Abramsky,UK Health Security Agency,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanepe.2022.100471,2022-09-23,2024-03-01,Unverified,hargreaves_epidemiology_2022,GBR
220824_England_UKHealthSecurityAgency_PrimaryStaff_Round4_Overall,220824_England_UKHealthSecurityAgency_PrimaryStaff_Round4,Epidemiology of SARS-CoV-2 infection among staff and students in a cohort of English primary and secondary schools during 2020-2021.,2022-08-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"All students from 4 years of age and all staff in primary schools were eligible to join the study from the start (November 2020). For secondary students, in the first term (November-December 2020), only those from two systematically selected consecutive year-groups were eligible in any one school: years 7 and 8 (ages 11–13); 9 and 10 (ages 13–15); or years 12 and 13 (ages 16–18) were randomly selected to participate in each school. In January 2021, the offer of enrolment was expanded to all students in secondary schools, except those from year 11 who, following guidance from the Department for Education, were not invited to participate throughout the year to limit disruption to learning during their final examination year.",,2021-03-15,2021-03-31,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,1138,0.2214,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Tanya Abramsky,UK Health Security Agency,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanepe.2022.100471,2022-09-23,2024-03-01,Unverified,hargreaves_epidemiology_2022,GBR
220824_England_UKHealthSecurityAgency_PrimaryStaff_Round5_Overall,220824_England_UKHealthSecurityAgency_PrimaryStaff_Round5,Epidemiology of SARS-CoV-2 infection among staff and students in a cohort of English primary and secondary schools during 2020-2021.,2022-08-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"All students from 4 years of age and all staff in primary schools were eligible to join the study from the start (November 2020). For secondary students, in the first term (November-December 2020), only those from two systematically selected consecutive year-groups were eligible in any one school: years 7 and 8 (ages 11–13); 9 and 10 (ages 13–15); or years 12 and 13 (ages 16–18) were randomly selected to participate in each school. In January 2021, the offer of enrolment was expanded to all students in secondary schools, except those from year 11 who, following guidance from the Department for Education, were not invited to participate throughout the year to limit disruption to learning during their final examination year.",,2021-05-03,2021-05-16,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,1051,0.23600000000000002,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Tanya Abramsky,UK Health Security Agency,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanepe.2022.100471,2022-09-23,2024-03-01,Unverified,hargreaves_epidemiology_2022,GBR
220824_England_UKHealthSecurityAgency_PrimaryStaff_Round6_Overall,220824_England_UKHealthSecurityAgency_PrimaryStaff_Round6,Epidemiology of SARS-CoV-2 infection among staff and students in a cohort of English primary and secondary schools during 2020-2021.,2022-08-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"All students from 4 years of age and all staff in primary schools were eligible to join the study from the start (November 2020). For secondary students, in the first term (November-December 2020), only those from two systematically selected consecutive year-groups were eligible in any one school: years 7 and 8 (ages 11–13); 9 and 10 (ages 13–15); or years 12 and 13 (ages 16–18) were randomly selected to participate in each school. In January 2021, the offer of enrolment was expanded to all students in secondary schools, except those from year 11 who, following guidance from the Department for Education, were not invited to participate throughout the year to limit disruption to learning during their final examination year.",,2021-06-13,2021-06-26,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,842,0.2625,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Tanya Abramsky,UK Health Security Agency,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanepe.2022.100471,2022-09-23,2024-03-01,Unverified,hargreaves_epidemiology_2022,GBR
220824_England_UKHealthSecurityAgency_PrimaryStudents_Round1_Overall,220824_England_UKHealthSecurityAgency_PrimaryStudents_Round1,Epidemiology of SARS-CoV-2 infection among staff and students in a cohort of English primary and secondary schools during 2020-2021.,2022-08-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"All students from 4 years of age and all staff in primary schools were eligible to join the study from the start (November 2020). For secondary students, in the first term (November-December 2020), only those from two systematically selected consecutive year-groups were eligible in any one school: years 7 and 8 (ages 11–13); 9 and 10 (ages 13–15); or years 12 and 13 (ages 16–18) were randomly selected to participate in each school. In January 2021, the offer of enrolment was expanded to all students in secondary schools, except those from year 11 who, following guidance from the Department for Education, were not invited to participate throughout the year to limit disruption to learning during their final examination year.",,2020-11-08,2020-11-21,Students and Daycares,All,Children and Youth (0-17 years),5.0,12.0,Primary Estimate,,2149,0.0533,,,True,True,,,True,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Saliva,IgG,Nucleocapsid(N-protein),Validated by developers,0.75,0.99,['High'],,No,Yes,No,,Unclear,Yes,Yes,,Tanya Abramsky,UK Health Security Agency,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanepe.2022.100471,2022-09-23,2022-09-23,Unverified,hargreaves_epidemiology_2022,GBR
220824_England_UKHealthSecurityAgency_PrimaryStudents_Round2_Overall,220824_England_UKHealthSecurityAgency_PrimaryStudents_Round2,Epidemiology of SARS-CoV-2 infection among staff and students in a cohort of English primary and secondary schools during 2020-2021.,2022-08-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"All students from 4 years of age and all staff in primary schools were eligible to join the study from the start (November 2020). For secondary students, in the first term (November-December 2020), only those from two systematically selected consecutive year-groups were eligible in any one school: years 7 and 8 (ages 11–13); 9 and 10 (ages 13–15); or years 12 and 13 (ages 16–18) were randomly selected to participate in each school. In January 2021, the offer of enrolment was expanded to all students in secondary schools, except those from year 11 who, following guidance from the Department for Education, were not invited to participate throughout the year to limit disruption to learning during their final examination year.",,2020-11-22,2020-12-05,Students and Daycares,All,Children and Youth (0-17 years),5.0,12.0,Primary Estimate,,2414,0.0707,,,True,True,,,True,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Saliva,IgG,Nucleocapsid(N-protein),Validated by developers,0.75,0.99,['High'],,No,Yes,No,,Unclear,Yes,Yes,,Tanya Abramsky,UK Health Security Agency,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanepe.2022.100471,2022-09-23,2022-09-23,Unverified,hargreaves_epidemiology_2022,GBR
220824_England_UKHealthSecurityAgency_PrimaryStudents_Round3_Overall,220824_England_UKHealthSecurityAgency_PrimaryStudents_Round3,Epidemiology of SARS-CoV-2 infection among staff and students in a cohort of English primary and secondary schools during 2020-2021.,2022-08-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"All students from 4 years of age and all staff in primary schools were eligible to join the study from the start (November 2020). For secondary students, in the first term (November-December 2020), only those from two systematically selected consecutive year-groups were eligible in any one school: years 7 and 8 (ages 11–13); 9 and 10 (ages 13–15); or years 12 and 13 (ages 16–18) were randomly selected to participate in each school. In January 2021, the offer of enrolment was expanded to all students in secondary schools, except those from year 11 who, following guidance from the Department for Education, were not invited to participate throughout the year to limit disruption to learning during their final examination year.",,2021-01-30,2021-02-07,Students and Daycares,All,Children and Youth (0-17 years),5.0,12.0,Primary Estimate,,191,0.1133,,,True,True,,,True,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Saliva,IgG,Nucleocapsid(N-protein),Validated by developers,0.75,0.99,['High'],,No,No,No,,Unclear,Yes,Yes,,Tanya Abramsky,UK Health Security Agency,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanepe.2022.100471,2022-09-23,2022-09-23,Unverified,hargreaves_epidemiology_2022,GBR
220824_England_UKHealthSecurityAgency_PrimaryStudents_Round4_Overall,220824_England_UKHealthSecurityAgency_PrimaryStudents_Round4,Epidemiology of SARS-CoV-2 infection among staff and students in a cohort of English primary and secondary schools during 2020-2021.,2022-08-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"All students from 4 years of age and all staff in primary schools were eligible to join the study from the start (November 2020). For secondary students, in the first term (November-December 2020), only those from two systematically selected consecutive year-groups were eligible in any one school: years 7 and 8 (ages 11–13); 9 and 10 (ages 13–15); or years 12 and 13 (ages 16–18) were randomly selected to participate in each school. In January 2021, the offer of enrolment was expanded to all students in secondary schools, except those from year 11 who, following guidance from the Department for Education, were not invited to participate throughout the year to limit disruption to learning during their final examination year.",,2021-03-15,2021-03-31,Students and Daycares,All,Children and Youth (0-17 years),5.0,12.0,Primary Estimate,,3628,0.1374,,,True,True,,,True,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Saliva,IgG,Nucleocapsid(N-protein),Validated by developers,0.75,0.99,['High'],,No,Yes,No,,Unclear,Yes,Yes,,Tanya Abramsky,UK Health Security Agency,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanepe.2022.100471,2022-09-23,2022-09-23,Unverified,hargreaves_epidemiology_2022,GBR
220824_England_UKHealthSecurityAgency_PrimaryStudents_Round5_Overall,220824_England_UKHealthSecurityAgency_PrimaryStudents_Round5,Epidemiology of SARS-CoV-2 infection among staff and students in a cohort of English primary and secondary schools during 2020-2021.,2022-08-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"All students from 4 years of age and all staff in primary schools were eligible to join the study from the start (November 2020). For secondary students, in the first term (November-December 2020), only those from two systematically selected consecutive year-groups were eligible in any one school: years 7 and 8 (ages 11–13); 9 and 10 (ages 13–15); or years 12 and 13 (ages 16–18) were randomly selected to participate in each school. In January 2021, the offer of enrolment was expanded to all students in secondary schools, except those from year 11 who, following guidance from the Department for Education, were not invited to participate throughout the year to limit disruption to learning during their final examination year.",,2021-05-03,2021-05-16,Students and Daycares,All,Children and Youth (0-17 years),5.0,12.0,Primary Estimate,,519,0.2068,,,True,True,,,True,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Saliva,IgG,Nucleocapsid(N-protein),Validated by developers,0.75,0.99,['High'],,No,No,No,,Unclear,Yes,Yes,,Tanya Abramsky,UK Health Security Agency,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanepe.2022.100471,2022-09-23,2022-09-23,Unverified,hargreaves_epidemiology_2022,GBR
220824_England_UKHealthSecurityAgency_PrimaryStudents_Round6_Overall,220824_England_UKHealthSecurityAgency_PrimaryStudents_Round6,Epidemiology of SARS-CoV-2 infection among staff and students in a cohort of English primary and secondary schools during 2020-2021.,2022-08-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"All students from 4 years of age and all staff in primary schools were eligible to join the study from the start (November 2020). For secondary students, in the first term (November-December 2020), only those from two systematically selected consecutive year-groups were eligible in any one school: years 7 and 8 (ages 11–13); 9 and 10 (ages 13–15); or years 12 and 13 (ages 16–18) were randomly selected to participate in each school. In January 2021, the offer of enrolment was expanded to all students in secondary schools, except those from year 11 who, following guidance from the Department for Education, were not invited to participate throughout the year to limit disruption to learning during their final examination year.",,2021-06-13,2021-06-26,Students and Daycares,All,Children and Youth (0-17 years),5.0,12.0,Primary Estimate,,3850,0.1149,,,True,True,,,True,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Saliva,IgG,Nucleocapsid(N-protein),Validated by developers,0.75,0.99,['High'],,No,Yes,No,,Unclear,Yes,Yes,,Tanya Abramsky,UK Health Security Agency,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanepe.2022.100471,2022-09-23,2022-09-23,Unverified,hargreaves_epidemiology_2022,GBR
220824_England_UKHealthSecurityAgency_SecondaryStaff_Round1_Overall,220824_England_UKHealthSecurityAgency_SecondaryStaff_Round1,Epidemiology of SARS-CoV-2 infection among staff and students in a cohort of English primary and secondary schools during 2020-2021.,2022-08-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"All students from 4 years of age and all staff in primary schools were eligible to join the study from the start (November 2020). For secondary students, in the first term (November-December 2020), only those from two systematically selected consecutive year-groups were eligible in any one school: years 7 and 8 (ages 11–13); 9 and 10 (ages 13–15); or years 12 and 13 (ages 16–18) were randomly selected to participate in each school. In January 2021, the offer of enrolment was expanded to all students in secondary schools, except those from year 11 who, following guidance from the Department for Education, were not invited to participate throughout the year to limit disruption to learning during their final examination year.",,2020-11-08,2020-11-21,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,2773,0.1125,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Tanya Abramsky,UK Health Security Agency,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanepe.2022.100471,2022-09-23,2024-03-01,Unverified,hargreaves_epidemiology_2022,GBR
220824_England_UKHealthSecurityAgency_SecondaryStaff_Round2_Overall,220824_England_UKHealthSecurityAgency_SecondaryStaff_Round2,Epidemiology of SARS-CoV-2 infection among staff and students in a cohort of English primary and secondary schools during 2020-2021.,2022-08-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"All students from 4 years of age and all staff in primary schools were eligible to join the study from the start (November 2020). For secondary students, in the first term (November-December 2020), only those from two systematically selected consecutive year-groups were eligible in any one school: years 7 and 8 (ages 11–13); 9 and 10 (ages 13–15); or years 12 and 13 (ages 16–18) were randomly selected to participate in each school. In January 2021, the offer of enrolment was expanded to all students in secondary schools, except those from year 11 who, following guidance from the Department for Education, were not invited to participate throughout the year to limit disruption to learning during their final examination year.",,2020-11-22,2020-12-05,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,3291,0.1301,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Tanya Abramsky,UK Health Security Agency,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanepe.2022.100471,2022-09-23,2024-03-01,Unverified,hargreaves_epidemiology_2022,GBR
220824_England_UKHealthSecurityAgency_SecondaryStaff_Round3_Overall,220824_England_UKHealthSecurityAgency_SecondaryStaff_Round3,Epidemiology of SARS-CoV-2 infection among staff and students in a cohort of English primary and secondary schools during 2020-2021.,2022-08-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"All students from 4 years of age and all staff in primary schools were eligible to join the study from the start (November 2020). For secondary students, in the first term (November-December 2020), only those from two systematically selected consecutive year-groups were eligible in any one school: years 7 and 8 (ages 11–13); 9 and 10 (ages 13–15); or years 12 and 13 (ages 16–18) were randomly selected to participate in each school. In January 2021, the offer of enrolment was expanded to all students in secondary schools, except those from year 11 who, following guidance from the Department for Education, were not invited to participate throughout the year to limit disruption to learning during their final examination year.",,2021-01-30,2021-02-07,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,467,0.17559999999999998,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,,Nucleocapsid(N-protein),,,,['High'],,No,No,No,,Yes,Yes,Yes,,Tanya Abramsky,UK Health Security Agency,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanepe.2022.100471,2022-09-23,2024-03-01,Unverified,hargreaves_epidemiology_2022,GBR
220824_England_UKHealthSecurityAgency_SecondaryStaff_Round4_Overall,220824_England_UKHealthSecurityAgency_SecondaryStaff_Round4,Epidemiology of SARS-CoV-2 infection among staff and students in a cohort of English primary and secondary schools during 2020-2021.,2022-08-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"All students from 4 years of age and all staff in primary schools were eligible to join the study from the start (November 2020). For secondary students, in the first term (November-December 2020), only those from two systematically selected consecutive year-groups were eligible in any one school: years 7 and 8 (ages 11–13); 9 and 10 (ages 13–15); or years 12 and 13 (ages 16–18) were randomly selected to participate in each school. In January 2021, the offer of enrolment was expanded to all students in secondary schools, except those from year 11 who, following guidance from the Department for Education, were not invited to participate throughout the year to limit disruption to learning during their final examination year.",,2021-03-15,2021-03-31,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,2214,0.1956,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Tanya Abramsky,UK Health Security Agency,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanepe.2022.100471,2022-09-23,2024-03-01,Unverified,hargreaves_epidemiology_2022,GBR
220824_England_UKHealthSecurityAgency_SecondaryStaff_Round5_Overall,220824_England_UKHealthSecurityAgency_SecondaryStaff_Round5,Epidemiology of SARS-CoV-2 infection among staff and students in a cohort of English primary and secondary schools during 2020-2021.,2022-08-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"All students from 4 years of age and all staff in primary schools were eligible to join the study from the start (November 2020). For secondary students, in the first term (November-December 2020), only those from two systematically selected consecutive year-groups were eligible in any one school: years 7 and 8 (ages 11–13); 9 and 10 (ages 13–15); or years 12 and 13 (ages 16–18) were randomly selected to participate in each school. In January 2021, the offer of enrolment was expanded to all students in secondary schools, except those from year 11 who, following guidance from the Department for Education, were not invited to participate throughout the year to limit disruption to learning during their final examination year.",,2021-05-03,2021-05-16,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,1985,0.21559999999999999,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Tanya Abramsky,UK Health Security Agency,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanepe.2022.100471,2022-09-23,2024-03-01,Unverified,hargreaves_epidemiology_2022,GBR
220824_England_UKHealthSecurityAgency_SecondaryStaff_Round6_Overall,220824_England_UKHealthSecurityAgency_SecondaryStaff_Round6,Epidemiology of SARS-CoV-2 infection among staff and students in a cohort of English primary and secondary schools during 2020-2021.,2022-08-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"All students from 4 years of age and all staff in primary schools were eligible to join the study from the start (November 2020). For secondary students, in the first term (November-December 2020), only those from two systematically selected consecutive year-groups were eligible in any one school: years 7 and 8 (ages 11–13); 9 and 10 (ages 13–15); or years 12 and 13 (ages 16–18) were randomly selected to participate in each school. In January 2021, the offer of enrolment was expanded to all students in secondary schools, except those from year 11 who, following guidance from the Department for Education, were not invited to participate throughout the year to limit disruption to learning during their final examination year.",,2021-06-13,2021-06-26,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,1594,0.2346,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Tanya Abramsky,UK Health Security Agency,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanepe.2022.100471,2022-09-23,2024-03-01,Unverified,hargreaves_epidemiology_2022,GBR
220824_England_UKHealthSecurityAgency_SecondaryStudents_Round1_Overall,220824_England_UKHealthSecurityAgency_SecondaryStudents_Round1,Epidemiology of SARS-CoV-2 infection among staff and students in a cohort of English primary and secondary schools during 2020-2021.,2022-08-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"All students from 4 years of age and all staff in primary schools were eligible to join the study from the start (November 2020). For secondary students, in the first term (November-December 2020), only those from two systematically selected consecutive year-groups were eligible in any one school: years 7 and 8 (ages 11–13); 9 and 10 (ages 13–15); or years 12 and 13 (ages 16–18) were randomly selected to participate in each school. In January 2021, the offer of enrolment was expanded to all students in secondary schools, except those from year 11 who, following guidance from the Department for Education, were not invited to participate throughout the year to limit disruption to learning during their final examination year.",,2020-11-08,2020-11-21,Students and Daycares,All,Children and Youth (0-17 years),12.0,18.0,Primary Estimate,,3032,0.09050000000000001,,,True,True,,,True,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Saliva,IgG,Nucleocapsid(N-protein),Validated by developers,0.75,0.99,['High'],,No,Yes,No,,Unclear,Yes,Yes,,Tanya Abramsky,UK Health Security Agency,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanepe.2022.100471,2022-09-23,2022-09-23,Unverified,hargreaves_epidemiology_2022,GBR
220824_England_UKHealthSecurityAgency_SecondaryStudents_Round2_Overall,220824_England_UKHealthSecurityAgency_SecondaryStudents_Round2,Epidemiology of SARS-CoV-2 infection among staff and students in a cohort of English primary and secondary schools during 2020-2021.,2022-08-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"All students from 4 years of age and all staff in primary schools were eligible to join the study from the start (November 2020). For secondary students, in the first term (November-December 2020), only those from two systematically selected consecutive year-groups were eligible in any one school: years 7 and 8 (ages 11–13); 9 and 10 (ages 13–15); or years 12 and 13 (ages 16–18) were randomly selected to participate in each school. In January 2021, the offer of enrolment was expanded to all students in secondary schools, except those from year 11 who, following guidance from the Department for Education, were not invited to participate throughout the year to limit disruption to learning during their final examination year.",,2020-11-22,2020-12-05,Students and Daycares,All,Children and Youth (0-17 years),12.0,18.0,Primary Estimate,,4461,0.10400000000000001,,,True,True,,,True,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Saliva,IgG,Nucleocapsid(N-protein),Validated by developers,0.75,0.99,['High'],,No,Yes,No,,Unclear,Yes,Yes,,Tanya Abramsky,UK Health Security Agency,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanepe.2022.100471,2022-09-23,2022-09-23,Unverified,hargreaves_epidemiology_2022,GBR
220824_England_UKHealthSecurityAgency_SecondaryStudents_Round3_Overall,220824_England_UKHealthSecurityAgency_SecondaryStudents_Round3,Epidemiology of SARS-CoV-2 infection among staff and students in a cohort of English primary and secondary schools during 2020-2021.,2022-08-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"All students from 4 years of age and all staff in primary schools were eligible to join the study from the start (November 2020). For secondary students, in the first term (November-December 2020), only those from two systematically selected consecutive year-groups were eligible in any one school: years 7 and 8 (ages 11–13); 9 and 10 (ages 13–15); or years 12 and 13 (ages 16–18) were randomly selected to participate in each school. In January 2021, the offer of enrolment was expanded to all students in secondary schools, except those from year 11 who, following guidance from the Department for Education, were not invited to participate throughout the year to limit disruption to learning during their final examination year.",,2021-01-30,2021-02-07,Students and Daycares,All,Children and Youth (0-17 years),12.0,18.0,Primary Estimate,,1850,0.19530000000000003,,,True,True,,,True,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Saliva,IgG,Nucleocapsid(N-protein),Validated by developers,0.75,0.99,['High'],,No,Yes,No,,Unclear,Yes,Yes,,Tanya Abramsky,UK Health Security Agency,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanepe.2022.100471,2022-09-23,2022-09-23,Unverified,hargreaves_epidemiology_2022,GBR
220824_England_UKHealthSecurityAgency_SecondaryStudents_Round4_Overall,220824_England_UKHealthSecurityAgency_SecondaryStudents_Round4,Epidemiology of SARS-CoV-2 infection among staff and students in a cohort of English primary and secondary schools during 2020-2021.,2022-08-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"All students from 4 years of age and all staff in primary schools were eligible to join the study from the start (November 2020). For secondary students, in the first term (November-December 2020), only those from two systematically selected consecutive year-groups were eligible in any one school: years 7 and 8 (ages 11–13); 9 and 10 (ages 13–15); or years 12 and 13 (ages 16–18) were randomly selected to participate in each school. In January 2021, the offer of enrolment was expanded to all students in secondary schools, except those from year 11 who, following guidance from the Department for Education, were not invited to participate throughout the year to limit disruption to learning during their final examination year.",,2021-03-15,2021-03-31,Students and Daycares,All,Children and Youth (0-17 years),12.0,18.0,Primary Estimate,,7308,0.1552,,,True,True,,,True,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Saliva,IgG,Nucleocapsid(N-protein),Validated by developers,0.75,0.99,['High'],,No,Yes,No,,Unclear,Yes,Yes,,Tanya Abramsky,UK Health Security Agency,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanepe.2022.100471,2022-09-23,2022-09-23,Unverified,hargreaves_epidemiology_2022,GBR
220824_England_UKHealthSecurityAgency_SecondaryStudents_Round5_Overall,220824_England_UKHealthSecurityAgency_SecondaryStudents_Round5,Epidemiology of SARS-CoV-2 infection among staff and students in a cohort of English primary and secondary schools during 2020-2021.,2022-08-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"All students from 4 years of age and all staff in primary schools were eligible to join the study from the start (November 2020). For secondary students, in the first term (November-December 2020), only those from two systematically selected consecutive year-groups were eligible in any one school: years 7 and 8 (ages 11–13); 9 and 10 (ages 13–15); or years 12 and 13 (ages 16–18) were randomly selected to participate in each school. In January 2021, the offer of enrolment was expanded to all students in secondary schools, except those from year 11 who, following guidance from the Department for Education, were not invited to participate throughout the year to limit disruption to learning during their final examination year.",,2021-05-03,2021-05-16,Students and Daycares,All,Children and Youth (0-17 years),12.0,18.0,Primary Estimate,,1343,0.15130000000000002,,,True,True,,,True,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Saliva,IgG,Nucleocapsid(N-protein),Validated by developers,0.75,0.99,['High'],,No,Yes,No,,Unclear,Yes,Yes,,Tanya Abramsky,UK Health Security Agency,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanepe.2022.100471,2022-09-23,2022-09-23,Unverified,hargreaves_epidemiology_2022,GBR
220824_England_UKHealthSecurityAgency_SecondaryStudents_Round6_Overall,220824_England_UKHealthSecurityAgency_SecondaryStudents_Round6,Epidemiology of SARS-CoV-2 infection among staff and students in a cohort of English primary and secondary schools during 2020-2021.,2022-08-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,"All students from 4 years of age and all staff in primary schools were eligible to join the study from the start (November 2020). For secondary students, in the first term (November-December 2020), only those from two systematically selected consecutive year-groups were eligible in any one school: years 7 and 8 (ages 11–13); 9 and 10 (ages 13–15); or years 12 and 13 (ages 16–18) were randomly selected to participate in each school. In January 2021, the offer of enrolment was expanded to all students in secondary schools, except those from year 11 who, following guidance from the Department for Education, were not invited to participate throughout the year to limit disruption to learning during their final examination year.",,2021-06-13,2021-06-26,Students and Daycares,All,Children and Youth (0-17 years),12.0,18.0,Primary Estimate,,7203,0.1169,,,True,True,,,True,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Saliva,IgG,Nucleocapsid(N-protein),Validated by developers,0.75,0.99,['High'],,No,Yes,No,,Unclear,Yes,Yes,,Tanya Abramsky,UK Health Security Agency,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanepe.2022.100471,2022-09-23,2022-09-23,Unverified,hargreaves_epidemiology_2022,GBR
220901_Cambridge_UniversityOfCambridge_Overall,220901_Cambridge_UniversityOfCambridge,A prospective study of risk factors associated with seroprevalence of SARS-CoV-2 antibodies in healthcare workers at a large UK teaching hospital,2022-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,Cambridge,"""All staff members [at Cambridge University Hospitals NHS Foundation Trust] were invited"".

""Cambridge University Hospitals NHS Foundation Trust (CUH) is a tertiary referral centre and teaching hospital ... in the East of England.""",Not giving written informed consent.,2020-06-10,2020-08-07,Health care workers and caregivers,All,Multiple groups,17.0,83.0,Primary Estimate,,5698,0.07200000000000001,,,True,,,,True,Convenience,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.981,0.9990000000000001,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Daniel Cooper,University of Cambridge,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2022.08.030,2022-09-15,2024-03-01,Unverified,cooper_prospective_2022,GBR
220902_London_ImperialCollegeLondon_overall,220902_London_ImperialCollegeLondon,Tracking the incidence and risk factors for SARS-CoV-2 infection using historical maternal booking serum samples.,2022-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,"London
","""we planned to analyse the results of 11,000 antenatal booking samples given at Imperial College Healthcare NHS Trust and Chelsea and Westminster NHS Founda- tion Trust from December 2019 to May 2020""

*actual sampling period was longer","""During the aliquoting process, a small number of pairs of samples was identified to have come from the same person; the second of such samples to be aliquoted was marked as a duplicate and excluded from the formal analysis. We gave an undertaking not to report on any cross-classification for which the observed count was under 25""",2019-10-22,2020-09-22,Residual sera,Female,Adults (18-64 years),18.0,44.0,Primary Estimate,,11291,0.062000000000000006,0.058,0.067,True,,,,True,Sequential,Hybrid DABA,Imperial College London,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9890000000000001,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Edward Mullins,Imperial College London,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273966,2022-09-21,2024-04-09,Verified,mullinsTrackingIncidenceRisk2022,GBR
220902_London_ImperialCollegeLondon_timepoint17,220902_London_ImperialCollegeLondon,Tracking the incidence and risk factors for SARS-CoV-2 infection using historical maternal booking serum samples.,2022-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,"London
","""we planned to analyse the results of 11,000 antenatal booking samples given at Imperial College Healthcare NHS Trust and Chelsea and Westminster NHS Founda- tion Trust from December 2019 to May 2020""

*actual sampling period was longer","""During the aliquoting process, a small number of pairs of samples was identified to have come from the same person; the second of such samples to be aliquoted was marked as a duplicate and excluded from the formal analysis. We gave an undertaking not to report on any cross-classification for which the observed count was under 25""",2020-06-03,2020-06-16,Residual sera,Female,Adults (18-64 years),18.0,44.0,Time frame,,499,0.1162,0.09,0.14800000000000002,,,,,,Sequential,Hybrid DABA,Imperial College London,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9890000000000001,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Edward Mullins,Imperial College London,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273966,2022-09-22,2024-04-09,Verified,mullinsTrackingIncidenceRisk2022,GBR
220902_London_ImperialCollegeLondon_timepoint10,220902_London_ImperialCollegeLondon,Tracking the incidence and risk factors for SARS-CoV-2 infection using historical maternal booking serum samples.,2022-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,"London
","""we planned to analyse the results of 11,000 antenatal booking samples given at Imperial College Healthcare NHS Trust and Chelsea and Westminster NHS Founda- tion Trust from December 2019 to May 2020""

*actual sampling period was longer","""During the aliquoting process, a small number of pairs of samples was identified to have come from the same person; the second of such samples to be aliquoted was marked as a duplicate and excluded from the formal analysis. We gave an undertaking not to report on any cross-classification for which the observed count was under 25""",2020-02-26,2020-03-10,Residual sera,Female,Adults (18-64 years),18.0,44.0,Time frame,,628,0.0111,0.005,0.023,,,,,,Sequential,Hybrid DABA,Imperial College London,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9890000000000001,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Edward Mullins,Imperial College London,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273966,2022-09-22,2024-04-09,Verified,mullinsTrackingIncidenceRisk2022,GBR
220902_London_ImperialCollegeLondon_35to44,220902_London_ImperialCollegeLondon,Tracking the incidence and risk factors for SARS-CoV-2 infection using historical maternal booking serum samples.,2022-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,"London
","""we planned to analyse the results of 11,000 antenatal booking samples given at Imperial College Healthcare NHS Trust and Chelsea and Westminster NHS Founda- tion Trust from December 2019 to May 2020""

*actual sampling period was longer","""During the aliquoting process, a small number of pairs of samples was identified to have come from the same person; the second of such samples to be aliquoted was marked as a duplicate and excluded from the formal analysis. We gave an undertaking not to report on any cross-classification for which the observed count was under 25""",2019-10-22,2020-09-22,Residual sera,Female,Adults (18-64 years),35.0,44.0,Age,35-44,4226,0.0516,0.045,0.059000000000000004,,,,,,Sequential,Hybrid DABA,Imperial College London,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9890000000000001,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Edward Mullins,Imperial College London,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273966,2022-09-21,2024-04-09,Verified,mullinsTrackingIncidenceRisk2022,GBR
220902_London_ImperialCollegeLondon_timepoint19,220902_London_ImperialCollegeLondon,Tracking the incidence and risk factors for SARS-CoV-2 infection using historical maternal booking serum samples.,2022-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,"London
","""we planned to analyse the results of 11,000 antenatal booking samples given at Imperial College Healthcare NHS Trust and Chelsea and Westminster NHS Founda- tion Trust from December 2019 to May 2020""

*actual sampling period was longer","""During the aliquoting process, a small number of pairs of samples was identified to have come from the same person; the second of such samples to be aliquoted was marked as a duplicate and excluded from the formal analysis. We gave an undertaking not to report on any cross-classification for which the observed count was under 25""",2020-07-01,2020-07-14,Residual sera,Female,Adults (18-64 years),18.0,44.0,Time frame,,254,0.1457,0.105,0.195,,,,,,Sequential,Hybrid DABA,Imperial College London,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9890000000000001,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Edward Mullins,Imperial College London,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273966,2022-09-22,2024-04-09,Verified,mullinsTrackingIncidenceRisk2022,GBR
220902_London_ImperialCollegeLondon_timepoint5,220902_London_ImperialCollegeLondon,Tracking the incidence and risk factors for SARS-CoV-2 infection using historical maternal booking serum samples.,2022-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,"London
","""we planned to analyse the results of 11,000 antenatal booking samples given at Imperial College Healthcare NHS Trust and Chelsea and Westminster NHS Founda- tion Trust from December 2019 to May 2020""

*actual sampling period was longer","""During the aliquoting process, a small number of pairs of samples was identified to have come from the same person; the second of such samples to be aliquoted was marked as a duplicate and excluded from the formal analysis. We gave an undertaking not to report on any cross-classification for which the observed count was under 25""",2019-12-17,2019-12-31,Residual sera,Female,Adults (18-64 years),18.0,44.0,Time frame,,554,0.009000000000000001,0.003,0.021,,,,,,Sequential,Hybrid DABA,Imperial College London,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9890000000000001,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Edward Mullins,Imperial College London,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273966,2022-09-22,2024-04-09,Verified,mullinsTrackingIncidenceRisk2022,GBR
220902_London_ImperialCollegeLondon_timepoint3,220902_London_ImperialCollegeLondon,Tracking the incidence and risk factors for SARS-CoV-2 infection using historical maternal booking serum samples.,2022-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,"London
","""we planned to analyse the results of 11,000 antenatal booking samples given at Imperial College Healthcare NHS Trust and Chelsea and Westminster NHS Founda- tion Trust from December 2019 to May 2020""

*actual sampling period was longer","""During the aliquoting process, a small number of pairs of samples was identified to have come from the same person; the second of such samples to be aliquoted was marked as a duplicate and excluded from the formal analysis. We gave an undertaking not to report on any cross-classification for which the observed count was under 25""",2019-11-19,2019-12-02,Residual sera,Female,Adults (18-64 years),18.0,44.0,Time frame,,546,0.011000000000000001,0.004,0.024,,,,,,Sequential,Hybrid DABA,Imperial College London,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9890000000000001,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Edward Mullins,Imperial College London,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273966,2022-09-22,2024-04-09,Verified,mullinsTrackingIncidenceRisk2022,GBR
220902_London_ImperialCollegeLondon_timepoint20,220902_London_ImperialCollegeLondon,Tracking the incidence and risk factors for SARS-CoV-2 infection using historical maternal booking serum samples.,2022-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,"London
","""we planned to analyse the results of 11,000 antenatal booking samples given at Imperial College Healthcare NHS Trust and Chelsea and Westminster NHS Founda- tion Trust from December 2019 to May 2020""

*actual sampling period was longer","""During the aliquoting process, a small number of pairs of samples was identified to have come from the same person; the second of such samples to be aliquoted was marked as a duplicate and excluded from the formal analysis. We gave an undertaking not to report on any cross-classification for which the observed count was under 25""",2020-07-15,2020-07-28,Residual sera,Female,Adults (18-64 years),18.0,44.0,Time frame,,288,0.12150000000000001,0.086,0.165,,,,,,Sequential,Hybrid DABA,Imperial College London,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9890000000000001,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Edward Mullins,Imperial College London,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273966,2022-09-22,2024-04-09,Verified,mullinsTrackingIncidenceRisk2022,GBR
220902_London_ImperialCollegeLondon_timepoint15,220902_London_ImperialCollegeLondon,Tracking the incidence and risk factors for SARS-CoV-2 infection using historical maternal booking serum samples.,2022-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,"London
","""we planned to analyse the results of 11,000 antenatal booking samples given at Imperial College Healthcare NHS Trust and Chelsea and Westminster NHS Founda- tion Trust from December 2019 to May 2020""

*actual sampling period was longer","""During the aliquoting process, a small number of pairs of samples was identified to have come from the same person; the second of such samples to be aliquoted was marked as a duplicate and excluded from the formal analysis. We gave an undertaking not to report on any cross-classification for which the observed count was under 25""",2020-05-06,2020-05-19,Residual sera,Female,Adults (18-64 years),18.0,44.0,Time frame,,584,0.1421,0.115,0.17300000000000001,,,,,,Sequential,Hybrid DABA,Imperial College London,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9890000000000001,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Edward Mullins,Imperial College London,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273966,2022-09-22,2024-04-09,Verified,mullinsTrackingIncidenceRisk2022,GBR
220902_London_ImperialCollegeLondon_timepoint6,220902_London_ImperialCollegeLondon,Tracking the incidence and risk factors for SARS-CoV-2 infection using historical maternal booking serum samples.,2022-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,"London
","""we planned to analyse the results of 11,000 antenatal booking samples given at Imperial College Healthcare NHS Trust and Chelsea and Westminster NHS Founda- tion Trust from December 2019 to May 2020""

*actual sampling period was longer","""During the aliquoting process, a small number of pairs of samples was identified to have come from the same person; the second of such samples to be aliquoted was marked as a duplicate and excluded from the formal analysis. We gave an undertaking not to report on any cross-classification for which the observed count was under 25""",2020-01-01,2020-01-14,Residual sera,Female,Adults (18-64 years),18.0,44.0,Time frame,,467,0.010700000000000001,0.004,0.025,,,,,,Sequential,Hybrid DABA,Imperial College London,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9890000000000001,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Edward Mullins,Imperial College London,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273966,2022-09-22,2024-04-09,Verified,mullinsTrackingIncidenceRisk2022,GBR
220902_London_ImperialCollegeLondon_timepoint16,220902_London_ImperialCollegeLondon,Tracking the incidence and risk factors for SARS-CoV-2 infection using historical maternal booking serum samples.,2022-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,"London
","""we planned to analyse the results of 11,000 antenatal booking samples given at Imperial College Healthcare NHS Trust and Chelsea and Westminster NHS Founda- tion Trust from December 2019 to May 2020""

*actual sampling period was longer","""During the aliquoting process, a small number of pairs of samples was identified to have come from the same person; the second of such samples to be aliquoted was marked as a duplicate and excluded from the formal analysis. We gave an undertaking not to report on any cross-classification for which the observed count was under 25""",2020-05-20,2020-06-02,Residual sera,Female,Adults (18-64 years),18.0,44.0,Time frame,,482,0.11,0.084,0.141,,,,,,Sequential,Hybrid DABA,Imperial College London,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9890000000000001,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Edward Mullins,Imperial College London,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273966,2022-09-22,2024-04-09,Verified,mullinsTrackingIncidenceRisk2022,GBR
220902_London_ImperialCollegeLondon_timepoint24,220902_London_ImperialCollegeLondon,Tracking the incidence and risk factors for SARS-CoV-2 infection using historical maternal booking serum samples.,2022-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,"London
","""we planned to analyse the results of 11,000 antenatal booking samples given at Imperial College Healthcare NHS Trust and Chelsea and Westminster NHS Founda- tion Trust from December 2019 to May 2020""

*actual sampling period was longer","""During the aliquoting process, a small number of pairs of samples was identified to have come from the same person; the second of such samples to be aliquoted was marked as a duplicate and excluded from the formal analysis. We gave an undertaking not to report on any cross-classification for which the observed count was under 25""",2020-09-09,2020-09-22,Residual sera,Female,Adults (18-64 years),18.0,44.0,Time frame,,165,0.2,0.142,0.269,,,,,,Sequential,Hybrid DABA,Imperial College London,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9890000000000001,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Edward Mullins,Imperial College London,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273966,2022-09-22,2024-04-09,Verified,mullinsTrackingIncidenceRisk2022,GBR
220902_London_ImperialCollegeLondon_timepoint21,220902_London_ImperialCollegeLondon,Tracking the incidence and risk factors for SARS-CoV-2 infection using historical maternal booking serum samples.,2022-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,"London
","""we planned to analyse the results of 11,000 antenatal booking samples given at Imperial College Healthcare NHS Trust and Chelsea and Westminster NHS Founda- tion Trust from December 2019 to May 2020""

*actual sampling period was longer","""During the aliquoting process, a small number of pairs of samples was identified to have come from the same person; the second of such samples to be aliquoted was marked as a duplicate and excluded from the formal analysis. We gave an undertaking not to report on any cross-classification for which the observed count was under 25""",2020-07-29,2020-08-11,Residual sera,Female,Adults (18-64 years),18.0,44.0,Time frame,,267,0.14980000000000002,0.109,0.198,,,,,,Sequential,Hybrid DABA,Imperial College London,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9890000000000001,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Edward Mullins,Imperial College London,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273966,2022-09-22,2024-04-09,Verified,mullinsTrackingIncidenceRisk2022,GBR
220902_London_ImperialCollegeLondon_timepoint23,220902_London_ImperialCollegeLondon,Tracking the incidence and risk factors for SARS-CoV-2 infection using historical maternal booking serum samples.,2022-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,"London
","""we planned to analyse the results of 11,000 antenatal booking samples given at Imperial College Healthcare NHS Trust and Chelsea and Westminster NHS Founda- tion Trust from December 2019 to May 2020""

*actual sampling period was longer","""During the aliquoting process, a small number of pairs of samples was identified to have come from the same person; the second of such samples to be aliquoted was marked as a duplicate and excluded from the formal analysis. We gave an undertaking not to report on any cross-classification for which the observed count was under 25""",2020-08-26,2020-09-08,Residual sera,Female,Adults (18-64 years),18.0,44.0,Time frame,,233,0.1502,0.107,0.203,,,,,,Sequential,Hybrid DABA,Imperial College London,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9890000000000001,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Edward Mullins,Imperial College London,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273966,2022-09-22,2024-04-09,Verified,mullinsTrackingIncidenceRisk2022,GBR
220902_London_ImperialCollegeLondon_18to29,220902_London_ImperialCollegeLondon,Tracking the incidence and risk factors for SARS-CoV-2 infection using historical maternal booking serum samples.,2022-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,"London
","""we planned to analyse the results of 11,000 antenatal booking samples given at Imperial College Healthcare NHS Trust and Chelsea and Westminster NHS Founda- tion Trust from December 2019 to May 2020""

*actual sampling period was longer","""During the aliquoting process, a small number of pairs of samples was identified to have come from the same person; the second of such samples to be aliquoted was marked as a duplicate and excluded from the formal analysis. We gave an undertaking not to report on any cross-classification for which the observed count was under 25""",2019-10-22,2020-09-22,Residual sera,Female,Adults (18-64 years),18.0,29.0,Age,18-29,2930,0.0771,0.068,0.087,,,,,,Sequential,Hybrid DABA,Imperial College London,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9890000000000001,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Edward Mullins,Imperial College London,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273966,2022-09-21,2024-04-09,Verified,mullinsTrackingIncidenceRisk2022,GBR
220902_London_ImperialCollegeLondon_timepoint18,220902_London_ImperialCollegeLondon,Tracking the incidence and risk factors for SARS-CoV-2 infection using historical maternal booking serum samples.,2022-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,"London
","""we planned to analyse the results of 11,000 antenatal booking samples given at Imperial College Healthcare NHS Trust and Chelsea and Westminster NHS Founda- tion Trust from December 2019 to May 2020""

*actual sampling period was longer","""During the aliquoting process, a small number of pairs of samples was identified to have come from the same person; the second of such samples to be aliquoted was marked as a duplicate and excluded from the formal analysis. We gave an undertaking not to report on any cross-classification for which the observed count was under 25""",2020-06-17,2020-06-30,Residual sera,Female,Adults (18-64 years),18.0,44.0,Time frame,,278,0.13670000000000002,0.099,0.18300000000000002,,,,,,Sequential,Hybrid DABA,Imperial College London,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9890000000000001,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Edward Mullins,Imperial College London,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273966,2022-09-22,2024-04-09,Verified,mullinsTrackingIncidenceRisk2022,GBR
220902_London_ImperialCollegeLondon_timepoint7,220902_London_ImperialCollegeLondon,Tracking the incidence and risk factors for SARS-CoV-2 infection using historical maternal booking serum samples.,2022-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,"London
","""we planned to analyse the results of 11,000 antenatal booking samples given at Imperial College Healthcare NHS Trust and Chelsea and Westminster NHS Founda- tion Trust from December 2019 to May 2020""

*actual sampling period was longer","""During the aliquoting process, a small number of pairs of samples was identified to have come from the same person; the second of such samples to be aliquoted was marked as a duplicate and excluded from the formal analysis. We gave an undertaking not to report on any cross-classification for which the observed count was under 25""",2020-01-15,2020-01-28,Residual sera,Female,Adults (18-64 years),18.0,44.0,Time frame,,572,0.0105,0.004,0.023,,,,,,Sequential,Hybrid DABA,Imperial College London,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9890000000000001,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Edward Mullins,Imperial College London,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273966,2022-09-22,2024-04-09,Verified,mullinsTrackingIncidenceRisk2022,GBR
220902_London_ImperialCollegeLondon_timepoint11,220902_London_ImperialCollegeLondon,Tracking the incidence and risk factors for SARS-CoV-2 infection using historical maternal booking serum samples.,2022-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,"London
","""we planned to analyse the results of 11,000 antenatal booking samples given at Imperial College Healthcare NHS Trust and Chelsea and Westminster NHS Founda- tion Trust from December 2019 to May 2020""

*actual sampling period was longer","""During the aliquoting process, a small number of pairs of samples was identified to have come from the same person; the second of such samples to be aliquoted was marked as a duplicate and excluded from the formal analysis. We gave an undertaking not to report on any cross-classification for which the observed count was under 25""",2020-03-11,2020-03-24,Residual sera,Female,Adults (18-64 years),18.0,44.0,Time frame,,659,0.0273,0.016,0.043,,,,,,Sequential,Hybrid DABA,Imperial College London,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9890000000000001,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Edward Mullins,Imperial College London,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273966,2022-09-22,2024-04-09,Verified,mullinsTrackingIncidenceRisk2022,GBR
220902_London_ImperialCollegeLondon_timepoint14,220902_London_ImperialCollegeLondon,Tracking the incidence and risk factors for SARS-CoV-2 infection using historical maternal booking serum samples.,2022-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,"London
","""we planned to analyse the results of 11,000 antenatal booking samples given at Imperial College Healthcare NHS Trust and Chelsea and Westminster NHS Founda- tion Trust from December 2019 to May 2020""

*actual sampling period was longer","""During the aliquoting process, a small number of pairs of samples was identified to have come from the same person; the second of such samples to be aliquoted was marked as a duplicate and excluded from the formal analysis. We gave an undertaking not to report on any cross-classification for which the observed count was under 25""",2020-04-22,2020-05-05,Residual sera,Female,Adults (18-64 years),18.0,44.0,Time frame,,637,0.12090000000000001,0.09699999999999999,0.149,,,,,,Sequential,Hybrid DABA,Imperial College London,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9890000000000001,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Edward Mullins,Imperial College London,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273966,2022-09-22,2024-04-09,Verified,mullinsTrackingIncidenceRisk2022,GBR
220902_London_ImperialCollegeLondon_timepoint4,220902_London_ImperialCollegeLondon,Tracking the incidence and risk factors for SARS-CoV-2 infection using historical maternal booking serum samples.,2022-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,"London
","""we planned to analyse the results of 11,000 antenatal booking samples given at Imperial College Healthcare NHS Trust and Chelsea and Westminster NHS Founda- tion Trust from December 2019 to May 2020""

*actual sampling period was longer","""During the aliquoting process, a small number of pairs of samples was identified to have come from the same person; the second of such samples to be aliquoted was marked as a duplicate and excluded from the formal analysis. We gave an undertaking not to report on any cross-classification for which the observed count was under 25""",2019-12-03,2019-12-16,Residual sera,Female,Adults (18-64 years),18.0,44.0,Time frame,,514,0.0058,0.001,0.017,,,,,,Sequential,Hybrid DABA,Imperial College London,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9890000000000001,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Edward Mullins,Imperial College London,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273966,2022-09-22,2024-04-09,Verified,mullinsTrackingIncidenceRisk2022,GBR
220902_London_ImperialCollegeLondon_30to34,220902_London_ImperialCollegeLondon,Tracking the incidence and risk factors for SARS-CoV-2 infection using historical maternal booking serum samples.,2022-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,"London
","""we planned to analyse the results of 11,000 antenatal booking samples given at Imperial College Healthcare NHS Trust and Chelsea and Westminster NHS Founda- tion Trust from December 2019 to May 2020""

*actual sampling period was longer","""During the aliquoting process, a small number of pairs of samples was identified to have come from the same person; the second of such samples to be aliquoted was marked as a duplicate and excluded from the formal analysis. We gave an undertaking not to report on any cross-classification for which the observed count was under 25""",2019-10-22,2020-09-22,Residual sera,Female,Adults (18-64 years),30.0,34.0,Age,30-34,4135,0.061900000000000004,0.055,0.07,,,,,,Sequential,Hybrid DABA,Imperial College London,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9890000000000001,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Edward Mullins,Imperial College London,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273966,2022-09-21,2024-04-09,Verified,mullinsTrackingIncidenceRisk2022,GBR
220902_London_ImperialCollegeLondon_timepoint1,220902_London_ImperialCollegeLondon,Tracking the incidence and risk factors for SARS-CoV-2 infection using historical maternal booking serum samples.,2022-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,"London
","""we planned to analyse the results of 11,000 antenatal booking samples given at Imperial College Healthcare NHS Trust and Chelsea and Westminster NHS Founda- tion Trust from December 2019 to May 2020""

*actual sampling period was longer","""During the aliquoting process, a small number of pairs of samples was identified to have come from the same person; the second of such samples to be aliquoted was marked as a duplicate and excluded from the formal analysis. We gave an undertaking not to report on any cross-classification for which the observed count was under 25""",2019-10-22,2019-11-04,Residual sera,Female,Adults (18-64 years),18.0,44.0,Time frame,,608,0.013200000000000002,0.006,0.026000000000000002,,,,,,Sequential,Hybrid DABA,Imperial College London,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9890000000000001,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Edward Mullins,Imperial College London,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273966,2022-09-22,2024-04-09,Verified,mullinsTrackingIncidenceRisk2022,GBR
220902_London_ImperialCollegeLondon_timepoint8,220902_London_ImperialCollegeLondon,Tracking the incidence and risk factors for SARS-CoV-2 infection using historical maternal booking serum samples.,2022-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,"London
","""we planned to analyse the results of 11,000 antenatal booking samples given at Imperial College Healthcare NHS Trust and Chelsea and Westminster NHS Founda- tion Trust from December 2019 to May 2020""

*actual sampling period was longer","""During the aliquoting process, a small number of pairs of samples was identified to have come from the same person; the second of such samples to be aliquoted was marked as a duplicate and excluded from the formal analysis. We gave an undertaking not to report on any cross-classification for which the observed count was under 25""",2020-01-29,2020-02-11,Residual sera,Female,Adults (18-64 years),18.0,44.0,Time frame,,669,0.0105,0.004,0.021,,,,,,Sequential,Hybrid DABA,Imperial College London,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9890000000000001,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Edward Mullins,Imperial College London,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273966,2022-09-22,2024-04-09,Verified,mullinsTrackingIncidenceRisk2022,GBR
220902_London_ImperialCollegeLondon_timepoint2,220902_London_ImperialCollegeLondon,Tracking the incidence and risk factors for SARS-CoV-2 infection using historical maternal booking serum samples.,2022-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,"London
","""we planned to analyse the results of 11,000 antenatal booking samples given at Imperial College Healthcare NHS Trust and Chelsea and Westminster NHS Founda- tion Trust from December 2019 to May 2020""

*actual sampling period was longer","""During the aliquoting process, a small number of pairs of samples was identified to have come from the same person; the second of such samples to be aliquoted was marked as a duplicate and excluded from the formal analysis. We gave an undertaking not to report on any cross-classification for which the observed count was under 25""",2019-11-05,2019-11-18,Residual sera,Female,Adults (18-64 years),18.0,44.0,Time frame,,610,0.008199999999999999,0.003,0.019,,,,,,Sequential,Hybrid DABA,Imperial College London,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9890000000000001,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Edward Mullins,Imperial College London,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273966,2022-09-22,2024-04-09,Verified,mullinsTrackingIncidenceRisk2022,GBR
220902_London_ImperialCollegeLondon_timepoint22,220902_London_ImperialCollegeLondon,Tracking the incidence and risk factors for SARS-CoV-2 infection using historical maternal booking serum samples.,2022-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,"London
","""we planned to analyse the results of 11,000 antenatal booking samples given at Imperial College Healthcare NHS Trust and Chelsea and Westminster NHS Founda- tion Trust from December 2019 to May 2020""

*actual sampling period was longer","""During the aliquoting process, a small number of pairs of samples was identified to have come from the same person; the second of such samples to be aliquoted was marked as a duplicate and excluded from the formal analysis. We gave an undertaking not to report on any cross-classification for which the observed count was under 25""",2020-08-12,2020-08-25,Residual sera,Female,Adults (18-64 years),18.0,44.0,Time frame,,198,0.12630000000000002,0.083,0.18100000000000002,,,,,,Sequential,Hybrid DABA,Imperial College London,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9890000000000001,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Edward Mullins,Imperial College London,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273966,2022-09-22,2024-04-09,Verified,mullinsTrackingIncidenceRisk2022,GBR
220902_London_ImperialCollegeLondon_timepoint13,220902_London_ImperialCollegeLondon,Tracking the incidence and risk factors for SARS-CoV-2 infection using historical maternal booking serum samples.,2022-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,"London
","""we planned to analyse the results of 11,000 antenatal booking samples given at Imperial College Healthcare NHS Trust and Chelsea and Westminster NHS Founda- tion Trust from December 2019 to May 2020""

*actual sampling period was longer","""During the aliquoting process, a small number of pairs of samples was identified to have come from the same person; the second of such samples to be aliquoted was marked as a duplicate and excluded from the formal analysis. We gave an undertaking not to report on any cross-classification for which the observed count was under 25""",2020-04-08,2020-04-21,Residual sera,Female,Adults (18-64 years),18.0,44.0,Time frame,,622,0.1174,0.09300000000000001,0.145,,,,,,Sequential,Hybrid DABA,Imperial College London,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9890000000000001,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Edward Mullins,Imperial College London,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273966,2022-09-22,2024-04-09,Verified,mullinsTrackingIncidenceRisk2022,GBR
220902_London_ImperialCollegeLondon_timepoint9,220902_London_ImperialCollegeLondon,Tracking the incidence and risk factors for SARS-CoV-2 infection using historical maternal booking serum samples.,2022-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,"London
","""we planned to analyse the results of 11,000 antenatal booking samples given at Imperial College Healthcare NHS Trust and Chelsea and Westminster NHS Founda- tion Trust from December 2019 to May 2020""

*actual sampling period was longer","""During the aliquoting process, a small number of pairs of samples was identified to have come from the same person; the second of such samples to be aliquoted was marked as a duplicate and excluded from the formal analysis. We gave an undertaking not to report on any cross-classification for which the observed count was under 25""",2020-02-12,2020-02-25,Residual sera,Female,Adults (18-64 years),18.0,44.0,Time frame,,530,0.017,0.008,0.032,,,,,,Sequential,Hybrid DABA,Imperial College London,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9890000000000001,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Edward Mullins,Imperial College London,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273966,2022-09-22,2024-04-09,Verified,mullinsTrackingIncidenceRisk2022,GBR
220902_London_ImperialCollegeLondon_timepoint12,220902_London_ImperialCollegeLondon,Tracking the incidence and risk factors for SARS-CoV-2 infection using historical maternal booking serum samples.,2022-09-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,"London
","""we planned to analyse the results of 11,000 antenatal booking samples given at Imperial College Healthcare NHS Trust and Chelsea and Westminster NHS Founda- tion Trust from December 2019 to May 2020""

*actual sampling period was longer","""During the aliquoting process, a small number of pairs of samples was identified to have come from the same person; the second of such samples to be aliquoted was marked as a duplicate and excluded from the formal analysis. We gave an undertaking not to report on any cross-classification for which the observed count was under 25""",2020-03-25,2020-04-07,Residual sera,Female,Adults (18-64 years),18.0,44.0,Time frame,,392,0.0867,0.061,0.11900000000000001,,,,,,Sequential,Hybrid DABA,Imperial College London,ELISA,Serum,TotalAntibody,,Validated by independent authors/third party/non-developers,0.9890000000000001,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,,Edward Mullins,Imperial College London,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273966,2022-09-22,2024-04-09,Verified,mullinsTrackingIncidenceRisk2022,GBR
220927_Birmingham_UniversityofBirmingham,220927_Birmingham_UniversityofBirmingham,Vitamin D status: a U-shaped relationship for SARS-CoV-2 seropositivity in UK healthcare workers.,2022-09-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,Birmingham,""" The inclusion criteria of
this cohort studied were staff members who had symptoms suggestive of COVID-19.""",,2020-05-12,2020-05-22,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,379,0.549,,,True,,,,True,Convenience,Human Anti-IgG/A/M SARS-CoV-2 ELISA,The Binding Site,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Sebastian Lugg,University of Birmingham,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjresp-2022-001258,2022-10-10,2022-10-10,Unverified,lugg_vitamin_2022,GBR
220927_Birmingham_UniversityofBirmingham_Age_>=50,220927_Birmingham_UniversityofBirmingham,Vitamin D status: a U-shaped relationship for SARS-CoV-2 seropositivity in UK healthcare workers.,2022-09-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,Birmingham,""" The inclusion criteria of
this cohort studied were staff members who had symptoms suggestive of COVID-19.""",,2020-05-12,2020-05-22,Health care workers and caregivers,All,Adults (18-64 years),50.0,,Age,>=50,105,0.535,,,,,,,,Convenience,Human Anti-IgG/A/M SARS-CoV-2 ELISA,The Binding Site,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Sebastian Lugg,University of Birmingham,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjresp-2022-001258,2022-10-10,2022-10-10,Unverified,lugg_vitamin_2022,GBR
220927_Birmingham_UniversityofBirmingham_Age_<50,220927_Birmingham_UniversityofBirmingham,Vitamin D status: a U-shaped relationship for SARS-CoV-2 seropositivity in UK healthcare workers.,2022-09-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,Birmingham,""" The inclusion criteria of
this cohort studied were staff members who had symptoms suggestive of COVID-19.""",,2020-05-12,2020-05-22,Health care workers and caregivers,All,Adults (18-64 years),,49.0,Age,<50,274,0.555,,,,,,,,Convenience,Human Anti-IgG/A/M SARS-CoV-2 ELISA,The Binding Site,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Sebastian Lugg,University of Birmingham,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjresp-2022-001258,2022-10-10,2022-10-10,Unverified,lugg_vitamin_2022,GBR
221012_UnitedKingdom_KingsCollege,221012_UnitedKingdom_KingsCollege,Trends in SARS-CoV-2 Infection and Vaccine Antibody Prevalence in a Multi-Ethnic Inner-City Antenatal Population: a Cohort Study,2022-10-12,Preprint,Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,,""" 960 pregnant women attending nuchal scans from July 2020-January 2022. """,,2020-07-15,2022-01-15,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,960,0.204,,,True,,,,True,Sequential,Not reported/ Unable to specify,,,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Daria Andreeva,King's College London,Not Unity-Aligned,10.22541/au.166560306.61695696/v1,2022-10-18,2022-10-20,Unverified,andreevaTrendsSARSCoV2Infection2022,GBR
221101_England_UniversityofCambridge,221101_England_UniversityofCambridge,"Demographic, behavioural and occupational risk factors associated with SARS-CoV-2 infection in UK healthcare workers: a retrospective observational study.",2022-11-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,Cambridge,Staff from Cambridge University Hospitals NHS Foundation Trust were invited to participate,,2020-06-10,2020-08-07,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,2044,0.109,,,True,,,,True,Convenience,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.981,0.9990000000000001,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Daniel James Cooper,University of Cambridge ,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2022-063159,2022-11-16,2024-03-01,Unverified,cooperDemographicBehaviouralOccupational2022,GBR
221117_London_GuysAndStThomasNHSFoundationTrust_Overall,221117_London_GuysAndStThomasNHSFoundationTrust,SARS-CoV-2 antibody seroprevalence in a London HIV clinic cohort,2022-11-17,Journal Article (Peer-Reviewed),Local,Retrospective cohort,United Kingdom of Great Britain and Northern Ireland,England,London,"""Patients attending our HIV clinic were able to opt-in for SARS-CoV-2 antibody testing during their routine monitoring visit for blood tests.""

""We collected data of people living with HIV who opted-in for SARS-CoV-2 antibody test from 1 May 2020 to 31 December 2020.""",,2020-05-01,2020-12-31,Residual sera,All,Multiple groups,,,Primary Estimate,,2567,0.106,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,Serum,,,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Venkateshwaran Sivaraj,Guy’s and St Thomas’ NHS Foundation Trust,Not Unity-Aligned,https://dx.doi.org/10.1136/sextrans-2021-055306,2022-12-09,2023-03-19,Unverified,sivaraj_sars-cov-2_2022,GBR
221117_London_GuysAndStThomasNHSFoundationTrust_Dec,221117_London_GuysAndStThomasNHSFoundationTrust,SARS-CoV-2 antibody seroprevalence in a London HIV clinic cohort,2022-11-17,Journal Article (Peer-Reviewed),Local,Retrospective cohort,United Kingdom of Great Britain and Northern Ireland,England,London,"""Patients attending our HIV clinic were able to opt-in for SARS-CoV-2 antibody testing during their routine monitoring visit for blood tests.""

""We collected data of people living with HIV who opted-in for SARS-CoV-2 antibody test from 1 May 2020 to 31 December 2020.""",,2020-12-01,2020-12-31,Residual sera,All,Multiple groups,,,Time frame,December 2020,154,0.214,,,,,,,,Convenience,Not reported/ Unable to specify,,,Serum,,,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Venkateshwaran Sivaraj,Guy’s and St Thomas’ NHS Foundation Trust,Not Unity-Aligned,https://dx.doi.org/10.1136/sextrans-2021-055306,2022-12-09,2023-03-19,Unverified,sivaraj_sars-cov-2_2022,GBR
221117_London_GuysAndStThomasNHSFoundationTrust_Sep,221117_London_GuysAndStThomasNHSFoundationTrust,SARS-CoV-2 antibody seroprevalence in a London HIV clinic cohort,2022-11-17,Journal Article (Peer-Reviewed),Local,Retrospective cohort,United Kingdom of Great Britain and Northern Ireland,England,London,"""Patients attending our HIV clinic were able to opt-in for SARS-CoV-2 antibody testing during their routine monitoring visit for blood tests.""

""We collected data of people living with HIV who opted-in for SARS-CoV-2 antibody test from 1 May 2020 to 31 December 2020.""",,2020-09-01,2020-09-30,Residual sera,All,Multiple groups,,,Time frame,September 2020,759,0.092,,,,,,,,Convenience,Not reported/ Unable to specify,,,Serum,,,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Venkateshwaran Sivaraj,Guy’s and St Thomas’ NHS Foundation Trust,Not Unity-Aligned,https://dx.doi.org/10.1136/sextrans-2021-055306,2022-12-09,2023-03-19,Unverified,sivaraj_sars-cov-2_2022,GBR
221117_London_GuysAndStThomasNHSFoundationTrust_Aug,221117_London_GuysAndStThomasNHSFoundationTrust,SARS-CoV-2 antibody seroprevalence in a London HIV clinic cohort,2022-11-17,Journal Article (Peer-Reviewed),Local,Retrospective cohort,United Kingdom of Great Britain and Northern Ireland,England,London,"""Patients attending our HIV clinic were able to opt-in for SARS-CoV-2 antibody testing during their routine monitoring visit for blood tests.""

""We collected data of people living with HIV who opted-in for SARS-CoV-2 antibody test from 1 May 2020 to 31 December 2020.""",,2020-08-01,2020-08-31,Residual sera,All,Multiple groups,,,Time frame,August 2020,459,0.1,,,,,,,,Convenience,Not reported/ Unable to specify,,,Serum,,,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Venkateshwaran Sivaraj,Guy’s and St Thomas’ NHS Foundation Trust,Not Unity-Aligned,https://dx.doi.org/10.1136/sextrans-2021-055306,2022-12-09,2023-03-19,Unverified,sivaraj_sars-cov-2_2022,GBR
221117_London_GuysAndStThomasNHSFoundationTrust_Oct,221117_London_GuysAndStThomasNHSFoundationTrust,SARS-CoV-2 antibody seroprevalence in a London HIV clinic cohort,2022-11-17,Journal Article (Peer-Reviewed),Local,Retrospective cohort,United Kingdom of Great Britain and Northern Ireland,England,London,"""Patients attending our HIV clinic were able to opt-in for SARS-CoV-2 antibody testing during their routine monitoring visit for blood tests.""

""We collected data of people living with HIV who opted-in for SARS-CoV-2 antibody test from 1 May 2020 to 31 December 2020.""",,2020-10-01,2020-10-31,Residual sera,All,Multiple groups,,,Time frame,October 2020,766,0.086,,,,,,,,Convenience,Not reported/ Unable to specify,,,Serum,,,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Venkateshwaran Sivaraj,Guy’s and St Thomas’ NHS Foundation Trust,Not Unity-Aligned,https://dx.doi.org/10.1136/sextrans-2021-055306,2022-12-09,2023-03-19,Unverified,sivaraj_sars-cov-2_2022,GBR
221117_London_GuysAndStThomasNHSFoundationTrust_Nov,221117_London_GuysAndStThomasNHSFoundationTrust,SARS-CoV-2 antibody seroprevalence in a London HIV clinic cohort,2022-11-17,Journal Article (Peer-Reviewed),Local,Retrospective cohort,United Kingdom of Great Britain and Northern Ireland,England,London,"""Patients attending our HIV clinic were able to opt-in for SARS-CoV-2 antibody testing during their routine monitoring visit for blood tests.""

""We collected data of people living with HIV who opted-in for SARS-CoV-2 antibody test from 1 May 2020 to 31 December 2020.""",,2020-11-01,2020-11-30,Residual sera,All,Multiple groups,,,Time frame,November 2020,509,0.11,,,,,,,,Convenience,Not reported/ Unable to specify,,,Serum,,,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Venkateshwaran Sivaraj,Guy’s and St Thomas’ NHS Foundation Trust,Not Unity-Aligned,https://dx.doi.org/10.1136/sextrans-2021-055306,2022-12-09,2023-03-19,Unverified,sivaraj_sars-cov-2_2022,GBR
230214_England_UKHealthSecurityAgency_PrimaryStudents_TestPopAdj_Overall,230214_England_UKHealthSecurityAgency_PrimaryStudents,"National and regional prevalence of SARS-CoV-2 antibodies in primary and secondary school children in England: the School Infection Survey, a national open cohort study, November 2021.",2023-02-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,Children (4-11-year-olds) from state-funded primary schools.,"""Independent schools, special education schools, pupil referral units, further education colleges and home-schooled children were excluded.""

""Those with inconclusive or no results (e.g. missing or poor sample quality) were excluded.""",2021-11-10,2021-12-10,Students and Daycares,All,Children and Youth (0-17 years),4.0,11.0,Primary Estimate,"Adjusted for test accuracy; Weighted for age, sex, ethnicity and sampling design; Anti-S or Anti-N",2706,0.401,0.373,0.43,True,True,True,True,,Stratified probability,Author designed (type unknown),,Other,Saliva,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Annabel Powell,UK Health Security Agency,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2023.02.016,2022-07-24,2023-03-09,Unverified,powell_national_2023,GBR
230214_England_UKHealthSecurityAgency_SecondaryStudents_TestPopAdj_Overall,230214_England_UKHealthSecurityAgency_SecondaryStudents,"National and regional prevalence of SARS-CoV-2 antibodies in primary and secondary school children in England: the School Infection Survey, a national open cohort study, November 2021.",2023-02-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,,Children (11-17-year-olds) from state-funded secondary schools.,"""Independent schools, special education schools, pupil referral units, further education colleges and home-schooled children were excluded.""

""Those with inconclusive or no results (e.g. missing or poor sample quality) were excluded.""",2021-11-10,2021-12-10,Students and Daycares,All,Children and Youth (0-17 years),11.0,17.0,Primary Estimate,"Adjusted for test accuracy; Weighted for age, sex, ethnicity and sampling design; Anti-S or Anti-N",2274,0.8240000000000001,0.795,0.851,True,True,True,True,,Stratified probability,Author designed (type unknown),,Other,Saliva,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Annabel Powell,UK Health Security Agency,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2023.02.016,2022-07-24,2023-03-09,Unverified,powell_national_2023,GBR
230301_England_UKHealthSecurityAgency_Round1_Staff_AntiN_Overall,230301_England_UKHealthSecurityAgency_Round1_Staff,"Antibody Persistence After Primary SARS-CoV-2 Infection and Protection Against Future Variants Including Omicron in Adolescents: National, Prospective Cohort Study",2023-03-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,"West London, East London, Hertfordshire, Derbyshire, Greater Manchester, Birmingham","""Through the sKIDsPLUS serosurveillance in secondary schools, we identified students and staff who had been infected with WT during the first wave of the pandemic and had measurable SARS-CoV-2 antibodies when they returned to school in September 2020.""

""Briefly, secondary schools in West London, East London, Hertfordshire, Derbyshire, Greater Manchester and Birmingham, where our pediatric investigation teams were assembled, were approached to participate in sKIDsPLUS.""

From study's protocol (https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/920906/sKIDsPLUS_protocol_v1_Aug20.pdf):
- Staff members and 16-18 year-old students in invited school and college years who provide online consent and complete an online questionnaire
- Students in invited school years whose parents/ guardians provide an online consent and complete an online questionnaire","From study's protocol (https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/920906/sKIDsPLUS_protocol_v1_Aug20.pdf):

- Staff members and students whose parents/guardians do not provide online consent.
- Students 16 years and over who do not provide online consent",2020-09-22,2020-10-17,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,Anti-N at baseline,861,0.0918,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,"CLIA, CMIA",Serum,IgG,Nucleocapsid (N-protein),,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Felicity Aiano,UK Health Security Agency,Not Unity-Aligned,https://dx.doi.org/10.1097/INF.0000000000003890,2023-04-12,2024-03-01,Unverified,aiano_antibody_2023,GBR
230301_England_UKHealthSecurityAgency_Round1_Students_AntiN_Overall,230301_England_UKHealthSecurityAgency_Round1_Students,"Antibody Persistence After Primary SARS-CoV-2 Infection and Protection Against Future Variants Including Omicron in Adolescents: National, Prospective Cohort Study",2023-03-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,England,"West London, East London, Hertfordshire, Derbyshire, Greater Manchester, Birmingham","""Through the sKIDsPLUS serosurveillance in secondary schools, we identified students and staff who had been infected with WT during the first wave of the pandemic and had measurable SARS-CoV-2 antibodies when they returned to school in September 2020.""

""Briefly, secondary schools in West London, East London, Hertfordshire, Derbyshire, Greater Manchester and Birmingham, where our pediatric investigation teams were assembled, were approached to participate in sKIDsPLUS.""

From study's protocol (https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/920906/sKIDsPLUS_protocol_v1_Aug20.pdf):
- Staff members and 16-18 year-old students in invited school and college years who provide online consent and complete an online questionnaire
- Students in invited school years whose parents/ guardians provide an online consent and complete an online questionnaire","From study's protocol (https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/920906/sKIDsPLUS_protocol_v1_Aug20.pdf):

- Staff members and students whose parents/guardians do not provide online consent.
- Students 16 years and over who do not provide online consent",2020-09-22,2020-10-17,Students and Daycares,All,Children and Youth (0-17 years),,,Primary Estimate,Anti-N at baseline,893,0.1277,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,"CLIA, CMIA",Serum,IgG,Nucleocapsid (N-protein),,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Felicity Aiano,UK Health Security Agency,Not Unity-Aligned,https://dx.doi.org/10.1097/INF.0000000000003890,2023-04-12,2024-03-01,Unverified,aiano_antibody_2023,GBR
230420_NottinghamAndGlasgow_NottinghamUniversityHospitalsNHSTrust,230420_NottinghamAndGlasgow_NottinghamUniversityHospitalsNHSTrust,Low seroprevalence of COVID-19 in UK children on renal replacement therapy - results from the ISpy COVID study,2023-04-20,Presentation or Conference,Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,"Nottingham, Glasgow","We established the ISpy study to investigate the seroprevalence of SARS-CoV-2 in paediatric patients on renal replacement therapy (RRT) in the United Kingdom.

Samples were obtained opportunistically using excess sera from patients during outpatient visits or haemodialysis sessions (prospective), and retrospective samples from CountOnMe home testing, where available. Two large paediatric centres contributed samples.

These two centres are:
- Nottingham University Hospital
- Royal Hospital for Children, Glasgow",,2021-08-01,2021-08-31,Residual sera,All,Children and Youth (0-17 years),,,Primary Estimate,,37,0.3243,,,True,,,,True,Convenience,Author designed (ELISA) - Unknown,,ELISA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Unclear,Yes,No,,Javairiya Afzaal,Nottingham University Hospitals NHS Trust,Not Unity-Aligned,https://doi.org/10.1007/s00467-022-05865-y,2023-07-31,2024-02-02,Unverified,afzaal_low_2023,GBR
230427_London_King'sCollegeLondon,230427_London_King'sCollegeLondon,Trends in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection and vaccine antibody prevalence in a multi-ethnic inner-city antenatal population: A cross-sectional surveillance study.,2023-04-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,London,"""Women presenting for antenatal nuchal scans (11–15weeks of gestation) at Guy's and St Thomas’ NHS Foundation Trust (GSTT) between July 2020 and January 2022 were in- vited to contribute to the Research Tissue Bank (COVID-19 Substudy) of the Early Life Cross Linkage in Research (eLIXIR) programme""",,2020-07-15,2022-01-15,Pregnant or parturient women,All,Adults (18-64 years),,,Primary Estimate,,960,0.205,,,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Daria Andreeva,King's College London,Not Unity-Aligned,https://dx.doi.org/10.1111/1471-0528.17508,2023-06-02,2023-06-02,Unverified,andreevaTrendsSevereAcute,GBR
230523_Leeds_LeedsBeckettUniversity,230523_Leeds_LeedsBeckettUniversity,Validation of dried blood spot sampling for detecting SARS-CoV-2 antibodies and total immunoglobulins in a large cohort of asymptomatic young adults,2023-05-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Kingdom of Great Britain and Northern Ireland,,Leeds,"""Samples were collected between 7 October 2020 and 14 June 2021 from university students at the campus of Leeds Beckett University, Leeds, and military recruits at the Infantry Training Centre, Catterick.""",,2020-10-07,2021-06-14,Multiple populations,All,Adults (18-64 years),,,Primary Estimate,,1070,0.1635,,,True,,,,True,Convenience,Anti-SARS-CoV-2 NCP ELISA (IgG),EUROIMMUN,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.946,0.9988,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,P. Ferentinos,Leeds Beckett University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jim.2023.113492,2023-06-29,2024-03-01,Unverified,ferentinosValidationDriedBlood2023,GBR
230624_UnitedKingdom_MountSinai,230624_UnitedKingdom_MountSinai,Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium,2023-06-24,Journal Article (Peer-Reviewed),National,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,,,"Our initial core objective was to include all adult patients with IBD who entered the infusion center for vedolizumab or infliximab (originator or biosimilars), as well as intravenous ustekinumab induction, regardless of history of known COVID-19 infection, and without any exclusion criteria.",None,2020-05-15,2021-12-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,563,0.0995,,,True,,,,True,Convenience,"SARS-CoV-2 Rapid Antibody Test,Atellica® IM SARS-CoV-2 Total (COV2T),Author designed (type unknown)","Roche Diagnostics,Siemens,NA",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Unclear,Yes,No,,Serre-Yu Wong,Mount Sinai,Not Unity-Aligned,https://dx.doi.org/10.1093/ibd/izad097,2023-08-02,2024-03-01,Unverified,wong_geography_2023,GBR
230912_UK_UniversityOfOxford_May-Dec_Overall,230912_UK_UniversityOfOxford,Social determinants of ethnic disparities in SARS-CoV-2 infection: UK Biobank SARS-CoV-2 Serology Study,2023-09-12,Journal Article (Peer-Reviewed),National,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,"England, Wales, Scotland.",,"The UK Biobank SARS-CoV-2 Serology Study is a longitudinal study of a subset of UK Biobank participants and their relatives (children or grandchildren >18 years).

In brief, UK Biobank is a prospective cohort study of 502 000 adults, recruited from the general population in England, Scotland and Wales between 2006 and 2010. Eligible participants were men and women aged 40–69 years, who were registered with the National Health Service (NHS) and living within approximately 25 miles of the 22 assessment centres; centres were distributed throughout the UK in settings to allow heterogeneity in socioeconomic, ethnic and urban-rural characteristics.

Between 7 May and 8 June 2020, all UK Biobank participants with a valid email address, resident in mainland UK and who had previously indicated willingness to be contacted about research activities were invited to join the Serology Study (see online supplemental figure S1).",excluding Northern Ireland,2020-05-15,2020-12-15,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,May to Dec 2020,18887,0.0884,,,True,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Wemimo Omiyale,University of Oxford,Not Unity-Aligned,https://dx.doi.org/10.1136/jech-2023-220353,2023-10-10,2023-10-11,Unverified,omiyale_social_2023,GBR
230912_UK_UniversityOfOxford_Oct,230912_UK_UniversityOfOxford,Social determinants of ethnic disparities in SARS-CoV-2 infection: UK Biobank SARS-CoV-2 Serology Study,2023-09-12,Journal Article (Peer-Reviewed),National,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,"England, Wales, Scotland.",,"The UK Biobank SARS-CoV-2 Serology Study is a longitudinal study of a subset of UK Biobank participants and their relatives (children or grandchildren >18 years).

In brief, UK Biobank is a prospective cohort study of 502 000 adults, recruited from the general population in England, Scotland and Wales between 2006 and 2010. Eligible participants were men and women aged 40–69 years, who were registered with the National Health Service (NHS) and living within approximately 25 miles of the 22 assessment centres; centres were distributed throughout the UK in settings to allow heterogeneity in socioeconomic, ethnic and urban-rural characteristics.

Between 7 May and 8 June 2020, all UK Biobank participants with a valid email address, resident in mainland UK and who had previously indicated willingness to be contacted about research activities were invited to join the Serology Study (see online supplemental figure S1).",excluding Northern Ireland,2020-10-01,2020-10-31,Household and community samples,All,Multiple groups,18.0,,Test used,October 2020,16202,0.077,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Wemimo Omiyale,University of Oxford,Not Unity-Aligned,https://dx.doi.org/10.1136/jech-2023-220353,2023-10-11,2023-10-11,Unverified,omiyale_social_2023,GBR
230912_UK_UniversityOfOxford_Jun,230912_UK_UniversityOfOxford,Social determinants of ethnic disparities in SARS-CoV-2 infection: UK Biobank SARS-CoV-2 Serology Study,2023-09-12,Journal Article (Peer-Reviewed),National,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,"England, Wales, Scotland.",,"The UK Biobank SARS-CoV-2 Serology Study is a longitudinal study of a subset of UK Biobank participants and their relatives (children or grandchildren >18 years).

In brief, UK Biobank is a prospective cohort study of 502 000 adults, recruited from the general population in England, Scotland and Wales between 2006 and 2010. Eligible participants were men and women aged 40–69 years, who were registered with the National Health Service (NHS) and living within approximately 25 miles of the 22 assessment centres; centres were distributed throughout the UK in settings to allow heterogeneity in socioeconomic, ethnic and urban-rural characteristics.

Between 7 May and 8 June 2020, all UK Biobank participants with a valid email address, resident in mainland UK and who had previously indicated willingness to be contacted about research activities were invited to join the Serology Study (see online supplemental figure S1).",excluding Northern Ireland,2020-06-01,2020-06-30,Household and community samples,All,Multiple groups,18.0,,Test used,June  2020,14254,0.0671,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Wemimo Omiyale,University of Oxford,Not Unity-Aligned,https://dx.doi.org/10.1136/jech-2023-220353,2023-10-11,2023-10-11,Unverified,omiyale_social_2023,GBR
230912_UK_UniversityOfOxford_Aug,230912_UK_UniversityOfOxford,Social determinants of ethnic disparities in SARS-CoV-2 infection: UK Biobank SARS-CoV-2 Serology Study,2023-09-12,Journal Article (Peer-Reviewed),National,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,"England, Wales, Scotland.",,"The UK Biobank SARS-CoV-2 Serology Study is a longitudinal study of a subset of UK Biobank participants and their relatives (children or grandchildren >18 years).

In brief, UK Biobank is a prospective cohort study of 502 000 adults, recruited from the general population in England, Scotland and Wales between 2006 and 2010. Eligible participants were men and women aged 40–69 years, who were registered with the National Health Service (NHS) and living within approximately 25 miles of the 22 assessment centres; centres were distributed throughout the UK in settings to allow heterogeneity in socioeconomic, ethnic and urban-rural characteristics.

Between 7 May and 8 June 2020, all UK Biobank participants with a valid email address, resident in mainland UK and who had previously indicated willingness to be contacted about research activities were invited to join the Serology Study (see online supplemental figure S1).",excluding Northern Ireland,2020-08-01,2020-08-31,Household and community samples,All,Multiple groups,18.0,,Test used,August 2020,16740,0.0677,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Wemimo Omiyale,University of Oxford,Not Unity-Aligned,https://dx.doi.org/10.1136/jech-2023-220353,2023-10-11,2023-10-11,Unverified,omiyale_social_2023,GBR
230912_UK_UniversityOfOxford_Sep,230912_UK_UniversityOfOxford,Social determinants of ethnic disparities in SARS-CoV-2 infection: UK Biobank SARS-CoV-2 Serology Study,2023-09-12,Journal Article (Peer-Reviewed),National,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,"England, Wales, Scotland.",,"The UK Biobank SARS-CoV-2 Serology Study is a longitudinal study of a subset of UK Biobank participants and their relatives (children or grandchildren >18 years).

In brief, UK Biobank is a prospective cohort study of 502 000 adults, recruited from the general population in England, Scotland and Wales between 2006 and 2010. Eligible participants were men and women aged 40–69 years, who were registered with the National Health Service (NHS) and living within approximately 25 miles of the 22 assessment centres; centres were distributed throughout the UK in settings to allow heterogeneity in socioeconomic, ethnic and urban-rural characteristics.

Between 7 May and 8 June 2020, all UK Biobank participants with a valid email address, resident in mainland UK and who had previously indicated willingness to be contacted about research activities were invited to join the Serology Study (see online supplemental figure S1).",excluding Northern Ireland,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,18.0,,Test used,September 2020,16481,0.0686,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Wemimo Omiyale,University of Oxford,Not Unity-Aligned,https://dx.doi.org/10.1136/jech-2023-220353,2023-10-11,2023-10-11,Unverified,omiyale_social_2023,GBR
230912_UK_UniversityOfOxford_Dec,230912_UK_UniversityOfOxford,Social determinants of ethnic disparities in SARS-CoV-2 infection: UK Biobank SARS-CoV-2 Serology Study,2023-09-12,Journal Article (Peer-Reviewed),National,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,"England, Wales, Scotland.",,"The UK Biobank SARS-CoV-2 Serology Study is a longitudinal study of a subset of UK Biobank participants and their relatives (children or grandchildren >18 years).

In brief, UK Biobank is a prospective cohort study of 502 000 adults, recruited from the general population in England, Scotland and Wales between 2006 and 2010. Eligible participants were men and women aged 40–69 years, who were registered with the National Health Service (NHS) and living within approximately 25 miles of the 22 assessment centres; centres were distributed throughout the UK in settings to allow heterogeneity in socioeconomic, ethnic and urban-rural characteristics.

Between 7 May and 8 June 2020, all UK Biobank participants with a valid email address, resident in mainland UK and who had previously indicated willingness to be contacted about research activities were invited to join the Serology Study (see online supplemental figure S1).",excluding Northern Ireland,2020-12-01,2020-12-31,Household and community samples,All,Multiple groups,18.0,,Test used,December 2020,56,0.2321,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Wemimo Omiyale,University of Oxford,Not Unity-Aligned,https://dx.doi.org/10.1136/jech-2023-220353,2023-10-11,2023-10-11,Unverified,omiyale_social_2023,GBR
230912_UK_UniversityOfOxford_Nov,230912_UK_UniversityOfOxford,Social determinants of ethnic disparities in SARS-CoV-2 infection: UK Biobank SARS-CoV-2 Serology Study,2023-09-12,Journal Article (Peer-Reviewed),National,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,"England, Wales, Scotland.",,"The UK Biobank SARS-CoV-2 Serology Study is a longitudinal study of a subset of UK Biobank participants and their relatives (children or grandchildren >18 years).

In brief, UK Biobank is a prospective cohort study of 502 000 adults, recruited from the general population in England, Scotland and Wales between 2006 and 2010. Eligible participants were men and women aged 40–69 years, who were registered with the National Health Service (NHS) and living within approximately 25 miles of the 22 assessment centres; centres were distributed throughout the UK in settings to allow heterogeneity in socioeconomic, ethnic and urban-rural characteristics.

Between 7 May and 8 June 2020, all UK Biobank participants with a valid email address, resident in mainland UK and who had previously indicated willingness to be contacted about research activities were invited to join the Serology Study (see online supplemental figure S1).",excluding Northern Ireland,2020-11-01,2020-11-30,Household and community samples,All,Multiple groups,18.0,,Test used,November 2020,12172,0.0877,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Wemimo Omiyale,University of Oxford,Not Unity-Aligned,https://dx.doi.org/10.1136/jech-2023-220353,2023-10-11,2023-10-11,Unverified,omiyale_social_2023,GBR
230912_UK_UniversityOfOxford_Jul,230912_UK_UniversityOfOxford,Social determinants of ethnic disparities in SARS-CoV-2 infection: UK Biobank SARS-CoV-2 Serology Study,2023-09-12,Journal Article (Peer-Reviewed),National,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,"England, Wales, Scotland.",,"The UK Biobank SARS-CoV-2 Serology Study is a longitudinal study of a subset of UK Biobank participants and their relatives (children or grandchildren >18 years).

In brief, UK Biobank is a prospective cohort study of 502 000 adults, recruited from the general population in England, Scotland and Wales between 2006 and 2010. Eligible participants were men and women aged 40–69 years, who were registered with the National Health Service (NHS) and living within approximately 25 miles of the 22 assessment centres; centres were distributed throughout the UK in settings to allow heterogeneity in socioeconomic, ethnic and urban-rural characteristics.

Between 7 May and 8 June 2020, all UK Biobank participants with a valid email address, resident in mainland UK and who had previously indicated willingness to be contacted about research activities were invited to join the Serology Study (see online supplemental figure S1).",excluding Northern Ireland,2020-07-01,2020-07-31,Household and community samples,All,Multiple groups,18.0,,Test used,July 2020,17384,0.0707,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Wemimo Omiyale,University of Oxford,Not Unity-Aligned,https://dx.doi.org/10.1136/jech-2023-220353,2023-10-11,2023-10-11,Unverified,omiyale_social_2023,GBR
230912_UK_UniversityOfOxford_May,230912_UK_UniversityOfOxford,Social determinants of ethnic disparities in SARS-CoV-2 infection: UK Biobank SARS-CoV-2 Serology Study,2023-09-12,Journal Article (Peer-Reviewed),National,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,"England, Wales, Scotland.",,"The UK Biobank SARS-CoV-2 Serology Study is a longitudinal study of a subset of UK Biobank participants and their relatives (children or grandchildren >18 years).

In brief, UK Biobank is a prospective cohort study of 502 000 adults, recruited from the general population in England, Scotland and Wales between 2006 and 2010. Eligible participants were men and women aged 40–69 years, who were registered with the National Health Service (NHS) and living within approximately 25 miles of the 22 assessment centres; centres were distributed throughout the UK in settings to allow heterogeneity in socioeconomic, ethnic and urban-rural characteristics.

Between 7 May and 8 June 2020, all UK Biobank participants with a valid email address, resident in mainland UK and who had previously indicated willingness to be contacted about research activities were invited to join the Serology Study (see online supplemental figure S1).",excluding Northern Ireland,2020-05-01,2020-05-31,Household and community samples,All,Multiple groups,18.0,,Test used,May 2020,1479,0.0534,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Wemimo Omiyale,University of Oxford,Not Unity-Aligned,https://dx.doi.org/10.1136/jech-2023-220353,2023-10-11,2023-10-11,Unverified,omiyale_social_2023,GBR
230920_NorthernIreland_Queen’sUniversityBelfast,230920_NorthernIreland_Queen’sUniversityBelfast,Analysis of SARS-CoV-2 Ig seroprevalence in Northern Ireland,,Preprint,National,Prospective cohort,United Kingdom of Great Britain and Northern Ireland,,,Sera/plasma samples from clinical biochemistry laboratories,,2020-06-15,2021-07-15,Residual sera,All,Multiple groups,,,Primary Estimate,,4844,0.15,,,True,,,,True,Sequential,"Elecsys® Anti‐SARS‐CoV‐2 (S),Anti-SARS-CoV-2 NCP ELISA (IgG),Author designed (ELISA) -Spike","Roche Diagnostics,EUROIMMUN,NA",ELISA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,No,,Unclear,No,No,,Michelle K Greene,Queen’s University Belfast,Not Unity-Aligned,10.1101/2023.09.19.23295776,2023-10-26,2024-03-01,Unverified,greene_analysis_2023,GBR
220704_Zanzibar_StateUniversityofZanzibar,220704_Zanzibar_StateUniversityofZanzibar,Anti SARS-CoV2 seroprevalence in Zanzibar in 2021 before the Omicron wave.,2022-07-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United Republic of Tanzania,Zanzibar Region,,"""All household members were enrolled, irrespective of their age or sex, as in a previous survey""",,2021-07-28,2021-10-20,Household and community samples,All,Multiple groups,,,Primary Estimate,,2051,0.569,,,True,,,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,0.9,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Salum Seif Salum,State University of Zanzibar,Unity-Aligned,https://dx.doi.org/10.1016/j.ijregi.2022.06.007,2022-07-20,2024-03-31,Verified,salum_anti_2022,TZA
220704_Zanzibar_StateUniversityofZanzibar_Age_10-13,220704_Zanzibar_StateUniversityofZanzibar,Anti SARS-CoV2 seroprevalence in Zanzibar in 2021 before the Omicron wave.,2022-07-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United Republic of Tanzania,Zanzibar Region,,"""All household members were enrolled, irrespective of their age or sex, as in a previous survey""",,2021-07-28,2021-10-20,Household and community samples,All,Children and Youth (0-17 years),10.0,13.0,Age,10-13,280,0.616,,,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,0.9,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Salum Seif Salum,State University of Zanzibar,Unity-Aligned,https://dx.doi.org/10.1016/j.ijregi.2022.06.007,2022-07-20,2024-03-31,Verified,salum_anti_2022,TZA
220704_Zanzibar_StateUniversityofZanzibar_Age_17-59,220704_Zanzibar_StateUniversityofZanzibar,Anti SARS-CoV2 seroprevalence in Zanzibar in 2021 before the Omicron wave.,2022-07-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United Republic of Tanzania,Zanzibar Region,,"""All household members were enrolled, irrespective of their age or sex, as in a previous survey""",,2021-07-28,2021-10-20,Household and community samples,All,Adults (18-64 years),17.0,59.0,Age,17-59,1094,0.549,,,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,0.9,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Salum Seif Salum,State University of Zanzibar,Unity-Aligned,https://dx.doi.org/10.1016/j.ijregi.2022.06.007,2022-07-20,2024-03-31,Verified,salum_anti_2022,TZA
220704_Zanzibar_StateUniversityofZanzibar_Sex_Female,220704_Zanzibar_StateUniversityofZanzibar,Anti SARS-CoV2 seroprevalence in Zanzibar in 2021 before the Omicron wave.,2022-07-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United Republic of Tanzania,Zanzibar Region,,"""All household members were enrolled, irrespective of their age or sex, as in a previous survey""",,2021-07-28,2021-10-20,Household and community samples,Female,Multiple groups,,,Sex/Gender,Female,1116,0.561,,,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,0.9,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Salum Seif Salum,State University of Zanzibar,Unity-Aligned,https://dx.doi.org/10.1016/j.ijregi.2022.06.007,2022-07-20,2024-03-31,Verified,salum_anti_2022,TZA
220704_Zanzibar_StateUniversityofZanzibar_Age_>59,220704_Zanzibar_StateUniversityofZanzibar,Anti SARS-CoV2 seroprevalence in Zanzibar in 2021 before the Omicron wave.,2022-07-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United Republic of Tanzania,Zanzibar Region,,"""All household members were enrolled, irrespective of their age or sex, as in a previous survey""",,2021-07-28,2021-10-20,Household and community samples,All,Multiple groups,59.0,,Age,>59,202,0.594,,,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,0.9,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Salum Seif Salum,State University of Zanzibar,Unity-Aligned,https://dx.doi.org/10.1016/j.ijregi.2022.06.007,2022-07-20,2024-03-31,Verified,salum_anti_2022,TZA
220704_Zanzibar_StateUniversityofZanzibar_Sex_Male,220704_Zanzibar_StateUniversityofZanzibar,Anti SARS-CoV2 seroprevalence in Zanzibar in 2021 before the Omicron wave.,2022-07-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United Republic of Tanzania,Zanzibar Region,,"""All household members were enrolled, irrespective of their age or sex, as in a previous survey""",,2021-07-28,2021-10-20,Household and community samples,Male,Multiple groups,,,Sex/Gender,Male,935,0.579,,,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,0.9,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Salum Seif Salum,State University of Zanzibar,Unity-Aligned,https://dx.doi.org/10.1016/j.ijregi.2022.06.007,2022-07-20,2024-03-31,Verified,salum_anti_2022,TZA
220704_Zanzibar_StateUniversityofZanzibar_Age_14-16,220704_Zanzibar_StateUniversityofZanzibar,Anti SARS-CoV2 seroprevalence in Zanzibar in 2021 before the Omicron wave.,2022-07-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United Republic of Tanzania,Zanzibar Region,,"""All household members were enrolled, irrespective of their age or sex, as in a previous survey""",,2021-07-28,2021-10-20,Household and community samples,All,Children and Youth (0-17 years),14.0,16.0,Age,14-16,182,0.665,,,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,0.9,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Salum Seif Salum,State University of Zanzibar,Unity-Aligned,https://dx.doi.org/10.1016/j.ijregi.2022.06.007,2022-07-20,2024-03-31,Verified,salum_anti_2022,TZA
220704_Zanzibar_StateUniversityofZanzibar_Age_<10,220704_Zanzibar_StateUniversityofZanzibar,Anti SARS-CoV2 seroprevalence in Zanzibar in 2021 before the Omicron wave.,2022-07-04,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United Republic of Tanzania,Zanzibar Region,,"""All household members were enrolled, irrespective of their age or sex, as in a previous survey""",,2021-07-28,2021-10-20,Household and community samples,All,Children and Youth (0-17 years),,9.0,Age,<10,293,0.519,,,,,,,,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,0.9,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Salum Seif Salum,State University of Zanzibar,Unity-Aligned,https://dx.doi.org/10.1016/j.ijregi.2022.06.007,2022-07-20,2024-03-31,Verified,salum_anti_2022,TZA
220916_Mwanza_CatholicUniversityofHealthandAlliedSciences_overall,220916_Mwanza_CatholicUniversityofHealthandAlliedSciences,"High Seroprevalence of SARS-CoV-2 in Mwanza, Northwestern Tanzania: A Population-Based Survey.",2022-09-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United Republic of Tanzania,"Mwanza
",,"""All household members aged 5 years and above were recruited for the investigation ... The enrollments involved only the household members who have been residing in the study area during the period between March 2020 (the first case of SARS-CoV-2 was reported in March 2020 in Tanzania) and the date of enrollment and were able to give informed consent for those above the age of 18 and above.""","""Household members who received any of the COVID-19 vaccines were excluded from the study.""",2021-09-01,2021-09-30,Household and community samples,All,Adults (18-64 years),5.0,,Primary Estimate,,805,0.4932,,,True,,,,True,Stratified probability,RADI COVID-19 IgG/IgM rapid test,"KH Medics, Limited",LFIA,Whole Blood,"['IgG', 'IgM']",,,0.9,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Helmu Nyawale,Catholic University of Health and Allied Sciences,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph191811664,2022-10-03,2024-03-01,Unverified,nyawaleHighSeroprevalenceSARSCoV22022,TZA
220916_Mwanza_CatholicUniversityofHealthandAlliedSciences_Ukerewe ,220916_Mwanza_CatholicUniversityofHealthandAlliedSciences,"High Seroprevalence of SARS-CoV-2 in Mwanza, Northwestern Tanzania: A Population-Based Survey.",2022-09-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Republic of Tanzania,"Mwanza
",Ukerewe,"""All household members aged 5 years and above were recruited for the investigation ... The enrollments involved only the household members who have been residing in the study area during the period between March 2020 (the first case of SARS-CoV-2 was reported in March 2020 in Tanzania) and the date of enrollment and were able to give informed consent for those above the age of 18 and above.""","""Household members who received any of the COVID-19 vaccines were excluded from the study.""",2021-09-01,2021-09-30,Household and community samples,All,Adults (18-64 years),5.0,,Geographical area,Ukerewe,259,0.5792,,,,,,,,Stratified probability,RADI COVID-19 IgG/IgM rapid test,"KH Medics, Limited",LFIA,Whole Blood,"['IgG', 'IgM']",,,0.9,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Helmu Nyawale,Catholic University of Health and Allied Sciences,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph191811664,2022-10-03,2024-03-01,Unverified,nyawaleHighSeroprevalenceSARSCoV22022,TZA
220916_Mwanza_CatholicUniversityofHealthandAlliedSciences_Magu,220916_Mwanza_CatholicUniversityofHealthandAlliedSciences,"High Seroprevalence of SARS-CoV-2 in Mwanza, Northwestern Tanzania: A Population-Based Survey.",2022-09-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Republic of Tanzania,"Mwanza
",Magu,"""All household members aged 5 years and above were recruited for the investigation ... The enrollments involved only the household members who have been residing in the study area during the period between March 2020 (the first case of SARS-CoV-2 was reported in March 2020 in Tanzania) and the date of enrollment and were able to give informed consent for those above the age of 18 and above.""","""Household members who received any of the COVID-19 vaccines were excluded from the study.""",2021-09-01,2021-09-30,Household and community samples,All,Adults (18-64 years),5.0,,Geographical area,Magu,249,0.4498,,,,,,,,Stratified probability,RADI COVID-19 IgG/IgM rapid test,"KH Medics, Limited",LFIA,Whole Blood,"['IgG', 'IgM']",,,0.9,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Helmu Nyawale,Catholic University of Health and Allied Sciences,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph191811664,2022-10-03,2024-03-01,Unverified,nyawaleHighSeroprevalenceSARSCoV22022,TZA
220916_Mwanza_CatholicUniversityofHealthandAlliedSciences_female,220916_Mwanza_CatholicUniversityofHealthandAlliedSciences,"High Seroprevalence of SARS-CoV-2 in Mwanza, Northwestern Tanzania: A Population-Based Survey.",2022-09-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United Republic of Tanzania,"Mwanza
",,"""All household members aged 5 years and above were recruited for the investigation ... The enrollments involved only the household members who have been residing in the study area during the period between March 2020 (the first case of SARS-CoV-2 was reported in March 2020 in Tanzania) and the date of enrollment and were able to give informed consent for those above the age of 18 and above.""","""Household members who received any of the COVID-19 vaccines were excluded from the study.""",2021-09-01,2021-09-30,Household and community samples,Female,Adults (18-64 years),5.0,,Sex/Gender,,347,0.5014000000000001,,,,,,,,Stratified probability,RADI COVID-19 IgG/IgM rapid test,"KH Medics, Limited",LFIA,Whole Blood,"['IgG', 'IgM']",,,0.9,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Helmu Nyawale,Catholic University of Health and Allied Sciences,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph191811664,2022-10-03,2024-03-01,Unverified,nyawaleHighSeroprevalenceSARSCoV22022,TZA
220916_Mwanza_CatholicUniversityofHealthandAlliedSciences_Misungwi,220916_Mwanza_CatholicUniversityofHealthandAlliedSciences,"High Seroprevalence of SARS-CoV-2 in Mwanza, Northwestern Tanzania: A Population-Based Survey.",2022-09-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Republic of Tanzania,"Mwanza
",Misungwi,"""All household members aged 5 years and above were recruited for the investigation ... The enrollments involved only the household members who have been residing in the study area during the period between March 2020 (the first case of SARS-CoV-2 was reported in March 2020 in Tanzania) and the date of enrollment and were able to give informed consent for those above the age of 18 and above.""","""Household members who received any of the COVID-19 vaccines were excluded from the study.""",2021-09-01,2021-09-30,Household and community samples,All,Adults (18-64 years),5.0,,Geographical area,Misungwi,297,0.4545,,,,,,,,Stratified probability,RADI COVID-19 IgG/IgM rapid test,"KH Medics, Limited",LFIA,Whole Blood,"['IgG', 'IgM']",,,0.9,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Helmu Nyawale,Catholic University of Health and Allied Sciences,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph191811664,2022-10-03,2024-03-01,Unverified,nyawaleHighSeroprevalenceSARSCoV22022,TZA
220916_Mwanza_CatholicUniversityofHealthandAlliedSciences_male,220916_Mwanza_CatholicUniversityofHealthandAlliedSciences,"High Seroprevalence of SARS-CoV-2 in Mwanza, Northwestern Tanzania: A Population-Based Survey.",2022-09-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United Republic of Tanzania,"Mwanza
",,"""All household members aged 5 years and above were recruited for the investigation ... The enrollments involved only the household members who have been residing in the study area during the period between March 2020 (the first case of SARS-CoV-2 was reported in March 2020 in Tanzania) and the date of enrollment and were able to give informed consent for those above the age of 18 and above.""","""Household members who received any of the COVID-19 vaccines were excluded from the study.""",2021-09-01,2021-09-30,Household and community samples,Male,Adults (18-64 years),5.0,,Sex/Gender,,458,0.4869,,,,,,,,Stratified probability,RADI COVID-19 IgG/IgM rapid test,"KH Medics, Limited",LFIA,Whole Blood,"['IgG', 'IgM']",,,0.9,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Helmu Nyawale,Catholic University of Health and Allied Sciences,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph191811664,2022-10-03,2024-03-01,Unverified,nyawaleHighSeroprevalenceSARSCoV22022,TZA
221112_Tanzania_NationalInstituteForMedicalResearch_Overall,221112_Tanzania_NationalInstituteForMedicalResearch,Seroprevalence of SARS-CoV-2 antibodies among children and adolescents recruited in a malariometric survey in north-eastern Tanzania July 2021,2022-11-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Republic of Tanzania,Korogwe,,"people from two rural villages in Tanzania, highland Kwamasimba and lowland Mkokola",,2021-07-19,2021-07-30,Household and community samples,All,Children and Youth (0-17 years),0.0,19.0,Primary Estimate,,501,0.363,,,True,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],,Yes,No,Yes,,Unclear,Yes,No,,Eric Lyimo,National Institute for Medical Research,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07820-6,2022-12-14,2023-03-19,Unverified,lyimo_seroprevalence_2022,TZA
221112_Tanzania_NationalInstituteForMedicalResearch_Age10to14,221112_Tanzania_NationalInstituteForMedicalResearch,Seroprevalence of SARS-CoV-2 antibodies among children and adolescents recruited in a malariometric survey in north-eastern Tanzania July 2021,2022-11-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Republic of Tanzania,Korogwe,,"people from two rural villages in Tanzania, highland Kwamasimba and lowland Mkokola",,2021-07-19,2021-07-30,Household and community samples,All,Children and Youth (0-17 years),0.0,19.0,Age,age: 10-14,164,0.445,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],,Yes,No,Yes,,Unclear,Yes,No,,Eric Lyimo,National Institute for Medical Research,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07820-6,2022-12-14,2023-03-22,Unverified,lyimo_seroprevalence_2022,TZA
221112_Tanzania_NationalInstituteForMedicalResearch_Age5to9,221112_Tanzania_NationalInstituteForMedicalResearch,Seroprevalence of SARS-CoV-2 antibodies among children and adolescents recruited in a malariometric survey in north-eastern Tanzania July 2021,2022-11-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Republic of Tanzania,Korogwe,,"people from two rural villages in Tanzania, highland Kwamasimba and lowland Mkokola",,2021-07-19,2021-07-30,Household and community samples,All,Children and Youth (0-17 years),0.0,19.0,Age,age: 5-9,151,0.252,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],,Yes,No,Yes,,Unclear,Yes,No,,Eric Lyimo,National Institute for Medical Research,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07820-6,2022-12-14,2023-03-19,Unverified,lyimo_seroprevalence_2022,TZA
221112_Tanzania_NationalInstituteForMedicalResearch_Age1to4,221112_Tanzania_NationalInstituteForMedicalResearch,Seroprevalence of SARS-CoV-2 antibodies among children and adolescents recruited in a malariometric survey in north-eastern Tanzania July 2021,2022-11-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Republic of Tanzania,Korogwe,,"people from two rural villages in Tanzania, highland Kwamasimba and lowland Mkokola",,2021-07-19,2021-07-30,Household and community samples,All,Children and Youth (0-17 years),0.0,19.0,Age,age: 1-4,91,0.198,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],,Yes,No,Yes,,Unclear,Yes,No,,Eric Lyimo,National Institute for Medical Research,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07820-6,2022-12-14,2023-03-19,Unverified,lyimo_seroprevalence_2022,TZA
221112_Tanzania_NationalInstituteForMedicalResearch_Age15to19,221112_Tanzania_NationalInstituteForMedicalResearch,Seroprevalence of SARS-CoV-2 antibodies among children and adolescents recruited in a malariometric survey in north-eastern Tanzania July 2021,2022-11-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Republic of Tanzania,Korogwe,,"people from two rural villages in Tanzania, highland Kwamasimba and lowland Mkokola",,2021-07-19,2021-07-30,Household and community samples,All,Multiple groups,0.0,19.0,Age,age: 15-19,67,0.5970000000000001,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],,Yes,No,Yes,,Unclear,Yes,No,,Eric Lyimo,National Institute for Medical Research,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07820-6,2022-12-14,2023-03-22,Unverified,lyimo_seroprevalence_2022,TZA
221112_Tanzania_NationalInstituteForMedicalResearch_AgeBelow1,221112_Tanzania_NationalInstituteForMedicalResearch,Seroprevalence of SARS-CoV-2 antibodies among children and adolescents recruited in a malariometric survey in north-eastern Tanzania July 2021,2022-11-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United Republic of Tanzania,Korogwe,,"people from two rural villages in Tanzania, highland Kwamasimba and lowland Mkokola",,2021-07-19,2021-07-30,Household and community samples,All,Children and Youth (0-17 years),0.0,19.0,Age,age: <1,28,0.35700000000000004,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],,Yes,No,Yes,,Unclear,Yes,No,,Eric Lyimo,National Institute for Medical Research,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-022-07820-6,2022-12-14,2023-03-19,Unverified,lyimo_seroprevalence_2022,TZA
221216_Tanzania_UniversityOfCopenhagen,221216_Tanzania_UniversityOfCopenhagen,High anti-SARS-CoV-2 seroprevalence among unvaccinated mother-child pairs from a rural setting of north-eastern Tanzania during the second wave of COVID-19.,2022-12-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United Republic of Tanzania,,,"From April 26 to October 27, 2021, when the children were between
5 and 6 years of age (FOETALforNCD) and between 11 and 12 years of
age (STOPPAM), the child and mother pairs were invited to participate
in a follow-up health examination study (the PONA2 study",,2021-04-26,2021-10-27,Household and community samples,All,Multiple groups,,,Primary Estimate,,1147,0.371,,,True,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Omari AbdulMsemo,University of Copenhagen,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijregi.2022.11.011,2023-01-13,2023-03-19,Unverified,msemo_high_2023,TZA
200422_Idaho_CrushTheCurveIdaho_Patients,200422_Idaho_CrushTheCurveIdaho,CrushTheCurveIdaho finds small population with antibodies: 'We are far from herd immunity',2020-04-22,News and Media,Regional,Cross-sectional survey ,United States of America,Idaho,,"NR - ""patients"" ",,2020-04-20,2020-04-22,Residual sera,All,Multiple groups,,,Primary Estimate,,1946,0.0175,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,IgG,,Validated by manufacturers,1.0,0.996,['High'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Ryan Morrison,Crush The Curve Idaho,Not Unity-Aligned,https://idahonews.com/news/coronavirus/crushthecurveidaho-finds-small-population-with-antibodies-we-are-far-from-herd-immunity,2020-05-02,2023-12-13,Verified,morrison_crushthecurveidaho_2020,USA
200424_Brevard_OMNI_GeneralPopulation,200424_Brevard_OMNIHealthcare,OMNI Healthcare's COVID-19 antibody testing data for Brevard shows low rates of immunity,2020-04-24,News and Media,Local,Cross-sectional survey ,United States of America,Florida,,Testing will be offered to patients who meet the following criteria: All OMNI Health and Parrish Medical Center employees at risk; Anyone over the age of 60; Anyone over the age of 45 with at least one chronic condition.,,2020-04-17,2020-04-24,Household and community samples,All,Multiple groups,,,Primary Estimate,,1000,0.01,,,True,,,,True,Self-referral,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,1.0,1.0,['Moderate'],Yes,No,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Alessandro Sassoon,OMNI Healthcare,Not Unity-Aligned,https://www.floridatoday.com/story/news/2020/04/24/omni-covid-19-immunity-testing-data-brevard-county-florida-antibody/3022571001/,2020-05-02,2022-07-16,Verified,alessandro_sassoon_omni_2020,USA
200423_BatonRouge_BatonRougeGeneralHospital_GenPop,200423_BatonRouge_BatonRougeGeneralHospital,Takeaways from coronavirus antibody tests: Infections might be more widespread than cases suggest,2020-04-28,News and Media,Local,Cross-sectional survey ,United States of America,Louisiana,Baton Rouge,,,,2020-04-21,Household and community samples,All,Multiple groups,,,Primary Estimate,,432,0.044000000000000004,,,True,,,,True,Unclear,Author designed (type unknown),,,,,,,,0.986,['High'],No,Unclear,No,No,Unclear,Unclear,Yes,No,Unclear,Blake Paterson,Baton Rouge General Hospital,Not Unity-Aligned,https://www.theadvocate.com/baton_rouge/news/coronavirus/article_b499efa0-8983-11ea-a3f1-af936ecb1d2c.html,2020-05-03,2022-07-16,Verified,blake_paterson_takeaways_2020,USA
200501_SanMiguelCounty_UnitedBiomedical_overall,200501_SanMiguelCounty_UnitedBiomedical,"San Miguel County, CO IgG Antibody Tests",2020-05-01,Institutional Report,Local,Cross-sectional survey ,United States of America,Colorado,,,,2020-03-26,2020-04-15,Household and community samples,All,Multiple groups,,,Primary Estimate,Overall,5283,0.0053,,,True,,,,True,Entire sample,Not reported/ Unable to specify,,,,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,San Miguel County,United Biomedical Group,Not Unity-Aligned,https://www.sanmiguelcountyco.gov/DocumentCenter/View/5717/San-Miguel-County-IgG-Antibody-Test-Statistics-and-Demographics-PDF,2021-05-05,2022-07-16,Verified,united_biomedical_san_2020,USA
200501_SanMiguelCounty_UnitedBiomedical_age6069,200501_SanMiguelCounty_UnitedBiomedical,"San Miguel County, CO IgG Antibody Tests",2020-05-01,Institutional Report,Local,Cross-sectional survey ,United States of America,Colorado,,,,2020-03-26,2020-04-15,Household and community samples,All,Seniors (65+ years),60.0,69.0,Age,60-69,708,0.0014000000000000002,,,,,,,,Entire sample,Not reported/ Unable to specify,,,,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,San Miguel County,United Biomedical Group,Not Unity-Aligned,https://www.sanmiguelcountyco.gov/DocumentCenter/View/5717/San-Miguel-County-IgG-Antibody-Test-Statistics-and-Demographics-PDF,2021-07-08,2022-07-16,Verified,united_biomedical_san_2020,USA
200501_SanMiguelCounty_UnitedBiomedical_age7079,200501_SanMiguelCounty_UnitedBiomedical,"San Miguel County, CO IgG Antibody Tests",2020-05-01,Institutional Report,Local,Cross-sectional survey ,United States of America,Colorado,,,,2020-03-26,2020-04-15,Household and community samples,All,Seniors (65+ years),70.0,79.0,Age,,363,0.0028000000000000004,,,,,,,,Entire sample,Not reported/ Unable to specify,,,,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,San Miguel County,United Biomedical Group,Not Unity-Aligned,https://www.sanmiguelcountyco.gov/DocumentCenter/View/5717/San-Miguel-County-IgG-Antibody-Test-Statistics-and-Demographics-PDF,2021-07-08,2022-07-16,Verified,united_biomedical_san_2020,USA
200501_SanMiguelCounty_UnitedBiomedical_age5059,200501_SanMiguelCounty_UnitedBiomedical,"San Miguel County, CO IgG Antibody Tests",2020-05-01,Institutional Report,Local,Cross-sectional survey ,United States of America,Colorado,,,,2020-03-26,2020-04-15,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,1001,0.005,,,,,,,,Entire sample,Not reported/ Unable to specify,,,,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,San Miguel County,United Biomedical Group,Not Unity-Aligned,https://www.sanmiguelcountyco.gov/DocumentCenter/View/5717/San-Miguel-County-IgG-Antibody-Test-Statistics-and-Demographics-PDF,2021-07-08,2022-07-16,Verified,united_biomedical_san_2020,USA
200501_SanMiguelCounty_UnitedBiomedical_SexFemale,200501_SanMiguelCounty_UnitedBiomedical,"San Miguel County, CO IgG Antibody Tests",2020-05-01,Institutional Report,Local,Cross-sectional survey ,United States of America,Colorado,,,,2020-03-26,2020-04-15,Household and community samples,Female,Multiple groups,,,Sex/Gender,,2576,0.0039000000000000003,,,,,,,,Entire sample,Not reported/ Unable to specify,,,,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,San Miguel County,United Biomedical Group,Not Unity-Aligned,https://www.sanmiguelcountyco.gov/DocumentCenter/View/5717/San-Miguel-County-IgG-Antibody-Test-Statistics-and-Demographics-PDF,2021-07-08,2022-07-16,Verified,united_biomedical_san_2020,USA
200501_SanMiguelCounty_UnitedBiomedical_age4049,200501_SanMiguelCounty_UnitedBiomedical,"San Miguel County, CO IgG Antibody Tests",2020-05-01,Institutional Report,Local,Cross-sectional survey ,United States of America,Colorado,,,,2020-03-26,2020-04-15,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,986,0.0070999999999999995,,,,,,,,Entire sample,Not reported/ Unable to specify,,,,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,San Miguel County,United Biomedical Group,Not Unity-Aligned,https://www.sanmiguelcountyco.gov/DocumentCenter/View/5717/San-Miguel-County-IgG-Antibody-Test-Statistics-and-Demographics-PDF,2021-07-08,2022-07-16,Verified,united_biomedical_san_2020,USA
200501_SanMiguelCounty_UnitedBiomedical_age3039,200501_SanMiguelCounty_UnitedBiomedical,"San Miguel County, CO IgG Antibody Tests",2020-05-01,Institutional Report,Local,Cross-sectional survey ,United States of America,Colorado,,,,2020-03-26,2020-04-15,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,914,0.0055000000000000005,,,,,,,,Entire sample,Not reported/ Unable to specify,,,,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,San Miguel County,United Biomedical Group,Not Unity-Aligned,https://www.sanmiguelcountyco.gov/DocumentCenter/View/5717/San-Miguel-County-IgG-Antibody-Test-Statistics-and-Demographics-PDF,2021-07-08,2022-07-16,Verified,united_biomedical_san_2020,USA
200501_SanMiguelCounty_UnitedBiomedical_age1019,200501_SanMiguelCounty_UnitedBiomedical,"San Miguel County, CO IgG Antibody Tests",2020-05-01,Institutional Report,Local,Cross-sectional survey ,United States of America,Colorado,,,,2020-03-26,2020-04-15,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,632,0.0079,,,,,,,,Entire sample,Not reported/ Unable to specify,,,,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,San Miguel County,United Biomedical Group,Not Unity-Aligned,https://www.sanmiguelcountyco.gov/DocumentCenter/View/5717/San-Miguel-County-IgG-Antibody-Test-Statistics-and-Demographics-PDF,2021-07-08,2022-07-16,Verified,united_biomedical_san_2020,USA
200501_SanMiguelCounty_UnitedBiomedical_age2029,200501_SanMiguelCounty_UnitedBiomedical,"San Miguel County, CO IgG Antibody Tests",2020-05-01,Institutional Report,Local,Cross-sectional survey ,United States of America,Colorado,,,,2020-03-26,2020-04-15,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,723,0.0055000000000000005,,,,,,,,Entire sample,Not reported/ Unable to specify,,,,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,San Miguel County,United Biomedical Group,Not Unity-Aligned,https://www.sanmiguelcountyco.gov/DocumentCenter/View/5717/San-Miguel-County-IgG-Antibody-Test-Statistics-and-Demographics-PDF,2021-07-08,2022-07-16,Verified,united_biomedical_san_2020,USA
200501_SanMiguelCounty_UnitedBiomedical_SexMale,200501_SanMiguelCounty_UnitedBiomedical,"San Miguel County, CO IgG Antibody Tests",2020-05-01,Institutional Report,Local,Cross-sectional survey ,United States of America,Colorado,,,,2020-03-26,2020-04-15,Household and community samples,Male,Multiple groups,,,Sex/Gender,,2827,0.0067,,,,,,,,Entire sample,Not reported/ Unable to specify,,,,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,San Miguel County,United Biomedical Group,Not Unity-Aligned,https://www.sanmiguelcountyco.gov/DocumentCenter/View/5717/San-Miguel-County-IgG-Antibody-Test-Statistics-and-Demographics-PDF,2021-07-08,2022-07-16,Verified,united_biomedical_san_2020,USA
200501_SanMiguelCounty_UnitedBiomedical_age8089,200501_SanMiguelCounty_UnitedBiomedical,"San Miguel County, CO IgG Antibody Tests",2020-05-01,Institutional Report,Local,Cross-sectional survey ,United States of America,Colorado,,,,2020-03-26,2020-04-15,Household and community samples,All,Seniors (65+ years),80.0,89.0,Age,,31,0.0323,,,,,,,,Entire sample,Not reported/ Unable to specify,,,,IgG,,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,San Miguel County,United Biomedical Group,Not Unity-Aligned,https://www.sanmiguelcountyco.gov/DocumentCenter/View/5717/San-Miguel-County-IgG-Antibody-Test-Statistics-and-Demographics-PDF,2021-07-08,2022-07-16,Verified,united_biomedical_san_2020,USA
200503_SaltLakeCity_UniversityofUtah_HCW,200503_SaltLakeCity_UniversityofUtah,Prevalence of IgG antibodies to SARS-CoV-2 among emergency department employees,2020-05-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Utah,Salt Lake City,All ED employees were eligible.,,2020-04-13,2020-04-19,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,270,0.059000000000000004,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9540000000000001,0.983,['High'],No,No,No,No,Unclear,Yes,Yes,Yes,Yes,Troy Madsen,University of Utah,Not Unity-Aligned,https://www.ajemjournal.com/article/S0735-6757(20)30306-5/fulltext,2020-05-14,2024-03-01,Verified,madsen_prevalence_2020,USA
200504_SouthCarolina_MedicalUniversitySouthCarolina_HealthcareWorkers_FirstResponders,200504_SouthCarolina_MedicalUniversitySouthCarolina,Results show 2% of tested MUSC staff have COVID-19 antibodies,2020-05-04,News and Media,Local,Cross-sectional survey ,United States of America,South Carolina,Charleston,"MUSC staff, which includes healthcare workers and first responders",,2020-04-27,2020-05-02,Multiple populations,All,Adults (18-64 years),,,Primary Estimate,,920,0.02,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],No,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,Nick Reagan,Medical University South Carolina,Not Unity-Aligned,https://www.live5news.com/2020/05/04/results-show-tested-musc-staff-have-covid-antibodies/,2020-06-27,2022-07-16,Verified,reagan_results_2020,USA
200506_Atlanta_GeorgiaStateUniversity_GeneralPop_IgG,200506_Atlanta_GeorgiaStateUniversity,Antibodies to SARS/CoV-2 in arbitrarily-selected Atlanta residents,2020-05-06,Preprint,Local,Cross-sectional survey ,United States of America,Georgia,Atlanta,Atlanta residents (in the zip codes listed in Table 1),"Participants who were NAT+, confirmed household members of symptomatic NAT+ individuals or contacted the study team after hearing of the study second-hand.",2020-04-17,2020-04-27,Household and community samples,All,Multiple groups,,,Primary Estimate,,127,0.0236,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],No,No,No,No,Unclear,Unclear,Yes,No,Unclear,Jun Zou,Georgia State University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.05.01.20087478v1,2020-05-14,2022-07-16,Verified,zou_antibodies_2020,USA
200507_Boise_UniversityofWashington_GenPop,200507_Boise_UniversityofWashington,"Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho",2020-05-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Idaho,Boise,"Individuals in Boise, Idaho during late April 2020",,2020-04-20,2020-04-26,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,4856,0.0179,,,True,,,,True,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,1.0,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Andrew Bryan,University of Washington School of Medicine,Not Unity-Aligned,https://jcm.asm.org/content/early/2020/05/07/JCM.00941-20,2020-07-18,2024-03-01,Verified,bryan_a_performance_2020,USA
200507_Boise_UniversityofWashington_GenPopAge20-29 ,200507_Boise_UniversityofWashington,"Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho",2020-05-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Idaho,Boise,"Individuals in Boise, Idaho during late April 2020",,2020-04-20,2020-04-26,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,301,0.023,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,1.0,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Andrew Bryan,University of Washington School of Medicine,Not Unity-Aligned,https://jcm.asm.org/content/early/2020/05/07/JCM.00941-20,2020-07-18,2024-03-01,Verified,bryan_a_performance_2020,USA
200507_Boise_UniversityofWashington_GenPopGenderUnknown,200507_Boise_UniversityofWashington,"Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho",2020-05-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Idaho,Boise,"Individuals in Boise, Idaho during late April 2020",,2020-04-20,2020-04-26,Household and community samples,Other,Multiple groups,0.0,,Sex/Gender,Unknown,190,0.0263,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,1.0,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Andrew Bryan,University of Washington School of Medicine,Not Unity-Aligned,https://jcm.asm.org/content/early/2020/05/07/JCM.00941-20,2020-07-18,2024-03-01,Verified,bryan_a_performance_2020,USA
200507_Boise_UniversityofWashington_GenPopAge50-59,200507_Boise_UniversityofWashington,"Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho",2020-05-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Idaho,Boise,"Individuals in Boise, Idaho during late April 2020",,2020-04-20,2020-04-26,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,1142,0.019,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,1.0,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Andrew Bryan,University of Washington School of Medicine,Not Unity-Aligned,https://jcm.asm.org/content/early/2020/05/07/JCM.00941-20,2020-07-18,2024-03-01,Verified,bryan_a_performance_2020,USA
200507_Boise_UniversityofWashington_GenPopFemales,200507_Boise_UniversityofWashington,"Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho",2020-05-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Idaho,Boise,"Individuals in Boise, Idaho during late April 2020",,2020-04-20,2020-04-26,Household and community samples,Female,Multiple groups,0.0,,Sex/Gender,Female,2632,0.016,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,1.0,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Andrew Bryan,University of Washington School of Medicine,Not Unity-Aligned,https://jcm.asm.org/content/early/2020/05/07/JCM.00941-20,2020-07-18,2024-03-01,Verified,bryan_a_performance_2020,USA
200507_Boise_UniversityofWashington_GenPopAge40-49,200507_Boise_UniversityofWashington,"Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho",2020-05-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Idaho,Boise,"Individuals in Boise, Idaho during late April 2020",,2020-04-20,2020-04-26,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,1102,0.016,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,1.0,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Andrew Bryan,University of Washington School of Medicine,Not Unity-Aligned,https://jcm.asm.org/content/early/2020/05/07/JCM.00941-20,2020-07-18,2024-03-01,Verified,bryan_a_performance_2020,USA
200507_Boise_UniversityofWashington_GenPopAge70-79,200507_Boise_UniversityofWashington,"Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho",2020-05-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Idaho,Boise,"Individuals in Boise, Idaho during late April 2020",,2020-04-20,2020-04-26,Household and community samples,All,Seniors (65+ years),70.0,79.0,Age,70-79,327,0.009000000000000001,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,1.0,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Andrew Bryan,University of Washington School of Medicine,Not Unity-Aligned,https://jcm.asm.org/content/early/2020/05/07/JCM.00941-20,2020-07-18,2024-03-01,Verified,bryan_a_performance_2020,USA
200507_Boise_UniversityofWashington_GenPopAge30-39,200507_Boise_UniversityofWashington,"Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho",2020-05-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Idaho,Boise,"Individuals in Boise, Idaho during late April 2020",,2020-04-20,2020-04-26,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,831,0.016,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,1.0,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Andrew Bryan,University of Washington School of Medicine,Not Unity-Aligned,https://jcm.asm.org/content/early/2020/05/07/JCM.00941-20,2020-07-18,2024-03-01,Verified,bryan_a_performance_2020,USA
200507_Boise_UniversityofWashington_GenPopMales,200507_Boise_UniversityofWashington,"Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho",2020-05-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Idaho,Boise,"Individuals in Boise, Idaho during late April 2020",,2020-04-20,2020-04-26,Household and community samples,Male,Multiple groups,0.0,,Sex/Gender,Male,2035,0.0197,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,1.0,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Andrew Bryan,University of Washington School of Medicine,Not Unity-Aligned,https://jcm.asm.org/content/early/2020/05/07/JCM.00941-20,2020-07-18,2024-03-01,Verified,bryan_a_performance_2020,USA
200507_Boise_UniversityofWashington_GenPopAge60-69,200507_Boise_UniversityofWashington,"Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho",2020-05-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Idaho,Boise,"Individuals in Boise, Idaho during late April 2020",,2020-04-20,2020-04-26,Household and community samples,All,Adults (18-64 years),60.0,69.0,Age,60-69,888,0.025,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,1.0,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Andrew Bryan,University of Washington School of Medicine,Not Unity-Aligned,https://jcm.asm.org/content/early/2020/05/07/JCM.00941-20,2020-07-11,2024-03-01,Verified,bryan_a_performance_2020,USA
200507_Boise_UniversityofWashington_GenPopAge80+,200507_Boise_UniversityofWashington,"Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho",2020-05-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Idaho,Boise,"Individuals in Boise, Idaho during late April 2020",,2020-04-20,2020-04-26,Household and community samples,All,Seniors (65+ years),80.0,,Age,>=80,25,0.04,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,1.0,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Andrew Bryan,University of Washington School of Medicine,Not Unity-Aligned,https://jcm.asm.org/content/early/2020/05/07/JCM.00941-20,2020-07-18,2024-03-01,Verified,bryan_a_performance_2020,USA
200507_Boise_UniversityofWashington_GenPopAge0-19 ,200507_Boise_UniversityofWashington,"Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho",2020-05-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Idaho,Boise,"Individuals in Boise, Idaho during late April 2020",,2020-04-20,2020-04-26,Household and community samples,All,Children and Youth (0-17 years),0.0,19.0,Age,0-19,240,0.004,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,1.0,['High'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Andrew Bryan,University of Washington School of Medicine,Not Unity-Aligned,https://jcm.asm.org/content/early/2020/05/07/JCM.00941-20,2020-07-18,2024-03-01,Verified,bryan_a_performance_2020,USA
200508_Seattle_UniversityofWashington_Adults,200508_Seattle_UniversityofWashington,"Public Health Response to the Initiation and Spread of Pandemic COVID-19 in the United States, February 24–April 21, 2020",2020-05-08,Institutional Report,Local,Cross-sectional survey ,United States of America,Washington,Seattle,healthy adults without respiratory illness,,2020-03-01,2020-03-31,Residual sera,All,Adults (18-64 years),,,Primary Estimate,,221,0.004,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,Serum,,,,,,['High'],No,No,No,No,Unclear,Unclear,Yes,No,Unclear,Anne Schuchat,University of Washington,Not Unity-Aligned,https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6918e2-H.pdf,2020-05-03,2022-07-16,Verified,anne_schuchat_public_2020,USA
200510_US_StanfordUniversity_MajorLeagueBaseballEmployees,200510_US_StanfordUniversity,MLB antibody study: 0.7% of those tested had been exposed to coronavirus,2020-05-10,News and Media,National,Cross-sectional survey ,United States of America,,,MLB employees,,2020-04-08,2020-04-21,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,5603,0.006999999999999999,0.0028000000000000004,0.0115,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['Moderate'],Yes,No,Yes,No,Unclear,Unclear,Yes,No,Unclear,Susan Slusser,Stanford University,Not Unity-Aligned,https://www.sfchronicle.com/athletics/article/MLB-antibody-study-7-percent-exposed-to-15260314.php,2020-06-02,2022-07-16,Verified,slusser_mlb_2020,USA
200515_Winona_WinonaHealth_GeneralPopulation,200515_Winona_WinonaHealth,"New COVID-19
  antibody testing in Winona gives health officials a better picture of the
  spread",2020-05-15,News and Media,Local,Cross-sectional survey ,United States of America,Minnesota,Winona,Anyone who wants to be tested for antibodies,,2020-05-10,2020-05-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,1000,0.07,,,True,,,,True,Self-referral,Not reported/ Unable to specify,,,,IgG,,,,,['High'],Yes,No,Yes,No,Unclear,Unclear,Yes,No,,Mal Meyer,Winona Health,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.news8000.com/new-covid-19-antibody-testing-in-winona-gives-health-officials-a-better-picture-of-the-spread/&ct=ga&cd=CAEYDyoTMTE4NjM1MjEyMTUyMjIzNTE5ODIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNE5fpVM7tRmIsEhSRedRkru-TpZOA,2020-05-18,2022-07-16,Verified,meyer_new_2020,USA
200515_Boston_BostonPublicHealthCommission,200515_Boston_BostonPublicHealthCommission,Results released for antibody and COVID-19 testing of Boston residents,2020-05-18,News and Media,Local,Cross-sectional survey ,United States of America,Massachusetts,Boston,"Residents in the neighbourhoods of  East Boston, Roslindale and part of Dorchester. In terms of neighborhoods: 36.8% are from Roslindale, 25.1% are from East Boston, 23.2% are from 02125 in Dorchester and 14.9% are from 02121 in Dorchester. ",People who had previously tested positive for infection or who were showing active symptoms were excluded from the tests.,,2020-05-15,Household and community samples,,,,,Primary Estimate,,750,0.099,,,True,,,,True,Unclear,Author designed (LFIA),,LFIA,Whole Blood,[],,,,,['High'],,Unclear,Yes,Yes,,Unclear,Yes,No,,City of Boston,Boston Public Health Commission ,Not Unity-Aligned,https://www.boston.gov/news/results-released-antibody-and-covid-19-testing-boston-residents,2021-11-23,2022-07-16,Unverified,city_of_boston_results_2020,USA
200518_LosAngelesCounty_StanfordUniversity_GenPopWeighted_TestAdj,200518_LosAngelesCounty_StanfordUniversity,"Seroprevalence of SARS-CoV-2–Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020",2020-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,California,,"Residents of Los Angeles County, California, within a 15-mile (24 km) radius of the testing site were eligible for participation. ",,2020-04-10,2020-04-14,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,"Adjusted: population, test",863,0.04650000000000001,0.0252,0.0707,True,True,True,,,Stratified probability,COVID-19 IgG/IgM Rapid Test Cassette,Premier Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8270000000000001,0.995,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Neeraj Sood,Stanford University School of Medicine,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2766367,2020-05-21,2023-07-04,Verified,sood_seroprevalence_2020,USA
200518_LosAngelesCounty_StanfordUniversity_35-54yrs,200518_LosAngelesCounty_StanfordUniversity,"Seroprevalence of SARS-CoV-2–Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020",2020-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,California,,"Residents of Los Angeles County, California, within a 15-mile (24 km) radius of the testing site were eligible for participation. ",,2020-04-10,2020-04-14,Household and community samples,All,Adults (18-64 years),35.0,54.0,Age,35-54 ,475,0.0442,0.0275,0.0668,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test Cassette,Premier Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8270000000000001,0.995,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Neeraj Sood,Stanford University School of Medicine,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2766367,2020-07-13,2024-03-01,Verified,sood_seroprevalence_2020,USA
200518_LosAngelesCounty_StanfordUniversity_18-34yrs,200518_LosAngelesCounty_StanfordUniversity,"Seroprevalence of SARS-CoV-2–Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020",2020-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,California,,"Residents of Los Angeles County, California, within a 15-mile (24 km) radius of the testing site were eligible for participation. ",,2020-04-10,2020-04-14,Household and community samples,All,Adults (18-64 years),18.0,34.0,Age,18-34,191,0.031400000000000004,0.0116,0.0671,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test Cassette,Premier Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8270000000000001,0.995,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Neeraj Sood,Stanford University School of Medicine,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2766367,2020-07-13,2024-03-01,Verified,sood_seroprevalence_2020,USA
200518_LosAngelesCounty_StanfordUniversity_Female,200518_LosAngelesCounty_StanfordUniversity,"Seroprevalence of SARS-CoV-2–Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020",2020-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,California,,"Residents of Los Angeles County, California, within a 15-mile (24 km) radius of the testing site were eligible for participation. ",,2020-04-10,2020-04-14,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,Female,514,0.033100000000000004,0.0194,0.0524,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test Cassette,Premier Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8270000000000001,0.995,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Neeraj Sood,Stanford University School of Medicine,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2766367,2020-07-13,2024-03-01,Verified,sood_seroprevalence_2020,USA
200518_LosAngelesCounty_StanfordUniversity_>=55yrs,200518_LosAngelesCounty_StanfordUniversity,"Seroprevalence of SARS-CoV-2–Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020",2020-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,California,,"Residents of Los Angeles County, California, within a 15-mile (24 km) radius of the testing site were eligible for participation. ",,2020-04-10,2020-04-14,Household and community samples,All,Multiple groups,55.0,,Age,>=55,197,0.0406,0.0177,0.0784,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test Cassette,Premier Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8270000000000001,0.995,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Neeraj Sood,Stanford University School of Medicine,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2766367,2020-07-13,2024-03-01,Verified,sood_seroprevalence_2020,USA
200518_LosAngelesCounty_StanfordUniversity_OtherEthnicity,200518_LosAngelesCounty_StanfordUniversity,"Seroprevalence of SARS-CoV-2–Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020",2020-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,California,,"Residents of Los Angeles County, California, within a 15-mile (24 km) radius of the testing site were eligible for participation. ",,2020-04-10,2020-04-14,Household and community samples,All,Multiple groups,18.0,,Race,Other,104,0.0385,0.0106,0.09550000000000002,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test Cassette,Premier Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8270000000000001,0.995,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Neeraj Sood,Stanford University School of Medicine,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2766367,2020-07-14,2024-03-01,Verified,sood_seroprevalence_2020,USA
200518_LosAngelesCounty_StanfordUniversity_GenPopWeighted_NoTestAdj,200518_LosAngelesCounty_StanfordUniversity,"Seroprevalence of SARS-CoV-2–Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020",2020-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,California,,"Residents of Los Angeles County, California, within a 15-mile (24 km) radius of the testing site were eligible for participation. ",,2020-04-10,2020-04-14,Household and community samples,All,Multiple groups,18.0,,Analysis,"population adjust, no test adjustment",863,0.0431,0.0259,0.062400000000000004,,,True,,True,Stratified probability,COVID-19 IgG/IgM Rapid Test Cassette,Premier Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8270000000000001,0.995,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Neeraj Sood,Stanford University School of Medicine,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2766367,2020-05-21,2024-03-01,Verified,sood_seroprevalence_2020,USA
200518_LosAngelesCounty_StanfordUniversity_Male,200518_LosAngelesCounty_StanfordUniversity,"Seroprevalence of SARS-CoV-2–Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020",2020-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,California,,"Residents of Los Angeles County, California, within a 15-mile (24 km) radius of the testing site were eligible for participation. ",,2020-04-10,2020-04-14,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,Male,347,0.0518,0.031000000000000003,0.08070000000000001,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test Cassette,Premier Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8270000000000001,0.995,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Neeraj Sood,Stanford University School of Medicine,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2766367,2020-07-13,2024-03-01,Verified,sood_seroprevalence_2020,USA
200518_LosAngelesCounty_StanfordUniversity_GenPopUnweighted_TestAdj,200518_LosAngelesCounty_StanfordUniversity,"Seroprevalence of SARS-CoV-2–Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020",2020-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,California,,"Residents of Los Angeles County, California, within a 15-mile (24 km) radius of the testing site were eligible for participation. ",,2020-04-10,2020-04-14,Household and community samples,All,Multiple groups,18.0,,Analysis,Adjusted: test,863,0.0434,0.0276,0.060700000000000004,,True,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test Cassette,Premier Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8270000000000001,0.995,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Neeraj Sood,Stanford University School of Medicine,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2766367,2020-05-21,2023-07-04,Verified,sood_seroprevalence_2020,USA
200518_LosAngelesCounty_StanfordUniversity_Black,200518_LosAngelesCounty_StanfordUniversity,"Seroprevalence of SARS-CoV-2–Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020",2020-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,California,,"Residents of Los Angeles County, California, within a 15-mile (24 km) radius of the testing site were eligible for participation. ",,2020-04-10,2020-04-14,Household and community samples,All,Multiple groups,18.0,,Race,Black (non-Hispanic),72,0.0694,0.0229,0.15460000000000002,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test Cassette,Premier Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8270000000000001,0.995,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Neeraj Sood,Stanford University School of Medicine,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2766367,2020-07-14,2024-03-01,Verified,sood_seroprevalence_2020,USA
200518_LosAngelesCounty_StanfordUniversity_White,200518_LosAngelesCounty_StanfordUniversity,"Seroprevalence of SARS-CoV-2–Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020",2020-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,California,,"Residents of Los Angeles County, California, within a 15-mile (24 km) radius of the testing site were eligible for participation. ",,2020-04-10,2020-04-14,Household and community samples,All,Multiple groups,18.0,,Race,White,497,0.0442,0.0279,0.06620000000000001,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test Cassette,Premier Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8270000000000001,0.995,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Neeraj Sood,Stanford University School of Medicine,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2766367,2020-07-14,2024-03-01,Verified,sood_seroprevalence_2020,USA
200518_LosAngelesCounty_StanfordUniversity_GenPopCrude,200518_LosAngelesCounty_StanfordUniversity,"Seroprevalence of SARS-CoV-2–Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020",2020-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,California,,"Residents of Los Angeles County, California, within a 15-mile (24 km) radius of the testing site were eligible for participation. ",,2020-04-10,2020-04-14,Household and community samples,All,Multiple groups,18.0,,Analysis,Unadjusted,863,0.0406,0.028399999999999998,0.055999999999999994,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test Cassette,Premier Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8270000000000001,0.995,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Neeraj Sood,Stanford University School of Medicine,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2766367,2020-05-21,2024-03-01,Verified,sood_seroprevalence_2020,USA
200518_LosAngelesCounty_StanfordUniversity_Hispanic,200518_LosAngelesCounty_StanfordUniversity,"Seroprevalence of SARS-CoV-2–Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020",2020-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,California,,"Residents of Los Angeles County, California, within a 15-mile (24 km) radius of the testing site were eligible for participation. ",,2020-04-10,2020-04-14,Household and community samples,All,Multiple groups,18.0,,Ethnicity,Hispanic,190,0.021,0.0058,0.053,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test Cassette,Premier Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8270000000000001,0.995,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Neeraj Sood,Stanford University School of Medicine,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2766367,2020-07-14,2024-03-01,Verified,sood_seroprevalence_2020,USA
200520_Madison_UWHealth_UnityPointClinic,200520_Madison_UWHealthMeriter_2,Antibody tests for coronavirus so far trend overwhelmingly negative,2020-05-20,News and Media,Local,Cross-sectional survey ,United States of America,Wisconsin,Madison,Madison-area hospitals and clinics opened antibody testing to the public and after thousands of tests,,2020-05-13,2020-05-20,Household and community samples,All,Multiple groups,,,Primary Estimate,,433,0.003,,,True,,,,True,Self-referral,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,No,No,No,Unclear,Unclear,Yes,No,Unclear,Michelle Alfini,UW Health,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://wkow.com/2020/05/20/antibody-tests-for-coronavirus-so-far-trend-overwhelmingly-negative/&ct=ga&cd=CAAYATIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNHstyT58meN6_pst9Z3Iu6amuxEQQ,2020-06-27,2022-07-16,Verified,alfini_antibody_2020,USA
200520_Madison_UWHealth_UniWisconsinHealthClinic,200520_Madison_UWHealth_1,Antibody tests for coronavirus so far trend overwhelmingly negative,2020-05-20,News and Media,Local,Cross-sectional survey ,United States of America,Wisconsin,Madison,Madison-area hospitals and clinics opened antibody testing to the public and after thousands of tests,,2020-05-13,2020-05-20,Household and community samples,All,Multiple groups,,,Primary Estimate,,5303,0.015,,,True,,,,True,Self-referral,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,No,Yes,No,Unclear,Unclear,Yes,No,Unclear,Michelle Alfini,UW Health,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://wkow.com/2020/05/20/antibody-tests-for-coronavirus-so-far-trend-overwhelmingly-negative/&ct=ga&cd=CAAYATIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNHstyT58meN6_pst9Z3Iu6amuxEQQ,2020-06-27,2022-07-16,Verified,alfini_antibody_2020,USA
200520_Iowa_IowaDepartmentofPublicHealth_IowaStateGeneralPopulation,200520_Iowa_IowaDepartmentofPublicHealth,"Iowa begins to release serology test results, showing greater local spread of COVID-19",2020-05-20,News and Media,Regional,Cross-sectional survey ,United States of America,Iowa,,"When a physician determines that a SARS-CoV-2 antibody test is needed, the patient should meet one of the following criteria:

A patient suspected or confirmed to have COVID-19 who is greater than 7 days post symptom onset

Identification of persons with an antibody response to serve as convalescent plasma donors

Healthcare worker, essential services personnel, first responder or critical infrastructure worker (e.g., healthcare worker, fire, EMS, law enforcement, food service worker and residential facility staff) for whom knowledge of antibody production is needed",,2020-04-01,2020-05-20,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,,18160,0.1,,,True,,,,True,Self-referral,Not reported/ Unable to specify,,,Serum,IgG,,,,,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,Unclear,Jeff Montgomery,Iowa Department of Public Health,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.telegraphherald.com/coronavirus/article_b5f56348-317d-5f49-abee-0e7cff653cbb.html&ct=ga&cd=CAAYBDIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNG6tWk8Wg2dbYV27AKz5iI4DLM97Q,2020-05-30,2022-07-16,Verified,montgomery_iowa_2020,USA
200520_LosAngeles_UniSouthernCalifornia_GenPop,200520_LosAngeles_UniversitySouthernCalifornia,"LA County 'Still Far Away From Herd Immunity"" New Antibody Numbers Show",2020-05-20,News and Media,Local,Cross-sectional survey ,United States of America,California,,Inhabitants of Los Angeles,,2020-05-08,2020-05-12,Household and community samples,All,Multiple groups,,,Primary Estimate,,1014,0.021,,,True,,,,True,Self-referral,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,No,Yes,No,Unclear,Unclear,Yes,No,Unclear,CBS Los Angeles,University of Southern California,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://losangeles.cbslocal.com/2020/05/20/la-county-still-far-away-from-herd-immunity-new-antibody-numbers-show/&ct=ga&cd=CAAYCDIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGRZYAUZKxAbfGM7Yh_03xi5M8tDg,2020-06-27,2022-07-16,Verified,cbs_los_angeles_county_2020-1,USA
200523_CoralSprings_CoralSpringsCityGovernment_CityEmployees,200523_CoralSprings_CoralSpringsCityGovernement,South Florida Cities Begin Testing Employees For COVID-19 Antibodies,2020-05-22,News and Media,Local,Cross-sectional survey ,United States of America,Florida,Coral Springs,City employees and first responders,,2020-05-17,2020-05-22,Essential non-healthcare workers,All,Multiple groups,,,Primary Estimate,,700,0.0,,,True,,,,True,Self-referral,COVID-19 IgG/IgM Rapid Test Cassette,Cellex Inc.,,,,,,,,['High'],Yes,No,Yes,No,Unclear,No,Yes,No,Unclear,Jenny Staletovich,Coral Springs City Government,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.wlrn.org/post/south-florida-cities-begin-testing-employees-covid-19-antibodies&ct=ga&cd=CAAYDjIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNHc4oWG79OOMovZOpWOY8qd-gm3kw,2020-06-27,2024-03-01,Verified,staletovich_south_2020-1,USA
200523_SouthCarolina_MUSCHealthLancaster_HCW,200523_SouthCarolina_MUSCHealthLancaster,"Antibody tests
  show just 2% exposure rate to COVID-19",2020-05-23,News and Media,Local,Cross-sectional survey ,United States of America,South Carolina,Lancaster,Healthcare worker,,2020-03-16,2020-05-20,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,230,0.0217,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],No,Unclear,No,No,Unclear,Unclear,Yes,No,Unclear,Lisa Geraci ,MUSC Health-Lancaster,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.thelancasternews.com/content/antibody-tests-show-just-2-exposure-rate-covid-19&ct=ga&cd=CAEYFSoSNjI0MTExNTA1MzQ0Mjc2MzA2Mho5MGRlYTk4OTk0ZTkxODU5OmNvbTplbjpVUw&usg=AFQjCNEYxEO1T-WE8tAinlY5KZVTRufQSA,2020-05-26,2022-07-16,Verified,geraci_antibody_2020,USA
200528_Michigan_MichiganDepartmentofCorrections_ParnallCFa,200528_Michigan_MichiganDepartmentofCorrections_1_ParnallCFa,Almost everyone at one Michigan prison tests  positive for COVID-19 antibodies,2020-05-28,News and Media,Local,Cross-sectional survey ,United States of America,Michigan,,Inmates at Parnall Correctional Facility,,2020-05-14,2020-05-22,Persons who are incarcerated,All,Multiple groups,,,Primary Estimate,,1248,0.92,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,No,Yes,No,Unclear,Unclear,Yes,No,Unclear,Angie Jackson,Michigan Department of Corrections ,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.petoskeynews.com/news/state-region/almost-everyone-at-one-michigan-prison-tests-positive-for-covid-19-antibodies/article_423c1ef0-a018-5b50-b746-c93fcb82f71f.html&ct=ga&cd=CAAYEDIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGW46yu1TPu2kCI0JVHs2BTsuSgjw,2020-07-06,2022-07-16,Verified,jackson_almost_2020,USA
200528_Michigan_MichiganDepartmentofCorrections_MacombCF,200528_Michigan_MichiganDepartmentofCorrections_2_MacombCF,Almost everyone at one Michigan prison tests  positive for COVID-19 antibodies,2020-05-28,News and Media,Local,Cross-sectional survey ,United States of America,Michigan,Lenox Township,Inmates at Macomb Correctional Facility,,2020-05-14,2020-05-22,Persons who are incarcerated,All,Multiple groups,,,Primary Estimate,,1201,0.6559999999999999,,,True,True,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['Moderate'],Yes,No,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Angie Jackson,Michigan Department of Corrections ,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.petoskeynews.com/news/state-region/almost-everyone-at-one-michigan-prison-tests-positive-for-covid-19-antibodies/article_423c1ef0-a018-5b50-b746-c93fcb82f71f.html&ct=ga&cd=CAAYEDIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGW46yu1TPu2kCI0JVHs2BTsuSgjw,2020-07-06,2022-07-16,Verified,jackson_almost_2020,USA
200528_Michigan_MichiganDepartmentofCorrections_DetroitRC,200528_Michigan_MichiganDepartmentofCorrections_3_DetroitRC,Almost everyone at one Michigan prison tests  positive for COVID-19 antibodies,2020-05-28,News and Media,Local,Cross-sectional survey ,United States of America,Michigan,Detroit,Inmates from the Detroit Reentry Center,,2020-05-14,2020-05-22,Persons who are incarcerated,All,Multiple groups,,,Primary Estimate,,57,0.35000000000000003,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,No,No,No,Unclear,Unclear,Yes,No,Unclear,Angie Jackson,Michigan Department of Corrections ,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.petoskeynews.com/news/state-region/almost-everyone-at-one-michigan-prison-tests-positive-for-covid-19-antibodies/article_423c1ef0-a018-5b50-b746-c93fcb82f71f.html&ct=ga&cd=CAAYEDIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGW46yu1TPu2kCI0JVHs2BTsuSgjw,2020-07-06,2022-07-16,Verified,jackson_almost_2020,USA
200528_Michigan_MichiganDepartmentofCorrections_GRobertCottonCF,200528_Michigan_MichiganDepartmentofCorrections_4_GRobertCottonCF,Almost everyone at one Michigan prison tests  positive for COVID-19 antibodies,2020-05-28,News and Media,Local,Cross-sectional survey ,United States of America,Michigan,,Inmates from G Robert Cotton CF,,2020-05-14,2020-05-22,Persons who are incarcerated,All,Multiple groups,,,Primary Estimate,,867,0.1222,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,No,Yes,No,Unclear,Unclear,Yes,No,Unclear,Angie Jackson,Michigan Department of Corrections ,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.petoskeynews.com/news/state-region/almost-everyone-at-one-michigan-prison-tests-positive-for-covid-19-antibodies/article_423c1ef0-a018-5b50-b746-c93fcb82f71f.html&ct=ga&cd=CAAYEDIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGW46yu1TPu2kCI0JVHs2BTsuSgjw,2020-07-06,2022-07-16,Verified,jackson_almost_2020,USA
200529_NorthCarolina_Psalms/SolidRockMedicineGroup_GenPop,200529_NorthCarolina_Psalms/SolidRockMedicineGroup,Antibody testing continues in Burke County,2020-05-29,News and Media,Local,Cross-sectional survey ,United States of America,North Carolina,,"Anyone who came to have antibody testing at Patton High School in Burke County, N.C., USA on May 29, 2020.",,2020-05-29,2020-05-29,Household and community samples,All,Multiple groups,,,Primary Estimate,,329,0.0152,,,True,,,,True,Self-referral,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,No,No,No,Unclear,Unclear,Yes,No,Unclear,Steve Ohnesorge,Psalms/Solid Rock Medicine Group,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.wbtv.com/2020/05/29/antibody-testing-continues-burke-county/&ct=ga&cd=CAAYGTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNEvSO7bk5TLI9MT5-BeF8ILKdseXA,2020-07-04,2022-07-16,Verified,steve_ohnesorge_antibody_2020,USA
200529_CoachellaValley_Desert Healthcare District_GenPop,200529_California_DesertHealthcareDistrict,"Coachella Valley far from COVID-19 herd  immunity, preliminary antibody test results show",2020-05-29,News and Media,Local,Cross-sectional survey ,United States of America,California,,Anyone turning up to one of 10 locations throughout the valley.,,,2020-05-28,Household and community samples,All,Multiple groups,,,Primary Estimate,,896,0.06,,,True,,,,True,Self-referral,COVID19 RAPID TEST,Phamatech,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['High'],Yes,No,Yes,No,Unclear,No,Yes,No,Unclear,Nicole Hayden,Desert Healthcare District,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.desertsun.com/story/news/health/2020/05/29/coachella-valley-far-covid-19-herd-immunity-preliminary-antibody-tests-show/5280021002/&ct=ga&cd=CAAYKzIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNFQxOqwjTX2Kz2_mnj1RV7Upa8rEg,2020-07-04,2024-03-01,Verified,hayden_coachella_2020,USA
200601_LongHillTownship_SummitMedicalCenter_FirstResponders,200601_LongHillTownship_SummitMedicalCenter,Few among Long Hill first responders test positive for COVID-19 antibodies,2020-06-01,News and Media,Local,Cross-sectional survey ,United States of America,New Jersey,Long Hill Township,"emergency first responders. 70 Long Hill police officers, firefighters and first aid squad members ",,2020-05-01,2020-05-14,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,70,0.04285,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,No,No,No,Unclear,Unclear,Yes,No,Unclear,Alex Parker Magyar,Summit Medical Center,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.newjerseyhills.com/echoes-sentinel/news/few-among-long-hill-first-responders-test-positive-for-covid-19-antibodies/article_007ac367-b3b2-5375-b471-f0a817998f62.html&ct=ga&cd=CAAYFDIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNHWg839bXiyzOxO1Y7-QOECGMRCMw,2020-06-02,2022-07-16,Verified,parker-magyar_few_2020,USA
200602_HumboldtCounty_HumboldtCountyDepartmentofHealthandHumanServices_GenPop,200602_HumboldtCounty_HumboldtCountyDepartmentofHealthandHumanServices,1%  of early Humboldt County coronavirus tests show antibodies,2020-06-02,News and Media,Local,Cross-sectional survey ,United States of America,California,,"The test results are from a sample size of 1,000 non-random residents, many of them from the same geographic area of the county. ",,,2020-05-26,Household and community samples,All,Multiple groups,,,Primary Estimate,,1000,0.01,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,Shomik Mukherjee ,Humboldt County Department of Health and Human Services,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.times-standard.com/1-of-early-humboldt-county-coronavirus-tests-show-antibodies&ct=ga&cd=CAAYDjIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNFdl7jBbUfA1cB9ZXhwgAM8IvQmrA,2020-06-07,2022-07-16,Verified,shomik_mukherjee_1_2020,USA
200602_NewYork_IcahnSchoolofMedicineatMountSinai_HealthCareWorkers,200602_NewYork_IcahnSchoolofMedicineatMountSinai,Prevalence of SARS-CoV-2 Antibodies Among Healthcare Workers at a Tertiary Academic Hospital in New York City,2020-06-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,We collected serum IgG antibody titers from self-referred HCW throughout our health system using a serologic ELISA assay,,2020-03-24,2020-04-04,Health care workers and caregivers,All,Multiple groups,18.0,84.0,Primary Estimate,,285,0.32630000000000003,,,True,,,,True,Self-referral,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,Validated by manufacturers,,,['High'],Yes,No,No,Yes,Yes,Unclear,Yes,No,Unclear,Mayce Mansour,Icahn School of Medicine at Mount Sinai,Not Unity-Aligned,https://link.springer.com/article/10.1007/s11606-020-05926-8,2020-06-04,2022-07-16,Verified,mansour_prevalence_2020,USA
200509_NewYork_ColumbiaUniversityIrvingMedicalCenter_HCW,200509_NewYork_ColumbiaUniversityIrvingMedicalCenter,"Anesthesiologists' and intensive care
  providers' exposure to COVID-19 infection in a New York City academic center:
  a prospective cohort study assessing symptoms and COVID-19 antibody testing",2020-06-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"Physicians working in close clinical interaction with patients during the COVID-19 outbreak, between March 1st 2020 and April 21st 2020, in either the general operating rooms (OR), the emergently
constructed ORICU 78-bed intensive care unit (ICU) built in the general OR), participating in the general adult and pediatric COVID-19 intubation team at the Columbia campus of NewYorkPresbyterian Hospital (NYPH) or caring for parturients admitted to the Morgan Stanley Children’s Hospital Labor and Delivery Unit, were approached by e-mail for participation. First 100 responders were invited to participate. ",,2020-03-01,2020-04-21,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,91,0.121,,,True,,,,True,Convenience,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9309999999999999,0.9920000000000001,['High'],No,No,No,No,No,Yes,Yes,Yes,No,Miguel Morcuende,Columbia University Irving Medical Center,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302070/,2020-07-19,2024-03-01,Verified,morcuende_anesthesiologists_2020,USA
200612_Guam_USNavy,200612_Guam_USNavy,"SARS-CoV-2 Infections and Serologic Responses from a Sample of U.S. Navy Service Members - USS Theodore Roosevelt, April 2020.",2020-06-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Guam,,USS Theodore Roosevelt  service members staying at the base on Guam or on the ship during April 20–24 and completed questionnaire.,,2020-04-20,2020-04-24,Essential non-healthcare workers,All,Adults (18-64 years),18.0,59.0,Primary Estimate,,382,0.5970000000000001,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.96,0.993,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,No,Daniel Payne,US Navy,Not Unity-Aligned,https://www.cdc.gov/mmwr/volumes/69/wr/mm6923e4.htm,2020-06-12,2022-07-16,Verified,payne_sars-cov-2_2020,USA
200612_NewJersey_MonmouthMedicalCentre_HealthCareWorkersUnadj,200612_NewJersey_MonmouthMedicalCentre,"The Prevalence of SARS-CoV-2 IgG Antibodies in Intensive Care Unit (ICU) Healthcare Personnel (HCP) and its Implications - A Single-Center, Prospective, Pilot Study",2020-06-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New Jersey,Long Branch,"All HCP caring for COVID19 patients between Mar 1 - April 30, 2020 in the ICU were eligible 
","HCP who tested positive by RT PCR, had symptoms consistent with COVID19, or had COVID19 exposure in a household setting ",2020-05-14,2020-05-19,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,121,0.0083,,,True,,,,True,Convenience,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Serum,IgG,,Validated by manufacturers,0.9620000000000001,0.966,['High'],No,No,No,Yes,Unclear,No,Yes,No,Yes,Mohsin Mughal ,Monmouth Medical Centre,Not Unity-Aligned,https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/article/prevalence-of-sarscov2-igg-antibodies-in-intensive-care-unit-icu-healthcare-personnel-hcp-and-its-implications-a-singlecenter-prospective-pilot-study/296957BF678E512283D4A3770467FFB7,2020-06-13,2024-03-01,Verified,mughal_prevalence_2020,USA
200614_Ohio_OhioStateUniversity_Period1,200614_Ohio_OhioStateUniversity_Baseline1,Exposure and seroconversion to severe acute respiratory syndrome coronavirus 2 among obstetrical healthcare providers following a contained outbreak,2020-06-14,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Ohio,Columbus,The study included HCWs employed in the inpatient obstetrical unit. ,,2020-03-25,2020-03-25,Health care workers and caregivers,Female,Adults (18-64 years),,,Primary Estimate,First testing of the same patient cohort,110,0.027000000000000003,,,,,,,,Convenience,"EDI™ Novel Coronavirus COVID-19 IgM ELISA Kit,EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit","Epitope Diagnostics, Inc.",ELISA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],No,No,No,No,No,Yes,Yes,No,No,Miranda Kiefer,Ohio State University College of Medicine,Not Unity-Aligned,https://www.ajog.org/article/S0002-9378(20)30649-9/fulltext,2020-08-02,2024-03-01,Verified,kiefer_exposure_2020-1,USA
200614_Ohio_OhioStateUniversity_Period 2,200614_Ohio_OhioStateUniversity_Followup2,Exposure and seroconversion to severe acute respiratory syndrome coronavirus 2 among obstetrical healthcare providers following a contained outbreak,2020-06-14,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Ohio,Columbus,The study included HCWs employed in the inpatient obstetrical unit. ,,2020-04-23,2020-04-23,Health care workers and caregivers,Female,Adults (18-64 years),,,Primary Estimate,,110,0.2,,,True,,,,True,Convenience,EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit,"Epitope Diagnostics, Inc.",ELISA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],No,No,No,No,No,Yes,Yes,Yes,No,Miranda Kiefer,Ohio State University College of Medicine,Not Unity-Aligned,https://www.ajog.org/article/S0002-9378(20)30649-9/fulltext,2020-08-02,2024-03-01,Verified,kiefer_exposure_2020-1,USA
200614_SteamboatSprings_RouttCountyBoardofHealth_GenPop,200614_SteamboatSprings_RouttCountyBoardofHealth,"One new positive COVID-19 case in Routt County, antibody testing ramping up",2020-06-14,News and Media,Local,Cross-sectional survey ,United States of America,Colorado,Steamboat Springs,,,,2020-06-10,Household and community samples,All,Multiple groups,,,Primary Estimate,,649,0.026000000000000002,,,True,,,,True,Self-referral,Not reported/ Unable to specify,,,,,,,,,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,Unclear,Kari Harden ,Routt County Board of Health,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.steamboatpilot.com/news/one-new-positive-covid-19-case-in-routt-county-antibody-testing-ramping-up/&ct=ga&cd=CAEYBSoTNzg3MTAwMjkzNzU0ODU4ODgzODIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGVI81Ue1Rqm7AhmKKlvb0xWvQDKQ,2020-06-15,2022-07-16,Verified,kari_harden_one_2020,USA
200617_NewYork_StateUniversityofNewYork_GeneralPopTestPopAdj,200617_NewYork_NewYorkStateDepartmentofHealth,Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York,2020-06-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,New York,,,Missing demographic data (did not complete demographic questionnaire and were not reachable by phone),2020-04-19,2020-04-28,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,"Adjusted: population, test",15101,0.14,0.133,0.147,True,True,True,,,Convenience,Author designed (ELISA) - Nucleocapsid,,CLIA,Dried Blood,IgG,Nucleocapsid(N-protein),Validated by developers,0.8790000000000001,0.9975,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Eli Rosenberg,New York State Department of Health,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2020.06.004,2020-05-30,2023-07-04,Verified,rosenberg_cumulative_2020,USA
200617_NewYork_StateUniversityofNewYork_GeneralPopUnadj,200617_NewYork_NewYorkStateDepartmentofHealth,Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York,2020-06-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,New York,,,Missing demographic data (did not complete demographic questionnaire and were not reachable by phone),2020-04-19,2020-04-28,Household and community samples,All,Multiple groups,18.0,,Analysis,,15101,0.125,,,,,,,True,Convenience,Author designed (ELISA) - Nucleocapsid,,CLIA,Dried Blood,IgG,Nucleocapsid(N-protein),Validated by developers,0.8790000000000001,0.9975,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Eli Rosenberg,New York State Department of Health,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2020.06.004,2020-05-30,2023-07-04,Verified,rosenberg_cumulative_2020,USA
200617_NewYork_StateUniversityofNewYork_OtherEthnicitiesTestAdj,200617_NewYork_NewYorkStateDepartmentofHealth,Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York,2020-06-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,New York,,,Missing demographic data (did not complete demographic questionnaire and were not reachable by phone),2020-04-19,2020-04-28,Household and community samples,All,Multiple groups,18.0,,Race,Other,279,0.11900000000000001,0.064,0.17500000000000002,,True,,,,Convenience,Author designed (ELISA) - Nucleocapsid,,CLIA,Dried Blood,IgG,Nucleocapsid(N-protein),Validated by developers,0.8790000000000001,0.9975,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Eli Rosenberg,New York State Department of Health,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2020.06.004,2020-07-06,2023-07-04,Verified,rosenberg_cumulative_2020,USA
200617_NewYork_StateUniversityofNewYork_Age18-34TestAdj,200617_NewYork_NewYorkStateDepartmentofHealth,Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York,2020-06-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,New York,,,Missing demographic data (did not complete demographic questionnaire and were not reachable by phone),2020-04-19,2020-04-28,Household and community samples,All,Adults (18-64 years),18.0,34.0,Age,18-34,3151,0.146,0.131,0.161,,True,,,,Convenience,Author designed (ELISA) - Nucleocapsid,,CLIA,Dried Blood,IgG,Nucleocapsid(N-protein),Validated by developers,0.8790000000000001,0.9975,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Eli Rosenberg,New York State Department of Health,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2020.06.004,2020-07-06,2023-07-04,Verified,rosenberg_cumulative_2020,USA
200617_NewYork_StateUniversityofNewYork_LongIslandTestAdj,200617_NewYork_NewYorkStateDepartmentofHealth,Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York,2020-06-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,,,Missing demographic data (did not complete demographic questionnaire and were not reachable by phone),2020-04-19,2020-04-28,Household and community samples,All,Multiple groups,18.0,,Geographical area,long island,2074,0.132,0.114,0.151,,True,,,,Convenience,Author designed (ELISA) - Nucleocapsid,,CLIA,Dried Blood,IgG,Nucleocapsid(N-protein),Validated by developers,0.8790000000000001,0.9975,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Eli Rosenberg,New York State Department of Health,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2020.06.004,2020-07-06,2023-07-04,Verified,rosenberg_cumulative_2020,USA
200617_NewYork_StateUniversityofNewYork_AsianTestAdj,200617_NewYork_NewYorkStateDepartmentofHealth,Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York,2020-06-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,New York,,,Missing demographic data (did not complete demographic questionnaire and were not reachable by phone),2020-04-19,2020-04-28,Household and community samples,All,Multiple groups,18.0,,Race,Asian,629,0.12400000000000001,0.094,0.154,,True,,,,Convenience,Author designed (ELISA) - Nucleocapsid,,CLIA,Dried Blood,IgG,Nucleocapsid(N-protein),Validated by developers,0.8790000000000001,0.9975,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Eli Rosenberg,New York State Department of Health,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2020.06.004,2020-07-06,2023-07-04,Verified,rosenberg_cumulative_2020,USA
200617_NewYork_StateUniversityofNewYork_BlackTestAdj,200617_NewYork_NewYorkStateDepartmentofHealth,Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York,2020-06-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,New York,,,Missing demographic data (did not complete demographic questionnaire and were not reachable by phone),2020-04-19,2020-04-28,Household and community samples,All,Multiple groups,18.0,,Race,Black,1913,0.20199999999999999,0.18100000000000002,0.223,,True,,,,Convenience,Author designed (ELISA) - Nucleocapsid,,CLIA,Dried Blood,IgG,Nucleocapsid(N-protein),Validated by developers,0.8790000000000001,0.9975,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Eli Rosenberg,New York State Department of Health,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2020.06.004,2020-07-06,2023-07-04,Verified,rosenberg_cumulative_2020,USA
200617_NewYork_StateUniversityofNewYork_Age55+TestAdj,200617_NewYork_NewYorkStateDepartmentofHealth,Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York,2020-06-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,New York,,,Missing demographic data (did not complete demographic questionnaire and were not reachable by phone),2020-04-19,2020-04-28,Household and community samples,All,Seniors (65+ years),55.0,,Age,>=55,5977,0.121,0.11199999999999999,0.131,,True,,,,Convenience,Author designed (ELISA) - Nucleocapsid,,CLIA,Dried Blood,IgG,Nucleocapsid(N-protein),Validated by developers,0.8790000000000001,0.9975,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Eli Rosenberg,New York State Department of Health,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2020.06.004,2020-07-06,2023-07-04,Verified,rosenberg_cumulative_2020,USA
200617_NewYork_StateUniversityofNewYork_Age45-54TestAdj,200617_NewYork_NewYorkStateDepartmentofHealth,Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York,2020-06-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,New York,,,Missing demographic data (did not complete demographic questionnaire and were not reachable by phone),2020-04-19,2020-04-28,Household and community samples,All,Adults (18-64 years),45.0,54.0,Age,45-54,3345,0.16,0.146,0.17500000000000002,,True,,,,Convenience,Author designed (ELISA) - Nucleocapsid,,CLIA,Dried Blood,IgG,Nucleocapsid(N-protein),Validated by developers,0.8790000000000001,0.9975,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Eli Rosenberg,New York State Department of Health,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2020.06.004,2020-07-06,2023-07-04,Verified,rosenberg_cumulative_2020,USA
200617_NewYork_StateUniversityofNewYork_NYCTestAdj,200617_NewYork_NewYorkStateDepartmentofHealth,Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York,2020-06-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,,Missing demographic data (did not complete demographic questionnaire and were not reachable by phone),2020-04-19,2020-04-28,Household and community samples,All,Multiple groups,18.0,,Geographical area,"NYC, incl boroughs",5946,0.227,0.215,0.24,,True,,,,Convenience,Author designed (ELISA) - Nucleocapsid,,CLIA,Dried Blood,IgG,Nucleocapsid(N-protein),Validated by developers,0.8790000000000001,0.9975,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Eli Rosenberg,New York State Department of Health,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2020.06.004,2020-07-06,2023-07-04,Verified,rosenberg_cumulative_2020,USA
200617_NewYork_StateUniversityofNewYork_HispanicTestAdj,200617_NewYork_NewYorkStateDepartmentofHealth,Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York,2020-06-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,New York,,,Missing demographic data (did not complete demographic questionnaire and were not reachable by phone),2020-04-19,2020-04-28,Household and community samples,All,Multiple groups,18.0,,Ethnicity,Hispanic,2735,0.292,0.272,0.312,,True,,,,Convenience,Author designed (ELISA) - Nucleocapsid,,CLIA,Dried Blood,IgG,Nucleocapsid(N-protein),Validated by developers,0.8790000000000001,0.9975,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Eli Rosenberg,New York State Department of Health,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2020.06.004,2020-07-06,2023-07-04,Verified,rosenberg_cumulative_2020,USA
200617_NewYork_StateUniversityofNewYork_RocklandWestchesterTestAdj,200617_NewYork_NewYorkStateDepartmentofHealth,Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York,2020-06-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,,,Missing demographic data (did not complete demographic questionnaire and were not reachable by phone),2020-04-19,2020-04-28,Household and community samples,All,Multiple groups,18.0,,Geographical area,"Rockland, NY",980,0.161,0.132,0.19,,True,,,,Convenience,Author designed (ELISA) - Nucleocapsid,,CLIA,Dried Blood,IgG,Nucleocapsid(N-protein),Validated by developers,0.8790000000000001,0.9975,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Eli Rosenberg,New York State Department of Health,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2020.06.004,2020-07-06,2023-07-04,Verified,rosenberg_cumulative_2020,USA
200617_NewYork_StateUniversityofNewYork_WhiteTestAdj,200617_NewYork_NewYorkStateDepartmentofHealth,Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York,2020-06-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,New York,,,Missing demographic data (did not complete demographic questionnaire and were not reachable by phone),2020-04-19,2020-04-28,Household and community samples,All,Multiple groups,18.0,,Race,White/Caucasian,9545,0.081,0.07400000000000001,0.087,,True,,,,Convenience,Author designed (ELISA) - Nucleocapsid,,CLIA,Dried Blood,IgG,Nucleocapsid(N-protein),Validated by developers,0.8790000000000001,0.9975,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Eli Rosenberg,New York State Department of Health,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2020.06.004,2020-07-06,2023-07-04,Verified,rosenberg_cumulative_2020,USA
200617_NewYork_StateUniversityofNewYork_RestofNYSTestAdj,200617_NewYork_NewYorkStateDepartmentofHealth,Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York,2020-06-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,New York,,,Missing demographic data (did not complete demographic questionnaire and were not reachable by phone),2020-04-19,2020-04-28,Household and community samples,All,Multiple groups,18.0,,Geographical area,remaining NY counties,6101,0.036000000000000004,0.03,0.040999999999999995,,True,,,,Convenience,Author designed (ELISA) - Nucleocapsid,,CLIA,Dried Blood,IgG,Nucleocapsid(N-protein),Validated by developers,0.8790000000000001,0.9975,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Eli Rosenberg,New York State Department of Health,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2020.06.004,2020-07-06,2023-07-04,Verified,rosenberg_cumulative_2020,USA
200617_NewYork_StateUniversityofNewYork_MaleTestAdj,200617_NewYork_NewYorkStateDepartmentofHealth,Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York,2020-06-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,New York,,,Missing demographic data (did not complete demographic questionnaire and were not reachable by phone),2020-04-19,2020-04-28,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,Male,6635,0.14800000000000002,0.138,0.158,,True,,,,Convenience,Author designed (ELISA) - Nucleocapsid,,CLIA,Dried Blood,IgG,Nucleocapsid(N-protein),Validated by developers,0.8790000000000001,0.9975,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Eli Rosenberg,New York State Department of Health,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2020.06.004,2020-07-06,2023-07-04,Verified,rosenberg_cumulative_2020,USA
200617_NewYork_StateUniversityofNewYork_FemaleTestAdj,200617_NewYork_NewYorkStateDepartmentofHealth,Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York,2020-06-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,New York,,,Missing demographic data (did not complete demographic questionnaire and were not reachable by phone),2020-04-19,2020-04-28,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,Female,8466,0.133,0.12400000000000001,0.142,,True,,,,Convenience,Author designed (ELISA) - Nucleocapsid,,CLIA,Dried Blood,IgG,Nucleocapsid(N-protein),Validated by developers,0.8790000000000001,0.9975,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Eli Rosenberg,New York State Department of Health,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2020.06.004,2020-07-06,2023-07-04,Verified,rosenberg_cumulative_2020,USA
200617_NewYork_StateUniversityofNewYork_Age35-44TestAdj,200617_NewYork_NewYorkStateDepartmentofHealth,Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York,2020-06-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,New York,,,Missing demographic data (did not complete demographic questionnaire and were not reachable by phone),2020-04-19,2020-04-28,Household and community samples,All,Adults (18-64 years),35.0,44.0,Age,35-44,2628,0.153,0.13699999999999998,0.171,,True,,,,Convenience,Author designed (ELISA) - Nucleocapsid,,CLIA,Dried Blood,IgG,Nucleocapsid(N-protein),Validated by developers,0.8790000000000001,0.9975,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Eli Rosenberg,New York State Department of Health,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2020.06.004,2020-07-06,2023-07-04,Verified,rosenberg_cumulative_2020,USA
200617_Indiana_IndianaUniversity_Wave2GenPop,200617_Indiana_IndianaUniversity_Wave2,Fairbanks study indicates that 'virus has  slowed its spread' in Indiana,2020-06-17,News and Media,Regional,Cross-sectional survey ,United States of America,Indiana,,"Indiana residents, people over 12 years of age",,2020-06-03,2020-06-08,Household and community samples,All,Multiple groups,12.0,,Primary Estimate,,3600,0.015,,,True,,,,True,Stratified probability,Not reported/ Unable to specify,,,,,,,,,['Moderate'],Yes,Yes,Yes,No,Yes,Unclear,Yes,No,Unclear,Shari Rudavsky,Indiana University Fairbanks School of Public Health,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.indystar.com/story/news/health/2020/06/17/indiana-coronavirus-fairbanks-study-indicates-spread-has-slowed/3208509001/&ct=ga&cd=CAAYETIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNH4O6wDIVkk1hAyMEzD78OGtB7YoQ,2020-06-23,2022-07-16,Verified,rudavsky_fairbanks_2020,USA
200622_Brooklyn_ColumbiaUniversityMedicalCenter_Overall,200622_Brooklyn_ColumbiaUniversityMedicalCenter,COVID-19 Seroconversion in Emergency Professionals at an Urban Academic Emergency Department in New York City.,2020-06-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,emergency professionals who were actively working in the adult ED from February through April 2020,,2020-02-01,2020-04-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Overall,50,0.46,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,,IgG,,,,,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Yes,Jordan Jeong,Columbia University Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annemergmed.2020.06.038,2021-01-22,2024-03-01,Verified,jeong_covid-19_2020,USA
200622_TruckeeMeadows_TruckeeMeadowsFireProtectionDistrict_FirstResponders,200622_TruckeeMeadows_TruckeeMeadowsFireProtectionDistrict,Prevalence Of COVID-19 Antibodies In Washoe Co. Expected To Be Low,2020-06-22,News and Media,Local,Cross-sectional survey ,United States of America,Nevada,,"Frontline staff (firefighters, paramedics, captains, battalion chiefs) in Washoe County",,2020-05-01,2020-05-31,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,132,0.14,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,No,No,No,Unclear,Unclear,Yes,No,Unclear,Anh Gray,Truckee Meadows Fire Protection District,Not Unity-Aligned,https://www.kunr.org/post/prevalence-covid-19-antibodies-washoe-co-expected-be-low#stream/0,2020-06-24,2022-07-16,Verified,gray_prevalence_2020,USA
200624_BaskingRidge_FellowshipVillage_Residents2_Overall,200624_BaskingRidge_FellowshipVillage_Residents2,"Fellowship
  Village Benefits from Covid-19 Antibody Tests",2020-06-24,News and Media,Local,Cross-sectional survey ,United States of America,New Jersey,Basking Ridge,,,2020-04-15,2020-05-06,Assisted living and long-term care facilities,All,Seniors (65+ years),,,Primary Estimate,,371,0.34770000000000006,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,Unclear,Yes,No,Unclear,Tim Regan,Fellowship Village,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://seniorhousingnews.com/2020/06/24/fellowship-village-benefits-from-covid-19-antibody-tests-juniper-plans-pilot/&ct=ga&cd=CAEYAyoTMTA4MjA1OTc5ODY3MTIyMzk1NTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNFY2y-eZOXQXVuQzcKPUzRHkiG26g,2020-06-29,2022-07-16,Verified,regan_fellowship_2020,USA
200624_BaskingRidge_FellowshipVillage_Staff1_Overall,200624_BaskingRidge_FellowshipVillage_Staff1,"Fellowship
  Village Benefits from Covid-19 Antibody Tests",2020-06-24,News and Media,Local,Cross-sectional survey ,United States of America,New Jersey,Basking Ridge,,,2020-04-15,2020-05-06,Assisted living and long-term care facilities,All,Adults (18-64 years),,,Primary Estimate,,305,0.23600000000000002,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],No,No,No,No,Unclear,Unclear,Yes,No,Unclear,Tim Regan,Fellowship Village,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://seniorhousingnews.com/2020/06/24/fellowship-village-benefits-from-covid-19-antibody-tests-juniper-plans-pilot/&ct=ga&cd=CAEYAyoTMTA4MjA1OTc5ODY3MTIyMzk1NTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNFY2y-eZOXQXVuQzcKPUzRHkiG26g,2021-01-09,2022-07-16,Verified,regan_fellowship_2020,USA
200708_WashoeCounty_WashoeCountyHealthDistrict_GenPop,200708_WashoeCounty_WashoeCountyHealthDistrict,"Nevada COVID-19 infection rate 5 times higher, antibody tests show",2020-07-08,News and Media,Local,Cross-sectional survey ,United States of America,Nevada,,"Study included 1,270 randomly selected households from 128 unique census blocks in Washoe County. There were 234 adult participants who provided a blood sample for a COVID-19 antibody test",,2020-06-09,2020-06-10,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,,234,0.023,,,True,,,,True,Stratified probability,Not reported/ Unable to specify,,,,,,Validated by independent authors/third party/non-developers,,0.996,['High'],Yes,Yes,No,No,Unclear,Unclear,Yes,No,No,Mary Hynes,Washoe County Health District,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.reviewjournal.com/local/local-nevada/nevada-covid-19-infection-rate-5-times-higher-antibody-tests-show-2070094/&ct=ga&cd=CAAYBzIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNGG4t16ng9mGv7ghgkKQP4Qm3hotw,2020-08-01,2022-07-16,Verified,mary_hynes_nevada_2020,USA
200715_Massachusetts_HarvardMedicalSchool_Residents_IgG/IgM,200715_Massachusetts_HarvardMedicalSchool_Residents,Presymptomatic Transmission of SARS-CoV-2 Amongst Residents and Staff at a Skilled Nursing Facility: Results of Real-Time PCR and Serologic Testing,2020-07-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Massachusetts,,Universal testing for SARS-CoV-2 for a 142-bed skilled nursing facility in Massachusetts,,2020-04-01,2020-04-06,Assisted living and long-term care facilities,All,Seniors (65+ years),,,Primary Estimate,Nursing home residents,56,0.196,,,,,,,,Convenience,COVID-19 IgM-IgG Dual Antibody Rapid Test,"BioMedomics, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9009999999999999,0.9974,['High'],Yes,No,No,No,Yes,Yes,Yes,Yes,Yes,Scott Goldberg,Harvard Medical School,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa991,2020-08-02,2024-03-01,Verified,goldberg_presymptomatic_2020-1,USA
200715_Massachusetts_HarvardMedicalSchool_Staff_IgG/IgM,200715_Massachusetts_HarvardMedicalSchool_Staff,Presymptomatic Transmission of SARS-CoV-2 Amongst Residents and Staff at a Skilled Nursing Facility: Results of Real-Time PCR and Serologic Testing,2020-07-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Massachusetts,,Universal testing for SARS-CoV-2 for a 142-bed skilled nursing facility in Massachusetts,,2020-04-01,2020-04-06,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Nursing home staff,84,0.048,,,,,,,,Convenience,COVID-19 IgM-IgG Dual Antibody Rapid Test,"BioMedomics, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.9009999999999999,0.9974,['High'],Yes,No,No,No,Yes,Yes,Yes,Yes,Yes,Scott Goldberg,Harvard Medical School,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa991,2020-08-02,2024-03-01,Verified,goldberg_presymptomatic_2020-1,USA
200715_WashintonDC_DCPublicHealth_GenPop,200715_WashintonDC_DCPublicHealth,The DC health lab has tested 13706 blood samples. Only 809 people carried coronavirus antibodies.,2020-07-15,News and Media,Local,Cross-sectional survey ,United States of America,Washington D.C,Washington DC,samples are from a month of testing that has been offered to the public as well as to health-care workers.,,2020-06-15,2020-07-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,13706,0.059000000000000004,,,True,,,,True,Self-referral,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,,,,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Julie Zauzmer,Washington DC Public Health,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.washingtonpost.com/dc-md-va/2020/07/15/dc-health-lab-has-tested-13706-blood-samples-only-809-people-carried-coronavirus-antibodies/&ct=ga&cd=CAAYKTIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNFVGZ6aDeXqXAEUfikIfjfhDgkSVw,2020-08-02,2024-03-01,Verified,julie_zauzmer_dc_2020,USA
200717_Chittenden_UniversityVermont_GenPop,200717_Chittenden_UniversityVermont,Early results of UVM research tracking COVID's spread in Vermont,2020-07-17,News and Media,Local,Cross-sectional survey ,United States of America,Vermont,,Chittenden County residents who had previously taken part in an online survey,,,2020-06-30,Household and community samples,All,Multiple groups,,,Primary Estimate,,455,0.022000000000000002,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,Whole Blood,,,,,,['High'],Yes,No,No,No,Unclear,Unclear,Yes,No,Unclear,Cat Viglienzoni,University of Vermont,Not Unity-Aligned,https://www.google.com/url?rct=j&sa=t&url=https://www.wcax.com/2020/07/17/early-results-of-uvm-research-tracking-covids-spread-in-vermont/&ct=ga&cd=CAAYCzIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNEblNmlKeakOFmkRkZMbbLnjhptxw,2020-08-01,2022-07-16,Verified,viglienzoni_early_2020,USA
200721_Idaho_UniversityofWashington_TotalPopTestAdj,200721_Idaho_UniversityofWashington,"High Community SARS-CoV-2 Antibody Seroprevalence in a Ski Resort Community, Blaine County, Idaho, US. Preliminary Results",2020-07-21,Preprint,Local,Cross-sectional survey ,United States of America,Idaho,,"From April 8-9, the City of Ketchum posted a secure website for Blaine County residents ≥18
years of age to volunteer for study participation",,2020-05-04,2020-05-19,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,"Adjusted: population, test",917,0.231,0.198,0.265,True,True,True,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.929,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Colleen McLaughlin, University of Washington,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.19.20157198v1,2020-08-03,2023-07-04,Verified,mclaughlin_high_2020,USA
200721_Idaho_UniversityofWashington_Non-HispanicorLatino_TestAdj,200721_Idaho_UniversityofWashington,"High Community SARS-CoV-2 Antibody Seroprevalence in a Ski Resort Community, Blaine County, Idaho, US. Preliminary Results",2020-07-21,Preprint,Local,Cross-sectional survey ,United States of America,Idaho,,"From April 8-9, the City of Ketchum posted a secure website for Blaine County residents ≥18
years of age to volunteer for study participation",,2020-05-04,2020-05-19,Household and community samples,All,Multiple groups,18.0,,Ethnicity,Non-Hispanic or Latino,735,0.22899999999999998,0.198,0.26,,True,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.929,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Colleen McLaughlin, University of Washington,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.19.20157198v1,2020-07-26,2023-07-04,Verified,mclaughlin_high_2020,USA
200721_Idaho_UniversityofWashington_Male_TestAdj,200721_Idaho_UniversityofWashington,"High Community SARS-CoV-2 Antibody Seroprevalence in a Ski Resort Community, Blaine County, Idaho, US. Preliminary Results",2020-07-21,Preprint,Local,Cross-sectional survey ,United States of America,Idaho,,"From April 8-9, the City of Ketchum posted a secure website for Blaine County residents ≥18
years of age to volunteer for study participation",,2020-05-04,2020-05-19,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,Male,438,0.24300000000000002,0.203,0.28500000000000003,,True,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.929,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Colleen McLaughlin, University of Washington,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.19.20157198v1,2020-07-26,2023-07-04,Verified,mclaughlin_high_2020,USA
200721_Idaho_UniversityofWashington_CityofKetchum_TestAdj,200721_Idaho_UniversityofWashington,"High Community SARS-CoV-2 Antibody Seroprevalence in a Ski Resort Community, Blaine County, Idaho, US. Preliminary Results",2020-07-21,Preprint,Local,Cross-sectional survey ,United States of America,Idaho,,"From April 8-9, the City of Ketchum posted a secure website for Blaine County residents ≥18
years of age to volunteer for study participation",,2020-05-04,2020-05-19,Household and community samples,All,Multiple groups,18.0,,Geographical area,City of Ketchum,294,0.348,0.29300000000000004,0.405,,True,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.929,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Colleen McLaughlin, University of Washington,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.19.20157198v1,2020-07-26,2023-07-04,Verified,mclaughlin_high_2020,USA
200721_Idaho_UniversityofWashington_TotalCrude,200721_Idaho_UniversityofWashington,"High Community SARS-CoV-2 Antibody Seroprevalence in a Ski Resort Community, Blaine County, Idaho, US. Preliminary Results",2020-07-21,Preprint,Local,Cross-sectional survey ,United States of America,Idaho,,"From April 8-9, the City of Ketchum posted a secure website for Blaine County residents ≥18
years of age to volunteer for study participation",,2020-05-04,2020-05-19,Household and community samples,All,Multiple groups,18.0,,Analysis,,917,0.227,0.2,0.255,,,,,True,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.929,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Colleen McLaughlin, University of Washington,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.19.20157198v1,2020-07-26,2024-03-01,Verified,mclaughlin_high_2020,USA
200721_Idaho_UniversityofWashington_18-29yrs_TestAdj,200721_Idaho_UniversityofWashington,"High Community SARS-CoV-2 Antibody Seroprevalence in a Ski Resort Community, Blaine County, Idaho, US. Preliminary Results",2020-07-21,Preprint,Local,Cross-sectional survey ,United States of America,Idaho,,"From April 8-9, the City of Ketchum posted a secure website for Blaine County residents ≥18
years of age to volunteer for study participation",,2020-05-04,2020-05-19,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,18-29,96,0.317,0.23,0.414,,True,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.929,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Colleen McLaughlin, University of Washington,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.19.20157198v1,2020-07-26,2023-07-04,Verified,mclaughlin_high_2020,USA
200721_Idaho_UniversityofWashington_Female_TestAdj,200721_Idaho_UniversityofWashington,"High Community SARS-CoV-2 Antibody Seroprevalence in a Ski Resort Community, Blaine County, Idaho, US. Preliminary Results",2020-07-21,Preprint,Local,Cross-sectional survey ,United States of America,Idaho,,"From April 8-9, the City of Ketchum posted a secure website for Blaine County residents ≥18
years of age to volunteer for study participation",,2020-05-04,2020-05-19,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,Female,479,0.214,0.18,0.253,,True,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.929,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Colleen McLaughlin, University of Washington,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.19.20157198v1,2020-07-26,2023-07-04,Verified,mclaughlin_high_2020,USA
200721_Idaho_UniversityofWashington_HispanicorLatino_TestAdj,200721_Idaho_UniversityofWashington,"High Community SARS-CoV-2 Antibody Seroprevalence in a Ski Resort Community, Blaine County, Idaho, US. Preliminary Results",2020-07-21,Preprint,Local,Cross-sectional survey ,United States of America,Idaho,,"From April 8-9, the City of Ketchum posted a secure website for Blaine County residents ≥18
years of age to volunteer for study participation",,2020-05-04,2020-05-19,Household and community samples,All,Multiple groups,18.0,,Ethnicity,Hispanic or Latino,39,0.19399999999999998,0.08800000000000001,0.331,,True,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.929,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Colleen McLaughlin, University of Washington,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.19.20157198v1,2020-07-26,2023-07-04,Verified,mclaughlin_high_2020,USA
200721_Idaho_UniversityofWashington_30-39yrs_TestAdj,200721_Idaho_UniversityofWashington,"High Community SARS-CoV-2 Antibody Seroprevalence in a Ski Resort Community, Blaine County, Idaho, US. Preliminary Results",2020-07-21,Preprint,Local,Cross-sectional survey ,United States of America,Idaho,,"From April 8-9, the City of Ketchum posted a secure website for Blaine County residents ≥18
years of age to volunteer for study participation",,2020-05-04,2020-05-19,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,151,0.22899999999999998,0.165,0.30100000000000005,,True,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.929,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Colleen McLaughlin, University of Washington,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.19.20157198v1,2020-07-26,2023-07-04,Verified,mclaughlin_high_2020,USA
200721_Idaho_UniversityofWashington_60-69yrs_TestAdj,200721_Idaho_UniversityofWashington,"High Community SARS-CoV-2 Antibody Seroprevalence in a Ski Resort Community, Blaine County, Idaho, US. Preliminary Results",2020-07-21,Preprint,Local,Cross-sectional survey ,United States of America,Idaho,,"From April 8-9, the City of Ketchum posted a secure website for Blaine County residents ≥18
years of age to volunteer for study participation",,2020-05-04,2020-05-19,Household and community samples,All,Adults (18-64 years),60.0,69.0,Age,60-69,172,0.20500000000000002,0.14800000000000002,0.27,,True,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.929,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Colleen McLaughlin, University of Washington,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.19.20157198v1,2020-07-26,2023-07-04,Verified,mclaughlin_high_2020,USA
200721_Idaho_UniversityofWashington_50-59yrs_TestAdj,200721_Idaho_UniversityofWashington,"High Community SARS-CoV-2 Antibody Seroprevalence in a Ski Resort Community, Blaine County, Idaho, US. Preliminary Results",2020-07-21,Preprint,Local,Cross-sectional survey ,United States of America,Idaho,,"From April 8-9, the City of Ketchum posted a secure website for Blaine County residents ≥18
years of age to volunteer for study participation",,2020-05-04,2020-05-19,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,225,0.219,0.16899999999999998,0.277,,True,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.929,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Colleen McLaughlin, University of Washington,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.19.20157198v1,2020-07-26,2023-07-04,Verified,mclaughlin_high_2020,USA
200721_Idaho_UniversityofWashington_CityofHailey_TestAdj,200721_Idaho_UniversityofWashington,"High Community SARS-CoV-2 Antibody Seroprevalence in a Ski Resort Community, Blaine County, Idaho, US. Preliminary Results",2020-07-21,Preprint,Local,Cross-sectional survey ,United States of America,Idaho,,"From April 8-9, the City of Ketchum posted a secure website for Blaine County residents ≥18
years of age to volunteer for study participation",,2020-05-04,2020-05-19,Household and community samples,All,Multiple groups,18.0,,Geographical area,City of Hailey,514,0.168,0.13699999999999998,0.203,,True,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.929,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Colleen McLaughlin, University of Washington,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.19.20157198v1,2020-07-26,2023-07-04,Verified,mclaughlin_high_2020,USA
200721_Idaho_UniversityofWashington_40-49yrs_TestAdj,200721_Idaho_UniversityofWashington,"High Community SARS-CoV-2 Antibody Seroprevalence in a Ski Resort Community, Blaine County, Idaho, US. Preliminary Results",2020-07-21,Preprint,Local,Cross-sectional survey ,United States of America,Idaho,,"From April 8-9, the City of Ketchum posted a secure website for Blaine County residents ≥18
years of age to volunteer for study participation",,2020-05-04,2020-05-19,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,186,0.22899999999999998,0.171,0.29100000000000004,,True,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.929,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Colleen McLaughlin, University of Washington,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.19.20157198v1,2020-07-26,2023-07-04,Verified,mclaughlin_high_2020,USA
200721_Idaho_UniversityofWashington_>=70years_TestAdj,200721_Idaho_UniversityofWashington,"High Community SARS-CoV-2 Antibody Seroprevalence in a Ski Resort Community, Blaine County, Idaho, US. Preliminary Results",2020-07-21,Preprint,Local,Cross-sectional survey ,United States of America,Idaho,,"From April 8-9, the City of Ketchum posted a secure website for Blaine County residents ≥18
years of age to volunteer for study participation",,2020-05-04,2020-05-19,Household and community samples,All,Seniors (65+ years),70.0,,Age,>=70,87,0.21300000000000002,0.135,0.305,,True,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.929,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Colleen McLaughlin, University of Washington,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.19.20157198v1,2020-07-26,2023-07-04,Verified,mclaughlin_high_2020,USA
200721_Idaho_UniversityofWashington_TotalTestAdj,200721_Idaho_UniversityofWashington,"High Community SARS-CoV-2 Antibody Seroprevalence in a Ski Resort Community, Blaine County, Idaho, US. Preliminary Results",2020-07-21,Preprint,Local,Cross-sectional survey ,United States of America,Idaho,,"From April 8-9, the City of Ketchum posted a secure website for Blaine County residents ≥18
years of age to volunteer for study participation",,2020-05-04,2020-05-19,Household and community samples,All,Multiple groups,18.0,,Analysis,Adjusted: test,917,0.227,0.201,0.255,,True,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.929,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Colleen McLaughlin, University of Washington,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.19.20157198v1,2020-07-26,2023-07-04,Verified,mclaughlin_high_2020,USA
200721_Idaho_UniversityofWashington_CityofSunValley_TestAdj,200721_Idaho_UniversityofWashington,"High Community SARS-CoV-2 Antibody Seroprevalence in a Ski Resort Community, Blaine County, Idaho, US. Preliminary Results",2020-07-21,Preprint,Local,Cross-sectional survey ,United States of America,Idaho,,"From April 8-9, the City of Ketchum posted a secure website for Blaine County residents ≥18
years of age to volunteer for study participation",,2020-05-04,2020-05-19,Household and community samples,All,Multiple groups,18.0,,Geographical area,City of Sun Valley,85,0.19399999999999998,0.11800000000000001,0.284,,True,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.929,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Colleen McLaughlin, University of Washington,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.19.20157198v1,2020-07-26,2023-07-04,Verified,mclaughlin_high_2020,USA
200721_NewYork_ShermanAbramsLaboratory_Overall,200721_NewYork_ShermanAbramsLaboratory,SARS-CoV-2 IgG antibody responses in New York City,2020-07-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York,Patients in New York City,,2020-05-15,2020-06-15,Residual sera,All,Multiple groups,0.0,105.0,Primary Estimate,,28523,0.44,,,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by manufacturers,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Josh Reifer,Sherman Abrams Laboratory ,Unity-Aligned,https://dx.doi.org/10.1016/j.diagmicrobio.2020.115128,2020-09-26,2024-03-01,Verified,reifer_sars-cov-2_2020,USA
200723_JeffersonCounty_UniversityofLouisville_genpop,200723_JeffersonCounty_UniversityofLouisville,Study Finds Rate of Exposure to COVID-19 in Louisville Higher Than Expected,2020-07-23,News and Media,Local,Cross-sectional survey ,United States of America,Kentucky,,"The study organized Jefferson County households into geographic regions so that researchers could obtain a representative sample. Households in each region received invitations to participate in proportion to the region's population, and areas that had higher concentrations of non-White residents were sampled at a higher rate to increase their representation.

Invitations were mailed to 18,232 addresses. One adult from each household was asked to provide a sample based on the ages and sexes of all adults in the household, provided by responses to the invitation.

Researchers tested 509 people who responded, and an additional 1,728 people booked appointments on their own and were tested. ",,2020-06-10,2020-06-19,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,2237,0.04,,,True,,,,True,Self-referral,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,No,Yes,No,Yes,Unclear,Yes,No,No,Spectrum News Staff, University of Louisville,Not Unity-Aligned,https://spectrumnews1.com/ky/louisville/news/2020/07/23/uofl-coimmunity-project-phase-2-results,2020-09-30,2022-07-16,Verified,spectrum_news_staff_study_2020-1,USA
200724_DeKalbFulton_CDCCOVID-19ResponseTeam_Overall_PopAdj,200724_DeKalbFulton_CDCCOVID-19ResponseTeam,"Estimated Community Seroprevalence of SARS-CoV-2 Antibodies - Two Georgia Counties, April 28-May 3, 2020.",2020-07-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Georgia,,People living in DeKalb and Fulton counties.,"Unoccupied buildings were excluded. If a household declined participation, did not respond to an initial door knock, or could not be enrolled for another reason,¶ an adjacent household was selected.",2020-04-28,2020-05-03,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,696,0.025,0.013999999999999999,0.045,True,,True,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.932,0.99,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Holly Biggs,CDC COVID-19 Response Team,Unity-Aligned,https://dx.doi.org/10.15585/mmwr.mm6929e2,2020-10-02,2024-03-01,Verified,biggs_estimated_2020,USA
200724_DeKalbFulton_CDCCOVID-19ResponseTeam_Female_PopAdj,200724_DeKalbFulton_CDCCOVID-19ResponseTeam,"Estimated Community Seroprevalence of SARS-CoV-2 Antibodies - Two Georgia Counties, April 28-May 3, 2020.",2020-07-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Georgia,,People living in DeKalb and Fulton counties.,"Unoccupied buildings were excluded. If a household declined participation, did not respond to an initial door knock, or could not be enrolled for another reason,¶ an adjacent household was selected.",2020-04-28,2020-05-03,Household and community samples,Female,Multiple groups,0.0,,Sex/Gender,Female,377,0.024,0.011000000000000001,0.051,,,True,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.932,0.99,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Holly Biggs,CDC COVID-19 Response Team,Unity-Aligned,https://dx.doi.org/10.15585/mmwr.mm6929e2,2020-10-04,2024-03-01,Verified,biggs_estimated_2020,USA
200724_DeKalbFulton_CDCCOVID-19ResponseTeam_Age0-17_PopAdj,200724_DeKalbFulton_CDCCOVID-19ResponseTeam,"Estimated Community Seroprevalence of SARS-CoV-2 Antibodies - Two Georgia Counties, April 28-May 3, 2020.",2020-07-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Georgia,,People living in DeKalb and Fulton counties.,"Unoccupied buildings were excluded. If a household declined participation, did not respond to an initial door knock, or could not be enrolled for another reason,¶ an adjacent household was selected.",2020-04-28,2020-05-03,Household and community samples,All,Children and Youth (0-17 years),0.0,17.0,Age,0-17,48,0.0,0.0,0.0,,,True,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.932,0.99,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Holly Biggs,CDC COVID-19 Response Team,Unity-Aligned,https://dx.doi.org/10.15585/mmwr.mm6929e2,2020-10-04,2024-03-01,Verified,biggs_estimated_2020,USA
200724_DeKalbFulton_CDCCOVID-19ResponseTeam_Multiple/Other/Unknown_PopAdj,200724_DeKalbFulton_CDCCOVID-19ResponseTeam,"Estimated Community Seroprevalence of SARS-CoV-2 Antibodies - Two Georgia Counties, April 28-May 3, 2020.",2020-07-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Georgia,,People living in DeKalb and Fulton counties.,"Unoccupied buildings were excluded. If a household declined participation, did not respond to an initial door knock, or could not be enrolled for another reason,¶ an adjacent household was selected.",2020-04-28,2020-05-03,Household and community samples,All,Multiple groups,0.0,,Race,"Multiple, other, or unknown",29,0.012,0.001,0.141,,,True,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.932,0.99,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Holly Biggs,CDC COVID-19 Response Team,Unity-Aligned,https://dx.doi.org/10.15585/mmwr.mm6929e2,2020-10-04,2024-03-01,Verified,biggs_estimated_2020,USA
200724_DeKalbFulton_CDCCOVID-19ResponseTeam_Age18-49_PopAdj,200724_DeKalbFulton_CDCCOVID-19ResponseTeam,"Estimated Community Seroprevalence of SARS-CoV-2 Antibodies - Two Georgia Counties, April 28-May 3, 2020.",2020-07-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Georgia,,People living in DeKalb and Fulton counties.,"Unoccupied buildings were excluded. If a household declined participation, did not respond to an initial door knock, or could not be enrolled for another reason,¶ an adjacent household was selected.",2020-04-28,2020-05-03,Household and community samples,All,Multiple groups,18.0,49.0,Age,18-49,347,0.033,0.016,0.064,,,True,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.932,0.99,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Holly Biggs,CDC COVID-19 Response Team,Unity-Aligned,https://dx.doi.org/10.15585/mmwr.mm6929e2,2020-10-04,2024-03-01,Verified,biggs_estimated_2020,USA
200724_DeKalbFulton_CDCCOVID-19ResponseTeam_Overall_UnAdj,200724_DeKalbFulton_CDCCOVID-19ResponseTeam,"Estimated Community Seroprevalence of SARS-CoV-2 Antibodies - Two Georgia Counties, April 28-May 3, 2020.",2020-07-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Georgia,,People living in DeKalb and Fulton counties.,"Unoccupied buildings were excluded. If a household declined participation, did not respond to an initial door knock, or could not be enrolled for another reason,¶ an adjacent household was selected.",2020-04-28,2020-05-03,Household and community samples,All,Multiple groups,0.0,,Analysis,,696,0.02729885057,,,,,,,True,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.932,0.99,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Holly Biggs,CDC COVID-19 Response Team,Unity-Aligned,https://dx.doi.org/10.15585/mmwr.mm6929e2,2020-10-02,2024-03-01,Verified,biggs_estimated_2020,USA
200724_DeKalbFulton_CDCCOVID-19ResponseTeam_Asian/PacificIslander_PopAdj,200724_DeKalbFulton_CDCCOVID-19ResponseTeam,"Estimated Community Seroprevalence of SARS-CoV-2 Antibodies - Two Georgia Counties, April 28-May 3, 2020.",2020-07-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Georgia,,People living in DeKalb and Fulton counties.,"Unoccupied buildings were excluded. If a household declined participation, did not respond to an initial door knock, or could not be enrolled for another reason,¶ an adjacent household was selected.",2020-04-28,2020-05-03,Household and community samples,All,Multiple groups,0.0,,Race,Asian or Pacific Islander,29,0.0,0.0,0.0,,,True,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.932,0.99,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Holly Biggs,CDC COVID-19 Response Team,Unity-Aligned,https://dx.doi.org/10.15585/mmwr.mm6929e2,2020-10-04,2024-03-01,Verified,biggs_estimated_2020,USA
200724_DeKalbFulton_CDCCOVID-19ResponseTeam_Age>=65_PopAdj,200724_DeKalbFulton_CDCCOVID-19ResponseTeam,"Estimated Community Seroprevalence of SARS-CoV-2 Antibodies - Two Georgia Counties, April 28-May 3, 2020.",2020-07-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Georgia,,People living in DeKalb and Fulton counties.,"Unoccupied buildings were excluded. If a household declined participation, did not respond to an initial door knock, or could not be enrolled for another reason,¶ an adjacent household was selected.",2020-04-28,2020-05-03,Household and community samples,All,Seniors (65+ years),65.0,,Age,>=65,112,0.006999999999999999,0.001,0.045,,,True,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.932,0.99,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Holly Biggs,CDC COVID-19 Response Team,Unity-Aligned,https://dx.doi.org/10.15585/mmwr.mm6929e2,2020-10-04,2024-03-01,Verified,biggs_estimated_2020,USA
200724_DeKalbFulton_CDCCOVID-19ResponseTeam_Age50-64_PopAdj,200724_DeKalbFulton_CDCCOVID-19ResponseTeam,"Estimated Community Seroprevalence of SARS-CoV-2 Antibodies - Two Georgia Counties, April 28-May 3, 2020.",2020-07-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Georgia,,People living in DeKalb and Fulton counties.,"Unoccupied buildings were excluded. If a household declined participation, did not respond to an initial door knock, or could not be enrolled for another reason,¶ an adjacent household was selected.",2020-04-28,2020-05-03,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50-64,189,0.049,0.018000000000000002,0.129,,,True,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.932,0.99,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Holly Biggs,CDC COVID-19 Response Team,Unity-Aligned,https://dx.doi.org/10.15585/mmwr.mm6929e2,2020-10-04,2024-03-01,Verified,biggs_estimated_2020,USA
200724_DeKalbFulton_CDCCOVID-19ResponseTeam_Black_PopAdj,200724_DeKalbFulton_CDCCOVID-19ResponseTeam,"Estimated Community Seroprevalence of SARS-CoV-2 Antibodies - Two Georgia Counties, April 28-May 3, 2020.",2020-07-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Georgia,,People living in DeKalb and Fulton counties.,"Unoccupied buildings were excluded. If a household declined participation, did not respond to an initial door knock, or could not be enrolled for another reason,¶ an adjacent household was selected.",2020-04-28,2020-05-03,Household and community samples,All,Multiple groups,0.0,,Race,"Black, non Hispanic",266,0.052000000000000005,0.028999999999999998,0.091,,,True,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.932,0.99,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Holly Biggs,CDC COVID-19 Response Team,Unity-Aligned,https://dx.doi.org/10.15585/mmwr.mm6929e2,2020-10-04,2024-03-01,Verified,biggs_estimated_2020,USA
200724_DeKalbFulton_CDCCOVID-19ResponseTeam_Male_PopAdj,200724_DeKalbFulton_CDCCOVID-19ResponseTeam,"Estimated Community Seroprevalence of SARS-CoV-2 Antibodies - Two Georgia Counties, April 28-May 3, 2020.",2020-07-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Georgia,,People living in DeKalb and Fulton counties.,"Unoccupied buildings were excluded. If a household declined participation, did not respond to an initial door knock, or could not be enrolled for another reason,¶ an adjacent household was selected.",2020-04-28,2020-05-03,Household and community samples,Male,Multiple groups,0.0,,Sex/Gender,Male ,317,0.026000000000000002,0.011000000000000001,0.063,,,True,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.932,0.99,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Holly Biggs,CDC COVID-19 Response Team,Unity-Aligned,https://dx.doi.org/10.15585/mmwr.mm6929e2,2020-10-04,2024-03-01,Verified,biggs_estimated_2020,USA
200724_DeKalbFulton_CDCCOVID-19ResponseTeam_Male_UnAdj,200724_DeKalbFulton_CDCCOVID-19ResponseTeam,"Estimated Community Seroprevalence of SARS-CoV-2 Antibodies - Two Georgia Counties, April 28-May 3, 2020.",2020-07-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Georgia,,People living in DeKalb and Fulton counties.,"Unoccupied buildings were excluded. If a household declined participation, did not respond to an initial door knock, or could not be enrolled for another reason,¶ an adjacent household was selected.",2020-04-28,2020-05-03,Household and community samples,Male,Multiple groups,0.0,,Sex/Gender,Male,317,0.025230000000000002,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.932,0.99,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Holly Biggs,CDC COVID-19 Response Team,Unity-Aligned,https://dx.doi.org/10.15585/mmwr.mm6929e2,2020-10-04,2024-03-01,Verified,biggs_estimated_2020,USA
200724_DeKalbFulton_CDCCOVID-19ResponseTeam_Female_UnAdj,200724_DeKalbFulton_CDCCOVID-19ResponseTeam,"Estimated Community Seroprevalence of SARS-CoV-2 Antibodies - Two Georgia Counties, April 28-May 3, 2020.",2020-07-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Georgia,,People living in DeKalb and Fulton counties.,"Unoccupied buildings were excluded. If a household declined participation, did not respond to an initial door knock, or could not be enrolled for another reason,¶ an adjacent household was selected.",2020-04-28,2020-05-03,Household and community samples,Female,Multiple groups,0.0,,Sex/Gender,Female,377,0.029177,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.932,0.99,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Holly Biggs,CDC COVID-19 Response Team,Unity-Aligned,https://dx.doi.org/10.15585/mmwr.mm6929e2,2020-10-04,2024-03-01,Verified,biggs_estimated_2020,USA
200724_DeKalbFulton_CDCCOVID-19ResponseTeam_Hispanic_PopAdj,200724_DeKalbFulton_CDCCOVID-19ResponseTeam,"Estimated Community Seroprevalence of SARS-CoV-2 Antibodies - Two Georgia Counties, April 28-May 3, 2020.",2020-07-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Georgia,,People living in DeKalb and Fulton counties.,"Unoccupied buildings were excluded. If a household declined participation, did not respond to an initial door knock, or could not be enrolled for another reason,¶ an adjacent household was selected.",2020-04-28,2020-05-03,Household and community samples,All,Multiple groups,0.0,,Ethnicity,Hispanic,44,0.0,0.0,0.0,,,True,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.932,0.99,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Holly Biggs,CDC COVID-19 Response Team,Unity-Aligned,https://dx.doi.org/10.15585/mmwr.mm6929e2,2020-10-04,2024-03-01,Verified,biggs_estimated_2020,USA
200724_DeKalbFulton_CDCCOVID-19ResponseTeam_White_PopAdj,200724_DeKalbFulton_CDCCOVID-19ResponseTeam,"Estimated Community Seroprevalence of SARS-CoV-2 Antibodies - Two Georgia Counties, April 28-May 3, 2020.",2020-07-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Georgia,,People living in DeKalb and Fulton counties.,"Unoccupied buildings were excluded. If a household declined participation, did not respond to an initial door knock, or could not be enrolled for another reason,¶ an adjacent household was selected.",2020-04-28,2020-05-03,Household and community samples,All,Multiple groups,0.0,,Race,"White, non Hispanic",329,0.003,0.001,0.017,,,True,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,"['IgA', 'IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.932,0.99,['Low'],Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Unclear,Holly Biggs,CDC COVID-19 Response Team,Unity-Aligned,https://dx.doi.org/10.15585/mmwr.mm6929e2,2020-10-04,2024-03-01,Verified,biggs_estimated_2020,USA
200513_Indiana_IndianaUniversity_Wave1_NonRandom_PopAdj,200513_Indiana_IndianaUniversity_Wave1_NonRandom,"Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–29, 2020",2020-07-24,Institutional Report,Local,Cross-sectional survey ,United States of America,Indiana,Indianapolis,"Non-random sampling was conducted in racial and
ethnic minority communities to better understand the impact
of the virus in certain racial and ethnic minority populations.  Civic leaders were enlisted to establish 2 days of non-random testing (May 2–3) hosted at Indianapolis locations in two racial/ethnic minority populations. Clergy and community leaders helped mobilize community members by increasing trust and engagement with the testing program. Because some participants in the non-random testing group might have chosen to participate because of concerns that they might be infected, possibly resulting in selection bias; findings from the non-random testing are reported separately.",,2020-05-02,2020-05-03,Household and community samples,All,Multiple groups,12.0,,Primary Estimate,,898,0.057999999999999996,,,True,,True,True,True,Convenience,Author designed (ELISA) -Unknown,,CLIA,,IgG,,,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Nir Menachemi,Indiana University Fairbanks School of Public Health,Not Unity-Aligned,https://www.cdc.gov/mmwr/volumes/69/wr/mm6929e1.htm?s_cid=mm6929e1_w,2020-08-04,2022-07-16,Verified,menachemi_population_2020,USA
200513_Indiana_IndianaUniversity_Wave1_NonRandom_Male_PopAdj,200513_Indiana_IndianaUniversity_Wave1_NonRandom,"Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–29, 2020",2020-07-24,Institutional Report,Local,Cross-sectional survey ,United States of America,Indiana,Indianapolis,"Non-random sampling was conducted in racial and
ethnic minority communities to better understand the impact
of the virus in certain racial and ethnic minority populations.  Civic leaders were enlisted to establish 2 days of non-random testing (May 2–3) hosted at Indianapolis locations in two racial/ethnic minority populations. Clergy and community leaders helped mobilize community members by increasing trust and engagement with the testing program. Because some participants in the non-random testing group might have chosen to participate because of concerns that they might be infected, possibly resulting in selection bias; findings from the non-random testing are reported separately.",,2020-05-02,2020-05-03,Household and community samples,Male,Multiple groups,12.0,,Sex/Gender,Male,375,0.055,,,,,True,True,,Convenience,Author designed (ELISA) -Unknown,,CLIA,,IgG,,,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Nir Menachemi,Indiana University Fairbanks School of Public Health,Not Unity-Aligned,https://www.cdc.gov/mmwr/volumes/69/wr/mm6929e1.htm?s_cid=mm6929e1_w,2020-08-06,2022-07-16,Verified,menachemi_population_2020,USA
200513_Indiana_IndianaUniversity_Wave1_NonRandom_Age>=80_PopAdj,200513_Indiana_IndianaUniversity_Wave1_NonRandom,"Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–29, 2020",2020-07-24,Institutional Report,Local,Cross-sectional survey ,United States of America,Indiana,Indianapolis,"Non-random sampling was conducted in racial and
ethnic minority communities to better understand the impact
of the virus in certain racial and ethnic minority populations.  Civic leaders were enlisted to establish 2 days of non-random testing (May 2–3) hosted at Indianapolis locations in two racial/ethnic minority populations. Clergy and community leaders helped mobilize community members by increasing trust and engagement with the testing program. Because some participants in the non-random testing group might have chosen to participate because of concerns that they might be infected, possibly resulting in selection bias; findings from the non-random testing are reported separately.",,2020-05-02,2020-05-03,Household and community samples,All,Seniors (65+ years),80.0,,Age,>=80,6,0.168,,,,,True,True,,Convenience,Author designed (ELISA) -Unknown,,CLIA,,IgG,,,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Nir Menachemi,Indiana University Fairbanks School of Public Health,Not Unity-Aligned,https://www.cdc.gov/mmwr/volumes/69/wr/mm6929e1.htm?s_cid=mm6929e1_w,2020-08-06,2022-07-16,Verified,menachemi_population_2020,USA
200513_Indiana_IndianaUniversity_Wave1_NonRandom_Female_PopAdj,200513_Indiana_IndianaUniversity_Wave1_NonRandom,"Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–29, 2020",2020-07-24,Institutional Report,Local,Cross-sectional survey ,United States of America,Indiana,Indianapolis,"Non-random sampling was conducted in racial and
ethnic minority communities to better understand the impact
of the virus in certain racial and ethnic minority populations.  Civic leaders were enlisted to establish 2 days of non-random testing (May 2–3) hosted at Indianapolis locations in two racial/ethnic minority populations. Clergy and community leaders helped mobilize community members by increasing trust and engagement with the testing program. Because some participants in the non-random testing group might have chosen to participate because of concerns that they might be infected, possibly resulting in selection bias; findings from the non-random testing are reported separately.",,2020-05-02,2020-05-03,Household and community samples,Female,Multiple groups,12.0,,Sex/Gender,Female ,523,0.06,,,,,True,True,,Convenience,Author designed (ELISA) -Unknown,,CLIA,,IgG,,,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Nir Menachemi,Indiana University Fairbanks School of Public Health,Not Unity-Aligned,https://www.cdc.gov/mmwr/volumes/69/wr/mm6929e1.htm?s_cid=mm6929e1_w,2020-08-06,2022-07-16,Verified,menachemi_population_2020,USA
200513_Indiana_IndianaUniversity_Wave1_NonRandom_Hispanic_PopAdj,200513_Indiana_IndianaUniversity_Wave1_NonRandom,"Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–29, 2020",2020-07-24,Institutional Report,Local,Cross-sectional survey ,United States of America,Indiana,Indianapolis,"Non-random sampling was conducted in racial and
ethnic minority communities to better understand the impact
of the virus in certain racial and ethnic minority populations.  Civic leaders were enlisted to establish 2 days of non-random testing (May 2–3) hosted at Indianapolis locations in two racial/ethnic minority populations. Clergy and community leaders helped mobilize community members by increasing trust and engagement with the testing program. Because some participants in the non-random testing group might have chosen to participate because of concerns that they might be infected, possibly resulting in selection bias; findings from the non-random testing are reported separately.",,2020-05-02,2020-05-03,Household and community samples,All,Multiple groups,12.0,,Ethnicity,Hispanic,396,0.07,,,,,True,True,,Convenience,Author designed (ELISA) -Unknown,,CLIA,,IgG,,,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Nir Menachemi,Indiana University Fairbanks School of Public Health,Not Unity-Aligned,https://www.cdc.gov/mmwr/volumes/69/wr/mm6929e1.htm?s_cid=mm6929e1_w,2020-08-06,2022-07-16,Verified,menachemi_population_2020,USA
200513_Indiana_IndianaUniversity_Wave1_NonRandom_Black_PopAdj,200513_Indiana_IndianaUniversity_Wave1_NonRandom,"Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–29, 2020",2020-07-24,Institutional Report,Local,Cross-sectional survey ,United States of America,Indiana,Indianapolis,"Non-random sampling was conducted in racial and
ethnic minority communities to better understand the impact
of the virus in certain racial and ethnic minority populations.  Civic leaders were enlisted to establish 2 days of non-random testing (May 2–3) hosted at Indianapolis locations in two racial/ethnic minority populations. Clergy and community leaders helped mobilize community members by increasing trust and engagement with the testing program. Because some participants in the non-random testing group might have chosen to participate because of concerns that they might be infected, possibly resulting in selection bias; findings from the non-random testing are reported separately.",,2020-05-02,2020-05-03,Household and community samples,All,Multiple groups,12.0,,Race,Black,295,0.068,,,,,True,True,,Convenience,Author designed (ELISA) -Unknown,,CLIA,,IgG,,,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Nir Menachemi,Indiana University Fairbanks School of Public Health,Not Unity-Aligned,https://www.cdc.gov/mmwr/volumes/69/wr/mm6929e1.htm?s_cid=mm6929e1_w,2020-08-06,2022-07-16,Verified,menachemi_population_2020,USA
200513_Indiana_IndianaUniversity_Wave1_NonRandom_OtherandMultiRacial_PopAdj,200513_Indiana_IndianaUniversity_Wave1_NonRandom,"Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–29, 2020",2020-07-24,Institutional Report,Local,Cross-sectional survey ,United States of America,Indiana,Indianapolis,"Non-random sampling was conducted in racial and
ethnic minority communities to better understand the impact
of the virus in certain racial and ethnic minority populations.  Civic leaders were enlisted to establish 2 days of non-random testing (May 2–3) hosted at Indianapolis locations in two racial/ethnic minority populations. Clergy and community leaders helped mobilize community members by increasing trust and engagement with the testing program. Because some participants in the non-random testing group might have chosen to participate because of concerns that they might be infected, possibly resulting in selection bias; findings from the non-random testing are reported separately.",,2020-05-02,2020-05-03,Household and community samples,All,Multiple groups,12.0,,Race,Other/Multi-racial,395,0.057,,,,,True,True,,Convenience,Author designed (ELISA) -Unknown,,CLIA,,IgG,,,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Nir Menachemi,Indiana University Fairbanks School of Public Health,Not Unity-Aligned,https://www.cdc.gov/mmwr/volumes/69/wr/mm6929e1.htm?s_cid=mm6929e1_w,2020-08-06,2022-07-16,Verified,menachemi_population_2020,USA
200513_Indiana_IndianaUniversity_Wave1_NonRandom_Age20to39_PopAdj,200513_Indiana_IndianaUniversity_Wave1_NonRandom,"Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–29, 2020",2020-07-24,Institutional Report,Local,Cross-sectional survey ,United States of America,Indiana,Indianapolis,"Non-random sampling was conducted in racial and
ethnic minority communities to better understand the impact
of the virus in certain racial and ethnic minority populations.  Civic leaders were enlisted to establish 2 days of non-random testing (May 2–3) hosted at Indianapolis locations in two racial/ethnic minority populations. Clergy and community leaders helped mobilize community members by increasing trust and engagement with the testing program. Because some participants in the non-random testing group might have chosen to participate because of concerns that they might be infected, possibly resulting in selection bias; findings from the non-random testing are reported separately.",,2020-05-02,2020-05-03,Household and community samples,All,Adults (18-64 years),20.0,39.0,Age,20-39,277,0.065,,,,,True,True,,Convenience,Author designed (ELISA) -Unknown,,CLIA,,IgG,,,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Nir Menachemi,Indiana University Fairbanks School of Public Health,Not Unity-Aligned,https://www.cdc.gov/mmwr/volumes/69/wr/mm6929e1.htm?s_cid=mm6929e1_w,2020-08-06,2022-07-16,Verified,menachemi_population_2020,USA
200513_Indiana_IndianaUniversity_Wave1_NonRandom_Age<20_PopAdj,200513_Indiana_IndianaUniversity_Wave1_NonRandom,"Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–29, 2020",2020-07-24,Institutional Report,Local,Cross-sectional survey ,United States of America,Indiana,Indianapolis,"Non-random sampling was conducted in racial and
ethnic minority communities to better understand the impact
of the virus in certain racial and ethnic minority populations.  Civic leaders were enlisted to establish 2 days of non-random testing (May 2–3) hosted at Indianapolis locations in two racial/ethnic minority populations. Clergy and community leaders helped mobilize community members by increasing trust and engagement with the testing program. Because some participants in the non-random testing group might have chosen to participate because of concerns that they might be infected, possibly resulting in selection bias; findings from the non-random testing are reported separately.",,2020-05-02,2020-05-03,Household and community samples,All,Children and Youth (0-17 years),12.0,19.0,Age,<20,77,0.075,,,,,True,True,,Convenience,Author designed (ELISA) -Unknown,,CLIA,,IgG,,,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Nir Menachemi,Indiana University Fairbanks School of Public Health,Not Unity-Aligned,https://www.cdc.gov/mmwr/volumes/69/wr/mm6929e1.htm?s_cid=mm6929e1_w,2020-08-06,2022-07-16,Verified,menachemi_population_2020,USA
200513_Indiana_IndianaUniversity_Wave1_NonRandom_White_PopAdj,200513_Indiana_IndianaUniversity_Wave1_NonRandom,"Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–29, 2020",2020-07-24,Institutional Report,Local,Cross-sectional survey ,United States of America,Indiana,Indianapolis,"Non-random sampling was conducted in racial and
ethnic minority communities to better understand the impact
of the virus in certain racial and ethnic minority populations.  Civic leaders were enlisted to establish 2 days of non-random testing (May 2–3) hosted at Indianapolis locations in two racial/ethnic minority populations. Clergy and community leaders helped mobilize community members by increasing trust and engagement with the testing program. Because some participants in the non-random testing group might have chosen to participate because of concerns that they might be infected, possibly resulting in selection bias; findings from the non-random testing are reported separately.",,2020-05-02,2020-05-03,Household and community samples,All,Multiple groups,12.0,,Race,White,208,0.047,,,,,True,True,,Convenience,Author designed (ELISA) -Unknown,,CLIA,,IgG,,,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Nir Menachemi,Indiana University Fairbanks School of Public Health,Not Unity-Aligned,https://www.cdc.gov/mmwr/volumes/69/wr/mm6929e1.htm?s_cid=mm6929e1_w,2020-08-06,2022-07-16,Verified,menachemi_population_2020,USA
200513_Indiana_IndianaUniversity_Wave1_NonRandom_Age40to59_PopAdj,200513_Indiana_IndianaUniversity_Wave1_NonRandom,"Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–29, 2020",2020-07-24,Institutional Report,Local,Cross-sectional survey ,United States of America,Indiana,Indianapolis,"Non-random sampling was conducted in racial and
ethnic minority communities to better understand the impact
of the virus in certain racial and ethnic minority populations.  Civic leaders were enlisted to establish 2 days of non-random testing (May 2–3) hosted at Indianapolis locations in two racial/ethnic minority populations. Clergy and community leaders helped mobilize community members by increasing trust and engagement with the testing program. Because some participants in the non-random testing group might have chosen to participate because of concerns that they might be infected, possibly resulting in selection bias; findings from the non-random testing are reported separately.",,2020-05-02,2020-05-03,Household and community samples,All,Adults (18-64 years),40.0,59.0,Age,40-59,369,0.052000000000000005,,,,,True,True,,Convenience,Author designed (ELISA) -Unknown,,CLIA,,IgG,,,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Nir Menachemi,Indiana University Fairbanks School of Public Health,Not Unity-Aligned,https://www.cdc.gov/mmwr/volumes/69/wr/mm6929e1.htm?s_cid=mm6929e1_w,2020-08-06,2022-07-16,Verified,menachemi_population_2020,USA
200513_Indiana_IndianaUniversity_Wave1_NonRandom_Age60to79_PopAdj,200513_Indiana_IndianaUniversity_Wave1_NonRandom,"Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–29, 2020",2020-07-24,Institutional Report,Local,Cross-sectional survey ,United States of America,Indiana,Indianapolis,"Non-random sampling was conducted in racial and
ethnic minority communities to better understand the impact
of the virus in certain racial and ethnic minority populations.  Civic leaders were enlisted to establish 2 days of non-random testing (May 2–3) hosted at Indianapolis locations in two racial/ethnic minority populations. Clergy and community leaders helped mobilize community members by increasing trust and engagement with the testing program. Because some participants in the non-random testing group might have chosen to participate because of concerns that they might be infected, possibly resulting in selection bias; findings from the non-random testing are reported separately.",,2020-05-02,2020-05-03,Household and community samples,All,Seniors (65+ years),60.0,79.0,Age,60-79,169,0.05,,,,,True,True,,Convenience,Author designed (ELISA) -Unknown,,CLIA,,IgG,,,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Nir Menachemi,Indiana University Fairbanks School of Public Health,Not Unity-Aligned,https://www.cdc.gov/mmwr/volumes/69/wr/mm6929e1.htm?s_cid=mm6929e1_w,2020-08-06,2022-07-16,Verified,menachemi_population_2020,USA
200513_Indiana_IndianaUniversity_Wave1_NonRandom_Nonhispanic_PopAdj,200513_Indiana_IndianaUniversity_Wave1_NonRandom,"Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–29, 2020",2020-07-24,Institutional Report,Local,Cross-sectional survey ,United States of America,Indiana,Indianapolis,"Non-random sampling was conducted in racial and
ethnic minority communities to better understand the impact
of the virus in certain racial and ethnic minority populations.  Civic leaders were enlisted to establish 2 days of non-random testing (May 2–3) hosted at Indianapolis locations in two racial/ethnic minority populations. Clergy and community leaders helped mobilize community members by increasing trust and engagement with the testing program. Because some participants in the non-random testing group might have chosen to participate because of concerns that they might be infected, possibly resulting in selection bias; findings from the non-random testing are reported separately.",,2020-05-02,2020-05-03,Household and community samples,All,Multiple groups,12.0,,Ethnicity,Non-hispanic,502,0.049,,,,,True,True,,Convenience,Author designed (ELISA) -Unknown,,CLIA,,IgG,,,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Nir Menachemi,Indiana University Fairbanks School of Public Health,Not Unity-Aligned,https://www.cdc.gov/mmwr/volumes/69/wr/mm6929e1.htm?s_cid=mm6929e1_w,2020-08-06,2022-07-16,Verified,menachemi_population_2020,USA
200513_Indiana_IndianaUniversity_Wave1GenPop_PopAdj,200513_Indiana_IndianaUniversity_Wave1_Random,"Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–29, 2020",2020-07-24,Institutional Report,Regional,Cross-sectional survey ,United States of America,Indiana,,"The study population was randomly selected from a list of Indiana residents derived from tax returns, including filers and
dependents.State databases were cross-checked for recent contact information, and institutionalized and deceased persons
were removed. Stratified random sampling was conducted
among all persons aged ≥12 years using Indiana’s 10 public
health preparedness districts as sampling strata. After the study
was announced, 15,495 participants were contacted by the
state health department via postcard, text message, e-mail,
or telephone, depending on available contact information. ",Sample selected all older than 12 years old,2020-04-25,2020-04-29,Household and community samples,All,Multiple groups,12.0,,Primary Estimate,,3518,0.010900000000000002,0.008,0.015,True,,True,,True,Stratified probability,Author designed (ELISA) -Unknown,,CLIA,,IgG,,,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,No,Unclear,Yes,Yes,No,Nir Menachemi,Indiana University Fairbanks School of Public Health,Unity-Aligned,https://www.cdc.gov/mmwr/volumes/69/wr/mm6929e1.htm?s_cid=mm6929e1_w,2020-05-19,2022-07-16,Verified,menachemi_population_2020,USA
200513_Indiana_IndianaUniversity_Wave1GenPop_Age40-59_PopAdj,200513_Indiana_IndianaUniversity_Wave1_Random,"Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–29, 2020",2020-07-24,Institutional Report,Regional,Cross-sectional survey ,United States of America,Indiana,,"The study population was randomly selected from a list of Indiana residents derived from tax returns, including filers and
dependents.State databases were cross-checked for recent contact information, and institutionalized and deceased persons
were removed. Stratified random sampling was conducted
among all persons aged ≥12 years using Indiana’s 10 public
health preparedness districts as sampling strata. After the study
was announced, 15,495 participants were contacted by the
state health department via postcard, text message, e-mail,
or telephone, depending on available contact information. ",Sample selected all older than 12 years old,2020-04-25,2020-04-29,Household and community samples,All,Adults (18-64 years),40.0,59.0,Age,40-59,1328,0.0108,0.005,0.018000000000000002,,,True,,,Stratified probability,Author designed (ELISA) -Unknown,,CLIA,,IgG,,,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,No,Unclear,Yes,Yes,No,Nir Menachemi,Indiana University Fairbanks School of Public Health,Unity-Aligned,https://www.cdc.gov/mmwr/volumes/69/wr/mm6929e1.htm?s_cid=mm6929e1_w,2020-08-04,2022-07-16,Verified,menachemi_population_2020,USA
200513_Indiana_IndianaUniversity_Wave1GenPop_Male_PopAdj,200513_Indiana_IndianaUniversity_Wave1_Random,"Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–29, 2020",2020-07-24,Institutional Report,Regional,Cross-sectional survey ,United States of America,Indiana,,"The study population was randomly selected from a list of Indiana residents derived from tax returns, including filers and
dependents.State databases were cross-checked for recent contact information, and institutionalized and deceased persons
were removed. Stratified random sampling was conducted
among all persons aged ≥12 years using Indiana’s 10 public
health preparedness districts as sampling strata. After the study
was announced, 15,495 participants were contacted by the
state health department via postcard, text message, e-mail,
or telephone, depending on available contact information. ",Sample selected all older than 12 years old,2020-04-25,2020-04-29,Household and community samples,Male,Multiple groups,12.0,,Sex/Gender,Male,1656,0.0118,0.006999999999999999,0.019,,,True,,,Stratified probability,Author designed (ELISA) -Unknown,,CLIA,,IgG,,,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,No,Unclear,Yes,Yes,No,Nir Menachemi,Indiana University Fairbanks School of Public Health,Unity-Aligned,https://www.cdc.gov/mmwr/volumes/69/wr/mm6929e1.htm?s_cid=mm6929e1_w,2020-08-04,2022-07-16,Verified,menachemi_population_2020,USA
200513_Indiana_IndianaUniversity_Wave1GenPop_White_PopAdj,200513_Indiana_IndianaUniversity_Wave1_Random,"Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–29, 2020",2020-07-24,Institutional Report,Regional,Cross-sectional survey ,United States of America,Indiana,,"The study population was randomly selected from a list of Indiana residents derived from tax returns, including filers and
dependents.State databases were cross-checked for recent contact information, and institutionalized and deceased persons
were removed. Stratified random sampling was conducted
among all persons aged ≥12 years using Indiana’s 10 public
health preparedness districts as sampling strata. After the study
was announced, 15,495 participants were contacted by the
state health department via postcard, text message, e-mail,
or telephone, depending on available contact information. ",Sample selected all older than 12 years old,2020-04-25,2020-04-29,Household and community samples,All,Multiple groups,12.0,,Race,White ,3373,0.0102,0.006,0.015,,,True,,,Stratified probability,Author designed (ELISA) -Unknown,,CLIA,,IgG,,,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,No,Unclear,Yes,Yes,No,Nir Menachemi,Indiana University Fairbanks School of Public Health,Unity-Aligned,https://www.cdc.gov/mmwr/volumes/69/wr/mm6929e1.htm?s_cid=mm6929e1_w,2020-08-04,2022-07-16,Verified,menachemi_population_2020,USA
200513_Indiana_IndianaUniversity_Wave1GenPop_Age<40_PopAdj,200513_Indiana_IndianaUniversity_Wave1_Random,"Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–29, 2020",2020-07-24,Institutional Report,Regional,Cross-sectional survey ,United States of America,Indiana,,"The study population was randomly selected from a list of Indiana residents derived from tax returns, including filers and
dependents.State databases were cross-checked for recent contact information, and institutionalized and deceased persons
were removed. Stratified random sampling was conducted
among all persons aged ≥12 years using Indiana’s 10 public
health preparedness districts as sampling strata. After the study
was announced, 15,495 participants were contacted by the
state health department via postcard, text message, e-mail,
or telephone, depending on available contact information. ",Sample selected all older than 12 years old,2020-04-25,2020-04-29,Household and community samples,All,Adults (18-64 years),12.0,39.0,Age,<40,1017,0.0139,0.006999999999999999,0.022000000000000002,,,True,,,Stratified probability,Author designed (ELISA) -Unknown,,CLIA,,IgG,,,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,No,Unclear,Yes,Yes,No,Nir Menachemi,Indiana University Fairbanks School of Public Health,Unity-Aligned,https://www.cdc.gov/mmwr/volumes/69/wr/mm6929e1.htm?s_cid=mm6929e1_w,2020-08-04,2022-07-16,Verified,menachemi_population_2020,USA
200513_Indiana_IndianaUniversity_Wave1GenPop_Female_PopAdj,200513_Indiana_IndianaUniversity_Wave1_Random,"Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–29, 2020",2020-07-24,Institutional Report,Regional,Cross-sectional survey ,United States of America,Indiana,,"The study population was randomly selected from a list of Indiana residents derived from tax returns, including filers and
dependents.State databases were cross-checked for recent contact information, and institutionalized and deceased persons
were removed. Stratified random sampling was conducted
among all persons aged ≥12 years using Indiana’s 10 public
health preparedness districts as sampling strata. After the study
was announced, 15,495 participants were contacted by the
state health department via postcard, text message, e-mail,
or telephone, depending on available contact information. ",Sample selected all older than 12 years old,2020-04-25,2020-04-29,Household and community samples,Female,Multiple groups,12.0,,Sex/Gender,Female,1995,0.0102,0.005,0.016,,,True,,,Stratified probability,Author designed (ELISA) -Unknown,,CLIA,,IgG,,,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,No,Unclear,Yes,Yes,No,Nir Menachemi,Indiana University Fairbanks School of Public Health,Unity-Aligned,https://www.cdc.gov/mmwr/volumes/69/wr/mm6929e1.htm?s_cid=mm6929e1_w,2020-08-04,2022-07-16,Verified,menachemi_population_2020,USA
200513_Indiana_IndianaUniversity_Wave1GenPop_Nonwhite_PopAdj,200513_Indiana_IndianaUniversity_Wave1_Random,"Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–29, 2020",2020-07-24,Institutional Report,Regional,Cross-sectional survey ,United States of America,Indiana,,"The study population was randomly selected from a list of Indiana residents derived from tax returns, including filers and
dependents.State databases were cross-checked for recent contact information, and institutionalized and deceased persons
were removed. Stratified random sampling was conducted
among all persons aged ≥12 years using Indiana’s 10 public
health preparedness districts as sampling strata. After the study
was announced, 15,495 participants were contacted by the
state health department via postcard, text message, e-mail,
or telephone, depending on available contact information. ",Sample selected all older than 12 years old,2020-04-25,2020-04-29,Household and community samples,All,Multiple groups,12.0,,Race,Non-white,281,0.0154,0.004,0.031000000000000003,,,True,,,Stratified probability,Author designed (ELISA) -Unknown,,CLIA,,IgG,,,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,No,Unclear,Yes,Yes,No,Nir Menachemi,Indiana University Fairbanks School of Public Health,Unity-Aligned,https://www.cdc.gov/mmwr/volumes/69/wr/mm6929e1.htm?s_cid=mm6929e1_w,2020-08-04,2022-07-16,Verified,menachemi_population_2020,USA
200513_Indiana_IndianaUniversity_Wave1GenPop_Hispanic_PopAdj,200513_Indiana_IndianaUniversity_Wave1_Random,"Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–29, 2020",2020-07-24,Institutional Report,Regional,Cross-sectional survey ,United States of America,Indiana,,"The study population was randomly selected from a list of Indiana residents derived from tax returns, including filers and
dependents.State databases were cross-checked for recent contact information, and institutionalized and deceased persons
were removed. Stratified random sampling was conducted
among all persons aged ≥12 years using Indiana’s 10 public
health preparedness districts as sampling strata. After the study
was announced, 15,495 participants were contacted by the
state health department via postcard, text message, e-mail,
or telephone, depending on available contact information. ",Sample selected all older than 12 years old,2020-04-25,2020-04-29,Household and community samples,All,Multiple groups,12.0,,Ethnicity,Hispanic ,80,0.0149,0.003,0.049,,,True,,,Stratified probability,Author designed (ELISA) -Unknown,,CLIA,,IgG,,,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,No,Unclear,Yes,Yes,No,Nir Menachemi,Indiana University Fairbanks School of Public Health,Unity-Aligned,https://www.cdc.gov/mmwr/volumes/69/wr/mm6929e1.htm?s_cid=mm6929e1_w,2020-08-04,2022-07-16,Verified,menachemi_population_2020,USA
200513_Indiana_IndianaUniversity_Wave1GenPop_Nonhispanic_PopAdj,200513_Indiana_IndianaUniversity_Wave1_Random,"Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–29, 2020",2020-07-24,Institutional Report,Regional,Cross-sectional survey ,United States of America,Indiana,,"The study population was randomly selected from a list of Indiana residents derived from tax returns, including filers and
dependents.State databases were cross-checked for recent contact information, and institutionalized and deceased persons
were removed. Stratified random sampling was conducted
among all persons aged ≥12 years using Indiana’s 10 public
health preparedness districts as sampling strata. After the study
was announced, 15,495 participants were contacted by the
state health department via postcard, text message, e-mail,
or telephone, depending on available contact information. ",Sample selected all older than 12 years old,2020-04-25,2020-04-29,Household and community samples,All,Multiple groups,12.0,,Ethnicity,Non-hispanic ,3578,0.0106,0.006999999999999999,0.015,,,True,,,Stratified probability,Author designed (ELISA) -Unknown,,CLIA,,IgG,,,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,No,Unclear,Yes,Yes,No,Nir Menachemi,Indiana University Fairbanks School of Public Health,Unity-Aligned,https://www.cdc.gov/mmwr/volumes/69/wr/mm6929e1.htm?s_cid=mm6929e1_w,2020-08-04,2022-07-16,Verified,menachemi_population_2020,USA
200513_Indiana_IndianaUniversity_Wave1GenPop_Age>=60_PopAdj,200513_Indiana_IndianaUniversity_Wave1_Random,"Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–29, 2020",2020-07-24,Institutional Report,Regional,Cross-sectional survey ,United States of America,Indiana,,"The study population was randomly selected from a list of Indiana residents derived from tax returns, including filers and
dependents.State databases were cross-checked for recent contact information, and institutionalized and deceased persons
were removed. Stratified random sampling was conducted
among all persons aged ≥12 years using Indiana’s 10 public
health preparedness districts as sampling strata. After the study
was announced, 15,495 participants were contacted by the
state health department via postcard, text message, e-mail,
or telephone, depending on available contact information. ",Sample selected all older than 12 years old,2020-04-25,2020-04-29,Household and community samples,All,Seniors (65+ years),60.0,,Age,>=60,1313,0.0077,0.003,0.013000000000000001,,,True,,,Stratified probability,Author designed (ELISA) -Unknown,,CLIA,,IgG,,,1.0,0.996,['Low'],Yes,Yes,Yes,Yes,No,Unclear,Yes,Yes,No,Nir Menachemi,Indiana University Fairbanks School of Public Health,Unity-Aligned,https://www.cdc.gov/mmwr/volumes/69/wr/mm6929e1.htm?s_cid=mm6929e1_w,2020-07-05,2022-07-16,Verified,menachemi_population_2020,USA
200729_RiversideCounty_RiversideUniversityHealthSystem_GenPop,200729_RiversideCounty_RiversideUniversityHealthSystem,"Riverside County may have more than 100,000 COVID-19 cases, antibody study suggests",2020-07-27,News and Media,Local,Cross-sectional survey ,United States of America,California,,Residents of Riverside County,,2020-07-06,2020-07-20,Household and community samples,All,Multiple groups,,,Primary Estimate,,1726,0.059000000000000004,,,True,,,,True,Simplified probability,Not reported/ Unable to specify,,,,,,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,ABC7 com staff,Riverside University Health System,Not Unity-Aligned,https://abc7.com/health/riverside-county-may-have-100000-covid-19-cases-study-says/6337677/,2020-09-26,2022-07-16,Verified,abc7com_riverside_2020,USA
200729_Philadelphia_UniversityofPennsylvania_TotalSampleTestAdj,200729_Philadelphia_UniversityofPennsylvania,SARS-CoV-2 Seroprevalence Among Parturient Women,2020-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Pennsylvania,Philadelphia,"Pregnant women presenting for delivery from April 4 to June 3, 2020 at two academic birth hospitals in Philadelphia, Pennsylvania with available discarded serum specimens",,2020-04-04,2020-06-03,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,1293,0.052000000000000005,,,True,True,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,No,Yes,Unclear,Yes,Yes,Yes,Dustin Flannery,University of Pennsylvania,Unity-Aligned,https://immunology.sciencemag.org/content/5/49/eabd5709,2020-07-13,2022-07-16,Verified,flannery_sars-cov-2_2020-2,USA
200729_Philadelphia_UniversityofPennsylvania_Other/UnknownEthnicity,200729_Philadelphia_UniversityofPennsylvania,SARS-CoV-2 Seroprevalence Among Parturient Women,2020-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Pennsylvania,Philadelphia,"Pregnant women presenting for delivery from April 4 to June 3, 2020 at two academic birth hospitals in Philadelphia, Pennsylvania with available discarded serum specimens",,2020-04-04,2020-06-03,Pregnant or parturient women,Female,Adults (18-64 years),,,Race,Unknown/Other,78,0.0641,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,No,Yes,Unclear,Yes,Yes,Yes,Dustin Flannery,University of Pennsylvania,Unity-Aligned,https://immunology.sciencemag.org/content/5/49/eabd5709,2020-07-13,2022-07-16,Verified,flannery_sars-cov-2_2020-2,USA
200729_Philadelphia_UniversityofPennsylvania_SurroundingPennsylvania,200729_Philadelphia_UniversityofPennsylvania,SARS-CoV-2 Seroprevalence Among Parturient Women,2020-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Pennsylvania,Philadelphia,"Pregnant women presenting for delivery from April 4 to June 3, 2020 at two academic birth hospitals in Philadelphia, Pennsylvania with available discarded serum specimens",,2020-04-04,2020-06-03,Pregnant or parturient women,Female,Adults (18-64 years),,,Geographical area,Living in surrounding areas in Pennsylvania,191,0.063,0.033,0.107,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,No,Yes,Unclear,Yes,Yes,Yes,Dustin Flannery,University of Pennsylvania,Unity-Aligned,https://immunology.sciencemag.org/content/5/49/eabd5709,2020-11-24,2022-07-16,Verified,flannery_sars-cov-2_2020-2,USA
200729_Philadelphia_UniversityofPennsylvania_White/Non-Hispanic,200729_Philadelphia_UniversityofPennsylvania,SARS-CoV-2 Seroprevalence Among Parturient Women,2020-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Pennsylvania,Philadelphia,"Pregnant women presenting for delivery from April 4 to June 3, 2020 at two academic birth hospitals in Philadelphia, Pennsylvania with available discarded serum specimens",,2020-04-04,2020-06-03,Pregnant or parturient women,Female,Adults (18-64 years),,,Race,White/Non-Hispanic,447,0.0201,0.009000000000000001,0.038,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,No,Yes,Unclear,Yes,Yes,Yes,Dustin Flannery,University of Pennsylvania,Unity-Aligned,https://immunology.sciencemag.org/content/5/49/eabd5709,2020-07-13,2022-07-16,Verified,flannery_sars-cov-2_2020-2,USA
200729_Philadelphia_UniversityofPennsylvania_Hispanic/Latino,200729_Philadelphia_UniversityofPennsylvania,SARS-CoV-2 Seroprevalence Among Parturient Women,2020-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Pennsylvania,Philadelphia,"Pregnant women presenting for delivery from April 4 to June 3, 2020 at two academic birth hospitals in Philadelphia, Pennsylvania with available discarded serum specimens",,2020-04-04,2020-06-03,Pregnant or parturient women,Female,Adults (18-64 years),,,Ethnicity,Hispanic/Latino,125,0.10400000000000001,0.057,0.171,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,No,Yes,Unclear,Yes,Yes,Yes,Dustin Flannery,University of Pennsylvania,Unity-Aligned,https://immunology.sciencemag.org/content/5/49/eabd5709,2020-07-13,2022-07-16,Verified,flannery_sars-cov-2_2020-2,USA
200729_Philadelphia_UniversityofPennsylvania_Black/Non-Hispanic,200729_Philadelphia_UniversityofPennsylvania,SARS-CoV-2 Seroprevalence Among Parturient Women,2020-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Pennsylvania,Philadelphia,"Pregnant women presenting for delivery from April 4 to June 3, 2020 at two academic birth hospitals in Philadelphia, Pennsylvania with available discarded serum specimens",,2020-04-04,2020-06-03,Pregnant or parturient women,Female,Adults (18-64 years),,,Race,Black/Non-Hispanic,537,0.09699999999999999,0.073,0.125,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,No,Yes,Unclear,Yes,Yes,Yes,Dustin Flannery,University of Pennsylvania,Unity-Aligned,https://immunology.sciencemag.org/content/5/49/eabd5709,2020-07-13,2022-07-16,Verified,flannery_sars-cov-2_2020-2,USA
200729_Philadelphia_UniversityofPennsylvania_SurroundingNewJersey,200729_Philadelphia_UniversityofPennsylvania,SARS-CoV-2 Seroprevalence Among Parturient Women,2020-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Pennsylvania,Philadelphia,"Pregnant women presenting for delivery from April 4 to June 3, 2020 at two academic birth hospitals in Philadelphia, Pennsylvania with available discarded serum specimens",,2020-04-04,2020-06-03,Pregnant or parturient women,Female,Adults (18-64 years),,,Geographical area,Living in surrounding areas in New Jersey,107,0.047,0.015,0.106,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,No,Yes,Unclear,Yes,Yes,Yes,Dustin Flannery,University of Pennsylvania,Unity-Aligned,https://immunology.sciencemag.org/content/5/49/eabd5709,2020-11-24,2022-07-16,Verified,flannery_sars-cov-2_2020-2,USA
200729_Philadelphia_UniversityofPennsylvania_Asian,200729_Philadelphia_UniversityofPennsylvania,SARS-CoV-2 Seroprevalence Among Parturient Women,2020-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Pennsylvania,Philadelphia,"Pregnant women presenting for delivery from April 4 to June 3, 2020 at two academic birth hospitals in Philadelphia, Pennsylvania with available discarded serum specimens",,2020-04-04,2020-06-03,Pregnant or parturient women,Female,Adults (18-64 years),,,Race,Asian,106,0.0094,0.0,0.051,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,No,Yes,Unclear,Yes,Yes,Yes,Dustin Flannery,University of Pennsylvania,Unity-Aligned,https://immunology.sciencemag.org/content/5/49/eabd5709,2020-07-13,2022-07-16,Verified,flannery_sars-cov-2_2020-2,USA
200729_Philadelphia_UniversityofPennsylvania_Philadelphia,200729_Philadelphia_UniversityofPennsylvania,SARS-CoV-2 Seroprevalence Among Parturient Women,2020-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Pennsylvania,Philadelphia,"Pregnant women presenting for delivery from April 4 to June 3, 2020 at two academic birth hospitals in Philadelphia, Pennsylvania with available discarded serum specimens",,2020-04-04,2020-06-03,Pregnant or parturient women,Female,Adults (18-64 years),,,Geographical area,Within city limits of Philadelphia,986,0.063,0.049,0.08,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,No,Yes,Unclear,Yes,Yes,Yes,Dustin Flannery,University of Pennsylvania,Unity-Aligned,https://immunology.sciencemag.org/content/5/49/eabd5709,2020-11-24,2022-07-16,Verified,flannery_sars-cov-2_2020-2,USA
200729_Philadelphia_UniversityofPennsylvania_TotalSampleCrude,200729_Philadelphia_UniversityofPennsylvania,SARS-CoV-2 Seroprevalence Among Parturient Women,2020-07-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Pennsylvania,Philadelphia,"Pregnant women presenting for delivery from April 4 to June 3, 2020 at two academic birth hospitals in Philadelphia, Pennsylvania with available discarded serum specimens",,2020-04-04,2020-06-03,Pregnant or parturient women,Female,Adults (18-64 years),,,Analysis,Unadjusted,1293,0.062000000000000006,0.049,0.08,,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,No,Yes,Unclear,Yes,Yes,Yes,Dustin Flannery,University of Pennsylvania,Unity-Aligned,https://immunology.sciencemag.org/content/5/49/eabd5709,2020-07-13,2022-07-16,Verified,flannery_sars-cov-2_2020-2,USA
200730_Louisiana_OschnerClinicFoundation_Overall_PopWeighted,200730_Louisiana_OschnerClinicFoundation,"Seroprevalence of SARS-CoV-2 and Infection Fatality Ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020",2020-07-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Louisiana,,"To recruit a representative sample for this high-throughput method, a novel 2-step system developed by Public Democracy considered >50 characteristics, including social determinants of health and US Census population data, to establish a pool of potential participants reflective of the demographics of the parishes, from which a randomized subset of 150,000 was selected.",Housemates of participants selected or persons from ineligible zip codes.,2020-05-09,2020-05-15,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,,2640,0.069,0.068,0.069,True,,True,,True,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Amy K Feehan,Oschner Clinic Foundation,Unity-Aligned,https://dx.doi.org/10.3201/eid2611.203029,2020-10-05,2024-03-01,Verified,feehan_seroprevalence_2020,USA
200730_Louisiana_OschnerClinicFoundation_PacificIslander,200730_Louisiana_OschnerClinicFoundation,"Seroprevalence of SARS-CoV-2 and Infection Fatality Ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020",2020-07-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Louisiana,,"To recruit a representative sample for this high-throughput method, a novel 2-step system developed by Public Democracy considered >50 characteristics, including social determinants of health and US Census population data, to establish a pool of potential participants reflective of the demographics of the parishes, from which a randomized subset of 150,000 was selected.",Housemates of participants selected or persons from ineligible zip codes.,2020-05-09,2020-05-15,Household and community samples,All,Adults (18-64 years),,,Race,Pacific Islander,3,0.0,,,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Amy K Feehan,Oschner Clinic Foundation,Unity-Aligned,https://dx.doi.org/10.3201/eid2611.203029,2020-10-27,2024-03-01,Verified,feehan_seroprevalence_2020,USA
200730_Louisiana_OschnerClinicFoundation_Asian_PopWeighted,200730_Louisiana_OschnerClinicFoundation,"Seroprevalence of SARS-CoV-2 and Infection Fatality Ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020",2020-07-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Louisiana,,"To recruit a representative sample for this high-throughput method, a novel 2-step system developed by Public Democracy considered >50 characteristics, including social determinants of health and US Census population data, to establish a pool of potential participants reflective of the demographics of the parishes, from which a randomized subset of 150,000 was selected.",Housemates of participants selected or persons from ineligible zip codes.,2020-05-09,2020-05-15,Household and community samples,All,Adults (18-64 years),,,Race,Asian,130,0.055,0.052000000000000005,0.057,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Amy K Feehan,Oschner Clinic Foundation,Unity-Aligned,https://dx.doi.org/10.3201/eid2611.203029,2020-10-05,2024-03-01,Verified,feehan_seroprevalence_2020,USA
200730_Louisiana_OschnerClinicFoundation_Overall,200730_Louisiana_OschnerClinicFoundation,"Seroprevalence of SARS-CoV-2 and Infection Fatality Ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020",2020-07-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Louisiana,,"To recruit a representative sample for this high-throughput method, a novel 2-step system developed by Public Democracy considered >50 characteristics, including social determinants of health and US Census population data, to establish a pool of potential participants reflective of the demographics of the parishes, from which a randomized subset of 150,000 was selected.",Housemates of participants selected or persons from ineligible zip codes.,2020-05-09,2020-05-15,Household and community samples,All,Adults (18-64 years),,,Analysis,Unadjusted,2640,0.0693,,,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Amy K Feehan,Oschner Clinic Foundation,Unity-Aligned,https://dx.doi.org/10.3201/eid2611.203029,2020-10-27,2024-03-01,Verified,feehan_seroprevalence_2020,USA
200730_Louisiana_OschnerClinicFoundation_Indigenous ,200730_Louisiana_OschnerClinicFoundation,"Seroprevalence of SARS-CoV-2 and Infection Fatality Ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020",2020-07-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Louisiana,,"To recruit a representative sample for this high-throughput method, a novel 2-step system developed by Public Democracy considered >50 characteristics, including social determinants of health and US Census population data, to establish a pool of potential participants reflective of the demographics of the parishes, from which a randomized subset of 150,000 was selected.",Housemates of participants selected or persons from ineligible zip codes.,2020-05-09,2020-05-15,Household and community samples,All,Adults (18-64 years),,,Race,Indigenous ,14,0.0,,,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Amy K Feehan,Oschner Clinic Foundation,Unity-Aligned,https://dx.doi.org/10.3201/eid2611.203029,2020-10-27,2024-03-01,Verified,feehan_seroprevalence_2020,USA
200730_Louisiana_OschnerClinicFoundation_White,200730_Louisiana_OschnerClinicFoundation,"Seroprevalence of SARS-CoV-2 and Infection Fatality Ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020",2020-07-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Louisiana,,"To recruit a representative sample for this high-throughput method, a novel 2-step system developed by Public Democracy considered >50 characteristics, including social determinants of health and US Census population data, to establish a pool of potential participants reflective of the demographics of the parishes, from which a randomized subset of 150,000 was selected.",Housemates of participants selected or persons from ineligible zip codes.,2020-05-09,2020-05-15,Household and community samples,All,Adults (18-64 years),,,Race,White,1607,0.0492,,,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Amy K Feehan,Oschner Clinic Foundation,Unity-Aligned,https://dx.doi.org/10.3201/eid2611.203029,2020-10-27,2024-03-01,Verified,feehan_seroprevalence_2020,USA
200730_Louisiana_OschnerClinicFoundation_Hispanic,200730_Louisiana_OschnerClinicFoundation,"Seroprevalence of SARS-CoV-2 and Infection Fatality Ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020",2020-07-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Louisiana,,"To recruit a representative sample for this high-throughput method, a novel 2-step system developed by Public Democracy considered >50 characteristics, including social determinants of health and US Census population data, to establish a pool of potential participants reflective of the demographics of the parishes, from which a randomized subset of 150,000 was selected.",Housemates of participants selected or persons from ineligible zip codes.,2020-05-09,2020-05-15,Household and community samples,All,Adults (18-64 years),,,Ethnicity,Hispanic,293,0.061399999999999996,,,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Amy K Feehan,Oschner Clinic Foundation,Unity-Aligned,https://dx.doi.org/10.3201/eid2611.203029,2020-10-27,2024-03-01,Verified,feehan_seroprevalence_2020,USA
200730_Louisiana_OschnerClinicFoundation_Hispanic_PopWeighted,200730_Louisiana_OschnerClinicFoundation,"Seroprevalence of SARS-CoV-2 and Infection Fatality Ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020",2020-07-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Louisiana,,"To recruit a representative sample for this high-throughput method, a novel 2-step system developed by Public Democracy considered >50 characteristics, including social determinants of health and US Census population data, to establish a pool of potential participants reflective of the demographics of the parishes, from which a randomized subset of 150,000 was selected.",Housemates of participants selected or persons from ineligible zip codes.,2020-05-09,2020-05-15,Household and community samples,All,Adults (18-64 years),,,Ethnicity,Hispanic,293,0.053,0.052000000000000005,0.055,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Amy K Feehan,Oschner Clinic Foundation,Unity-Aligned,https://dx.doi.org/10.3201/eid2611.203029,2020-10-05,2024-03-01,Verified,feehan_seroprevalence_2020,USA
200730_Louisiana_OschnerClinicFoundation_Multiracialorother,200730_Louisiana_OschnerClinicFoundation,"Seroprevalence of SARS-CoV-2 and Infection Fatality Ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020",2020-07-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Louisiana,,"To recruit a representative sample for this high-throughput method, a novel 2-step system developed by Public Democracy considered >50 characteristics, including social determinants of health and US Census population data, to establish a pool of potential participants reflective of the demographics of the parishes, from which a randomized subset of 150,000 was selected.",Housemates of participants selected or persons from ineligible zip codes.,2020-05-09,2020-05-15,Household and community samples,All,Adults (18-64 years),,,Race,Multiracial or other,58,0.0862,,,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Amy K Feehan,Oschner Clinic Foundation,Unity-Aligned,https://dx.doi.org/10.3201/eid2611.203029,2020-10-27,2024-03-01,Verified,feehan_seroprevalence_2020,USA
200730_Louisiana_OschnerClinicFoundation_Asian,200730_Louisiana_OschnerClinicFoundation,"Seroprevalence of SARS-CoV-2 and Infection Fatality Ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020",2020-07-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Louisiana,,"To recruit a representative sample for this high-throughput method, a novel 2-step system developed by Public Democracy considered >50 characteristics, including social determinants of health and US Census population data, to establish a pool of potential participants reflective of the demographics of the parishes, from which a randomized subset of 150,000 was selected.",Housemates of participants selected or persons from ineligible zip codes.,2020-05-09,2020-05-15,Household and community samples,All,Adults (18-64 years),,,Race,Asian,130,0.0692,,,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Amy K Feehan,Oschner Clinic Foundation,Unity-Aligned,https://dx.doi.org/10.3201/eid2611.203029,2020-10-27,2024-03-01,Verified,feehan_seroprevalence_2020,USA
200730_Louisiana_OschnerClinicFoundation_Indigenous_PopWeighted,200730_Louisiana_OschnerClinicFoundation,"Seroprevalence of SARS-CoV-2 and Infection Fatality Ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020",2020-07-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Louisiana,,"To recruit a representative sample for this high-throughput method, a novel 2-step system developed by Public Democracy considered >50 characteristics, including social determinants of health and US Census population data, to establish a pool of potential participants reflective of the demographics of the parishes, from which a randomized subset of 150,000 was selected.",Housemates of participants selected or persons from ineligible zip codes.,2020-05-09,2020-05-15,Household and community samples,All,Adults (18-64 years),,,Race,Indigenous ,14,0.0,,,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Amy K Feehan,Oschner Clinic Foundation,Unity-Aligned,https://dx.doi.org/10.3201/eid2611.203029,2020-10-05,2024-03-01,Verified,feehan_seroprevalence_2020,USA
200730_Louisiana_OschnerClinicFoundation_Multiracialorother_PopWeighted,200730_Louisiana_OschnerClinicFoundation,"Seroprevalence of SARS-CoV-2 and Infection Fatality Ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020",2020-07-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Louisiana,,"To recruit a representative sample for this high-throughput method, a novel 2-step system developed by Public Democracy considered >50 characteristics, including social determinants of health and US Census population data, to establish a pool of potential participants reflective of the demographics of the parishes, from which a randomized subset of 150,000 was selected.",Housemates of participants selected or persons from ineligible zip codes.,2020-05-09,2020-05-15,Household and community samples,All,Adults (18-64 years),,,Race,Multiracial or other,58,0.071,0.067,0.076,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Amy K Feehan,Oschner Clinic Foundation,Unity-Aligned,https://dx.doi.org/10.3201/eid2611.203029,2020-10-05,2024-03-01,Verified,feehan_seroprevalence_2020,USA
200730_Louisiana_OschnerClinicFoundation_PacificIslander_PopWeighted,200730_Louisiana_OschnerClinicFoundation,"Seroprevalence of SARS-CoV-2 and Infection Fatality Ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020",2020-07-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Louisiana,,"To recruit a representative sample for this high-throughput method, a novel 2-step system developed by Public Democracy considered >50 characteristics, including social determinants of health and US Census population data, to establish a pool of potential participants reflective of the demographics of the parishes, from which a randomized subset of 150,000 was selected.",Housemates of participants selected or persons from ineligible zip codes.,2020-05-09,2020-05-15,Household and community samples,All,Adults (18-64 years),,,Race,Pacific Islander,3,0.0,,,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Amy K Feehan,Oschner Clinic Foundation,Unity-Aligned,https://dx.doi.org/10.3201/eid2611.203029,2020-10-05,2024-03-01,Verified,feehan_seroprevalence_2020,USA
200730_Louisiana_OschnerClinicFoundation_White_PopWeighted,200730_Louisiana_OschnerClinicFoundation,"Seroprevalence of SARS-CoV-2 and Infection Fatality Ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020",2020-07-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Louisiana,,"To recruit a representative sample for this high-throughput method, a novel 2-step system developed by Public Democracy considered >50 characteristics, including social determinants of health and US Census population data, to establish a pool of potential participants reflective of the demographics of the parishes, from which a randomized subset of 150,000 was selected.",Housemates of participants selected or persons from ineligible zip codes.,2020-05-09,2020-05-15,Household and community samples,All,Adults (18-64 years),,,Race,White,1607,0.045,0.044000000000000004,0.046,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Amy K Feehan,Oschner Clinic Foundation,Unity-Aligned,https://dx.doi.org/10.3201/eid2611.203029,2020-10-05,2024-03-01,Verified,feehan_seroprevalence_2020,USA
200730_Louisiana_OschnerClinicFoundation_Black_PopWeighted,200730_Louisiana_OschnerClinicFoundation,"Seroprevalence of SARS-CoV-2 and Infection Fatality Ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020",2020-07-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Louisiana,,"To recruit a representative sample for this high-throughput method, a novel 2-step system developed by Public Democracy considered >50 characteristics, including social determinants of health and US Census population data, to establish a pool of potential participants reflective of the demographics of the parishes, from which a randomized subset of 150,000 was selected.",Housemates of participants selected or persons from ineligible zip codes.,2020-05-09,2020-05-15,Household and community samples,All,Adults (18-64 years),,,Race,Black,828,0.098,0.09699999999999999,0.099,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Amy K Feehan,Oschner Clinic Foundation,Unity-Aligned,https://dx.doi.org/10.3201/eid2611.203029,2020-10-05,2024-03-01,Verified,feehan_seroprevalence_2020,USA
200730_Louisiana_OschnerClinicFoundation_Black,200730_Louisiana_OschnerClinicFoundation,"Seroprevalence of SARS-CoV-2 and Infection Fatality Ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020",2020-07-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Louisiana,,"To recruit a representative sample for this high-throughput method, a novel 2-step system developed by Public Democracy considered >50 characteristics, including social determinants of health and US Census population data, to establish a pool of potential participants reflective of the demographics of the parishes, from which a randomized subset of 150,000 was selected.",Housemates of participants selected or persons from ineligible zip codes.,2020-05-09,2020-05-15,Household and community samples,All,Adults (18-64 years),,,Race,Black,828,0.10869999999999999,,,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,,Amy K Feehan,Oschner Clinic Foundation,Unity-Aligned,https://dx.doi.org/10.3201/eid2611.203029,2020-10-27,2024-03-01,Verified,feehan_seroprevalence_2020,USA
200803_Indiana_IndianaUniversity_healthcareworkers,200803_Indiana_IndianaUniversity,Seroprevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) antibodies among healthcare workers with differing levels of coronavirus disease 2019 (COVID-19) patient exposure.,2020-08-03,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Indiana,Indianapolis,"had to be an employee of the Indiana University Health, asymptomatic","Employees with active
symptoms or previously confirmed COVID-19 were excluded",2020-04-29,2020-05-08,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,734,0.0163,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.996,['High'],Yes,No,Yes,No,No,Yes,Yes,Yes,Unclear,Benton Hunter, Indiana University,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2020.390,2020-10-04,2024-03-01,Verified,hunter_seroprevalence_2020,USA
200804_Miami_DaVitaClinicalResearch_HemodialysisPatients_Overall,200804_Miami_DaVitaClinicalResearch,Assessment of a Laboratory-Based SARS-CoV-2 Antibody Test Among Hemodialysis Patients: A Quality Improvement Initiative,2020-08-04,Preprint,Local,Cross-sectional survey ,United States of America,Florida,Miami,"Eligible patients were adults (≥18 years of age) receiving dialysis care at a large dialysis organization operating in the greater Miami, Florida, region (23-30 April 2020). Patients with and without a recorded history of symptoms consistent with COVID-19 were included",,2020-04-23,2020-04-30,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,,Primary Estimate,,677,0.055999999999999994,0.04,0.076,True,,,,True,Convenience,"Diazyme DZ-Lite SARS-CoV-2 IgG  CLIA tests,Diazyme DZ-Lite SARS-CoV-2 IgM  CLIA tests",Diazyme Laboratories Inc,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.5710000000000001,0.85,['High'],Yes,No,Yes,Yes,Unclear,No,Yes,No,Unclear,Dena Cohen,DaVita Clinical Research,Not Unity-Aligned,https://doi.org/10.1101/2020.08.03.20163642,2020-09-24,2024-03-01,Verified,cohen_assessment_2020-2,USA
200806_Florida_UniversityofMiamiMillerSchoolofMedicine_FirstResponders_UnAdj,200806_Florida_UniversityofMiamiMillerSchoolofMedicine,Epidemiology of SARS-CoV-2 antibodies among firefighters/paramedics of a US fire department: A cross-sectional study,2020-08-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Florida,,Firefighters/paramedics of a US fire department in Florida were invited by department and local union leadership to voluntarily consent to participate in a one-time surveillance assessment for SARS-CoV-2 antibodies. ,,2020-04-16,2020-04-17,Essential non-healthcare workers,All,Multiple groups,21.0,,Primary Estimate,,203,0.08900000000000001,,,True,,,,True,Convenience,COVID-19 IgM-IgG Dual Antibody Rapid Test,"BioMedomics, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.8865999999999999,0.9063,['High'],No,No,No,Yes,Yes,Yes,Yes,No,Unclear,Alberto J Caban Martinez,University of Miami,Not Unity-Aligned,http://dx.doi.org/10.1136/oemed-2020-106676,2020-10-09,2024-03-01,Verified,caban-martinez_epidemiology_2020,USA
200806_Florida_UniversityofMiamiMillerSchoolofMedicine_FirstResponders_AgeOlder51_UnAdj,200806_Florida_UniversityofMiamiMillerSchoolofMedicine,Epidemiology of SARS-CoV-2 antibodies among firefighters/paramedics of a US fire department: A cross-sectional study,2020-08-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Florida,,Firefighters/paramedics of a US fire department in Florida were invited by department and local union leadership to voluntarily consent to participate in a one-time surveillance assessment for SARS-CoV-2 antibodies. ,,2020-04-16,2020-04-17,Essential non-healthcare workers,All,Multiple groups,51.0,,Age,>=51,52,0.05769230769,,,,,,,,Convenience,COVID-19 IgM-IgG Dual Antibody Rapid Test,"BioMedomics, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.8865999999999999,0.9063,['High'],No,No,No,Yes,Yes,Yes,Yes,No,Unclear,Alberto J Caban Martinez,University of Miami,Not Unity-Aligned,http://dx.doi.org/10.1136/oemed-2020-106676,2020-10-09,2024-03-01,Verified,caban-martinez_epidemiology_2020,USA
200806_Florida_UniversityofMiamiMillerSchoolofMedicine_FirstResponders_Age21-30_UnAdj,200806_Florida_UniversityofMiamiMillerSchoolofMedicine,Epidemiology of SARS-CoV-2 antibodies among firefighters/paramedics of a US fire department: A cross-sectional study,2020-08-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Florida,,Firefighters/paramedics of a US fire department in Florida were invited by department and local union leadership to voluntarily consent to participate in a one-time surveillance assessment for SARS-CoV-2 antibodies. ,,2020-04-16,2020-04-17,Essential non-healthcare workers,All,Adults (18-64 years),21.0,30.0,Age,21-30,33,0.06060606061,,,,,,,,Convenience,COVID-19 IgM-IgG Dual Antibody Rapid Test,"BioMedomics, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.8865999999999999,0.9063,['High'],No,No,No,Yes,Yes,Yes,Yes,No,Unclear,Alberto J Caban Martinez,University of Miami,Not Unity-Aligned,http://dx.doi.org/10.1136/oemed-2020-106676,2020-10-09,2024-03-01,Verified,caban-martinez_epidemiology_2020,USA
200806_Florida_UniversityofMiamiMillerSchoolofMedicine_FirstResponders_Age41-50_UnAdj,200806_Florida_UniversityofMiamiMillerSchoolofMedicine,Epidemiology of SARS-CoV-2 antibodies among firefighters/paramedics of a US fire department: A cross-sectional study,2020-08-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Florida,,Firefighters/paramedics of a US fire department in Florida were invited by department and local union leadership to voluntarily consent to participate in a one-time surveillance assessment for SARS-CoV-2 antibodies. ,,2020-04-16,2020-04-17,Essential non-healthcare workers,All,Adults (18-64 years),41.0,50.0,Age,41-50,56,0.125,,,,,,,,Convenience,COVID-19 IgM-IgG Dual Antibody Rapid Test,"BioMedomics, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.8865999999999999,0.9063,['High'],No,No,No,Yes,Yes,Yes,Yes,No,Unclear,Alberto J Caban Martinez,University of Miami,Not Unity-Aligned,http://dx.doi.org/10.1136/oemed-2020-106676,2020-10-09,2024-03-01,Verified,caban-martinez_epidemiology_2020,USA
200806_Florida_UniversityofMiamiMillerSchoolofMedicine_FirstResponders_Age31-40_UnAdj,200806_Florida_UniversityofMiamiMillerSchoolofMedicine,Epidemiology of SARS-CoV-2 antibodies among firefighters/paramedics of a US fire department: A cross-sectional study,2020-08-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Florida,,Firefighters/paramedics of a US fire department in Florida were invited by department and local union leadership to voluntarily consent to participate in a one-time surveillance assessment for SARS-CoV-2 antibodies. ,,2020-04-16,2020-04-17,Essential non-healthcare workers,All,Adults (18-64 years),31.0,40.0,Age,31-40,51,0.1176470588,,,,,,,,Convenience,COVID-19 IgM-IgG Dual Antibody Rapid Test,"BioMedomics, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,0.8865999999999999,0.9063,['High'],No,No,No,Yes,Yes,Yes,Yes,No,Unclear,Alberto J Caban Martinez,University of Miami,Not Unity-Aligned,http://dx.doi.org/10.1136/oemed-2020-106676,2020-10-09,2024-03-01,Verified,caban-martinez_epidemiology_2020,USA
200810_USA_Illinois_PhysicianPractice_Overall,200810_USA_Illinois_PhysicianPractice,"Observational study of SARS-CoV-2 antibody immune response in a cohort of patients at a North Suburban Chicago, Illinois, in a physician's practice",2020-08-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Illinois,Chicago,Patients routinely managed by the practicing physicians who consented to a serological test. ,,2020-04-22,2020-05-26,Residual sera,All,Multiple groups,3.0,84.0,Primary Estimate,,113,0.159,,,True,,,,True,Convenience,CLUNGENE SARS-COV-2 VIRUS (COVID-19) IgG/IgM Rapid Test Cassette lateral flow immunoassay,CLUNGENE,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Gerald Osher,BioSolutions Services LLC,Not Unity-Aligned,https://lymphosign.com/doi/full/10.14785/lymphosign-2020-0007,2021-01-06,2024-03-01,Verified,osher_observational_2020,USA
200901_NewYorkCity_NorthwellHealthCOVID-19ResearchConsortium,200901_NewYorkCity_NorthwellHealthCOVID-19ResearchConsortium,Prevalence of SARS-CoV-2 Antibodies in Health Care Personnel in the New York City Area,2020-08-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"ll Northwell HCPwere offered free, voluntary antibody testing, regardless ofsymptoms, at 52 sites in the greater NYC area.",Missing all identifying data,2020-04-20,2020-06-23,Health care workers and caregivers,All,Multiple groups,18.0,,Primary Estimate,,40329,0.13699999999999998,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,SARS-CoV-2 IgG ELISA,Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,AnshLabs ,Abbott Laboratories,Ortho Clinical Diagnostics Inc.,DiaSorin,Roche Diagnostics",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,No,No,Unclear,Joseph Moscola,Northwell Health COVID-19 Research Consortium,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/32780804/,2021-01-28,2024-03-01,Verified,moscola_prevalence_2020,USA
200901_NewYorkCity_NorthwellHealthCOVID-19ResearchConsortium_50-59,200901_NewYorkCity_NorthwellHealthCOVID-19ResearchConsortium,Prevalence of SARS-CoV-2 Antibodies in Health Care Personnel in the New York City Area,2020-08-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York City,"ll Northwell HCPwere offered free, voluntary antibody testing, regardless ofsymptoms, at 52 sites in the greater NYC area.",Missing all identifying data,2020-04-20,2020-06-23,Health care workers and caregivers,All,Adults (18-64 years),50.0,59.0,Age,50-59,8550,0.12300000000000001,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,SARS-CoV-2 IgG ELISA,Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,AnshLabs ,Abbott Laboratories,Ortho Clinical Diagnostics Inc.,DiaSorin,Roche Diagnostics",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,No,No,Unclear,Joseph Moscola,Northwell Health COVID-19 Research Consortium,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/32780804/,2021-03-10,2024-03-01,Verified,moscola_prevalence_2020,USA
200901_NewYorkCity_NorthwellHealthCOVID-19ResearchConsortium_40-49,200901_NewYorkCity_NorthwellHealthCOVID-19ResearchConsortium,Prevalence of SARS-CoV-2 Antibodies in Health Care Personnel in the New York City Area,2020-08-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York City,"ll Northwell HCPwere offered free, voluntary antibody testing, regardless ofsymptoms, at 52 sites in the greater NYC area.",Missing all identifying data,2020-04-20,2020-06-23,Health care workers and caregivers,All,Adults (18-64 years),40.0,49.0,Age,40-49,7829,0.141,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,SARS-CoV-2 IgG ELISA,Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,AnshLabs ,Abbott Laboratories,Ortho Clinical Diagnostics Inc.,DiaSorin,Roche Diagnostics",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,No,No,Unclear,Joseph Moscola,Northwell Health COVID-19 Research Consortium,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/32780804/,2021-03-10,2024-03-01,Verified,moscola_prevalence_2020,USA
200901_NewYorkCity_NorthwellHealthCOVID-19ResearchConsortium_18-39,200901_NewYorkCity_NorthwellHealthCOVID-19ResearchConsortium,Prevalence of SARS-CoV-2 Antibodies in Health Care Personnel in the New York City Area,2020-08-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York City,"ll Northwell HCPwere offered free, voluntary antibody testing, regardless ofsymptoms, at 52 sites in the greater NYC area.",Missing all identifying data,2020-04-20,2020-06-23,Health care workers and caregivers,All,Adults (18-64 years),18.0,39.0,Age,18-39,18193,0.15,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,SARS-CoV-2 IgG ELISA,Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,AnshLabs ,Abbott Laboratories,Ortho Clinical Diagnostics Inc.,DiaSorin,Roche Diagnostics",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,No,No,Unclear,Joseph Moscola,Northwell Health COVID-19 Research Consortium,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/32780804/,2021-03-10,2024-03-01,Verified,moscola_prevalence_2020,USA
200901_NewYorkCity_NorthwellHealthCOVID-19ResearchConsortium_70+,200901_NewYorkCity_NorthwellHealthCOVID-19ResearchConsortium,Prevalence of SARS-CoV-2 Antibodies in Health Care Personnel in the New York City Area,2020-08-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York City,"ll Northwell HCPwere offered free, voluntary antibody testing, regardless ofsymptoms, at 52 sites in the greater NYC area.",Missing all identifying data,2020-04-20,2020-06-23,Health care workers and caregivers,All,Seniors (65+ years),70.0,,Age,70+,542,0.08900000000000001,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,SARS-CoV-2 IgG ELISA,Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,AnshLabs ,Abbott Laboratories,Ortho Clinical Diagnostics Inc.,DiaSorin,Roche Diagnostics",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,No,No,Unclear,Joseph Moscola,Northwell Health COVID-19 Research Consortium,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/32780804/,2021-03-10,2024-03-01,Verified,moscola_prevalence_2020,USA
200901_NewYorkCity_NorthwellHealthCOVID-19ResearchConsortium_60-69,200901_NewYorkCity_NorthwellHealthCOVID-19ResearchConsortium,Prevalence of SARS-CoV-2 Antibodies in Health Care Personnel in the New York City Area,2020-08-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York City,"ll Northwell HCPwere offered free, voluntary antibody testing, regardless ofsymptoms, at 52 sites in the greater NYC area.",Missing all identifying data,2020-04-20,2020-06-23,Health care workers and caregivers,All,Adults (18-64 years),60.0,69.0,Age,60-69,5215,0.114,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,SARS-CoV-2 IgG ELISA,Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,AnshLabs ,Abbott Laboratories,Ortho Clinical Diagnostics Inc.,DiaSorin,Roche Diagnostics",Multiple Types,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,No,No,Unclear,Joseph Moscola,Northwell Health COVID-19 Research Consortium,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/32780804/,2021-03-10,2024-03-01,Verified,moscola_prevalence_2020,USA
200811_NewYork_StFrancisHospital_Overall,200811_NewYork_StFrancisHospital,Prevalence of SARS-CoV-2 Infection among Health Care Workers in a Tertiary Community Hospital,2020-08-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"All employees of the New York health care system, asymptomatic or were previously symptomatic with no symptoms for at least 14 days.",,2020-03-01,2020-04-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,HCW,1699,0.098,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Abbott Architect SARS-CoV-2 IgG","EUROIMMUN,Abbott Laboratories",,Multiple Types,IgG,,,,,['High'],No,No,Yes,Yes,Yes,Unclear,No,No,No,Allen Jeremias,St Francis Hospital,Not Unity-Aligned,http://dx.doi.org/10.1001/jamainternmed.2020.4214,2020-10-09,2024-03-01,Verified,jeremias_prevalence_2020,USA
200814_NewYorkCity_MemorialSloanKetteringCancerCenter_CancerPatients,200814_NewYorkCity_MemorialSloanKetteringCancerCenter,"Results and Impact of Intensive SARS-CoV-2 Testing in a High Volume, Outpatient Radiation Oncology Clinic in a Pandemic Hotspot",2020-08-14,Preprint,Local,Cross-sectional survey ,United States of America,New York,New York City,"Outpatients coming into Department of Radiation Oncology for either simulation or brachytherapy were offered antibody testing, in addition to PCR testing for SARS-CoV-2",,2020-05-07,2020-06-25,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,952,0.0546,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Sean McBride,Memorial Sloan Kettering Cancer Center,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.11.20172551v1,2020-10-08,2024-03-01,Verified,mcbride_results_2020,USA
200814_Oregon_OregonHealthAuthority_Overall_UnAdj,200814_Oregon_OregonHealthAuthority,"Seroprevalence Estimates of SARS- CoV-2 Infection in Convenience Sample - Oregon, May 11-June 15, 2020",2020-08-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Oregon,,"Facilities were asked to submit random subsamples of deidentified sera from patients of all ages visiting any ambulatory, emergency, or inpatient health care setting",,2020-05-11,2020-06-15,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,897,0.01,0.002,0.018000000000000002,True,,,,True,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.968,0.991,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Melissa Sutton,Oregon Health Authority,Unity-Aligned,https://www.cdc.gov/mmwr/volumes/69/wr/mm6932a4.htm,2020-10-10,2024-03-01,Verified,sutton_notes_2020-1,USA
200814_Oregon_OregonHealthAuthority_Age5-17_UnAdj,200814_Oregon_OregonHealthAuthority,"Seroprevalence Estimates of SARS- CoV-2 Infection in Convenience Sample - Oregon, May 11-June 15, 2020",2020-08-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Oregon,,"Facilities were asked to submit random subsamples of deidentified sera from patients of all ages visiting any ambulatory, emergency, or inpatient health care setting",,2020-05-11,2020-06-15,Residual sera,All,Children and Youth (0-17 years),5.0,17.0,Age,5-17,24,0.0,,,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.968,0.991,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Melissa Sutton,Oregon Health Authority,Unity-Aligned,https://www.cdc.gov/mmwr/volumes/69/wr/mm6932a4.htm,2020-10-13,2024-03-01,Verified,sutton_notes_2020-1,USA
200814_Oregon_OregonHealthAuthority_Age18-49_UnAdj,200814_Oregon_OregonHealthAuthority,"Seroprevalence Estimates of SARS- CoV-2 Infection in Convenience Sample - Oregon, May 11-June 15, 2020",2020-08-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Oregon,,"Facilities were asked to submit random subsamples of deidentified sera from patients of all ages visiting any ambulatory, emergency, or inpatient health care setting",,2020-05-11,2020-06-15,Residual sera,All,Adults (18-64 years),18.0,49.0,Age,18-49,274,0.00364963504,0.0,0.02,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.968,0.991,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Melissa Sutton,Oregon Health Authority,Unity-Aligned,https://www.cdc.gov/mmwr/volumes/69/wr/mm6932a4.htm,2020-10-13,2024-03-01,Verified,sutton_notes_2020-1,USA
200814_Oregon_OregonHealthAuthority_Age50-64_UnAdj,200814_Oregon_OregonHealthAuthority,"Seroprevalence Estimates of SARS- CoV-2 Infection in Convenience Sample - Oregon, May 11-June 15, 2020",2020-08-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Oregon,,"Facilities were asked to submit random subsamples of deidentified sera from patients of all ages visiting any ambulatory, emergency, or inpatient health care setting",,2020-05-11,2020-06-15,Residual sera,All,Adults (18-64 years),50.0,64.0,Age,50-64,211,0.00473933649,0.0,0.026000000000000002,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.968,0.991,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Melissa Sutton,Oregon Health Authority,Unity-Aligned,https://www.cdc.gov/mmwr/volumes/69/wr/mm6932a4.htm,2020-10-13,2024-03-01,Verified,sutton_notes_2020-1,USA
200814_Oregon_OregonHealthAuthority_Age85plus_UnAdj,200814_Oregon_OregonHealthAuthority,"Seroprevalence Estimates of SARS- CoV-2 Infection in Convenience Sample - Oregon, May 11-June 15, 2020",2020-08-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Oregon,,"Facilities were asked to submit random subsamples of deidentified sera from patients of all ages visiting any ambulatory, emergency, or inpatient health care setting",,2020-05-11,2020-06-15,Residual sera,All,Seniors (65+ years),85.0,,Age,=>85,61,0.01639344262,0.0,0.08800000000000001,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.968,0.991,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Melissa Sutton,Oregon Health Authority,Unity-Aligned,https://www.cdc.gov/mmwr/volumes/69/wr/mm6932a4.htm,2020-10-13,2024-03-01,Verified,sutton_notes_2020-1,USA
200814_Oregon_OregonHealthAuthority_Age0-4_UnAdj,200814_Oregon_OregonHealthAuthority,"Seroprevalence Estimates of SARS- CoV-2 Infection in Convenience Sample - Oregon, May 11-June 15, 2020",2020-08-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Oregon,,"Facilities were asked to submit random subsamples of deidentified sera from patients of all ages visiting any ambulatory, emergency, or inpatient health care setting",,2020-05-11,2020-06-15,Residual sera,All,Children and Youth (0-17 years),0.0,4.0,Age,0-4,5,0.0,0.0,0.52,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.968,0.991,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Melissa Sutton,Oregon Health Authority,Unity-Aligned,https://www.cdc.gov/mmwr/volumes/69/wr/mm6932a4.htm,2020-10-13,2024-03-01,Verified,sutton_notes_2020-1,USA
200814_Oregon_OregonHealthAuthority_Age65-74_UnAdj,200814_Oregon_OregonHealthAuthority,"Seroprevalence Estimates of SARS- CoV-2 Infection in Convenience Sample - Oregon, May 11-June 15, 2020",2020-08-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Oregon,,"Facilities were asked to submit random subsamples of deidentified sera from patients of all ages visiting any ambulatory, emergency, or inpatient health care setting",,2020-05-11,2020-06-15,Residual sera,All,Seniors (65+ years),65.0,74.0,Age,65-74,178,0.01685393258,0.003,0.048,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.968,0.991,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Melissa Sutton,Oregon Health Authority,Unity-Aligned,https://www.cdc.gov/mmwr/volumes/69/wr/mm6932a4.htm,2020-10-13,2024-03-01,Verified,sutton_notes_2020-1,USA
200814_Oregon_OregonHealthAuthority_Age75-84_UnAdj,200814_Oregon_OregonHealthAuthority,"Seroprevalence Estimates of SARS- CoV-2 Infection in Convenience Sample - Oregon, May 11-June 15, 2020",2020-08-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Oregon,,"Facilities were asked to submit random subsamples of deidentified sera from patients of all ages visiting any ambulatory, emergency, or inpatient health care setting",,2020-05-11,2020-06-15,Residual sera,All,Seniors (65+ years),75.0,84.0,Age,75-84,144,0.020833333330000002,0.004,0.06,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.968,0.991,['Moderate'],No,Yes,Yes,No,Unclear,Yes,Yes,Yes,,Melissa Sutton,Oregon Health Authority,Unity-Aligned,https://www.cdc.gov/mmwr/volumes/69/wr/mm6932a4.htm,2020-10-13,2024-03-01,Verified,sutton_notes_2020-1,USA
200816_SaltLakeCityMilwaukee_CentersforDiseaseControl_householdcontacts,200816_SaltLakeCityMilwaukee_CentersforDiseaseControl,Household Transmission of SARS-CoV-2 in the United States,2020-08-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,"Utah, Wisconsin","Salt Lake City, Milwaukee","Hoseholds were included if the index patient was not hospitalized at the time, lived with ≥1 additional person, and tested positive for SARS-CoV-2 rRT-PCR from a nasopharyngeal (NP) swab collected ≤10 days prior to enrollment. All persons in the household were asked to participate.", Excluded households where >1 person declined,2020-03-22,2020-04-25,Contacts of COVID patients,All,Multiple groups,0.0,76.0,Primary Estimate,,178,0.258,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,,Spike,Validated by developers,,,['High'],Yes,No,No,Yes,Yes,Unclear,Yes,No,Yes,Nathaniel M Lewis,Centers for Disease Control ,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1166,2020-12-16,2022-07-16,Verified,lewis_household_2020,USA
200818_Cambridge_CambridgeHealthAllianceOverall,200818_Cambridge_CambridgeHealthAlliance,Evaluation of SARS-CoV-2 antibodies in 24 patients presenting with chilblains-like lesions during the COVID-19 pandemic,2020-08-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Massachusetts,Cambridge,Patients presenting to dermatology clinic with chilblain-like skin lesions,,2020-04-13,2020-05-24,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),11.0,64.0,Primary Estimate,,24,0.167,,,True,,,,,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,Anti-SARS-CoV-2 ELISA IgG,Abbott Architect SARS-CoV-2 IgG","DiaSorin,EUROIMMUN,Abbott Laboratories",,Multiple Types,"['IgA', 'IgG', 'IgM']",,,,,['High'],No,No,No,No,Unclear,Unclear,Yes,No,Unclear,Robert Stavert,Cambridge Health Alliance,Not Unity-Aligned,http://dx.doi.org/10.1016/j.jaad.2020.08.049,2020-10-15,2024-03-01,Verified,stavert_evaluation_2020,USA
200818_Oregon_EarleA.ChilesResearchInstitute_Overall,200818_Oregon_EarleA.ChilesResearchInstitute,Longitudinal SARS-CoV-2 serosurveillance of over ten thousand health care workers in the Providence Oregon cohort,2020-08-18,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Oregon,"Portland, Oregon City, Medford, Seaside, Hood River, Newberg, Milwaukie","Testing was free and voluntary, with confidential results notification, and was offered to all HCW with direct patient contact, contact with patient biospecimens or patient linens. Only asymptomatic HCW!",,2020-04-08,2020-05-22,Health care workers and caregivers,All,Multiple groups,18.0,82.0,Primary Estimate,,10019,0.0253,,,True,,,,True,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by developers,0.8,1.0,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Rom Leidner,Chiles Research Institute,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.16.20176107v1,2020-10-18,2022-07-16,Verified,leidner_longitudinal_2020,USA
200818_Oregon_EarleA.ChilesResearchInstitute_Age50plus,200818_Oregon_EarleA.ChilesResearchInstitute,Longitudinal SARS-CoV-2 serosurveillance of over ten thousand health care workers in the Providence Oregon cohort,2020-08-18,Preprint,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Oregon,"Portland, Oregon City, Medford, Seaside, Hood River, Newberg, Milwaukie","Testing was free and voluntary, with confidential results notification, and was offered to all HCW with direct patient contact, contact with patient biospecimens or patient linens. Only asymptomatic HCW!",,2020-04-08,2020-05-22,Health care workers and caregivers,Male,Multiple groups,18.0,82.0,Age,=>50,3124,0.0327,,,,,,,,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by developers,0.8,1.0,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Rom Leidner,Chiles Research Institute,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.08.16.20176107v1,2020-10-20,2022-07-16,Verified,leidner_longitudinal_2020,USA
200821_NewYorkCityHealthSystem_AlbertEinsteinCollegeofMedicine,200821_NewYorkCityHealthSystem_AlbertEinsteinCollegeofMedicine,COVID-19 Infection Among Healthcare Workers: Serological Findings Supporting Routine Testing.,2020-08-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"Adult clinicians working within the Montefiore Health System,
Bronx, New York City, active during the COVID-19 pandemic,
were recruited to participate in the study (testing conducted between 04/04–20/2020).","Exclusion criteria included an age over 65, as
the risk of infection during testing outweighed the benefits, and
individuals with any signs or symptoms typical of COVID-19.",2020-04-04,2020-04-20,Health care workers and caregivers,All,Adults (18-64 years),18.0,65.0,Primary Estimate,,98,0.153,,,True,,,,True,Convenience,EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit,"Epitope Diagnostics, Inc.",ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,No,Yes,No,Yes,Yes,Yes,Unclear,Ariel D Stock,Albert Einstein College of Medicine,Not Unity-Aligned,https://dx.doi.org/10.3389/fmed.2020.00471,2020-10-24,2024-03-01,Verified,stock_covid-19_2020,USA
200818_SanFrancisco_UniversityofCaliforniaSanFrancisco,200818_SanFrancisco_UniversityofCaliforniaSanFrancisco,SARS-CoV-2 Community Transmission disproportionately affects Latinx population during Shelter-in-Place in San Francisco,2020-08-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,San Francisco,"From 25–28 April 2020, we offered outdoor testing at public parks and schools to those who provided an address in the census tract or worked in the tract. On 28 April, we expanded eligibility to residents of neighboring city blocks (2 blocks north, 3 blocks east, and 1 block south), responding to high community demand.",,2020-04-25,2020-04-28,Household and community samples,All,Multiple groups,4.0,,Primary Estimate,Primary Estimate,3861,0.034,0.028999999999999998,0.040999999999999995,True,,,,True,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Gabriel Chamie,"University of California, San Francisco",Not Unity-Aligned,http://dx.doi.org/10.1093/cid/ciaa1234,2020-10-17,2024-03-01,Verified,chamie_community_2020,USA
200818_SanFrancisco_UniversityofCaliforniaSanFrancisco_Female,200818_SanFrancisco_UniversityofCaliforniaSanFrancisco,SARS-CoV-2 Community Transmission disproportionately affects Latinx population during Shelter-in-Place in San Francisco,2020-08-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,San Francisco,"From 25–28 April 2020, we offered outdoor testing at public parks and schools to those who provided an address in the census tract or worked in the tract. On 28 April, we expanded eligibility to residents of neighboring city blocks (2 blocks north, 3 blocks east, and 1 block south), responding to high community demand.",,2020-04-25,2020-04-28,Household and community samples,Female,Multiple groups,4.0,,Sex/Gender,Female,1643,0.026000000000000002,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Gabriel Chamie,"University of California, San Francisco",Not Unity-Aligned,http://dx.doi.org/10.1093/cid/ciaa1234,2020-10-29,2024-03-01,Verified,chamie_community_2020,USA
200818_SanFrancisco_UniversityofCaliforniaSanFrancisco_18-50yrs,200818_SanFrancisco_UniversityofCaliforniaSanFrancisco,SARS-CoV-2 Community Transmission disproportionately affects Latinx population during Shelter-in-Place in San Francisco,2020-08-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,San Francisco,"From 25–28 April 2020, we offered outdoor testing at public parks and schools to those who provided an address in the census tract or worked in the tract. On 28 April, we expanded eligibility to residents of neighboring city blocks (2 blocks north, 3 blocks east, and 1 block south), responding to high community demand.",,2020-04-25,2020-04-28,Household and community samples,All,Adults (18-64 years),18.0,50.0,Age,18-50,2466,0.034,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Gabriel Chamie,"University of California, San Francisco",Not Unity-Aligned,http://dx.doi.org/10.1093/cid/ciaa1234,2020-10-29,2024-03-01,Verified,chamie_community_2020,USA
200818_SanFrancisco_UniversityofCaliforniaSanFrancisco_AdjacentCityBlockResidents,200818_SanFrancisco_UniversityofCaliforniaSanFrancisco,SARS-CoV-2 Community Transmission disproportionately affects Latinx population during Shelter-in-Place in San Francisco,2020-08-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,San Francisco,"From 25–28 April 2020, we offered outdoor testing at public parks and schools to those who provided an address in the census tract or worked in the tract. On 28 April, we expanded eligibility to residents of neighboring city blocks (2 blocks north, 3 blocks east, and 1 block south), responding to high community demand.",,2020-04-25,2020-04-28,Household and community samples,All,Multiple groups,4.0,,Geographical area,Residents from adjacent city blocks,829,0.021,0.012,0.033,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Gabriel Chamie,"University of California, San Francisco",Not Unity-Aligned,http://dx.doi.org/10.1093/cid/ciaa1234,2020-10-17,2024-03-01,Verified,chamie_community_2020,USA
200818_SanFrancisco_UniversityofCaliforniaSanFrancisco_Male,200818_SanFrancisco_UniversityofCaliforniaSanFrancisco,SARS-CoV-2 Community Transmission disproportionately affects Latinx population during Shelter-in-Place in San Francisco,2020-08-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,San Francisco,"From 25–28 April 2020, we offered outdoor testing at public parks and schools to those who provided an address in the census tract or worked in the tract. On 28 April, we expanded eligibility to residents of neighboring city blocks (2 blocks north, 3 blocks east, and 1 block south), responding to high community demand.",,2020-04-25,2020-04-28,Household and community samples,Male,Multiple groups,4.0,,Sex/Gender,Male,1871,0.042,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Gabriel Chamie,"University of California, San Francisco",Not Unity-Aligned,http://dx.doi.org/10.1093/cid/ciaa1234,2020-10-29,2024-03-01,Verified,chamie_community_2020,USA
200818_SanFrancisco_UniversityofCaliforniaSanFrancisco_Black/AfricanAmerican,200818_SanFrancisco_UniversityofCaliforniaSanFrancisco,SARS-CoV-2 Community Transmission disproportionately affects Latinx population during Shelter-in-Place in San Francisco,2020-08-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,San Francisco,"From 25–28 April 2020, we offered outdoor testing at public parks and schools to those who provided an address in the census tract or worked in the tract. On 28 April, we expanded eligibility to residents of neighboring city blocks (2 blocks north, 3 blocks east, and 1 block south), responding to high community demand.",,2020-04-25,2020-04-28,Household and community samples,All,Multiple groups,4.0,,Race,Black/African American,79,0.038,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Gabriel Chamie,"University of California, San Francisco",Not Unity-Aligned,http://dx.doi.org/10.1093/cid/ciaa1234,2020-10-29,2024-03-01,Verified,chamie_community_2020,USA
200818_SanFrancisco_UniversityofCaliforniaSanFrancisco_11-17yrs,200818_SanFrancisco_UniversityofCaliforniaSanFrancisco,SARS-CoV-2 Community Transmission disproportionately affects Latinx population during Shelter-in-Place in San Francisco,2020-08-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,San Francisco,"From 25–28 April 2020, we offered outdoor testing at public parks and schools to those who provided an address in the census tract or worked in the tract. On 28 April, we expanded eligibility to residents of neighboring city blocks (2 blocks north, 3 blocks east, and 1 block south), responding to high community demand.",,2020-04-25,2020-04-28,Household and community samples,All,Children and Youth (0-17 years),11.0,17.0,Age,11-17,135,0.067,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Gabriel Chamie,"University of California, San Francisco",Not Unity-Aligned,http://dx.doi.org/10.1093/cid/ciaa1234,2020-10-29,2024-03-01,Verified,chamie_community_2020,USA
200818_SanFrancisco_UniversityofCaliforniaSanFrancisco_White/Caucasian,200818_SanFrancisco_UniversityofCaliforniaSanFrancisco,SARS-CoV-2 Community Transmission disproportionately affects Latinx population during Shelter-in-Place in San Francisco,2020-08-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,San Francisco,"From 25–28 April 2020, we offered outdoor testing at public parks and schools to those who provided an address in the census tract or worked in the tract. On 28 April, we expanded eligibility to residents of neighboring city blocks (2 blocks north, 3 blocks east, and 1 block south), responding to high community demand.",,2020-04-25,2020-04-28,Household and community samples,All,Multiple groups,4.0,,Race,White/Caucasian,1433,0.011000000000000001,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Gabriel Chamie,"University of California, San Francisco",Not Unity-Aligned,http://dx.doi.org/10.1093/cid/ciaa1234,2020-10-29,2024-03-01,Verified,chamie_community_2020,USA
200818_SanFrancisco_UniversityofCaliforniaSanFrancisco_51-70yrs,200818_SanFrancisco_UniversityofCaliforniaSanFrancisco,SARS-CoV-2 Community Transmission disproportionately affects Latinx population during Shelter-in-Place in San Francisco,2020-08-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,San Francisco,"From 25–28 April 2020, we offered outdoor testing at public parks and schools to those who provided an address in the census tract or worked in the tract. On 28 April, we expanded eligibility to residents of neighboring city blocks (2 blocks north, 3 blocks east, and 1 block south), responding to high community demand.",,2020-04-25,2020-04-28,Household and community samples,All,Multiple groups,51.0,70.0,Age,51-70,916,0.032,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Gabriel Chamie,"University of California, San Francisco",Not Unity-Aligned,http://dx.doi.org/10.1093/cid/ciaa1234,2020-10-29,2024-03-01,Verified,chamie_community_2020,USA
200818_SanFrancisco_UniversityofCaliforniaSanFrancisco_OtherEthnicity,200818_SanFrancisco_UniversityofCaliforniaSanFrancisco,SARS-CoV-2 Community Transmission disproportionately affects Latinx population during Shelter-in-Place in San Francisco,2020-08-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,San Francisco,"From 25–28 April 2020, we offered outdoor testing at public parks and schools to those who provided an address in the census tract or worked in the tract. On 28 April, we expanded eligibility to residents of neighboring city blocks (2 blocks north, 3 blocks east, and 1 block south), responding to high community demand.",,2020-04-25,2020-04-28,Household and community samples,All,Multiple groups,4.0,,Race,Other,244,0.028999999999999998,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Gabriel Chamie,"University of California, San Francisco",Not Unity-Aligned,http://dx.doi.org/10.1093/cid/ciaa1234,2020-10-29,2024-03-01,Verified,chamie_community_2020,USA
200818_SanFrancisco_UniversityofCaliforniaSanFrancisco_>70yrs,200818_SanFrancisco_UniversityofCaliforniaSanFrancisco,SARS-CoV-2 Community Transmission disproportionately affects Latinx population during Shelter-in-Place in San Francisco,2020-08-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,San Francisco,"From 25–28 April 2020, we offered outdoor testing at public parks and schools to those who provided an address in the census tract or worked in the tract. On 28 April, we expanded eligibility to residents of neighboring city blocks (2 blocks north, 3 blocks east, and 1 block south), responding to high community demand.",,2020-04-25,2020-04-28,Household and community samples,All,Seniors (65+ years),70.0,,Age,>70,190,0.021,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Gabriel Chamie,"University of California, San Francisco",Not Unity-Aligned,http://dx.doi.org/10.1093/cid/ciaa1234,2020-10-29,2024-03-01,Verified,chamie_community_2020,USA
200818_SanFrancisco_UniversityofCaliforniaSanFrancisco_Hispanic/Latinx,200818_SanFrancisco_UniversityofCaliforniaSanFrancisco,SARS-CoV-2 Community Transmission disproportionately affects Latinx population during Shelter-in-Place in San Francisco,2020-08-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,San Francisco,"From 25–28 April 2020, we offered outdoor testing at public parks and schools to those who provided an address in the census tract or worked in the tract. On 28 April, we expanded eligibility to residents of neighboring city blocks (2 blocks north, 3 blocks east, and 1 block south), responding to high community demand.",,2020-04-25,2020-04-28,Household and community samples,All,Multiple groups,4.0,,Ethnicity,Hispanic/Latinx,1389,0.064,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Gabriel Chamie,"University of California, San Francisco",Not Unity-Aligned,http://dx.doi.org/10.1093/cid/ciaa1234,2020-10-29,2024-03-01,Verified,chamie_community_2020,USA
200818_SanFrancisco_UniversityofCaliforniaSanFrancisco_4-10yrs,200818_SanFrancisco_UniversityofCaliforniaSanFrancisco,SARS-CoV-2 Community Transmission disproportionately affects Latinx population during Shelter-in-Place in San Francisco,2020-08-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,San Francisco,"From 25–28 April 2020, we offered outdoor testing at public parks and schools to those who provided an address in the census tract or worked in the tract. On 28 April, we expanded eligibility to residents of neighboring city blocks (2 blocks north, 3 blocks east, and 1 block south), responding to high community demand.",,2020-04-25,2020-04-28,Household and community samples,All,Children and Youth (0-17 years),4.0,10.0,Age,4-10,109,0.055,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Gabriel Chamie,"University of California, San Francisco",Not Unity-Aligned,http://dx.doi.org/10.1093/cid/ciaa1234,2020-10-29,2024-03-01,Verified,chamie_community_2020,USA
200818_SanFrancisco_UniversityofCaliforniaSanFrancisco_Asian/PacificIslander,200818_SanFrancisco_UniversityofCaliforniaSanFrancisco,SARS-CoV-2 Community Transmission disproportionately affects Latinx population during Shelter-in-Place in San Francisco,2020-08-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,San Francisco,"From 25–28 April 2020, we offered outdoor testing at public parks and schools to those who provided an address in the census tract or worked in the tract. On 28 April, we expanded eligibility to residents of neighboring city blocks (2 blocks north, 3 blocks east, and 1 block south), responding to high community demand.",,2020-04-25,2020-04-28,Household and community samples,All,Multiple groups,4.0,,Race,Asian/Pacific Islander,325,0.015,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Gabriel Chamie,"University of California, San Francisco",Not Unity-Aligned,http://dx.doi.org/10.1093/cid/ciaa1234,2020-10-29,2024-03-01,Verified,chamie_community_2020,USA
200824_Louiseville_UniversityOfLouiseville_HCW_AprilMay,200824_Louiseville_UniversityOfLouiseville_AprilMay,New Co-Immunity Project data show COVID-19 infection among health care workers may be lower than the general population,2020-08-24,News and Media,Local,Cross-sectional survey ,United States of America,Kentucky,Louiseville,"Healthcare personnel who are employed by Norton, Baptist, or UofL Health, beginning with those who have recently worked on COVID-19 floors, in the Louisville area. (Taken from: https://co-immunityproject.com/)",,2020-04-01,2020-05-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1372,0.01,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,No,Yes,No,Unclear,Unclear,Yes,No,Unclear,Betty Coffman,University of Louiseville ,Not Unity-Aligned,http://www.uoflnews.com/post/uofltoday/new-co-immunity-project-data-show-covid-19-infection-among-health-care-workers-may-be-lower-than-the-general-population/,2021-03-09,2022-07-16,Verified,coffman_new_2020,USA
200824_Louiseville_UniversityOfLouiseville_HCW_July,200824_Louiseville_UniversityOfLouiseville_July,New Co-Immunity Project data show COVID-19 infection among health care workers may be lower than the general population,2020-08-24,News and Media,Local,Cross-sectional survey ,United States of America,Kentucky,Louiseville,"Healthcare personnel who are employed by Norton, Baptist, or UofL Health, beginning with those who have recently worked on COVID-19 floors, in the Louisville area. (Taken from: https://co-immunityproject.com/)",,2020-07-01,2020-07-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1100,0.022000000000000002,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,No,Yes,No,Unclear,Unclear,Yes,No,Unclear,Betty Coffman,University of Louiseville ,Not Unity-Aligned,http://www.uoflnews.com/post/uofltoday/new-co-immunity-project-data-show-covid-19-infection-among-health-care-workers-may-be-lower-than-the-general-population/,2021-03-08,2022-07-16,Verified,coffman_new_2020,USA
200826_NewYorkCity_JacobiMedicalCenter_HealthCareWorkers,200826_NewYorkCity_JacobiMedicalCenter,Antibody evidence of SARS-CoV-2 infection in healthcare workers in the Bronx,2020-08-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,health care workers at Jacobi Medical Center ,not health care workers or at not at Jacobi Medical Center ,2020-04-28,2020-05-04,Health care workers and caregivers,All,Multiple groups,22.0,73.0,Primary Estimate,,1700,0.192,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['High'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,No,Elana Sydney,Jacobi Medical Center,Not Unity-Aligned,http://dx.doi.org/10.1017/ice.2020.437,2020-10-21,2024-03-01,Verified,sydney_antibody_2020,USA
200828_LosAngeles_VeteransAffairsHealthcareSystem_Residents,200828_LosAngeles_VeteransAffairsHealthcareSystem,"Using Serologic Testing to Assess the Effectiveness of Outbreak Control Efforts, Serial PCR Testing, and Cohorting of Positive SARS-CoV-2 Patients in a Skilled Nursing Facility",2020-08-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,Los Angeles,Residents in Skilled nursing facility,,2020-06-05,2020-06-12,Assisted living and long-term care facilities,All,Multiple groups,,,Primary Estimate,,150,0.17300000000000001,,,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.92,0.98,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Amy V Dora,Veterans Affairs Healthcare System,Not Unity-Aligned,http://dx.doi.org/10.1093/cid/ciaa1286,2020-10-21,2024-03-01,Verified,dora_using_2020,USA
200830_VenturaCounty_OxnardFireDepartment_overall,200830_VenturaCounty_OxnardFireDepartment,Study reveals data on COVID-19 antibody prevalence in Ventura County,2020-08-30,News and Media,Local,Cross-sectional survey ,United States of America,California,,Ventura County residents (not specified),,2020-06-22,2020-07-06,Household and community samples,All,Multiple groups,13.0,,Primary Estimate,,6794,0.013000000000000001,,,True,,,,True,Self-referral,"Abbott Architect SARS-CoV-2 IgG,Platelia SARS-CoV-2 Total Ab assay","Abbott Laboratories,Bio-rad",,,,,,,,['High'],Yes,No,Yes,Yes,No,Unclear,No,No,Unclear,Jeremy Childs,Oxnard Fire Department,Not Unity-Aligned,https://www.vcstar.com/story/news/2020/08/30/covid-19-data-coronavirus-antibodies-ventura-county/3436858001/,2021-03-07,2024-03-01,Verified,childs_study_2020,USA
200830_VenturaCounty_OxnardFireDepartment_male,200830_VenturaCounty_OxnardFireDepartment,Study reveals data on COVID-19 antibody prevalence in Ventura County,2020-08-30,News and Media,Local,Cross-sectional survey ,United States of America,California,,Ventura County residents (not specified),,2020-06-22,2020-07-06,Household and community samples,Male,Multiple groups,13.0,,Sex/Gender,,2667,0.016,,,,,,,,Self-referral,"Abbott Architect SARS-CoV-2 IgG,Platelia SARS-CoV-2 Total Ab assay","Abbott Laboratories,Bio-rad",,,,,,,,['High'],Yes,No,Yes,Yes,No,Unclear,No,No,Unclear,Jeremy Childs,Oxnard Fire Department,Not Unity-Aligned,https://www.vcstar.com/story/news/2020/08/30/covid-19-data-coronavirus-antibodies-ventura-county/3436858001/,2021-03-08,2024-03-01,Verified,childs_study_2020,USA
200830_VenturaCounty_OxnardFireDepartment_female,200830_VenturaCounty_OxnardFireDepartment,Study reveals data on COVID-19 antibody prevalence in Ventura County,2020-08-30,News and Media,Local,Cross-sectional survey ,United States of America,California,,Ventura County residents (not specified),,2020-06-22,2020-07-06,Household and community samples,Female,Multiple groups,13.0,,Sex/Gender,Female,4127,0.01,,,,,,,,Self-referral,"Abbott Architect SARS-CoV-2 IgG,Platelia SARS-CoV-2 Total Ab assay","Abbott Laboratories,Bio-rad",,,,,,,,['High'],Yes,No,Yes,Yes,No,Unclear,No,No,Unclear,Jeremy Childs,Oxnard Fire Department,Not Unity-Aligned,https://www.vcstar.com/story/news/2020/08/30/covid-19-data-coronavirus-antibodies-ventura-county/3436858001/,2021-03-08,2024-03-01,Verified,childs_study_2020,USA
200831_KingCounty_UniversityOfWashington_overall,200831_KingCounty_UniversityOfWashington,"King County, Washington Anti-SARS-CoV-2 Seroprevalence Survey, August 2020",2020-08-31,Institutional Report,Local,Cross-sectional survey ,United States of America,Washington,,"The address-based sample included residents living at selected non-institutional addresses; households of any size, including single people, were eligible to participate.",,2020-08-08,2020-08-29,Household and community samples,All,Multiple groups,,,Primary Estimate,,1364,0.039,0.024,0.06,True,True,True,,True,Stratified probability,"Platelia SARS-CoV-2 Total Ab assay,Anti-SARS-CoV-2 ELISA IgG","Bio-rad,EUROIMMUN",ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,0.8294,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,No,Karen Cowgill,University of Washington,Not Unity-Aligned,https://www.kingcounty.gov/depts/health/covid-19/data/~/media/depts/health/communicable-diseases/documents/C19/serosurvey-report-covid19.ashx https://kingcounty.gov/depts/health/covid-19/seroprevalence.aspx https://www.kingcounty.gov/depts/health/covid-19/seroprevalence-study.aspx page 9: http://www.co.cowlitz.wa.us/DocumentCenter/View/20793/8122020-Cowlitz-County-COVID-update-to-Board-of-County-Commissioners,2021-05-05,2023-08-15,Verified,cowgill_king_nodate,USA
200831_KingCounty_UniversityOfWashingtonAge_45-64,200831_KingCounty_UniversityOfWashington,"King County, Washington Anti-SARS-CoV-2 Seroprevalence Survey, August 2020",2020-08-31,Institutional Report,Local,Cross-sectional survey ,United States of America,Washington,,"The address-based sample included residents living at selected non-institutional addresses; households of any size, including single people, were eligible to participate.",,2020-08-08,2020-08-29,Household and community samples,All,Adults (18-64 years),45.0,64.0,Age,45-64,391,0.0487,0.030299999999999997,0.11140000000000001,,True,True,,,Stratified probability,"Platelia SARS-CoV-2 Total Ab assay,Anti-SARS-CoV-2 ELISA IgG","Bio-rad,EUROIMMUN",ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,0.8294,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,No,Karen Cowgill,University of Washington,Not Unity-Aligned,https://www.kingcounty.gov/depts/health/covid-19/data/~/media/depts/health/communicable-diseases/documents/C19/serosurvey-report-covid19.ashx https://kingcounty.gov/depts/health/covid-19/seroprevalence.aspx https://www.kingcounty.gov/depts/health/covid-19/seroprevalence-study.aspx page 9: http://www.co.cowlitz.wa.us/DocumentCenter/View/20793/8122020-Cowlitz-County-COVID-update-to-Board-of-County-Commissioners,2021-05-05,2023-08-15,Verified,cowgill_king_nodate,USA
200831_KingCounty_UniversityOfWashingtonAge_25-44,200831_KingCounty_UniversityOfWashington,"King County, Washington Anti-SARS-CoV-2 Seroprevalence Survey, August 2020",2020-08-31,Institutional Report,Local,Cross-sectional survey ,United States of America,Washington,,"The address-based sample included residents living at selected non-institutional addresses; households of any size, including single people, were eligible to participate.",,2020-08-08,2020-08-29,Household and community samples,All,Adults (18-64 years),25.0,44.0,Age,25-44,488,0.0221,0.011899999999999999,0.0525,,True,True,,,Stratified probability,"Platelia SARS-CoV-2 Total Ab assay,Anti-SARS-CoV-2 ELISA IgG","Bio-rad,EUROIMMUN",ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,0.8294,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,No,Karen Cowgill,University of Washington,Not Unity-Aligned,https://www.kingcounty.gov/depts/health/covid-19/data/~/media/depts/health/communicable-diseases/documents/C19/serosurvey-report-covid19.ashx https://kingcounty.gov/depts/health/covid-19/seroprevalence.aspx https://www.kingcounty.gov/depts/health/covid-19/seroprevalence-study.aspx page 9: http://www.co.cowlitz.wa.us/DocumentCenter/View/20793/8122020-Cowlitz-County-COVID-update-to-Board-of-County-Commissioners,2021-05-05,2023-08-15,Verified,cowgill_king_nodate,USA
200831_KingCounty_UniversityOfWashington_BioRad,200831_KingCounty_UniversityOfWashington,"King County, Washington Anti-SARS-CoV-2 Seroprevalence Survey, August 2020",2020-08-31,Institutional Report,Local,Cross-sectional survey ,United States of America,Washington,,"The address-based sample included residents living at selected non-institutional addresses; households of any size, including single people, were eligible to participate.",,2020-08-08,2020-08-29,Household and community samples,All,Multiple groups,,,Test used,Using the Bio-Rad assay only,1364,0.0308,,,,,,,,Stratified probability,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.9216,0.9956,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,No,Karen Cowgill,University of Washington,Not Unity-Aligned,https://www.kingcounty.gov/depts/health/covid-19/data/~/media/depts/health/communicable-diseases/documents/C19/serosurvey-report-covid19.ashx https://kingcounty.gov/depts/health/covid-19/seroprevalence.aspx https://www.kingcounty.gov/depts/health/covid-19/seroprevalence-study.aspx page 9: http://www.co.cowlitz.wa.us/DocumentCenter/View/20793/8122020-Cowlitz-County-COVID-update-to-Board-of-County-Commissioners,2021-05-05,2024-03-01,Verified,cowgill_king_nodate,USA
200831_KingCounty_UniversityOfWashingtonFemale,200831_KingCounty_UniversityOfWashington,"King County, Washington Anti-SARS-CoV-2 Seroprevalence Survey, August 2020",2020-08-31,Institutional Report,Local,Cross-sectional survey ,United States of America,Washington,,"The address-based sample included residents living at selected non-institutional addresses; households of any size, including single people, were eligible to participate.",,2020-08-08,2020-08-29,Household and community samples,Female,Multiple groups,,,Sex/Gender,female,714,0.0342,0.023700000000000002,0.0738,,True,True,,,Stratified probability,"Platelia SARS-CoV-2 Total Ab assay,Anti-SARS-CoV-2 ELISA IgG","Bio-rad,EUROIMMUN",ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,0.8294,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,No,Karen Cowgill,University of Washington,Not Unity-Aligned,https://www.kingcounty.gov/depts/health/covid-19/data/~/media/depts/health/communicable-diseases/documents/C19/serosurvey-report-covid19.ashx https://kingcounty.gov/depts/health/covid-19/seroprevalence.aspx https://www.kingcounty.gov/depts/health/covid-19/seroprevalence-study.aspx page 9: http://www.co.cowlitz.wa.us/DocumentCenter/View/20793/8122020-Cowlitz-County-COVID-update-to-Board-of-County-Commissioners,2021-05-05,2023-08-15,Verified,cowgill_king_nodate,USA
200831_KingCounty_UniversityOfWashingtonAge_0-15,200831_KingCounty_UniversityOfWashington,"King County, Washington Anti-SARS-CoV-2 Seroprevalence Survey, August 2020",2020-08-31,Institutional Report,Local,Cross-sectional survey ,United States of America,Washington,,"The address-based sample included residents living at selected non-institutional addresses; households of any size, including single people, were eligible to participate.",,2020-08-08,2020-08-29,Household and community samples,All,Children and Youth (0-17 years),0.0,15.0,Age,0-15,171,0.0159,0.0028000000000000004,0.058499999999999996,,True,True,,,Stratified probability,"Platelia SARS-CoV-2 Total Ab assay,Anti-SARS-CoV-2 ELISA IgG","Bio-rad,EUROIMMUN",ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,0.8294,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,No,Karen Cowgill,University of Washington,Not Unity-Aligned,https://www.kingcounty.gov/depts/health/covid-19/data/~/media/depts/health/communicable-diseases/documents/C19/serosurvey-report-covid19.ashx https://kingcounty.gov/depts/health/covid-19/seroprevalence.aspx https://www.kingcounty.gov/depts/health/covid-19/seroprevalence-study.aspx page 9: http://www.co.cowlitz.wa.us/DocumentCenter/View/20793/8122020-Cowlitz-County-COVID-update-to-Board-of-County-Commissioners,2021-05-05,2023-08-15,Verified,cowgill_king_nodate,USA
200831_KingCounty_UniversityOfWashingtonAge_16-24,200831_KingCounty_UniversityOfWashington,"King County, Washington Anti-SARS-CoV-2 Seroprevalence Survey, August 2020",2020-08-31,Institutional Report,Local,Cross-sectional survey ,United States of America,Washington,,"The address-based sample included residents living at selected non-institutional addresses; households of any size, including single people, were eligible to participate.",,2020-08-08,2020-08-29,Household and community samples,All,Adults (18-64 years),16.0,24.0,Age,16-24,108,0.12890000000000001,0.06420000000000001,0.3274,,True,True,,,Stratified probability,"Platelia SARS-CoV-2 Total Ab assay,Anti-SARS-CoV-2 ELISA IgG","Bio-rad,EUROIMMUN",ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,0.8294,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,No,Karen Cowgill,University of Washington,Not Unity-Aligned,https://www.kingcounty.gov/depts/health/covid-19/data/~/media/depts/health/communicable-diseases/documents/C19/serosurvey-report-covid19.ashx https://kingcounty.gov/depts/health/covid-19/seroprevalence.aspx https://www.kingcounty.gov/depts/health/covid-19/seroprevalence-study.aspx page 9: http://www.co.cowlitz.wa.us/DocumentCenter/View/20793/8122020-Cowlitz-County-COVID-update-to-Board-of-County-Commissioners,2021-05-05,2023-08-15,Verified,cowgill_king_nodate,USA
200831_KingCounty_UniversityOfWashingtonMale,200831_KingCounty_UniversityOfWashington,"King County, Washington Anti-SARS-CoV-2 Seroprevalence Survey, August 2020",2020-08-31,Institutional Report,Local,Cross-sectional survey ,United States of America,Washington,,"The address-based sample included residents living at selected non-institutional addresses; households of any size, including single people, were eligible to participate.",,2020-08-08,2020-08-29,Household and community samples,Male,Multiple groups,,,Sex/Gender,male,650,0.043899999999999995,0.029900000000000003,0.085,,True,True,,,Stratified probability,"Platelia SARS-CoV-2 Total Ab assay,Anti-SARS-CoV-2 ELISA IgG","Bio-rad,EUROIMMUN",ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,0.8294,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,No,Karen Cowgill,University of Washington,Not Unity-Aligned,https://www.kingcounty.gov/depts/health/covid-19/data/~/media/depts/health/communicable-diseases/documents/C19/serosurvey-report-covid19.ashx https://kingcounty.gov/depts/health/covid-19/seroprevalence.aspx https://www.kingcounty.gov/depts/health/covid-19/seroprevalence-study.aspx page 9: http://www.co.cowlitz.wa.us/DocumentCenter/View/20793/8122020-Cowlitz-County-COVID-update-to-Board-of-County-Commissioners,2021-05-05,2023-08-15,Verified,cowgill_king_nodate,USA
200831_KingCounty_UniversityOfWashingtonAge_65+,200831_KingCounty_UniversityOfWashington,"King County, Washington Anti-SARS-CoV-2 Seroprevalence Survey, August 2020",2020-08-31,Institutional Report,Local,Cross-sectional survey ,United States of America,Washington,,"The address-based sample included residents living at selected non-institutional addresses; households of any size, including single people, were eligible to participate.",,2020-08-08,2020-08-29,Household and community samples,All,Seniors (65+ years),65.0,,Age,65+,206,0.0301,0.013200000000000002,0.0931,,True,True,,,Stratified probability,"Platelia SARS-CoV-2 Total Ab assay,Anti-SARS-CoV-2 ELISA IgG","Bio-rad,EUROIMMUN",ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,0.8294,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,No,Karen Cowgill,University of Washington,Not Unity-Aligned,https://www.kingcounty.gov/depts/health/covid-19/data/~/media/depts/health/communicable-diseases/documents/C19/serosurvey-report-covid19.ashx https://kingcounty.gov/depts/health/covid-19/seroprevalence.aspx https://www.kingcounty.gov/depts/health/covid-19/seroprevalence-study.aspx page 9: http://www.co.cowlitz.wa.us/DocumentCenter/View/20793/8122020-Cowlitz-County-COVID-update-to-Board-of-County-Commissioners,2021-05-05,2023-08-15,Verified,cowgill_king_nodate,USA
200901_Seattle_FredHutchinsonCancerResearchCenter_Overall,200901_Seattle_FredHutchinsonCancerResearchCenter,Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak,2020-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Washington,Seattle,"any residual sera samples collected starting Mar 3, 2020 from children seeking medical care at Seattle Children’s Hospital",,2020-03-03,2020-04-24,Residual sera,All,Children and Youth (0-17 years),0.0,,Primary Estimate,,1076,0.009290000000000001,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Author designed (ELISA) -Spike","Abbott Laboratories,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Adam S Dingens,Fred Hutchinson Cancer Research Center,Unity-Aligned,https://www.nature.com/articles/s41467-020-18178-1,2021-04-08,2024-03-01,Verified,dingens_serological_2020,USA
200901_Seattle_FredHutchinsonCancerResearchCenter_age0-4,200901_Seattle_FredHutchinsonCancerResearchCenter,Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak,2020-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Washington,Seattle,"any residual sera samples collected starting Mar 3, 2020 from children seeking medical care at Seattle Children’s Hospital",,2020-03-03,2020-04-24,Residual sera,All,Children and Youth (0-17 years),0.0,4.0,Age,age 0-4,192,0.020800000000000003,,,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Author designed (ELISA) -Spike","Abbott Laboratories,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Adam S Dingens,Fred Hutchinson Cancer Research Center,Unity-Aligned,https://www.nature.com/articles/s41467-020-18178-1,2021-04-08,2024-03-01,Verified,dingens_serological_2020,USA
200901_Seattle_FredHutchinsonCancerResearchCenter_age15+,200901_Seattle_FredHutchinsonCancerResearchCenter,Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak,2020-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Washington,Seattle,"any residual sera samples collected starting Mar 3, 2020 from children seeking medical care at Seattle Children’s Hospital",,2020-03-03,2020-04-24,Residual sera,All,Children and Youth (0-17 years),15.0,,Age,age 15+,369,0.008100000000000001,,,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Author designed (ELISA) -Spike","Abbott Laboratories,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Adam S Dingens,Fred Hutchinson Cancer Research Center,Unity-Aligned,https://www.nature.com/articles/s41467-020-18178-1,2021-04-08,2024-03-01,Verified,dingens_serological_2020,USA
200901_Seattle_FredHutchinsonCancerResearchCenter_age5-9,200901_Seattle_FredHutchinsonCancerResearchCenter,Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak,2020-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Washington,Seattle,"any residual sera samples collected starting Mar 3, 2020 from children seeking medical care at Seattle Children’s Hospital",,2020-03-03,2020-04-24,Residual sera,All,Children and Youth (0-17 years),5.0,9.0,Age,age 5-9,214,0.0046,,,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Author designed (ELISA) -Spike","Abbott Laboratories,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Adam S Dingens,Fred Hutchinson Cancer Research Center,Unity-Aligned,https://www.nature.com/articles/s41467-020-18178-1,2021-04-08,2024-03-01,Verified,dingens_serological_2020,USA
200901_Seattle_FredHutchinsonCancerResearchCenter_male,200901_Seattle_FredHutchinsonCancerResearchCenter,Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak,2020-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Washington,Seattle,"any residual sera samples collected starting Mar 3, 2020 from children seeking medical care at Seattle Children’s Hospital",,2020-03-03,2020-04-24,Residual sera,Male,Children and Youth (0-17 years),0.0,,Sex/Gender,male,541,0.0111,,,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Author designed (ELISA) -Spike","Abbott Laboratories,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Adam S Dingens,Fred Hutchinson Cancer Research Center,Unity-Aligned,https://www.nature.com/articles/s41467-020-18178-1,2021-04-08,2024-03-01,Verified,dingens_serological_2020,USA
200901_Seattle_FredHutchinsonCancerResearchCenter_female,200901_Seattle_FredHutchinsonCancerResearchCenter,Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak,2020-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Washington,Seattle,"any residual sera samples collected starting Mar 3, 2020 from children seeking medical care at Seattle Children’s Hospital",,2020-03-03,2020-04-24,Residual sera,Female,Children and Youth (0-17 years),0.0,,Sex/Gender,female,535,0.0075,,,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Author designed (ELISA) -Spike","Abbott Laboratories,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Adam S Dingens,Fred Hutchinson Cancer Research Center,Unity-Aligned,https://www.nature.com/articles/s41467-020-18178-1,2021-04-08,2024-03-01,Verified,dingens_serological_2020,USA
200901_Seattle_FredHutchinsonCancerResearchCenter_age10-14,200901_Seattle_FredHutchinsonCancerResearchCenter,Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak,2020-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Washington,Seattle,"any residual sera samples collected starting Mar 3, 2020 from children seeking medical care at Seattle Children’s Hospital",,2020-03-03,2020-04-24,Residual sera,All,Children and Youth (0-17 years),10.0,14.0,Age,age 10-14,301,0.006600000000000001,,,,,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Author designed (ELISA) -Spike","Abbott Laboratories,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Adam S Dingens,Fred Hutchinson Cancer Research Center,Unity-Aligned,https://www.nature.com/articles/s41467-020-18178-1,2021-04-08,2024-03-01,Verified,dingens_serological_2020,USA
200904_USA_CDC_HCWs_Overall,200904_USA_CDC,"Seroprevalence of SARS-CoV-2 Among Frontline Health Care Personnel in a Multistate Hospital Network-13 Academic Medical Centers, April-June 2020",2020-09-04,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,"New York, Massachusetts, Tennessee, Colorado, California, Washington, Minnesota, Maryland, Oregon, North Carolina, Utah, Ohio","Bronx, Springfield, Nashville, Aurora, Boston, Los Angeles, Seattle, Minneapolis, Baltimore, Portland, Winston-Salem, Murray, Columbus","Health care providers who work with COVID-19 patients at the following medical centers and who were working during the following time periods: Montefiore Medical Center, Bronx, New York (Bronx, Kings, New York, Queens, and Richmond counties, May 4–5, 2020); Baystate Medical Center, Springfield, Massachusetts (Hampden County, April 22–29, 2020); Vanderbilt University Medical Center, Nashville, Tennessee (Davidson County, April 3–13, 2020); UCHealth University of Colorado Hospital, Aurora, Colorado (Adams, Arapahoe, and Denver counties, April 16–20, 2020); Beth Israel Deaconess Medical Center, Boston, Massachusetts (Suffolk County, April 20–27, 2020); UCLA Medical Center, Los Angeles, California (Los Angeles County, May 26–June 5, 2020); Harborview Medical Center, Seattle, Washington (King County, April 30–May 11, 2020); Hennepin County Medical Center, Minneapolis, Minnesota (Hennepin County, April 23–28, 2020); Johns Hopkins Hospital, Baltimore, Maryland (Baltimore County and Baltimore City, June 12–19, 2020); Oregon Health & Sciences University Hospital, Portland, Oregon (Multnomah County, May 6–7, 2020); Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina (Forsyth County April 29–May 7, 2020); Intermountain Medical Center, Murray, Utah (Salt Lake County, April 30, 2020); Ohio State University Wexner Medical Center, Columbus, Ohio (Franklin, ",,2020-04-03,2020-06-19,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,N/A - overall estimate for all HCWs,3248,0.059699999999999996,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,TotalAntibody,Spike,Validated by developers,0.96,0.99,['Moderate'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Wesley Self,CDC COVID-19 Response Team,Not Unity-Aligned,https://www.cdc.gov/mmwr/volumes/69/wr/mm6935e2.htm,2020-09-28,2022-07-16,Verified,self_seroprevalence_2020,USA
200909_Chelsea_MassachusettsGeneralHospital_Overall_TestAdj,200909_Chelsea_MassachusettsGeneralHospital,"High seroprevalence of anti-SARS-CoV-2 antibodies in Chelsea, Massachusetts",2020-09-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Massachusetts,Chelsea,"Chelsea residents, aged ≥18 years, with no current symptoms and no history of a positive SARS-CoV-2 PCR test","""no history of a positive test"" therefore excluded ppl with prior COVID-19",2020-04-14,2020-04-15,Household and community samples,All,Adults (18-64 years),18.0,,Primary Estimate,"Overall estimate of participants, test adjusted",200,0.32799999999999996,0.272,0.38799999999999996,True,True,,,,Convenience,COVID-19 IgM-IgG Dual Antibody Rapid Test,"BioMedomics, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9,0.99,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,,Vivek Naranbhai,Massachusetts General Hospital,Not Unity-Aligned,http://dx.doi.org/10.1093/infdis/jiaa579,2020-10-21,2023-07-04,Verified,naranbhai_high_2020,USA
200909_Chelsea_MassachusettsGeneralHospital_Female,200909_Chelsea_MassachusettsGeneralHospital,"High seroprevalence of anti-SARS-CoV-2 antibodies in Chelsea, Massachusetts",2020-09-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Massachusetts,Chelsea,"Chelsea residents, aged ≥18 years, with no current symptoms and no history of a positive SARS-CoV-2 PCR test","""no history of a positive test"" therefore excluded ppl with prior COVID-19",2020-04-14,2020-04-15,Household and community samples,Female,Adults (18-64 years),18.0,,Sex/Gender,Females,80,0.41250000000000003,,,,,,,,Convenience,COVID-19 IgM-IgG Dual Antibody Rapid Test,"BioMedomics, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9,0.99,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,,Vivek Naranbhai,Massachusetts General Hospital,Not Unity-Aligned,http://dx.doi.org/10.1093/infdis/jiaa579,2020-10-21,2024-03-01,Verified,naranbhai_high_2020,USA
200909_Chelsea_MassachusettsGeneralHospital_OverallUnadj,200909_Chelsea_MassachusettsGeneralHospital,"High seroprevalence of anti-SARS-CoV-2 antibodies in Chelsea, Massachusetts",2020-09-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Massachusetts,Chelsea,"Chelsea residents, aged ≥18 years, with no current symptoms and no history of a positive SARS-CoV-2 PCR test","""no history of a positive test"" therefore excluded ppl with prior COVID-19",2020-04-14,2020-04-15,Household and community samples,All,Adults (18-64 years),18.0,,Analysis,"Overall estimate of participants, unadjusted",200,0.315,,,,,,,True,Convenience,COVID-19 IgM-IgG Dual Antibody Rapid Test,"BioMedomics, Inc.",LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9,0.99,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,,Vivek Naranbhai,Massachusetts General Hospital,Not Unity-Aligned,http://dx.doi.org/10.1093/infdis/jiaa579,2020-10-21,2024-03-01,Verified,naranbhai_high_2020,USA
200911_NewYorkCity_WeillCornellMedicine_IgGorIgM,200911_NewYorkCity_WeillCornellMedicine,COVID-19 Viral and Serology Testing in New York City Health Care Workers,2020-09-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"HCWs who were employed at our 862-bed Manhattan quaternary-care teaching hospital, an affiliated Queens 535-bed tertiary-care community teaching hospital, and an affiliated 180-bed Manhattan nonteaching commu- nity hospital",Had symptoms consistent with COVID-19 in last 14 days,2020-04-17,2020-05-07,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,"Overall, positive for IgG OR IgM",2274,0.354,,,True,,,,True,Convenience,Cyclic Enhanced Fluorescence Assay® (CEFA),ET Healthcare,Other,Multiple Types,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,0.988,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Sabrina Racine Brzostek,Weill Cornell Medicine,Not Unity-Aligned,http://dx.doi.org/10.1093/ajcp/aqaa142,2020-11-02,2023-07-04,Verified,racine-brzostek_covid-19_2020,USA
200917_Nashville_VanderbiltUniversityMedicalCenter_60DaysOverall,200917_Nashville_VanderbiltUniversityMedicalCenter_60dayfollow,"Change in Antibodies to SARS-CoV-2 Over 60 Days Among Health Care Personnel in Nashville, Tennessee",2020-09-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Tennessee,Nashville,health care personnel at Vanderbilt University Medical Cen- ter who regularly had direct contact with adult patients with coronavirus disease 2019,,2020-06-02,2020-06-27,Health care workers and caregivers,All,Multiple groups,21.0,70.0,Primary Estimate,Overall after 60 days,230,0.0348,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,TotalAntibody,Spike,Validated by developers,0.96,0.99,['High'],Yes,No,No,No,Unclear,Unclear,Yes,Yes,No,Manish Patel,Vanderbilt University Medical Center,Not Unity-Aligned,http://dx.doi.org/10.1001/jama.2020.18796,2020-11-24,2022-07-16,Verified,patel_change_2020,USA
200917_Nashville_VanderbiltUniversityMedicalCenter_BaselineOverall,200917_Nashville_VanderbiltUniversityMedicalCenter_Baseline,"Change in Antibodies to SARS-CoV-2 Over 60 Days Among Health Care Personnel in Nashville, Tennessee",2020-09-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Tennessee,Nashville,health care personnel at Vanderbilt University Medical Cen- ter who regularly had direct contact with adult patients with coronavirus disease 2019,,2020-04-03,2020-04-13,Health care workers and caregivers,All,Multiple groups,21.0,70.0,Primary Estimate,Overall baseline estimate,249,0.0763,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,TotalAntibody,Spike,Validated by developers,0.96,0.99,['High'],Yes,No,No,Yes,Unclear,Unclear,Yes,Yes,No,Manish Patel,Vanderbilt University Medical Center,Not Unity-Aligned,http://dx.doi.org/10.1001/jama.2020.18796,2020-11-24,2022-07-16,Verified,patel_change_2020,USA
200917_SanFrancisco_UniversityofCalifornia_BloodDonors,200917_SanFrancisco_UniversityofCalifornia_BloodDonors,SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood ,2020-09-17,Journal Article (Peer-Reviewed),Local,Retrospective cohort,United States of America,California,San Francisco,Individuals who donated blood in March 2020 at blood bank centers throughout the Bay Area,Routine blood donor screening was performed to exclude those with self-reported symptoms of acute illness and abnormal vital signs. also excluded immunocompromised,2020-03-01,2020-03-31,Blood donors,All,Multiple groups,19.0,89.0,Primary Estimate,Overall estimate,1000,0.001,0.0,0.005600000000000001,True,,,,True,Sequential,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Author designed (Neutralization Assay)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,NA",Multiple Types,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,Yes,No,Yes,Yes,Yes,No,,Dianna Ng,"University of California, San Francisco",Unity-Aligned,https://dx.doi.org/10.1038/s41467-020-18468-8,2020-11-06,2024-03-01,Verified,ng_sars-cov-2_2020,USA
200917_SanFrancisco_UniversityofCalifornia_Patients,200917_SanFrancisco_UniversityofCalifornia_Patients,SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood ,2020-09-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,San Francisco,"Patients who received care at adult inpatient units or clinics at the UCSF Medical Center for indications other than COVID- 19 respiratory disease (non-COVID-19, never tested for SARS- CoV-2 by RT-PCR)",COVID-19,2020-03-17,2020-04-13,Residual sera,All,Multiple groups,19.0,99.0,Primary Estimate,Overall estimate,387,0.0026000000000000003,0.0,0.0076,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.99,0.998,['High'],No,No,No,No,Yes,Yes,Yes,Yes,Unclear,Dianna Ng,"University of California, San Francisco",Not Unity-Aligned,https://dx.doi.org/10.1038/s41467-020-18468-8,2020-11-06,2024-03-01,Verified,ng_sars-cov-2_2020,USA
200918_Arizona_VincereCancerCenter_Total,200918_Arizona_VincereCancerCenter,COVID-19 Exposure among First Responders in Arizona,2020-09-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Arizona,"Phoenix, Tempe, Glendale, Surprise, Peoria, Chandler","All first responders (including firefighters, EMS, and police officers) age 18 and older who are members of the United Phoenix Firefighters Association Local 493 or Phoenix Law Enforcement Association or work for the Cities of Phoenix, Tempe, or Glendale were eligible to participate in this study. United Phoenix Firefighters Association 493 includes professional firefighters from Phoenix, Tempe, Glendale, Peoria, Surprise, and Chandler.
",,2020-04-24,2020-05-21,Essential non-healthcare workers,All,Multiple groups,18.0,,Primary Estimate,,3326,0.01503307276,,,True,,,,True,Convenience,Novel Coronavirus IgG antibody test kit (colloidal gold method),RayBiotech,LFIA,Whole Blood,IgG,,Validated by manufacturers,0.904,0.983,['High'],Yes,No,Yes,Yes,Unclear,No,Yes,Yes,Unclear,Vershalee Shukla,Vincere Cancer Center,Not Unity-Aligned,https://dx.doi.org/10.1097/JOM.0000000000002027,2020-11-23,2024-03-01,Verified,shukla_covid-19_2020,USA
200918_Arizona_VincereCancerCenter_Age_55-64,200918_Arizona_VincereCancerCenter,COVID-19 Exposure among First Responders in Arizona,2020-09-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Arizona,"Phoenix, Tempe, Glendale, Surprise, Peoria, Chandler","All first responders (including firefighters, EMS, and police officers) age 18 and older who are members of the United Phoenix Firefighters Association Local 493 or Phoenix Law Enforcement Association or work for the Cities of Phoenix, Tempe, or Glendale were eligible to participate in this study. United Phoenix Firefighters Association 493 includes professional firefighters from Phoenix, Tempe, Glendale, Peoria, Surprise, and Chandler.
",,2020-04-24,2020-05-21,Essential non-healthcare workers,All,Adults (18-64 years),55.0,64.0,Age,Age 55-64,266,0.01503759398,,,,,,,,Convenience,Novel Coronavirus IgG antibody test kit (colloidal gold method),RayBiotech,LFIA,Whole Blood,IgG,,Validated by manufacturers,0.904,0.983,['High'],Yes,No,Yes,Yes,Unclear,No,Yes,Yes,Unclear,Vershalee Shukla,Vincere Cancer Center,Not Unity-Aligned,https://dx.doi.org/10.1097/JOM.0000000000002027,2020-11-23,2024-03-01,Verified,shukla_covid-19_2020,USA
200918_Arizona_VincereCancerCenter_Age_18-24,200918_Arizona_VincereCancerCenter,COVID-19 Exposure among First Responders in Arizona,2020-09-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Arizona,"Phoenix, Tempe, Glendale, Surprise, Peoria, Chandler","All first responders (including firefighters, EMS, and police officers) age 18 and older who are members of the United Phoenix Firefighters Association Local 493 or Phoenix Law Enforcement Association or work for the Cities of Phoenix, Tempe, or Glendale were eligible to participate in this study. United Phoenix Firefighters Association 493 includes professional firefighters from Phoenix, Tempe, Glendale, Peoria, Surprise, and Chandler.
",,2020-04-24,2020-05-21,Essential non-healthcare workers,All,Adults (18-64 years),18.0,24.0,Age,Age 18-24,100,0.0,,,,,,,,Convenience,Novel Coronavirus IgG antibody test kit (colloidal gold method),RayBiotech,LFIA,Whole Blood,IgG,,Validated by manufacturers,0.904,0.983,['High'],Yes,No,Yes,Yes,Unclear,No,Yes,Yes,Unclear,Vershalee Shukla,Vincere Cancer Center,Not Unity-Aligned,https://dx.doi.org/10.1097/JOM.0000000000002027,2020-11-23,2024-03-01,Verified,shukla_covid-19_2020,USA
200918_Arizona_VincereCancerCenter_Age_35-44,200918_Arizona_VincereCancerCenter,COVID-19 Exposure among First Responders in Arizona,2020-09-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Arizona,"Phoenix, Tempe, Glendale, Surprise, Peoria, Chandler","All first responders (including firefighters, EMS, and police officers) age 18 and older who are members of the United Phoenix Firefighters Association Local 493 or Phoenix Law Enforcement Association or work for the Cities of Phoenix, Tempe, or Glendale were eligible to participate in this study. United Phoenix Firefighters Association 493 includes professional firefighters from Phoenix, Tempe, Glendale, Peoria, Surprise, and Chandler.
",,2020-04-24,2020-05-21,Essential non-healthcare workers,All,Adults (18-64 years),35.0,44.0,Age,Age 35-44,1186,0.01349072513,,,,,,,,Convenience,Novel Coronavirus IgG antibody test kit (colloidal gold method),RayBiotech,LFIA,Whole Blood,IgG,,Validated by manufacturers,0.904,0.983,['High'],Yes,No,Yes,Yes,Unclear,No,Yes,Yes,Unclear,Vershalee Shukla,Vincere Cancer Center,Not Unity-Aligned,https://dx.doi.org/10.1097/JOM.0000000000002027,2020-11-23,2024-03-01,Verified,shukla_covid-19_2020,USA
200918_Arizona_VincereCancerCenter_Age_65+,200918_Arizona_VincereCancerCenter,COVID-19 Exposure among First Responders in Arizona,2020-09-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Arizona,"Phoenix, Tempe, Glendale, Surprise, Peoria, Chandler","All first responders (including firefighters, EMS, and police officers) age 18 and older who are members of the United Phoenix Firefighters Association Local 493 or Phoenix Law Enforcement Association or work for the Cities of Phoenix, Tempe, or Glendale were eligible to participate in this study. United Phoenix Firefighters Association 493 includes professional firefighters from Phoenix, Tempe, Glendale, Peoria, Surprise, and Chandler.
",,2020-04-24,2020-05-21,Essential non-healthcare workers,All,Seniors (65+ years),65.0,,Age,Age 65+,16,0.0,,,,,,,,Convenience,Novel Coronavirus IgG antibody test kit (colloidal gold method),RayBiotech,LFIA,Whole Blood,IgG,,Validated by manufacturers,0.904,0.983,['High'],Yes,No,Yes,Yes,Unclear,No,Yes,Yes,Unclear,Vershalee Shukla,Vincere Cancer Center,Not Unity-Aligned,https://dx.doi.org/10.1097/JOM.0000000000002027,2020-11-23,2024-03-01,Verified,shukla_covid-19_2020,USA
200918_Arizona_VincereCancerCenter_Age_45-54,200918_Arizona_VincereCancerCenter,COVID-19 Exposure among First Responders in Arizona,2020-09-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Arizona,"Phoenix, Tempe, Glendale, Surprise, Peoria, Chandler","All first responders (including firefighters, EMS, and police officers) age 18 and older who are members of the United Phoenix Firefighters Association Local 493 or Phoenix Law Enforcement Association or work for the Cities of Phoenix, Tempe, or Glendale were eligible to participate in this study. United Phoenix Firefighters Association 493 includes professional firefighters from Phoenix, Tempe, Glendale, Peoria, Surprise, and Chandler.
",,2020-04-24,2020-05-21,Essential non-healthcare workers,All,Adults (18-64 years),45.0,54.0,Age,Age 45-54,984,0.018292682929999998,,,,,,,,Convenience,Novel Coronavirus IgG antibody test kit (colloidal gold method),RayBiotech,LFIA,Whole Blood,IgG,,Validated by manufacturers,0.904,0.983,['High'],Yes,No,Yes,Yes,Unclear,No,Yes,Yes,Unclear,Vershalee Shukla,Vincere Cancer Center,Not Unity-Aligned,https://dx.doi.org/10.1097/JOM.0000000000002027,2020-11-23,2024-03-01,Verified,shukla_covid-19_2020,USA
200918_Arizona_VincereCancerCenter_Age_25-34,200918_Arizona_VincereCancerCenter,COVID-19 Exposure among First Responders in Arizona,2020-09-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Arizona,"Phoenix, Tempe, Glendale, Surprise, Peoria, Chandler","All first responders (including firefighters, EMS, and police officers) age 18 and older who are members of the United Phoenix Firefighters Association Local 493 or Phoenix Law Enforcement Association or work for the Cities of Phoenix, Tempe, or Glendale were eligible to participate in this study. United Phoenix Firefighters Association 493 includes professional firefighters from Phoenix, Tempe, Glendale, Peoria, Surprise, and Chandler.
",,2020-04-24,2020-05-21,Essential non-healthcare workers,All,Adults (18-64 years),25.0,34.0,Age,Age 25-34,730,0.01506849315,,,,,,,,Convenience,Novel Coronavirus IgG antibody test kit (colloidal gold method),RayBiotech,LFIA,Whole Blood,IgG,,Validated by manufacturers,0.904,0.983,['High'],Yes,No,Yes,Yes,Unclear,No,Yes,Yes,Unclear,Vershalee Shukla,Vincere Cancer Center,Not Unity-Aligned,https://dx.doi.org/10.1097/JOM.0000000000002027,2020-11-23,2024-03-01,Verified,shukla_covid-19_2020,USA
200919_Houston_HoustonHealthDepartmentSa,200919_Houston_HoustonHealthDepartment,Houston Health Department Antibody Testing Survey,2020-09-19,News and Media,Local,Cross-sectional survey ,United States of America,Texas,Houston,Data released by the city is based on blood collected from volunteers in randomly selected households,,2020-09-08,2020-09-19,Household and community samples,All,Multiple groups,,,Primary Estimate,Houston households,678,0.135,,,,,,,,Simplified probability,Not reported/ Unable to specify,,,,,,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,Houston Health Department,Houston Health Department,Not Unity-Aligned,https://kinder.rice.edu/houston-health-department-antibody-testing-survey,2021-05-10,2022-07-16,Verified,houston_health_department_houston_2020,USA
200920_NewYorkState_DonaldAndBarbaraZuckerSchoolOfMedicine_Patients_Overall,200920_NewYorkState_DonaldAndBarbaraZuckerSchoolOfMedicine,SARS-CoV-2 Antibodies in Pregnant Women Admitted to Labor and Delivery,2020-09-20,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,New York,,Women admitted to the labor and delivery unit of 7 hospitals part of the Northwell Health System,,2020-05-27,2020-07-24,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,All patients admitted to the L&D ward,1671,0.161,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,,IgG,,Validated by manufacturers,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Lylach Haizler Cohen,Donald and Barbara Zucker School of Medicine,Unity-Aligned,https://dx.doi.org/10.1016/j.ajog.2020.09.022,2020-10-30,2024-03-01,Verified,haizler-cohen_severe_2020,USA
200921_Detroit_Region2SouthHealthcareCoalition_Overall,200921_Detroit_Region2SouthHealthcareCoalition,"SARS-CoV-2 Seroprevalence among Healthcare, First Response, and Public Safety Personnel, Detroit Metropolitan Area, Michigan, USA, May-June 2020.",2020-09-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Michigan,Detroit,"Eligible participants for the serology survey included adults >18 years of age who worked onsite in a first response, hospital, or public safety setting and consented to phlebotomy and serum sample storage for confirmation of test results if needed","Persons were not eligible to participate if, in the 2 weeks before tak- ing the survey, they reported having new symptoms of cough, shortness of breath, or change in sense of taste or smell, or had tested positive for SARS-CoV-2 by RT-PCR test using a nasal, throat, or saliva sample",2020-05-18,2020-06-13,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,Overall,16397,0.069,0.065,0.073,True,,,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,,,IgG,,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Lara Akinbami,Region 2 South Healthcare Coalition,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2612.203764,2020-12-04,2024-03-01,Verified,akinbami_sars-cov-2_2020,USA
200921_Detroit_Region2SouthHealthcareCoalition_25-34,200921_Detroit_Region2SouthHealthcareCoalition,"SARS-CoV-2 Seroprevalence among Healthcare, First Response, and Public Safety Personnel, Detroit Metropolitan Area, Michigan, USA, May-June 2020.",2020-09-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Michigan,Detroit,"Eligible participants for the serology survey included adults >18 years of age who worked onsite in a first response, hospital, or public safety setting and consented to phlebotomy and serum sample storage for confirmation of test results if needed","Persons were not eligible to participate if, in the 2 weeks before tak- ing the survey, they reported having new symptoms of cough, shortness of breath, or change in sense of taste or smell, or had tested positive for SARS-CoV-2 by RT-PCR test using a nasal, throat, or saliva sample",2020-05-18,2020-06-13,Health care workers and caregivers,All,Adults (18-64 years),25.0,34.0,Age,25-34,4885,0.069,0.062000000000000006,0.076,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,,,IgG,,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Lara Akinbami,Region 2 South Healthcare Coalition,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2612.203764,2020-12-04,2024-03-01,Verified,akinbami_sars-cov-2_2020,USA
200921_Detroit_Region2SouthHealthcareCoalition_45-59,200921_Detroit_Region2SouthHealthcareCoalition,"SARS-CoV-2 Seroprevalence among Healthcare, First Response, and Public Safety Personnel, Detroit Metropolitan Area, Michigan, USA, May-June 2020.",2020-09-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Michigan,Detroit,"Eligible participants for the serology survey included adults >18 years of age who worked onsite in a first response, hospital, or public safety setting and consented to phlebotomy and serum sample storage for confirmation of test results if needed","Persons were not eligible to participate if, in the 2 weeks before tak- ing the survey, they reported having new symptoms of cough, shortness of breath, or change in sense of taste or smell, or had tested positive for SARS-CoV-2 by RT-PCR test using a nasal, throat, or saliva sample",2020-05-18,2020-06-13,Health care workers and caregivers,All,Adults (18-64 years),45.0,59.0,Age,45-59,5222,0.069,0.062000000000000006,0.076,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,,,IgG,,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Lara Akinbami,Region 2 South Healthcare Coalition,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2612.203764,2020-12-04,2024-03-01,Verified,akinbami_sars-cov-2_2020,USA
200921_Detroit_Region2SouthHealthcareCoalition_35-44,200921_Detroit_Region2SouthHealthcareCoalition,"SARS-CoV-2 Seroprevalence among Healthcare, First Response, and Public Safety Personnel, Detroit Metropolitan Area, Michigan, USA, May-June 2020.",2020-09-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Michigan,Detroit,"Eligible participants for the serology survey included adults >18 years of age who worked onsite in a first response, hospital, or public safety setting and consented to phlebotomy and serum sample storage for confirmation of test results if needed","Persons were not eligible to participate if, in the 2 weeks before tak- ing the survey, they reported having new symptoms of cough, shortness of breath, or change in sense of taste or smell, or had tested positive for SARS-CoV-2 by RT-PCR test using a nasal, throat, or saliva sample",2020-05-18,2020-06-13,Health care workers and caregivers,All,Adults (18-64 years),35.0,44.0,Age,35-44,3977,0.07,0.062000000000000006,0.079,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,,,IgG,,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Lara Akinbami,Region 2 South Healthcare Coalition,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2612.203764,2020-12-04,2024-03-01,Verified,akinbami_sars-cov-2_2020,USA
200921_Detroit_Region2SouthHealthcareCoalition_60-64,200921_Detroit_Region2SouthHealthcareCoalition,"SARS-CoV-2 Seroprevalence among Healthcare, First Response, and Public Safety Personnel, Detroit Metropolitan Area, Michigan, USA, May-June 2020.",2020-09-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Michigan,Detroit,"Eligible participants for the serology survey included adults >18 years of age who worked onsite in a first response, hospital, or public safety setting and consented to phlebotomy and serum sample storage for confirmation of test results if needed","Persons were not eligible to participate if, in the 2 weeks before tak- ing the survey, they reported having new symptoms of cough, shortness of breath, or change in sense of taste or smell, or had tested positive for SARS-CoV-2 by RT-PCR test using a nasal, throat, or saliva sample",2020-05-18,2020-06-13,Health care workers and caregivers,All,Adults (18-64 years),60.0,64.0,Age,60-64,1106,0.075,0.06,0.092,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,,,IgG,,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Lara Akinbami,Region 2 South Healthcare Coalition,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2612.203764,2020-12-04,2024-03-01,Verified,akinbami_sars-cov-2_2020,USA
200921_Detroit_Region2SouthHealthcareCoalition_65+,200921_Detroit_Region2SouthHealthcareCoalition,"SARS-CoV-2 Seroprevalence among Healthcare, First Response, and Public Safety Personnel, Detroit Metropolitan Area, Michigan, USA, May-June 2020.",2020-09-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Michigan,Detroit,"Eligible participants for the serology survey included adults >18 years of age who worked onsite in a first response, hospital, or public safety setting and consented to phlebotomy and serum sample storage for confirmation of test results if needed","Persons were not eligible to participate if, in the 2 weeks before tak- ing the survey, they reported having new symptoms of cough, shortness of breath, or change in sense of taste or smell, or had tested positive for SARS-CoV-2 by RT-PCR test using a nasal, throat, or saliva sample",2020-05-18,2020-06-13,Health care workers and caregivers,All,Seniors (65+ years),65.0,,Age,65+,521,0.035,0.021,0.054000000000000006,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,,,IgG,,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Lara Akinbami,Region 2 South Healthcare Coalition,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2612.203764,2020-12-04,2024-03-01,Verified,akinbami_sars-cov-2_2020,USA
200921_Detroit_Region2SouthHealthcareCoalition_18-24,200921_Detroit_Region2SouthHealthcareCoalition,"SARS-CoV-2 Seroprevalence among Healthcare, First Response, and Public Safety Personnel, Detroit Metropolitan Area, Michigan, USA, May-June 2020.",2020-09-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Michigan,Detroit,"Eligible participants for the serology survey included adults >18 years of age who worked onsite in a first response, hospital, or public safety setting and consented to phlebotomy and serum sample storage for confirmation of test results if needed","Persons were not eligible to participate if, in the 2 weeks before tak- ing the survey, they reported having new symptoms of cough, shortness of breath, or change in sense of taste or smell, or had tested positive for SARS-CoV-2 by RT-PCR test using a nasal, throat, or saliva sample",2020-05-18,2020-06-13,Health care workers and caregivers,All,Adults (18-64 years),18.0,24.0,Age,18-24,686,0.079,0.06,0.102,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,,,IgG,,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Lara Akinbami,Region 2 South Healthcare Coalition,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2612.203764,2020-12-04,2024-03-01,Verified,akinbami_sars-cov-2_2020,USA
200923_AnnArbor_VeteransAffairsAnnArborHealthcareSystem,200923_AnnArbor_VeteransAffairsAnnArborHealthcareSystem,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection Among VA Healthcare System Employees Suggests Higher Risk of Infection When Exposed to SARS-CoV-2 Outside of the Work Environment,2020-09-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Michigan,,"In this study, we invited all paid employees to participate in a serologic survey and questionnaire at the Veterans Affairs Ann Arbor Healthcare System (VAAAHS) from June 8 to July 8, 2020, after the first wave of SARS-CoV-2 infection during March through May 2020. We assessed risk for SARS-CoV-2 seroconversion in VA employees in the healthcare system across multiple exposure settings.",,2020-06-08,2020-07-08,Health care workers and caregivers,All,Multiple groups,18.0,,Primary Estimate,Primary,1476,0.049,0.038,0.061,True,,,,True,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,0.99,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Derek Dimcheff,Veterans Affairs Ann Arbor Healthcare System,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2020.1220,2020-11-23,2024-03-01,Verified,dimcheff_seroprevalence_nodate,USA
200923_AnnArbor_VeteransAffairsAnnArborHealthcareSystem_18-30years,200923_AnnArbor_VeteransAffairsAnnArborHealthcareSystem,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection Among VA Healthcare System Employees Suggests Higher Risk of Infection When Exposed to SARS-CoV-2 Outside of the Work Environment,2020-09-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Michigan,,"In this study, we invited all paid employees to participate in a serologic survey and questionnaire at the Veterans Affairs Ann Arbor Healthcare System (VAAAHS) from June 8 to July 8, 2020, after the first wave of SARS-CoV-2 infection during March through May 2020. We assessed risk for SARS-CoV-2 seroconversion in VA employees in the healthcare system across multiple exposure settings.",,2020-06-08,2020-07-08,Health care workers and caregivers,All,Adults (18-64 years),18.0,30.0,Age,18-30 years,111,0.07200000000000001,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,0.99,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Derek Dimcheff,Veterans Affairs Ann Arbor Healthcare System,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2020.1220,2020-11-23,2024-03-01,Verified,dimcheff_seroprevalence_nodate,USA
200923_AnnArbor_VeteransAffairsAnnArborHealthcareSystem_NoResponseAge,200923_AnnArbor_VeteransAffairsAnnArborHealthcareSystem,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection Among VA Healthcare System Employees Suggests Higher Risk of Infection When Exposed to SARS-CoV-2 Outside of the Work Environment,2020-09-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Michigan,,"In this study, we invited all paid employees to participate in a serologic survey and questionnaire at the Veterans Affairs Ann Arbor Healthcare System (VAAAHS) from June 8 to July 8, 2020, after the first wave of SARS-CoV-2 infection during March through May 2020. We assessed risk for SARS-CoV-2 seroconversion in VA employees in the healthcare system across multiple exposure settings.",,2020-06-08,2020-07-08,Health care workers and caregivers,All,Multiple groups,,,Age,No response,46,0.065,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,0.99,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Derek Dimcheff,Veterans Affairs Ann Arbor Healthcare System,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2020.1220,2020-11-23,2024-03-01,Verified,dimcheff_seroprevalence_nodate,USA
200923_AnnArbor_VeteransAffairsAnnArborHealthcareSystem_>60years,200923_AnnArbor_VeteransAffairsAnnArborHealthcareSystem,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection Among VA Healthcare System Employees Suggests Higher Risk of Infection When Exposed to SARS-CoV-2 Outside of the Work Environment,2020-09-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Michigan,,"In this study, we invited all paid employees to participate in a serologic survey and questionnaire at the Veterans Affairs Ann Arbor Healthcare System (VAAAHS) from June 8 to July 8, 2020, after the first wave of SARS-CoV-2 infection during March through May 2020. We assessed risk for SARS-CoV-2 seroconversion in VA employees in the healthcare system across multiple exposure settings.",,2020-06-08,2020-07-08,Health care workers and caregivers,All,Seniors (65+ years),61.0,,Age,>60 years,149,0.054000000000000006,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,0.99,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Derek Dimcheff,Veterans Affairs Ann Arbor Healthcare System,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2020.1220,2020-11-23,2024-03-01,Verified,dimcheff_seroprevalence_nodate,USA
200923_AnnArbor_VeteransAffairsAnnArborHealthcareSystem_41-50years,200923_AnnArbor_VeteransAffairsAnnArborHealthcareSystem,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection Among VA Healthcare System Employees Suggests Higher Risk of Infection When Exposed to SARS-CoV-2 Outside of the Work Environment,2020-09-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Michigan,,"In this study, we invited all paid employees to participate in a serologic survey and questionnaire at the Veterans Affairs Ann Arbor Healthcare System (VAAAHS) from June 8 to July 8, 2020, after the first wave of SARS-CoV-2 infection during March through May 2020. We assessed risk for SARS-CoV-2 seroconversion in VA employees in the healthcare system across multiple exposure settings.",,2020-06-08,2020-07-08,Health care workers and caregivers,All,Adults (18-64 years),41.0,50.0,Age,41-50 years,392,0.043,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,0.99,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Derek Dimcheff,Veterans Affairs Ann Arbor Healthcare System,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2020.1220,2020-11-23,2024-03-01,Verified,dimcheff_seroprevalence_nodate,USA
200923_AnnArbor_VeteransAffairsAnnArborHealthcareSystem_51-60years,200923_AnnArbor_VeteransAffairsAnnArborHealthcareSystem,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection Among VA Healthcare System Employees Suggests Higher Risk of Infection When Exposed to SARS-CoV-2 Outside of the Work Environment,2020-09-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Michigan,,"In this study, we invited all paid employees to participate in a serologic survey and questionnaire at the Veterans Affairs Ann Arbor Healthcare System (VAAAHS) from June 8 to July 8, 2020, after the first wave of SARS-CoV-2 infection during March through May 2020. We assessed risk for SARS-CoV-2 seroconversion in VA employees in the healthcare system across multiple exposure settings.",,2020-06-08,2020-07-08,Health care workers and caregivers,All,Adults (18-64 years),51.0,60.0,Age,51-60 years,406,0.062000000000000006,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,0.99,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Derek Dimcheff,Veterans Affairs Ann Arbor Healthcare System,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2020.1220,2020-11-23,2024-03-01,Verified,dimcheff_seroprevalence_nodate,USA
200923_AnnArbor_VeteransAffairsAnnArborHealthcareSystem_31-40years,200923_AnnArbor_VeteransAffairsAnnArborHealthcareSystem,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection Among VA Healthcare System Employees Suggests Higher Risk of Infection When Exposed to SARS-CoV-2 Outside of the Work Environment,2020-09-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Michigan,,"In this study, we invited all paid employees to participate in a serologic survey and questionnaire at the Veterans Affairs Ann Arbor Healthcare System (VAAAHS) from June 8 to July 8, 2020, after the first wave of SARS-CoV-2 infection during March through May 2020. We assessed risk for SARS-CoV-2 seroconversion in VA employees in the healthcare system across multiple exposure settings.",,2020-06-08,2020-07-08,Health care workers and caregivers,All,Adults (18-64 years),31.0,40.0,Age,31-40 years,372,0.03,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,0.99,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Derek Dimcheff,Veterans Affairs Ann Arbor Healthcare System,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2020.1220,2020-11-23,2024-03-01,Verified,dimcheff_seroprevalence_nodate,USA
200925_UnitedStates_StanfordUniversity_OverallPopAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-07-01,2020-07-31,Residual sera,All,Multiple groups,18.0,,Primary Estimate,"Overall, adjusted to US population characteristics",28503,0.09300000000000001,0.08800000000000001,0.099,True,,True,,True,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_ZCTAIntegratedPopAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Ethnicity,Integrated ethnicity adjusted to US general population,9737,0.08900000000000001,0.08,0.098,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_BlackPopAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Race,Black adjusted to US general population,4894,0.099,0.087,0.113,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_45-64PopAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Adults (18-64 years),45.0,64.0,Age,Ages 45-64 adjusted to US general population,11541,0.095,0.08900000000000001,0.10099999999999999,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_OtherDialysisAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Race,Other ethnicity adjusted to general population,2479,0.049,0.040999999999999995,0.059000000000000004,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_OverallTestAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-07-01,2020-07-31,Residual sera,All,Multiple groups,18.0,,Analysis,Overall estimate test adjusted,28503,0.08199999999999999,0.079,0.085,,True,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2023-08-15,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_Male,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,Male,Multiple groups,18.0,,Sex/Gender,Male,16348,0.081,0.077,0.085,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_ZCTAWhiteDialysisAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Race,ZCTA White adjusted to dialysis population,8733,0.043,0.038,0.047,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_Midwest,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Geographical area,Midwest region,3763,0.07,0.062000000000000006,0.079,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_SouthPopAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Geographical area,South region adjusted to US general population,10939,0.051,0.045,0.057,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_SouthDialysisAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Geographical area,South region adjusted to dialysis population,10939,0.044000000000000004,0.04,0.048,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_NortheastDialysisAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Geographical area,Northeast region adjusted to dialysis population,4536,0.272,0.259,0.28500000000000003,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_Overall,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-07-01,2020-07-31,Residual sera,All,Multiple groups,18.0,,Analysis,Overall,28503,0.08,0.077,0.084,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-21,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_18-44DialysisAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Adults (18-64 years),18.0,44.0,Age,Ages 18-44 adjusted to dialysis population,3303,0.08900000000000001,0.08,0.1,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_65-79,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Seniors (65+ years),65.0,79.0,Age,Ages 65-79,10220,0.079,0.07400000000000001,0.085,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_45-64,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Adults (18-64 years),45.0,64.0,Age,Ages 45-64,11541,0.083,0.078,0.08800000000000001,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_ZCTABlack,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Race,ZCTA Black,2585,0.147,0.133,0.163,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_18-44PopAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Adults (18-64 years),18.0,44.0,Age,Ages 18-44 adjusted to US general population,3303,0.098,0.087,0.109,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_FemaleDialysisAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,Female,Multiple groups,18.0,,Sex/Gender,Females adjusted to dialysis population,12155,0.08199999999999999,0.077,0.087,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_ZCTAWhitePopAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Race,ZCTA White adjusted to US general population,8733,0.048,0.040999999999999995,0.055,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_ZCTAIntegrated,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Ethnicity,Integrated ethnicity,9737,0.073,0.068,0.079,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_45-64DialysisAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Adults (18-64 years),45.0,64.0,Age,Ages 45-64 adjusted to dialysis population,11541,0.086,0.081,0.092,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
20 0925_UnitedStates_StanfordUniversity_80+,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Seniors (65+ years),80.0,,Age,Ages 80+,3439,0.069,0.06,0.078,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_Black,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Race,Black,4894,0.095,0.087,0.10400000000000001,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_WestPopAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Geographical area,West region adjusted to US general population,9265,0.042,0.036000000000000004,0.049,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_ZCTAHispanicBlackDialysisAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Ethnicity,ZCTA Hispanic-Black adjusted to dialysis population,2878,0.145,0.132,0.159,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_ZCTAHispanicBlack,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Ethnicity,ZCTA Hispanic-Black,2878,0.146,0.133,0.161,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_WestDialysisAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Geographical area,West region adjusted to dialysis population,9265,0.035,0.031000000000000003,0.039,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_Unknown,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Race,Unknown ethnicity,11410,0.113,0.107,0.12,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_MalePopAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,Male,Multiple groups,18.0,,Sex/Gender,Male adjusted to US general population,16348,0.09300000000000001,0.086,0.1,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_NortheastPopAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Geographical area,Northeast region adjusted to US general population,4536,0.276,0.257,0.297,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_OtherPopAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Race,Other ethnicity adjusted to US general population,2479,0.057,0.042,0.077,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_Other,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Race,Other ethnicity ,2479,0.042,0.034,0.05,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_WhiteDialysisAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Race,White adjusted to dialysis population,6533,0.034,0.03,0.039,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_HispanicDialysisAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Ethnicity,Hispanic adjusted to dialysis populaiton,3187,0.063,0.055,0.073,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_ZCTAHispanicPopAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Ethnicity,ZCTA Hispanic adjusted to US general population,4568,0.113,0.098,0.129,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_FemalePopAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,Female,Multiple groups,18.0,,Sex/Gender,Females ajdusted to US general population,12155,0.09300000000000001,0.086,0.102,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_18-44,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Adults (18-64 years),18.0,44.0,Age,Ages 18-44,3303,0.08800000000000001,0.079,0.099,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_OverallDialysisAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-07-01,2020-07-31,Residual sera,All,Multiple groups,18.0,,Analysis,"Overall, adjusted to dialysis patient population characteristics",28503,0.083,0.08,0.086,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_UnknownDialysisAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Race,Unknown ethnicity adjusted to dialysis population,11410,0.11800000000000001,0.111,0.12400000000000001,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_65-79DialysisAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Seniors (65+ years),65.0,79.0,Age,Ages 65-79 adjusted to dialysis population,10220,0.079,0.07400000000000001,0.085,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_HispanicPopAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Ethnicity,Hispanic adjusted to US general population,3187,0.08,0.066,0.096,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_White,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Race,White,6533,0.035,0.031000000000000003,0.04,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_ZCTAWhite,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Race,ZCTA White,8733,0.042,0.038,0.047,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_BlackDialysisAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Race,Black adjusted to dialysis population,4894,0.09300000000000001,0.085,0.10099999999999999,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_West,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Geographical area,West region,9265,0.035,0.031000000000000003,0.039,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_ZCTAHispanic,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Ethnicity,ZIP code tabulation area (ZCTA) ethnicity Hispanic,4568,0.09,0.08199999999999999,0.1,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_Hispanic,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Ethnicity,Hispanic,3187,0.063,0.055,0.07200000000000001,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_MaleDialysisAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,Male,Multiple groups,18.0,,Sex/Gender,Male adjusted to dialysis population,16348,0.084,0.079,0.08800000000000001,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_80+PopAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Seniors (65+ years),80.0,,Age,Ages 80+ adjusted to US general population,3439,0.07400000000000001,0.065,0.085,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_Female,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,Female,Multiple groups,18.0,,Sex/Gender,Female,12155,0.08,0.075,0.085,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_ZZCTAHispanicBlackPopAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Ethnicity,ZCTA Hispanic-Black adjusted to US general population,2878,0.163,0.14300000000000002,0.185,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_ZCTABlackPopAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Race,ZCTA Black adjusted to US general population,2585,0.139,0.121,0.16,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_Northeast,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Geographical area,Northeast region,4536,0.271,0.257,0.287,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_WhitePopAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Race,White adjusted to US general population,6533,0.043,0.035,0.052000000000000005,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_UnknownPopAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Ethnicity,Unknown ethnicity adjusted to US general population,11410,0.125,0.11599999999999999,0.135,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_South,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Geographical area,South region ,10939,0.043,0.04,0.047,,,,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_80+DialysisAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Seniors (65+ years),80.0,,Age,Ages 80+ adjusted to dialysis population,3439,0.073,0.065,0.083,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_MidwestPopAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Geographical area,Midwest region adjusted to US general population,3763,0.07400000000000001,0.063,0.08800000000000001,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_ZCTAHispanicDialysisAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Ethnicity,ZCTA Hispanic adjusted to dialysis population,4568,0.094,0.085,0.10300000000000001,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_MidwestDialysisAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Geographical area,Midwest region adjusted to dialysis population,3763,0.071,0.063,0.079,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_ZCTAIntegratedDialysisAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Ethnicity,Integrated ethnicity adjusted to dialysis population,9737,0.08,0.07400000000000001,0.086,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_65-79PopAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Seniors (65+ years),65.0,79.0,Age,Ages 65-79 adjusted to US general population,10220,0.083,0.078,0.08900000000000001,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200925_UnitedStates_StanfordUniversity_ZCTABlackDialysisAdj,200925_UnitedStates_StanfordUniversity,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,2020-09-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Adult (≥18 years) from accross the USA patients undergoing monthly laboratory testing at Ascend Clinical, which is a commercial clinical laboratory based in
Redwood City, California, that receives samples from a
nationwide network of around 1300 dialysis facilities,
serving approximately 65000 patients.",,2020-06-15,2020-06-15,Residual sera,All,Multiple groups,18.0,,Race,ZCTA Black adjusted to dialysis population,2585,0.141,0.129,0.155,,,True,,,Stratified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Shuchi Anand,Stanford University,Unity-Aligned,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,2020-11-22,2024-03-01,Verified,anand_prevalence_2020,USA
200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC_OverallAdj,200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC1,SARS-CoV-2 seroprevalence among a southern U.S. population indicates limited asymptomatic spread under physical distancing measures,2020-09-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,"Outpatient asymptomatic participants ages 18+ across the University of North Carolina Health System (UNC Health), representing 267 different ZIP codes. These individuals sought medical care unrelated to COVID-19","Individuals with known COVID-19 symptoms, at screening or in their recent past, were excluded.",2020-04-28,2020-06-19,Residual sera,All,Adults (18-64 years),18.0,,Primary Estimate,"Overall estimate, pop adj test adj",2973,0.0,0.0,0.009000000000000001,True,True,True,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Amir Barzin,University of North Carolina Chapel Hill,Not Unity-Aligned,http://dx.doi.org/10.1128/mBio.02426-20,2020-12-07,2023-07-04,Verified,barzin_sars-cov-2_2020,USA
200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC_White,200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC1,SARS-CoV-2 seroprevalence among a southern U.S. population indicates limited asymptomatic spread under physical distancing measures,2020-09-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,"Outpatient asymptomatic participants ages 18+ across the University of North Carolina Health System (UNC Health), representing 267 different ZIP codes. These individuals sought medical care unrelated to COVID-19","Individuals with known COVID-19 symptoms, at screening or in their recent past, were excluded.",2020-04-28,2020-06-19,Residual sera,All,Adults (18-64 years),18.0,,Race,White,2200,0.006999999999999999,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Amir Barzin,University of North Carolina Chapel Hill,Not Unity-Aligned,http://dx.doi.org/10.1128/mBio.02426-20,2020-12-07,2024-03-01,Verified,barzin_sars-cov-2_2020,USA
200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC_06/15/2020,200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC1,SARS-CoV-2 seroprevalence among a southern U.S. population indicates limited asymptomatic spread under physical distancing measures,2020-09-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,"Outpatient asymptomatic participants ages 18+ across the University of North Carolina Health System (UNC Health), representing 267 different ZIP codes. These individuals sought medical care unrelated to COVID-19","Individuals with known COVID-19 symptoms, at screening or in their recent past, were excluded.",2020-04-28,2020-06-19,Residual sera,All,Adults (18-64 years),18.0,,Time frame,Week of 06/15/2020,2973,0.013999999999999999,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Amir Barzin,University of North Carolina Chapel Hill,Not Unity-Aligned,http://dx.doi.org/10.1128/mBio.02426-20,2020-12-07,2024-03-01,Verified,barzin_sars-cov-2_2020,USA
200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC_05/18/2020,200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC1,SARS-CoV-2 seroprevalence among a southern U.S. population indicates limited asymptomatic spread under physical distancing measures,2020-09-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,"Outpatient asymptomatic participants ages 18+ across the University of North Carolina Health System (UNC Health), representing 267 different ZIP codes. These individuals sought medical care unrelated to COVID-19","Individuals with known COVID-19 symptoms, at screening or in their recent past, were excluded.",2020-04-28,2020-06-19,Residual sera,All,Adults (18-64 years),18.0,,Time frame,Week of 05/18/2020,2973,0.009000000000000001,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Amir Barzin,University of North Carolina Chapel Hill,Not Unity-Aligned,http://dx.doi.org/10.1128/mBio.02426-20,2020-12-07,2024-03-01,Verified,barzin_sars-cov-2_2020,USA
200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC_05/11/2020,200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC1,SARS-CoV-2 seroprevalence among a southern U.S. population indicates limited asymptomatic spread under physical distancing measures,2020-09-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,"Outpatient asymptomatic participants ages 18+ across the University of North Carolina Health System (UNC Health), representing 267 different ZIP codes. These individuals sought medical care unrelated to COVID-19","Individuals with known COVID-19 symptoms, at screening or in their recent past, were excluded.",2020-04-28,2020-06-19,Residual sera,All,Adults (18-64 years),18.0,,Time frame,Week of 05/11/2020,2973,0.006999999999999999,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Amir Barzin,University of North Carolina Chapel Hill,Not Unity-Aligned,http://dx.doi.org/10.1128/mBio.02426-20,2020-12-07,2024-03-01,Verified,barzin_sars-cov-2_2020,USA
200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC_04/27/2020,200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC1,SARS-CoV-2 seroprevalence among a southern U.S. population indicates limited asymptomatic spread under physical distancing measures,2020-09-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,"Outpatient asymptomatic participants ages 18+ across the University of North Carolina Health System (UNC Health), representing 267 different ZIP codes. These individuals sought medical care unrelated to COVID-19","Individuals with known COVID-19 symptoms, at screening or in their recent past, were excluded.",2020-04-28,2020-06-19,Residual sera,All,Adults (18-64 years),18.0,,Time frame,Week of 04/27/2020,2973,0.01,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Amir Barzin,University of North Carolina Chapel Hill,Not Unity-Aligned,http://dx.doi.org/10.1128/mBio.02426-20,2020-12-07,2024-03-01,Verified,barzin_sars-cov-2_2020,USA
200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC_05/25/2020,200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC1,SARS-CoV-2 seroprevalence among a southern U.S. population indicates limited asymptomatic spread under physical distancing measures,2020-09-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,"Outpatient asymptomatic participants ages 18+ across the University of North Carolina Health System (UNC Health), representing 267 different ZIP codes. These individuals sought medical care unrelated to COVID-19","Individuals with known COVID-19 symptoms, at screening or in their recent past, were excluded.",2020-04-28,2020-06-19,Residual sera,All,Adults (18-64 years),18.0,,Time frame,Week of 05/25/2020,2973,0.009000000000000001,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Amir Barzin,University of North Carolina Chapel Hill,Not Unity-Aligned,http://dx.doi.org/10.1128/mBio.02426-20,2020-12-07,2024-03-01,Verified,barzin_sars-cov-2_2020,USA
200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC_06/01/2020,200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC1,SARS-CoV-2 seroprevalence among a southern U.S. population indicates limited asymptomatic spread under physical distancing measures,2020-09-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,"Outpatient asymptomatic participants ages 18+ across the University of North Carolina Health System (UNC Health), representing 267 different ZIP codes. These individuals sought medical care unrelated to COVID-19","Individuals with known COVID-19 symptoms, at screening or in their recent past, were excluded.",2020-04-28,2020-06-19,Residual sera,All,Adults (18-64 years),18.0,,Time frame,Week of 06/01/2020,2973,0.012,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Amir Barzin,University of North Carolina Chapel Hill,Not Unity-Aligned,http://dx.doi.org/10.1128/mBio.02426-20,2020-12-07,2024-03-01,Verified,barzin_sars-cov-2_2020,USA
200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC_Black,200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC1,SARS-CoV-2 seroprevalence among a southern U.S. population indicates limited asymptomatic spread under physical distancing measures,2020-09-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,"Outpatient asymptomatic participants ages 18+ across the University of North Carolina Health System (UNC Health), representing 267 different ZIP codes. These individuals sought medical care unrelated to COVID-19","Individuals with known COVID-19 symptoms, at screening or in their recent past, were excluded.",2020-04-28,2020-06-19,Residual sera,All,Adults (18-64 years),18.0,,Race,Black,395,0.015,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Amir Barzin,University of North Carolina Chapel Hill,Not Unity-Aligned,http://dx.doi.org/10.1128/mBio.02426-20,2020-12-07,2024-03-01,Verified,barzin_sars-cov-2_2020,USA
200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC_06/08/2020,200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC1,SARS-CoV-2 seroprevalence among a southern U.S. population indicates limited asymptomatic spread under physical distancing measures,2020-09-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,"Outpatient asymptomatic participants ages 18+ across the University of North Carolina Health System (UNC Health), representing 267 different ZIP codes. These individuals sought medical care unrelated to COVID-19","Individuals with known COVID-19 symptoms, at screening or in their recent past, were excluded.",2020-04-28,2020-06-19,Residual sera,All,Adults (18-64 years),18.0,,Time frame,Week of 06/08/2020,2973,0.009000000000000001,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Amir Barzin,University of North Carolina Chapel Hill,Not Unity-Aligned,http://dx.doi.org/10.1128/mBio.02426-20,2020-12-07,2024-03-01,Verified,barzin_sars-cov-2_2020,USA
200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC_05/04/2020,200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC1,SARS-CoV-2 seroprevalence among a southern U.S. population indicates limited asymptomatic spread under physical distancing measures,2020-09-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,"Outpatient asymptomatic participants ages 18+ across the University of North Carolina Health System (UNC Health), representing 267 different ZIP codes. These individuals sought medical care unrelated to COVID-19","Individuals with known COVID-19 symptoms, at screening or in their recent past, were excluded.",2020-04-28,2020-06-19,Residual sera,All,Adults (18-64 years),18.0,,Time frame,Week of 05/04/2020,2973,0.0,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Amir Barzin,University of North Carolina Chapel Hill,Not Unity-Aligned,http://dx.doi.org/10.1128/mBio.02426-20,2020-12-07,2024-03-01,Verified,barzin_sars-cov-2_2020,USA
200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC_Overall,200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC1,SARS-CoV-2 seroprevalence among a southern U.S. population indicates limited asymptomatic spread under physical distancing measures,2020-09-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,"Outpatient asymptomatic participants ages 18+ across the University of North Carolina Health System (UNC Health), representing 267 different ZIP codes. These individuals sought medical care unrelated to COVID-19","Individuals with known COVID-19 symptoms, at screening or in their recent past, were excluded.",2020-04-28,2020-06-19,Residual sera,All,Adults (18-64 years),18.0,,Analysis,Overall raw estimate,2973,0.008,,,,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Amir Barzin,University of North Carolina Chapel Hill,Not Unity-Aligned,http://dx.doi.org/10.1128/mBio.02426-20,2020-12-07,2024-03-01,Verified,barzin_sars-cov-2_2020,USA
200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC2_Overall,200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC2,SARS-CoV-2 seroprevalence among a southern U.S. population indicates limited asymptomatic spread under physical distancing measures,2020-09-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,inpatients patients in clinical care not related to COVID-19 or recruited to the study,,2020-03-03,2020-06-04,Residual sera,All,Adults (18-64 years),18.0,,Primary Estimate,Overall estimate,1449,0.006999999999999999,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['High'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Amir Barzin,University of North Carolina Chapel Hill,Unity-Aligned,http://dx.doi.org/10.1128/mBio.02426-20,2020-12-07,2024-03-01,Verified,barzin_sars-cov-2_2020,USA
200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC2_05/18/2020,200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC2,SARS-CoV-2 seroprevalence among a southern U.S. population indicates limited asymptomatic spread under physical distancing measures,2020-09-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,inpatients patients in clinical care not related to COVID-19 or recruited to the study,,2020-05-18,2020-05-24,Residual sera,All,Adults (18-64 years),18.0,,Time frame,Week of 05/18/2020,1449,0.0,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['High'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Amir Barzin,University of North Carolina Chapel Hill,Unity-Aligned,http://dx.doi.org/10.1128/mBio.02426-20,2020-12-07,2024-03-01,Verified,barzin_sars-cov-2_2020,USA
200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC2_03/02/2020,200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC2,SARS-CoV-2 seroprevalence among a southern U.S. population indicates limited asymptomatic spread under physical distancing measures,2020-09-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,inpatients patients in clinical care not related to COVID-19 or recruited to the study,,2020-03-03,2020-03-09,Residual sera,All,Adults (18-64 years),18.0,,Time frame,Week of 03/02/2020,1449,0.005,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['High'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Amir Barzin,University of North Carolina Chapel Hill,Unity-Aligned,http://dx.doi.org/10.1128/mBio.02426-20,2020-12-07,2024-03-01,Verified,barzin_sars-cov-2_2020,USA
200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC2_05/04/2020,200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC2,SARS-CoV-2 seroprevalence among a southern U.S. population indicates limited asymptomatic spread under physical distancing measures,2020-09-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,inpatients patients in clinical care not related to COVID-19 or recruited to the study,,2020-05-04,2020-05-10,Residual sera,All,Adults (18-64 years),18.0,,Time frame,Week of 05/04/2020,1449,0.008,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['High'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Amir Barzin,University of North Carolina Chapel Hill,Unity-Aligned,http://dx.doi.org/10.1128/mBio.02426-20,2020-12-07,2024-03-01,Verified,barzin_sars-cov-2_2020,USA
200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC2_05/11/2020,200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC2,SARS-CoV-2 seroprevalence among a southern U.S. population indicates limited asymptomatic spread under physical distancing measures,2020-09-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,inpatients patients in clinical care not related to COVID-19 or recruited to the study,,2020-05-11,2020-05-17,Residual sera,All,Adults (18-64 years),18.0,,Time frame,Week of 05/11/2020,1449,0.0,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['High'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Amir Barzin,University of North Carolina Chapel Hill,Unity-Aligned,http://dx.doi.org/10.1128/mBio.02426-20,2020-12-07,2024-03-01,Verified,barzin_sars-cov-2_2020,USA
200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC2_04/13/2020,200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC2,SARS-CoV-2 seroprevalence among a southern U.S. population indicates limited asymptomatic spread under physical distancing measures,2020-09-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,inpatients patients in clinical care not related to COVID-19 or recruited to the study,,2020-04-13,2020-04-19,Residual sera,All,Adults (18-64 years),18.0,,Time frame,Week of 04/13/2020,1449,0.0,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['High'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Amir Barzin,University of North Carolina Chapel Hill,Unity-Aligned,http://dx.doi.org/10.1128/mBio.02426-20,2020-12-07,2024-03-01,Verified,barzin_sars-cov-2_2020,USA
200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC2_06/01/2020,200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC2,SARS-CoV-2 seroprevalence among a southern U.S. population indicates limited asymptomatic spread under physical distancing measures,2020-09-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,inpatients patients in clinical care not related to COVID-19 or recruited to the study,,2020-06-01,2020-06-04,Residual sera,All,Adults (18-64 years),18.0,,Time frame,Week of 06/01/2020,1449,0.0,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['High'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Amir Barzin,University of North Carolina Chapel Hill,Unity-Aligned,http://dx.doi.org/10.1128/mBio.02426-20,2020-12-07,2024-03-01,Verified,barzin_sars-cov-2_2020,USA
200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC2_03/30/2020,200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC2,SARS-CoV-2 seroprevalence among a southern U.S. population indicates limited asymptomatic spread under physical distancing measures,2020-09-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,inpatients patients in clinical care not related to COVID-19 or recruited to the study,,2020-03-30,2020-04-05,Residual sera,All,Adults (18-64 years),18.0,,Time frame,Week of 03/30/2020,1449,0.0,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['High'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Amir Barzin,University of North Carolina Chapel Hill,Unity-Aligned,http://dx.doi.org/10.1128/mBio.02426-20,2020-12-07,2024-03-01,Verified,barzin_sars-cov-2_2020,USA
200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC2_04/06/2020,200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC2,SARS-CoV-2 seroprevalence among a southern U.S. population indicates limited asymptomatic spread under physical distancing measures,2020-09-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,inpatients patients in clinical care not related to COVID-19 or recruited to the study,,2020-04-06,2020-04-12,Residual sera,All,Adults (18-64 years),18.0,,Time frame,Week of 04/06/2020,1449,0.025,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['High'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Amir Barzin,University of North Carolina Chapel Hill,Unity-Aligned,http://dx.doi.org/10.1128/mBio.02426-20,2020-12-07,2024-03-01,Verified,barzin_sars-cov-2_2020,USA
200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC2_04/20/2020,200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC2,SARS-CoV-2 seroprevalence among a southern U.S. population indicates limited asymptomatic spread under physical distancing measures,2020-09-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,inpatients patients in clinical care not related to COVID-19 or recruited to the study,,2020-04-20,2020-04-26,Residual sera,All,Adults (18-64 years),18.0,,Time frame,Week of 04/20/2020,1449,0.005,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['High'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Amir Barzin,University of North Carolina Chapel Hill,Unity-Aligned,http://dx.doi.org/10.1128/mBio.02426-20,2020-12-07,2024-03-01,Verified,barzin_sars-cov-2_2020,USA
200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC2_04/27/2020,200929_NorthCarolina_UniversityofNorthCarolinaChapelHill_ScreenNC2,SARS-CoV-2 seroprevalence among a southern U.S. population indicates limited asymptomatic spread under physical distancing measures,2020-09-29,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,inpatients patients in clinical care not related to COVID-19 or recruited to the study,,2020-04-27,2020-05-03,Residual sera,All,Adults (18-64 years),18.0,,Time frame,Week of 04/27/2020,1449,0.026000000000000002,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Whole Blood,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['High'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Amir Barzin,University of North Carolina Chapel Hill,Unity-Aligned,http://dx.doi.org/10.1128/mBio.02426-20,2020-12-07,2024-03-01,Verified,barzin_sars-cov-2_2020,USA
201005_Wisconsin_UW-Madison_overall,201005_Wisconsin_UW-Madison,"Less than 2% of Wisconsinites have coronavirus antibodies, preliminary results from study show",2020-10-05,News and Media,Regional,Cross-sectional survey ,United States of America,Wisconsin,,"The sample was chosen from people who had previously been recruited for the Survey of the Health of Wisconsin (SHOW) , a statewide research survey out of UW-Madison that collects data on health and health determinants.

More info about SHOW sampling: https://show.wisc.edu/services/survey-methods/",,2020-07-15,2020-08-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,1056,0.016,,,True,,,,True,Stratified probability,Not reported/ Unable to specify,,,,,,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,Madeline Heim,UW-Madison,Not Unity-Aligned,https://www.postcrescent.com/story/news/2020/10/05/wisconsin-covid-19-less-than-2-of-state-population-have-antibodies/3457334001/,2021-03-07,2022-07-16,Verified,heim_wisconsin_2020,USA
201013_Pittsburgh_UniversityPittsburgh_PedImmunocompPatients_Overall,201013_Pittsburgh_UniversityPittsburgh,Immunocompromised Seroprevalence and Course of Illness of SARS-CoV-2 in One Pediatric Quaternary Care Center,2020-10-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Pennsylvania,Pittsburgh,"Samples included were from patients aged less than 19 years old who had an underlying condition for which they were immunocompromised, including SOT, BMT, oncologic diagnosis on active chemotherapy, primary immunodeficiency, and rheumatologic condition or inflammatory bowel disease on systemic immunosuppression.","Patients were excluded if they were below the age of 6  months (due to maternal antibody confounding), had a prolonged hospitalization of greater than 30 days at the time of blood collection (due to lack of community exposure), and if they were receiving treatments that would specifically interfere with antibody production or profile (i.e., intravenous or subcutaneous immunoglobulin, rituximab, or bortezomib) in the 6 months prior to sample collection.",2020-03-15,2020-07-04,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),1.0,19.0,Primary Estimate,,485,0.01,0.003,0.024,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,ADVIA Centaur Immunoassay System","EUROIMMUN,Beckman Coulter,Siemens",ELISA,Serum,IgG,,,,,['High'],Yes,No,No,Yes,No,Unclear,Yes,No,,Megan Freeman,University of Pittsburgh School of Medicine,Not Unity-Aligned,http://dx.doi.org/10.1093/jpids/piaa123,2021-01-07,2024-03-01,Verified,freeman_immunocompromised_2020,USA
201013_PimaCounty_UniversityofArizona_Overall,201013_PimaCounty_UniversityofArizona,Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity,2020-10-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Arizona,,"General population responding to UArizona Antibody testing survey, Afebrile and without COVID-19 symptoms based on questionnaire",Under 18 or did not consent to give blood. Currently febrile or otherwise symptomatic patients were excluded from the general population sample.,2020-04-30,2020-05-07,Household and community samples,All,Multiple groups,18.0,85.0,Primary Estimate,,5882,0.0124,,,True,,,,True,Self-referral,Not reported/ Unable to specify,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.976,1.0,['Moderate'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Tyler Ripperger,University of Arizona,Not Unity-Aligned,http://dx.doi.org/10.1016/j.immuni.2020.10.004,2020-12-18,2022-07-16,Verified,ripperger_orthogonal_2020-1,USA
201013_PimaCounty_UniversityofArizona_Neutralizing,201013_PimaCounty_UniversityofArizona,Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity,2020-10-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Arizona,,"General population responding to UArizona Antibody testing survey, Afebrile and without COVID-19 symptoms based on questionnaire",Under 18 or did not consent to give blood. Currently febrile or otherwise symptomatic patients were excluded from the general population sample.,2020-04-30,2020-05-07,Household and community samples,All,Multiple groups,18.0,85.0,Test used,Neutralizing,5882,0.0015,,,,,,,,Self-referral,Not reported/ Unable to specify,,Multiple Types,Serum,"['IgG', 'IgM', 'Neutralizing']",Spike,Validated by manufacturers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Tyler Ripperger,University of Arizona,Not Unity-Aligned,http://dx.doi.org/10.1016/j.immuni.2020.10.004,2021-02-27,2022-07-16,Verified,ripperger_orthogonal_2020-1,USA
201015_BronxNY_AlbertEinsteinCollegeofMedicine_KidneyTransplantlPatients,201015_BronxNY_AlbertEinsteinCollegeofMedicine,COVID-19 infection in kidney transplant recipients at the epicenter of pandemics,2020-10-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,kidney transplant recipients,,2020-05-03,2020-07-29,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),,,Primary Estimate,,912,0.1666,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,1.0,['Moderate'],Yes,No,Yes,No,No,Yes,Yes,Yes,,Yorg Azzi,Albert Einstein College of Medicine,Not Unity-Aligned,http://dx.doi.org/10.1016/j.kint.2020.10.004,2021-01-13,2024-03-01,Verified,azzi_covid-19_2020,USA
201015_NewYorkCity_NYCHealth+Hospitals/Lincoln_Overall,201015_NewYorkCity_NYC Health+Hospitals/Lincoln,SARS-CoV-2 Seroprevalence Among Health Care Workers in a New York City Hospital: A Cross-Sectional Analysis During the COVID-19 Pandemic,2020-10-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"HCWs across all hospital services who worked at the level one trauma center in the South Bronx during the period from March 1 to May 1, 2020",,2020-03-01,2020-05-01,Health care workers and caregivers,All,Adults (18-64 years),20.0,,Primary Estimate,Overall primary estimate,500,0.27,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['High'],Yes,No,No,Yes,Yes,Yes,Yes,Yes,Yes,Usha Venugopal,NYC Health + Hospitals/Lincoln,Not Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2020.10.036,2020-12-19,2024-03-01,Verified,venugopal_sars-cov-2_2020,USA
201015_NewYorkCity_NYCHealth+Hospitals/Lincoln_60+,201015_NewYorkCity_NYC Health+Hospitals/Lincoln,SARS-CoV-2 Seroprevalence Among Health Care Workers in a New York City Hospital: A Cross-Sectional Analysis During the COVID-19 Pandemic,2020-10-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"HCWs across all hospital services who worked at the level one trauma center in the South Bronx during the period from March 1 to May 1, 2020",,2020-03-01,2020-05-01,Health care workers and caregivers,All,Seniors (65+ years),60.0,,Age,Age 60 and over,52,0.23,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['High'],Yes,No,No,Yes,Yes,Yes,Yes,Yes,Yes,Usha Venugopal,NYC Health + Hospitals/Lincoln,Not Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2020.10.036,2020-12-19,2024-03-01,Verified,venugopal_sars-cov-2_2020,USA
201015_NewYorkCity_NYCHealth+Hospitals/Lincoln_40-59,201015_NewYorkCity_NYC Health+Hospitals/Lincoln,SARS-CoV-2 Seroprevalence Among Health Care Workers in a New York City Hospital: A Cross-Sectional Analysis During the COVID-19 Pandemic,2020-10-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"HCWs across all hospital services who worked at the level one trauma center in the South Bronx during the period from March 1 to May 1, 2020",,2020-03-01,2020-05-01,Health care workers and caregivers,All,Adults (18-64 years),40.0,59.0,Age,Age 40-59,196,0.3061,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['High'],Yes,No,No,Yes,Yes,Yes,Yes,Yes,Yes,Usha Venugopal,NYC Health + Hospitals/Lincoln,Not Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2020.10.036,2020-12-19,2024-03-01,Verified,venugopal_sars-cov-2_2020,USA
201015_NewYorkCity_NYCHealth+Hospitals/Lincoln_20-39,201015_NewYorkCity_NYC Health+Hospitals/Lincoln,SARS-CoV-2 Seroprevalence Among Health Care Workers in a New York City Hospital: A Cross-Sectional Analysis During the COVID-19 Pandemic,2020-10-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"HCWs across all hospital services who worked at the level one trauma center in the South Bronx during the period from March 1 to May 1, 2020",,2020-03-01,2020-05-01,Health care workers and caregivers,All,Adults (18-64 years),20.0,39.0,Age,Age 20-39,230,0.25,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['High'],Yes,No,No,Yes,Yes,Yes,Yes,Yes,Yes,Usha Venugopal,NYC Health + Hospitals/Lincoln,Not Unity-Aligned,http://dx.doi.org/10.1016/j.ijid.2020.10.036,2020-12-19,2024-03-01,Verified,venugopal_sars-cov-2_2020,USA
201216_Seattle_WashingtonUniversity_fishermen_unadjusted,201216_Seattle_WashingtonUniversity,Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate,2020-10-21,Journal Article (Peer-Reviewed),Local,Retrospective cohort,United States of America,Washington,Seattle,"Crew from a fishing vessel that departed from Seattle, Washington, in May 2020",,2020-05-01,2020-05-31,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,Pre-outbreak,120,0.05,,,,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,No,No,No,Yes,Yes,Yes,Yes,Amin Addetia,University of Washington,Not Unity-Aligned,https://jcm.asm.org/content/58/11/e02107-20,2020-12-16,2024-03-01,Verified,addetia_neutralizing_2020,USA
201021_NewYork_Serimmune_Overall,201021_NewYork_Serimmune,Prevalence of antibodies to SARS-CoV-2 in healthy blood donors in New York,2020-10-21,Preprint,Local,Cross-sectional survey ,United States of America,New York,New York City,Individuals who were suspected of having COVID-19 were deferred from donation for 14 days after resolution of symptoms.,"Currently symptomatic were deferred, not excluded: healthy but history of covid was OK",2020-03-01,2020-07-07,Blood donors,All,Multiple groups,17.0,80.0,Primary Estimate,Primary ,1559,0.04360000000000001,,,True,,,,True,Sequential,Serum Epitope Repertoire Analysis (SERA),Serimmune,Other,Whole Blood,IgG,,Validated by manufacturers,0.91,0.993,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Kathy Kamath,Serimmune,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.19.20215368v1,2020-12-18,2022-07-16,Verified,kamath_prevalence_2020,USA
201021_NewYork_Serimmune_Overall_July,201021_NewYork_Serimmune,Prevalence of antibodies to SARS-CoV-2 in healthy blood donors in New York,2020-10-21,Preprint,Local,Cross-sectional survey ,United States of America,New York,New York City,Individuals who were suspected of having COVID-19 were deferred from donation for 14 days after resolution of symptoms.,"Currently symptomatic were deferred, not excluded: healthy but history of covid was OK",2020-06-24,2020-07-07,Blood donors,All,Multiple groups,17.0,80.0,Time frame,"Samples shipped on July 7, 2020",69,0.11599999999999999,0.06,0.212,,,,,,Sequential,Serum Epitope Repertoire Analysis (SERA),Serimmune,Other,Whole Blood,IgG,,Validated by manufacturers,0.91,0.993,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Kathy Kamath,Serimmune,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.19.20215368v1,2020-12-18,2022-07-16,Verified,kamath_prevalence_2020,USA
201021_NewYork_Serimmune_Overall_ELISA,201021_NewYork_Serimmune,Prevalence of antibodies to SARS-CoV-2 in healthy blood donors in New York,2020-10-21,Preprint,Local,Cross-sectional survey ,United States of America,New York,New York City,Individuals who were suspected of having COVID-19 were deferred from donation for 14 days after resolution of symptoms.,"Currently symptomatic were deferred, not excluded: healthy but history of covid was OK",2020-03-01,2020-07-07,Blood donors,All,Multiple groups,17.0,80.0,Test used,Follow up ELISA analysis,1559,0.0366,,,,,,,,Sequential,Serum Epitope Repertoire Analysis (SERA),Serimmune,ELISA,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Kathy Kamath,Serimmune,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.19.20215368v1,2020-12-18,2022-07-16,Verified,kamath_prevalence_2020,USA
201021_NewYork_Serimmune_Overall_EndofMarch,201021_NewYork_Serimmune,Prevalence of antibodies to SARS-CoV-2 in healthy blood donors in New York,2020-10-21,Preprint,Local,Cross-sectional survey ,United States of America,New York,New York City,Individuals who were suspected of having COVID-19 were deferred from donation for 14 days after resolution of symptoms.,"Currently symptomatic were deferred, not excluded: healthy but history of covid was OK",2020-03-11,2020-03-25,Blood donors,All,Multiple groups,17.0,80.0,Time frame,"Samples shipped on March 26, 2020",250,0.008,0.002,0.028999999999999998,,,,,,Sequential,Serum Epitope Repertoire Analysis (SERA),Serimmune,Other,Whole Blood,IgG,,Validated by manufacturers,0.91,0.993,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Kathy Kamath,Serimmune,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.19.20215368v1,2020-12-18,2022-07-16,Verified,kamath_prevalence_2020,USA
201021_NewYork_Serimmune_Overall_March,201021_NewYork_Serimmune,Prevalence of antibodies to SARS-CoV-2 in healthy blood donors in New York,2020-10-21,Preprint,Local,Cross-sectional survey ,United States of America,New York,New York City,Individuals who were suspected of having COVID-19 were deferred from donation for 14 days after resolution of symptoms.,"Currently symptomatic were deferred, not excluded: healthy but history of covid was OK",2020-03-01,2020-03-11,Blood donors,All,Multiple groups,17.0,80.0,Time frame,"Samples shipped on March 12, 2020",250,0.0,0.0,0.015,,,,,,Sequential,Serum Epitope Repertoire Analysis (SERA),Serimmune,Other,Whole Blood,IgG,,Validated by manufacturers,0.91,0.993,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Kathy Kamath,Serimmune,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.19.20215368v1,2020-12-18,2022-07-16,Verified,kamath_prevalence_2020,USA
201021_NewYork_Serimmune_Overall_MidApril,201021_NewYork_Serimmune,Prevalence of antibodies to SARS-CoV-2 in healthy blood donors in New York,2020-10-21,Preprint,Local,Cross-sectional survey ,United States of America,New York,New York City,Individuals who were suspected of having COVID-19 were deferred from donation for 14 days after resolution of symptoms.,"Currently symptomatic were deferred, not excluded: healthy but history of covid was OK",2020-03-26,2020-04-15,Blood donors,All,Multiple groups,17.0,80.0,Time frame,"Samples shipped on April 16, 2020",249,0.02,0.009000000000000001,0.046,,,,,,Sequential,Serum Epitope Repertoire Analysis (SERA),Serimmune,Other,Whole Blood,IgG,,Validated by manufacturers,0.91,0.993,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Kathy Kamath,Serimmune,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.19.20215368v1,2020-12-18,2022-07-16,Verified,kamath_prevalence_2020,USA
201021_NewYork_Serimmune_Overall_EndofMay,201021_NewYork_Serimmune,Prevalence of antibodies to SARS-CoV-2 in healthy blood donors in New York,2020-10-21,Preprint,Local,Cross-sectional survey ,United States of America,New York,New York City,Individuals who were suspected of having COVID-19 were deferred from donation for 14 days after resolution of symptoms.,"Currently symptomatic were deferred, not excluded: healthy but history of covid was OK",2020-04-16,2020-05-27,Blood donors,All,Multiple groups,17.0,80.0,Time frame,"Samples shipped on May 28, 2020",247,0.061,0.037000000000000005,0.098,,,,,,Sequential,Serum Epitope Repertoire Analysis (SERA),Serimmune,Other,Whole Blood,IgG,,Validated by manufacturers,0.91,0.993,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Kathy Kamath,Serimmune,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.19.20215368v1,2020-12-18,2022-07-16,Verified,kamath_prevalence_2020,USA
201021_NewYork_Serimmune_Overall_June,201021_NewYork_Serimmune,Prevalence of antibodies to SARS-CoV-2 in healthy blood donors in New York,2020-10-21,Preprint,Local,Cross-sectional survey ,United States of America,New York,New York City,Individuals who were suspected of having COVID-19 were deferred from donation for 14 days after resolution of symptoms.,"Currently symptomatic were deferred, not excluded: healthy but history of covid was OK",2020-05-28,2020-06-09,Blood donors,All,Multiple groups,17.0,80.0,Time frame,"Samples shipped on June 10, 2020",249,0.08,0.053,0.12,,,,,,Sequential,Serum Epitope Repertoire Analysis (SERA),Serimmune,Other,Whole Blood,IgG,,Validated by manufacturers,0.91,0.993,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Kathy Kamath,Serimmune,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.19.20215368v1,2020-12-18,2022-07-16,Verified,kamath_prevalence_2020,USA
201021_NewYork_Serimmune_Overall_EndofJune,201021_NewYork_Serimmune,Prevalence of antibodies to SARS-CoV-2 in healthy blood donors in New York,2020-10-21,Preprint,Local,Cross-sectional survey ,United States of America,New York,New York City,Individuals who were suspected of having COVID-19 were deferred from donation for 14 days after resolution of symptoms.,"Currently symptomatic were deferred, not excluded: healthy but history of covid was OK",2020-06-10,2020-06-23,Blood donors,All,Multiple groups,17.0,80.0,Time frame,"Samples shipped on June 24, 2020",245,0.073,0.047,0.113,,,,,,Sequential,Serum Epitope Repertoire Analysis (SERA),Serimmune,Other,Whole Blood,IgG,,Validated by manufacturers,0.91,0.993,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Kathy Kamath,Serimmune,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.19.20215368v1,2020-12-18,2022-07-16,Verified,kamath_prevalence_2020,USA
201023_BatonRouge_LouisianaStateUniversity_Total_popadj,201023_BatonRouge_LouisianaStateUniversity,"Racial and Workplace Disparities in Seroprevalence of SARS-CoV-2, Baton Rouge, Louisiana, USA",2020-10-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Louisiana,Baton Rouge,"In this study, we invited all paid employees to participate in a serologic survey and questionnaire at the Veterans Affairs Ann Arbor Healthcare System (VAAAHS) from June 8 to July 8, 2020, after the first wave of SARS-CoV-2 infection during March through May 2020.",Living an ineligible ZIP codes,2020-07-15,2020-07-31,Household and community samples,All,Multiple groups,18.0,91.0,Primary Estimate,,2138,0.036000000000000004,0.027999999999999997,0.044000000000000004,True,,True,,True,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,,,,,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Amy K Feehan,Louisiana State University,Unity-Aligned,https://dx.doi.org/10.3201/eid2701.203808,2020-11-04,2024-03-01,Verified,feehan_racial_2021,USA
201023_BatonRouge_LouisianaStateUniversity_White,201023_BatonRouge_LouisianaStateUniversity,"Racial and Workplace Disparities in Seroprevalence of SARS-CoV-2, Baton Rouge, Louisiana, USA",2020-10-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Louisiana,Baton Rouge,"In this study, we invited all paid employees to participate in a serologic survey and questionnaire at the Veterans Affairs Ann Arbor Healthcare System (VAAAHS) from June 8 to July 8, 2020, after the first wave of SARS-CoV-2 infection during March through May 2020.",Living an ineligible ZIP codes,2020-07-15,2020-07-31,Household and community samples,All,Multiple groups,18.0,91.0,Race,White,1431,0.018000000000000002,0.011000000000000001,0.025,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,,,,,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Amy K Feehan,Louisiana State University,Unity-Aligned,https://dx.doi.org/10.3201/eid2701.203808,2021-04-23,2024-03-01,Verified,feehan_racial_2021,USA
201023_BatonRouge_LouisianaStateUniversity_Asian,201023_BatonRouge_LouisianaStateUniversity,"Racial and Workplace Disparities in Seroprevalence of SARS-CoV-2, Baton Rouge, Louisiana, USA",2020-10-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Louisiana,Baton Rouge,"In this study, we invited all paid employees to participate in a serologic survey and questionnaire at the Veterans Affairs Ann Arbor Healthcare System (VAAAHS) from June 8 to July 8, 2020, after the first wave of SARS-CoV-2 infection during March through May 2020.",Living an ineligible ZIP codes,2020-07-15,2020-07-31,Household and community samples,All,Multiple groups,18.0,91.0,Race,Asian,59,0.017,0.0,0.091,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,,,,,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Amy K Feehan,Louisiana State University,Unity-Aligned,https://dx.doi.org/10.3201/eid2701.203808,2021-04-23,2024-03-01,Verified,feehan_racial_2021,USA
201023_BatonRouge_LouisianaStateUniversity_Otherrace,201023_BatonRouge_LouisianaStateUniversity,"Racial and Workplace Disparities in Seroprevalence of SARS-CoV-2, Baton Rouge, Louisiana, USA",2020-10-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Louisiana,Baton Rouge,"In this study, we invited all paid employees to participate in a serologic survey and questionnaire at the Veterans Affairs Ann Arbor Healthcare System (VAAAHS) from June 8 to July 8, 2020, after the first wave of SARS-CoV-2 infection during March through May 2020.",Living an ineligible ZIP codes,2020-07-15,2020-07-31,Household and community samples,All,Multiple groups,18.0,91.0,Race,Other race,28,0.027000000000000003,0.0,0.087,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,,,,,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Amy K Feehan,Louisiana State University,Unity-Aligned,https://dx.doi.org/10.3201/eid2701.203808,2021-04-23,2024-03-01,Verified,feehan_racial_2021,USA
201023_BatonRouge_LouisianaStateUniversity_Black,201023_BatonRouge_LouisianaStateUniversity,"Racial and Workplace Disparities in Seroprevalence of SARS-CoV-2, Baton Rouge, Louisiana, USA",2020-10-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Louisiana,Baton Rouge,"In this study, we invited all paid employees to participate in a serologic survey and questionnaire at the Veterans Affairs Ann Arbor Healthcare System (VAAAHS) from June 8 to July 8, 2020, after the first wave of SARS-CoV-2 infection during March through May 2020.",Living an ineligible ZIP codes,2020-07-15,2020-07-31,Household and community samples,All,Multiple groups,18.0,91.0,Race,Black,516,0.075,0.052000000000000005,0.098,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,,,,,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Amy K Feehan,Louisiana State University,Unity-Aligned,https://dx.doi.org/10.3201/eid2701.203808,2021-04-23,2024-03-01,Verified,feehan_racial_2021,USA
201023_BatonRouge_LouisianaStateUniversity_Hispanic or Latino,201023_BatonRouge_LouisianaStateUniversity,"Racial and Workplace Disparities in Seroprevalence of SARS-CoV-2, Baton Rouge, Louisiana, USA",2020-10-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Louisiana,Baton Rouge,"In this study, we invited all paid employees to participate in a serologic survey and questionnaire at the Veterans Affairs Ann Arbor Healthcare System (VAAAHS) from June 8 to July 8, 2020, after the first wave of SARS-CoV-2 infection during March through May 2020.",Living an ineligible ZIP codes,2020-07-15,2020-07-31,Household and community samples,All,Multiple groups,18.0,91.0,Ethnicity,"Hispanic or Latino, any race",104,0.016,0.0,0.04,,,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,,,,,['Low'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Amy K Feehan,Louisiana State University,Unity-Aligned,https://dx.doi.org/10.3201/eid2701.203808,2021-04-23,2024-03-01,Verified,feehan_racial_2021,USA
201026_UpstateNewYork_BassettMedicalCenter_Overall,201026_UpstateNewYork_BassettMedicalCenter_Staff2,SARS-CoV-2 IgG Results Among Healthcare Workers in a Rural Upstate New York Hospital System,2020-10-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,Upstate New York,"We surveyed and antibody tested employees of Bassett Healthcare Network. A 21.7% random sample of employees was also included for antibody testing to ensure that our seroprevalence estimate was representative of all network
employees.",,2020-05-04,2020-05-29,Health care workers and caregivers,All,Multiple groups,19.0,78.0,Primary Estimate,,764,0.02,,,True,,,,True,Unclear,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,,Validated by independent authors/third party/non-developers,1.0,0.996,['High'],Yes,Unclear,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Wendy M Brunner,Bassett Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2020.1296,2020-12-28,2024-03-01,Verified,brunner_severe_2020,USA
201026_UpstateNewYork_BassettMedicalCenter_Overall copy,201026_UpstateNewYork_BassettMedicalCenter_patients1,SARS-CoV-2 IgG Results Among Healthcare Workers in a Rural Upstate New York Hospital System,2020-10-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,Upstate New York,"We compared seroprevalence among employees to that for
patients tested during the same period.",,2020-05-04,2020-05-29,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,762,0.045,,,True,,,,True,Unclear,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,,IgG,,Validated by independent authors/third party/non-developers,1.0,0.996,['High'],Unclear,Unclear,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Wendy M Brunner,Bassett Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2020.1296,2021-02-27,2024-03-01,Verified,brunner_severe_2020,USA
201028_Connecticut_YaleSchoolOfMedicine_Black2Overall_PopAdj,201028_Connecticut_YaleSchoolOfMedicine_Black2,Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study,2020-10-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Connecticut,,"aged ≥18 years, residing in non-congregate settings who completed both the survey and the serology test.","excluding individuals living in long-term care facilities, assisted living, facilities, nursing homes, and prisons or jails),",2020-06-23,2020-07-22,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,148,0.064,0.009000000000000001,0.11900000000000001,True,,True,,True,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,Yes,No,Yes,No,Yes,Yes,Yes,No,Shiwani Mahajan,Yale School of Medicine,Unity-Aligned,http://dx.doi.org/10.1016/j.amjmed.2020.09.024,2021-03-13,2024-03-01,Verified,mahajan_seroprevalence_2020,USA
201028_Connecticut_YaleSchoolOfMedicine_GenPop1_Overall_PopAdj,201028_Connecticut_YaleSchoolOfMedicine_Genpop1,Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study,2020-10-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Connecticut,,"aged ≥18 years, residing in non-congregate settings who completed both the survey and the serology test.","excluding individuals living in long-term care facilities, assisted living, facilities, nursing homes, and prisons or jails),",2020-06-04,2020-06-23,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,Adjustment: population,567,0.04,0.02,0.06,True,,True,,True,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Shiwani Mahajan,Yale School of Medicine,Unity-Aligned,http://dx.doi.org/10.1016/j.amjmed.2020.09.024,2020-09-24,2024-03-01,Verified,mahajan_seroprevalence_2020,USA
201028_Connecticut_YaleSchoolOfMedicine_GenPop1_race_black_PopAdj,201028_Connecticut_YaleSchoolOfMedicine_Genpop1,Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study,2020-10-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Connecticut,,"aged ≥18 years, residing in non-congregate settings who completed both the survey and the serology test.","excluding individuals living in long-term care facilities, assisted living, facilities, nursing homes, and prisons or jails),",2020-06-04,2020-06-23,Household and community samples,All,Multiple groups,18.0,,Race,Non-hispanic black,37,0.026000000000000002,,,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Shiwani Mahajan,Yale School of Medicine,Unity-Aligned,http://dx.doi.org/10.1016/j.amjmed.2020.09.024,2021-03-13,2024-03-01,Verified,mahajan_seroprevalence_2020,USA
201028_Connecticut_YaleSchoolOfMedicine_GenPop1_Litchfield_PopAdj,201028_Connecticut_YaleSchoolOfMedicine_Genpop1,Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study,2020-10-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Connecticut,,"aged ≥18 years, residing in non-congregate settings who completed both the survey and the serology test.","excluding individuals living in long-term care facilities, assisted living, facilities, nursing homes, and prisons or jails),",2020-06-04,2020-06-23,Household and community samples,All,Multiple groups,18.0,,Geographical area,Litchfield,42,0.016,,,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Shiwani Mahajan,Yale School of Medicine,Unity-Aligned,http://dx.doi.org/10.1016/j.amjmed.2020.09.024,2021-03-13,2024-03-01,Verified,mahajan_seroprevalence_2020,USA
201028_Connecticut_YaleSchoolOfMedicine_GenPop1_Overall_UnAdj,201028_Connecticut_YaleSchoolOfMedicine_Genpop1,Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study,2020-10-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Connecticut,,"aged ≥18 years, residing in non-congregate settings who completed both the survey and the serology test.","excluding individuals living in long-term care facilities, assisted living, facilities, nursing homes, and prisons or jails),",2020-06-04,2020-06-23,Household and community samples,All,Multiple groups,18.0,,Analysis,Unadjusted,567,0.040999999999999995,,,,,,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Shiwani Mahajan,Yale School of Medicine,Unity-Aligned,http://dx.doi.org/10.1016/j.amjmed.2020.09.024,2020-09-24,2024-03-01,Verified,mahajan_seroprevalence_2020,USA
201028_Connecticut_YaleSchoolOfMedicine_GenPop1_age_65+_UnAdj,201028_Connecticut_YaleSchoolOfMedicine_Genpop1,Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study,2020-10-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Connecticut,,"aged ≥18 years, residing in non-congregate settings who completed both the survey and the serology test.","excluding individuals living in long-term care facilities, assisted living, facilities, nursing homes, and prisons or jails),",2020-06-04,2020-06-23,Household and community samples,All,Seniors (65+ years),65.0,,Age,65+ years,187,0.011000000000000001,,,,,,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Shiwani Mahajan,Yale School of Medicine,Unity-Aligned,http://dx.doi.org/10.1016/j.amjmed.2020.09.024,2020-12-17,2024-03-01,Verified,mahajan_seroprevalence_2020,USA
201028_Connecticut_YaleSchoolOfMedicine_GenPop1_age_30-44_PopAdj,201028_Connecticut_YaleSchoolOfMedicine_Genpop1,Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study,2020-10-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Connecticut,,"aged ≥18 years, residing in non-congregate settings who completed both the survey and the serology test.","excluding individuals living in long-term care facilities, assisted living, facilities, nursing homes, and prisons or jails),",2020-06-04,2020-06-23,Household and community samples,All,Adults (18-64 years),30.0,44.0,Age,30-44,90,0.049,,,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Shiwani Mahajan,Yale School of Medicine,Unity-Aligned,http://dx.doi.org/10.1016/j.amjmed.2020.09.024,2020-12-17,2024-03-01,Verified,mahajan_seroprevalence_2020,USA
201028_Connecticut_YaleSchoolOfMedicine_GenPop1_age_55-64_PopAdj,201028_Connecticut_YaleSchoolOfMedicine_Genpop1,Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study,2020-10-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Connecticut,,"aged ≥18 years, residing in non-congregate settings who completed both the survey and the serology test.","excluding individuals living in long-term care facilities, assisted living, facilities, nursing homes, and prisons or jails),",2020-06-04,2020-06-23,Household and community samples,All,Adults (18-64 years),55.0,64.0,Age,55-64,134,0.026000000000000002,,,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Shiwani Mahajan,Yale School of Medicine,Unity-Aligned,http://dx.doi.org/10.1016/j.amjmed.2020.09.024,2020-12-17,2024-03-01,Verified,mahajan_seroprevalence_2020,USA
201028_Connecticut_YaleSchoolOfMedicine_GenPop1_age_30-44_UnAdj,201028_Connecticut_YaleSchoolOfMedicine_Genpop1,Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study,2020-10-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Connecticut,,"aged ≥18 years, residing in non-congregate settings who completed both the survey and the serology test.","excluding individuals living in long-term care facilities, assisted living, facilities, nursing homes, and prisons or jails),",2020-06-04,2020-06-23,Household and community samples,All,Adults (18-64 years),30.0,44.0,Age,30-44 unadjusted,90,0.044000000000000004,,,,,,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Shiwani Mahajan,Yale School of Medicine,Unity-Aligned,http://dx.doi.org/10.1016/j.amjmed.2020.09.024,2020-12-17,2024-03-01,Verified,mahajan_seroprevalence_2020,USA
201028_Connecticut_YaleSchoolOfMedicine_GenPop1_sex_men_UnAdj,201028_Connecticut_YaleSchoolOfMedicine_Genpop1,Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study,2020-10-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Connecticut,,"aged ≥18 years, residing in non-congregate settings who completed both the survey and the serology test.","excluding individuals living in long-term care facilities, assisted living, facilities, nursing homes, and prisons or jails),",2020-06-04,2020-06-23,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,244,0.033,,,,,,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Shiwani Mahajan,Yale School of Medicine,Unity-Aligned,http://dx.doi.org/10.1016/j.amjmed.2020.09.024,2020-12-17,2024-03-01,Verified,mahajan_seroprevalence_2020,USA
201028_Connecticut_YaleSchoolOfMedicine_GenPop1_age_45-54_PopAdj,201028_Connecticut_YaleSchoolOfMedicine_Genpop1,Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study,2020-10-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Connecticut,,"aged ≥18 years, residing in non-congregate settings who completed both the survey and the serology test.","excluding individuals living in long-term care facilities, assisted living, facilities, nursing homes, and prisons or jails),",2020-06-04,2020-06-23,Household and community samples,All,Adults (18-64 years),45.0,54.0,Age,45-54,113,0.066,,,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Shiwani Mahajan,Yale School of Medicine,Unity-Aligned,http://dx.doi.org/10.1016/j.amjmed.2020.09.024,2020-12-17,2024-03-01,Verified,mahajan_seroprevalence_2020,USA
201028_Connecticut_YaleSchoolOfMedicine_GenPop1_sex_female_PopAdj,201028_Connecticut_YaleSchoolOfMedicine_Genpop1,Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study,2020-10-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Connecticut,,"aged ≥18 years, residing in non-congregate settings who completed both the survey and the serology test.","excluding individuals living in long-term care facilities, assisted living, facilities, nursing homes, and prisons or jails),",2020-06-04,2020-06-23,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,Female,323,0.053,,,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Shiwani Mahajan,Yale School of Medicine,Unity-Aligned,http://dx.doi.org/10.1016/j.amjmed.2020.09.024,2020-12-17,2024-03-01,Verified,mahajan_seroprevalence_2020,USA
201028_Connecticut_YaleSchoolOfMedicine_GenPop1_age_18-29_PopAdj,201028_Connecticut_YaleSchoolOfMedicine_Genpop1,Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study,2020-10-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Connecticut,,"aged ≥18 years, residing in non-congregate settings who completed both the survey and the serology test.","excluding individuals living in long-term care facilities, assisted living, facilities, nursing homes, and prisons or jails),",2020-06-04,2020-06-23,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,18-29,41,0.064,,,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Shiwani Mahajan,Yale School of Medicine,Unity-Aligned,http://dx.doi.org/10.1016/j.amjmed.2020.09.024,2020-12-17,2024-03-01,Verified,mahajan_seroprevalence_2020,USA
201028_Connecticut_YaleSchoolOfMedicine_GenPop1_age_18-29_UnAdj,201028_Connecticut_YaleSchoolOfMedicine_Genpop1,Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study,2020-10-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Connecticut,,"aged ≥18 years, residing in non-congregate settings who completed both the survey and the serology test.","excluding individuals living in long-term care facilities, assisted living, facilities, nursing homes, and prisons or jails),",2020-06-04,2020-06-23,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,18-29,41,0.049,,,,,,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Shiwani Mahajan,Yale School of Medicine,Unity-Aligned,http://dx.doi.org/10.1016/j.amjmed.2020.09.024,2020-12-17,2024-03-01,Verified,mahajan_seroprevalence_2020,USA
201028_Connecticut_YaleSchoolOfMedicine_GenPop1_NewHaven_PopAdj,201028_Connecticut_YaleSchoolOfMedicine_Genpop1,Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study,2020-10-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Connecticut,,"aged ≥18 years, residing in non-congregate settings who completed both the survey and the serology test.","excluding individuals living in long-term care facilities, assisted living, facilities, nursing homes, and prisons or jails),",2020-06-04,2020-06-23,Household and community samples,All,Multiple groups,18.0,,Geographical area,New Haven,131,0.034,,,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Shiwani Mahajan,Yale School of Medicine,Unity-Aligned,http://dx.doi.org/10.1016/j.amjmed.2020.09.024,2021-03-13,2024-03-01,Verified,mahajan_seroprevalence_2020,USA
201028_Connecticut_YaleSchoolOfMedicine_GenPop1_age_45-54_UnAdj,201028_Connecticut_YaleSchoolOfMedicine_Genpop1,Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study,2020-10-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Connecticut,,"aged ≥18 years, residing in non-congregate settings who completed both the survey and the serology test.","excluding individuals living in long-term care facilities, assisted living, facilities, nursing homes, and prisons or jails),",2020-06-04,2020-06-23,Household and community samples,All,Adults (18-64 years),45.0,54.0,Age,45-54,113,0.08,,,,,,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Shiwani Mahajan,Yale School of Medicine,Unity-Aligned,http://dx.doi.org/10.1016/j.amjmed.2020.09.024,2020-12-17,2024-03-01,Verified,mahajan_seroprevalence_2020,USA
201028_Connecticut_YaleSchoolOfMedicine_GenPop1_age_65+_PopAdj,201028_Connecticut_YaleSchoolOfMedicine_Genpop1,Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study,2020-10-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Connecticut,,"aged ≥18 years, residing in non-congregate settings who completed both the survey and the serology test.","excluding individuals living in long-term care facilities, assisted living, facilities, nursing homes, and prisons or jails),",2020-06-04,2020-06-23,Household and community samples,All,Seniors (65+ years),65.0,,Age,65+ years,187,0.008,,,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Shiwani Mahajan,Yale School of Medicine,Unity-Aligned,http://dx.doi.org/10.1016/j.amjmed.2020.09.024,2020-12-17,2024-03-01,Verified,mahajan_seroprevalence_2020,USA
201028_Connecticut_YaleSchoolOfMedicine_GenPop1_sex_female_UnAdj,201028_Connecticut_YaleSchoolOfMedicine_Genpop1,Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study,2020-10-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Connecticut,,"aged ≥18 years, residing in non-congregate settings who completed both the survey and the serology test.","excluding individuals living in long-term care facilities, assisted living, facilities, nursing homes, and prisons or jails),",2020-06-04,2020-06-23,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,Female,323,0.046,,,,,,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Shiwani Mahajan,Yale School of Medicine,Unity-Aligned,http://dx.doi.org/10.1016/j.amjmed.2020.09.024,2020-12-17,2024-03-01,Verified,mahajan_seroprevalence_2020,USA
201028_Connecticut_YaleSchoolOfMedicine_GenPop1_age_55-64_UnAdj,201028_Connecticut_YaleSchoolOfMedicine_Genpop1,Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study,2020-10-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Connecticut,,"aged ≥18 years, residing in non-congregate settings who completed both the survey and the serology test.","excluding individuals living in long-term care facilities, assisted living, facilities, nursing homes, and prisons or jails),",2020-06-04,2020-06-23,Household and community samples,All,Adults (18-64 years),55.0,64.0,Age,55-64,134,0.045,,,,,,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Shiwani Mahajan,Yale School of Medicine,Unity-Aligned,http://dx.doi.org/10.1016/j.amjmed.2020.09.024,2020-12-17,2024-03-01,Verified,mahajan_seroprevalence_2020,USA
201028_Connecticut_YaleSchoolOfMedicine_GenPop1_NewLondon_PopAdj,201028_Connecticut_YaleSchoolOfMedicine_Genpop1,Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study,2020-10-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Connecticut,,"aged ≥18 years, residing in non-congregate settings who completed both the survey and the serology test.","excluding individuals living in long-term care facilities, assisted living, facilities, nursing homes, and prisons or jails),",2020-06-04,2020-06-23,Household and community samples,All,Multiple groups,18.0,,Geographical area,New London,41,0.017,,,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Shiwani Mahajan,Yale School of Medicine,Unity-Aligned,http://dx.doi.org/10.1016/j.amjmed.2020.09.024,2021-03-13,2024-03-01,Verified,mahajan_seroprevalence_2020,USA
201028_Connecticut_YaleSchoolOfMedicine_GenPop1_sex_male_PopAdj,201028_Connecticut_YaleSchoolOfMedicine_Genpop1,Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study,2020-10-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Connecticut,,"aged ≥18 years, residing in non-congregate settings who completed both the survey and the serology test.","excluding individuals living in long-term care facilities, assisted living, facilities, nursing homes, and prisons or jails),",2020-06-04,2020-06-23,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,244,0.025,,,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Shiwani Mahajan,Yale School of Medicine,Unity-Aligned,http://dx.doi.org/10.1016/j.amjmed.2020.09.024,2020-12-17,2024-03-01,Verified,mahajan_seroprevalence_2020,USA
201028_Connecticut_YaleSchoolOfMedicine_GenPop1_ethnicity_hispanic_PopAdj,201028_Connecticut_YaleSchoolOfMedicine_Genpop1,Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study,2020-10-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Connecticut,,"aged ≥18 years, residing in non-congregate settings who completed both the survey and the serology test.","excluding individuals living in long-term care facilities, assisted living, facilities, nursing homes, and prisons or jails),",2020-06-04,2020-06-23,Household and community samples,All,Multiple groups,18.0,,Ethnicity,hispanic ,49,0.128,,,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Shiwani Mahajan,Yale School of Medicine,Unity-Aligned,http://dx.doi.org/10.1016/j.amjmed.2020.09.024,2021-03-13,2024-03-01,Verified,mahajan_seroprevalence_2020,USA
201028_Connecticut_YaleSchoolOfMedicine_GenPop1_Fairfield_PopAdj,201028_Connecticut_YaleSchoolOfMedicine_Genpop1,Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study,2020-10-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Connecticut,,"aged ≥18 years, residing in non-congregate settings who completed both the survey and the serology test.","excluding individuals living in long-term care facilities, assisted living, facilities, nursing homes, and prisons or jails),",2020-06-04,2020-06-23,Household and community samples,All,Multiple groups,18.0,,Geographical area,Fairfield,126,0.057,,,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Shiwani Mahajan,Yale School of Medicine,Unity-Aligned,http://dx.doi.org/10.1016/j.amjmed.2020.09.024,2021-03-13,2024-03-01,Verified,mahajan_seroprevalence_2020,USA
201028_Connecticut_YaleSchoolOfMedicine_GenPop1_Hartford_PopAdj,201028_Connecticut_YaleSchoolOfMedicine_Genpop1,Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study,2020-10-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Connecticut,,"aged ≥18 years, residing in non-congregate settings who completed both the survey and the serology test.","excluding individuals living in long-term care facilities, assisted living, facilities, nursing homes, and prisons or jails),",2020-06-04,2020-06-23,Household and community samples,All,Multiple groups,18.0,,Geographical area,Hartford,157,0.04,,,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Shiwani Mahajan,Yale School of Medicine,Unity-Aligned,http://dx.doi.org/10.1016/j.amjmed.2020.09.024,2021-03-13,2024-03-01,Verified,mahajan_seroprevalence_2020,USA
201028_Connecticut_YaleSchoolOfMedicine_Hispanic3_Overall_PopAdj,201028_Connecticut_YaleSchoolOfMedicine_Hispanic3,Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study,2020-10-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Connecticut,,"aged ≥18 years, residing in non-congregate settings who completed both the survey and the serology test.","excluding individuals living in long-term care facilities, assisted living, facilities, nursing homes, and prisons or jails),",2020-06-23,2020-07-22,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,171,0.19899999999999998,0.132,0.266,True,,True,,True,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,Yes,No,Yes,No,Yes,Yes,Yes,No,Shiwani Mahajan,Yale School of Medicine,Unity-Aligned,http://dx.doi.org/10.1016/j.amjmed.2020.09.024,2021-03-13,2024-03-01,Verified,mahajan_seroprevalence_2020,USA
201030_Indianapolis_IndianaUniversity_Overall,201030_Indianapolis_IndianaUniversity,Assessment of Seroconversion to SARS-CoV-2 in a Cohort of Pediatric Kidney Transplant Recipients,2020-10-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Indiana,Indianapolis ,"Patients of any age seen in person in theroutine pediatric post-KT clinics at our institution immediatelyfollowing the end of our state’s Stay-At-Home order, in May andJune of 2020",having received blood products in the past 6 months,2020-05-01,2020-06-30,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),2.0,21.0,Primary Estimate,,31,0.032,,,True,,,,True,Convenience,"COVID-19 Human IgM IgG Assay Kit,Author designed (ELISA) -Spike","Abnova,NA",ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9440000000000001,0.985,['High'],Yes,No,No,Yes,Yes,Yes,Yes,Yes,Unclear,Corina Nailescu,Indiana University ,Not Unity-Aligned,https://dx.doi.org/10.3389/fped.2020.601327,2020-12-17,2022-07-16,Verified,nailescu_assessment_2020,USA
201030_Cleveland_CaseWesternReserveUniversity_Overall,201030_Cleveland_CaseWesternReserveUniversity,SARS-CoV-2 Infection Among Serially Tested Emergency Medical Services Workers,2020-10-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Ohio,Cleveland,"Participants were volunteer adults aged 18 and over, currently working as emer- gency services personnel from Cleveland Emergency Medical Services (EMS) and Cleveland Fire.",,2020-04-20,2020-05-19,Essential non-healthcare workers,All,Adults (18-64 years),22.0,65.0,Primary Estimate,,296,0.054000000000000006,0.031000000000000003,0.086,True,,,,True,Convenience,"EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit,EDI™ Novel Coronavirus COVID-19 IgM ELISA Kit","Epitope Diagnostics, Inc.",ELISA,Serum,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,,,['High'],Yes,No,No,Yes,Yes,Yes,Yes,No,Yes,Yasir Tarabichi,Case Western Reserve University,Not Unity-Aligned,https://dx.doi.org/10.1080/10903127.2020.1831668,2020-12-21,2024-03-01,Verified,tarabichi_sars-cov-2_2020,USA
2010330_Bolinas_UniversityofCalifornia_Abbott+ELISA,201030_Bolinas_UniversityofCalifornia,Universal polymerase chain reaction and antibody testing demonstrate little to no transmission of severe acute respiratory syndrome coronavirus 2 in a rural community,2020-10-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,Bolinas,"Bolinas, California among residents over 4 years of age and in Marin County first responders and essential workers",,2020-04-20,2020-04-24,Household and community samples,All,Multiple groups,4.0,,Primary Estimate,Abbott and ELISA positive,1880,0.0005,,,True,,,,,Self-referral,"Abbott Architect SARS-CoV-2 IgG,Author designed (ELISA) -Spike","Abbott Laboratories,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,No,No,Yes,Yes,No,Yes,Ayesha Appa,University of California San Francisco,Not Unity-Aligned,http://dx.doi.org/10.1093/ofid/ofaa531,2021-04-08,2024-03-01,Verified,appa_universal_2021,USA
2010330_Bolinas_UniversityofCalifornia_Abbott,201030_Bolinas_UniversityofCalifornia,Universal polymerase chain reaction and antibody testing demonstrate little to no transmission of severe acute respiratory syndrome coronavirus 2 in a rural community,2020-10-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,Bolinas,"Bolinas, California among residents over 4 years of age and in Marin County first responders and essential workers",,2020-04-20,2020-04-24,Household and community samples,All,Multiple groups,4.0,,Test used,Abbott only positive,1880,0.0048,,,,,,,,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9961,0.9968000000000001,['Moderate'],Yes,No,Yes,No,No,Yes,Yes,No,Yes,Ayesha Appa,University of California San Francisco,Not Unity-Aligned,http://dx.doi.org/10.1093/ofid/ofaa531,2021-04-08,2024-03-01,Verified,appa_universal_2021,USA
2010330_Bolinas_UniversityofCalifornia_ELISA,201030_Bolinas_UniversityofCalifornia,Universal polymerase chain reaction and antibody testing demonstrate little to no transmission of severe acute respiratory syndrome coronavirus 2 in a rural community,2020-10-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,Bolinas,"Bolinas, California among residents over 4 years of age and in Marin County first responders and essential workers",,2020-04-20,2020-04-24,Household and community samples,All,Multiple groups,4.0,,Test used,ELISA only positive,1880,0.0021,,,,,,,True,Self-referral,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9625,0.9988,['Moderate'],Yes,No,Yes,No,No,Yes,Yes,No,Yes,Ayesha Appa,University of California San Francisco,Not Unity-Aligned,http://dx.doi.org/10.1093/ofid/ofaa531,2021-04-08,2022-07-16,Verified,appa_universal_2021,USA
201031_NewJersey_RutgersRobertWoodJohnsonMedicalSchool,201031_NewJersey_RutgersRobertWoodJohnsonMedicalSchool,"Risk Factors for Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Hospital Workers: Results From a Screening Study in New Jersey, United States in Spring 2020.",2020-10-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New Jersey,"New Brunswick, Somerville","Robert Wood Johnson University Hospital employees and affiliated Rutgers Robert Wood Johnson Medical School (RWJMS) clinician, over 18 years old",,2020-04-28,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,3907,0.096,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9690000000000001,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Emily Barrett,Rutgers Robert Wood Johnson Medical School,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofaa534,2021-02-05,2024-03-01,Verified,barrett_risk_2020,USA
201103_NewYorkCity_MountSinai_RoutineCare_1 _Overall,201103_NewYorkCity_MountSinai_RoutineCare_1,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-02-02,2020-07-05,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,6590,0.111,,,True,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9500000000000001,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2020-06-29,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_RoutineCare_1 _WeekEndingonMay3,201103_NewYorkCity_MountSinai_RoutineCare_1,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-04-27,2020-05-03,Residual sera,All,Multiple groups,0.0,,Time frame,"Routine Patient Care Group (visiting OB/GYN, Oncology, Surgery) the week ending May 3",262,0.195,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9500000000000001,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_RoutineCare_1 _WeekEndingonApril12,201103_NewYorkCity_MountSinai_RoutineCare_1,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-04-06,2020-04-12,Residual sera,All,Multiple groups,0.0,,Time frame,"Routine Patient Care Group (visiting OB/GYN, Oncology, Surgery) the week ending April 12",231,0.11699999999999999,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9500000000000001,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_RoutineCare_1 _WeekEndingonMarch1,201103_NewYorkCity_MountSinai_RoutineCare_1,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-02-24,2020-03-01,Residual sera,All,Multiple groups,0.0,,Time frame,"Routine Patient Care Group (visiting OB/GYN, Oncology, Surgery) the week ending March 1",403,0.02,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9500000000000001,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_RoutineCare_1 _WeekEndingonMarch29,201103_NewYorkCity_MountSinai_RoutineCare_1,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-03-23,2020-03-29,Residual sera,All,Multiple groups,0.0,,Time frame,"Routine Patient Care Group (visiting OB/GYN, Oncology, Surgery) the week ending March 29",412,0.022000000000000002,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9500000000000001,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_RoutineCare_1 _WeekEndingonJune14,201103_NewYorkCity_MountSinai_RoutineCare_1,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-06-08,2020-06-14,Residual sera,All,Multiple groups,0.0,,Time frame,"Routine Patient Care Group (visiting OB/GYN, Oncology, Surgery) the week ending June 14",309,0.184,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9500000000000001,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_RoutineCare_1 _WeekEndingonFeb16,201103_NewYorkCity_MountSinai_RoutineCare_1,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-02-09,2020-02-16,Residual sera,All,Multiple groups,0.0,,Time frame,"Routine Patient Care Group (visiting OB/GYN, Oncology, Surgery) the week ending Feb 16 2020",13,0.0,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9500000000000001,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_RoutineCare_1 _WeekEndingonApril19,201103_NewYorkCity_MountSinai_RoutineCare_1,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-04-13,2020-04-19,Residual sera,All,Multiple groups,0.0,,Time frame,"Routine Patient Care Group (visiting OB/GYN, Oncology, Surgery) the week ending April 19",241,0.19100000000000003,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9500000000000001,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_RoutineCare_1 _WeekEndingonMarch8,201103_NewYorkCity_MountSinai_RoutineCare_1,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-03-02,2020-03-08,Residual sera,All,Multiple groups,0.0,,Time frame,"Routine Patient Care Group (visiting OB/GYN, Oncology, Surgery) the week ending March 8",407,0.005,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9500000000000001,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_RoutineCare_1 _WeekEndingonMarch22,201103_NewYorkCity_MountSinai_RoutineCare_1,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-03-16,2020-03-22,Residual sera,All,Multiple groups,0.0,,Time frame,"Routine Patient Care Group (visiting OB/GYN, Oncology, Surgery) the week ending March 22",425,0.017,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9500000000000001,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_RoutineCare_1 _WeekEndingonJuly5,201103_NewYorkCity_MountSinai_RoutineCare_1,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-06-29,2020-07-05,Residual sera,All,Multiple groups,0.0,,Time frame,"Routine Patient Care Group (visiting OB/GYN, Oncology, Surgery) the week ending July5",311,0.222,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9500000000000001,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_RoutineCare_1 _WeekEndingonJune7,201103_NewYorkCity_MountSinai_RoutineCare_1,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-06-01,2020-06-07,Residual sera,All,Multiple groups,0.0,,Time frame,"Routine Patient Care Group (visiting OB/GYN, Oncology, Surgery) the week ending June 7",285,0.133,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9500000000000001,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_RoutineCare_1 _WeekEndingonMarch15,201103_NewYorkCity_MountSinai_RoutineCare_1,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-03-09,2020-03-15,Residual sera,All,Multiple groups,0.0,,Time frame,"Routine Patient Care Group (visiting OB/GYN, Oncology, Surgery) the week ending March 15",493,0.016,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9500000000000001,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_RoutineCare_1 _WeekEndingonJune21,201103_NewYorkCity_MountSinai_RoutineCare_1,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-06-15,2020-06-21,Residual sera,All,Multiple groups,0.0,,Time frame,"Routine Patient Care Group (visiting OB/GYN, Oncology, Surgery) the week ending June 21",279,0.197,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9500000000000001,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_RoutineCare_1 _WeekEndingonMay31,201103_NewYorkCity_MountSinai_RoutineCare_1,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-05-25,2020-05-31,Residual sera,All,Multiple groups,0.0,,Time frame,"Routine Patient Care Group (visiting OB/GYN, Oncology, Surgery) the week ending May 31",322,0.18300000000000002,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9500000000000001,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_RoutineCare_1 _WeekEndingonMay17,201103_NewYorkCity_MountSinai_RoutineCare_1,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-05-11,2020-05-17,Residual sera,All,Multiple groups,0.0,,Time frame,"Routine Patient Care Group (visiting OB/GYN, Oncology, Surgery) the week ending May 17",285,0.165,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9500000000000001,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_RoutineCare_1 _WeekEndingonJune28,201103_NewYorkCity_MountSinai_RoutineCare_1,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-06-22,2020-06-28,Residual sera,All,Multiple groups,0.0,,Time frame,"Routine Patient Care Group (visiting OB/GYN, Oncology, Surgery) the week ending June 28",305,0.167,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9500000000000001,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_RoutineCare_1 _WeekEndingonApril26,201103_NewYorkCity_MountSinai_RoutineCare_1,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-04-20,2020-04-26,Residual sera,All,Multiple groups,0.0,,Time frame,"Routine Patient Care Group (visiting OB/GYN, Oncology, Surgery) the week ending April 26",231,0.18600000000000003,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9500000000000001,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_RoutineCare_1 _WeekEndingonFeb23,201103_NewYorkCity_MountSinai_RoutineCare_1,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-02-17,2020-02-23,Residual sera,All,Multiple groups,0.0,,Time frame,"Routine Patient Care Group (visiting OB/GYN, Oncology, Surgery) the week ending Feb 23 2020",460,0.009000000000000001,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9500000000000001,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_RoutineCare_1 _WeekEndingonMay24,201103_NewYorkCity_MountSinai_RoutineCare_1,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-05-18,2020-05-24,Residual sera,All,Multiple groups,0.0,,Time frame,"Routine Patient Care Group (visiting OB/GYN, Oncology, Surgery) the week ending May 24",312,0.20500000000000002,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9500000000000001,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_RoutineCare_1 _WeekEndingonApril5,201103_NewYorkCity_MountSinai_RoutineCare_1,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-03-30,2020-04-05,Residual sera,All,Multiple groups,0.0,,Time frame,"Routine Patient Care Group (visiting OB/GYN, Oncology, Surgery) the week ending April 5",326,0.10099999999999999,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9500000000000001,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_RoutineCare_1 _WeekEndingonMay10,201103_NewYorkCity_MountSinai_RoutineCare_1,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-05-04,2020-05-10,Residual sera,All,Multiple groups,0.0,,Time frame,"Routine Patient Care Group (visiting OB/GYN, Oncology, Surgery) the week ending May 10",278,0.19100000000000003,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9500000000000001,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_UrgentCare_2_Overall,201103_NewYorkCity_MountSinai_UrgentCare_2,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-02-02,2020-07-05,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,4101,0.26,,,True,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.95,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-01-08,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_UrgentCare_2_WeekEndingonJune28,201103_NewYorkCity_MountSinai_UrgentCare_2,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-06-22,2020-06-28,Residual sera,All,Multiple groups,0.0,,Time frame,Urgent Care Patient Care Group the week ending June 28,186,0.231,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.95,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_UrgentCare_2_WeekEndingonMay3,201103_NewYorkCity_MountSinai_UrgentCare_2,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-04-27,2020-05-03,Residual sera,All,Multiple groups,0.0,,Time frame,Urgent Care Patient Care Group the week ending May 3,198,0.48,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.95,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_UrgentCare_2_WeekEndingonMarch15,201103_NewYorkCity_MountSinai_UrgentCare_2,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-03-09,2020-03-15,Residual sera,All,Multiple groups,0.0,,Time frame,Urgent Care Patient Care Group the week ending March 15,223,0.018000000000000002,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.95,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_UrgentCare_2_WeekEndingonMay10,201103_NewYorkCity_MountSinai_UrgentCare_2,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-05-04,2020-05-10,Residual sera,All,Multiple groups,0.0,,Time frame,Urgent Care Patient Care Group the week ending May 10,197,0.42100000000000004,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.95,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_UrgentCare_2_WeekEndingonMay24,201103_NewYorkCity_MountSinai_UrgentCare_2,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-05-18,2020-05-24,Residual sera,All,Multiple groups,0.0,,Time frame,Urgent Care Patient Care Group the week ending May 24,169,0.225,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.95,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_UrgentCare_2_WeekEndingonJune21,201103_NewYorkCity_MountSinai_UrgentCare_2,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-06-15,2020-06-21,Residual sera,All,Multiple groups,0.0,,Time frame,Urgent Care Patient Care Group the week ending June 21,194,0.253,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.95,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_UrgentCare_2_WeekEndingonFeb23,201103_NewYorkCity_MountSinai_UrgentCare_2,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-02-17,2020-02-23,Residual sera,All,Multiple groups,0.0,,Time frame,Urgent Care Patient Care Group the week ending Feb 23,213,0.013999999999999999,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.95,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_UrgentCare_2_WeekEndingonMay31,201103_NewYorkCity_MountSinai_UrgentCare_2,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-05-25,2020-05-31,Residual sera,All,Multiple groups,0.0,,Time frame,Urgent Care Patient Care Group the week ending May 31,171,0.24,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.95,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_UrgentCare_2_WeekEndingonMarch22,201103_NewYorkCity_MountSinai_UrgentCare_2,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-03-16,2020-03-22,Residual sera,All,Multiple groups,0.0,,Time frame,Urgent Care Patient Care Group the week ending March 22,243,0.062000000000000006,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.95,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_UrgentCare_2_WeekEndingonApril26,201103_NewYorkCity_MountSinai_UrgentCare_2,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-04-20,2020-04-26,Residual sera,All,Multiple groups,0.0,,Time frame,Urgent Care Patient Care Group the week ending April 19,200,0.43,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.95,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_UrgentCare_2_WeekEndingonJune7,201103_NewYorkCity_MountSinai_UrgentCare_2,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-06-01,2020-06-07,Residual sera,All,Multiple groups,0.0,,Time frame,Urgent Care Patient Care Group the week ending June 7,168,0.256,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.95,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_UrgentCare_2_WeekEndingonMarch8,201103_NewYorkCity_MountSinai_UrgentCare_2,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-03-02,2020-03-08,Residual sera,All,Multiple groups,0.0,,Time frame,Urgent Care Patient Care Group the week ending March 8,238,0.021,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.95,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_UrgentCare_2_WeekEndingonApril5,201103_NewYorkCity_MountSinai_UrgentCare_2,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-03-30,2020-04-05,Residual sera,All,Multiple groups,0.0,,Time frame,Urgent Care Patient Care Group the week ending April 5,274,0.467,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.95,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_UrgentCare_2_WeekEndingonApril12,201103_NewYorkCity_MountSinai_UrgentCare_2,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-04-06,2020-04-12,Residual sera,All,Multiple groups,0.0,,Time frame,Urgent Care Patient Care Group the week ending April 12,194,0.5670000000000001,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.95,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_UrgentCare_2_WeekEndingonApril19,201103_NewYorkCity_MountSinai_UrgentCare_2,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-04-13,2020-04-19,Residual sera,All,Multiple groups,0.0,,Time frame,Urgent Care Patient Care Group the week ending April 19,203,0.616,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.95,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_UrgentCare_2_WeekEndingonFeb16,201103_NewYorkCity_MountSinai_UrgentCare_2,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-02-09,2020-02-16,Residual sera,All,Multiple groups,0.0,,Time frame,Urgent Care Patient Care Group the week ending Feb 16,3,0.0,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.95,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_UrgentCare_2_WeekEndingonMarch29,201103_NewYorkCity_MountSinai_UrgentCare_2,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-03-23,2020-03-29,Residual sera,All,Multiple groups,0.0,,Time frame,Urgent Care Patient Care Group the week ending March 29,265,0.174,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.95,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_UrgentCare_2_WeekEndingonJuly5,201103_NewYorkCity_MountSinai_UrgentCare_2,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-06-29,2020-07-05,Residual sera,All,Multiple groups,0.0,,Time frame,Urgent Care Patient Care Group the week ending July 5,182,0.231,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.95,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_UrgentCare_2_WeekEndingonMarch1,201103_NewYorkCity_MountSinai_UrgentCare_2,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-02-24,2020-03-01,Residual sera,All,Multiple groups,0.0,,Time frame,Urgent Care Patient Care Group the week ending March 1,217,0.032,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.95,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_UrgentCare_2_WeekEndingonMay17,201103_NewYorkCity_MountSinai_UrgentCare_2,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-05-11,2020-05-17,Residual sera,All,Multiple groups,0.0,,Time frame,Urgent Care Patient Care Group the week ending May 17,189,0.317,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.95,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201103_NewYorkCity_MountSinai_UrgentCare_2_WeekEndingonJune14,201103_NewYorkCity_MountSinai_UrgentCare_2,Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City,2020-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The first group included samples from patients seen in the emergency department at Mount Sinai Hospital and from patients that were admitted to the hospital for urgent care during the period starting from the week ending on 9 February to the week ending on 5 July 2020. 

The second group of samples, termed the routine care group, were obtained from patients who visited the obstet- rics and gynaecology department and visits for labour and deliveries, oncology-related visits, as well as hospitalizations owing to elective surgeries, transplant surgeries, pre-operative medical assessments and related outpatient visits, cardiology office visits and other regular office and/or treatment visits. ",,2020-06-08,2020-06-14,Residual sera,All,Multiple groups,0.0,,Time frame,Urgent Care Patient Care Group the week ending June 14,174,0.253,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.95,1.0,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Daniel Stadlbauer,Icahn School of Medicine at Mount Sinai,Unity-Aligned,http://dx.doi.org/10.1038/s41586-020-2912-6,2021-03-06,2022-07-16,Verified,stadlbauer_repeated_2020,USA
201105_Michigan_OaklandUniversity_testadj,201105_Michigan_OaklandUniversity,COVID-19 seropositivity and asymptomatic rates in healthcare workers are associated with job function and masking.,2020-11-05,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Michigan,"Dearborn, Farmington Hills, Grosse Pointe, Royal Oak, Taylor, Trenton, Troy, Wayne, Canton","The entire employee population
of Beaumont Health (approximately 43 000 individuals) was
invited to participate in the study",,2020-04-13,2020-05-28,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,entire employee population of Beaumont Health,20614,0.081,0.068,0.08900000000000001,True,True,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9814,0.9934999999999999,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,No,Matthew D Sims,Oakland University,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1684,2020-12-17,2023-07-04,Verified,sims_covid-19_2020,USA
201105_Detroit_OaklandUniversity_TestAdjustment,201105_Detroit_OaklandUniversity,Coronavirus disease 2019 (covid-19) seropositivity and asymptomatic rates in healthcare workers are associated with job function and masking,2020-11-05,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Michigan,Detroit,The entire employee population of Beaumont Health (approximately 43 000 individuals) was invited to participate in the study.,Participants were required to be symptom-free for at least 72 hours prior to their scheduled blood draw. Excluded participants could re-enter the study after they met  all health system requirements to return to work.,2020-04-13,2020-05-28,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Test adjusted,20614,0.08070000000000001,0.0683,0.0886,True,True,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9814,0.9934999999999999,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,No,Matthew Sims,Oakland University,Not Unity-Aligned,http://dx.doi.org/10.1093/cid/ciaa1684,2021-08-25,2023-08-15,Verified,simsCoronavirusDisease20192020,USA
201106_Utah_UniversityofUtah_immunosupressed_primary,201106_Utah_UniversityofUtah,Assessing Cytokine Profiles and COVID Serology in Patients on Immunosuppression to Guide Care Recommendations,2020-11-06,Preprint,Local,Cross-sectional survey ,United States of America,Utah,Salt Lake City ,patients with autoimmune disease on immunosuppressive/immunomodulatory therapy,,2020-04-18,2020-05-21,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,23.0,76.0,Primary Estimate,,39,0.026000000000000002,,,True,,,,True,Unclear,Author designed (ELISA) -Unknown,,,Serum,IgG,,,,,['High'],No,Unclear,No,Yes,Unclear,Unclear,Yes,No,Unclear,Quinn Pritchett,University of Utah,Not Unity-Aligned,https://acrabstracts.org/abstract/assessing-cytokine-profiles-and-covid-serology-in-patients-on-immunosuppression-to-guide-care-recommendations/,2021-02-04,2022-07-16,Verified,noauthor_assessing_nodate,USA
201107_Lubbock_TexasTechUniversity_Overall,201107_Lubbock_TexasTechUniversity,"Prevalence of Coronavirus Antibody Among First Responders in Lubbock, Texas",2020-11-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Texas,Lubbock,"Age range: 18 to 89 years old, First responders in Lubbock county and surrounding areas who are currently asymptomatic from SARSCoV-2 infection.","1. Pregnant or breastfeeding females
2. Inability to give consent by subject
3. Acute respiratory infection (cough, fever, malaise,
shortness of breath)",2020-05-12,2020-05-13,Essential non-healthcare workers,All,Multiple groups,18.0,76.0,Primary Estimate,,683,0.006999999999999999,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.9990000000000001,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Kenneth Iwuji,Texas Tech University,Not Unity-Aligned,https://dx.doi.org/10.1177/2150132720971390,2020-12-18,2024-03-01,Verified,iwuji_prevalence_2020,USA
201116_Tennessee_VanderbiltUniversity_HCW_Overall,201116_Tennessee_VanderbiltUniversity,"Prevalence of IgG antibodies against the severe acute respiratory syndrome coronavirus-2 among healthcare workers in Tennessee during May and June, 2020",2020-11-16,Preprint,Regional,Cross-sectional survey ,United States of America,Tennessee,,"Health care workers over 18 years of age at Erlanger Health System, Ballad Health, University of Tennessee Medical Center, Vanderbilt Wilson County Hospital, Vanderbilt University Medical CEnter",,2020-05-15,2020-06-15,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,Overall estimate,11787,0.0098,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Peter Rebeiro,Vanderbilt University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.11.12.20230912v1,2020-12-16,2024-03-01,Verified,rebeiro_prevalence_2020,USA
201119_LosAngeles_CedarsSinaiMedicalCenter_Overall,201119_LosAngeles_CedarsSinaiMedicalCenter,BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of healthcare workers,2020-11-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,Los Angeles,"6679 active HCWs employed by Cedars-Sinai Health System in multiple sites around Los Angeles county, including two major hospitals (Cedars Sinai Medical Center and Marina Del Rey Hospital) and several outpatients clinics affiliated to the Cedars Sinai Medical Network ",,2020-05-11,2020-06-28,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,6201,0.035,,,True,,,,True,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9690000000000001,0.9990000000000001,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Magali Rivas,Cedars-Sinai Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1172/JCI145157,2021-01-05,2024-03-01,Verified,noval_rivas_bcg_2020,USA
201119_USA_QuestDiagnostics_Overall,201119_USA_QuestDiagnostics,"Insights from Patterns of SARS-CoV-2 Immunoglobulin G Serology Test Results from a National Clinical Laboratory, United States, March-July 2020",2020-11-19,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Results from SARS-CoV-2 NAAT and qualitative IgG tests performed at Quest Diagnostics through July 10, 2020, were included in the analysis.","Results were excluded for pa-
tients who were <2 years of age at the time of testing",2020-04-21,2020-07-10,Household and community samples,All,Multiple groups,2.0,,Primary Estimate,,2402282,0.11810000000000001,,,True,,,,True,Sequential,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,EUROIMMUN",Multiple Types,Serum,IgG,,,,,['High'],Yes,No,Yes,No,Unclear,Unclear,Yes,No,,Harvey W Kaufman,Quest Diagnostics,Not Unity-Aligned,http://dx.doi.org/10.1089/pop.2020.0256,2021-01-23,2024-03-01,Verified,kaufman_insights_2020,USA
201120_Rochester_MayoClinic_HighRiskCohort_1_Overall,201120_Rochester_MayoClinic_HighRiskCohort_1,Unrecognized SARS-CoV-2 Seroprevalence among healthcare personnel in a low prevalence area,2020-11-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Minnesota,Rochester,"Mayo Clinic employees in Rochester, Minnesota, were recruited between May 25 and July 9, 2020, and were placed into high- and low-risk cohorts based on their role and work unit. The high-risk cohort included HCP in a direct patient care role, working in the emergency department, COVID-19 intensive care unit, or COVID-19 general care ward. Low-risk HCP were those not involved in direct patient care. ",HCP who previously tested positive or who had a household member previously test positive for COVID-19 were excluded from the study. ,2020-05-25,2020-07-09,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,320,0.0063,,,True,,,,True,Unclear,"Anti-SARS-CoV-2 ELISA IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",Multiple Types,Serum,IgG,,,,,['High'],Yes,Unclear,No,Yes,No,Unclear,Yes,No,Unclear,Vishal Shah,Mayo Clinic,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2020.1341,2021-01-05,2024-03-01,Verified,shah_unrecognized_2020,USA
201120_Rochester_MayoClinic_LowRiskCohort_2_Overall,201120_Rochester_MayoClinic_LowRiskCohort_2,Unrecognized SARS-CoV-2 Seroprevalence among healthcare personnel in a low prevalence area,2020-11-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Minnesota,Rochester,"Mayo Clinic employees in Rochester, Minnesota, were recruited between May 25 and July 9, 2020, and were placed into high- and low-risk cohorts based on their role and work unit. The high-risk cohort included HCP in a direct patient care role, working in the emergency department, COVID-19 intensive care unit, or COVID-19 general care ward. Low-risk HCP were those not involved in direct patient care. ",HCP who previously tested positive or who had a household member previously test positive for COVID-19 were excluded from the study. ,2020-05-25,2020-07-09,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,248,0.0,,,True,,,,True,Unclear,"Anti-SARS-CoV-2 ELISA IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",Multiple Types,Serum,IgG,,,,,['High'],Yes,Unclear,No,Yes,No,Unclear,Yes,No,Unclear,Vishal Shah,Mayo Clinic,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2020.1341,2021-01-05,2024-03-01,Verified,shah_unrecognized_2020,USA
201121_LosAngeles_UniversityofCaliforniaLosAngeles_FirstResponders,201121_LosAngeles_UniversityofCaliforniaLosAngeles_FirstResponders2,"Incidence of SARS-CoV-2 infection among asymptomatic frontline health workers in Los Angeles County, California",2020-11-21,Preprint,Local,Cross-sectional survey ,United States of America,California,,"Beginning on May 19, 2020, LACoFD first responders (FR) from eight battalions— including firefighters,
paramedics, lifeguards, and dispatchers—were invited to enroll in this study. Eligible participants were over 18 years of age and free of new symptoms associated with COVID-19 in the 2 days prior to
enrollment.",,2020-05-19,2020-08-31,Essential non-healthcare workers,All,Multiple groups,20.0,,Primary Estimate,,679,0.081,,,True,,,,True,Unclear,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,,,,['High'],Yes,Unclear,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Megan Halbrook,University of California Los Angeles,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.11.18.20234211v1,2021-01-21,2022-07-16,Verified,halbrook_incidence_2020,USA
201121_LosAngeles_UniversityofCaliforniaLosAngeles_FirstResponders_age30-39 ,201121_LosAngeles_UniversityofCaliforniaLosAngeles_FirstResponders2,"Incidence of SARS-CoV-2 infection among asymptomatic frontline health workers in Los Angeles County, California",2020-11-21,Preprint,Local,Cross-sectional survey ,United States of America,California,,"Beginning on May 19, 2020, LACoFD first responders (FR) from eight battalions— including firefighters,
paramedics, lifeguards, and dispatchers—were invited to enroll in this study. Eligible participants were over 18 years of age and free of new symptoms associated with COVID-19 in the 2 days prior to
enrollment.",,2020-05-19,2020-08-31,Essential non-healthcare workers,All,Adults (18-64 years),30.0,39.0,Age,30-39,237,0.09699999999999999,,,,,,,,Unclear,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,,,,['High'],Yes,Unclear,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Megan Halbrook,University of California Los Angeles,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.11.18.20234211v1,2021-01-21,2022-07-16,Verified,halbrook_incidence_2020,USA
201121_LosAngeles_UniversityofCaliforniaLosAngeles_FirstResponders_age20-29 ,201121_LosAngeles_UniversityofCaliforniaLosAngeles_FirstResponders2,"Incidence of SARS-CoV-2 infection among asymptomatic frontline health workers in Los Angeles County, California",2020-11-21,Preprint,Local,Cross-sectional survey ,United States of America,California,,"Beginning on May 19, 2020, LACoFD first responders (FR) from eight battalions— including firefighters,
paramedics, lifeguards, and dispatchers—were invited to enroll in this study. Eligible participants were over 18 years of age and free of new symptoms associated with COVID-19 in the 2 days prior to
enrollment.",,2020-05-19,2020-08-31,Essential non-healthcare workers,All,Adults (18-64 years),20.0,29.0,Age,20-29,53,0.0943,,,,,,,,Unclear,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,,,,['High'],Yes,Unclear,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Megan Halbrook,University of California Los Angeles,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.11.18.20234211v1,2021-01-21,2022-07-16,Verified,halbrook_incidence_2020,USA
201121_LosAngeles_UniversityofCaliforniaLosAngeles_FirstResponders_age60+ ,201121_LosAngeles_UniversityofCaliforniaLosAngeles_FirstResponders2,"Incidence of SARS-CoV-2 infection among asymptomatic frontline health workers in Los Angeles County, California",2020-11-21,Preprint,Local,Cross-sectional survey ,United States of America,California,,"Beginning on May 19, 2020, LACoFD first responders (FR) from eight battalions— including firefighters,
paramedics, lifeguards, and dispatchers—were invited to enroll in this study. Eligible participants were over 18 years of age and free of new symptoms associated with COVID-19 in the 2 days prior to
enrollment.",,2020-05-19,2020-08-31,Essential non-healthcare workers,All,Seniors (65+ years),60.0,,Age,60 and older,15,0.0667,,,,,,,,Unclear,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,,,,['High'],Yes,Unclear,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Megan Halbrook,University of California Los Angeles,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.11.18.20234211v1,2021-01-21,2022-07-16,Verified,halbrook_incidence_2020,USA
201121_LosAngeles_UniversityofCaliforniaLosAngeles_FirstResponders_age50-59 ,201121_LosAngeles_UniversityofCaliforniaLosAngeles_FirstResponders2,"Incidence of SARS-CoV-2 infection among asymptomatic frontline health workers in Los Angeles County, California",2020-11-21,Preprint,Local,Cross-sectional survey ,United States of America,California,,"Beginning on May 19, 2020, LACoFD first responders (FR) from eight battalions— including firefighters,
paramedics, lifeguards, and dispatchers—were invited to enroll in this study. Eligible participants were over 18 years of age and free of new symptoms associated with COVID-19 in the 2 days prior to
enrollment.",,2020-05-19,2020-08-31,Essential non-healthcare workers,All,Adults (18-64 years),50.0,59.0,Age,50-59,182,0.044000000000000004,,,,,,,,Unclear,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,,,,['High'],Yes,Unclear,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Megan Halbrook,University of California Los Angeles,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.11.18.20234211v1,2021-01-21,2022-07-16,Verified,halbrook_incidence_2020,USA
201121_LosAngeles_UniversityofCaliforniaLosAngeles_FirstResponders_age40-49,201121_LosAngeles_UniversityofCaliforniaLosAngeles_FirstResponders2,"Incidence of SARS-CoV-2 infection among asymptomatic frontline health workers in Los Angeles County, California",2020-11-21,Preprint,Local,Cross-sectional survey ,United States of America,California,,"Beginning on May 19, 2020, LACoFD first responders (FR) from eight battalions— including firefighters,
paramedics, lifeguards, and dispatchers—were invited to enroll in this study. Eligible participants were over 18 years of age and free of new symptoms associated with COVID-19 in the 2 days prior to
enrollment.",,2020-05-19,2020-08-31,Essential non-healthcare workers,All,Adults (18-64 years),40.0,49.0,Age,40-49,182,0.0659,,,,,,,,Unclear,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,,,,['High'],Yes,Unclear,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Megan Halbrook,University of California Los Angeles,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.11.18.20234211v1,2021-01-21,2022-07-16,Verified,halbrook_incidence_2020,USA
201121_LosAngeles_UniversityofCaliforniaLosAngeles_HCW,201121_LosAngeles_UniversityofCaliforniaLosAngeles_HCW1,"Incidence of SARS-CoV-2 infection among asymptomatic frontline health workers in Los Angeles County, California",2020-11-21,Preprint,Local,Cross-sectional survey ,United States of America,California,,"Beginning on April 8, 2020 health system workers
(HSW) employed by UCLA Health—including those with and without direct patient care responsibilities— were invited to enroll in this study. Eligible participants were over 18 years of age and free of new symptoms associated with COVID-19 in the 2 days prior to enrollment.",,2020-04-08,2020-08-31,Health care workers and caregivers,All,Multiple groups,20.0,,Primary Estimate,,1108,0.039,,,True,,,,True,Unclear,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,,,,['High'],Yes,Unclear,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Megan Halbrook,University of California Los Angeles,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.11.18.20234211v1,2021-01-21,2022-07-16,Verified,halbrook_incidence_2020,USA
201121_LosAngeles_UniversityofCaliforniaLosAngeles_HCW_age20-29,201121_LosAngeles_UniversityofCaliforniaLosAngeles_HCW1,"Incidence of SARS-CoV-2 infection among asymptomatic frontline health workers in Los Angeles County, California",2020-11-21,Preprint,Local,Cross-sectional survey ,United States of America,California,,"Beginning on April 8, 2020 health system workers
(HSW) employed by UCLA Health—including those with and without direct patient care responsibilities— were invited to enroll in this study. Eligible participants were over 18 years of age and free of new symptoms associated with COVID-19 in the 2 days prior to enrollment.",,2020-04-08,2020-08-31,Health care workers and caregivers,All,Adults (18-64 years),20.0,29.0,Age,20-29,172,0.0581,,,,,,,,Unclear,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,,,,['High'],Yes,Unclear,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Megan Halbrook,University of California Los Angeles,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.11.18.20234211v1,2021-01-21,2022-07-16,Verified,halbrook_incidence_2020,USA
201121_LosAngeles_UniversityofCaliforniaLosAngeles_HCW_age30-39,201121_LosAngeles_UniversityofCaliforniaLosAngeles_HCW1,"Incidence of SARS-CoV-2 infection among asymptomatic frontline health workers in Los Angeles County, California",2020-11-21,Preprint,Local,Cross-sectional survey ,United States of America,California,,"Beginning on April 8, 2020 health system workers
(HSW) employed by UCLA Health—including those with and without direct patient care responsibilities— were invited to enroll in this study. Eligible participants were over 18 years of age and free of new symptoms associated with COVID-19 in the 2 days prior to enrollment.",,2020-04-08,2020-08-31,Health care workers and caregivers,All,Adults (18-64 years),30.0,39.0,Age,30-39,418,0.0359,,,,,,,,Unclear,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,,,,['High'],Yes,Unclear,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Megan Halbrook,University of California Los Angeles,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.11.18.20234211v1,2021-01-21,2022-07-16,Verified,halbrook_incidence_2020,USA
201121_LosAngeles_UniversityofCaliforniaLosAngeles_HCW_age40-49,201121_LosAngeles_UniversityofCaliforniaLosAngeles_HCW1,"Incidence of SARS-CoV-2 infection among asymptomatic frontline health workers in Los Angeles County, California",2020-11-21,Preprint,Local,Cross-sectional survey ,United States of America,California,,"Beginning on April 8, 2020 health system workers
(HSW) employed by UCLA Health—including those with and without direct patient care responsibilities— were invited to enroll in this study. Eligible participants were over 18 years of age and free of new symptoms associated with COVID-19 in the 2 days prior to enrollment.",,2020-04-08,2020-08-31,Health care workers and caregivers,All,Adults (18-64 years),40.0,49.0,Age,40-49,235,0.0213,,,,,,,,Unclear,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,,,,['High'],Yes,Unclear,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Megan Halbrook,University of California Los Angeles,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.11.18.20234211v1,2021-01-21,2022-07-16,Verified,halbrook_incidence_2020,USA
201121_LosAngeles_UniversityofCaliforniaLosAngeles_HCW_age60+,201121_LosAngeles_UniversityofCaliforniaLosAngeles_HCW1,"Incidence of SARS-CoV-2 infection among asymptomatic frontline health workers in Los Angeles County, California",2020-11-21,Preprint,Local,Cross-sectional survey ,United States of America,California,,"Beginning on April 8, 2020 health system workers
(HSW) employed by UCLA Health—including those with and without direct patient care responsibilities— were invited to enroll in this study. Eligible participants were over 18 years of age and free of new symptoms associated with COVID-19 in the 2 days prior to enrollment.",,2020-04-08,2020-08-31,Health care workers and caregivers,All,Seniors (65+ years),60.0,,Age,60 and older,55,0.0727,,,,,,,,Unclear,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,,,,['High'],Yes,Unclear,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Megan Halbrook,University of California Los Angeles,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.11.18.20234211v1,2021-01-21,2022-07-16,Verified,halbrook_incidence_2020,USA
201121_LosAngeles_UniversityofCaliforniaLosAngeles_HCW_age50-59,201121_LosAngeles_UniversityofCaliforniaLosAngeles_HCW1,"Incidence of SARS-CoV-2 infection among asymptomatic frontline health workers in Los Angeles County, California",2020-11-21,Preprint,Local,Cross-sectional survey ,United States of America,California,,"Beginning on April 8, 2020 health system workers
(HSW) employed by UCLA Health—including those with and without direct patient care responsibilities— were invited to enroll in this study. Eligible participants were over 18 years of age and free of new symptoms associated with COVID-19 in the 2 days prior to enrollment.",,2020-04-08,2020-08-31,Health care workers and caregivers,All,Adults (18-64 years),50.0,59.0,Age,50-59,148,0.0541,,,,,,,,Unclear,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,,,,['High'],Yes,Unclear,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Megan Halbrook,University of California Los Angeles,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.11.18.20234211v1,2021-01-21,2022-07-16,Verified,halbrook_incidence_2020,USA
201123_OrangeCounty_StJudeMedicalCenter_Overall,201123_OrangeCounty_StJudeMedicalCenter,"Seroprevalence of Novel Coronavirus SARS-CoV-2 at a Community Hospital Emergency Department and Outpatient Laboratory in Northern Orange County, California",2020-11-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,Fullerton,patients who had visited an affiliated outpatient clinic or our emergency department.,Repeat patients/tests excluded,2020-07-15,2020-07-27,Residual sera,All,Multiple groups,10.0,109.0,Primary Estimate,Overall,865,0.094,0.08,0.12,True,,,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Jason Yamaki,St. Jude Medical Center,Unity-Aligned,https://dx.doi.org/10.1007/s40615-020-00918-0,2021-01-21,2024-03-01,Verified,yamaki_seroprevalence_2020,USA
201123_OrangeCounty_StJudeMedicalCenter_10-19,201123_OrangeCounty_StJudeMedicalCenter,"Seroprevalence of Novel Coronavirus SARS-CoV-2 at a Community Hospital Emergency Department and Outpatient Laboratory in Northern Orange County, California",2020-11-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,Fullerton,patients who had visited an affiliated outpatient clinic or our emergency department.,Repeat patients/tests excluded,2020-07-15,2020-07-27,Residual sera,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,9,0.111,0.0001,0.457,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Jason Yamaki,St. Jude Medical Center,Unity-Aligned,https://dx.doi.org/10.1007/s40615-020-00918-0,2021-01-21,2024-03-01,Verified,yamaki_seroprevalence_2020,USA
201123_OrangeCounty_StJudeMedicalCenter_20-29,201123_OrangeCounty_StJudeMedicalCenter,"Seroprevalence of Novel Coronavirus SARS-CoV-2 at a Community Hospital Emergency Department and Outpatient Laboratory in Northern Orange County, California",2020-11-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,Fullerton,patients who had visited an affiliated outpatient clinic or our emergency department.,Repeat patients/tests excluded,2020-07-15,2020-07-27,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29,55,0.218,0.128,0.34500000000000003,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Jason Yamaki,St. Jude Medical Center,Unity-Aligned,https://dx.doi.org/10.1007/s40615-020-00918-0,2021-01-21,2024-03-01,Verified,yamaki_seroprevalence_2020,USA
201123_OrangeCounty_StJudeMedicalCenter_50-59,201123_OrangeCounty_StJudeMedicalCenter,"Seroprevalence of Novel Coronavirus SARS-CoV-2 at a Community Hospital Emergency Department and Outpatient Laboratory in Northern Orange County, California",2020-11-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,Fullerton,patients who had visited an affiliated outpatient clinic or our emergency department.,Repeat patients/tests excluded,2020-07-15,2020-07-27,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,133,0.098,0.057,0.161,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Jason Yamaki,St. Jude Medical Center,Unity-Aligned,https://dx.doi.org/10.1007/s40615-020-00918-0,2021-01-21,2024-03-01,Verified,yamaki_seroprevalence_2020,USA
201123_OrangeCounty_StJudeMedicalCenter_60-69,201123_OrangeCounty_StJudeMedicalCenter,"Seroprevalence of Novel Coronavirus SARS-CoV-2 at a Community Hospital Emergency Department and Outpatient Laboratory in Northern Orange County, California",2020-11-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,Fullerton,patients who had visited an affiliated outpatient clinic or our emergency department.,Repeat patients/tests excluded,2020-07-15,2020-07-27,Residual sera,All,Adults (18-64 years),60.0,69.0,Age,60-69,159,0.08800000000000001,0.052000000000000005,0.14300000000000002,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Jason Yamaki,St. Jude Medical Center,Unity-Aligned,https://dx.doi.org/10.1007/s40615-020-00918-0,2021-01-21,2024-03-01,Verified,yamaki_seroprevalence_2020,USA
201123_OrangeCounty_StJudeMedicalCenter_NonHispanic,201123_OrangeCounty_StJudeMedicalCenter,"Seroprevalence of Novel Coronavirus SARS-CoV-2 at a Community Hospital Emergency Department and Outpatient Laboratory in Northern Orange County, California",2020-11-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,Fullerton,patients who had visited an affiliated outpatient clinic or our emergency department.,Repeat patients/tests excluded,2020-07-15,2020-07-27,Residual sera,All,Multiple groups,10.0,109.0,Ethnicity,Non-Hispanic or Latino,616,0.067,0.049,0.08900000000000001,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Jason Yamaki,St. Jude Medical Center,Unity-Aligned,https://dx.doi.org/10.1007/s40615-020-00918-0,2021-01-21,2024-03-01,Verified,yamaki_seroprevalence_2020,USA
201123_OrangeCounty_StJudeMedicalCenter_40-49,201123_OrangeCounty_StJudeMedicalCenter,"Seroprevalence of Novel Coronavirus SARS-CoV-2 at a Community Hospital Emergency Department and Outpatient Laboratory in Northern Orange County, California",2020-11-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,Fullerton,patients who had visited an affiliated outpatient clinic or our emergency department.,Repeat patients/tests excluded,2020-07-15,2020-07-27,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,83,0.217,0.141,0.318,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Jason Yamaki,St. Jude Medical Center,Unity-Aligned,https://dx.doi.org/10.1007/s40615-020-00918-0,2021-01-21,2024-03-01,Verified,yamaki_seroprevalence_2020,USA
201123_OrangeCounty_StJudeMedicalCenter_Male,201123_OrangeCounty_StJudeMedicalCenter,"Seroprevalence of Novel Coronavirus SARS-CoV-2 at a Community Hospital Emergency Department and Outpatient Laboratory in Northern Orange County, California",2020-11-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,Fullerton,patients who had visited an affiliated outpatient clinic or our emergency department.,Repeat patients/tests excluded,2020-07-15,2020-07-27,Residual sera,Male,Multiple groups,10.0,109.0,Sex/Gender,Male,387,0.1085,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Jason Yamaki,St. Jude Medical Center,Unity-Aligned,https://dx.doi.org/10.1007/s40615-020-00918-0,2021-01-21,2024-03-01,Verified,yamaki_seroprevalence_2020,USA
201123_OrangeCounty_StJudeMedicalCenter_30-39,201123_OrangeCounty_StJudeMedicalCenter,"Seroprevalence of Novel Coronavirus SARS-CoV-2 at a Community Hospital Emergency Department and Outpatient Laboratory in Northern Orange County, California",2020-11-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,Fullerton,patients who had visited an affiliated outpatient clinic or our emergency department.,Repeat patients/tests excluded,2020-07-15,2020-07-27,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,81,0.12400000000000001,0.067,0.215,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Jason Yamaki,St. Jude Medical Center,Unity-Aligned,https://dx.doi.org/10.1007/s40615-020-00918-0,2021-01-21,2024-03-01,Verified,yamaki_seroprevalence_2020,USA
201123_OrangeCounty_StJudeMedicalCenter_90-99,201123_OrangeCounty_StJudeMedicalCenter,"Seroprevalence of Novel Coronavirus SARS-CoV-2 at a Community Hospital Emergency Department and Outpatient Laboratory in Northern Orange County, California",2020-11-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,Fullerton,patients who had visited an affiliated outpatient clinic or our emergency department.,Repeat patients/tests excluded,2020-07-15,2020-07-27,Residual sera,All,Seniors (65+ years),90.0,99.0,Age,90-99,35,0.086,0.022000000000000002,0.231,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Jason Yamaki,St. Jude Medical Center,Unity-Aligned,https://dx.doi.org/10.1007/s40615-020-00918-0,2021-01-21,2024-03-01,Verified,yamaki_seroprevalence_2020,USA
201123_OrangeCounty_StJudeMedicalCenter_70-79,201123_OrangeCounty_StJudeMedicalCenter,"Seroprevalence of Novel Coronavirus SARS-CoV-2 at a Community Hospital Emergency Department and Outpatient Laboratory in Northern Orange County, California",2020-11-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,Fullerton,patients who had visited an affiliated outpatient clinic or our emergency department.,Repeat patients/tests excluded,2020-07-15,2020-07-27,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,164,0.024,0.0007000000000000001,0.063,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Jason Yamaki,St. Jude Medical Center,Unity-Aligned,https://dx.doi.org/10.1007/s40615-020-00918-0,2021-01-21,2024-03-01,Verified,yamaki_seroprevalence_2020,USA
201123_OrangeCounty_StJudeMedicalCenter_Hispanic,201123_OrangeCounty_StJudeMedicalCenter,"Seroprevalence of Novel Coronavirus SARS-CoV-2 at a Community Hospital Emergency Department and Outpatient Laboratory in Northern Orange County, California",2020-11-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,Fullerton,patients who had visited an affiliated outpatient clinic or our emergency department.,Repeat patients/tests excluded,2020-07-15,2020-07-27,Residual sera,All,Multiple groups,10.0,109.0,Ethnicity,Hispanic or Latino,204,0.18100000000000002,0.134,0.24,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Jason Yamaki,St. Jude Medical Center,Unity-Aligned,https://dx.doi.org/10.1007/s40615-020-00918-0,2021-01-21,2024-03-01,Verified,yamaki_seroprevalence_2020,USA
201123_OrangeCounty_StJudeMedicalCenter_Declined,201123_OrangeCounty_StJudeMedicalCenter,"Seroprevalence of Novel Coronavirus SARS-CoV-2 at a Community Hospital Emergency Department and Outpatient Laboratory in Northern Orange County, California",2020-11-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,Fullerton,patients who had visited an affiliated outpatient clinic or our emergency department.,Repeat patients/tests excluded,2020-07-15,2020-07-27,Residual sera,All,Multiple groups,10.0,109.0,Ethnicity,Not available/declined to state,24,0.20800000000000002,0.08800000000000001,0.409,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Jason Yamaki,St. Jude Medical Center,Unity-Aligned,https://dx.doi.org/10.1007/s40615-020-00918-0,2021-01-21,2024-03-01,Verified,yamaki_seroprevalence_2020,USA
201123_OrangeCounty_StJudeMedicalCenter_Female,201123_OrangeCounty_StJudeMedicalCenter,"Seroprevalence of Novel Coronavirus SARS-CoV-2 at a Community Hospital Emergency Department and Outpatient Laboratory in Northern Orange County, California",2020-11-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,Fullerton,patients who had visited an affiliated outpatient clinic or our emergency department.,Repeat patients/tests excluded,2020-07-15,2020-07-27,Residual sera,Female,Multiple groups,10.0,109.0,Sex/Gender,Female,478,0.0816,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Jason Yamaki,St. Jude Medical Center,Unity-Aligned,https://dx.doi.org/10.1007/s40615-020-00918-0,2021-01-21,2024-03-01,Verified,yamaki_seroprevalence_2020,USA
201123_OrangeCounty_StJudeMedicalCenter_80-89,201123_OrangeCounty_StJudeMedicalCenter,"Seroprevalence of Novel Coronavirus SARS-CoV-2 at a Community Hospital Emergency Department and Outpatient Laboratory in Northern Orange County, California",2020-11-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,Fullerton,patients who had visited an affiliated outpatient clinic or our emergency department.,Repeat patients/tests excluded,2020-07-15,2020-07-27,Residual sera,All,Seniors (65+ years),80.0,89.0,Age,80-89,144,0.042,0.017,0.09,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Jason Yamaki,St. Jude Medical Center,Unity-Aligned,https://dx.doi.org/10.1007/s40615-020-00918-0,2021-01-21,2024-03-01,Verified,yamaki_seroprevalence_2020,USA
201123_OrangeCounty_StJudeMedicalCenter_100-109,201123_OrangeCounty_StJudeMedicalCenter,"Seroprevalence of Novel Coronavirus SARS-CoV-2 at a Community Hospital Emergency Department and Outpatient Laboratory in Northern Orange County, California",2020-11-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,Fullerton,patients who had visited an affiliated outpatient clinic or our emergency department.,Repeat patients/tests excluded,2020-07-15,2020-07-27,Residual sera,All,Seniors (65+ years),100.0,109.0,Age,100-109,2,0.0,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Jason Yamaki,St. Jude Medical Center,Unity-Aligned,https://dx.doi.org/10.1007/s40615-020-00918-0,2021-01-21,2024-03-01,Verified,yamaki_seroprevalence_2020,USA
201124_JeffersonCounty_UniversityofLouiseville_ProbabilitySampling,201124_JeffersonCounty_UniversityofLouiseville_ProbabilitySampling,Co-Immunity Project shows COVID-19 infection rate in Jefferson County increased tenfold since September,2020-11-24,News and Media,Local,Cross-sectional survey ,United States of America,Kentucky,,"Residents of Jefferson County, Kentucky. The invitations were sent to individuals selected using addresses derived from U.S. Census Bureau tract boundaries in proportion to the total population in each geographic area.",,2020-11-09,2020-11-16,Household and community samples,All,Multiple groups,,,Primary Estimate,,1091,0.02,,,True,,,,True,Stratified probability,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,No,Betty Coffman,University of Louiseville ,Not Unity-Aligned,https://www.uoflnews.com/post/uofltoday/co-immunity-project-shows-covid-19-infection-rate-in-jefferson-county-increased-tenfold-since-september/,2021-03-08,2022-07-16,Verified,coffman_co-immunity_2020,USA
201124_JeffersonCounty_UniversityofLouiseville_SelfReferal_overall,201124_JeffersonCounty_UniversityofLouiseville_SelfReferal,Co-Immunity Project shows COVID-19 infection rate in Jefferson County increased tenfold since September,2020-11-24,News and Media,Local,Cross-sectional survey ,United States of America,Kentucky,,any adult resident of Jefferson County was invited to participate through news and social media messages.,,2020-11-09,2020-11-16,Household and community samples,All,Multiple groups,,,Primary Estimate,,1709,0.033,,,True,,,,True,Self-referral,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,No,Yes,No,Unclear,Unclear,Yes,No,Unclear,Betty Coffman,University of Louiseville ,Not Unity-Aligned,https://www.uoflnews.com/post/uofltoday/co-immunity-project-shows-covid-19-infection-rate-in-jefferson-county-increased-tenfold-since-september/,2021-03-08,2022-07-16,Verified,coffman_co-immunity_2020,USA
201124_USA_CDC_August/September3_Alabama,201124_USA_CDC_August/September3_Alabama,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Alabama,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-26,2020-09-08,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Alabama,955,0.099,0.0719,0.12789999999999999,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Alaska,201124_USA_CDC_August/September3_Alaska,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Alaska,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-26,2020-09-09,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Alaska,610,0.01,0.0024,0.0217,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Arizona,201124_USA_CDC_August/September3_Arizona,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Arizona,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-26,2020-09-09,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Arizona,1030,0.049,0.0305,0.07110000000000001,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Arkansas,201124_USA_CDC_August/September3_Arkansas,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Arkansas,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-24,2020-09-08,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Arkansas,992,0.049,0.035,0.0641,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_California,201124_USA_CDC_August/September3_California,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,California,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-28,2020-09-09,Residual sera,All,Multiple groups,0.0,,Primary Estimate,California,983,0.06,0.042,0.0782,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Colorado,201124_USA_CDC_August/September3_Colorado,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Colorado,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-24,2020-09-04,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Colorado,1025,0.036000000000000004,0.023100000000000002,0.0509,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Connecticut,201124_USA_CDC_August/September3_Connecticut,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Connecticut,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-26,2020-09-04,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Connecticut,983,0.043,0.028999999999999998,0.056900000000000006,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Delaware,201124_USA_CDC_August/September3_Delaware,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Delaware,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-26,2020-09-10,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Delaware,914,0.045,0.0242,0.0712,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Florida,201124_USA_CDC_August/September3_Florida,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Florida,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-27,2020-09-09,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Florida,981,0.057,0.0393,0.07490000000000001,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Georgia,201124_USA_CDC_August/September3_Georgia,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Georgia,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-25,2020-09-10,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Georgia,1020,0.087,0.0669,0.11140000000000001,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Idaho,201124_USA_CDC_August/September3_Idaho,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Idaho,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-26,2020-09-10,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Idaho,790,0.057,0.028999999999999998,0.09699999999999999,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Illinois,201124_USA_CDC_August/September3_Illinois,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Illinois,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-26,2020-09-03,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Illinois,979,0.055999999999999994,0.039,0.0767,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Indiana,201124_USA_CDC_August/September3_Indiana,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Indiana,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-26,2020-09-09,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Indiana,984,0.024,0.013600000000000001,0.0352,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Iowa,201124_USA_CDC_August/September3_Iowa,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Iowa,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-25,2020-09-10,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Iowa,1006,0.084,0.061500000000000006,0.10740000000000001,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Kansas,201124_USA_CDC_August/September3_Kansas,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Kansas,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-24,2020-09-03,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Kansas,1025,0.028999999999999998,0.015700000000000002,0.0431,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Kentucky,201124_USA_CDC_August/September3_Kentucky,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Kentucky,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-26,2020-09-08,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Kentucky,983,0.031000000000000003,0.0191,0.0433,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Louisiana,201124_USA_CDC_August/September3_Louisiana,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Louisiana,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-26,2020-09-08,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Louisiana,1001,0.086,0.0665,0.113,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Maine,201124_USA_CDC_August/September3_Maine,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Maine,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-26,2020-09-10,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Maine,759,0.015,0.0044,0.0322,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Maryland,201124_USA_CDC_August/September3_Maryland,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Maryland,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-26,2020-09-08,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Maryland,980,0.079,0.0572,0.1035,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Massachusetts,201124_USA_CDC_August/September3_Massachusetts,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Massachusetts,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-27,2020-09-05,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Massachusetts,981,0.036000000000000004,0.0236,0.050800000000000005,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Michigan,201124_USA_CDC_August/September3_Michigan,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Michigan,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-26,2020-09-03,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Michigan,976,0.034,0.0216,0.0495,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Minnesota,201124_USA_CDC_August/September3_Minnesota,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Minnesota,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-26,2020-09-08,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Minnesota,974,0.092,0.0671,0.1195,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Mississippi,201124_USA_CDC_August/September3_Mississippi,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Mississippi,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-26,2020-09-10,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Mississippi,987,0.084,0.0489,0.1273,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Missouri,201124_USA_CDC_August/September3_Missouri,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Missouri,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-24,2020-09-10,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Missouri,1024,0.028999999999999998,0.0174,0.0417,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Montana,201124_USA_CDC_August/September3_Montana,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Montana,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-24,2020-09-09,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Montana,518,0.009000000000000001,0.0023,0.0182,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Nebraska,201124_USA_CDC_August/September3_Nebraska,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Nebraska,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-24,2020-09-10,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Nebraska,938,0.063,0.0447,0.0827,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Nevada,201124_USA_CDC_August/September3_Nevada,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Nevada,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-27,2020-08-29,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Nevada,980,0.065,0.0463,0.0858,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_NewHampshire,201124_USA_CDC_August/September3_NewHampshire,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, New Hampshire,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-26,2020-09-03,Residual sera,All,Multiple groups,0.0,,Primary Estimate, New Hampshire,1147,0.016,0.0073,0.028399999999999998,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_NewJersey,201124_USA_CDC_August/September3_NewJersey,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, New Jersey,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-26,2020-09-07,Residual sera,All,Multiple groups,0.0,,Primary Estimate, New Jersey,944,0.128,0.10490000000000001,0.1535,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_NewMexico,201124_USA_CDC_August/September3_NewMexico,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, New Mexico,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-25,2020-09-08,Residual sera,All,Multiple groups,0.0,,Primary Estimate, New Mexico,985,0.037000000000000005,0.022799999999999997,0.0555,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_NewYork,201124_USA_CDC_August/September3_NewYork,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, New York,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-26,2020-09-10,Residual sera,All,Multiple groups,0.0,,Primary Estimate, New York,1043,0.195,0.1688,0.2238,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_NorthCarolina,201124_USA_CDC_August/September3_NorthCarolina,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, North Carolina,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-26,2020-09-09,Residual sera,All,Multiple groups,0.0,,Primary Estimate, North Carolina,982,0.038,0.0233,0.0526,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_NorthDakota,201124_USA_CDC_August/September3_NorthDakota,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, North Dakota,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-26,2020-09-09,Residual sera,All,Multiple groups,0.0,,Primary Estimate, North Dakota,109,0.002,0.0,0.0099,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Ohio,201124_USA_CDC_August/September3_Ohio,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Ohio,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-27,2020-09-10,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Ohio,983,0.05,0.0317,0.0714,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Oklahoma,201124_USA_CDC_August/September3_Oklahoma,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Oklahoma,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-24,2020-09-01,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Oklahoma,979,0.054000000000000006,0.0383,0.0729,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Oregon,201124_USA_CDC_August/September3_Oregon,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Oregon,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-26,2020-09-10,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Oregon,968,0.019,0.0092,0.0294,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Pennsylvania,201124_USA_CDC_August/September3_Pennsylvania,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Pennsylvania,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-26,2020-09-09,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Pennsylvania,845,0.095,0.0658,0.1356,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_PuertoRico,201124_USA_CDC_August/September3_PuertoRico,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Puerto Rico,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-24,2020-09-03,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Puerto Rico,980,0.025,0.013600000000000001,0.0376,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_RhodeIsland,201124_USA_CDC_August/September3_RhodeIsland,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Rhode Island,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-27,2020-09-10,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Rhode Island,786,0.031000000000000003,0.0173,0.0464,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_SouthCarolina,201124_USA_CDC_August/September3_SouthCarolina,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, South Carolina,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-26,2020-09-10,Residual sera,All,Multiple groups,0.0,,Primary Estimate, South Carolina,927,0.07200000000000001,0.0512,0.09570000000000001,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_SouthDakota,201124_USA_CDC_August/September3_SouthDakota,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, South Dakota,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-26,2020-09-10,Residual sera,All,Multiple groups,0.0,,Primary Estimate, South Dakota,97,0.006999999999999999,0.0,0.024700000000000003,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Tennessee,201124_USA_CDC_August/September3_Tennessee,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Tennessee,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-25,2020-09-08,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Tennessee,950,0.054000000000000006,0.0362,0.0731,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Texas,201124_USA_CDC_August/September3_Texas,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Texas,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-25,2020-09-02,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Texas,979,0.057999999999999996,0.0404,0.0792,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Utah,201124_USA_CDC_August/September3_Utah,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Utah,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-24,2020-09-08,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Utah,1104,0.049,0.0282,0.0767,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Vermont,201124_USA_CDC_August/September3_Vermont,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Vermont,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-26,2020-09-10,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Vermont,485,0.004,0.0,0.0094,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Virginia,201124_USA_CDC_August/September3_Virginia,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Virginia,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-26,2020-09-08,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Virginia,1007,0.035,0.0197,0.0526,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Washington,201124_USA_CDC_August/September3_Washington,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Washington,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-25,2020-09-10,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Washington,820,0.045,0.0263,0.0694,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_WashingtonD.C,201124_USA_CDC_August/September3_WashingtonD.C,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Washington D.C,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-27,2020-09-10,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Washington D.C,643,0.05,0.028300000000000002,0.0755,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_WestVirginia,201124_USA_CDC_August/September3_WestVirginia,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, West Virginia,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-26,2020-09-10,Residual sera,All,Multiple groups,0.0,,Primary Estimate, West Virginia,1128,0.015,0.0078000000000000005,0.023799999999999998,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August/September3_Wisconsin,201124_USA_CDC_August/September3_Wisconsin,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Wisconsin,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-25,2020-09-10,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Wisconsin,976,0.026000000000000002,0.0148,0.0395,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Alabama,201124_USA_CDC_August2_Alabama,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Alabama,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-12,2020-08-26,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Alabama,974,0.076,0.0533,0.0976,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Alaska,201124_USA_CDC_August2_Alaska,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Alaska,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-12,2020-08-26,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Alaska,704,0.013000000000000001,0.005,0.0233,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Arizona,201124_USA_CDC_August2_Arizona,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Arizona,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-12,2020-08-26,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Arizona,1304,0.047,0.027000000000000003,0.0761,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Arkansas,201124_USA_CDC_August2_Arkansas,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Arkansas,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-11,2020-08-25,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Arkansas,998,0.03,0.0176,0.0435,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_California,201124_USA_CDC_August2_California,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,California,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-13,2020-08-19,Residual sera,All,Multiple groups,0.0,,Primary Estimate,California,980,0.043,0.0285,0.060599999999999994,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Colorado,201124_USA_CDC_August2_Colorado,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Colorado,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-10,2020-08-25,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Colorado,1019,0.033,0.0183,0.048,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Connecticut,201124_USA_CDC_August2_Connecticut,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Connecticut,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-11,2020-08-24,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Connecticut,983,0.024,0.014499999999999999,0.0352,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Delaware,201124_USA_CDC_August2_Delaware,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Delaware,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-12,2020-08-27,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Delaware,1004,0.085,0.0579,0.1125,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Florida,201124_USA_CDC_August2_Florida,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Florida,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-14,2020-08-14,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Florida,978,0.045,0.0315,0.060599999999999994,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Georgia,201124_USA_CDC_August2_Georgia,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Georgia,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-13,2020-08-26,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Georgia,1031,0.07400000000000001,0.0552,0.0951,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Idaho,201124_USA_CDC_August2_Idaho,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Idaho,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-12,2020-08-26,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Idaho,651,0.046,0.0167,0.09050000000000001,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Illinois,201124_USA_CDC_August2_Illinois,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Illinois,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-12,2020-08-27,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Illinois,985,0.049,0.034,0.0665,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Indiana,201124_USA_CDC_August2_Indiana,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Indiana,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-12,2020-08-26,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Indiana,906,0.031000000000000003,0.015300000000000001,0.047599999999999996,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Iowa,201124_USA_CDC_August2_Iowa,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Iowa,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-12,2020-08-27,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Iowa,980,0.094,0.0712,0.11630000000000001,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Kansas,201124_USA_CDC_August2_Kansas,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Kansas,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-11,2020-08-25,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Kansas,1016,0.037000000000000005,0.0202,0.0547,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Kentucky,201124_USA_CDC_August2_Kentucky,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Kentucky,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-12,2020-08-26,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Kentucky,1126,0.031000000000000003,0.020499999999999997,0.0449,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Louisiana,201124_USA_CDC_August2_Louisiana,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Louisiana,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-12,2020-08-25,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Louisiana,989,0.11800000000000001,0.09269999999999999,0.1481,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Maine,201124_USA_CDC_August2_Maine,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Maine,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-12,2020-08-27,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Maine,609,0.006,0.0,0.0144,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Maryland,201124_USA_CDC_August2_Maryland,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Maryland,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-10,2020-08-26,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Maryland,1174,0.07,0.0492,0.09330000000000001,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Massachusetts,201124_USA_CDC_August2_Massachusetts,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Massachusetts,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-12,2020-08-27,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Massachusetts,980,0.037000000000000005,0.0227,0.0521,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Michigan,201124_USA_CDC_August2_Michigan,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Michigan,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-12,2020-08-25,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Michigan,983,0.042,0.0288,0.0576,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Minnesota,201124_USA_CDC_August2_Minnesota,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Minnesota,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-11,2020-08-27,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Minnesota,978,0.045,0.0305,0.0587,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Mississippi,201124_USA_CDC_August2_Mississippi,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Mississippi,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-12,2020-08-27,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Mississippi,968,0.1,0.0669,0.1471,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Missouri,201124_USA_CDC_August2_Missouri,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Missouri,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-12,2020-08-21,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Missouri,1021,0.035,0.0223,0.0506,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Montana,201124_USA_CDC_August2_Montana,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Montana,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-12,2020-08-24,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Montana,383,0.013000000000000001,0.0038,0.024900000000000002,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Nebraska,201124_USA_CDC_August2_Nebraska,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Nebraska,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-11,2020-08-25,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Nebraska,990,0.079,0.055099999999999996,0.1061,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Nevada,201124_USA_CDC_August2_Nevada,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Nevada,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-12,2020-08-26,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Nevada,972,0.079,0.0613,0.0983,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_NewHampshire,201124_USA_CDC_August2_NewHampshire,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, New Hampshire,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-13,2020-08-25,Residual sera,All,Multiple groups,0.0,,Primary Estimate, New Hampshire,1125,0.008,0.003,0.0122,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_NewJersey,201124_USA_CDC_August2_NewJersey,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, New Jersey,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-10,2020-08-26,Residual sera,All,Multiple groups,0.0,,Primary Estimate, New Jersey,1127,0.122,0.1015,0.14529999999999998,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_NewMexico,201124_USA_CDC_August2_NewMexico,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, New Mexico,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-10,2020-08-27,Residual sera,All,Multiple groups,0.0,,Primary Estimate,New Mexico,976,0.025,0.0147,0.0379,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_NewYork,201124_USA_CDC_August2_NewYork,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, New York,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-10,2020-08-26,Residual sera,All,Multiple groups,0.0,,Primary Estimate, New York,1122,0.20600000000000002,0.1804,0.23140000000000002,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_NorthCarolina,201124_USA_CDC_August2_NorthCarolina,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, North Carolina,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-11,2020-08-27,Residual sera,All,Multiple groups,0.0,,Primary Estimate, North Carolina,982,0.038,0.0233,0.0529,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_NorthDakota,201124_USA_CDC_August2_NorthDakota,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, North Dakota,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-12,2020-08-26,Residual sera,All,Multiple groups,0.0,,Primary Estimate, North Dakota,135,0.006,0.0,0.014499999999999999,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Ohio,201124_USA_CDC_August2_Ohio,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Ohio,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-12,2020-08-27,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Ohio,985,0.021,0.0106,0.0329,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Oklahoma,201124_USA_CDC_August2_Oklahoma,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Oklahoma,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-10,2020-08-18,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Oklahoma,979,0.04,0.027200000000000002,0.055099999999999996,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Oregon,201124_USA_CDC_August2_Oregon,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Oregon,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-10,2020-08-27,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Oregon,1086,0.024,0.0141,0.036000000000000004,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Pennsylvania,201124_USA_CDC_August2_Pennsylvania,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Pennsylvania,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-10,2020-08-26,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Pennsylvania,887,0.10099999999999999,0.0753,0.1374,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_PuertoRico,201124_USA_CDC_August2_PuertoRico,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Puerto Rico,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-10,2020-08-17,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Puerto Rico,986,0.022000000000000002,0.0118,0.0326,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_RhodeIsland,201124_USA_CDC_August2_RhodeIsland,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Rhode Island,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-12,2020-08-27,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Rhode Island,570,0.036000000000000004,0.0169,0.0589,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_SouthCarolina,201124_USA_CDC_August2_SouthCarolina,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, South Carolina,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-12,2020-08-27,Residual sera,All,Multiple groups,0.0,,Primary Estimate, South Carolina,1063,0.06,0.0437,0.0795,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_SouthDakota,201124_USA_CDC_August2_SouthDakota,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, South Dakota,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-12,2020-08-26,Residual sera,All,Multiple groups,0.0,,Primary Estimate, South Dakota,83,0.0,0.0,0.0435,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Tennessee,201124_USA_CDC_August2_Tennessee,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Tennessee,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-12,2020-08-26,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Tennessee,1029,0.067,0.051100000000000007,0.0857,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Texas,201124_USA_CDC_August2_Texas,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Texas,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-12,2020-08-24,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Texas,1001,0.065,0.046900000000000004,0.08470000000000001,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Utah,201124_USA_CDC_August2_Utah,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Utah,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-15,2020-08-25,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Utah,871,0.055,0.0294,0.08710000000000001,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Vermont,201124_USA_CDC_August2_Vermont,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Vermont,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-13,2020-08-27,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Vermont,382,0.003,0.0,0.008100000000000001,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Virginia,201124_USA_CDC_August2_Virginia,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Virginia,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-10,2020-08-26,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Virginia,1243,0.047,0.025099999999999997,0.0722,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Washington,201124_USA_CDC_August2_Washington,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Washington,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-12,2020-08-27,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Washington,1238,0.03,0.0179,0.0447,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Washington D.C,201124_USA_CDC_August2_Washington D.C,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Washington D.C,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-13,2020-08-27,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Washington D.C,781,0.068,0.045899999999999996,0.09210000000000002,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_WestVirginia,201124_USA_CDC_August2_WestVirginia,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, West Virginia,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-13,2020-08-27,Residual sera,All,Multiple groups,0.0,,Primary Estimate, West Virginia,637,0.022000000000000002,0.005200000000000001,0.049,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Wisconsin,201124_USA_CDC_August2_Wisconsin,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Wisconsin,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-12,2020-08-27,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Wisconsin,838,0.033,0.0203,0.0472,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_August2_Wyoming,201124_USA_CDC_August2_Wyoming,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Wyoming,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-13,2020-08-24,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Wyoming,86,0.008,0.0,0.0311,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Alabama,201124_USA_CDC_July/August1_Alabama,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Alabama,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-29,2020-08-13,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Alabama,938,0.057999999999999996,0.041600000000000005,0.0771,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Alaska,201124_USA_CDC_July/August1_Alaska,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Alaska,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-06,2020-08-11,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Alaska,242,0.003,0.0,0.011200000000000002,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Arizona,201124_USA_CDC_July/August1_Arizona,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Arizona,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-31,2020-08-11,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Arizona,591,0.08199999999999999,0.041100000000000005,0.1359,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Arkansas,201124_USA_CDC_July/August1_Arkansas,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Arkansas,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-29,2020-08-13,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Arkansas,937,0.040999999999999995,0.027400000000000004,0.0563,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_California,201124_USA_CDC_July/August1_California,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,California,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-30,2020-08-05,Residual sera,All,Multiple groups,0.0,,Primary Estimate,California,980,0.057,0.0405,0.07769999999999999,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Colorado,201124_USA_CDC_July/August1_Colorado,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Colorado,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-30,2020-08-07,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Colorado,1001,0.024,0.0089,0.0453,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Connecticut,201124_USA_CDC_July/August1_Connecticut,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Connecticut,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-30,2020-08-03,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Connecticut,994,0.034,0.0204,0.0472,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Delaware,201124_USA_CDC_July/August1_Delaware,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Delaware,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-29,2020-08-13,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Delaware,804,0.057,0.0355,0.08220000000000001,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Florida,201124_USA_CDC_July/August1_Florida,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Florida,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-31,2020-08-03,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Florida,980,0.043,0.027700000000000002,0.058600000000000006,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Georgia,201124_USA_CDC_July/August1_Georgia,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Georgia,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-02,2020-08-11,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Georgia,985,0.068,0.0483,0.08810000000000001,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Idaho,201124_USA_CDC_July/August1_Idaho,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Idaho,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-04,2020-08-11,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Idaho,246,0.045,0.018000000000000002,0.0799,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Illinois,201124_USA_CDC_July/August1_Illinois,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Illinois,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-29,2020-08-10,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Illinois,1004,0.039,0.0252,0.0521,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Indiana,201124_USA_CDC_July/August1_Indiana,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Indiana,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-31,2020-08-11,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Indiana,579,0.022000000000000002,0.011000000000000001,0.0363,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Iowa,201124_USA_CDC_July/August1_Iowa,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Iowa,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-29,2020-08-13,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Iowa,811,0.086,0.059800000000000006,0.1134,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Kansas,201124_USA_CDC_July/August1_Kansas,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Kansas,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-29,2020-08-08,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Kansas,962,0.016,0.006999999999999999,0.027999999999999997,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Kentucky,201124_USA_CDC_July/August1_Kentucky,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Kentucky,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-30,2020-08-13,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Kentucky,975,0.024,0.013200000000000002,0.0362,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Louisiana,201124_USA_CDC_July/August1_Louisiana,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Louisiana,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-28,2020-08-13,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Louisiana,1002,0.096,0.0688,0.1229,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Maine,201124_USA_CDC_July/August1_Maine,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Maine,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-30,2020-08-11,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Maine,598,0.005,0.0,0.0116,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Maryland,201124_USA_CDC_July/August1_Maryland,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Maryland,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-31,2020-08-11,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Maryland,783,0.09699999999999999,0.0726,0.12869999999999998,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Massachusetts,201124_USA_CDC_July/August1_Massachusetts,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Massachusetts,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-30,2020-08-10,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Massachusetts,978,0.042,0.028900000000000002,0.0581,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Michigan,201124_USA_CDC_July/August1_Michigan,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Michigan,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-30,2020-08-11,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Michigan,982,0.034,0.0216,0.0484,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Minnesota,201124_USA_CDC_July/August1_Minnesota,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Minnesota,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-29,2020-08-13,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Minnesota,879,0.035,0.0206,0.0501,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Mississippi,201124_USA_CDC_July/August1_Mississippi,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Mississippi,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-30,2020-08-13,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Mississippi,769,0.071,0.0375,0.1109,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Missouri,201124_USA_CDC_July/August1_Missouri,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Missouri,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-28,2020-08-10,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Missouri,979,0.025,0.0144,0.0361,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Montana,201124_USA_CDC_July/August1_Montana,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Montana,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-29,2020-08-10,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Montana,199,0.005,0.0,0.0167,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Nebraska,201124_USA_CDC_July/August1_Nebraska,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Nebraska,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-28,2020-08-13,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Nebraska,954,0.07400000000000001,0.0525,0.0975,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Nevada,201124_USA_CDC_July/August1_Nevada,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Nevada,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-30,2020-08-02,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Nevada,979,0.051,0.0363,0.0666,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_NewHampshire,201124_USA_CDC_July/August1_NewHampshire,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, New Hampshire,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-30,2020-08-11,Residual sera,All,Multiple groups,0.0,,Primary Estimate, New Hampshire,809,0.008,0.0022,0.0148,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_NewJersey,201124_USA_CDC_July/August1_NewJersey,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, New Jersey,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-31,2020-08-11,Residual sera,All,Multiple groups,0.0,,Primary Estimate, New Jersey,871,0.14800000000000002,0.1223,0.1757,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_NewMexico,201124_USA_CDC_July/August1_NewMexico,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, New Mexico,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-29,2020-08-13,Residual sera,All,Multiple groups,0.0,,Primary Estimate, New Mexico,964,0.02,0.010900000000000002,0.0302,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_NewYork,201124_USA_CDC_July/August1_NewYork,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, New York,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-31,2020-08-11,Residual sera,All,Multiple groups,0.0,,Primary Estimate, New York,846,0.233,0.20070000000000002,0.2632,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_NorthCarolina,201124_USA_CDC_July/August1_NorthCarolina,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, North Carolina,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-29,2020-08-10,Residual sera,All,Multiple groups,0.0,,Primary Estimate, North Carolina,928,0.025,0.0131,0.037200000000000004,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_NorthDakota,201124_USA_CDC_July/August1_NorthDakota,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, North Dakota,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-29,2020-08-12,Residual sera,All,Multiple groups,0.0,,Primary Estimate, North Dakota,121,0.073,0.013000000000000001,0.1428,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Ohio,201124_USA_CDC_July/August1_Ohio,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Ohio,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-29,2020-08-11,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Ohio,786,0.023,0.0111,0.0361,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Oklahoma,201124_USA_CDC_July/August1_Oklahoma,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Oklahoma,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-28,2020-08-04,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Oklahoma,979,0.016,0.0085,0.024900000000000002,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Oregon,201124_USA_CDC_July/August1_Oregon,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Oregon,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-08-05,2020-08-11,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Oregon,658,0.023,0.0103,0.0384,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Pennsylvania,201124_USA_CDC_July/August1_Pennsylvania,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Pennsylvania,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-31,2020-08-11,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Pennsylvania,575,0.102,0.0571,0.1721,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_PuertoRico,201124_USA_CDC_July/August1_PuertoRico,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Puerto Rico,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-27,2020-08-07,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Puerto Rico,984,0.011000000000000001,0.0043,0.018000000000000002,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_RhodeIsland,201124_USA_CDC_July/August1_RhodeIsland,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Rhode Island,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-30,2020-08-11,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Rhode Island,684,0.03,0.0123,0.055099999999999996,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_SouthCarolina,201124_USA_CDC_July/August1_SouthCarolina,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, South Carolina,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-30,2020-08-13,Residual sera,All,Multiple groups,0.0,,Primary Estimate, South Carolina,840,0.081,0.0579,0.1069,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Tennessee,201124_USA_CDC_July/August1_Tennessee,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Tennessee,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-30,2020-08-11,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Tennessee,1003,0.063,0.0441,0.0825,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Texas,201124_USA_CDC_July/August1_Texas,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Texas,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-29,2020-08-05,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Texas,986,0.059000000000000004,0.0404,0.0795,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Utah,201124_USA_CDC_July/August1_Utah,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Utah,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-30,2020-08-11,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Utah,880,0.032,0.017,0.050300000000000004,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Vermont,201124_USA_CDC_July/August1_Vermont,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Vermont,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-30,2020-08-11,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Vermont,346,0.005,0.0,0.0184,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Virginia,201124_USA_CDC_July/August1_Virginia,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Virginia,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-31,2020-08-11,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Virginia,730,0.040999999999999995,0.018000000000000002,0.0693,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Washington,201124_USA_CDC_July/August1_Washington,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Washington,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-29,2020-08-11,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Washington,684,0.021,0.008100000000000001,0.037000000000000005,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Washington D.C,201124_USA_CDC_July/August1_Washington D.C,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Washington D.C,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-30,2020-08-13,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Washington D.C,717,0.039,0.021800000000000003,0.0576,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_WestVirginia,201124_USA_CDC_July/August1_WestVirginia,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, West Virginia,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-30,2020-08-13,Residual sera,All,Multiple groups,0.0,,Primary Estimate, West Virginia,317,0.012,0.0023,0.025,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_July/August1_Wisconsin,201124_USA_CDC_July/August1_Wisconsin,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Wisconsin,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-07-30,2020-08-13,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Wisconsin,814,0.018000000000000002,0.0076,0.0318,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Alabama,201124_USA_CDC_September4_Alabama,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Alabama,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-18,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Alabama,905,0.087,0.061900000000000004,0.1131,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Alaska,201124_USA_CDC_September4_Alaska,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Alaska,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-18,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Alaska,681,0.004,0.0011,0.008199999999999999,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Arizona,201124_USA_CDC_September4_Arizona,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Arizona,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-23,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Arizona,1208,0.054000000000000006,0.0308,0.0852,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Arkansas,201124_USA_CDC_September4_Arkansas,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Arkansas,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-18,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Arkansas,990,0.063,0.046,0.0803,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_California,201124_USA_CDC_September4_California,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,California,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-10,2020-09-16,Residual sera,All,Multiple groups,0.0,,Primary Estimate,California,979,0.049,0.0317,0.06849999999999999,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Colorado,201124_USA_CDC_September4_Colorado,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Colorado,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-18,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Colorado,1032,0.033,0.019,0.0492,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Connecticut,201124_USA_CDC_September4_Connecticut,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Connecticut,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-14,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Connecticut,982,0.031000000000000003,0.0206,0.0437,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Delaware,201124_USA_CDC_September4_Delaware,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Delaware,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-24,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Delaware,980,0.075,0.0489,0.105,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Florida,201124_USA_CDC_September4_Florida,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Florida,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-11,2020-09-11,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Florida,979,0.085,0.0655,0.1068,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Georgia,201124_USA_CDC_September4_Georgia,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Georgia,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-18,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Georgia,1100,0.13,0.1051,0.15789999999999998,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Hawaii,201124_USA_CDC_September4_Hawaii,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Hawaii,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-08,2020-09-22,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Hawaii,516,0.008,0.0,0.021800000000000003,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Idaho,201124_USA_CDC_September4_Idaho,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Idaho,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-08,2020-09-18,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Idaho,732,0.052000000000000005,0.027400000000000004,0.08460000000000001,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Illinois,201124_USA_CDC_September4_Illinois,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Illinois,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-08,2020-09-17,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Illinois,992,0.045,0.031000000000000003,0.060700000000000004,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Indiana,201124_USA_CDC_September4_Indiana,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Indiana,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-23,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Indiana,1155,0.04,0.0144,0.08789999999999999,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Iowa,201124_USA_CDC_September4_Iowa,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Iowa,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-24,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Iowa,977,0.076,0.0556,0.1002,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Kansas,201124_USA_CDC_September4_Kansas,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Kansas,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-19,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Kansas,1007,0.035,0.023100000000000002,0.0484,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Kentucky,201124_USA_CDC_September4_Kentucky,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Kentucky,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-18,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Kentucky,980,0.036000000000000004,0.0233,0.0521,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Louisiana,201124_USA_CDC_September4_Louisiana,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Louisiana,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-19,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Louisiana,952,0.125,0.1002,0.1561,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Maine,201124_USA_CDC_September4_Maine,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Maine,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-08,2020-09-24,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Maine,987,0.005,0.0009,0.0087,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Maryland,201124_USA_CDC_September4_Maryland,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Maryland,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-10,2020-09-23,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Maryland,1242,0.102,0.0791,0.1268,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Massachusetts,201124_USA_CDC_September4_Massachusetts,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Massachusetts,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-15,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Massachusetts,988,0.037000000000000005,0.0223,0.0516,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Michigan,201124_USA_CDC_September4_Michigan,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Michigan,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-08,2020-09-22,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Michigan,980,0.037000000000000005,0.025400000000000002,0.0493,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Minnesota,201124_USA_CDC_September4_Minnesota,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Minnesota,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-23,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Minnesota,1033,0.08,0.047400000000000005,0.1143,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Mississippi,201124_USA_CDC_September4_Mississippi,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Mississippi,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-22,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Mississippi,980,0.079,0.0535,0.10869999999999999,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Missouri,201124_USA_CDC_September4_Missouri,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Missouri,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-08,2020-09-24,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Missouri,1031,0.035,0.0215,0.0501,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Montana,201124_USA_CDC_September4_Montana,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Montana,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-23,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Montana,508,0.022000000000000002,0.0067,0.0438,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Nebraska,201124_USA_CDC_September4_Nebraska,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Nebraska,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-18,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Nebraska,976,0.067,0.048,0.0888,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Nevada,201124_USA_CDC_September4_Nevada,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Nevada,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-12,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Nevada,979,0.078,0.059000000000000004,0.0999,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_NewHampshire,201124_USA_CDC_September4_NewHampshire,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, New Hampshire,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-17,Residual sera,All,Multiple groups,0.0,,Primary Estimate, New Hampshire,1034,0.006999999999999999,0.0026000000000000003,0.013200000000000002,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_NewJersey,201124_USA_CDC_September4_NewJersey,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, New Jersey,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-23,Residual sera,All,Multiple groups,0.0,,Primary Estimate, New Jersey,1050,0.151,0.1265,0.17629999999999998,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_NewMexico,201124_USA_CDC_September4_NewMexico,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, New Mexico,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-08,2020-09-24,Residual sera,All,Multiple groups,0.0,,Primary Estimate, New Mexico,1014,0.024,0.011899999999999999,0.0365,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_NewYork,201124_USA_CDC_September4_NewYork,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, New York,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-11,2020-09-24,Residual sera,All,Multiple groups,0.0,,Primary Estimate, New York,1168,0.17,0.1472,0.1923,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_NorthCarolina,201124_USA_CDC_September4_NorthCarolina,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, North Carolina,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-17,Residual sera,All,Multiple groups,0.0,,Primary Estimate, North Carolina,925,0.068,0.0483,0.08869999999999999,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_NorthDakota,201124_USA_CDC_September4_NorthDakota,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, North Dakota,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-24,Residual sera,All,Multiple groups,0.0,,Primary Estimate, North Dakota,113,0.012,0.0,0.034,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Ohio,201124_USA_CDC_September4_Ohio,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Ohio,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-10,2020-09-22,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Ohio,978,0.027999999999999997,0.0169,0.041600000000000005,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Oklahoma,201124_USA_CDC_September4_Oklahoma,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Oklahoma,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-18,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Oklahoma,980,0.05,0.0344,0.0654,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Oregon,201124_USA_CDC_September4_Oregon,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Oregon,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-08,2020-09-22,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Oregon,971,0.026000000000000002,0.0151,0.0406,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Pennsylvania,201124_USA_CDC_September4_Pennsylvania,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Pennsylvania,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-23,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Pennsylvania,1341,0.111,0.0885,0.1371,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_PuertoRico,201124_USA_CDC_September4_PuertoRico,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Puerto Rico,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-08,2020-09-15,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Puerto Rico,970,0.03,0.0178,0.042699999999999995,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_RhodeIsland,201124_USA_CDC_September4_RhodeIsland,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Rhode Island,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-24,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Rhode Island,795,0.027000000000000003,0.0115,0.049100000000000005,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_SouthCarolina,201124_USA_CDC_September4_SouthCarolina,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, South Carolina,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-18,Residual sera,All,Multiple groups,0.0,,Primary Estimate, South Carolina,975,0.078,0.0558,0.10189999999999999,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_SouthDakota,201124_USA_CDC_September4_SouthDakota,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, South Dakota,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-23,Residual sera,All,Multiple groups,0.0,,Primary Estimate, South Dakota,99,0.018000000000000002,0.0,0.04820000000000001,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Tennessee,201124_USA_CDC_September4_Tennessee,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Tennessee,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-08,2020-09-16,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Tennessee,1028,0.067,0.0496,0.0857,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Texas,201124_USA_CDC_September4_Texas,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Texas,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-24,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Texas,988,0.08199999999999999,0.0616,0.10470000000000002,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Utah,201124_USA_CDC_September4_Utah,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Utah,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-18,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Utah,1022,0.051,0.0329,0.079,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Vermont,201124_USA_CDC_September4_Vermont,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Vermont,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-24,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Vermont,497,0.017,0.0027,0.0415,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Virginia,201124_USA_CDC_September4_Virginia,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Virginia,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-10,2020-09-23,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Virginia,1111,0.032,0.0181,0.0513,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Washington,201124_USA_CDC_September4_Washington,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Washington,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-22,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Washington,968,0.025,0.0129,0.0383,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Washington D.C,201124_USA_CDC_September4_Washington D.C,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Washington D.C,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-08,2020-09-24,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Washington D.C,976,0.065,0.0447,0.08289999999999999,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_WestVirginia,201124_USA_CDC_September4_WestVirginia,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, West Virginia,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-22,Residual sera,All,Multiple groups,0.0,,Primary Estimate, West Virginia,968,0.013000000000000001,0.0051,0.021800000000000003,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Wisconsin,201124_USA_CDC_September4_Wisconsin,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Wisconsin,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-24,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Wisconsin,976,0.038,0.022000000000000002,0.057300000000000004,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201124_USA_CDC_September4_Wyoming,201124_USA_CDC_September4_Wyoming,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,2020-11-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America, Wyoming,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico between July 27 and September 24, 2020, were analyzed. ",Specimens excluded if any requests for SARS- CoV-2 antibody testing were noted. (To reduce selection bias,2020-09-09,2020-09-24,Residual sera,All,Multiple groups,0.0,,Primary Estimate, Wyoming,111,0.015,0.0,0.039700000000000006,True,True,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,No,Unclear,Unclear,No,Yes,,Kristina Bajema,CDC COVID-19 Response,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2020.7976,2021-03-20,2023-08-15,Verified,bajema_estimated_2020,USA
201120_LosAngeles_TheLundquistInstitute_genpop,201120_LosAngeles_TheLundquistInstitute,"COVID-19 IgG/IgM antibody testing in Los Angeles County, California",2020-11-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,"We administered the test to 244 participants from three
groups, those with past exposure/possible infection,
healthcare professionals at an LA County hospital, and first
responders (firefighters, police officers, and paramedics)",,2020-04-21,2020-05-22,Multiple populations,All,Multiple groups,,,Primary Estimate,,244,0.209,,,True,,,,True,Unclear,SARS-COV-2-IgG/IgM Test Cassette,Hangzhou Testsea Biotechnology Co. Ltd,LFIA,Multiple Types,"['IgG', 'IgM']",,Validated by manufacturers,0.96,1.0,['High'],No,Unclear,No,Yes,Unclear,Unclear,Yes,Yes,Unclear,Khadije Ahmad,The Lundquist Institute ,Not Unity-Aligned,https://dx.doi.org/10.1007/s10096-020-04111-3,2021-01-19,2023-07-04,Verified,ahmad_covid-19_2020,USA
201127_DistrictofColumbia_DCHealth_Overall,201127_DistrictofColumbia_DCHealth,"SARS-CoV-2 Seroprevalence among First Responders in the District of Columbia, May – July 2020",2020-11-27,Preprint,Regional,Cross-sectional survey ,United States of America,Washington D.C,Washington,"any employee, staff, or volunteer working for or contracted by the District of Columbia to perform fire safety and rescue, police, or any other function to protect the health, safety, and welfare of the public. This included personnel in law enforcement, fire and rescue, and emergency medical response",Otherwise eligible persons who reported having a positive COVID-19 diagnostic test within the past 14 days or reported onset of symptoms consistent with COVID-19 in the past seven days of questionnaire administration were excluded.,2020-05-28,2020-07-15,Essential non-healthcare workers,All,Adults (18-64 years),22.0,68.0,Primary Estimate,Overall,310,0.0355,,,True,,,,True,Self-referral,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.97,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,Yes,Jacqueline Reuben,District of Columbia Department of Health (DC Health),Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.11.25.20225490v1,2021-01-21,2024-03-01,Verified,reuben_sars-cov-2_2020,USA
201027_Indiana_Harvard_Overall_testadj,201027_Indiana_Harvard,Seroprevalence of anti-SARS-CoV-2 IgG Antibodies in the Staff of a Public School System in the Midwestern United States,2020-11-27,Preprint,Local,Cross-sectional survey ,United States of America,Indiana,St. John Township,Staff in Lake Central School Corporation,,2020-07-15,2020-07-20,Essential non-healthcare workers,All,Multiple groups,18.0,,Primary Estimate,,753,0.017,0.0027,0.033,True,True,,,,Self-referral,Not reported/ Unable to specify,,,Whole Blood,IgG,,,1.0,0.99,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Lilah Lopez,Harvard Medical School,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.10.23.20218651v1,2021-01-05,2023-07-04,Verified,lopez_seroprevalence_2020,USA
201128_LasVegas_SunriseHealthConsortium_Overall,201128_LasVegas_SunriseHealthConsortium,"SARS-CoV-2 Antibody Positivity and Prevalence in an Outpatient Medical Setting in Las Vegas, NV",2020-11-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Nevada,Las Vegas,"patients, staff and visitors of a primary care clinic in Las Vegas, NV",There were no exclusion criteria.,2020-04-15,2020-06-15,Multiple populations,All,Multiple groups,3.0,92.0,Primary Estimate,IgG or IgM,319,0.0376,,,True,,,,True,Convenience,SARS-COV-2-IgG/IgM Test Cassette,Hangzhou Testsea Biotechnology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",Spike,Validated by manufacturers,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Sassan Kaveh,Sunrise Health Consortium,Not Unity-Aligned,https://dx.doi.org/10.36518/2689-0216.1158,2023-08-01,2023-08-15,Unverified,kaveh_sars-cov-2_2020,USA
201130_SanFrancisco_StanfordUniversity_Overall,201130_SanFrancisco_StanfordUniversity,Large-Scale Testing of Asymptomatic Healthcare Personnel for Severe Acute Respiratory Syndrome Coronavirus 2,2020-11-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,San Francisco,All health care personnel in the Stanford Health Care system,persons with a positive rRT-PCR result and an illness consistent with COVID-19 in the preceding 6 weeks,2020-04-20,2020-06-08,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Overall,12418,0.009000000000000001,0.006999999999999999,0.011000000000000001,True,,,,True,Self-referral,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,Validated by developers,,0.9975,['Moderate'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,No,Yes,Catherine Hogan,Stanford University,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2701.203892,2021-01-22,2022-07-16,Verified,hogan_large-scale_2020,USA
201201_LosAngeles_UniversityofSouthernCalifornia_UniversityStudents_Overall,201201_LosAngeles_UniversityofSouthernCalifornia,A Cross-Sectional Study Examining the Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in a University Student Population,2020-12-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,Los Angeles,"Inclusion criteria were (1) participants were eligible to access services at the student health center (i.e., students must be enrolled in six or more credit hours for on-campus programs, not in online degree programs) and (2) students’ primary campus was the main campus for this institution (this was a practical consideration).  Study was conducted at a large urban University in Los Angeles, CA.","Exclusion criteria included (1) students aged <18 years and (2) students who were not in the randomly selected pool of potential participants (i.e., students who heard of the study via word of mouth or other similar means were excluded from participating). Although not a criterion for receiving a study invitation, only students still living in the region were truly eligible to participate in this study, given that they had to come to the student health center for a blood draw.",2020-04-29,2020-05-08,Students and Daycares,All,Adults (18-64 years),18.0,,Primary Estimate,,790,0.04,0.03,0.051,True,True,True,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Multiple Types,IgG,,Validated by independent authors/third party/non-developers,0.9,1.0,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Kimberly Tilley,University of Southern California,Not Unity-Aligned,http://dx.doi.org/10.1016/j.jadohealth.2020.09.001,2021-01-07,2023-07-04,Verified,tilley_cross-sectional_2020,USA
201202_Utah_UniversityofUtah_Phase1A_TestAdj,201202_Utah_UniversityofUtah_Phase1A,"Utah HERO Project Tracking Covid-19 to Inform Decision-Makers Summary of Key Findings, Current Trends, and Implications",2020-12-02,Institutional Report,Regional,Cross-sectional survey ,United States of America,Utah,"Salt Lake City, Park City","Households in Utah counties: Salt Lake, Utah, Davis, Summit",,2020-05-01,2020-07-01,Household and community samples,All,Multiple groups,12.0,,Primary Estimate,Phase 1A Test adj,8108,0.008100000000000001,0.0015,0.016200000000000003,True,True,,,,Stratified non-probability,Not reported/ Unable to specify,,,,,,Validated by independent authors/third party/non-developers,0.8300000000000001,0.996,['Moderate'],,No,Yes,No,,Unclear,Yes,Yes,,University of Utah,University of Utah,Not Unity-Aligned,https://issuu.com/ecclesschool/docs/utah_hero_report_11.24.20_gardner_at_front,2021-05-20,2022-07-16,Unverified,noauthor_utah_2020,USA
201202_Utah_UniversityofUtah_Phase1A_Unadj,201202_Utah_UniversityofUtah_Phase1A,"Utah HERO Project Tracking Covid-19 to Inform Decision-Makers Summary of Key Findings, Current Trends, and Implications",2020-12-02,Institutional Report,Regional,Cross-sectional survey ,United States of America,Utah,"Salt Lake City, Park City","Households in Utah counties: Salt Lake, Utah, Davis, Summit",,2020-05-01,2020-07-01,Household and community samples,All,Multiple groups,12.0,,Analysis,Phase 1A Unadj,8108,0.011000000000000001,,,,,,,True,Stratified non-probability,Not reported/ Unable to specify,,,,,,Validated by independent authors/third party/non-developers,0.8300000000000001,0.996,['Moderate'],,No,Yes,No,,Unclear,Yes,Yes,,University of Utah,University of Utah,Not Unity-Aligned,https://issuu.com/ecclesschool/docs/utah_hero_report_11.24.20_gardner_at_front,2021-05-20,2022-07-16,Unverified,noauthor_utah_2020,USA
201202_Utah_UniversityofUtah_Phase1BCache_TestAdj,201202_Utah_UniversityofUtah_Phase1BCache,"Utah HERO Project Tracking Covid-19 to Inform Decision-Makers Summary of Key Findings, Current Trends, and Implications",2020-12-02,Institutional Report,Local,Cross-sectional survey ,United States of America,Utah,,households in Utah: Cache County,,2020-05-01,2020-07-01,Household and community samples,All,Multiple groups,12.0,,Primary Estimate,Phase 1B Cache County test adj,1622,0.023100000000000002,0.0068000000000000005,0.0571,True,True,,,,Simplified probability,Not reported/ Unable to specify,,,,,,Validated by independent authors/third party/non-developers,0.8300000000000001,0.996,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,University of Utah,University of Utah,Not Unity-Aligned,https://issuu.com/ecclesschool/docs/utah_hero_report_11.24.20_gardner_at_front,2021-05-20,2022-07-16,Unverified,noauthor_utah_2020,USA
201202_Utah_UniversityofUtah_Phase1BCache_Unadj,201202_Utah_UniversityofUtah_Phase1BCache,"Utah HERO Project Tracking Covid-19 to Inform Decision-Makers Summary of Key Findings, Current Trends, and Implications",2020-12-02,Institutional Report,Local,Cross-sectional survey ,United States of America,Utah ,,households in Utah: Cache County,,2020-05-01,2020-07-01,Household and community samples,All,Multiple groups,12.0,,Analysis,Phase 1B Cache County unadj,1622,0.021,,,,,,,True,Simplified probability,Not reported/ Unable to specify,,,,,,Validated by independent authors/third party/non-developers,0.8300000000000001,0.996,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,University of Utah,University of Utah,Not Unity-Aligned,https://issuu.com/ecclesschool/docs/utah_hero_report_11.24.20_gardner_at_front,2021-05-20,2022-07-16,Unverified,noauthor_utah_2020,USA
201202_Utah_UniversityofUtah_Phase1BWashington_TestAdj,201202_Utah_UniversityofUtah_Phase1BWashington,"Utah HERO Project Tracking Covid-19 to Inform Decision-Makers Summary of Key Findings, Current Trends, and Implications",2020-12-02,Institutional Report,Local,Cross-sectional survey ,United States of America,Utah,,Households in Utah: Washington County,,2020-05-01,2020-07-01,Household and community samples,All,Multiple groups,12.0,,Primary Estimate,Phase 1B Washington County test adj,1594,0.0051,0.0,0.0159,True,True,,,,Simplified probability,Not reported/ Unable to specify,,,,,,Validated by independent authors/third party/non-developers,0.8300000000000001,0.996,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,University of Utah,University of Utah,Not Unity-Aligned,https://issuu.com/ecclesschool/docs/utah_hero_report_11.24.20_gardner_at_front,2021-05-20,2022-07-16,Unverified,noauthor_utah_2020,USA
201202_Utah_UniversityofUtah_Phase1BWashington_Unadj,201202_Utah_UniversityofUtah_Phase1BWashington,"Utah HERO Project Tracking Covid-19 to Inform Decision-Makers Summary of Key Findings, Current Trends, and Implications",2020-12-02,Institutional Report,Local,Cross-sectional survey ,United States of America,Utah,,Households in Utah: Washington County,,2020-05-01,2020-07-01,Household and community samples,All,Multiple groups,12.0,,Analysis,Phase 1B Washington County unadj,1594,0.0088,,,,,,,True,Simplified probability,Not reported/ Unable to specify,,,,,,Validated by independent authors/third party/non-developers,0.8300000000000001,0.996,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,University of Utah,University of Utah,Not Unity-Aligned,https://issuu.com/ecclesschool/docs/utah_hero_report_11.24.20_gardner_at_front,2021-05-20,2022-07-16,Unverified,noauthor_utah_2020,USA
201202_Utah_UniversityofUtah_Phase1BWeber_TestAdj,201202_Utah_UniversityofUtah_Phase1BWeber,"Utah HERO Project Tracking Covid-19 to Inform Decision-Makers Summary of Key Findings, Current Trends, and Implications",2020-12-02,Institutional Report,Local,Cross-sectional survey ,United States of America,Utah,,Households in Utah: Weber County,,2020-05-01,2020-07-01,Household and community samples,All,Multiple groups,12.0,,Primary Estimate,Phase 1b Weber county test adj,1211,0.0139,0.0027,0.0366,True,True,,,,Simplified probability,Not reported/ Unable to specify,,,,,,Validated by independent authors/third party/non-developers,0.8300000000000001,0.996,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,University of Utah,University of Utah,Not Unity-Aligned,https://issuu.com/ecclesschool/docs/utah_hero_report_11.24.20_gardner_at_front,2021-05-20,2022-07-16,Unverified,noauthor_utah_2020,USA
201202_Utah_UniversityofUtah_Phase1BWeber_Unadj,201202_Utah_UniversityofUtah_Phase1BWeber,"Utah HERO Project Tracking Covid-19 to Inform Decision-Makers Summary of Key Findings, Current Trends, and Implications",2020-12-02,Institutional Report,Local,Cross-sectional survey ,United States of America,Utah,,Households in Utah: Weber County,,2020-05-01,2020-07-01,Household and community samples,All,Multiple groups,12.0,,Analysis,Phase 1B Weber county Test adj,1211,0.0149,,,,,,,True,Simplified probability,Not reported/ Unable to specify,,,,,,Validated by independent authors/third party/non-developers,0.8300000000000001,0.996,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,University of Utah,University of Utah,Not Unity-Aligned,https://issuu.com/ecclesschool/docs/utah_hero_report_11.24.20_gardner_at_front,2021-05-20,2022-07-16,Unverified,noauthor_utah_2020,USA
201202_Utah_UniversityofUtah_Phase2Prelim_TestAdj,201202_Utah_UniversityofUtah_Phase2Prelim,"Utah HERO Project Tracking Covid-19 to Inform Decision-Makers Summary of Key Findings, Current Trends, and Implications",2020-12-02,Institutional Report,Local,Cross-sectional survey ,United States of America,Utah,,Households in Utah: West Salt Lake County ,,2020-07-07,2020-08-15,Household and community samples,All,Multiple groups,12.0,,Primary Estimate,Phase 2 West Salt Lake County test adj,1622,0.0281,0.01,0.0636,True,True,,,,Simplified probability,Not reported/ Unable to specify,,,,,,Validated by independent authors/third party/non-developers,0.8300000000000001,0.996,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,University of Utah,University of Utah,Not Unity-Aligned,https://issuu.com/ecclesschool/docs/utah_hero_report_11.24.20_gardner_at_front,2021-05-20,2022-07-16,Unverified,noauthor_utah_2020,USA
201202_Utah_UniversityofUtah_Phase2Prelim_Unadj,201202_Utah_UniversityofUtah_Phase2Prelim,"Utah HERO Project Tracking Covid-19 to Inform Decision-Makers Summary of Key Findings, Current Trends, and Implications",2020-12-02,Institutional Report,Local,Cross-sectional survey ,United States of America,Utah,,Households in Utah: West Salt Lake County ,,2020-07-07,2020-08-15,Household and community samples,All,Multiple groups,12.0,,Analysis,Phase 2 West Salt Lake County unadj,1622,0.021,,,,,,,True,Simplified probability,Not reported/ Unable to specify,,,,,,Validated by independent authors/third party/non-developers,0.8300000000000001,0.996,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,University of Utah,University of Utah,Not Unity-Aligned,https://issuu.com/ecclesschool/docs/utah_hero_report_11.24.20_gardner_at_front,2021-05-20,2022-07-16,Unverified,noauthor_utah_2020,USA
201203_Florida_FloridaDepartmentOfHealth_primary,201203_Florida_FloridaDepartmentOfHealth,"Lake, Sumter residents testing positive for COVID antibody remain below state average",2020-12-03,News and Media,Regional,Cross-sectional survey ,United States of America,Florida,,Florida residents (unspecified),,2020-05-01,2020-11-30,Household and community samples,All,Multiple groups,,,Primary Estimate,,630838,0.1103,,,True,,,,True,Self-referral,Not reported/ Unable to specify,,,,"['IgG', 'TotalAntibody']",,,,,['High'],Yes,No,Yes,No,Unclear,Unclear,Yes,No,Unclear,Frank Jolley,Florida Department of Health,Not Unity-Aligned,https://www.dailycommercial.com/story/news/2020/12/03/area-residents-covid-antibody-below-state-average/6475413002/,2021-03-07,2022-07-16,Verified,jolley_lake_2020,USA
201203_Florida_FloridaDepartmentOfHealth_age0-4,201203_Florida_FloridaDepartmentOfHealth,"Lake, Sumter residents testing positive for COVID antibody remain below state average",2020-12-03,News and Media,Regional,Cross-sectional survey ,United States of America,Florida,,Florida residents (unspecified),,2020-05-01,2020-11-30,Household and community samples,All,Children and Youth (0-17 years),0.0,4.0,Age,0-4,2483,0.20420000000000002,,,,,,,,Self-referral,Not reported/ Unable to specify,,,,"['IgG', 'TotalAntibody']",,,,,['High'],Yes,No,Yes,No,Unclear,Unclear,Yes,No,Unclear,Frank Jolley,Florida Department of Health,Not Unity-Aligned,https://www.dailycommercial.com/story/news/2020/12/03/area-residents-covid-antibody-below-state-average/6475413002/,2021-03-07,2022-07-16,Verified,jolley_lake_2020,USA
201203_AraphoeCounty_UniversityofColorado,201203_AraphoeCounty_UniversityofColorado,Risk Factors of SARS-CoV-2 Antibodies in Arapahoe County First Responders - the COVID-19 Arapahoe SErosurveillance Study (CASES) Project.,2020-12-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Colorado,,"Individuals were eligible to participate in the study if they were First Responders employed by an Arapahoe County agency since January 2020, had direct contact with the public, and were 20-69 years old",Excluded if exhibiting COVID-19 like symptoms,2020-07-15,2020-08-15,Essential non-healthcare workers,All,Adults (18-64 years),20.0,69.0,Primary Estimate,Overall estimate,264,0.04,,,True,,,,True,Convenience,,Exsera BioLabs,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.85,0.986,['High'],Yes,No,No,Yes,Unclear,Unclear,Yes,No,Unclear,Katherine Sabourin,University of Colorado,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/33298759/,2021-01-28,2022-07-16,Verified,sabourin_risk_2020,USA
201203_AraphoeCounty_UniversityofColorado_65+,201203_AraphoeCounty_UniversityofColorado,Risk Factors of SARS-CoV-2 Antibodies in Arapahoe County First Responders - the COVID-19 Arapahoe SErosurveillance Study (CASES) Project.,2020-12-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Colorado,,"Individuals were eligible to participate in the study if they were First Responders employed by an Arapahoe County agency since January 2020, had direct contact with the public, and were 20-69 years old",Excluded if exhibiting COVID-19 like symptoms,2020-07-15,2020-08-15,Essential non-healthcare workers,All,Seniors (65+ years),65.0,,Age,65+,4,0.0,,,,,,,,Convenience,,Exsera BioLabs,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.85,0.986,['High'],Yes,No,No,Yes,Unclear,Unclear,Yes,No,Unclear,Katherine Sabourin,University of Colorado,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/33298759/,2021-02-27,2022-07-16,Verified,sabourin_risk_2020,USA
201204_SantaClara_O’ConnorHospital_Overall,201204_SantaClara_O’ConnorHospital,Effectiveness of an infection prevention strategy to limit exposure of high-risk patients to COVID-19 in a hospital-based subacute unit: a descriptive report,2020-12-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,San Jose,"On 6 May 2020, surveillance testing was performed for all 24 residents of the unit, after patients and families were informed.",,2020-05-06,2020-05-06,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,25.0,93.0,Primary Estimate,Subacute adult patients,24,0.0,,,True,,,,True,Convenience,"Diazyme DZ-Lite SARS-CoV-2 IgG  CLIA tests,Diazyme DZ-Lite SARS-CoV-2 IgM  CLIA tests",Diazyme Laboratories Inc,CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,,,['High'],,No,No,Yes,,Yes,Yes,No,,Brian D McBeth,O'Connor Hospital,Not Unity-Aligned,https://dx.doi.org/10.1177/1757177420976814,2021-05-04,2024-03-01,Unverified,mcbeth_effectiveness_2021,USA
201207_Massachusetts_MassachusettsGeneralHospital_Cohabitants,201207_Massachusetts_MassachusettsGeneralHospital_Cohabitants1,Low prevalence of SARS-COV-2 antibodies in people with multiple sclerosis residing in massachusetts,2020-12-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Massachusetts,Boston,Cohabitants of people with MS residing in MA and receiving care at Massachusetts General Hospital or Brigham and Women’s Hospital,,2020-05-29,2020-07-23,Multiple populations,All,Multiple groups,,,Primary Estimate,,143,0.063,,,True,,,,True,Sequential,Author designed (ELISA) -Unknown,,ELISA,Dried Blood,IgG,,Validated by developers,0.997,1.0,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Unclear,E Klawiter,Massachusetts General Hospital,Not Unity-Aligned,https://journals.sagepub.com/doi/10.1177/1352458520974938#_i1,2021-01-27,2022-07-16,Verified,klawiter_low_2020,USA
201207_Massachusetts_MassachusettsGeneralHospital_MS,201207_Massachusetts_MassachusettsGeneralHospital_MS2,Low prevalence of SARS-COV-2 antibodies in people with multiple sclerosis residing in massachusetts,2020-12-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Massachusetts,Boston,people with MS residing in MA and receiving care at Massachusetts General Hospital or Brigham and Women’s Hospital,,2020-05-29,2020-07-23,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,227,0.035,,,True,,,,True,Sequential,Author designed (ELISA) -Unknown,,ELISA,Dried Blood,IgG,,Validated by developers,0.997,1.0,['High'],Yes,No,No,No,Unclear,Unclear,Yes,Yes,Unclear,E Klawiter,Massachusetts General Hospital,Not Unity-Aligned,https://journals.sagepub.com/doi/10.1177/1352458520974938#_i1,2021-01-27,2022-07-16,Verified,klawiter_low_2020,USA
201209_Chicago_NorthwesternUniversity_OverallPopAdj,201209_Chicago_NorthwesternUniversity,Seroprevalence and Correlates of SARS-CoV-2 Antibodies in Health Care Workers in Chicago,2020-12-09,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Illinois,Chicago,All HCWs (employees and physician members of affiliated outpatient practices) were invited to join,withdrawal of consent,2020-05-28,2020-06-30,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,Overall pop adj,6510,0.053,0.048,0.059000000000000004,True,,True,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,John T Wilkins,Northwestern University ,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofaa582,2021-02-19,2024-03-01,Verified,wilkins_seroprevalence_2021-1,USA
200912_Chicago_NorthwesternUniversity_60+,201209_Chicago_NorthwesternUniversity,Seroprevalence and Correlates of SARS-CoV-2 Antibodies in Health Care Workers in Chicago,2020-12-09,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Illinois,Chicago,All HCWs (employees and physician members of affiliated outpatient practices) were invited to join,withdrawal of consent,2020-05-28,2020-06-30,Health care workers and caregivers,All,Seniors (65+ years),60.0,,Age,Age group 60+,588,0.026000000000000002,0.013999999999999999,0.042,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,John T Wilkins,Northwestern University ,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofaa582,2020-11-04,2024-03-01,Verified,wilkins_seroprevalence_2021-1,USA
201209_Chicago_NorthwesternUniversity_40-49,201209_Chicago_NorthwesternUniversity,Seroprevalence and Correlates of SARS-CoV-2 Antibodies in Health Care Workers in Chicago,2020-12-09,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Illinois,Chicago,All HCWs (employees and physician members of affiliated outpatient practices) were invited to join,withdrawal of consent,2020-05-28,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),40.0,49.0,Age,Age group 40-49,1368,0.044000000000000004,0.034,0.055999999999999994,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,John T Wilkins,Northwestern University ,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofaa582,2020-11-04,2024-03-01,Verified,wilkins_seroprevalence_2021-1,USA
201209_Chicago_NorthwesternUniversity_30-39,201209_Chicago_NorthwesternUniversity,Seroprevalence and Correlates of SARS-CoV-2 Antibodies in Health Care Workers in Chicago,2020-12-09,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Illinois,Chicago,All HCWs (employees and physician members of affiliated outpatient practices) were invited to join,withdrawal of consent,2020-05-28,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),30.0,39.0,Age,Age group 30-39,2208,0.044000000000000004,0.036000000000000004,0.053,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,John T Wilkins,Northwestern University ,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofaa582,2020-11-04,2024-03-01,Verified,wilkins_seroprevalence_2021-1,USA
201209_Chicago_NorthwesternUniversity_18-29,201209_Chicago_NorthwesternUniversity,Seroprevalence and Correlates of SARS-CoV-2 Antibodies in Health Care Workers in Chicago,2020-12-09,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Illinois,Chicago,All HCWs (employees and physician members of affiliated outpatient practices) were invited to join,withdrawal of consent,2020-05-28,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),18.0,29.0,Age,Age group 18-29,1304,0.07400000000000001,0.061,0.09,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,John T Wilkins,Northwestern University ,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofaa582,2020-11-04,2024-03-01,Verified,wilkins_seroprevalence_2021-1,USA
201209_Chicago_NorthwesternUniversity_50-59,201209_Chicago_NorthwesternUniversity,Seroprevalence and Correlates of SARS-CoV-2 Antibodies in Health Care Workers in Chicago,2020-12-09,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Illinois,Chicago,All HCWs (employees and physician members of affiliated outpatient practices) were invited to join,withdrawal of consent,2020-05-28,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),50.0,59.0,Age,Age group 50-59,1042,0.045,0.033,0.06,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,John T Wilkins,Northwestern University ,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofaa582,2020-11-04,2024-03-01,Verified,wilkins_seroprevalence_2021-1,USA
201209_SantaClara_StanfordHealthCare,201209_SantaClara_StanfordHealthCare,Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence in healthcare personnel in northern California early in the coronavirus disease 2019 (COVID-19) pandemic.,2020-12-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,San Francisco Bay Area,asymptomatic employees who underwent voluntary serologic testing and completed an online survey,anyone who reported symptoms at the time of serologic testing or did not complete the survey,2020-04-20,2020-05-20,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,10449,0.013015599579999999,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.87,0.9975,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Unclear,Joelle Rosser,Stanford Health Care,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2020.1358,2021-02-04,2022-07-16,Verified,rosser_severe_2020,USA
201210_Atlanta_CDC_Lab_OverallPopTestAdj,201210_Atlanta_CDC_Lab,Comparison of Estimated Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Through Commercial Laboratory Residual Sera Testing and a Community Survey,2020-12-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Georgia,Atlanta,"persons of all ages throughout the Atlanta MSA, which includes DeKalb and Fulton Counties, who had blood testing through a commercial laboratory",,2020-04-27,2020-05-01,Residual sera,All,Multiple groups,0.0,,Primary Estimate,Overall population and test adjusted,1343,0.049400000000000006,0.0334,0.0664,True,True,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,TotalAntibody,Spike,Validated by developers,0.96,0.993,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,,Kristina Bajema,Centers for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1804,2021-01-22,2022-07-16,Verified,bajema_comparison_2020,USA
201210_Atlanta_CDC_Lab_OverallCrude,201210_Atlanta_CDC_Lab,Comparison of Estimated Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Through Commercial Laboratory Residual Sera Testing and a Community Survey,2020-12-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Georgia,Atlanta,"persons of all ages throughout the Atlanta MSA, which includes DeKalb and Fulton Counties, who had blood testing through a commercial laboratory",,2020-04-27,2020-05-01,Residual sera,All,Multiple groups,0.0,,Analysis,Crude overall,1343,0.0417,,,,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,TotalAntibody,Spike,Validated by developers,0.96,0.993,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,,Kristina Bajema,Centers for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciaa1804,2021-01-22,2022-07-16,Verified,bajema_comparison_2020,USA
201201_NewHeaven_Yale_SchoolofMedicine_newborns,201201_NewHeaven_YaleSchoolofMedicine,NEWBORN DRIED BLOOD SPOTS FOR SEROLOGIC SURVEYS OF COVID-19.,2020-12-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Connecticut,New Haven,all infants born in the Yale New Haven hospital system,,2020-02-19,2020-05-26,Residual sera,All,Children and Youth (0-17 years),0.0,0.0,Primary Estimate,,3048,0.059000000000000004,,,True,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,,,,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,Unclear,Feimei  Liu,Yale School of Medicine,Not Unity-Aligned,https://dx.doi.org/10.1097/INF.0000000000002918,2020-12-18,2022-07-16,Verified,liu_newborn_2020,USA
201214_VirginaUSA_VirginiaCommonwealthUniversity_Overall,201214_VirginaUSA_VirginiaCommonwealthUniversity,COVID-19 seroprevalence among healthcare workers in a low prevalence region.,2020-12-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Virginia,Richmond,"We enrolled HCWs who directly cared for any patient (adult or pediatric), regardless of the patient’s SARS-CoV-2 status.","HCWs without direct patient care or those who had previously tested positive
for SARS-CoV-2 via PCR were excluded.",2020-07-27,2020-10-02,Health care workers and caregivers,All,Multiple groups,18.0,75.0,Primary Estimate,Overal,1962,0.013700000000000002,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,,,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Emily Godbout,Virginia Commonwealth University,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2020.1374,2021-01-23,2024-03-01,Verified,godbout_severe_2020,USA
201214_Maricopa_MaricopaCountyDepartmentOfPublicHealth_overall,201214_Maricopa_MaricopaCountyDepartmentOfPublicHealth,Maricopa County COVID-19 serosurvey results reported,2020-12-14,News and Media,Local,Cross-sectional survey ,United States of America,Arizona,,260 participants in 169 households randomly selected from across the county,,2020-09-11,2020-09-21,Household and community samples,All,Multiple groups,,,Primary Estimate,,260,0.107,,,True,,,,True,Stratified probability,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,Yes,No,No,Unclear,Unclear,Yes,No,Unclear,Fountain Hills Times,Maricopa County Department of Public Health,Not Unity-Aligned,https://www.fhtimes.com/news/local_news/maricopa-county-covid-19-serosurvey-results-reported/article_6be4ab0a-3983-11eb-ab22-a3b73c8957c7.html,2021-03-06,2022-07-16,Verified,noauthor_maricopa_nodate,USA
201215_SanDiego_SharpHealthCare_Overall,201215_SanDiego_SharpHealthCare,Point prevalence survey to evaluate the seropositivity for coronavirus disease 2019 (COVID-19) among high-risk healthcare workers,2020-12-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,San Diego,HCWs with direct contact to patients with COVID-19 and those working in congregate care areas were invited to this study.,"Staff without direct patient care responsibilities and
HCWs with active symptoms of COVID-19 were excluded from
the study.",2020-05-20,2020-06-08,Health care workers and caregivers,All,Multiple groups,18.0,,Primary Estimate,Overall,1770,0.022000000000000002,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,,Validated by manufacturers,1.0,0.998,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Norihiro Yogo,Sharp Healthcare,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2020.1370,2021-01-23,2024-03-01,Verified,yogo_point_2020,USA
201205_Maryland_MarylandDepartmentOfHealth_overall,201205_Maryland_MarylandDepartmentOfHealth,"Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Status in Decedents Undergoing Forensic Postmortem Examination in Maryland, May 24 to June 30, 2020",2020-12-15,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Maryland,,"The study population included all decedents undergoing forensic postmortem examination (including toxicology for drugs and alcohol) by the OCME from May 24 to June 30, 2020 from whom 5 mL whole blood could be collected.",,2020-05-24,2020-06-30,Residual sera,All,Multiple groups,,,Primary Estimate,,500,0.1,,,True,,,,True,Sequential,RightSign COVID-19 IgG/IgM Rapid Test Cassette,Hangzhou Biotest Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9500000000000001,1.0,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Keri N Althoff,The Maryland Department of Health,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofaa611,2021-05-27,2024-03-01,Unverified,althoff_severe_2021,USA
201217_UnitedStates_UniversityofIowa,201217_UnitedStates_UniversityofIowa,Diagnosed and Undiagnosed COVID-19 in US Emergency Department Health Care Personnel: A Cross-sectional Analysis,2020-12-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,Not received a diagnosis of COVID-19,,2020-05-13,2020-07-08,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,1606,0.0174,,,True,,,,True,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG","Abbott Laboratories,EUROIMMUN",Multiple Types,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],Yes,No,Yes,Yes,Yes,No,Yes,No,Unclear,Nicholas M Mohr,University of Iowa,Not Unity-Aligned,http://dx.doi.org/10.1016/j.annemergmed.2020.12.007,2021-04-18,2024-03-01,Verified,mohr_diagnosed_2020,USA
201217_UnitedStates_UniversityofIowa_41-50,201217_UnitedStates_UniversityofIowa,Diagnosed and Undiagnosed COVID-19 in US Emergency Department Health Care Personnel: A Cross-sectional Analysis,2020-12-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,Not received a diagnosis of COVID-19,,2020-05-13,2020-07-08,Health care workers and caregivers,All,Adults (18-64 years),41.0,50.0,Age,41-50,319,0.018808777430000003,,,,,,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG","Abbott Laboratories,EUROIMMUN",Multiple Types,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],Yes,No,Yes,Yes,Yes,No,Yes,No,Unclear,Nicholas M Mohr,University of Iowa,Not Unity-Aligned,http://dx.doi.org/10.1016/j.annemergmed.2020.12.007,2021-04-22,2024-03-01,Verified,mohr_diagnosed_2020,USA
201217_UnitedStates_UniversityofIowa<=30,201217_UnitedStates_UniversityofIowa,Diagnosed and Undiagnosed COVID-19 in US Emergency Department Health Care Personnel: A Cross-sectional Analysis,2020-12-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,Not received a diagnosis of COVID-19,,2020-05-13,2020-07-08,Health care workers and caregivers,All,Adults (18-64 years),,30.0,Age,<=30,376,0.02127659574,,,,,,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG","Abbott Laboratories,EUROIMMUN",Multiple Types,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],Yes,No,Yes,Yes,Yes,No,Yes,No,Unclear,Nicholas M Mohr,University of Iowa,Not Unity-Aligned,http://dx.doi.org/10.1016/j.annemergmed.2020.12.007,2021-04-22,2024-03-01,Verified,mohr_diagnosed_2020,USA
201217_UnitedStates_UniversityofIowa_51-60,201217_UnitedStates_UniversityofIowa,Diagnosed and Undiagnosed COVID-19 in US Emergency Department Health Care Personnel: A Cross-sectional Analysis,2020-12-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,Not received a diagnosis of COVID-19,,2020-05-13,2020-07-08,Health care workers and caregivers,All,Adults (18-64 years),51.0,60.0,Age,51-60,222,0.02702702703,,,,,,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG","Abbott Laboratories,EUROIMMUN",Multiple Types,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],Yes,No,Yes,Yes,Yes,No,Yes,No,Unclear,Nicholas M Mohr,University of Iowa,Not Unity-Aligned,http://dx.doi.org/10.1016/j.annemergmed.2020.12.007,2021-04-22,2024-03-01,Verified,mohr_diagnosed_2020,USA
201217_UnitedStates_UniversityofIowa_>=61,201217_UnitedStates_UniversityofIowa,Diagnosed and Undiagnosed COVID-19 in US Emergency Department Health Care Personnel: A Cross-sectional Analysis,2020-12-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,Not received a diagnosis of COVID-19,,2020-05-13,2020-07-08,Health care workers and caregivers,All,Seniors (65+ years),61.0,,Age,>=61,67,0.0,,,,,,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG","Abbott Laboratories,EUROIMMUN",Multiple Types,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],Yes,No,Yes,Yes,Yes,No,Yes,No,Unclear,Nicholas M Mohr,University of Iowa,Not Unity-Aligned,http://dx.doi.org/10.1016/j.annemergmed.2020.12.007,2021-04-22,2024-03-01,Verified,mohr_diagnosed_2020,USA
201217_UnitedStates_UniversityofIowa_31-40,201217_UnitedStates_UniversityofIowa,Diagnosed and Undiagnosed COVID-19 in US Emergency Department Health Care Personnel: A Cross-sectional Analysis,2020-12-17,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,Not received a diagnosis of COVID-19,,2020-05-13,2020-07-08,Health care workers and caregivers,All,Adults (18-64 years),31.0,40.0,Age,31-40,622,0.014469453379999999,,,,,,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG","Abbott Laboratories,EUROIMMUN",Multiple Types,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],Yes,No,Yes,Yes,Yes,No,Yes,No,Unclear,Nicholas M Mohr,University of Iowa,Not Unity-Aligned,http://dx.doi.org/10.1016/j.annemergmed.2020.12.007,2021-04-22,2024-03-01,Verified,mohr_diagnosed_2020,USA
211231_Denver_DenverPublicHealth,211231_Denver_DenverPublicHealth,"SARS-Cov-2 RNA and antibodies among people experiencing homelessness and staying in shelters or outdoor encampments in Denver, Colorado, May-July 2020",2020-12-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Colorado,Denver,"In May 2020, Denver Public Health collaborated with local leaders to identify 4 homeless shelters and 3 outdoor encampments for voluntary, universal SARS-CoV-2 testing. ",,2020-06-02,2020-07-28,Persons experiencing homelessness,All,Adults (18-64 years),,,Primary Estimate,,334,0.1672,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,No,No,Yes,Unclear,Unclear,Yes,No,Unclear,David McCormick,Denver Public Health,Not Unity-Aligned,http://dx.doi.org/10.1093/ofid/ofaa515.1909,2021-05-02,2022-07-16,Verified,mccormick_lb-12_2020,USA
201222_Wisconsin_UniversityofWisconsin_WaveI_overall_popadj,201222_Wisconsin_UniversityofWisconsin_WaveI,Population Changes in Seroprevalence among a Statewide Sample in the United States,2020-12-22,Preprint,Regional,Prospective cohort,United States of America,Wisconsin,,This study includes a longitudinal sample of adults recruited from the statewide Survey of the Health of Wisconsin (SHOW) study. Individuals were eligible if they had participated in SHOW health examination protocols between 2014-2016 or were included in the special population oversample conducted in the city of Milwaukee during 2018-2019. ,Those with active COVID-19 infection or COVID-19 exposure within the past 2 weeks were excluded.,2020-07-01,2020-08-31,Household and community samples,All,Multiple groups,12.0,,Primary Estimate,,996,0.016,0.006,0.025,True,True,True,True,True,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,0.996,['Low'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,No,Kristen Maleck,University of Wisconsin,Not Unity-Aligned,https://doi.org/10.1101/2020.12.18.20248479,2021-02-03,2023-07-04,Verified,malecki_population_2020-1,USA
201222_Wisconsin_UniversityofWisconsin_WaveII_overall_popadj,201222_Wisconsin_UniversityofWisconsin_WaveII,Population Changes in Seroprevalence among a Statewide Sample in the United States,2020-12-22,Preprint,Regional,Prospective cohort,United States of America,Wisconsin,,This study includes a longitudinal sample of adults recruited from the statewide Survey of the Health of Wisconsin (SHOW) study. Individuals were eligible if they had participated in SHOW health examination protocols between 2014-2016 or were included in the special population oversample conducted in the city of Milwaukee during 2018-2019. ,Those with active COVID-19 infection or COVID-19 exposure within the past 2 weeks were excluded.,2020-10-18,2020-12-14,Household and community samples,All,Multiple groups,12.0,,Primary Estimate,,994,0.068,0.043,0.094,True,True,True,True,True,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,0.996,['Low'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,No,Kristen Maleck,University of Wisconsin,Not Unity-Aligned,https://doi.org/10.1101/2020.12.18.20248479,2021-02-03,2023-07-04,Verified,malecki_population_2020-1,USA
201222_Wisconsin_UniversityofWisconsin_WaveII_age12-44 ,201222_Wisconsin_UniversityofWisconsin_WaveII,Population Changes in Seroprevalence among a Statewide Sample in the United States,2020-12-22,Preprint,Regional,Prospective cohort,United States of America,Wisconsin,,This study includes a longitudinal sample of adults recruited from the statewide Survey of the Health of Wisconsin (SHOW) study. Individuals were eligible if they had participated in SHOW health examination protocols between 2014-2016 or were included in the special population oversample conducted in the city of Milwaukee during 2018-2019. ,Those with active COVID-19 infection or COVID-19 exposure within the past 2 weeks were excluded.,2020-10-18,2020-12-14,Household and community samples,All,Adults (18-64 years),12.0,44.0,Age,12 to 44,297,0.061,0.015,0.10800000000000001,,True,True,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,0.996,['Low'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,No,Kristen Maleck,University of Wisconsin,Not Unity-Aligned,https://doi.org/10.1101/2020.12.18.20248479,2021-02-03,2023-07-04,Verified,malecki_population_2020-1,USA
201222_Wisconsin_UniversityofWisconsin_WaveII_female ,201222_Wisconsin_UniversityofWisconsin_WaveII,Population Changes in Seroprevalence among a Statewide Sample in the United States,2020-12-22,Preprint,Regional,Prospective cohort,United States of America,Wisconsin,,This study includes a longitudinal sample of adults recruited from the statewide Survey of the Health of Wisconsin (SHOW) study. Individuals were eligible if they had participated in SHOW health examination protocols between 2014-2016 or were included in the special population oversample conducted in the city of Milwaukee during 2018-2019. ,Those with active COVID-19 infection or COVID-19 exposure within the past 2 weeks were excluded.,2020-10-18,2020-12-14,Household and community samples,Female,Multiple groups,12.0,,Sex/Gender,Female,589,0.043,0.027000000000000003,0.057999999999999996,,True,True,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,0.996,['Low'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,No,Kristen Maleck,University of Wisconsin,Not Unity-Aligned,https://doi.org/10.1101/2020.12.18.20248479,2021-02-03,2023-07-04,Verified,malecki_population_2020-1,USA
201222_Wisconsin_UniversityofWisconsin_WaveII_age45-64,201222_Wisconsin_UniversityofWisconsin_WaveII,Population Changes in Seroprevalence among a Statewide Sample in the United States,2020-12-22,Preprint,Regional,Prospective cohort,United States of America,Wisconsin,,This study includes a longitudinal sample of adults recruited from the statewide Survey of the Health of Wisconsin (SHOW) study. Individuals were eligible if they had participated in SHOW health examination protocols between 2014-2016 or were included in the special population oversample conducted in the city of Milwaukee during 2018-2019. ,Those with active COVID-19 infection or COVID-19 exposure within the past 2 weeks were excluded.,2020-10-18,2020-12-14,Household and community samples,All,Adults (18-64 years),45.0,64.0,Age,45 to 64,318,0.081,0.055999999999999994,0.107,,True,True,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,0.996,['Low'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,No,Kristen Maleck,University of Wisconsin,Not Unity-Aligned,https://doi.org/10.1101/2020.12.18.20248479,2021-02-03,2023-07-04,Verified,malecki_population_2020-1,USA
201222_Wisconsin_UniversityofWisconsin_WaveII_age65+ ,201222_Wisconsin_UniversityofWisconsin_WaveII,Population Changes in Seroprevalence among a Statewide Sample in the United States,2020-12-22,Preprint,Regional,Prospective cohort,United States of America,Wisconsin,,This study includes a longitudinal sample of adults recruited from the statewide Survey of the Health of Wisconsin (SHOW) study. Individuals were eligible if they had participated in SHOW health examination protocols between 2014-2016 or were included in the special population oversample conducted in the city of Milwaukee during 2018-2019. ,Those with active COVID-19 infection or COVID-19 exposure within the past 2 weeks were excluded.,2020-10-18,2020-12-14,Household and community samples,All,Seniors (65+ years),65.0,,Age,65 or older,379,0.064,0.033,0.095,,True,True,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,0.996,['Low'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,No,Kristen Maleck,University of Wisconsin,Not Unity-Aligned,https://doi.org/10.1101/2020.12.18.20248479,2021-02-03,2023-07-04,Verified,malecki_population_2020-1,USA
201222_Wisconsin_UniversityofWisconsin_WaveII_male ,201222_Wisconsin_UniversityofWisconsin_WaveII,Population Changes in Seroprevalence among a Statewide Sample in the United States,2020-12-22,Preprint,Regional,Prospective cohort,United States of America,Wisconsin,,This study includes a longitudinal sample of adults recruited from the statewide Survey of the Health of Wisconsin (SHOW) study. Individuals were eligible if they had participated in SHOW health examination protocols between 2014-2016 or were included in the special population oversample conducted in the city of Milwaukee during 2018-2019. ,Those with active COVID-19 infection or COVID-19 exposure within the past 2 weeks were excluded.,2020-10-18,2020-12-14,Household and community samples,Male,Multiple groups,12.0,,Sex/Gender,,405,0.094,0.043,0.145,,True,True,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,0.996,['Low'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,No,Kristen Maleck,University of Wisconsin,Not Unity-Aligned,https://doi.org/10.1101/2020.12.18.20248479,2021-02-03,2023-07-04,Verified,malecki_population_2020-1,USA
201223_NewYork_MemorialSloanKetteringCancerCenter,201223_NewYork_MemorialSloanKetteringCancerCenter,COVID-19 in pediatric survivors of childhood cancer and hematopoietic cell transplantation from a single center in New York City,2020-12-23,Journal Article (Peer-Reviewed),Local,Retrospective cohort,United States of America,New York,New York City,"This retrospective review included all consecutive survivors seen in Memorial Sloan Kettering (MSK)’s Pediatric LTFU Clinic between May 5 and September 10, 2020, which provides risk-based care to survivors of childhood cancer and HCT diagnosed at age ≤18 who are ≥1-year off-therapy at program entry.",,2020-05-05,2020-09-10,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),1.0,18.0,Primary Estimate,Overall ,257,0.078,,,True,,,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,,IgG,,,,,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Lauren Jimenez Kurlander,Memorial Sloan Kettering Cancer Center,Not Unity-Aligned,https://dx.doi.org/10.1002/pbc.28857,2021-02-04,2024-03-01,Verified,jimenezkurlander_covid19_2020,USA
201225_Seattle_UniversityofWashington_GenPop_ELISA+Neutralizaion,201225_Seattle_UniversityofWashington,SARS-CoV-2 Serologic Assays in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing,2020-12-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Washington,Seattle,Members of the Seattle community ,,2020-03-26,2020-04-15,Household and community samples,All,Multiple groups,,,Primary Estimate,"Overall, positive on IgG ELISA and neutralization assay",100,0.04,,,True,,,,True,Simplified probability,"Author designed (Neutralization Assay),Abbott Architect SARS-CoV-2 IgG,Author designed (ELISA) -Spike","NA,Abbott Laboratories",Multiple Types,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],Unclear,Yes,No,No,Unclear,Yes,Yes,No,Unclear,Jennifer Rathe,University of Washington,Unity-Aligned,http://dx.doi.org/10.1093/infdis/jiaa797,2021-05-17,2024-03-01,Verified,rathe_sars-cov-2_2021,USA
201225_Seattle_UniversityofWashington_GenPop_ELISA_RBDIgG,201225_Seattle_UniversityofWashington,SARS-CoV-2 Serologic Assays in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing,2020-12-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Washington,Seattle,Members of the Seattle community ,,2020-03-26,2020-04-15,Household and community samples,All,Multiple groups,,,Test used,"Overall, positive on RBD IgG ELISA ",100,0.04,,,,,,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.87,1.0,['High'],Unclear,Yes,No,No,Unclear,Yes,Yes,No,Unclear,Jennifer Rathe,University of Washington,Unity-Aligned,http://dx.doi.org/10.1093/infdis/jiaa797,2021-06-11,2022-07-16,Verified,rathe_sars-cov-2_2021,USA
201225_Seattle_UniversityofWashington_GenPop_ELISA_SpikeIgG,201225_Seattle_UniversityofWashington,SARS-CoV-2 Serologic Assays in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing,2020-12-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Washington,Seattle,Members of the Seattle community ,,2020-03-26,2020-04-15,Household and community samples,All,Multiple groups,,,Test used,"Overall, positive on spike IgG ELISA ",100,0.07,,,,,,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.67,0.97,['High'],Unclear,Yes,No,No,Unclear,Yes,Yes,No,Unclear,Jennifer Rathe,University of Washington,Unity-Aligned,http://dx.doi.org/10.1093/infdis/jiaa797,2021-06-11,2022-07-16,Verified,rathe_sars-cov-2_2021,USA
201225_Seattle_UniversityofWashington_GenPop_Abbott,201225_Seattle_UniversityofWashington,SARS-CoV-2 Serologic Assays in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing,2020-12-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Washington,Seattle,Members of the Seattle community ,,2020-03-26,2020-04-15,Household and community samples,All,Multiple groups,,,Test used,"Overall, positive on Abbott CLIA",100,0.02,,,,,,,,Simplified probability,Author designed (ELISA) -Spike,,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.93,0.97,['High'],Unclear,Yes,No,No,Unclear,Yes,Yes,No,Unclear,Jennifer Rathe,University of Washington,Unity-Aligned,http://dx.doi.org/10.1093/infdis/jiaa797,2021-06-11,2022-07-16,Verified,rathe_sars-cov-2_2021,USA
201225_Seattle_UniversityofWashington_GenPop_ELISA_SpikeIgG3,201225_Seattle_UniversityofWashington,SARS-CoV-2 Serologic Assays in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing,2020-12-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Washington,Seattle,Members of the Seattle community ,,2020-03-26,2020-04-15,Household and community samples,All,Multiple groups,,,Test used,"Overall, positive on spike IgG3 ELISA and neutralization assay",100,0.03,,,,,,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.93,0.97,['High'],Unclear,Yes,No,No,Unclear,Yes,Yes,No,Unclear,Jennifer Rathe,University of Washington,Unity-Aligned,http://dx.doi.org/10.1093/infdis/jiaa797,2021-06-11,2022-07-16,Verified,rathe_sars-cov-2_2021,USA
201230_SanDiego_ScrippsClinic_Overall,201230_SanDiego_ScrippsClinic,Healthcare worker seroconversion for SARS-CoV-2 at two large health systems in San Diego,2020-12-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,San Diego,Employees at one of two San Siego Health Care systems sampled from ,Employees actively experiencing symptoms were asked not to participate in this screening and instead referred for clinical evaluation,2020-04-14,2020-07-28,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,Overall,11993,0.0094,,,True,,,,,Convenience,"Diazyme DZ-Lite SARS-CoV-2 IgG  CLIA tests,Abbott Architect SARS-CoV-2 IgG","Diazyme Laboratories Inc,Abbott Laboratories",CLIA,Serum,IgG,,,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,Unclear,Laura Nicholson,Scripps Clinic,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ajic.2020.12.017,2021-01-29,2024-03-01,Verified,nicholson_healthcare_2020,USA
201231_SanDiego_UniversityofCaliforniaSanDiegoHealth_HCW,201231_SanDiego_UniversityofCaliforniaSanDiegoHealth,Asymptomatic healthcare worker COVID-19 testing program,2020-12-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,San Diego,Healthcare workers at University of California San Diego Health,,2020-04-22,2020-06-02,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,5589,0.0102,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,Serum,IgG,,,,,['Moderate'],Yes,No,Yes,No,Unclear,Unclear,Yes,No,Yes,Lucy E Horton,University of California San Diego Health,Not Unity-Aligned,http://dx.doi.org/10.1093/ofid/ofaa439.630,2021-05-05,2022-07-16,Verified,horton_asymptomatic_2020,USA
201231_LosAngeles_UniversityofCaliforniaLosAngeles,201231_LosAngeles_UniversityofCaliforniaLosAngeles,Lack of SARS-CoV-2 antibody seroconversion after prompt identification and cohorting of sentinel SARS-CoV-2-positive residents in a skilled nursing facility,2020-12-31,Presentation or Conference,Local,Cross-sectional survey ,United States of America,California,Los Angeles,All SNF residents (SARS-CoV-2 PCR positive and negative) underwent serologic testing for SARS-CoV-2 Spike (S1/S2) IgG (DiaSorin).,,2020-06-01,2020-06-15,Assisted living and long-term care facilities,All,Adults (18-64 years),,,Primary Estimate,,121,0.0165,,,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,,Plasma,IgG,Spike,,,,['High'],,No,No,No,,Yes,Yes,Yes,,Debika Bhattacharya,University of California Los Angeles,Not Unity-Aligned,https://academic.oup.com/ofid/article/7/Supplement_1/S165/6058251,2021-05-06,2024-03-01,Unverified,bhattacharya_70_2020,USA
201231_Charleston_MedicalUniversityofSouthCarolina,201231_Charleston_MedicalUniversityofSouthCarolina,"Point-of-care, in-home SARS-CoV-2 IgG antibody testing to assess seroprevalence in at-risk health care workers",2020-12-31,Presentation or Conference,Local,Cross-sectional survey ,United States of America,South Carolina ,Charleston,Health care workers,,2020-04-14,2020-05-06,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,439,0.013700000000000002,,,True,,,,True,Convenience,Novel Coronavirus IgG antibody test kit (colloidal gold method),RayBiotech,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,0.76,0.9500000000000001,['High'],,No,No,No,,No,Yes,No,,Eric G Meissner,Medical University of South Carolina,Not Unity-Aligned,http://dx.doi.org/10.1093/ofid/ofaa439.653,2021-05-08,2024-03-01,Unverified,meissner_460_2020,USA
201231_WestVirginia_WestVirginiaUniversityMedicine_HCW,201231_WestVirginia_WestVirginiaUniversityMedicine,Serum IgG antibody testing against severe acute respiratory syndrome coronavirus 2 in healthcare workers,2020-12-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,West Virginia,Morgantown,"Serum samples from randomly selected HCW across 4 WVU 
Medicine hospitals, ranging from 170 to 690 beds with 121 cumulative SARS-CoV-2 PCR positive patients.  Environmental services workers were included but not risk-stratified. ",,2020-05-26,2020-06-05,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1042,0.0086,,,True,,,,True,Simplified probability,Not reported/ Unable to specify,,,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,Joy J Juskowich,West Virginia University Medicine,Not Unity-Aligned,http://dx.doi.org/10.1093/ofid/ofaa439.694,2021-05-05,2022-07-16,Verified,juskowich_serum_2020,USA
210101_Seattle_SeattleChildren'sResearchInstitute_Baseline_Overall,210101_Seattle_SeattleChildren'sResearchInstitute_Baseline,Prevalence of health care and hospital worker SARS-CoV-2 IgG antibody in a pediatric hospital,2021-01-01,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Washington ,Seattle,"All staff members (including physicians, nurses, allied health professionals, pharmacists, social workers, mental health evaluators, security team members, child life specialists and environmental services staff were eligible to participate if they were over 18 years of age and worked in a clinical environment. Participants must have worked at least one shift in a clinical setting in the 14 days prior to enrollment.","participants could not be experiencing any COVID-19-related symptoms (including cough, fever, sore throat, runny nose, body aches, chills, wheezing, shortness of breath, diarrhea, or vomiting) at the time of their blood draw.",2020-05-04,2020-06-02,Health care workers and caregivers,All,Adults (18-64 years),19.0,67.0,Primary Estimate,Primary estimate for baseline study,530,0.009000000000000001,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Yekaterina Tokareva,Seattle Childrens Research Institute,Not Unity-Aligned,https://dx.doi.org/10.1542/hpeds.2020-003517,2021-01-23,2024-03-01,Verified,tokareva_prevalence_2021,USA
210101_Seattle_SeattleChildren'sResearchInstitute_FollowUp_Overall,210101_Seattle_SeattleChildren'sResearchInstitute_FollowUp,Prevalence of health care and hospital worker SARS-CoV-2 IgG antibody in a pediatric hospital,2021-01-01,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Washington ,Seattle,"All staff members (including physicians, nurses, allied health professionals, pharmacists, social workers, mental health evaluators, security team members, child life specialists and environmental services staff were eligible to participate if they were over 18 years of age and worked in a clinical environment. Participants must have worked at least one shift in a clinical setting in the 14 days prior to enrollment.","participants could not be experiencing any COVID-19-related symptoms (including cough, fever, sore throat, runny nose, body aches, chills, wheezing, shortness of breath, diarrhea, or vomiting) at the time of their blood draw.",2020-07-06,2020-08-07,Health care workers and caregivers,All,Adults (18-64 years),19.0,67.0,Primary Estimate,Primary estimate for two-month follow up,481,0.01,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,,['High'],,No,No,No,,Yes,Yes,Yes,,Yekaterina Tokareva,Seattle Childrens Research Institute,Not Unity-Aligned,https://dx.doi.org/10.1542/hpeds.2020-003517,2021-01-23,2024-03-01,Verified,tokareva_prevalence_2021,USA
210104_Louisville_UniversityOfLouisville,210104_Louisville_UniversityOfLouisville,"COVID-19 rates continue to
  increase, with highest rates among 18-34-year-olds",2021-01-04,News and Media,Regional,Cross-sectional survey ,United States of America,Kentucky,Louisville,,,2020-12-10,2020-12-14,Household and community samples,All,Multiple groups,,,Primary Estimate,,700,0.1116,,,True,,,,True,Simplified probability,Not reported/ Unable to specify,,,,,,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,Betty Coffman,University of Louisville,Not Unity-Aligned,https://www.uoflnews.com/post/uofltoday/covid-19-rates-continue-to-increase-with-highest-rates-among-18-34-year-olds/,2021-05-18,2022-07-16,Unverified,coffman_covid-19_2021,USA
210105_USA_MayoClinic_overall,210105_USA_MayoClinic,Prevalence of COVID-19 IgG Antibodies in a Cohort of Municipal First Responders,2021-01-05,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Minnesota,Rochester,"On the weekend of May 16-17, 2020, municipal FRs from the Rochester Police Department and Rochester Fire Department were offered voluntary, anonymous SARS-CoV-2 serology.",,2020-05-16,2020-05-17,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,255,0.012,,,True,,,,True,Convenience,Author designed (ELISA) -Unknown,,ELISA,Serum,IgG,,Validated by developers,0.881,0.996,['High'],,No,No,No,,Unclear,Yes,No,,Sarayna S McGuire,Mayo Clinic,Not Unity-Aligned,https://dx.doi.org/10.1017/S1049023X2000151X,2021-02-03,2022-07-16,Unverified,mcguire_prevalence_nodate,USA
210105_USA_ClinicalReferenceLaboratory_GenPop_December,210105_USA_ClinicalReferenceLaboratory_December,The Silent Pandemic COVID-19 in the Asymptomatic Population,2021-01-05,Preprint,National,Cross-sectional survey ,United States of America,,,Individuals applying for life insurance,,2020-12-01,2020-12-06,Residual sera,All,Multiple groups,16.0,85.0,Primary Estimate,December sampling period,14605,0.10400000000000001,,,,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,,Validated by manufacturers,1.0,0.998,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc.,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.11.10.20215145v3.full.pdf,2021-01-18,2024-03-01,Verified,stout_silent_2021,USA
210105_USA_ClinicalReferenceLaboratory_GenPop_MayJune,210105_USA_ClinicalReferenceLaboratory_MayJune,The Silent Pandemic COVID-19 in the Asymptomatic Population,2021-01-05,Preprint,National,Cross-sectional survey ,United States of America,,,Individuals applying for life insurance,,2020-05-12,2020-06-15,Residual sera,All,Multiple groups,16.0,85.0,Primary Estimate,May to June sampling period,50072,0.03,,,,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,,Validated by manufacturers,1.0,0.998,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc.,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.11.10.20215145v3.full.pdf,2021-01-18,2024-03-01,Verified,stout_silent_2021,USA
210108_Washington_CentersForDiseaseControlAndPrevention_Overall,210108_Washington_CentersForDiseaseControlAndPrevention,"SARS-CoV-2 Infection and Mitigation Efforts among Office Workers, Washington, DC, USA",2021-01-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,,Washington,"""Staff who worked in the FEMA building during April 1–22 were identified by using turnstile records and were invited by email to participate in a survey.""","""Persons who had had symptoms of COVID-19 within 2 weeks of the survey were ineligible to participate.""

""Indeterminate test results or incomplete questionnaires resulted in the exclusion of 10 participants.""",2020-04-23,2020-04-29,Essential non-healthcare workers,All,Multiple groups,18.0,,Primary Estimate,,466,0.032,,,,,,,,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Samira Sami,Centers for Disease Control and Prevention,Not Unity-Aligned,http://doi.org/10.3201/eid2702.204529,2022-12-14,2023-03-19,Unverified,sami_sars-cov-2_2021,USA
210111_Burlington_UniversityOfVermont_overall,210111_Bulington_UniversityOfVermont,"Jobs, Housing, and Mask Wearing: Cross-Sectional Study of Risk Factors for COVID-19",2021-01-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Vermont,Burlington,Our sampling frame included community members from Chittenden county in the hospital service area of University of Vermont Medical Center who had an encounter with their primary care provider in the past 3 years.,,2020-06-25,2020-06-28,Household and community samples,All,Multiple groups,,,Primary Estimate,,454,0.022000000000000002,0.008,0.036000000000000004,True,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],No,Yes,No,No,No,Unclear,Yes,No,No,Eline M van den Broek Altenburg,University of Vermont,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7800904/,2021-04-22,2022-07-16,Verified,van_den_broek-altenburg_jobs_2021,USA
210111_SanFrancisco_UniversityofCalifornia_EDproviders,210111_SanFrancisco_UniversityofCalifornia,Prevalence of SARS-Cov-2 Antibodies in Emergency Medicine Healthcare Workers,2021-01-11,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,California,San Francisco,"ED providers (attending physicians, nurses, midlevel practitioners, patient care technicians, and pharmacists) at an academic medical center in San Francisco",Exclusion criteria were pregnancy or immunocompromise. ,2020-09-01,2020-10-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,139,0.028999999999999998,0.008,0.07200000000000001,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,No,Yes,Yes,Yes,Yes,No,No,Ralph Wang,University of California,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annemergmed.2021.01.010,2021-05-20,2024-03-01,Verified,wang_prevalence_2021,USA
210111_Michigan_ UniversityofMichigan_overall,210111_Michigan_ UniversityofMichigan,Seroprevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) antibodies by risk of exposure in a community health system,2021-01-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Michigan,,All healthcare workers in the Metro Health University of Michigan Health community health system were invited to participate,Participants were excluded if they were <18 years of age or reported active COVID-19.,2020-08-17,2020-09-04,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1385,0.0188,,,True,,,,True,Convenience,"Atellica® IM SARS-CoV-2 Total (COV2T),Coronavirus COVID-19 IgG ELISA Assay","Siemens,Eagle Bioscience",CLIA,Serum,TotalAntibody,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Jeffrey Fletcher,Metro Health University of Michigan Health,Not Unity-Aligned,http://dx.doi.org/10.1017/ice.2020.1438,2021-02-04,2024-03-01,Unverified,fletcher_seroprevalence_2021,USA
210112_PlacerCounty_StanfordUniversity,210112_PlacerCounty_StanfordUniversity,CA-FACTS Seroprevalence for SARS- CoV-2 in Placer County,2021-01-12,Institutional Report,Local,Cross-sectional survey ,United States of America,California,,Placer residents,,2020-11-01,2020-11-30,Household and community samples,All,Multiple groups,,,Primary Estimate,,810,0.0234,,,True,,,,True,Simplified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,,,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,No,Julie Parsonnet,Stanford University,Not Unity-Aligned,https://www.placer.ca.gov/DocumentCenter/View/49523/2021-011221-PowerPoint-Item-02A,2021-05-21,2022-07-16,Verified,julie_parsonnet_ca-facts_2021,USA
210115_Massachusetts_HarvardUniversity_Overall,210115_Massachusetts_HarvardUniversity,Development of at-home sample collection logistics for large scale SARS-CoV-2 seroprevalence studies,2021-01-15,Preprint,Regional,Cross-sectional survey ,United States of America,Massachusetts,,">= 18 years old, residents of Massachusetts
Reliable internet access, and could speak English",,2020-06-16,2020-08-24,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,1872,0.0315,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Aishani Aatresh,Harvard University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.01.14.21249824v1,2021-02-11,2024-03-01,Verified,aatresh_development_2021,USA
210115_Massachusetts_HarvardUniversity_50-59,210115_Massachusetts_HarvardUniversity,Development of at-home sample collection logistics for large scale SARS-CoV-2 seroprevalence studies,2021-01-15,Preprint,Regional,Cross-sectional survey ,United States of America,Massachusetts,,">= 18 years old, residents of Massachusetts
Reliable internet access, and could speak English",,2020-06-16,2020-08-24,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,,314,0.0605,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Aishani Aatresh,Harvard University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.01.14.21249824v1,2021-02-11,2024-03-01,Verified,aatresh_development_2021,USA
210115_Massachusetts_HarvardUniversity_80-89,210115_Massachusetts_HarvardUniversity,Development of at-home sample collection logistics for large scale SARS-CoV-2 seroprevalence studies,2021-01-15,Preprint,Regional,Cross-sectional survey ,United States of America,Massachusetts,,">= 18 years old, residents of Massachusetts
Reliable internet access, and could speak English",,2020-06-16,2020-08-24,Household and community samples,All,Seniors (65+ years),80.0,89.0,Age,Age 80-89,5,0.0,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Aishani Aatresh,Harvard University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.01.14.21249824v1,2021-02-11,2024-03-01,Verified,aatresh_development_2021,USA
210115_Massachusetts_HarvardUniversity_Males,210115_Massachusetts_HarvardUniversity,Development of at-home sample collection logistics for large scale SARS-CoV-2 seroprevalence studies,2021-01-15,Preprint,Regional,Cross-sectional survey ,United States of America,Massachusetts,,">= 18 years old, residents of Massachusetts
Reliable internet access, and could speak English",,2020-06-16,2020-08-24,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,465,0.0215,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Aishani Aatresh,Harvard University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.01.14.21249824v1,2021-02-11,2024-03-01,Verified,aatresh_development_2021,USA
210115_Massachusetts_HarvardUniversity_40-49,210115_Massachusetts_HarvardUniversity,Development of at-home sample collection logistics for large scale SARS-CoV-2 seroprevalence studies,2021-01-15,Preprint,Regional,Cross-sectional survey ,United States of America,Massachusetts,,">= 18 years old, residents of Massachusetts
Reliable internet access, and could speak English",,2020-06-16,2020-08-24,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,,439,0.020499999999999997,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Aishani Aatresh,Harvard University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.01.14.21249824v1,2021-02-11,2024-03-01,Verified,aatresh_development_2021,USA
210115_Massachusetts_HarvardUniversity_70-79,210115_Massachusetts_HarvardUniversity,Development of at-home sample collection logistics for large scale SARS-CoV-2 seroprevalence studies,2021-01-15,Preprint,Regional,Cross-sectional survey ,United States of America,Massachusetts,,">= 18 years old, residents of Massachusetts
Reliable internet access, and could speak English",,2020-06-16,2020-08-24,Household and community samples,All,Seniors (65+ years),70.0,79.0,Age,Age 70-79,41,0.0244,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Aishani Aatresh,Harvard University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.01.14.21249824v1,2021-02-11,2024-03-01,Verified,aatresh_development_2021,USA
210115_Massachusetts_HarvardUniversity_18-29,210115_Massachusetts_HarvardUniversity,Development of at-home sample collection logistics for large scale SARS-CoV-2 seroprevalence studies,2021-01-15,Preprint,Regional,Cross-sectional survey ,United States of America,Massachusetts,,">= 18 years old, residents of Massachusetts
Reliable internet access, and could speak English",,2020-06-16,2020-08-24,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,Age 18-29,313,0.0319,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Aishani Aatresh,Harvard University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.01.14.21249824v1,2021-02-11,2024-03-01,Verified,aatresh_development_2021,USA
210115_Massachusetts_HarvardUniversity_60-69,210115_Massachusetts_HarvardUniversity,Development of at-home sample collection logistics for large scale SARS-CoV-2 seroprevalence studies,2021-01-15,Preprint,Regional,Cross-sectional survey ,United States of America,Massachusetts,,">= 18 years old, residents of Massachusetts
Reliable internet access, and could speak English",,2020-06-16,2020-08-24,Household and community samples,All,Adults (18-64 years),60.0,69.0,Age,,198,0.0253,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Aishani Aatresh,Harvard University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.01.14.21249824v1,2021-02-11,2024-03-01,Verified,aatresh_development_2021,USA
210115_Massachusetts_HarvardUniversity_30-39,210115_Massachusetts_HarvardUniversity,Development of at-home sample collection logistics for large scale SARS-CoV-2 seroprevalence studies,2021-01-15,Preprint,Regional,Cross-sectional survey ,United States of America,Massachusetts,,">= 18 years old, residents of Massachusetts
Reliable internet access, and could speak English",,2020-06-16,2020-08-24,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,,540,0.0167,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Aishani Aatresh,Harvard University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.01.14.21249824v1,2021-02-11,2024-03-01,Verified,aatresh_development_2021,USA
210115_Massachusetts_HarvardUniversity_Females,210115_Massachusetts_HarvardUniversity,Development of at-home sample collection logistics for large scale SARS-CoV-2 seroprevalence studies,2021-01-15,Preprint,Regional,Cross-sectional survey ,United States of America,Massachusetts,,">= 18 years old, residents of Massachusetts
Reliable internet access, and could speak English",,2020-06-16,2020-08-24,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,1368,0.03,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Aishani Aatresh,Harvard University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.01.14.21249824v1,2021-02-11,2024-03-01,Verified,aatresh_development_2021,USA
210116_Philadelphia_UniversityofPennsylvania_Overall,210116_Philadelphia_UniversityofPennsylvania,SARS-CoV-2 seropositivity and seroconversion in patients undergoing active cancer-directed therapy,2021-01-16,Preprint,Local,Prospective cohort,United States of America,Pennsylvania,Philadelphia,Patients with solid malignancies presenting to the Penn Abramson Cancer Center for chemotherapy and/or immunotherapy,,2020-05-21,2020-10-08,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,124,0.016,,,True,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,"['IgG', 'IgM']",Spike,,,,['High'],No,No,No,Yes,Unclear,Unclear,Yes,No,No,Lova Sun,University of Pennsylvania,Not Unity-Aligned,https://dx.doi.org/10.1101/2021.01.15.21249810,2021-04-05,2022-07-16,Verified,sun_sars-cov-2_2021,USA
210117_OrangeCounty_HoagMemorialHospitalPresbyterian_First_responders,210117_OrangeCounty_HoagMemorialHospitalPresbyterian_First_responders,Prevalence and Longevity of SARS-CoV-2 Antibodies Among Health Care Workers,2021-01-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,California,,"Study subjects from first responders were recruited from fire and police departments in
Orange County, California, by direct email notifications.",,2020-07-15,2020-08-15,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,92,0.0435,0.012,0.1076,True,True,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9359999999999999,1.0,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Michael Brant Zawadzki,Hoag Memorial Hospital Presbyterian,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab015,2021-03-28,2023-07-04,Verified,brant-zawadzki_prevalence_2021,USA
210117_OrangeCounty_HoagMemorialHospitalPresbyterian_HCW,210117_OrangeCounty_HoagMemorialHospitalPresbyterian_HCW,Prevalence and Longevity of SARS-CoV-2 Antibodies Among Health Care Workers,2021-01-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,California,,"Study HCW subjects were recruited by direct email notifications
to the entire employee workforce (6500+ individuals) and
independent medical staff (1600+ physicians), whose work locations
include 2 hospital campuses, 9 health centers, 13 urgent
care locations, and other clinical and administrative facilities all
within a ~20-mile radius.",,2020-07-15,2020-08-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,2754,0.0276,0.021800000000000003,0.0344,True,True,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9359999999999999,1.0,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Michael Brant Zawadzki,Hoag Memorial Hospital Presbyterian,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab015,2021-03-28,2023-07-04,Verified,brant-zawadzki_prevalence_2021,USA
210117_Maryland_UniversityofMaryland_overall_adj,210117_Maryland_UniversityofMaryland,Validation of COVID-19 serologic tests and large scale screening of asymptomatic healthcare workers,2021-01-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Maryland,Baltimore,Free antibody testing was offered to all employees and affiliates of the University of Maryland Health System,,2020-06-03,2020-07-24,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,8399,0.0352,0.0301,0.0398,True,True,,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Author designed (ELISA) -Spike","Ortho Clinical Diagnostics Inc.,NA",Multiple Types,Plasma,"['IgA', 'IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Kristin E Mullins,University of Maryland,Not Unity-Aligned,http://dx.doi.org/10.1016/j.clinbiochem.2021.01.004,2021-02-22,2023-08-15,Verified,mullins_validation_2021,USA
210119_NewJersey_CooperUniversityHospital_overall,210119_NewJersey_CooperUniversityHospital,COVID-19 Serologic Testing Among the Highest Risk Healthcare Workers,2021-01-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New Jersey ,,"A convenience sample of healthcare workers at an academic medical center in southern New Jersey were included. Inclu- sion criteria were as follows: (1) age ≥ 18 years; (2) physician, physician assistant, advance practice nurse, nurse, technician, or other patient facing in-hospital support staff involved in aerosolizing procedures (e.g., endotracheal intubation) for known COVID-19-positive patients",,2020-06-10,2020-08-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,172,0.052000000000000005,0.024,0.09699999999999999,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,Roche Diagnostics",CLIA,Serum,TotalAntibody,,,,,['High'],,No,No,Yes,,Yes,Yes,No,,Snehal Gandhi,Cooper University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1007/s11606-020-06462-1,2021-02-04,2024-03-01,Unverified,gandhi_covid-19_2021,USA
210120_NorthDakota_NorthDakotaStateUniversity_PharmacyPersonnel,210120_NorthDakota_NorthDakotaStateUniversity,Prevalence of SARS-CoV-2 antibodies among North Dakota community pharmacy personnel: A seroprevalence survey,2021-01-20,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Dakota,"Fargo, Grand Forks","All community pharmacy personnel in Fargo or Grand
Forks were eligible to participate in the study.",,2020-07-01,2020-07-31,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,Pharmacy personnel,247,0.146,0.10400000000000001,0.196,True,,,,True,Convenience,The BioSys Plus COVID-19 IgM/IgG Rapid Test,BioSys Laboratories,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,0.935,1.0,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Amanda Johnson,North Dakota State University,Not Unity-Aligned,https://www.japha.org/article/S1544-3191(21)00025-X/abstract,2021-03-14,2024-03-01,Verified,johnson_prevalence_2021,USA
210122_USA_YourCareChoice_GenPop,210122_USA_YourCareChoice,COVID-19 prevalence and predictors in United States adults during peak stay-at-home orders,2021-01-22,Journal Article (Peer-Reviewed),National,Retrospective cohort,United States of America,,,"Respondents were required to be 18 years old or older, reside in the United States, and confirm their voluntarily agreement to participate. The survey was open to the general population and not restricted to patients hospitalized with COVID-19.",,2020-04-24,2020-05-13,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,407,0.2162,,,True,,,,True,Stratified probability,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,Yes,No,No,Unclear,Unclear,Yes,No,Yes,Robert Morlock,YourCareChoice,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0245586,2021-03-13,2022-07-16,Verified,morlock_covid-19_2021,USA
210123_Norfolk_NavalMedicalCenterPortsmouth_Overall,210123_Norfolk_NavalMedicalCenterPortsmouth,SARS-CoV-2 Infections and Serologic Responses Among Military Personnel Deployed on the USNS COMFORT to New York City During the COVID-19 Pandemic,2021-01-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Virginia,Norfolk,"All 1159 crewmembers who returned to Norfolk, Virginia, for ROM were eligible for the study, and no specific groups among the crew were targeted for enrollment.",,2020-04-28,2020-05-12,Essential non-healthcare workers,All,Adults (18-64 years),18.0,,Primary Estimate,,432,0.0301,0.0161,0.0509,True,,,,True,Convenience,SARS-CoV-2 spike protein IgG MMIA assay,LakePharma Inc.,Other,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.98,1.0,['High'],Yes,No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Tahaniyat Lalani,Naval Medical Center Portsmouth,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofaa654,2021-03-13,2022-07-16,Verified,lalani_sars-cov-2_2021,USA
210125_NewYork_CDC+NewYorkCity_Total,210125_NewYork_CDC+NewYorkCity,"Prevalence of SARS-CoV-2 Antibodies in First Responders and Public Safety Personnel, New York City, New York, USA, May-July 2020",2021-01-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"Adults >18 years of age working onsite in a public service agency were eligible to participate, including employees of city departments of corrections, police, fire, medical examiner, and education, for a total of ≈60,000 persons. Educational settings were limited to Regional Enrichment Centers that served children of first responders and healthcare personnel.",Persons who self-reported a positive result for SARS-CoV-2 or occurrence of COVID-19 symptoms <2 weeks before completing the questionnaire were ineligible.,2020-05-18,2020-07-02,Essential non-healthcare workers,All,Multiple groups,18.0,,Primary Estimate,,22647,0.225,0.219,0.23,True,,,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Samira Sami,CDC and New York City Department of Health and Mental Hygiene,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2703.204340,2021-03-05,2024-03-01,Unverified,sami_prevalence_2021,USA
210125_NewYork_CDC+NewYorkCity_age45to59,210125_NewYork_CDC+NewYorkCity,"Prevalence of SARS-CoV-2 Antibodies in First Responders and Public Safety Personnel, New York City, New York, USA, May-July 2020",2021-01-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"Adults >18 years of age working onsite in a public service agency were eligible to participate, including employees of city departments of corrections, police, fire, medical examiner, and education, for a total of ≈60,000 persons. Educational settings were limited to Regional Enrichment Centers that served children of first responders and healthcare personnel.",Persons who self-reported a positive result for SARS-CoV-2 or occurrence of COVID-19 symptoms <2 weeks before completing the questionnaire were ineligible.,2020-05-18,2020-07-02,Essential non-healthcare workers,All,Adults (18-64 years),45.0,59.0,Age,45-59,6328,0.203,0.19399999999999998,0.214,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Samira Sami,CDC and New York City Department of Health and Mental Hygiene,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2703.204340,2021-03-05,2024-03-01,Unverified,sami_prevalence_2021,USA
210125_NewYork_CDC+NewYorkCity_age15to34,210125_NewYork_CDC+NewYorkCity,"Prevalence of SARS-CoV-2 Antibodies in First Responders and Public Safety Personnel, New York City, New York, USA, May-July 2020",2021-01-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"Adults >18 years of age working onsite in a public service agency were eligible to participate, including employees of city departments of corrections, police, fire, medical examiner, and education, for a total of ≈60,000 persons. Educational settings were limited to Regional Enrichment Centers that served children of first responders and healthcare personnel.",Persons who self-reported a positive result for SARS-CoV-2 or occurrence of COVID-19 symptoms <2 weeks before completing the questionnaire were ineligible.,2020-05-18,2020-07-02,Essential non-healthcare workers,All,Adults (18-64 years),25.0,34.0,Age,25-34,6677,0.264,0.253,0.275,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Samira Sami,CDC and New York City Department of Health and Mental Hygiene,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2703.204340,2021-03-05,2024-03-01,Unverified,sami_prevalence_2021,USA
210125_NewYork_CDC+NewYorkCity_age35to44,210125_NewYork_CDC+NewYorkCity,"Prevalence of SARS-CoV-2 Antibodies in First Responders and Public Safety Personnel, New York City, New York, USA, May-July 2020",2021-01-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"Adults >18 years of age working onsite in a public service agency were eligible to participate, including employees of city departments of corrections, police, fire, medical examiner, and education, for a total of ≈60,000 persons. Educational settings were limited to Regional Enrichment Centers that served children of first responders and healthcare personnel.",Persons who self-reported a positive result for SARS-CoV-2 or occurrence of COVID-19 symptoms <2 weeks before completing the questionnaire were ineligible.,2020-05-18,2020-07-02,Essential non-healthcare workers,All,Adults (18-64 years),35.0,44.0,Age,35-44,8034,0.20199999999999999,0.19399999999999998,0.21100000000000002,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Samira Sami,CDC and New York City Department of Health and Mental Hygiene,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2703.204340,2021-03-05,2024-03-01,Unverified,sami_prevalence_2021,USA
210125_NewYork_CDC+NewYorkCity_age60to64,210125_NewYork_CDC+NewYorkCity,"Prevalence of SARS-CoV-2 Antibodies in First Responders and Public Safety Personnel, New York City, New York, USA, May-July 2020",2021-01-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"Adults >18 years of age working onsite in a public service agency were eligible to participate, including employees of city departments of corrections, police, fire, medical examiner, and education, for a total of ≈60,000 persons. Educational settings were limited to Regional Enrichment Centers that served children of first responders and healthcare personnel.",Persons who self-reported a positive result for SARS-CoV-2 or occurrence of COVID-19 symptoms <2 weeks before completing the questionnaire were ineligible.,2020-05-18,2020-07-02,Essential non-healthcare workers,All,Adults (18-64 years),60.0,64.0,Age,60-64,589,0.207,0.17500000000000002,0.242,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Samira Sami,CDC and New York City Department of Health and Mental Hygiene,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2703.204340,2021-03-05,2024-03-01,Unverified,sami_prevalence_2021,USA
210125_NewYork_CDC+NewYorkCity_age18to24,210125_NewYork_CDC+NewYorkCity,"Prevalence of SARS-CoV-2 Antibodies in First Responders and Public Safety Personnel, New York City, New York, USA, May-July 2020",2021-01-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"Adults >18 years of age working onsite in a public service agency were eligible to participate, including employees of city departments of corrections, police, fire, medical examiner, and education, for a total of ≈60,000 persons. Educational settings were limited to Regional Enrichment Centers that served children of first responders and healthcare personnel.",Persons who self-reported a positive result for SARS-CoV-2 or occurrence of COVID-19 symptoms <2 weeks before completing the questionnaire were ineligible.,2020-05-18,2020-07-02,Essential non-healthcare workers,All,Adults (18-64 years),18.0,24.0,Age,18-24,795,0.32,0.287,0.353,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Samira Sami,CDC and New York City Department of Health and Mental Hygiene,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2703.204340,2021-03-05,2024-03-01,Unverified,sami_prevalence_2021,USA
210125_NewYork_CDC+NewYorkCity_age>65,210125_NewYork_CDC+NewYorkCity,"Prevalence of SARS-CoV-2 Antibodies in First Responders and Public Safety Personnel, New York City, New York, USA, May-July 2020",2021-01-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"Adults >18 years of age working onsite in a public service agency were eligible to participate, including employees of city departments of corrections, police, fire, medical examiner, and education, for a total of ≈60,000 persons. Educational settings were limited to Regional Enrichment Centers that served children of first responders and healthcare personnel.",Persons who self-reported a positive result for SARS-CoV-2 or occurrence of COVID-19 symptoms <2 weeks before completing the questionnaire were ineligible.,2020-05-18,2020-07-02,Essential non-healthcare workers,All,Seniors (65+ years),65.0,,Age,Equal or greater than 65,224,0.18300000000000002,0.135,0.24,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Samira Sami,CDC and New York City Department of Health and Mental Hygiene,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2703.204340,2021-03-05,2024-03-01,Unverified,sami_prevalence_2021,USA
210129_NewYork_NorthwellHealth,210129_NewYork_NorthwellHealth,610 ABO and Rh blood groups and SARS-CoV-2 susceptibility in pregnancy,2021-01-29,Journal Article (Peer-Reviewed),Regional,Retrospective cohort,United States of America,New York,,Women withavailable SARS-CoV-2 antibody results were included in the study,,2020-05-27,2020-08-23,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,Pregnant women,2930,0.153,,,True,,,,True,Sequential,Not reported/ Unable to specify,,,Whole Blood,,,,,,['High'],Yes,No,Yes,No,Unclear,Unclear,Yes,No,Unclear,Lylach Haizler Cohen,Northwell Health,Not Unity-Aligned,http://dx.doi.org/10.1016/j.ajog.2020.12.631,2021-03-20,2022-07-16,Verified,haizler-cohen_610_2021,USA
210129_Philadelphia_UniversityofPennsylvania_overallmother_unadj,210129_Philadelphia_UniversityofPennsylvania,Assessment of Maternal and Neonatal Cord Blood SARS-CoV-2 Antibodies and Placental Transfer Ratios,2021-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Pennsylvania,Philadelphia,"Women and their newborns delivered at Pennsylvania Hospital in Philadelphia between April 9, 2020, and August 8, 2020, were included in the study.",,2020-04-09,2020-08-08,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,1471,0.06,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,,,['High'],No,No,Yes,No,Yes,Unclear,Yes,No,Unclear,Dustin D Flannery,University of Pennsylvania,Not Unity-Aligned,https://dx.doi.org/10.1001/jamapediatrics.2021.0038,2021-02-20,2022-07-16,Verified,flannery_assessment_2021,USA
210129_Atlanta_EmoryUniversityHospital_primary,210129_Atlanta_EmoryUniversityHospital,Quantification of occupational and community risk factors for SARS-CoV-2 seropositivity among healthcare workers in a large U.S. healthcare system,2021-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Georgia,Atlanta,All Emory Healthcare employees and medical staff members received e-mail solicitations offering free antibody testing,,2020-04-19,2020-06-26,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,10275,0.038,0.034,0.043,True,True,True,,,Self-referral,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.975,0.98,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,No,Julia M Baker,Emory University Hospital,Not Unity-Aligned,https://dx.doi.org/10.7326/M20-7145,2021-03-19,2022-07-16,Verified,baker_quantification_2020,USA
210129_Atlanta_EmoryUniversityHospital_primary_40-49,210129_Atlanta_EmoryUniversityHospital,Quantification of occupational and community risk factors for SARS-CoV-2 seropositivity among healthcare workers in a large U.S. healthcare system,2021-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Georgia,Atlanta,All Emory Healthcare employees and medical staff members received e-mail solicitations offering free antibody testing,,2020-04-19,2020-06-26,Health care workers and caregivers,All,Adults (18-64 years),40.0,49.0,Age,40-49,2118,0.059000000000000004,,,,,,,,Self-referral,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.975,0.98,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,No,Julia M Baker,Emory University Hospital,Not Unity-Aligned,https://dx.doi.org/10.7326/M20-7145,2021-03-28,2022-07-16,Verified,baker_quantification_2020,USA
210129_Atlanta_EmoryUniversityHospital_primary<30,210129_Atlanta_EmoryUniversityHospital,Quantification of occupational and community risk factors for SARS-CoV-2 seropositivity among healthcare workers in a large U.S. healthcare system,2021-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Georgia,Atlanta,All Emory Healthcare employees and medical staff members received e-mail solicitations offering free antibody testing,,2020-04-19,2020-06-26,Health care workers and caregivers,All,Adults (18-64 years),,30.0,Age,<30,1581,0.069,,,,,,,,Self-referral,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.975,0.98,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,No,Julia M Baker,Emory University Hospital,Not Unity-Aligned,https://dx.doi.org/10.7326/M20-7145,2021-03-28,2022-07-16,Verified,baker_quantification_2020,USA
210129_Atlanta_EmoryUniversityHospital_primary>=60,210129_Atlanta_EmoryUniversityHospital,Quantification of occupational and community risk factors for SARS-CoV-2 seropositivity among healthcare workers in a large U.S. healthcare system,2021-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Georgia,Atlanta,All Emory Healthcare employees and medical staff members received e-mail solicitations offering free antibody testing,,2020-04-19,2020-06-26,Health care workers and caregivers,All,Seniors (65+ years),60.0,,Age,>=60,1153,0.049,,,,,,,,Self-referral,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.975,0.98,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,No,Julia M Baker,Emory University Hospital,Not Unity-Aligned,https://dx.doi.org/10.7326/M20-7145,2021-03-28,2022-07-16,Verified,baker_quantification_2020,USA
210129_Atlanta_EmoryUniversityHospital_primary_30-39,210129_Atlanta_EmoryUniversityHospital,Quantification of occupational and community risk factors for SARS-CoV-2 seropositivity among healthcare workers in a large U.S. healthcare system,2021-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Georgia,Atlanta,All Emory Healthcare employees and medical staff members received e-mail solicitations offering free antibody testing,,2020-04-19,2020-06-26,Health care workers and caregivers,All,Adults (18-64 years),30.0,39.0,Age,30-39,2953,0.057999999999999996,,,,,,,,Self-referral,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.975,0.98,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,No,Julia M Baker,Emory University Hospital,Not Unity-Aligned,https://dx.doi.org/10.7326/M20-7145,2021-03-28,2022-07-16,Verified,baker_quantification_2020,USA
210129_Atlanta_EmoryUniversityHospital_primary_50-59,210129_Atlanta_EmoryUniversityHospital,Quantification of occupational and community risk factors for SARS-CoV-2 seropositivity among healthcare workers in a large U.S. healthcare system,2021-01-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Georgia,Atlanta,All Emory Healthcare employees and medical staff members received e-mail solicitations offering free antibody testing,,2020-04-19,2020-06-26,Health care workers and caregivers,All,Adults (18-64 years),50.0,59.0,Age,50-59,1805,0.052000000000000005,,,,,,,,Self-referral,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.975,0.98,['High'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,No,Julia M Baker,Emory University Hospital,Not Unity-Aligned,https://dx.doi.org/10.7326/M20-7145,2021-03-28,2022-07-16,Verified,baker_quantification_2020,USA
210130_USA_UniversityofArizona_primary,210130_USA_UniversityofArizona,"Coronavirus Disease 2019 symptoms and SARS-CoV-2 antibody positivity in a large survey of first responders and healthcare personnel, May-July 2020",2021-01-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,,Detroit and New York City,Staff of  hospitals and emergency medical and public service agencies ,,2020-05-17,2020-07-02,Health care workers and caregivers,All,Multiple groups,18.0,,Primary Estimate,,40938,0.162,0.159,0.166,True,,,,True,Self-referral,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,ELISA,Serum,IgG,,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Lara J Akinbami,University of Arizona ,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab080,2021-03-19,2024-03-01,Verified,akinbami_coronavirus_2021,USA
210201_NewYorkCity_ColumbiaUniversity,210201_NewYorkCity_ColumbiaUniversity,919 Rates of seroprevalance of COVID-19 among pregnant patients in New York City,2021-02-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,"New York
",New York City,women presenting to L&D at a single tertiary care center in NYC.,positive PCR testing upon entry to the hospital,2020-06-24,2020-07-16,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,Overall (all female),47,0.40399999999999997,,,True,,,,True,Sequential,Not reported/ Unable to specify,,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.92,,['High'],,No,No,No,,Unclear,Yes,No,,Caitlin Baptiste,Columbia University,Not Unity-Aligned,http://dx.doi.org/10.1016/j.ajog.2020.12.944,2021-03-18,2022-07-16,Verified,baptiste_919_2021,USA
201125_Washington_GeorgeWashingtonUniversity_hcw,201125_Washington_GeorgeWashingtonUniversity,COVID-19 infection among emergency department healthcare providers in a large tertiary academic medical center following the peak of the pandemic,2021-02-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,District of Columbia,Washington ,"ED HCP were defined as any ED staff that come into close contact with ED patients while delivering medical care. Roles included in the study were physicians, advanced practice providers, nurses, and technicians. About 200 ED HCP were eligible for inclusion in the study; 138 consented and were enrolled over a 2-week period.",,2020-05-26,2020-06-14,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Emergency department staff,138,0.0507,,,True,,,,True,Convenience,"2019 nCoV IgM/IgG detection kit,Author designed (ELISA) -Spike","Biolidics Ltd,NA",Multiple Types,Multiple Types,"['IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],No,No,No,Yes,Yes,Unclear,Yes,No,Yes,Eric Murakami,George Washington University,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/33340874/,2021-04-19,2024-03-01,Verified,murakami_covid-19_2021,USA
210201_Washington_ChildrensNationalHospital_Overall_TestAdj,210201_WashingtonDC_ChildrensNationalHospital,Estimated SARS-CoV-2 Seroprevalence in Healthy Children and Those with Chronic Illnesses in The Washington Metropolitan Area as of October 2020,2021-02-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,"Washington, D.C, Maryland, Virginia, West Virginia",Washington D.C,"Pediatric patients aged 22 yrs and younger. Patients from CNH Hematology Oncology Clinic, CNH Primary Care
Center, two CNH Emergency Departments, and three public, community-based testing sites operated by DC Health",,2020-07-07,2020-10-29,Residual sera,All,Children and Youth (0-17 years),0.0,22.0,Primary Estimate,Adjusted for test,385,0.09460000000000002,0.0668,0.13,True,True,,,,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.976,0.993,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Burak Bahar,Children's National Hospital,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.01.30.21250830v1.full-text,2021-03-04,2023-07-04,Verified,bahar_estimated_2021-1,USA
210201_Washington_ChildrensNationalHospital_Overall_Unadj,210201_WashingtonDC_ChildrensNationalHospital,Estimated SARS-CoV-2 Seroprevalence in Healthy Children and Those with Chronic Illnesses in The Washington Metropolitan Area as of October 2020,2021-02-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,"Washington, D.C, Maryland, Virginia, West Virginia",Washington D.C,"Pediatric patients aged 22 yrs and younger. Patients from CNH Hematology Oncology Clinic, CNH Primary Care
Center, two CNH Emergency Departments, and three public, community-based testing sites operated by DC Health",,2020-07-07,2020-10-29,Residual sera,All,Children and Youth (0-17 years),0.0,22.0,Analysis,Unadjusted.,385,0.0987,,,,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.976,0.993,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Burak Bahar,Children's National Hospital,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.01.30.21250830v1.full-text,2021-03-04,2024-03-01,Verified,bahar_estimated_2021-1,USA
210201_Minnesota_UniversityofMinnesota_HCW_Primary,210201_Minnesota_UniversityofMinnesota_HCW,Initial determination of COVID-19 seroprevalence among outpatients and healthcare workers in Minnesota using a novel SARS-CoV-2 total antibody ELISA,2021-02-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Minnesota,,These samples were obtained from healthcare workers from within the M Health Fairview system with confirmed and non-confirmed COVID-19 ex- posures ≥ 14 days prior. ,,2020-04-13,2020-05-21,Health care workers and caregivers,All,Multiple groups,18.0,73.0,Primary Estimate,,1282,0.0296,0.0204,0.038900000000000004,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.861,1.0,['Moderate'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,No,,Stefani Thomas,University of Minnesota,Not Unity-Aligned,https://dx.doi.org/10.1016/j.clinbiochem.2021.01.010,2021-02-25,2022-07-16,Verified,thomas_initial_2021,USA
210201_Minnesota_UniversityofMinnesota_OutPatients_Primary ,210201_Minnesota_UniversityofMinnesota_OutPatients,Initial determination of COVID-19 seroprevalence among outpatients and healthcare workers in Minnesota using a novel SARS-CoV-2 total antibody ELISA,2021-02-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Minnesota,,These samples were obtained from asymptomatic outpatients from within the M Health Fairview system with potential COVID-19 exposures or history of prior symptoms consistent with COVID-19 ≥ 14 days prior ,,2020-04-13,2020-05-21,Residual sera,All,Multiple groups,0.0,93.0,Primary Estimate,,2379,0.0446,0.0363,0.05280000000000001,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.861,1.0,['High'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,No,,Stefani Thomas,University of Minnesota,Not Unity-Aligned,https://dx.doi.org/10.1016/j.clinbiochem.2021.01.010,2021-02-25,2022-07-16,Verified,thomas_initial_2021,USA
210201_Indianapolis_IndianaUniversity_HCW_primary,210201_Indianapolis_IndianaUniversity_HCW,Longitudinal SARS-CoV-2 seroconversion and functional heterogeneity in a pediatric dialysis unit,2021-02-01,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Indiana,Indianapolis,"nurses, physicians, and staff in a pediatric hemodialysis unit at Riley Hospital for Children, Indianapolis, Indiana",,2020-04-01,2020-06-24,Health care workers and caregivers,All,Adults (18-64 years),24.0,61.0,Primary Estimate,,34,0.35000000000000003,,,True,,,,True,Convenience,"COVID-19 Human IgM IgG Assay Kit,Author designed (ELISA) - Unknown","Abnova,NA",ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9440000000000001,0.985,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,Yes,Jorge J Canas ,Indiana University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.kint.2020.11.014,2021-03-24,2022-07-16,Verified,canas_longitudinal_2021,USA
210201_Indianapolis_IndianaUniversity_HDpatients_primary,210201_Indianapolis_IndianaUniversity_HDpatients,Longitudinal SARS-CoV-2 seroconversion and functional heterogeneity in a pediatric dialysis unit,2021-02-01,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Indiana,Indianapolis,"patients from a pediatric
dedicated chronic in-center hemodialysis unit at
Riley Hospital for Children, Indianapolis, Indiana",,2020-04-01,2020-06-24,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),2.0,18.0,Primary Estimate,,14,0.36,,,True,,,,True,Convenience,"COVID-19 Human IgM IgG Assay Kit,Author designed (ELISA) - Unknown","Abnova,NA",ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9440000000000001,0.985,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,Yes,Jorge J Canas ,Indiana University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.kint.2020.11.014,2021-03-24,2022-07-16,Verified,canas_longitudinal_2021,USA
210202_ParrisIsland_IcahnSchoolofMedicineatMountSinai,210202_ParrisIsland_IcahnSchoolofMedicineatMountSinai,"SARS-CoV-2 Seropositivity among US Marine Recruits Attending Basic Training, United States, Spring-Fall 2020",2021-02-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,North Carolina,Parris Island,"US Marine recruits preparing and quarantining for basic training at Marine Corps Recruit Depot Parris Island, South Carolina, Recruits were eligible if they were >18 years and could complete follow-up encounters",17 or younger,2020-05-11,2020-09-07,Essential non-healthcare workers,All,Adults (18-64 years),18.0,31.0,Primary Estimate,Overall military ,3196,0.09,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9608,0.9714,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Andrew Letizia,Icahn School of Medicine at Mount Sinai,Not Unity-Aligned,http://dx.doi.org/10.3201/eid2704.204732,2021-03-17,2022-07-16,Verified,letizia_sars-cov-2_2021-1,USA
210203_StLouis_WashingtonUniversitySchoolofMedicine_Adults_overall_adj,210203_StLouis_WashingtonUniversity_Adults,"Seroprevalence of SARS-CoV-2 Antibodies in Children and Adults in St. Louis, Missouri, USA",2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Missouri,St Louis,The adult samples were residual samples sent to Barnes-Jewish Hospital for physician-ordered vitamin D testing between 27 April 2020 and 12 May 2020. ,Specimens with orders for immunosuppressant therapeutic drug monitoring were excluded.,2020-04-27,2020-05-12,Residual sera,All,Multiple groups,18.0,93.0,Primary Estimate,,503,0.0311,0.0092,0.053200000000000004,True,True,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.9820000000000001,0.9870000000000001,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,,Brittany Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.01207-20,2021-03-13,2022-07-16,Verified,smith_seroprevalence_2021,USA
210203_StLouis_WashingtonUniversitySchoolofMedicine_Adults_30-39,210203_StLouis_WashingtonUniversity_Adults,"Seroprevalence of SARS-CoV-2 Antibodies in Children and Adults in St. Louis, Missouri, USA",2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Missouri,St Louis,The adult samples were residual samples sent to Barnes-Jewish Hospital for physician-ordered vitamin D testing between 27 April 2020 and 12 May 2020. ,Specimens with orders for immunosuppressant therapeutic drug monitoring were excluded.,2020-04-27,2020-05-12,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39 ,41,0.0244,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.9820000000000001,0.9870000000000001,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,,Brittany Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.01207-20,2021-03-13,2022-07-16,Verified,smith_seroprevalence_2021,USA
210203_StLouis_WashingtonUniversitySchoolofMedicine_Adults_male,210203_StLouis_WashingtonUniversity_Adults,"Seroprevalence of SARS-CoV-2 Antibodies in Children and Adults in St. Louis, Missouri, USA",2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Missouri,St Louis,The adult samples were residual samples sent to Barnes-Jewish Hospital for physician-ordered vitamin D testing between 27 April 2020 and 12 May 2020. ,Specimens with orders for immunosuppressant therapeutic drug monitoring were excluded.,2020-04-27,2020-05-12,Residual sera,Male,Multiple groups,18.0,93.0,Sex/Gender,,207,0.0435,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.9820000000000001,0.9870000000000001,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,,Brittany Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.01207-20,2021-03-13,2022-07-16,Verified,smith_seroprevalence_2021,USA
210203_StLouis_WashingtonUniversitySchoolofMedicine_Adults_18-30,210203_StLouis_WashingtonUniversity_Adults,"Seroprevalence of SARS-CoV-2 Antibodies in Children and Adults in St. Louis, Missouri, USA",2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Missouri,St Louis,The adult samples were residual samples sent to Barnes-Jewish Hospital for physician-ordered vitamin D testing between 27 April 2020 and 12 May 2020. ,Specimens with orders for immunosuppressant therapeutic drug monitoring were excluded.,2020-04-27,2020-05-12,Residual sera,All,Adults (18-64 years),18.0,30.0,Age,18-30 ,29,0.0345,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.9820000000000001,0.9870000000000001,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,,Brittany Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.01207-20,2021-03-13,2022-07-16,Verified,smith_seroprevalence_2021,USA
210203_StLouis_WashingtonUniversitySchoolofMedicine_Adults_40-49,210203_StLouis_WashingtonUniversity_Adults,"Seroprevalence of SARS-CoV-2 Antibodies in Children and Adults in St. Louis, Missouri, USA",2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Missouri,St Louis,The adult samples were residual samples sent to Barnes-Jewish Hospital for physician-ordered vitamin D testing between 27 April 2020 and 12 May 2020. ,Specimens with orders for immunosuppressant therapeutic drug monitoring were excluded.,2020-04-27,2020-05-12,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,57,0.0351,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.9820000000000001,0.9870000000000001,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,,Brittany Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.01207-20,2021-03-13,2022-07-16,Verified,smith_seroprevalence_2021,USA
210203_StLouis_WashingtonUniversitySchoolofMedicine_Adults_overall_unadj,210203_StLouis_WashingtonUniversity_Adults,"Seroprevalence of SARS-CoV-2 Antibodies in Children and Adults in St. Louis, Missouri, USA",2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Missouri,St Louis,The adult samples were residual samples sent to Barnes-Jewish Hospital for physician-ordered vitamin D testing between 27 April 2020 and 12 May 2020. ,Specimens with orders for immunosuppressant therapeutic drug monitoring were excluded.,2020-04-27,2020-05-12,Residual sera,All,Multiple groups,18.0,93.0,Analysis,,503,0.0417,,,,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.9820000000000001,0.9870000000000001,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,,Brittany Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.01207-20,2021-03-13,2022-07-16,Verified,smith_seroprevalence_2021,USA
210203_StLouis_WashingtonUniversitySchoolofMedicine_Adults_female,210203_StLouis_WashingtonUniversity_Adults,"Seroprevalence of SARS-CoV-2 Antibodies in Children and Adults in St. Louis, Missouri, USA",2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Missouri,St Louis,The adult samples were residual samples sent to Barnes-Jewish Hospital for physician-ordered vitamin D testing between 27 April 2020 and 12 May 2020. ,Specimens with orders for immunosuppressant therapeutic drug monitoring were excluded.,2020-04-27,2020-05-12,Residual sera,Female,Multiple groups,18.0,93.0,Sex/Gender,,296,0.0405,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.9820000000000001,0.9870000000000001,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,,Brittany Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.01207-20,2021-03-13,2022-07-16,Verified,smith_seroprevalence_2021,USA
210203_StLouis_WashingtonUniversitySchoolofMedicine_Adults_60-69,210203_StLouis_WashingtonUniversity_Adults,"Seroprevalence of SARS-CoV-2 Antibodies in Children and Adults in St. Louis, Missouri, USA",2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Missouri,St Louis,The adult samples were residual samples sent to Barnes-Jewish Hospital for physician-ordered vitamin D testing between 27 April 2020 and 12 May 2020. ,Specimens with orders for immunosuppressant therapeutic drug monitoring were excluded.,2020-04-27,2020-05-12,Residual sera,All,Adults (18-64 years),60.0,69.0,Age,60-69,147,0.047599999999999996,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.9820000000000001,0.9870000000000001,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,,Brittany Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.01207-20,2021-03-13,2022-07-16,Verified,smith_seroprevalence_2021,USA
210203_StLouis_WashingtonUniversitySchoolofMedicine_Adults_>69,210203_StLouis_WashingtonUniversity_Adults,"Seroprevalence of SARS-CoV-2 Antibodies in Children and Adults in St. Louis, Missouri, USA",2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Missouri,St Louis,The adult samples were residual samples sent to Barnes-Jewish Hospital for physician-ordered vitamin D testing between 27 April 2020 and 12 May 2020. ,Specimens with orders for immunosuppressant therapeutic drug monitoring were excluded.,2020-04-27,2020-05-12,Residual sera,All,Seniors (65+ years),69.0,93.0,Age,69-93,118,0.0085,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.9820000000000001,0.9870000000000001,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,,Brittany Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.01207-20,2021-03-13,2022-07-16,Verified,smith_seroprevalence_2021,USA
210203_StLouis_WashingtonUniversitySchoolofMedicine_Adults_50-59,210203_StLouis_WashingtonUniversity_Adults,"Seroprevalence of SARS-CoV-2 Antibodies in Children and Adults in St. Louis, Missouri, USA",2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Missouri,St Louis,The adult samples were residual samples sent to Barnes-Jewish Hospital for physician-ordered vitamin D testing between 27 April 2020 and 12 May 2020. ,Specimens with orders for immunosuppressant therapeutic drug monitoring were excluded.,2020-04-27,2020-05-12,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,111,0.08109999999999999,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.9820000000000001,0.9870000000000001,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,,Brittany Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.01207-20,2021-03-13,2022-07-16,Verified,smith_seroprevalence_2021,USA
210203_StLouis_WashingtonUniversitySchoolofMedicine_Children_overall_adj,210203_StLouis_WashingtonUniversity_Children,"Seroprevalence of SARS-CoV-2 Antibodies in Children and Adults in St. Louis, Missouri, USA",2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Missouri,St Louis,Residual pediatric specimens were collected from unique out- patients presenting to St. Louis Children’s Hospital between 14 April 2020 and 8 May 2020. ,Specimens with orders for immunosuppressant therapeutic drug monitoring were excluded.,2020-04-14,2020-05-08,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,,555,0.0171,0.0004,0.0338,True,True,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.9820000000000001,0.9870000000000001,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,,Brittany Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.01207-20,2021-03-13,2022-07-16,Verified,smith_seroprevalence_2021,USA
210203_StLouis_WashingtonUniversitySchoolofMedicine_Children_<1,210203_StLouis_WashingtonUniversity_Children,"Seroprevalence of SARS-CoV-2 Antibodies in Children and Adults in St. Louis, Missouri, USA",2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Missouri,St Louis,Residual pediatric specimens were collected from unique out- patients presenting to St. Louis Children’s Hospital between 14 April 2020 and 8 May 2020. ,Specimens with orders for immunosuppressant therapeutic drug monitoring were excluded.,2020-04-14,2020-05-08,Residual sera,All,Children and Youth (0-17 years),0.0,1.0,Age,< 1,89,0.0,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.9820000000000001,0.9870000000000001,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,,Brittany Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.01207-20,2021-03-13,2022-07-16,Verified,smith_seroprevalence_2021,USA
210203_StLouis_WashingtonUniversitySchoolofMedicine_Children_5-9,210203_StLouis_WashingtonUniversity_Children,"Seroprevalence of SARS-CoV-2 Antibodies in Children and Adults in St. Louis, Missouri, USA",2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Missouri,St Louis,Residual pediatric specimens were collected from unique out- patients presenting to St. Louis Children’s Hospital between 14 April 2020 and 8 May 2020. ,Specimens with orders for immunosuppressant therapeutic drug monitoring were excluded.,2020-04-14,2020-05-08,Residual sera,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,79,0.0506,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.9820000000000001,0.9870000000000001,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,,Brittany Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.01207-20,2021-03-13,2022-07-16,Verified,smith_seroprevalence_2021,USA
210203_StLouis_WashingtonUniversitySchoolofMedicine_Children_15-17,210203_StLouis_WashingtonUniversity_Children,"Seroprevalence of SARS-CoV-2 Antibodies in Children and Adults in St. Louis, Missouri, USA",2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Missouri,St Louis,Residual pediatric specimens were collected from unique out- patients presenting to St. Louis Children’s Hospital between 14 April 2020 and 8 May 2020. ,Specimens with orders for immunosuppressant therapeutic drug monitoring were excluded.,2020-04-14,2020-05-08,Residual sera,All,Children and Youth (0-17 years),15.0,17.0,Age,15-17,126,0.0317,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.9820000000000001,0.9870000000000001,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,,Brittany Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.01207-20,2021-03-13,2022-07-16,Verified,smith_seroprevalence_2021,USA
210203_StLouis_WashingtonUniversitySchoolofMedicine_Children_female,210203_StLouis_WashingtonUniversity_Children,"Seroprevalence of SARS-CoV-2 Antibodies in Children and Adults in St. Louis, Missouri, USA",2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Missouri,St Louis,Residual pediatric specimens were collected from unique out- patients presenting to St. Louis Children’s Hospital between 14 April 2020 and 8 May 2020. ,Specimens with orders for immunosuppressant therapeutic drug monitoring were excluded.,2020-04-14,2020-05-08,Residual sera,Female,Children and Youth (0-17 years),0.0,17.0,Sex/Gender,,286,0.0385,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.9820000000000001,0.9870000000000001,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,,Brittany Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.01207-20,2021-03-13,2022-07-16,Verified,smith_seroprevalence_2021,USA
210203_StLouis_WashingtonUniversitySchoolofMedicine_Children_1-4,210203_StLouis_WashingtonUniversity_Children,"Seroprevalence of SARS-CoV-2 Antibodies in Children and Adults in St. Louis, Missouri, USA",2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Missouri,St Louis,Residual pediatric specimens were collected from unique out- patients presenting to St. Louis Children’s Hospital between 14 April 2020 and 8 May 2020. ,Specimens with orders for immunosuppressant therapeutic drug monitoring were excluded.,2020-04-14,2020-05-08,Residual sera,All,Children and Youth (0-17 years),1.0,4.0,Age,1-4,118,0.0085,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.9820000000000001,0.9870000000000001,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,,Brittany Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.01207-20,2021-03-13,2022-07-16,Verified,smith_seroprevalence_2021,USA
210203_StLouis_WashingtonUniversitySchoolofMedicine_Children_male,210203_StLouis_WashingtonUniversity_Children,"Seroprevalence of SARS-CoV-2 Antibodies in Children and Adults in St. Louis, Missouri, USA",2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Missouri,St Louis,Residual pediatric specimens were collected from unique out- patients presenting to St. Louis Children’s Hospital between 14 April 2020 and 8 May 2020. ,Specimens with orders for immunosuppressant therapeutic drug monitoring were excluded.,2020-04-14,2020-05-08,Residual sera,Male,Children and Youth (0-17 years),0.0,17.0,Sex/Gender,,269,0.0149,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.9820000000000001,0.9870000000000001,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,,Brittany Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.01207-20,2021-03-13,2022-07-16,Verified,smith_seroprevalence_2021,USA
210203_StLouis_WashingtonUniversitySchoolofMedicine_Children_10-14,210203_StLouis_WashingtonUniversity_Children,"Seroprevalence of SARS-CoV-2 Antibodies in Children and Adults in St. Louis, Missouri, USA",2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Missouri,St Louis,Residual pediatric specimens were collected from unique out- patients presenting to St. Louis Children’s Hospital between 14 April 2020 and 8 May 2020. ,Specimens with orders for immunosuppressant therapeutic drug monitoring were excluded.,2020-04-14,2020-05-08,Residual sera,All,Children and Youth (0-17 years),10.0,14.0,Age,10-14,143,0.042,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.9820000000000001,0.9870000000000001,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,,Brittany Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.01207-20,2021-03-13,2022-07-16,Verified,smith_seroprevalence_2021,USA
210203_StLouis_WashingtonUniversitySchoolofMedicine_Children_overall_unadj,210203_StLouis_WashingtonUniversity_Children,"Seroprevalence of SARS-CoV-2 Antibodies in Children and Adults in St. Louis, Missouri, USA",2021-02-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Missouri,St Louis,Residual pediatric specimens were collected from unique out- patients presenting to St. Louis Children’s Hospital between 14 April 2020 and 8 May 2020. ,Specimens with orders for immunosuppressant therapeutic drug monitoring were excluded.,2020-04-14,2020-05-08,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Analysis,,555,0.027000000000000003,,,,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.9820000000000001,0.9870000000000001,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,,Brittany Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.01207-20,2021-03-13,2022-07-16,Verified,smith_seroprevalence_2021,USA
210204_OrangeCounty_UniversityofCaliforniaIrvine_Overall_PopTestAdj,210204_OrangeCounty_UniversityofCaliforniaIrvine,"Estimated Seroprevalence of SARS-CoV-2 Antibodies Among Adults in Orange County, California",2021-02-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,adults 18 years or older residing in Orange County on July 1st 2020,Participants for this analysis were not enrolled if other members of the household already were enrolled.,2020-07-10,2020-08-16,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,Pop/Test Adj,2979,0.113,0.081,0.132,True,True,True,,,Stratified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Plasma,"['IgG', 'IgM']","['Membraneprotein', 'Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.9400000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Tim Bruckner,University of California Irvine,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-82662-x,2021-03-28,2022-07-16,Verified,bruckner_estimated_2020,USA
210204_OrangeCounty_UniversityofCaliforniaIrvine_18-34,210204_OrangeCounty_UniversityofCaliforniaIrvine,"Estimated Seroprevalence of SARS-CoV-2 Antibodies Among Adults in Orange County, California",2021-02-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,adults 18 years or older residing in Orange County on July 1st 2020,Participants for this analysis were not enrolled if other members of the household already were enrolled.,2020-07-10,2020-08-16,Household and community samples,All,Adults (18-64 years),18.0,34.0,Age,18-34,673,0.12300000000000001,,,,,,,,Stratified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Plasma,"['IgG', 'IgM']","['Membraneprotein', 'Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.9400000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Tim Bruckner,University of California Irvine,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-82662-x,2021-03-28,2022-07-16,Verified,bruckner_estimated_2020,USA
210204_OrangeCounty_UniversityofCaliforniaIrvine_Overall_PopAdj,210204_OrangeCounty_UniversityofCaliforniaIrvine,"Estimated Seroprevalence of SARS-CoV-2 Antibodies Among Adults in Orange County, California",2021-02-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,adults 18 years or older residing in Orange County on July 1st 2020,Participants for this analysis were not enrolled if other members of the household already were enrolled.,2020-07-10,2020-08-16,Household and community samples,All,Multiple groups,18.0,,Analysis,Pop Ad,2979,0.115,0.105,0.12400000000000001,,,True,,True,Stratified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Plasma,"['IgG', 'IgM']","['Membraneprotein', 'Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.9400000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Tim Bruckner,University of California Irvine,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-82662-x,2021-03-28,2022-07-16,Verified,bruckner_estimated_2020,USA
210204_OrangeCounty_UniversityofCaliforniaIrvine_Female,210204_OrangeCounty_UniversityofCaliforniaIrvine,"Estimated Seroprevalence of SARS-CoV-2 Antibodies Among Adults in Orange County, California",2021-02-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,adults 18 years or older residing in Orange County on July 1st 2020,Participants for this analysis were not enrolled if other members of the household already were enrolled.,2020-07-10,2020-08-16,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,Female,1680,0.133,,,,,,,,Stratified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Plasma,"['IgG', 'IgM']","['Membraneprotein', 'Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.9400000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Tim Bruckner,University of California Irvine,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-82662-x,2021-03-28,2022-07-16,Verified,bruckner_estimated_2020,USA
210204_OrangeCounty_UniversityofCaliforniaIrvine_Hispanic,210204_OrangeCounty_UniversityofCaliforniaIrvine,"Estimated Seroprevalence of SARS-CoV-2 Antibodies Among Adults in Orange County, California",2021-02-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,adults 18 years or older residing in Orange County on July 1st 2020,Participants for this analysis were not enrolled if other members of the household already were enrolled.,2020-07-10,2020-08-16,Household and community samples,All,Multiple groups,18.0,,Ethnicity,Hispanic (including multi-race),1108,0.155,,,,,,,,Stratified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Plasma,"['IgG', 'IgM']","['Membraneprotein', 'Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.9400000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Tim Bruckner,University of California Irvine,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-82662-x,2021-03-28,2022-07-16,Verified,bruckner_estimated_2020,USA
210204_OrangeCounty_UniversityofCaliforniaIrvine_Asian,210204_OrangeCounty_UniversityofCaliforniaIrvine,"Estimated Seroprevalence of SARS-CoV-2 Antibodies Among Adults in Orange County, California",2021-02-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,adults 18 years or older residing in Orange County on July 1st 2020,Participants for this analysis were not enrolled if other members of the household already were enrolled.,2020-07-10,2020-08-16,Household and community samples,All,Multiple groups,18.0,,Race,"Asian (Non-Hispanic, Non-African American)",469,0.107,,,,,,,,Stratified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Plasma,"['IgG', 'IgM']","['Membraneprotein', 'Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.9400000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Tim Bruckner,University of California Irvine,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-82662-x,2021-03-28,2022-07-16,Verified,bruckner_estimated_2020,USA
210204_OrangeCounty_UniversityofCaliforniaIrvine_55+,210204_OrangeCounty_UniversityofCaliforniaIrvine,"Estimated Seroprevalence of SARS-CoV-2 Antibodies Among Adults in Orange County, California",2021-02-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,adults 18 years or older residing in Orange County on July 1st 2020,Participants for this analysis were not enrolled if other members of the household already were enrolled.,2020-07-10,2020-08-16,Household and community samples,All,Multiple groups,55.0,,Age,55+,944,0.106,,,,,,,,Stratified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Plasma,"['IgG', 'IgM']","['Membraneprotein', 'Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.9400000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Tim Bruckner,University of California Irvine,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-82662-x,2021-03-28,2022-07-16,Verified,bruckner_estimated_2020,USA
210204_OrangeCounty_UniversityofCaliforniaIrvine_Overall_Unadj,210204_OrangeCounty_UniversityofCaliforniaIrvine,"Estimated Seroprevalence of SARS-CoV-2 Antibodies Among Adults in Orange County, California",2021-02-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,adults 18 years or older residing in Orange County on July 1st 2020,Participants for this analysis were not enrolled if other members of the household already were enrolled.,2020-07-10,2020-08-16,Household and community samples,All,Multiple groups,18.0,,Analysis,Overall crude,2979,0.11800000000000001,,,,,,,,Stratified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Plasma,"['IgG', 'IgM']","['Membraneprotein', 'Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.9400000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Tim Bruckner,University of California Irvine,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-82662-x,2021-03-28,2022-07-16,Verified,bruckner_estimated_2020,USA
210204_OrangeCounty_UniversityofCaliforniaIrvine_35-54,210204_OrangeCounty_UniversityofCaliforniaIrvine,"Estimated Seroprevalence of SARS-CoV-2 Antibodies Among Adults in Orange County, California",2021-02-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,adults 18 years or older residing in Orange County on July 1st 2020,Participants for this analysis were not enrolled if other members of the household already were enrolled.,2020-07-10,2020-08-16,Household and community samples,All,Adults (18-64 years),35.0,54.0,Age,35-54,1362,0.12300000000000001,,,,,,,,Stratified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Plasma,"['IgG', 'IgM']","['Membraneprotein', 'Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.9400000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Tim Bruckner,University of California Irvine,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-82662-x,2021-03-28,2022-07-16,Verified,bruckner_estimated_2020,USA
210204_OrangeCounty_UniversityofCaliforniaIrvine_OtherNon-Hispanic,210204_OrangeCounty_UniversityofCaliforniaIrvine,"Estimated Seroprevalence of SARS-CoV-2 Antibodies Among Adults in Orange County, California",2021-02-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,adults 18 years or older residing in Orange County on July 1st 2020,Participants for this analysis were not enrolled if other members of the household already were enrolled.,2020-07-10,2020-08-16,Household and community samples,All,Multiple groups,18.0,,Ethnicity,Other Non-Hispanic (including White and African American),1402,0.092,,,,,,,,Stratified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Plasma,"['IgG', 'IgM']","['Membraneprotein', 'Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.9400000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Tim Bruckner,University of California Irvine,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-82662-x,2021-03-28,2022-07-16,Verified,bruckner_estimated_2020,USA
210204_OrangeCounty_UniversityofCaliforniaIrvine_Male,210204_OrangeCounty_UniversityofCaliforniaIrvine,"Estimated Seroprevalence of SARS-CoV-2 Antibodies Among Adults in Orange County, California",2021-02-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,adults 18 years or older residing in Orange County on July 1st 2020,Participants for this analysis were not enrolled if other members of the household already were enrolled.,2020-07-10,2020-08-16,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,Male,1296,0.099,,,,,,,,Stratified probability,Author designed (IFA) - MULTIPLEXED,,IFA,Plasma,"['IgG', 'IgM']","['Membraneprotein', 'Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.9400000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Tim Bruckner,University of California Irvine,Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-82662-x,2021-03-28,2022-07-16,Verified,bruckner_estimated_2020,USA
210204_UnitedStates_DaVitaClinicalResearch_Overall,210204_UnitedStates_DaVitaClinicalResearch,SARS-CoV-2 Antibody Seroprevalence Among Maintenance Dialysis Patients in the United States.,2021-02-04,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,deidentified remnant serum samples collected for routine laboratory screening from a national sample of maintenance dialysis patients treating with DaVita in the United States,,2020-05-27,2020-07-01,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,Overall ,12932,0.05776368697803897,0.054000000000000006,0.062000000000000006,True,,,,True,Simplified probability,Diazyme DZ-Lite SARS-CoV-2 IgG  CLIA tests,Diazyme Laboratories Inc,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Adam Walker,DaVita Clinical Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.xkme.2021.01.002,2021-03-18,2024-03-01,Verified,walker_sars-cov-2_2021,USA
210204_UnitedStates_DaVitaClinicalResearch_70-79,210204_UnitedStates_DaVitaClinicalResearch,SARS-CoV-2 Antibody Seroprevalence Among Maintenance Dialysis Patients in the United States.,2021-02-04,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,deidentified remnant serum samples collected for routine laboratory screening from a national sample of maintenance dialysis patients treating with DaVita in the United States,,2020-05-27,2020-07-01,Patients seeking care for non-COVID-19 reasons,All,Seniors (65+ years),70.0,79.0,Age,70-79,2873,0.052000000000000005,,,,,,,,Simplified probability,Diazyme DZ-Lite SARS-CoV-2 IgG  CLIA tests,Diazyme Laboratories Inc,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Adam Walker,DaVita Clinical Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.xkme.2021.01.002,2021-03-18,2024-03-01,Verified,walker_sars-cov-2_2021,USA
210204_UnitedStates_DaVitaClinicalResearch_80+,210204_UnitedStates_DaVitaClinicalResearch,SARS-CoV-2 Antibody Seroprevalence Among Maintenance Dialysis Patients in the United States.,2021-02-04,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,deidentified remnant serum samples collected for routine laboratory screening from a national sample of maintenance dialysis patients treating with DaVita in the United States,,2020-05-27,2020-07-01,Patients seeking care for non-COVID-19 reasons,All,Seniors (65+ years),80.0,,Age,80+,1424,0.039,,,,,,,,Simplified probability,Diazyme DZ-Lite SARS-CoV-2 IgG  CLIA tests,Diazyme Laboratories Inc,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,Adam Walker,DaVita Clinical Research,Not Unity-Aligned,https://dx.doi.org/10.1016/j.xkme.2021.01.002,2021-03-18,2024-03-01,Verified,walker_sars-cov-2_2021,USA
210205_UnitedStates_BrownUniversity,210205_UnitedStates_BrownUniversity,SARS-CoV-2 antibody detection in skilled nursing facility residents,2021-02-05,Journal Article (Peer-Reviewed),National,Retrospective cohort,United States of America,Multiple states,,"We limited the sample to residents who underwent antibody testing at least 1 week after a first positive PCR test for cases, or first PCR test for non‐cases (hereafter referred to as their reference PCR test).",,,2020-08-01,Assisted living and long-term care facilities,All,Seniors (65+ years),,,Primary Estimate,Overall,272,0.43,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,"['IgG', 'IgM', 'TotalAntibody']",,,,,['High'],No,No,No,Yes,No,Unclear,Yes,No,Unclear,Elizabeth White,Brown University,Not Unity-Aligned,http://dx.doi.org/10.1111/jgs.17061,2021-03-22,2022-07-16,Verified,white_sars-cov-2_nodate,USA
210208_Virginia_UniversityOfVirginia_Overall_PopAdj,210208_Virginia_UniversityOfVirginia,Assessment of Seroprevalence of SARS-CoV-2 and Risk Factors Associated With COVID-19 Infection Among Outpatients in Virginia,2021-02-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Virginia,,Adults 18 years or older who presented in person for scheduled outpatient clinic or outpatientlaboratory appointments were eligible, All outpatient sites conducted prescreening of individuals to ensure no COVID-19–like symptoms,2020-06-01,2020-08-14,Residual sera,All,Multiple groups,18.0,,Primary Estimate,,4675,0.024,0.018000000000000002,0.031000000000000003,True,True,True,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,,Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Elizabeth T Rogawski McQuade,"University of Virginia
",Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2020.35234,2021-03-18,2023-07-04,Verified,rogawski_mcquade_assessment_2021,USA
210208_Virginia_UniversityOfVirginia_50-59_PopAdj,210208_Virginia_UniversityOfVirginia,Assessment of Seroprevalence of SARS-CoV-2 and Risk Factors Associated With COVID-19 Infection Among Outpatients in Virginia,2021-02-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Virginia,,Adults 18 years or older who presented in person for scheduled outpatient clinic or outpatientlaboratory appointments were eligible, All outpatient sites conducted prescreening of individuals to ensure no COVID-19–like symptoms,2020-06-01,2020-08-14,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59 y.o,933,0.01,0.002,0.017,,True,True,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,,Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Elizabeth T Rogawski McQuade,"University of Virginia
",Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2020.35234,2021-03-19,2023-07-04,Verified,rogawski_mcquade_assessment_2021,USA
210208_Virginia_UniversityOfVirginia_Males_PopAdj,210208_Virginia_UniversityOfVirginia,Assessment of Seroprevalence of SARS-CoV-2 and Risk Factors Associated With COVID-19 Infection Among Outpatients in Virginia,2021-02-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Virginia,,Adults 18 years or older who presented in person for scheduled outpatient clinic or outpatientlaboratory appointments were eligible, All outpatient sites conducted prescreening of individuals to ensure no COVID-19–like symptoms,2020-06-01,2020-08-14,Residual sera,Male,Multiple groups,18.0,,Sex/Gender,,1556,0.024,0.013000000000000001,0.035,,True,True,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,,Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Elizabeth T Rogawski McQuade,"University of Virginia
",Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2020.35234,2021-03-19,2023-07-04,Verified,rogawski_mcquade_assessment_2021,USA
210208_Virginia_UniversityOfVirginia_70-79_PopAdj,210208_Virginia_UniversityOfVirginia,Assessment of Seroprevalence of SARS-CoV-2 and Risk Factors Associated With COVID-19 Infection Among Outpatients in Virginia,2021-02-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Virginia,,Adults 18 years or older who presented in person for scheduled outpatient clinic or outpatientlaboratory appointments were eligible, All outpatient sites conducted prescreening of individuals to ensure no COVID-19–like symptoms,2020-06-01,2020-08-14,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79 y.o,482,0.021,0.006999999999999999,0.034,,True,True,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,,Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Elizabeth T Rogawski McQuade,"University of Virginia
",Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2020.35234,2021-03-19,2023-07-04,Verified,rogawski_mcquade_assessment_2021,USA
210208_Virginia_UniversityOfVirginia_Overall_Unadj,210208_Virginia_UniversityOfVirginia,Assessment of Seroprevalence of SARS-CoV-2 and Risk Factors Associated With COVID-19 Infection Among Outpatients in Virginia,2021-02-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Virginia,,Adults 18 years or older who presented in person for scheduled outpatient clinic or outpatientlaboratory appointments were eligible, All outpatient sites conducted prescreening of individuals to ensure no COVID-19–like symptoms,2020-06-01,2020-08-14,Residual sera,All,Multiple groups,18.0,,Analysis,,4675,0.022000000000000002,,,,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,,Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Elizabeth T Rogawski McQuade,"University of Virginia
",Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2020.35234,2021-03-19,2024-03-01,Verified,rogawski_mcquade_assessment_2021,USA
210208_Virginia_UniversityOfVirginia_30-39_PopAdj,210208_Virginia_UniversityOfVirginia,Assessment of Seroprevalence of SARS-CoV-2 and Risk Factors Associated With COVID-19 Infection Among Outpatients in Virginia,2021-02-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Virginia,,Adults 18 years or older who presented in person for scheduled outpatient clinic or outpatientlaboratory appointments were eligible, All outpatient sites conducted prescreening of individuals to ensure no COVID-19–like symptoms,2020-06-01,2020-08-14,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39 y.o,950,0.023,0.011000000000000001,0.036000000000000004,,True,True,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,,Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Elizabeth T Rogawski McQuade,"University of Virginia
",Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2020.35234,2021-03-19,2023-07-04,Verified,rogawski_mcquade_assessment_2021,USA
210208_Virginia_UniversityOfVirginia_>=80_PopAdj,210208_Virginia_UniversityOfVirginia,Assessment of Seroprevalence of SARS-CoV-2 and Risk Factors Associated With COVID-19 Infection Among Outpatients in Virginia,2021-02-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Virginia,,Adults 18 years or older who presented in person for scheduled outpatient clinic or outpatientlaboratory appointments were eligible, All outpatient sites conducted prescreening of individuals to ensure no COVID-19–like symptoms,2020-06-01,2020-08-14,Residual sera,All,Seniors (65+ years),80.0,,Age,>= 80 y.o,123,0.026000000000000002,0.0,0.062000000000000006,,True,True,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,,Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Elizabeth T Rogawski McQuade,"University of Virginia
",Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2020.35234,2021-03-19,2023-07-04,Verified,rogawski_mcquade_assessment_2021,USA
210208_Virginia_UniversityOfVirginia_18-29_PopAdj,210208_Virginia_UniversityOfVirginia,Assessment of Seroprevalence of SARS-CoV-2 and Risk Factors Associated With COVID-19 Infection Among Outpatients in Virginia,2021-02-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Virginia,,Adults 18 years or older who presented in person for scheduled outpatient clinic or outpatientlaboratory appointments were eligible, All outpatient sites conducted prescreening of individuals to ensure no COVID-19–like symptoms,2020-06-01,2020-08-14,Residual sera,All,Adults (18-64 years),18.0,29.0,Age,18-29 y.o,735,0.031000000000000003,0.015,0.047,,True,True,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,,Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Elizabeth T Rogawski McQuade,"University of Virginia
",Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2020.35234,2021-03-19,2023-07-04,Verified,rogawski_mcquade_assessment_2021,USA
210208_Virginia_UniversityOfVirginia_60-69_PopAdj,210208_Virginia_UniversityOfVirginia,Assessment of Seroprevalence of SARS-CoV-2 and Risk Factors Associated With COVID-19 Infection Among Outpatients in Virginia,2021-02-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Virginia,,Adults 18 years or older who presented in person for scheduled outpatient clinic or outpatientlaboratory appointments were eligible, All outpatient sites conducted prescreening of individuals to ensure no COVID-19–like symptoms,2020-06-01,2020-08-14,Residual sera,All,Adults (18-64 years),60.0,69.0,Age,60-69 y.o,781,0.013000000000000001,0.005,0.021,,True,True,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,,Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Elizabeth T Rogawski McQuade,"University of Virginia
",Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2020.35234,2021-03-19,2023-07-04,Verified,rogawski_mcquade_assessment_2021,USA
210208_Virginia_UniversityOfVirginia_40-49_PopAdj,210208_Virginia_UniversityOfVirginia,Assessment of Seroprevalence of SARS-CoV-2 and Risk Factors Associated With COVID-19 Infection Among Outpatients in Virginia,2021-02-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Virginia,,Adults 18 years or older who presented in person for scheduled outpatient clinic or outpatientlaboratory appointments were eligible, All outpatient sites conducted prescreening of individuals to ensure no COVID-19–like symptoms,2020-06-01,2020-08-14,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49 y.o,671,0.044000000000000004,0.018000000000000002,0.071,,True,True,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,,Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Elizabeth T Rogawski McQuade,"University of Virginia
",Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2020.35234,2021-03-19,2023-07-04,Verified,rogawski_mcquade_assessment_2021,USA
210208_Virginia_UniversityOfVirginia_Females_PopAdj,210208_Virginia_UniversityOfVirginia,Assessment of Seroprevalence of SARS-CoV-2 and Risk Factors Associated With COVID-19 Infection Among Outpatients in Virginia,2021-02-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Virginia,,Adults 18 years or older who presented in person for scheduled outpatient clinic or outpatientlaboratory appointments were eligible, All outpatient sites conducted prescreening of individuals to ensure no COVID-19–like symptoms,2020-06-01,2020-08-14,Residual sera,Female,Multiple groups,18.0,,Sex/Gender,,3119,0.025,0.018000000000000002,0.032,,True,True,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,,Validated by independent authors/third party/non-developers,0.927,0.9990000000000001,['Moderate'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Elizabeth T Rogawski McQuade,"University of Virginia
",Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2020.35234,2021-03-19,2023-07-04,Verified,rogawski_mcquade_assessment_2021,USA
210208_Chicago_NorthwesternUniversity_overall,210208_Chicago_NorthwesternUniversity,Symptoms of COVID-19 infection and magnitude of antibody response in a large community-based study,2021-02-08,Preprint,Local,Cross-sectional survey ,United States of America,Illinois,Chicago,Chicago residents and Feinberg School of Medicine employees,,2020-06-24,2020-11-11,Household and community samples,All,Multiple groups,18.0,86.0,Primary Estimate,,3365,0.17800000000000002,,,True,,,,True,Self-referral,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,No,Yes,No,Unclear,Unclear,Yes,No,,Thomas McDade,Northwestern University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.04.21251170v1,2021-03-27,2022-07-16,Verified,mcdade_symptoms_2021,USA
210120_LosAngelesCounty_CedarsSinaiMedicalCenter_overall_adj,210120_LosAngelesCounty_CedarsSinaiMedicalCenter,Seroprevalence of antibodies to SARS-CoV-2 in healthcare workers: a cross-sectional study,2021-02-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,,,"For the current study, we included all participants who completed both SARS-CoV-2 antibody testing and electronic survey forms (n=6062). Survey forms collected data on pre-existing traits, exposure factors including work location and previously experienced symptoms. Work location was specified as spending most working hours in an intensive care unit (ICU) (COVID-19 or non-COVID-19 designated), non-ICU ward (COVID-19 or non-COVID-19 designated), outpatient clinic, office, work from home or other location.",,2020-05-11,2020-05-11,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,6062,0.040999999999999995,0.031000000000000003,0.057,True,True,True,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,,Validated by independent authors/third party/non-developers,0.883,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Joseph Ebinger,Cedars-Sinai Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2020-043584,2021-03-22,2023-07-04,Verified,ebingerSeroprevalenceAntibodiesSARSCoV22021,USA
210212_Arizona_KingmanRegionalMedicalCenter_Overall,210212_Arizona_KingmanRegionalMedicalCenter,The seroprevalence of SARS-CoV-2 in a rural southwest community,2021-02-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Arizona,Kingman,Aged 18 years or older. Participants self-selected inclusion in the study by either calling into the hospital’s COVID-19 hotline or via a walk-in appointment at the testing center. Participants were included in the study following the self-reported absence of COVID-19 symptoms during study enrolment.,"Participants were excluded from the study if they lived outside of Mohave County or failed to complete more than 50% of their
behavioral health survey",2020-09-28,2020-10-09,Household and community samples,All,Adults (18-64 years),18.0,,Primary Estimate,Primary estimate,566,0.08,,,True,,,,True,Self-referral,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,LFIA,Whole Blood,IgG,,,0.875,1.0,['High'],No,No,No,Yes,Yes,Yes,Yes,No,Yes,Anthony Santarelli,Kingman Regional Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1515/jom-2020-0287,2021-03-14,2024-03-01,Verified,santarelli_seroprevalence_2021,USA
210212_Arizona_KingmanRegionalMedicalCenter_NativeAmerican,210212_Arizona_KingmanRegionalMedicalCenter,The seroprevalence of SARS-CoV-2 in a rural southwest community,2021-02-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Arizona,Kingman,Aged 18 years or older. Participants self-selected inclusion in the study by either calling into the hospital’s COVID-19 hotline or via a walk-in appointment at the testing center. Participants were included in the study following the self-reported absence of COVID-19 symptoms during study enrolment.,"Participants were excluded from the study if they lived outside of Mohave County or failed to complete more than 50% of their
behavioral health survey",2020-09-28,2020-10-09,Household and community samples,All,Adults (18-64 years),18.0,,Ethnicity,Native American ethnicity,4,0.0,,,,,,,,Self-referral,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,LFIA,Whole Blood,IgG,,,0.875,1.0,['High'],No,No,No,Yes,Yes,Yes,Yes,No,Yes,Anthony Santarelli,Kingman Regional Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1515/jom-2020-0287,2021-03-14,2024-03-01,Verified,santarelli_seroprevalence_2021,USA
210212_Arizona_KingmanRegionalMedicalCenter_Male,210212_Arizona_KingmanRegionalMedicalCenter,The seroprevalence of SARS-CoV-2 in a rural southwest community,2021-02-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Arizona,Kingman,Aged 18 years or older. Participants self-selected inclusion in the study by either calling into the hospital’s COVID-19 hotline or via a walk-in appointment at the testing center. Participants were included in the study following the self-reported absence of COVID-19 symptoms during study enrolment.,"Participants were excluded from the study if they lived outside of Mohave County or failed to complete more than 50% of their
behavioral health survey",2020-09-28,2020-10-09,Household and community samples,Male,Adults (18-64 years),18.0,,Sex/Gender,Male,186,0.0753,,,,,,,,Self-referral,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,LFIA,Whole Blood,IgG,,,0.875,1.0,['High'],No,No,No,Yes,Yes,Yes,Yes,No,Yes,Anthony Santarelli,Kingman Regional Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1515/jom-2020-0287,2021-03-14,2024-03-01,Verified,santarelli_seroprevalence_2021,USA
210212_Arizona_KingmanRegionalMedicalCenter_White,210212_Arizona_KingmanRegionalMedicalCenter,The seroprevalence of SARS-CoV-2 in a rural southwest community,2021-02-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Arizona,Kingman,Aged 18 years or older. Participants self-selected inclusion in the study by either calling into the hospital’s COVID-19 hotline or via a walk-in appointment at the testing center. Participants were included in the study following the self-reported absence of COVID-19 symptoms during study enrolment.,"Participants were excluded from the study if they lived outside of Mohave County or failed to complete more than 50% of their
behavioral health survey",2020-09-28,2020-10-09,Household and community samples,All,Adults (18-64 years),18.0,,Ethnicity,White ethnicity,458,0.0764,,,,,,,,Self-referral,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,LFIA,Whole Blood,IgG,,,0.875,1.0,['High'],No,No,No,Yes,Yes,Yes,Yes,No,Yes,Anthony Santarelli,Kingman Regional Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1515/jom-2020-0287,2021-03-14,2024-03-01,Verified,santarelli_seroprevalence_2021,USA
210212_Arizona_KingmanRegionalMedicalCenter_Female,210212_Arizona_KingmanRegionalMedicalCenter,The seroprevalence of SARS-CoV-2 in a rural southwest community,2021-02-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Arizona,Kingman,Aged 18 years or older. Participants self-selected inclusion in the study by either calling into the hospital’s COVID-19 hotline or via a walk-in appointment at the testing center. Participants were included in the study following the self-reported absence of COVID-19 symptoms during study enrolment.,"Participants were excluded from the study if they lived outside of Mohave County or failed to complete more than 50% of their
behavioral health survey",2020-09-28,2020-10-09,Household and community samples,Female,Adults (18-64 years),18.0,,Sex/Gender,Female,380,0.0816,,,,,,,,Self-referral,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,LFIA,Whole Blood,IgG,,,0.875,1.0,['High'],No,No,No,Yes,Yes,Yes,Yes,No,Yes,Anthony Santarelli,Kingman Regional Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1515/jom-2020-0287,2021-03-14,2024-03-01,Verified,santarelli_seroprevalence_2021,USA
210212_Arizona_KingmanRegionalMedicalCenter_OtherEthnicity,210212_Arizona_KingmanRegionalMedicalCenter,The seroprevalence of SARS-CoV-2 in a rural southwest community,2021-02-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Arizona,Kingman,Aged 18 years or older. Participants self-selected inclusion in the study by either calling into the hospital’s COVID-19 hotline or via a walk-in appointment at the testing center. Participants were included in the study following the self-reported absence of COVID-19 symptoms during study enrolment.,"Participants were excluded from the study if they lived outside of Mohave County or failed to complete more than 50% of their
behavioral health survey",2020-09-28,2020-10-09,Household and community samples,All,Adults (18-64 years),18.0,,Ethnicity,Other ethnicity,53,0.09433960000000001,,,,,,,,Self-referral,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,LFIA,Whole Blood,IgG,,,0.875,1.0,['High'],No,No,No,Yes,Yes,Yes,Yes,No,Yes,Anthony Santarelli,Kingman Regional Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1515/jom-2020-0287,2021-03-14,2024-03-01,Verified,santarelli_seroprevalence_2021,USA
210212_Arizona_KingmanRegionalMedicalCenter_Hispanic/Latino,210212_Arizona_KingmanRegionalMedicalCenter,The seroprevalence of SARS-CoV-2 in a rural southwest community,2021-02-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Arizona,Kingman,Aged 18 years or older. Participants self-selected inclusion in the study by either calling into the hospital’s COVID-19 hotline or via a walk-in appointment at the testing center. Participants were included in the study following the self-reported absence of COVID-19 symptoms during study enrolment.,"Participants were excluded from the study if they lived outside of Mohave County or failed to complete more than 50% of their
behavioral health survey",2020-09-28,2020-10-09,Household and community samples,All,Adults (18-64 years),18.0,,Ethnicity,Hispanic/Latino ethnicity,45,0.08888,,,,,,,,Self-referral,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,LFIA,Whole Blood,IgG,,,0.875,1.0,['High'],No,No,No,Yes,Yes,Yes,Yes,No,Yes,Anthony Santarelli,Kingman Regional Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1515/jom-2020-0287,2021-03-14,2024-03-01,Verified,santarelli_seroprevalence_2021,USA
210212_Arizona_KingmanRegionalMedicalCenter_Black,210212_Arizona_KingmanRegionalMedicalCenter,The seroprevalence of SARS-CoV-2 in a rural southwest community,2021-02-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Arizona,Kingman,Aged 18 years or older. Participants self-selected inclusion in the study by either calling into the hospital’s COVID-19 hotline or via a walk-in appointment at the testing center. Participants were included in the study following the self-reported absence of COVID-19 symptoms during study enrolment.,"Participants were excluded from the study if they lived outside of Mohave County or failed to complete more than 50% of their
behavioral health survey",2020-09-28,2020-10-09,Household and community samples,All,Adults (18-64 years),18.0,,Ethnicity,Black ethnicity,5,0.2,,,,,,,,Self-referral,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,LFIA,Whole Blood,IgG,,,0.875,1.0,['High'],No,No,No,Yes,Yes,Yes,Yes,No,Yes,Anthony Santarelli,Kingman Regional Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1515/jom-2020-0287,2021-03-14,2024-03-01,Verified,santarelli_seroprevalence_2021,USA
210215_USA_SpaceX_overall,210215_USA_SpaceX,Discrete SARS-CoV-2 antibody titers track with functional humoral stability,2021-02-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Multiple,Multiple,"The parent cohort study was launched in mid-April 2020, providing an opportunity for industry employees to volunteer for COVID-19 testing and surveillance (Space Exploration Technologies Corp.). All employees were invited to participate by email.",There were no exclusion criteria. ,2020-04-01,2020-06-10,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,SpaceX employees,4300,0.027999999999999997,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,Validated by independent authors/third party/non-developers,0.995,,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,Unclear,Yannic Bartsch,"Ragon Institute of MGH, MIT and Harvard",Not Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-21336-8,2021-03-27,2022-07-16,Verified,bartsch_discrete_2021,USA
210218_WashingtonDC_GovernmentOfTheDistrictOfColumbia_overall,210218_WashingtonDC_GovernmentOfTheDistrictOfColumbia,"SARS-CoV-2 Seroprevalence Survey Among District Residents Presenting for Serologic Testing at Three Community-Based Test Sites — Washington, DC, July-August, 2020",2021-02-18,Preprint,Local,Cross-sectional survey ,United States of America,,Washington DC,Consenting DC residents. The minimum age for serology testing was six years,Actively ill or symptomatic people were excluded,2020-07-27,2020-08-21,Household and community samples,All,Multiple groups,6.0,,Primary Estimate,,671,0.076,0.057,0.099,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.97,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Adrienne Sherman,Government of the District of Columbia,Unity-Aligned,10.1101/2021.02.15.21251764,2021-03-19,2024-03-01,Verified,sherman_sars-cov-2_2021,USA
210218_WashingtonDC_GovernmentOfTheDistrictOfColumbia_age65+,210218_WashingtonDC_GovernmentOfTheDistrictOfColumbia,"SARS-CoV-2 Seroprevalence Survey Among District Residents Presenting for Serologic Testing at Three Community-Based Test Sites — Washington, DC, July-August, 2020",2021-02-18,Preprint,Local,Cross-sectional survey ,United States of America,,Washington DC,Consenting DC residents. The minimum age for serology testing was six years,Actively ill or symptomatic people were excluded,2020-07-27,2020-08-21,Household and community samples,All,Seniors (65+ years),65.0,,Age,≥65,64,0.031000000000000003,0.004,0.10800000000000001,,,,,,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.97,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Adrienne Sherman,Government of the District of Columbia,Unity-Aligned,10.1101/2021.02.15.21251764,2021-03-19,2024-03-01,Verified,sherman_sars-cov-2_2021,USA
210218_WashingtonDC_GovernmentOfTheDistrictOfColumbia_age18-29,210218_WashingtonDC_GovernmentOfTheDistrictOfColumbia,"SARS-CoV-2 Seroprevalence Survey Among District Residents Presenting for Serologic Testing at Three Community-Based Test Sites — Washington, DC, July-August, 2020",2021-02-18,Preprint,Local,Cross-sectional survey ,United States of America,,Washington DC,Consenting DC residents. The minimum age for serology testing was six years,Actively ill or symptomatic people were excluded,2020-07-27,2020-08-21,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,18–29,125,0.11199999999999999,0.063,0.18100000000000002,,,,,,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.97,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Adrienne Sherman,Government of the District of Columbia,Unity-Aligned,10.1101/2021.02.15.21251764,2021-03-19,2024-03-01,Verified,sherman_sars-cov-2_2021,USA
210218_WashingtonDC_GovernmentOfTheDistrictOfColumbia_age30-49,210218_WashingtonDC_GovernmentOfTheDistrictOfColumbia,"SARS-CoV-2 Seroprevalence Survey Among District Residents Presenting for Serologic Testing at Three Community-Based Test Sites — Washington, DC, July-August, 2020",2021-02-18,Preprint,Local,Cross-sectional survey ,United States of America,,Washington DC,Consenting DC residents. The minimum age for serology testing was six years,Actively ill or symptomatic people were excluded,2020-07-27,2020-08-21,Household and community samples,All,Adults (18-64 years),30.0,49.0,Age,30–49,321,0.069,0.043,0.102,,,,,,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.97,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Adrienne Sherman,Government of the District of Columbia,Unity-Aligned,10.1101/2021.02.15.21251764,2021-03-19,2024-03-01,Verified,sherman_sars-cov-2_2021,USA
210218_WashingtonDC_GovernmentOfTheDistrictOfColumbia_female,210218_WashingtonDC_GovernmentOfTheDistrictOfColumbia,"SARS-CoV-2 Seroprevalence Survey Among District Residents Presenting for Serologic Testing at Three Community-Based Test Sites — Washington, DC, July-August, 2020",2021-02-18,Preprint,Local,Cross-sectional survey ,United States of America,,Washington DC,Consenting DC residents. The minimum age for serology testing was six years,Actively ill or symptomatic people were excluded,2020-07-27,2020-08-21,Household and community samples,Female,Multiple groups,6.0,,Sex/Gender,female,359,0.084,0.057,0.11699999999999999,,,,,,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.97,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Adrienne Sherman,Government of the District of Columbia,Unity-Aligned,10.1101/2021.02.15.21251764,2021-03-19,2024-03-01,Verified,sherman_sars-cov-2_2021,USA
210218_WashingtonDC_GovernmentOfTheDistrictOfColumbia_age50-64,210218_WashingtonDC_GovernmentOfTheDistrictOfColumbia,"SARS-CoV-2 Seroprevalence Survey Among District Residents Presenting for Serologic Testing at Three Community-Based Test Sites — Washington, DC, July-August, 2020",2021-02-18,Preprint,Local,Cross-sectional survey ,United States of America,,Washington DC,Consenting DC residents. The minimum age for serology testing was six years,Actively ill or symptomatic people were excluded,2020-07-27,2020-08-21,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50–64,132,0.076,0.037000000000000005,0.135,,,,,,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.97,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Adrienne Sherman,Government of the District of Columbia,Unity-Aligned,10.1101/2021.02.15.21251764,2021-03-19,2024-03-01,Verified,sherman_sars-cov-2_2021,USA
210218_WashingtonDC_GovernmentOfTheDistrictOfColumbia_male,210218_WashingtonDC_GovernmentOfTheDistrictOfColumbia,"SARS-CoV-2 Seroprevalence Survey Among District Residents Presenting for Serologic Testing at Three Community-Based Test Sites — Washington, DC, July-August, 2020",2021-02-18,Preprint,Local,Cross-sectional survey ,United States of America,,Washington DC,Consenting DC residents. The minimum age for serology testing was six years,Actively ill or symptomatic people were excluded,2020-07-27,2020-08-21,Household and community samples,Male,Multiple groups,6.0,,Sex/Gender,male,312,0.067,0.042,0.10099999999999999,,,,,,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.97,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Adrienne Sherman,Government of the District of Columbia,Unity-Aligned,10.1101/2021.02.15.21251764,2021-03-19,2024-03-01,Verified,sherman_sars-cov-2_2021,USA
210218_WashingtonDC_GovernmentOfTheDistrictOfColumbia_age6-17,210218_WashingtonDC_GovernmentOfTheDistrictOfColumbia,"SARS-CoV-2 Seroprevalence Survey Among District Residents Presenting for Serologic Testing at Three Community-Based Test Sites — Washington, DC, July-August, 2020",2021-02-18,Preprint,Local,Cross-sectional survey ,United States of America,,Washington DC,Consenting DC residents. The minimum age for serology testing was six years,Actively ill or symptomatic people were excluded,2020-07-27,2020-08-21,Household and community samples,All,Children and Youth (0-17 years),6.0,17.0,Age,6–17,29,0.10300000000000001,0.022000000000000002,0.27399999999999997,,,,,,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.97,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Adrienne Sherman,Government of the District of Columbia,Unity-Aligned,10.1101/2021.02.15.21251764,2021-03-19,2024-03-01,Verified,sherman_sars-cov-2_2021,USA
210218_RhodeIsland_BrownUniversity_overall_adj,210218_RhodeIsland_BrownUniversity,Seroprevalence of SARS-CoV-2 Antibodies in Rhode Island From a Statewide Random Sample,2021-02-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Rhode Island,,Residents of Rhode Island,,2020-05-05,2020-05-22,Household and community samples,All,Multiple groups,,,Primary Estimate,,1032,0.028999999999999998,0.01,0.062000000000000006,True,True,True,True,True,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,0.8840000000000001,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Philip A Chan,Brown University,Unity-Aligned,https://dx.doi.org/10.2105/AJPH.2020.306115,2021-04-02,2023-08-15,Verified,chan_seroprevalence_2021,USA
210218_RhodeIsland_BrownUniversity_age35-64,210218_RhodeIsland_BrownUniversity,Seroprevalence of SARS-CoV-2 Antibodies in Rhode Island From a Statewide Random Sample,2021-02-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Rhode Island,,Residents of Rhode Island,,2020-05-05,2020-05-22,Household and community samples,All,Multiple groups,,,Age,age35-64,512,0.01,0.0,0.031000000000000003,,True,,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,0.8840000000000001,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Philip A Chan,Brown University,Unity-Aligned,https://dx.doi.org/10.2105/AJPH.2020.306115,2021-04-02,2023-08-15,Verified,chan_seroprevalence_2021,USA
210218_RhodeIsland_BrownUniversity_age0-14,210218_RhodeIsland_BrownUniversity,Seroprevalence of SARS-CoV-2 Antibodies in Rhode Island From a Statewide Random Sample,2021-02-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Rhode Island,,Residents of Rhode Island,,2020-05-05,2020-05-22,Household and community samples,All,Multiple groups,,,Age,age0-14,57,0.051,0.0,0.20199999999999999,,True,,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,0.8840000000000001,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Philip A Chan,Brown University,Unity-Aligned,https://dx.doi.org/10.2105/AJPH.2020.306115,2021-04-02,2023-08-15,Verified,chan_seroprevalence_2021,USA
210218_RhodeIsland_BrownUniversity_female,210218_RhodeIsland_BrownUniversity,Seroprevalence of SARS-CoV-2 Antibodies in Rhode Island From a Statewide Random Sample,2021-02-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Rhode Island,,Residents of Rhode Island,,2020-05-05,2020-05-22,Household and community samples,Female,Multiple groups,,,Sex/Gender,female,587,0.02,0.004,0.043,,True,,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,0.8840000000000001,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Philip A Chan,Brown University,Unity-Aligned,https://dx.doi.org/10.2105/AJPH.2020.306115,2021-04-02,2023-08-15,Verified,chan_seroprevalence_2021,USA
210218_RhodeIsland_BrownUniversity_age15-34,210218_RhodeIsland_BrownUniversity,Seroprevalence of SARS-CoV-2 Antibodies in Rhode Island From a Statewide Random Sample,2021-02-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Rhode Island,,Residents of Rhode Island,,2020-05-05,2020-05-22,Household and community samples,All,Multiple groups,,,Age,age15-34,221,0.040999999999999995,0.006,0.095,,True,,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,0.8840000000000001,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Philip A Chan,Brown University,Unity-Aligned,https://dx.doi.org/10.2105/AJPH.2020.306115,2021-04-02,2023-08-15,Verified,chan_seroprevalence_2021,USA
210218_RhodeIsland_BrownUniversity_age65+,210218_RhodeIsland_BrownUniversity,Seroprevalence of SARS-CoV-2 Antibodies in Rhode Island From a Statewide Random Sample,2021-02-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Rhode Island,,Residents of Rhode Island,,2020-05-05,2020-05-22,Household and community samples,All,Multiple groups,,,Age,age65+,242,0.017,0.0,0.059000000000000004,,True,,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,0.8840000000000001,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Philip A Chan,Brown University,Unity-Aligned,https://dx.doi.org/10.2105/AJPH.2020.306115,2021-04-02,2023-08-15,Verified,chan_seroprevalence_2021,USA
210218_RhodeIsland_BrownUniversity_male,210218_RhodeIsland_BrownUniversity,Seroprevalence of SARS-CoV-2 Antibodies in Rhode Island From a Statewide Random Sample,2021-02-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Rhode Island,,Residents of Rhode Island,,2020-05-05,2020-05-22,Household and community samples,Male,Multiple groups,,,Sex/Gender,male,445,0.022000000000000002,0.002,0.055,,True,,True,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by manufacturers,0.8840000000000001,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Philip A Chan,Brown University,Unity-Aligned,https://dx.doi.org/10.2105/AJPH.2020.306115,2021-04-02,2023-08-15,Verified,chan_seroprevalence_2021,USA
210221_Iowa_UniversityofIowa,210221_Iowa_UniversityofIowa,SARS-CoV-2 Infection during Pregnancy in a Rural Midwest All-delivery Cohort and Associated Maternal and Neonatal Outcomes,2021-02-21,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Iowa,,"This prospective cohort study included all pregnant patients
who delivered at UIHC between May 1 and September 22, 2020.",,2020-05-01,2020-09-22,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,1000,0.057999999999999996,,,True,,,,True,Sequential,"Liaison SARS-CoV-2 S1/S2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N),Anti-SARS-CoV-2 ELISA IgG","DiaSorin,Roche Diagnostics,EUROIMMUN",Multiple Types,Plasma,IgG,,,,,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,No,,Haley Steffen,University of Iowa,Unity-Aligned,https://dx.doi.org/10.1055/s-0041-1723938,2021-03-27,2024-03-01,Verified,steffen_sars-cov-2_2021,USA
210222_SantaClaraCounty_UniversityofStanford_GenPop_PopTestAdj,210222_SantaClaraCounty_StanfordUniversitySchoolofMedicine,"COVID-19 Antibody Seroprevalence in Santa Clara County, California",2021-02-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,Included individuals that registered for the study and arrived at testing sites,"Excluded  individuals who could not be tested (e.g. unable to obtain blood or blood clotted, N=49), whose test results could not be matched to their personal data (e.g. if an incorrect participant ID was recorded onsite, N=30), who did not reside in Santa Clara County (N=29), and who had invalid test results (no Control band, N=1)",2020-04-03,2020-04-04,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,"Adjusted: population, test",3328,0.0276,0.013200000000000002,0.0422,True,True,True,,,Stratified non-probability,COVID-19 IgG/IgM Rapid Test Cassette,Premier Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8556,0.9953000000000001,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Eran Bendavid,Stanford University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1093/ije/dyab010,2021-03-28,2023-07-04,Verified,bendavid_covid-19_2020,USA
210222_SantaClaraCounty_UniversityofStanford_GenPop_Asian,210222_SantaClaraCounty_StanfordUniversitySchoolofMedicine,"COVID-19 Antibody Seroprevalence in Santa Clara County, California",2021-02-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,Included individuals that registered for the study and arrived at testing sites,"Excluded  individuals who could not be tested (e.g. unable to obtain blood or blood clotted, N=49), whose test results could not be matched to their personal data (e.g. if an incorrect participant ID was recorded onsite, N=30), who did not reside in Santa Clara County (N=29), and who had invalid test results (no Control band, N=1)",2020-04-03,2020-04-04,Household and community samples,All,Multiple groups,0.0,,Race,Asian,623,0.01926163724,,,,,,,,Stratified non-probability,COVID-19 IgG/IgM Rapid Test Cassette,Premier Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8556,0.9953000000000001,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Eran Bendavid,Stanford University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1093/ije/dyab010,2021-03-28,2024-03-01,Verified,bendavid_covid-19_2020,USA
210222_SantaClaraCounty_UniversityofStanford_GenPop_70+,210222_SantaClaraCounty_StanfordUniversitySchoolofMedicine,"COVID-19 Antibody Seroprevalence in Santa Clara County, California",2021-02-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,Included individuals that registered for the study and arrived at testing sites,"Excluded  individuals who could not be tested (e.g. unable to obtain blood or blood clotted, N=49), whose test results could not be matched to their personal data (e.g. if an incorrect participant ID was recorded onsite, N=30), who did not reside in Santa Clara County (N=29), and who had invalid test results (no Control band, N=1)",2020-04-03,2020-04-04,Household and community samples,All,Seniors (65+ years),70.0,,Age,70+ years,78,0.012820512820000001,,,,,,,,Stratified non-probability,COVID-19 IgG/IgM Rapid Test Cassette,Premier Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8556,0.9953000000000001,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Eran Bendavid,Stanford University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1093/ije/dyab010,2021-03-28,2024-03-01,Verified,bendavid_covid-19_2020,USA
210222_SantaClaraCounty_UniversityofStanford_GenPop_0-19,210222_SantaClaraCounty_StanfordUniversitySchoolofMedicine,"COVID-19 Antibody Seroprevalence in Santa Clara County, California",2021-02-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,Included individuals that registered for the study and arrived at testing sites,"Excluded  individuals who could not be tested (e.g. unable to obtain blood or blood clotted, N=49), whose test results could not be matched to their personal data (e.g. if an incorrect participant ID was recorded onsite, N=30), who did not reside in Santa Clara County (N=29), and who had invalid test results (no Control band, N=1)",2020-04-03,2020-04-04,Household and community samples,All,Children and Youth (0-17 years),0.0,19.0,Age,0-19 years,637,0.01412872841,,,,,,,,Stratified non-probability,COVID-19 IgG/IgM Rapid Test Cassette,Premier Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8556,0.9953000000000001,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Eran Bendavid,Stanford University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1093/ije/dyab010,2021-03-28,2024-03-01,Verified,bendavid_covid-19_2020,USA
210222_SantaClaraCounty_UniversityofStanford_GenPop_20-39,210222_SantaClaraCounty_StanfordUniversitySchoolofMedicine,"COVID-19 Antibody Seroprevalence in Santa Clara County, California",2021-02-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,Included individuals that registered for the study and arrived at testing sites,"Excluded  individuals who could not be tested (e.g. unable to obtain blood or blood clotted, N=49), whose test results could not be matched to their personal data (e.g. if an incorrect participant ID was recorded onsite, N=30), who did not reside in Santa Clara County (N=29), and who had invalid test results (no Control band, N=1)",2020-04-03,2020-04-04,Household and community samples,All,Adults (18-64 years),20.0,39.0,Age,20-39 years,907,0.01874310915,,,,,,,,Stratified non-probability,COVID-19 IgG/IgM Rapid Test Cassette,Premier Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8556,0.9953000000000001,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Eran Bendavid,Stanford University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1093/ije/dyab010,2021-03-28,2024-03-01,Verified,bendavid_covid-19_2020,USA
210222_SantaClaraCounty_UniversityofStanford_GenPop_40-69,210222_SantaClaraCounty_StanfordUniversitySchoolofMedicine,"COVID-19 Antibody Seroprevalence in Santa Clara County, California",2021-02-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,Included individuals that registered for the study and arrived at testing sites,"Excluded  individuals who could not be tested (e.g. unable to obtain blood or blood clotted, N=49), whose test results could not be matched to their personal data (e.g. if an incorrect participant ID was recorded onsite, N=30), who did not reside in Santa Clara County (N=29), and who had invalid test results (no Control band, N=1)",2020-04-03,2020-04-04,Household and community samples,All,Adults (18-64 years),40.0,69.0,Age,40-69 years,1706,0.013481828840000001,,,,,,,,Stratified non-probability,COVID-19 IgG/IgM Rapid Test Cassette,Premier Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8556,0.9953000000000001,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Eran Bendavid,Stanford University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1093/ije/dyab010,2021-03-28,2024-03-01,Verified,bendavid_covid-19_2020,USA
210222_SantaClaraCounty_UniversityofStanford_GenPop_Male,210222_SantaClaraCounty_StanfordUniversitySchoolofMedicine,"COVID-19 Antibody Seroprevalence in Santa Clara County, California",2021-02-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,Included individuals that registered for the study and arrived at testing sites,"Excluded  individuals who could not be tested (e.g. unable to obtain blood or blood clotted, N=49), whose test results could not be matched to their personal data (e.g. if an incorrect participant ID was recorded onsite, N=30), who did not reside in Santa Clara County (N=29), and who had invalid test results (no Control band, N=1)",2020-04-03,2020-04-04,Household and community samples,Male,Multiple groups,0.0,,Sex/Gender,Male,1228,0.0154723127,,,,,,,,Stratified non-probability,COVID-19 IgG/IgM Rapid Test Cassette,Premier Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8556,0.9953000000000001,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Eran Bendavid,Stanford University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1093/ije/dyab010,2021-03-28,2024-03-01,Verified,bendavid_covid-19_2020,USA
210222_SantaClaraCounty_UniversityofStanford_GenPop_Female,210222_SantaClaraCounty_StanfordUniversitySchoolofMedicine,"COVID-19 Antibody Seroprevalence in Santa Clara County, California",2021-02-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,Included individuals that registered for the study and arrived at testing sites,"Excluded  individuals who could not be tested (e.g. unable to obtain blood or blood clotted, N=49), whose test results could not be matched to their personal data (e.g. if an incorrect participant ID was recorded onsite, N=30), who did not reside in Santa Clara County (N=29), and who had invalid test results (no Control band, N=1)",2020-04-03,2020-04-04,Household and community samples,Female,Multiple groups,0.0,,Sex/Gender,Female,2100,0.01476190476,,,,,,,,Stratified non-probability,COVID-19 IgG/IgM Rapid Test Cassette,Premier Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8556,0.9953000000000001,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Eran Bendavid,Stanford University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1093/ije/dyab010,2021-03-28,2024-03-01,Verified,bendavid_covid-19_2020,USA
210222_SantaClaraCounty_UniversityofStanford_GenPop_White,210222_SantaClaraCounty_StanfordUniversitySchoolofMedicine,"COVID-19 Antibody Seroprevalence in Santa Clara County, California",2021-02-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,Included individuals that registered for the study and arrived at testing sites,"Excluded  individuals who could not be tested (e.g. unable to obtain blood or blood clotted, N=49), whose test results could not be matched to their personal data (e.g. if an incorrect participant ID was recorded onsite, N=30), who did not reside in Santa Clara County (N=29), and who had invalid test results (no Control band, N=1)",2020-04-03,2020-04-04,Household and community samples,All,Multiple groups,0.0,,Race,White,2116,0.009924385630000001,,,,,,,,Stratified non-probability,COVID-19 IgG/IgM Rapid Test Cassette,Premier Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8556,0.9953000000000001,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Eran Bendavid,Stanford University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1093/ije/dyab010,2021-03-28,2024-03-01,Verified,bendavid_covid-19_2020,USA
210222_SantaClaraCounty_UniversityofStanford_GenPop_UnAdj,210222_SantaClaraCounty_StanfordUniversitySchoolofMedicine,"COVID-19 Antibody Seroprevalence in Santa Clara County, California",2021-02-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,Included individuals that registered for the study and arrived at testing sites,"Excluded  individuals who could not be tested (e.g. unable to obtain blood or blood clotted, N=49), whose test results could not be matched to their personal data (e.g. if an incorrect participant ID was recorded onsite, N=30), who did not reside in Santa Clara County (N=29), and who had invalid test results (no Control band, N=1)",2020-04-03,2020-04-04,Household and community samples,All,Multiple groups,0.0,,Analysis,,3328,0.015,0.011000000000000001,0.0198,,,,,True,Stratified non-probability,COVID-19 IgG/IgM Rapid Test Cassette,Premier Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8556,0.9953000000000001,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Eran Bendavid,Stanford University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1093/ije/dyab010,2021-03-28,2024-03-01,Verified,bendavid_covid-19_2020,USA
210222_SantaClaraCounty_UniversityofStanford_GenPop_Hispanic,210222_SantaClaraCounty_StanfordUniversitySchoolofMedicine,"COVID-19 Antibody Seroprevalence in Santa Clara County, California",2021-02-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,Included individuals that registered for the study and arrived at testing sites,"Excluded  individuals who could not be tested (e.g. unable to obtain blood or blood clotted, N=49), whose test results could not be matched to their personal data (e.g. if an incorrect participant ID was recorded onsite, N=30), who did not reside in Santa Clara County (N=29), and who had invalid test results (no Control band, N=1)",2020-04-03,2020-04-04,Household and community samples,All,Multiple groups,0.0,,Ethnicity,Hispanic,266,0.048872180450000004,,,,,,,,Stratified non-probability,COVID-19 IgG/IgM Rapid Test Cassette,Premier Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8556,0.9953000000000001,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Eran Bendavid,Stanford University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1093/ije/dyab010,2021-03-28,2024-03-01,Verified,bendavid_covid-19_2020,USA
210222_SantaClaraCounty_UniversityofStanford_GenPop_TestAdj,210222_SantaClaraCounty_StanfordUniversitySchoolofMedicine,"COVID-19 Antibody Seroprevalence in Santa Clara County, California",2021-02-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,Included individuals that registered for the study and arrived at testing sites,"Excluded  individuals who could not be tested (e.g. unable to obtain blood or blood clotted, N=49), whose test results could not be matched to their personal data (e.g. if an incorrect participant ID was recorded onsite, N=30), who did not reside in Santa Clara County (N=29), and who had invalid test results (no Control band, N=1)",2020-04-03,2020-04-04,Household and community samples,All,Multiple groups,0.0,,Analysis,Adjusted: test,3328,0.0122,0.006600000000000001,0.0179,,True,,,,Stratified non-probability,COVID-19 IgG/IgM Rapid Test Cassette,Premier Biotech,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.8556,0.9953000000000001,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Eran Bendavid,Stanford University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1093/ije/dyab010,2021-03-28,2023-07-04,Verified,bendavid_covid-19_2020,USA
210224_USA_NationalInstitutesofHealth_primary,210224_USA_NationalInstitutesofHealth,Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection,2021-02-24,Journal Article (Peer-Reviewed),National,Retrospective cohort,United States of America,,,"deidentified individual-level laboratory testing data provided by HealthVerity (Philadelphia, PA), a for-profit data aggregator that provides access to linked data from 70 different commercial health data sources.",,2020-01-01,2020-08-26,Residual sera,All,Multiple groups,,,Primary Estimate,Lab samples,3257478,0.11599999999999999,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,Multiple Types,"['IgA', 'IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,No,No,,Raymond Harvey,National Institutes of Health,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2021.0366,2021-04-09,2022-07-16,Verified,harvey_association_2021-1,USA
210224_USA_NationalInstitutesofHealth_sex_female,210224_USA_NationalInstitutesofHealth,Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection,2021-02-24,Journal Article (Peer-Reviewed),National,Retrospective cohort,United States of America,,,"deidentified individual-level laboratory testing data provided by HealthVerity (Philadelphia, PA), a for-profit data aggregator that provides access to linked data from 70 different commercial health data sources.",,2020-01-01,2020-08-26,Residual sera,Female,Multiple groups,,,Sex/Gender,Lab samples,1803198,0.11199999999999999,,,,,,,,Convenience,Not reported/ Unable to specify,,,Multiple Types,"['IgA', 'IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,No,No,,Raymond Harvey,National Institutes of Health,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2021.0366,2021-04-09,2022-07-16,Verified,harvey_association_2021-1,USA
210224_USA_NationalInstitutesofHealth_region_south,210224_USA_NationalInstitutesofHealth,Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection,2021-02-24,Journal Article (Peer-Reviewed),National,Retrospective cohort,United States of America,,,"deidentified individual-level laboratory testing data provided by HealthVerity (Philadelphia, PA), a for-profit data aggregator that provides access to linked data from 70 different commercial health data sources.",,2020-01-01,2020-08-26,Residual sera,All,Multiple groups,,,Geographical area,Lab samples,838602,0.062000000000000006,,,,,,,,Convenience,Not reported/ Unable to specify,,,Multiple Types,"['IgA', 'IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,No,No,,Raymond Harvey,National Institutes of Health,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2021.0366,2021-04-09,2022-07-16,Verified,harvey_association_2021-1,USA
210224_USA_NationalInstitutesofHealth_region_west,210224_USA_NationalInstitutesofHealth,Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection,2021-02-24,Journal Article (Peer-Reviewed),National,Retrospective cohort,United States of America,,,"deidentified individual-level laboratory testing data provided by HealthVerity (Philadelphia, PA), a for-profit data aggregator that provides access to linked data from 70 different commercial health data sources.",,2020-01-01,2020-08-26,Residual sera,All,Multiple groups,,,Geographical area,Lab samples,542213,0.049,,,,,,,,Convenience,Not reported/ Unable to specify,,,Multiple Types,"['IgA', 'IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,No,No,,Raymond Harvey,National Institutes of Health,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2021.0366,2021-04-09,2022-07-16,Verified,harvey_association_2021-1,USA
210224_USA_NationalInstitutesofHealth_region_northeast,210224_USA_NationalInstitutesofHealth,Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection,2021-02-24,Journal Article (Peer-Reviewed),National,Retrospective cohort,United States of America,,,"deidentified individual-level laboratory testing data provided by HealthVerity (Philadelphia, PA), a for-profit data aggregator that provides access to linked data from 70 different commercial health data sources.",,2020-01-01,2020-08-26,Residual sera,All,Multiple groups,,,Geographical area,Lab samples,1239538,0.18600000000000003,,,,,,,,Convenience,Not reported/ Unable to specify,,,Multiple Types,"['IgA', 'IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,No,No,,Raymond Harvey,National Institutes of Health,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2021.0366,2021-04-09,2022-07-16,Verified,harvey_association_2021-1,USA
210224_USA_NationalInstitutesofHealth_sex_male,210224_USA_NationalInstitutesofHealth,Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection,2021-02-24,Journal Article (Peer-Reviewed),National,Retrospective cohort,United States of America,,,"deidentified individual-level laboratory testing data provided by HealthVerity (Philadelphia, PA), a for-profit data aggregator that provides access to linked data from 70 different commercial health data sources.",,2020-01-01,2020-08-26,Residual sera,Male,Multiple groups,,,Sex/Gender,Lab samples,1392074,0.12300000000000001,,,,,,,,Convenience,Not reported/ Unable to specify,,,Multiple Types,"['IgA', 'IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,No,No,,Raymond Harvey,National Institutes of Health,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2021.0366,2021-04-09,2022-07-16,Verified,harvey_association_2021-1,USA
210224_USA_NationalInstitutesofHealth_region_midwest,210224_USA_NationalInstitutesofHealth,Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection,2021-02-24,Journal Article (Peer-Reviewed),National,Retrospective cohort,United States of America,,,"deidentified individual-level laboratory testing data provided by HealthVerity (Philadelphia, PA), a for-profit data aggregator that provides access to linked data from 70 different commercial health data sources.",,2020-01-01,2020-08-26,Residual sera,All,Multiple groups,,,Geographical area,Lab samples,256628,0.065,,,,,,,,Convenience,Not reported/ Unable to specify,,,Multiple Types,"['IgA', 'IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,No,No,,Raymond Harvey,National Institutes of Health,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2021.0366,2021-04-09,2022-07-16,Verified,harvey_association_2021-1,USA
210225_Denver_UniversityofColorado_EstablishedDiabetes,210225_Denver_UniversityofColorado_EstablishedDiabetes,Prevalence of SARS-CoV-2 Antibodies in Children and Adults with Type 1 Diabetes,2021-02-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Colorado,Denver,"Children and Adults with established type 1 diabetes seen for routine diabetes care at the Barbara Davis Center for Diabetes Clinics in Denver, Colorado. All patients met the American Diabetes Association diagnostic criteria for type 1 diabetes mellitus. All participants were from or near the rest Denver area.",,2020-01-03,2020-10-16,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,1.0,66.0,Primary Estimate,,94,0.043,0.017,0.10400000000000001,True,,,,True,Sequential,Author designed (CLIA),,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,1.0,0.9990000000000001,['High'],Yes,No,No,No,Unclear,Unclear,Yes,Yes,Unclear,Xiaofan Jia,University of Colorado,Not Unity-Aligned,https://dx.doi.org/10.1089/dia.2020.0609,2021-03-14,2022-07-16,Verified,jia_prevalence_2021,USA
210225_Denver_UniversityofColorado_GenPopAdults,210225_Denver_UniversityofColorado_GenPopAdults,Prevalence of SARS-CoV-2 Antibodies in Children and Adults with Type 1 Diabetes,2021-02-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Colorado,Denver,General population parents of nondiabetic children participating in the Autoimmunity Screening for Kids (ASK) study,,2020-07-08,2020-10-23,Household and community samples,All,Adults (18-64 years),19.0,60.0,Primary Estimate,,102,0.039,0.015,0.09699999999999999,True,,,,True,Convenience,Author designed (CLIA),,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,1.0,0.9990000000000001,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,Unclear,Xiaofan Jia,University of Colorado,Unity-Aligned,https://dx.doi.org/10.1089/dia.2020.0609,2021-03-14,2022-07-16,Verified,jia_prevalence_2021,USA
210225_Denver_UniversityofColorado_GenPopChildren,210225_Denver_UniversityofColorado_GenPopChildren,Prevalence of SARS-CoV-2 Antibodies in Children and Adults with Type 1 Diabetes,2021-02-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Colorado,Denver,General population nondiabetic children participating in the Autoimmunity Screening for Kids (ASK) study ,,2020-07-08,2020-10-23,Household and community samples,All,Children and Youth (0-17 years),1.0,18.0,Primary Estimate,,562,0.027999999999999997,0.018000000000000002,0.046,True,,,,True,Convenience,Author designed (CLIA),,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,1.0,0.9990000000000001,['High'],Unclear,No,No,No,Unclear,Unclear,Yes,Yes,Unclear,Xiaofan Jia,University of Colorado,Unity-Aligned,https://dx.doi.org/10.1089/dia.2020.0609,2021-03-14,2022-07-16,Verified,jia_prevalence_2021,USA
210225_Denver_UniversityofColorado_NewOnsetDiabetes,210225_Denver_UniversityofColorado_NewOnsetDiabetes,Prevalence of SARS-CoV-2 Antibodies in Children and Adults with Type 1 Diabetes,2021-02-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Colorado,Denver,"Children and Adults with new onset type 1 diabetes seen for routine diabetes care at the Barbara Davis Center for Diabetes Clinics in Denver, Colorado. All patients met the American Diabetes Association diagnostic criteria for type 1 diabetes mellitus. All participants were from or near the rest Denver area.",,2020-01-03,2020-10-16,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,1.0,69.0,Primary Estimate,,129,0.008,0.001,0.042,True,,,,True,Sequential,Author designed (CLIA),,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,1.0,0.9990000000000001,['High'],,No,No,No,,Unclear,Yes,Yes,,Xiaofan Jia,University of Colorado,Not Unity-Aligned,https://dx.doi.org/10.1089/dia.2020.0609,2021-03-14,2022-07-16,Verified,jia_prevalence_2021,USA
210226_California_CentersforDiseaseControlandPrevention_Overall,210226_California_CentersforDiseaseControlandPrevention_SF,"Changes in SARS CoV-2 Seroprevalence Over Time in Ten Sites in the United States, March - August, 2020",2021-02-26,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,California,,"To be included, specimens must have been from routine
diagnostic tests, such as metabolic panels or cholesterol levels, blinded to COVID-19 symptoms or
diagnosis, that were collected from patients between March 23 and August 14, 2020, and, at
minimum, included demographic information on age, sex, zip code of patient, and date of specimen
collection",,2020-03-23,2020-08-14,Residual sera,All,Multiple groups,18.0,,Primary Estimate,Overall,4980,0.019,,,True,,True,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,TotalAntibody,Spike,Validated by developers,0.96,0.993,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Travis Lim,Centers for Disease and Control ,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab185,2021-03-27,2024-02-01,Verified,lim_changes_2021,USA
210226_Connecticut_CentersforDiseaseControlandPrevention_Overall,210226_Connecticut_CentersforDiseaseControlandPrevention_conne,"Changes in SARS CoV-2 Seroprevalence Over Time in Ten Sites in the United States, March - August, 2020",2021-02-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Connecticut,,"To be included, specimens must have been from routine
diagnostic tests, such as metabolic panels or cholesterol levels, blinded to COVID-19 symptoms or
diagnosis, that were collected from patients between March 23 and August 14, 2020, and, at
minimum, included demographic information on age, sex, zip code of patient, and date of specimen
collection",,2020-03-23,2020-08-14,Residual sera,All,Multiple groups,18.0,,Primary Estimate,Overall,8929,0.057,,,True,,True,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,TotalAntibody,Spike,Validated by developers,0.96,0.993,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Travis Lim,Centers for Disease and Control ,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab185,2021-03-27,2024-02-01,Verified,lim_changes_2021,USA
210226_Florida_CentersforDiseaseControlandPrevention_Overall,210226_Florida_CentersforDiseaseControlandPrevention_Florida,"Changes in SARS CoV-2 Seroprevalence Over Time in Ten Sites in the United States, March - August, 2020",2021-02-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Florida,,"To be included, specimens must have been from routine
diagnostic tests, such as metabolic panels or cholesterol levels, blinded to COVID-19 symptoms or
diagnosis, that were collected from patients between March 23 and August 14, 2020, and, at
minimum, included demographic information on age, sex, zip code of patient, and date of specimen
collection",,2020-03-23,2020-08-14,Residual sera,All,Multiple groups,18.0,,Primary Estimate,Overall,7787,0.048,,,True,,True,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,TotalAntibody,Spike,Validated by developers,0.96,0.993,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Travis Lim,Centers for Disease and Control ,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab185,2021-03-27,2024-02-01,Verified,lim_changes_2021,USA
210226_Louisiana_CentersforDiseaseControlandPrevention_Overall,210226_Louisiana_CentersforDiseaseControlandPrevention_Louis,"Changes in SARS CoV-2 Seroprevalence Over Time in Ten Sites in the United States, March - August, 2020",2021-02-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Louisiana,,"To be included, specimens must have been from routine
diagnostic tests, such as metabolic panels or cholesterol levels, blinded to COVID-19 symptoms or
diagnosis, that were collected from patients between March 23 and August 14, 2020, and, at
minimum, included demographic information on age, sex, zip code of patient, and date of specimen
collection",,2020-03-23,2020-08-14,Residual sera,All,Multiple groups,18.0,,Primary Estimate,Overall,2849,0.077,,,True,,True,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,TotalAntibody,Spike,Validated by developers,0.96,0.993,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Travis Lim,Centers for Disease and Control ,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab185,2021-03-27,2024-02-01,Verified,lim_changes_2021,USA
210226_Minnesota_CentersforDiseaseControlandPrevention_Overall,210226_Minnesota_CentersforDiseaseControlandPrevention_minnea,"Changes in SARS CoV-2 Seroprevalence Over Time in Ten Sites in the United States, March - August, 2020",2021-02-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Minnesota,"Minneapolis, St. Paul, St. Cloud","To be included, specimens must have been from routine
diagnostic tests, such as metabolic panels or cholesterol levels, blinded to COVID-19 symptoms or
diagnosis, that were collected from patients between March 23 and August 14, 2020, and, at
minimum, included demographic information on age, sex, zip code of patient, and date of specimen
collection",,2020-03-23,2020-08-14,Residual sera,All,Multiple groups,18.0,,Primary Estimate,Overall,7944,0.049,,,True,,True,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,TotalAntibody,Spike,Validated by developers,0.96,0.993,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Travis Lim,Centers for Disease and Control ,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab185,2021-03-27,2024-02-01,Verified,lim_changes_2021,USA
210226_Missouri_CentersforDiseaseControlandPrevention_Overall,210226_Missouri_CentersforDiseaseControlandPrevention_miss,"Changes in SARS CoV-2 Seroprevalence Over Time in Ten Sites in the United States, March - August, 2020",2021-02-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Missouri,,"To be included, specimens must have been from routine
diagnostic tests, such as metabolic panels or cholesterol levels, blinded to COVID-19 symptoms or
diagnosis, that were collected from patients between March 23 and August 14, 2020, and, at
minimum, included demographic information on age, sex, zip code of patient, and date of specimen
collection",,2020-03-23,2020-08-14,Residual sera,All,Multiple groups,18.0,,Primary Estimate,Overall,9356,0.025,,,True,,True,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,TotalAntibody,Spike,Validated by developers,0.96,0.993,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Travis Lim,Centers for Disease and Control ,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab185,2021-03-27,2024-02-01,Verified,lim_changes_2021,USA
210226_NewYork_CentersforDiseaseControlandPrevention_Overall,210226_NewYork_CentersforDiseaseControlandPrevention_NYC,"Changes in SARS CoV-2 Seroprevalence Over Time in Ten Sites in the United States, March - August, 2020",2021-02-26,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,New York,New York City,"To be included, specimens must have been from routine
diagnostic tests, such as metabolic panels or cholesterol levels, blinded to COVID-19 symptoms or
diagnosis, that were collected from patients between March 23 and August 14, 2020, and, at
minimum, included demographic information on age, sex, zip code of patient, and date of specimen
collection",,2020-03-23,2020-08-14,Residual sera,All,Multiple groups,18.0,,Primary Estimate,Overall,7746,0.172,,,True,,True,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,TotalAntibody,Spike,Validated by developers,0.96,0.993,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Travis Lim,Centers for Disease and Control ,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab185,2021-03-27,2024-02-01,Verified,lim_changes_2021,USA
210226_Pennsylvania_CentersforDiseaseControlandPrevention_Overall,210226_Pennsylvania_CentersforDiseaseControlandPrevention_phil,"Changes in SARS CoV-2 Seroprevalence Over Time in Ten Sites in the United States, March - August, 2020",2021-02-26,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Pennsylvania,Philadelphia,"To be included, specimens must have been from routine
diagnostic tests, such as metabolic panels or cholesterol levels, blinded to COVID-19 symptoms or
diagnosis, that were collected from patients between March 23 and August 14, 2020, and, at
minimum, included demographic information on age, sex, zip code of patient, and date of specimen
collection",,2020-03-23,2020-08-14,Residual sera,All,Multiple groups,18.0,,Primary Estimate,Overall,8657,0.043,,,True,,True,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,TotalAntibody,Spike,Validated by developers,0.96,0.993,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Travis Lim,Centers for Disease and Control ,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab185,2021-03-27,2024-02-01,Verified,lim_changes_2021,USA
210226_Utah_CentersforDiseaseControlandPrevention_Overall,210226_Utah_CentersforDiseaseControlandPrevention_Utah,"Changes in SARS CoV-2 Seroprevalence Over Time in Ten Sites in the United States, March - August, 2020",2021-02-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Utah,,"To be included, specimens must have been from routine
diagnostic tests, such as metabolic panels or cholesterol levels, blinded to COVID-19 symptoms or
diagnosis, that were collected from patients between March 23 and August 14, 2020, and, at
minimum, included demographic information on age, sex, zip code of patient, and date of specimen
collection",,2020-03-23,2020-08-14,Residual sera,All,Multiple groups,18.0,,Primary Estimate,Overall,8769,0.027000000000000003,,,True,,True,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,TotalAntibody,Spike,Validated by developers,0.96,0.993,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Travis Lim,Centers for Disease and Control ,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab185,2021-03-27,2024-02-01,Verified,lim_changes_2021,USA
210226_Washington_CentersforDiseaseControlandPrevention_Overall,210226_Washington_CentersforDiseaseControlandPrevention_washington,"Changes in SARS CoV-2 Seroprevalence Over Time in Ten Sites in the United States, March - August, 2020",2021-02-26,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Washington,,"To be included, specimens must have been from routine
diagnostic tests, such as metabolic panels or cholesterol levels, blinded to COVID-19 symptoms or
diagnosis, that were collected from patients between March 23 and August 14, 2020, and, at
minimum, included demographic information on age, sex, zip code of patient, and date of specimen
collection",,2020-03-23,2020-08-14,Residual sera,All,Multiple groups,18.0,,Primary Estimate,Overall,7544,0.02,,,True,,True,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,TotalAntibody,Spike,Validated by developers,0.96,0.993,['Low'],No,Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Unclear,Travis Lim,Centers for Disease and Control ,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab185,2021-03-27,2022-07-16,Verified,lim_changes_2021,USA
210226_SouthBronx_IcahnSchoolOfMedicine_Phase1_In-houseELISA,210226_SouthBronx_IcahnSchoolOfMedicine_Phase1,Longitudinal analysis of SARS-CoV-2 seroprevalence using multiple serology platforms,2021-02-26,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,New York,New York City,HCWs at the NYC Public Hospital in the South Bronx.,,2020-05-01,2020-05-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Tested used: in-house ELISA (primary) ,501,0.284,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9500000000000001,1.0,['High'],No,No,No,No,Unclear,Unclear,Yes,Yes,,Juan Carreno,Icahn School of Medicine at Mount Sinai,Not Unity-Aligned,10.1101/2021.02.24.21252340,2021-04-17,2022-07-16,Verified,carreno_longitudinal_2021,USA
210226_CentreCounty_PennsylvaniaStateUniversity_Community,210226_CentreCounty_PennsylvaniaStateUniversity_Community,SARS-CoV-2 Seroprevalence in a University Community: A Longitudinal Study of the Impact of Student Return to Campus on Infection Risk Among Community Members,2021-02-26,Preprint,Local,Prospective cohort,United States of America,Pennsylvania,,"Individuals were eligible for participation in the community resident cohort if they were: ≥18 years old, residing in Centre County at the time of recruitment (June through September 2020); expecting to reside in Centre County until June 2021; fluent in English; and capable of providing their own consent. PSU students who remained in Centre County through spring and summer university closure were eligible for inclusion in the community resident cohort as this group experienced similar geographic COVID-19 risks as community residents (versus returning students who experienced variable risk during spring and summer depending on their residence).","In both cohorts, individuals were invited to participate in the survey-only portion of the study if they were: lactating, pregnant, or intended to become pregnant in the next 12 months; unable to wear a mask for the clinic visit; demonstrated acute COVID-19 symptoms within the previous 14 days; or reported a health condition that made them uncomfortable with participating in the clinic visit.",2020-08-07,2020-12-20,Household and community samples,All,Adults (18-64 years),18.0,,Primary Estimate,Overall community,345,0.08199999999999999,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9329999999999999,0.99,['High'],Yes,No,No,Yes,No,Unclear,Yes,Yes,No,Callum Arnold,Pennsylvania State University,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.17.21251942v3,2021-03-17,2022-07-16,Verified,arnold_sars-cov-2_2021,USA
210226_CentreCounty_PennsylvaniaStateUniversity_Students,210226_CentreCounty_PennsylvaniaStateUniversity_Students,SARS-CoV-2 Seroprevalence in a University Community: A Longitudinal Study of the Impact of Student Return to Campus on Infection Risk Among Community Members,2021-02-26,Preprint,Local,Cross-sectional survey ,United States of America,Pennsylvania,,Participants were eligible for participation in the returning student cohort if they were: ≥18 years old; fluent in English; capable of providing their own consent; residing in Centre County at the time of recruitment (October 2020); officially enrolled as PSU UP students for the Fall 2020 term; and intended to be living in Centre County through April 2021.,"In both cohorts, individuals were invited to participate in the survey-only portion of the study if they were: lactating, pregnant, or intended to become pregnant in the next 12 months; unable to wear a mask for the clinic visit; demonstrated acute COVID-19 symptoms within the previous 14 days; or reported a health condition that made them uncomfortable with participating in the clinic visit.",2020-10-26,2020-11-23,Students and Daycares,All,Adults (18-64 years),18.0,,Primary Estimate,Overall students,625,0.312,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9329999999999999,0.99,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Callum Arnold,Pennsylvania State University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.02.17.21251942v3,2021-03-17,2022-07-16,Verified,arnold_sars-cov-2_2021,USA
120301_RhodeIsland_CDC,120301_RhodeIsland_CDC,"Severe Acute Respiratory Syndrome Coronavirus 2 Seropositivity among Healthcare Personnel in Hospitals and Nursing Homes, Rhode Island, USA, July-August 2020",2021-03-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Rhode Island,,Included and excluded occupational subgroups included in appendix,Included and excluded occupational subgroups included in appendix,2020-07-17,2020-08-28,Health care workers and caregivers,All,Multiple groups,18.0,,Primary Estimate,,9863,0.046,0.042,0.05,True,,,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,,Serum,IgG,Spike,Validated by manufacturers,0.9,1.0,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Lara Akinbami,Centers for Disease Control,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2703.204508,2021-03-27,2024-03-01,Verified,akinbami_severe_2021,USA
210302_NewYork_RenaissanceStonyBrookSchoolofMedicine,210302_NewYork_RenaissanceStonyBrookSchoolofMedicine,Prevalence of IgM and IgG antibodies to SARS-CoV-2 in health care workers at a tertiary care New York hospital during the Spring COVID-19 surge,2021-03-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,,Participants were required to be free from any active symptoms of illness at the time of study entry.,,2020-04-02,2020-04-18,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,474,0.16899999999999998,0.136,0.20600000000000002,True,,,,True,Convenience,DPP COVID-19 IgM/IgG System,ChemBio Diagnostics Inc.,,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),,0.843,0.8890000000000001,['High'],Yes,No,No,Yes,Yes,No,Yes,No,Unclear,Lilian Talbot,Renaissance Stony Brook School of Medicine,Not Unity-Aligned,https://dx.doi.org/10.1186/s13741-021-00177-5,2021-04-16,2024-03-01,Verified,talbot_prevalence_2021,USA
210303_MontereyCounty_UniversityofCaliforniaBerkeley_Overall,210303_MontereyCounty_UniversityofCaliforniaBerkeley,"Prevalence and Clinical Profile of Severe Acute Respiratory Syndrome Coronavirus 2 Infection among Farmworkers, California, June-November 2020.",2021-03-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,"Eligible participants were nonpregnant adult farmworkers >18 years of age receiving SARS-CoV-2 TMA testing at CSVS. Participants were eligible if they had conducted farm work <14 days before their testing date, had not participated previously, and spoke sufficient English or Spanish to give consent and complete study procedures.",Unable to speak Spanish/English,2020-07-16,2020-11-30,Essential non-healthcare workers,All,Adults (18-64 years),18.0,,Primary Estimate,"Farm workers in Salinas Valley, CA, USA",1058,0.19,,,True,,,,True,Self-referral,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,Validated by manufacturers,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,Unclear,Joseph Lewnard,"University of California, Berkeley",Not Unity-Aligned,https://dx.doi.org/10.3201/eid2705.204949,2021-04-23,2022-07-16,Verified, lewnard_prevalence_2021,USA
210305_Illinois-Wisconsin_AdvocateAuroraHealth,210305_Illinois-Wisconsin_AdvocateAuroraHealth,Disparities in Seroprevalence of SARS-CoV-2 Immunoglobulin Antibodies in a Large Midwestern Health Care System,2021-03-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,"Illinois, Wisconsin (Midwest)",,"For study inclusion, English- and Spanish- speaking adults aged ≥18 employed by the health care system in full- or part- time roles as of the study initiation date were eligible for study inclusion. Employees who met  study  inclusion  criteria  and  completed  a  laboratory  blood  draw to test for SARS- CoV-2 IgG were included in the study",,2020-06-08,2020-07-10,Health care workers and caregivers,All,Multiple groups,18.0,82.0,Primary Estimate,,16233,0.038,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9870000000000001,0.9920000000000001,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Veronica Fitzpatrick,Advocate Aurora Health,Not Unity-Aligned,https://dx.doi.org/10.1177/0033354921999168,2021-04-30,2024-03-01,Unverified,fitzpatrick_disparities_2021,USA
210305_Mississippi_CDCCOVID-19ResponseTeam_Overall,210305_Mississippi_CDCCOVID-19ResponseTeam,"Estimated SARS-CoV-2 Seroprevalence Among Persons Aged <18 Years - Mississippi, May-September 2020",2021-03-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Mississippi,,"Demographic data including age, sex, race/ethnicity, and date of collection were obtained for deidentified residual serum specimens collected for routine clinical testing during May 17–September 19, 2020, from persons aged <18 years. One specimen per person was included in the analysis, either the first seropositive specimen or the earliest specimen from persons with all seronegative specimens, to avoid potential bias in underestimating infections from decline in antibodies below the limit of detection for seropositivity",,2020-05-17,2020-09-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,Overall,1603,0.109,0.094,0.12400000000000001,True,,,,True,Sequential,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Author designed (ELISA) - Unknown","Ortho Clinical Diagnostics Inc.,NA",Multiple Types,Serum,TotalAntibody,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Unclear,No,No,Unclear,Charlotte Hobbs,CDC COVID-19 Response Team,Not Unity-Aligned,https://dx.doi.org/10.15585/mmwr.mm7009a4,2021-04-22,2024-03-01,Unverified,hobbs_estimated_2021-1,USA
210305_Mississippi_CDCCOVID-19ResponseTeam_VITROS,210305_Mississippi_CDCCOVID-19ResponseTeam,"Estimated SARS-CoV-2 Seroprevalence Among Persons Aged <18 Years - Mississippi, May-September 2020",2021-03-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Mississippi,,"Demographic data including age, sex, race/ethnicity, and date of collection were obtained for deidentified residual serum specimens collected for routine clinical testing during May 17–September 19, 2020, from persons aged <18 years. One specimen per person was included in the analysis, either the first seropositive specimen or the earliest specimen from persons with all seronegative specimens, to avoid potential bias in underestimating infections from decline in antibodies below the limit of detection for seropositivity",,2020-05-17,2020-09-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Test used,Ortho VITROS assay,1469,0.10400000000000001,0.08800000000000001,0.11900000000000001,,,,,,Sequential,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,,,,,['High'],No,No,Yes,Yes,Yes,Unclear,No,No,Unclear,Charlotte Hobbs,CDC COVID-19 Response Team,Not Unity-Aligned,https://dx.doi.org/10.15585/mmwr.mm7009a4,2021-04-22,2024-03-01,Unverified,hobbs_estimated_2021-1,USA
210305_Mississippi_CDCCOVID-19ResponseTeam_Female,210305_Mississippi_CDCCOVID-19ResponseTeam,"Estimated SARS-CoV-2 Seroprevalence Among Persons Aged <18 Years - Mississippi, May-September 2020",2021-03-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Mississippi,,"Demographic data including age, sex, race/ethnicity, and date of collection were obtained for deidentified residual serum specimens collected for routine clinical testing during May 17–September 19, 2020, from persons aged <18 years. One specimen per person was included in the analysis, either the first seropositive specimen or the earliest specimen from persons with all seronegative specimens, to avoid potential bias in underestimating infections from decline in antibodies below the limit of detection for seropositivity",,2020-05-17,2020-09-19,Residual sera,Female,Children and Youth (0-17 years),0.0,17.0,Sex/Gender,,771,0.11800000000000001,0.096,0.141,,,,,,Sequential,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Author designed (ELISA) - Unknown","Ortho Clinical Diagnostics Inc.,NA",Multiple Types,Serum,TotalAntibody,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Unclear,No,No,Unclear,Charlotte Hobbs,CDC COVID-19 Response Team,Not Unity-Aligned,https://dx.doi.org/10.15585/mmwr.mm7009a4,2021-04-22,2024-03-01,Unverified,hobbs_estimated_2021-1,USA
210305_Mississippi_CDCCOVID-19ResponseTeam_9-17yrs,210305_Mississippi_CDCCOVID-19ResponseTeam,"Estimated SARS-CoV-2 Seroprevalence Among Persons Aged <18 Years - Mississippi, May-September 2020",2021-03-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Mississippi,,"Demographic data including age, sex, race/ethnicity, and date of collection were obtained for deidentified residual serum specimens collected for routine clinical testing during May 17–September 19, 2020, from persons aged <18 years. One specimen per person was included in the analysis, either the first seropositive specimen or the earliest specimen from persons with all seronegative specimens, to avoid potential bias in underestimating infections from decline in antibodies below the limit of detection for seropositivity",,2020-05-17,2020-09-19,Residual sera,All,Children and Youth (0-17 years),9.0,17.0,Age,9-17 years old,697,0.09,0.069,0.11199999999999999,,,,,,Sequential,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Author designed (ELISA) - Unknown","Ortho Clinical Diagnostics Inc.,NA",Multiple Types,Serum,TotalAntibody,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Unclear,No,No,Unclear,Charlotte Hobbs,CDC COVID-19 Response Team,Not Unity-Aligned,https://dx.doi.org/10.15585/mmwr.mm7009a4,2021-04-22,2024-03-01,Unverified,hobbs_estimated_2021-1,USA
210305_Mississippi_CDCCOVID-19ResponseTeam_Male,210305_Mississippi_CDCCOVID-19ResponseTeam,"Estimated SARS-CoV-2 Seroprevalence Among Persons Aged <18 Years - Mississippi, May-September 2020",2021-03-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Mississippi,,"Demographic data including age, sex, race/ethnicity, and date of collection were obtained for deidentified residual serum specimens collected for routine clinical testing during May 17–September 19, 2020, from persons aged <18 years. One specimen per person was included in the analysis, either the first seropositive specimen or the earliest specimen from persons with all seronegative specimens, to avoid potential bias in underestimating infections from decline in antibodies below the limit of detection for seropositivity",,2020-05-17,2020-09-19,Residual sera,Male,Children and Youth (0-17 years),0.0,17.0,Sex/Gender,,830,0.10099999999999999,0.081,0.122,,,,,,Sequential,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Author designed (ELISA) - Unknown","Ortho Clinical Diagnostics Inc.,NA",Multiple Types,Serum,TotalAntibody,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Unclear,No,No,Unclear,Charlotte Hobbs,CDC COVID-19 Response Team,Not Unity-Aligned,https://dx.doi.org/10.15585/mmwr.mm7009a4,2021-04-22,2024-03-01,Unverified,hobbs_estimated_2021-1,USA
210305_Mississippi_CDCCOVID-19ResponseTeam_1-8yrs,210305_Mississippi_CDCCOVID-19ResponseTeam,"Estimated SARS-CoV-2 Seroprevalence Among Persons Aged <18 Years - Mississippi, May-September 2020",2021-03-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Mississippi,,"Demographic data including age, sex, race/ethnicity, and date of collection were obtained for deidentified residual serum specimens collected for routine clinical testing during May 17–September 19, 2020, from persons aged <18 years. One specimen per person was included in the analysis, either the first seropositive specimen or the earliest specimen from persons with all seronegative specimens, to avoid potential bias in underestimating infections from decline in antibodies below the limit of detection for seropositivity",,2020-05-17,2020-09-19,Residual sera,All,Children and Youth (0-17 years),1.0,8.0,Age,1-8 years old,423,0.099,0.071,0.128,,,,,,Sequential,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Author designed (ELISA) - Unknown","Ortho Clinical Diagnostics Inc.,NA",Multiple Types,Serum,TotalAntibody,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Unclear,No,No,Unclear,Charlotte Hobbs,CDC COVID-19 Response Team,Not Unity-Aligned,https://dx.doi.org/10.15585/mmwr.mm7009a4,2021-04-22,2024-03-01,Unverified,hobbs_estimated_2021-1,USA
210305_Mississippi_CDCCOVID-19ResponseTeam_ELISA,210305_Mississippi_CDCCOVID-19ResponseTeam,"Estimated SARS-CoV-2 Seroprevalence Among Persons Aged <18 Years - Mississippi, May-September 2020",2021-03-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Mississippi,,"Demographic data including age, sex, race/ethnicity, and date of collection were obtained for deidentified residual serum specimens collected for routine clinical testing during May 17–September 19, 2020, from persons aged <18 years. One specimen per person was included in the analysis, either the first seropositive specimen or the earliest specimen from persons with all seronegative specimens, to avoid potential bias in underestimating infections from decline in antibodies below the limit of detection for seropositivity",,2020-05-17,2020-09-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Test used,CDC in-house ELISA,134,0.172,0.10800000000000001,0.23600000000000002,,,,,,Sequential,Author designed (ELISA) - Unknown,,ELISA,Serum,TotalAntibody,Spike,,,,['High'],No,No,Yes,Yes,Yes,Unclear,No,No,Unclear,Charlotte Hobbs,CDC COVID-19 Response Team,Not Unity-Aligned,https://dx.doi.org/10.15585/mmwr.mm7009a4,2021-04-22,2022-07-16,Unverified,hobbs_estimated_2021-1,USA
210305_Mississippi_CDCCOVID-19ResponseTeam_<6mos,210305_Mississippi_CDCCOVID-19ResponseTeam,"Estimated SARS-CoV-2 Seroprevalence Among Persons Aged <18 Years - Mississippi, May-September 2020",2021-03-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Mississippi,,"Demographic data including age, sex, race/ethnicity, and date of collection were obtained for deidentified residual serum specimens collected for routine clinical testing during May 17–September 19, 2020, from persons aged <18 years. One specimen per person was included in the analysis, either the first seropositive specimen or the earliest specimen from persons with all seronegative specimens, to avoid potential bias in underestimating infections from decline in antibodies below the limit of detection for seropositivity",,2020-05-17,2020-09-19,Residual sera,All,Children and Youth (0-17 years),0.0,0.0,Age,<6 months old,420,0.145,0.11199999999999999,0.179,,,,,,Sequential,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Author designed (ELISA) - Unknown","Ortho Clinical Diagnostics Inc.,NA",Multiple Types,Serum,TotalAntibody,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Unclear,No,No,Unclear,Charlotte Hobbs,CDC COVID-19 Response Team,Not Unity-Aligned,https://dx.doi.org/10.15585/mmwr.mm7009a4,2021-04-22,2024-03-01,Unverified,hobbs_estimated_2021-1,USA
210305_Mississippi_CDCCOVID-19ResponseTeam6-11mos,210305_Mississippi_CDCCOVID-19ResponseTeam,"Estimated SARS-CoV-2 Seroprevalence Among Persons Aged <18 Years - Mississippi, May-September 2020",2021-03-05,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Mississippi,,"Demographic data including age, sex, race/ethnicity, and date of collection were obtained for deidentified residual serum specimens collected for routine clinical testing during May 17–September 19, 2020, from persons aged <18 years. One specimen per person was included in the analysis, either the first seropositive specimen or the earliest specimen from persons with all seronegative specimens, to avoid potential bias in underestimating infections from decline in antibodies below the limit of detection for seropositivity",,2020-05-17,2020-09-19,Residual sera,All,Children and Youth (0-17 years),0.0,1.0,Age,6-11 months old,63,0.14300000000000002,0.055999999999999994,0.22899999999999998,,,,,,Sequential,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Author designed (ELISA) - Unknown","Ortho Clinical Diagnostics Inc.,NA",Multiple Types,Serum,TotalAntibody,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Unclear,No,No,Unclear,Charlotte Hobbs,CDC COVID-19 Response Team,Not Unity-Aligned,https://dx.doi.org/10.15585/mmwr.mm7009a4,2021-04-22,2024-03-01,Unverified,hobbs_estimated_2021-1,USA
210305_Chicago_NorthwesternUniversity_overall,210305_Chicago_NorthwesternUniversity,Geographic disparities in COVID-19 case rates are not reflected in seropositivity rates using a neighborhood survey in Chicago,2021-03-05,Preprint,Local,Cross-sectional survey ,United States of America,Illinois,Chicago,Chicago residents in one of the selected ZIP code areas who were over the age of 18,,2020-06-24,2020-11-23,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,Overall unadj,1667,0.187,,,True,,,,True,Stratified non-probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,No,No,Brian Mustanski,Northwestern University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.02.21252767v1,2021-03-22,2022-07-16,Verified,mustanski_geographic_2021,USA
210305_Chicago_NorthwesternUniversity_age18-29 ,210305_Chicago_NorthwesternUniversity,Geographic disparities in COVID-19 case rates are not reflected in seropositivity rates using a neighborhood survey in Chicago,2021-03-05,Preprint,Local,Cross-sectional survey ,United States of America,Illinois,Chicago,Chicago residents in one of the selected ZIP code areas who were over the age of 18,,2020-06-24,2020-11-23,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,18-29 ,300,0.197,0.152,0.242,,,,,,Stratified non-probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,No,No,Brian Mustanski,Northwestern University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.02.21252767v1,2021-03-22,2022-07-16,Verified,mustanski_geographic_2021,USA
210305_Chicago_NorthwesternUniversity_female,210305_Chicago_NorthwesternUniversity,Geographic disparities in COVID-19 case rates are not reflected in seropositivity rates using a neighborhood survey in Chicago,2021-03-05,Preprint,Local,Cross-sectional survey ,United States of America,Illinois,Chicago,Chicago residents in one of the selected ZIP code areas who were over the age of 18,,2020-06-24,2020-11-23,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,female,954,0.196,0.171,0.22100000000000003,,,,,,Stratified non-probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,No,No,Brian Mustanski,Northwestern University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.02.21252767v1,2021-03-22,2022-07-16,Verified,mustanski_geographic_2021,USA
210305_Chicago_NorthwesternUniversity_70+,210305_Chicago_NorthwesternUniversity,Geographic disparities in COVID-19 case rates are not reflected in seropositivity rates using a neighborhood survey in Chicago,2021-03-05,Preprint,Local,Cross-sectional survey ,United States of America,Illinois,Chicago,Chicago residents in one of the selected ZIP code areas who were over the age of 18,,2020-06-24,2020-11-23,Household and community samples,All,Seniors (65+ years),70.0,,Age,70+,61,0.16399999999999998,0.071,0.257,,,,,,Stratified non-probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,No,No,Brian Mustanski,Northwestern University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.02.21252767v1,2021-03-22,2022-07-16,Verified,mustanski_geographic_2021,USA
210305_Chicago_NorthwesternUniversity_40-49,210305_Chicago_NorthwesternUniversity,Geographic disparities in COVID-19 case rates are not reflected in seropositivity rates using a neighborhood survey in Chicago,2021-03-05,Preprint,Local,Cross-sectional survey ,United States of America,Illinois,Chicago,Chicago residents in one of the selected ZIP code areas who were over the age of 18,,2020-06-24,2020-11-23,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,366,0.227,0.184,0.27,,,,,,Stratified non-probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,No,No,Brian Mustanski,Northwestern University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.02.21252767v1,2021-03-22,2022-07-16,Verified,mustanski_geographic_2021,USA
210305_Chicago_NorthwesternUniversity_age30-39,210305_Chicago_NorthwesternUniversity,Geographic disparities in COVID-19 case rates are not reflected in seropositivity rates using a neighborhood survey in Chicago,2021-03-05,Preprint,Local,Cross-sectional survey ,United States of America,Illinois,Chicago,Chicago residents in one of the selected ZIP code areas who were over the age of 18,,2020-06-24,2020-11-23,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,542,0.17500000000000002,0.14300000000000002,0.207,,,,,,Stratified non-probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,No,No,Brian Mustanski,Northwestern University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.02.21252767v1,2021-03-22,2022-07-16,Verified,mustanski_geographic_2021,USA
210305_Chicago_NorthwesternUniversity_60-69,210305_Chicago_NorthwesternUniversity,Geographic disparities in COVID-19 case rates are not reflected in seropositivity rates using a neighborhood survey in Chicago,2021-03-05,Preprint,Local,Cross-sectional survey ,United States of America,Illinois,Chicago,Chicago residents in one of the selected ZIP code areas who were over the age of 18,,2020-06-24,2020-11-23,Household and community samples,All,Multiple groups,60.0,69.0,Age,60-69,146,0.13699999999999998,0.081,0.193,,,,,,Stratified non-probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,No,No,Brian Mustanski,Northwestern University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.02.21252767v1,2021-03-22,2022-07-16,Verified,mustanski_geographic_2021,USA
210305_Chicago_NorthwesternUniversity_male,210305_Chicago_NorthwesternUniversity,Geographic disparities in COVID-19 case rates are not reflected in seropositivity rates using a neighborhood survey in Chicago,2021-03-05,Preprint,Local,Cross-sectional survey ,United States of America,Illinois,Chicago,Chicago residents in one of the selected ZIP code areas who were over the age of 18,,2020-06-24,2020-11-23,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,male,707,0.177,0.149,0.20500000000000002,,,,,,Stratified non-probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,No,No,Brian Mustanski,Northwestern University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.02.21252767v1,2021-03-22,2022-07-16,Verified,mustanski_geographic_2021,USA
210305_Chicago_NorthwesternUniversity_50-59,210305_Chicago_NorthwesternUniversity,Geographic disparities in COVID-19 case rates are not reflected in seropositivity rates using a neighborhood survey in Chicago,2021-03-05,Preprint,Local,Cross-sectional survey ,United States of America,Illinois,Chicago,Chicago residents in one of the selected ZIP code areas who were over the age of 18,,2020-06-24,2020-11-23,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,252,0.179,0.131,0.226,,,,,,Stratified non-probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,No,No,Brian Mustanski,Northwestern University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.02.21252767v1,2021-03-22,2022-07-16,Verified,mustanski_geographic_2021,USA
210309_Texas_UTSouthwesternMedicalCenter_Dallas_overall_unadj,210309_Texas_UTSouthwesternMedicalCenter_Dallas,DFW COVID-19 Prevlance Study Update for Dallas & Tarrant Counties – March 2021,2021-03-09,Institutional Report,Local,Cross-sectional survey ,United States of America,,,,,2020-08-15,2021-02-15,Household and community samples,All,Multiple groups,18.0,89.0,Primary Estimate,,11580,0.07200000000000001,,,True,,,,True,Self-referral,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,No,Yes,No,Unclear,Unclear,Yes,No,Unclear,UT Southwestern Medical Center,UT Southwestern Medical Center ,Not Unity-Aligned,https://s3-us-west-2.amazonaws.com/utsw-patientcare-web-production/documents/DFWCPS_Update_03.09.21_FINAL.pdf,2021-05-20,2022-07-16,Verified,noauthor_dfw_2021,USA
210309_Texas_UTSouthwesternMedicalCenter_Employees_overall_unadj,210309_Texas_UTSouthwesternMedicalCenter_Employees,DFW COVID-19 Prevlance Study Update for Dallas & Tarrant Counties – March 2021,2021-03-09,Institutional Report,Local,Cross-sectional survey ,United States of America,,,,,2020-08-15,2021-02-15,Essential non-healthcare workers,All,Multiple groups,18.0,89.0,Primary Estimate,,4098,0.052000000000000005,,,True,,,,True,Self-referral,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,No,Yes,No,Unclear,Unclear,Yes,No,Unclear,UT Southwestern Medical Center,UT Southwestern Medical Center ,Not Unity-Aligned,https://s3-us-west-2.amazonaws.com/utsw-patientcare-web-production/documents/DFWCPS_Update_03.09.21_FINAL.pdf,2021-05-20,2022-07-16,Verified,noauthor_dfw_2021,USA
210309_Texas_UTSouthwesternMedicalCenter_Tarrant_overall_unadj,210309_Texas_UTSouthwesternMedicalCenter_Tarrant,DFW COVID-19 Prevlance Study Update for Dallas & Tarrant Counties – March 2021,2021-03-09,Institutional Report,Local,Cross-sectional survey ,United States of America,,,,,2020-08-15,2021-02-15,Household and community samples,All,Multiple groups,18.0,89.0,Primary Estimate,,5697,0.085,,,True,,,,True,Self-referral,Not reported/ Unable to specify,,,,,,,,,['High'],Yes,No,Yes,No,Unclear,Unclear,Yes,No,Unclear,UT Southwestern Medical Center,UT Southwestern Medical Center ,Not Unity-Aligned,https://s3-us-west-2.amazonaws.com/utsw-patientcare-web-production/documents/DFWCPS_Update_03.09.21_FINAL.pdf,2021-05-20,2022-07-16,Verified,noauthor_dfw_2021,USA
210309_HarrisCounty_HarrisCountyPublicHealth_genpop,210309_HarrisCounty_HarrisCountyPublicHealth,Harris County Public Health announces initial results of COVID-19 antibody project ,2021-03-09,News and Media,Local,Cross-sectional survey ,United States of America,Texas,,Volunteers from randomly selected households,,2020-11-15,2020-12-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,646,0.16,,,True,,,,True,Simplified probability,Not reported/ Unable to specify,,,,,,,,,['High'],Unclear,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,Harris County Public Health,Harris County Public Health,Not Unity-Aligned,https://publichealth.harriscountytx.gov/Portals/27/Documents/HCPH%20Antibody%20Results%20NR.pdf?ver=ZkoB5qeX0P1G--8gfGH8fg%3d%3d,2021-05-10,2022-07-16,Verified,harris_county_public_health_harris_2021,USA
210309_Massachusetts_UniversityofMassachusetts-Amherst_LocalPop_Primary,210309_Massachusetts_University of Massachusetts-Amherst_LocalPop,"Serological surveys to estimate cumulative incidence of SARS-CoV-2 infection in adults (Sero-MAss study), Massachusetts, July-August 2020: a mail-based cross-sectional study",2021-03-09,Preprint,Local,Cross-sectional survey ,United States of America,Massachusetts ,Amherst,"UMass affiliates were eligible to participate in this study if they were above the age of 18, had been living in Massachusetts for the past eight weeks; had never received a COVID-19 diagnosis from a medical professional; and did not have a fever greater than 100.4° F at the time of survey completion. Household members were eligible for inclusion if they met all of these same criteria and were between the ages of 23 and 78 (chosen to expand sampling beyond college-age population groups).",,2020-07-15,2020-08-15,Non-essential workers and unemployed persons,All,Multiple groups,21.0,75.0,Primary Estimate,"Primary estimate for staff, faculty, graduate students and librarians.",292,0.04,0.016,0.065,True,,True,,True,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,,,,['High'],No,Yes,No,Yes,Yes,Unclear,Yes,No,No,Teah Snyder,University of Massachusetts-Amherst,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.05.21249174v2.full.pdf,2021-03-30,2022-07-16,Verified,snyder_serological_2021,USA
210309_Massachusetts_UniversityofMassachusetts-Amherst_Undergrad_Primary,210309_Massachusetts_UniversityOfMassachusetts-Amherst_Undergrad,"Serological surveys to estimate cumulative incidence of SARS-CoV-2 infection in adults (Sero-MAss study), Massachusetts, July-August 2020: a mail-based cross-sectional study",2021-03-09,Preprint,Local,Cross-sectional survey ,United States of America,Massachusetts ,Amherst,"UMass affiliates were eligible to participate in this study if they were above the age of 18, had been living in Massachusetts for the past eight weeks; had never received a COVID-19 diagnosis from a medical professional; and did not have a fever greater than 100.4° F at the time of survey completion. Household members were eligible for inclusion if they met all of these same criteria and were between the ages of 23 and 78 (chosen to expand sampling beyond college-age population groups).",,2020-07-15,2020-08-15,Multiple populations,All,Multiple groups,18.0,75.0,Primary Estimate,Primary estimate for undergraduate students and their household contacts,779,0.053,0.031000000000000003,0.075,True,,True,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,,,,['Moderate'],No,Yes,Yes,Yes,Yes,Unclear,Yes,No,No,Teah Snyder,University of Massachusetts-Amherst,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.05.21249174v2.full.pdf,2021-03-30,2022-07-16,Verified,snyder_serological_2021,USA
210310_UnitedStatesofAmerica_EmoryUniversity,210310_UnitedStatesofAmerica_EmoryUniversity,Risk Factors Associated With SARS-CoV-2 Seropositivity Among US Health Care Personnel,2021-03-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,"Georgia, Maryland, Illinois","Atlanta, Baltimore, Chicago",All badged HCP at each site were eligible to participate,Not including zip codes,2020-04-19,2020-08-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,24749,0.044000000000000004,0.040999999999999995,0.046,True,,,,True,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,EUROIMMUN",Multiple Types,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Jesse Jacob,Emory University,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.1283,2021-04-30,2024-03-01,Unverified,jacob_risk_2021,USA
210311_USA_IgenomixUSAandCanada_Overall,210311_USA_IgenomixUSAandCanada,"SARS-CoV-2 immunity, infective and naive incidence in fertility clinics after lockdown",2021-03-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,"Utah, Massachuetts",Boston,"asymptomatic clinical staff and patients in 2 fertility centers
located in Massachusetts and Utah,",,2020-06-18,2020-07-30,Multiple populations,All,Adults (18-64 years),,,Primary Estimate,,337,0.0148,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Russel Foulk,Igenomix USA and Canada,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ajog.2021.03.008,2021-04-17,2024-03-01,Verified,foulk_severe_2021,USA
210312_NorthCarolina_WakeForestBaptistHealth,210312_NorthCarolina_WakeForestBaptistHealth_2020,Analysis of Accumulated SARS-CoV-2 Seroconversion in North Carolina: The COVID-19 Community Research Partnership,2021-03-12,Preprint,Regional,Cross-sectional survey ,United States of America,North Carolina,,Community residents age 18 years or older within six North Carolina health systems were invited to participate in the study,,2020-04-16,2020-12-20,Household and community samples,All,Adults (18-64 years),18.0,,Primary Estimate,Overall ,17688,0.326,0.284,0.35000000000000003,True,,True,,True,Stratified non-probability,"Rapid lgM-lgG Combined Antibody Test for Coronavirus,2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo)","Syntron Bioresearch Inc. ,Innovita Biological Technology Co. Ltd",LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,Yes,Yes,Unclear,No,No,Unclear,John Williamson,Wake Forest Baptist Health,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.11.21253226v1,2021-04-22,2024-03-01,Verified,williamson_analysis_2021,USA
210312_Atlanta_EmoryUniversitySchoolOfMedicine_Overall,210312_Atlanta_EmoryUniversitySchoolOfMedicine,Prevalence of SARS-CoV-2 Antibodies in Pediatric Healthcare Workers,2021-03-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Georgia,Atlanta,"Healthcare employees and support staff of the Department ofPediatrics at Emory University School of Medicine, Children’sHealthcare of Atlanta (Children’s) and private pediatric practi-tioners or contractors who regularly work at Children’s facilitieswere eligible for study participation.",,2020-04-15,2020-08-15,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,642,0.04,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,,,,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Claudia Morris,Emory University School of Medicine,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.03.017,2021-04-09,2022-07-16,Verified,morris_prevalence_2021-1,USA
210312_UnitedStatesOlympicandParalympicTrainingfacilities_MassachusettsGeneralHospital,210312_UnitedStatesOlympicandParalympicTrainingfacilities_MassachusettsGeneralHospital,Resumption of Sport at the United States Olympic and Paralympic Training Facilities During the COVID-19 Pandemic,2021-03-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,Colorado,Colorado Springs,"All athletes returning to a US Olympic and Paralympic Training facilities were required to go through a reentry protocol consisting of an electronic health history, a 6-day quarantine including twice-daily symptom surveys, COVID-19 polymerase chain reaction and antibody testing,",,2020-07-01,2020-07-31,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,301,0.0365,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Ankit B Shah,Massachusetts General Hospital,Not Unity-Aligned,https://dx.doi.org/10.1177/19417381211002761,2021-05-09,2022-07-16,Unverified,shah_resumption_2021,USA
210312_Cincinnati_UniversityOfCincinnati_overall,210312_Cincinnati_UniversityOfCincinnati,Seroprevalence of SARS-CoV-2 Infection in Cincinnati Ohio USA from August to December 2020,2021-03-12,Preprint,Local,Cross-sectional survey ,United States of America,Ohio,Greater Cincinnati Metropolitan Area,volunteer donors presenting to the Hoxworth Blood Center,"Donors who felt unhealthy including, but not limited to, elevated temperature, low blood hematocrit or signs of respiratory infection were excluded.",2020-08-13,2020-12-08,Blood donors,All,Multiple groups,16.0,91.0,Primary Estimate,,9550,0.084,,,True,,,,True,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['Moderate'],No,Yes,Yes,Yes,Yes,Unclear,Yes,No,,Greg Davis,University of Cincinnati,Not Unity-Aligned,10.1101/2021.03.11.21253263,2021-03-31,2022-07-16,Verified,davis_seroprevalence_2021,USA
210312_Cincinnati_UniversityOfCincinnati_age60+,210312_Cincinnati_UniversityOfCincinnati,Seroprevalence of SARS-CoV-2 Infection in Cincinnati Ohio USA from August to December 2020,2021-03-12,Preprint,Local,Cross-sectional survey ,United States of America,Ohio,Greater Cincinnati Metropolitan Area,volunteer donors presenting to the Hoxworth Blood Center,"Donors who felt unhealthy including, but not limited to, elevated temperature, low blood hematocrit or signs of respiratory infection were excluded.",2020-08-13,2020-12-08,Blood donors,All,Multiple groups,60.0,91.0,Age,age 60+,2905,0.0698,,,,,,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['Moderate'],No,Yes,Yes,Yes,Yes,Unclear,Yes,No,,Greg Davis,University of Cincinnati,Not Unity-Aligned,10.1101/2021.03.11.21253263,2021-03-31,2022-07-16,Verified,davis_seroprevalence_2021,USA
210312_Cincinnati_UniversityOfCincinnati_age51-60,210312_Cincinnati_UniversityOfCincinnati,Seroprevalence of SARS-CoV-2 Infection in Cincinnati Ohio USA from August to December 2020,2021-03-12,Preprint,Local,Cross-sectional survey ,United States of America,Ohio,Greater Cincinnati Metropolitan Area,volunteer donors presenting to the Hoxworth Blood Center,"Donors who felt unhealthy including, but not limited to, elevated temperature, low blood hematocrit or signs of respiratory infection were excluded.",2020-08-13,2020-12-08,Blood donors,All,Adults (18-64 years),51.0,60.0,Age,age 51-60,2185,0.09150000000000001,,,,,,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['Moderate'],No,Yes,Yes,Yes,Yes,Unclear,Yes,No,,Greg Davis,University of Cincinnati,Not Unity-Aligned,10.1101/2021.03.11.21253263,2021-03-31,2022-07-16,Verified,davis_seroprevalence_2021,USA
210312_Cincinnati_UniversityOfCincinnati_female,210312_Cincinnati_UniversityOfCincinnati,Seroprevalence of SARS-CoV-2 Infection in Cincinnati Ohio USA from August to December 2020,2021-03-12,Preprint,Local,Cross-sectional survey ,United States of America,Ohio,Greater Cincinnati Metropolitan Area,volunteer donors presenting to the Hoxworth Blood Center,"Donors who felt unhealthy including, but not limited to, elevated temperature, low blood hematocrit or signs of respiratory infection were excluded.",2020-08-13,2020-12-08,Blood donors,Female,Multiple groups,16.0,91.0,Sex/Gender,female,4986,0.0828,,,,,,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['Moderate'],No,Yes,Yes,Yes,Yes,Unclear,Yes,No,,Greg Davis,University of Cincinnati,Not Unity-Aligned,10.1101/2021.03.11.21253263,2021-03-31,2022-07-16,Verified,davis_seroprevalence_2021,USA
210312_Cincinnati_UniversityOfCincinnati_male,210312_Cincinnati_UniversityOfCincinnati,Seroprevalence of SARS-CoV-2 Infection in Cincinnati Ohio USA from August to December 2020,2021-03-12,Preprint,Local,Cross-sectional survey ,United States of America,Ohio,Greater Cincinnati Metropolitan Area,volunteer donors presenting to the Hoxworth Blood Center,"Donors who felt unhealthy including, but not limited to, elevated temperature, low blood hematocrit or signs of respiratory infection were excluded.",2020-08-13,2020-12-08,Blood donors,Male,Multiple groups,16.0,91.0,Sex/Gender,male,4564,0.0852,,,,,,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['Moderate'],No,Yes,Yes,Yes,Yes,Unclear,Yes,No,,Greg Davis,University of Cincinnati,Not Unity-Aligned,10.1101/2021.03.11.21253263,2021-03-31,2022-07-16,Verified,davis_seroprevalence_2021,USA
210312_Cincinnati_UniversityOfCincinnati_FirstHalf,210312_Cincinnati_UniversityOfCincinnati,Seroprevalence of SARS-CoV-2 Infection in Cincinnati Ohio USA from August to December 2020,2021-03-12,Preprint,Local,Cross-sectional survey ,United States of America,Ohio,Greater Cincinnati Metropolitan Area,volunteer donors presenting to the Hoxworth Blood Center,"Donors who felt unhealthy including, but not limited to, elevated temperature, low blood hematocrit or signs of respiratory infection were excluded.",2020-08-13,2020-10-10,Blood donors,All,Multiple groups,16.0,91.0,Time frame,First half of the study (first 58 days),4786,0.0756,,,,,,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['Moderate'],No,Yes,Yes,Yes,Yes,Unclear,Yes,No,,Greg Davis,University of Cincinnati,Not Unity-Aligned,10.1101/2021.03.11.21253263,2021-07-22,2022-07-16,Verified,davis_seroprevalence_2021,USA
210312_Cincinnati_UniversityOfCincinnati_age41-50,210312_Cincinnati_UniversityOfCincinnati,Seroprevalence of SARS-CoV-2 Infection in Cincinnati Ohio USA from August to December 2020,2021-03-12,Preprint,Local,Cross-sectional survey ,United States of America,Ohio,Greater Cincinnati Metropolitan Area,volunteer donors presenting to the Hoxworth Blood Center,"Donors who felt unhealthy including, but not limited to, elevated temperature, low blood hematocrit or signs of respiratory infection were excluded.",2020-08-13,2020-12-08,Blood donors,All,Adults (18-64 years),41.0,50.0,Age,age 41-50,1571,0.0891,,,,,,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['Moderate'],No,Yes,Yes,Yes,Yes,Unclear,Yes,No,,Greg Davis,University of Cincinnati,Not Unity-Aligned,10.1101/2021.03.11.21253263,2021-03-31,2022-07-16,Verified,davis_seroprevalence_2021,USA
210312_Cincinnati_UniversityOfCincinnati_SecondHalf ,210312_Cincinnati_UniversityOfCincinnati,Seroprevalence of SARS-CoV-2 Infection in Cincinnati Ohio USA from August to December 2020,2021-03-12,Preprint,Local,Cross-sectional survey ,United States of America,Ohio,Greater Cincinnati Metropolitan Area,volunteer donors presenting to the Hoxworth Blood Center,"Donors who felt unhealthy including, but not limited to, elevated temperature, low blood hematocrit or signs of respiratory infection were excluded.",2020-10-11,2020-12-08,Blood donors,All,Multiple groups,16.0,91.0,Time frame,Second half of the study (Latter 58 days),4764,0.09240000000000001,,,,,,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['Moderate'],No,Yes,Yes,Yes,Yes,Unclear,Yes,No,,Greg Davis,University of Cincinnati,Not Unity-Aligned,10.1101/2021.03.11.21253263,2021-07-22,2022-07-16,Verified,davis_seroprevalence_2021,USA
210312_Cincinnati_UniversityOfCincinnati_age31-40,210312_Cincinnati_UniversityOfCincinnati,Seroprevalence of SARS-CoV-2 Infection in Cincinnati Ohio USA from August to December 2020,2021-03-12,Preprint,Local,Cross-sectional survey ,United States of America,Ohio,Greater Cincinnati Metropolitan Area,volunteer donors presenting to the Hoxworth Blood Center,"Donors who felt unhealthy including, but not limited to, elevated temperature, low blood hematocrit or signs of respiratory infection were excluded.",2020-08-13,2020-12-08,Blood donors,All,Adults (18-64 years),31.0,40.0,Age,age 31-40,1447,0.0746,,,,,,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['Moderate'],No,Yes,Yes,Yes,Yes,Unclear,Yes,No,,Greg Davis,University of Cincinnati,Not Unity-Aligned,10.1101/2021.03.11.21253263,2021-03-31,2022-07-16,Verified,davis_seroprevalence_2021,USA
210312_Cincinnati_UniversityOfCincinnati_age16-30,210312_Cincinnati_UniversityOfCincinnati,Seroprevalence of SARS-CoV-2 Infection in Cincinnati Ohio USA from August to December 2020,2021-03-12,Preprint,Local,Cross-sectional survey ,United States of America,Ohio,Greater Cincinnati Metropolitan Area,volunteer donors presenting to the Hoxworth Blood Center,"Donors who felt unhealthy including, but not limited to, elevated temperature, low blood hematocrit or signs of respiratory infection were excluded.",2020-08-13,2020-12-08,Blood donors,All,Adults (18-64 years),16.0,30.0,Age,age 16-30,1442,0.0943,,,,,,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['Moderate'],No,Yes,Yes,Yes,Yes,Unclear,Yes,No,,Greg Davis,University of Cincinnati,Not Unity-Aligned,10.1101/2021.03.11.21253263,2021-03-31,2022-07-16,Verified,davis_seroprevalence_2021,USA
210315_SanFranciscoBayArea_StanfordUniversity_overall_unadj,210315_SanFranciscoBayArea_StanfordUniversity,Case-Control Study of Individuals with Discrepant Nucleocapsid and Spike Protein SARS-CoV-2 IgG Results.,2021-03-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,"Venipuncture blood samples submitted for testing were collected in lithium heparin- coated vacutainers from asymptomatic, symptomatic, and convalescent inpatients and outpatients, either for clinical care, or in the context of COVID-19 related epidemiologic surveillance studies and drug trials at our institution.",,2020-08-03,2020-08-15,Residual sera,All,Multiple groups,,,Primary Estimate,,1080,0.10650000000000001,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG","Abbott Laboratories,EUROIMMUN",Multiple Types,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,,Hannah Wang,Stanford University ,Not Unity-Aligned,https://dx.doi.org/10.1093/clinchem/hvab045,2021-05-19,2024-03-01,Verified,wang_case-control_2021,USA
210315_NewMexico_DiaSorinInc_overall_unadj,210315_NewMexico_DiaSorinInc,Evaluation of the automated LIAISON SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies,2021-03-15,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,New Mexico,,"Specimens were collected from the general population including persons seeking care for general wellness visits. The NY site, did however, include samples from asymptomatic people attending community drives for SARS-CoV-2 antibody detection.",,2020-09-01,2020-09-30,Residual sera,All,Multiple groups,,,Primary Estimate,,1931,0.0197,,,True,,,,True,Sequential,"Liaison SARS-CoV-2 S1/S2 IgG,Access SARS-CoV-2 IgG Reagent Antibody Test","DiaSorin,Beckman Coulter",CLIA,Multiple Types,IgG,Spike,Validated by manufacturers,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,,Fabrizio Bonelli,Dia Sorin Inc,Unity-Aligned,http://dx.doi.org/10.1515/cclm-2021-0023,2021-05-18,2024-03-01,Verified,bonelli_evaluation_2021,USA
210315_NewMexico_DiaSorinInc_DiaSorin,210315_NewMexico_DiaSorinInc,Evaluation of the automated LIAISON SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies,2021-03-15,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,New Mexico,,"Specimens were collected from the general population including persons seeking care for general wellness visits. The NY site, did however, include samples from asymptomatic people attending community drives for SARS-CoV-2 antibody detection.",,2020-09-01,2020-09-30,Residual sera,All,Multiple groups,,,Test used,"diasorin test, only",1931,0.013999999999999999,,,,,,,,Sequential,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,IgG,Spike,Validated by manufacturers,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,,Fabrizio Bonelli,Dia Sorin Inc,Unity-Aligned,http://dx.doi.org/10.1515/cclm-2021-0023,2021-07-22,2024-03-01,Verified,bonelli_evaluation_2021,USA
210315_NewMexico_DiaSorinInc_Beckman,210315_NewMexico_DiaSorinInc,Evaluation of the automated LIAISON SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies,2021-03-15,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,New Mexico,,"Specimens were collected from the general population including persons seeking care for general wellness visits. The NY site, did however, include samples from asymptomatic people attending community drives for SARS-CoV-2 antibody detection.",,2020-09-01,2020-09-30,Residual sera,All,Multiple groups,,,Test used,"Beckman test, only",1931,0.0176,,,,,,,,Sequential,Access SARS-CoV-2 IgG Reagent Antibody Test,Beckman Coulter,CLIA,Multiple Types,IgG,Spike,Validated by manufacturers,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,,Fabrizio Bonelli,Dia Sorin Inc,Unity-Aligned,http://dx.doi.org/10.1515/cclm-2021-0023,2021-07-22,2024-03-01,Verified,bonelli_evaluation_2021,USA
210315_NewYork_DiaSorinInc_overall_unadj,210315_NewYork_DiaSorinInc,Evaluation of the automated LIAISON SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies,2021-03-15,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,New York,,"Specimens were collected from the general population including persons seeking care for general wellness visits. The NY site, did however, include samples from asymptomatic people attending community drives for SARS-CoV-2 antibody detection.",,2020-09-01,2020-09-30,Residual sera,All,Multiple groups,,,Primary Estimate,,1491,0.244,,,True,,,,True,Sequential,"ADVIA Centaur Immunoassay System,Liaison SARS-CoV-2 S1/S2 IgG","Siemens,DiaSorin",CLIA,Multiple Types,"['IgG', 'TotalAntibody']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,,Fabrizio Bonelli,Dia Sorin Inc,Unity-Aligned,http://dx.doi.org/10.1515/cclm-2021-0023,2021-05-18,2024-03-01,Verified,bonelli_evaluation_2021,USA
210315_NewYork_DiaSorinInc_Siemens,210315_NewYork_DiaSorinInc,Evaluation of the automated LIAISON SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies,2021-03-15,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,New York,,"Specimens were collected from the general population including persons seeking care for general wellness visits. The NY site, did however, include samples from asymptomatic people attending community drives for SARS-CoV-2 antibody detection.",,2020-09-01,2020-09-30,Residual sera,All,Multiple groups,,,Test used,"Siemens test , only",1491,0.20199999999999999,,,,,,,,Sequential,ADVIA Centaur Immunoassay System,Siemens,CLIA,Multiple Types,TotalAntibody,Spike,Validated by manufacturers,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,,Fabrizio Bonelli,Dia Sorin Inc,Unity-Aligned,http://dx.doi.org/10.1515/cclm-2021-0023,2021-07-22,2024-03-01,Verified,bonelli_evaluation_2021,USA
210315_NewYork_DiaSorinInc_DiaSorin,210315_NewYork_DiaSorinInc,Evaluation of the automated LIAISON SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies,2021-03-15,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,New York,,"Specimens were collected from the general population including persons seeking care for general wellness visits. The NY site, did however, include samples from asymptomatic people attending community drives for SARS-CoV-2 antibody detection.",,2020-09-01,2020-09-30,Residual sera,All,Multiple groups,,,Test used,"DiaSorin test, only",1491,0.23800000000000002,,,,,,,,Sequential,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Multiple Types,"['IgG', 'TotalAntibody']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,No,,Fabrizio Bonelli,Dia Sorin Inc,Unity-Aligned,http://dx.doi.org/10.1515/cclm-2021-0023,2021-07-21,2024-03-01,Verified,bonelli_evaluation_2021,USA
210316_MetropolitanDetroit_HenryFordHealthSystem,210316_MetropolitanDetroit_HenryFordHealthSystem,SARS-CoV-2 RT-PCR positivity and antibody prevalence among asymptomatic hospital-based health care workers.,2021-03-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Michigan,Detroit,"A list of employees actively working at the HFHS academic hospital and its 3 Detroit-area community hospitals in patient-facing clinical areas was created that included names, occupation, work location, email and phone number. ",,2020-06-17,2020-07-24,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Healthcare Workers,374,0.024100000000000003,0.012700000000000001,0.0451,True,,,,True,Simplified probability,Access SARS-CoV-2 IgG Reagent Antibody Test,Beckman Coulter,,Serum,IgG,,,,,['Moderate'],,Yes,No,No,,Yes,Yes,Yes,,Christine C Johnson,Henry Ford Health System,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcv.2021.104794,2021-06-04,2024-03-01,Unverified,christinec.johnsonSARSCoV2RTPCRPositivity2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_OverallGenPop,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Primary Estimate,Overall,61910,0.066,,,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_DE,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Delaware,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Delaware,166,0.07200000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_IN,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Indiana,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Indiana,1109,0.051,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_CT,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Connecticut,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Connecticut,869,0.06,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_AR,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Arkansas,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Arkansas,445,0.049,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_MT,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Montana,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Montana,128,0.023,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_Male,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,Male,Multiple groups,,,Sex/Gender,male,34737,0.064,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_MA,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Massachusetts,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Massachusetts,1460,0.042,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_IL,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Illinois,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Illinois,2361,0.057999999999999996,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_NE,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Nebraska,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Nebraska,516,0.043,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_WA,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Washington,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Washington,1065,0.038,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.9950000000000029,0.9980000000000006,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_PR,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Puerto Rico,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Puerto Rico,384,0.039,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.9950000000000021,0.9980000000000003,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_MO,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Missouri,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Missouri,928,0.061,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_OR,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Oregon,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Oregon,512,0.013999999999999999,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995000000000002,0.9980000000000003,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_60-69,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Adults (18-64 years),60.0,69.0,Age,60-69,7367,0.044000000000000004,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_RI,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Rhode Island,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Rhode Island,185,0.038,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.9950000000000022,0.9980000000000003,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_WI,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Wisconsin,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Wisconsin,1043,0.049,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.9950000000000031,0.9980000000000006,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_TX,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Texas,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Texas,5737,0.081,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.9950000000000025,0.9980000000000004,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_AK,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Alaska,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Alaska,85,0.0,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_NH,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,New Hampshire,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,New Hampshire,222,0.027000000000000003,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_NC,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,North Carolina,2105,0.03,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_NY,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,New York,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,New York,5020,0.14400000000000002,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.9950000000000017,0.9980000000000002,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_OK,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Oklahoma,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Oklahoma,392,0.051,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.9950000000000019,0.9980000000000003,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_HI,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Hawaii,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Hawaii,388,0.018000000000000002,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_LA,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Louisiana,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Louisiana,634,0.12,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_NV,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Nevada,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Nevada,469,0.1,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_WY,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Wyoming,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Wyoming,83,0.024,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.9950000000000031,0.9980000000000006,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_OH,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Ohio,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Ohio,1741,0.049,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.9950000000000018,0.9980000000000003,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_FL,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Florida,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Florida,4388,0.09300000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_DC,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,District of Columbia,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,District of Columbia,136,0.066,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_KS,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Kansas,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Kansas,444,0.081,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_WV,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,West Virginia,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,West Virginia,177,0.023,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995000000000003,0.9980000000000006,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_NM,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,New Mexico,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,New Mexico,313,0.019,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.9950000000000017,0.9980000000000002,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_AZ,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Arizona,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Arizona,900,0.07400000000000001,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_MI,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Michigan,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Michigan,1257,0.055,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_70+,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Seniors (65+ years),70.0,,Age,70+,1491,0.027999999999999997,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_<30,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Adults (18-64 years),,29.0,Age,<30,8583,0.098,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_CA,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,California,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,California,7459,0.045,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_IA,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Iowa,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Iowa,592,0.051,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_CO,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Colorado,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Colorado,1212,0.040999999999999995,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_TN,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Tenessee,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Tennessee,1163,0.067,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.9950000000000024,0.9980000000000004,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_MS,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Mississippi,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Mississippi,630,0.09,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_VT,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Vermont,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Vermont,88,0.023,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.9950000000000027,0.9980000000000004,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_30-39,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,18326,0.067,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_Female,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,Female,Multiple groups,,,Sex/Gender,female,27173,0.069,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_PA,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Pennsylvania,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Pennsylvania,2155,0.037000000000000005,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995000000000002,0.9980000000000003,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_MN,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Minnesota,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Minnesota,1167,0.039,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_50-59,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,11630,0.059000000000000004,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_ME,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Maine,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Maine,155,0.006,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_AL,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Alabama,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Alabama,750,0.079,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_VA,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Virginia,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Virginia,1855,0.046,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.9950000000000028,0.9980000000000004,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_UT,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Utah,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Utah,743,0.036000000000000004,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.9950000000000027,0.9980000000000004,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_SC,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,South Carolina,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,South Carolina,874,0.068,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.9950000000000023,0.9980000000000004,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_ID,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Idaho,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Idaho,268,0.055999999999999994,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_GA,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Georgia,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Georgia,2131,0.078,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_NJ,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,New Jersey,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,New Jersey,2324,0.095,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.9950000000000015,0.9980000000000002,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_ND,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Dakota,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,North Dakota,155,0.026000000000000002,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_MD,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Maryland,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Maryland,1212,0.063,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_KY,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Kentucky,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,Kentucky,706,0.034,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_40-49,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,14513,0.067,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_SD,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,South Dakota,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,South Dakota,178,0.062000000000000006,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.9950000000000023,0.9980000000000004,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210316_UnitedStates_ClinicalReferenceLaboratoryInc_Others,210316_UnitedStates_ClinicalReferenceLaboratoryInc,"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020",2021-03-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,Well life insurance applicants in Sept 2020,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,,,Geographical area,"Others, unknown",431,0.081,,,,,,,,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Multiple Types,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.9950000000000032,0.9980000000000006,['High'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Robert Stout,Clinical Reference Laboratory Inc,Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777502?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031621,2021-03-22,2024-03-01,Verified,stout_seroprevalence_2021,USA
210317_Boston_HarvardMedicalSchool_Primary,210317_Boston_HarvardMedicalSchool,SARS-CoV-2 antibody seroprevalence after the first wave among workers at a community healthcare system in the Greater Boston area,2021-03-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Massachusetts,Boston,All healthcare workers at Cambridge Health Alliance,,2020-06-16,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,433,0.113,,,True,,,,True,Self-referral,Not reported/ Unable to specify,,ELISA,Dried Blood,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.8,0.995,['High'],No,No,No,Yes,Yes,Unclear,Yes,No,No,Lou Ann Bruno-Murtha,"Harvard Medical School
",Not Unity-Aligned,https://dx.doi.org/10.1080/20477724.2021.1901041,2021-04-17,2022-07-16,Verified,bruno-murtha_sars-cov-2_2021,USA
210317_NewYorkCity_IcahnSchoolOfMedicine,210317_NewYorkCity_IcahnSchoolOfMedicine,Safety of administering biologics to IBD patients at an outpatient infusion center In New York City during the COVID-19 pandemic: Sars-CoV-2 seroprevalence and clinical and social characteristics,2021-03-17,Preprint,Local,Cross-sectional survey ,United States of America,New York,Mount Sinai,All patients were negative for COVID-19 symptoms at the time of blood collection. ,,2020-05-26,2020-07-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,93.0,Primary Estimate,,383,0.10443864229765012,,,True,,,,True,Convenience,Author designed (ELISA) - Unknown,,,,,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Serre Yu Wong,Icahn School Of Medicine,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.03.15.21253615v1,2021-05-23,2022-07-16,Verified,wong_safety_2021,USA
210321_NewYork_WeillCornellMedicine_Adults,210321_NewYork_WeillCornellMedicine_Adults,Association of Age With SARS-CoV-2 Antibody Response,2021-03-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York City ,Above 18 years of age,Infants younger than 1 year were not included in this study to exclude the possibility of maternal antibody transfe,2020-04-09,2020-08-31,Residual sera,All,Multiple groups,18.0,,Primary Estimate,Primary,30232,0.18600000000000003,0.182,0.19100000000000003,True,,,,True,Sequential,Pylon COVID-19 IgG/IgM assay,ET Healthcare,Other,Serum,IgG,Spike,,,,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,He Yang,NewYork–Presbyterian Hospital/Weill Cornell Medical Center,Not Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777743,2021-04-04,2022-07-16,Verified,yang_association_2021,USA
210321_NewYork_WeillCornellMedicine_>80yrs ,210321_NewYork_WeillCornellMedicine_Adults,Association of Age With SARS-CoV-2 Antibody Response,2021-03-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York City ,Above 18 years of age,Infants younger than 1 year were not included in this study to exclude the possibility of maternal antibody transfe,2020-04-09,2020-08-31,Residual sera,All,Seniors (65+ years),80.0,,Age,>80 years,1208,0.133,0.115,0.154,,,,,,Sequential,Pylon COVID-19 IgG/IgM assay,ET Healthcare,Other,Serum,IgG,Spike,,,,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,He Yang,NewYork–Presbyterian Hospital/Weill Cornell Medical Center,Not Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777743,2021-04-04,2022-07-16,Verified,yang_association_2021,USA
210321_NewYork_WeillCornellMedicine_71-80yrs,210321_NewYork_WeillCornellMedicine_Adults,Association of Age With SARS-CoV-2 Antibody Response,2021-03-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York City ,Above 18 years of age,Infants younger than 1 year were not included in this study to exclude the possibility of maternal antibody transfe,2020-04-09,2020-08-31,Residual sera,All,Seniors (65+ years),71.0,80.0,Age,71-80 years,2824,0.129,0.11699999999999999,0.142,,,,,,Sequential,Pylon COVID-19 IgG/IgM assay,ET Healthcare,Other,Serum,IgG,Spike,,,,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,He Yang,NewYork–Presbyterian Hospital/Weill Cornell Medical Center,Not Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777743,2021-04-04,2022-07-16,Verified,yang_association_2021,USA
210321_NewYork_WeillCornellMedicine_25-30yrs,210321_NewYork_WeillCornellMedicine_Adults,Association of Age With SARS-CoV-2 Antibody Response,2021-03-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York City ,Above 18 years of age,Infants younger than 1 year were not included in this study to exclude the possibility of maternal antibody transfe,2020-04-09,2020-08-31,Residual sera,All,Adults (18-64 years),25.0,30.0,Age,25-30 years,3468,0.23500000000000001,0.22100000000000003,0.25,,,,,,Sequential,Pylon COVID-19 IgG/IgM assay,ET Healthcare,Other,Serum,IgG,Spike,,,,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,He Yang,NewYork–Presbyterian Hospital/Weill Cornell Medical Center,Not Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777743,2021-04-04,2022-07-16,Verified,yang_association_2021,USA
210321_NewYork_WeillCornellMedicine_19-24YRS,210321_NewYork_WeillCornellMedicine_Adults,Association of Age With SARS-CoV-2 Antibody Response,2021-03-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York City ,Above 18 years of age,Infants younger than 1 year were not included in this study to exclude the possibility of maternal antibody transfe,2020-04-09,2020-08-31,Residual sera,All,Adults (18-64 years),19.0,24.0,Age,Young Adults (19-24 y.o),990,0.244,0.218,0.273,,,,,,Sequential,Pylon COVID-19 IgG/IgM assay,ET Healthcare,Other,Serum,IgG,Spike,,,,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,He Yang,NewYork–Presbyterian Hospital/Weill Cornell Medical Center,Not Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777743,2021-04-04,2022-07-16,Verified,yang_association_2021,USA
210321_NewYork_WeillCornellMedicine_61-70yrs,210321_NewYork_WeillCornellMedicine_Adults,Association of Age With SARS-CoV-2 Antibody Response,2021-03-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York City ,Above 18 years of age,Infants younger than 1 year were not included in this study to exclude the possibility of maternal antibody transfe,2020-04-09,2020-08-31,Residual sera,All,Multiple groups,61.0,70.0,Age,61-70 years,4494,0.159,0.14800000000000002,0.17,,,,,,Sequential,Pylon COVID-19 IgG/IgM assay,ET Healthcare,Other,Serum,IgG,Spike,,,,['High'],No,No,Yes,No,Unclear,Unclear,Yes,No,,He Yang,NewYork–Presbyterian Hospital/Weill Cornell Medical Center,Not Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777743,2021-04-04,2022-07-16,Verified,yang_association_2021,USA
210321_NewYork_WeillCornellMedicine_Pediatrics,210321_NewYork_WeillCornellMedicine_Pediatrics,Association of Age With SARS-CoV-2 Antibody Response,2021-03-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York City ,Aged 1-18 years,Infants younger than 1 year were not included in this study to exclude possibility of maternal antibody transfer.,2020-04-09,2020-08-31,Residual sera,All,Children and Youth (0-17 years),1.0,18.0,Primary Estimate,Primary,1194,0.165,0.14400000000000002,0.187,True,,,,True,Sequential,Pylon COVID-19 IgG/IgM assay,ET Healthcare,Other,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Unclear,No,Yes,No,Unclear,Unclear,Yes,No,,He Yang,NewYork–Presbyterian Hospital/Weill Cornell Medical Center,Not Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777743,2021-04-03,2022-07-16,Verified,yang_association_2021,USA
210321_NewYork_WeillCornellMedicine_1-10yrs,210321_NewYork_WeillCornellMedicine_Pediatrics,Association of Age With SARS-CoV-2 Antibody Response,2021-03-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York City ,Aged 1-18 years,Infants younger than 1 year were not included in this study to exclude possibility of maternal antibody transfer.,2020-04-09,2020-08-31,Residual sera,All,Children and Youth (0-17 years),1.0,10.0,Age,1-10 years,500,0.152,0.122,0.18600000000000003,,,,,,Sequential,Pylon COVID-19 IgG/IgM assay,ET Healthcare,Other,Serum,IgG,Spike,,,,['High'],Unclear,No,Yes,No,Unclear,Unclear,Yes,No,,He Yang,NewYork–Presbyterian Hospital/Weill Cornell Medical Center,Not Unity-Aligned,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777743,2021-04-04,2022-07-16,Verified,yang_association_2021,USA
210501_UnitedStates_MayoClinic,210501_UnitedStates_MayoClinic,Prevalence of SARS-CoV-2 Antibodies in a Multistate Academic Medical Center.,2021-03-26,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,"Minnesota, Wisconsin, Florida, Arizona, Iowa",Rochester,"To ensure participants had access to testing at Mayo Clinic sites, only HCP with a home-state location in Arizona, Florida, Minnesota, Iowa, or Wisconsin were included in this report.",,2020-06-15,2020-08-08,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,29606,0.006,0.005200000000000001,0.0069,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",Multiple Types,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],Yes,No,Yes,Yes,No,Unclear,Yes,No,No,Rickey Carter,The Mayo Clinic,Not Unity-Aligned,https://dx.doi.org/10.1016/j.mayocp.2021.03.015,2021-05-25,2024-03-01,Verified,carter_prevalence_2021,USA
210401_Colorado_AnschutzMedicalCampus_primary,210401_Colorado_AnschutzMedicalCampus,"Development and validation of a multiplex microsphere immunoassay using dried blood spots for SARS-CoV-2 seroprevalence: application in first responders in Colorado, USA.",2021-04-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Colorado,Aurora,"first responders (police, firefighters, paramedics, emergency medical
technicians) in Arapahoe county, Colorado ",,2020-07-01,2020-08-31,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,264,0.042,,,True,,,,True,Convenience,Author designed (IFA) - MULTIPLEXED,,Other,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,,,['High'],No,No,No,No,Unclear,Unclear,Yes,No,Unclear,Jonathan S Schultz,Anschutz Medical Campus,Not Unity-Aligned,https://dx.doi.org/10.1128/JCM.00290-21,2021-05-18,2022-07-16,Verified,schultz_development_2021,USA
210519_Rochester_MayoClinic_primary,210519_Rochester_MayoClinic,Providing safe care for patients in the coronavirus disease 2019 (COVID-19) era: A case series evaluating risk for hospital-associated COVID-19.,2021-04-05,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Minesota,Rochester,"Patients were eligible for inclusion if they were hospitalized for 2 or
more nights, were admitted on or after May 15, and were discharged by June 15 ","Patients hospitalized
for 1 night or less were ineligible because our definition of hospital-acquired infection was based upon a minimum 2-night stay",2020-05-15,2020-06-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,1339,0.019,,,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","EUROIMMUN,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",ELISA,Serum,IgG,,,,,['High'],Yes,No,Yes,No,Unclear,Unclear,Yes,No,,Elizabeth B Habermann,Mayo Clinic,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2021.38,2021-05-19,2024-03-01,Verified,habermann_providing_2021,USA
210409_OrangeCounty_UniversityofCaliforniaIrvine_Primary,210409_OrangeCounty_UniversityofCaliforniaIrvine,Provider Antibody Serology Study of Virus in the Emergency Room (PASSOVER) Study: Special Population COVID-19 Seroprevalence.,2021-04-09,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,California,Orange County ,"All study participants
were ≥18 years of age and active employees in the CHOC
Children’s ED with direct patient contact, or clerical staff
present in the same area as patients. This included physicians,
physician assistants, nurse practitioners, nurses, medical
technicians, secretaries, monitor technicians, and additional
administrative staff. ",None,2020-04-14,2020-05-13,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,143,0.105,,,True,,,,True,Convenience,COVID-19 Rapid Test Kit IgG + IgM,Superbio Biomedical Company ,Other,Serum,"['IgG', 'IgM']",,Validated by manufacturers,1.0,0.838,['High'],Yes,No,No,No,Unclear,No,Yes,No,Yes,Theodore W. Heyming,University of California Irvine,Not Unity-Aligned,https://dx.doi.org/10.5811/westjem.2021.1.50058,2021-06-20,2024-03-01,Verified,heyming_provider_2021,USA
210409_NewYorkCity_NYCdepthealth_overall,210409_NewYorkCity_NewYorkCityDepartmentOfHealthAndMentalHygiene,"Seroprevalence of SARS-CoV-2 following the largest initial epidemic wave in the United States: Findings from New York City, May 13-July 21, 2020",2021-04-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York,NYC residents aged >18 years,"During online self-registration, required screening questions identified persons who may have had very recent infections and were either potentially infectious or had insufficient time to develop antibodies to SARS-CoV-2. Those who self-reported that they tested positive for SARS-CoV-2 by nasal or throat swab, or had fever, new onset or worsening cough, shortness of breath, or loss of taste (ageusia) or smell (anosmia) in the prior two weeks were not eligible for serosurvey",2020-05-13,2020-07-21,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,45367,0.23600000000000002,0.23199999999999998,0.24,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.976,0.993,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Preeti Pathela,New York City Department of Health and Mental Hygiene,Not Unity-Aligned,https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiab200/6219118,2021-05-22,2024-03-01,Verified,pathela_seroprevalence_2021,USA
210409_NewYorkCity_NYCdepthealth_Males,210409_NewYorkCity_NewYorkCityDepartmentOfHealthAndMentalHygiene,"Seroprevalence of SARS-CoV-2 following the largest initial epidemic wave in the United States: Findings from New York City, May 13-July 21, 2020",2021-04-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York,NYC residents aged >18 years,"During online self-registration, required screening questions identified persons who may have had very recent infections and were either potentially infectious or had insufficient time to develop antibodies to SARS-CoV-2. Those who self-reported that they tested positive for SARS-CoV-2 by nasal or throat swab, or had fever, new onset or worsening cough, shortness of breath, or loss of taste (ageusia) or smell (anosmia) in the prior two weeks were not eligible for serosurvey",2020-05-13,2020-07-21,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,20285,0.24100000000000002,0.23500000000000001,0.247,,,,,,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.976,0.993,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Preeti Pathela,New York City Department of Health and Mental Hygiene,Not Unity-Aligned,https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiab200/6219118,2021-08-04,2024-03-01,Verified,pathela_seroprevalence_2021,USA
210409_NewYorkCity_NYCdepthealth_Females,210409_NewYorkCity_NewYorkCityDepartmentOfHealthAndMentalHygiene,"Seroprevalence of SARS-CoV-2 following the largest initial epidemic wave in the United States: Findings from New York City, May 13-July 21, 2020",2021-04-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York,NYC residents aged >18 years,"During online self-registration, required screening questions identified persons who may have had very recent infections and were either potentially infectious or had insufficient time to develop antibodies to SARS-CoV-2. Those who self-reported that they tested positive for SARS-CoV-2 by nasal or throat swab, or had fever, new onset or worsening cough, shortness of breath, or loss of taste (ageusia) or smell (anosmia) in the prior two weeks were not eligible for serosurvey",2020-05-13,2020-07-21,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,23286,0.23,0.225,0.23600000000000002,,,,,,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.976,0.993,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Preeti Pathela,New York City Department of Health and Mental Hygiene,Not Unity-Aligned,https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiab200/6219118,2021-08-04,2024-03-01,Verified,pathela_seroprevalence_2021,USA
210409_NewYorkCity_NYCdepthealth_18-44,210409_NewYorkCity_NewYorkCityDepartmentOfHealthAndMentalHygiene,"Seroprevalence of SARS-CoV-2 following the largest initial epidemic wave in the United States: Findings from New York City, May 13-July 21, 2020",2021-04-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York,NYC residents aged >18 years,"During online self-registration, required screening questions identified persons who may have had very recent infections and were either potentially infectious or had insufficient time to develop antibodies to SARS-CoV-2. Those who self-reported that they tested positive for SARS-CoV-2 by nasal or throat swab, or had fever, new onset or worsening cough, shortness of breath, or loss of taste (ageusia) or smell (anosmia) in the prior two weeks were not eligible for serosurvey",2020-05-13,2020-07-21,Household and community samples,All,Adults (18-64 years),18.0,44.0,Age,18-44 years old,27667,0.23199999999999998,0.227,0.237,,,,,,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.976,0.993,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Preeti Pathela,New York City Department of Health and Mental Hygiene,Not Unity-Aligned,https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiab200/6219118,2021-08-04,2024-03-01,Verified,pathela_seroprevalence_2021,USA
210409_NewYorkCity_NYCdepthealth_65+,210409_NewYorkCity_NewYorkCityDepartmentOfHealthAndMentalHygiene,"Seroprevalence of SARS-CoV-2 following the largest initial epidemic wave in the United States: Findings from New York City, May 13-July 21, 2020",2021-04-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York,NYC residents aged >18 years,"During online self-registration, required screening questions identified persons who may have had very recent infections and were either potentially infectious or had insufficient time to develop antibodies to SARS-CoV-2. Those who self-reported that they tested positive for SARS-CoV-2 by nasal or throat swab, or had fever, new onset or worsening cough, shortness of breath, or loss of taste (ageusia) or smell (anosmia) in the prior two weeks were not eligible for serosurvey",2020-05-13,2020-07-21,Household and community samples,All,Adults (18-64 years),65.0,,Age,65+ years old,3243,0.215,0.201,0.22899999999999998,,,,,,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.976,0.993,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Preeti Pathela,New York City Department of Health and Mental Hygiene,Not Unity-Aligned,https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiab200/6219118,2021-08-04,2024-03-01,Verified,pathela_seroprevalence_2021,USA
210409_NewYorkCity_NYCdepthealth_45-64,210409_NewYorkCity_NewYorkCityDepartmentOfHealthAndMentalHygiene,"Seroprevalence of SARS-CoV-2 following the largest initial epidemic wave in the United States: Findings from New York City, May 13-July 21, 2020",2021-04-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York,NYC residents aged >18 years,"During online self-registration, required screening questions identified persons who may have had very recent infections and were either potentially infectious or had insufficient time to develop antibodies to SARS-CoV-2. Those who self-reported that they tested positive for SARS-CoV-2 by nasal or throat swab, or had fever, new onset or worsening cough, shortness of breath, or loss of taste (ageusia) or smell (anosmia) in the prior two weeks were not eligible for serosurvey",2020-05-13,2020-07-21,Household and community samples,All,Adults (18-64 years),45.0,64.0,Age,45-64 years old,14457,0.25,0.24300000000000002,0.257,,,,,,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.976,0.993,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Preeti Pathela,New York City Department of Health and Mental Hygiene,Not Unity-Aligned,https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiab200/6219118,2021-08-04,2024-03-01,Verified,pathela_seroprevalence_2021,USA
210409_NewYorkCity_NYCdepthealth_Transgender/Nonconforming,210409_NewYorkCity_NewYorkCityDepartmentOfHealthAndMentalHygiene,"Seroprevalence of SARS-CoV-2 following the largest initial epidemic wave in the United States: Findings from New York City, May 13-July 21, 2020",2021-04-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York,NYC residents aged >18 years,"During online self-registration, required screening questions identified persons who may have had very recent infections and were either potentially infectious or had insufficient time to develop antibodies to SARS-CoV-2. Those who self-reported that they tested positive for SARS-CoV-2 by nasal or throat swab, or had fever, new onset or worsening cough, shortness of breath, or loss of taste (ageusia) or smell (anosmia) in the prior two weeks were not eligible for serosurvey",2020-05-13,2020-07-21,Household and community samples,Other,Multiple groups,18.0,,Sex/Gender,Transgender/non-confirming individuals,260,0.18100000000000002,0.139,0.23199999999999998,,,,,,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.976,0.993,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Preeti Pathela,New York City Department of Health and Mental Hygiene,Not Unity-Aligned,https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiab200/6219118,2021-08-04,2024-03-01,Verified,pathela_seroprevalence_2021,USA
210225_Florida_FloridaDepartmentOfHealth_overall,210225_Florida_FloridaDepartmentOfHealth,"SARS-COV-2 ANTIBODY PREVALENCE AMONG HEALTHCARE WORKERS AND FIRST RESPONDERS, FLORIDA, MAY-JUNE 2020",2021-04-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Florida,,healthcare workers and first responder's self-seeking SARS-CoV-2 testing,,2020-05-06,2020-06-03,Health care workers and caregivers,All,Multiple groups,17.0,89.0,Primary Estimate,,5776,0.040999999999999995,0.026000000000000002,0.08199999999999999,True,,,,True,Convenience,COVID-19 IgG/IgM Rapid Test Cassette,Cellex Inc.,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.938,0.96,['High'],No,No,Yes,Yes,Unclear,No,Yes,No,Yes,James Matthias,Florida Department of Health,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040388/,2021-05-02,2024-03-01,Verified,matthias_sars-cov-2_2021,USA
210412_NewYork_CityUniversityofNewYork_Primary,210412_NewYork_CityUniversityofNewYork,"The emergence, surge and subsequent wave of the SARS-CoV-2 pandemic in New York metropolitan area: The view from a major region-wide urgent care provider",2021-04-12,Preprint,Regional,Retrospective cohort,United States of America,New York ,"New York City
Bronx
Brooklyn
Long Island
Manhatten
Metro North
Queens
Staten Island","This study includes all patients who received a COVID-19 diagnostic or serologic test at CityMD urgent care sites in the New York metropolitan area (NYC, Long Island and Westchester areas).",Pending or missing test results were excluded.,2020-03-08,2021-01-01,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,693205,0.21600000000000003,0.215,0.217,True,,,,True,Sequential,Not reported/ Unable to specify,,,Serum,IgG,,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,,Madhura S Rane,City University of New York,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.04.06.21255009v3,2021-05-22,2022-07-16,Verified,rane_emergence_2021,USA
210412_NewYork_CityUniversityofNewYork_Age70to79,210412_NewYork_CityUniversityofNewYork,"The emergence, surge and subsequent wave of the SARS-CoV-2 pandemic in New York metropolitan area: The view from a major region-wide urgent care provider",2021-04-12,Preprint,Regional,Retrospective cohort,United States of America,New York ,"New York City
Bronx
Brooklyn
Long Island
Manhatten
Metro North
Queens
Staten Island","This study includes all patients who received a COVID-19 diagnostic or serologic test at CityMD urgent care sites in the New York metropolitan area (NYC, Long Island and Westchester areas).",Pending or missing test results were excluded.,2020-03-08,2021-01-01,Household and community samples,All,Seniors (65+ years),70.0,79.0,Age,70-79,31036,0.2082,,,,,,,,Sequential,Not reported/ Unable to specify,,,Serum,IgG,,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,,Madhura S Rane,City University of New York,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.04.06.21255009v3,2021-08-05,2022-07-16,Verified,rane_emergence_2021,USA
210412_NewYork_CityUniversityofNewYork_Age5to9a,210412_NewYork_CityUniversityofNewYork,"The emergence, surge and subsequent wave of the SARS-CoV-2 pandemic in New York metropolitan area: The view from a major region-wide urgent care provider",2021-04-12,Preprint,Regional,Retrospective cohort,United States of America,New York ,"New York City
Bronx
Brooklyn
Long Island
Manhatten
Metro North
Queens
Staten Island","This study includes all patients who received a COVID-19 diagnostic or serologic test at CityMD urgent care sites in the New York metropolitan area (NYC, Long Island and Westchester areas).",Pending or missing test results were excluded.,2020-03-08,2021-01-01,Household and community samples,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,2813,0.2691,,,,,,,,Sequential,Not reported/ Unable to specify,,,Serum,IgG,,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,,Madhura S Rane,City University of New York,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.04.06.21255009v3,2021-08-05,2022-07-16,Verified,rane_emergence_2021,USA
210412_NewYork_CityUniversityofNewYork_Age80to89,210412_NewYork_CityUniversityofNewYork,"The emergence, surge and subsequent wave of the SARS-CoV-2 pandemic in New York metropolitan area: The view from a major region-wide urgent care provider",2021-04-12,Preprint,Regional,Retrospective cohort,United States of America,New York ,"New York City
Bronx
Brooklyn
Long Island
Manhatten
Metro North
Queens
Staten Island","This study includes all patients who received a COVID-19 diagnostic or serologic test at CityMD urgent care sites in the New York metropolitan area (NYC, Long Island and Westchester areas).",Pending or missing test results were excluded.,2020-03-08,2021-01-01,Household and community samples,All,Seniors (65+ years),80.0,89.0,Age,80-89,7015,0.2029,,,,,,,,Sequential,Not reported/ Unable to specify,,,Serum,IgG,,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,,Madhura S Rane,City University of New York,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.04.06.21255009v3,2021-08-05,2022-07-16,Verified,rane_emergence_2021,USA
210412_NewYork_CityUniversityofNewYork_Age0to5,210412_NewYork_CityUniversityofNewYork,"The emergence, surge and subsequent wave of the SARS-CoV-2 pandemic in New York metropolitan area: The view from a major region-wide urgent care provider",2021-04-12,Preprint,Regional,Retrospective cohort,United States of America,New York ,"New York City
Bronx
Brooklyn
Long Island
Manhatten
Metro North
Queens
Staten Island","This study includes all patients who received a COVID-19 diagnostic or serologic test at CityMD urgent care sites in the New York metropolitan area (NYC, Long Island and Westchester areas).",Pending or missing test results were excluded.,2020-03-08,2021-01-01,Household and community samples,All,Children and Youth (0-17 years),0.0,4.0,Age,<5,91,0.1648,,,,,,,,Sequential,Not reported/ Unable to specify,,,Serum,IgG,,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,,Madhura S Rane,City University of New York,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.04.06.21255009v3,2021-08-05,2022-07-16,Verified,rane_emergence_2021,USA
210412_NewYork_CityUniversityofNewYork_Age15to19,210412_NewYork_CityUniversityofNewYork,"The emergence, surge and subsequent wave of the SARS-CoV-2 pandemic in New York metropolitan area: The view from a major region-wide urgent care provider",2021-04-12,Preprint,Regional,Retrospective cohort,United States of America,New York ,"New York City
Bronx
Brooklyn
Long Island
Manhatten
Metro North
Queens
Staten Island","This study includes all patients who received a COVID-19 diagnostic or serologic test at CityMD urgent care sites in the New York metropolitan area (NYC, Long Island and Westchester areas).",Pending or missing test results were excluded.,2020-03-08,2021-01-01,Household and community samples,All,Children and Youth (0-17 years),15.0,19.0,Age,15-19,24636,0.23510000000000003,,,,,,,,Sequential,Not reported/ Unable to specify,,,Serum,IgG,,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,,Madhura S Rane,City University of New York,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.04.06.21255009v3,2021-08-05,2022-07-16,Verified,rane_emergence_2021,USA
210412_NewYork_CityUniversityofNewYork_Age100plus,210412_NewYork_CityUniversityofNewYork,"The emergence, surge and subsequent wave of the SARS-CoV-2 pandemic in New York metropolitan area: The view from a major region-wide urgent care provider",2021-04-12,Preprint,Regional,Retrospective cohort,United States of America,New York ,"New York City
Bronx
Brooklyn
Long Island
Manhatten
Metro North
Queens
Staten Island","This study includes all patients who received a COVID-19 diagnostic or serologic test at CityMD urgent care sites in the New York metropolitan area (NYC, Long Island and Westchester areas).",Pending or missing test results were excluded.,2020-03-08,2021-01-01,Household and community samples,All,Seniors (65+ years),100.0,,Age,>100,1,1.0,,,,,,,,Sequential,Not reported/ Unable to specify,,,Serum,IgG,,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,,Madhura S Rane,City University of New York,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.04.06.21255009v3,2021-08-05,2022-07-16,Verified,rane_emergence_2021,USA
210412_NewYork_CityUniversityofNewYork_Age60to69,210412_NewYork_CityUniversityofNewYork,"The emergence, surge and subsequent wave of the SARS-CoV-2 pandemic in New York metropolitan area: The view from a major region-wide urgent care provider",2021-04-12,Preprint,Regional,Retrospective cohort,United States of America,New York ,"New York City
Bronx
Brooklyn
Long Island
Manhatten
Metro North
Queens
Staten Island","This study includes all patients who received a COVID-19 diagnostic or serologic test at CityMD urgent care sites in the New York metropolitan area (NYC, Long Island and Westchester areas).",Pending or missing test results were excluded.,2020-03-08,2021-01-01,Household and community samples,All,Multiple groups,60.0,69.0,Age,60-69,76128,0.2425,,,,,,,,Sequential,Not reported/ Unable to specify,,,Serum,IgG,,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,,Madhura S Rane,City University of New York,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.04.06.21255009v3,2021-08-05,2022-07-16,Verified,rane_emergence_2021,USA
210412_NewYork_CityUniversityofNewYork_Age30to39,210412_NewYork_CityUniversityofNewYork,"The emergence, surge and subsequent wave of the SARS-CoV-2 pandemic in New York metropolitan area: The view from a major region-wide urgent care provider",2021-04-12,Preprint,Regional,Retrospective cohort,United States of America,New York ,"New York City
Bronx
Brooklyn
Long Island
Manhatten
Metro North
Queens
Staten Island","This study includes all patients who received a COVID-19 diagnostic or serologic test at CityMD urgent care sites in the New York metropolitan area (NYC, Long Island and Westchester areas).",Pending or missing test results were excluded.,2020-03-08,2021-01-01,Household and community samples,All,Multiple groups,30.0,39.0,Age,30-39,157453,0.192,,,,,,,,Sequential,Not reported/ Unable to specify,,,Serum,IgG,,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,,Madhura S Rane,City University of New York,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.04.06.21255009v3,2021-08-05,2022-07-16,Verified,rane_emergence_2021,USA
210412_NewYork_CityUniversityofNewYork_Males,210412_NewYork_CityUniversityofNewYork,"The emergence, surge and subsequent wave of the SARS-CoV-2 pandemic in New York metropolitan area: The view from a major region-wide urgent care provider",2021-04-12,Preprint,Regional,Retrospective cohort,United States of America,New York ,"New York City
Bronx
Brooklyn
Long Island
Manhatten
Metro North
Queens
Staten Island","This study includes all patients who received a COVID-19 diagnostic or serologic test at CityMD urgent care sites in the New York metropolitan area (NYC, Long Island and Westchester areas).",Pending or missing test results were excluded.,2020-03-08,2021-01-01,Household and community samples,Male,Multiple groups,0.0,,Sex/Gender,,304218,0.2233,,,,,,,,Sequential,Not reported/ Unable to specify,,,Serum,IgG,,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,,Madhura S Rane,City University of New York,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.04.06.21255009v3,2021-08-05,2022-07-16,Verified,rane_emergence_2021,USA
210412_NewYork_CityUniversityofNewYork_Age10to14,210412_NewYork_CityUniversityofNewYork,"The emergence, surge and subsequent wave of the SARS-CoV-2 pandemic in New York metropolitan area: The view from a major region-wide urgent care provider",2021-04-12,Preprint,Regional,Retrospective cohort,United States of America,New York ,"New York City
Bronx
Brooklyn
Long Island
Manhatten
Metro North
Queens
Staten Island","This study includes all patients who received a COVID-19 diagnostic or serologic test at CityMD urgent care sites in the New York metropolitan area (NYC, Long Island and Westchester areas).",Pending or missing test results were excluded.,2020-03-08,2021-01-01,Household and community samples,All,Children and Youth (0-17 years),10.0,14.0,Age,10-14,10984,0.2726,,,,,,,,Sequential,Not reported/ Unable to specify,,,Serum,IgG,,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,,Madhura S Rane,City University of New York,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.04.06.21255009v3,2021-08-05,2022-07-16,Verified,rane_emergence_2021,USA
210412_NewYork_CityUniversityofNewYork_Age90to99,210412_NewYork_CityUniversityofNewYork,"The emergence, surge and subsequent wave of the SARS-CoV-2 pandemic in New York metropolitan area: The view from a major region-wide urgent care provider",2021-04-12,Preprint,Regional,Retrospective cohort,United States of America,New York ,"New York City
Bronx
Brooklyn
Long Island
Manhatten
Metro North
Queens
Staten Island","This study includes all patients who received a COVID-19 diagnostic or serologic test at CityMD urgent care sites in the New York metropolitan area (NYC, Long Island and Westchester areas).",Pending or missing test results were excluded.,2020-03-08,2021-01-01,Household and community samples,All,Seniors (65+ years),90.0,99.0,Age,90-99,626,0.2125,,,,,,,,Sequential,Not reported/ Unable to specify,,,Serum,IgG,,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,,Madhura S Rane,City University of New York,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.04.06.21255009v3,2021-08-05,2022-07-16,Verified,rane_emergence_2021,USA
210412_NewYork_CityUniversityofNewYork_Age20to29,210412_NewYork_CityUniversityofNewYork,"The emergence, surge and subsequent wave of the SARS-CoV-2 pandemic in New York metropolitan area: The view from a major region-wide urgent care provider",2021-04-12,Preprint,Regional,Retrospective cohort,United States of America,New York ,"New York City
Bronx
Brooklyn
Long Island
Manhatten
Metro North
Queens
Staten Island","This study includes all patients who received a COVID-19 diagnostic or serologic test at CityMD urgent care sites in the New York metropolitan area (NYC, Long Island and Westchester areas).",Pending or missing test results were excluded.,2020-03-08,2021-01-01,Household and community samples,All,Multiple groups,20.0,29.0,Age,20-29,148801,0.1818,,,,,,,,Sequential,Not reported/ Unable to specify,,,Serum,IgG,,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,,Madhura S Rane,City University of New York,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.04.06.21255009v3,2021-08-05,2022-07-16,Verified,rane_emergence_2021,USA
210412_NewYork_CityUniversityofNewYork_Age50to59,210412_NewYork_CityUniversityofNewYork,"The emergence, surge and subsequent wave of the SARS-CoV-2 pandemic in New York metropolitan area: The view from a major region-wide urgent care provider",2021-04-12,Preprint,Regional,Retrospective cohort,United States of America,New York ,"New York City
Bronx
Brooklyn
Long Island
Manhatten
Metro North
Queens
Staten Island","This study includes all patients who received a COVID-19 diagnostic or serologic test at CityMD urgent care sites in the New York metropolitan area (NYC, Long Island and Westchester areas).",Pending or missing test results were excluded.,2020-03-08,2021-01-01,Household and community samples,All,Multiple groups,50.0,59.0,Age,50-59,116674,0.25010000000000004,,,,,,,,Sequential,Not reported/ Unable to specify,,,Serum,IgG,,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,,Madhura S Rane,City University of New York,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.04.06.21255009v3,2021-08-05,2022-07-16,Verified,rane_emergence_2021,USA
210412_NewYork_CityUniversityofNewYork_Female,210412_NewYork_CityUniversityofNewYork,"The emergence, surge and subsequent wave of the SARS-CoV-2 pandemic in New York metropolitan area: The view from a major region-wide urgent care provider",2021-04-12,Preprint,Regional,Retrospective cohort,United States of America,New York ,"New York City
Bronx
Brooklyn
Long Island
Manhatten
Metro North
Queens
Staten Island","This study includes all patients who received a COVID-19 diagnostic or serologic test at CityMD urgent care sites in the New York metropolitan area (NYC, Long Island and Westchester areas).",Pending or missing test results were excluded.,2020-03-08,2021-01-01,Household and community samples,Female,Multiple groups,0.0,,Sex/Gender,,388897,0.2113,,,,,,,,Sequential,Not reported/ Unable to specify,,,Serum,IgG,,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,,Madhura S Rane,City University of New York,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.04.06.21255009v3,2021-08-05,2022-07-16,Verified,rane_emergence_2021,USA
210412_NewYork_CityUniversityofNewYork_Age40to49,210412_NewYork_CityUniversityofNewYork,"The emergence, surge and subsequent wave of the SARS-CoV-2 pandemic in New York metropolitan area: The view from a major region-wide urgent care provider",2021-04-12,Preprint,Regional,Retrospective cohort,United States of America,New York ,"New York City
Bronx
Brooklyn
Long Island
Manhatten
Metro North
Queens
Staten Island","This study includes all patients who received a COVID-19 diagnostic or serologic test at CityMD urgent care sites in the New York metropolitan area (NYC, Long Island and Westchester areas).",Pending or missing test results were excluded.,2020-03-08,2021-01-01,Household and community samples,All,Multiple groups,40.0,49.0,Age,40-49,116947,0.23620000000000002,,,,,,,,Sequential,Not reported/ Unable to specify,,,Serum,IgG,,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,,Madhura S Rane,City University of New York,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.04.06.21255009v3,2021-08-05,2022-07-16,Verified,rane_emergence_2021,USA
210413_Texas_UniversityOfTexasSouthwesternMedicalCenter_Dallas1,210413_Texas_UniversityOfTexasSouthwesternMedicalCenter_Dallas1,Expanding COVID-19 Vaccine Availability: Role for Combined Orthogonal Serology Testing (COST).,2021-04-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Texas,Dallas,,,2020-03-01,2021-03-31,Residual sera,All,Multiple groups,,,Primary Estimate,,2533,0.389,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Madhusudhanan Narasimhan ,University of Texas Southwestern Medical Center,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines9040376,2021-05-30,2024-03-01,Unverified,narasimhan_expanding_2021,USA
210413_Texas_UniversityOfTexasSouthwesternMedicalCenter_DallasFortWorth2,210413_Texas_UniversityOfTexasSouthwesternMedicalCenter_DallasFortWorth2,Expanding COVID-19 Vaccine Availability: Role for Combined Orthogonal Serology Testing (COST).,2021-04-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Texas,Dallas-Fort Worth,,"Confirmed non-vaccinated, no paired PCR and serology results",2020-06-01,2021-02-28,Residual sera,All,Multiple groups,,,Primary Estimate,,21101,0.071,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Madhusudhanan Narasimhan ,University of Texas Southwestern Medical Center,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines9040376,2021-05-30,2024-03-01,Unverified,narasimhan_expanding_2021,USA
210413_NewOrleans_OchsnerClinicFoundation_HospitalStaff,210413_NewOrleans_OchsnerClinicFoundation_HospitalStaff,The Surgeon’s Risk of SARS-CoV-2 Infection During the Initial Peak of the COVID-19 Pandemic in New Orleans,2021-04-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Louisiana,New Orleans,,,2020-04-22,2020-05-01,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,13343,0.08,0.075,0.085,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Tung Vu,Ochsner Clinic Foundation,Not Unity-Aligned,https://journals.sagepub.com/doi/10.1177/00031348211011090,2021-05-19,2024-03-01,Unverified,vu_surgeons_2021,USA
210413_NewOrleans_OchsnerClinicFoundation_Surgeons,210413_NewOrleans_OchsnerClinicFoundation_Surgeons,The Surgeon’s Risk of SARS-CoV-2 Infection During the Initial Peak of the COVID-19 Pandemic in New Orleans,2021-04-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Louisiana,New Orleans,,,2020-03-01,2020-04-22,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,105,0.019,0.002,0.067,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,No,,Yes,Yes,Yes,,Tung Vu,Ochsner Clinic Foundation,Not Unity-Aligned,https://journals.sagepub.com/doi/10.1177/00031348211011090,2021-05-19,2024-03-01,Unverified,vu_surgeons_2021,USA
210415_KentCounty_UniversityofMichigan_S1,210415_KentCounty_UniversityofMichigan_S1,Health Care Acquired COVID-19 is Less Symptomatic than Community Acquired Disease Among Healthcare Workers.,2021-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Michigan,,all adult employed and contracted HCW were sent survey invitations via email inviting them to participate in a voluntary survey on risk of exposure to COVID-19 and antibody testing. ,"Participants were excluded if they had not worked in the healthcare system since March 1, 2020.",2020-08-17,2020-09-04,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,overall time frame 1,1385,0.019,0.012,0.026000000000000002,True,,,,True,Convenience,"Atellica® IM SARS-CoV-2 Total (COV2T),VIDAS® SARS-COV-2 IgG","Siemens,BioMérieux",Multiple Types,Serum,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,No,Yes,Yes,No,No,Jeffrey Fletcher,University of Michigan,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2021.167,2021-05-21,2024-03-01,Verified,fletcher_health_2021,USA
210415_KentCounty_UniversityofMichigan_S2,210415_KentCounty_UniversityofMichigan_S2,Health Care Acquired COVID-19 is Less Symptomatic than Community Acquired Disease Among Healthcare Workers.,2021-04-15,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Michigan,,all adult employed and contracted HCW were sent survey invitations via email inviting them to participate in a voluntary survey on risk of exposure to COVID-19 and antibody testing. ,"Participants were excluded if they had not worked in the healthcare system since March 1, 2020.",2020-12-02,2020-12-23,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,overall time frame 2,1445,0.13699999999999998,0.11900000000000001,0.155,True,,,,True,Convenience,"Atellica® IM SARS-CoV-2 Total (COV2T),VIDAS® SARS-COV-2 IgG","Siemens,BioMérieux",Multiple Types,Serum,"['IgG', 'IgM']",,Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,No,Yes,Yes,No,No,Jeffrey Fletcher,University of Michigan,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2021.167,2021-05-21,2024-03-01,Verified,fletcher_health_2021,USA
210415_ParrisIsland_IchanSchoolofMedicine,210415_ParrisIsland_IchanSchoolofMedicine,SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study,2021-04-15,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,South Carolina,Port Royal,Recruits were eligible if they were ≥18 years of age.,"Without PCR results, or PCR+ result at any point during the MCRDPI study period.",2020-05-11,2020-11-02,Essential non-healthcare workers,All,Adults (18-64 years),18.0,20.0,Primary Estimate,Marine recruits,3076,0.073,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,1.0,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,Yes,Andrew G Letizia,Icahn School of Medicine at Mount Sinai,Not Unity-Aligned,https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00158-2/fulltext,2021-05-23,2022-07-16,Verified,letizia_sars-cov-2_2021,USA
210419_Milwakee_UniversityOfWisconsin,210419_Milwaukee_UniversityOfWisconsin,Seroprevalence of SARS-CoV-2 Antibody in Echocardiography and Stress Laboratory,2021-04-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Wisconsin,Milwaukee,"All full-time staff members who were employed exclusively by and physically present at the stress and echocardiography laboratories of a single urban, community-based hospital (Aurora St. Luke’s Medical Center, Milwaukee, WI) from March 15, 2020, through June 15, 2020", Staff members who were on a leave of absence or  who  worked  remotely  during  this  time  period  were  excluded,2020-06-15,2020-07-03,Health care workers and caregivers,All,Adults (18-64 years),20.0,,Primary Estimate,,43,0.07,0.02,0.2,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,0.9920000000000001,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Yes,Renuka Jain,University of Wisconsin,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8060043/,2021-05-20,2024-03-01,Verified,jain_seroprevalence_2021,USA
210420_NewYorkCity_BronxCareHealthSystem,210420_NewYorkCity_BronxCareHealthSystem,SARS-CoV-2 Seroprevalence Among Healthcare Workers by Job Function and Work Location in a New York Inner-City Hospital.,2021-04-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York State,New York City,"HCWs were offered voluntary testing for serum antibodies to SARS-CoV-2 between May 18 and June 26, 2020.",,2020-05-18,2020-06-26,Health care workers and caregivers,All,Multiple groups,18.0,,Primary Estimate,,2749,0.302,0.29,0.32,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,,,,,0.971,1.0,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,, Murli U Purswani,BronxCare Health System,Not Unity-Aligned,https://dx.doi.org/10.12788/jhm.3627,2021-05-26,2024-03-01,Unverified,murliu.purswaniSARSCoV2SeroprevalenceHealthcare2021,USA
210422_Illinois+Wisconsin_AdvocateAuroraHealth_Overall,210422_Illinois+Wisconsin_AdvocateAuroraHealth,Incidence of COVID-19 recurrence among large cohort of healthcare employees.,2021-04-22,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,"Illinois, Wisconsin",,"For study inclusion, English- and Spanish-speaking adults ages ≥ 18 employed by a large Midwestern healthcare system as of the study initiation date were eligible. Team members who met study inclusion criteria and completed a lab blood draw to test for SARS-CoV-2 IgG were participants in this study.","Primary analysis (exposure is IgG status) excluded 1,372 participants with a documented COVID-19 infection prior to study initiation (N=14,921).",2020-06-08,2020-07-10,Health care workers and caregivers,All,Multiple groups,18.0,82.0,Primary Estimate,,14921,0.0359,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.9870000000000001,0.9920000000000001,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Fitzpatrick Veronica,Advocate Aurora Health,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2021.04.005,2021-05-25,2024-03-01,Verified,veronica_incidence_2021,USA
210422_Orlando_JohnsHopkinsUniversity,210422_Orlando_JohnsHopkinsUniversity,"SARS-CoV-2 Transmission Risk Among National Basketball Association Players, Staff, and Vendors Exposed to Individuals With Positive Test Results After COVID-19 Recovery During the 2020 Regular and Postseason.",2021-04-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Florida,Orlando,"Included individuals participated as an on-campus resident or off-campus/vendor From June 11, 2020 to October 19, 2020, data were collected as part of the NBA’s occupational health and safety program to safely resume the 2019 to 2020 basketball season and the 2020 Playoffs in Orlando, Florida, within a closed campus (referred to publicly as the NBA bubble). The NBA Orlando Health and Safety protocols required routine testing for 2 weeks before arrival at the campus, with a mandatory quarantine that ended on receipt of 2 negative PCR test results at least 24 hours apart on arriva",,2020-06-11,2020-10-19,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,Overall NBA bubble,3648,0.009000000000000001,,,True,,,,True,Convenience,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Elecsys® Anti‐SARS‐CoV‐2 (S)","Siemens,Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],Yes,No,Yes,No,Unclear,Unclear,Yes,No,Unclear,Christina Mack,Johns Hopkins University School of Medicine,Not Unity-Aligned,https://dx.doi.org/10.1001/jamainternmed.2021.2114,2021-05-19,2024-03-01,Verified,mack_sars-cov-2_2021,USA
210426_Pittsburgh_UniversityofPittsburgh_PediatricPatient_Overall,210426_Pittsburgh_UniversityofPittsburgh,Unexpected False-Positive Rates in Pediatric SARS-CoV-2 Serology Using the EUROIMMUN Anti-SARS-CoV-2 ELISA IgG Assay.,2021-04-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Pennsylvania,Pittsburgh,"remnant serum samples from 2,338 consecu- tive patients younger than 19 years of age at the UPMC Children’s Hospital of Pittsburgh clinical laboratory re- ceived for routine testing",,2020-04-27,2020-07-04,Residual sera,All,Children and Youth (0-17 years),,19.0,Primary Estimate,Overall - EuroIGG,2338,0.0364,0.0291,0.044800000000000006,,,,,True,Sequential,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,,,0.9870000000000001,0.9890000000000001,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Daniel Geisler,University of Pittsburgh School of Medicine,Unity-Aligned,https://dx.doi.org/10.1093/ajcp/aqab033,2021-05-22,2024-03-01,Verified,geisler_unexpected_2021,USA
210426_Pittsburgh_UniversityofPittsburgh_PediatricPatient_RepeatTest,210426_Pittsburgh_UniversityofPittsburgh,Unexpected False-Positive Rates in Pediatric SARS-CoV-2 Serology Using the EUROIMMUN Anti-SARS-CoV-2 ELISA IgG Assay.,2021-04-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Pennsylvania,Pittsburgh,"remnant serum samples from 2,338 consecu- tive patients younger than 19 years of age at the UPMC Children’s Hospital of Pittsburgh clinical laboratory re- ceived for routine testing",,2020-04-27,2020-07-04,Residual sera,All,Children and Youth (0-17 years),,,Test used,Second/third test - Siemens V and C,2338,0.0068000000000000005,,,,,,,,Sequential,"Access SARS-CoV-2 IgG Reagent Antibody Test,ADVIA Centaur Immunoassay System,Anti-SARS-CoV-2 ELISA IgG","Beckman Coulter,Siemens,EUROIMMUN",ELISA,Serum,"['IgG', 'TotalAntibody']",,Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Daniel Geisler,University of Pittsburgh School of Medicine,Unity-Aligned,https://dx.doi.org/10.1093/ajcp/aqab033,2021-08-12,2024-03-01,Verified,geisler_unexpected_2021,USA
210427_NewYorkCity_AlbertEinsteinCollegeofMedicine,210427_NewYorkCity_AlbertEinsteinCollegeofMedicine,COVID‐19 in heart transplant recipients—A seroprevalence survey,2021-04-27,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,New York state,New York City,"The first cases of COVID‐19 were detected in New York after March 1, 2020, at which time the Montefiore/Einstein HTX program was actively following 268 adult heart transplant recipients. By June 1, the pandemic had receded in New York; therefore, at this time we initiated serological testing on all recipients followed by our program.","The total of 37 COVID‐19‐positive subjects was comprised of 31 with a detectable Ab plus 1 who was PCR positive but did not develop Ab and five others who were PCR positive but died before Ab testing could be obtained

- Extraction only included Ab positive",2020-06-01,2020-08-01,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,232,0.1336206896551724,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Snehal R Patel,Albert Einstein College of Medicine,Not Unity-Aligned,https://onlinelibrary.wiley.com/doi/10.1111/ctr.14329,2021-05-17,2022-07-16,Unverified,patel_covid-19_2021,USA
210427_Connecticut_HartfordHealthcare_overall,210427_Connecticut_HartfordHealthcare,"Seroprevalence of SARS-CoV-2 antibodies, associated epidemiological factors and antibody kinetics among healthcare workers in Connecticut.",2021-04-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Connecticut,Hartford,"Inclusion criteria were: current employment or affiliated medical staff and age ≥18 years. HCW included all staff providing any level of direct or indirect care to patients. This included healthcare professionals, allied health workers, auxiliary health workers, cleaning and laundry personnel, radiology staff, clerks, phlebotomists, respiratory therapists, nutritionists, social workers, physical therapists, laboratory personnel, administrators, patient transporters, and food service staff.",The only exclusion criterion was symptoms suspicious for active SARS-CoV-2 infection at the time of testing.,2020-05-11,2020-08-16,Health care workers and caregivers,All,Multiple groups,18.0,81.0,Primary Estimate,,6863,0.063,0.057,0.069,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,No,Pavlos Papasavas,Hartford Healthcare,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jhin.2021.04.021,2021-05-27,2024-03-01,Verified,papasavas_seroprevalence_2021,USA
210428_NewYorkCity_NewYorkBloodCenter_Ortho+Neut,210428_NewYorkCity_NewYorkBloodCenter,Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and “Reopening”,2021-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,consecutive NYC metro donors,,2020-06-15,2020-07-15,Blood donors,All,Multiple groups,16.0,78.0,Primary Estimate,Positive ortho and neutralization test,1000,0.09,,,True,,,,True,Sequential,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Author designed (Neutralization Assay)","Ortho Clinical Diagnostics Inc.,NA",Multiple Types,Plasma,"['Neutralizing', 'TotalAntibody']",Spike,,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,,Daniel Jin,New York Blood Centre,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0250319,2021-05-23,2024-03-01,Verified,jin_seroprevalence_2021,USA
210428_NewYorkCity_NewYorkBloodCenter_Ortho,210428_NewYorkCity_NewYorkBloodCenter,Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and “Reopening”,2021-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,consecutive NYC metro donors,,2020-06-15,2020-07-15,Blood donors,All,Multiple groups,16.0,78.0,Test used,Ortho,1000,0.121,0.102,0.14300000000000002,,,,,,Sequential,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,TotalAntibody,Spike,,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,,Daniel Jin,New York Blood Centre,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0250319,2021-08-06,2024-03-01,Verified,jin_seroprevalence_2021,USA
210428_NewYorkCity_NewYorkBloodCenter_Ortho_Female,210428_NewYorkCity_NewYorkBloodCenter,Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and “Reopening”,2021-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,consecutive NYC metro donors,,2020-06-15,2020-07-15,Blood donors,Female,Multiple groups,16.0,78.0,Sex/Gender,Ortho,385,0.14300000000000002,0.111,0.18100000000000002,,,,,,Sequential,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,TotalAntibody,Spike,,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,,Daniel Jin,New York Blood Centre,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0250319,2021-08-06,2024-03-01,Verified,jin_seroprevalence_2021,USA
210428_NewYorkCity_NewYorkBloodCenter_Ortho_Age18-34,210428_NewYorkCity_NewYorkBloodCenter,Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and “Reopening”,2021-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,consecutive NYC metro donors,,2020-06-15,2020-07-15,Blood donors,All,Adults (18-64 years),18.0,34.0,Age,18-34,281,0.16,0.122,0.20800000000000002,,,,,,Sequential,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,TotalAntibody,Spike,,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,,Daniel Jin,New York Blood Centre,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0250319,2021-08-06,2024-03-01,Verified,jin_seroprevalence_2021,USA
210428_NewYorkCity_NewYorkBloodCenter_Abbott,210428_NewYorkCity_NewYorkBloodCenter,Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and “Reopening”,2021-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,consecutive NYC metro donors,,2020-06-15,2020-07-15,Blood donors,All,Multiple groups,16.0,78.0,Test used,Abbott,1000,0.109,0.091,0.129,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,,Daniel Jin,New York Blood Centre,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0250319,2021-08-06,2024-03-01,Verified,jin_seroprevalence_2021,USA
210428_NewYorkCity_NewYorkBloodCenter_OrthoORAbbott,210428_NewYorkCity_NewYorkBloodCenter,Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and “Reopening”,2021-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,consecutive NYC metro donors,,2020-06-15,2020-07-15,Blood donors,All,Multiple groups,16.0,78.0,Test used,Positive ortho or Abbott,1000,0.128,,,,,,,,Sequential,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG","Ortho Clinical Diagnostics Inc.,Abbott Laboratories",CLIA,Plasma,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,,Daniel Jin,New York Blood Centre,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0250319,2021-08-06,2024-03-01,Verified,jin_seroprevalence_2021,USA
210428_NewYorkCity_NewYorkBloodCenter_Ortho_Age35-49,210428_NewYorkCity_NewYorkBloodCenter,Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and “Reopening”,2021-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,consecutive NYC metro donors,,2020-06-15,2020-07-15,Blood donors,All,Adults (18-64 years),35.0,49.0,Age,35-49,260,0.11199999999999999,0.079,0.156,,,,,,Sequential,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,TotalAntibody,Spike,,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,,Daniel Jin,New York Blood Centre,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0250319,2021-08-06,2024-03-01,Verified,jin_seroprevalence_2021,USA
210428_NewYorkCity_NewYorkBloodCenter_Ortho_Age35-64,210428_NewYorkCity_NewYorkBloodCenter,Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and “Reopening”,2021-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,consecutive NYC metro donors,,2020-06-15,2020-07-15,Blood donors,All,Adults (18-64 years),35.0,64.0,Age,35-64,605,0.11599999999999999,0.09300000000000001,0.14400000000000002,,,,,,Sequential,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,TotalAntibody,Spike,,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,,Daniel Jin,New York Blood Centre,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0250319,2021-08-06,2024-03-01,Verified,jin_seroprevalence_2021,USA
210428_NewYorkCity_NewYorkBloodCenter_OrthoANDAbbott,210428_NewYorkCity_NewYorkBloodCenter,Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and “Reopening”,2021-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,consecutive NYC metro donors,,2020-06-15,2020-07-15,Blood donors,All,Multiple groups,16.0,78.0,Test used,Positive ortho and Abbott,1000,0.102,,,,,,,,Sequential,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG","Ortho Clinical Diagnostics Inc.,Abbott Laboratories",CLIA,Plasma,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,,Daniel Jin,New York Blood Centre,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0250319,2021-08-06,2024-03-01,Verified,jin_seroprevalence_2021,USA
210428_NewYorkCity_NewYorkBloodCenter_Ortho_Age65+,210428_NewYorkCity_NewYorkBloodCenter,Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and “Reopening”,2021-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,consecutive NYC metro donors,,2020-06-15,2020-07-15,Blood donors,All,Seniors (65+ years),65.0,78.0,Age,,114,0.044000000000000004,0.019,0.099,,,,,,Sequential,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,TotalAntibody,Spike,,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,,Daniel Jin,New York Blood Centre,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0250319,2021-08-06,2024-03-01,Verified,jin_seroprevalence_2021,USA
210428_NewYorkCity_NewYorkBloodCenter_Ortho_Male,210428_NewYorkCity_NewYorkBloodCenter,Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and “Reopening”,2021-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,consecutive NYC metro donors,,2020-06-15,2020-07-15,Blood donors,Male,Multiple groups,16.0,78.0,Sex/Gender,Ortho,615,0.107,0.085,0.134,,,,,,Sequential,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,TotalAntibody,Spike,,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,,Daniel Jin,New York Blood Centre,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0250319,2021-08-06,2024-03-01,Verified,jin_seroprevalence_2021,USA
210428_NewYorkCity_NewYorkBloodCenter_Ortho_Age50-64,210428_NewYorkCity_NewYorkBloodCenter,Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and “Reopening”,2021-04-28,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,consecutive NYC metro donors,,2020-06-15,2020-07-15,Blood donors,All,Adults (18-64 years),50.0,64.0,Age,50-64,345,0.11900000000000001,0.08900000000000001,0.157,,,,,,Sequential,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,TotalAntibody,Spike,,,,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,No,,Daniel Jin,New York Blood Centre,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0250319,2021-08-06,2024-03-01,Verified,jin_seroprevalence_2021,USA
210429_Phoenix_VincereCancerCenter_December_IgG_Unadj,210429_Phoenix_VincereCancerCenter_December,COVID-19 Trends in the Phoenix Metropolitan Area from a Mobile Testing Program: Last Quarter of 2020.,2021-04-29,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arizona,Phoenix Metropolitan Area,Individuals of 12 years old or older had the option to schedule an appointment or do a walk-up visit in a mobile testing program,Children under 12 years old were excluded from testing ,2020-12-05,2020-12-11,Household and community samples,All,Multiple groups,12.0,,Primary Estimate,,3038,0.165,,,True,,,,True,Self-referral,COVID-19 IgG/IgM Rapid Test Device,Assure Tech. (Hangzhou) Co. Ltd,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,1.0,0.988,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Christine Lau,"Vincere Cancer Center,",Not Unity-Aligned,https://dx.doi.org/10.1007/s10900-021-00991-4,2021-05-21,2024-03-01,Verified,lau_covid-19_2021,USA
210429_Phoenix_VincereCancerCenter_November_IgG_Unadj,210429_Phoenix_VincereCancerCenter_November,COVID-19 Trends in the Phoenix Metropolitan Area from a Mobile Testing Program: Last Quarter of 2020.,2021-04-29,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arizona,Phoenix Metropolitan Area,Individuals of 12 years old or older had the option to schedule an appointment or do a walk-up visit in a mobile testing program,Children under 12 years old were excluded from testing ,2020-11-07,2020-11-13,Household and community samples,All,Multiple groups,12.0,,Primary Estimate,,2037,0.16649999999999998,,,True,,,,True,Self-referral,COVID-19 IgG/IgM Rapid Test Device,Assure Tech. (Hangzhou) Co. Ltd,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,1.0,0.988,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Christine Lau,"Vincere Cancer Center,",Not Unity-Aligned,https://dx.doi.org/10.1007/s10900-021-00991-4,2021-05-21,2024-03-01,Verified,lau_covid-19_2021,USA
210429_Phoenix_VincereCancerCenter_October_IgG_Unadj,210429_Phoenix_VincereCancerCenter_October,COVID-19 Trends in the Phoenix Metropolitan Area from a Mobile Testing Program: Last Quarter of 2020.,2021-04-29,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arizona,Phoenix Metropolitan Area,Individuals of 12 years old or older had the option to schedule an appointment or do a walk-up visit in a mobile testing program,Children under 12 years old were excluded from testing ,2020-10-10,2020-10-16,Household and community samples,All,Multiple groups,12.0,,Primary Estimate,,1635,0.0874,,,True,,,,True,Self-referral,COVID-19 IgG/IgM Rapid Test Device,Assure Tech. (Hangzhou) Co. Ltd,LFIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,1.0,0.988,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Christine Lau,"Vincere Cancer Center,",Not Unity-Aligned,https://dx.doi.org/10.1007/s10900-021-00991-4,2021-05-21,2024-03-01,Verified,lau_covid-19_2021,USA
210429_Indianapolis_IndianaUniversity_overall,210429_Indianapolis_IndianaUniversity,Placement on COVID-19 Units Does Not Increase Seroconversion Rate of Pediatric Graduate Medical Residents.,2021-04-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Indiana,Indianapolis,"All graduate medical residents in pediatrics, including pediatric, internal medicine/pediatric, and emergency medicine/pediatric residents working at Riley Children's Health, a 247-bed pediatric tertiary care hospital, between February 1, 2020, and May 22, 2020, were eligible for inclusion in this cross-sectional observational study.",There was no exclusion criteria,2020-05-18,2020-05-22,Health care workers and caregivers,All,Adults (18-64 years),24.0,36.0,Primary Estimate,,44,0.2727,,,True,,,,True,Convenience,COVID-19 Human IgM IgG Assay Kit,Abnova,ELISA,Serum,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['High'],No,No,No,Yes,Unclear,Unclear,Yes,No,No,Timothy Crisci,Indiana Univeristy,Not Unity-Aligned,https://dx.doi.org/10.3389/fped.2021.633082,2021-06-07,2022-07-16,Verified,crisci_placement_2021,USA
210429_Houston_HoustonHealthDepartment_MultipleTest_Primary,210429_Houston_HoustonHealthDepartment,"Population-Based Estimates of SARS-CoV-2 Seroprevalence in Houston, TX as of September 2020",2021-04-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Texas,Houston,"Households living in Houston, TX.",,2020-09-01,2020-09-19,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,,685,0.1153,,,True,,True,,True,Stratified probability,"Platelia SARS-CoV-2 Total Ab assay,Author designed (ELISA) -Spike","Bio-rad,NA",ELISA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Elaine Symanski,Houston Health Department,Unity-Aligned,https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiab203/6258999,2021-09-03,2024-03-01,Verified,symanski_population-based_2021,USA
210429_Houston_HoustonHealthDepartment_BioRad,210429_Houston_HoustonHealthDepartment,"Population-Based Estimates of SARS-CoV-2 Seroprevalence in Houston, TX as of September 2020",2021-04-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Texas,Houston,"Households living in Houston, TX.",,2020-09-01,2020-09-19,Household and community samples,All,Multiple groups,5.0,,Test used,BioRad ELISA,678,0.131,,,,,True,,,Stratified probability,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9890000000000001,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Elaine Symanski,Houston Health Department,Unity-Aligned,https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiab203/6258999,2021-09-03,2024-03-01,Verified,symanski_population-based_2021,USA
210429_Houston_HoustonHealthDepartment_MultipleTest_Male,210429_Houston_HoustonHealthDepartment,"Population-Based Estimates of SARS-CoV-2 Seroprevalence in Houston, TX as of September 2020",2021-04-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Texas,Houston,"Households living in Houston, TX.",,2020-09-01,2020-09-19,Household and community samples,Male,Multiple groups,,,Sex/Gender,,302,0.08900000000000001,0.053,0.125,,True,True,,,Stratified probability,"Platelia SARS-CoV-2 Total Ab assay,Author designed (ELISA) -Spike","Bio-rad,NA",ELISA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Elaine Symanski,Houston Health Department,Unity-Aligned,https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiab203/6258999,2021-11-03,2023-08-15,Verified,symanski_population-based_2021,USA
210429_Houston_HoustonHealthDepartment_MultipleTest_Age60+,210429_Houston_HoustonHealthDepartment,"Population-Based Estimates of SARS-CoV-2 Seroprevalence in Houston, TX as of September 2020",2021-04-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Texas,Houston,"Households living in Houston, TX.",,2020-09-01,2020-09-19,Household and community samples,All,Seniors (65+ years),60.0,,Age,,175,0.08,0.02,0.139,,True,True,,,Stratified probability,"Platelia SARS-CoV-2 Total Ab assay,Author designed (ELISA) -Spike","Bio-rad,NA",ELISA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Elaine Symanski,Houston Health Department,Unity-Aligned,https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiab203/6258999,2021-11-03,2023-08-15,Verified,symanski_population-based_2021,USA
210429_Houston_HoustonHealthDepartment_MultipleTest_Age5-17,210429_Houston_HoustonHealthDepartment,"Population-Based Estimates of SARS-CoV-2 Seroprevalence in Houston, TX as of September 2020",2021-04-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Texas,Houston,"Households living in Houston, TX.",,2020-09-01,2020-09-19,Household and community samples,All,Children and Youth (0-17 years),5.0,17.0,Age,5-17,62,0.177,0.053,0.30100000000000005,,True,True,,,Stratified probability,"Platelia SARS-CoV-2 Total Ab assay,Author designed (ELISA) -Spike","Bio-rad,NA",ELISA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Elaine Symanski,Houston Health Department,Unity-Aligned,https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiab203/6258999,2021-11-03,2023-08-15,Verified,symanski_population-based_2021,USA
210429_Houston_HoustonHealthDepartment_MultipleTest_Female,210429_Houston_HoustonHealthDepartment,"Population-Based Estimates of SARS-CoV-2 Seroprevalence in Houston, TX as of September 2020",2021-04-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Texas,Houston,"Households living in Houston, TX.",,2020-09-01,2020-09-19,Household and community samples,Female,Multiple groups,,,Sex/Gender,,376,0.159,0.095,0.223,,True,True,,,Stratified probability,"Platelia SARS-CoV-2 Total Ab assay,Author designed (ELISA) -Spike","Bio-rad,NA",ELISA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Elaine Symanski,Houston Health Department,Unity-Aligned,https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiab203/6258999,2021-11-03,2023-08-15,Verified,symanski_population-based_2021,USA
210429_Houston_HoustonHealthDepartment_MultipleTest_Age40-59,210429_Houston_HoustonHealthDepartment,"Population-Based Estimates of SARS-CoV-2 Seroprevalence in Houston, TX as of September 2020",2021-04-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Texas,Houston,"Households living in Houston, TX.",,2020-09-01,2020-09-19,Household and community samples,All,Adults (18-64 years),40.0,59.0,Age,40-59,227,0.095,0.046,0.14400000000000002,,True,True,,,Stratified probability,"Platelia SARS-CoV-2 Total Ab assay,Author designed (ELISA) -Spike","Bio-rad,NA",ELISA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Elaine Symanski,Houston Health Department,Unity-Aligned,https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiab203/6258999,2021-11-03,2023-08-15,Verified,symanski_population-based_2021,USA
210429_Houston_HoustonHealthDepartment_InHouse,210429_Houston_HoustonHealthDepartment,"Population-Based Estimates of SARS-CoV-2 Seroprevalence in Houston, TX as of September 2020",2021-04-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Texas,Houston,"Households living in Houston, TX.",,2020-09-01,2020-09-19,Household and community samples,All,Multiple groups,5.0,,Test used,In-house ELISA,678,0.135,0.09,0.18100000000000002,,True,True,,,Stratified probability,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9400000000000001,0.99,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Elaine Symanski,Houston Health Department,Unity-Aligned,https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiab203/6258999,2021-05-16,2023-08-15,Verified,symanski_population-based_2021,USA
210429_Houston_HoustonHealthDepartment_MultipleTest_Age18-39,210429_Houston_HoustonHealthDepartment,"Population-Based Estimates of SARS-CoV-2 Seroprevalence in Houston, TX as of September 2020",2021-04-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Texas,Houston,"Households living in Houston, TX.",,2020-09-01,2020-09-19,Household and community samples,All,Adults (18-64 years),18.0,39.0,Age,18-39,214,0.134,0.075,0.19399999999999998,,True,True,,,Stratified probability,"Platelia SARS-CoV-2 Total Ab assay,Author designed (ELISA) -Spike","Bio-rad,NA",ELISA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Unclear,Elaine Symanski,Houston Health Department,Unity-Aligned,https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiab203/6258999,2021-11-03,2023-08-15,Verified,symanski_population-based_2021,USA
210429_SanFrancisco_UniversityOfCaliforniaSanFrancisco_HIV1_TestAdj,210429_SanFrancisco_UniversityOfCaliforniaSanFrancisco_HIV1,"SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study",2021-04-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,San Francisco,"all people living with HIV who underwent routine outpatient laboratory testing in a municipal health-care system (San Francisco General Hospital, CA, USA). Samples from people living with HIV were date of collection-matched (same day) and age-matched (±5 years) to samples from randomly selected adults (aged 18 years or older) without HIV receiving care for chronic conditions at the same hospital",,2020-08-01,2020-10-31,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,955,0.037000000000000005,0.024,0.05,True,True,,,,Sequential,Pylon COVID-19 IgG/IgM assay,ET Healthcare,Other,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.89,1.0,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,,Matthew A Spinelli,University of California San Francisco,Not Unity-Aligned,https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(21)00072-2/fulltext,2021-05-18,2022-07-16,Unverified,spinelli_sars-cov-2_2021,USA
210429_SanFrancisco_UniversityOfCaliforniaSanFrancisco_Outpatients2_TestAdj,210429_SanFrancisco_UniversityOfCaliforniaSanFrancisco_Outpatients2,"SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study",2021-04-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,San Francisco,Each sample from people living with HIV was matched 1:1 by date of collection (same day) and age (±5 years) to samples from randomly selected adults (aged 18 years or older) from internal medicine and family medicine clinics receiving outpatient metabolic panel laboratory testing in the same hospital,,2020-08-01,2020-10-31,Residual sera,All,Multiple groups,,,Primary Estimate,,1062,0.07400000000000001,0.057,0.092,,True,,,True,Sequential,Pylon COVID-19 IgG/IgM assay,ET Healthcare,Other,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.89,1.0,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,Yes,,Matthew A Spinelli,University of California San Francisco,Not Unity-Aligned,https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(21)00072-2/fulltext,2021-05-18,2022-07-16,Unverified,spinelli_sars-cov-2_2021,USA
210430_UnitedStates_MedicalUniversityofSouthCarolina,210430_UnitedStates_MedicalUniversityofSouthCarolina,Comparative Analysis of Antibodies to SARS-CoV-2 between Asymptomatic and Convalescent Patients.,2021-04-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,"South Carolina, North Carolina, Georgia",,"The general population samples were obtained through The Blood Connection, a community blood center in the Southeast. Samples were collected from 687 zip codes from states of South Carolina (534 zip codes, 46 counties), North Carolina (133 zip codes, 56 counties), and GA (20 zip codes, 15 counties). Asymptomatic samples were obtained from both males and females ages 16 to 83.",,2020-05-15,2020-07-15,Blood donors,All,Multiple groups,16.0,83.0,Primary Estimate,Overall blood donors,60835,0.026000000000000002,,,True,,,,True,Sequential,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Author designed (Neutralization Assay)","GenScript,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Connor Dwyer,Medical University of South Carolina,Not Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2021.102489,2021-06-03,2024-03-01,Verified,dwyer_comparative_2021,USA
210430_UnitedStates_MedicalUniversityofSouthCarolina_60-69,210430_UnitedStates_MedicalUniversityofSouthCarolina,Comparative Analysis of Antibodies to SARS-CoV-2 between Asymptomatic and Convalescent Patients.,2021-04-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,"South Carolina, North Carolina, Georgia",,"The general population samples were obtained through The Blood Connection, a community blood center in the Southeast. Samples were collected from 687 zip codes from states of South Carolina (534 zip codes, 46 counties), North Carolina (133 zip codes, 56 counties), and GA (20 zip codes, 15 counties). Asymptomatic samples were obtained from both males and females ages 16 to 83.",,2020-05-15,2020-07-15,Blood donors,All,Multiple groups,60.0,69.0,Age,60-69,10159,0.0211,,,,,,,,Sequential,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Author designed (Neutralization Assay)","GenScript,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Connor Dwyer,Medical University of South Carolina,Not Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2021.102489,2021-11-08,2024-03-01,Verified,dwyer_comparative_2021,USA
210430_UnitedStates_MedicalUniversityofSouthCarolina_70+,210430_UnitedStates_MedicalUniversityofSouthCarolina,Comparative Analysis of Antibodies to SARS-CoV-2 between Asymptomatic and Convalescent Patients.,2021-04-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,"South Carolina, North Carolina, Georgia",,"The general population samples were obtained through The Blood Connection, a community blood center in the Southeast. Samples were collected from 687 zip codes from states of South Carolina (534 zip codes, 46 counties), North Carolina (133 zip codes, 56 counties), and GA (20 zip codes, 15 counties). Asymptomatic samples were obtained from both males and females ages 16 to 83.",,2020-05-15,2020-07-15,Blood donors,All,Seniors (65+ years),70.0,83.0,Age,70+,3528,0.0198,,,,,,,,Sequential,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Author designed (Neutralization Assay)","GenScript,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Connor Dwyer,Medical University of South Carolina,Not Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2021.102489,2021-11-08,2024-03-01,Verified,dwyer_comparative_2021,USA
210430_UnitedStates_MedicalUniversityofSouthCarolina_50-59,210430_UnitedStates_MedicalUniversityofSouthCarolina,Comparative Analysis of Antibodies to SARS-CoV-2 between Asymptomatic and Convalescent Patients.,2021-04-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,"South Carolina, North Carolina, Georgia",,"The general population samples were obtained through The Blood Connection, a community blood center in the Southeast. Samples were collected from 687 zip codes from states of South Carolina (534 zip codes, 46 counties), North Carolina (133 zip codes, 56 counties), and GA (20 zip codes, 15 counties). Asymptomatic samples were obtained from both males and females ages 16 to 83.",,2020-05-15,2020-07-15,Blood donors,All,Adults (18-64 years),50.0,59.0,Age,50-59,13810,0.026600000000000002,,,,,,,,Sequential,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Author designed (Neutralization Assay)","GenScript,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Connor Dwyer,Medical University of South Carolina,Not Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2021.102489,2021-11-08,2024-03-01,Verified,dwyer_comparative_2021,USA
210430_UnitedStates_MedicalUniversityofSouthCarolina_female,210430_UnitedStates_MedicalUniversityofSouthCarolina,Comparative Analysis of Antibodies to SARS-CoV-2 between Asymptomatic and Convalescent Patients.,2021-04-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,"South Carolina, North Carolina, Georgia",,"The general population samples were obtained through The Blood Connection, a community blood center in the Southeast. Samples were collected from 687 zip codes from states of South Carolina (534 zip codes, 46 counties), North Carolina (133 zip codes, 56 counties), and GA (20 zip codes, 15 counties). Asymptomatic samples were obtained from both males and females ages 16 to 83.",,2020-05-15,2020-07-15,Blood donors,Female,Multiple groups,16.0,83.0,Sex/Gender,,33946,0.026400000000000003,,,,,,,,Sequential,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Author designed (Neutralization Assay)","GenScript,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Connor Dwyer,Medical University of South Carolina,Not Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2021.102489,2021-11-08,2024-03-01,Verified,dwyer_comparative_2021,USA
210430_UnitedStates_MedicalUniversityofSouthCarolina_<30,210430_UnitedStates_MedicalUniversityofSouthCarolina,Comparative Analysis of Antibodies to SARS-CoV-2 between Asymptomatic and Convalescent Patients.,2021-04-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,"South Carolina, North Carolina, Georgia",,"The general population samples were obtained through The Blood Connection, a community blood center in the Southeast. Samples were collected from 687 zip codes from states of South Carolina (534 zip codes, 46 counties), North Carolina (133 zip codes, 56 counties), and GA (20 zip codes, 15 counties). Asymptomatic samples were obtained from both males and females ages 16 to 83.",,2020-05-15,2020-07-15,Blood donors,All,Multiple groups,16.0,29.0,Age,<30,10220,0.0378,,,,,,,,Sequential,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Author designed (Neutralization Assay)","GenScript,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Connor Dwyer,Medical University of South Carolina,Not Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2021.102489,2021-11-08,2024-03-01,Verified,dwyer_comparative_2021,USA
210430_UnitedStates_MedicalUniversityofSouthCarolina_30-39,210430_UnitedStates_MedicalUniversityofSouthCarolina,Comparative Analysis of Antibodies to SARS-CoV-2 between Asymptomatic and Convalescent Patients.,2021-04-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,"South Carolina, North Carolina, Georgia",,"The general population samples were obtained through The Blood Connection, a community blood center in the Southeast. Samples were collected from 687 zip codes from states of South Carolina (534 zip codes, 46 counties), North Carolina (133 zip codes, 56 counties), and GA (20 zip codes, 15 counties). Asymptomatic samples were obtained from both males and females ages 16 to 83.",,2020-05-15,2020-07-15,Blood donors,All,Adults (18-64 years),30.0,39.0,Age,30-39,10950,0.024700000000000003,,,,,,,,Sequential,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Author designed (Neutralization Assay)","GenScript,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Connor Dwyer,Medical University of South Carolina,Not Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2021.102489,2021-11-08,2024-03-01,Verified,dwyer_comparative_2021,USA
210430_UnitedStates_MedicalUniversityofSouthCarolina_male,210430_UnitedStates_MedicalUniversityofSouthCarolina,Comparative Analysis of Antibodies to SARS-CoV-2 between Asymptomatic and Convalescent Patients.,2021-04-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,"South Carolina, North Carolina, Georgia",,"The general population samples were obtained through The Blood Connection, a community blood center in the Southeast. Samples were collected from 687 zip codes from states of South Carolina (534 zip codes, 46 counties), North Carolina (133 zip codes, 56 counties), and GA (20 zip codes, 15 counties). Asymptomatic samples were obtained from both males and females ages 16 to 83.",,2020-05-15,2020-07-15,Blood donors,Male,Multiple groups,16.0,83.0,Sex/Gender,,26889,0.0255,,,,,,,,Sequential,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Author designed (Neutralization Assay)","GenScript,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Connor Dwyer,Medical University of South Carolina,Not Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2021.102489,2021-11-08,2024-03-01,Verified,dwyer_comparative_2021,USA
210430_UnitedStates_MedicalUniversityofSouthCarolina_40-49,210430_UnitedStates_MedicalUniversityofSouthCarolina,Comparative Analysis of Antibodies to SARS-CoV-2 between Asymptomatic and Convalescent Patients.,2021-04-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,"South Carolina, North Carolina, Georgia",,"The general population samples were obtained through The Blood Connection, a community blood center in the Southeast. Samples were collected from 687 zip codes from states of South Carolina (534 zip codes, 46 counties), North Carolina (133 zip codes, 56 counties), and GA (20 zip codes, 15 counties). Asymptomatic samples were obtained from both males and females ages 16 to 83.",,2020-05-15,2020-07-15,Blood donors,All,Adults (18-64 years),40.0,49.0,Age,40-49,12106,0.0227,,,,,,,,Sequential,"cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Author designed (Neutralization Assay)","GenScript,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM', 'Neutralizing']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Connor Dwyer,Medical University of South Carolina,Not Unity-Aligned,https://dx.doi.org/10.1016/j.isci.2021.102489,2021-11-08,2024-03-01,Verified,dwyer_comparative_2021,USA
210430_Baltimore_JohnsHopkinsUniversity_Overall,210430_Baltimore_JohnsHopkinsUniversity,Demographic and clinical correlates of acute and convalescent SARS-CoV-2 infection among patients of a U.S. emergency department.,2021-04-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Maryland,Baltimore,all available remnant blood from hema-tology samples from ED patients aged >17 years were collected duringthe study period.,,2020-03-16,2020-05-31,Residual sera,All,Multiple groups,18.0,,Primary Estimate,Overall,3255,0.035,0.028999999999999998,0.042,True,,,,True,Sequential,"RightSign COVID-19 IgG/IgM Rapid Test Cassette,Anti-SARS-CoV-2 ELISA IgG","Hangzhou Biotest Biotech Co. Ltd,EUROIMMUN",Multiple Types,Plasma,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.84,1.0,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Oliver Laeyendecker,Johns Hopkins University ,Unity-Aligned,https://dx.doi.org/10.1016/j.ajem.2021.04.081,2021-06-01,2024-03-01,Verified,laeyendecker_demographic_2021,USA
210430_Baltimore_JohnsHopkinsUniversity_45-64,210430_Baltimore_JohnsHopkinsUniversity,Demographic and clinical correlates of acute and convalescent SARS-CoV-2 infection among patients of a U.S. emergency department.,2021-04-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Maryland,Baltimore,all available remnant blood from hema-tology samples from ED patients aged >17 years were collected duringthe study period.,,2020-03-16,2020-05-31,Residual sera,All,Adults (18-64 years),45.0,64.0,Age,Age 45-64,1162,0.041299999999999996,,,,,,,,Sequential,"RightSign COVID-19 IgG/IgM Rapid Test Cassette,Anti-SARS-CoV-2 ELISA IgG","Hangzhou Biotest Biotech Co. Ltd,EUROIMMUN",Multiple Types,Plasma,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.84,1.0,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Oliver Laeyendecker,Johns Hopkins University ,Unity-Aligned,https://dx.doi.org/10.1016/j.ajem.2021.04.081,2021-08-30,2024-03-01,Verified,laeyendecker_demographic_2021,USA
210430_Baltimore_JohnsHopkinsUniversity_18-44,210430_Baltimore_JohnsHopkinsUniversity,Demographic and clinical correlates of acute and convalescent SARS-CoV-2 infection among patients of a U.S. emergency department.,2021-04-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Maryland,Baltimore,all available remnant blood from hema-tology samples from ED patients aged >17 years were collected duringthe study period.,,2020-03-16,2020-05-31,Residual sera,All,Adults (18-64 years),18.0,44.0,Age,Age 18-44,1522,0.028300000000000002,,,,,,,,Sequential,"RightSign COVID-19 IgG/IgM Rapid Test Cassette,Anti-SARS-CoV-2 ELISA IgG","Hangzhou Biotest Biotech Co. Ltd,EUROIMMUN",Multiple Types,Plasma,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.84,1.0,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Oliver Laeyendecker,Johns Hopkins University ,Unity-Aligned,https://dx.doi.org/10.1016/j.ajem.2021.04.081,2021-08-30,2024-03-01,Verified,laeyendecker_demographic_2021,USA
210430_Baltimore_JohnsHopkinsUniversity_65+,210430_Baltimore_JohnsHopkinsUniversity,Demographic and clinical correlates of acute and convalescent SARS-CoV-2 infection among patients of a U.S. emergency department.,2021-04-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Maryland,Baltimore,all available remnant blood from hema-tology samples from ED patients aged >17 years were collected duringthe study period.,,2020-03-16,2020-05-31,Residual sera,All,Seniors (65+ years),65.0,,Age,Age 65+,568,0.038700000000000005,,,,,,,,Sequential,"RightSign COVID-19 IgG/IgM Rapid Test Cassette,Anti-SARS-CoV-2 ELISA IgG","Hangzhou Biotest Biotech Co. Ltd,EUROIMMUN",Multiple Types,Plasma,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.84,1.0,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Oliver Laeyendecker,Johns Hopkins University ,Unity-Aligned,https://dx.doi.org/10.1016/j.ajem.2021.04.081,2021-08-30,2024-03-01,Verified,laeyendecker_demographic_2021,USA
210430_StLouis_WashingtonUniversityinStLouis_Overall,210430_StLouis_WashingtonUniversityinStLouis,Limited Diagnostic Utility of SARS-CoV2 Serologic Testing in Symptomatic PCR Negative Patients,2021-04-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Missouri,St. Louis,"Patients presenting to the Barnes Jewish Hospital ED between August 29, 2020 and September 19, 2020 who tested negative for SARS-COV-2 RNA by nasopharyngeal swab collected within 4 hours of presentation. Patients were tested for SARS-CoV-2 RNA due to clinical suspicion for COVID-19 or as a standard of care screen for hospital admission",those who tested positive for SARS-COV-2 RNA by nasopharyngeal swab collected within 4 hours of presentation.,2020-08-29,2020-09-19,Residual sera,All,Multiple groups,,,Primary Estimate,,393,0.036000000000000004,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,,,,,['High'],No,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Kwaku Tawiah,Washington University in St. Louis,Not Unity-Aligned,https://doi.org/10.1093/jalm/jfab021,2021-11-30,2024-03-01,Verified,tawiah_limited_2021,USA
210501_Ithaca_CornellUniversity_Primary_AntiRBD,210501_Ithaca_CornellUniversity,Development of a quantitative COVID-19 Multiplex Assay and its use for serological surveillance in a low SARS-CoV-2 incidence community,2021-05-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,Ithaca,Healthy at the time of testing,,2020-06-01,2020-06-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,332,0.051,,,True,,,,True,Unclear,Author designed (type unknown),,,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,,,['High'],,Unclear,No,No,,Unclear,Yes,No,,Cassandra Guarino,Cornell University,Not Unity-Aligned,https://www.jimmunol.org/content/206/1_Supplement/114.11?ct=&utm_source=TrendMD&utm_medium=cpc&utm_campaign=J_Immunol_TrendMD_1,2021-12-08,2022-07-16,Unverified,cassandra_m_guarino_development_2020,USA
210501_Ithaca_CornellUniversity_AntiN,210501_Ithaca_CornellUniversity,Development of a quantitative COVID-19 Multiplex Assay and its use for serological surveillance in a low SARS-CoV-2 incidence community,2021-05-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,Ithaca,Healthy at the time of testing,,2020-06-01,2020-06-15,Household and community samples,All,Multiple groups,,,Test used,Anti-nucleocapsid,332,0.012,,,,,,,,Unclear,Author designed (type unknown),,,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by developers,,,['High'],,Unclear,No,No,,Unclear,Yes,No,,Cassandra Guarino,Cornell University,Not Unity-Aligned,https://www.jimmunol.org/content/206/1_Supplement/114.11?ct=&utm_source=TrendMD&utm_medium=cpc&utm_campaign=J_Immunol_TrendMD_1,2021-12-08,2022-07-16,Unverified,cassandra_m_guarino_development_2020,USA
210503_USA_HIV_ClinicalReferenceLaboratory,210503_USA_HIV_ClinicalReferenceLaboratory,HIV and the Seroprevalence of SARS-CoV-2,2021-05-03,Preprint,National,Cross-sectional survey ,United States of America,,,"A national adult convenience sample of self reported healthy life insurance applicants. For HIV-positive applicants to be considered for life insurance, they generally must meet current treatment guidelines, have undetectable viral loads, have been
on high-activity antiviral therapy (HAART) for several years, have a CD-4 lymphocyte count greater than 300-500 cell/microliter and have no other significant comorbidities.",,2020-01-01,2021-03-31,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),,,Primary Estimate,,1191,0.128,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Robert Stout,Clinical Reference Laboratory ,Not Unity-Aligned,10.1101/2021.04.29.21256302,2021-06-07,2024-03-01,Verified,Stout_hiv_2021,USA
210504_DallasTexas_UniversityofTexasSouthwestern,210504_DallasTexas_UniversityofTexasSouthwestern,Childcare providers anxiety levels and SARS-CoV- 2 testing,2021-05-04,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,,Dallas,Childcare providers at a city funded center focusing on homeless children ,,2020-10-01,2020-11-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,37,0.0,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,,IgG,,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Lauren Diercks,University of Texas Southwestern,Not Unity-Aligned,http://dx.doi.org/10.1111/acem.14249 ,2021-06-07,2024-03-01,Unverified,Diercks_childcare_2021,USA
210504_Texas_UniversityofTexasSouthwestern,210504_Texas_UniversityofTexasSouthwestern,Front line provider risk for SARS-CoV- 2 over time in an urban county,2021-05-04,Presentation or Conference,Local,Cross-sectional survey ,United States of America,Texas,Dallas,"Urban emergency medical services (EMS) and ED providers (HCP) 

Participants were volunteers from local hospitals and EMS agencies.",,2020-06-01,2020-08-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Emergency medical services and emergency department providers.,549,0.032799999999999996,,,True,,,,True,Self-referral,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,,IgG,,,,,['High'],Unclear,No,No,No,No,Yes,Yes,Yes,Unclear,Gilberto Salazar,University of Texas Southwestern,Not Unity-Aligned,http://dx.doi.org/10.1111/acem.14249,2021-06-05,2024-03-01,Verified,salazar_front_2021,USA
210405_California_StanfordUniversitySchoolofMedicine_overall,210405_California_StanfordUniversitySchoolofMedicine,SARS-CoV-2 IgG Seropositivity and Acute Asymptomatic Infection Rate Among Firefighter First Responders in an Early Outbreak County in California,2021-05-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,"clinically active firefighters cross-trained as paramedics or EMTs in the fire departments of Santa Clara County, California.",We excluded the single fire department staffed by cross-trained public safety officers who do not work as paramedics.,2020-06-15,2020-08-15,Essential non-healthcare workers,All,Adults (18-64 years),18.0,,Primary Estimate,,983,0.025400000000000002,0.0165,0.0373,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG,Author designed (ELISA) -Spike","Abbott Laboratories,EUROIMMUN,NA",Multiple Types,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Jennifer Newberry,Stanford University,Not Unity-Aligned,http://dx.doi.org/10.1080/10903127.2021.1912227,2021-05-02,2024-03-01,Verified,newberry_sars-cov-2_2021,USA
210506_Boston_BostonMedicalCenter_Overall,210506_Boston_BostonMedicalCenter,"Seroprevalence of SARS-CoV-2 IgG antibodies and risk factors in health care workers at an academic medical center in Boston, Massachusetts.",2021-05-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Massachusetts,Boston,"Eligible participants worked at BMC during the initial COVID-19 surge at BMC (March 13th to May 31st, 2020). Eligible HCWs were at least 18 years old and worked physically on the BMC campus during the study period.",,2020-07-13,2020-07-26,Health care workers and caregivers,All,Multiple groups,18.0,,Primary Estimate,,1743,0.0545,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Yachana Kataria,Boston Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89107-5,2021-05-27,2024-03-01,Verified,kataria_seroprevalence_2021,USA
210506_Boston_BostonMedicalCenter_Age40-49,210506_Boston_BostonMedicalCenter,"Seroprevalence of SARS-CoV-2 IgG antibodies and risk factors in health care workers at an academic medical center in Boston, Massachusetts.",2021-05-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Massachusetts,Boston,"Eligible participants worked at BMC during the initial COVID-19 surge at BMC (March 13th to May 31st, 2020). Eligible HCWs were at least 18 years old and worked physically on the BMC campus during the study period.",,2020-07-13,2020-07-26,Health care workers and caregivers,All,Adults (18-64 years),40.0,49.0,Age,,322,0.0466,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Yachana Kataria,Boston Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89107-5,2022-02-02,2024-03-01,Verified,kataria_seroprevalence_2021,USA
210506_Boston_BostonMedicalCenter_Age60-69,210506_Boston_BostonMedicalCenter,"Seroprevalence of SARS-CoV-2 IgG antibodies and risk factors in health care workers at an academic medical center in Boston, Massachusetts.",2021-05-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Massachusetts,Boston,"Eligible participants worked at BMC during the initial COVID-19 surge at BMC (March 13th to May 31st, 2020). Eligible HCWs were at least 18 years old and worked physically on the BMC campus during the study period.",,2020-07-13,2020-07-26,Health care workers and caregivers,All,Seniors (65+ years),60.0,69.0,Age,,155,0.0323,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Yachana Kataria,Boston Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89107-5,2022-02-02,2024-03-01,Verified,kataria_seroprevalence_2021,USA
210506_Boston_BostonMedicalCenter_Age30-39,210506_Boston_BostonMedicalCenter,"Seroprevalence of SARS-CoV-2 IgG antibodies and risk factors in health care workers at an academic medical center in Boston, Massachusetts.",2021-05-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Massachusetts,Boston,"Eligible participants worked at BMC during the initial COVID-19 surge at BMC (March 13th to May 31st, 2020). Eligible HCWs were at least 18 years old and worked physically on the BMC campus during the study period.",,2020-07-13,2020-07-26,Health care workers and caregivers,All,Adults (18-64 years),30.0,39.0,Age,,534,0.0412,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Yachana Kataria,Boston Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89107-5,2022-02-02,2024-03-01,Verified,kataria_seroprevalence_2021,USA
210506_Boston_BostonMedicalCenter_Age50-59,210506_Boston_BostonMedicalCenter,"Seroprevalence of SARS-CoV-2 IgG antibodies and risk factors in health care workers at an academic medical center in Boston, Massachusetts.",2021-05-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Massachusetts,Boston,"Eligible participants worked at BMC during the initial COVID-19 surge at BMC (March 13th to May 31st, 2020). Eligible HCWs were at least 18 years old and worked physically on the BMC campus during the study period.",,2020-07-13,2020-07-26,Health care workers and caregivers,All,Adults (18-64 years),50.0,59.0,Age,,294,0.068,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Yachana Kataria,Boston Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89107-5,2022-02-02,2024-03-01,Verified,kataria_seroprevalence_2021,USA
210506_Boston_BostonMedicalCenter_Age<20,210506_Boston_BostonMedicalCenter,"Seroprevalence of SARS-CoV-2 IgG antibodies and risk factors in health care workers at an academic medical center in Boston, Massachusetts.",2021-05-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Massachusetts,Boston,"Eligible participants worked at BMC during the initial COVID-19 surge at BMC (March 13th to May 31st, 2020). Eligible HCWs were at least 18 years old and worked physically on the BMC campus during the study period.",,2020-07-13,2020-07-26,Health care workers and caregivers,All,Adults (18-64 years),18.0,19.0,Age,<20,93,0.172,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Yachana Kataria,Boston Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89107-5,2022-02-02,2024-03-01,Verified,kataria_seroprevalence_2021,USA
210506_Boston_BostonMedicalCenter_Age20-29,210506_Boston_BostonMedicalCenter,"Seroprevalence of SARS-CoV-2 IgG antibodies and risk factors in health care workers at an academic medical center in Boston, Massachusetts.",2021-05-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Massachusetts,Boston,"Eligible participants worked at BMC during the initial COVID-19 surge at BMC (March 13th to May 31st, 2020). Eligible HCWs were at least 18 years old and worked physically on the BMC campus during the study period.",,2020-07-13,2020-07-26,Health care workers and caregivers,All,Adults (18-64 years),20.0,29.0,Age,20-29,334,0.0509,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Yachana Kataria,Boston Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89107-5,2022-02-02,2024-03-01,Verified,kataria_seroprevalence_2021,USA
210506_Boston_BostonMedicalCenter_Age70+,210506_Boston_BostonMedicalCenter,"Seroprevalence of SARS-CoV-2 IgG antibodies and risk factors in health care workers at an academic medical center in Boston, Massachusetts.",2021-05-06,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Massachusetts,Boston,"Eligible participants worked at BMC during the initial COVID-19 surge at BMC (March 13th to May 31st, 2020). Eligible HCWs were at least 18 years old and worked physically on the BMC campus during the study period.",,2020-07-13,2020-07-26,Health care workers and caregivers,All,Seniors (65+ years),70.0,,Age,,11,0.0,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Yachana Kataria,Boston Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-89107-5,2022-02-02,2024-03-01,Verified,kataria_seroprevalence_2021,USA
210508_NorthCarolina_FirstHealthoftheCarolinas_Overall,210508_NorthCarolina_FirstHealthoftheCarolinas,SARS-CoV2 Antibody Positivity Rates and Employee Expectations of Positivity Rates among Health Care Workers at a Community Hospital in North Carolina.,2021-05-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,All health system employees and associated clinical staff over the age of 18 were eligible to participate.,,2020-06-10,2020-07-17,Health care workers and caregivers,All,Multiple groups,18.0,66.0,Primary Estimate,,2076,0.03,0.019,0.033,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,,,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,GS Arnoczy,FirstHealth of the Carolinas,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ajic.2021.04.086,2021-05-28,2024-03-01,Unverified,arnoczy_sars-cov2_2021,USA
210510_Chicago_NorthwesternUniversity_Overall,210510_Chicago_NorthwesternUniversity,Patterns and persistence of SARS-CoV-2 IgG antibodies in Chicago to monitor COVID-19 exposure,2021-05-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Illinois,Chicago,Participants were screened for eligibility (zip code and demographics or affiliation to Northwestern).,,2020-06-24,2020-12-15,Multiple populations,All,Multiple groups,18.0,,Primary Estimate,Overall,7935,0.179,,,,,,,,Unclear,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,Validated by developers,,,['High'],,Unclear,Yes,Yes,,Unclear,Yes,No,,Alexis R Demonbreun,Northwestern University,Not Unity-Aligned,https://dx.doi.org/10.1172/jci.insight.146148,2021-05-22,2022-07-16,Unverified,demonbreun_patterns_2021,USA
210519_UnitedStates_QuestDiagnostics,210519_UnitedStates_QuestDiagnostics,Assessment of the Association of Vitamin D Level With SARS-CoV-2 Seropositivity Among Working-Age Adults.,2021-05-19,Journal Article (Peer-Reviewed),National,Prospective cohort,United States of America,,,"Participants are eligible for a reduced-cost employer-sponsored health plan. The annual screening program collects biometric (body mass index [BMI; calculated as weight in kilograms divided by height in meters squared], waist circumference, and blood pressure), demographic (sex, age, race/ethnicity, and state of residence), and laboratory testing (eg, lipid panel and total vitamin D) data. In 2020, participants could also opt in to be tested for SARS-CoV-2 IgG. All tests were conducted at the Quest Diagnostics laboratories, and the test results were not linked to other databases such as electronic health records. The analysis included results from participants who opted to be tested for SARS-CoV-2 IgG during the 2020 screening event, conducted in August 2020 to November 2020 (pandemic period), and had also participated in the previous year’s screening program, conducted in September 2019 to January 2020 (ie, prepandemic baseline). ",,2020-08-15,2020-11-15,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,Overall,18148,0.05,,,True,,,,True,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Abbott Architect SARS-CoV-2 IgG","Ortho Clinical Diagnostics Inc.,Abbott Laboratories",CLIA,Serum,IgG,,Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Yonghong Li,Quest Diagnostics,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.11634,2021-06-03,2024-03-01,Verified,li_assessment_2021,USA
210524_LosAngelesCounty_LosAngelesCountyDepartmentofPublicHealth_Residents1,210524_LosAngelesCounty_LosAngelesCountyDepartmentofPublicHealth_Residents1,"Seroprevalence of SARS-CoV-2 Among Skilled Nursing Facility Residents and Staff Members - Los Angeles County, August-September 2020.",2021-05-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,California,,"From August 18 to September 24, 2020, DPH nursing teams were deployed to obtain from residents and staff at the 24 SNFs nasopharyngeal (NP) swab specimen for SARS-CoV-2 PCR testing and serum for detection of IgG antibodies against SARS-CoV-2","Informed verbal consent was obtained from all participants; persons who did not have capacity to provide verbal consent were excluded 
from participation",2020-08-18,2020-09-24,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,Nursing facility Residents,1806,0.25,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Jason Malenfant,Los Angeles County Department of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab281,2021-06-07,2024-03-01,Unverified,jasonh.malenfantSeroprevalenceSARSCoV2Skilled2021,USA
210524_LosAngelesCounty_LosAngelesCountyDepartmentofPublicHealth_Staff2,210524_LosAngelesCounty_LosAngelesCountyDepartmentofPublicHealth_Staff2,"Seroprevalence of SARS-CoV-2 Among Skilled Nursing Facility Residents and Staff Members - Los Angeles County, August-September 2020.",2021-05-24,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,California,,"From August 18 to September 24, 2020, DPH nursing teams were deployed to obtain from residents and staff at the 24 SNFs nasopharyngeal (NP) swab specimen for SARS-CoV-2 PCR testing and serum for detection of IgG antibodies against SARS-CoV-2","Informed verbal consent was obtained from all participants; persons who did not have capacity to provide verbal consent were excluded 
from participation",2020-08-18,2020-09-24,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,Nursing Facility Staff,856,0.4,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Multiple Types,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Jason Malenfant,Los Angeles County Department of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab281,2021-06-07,2024-03-01,Unverified,jasonh.malenfantSeroprevalenceSARSCoV2Skilled2021,USA
210525_UnitedStates_RutgersUniversity_Primary,210525_UnitedStates_RutgersUniversity,A Nationwide Survey of COVID-19 Testing in LGBTQ+ Populations in the United States.,2021-05-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Participants were eligible if they were aged ≥18, lived in the United States or in a US territory, and identified as LGBTQ+. We asked participants to self-report sex assigned at birth, gender identity, and sexual orientation. ","Using best practices of a 2-step approach to collect data on gender, we excluded participants who were cisgender and heterosexual.",2020-05-07,2020-07-31,Household and community samples,All,Multiple groups,,,Primary Estimate,LGBTQ+ community,124,0.363,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],No,No,No,No,No,Unclear,Yes,No,No,Richard Martino,Rutgers University,Not Unity-Aligned,https://dx.doi.org/10.1177/00333549211018190,2021-06-05,2022-07-16,Verified,richardj.martinoNationwideSurveyCOVID192021,USA
210525_UnitedStates_RutgersUniversity_Female,210525_UnitedStates_RutgersUniversity,A Nationwide Survey of COVID-19 Testing in LGBTQ+ Populations in the United States.,2021-05-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Participants were eligible if they were aged ≥18, lived in the United States or in a US territory, and identified as LGBTQ+. We asked participants to self-report sex assigned at birth, gender identity, and sexual orientation. ","Using best practices of a 2-step approach to collect data on gender, we excluded participants who were cisgender and heterosexual.",2020-05-07,2020-07-31,Household and community samples,Female,Multiple groups,,,Sex/Gender,Male,29,0.3448,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],No,No,No,No,No,Unclear,Yes,No,No,Richard Martino,Rutgers University,Not Unity-Aligned,https://dx.doi.org/10.1177/00333549211018190,2021-07-28,2022-07-16,Verified,richardj.martinoNationwideSurveyCOVID192021,USA
210525_UnitedStates_RutgersUniversity_Northeast,210525_UnitedStates_RutgersUniversity,A Nationwide Survey of COVID-19 Testing in LGBTQ+ Populations in the United States.,2021-05-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Participants were eligible if they were aged ≥18, lived in the United States or in a US territory, and identified as LGBTQ+. We asked participants to self-report sex assigned at birth, gender identity, and sexual orientation. ","Using best practices of a 2-step approach to collect data on gender, we excluded participants who were cisgender and heterosexual.",2020-05-07,2020-07-31,Household and community samples,All,Multiple groups,,,Geographical area,US Region (Northeast),83,0.3494,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],No,No,No,No,No,Unclear,Yes,No,No,Richard Martino,Rutgers University,Not Unity-Aligned,https://dx.doi.org/10.1177/00333549211018190,2021-07-28,2022-07-16,Verified,richardj.martinoNationwideSurveyCOVID192021,USA
210525_UnitedStates_RutgersUniversity_South,210525_UnitedStates_RutgersUniversity,A Nationwide Survey of COVID-19 Testing in LGBTQ+ Populations in the United States.,2021-05-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Participants were eligible if they were aged ≥18, lived in the United States or in a US territory, and identified as LGBTQ+. We asked participants to self-report sex assigned at birth, gender identity, and sexual orientation. ","Using best practices of a 2-step approach to collect data on gender, we excluded participants who were cisgender and heterosexual.",2020-05-07,2020-07-31,Household and community samples,All,Multiple groups,,,Geographical area,US Region (South),11,0.1818,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],No,No,No,No,No,Unclear,Yes,No,No,Richard Martino,Rutgers University,Not Unity-Aligned,https://dx.doi.org/10.1177/00333549211018190,2021-07-28,2022-07-16,Verified,richardj.martinoNationwideSurveyCOVID192021,USA
210525_UnitedStates_RutgersUniversity_30-39,210525_UnitedStates_RutgersUniversity,A Nationwide Survey of COVID-19 Testing in LGBTQ+ Populations in the United States.,2021-05-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Participants were eligible if they were aged ≥18, lived in the United States or in a US territory, and identified as LGBTQ+. We asked participants to self-report sex assigned at birth, gender identity, and sexual orientation. ","Using best practices of a 2-step approach to collect data on gender, we excluded participants who were cisgender and heterosexual.",2020-05-07,2020-07-31,Household and community samples,All,Adults (18-64 years),,,Age,,38,0.3421,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],No,No,No,No,No,Unclear,Yes,No,No,Richard Martino,Rutgers University,Not Unity-Aligned,https://dx.doi.org/10.1177/00333549211018190,2021-07-28,2022-07-16,Verified,richardj.martinoNationwideSurveyCOVID192021,USA
210525_UnitedStates_RutgersUniversity_Midwest,210525_UnitedStates_RutgersUniversity,A Nationwide Survey of COVID-19 Testing in LGBTQ+ Populations in the United States.,2021-05-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Participants were eligible if they were aged ≥18, lived in the United States or in a US territory, and identified as LGBTQ+. We asked participants to self-report sex assigned at birth, gender identity, and sexual orientation. ","Using best practices of a 2-step approach to collect data on gender, we excluded participants who were cisgender and heterosexual.",2020-05-07,2020-07-31,Household and community samples,All,Multiple groups,,,Geographical area,US Region (Midwest),13,0.5385,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],No,No,No,No,No,Unclear,Yes,No,No,Richard Martino,Rutgers University,Not Unity-Aligned,https://dx.doi.org/10.1177/00333549211018190,2021-07-28,2022-07-16,Verified,richardj.martinoNationwideSurveyCOVID192021,USA
210525_UnitedStates_RutgersUniversity_Noncontiguous,210525_UnitedStates_RutgersUniversity,A Nationwide Survey of COVID-19 Testing in LGBTQ+ Populations in the United States.,2021-05-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Participants were eligible if they were aged ≥18, lived in the United States or in a US territory, and identified as LGBTQ+. We asked participants to self-report sex assigned at birth, gender identity, and sexual orientation. ","Using best practices of a 2-step approach to collect data on gender, we excluded participants who were cisgender and heterosexual.",2020-05-07,2020-07-31,Household and community samples,All,Multiple groups,,,Geographical area,US Region (Noncontiguous),2,1.0,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],No,No,No,No,No,Unclear,Yes,No,No,Richard Martino,Rutgers University,Not Unity-Aligned,https://dx.doi.org/10.1177/00333549211018190,2021-07-28,2022-07-16,Verified,richardj.martinoNationwideSurveyCOVID192021,USA
210525_UnitedStates_RutgersUniversity_TransgenderAndNon-Binary,210525_UnitedStates_RutgersUniversity,A Nationwide Survey of COVID-19 Testing in LGBTQ+ Populations in the United States.,2021-05-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Participants were eligible if they were aged ≥18, lived in the United States or in a US territory, and identified as LGBTQ+. We asked participants to self-report sex assigned at birth, gender identity, and sexual orientation. ","Using best practices of a 2-step approach to collect data on gender, we excluded participants who were cisgender and heterosexual.",2020-05-07,2020-07-31,Household and community samples,Other,Multiple groups,,,Sex/Gender,Non-Binary,21,0.23809999999999998,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],No,No,No,No,No,Unclear,Yes,No,No,Richard Martino,Rutgers University,Not Unity-Aligned,https://dx.doi.org/10.1177/00333549211018190,2021-07-28,2022-07-16,Verified,richardj.martinoNationwideSurveyCOVID192021,USA
210525_UnitedStates_RutgersUniversity_50+,210525_UnitedStates_RutgersUniversity,A Nationwide Survey of COVID-19 Testing in LGBTQ+ Populations in the United States.,2021-05-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Participants were eligible if they were aged ≥18, lived in the United States or in a US territory, and identified as LGBTQ+. We asked participants to self-report sex assigned at birth, gender identity, and sexual orientation. ","Using best practices of a 2-step approach to collect data on gender, we excluded participants who were cisgender and heterosexual.",2020-05-07,2020-07-31,Household and community samples,All,Multiple groups,,,Age,,27,0.2593,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],No,No,No,No,No,Unclear,Yes,No,No,Richard Martino,Rutgers University,Not Unity-Aligned,https://dx.doi.org/10.1177/00333549211018190,2021-07-28,2022-07-16,Verified,richardj.martinoNationwideSurveyCOVID192021,USA
210525_UnitedStates_RutgersUniversity_40-49,210525_UnitedStates_RutgersUniversity,A Nationwide Survey of COVID-19 Testing in LGBTQ+ Populations in the United States.,2021-05-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Participants were eligible if they were aged ≥18, lived in the United States or in a US territory, and identified as LGBTQ+. We asked participants to self-report sex assigned at birth, gender identity, and sexual orientation. ","Using best practices of a 2-step approach to collect data on gender, we excluded participants who were cisgender and heterosexual.",2020-05-07,2020-07-31,Household and community samples,All,Adults (18-64 years),,,Age,,19,0.2632,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],No,No,No,No,No,Unclear,Yes,No,No,Richard Martino,Rutgers University,Not Unity-Aligned,https://dx.doi.org/10.1177/00333549211018190,2021-07-28,2022-07-16,Verified,richardj.martinoNationwideSurveyCOVID192021,USA
210525_UnitedStates_RutgersUniversity_Mountain,210525_UnitedStates_RutgersUniversity,A Nationwide Survey of COVID-19 Testing in LGBTQ+ Populations in the United States.,2021-05-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Participants were eligible if they were aged ≥18, lived in the United States or in a US territory, and identified as LGBTQ+. We asked participants to self-report sex assigned at birth, gender identity, and sexual orientation. ","Using best practices of a 2-step approach to collect data on gender, we excluded participants who were cisgender and heterosexual.",2020-05-07,2020-07-31,Household and community samples,All,Multiple groups,,,Geographical area,US Region (Mountain),7,0.2857,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],No,No,No,No,No,Unclear,Yes,No,No,Richard Martino,Rutgers University,Not Unity-Aligned,https://dx.doi.org/10.1177/00333549211018190,2021-07-28,2022-07-16,Verified,richardj.martinoNationwideSurveyCOVID192021,USA
210525_UnitedStates_RutgersUniversity_Pacific,210525_UnitedStates_RutgersUniversity,A Nationwide Survey of COVID-19 Testing in LGBTQ+ Populations in the United States.,2021-05-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Participants were eligible if they were aged ≥18, lived in the United States or in a US territory, and identified as LGBTQ+. We asked participants to self-report sex assigned at birth, gender identity, and sexual orientation. ","Using best practices of a 2-step approach to collect data on gender, we excluded participants who were cisgender and heterosexual.",2020-05-07,2020-07-31,Household and community samples,All,Multiple groups,,,Geographical area,US Region (Pacific),8,0.375,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],No,No,No,No,No,Unclear,Yes,No,No,Richard Martino,Rutgers University,Not Unity-Aligned,https://dx.doi.org/10.1177/00333549211018190,2021-07-28,2022-07-16,Verified,richardj.martinoNationwideSurveyCOVID192021,USA
210525_UnitedStates_RutgersUniversity_Male,210525_UnitedStates_RutgersUniversity,A Nationwide Survey of COVID-19 Testing in LGBTQ+ Populations in the United States.,2021-05-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Participants were eligible if they were aged ≥18, lived in the United States or in a US territory, and identified as LGBTQ+. We asked participants to self-report sex assigned at birth, gender identity, and sexual orientation. ","Using best practices of a 2-step approach to collect data on gender, we excluded participants who were cisgender and heterosexual.",2020-05-07,2020-07-31,Household and community samples,Male,Multiple groups,,,Sex/Gender,Female,74,0.4054,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],No,No,No,No,No,Unclear,Yes,No,No,Richard Martino,Rutgers University,Not Unity-Aligned,https://dx.doi.org/10.1177/00333549211018190,2021-07-28,2022-07-16,Verified,richardj.martinoNationwideSurveyCOVID192021,USA
210525_UnitedStates_RutgersUniversity_18-29,210525_UnitedStates_RutgersUniversity,A Nationwide Survey of COVID-19 Testing in LGBTQ+ Populations in the United States.,2021-05-25,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Participants were eligible if they were aged ≥18, lived in the United States or in a US territory, and identified as LGBTQ+. We asked participants to self-report sex assigned at birth, gender identity, and sexual orientation. ","Using best practices of a 2-step approach to collect data on gender, we excluded participants who were cisgender and heterosexual.",2020-05-07,2020-07-31,Household and community samples,All,Adults (18-64 years),,,Age,,40,0.5,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],No,No,No,No,No,Unclear,Yes,No,No,Richard Martino,Rutgers University,Not Unity-Aligned,https://dx.doi.org/10.1177/00333549211018190,2021-07-28,2022-07-16,Verified,richardj.martinoNationwideSurveyCOVID192021,USA
210527_NewYorkCity_HospitalForSpecialSurgery_overall,210527_NewYorkCity_HospitalForSpecialSurgery,Coronavirus Disease 2019 Exposure in Surgeons and Anesthesiologists at a New York City Specialty Hospital; A Cross-Sectional Study of Symptoms and SARS-CoV-2 Antibody Status,2021-05-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"A recruitment email was sent to all attending surgeons, anesthesiologists, and trainees in both departments (orthopedic surgery fellows, anesthesiology fellows, and orthopedic surgery residents) as identified via an institutional listserv. Inclusion criteria were defined as: a positive response to the recruitment invitation, completion of the survey, and/or scheduling an appointment for serology testing. Only those participants who completed both the survey and serology testing were included in the analyses.",,2020-05-06,2020-06-05,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,143,0.09789999999999999,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Whole Blood,IgG,,Validated by independent authors/third party/non-developers,,,['High'],No,No,No,Yes,Yes,Yes,Yes,Yes,No,Ellen Soffin,Hospital for Special Surgery,Not Unity-Aligned,http://dx.doi.org/10.1097/JOM.0000000000002182,2021-08-01,2024-03-01,Verified,soffin_coronavirus_2021,USA
210527_NewYorkCity_NewYorkUniversityGrossmanSchoolofMedicine_primary,210527_NewYorkCity_NewYorkUniversityGrossmanSchoolofMedicine,Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort.,2021-05-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City," age 18 years or older and had SLE fulfilling at least 1 of the following
criteria sets: 1) the American College of Rheumatology (ACR) revised classification criteria1,2; 2) the Systemic
Lupus International Collaborating Clinics classification criteria3
; 3) the European League Against Rheumatism/ACR
classification criteria or had been diagnosed by a rheumatologist as having SLE (if fulfillment of classification
criteria for SLE could not be confirmed due to incomplete or unavailable data). Only English‐, Spanish‐ or
Mandarin‐speaking patients were included in the study.All SLE patients in the NYU Lupus Cohort are age 18 or older and fulfill at least one of the following criteria for SLE: 1) the American College of
Rheumatology (ACR) revised classification criteria1,2; 2) the Systemic Lupus International Collaborating Clinics
(SLICC) classification criteria 3; 3) the European League Against Rheumatism (EULAR)/ACR classification criteria.
",,2020-04-29,2021-02-09,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,329,0.16,,,True,,,,True,Convenience,"Not reported/ Unable to specify,Abbott Architect SARS-CoV-2 IgG","NA,Abbott Laboratories",CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Amit Saxena,New York University Grossman School of Medicine,Not Unity-Aligned,https://dx.doi.org/10.1016/S2665-9913(21)00114-4,2021-06-07,2024-03-01,Unverified,saxena_evaluation_2021,USA
210527_Seattle_UniversityofWashington_WeekOf20200318,210527_Seattle_UniversityofWashington,"Seroprevalence of SARS-CoV-2 antibodies in Seattle, Washington: October 2019-April 2020.",2021-05-27,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Washington,Seattle,Residual sera were obtained from the virology laboratory at the University of Washington Medical Center. inpatients and outpatients >18 years who underwent routine screening for hepatitis viruses.,,2020-03-14,2020-03-18,Residual sera,All,Adults (18-64 years),,,Time frame,"Week of March 18, 2020",109,0.0092,0.0002,0.05,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.96,0.993,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,,Denise J McCulloch,University of Washington,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0252235,2021-12-10,2022-07-16,Verified,mcculloch_seroprevalence_2021,USA
210527_Seattle_UniversityofWashington_WeekOf20191002,210527_Seattle_UniversityofWashington,"Seroprevalence of SARS-CoV-2 antibodies in Seattle, Washington: October 2019-April 2020.",2021-05-27,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Washington,Seattle,Residual sera were obtained from the virology laboratory at the University of Washington Medical Center. inpatients and outpatients >18 years who underwent routine screening for hepatitis viruses.,,2019-09-28,2019-10-04,Residual sera,All,Adults (18-64 years),,,Time frame,"Week of October 2, 2019",87,0.0,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.96,0.993,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,,Denise J McCulloch,University of Washington,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0252235,2021-06-07,2022-07-16,Verified,mcculloch_seroprevalence_2021,USA
210527_Seattle_UniversityofWashington_WeekOf20200305,210527_Seattle_UniversityofWashington,"Seroprevalence of SARS-CoV-2 antibodies in Seattle, Washington: October 2019-April 2020.",2021-05-27,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Washington,Seattle,Residual sera were obtained from the virology laboratory at the University of Washington Medical Center. inpatients and outpatients >18 years who underwent routine screening for hepatitis viruses.,,2020-02-28,2020-03-05,Residual sera,All,Adults (18-64 years),,,Time frame,"Week of March 5, 2020",5,0.0,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.96,0.993,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,,Denise J McCulloch,University of Washington,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0252235,2021-06-07,2022-07-16,Verified,mcculloch_seroprevalence_2021,USA
210527_Seattle_UniversityofWashington_WeekOf20200401,210527_Seattle_UniversityofWashington,"Seroprevalence of SARS-CoV-2 antibodies in Seattle, Washington: October 2019-April 2020.",2021-05-27,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Washington,Seattle,Residual sera were obtained from the virology laboratory at the University of Washington Medical Center. inpatients and outpatients >18 years who underwent routine screening for hepatitis viruses.,,2020-03-26,2020-04-01,Residual sera,All,Adults (18-64 years),,,Time frame,"Week of April 1, 2020",95,0.0105,0.0003,0.057,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.96,0.993,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,,Denise J McCulloch,University of Washington,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0252235,2021-12-10,2022-07-16,Verified,mcculloch_seroprevalence_2021,USA
210527_Seattle_UniversityofWashington_WeekOf20200313,210527_Seattle_UniversityofWashington,"Seroprevalence of SARS-CoV-2 antibodies in Seattle, Washington: October 2019-April 2020.",2021-05-27,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Washington,Seattle,Residual sera were obtained from the virology laboratory at the University of Washington Medical Center. inpatients and outpatients >18 years who underwent routine screening for hepatitis viruses.,,2020-03-07,2020-03-13,Residual sera,All,Adults (18-64 years),,,Time frame,"Week of March 13, 2020",114,0.0,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.96,0.993,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,,Denise J McCulloch,University of Washington,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0252235,2021-12-10,2022-07-16,Verified,mcculloch_seroprevalence_2021,USA
210527_Seattle_UniversityofWashington_WeekOf20191105,210527_Seattle_UniversityofWashington,"Seroprevalence of SARS-CoV-2 antibodies in Seattle, Washington: October 2019-April 2020.",2021-05-27,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Washington,Seattle,Residual sera were obtained from the virology laboratory at the University of Washington Medical Center. inpatients and outpatients >18 years who underwent routine screening for hepatitis viruses.,,2019-11-02,2019-11-08,Residual sera,All,Adults (18-64 years),,,Time frame,"Week of November 5, 2019",89,0.0,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.96,0.993,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,,Denise J McCulloch,University of Washington,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0252235,2021-06-07,2022-07-16,Verified,mcculloch_seroprevalence_2021,USA
210527_Seattle_UniversityofWashington_Overall,210527_Seattle_UniversityofWashington,"Seroprevalence of SARS-CoV-2 antibodies in Seattle, Washington: October 2019-April 2020.",2021-05-27,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Washington,Seattle,Residual sera were obtained from the virology laboratory at the University of Washington Medical Center. inpatients and outpatients >18 years who underwent routine screening for hepatitis viruses.,,2019-09-28,2020-04-01,Residual sera,All,Adults (18-64 years),,,Primary Estimate,,95,0.0105,0.0003,0.057,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.96,0.993,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,,Denise J McCulloch,University of Washington,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0252235,2021-12-10,2022-07-16,Verified,mcculloch_seroprevalence_2021,USA
210527_Seattle_UniversityofWashington_WeekOf20191206,210527_Seattle_UniversityofWashington,"Seroprevalence of SARS-CoV-2 antibodies in Seattle, Washington: October 2019-April 2020.",2021-05-27,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Washington,Seattle,Residual sera were obtained from the virology laboratory at the University of Washington Medical Center. inpatients and outpatients >18 years who underwent routine screening for hepatitis viruses.,,2019-11-30,2019-12-06,Residual sera,All,Adults (18-64 years),,,Time frame,"Week of December 6, 2019",87,0.0,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.96,0.993,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,,Denise J McCulloch,University of Washington,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0252235,2021-06-07,2022-07-16,Verified,mcculloch_seroprevalence_2021,USA
210527_Seattle_UniversityofWashington_WeekOf20200108,210527_Seattle_UniversityofWashington,"Seroprevalence of SARS-CoV-2 antibodies in Seattle, Washington: October 2019-April 2020.",2021-05-27,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Washington,Seattle,Residual sera were obtained from the virology laboratory at the University of Washington Medical Center. inpatients and outpatients >18 years who underwent routine screening for hepatitis viruses.,,2020-01-02,2020-01-08,Residual sera,All,Adults (18-64 years),,,Time frame,"Week of January 8, 2020",90,0.0,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.96,0.993,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,,Denise J McCulloch,University of Washington,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0252235,2021-06-07,2022-07-16,Verified,mcculloch_seroprevalence_2021,USA
210527_Seattle_UniversityofWashington_WeekOf20200325,210527_Seattle_UniversityofWashington,"Seroprevalence of SARS-CoV-2 antibodies in Seattle, Washington: October 2019-April 2020.",2021-05-27,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Washington,Seattle,Residual sera were obtained from the virology laboratory at the University of Washington Medical Center. inpatients and outpatients >18 years who underwent routine screening for hepatitis viruses.,,2020-03-19,2020-03-25,Residual sera,All,Adults (18-64 years),,,Time frame,"Week of March 25, 2020",90,0.0333,0.006999999999999999,0.094,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.96,0.993,['High'],No,No,No,Yes,Unclear,Unclear,Yes,Yes,,Denise J McCulloch,University of Washington,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0252235,2021-12-10,2022-07-16,Verified,mcculloch_seroprevalence_2021,USA
210529_NewYorkCity_RenalResearchInstitute_Primary,210529_NewYorkCity_RenalResearchInstitute,Prevalence and persistence of covid-19 antibodies in New York City hemodialysis clinic,2021-05-29,Presentation or Conference,Local,Prospective cohort,United States of America,New York,New York City,MHD patients from four New York City dialysis clinics,,2020-06-10,2020-07-13,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,429,0.303,,,True,,,,True,Convenience,Diazyme DZ-Lite SARS-CoV-2 IgG  CLIA tests,Diazyme Laboratories Inc,CLIA,Serum,IgG,,Validated by manufacturers,1.0,0.98,['High'],,No,No,No,,Yes,Yes,Yes,,Ohnmar Thwin,Renal Research Institute,Not Unity-Aligned,http://dx.doi.org/10.1093/ndt/gfab100.002,2021-09-14,2024-03-01,Unverified,thwin_mo877prevalence_2021,USA
210601_Providence_BrownUniversity,210601_Providence_BrownUniversity,Seroprevalence of SARS-CoV-2 among Internal Medicine Residents at a Major Academic Medicine Residency Program.,2021-06-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Rhode Island,Providence,,,2020-06-08,2020-06-23,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,101,0.028999999999999998,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,,,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,Yes,Matthew Murphy,Brown University,Not Unity-Aligned,http://rimed.org/rimedicaljournal/2021/06/2021-06-20-contribution-murphy.pdf,2021-06-05,2024-03-01,Verified,murphy_seroprevalence_2021,USA
210602_UnitedStates_TranslationalPulmonaryAndImmunologyResearchCenter_Overall,210602_UnitedStates_TranslationalPulmonaryAndImmunologyResearchCenter,Immune response to sars-cov-2 in an asymptomatic pediatric allergic cohort,2021-06-02,Journal Article (Peer-Reviewed),National,Retrospective cohort,United States of America,,,"Patients were screened to meet the following criteria at time of blood draw: between the ages of 4 and 18 years,
residence in the US, and asymptomatic",,2020-02-01,2020-04-20,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),4.0,18.0,Primary Estimate,,172,0.04,,,True,,,,True,Convenience,"anti-SARS-CoV-2 IgG,anti-SARS-CoV-2 IgM","InBios International, Inc.",ELISA,Serum,"['IgG', 'IgM']",Spike,,,,['High'],Yes,No,No,Yes,Unclear,Unclear,Yes,No,Yes,Nathan Marsteller,Translational Pulmonary and Immunology Research Center,Not Unity-Aligned,http://dx.doi.org/10.3390/antib10020022,2021-07-06,2024-03-01,Verified,marsteller_immune_2021,USA
210602_USA_MontantaStateUniversity_Primary,210602_USA_MontantaStateUniversity,"Titers, prevalence, and duration of sars-cov-2 antibodies in a local covid-19 outbreak and following vaccination",2021-06-02,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Montana,Bozeman,"individuals with previous clinical positive or
negative SARS-CoV-2 tests, those with suspected COVID-19 symptoms, and those with no diagnosis, history of contact, or symptoms.",,2020-04-15,2020-11-15,Blood donors,All,Adults (18-64 years),,,Primary Estimate,,168,0.19,,,True,,,,True,Self-referral,Author designed (Neutralization Assay),,Neutralization,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Jodi Hedges,Montana State University,Not Unity-Aligned,http://dx.doi.org/10.3390/vaccines9060587,2021-06-21,2022-07-16,Unverified,hedges_titers_2021,USA
210602_USA_MontantaStateUniversity_ELISA,210602_USA_MontantaStateUniversity,"Titers, prevalence, and duration of sars-cov-2 antibodies in a local covid-19 outbreak and following vaccination",2021-06-02,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Montana,Bozeman,"individuals with previous clinical positive or
negative SARS-CoV-2 tests, those with suspected COVID-19 symptoms, and those with no diagnosis, history of contact, or symptoms.",,2020-04-15,2020-11-15,Blood donors,All,Adults (18-64 years),,,Test used,ELISA,168,0.23600000000000002,,,,,,,,Self-referral,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Jodi Hedges,Montana State University,Not Unity-Aligned,http://dx.doi.org/10.3390/vaccines9060587,2021-06-21,2022-07-16,Unverified,hedges_titers_2021,USA
210603_UnitedStates_EmoryUniversity,210603_UnitedStates_EmoryUniversity,Us population-based survey of vaccine willingness and sars-cov- 2 antibody prevalence,2021-06-03,Presentation or Conference,National,Cross-sectional survey ,United States of America,,,address-based sample frame that includes nearly all residential addresses in the US.,,2020-08-09,2020-12-08,Household and community samples,All,Multiple groups,,,Primary Estimate,OVerall,1454,0.0468,,,True,,,,True,Simplified probability,Not reported/ Unable to specify,,,Dried Blood,,,,,,['Moderate'],Yes,Yes,Yes,No,No,Unclear,Yes,No,No,Aaron Siegler,"Emory University
",Not Unity-Aligned,https://www.croiconference.org/abstract/us-population-based-survey-of-vaccine-willingness-and-sars-cov-2-antibody-prevalence/,2021-06-07,2022-07-16,Verified,Siegler_US_2021,USA
210604_NewYorkCity_LiveOnNY,210604_NewYorkCity_LiveOnNY,Covid studies in 208 patients with consent for donation,2021-06-04,Presentation or Conference,Local,Cross-sectional survey ,United States of America,New York,New York City, potential deceased organ donors,active infection with SARS CoV 2,2020-03-16,2020-12-02,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,208,0.0337,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,,,,,['High'],,Unclear,No,No,,Unclear,Yes,No,,Amy Friedman,LiveOnNY,Not Unity-Aligned,https://atcmeetingabstracts.com/abstract/covid-studies-in-208-patients-with-consent-for-donation/,2021-11-11,2022-07-16,Unverified,amy_l_friedman_covid_2021,USA
210604_NewYorkCity_NewYorkCityDepartmentOfHealthAndMentalHygiene_Overall,210604_NewYorkCity_NewYorkCityDepartmentOfHealthAndMentalHygiene,"Prevalence of SARS-CoV-2 antibodies in New York City adults, June-October, 2020: a population-based survey.",2021-06-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York State,New York City,noninstitutionalized adult NYC residents (≥18 years). ,,2020-06-01,2020-10-09,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,overall,1074,0.24300000000000002,0.207,0.28300000000000003,True,,True,,True,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.976,0.993,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Jannae Parrott,New York City Department of Health and Mental Hygiene,Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab296,2021-06-22,2024-03-01,Verified,parrott_prevalence_2021,USA
210604_NewYorkCity_NewYorkCityDepartmentOfHealthAndMentalHygiene_18-44,210604_NewYorkCity_NewYorkCityDepartmentOfHealthAndMentalHygiene,"Prevalence of SARS-CoV-2 antibodies in New York City adults, June-October, 2020: a population-based survey.",2021-06-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York State,New York City,noninstitutionalized adult NYC residents (≥18 years). ,,2020-06-01,2020-10-09,Household and community samples,All,Adults (18-64 years),18.0,44.0,Age,18-44,458,0.264,0.21,0.327,,,True,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.976,0.993,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Jannae Parrott,New York City Department of Health and Mental Hygiene,Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab296,2021-08-12,2024-03-01,Verified,parrott_prevalence_2021,USA
210604_NewYorkCity_NewYorkCityDepartmentOfHealthAndMentalHygiene_Female,210604_NewYorkCity_NewYorkCityDepartmentOfHealthAndMentalHygiene,"Prevalence of SARS-CoV-2 antibodies in New York City adults, June-October, 2020: a population-based survey.",2021-06-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York State,New York City,noninstitutionalized adult NYC residents (≥18 years). ,,2020-06-01,2020-10-09,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,female,628,0.259,0.21100000000000002,0.314,,,True,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.976,0.993,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Jannae Parrott,New York City Department of Health and Mental Hygiene,Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab296,2021-08-12,2024-03-01,Verified,parrott_prevalence_2021,USA
210604_NewYorkCity_NewYorkCityDepartmentOfHealthAndMentalHygiene_45-64,210604_NewYorkCity_NewYorkCityDepartmentOfHealthAndMentalHygiene,"Prevalence of SARS-CoV-2 antibodies in New York City adults, June-October, 2020: a population-based survey.",2021-06-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York State,New York City,noninstitutionalized adult NYC residents (≥18 years). ,,2020-06-01,2020-10-09,Household and community samples,All,Adults (18-64 years),45.0,64.0,Age,45-64,406,0.25,0.196,0.313,,,True,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.976,0.993,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Jannae Parrott,New York City Department of Health and Mental Hygiene,Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab296,2021-08-12,2024-03-01,Verified,parrott_prevalence_2021,USA
210604_NewYorkCity_NewYorkCityDepartmentOfHealthAndMentalHygiene_65+,210604_NewYorkCity_NewYorkCityDepartmentOfHealthAndMentalHygiene,"Prevalence of SARS-CoV-2 antibodies in New York City adults, June-October, 2020: a population-based survey.",2021-06-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York State,New York City,noninstitutionalized adult NYC residents (≥18 years). ,,2020-06-01,2020-10-09,Household and community samples,All,Seniors (65+ years),65.0,,Age,65+,210,0.151,0.092,0.24,,,True,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.976,0.993,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Jannae Parrott,New York City Department of Health and Mental Hygiene,Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab296,2021-08-12,2024-03-01,Verified,parrott_prevalence_2021,USA
210604_NewYorkCity_NewYorkCityDepartmentOfHealthAndMentalHygiene_Male,210604_NewYorkCity_NewYorkCityDepartmentOfHealthAndMentalHygiene,"Prevalence of SARS-CoV-2 antibodies in New York City adults, June-October, 2020: a population-based survey.",2021-06-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York State,New York City,noninstitutionalized adult NYC residents (≥18 years). ,,2020-06-01,2020-10-09,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,male,442,0.22,0.168,0.282,,,True,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.976,0.993,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Jannae Parrott,New York City Department of Health and Mental Hygiene,Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab296,2021-08-12,2024-03-01,Verified,parrott_prevalence_2021,USA
210605_Bronx_MontefioreMedicalCenter,210605_Bronx_MontefioreMedicalCenter,Prevalence and dynamics of SARS-CoV-2 IGG in kidney transplant recipients,2021-06-05,Presentation or Conference,Local,Cross-sectional survey ,United States of America,New York,New York,"kidney transplant recipients in the Bronx, New York, one of the epicenters of the pandemic",,2020-05-03,2020-11-30,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,1042,0.1574,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,IgG,,,,,['High'],,Unclear,Yes,No,,Unclear,Yes,No,,Yorg Azzi,Montefiore Medical Center,Not Unity-Aligned,https://atcmeetingabstracts.com/abstract/prevalence-and-dynamics-of-sars-cov-2-igg-in-kidney-transplant-recipients/,2021-11-11,2022-07-16,Unverified,yorg_al_azzi_prevalence_2021-1,USA
210606_Pennsylvania_UniversityOfPittsburgh_Fall1_overall,210606_Pennsylvania_UniversityOfPittsburgh_Fall1,"A cross-sectional study of sars-cov-2 seroprevalence between fall 2020 and february 2021 in allegheny county, western pennsylvania, usa",2021-06-06,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,One cohort included 100 samples obtained between 21 September 2020 and 13 October 2020 from healthy adults who were willing to have phlebotomy performed for infectious disease research. A second cohort of 99 samples were residual specimens obtained from the UPMC Mercy clinical laboratory between 2 November 2020 to 4 November 2020; these specimens were from outpatients undergoing routine bloodwork.,,2020-09-21,2020-11-04,Multiple general populations,All,Multiple groups,15.0,,Primary Estimate,,199,0.0201,0.01,0.05,True,,,,True,Convenience,"Author designed (Neutralization Assay),Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Spike,Validated by independent authors/third party/non-developers,,,['High'],No,No,No,Yes,No,Yes,Yes,No,,Lingqing Xu,University of Pittsburgh,Not Unity-Aligned,http://dx.doi.org/10.3390/pathogens10060710,2021-06-29,2022-07-16,Verified,xu_cross-sectional_2021,USA
210606_Pennsylvania_UniversityOfPittsburgh_Feb2,210606_Pennsylvania_UniversityOfPittsburgh_Feb2,"A cross-sectional study of sars-cov-2 seroprevalence between fall 2020 and february 2021 in allegheny county, western pennsylvania, usa",2021-06-06,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Pennsylvania,Pittsburgh,Blood samples from February 2021 were all residual specimens obtained from the UPMC Mercy outpatient laboratory between 1 February 2021 and 5 February 2021,,2021-02-01,2021-02-05,Residual sera,All,Multiple groups,,,Primary Estimate,,194,0.1649,0.12,0.22,True,,,,True,Sequential,"Author designed (Neutralization Assay),Author designed (ELISA) - Nucleocapsid",,Multiple Types,Serum,"['IgG', 'Neutralizing']",Spike,Validated by independent authors/third party/non-developers,,,['High'],No,No,No,Yes,No,Yes,Yes,No,,Lingqing Xu,University of Pittsburgh,Unity-Aligned,http://dx.doi.org/10.3390/pathogens10060710,2021-06-29,2022-07-16,Verified,xu_cross-sectional_2021,USA
210508_SouthDakota_SouthDakotaStateUniversity_Phase1,210508_SouthDakota_SouthDakotaStateUniversity_Phase1,Seroprevalence of SARS-CoV-2 Antibodies Among Rural Healthcare Workers,2021-06-08,Preprint,Regional,Prospective cohort,United States of America,"South Dakota, Minnesota",,healthcare workers in eastern South Dakota and western Minnesota,,2020-05-13,2020-07-13,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Healthcare workers,336,0.003,,,True,,,,True,Convenience,,,Other,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Jordan Neises,South Dakota State University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.06.07.21258375v1,2021-06-17,2021-10-05,Unverified,jordanz.neiseSeroprevalenceSARSCoV2Antibodies2021,USA
210508_SouthDakota_SouthDakotaStateUniversity_Phase2,210508_SouthDakota_SouthDakotaStateUniversity_Phase2,Seroprevalence of SARS-CoV-2 Antibodies Among Rural Healthcare Workers,2021-06-08,Preprint,Regional,Prospective cohort,United States of America,"South Dakota, Minnesota",,healthcare workers in eastern South Dakota and western Minnesota,,2021-08-13,2020-09-25,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Healthcare workers,290,0.019,,,True,,,,True,Convenience,,,Other,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,,,['High'],,No,No,No,,Unclear,Yes,No,,Jordan Neises,South Dakota State University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.06.07.21258375v1,2021-06-17,2022-03-17,Unverified,jordanz.neiseSeroprevalenceSARSCoV2Antibodies2021,USA
210508_SouthDakota_SouthDakotaStateUniversity_Phase3,210508_SouthDakota_SouthDakotaStateUniversity_Phase3,Seroprevalence of SARS-CoV-2 Antibodies Among Rural Healthcare Workers,2021-06-08,Preprint,Regional,Prospective cohort,United States of America,"South Dakota, Minnesota",,healthcare workers in eastern South Dakota and western Minnesota,,2020-10-16,2020-12-22,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Healthcare workers,235,0.14800000000000002,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,Other,Serum,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),,,,['High'],,No,No,No,,Yes,Yes,Yes,,Jordan Neises,South Dakota State University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.06.07.21258375v1,2021-06-17,2024-03-01,Unverified,jordanz.neiseSeroprevalenceSARSCoV2Antibodies2021,USA
210609_Pennsylvania_UPMCChildrensHospitalofPittsburgh_RedPhase_Primary,210609_Pennsylvania_UPMCChildrensHospitalofPittsburgh_RedPhase,Pediatric SARS-CoV-2 seroprevalence during mitigation procedures in Southwestern Pennsylvania.,2021-06-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"All samples that arrived in the lab were screened for inclusion, and samples from patients aged less than 19 years-old whose residential zip code was within 11 SWPA counties were included.","Additional exclusion criteria were: 1) age ≤ 6 months due to confounding maternal antibodies, 2) hospital length of stay > 30 days when the sample was collected due to lack of commu- nity exposure, or 3) receipt of treatments that alter antibody production or antibody profile (e.g. immunoglobulin, rituximab, or bortezomib) in the six months prior to collection.",2020-04-27,2020-05-19,Residual sera,All,Children and Youth (0-17 years),0.0,18.0,Primary Estimate,,1142,0.0053,0.0019,0.011399999999999999,True,,,,True,Sequential,"Anti-SARS-CoV-2 ELISA IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,ADVIA Centaur Immunoassay System","EUROIMMUN,Beckman Coulter,Siemens",CLIA,,IgG,,Validated by independent authors/third party/non-developers,,0.9999,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Glenn J. Rapsinski,UPMC Children’s Hospital of Pittsburgh,Unity-Aligned,https://dx.doi.org/10.1016/j.jcvp.2021.100026,2022-03-15,2024-03-01,Verified,rapsinski_pediatric_2021,USA
210609_Pennsylvania_UPMCChildrensHospitalofPittsburgh_RedPhase_Age6to12,210609_Pennsylvania_UPMCChildrensHospitalofPittsburgh_RedPhase,Pediatric SARS-CoV-2 seroprevalence during mitigation procedures in Southwestern Pennsylvania.,2021-06-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"All samples that arrived in the lab were screened for inclusion, and samples from patients aged less than 19 years-old whose residential zip code was within 11 SWPA counties were included.","Additional exclusion criteria were: 1) age ≤ 6 months due to confounding maternal antibodies, 2) hospital length of stay > 30 days when the sample was collected due to lack of commu- nity exposure, or 3) receipt of treatments that alter antibody production or antibody profile (e.g. immunoglobulin, rituximab, or bortezomib) in the six months prior to collection.",2020-04-27,2020-05-19,Residual sera,All,Children and Youth (0-17 years),6.0,12.0,Age,age: 6-12,294,0.0102,0.0021,0.029500000000000002,,,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,ADVIA Centaur Immunoassay System","EUROIMMUN,Beckman Coulter,Siemens",CLIA,,IgG,,Validated by independent authors/third party/non-developers,,0.9999,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Glenn J. Rapsinski,UPMC Children’s Hospital of Pittsburgh,Unity-Aligned,https://dx.doi.org/10.1016/j.jcvp.2021.100026,2022-03-15,2024-03-01,Verified,rapsinski_pediatric_2021,USA
210609_Pennsylvania_UPMCChildrensHospitalofPittsburgh_RedPhase_Age0to6,210609_Pennsylvania_UPMCChildrensHospitalofPittsburgh_RedPhase,Pediatric SARS-CoV-2 seroprevalence during mitigation procedures in Southwestern Pennsylvania.,2021-06-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"All samples that arrived in the lab were screened for inclusion, and samples from patients aged less than 19 years-old whose residential zip code was within 11 SWPA counties were included.","Additional exclusion criteria were: 1) age ≤ 6 months due to confounding maternal antibodies, 2) hospital length of stay > 30 days when the sample was collected due to lack of commu- nity exposure, or 3) receipt of treatments that alter antibody production or antibody profile (e.g. immunoglobulin, rituximab, or bortezomib) in the six months prior to collection.",2020-04-27,2020-05-19,Residual sera,All,Children and Youth (0-17 years),0.0,6.0,Age,age: 0-6,290,0.0069,0.0008,0.024700000000000003,,,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,ADVIA Centaur Immunoassay System","EUROIMMUN,Beckman Coulter,Siemens",CLIA,,IgG,,Validated by independent authors/third party/non-developers,,0.9999,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Glenn J. Rapsinski,UPMC Children’s Hospital of Pittsburgh,Unity-Aligned,https://dx.doi.org/10.1016/j.jcvp.2021.100026,2022-03-15,2024-03-01,Verified,rapsinski_pediatric_2021,USA
210609_Pennsylvania_UPMCChildrensHospitalofPittsburgh_RedPhase_Age12to18,210609_Pennsylvania_UPMCChildrensHospitalofPittsburgh_RedPhase,Pediatric SARS-CoV-2 seroprevalence during mitigation procedures in Southwestern Pennsylvania.,2021-06-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"All samples that arrived in the lab were screened for inclusion, and samples from patients aged less than 19 years-old whose residential zip code was within 11 SWPA counties were included.","Additional exclusion criteria were: 1) age ≤ 6 months due to confounding maternal antibodies, 2) hospital length of stay > 30 days when the sample was collected due to lack of commu- nity exposure, or 3) receipt of treatments that alter antibody production or antibody profile (e.g. immunoglobulin, rituximab, or bortezomib) in the six months prior to collection.",2020-04-27,2020-05-19,Residual sera,All,Children and Youth (0-17 years),12.0,18.0,Age,age: 12-18,558,0.0018,0.0,0.0099,,,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,ADVIA Centaur Immunoassay System","EUROIMMUN,Beckman Coulter,Siemens",CLIA,,IgG,,Validated by independent authors/third party/non-developers,,0.9999,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Glenn J. Rapsinski,UPMC Children’s Hospital of Pittsburgh,Unity-Aligned,https://dx.doi.org/10.1016/j.jcvp.2021.100026,2022-03-15,2024-03-01,Verified,rapsinski_pediatric_2021,USA
210609_Pennsylvania_UPMCChildrensHospitalofPittsburgh_RedPhase_Male,210609_Pennsylvania_UPMCChildrensHospitalofPittsburgh_RedPhase,Pediatric SARS-CoV-2 seroprevalence during mitigation procedures in Southwestern Pennsylvania.,2021-06-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"All samples that arrived in the lab were screened for inclusion, and samples from patients aged less than 19 years-old whose residential zip code was within 11 SWPA counties were included.","Additional exclusion criteria were: 1) age ≤ 6 months due to confounding maternal antibodies, 2) hospital length of stay > 30 days when the sample was collected due to lack of commu- nity exposure, or 3) receipt of treatments that alter antibody production or antibody profile (e.g. immunoglobulin, rituximab, or bortezomib) in the six months prior to collection.",2020-04-27,2020-05-19,Residual sera,Male,Children and Youth (0-17 years),0.0,18.0,Sex/Gender,,523,0.0038,0.0005,0.013700000000000002,,,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,ADVIA Centaur Immunoassay System","EUROIMMUN,Beckman Coulter,Siemens",CLIA,,IgG,,Validated by independent authors/third party/non-developers,,0.9999,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Glenn J. Rapsinski,UPMC Children’s Hospital of Pittsburgh,Unity-Aligned,https://dx.doi.org/10.1016/j.jcvp.2021.100026,2022-03-15,2024-03-01,Verified,rapsinski_pediatric_2021,USA
210609_Pennsylvania_UPMCChildrensHospitalofPittsburgh_RedPhase_Female,210609_Pennsylvania_UPMCChildrensHospitalofPittsburgh_RedPhase,Pediatric SARS-CoV-2 seroprevalence during mitigation procedures in Southwestern Pennsylvania.,2021-06-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"All samples that arrived in the lab were screened for inclusion, and samples from patients aged less than 19 years-old whose residential zip code was within 11 SWPA counties were included.","Additional exclusion criteria were: 1) age ≤ 6 months due to confounding maternal antibodies, 2) hospital length of stay > 30 days when the sample was collected due to lack of commu- nity exposure, or 3) receipt of treatments that alter antibody production or antibody profile (e.g. immunoglobulin, rituximab, or bortezomib) in the six months prior to collection.",2020-04-27,2020-05-19,Residual sera,Female,Children and Youth (0-17 years),0.0,18.0,Sex/Gender,,619,0.006500000000000001,0.0018,0.0165,,,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,ADVIA Centaur Immunoassay System","EUROIMMUN,Beckman Coulter,Siemens",CLIA,,IgG,,Validated by independent authors/third party/non-developers,,0.9999,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Glenn J. Rapsinski,UPMC Children’s Hospital of Pittsburgh,Unity-Aligned,https://dx.doi.org/10.1016/j.jcvp.2021.100026,2022-03-15,2024-03-01,Verified,rapsinski_pediatric_2021,USA
210609_Pennsylvania_UPMCChildrensHospitalofPittsburgh_YellowPhase_Primary,210609_Pennsylvania_UPMCChildrensHospitalofPittsburgh_YellowPhase,Pediatric SARS-CoV-2 seroprevalence during mitigation procedures in Southwestern Pennsylvania.,2021-06-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"All samples that arrived in the lab were screened for inclusion, and samples from patients aged less than 19 years-old whose residential zip code was within 11 SWPA counties were included.","Additional exclusion criteria were: 1) age ≤ 6 months due to confounding maternal antibodies, 2) hospital length of stay > 30 days when the sample was collected due to lack of commu- nity exposure, or 3) receipt of treatments that alter antibody production or antibody profile (e.g. immunoglobulin, rituximab, or bortezomib) in the six months prior to collection.",2020-06-22,2020-07-03,Residual sera,All,Children and Youth (0-17 years),0.0,18.0,Primary Estimate,,1196,0.0092,0.0046,0.016399999999999998,True,,,,True,Sequential,"Anti-SARS-CoV-2 ELISA IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,ADVIA Centaur Immunoassay System","EUROIMMUN,Beckman Coulter,Siemens",CLIA,,IgG,,Validated by independent authors/third party/non-developers,,0.9999,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Glenn J. Rapsinski,UPMC Children’s Hospital of Pittsburgh,Unity-Aligned,https://dx.doi.org/10.1016/j.jcvp.2021.100026,2022-03-15,2024-03-01,Verified,rapsinski_pediatric_2021,USA
210609_Pennsylvania_UPMCChildrensHospitalofPittsburgh_YellowPhase_Age12to18,210609_Pennsylvania_UPMCChildrensHospitalofPittsburgh_YellowPhase,Pediatric SARS-CoV-2 seroprevalence during mitigation procedures in Southwestern Pennsylvania.,2021-06-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"All samples that arrived in the lab were screened for inclusion, and samples from patients aged less than 19 years-old whose residential zip code was within 11 SWPA counties were included.","Additional exclusion criteria were: 1) age ≤ 6 months due to confounding maternal antibodies, 2) hospital length of stay > 30 days when the sample was collected due to lack of commu- nity exposure, or 3) receipt of treatments that alter antibody production or antibody profile (e.g. immunoglobulin, rituximab, or bortezomib) in the six months prior to collection.",2020-06-22,2020-07-03,Residual sera,All,Children and Youth (0-17 years),12.0,18.0,Age,age: 12-18,593,0.0101,0.0037,0.0219,,,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,ADVIA Centaur Immunoassay System","EUROIMMUN,Beckman Coulter,Siemens",CLIA,,IgG,,Validated by independent authors/third party/non-developers,,0.9999,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Glenn J. Rapsinski,UPMC Children’s Hospital of Pittsburgh,Unity-Aligned,https://dx.doi.org/10.1016/j.jcvp.2021.100026,2022-03-15,2024-03-01,Verified,rapsinski_pediatric_2021,USA
210609_Pennsylvania_UPMCChildrensHospitalofPittsburgh_YellowPhase_Age6to12,210609_Pennsylvania_UPMCChildrensHospitalofPittsburgh_YellowPhase,Pediatric SARS-CoV-2 seroprevalence during mitigation procedures in Southwestern Pennsylvania.,2021-06-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"All samples that arrived in the lab were screened for inclusion, and samples from patients aged less than 19 years-old whose residential zip code was within 11 SWPA counties were included.","Additional exclusion criteria were: 1) age ≤ 6 months due to confounding maternal antibodies, 2) hospital length of stay > 30 days when the sample was collected due to lack of commu- nity exposure, or 3) receipt of treatments that alter antibody production or antibody profile (e.g. immunoglobulin, rituximab, or bortezomib) in the six months prior to collection.",2020-06-22,2020-07-03,Residual sera,All,Children and Youth (0-17 years),6.0,12.0,Age,age: 6-12,341,0.0117,0.0032,0.0298,,,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,ADVIA Centaur Immunoassay System","EUROIMMUN,Beckman Coulter,Siemens",CLIA,,IgG,,Validated by independent authors/third party/non-developers,,0.9999,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Glenn J. Rapsinski,UPMC Children’s Hospital of Pittsburgh,Unity-Aligned,https://dx.doi.org/10.1016/j.jcvp.2021.100026,2022-03-15,2024-03-01,Verified,rapsinski_pediatric_2021,USA
210609_Pennsylvania_UPMCChildrensHospitalofPittsburgh_YellowPhase_Female,210609_Pennsylvania_UPMCChildrensHospitalofPittsburgh_YellowPhase,Pediatric SARS-CoV-2 seroprevalence during mitigation procedures in Southwestern Pennsylvania.,2021-06-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"All samples that arrived in the lab were screened for inclusion, and samples from patients aged less than 19 years-old whose residential zip code was within 11 SWPA counties were included.","Additional exclusion criteria were: 1) age ≤ 6 months due to confounding maternal antibodies, 2) hospital length of stay > 30 days when the sample was collected due to lack of commu- nity exposure, or 3) receipt of treatments that alter antibody production or antibody profile (e.g. immunoglobulin, rituximab, or bortezomib) in the six months prior to collection.",2020-06-22,2020-07-03,Residual sera,Female,Children and Youth (0-17 years),0.0,18.0,Sex/Gender,,595,0.0084,0.0027,0.0195,,,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,ADVIA Centaur Immunoassay System","EUROIMMUN,Beckman Coulter,Siemens",CLIA,,IgG,,Validated by independent authors/third party/non-developers,,0.9999,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Glenn J. Rapsinski,UPMC Children’s Hospital of Pittsburgh,Unity-Aligned,https://dx.doi.org/10.1016/j.jcvp.2021.100026,2022-03-15,2024-03-01,Verified,rapsinski_pediatric_2021,USA
210609_Pennsylvania_UPMCChildrensHospitalofPittsburgh_YellowPhase_Age0to6,210609_Pennsylvania_UPMCChildrensHospitalofPittsburgh_YellowPhase,Pediatric SARS-CoV-2 seroprevalence during mitigation procedures in Southwestern Pennsylvania.,2021-06-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"All samples that arrived in the lab were screened for inclusion, and samples from patients aged less than 19 years-old whose residential zip code was within 11 SWPA counties were included.","Additional exclusion criteria were: 1) age ≤ 6 months due to confounding maternal antibodies, 2) hospital length of stay > 30 days when the sample was collected due to lack of commu- nity exposure, or 3) receipt of treatments that alter antibody production or antibody profile (e.g. immunoglobulin, rituximab, or bortezomib) in the six months prior to collection.",2020-06-22,2020-07-03,Residual sera,All,Children and Youth (0-17 years),0.0,6.0,Age,age: 0-6,262,0.0038,0.0,0.0211,,,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,ADVIA Centaur Immunoassay System","EUROIMMUN,Beckman Coulter,Siemens",CLIA,,IgG,,Validated by independent authors/third party/non-developers,,0.9999,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Glenn J. Rapsinski,UPMC Children’s Hospital of Pittsburgh,Unity-Aligned,https://dx.doi.org/10.1016/j.jcvp.2021.100026,2022-03-15,2024-03-01,Verified,rapsinski_pediatric_2021,USA
210609_Pennsylvania_UPMCChildrensHospitalofPittsburgh_YellowPhase_Male,210609_Pennsylvania_UPMCChildrensHospitalofPittsburgh_YellowPhase,Pediatric SARS-CoV-2 seroprevalence during mitigation procedures in Southwestern Pennsylvania.,2021-06-09,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"All samples that arrived in the lab were screened for inclusion, and samples from patients aged less than 19 years-old whose residential zip code was within 11 SWPA counties were included.","Additional exclusion criteria were: 1) age ≤ 6 months due to confounding maternal antibodies, 2) hospital length of stay > 30 days when the sample was collected due to lack of commu- nity exposure, or 3) receipt of treatments that alter antibody production or antibody profile (e.g. immunoglobulin, rituximab, or bortezomib) in the six months prior to collection.",2020-06-22,2020-07-03,Residual sera,Male,Children and Youth (0-17 years),0.0,18.0,Sex/Gender,,601,0.01,0.0037,0.0216,,,,,,Sequential,"Anti-SARS-CoV-2 ELISA IgG,Access SARS-CoV-2 IgG Reagent Antibody Test,ADVIA Centaur Immunoassay System","EUROIMMUN,Beckman Coulter,Siemens",CLIA,,IgG,,Validated by independent authors/third party/non-developers,,0.9999,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,No,,Glenn J. Rapsinski,UPMC Children’s Hospital of Pittsburgh,Unity-Aligned,https://dx.doi.org/10.1016/j.jcvp.2021.100026,2022-03-15,2024-03-01,Verified,rapsinski_pediatric_2021,USA
210610_USA_BostonHeartDiagnostics,210610_USA_BostonHeartDiagnostics,"Corona Virus Disease-19 serology, inflammatory markers, hospitalizations, case finding, and aging",2021-06-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,,,2020-04-06,2020-12-01,Residual sera,All,Multiple groups,,,Primary Estimate,,81624,0.0521,,,True,,,,True,Unclear,Diazyme DZ-Lite SARS-CoV-2 IgG  CLIA tests,Diazyme Laboratories Inc,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.9840000000000001,0.9740000000000001,['High'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Ernst J. Schaefer,Boston Heart Diagnostics,Not Unity-Aligned,http://dx.doi.org/10.1371/journal.pone.0252818,2021-06-22,2024-03-01,Unverified,schaefer_corona_2021,USA
210611_SanFrancisco_UniversityofCaliforniaSanFrancisco_mostadj,210611_SanFrancisco_UniversityofCaliforniaSanFrancisco,Citywide serosurveillance of the initial SARS-CoV-2 outbreak in San Francisco using electronic health records.,2021-06-11,Journal Article (Peer-Reviewed),Local,Retrospective cohort,United States of America,California,San Francisco,"We restricted our sampling frame to samples from individuals undergoing routine blood testing. We included patients residing in San Francisco, including those experiencing homelessness. We restricted our sample to outpatient and emergency department visits for adults; for the youngest age group, we included both inpatient and outpatient visits due to small numbers of available samples.","We excluded individuals who were tested for SARS-CoV-2 during the visit when they received their blood draw (except if the test was for routine purposes, such as testing prior to an elective procedure or admittance to the hospital). Finally, we excluded samples if a sample from the same patient had been selected within the previous 30 days.",2020-03-28,2020-06-26,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,4735,0.042,0.021,0.063,True,True,True,,,Stratified non-probability,"Author designed (Luminex),Author designed (ELISA) -Unknown",,Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.937,0.996,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Isobel Routledge,University of California San Francisco,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23651-6,2021-06-21,2022-07-16,Verified,routledge_citywide_2021-1,USA
210611_SanFrancisco_UniversityofCaliforniaSanFrancisco_female,210611_SanFrancisco_UniversityofCaliforniaSanFrancisco,Citywide serosurveillance of the initial SARS-CoV-2 outbreak in San Francisco using electronic health records.,2021-06-11,Journal Article (Peer-Reviewed),Local,Retrospective cohort,United States of America,California,San Francisco,"We restricted our sampling frame to samples from individuals undergoing routine blood testing. We included patients residing in San Francisco, including those experiencing homelessness. We restricted our sample to outpatient and emergency department visits for adults; for the youngest age group, we included both inpatient and outpatient visits due to small numbers of available samples.","We excluded individuals who were tested for SARS-CoV-2 during the visit when they received their blood draw (except if the test was for routine purposes, such as testing prior to an elective procedure or admittance to the hospital). Finally, we excluded samples if a sample from the same patient had been selected within the previous 30 days.",2020-03-28,2020-06-26,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,2491,0.027000000000000003,0.010900000000000002,0.0361,,True,True,,,Stratified non-probability,"Author designed (Luminex),Author designed (ELISA) -Unknown",,Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.937,0.996,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Isobel Routledge,University of California San Francisco,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23651-6,2021-06-21,2022-07-16,Verified,routledge_citywide_2021-1,USA
210611_SanFrancisco_UniversityofCaliforniaSanFrancisco_noadj,210611_SanFrancisco_UniversityofCaliforniaSanFrancisco,Citywide serosurveillance of the initial SARS-CoV-2 outbreak in San Francisco using electronic health records.,2021-06-11,Journal Article (Peer-Reviewed),Local,Retrospective cohort,United States of America,California,San Francisco,"We restricted our sampling frame to samples from individuals undergoing routine blood testing. We included patients residing in San Francisco, including those experiencing homelessness. We restricted our sample to outpatient and emergency department visits for adults; for the youngest age group, we included both inpatient and outpatient visits due to small numbers of available samples.","We excluded individuals who were tested for SARS-CoV-2 during the visit when they received their blood draw (except if the test was for routine purposes, such as testing prior to an elective procedure or admittance to the hospital). Finally, we excluded samples if a sample from the same patient had been selected within the previous 30 days.",2020-03-28,2020-06-26,Residual sera,All,Multiple groups,0.0,,Analysis,,4735,0.040999999999999995,,,,,,,True,Stratified non-probability,"Author designed (Luminex),Author designed (ELISA) -Unknown",,Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.937,0.996,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Isobel Routledge,University of California San Francisco,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23651-6,2021-06-21,2022-07-16,Verified,routledge_citywide_2021-1,USA
210611_SanFrancisco_UniversityofCaliforniaSanFrancisco_40-59yrs,210611_SanFrancisco_UniversityofCaliforniaSanFrancisco,Citywide serosurveillance of the initial SARS-CoV-2 outbreak in San Francisco using electronic health records.,2021-06-11,Journal Article (Peer-Reviewed),Local,Retrospective cohort,United States of America,California,San Francisco,"We restricted our sampling frame to samples from individuals undergoing routine blood testing. We included patients residing in San Francisco, including those experiencing homelessness. We restricted our sample to outpatient and emergency department visits for adults; for the youngest age group, we included both inpatient and outpatient visits due to small numbers of available samples.","We excluded individuals who were tested for SARS-CoV-2 during the visit when they received their blood draw (except if the test was for routine purposes, such as testing prior to an elective procedure or admittance to the hospital). Finally, we excluded samples if a sample from the same patient had been selected within the previous 30 days.",2020-03-28,2020-06-26,Residual sera,All,Adults (18-64 years),40.0,59.0,Age,40-59 years,1322,0.0546,0.0364,0.0713,,True,True,,,Stratified non-probability,"Author designed (Luminex),Author designed (ELISA) -Unknown",,Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.937,0.996,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Isobel Routledge,University of California San Francisco,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23651-6,2021-06-21,2022-07-16,Verified,routledge_citywide_2021-1,USA
210611_SanFrancisco_UniversityofCaliforniaSanFrancisco_male,210611_SanFrancisco_UniversityofCaliforniaSanFrancisco,Citywide serosurveillance of the initial SARS-CoV-2 outbreak in San Francisco using electronic health records.,2021-06-11,Journal Article (Peer-Reviewed),Local,Retrospective cohort,United States of America,California,San Francisco,"We restricted our sampling frame to samples from individuals undergoing routine blood testing. We included patients residing in San Francisco, including those experiencing homelessness. We restricted our sample to outpatient and emergency department visits for adults; for the youngest age group, we included both inpatient and outpatient visits due to small numbers of available samples.","We excluded individuals who were tested for SARS-CoV-2 during the visit when they received their blood draw (except if the test was for routine purposes, such as testing prior to an elective procedure or admittance to the hospital). Finally, we excluded samples if a sample from the same patient had been selected within the previous 30 days.",2020-03-28,2020-06-26,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,2231,0.053099999999999994,0.0373,0.0661,,True,True,,,Stratified non-probability,"Author designed (Luminex),Author designed (ELISA) -Unknown",,Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.937,0.996,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Isobel Routledge,University of California San Francisco,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23651-6,2021-06-21,2022-07-16,Verified,routledge_citywide_2021-1,USA
210611_SanFrancisco_UniversityofCaliforniaSanFrancisco_60-79yrs,210611_SanFrancisco_UniversityofCaliforniaSanFrancisco,Citywide serosurveillance of the initial SARS-CoV-2 outbreak in San Francisco using electronic health records.,2021-06-11,Journal Article (Peer-Reviewed),Local,Retrospective cohort,United States of America,California,San Francisco,"We restricted our sampling frame to samples from individuals undergoing routine blood testing. We included patients residing in San Francisco, including those experiencing homelessness. We restricted our sample to outpatient and emergency department visits for adults; for the youngest age group, we included both inpatient and outpatient visits due to small numbers of available samples.","We excluded individuals who were tested for SARS-CoV-2 during the visit when they received their blood draw (except if the test was for routine purposes, such as testing prior to an elective procedure or admittance to the hospital). Finally, we excluded samples if a sample from the same patient had been selected within the previous 30 days.",2020-03-28,2020-06-26,Residual sera,All,Multiple groups,60.0,79.0,Age,60-79 years,1390,0.0281,0.011000000000000001,0.0404,,True,True,,,Stratified non-probability,"Author designed (Luminex),Author designed (ELISA) -Unknown",,Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.937,0.996,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Isobel Routledge,University of California San Francisco,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23651-6,2021-06-21,2022-07-16,Verified,routledge_citywide_2021-1,USA
210611_SanFrancisco_UniversityofCaliforniaSanFrancisco_0-19yrs,210611_SanFrancisco_UniversityofCaliforniaSanFrancisco,Citywide serosurveillance of the initial SARS-CoV-2 outbreak in San Francisco using electronic health records.,2021-06-11,Journal Article (Peer-Reviewed),Local,Retrospective cohort,United States of America,California,San Francisco,"We restricted our sampling frame to samples from individuals undergoing routine blood testing. We included patients residing in San Francisco, including those experiencing homelessness. We restricted our sample to outpatient and emergency department visits for adults; for the youngest age group, we included both inpatient and outpatient visits due to small numbers of available samples.","We excluded individuals who were tested for SARS-CoV-2 during the visit when they received their blood draw (except if the test was for routine purposes, such as testing prior to an elective procedure or admittance to the hospital). Finally, we excluded samples if a sample from the same patient had been selected within the previous 30 days.",2020-03-28,2020-06-26,Residual sera,All,Children and Youth (0-17 years),0.0,19.0,Age,0-19 years,281,0.040999999999999995,0.016,0.069,,True,True,,,Stratified non-probability,"Author designed (Luminex),Author designed (ELISA) -Unknown",,Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.937,0.996,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Isobel Routledge,University of California San Francisco,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23651-6,2021-06-21,2022-07-16,Verified,routledge_citywide_2021-1,USA
210611_SanFrancisco_UniversityofCaliforniaSanFrancisco_80+yrs,210611_SanFrancisco_UniversityofCaliforniaSanFrancisco,Citywide serosurveillance of the initial SARS-CoV-2 outbreak in San Francisco using electronic health records.,2021-06-11,Journal Article (Peer-Reviewed),Local,Retrospective cohort,United States of America,California,San Francisco,"We restricted our sampling frame to samples from individuals undergoing routine blood testing. We included patients residing in San Francisco, including those experiencing homelessness. We restricted our sample to outpatient and emergency department visits for adults; for the youngest age group, we included both inpatient and outpatient visits due to small numbers of available samples.","We excluded individuals who were tested for SARS-CoV-2 during the visit when they received their blood draw (except if the test was for routine purposes, such as testing prior to an elective procedure or admittance to the hospital). Finally, we excluded samples if a sample from the same patient had been selected within the previous 30 days.",2020-03-28,2020-06-26,Residual sera,All,Seniors (65+ years),80.0,,Age,80 + years,481,0.0363,0.015500000000000002,0.057999999999999996,,True,True,,,Stratified non-probability,"Author designed (Luminex),Author designed (ELISA) -Unknown",,Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.937,0.996,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Isobel Routledge,University of California San Francisco,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23651-6,2021-06-21,2022-07-16,Verified,routledge_citywide_2021-1,USA
210611_SanFrancisco_UniversityofCaliforniaSanFrancisco_20-39yrs,210611_SanFrancisco_UniversityofCaliforniaSanFrancisco,Citywide serosurveillance of the initial SARS-CoV-2 outbreak in San Francisco using electronic health records.,2021-06-11,Journal Article (Peer-Reviewed),Local,Retrospective cohort,United States of America,California,San Francisco,"We restricted our sampling frame to samples from individuals undergoing routine blood testing. We included patients residing in San Francisco, including those experiencing homelessness. We restricted our sample to outpatient and emergency department visits for adults; for the youngest age group, we included both inpatient and outpatient visits due to small numbers of available samples.","We excluded individuals who were tested for SARS-CoV-2 during the visit when they received their blood draw (except if the test was for routine purposes, such as testing prior to an elective procedure or admittance to the hospital). Finally, we excluded samples if a sample from the same patient had been selected within the previous 30 days.",2020-03-28,2020-06-26,Residual sera,All,Adults (18-64 years),20.0,39.0,Age,20-39 years,1261,0.039900000000000005,0.0229,0.0545,,True,True,,,Stratified non-probability,"Author designed (Luminex),Author designed (ELISA) -Unknown",,Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.937,0.996,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Isobel Routledge,University of California San Francisco,Unity-Aligned,https://dx.doi.org/10.1038/s41467-021-23651-6,2021-06-21,2022-07-16,Verified,routledge_citywide_2021-1,USA
210615_Nashville_VanderbiltUniversityMedicalCenter_Baseline1_Overall,210615_Nashville_VanderbiltUniversityMedicalCenter_Baseline1,Low in-school COVID-19 transmission and asymptomatic infection despite high community prevalence.,2021-06-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Tennessee,Nashville,Consenting faculty/staff,,2020-09-08,2020-09-08,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,33,0.03,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,No,,Yes,Yes,Yes,,Sophie E. Katz,Vanderbilt University Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jpeds.2021.06.015,2021-07-01,2024-03-01,Unverified,katz_low_2021,USA
210615_Nashville_VanderbiltUniversityMedicalCenter_FollowUp2_Overall,210615_Nashville_VanderbiltUniversityMedicalCenter_FollowUp2,Low in-school COVID-19 transmission and asymptomatic infection despite high community prevalence.,2021-06-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Tennessee,Nashville,Consenting faculty/staff,,2021-01-27,2021-01-27,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,34,0.1471,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,No,No,Unclear,Yes,Yes,Yes,No,Sophie E. Katz,Vanderbilt University Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jpeds.2021.06.015,2021-07-01,2024-03-01,Verified,katz_low_2021,USA
210616_LomaLinda_LomaLindaUniversityChildren'sHospital_Overall,210616_LomaLinda_LomaLindaUniversityChildren'sHospital,COVID-19 diagnosis and testing in pediatric heart transplant recipients.,2021-06-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,Loma Linda,Children having received a heart transplant at Loma Linda University Children’s Hospital ,,2020-03-15,2021-03-15,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),,,Primary Estimate,Pediatric heart transplant recipients,146,0.0616,,,True,,,,True,Sequential,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],Yes,No,No,No,Unclear,Unclear,Yes,No,Unclear,Matthew J. Bock,Loma Linda University Children's Hospital ,Not Unity-Aligned,https://dx.doi.org/10.1016/j.healun.2021.06.009,2021-07-18,2022-07-16,Verified,bock_covid-19_2021,USA
210618_LosAngeles_UniversityCaliforniaLosAngeles,210618_LosAngeles_UniversityCaliforniaLosAngeles,Sars-cov-2 infection detection by pcr and serologic testing in clinical practice,2021-06-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,Los Angeles,Samples from UCLA outpatient testing sites and clinics as well as inpatient wards before 11 August 2020 with at least one PCR test and one antibody test were retained for analysis,,,2020-08-10,Residual sera,All,Multiple groups,,,Primary Estimate,,3075,0.08810000000000001,,,True,,,,True,Convenience,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Douglas Murad,University of California Los Angeles,Not Unity-Aligned,http://dx.doi.org/10.1128/JCM.00431-21,2021-07-07,2024-03-01,Verified,murad_sars-cov-2_2021,USA
210621_Jacksonville_MayoClinic,210621_Jacksonville_MayoClinic,Seroprevalence of SARS-CoV-2 antibodies in healthcare workers in a surgical environment.,2021-06-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Florida,Jacksonville,All surgical personnel who participated in a previous study evaluating COVID-19 transmission risk were invited to undergo SARS-CoV-2 IgG serum antibody testing,,2020-05-06,2020-07-01,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,292,0.027000000000000003,0.012,0.053,True,,,,True,Convenience,EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit,"Epitope Diagnostics, Inc.",ELISA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,1.0,['High'],,No,No,No,,Yes,Yes,Yes,,Martin L.De Ruyter,Mayo Clinic,Not Unity-Aligned,https://dx.doi.org/10.1093/bjs/znab109,2021-06-30,2024-03-01,Unverified,de_ruyter_seroprevalence_2021,USA
210414_Holyoke_CityofHolyoke_Overall_PopAdj,210414_Holyoke_CityofHolyoke, City of Holyoke Serosurvey Report,2021-06-23,Institutional Report,Local,Cross-sectional survey ,United States of America,Massachusetts,Holyoke,All household members for selected addresses were invited to participate,,2020-11-05,2021-01-31,Household and community samples,All,Multiple groups,,,Primary Estimate,Population Adjusted,328,0.139,0.078,0.218,True,,True,,True,Simplified probability,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],Yes,Yes,No,No,Yes,Unclear,Yes,No,No,City of Holyoke,City of Holyoke,Not Unity-Aligned,https://www.holyoke.org/documents/city-of-holyoke-serosurvey-report/,2021-07-05,2022-07-16,Verified,city_of_holyoke_government_city_2021,USA
210414_Holyoke_CityofHolyoke_Age_45-59,210414_Holyoke_CityofHolyoke, City of Holyoke Serosurvey Report,2021-06-23,Institutional Report,Local,Cross-sectional survey ,United States of America,Massachusetts,Holyoke,All household members for selected addresses were invited to participate,,2020-11-05,2021-01-31,Household and community samples,All,Adults (18-64 years),45.0,59.0,Age,45-59,94,0.096,0.0,0.20500000000000002,,,True,,,Simplified probability,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],Yes,Yes,No,No,Yes,Unclear,Yes,No,No,City of Holyoke,City of Holyoke,Not Unity-Aligned,https://www.holyoke.org/documents/city-of-holyoke-serosurvey-report/,2021-07-05,2022-07-16,Verified,city_of_holyoke_government_city_2021,USA
210414_Holyoke_CityofHolyoke_Female,210414_Holyoke_CityofHolyoke, City of Holyoke Serosurvey Report,2021-06-23,Institutional Report,Local,Cross-sectional survey ,United States of America,Massachusetts,Holyoke,All household members for selected addresses were invited to participate,,2020-11-05,2021-01-31,Household and community samples,Female,Multiple groups,,,Sex/Gender,Female,180,0.127,0.055,0.19899999999999998,,,True,,,Simplified probability,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],Yes,Yes,No,No,Yes,Unclear,Yes,No,No,City of Holyoke,City of Holyoke,Not Unity-Aligned,https://www.holyoke.org/documents/city-of-holyoke-serosurvey-report/,2021-07-05,2022-07-16,Verified,city_of_holyoke_government_city_2021,USA
210414_Holyoke_CityofHolyoke_Age_85+,210414_Holyoke_CityofHolyoke, City of Holyoke Serosurvey Report,2021-06-23,Institutional Report,Local,Cross-sectional survey ,United States of America,Massachusetts,Holyoke,All household members for selected addresses were invited to participate,,2020-11-05,2021-01-31,Household and community samples,All,Seniors (65+ years),85.0,,Age,85+,8,0.429,0.0,1.0,,,True,,,Simplified probability,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],Yes,Yes,No,No,Yes,Unclear,Yes,No,No,City of Holyoke,City of Holyoke,Not Unity-Aligned,https://www.holyoke.org/documents/city-of-holyoke-serosurvey-report/,2021-07-05,2022-07-16,Verified,city_of_holyoke_government_city_2021,USA
210414_Holyoke_CityofHolyoke_Age_0-19,210414_Holyoke_CityofHolyoke, City of Holyoke Serosurvey Report,2021-06-23,Institutional Report,Local,Cross-sectional survey ,United States of America,Massachusetts,Holyoke,All household members for selected addresses were invited to participate,,2020-11-05,2021-01-31,Household and community samples,All,Children and Youth (0-17 years),0.0,19.0,Age,0-19,27,0.207,0.022000000000000002,0.392,,,True,,,Simplified probability,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],Yes,Yes,No,No,Yes,Unclear,Yes,No,No,City of Holyoke,City of Holyoke,Not Unity-Aligned,https://www.holyoke.org/documents/city-of-holyoke-serosurvey-report/,2021-07-05,2022-07-16,Verified,city_of_holyoke_government_city_2021,USA
210414_Holyoke_CityofHolyoke_Age_20-44,210414_Holyoke_CityofHolyoke, City of Holyoke Serosurvey Report,2021-06-23,Institutional Report,Local,Cross-sectional survey ,United States of America,Massachusetts,Holyoke,All household members for selected addresses were invited to participate,,2020-11-05,2021-01-31,Household and community samples,All,Adults (18-64 years),20.0,44.0,Age,20-44,76,0.138,0.055999999999999994,0.22,,,True,,,Simplified probability,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],Yes,Yes,No,No,Yes,Unclear,Yes,No,No,City of Holyoke,City of Holyoke,Not Unity-Aligned,https://www.holyoke.org/documents/city-of-holyoke-serosurvey-report/,2021-07-05,2022-07-16,Verified,city_of_holyoke_government_city_2021,USA
210414_Holyoke_CityofHolyoke_Overall_PopUnAdj,210414_Holyoke_CityofHolyoke, City of Holyoke Serosurvey Report,2021-06-23,Institutional Report,Local,Cross-sectional survey ,United States of America,Massachusetts,Holyoke,All household members for selected addresses were invited to participate,,2020-11-05,2021-01-31,Household and community samples,All,Multiple groups,,,Analysis,Population Unadjusted,328,0.08199999999999999,0.05,0.125,,,,,,Simplified probability,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],Yes,Yes,No,No,Yes,Unclear,Yes,No,No,City of Holyoke,City of Holyoke,Not Unity-Aligned,https://www.holyoke.org/documents/city-of-holyoke-serosurvey-report/,2021-07-05,2022-07-16,Verified,city_of_holyoke_government_city_2021,USA
210414_Holyoke_CityofHolyoke_Age_60-84,210414_Holyoke_CityofHolyoke, City of Holyoke Serosurvey Report,2021-06-23,Institutional Report,Local,Cross-sectional survey ,United States of America,Massachusetts,Holyoke,All household members for selected addresses were invited to participate,,2020-11-05,2021-01-31,Household and community samples,All,Multiple groups,60.0,84.0,Age,60-84,123,0.048,0.0,0.102,,,True,,,Simplified probability,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],Yes,Yes,No,No,Yes,Unclear,Yes,No,No,City of Holyoke,City of Holyoke,Not Unity-Aligned,https://www.holyoke.org/documents/city-of-holyoke-serosurvey-report/,2021-07-05,2022-07-16,Verified,city_of_holyoke_government_city_2021,USA
210414_Holyoke_CityofHolyoke_Male,210414_Holyoke_CityofHolyoke, City of Holyoke Serosurvey Report,2021-06-23,Institutional Report,Local,Cross-sectional survey ,United States of America,Massachusetts,Holyoke,All household members for selected addresses were invited to participate,,2020-11-05,2021-01-31,Household and community samples,Male,Multiple groups,,,Sex/Gender,Male,139,0.153,0.047,0.259,,,True,,,Simplified probability,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],Yes,Yes,No,No,Yes,Unclear,Yes,No,No,City of Holyoke,City of Holyoke,Not Unity-Aligned,https://www.holyoke.org/documents/city-of-holyoke-serosurvey-report/,2021-07-05,2022-07-16,Verified,city_of_holyoke_government_city_2021,USA
210624_StLouis_WashingtonUniversitySchoolofMedicine_HCW,210624_StLouis_WashingtonUniversitySchoolofMedicine_HCW,SARS-CoV-2 Infection Risk Factors among Maintenance Hemodialysis Patients and Health Care Personnel In Outpatient Hemodialysis Centers.,2021-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Missouri,St. Louis,"This study was conducted in three outpatient HD units at Washington University School of
Medicine (WUSM) in St. Louis, Missouri. Dialysis center HCWs were enrolled. ",,2020-09-01,2020-09-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,39,0.0,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.99,['High'],,No,No,No,,Yes,Yes,Yes,,Sumanth Gandra,Washington University School of Medicine,Not Unity-Aligned,https://dx.doi.org/10.34067/KID.0001282021,2022-04-15,2024-03-01,Unverified,gandra_sars-cov-2_2021,USA
210624_StLouis_WashingtonUniversitySchoolofMedicine_Patients,210624_StLouis_WashingtonUniversitySchoolofMedicine_Patients,SARS-CoV-2 Infection Risk Factors among Maintenance Hemodialysis Patients and Health Care Personnel In Outpatient Hemodialysis Centers.,2021-06-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Missouri,St. Louis,"This study was conducted in three outpatient HD units at Washington University School of
Medicine (WUSM) in St. Louis, Missouri, USA. Adult patients on in-center HD were enrolled. ",,2020-09-01,2020-09-30,Residual sera,All,Multiple groups,,,Primary Estimate,,226,0.084,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9,0.99,['High'],No,No,No,Yes,No,Yes,Yes,Yes,Unclear,Sumanth Gandra,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.34067/KID.0001282021,2022-04-15,2024-03-01,Unverified,gandra_sars-cov-2_2021,USA
210625_Ohio_OhioStateUniversity_Overall_PopTestAdj,210625_Ohio_OhioStateUniversity,Estimating seroprevalence of SARS-CoV-2 in Ohio: A Bayesian multilevel poststratification approach with multiple diagnostic tests,2021-06-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Ohio,,"""Adults were eligible for the study if they were aged 18 y or older, slept in the home at least 4 d of the last 7 d, were proficient in English or Spanish, were willing to provide blood and nasopharyngeal swab samples, and were able to provide consent.""","""If the selected individual declined to participate, the team moved to the next selected household.""",2020-07-09,2020-07-28,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,667,0.013000000000000001,0.002,0.027000000000000003,True,True,True,True,,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,EDI™ Novel Coronavirus COVID-19 IgM ELISA Kit","Abbott Laboratories,DiaSorin,Epitope Diagnostics, Inc.",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,David Kline,Ohio State University,Not Unity-Aligned,https://doi.org/10.1073/pnas.2023947118,2022-12-09,2023-03-19,Unverified,kline_estimating_2021,USA
210625_Ohio_OhioStateUniversity_Age18-44,210625_Ohio_OhioStateUniversity,Estimating seroprevalence of SARS-CoV-2 in Ohio: A Bayesian multilevel poststratification approach with multiple diagnostic tests,2021-06-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Ohio,,"""Adults were eligible for the study if they were aged 18 y or older, slept in the home at least 4 d of the last 7 d, were proficient in English or Spanish, were willing to provide blood and nasopharyngeal swab samples, and were able to provide consent.""","""If the selected individual declined to participate, the team moved to the next selected household.""",2020-07-09,2020-07-28,Household and community samples,All,Adults (18-64 years),18.0,44.0,Age,,175,0.011399999999999999,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,David Kline,Ohio State University,Not Unity-Aligned,https://doi.org/10.1073/pnas.2023947118,2022-12-09,2024-03-01,Unverified,kline_estimating_2021,USA
210625_Ohio_OhioStateUniversity_SexMale,210625_Ohio_OhioStateUniversity,Estimating seroprevalence of SARS-CoV-2 in Ohio: A Bayesian multilevel poststratification approach with multiple diagnostic tests,2021-06-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Ohio,,"""Adults were eligible for the study if they were aged 18 y or older, slept in the home at least 4 d of the last 7 d, were proficient in English or Spanish, were willing to provide blood and nasopharyngeal swab samples, and were able to provide consent.""","""If the selected individual declined to participate, the team moved to the next selected household.""",2020-07-09,2020-07-28,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,275,0.0182,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,David Kline,Ohio State University,Not Unity-Aligned,https://doi.org/10.1073/pnas.2023947118,2022-12-09,2024-03-01,Unverified,kline_estimating_2021,USA
210625_Ohio_OhioStateUniversity_SexFemale,210625_Ohio_OhioStateUniversity,Estimating seroprevalence of SARS-CoV-2 in Ohio: A Bayesian multilevel poststratification approach with multiple diagnostic tests,2021-06-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Ohio,,"""Adults were eligible for the study if they were aged 18 y or older, slept in the home at least 4 d of the last 7 d, were proficient in English or Spanish, were willing to provide blood and nasopharyngeal swab samples, and were able to provide consent.""","""If the selected individual declined to participate, the team moved to the next selected household.""",2020-07-09,2020-07-28,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,392,0.015300000000000001,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,David Kline,Ohio State University,Not Unity-Aligned,https://doi.org/10.1073/pnas.2023947118,2022-12-09,2024-03-01,Unverified,kline_estimating_2021,USA
210625_Ohio_OhioStateUniversity_Overall_UnAdj,210625_Ohio_OhioStateUniversity,Estimating seroprevalence of SARS-CoV-2 in Ohio: A Bayesian multilevel poststratification approach with multiple diagnostic tests,2021-06-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Ohio,,"""Adults were eligible for the study if they were aged 18 y or older, slept in the home at least 4 d of the last 7 d, were proficient in English or Spanish, were willing to provide blood and nasopharyngeal swab samples, and were able to provide consent.""","""If the selected individual declined to participate, the team moved to the next selected household.""",2020-07-09,2020-07-28,Household and community samples,All,Multiple groups,18.0,,Analysis,,667,0.058499999999999996,,,,,,,True,Stratified probability,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,EDI™ Novel Coronavirus COVID-19 IgM ELISA Kit","Abbott Laboratories,DiaSorin,Epitope Diagnostics, Inc.",Multiple Types,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,David Kline,Ohio State University,Not Unity-Aligned,https://doi.org/10.1073/pnas.2023947118,2022-12-09,2024-03-01,Unverified,kline_estimating_2021,USA
210625_Ohio_OhioStateUniversity_Age65+,210625_Ohio_OhioStateUniversity,Estimating seroprevalence of SARS-CoV-2 in Ohio: A Bayesian multilevel poststratification approach with multiple diagnostic tests,2021-06-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Ohio,,"""Adults were eligible for the study if they were aged 18 y or older, slept in the home at least 4 d of the last 7 d, were proficient in English or Spanish, were willing to provide blood and nasopharyngeal swab samples, and were able to provide consent.""","""If the selected individual declined to participate, the team moved to the next selected household.""",2020-07-09,2020-07-28,Household and community samples,All,Seniors (65+ years),65.0,,Age,,253,0.027700000000000002,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,David Kline,Ohio State University,Not Unity-Aligned,https://doi.org/10.1073/pnas.2023947118,2022-12-09,2024-03-01,Unverified,kline_estimating_2021,USA
210625_Ohio_OhioStateUniversity_Age45-64,210625_Ohio_OhioStateUniversity,Estimating seroprevalence of SARS-CoV-2 in Ohio: A Bayesian multilevel poststratification approach with multiple diagnostic tests,2021-06-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Ohio,,"""Adults were eligible for the study if they were aged 18 y or older, slept in the home at least 4 d of the last 7 d, were proficient in English or Spanish, were willing to provide blood and nasopharyngeal swab samples, and were able to provide consent.""","""If the selected individual declined to participate, the team moved to the next selected household.""",2020-07-09,2020-07-28,Household and community samples,All,Adults (18-64 years),45.0,64.0,Age,,239,0.0084,,,,,,,,Stratified probability,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,David Kline,Ohio State University,Not Unity-Aligned,https://doi.org/10.1073/pnas.2023947118,2022-12-09,2024-03-01,Unverified,kline_estimating_2021,USA
210702_USA_DaVitaClinicalResearch,210702_USA_DaVitaClinicalResearch,"Antibody Status, Disease History, and Incidence of SARS-CoV-2 Infection Among Patients on Chronic Dialysis.",2021-07-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,"California, Connecticut, Minnesota, Nevada, New York, Ohio, Texas, Virginia, and Wisconsin",,"Eligible subjects were patients aged 18-80 years who were receiving hemodialysis at participating clinics operated by a large dialysis organization in the United States (participating clinics were located in California, Connecticut, Minnesota, Nevada, New York, Ohio, Texas, Virginia, and Wisconsin) who were able to provide written informed consent",,2020-07-01,2020-07-31,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,80.0,Primary Estimate,,2337,0.095,,,True,,,,True,Convenience,Diazyme DZ-Lite SARS-CoV-2 IgG  CLIA tests,Diazyme Laboratories Inc,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Dena Cohen,DaVita Clinical Research,Not Unity-Aligned,https://dx.doi.org/10.1681/ASN.2021030387,2021-07-13,2024-03-01,Verified,cohen_antibody_2021,USA
210702_Ohio_UniversityHospitalsClevelandMedicalCenter_Overall,210702_Ohio_UniversityHospitalsClevelandMedicalCenter,SARS-CoV-2 Seroprevalence among First Responders in Northeastern Ohio,2021-07-02,Preprint,Regional,Cross-sectional survey ,United States of America,Northeastern Ohio,,"All first responders who work in the region, were older than 18 years of age and able to provide consent were invited to participate. ",There were no additional exclusion criteria.,2020-05-22,2020-09-15,Essential non-healthcare workers,All,Multiple groups,18.0,,Primary Estimate,Overall,3080,0.024,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Xiaochun Zhang,University Hospitals Cleveland Medical Center,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.06.27.21259432v1.full-text,2021-07-16,2024-03-01,Unverified,zhangSARSCoV2SeroprevalenceFirst2021,USA
210702_Ohio_UniversityHospitalsClevelandMedicalCenter_50-59,210702_Ohio_UniversityHospitalsClevelandMedicalCenter,SARS-CoV-2 Seroprevalence among First Responders in Northeastern Ohio,2021-07-02,Preprint,Regional,Cross-sectional survey ,United States of America,Northeastern Ohio,,"All first responders who work in the region, were older than 18 years of age and able to provide consent were invited to participate. ",There were no additional exclusion criteria.,2020-05-22,2020-09-15,Essential non-healthcare workers,All,Adults (18-64 years),50.0,60.0,Age,50-60,695,0.0187,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Xiaochun Zhang,University Hospitals Cleveland Medical Center,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.06.27.21259432v1.full-text,2021-07-16,2024-03-01,Unverified,zhangSARSCoV2SeroprevalenceFirst2021,USA
210702_Ohio_UniversityHospitalsClevelandMedicalCenter_30-39,210702_Ohio_UniversityHospitalsClevelandMedicalCenter,SARS-CoV-2 Seroprevalence among First Responders in Northeastern Ohio,2021-07-02,Preprint,Regional,Cross-sectional survey ,United States of America,Northeastern Ohio,,"All first responders who work in the region, were older than 18 years of age and able to provide consent were invited to participate. ",There were no additional exclusion criteria.,2020-05-22,2020-09-15,Essential non-healthcare workers,All,Adults (18-64 years),30.0,39.0,Age,30-39,773,0.0233,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Xiaochun Zhang,University Hospitals Cleveland Medical Center,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.06.27.21259432v1.full-text,2021-07-16,2024-03-01,Unverified,zhangSARSCoV2SeroprevalenceFirst2021,USA
210702_Ohio_UniversityHospitalsClevelandMedicalCenter_40-49,210702_Ohio_UniversityHospitalsClevelandMedicalCenter,SARS-CoV-2 Seroprevalence among First Responders in Northeastern Ohio,2021-07-02,Preprint,Regional,Cross-sectional survey ,United States of America,Northeastern Ohio,,"All first responders who work in the region, were older than 18 years of age and able to provide consent were invited to participate. ",There were no additional exclusion criteria.,2020-05-22,2020-09-15,Essential non-healthcare workers,All,Adults (18-64 years),40.0,49.0,Age,40-49,858,0.0245,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Xiaochun Zhang,University Hospitals Cleveland Medical Center,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.06.27.21259432v1.full-text,2021-07-16,2024-03-01,Unverified,zhangSARSCoV2SeroprevalenceFirst2021,USA
210702_Ohio_UniversityHospitalsClevelandMedicalCenter_60+,210702_Ohio_UniversityHospitalsClevelandMedicalCenter,SARS-CoV-2 Seroprevalence among First Responders in Northeastern Ohio,2021-07-02,Preprint,Regional,Cross-sectional survey ,United States of America,Northeastern Ohio,,"All first responders who work in the region, were older than 18 years of age and able to provide consent were invited to participate. ",There were no additional exclusion criteria.,2020-05-22,2020-09-15,Essential non-healthcare workers,All,Seniors (65+ years),60.0,,Age,60+,248,0.0202,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Xiaochun Zhang,University Hospitals Cleveland Medical Center,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.06.27.21259432v1.full-text,2021-07-16,2024-03-01,Unverified,zhangSARSCoV2SeroprevalenceFirst2021,USA
210702_Ohio_UniversityHospitalsClevelandMedicalCenter_18-29,210702_Ohio_UniversityHospitalsClevelandMedicalCenter,SARS-CoV-2 Seroprevalence among First Responders in Northeastern Ohio,2021-07-02,Preprint,Regional,Cross-sectional survey ,United States of America,Northeastern Ohio,,"All first responders who work in the region, were older than 18 years of age and able to provide consent were invited to participate. ",There were no additional exclusion criteria.,2020-05-22,2020-09-15,Essential non-healthcare workers,All,Adults (18-64 years),18.0,29.0,Age,18-29,505,0.0317,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Xiaochun Zhang,University Hospitals Cleveland Medical Center,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.06.27.21259432v1.full-text,2021-07-16,2024-03-01,Unverified,zhangSARSCoV2SeroprevalenceFirst2021,USA
210703_Atlanta_CentersForDiseaseControlAndPrevention,210703_Atlanta_CentersForDiseaseControlAndPrevention,"Epidemiologic, immunologic, and virus characteristics in patients with paired SARS-CoV-2 serology and reverse transcription polymerase chain reaction testing.",2021-07-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Georgia,Atlanta,"they were eligible to enroll if the treating clinician ordered an NP swab for SARS-CoV-2 RT-PCR testing for
any reason including diagnostic and screening purposes","Patients were excluded if they were unable to consent, if they declined participation, they
were under 18 years of age, or if they had been enrolled on a previous hospital visit",2020-08-31,2020-11-23,Residual sera,All,Multiple groups,18.0,,Primary Estimate,,592,0.179,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],Unclear,No,No,Yes,Unclear,Unclear,Yes,No,Unclear,Talya Shragai,United States Centers for Disease Control and Prevention,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab349,2021-07-14,2022-07-16,Verified,shragai_epidemiologic_2021,USA
210707_Monrovia_OakCrestInstituteOfScience_Overall,210707_Monrovia_OakCrestInstituteOfScience,Longitudinal COVID-19 Surveillance and Characterization in the Workplace with Public Health and Diagnostic Endpoints.,2021-07-07,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,California,Monrovia,"All employees, students, and volunteers at Oak Crest (https://www.oak-crest.org/), a small nonprofit academic science research organization located in Monrovia, CA, were asked to participate in the prospective, longitudinal, observational study designed to last 12 weeks, or longer. 

Household members from the above-described study population also were invited to participate in the study.",,2020-03-27,2020-05-26,Non-essential workers and unemployed persons,All,Adults (18-64 years),,,Primary Estimate,,33,0.061,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],Yes,No,No,No,Unclear,Unclear,Yes,No,Yes,Manjula Gunawardana,Oak Crest Institute of Science,Not Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00542-21,2021-07-13,2022-07-16,Verified,gunawardana_longitudinal_2021,USA
210707_UnitedStates_NationalInstitutesOfHealth_Overall,210707_UnitedStates_NationalInstitutesOfHealth,Undiagnosed sars-cov-2 seropositivity during the first 6 months of the covid-19 pandemic in the united states,2021-07-07,Journal Article (Peer-Reviewed),National,Prospective cohort,United States of America,,,"This study was designed to determine the seroprevalence of anti–
SARS-CoV-2 antibodies in adults 18 years of age or older in the 
United States who had not been previously diagnosed with COVID-19.",,2020-04-01,2020-08-04,Household and community samples,All,Multiple groups,18.0,95.0,Primary Estimate,Overall,8058,0.046,0.026000000000000002,0.065,True,True,True,,True,Stratified non-probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,"['IgG', 'IgM']",Spike,Validated by developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Heather Kalish,National Institutes of Health,Not Unity-Aligned,http://dx.doi.org/10.1126/scitranslmed.abh3826,2021-07-19,2022-07-16,Verified,kalishUndiagnosedSARSCoV2Seropositivity2021,USA
210707_UnitedStates_NationalInstitutesOfHealth_Male,210707_UnitedStates_NationalInstitutesOfHealth,Undiagnosed sars-cov-2 seropositivity during the first 6 months of the covid-19 pandemic in the united states,2021-07-07,Journal Article (Peer-Reviewed),National,Prospective cohort,United States of America,,,"This study was designed to determine the seroprevalence of anti–
SARS-CoV-2 antibodies in adults 18 years of age or older in the 
United States who had not been previously diagnosed with COVID-19.",,2020-04-01,2020-08-04,Household and community samples,Male,Multiple groups,18.0,95.0,Sex/Gender,Male,3817,0.035,0.015,0.057999999999999996,,True,True,,,Stratified non-probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,"['IgG', 'IgM']",Spike,Validated by developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Heather Kalish,National Institutes of Health,Not Unity-Aligned,http://dx.doi.org/10.1126/scitranslmed.abh3826,2021-07-19,2022-07-16,Verified,kalishUndiagnosedSARSCoV2Seropositivity2021,USA
210707_UnitedStates_NationalInstitutesOfHealth_Female,210707_UnitedStates_NationalInstitutesOfHealth,Undiagnosed sars-cov-2 seropositivity during the first 6 months of the covid-19 pandemic in the united states,2021-07-07,Journal Article (Peer-Reviewed),National,Prospective cohort,United States of America,,,"This study was designed to determine the seroprevalence of anti–
SARS-CoV-2 antibodies in adults 18 years of age or older in the 
United States who had not been previously diagnosed with COVID-19.",,2020-04-01,2020-08-04,Household and community samples,Female,Multiple groups,18.0,95.0,Sex/Gender,Female,4241,0.055,0.027999999999999997,0.09,,True,True,,,Stratified non-probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,"['IgG', 'IgM']",Spike,Validated by developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Heather Kalish,National Institutes of Health,Not Unity-Aligned,http://dx.doi.org/10.1126/scitranslmed.abh3826,2021-07-19,2022-07-16,Verified,kalishUndiagnosedSARSCoV2Seropositivity2021,USA
210707_UnitedStates_NationalInstitutesOfHealth_45-70,210707_UnitedStates_NationalInstitutesOfHealth,Undiagnosed sars-cov-2 seropositivity during the first 6 months of the covid-19 pandemic in the united states,2021-07-07,Journal Article (Peer-Reviewed),National,Prospective cohort,United States of America,,,"This study was designed to determine the seroprevalence of anti–
SARS-CoV-2 antibodies in adults 18 years of age or older in the 
United States who had not been previously diagnosed with COVID-19.",,2020-04-01,2020-08-04,Household and community samples,All,Adults (18-64 years),40.0,75.0,Age,45-70,3436,0.034,0.017,0.05,,True,True,,,Stratified non-probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,"['IgG', 'IgM']",Spike,Validated by developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Heather Kalish,National Institutes of Health,Not Unity-Aligned,http://dx.doi.org/10.1126/scitranslmed.abh3826,2021-07-19,2022-07-16,Verified,kalishUndiagnosedSARSCoV2Seropositivity2021,USA
210707_UnitedStates_NationalInstitutesOfHealth_18-45,210707_UnitedStates_NationalInstitutesOfHealth,Undiagnosed sars-cov-2 seropositivity during the first 6 months of the covid-19 pandemic in the united states,2021-07-07,Journal Article (Peer-Reviewed),National,Prospective cohort,United States of America,,,"This study was designed to determine the seroprevalence of anti–
SARS-CoV-2 antibodies in adults 18 years of age or older in the 
United States who had not been previously diagnosed with COVID-19.",,2020-04-01,2020-08-04,Household and community samples,All,Adults (18-64 years),18.0,40.0,Age,18-45,3349,0.059000000000000004,0.027999999999999997,0.099,,True,True,,,Stratified non-probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,"['IgG', 'IgM']",Spike,Validated by developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Heather Kalish,National Institutes of Health,Not Unity-Aligned,http://dx.doi.org/10.1126/scitranslmed.abh3826,2021-07-19,2022-07-16,Verified,kalishUndiagnosedSARSCoV2Seropositivity2021,USA
210707_UnitedStates_NationalInstitutesOfHealth_70-95,210707_UnitedStates_NationalInstitutesOfHealth,Undiagnosed sars-cov-2 seropositivity during the first 6 months of the covid-19 pandemic in the united states,2021-07-07,Journal Article (Peer-Reviewed),National,Prospective cohort,United States of America,,,"This study was designed to determine the seroprevalence of anti–
SARS-CoV-2 antibodies in adults 18 years of age or older in the 
United States who had not been previously diagnosed with COVID-19.",,2020-04-01,2020-08-04,Household and community samples,All,Seniors (65+ years),75.0,90.0,Age,70-95,1273,0.035,0.009000000000000001,0.07400000000000001,,True,True,,,Stratified non-probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,"['IgG', 'IgM']",Spike,Validated by developers,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Heather Kalish,National Institutes of Health,Not Unity-Aligned,http://dx.doi.org/10.1126/scitranslmed.abh3826,2021-07-19,2022-07-16,Verified,kalishUndiagnosedSARSCoV2Seropositivity2021,USA
210708_Philadelphia_UniversityofPennsylvania,210708_Philadelphia_UniversityofPennsylvania,Health care worker sero-monitoring reveals complex relationships between common coronavirus antibodies and COVID-19 symptom duration,2021-07-08,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Pennsylvania,Philadelphia,"Only health care workers with direct
contact with patients or who worked on units where patients with COVID-19 received care were
included in this study.",We excluded anyone who was previously diagnosed with a SARS-CoV-2 infection.,2020-04-13,2020-05-20,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Baseline seroprevalence of cohort,2043,0.02,,,True,,,,True,Convenience,Author designed (ELISA) - MULTIPLEXED,,ELISA,Serum,"['IgG', 'IgM']",Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Sigrid Gouma,University of Pennsylvania,Not Unity-Aligned,http://dx.doi.org/10.1172/jci.insight.150449,2021-08-15,2022-07-16,Unverified,gouma_health_2021,USA
210710_Athens_UniversityofGeorgia_PopTestAdj,210710_Athens_UniversityofGeorgia,Prevalence of previous infection with SARS-CoV-2 and persistent symptoms at a large university,2021-07-10,Preprint,Local,Cross-sectional survey ,United States of America,Georgia,Athens,"We identified classes with at least 20 students from each of the university’s 17 colleges, selecting both early undergraduate, late undergraduate, and graduate classes to develop as representative a sample as possible.",,2021-01-22,2021-03-22,Students and Daycares,All,Adults (18-64 years),,,Primary Estimate,"cutoff  > 61.85 ng/mL, ",432,0.41000000000000003,0.314,0.507,True,True,True,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgA,Spike,Validated by independent authors/third party/non-developers,0.8889,0.8889,['High'],,No,No,Yes,,Unclear,Yes,Yes,,Mark Ebell,University of Georgia,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.08.21260201v1,2021-07-21,2022-07-16,Unverified,ebell_prevalence_2021,USA
210710_USA_EmoryUniversity_overall_PopAdj_TestAdj,210710_USA_EmoryUniversity,"Severe Acute Respiratory Syndrome Coronavirus 2 Cumulative Incidence, United States, August 2020–December 2020",2021-07-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,household members aged >= 18 years old,,2020-08-09,2020-12-08,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,"Overall, population and test adjusted",4654,0.0471,0.033,0.0611,True,True,True,,,Stratified probability,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.98,0.993,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Patrick Sullivan,Emory University,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab626,2021-07-19,2023-08-15,Verified,sullivan_sars-cov-2_2021,USA
210710_USA_EmoryUniversity_August,210710_USA_EmoryUniversity,"Severe Acute Respiratory Syndrome Coronavirus 2 Cumulative Incidence, United States, August 2020–December 2020",2021-07-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,household members aged >= 18 years old,,2020-08-09,2020-08-31,Household and community samples,All,Multiple groups,18.0,,Time frame,Samples collected in August,1195,0.0414,0.0267,0.0637,,,True,,,Stratified probability,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.98,0.993,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Patrick Sullivan,Emory University,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab626,2021-08-14,2024-03-01,Verified,sullivan_sars-cov-2_2021,USA
210710_USA_EmoryUniversity_age18-34,210710_USA_EmoryUniversity,"Severe Acute Respiratory Syndrome Coronavirus 2 Cumulative Incidence, United States, August 2020–December 2020",2021-07-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,household members aged >= 18 years old,,2020-08-09,2020-12-08,Household and community samples,All,Adults (18-64 years),18.0,34.0,Age,age 18-34,1013,0.0671,0.0444,0.1001,,,True,,,Stratified probability,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.98,0.993,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Patrick Sullivan,Emory University,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab626,2021-07-19,2024-03-01,Verified,sullivan_sars-cov-2_2021,USA
210710_USA_EmoryUniversity_age35-44,210710_USA_EmoryUniversity,"Severe Acute Respiratory Syndrome Coronavirus 2 Cumulative Incidence, United States, August 2020–December 2020",2021-07-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,household members aged >= 18 years old,,2020-08-09,2020-12-08,Household and community samples,All,Adults (18-64 years),35.0,44.0,Age,age 35-44,777,0.0734,0.04650000000000001,0.11410000000000001,,,True,,,Stratified probability,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.98,0.993,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Patrick Sullivan,Emory University,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab626,2021-07-19,2024-03-01,Verified,sullivan_sars-cov-2_2021,USA
210710_USA_EmoryUniversity_male,210710_USA_EmoryUniversity,"Severe Acute Respiratory Syndrome Coronavirus 2 Cumulative Incidence, United States, August 2020–December 2020",2021-07-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,household members aged >= 18 years old,,2020-08-09,2020-12-08,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,1927,0.0518,0.0359,0.0741,,,True,,,Stratified probability,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.98,0.993,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Patrick Sullivan,Emory University,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab626,2021-07-19,2024-03-01,Verified,sullivan_sars-cov-2_2021,USA
210710_USA_EmoryUniversity_September,210710_USA_EmoryUniversity,"Severe Acute Respiratory Syndrome Coronavirus 2 Cumulative Incidence, United States, August 2020–December 2020",2021-07-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,household members aged >= 18 years old,,2020-09-01,2020-09-30,Household and community samples,All,Multiple groups,18.0,,Time frame,Samples collected in September,406,0.0592,0.0333,0.10310000000000001,,,True,,,Stratified probability,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.98,0.993,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Patrick Sullivan,Emory University,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab626,2021-08-14,2024-03-01,Verified,sullivan_sars-cov-2_2021,USA
210710_USA_EmoryUniversity_age55-64,210710_USA_EmoryUniversity,"Severe Acute Respiratory Syndrome Coronavirus 2 Cumulative Incidence, United States, August 2020–December 2020",2021-07-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,household members aged >= 18 years old,,2020-08-09,2020-12-08,Household and community samples,All,Adults (18-64 years),18.0,,Age,age 55-64,926,0.0471,0.0276,0.07940000000000001,,,True,,,Stratified probability,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.98,0.993,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Patrick Sullivan,Emory University,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab626,2021-07-19,2024-03-01,Verified,sullivan_sars-cov-2_2021,USA
210710_USA_EmoryUniversity_female,210710_USA_EmoryUniversity,"Severe Acute Respiratory Syndrome Coronavirus 2 Cumulative Incidence, United States, August 2020–December 2020",2021-07-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,household members aged >= 18 years old,,2020-08-09,2020-12-08,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,2727,0.053,0.0393,0.071,,,True,,,Stratified probability,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.98,0.993,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Patrick Sullivan,Emory University,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab626,2021-07-19,2024-03-01,Verified,sullivan_sars-cov-2_2021,USA
210710_USA_EmoryUniversity_November-December,210710_USA_EmoryUniversity,"Severe Acute Respiratory Syndrome Coronavirus 2 Cumulative Incidence, United States, August 2020–December 2020",2021-07-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,household members aged >= 18 years old,,2020-11-01,2020-12-08,Household and community samples,All,Multiple groups,18.0,,Time frame,Samples collected from November to December,2241,0.0716,0.048600000000000004,0.10439999999999999,,,True,,,Stratified probability,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.98,0.993,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Patrick Sullivan,Emory University,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab626,2021-08-14,2024-03-01,Verified,sullivan_sars-cov-2_2021,USA
210710_USA_EmoryUniversity_age65+,210710_USA_EmoryUniversity,"Severe Acute Respiratory Syndrome Coronavirus 2 Cumulative Incidence, United States, August 2020–December 2020",2021-07-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,household members aged >= 18 years old,,2020-08-09,2020-12-08,Household and community samples,All,Seniors (65+ years),65.0,,Age,age 65+,1173,0.0248,0.0122,0.049800000000000004,,,True,,,Stratified probability,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.98,0.993,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Patrick Sullivan,Emory University,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab626,2021-07-19,2024-03-01,Verified,sullivan_sars-cov-2_2021,USA
210710_USA_EmoryUniversity_October,210710_USA_EmoryUniversity,"Severe Acute Respiratory Syndrome Coronavirus 2 Cumulative Incidence, United States, August 2020–December 2020",2021-07-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,household members aged >= 18 years old,,2020-10-01,2020-10-31,Household and community samples,All,Multiple groups,18.0,,Time frame,Samples collected in October,812,0.048600000000000004,0.028999999999999998,0.0802,,,True,,,Stratified probability,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.98,0.993,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Patrick Sullivan,Emory University,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab626,2021-08-14,2024-03-01,Verified,sullivan_sars-cov-2_2021,USA
210710_USA_EmoryUniversity_overall_PopAdj,210710_USA_EmoryUniversity,"Severe Acute Respiratory Syndrome Coronavirus 2 Cumulative Incidence, United States, August 2020–December 2020",2021-07-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,household members aged >= 18 years old,,2020-08-09,2020-12-08,Household and community samples,All,Multiple groups,18.0,,Analysis,"Overall, population adjusted",4654,0.0524,0.0414,0.066,,,True,,True,Stratified probability,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.98,0.993,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Patrick Sullivan,Emory University,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab626,2021-07-19,2024-03-01,Verified,sullivan_sars-cov-2_2021,USA
210710_USA_EmoryUniversity_age45-54,210710_USA_EmoryUniversity,"Severe Acute Respiratory Syndrome Coronavirus 2 Cumulative Incidence, United States, August 2020–December 2020",2021-07-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,household members aged >= 18 years old,,2020-08-09,2020-12-08,Household and community samples,All,Adults (18-64 years),45.0,54.0,Age,age 45-54,765,0.0484,0.0259,0.0884,,,True,,,Stratified probability,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.98,0.993,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Patrick Sullivan,Emory University,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab626,2021-07-19,2024-03-01,Verified,sullivan_sars-cov-2_2021,USA
210712_UnitedStates_StanfordUniversity_Overall,210712_UnitedStates_StanfordUniversity,Estimated SARS-CoV-2 Seroprevalence in US Patients Receiving Dialysis 1 Year After the Beginning of the COVID-19 Pandemic.,2021-07-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"We tested for SARS-CoV-2 seroprevalence among patients receiving dialysis at facilities within a single dialysis network (US Renal Care), which is the third largest dialysis provider in the US and has more
than 500 facilities located nationwide.",Patients were excluded if they had a documented dose of SARS-CoV-2 vaccination or if a residence zip code was missing from the electronic medical record (eFigure 1 in the Supplement).,2021-01-01,2021-01-31,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,21464,0.187,0.18100000000000002,0.192,True,,True,,True,Convenience,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Plasma,"['IgG', 'IgM']",Spike,Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Shuchi Anand,Stanford University,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.16572,2021-07-21,2024-03-01,Unverified,anand_estimated_2021,USA
210715_USA_GeorgeWashingtonUniversity_Overall,210715_USA_GeorgeWashingtonUniversity,Association of varying clinical manifestations and positive anti-SARS-CoV-2 IgG antibodies: a cross-sectional observational study.,2021-07-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,"California, Connecticut, Michigan, New Jersey, New York",,"Adults 18 years or older with informed consent:

""adults (≥18 years)""
""Subjects were recruited by local not-for-profit and social service organizations within orthodox Jewish communities across 5 states (California, Connecticut, Michigan, New Jersey, and New York) between May 13 and July 6, 2020.""
""Electronic informed consent was taken and disclosure of the study purpose was done before beginning the survey.""",,2020-05-14,2020-05-30,Household and community samples,All,Multiple groups,18.0,94.0,Primary Estimate,,6665,0.3,,,True,,,,True,Convenience,EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit,"Epitope Diagnostics, Inc.",ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,No,Jonathan Silverberg,George Washington University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jaip.2021.06.046,2021-08-03,2024-03-01,Verified,silverberg_association_2021,USA
210715_USA_GeorgeWashingtonUniversity_Female,210715_USA_GeorgeWashingtonUniversity,Association of varying clinical manifestations and positive anti-SARS-CoV-2 IgG antibodies: a cross-sectional observational study.,2021-07-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,"California, Connecticut, Michigan, New Jersey, New York",,"Adults 18 years or older with informed consent:

""adults (≥18 years)""
""Subjects were recruited by local not-for-profit and social service organizations within orthodox Jewish communities across 5 states (California, Connecticut, Michigan, New Jersey, and New York) between May 13 and July 6, 2020.""
""Electronic informed consent was taken and disclosure of the study purpose was done before beginning the survey.""",,2020-05-14,2020-05-30,Household and community samples,Female,Multiple groups,18.0,94.0,Sex/Gender,,3068,0.245,,,,,,,,Convenience,EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit,"Epitope Diagnostics, Inc.",ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,No,Jonathan Silverberg,George Washington University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jaip.2021.06.046,2021-11-04,2024-03-01,Verified,silverberg_association_2021,USA
210715_USA_GeorgeWashingtonUniversity_50-69,210715_USA_GeorgeWashingtonUniversity,Association of varying clinical manifestations and positive anti-SARS-CoV-2 IgG antibodies: a cross-sectional observational study.,2021-07-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,"California, Connecticut, Michigan, New Jersey, New York",,"Adults 18 years or older with informed consent:

""adults (≥18 years)""
""Subjects were recruited by local not-for-profit and social service organizations within orthodox Jewish communities across 5 states (California, Connecticut, Michigan, New Jersey, and New York) between May 13 and July 6, 2020.""
""Electronic informed consent was taken and disclosure of the study purpose was done before beginning the survey.""",,2020-05-14,2020-05-30,Household and community samples,All,Adults (18-64 years),50.0,69.0,Age,50-69,1400,0.371,,,,,,,,Convenience,EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit,"Epitope Diagnostics, Inc.",ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,No,Jonathan Silverberg,George Washington University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jaip.2021.06.046,2021-08-05,2024-03-01,Verified,silverberg_association_2021,USA
210715_USA_GeorgeWashingtonUniversity_70+,210715_USA_GeorgeWashingtonUniversity,Association of varying clinical manifestations and positive anti-SARS-CoV-2 IgG antibodies: a cross-sectional observational study.,2021-07-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,"California, Connecticut, Michigan, New Jersey, New York",,"Adults 18 years or older with informed consent:

""adults (≥18 years)""
""Subjects were recruited by local not-for-profit and social service organizations within orthodox Jewish communities across 5 states (California, Connecticut, Michigan, New Jersey, and New York) between May 13 and July 6, 2020.""
""Electronic informed consent was taken and disclosure of the study purpose was done before beginning the survey.""",,2020-05-14,2020-05-30,Household and community samples,All,Seniors (65+ years),70.0,94.0,Age,>=70,243,0.36600000000000005,,,,,,,,Convenience,EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit,"Epitope Diagnostics, Inc.",ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,No,Jonathan Silverberg,George Washington University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jaip.2021.06.046,2021-08-05,2024-03-01,Verified,silverberg_association_2021,USA
210715_USA_GeorgeWashingtonUniversity_18-49,210715_USA_GeorgeWashingtonUniversity,Association of varying clinical manifestations and positive anti-SARS-CoV-2 IgG antibodies: a cross-sectional observational study.,2021-07-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,"California, Connecticut, Michigan, New Jersey, New York",,"Adults 18 years or older with informed consent:

""adults (≥18 years)""
""Subjects were recruited by local not-for-profit and social service organizations within orthodox Jewish communities across 5 states (California, Connecticut, Michigan, New Jersey, and New York) between May 13 and July 6, 2020.""
""Electronic informed consent was taken and disclosure of the study purpose was done before beginning the survey.""",,2020-05-14,2020-05-30,Household and community samples,All,Adults (18-64 years),18.0,49.0,Age,18-49,5003,0.276,,,,,,,,Convenience,EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit,"Epitope Diagnostics, Inc.",ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,No,Jonathan Silverberg,George Washington University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jaip.2021.06.046,2021-08-05,2024-03-01,Verified,silverberg_association_2021,USA
210715_USA_GeorgeWashingtonUniversity_Male,210715_USA_GeorgeWashingtonUniversity,Association of varying clinical manifestations and positive anti-SARS-CoV-2 IgG antibodies: a cross-sectional observational study.,2021-07-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,"California, Connecticut, Michigan, New Jersey, New York",,"Adults 18 years or older with informed consent:

""adults (≥18 years)""
""Subjects were recruited by local not-for-profit and social service organizations within orthodox Jewish communities across 5 states (California, Connecticut, Michigan, New Jersey, and New York) between May 13 and July 6, 2020.""
""Electronic informed consent was taken and disclosure of the study purpose was done before beginning the survey.""",,2020-05-14,2020-05-30,Household and community samples,Male,Multiple groups,18.0,94.0,Sex/Gender,,3597,0.34600000000000003,,,,,,,,Convenience,EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit,"Epitope Diagnostics, Inc.",ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,No,Jonathan Silverberg,George Washington University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jaip.2021.06.046,2021-08-05,2024-03-01,Verified,silverberg_association_2021,USA
210719_Arkansas_UniversityOfArkansasForMedicalSciences_1_Overall,210719_Arkansas_UniversityOfArkansasForMedicalSciences_1,Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas,2021-07-19,Preprint,Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Pine Bluff","""Inclusion criteria for serum collection were age 18 years or older, Arkansas resident, and outpatient source.""","""Samples were excluded with the following diagnosis codes: immunodeficiency (primary immune deficiency (D80-D89), transplant recipient (all codes beginning with Z94), and cancer (C00-D49)). In addition, samples from patients with chemotherapy (prior two months), steroids (prior 30 days), and/or intravenous immunoglobulin (prior 6 months) were excluded.""",2020-08-15,2020-09-05,Residual sera,All,Multiple groups,18.0,,Primary Estimate,,1301,0.026000000000000002,0.017,0.035,True,,True,,True,Convenience,"Access SARS-CoV-2 IgG Reagent Antibody Test,Author designed (ELISA) - Unknown","Beckman Coulter,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,,Joshua Kennedy,University of Arkansas for Medical Sciences,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.15.21260213v1,2021-07-26,2024-03-01,Verified,kennedy_temporal_2021,USA
210719_Arkansas_UniversityOfArkansasForMedicalSciences_1_60-69,210719_Arkansas_UniversityOfArkansasForMedicalSciences_1,Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas,2021-07-19,Preprint,Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Pine Bluff","""Inclusion criteria for serum collection were age 18 years or older, Arkansas resident, and outpatient source.""","""Samples were excluded with the following diagnosis codes: immunodeficiency (primary immune deficiency (D80-D89), transplant recipient (all codes beginning with Z94), and cancer (C00-D49)). In addition, samples from patients with chemotherapy (prior two months), steroids (prior 30 days), and/or intravenous immunoglobulin (prior 6 months) were excluded.""",2020-08-15,2020-09-05,Residual sera,All,Multiple groups,60.0,69.0,Age,,209,0.013999999999999999,,,,,,,,Convenience,"Access SARS-CoV-2 IgG Reagent Antibody Test,Author designed (ELISA) - Unknown","Beckman Coulter,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,,Joshua Kennedy,University of Arkansas for Medical Sciences,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.15.21260213v1,2021-07-26,2024-03-01,Verified,kennedy_temporal_2021,USA
210719_Arkansas_UniversityOfArkansasForMedicalSciences_1_30-39,210719_Arkansas_UniversityOfArkansasForMedicalSciences_1,Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas,2021-07-19,Preprint,Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Pine Bluff","""Inclusion criteria for serum collection were age 18 years or older, Arkansas resident, and outpatient source.""","""Samples were excluded with the following diagnosis codes: immunodeficiency (primary immune deficiency (D80-D89), transplant recipient (all codes beginning with Z94), and cancer (C00-D49)). In addition, samples from patients with chemotherapy (prior two months), steroids (prior 30 days), and/or intravenous immunoglobulin (prior 6 months) were excluded.""",2020-08-15,2020-09-05,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,,244,0.053,,,,,,,,Convenience,"Access SARS-CoV-2 IgG Reagent Antibody Test,Author designed (ELISA) - Unknown","Beckman Coulter,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,,Joshua Kennedy,University of Arkansas for Medical Sciences,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.15.21260213v1,2021-07-26,2024-03-01,Verified,kennedy_temporal_2021,USA
210719_Arkansas_UniversityOfArkansasForMedicalSciences_1_Female,210719_Arkansas_UniversityOfArkansasForMedicalSciences_1,Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas,2021-07-19,Preprint,Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Pine Bluff","""Inclusion criteria for serum collection were age 18 years or older, Arkansas resident, and outpatient source.""","""Samples were excluded with the following diagnosis codes: immunodeficiency (primary immune deficiency (D80-D89), transplant recipient (all codes beginning with Z94), and cancer (C00-D49)). In addition, samples from patients with chemotherapy (prior two months), steroids (prior 30 days), and/or intravenous immunoglobulin (prior 6 months) were excluded.""",2020-08-15,2020-09-05,Residual sera,Female,Multiple groups,18.0,,Sex/Gender,,898,0.043,,,,,,,,Convenience,"Access SARS-CoV-2 IgG Reagent Antibody Test,Author designed (ELISA) - Unknown","Beckman Coulter,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,,Joshua Kennedy,University of Arkansas for Medical Sciences,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.15.21260213v1,2021-07-26,2024-03-01,Verified,kennedy_temporal_2021,USA
210719_Arkansas_UniversityOfArkansasForMedicalSciences_1_40-49,210719_Arkansas_UniversityOfArkansasForMedicalSciences_1,Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas,2021-07-19,Preprint,Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Pine Bluff","""Inclusion criteria for serum collection were age 18 years or older, Arkansas resident, and outpatient source.""","""Samples were excluded with the following diagnosis codes: immunodeficiency (primary immune deficiency (D80-D89), transplant recipient (all codes beginning with Z94), and cancer (C00-D49)). In addition, samples from patients with chemotherapy (prior two months), steroids (prior 30 days), and/or intravenous immunoglobulin (prior 6 months) were excluded.""",2020-08-15,2020-09-05,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,,205,0.028999999999999998,,,,,,,,Convenience,"Access SARS-CoV-2 IgG Reagent Antibody Test,Author designed (ELISA) - Unknown","Beckman Coulter,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,,Joshua Kennedy,University of Arkansas for Medical Sciences,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.15.21260213v1,2021-07-26,2024-03-01,Verified,kennedy_temporal_2021,USA
210719_Arkansas_UniversityOfArkansasForMedicalSciences_1_>70,210719_Arkansas_UniversityOfArkansasForMedicalSciences_1,Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas,2021-07-19,Preprint,Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Pine Bluff","""Inclusion criteria for serum collection were age 18 years or older, Arkansas resident, and outpatient source.""","""Samples were excluded with the following diagnosis codes: immunodeficiency (primary immune deficiency (D80-D89), transplant recipient (all codes beginning with Z94), and cancer (C00-D49)). In addition, samples from patients with chemotherapy (prior two months), steroids (prior 30 days), and/or intravenous immunoglobulin (prior 6 months) were excluded.""",2020-08-15,2020-09-05,Residual sera,All,Seniors (65+ years),70.0,,Age,,175,0.017,,,,,,,,Convenience,"Access SARS-CoV-2 IgG Reagent Antibody Test,Author designed (ELISA) - Unknown","Beckman Coulter,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,,Joshua Kennedy,University of Arkansas for Medical Sciences,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.15.21260213v1,2021-07-26,2024-03-01,Verified,kennedy_temporal_2021,USA
210719_Arkansas_UniversityOfArkansasForMedicalSciences_1_50-59,210719_Arkansas_UniversityOfArkansasForMedicalSciences_1,Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas,2021-07-19,Preprint,Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Pine Bluff","""Inclusion criteria for serum collection were age 18 years or older, Arkansas resident, and outpatient source.""","""Samples were excluded with the following diagnosis codes: immunodeficiency (primary immune deficiency (D80-D89), transplant recipient (all codes beginning with Z94), and cancer (C00-D49)). In addition, samples from patients with chemotherapy (prior two months), steroids (prior 30 days), and/or intravenous immunoglobulin (prior 6 months) were excluded.""",2020-08-15,2020-09-05,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,,211,0.033,,,,,,,,Convenience,"Access SARS-CoV-2 IgG Reagent Antibody Test,Author designed (ELISA) - Unknown","Beckman Coulter,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,,Joshua Kennedy,University of Arkansas for Medical Sciences,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.15.21260213v1,2021-07-26,2024-03-01,Verified,kennedy_temporal_2021,USA
210719_Arkansas_UniversityOfArkansasForMedicalSciences_1_Male,210719_Arkansas_UniversityOfArkansasForMedicalSciences_1,Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas,2021-07-19,Preprint,Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Pine Bluff","""Inclusion criteria for serum collection were age 18 years or older, Arkansas resident, and outpatient source.""","""Samples were excluded with the following diagnosis codes: immunodeficiency (primary immune deficiency (D80-D89), transplant recipient (all codes beginning with Z94), and cancer (C00-D49)). In addition, samples from patients with chemotherapy (prior two months), steroids (prior 30 days), and/or intravenous immunoglobulin (prior 6 months) were excluded.""",2020-08-15,2020-09-05,Residual sera,Male,Multiple groups,18.0,,Sex/Gender,,398,0.025,,,,,,,,Convenience,"Access SARS-CoV-2 IgG Reagent Antibody Test,Author designed (ELISA) - Unknown","Beckman Coulter,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,,Joshua Kennedy,University of Arkansas for Medical Sciences,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.15.21260213v1,2021-07-26,2024-03-01,Verified,kennedy_temporal_2021,USA
210719_Arkansas_UniversityOfArkansasForMedicalSciences_1_18-29,210719_Arkansas_UniversityOfArkansasForMedicalSciences_1,Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas,2021-07-19,Preprint,Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Pine Bluff","""Inclusion criteria for serum collection were age 18 years or older, Arkansas resident, and outpatient source.""","""Samples were excluded with the following diagnosis codes: immunodeficiency (primary immune deficiency (D80-D89), transplant recipient (all codes beginning with Z94), and cancer (C00-D49)). In addition, samples from patients with chemotherapy (prior two months), steroids (prior 30 days), and/or intravenous immunoglobulin (prior 6 months) were excluded.""",2020-08-15,2020-09-05,Residual sera,All,Adults (18-64 years),18.0,29.0,Age,18-29,257,0.066,,,,,,,,Convenience,"Access SARS-CoV-2 IgG Reagent Antibody Test,Author designed (ELISA) - Unknown","Beckman Coulter,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,,Joshua Kennedy,University of Arkansas for Medical Sciences,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.15.21260213v1,2021-07-26,2024-03-01,Verified,kennedy_temporal_2021,USA
210719_Arkansas_UniversityOfArkansasForMedicalSciences_2_Overall,210719_Arkansas_UniversityOfArkansasForMedicalSciences_2,Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas,2021-07-19,Preprint,Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Pine Bluff, Fort Smith","""Inclusion criteria for serum collection were age 18 years or older, Arkansas resident, and outpatient source.""","""Samples were excluded with the following diagnosis codes: immunodeficiency (primary immune deficiency (D80-D89), transplant recipient (all codes beginning with Z94), and cancer (C00-D49)). In addition, samples from patients with chemotherapy (prior two months), steroids (prior 30 days), and/or intravenous immunoglobulin (prior 6 months) were excluded.""",2020-09-12,2020-10-24,Residual sera,All,Multiple groups,18.0,,Primary Estimate,,2098,0.040999999999999995,0.031000000000000003,0.051,True,,True,,True,Convenience,"Access SARS-CoV-2 IgG Reagent Antibody Test,Author designed (ELISA) - Unknown","Beckman Coulter,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,,Joshua Kennedy,University of Arkansas for Medical Sciences,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.15.21260213v1,2021-07-26,2024-03-01,Verified,kennedy_temporal_2021,USA
210719_Arkansas_UniversityOfArkansasForMedicalSciences_2_>70,210719_Arkansas_UniversityOfArkansasForMedicalSciences_2,Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas,2021-07-19,Preprint,Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Pine Bluff, Fort Smith","""Inclusion criteria for serum collection were age 18 years or older, Arkansas resident, and outpatient source.""","""Samples were excluded with the following diagnosis codes: immunodeficiency (primary immune deficiency (D80-D89), transplant recipient (all codes beginning with Z94), and cancer (C00-D49)). In addition, samples from patients with chemotherapy (prior two months), steroids (prior 30 days), and/or intravenous immunoglobulin (prior 6 months) were excluded.""",2020-09-12,2020-10-24,Residual sera,All,Seniors (65+ years),70.0,,Age,,319,0.035,,,,,,,,Convenience,"Access SARS-CoV-2 IgG Reagent Antibody Test,Author designed (ELISA) - Unknown","Beckman Coulter,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,,Joshua Kennedy,University of Arkansas for Medical Sciences,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.15.21260213v1,2021-07-26,2024-03-01,Verified,kennedy_temporal_2021,USA
210719_Arkansas_UniversityOfArkansasForMedicalSciences_2_30-39,210719_Arkansas_UniversityOfArkansasForMedicalSciences_2,Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas,2021-07-19,Preprint,Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Pine Bluff, Fort Smith","""Inclusion criteria for serum collection were age 18 years or older, Arkansas resident, and outpatient source.""","""Samples were excluded with the following diagnosis codes: immunodeficiency (primary immune deficiency (D80-D89), transplant recipient (all codes beginning with Z94), and cancer (C00-D49)). In addition, samples from patients with chemotherapy (prior two months), steroids (prior 30 days), and/or intravenous immunoglobulin (prior 6 months) were excluded.""",2020-09-12,2020-10-24,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,,394,0.07400000000000001,,,,,,,,Convenience,"Access SARS-CoV-2 IgG Reagent Antibody Test,Author designed (ELISA) - Unknown","Beckman Coulter,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,,Joshua Kennedy,University of Arkansas for Medical Sciences,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.15.21260213v1,2021-07-26,2024-03-01,Verified,kennedy_temporal_2021,USA
210719_Arkansas_UniversityOfArkansasForMedicalSciences_2_Male,210719_Arkansas_UniversityOfArkansasForMedicalSciences_2,Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas,2021-07-19,Preprint,Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Pine Bluff, Fort Smith","""Inclusion criteria for serum collection were age 18 years or older, Arkansas resident, and outpatient source.""","""Samples were excluded with the following diagnosis codes: immunodeficiency (primary immune deficiency (D80-D89), transplant recipient (all codes beginning with Z94), and cancer (C00-D49)). In addition, samples from patients with chemotherapy (prior two months), steroids (prior 30 days), and/or intravenous immunoglobulin (prior 6 months) were excluded.""",2020-09-12,2020-10-24,Residual sera,Male,Multiple groups,18.0,,Sex/Gender,,668,0.046,,,,,,,,Convenience,"Access SARS-CoV-2 IgG Reagent Antibody Test,Author designed (ELISA) - Unknown","Beckman Coulter,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,,Joshua Kennedy,University of Arkansas for Medical Sciences,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.15.21260213v1,2021-07-26,2024-03-01,Verified,kennedy_temporal_2021,USA
210719_Arkansas_UniversityOfArkansasForMedicalSciences_2_18-29,210719_Arkansas_UniversityOfArkansasForMedicalSciences_2,Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas,2021-07-19,Preprint,Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Pine Bluff, Fort Smith","""Inclusion criteria for serum collection were age 18 years or older, Arkansas resident, and outpatient source.""","""Samples were excluded with the following diagnosis codes: immunodeficiency (primary immune deficiency (D80-D89), transplant recipient (all codes beginning with Z94), and cancer (C00-D49)). In addition, samples from patients with chemotherapy (prior two months), steroids (prior 30 days), and/or intravenous immunoglobulin (prior 6 months) were excluded.""",2020-09-12,2020-10-24,Residual sera,All,Adults (18-64 years),18.0,29.0,Age,18-29,406,0.054000000000000006,,,,,,,,Convenience,"Access SARS-CoV-2 IgG Reagent Antibody Test,Author designed (ELISA) - Unknown","Beckman Coulter,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,,Joshua Kennedy,University of Arkansas for Medical Sciences,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.15.21260213v1,2021-07-26,2024-03-01,Verified,kennedy_temporal_2021,USA
210719_Arkansas_UniversityOfArkansasForMedicalSciences_2_60-69,210719_Arkansas_UniversityOfArkansasForMedicalSciences_2,Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas,2021-07-19,Preprint,Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Pine Bluff, Fort Smith","""Inclusion criteria for serum collection were age 18 years or older, Arkansas resident, and outpatient source.""","""Samples were excluded with the following diagnosis codes: immunodeficiency (primary immune deficiency (D80-D89), transplant recipient (all codes beginning with Z94), and cancer (C00-D49)). In addition, samples from patients with chemotherapy (prior two months), steroids (prior 30 days), and/or intravenous immunoglobulin (prior 6 months) were excluded.""",2020-09-12,2020-10-24,Residual sera,All,Multiple groups,60.0,69.0,Age,,349,0.037000000000000005,,,,,,,,Convenience,"Access SARS-CoV-2 IgG Reagent Antibody Test,Author designed (ELISA) - Unknown","Beckman Coulter,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,,Joshua Kennedy,University of Arkansas for Medical Sciences,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.15.21260213v1,2021-07-26,2024-03-01,Verified,kennedy_temporal_2021,USA
210719_Arkansas_UniversityOfArkansasForMedicalSciences_2_50-59,210719_Arkansas_UniversityOfArkansasForMedicalSciences_2,Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas,2021-07-19,Preprint,Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Pine Bluff, Fort Smith","""Inclusion criteria for serum collection were age 18 years or older, Arkansas resident, and outpatient source.""","""Samples were excluded with the following diagnosis codes: immunodeficiency (primary immune deficiency (D80-D89), transplant recipient (all codes beginning with Z94), and cancer (C00-D49)). In addition, samples from patients with chemotherapy (prior two months), steroids (prior 30 days), and/or intravenous immunoglobulin (prior 6 months) were excluded.""",2020-09-12,2020-10-24,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,,335,0.042,,,,,,,,Convenience,"Access SARS-CoV-2 IgG Reagent Antibody Test,Author designed (ELISA) - Unknown","Beckman Coulter,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,,Joshua Kennedy,University of Arkansas for Medical Sciences,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.15.21260213v1,2021-07-26,2024-03-01,Verified,kennedy_temporal_2021,USA
210719_Arkansas_UniversityOfArkansasForMedicalSciences_2_40-49,210719_Arkansas_UniversityOfArkansasForMedicalSciences_2,Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas,2021-07-19,Preprint,Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Pine Bluff, Fort Smith","""Inclusion criteria for serum collection were age 18 years or older, Arkansas resident, and outpatient source.""","""Samples were excluded with the following diagnosis codes: immunodeficiency (primary immune deficiency (D80-D89), transplant recipient (all codes beginning with Z94), and cancer (C00-D49)). In addition, samples from patients with chemotherapy (prior two months), steroids (prior 30 days), and/or intravenous immunoglobulin (prior 6 months) were excluded.""",2020-09-12,2020-10-24,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,,294,0.044000000000000004,,,,,,,,Convenience,"Access SARS-CoV-2 IgG Reagent Antibody Test,Author designed (ELISA) - Unknown","Beckman Coulter,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,,Joshua Kennedy,University of Arkansas for Medical Sciences,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.15.21260213v1,2021-07-26,2024-03-01,Verified,kennedy_temporal_2021,USA
210719_Arkansas_UniversityOfArkansasForMedicalSciences_2_Female,210719_Arkansas_UniversityOfArkansasForMedicalSciences_2,Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas,2021-07-19,Preprint,Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Pine Bluff, Fort Smith","""Inclusion criteria for serum collection were age 18 years or older, Arkansas resident, and outpatient source.""","""Samples were excluded with the following diagnosis codes: immunodeficiency (primary immune deficiency (D80-D89), transplant recipient (all codes beginning with Z94), and cancer (C00-D49)). In addition, samples from patients with chemotherapy (prior two months), steroids (prior 30 days), and/or intravenous immunoglobulin (prior 6 months) were excluded.""",2020-09-12,2020-10-24,Residual sera,Female,Multiple groups,18.0,,Sex/Gender,,1430,0.05,,,,,,,,Convenience,"Access SARS-CoV-2 IgG Reagent Antibody Test,Author designed (ELISA) - Unknown","Beckman Coulter,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,,Joshua Kennedy,University of Arkansas for Medical Sciences,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.15.21260213v1,2021-07-26,2024-03-01,Verified,kennedy_temporal_2021,USA
210719_Arkansas_UniversityOfArkansasForMedicalSciences_3_Overall,210719_Arkansas_UniversityOfArkansasForMedicalSciences_3,Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas,2021-07-19,Preprint,Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Pine Bluff, Fort Smith","""Inclusion criteria for serum collection were age 18 years or older, Arkansas resident, and outpatient source.""","""Samples were excluded with the following diagnosis codes: immunodeficiency (primary immune deficiency (D80-D89), transplant recipient (all codes beginning with Z94), and cancer (C00-D49)). In addition, samples from patients with chemotherapy (prior two months), steroids (prior 30 days), and/or intravenous immunoglobulin (prior 6 months) were excluded.""",2020-11-07,2020-12-19,Residual sera,All,Multiple groups,18.0,,Primary Estimate,,2405,0.07400000000000001,0.06,0.087,True,,True,,True,Convenience,"Access SARS-CoV-2 IgG Reagent Antibody Test,Author designed (ELISA) - Unknown","Beckman Coulter,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,,Joshua Kennedy,University of Arkansas for Medical Sciences,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.15.21260213v1,2021-07-26,2024-03-01,Verified,kennedy_temporal_2021,USA
210719_Arkansas_UniversityOfArkansasForMedicalSciences_3_>70,210719_Arkansas_UniversityOfArkansasForMedicalSciences_3,Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas,2021-07-19,Preprint,Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Pine Bluff, Fort Smith","""Inclusion criteria for serum collection were age 18 years or older, Arkansas resident, and outpatient source.""","""Samples were excluded with the following diagnosis codes: immunodeficiency (primary immune deficiency (D80-D89), transplant recipient (all codes beginning with Z94), and cancer (C00-D49)). In addition, samples from patients with chemotherapy (prior two months), steroids (prior 30 days), and/or intravenous immunoglobulin (prior 6 months) were excluded.""",2020-11-07,2020-12-19,Residual sera,All,Seniors (65+ years),70.0,,Age,,345,0.055,,,,,,,,Convenience,"Access SARS-CoV-2 IgG Reagent Antibody Test,Author designed (ELISA) - Unknown","Beckman Coulter,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,,Joshua Kennedy,University of Arkansas for Medical Sciences,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.15.21260213v1,2021-07-26,2024-03-01,Verified,kennedy_temporal_2021,USA
210719_Arkansas_UniversityOfArkansasForMedicalSciences_3_60-69,210719_Arkansas_UniversityOfArkansasForMedicalSciences_3,Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas,2021-07-19,Preprint,Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Pine Bluff, Fort Smith","""Inclusion criteria for serum collection were age 18 years or older, Arkansas resident, and outpatient source.""","""Samples were excluded with the following diagnosis codes: immunodeficiency (primary immune deficiency (D80-D89), transplant recipient (all codes beginning with Z94), and cancer (C00-D49)). In addition, samples from patients with chemotherapy (prior two months), steroids (prior 30 days), and/or intravenous immunoglobulin (prior 6 months) were excluded.""",2020-11-07,2020-12-19,Residual sera,All,Multiple groups,60.0,69.0,Age,,377,0.077,,,,,,,,Convenience,"Access SARS-CoV-2 IgG Reagent Antibody Test,Author designed (ELISA) - Unknown","Beckman Coulter,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,,Joshua Kennedy,University of Arkansas for Medical Sciences,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.15.21260213v1,2021-07-26,2024-03-01,Verified,kennedy_temporal_2021,USA
210719_Arkansas_UniversityOfArkansasForMedicalSciences_3_Male,210719_Arkansas_UniversityOfArkansasForMedicalSciences_3,Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas,2021-07-19,Preprint,Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Pine Bluff, Fort Smith","""Inclusion criteria for serum collection were age 18 years or older, Arkansas resident, and outpatient source.""","""Samples were excluded with the following diagnosis codes: immunodeficiency (primary immune deficiency (D80-D89), transplant recipient (all codes beginning with Z94), and cancer (C00-D49)). In addition, samples from patients with chemotherapy (prior two months), steroids (prior 30 days), and/or intravenous immunoglobulin (prior 6 months) were excluded.""",2020-11-07,2020-12-19,Residual sera,Male,Multiple groups,18.0,,Sex/Gender,,742,0.092,,,,,,,,Convenience,"Access SARS-CoV-2 IgG Reagent Antibody Test,Author designed (ELISA) - Unknown","Beckman Coulter,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,,Joshua Kennedy,University of Arkansas for Medical Sciences,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.15.21260213v1,2021-07-26,2024-03-01,Verified,kennedy_temporal_2021,USA
210719_Arkansas_UniversityOfArkansasForMedicalSciences_3_40-49,210719_Arkansas_UniversityOfArkansasForMedicalSciences_3,Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas,2021-07-19,Preprint,Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Pine Bluff, Fort Smith","""Inclusion criteria for serum collection were age 18 years or older, Arkansas resident, and outpatient source.""","""Samples were excluded with the following diagnosis codes: immunodeficiency (primary immune deficiency (D80-D89), transplant recipient (all codes beginning with Z94), and cancer (C00-D49)). In addition, samples from patients with chemotherapy (prior two months), steroids (prior 30 days), and/or intravenous immunoglobulin (prior 6 months) were excluded.""",2020-11-07,2020-12-19,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,,335,0.07200000000000001,,,,,,,,Convenience,"Access SARS-CoV-2 IgG Reagent Antibody Test,Author designed (ELISA) - Unknown","Beckman Coulter,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,,Joshua Kennedy,University of Arkansas for Medical Sciences,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.15.21260213v1,2021-07-26,2024-03-01,Verified,kennedy_temporal_2021,USA
210719_Arkansas_UniversityOfArkansasForMedicalSciences_3_Female,210719_Arkansas_UniversityOfArkansasForMedicalSciences_3,Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas,2021-07-19,Preprint,Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Pine Bluff, Fort Smith","""Inclusion criteria for serum collection were age 18 years or older, Arkansas resident, and outpatient source.""","""Samples were excluded with the following diagnosis codes: immunodeficiency (primary immune deficiency (D80-D89), transplant recipient (all codes beginning with Z94), and cancer (C00-D49)). In addition, samples from patients with chemotherapy (prior two months), steroids (prior 30 days), and/or intravenous immunoglobulin (prior 6 months) were excluded.""",2020-11-07,2020-12-19,Residual sera,Female,Multiple groups,18.0,,Sex/Gender,,1661,0.076,,,,,,,,Convenience,"Access SARS-CoV-2 IgG Reagent Antibody Test,Author designed (ELISA) - Unknown","Beckman Coulter,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,,Joshua Kennedy,University of Arkansas for Medical Sciences,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.15.21260213v1,2021-07-26,2024-03-01,Verified,kennedy_temporal_2021,USA
210719_Arkansas_UniversityOfArkansasForMedicalSciences_3_50-59,210719_Arkansas_UniversityOfArkansasForMedicalSciences_3,Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas,2021-07-19,Preprint,Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Pine Bluff, Fort Smith","""Inclusion criteria for serum collection were age 18 years or older, Arkansas resident, and outpatient source.""","""Samples were excluded with the following diagnosis codes: immunodeficiency (primary immune deficiency (D80-D89), transplant recipient (all codes beginning with Z94), and cancer (C00-D49)). In addition, samples from patients with chemotherapy (prior two months), steroids (prior 30 days), and/or intravenous immunoglobulin (prior 6 months) were excluded.""",2020-11-07,2020-12-19,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,,358,0.08900000000000001,,,,,,,,Convenience,"Access SARS-CoV-2 IgG Reagent Antibody Test,Author designed (ELISA) - Unknown","Beckman Coulter,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,,Joshua Kennedy,University of Arkansas for Medical Sciences,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.15.21260213v1,2021-07-26,2024-03-01,Verified,kennedy_temporal_2021,USA
210719_Arkansas_UniversityOfArkansasForMedicalSciences_3_18-29,210719_Arkansas_UniversityOfArkansasForMedicalSciences_3,Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas,2021-07-19,Preprint,Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Pine Bluff, Fort Smith","""Inclusion criteria for serum collection were age 18 years or older, Arkansas resident, and outpatient source.""","""Samples were excluded with the following diagnosis codes: immunodeficiency (primary immune deficiency (D80-D89), transplant recipient (all codes beginning with Z94), and cancer (C00-D49)). In addition, samples from patients with chemotherapy (prior two months), steroids (prior 30 days), and/or intravenous immunoglobulin (prior 6 months) were excluded.""",2020-11-07,2020-12-19,Residual sera,All,Adults (18-64 years),18.0,29.0,Age,18-29,562,0.08900000000000001,,,,,,,,Convenience,"Access SARS-CoV-2 IgG Reagent Antibody Test,Author designed (ELISA) - Unknown","Beckman Coulter,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,,Joshua Kennedy,University of Arkansas for Medical Sciences,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.15.21260213v1,2021-07-26,2024-03-01,Verified,kennedy_temporal_2021,USA
210719_Arkansas_UniversityOfArkansasForMedicalSciences_3_30-39,210719_Arkansas_UniversityOfArkansasForMedicalSciences_3,Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas,2021-07-19,Preprint,Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Pine Bluff, Fort Smith","""Inclusion criteria for serum collection were age 18 years or older, Arkansas resident, and outpatient source.""","""Samples were excluded with the following diagnosis codes: immunodeficiency (primary immune deficiency (D80-D89), transplant recipient (all codes beginning with Z94), and cancer (C00-D49)). In addition, samples from patients with chemotherapy (prior two months), steroids (prior 30 days), and/or intravenous immunoglobulin (prior 6 months) were excluded.""",2020-11-07,2020-12-19,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,,428,0.094,,,,,,,,Convenience,"Access SARS-CoV-2 IgG Reagent Antibody Test,Author designed (ELISA) - Unknown","Beckman Coulter,NA",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,No,,Joshua Kennedy,University of Arkansas for Medical Sciences,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.15.21260213v1,2021-07-26,2024-03-01,Verified,kennedy_temporal_2021,USA
210720_LongIsland_StonyBrookUniversity_Totaladj,210720_LongIsland_StonyBrookUniversity,"COVID-19 cumulative incidence, asymptomatic infections, and fatality in Long Island, NY, January-August 2020: A cohort of World Trade Center responders.",2021-07-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,Long Island,"men and women who worked or volunteered
at the WTC sites during and after the tragic events of 9/11/2001",,2020-03-25,2020-09-18,Household and community samples,All,Multiple groups,30.0,,Primary Estimate,,1042,0.21300000000000002,0.195,0.23199999999999998,True,,True,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.934,1.0,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Olga Morozova,Stony Brook University,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254713,2021-07-27,2024-03-01,Verified,morozova_covid-19_2021,USA
210720_LongIsland_StonyBrookUniversity_Age70+,210720_LongIsland_StonyBrookUniversity,"COVID-19 cumulative incidence, asymptomatic infections, and fatality in Long Island, NY, January-August 2020: A cohort of World Trade Center responders.",2021-07-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,Long Island,"men and women who worked or volunteered
at the WTC sites during and after the tragic events of 9/11/2001",,2020-03-25,2020-09-18,Household and community samples,All,Seniors (65+ years),70.0,,Age,70+,75,0.12,0.055999999999999994,0.21600000000000003,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.934,1.0,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Olga Morozova,Stony Brook University,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254713,2021-08-05,2024-03-01,Verified,morozova_covid-19_2021,USA
210720_LongIsland_StonyBrookUniversity_Age60-69,210720_LongIsland_StonyBrookUniversity,"COVID-19 cumulative incidence, asymptomatic infections, and fatality in Long Island, NY, January-August 2020: A cohort of World Trade Center responders.",2021-07-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,Long Island,"men and women who worked or volunteered
at the WTC sites during and after the tragic events of 9/11/2001",,2020-03-25,2020-09-18,Household and community samples,All,Seniors (65+ years),60.0,69.0,Age,60-69,257,0.14400000000000002,0.10300000000000001,0.193,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.934,1.0,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Olga Morozova,Stony Brook University,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254713,2021-08-05,2024-03-01,Verified,morozova_covid-19_2021,USA
210720_LongIsland_StonyBrookUniversity_Male,210720_LongIsland_StonyBrookUniversity,"COVID-19 cumulative incidence, asymptomatic infections, and fatality in Long Island, NY, January-August 2020: A cohort of World Trade Center responders.",2021-07-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,Long Island,"men and women who worked or volunteered
at the WTC sites during and after the tragic events of 9/11/2001",,2020-03-25,2020-09-18,Household and community samples,Male,Multiple groups,30.0,,Sex/Gender,,944,0.204,0.179,0.23199999999999998,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.934,1.0,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Olga Morozova,Stony Brook University,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254713,2021-08-05,2024-03-01,Verified,morozova_covid-19_2021,USA
210720_LongIsland_StonyBrookUniversity_Unadj,210720_LongIsland_StonyBrookUniversity,"COVID-19 cumulative incidence, asymptomatic infections, and fatality in Long Island, NY, January-August 2020: A cohort of World Trade Center responders.",2021-07-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,Long Island,"men and women who worked or volunteered
at the WTC sites during and after the tragic events of 9/11/2001",,2020-03-25,2020-09-18,Household and community samples,All,Multiple groups,30.0,,Analysis,,1042,0.21,0.18600000000000003,0.23600000000000002,,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.934,1.0,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Olga Morozova,Stony Brook University,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254713,2021-08-05,2024-03-01,Verified,morozova_covid-19_2021,USA
210720_LongIsland_StonyBrookUniversity_Female,210720_LongIsland_StonyBrookUniversity,"COVID-19 cumulative incidence, asymptomatic infections, and fatality in Long Island, NY, January-August 2020: A cohort of World Trade Center responders.",2021-07-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,Long Island,"men and women who worked or volunteered
at the WTC sites during and after the tragic events of 9/11/2001",,2020-03-25,2020-09-18,Household and community samples,Female,Multiple groups,30.0,,Sex/Gender,,98,0.265,0.18100000000000002,0.364,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.934,1.0,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Olga Morozova,Stony Brook University,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254713,2021-08-05,2024-03-01,Verified,morozova_covid-19_2021,USA
210720_LongIsland_StonyBrookUniversity_Age50-59,210720_LongIsland_StonyBrookUniversity,"COVID-19 cumulative incidence, asymptomatic infections, and fatality in Long Island, NY, January-August 2020: A cohort of World Trade Center responders.",2021-07-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,Long Island,"men and women who worked or volunteered
at the WTC sites during and after the tragic events of 9/11/2001",,2020-03-25,2020-09-18,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,516,0.215,0.18,0.253,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.934,1.0,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Olga Morozova,Stony Brook University,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254713,2021-08-05,2024-03-01,Verified,morozova_covid-19_2021,USA
210720_LongIsland_StonyBrookUniversity_Age30-49,210720_LongIsland_StonyBrookUniversity,"COVID-19 cumulative incidence, asymptomatic infections, and fatality in Long Island, NY, January-August 2020: A cohort of World Trade Center responders.",2021-07-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,Long Island,"men and women who worked or volunteered
at the WTC sites during and after the tragic events of 9/11/2001",,2020-03-25,2020-09-18,Household and community samples,All,Adults (18-64 years),30.0,49.0,Age,30-49,194,0.32,0.255,0.39,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.934,1.0,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Olga Morozova,Stony Brook University,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0254713,2021-08-05,2024-03-01,Verified,morozova_covid-19_2021,USA
210721_FortCollins_ColoradoStateUniversity,210721_FortCollins_ColoradoStateUniversity,Association Between COVID-19 Exposure and Self-reported Compliance With Public Health Guidelines Among Essential Employees at an Institution of Higher Education in the US.,2021-07-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Colorado,Fort Collins," Employees of Colorado State University (CSU) were recruited to participate if they were identified by the human resources office to be essential in-person workers at the time of the stay-at-home (March 26 to April 26, 2020) and safer-at-home orders (April 27 to July 6, 2020) implemented by the State of Colorado Governor’s Office.Criteria for inclusion were age 18 years or older, ability to read and understand English, and not currently experiencing cough, shortness of breath or difficulty breathing, temperature >38 °C, chills or shaking with chills, muscle pain, new or worsening headaches, sore throat, or new loss of sense of taste or smell",NR - see inclusion criteria,2020-07-13,2020-09-02,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,508,0.004,0.001,0.013999999999999999,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Tracy Nelson,Colorado State University,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.16543,2021-08-02,2024-03-01,Unverified,nelson_association_2021,USA
210727_California_EmoryUniversity_primary,210727_California_EmoryUniversity,SARS-CoV-2 Cumulative Incidence and Period Seroprevalence: Results From a Statewide Population-Based Serosurvey in California.,2021-07-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,California,,"We randomly sampled 8726 households in California from a frame derived from the USPS Computerized Delivery Sequence File, which has been used extensively for survey research [13–15] and represents nearly all housed, noninstitutionalized persons in the state.",,2020-08-15,2020-12-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,983,0.045,0.027999999999999997,0.07400000000000001,True,,True,,True,Simplified probability,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.922,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Katherine Lamba,Emory University,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab379,2021-08-17,2024-03-01,Verified,lamba_sars-cov-2_2021,USA
210727_California_EmoryUniversity_age_45-54,210727_California_EmoryUniversity,SARS-CoV-2 Cumulative Incidence and Period Seroprevalence: Results From a Statewide Population-Based Serosurvey in California.,2021-07-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,California,,"We randomly sampled 8726 households in California from a frame derived from the USPS Computerized Delivery Sequence File, which has been used extensively for survey research [13–15] and represents nearly all housed, noninstitutionalized persons in the state.",,2020-08-15,2020-12-15,Household and community samples,All,Adults (18-64 years),45.0,54.0,Age,45-54,167,0.087,0.025,0.256,,,True,,,Simplified probability,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.922,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Katherine Lamba,Emory University,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab379,2021-08-17,2024-03-01,Verified,lamba_sars-cov-2_2021,USA
210727_California_EmoryUniversity_sex_female,210727_California_EmoryUniversity,SARS-CoV-2 Cumulative Incidence and Period Seroprevalence: Results From a Statewide Population-Based Serosurvey in California.,2021-07-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,California,,"We randomly sampled 8726 households in California from a frame derived from the USPS Computerized Delivery Sequence File, which has been used extensively for survey research [13–15] and represents nearly all housed, noninstitutionalized persons in the state.",,2020-08-15,2020-12-15,Household and community samples,Female,Multiple groups,,,Sex/Gender,,567,0.051,0.027000000000000003,0.09300000000000001,,,True,,,Simplified probability,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.922,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Katherine Lamba,Emory University,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab379,2021-08-17,2024-03-01,Verified,lamba_sars-cov-2_2021,USA
210727_California_EmoryUniversity_age_65+,210727_California_EmoryUniversity,SARS-CoV-2 Cumulative Incidence and Period Seroprevalence: Results From a Statewide Population-Based Serosurvey in California.,2021-07-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,California,,"We randomly sampled 8726 households in California from a frame derived from the USPS Computerized Delivery Sequence File, which has been used extensively for survey research [13–15] and represents nearly all housed, noninstitutionalized persons in the state.",,2020-08-15,2020-12-15,Household and community samples,All,Seniors (65+ years),65.0,,Age,65+,236,0.008,0.001,0.045,,,True,,,Simplified probability,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.922,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Katherine Lamba,Emory University,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab379,2021-08-17,2024-03-01,Verified,lamba_sars-cov-2_2021,USA
210727_California_EmoryUniversity_sex_male,210727_California_EmoryUniversity,SARS-CoV-2 Cumulative Incidence and Period Seroprevalence: Results From a Statewide Population-Based Serosurvey in California.,2021-07-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,California,,"We randomly sampled 8726 households in California from a frame derived from the USPS Computerized Delivery Sequence File, which has been used extensively for survey research [13–15] and represents nearly all housed, noninstitutionalized persons in the state.",,2020-08-15,2020-12-15,Household and community samples,Male,Multiple groups,,,Sex/Gender,,416,0.04,0.018000000000000002,0.087,,,True,,,Simplified probability,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.922,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Katherine Lamba,Emory University,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab379,2021-08-17,2024-03-01,Verified,lamba_sars-cov-2_2021,USA
210727_California_EmoryUniversity_age_55-64,210727_California_EmoryUniversity,SARS-CoV-2 Cumulative Incidence and Period Seroprevalence: Results From a Statewide Population-Based Serosurvey in California.,2021-07-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,California,,"We randomly sampled 8726 households in California from a frame derived from the USPS Computerized Delivery Sequence File, which has been used extensively for survey research [13–15] and represents nearly all housed, noninstitutionalized persons in the state.",,2020-08-15,2020-12-15,Household and community samples,All,Adults (18-64 years),55.0,64.0,Age,55-64,188,0.019,0.006999999999999999,0.05,,,True,,,Simplified probability,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.922,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Katherine Lamba,Emory University,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab379,2021-08-17,2024-03-01,Verified,lamba_sars-cov-2_2021,USA
210727_California_EmoryUniversity_age_35-44,210727_California_EmoryUniversity,SARS-CoV-2 Cumulative Incidence and Period Seroprevalence: Results From a Statewide Population-Based Serosurvey in California.,2021-07-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,California,,"We randomly sampled 8726 households in California from a frame derived from the USPS Computerized Delivery Sequence File, which has been used extensively for survey research [13–15] and represents nearly all housed, noninstitutionalized persons in the state.",,2020-08-15,2020-12-15,Household and community samples,All,Adults (18-64 years),35.0,44.0,Age,35-44,156,0.062000000000000006,0.03,0.12300000000000001,,,True,,,Simplified probability,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.922,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Katherine Lamba,Emory University,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab379,2021-08-17,2024-03-01,Verified,lamba_sars-cov-2_2021,USA
210727_California_EmoryUniversity_age_18-34,210727_California_EmoryUniversity,SARS-CoV-2 Cumulative Incidence and Period Seroprevalence: Results From a Statewide Population-Based Serosurvey in California.,2021-07-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,California,,"We randomly sampled 8726 households in California from a frame derived from the USPS Computerized Delivery Sequence File, which has been used extensively for survey research [13–15] and represents nearly all housed, noninstitutionalized persons in the state.",,2020-08-15,2020-12-15,Household and community samples,All,Adults (18-64 years),18.0,34.0,Age,18-34,236,0.052000000000000005,0.027999999999999997,0.095,,,True,,,Simplified probability,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.922,0.996,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Katherine Lamba,Emory University,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab379,2021-08-17,2024-03-01,Verified,lamba_sars-cov-2_2021,USA
210728_NewYorkCity_WeillCornellMedicine_overall,210728_NewYorkCity_WeillCornellMedicine,SARS-CoV-2 Antibody Response in Patients Undergoing Kidney Transplantation,2021-07-28,Preprint,Local,Retrospective cohort,United States of America,New York ,New York City,Inclusion criteria for the study was any patient admitted for kidney transplant who had SARS-CoV-2 antibody testing both before and after kidney transplantation (n = 72). ,,2020-05-28,2020-12-12,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,Overall; post-transplant (kidney transplant recipients),72,0.3194,,,True,,,,True,Sequential,Not reported/ Unable to specify,,,Serum,IgG,Spike,,,,['High'],Yes,No,No,Yes,Unclear,Unclear,Yes,No,,Michelle Lubetzky,Weill Cornell Medicine,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.07.25.21261066v1.full-text,2021-08-04,2022-07-16,Verified, lubetzky_sars-cov-2_2021,USA
210729_SouthernUSA_WalterReedArmyInstituteOfResearch_Timepoint1,210729_SouthernUSA_WalterReedArmyInstituteOfResearch_Timepoint1 ,Serological and RT-PCR Surveillance for COVID-19 in an Asymptomatic US Army Trainee Population.,2021-07-29,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Southern United States,,Recruits arriving for basic combat training,,2020-08-26,2020-10-11,Essential non-healthcare workers,All,Adults (18-64 years),17.0,44.0,Primary Estimate,,1403,0.09,0.076,0.106,True,,,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Shilpa Hakre,Walter Reed Army Institute of Research,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab407,2021-09-24,2024-03-01,Unverified,hakre_serological_2021,USA
210729_SouthernUSA_WalterReedArmyInstituteOfResearch_Timepoint2,210729_SouthernUSA_WalterReedArmyInstituteOfResearch_Timepoint2,Serological and RT-PCR Surveillance for COVID-19 in an Asymptomatic US Army Trainee Population.,2021-07-29,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Southern United States,,Recruits arriving for basic combat training,,2020-09-09,2020-10-25,Essential non-healthcare workers,All,Adults (18-64 years),17.0,44.0,Primary Estimate,,1304,0.087,0.07200000000000001,0.10300000000000001,True,,,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Shilpa Hakre,Walter Reed Army Institute of Research,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab407,2021-09-24,2024-03-01,Unverified,hakre_serological_2021,USA
210729_SouthernUSA_WalterReedArmyInstituteOfResearch_Timepoint3,210729_SouthernUSA_WalterReedArmyInstituteOfResearch_Timepoint3,Serological and RT-PCR Surveillance for COVID-19 in an Asymptomatic US Army Trainee Population.,2021-07-29,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Southern United States,,Recruits arriving for basic combat training,,2020-11-18,2021-01-03,Essential non-healthcare workers,All,Adults (18-64 years),17.0,44.0,Primary Estimate,,1211,0.095,0.079,0.11199999999999999,True,,,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Shilpa Hakre,Walter Reed Army Institute of Research,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab407,2021-09-24,2024-03-01,Unverified,hakre_serological_2021,USA
210729_NorthernVirginia_InovaHeartandVascularInstitute_Community4_Primary,210729_NorthernVirginia_InovaHeartandVascularInstitute_Community4,"Seropositivity of COVID-19 among asymptomatic healthcare workers: A multi-site prospective cohort study from Northern Virginia, United States.",2021-07-29,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Virginia,,"""Asymptomatic participants without a known COVID-19 diagnosis residing in the community... participants were included in this analysis if they were adults >18 years of age, resided in the Northern Virginia region willing to sign an informed consent to participate in the study.""",,2020-06-01,2020-08-14,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,949,0.0453,,,True,,,,True,Convenience,AdviseDX SARS-CoV-2 anti-IgG II assay,Abbott Laboratories,CLIA,Serum,IgG,,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Abdulla Damluji,Inova Heart and Vascular Institute,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2021.100030,2021-08-30,2024-03-01,Unverified,damluji_seropositivity_2021,USA
210729_NorthernVirginia_InovaHeartandVascularInstitute_Community4_>=70,210729_NorthernVirginia_InovaHeartandVascularInstitute_Community4,"Seropositivity of COVID-19 among asymptomatic healthcare workers: A multi-site prospective cohort study from Northern Virginia, United States.",2021-07-29,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Virginia,,"""Asymptomatic participants without a known COVID-19 diagnosis residing in the community... participants were included in this analysis if they were adults >18 years of age, resided in the Northern Virginia region willing to sign an informed consent to participate in the study.""",,2020-06-01,2020-08-14,Household and community samples,All,Seniors (65+ years),70.0,,Age,>= 70 years,92,0.0543,,,,,,,,Convenience,AdviseDX SARS-CoV-2 anti-IgG II assay,Abbott Laboratories,CLIA,Serum,IgG,,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Abdulla Damluji,Inova Heart and Vascular Institute,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2021.100030,2021-08-30,2024-03-01,Unverified,damluji_seropositivity_2021,USA
210729_NorthernVirginia_InovaHeartandVascularInstitute_Community4_30-39,210729_NorthernVirginia_InovaHeartandVascularInstitute_Community4,"Seropositivity of COVID-19 among asymptomatic healthcare workers: A multi-site prospective cohort study from Northern Virginia, United States.",2021-07-29,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Virginia,,"""Asymptomatic participants without a known COVID-19 diagnosis residing in the community... participants were included in this analysis if they were adults >18 years of age, resided in the Northern Virginia region willing to sign an informed consent to participate in the study.""",,2020-06-01,2020-08-14,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39 years,206,0.0533,,,,,,,,Convenience,AdviseDX SARS-CoV-2 anti-IgG II assay,Abbott Laboratories,CLIA,Serum,IgG,,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Abdulla Damluji,Inova Heart and Vascular Institute,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2021.100030,2021-08-30,2024-03-01,Unverified,damluji_seropositivity_2021,USA
210729_NorthernVirginia_InovaHeartandVascularInstitute_Community4_40-49,210729_NorthernVirginia_InovaHeartandVascularInstitute_Community4,"Seropositivity of COVID-19 among asymptomatic healthcare workers: A multi-site prospective cohort study from Northern Virginia, United States.",2021-07-29,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Virginia,,"""Asymptomatic participants without a known COVID-19 diagnosis residing in the community... participants were included in this analysis if they were adults >18 years of age, resided in the Northern Virginia region willing to sign an informed consent to participate in the study.""",,2020-06-01,2020-08-14,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49 years,184,0.0652,,,,,,,,Convenience,AdviseDX SARS-CoV-2 anti-IgG II assay,Abbott Laboratories,CLIA,Serum,IgG,,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Abdulla Damluji,Inova Heart and Vascular Institute,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2021.100030,2021-08-30,2024-03-01,Unverified,damluji_seropositivity_2021,USA
210729_NorthernVirginia_InovaHeartandVascularInstitute_Community4_Female,210729_NorthernVirginia_InovaHeartandVascularInstitute_Community4,"Seropositivity of COVID-19 among asymptomatic healthcare workers: A multi-site prospective cohort study from Northern Virginia, United States.",2021-07-29,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Virginia,,"""Asymptomatic participants without a known COVID-19 diagnosis residing in the community... participants were included in this analysis if they were adults >18 years of age, resided in the Northern Virginia region willing to sign an informed consent to participate in the study.""",,2020-06-01,2020-08-14,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,596,0.0403,,,,,,,,Convenience,AdviseDX SARS-CoV-2 anti-IgG II assay,Abbott Laboratories,CLIA,Serum,IgG,,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Abdulla Damluji,Inova Heart and Vascular Institute,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2021.100030,2021-08-30,2024-03-01,Unverified,damluji_seropositivity_2021,USA
210729_NorthernVirginia_InovaHeartandVascularInstitute_Community4_50-59,210729_NorthernVirginia_InovaHeartandVascularInstitute_Community4,"Seropositivity of COVID-19 among asymptomatic healthcare workers: A multi-site prospective cohort study from Northern Virginia, United States.",2021-07-29,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Virginia,,"""Asymptomatic participants without a known COVID-19 diagnosis residing in the community... participants were included in this analysis if they were adults >18 years of age, resided in the Northern Virginia region willing to sign an informed consent to participate in the study.""",,2020-06-01,2020-08-14,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59 years,170,0.0235,,,,,,,,Convenience,AdviseDX SARS-CoV-2 anti-IgG II assay,Abbott Laboratories,CLIA,Serum,IgG,,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Abdulla Damluji,Inova Heart and Vascular Institute,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2021.100030,2021-08-30,2024-03-01,Unverified,damluji_seropositivity_2021,USA
210729_NorthernVirginia_InovaHeartandVascularInstitute_Community4_20-29,210729_NorthernVirginia_InovaHeartandVascularInstitute_Community4,"Seropositivity of COVID-19 among asymptomatic healthcare workers: A multi-site prospective cohort study from Northern Virginia, United States.",2021-07-29,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Virginia,,"""Asymptomatic participants without a known COVID-19 diagnosis residing in the community... participants were included in this analysis if they were adults >18 years of age, resided in the Northern Virginia region willing to sign an informed consent to participate in the study.""",,2020-06-01,2020-08-14,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29 years,166,0.0542,,,,,,,,Convenience,AdviseDX SARS-CoV-2 anti-IgG II assay,Abbott Laboratories,CLIA,Serum,IgG,,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Abdulla Damluji,Inova Heart and Vascular Institute,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2021.100030,2021-08-30,2024-03-01,Unverified,damluji_seropositivity_2021,USA
210729_NorthernVirginia_InovaHeartandVascularInstitute_Community4_Male,210729_NorthernVirginia_InovaHeartandVascularInstitute_Community4,"Seropositivity of COVID-19 among asymptomatic healthcare workers: A multi-site prospective cohort study from Northern Virginia, United States.",2021-07-29,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Virginia,,"""Asymptomatic participants without a known COVID-19 diagnosis residing in the community... participants were included in this analysis if they were adults >18 years of age, resided in the Northern Virginia region willing to sign an informed consent to participate in the study.""",,2020-06-01,2020-08-14,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,350,0.0514,,,,,,,,Convenience,AdviseDX SARS-CoV-2 anti-IgG II assay,Abbott Laboratories,CLIA,Serum,IgG,,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Abdulla Damluji,Inova Heart and Vascular Institute,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2021.100030,2021-08-30,2024-03-01,Unverified,damluji_seropositivity_2021,USA
210729_NorthernVirginia_InovaHeartandVascularInstitute_Community4_60-69,210729_NorthernVirginia_InovaHeartandVascularInstitute_Community4,"Seropositivity of COVID-19 among asymptomatic healthcare workers: A multi-site prospective cohort study from Northern Virginia, United States.",2021-07-29,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Virginia,,"""Asymptomatic participants without a known COVID-19 diagnosis residing in the community... participants were included in this analysis if they were adults >18 years of age, resided in the Northern Virginia region willing to sign an informed consent to participate in the study.""",,2020-06-01,2020-08-14,Household and community samples,All,Multiple groups,60.0,69.0,Age,60-69 years,131,0.015300000000000001,,,,,,,,Convenience,AdviseDX SARS-CoV-2 anti-IgG II assay,Abbott Laboratories,CLIA,Serum,IgG,,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Abdulla Damluji,Inova Heart and Vascular Institute,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2021.100030,2021-08-30,2024-03-01,Unverified,damluji_seropositivity_2021,USA
210729_NorthernVirginia_InovaHeartandVascularInstitute_HCWAprilMay1_Primary,210729_NorthernVirginia_InovaHeartandVascularInstitute_HCWAprilMay1,"Seropositivity of COVID-19 among asymptomatic healthcare workers: A multi-site prospective cohort study from Northern Virginia, United States.",2021-07-29,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Virginia,,"""Asymptomatic HCW were included if they were > 18 years of age, employed or contracted by a large inte- grated health system in Northern Virginia (Inova Health), and will- ing to sign an informed consent to participate and follow study procedures.""","""Participants were excluded if there was a known or suspected symptomatic COVID-19 infection at first enrolment time point with symptoms including fever, cough or shortness of breath.""",2020-04-15,2020-11-15,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,1819,0.012,,,True,,,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgG', 'IgM']",Spike,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Abdulla Damluji,Inova Heart and Vascular Institute,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2021.100030,2021-08-29,2024-03-01,Unverified,damluji_seropositivity_2021,USA
210729_NorthernVirginia_InovaHeartandVascularInstitute_HCWJuneJuly2_Primary,210729_NorthernVirginia_InovaHeartandVascularInstitute_HCWJuneJuly2,"Seropositivity of COVID-19 among asymptomatic healthcare workers: A multi-site prospective cohort study from Northern Virginia, United States.",2021-07-29,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Virginia,,"""Asymptomatic HCW were included if they were > 18 years of age, employed or contracted by a large inte- grated health system in Northern Virginia (Inova Health), and will- ing to sign an informed consent to participate and follow study procedures.""","""Participants were excluded if there was a known or suspected symptomatic COVID-19 infection at first enrolment time point with symptoms including fever, cough or shortness of breath.""",2020-04-15,2020-11-15,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,1473,0.027999999999999997,,,True,,,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgG', 'IgM']",Spike,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Abdulla Damluji,Inova Heart and Vascular Institute,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2021.100030,2021-08-29,2024-03-01,Unverified,damluji_seropositivity_2021,USA
210729_NorthernVirginia_InovaHeartandVascularInstitute_HCWOctoberNovember3_Primary,210729_NorthernVirginia_InovaHeartandVascularInstitute_HCWOctoberNovember3,"Seropositivity of COVID-19 among asymptomatic healthcare workers: A multi-site prospective cohort study from Northern Virginia, United States.",2021-07-29,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Virginia,,"""Asymptomatic HCW were included if they were > 18 years of age, employed or contracted by a large inte- grated health system in Northern Virginia (Inova Health), and will- ing to sign an informed consent to participate and follow study procedures.""","""Participants were excluded if there was a known or suspected symptomatic COVID-19 infection at first enrolment time point with symptoms including fever, cough or shortness of breath.""",2020-04-15,2020-11-15,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,1323,0.048,,,True,,,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,"['IgG', 'IgM']",Spike,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Abdulla Damluji,Inova Heart and Vascular Institute,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lana.2021.100030,2021-08-30,2024-03-01,Unverified,damluji_seropositivity_2021,USA
210730_USA_AmericanRedCross_overall,210730_USA_AmericanRedCross,Characteristics of US Blood Donors Testing Reactive for Antibodies to SARS-CoV-2 Prior to the Availability of Authorized Vaccines.,2021-07-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Blood donors who made donations of whole blood, double red-cells or single-donor platelets between June 15th and November 30th, 2020 to the American Red Cross","""donors of COVID-19 convalescent plasma were excluded""",2020-06-15,2020-11-30,Blood donors,All,Multiple groups,16.0,,Primary Estimate,,1531221,0.0422,,,True,,,,True,Sequential,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Whole Blood,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Roger Dodd,American Red Cross,Unity-Aligned,https://dx.doi.org/10.1016/j.tmrv.2021.07.001,2021-08-17,2024-03-01,Verified,dodd_characteristics_2021,USA
210730_USA_AmericanRedCross_25-39,210730_USA_AmericanRedCross,Characteristics of US Blood Donors Testing Reactive for Antibodies to SARS-CoV-2 Prior to the Availability of Authorized Vaccines.,2021-07-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Blood donors who made donations of whole blood, double red-cells or single-donor platelets between June 15th and November 30th, 2020 to the American Red Cross","""donors of COVID-19 convalescent plasma were excluded""",2020-06-15,2020-11-30,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39,336231,0.0454,,,,,,,,Sequential,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Whole Blood,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Roger Dodd,American Red Cross,Unity-Aligned,https://dx.doi.org/10.1016/j.tmrv.2021.07.001,2021-08-17,2024-03-01,Verified,dodd_characteristics_2021,USA
210730_USA_AmericanRedCross_40-54,210730_USA_AmericanRedCross,Characteristics of US Blood Donors Testing Reactive for Antibodies to SARS-CoV-2 Prior to the Availability of Authorized Vaccines.,2021-07-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Blood donors who made donations of whole blood, double red-cells or single-donor platelets between June 15th and November 30th, 2020 to the American Red Cross","""donors of COVID-19 convalescent plasma were excluded""",2020-06-15,2020-11-30,Blood donors,All,Adults (18-64 years),40.0,54.0,Age,40-54,422783,0.0434,,,,,,,,Sequential,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Whole Blood,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Roger Dodd,American Red Cross,Unity-Aligned,https://dx.doi.org/10.1016/j.tmrv.2021.07.001,2021-08-17,2024-03-01,Verified,dodd_characteristics_2021,USA
210730_USA_AmericanRedCross_Male,210730_USA_AmericanRedCross,Characteristics of US Blood Donors Testing Reactive for Antibodies to SARS-CoV-2 Prior to the Availability of Authorized Vaccines.,2021-07-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Blood donors who made donations of whole blood, double red-cells or single-donor platelets between June 15th and November 30th, 2020 to the American Red Cross","""donors of COVID-19 convalescent plasma were excluded""",2020-06-15,2020-11-30,Blood donors,Male,Multiple groups,16.0,,Sex/Gender,,680285,0.042300000000000004,,,,,,,,Sequential,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Whole Blood,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Roger Dodd,American Red Cross,Unity-Aligned,https://dx.doi.org/10.1016/j.tmrv.2021.07.001,2021-08-17,2024-03-01,Verified,dodd_characteristics_2021,USA
210730_USA_AmericanRedCross_week48,210730_USA_AmericanRedCross,Characteristics of US Blood Donors Testing Reactive for Antibodies to SARS-CoV-2 Prior to the Availability of Authorized Vaccines.,2021-07-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Blood donors who made donations of whole blood, double red-cells or single-donor platelets between June 15th and November 30th, 2020 to the American Red Cross","""donors of COVID-19 convalescent plasma were excluded""",2020-11-22,2020-11-28,Blood donors,All,Multiple groups,16.0,,Time frame,Calendar week 48,75505,0.08070000000000001,,,,,,,,Sequential,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Whole Blood,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Roger Dodd,American Red Cross,Unity-Aligned,https://dx.doi.org/10.1016/j.tmrv.2021.07.001,2021-08-17,2024-03-01,Verified,dodd_characteristics_2021,USA
210730_USA_AmericanRedCross_55+,210730_USA_AmericanRedCross,Characteristics of US Blood Donors Testing Reactive for Antibodies to SARS-CoV-2 Prior to the Availability of Authorized Vaccines.,2021-07-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Blood donors who made donations of whole blood, double red-cells or single-donor platelets between June 15th and November 30th, 2020 to the American Red Cross","""donors of COVID-19 convalescent plasma were excluded""",2020-06-15,2020-11-30,Blood donors,All,Multiple groups,55.0,,Age,>=55,635455,0.0294,,,,,,,,Sequential,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Whole Blood,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Roger Dodd,American Red Cross,Unity-Aligned,https://dx.doi.org/10.1016/j.tmrv.2021.07.001,2021-08-17,2024-03-01,Verified,dodd_characteristics_2021,USA
210730_USA_AmericanRedCross_week25,210730_USA_AmericanRedCross,Characteristics of US Blood Donors Testing Reactive for Antibodies to SARS-CoV-2 Prior to the Availability of Authorized Vaccines.,2021-07-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Blood donors who made donations of whole blood, double red-cells or single-donor platelets between June 15th and November 30th, 2020 to the American Red Cross","""donors of COVID-19 convalescent plasma were excluded""",2020-06-15,2020-06-20,Blood donors,All,Multiple groups,16.0,,Time frame,Calendar week 25,98729,0.0118,,,,,,,,Sequential,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Whole Blood,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Roger Dodd,American Red Cross,Unity-Aligned,https://dx.doi.org/10.1016/j.tmrv.2021.07.001,2021-08-17,2024-03-01,Verified,dodd_characteristics_2021,USA
210730_USA_AmericanRedCross_16-17,210730_USA_AmericanRedCross,Characteristics of US Blood Donors Testing Reactive for Antibodies to SARS-CoV-2 Prior to the Availability of Authorized Vaccines.,2021-07-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Blood donors who made donations of whole blood, double red-cells or single-donor platelets between June 15th and November 30th, 2020 to the American Red Cross","""donors of COVID-19 convalescent plasma were excluded""",2020-06-15,2020-11-30,Blood donors,All,Children and Youth (0-17 years),16.0,17.0,Age,16-17,24906,0.0804,,,,,,,,Sequential,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Whole Blood,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Roger Dodd,American Red Cross,Unity-Aligned,https://dx.doi.org/10.1016/j.tmrv.2021.07.001,2021-08-17,2024-03-01,Verified,dodd_characteristics_2021,USA
210730_USA_AmericanRedCross_week49,210730_USA_AmericanRedCross,Characteristics of US Blood Donors Testing Reactive for Antibodies to SARS-CoV-2 Prior to the Availability of Authorized Vaccines.,2021-07-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Blood donors who made donations of whole blood, double red-cells or single-donor platelets between June 15th and November 30th, 2020 to the American Red Cross","""donors of COVID-19 convalescent plasma were excluded""",2020-11-29,2020-11-30,Blood donors,All,Multiple groups,16.0,,Time frame,Calendar week 49,13268,0.09670000000000001,,,,,,,,Sequential,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Whole Blood,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Roger Dodd,American Red Cross,Unity-Aligned,https://dx.doi.org/10.1016/j.tmrv.2021.07.001,2021-08-17,2024-03-01,Verified,dodd_characteristics_2021,USA
210730_USA_AmericanRedCross_18-24,210730_USA_AmericanRedCross,Characteristics of US Blood Donors Testing Reactive for Antibodies to SARS-CoV-2 Prior to the Availability of Authorized Vaccines.,2021-07-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Blood donors who made donations of whole blood, double red-cells or single-donor platelets between June 15th and November 30th, 2020 to the American Red Cross","""donors of COVID-19 convalescent plasma were excluded""",2020-06-15,2020-11-30,Blood donors,All,Adults (18-64 years),18.0,24.0,Age,18-24,111846,0.0926,,,,,,,,Sequential,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Whole Blood,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Roger Dodd,American Red Cross,Unity-Aligned,https://dx.doi.org/10.1016/j.tmrv.2021.07.001,2021-08-17,2024-03-01,Verified,dodd_characteristics_2021,USA
210730_USA_AmericanRedCross_Female,210730_USA_AmericanRedCross,Characteristics of US Blood Donors Testing Reactive for Antibodies to SARS-CoV-2 Prior to the Availability of Authorized Vaccines.,2021-07-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Blood donors who made donations of whole blood, double red-cells or single-donor platelets between June 15th and November 30th, 2020 to the American Red Cross","""donors of COVID-19 convalescent plasma were excluded""",2020-06-15,2020-11-30,Blood donors,Female,Multiple groups,16.0,,Sex/Gender,,850936,0.0422,,,,,,,,Sequential,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Whole Blood,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Yes,Yes,Yes,Yes,,Roger Dodd,American Red Cross,Unity-Aligned,https://dx.doi.org/10.1016/j.tmrv.2021.07.001,2021-08-17,2024-03-01,Verified,dodd_characteristics_2021,USA
210731_Wisconsin_CentersforDiseaseControlandPrevention_1September,210731_Wisconsin_CentersforDiseaseControlandPrevention_1September,"Risk Factors for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Presence of Anti-SARS-CoV-2 Antibodies Among University Student Dormitory Residents, September-November 2020.",2021-07-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Wisconsin,,"""Students living in 19 dormitories at a major public university in Wisconsin were invited to participate in data collection""",,2020-09-01,2020-09-04,Students and Daycares,All,Adults (18-64 years),17.0,38.0,Primary Estimate,,517,0.0406,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,,,,['High'],,No,No,No,,Yes,Yes,Yes,,Hannah Segaloff,Centers for Disease Control and Prevention,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab405,2021-09-29,2024-03-01,Unverified,segaloff_risk_2021,USA
210731_Wisconsin_CentersforDiseaseControlandPrevention_2November,210731_Wisconsin_CentersforDiseaseControlandPrevention_2November,"Risk Factors for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Presence of Anti-SARS-CoV-2 Antibodies Among University Student Dormitory Residents, September-November 2020.",2021-07-31,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Wisconsin,,"""Students living in 19 dormitories at a major public university in Wisconsin were invited to participate in data collection""",,2020-11-09,2020-11-13,Students and Daycares,All,Adults (18-64 years),17.0,24.0,Primary Estimate,,413,0.1864,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,,,,['High'],,No,No,No,,Yes,Yes,Yes,,Hannah Segaloff,Centers for Disease Control and Prevention,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab405,2021-09-29,2024-03-01,Unverified,segaloff_risk_2021,USA
210801_Phoenix_DignityHealthResearchInstitute, 210801_Phoenix_DignityHealthResearchInstitute,32 Decay of Anti-SARS-CoV-2 Nucleocapsid IgG in Seropositive Health Care Workers Over Time,2021-08-01,Presentation or Conference,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Arizona,Phoenix,,,2020-06-15,2020-08-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,"HCWs from six acute-care hospitals in Phoenix, AZ who were working in June 2019.",1358,0.214,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,B. Tiffany,Dignity Health Research Institute,Not Unity-Aligned,http://dx.doi.org/10.1016/j.annemergmed.2021.07.033,2021-08-15,2024-03-01,Unverified,tiffany_32_2021,USA
210801_SouthBronx_MountSinai_primary,210801_SouthBronx_MountSinai,Longitudinal analysis of severe acute respiratory syndrome coronavirus 2 seroprevalence using multiple serology platforms,2021-08-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"healthcare workers
(HCWs) of the New York City Public Hospital in the South Bronx (NYC Health + Hospitals/Lincoln).",,2020-05-01,2020-05-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Tested used: in-house ELISA (primary) ,501,0.284,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9500000000000001,1.0,['High'],,No,No,No,,Unclear,Yes,Yes,,Juan Manuel Carreno,Icahn School of Medicine at Mount Sinai,Not Unity-Aligned,https://www.cell.com/iscience/fulltext/S2589-0042(21)00905-6?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2589004221009056%3Fshowall%3Dtrue,2021-10-22,2022-07-16,Unverified,carreno_longitudinal_2021-1,USA
210803_NewYorkCity_NewYorkUniversity_Overall_UnAdj,210803_NewYorkCity_NewYorkUniversity,EVALUATION OF SARS-COV-2 IGG ANTIBODY REACTIVITY IN A MULTI-RACIAL/ETHNIC COHORT OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS,2021-08-03,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,New York,New York City,"All patients in the WARCOV cohort were age 18 years or older and had SLE fulfilling at least 1 of the following criteria sets: 1) the American College of Rheumatology (ACR) revised classification criteria,  2) the Systemic
Lupus International Collaborating Clinics classification criteria, 3) the European League Against Rheumatism/ACR classification criteria or had been diagnosed by a rheumatologist as having SLE (if fulfillment of classification criteria for SLE could not be confirmed due to incomplete or unavailable data). Only English‐, Spanish‐ or Mandarin‐speaking patients were included in the study.
The NYU Lupus Cohort is a prospective convenience registry open to enrollment of any patient with SLE seen at NYU Langone Health and NYC Health + Hospitals/Bellevue since 2014. All SLE patients in the NYU Lupus
Cohort are age 18 or older and fulfill at least one of the following criteria for SLE: 1) the American College of Rheumatology (ACR) revised classification criteria; 2) the Systemic Lupus International Collaborating Clinics (SLICC) classification criteria; 3) the European League Against Rheumatism (EULAR)/ACR classification criteria. All patients and controls signed an informed consent to be in the NYU Lupus Cohort. NYU Lupus Cohort
consents are available in English, Spanish and Mandarin.",No Exclusion Criteria noted?,2020-04-29,2021-02-09,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,,Primary Estimate,,329,0.16,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,1.0,0.996,['High'],,No,No,Yes,,Yes,Yes,Yes,,Amit Saxena,New York University,Not Unity-Aligned,https://dx.doi.org/10.1136/lupus-2021-lupus21century.73,2022-07-06,2024-03-01,Unverified,saxena_evaluation_2021,USA
210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jan_Age<5,210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jan3,"Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.",2021-08-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Missouri,St Louis,Adult patients presenting to hospitals in the St. Louis metropolitan area in Missouri and pediatric samples including residual serum or plasma specimens from unique outpatients presenting to St. Louis Children’s Hospital who had blood drawn for screening for a variety of conditions during three collection window,,2020-12-24,2021-01-21,Residual sera,All,Children and Youth (0-17 years),0.0,4.0,Age,<5,133,0.18050000000000002,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9820000000000001,0.9870000000000001,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Brittany K. Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00450-21,2021-08-10,2022-07-16,Verified,smith_progression_2021,USA
210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jan_Male,210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jan3,"Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.",2021-08-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Missouri,St Louis,Adult patients presenting to hospitals in the St. Louis metropolitan area in Missouri and pediatric samples including residual serum or plasma specimens from unique outpatients presenting to St. Louis Children’s Hospital who had blood drawn for screening for a variety of conditions during three collection window,,2020-12-24,2021-01-21,Residual sera,Male,Multiple groups,,,Sex/Gender,,461,0.22340000000000002,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9820000000000001,0.9870000000000001,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Brittany K. Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00450-21,2021-08-10,2022-07-16,Verified,smith_progression_2021,USA
210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jan_Age18to39,210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jan3,"Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.",2021-08-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Missouri,St Louis,Adult patients presenting to hospitals in the St. Louis metropolitan area in Missouri and pediatric samples including residual serum or plasma specimens from unique outpatients presenting to St. Louis Children’s Hospital who had blood drawn for screening for a variety of conditions during three collection window,,2020-12-25,2021-01-05,Residual sera,All,Adults (18-64 years),18.0,39.0,Age,18-39,75,0.24,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9820000000000001,0.9870000000000001,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Brittany K. Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00450-21,2021-08-10,2022-07-16,Verified,smith_progression_2021,USA
210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jan_Female,210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jan3,"Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.",2021-08-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Missouri,St Louis,Adult patients presenting to hospitals in the St. Louis metropolitan area in Missouri and pediatric samples including residual serum or plasma specimens from unique outpatients presenting to St. Louis Children’s Hospital who had blood drawn for screening for a variety of conditions during three collection window,,2020-12-24,2021-01-21,Residual sera,Female,Multiple groups,,,Sex/Gender,,540,0.19260000000000002,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9820000000000001,0.9870000000000001,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Brittany K. Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00450-21,2021-08-10,2022-07-16,Verified,smith_progression_2021,USA
210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jan_Adults,210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jan3,"Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.",2021-08-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Missouri,St Louis,Adult patients presenting to hospitals in the St. Louis metropolitan area in Missouri and pediatric samples including residual serum or plasma specimens from unique outpatients presenting to St. Louis Children’s Hospital who had blood drawn for screening for a variety of conditions during three collection window,,2020-12-25,2021-01-05,Residual sera,All,Multiple groups,18.0,,Age,>18,499,0.19030000000000002,0.1524,0.228,,True,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9820000000000001,0.9870000000000001,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Brittany K. Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00450-21,2021-08-10,2022-07-16,Verified,smith_progression_2021,USA
210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jan_AntiN,210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jan3,"Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.",2021-08-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Missouri,St Louis,Adult patients presenting to hospitals in the St. Louis metropolitan area in Missouri and pediatric samples including residual serum or plasma specimens from unique outpatients presenting to St. Louis Children’s Hospital who had blood drawn for screening for a variety of conditions during three collection window,,2020-12-25,2021-01-05,Residual sera,All,Multiple groups,18.0,,Test used,Anti-N ELISA,499,0.21100000000000002,0.1536,0.2686,,True,,,,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Multiple Types,IgG,Nucleocapsid(N-protein),Validated by developers,0.865,0.9309999999999999,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Brittany K. Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00450-21,2021-08-18,2022-07-16,Verified,smith_progression_2021,USA
210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jan_Age10to17,210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jan3,"Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.",2021-08-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Missouri,St Louis,Adult patients presenting to hospitals in the St. Louis metropolitan area in Missouri and pediatric samples including residual serum or plasma specimens from unique outpatients presenting to St. Louis Children’s Hospital who had blood drawn for screening for a variety of conditions during three collection window,,2020-12-24,2021-01-21,Residual sera,All,Children and Youth (0-17 years),10.0,17.0,Age,10-17,254,0.25980000000000003,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9820000000000001,0.9870000000000001,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Brittany K. Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00450-21,2021-08-10,2022-07-16,Verified,smith_progression_2021,USA
210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jan_Primary,210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jan3,"Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.",2021-08-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Missouri,St Louis,Adult patients presenting to hospitals in the St. Louis metropolitan area in Missouri and pediatric samples including residual serum or plasma specimens from unique outpatients presenting to St. Louis Children’s Hospital who had blood drawn for screening for a variety of conditions during three collection window,,2020-12-24,2021-01-21,Residual sera,All,Multiple groups,,,Primary Estimate,,1001,0.2068,,,,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9820000000000001,0.9870000000000001,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Brittany K. Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00450-21,2021-08-18,2022-07-16,Verified,smith_progression_2021,USA
210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jan_Age40to64,210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jan3,"Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.",2021-08-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Missouri,St Louis,Adult patients presenting to hospitals in the St. Louis metropolitan area in Missouri and pediatric samples including residual serum or plasma specimens from unique outpatients presenting to St. Louis Children’s Hospital who had blood drawn for screening for a variety of conditions during three collection window,,2020-12-25,2021-01-05,Residual sera,All,Adults (18-64 years),40.0,64.0,Age,40-64,219,0.1918,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9820000000000001,0.9870000000000001,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Brittany K. Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00450-21,2021-08-10,2022-07-16,Verified,smith_progression_2021,USA
210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jan_Children,210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jan3,"Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.",2021-08-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Missouri,St Louis,Adult patients presenting to hospitals in the St. Louis metropolitan area in Missouri and pediatric samples including residual serum or plasma specimens from unique outpatients presenting to St. Louis Children’s Hospital who had blood drawn for screening for a variety of conditions during three collection window,,2020-12-24,2021-01-21,Residual sera,All,Children and Youth (0-17 years),,17.0,Age,<18,502,0.2116,0.1721,0.2509,,True,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9820000000000001,0.9870000000000001,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Brittany K. Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00450-21,2021-08-10,2022-07-16,Verified,smith_progression_2021,USA
210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jan_Age65plus,210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jan3,"Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.",2021-08-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Missouri,St Louis,Adult patients presenting to hospitals in the St. Louis metropolitan area in Missouri and pediatric samples including residual serum or plasma specimens from unique outpatients presenting to St. Louis Children’s Hospital who had blood drawn for screening for a variety of conditions during three collection window,,2020-12-25,2021-01-05,Residual sera,All,Seniors (65+ years),65.0,,Age,>65,205,0.18539999999999998,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9820000000000001,0.9870000000000001,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Brittany K. Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00450-21,2021-08-10,2022-07-16,Verified,smith_progression_2021,USA
210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jan_Age5to9,210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jan3,"Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.",2021-08-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Missouri,St Louis,Adult patients presenting to hospitals in the St. Louis metropolitan area in Missouri and pediatric samples including residual serum or plasma specimens from unique outpatients presenting to St. Louis Children’s Hospital who had blood drawn for screening for a variety of conditions during three collection window,,2020-12-24,2021-01-21,Residual sera,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,115,0.16519999999999999,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9820000000000001,0.9870000000000001,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Brittany K. Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00450-21,2021-08-10,2022-07-16,Verified,smith_progression_2021,USA
210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jul_Children,210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jul1,"Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.",2021-08-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Missouri,St Louis,Adult patients presenting to hospitals in the St. Louis metropolitan area in Missouri and pediatric samples including residual serum or plasma specimens from unique outpatients presenting to St. Louis Children’s Hospital who had blood drawn for screening for a variety of conditions during three collection window,,2020-07-22,2020-08-16,Residual sera,All,Children and Youth (0-17 years),,17.0,Age,<18,546,0.052199999999999996,0.0276,0.0768,True,True,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9820000000000001,0.9870000000000001,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Brittany K. Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00450-21,2021-08-10,2022-07-16,Verified,smith_progression_2021,USA
210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jul_Adults,210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jul1,"Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.",2021-08-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Missouri,St Louis,Adult patients presenting to hospitals in the St. Louis metropolitan area in Missouri and pediatric samples including residual serum or plasma specimens from unique outpatients presenting to St. Louis Children’s Hospital who had blood drawn for screening for a variety of conditions during three collection window,,2020-07-25,2020-07-31,Residual sera,All,Multiple groups,18.0,,Age,>18,506,0.0452,0.0207,0.0693,True,True,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9820000000000001,0.9870000000000001,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Brittany K. Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00450-21,2021-08-10,2022-07-16,Verified,smith_progression_2021,USA
210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jul_Primary,210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jul1,"Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.",2021-08-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Missouri,St Louis,Adult patients presenting to hospitals in the St. Louis metropolitan area in Missouri and pediatric samples including residual serum or plasma specimens from unique outpatients presenting to St. Louis Children’s Hospital who had blood drawn for screening for a variety of conditions during three collection window,,2020-07-22,2020-08-16,Residual sera,All,Multiple groups,,,Primary Estimate,,1052,0.0589,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9820000000000001,0.9870000000000001,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Brittany K. Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00450-21,2021-08-18,2022-07-16,Verified,smith_progression_2021,USA
210804_StLouis_WashingtonUniversitySchoolOfMedicine_July_Age10to17,210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jul1,"Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.",2021-08-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Missouri,St Louis,Adult patients presenting to hospitals in the St. Louis metropolitan area in Missouri and pediatric samples including residual serum or plasma specimens from unique outpatients presenting to St. Louis Children’s Hospital who had blood drawn for screening for a variety of conditions during three collection window,,2020-07-22,2020-08-16,Residual sera,All,Children and Youth (0-17 years),10.0,17.0,Age,10-17,279,0.0789,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9820000000000001,0.9870000000000001,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Brittany K. Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00450-21,2021-08-10,2022-07-16,Verified,smith_progression_2021,USA
210804_StLouis_WashingtonUniversitySchoolOfMedicine_July_Age<5,210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jul1,"Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.",2021-08-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Missouri,St Louis,Adult patients presenting to hospitals in the St. Louis metropolitan area in Missouri and pediatric samples including residual serum or plasma specimens from unique outpatients presenting to St. Louis Children’s Hospital who had blood drawn for screening for a variety of conditions during three collection window,,2020-07-22,2020-08-16,Residual sera,All,Children and Youth (0-17 years),0.0,4.0,Age,<5,142,0.0352,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9820000000000001,0.9870000000000001,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Brittany K. Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00450-21,2021-08-10,2022-07-16,Verified,smith_progression_2021,USA
210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jul_Age18to39,210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jul1,"Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.",2021-08-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Missouri,St Louis,Adult patients presenting to hospitals in the St. Louis metropolitan area in Missouri and pediatric samples including residual serum or plasma specimens from unique outpatients presenting to St. Louis Children’s Hospital who had blood drawn for screening for a variety of conditions during three collection window,,2020-07-25,2020-07-31,Residual sera,All,Adults (18-64 years),18.0,39.0,Age,18-39,73,0.05480000000000001,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9820000000000001,0.9870000000000001,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Brittany K. Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00450-21,2021-08-10,2022-07-16,Verified,smith_progression_2021,USA
210804_StLouis_WashingtonUniversitySchoolOfMedicine_July_Age5to9,210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jul1,"Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.",2021-08-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Missouri,St Louis,Adult patients presenting to hospitals in the St. Louis metropolitan area in Missouri and pediatric samples including residual serum or plasma specimens from unique outpatients presenting to St. Louis Children’s Hospital who had blood drawn for screening for a variety of conditions during three collection window,,2020-07-22,2020-08-16,Residual sera,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,125,0.055999999999999994,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9820000000000001,0.9870000000000001,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Brittany K. Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00450-21,2021-08-10,2022-07-16,Verified,smith_progression_2021,USA
210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jul_Age65plus,210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jul1,"Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.",2021-08-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Missouri,St Louis,Adult patients presenting to hospitals in the St. Louis metropolitan area in Missouri and pediatric samples including residual serum or plasma specimens from unique outpatients presenting to St. Louis Children’s Hospital who had blood drawn for screening for a variety of conditions during three collection window,,2020-07-25,2020-07-31,Residual sera,All,Seniors (65+ years),65.0,,Age,>65,208,0.0721,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9820000000000001,0.9870000000000001,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Brittany K. Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00450-21,2021-08-10,2022-07-16,Verified,smith_progression_2021,USA
210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jul_Male,210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jul1,"Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.",2021-08-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Missouri,St Louis,Adult patients presenting to hospitals in the St. Louis metropolitan area in Missouri and pediatric samples including residual serum or plasma specimens from unique outpatients presenting to St. Louis Children’s Hospital who had blood drawn for screening for a variety of conditions during three collection window,,2020-07-22,2020-08-16,Residual sera,Male,Multiple groups,,,Sex/Gender,,415,0.0434,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9820000000000001,0.9870000000000001,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Brittany K. Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00450-21,2021-08-10,2022-07-16,Verified,smith_progression_2021,USA
210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jul_Female,210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jul1,"Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.",2021-08-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Missouri,St Louis,Adult patients presenting to hospitals in the St. Louis metropolitan area in Missouri and pediatric samples including residual serum or plasma specimens from unique outpatients presenting to St. Louis Children’s Hospital who had blood drawn for screening for a variety of conditions during three collection window,,2020-07-22,2020-08-16,Residual sera,Female,Multiple groups,,,Sex/Gender,,637,0.06910000000000001,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9820000000000001,0.9870000000000001,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Brittany K. Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00450-21,2021-08-10,2022-07-16,Verified,smith_progression_2021,USA
210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jul_Age40to64,210804_StLouis_WashingtonUniversitySchoolOfMedicine_Jul1,"Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.",2021-08-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Missouri,St Louis,Adult patients presenting to hospitals in the St. Louis metropolitan area in Missouri and pediatric samples including residual serum or plasma specimens from unique outpatients presenting to St. Louis Children’s Hospital who had blood drawn for screening for a variety of conditions during three collection window,,2020-07-25,2020-07-31,Residual sera,All,Adults (18-64 years),40.0,64.0,Age,40-64,225,0.04,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9820000000000001,0.9870000000000001,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Brittany K. Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00450-21,2021-08-10,2022-07-16,Verified,smith_progression_2021,USA
210804_StLouis_WashingtonUniversitySchoolOfMedicine_Nov_Adults,210804_StLouis_WashingtonUniversitySchoolOfMedicine_Nov2,"Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.",2021-08-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Missouri,St Louis,Adult patients presenting to hospitals in the St. Louis metropolitan area in Missouri and pediatric samples including residual serum or plasma specimens from unique outpatients presenting to St. Louis Children’s Hospital who had blood drawn for screening for a variety of conditions during three collection window,,2020-10-27,2020-11-07,Residual sera,All,Multiple groups,18.0,,Age,>18,509,0.0609,0.0345,0.0873,,True,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9820000000000001,0.9870000000000001,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Brittany K. Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00450-21,2021-08-18,2022-07-16,Verified,smith_progression_2021,USA
210804_StLouis_WashingtonUniversitySchoolOfMedicine_Nov_Age18to39,210804_StLouis_WashingtonUniversitySchoolOfMedicine_Nov2,"Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.",2021-08-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Missouri,St Louis,Adult patients presenting to hospitals in the St. Louis metropolitan area in Missouri and pediatric samples including residual serum or plasma specimens from unique outpatients presenting to St. Louis Children’s Hospital who had blood drawn for screening for a variety of conditions during three collection window,,2020-10-27,2020-11-07,Residual sera,All,Adults (18-64 years),18.0,39.0,Age,18-39,89,0.1011,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9820000000000001,0.9870000000000001,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Brittany K. Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00450-21,2021-08-10,2022-07-16,Verified,smith_progression_2021,USA
210804_StLouis_WashingtonUniversitySchoolOfMedicine_Nov_Age5to9,210804_StLouis_WashingtonUniversitySchoolOfMedicine_Nov2,"Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.",2021-08-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Missouri,St Louis,Adult patients presenting to hospitals in the St. Louis metropolitan area in Missouri and pediatric samples including residual serum or plasma specimens from unique outpatients presenting to St. Louis Children’s Hospital who had blood drawn for screening for a variety of conditions during three collection window,,2020-11-01,2020-11-30,Residual sera,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,78,0.1923,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9820000000000001,0.9870000000000001,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Brittany K. Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00450-21,2021-08-10,2022-07-16,Verified,smith_progression_2021,USA
210804_StLouis_WashingtonUniversitySchoolOfMedicine_Nov_Female,210804_StLouis_WashingtonUniversitySchoolOfMedicine_Nov2,"Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.",2021-08-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Missouri,St Louis,Adult patients presenting to hospitals in the St. Louis metropolitan area in Missouri and pediatric samples including residual serum or plasma specimens from unique outpatients presenting to St. Louis Children’s Hospital who had blood drawn for screening for a variety of conditions during three collection window,,2020-10-27,2020-11-30,Residual sera,Female,Multiple groups,,,Sex/Gender,,542,0.0922,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9820000000000001,0.9870000000000001,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Brittany K. Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00450-21,2021-08-10,2022-07-16,Verified,smith_progression_2021,USA
210804_StLouis_WashingtonUniversitySchoolOfMedicine_Nov_Primary,210804_StLouis_WashingtonUniversitySchoolOfMedicine_Nov2,"Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.",2021-08-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Missouri,St Louis,Adult patients presenting to hospitals in the St. Louis metropolitan area in Missouri and pediatric samples including residual serum or plasma specimens from unique outpatients presenting to St. Louis Children’s Hospital who had blood drawn for screening for a variety of conditions during three collection window,,2020-10-27,2020-11-30,Residual sera,All,Multiple groups,,,Primary Estimate,,1013,0.1165,,,,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9820000000000001,0.9870000000000001,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Brittany K. Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00450-21,2021-08-18,2022-07-16,Verified,smith_progression_2021,USA
210804_StLouis_WashingtonUniversitySchoolOfMedicine_Nov_Children,210804_StLouis_WashingtonUniversitySchoolOfMedicine_Nov2,"Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.",2021-08-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Missouri,St Louis,Adult patients presenting to hospitals in the St. Louis metropolitan area in Missouri and pediatric samples including residual serum or plasma specimens from unique outpatients presenting to St. Louis Children’s Hospital who had blood drawn for screening for a variety of conditions during three collection window,,2020-11-01,2020-11-30,Residual sera,All,Children and Youth (0-17 years),,17.0,Age,<18,504,0.15560000000000002,0.1207,0.1905,,True,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9820000000000001,0.9870000000000001,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Brittany K. Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00450-21,2021-08-10,2022-07-16,Verified,smith_progression_2021,USA
210804_StLouis_WashingtonUniversitySchoolOfMedicine_Nov_Age<5,210804_StLouis_WashingtonUniversitySchoolOfMedicine_Nov2,"Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.",2021-08-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Missouri,St Louis,Adult patients presenting to hospitals in the St. Louis metropolitan area in Missouri and pediatric samples including residual serum or plasma specimens from unique outpatients presenting to St. Louis Children’s Hospital who had blood drawn for screening for a variety of conditions during three collection window,,2020-11-01,2020-11-30,Residual sera,All,Children and Youth (0-17 years),0.0,4.0,Age,<5,144,0.09029999999999999,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9820000000000001,0.9870000000000001,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Brittany K. Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00450-21,2021-08-10,2022-07-16,Verified,smith_progression_2021,USA
210804_StLouis_WashingtonUniversitySchoolOfMedicine_Nov_Age10to17,210804_StLouis_WashingtonUniversitySchoolOfMedicine_Nov2,"Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.",2021-08-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Missouri,St Louis,Adult patients presenting to hospitals in the St. Louis metropolitan area in Missouri and pediatric samples including residual serum or plasma specimens from unique outpatients presenting to St. Louis Children’s Hospital who had blood drawn for screening for a variety of conditions during three collection window,,2020-11-01,2020-11-30,Residual sera,All,Children and Youth (0-17 years),10.0,17.0,Age,10-17,282,0.1915,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9820000000000001,0.9870000000000001,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Brittany K. Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00450-21,2021-08-10,2022-07-16,Verified,smith_progression_2021,USA
210804_StLouis_WashingtonUniversitySchoolOfMedicine_Nov_Male,210804_StLouis_WashingtonUniversitySchoolOfMedicine_Nov2,"Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.",2021-08-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Missouri,St Louis,Adult patients presenting to hospitals in the St. Louis metropolitan area in Missouri and pediatric samples including residual serum or plasma specimens from unique outpatients presenting to St. Louis Children’s Hospital who had blood drawn for screening for a variety of conditions during three collection window,,2020-10-27,2020-11-30,Residual sera,Male,Multiple groups,,,Sex/Gender,,471,0.1444,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9820000000000001,0.9870000000000001,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Brittany K. Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00450-21,2021-08-10,2022-07-16,Verified,smith_progression_2021,USA
210804_StLouis_WashingtonUniversitySchoolOfMedicine_Nov_Age40to64,210804_StLouis_WashingtonUniversitySchoolOfMedicine_Nov2,"Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.",2021-08-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Missouri,St Louis,Adult patients presenting to hospitals in the St. Louis metropolitan area in Missouri and pediatric samples including residual serum or plasma specimens from unique outpatients presenting to St. Louis Children’s Hospital who had blood drawn for screening for a variety of conditions during three collection window,,2020-10-27,2020-11-07,Residual sera,All,Adults (18-64 years),40.0,64.0,Age,40-64,232,0.0776,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9820000000000001,0.9870000000000001,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Brittany K. Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00450-21,2021-08-10,2022-07-16,Verified,smith_progression_2021,USA
210804_StLouis_WashingtonUniversitySchoolOfMedicine_Nov_Age65plus,210804_StLouis_WashingtonUniversitySchoolOfMedicine_Nov2,"Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.",2021-08-04,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Missouri,St Louis,Adult patients presenting to hospitals in the St. Louis metropolitan area in Missouri and pediatric samples including residual serum or plasma specimens from unique outpatients presenting to St. Louis Children’s Hospital who had blood drawn for screening for a variety of conditions during three collection window,,2020-10-27,2020-11-07,Residual sera,All,Seniors (65+ years),65.0,,Age,>65,188,0.0479,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Multiple Types,IgG,Spike,Validated by developers,0.9820000000000001,0.9870000000000001,['High'],No,No,Yes,Yes,No,Unclear,Yes,Yes,Unclear,Brittany K. Smith,Washington University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1128/mSphere.00450-21,2021-08-10,2022-07-16,Verified,smith_progression_2021,USA
210806_Columbus_OhioStateUniversityCollegeofMedicine,210806_Columbus_OhioStateUniversityCollegeofMedicine,Decline in Sars-CoV-2 antibodies over 6 month follow up in Obstetrical Healthcare workers.,2021-08-06,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Ohio,Columbus,"HCWs employed in the antepartum and triage units, labor and delivery, and outpatient facilities inclusive of clinic and ultrasound staff",,2020-09-18,2020-09-25,Health care workers and caregivers,Female,Adults (18-64 years),,,Primary Estimate,overall ,126,0.2143,,,True,,,,True,Convenience,EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit,"Epitope Diagnostics, Inc.",ELISA,Serum,"['IgG', 'IgM']",,,,,['High'],,No,No,No,,Yes,Yes,Yes,,Miranda Kiefer,Ohio State University College of Medicine,Not Unity-Aligned,https://dx.doi.org/10.1111/aji.13490,2021-08-17,2024-03-01,Unverified,kiefer_decline_2021,USA
210809_Chicago_NorthwesternUniversity,210809_Chicago_NorthwesternUniversity,Serologic Status and SARS CoV-2 Infection over 6-Months of Follow-Up in Healthcare Workers in Chicago: A Cohort Study.,2021-08-09,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Illinois,"Chicago
","HCW in the Chicago area, USA",,2020-11-09,2021-01-08,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,overall hcws,4947,0.0835,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,John Wilkins,Northwestern University,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2021.367,2021-08-17,2024-03-01,Unverified,wilkins_serologic_2021,USA
210811_UnitedStates_NationalInstitutesOfHealth_Primary,210811_UnitedStates_NationalInstitutesOfHealth,SARS-CoV-2 Seroprevalence and Drug Use in Trauma Patients from Six Sites in the United States,2021-08-11,Preprint,National,Cross-sectional survey ,United States of America,,,"human serum samples were obtained as part of an ongoing National Highway Traffic Safety Administration (NHTSA) study of drug prevalence among adult (age 18+) trauma victims who were transported by EMS due to the severity of their injuries and had a trauma team activated/alerted at selected Level-1 trauma centers. The specimens from this convenience sample were available for research purposes from patients who were already having blood drawn as part of medical treatment at the trauma centers. Samples were collected at six study sites in the United States: Baltimore, Maryland (28.13%), Jacksonville, Florida (18.37%), Worcester, Massachusetts (10.70%), Charlotte, North Carolina (19.43%), Miami, Florida (16.48%), and Iowa City, Iowa (6.88%).",,2020-04-15,2020-10-15,Residual sera,All,Multiple groups,18.0,,Primary Estimate,,2542,0.0787,0.0688,0.0898,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Tran B Ngo,National Institutes of Health,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.10.21261849v1,2021-08-16,2022-07-16,Verified,ngoSARSCoV2SeroprevalenceDrug2021,USA
210811_UnitedStates_NationalInstitutesOfHealth_45-69,210811_UnitedStates_NationalInstitutesOfHealth,SARS-CoV-2 Seroprevalence and Drug Use in Trauma Patients from Six Sites in the United States,2021-08-11,Preprint,National,Cross-sectional survey ,United States of America,,,"human serum samples were obtained as part of an ongoing National Highway Traffic Safety Administration (NHTSA) study of drug prevalence among adult (age 18+) trauma victims who were transported by EMS due to the severity of their injuries and had a trauma team activated/alerted at selected Level-1 trauma centers. The specimens from this convenience sample were available for research purposes from patients who were already having blood drawn as part of medical treatment at the trauma centers. Samples were collected at six study sites in the United States: Baltimore, Maryland (28.13%), Jacksonville, Florida (18.37%), Worcester, Massachusetts (10.70%), Charlotte, North Carolina (19.43%), Miami, Florida (16.48%), and Iowa City, Iowa (6.88%).",,2020-04-15,2020-10-15,Residual sera,All,Multiple groups,45.0,69.0,Age,45-69,829,0.060300000000000006,0.045899999999999996,0.0788,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Tran B Ngo,National Institutes of Health,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.10.21261849v1,2021-08-16,2022-07-16,Verified,ngoSARSCoV2SeroprevalenceDrug2021,USA
210811_UnitedStates_NationalInstitutesOfHealth_Charlotte,210811_UnitedStates_NationalInstitutesOfHealth,SARS-CoV-2 Seroprevalence and Drug Use in Trauma Patients from Six Sites in the United States,2021-08-11,Preprint,Regional,Cross-sectional survey ,United States of America,North Carolina,Charlotte,"human serum samples were obtained as part of an ongoing National Highway Traffic Safety Administration (NHTSA) study of drug prevalence among adult (age 18+) trauma victims who were transported by EMS due to the severity of their injuries and had a trauma team activated/alerted at selected Level-1 trauma centers. The specimens from this convenience sample were available for research purposes from patients who were already having blood drawn as part of medical treatment at the trauma centers. Samples were collected at six study sites in the United States: Baltimore, Maryland (28.13%), Jacksonville, Florida (18.37%), Worcester, Massachusetts (10.70%), Charlotte, North Carolina (19.43%), Miami, Florida (16.48%), and Iowa City, Iowa (6.88%).",,2020-04-15,2020-10-15,Residual sera,All,Multiple groups,18.0,,Geographical area,Charlotte,494,0.0729,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Tran B Ngo,National Institutes of Health,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.10.21261849v1,2021-08-16,2022-07-16,Verified,ngoSARSCoV2SeroprevalenceDrug2021,USA
210811_UnitedStates_NationalInstitutesOfHealth_Miami,210811_UnitedStates_NationalInstitutesOfHealth,SARS-CoV-2 Seroprevalence and Drug Use in Trauma Patients from Six Sites in the United States,2021-08-11,Preprint,Regional,Cross-sectional survey ,United States of America,Florida,Miami,"human serum samples were obtained as part of an ongoing National Highway Traffic Safety Administration (NHTSA) study of drug prevalence among adult (age 18+) trauma victims who were transported by EMS due to the severity of their injuries and had a trauma team activated/alerted at selected Level-1 trauma centers. The specimens from this convenience sample were available for research purposes from patients who were already having blood drawn as part of medical treatment at the trauma centers. Samples were collected at six study sites in the United States: Baltimore, Maryland (28.13%), Jacksonville, Florida (18.37%), Worcester, Massachusetts (10.70%), Charlotte, North Carolina (19.43%), Miami, Florida (16.48%), and Iowa City, Iowa (6.88%).",,2020-04-15,2020-10-15,Residual sera,All,Multiple groups,18.0,,Geographical area,Miami,419,0.1217,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Tran B Ngo,National Institutes of Health,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.10.21261849v1,2021-08-16,2022-07-16,Verified,ngoSARSCoV2SeroprevalenceDrug2021,USA
210811_UnitedStates_NationalInstitutesOfHealth_Jacksonville,210811_UnitedStates_NationalInstitutesOfHealth,SARS-CoV-2 Seroprevalence and Drug Use in Trauma Patients from Six Sites in the United States,2021-08-11,Preprint,Regional,Cross-sectional survey ,United States of America,Florida,Jacksonville,"human serum samples were obtained as part of an ongoing National Highway Traffic Safety Administration (NHTSA) study of drug prevalence among adult (age 18+) trauma victims who were transported by EMS due to the severity of their injuries and had a trauma team activated/alerted at selected Level-1 trauma centers. The specimens from this convenience sample were available for research purposes from patients who were already having blood drawn as part of medical treatment at the trauma centers. Samples were collected at six study sites in the United States: Baltimore, Maryland (28.13%), Jacksonville, Florida (18.37%), Worcester, Massachusetts (10.70%), Charlotte, North Carolina (19.43%), Miami, Florida (16.48%), and Iowa City, Iowa (6.88%).",,2020-04-15,2020-10-15,Residual sera,All,Multiple groups,18.0,,Geographical area,Jacksonville,467,0.06849999999999999,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Tran B Ngo,National Institutes of Health,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.10.21261849v1,2021-08-16,2022-07-16,Verified,ngoSARSCoV2SeroprevalenceDrug2021,USA
210811_UnitedStates_NationalInstitutesOfHealth_IowaCity,210811_UnitedStates_NationalInstitutesOfHealth,SARS-CoV-2 Seroprevalence and Drug Use in Trauma Patients from Six Sites in the United States,2021-08-11,Preprint,Regional,Cross-sectional survey ,United States of America,Iowa,Iowa City,"human serum samples were obtained as part of an ongoing National Highway Traffic Safety Administration (NHTSA) study of drug prevalence among adult (age 18+) trauma victims who were transported by EMS due to the severity of their injuries and had a trauma team activated/alerted at selected Level-1 trauma centers. The specimens from this convenience sample were available for research purposes from patients who were already having blood drawn as part of medical treatment at the trauma centers. Samples were collected at six study sites in the United States: Baltimore, Maryland (28.13%), Jacksonville, Florida (18.37%), Worcester, Massachusetts (10.70%), Charlotte, North Carolina (19.43%), Miami, Florida (16.48%), and Iowa City, Iowa (6.88%).",,2020-04-15,2020-10-15,Residual sera,All,Multiple groups,18.0,,Geographical area,Iowa City,175,0.06860000000000001,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Tran B Ngo,National Institutes of Health,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.10.21261849v1,2021-08-16,2022-07-16,Verified,ngoSARSCoV2SeroprevalenceDrug2021,USA
210811_UnitedStates_NationalInstitutesOfHealth_18-44,210811_UnitedStates_NationalInstitutesOfHealth,SARS-CoV-2 Seroprevalence and Drug Use in Trauma Patients from Six Sites in the United States,2021-08-11,Preprint,National,Cross-sectional survey ,United States of America,,,"human serum samples were obtained as part of an ongoing National Highway Traffic Safety Administration (NHTSA) study of drug prevalence among adult (age 18+) trauma victims who were transported by EMS due to the severity of their injuries and had a trauma team activated/alerted at selected Level-1 trauma centers. The specimens from this convenience sample were available for research purposes from patients who were already having blood drawn as part of medical treatment at the trauma centers. Samples were collected at six study sites in the United States: Baltimore, Maryland (28.13%), Jacksonville, Florida (18.37%), Worcester, Massachusetts (10.70%), Charlotte, North Carolina (19.43%), Miami, Florida (16.48%), and Iowa City, Iowa (6.88%).",,2020-04-15,2020-10-15,Residual sera,All,Adults (18-64 years),18.0,44.0,Age,18-44,1389,0.09789999999999999,0.0833,0.11470000000000001,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Tran B Ngo,National Institutes of Health,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.10.21261849v1,2021-08-16,2022-07-16,Verified,ngoSARSCoV2SeroprevalenceDrug2021,USA
210811_UnitedStates_NationalInstitutesOfHealth_Female,210811_UnitedStates_NationalInstitutesOfHealth,SARS-CoV-2 Seroprevalence and Drug Use in Trauma Patients from Six Sites in the United States,2021-08-11,Preprint,National,Cross-sectional survey ,United States of America,,,"human serum samples were obtained as part of an ongoing National Highway Traffic Safety Administration (NHTSA) study of drug prevalence among adult (age 18+) trauma victims who were transported by EMS due to the severity of their injuries and had a trauma team activated/alerted at selected Level-1 trauma centers. The specimens from this convenience sample were available for research purposes from patients who were already having blood drawn as part of medical treatment at the trauma centers. Samples were collected at six study sites in the United States: Baltimore, Maryland (28.13%), Jacksonville, Florida (18.37%), Worcester, Massachusetts (10.70%), Charlotte, North Carolina (19.43%), Miami, Florida (16.48%), and Iowa City, Iowa (6.88%).",,2020-04-15,2020-10-15,Residual sera,Female,Multiple groups,18.0,,Sex/Gender,,662,0.08310000000000001,0.06420000000000001,0.1067,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Tran B Ngo,National Institutes of Health,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.10.21261849v1,2021-08-16,2022-07-16,Verified,ngoSARSCoV2SeroprevalenceDrug2021,USA
210811_UnitedStates_NationalInstitutesOfHealth_Worcester,210811_UnitedStates_NationalInstitutesOfHealth,SARS-CoV-2 Seroprevalence and Drug Use in Trauma Patients from Six Sites in the United States,2021-08-11,Preprint,Regional,Cross-sectional survey ,United States of America,Massachusetts,Worcester,"human serum samples were obtained as part of an ongoing National Highway Traffic Safety Administration (NHTSA) study of drug prevalence among adult (age 18+) trauma victims who were transported by EMS due to the severity of their injuries and had a trauma team activated/alerted at selected Level-1 trauma centers. The specimens from this convenience sample were available for research purposes from patients who were already having blood drawn as part of medical treatment at the trauma centers. Samples were collected at six study sites in the United States: Baltimore, Maryland (28.13%), Jacksonville, Florida (18.37%), Worcester, Massachusetts (10.70%), Charlotte, North Carolina (19.43%), Miami, Florida (16.48%), and Iowa City, Iowa (6.88%).",,2020-04-15,2020-10-15,Residual sera,All,Multiple groups,18.0,,Geographical area,Worcester,272,0.0772,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Tran B Ngo,National Institutes of Health,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.10.21261849v1,2021-08-16,2022-07-16,Verified,ngoSARSCoV2SeroprevalenceDrug2021,USA
210811_UnitedStates_NationalInstitutesOfHealth_70+,210811_UnitedStates_NationalInstitutesOfHealth,SARS-CoV-2 Seroprevalence and Drug Use in Trauma Patients from Six Sites in the United States,2021-08-11,Preprint,National,Cross-sectional survey ,United States of America,,,"human serum samples were obtained as part of an ongoing National Highway Traffic Safety Administration (NHTSA) study of drug prevalence among adult (age 18+) trauma victims who were transported by EMS due to the severity of their injuries and had a trauma team activated/alerted at selected Level-1 trauma centers. The specimens from this convenience sample were available for research purposes from patients who were already having blood drawn as part of medical treatment at the trauma centers. Samples were collected at six study sites in the United States: Baltimore, Maryland (28.13%), Jacksonville, Florida (18.37%), Worcester, Massachusetts (10.70%), Charlotte, North Carolina (19.43%), Miami, Florida (16.48%), and Iowa City, Iowa (6.88%).",,2020-04-15,2020-10-15,Residual sera,All,Seniors (65+ years),70.0,,Age,>70,323,0.0433,0.025400000000000002,0.07200000000000001,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Tran B Ngo,National Institutes of Health,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.10.21261849v1,2021-08-16,2022-07-16,Verified,ngoSARSCoV2SeroprevalenceDrug2021,USA
210811_UnitedStates_NationalInstitutesOfHealth_Male,210811_UnitedStates_NationalInstitutesOfHealth,SARS-CoV-2 Seroprevalence and Drug Use in Trauma Patients from Six Sites in the United States,2021-08-11,Preprint,National,Cross-sectional survey ,United States of America,,,"human serum samples were obtained as part of an ongoing National Highway Traffic Safety Administration (NHTSA) study of drug prevalence among adult (age 18+) trauma victims who were transported by EMS due to the severity of their injuries and had a trauma team activated/alerted at selected Level-1 trauma centers. The specimens from this convenience sample were available for research purposes from patients who were already having blood drawn as part of medical treatment at the trauma centers. Samples were collected at six study sites in the United States: Baltimore, Maryland (28.13%), Jacksonville, Florida (18.37%), Worcester, Massachusetts (10.70%), Charlotte, North Carolina (19.43%), Miami, Florida (16.48%), and Iowa City, Iowa (6.88%).",,2020-04-15,2020-10-15,Residual sera,Male,Multiple groups,18.0,,Sex/Gender,,1876,0.07730000000000001,0.066,0.09029999999999999,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Tran B Ngo,National Institutes of Health,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.10.21261849v1,2021-08-16,2022-07-16,Verified,ngoSARSCoV2SeroprevalenceDrug2021,USA
210811_UnitedStates_NationalInstitutesOfHealth_Baltimore,210811_UnitedStates_NationalInstitutesOfHealth,SARS-CoV-2 Seroprevalence and Drug Use in Trauma Patients from Six Sites in the United States,2021-08-11,Preprint,Regional,Cross-sectional survey ,United States of America,Maryland,Baltimore,"human serum samples were obtained as part of an ongoing National Highway Traffic Safety Administration (NHTSA) study of drug prevalence among adult (age 18+) trauma victims who were transported by EMS due to the severity of their injuries and had a trauma team activated/alerted at selected Level-1 trauma centers. The specimens from this convenience sample were available for research purposes from patients who were already having blood drawn as part of medical treatment at the trauma centers. Samples were collected at six study sites in the United States: Baltimore, Maryland (28.13%), Jacksonville, Florida (18.37%), Worcester, Massachusetts (10.70%), Charlotte, North Carolina (19.43%), Miami, Florida (16.48%), and Iowa City, Iowa (6.88%).",,2020-04-15,2020-10-15,Residual sera,All,Multiple groups,18.0,,Geographical area,Baltimore,715,0.0671,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['High'],No,No,Yes,Yes,Yes,Unclear,Yes,Yes,,Tran B Ngo,National Institutes of Health,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.08.10.21261849v1,2021-08-16,2022-07-16,Verified,ngoSARSCoV2SeroprevalenceDrug2021,USA
210812_NorthCarolina_UniversityOfNorthCarolina,210812_NorthCarolina_UniversityOfNorthCarolina,"Household transmission of SARS-CoV-2 in the United States: living density, viral load, and disproportionate impact on communities of color",2021-08-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,"Households were enrolled a median of 6 (IQR 4-7) days after symptom
onset of the designated index case

Inclusion criteria for household contacts of index patients included age > 1 year, and currently living in the same home as the index case without plans to live elsewhere during the 28-day study","Those with evidence of prior
infection (antibody-positive and PCR-negative) or household contacts who reported the same COVID
exposure outside the household as the index case were excluded from the analysi",2020-04-15,2020-10-15,Household and community samples,All,Multiple groups,2.0,77.0,Primary Estimate,,103,0.28,,,True,,,,True,Convenience,"COVID-19 IgM-IgG Dual Antibody Rapid Test,Author designed (ELISA) -Spike","BioMedomics, Inc.,NA",Multiple Types,Multiple Types,"['IgG', 'IgM']",Spike,,,,['High'],Yes,No,No,No,Unclear,Unclear,No,No,Yes,Carla Cerami,University of North Carolina ,Not Unity-Aligned,http://dx.doi.org/10.1093/cid/ciab701,2021-09-15,2024-03-01,Verified,cerami_household_2021,USA
210813_NewJersey_RutgersUniversity,210813_NewJersey_RutgersUniversity,Determinants and dynamics of SARS-CoV-2 infection in a diverse population: 6-month evaluation of a prospective cohort study.,2021-08-13,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,New Jersey,"Newark, New Brunswick, Piscataway","Eligibility criteria included: (1) age ≥20 years; (2) not pregnant or breastfeeding; (3) no recent (prior 30 days) urgent care or emergency department (ED) visits, hospitalizations, operations, or changes in prescribed medicines; (4) no previously diagnosed SARS-CoV-2 infection/COVID-19; and (5) no fever at the baseline visit. Eligibility for HCWs required: (1) ≥20 hours of weekly hospital work; (2) roles with regular patient exposure (e.g., physicians, nurses, technicians, respiratory therapists); and (3) regular direct patient contact (≥3 patients/shift). Eligibility for a comparator group of non-HCWs required: (1) work as faculty, staff, or students at Rutgers for ≥20 hours weekly; and (2) no patient contact.",Hospital-based employees without direct patient care responsibilities were not eligible for enrollment. ,2020-03-24,2020-09-22,Health care workers and caregivers,All,Adults (18-64 years),20.0,,Primary Estimate,,831,0.0999,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,,0.943,0.997,['High'],Yes,No,Yes,Yes,Unclear,Unclear,Yes,Yes,Unclear,Daniel Horton,Rutgers University,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab411,2021-08-25,2022-07-16,Verified,horton_determinants_2021,USA
210818_NewYork_SunRiverHealth,210818_NewYork_SunRiverHealth,Covid-19 Sero-Prevalence and Risk Factors in a Sample of Community Health Center Employees in New York State,2021-08-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,New York,,"All of Sun River’s workforce – approximately 1,800 employees – were invited via email to participate in the study on a voluntary basis. All employees were deemed eligible.",All employees were deemed eligible unless they reported having either: Covid-19 symptoms within the past 3 weeks; a known exposure within the past 3 weeks; or a positive PCR test within the past 2 weeks.,2020-07-15,2020-09-15,Health care workers and caregivers,All,Multiple groups,20.0,77.0,Primary Estimate,,325,0.154,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Anne Kauffman Nolon,Sun River Health,Not Unity-Aligned,http://dx.doi.org/10.1097/JOM.0000000000002357,2021-09-21,2024-03-01,Unverified,nolon_covid-19_2021,USA
210818_Mongomery_WestVirginiaUniversity,210818_Mongomery_WestVirginiaUniversity,Serological survey of SARS-CoV-2 incidence conducted at a rural West Virginia hospital.,2021-08-18,Preprint,Local,Cross-sectional survey ,United States of America,West Virginia,Montgomery,"Study recruitment was conducted on September 10, 2020 at Montgomery General Hospital. After reviewing the informed consent document with any questions answered by onsite study personnel, those desiring to participate in the study signed the informed consent document.",,2020-09-10,2020-09-10,Hospital visitors,All,Multiple groups,,,Primary Estimate,,150,0.1,,,True,,,,True,Convenience,"SARS-CoV-2 ELISA IgM, IgG, and IgA",Tecan,ELISA,Whole Blood,IgG,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Alexander Horspool,West Virginia University,Not Unity-Aligned,https://dx.doi.org/10.1101/2021.08.16.21262128,2021-08-29,2022-07-16,Unverified,horspool_serological_2021,USA
210819_NewYork_ColumbiaUniversityIrvingMedicalCenter_Overall,210819_NewYork_ColumbiaUniversityIrvingMedicalCenter,Household level SARS-CoV-2 sero-epidemiology in a high prevalence group of adults and children-implications for community infection control.,2021-08-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,,households in an orthodox Jewish village in New York State,Households with currently symptomatic members were excluded,2021-01-03,2021-01-21,Household and community samples,All,Multiple groups,,,Primary Estimate,,474,0.679,,,True,,,,True,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],Yes,Yes,No,No,Unclear,Unclear,Yes,No,No,Alan Werzberger,Columbia University Irving Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ajic.2021.08.015,2021-08-30,2022-07-16,Verified,werzberger_household_2021,USA
210819_NewYork_ColumbiaUniversityIrvingMedicalCenter_1-5,210819_NewYork_ColumbiaUniversityIrvingMedicalCenter,Household level SARS-CoV-2 sero-epidemiology in a high prevalence group of adults and children-implications for community infection control.,2021-08-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,,households in an orthodox Jewish village in New York State,Households with currently symptomatic members were excluded,2021-01-03,2021-01-21,Household and community samples,All,Children and Youth (0-17 years),1.0,5.0,Age,>1-5,48,0.375,0.252,0.517,,,,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],Yes,Yes,No,No,Unclear,Unclear,Yes,No,No,Alan Werzberger,Columbia University Irving Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ajic.2021.08.015,2021-08-30,2022-07-16,Verified,werzberger_household_2021,USA
210819_NewYork_ColumbiaUniversityIrvingMedicalCenter_18-60,210819_NewYork_ColumbiaUniversityIrvingMedicalCenter,Household level SARS-CoV-2 sero-epidemiology in a high prevalence group of adults and children-implications for community infection control.,2021-08-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,,households in an orthodox Jewish village in New York State,Households with currently symptomatic members were excluded,2021-01-03,2021-01-21,Household and community samples,All,Adults (18-64 years),18.0,60.0,Age,>18-60,174,0.77,0.7020000000000001,0.8270000000000001,,,,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],Yes,Yes,No,No,Unclear,Unclear,Yes,No,No,Alan Werzberger,Columbia University Irving Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ajic.2021.08.015,2021-08-30,2022-07-16,Verified,werzberger_household_2021,USA
210819_NewYork_ColumbiaUniversityIrvingMedicalCenter_5-10,210819_NewYork_ColumbiaUniversityIrvingMedicalCenter,Household level SARS-CoV-2 sero-epidemiology in a high prevalence group of adults and children-implications for community infection control.,2021-08-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,,households in an orthodox Jewish village in New York State,Households with currently symptomatic members were excluded,2021-01-03,2021-01-21,Household and community samples,All,Children and Youth (0-17 years),5.0,10.0,Age,>5-10,105,0.523,0.429,0.617,,,,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],Yes,Yes,No,No,Unclear,Unclear,Yes,No,No,Alan Werzberger,Columbia University Irving Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ajic.2021.08.015,2021-08-30,2022-07-16,Verified,werzberger_household_2021,USA
210819_NewYork_ColumbiaUniversityIrvingMedicalCenter_>60,210819_NewYork_ColumbiaUniversityIrvingMedicalCenter,Household level SARS-CoV-2 sero-epidemiology in a high prevalence group of adults and children-implications for community infection control.,2021-08-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,,households in an orthodox Jewish village in New York State,Households with currently symptomatic members were excluded,2021-01-03,2021-01-21,Household and community samples,All,Multiple groups,60.0,,Age,>60,20,0.75,0.5275,0.892,,,,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],Yes,Yes,No,No,Unclear,Unclear,Yes,No,No,Alan Werzberger,Columbia University Irving Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ajic.2021.08.015,2021-08-30,2022-07-16,Verified,werzberger_household_2021,USA
210819_NewYork_ColumbiaUniversityIrvingMedicalCenter_10-18,210819_NewYork_ColumbiaUniversityIrvingMedicalCenter,Household level SARS-CoV-2 sero-epidemiology in a high prevalence group of adults and children-implications for community infection control.,2021-08-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,,households in an orthodox Jewish village in New York State,Households with currently symptomatic members were excluded,2021-01-03,2021-01-21,Household and community samples,All,Children and Youth (0-17 years),10.0,18.0,Age,>10-18,127,0.787,0.7070000000000001,0.85,,,,,,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],Yes,Yes,No,No,Unclear,Unclear,Yes,No,No,Alan Werzberger,Columbia University Irving Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ajic.2021.08.015,2021-08-30,2022-07-16,Verified,werzberger_household_2021,USA
210820_Maryland_UniversityofMaryland,210820_Maryland_UniversityofMaryland,"COVID-19 symptoms, patient contacts, PCR-positivity and seropositivity among healthcare personnel in a Maryland healthcare system.",2021-08-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,"Maryland
",,"""Health care professionals report[ing] ... contacts with suspected or confirmed COVID-19 patients."" Some had previously reported a positive PCR test. ",,2020-06-01,2020-08-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,778,0.026000000000000002,,,True,,,,True,Self-referral,Not reported/ Unable to specify,,,,,,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Lyndsay O'Hara,University of Maryland,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2021.373,2021-08-30,2022-07-16,Unverified,ohara_covid-19_2021,USA
210825_RhodeIsland_LindsleyFKimballResearchInstitute_CLIA_OverallAdj,210825_RhodeIsland_LindsleyFKimballResearchInstitute,Low Seroprevalence of SARS-CoV-2 in Rhode Island blood donors during may 2020 as determined using multiple serological assay formats.,2021-08-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Rhode Island,,Rhode Island Blood Center (RIBC) donors,,2020-04-27,2020-05-11,Blood donors,All,Multiple groups,,,Primary Estimate,CLIA (target S antigen) test-adjusted estimate,1996,0.006,0.002,0.011000000000000001,True,True,,,,Sequential,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Daniel Nesbitt,Lindsley F Kimball Research Institute,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06438-4,2021-08-30,2023-08-15,Verified,nesbitt_low_2021,USA
210825_RhodeIsland_LindsleyFKimballResearchInstitute_CLIA_15-34,210825_RhodeIsland_LindsleyFKimballResearchInstitute,Low Seroprevalence of SARS-CoV-2 in Rhode Island blood donors during may 2020 as determined using multiple serological assay formats.,2021-08-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Rhode Island,,Rhode Island Blood Center (RIBC) donors,,2020-04-27,2020-05-11,Blood donors,All,Multiple groups,15.0,34.0,Age,CLIA; Age: 15-34,348,0.0144,,,,,,,,Sequential,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Daniel Nesbitt,Lindsley F Kimball Research Institute,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06438-4,2021-08-30,2024-03-01,Verified,nesbitt_low_2021,USA
210825_RhodeIsland_LindsleyFKimballResearchInstitute_CLIA_65+,210825_RhodeIsland_LindsleyFKimballResearchInstitute,Low Seroprevalence of SARS-CoV-2 in Rhode Island blood donors during may 2020 as determined using multiple serological assay formats.,2021-08-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Rhode Island,,Rhode Island Blood Center (RIBC) donors,,2020-04-27,2020-05-11,Blood donors,All,Seniors (65+ years),65.0,,Age,CLIA; Age: 65+,467,0.0064,,,,,,,,Sequential,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Daniel Nesbitt,Lindsley F Kimball Research Institute,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06438-4,2021-08-30,2024-03-01,Verified,nesbitt_low_2021,USA
210825_RhodeIsland_LindsleyFKimballResearchInstitute_CLIA_OverallUnadj,210825_RhodeIsland_LindsleyFKimballResearchInstitute,Low Seroprevalence of SARS-CoV-2 in Rhode Island blood donors during may 2020 as determined using multiple serological assay formats.,2021-08-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Rhode Island,,Rhode Island Blood Center (RIBC) donors,,2020-04-27,2020-05-11,Blood donors,All,Multiple groups,,,Analysis,CLIA (target S antigen) unadjusted estimate,1996,0.006999999999999999,,,,,,,True,Sequential,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Daniel Nesbitt,Lindsley F Kimball Research Institute,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06438-4,2021-08-30,2024-03-01,Verified,nesbitt_low_2021,USA
210825_RhodeIsland_LindsleyFKimballResearchInstitute_CLIA_Female,210825_RhodeIsland_LindsleyFKimballResearchInstitute,Low Seroprevalence of SARS-CoV-2 in Rhode Island blood donors during may 2020 as determined using multiple serological assay formats.,2021-08-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Rhode Island,,Rhode Island Blood Center (RIBC) donors,,2020-04-27,2020-05-11,Blood donors,Female,Multiple groups,,,Sex/Gender,,939,0.0032,,,,,,,,Sequential,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Daniel Nesbitt,Lindsley F Kimball Research Institute,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06438-4,2021-08-30,2024-03-01,Verified,nesbitt_low_2021,USA
210825_RhodeIsland_LindsleyFKimballResearchInstitute_CLIA_35-64,210825_RhodeIsland_LindsleyFKimballResearchInstitute,Low Seroprevalence of SARS-CoV-2 in Rhode Island blood donors during may 2020 as determined using multiple serological assay formats.,2021-08-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Rhode Island,,Rhode Island Blood Center (RIBC) donors,,2020-04-27,2020-05-11,Blood donors,All,Adults (18-64 years),35.0,64.0,Age,CLIA; Age: 35-64,1181,0.0051,,,,,,,,Sequential,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Daniel Nesbitt,Lindsley F Kimball Research Institute,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06438-4,2021-08-30,2024-03-01,Verified,nesbitt_low_2021,USA
210825_RhodeIsland_LindsleyFKimballResearchInstitute_CLIA_Male,210825_RhodeIsland_LindsleyFKimballResearchInstitute,Low Seroprevalence of SARS-CoV-2 in Rhode Island blood donors during may 2020 as determined using multiple serological assay formats.,2021-08-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Rhode Island,,Rhode Island Blood Center (RIBC) donors,,2020-04-27,2020-05-11,Blood donors,Male,Multiple groups,,,Sex/Gender,,1057,0.010400000000000001,,,,,,,,Sequential,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Daniel Nesbitt,Lindsley F Kimball Research Institute,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06438-4,2021-08-30,2024-03-01,Verified,nesbitt_low_2021,USA
210825_RhodeIsland_LindsleyFKimballResearchInstitute_LFIA_Overall,210825_RhodeIsland_LindsleyFKimballResearchInstitute,Low Seroprevalence of SARS-CoV-2 in Rhode Island blood donors during may 2020 as determined using multiple serological assay formats.,2021-08-25,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Rhode Island,,Rhode Island Blood Center (RIBC) donors,,2020-04-27,2020-05-11,Blood donors,All,Multiple groups,,,Test used,LFIA (target N antigen) unadjusted estimate,1996,0.0361,,,,,,,,Sequential,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ,SD Biosensor,LFIA,Serum,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Daniel Nesbitt,Lindsley F Kimball Research Institute,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06438-4,2021-08-30,2024-03-01,Verified,nesbitt_low_2021,USA
210825_OrangeCounty_UniversityofCaliforniaIrvine,210825_OrangeCounty_UniversityofCaliforniaIrvine,"SARS-CoV-2 antibody seroprevalence among firefighters in Orange County, California.",2021-08-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,Personnel from all 10 fire departments providing emergency medical services in OC were invited to participate,,2020-10-05,2020-10-23,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,Overall firefighters,923,0.054000000000000006,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.996,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Veronica Vieira,University of California Irvine,Not Unity-Aligned,https://dx.doi.org/10.1136/oemed-2021-107461,2021-08-31,2024-03-01,Unverified,vieira_sars-cov-2_2021,USA
210830_Conneticut_YaleUniversity,210830_Conneticut_YaleUniversity,Associations of SARS-CoV-2 serum IgG with occupation and demographics of military personnel.,2021-08-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Connecticut,,soldiers enlisted in the Connecticut Army and Air National Guard,,2021-04-15,2020-06-15,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,USA Soldiers,988,0.10400000000000001,,,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,Serum,IgG,Spike,,0.995,0.998,['Moderate'],,No,Yes,No,,Unclear,Yes,Yes,,Joseph Zell,Yale University,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0251114,2021-09-08,2022-07-16,Unverified,zellAssociationsSARSCoV2Serum2021a,USA
210901_Kentucky_UniversityofKentucky_Primary,210901_Kentucky_UniversityofKentucky,Prevalence of SARS-CoV-2 IgG antibodies in health care workers at a tertiary care academic medical center - An assessment of occupational infection risk.,2021-09-01,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Kentucky,Lexington,"Participants were included if they were HCW at University of Kentucky HealthCare (UKHC), ≥18 years of age and elected to undergo SARSCoV-2 serology testing at UKHC. Notably, these individuals were not known to have an active SARS-COV-2 infection at time of inclusion.","Participants were excluded from the study
population if they were prisoners, if they had a psychiatric illness or social situation that would limit compliance with study requirements. Symptomatic individuals were required to stay home from work, so no individual exhibiting
symptoms was included in testing group.",2020-06-22,2020-06-26,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,322,0.015500000000000002,0.006500000000000001,0.0371,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,0.996,['High'],,No,No,Yes,,Yes,Yes,Yes,,Derek Forster,University of Kentucky,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ajic.2021.04.005,2021-09-10,2024-03-01,Unverified,forster_prevalence_2021,USA
210901_Utah_UniversityofUtah_genpop_popadj_testadj,210901_Utah_UniversityofUtah,"Probability-Based Estimates of Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Detection Fraction, Utah, USA.",2021-09-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Utah,,"Residents of Utah, Salt Lake, Davis, and Summit counties >=12 years old",,2020-05-04,2020-06-30,Household and community samples,All,Multiple groups,12.0,,Primary Estimate,,8108,0.008,0.001,0.016,True,True,True,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.8640000000000001,0.996,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Matthew Samore,University of Utah,Unity-Aligned,https://wwwnc.cdc.gov/eid/article/27/11/20-4435_article,2021-09-07,2023-08-15,Verified,samore_early_2021,USA
210901_Utah_UniversityofUtah_genpop_65+,210901_Utah_UniversityofUtah,"Probability-Based Estimates of Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Detection Fraction, Utah, USA.",2021-09-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Utah,,"Residents of Utah, Salt Lake, Davis, and Summit counties >=12 years old",,2020-05-04,2020-06-30,Household and community samples,All,Seniors (65+ years),65.0,,Age,>=65,1642,0.012,,,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.8640000000000001,0.996,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Matthew Samore,University of Utah,Unity-Aligned,https://wwwnc.cdc.gov/eid/article/27/11/20-4435_article,2021-09-07,2024-03-01,Verified,samore_early_2021,USA
210901_Utah_UniversityofUtah_genpop_unadj,210901_Utah_UniversityofUtah,"Probability-Based Estimates of Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Detection Fraction, Utah, USA.",2021-09-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Utah,,"Residents of Utah, Salt Lake, Davis, and Summit counties >=12 years old",,2020-05-04,2020-06-30,Household and community samples,All,Multiple groups,12.0,,Analysis,,8108,0.011000000000000001,,,,,,,True,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.8640000000000001,0.996,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Matthew Samore,University of Utah,Unity-Aligned,https://wwwnc.cdc.gov/eid/article/27/11/20-4435_article,2021-09-07,2024-03-01,Verified,samore_early_2021,USA
210901_Utah_UniversityofUtah_genpop_45-64,210901_Utah_UniversityofUtah,"Probability-Based Estimates of Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Detection Fraction, Utah, USA.",2021-09-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Utah,,"Residents of Utah, Salt Lake, Davis, and Summit counties >=12 years old",,2020-05-04,2020-06-30,Household and community samples,All,Adults (18-64 years),45.0,64.0,Age,45-64,2345,0.013000000000000001,,,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.8640000000000001,0.996,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Matthew Samore,University of Utah,Unity-Aligned,https://wwwnc.cdc.gov/eid/article/27/11/20-4435_article,2021-09-07,2024-03-01,Verified,samore_early_2021,USA
210901_Utah_UniversityofUtah_genpop_male,210901_Utah_UniversityofUtah,"Probability-Based Estimates of Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Detection Fraction, Utah, USA.",2021-09-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Utah,,"Residents of Utah, Salt Lake, Davis, and Summit counties >=12 years old",,2020-05-04,2020-06-30,Household and community samples,Male,Multiple groups,12.0,,Sex/Gender,,3773,0.011000000000000001,,,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.8640000000000001,0.996,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Matthew Samore,University of Utah,Unity-Aligned,https://wwwnc.cdc.gov/eid/article/27/11/20-4435_article,2021-09-07,2024-03-01,Verified,samore_early_2021,USA
210901_Utah_UniversityofUtah_genpop_<45,210901_Utah_UniversityofUtah,"Probability-Based Estimates of Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Detection Fraction, Utah, USA.",2021-09-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Utah,,"Residents of Utah, Salt Lake, Davis, and Summit counties >=12 years old",,2020-05-04,2020-06-30,Household and community samples,All,Multiple groups,12.0,44.0,Age,<45,4119,0.009000000000000001,,,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.8640000000000001,0.996,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Matthew Samore,University of Utah,Unity-Aligned,https://wwwnc.cdc.gov/eid/article/27/11/20-4435_article,2021-09-07,2024-03-01,Verified,samore_early_2021,USA
210901_Utah_UniversityofUtah_genpop_female,210901_Utah_UniversityofUtah,"Probability-Based Estimates of Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Detection Fraction, Utah, USA.",2021-09-01,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Utah,,"Residents of Utah, Salt Lake, Davis, and Summit counties >=12 years old",,2020-05-04,2020-06-30,Household and community samples,Female,Multiple groups,12.0,,Sex/Gender,,4293,0.011000000000000001,,,,,,,,Stratified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.8640000000000001,0.996,['Low'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Matthew Samore,University of Utah,Unity-Aligned,https://wwwnc.cdc.gov/eid/article/27/11/20-4435_article,2021-09-07,2024-03-01,Verified,samore_early_2021,USA
210908_SanFrancisco_UniversityofCalifornia_overall,210908_SanFrancisco_UniversityofCalifornia,"Seroprevalence of SARS-CoV-2 Among Firefighters/Paramedics in San Francisco, CA.",2021-09-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,San Francisco,"All active personnel of the municipal fire department in San Francisco, CA were invited to participate in this study. “Active” was defined as having been employed for at least three shifts since January 1, 2020 and status as a current employee (ie, not retired or otherwise separated from service).",There were no formal exclusion criteria. Participants were screened for symptoms of COVID-19 and had their temperature checked upon arrival at the testing site (this would have acted as a de facto exclusion criterion—as would have a positive preshift symptom screen).,2020-06-15,2020-07-02,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,1231,0.0024,0.0005,0.0070999999999999995,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Megan Grant,University of California,Not Unity-Aligned,https://dx.doi.org/10.1097/JOM.0000000000002383,2021-11-17,2024-03-01,Unverified,grant_seroprevalence_2021,USA
210913_UnitedStates_AirForceResearchLaboratory,210913_UnitedStates_AirForceResearchLaboratory,COVID-19 Seroprevalence and Active Infection in an Asymptomatic Population.,2021-09-13,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Ohio,,"""Participants had to be in healthy condition and asymptomatic with no known prior SARS-CoV-2 infection or exposure.""","""If participants were found to be at risk of COVID-19 due to exhibiting symptoms or being in close contact with a person diagnosed with COVID-19, or upon testing positive for SARS-CoV-2 infection in a saliva sample, participants were referred to their medical provider and excluded from the remainder of the study.""",2020-07-23,2020-10-23,Household and community samples,All,Multiple groups,18.0,95.0,Primary Estimate,,582,0.0309,,,True,,,,,Convenience,Author designed (ELISA) -Spike,,Multiple Types,Multiple Types,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,No,Unclear,Amy Breedon,"Air Force Research Laboratory, Wright-Patterson Air Force Base",Not Unity-Aligned,https://dx.doi.org/10.3389/fmed.2021.749732,2021-10-05,2022-07-16,Verified,breedon_covid-19_2021,USA
210914_AlfredIduPontHospitalforChildren_AlfredIduPontHospitalforChildren,210914_AlfredIduPontHospitalforChildren_AlfredIduPontHospitalforChildren,Poster 021: Impact of the Pandemic: Investigating the Novel SARS-CoV-2 Virus and the Increase in New-Onset Type 1 and Type 2 Pediatric Diabetes Diagnoses,2021-09-14,Presentation or Conference,Local,Prospective cohort,United States of America,Delaware,Wilmington,patients admitted to AIDHC with new onset T1DM and T2DM between June and December 2020,N,2020-06-15,2020-12-15,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),,,Primary Estimate,,81,0.0617,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,IgG,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Domenic Filingeri,"Alfred I. duPont Hospital for
Children",Not Unity-Aligned,https://www.karger.com/Article/Pdf/519117,2022-03-09,2022-07-16,Unverified,domenic_filingeri_poster_2021,USA
210914_Louisville_UniversityofLouisville_July2020,210914_Louisville_UniversityofLouisville_July2020,Serological assessment of SARS-CoV-2 infection during the first wave of the pandemic in Louisville Kentucky.,2021-09-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Kentucky,Louisville,"Healthcare workers who had been actively working in areas with patient contact afer mid-March in Louisville, KY healthcare systems were invited to participate in a study to look at infection rates and immune responses to SARS-CoV-2",Participants need to have worked outside their home during the 30 days prior to the start of the study in mid-May 2020.,2020-07-06,2020-07-20,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,915,0.023,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Whole Blood,IgG,Spike,Validated by developers,,,['Moderate'],,No,Yes,No,,Yes,Yes,No,,Krystal Hamorsky, University of Louisville,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-021-97423-z,2021-09-21,2022-07-16,Unverified,hamorsky_serological_2021,USA
210915_Monterey_UniversityofCalifornia_Primary,210915_Monterey_UniversityofCalifornia,"Risk Factors Associated With SARS-CoV-2 Infection Among Farmworkers in Monterey County, California.",2021-09-15,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,California,,"Between July 16 and November 30, 2020, we invited farmworkers receiving care or getting tested for SARS-CoV-2 infection
at CSVS clinics and community sites to participate in our study.We posted flyers about the study at the clinics and around town and provided study information to community groups and growers.
Farmworkers were eligible for participation if they were not pregnant, were aged 18 years or older, had conducted farmwork within the 2 weeks preceding their testing date, and were sufficiently proficient in English or Spanish to give consent and complete study procedures. Beginning October
5, we enrolled any individual who had engaged in agricultural work at any time since March 2020 because the growing season was ending.","We excluded from analyses 8 farmworkers who did not provide blood samples or were not employed as farmworkers at the time of enrollment, leaving a total of 1107 participants.",2020-07-16,2020-11-30,Essential non-healthcare workers,All,Adults (18-64 years),18.0,,Primary Estimate,,1058,0.19,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,,IgG,Spike,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Ana M. Mora,"Universityof California,Berkeley",Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.24116,2021-09-21,2022-07-16,Unverified,risk_mora_2021-2,USA
210915_Monterey_UniversityofCalifornia_Age18to29,210915_Monterey_UniversityofCalifornia,"Risk Factors Associated With SARS-CoV-2 Infection Among Farmworkers in Monterey County, California.",2021-09-15,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,California,,"Between July 16 and November 30, 2020, we invited farmworkers receiving care or getting tested for SARS-CoV-2 infection
at CSVS clinics and community sites to participate in our study.We posted flyers about the study at the clinics and around town and provided study information to community groups and growers.
Farmworkers were eligible for participation if they were not pregnant, were aged 18 years or older, had conducted farmwork within the 2 weeks preceding their testing date, and were sufficiently proficient in English or Spanish to give consent and complete study procedures. Beginning October
5, we enrolled any individual who had engaged in agricultural work at any time since March 2020 because the growing season was ending.","We excluded from analyses 8 farmworkers who did not provide blood samples or were not employed as farmworkers at the time of enrollment, leaving a total of 1107 participants.",2020-07-16,2020-11-30,Essential non-healthcare workers,All,Adults (18-64 years),18.0,29.0,Age,18-29,263,0.163,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,,IgG,Spike,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Ana M. Mora,"Universityof California,Berkeley",Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.24116,2021-09-21,2022-07-16,Unverified,risk_mora_2021-2,USA
210915_Monterey_UniversityofCalifornia_AgeOver60,210915_Monterey_UniversityofCalifornia,"Risk Factors Associated With SARS-CoV-2 Infection Among Farmworkers in Monterey County, California.",2021-09-15,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,California,,"Between July 16 and November 30, 2020, we invited farmworkers receiving care or getting tested for SARS-CoV-2 infection
at CSVS clinics and community sites to participate in our study.We posted flyers about the study at the clinics and around town and provided study information to community groups and growers.
Farmworkers were eligible for participation if they were not pregnant, were aged 18 years or older, had conducted farmwork within the 2 weeks preceding their testing date, and were sufficiently proficient in English or Spanish to give consent and complete study procedures. Beginning October
5, we enrolled any individual who had engaged in agricultural work at any time since March 2020 because the growing season was ending.","We excluded from analyses 8 farmworkers who did not provide blood samples or were not employed as farmworkers at the time of enrollment, leaving a total of 1107 participants.",2020-07-16,2020-11-30,Essential non-healthcare workers,All,Adults (18-64 years),60.0,,Age,>=60,63,0.20600000000000002,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,,IgG,Spike,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Ana M. Mora,"Universityof California,Berkeley",Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.24116,2021-09-21,2022-07-16,Unverified,risk_mora_2021-2,USA
210915_Monterey_UniversityofCalifornia_Age40to49,210915_Monterey_UniversityofCalifornia,"Risk Factors Associated With SARS-CoV-2 Infection Among Farmworkers in Monterey County, California.",2021-09-15,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,California,,"Between July 16 and November 30, 2020, we invited farmworkers receiving care or getting tested for SARS-CoV-2 infection
at CSVS clinics and community sites to participate in our study.We posted flyers about the study at the clinics and around town and provided study information to community groups and growers.
Farmworkers were eligible for participation if they were not pregnant, were aged 18 years or older, had conducted farmwork within the 2 weeks preceding their testing date, and were sufficiently proficient in English or Spanish to give consent and complete study procedures. Beginning October
5, we enrolled any individual who had engaged in agricultural work at any time since March 2020 because the growing season was ending.","We excluded from analyses 8 farmworkers who did not provide blood samples or were not employed as farmworkers at the time of enrollment, leaving a total of 1107 participants.",2020-07-16,2020-11-30,Essential non-healthcare workers,All,Adults (18-64 years),40.0,49.0,Age,40-49,284,0.20800000000000002,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,,IgG,Spike,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Ana M. Mora,"Universityof California,Berkeley",Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.24116,2021-09-21,2022-07-16,Unverified,risk_mora_2021-2,USA
210915_Monterey_UniversityofCalifornia_Age50to59,210915_Monterey_UniversityofCalifornia,"Risk Factors Associated With SARS-CoV-2 Infection Among Farmworkers in Monterey County, California.",2021-09-15,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,California,,"Between July 16 and November 30, 2020, we invited farmworkers receiving care or getting tested for SARS-CoV-2 infection
at CSVS clinics and community sites to participate in our study.We posted flyers about the study at the clinics and around town and provided study information to community groups and growers.
Farmworkers were eligible for participation if they were not pregnant, were aged 18 years or older, had conducted farmwork within the 2 weeks preceding their testing date, and were sufficiently proficient in English or Spanish to give consent and complete study procedures. Beginning October
5, we enrolled any individual who had engaged in agricultural work at any time since March 2020 because the growing season was ending.","We excluded from analyses 8 farmworkers who did not provide blood samples or were not employed as farmworkers at the time of enrollment, leaving a total of 1107 participants.",2020-07-16,2020-11-30,Essential non-healthcare workers,All,Adults (18-64 years),50.0,59.0,Age,50-59,186,0.145,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,,IgG,Spike,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Ana M. Mora,"Universityof California,Berkeley",Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.24116,2021-09-21,2022-07-16,Unverified,risk_mora_2021-2,USA
210915_Monterey_UniversityofCalifornia_Age30ro39,210915_Monterey_UniversityofCalifornia,"Risk Factors Associated With SARS-CoV-2 Infection Among Farmworkers in Monterey County, California.",2021-09-15,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,California,,"Between July 16 and November 30, 2020, we invited farmworkers receiving care or getting tested for SARS-CoV-2 infection
at CSVS clinics and community sites to participate in our study.We posted flyers about the study at the clinics and around town and provided study information to community groups and growers.
Farmworkers were eligible for participation if they were not pregnant, were aged 18 years or older, had conducted farmwork within the 2 weeks preceding their testing date, and were sufficiently proficient in English or Spanish to give consent and complete study procedures. Beginning October
5, we enrolled any individual who had engaged in agricultural work at any time since March 2020 because the growing season was ending.","We excluded from analyses 8 farmworkers who did not provide blood samples or were not employed as farmworkers at the time of enrollment, leaving a total of 1107 participants.",2020-07-16,2020-11-30,Essential non-healthcare workers,All,Adults (18-64 years),30.0,39.0,Age,30-39,262,0.225,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,,IgG,Spike,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Ana M. Mora,"Universityof California,Berkeley",Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.24116,2021-09-21,2022-07-16,Unverified,risk_mora_2021-2,USA
210917_Lakewood_JointBaseLewisMcChord_Overall,210917_Lakewood_JointBaseLewisMcChord,COVID-19 Antibody Prevalence From July to September 2020: One Army Infantry Brigade's Experience,2021-09-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Washington,Lakewood,Active-duty military Servicemembers (= 18 years) from a mechanized infantry brigade at Joint Base Lewis McChord (JBLM),NRR,2020-06-15,2020-09-15,Essential non-healthcare workers,All,Adults (18-64 years),18.0,,Primary Estimate,,264,0.004,,,True,,,,True,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,,,,,['High'],,Unclear,No,No,,Yes,Yes,Yes,,Alex Koo,Joint Base Lewis McChord,Not Unity-Aligned,https://pubmed.ncbi.nlm.nih.gov/34529807/,2021-10-19,2024-03-01,Unverified,koo_covid-19_2021,USA
210924_Michigan_UniversityOfMichigan_AfterDec14_Overall,210924_Michigan_UniversityOfMichigan_AfterDec14,Understanding the patterns of serological testing for covid-19 pre-and post-vaccination rollout in michigan,2021-09-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Michigan,,"Our study sample includes 10,416 individuals who presented to Michigan Medicine
for spike protein immunoglobulin G (IgG) SARS-CoV-2 antibody testing between 27 April
2020 and 3 May 2021 (10932 tests in total).",,2020-12-14,2021-05-03,Household and community samples,All,Multiple groups,,,Primary Estimate,,2024,0.36200000000000004,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,Serum,IgG,Spike,,,,['High'],Unclear,Unclear,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Zhangchen Zhao,University of Michigan,Not Unity-Aligned,http://dx.doi.org/10.3390/jcm10194341,2021-10-07,2022-07-16,Verified,zhao_understanding_2021,USA
210924_Michigan_UniversityOfMichigan_AfterDec14_12-18,210924_Michigan_UniversityOfMichigan_AfterDec14,Understanding the patterns of serological testing for covid-19 pre-and post-vaccination rollout in michigan,2021-09-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Michigan,,"Our study sample includes 10,416 individuals who presented to Michigan Medicine
for spike protein immunoglobulin G (IgG) SARS-CoV-2 antibody testing between 27 April
2020 and 3 May 2021 (10932 tests in total).",,2020-12-14,2021-05-03,Household and community samples,All,Children and Youth (0-17 years),12.0,17.0,Age,12-17,85,0.294,,,,,,,,Unclear,Not reported/ Unable to specify,,,Serum,IgG,Spike,,,,['High'],Unclear,Unclear,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Zhangchen Zhao,University of Michigan,Not Unity-Aligned,http://dx.doi.org/10.3390/jcm10194341,2021-10-08,2022-07-16,Verified,zhao_understanding_2021,USA
210924_Michigan_UniversityOfMichigan_AfterDec14_Male,210924_Michigan_UniversityOfMichigan_AfterDec14,Understanding the patterns of serological testing for covid-19 pre-and post-vaccination rollout in michigan,2021-09-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Michigan,,"Our study sample includes 10,416 individuals who presented to Michigan Medicine
for spike protein immunoglobulin G (IgG) SARS-CoV-2 antibody testing between 27 April
2020 and 3 May 2021 (10932 tests in total).",,2020-12-14,2021-05-03,Household and community samples,Male,Multiple groups,,,Sex/Gender,,807,0.369,,,,,,,,Unclear,Not reported/ Unable to specify,,,Serum,IgG,Spike,,,,['High'],Unclear,Unclear,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Zhangchen Zhao,University of Michigan,Not Unity-Aligned,http://dx.doi.org/10.3390/jcm10194341,2021-10-08,2022-07-16,Verified,zhao_understanding_2021,USA
210924_Michigan_UniversityOfMichigan_AfterDec14_Female,210924_Michigan_UniversityOfMichigan_AfterDec14,Understanding the patterns of serological testing for covid-19 pre-and post-vaccination rollout in michigan,2021-09-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Michigan,,"Our study sample includes 10,416 individuals who presented to Michigan Medicine
for spike protein immunoglobulin G (IgG) SARS-CoV-2 antibody testing between 27 April
2020 and 3 May 2021 (10932 tests in total).",,2020-12-14,2021-05-03,Household and community samples,Female,Multiple groups,,,Sex/Gender,,1217,0.35700000000000004,,,,,,,,Unclear,Not reported/ Unable to specify,,,Serum,IgG,Spike,,,,['High'],Unclear,Unclear,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Zhangchen Zhao,University of Michigan,Not Unity-Aligned,http://dx.doi.org/10.3390/jcm10194341,2021-10-08,2022-07-16,Verified,zhao_understanding_2021,USA
210924_Michigan_UniversityOfMichigan_AfterDec14_AgeBelow12,210924_Michigan_UniversityOfMichigan_AfterDec14,Understanding the patterns of serological testing for covid-19 pre-and post-vaccination rollout in michigan,2021-09-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Michigan,,"Our study sample includes 10,416 individuals who presented to Michigan Medicine
for spike protein immunoglobulin G (IgG) SARS-CoV-2 antibody testing between 27 April
2020 and 3 May 2021 (10932 tests in total).",,2020-12-14,2021-05-03,Household and community samples,All,Children and Youth (0-17 years),,11.0,Age,<12,103,0.262,,,,,,,,Unclear,Not reported/ Unable to specify,,,Serum,IgG,Spike,,,,['High'],Unclear,Unclear,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Zhangchen Zhao,University of Michigan,Not Unity-Aligned,http://dx.doi.org/10.3390/jcm10194341,2021-10-08,2022-07-16,Verified,zhao_understanding_2021,USA
210924_Michigan_UniversityOfMichigan_AfterDec14_≥18,210924_Michigan_UniversityOfMichigan_AfterDec14,Understanding the patterns of serological testing for covid-19 pre-and post-vaccination rollout in michigan,2021-09-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Michigan,,"Our study sample includes 10,416 individuals who presented to Michigan Medicine
for spike protein immunoglobulin G (IgG) SARS-CoV-2 antibody testing between 27 April
2020 and 3 May 2021 (10932 tests in total).",,2020-12-14,2021-05-03,Household and community samples,All,Multiple groups,18.0,,Age,≥18,1836,0.371,,,,,,,,Unclear,Not reported/ Unable to specify,,,Serum,IgG,Spike,,,,['High'],Unclear,Unclear,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Zhangchen Zhao,University of Michigan,Not Unity-Aligned,http://dx.doi.org/10.3390/jcm10194341,2021-10-08,2022-07-16,Verified,zhao_understanding_2021,USA
210924_Michigan_UniversityOfMichigan_BeforeDec14_Overall,210924_Michigan_UniversityOfMichigan_BeforeDec14,Understanding the patterns of serological testing for covid-19 pre-and post-vaccination rollout in michigan,2021-09-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Michigan,,"Our study sample includes 10,416 individuals who presented to Michigan Medicine
for spike protein immunoglobulin G (IgG) SARS-CoV-2 antibody testing between 27 April
2020 and 3 May 2021 (10932 tests in total).",,2020-04-27,2020-12-13,Household and community samples,All,Multiple groups,,,Primary Estimate,,8026,0.092,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,Serum,IgG,Spike,,,,['High'],Unclear,Unclear,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Zhangchen Zhao,University of Michigan,Not Unity-Aligned,http://dx.doi.org/10.3390/jcm10194341,2021-10-07,2022-07-16,Verified,zhao_understanding_2021,USA
210924_Michigan_UniversityOfMichigan_BeforeDec14_12-17,210924_Michigan_UniversityOfMichigan_BeforeDec14,Understanding the patterns of serological testing for covid-19 pre-and post-vaccination rollout in michigan,2021-09-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Michigan,,"Our study sample includes 10,416 individuals who presented to Michigan Medicine
for spike protein immunoglobulin G (IgG) SARS-CoV-2 antibody testing between 27 April
2020 and 3 May 2021 (10932 tests in total).",,2020-04-27,2020-12-13,Household and community samples,All,Children and Youth (0-17 years),12.0,17.0,Age,12-17,131,0.13,,,,,,,,Unclear,Not reported/ Unable to specify,,,Serum,IgG,Spike,,,,['High'],Unclear,Unclear,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Zhangchen Zhao,University of Michigan,Not Unity-Aligned,http://dx.doi.org/10.3390/jcm10194341,2021-10-07,2022-07-16,Verified,zhao_understanding_2021,USA
210924_Michigan_UniversityOfMichigan_BeforeDec14_Male,210924_Michigan_UniversityOfMichigan_BeforeDec14,Understanding the patterns of serological testing for covid-19 pre-and post-vaccination rollout in michigan,2021-09-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Michigan,,"Our study sample includes 10,416 individuals who presented to Michigan Medicine
for spike protein immunoglobulin G (IgG) SARS-CoV-2 antibody testing between 27 April
2020 and 3 May 2021 (10932 tests in total).",,2020-04-27,2020-12-13,Household and community samples,Male,Multiple groups,,,Sex/Gender,,3100,0.102,,,,,,,,Unclear,Not reported/ Unable to specify,,,Serum,IgG,Spike,,,,['High'],Unclear,Unclear,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Zhangchen Zhao,University of Michigan,Not Unity-Aligned,http://dx.doi.org/10.3390/jcm10194341,2021-10-07,2022-07-16,Verified,zhao_understanding_2021,USA
210924_Michigan_UniversityOfMichigan_BeforeDec14_Female,210924_Michigan_UniversityOfMichigan_BeforeDec14,Understanding the patterns of serological testing for covid-19 pre-and post-vaccination rollout in michigan,2021-09-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Michigan,,"Our study sample includes 10,416 individuals who presented to Michigan Medicine
for spike protein immunoglobulin G (IgG) SARS-CoV-2 antibody testing between 27 April
2020 and 3 May 2021 (10932 tests in total).",,2020-04-27,2020-12-13,Household and community samples,Female,Multiple groups,,,Sex/Gender,,4926,0.085,,,,,,,,Unclear,Not reported/ Unable to specify,,,Serum,IgG,Spike,,,,['High'],Unclear,Unclear,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Zhangchen Zhao,University of Michigan,Not Unity-Aligned,http://dx.doi.org/10.3390/jcm10194341,2021-10-07,2022-07-16,Verified,zhao_understanding_2021,USA
210924_Michigan_UniversityOfMichigan_BeforeDec14_≥18,210924_Michigan_UniversityOfMichigan_BeforeDec14,Understanding the patterns of serological testing for covid-19 pre-and post-vaccination rollout in michigan,2021-09-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Michigan,,"Our study sample includes 10,416 individuals who presented to Michigan Medicine
for spike protein immunoglobulin G (IgG) SARS-CoV-2 antibody testing between 27 April
2020 and 3 May 2021 (10932 tests in total).",,2020-04-27,2020-12-13,Household and community samples,All,Multiple groups,18.0,,Age,≥18,7755,0.091,,,,,,,,Unclear,Not reported/ Unable to specify,,,Serum,IgG,Spike,,,,['High'],Unclear,Unclear,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Zhangchen Zhao,University of Michigan,Not Unity-Aligned,http://dx.doi.org/10.3390/jcm10194341,2021-10-07,2022-07-16,Verified,zhao_understanding_2021,USA
210924_Michigan_UniversityOfMichigan_BeforeDec14_<12,210924_Michigan_UniversityOfMichigan_BeforeDec14,Understanding the patterns of serological testing for covid-19 pre-and post-vaccination rollout in michigan,2021-09-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Michigan,,"Our study sample includes 10,416 individuals who presented to Michigan Medicine
for spike protein immunoglobulin G (IgG) SARS-CoV-2 antibody testing between 27 April
2020 and 3 May 2021 (10932 tests in total).",,2020-04-27,2020-12-13,Household and community samples,All,Children and Youth (0-17 years),,11.0,Age,<12,140,0.086,,,,,,,,Unclear,Not reported/ Unable to specify,,,Serum,IgG,Spike,,,,['High'],Unclear,Unclear,Yes,Yes,Unclear,Unclear,Yes,No,Unclear,Zhangchen Zhao,University of Michigan,Not Unity-Aligned,http://dx.doi.org/10.3390/jcm10194341,2021-10-07,2022-07-16,Verified,zhao_understanding_2021,USA
211001_Phoenix_DignityHealthResearchInstituteArizona_Draw1_Overall,211001_Phoenix_DignityHealthResearchInstituteArizona_Draw1,209 Seroprevalence of Anti-SARS CoV-2 Nucleocapsid IgG in a Cohort of Healthcare Workers Over Nine Months,2021-10-01,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Arizona,Phoenix,"All HCWs who were either employed or part of the medical staff at
six acute-care hospitals in Phoenix, Arizona in June 2019 were invited to
participate.","NR
",2020-06-15,2020-08-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1358,0.08800000000000001,0.073,0.10300000000000001,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Brian Tiffany,"Dignity Health Research
Institute Arizona",Not Unity-Aligned,https://dx.doi.org/10.1016/j.annemergmed.2021.09.221,2022-03-22,2024-03-01,Unverified,the_conserve-hcw_research_group_209_2021,USA
211001_Phoenix_DignityHealthResearchInstituteArizona_Draw2__Overall,211001_Phoenix_DignityHealthResearchInstituteArizona_Draw2,209 Seroprevalence of Anti-SARS CoV-2 Nucleocapsid IgG in a Cohort of Healthcare Workers Over Nine Months,2021-10-01,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Arizona,Phoenix,"All HCWs who were either employed or part of the medical staff at
six acute-care hospitals in Phoenix, Arizona in June 2019 were invited to
participate.","NR
",2020-10-01,2020-10-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1358,0.113,0.096,0.13,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Brian Tiffany,"Dignity Health Research
Institute Arizona",Not Unity-Aligned,https://dx.doi.org/10.1016/j.annemergmed.2021.09.221,2022-03-22,2024-03-01,Unverified,the_conserve-hcw_research_group_209_2021,USA
211001_Phoenix_DignityHealthResearchInstituteArizona_Draw3_Overall,211001_Phoenix_DignityHealthResearchInstituteArizona_Draw3,209 Seroprevalence of Anti-SARS CoV-2 Nucleocapsid IgG in a Cohort of Healthcare Workers Over Nine Months,2021-10-01,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Arizona,Phoenix,"All HCWs who were either employed or part of the medical staff at
six acute-care hospitals in Phoenix, Arizona in June 2019 were invited to
participate.","NR
",2021-01-01,2021-01-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1358,0.19899999999999998,0.17800000000000002,0.22,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Brian Tiffany,"Dignity Health Research
Institute Arizona",Not Unity-Aligned,https://dx.doi.org/10.1016/j.annemergmed.2021.09.221,2022-03-22,2024-03-01,Unverified,the_conserve-hcw_research_group_209_2021,USA
211001_Phoenix_DignityHealthResearchInstituteArizona_Draw4_Overall,211001_Phoenix_DignityHealthResearchInstituteArizona_Draw4,209 Seroprevalence of Anti-SARS CoV-2 Nucleocapsid IgG in a Cohort of Healthcare Workers Over Nine Months,2021-10-01,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Arizona,Phoenix,"All HCWs who were either employed or part of the medical staff at
six acute-care hospitals in Phoenix, Arizona in June 2019 were invited to
participate.","NR
",2021-04-01,2021-04-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1358,0.20800000000000002,0.18600000000000003,0.23,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Brian Tiffany,"Dignity Health Research
Institute Arizona",Not Unity-Aligned,https://dx.doi.org/10.1016/j.annemergmed.2021.09.221,2022-03-22,2024-03-01,Unverified,the_conserve-hcw_research_group_209_2021,USA
211001_Charleston_WestVirginiaUniversity_CEW,211001_Charleston_WestVirginiaUniversity_CEW,COVID-19: ESSENTIAL WORKERS AND THE RISKS WE FACE,2021-10-01,Presentation or Conference,Local,Cross-sectional survey ,United States of America,West Virginia,Charleston,"essential workers in Charleston, WV in a variety of occupations.

Community Essential Workers (CEW) included law enforcement, firefighters, restaurant workers, teachers, and grocery workers.",,2020-09-15,2020-12-15,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,623,0.057999999999999996,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,IgG,,,,,['High'],,Unclear,Yes,No,,Unclear,Yes,No,,Syed Mahmood,West Virginia University,Not Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S0012369221020201,2021-10-20,2022-07-16,Unverified,mahmood_covid-19_2021,USA
211001_Charleston_WestVirginiaUniversity_HCW,211001_Charleston_WestVirginiaUniversity_HCW,COVID-19: ESSENTIAL WORKERS AND THE RISKS WE FACE,2021-10-01,Presentation or Conference,Local,Cross-sectional survey ,United States of America,West Virginia,Charleston,"essential workers in Charleston, WV in a variety of occupations.

Healthcare workers (HCW) was defined as those working in the medical profession including Emergency Medical Services (EMS)
personnel with direct patient care with COVID-19 patients.",,2020-09-15,2020-12-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,458,0.1,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,IgG,,,,,['High'],,Unclear,No,No,,Unclear,Yes,No,,Syed Mahmood,West Virginia University,Not Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S0012369221020201,2021-10-20,2022-07-16,Unverified,mahmood_covid-19_2021,USA
211001_UnitedStates_OchsnerHealth,211001_UnitedStates_OchsnerHealth,"Prevalence, Distribution and IgG Antibody Levels Associated with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Among Health-System and Community-Based Employees and Patients.",2021-10-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Louisiana,New Orleans,"Any employee or patient volunteer from any of the Ochsner facilities was eligible for inclusion in the study if they took the IgG test on or before May 1, 2020.",,2020-03-01,2020-05-01,Multiple populations,All,Adults (18-64 years),,,Primary Estimate,,13343,0.0799,0.0753,0.08449999999999999,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,,1.0,0.9963,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Edmond Kabagambe,Ochsner Health,Not Unity-Aligned,https://dx.doi.org/10.1016/j.amjms.2021.09.006,2021-10-12,2024-03-01,Unverified,kabagambe_prevalence_2021,USA
211001_NewYorkCity_NorthShoreUniversityHospital_Overall,211001_NewYorkCity_NorthShoreUniversityHospital,THE CLINICAL IMPACT OF COVID-19 ON CYSTIC FIBROSIS PATIENTS IN NEW YORK,2021-10-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,All patients with CF treated at 11 adult and pediatric CF centers in New York City from 3/1/20 to 8/31/20 were included in the study.,,2020-03-01,2020-08-31,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,812,0.0233,,,True,,,,True,Convenience,,,,,IgG,,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Janice Wang,North Shore University Hospital,Not Unity-Aligned,http://dx.doi.org/10.1016/j.chest.2021.07.1326,2021-10-19,2021-10-28,Unverified,simonson_clinical_2021,USA
211002_NewYork_NorthShoreUniversityHospital_Delivery,211002_NewYork_NorthShoreUniversityHospital_Delivery,Persistence of infection-induced SARS-CoV-2 seropositivity throughout gestation.,2021-10-02,Preprint,Local,Prospective cohort,United States of America,New York,,"This retrospective cohort study evaluated all patients who had first and second trimester biochemical screening to detect fetal aneuploidy between May 2020 and June 2020 at three hospitals within a large integrated health system in New York.

All patients were pregnant at the start of the coronavirus disease 2019 (COVID-19) pandemic and delivered prior to availability of SARS-CoV-2 vaccination.",,2020-10-15,2020-11-15,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,37-40 weeks of gestation,149,0.141,,,True,,,,True,Sequential,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Cara Staszewski,North Shore University Hospital,Unity-Aligned,https://dx.doi.org/10.1016/j.ajog.2021.09.037,2021-10-14,2024-03-01,Verified,staszewski_persistence_2021,USA
211002_NewYork_NorthShoreUniversityHospital_1stTrimester,211002_NewYork_NorthShoreUniversityHospital_FirstTrimester,Persistence of infection-induced SARS-CoV-2 seropositivity throughout gestation.,2021-10-02,Preprint,Local,Prospective cohort,United States of America,New York,,"This retrospective cohort study evaluated all patients who had first and second trimester biochemical screening to detect fetal aneuploidy between May 2020 and June 2020 at three hospitals within a large integrated health system in New York.

All patients were pregnant at the start of the coronavirus disease 2019 (COVID-19) pandemic and delivered prior to availability of SARS-CoV-2 vaccination.",,2020-05-15,2020-06-15,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,11-14 weeks of gestation,149,0.121,,,True,,,,True,Sequential,SARS-CoV-2 IgG ELISA Assay,Gold Standard Diagnostic,ELISA,Dried Blood,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Cara Staszewski,North Shore University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ajog.2021.09.037,2021-10-14,2024-03-01,Verified,staszewski_persistence_2021,USA
211002_NewYork_NorthShoreUniversityHospital_2ndTrimester,211002_NewYork_NorthShoreUniversityHospital_SecondTrimester,Persistence of infection-induced SARS-CoV-2 seropositivity throughout gestation.,2021-10-02,Preprint,Local,Prospective cohort,United States of America,New York,,"This retrospective cohort study evaluated all patients who had first and second trimester biochemical screening to detect fetal aneuploidy between May 2020 and June 2020 at three hospitals within a large integrated health system in New York.

All patients were pregnant at the start of the coronavirus disease 2019 (COVID-19) pandemic and delivered prior to availability of SARS-CoV-2 vaccination.",,2020-05-15,2020-06-15,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,15-20 weeks of gestation,149,0.161,,,True,,,,True,Sequential,SARS-CoV-2 IgG ELISA Assay,Gold Standard Diagnostic,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Cara Staszewski,North Shore University Hospital,Unity-Aligned,https://dx.doi.org/10.1016/j.ajog.2021.09.037,2021-10-14,2024-03-01,Verified,staszewski_persistence_2021,USA
211002_UnitedStates_CohenChildrensMedicalCenter,211002_UnitedStates_CohenChildrensMedicalCenter,Seroprevalence and Clinical Outcomes of SARS-CoV-2 in Paediatric Patients with Rheumatic Disease.,2021-10-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,Patients treated with at least one immunosuppressive medication for at least three months were enrolled if they underwent routine SARS-CoV-2 IgG antibody testing from May to November 2020.,The remaining patients were not on immunosuppressive medications during the time of the study or did not have a clear RD diagnosis.,2020-05-01,2020-11-30,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),,18.0,Primary Estimate,,262,0.13,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG,Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,DiaSorin,EUROIMMUN,Roche Diagnostics",Multiple Types,Serum,IgG,,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Heather Walters ,"Cohen Children’s Medical Center,",Not Unity-Aligned,https://dx.doi.org/10.1093/rheumatology/keab730,2021-10-12,2024-03-01,Unverified,walters_seroprevalence_2021,USA
211006_UnitedStates_UniversityofMinnesota_EarlyTreatment,211006_UnitedStates_UniversityofMinnesota_EarlyTreatment,Feasibility of SARS-CoV-2 Antibody Testing in Remote Outpatient Trials,2021-10-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"""Inclusion criteria for the postexposure prophylaxis trial required persons to have a known exposure (within the previous 4 days) to a lab-confirmed SARS-CoV-2 case either as a health care worker, a first responder, or a household contact. Individuals were enrolled into the preemptive early treatment trial with COVID-19 symptoms (≤4 days duration) and either
lab-confirmed SARS-CoV-2 or high-risk exposure to a known case within 14 days of symptom onset. The pre-exposure prophylaxis trial inclusion criteria required persons to be high-risk health care workers or first responders with ongoing occupational exposure to COVID-19 patients.""

""While overall trial participation included persons living in the United States or select Canadian provinces, only participants in the United States were eligible for participation in the serology substudy.""

""Full details regarding inclusion and exclusion criteria have been published elsewhere [10-12]"".","""Full details regarding inclusion and exclusion criteria have been published elsewhere [10-12]"".",2020-03-17,2020-05-20,Multiple populations,All,Multiple groups,,,Primary Estimate,,123,0.29,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,,,['High'],,No,No,No,,Yes,Yes,Yes,,Sarah Lofgren,University of Minnesota,Not Unity-Aligned,https://academic.oup.com/ofid/article/8/11/ofab506/6382457?login=true,2022-01-11,2024-03-01,Unverified,lofgren_feasibility_2021,USA
211006_UnitedStates_UniversityofMinnesota_PostexposureProphylaxis,211006_UnitedStates_UniversityofMinnesota_PostexposureProphylaxis,Feasibility of SARS-CoV-2 Antibody Testing in Remote Outpatient Trials,2021-10-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"""Inclusion criteria for the postexposure prophylaxis trial required persons to have a known exposure (within the previous 4 days) to a lab-confirmed SARS-CoV-2 case either as a health care worker, a first responder, or a household contact. Individuals were enrolled into the preemptive early treatment trial with COVID-19 symptoms (≤4 days duration) and either
lab-confirmed SARS-CoV-2 or high-risk exposure to a known case within 14 days of symptom onset. The pre-exposure prophylaxis trial inclusion criteria required persons to be high-risk health care workers or first responders with ongoing occupational exposure to COVID-19 patients.""

""While overall trial participation included persons living in the United States or select Canadian provinces, only participants in the United States were eligible for participation in the serology substudy.""

""Full details regarding inclusion and exclusion criteria have been published elsewhere [10-12]"".","""Full details regarding inclusion and exclusion criteria have been published elsewhere [10-12]"".",2020-03-17,2020-05-20,Multiple populations,All,Multiple groups,,,Primary Estimate,,266,0.11,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,,,['High'],,No,No,No,,Yes,Yes,Yes,,Sarah Lofgren,University of Minnesota,Not Unity-Aligned,https://academic.oup.com/ofid/article/8/11/ofab506/6382457?login=true,2022-01-11,2024-03-01,Unverified,lofgren_feasibility_2021,USA
211006_UnitedStates_UniversityofMinnesota_Pre-exposureProphylaxis,211006_UnitedStates_UniversityofMinnesota_Pre-exposureProphylaxis,Feasibility of SARS-CoV-2 Antibody Testing in Remote Outpatient Trials,2021-10-06,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"""Inclusion criteria for the postexposure prophylaxis trial required persons to have a known exposure (within the previous 4 days) to a lab-confirmed SARS-CoV-2 case either as a health care worker, a first responder, or a household contact. Individuals were enrolled into the preemptive early treatment trial with COVID-19 symptoms (≤4 days duration) and either
lab-confirmed SARS-CoV-2 or high-risk exposure to a known case within 14 days of symptom onset. The pre-exposure prophylaxis trial inclusion criteria required persons to be high-risk health care workers or first responders with ongoing occupational exposure to COVID-19 patients.""

""While overall trial participation included persons living in the United States or select Canadian provinces, only participants in the United States were eligible for participation in the serology substudy.""

""Full details regarding inclusion and exclusion criteria have been published elsewhere [10-12]"".","""Full details regarding inclusion and exclusion criteria have been published elsewhere [10-12]"".",2020-04-06,2020-07-13,Multiple populations,All,Multiple groups,,,Primary Estimate,,542,0.04,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,,,['High'],,No,No,No,,Yes,Yes,Yes,,Sarah Lofgren,University of Minnesota,Not Unity-Aligned,https://academic.oup.com/ofid/article/8/11/ofab506/6382457?login=true,2022-01-11,2024-03-01,Unverified,lofgren_feasibility_2021,USA
211009_UnitedStates_AmericanRedCross_Overall_S1,211009_UnitedStates_AmericanRedCross,"Patterns of antibody response to SARS-CoV-2 among 1.6 million blood donors: Impact of vaccination, United States December 2020 - June 2021.",2021-10-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,All whole blood or platelet donors to the American Red Cross,,2020-12-07,2021-06-25,Blood donors,All,Multiple groups,,,Primary Estimate,Positive to S1,1567446,0.6007,,,True,,,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Roger Dodd,American Red Cross,Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab514,2021-10-19,2024-03-01,Verified,dodd_patterns_2021,USA
211009_UnitedStates_AmericanRedCross_Female,211009_UnitedStates_AmericanRedCross,"Patterns of antibody response to SARS-CoV-2 among 1.6 million blood donors: Impact of vaccination, United States December 2020 - June 2021.",2021-10-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,All whole blood or platelet donors to the American Red Cross,,2020-12-07,2021-06-25,Blood donors,Female,Multiple groups,,,Sex/Gender,,862202,0.6043000000000001,,,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Roger Dodd,American Red Cross,Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab514,2021-10-19,2024-03-01,Verified,dodd_patterns_2021,USA
211009_UnitedStates_AmericanRedCross_June_S1,211009_UnitedStates_AmericanRedCross,"Patterns of antibody response to SARS-CoV-2 among 1.6 million blood donors: Impact of vaccination, United States December 2020 - June 2021.",2021-10-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,All whole blood or platelet donors to the American Red Cross,,2021-06-18,2021-06-25,Blood donors,All,Multiple groups,,,Time frame,"June 18-25, 2021",45966,0.9007,,,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Roger Dodd,American Red Cross,Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab514,2022-02-10,2024-03-01,Unverified,dodd_patterns_2021,USA
211009_UnitedStates_AmericanRedCross_Age40-54,211009_UnitedStates_AmericanRedCross,"Patterns of antibody response to SARS-CoV-2 among 1.6 million blood donors: Impact of vaccination, United States December 2020 - June 2021.",2021-10-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,All whole blood or platelet donors to the American Red Cross,,2020-12-07,2021-06-25,Blood donors,All,Adults (18-64 years),40.0,54.0,Age,40-54,431312,0.5686,,,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Roger Dodd,American Red Cross,Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab514,2021-10-19,2024-03-01,Verified,dodd_patterns_2021,USA
211009_UnitedStates_AmericanRedCross_RegionMidwest,211009_UnitedStates_AmericanRedCross,"Patterns of antibody response to SARS-CoV-2 among 1.6 million blood donors: Impact of vaccination, United States December 2020 - June 2021.",2021-10-09,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,"Indiana, Illinois, Michigan, Ohio, Wisconsin, Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, South Dakota",,All whole blood or platelet donors to the American Red Cross,,2020-12-07,2021-06-25,Blood donors,All,Multiple groups,,,Geographical area,Midwest,551520,0.6123,,,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Roger Dodd,American Red Cross,Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab514,2021-10-19,2024-03-01,Verified,dodd_patterns_2021,USA
211009_UnitedStates_AmericanRedCross_RegionWest,211009_UnitedStates_AmericanRedCross,"Patterns of antibody response to SARS-CoV-2 among 1.6 million blood donors: Impact of vaccination, United States December 2020 - June 2021.",2021-10-09,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,"Arizona, Colorado, Idaho, New Mexico, Montana, Utah, Nevada, Wyoming, Alaska, California, Hawaii, Oregon, Washington",,All whole blood or platelet donors to the American Red Cross,,2020-12-07,2021-06-25,Blood donors,All,Multiple groups,,,Geographical area,West,303714,0.5939,,,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Roger Dodd,American Red Cross,Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab514,2021-10-19,2024-03-01,Verified,dodd_patterns_2021,USA
211009_UnitedStates_AmericanRedCross_Unvaccinated,211009_UnitedStates_AmericanRedCross,"Patterns of antibody response to SARS-CoV-2 among 1.6 million blood donors: Impact of vaccination, United States December 2020 - June 2021.",2021-10-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,All whole blood or platelet donors to the American Red Cross,,2020-12-07,2021-06-25,Blood donors,All,Multiple groups,,,COVID-19 vaccination status,,837675,0.2859,,,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Roger Dodd,American Red Cross,Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab514,2021-10-19,2024-03-01,Verified,dodd_patterns_2021,USA
211009_UnitedStates_AmericanRedCross_Vaccinated,211009_UnitedStates_AmericanRedCross,"Patterns of antibody response to SARS-CoV-2 among 1.6 million blood donors: Impact of vaccination, United States December 2020 - June 2021.",2021-10-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,All whole blood or platelet donors to the American Red Cross,,2020-12-07,2021-06-25,Blood donors,All,Multiple groups,,,COVID-19 vaccination status,,729771,0.9620000000000001,,,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Roger Dodd,American Red Cross,Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab514,2021-10-19,2024-03-01,Verified,dodd_patterns_2021,USA
211009_UnitedStates_AmericanRedCross_Age18-24,211009_UnitedStates_AmericanRedCross,"Patterns of antibody response to SARS-CoV-2 among 1.6 million blood donors: Impact of vaccination, United States December 2020 - June 2021.",2021-10-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,All whole blood or platelet donors to the American Red Cross,,2020-12-07,2021-06-25,Blood donors,All,Adults (18-64 years),18.0,24.0,Age,18-24,112033,0.5192,,,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Roger Dodd,American Red Cross,Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab514,2021-10-19,2024-03-01,Verified,dodd_patterns_2021,USA
211009_UnitedStates_AmericanRedCross_RegionNortheast,211009_UnitedStates_AmericanRedCross,"Patterns of antibody response to SARS-CoV-2 among 1.6 million blood donors: Impact of vaccination, United States December 2020 - June 2021.",2021-10-09,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,"Connecticut, Maine, Massachusetts, New Hampshire, Vermont, New Jersey, New York, Pennsylvania",,All whole blood or platelet donors to the American Red Cross,,2020-12-07,2021-06-25,Blood donors,All,Multiple groups,,,Geographical area,Northeast,314514,0.6078,,,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Roger Dodd,American Red Cross,Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab514,2021-10-19,2024-03-01,Verified,dodd_patterns_2021,USA
211009_UnitedStates_AmericanRedCross_Male,211009_UnitedStates_AmericanRedCross,"Patterns of antibody response to SARS-CoV-2 among 1.6 million blood donors: Impact of vaccination, United States December 2020 - June 2021.",2021-10-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,All whole blood or platelet donors to the American Red Cross,,2020-12-07,2021-06-25,Blood donors,Male,Multiple groups,,,Sex/Gender,,705244,0.5962,,,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Roger Dodd,American Red Cross,Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab514,2021-10-19,2024-03-01,Verified,dodd_patterns_2021,USA
211009_UnitedStates_AmericanRedCross_Age25-39,211009_UnitedStates_AmericanRedCross,"Patterns of antibody response to SARS-CoV-2 among 1.6 million blood donors: Impact of vaccination, United States December 2020 - June 2021.",2021-10-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,All whole blood or platelet donors to the American Red Cross,,2020-12-07,2021-06-25,Blood donors,All,Adults (18-64 years),25.0,39.0,Age,25-39,317623,0.5403,,,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Roger Dodd,American Red Cross,Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab514,2021-10-19,2024-03-01,Verified,dodd_patterns_2021,USA
211009_UnitedStates_AmericanRedCross_Age65+,211009_UnitedStates_AmericanRedCross,"Patterns of antibody response to SARS-CoV-2 among 1.6 million blood donors: Impact of vaccination, United States December 2020 - June 2021.",2021-10-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,All whole blood or platelet donors to the American Red Cross,,2020-12-07,2021-06-25,Blood donors,All,Seniors (65+ years),65.0,,Age,,295688,0.7463,,,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Roger Dodd,American Red Cross,Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab514,2021-10-19,2024-03-01,Verified,dodd_patterns_2021,USA
211009_UnitedStates_AmericanRedCross_Overall_S1andN,211009_UnitedStates_AmericanRedCross,"Patterns of antibody response to SARS-CoV-2 among 1.6 million blood donors: Impact of vaccination, United States December 2020 - June 2021.",2021-10-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,All whole blood or platelet donors to the American Red Cross,,2021-06-01,2021-06-25,Blood donors,All,Multiple groups,,,Test used,Positive to S1 and N,1567446,0.1775,,,,,,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Roger Dodd,American Red Cross,Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab514,2021-10-28,2024-03-01,Verified,dodd_patterns_2021,USA
211009_UnitedStates_AmericanRedCross_Age55-64,211009_UnitedStates_AmericanRedCross,"Patterns of antibody response to SARS-CoV-2 among 1.6 million blood donors: Impact of vaccination, United States December 2020 - June 2021.",2021-10-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,All whole blood or platelet donors to the American Red Cross,,2020-12-07,2021-06-25,Blood donors,All,Adults (18-64 years),55.0,64.0,Age,55-64,379306,0.6152000000000001,,,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Roger Dodd,American Red Cross,Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab514,2021-10-19,2024-03-01,Verified,dodd_patterns_2021,USA
211009_UnitedStates_AmericanRedCross_RegionSouth,211009_UnitedStates_AmericanRedCross,"Patterns of antibody response to SARS-CoV-2 among 1.6 million blood donors: Impact of vaccination, United States December 2020 - June 2021.",2021-10-09,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,"Delaware, District of Columbia, Florida, Georgia, Maryland, North Carolina, South Carolina, Virginia, West Virginia, Alabama, Kentucky, Mississippi, Tennessee, Arkansas, Louisiana, Oklahoma, Texas",,All whole blood or platelet donors to the American Red Cross,,2020-12-07,2021-06-25,Blood donors,All,Multiple groups,,,Geographical area,South,397698,0.584,,,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Roger Dodd,American Red Cross,Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab514,2021-10-19,2024-03-01,Verified,dodd_patterns_2021,USA
211009_UnitedStates_AmericanRedCross_Age16-17,211009_UnitedStates_AmericanRedCross,"Patterns of antibody response to SARS-CoV-2 among 1.6 million blood donors: Impact of vaccination, United States December 2020 - June 2021.",2021-10-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,All whole blood or platelet donors to the American Red Cross,,2020-12-07,2021-06-25,Blood donors,All,Children and Youth (0-17 years),16.0,17.0,Age,16-17,31484,0.39490000000000003,,,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,Roger Dodd,American Red Cross,Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab514,2021-10-19,2024-03-01,Verified,dodd_patterns_2021,USA
211011_NewYork_ChildrensHospitalAtMontefiore,211011_NewYork_ChildrensHospitalAtMontefiore,COVID-19 infection in pediatric solid organ transplant patients.,2021-10-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York,,,2020-04-15,2020-12-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,0.0,26.0,Primary Estimate,,108,0.111,,,True,,,,True,Convenience,SARS-CoV-2 ELISA,Eurofins-Viracor ,ELISA,Serum,"['IgG', 'IgM']",,,,1.0,['High'],,No,No,Yes,,Unclear,Yes,No,,Neha Bansal,Childrens Hospital at Montefiore,Not Unity-Aligned,https://dx.doi.org/10.1111/petr.14156,2021-10-19,2024-03-01,Unverified,bansal_covid-19_2021,USA
211012_Colorado_UniversityofColorado_Baseline_TestAdjusted,211012_Colorado_UniversityofColorado_Baseline,Anti-SARS-CoV-2 IgA Identifies Asymptomatic Infection in First Responders.,2021-10-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Colorado,,"first responders (police, emergency medical service providers, fire fighters, and other staff) in Colorado",,2020-05-15,2021-03-15,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,Test Adjusted,1007,0.12,,,True,True,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgA,Anti-SARS-CoV-2 ELISA IgG","Abbott Laboratories,EUROIMMUN",Multiple Types,Serum,"['IgA', 'IgG']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Brian Montague,University of Colorado,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab524,2021-10-19,2023-08-15,Unverified,montague_anti-sars-cov-2_2021,USA
211012_Colorado_UniversityofColorado_Followup_TestAdjusted,211012_Colorado_UniversityofColorado_Followup,Anti-SARS-CoV-2 IgA Identifies Asymptomatic Infection in First Responders.,2021-10-12,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Colorado,,"first responders (police, emergency medical service providers, fire fighters, and other staff) in Colorado",Participants who received SARS-CoV-2 vaccination prior to the follow-up collection were excluded.,2020-05-15,2021-03-15,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,Test Adjusted,783,0.2,,,True,True,,,,Convenience,"Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgA,Anti-SARS-CoV-2 ELISA IgG","Abbott Laboratories,EUROIMMUN",Multiple Types,Serum,"['IgA', 'IgG']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,No,,Unclear,Yes,Yes,,Brian Montague,University of Colorado,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab524,2021-10-19,2023-08-15,Unverified,montague_anti-sars-cov-2_2021,USA
211018_Georgia_EmoryUniversity_PopAdj,211018_Georgia_EmoryUniversity,"Cumulative Incidence of SARS-CoV-2 Infections Among Adults in Georgia, United States, August to December 2020",2021-10-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Georgia,,Adult >= 18,,2020-08-15,2020-12-15,Household and community samples,All,Adults (18-64 years),18.0,,Primary Estimate,,1370,0.086,0.063,0.11800000000000001,True,,True,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.993,0.98,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Allison Chamberlain,Emory University,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab522,2022-05-11,2024-03-01,Verified,chamberlain_cumulative_2022,USA
211018_Georgia_EmoryUniversity_SamplingDate_AugtoOct,211018_Georgia_EmoryUniversity,"Cumulative Incidence of SARS-CoV-2 Infections Among Adults in Georgia, United States, August to December 2020",2021-10-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Georgia,,Adult >= 18,,2020-08-15,2020-10-31,Household and community samples,All,Adults (18-64 years),18.0,,Time frame,Sample collected Aug to Oct,119,0.09300000000000001,0.033,0.23500000000000001,,,True,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.993,0.98,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Allison Chamberlain,Emory University,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab522,2022-05-12,2024-03-01,Verified,chamberlain_cumulative_2022,USA
211018_Georgia_EmoryUniversity_Age_45-54,211018_Georgia_EmoryUniversity,"Cumulative Incidence of SARS-CoV-2 Infections Among Adults in Georgia, United States, August to December 2020",2021-10-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Georgia,,Adult >= 18,,2020-08-15,2020-12-15,Household and community samples,All,Adults (18-64 years),45.0,54.0,Age,45-54,229,0.066,0.035,0.12,,,True,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.993,0.98,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Allison Chamberlain,Emory University,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab522,2022-05-12,2024-03-01,Verified,chamberlain_cumulative_2022,USA
211018_Georgia_EmoryUniversity_SamplingDate_NovtoDec,211018_Georgia_EmoryUniversity,"Cumulative Incidence of SARS-CoV-2 Infections Among Adults in Georgia, United States, August to December 2020",2021-10-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Georgia,,Adult >= 18,,2020-11-01,2020-12-31,Household and community samples,All,Adults (18-64 years),18.0,,Time frame,Sample collected Nov to Dec,1251,0.085,0.061,0.11800000000000001,,,True,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.993,0.98,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Allison Chamberlain,Emory University,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab522,2022-05-12,2024-03-01,Verified,chamberlain_cumulative_2022,USA
211018_Georgia_EmoryUniversity_Sex_Male,211018_Georgia_EmoryUniversity,"Cumulative Incidence of SARS-CoV-2 Infections Among Adults in Georgia, United States, August to December 2020",2021-10-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Georgia,,Adult >= 18,,2020-08-15,2020-12-15,Household and community samples,Male,Adults (18-64 years),18.0,,Sex/Gender,,523,0.091,0.054000000000000006,0.15,,,True,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.993,0.98,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Allison Chamberlain,Emory University,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab522,2022-05-12,2024-03-01,Verified,chamberlain_cumulative_2022,USA
211018_Georgia_EmoryUniversity_Age_35-44,211018_Georgia_EmoryUniversity,"Cumulative Incidence of SARS-CoV-2 Infections Among Adults in Georgia, United States, August to December 2020",2021-10-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Georgia,,Adult >= 18,,2020-08-15,2020-12-15,Household and community samples,All,Adults (18-64 years),35.0,44.0,Age,35-44,235,0.126,0.057999999999999996,0.252,,,True,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.993,0.98,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Allison Chamberlain,Emory University,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab522,2022-05-12,2024-03-01,Verified,chamberlain_cumulative_2022,USA
211018_Georgia_EmoryUniversity_Age_55-64,211018_Georgia_EmoryUniversity,"Cumulative Incidence of SARS-CoV-2 Infections Among Adults in Georgia, United States, August to December 2020",2021-10-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Georgia,,Adult >= 18,,2020-08-15,2020-12-15,Household and community samples,All,Adults (18-64 years),55.0,64.0,Age,55-64,272,0.09300000000000001,0.040999999999999995,0.195,,,True,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.993,0.98,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Allison Chamberlain,Emory University,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab522,2022-05-12,2024-03-01,Verified,chamberlain_cumulative_2022,USA
211018_Georgia_EmoryUniversity_Age_18-34,211018_Georgia_EmoryUniversity,"Cumulative Incidence of SARS-CoV-2 Infections Among Adults in Georgia, United States, August to December 2020",2021-10-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Georgia,,Adult >= 18,,2020-08-15,2020-12-15,Household and community samples,All,Adults (18-64 years),18.0,34.0,Age,18-34,313,0.083,0.048,0.138,,,True,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.993,0.98,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Allison Chamberlain,Emory University,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab522,2022-05-11,2024-03-01,Verified,chamberlain_cumulative_2022,USA
211018_Georgia_EmoryUniversity_UnAdj,211018_Georgia_EmoryUniversity,"Cumulative Incidence of SARS-CoV-2 Infections Among Adults in Georgia, United States, August to December 2020",2021-10-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Georgia,,Adult >= 18,,2020-08-15,2020-12-15,Household and community samples,All,Adults (18-64 years),18.0,,Analysis,,1370,0.0723,,,,,True,,True,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.993,0.98,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Allison Chamberlain,Emory University,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab522,2022-05-11,2024-03-01,Verified,chamberlain_cumulative_2022,USA
211018_Georgia_EmoryUniversity_Sex_Female,211018_Georgia_EmoryUniversity,"Cumulative Incidence of SARS-CoV-2 Infections Among Adults in Georgia, United States, August to December 2020",2021-10-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Georgia,,Adult >= 18,,2020-08-15,2020-12-15,Household and community samples,Female,Adults (18-64 years),18.0,,Sex/Gender,,847,0.08199999999999999,0.057,0.11599999999999999,,,True,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.993,0.98,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Allison Chamberlain,Emory University,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab522,2022-05-12,2024-03-01,Verified,chamberlain_cumulative_2022,USA
211018_Georgia_EmoryUniversity_Age_>65,211018_Georgia_EmoryUniversity,"Cumulative Incidence of SARS-CoV-2 Infections Among Adults in Georgia, United States, August to December 2020",2021-10-18,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Georgia,,Adult >= 18,,2020-08-15,2020-12-15,Household and community samples,All,Adults (18-64 years),65.0,,Age,>65,321,0.068,0.036000000000000004,0.127,,,True,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,0.993,0.98,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,No,Allison Chamberlain,Emory University,Not Unity-Aligned,https://dx.doi.org/10.1093/infdis/jiab522,2022-05-12,2024-03-01,Verified,chamberlain_cumulative_2022,USA
211018_WRNMMC_UniformedServicesUniversity,211018_WRNMMC_UniformedServicesUniversity,Durability of antibody responses and frequency of clinical and subclinical SARS-CoV-2 infection six months after BNT162b2 COVID-19 vaccination in healthcare workers,2021-10-18,Preprint,Local,Prospective cohort,United States of America,Maryland,Bethesda,Adult HCWs at the Walter Reed National Military Medical Center (WRNMMC) who were seronegative for IgG antibodies to SARS-CoV-2 spike glycoprotein (spike) and had no history of COVID-19.,History of COVID-19,2021-02-01,2021-08-15,Health care workers and caregivers,All,Adults (18-64 years),19.0,50.0,Primary Estimate,,17,0.2353,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9400000000000001,1.0,['High'],,No,No,Yes,,Unclear,Yes,Yes,,Eric Laing,Uniformed Services University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.10.16.21265087v1,2021-10-26,2022-07-16,Unverified,laing_durability_2021,USA
211021_OrangeCounty_Children’sHospitalofOrangeCounty_Overall,211021_OrangeCounty_Children’sHospitalofOrangeCounty,"SARS-CoV-2 Serology Testing in an Asymptomatic, At-Risk Population: Methods, Results, Pitfalls.",2021-10-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,"Study subjects were recruited via department-wide emails to the Emergency Department, Intensive Care Unit, interhospital transport team, and operative services teams, and included physicians, physician assistants, nurse practitioners, registered nurses, medical technicians, and secretaries with direct patient contact or who were in close proximity to patient-care areas",,2020-05-14,2020-07-13,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,Overall ,282,0.003,,,True,,,,True,Convenience,"COVID-19 Rapid Test Kit IgG + IgM,Abbott Architect SARS-CoV-2 IgG","Superbio Biomedical Company ,Abbott Laboratories",Multiple Types,Multiple Types,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Yes,Yes,No,,Theodore Heyming,Children’s Hospital of Orange County,Not Unity-Aligned,https://dx.doi.org/10.3390/idr13040082,2021-11-02,2024-03-01,Unverified,heyming_sars-cov-2_2021,USA
211026_NewYorkCity_MountSinaiHealthSystem_Phase2_Overall_Spike,211026_NewYorkCity_MountSinaiHealthSystem_Phase2,Longitudinal humoral antibody response to SARS-CoV-2 infection among healthcare workers in a New York City hospital.,2021-10-26,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,New York,New York,"""The cohort included HCWs who worked at the NYC public hospital in the South Bronx.""
The hospital was not specified.",,2020-08-15,2020-09-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,176,0.3864,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9400000000000001,1.0,['High'],,No,No,Yes,,Unclear,Yes,Yes,,Vidya Menon,Mount Sinai Health System,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-051045,2021-11-04,2022-07-16,Unverified,menon_longitudinal_2021,USA
201027_Vermont_UniversityOfVermont_Staff_Primary,201027_Vermont_UniversityOfVermont_Staff,SARS CoV-2 seroprevalence in a US school district during COVID-19.,2021-10-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Vermont,,"students and staff attending ≥2 days/week of in-person
learning in Colchester School District (Vermont,
USA).",Exclusion criteria including bleeding or clotting disorder or other condition that would preclude safe blood collection.,2020-12-02,2020-12-19,Students and Daycares,All,Adults (18-64 years),,,Primary Estimate,,336,0.046,0.025,0.077,True,True,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9500000000000001,0.99,['High'],,No,No,No,,Unclear,Yes,Yes,,Sean S M Bullis,University of Vermont,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjpo-2021-001259,2021-11-08,2022-07-16,Unverified,sars_bullis_2021,USA
201027_Vermont_UniversityOfVermont_Student_Primary,201027_Vermont_UniversityOfVermont_Student,SARS CoV-2 seroprevalence in a US school district during COVID-19.,2021-10-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Vermont,,"students and staff attending ≥2 days/week of in-person
learning in Colchester School District (Vermont,
USA).",Exclusion criteria including bleeding or clotting disorder or other condition that would preclude safe blood collection.,2020-12-02,2020-12-19,Students and Daycares,All,Children and Youth (0-17 years),,18.0,Primary Estimate,,196,0.049,0.02,0.09300000000000001,True,True,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9500000000000001,0.99,['High'],,No,No,No,,Unclear,Yes,Yes,,Sean S M Bullis,University of Vermont,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjpo-2021-001259,2021-11-08,2022-07-16,Unverified,sars_bullis_2021,USA
210828_Georgia_EmoryUniversityRollinsSchoolOfPublicHealth,210828_Georgia_EmoryUniversityRollinsSchoolOfPublicHealth,Risk factors for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seropositivity among nursing home staff.,2021-10-28,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Georgia,,Nursing home staff in Georgia,,2020-08-25,2020-11-22,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,749,0.23500000000000001,,,True,,,,True,Unclear,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,,,,['Moderate'],,Unclear,Yes,No,,Yes,Yes,Yes,,Avnika V Amin,Emory University Rollins School of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1017/ash.2021.193,2022-10-18,2024-03-01,Unverified,amin_risk_2021,USA
211031_Texas_UniversityOfTexas_PopTestAdj_AntiS_Overall,211031_Texas_UniversityOfTexas,Texas Coronavirus Antibody Response Survey October 2021,2021-10-31,Institutional Report,Regional,Cross-sectional survey ,United States of America,Texas,,Any Texan between the ages of 5-90 years of age.,,2021-10-04,2021-10-04,Household and community samples,All,Multiple groups,5.0,90.0,Primary Estimate,Test used: Anti-S,88091,0.755,,,True,True,True,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,The University of Texas Health Science Center at Houston,University of Texas Health Science Center at Houston,Unity-Aligned,https://sph.uth.edu/projects/texascares/docs/TexasCARES%20-%20October%20Report.pdf,2022-03-14,2023-12-13,Verified,university_of_texas_health_science_center_texas_2021,USA
211031_Texas_UniversityOfTexas_PopTestAdj_AntiN_Age5-9,211031_Texas_UniversityOfTexas,Texas Coronavirus Antibody Response Survey October 2021,2021-10-31,Institutional Report,Regional,Cross-sectional survey ,United States of America,Texas,,Any Texan between the ages of 5-90 years of age.,,,2021-10-04,Household and community samples,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,869,0.35100000000000003,,,,True,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,The University of Texas Health Science Center at Houston,University of Texas Health Science Center at Houston,Unity-Aligned,https://sph.uth.edu/projects/texascares/docs/TexasCARES%20-%20October%20Report.pdf,2022-05-29,2023-08-15,Verified,university_of_texas_health_science_center_texas_2021,USA
211031_Texas_UniversityOfTexas_PopTestAdj_AntiN_Age30-39,211031_Texas_UniversityOfTexas,Texas Coronavirus Antibody Response Survey October 2021,2021-10-31,Institutional Report,Regional,Cross-sectional survey ,United States of America,Texas,,Any Texan between the ages of 5-90 years of age.,,,2021-10-04,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,13953,0.247,,,,True,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,The University of Texas Health Science Center at Houston,University of Texas Health Science Center at Houston,Unity-Aligned,https://sph.uth.edu/projects/texascares/docs/TexasCARES%20-%20October%20Report.pdf,2021-11-25,2023-08-15,Verified,university_of_texas_health_science_center_texas_2021,USA
211031_Texas_UniversityOfTexas_PopTestAdj_AntiN_Age80-90,211031_Texas_UniversityOfTexas,Texas Coronavirus Antibody Response Survey October 2021,2021-10-31,Institutional Report,Regional,Cross-sectional survey ,United States of America,Texas,,Any Texan between the ages of 5-90 years of age.,,,2021-10-04,Household and community samples,All,Seniors (65+ years),80.0,90.0,Age,80-90,962,0.146,,,,True,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,The University of Texas Health Science Center at Houston,University of Texas Health Science Center at Houston,Unity-Aligned,https://sph.uth.edu/projects/texascares/docs/TexasCARES%20-%20October%20Report.pdf,2021-11-25,2023-08-15,Verified,university_of_texas_health_science_center_texas_2021,USA
211031_Texas_UniversityOfTexas_PopTestAdj_AntiN_Age20-29,211031_Texas_UniversityOfTexas,Texas Coronavirus Antibody Response Survey October 2021,2021-10-31,Institutional Report,Regional,Cross-sectional survey ,United States of America,Texas,,Any Texan between the ages of 5-90 years of age.,,,2021-10-04,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,4301,0.305,,,,True,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,The University of Texas Health Science Center at Houston,University of Texas Health Science Center at Houston,Unity-Aligned,https://sph.uth.edu/projects/texascares/docs/TexasCARES%20-%20October%20Report.pdf,2021-11-25,2023-08-15,Verified,university_of_texas_health_science_center_texas_2021,USA
211031_Texas_UniversityOfTexas_PopTestAdj_AntiN_Adults_Overall,211031_Texas_UniversityOfTexas,Texas Coronavirus Antibody Response Survey October 2021,2021-10-31,Institutional Report,Regional,Cross-sectional survey ,United States of America,Texas,,Any Texan between the ages of 5-90 years of age.,,,2021-10-04,Household and community samples,All,Multiple groups,20.0,90.0,Test used,Test used: Anti-N,83977,0.231,0.22899999999999998,0.23399999999999999,,True,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,The University of Texas Health Science Center at Houston,University of Texas Health Science Center at Houston,Unity-Aligned,https://sph.uth.edu/projects/texascares/docs/TexasCARES%20-%20October%20Report.pdf,2021-11-25,2023-08-15,Verified,university_of_texas_health_science_center_texas_2021,USA
211031_Texas_UniversityOfTexas_PopTestAdj_AntiN_SexMale,211031_Texas_UniversityOfTexas,Texas Coronavirus Antibody Response Survey October 2021,2021-10-31,Institutional Report,Regional,Cross-sectional survey ,United States of America,Texas,,Any Texan between the ages of 5-90 years of age.,,,2021-10-04,Household and community samples,Male,Multiple groups,5.0,90.0,Sex/Gender,,28861,0.242,,,,True,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,The University of Texas Health Science Center at Houston,University of Texas Health Science Center at Houston,Unity-Aligned,https://sph.uth.edu/projects/texascares/docs/TexasCARES%20-%20October%20Report.pdf,2022-05-29,2023-08-15,Verified,university_of_texas_health_science_center_texas_2021,USA
211031_Texas_UniversityOfTexas_PopTestAdj_AntiN_Age70-79,211031_Texas_UniversityOfTexas,Texas Coronavirus Antibody Response Survey October 2021,2021-10-31,Institutional Report,Regional,Cross-sectional survey ,United States of America,Texas,,Any Texan between the ages of 5-90 years of age.,,,2021-10-04,Household and community samples,All,Seniors (65+ years),70.0,79.0,Age,70-79,10024,0.146,,,,True,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,The University of Texas Health Science Center at Houston,University of Texas Health Science Center at Houston,Unity-Aligned,https://sph.uth.edu/projects/texascares/docs/TexasCARES%20-%20October%20Report.pdf,2021-11-25,2023-08-15,Verified,university_of_texas_health_science_center_texas_2021,USA
211031_Texas_UniversityOfTexas_PopTestAdj_AntiN_Age40-49,211031_Texas_UniversityOfTexas,Texas Coronavirus Antibody Response Survey October 2021,2021-10-31,Institutional Report,Regional,Cross-sectional survey ,United States of America,Texas,,Any Texan between the ages of 5-90 years of age.,,,2021-10-04,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,18832,0.265,,,,True,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,The University of Texas Health Science Center at Houston,University of Texas Health Science Center at Houston,Unity-Aligned,https://sph.uth.edu/projects/texascares/docs/TexasCARES%20-%20October%20Report.pdf,2021-11-25,2023-08-15,Verified,university_of_texas_health_science_center_texas_2021,USA
211031_Texas_UniversityOfTexas_PopTestAdj_AntiN_Age10-19,211031_Texas_UniversityOfTexas,Texas Coronavirus Antibody Response Survey October 2021,2021-10-31,Institutional Report,Regional,Cross-sectional survey ,United States of America,Texas,,Any Texan between the ages of 5-90 years of age.,,,2021-10-04,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,10-19,3020,0.37,,,,True,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,The University of Texas Health Science Center at Houston,University of Texas Health Science Center at Houston,Unity-Aligned,https://sph.uth.edu/projects/texascares/docs/TexasCARES%20-%20October%20Report.pdf,2022-05-29,2023-08-15,Verified,university_of_texas_health_science_center_texas_2021,USA
211031_Texas_UniversityOfTexas_PopTestAdj_AntiN_Children_Overall,211031_Texas_UniversityOfTexas,Texas Coronavirus Antibody Response Survey October 2021,2021-10-31,Institutional Report,Regional,Cross-sectional survey ,United States of America,Texas,,Any Texan between the ages of 5-90 years of age.,,,2021-10-04,Household and community samples,All,Children and Youth (0-17 years),5.0,19.0,Test used,Test used: Anti-N,3889,0.365,0.35000000000000003,0.381,,True,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,The University of Texas Health Science Center at Houston,University of Texas Health Science Center at Houston,Unity-Aligned,https://sph.uth.edu/projects/texascares/docs/TexasCARES%20-%20October%20Report.pdf,2022-05-29,2023-08-15,Verified,university_of_texas_health_science_center_texas_2021,USA
211031_Texas_UniversityOfTexas_PopTestAdj_AntiN_Age50-59,211031_Texas_UniversityOfTexas,Texas Coronavirus Antibody Response Survey October 2021,2021-10-31,Institutional Report,Regional,Cross-sectional survey ,United States of America,Texas,,Any Texan between the ages of 5-90 years of age.,,,2021-10-04,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,17545,0.261,,,,True,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,The University of Texas Health Science Center at Houston,University of Texas Health Science Center at Houston,Unity-Aligned,https://sph.uth.edu/projects/texascares/docs/TexasCARES%20-%20October%20Report.pdf,2021-11-25,2023-08-15,Verified,university_of_texas_health_science_center_texas_2021,USA
211031_Texas_UniversityOfTexas_PopTestAdj_AntiN_Age60-69,211031_Texas_UniversityOfTexas,Texas Coronavirus Antibody Response Survey October 2021,2021-10-31,Institutional Report,Regional,Cross-sectional survey ,United States of America,Texas,,Any Texan between the ages of 5-90 years of age.,,,2021-10-04,Household and community samples,All,Seniors (65+ years),60.0,69.0,Age,60-69,18360,0.19100000000000003,,,,True,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,The University of Texas Health Science Center at Houston,University of Texas Health Science Center at Houston,Unity-Aligned,https://sph.uth.edu/projects/texascares/docs/TexasCARES%20-%20October%20Report.pdf,2021-11-25,2023-08-15,Verified,university_of_texas_health_science_center_texas_2021,USA
211031_Texas_UniversityOfTexas_PopTestAdj_AntiN_SexFemale,211031_Texas_UniversityOfTexas,Texas Coronavirus Antibody Response Survey October 2021,2021-10-31,Institutional Report,Regional,Cross-sectional survey ,United States of America,Texas,,Any Texan between the ages of 5-90 years of age.,,,2021-10-04,Household and community samples,Female,Multiple groups,5.0,90.0,Sex/Gender,,59163,0.23500000000000001,,,,True,True,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,The University of Texas Health Science Center at Houston,University of Texas Health Science Center at Houston,Unity-Aligned,https://sph.uth.edu/projects/texascares/docs/TexasCARES%20-%20October%20Report.pdf,2022-05-29,2023-08-15,Verified,university_of_texas_health_science_center_texas_2021,USA
211102_Seattle_UniversityOfWashington_Baseline,211102_Seattle_UniversityOfWashington_Baseline,25 Seroprevalence and clinical characteristics of SARS-CoV-2 infection in children and adolescents with cystic fibrosis,2021-11-02,Presentation or Conference,Local,Prospective cohort,United States of America,Washington,Seattle,"All children with CF followed at Seattle Children’s Hospital CF
Center were eligible to enroll between July 20, 2020 and February 28, 2021.",,2020-07-20,2021-02-28,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),0.0,20.0,Primary Estimate,,125,0.04,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Georgene Hergenroeder,University of Washington,Not Unity-Aligned,https://dx.doi.org/10.1016/S1569-1993%2821%2901450-8,2022-01-10,2022-07-16,Unverified,hergenroeder_25_2021,USA
211103_NewYorkCity_NewYorkCityHealthandHospitals_Overall,211103_NewYorkCity_NewYorkCityHealthandHospitals,Cross-sectional study evaluating the seroprevalence of SARS-CoV-2 antibodies among healthcare workers and factors associated with exposure during the first wave of the COVID-19 pandemic in New York.,2021-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"In order to be eligible for the study, participants needed 
to meet the following criteria:
1. Employed by NYC H+H and either (A) completed serological testing at NYC H+H or (B) completed SARS-CoV-2 antibody testing outside of NYC H+H and were able to self-report results.
2. 18 years of age or older.
3. Capable of providing consent to participate in the study, including English or Spanish fluency",No consent in English or Spanish,2020-04-30,2020-06-30,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,727,0.2944,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Alexander Bryan,New York City Health and hospitals,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-053158,2021-11-08,2022-07-16,Unverified,bryan_cross-sectional_2021,USA
211103_NewYorkCity_NewYorkCityHealthandHospitals_Age55-64,211103_NewYorkCity_NewYorkCityHealthandHospitals,Cross-sectional study evaluating the seroprevalence of SARS-CoV-2 antibodies among healthcare workers and factors associated with exposure during the first wave of the COVID-19 pandemic in New York.,2021-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"In order to be eligible for the study, participants needed 
to meet the following criteria:
1. Employed by NYC H+H and either (A) completed serological testing at NYC H+H or (B) completed SARS-CoV-2 antibody testing outside of NYC H+H and were able to self-report results.
2. 18 years of age or older.
3. Capable of providing consent to participate in the study, including English or Spanish fluency",No consent in English or Spanish,2020-04-30,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),55.0,64.0,Age,55-64,168,0.2857,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Alexander Bryan,New York City Health and hospitals,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-053158,2021-11-08,2022-07-16,Unverified,bryan_cross-sectional_2021,USA
211103_NewYorkCity_NewYorkCityHealthandHospitals_Age65-74,211103_NewYorkCity_NewYorkCityHealthandHospitals,Cross-sectional study evaluating the seroprevalence of SARS-CoV-2 antibodies among healthcare workers and factors associated with exposure during the first wave of the COVID-19 pandemic in New York.,2021-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"In order to be eligible for the study, participants needed 
to meet the following criteria:
1. Employed by NYC H+H and either (A) completed serological testing at NYC H+H or (B) completed SARS-CoV-2 antibody testing outside of NYC H+H and were able to self-report results.
2. 18 years of age or older.
3. Capable of providing consent to participate in the study, including English or Spanish fluency",No consent in English or Spanish,2020-04-30,2020-06-30,Health care workers and caregivers,All,Seniors (65+ years),65.0,74.0,Age,65-74,41,0.2683,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Alexander Bryan,New York City Health and hospitals,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-053158,2021-11-08,2022-07-16,Unverified,bryan_cross-sectional_2021,USA
211103_NewYorkCity_NewYorkCityHealthandHospitals_Age35-44,211103_NewYorkCity_NewYorkCityHealthandHospitals,Cross-sectional study evaluating the seroprevalence of SARS-CoV-2 antibodies among healthcare workers and factors associated with exposure during the first wave of the COVID-19 pandemic in New York.,2021-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"In order to be eligible for the study, participants needed 
to meet the following criteria:
1. Employed by NYC H+H and either (A) completed serological testing at NYC H+H or (B) completed SARS-CoV-2 antibody testing outside of NYC H+H and were able to self-report results.
2. 18 years of age or older.
3. Capable of providing consent to participate in the study, including English or Spanish fluency",No consent in English or Spanish,2020-04-30,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),35.0,44.0,Age,35-44,173,0.3237,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Alexander Bryan,New York City Health and hospitals,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-053158,2021-11-08,2022-07-16,Unverified,bryan_cross-sectional_2021,USA
211103_NewYorkCity_NewYorkCityHealthandHospitals_Age45-54,211103_NewYorkCity_NewYorkCityHealthandHospitals,Cross-sectional study evaluating the seroprevalence of SARS-CoV-2 antibodies among healthcare workers and factors associated with exposure during the first wave of the COVID-19 pandemic in New York.,2021-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"In order to be eligible for the study, participants needed 
to meet the following criteria:
1. Employed by NYC H+H and either (A) completed serological testing at NYC H+H or (B) completed SARS-CoV-2 antibody testing outside of NYC H+H and were able to self-report results.
2. 18 years of age or older.
3. Capable of providing consent to participate in the study, including English or Spanish fluency",No consent in English or Spanish,2020-04-30,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),45.0,54.0,Age,45-54,174,0.32180000000000003,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Alexander Bryan,New York City Health and hospitals,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-053158,2021-11-08,2022-07-16,Unverified,bryan_cross-sectional_2021,USA
211103_NewYorkCity_NewYorkCityHealthandHospitals_Age21-34,211103_NewYorkCity_NewYorkCityHealthandHospitals,Cross-sectional study evaluating the seroprevalence of SARS-CoV-2 antibodies among healthcare workers and factors associated with exposure during the first wave of the COVID-19 pandemic in New York.,2021-11-03,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"In order to be eligible for the study, participants needed 
to meet the following criteria:
1. Employed by NYC H+H and either (A) completed serological testing at NYC H+H or (B) completed SARS-CoV-2 antibody testing outside of NYC H+H and were able to self-report results.
2. 18 years of age or older.
3. Capable of providing consent to participate in the study, including English or Spanish fluency",No consent in English or Spanish,2020-04-30,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),21.0,34.0,Age,21-34,168,0.25,,,,,,,,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Alexander Bryan,New York City Health and hospitals,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2021-053158,2021-11-08,2022-07-16,Unverified,bryan_cross-sectional_2021,USA
211104_OrangeCounty_UniversityofCaliforniaIrvine_1_SantaAna_Multiplex,211104_OrangeCounty_UniversityofCaliforniaIrvine_1_SantaAna,Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccination.,2021-11-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,Santa Ana,Santa Ana residents,,2020-12-01,2020-12-30,Household and community samples,All,Multiple groups,,,Primary Estimate,COVAM seroprevalence prediction (multiplex test),3347,0.26,,,True,,,,True,Stratified probability,Author designed (Multiplex),,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,Yes,Yes,No,,Unclear,Yes,No,,Rafael Assis,University of California Irvine,Not Unity-Aligned,https://dx.doi.org/10.1038/s41541-021-00396-3,2021-11-18,2022-07-16,Unverified,assis_distinct_2021-1,USA
211104_OrangeCounty_UniversityofCaliforniaIrvine_1_SantaAna_Nucleocapsid,211104_OrangeCounty_UniversityofCaliforniaIrvine_1_SantaAna,Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccination.,2021-11-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,Santa Ana,Santa Ana residents,,2020-12-01,2020-12-30,Household and community samples,All,Multiple groups,,,Test used,Nucleocapsid only,3347,0.25,,,,,,,,Stratified probability,Author designed (Multiplex),,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,No,,Unclear,Yes,No,,Rafael Assis,University of California Irvine,Not Unity-Aligned,https://dx.doi.org/10.1038/s41541-021-00396-3,2021-11-18,2022-07-16,Unverified,assis_distinct_2021-1,USA
211104_OrangeCounty_UniversityofCaliforniaIrvine_2_HCW_May_Multiplex,211104_OrangeCounty_UniversityofCaliforniaIrvine_2_HCW_May,Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccination.,2021-11-04,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,California,Inrvine,Healthcare workers at the University of California Irvine Medical Center (UCIMC),,2020-05-01,2020-05-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,COVAM seroprevalence prediction (multiplex test),1060,0.04,,,True,,,,True,Convenience,Author designed (Multiplex),,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Rafael Assis,University of California Irvine,Not Unity-Aligned,https://dx.doi.org/10.1038/s41541-021-00396-3,2021-11-18,2022-07-16,Unverified,assis_distinct_2021-1,USA
211104_OrangeCounty_UniversityofCaliforniaIrvine_3_HCW_December_Multiplex,211104_OrangeCounty_UniversityofCaliforniaIrvine_3_HCW_December,Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccination.,2021-11-04,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,California,Irvine,Healthcare workers at the University of California Irvine Medical Center (UCIMC),,2020-12-01,2020-12-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,COVAM seroprevalence prediction (multiplex test),313,0.11,,,True,,,,True,Convenience,Author designed (Multiplex),,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Unclear,Yes,No,,Rafael Assis,University of California Irvine,Not Unity-Aligned,https://dx.doi.org/10.1038/s41541-021-00396-3,2021-11-18,2022-07-16,Unverified,assis_distinct_2021-1,USA
211104_Bronx_MontefioreMedicalCenter,211104_Bronx_MontefioreMedicalCenter,Prevalence and dynamics of SARS-CoV-2 nucleocapsid IGG in kidney transplant recipients,2021-11-04,Presentation or Conference,Local,Cross-sectional survey ,United States of America,New York,New York,"kidney transplant recipients in the Bronx, New York, one of the epicenters of the pandemic",,2021-05-03,2021-05-05,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,1164,0.171,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,IgG,,,,,['High'],,Unclear,Yes,No,,Unclear,Yes,No,,Yorg Azzi,Montefiore Medical Center,Not Unity-Aligned,http://dx.doi.org/10.1681/asn.2020030362,2021-11-10,2022-07-16,Unverified,yorg_al_azzi_prevalence_2021,USA
211108_Virginia_InovaHealthSystem,211108_Virginia_InovaHealthSystem,A cross-sectional investigation of SARS-CoV-2 seroprevalence and associated risk factors in children and adolescents in the United States.,2021-11-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Virginia,, Inclusion criteria were ≤19 years and residence in Virginia. Only one individual per household could enroll.,Exclusion criteria included receipt of immunoglobulin therapy within the past 11 months.,2020-07-31,2020-10-13,Multiple general populations,All,Children and Youth (0-17 years),0.0,19.0,Primary Estimate,,1038,0.085,0.069,0.10300000000000001,True,,,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Rebecca Levorson,Inova Health System,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0259823,2021-11-15,2024-03-01,Verified,levorson_cross-sectional_2021,USA
211108_Virginia_InovaHealthSystem_Age0-5,211108_Virginia_InovaHealthSystem,A cross-sectional investigation of SARS-CoV-2 seroprevalence and associated risk factors in children and adolescents in the United States.,2021-11-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Virginia,, Inclusion criteria were ≤19 years and residence in Virginia. Only one individual per household could enroll.,Exclusion criteria included receipt of immunoglobulin therapy within the past 11 months.,2020-07-31,2020-10-13,Multiple general populations,All,Children and Youth (0-17 years),0.0,5.0,Age,0-5,182,0.13699999999999998,0.095,0.195,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Rebecca Levorson,Inova Health System,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0259823,2021-11-15,2024-03-01,Verified,levorson_cross-sectional_2021,USA
211108_Virginia_InovaHealthSystem_Age11-15,211108_Virginia_InovaHealthSystem,A cross-sectional investigation of SARS-CoV-2 seroprevalence and associated risk factors in children and adolescents in the United States.,2021-11-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Virginia,, Inclusion criteria were ≤19 years and residence in Virginia. Only one individual per household could enroll.,Exclusion criteria included receipt of immunoglobulin therapy within the past 11 months.,2020-07-31,2020-10-13,Multiple general populations,All,Children and Youth (0-17 years),11.0,15.0,Age,11-15,374,0.051,0.033,0.078,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Rebecca Levorson,Inova Health System,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0259823,2021-11-15,2024-03-01,Verified,levorson_cross-sectional_2021,USA
211108_Virginia_InovaHealthSystem_SexFemale,211108_Virginia_InovaHealthSystem,A cross-sectional investigation of SARS-CoV-2 seroprevalence and associated risk factors in children and adolescents in the United States.,2021-11-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Virginia,, Inclusion criteria were ≤19 years and residence in Virginia. Only one individual per household could enroll.,Exclusion criteria included receipt of immunoglobulin therapy within the past 11 months.,2020-07-31,2020-10-13,Multiple general populations,Female,Children and Youth (0-17 years),0.0,19.0,Sex/Gender,,536,0.086,0.065,0.113,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Rebecca Levorson,Inova Health System,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0259823,2021-11-15,2024-03-01,Verified,levorson_cross-sectional_2021,USA
211108_Virginia_InovaHealthSystem_Age6-10,211108_Virginia_InovaHealthSystem,A cross-sectional investigation of SARS-CoV-2 seroprevalence and associated risk factors in children and adolescents in the United States.,2021-11-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Virginia,, Inclusion criteria were ≤19 years and residence in Virginia. Only one individual per household could enroll.,Exclusion criteria included receipt of immunoglobulin therapy within the past 11 months.,2020-07-31,2020-10-13,Multiple general populations,All,Children and Youth (0-17 years),6.0,10.0,Age,6-10,241,0.075,0.048,0.115,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Rebecca Levorson,Inova Health System,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0259823,2021-11-15,2024-03-01,Verified,levorson_cross-sectional_2021,USA
211108_Virginia_InovaHealthSystem_SexMale,211108_Virginia_InovaHealthSystem,A cross-sectional investigation of SARS-CoV-2 seroprevalence and associated risk factors in children and adolescents in the United States.,2021-11-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Virginia,, Inclusion criteria were ≤19 years and residence in Virginia. Only one individual per household could enroll.,Exclusion criteria included receipt of immunoglobulin therapy within the past 11 months.,2020-07-31,2020-10-13,Multiple general populations,Male,Children and Youth (0-17 years),0.0,19.0,Sex/Gender,,499,0.084,0.063,0.11199999999999999,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Rebecca Levorson,Inova Health System,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0259823,2021-11-15,2024-03-01,Verified,levorson_cross-sectional_2021,USA
211108_Virginia_InovaHealthSystem_Age16-19,211108_Virginia_InovaHealthSystem,A cross-sectional investigation of SARS-CoV-2 seroprevalence and associated risk factors in children and adolescents in the United States.,2021-11-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Virginia,, Inclusion criteria were ≤19 years and residence in Virginia. Only one individual per household could enroll.,Exclusion criteria included receipt of immunoglobulin therapy within the past 11 months.,2020-07-31,2020-10-13,Multiple general populations,All,Multiple groups,16.0,19.0,Age,16-19,241,0.10800000000000001,0.075,0.153,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Rebecca Levorson,Inova Health System,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0259823,2021-11-15,2024-03-01,Verified,levorson_cross-sectional_2021,USA
211021_EssexCounty_RutgersUniversity_Overall,211021_EssexCounty_RutgersUniversity,"Prevalence and Correlates of SARS CoV-2 Among a Community-Based Sample Recruited Using Randomized Venue-Based Sampling. Essex County, NJ, 2020.",2021-11-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New Jersey,,members of the community in Essex County,,2020-09-15,2020-12-22,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,924,0.0898,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Henry Raymond,Rutgers University,Not Unity-Aligned,https://dx.doi.org/10.1007/s40615-021-01175-5,2021-11-17,2022-07-16,Verified,raymond_prevalence_2021,USA
211021_EssexCounty_RutgersUniversity_Age18-21,211021_EssexCounty_RutgersUniversity,"Prevalence and Correlates of SARS CoV-2 Among a Community-Based Sample Recruited Using Randomized Venue-Based Sampling. Essex County, NJ, 2020.",2021-11-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New Jersey,,members of the community in Essex County,,2020-09-15,2020-12-22,Household and community samples,All,Adults (18-64 years),18.0,21.0,Age,18-21,63,0.1905,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Henry Raymond,Rutgers University,Not Unity-Aligned,https://dx.doi.org/10.1007/s40615-021-01175-5,2021-11-17,2022-07-16,Verified,raymond_prevalence_2021,USA
211021_EssexCounty_RutgersUniversity_Age40-49,211021_EssexCounty_RutgersUniversity,"Prevalence and Correlates of SARS CoV-2 Among a Community-Based Sample Recruited Using Randomized Venue-Based Sampling. Essex County, NJ, 2020.",2021-11-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New Jersey,,members of the community in Essex County,,2020-09-15,2020-12-22,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,,185,0.0541,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Henry Raymond,Rutgers University,Not Unity-Aligned,https://dx.doi.org/10.1007/s40615-021-01175-5,2021-11-17,2022-07-16,Verified,raymond_prevalence_2021,USA
211021_EssexCounty_RutgersUniversity_Female,211021_EssexCounty_RutgersUniversity,"Prevalence and Correlates of SARS CoV-2 Among a Community-Based Sample Recruited Using Randomized Venue-Based Sampling. Essex County, NJ, 2020.",2021-11-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New Jersey,,members of the community in Essex County,,2020-09-15,2020-12-22,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,340,0.10289999999999999,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Henry Raymond,Rutgers University,Not Unity-Aligned,https://dx.doi.org/10.1007/s40615-021-01175-5,2021-11-17,2022-07-16,Verified,raymond_prevalence_2021,USA
211021_EssexCounty_RutgersUniversity_Age22-29,211021_EssexCounty_RutgersUniversity,"Prevalence and Correlates of SARS CoV-2 Among a Community-Based Sample Recruited Using Randomized Venue-Based Sampling. Essex County, NJ, 2020.",2021-11-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New Jersey,,members of the community in Essex County,,2020-09-15,2020-12-22,Household and community samples,All,Adults (18-64 years),22.0,29.0,Age,22-29,111,0.045,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Henry Raymond,Rutgers University,Not Unity-Aligned,https://dx.doi.org/10.1007/s40615-021-01175-5,2021-11-17,2022-07-16,Verified,raymond_prevalence_2021,USA
211021_EssexCounty_RutgersUniversity_Male,211021_EssexCounty_RutgersUniversity,"Prevalence and Correlates of SARS CoV-2 Among a Community-Based Sample Recruited Using Randomized Venue-Based Sampling. Essex County, NJ, 2020.",2021-11-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New Jersey,,members of the community in Essex County,,2020-09-15,2020-12-22,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,584,0.08220000000000001,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Henry Raymond,Rutgers University,Not Unity-Aligned,https://dx.doi.org/10.1007/s40615-021-01175-5,2021-11-17,2022-07-16,Verified,raymond_prevalence_2021,USA
211021_EssexCounty_RutgersUniversity_Age50+,211021_EssexCounty_RutgersUniversity,"Prevalence and Correlates of SARS CoV-2 Among a Community-Based Sample Recruited Using Randomized Venue-Based Sampling. Essex County, NJ, 2020.",2021-11-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New Jersey,,members of the community in Essex County,,2020-09-15,2020-12-22,Household and community samples,All,Multiple groups,50.0,,Age,50+,408,0.0882,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Henry Raymond,Rutgers University,Not Unity-Aligned,https://dx.doi.org/10.1007/s40615-021-01175-5,2021-11-17,2022-07-16,Verified,raymond_prevalence_2021,USA
211021_EssexCounty_RutgersUniversity_Age30-39,211021_EssexCounty_RutgersUniversity,"Prevalence and Correlates of SARS CoV-2 Among a Community-Based Sample Recruited Using Randomized Venue-Based Sampling. Essex County, NJ, 2020.",2021-11-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New Jersey,,members of the community in Essex County,,2020-09-15,2020-12-22,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,,157,0.1274,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Dried Blood,IgG,Spike,,,,['Moderate'],Yes,No,Yes,Yes,Yes,Unclear,Yes,No,Yes,Henry Raymond,Rutgers University,Not Unity-Aligned,https://dx.doi.org/10.1007/s40615-021-01175-5,2021-11-17,2022-07-16,Verified,raymond_prevalence_2021,USA
211109_Denver_CentersforDiseaseControlandPrevention_ClinicalResidualSera_Overall,211109_Denver_CentersforDiseaseControlandPrevention_ClinicalResidualSera,"Assessment of SARS-CoV-2 Seroprevalence by Community Survey and Residual Specimens, Denver, Colorado, July-August 2020.",2021-11-09,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Colorado,,"Of 1598 residual clinical sera tested from the Denver area, 462 (28.9%) were from residents of Denver County, 1102 (68.9%) were from 4 contiguous counties, and the remaining 34 (2.1%) were from other nearby counties.",,2020-07-22,2020-08-08,Residual sera,All,Multiple groups,,,Primary Estimate,,1598,0.068,0.05,0.092,True,,True,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.932,0.99,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Kiersten Kugeler,Centers for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1177/00333549211055137,2021-11-19,2024-03-01,Verified,kugeler_assessment_2021,USA
211109_Denver_CentersforDiseaseControlandPrevention_ClinicalResidualSera_Sex_Female,211109_Denver_CentersforDiseaseControlandPrevention_ClinicalResidualSera,"Assessment of SARS-CoV-2 Seroprevalence by Community Survey and Residual Specimens, Denver, Colorado, July-August 2020.",2021-11-09,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Colorado,,"Of 1598 residual clinical sera tested from the Denver area, 462 (28.9%) were from residents of Denver County, 1102 (68.9%) were from 4 contiguous counties, and the remaining 34 (2.1%) were from other nearby counties.",,2020-07-22,2020-08-08,Residual sera,Female,Multiple groups,,,Sex/Gender,,673,0.062000000000000006,0.04,0.095,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.932,0.99,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Kiersten Kugeler,Centers for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1177/00333549211055137,2021-11-19,2024-03-01,Verified,kugeler_assessment_2021,USA
211109_Denver_CentersforDiseaseControlandPrevention_ClinicalResidualSera_Sex_Male,211109_Denver_CentersforDiseaseControlandPrevention_ClinicalResidualSera,"Assessment of SARS-CoV-2 Seroprevalence by Community Survey and Residual Specimens, Denver, Colorado, July-August 2020.",2021-11-09,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Colorado,,"Of 1598 residual clinical sera tested from the Denver area, 462 (28.9%) were from residents of Denver County, 1102 (68.9%) were from 4 contiguous counties, and the remaining 34 (2.1%) were from other nearby counties.",,2020-07-22,2020-08-08,Residual sera,Male,Multiple groups,,,Sex/Gender,,925,0.07400000000000001,0.047,0.113,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.932,0.99,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Kiersten Kugeler,Centers for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1177/00333549211055137,2021-11-19,2024-03-01,Verified,kugeler_assessment_2021,USA
211109_Denver_CentersforDiseaseControlandPrevention_ClinicalResidualSera_Age_>=65,211109_Denver_CentersforDiseaseControlandPrevention_ClinicalResidualSera,"Assessment of SARS-CoV-2 Seroprevalence by Community Survey and Residual Specimens, Denver, Colorado, July-August 2020.",2021-11-09,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Colorado,,"Of 1598 residual clinical sera tested from the Denver area, 462 (28.9%) were from residents of Denver County, 1102 (68.9%) were from 4 contiguous counties, and the remaining 34 (2.1%) were from other nearby counties.",,2020-07-22,2020-08-08,Residual sera,All,Seniors (65+ years),65.0,,Age,>=65,575,0.019,0.011000000000000001,0.034,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.932,0.99,['Moderate'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Kiersten Kugeler,Centers for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1177/00333549211055137,2021-11-19,2024-03-01,Verified,kugeler_assessment_2021,USA
211109_Denver_CentersforDiseaseControlandPrevention_CommunitySurvey_Overall,211109_Denver_CentersforDiseaseControlandPrevention_CommunitySurvey,"Assessment of SARS-CoV-2 Seroprevalence by Community Survey and Residual Specimens, Denver, Colorado, July-August 2020.",2021-11-09,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Colorado,Denver,Residents of Denver County (35 census blocks were used due to a method of cluster sampling). ,Excluded institutional settings such as long-term care and correctional facilities.,2020-07-22,2020-08-08,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,,381,0.08,0.039,0.157,True,,True,,True,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.932,0.99,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,No,Kiersten Kugeler,Centers for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1177/00333549211055137,2021-11-16,2024-03-01,Verified,kugeler_assessment_2021,USA
211109_Denver_CentersforDiseaseControlandPrevention_CommunitySurvey_Age_0-17,211109_Denver_CentersforDiseaseControlandPrevention_CommunitySurvey,"Assessment of SARS-CoV-2 Seroprevalence by Community Survey and Residual Specimens, Denver, Colorado, July-August 2020.",2021-11-09,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Colorado,Denver,Residents of Denver County (35 census blocks were used due to a method of cluster sampling). ,Excluded institutional settings such as long-term care and correctional facilities.,2020-07-22,2020-08-08,Household and community samples,All,Children and Youth (0-17 years),0.0,17.0,Age,0-17,21,0.131,0.042,0.344,,,True,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.932,0.99,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,No,Kiersten Kugeler,Centers for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1177/00333549211055137,2021-11-16,2024-03-01,Verified,kugeler_assessment_2021,USA
211109_Denver_CentersforDiseaseControlandPrevention_CommunitySurvey_Age_18-49,211109_Denver_CentersforDiseaseControlandPrevention_CommunitySurvey,"Assessment of SARS-CoV-2 Seroprevalence by Community Survey and Residual Specimens, Denver, Colorado, July-August 2020.",2021-11-09,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Colorado,Denver,Residents of Denver County (35 census blocks were used due to a method of cluster sampling). ,Excluded institutional settings such as long-term care and correctional facilities.,2020-07-22,2020-08-08,Household and community samples,All,Adults (18-64 years),18.0,49.0,Age,18-49,267,0.084,0.043,0.157,,,True,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.932,0.99,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,No,Kiersten Kugeler,Centers for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1177/00333549211055137,2021-11-16,2024-03-01,Verified,kugeler_assessment_2021,USA
211109_Denver_CentersforDiseaseControlandPrevention_CommunitySurvey_Age_>=65,211109_Denver_CentersforDiseaseControlandPrevention_CommunitySurvey,"Assessment of SARS-CoV-2 Seroprevalence by Community Survey and Residual Specimens, Denver, Colorado, July-August 2020.",2021-11-09,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Colorado,Denver,Residents of Denver County (35 census blocks were used due to a method of cluster sampling). ,Excluded institutional settings such as long-term care and correctional facilities.,2020-07-22,2020-08-08,Household and community samples,All,Seniors (65+ years),65.0,,Age,>=65,47,0.0,0.0,0.076,,,True,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.932,0.99,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,No,Kiersten Kugeler,Centers for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1177/00333549211055137,2021-11-16,2024-03-01,Verified,kugeler_assessment_2021,USA
211109_Denver_CentersforDiseaseControlandPrevention_CommunitySurvey_Sex_NonBinary,211109_Denver_CentersforDiseaseControlandPrevention_CommunitySurvey,"Assessment of SARS-CoV-2 Seroprevalence by Community Survey and Residual Specimens, Denver, Colorado, July-August 2020.",2021-11-09,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Colorado,Denver,Residents of Denver County (35 census blocks were used due to a method of cluster sampling). ,Excluded institutional settings such as long-term care and correctional facilities.,2020-07-22,2020-08-08,Household and community samples,Other,Multiple groups,,,Sex/Gender,Non-binary,1,0.0,,,,,,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.932,0.99,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,No,Kiersten Kugeler,Centers for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1177/00333549211055137,2021-11-16,2024-03-01,Verified,kugeler_assessment_2021,USA
211109_Denver_CentersforDiseaseControlandPrevention_CommunitySurvey_Sex_Male,211109_Denver_CentersforDiseaseControlandPrevention_CommunitySurvey,"Assessment of SARS-CoV-2 Seroprevalence by Community Survey and Residual Specimens, Denver, Colorado, July-August 2020.",2021-11-09,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Colorado,Denver,Residents of Denver County (35 census blocks were used due to a method of cluster sampling). ,Excluded institutional settings such as long-term care and correctional facilities.,2020-07-22,2020-08-08,Household and community samples,Male,Multiple groups,,,Sex/Gender,,189,0.12400000000000001,0.065,0.222,,,True,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.932,0.99,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,No,Kiersten Kugeler,Centers for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1177/00333549211055137,2021-11-16,2024-03-01,Verified,kugeler_assessment_2021,USA
211109_Denver_CentersforDiseaseControlandPrevention_CommunitySurvey_Age_50-64,211109_Denver_CentersforDiseaseControlandPrevention_CommunitySurvey,"Assessment of SARS-CoV-2 Seroprevalence by Community Survey and Residual Specimens, Denver, Colorado, July-August 2020.",2021-11-09,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Colorado,Denver,Residents of Denver County (35 census blocks were used due to a method of cluster sampling). ,Excluded institutional settings such as long-term care and correctional facilities.,2020-07-22,2020-08-08,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50-64,69,0.063,0.018000000000000002,0.19899999999999998,,,True,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.932,0.99,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,No,Kiersten Kugeler,Centers for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1177/00333549211055137,2021-11-16,2024-03-01,Verified,kugeler_assessment_2021,USA
211109_Denver_CentersforDiseaseControlandPrevention_CommunitySurvey_Sex_Female,211109_Denver_CentersforDiseaseControlandPrevention_CommunitySurvey,"Assessment of SARS-CoV-2 Seroprevalence by Community Survey and Residual Specimens, Denver, Colorado, July-August 2020.",2021-11-09,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Colorado,Denver,Residents of Denver County (35 census blocks were used due to a method of cluster sampling). ,Excluded institutional settings such as long-term care and correctional facilities.,2020-07-22,2020-08-08,Household and community samples,Female,Multiple groups,,,Sex/Gender,,214,0.036000000000000004,0.018000000000000002,0.071,,,True,,,Stratified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Plasma,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.932,0.99,['Moderate'],Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,No,Kiersten Kugeler,Centers for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1177/00333549211055137,2021-11-16,2024-03-01,Verified,kugeler_assessment_2021,USA
211110_PalmBeachCounty_FloridaDepartmentofHealth_overall,211110_PalmBeachCounty_FloridaDepartmentofHealth,SARS-CoV-2 Seroprevalence in Florida Department of Health in Palm Beach County Obstetric Clinics: A Cross-Sectional Study during the First Pandemic Surge.,2021-11-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Florida,"Lantana, West Palm Beach, Delray Beach, Belle Glade","registered obstetric patients presenting for either scheduled antenatal or postpartum ambulatory care at four clinics (Lantana, West Palm Beach, Delray Beach, and Belle Glade) in the Florida Department of Health in Palm Beach County health care system.
...
All patients who entered the clinics were screened by clinical symptomatology, and only those who were asymptomatic underwent antibody testing.",COVID-19 symptoms,2020-06-29,2020-08-05,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,618,0.264,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,1.0,0.996,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Charles Gonik,Wayne State University School of Medicine,Unity-Aligned,https://dx.doi.org/10.1055/s-0041-1739353,2021-12-01,2024-03-01,Unverified,gonik_sars-cov-2_2021,USA
211121_NewYorkCity_ IcahnSchoolofMedicine,211121_NewYorkCity_ IcahnSchoolofMedicine,SARS-CoV-2 during pregnancy and associated outcomes: Results from an ongoing prospective cohort.,2021-11-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,"The Generation C Study is an ongoing prospective cohort study conducted at the Mount Sinai Health System. All pregnant individuals receiving obstetrical care at the Mount Sinai Healthcare System from 20 April 2020 onwards are eligible for participation. For the current analysis, we included participants who had given birth to a liveborn singleton infant on or before 22 September 2020.

We only included individuals whose latest blood sample was collected during a second or third trimester prenatal visit or upon admission to labour and delivery to prevent misclassification of individuals as seronegative. ","For the current interim analysis, we focussed on participants who gave birth to a liveborn singleton infant on or before 22 September 2020; we excluded (from this interim analysis) participants with other outcomes (e.g., miscarriage, abortion, stillbirth) due to limited statistical power (n = 3)",2020-04-20,2020-09-22,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,708,0.16399999999999998,0.13699999999999998,0.193,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9500000000000001,1.0,['High'],No,No,Yes,No,Yes,Unclear,Yes,Yes,Unclear,Nina Molenaar, Icahn School of Medicine,Unity-Aligned,https://dx.doi.org/10.1111/ppe.12812,2021-12-02,2022-07-16,Verified,molenaar_sars-cov-2_2021,USA
211122_OrangeCounty_UniversityofCalifornia_Primary,211122_OrangeCounty_UniversityofCalifornia,Infection prevention strategies are highly protective in COVID-19 units while main risks to healthcare professionals come from coworkers and the community.,2021-11-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,"HCP at
an academic medical center in Orange County. All HCP assigned to designated COVID-19 units (3), hospital units that experienced a COVID-19 HCP outbreak,
defned as 2 or more HCP with epidemiologically linked
infections (3), and matched control units not designated
for COVID-19 care and without an active HCP outbreak
(3) during the study period. HCPs included those
involved in direct patient care (e.g. doctors, nurses, nursing assistants, physical/speech/respiratory therapists),
and those assigned for non-patient care duties (e.g. environmental services, pharmacy, dietary, social work, case
management). ",,2020-05-01,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,654,0.133,,,True,,,,True,Convenience,"Not reported/ Unable to specify,Diazyme DZ-Lite SARS-CoV-2 IgG  CLIA tests,Access SARS-CoV-2 IgG Reagent Antibody Test,Abbott Architect SARS-CoV-2 IgG","NA,Diazyme Laboratories Inc,Beckman Coulter,Abbott Laboratories",Multiple Types,,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Shruti Gohil,University of California,Not Unity-Aligned,https://dx.doi.org/10.1186/s13756-021-01031-5,2021-12-01,2024-03-01,Unverified,gohil_infection_2021,USA
211128_SanFrancisco_UniversityofCalifornia_Round1,211128_SanFrancisco_UniversityofCalifornia_Round1,Development and Implementation of Dried Blood Spot-based COVID-19 Serological Assays for Epidemiologic Studies,2021-11-28,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,California,,"In the screening phase, all residential addresses within the East Bay cities and communities of Albany, Berkeley, El Cerrito, El Sobrante, Emeryville, Hercules, Kensington, Oakland, Piedmont, Pinole, Richmond, and San Pablo (∼307,000 residential households) were mailed an invitation to participate. The household member aged 18 or older with the next birthday was invited to complete a consent form and screening questionnaire.

Eligible participants were required to be the household member with the next birthday, live within the study region, be willing to provide biospecimens (including DBS) and questionnaire responses, read and speak English or Spanish, and have internet access and a valid email address.",,2020-07-15,2020-09-15,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,4670,0.006,,,True,,,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Dried Blood,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.795,1.0,['Moderate'],Yes,No,Yes,No,No,Yes,Yes,No,Yes,Marcus Wong,University of California,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.25.21266786v1.full-text,2021-12-09,2024-03-01,Verified,wong_development_2021,USA
211128_SanFrancisco_UniversityofCalifornia_Round2,211128_SanFrancisco_UniversityofCalifornia_Round2,Development and Implementation of Dried Blood Spot-based COVID-19 Serological Assays for Epidemiologic Studies,2021-11-28,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,California,,"In the screening phase, all residential addresses within the East Bay cities and communities of Albany, Berkeley, El Cerrito, El Sobrante, Emeryville, Hercules, Kensington, Oakland, Piedmont, Pinole, Richmond, and San Pablo (∼307,000 residential households) were mailed an invitation to participate. The household member aged 18 or older with the next birthday was invited to complete a consent form and screening questionnaire.

Eligible participants were required to be the household member with the next birthday, live within the study region, be willing to provide biospecimens (including DBS) and questionnaire responses, read and speak English or Spanish, and have internet access and a valid email address.",,2020-10-15,2020-12-15,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,5308,0.006,,,True,,,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,Multiple Types,Dried Blood,"['IgG', 'TotalAntibody']",Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Yes,Marcus Wong,University of California,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.25.21266786v1.full-text,2021-12-09,2024-03-01,Verified,wong_development_2021,USA
211128_SanFrancisco_UniversityofCalifornia_Round3,211128_SanFrancisco_UniversityofCalifornia_Round3,Development and Implementation of Dried Blood Spot-based COVID-19 Serological Assays for Epidemiologic Studies,2021-11-28,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,California,,"In the screening phase, all residential addresses within the East Bay cities and communities of Albany, Berkeley, El Cerrito, El Sobrante, Emeryville, Hercules, Kensington, Oakland, Piedmont, Pinole, Richmond, and San Pablo (∼307,000 residential households) were mailed an invitation to participate. The household member aged 18 or older with the next birthday was invited to complete a consent form and screening questionnaire.

Eligible participants were required to be the household member with the next birthday, live within the study region, be willing to provide biospecimens (including DBS) and questionnaire responses, read and speak English or Spanish, and have internet access and a valid email address.",,2021-02-15,2021-04-15,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,4641,0.313,,,True,,,,True,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Author designed (ELISA) -Spike","Ortho Clinical Diagnostics Inc.,NA",Multiple Types,Dried Blood,"['IgG', 'TotalAntibody']",Spike,Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,Yes,Marcus Wong,University of California,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.25.21266786v1.full-text,2021-12-09,2024-03-01,Verified,wong_development_2021,USA
211128_SanFrancisco_UniversityofCalifornia_Round3_S+N,211128_SanFrancisco_UniversityofCalifornia_Round3,Development and Implementation of Dried Blood Spot-based COVID-19 Serological Assays for Epidemiologic Studies,2021-11-28,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,California,,"In the screening phase, all residential addresses within the East Bay cities and communities of Albany, Berkeley, El Cerrito, El Sobrante, Emeryville, Hercules, Kensington, Oakland, Piedmont, Pinole, Richmond, and San Pablo (∼307,000 residential households) were mailed an invitation to participate. The household member aged 18 or older with the next birthday was invited to complete a consent form and screening questionnaire.

Eligible participants were required to be the household member with the next birthday, live within the study region, be willing to provide biospecimens (including DBS) and questionnaire responses, read and speak English or Spanish, and have internet access and a valid email address.",,2021-02-15,2021-04-15,Household and community samples,All,Multiple groups,18.0,,Test used,,4641,0.018000000000000002,,,,,,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Author designed (ELISA) -Spike,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,NA,Roche Diagnostics",Multiple Types,Dried Blood,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,No,Yes,Marcus Wong,University of California,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.11.25.21266786v1.full-text,2021-12-09,2024-03-01,Verified,wong_development_2021,USA
211201_Louisiana_TulaneUniversity_Primary,211201_Louisiana_TulaneUniversity,SARS-CoV-2 seroprevalence rates of children seeking medical care in Louisiana during the state stay at home order.,2021-12-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Louisiana,New Orleans,""" Samples were from children ≤18 years of age who had blood drawn as part of their care in the hospital or ambulatory clinics. "" ",,2020-03-18,2020-05-15,Residual sera,All,Children and Youth (0-17 years),,18.0,Primary Estimate,,812,0.068,,,True,,,,True,Sequential,"Author designed (ELISA) -Spike,ReSARS CoV-2 (N) IgG ELISA","NA,Zalgen Labs",ELISA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Unclear,Unclear,Yes,No,,Monika Dietrich,Tulane University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcvp.2021.100047,2022-03-16,2022-07-16,Verified,dietrich_sars-cov-2_2021,USA
211202_Philadelphia_UniversityofPennsylvania_Overall,211202_Philadelphia_UniversityofPennsylvania,Evolution of SARS-CoV-2 Seroprevalence Among Employees of a United States Academic Children's Hospital During the COVID-19 Pandemic.,2021-12-02,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Pennsylvania,Philadelphia,"employees at Children’s Hospital of Philadelphia - includes the SARS-CoV-2 treatment unit, intensive care unit, emergency department and infectious diseases division, clinical work groups, employees providing on-campus non-healthcare services (environmental, nutritional, security, administrative, and research services)",,2020-04-20,2020-11-04,Health care workers and caregivers,All,Multiple groups,18.0,,Primary Estimate,,1740,0.053,,,True,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Brian T Fisher,University of Pennsylvania,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2021.487,2021-12-06,2024-03-01,Unverified,fisher_evolution_2021,USA
211202_Philadelphia_UniversityofPennsylvania_18-29,211202_Philadelphia_UniversityofPennsylvania,Evolution of SARS-CoV-2 Seroprevalence Among Employees of a United States Academic Children's Hospital During the COVID-19 Pandemic.,2021-12-02,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Pennsylvania,Philadelphia,"employees at Children’s Hospital of Philadelphia - includes the SARS-CoV-2 treatment unit, intensive care unit, emergency department and infectious diseases division, clinical work groups, employees providing on-campus non-healthcare services (environmental, nutritional, security, administrative, and research services)",,2020-04-20,2020-11-04,Health care workers and caregivers,All,Adults (18-64 years),18.0,29.0,Age,18-29,352,0.048,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Brian T Fisher,University of Pennsylvania,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2021.487,2021-12-06,2024-03-01,Unverified,fisher_evolution_2021,USA
211202_Philadelphia_UniversityofPennsylvania_30-39,211202_Philadelphia_UniversityofPennsylvania,Evolution of SARS-CoV-2 Seroprevalence Among Employees of a United States Academic Children's Hospital During the COVID-19 Pandemic.,2021-12-02,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Pennsylvania,Philadelphia,"employees at Children’s Hospital of Philadelphia - includes the SARS-CoV-2 treatment unit, intensive care unit, emergency department and infectious diseases division, clinical work groups, employees providing on-campus non-healthcare services (environmental, nutritional, security, administrative, and research services)",,2020-04-20,2020-11-04,Health care workers and caregivers,All,Adults (18-64 years),30.0,39.0,Age,30-39,645,0.055999999999999994,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Brian T Fisher,University of Pennsylvania,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2021.487,2021-12-06,2024-03-01,Unverified,fisher_evolution_2021,USA
211202_Philadelphia_UniversityofPennsylvania_40-49,211202_Philadelphia_UniversityofPennsylvania,Evolution of SARS-CoV-2 Seroprevalence Among Employees of a United States Academic Children's Hospital During the COVID-19 Pandemic.,2021-12-02,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Pennsylvania,Philadelphia,"employees at Children’s Hospital of Philadelphia - includes the SARS-CoV-2 treatment unit, intensive care unit, emergency department and infectious diseases division, clinical work groups, employees providing on-campus non-healthcare services (environmental, nutritional, security, administrative, and research services)",,2020-04-20,2020-11-04,Health care workers and caregivers,All,Adults (18-64 years),40.0,49.0,Age,40-49,344,0.044000000000000004,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Brian T Fisher,University of Pennsylvania,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2021.487,2021-12-06,2024-03-01,Unverified,fisher_evolution_2021,USA
211202_Philadelphia_UniversityofPennsylvania_50-59,211202_Philadelphia_UniversityofPennsylvania,Evolution of SARS-CoV-2 Seroprevalence Among Employees of a United States Academic Children's Hospital During the COVID-19 Pandemic.,2021-12-02,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Pennsylvania,Philadelphia,"employees at Children’s Hospital of Philadelphia - includes the SARS-CoV-2 treatment unit, intensive care unit, emergency department and infectious diseases division, clinical work groups, employees providing on-campus non-healthcare services (environmental, nutritional, security, administrative, and research services)",,2020-04-20,2020-11-04,Health care workers and caregivers,All,Adults (18-64 years),50.0,59.0,Age,50-59,261,0.069,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Brian T Fisher,University of Pennsylvania,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2021.487,2021-12-06,2024-03-01,Unverified,fisher_evolution_2021,USA
211202_Philadelphia_UniversityofPennsylvania_>60,211202_Philadelphia_UniversityofPennsylvania,Evolution of SARS-CoV-2 Seroprevalence Among Employees of a United States Academic Children's Hospital During the COVID-19 Pandemic.,2021-12-02,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Pennsylvania,Philadelphia,"employees at Children’s Hospital of Philadelphia - includes the SARS-CoV-2 treatment unit, intensive care unit, emergency department and infectious diseases division, clinical work groups, employees providing on-campus non-healthcare services (environmental, nutritional, security, administrative, and research services)",,2020-04-20,2020-11-04,Health care workers and caregivers,All,Multiple groups,60.0,,Age,>60,131,0.046,,,,,,,,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Brian T Fisher,University of Pennsylvania,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2021.487,2021-12-06,2024-03-01,Unverified,fisher_evolution_2021,USA
211204_Atlanta_EmoryUniversitySchoolofMedicine_Overall,211204_Atlanta_EmoryUniversitySchoolofMedicine,"Estimating SARS-CoV-2 Seroprevalence from Spent Blood Samples, January-March 2021",2021-12-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Georgia,Atlanta,"Blood samples collected for clinical testing and then discarded (""spent
samples"") were obtained from the clinical laboratory of a medical center in Atlanta.
A convenience sample of spent samples from both inpatients (medical/surgical floors, intensive care, obstetrics) and outpatients (clinics and ambulatory surgery) were collected.",,2021-01-15,2021-03-15,Blood donors,All,Multiple groups,,,Primary Estimate,,2406,0.17,,,True,,,,True,Convenience,"Author designed (ELISA) - Nucleocapsid,Author designed (ELISA) -Spike",,,,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Daniel Graciaa,Emory University,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab466.572,2022-03-22,2022-07-16,Unverified,graciaa_371_2021,USA
211204_LA_UCLAMedicalCenter_Primary,211204_LA_UCLAMedicalCenter,Predictors of Seropositivity to SARS-CoV-2 among Workforce Members at a Large Urban Medical Center,2021-12-04,Presentation or Conference,Local,Cross-sectional survey ,United States of America,California,,all Los Angeles County-Univ. of Southern California Medical Center (LAC+USC) workforce members (clinical and non-clinical) via repeated email blasts,individuals failed to complete the questionnaire ,2020-09-15,2020-12-15,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,1273,0.047,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Evelyn A Flores,UCLA Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab466.588,2022-03-22,2024-03-01,Unverified,flores_predictors_2021,USA
211204_Seattle_UniversityOfWashington_Primary,211204_Seattle_UniversityOfWashington,"SARS-CoV-2 Seroprevalence and Antibody Response among Pregnant People in Seattle, WA",2021-12-04,Presentation or Conference,Local,Cross-sectional survey ,United States of America,"Washington
","Seattle
","Pregnant people were screened for SARS-CoV-2 IgG during antenatal care or delivery in Seattle, Washington. Participants with IgG+ results or identified with RT-PCR+ results via medical records were invited to enroll in a longitudinal evaluation of antibody responses. ",,2020-09-09,2021-05-07,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,1304,0.048,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Sylvia LaCourse,University of Washington,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab466.688,2022-03-22,2024-03-01,Verified,lacourse_sars-cov-2_2021,USA
211204_Seattle_UniversityOfWashington_AmericanIndian/AlaskaNative,211204_Seattle_UniversityOfWashington,"SARS-CoV-2 Seroprevalence and Antibody Response among Pregnant People in Seattle, WA",2021-12-04,Presentation or Conference,Local,Cross-sectional survey ,United States of America,"Washington
","Seattle
","Pregnant people were screened for SARS-CoV-2 IgG during antenatal care or delivery in Seattle, Washington. Participants with IgG+ results or identified with RT-PCR+ results via medical records were invited to enroll in a longitudinal evaluation of antibody responses. ",,2020-09-09,2021-05-07,Pregnant or parturient women,Female,Adults (18-64 years),,,Race,American Indian or Alaska Native,17,0.1176470588,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Sylvia LaCourse,University of Washington,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab466.688,2022-05-26,2024-03-01,Verified,lacourse_sars-cov-2_2021,USA
211204_Seattle_UniversityOfWashington_Hispanic,211204_Seattle_UniversityOfWashington,"SARS-CoV-2 Seroprevalence and Antibody Response among Pregnant People in Seattle, WA",2021-12-04,Presentation or Conference,Local,Cross-sectional survey ,United States of America,"Washington
","Seattle
","Pregnant people were screened for SARS-CoV-2 IgG during antenatal care or delivery in Seattle, Washington. Participants with IgG+ results or identified with RT-PCR+ results via medical records were invited to enroll in a longitudinal evaluation of antibody responses. ",,2020-09-09,2021-05-07,Pregnant or parturient women,Female,Adults (18-64 years),,,Ethnicity,,137,0.13868613140000002,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Sylvia LaCourse,University of Washington,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab466.688,2022-05-26,2024-03-01,Verified,lacourse_sars-cov-2_2021,USA
211204_Seattle_UniversityOfWashington_NonHispanic,211204_Seattle_UniversityOfWashington,"SARS-CoV-2 Seroprevalence and Antibody Response among Pregnant People in Seattle, WA",2021-12-04,Presentation or Conference,Local,Cross-sectional survey ,United States of America,"Washington
","Seattle
","Pregnant people were screened for SARS-CoV-2 IgG during antenatal care or delivery in Seattle, Washington. Participants with IgG+ results or identified with RT-PCR+ results via medical records were invited to enroll in a longitudinal evaluation of antibody responses. ",,2020-09-09,2021-05-07,Pregnant or parturient women,Female,Adults (18-64 years),,,Ethnicity,,1255,0.04860557769,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Sylvia LaCourse,University of Washington,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab466.688,2022-05-26,2024-03-01,Verified,lacourse_sars-cov-2_2021,USA
211204_Seattle_UniversityOfWashington_NativeHawaiian/PacificIslander,211204_Seattle_UniversityOfWashington,"SARS-CoV-2 Seroprevalence and Antibody Response among Pregnant People in Seattle, WA",2021-12-04,Presentation or Conference,Local,Cross-sectional survey ,United States of America,"Washington
","Seattle
","Pregnant people were screened for SARS-CoV-2 IgG during antenatal care or delivery in Seattle, Washington. Participants with IgG+ results or identified with RT-PCR+ results via medical records were invited to enroll in a longitudinal evaluation of antibody responses. ",,2020-09-09,2021-05-07,Pregnant or parturient women,Female,Adults (18-64 years),,,Race,Native Hawaiian/Pacific Islander,27,0.1481481481,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Sylvia LaCourse,University of Washington,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab466.688,2022-05-26,2024-03-01,Verified,lacourse_sars-cov-2_2021,USA
211204_Seattle_UniversityOfWashington_Black,211204_Seattle_UniversityOfWashington,"SARS-CoV-2 Seroprevalence and Antibody Response among Pregnant People in Seattle, WA",2021-12-04,Presentation or Conference,Local,Cross-sectional survey ,United States of America,"Washington
","Seattle
","Pregnant people were screened for SARS-CoV-2 IgG during antenatal care or delivery in Seattle, Washington. Participants with IgG+ results or identified with RT-PCR+ results via medical records were invited to enroll in a longitudinal evaluation of antibody responses. ",,2020-09-09,2021-05-07,Pregnant or parturient women,Female,Adults (18-64 years),,,Race,Black,100,0.13,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Sylvia LaCourse,University of Washington,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab466.688,2022-05-26,2024-03-01,Verified,lacourse_sars-cov-2_2021,USA
211204_Seattle_UniversityOfWashington_White,211204_Seattle_UniversityOfWashington,"SARS-CoV-2 Seroprevalence and Antibody Response among Pregnant People in Seattle, WA",2021-12-04,Presentation or Conference,Local,Cross-sectional survey ,United States of America,"Washington
","Seattle
","Pregnant people were screened for SARS-CoV-2 IgG during antenatal care or delivery in Seattle, Washington. Participants with IgG+ results or identified with RT-PCR+ results via medical records were invited to enroll in a longitudinal evaluation of antibody responses. ",,2020-09-09,2021-05-07,Pregnant or parturient women,Female,Adults (18-64 years),,,Race,White,732,0.02595628415,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Sylvia LaCourse,University of Washington,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab466.688,2022-05-26,2024-03-01,Verified,lacourse_sars-cov-2_2021,USA
211204_Seattle_UniversityOfWashington_Asian,211204_Seattle_UniversityOfWashington,"SARS-CoV-2 Seroprevalence and Antibody Response among Pregnant People in Seattle, WA",2021-12-04,Presentation or Conference,Local,Cross-sectional survey ,United States of America,"Washington
","Seattle
","Pregnant people were screened for SARS-CoV-2 IgG during antenatal care or delivery in Seattle, Washington. Participants with IgG+ results or identified with RT-PCR+ results via medical records were invited to enroll in a longitudinal evaluation of antibody responses. ",,2020-09-09,2021-05-07,Pregnant or parturient women,Female,Adults (18-64 years),,,Race,Asian,265,0.01509433962,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Nucleocapsid(N-protein),,,,['Moderate'],No,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,Sylvia LaCourse,University of Washington,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab466.688,2022-05-26,2024-03-01,Verified,lacourse_sars-cov-2_2021,USA
211204_Annapolis_InfectiousDiseaseClinicalResearchProgram_Baseline_DBS,211204_Annapolis_InfectiousDiseaseClinicalResearchProgram_Baseline,TOSCANA: The Observational Seroepidemiologic Study of COVID-19 at the United States Naval Academy,2021-12-04,Presentation or Conference,Local,Prospective cohort,United States of America,Maryland,Annapolis,"Midshipmen at the United States Naval Academy (USNA), who consented to the study.",,2020-08-15,2020-10-15,Students and Daycares,All,Adults (18-64 years),,,Primary Estimate,Dried blood spot specimen,97,0.1753,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,Dried Blood,IgG,,,,,['High'],,Unclear,No,No,,Unclear,Yes,No,,Eugene Millar,Infectious Disease Clinical Research Program,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab466.1534,2022-03-22,2022-07-16,Unverified,millar_1342_2021,USA
211204_Annapolis_InfectiousDiseaseClinicalResearchProgram_Followup1_DBS,211204_Annapolis_InfectiousDiseaseClinicalResearchProgram_Followup1,TOSCANA: The Observational Seroepidemiologic Study of COVID-19 at the United States Naval Academy,2021-12-04,Presentation or Conference,Local,Prospective cohort,United States of America,Maryland,Annapolis,"Midshipmen at the United States Naval Academy (USNA), who consented to the study.",,2020-12-01,2020-12-31,Students and Daycares,All,Adults (18-64 years),,,Primary Estimate,Dried blood spot specimen,61,0.26230000000000003,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,Dried Blood,IgG,,,,,['High'],,Unclear,No,No,,Unclear,Yes,No,,Eugene Millar,Infectious Disease Clinical Research Program,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab466.1534,2022-03-22,2022-07-16,Unverified,millar_1342_2021,USA
211204_Annapolis_InfectiousDiseaseClinicalResearchProgram_Followup2_DBS,211204_Annapolis_InfectiousDiseaseClinicalResearchProgram_Followup2,TOSCANA: The Observational Seroepidemiologic Study of COVID-19 at the United States Naval Academy,2021-12-04,Presentation or Conference,Local,Prospective cohort,United States of America,Maryland,Annapolis,"Midshipmen at the United States Naval Academy (USNA), who consented to the study.",,2021-05-01,2021-05-31,Students and Daycares,All,Adults (18-64 years),,,Primary Estimate,Dried blood spot specimen,63,1.0,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,Dried Blood,IgG,,,,,['High'],,Unclear,No,No,,Unclear,Yes,No,,Eugene Millar,Infectious Disease Clinical Research Program,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofab466.1534,2022-03-22,2022-07-16,Unverified,millar_1342_2021,USA
211205_CaliforniaBayArea_UniversityofCalifornia_Round1_primary,211205_CaliforniaBayArea_UniversityofCalifornia_Round1,Impact of individual-level characteristics and transmission mitigation behaviors on SARS-CoV-2 infection and seroprevalence in a large Northern California Bay Area cohort,2021-12-05,Preprint,Regional,Prospective cohort,United States of America,California,,"all residential addresses within the East Bay cities and communities of Albany, Berkeley, El Cerrito, El Sobrante, Emeryville, Hercules, Kensington, Oakland, Piedmont, Pinole, Richmond, and San Pablo (∼307,000 residential households).

 In a household, the individual aged 18 years or older with the next birthday was eligible to participate. Additional eligibility criteria included living within the study region, willingness to provide biospecimens and questionnaire responses, ability to read and speak English or Spanish, and having internet access and an email address.",Did not provide biospecimen,2020-07-04,2020-09-01,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,4760,0.0063,0.0004,0.02,True,True,True,,,Stratified non-probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Dried Blood,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.8059999999999999,1.0,['Moderate'],No,No,Yes,No,No,Yes,Yes,Yes,Yes,Cameron Adams,"University of California, Berkeley",Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.12.02.21266871v1.full-text,2021-12-16,2023-08-15,Verified,adams_impact_2021,USA
211205_CaliforniaBayArea_UniversityofCalifornia_Round1_popadj,211205_CaliforniaBayArea_UniversityofCalifornia_Round1,Impact of individual-level characteristics and transmission mitigation behaviors on SARS-CoV-2 infection and seroprevalence in a large Northern California Bay Area cohort,2021-12-05,Preprint,Regional,Prospective cohort,United States of America,California,,"all residential addresses within the East Bay cities and communities of Albany, Berkeley, El Cerrito, El Sobrante, Emeryville, Hercules, Kensington, Oakland, Piedmont, Pinole, Richmond, and San Pablo (∼307,000 residential households).

 In a household, the individual aged 18 years or older with the next birthday was eligible to participate. Additional eligibility criteria included living within the study region, willingness to provide biospecimens and questionnaire responses, ability to read and speak English or Spanish, and having internet access and an email address.",Did not provide biospecimen,2020-07-04,2020-09-01,Household and community samples,All,Multiple groups,18.0,,Analysis,Population adjusted,4760,0.0103,0.005,0.0196,,,True,,True,Stratified non-probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Dried Blood,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.8059999999999999,1.0,['Moderate'],No,No,Yes,No,No,Yes,Yes,Yes,Yes,Cameron Adams,"University of California, Berkeley",Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.12.02.21266871v1.full-text,2021-12-16,2024-03-01,Verified,adams_impact_2021,USA
211205_CaliforniaBayArea_UniversityofCalifornia_Round1_unadj,211205_CaliforniaBayArea_UniversityofCalifornia_Round1,Impact of individual-level characteristics and transmission mitigation behaviors on SARS-CoV-2 infection and seroprevalence in a large Northern California Bay Area cohort,2021-12-05,Preprint,Regional,Prospective cohort,United States of America,California,,"all residential addresses within the East Bay cities and communities of Albany, Berkeley, El Cerrito, El Sobrante, Emeryville, Hercules, Kensington, Oakland, Piedmont, Pinole, Richmond, and San Pablo (∼307,000 residential households).

 In a household, the individual aged 18 years or older with the next birthday was eligible to participate. Additional eligibility criteria included living within the study region, willingness to provide biospecimens and questionnaire responses, ability to read and speak English or Spanish, and having internet access and an email address.",Did not provide biospecimen,2020-07-04,2020-09-01,Household and community samples,All,Multiple groups,18.0,,Analysis,Unadjusted,4760,0.0062,,,,,,,,Stratified non-probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Dried Blood,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.8059999999999999,1.0,['Moderate'],No,No,Yes,No,No,Yes,Yes,Yes,Yes,Cameron Adams,"University of California, Berkeley",Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.12.02.21266871v1.full-text,2021-12-16,2024-03-01,Verified,adams_impact_2021,USA
211205_CaliforniaBayArea_UniversityofCalifornia_Round2_primary,211205_CaliforniaBayArea_UniversityofCalifornia_Round2,Impact of individual-level characteristics and transmission mitigation behaviors on SARS-CoV-2 infection and seroprevalence in a large Northern California Bay Area cohort,2021-12-05,Preprint,Regional,Prospective cohort,United States of America,California,,"all residential addresses within the East Bay cities and communities of Albany, Berkeley, El Cerrito, El Sobrante, Emeryville, Hercules, Kensington, Oakland, Piedmont, Pinole, Richmond, and San Pablo (∼307,000 residential households).

 In a household, the individual aged 18 years or older with the next birthday was eligible to participate. Additional eligibility criteria included living within the study region, willingness to provide biospecimens and questionnaire responses, ability to read and speak English or Spanish, and having internet access and an email address.",Did not provide biospecimen,2020-10-10,2020-12-16,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,5949,0.0102,0.0017000000000000001,0.024,True,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Author designed (ELISA) -Spike","Ortho Clinical Diagnostics Inc.,NA",Multiple Types,Dried Blood,"['IgG', 'TotalAntibody']",Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,No,No,Unclear,Yes,Yes,Yes,Cameron Adams,"University of California, Berkeley",Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.12.02.21266871v1.full-text,2021-12-16,2023-08-15,Verified,adams_impact_2021,USA
211205_CaliforniaBayArea_UniversityofCalifornia_Round2_popadj,211205_CaliforniaBayArea_UniversityofCalifornia_Round2,Impact of individual-level characteristics and transmission mitigation behaviors on SARS-CoV-2 infection and seroprevalence in a large Northern California Bay Area cohort,2021-12-05,Preprint,Regional,Prospective cohort,United States of America,California,,"all residential addresses within the East Bay cities and communities of Albany, Berkeley, El Cerrito, El Sobrante, Emeryville, Hercules, Kensington, Oakland, Piedmont, Pinole, Richmond, and San Pablo (∼307,000 residential households).

 In a household, the individual aged 18 years or older with the next birthday was eligible to participate. Additional eligibility criteria included living within the study region, willingness to provide biospecimens and questionnaire responses, ability to read and speak English or Spanish, and having internet access and an email address.",Did not provide biospecimen,2020-10-10,2020-12-16,Household and community samples,All,Multiple groups,18.0,,Analysis,Population adjusted,5949,0.013700000000000002,0.0075,0.0239,,,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Author designed (ELISA) -Spike","Ortho Clinical Diagnostics Inc.,NA",Multiple Types,Dried Blood,"['IgG', 'TotalAntibody']",Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,No,No,Unclear,Yes,Yes,Yes,Cameron Adams,"University of California, Berkeley",Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.12.02.21266871v1.full-text,2021-12-16,2024-03-01,Verified,adams_impact_2021,USA
211205_CaliforniaBayArea_UniversityofCalifornia_Round2_unadj,211205_CaliforniaBayArea_UniversityofCalifornia_Round2,Impact of individual-level characteristics and transmission mitigation behaviors on SARS-CoV-2 infection and seroprevalence in a large Northern California Bay Area cohort,2021-12-05,Preprint,Regional,Prospective cohort,United States of America,California,,"all residential addresses within the East Bay cities and communities of Albany, Berkeley, El Cerrito, El Sobrante, Emeryville, Hercules, Kensington, Oakland, Piedmont, Pinole, Richmond, and San Pablo (∼307,000 residential households).

 In a household, the individual aged 18 years or older with the next birthday was eligible to participate. Additional eligibility criteria included living within the study region, willingness to provide biospecimens and questionnaire responses, ability to read and speak English or Spanish, and having internet access and an email address.",Did not provide biospecimen,2020-10-10,2020-12-16,Household and community samples,All,Multiple groups,18.0,,Analysis,Unadjusted,5949,0.008100000000000001,,,,,,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Author designed (ELISA) -Spike","Ortho Clinical Diagnostics Inc.,NA",Multiple Types,Dried Blood,"['IgG', 'TotalAntibody']",Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,No,No,Unclear,Yes,Yes,Yes,Cameron Adams,"University of California, Berkeley",Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.12.02.21266871v1.full-text,2021-12-16,2024-03-01,Verified,adams_impact_2021,USA
211205_CaliforniaBayArea_UniversityofCalifornia_Round3_primary,211205_CaliforniaBayArea_UniversityofCalifornia_Round3,Impact of individual-level characteristics and transmission mitigation behaviors on SARS-CoV-2 infection and seroprevalence in a large Northern California Bay Area cohort,2021-12-05,Preprint,Regional,Prospective cohort,United States of America,California,,"all residential addresses within the East Bay cities and communities of Albany, Berkeley, El Cerrito, El Sobrante, Emeryville, Hercules, Kensington, Oakland, Piedmont, Pinole, Richmond, and San Pablo (∼307,000 residential households).

 In a household, the individual aged 18 years or older with the next birthday was eligible to participate. Additional eligibility criteria included living within the study region, willingness to provide biospecimens and questionnaire responses, ability to read and speak English or Spanish, and having internet access and an email address.",Did not provide biospecimen,2021-02-11,2021-03-20,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,4608,0.2756,0.2284,0.33549999999999996,True,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Author designed (ELISA) -Spike","Ortho Clinical Diagnostics Inc.,NA",Multiple Types,Dried Blood,"['IgG', 'TotalAntibody']",Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,No,No,Unclear,Yes,Yes,Yes,Cameron Adams,"University of California, Berkeley",Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.12.02.21266871v1.full-text,2021-12-16,2023-08-15,Verified,adams_impact_2021,USA
211205_CaliforniaBayArea_UniversityofCalifornia_Round3_NaturalInfection_PopAdj,211205_CaliforniaBayArea_UniversityofCalifornia_Round3,Impact of individual-level characteristics and transmission mitigation behaviors on SARS-CoV-2 infection and seroprevalence in a large Northern California Bay Area cohort,2021-12-05,Preprint,Regional,Prospective cohort,United States of America,California,,"all residential addresses within the East Bay cities and communities of Albany, Berkeley, El Cerrito, El Sobrante, Emeryville, Hercules, Kensington, Oakland, Piedmont, Pinole, Richmond, and San Pablo (∼307,000 residential households).

 In a household, the individual aged 18 years or older with the next birthday was eligible to participate. Additional eligibility criteria included living within the study region, willingness to provide biospecimens and questionnaire responses, ability to read and speak English or Spanish, and having internet access and an email address.",Did not provide biospecimen,2021-02-11,2021-03-20,Household and community samples,All,Multiple groups,18.0,,Test used,Roche Anti-N Test ,5991,0.021800000000000003,0.0148,0.0317,,True,True,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Dried Blood,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,No,No,Unclear,Yes,Yes,Yes,Cameron Adams,"University of California, Berkeley",Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.12.02.21266871v1.full-text,2021-12-16,2023-08-15,Verified,adams_impact_2021,USA
211205_CaliforniaBayArea_UniversityofCalifornia_Round3_popadj,211205_CaliforniaBayArea_UniversityofCalifornia_Round3,Impact of individual-level characteristics and transmission mitigation behaviors on SARS-CoV-2 infection and seroprevalence in a large Northern California Bay Area cohort,2021-12-05,Preprint,Regional,Prospective cohort,United States of America,California,,"all residential addresses within the East Bay cities and communities of Albany, Berkeley, El Cerrito, El Sobrante, Emeryville, Hercules, Kensington, Oakland, Piedmont, Pinole, Richmond, and San Pablo (∼307,000 residential households).

 In a household, the individual aged 18 years or older with the next birthday was eligible to participate. Additional eligibility criteria included living within the study region, willingness to provide biospecimens and questionnaire responses, ability to read and speak English or Spanish, and having internet access and an email address.",Did not provide biospecimen,2021-02-11,2021-03-20,Household and community samples,All,Multiple groups,18.0,,Analysis,Population adjusted,4608,0.2164,0.192,0.2434,,,True,,True,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Author designed (ELISA) -Spike","Ortho Clinical Diagnostics Inc.,NA",Multiple Types,Dried Blood,"['IgG', 'TotalAntibody']",Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,No,No,Unclear,Yes,Yes,Yes,Cameron Adams,"University of California, Berkeley",Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.12.02.21266871v1.full-text,2021-12-16,2024-03-01,Verified,adams_impact_2021,USA
211205_CaliforniaBayArea_UniversityofCalifornia_Round3_unadj,211205_CaliforniaBayArea_UniversityofCalifornia_Round3,Impact of individual-level characteristics and transmission mitigation behaviors on SARS-CoV-2 infection and seroprevalence in a large Northern California Bay Area cohort,2021-12-05,Preprint,Regional,Prospective cohort,United States of America,California,,"all residential addresses within the East Bay cities and communities of Albany, Berkeley, El Cerrito, El Sobrante, Emeryville, Hercules, Kensington, Oakland, Piedmont, Pinole, Richmond, and San Pablo (∼307,000 residential households).

 In a household, the individual aged 18 years or older with the next birthday was eligible to participate. Additional eligibility criteria included living within the study region, willingness to provide biospecimens and questionnaire responses, ability to read and speak English or Spanish, and having internet access and an email address.",Did not provide biospecimen,2021-02-11,2021-03-20,Household and community samples,All,Multiple groups,18.0,,Analysis,Unadjusted,4608,0.297,,,,,,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Author designed (ELISA) -Spike","Ortho Clinical Diagnostics Inc.,NA",Multiple Types,Dried Blood,"['IgG', 'TotalAntibody']",Spike,Validated by independent authors/third party/non-developers,,,['Moderate'],No,No,Yes,No,No,Unclear,Yes,Yes,Yes,Cameron Adams,"University of California, Berkeley",Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.12.02.21266871v1.full-text,2021-12-16,2024-03-01,Verified,adams_impact_2021,USA
211207_MayoClinicRochester_MayoClinic,211207_MayoClinicRochester_MayoClinic,"Autoimmune Encephalitis After SARS-CoV-2 Infection Case Frequency, Findings, and Outcomes",2021-12-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Minnesota,Rochester,Medical records of patients who consented to research review were included.,,2019-11-01,2020-12-31,Residual sera,All,Multiple groups,1.0,91.0,Primary Estimate,,556,0.032374100700000005,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,,,,['High'],No,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Cristina Sanchez,Mayo Clinic,Unity-Aligned,http://dx.doi.org/10.1212/WNL.0000000000012931,2021-12-13,2024-03-01,Verified,valencia_sanchez_autoimmune_2021,USA
211207_Philadelphia_ThomasJeffersonUniversity,211207_Philadelphia_ThomasJeffersonUniversity,Comprehensive Serological Profile and Specificity of Maternal and Neonatal Cord Blood SARS CoV-2 Antibodies,2021-12-07,Preprint,Local,Prospective cohort,United States of America,Pennsylvania,Philadelphia,"""Participants were included if they were consented and had maternal and/or cordblood samples available for this study.""","""Those with prior COVID vaccination were excluded. """,2020-04-01,2021-02-28,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,76,0.2,,,True,,,,True,Convenience,Meso Scale Discovery multiplex assay,Meso Scale Discovery,,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Unclear,Yes,No,,Rupsa Boelig,Thomas Jefferson University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.12.06.21267328v1.full-text,2021-12-15,2023-06-22,Unverified,boelig_comprehensive_2021,USA
211210_California_SutterHealth_Overall,211210_California_SutterHealth,COVID-19 in pregnancy by race and ethnicity: Implications for development of a vaccination strategy.,2021-12-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,California,,"Participant delivering at a Sutter Health facility between 1 October 2020 to 31 December 2020 (Sutter Health is a large integrated healthcare delivery system in northern California. Sutter delivers comprehensive medical services in more than 100+ ambulatory clinics and 23 acute care hospitals, caring for approximately 3.5 million people each year, across 22 counties in both urban and rural settings). All patients who presented for delivery and had stored blood samples were included in the study.",Patients with blood samples missing or quantity insufficient for aliquoting were excluded from the analysis.,2020-10-01,2020-12-31,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,4500,0.081,,,True,,,,True,Convenience,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Plasma,TotalAntibody,Spike,Validated by manufacturers,1.0,0.998,['Moderate'],Yes,No,Yes,No,Yes,Yes,Yes,Yes,Yes,Alice Pressman,Sutter Health,Unity-Aligned,https://dx.doi.org/10.1177/17455065211063300,2022-01-03,2024-03-01,Verified,pressman_covid-19_2021,USA
211210_Athens_UniversityofGeorgia_Primary,211210_Athens_UniversityofGeorgia,High Prevalence of Both Previous Infection with SARS-CoV-2 and Persistent Symptoms.,2021-12-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Georgia,Atlanta,,,2021-01-20,2021-03-22,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,,432,0.41000000000000003,0.314,0.507,True,True,True,,True,Self-referral,Author designed (ELISA) - Unknown,,ELISA,Saliva,IgA,,Validated by developers,0.7778,1.0,['High'],,No,No,Yes,,Unclear,Yes,Yes,,Mark Ebell,University of Georgia,Not Unity-Aligned,https://dx.doi.org/10.3122/jabfm.2022.03.210348,2022-06-10,2022-07-16,Unverified,ebell_high_2022,USA
211210_Athens_UniversityofGeorgia_Sex_Female,211210_Athens_UniversityofGeorgia,High Prevalence of Both Previous Infection with SARS-CoV-2 and Persistent Symptoms.,2021-12-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Georgia,Atlanta,,,2021-01-20,2021-03-22,Household and community samples,Female,Adults (18-64 years),,,Sex/Gender,,294,0.3095,,,,,,,,Self-referral,Author designed (ELISA) - Unknown,,ELISA,Saliva,IgA,,Validated by developers,0.7778,1.0,['High'],,No,No,Yes,,Unclear,Yes,Yes,,Mark Ebell,University of Georgia,Not Unity-Aligned,https://dx.doi.org/10.3122/jabfm.2022.03.210348,2022-06-10,2022-07-16,Unverified,ebell_high_2022,USA
211210_Athens_UniversityofGeorgia_Sex_Other,211210_Athens_UniversityofGeorgia,High Prevalence of Both Previous Infection with SARS-CoV-2 and Persistent Symptoms.,2021-12-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Georgia,Atlanta,,,2021-01-20,2021-03-22,Household and community samples,Other,Adults (18-64 years),,,Sex/Gender,,1,0.0,,,,,,,,Self-referral,Author designed (ELISA) - Unknown,,ELISA,Saliva,IgA,,Validated by developers,0.7778,1.0,['High'],,No,No,Yes,,Unclear,Yes,Yes,,Mark Ebell,University of Georgia,Not Unity-Aligned,https://dx.doi.org/10.3122/jabfm.2022.03.210348,2022-06-10,2022-07-16,Unverified,ebell_high_2022,USA
211210_Athens_UniversityofGeorgia_Sex_Male,211210_Athens_UniversityofGeorgia,High Prevalence of Both Previous Infection with SARS-CoV-2 and Persistent Symptoms.,2021-12-10,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Georgia,Atlanta,,,2021-01-20,2021-03-22,Household and community samples,Male,Adults (18-64 years),,,Sex/Gender,,133,0.40601503800000005,,,,,,,,Self-referral,Author designed (ELISA) - Unknown,,ELISA,Saliva,IgA,,Validated by developers,0.7778,1.0,['High'],,No,No,Yes,,Unclear,Yes,Yes,,Mark Ebell,University of Georgia,Not Unity-Aligned,https://dx.doi.org/10.3122/jabfm.2022.03.210348,2022-06-10,2022-07-16,Unverified,ebell_high_2022,USA
122221_MaricopaCounty_ArizonaStateUniversity_popadj,122221_MaricopaCounty_ArizonaStateUniversity,"Accuracy of Case-Based Seroprevalence of SARS-CoV-2 Antibodies in Maricopa County, Arizona.",2021-12-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Arizona,,all consenting household members aged older than 6 years,persons who were living on tribal lands or in congregate settings,2020-09-12,2020-10-01,Household and community samples,All,Multiple groups,6.0,,Primary Estimate,,260,0.14,0.07200000000000001,0.24,True,,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.998,0.995,['Moderate'],Yes,Yes,No,Yes,No,Yes,Yes,Yes,No,Megan Jehn,Arizona State University,Unity-Aligned,https://dx.doi.org/10.2105/AJPH.2021.306568,2022-01-13,2024-03-01,Verified,jehn_accuracy_2022,USA
122221_MaricopaCounty_ArizonaStateUniversity_unadj,122221_MaricopaCounty_ArizonaStateUniversity,"Accuracy of Case-Based Seroprevalence of SARS-CoV-2 Antibodies in Maricopa County, Arizona.",2021-12-22,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Arizona,,all consenting household members aged older than 6 years,persons who were living on tribal lands or in congregate settings,2020-09-12,2020-10-01,Household and community samples,All,Multiple groups,6.0,,Analysis,,260,0.115,,,,,,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,0.998,0.995,['Moderate'],Yes,Yes,No,Yes,No,Yes,Yes,Yes,No,Megan Jehn,Arizona State University,Unity-Aligned,https://dx.doi.org/10.2105/AJPH.2021.306568,2022-01-13,2024-03-01,Verified,jehn_accuracy_2022,USA
211227_Chicago_NorthwesternUniversity,211227_Chicago_NorthwesternUniversity,COVID-19 vaccine intentions and uptake in a tertiary care healthcare system: A longitudinal study.,2021-12-27,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Illinois,Chicago,"""Participants were HCWs from 10 hospitals (the largest in downtown Chicago, with others in the west, northwest, and north suburbs of Chicago), 18 immediate care centers, and 325 outpatient practices in the Chicago area and surrounding Illinois suburbs.""",,2020-05-26,2020-07-10,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,4180,0.0431,,,True,,,,True,Convenience,AdviseDX SARS-CoV-2 anti-IgG II assay,Abbott Laboratories,CLIA,,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Charlesnika Evans,Northwestern University Feinberg School of Medicine,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2021.523,2022-01-12,2024-03-01,Unverified,evans_covid-19_2021,USA
220101_Philadelphia_ChildrensHospitalofPhiladelphia,220101_Philadelphia_ChildrensHospitalofPhiladelphia,36 Assessment of SARS-CoV-2 serostatus and hypertensive disorders of pregnancy,2022-01-01,Presentation or Conference,Local,Prospective cohort,United States of America,Pennsylvania,Philadelphia,"""pregnant patients delivering at 2 urban tertiary care centers between 4/2020 and 12/2020.""

the urban centers were not specified, but all authors are from institution in Philadelphia, so I assumed that the institutions mentioned were also in Philadelphia",,2020-04-15,2020-12-15,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,6192,0.0917,,,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,Serum,"['IgG', 'IgM']",,,,,['Moderate'],,No,Yes,No,,Unclear,Yes,No,,Jourdan Triebwasser,Children’s Hospital of Philadelphia,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ajog.2021.11.092,2022-01-10,2022-07-16,Unverified,triebwasser_assessment_2022,USA
220110_NewYork_F.Hoffmann-LaRocheLtd_Overall,220110_NewYork_F.Hoffmann-LaRocheLtd,Cellular and humoral immunity to SARS-CoV-2 infection in multiple sclerosis patients on ocrelizumab and other disease-modifying therapies: a multi-ethnic observational study,2022-01-10,Preprint,Local,Cross-sectional survey ,United States of America,New York,New York,"Patients seen for routine visits at the NYU Multiple Sclerosis Comprehensive Care Center in New York City (New York) were invited to participate if they had clinician-diagnosed MS (revised 2017 McDonald criteria); were treated with an FDA-approved DMT for MS, or were on no treatment; were aged 18 to 60; had Expanded Disability Status Scale (EDSS) score of 0 (normal) to 7 (wheelchair-bound). ","Exclusion criteria were: concurrent immunosuppressive therapy; active systemic cancer; primary or acquired immunodeficiency (unrelated to DMT); active drug or alcohol abuse; aCD20 therapy other than OCR; uncontrolled diabetes mellitus; end-organ failure (cardiac, pulmonary, renal, hepatic); systemic lupus erythematosus or other systemic autoimmune disease. Patients were also excluded if they received high-dose oral or parenteral corticosteroids, intravenous immunoglobulin (IVIG), plasmapheresis (PLEX), or convalescent plasma or polyclonal antibody treatments for COVID-19 within three months of sample collection; or if they had COVID-19 symptom onset or tested positive by SARS-CoV-2 real-time PCR within two weeks of sample collection.",2021-01-06,2021-07-21,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),18.0,60.0,Primary Estimate,,212,0.10800000000000001,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.81,,['High'],,No,No,No,,Yes,Yes,No,,Ilya Kister,F. Hoffmann-La Roche Ltd,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.01.10.22268752v1.full-text,2022-01-18,2024-03-01,Unverified,kister_cellular_2022,USA
220117_Maryland_JohnsHopkinsUniversitySchoolofMedicine_Residents,220117_Maryland_JohnsHopkinsUniversitySchoolofMedicine_Residents,Evaluating Immunity to SARS-CoV-2 in Nursing Home Residents using Saliva IgG.,2022-01-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Maryland,,"Staff and residents at a 150-bed skilled nursing facility (SNF) in Maryland
",,2020-10-01,2021-02-16,Assisted living and long-term care facilities,All,Multiple groups,25.0,,Primary Estimate,,124,0.5700000000000001,,,True,,,,True,Convenience,Salivary Human Total IgG ELISA Kits,Salimetrics,ELISA,Saliva,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.988,1.0,['High'],,No,No,Yes,,Unclear,Yes,Yes,,Morgan Katz,"Johns Hopkins University School of Medicine
",Not Unity-Aligned,https://dx.doi.org/10.1111/jgs.17660,2022-01-26,2022-07-16,Unverified,katz_evaluating_2022,USA
220117_Maryland_JohnsHopkinsUniversitySchoolofMedicine_Staff,220117_Maryland_JohnsHopkinsUniversitySchoolofMedicine_Staff,Evaluating Immunity to SARS-CoV-2 in Nursing Home Residents using Saliva IgG.,2022-01-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,"Maryland
",,"Staff and residents at a 150-bed skilled nursing facility (SNF) in Maryland
",,2020-10-01,2021-02-16,Health care workers and caregivers,All,Multiple groups,25.0,,Primary Estimate,,28,0.79,,,True,,,,True,Convenience,Salivary Human Total IgG ELISA Kits,Salimetrics,ELISA,Saliva,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.988,1.0,['High'],,No,No,Yes,,Unclear,Yes,Yes,,Morgan Katz,"Johns Hopkins University School of Medicine
",Not Unity-Aligned,https://dx.doi.org/10.1111/jgs.17660,2022-01-26,2022-07-16,Unverified,katz_evaluating_2022,USA
220117_ Milwaukee_AdvocateAuroraHealth_Overall,220117_ Milwaukee_AdvocateAuroraHealth,"Seroprevalence of COVID-19 IgG Antibody in Resident and Fellow Physicians in Milwaukee, Wisconsin: Analysis of a Cross-Sectional Survey.",2022-01-17,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Wisconsin,Milwaukee,"""residents and fellows employed by a single integrated health system and based in Milwaukee, Wisconsin""","""Those among the 148 residents and fellows who did not acknowledge consent for participation, who indicated they were not based in Milwaukee, or who did not participate in a program within the last 8 training program block intervals were excluded.""",2020-06-15,2020-07-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,75,0.013300000000000001,0.0,0.039,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,,,['High'],,No,No,No,,Yes,Yes,Yes,,Dennis Baumgardner,Advocate Aurora Health,Not Unity-Aligned,https://dx.doi.org/10.17294/2330-0698.1846,2022-02-10,2024-03-01,Unverified,baumgardner_seroprevalence_2022,USA
220118_Denver_UniversityofColoradoDenver_Overall,220118_Denver_UniversityofColoradoDenver,"Lower Prevalence of SARS-CoV-2 Infection Among People Experiencing Homelessness Tested in Outdoor Encampments Compared with Overnight Shelters - Denver, Colorado, June - July 2020.",2022-01-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Colorado,Denver,All guests and staff at four homeless shelters as well as people experiencing homelessness staying in three outdoor encampments,,2020-06-02,2020-07-28,Persons experiencing homelessness,All,Multiple groups,,,Primary Estimate,,271,0.155,,,True,,,,True,Convenience,"SARS-CoV-2 IgG ELISA Assay,Access SARS-CoV-2 IgG Reagent Antibody Test","Gold Standard Diagnostic,Beckman Coulter",,,IgG,,,,,['High'],,No,No,Yes,,Yes,Yes,No,,Sarah Rowan,University of Colorado Denver,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac039,2022-01-25,2024-03-01,Unverified,rowan_lower_2022,USA
220118_Denver_UniversityofColoradoDenver_Age<40,220118_Denver_UniversityofColoradoDenver,"Lower Prevalence of SARS-CoV-2 Infection Among People Experiencing Homelessness Tested in Outdoor Encampments Compared with Overnight Shelters - Denver, Colorado, June - July 2020.",2022-01-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Colorado,Denver,All guests and staff at four homeless shelters as well as people experiencing homelessness staying in three outdoor encampments,,2020-06-02,2020-07-28,Persons experiencing homelessness,All,Multiple groups,,39.0,Age,<40,103,0.07769999999999999,,,,,,,,Convenience,"SARS-CoV-2 IgG ELISA Assay,Access SARS-CoV-2 IgG Reagent Antibody Test","Gold Standard Diagnostic,Beckman Coulter",,,IgG,,,,,['High'],,No,No,Yes,,Yes,Yes,No,,Sarah Rowan,University of Colorado Denver,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac039,2022-01-25,2024-03-01,Unverified,rowan_lower_2022,USA
220118_Denver_UniversityofColoradoDenver_Age40-59,220118_Denver_UniversityofColoradoDenver,"Lower Prevalence of SARS-CoV-2 Infection Among People Experiencing Homelessness Tested in Outdoor Encampments Compared with Overnight Shelters - Denver, Colorado, June - July 2020.",2022-01-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Colorado,Denver,All guests and staff at four homeless shelters as well as people experiencing homelessness staying in three outdoor encampments,,2020-06-02,2020-07-28,Persons experiencing homelessness,All,Adults (18-64 years),40.0,59.0,Age,40-59,141,0.1702,,,,,,,,Convenience,"SARS-CoV-2 IgG ELISA Assay,Access SARS-CoV-2 IgG Reagent Antibody Test","Gold Standard Diagnostic,Beckman Coulter",,,IgG,,,,,['High'],,No,No,Yes,,Yes,Yes,No,,Sarah Rowan,University of Colorado Denver,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac039,2022-01-25,2024-03-01,Unverified,rowan_lower_2022,USA
220118_Denver_UniversityofColoradoDenver_Age>=60,220118_Denver_UniversityofColoradoDenver,"Lower Prevalence of SARS-CoV-2 Infection Among People Experiencing Homelessness Tested in Outdoor Encampments Compared with Overnight Shelters - Denver, Colorado, June - July 2020.",2022-01-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Colorado,Denver,All guests and staff at four homeless shelters as well as people experiencing homelessness staying in three outdoor encampments,,2020-06-02,2020-07-28,Persons experiencing homelessness,All,Seniors (65+ years),60.0,,Age,60+,27,0.3704,,,,,,,,Convenience,"SARS-CoV-2 IgG ELISA Assay,Access SARS-CoV-2 IgG Reagent Antibody Test","Gold Standard Diagnostic,Beckman Coulter",,,IgG,,,,,['High'],,No,No,Yes,,Yes,Yes,No,,Sarah Rowan,University of Colorado Denver,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac039,2022-01-25,2024-03-01,Unverified,rowan_lower_2022,USA
220119_JohnsHopkinsHospital_JohnsHopkinsUniversity_2021_Overall_All,220119_JohnsHopkinsHospital_JohnsHopkinsUniversity_2021,Differentiation of SARS-CoV-2 previously infected and vaccinated individuals in an inner-city emergency department.,2022-01-19,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Maryland,Baltimore,CBC blood samples from ED patients aged >17 years were collected during the study period,,2021-01-11,2021-03-10,Residual sera,All,Multiple groups,,,Primary Estimate,,2824,0.23829999999999998,0.222,0.254,True,,,,True,Convenience,"Anti-SARS-CoV-2 ELISA IgG,CoronaCHEK COVID-19 IgG/IgM Rapid Test Cassette","EUROIMMUN,Hangzhou Biotest Biotech Co Ltd",Multiple Types,Serum,"['IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,0.8440000000000001,1.0,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Evan Beck,Johns Hopkins University,Not Unity-Aligned,https://dx.doi.org/10.1128/jcm.02390-21,2022-01-24,2024-03-01,Unverified,beck_differentiation_2022,USA
220119_JohnsHopkinsHospital_JohnsHopkinsUniversity_2021_Age75+,220119_JohnsHopkinsHospital_JohnsHopkinsUniversity_2021,Differentiation of SARS-CoV-2 previously infected and vaccinated individuals in an inner-city emergency department.,2022-01-19,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Maryland,Baltimore,CBC blood samples from ED patients aged >17 years were collected during the study period,,2021-01-11,2021-03-10,Residual sera,All,Seniors (65+ years),75.0,,Age,75+,215,0.2372,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,CoronaCHEK COVID-19 IgG/IgM Rapid Test Cassette","EUROIMMUN,Hangzhou Biotest Biotech Co Ltd",Multiple Types,Serum,"['IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Evan Beck,Johns Hopkins University,Not Unity-Aligned,https://dx.doi.org/10.1128/jcm.02390-21,2022-01-24,2024-03-01,Unverified,beck_differentiation_2022,USA
220119_JohnsHopkinsHospital_JohnsHopkinsUniversity_2021_SexFemale,220119_JohnsHopkinsHospital_JohnsHopkinsUniversity_2021,Differentiation of SARS-CoV-2 previously infected and vaccinated individuals in an inner-city emergency department.,2022-01-19,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Maryland,Baltimore,CBC blood samples from ED patients aged >17 years were collected during the study period,,2021-01-11,2021-03-10,Residual sera,Female,Multiple groups,,,Sex/Gender,,1525,0.24980000000000002,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,CoronaCHEK COVID-19 IgG/IgM Rapid Test Cassette","EUROIMMUN,Hangzhou Biotest Biotech Co Ltd",Multiple Types,Serum,"['IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Evan Beck,Johns Hopkins University,Not Unity-Aligned,https://dx.doi.org/10.1128/jcm.02390-21,2022-01-24,2024-03-01,Unverified,beck_differentiation_2022,USA
220119_JohnsHopkinsHospital_JohnsHopkinsUniversity_2021_Age45-59,220119_JohnsHopkinsHospital_JohnsHopkinsUniversity_2021,Differentiation of SARS-CoV-2 previously infected and vaccinated individuals in an inner-city emergency department.,2022-01-19,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Maryland,Baltimore,CBC blood samples from ED patients aged >17 years were collected during the study period,,2021-01-11,2021-03-10,Residual sera,All,Adults (18-64 years),45.0,59.0,Age,45-59,664,0.1973,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,CoronaCHEK COVID-19 IgG/IgM Rapid Test Cassette","EUROIMMUN,Hangzhou Biotest Biotech Co Ltd",Multiple Types,Serum,"['IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Evan Beck,Johns Hopkins University,Not Unity-Aligned,https://dx.doi.org/10.1128/jcm.02390-21,2022-01-24,2024-03-01,Unverified,beck_differentiation_2022,USA
220119_JohnsHopkinsHospital_JohnsHopkinsUniversity_2021_Age18-29,220119_JohnsHopkinsHospital_JohnsHopkinsUniversity_2021,Differentiation of SARS-CoV-2 previously infected and vaccinated individuals in an inner-city emergency department.,2022-01-19,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Maryland,Baltimore,CBC blood samples from ED patients aged >17 years were collected during the study period,,2021-01-11,2021-03-10,Residual sera,All,Adults (18-64 years),18.0,29.0,Age,18-29,578,0.2664,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,CoronaCHEK COVID-19 IgG/IgM Rapid Test Cassette","EUROIMMUN,Hangzhou Biotest Biotech Co Ltd",Multiple Types,Serum,"['IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Evan Beck,Johns Hopkins University,Not Unity-Aligned,https://dx.doi.org/10.1128/jcm.02390-21,2022-01-24,2024-03-01,Unverified,beck_differentiation_2022,USA
220119_JohnsHopkinsHospital_JohnsHopkinsUniversity_2021_Age30-44,220119_JohnsHopkinsHospital_JohnsHopkinsUniversity_2021,Differentiation of SARS-CoV-2 previously infected and vaccinated individuals in an inner-city emergency department.,2022-01-19,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Maryland,Baltimore,CBC blood samples from ED patients aged >17 years were collected during the study period,,2021-01-11,2021-03-10,Residual sera,All,Adults (18-64 years),30.0,44.0,Age,30-44,763,0.2595,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,CoronaCHEK COVID-19 IgG/IgM Rapid Test Cassette","EUROIMMUN,Hangzhou Biotest Biotech Co Ltd",Multiple Types,Serum,"['IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Evan Beck,Johns Hopkins University,Not Unity-Aligned,https://dx.doi.org/10.1128/jcm.02390-21,2022-01-24,2024-03-01,Unverified,beck_differentiation_2022,USA
220119_JohnsHopkinsHospital_JohnsHopkinsUniversity_2021_SexMale,220119_JohnsHopkinsHospital_JohnsHopkinsUniversity_2021,Differentiation of SARS-CoV-2 previously infected and vaccinated individuals in an inner-city emergency department.,2022-01-19,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Maryland,Baltimore,CBC blood samples from ED patients aged >17 years were collected during the study period,,2021-01-11,2021-03-10,Residual sera,Male,Multiple groups,,,Sex/Gender,,1299,0.2248,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,CoronaCHEK COVID-19 IgG/IgM Rapid Test Cassette","EUROIMMUN,Hangzhou Biotest Biotech Co Ltd",Multiple Types,Serum,"['IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Evan Beck,Johns Hopkins University,Not Unity-Aligned,https://dx.doi.org/10.1128/jcm.02390-21,2022-01-24,2024-03-01,Unverified,beck_differentiation_2022,USA
220119_JohnsHopkinsHospital_JohnsHopkinsUniversity_2021_Age60-74,220119_JohnsHopkinsHospital_JohnsHopkinsUniversity_2021,Differentiation of SARS-CoV-2 previously infected and vaccinated individuals in an inner-city emergency department.,2022-01-19,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Maryland,Baltimore,CBC blood samples from ED patients aged >17 years were collected during the study period,,2021-01-11,2021-03-10,Residual sera,All,Seniors (65+ years),60.0,74.0,Age,60-74,599,0.2304,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,CoronaCHEK COVID-19 IgG/IgM Rapid Test Cassette","EUROIMMUN,Hangzhou Biotest Biotech Co Ltd",Multiple Types,Serum,"['IgG', 'IgM']",Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Evan Beck,Johns Hopkins University,Not Unity-Aligned,https://dx.doi.org/10.1128/jcm.02390-21,2022-01-24,2024-03-01,Unverified,beck_differentiation_2022,USA
220119_JohnsHopkinsHospital_JohnsHopkinsUniversity_2021_Overall_Infected,220119_JohnsHopkinsHospital_JohnsHopkinsUniversity_2021,Differentiation of SARS-CoV-2 previously infected and vaccinated individuals in an inner-city emergency department.,2022-01-19,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Maryland,Baltimore,CBC blood samples from ED patients aged >17 years were collected during the study period,,2021-01-11,2021-03-10,Residual sera,All,Multiple groups,,,Test used,,2824,0.1572,,,,,,,,Convenience,"Anti-SARS-CoV-2 ELISA IgG,Platelia SARS-CoV-2 Total Ab assay,CoronaCHEK COVID-19 IgG/IgM Rapid Test Cassette","EUROIMMUN,Bio-rad,Hangzhou Biotest Biotech Co Ltd",Multiple Types,Serum,"['IgG', 'IgM', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.8440000000000001,1.0,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Evan Beck,Johns Hopkins University,Not Unity-Aligned,https://dx.doi.org/10.1128/jcm.02390-21,2022-01-24,2024-03-01,Unverified,beck_differentiation_2022,USA
220119_GeorgeWashingtonUniversityHospital_UniversityofNorthCarolina,220119_GeorgeWashingtonUniversityHospital_UniversityofNorthCarolina,SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people,2022-01-19,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,,Washington DC,"health care workers in a large tertiary academic medical center (George Washington University, United States)",,2020-06-15,2021-03-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,237,0.1266,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Tara Narowski,University of North Carolina,Not Unity-Aligned,https://dx.doi.org/10.1016/j.celrep.2022.110336,2022-02-10,2022-07-16,Unverified,narowski_sars-cov-2_2022,USA
220120_LosAngelesCounty_UniversityOfSouthernCalifornia_Overall,220120_LosAngelesCounty_UniversityOfSouthernCalifornia,"Seroprevalence of Antibodies Specific to Receptor Binding Domain of SARS-CoV-2 and Vaccination Coverage Among Adults in Los Angeles County, April 2021: The LA Pandemic Surveillance Cohort Study.",2022-01-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,"We established 8 testing sites in LAC and residents who lived within a 15-mile radius (99% of LAC population) were eligible for participation.

We used a proprietary database representing about a quarter of the LAC population maintained by a market research firm (LRW Group, a Material Company), to select participants.",Not providing electronic informed consent.,2021-04-09,2021-04-25,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,1335,0.669,0.644,0.6940000000000001,True,,True,,True,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,,,Spike,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Neeraj Sood,University of Southern California,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.44258,2022-01-24,2024-03-01,Verified,sood_seroprevalence_2022,USA
220120_LosAngelesCounty_UniversityOfSouthernCalifornia_Unvaccinated,220120_LosAngelesCounty_UniversityOfSouthernCalifornia,"Seroprevalence of Antibodies Specific to Receptor Binding Domain of SARS-CoV-2 and Vaccination Coverage Among Adults in Los Angeles County, April 2021: The LA Pandemic Surveillance Cohort Study.",2022-01-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,"We established 8 testing sites in LAC and residents who lived within a 15-mile radius (99% of LAC population) were eligible for participation.

We used a proprietary database representing about a quarter of the LAC population maintained by a market research firm (LRW Group, a Material Company), to select participants.",Not providing electronic informed consent.,2021-04-09,2021-04-25,Household and community samples,All,Multiple groups,18.0,,COVID-19 vaccination status,,300,0.28800000000000003,0.233,0.349,,,True,,,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,,,Spike,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Neeraj Sood,University of Southern California,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.44258,2022-01-24,2024-03-01,Verified,sood_seroprevalence_2022,USA
220120_LosAngelesCounty_UniversityOfSouthernCalifornia_Vaccinated,220120_LosAngelesCounty_UniversityOfSouthernCalifornia,"Seroprevalence of Antibodies Specific to Receptor Binding Domain of SARS-CoV-2 and Vaccination Coverage Among Adults in Los Angeles County, April 2021: The LA Pandemic Surveillance Cohort Study.",2022-01-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,"We established 8 testing sites in LAC and residents who lived within a 15-mile radius (99% of LAC population) were eligible for participation.

We used a proprietary database representing about a quarter of the LAC population maintained by a market research firm (LRW Group, a Material Company), to select participants.",Not providing electronic informed consent.,2021-04-09,2021-04-25,Household and community samples,All,Multiple groups,18.0,,COVID-19 vaccination status,,1035,0.914,0.895,0.93,,,True,,,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,,,Spike,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Neeraj Sood,University of Southern California,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.44258,2022-01-24,2024-03-01,Verified,sood_seroprevalence_2022,USA
220120_LosAngelesCounty_UniversityOfSouthernCalifornia_Age≥65,220120_LosAngelesCounty_UniversityOfSouthernCalifornia,"Seroprevalence of Antibodies Specific to Receptor Binding Domain of SARS-CoV-2 and Vaccination Coverage Among Adults in Los Angeles County, April 2021: The LA Pandemic Surveillance Cohort Study.",2022-01-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,"We established 8 testing sites in LAC and residents who lived within a 15-mile radius (99% of LAC population) were eligible for participation.

We used a proprietary database representing about a quarter of the LAC population maintained by a market research firm (LRW Group, a Material Company), to select participants.",Not providing electronic informed consent.,2021-04-09,2021-04-25,Household and community samples,All,Seniors (65+ years),65.0,,Age,≥65,125,0.7070000000000001,0.616,0.784,,,True,,,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,,,Spike,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Neeraj Sood,University of Southern California,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.44258,2022-01-24,2024-03-01,Verified,sood_seroprevalence_2022,USA
220120_LosAngelesCounty_UniversityOfSouthernCalifornia_Age3039,220120_LosAngelesCounty_UniversityOfSouthernCalifornia,"Seroprevalence of Antibodies Specific to Receptor Binding Domain of SARS-CoV-2 and Vaccination Coverage Among Adults in Los Angeles County, April 2021: The LA Pandemic Surveillance Cohort Study.",2022-01-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,"We established 8 testing sites in LAC and residents who lived within a 15-mile radius (99% of LAC population) were eligible for participation.

We used a proprietary database representing about a quarter of the LAC population maintained by a market research firm (LRW Group, a Material Company), to select participants.",Not providing electronic informed consent.,2021-04-09,2021-04-25,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,672,0.668,0.633,0.7020000000000001,,,True,,,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,,,Spike,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Neeraj Sood,University of Southern California,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.44258,2022-01-24,2024-03-01,Verified,sood_seroprevalence_2022,USA
220120_LosAngelesCounty_UniversityOfSouthernCalifornia_Age50-64,220120_LosAngelesCounty_UniversityOfSouthernCalifornia,"Seroprevalence of Antibodies Specific to Receptor Binding Domain of SARS-CoV-2 and Vaccination Coverage Among Adults in Los Angeles County, April 2021: The LA Pandemic Surveillance Cohort Study.",2022-01-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,"We established 8 testing sites in LAC and residents who lived within a 15-mile radius (99% of LAC population) were eligible for participation.

We used a proprietary database representing about a quarter of the LAC population maintained by a market research firm (LRW Group, a Material Company), to select participants.",Not providing electronic informed consent.,2021-04-09,2021-04-25,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50-64,362,0.6829999999999999,0.628,0.7340000000000001,,,True,,,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,,,Spike,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Neeraj Sood,University of Southern California,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.44258,2022-01-24,2024-03-01,Verified,sood_seroprevalence_2022,USA
220120_LosAngelesCounty_UniversityOfSouthernCalifornia_SexMale,220120_LosAngelesCounty_UniversityOfSouthernCalifornia,"Seroprevalence of Antibodies Specific to Receptor Binding Domain of SARS-CoV-2 and Vaccination Coverage Among Adults in Los Angeles County, April 2021: The LA Pandemic Surveillance Cohort Study.",2022-01-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,"We established 8 testing sites in LAC and residents who lived within a 15-mile radius (99% of LAC population) were eligible for participation.

We used a proprietary database representing about a quarter of the LAC population maintained by a market research firm (LRW Group, a Material Company), to select participants.",Not providing electronic informed consent.,2021-04-09,2021-04-25,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,536,0.6609999999999999,0.616,0.7040000000000001,,,True,,,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,,,Spike,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Neeraj Sood,University of Southern California,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.44258,2022-01-24,2024-03-01,Verified,sood_seroprevalence_2022,USA
220120_LosAngelesCounty_UniversityOfSouthernCalifornia_SexFemale,220120_LosAngelesCounty_UniversityOfSouthernCalifornia,"Seroprevalence of Antibodies Specific to Receptor Binding Domain of SARS-CoV-2 and Vaccination Coverage Among Adults in Los Angeles County, April 2021: The LA Pandemic Surveillance Cohort Study.",2022-01-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,"We established 8 testing sites in LAC and residents who lived within a 15-mile radius (99% of LAC population) were eligible for participation.

We used a proprietary database representing about a quarter of the LAC population maintained by a market research firm (LRW Group, a Material Company), to select participants.",Not providing electronic informed consent.,2021-04-09,2021-04-25,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,790,0.6809999999999999,0.647,0.713,,,True,,,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,,,Spike,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Neeraj Sood,University of Southern California,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.44258,2022-01-24,2024-03-01,Verified,sood_seroprevalence_2022,USA
220120_LosAngelesCounty_UniversityOfSouthernCalifornia_SexNonbinary,220120_LosAngelesCounty_UniversityOfSouthernCalifornia,"Seroprevalence of Antibodies Specific to Receptor Binding Domain of SARS-CoV-2 and Vaccination Coverage Among Adults in Los Angeles County, April 2021: The LA Pandemic Surveillance Cohort Study.",2022-01-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,"We established 8 testing sites in LAC and residents who lived within a 15-mile radius (99% of LAC population) were eligible for participation.

We used a proprietary database representing about a quarter of the LAC population maintained by a market research firm (LRW Group, a Material Company), to select participants.",Not providing electronic informed consent.,2021-04-09,2021-04-25,Household and community samples,Other,Multiple groups,18.0,,Sex/Gender,,9,0.34299999999999997,0.1,0.71,,,True,,,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,,,Spike,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Neeraj Sood,University of Southern California,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.44258,2022-01-24,2024-03-01,Verified,sood_seroprevalence_2022,USA
220120_LosAngelesCounty_UniversityOfSouthernCalifornia_Age1829,220120_LosAngelesCounty_UniversityOfSouthernCalifornia,"Seroprevalence of Antibodies Specific to Receptor Binding Domain of SARS-CoV-2 and Vaccination Coverage Among Adults in Los Angeles County, April 2021: The LA Pandemic Surveillance Cohort Study.",2022-01-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,"We established 8 testing sites in LAC and residents who lived within a 15-mile radius (99% of LAC population) were eligible for participation.

We used a proprietary database representing about a quarter of the LAC population maintained by a market research firm (LRW Group, a Material Company), to select participants.",Not providing electronic informed consent.,2021-04-09,2021-04-25,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,18-29,176,0.617,0.55,0.68,,,True,,,Stratified probability,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,,,Spike,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Neeraj Sood,University of Southern California,Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2021.44258,2022-01-24,2024-03-01,Verified,sood_seroprevalence_2022,USA
220121_NewYork_UniversityOfOxford,220121_NewYork_UniversityOfOxford,"Trans-continental analysis of over, 2000 inflammatory bowel disease patients implicates geography, disease type, and exposure to immunosuppression as drivers of SARS-CoV-2 seroprevalence: Data from the ICARUS-IBD consortium",2022-01-21,Presentation or Conference,Local,Cross-sectional survey ,United States of America,,New York,IBD patients prior to vaccination,,2020-05-26,2021-09-24,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,235,0.0894,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Atellica® IM SARS-CoV-2 Total (COV2T)","Roche Diagnostics,Siemens",,Serum,TotalAntibody,Spike,,,,['High'],,No,No,No,,Unclear,No,No,,S Y Wong,University of Oxford,Not Unity-Aligned,https://dx.doi.org/10.1093/ecco-jcc/jjab232.469,2022-03-08,2024-03-01,Unverified,wong_p342_2022,USA
220124_LosAngeles_UniversityofSouthernCalifornia_PopAdj,220124_LosAngeles_UniversityofSouthernCalifornia,"SARS-CoV-2 seroprevalence among firefighters in Los Angeles, California.",2022-01-24,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,California,Los Angeles,"""An estimated 3371 firefighters actively employed by"" Los Angeles Fire Department (LAFD) ""were eligible for study participation.""","""Participants who self-reported symptoms on a COVID-19 symptom screener on the test day were excluded from the study (N=4).""",2020-10-20,2020-10-28,Essential non-healthcare workers,All,Adults (18-64 years),18.0,,Primary Estimate,Firefighters,686,0.09300000000000001,0.07,0.11699999999999999,True,,True,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Karen Mulligan,University of Southern California,Not Unity-Aligned,https://dx.doi.org/10.1136/oemed-2021-107805,2022-02-03,2024-03-01,Unverified,mulligan_sars-cov-2_2022,USA
220125_UniversityofMissouri_UniversityofMissouri_Random,220125_UniversityofMissouri_UniversityofMissouri_Random,The MU Study of Seropositivity and Risk for SARS-CoV-2 and COVID-19: Crucial Behavioral and Immunological Data from Midwestern College Students,2022-01-25,Preprint,Local,Cross-sectional survey ,United States of America,Missouri,Columbia,Any student at the University of Missouri enrolled during the Fall semester of 2020,,2020-09-15,2020-12-15,Students and Daycares,All,Adults (18-64 years),,,Primary Estimate,,833,0.1489,,,True,,,,True,Stratified probability,Not reported/ Unable to specify,,,,,,,,,['Moderate'],,Yes,Yes,No,,Unclear,Yes,No,,Tyler Myroniuk,University of Missouri,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.01.24.22269758v1.full-text,2022-02-02,2022-07-16,Unverified,myroniuk_mu_2022,USA
220125_UniversityofMissouri_UniversityofMissouri_SelfReferral,220125_UniversityofMissouri_UniversityofMissouri_SelfReferral,The MU Study of Seropositivity and Risk for SARS-CoV-2 and COVID-19: Crucial Behavioral and Immunological Data from Midwestern College Students,2022-01-25,Preprint,Local,Cross-sectional survey ,United States of America,Missouri,Columbia,Any student at the University of Missouri enrolled during the Fall semester of 2020,,2020-10-12,2020-12-15,Students and Daycares,All,Adults (18-64 years),,,Primary Estimate,,69,0.1739,,,True,,,,True,Self-referral,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Tyler Myroniuk,University of Missouri,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.01.24.22269758v1.full-text,2022-02-02,2022-07-16,Unverified,myroniuk_mu_2022,USA
220126_HillsboroughCounty_MoffittCancerCenter_Overall,220126_HillsboroughCounty_MoffittCancerCenter,"SARS-CoV-2 Period Seroprevalence and Related Factors, Hillsborough County, Florida, October 2020-March 2021.",2022-01-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Florida,,"""...included residency in Hillsborough County and age of ≥18 years. At the time of the scheduled clinic visit, eligibility for the blood draw also included not currently experiencing COVID-19 symptoms (e.g., being free of fever [body temperature <100.4°F, as assessed using a noncontact infrared thermometer], cough, and shortness of breath).""","""Fifty-five of the study participants had received ≥1 COVID-19 vaccine doses and were excluded from the analyses""",2020-10-15,2021-03-15,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,867,0.195,0.16899999999999998,0.223,True,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.968,0.941,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anna Giuliano,Moffitt Cancer Center,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2803.211495,2022-02-03,2022-07-16,Unverified,giuliano_sars-cov-2_2022,USA
220126_HillsboroughCounty_MoffittCancerCenter_Sex_Male,220126_HillsboroughCounty_MoffittCancerCenter,"SARS-CoV-2 Period Seroprevalence and Related Factors, Hillsborough County, Florida, October 2020-March 2021.",2022-01-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Florida,,"""...included residency in Hillsborough County and age of ≥18 years. At the time of the scheduled clinic visit, eligibility for the blood draw also included not currently experiencing COVID-19 symptoms (e.g., being free of fever [body temperature <100.4°F, as assessed using a noncontact infrared thermometer], cough, and shortness of breath).""","""Fifty-five of the study participants had received ≥1 COVID-19 vaccine doses and were excluded from the analyses""",2020-10-15,2021-03-15,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,Sex: Male,293,0.201,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.968,0.941,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anna Giuliano,Moffitt Cancer Center,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2803.211495,2022-02-03,2022-07-16,Unverified,giuliano_sars-cov-2_2022,USA
220126_HillsboroughCounty_MoffittCancerCenter_Age_55–64,220126_HillsboroughCounty_MoffittCancerCenter,"SARS-CoV-2 Period Seroprevalence and Related Factors, Hillsborough County, Florida, October 2020-March 2021.",2022-01-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Florida,,"""...included residency in Hillsborough County and age of ≥18 years. At the time of the scheduled clinic visit, eligibility for the blood draw also included not currently experiencing COVID-19 symptoms (e.g., being free of fever [body temperature <100.4°F, as assessed using a noncontact infrared thermometer], cough, and shortness of breath).""","""Fifty-five of the study participants had received ≥1 COVID-19 vaccine doses and were excluded from the analyses""",2020-10-15,2021-03-15,Household and community samples,All,Adults (18-64 years),55.0,64.0,Age,Age: 55–64,213,0.16899999999999998,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.968,0.941,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anna Giuliano,Moffitt Cancer Center,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2803.211495,2022-02-03,2022-07-16,Unverified,giuliano_sars-cov-2_2022,USA
220126_HillsboroughCounty_MoffittCancerCenter_Age_45–54,220126_HillsboroughCounty_MoffittCancerCenter,"SARS-CoV-2 Period Seroprevalence and Related Factors, Hillsborough County, Florida, October 2020-March 2021.",2022-01-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Florida,,"""...included residency in Hillsborough County and age of ≥18 years. At the time of the scheduled clinic visit, eligibility for the blood draw also included not currently experiencing COVID-19 symptoms (e.g., being free of fever [body temperature <100.4°F, as assessed using a noncontact infrared thermometer], cough, and shortness of breath).""","""Fifty-five of the study participants had received ≥1 COVID-19 vaccine doses and were excluded from the analyses""",2020-10-15,2021-03-15,Household and community samples,All,Adults (18-64 years),45.0,54.0,Age,Age: 45–54,190,0.2,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.968,0.941,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anna Giuliano,Moffitt Cancer Center,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2803.211495,2022-02-03,2022-07-16,Unverified,giuliano_sars-cov-2_2022,USA
220126_HillsboroughCounty_MoffittCancerCenter_Sex_Female,220126_HillsboroughCounty_MoffittCancerCenter,"SARS-CoV-2 Period Seroprevalence and Related Factors, Hillsborough County, Florida, October 2020-March 2021.",2022-01-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Florida,,"""...included residency in Hillsborough County and age of ≥18 years. At the time of the scheduled clinic visit, eligibility for the blood draw also included not currently experiencing COVID-19 symptoms (e.g., being free of fever [body temperature <100.4°F, as assessed using a noncontact infrared thermometer], cough, and shortness of breath).""","""Fifty-five of the study participants had received ≥1 COVID-19 vaccine doses and were excluded from the analyses""",2020-10-15,2021-03-15,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,Sex: Female,570,0.193,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.968,0.941,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anna Giuliano,Moffitt Cancer Center,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2803.211495,2022-02-03,2022-07-16,Unverified,giuliano_sars-cov-2_2022,USA
220126_HillsboroughCounty_MoffittCancerCenter_Age_18–44,220126_HillsboroughCounty_MoffittCancerCenter,"SARS-CoV-2 Period Seroprevalence and Related Factors, Hillsborough County, Florida, October 2020-March 2021.",2022-01-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Florida,,"""...included residency in Hillsborough County and age of ≥18 years. At the time of the scheduled clinic visit, eligibility for the blood draw also included not currently experiencing COVID-19 symptoms (e.g., being free of fever [body temperature <100.4°F, as assessed using a noncontact infrared thermometer], cough, and shortness of breath).""","""Fifty-five of the study participants had received ≥1 COVID-19 vaccine doses and were excluded from the analyses""",2020-10-15,2021-03-15,Household and community samples,All,Adults (18-64 years),18.0,44.0,Age,Age: 18–44,316,0.222,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.968,0.941,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anna Giuliano,Moffitt Cancer Center,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2803.211495,2022-02-03,2022-07-16,Unverified,giuliano_sars-cov-2_2022,USA
220126_HillsboroughCounty_MoffittCancerCenter_Age_65+,220126_HillsboroughCounty_MoffittCancerCenter,"SARS-CoV-2 Period Seroprevalence and Related Factors, Hillsborough County, Florida, October 2020-March 2021.",2022-01-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Florida,,"""...included residency in Hillsborough County and age of ≥18 years. At the time of the scheduled clinic visit, eligibility for the blood draw also included not currently experiencing COVID-19 symptoms (e.g., being free of fever [body temperature <100.4°F, as assessed using a noncontact infrared thermometer], cough, and shortness of breath).""","""Fifty-five of the study participants had received ≥1 COVID-19 vaccine doses and were excluded from the analyses""",2020-10-15,2021-03-15,Household and community samples,All,Seniors (65+ years),65.0,,Age,Age: 65 and above,148,0.16899999999999998,,,,,,,,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.968,0.941,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Anna Giuliano,Moffitt Cancer Center,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2803.211495,2022-02-03,2022-07-16,Unverified,giuliano_sars-cov-2_2022,USA
012722_NewYorkCity_SUNYDownstateHealthSciencesUniversity,012722_NewYorkCity_SUNYDownstateHealthSciencesUniversity,COVID-19 Infection and Symptoms Among Emergency Medicine Residents and Fellows in an Urban Academic Hospital Setting: Cross-sectional Questionnaire Study.,2022-01-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,New York City,Residents and fellows in 2 New York City hospitals,,2020-05-15,2020-08-31,Health care workers and caregivers,All,Adults (18-64 years),26.0,40.0,Primary Estimate,,64,0.42,,,True,,,,True,Convenience,"Not reported/ Unable to specify,Abbott Architect SARS-CoV-2 IgG","NA,Abbott Laboratories",Multiple Types,,"['IgG', 'Notreported']","['Notreported', 'Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,No,No,,Stacey Frisch,SUNY Downstate Health Sciences University,Not Unity-Aligned,https://dx.doi.org/10.2196/29539,2022-03-15,2024-03-01,Unverified,frisch_covid-19_2022,USA
220130_USA_CentersforDiseaseControlandPrevention_CA_May2021,220130_USA_CentersforDiseaseControlandPrevention_CA,"Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Reported Coronavirus Disease 2019 Cases in US Children, August 2020–May 2021",2022-01-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,California,,"commercial laboratory residual sera of children and adolescents aged 0–17 years in California. residual sera included were those submitted for routine clinical testing, including but not limited to lipid testing, sodium level testing, and hormone testing.
restricted analysis to states in which commercial laboratories tested ≥100 residual specimens from individuals aged 0–17 years",Serum specimens submitted for COVID-19 or SARS-CoV-2 antibody testing were excluded,2021-05-01,2021-05-31,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,,651,0.43700000000000006,0.38799999999999996,0.509,True,True,True,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Alexia Couture,Centers for Disease Control and Prevention,Unity-Aligned,https://doi.org/10.1093/ofid/ofac044,2022-02-24,2023-08-15,Unverified,couture_severe_2022,USA
220130_USA_CentersforDiseaseControlandPrevention_IL_May2021,220130_USA_CentersforDiseaseControlandPrevention_IL,"Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Reported Coronavirus Disease 2019 Cases in US Children, August 2020–May 2021",2022-01-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Illinois,,"commercial laboratory residual sera of children and adolescents aged 0–17 years in California. residual sera included were those submitted for routine clinical testing, including but not limited to lipid testing, sodium level testing, and hormone testing.
restricted analysis to states in which commercial laboratories tested ≥100 residual specimens from individuals aged 0–17 years",Serum specimens submitted for COVID-19 or SARS-CoV-2 antibody testing were excluded,2021-05-01,2021-05-31,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,,942,0.41500000000000004,0.353,0.469,True,True,True,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Alexia Couture,Centers for Disease Control and Prevention,Unity-Aligned,https://doi.org/10.1093/ofid/ofac044,2022-02-24,2023-08-15,Unverified,couture_severe_2022,USA
220130_USA_CentersforDiseaseControlandPrevention_NC_May2021,220130_USA_CentersforDiseaseControlandPrevention_NC,"Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Reported Coronavirus Disease 2019 Cases in US Children, August 2020–May 2021",2022-01-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Carolina,,"commercial laboratory residual sera of children and adolescents aged 0–17 years in California. residual sera included were those submitted for routine clinical testing, including but not limited to lipid testing, sodium level testing, and hormone testing.
restricted analysis to states in which commercial laboratories tested ≥100 residual specimens from individuals aged 0–17 years",Serum specimens submitted for COVID-19 or SARS-CoV-2 antibody testing were excluded,2021-05-01,2021-05-31,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,,648,0.263,0.20800000000000002,0.32299999999999995,True,True,True,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Alexia Couture,Centers for Disease Control and Prevention,Unity-Aligned,https://doi.org/10.1093/ofid/ofac044,2022-02-24,2023-08-15,Unverified,couture_severe_2022,USA
220130_USA_CentersforDiseaseControlandPrevention_NJ_May2021,220130_USA_CentersforDiseaseControlandPrevention_NJ,"Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Reported Coronavirus Disease 2019 Cases in US Children, August 2020–May 2021",2022-01-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,New Jersey,,"commercial laboratory residual sera of children and adolescents aged 0–17 years in California. residual sera included were those submitted for routine clinical testing, including but not limited to lipid testing, sodium level testing, and hormone testing.
restricted analysis to states in which commercial laboratories tested ≥100 residual specimens from individuals aged 0–17 years",Serum specimens submitted for COVID-19 or SARS-CoV-2 antibody testing were excluded,2021-05-01,2021-05-31,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,,393,0.44,0.384,0.502,True,True,True,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Yes,Yes,Yes,,Alexia Couture,Centers for Disease Control and Prevention,Unity-Aligned,https://doi.org/10.1093/ofid/ofac044,2022-02-24,2023-08-15,Unverified,couture_severe_2022,USA
220130_USA_CentersforDiseaseControlandPrevention_NV_May2021,220130_USA_CentersforDiseaseControlandPrevention_NV,"Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Reported Coronavirus Disease 2019 Cases in US Children, August 2020–May 2021",2022-01-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Nevada,,"commercial laboratory residual sera of children and adolescents aged 0–17 years in California. residual sera included were those submitted for routine clinical testing, including but not limited to lipid testing, sodium level testing, and hormone testing.
restricted analysis to states in which commercial laboratories tested ≥100 residual specimens from individuals aged 0–17 years",Serum specimens submitted for COVID-19 or SARS-CoV-2 antibody testing were excluded,2021-05-01,2021-05-31,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,,237,0.304,0.20600000000000002,0.369,True,True,True,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Yes,Yes,Yes,,Alexia Couture,Centers for Disease Control and Prevention,Unity-Aligned,https://doi.org/10.1093/ofid/ofac044,2022-02-24,2023-08-15,Unverified,couture_severe_2022,USA
220130_USA_CentersforDiseaseControlandPrevention_OH_May2021,220130_USA_CentersforDiseaseControlandPrevention_OH,"Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Reported Coronavirus Disease 2019 Cases in US Children, August 2020–May 2021",2022-01-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Ohio,,"commercial laboratory residual sera of children and adolescents aged 0–17 years in California. residual sera included were those submitted for routine clinical testing, including but not limited to lipid testing, sodium level testing, and hormone testing.
restricted analysis to states in which commercial laboratories tested ≥100 residual specimens from individuals aged 0–17 years",Serum specimens submitted for COVID-19 or SARS-CoV-2 antibody testing were excluded,2021-05-01,2021-05-31,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,,627,0.37,0.294,0.41700000000000004,True,True,True,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Alexia Couture,Centers for Disease Control and Prevention,Unity-Aligned,https://doi.org/10.1093/ofid/ofac044,2022-02-24,2023-08-15,Unverified,couture_severe_2022,USA
220130_USA_CentersforDiseaseControlandPrevention_SC_May2021,220130_USA_CentersforDiseaseControlandPrevention_SC,"Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Reported Coronavirus Disease 2019 Cases in US Children, August 2020–May 2021",2022-01-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,South Carolina,,"commercial laboratory residual sera of children and adolescents aged 0–17 years in California. residual sera included were those submitted for routine clinical testing, including but not limited to lipid testing, sodium level testing, and hormone testing.
restricted analysis to states in which commercial laboratories tested ≥100 residual specimens from individuals aged 0–17 years",Serum specimens submitted for COVID-19 or SARS-CoV-2 antibody testing were excluded,2021-05-01,2021-05-31,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,,618,0.348,0.295,0.409,True,True,True,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Alexia Couture,Centers for Disease Control and Prevention,Unity-Aligned,https://doi.org/10.1093/ofid/ofac044,2022-02-24,2023-08-15,Unverified,couture_severe_2022,USA
220130_USA_CentersforDiseaseControlandPrevention_TN_May2021,220130_USA_CentersforDiseaseControlandPrevention_TN,"Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Reported Coronavirus Disease 2019 Cases in US Children, August 2020–May 2021",2022-01-30,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Tennessee,,"commercial laboratory residual sera of children and adolescents aged 0–17 years in California. residual sera included were those submitted for routine clinical testing, including but not limited to lipid testing, sodium level testing, and hormone testing.
restricted analysis to states in which commercial laboratories tested ≥100 residual specimens from individuals aged 0–17 years",Serum specimens submitted for COVID-19 or SARS-CoV-2 antibody testing were excluded,2021-05-01,2021-05-31,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,,192,0.365,0.275,0.46299999999999997,True,True,True,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Yes,Yes,Yes,,Alexia Couture,Centers for Disease Control and Prevention,Unity-Aligned,https://doi.org/10.1093/ofid/ofac044,2022-02-24,2023-08-15,Unverified,couture_severe_2022,USA
220201_ParkRidge_AdvocateLutheranGeneralHospital_Dec2020_Overall,220201_ParkRidge_AdvocateLutheranGeneralHospital_Dec2020,"A Prospective, Longitudinal Evaluation of SARS-CoV-2 COVID-19 Exposure, Use of Protective Equipment and Social Distancing in a Group of Community Physicians.",2022-02-01,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Illinois,Park Ridge,"Attending
physicians, fellows, and residents who participated in September 2020 or T0.",,2020-12-01,2020-12-31,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,458,0.085,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9870000000000001,0.9920000000000001,['High'],,No,No,No,,Yes,Yes,Yes,,Eli Ehrenpreis,Advocate Lutheran General Hospital,Not Unity-Aligned,https://dx.doi.org/10.3390/healthcare10020285,2022-03-07,2024-03-01,Unverified,ehrenpreis_prospective_2022,USA
220201_ParkRidge_AdvocateLutheranGeneralHospital_Sep2020_Overall,220201_ParkRidge_AdvocateLutheranGeneralHospital_Sep2020,"A Prospective, Longitudinal Evaluation of SARS-CoV-2 COVID-19 Exposure, Use of Protective Equipment and Social Distancing in a Group of Community Physicians.",2022-02-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Illinois,Park Ridge,"Attending
physicians, fellows, and residents working on staff from at least 1 March 2020, were invited
to participate.","NR
",2020-09-14,2020-09-25,Health care workers and caregivers,All,Multiple groups,25.0,79.0,Primary Estimate,,481,0.044000000000000004,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.9870000000000001,0.9920000000000001,['High'],,No,No,Yes,,Yes,Yes,Yes,,Eli Ehrenpreis,Advocate Lutheran General Hospital,Not Unity-Aligned,https://dx.doi.org/10.3390/healthcare10020285,2022-03-07,2024-03-01,Unverified,ehrenpreis_prospective_2022,USA
220202_LakeCounty_UniversityofTexasMedicalBranch_Overall,220202_LakeCounty_UniversityofTexasMedicalBranch,"EpidemiologiCal POpulatioN STudy of SARS-CoV-2 in Lake CounTy, Illinois (CONTACT): Methodology and Baseline Characteristics of a Community-Based Surveillance Study.",2022-02-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Illinois,,"This is part of the EpidemiologiCal POpulatioN STudy of SARS-CoV-2 in Lake CounTy, Illinois (CONTACT) prospective cohort study, which includes persons aged 18 years or older who are currently living or employed in Lake County, IL.
To be eligible for the study, participants had to (a) provide informed consent, (b) be proficient in English or Spanish, (c) have access to the web-based study portal, and (d) not be hospitalized at the time of enrollment.",RT-PCR test conducted at baseline - a result of “invalid” was considered as missing and excluded from the analysis.,2020-11-15,2021-01-15,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,1008,0.045,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,0.996,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Ryan Kilpatrick,University of Texas Medical Branch,Unity-Aligned,https://dx.doi.org/10.1007/s40121-022-00593-0,2022-02-08,2024-03-01,Verified,kilpatrick_epidemiological_2022,USA
220202_LakeCounty_UniversityofTexasMedicalBranch_30-39,220202_LakeCounty_UniversityofTexasMedicalBranch,"EpidemiologiCal POpulatioN STudy of SARS-CoV-2 in Lake CounTy, Illinois (CONTACT): Methodology and Baseline Characteristics of a Community-Based Surveillance Study.",2022-02-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Illinois,,"This is part of the EpidemiologiCal POpulatioN STudy of SARS-CoV-2 in Lake CounTy, Illinois (CONTACT) prospective cohort study, which includes persons aged 18 years or older who are currently living or employed in Lake County, IL.
To be eligible for the study, participants had to (a) provide informed consent, (b) be proficient in English or Spanish, (c) have access to the web-based study portal, and (d) not be hospitalized at the time of enrollment.",RT-PCR test conducted at baseline - a result of “invalid” was considered as missing and excluded from the analysis.,2020-11-15,2021-01-15,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,147,0.054000000000000006,0.023799999999999998,0.10439999999999999,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,0.996,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Ryan Kilpatrick,University of Texas Medical Branch,Unity-Aligned,https://dx.doi.org/10.1007/s40121-022-00593-0,2022-02-08,2024-03-01,Verified,kilpatrick_epidemiological_2022,USA
220202_LakeCounty_UniversityofTexasMedicalBranch_40-49,220202_LakeCounty_UniversityofTexasMedicalBranch,"EpidemiologiCal POpulatioN STudy of SARS-CoV-2 in Lake CounTy, Illinois (CONTACT): Methodology and Baseline Characteristics of a Community-Based Surveillance Study.",2022-02-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Illinois,,"This is part of the EpidemiologiCal POpulatioN STudy of SARS-CoV-2 in Lake CounTy, Illinois (CONTACT) prospective cohort study, which includes persons aged 18 years or older who are currently living or employed in Lake County, IL.
To be eligible for the study, participants had to (a) provide informed consent, (b) be proficient in English or Spanish, (c) have access to the web-based study portal, and (d) not be hospitalized at the time of enrollment.",RT-PCR test conducted at baseline - a result of “invalid” was considered as missing and excluded from the analysis.,2020-11-15,2021-01-15,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,173,0.040999999999999995,0.016399999999999998,0.0816,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,0.996,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Ryan Kilpatrick,University of Texas Medical Branch,Unity-Aligned,https://dx.doi.org/10.1007/s40121-022-00593-0,2022-02-08,2024-03-01,Verified,kilpatrick_epidemiological_2022,USA
220202_LakeCounty_UniversityofTexasMedicalBranch_Female,220202_LakeCounty_UniversityofTexasMedicalBranch,"EpidemiologiCal POpulatioN STudy of SARS-CoV-2 in Lake CounTy, Illinois (CONTACT): Methodology and Baseline Characteristics of a Community-Based Surveillance Study.",2022-02-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Illinois,,"This is part of the EpidemiologiCal POpulatioN STudy of SARS-CoV-2 in Lake CounTy, Illinois (CONTACT) prospective cohort study, which includes persons aged 18 years or older who are currently living or employed in Lake County, IL.
To be eligible for the study, participants had to (a) provide informed consent, (b) be proficient in English or Spanish, (c) have access to the web-based study portal, and (d) not be hospitalized at the time of enrollment.",RT-PCR test conducted at baseline - a result of “invalid” was considered as missing and excluded from the analysis.,2020-11-15,2021-01-15,Household and community samples,Female,Multiple groups,,,Sex/Gender,,713,0.040999999999999995,0.027400000000000004,0.0579,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,0.996,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Ryan Kilpatrick,University of Texas Medical Branch,Unity-Aligned,https://dx.doi.org/10.1007/s40121-022-00593-0,2022-02-08,2024-03-01,Verified,kilpatrick_epidemiological_2022,USA
220202_LakeCounty_UniversityofTexasMedicalBranch_65+,220202_LakeCounty_UniversityofTexasMedicalBranch,"EpidemiologiCal POpulatioN STudy of SARS-CoV-2 in Lake CounTy, Illinois (CONTACT): Methodology and Baseline Characteristics of a Community-Based Surveillance Study.",2022-02-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Illinois,,"This is part of the EpidemiologiCal POpulatioN STudy of SARS-CoV-2 in Lake CounTy, Illinois (CONTACT) prospective cohort study, which includes persons aged 18 years or older who are currently living or employed in Lake County, IL.
To be eligible for the study, participants had to (a) provide informed consent, (b) be proficient in English or Spanish, (c) have access to the web-based study portal, and (d) not be hospitalized at the time of enrollment.",RT-PCR test conducted at baseline - a result of “invalid” was considered as missing and excluded from the analysis.,2020-11-15,2021-01-15,Household and community samples,All,Seniors (65+ years),65.0,,Age,65+,159,0.05,0.022000000000000002,0.09670000000000001,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,0.996,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Ryan Kilpatrick,University of Texas Medical Branch,Unity-Aligned,https://dx.doi.org/10.1007/s40121-022-00593-0,2022-02-08,2024-03-01,Verified,kilpatrick_epidemiological_2022,USA
220202_LakeCounty_UniversityofTexasMedicalBranch_Male,220202_LakeCounty_UniversityofTexasMedicalBranch,"EpidemiologiCal POpulatioN STudy of SARS-CoV-2 in Lake CounTy, Illinois (CONTACT): Methodology and Baseline Characteristics of a Community-Based Surveillance Study.",2022-02-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Illinois,,"This is part of the EpidemiologiCal POpulatioN STudy of SARS-CoV-2 in Lake CounTy, Illinois (CONTACT) prospective cohort study, which includes persons aged 18 years or older who are currently living or employed in Lake County, IL.
To be eligible for the study, participants had to (a) provide informed consent, (b) be proficient in English or Spanish, (c) have access to the web-based study portal, and (d) not be hospitalized at the time of enrollment.",RT-PCR test conducted at baseline - a result of “invalid” was considered as missing and excluded from the analysis.,2020-11-15,2021-01-15,Household and community samples,Male,Multiple groups,,,Sex/Gender,,293,0.055,0.0315,0.08720000000000001,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,0.996,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Ryan Kilpatrick,University of Texas Medical Branch,Unity-Aligned,https://dx.doi.org/10.1007/s40121-022-00593-0,2022-02-08,2024-03-01,Verified,kilpatrick_epidemiological_2022,USA
220202_LakeCounty_UniversityofTexasMedicalBranch_18-29,220202_LakeCounty_UniversityofTexasMedicalBranch,"EpidemiologiCal POpulatioN STudy of SARS-CoV-2 in Lake CounTy, Illinois (CONTACT): Methodology and Baseline Characteristics of a Community-Based Surveillance Study.",2022-02-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Illinois,,"This is part of the EpidemiologiCal POpulatioN STudy of SARS-CoV-2 in Lake CounTy, Illinois (CONTACT) prospective cohort study, which includes persons aged 18 years or older who are currently living or employed in Lake County, IL.
To be eligible for the study, participants had to (a) provide informed consent, (b) be proficient in English or Spanish, (c) have access to the web-based study portal, and (d) not be hospitalized at the time of enrollment.",RT-PCR test conducted at baseline - a result of “invalid” was considered as missing and excluded from the analysis.,2020-11-15,2021-01-15,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,18-29,78,0.077,0.0288,0.16,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,0.996,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Ryan Kilpatrick,University of Texas Medical Branch,Unity-Aligned,https://dx.doi.org/10.1007/s40121-022-00593-0,2022-02-08,2024-03-01,Verified,kilpatrick_epidemiological_2022,USA
220202_LakeCounty_UniversityofTexasMedicalBranch_50-64,220202_LakeCounty_UniversityofTexasMedicalBranch,"EpidemiologiCal POpulatioN STudy of SARS-CoV-2 in Lake CounTy, Illinois (CONTACT): Methodology and Baseline Characteristics of a Community-Based Surveillance Study.",2022-02-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Illinois,,"This is part of the EpidemiologiCal POpulatioN STudy of SARS-CoV-2 in Lake CounTy, Illinois (CONTACT) prospective cohort study, which includes persons aged 18 years or older who are currently living or employed in Lake County, IL.
To be eligible for the study, participants had to (a) provide informed consent, (b) be proficient in English or Spanish, (c) have access to the web-based study portal, and (d) not be hospitalized at the time of enrollment.",RT-PCR test conducted at baseline - a result of “invalid” was considered as missing and excluded from the analysis.,2020-11-15,2021-01-15,Household and community samples,All,Adults (18-64 years),50.0,64.0,Age,50-64,451,0.036000000000000004,0.0204,0.057,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,1.0,0.996,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Ryan Kilpatrick,University of Texas Medical Branch,Unity-Aligned,https://dx.doi.org/10.1007/s40121-022-00593-0,2022-02-08,2024-03-01,Verified,kilpatrick_epidemiological_2022,USA
220202_SanFrancisco_UniversityofCalifornia_3months_Overall,220202_SanFrancisco_UniversityofCalifornia_3months,SARS COV-2 anti-nucleocapsid and anti-spike antibodies in an emergency department healthcare worker cohort: September 2020 - April 2021,2022-02-02,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,California,San Francisco,"We enrolled ED healthcare workers (attending physicians, resident physicians, nurses, nurse practitioners, physician assistants, patient care technicians, and pharmacists).","We excluded healthcare
workers who were pregnant, immune compromised, or who were planning to move or unable to attend study visits.",2020-12-01,2020-12-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,135,0.022000000000000002,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,No,,Yes,Yes,No,,Ralph Wang,University of California,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ajem.2022.01.055,2022-02-22,2024-03-01,Unverified,wang_sars_2022,USA
220202_SanFrancisco_UniversityofCalifornia_6months_Overall,220202_SanFrancisco_UniversityofCalifornia_6months,SARS COV-2 anti-nucleocapsid and anti-spike antibodies in an emergency department healthcare worker cohort: September 2020 - April 2021,2022-02-02,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,California,San Francisco,"We enrolled ED healthcare workers (attending physicians, resident physicians, nurses, nurse practitioners, physician assistants, patient care technicians, and pharmacists).","We excluded healthcare
workers who were pregnant, immune compromised, or who were planning to move or unable to attend study visits.",2021-03-01,2021-03-31,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,134,0.022000000000000002,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,No,,Yes,Yes,Yes,,Ralph Wang,University of California,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ajem.2022.01.055,2022-02-22,2024-03-01,Unverified,wang_sars_2022,USA
220202_SanFrancisco_UniversityofCalifornia_Baseline_Overall,220202_SanFrancisco_UniversityofCalifornia_Baseline,SARS COV-2 anti-nucleocapsid and anti-spike antibodies in an emergency department healthcare worker cohort: September 2020 - April 2021,2022-02-02,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,California,San Francisco,"We enrolled ED healthcare workers (attending physicians, resident physicians, nurses, nurse practitioners, physician assistants, patient care technicians, and pharmacists).","We excluded healthcare
workers who were pregnant, immune compromised, or who were planning to move or unable to attend study visits.",2020-09-01,2020-09-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,139,0.036000000000000004,0.012,0.08199999999999999,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,DiaSorin",CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,Yes,,Yes,Yes,No,,Ralph Wang,University of California,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ajem.2022.01.055,2022-02-22,2024-03-01,Unverified,wang_sars_2022,USA
220203_USA_JohnsHopkinsUniversity_noCOVID_Spike,220203_USA_JohnsHopkinsUniversity_noCOVID,Prevalence and Durability of SARS-CoV-2 Antibodies Among Unvaccinated US Adults by History of COVID-19.,2022-02-03,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Healthy adults who reported no SARS-CoV-2 vaccination

... did not believe they ever had COVID-19 and never tested positive.","Previously ttested for COVID-19

Believed they had previously been infected",2021-09-24,2021-11-05,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,,246,0.1057,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,,,,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Jennifer Alejo,Johns Hopkins University,Not Unity-Aligned,https://dx.doi.org/10.1001/jama.2022.1393,2022-02-10,2024-03-01,Unverified,alejo_prevalence_2022,USA
220203_USA_JohnsHopkinsUniversity_noCOVID_Nucleocapsid,220203_USA_JohnsHopkinsUniversity_noCOVID,Prevalence and Durability of SARS-CoV-2 Antibodies Among Unvaccinated US Adults by History of COVID-19.,2022-02-03,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Healthy adults who reported no SARS-CoV-2 vaccination

... did not believe they ever had COVID-19 and never tested positive.","Previously ttested for COVID-19

Believed they had previously been infected",2021-09-24,2021-11-05,Household and community samples,All,Adults (18-64 years),,,Test used,,246,0.0894,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,,,Nucleocapsid(N-protein),,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Jennifer Alejo,Johns Hopkins University,Not Unity-Aligned,https://dx.doi.org/10.1001/jama.2022.1393,2022-02-10,2024-03-01,Unverified,alejo_prevalence_2022,USA
220207_Indiana_IndianaUniversitySchoolofPublicHealth-Bloomington_Baseline,220207_Indiana_IndianaUniversitySchoolofPublicHealth-Bloomington_Baseline,Relationship between high-risk alcohol consumption and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroconversion: a prospective seroepidemiologic cohort study among American college students.,2022-02-07,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Indiana,Bloomington,"Inclusion criteria were: 1) age≥18 years, 2)IUB undergraduate student in fall 2020, and 3) residing in Monroe County, Indiana.",,2020-09-14,2020-09-30,Students and Daycares,All,Adults (18-64 years),18.0,,Primary Estimate,,1076,0.0455390335,,,True,,,,True,Simplified probability,SARS-CoV-2 Virus IgG Antibody Detection Kit (ELISA),BGI Genomics,LFIA,Plasma,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.64,1.0,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Sina Kianersi,Indiana University School of Public Health-Bloomington,Not Unity-Aligned,https://dx.doi.org/10.1111/add.15835,2022-02-18,2024-03-01,Unverified,kianersi_relationship_2022,USA
220207_Indiana_IndianaUniversitySchoolofPublicHealth-Bloomington_Cohort,220207_Indiana_IndianaUniversitySchoolofPublicHealth-Bloomington_Cohort,Relationship between high-risk alcohol consumption and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroconversion: a prospective seroepidemiologic cohort study among American college students.,2022-02-07,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Indiana,Bloomington,"No previous COVID-19 infection. Inclusion criteria were: 1) age≥18 years, 2)IUB undergraduate student in fall 2020, and 3) residing in Monroe County, Indiana.",Previous COVID-19 infection.,2020-09-28,2020-11-23,Household and community samples,All,Adults (18-64 years),18.0,,Primary Estimate,,808,0.051980198,,,True,,,,True,Simplified probability,SARS-CoV-2 Virus IgG Antibody Detection Kit (ELISA),BGI Genomics,LFIA,Plasma,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.64,1.0,['Moderate'],,Yes,Yes,No,,Yes,Yes,No,,Sina Kianersi,Indiana University School of Public Health-Bloomington,Not Unity-Aligned,https://dx.doi.org/10.1111/add.15835,2022-02-18,2024-03-01,Unverified,kianersi_relationship_2022,USA
220207_SiouxFalls_SanfordHealth_Visit1_Overall,220207_SiouxFalls_SanfordHealth_Visit1,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody prevalence in a healthcare worker population exceeded self-reported infection rates, 2020.",2022-02-07,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,South Dakota,Sioux Falls,"""Employees of Sanford Health were invited to participate"".

""Enrollment was initially confined to those working in areas expected to see many COVID-19 patients and was later expanded to any employee with patient contact. Laboratory workers were also eligible.""",,2020-06-15,2020-09-17,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1811,0.2463,,,True,,,,True,Convenience,"Atellica® IM SARS-CoV-2 Total (COV2T),Liaison SARS-CoV-2 S1/S2 IgG","Siemens,DiaSorin",CLIA,Serum,"['IgG', 'TotalAntibody']",Spike,,,,['High'],,No,Yes,No,,Unclear,No,No,,Susan Hoover,Sanford Health,Not Unity-Aligned,https://dx.doi.org/10.1017/ash.2022.9,2022-11-07,2024-03-01,Unverified,hoover_severe_2022,USA
220207_SiouxFalls_SanfordHealth_Visit2_Overall,220207_SiouxFalls_SanfordHealth_Visit2,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody prevalence in a healthcare worker population exceeded self-reported infection rates, 2020.",2022-02-07,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,South Dakota,Sioux Falls,"""Employees of Sanford Health were invited to participate"".

""Enrollment was initially confined to those working in areas expected to see many COVID-19 patients and was later expanded to any employee with patient contact. Laboratory workers were also eligible.""",,2020-08-14,2020-11-16,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,986,0.41990000000000005,,,True,,,,True,Convenience,"Atellica® IM SARS-CoV-2 Total (COV2T),Liaison SARS-CoV-2 S1/S2 IgG","Siemens,DiaSorin",CLIA,Serum,"['IgG', 'TotalAntibody']",Spike,,,,['High'],,No,Yes,No,,Unclear,No,No,,Susan Hoover,Sanford Health,Not Unity-Aligned,https://dx.doi.org/10.1017/ash.2022.9,2022-11-07,2024-03-01,Unverified,hoover_severe_2022,USA
220207_SiouxFalls_SanfordHealth_Visit3_Overall,220207_SiouxFalls_SanfordHealth_Visit3,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody prevalence in a healthcare worker population exceeded self-reported infection rates, 2020.",2022-02-07,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,South Dakota,Sioux Falls,"""Employees of Sanford Health were invited to participate"".

""Enrollment was initially confined to those working in areas expected to see many COVID-19 patients and was later expanded to any employee with patient contact. Laboratory workers were also eligible.""",,2020-10-13,2021-01-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,201,0.5522,,,True,,,,True,Convenience,"Atellica® IM SARS-CoV-2 Total (COV2T),Liaison SARS-CoV-2 S1/S2 IgG","Siemens,DiaSorin",CLIA,Serum,"['IgG', 'TotalAntibody']",Spike,,,,['High'],,No,No,No,,Unclear,No,No,,Susan Hoover,Sanford Health,Not Unity-Aligned,https://dx.doi.org/10.1017/ash.2022.9,2022-11-07,2024-03-01,Unverified,hoover_severe_2022,USA
220207_USA_CentersforDiseaseControlandPrevention_202116_Overall_Anti-S,220207_USA_CentersforDiseaseControlandPrevention_202106,"Social vulnerability and rurality associated with higher SARS-CoV-2 infection-induced seroprevalence: a nationwide blood donor study, United States, July 2020 - June 2021.",2022-02-07,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"Catchment areas from 17 blood collection organizations were combined into 65 study regions defined by state and metropolitan borders, representing 50 states and Washington D.C. Each month, approximately 500–4,000 anonymous blood donation specimens from each study region were
selected",Excluded donations made specifically to provide COVID-19 convalescent plasma and samples with missing donor demographic data (2.85% excluded for missing race/ethnicity).,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Primary Estimate,Vitros Anti-S test only,133000,0.873,0.87,0.876,True,,True,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Zheng Li,Centers for Disease Control and Prevention,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac105,2022-02-25,2024-03-01,Verified,li_social_2022,USA
220207_USA_CentersforDiseaseControlandPrevention_202108_Male_PopAdj,220207_USA_CentersforDiseaseControlandPrevention_202106,"Social vulnerability and rurality associated with higher SARS-CoV-2 infection-induced seroprevalence: a nationwide blood donor study, United States, July 2020 - June 2021.",2022-02-07,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"Catchment areas from 17 blood collection organizations were combined into 65 study regions defined by state and metropolitan borders, representing 50 states and Washington D.C. Each month, approximately 500–4,000 anonymous blood donation specimens from each study region were
selected",Excluded donations made specifically to provide COVID-19 convalescent plasma and samples with missing donor demographic data (2.85% excluded for missing race/ethnicity).,2021-06-01,2021-06-30,Blood donors,Male,Multiple groups,16.0,,Sex/Gender,Male,66000,0.21,0.20600000000000002,0.214,,,True,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Zheng Li,Centers for Disease Control and Prevention,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac105,2022-02-25,2024-03-01,Verified,li_social_2022,USA
220207_USA_CentersforDiseaseControlandPrevention_202116_West_PopAdj,220207_USA_CentersforDiseaseControlandPrevention_202106,"Social vulnerability and rurality associated with higher SARS-CoV-2 infection-induced seroprevalence: a nationwide blood donor study, United States, July 2020 - June 2021.",2022-02-07,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,West census region,,"Catchment areas from 17 blood collection organizations were combined into 65 study regions defined by state and metropolitan borders, representing 50 states and Washington D.C. Each month, approximately 500–4,000 anonymous blood donation specimens from each study region were
selected",Excluded donations made specifically to provide COVID-19 convalescent plasma and samples with missing donor demographic data (2.85% excluded for missing race/ethnicity).,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,West census region,35000,0.17,0.16399999999999998,0.17600000000000002,,,True,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Zheng Li,Centers for Disease Control and Prevention,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac105,2022-02-25,2024-03-01,Verified,li_social_2022,USA
220207_USA_CentersforDiseaseControlandPrevention_202115_South_PopAdj,220207_USA_CentersforDiseaseControlandPrevention_202106,"Social vulnerability and rurality associated with higher SARS-CoV-2 infection-induced seroprevalence: a nationwide blood donor study, United States, July 2020 - June 2021.",2022-02-07,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,South census region,,"Catchment areas from 17 blood collection organizations were combined into 65 study regions defined by state and metropolitan borders, representing 50 states and Washington D.C. Each month, approximately 500–4,000 anonymous blood donation specimens from each study region were
selected",Excluded donations made specifically to provide COVID-19 convalescent plasma and samples with missing donor demographic data (2.85% excluded for missing race/ethnicity).,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,South census region,43000,0.22100000000000003,0.215,0.227,,,True,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Zheng Li,Centers for Disease Control and Prevention,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac105,2022-02-25,2024-03-01,Verified,li_social_2022,USA
220207_USA_CentersforDiseaseControlandPrevention_202107_Female_PopAdj,220207_USA_CentersforDiseaseControlandPrevention_202106,"Social vulnerability and rurality associated with higher SARS-CoV-2 infection-induced seroprevalence: a nationwide blood donor study, United States, July 2020 - June 2021.",2022-02-07,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"Catchment areas from 17 blood collection organizations were combined into 65 study regions defined by state and metropolitan borders, representing 50 states and Washington D.C. Each month, approximately 500–4,000 anonymous blood donation specimens from each study region were
selected",Excluded donations made specifically to provide COVID-19 convalescent plasma and samples with missing donor demographic data (2.85% excluded for missing race/ethnicity).,2021-06-01,2021-06-30,Blood donors,Female,Multiple groups,16.0,,Sex/Gender,Female,66000,0.204,0.198,0.21,,,True,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Zheng Li,Centers for Disease Control and Prevention,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac105,2022-02-25,2024-03-01,Verified,li_social_2022,USA
220207_USA_CentersforDiseaseControlandPrevention_202106_Overall_PopAdj,220207_USA_CentersforDiseaseControlandPrevention_202106,"Social vulnerability and rurality associated with higher SARS-CoV-2 infection-induced seroprevalence: a nationwide blood donor study, United States, July 2020 - June 2021.",2022-02-07,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"Catchment areas from 17 blood collection organizations were combined into 65 study regions defined by state and metropolitan borders, representing 50 states and Washington D.C. Each month, approximately 500–4,000 anonymous blood donation specimens from each study region were
selected",Excluded donations made specifically to provide COVID-19 convalescent plasma and samples with missing donor demographic data (2.85% excluded for missing race/ethnicity).,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Test used,"Overall, pop adjusted",133000,0.207,0.203,0.21100000000000002,,,True,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Zheng Li,Centers for Disease Control and Prevention,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac105,2022-02-25,2024-03-01,Verified,li_social_2022,USA
220207_USA_CentersforDiseaseControlandPrevention_202110_Age30-49_PopAdj,220207_USA_CentersforDiseaseControlandPrevention_202106,"Social vulnerability and rurality associated with higher SARS-CoV-2 infection-induced seroprevalence: a nationwide blood donor study, United States, July 2020 - June 2021.",2022-02-07,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"Catchment areas from 17 blood collection organizations were combined into 65 study regions defined by state and metropolitan borders, representing 50 states and Washington D.C. Each month, approximately 500–4,000 anonymous blood donation specimens from each study region were
selected",Excluded donations made specifically to provide COVID-19 convalescent plasma and samples with missing donor demographic data (2.85% excluded for missing race/ethnicity).,2021-06-01,2021-06-30,Blood donors,All,Adults (18-64 years),30.0,49.0,Age,age 30-34,40000,0.22100000000000003,0.215,0.227,,,True,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Zheng Li,Centers for Disease Control and Prevention,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac105,2022-02-25,2024-03-01,Verified,li_social_2022,USA
220207_USA_CentersforDiseaseControlandPrevention_202111_Age50-64_PopAdj,220207_USA_CentersforDiseaseControlandPrevention_202106,"Social vulnerability and rurality associated with higher SARS-CoV-2 infection-induced seroprevalence: a nationwide blood donor study, United States, July 2020 - June 2021.",2022-02-07,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"Catchment areas from 17 blood collection organizations were combined into 65 study regions defined by state and metropolitan borders, representing 50 states and Washington D.C. Each month, approximately 500–4,000 anonymous blood donation specimens from each study region were
selected",Excluded donations made specifically to provide COVID-19 convalescent plasma and samples with missing donor demographic data (2.85% excluded for missing race/ethnicity).,2021-06-01,2021-06-30,Blood donors,All,Adults (18-64 years),50.0,64.0,Age,age 50-64,49000,0.192,0.187,0.197,,,True,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Zheng Li,Centers for Disease Control and Prevention,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac105,2022-02-25,2024-03-01,Verified,li_social_2022,USA
220207_USA_CentersforDiseaseControlandPrevention_202109_Age16-29_PopAdj,220207_USA_CentersforDiseaseControlandPrevention_202106,"Social vulnerability and rurality associated with higher SARS-CoV-2 infection-induced seroprevalence: a nationwide blood donor study, United States, July 2020 - June 2021.",2022-02-07,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"Catchment areas from 17 blood collection organizations were combined into 65 study regions defined by state and metropolitan borders, representing 50 states and Washington D.C. Each month, approximately 500–4,000 anonymous blood donation specimens from each study region were
selected",Excluded donations made specifically to provide COVID-19 convalescent plasma and samples with missing donor demographic data (2.85% excluded for missing race/ethnicity).,2021-06-01,2021-06-30,Blood donors,All,Adults (18-64 years),16.0,29.0,Age,age 16-29,13000,0.27399999999999997,0.263,0.28500000000000003,,,True,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Zheng Li,Centers for Disease Control and Prevention,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac105,2022-02-25,2024-03-01,Verified,li_social_2022,USA
220207_USA_CentersforDiseaseControlandPrevention_202113_Northeast_PopAdj,220207_USA_CentersforDiseaseControlandPrevention_202106,"Social vulnerability and rurality associated with higher SARS-CoV-2 infection-induced seroprevalence: a nationwide blood donor study, United States, July 2020 - June 2021.",2022-02-07,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeast census region,,"Catchment areas from 17 blood collection organizations were combined into 65 study regions defined by state and metropolitan borders, representing 50 states and Washington D.C. Each month, approximately 500–4,000 anonymous blood donation specimens from each study region were
selected",Excluded donations made specifically to provide COVID-19 convalescent plasma and samples with missing donor demographic data (2.85% excluded for missing race/ethnicity).,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,Northeast census region,24000,0.204,0.195,0.21300000000000002,,,True,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Zheng Li,Centers for Disease Control and Prevention,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac105,2022-02-25,2024-03-01,Verified,li_social_2022,USA
220207_USA_CentersforDiseaseControlandPrevention_202114_Midwest_PopAdj,220207_USA_CentersforDiseaseControlandPrevention_202106,"Social vulnerability and rurality associated with higher SARS-CoV-2 infection-induced seroprevalence: a nationwide blood donor study, United States, July 2020 - June 2021.",2022-02-07,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Midwest census region,,"Catchment areas from 17 blood collection organizations were combined into 65 study regions defined by state and metropolitan borders, representing 50 states and Washington D.C. Each month, approximately 500–4,000 anonymous blood donation specimens from each study region were
selected",Excluded donations made specifically to provide COVID-19 convalescent plasma and samples with missing donor demographic data (2.85% excluded for missing race/ethnicity).,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,Midwest census region,31000,0.23399999999999999,0.226,0.242,,,True,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Zheng Li,Centers for Disease Control and Prevention,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac105,2022-02-25,2024-03-01,Verified,li_social_2022,USA
220207_USA_CentersforDiseaseControlandPrevention_202112_Age65+_PopAdj,220207_USA_CentersforDiseaseControlandPrevention_202106,"Social vulnerability and rurality associated with higher SARS-CoV-2 infection-induced seroprevalence: a nationwide blood donor study, United States, July 2020 - June 2021.",2022-02-07,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"Catchment areas from 17 blood collection organizations were combined into 65 study regions defined by state and metropolitan borders, representing 50 states and Washington D.C. Each month, approximately 500–4,000 anonymous blood donation specimens from each study region were
selected",Excluded donations made specifically to provide COVID-19 convalescent plasma and samples with missing donor demographic data (2.85% excluded for missing race/ethnicity).,2021-06-01,2021-06-30,Blood donors,All,Seniors (65+ years),65.0,,Age,age 65+ ,30000,0.12,0.115,0.125,,,True,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],No,No,Yes,Yes,No,Yes,Yes,Yes,,Zheng Li,Centers for Disease Control and Prevention,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac105,2022-02-25,2024-03-01,Verified,li_social_2022,USA
220210_SpaceX_LondonSchoolOfHygiene&TropicalMedicine_TestAdj,220210_SpaceX_LondonSchoolOfHygiene&TropicalMedicine,SARS-CoV-2 antibodies protect against reinfection for at least 6 months in a multicentre seroepidemiological workplace cohort,2022-02-10,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,"California, Florida, Texas, and Washington State.",,"""We used data from a seroepidemiological study of US employees at SpaceX"".

""this study involved employees from 7 work locations in California, Florida, Texas, and Washington State, with ages ranging from 18 to 71.""",None.,2020-03-29,2020-08-23,Non-essential workers and unemployed persons,All,Multiple groups,18.0,71.0,Primary Estimate,,4411,0.08199999999999999,0.073,0.091,True,True,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.8240000000000001,0.996,['High'],,No,Yes,No,,Unclear,Yes,Yes,,Emilie Finch,London School of Hygiene & Tropical Medicine,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pbio.3001531,2022-02-24,2022-07-16,Unverified,finch_sars-cov-2_2022,USA
220214_Atlanta_EmoryUniversity_Baseline_Overall,220214_Atlanta_EmoryUniversity_Baseline,Occupational Risk Factors for SARS-CoV-2 Infection among Healthcare Personnel: A 6-month prospective analysis of the COVID-19 Prevention in Emory Healthcare Personnel (COPE) Study.,2022-02-14,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Georgia,Atlanta,"At
enrollment, HCP had to be >18 years old, have worked ≥1 shift in the previous two weeks, have
no self-reported COVID-19 symptoms in the week prior, and have no anticipated employment
changes.","NR
",2020-05-06,2020-06-12,Health care workers and caregivers,All,Adults (18-64 years),19.0,,Primary Estimate,,353,0.054000000000000006,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.867,0.993,['High'],,No,Yes,No,,Unclear,Yes,No,,Jessica Howard-Anderson,Emory University,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2021.518,2022-02-24,2022-07-16,Unverified,howard-anderson_occupational_2022,USA
220214_Atlanta_EmoryUniversity_Follow-up_Overall,220214_Atlanta_EmoryUniversity_Follow-up,Occupational Risk Factors for SARS-CoV-2 Infection among Healthcare Personnel: A 6-month prospective analysis of the COVID-19 Prevention in Emory Healthcare Personnel (COPE) Study.,2022-02-14,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Georgia,Atlanta,"At
enrollment, HCP had to be >18 years old, have worked ≥1 shift in the previous two weeks, have
no self-reported COVID-19 symptoms in the week prior, and have no anticipated employment
changes.",,2020-05-06,2020-06-12,Health care workers and caregivers,All,Adults (18-64 years),19.0,,Primary Estimate,,304,0.086,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.867,0.993,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Jessica Howard-Anderson,Emory University,Not Unity-Aligned,https://dx.doi.org/10.1017/ice.2021.518,2022-02-24,2022-07-16,Unverified,howard-anderson_occupational_2022,USA
220214_Bethesda_UniformedServicesUniversityoftheHealthSciences,220214_Bethesda_UniformedServicesUniversityoftheHealthSciences,Prospective Assessment of Symptoms to Evaluate Asymptomatic SARS-CoV-2 Infections in a Cohort of Health Care Workers.,2022-02-14,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Maryland,Betheseda,"Briefly, inclusion criteria included being generally healthy, ≥18 years old, and  employed  at  WRNMMC.","Exclusion  criteria  included  history  of  coronavirus  disease  2019  (COVID-19),  SARS-CoV-2  immunoglobulin   (IgG)   seropositivity,  and   being   immunocompromised  at  screening. ",2020-08-25,2020-12-31,Health care workers and caregivers,All,Multiple groups,19.0,69.0,Primary Estimate,,263,0.0418,,,True,,,,True,Convenience,Author designed (Luminex),,Other,Serum,IgG,Spike,Validated by developers,0.9400000000000001,1.0,['High'],,No,No,Yes,,Unclear,Yes,Yes,,Emilie Goguet,Uniformed Services University of the Health Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac030,2022-03-08,2022-07-16,Unverified,goguet_prospective_2022,USA
220219_USA_LombardiComprehensiveCancerCenter_HCW,220219_USA_LombardiComprehensiveCancerCenter_HCW,Incidence and Durability of SARS-CoV-2 Antibodies in Patients with Cancer and Health Care Workers following the First Wave of the Pandemic.,2022-02-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,New Jersey,"Washington DC, Hackensack","Eligible subjects were at least 18 years old and had to be afebrile and without other COVID-19-related symptoms at the time of enrollment.
HCWs were eligible if actively employed at MGUH/GUMC or HMH/JTCC and if coming to work in person for any period of time either inpatient or outpatient. HCWs included physicians, nurses, allied health providers, administrative and tech staff. Allied health providers consisted of nurse practitioners and physicians assistants; administrative staff were HCWs who worked at the front desk of clinics or in a supportive capacity in non-clinical areas, and techs included but were not limited to those directly involved in hospital operations, for example, patient transport, radiology, phlebotomy, and/or food services.",,2020-04-15,2020-07-15,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,1220,0.037000000000000005,0.027000000000000003,0.049,True,,,,True,Convenience,"Author designed (ELISA) -Spike,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown)","NA,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,No,,Unclear,No,No,,Catherine Lai,Lombardi Comprehensive Cancer Center,Not Unity-Aligned,https://dx.doi.org/10.1155/2022/8798306,2022-03-09,2022-07-16,Unverified,lai_incidence_2022,USA
220219_USA_LombardiComprehensiveCancerCenter_Patients,220219_USA_LombardiComprehensiveCancerCenter_Patients,Incidence and Durability of SARS-CoV-2 Antibodies in Patients with Cancer and Health Care Workers following the First Wave of the Pandemic.,2022-02-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,New Jersey,"Washington DC, Hackensack",Eligible subjects were at least 18 years old and had to be afebrile and without other COVID-19-related symptoms at the time of enrollment. Patients could have any type of cancer,Currently hospitalized patients were excluded.,2020-04-15,2020-07-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,733,0.031000000000000003,0.02,0.047,True,,,,True,Convenience,"Author designed (ELISA) -Spike,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown)","NA,Roche Diagnostics",Multiple Types,Serum,TotalAntibody,Spike,Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,No,,Unclear,No,No,,Catherine Lai,Lombardi Comprehensive Cancer Center,Not Unity-Aligned,https://dx.doi.org/10.1155/2022/8798306,2022-03-09,2022-07-16,Unverified,lai_incidence_2022,USA
220221_NewYork_DonaldAndBarbaraZuckerSchoolOfMedicineAtHofstra/Northwell_Overall,220221_NewYork_DonaldAndBarbaraZuckerSchoolOfMedicineAtHofstra/Northwell,The clinical impact of the Covid-19 pandemic first wave on patients with cystic fibrosis in New York.,2022-02-21,Journal Article (Peer-Reviewed),Regional,Retrospective cohort,United States of America,New York,,Reasons for antibody screening included: (1) PCR testing was not readily available during the early pandemic; (2) patients did not obtain PCR testing at the time of suspected COVID-19; (3) patients exhibited symptoms indistinguishable from COVID-19; and (4) patients reported suspected exposure,,2020-05-01,2020-08-31,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,147,0.122,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,IgG,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Joseph L.Simonson,Donald and Barbara Zucker School of Medicine at Hofstra/Northwell,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jcf.2022.02.012,2022-03-15,2022-07-16,Unverified,simonson_clinical_2022,USA
220225_NewYork_NewYorkUniversityLongIslandSchoolofMedicine_Overall,220225_NewYork_NewYorkUniversityLongIslandSchoolofMedicine,COVID-19 Antibodies and Outcomes among Outpatient Maintenance Hemodialysis Patients.,2022-02-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York,Long Island,"Inclusion criteria included all patients with ESKD on in-center hemodialysis who were active at one of these units as of February 1, 2020, because COVID-19 may have been undergoing community transmission in the New York region as early as February 2020 (D. Stadlbauer et al., unpublished observations). ","Exclusion criteria were all patients on home dialysis (peritoneal dialysis and home hemodialysis), because their risks of SARS-CoV-2 acquisition are vastly different, and any patients who did not undergo either SARS-CoV-2 antibody or PCR testing due to passing away, transfer to another dialysis unit, or other circumstances.",2020-02-01,2020-08-25,Residual sera,All,Multiple groups,,,Primary Estimate,,343,0.257,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9990000000000001,['High'],Yes,No,No,No,Unclear,Yes,Yes,Yes,Unclear,Minesh Khatri,New York University Long Island School of Medicine,Unity-Aligned,https://dx.doi.org/10.34067/KID.0006292020,2022-04-11,2024-03-01,Verified,khatri_covid-19_2021,USA
220228_Georgia_EmoryUniversity_MixedImmunity,220228_Georgia_EmoryUniversity,"Quantifying Risk for SARS-CoV-2 Infection Among Nursing Home Workers for the 2020-2021 Winter Surge of the COVID-19 Pandemic in Georgia, USA.",2022-02-28,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Georgia,,"""We recruited voluntary participants from 14 nursing homes that had previously participated in the COVID-19 Prevention in Nursing Homes (COPING) serologic survey study.""

""... contracted or employed staff members from those 14 participating nursing homes who were seronegative at the first time point and provided a serology specimen at second time point""

""Staff who reported their most recent vaccine dose ≤ 4 weeks of the second time point.""",,2021-02-11,2021-05-07,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Mixed type of immunity,203,0.7192000000000001,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Dried Blood,IgG,Spike,Validated by manufacturers,0.9,1.0,['High'],,No,No,Yes,,Yes,Yes,Yes,,William Dube,Emory University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jamda.2022.02.014,2022-04-07,2024-03-01,Unverified,dube_quantifying_2022,USA
220303_Charleston_MedicalUniversityOfSouthCarolina_Period1,220303_Charleston_MedicalUniversityOfSouthCarolina,"Self-Administered, Remote Assessment of SARS-CoV-2 Seroprevalence in Health Care Workers.",2022-03-08,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,South Carolina,Charleston,"Group 1 (n=339) had risk factors for occupational exposure and included employees who provided direct care or services for patients with SARS-CoV-2 infection, worked in the emergency department or SARS-CoV-2 testing site, or worked where aerosolizing procedures were performed. Employees in this group included clinicians (physicians, physician’s assistants, nurse practitioners), nurses, patient care technicians, respiratory therapists, social workers, environmental or food services staff, unit secretaries, occupational therapists, speech therapists, and pharmacists. Group 2 (n=100) included MUSC employees without identifiable risk factors for occupational exposure and whose job duties did not involve direct patient care within the 6 months prior to enrollment. Participants had to be ≥ 18 years old and be able to take and transmit a picture of their test result.","Participants were excluded if they had respiratory symptoms within the preceding 14 days (e.g., cough, fever, shortness of breath), had been tested for or diagnosed with SARS-CoV-2 infection in the prior 14 days, or if they had a bleeding disorder or were taking systemic anticoagulants.",2020-04-17,2020-06-07,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Period 1: 4/17-6/7,427,0.006999999999999999,,,True,,,,True,Convenience,Novel Coronavirus IgG antibody test kit (colloidal gold method),RayBiotech,LFIA,Whole Blood,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,No,Yes,No,,Lauren Card,Medical University of South Carolina,Not Unity-Aligned,https://dx.doi.org/10.1016/j.amjms.2022.01.025,2022-03-22,2024-03-01,Unverified,card_self-administered_2022,USA
220310_USA_UniversityOfSouthCarolinaArnold SchoolOfPublicHealth_OverallAdj,220310_USA_UniversityOfSouthCarolinaArnold SchoolOfPublicHealth,"SARS-CoV-2 Viral Incidence, Antibody Point Prevalence, Associated Population Characteristics, and Vaccine Attitudes, South Carolina, February 2021.",2022-03-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,South Carolina,,"South Carolina residents. All selected participants, and 1 household member aged ≥5 years of the initially selected participants’ choosing",,2021-02-01,2021-03-04,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,,1803,0.16399999999999998,0.14400000000000002,0.185,True,,True,,True,Stratified probability,"COVID-19 IgG/IgM Rapid Test Cassette,COVID-19 IgG/IgM Rapid Test Device","Healgen,Assure Tech. (Hangzhou) Co. Ltd",Multiple Types,,"['IgG', 'IgM']",Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,No,No,No,Melissa S. Nolan,University of South Carolina Arnold School of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1177/00333549221081128,2022-03-18,2024-03-01,Verified,nolanSARSCoV2ViralIncidence,USA
220310_USA_UniversityOfSouthCarolinaArnold SchoolOfPublicHealth_Male,220310_USA_UniversityOfSouthCarolinaArnold SchoolOfPublicHealth,"SARS-CoV-2 Viral Incidence, Antibody Point Prevalence, Associated Population Characteristics, and Vaccine Attitudes, South Carolina, February 2021.",2022-03-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,South Carolina,,"South Carolina residents. All selected participants, and 1 household member aged ≥5 years of the initially selected participants’ choosing",,2021-02-01,2021-03-04,Household and community samples,Male,Multiple groups,5.0,,Sex/Gender,,766,0.1586,0.1303,0.19140000000000001,,,True,,,Stratified probability,"COVID-19 IgG/IgM Rapid Test Cassette,COVID-19 IgG/IgM Rapid Test Device","Healgen,Assure Tech. (Hangzhou) Co. Ltd",Multiple Types,,"['IgG', 'IgM']",Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,No,No,No,Melissa S. Nolan,University of South Carolina Arnold School of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1177/00333549221081128,2022-05-30,2024-03-01,Verified,nolanSARSCoV2ViralIncidence,USA
220310_USA_UniversityOfSouthCarolinaArnold SchoolOfPublicHealth_Age5to19,220310_USA_UniversityOfSouthCarolinaArnold SchoolOfPublicHealth,"SARS-CoV-2 Viral Incidence, Antibody Point Prevalence, Associated Population Characteristics, and Vaccine Attitudes, South Carolina, February 2021.",2022-03-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,South Carolina,,"South Carolina residents. All selected participants, and 1 household member aged ≥5 years of the initially selected participants’ choosing",,2021-02-01,2021-03-04,Household and community samples,All,Children and Youth (0-17 years),5.0,,Age,age: 5-19,64,0.1578,0.0827,0.2783,,,True,,,Stratified probability,"COVID-19 IgG/IgM Rapid Test Cassette,COVID-19 IgG/IgM Rapid Test Device","Healgen,Assure Tech. (Hangzhou) Co. Ltd",Multiple Types,,"['IgG', 'IgM']",Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,No,No,No,Melissa S. Nolan,University of South Carolina Arnold School of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1177/00333549221081128,2022-05-30,2024-03-01,Verified,nolanSARSCoV2ViralIncidence,USA
220310_USA_UniversityOfSouthCarolinaArnold SchoolOfPublicHealth_Female,220310_USA_UniversityOfSouthCarolinaArnold SchoolOfPublicHealth,"SARS-CoV-2 Viral Incidence, Antibody Point Prevalence, Associated Population Characteristics, and Vaccine Attitudes, South Carolina, February 2021.",2022-03-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,South Carolina,,"South Carolina residents. All selected participants, and 1 household member aged ≥5 years of the initially selected participants’ choosing",,2021-02-01,2021-03-04,Household and community samples,Female,Multiple groups,5.0,,Sex/Gender,,1037,0.1679,0.1414,0.1981,,,True,,,Stratified probability,"COVID-19 IgG/IgM Rapid Test Cassette,COVID-19 IgG/IgM Rapid Test Device","Healgen,Assure Tech. (Hangzhou) Co. Ltd",Multiple Types,,"['IgG', 'IgM']",Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,No,No,No,Melissa S. Nolan,University of South Carolina Arnold School of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1177/00333549221081128,2022-05-30,2024-03-01,Verified,nolanSARSCoV2ViralIncidence,USA
220310_USA_UniversityOfSouthCarolinaArnold SchoolOfPublicHealth_Age20to59,220310_USA_UniversityOfSouthCarolinaArnold SchoolOfPublicHealth,"SARS-CoV-2 Viral Incidence, Antibody Point Prevalence, Associated Population Characteristics, and Vaccine Attitudes, South Carolina, February 2021.",2022-03-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,South Carolina,,"South Carolina residents. All selected participants, and 1 household member aged ≥5 years of the initially selected participants’ choosing",,2021-02-01,2021-03-04,Household and community samples,All,Adults (18-64 years),20.0,,Age,age: 20-59,805,0.1378,0.1129,0.167,,,True,,,Stratified probability,"COVID-19 IgG/IgM Rapid Test Cassette,COVID-19 IgG/IgM Rapid Test Device","Healgen,Assure Tech. (Hangzhou) Co. Ltd",Multiple Types,,"['IgG', 'IgM']",Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,No,No,No,Melissa S. Nolan,University of South Carolina Arnold School of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1177/00333549221081128,2022-05-30,2024-03-01,Verified,nolanSARSCoV2ViralIncidence,USA
220310_USA_UniversityOfSouthCarolinaArnold SchoolOfPublicHealth_OverallUnadj,220310_USA_UniversityOfSouthCarolinaArnold SchoolOfPublicHealth,"SARS-CoV-2 Viral Incidence, Antibody Point Prevalence, Associated Population Characteristics, and Vaccine Attitudes, South Carolina, February 2021.",2022-03-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,South Carolina,,"South Carolina residents. All selected participants, and 1 household member aged ≥5 years of the initially selected participants’ choosing",,2021-02-01,2021-03-04,Household and community samples,All,Multiple groups,5.0,,Analysis,,1803,0.18,,,,,,,,Stratified probability,"COVID-19 IgG/IgM Rapid Test Cassette,COVID-19 IgG/IgM Rapid Test Device","Healgen,Assure Tech. (Hangzhou) Co. Ltd",Multiple Types,,"['IgG', 'IgM']",Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,No,No,No,Melissa S. Nolan,University of South Carolina Arnold School of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1177/00333549221081128,2022-05-30,2024-03-01,Verified,nolanSARSCoV2ViralIncidence,USA
220310_USA_UniversityOfSouthCarolinaArnold SchoolOfPublicHealth_AgeOver60,220310_USA_UniversityOfSouthCarolinaArnold SchoolOfPublicHealth,"SARS-CoV-2 Viral Incidence, Antibody Point Prevalence, Associated Population Characteristics, and Vaccine Attitudes, South Carolina, February 2021.",2022-03-10,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,South Carolina,,"South Carolina residents. All selected participants, and 1 household member aged ≥5 years of the initially selected participants’ choosing",,2021-02-01,2021-03-04,Household and community samples,All,Seniors (65+ years),60.0,,Age,age: >= 60,934,0.21559999999999999,0.18780000000000002,0.2463,,,True,,,Stratified probability,"COVID-19 IgG/IgM Rapid Test Cassette,COVID-19 IgG/IgM Rapid Test Device","Healgen,Assure Tech. (Hangzhou) Co. Ltd",Multiple Types,,"['IgG', 'IgM']",Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,No,No,No,Melissa S. Nolan,University of South Carolina Arnold School of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1177/00333549221081128,2022-05-30,2024-03-01,Verified,nolanSARSCoV2ViralIncidence,USA
220312_California_StanfordUniversity,220312_California_StanfordUniversity,Incidence and prevalence of COVID-19 within a healthcare worker cohort during the first year of the SARS-CoV-2 pandemic.,2022-03-12,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,California,,"HCW from Stanford Health (SHC), UCSF Health (UCSF), and Zuckerberg San Francisco General Hospital (ZSFGH) for this longitudinal, prospective cohort study. These three medical centers serve large, mostly non-overlapping catchment populations in the San Francisco Bay Area and implemented similar mitigation policies over time (Supplementary Table 1). Recruitment included medical center-wide email and verbal announcements, targeted email notifications to department leaders, and recruitment flyers.

Inclusion criteria were (1) age ≥18 years old, (2) employment at one of the three medical centers, and (3) did not anticipate ending employment or taking leave in the next 6 months.",,2020-05-15,2020-09-15,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,2435,0.0374,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG,Author designed (type unknown),Author designed (Neutralization Assay)","Abbott Laboratories,EUROIMMUN,NA",,Serum,"['IgG', 'Neutralizing']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Yes,Yes,No,,Sarah Doernberg,Stanford University,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac210,2022-03-25,2024-03-01,Unverified,doernberg_incidence_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave1_Overall,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave1,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2020-04-02,2020-05-06,Residual sera,All,Children and Youth (0-17 years),1.0,18.0,Primary Estimate,,316,0.086,0.049,0.11599999999999999,True,,True,,True,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave1_Female,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave1,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2020-04-02,2020-05-06,Residual sera,Female,Children and Youth (0-17 years),,,Sex/Gender,,161,0.087,0.043,0.131,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave1_10-14,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave1,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2020-04-02,2020-05-06,Residual sera,All,Children and Youth (0-17 years),10.0,14.0,Age,10-14,90,0.08900000000000001,0.028999999999999998,0.149,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave1_Male,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave1,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2020-04-02,2020-05-06,Residual sera,Male,Children and Youth (0-17 years),,,Sex/Gender,,155,0.071,0.03,0.11199999999999999,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave1_5-9,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave1,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2020-04-02,2020-05-06,Residual sera,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,61,0.049,0.0,0.105,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave1_1-4,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave1,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2020-04-02,2020-05-06,Residual sera,All,Children and Youth (0-17 years),1.0,4.0,Age,1-4,56,0.107,0.024,0.19100000000000003,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave1_15-18,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave1,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2020-04-02,2020-05-06,Residual sera,All,Children and Youth (0-17 years),15.0,18.0,Age,15-18,109,0.073,0.013999999999999999,0.12300000000000001,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave2_Overall,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave2,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2020-06-06,2020-08-10,Residual sera,All,Children and Youth (0-17 years),1.0,18.0,Primary Estimate,,299,0.095,0.057999999999999996,0.132,True,,True,,True,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave2_Male,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave2,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2020-06-06,2020-08-10,Residual sera,Male,Children and Youth (0-17 years),,,Sex/Gender,,144,0.09699999999999999,0.048,0.146,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave2_1-4,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave2,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2020-06-06,2020-08-10,Residual sera,All,Children and Youth (0-17 years),1.0,4.0,Age,1-4,33,0.152,0.022000000000000002,0.281,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave2_15-18,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave2,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2020-06-06,2020-08-10,Residual sera,All,Children and Youth (0-17 years),15.0,18.0,Age,15-18,93,0.065,0.013999999999999999,0.115,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave2_10-14,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave2,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2020-06-06,2020-08-10,Residual sera,All,Children and Youth (0-17 years),10.0,14.0,Age,10-14,98,0.11199999999999999,0.049,0.17600000000000002,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave2_Female,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave2,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2020-06-06,2020-08-10,Residual sera,Female,Children and Youth (0-17 years),,,Sex/Gender,,155,0.09,0.045,0.136,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave2_5-9,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave2,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2020-06-06,2020-08-10,Residual sera,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,75,0.08,0.017,0.14300000000000002,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave3_Overall,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave3,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2020-09-08,2020-10-17,Residual sera,All,Children and Youth (0-17 years),1.0,18.0,Primary Estimate,,583,0.17300000000000001,0.136,0.21,True,,True,,True,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave3_5-9,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave3,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2020-09-08,2020-10-17,Residual sera,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,112,0.188,0.114,0.261,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave3_Male,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave3,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2020-09-08,2020-10-17,Residual sera,Male,Children and Youth (0-17 years),,,Sex/Gender,,265,0.147,0.10400000000000001,0.19,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave3_15-18,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave3,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2020-09-08,2020-10-17,Residual sera,All,Children and Youth (0-17 years),15.0,18.0,Age,15-18 ,194,0.155,0.10300000000000001,0.20600000000000002,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave3_10-14,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave3,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2020-09-08,2020-10-17,Residual sera,All,Children and Youth (0-17 years),10.0,14.0,Age,10-14,200,0.145,0.096,0.19399999999999998,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave3_1-4,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave3,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2020-09-08,2020-10-17,Residual sera,All,Children and Youth (0-17 years),1.0,4.0,Age,1-4,77,0.20800000000000002,0.115,0.3,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave3_Female,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave3,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2020-09-08,2020-10-17,Residual sera,Female,Children and Youth (0-17 years),,,Sex/Gender,,318,0.179,0.13699999999999998,0.222,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave4_Overall,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave4,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2020-11-07,2020-12-17,Residual sera,All,Children and Youth (0-17 years),1.0,18.0,Primary Estimate,,570,0.131,0.1,0.162,True,,True,,True,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave4_Male,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave4,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2020-11-07,2020-12-17,Residual sera,Male,Children and Youth (0-17 years),,,Sex/Gender,,245,0.131,0.08800000000000001,0.17300000000000001,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave4_Female,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave4,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2020-11-07,2020-12-17,Residual sera,Female,Children and Youth (0-17 years),,,Sex/Gender,,320,0.14400000000000002,0.105,0.182,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave4_10-14,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave4,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2020-11-07,2020-12-17,Residual sera,All,Children and Youth (0-17 years),10.0,14.0,Age,10-14,204,0.147,0.098,0.196,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave4_1-4,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave4,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2020-11-07,2020-12-17,Residual sera,All,Children and Youth (0-17 years),1.0,4.0,Age,1-4,76,0.079,0.017,0.141,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave4_5-9,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave4,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2020-11-07,2020-12-17,Residual sera,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,114,0.132,0.069,0.195,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave4_15-18,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave4,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2020-11-07,2020-12-17,Residual sera,All,Children and Youth (0-17 years),15.0,18.0,Age,15-18,171,0.158,0.10300000000000001,0.21300000000000002,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave5_Overall,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave5,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2021-04-05,2021-04-28,Residual sera,All,Children and Youth (0-17 years),1.0,18.0,Primary Estimate,,589,0.23399999999999999,0.19399999999999998,0.27399999999999997,True,,True,,True,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave5_Female,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave5,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2021-04-05,2021-04-28,Residual sera,Female,Children and Youth (0-17 years),,,Sex/Gender,,332,0.265,0.217,0.313,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave5_Male,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave5,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2021-04-05,2021-04-28,Residual sera,Male,Children and Youth (0-17 years),,,Sex/Gender,,255,0.228,0.17600000000000002,0.27899999999999997,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave5_1-4,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave5,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2021-04-05,2021-04-28,Residual sera,All,Children and Youth (0-17 years),1.0,4.0,Age,1-4,75,0.16,0.075,0.245,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave5_15-18,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave5,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2021-04-05,2021-04-28,Residual sera,All,Children and Youth (0-17 years),15.0,18.0,Age,15-18,182,0.29100000000000004,0.225,0.358,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave5_10-14,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave5,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2021-04-05,2021-04-28,Residual sera,All,Children and Youth (0-17 years),10.0,14.0,Age,10-14,188,0.287,0.222,0.353,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave5_5-9,220316_Arkansas_UniversityofArkansasforMedicalSciences_Wave5,Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.,2022-03-16,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Arkansas,"Little Rock, Springdale, Fort Smith, Pine Bluf","Inclusion criteria were ages 1-18
years and Arkansas resident. Samples were only collected from
outpatient visits.","Samples were excluded with the following International
Classifcation of Diseases-10 (ICD-10) and Current Procedural
Technology (CPT) codes: immunodefciency (primary immune defciency, D80-D89), transplant recipient (codes beginning with Z94), and cancer (C00-D49). Samples from patients
receiving chemotherapy (before 2 months), steroids (before 30
days), and/or intravenous immunoglobulin (before 6 months)
were excluded",2021-04-05,2021-04-28,Residual sera,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,142,0.19,0.125,0.255,,,True,,,Convenience,"Author designed (ELISA) -Spike,Author designed (ELISA) - Nucleocapsid",,ELISA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Karl Boehme, University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/jpids/piac010,2022-03-21,2022-07-16,Unverified,boehme_pediatric_2022,USA
220316_Minnesota_University of Minnesota,220316_Minnesota_University of Minnesota,"SARS-CoV-2 Seroprevalence Survey in Grocery Store Workers-Minnesota, 2020-2021",2022-03-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Minnesota,,Grocery store workers in Minnesota age 18 and over,Under age 18,2020-12-08,2021-03-24,Non-essential workers and unemployed persons,All,Multiple groups,18.0,,Primary Estimate,,706,0.0793201133,,,True,,,,True,Convenience,Q-Plex SARS-CoV-2 Human IgG (4-Plex),Quansys Biosciences,ELISA,Whole Blood,IgG,Spike,Validated by manufacturers,0.97,1.0,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Madhura Vachon,University of Minnesota,Not Unity-Aligned,https://dx.doi.org/10.3390/ijerph19063501,2022-04-02,2024-03-01,Unverified,vachon_sars-cov-2_2022,USA
220318_Texas_TheUniversityOfTexasSystem_Round1_Overall,220318_Texas_TheUniversityOfTexasSystem_Round1,Durability of SARS-CoV-2 Antibodies From Natural Infection in Children and Adolescents,2022-03-18,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Texas,,"This analysis included participants ages 5-to-19 years old
who have completed all three antibody assessments",,2020-10-01,2020-11-30,Household and community samples,All,Children and Youth (0-17 years),5.0,19.0,Primary Estimate,Overall,218,0.344,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.97,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Sarah Messiah,The University of Texas System,Not Unity-Aligned,http://doi.org/10.1542/peds.2021-055505,2022-04-07,2024-03-01,Unverified,messiah_durability_2022,USA
220318_Texas_TheUniversityOfTexasSystem_Round1_age10-14,220318_Texas_TheUniversityOfTexasSystem_Round1,Durability of SARS-CoV-2 Antibodies From Natural Infection in Children and Adolescents,2022-03-18,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Texas,,"This analysis included participants ages 5-to-19 years old
who have completed all three antibody assessments",,2020-10-01,2020-11-30,Household and community samples,All,Children and Youth (0-17 years),10.0,14.0,Age,Age10-14,75,0.36,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.97,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Sarah Messiah,The University of Texas System,Not Unity-Aligned,http://doi.org/10.1542/peds.2021-055505,2022-04-07,2024-03-01,Unverified,messiah_durability_2022,USA
220318_Texas_TheUniversityOfTexasSystem_Round1_males,220318_Texas_TheUniversityOfTexasSystem_Round1,Durability of SARS-CoV-2 Antibodies From Natural Infection in Children and Adolescents,2022-03-18,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Texas,,"This analysis included participants ages 5-to-19 years old
who have completed all three antibody assessments",,2020-10-01,2020-11-30,Household and community samples,Male,Children and Youth (0-17 years),5.0,19.0,Sex/Gender,Males,74,0.48600000000000004,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.97,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Sarah Messiah,The University of Texas System,Not Unity-Aligned,http://doi.org/10.1542/peds.2021-055505,2022-04-07,2024-03-01,Unverified,messiah_durability_2022,USA
220318_Texas_TheUniversityOfTexasSystem_Round1_age5-9,220318_Texas_TheUniversityOfTexasSystem_Round1,Durability of SARS-CoV-2 Antibodies From Natural Infection in Children and Adolescents,2022-03-18,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Texas,,"This analysis included participants ages 5-to-19 years old
who have completed all three antibody assessments",,2020-10-01,2020-11-30,Household and community samples,All,Children and Youth (0-17 years),5.0,9.0,Age,Age5-9,75,0.267,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.97,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Sarah Messiah,The University of Texas System,Not Unity-Aligned,http://doi.org/10.1542/peds.2021-055505,2022-04-07,2024-03-01,Unverified,messiah_durability_2022,USA
220318_Texas_TheUniversityOfTexasSystem_Round1_age15-19,220318_Texas_TheUniversityOfTexasSystem_Round1,Durability of SARS-CoV-2 Antibodies From Natural Infection in Children and Adolescents,2022-03-18,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Texas,,"This analysis included participants ages 5-to-19 years old
who have completed all three antibody assessments",,2020-10-01,2020-11-30,Household and community samples,All,Children and Youth (0-17 years),15.0,19.0,Age,Age15-19,75,0.373,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.97,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Sarah Messiah,The University of Texas System,Not Unity-Aligned,http://doi.org/10.1542/peds.2021-055505,2022-04-07,2024-03-01,Unverified,messiah_durability_2022,USA
220318_Texas_TheUniversityOfTexasSystem_Round1_females,220318_Texas_TheUniversityOfTexasSystem_Round1,Durability of SARS-CoV-2 Antibodies From Natural Infection in Children and Adolescents,2022-03-18,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Texas,,"This analysis included participants ages 5-to-19 years old
who have completed all three antibody assessments",,2020-10-01,2020-11-30,Household and community samples,Female,Children and Youth (0-17 years),5.0,19.0,Sex/Gender,Females,74,0.514,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.97,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Sarah Messiah,The University of Texas System,Not Unity-Aligned,http://doi.org/10.1542/peds.2021-055505,2022-04-07,2024-03-01,Unverified,messiah_durability_2022,USA
220318_Texas_TheUniversityOfTexasSystem_Round2_Overall,220318_Texas_TheUniversityOfTexasSystem_Round2,Durability of SARS-CoV-2 Antibodies From Natural Infection in Children and Adolescents,2022-03-18,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Texas,,"This analysis included participants ages 5-to-19 years old
who have completed all three antibody assessments",,2021-01-01,2021-02-28,Household and community samples,All,Children and Youth (0-17 years),5.0,19.0,Primary Estimate,Overall,218,0.408,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.97,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Sarah Messiah,The University of Texas System,Not Unity-Aligned,http://doi.org/10.1542/peds.2021-055505,2022-04-07,2024-03-01,Unverified,messiah_durability_2022,USA
220318_Texas_TheUniversityOfTexasSystem_Round2_Males,220318_Texas_TheUniversityOfTexasSystem_Round2,Durability of SARS-CoV-2 Antibodies From Natural Infection in Children and Adolescents,2022-03-18,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Texas,,"This analysis included participants ages 5-to-19 years old
who have completed all three antibody assessments",,2021-01-01,2021-02-28,Household and community samples,Male,Children and Youth (0-17 years),5.0,19.0,Sex/Gender,Males,88,0.466,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.97,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Sarah Messiah,The University of Texas System,Not Unity-Aligned,http://doi.org/10.1542/peds.2021-055505,2022-04-07,2024-03-01,Unverified,messiah_durability_2022,USA
220318_Texas_TheUniversityOfTexasSystem_Round2_Females,220318_Texas_TheUniversityOfTexasSystem_Round2,Durability of SARS-CoV-2 Antibodies From Natural Infection in Children and Adolescents,2022-03-18,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Texas,,"This analysis included participants ages 5-to-19 years old
who have completed all three antibody assessments",,2021-01-01,2021-02-28,Household and community samples,Female,Children and Youth (0-17 years),5.0,19.0,Sex/Gender,Females,88,0.534,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.97,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Sarah Messiah,The University of Texas System,Not Unity-Aligned,http://doi.org/10.1542/peds.2021-055505,2022-04-07,2024-03-01,Unverified,messiah_durability_2022,USA
220318_Texas_TheUniversityOfTexasSystem_Round2_Age15-19,220318_Texas_TheUniversityOfTexasSystem_Round2,Durability of SARS-CoV-2 Antibodies From Natural Infection in Children and Adolescents,2022-03-18,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Texas,,"This analysis included participants ages 5-to-19 years old
who have completed all three antibody assessments",,2021-01-01,2021-02-28,Household and community samples,All,Children and Youth (0-17 years),15.0,19.0,Age,Age15-19,89,0.36,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.97,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Sarah Messiah,The University of Texas System,Not Unity-Aligned,http://doi.org/10.1542/peds.2021-055505,2022-04-07,2024-03-01,Unverified,messiah_durability_2022,USA
220318_Texas_TheUniversityOfTexasSystem_Round2_Age10-14,220318_Texas_TheUniversityOfTexasSystem_Round2,Durability of SARS-CoV-2 Antibodies From Natural Infection in Children and Adolescents,2022-03-18,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Texas,,"This analysis included participants ages 5-to-19 years old
who have completed all three antibody assessments",,2021-01-01,2021-02-28,Household and community samples,All,Children and Youth (0-17 years),10.0,14.0,Age,Age10-14,89,0.40399999999999997,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.97,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Sarah Messiah,The University of Texas System,Not Unity-Aligned,http://doi.org/10.1542/peds.2021-055505,2022-04-07,2024-03-01,Unverified,messiah_durability_2022,USA
220318_Texas_TheUniversityOfTexasSystem_Round2_Age5-9,220318_Texas_TheUniversityOfTexasSystem_Round2,Durability of SARS-CoV-2 Antibodies From Natural Infection in Children and Adolescents,2022-03-18,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Texas,,"This analysis included participants ages 5-to-19 years old
who have completed all three antibody assessments",,2021-01-01,2021-02-28,Household and community samples,All,Children and Youth (0-17 years),5.0,9.0,Age,Age5-9,89,0.23600000000000002,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.97,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Sarah Messiah,The University of Texas System,Not Unity-Aligned,http://doi.org/10.1542/peds.2021-055505,2022-04-07,2024-03-01,Unverified,messiah_durability_2022,USA
220318_Texas_TheUniversityOfTexasSystem_Round3_Overall,220318_Texas_TheUniversityOfTexasSystem_Round3,Durability of SARS-CoV-2 Antibodies From Natural Infection in Children and Adolescents,2022-03-18,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Texas,,"This analysis included participants ages 5-to-19 years old
who have completed all three antibody assessments",,2021-04-01,2021-05-31,Household and community samples,All,Children and Youth (0-17 years),5.0,19.0,Primary Estimate,Overall,218,0.449,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.97,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Sarah Messiah,The University of Texas System,Not Unity-Aligned,http://doi.org/10.1542/peds.2021-055505,2022-04-07,2024-03-01,Unverified,messiah_durability_2022,USA
220318_Texas_TheUniversityOfTexasSystem_Round3_Age15-19,220318_Texas_TheUniversityOfTexasSystem_Round3,Durability of SARS-CoV-2 Antibodies From Natural Infection in Children and Adolescents,2022-03-18,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Texas,,"This analysis included participants ages 5-to-19 years old
who have completed all three antibody assessments",,2021-04-01,2021-05-31,Household and community samples,All,Children and Youth (0-17 years),15.0,19.0,Age,Age15-19,98,0.327,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.9699999999999995,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Sarah Messiah,The University of Texas System,Not Unity-Aligned,http://doi.org/10.1542/peds.2021-055505,2022-04-07,2024-03-01,Unverified,messiah_durability_2022,USA
220318_Texas_TheUniversityOfTexasSystem_Round3_Males,220318_Texas_TheUniversityOfTexasSystem_Round3,Durability of SARS-CoV-2 Antibodies From Natural Infection in Children and Adolescents,2022-03-18,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Texas,,"This analysis included participants ages 5-to-19 years old
who have completed all three antibody assessments",,2021-04-01,2021-05-31,Household and community samples,Male,Children and Youth (0-17 years),5.0,19.0,Sex/Gender,Males,97,0.474,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.97,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Sarah Messiah,The University of Texas System,Not Unity-Aligned,http://doi.org/10.1542/peds.2021-055505,2022-04-07,2024-03-01,Unverified,messiah_durability_2022,USA
220318_Texas_TheUniversityOfTexasSystem_Round3_Age10-14,220318_Texas_TheUniversityOfTexasSystem_Round3,Durability of SARS-CoV-2 Antibodies From Natural Infection in Children and Adolescents,2022-03-18,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Texas,,"This analysis included participants ages 5-to-19 years old
who have completed all three antibody assessments",,2021-04-01,2021-05-31,Household and community samples,All,Children and Youth (0-17 years),10.0,14.0,Age,Age10-14,98,0.439,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.97,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Sarah Messiah,The University of Texas System,Not Unity-Aligned,http://doi.org/10.1542/peds.2021-055505,2022-04-07,2024-03-01,Unverified,messiah_durability_2022,USA
220318_Texas_TheUniversityOfTexasSystem_Round3_Females,220318_Texas_TheUniversityOfTexasSystem_Round3,Durability of SARS-CoV-2 Antibodies From Natural Infection in Children and Adolescents,2022-03-18,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Texas,,"This analysis included participants ages 5-to-19 years old
who have completed all three antibody assessments",,2021-04-01,2021-05-31,Household and community samples,Female,Children and Youth (0-17 years),5.0,19.0,Sex/Gender,Females,97,0.526,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.97,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Sarah Messiah,The University of Texas System,Not Unity-Aligned,http://doi.org/10.1542/peds.2021-055505,2022-04-07,2024-03-01,Unverified,messiah_durability_2022,USA
220318_Texas_TheUniversityOfTexasSystem_Round3_Age5-9,220318_Texas_TheUniversityOfTexasSystem_Round3,Durability of SARS-CoV-2 Antibodies From Natural Infection in Children and Adolescents,2022-03-18,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Texas,,"This analysis included participants ages 5-to-19 years old
who have completed all three antibody assessments",,2021-04-01,2021-05-31,Household and community samples,All,Children and Youth (0-17 years),5.0,9.0,Age,Age5-9,98,0.23500000000000001,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,0.97,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Sarah Messiah,The University of Texas System,Not Unity-Aligned,http://doi.org/10.1542/peds.2021-055505,2022-04-07,2024-03-01,Unverified,messiah_durability_2022,USA
220320_Baltimore_JohnsHopkinsUniversity_Baseline_Overall,220320_Baltimore_JohnsHopkinsUniversity_Baseline,Characteristics of SARS-CoV-2 Seropositivity among Emergency Department Healthcare Workers at a Tertiary Care Center in Baltimore.,2022-03-20,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Maryland,Baltimore,"ED HCWs who worked in the ED at The Johns Hopkins Hospital, a tertiary care academic medical center located in Baltimore, Maryland. The operational definition of ED HCW included clinical as well as non-clinical staff, a definition that has been used by CDC guidance on COVID-19 exposure among HCWs [17]. Non-clinical staff included staff who worked in the ED but were not directly responsible for clinical care, inclusive of security, environmental services, and administrative and registrar personnel.",,2020-07-01,2020-07-31,Health care workers and caregivers,All,Adults (18-64 years),20.0,64.0,Primary Estimate,,191,0.0576,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.97,0.98,['High'],,No,No,Yes,,Yes,Yes,Yes,,Anna Russell,Johns Hopkins University,Not Unity-Aligned,https://www.mdpi.com/2227-9032/10/3/576/htm,2022-04-04,2024-03-01,Unverified,russell_characteristics_2022,USA
220320_Baltimore_JohnsHopkinsUniversity_Baseline_Age60-64,220320_Baltimore_JohnsHopkinsUniversity_Baseline,Characteristics of SARS-CoV-2 Seropositivity among Emergency Department Healthcare Workers at a Tertiary Care Center in Baltimore.,2022-03-20,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Maryland,Baltimore,"ED HCWs who worked in the ED at The Johns Hopkins Hospital, a tertiary care academic medical center located in Baltimore, Maryland. The operational definition of ED HCW included clinical as well as non-clinical staff, a definition that has been used by CDC guidance on COVID-19 exposure among HCWs [17]. Non-clinical staff included staff who worked in the ED but were not directly responsible for clinical care, inclusive of security, environmental services, and administrative and registrar personnel.",,2020-07-01,2020-07-31,Health care workers and caregivers,All,Adults (18-64 years),60.0,64.0,Age,60-64,5,0.0,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.97,0.98,['High'],,No,No,Yes,,Yes,Yes,Yes,,Anna Russell,Johns Hopkins University,Not Unity-Aligned,https://www.mdpi.com/2227-9032/10/3/576/htm,2022-04-04,2024-03-01,Unverified,russell_characteristics_2022,USA
220320_Baltimore_JohnsHopkinsUniversity_Baseline_Age55-59,220320_Baltimore_JohnsHopkinsUniversity_Baseline,Characteristics of SARS-CoV-2 Seropositivity among Emergency Department Healthcare Workers at a Tertiary Care Center in Baltimore.,2022-03-20,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Maryland,Baltimore,"ED HCWs who worked in the ED at The Johns Hopkins Hospital, a tertiary care academic medical center located in Baltimore, Maryland. The operational definition of ED HCW included clinical as well as non-clinical staff, a definition that has been used by CDC guidance on COVID-19 exposure among HCWs [17]. Non-clinical staff included staff who worked in the ED but were not directly responsible for clinical care, inclusive of security, environmental services, and administrative and registrar personnel.",,2020-07-01,2020-07-31,Health care workers and caregivers,All,Adults (18-64 years),55.0,59.0,Age,55-59,9,0.11109999999999999,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.97,0.98,['High'],,No,No,Yes,,Yes,Yes,Yes,,Anna Russell,Johns Hopkins University,Not Unity-Aligned,https://www.mdpi.com/2227-9032/10/3/576/htm,2022-04-04,2024-03-01,Unverified,russell_characteristics_2022,USA
220320_Baltimore_JohnsHopkinsUniversity_Baseline_Age20-24,220320_Baltimore_JohnsHopkinsUniversity_Baseline,Characteristics of SARS-CoV-2 Seropositivity among Emergency Department Healthcare Workers at a Tertiary Care Center in Baltimore.,2022-03-20,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Maryland,Baltimore,"ED HCWs who worked in the ED at The Johns Hopkins Hospital, a tertiary care academic medical center located in Baltimore, Maryland. The operational definition of ED HCW included clinical as well as non-clinical staff, a definition that has been used by CDC guidance on COVID-19 exposure among HCWs [17]. Non-clinical staff included staff who worked in the ED but were not directly responsible for clinical care, inclusive of security, environmental services, and administrative and registrar personnel.",,2020-07-01,2020-07-31,Health care workers and caregivers,All,Adults (18-64 years),20.0,24.0,Age,20-24,18,0.0,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.97,0.98,['High'],,No,No,Yes,,Yes,Yes,Yes,,Anna Russell,Johns Hopkins University,Not Unity-Aligned,https://www.mdpi.com/2227-9032/10/3/576/htm,2022-04-04,2024-03-01,Unverified,russell_characteristics_2022,USA
220320_Baltimore_JohnsHopkinsUniversity_Baseline_Age45-49,220320_Baltimore_JohnsHopkinsUniversity_Baseline,Characteristics of SARS-CoV-2 Seropositivity among Emergency Department Healthcare Workers at a Tertiary Care Center in Baltimore.,2022-03-20,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Maryland,Baltimore,"ED HCWs who worked in the ED at The Johns Hopkins Hospital, a tertiary care academic medical center located in Baltimore, Maryland. The operational definition of ED HCW included clinical as well as non-clinical staff, a definition that has been used by CDC guidance on COVID-19 exposure among HCWs [17]. Non-clinical staff included staff who worked in the ED but were not directly responsible for clinical care, inclusive of security, environmental services, and administrative and registrar personnel.",,2020-07-01,2020-07-31,Health care workers and caregivers,All,Adults (18-64 years),45.0,49.0,Age,45-49,13,0.0,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.97,0.98,['High'],,No,No,Yes,,Yes,Yes,Yes,,Anna Russell,Johns Hopkins University,Not Unity-Aligned,https://www.mdpi.com/2227-9032/10/3/576/htm,2022-04-04,2024-03-01,Unverified,russell_characteristics_2022,USA
220320_Baltimore_JohnsHopkinsUniversity_Baseline_Age30-34,220320_Baltimore_JohnsHopkinsUniversity_Baseline,Characteristics of SARS-CoV-2 Seropositivity among Emergency Department Healthcare Workers at a Tertiary Care Center in Baltimore.,2022-03-20,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Maryland,Baltimore,"ED HCWs who worked in the ED at The Johns Hopkins Hospital, a tertiary care academic medical center located in Baltimore, Maryland. The operational definition of ED HCW included clinical as well as non-clinical staff, a definition that has been used by CDC guidance on COVID-19 exposure among HCWs [17]. Non-clinical staff included staff who worked in the ED but were not directly responsible for clinical care, inclusive of security, environmental services, and administrative and registrar personnel.",,2020-07-01,2020-07-31,Health care workers and caregivers,All,Adults (18-64 years),30.0,34.0,Age,30-34,44,0.06820000000000001,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.97,0.98,['High'],,No,No,Yes,,Yes,Yes,Yes,,Anna Russell,Johns Hopkins University,Not Unity-Aligned,https://www.mdpi.com/2227-9032/10/3/576/htm,2022-04-04,2024-03-01,Unverified,russell_characteristics_2022,USA
220320_Baltimore_JohnsHopkinsUniversity_Baseline_Age35-39,220320_Baltimore_JohnsHopkinsUniversity_Baseline,Characteristics of SARS-CoV-2 Seropositivity among Emergency Department Healthcare Workers at a Tertiary Care Center in Baltimore.,2022-03-20,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Maryland,Baltimore,"ED HCWs who worked in the ED at The Johns Hopkins Hospital, a tertiary care academic medical center located in Baltimore, Maryland. The operational definition of ED HCW included clinical as well as non-clinical staff, a definition that has been used by CDC guidance on COVID-19 exposure among HCWs [17]. Non-clinical staff included staff who worked in the ED but were not directly responsible for clinical care, inclusive of security, environmental services, and administrative and registrar personnel.",,2020-07-01,2020-07-31,Health care workers and caregivers,All,Adults (18-64 years),35.0,39.0,Age,35-39,33,0.060599999999999994,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.97,0.98,['High'],,No,No,Yes,,Yes,Yes,Yes,,Anna Russell,Johns Hopkins University,Not Unity-Aligned,https://www.mdpi.com/2227-9032/10/3/576/htm,2022-04-04,2024-03-01,Unverified,russell_characteristics_2022,USA
220320_Baltimore_JohnsHopkinsUniversity_Baseline_Age50-54,220320_Baltimore_JohnsHopkinsUniversity_Baseline,Characteristics of SARS-CoV-2 Seropositivity among Emergency Department Healthcare Workers at a Tertiary Care Center in Baltimore.,2022-03-20,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Maryland,Baltimore,"ED HCWs who worked in the ED at The Johns Hopkins Hospital, a tertiary care academic medical center located in Baltimore, Maryland. The operational definition of ED HCW included clinical as well as non-clinical staff, a definition that has been used by CDC guidance on COVID-19 exposure among HCWs [17]. Non-clinical staff included staff who worked in the ED but were not directly responsible for clinical care, inclusive of security, environmental services, and administrative and registrar personnel.",,2020-07-01,2020-07-31,Health care workers and caregivers,All,Adults (18-64 years),50.0,54.0,Age,50-54,6,0.0,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.97,0.98,['High'],,No,No,Yes,,Yes,Yes,Yes,,Anna Russell,Johns Hopkins University,Not Unity-Aligned,https://www.mdpi.com/2227-9032/10/3/576/htm,2022-04-04,2024-03-01,Unverified,russell_characteristics_2022,USA
220320_Baltimore_JohnsHopkinsUniversity_Baseline_Age25-29,220320_Baltimore_JohnsHopkinsUniversity_Baseline,Characteristics of SARS-CoV-2 Seropositivity among Emergency Department Healthcare Workers at a Tertiary Care Center in Baltimore.,2022-03-20,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Maryland,Baltimore,"ED HCWs who worked in the ED at The Johns Hopkins Hospital, a tertiary care academic medical center located in Baltimore, Maryland. The operational definition of ED HCW included clinical as well as non-clinical staff, a definition that has been used by CDC guidance on COVID-19 exposure among HCWs [17]. Non-clinical staff included staff who worked in the ED but were not directly responsible for clinical care, inclusive of security, environmental services, and administrative and registrar personnel.",,2020-07-01,2020-07-31,Health care workers and caregivers,All,Adults (18-64 years),25.0,29.0,Age,25-29,51,0.0588,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.97,0.98,['High'],,No,No,Yes,,Yes,Yes,Yes,,Anna Russell,Johns Hopkins University,Not Unity-Aligned,https://www.mdpi.com/2227-9032/10/3/576/htm,2022-04-04,2024-03-01,Unverified,russell_characteristics_2022,USA
220320_Baltimore_JohnsHopkinsUniversity_Baseline_Age40-44,220320_Baltimore_JohnsHopkinsUniversity_Baseline,Characteristics of SARS-CoV-2 Seropositivity among Emergency Department Healthcare Workers at a Tertiary Care Center in Baltimore.,2022-03-20,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Maryland,Baltimore,"ED HCWs who worked in the ED at The Johns Hopkins Hospital, a tertiary care academic medical center located in Baltimore, Maryland. The operational definition of ED HCW included clinical as well as non-clinical staff, a definition that has been used by CDC guidance on COVID-19 exposure among HCWs [17]. Non-clinical staff included staff who worked in the ED but were not directly responsible for clinical care, inclusive of security, environmental services, and administrative and registrar personnel.",,2020-07-01,2020-07-31,Health care workers and caregivers,All,Adults (18-64 years),40.0,44.0,Age,40-44,12,0.16670000000000001,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.97,0.98,['High'],,No,No,Yes,,Yes,Yes,Yes,,Anna Russell,Johns Hopkins University,Not Unity-Aligned,https://www.mdpi.com/2227-9032/10/3/576/htm,2022-04-04,2024-03-01,Unverified,russell_characteristics_2022,USA
220320_Baltimore_JohnsHopkinsUniversity_FollowUp_Overall,220320_Baltimore_JohnsHopkinsUniversity_FollowUp,Characteristics of SARS-CoV-2 Seropositivity among Emergency Department Healthcare Workers at a Tertiary Care Center in Baltimore.,2022-03-20,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Maryland,Baltimore,"ED HCWs who worked in the ED at The Johns Hopkins Hospital, a tertiary care academic medical center located in Baltimore, Maryland. The operational definition of ED HCW included clinical as well as non-clinical staff, a definition that has been used by CDC guidance on COVID-19 exposure among HCWs [17]. Non-clinical staff included staff who worked in the ED but were not directly responsible for clinical care, inclusive of security, environmental services, and administrative and registrar personnel.",,2020-12-01,2020-12-31,Health care workers and caregivers,All,Adults (18-64 years),20.0,64.0,Primary Estimate,,174,0.1207,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.97,0.98,['High'],,No,No,Yes,,Yes,Yes,Yes,,Anna Russell,Johns Hopkins University,Not Unity-Aligned,https://www.mdpi.com/2227-9032/10/3/576/htm,2022-04-04,2024-03-01,Unverified,russell_characteristics_2022,USA
220320_Baltimore_JohnsHopkinsUniversity_FollowUp_Age35-39,220320_Baltimore_JohnsHopkinsUniversity_FollowUp,Characteristics of SARS-CoV-2 Seropositivity among Emergency Department Healthcare Workers at a Tertiary Care Center in Baltimore.,2022-03-20,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Maryland,Baltimore,"ED HCWs who worked in the ED at The Johns Hopkins Hospital, a tertiary care academic medical center located in Baltimore, Maryland. The operational definition of ED HCW included clinical as well as non-clinical staff, a definition that has been used by CDC guidance on COVID-19 exposure among HCWs [17]. Non-clinical staff included staff who worked in the ED but were not directly responsible for clinical care, inclusive of security, environmental services, and administrative and registrar personnel.",,2020-12-01,2020-12-31,Health care workers and caregivers,All,Adults (18-64 years),35.0,39.0,Age,35-39,29,0.069,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.97,0.98,['High'],,No,No,Yes,,Yes,Yes,Yes,,Anna Russell,Johns Hopkins University,Not Unity-Aligned,https://www.mdpi.com/2227-9032/10/3/576/htm,2022-04-04,2024-03-01,Unverified,russell_characteristics_2022,USA
220320_Baltimore_JohnsHopkinsUniversity_FollowUp_Age20-24,220320_Baltimore_JohnsHopkinsUniversity_FollowUp,Characteristics of SARS-CoV-2 Seropositivity among Emergency Department Healthcare Workers at a Tertiary Care Center in Baltimore.,2022-03-20,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Maryland,Baltimore,"ED HCWs who worked in the ED at The Johns Hopkins Hospital, a tertiary care academic medical center located in Baltimore, Maryland. The operational definition of ED HCW included clinical as well as non-clinical staff, a definition that has been used by CDC guidance on COVID-19 exposure among HCWs [17]. Non-clinical staff included staff who worked in the ED but were not directly responsible for clinical care, inclusive of security, environmental services, and administrative and registrar personnel.",,2020-12-01,2020-12-31,Health care workers and caregivers,All,Adults (18-64 years),20.0,24.0,Age,20-24,16,0.0625,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.97,0.98,['High'],,No,No,Yes,,Yes,Yes,Yes,,Anna Russell,Johns Hopkins University,Not Unity-Aligned,https://www.mdpi.com/2227-9032/10/3/576/htm,2022-04-04,2024-03-01,Unverified,russell_characteristics_2022,USA
220320_Baltimore_JohnsHopkinsUniversity_FollowUp_Age45-49,220320_Baltimore_JohnsHopkinsUniversity_FollowUp,Characteristics of SARS-CoV-2 Seropositivity among Emergency Department Healthcare Workers at a Tertiary Care Center in Baltimore.,2022-03-20,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Maryland,Baltimore,"ED HCWs who worked in the ED at The Johns Hopkins Hospital, a tertiary care academic medical center located in Baltimore, Maryland. The operational definition of ED HCW included clinical as well as non-clinical staff, a definition that has been used by CDC guidance on COVID-19 exposure among HCWs [17]. Non-clinical staff included staff who worked in the ED but were not directly responsible for clinical care, inclusive of security, environmental services, and administrative and registrar personnel.",,2020-12-01,2020-12-31,Health care workers and caregivers,All,Adults (18-64 years),45.0,49.0,Age,45-49,11,0.0909,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.97,0.98,['High'],,No,No,Yes,,Yes,Yes,Yes,,Anna Russell,Johns Hopkins University,Not Unity-Aligned,https://www.mdpi.com/2227-9032/10/3/576/htm,2022-04-04,2024-03-01,Unverified,russell_characteristics_2022,USA
220320_Baltimore_JohnsHopkinsUniversity_FollowUp_Age55-59,220320_Baltimore_JohnsHopkinsUniversity_FollowUp,Characteristics of SARS-CoV-2 Seropositivity among Emergency Department Healthcare Workers at a Tertiary Care Center in Baltimore.,2022-03-20,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Maryland,Baltimore,"ED HCWs who worked in the ED at The Johns Hopkins Hospital, a tertiary care academic medical center located in Baltimore, Maryland. The operational definition of ED HCW included clinical as well as non-clinical staff, a definition that has been used by CDC guidance on COVID-19 exposure among HCWs [17]. Non-clinical staff included staff who worked in the ED but were not directly responsible for clinical care, inclusive of security, environmental services, and administrative and registrar personnel.",,2020-12-01,2020-12-31,Health care workers and caregivers,All,Adults (18-64 years),55.0,59.0,Age,55-59,9,0.11109999999999999,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.97,0.98,['High'],,No,No,Yes,,Yes,Yes,Yes,,Anna Russell,Johns Hopkins University,Not Unity-Aligned,https://www.mdpi.com/2227-9032/10/3/576/htm,2022-04-04,2024-03-01,Unverified,russell_characteristics_2022,USA
220320_Baltimore_JohnsHopkinsUniversity_FollowUp_Age30-34,220320_Baltimore_JohnsHopkinsUniversity_FollowUp,Characteristics of SARS-CoV-2 Seropositivity among Emergency Department Healthcare Workers at a Tertiary Care Center in Baltimore.,2022-03-20,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Maryland,Baltimore,"ED HCWs who worked in the ED at The Johns Hopkins Hospital, a tertiary care academic medical center located in Baltimore, Maryland. The operational definition of ED HCW included clinical as well as non-clinical staff, a definition that has been used by CDC guidance on COVID-19 exposure among HCWs [17]. Non-clinical staff included staff who worked in the ED but were not directly responsible for clinical care, inclusive of security, environmental services, and administrative and registrar personnel.",,2020-12-01,2020-12-31,Health care workers and caregivers,All,Adults (18-64 years),30.0,34.0,Age,30-34,38,0.18420000000000003,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.97,0.98,['High'],,No,No,Yes,,Yes,Yes,Yes,,Anna Russell,Johns Hopkins University,Not Unity-Aligned,https://www.mdpi.com/2227-9032/10/3/576/htm,2022-04-04,2024-03-01,Unverified,russell_characteristics_2022,USA
220320_Baltimore_JohnsHopkinsUniversity_FollowUp_Age25-29,220320_Baltimore_JohnsHopkinsUniversity_FollowUp,Characteristics of SARS-CoV-2 Seropositivity among Emergency Department Healthcare Workers at a Tertiary Care Center in Baltimore.,2022-03-20,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Maryland,Baltimore,"ED HCWs who worked in the ED at The Johns Hopkins Hospital, a tertiary care academic medical center located in Baltimore, Maryland. The operational definition of ED HCW included clinical as well as non-clinical staff, a definition that has been used by CDC guidance on COVID-19 exposure among HCWs [17]. Non-clinical staff included staff who worked in the ED but were not directly responsible for clinical care, inclusive of security, environmental services, and administrative and registrar personnel.",,2020-12-01,2020-12-31,Health care workers and caregivers,All,Adults (18-64 years),25.0,29.0,Age,25-29,48,0.125,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.97,0.98,['High'],,No,No,Yes,,Yes,Yes,Yes,,Anna Russell,Johns Hopkins University,Not Unity-Aligned,https://www.mdpi.com/2227-9032/10/3/576/htm,2022-04-04,2024-03-01,Unverified,russell_characteristics_2022,USA
220320_Baltimore_JohnsHopkinsUniversity_FollowUp_Age50-54,220320_Baltimore_JohnsHopkinsUniversity_FollowUp,Characteristics of SARS-CoV-2 Seropositivity among Emergency Department Healthcare Workers at a Tertiary Care Center in Baltimore.,2022-03-20,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Maryland,Baltimore,"ED HCWs who worked in the ED at The Johns Hopkins Hospital, a tertiary care academic medical center located in Baltimore, Maryland. The operational definition of ED HCW included clinical as well as non-clinical staff, a definition that has been used by CDC guidance on COVID-19 exposure among HCWs [17]. Non-clinical staff included staff who worked in the ED but were not directly responsible for clinical care, inclusive of security, environmental services, and administrative and registrar personnel.",,2020-12-01,2020-12-31,Health care workers and caregivers,All,Adults (18-64 years),50.0,54.0,Age,50-54,6,0.16670000000000001,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.97,0.98,['High'],,No,No,Yes,,Yes,Yes,Yes,,Anna Russell,Johns Hopkins University,Not Unity-Aligned,https://www.mdpi.com/2227-9032/10/3/576/htm,2022-04-04,2024-03-01,Unverified,russell_characteristics_2022,USA
220320_Baltimore_JohnsHopkinsUniversity_FollowUp_Age60-64,220320_Baltimore_JohnsHopkinsUniversity_FollowUp,Characteristics of SARS-CoV-2 Seropositivity among Emergency Department Healthcare Workers at a Tertiary Care Center in Baltimore.,2022-03-20,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Maryland,Baltimore,"ED HCWs who worked in the ED at The Johns Hopkins Hospital, a tertiary care academic medical center located in Baltimore, Maryland. The operational definition of ED HCW included clinical as well as non-clinical staff, a definition that has been used by CDC guidance on COVID-19 exposure among HCWs [17]. Non-clinical staff included staff who worked in the ED but were not directly responsible for clinical care, inclusive of security, environmental services, and administrative and registrar personnel.",,2020-12-01,2020-12-31,Health care workers and caregivers,All,Adults (18-64 years),60.0,64.0,Age,60-64,5,0.0,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.97,0.98,['High'],,No,No,Yes,,Yes,Yes,Yes,,Anna Russell,Johns Hopkins University,Not Unity-Aligned,https://www.mdpi.com/2227-9032/10/3/576/htm,2022-04-04,2024-03-01,Unverified,russell_characteristics_2022,USA
220320_Baltimore_JohnsHopkinsUniversity_FollowUp_Age40-44,220320_Baltimore_JohnsHopkinsUniversity_FollowUp,Characteristics of SARS-CoV-2 Seropositivity among Emergency Department Healthcare Workers at a Tertiary Care Center in Baltimore.,2022-03-20,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Maryland,Baltimore,"ED HCWs who worked in the ED at The Johns Hopkins Hospital, a tertiary care academic medical center located in Baltimore, Maryland. The operational definition of ED HCW included clinical as well as non-clinical staff, a definition that has been used by CDC guidance on COVID-19 exposure among HCWs [17]. Non-clinical staff included staff who worked in the ED but were not directly responsible for clinical care, inclusive of security, environmental services, and administrative and registrar personnel.",,2020-12-01,2020-12-31,Health care workers and caregivers,All,Adults (18-64 years),40.0,44.0,Age,40-44,12,0.16670000000000001,,,,,,,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.97,0.98,['High'],,No,No,Yes,,Yes,Yes,Yes,,Anna Russell,Johns Hopkins University,Not Unity-Aligned,https://www.mdpi.com/2227-9032/10/3/576/htm,2022-04-04,2024-03-01,Unverified,russell_characteristics_2022,USA
220322_Maryland_JohnsHopkins_Overall,220322_Maryland_JohnsHopkins,Binding and neutralizing antibody responses to SARS-CoV-2 in very young children exceed those in adults,2022-03-22,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Maryland,,"""Households were eligible if they contained at least 1 child aged
0–4 years; individuals were eligible if they had not yet received a COVID-19 vaccine.""",,2020-11-15,2021-03-15,Household and community samples,All,Multiple groups,0.0,62.0,Primary Estimate,,682,0.0821,,,True,,,,True,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,,,,,,['Moderate'],,Unclear,Yes,No,,Yes,Yes,Yes,,Ruth Karron,Johns Hopkins University,Not Unity-Aligned,https://doi.org/10.1172/jci.insight.157963,2022-09-09,2024-03-01,Unverified,karron_binding_2022,USA
220322_Maryland_JohnsHopkins_Ages5-17,220322_Maryland_JohnsHopkins,Binding and neutralizing antibody responses to SARS-CoV-2 in very young children exceed those in adults,2022-03-22,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Maryland,,"""Households were eligible if they contained at least 1 child aged
0–4 years; individuals were eligible if they had not yet received a COVID-19 vaccine.""",,2020-11-15,2021-03-15,Household and community samples,All,Children and Youth (0-17 years),5.0,17.0,Age,Ages 5-17,96,0.1354,,,,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,,,,,,['Moderate'],,Unclear,Yes,No,,Yes,Yes,Yes,,Ruth Karron,Johns Hopkins University,Not Unity-Aligned,https://doi.org/10.1172/jci.insight.157963,2022-09-09,2024-03-01,Unverified,karron_binding_2022,USA
220322_Maryland_JohnsHopkins_Ages18+,220322_Maryland_JohnsHopkins,Binding and neutralizing antibody responses to SARS-CoV-2 in very young children exceed those in adults,2022-03-22,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Maryland,,"""Households were eligible if they contained at least 1 child aged
0–4 years; individuals were eligible if they had not yet received a COVID-19 vaccine.""",,2020-11-15,2021-03-15,Household and community samples,All,Adults (18-64 years),18.0,62.0,Age,Ages 18+,332,0.0843,,,,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,,,,,,['Moderate'],,Unclear,Yes,No,,Yes,Yes,Yes,,Ruth Karron,Johns Hopkins University,Not Unity-Aligned,https://doi.org/10.1172/jci.insight.157963,2022-09-09,2024-03-01,Unverified,karron_binding_2022,USA
220322_Maryland_JohnsHopkins_Ages0-4,220322_Maryland_JohnsHopkins,Binding and neutralizing antibody responses to SARS-CoV-2 in very young children exceed those in adults,2022-03-22,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Maryland,,"""Households were eligible if they contained at least 1 child aged
0–4 years; individuals were eligible if they had not yet received a COVID-19 vaccine.""",,2020-11-15,2021-03-15,Household and community samples,All,Children and Youth (0-17 years),0.0,4.0,Age,Ages 0-4,254,0.0591,,,,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,,,,,,['Moderate'],,Unclear,Yes,No,,Yes,Yes,Yes,,Ruth Karron,Johns Hopkins University,Not Unity-Aligned,https://doi.org/10.1172/jci.insight.157963,2022-09-09,2024-03-01,Unverified,karron_binding_2022,USA
220323_Ohio_UniversityHospitalsClevelandMedicalCentre,220323_Ohio_UniversityHospitalsClevelandMedicalCentre,Seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) among healthcare providers prior to the vaccine era in an integrated midwestern healthcare system.,2022-03-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Ohio,,"""All patient-facing HCWs and a sample of non–patient-facing HCWs working at an acute-care facility were invited to participate""",none listed,2020-06-07,2020-12-05,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,5577,0.039,,,,,,,True,Convenience,Not reported/ Unable to specify,,,,IgG,,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Elie A. Saade,University Hospitals Cleveland Medical Centre,Not Unity-Aligned,https://dx.doi.org/10.1017/ash.2022.29,2022-11-07,2023-02-26,Unverified,saade_seroprevalence_2022,USA
220323_UnitedStatesofAmerica_NationalInstitutesofHealth_Children_Spike,220323_UnitedStatesofAmerica_NationalInstitutesofHealth_Children,Undiagnosed COVID-19 in households with a child with mitochondrial disease,2022-03-23,Preprint,National,Cross-sectional survey ,United States of America,"California, Arizona, Texas, Louisiana, Kansas, Minnesota, Illinois, Michigan, Tennessee, Georgia, Florida, Maryland, New Jersey",,"(Participants were taken from a cohort described on ClinicalTrials.gov site. Criteria taken from their registration page [ID NCT04419870]):

Group 1a

Participants must be two months of age or older.
Participants must have a diagnosis of mitochondrial disease based on a determination by a physician with expertise in genetics and/or neurology. Supportive evidence may include genetic testing, muscle biopsy, biochemical testing, neuroimaging or enzyme analysis consistent with mitochondrial disease.
At the time of enrollment, participants must have suspected or confirmed COVID-19 as defined by:
- New onset of any of the following symptoms after January 2020 without an alternative diagnosis: fever, cough, shortness of breath, fatigue, sore throat, rhinorrhea, musculoskeletal pain, vomiting, diarrhea, anosmia, neurologic decline;
AND report that testing for COVID-19/SARS-COV-2 is clinically indicated based on evaluation by a healthcare provider.

OR

- Laboratory confirmed positive testing for COVID-19/SARS-Cov-2 performed at a local healthcare setting.

Group 1b

Participants must be two months of age or older.
Participants must have a diagnosis of mitochondrial disease based on a determination by a physician with expertise in genetics and/or neurology. Supportive evidence may include genetic testing, muscle biopsy, biochemical testing, neuroimaging or enzyme analysis consistent with mitochondrial disease.
At the time of enrollment, participants may not have evidence of any acute infection.

Group 2

Participants must be two months of age or older.
Participants must weigh greater than 4 kilograms.
Participants must be genetically related family member of a participant in Group 1 above.","Groups 1 a&b (children with mitochondrial disease)

Participants who are less than two months of age.
Participants who do not have mitochondrial disease.
Study team may decline to enroll a participant for other reasons based on clinical judgement.

Group 2 (household members)

Participants who are less than two months of age.
Participants who are not family members of Group 1.
Study team may decline to enroll a participant for other reasons based on clinical judgement.",2020-12-21,2021-03-21,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),,,Primary Estimate,,22,0.909,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Whole Blood,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Eliza Gordon-Lipkin,National Institutes of Health,Not Unity-Aligned,10.1101/2022.03.21.22272358,2022-03-31,2022-07-16,Unverified,gordon-lipkin_undiagnosed_2022,USA
220323_UnitedStatesofAmerica_NationalInstitutesofHealth_HouseholdMembers_Spike,220323_UnitedStatesofAmerica_NationalInstitutesofHealth_HouseholdMembers,Undiagnosed COVID-19 in households with a child with mitochondrial disease,2022-03-23,Preprint,National,Cross-sectional survey ,United States of America,"California, Arizona, Texas, Louisiana, Kansas, Minnesota, Illinois, Michigan, Tennessee, Georgia, Florida, Maryland, New Jersey",,"(Participants were taken from a cohort described on ClinicalTrials.gov site. Criteria taken from their registration page [ID NCT04419870]):

Group 1a

Participants must be two months of age or older.
Participants must have a diagnosis of mitochondrial disease based on a determination by a physician with expertise in genetics and/or neurology. Supportive evidence may include genetic testing, muscle biopsy, biochemical testing, neuroimaging or enzyme analysis consistent with mitochondrial disease.
At the time of enrollment, participants must have suspected or confirmed COVID-19 as defined by:
- New onset of any of the following symptoms after January 2020 without an alternative diagnosis: fever, cough, shortness of breath, fatigue, sore throat, rhinorrhea, musculoskeletal pain, vomiting, diarrhea, anosmia, neurologic decline;
AND report that testing for COVID-19/SARS-COV-2 is clinically indicated based on evaluation by a healthcare provider.

OR

- Laboratory confirmed positive testing for COVID-19/SARS-Cov-2 performed at a local healthcare setting.

Group 1b

Participants must be two months of age or older.
Participants must have a diagnosis of mitochondrial disease based on a determination by a physician with expertise in genetics and/or neurology. Supportive evidence may include genetic testing, muscle biopsy, biochemical testing, neuroimaging or enzyme analysis consistent with mitochondrial disease.
At the time of enrollment, participants may not have evidence of any acute infection.

Group 2

Participants must be two months of age or older.
Participants must weigh greater than 4 kilograms.
Participants must be genetically related family member of a participant in Group 1 above.","Groups 1 a&b (children with mitochondrial disease)

Participants who are less than two months of age.
Participants who do not have mitochondrial disease.
Study team may decline to enroll a participant for other reasons based on clinical judgement.

Group 2 (household members)

Participants who are less than two months of age.
Participants who are not family members of Group 1.
Study team may decline to enroll a participant for other reasons based on clinical judgement.",2020-12-21,2021-03-21,Contacts of COVID patients,All,Adults (18-64 years),,,Primary Estimate,,61,0.6890000000000001,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Whole Blood,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],,No,No,No,,Unclear,Yes,No,,Eliza Gordon-Lipkin,National Institutes of Health,Not Unity-Aligned,10.1101/2022.03.21.22272358,2022-03-31,2022-07-16,Unverified,gordon-lipkin_undiagnosed_2022,USA
220325_Detroit_HenryFordHospital_Overall,220325_Detroit_HenryFordHospital,The seroprevalence of COVID-19 in patients living with HIV in metropolitan Detroit,2022-03-25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Michigan,Detroit,"Recruited people
living with HIV in the Ryan White program at Henry Ford
Hospital in Detroit, Michigan. All Ryan White patients were offered participation during clinic visits if they had not already received a dosage of any
COVID-19 vaccine. ",A dosage of any COVID-19 vaccine. ,2020-09-15,2021-05-15,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),,,Primary Estimate,,504,0.10300000000000001,,,True,,,,True,Convenience,Access SARS-CoV-2 IgG Reagent Antibody Test,Beckman Coulter,,,IgG,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Smitha Gudipati,Henry Ford Hospital,Not Unity-Aligned,https://dx.doi.org/10.1177/09564624221076629,2022-04-05,2024-03-01,Unverified,gudipati_seroprevalence_2022,USA
220330_NewYorkCity_MountSinaiHealthSystem,220330_NewYorkCity_MountSinaiHealthSystem,SARS-CoV-2 spike-binding antibody longevity and protection from re-infection with antigenically similar SARS-CoV-2 variants,2022-03-30,Preprint,Local,Cross-sectional survey ,United States of America,New York,New York City ,Healthcare workers of the Mount Sinai Health System ,,2020-04-15,2021-08-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,400,0.375,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,John Kubale,Mount Sinai Health System,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2022.03.28.22273068v1.full-text,2022-04-05,2022-07-16,Unverified,kubale_sars-cov-2_2022,USA
220331_Wisconsin_CDC_UniversityB_1September_AntiS,220331_Wisconsin_CDC_UniversityB_1September,A cohort study measuring SARS-CoV-2 seroconversion and serial viral testing in university students,2022-03-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Wisconsin,,College students primarily living on-campus at two large public universities in Wisconsin were invited by email to participate in free antibody testing during the fall semester of 2020.,,2020-09-01,2020-09-11,Students and Daycares,All,Adults (18-64 years),18.0,,Primary Estimate,Anti-S assay,36,0.19440000000000002,,,True,,,,True,Convenience,AdviseDX SARS-CoV-2 anti-IgG II assay,Abbott Laboratories,,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,No,No,,Yes,Yes,Yes,,Christine Lee,CDC COVID‑19 Response Team,Not Unity-Aligned,https://doi.org/10.1186/s12879-022-07314-5,2022-04-05,2024-03-01,Unverified,lee_cohort_2022,USA
220331_Wisconsin_CDC_UniversityB_2November_AntiS,220331_Wisconsin_CDC_UniversityB_2November,A cohort study measuring SARS-CoV-2 seroconversion and serial viral testing in university students,2022-03-31,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Wisconsin,,College students primarily living on-campus at two large public universities in Wisconsin were invited by email to participate in free antibody testing during the fall semester of 2020.,,2020-11-09,2020-11-14,Students and Daycares,All,Adults (18-64 years),18.0,,Primary Estimate,Anti-S assay,36,0.3611,,,True,,,,True,Convenience,AdviseDX SARS-CoV-2 anti-IgG II assay,Abbott Laboratories,,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,,,['High'],,No,No,No,,Yes,Yes,Yes,,Christine Lee,CDC COVID‑19 Response Team,Not Unity-Aligned,https://doi.org/10.1186/s12879-022-07314-5,2022-04-05,2024-03-01,Unverified,lee_cohort_2022,USA
220401_NewYork_LincolnMedicalCenter_June_patients,220401_NewYork_LincolnMedicalCenter_June,151 STRATEGIES TO CONTAIN COVID-19 INFECTION IN A HOSPITAL BASED OUTPATIENT HEMODIALYSIS UNIT IN THE SOUTH BRONX:,2022-04-01,Presentation or Conference,Local,Repeated cross-sectional study,United States of America,New York,,"HD patients from a hospital-based hemodialysis (HD) unit is located in Bronx County, which had the highest rates of infections and deaths due to COVID-19",,2020-06-01,2020-06-30,Residual sera,All,Multiple groups,,,Primary Estimate,,32,0.188,,,True,,,,True,Sequential,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Susan Kim,Lincoln Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1053/j.ajkd.2021.02.156,2022-04-05,2022-07-16,Unverified,kim_strategies_2022,USA
220401_NewYork_LincolnMedicalCenter_May_HCWs,220401_NewYork_LincolnMedicalCenter_May,151 STRATEGIES TO CONTAIN COVID-19 INFECTION IN A HOSPITAL BASED OUTPATIENT HEMODIALYSIS UNIT IN THE SOUTH BRONX:,2022-04-01,Presentation or Conference,Local,Repeated cross-sectional study,United States of America,New York,,"HCWs from a hospital-based hemodialysis (HD) unit is located in Bronx County, which had the highest rates of infections and deaths due to COVID-19",,2020-05-01,2020-05-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,42,0.14300000000000002,,,True,,,,True,Entire sample,Not reported/ Unable to specify,,,,,,,,,['High'],,Yes,No,No,,Unclear,Yes,No,,Susan Kim,Lincoln Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1053/j.ajkd.2021.02.156,2022-04-05,2022-07-16,Unverified,kim_strategies_2022,USA
220408_Tennessee_AccessBiologicals,220408_Tennessee_AccessBiologicals,Seroconversion panels demonstrate anti-SARS-CoV-2 antibody development after administration of the mRNA-1273 vaccine,2022-04-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Tennessee,,"The samples in these seroconversion panels were collected from
consenting healthcare workers at a hospital (Tennessee, USA)",,2020-12-22,2021-02-25,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,15,0.1333,,,True,,,,True,Convenience,"Liaison SARS-CoV-2 S1/S2 IgG,Progenika anti-SARS-CoV-2 IgG","DiaSorin,Progenika Biopharma, Derio, Bizkaia, Spain",ELISA,Multiple Types,IgG,Spike,Validated by manufacturers,,,['High'],,No,No,No,,Unclear,Yes,No,,Francisco Belda,Access Biologicals,Not Unity-Aligned,https://dx.doi.org/10.1016/j.vaccine.2022.04.006,2022-04-28,2024-03-01,Unverified,belda_seroconversion_2022,USA
220412_Boston_DanaFarberCancerInstitute_1_MayJul2020_TestAdj,220412_Boston_DanaFarberCancerInstitute_1_MayJul2020,Serological testing for SARS-CoV-2 antibodies of employees shows low transmission working in a cancer center.,2022-04-12,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Massachusetts,Boston,"""Eligibility for participation included age at least 18 years old; employment at the Dana-Farber Cancer Institute (main campus or satellite facilities), no COVID-related symptoms or known active infection at time of initial enrollment; able and willing to provide COVID-19 infection history and potential exposure information; willingness to provide preferred email address for study contact; did not receive any live viral vaccine within 4 weeks of enrollment or inactivated viral vaccine within 2 weeks; no known history of immune deficiency syndrome or undergoing therapy which can suppress immune system; no receipt of intravenous immunoglobulin within the month prior to initial enrollment; and ability to consent.""",,2020-05-15,2020-07-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Test adjusted,519,0.092,0.067,0.12,True,True,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,,,['High'],,No,No,No,,Unclear,Yes,Yes,,Jeffrey Meyerhardt,Dana-Farber Cancer Institute,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266791,2022-04-23,2022-07-16,Unverified,meyerhardt_serological_2022,USA
220412_Boston_DanaFarberCancerInstitute_2_SepOct2020_TestAdj,220412_Boston_DanaFarberCancerInstitute_2_SepOct2020,Serological testing for SARS-CoV-2 antibodies of employees shows low transmission working in a cancer center.,2022-04-12,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Massachusetts,Boston,"""Eligibility for participation included age at least 18 years old; employment at the Dana-Farber Cancer Institute (main campus or satellite facilities), no COVID-related symptoms or known active infection at time of initial enrollment; able and willing to provide COVID-19 infection history and potential exposure information; willingness to provide preferred email address for study contact; did not receive any live viral vaccine within 4 weeks of enrollment or inactivated viral vaccine within 2 weeks; no known history of immune deficiency syndrome or undergoing therapy which can suppress immune system; no receipt of intravenous immunoglobulin within the month prior to initial enrollment; and ability to consent.""",,2020-09-15,2020-10-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Test adjusted,479,0.085,0.06,0.11,True,True,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,,,['High'],,No,No,No,,Unclear,Yes,Yes,,Jeffrey Meyerhardt,Dana-Farber Cancer Institute,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266791,2022-04-23,2022-07-16,Unverified,meyerhardt_serological_2022,USA
220413_Atlanta_EmoryUniversity_Overall,220413_Atlanta_EmoryUniversity,SARS-CoV-2 seroprevalence among healthcare personnel at a large health system in Atlanta: SARS-CoV-2 among healthcare personnel in Atlanta.,2022-04-13,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Atlanta,,"""The Grady Health System COVID-19 screening program used re-deployed hospital staff and was implemented through employee health services.""

""All employees were eligible to be tested regardless of position or symptoms.""

""Asymptomatic HCP were scheduled for both IgG and PCR testing for SARS-CoV-2, while symptomatic HCP were offered PCR.""",,2020-05-11,2020-07-20,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1412,0.064,0.053,0.078,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Daniel Graciaa,Emory University,Not Unity-Aligned,https://dx.doi.org/10.1016/j.amjms.2022.04.009,2022-05-02,2024-03-01,Unverified,graciaa_sars-cov-2_2022,USA
220421_Massachusetts_MassachusettsGeneralHospital_Overall,220421_Massachusetts_MassachusettsGeneralHospital,COVID-19 Seroprevalence in ED Health Care Professionals Study: A Cross-sectional Study.,2022-04-21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Massachusetts,Boston,"ED HCPs are defined as attending physician, emergency resident physician, advanced practice provider, or full-time emergency nurse. An ED HCP was deemed eligible for the study if they had worked at least 4 shifts in the adult emergency department within and including the dates of April 1, 2020, and May 31, 2020.",,2020-12-17,2021-01-27,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,103,0.028999999999999998,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Whole Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9,0.99,['High'],,No,No,No,,Yes,Yes,Yes,,Brian Yun,Massachusetts General Hospital,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jen.2022.04.003,2022-06-20,2024-03-01,Unverified,yun_covid-19_2022,USA
220421_NYC_UniversityofPennsylvania,220421_NYC_UniversityofPennsylvania,"The influence of structural racism, pandemic stress, and SARS-CoV-2 infection during pregnancy with adverse birth outcomes.",2022-04-21,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,New York,New York City,Birthing patients aged 18 years or older receiving obstetrical care in the Mount Sinai Health System were recruited starting in April 2020.,,2020-04-15,2020-12-15,Pregnant or parturient women,Female,Adults (18-64 years),18.0,,Primary Estimate,,967,0.2,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by developers,0.9500000000000001,1.0,['Moderate'],Yes,No,Yes,No,Unclear,Unclear,Yes,Yes,Unclear,Teresa Janevic,University of Pennsylvania,Unity-Aligned,https://dx.doi.org/10.1016/j.ajogmf.2022.100649,2022-05-04,2022-07-16,Verified,janevic_influence_2022,USA
220425_ChapelHill_UniversityofNorthCarolinaatChapelHill_1month_Overall,220425_ChapelHill_UniversityofNorthCarolinaatChapelHill_1month,A prospective study of asymptomatic SARS-CoV-2 infection among individuals involved in academic research under limited operations during the COVID-19 pandemic.,2022-04-25,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,North Carolina,Chapel Hill,"Employees or students who conducted or supported research activities, reported coming to campus at least one day a week, and were age 18
or older were eligible to enroll. All individuals who received funding from research grants
were invited to participate.","Participants who also enrolled in a COVID-19 vaccine trial during the study period were
excluded from the analyses.",2020-07-15,2020-12-15,Multiple populations,All,Adults (18-64 years),,,Primary Estimate,1 month post baseline,751,0.09210000000000002,0.0674,0.1168,True,,True,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.98,1.0,['High'],,No,Yes,No,,Unclear,Yes,Yes,,Audrey Pettifor,University of North Carolina at Chapel Hill,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0267353,2022-05-03,2022-07-16,Unverified,pettifor_prospective_2022,USA
220425_ChapelHill_UniversityofNorthCarolinaatChapelHill_3months_Overall,220425_ChapelHill_UniversityofNorthCarolinaatChapelHill_3months,A prospective study of asymptomatic SARS-CoV-2 infection among individuals involved in academic research under limited operations during the COVID-19 pandemic.,2022-04-25,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,North Carolina,Chapel Hill,"Employees or students who conducted or supported research activities, reported coming to campus at least one day a week, and were age 18
or older were eligible to enroll. All individuals who received funding from research grants
were invited to participate.","Participants who also enrolled in a COVID-19 vaccine trial during the study period were
excluded from the analyses.",2020-07-15,2020-12-15,Multiple populations,All,Adults (18-64 years),,,Primary Estimate,3 months post baseline,751,0.10070000000000001,0.0741,0.1272,True,,True,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.98,1.0,['High'],,No,Yes,No,,Unclear,Yes,Yes,,Audrey Pettifor,University of North Carolina at Chapel Hill,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0267353,2022-05-03,2022-07-16,Unverified,pettifor_prospective_2022,USA
220425_ChapelHill_UniversityofNorthCarolinaatChapelHill_Baseline_Overall,220425_ChapelHill_UniversityofNorthCarolinaatChapelHill_Baseline,A prospective study of asymptomatic SARS-CoV-2 infection among individuals involved in academic research under limited operations during the COVID-19 pandemic.,2022-04-25,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,North Carolina,Chapel Hill,"Employees or students who conducted or supported research activities, reported coming to campus at least one day a week, and were age 18
or older were eligible to enroll. All individuals who received funding from research grants
were invited to participate.","Participants who also enrolled in a COVID-19 vaccine trial during the study period were
excluded from the analyses.",2020-07-15,2020-12-15,Multiple populations,All,Adults (18-64 years),,,Primary Estimate,Baseline,910,0.062400000000000004,0.0429,0.0819,True,,True,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.98,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Audrey Pettifor,University of North Carolina at Chapel Hill,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0267353,2022-05-03,2022-07-16,Unverified,pettifor_prospective_2022,USA
220425_Minneapolis_UniversityOfMinnesota_Sample1,220425_Minneapolis_UniversityOfMinnesota_Sample1,SARS-CoV-2 seroprevalence among healthcare workers.,2022-04-25,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Minnesota,Minneapolis,"The cohort included HCWs from a cross-sectional convenience sample of individuals working in healthcare facilities located in the Minneapolis/St. Paul, MN metropolitan area.

Eligibility criteria were: i) employed or volunteering in a healthcare facility; ii) free of fever, chills, anosmia, pharyngitis, recently developed persistent cough, nasal congestion suspected to be unrelated to season allergies; iii) age 18–80 years; iv) not pregnant. Participants who enrolled and consented to participate in the previous study were then recruited via an email sent on 11/17/2020 to participate in a seroprevalence study. Participants were invited to provide up to 2 capillary blood samples for serology testing. Participants’ first samples (“sample 1”) were collected between 11/22/20–02/21/21 and participants’ second samples (“sample 2”) were collected between 12/18/20–02/15/21","Not healthcare worker, prior COVID-10 diagnosis, pregnant, symptomatic",2020-11-22,2021-02-02,Health care workers and caregivers,All,Multiple groups,18.0,80.0,Primary Estimate,,454,0.0947,,,True,,,,True,Convenience,Q-Plex SARS-CoV-2 Human IgG (4-Plex),Quansys Biosciences,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.97,1.0,['High'],,No,No,Yes,,Yes,Yes,Yes,,Talia D. Wiggen,University Of Minnesota,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266410,2022-05-04,2024-03-01,Unverified,wiggenSARSCoV2SeroprevalenceHealthcare2022,USA
220425_Minneapolis_UniversityOfMinnesota_Sample2,220425_Minneapolis_UniversityOfMinnesota_Sample2,SARS-CoV-2 seroprevalence among healthcare workers.,2022-04-25,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Minnesota,Minneapolis,"The cohort included HCWs from a cross-sectional convenience sample of individuals working in healthcare facilities located in the Minneapolis/St. Paul, MN metropolitan area.

Eligibility criteria were: i) employed or volunteering in a healthcare facility; ii) free of fever, chills, anosmia, pharyngitis, recently developed persistent cough, nasal congestion suspected to be unrelated to season allergies; iii) age 18–80 years; iv) not pregnant. Participants who enrolled and consented to participate in the previous study were then recruited via an email sent on 11/17/2020 to participate in a seroprevalence study. Participants were invited to provide up to 2 capillary blood samples for serology testing. Participants’ first samples (“sample 1”) were collected between 11/22/20–02/21/21 and participants’ second samples (“sample 2”) were collected between 12/18/20–02/15/21","Not healthcare worker, prior COVID-10 diagnosis, pregnant, symptomatic",2020-12-18,2021-02-15,Health care workers and caregivers,All,Multiple groups,18.0,80.0,Primary Estimate,,423,0.1773,,,True,,,,True,Convenience,Q-Plex SARS-CoV-2 Human IgG (4-Plex),Quansys Biosciences,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.97,1.0,['High'],,No,No,Yes,,Yes,Yes,Yes,,Talia D. Wiggen,University Of Minnesota,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0266410,2022-05-05,2024-03-01,Unverified,wiggenSARSCoV2SeroprevalenceHealthcare2022,USA
220426_UnitedStates_CDC_200727to200813_Overall,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-27,2020-08-13,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,38776,0.059000000000000004,0.0553,0.0626,True,,True,,True,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-08-31,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_Age18to49,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-27,2020-08-13,Residual sera,All,Adults (18-64 years),18.0,49.0,Age,Age: 18-49,11237,0.068,0.0601,0.0742,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionNH,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Hampshire,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-30,2020-08-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Hampshire,809,0.008,0.0022,0.0148,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionCA,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-30,2020-08-05,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: California,980,0.057,0.0405,0.07769999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionMD,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maryland,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-31,2020-08-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maryland,783,0.09699999999999999,0.0726,0.12869999999999998,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionUT,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Utah,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-30,2020-08-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Utah,880,0.032,0.017,0.050300000000000004,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionWI,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-30,2020-08-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wisconsin,814,0.018000000000000002,0.0076,0.0318,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionND,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Dakota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-29,2020-08-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: North Dakota,121,0.073,0.013000000000000001,0.1428,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionMN,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-29,2020-08-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Minnesota,879,0.035,0.0206,0.0501,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionIL,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-29,2020-08-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Illinois,1004,0.039,0.0252,0.0521,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionDE,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-29,2020-08-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Delaware,804,0.057,0.0355,0.08220000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionNV,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nevada,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-30,2020-08-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nevada,979,0.051,0.0363,0.0666,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionIN,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Indiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-31,2020-08-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Indiana,579,0.022000000000000002,0.011000000000000001,0.0363,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionMA,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-30,2020-08-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Massachusetts,978,0.042,0.028900000000000002,0.0581,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionNJ,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Jersey,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-31,2020-08-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Jersey,871,0.14800000000000002,0.1223,0.1757,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionDC,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-30,2020-08-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: District of Columbia,717,0.039,0.021800000000000003,0.0576,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionOK,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-28,2020-08-04,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oklahoma,979,0.016,0.0085,0.024900000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionWA,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-29,2020-08-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Washington,684,0.021,0.008100000000000001,0.037000000000000005,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionOR,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-05,2020-08-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oregon,658,0.023,0.0103,0.0384,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionAZ,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arizona,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-31,2020-08-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arizona,591,0.08199999999999999,0.041100000000000005,0.1359,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionRI,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Rhode Island,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-30,2020-08-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Rhode Island,684,0.03,0.0123,0.055099999999999996,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_Female,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-27,2020-08-13,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,22751,0.059000000000000004,0.0547,0.0644,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionAR,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-29,2020-08-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arkansas,937,0.040999999999999995,0.027400000000000004,0.0563,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionTN,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-30,2020-08-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Tennessee,1003,0.063,0.0441,0.0825,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionNC,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-29,2020-08-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: North Carolina,928,0.025,0.0131,0.037200000000000004,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionWV,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-30,2020-08-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: West Virginia,317,0.012,0.0023,0.025,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionPR,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-27,2020-08-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Puerto Rico,984,0.011000000000000001,0.0043,0.018000000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionMS,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-30,2020-08-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Mississippi,769,0.071,0.0375,0.1109,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionNM,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-29,2020-08-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Mexico,964,0.02,0.010900000000000002,0.0302,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionKS,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-29,2020-08-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kansas,962,0.016,0.006999999999999999,0.027999999999999997,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionVT,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Vermont,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-30,2020-08-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Vermont,346,0.005,0.0,0.0184,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionOH,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-29,2020-08-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Ohio,786,0.023,0.0111,0.0361,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionNY,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-31,2020-08-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New York,846,0.233,0.20070000000000002,0.2632,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_AgeOver65,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-27,2020-08-13,Residual sera,All,Seniors (65+ years),65.0,,Age,Age: ≥65,10408,0.025,0.02,0.03,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionIA,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Iowa,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-29,2020-08-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Iowa,811,0.086,0.059800000000000006,0.1134,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionCO,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-30,2020-08-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Colorado,1001,0.024,0.0089,0.0453,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_Male,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-27,2020-08-13,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,16024,0.059000000000000004,0.0527,0.0641,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionAK,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alaska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-06,2020-08-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alaska,242,0.003,0.0,0.011200000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionVA,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-31,2020-08-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Virginia,730,0.040999999999999995,0.018000000000000002,0.0693,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionGA,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-02,2020-08-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Georgia,985,0.068,0.0483,0.08810000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_Age50to64,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-27,2020-08-13,Residual sera,All,Adults (18-64 years),50.0,64.0,Age,Age: 50-64,10367,0.05,0.04360000000000001,0.056900000000000006,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionCT,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-30,2020-08-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Connecticut,994,0.034,0.0204,0.0472,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionNE,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nebraska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-28,2020-08-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nebraska,954,0.07400000000000001,0.0525,0.0975,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionLA,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-28,2020-08-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Louisiana,1002,0.096,0.0688,0.1229,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionPA,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-31,2020-08-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Pennsylvania,575,0.102,0.0571,0.1721,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionAL,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-29,2020-08-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alabama,938,0.057999999999999996,0.041600000000000005,0.0771,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionMT,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Montana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-29,2020-08-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Montana,199,0.005,0.0,0.0167,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_Age0to17,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-27,2020-08-13,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Age,Age: 0-17,6700,0.079,0.0697,0.0882,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionKY,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-30,2020-08-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kentucky,975,0.024,0.013200000000000002,0.0362,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionID,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Idaho,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-04,2020-08-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Idaho,246,0.045,0.018000000000000002,0.0799,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionTX,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Texas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-29,2020-08-05,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Texas,986,0.059000000000000004,0.0404,0.0795,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionMI,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-30,2020-08-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Michigan,982,0.034,0.0216,0.0484,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionME,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maine,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-30,2020-08-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maine,598,0.005,0.0,0.0116,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionSC,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-30,2020-08-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Carolina,840,0.081,0.0579,0.1069,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionFL,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-31,2020-08-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Florida,980,0.043,0.027700000000000002,0.058600000000000006,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200727to200813_RegionMO,220426_UnitedStates_CDC_200727to200813,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-07-28,2020-08-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Missouri,979,0.025,0.0144,0.0361,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_Overall,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-10,2020-08-27,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,45907,0.062000000000000006,0.058600000000000006,0.0651,True,,True,,True,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-08-31,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionIA,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Iowa,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-12,2020-08-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Iowa,980,0.094,0.0712,0.11630000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionUT,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Utah,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-15,2020-08-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Utah,871,0.055,0.0294,0.08710000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionDC,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-13,2020-08-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: District of Columbia,781,0.068,0.045899999999999996,0.09210000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionIN,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Indiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-12,2020-08-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Indiana,906,0.031000000000000003,0.015300000000000001,0.047599999999999996,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_Age18to49,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-10,2020-08-27,Residual sera,All,Adults (18-64 years),18.0,49.0,Age,Age: 18-49,14571,0.07200000000000001,0.0665,0.07740000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionLA,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-12,2020-08-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Louisiana,989,0.11800000000000001,0.09269999999999999,0.1481,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionKY,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-12,2020-08-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kentucky,1126,0.031000000000000003,0.020499999999999997,0.0449,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_Male,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-10,2020-08-27,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,18794,0.064,0.059800000000000006,0.069,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionSC,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-12,2020-08-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Carolina,1063,0.06,0.0437,0.0795,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionVT,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Vermont,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-13,2020-08-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Vermont,382,0.003,0.0,0.008100000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionWI,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-12,2020-08-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wisconsin,838,0.033,0.0203,0.0472,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_Female,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-10,2020-08-27,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,27112,0.06,0.0552,0.0641,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionAZ,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arizona,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-12,2020-08-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arizona,1304,0.047,0.027000000000000003,0.0761,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionDE,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-12,2020-08-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Delaware,1004,0.085,0.0579,0.1125,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_Age50to64,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-10,2020-08-27,Residual sera,All,Adults (18-64 years),50.0,64.0,Age,Age: 50-64,12514,0.05,0.0447,0.055999999999999994,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionIL,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-12,2020-08-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Illinois,985,0.049,0.034,0.0665,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionND,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Dakota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-12,2020-08-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: North Dakota,135,0.006,0.0,0.014499999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionNC,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-11,2020-08-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: North Carolina,982,0.038,0.0233,0.0529,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionTN,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-12,2020-08-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Tennessee,1029,0.067,0.051100000000000007,0.0857,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionSD,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Dakota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-12,2020-08-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Dakota,83,0.0,0.0,0.0435,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionMD,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maryland,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-10,2020-08-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maryland,1174,0.07,0.0492,0.09330000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionOH,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-12,2020-08-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Ohio,985,0.021,0.0106,0.0329,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionAR,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-11,2020-08-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arkansas,998,0.03,0.0176,0.0435,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionID,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Idaho,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-12,2020-08-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Idaho,651,0.046,0.0167,0.09050000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionRI,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Rhode Island,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-12,2020-08-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Rhode Island,570,0.036000000000000004,0.0169,0.0589,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionMA,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-12,2020-08-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Massachusetts,980,0.037000000000000005,0.0227,0.0521,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionMI,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-12,2020-08-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Michigan,983,0.042,0.0288,0.0576,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionCT,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-11,2020-08-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Connecticut,983,0.024,0.014499999999999999,0.0352,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_Age0to17,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-10,2020-08-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Age,Age: 0-17,6920,0.076,0.0684,0.0857,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionME,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maine,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-12,2020-08-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maine,609,0.006,0.0,0.0144,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionKS,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-11,2020-08-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kansas,1016,0.037000000000000005,0.0202,0.0547,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionNH,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Hampshire,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-13,2020-08-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Hampshire,1125,0.008,0.003,0.0122,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionWV,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-13,2020-08-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: West Virginia,637,0.022000000000000002,0.005200000000000001,0.049,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionMO,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-12,2020-08-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Missouri,1021,0.035,0.0223,0.0506,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionCA,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-13,2020-08-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: California,980,0.043,0.0285,0.060599999999999994,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionVA,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-10,2020-08-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Virginia,1243,0.047,0.025099999999999997,0.0722,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionNY,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-10,2020-08-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New York,1122,0.20600000000000002,0.1804,0.23140000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionWY,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wyoming,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-13,2020-08-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wyoming,86,0.008,0.0,0.0311,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionAK,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alaska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-12,2020-08-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alaska,704,0.013000000000000001,0.005,0.0233,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionGA,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-13,2020-08-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Georgia,1031,0.07400000000000001,0.0552,0.0951,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionFL,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-14,2020-08-14,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Florida,978,0.045,0.0315,0.060599999999999994,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionMT,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Montana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-12,2020-08-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Montana,383,0.013000000000000001,0.0038,0.024900000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionNM,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-10,2020-08-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Mexico,976,0.025,0.0147,0.0379,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionTX,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Texas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-12,2020-08-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Texas,1001,0.065,0.046900000000000004,0.08470000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionOR,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-10,2020-08-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oregon,1086,0.024,0.0141,0.036000000000000004,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionMN,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-11,2020-08-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Minnesota,978,0.045,0.0305,0.0587,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionNE,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nebraska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-11,2020-08-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nebraska,990,0.079,0.055099999999999996,0.1061,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionNV,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nevada,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-12,2020-08-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nevada,972,0.079,0.0613,0.0983,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionMS,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-12,2020-08-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Mississippi,968,0.1,0.0669,0.1471,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_AgeOver65,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-10,2020-08-27,Residual sera,All,Seniors (65+ years),65.0,,Age,Age: ≥65,11856,0.034,0.029500000000000002,0.0393,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionPR,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-10,2020-08-17,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Puerto Rico,986,0.022000000000000002,0.0118,0.0326,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionAL,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-12,2020-08-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alabama,974,0.076,0.0533,0.0976,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionPA,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-10,2020-08-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Pennsylvania,887,0.10099999999999999,0.0753,0.1374,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionOK,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-10,2020-08-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oklahoma,979,0.04,0.027200000000000002,0.055099999999999996,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionCO,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-10,2020-08-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Colorado,1019,0.033,0.0183,0.048,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionNJ,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Jersey,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-10,2020-08-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Jersey,1127,0.122,0.1015,0.14529999999999998,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200810to200827_RegionWA,220426_UnitedStates_CDC_200810to200827,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-12,2020-08-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Washington,1238,0.03,0.0179,0.0447,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_Overall,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-24,2020-09-10,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,45327,0.064,0.060700000000000004,0.0677,True,,True,,True,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-08-31,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionWV,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-26,2020-09-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: West Virginia,1128,0.015,0.0078000000000000005,0.023799999999999998,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionPA,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-26,2020-09-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Pennsylvania,845,0.095,0.0658,0.1356,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionSD,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Dakota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-26,2020-09-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Dakota,97,0.006999999999999999,0.0,0.024700000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionLA,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-26,2020-09-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Louisiana,1001,0.086,0.0665,0.113,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionCA,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-28,2020-09-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: California,983,0.06,0.042,0.0782,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_Female,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-24,2020-09-10,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,26344,0.064,0.059000000000000004,0.0684,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionPR,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-24,2020-09-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Puerto Rico,980,0.025,0.013600000000000001,0.0376,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionNM,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-25,2020-09-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Mexico,985,0.037000000000000005,0.022799999999999997,0.0555,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionAZ,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arizona,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-26,2020-09-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arizona,1030,0.049,0.0305,0.07110000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionOK,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-24,2020-09-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oklahoma,979,0.054000000000000006,0.0383,0.0729,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionMI,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-26,2020-09-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Michigan,976,0.034,0.0216,0.0495,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionAL,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-26,2020-09-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alabama,955,0.099,0.0719,0.12789999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionAK,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alaska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-26,2020-09-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alaska,610,0.01,0.0024,0.0217,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_Age0to17,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-24,2020-09-10,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Age,Age: 0-17,6484,0.077,0.06849999999999999,0.0862,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionND,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Dakota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-26,2020-09-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: North Dakota,109,0.002,0.0,0.0099,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionID,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Idaho,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-26,2020-09-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Idaho,790,0.057,0.028999999999999998,0.09699999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionDE,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-26,2020-09-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Delaware,914,0.045,0.0242,0.0712,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionAR,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-24,2020-09-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arkansas,992,0.049,0.035,0.0641,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionWI,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-25,2020-09-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wisconsin,976,0.026000000000000002,0.0148,0.0395,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionOR,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-26,2020-09-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oregon,968,0.019,0.0092,0.0294,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionDC,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-27,2020-09-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: District of Columbia,643,0.05,0.028300000000000002,0.0755,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionMS,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-26,2020-09-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Mississippi,987,0.084,0.0489,0.1273,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionWA,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-25,2020-09-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Washington,820,0.045,0.0263,0.0694,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionSC,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-26,2020-09-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Carolina,927,0.07200000000000001,0.0512,0.09570000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionNV,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nevada,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-27,2020-08-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nevada,980,0.065,0.0463,0.0858,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionMT,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Montana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-24,2020-09-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Montana,518,0.009000000000000001,0.0023,0.0182,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionME,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maine,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-26,2020-09-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maine,759,0.015,0.0044,0.0322,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionMA,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-27,2020-09-05,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Massachusetts,981,0.036000000000000004,0.0236,0.050800000000000005,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionCT,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-26,2020-09-04,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Connecticut,983,0.043,0.028999999999999998,0.056900000000000006,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionKY,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-26,2020-09-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kentucky,983,0.031000000000000003,0.0191,0.0433,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionNJ,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Jersey,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-26,2020-09-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Jersey,944,0.128,0.10490000000000001,0.1535,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionMN,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-26,2020-09-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Minnesota,974,0.092,0.0671,0.1195,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionVT,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Vermont,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-26,2020-09-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Vermont,485,0.004,0.0,0.0094,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionMD,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maryland,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-26,2020-09-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maryland,980,0.079,0.0572,0.1035,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionIL,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-26,2020-09-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Illinois,979,0.055999999999999994,0.039,0.0767,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionKS,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-24,2020-09-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kansas,1025,0.028999999999999998,0.015700000000000002,0.0431,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionCO,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-24,2020-09-04,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Colorado,1025,0.036000000000000004,0.023100000000000002,0.0509,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionFL,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-27,2020-09-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Florida,981,0.057,0.0393,0.07490000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionIA,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Iowa,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-25,2020-09-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Iowa,1006,0.084,0.061500000000000006,0.10740000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionNE,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nebraska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-24,2020-09-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nebraska,938,0.063,0.0447,0.0827,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionNH,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Hampshire,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-26,2020-09-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Hampshire,1147,0.016,0.0073,0.028399999999999998,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionIN,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Indiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-26,2020-09-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Indiana,984,0.024,0.013600000000000001,0.0352,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_AgeOver65,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-24,2020-09-10,Residual sera,All,Seniors (65+ years),65.0,,Age,Age: ≥65,12316,0.033,0.0279,0.038,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionNC,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-26,2020-09-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: North Carolina,982,0.038,0.0233,0.0526,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionNY,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-26,2020-09-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New York,1043,0.195,0.1688,0.2238,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionRI,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Rhode Island,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-27,2020-09-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Rhode Island,786,0.031000000000000003,0.0173,0.0464,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_Age18to49,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-24,2020-09-10,Residual sera,All,Adults (18-64 years),18.0,49.0,Age,Age: 18-49,14079,0.07400000000000001,0.068,0.0799,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionTN,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-25,2020-09-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Tennessee,950,0.054000000000000006,0.0362,0.0731,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionTX,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Texas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-25,2020-09-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Texas,979,0.057999999999999996,0.0404,0.0792,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionGA,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-25,2020-09-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Georgia,1020,0.087,0.0669,0.11140000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_Male,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-24,2020-09-10,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,18983,0.064,0.05940000000000001,0.07,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionOH,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-27,2020-09-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Ohio,983,0.05,0.0317,0.0714,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionMO,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-24,2020-09-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Missouri,1024,0.028999999999999998,0.0174,0.0417,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_Age50to64,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-24,2020-09-10,Residual sera,All,Adults (18-64 years),50.0,64.0,Age,Age: 50-64,12426,0.059000000000000004,0.0524,0.0659,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionUT,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Utah,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-24,2020-09-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Utah,1104,0.049,0.0282,0.0767,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200824to200910_RegionVA,220426_UnitedStates_CDC_200824to200910,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-08-26,2020-09-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Virginia,1007,0.035,0.0197,0.0526,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_Overall,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-08,2020-09-24,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,47909,0.068,0.0649,0.0718,True,,True,,True,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-08-31,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionAZ,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arizona,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arizona,1208,0.054000000000000006,0.0308,0.0852,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionMN,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Minnesota,1033,0.08,0.047400000000000005,0.1143,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionIN,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Indiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Indiana,1155,0.04,0.0144,0.08789999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionME,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maine,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-08,2020-09-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maine,987,0.005,0.0009,0.0087,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionSD,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Dakota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Dakota,99,0.018000000000000002,0.0,0.04820000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionMD,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maryland,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-10,2020-09-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maryland,1242,0.102,0.0791,0.1268,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionMT,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Montana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Montana,508,0.022000000000000002,0.0067,0.0438,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionOH,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-10,2020-09-22,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Ohio,978,0.027999999999999997,0.0169,0.041600000000000005,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_Female,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-08,2020-09-24,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,27564,0.064,0.0599,0.0687,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionWA,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-22,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Washington,968,0.025,0.0129,0.0383,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionVA,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-10,2020-09-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Virginia,1111,0.032,0.0181,0.0513,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionFL,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-11,2020-09-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Florida,979,0.085,0.0655,0.1068,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionPR,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-08,2020-09-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Puerto Rico,970,0.03,0.0178,0.042699999999999995,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionNM,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-08,2020-09-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Mexico,1014,0.024,0.011899999999999999,0.0365,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionNC,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-17,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: North Carolina,925,0.068,0.0483,0.08869999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionAL,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alabama,905,0.087,0.061900000000000004,0.1131,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionDC,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-08,2020-09-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: District of Columbia,976,0.065,0.0447,0.08289999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionND,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Dakota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: North Dakota,113,0.012,0.0,0.034,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionRI,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Rhode Island,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Rhode Island,795,0.027000000000000003,0.0115,0.049100000000000005,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionKY,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kentucky,980,0.036000000000000004,0.0233,0.0521,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionOR,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-08,2020-09-22,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oregon,971,0.026000000000000002,0.0151,0.0406,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionMO,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-08,2020-09-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Missouri,1031,0.035,0.0215,0.0501,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_Age0to17,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-08,2020-09-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Age,Age: 0-17,6612,0.09699999999999999,0.08800000000000001,0.1061,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionMA,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Massachusetts,988,0.037000000000000005,0.0223,0.0516,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionNE,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nebraska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nebraska,976,0.067,0.048,0.0888,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionTX,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Texas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Texas,988,0.08199999999999999,0.0616,0.10470000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionUT,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Utah,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Utah,1022,0.051,0.0329,0.079,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionHI,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Hawaii,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-08,2020-09-22,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Hawaii,516,0.008,0.0,0.021800000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionWY,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wyoming,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wyoming,111,0.015,0.0,0.039700000000000006,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_AgeOver65,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-08,2020-09-24,Residual sera,All,Seniors (65+ years),65.0,,Age,Age: ≥65,12933,0.031000000000000003,0.026600000000000002,0.0359,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionIA,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Iowa,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Iowa,977,0.076,0.0556,0.1002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionAK,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alaska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alaska,681,0.004,0.0011,0.008199999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionNV,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nevada,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nevada,979,0.078,0.059000000000000004,0.0999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionCO,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Colorado,1032,0.033,0.019,0.0492,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionDE,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Delaware,980,0.075,0.0489,0.105,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionMS,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-22,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Mississippi,980,0.079,0.0535,0.10869999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionNY,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-11,2020-09-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New York,1168,0.17,0.1472,0.1923,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_Age50to64,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-08,2020-09-24,Residual sera,All,Adults (18-64 years),50.0,64.0,Age,Age: 50-64,13207,0.055,0.049100000000000005,0.0609,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionKS,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kansas,1007,0.035,0.023100000000000002,0.0484,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionOK,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oklahoma,980,0.05,0.0344,0.0654,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionCA,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-10,2020-09-16,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: California,979,0.049,0.0317,0.06849999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionCT,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-14,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Connecticut,982,0.031000000000000003,0.0206,0.0437,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionPA,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Pennsylvania,1341,0.111,0.0885,0.1371,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionWI,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wisconsin,976,0.038,0.022000000000000002,0.057300000000000004,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_Age18to49,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-08,2020-09-24,Residual sera,All,Adults (18-64 years),18.0,49.0,Age,Age: 18-49,15157,0.077,0.0713,0.08310000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionLA,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Louisiana,952,0.125,0.1002,0.1561,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionTN,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-08,2020-09-16,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Tennessee,1028,0.067,0.0496,0.0857,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionVT,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Vermont,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Vermont,497,0.017,0.0027,0.0415,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionID,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Idaho,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-08,2020-09-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Idaho,732,0.052000000000000005,0.027400000000000004,0.08460000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionSC,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Carolina,975,0.078,0.0558,0.10189999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionGA,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Georgia,1100,0.13,0.1051,0.15789999999999998,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionMI,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-08,2020-09-22,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Michigan,980,0.037000000000000005,0.025400000000000002,0.0493,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionWV,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-22,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: West Virginia,968,0.013000000000000001,0.0051,0.021800000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionIL,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-08,2020-09-17,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Illinois,992,0.045,0.031000000000000003,0.060700000000000004,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionAR,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arkansas,990,0.063,0.046,0.0803,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_Male,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-08,2020-09-24,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,20343,0.073,0.0678,0.0781,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionNH,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Hampshire,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-17,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Hampshire,1034,0.006999999999999999,0.0026000000000000003,0.013200000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200908to200924_RegionNJ,220426_UnitedStates_CDC_200908to200924,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Jersey,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-09,2020-09-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Jersey,1050,0.151,0.1265,0.17629999999999998,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_Overall,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-20,2020-10-08,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,45960,0.068,0.0649,0.07200000000000001,True,,True,,True,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-08-31,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionMD,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maryland,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-21,2020-10-05,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maryland,1058,0.099,0.078,0.122,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionVA,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-21,2020-10-05,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Virginia,899,0.05,0.0234,0.0926,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionIN,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Indiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-21,2020-10-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Indiana,1011,0.06,0.021400000000000002,0.1202,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_Male,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-20,2020-10-08,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,19583,0.07200000000000001,0.0663,0.077,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_Age18to49,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-20,2020-10-08,Residual sera,All,Adults (18-64 years),18.0,49.0,Age,Age: 18-49,14625,0.079,0.0725,0.0852,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionID,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Idaho,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-23,2020-10-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Idaho,977,0.049,0.0273,0.0717,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionIL,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-23,2020-10-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Illinois,923,0.054000000000000006,0.0381,0.0718,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionWI,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-23,2020-10-06,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wisconsin,978,0.031000000000000003,0.0196,0.046200000000000005,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionWA,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-22,2020-10-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Washington,1024,0.023,0.0125,0.036000000000000004,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionCT,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-24,2020-09-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Connecticut,984,0.025,0.0147,0.038,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionWV,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-23,2020-10-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: West Virginia,959,0.032,0.0111,0.0618,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_Age50to64,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-20,2020-10-08,Residual sera,All,Adults (18-64 years),50.0,64.0,Age,Age: 50-64,12573,0.057,0.0507,0.0636,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionVT,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Vermont,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-25,2020-10-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Vermont,514,0.005,0.0,0.011899999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionCA,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-25,2020-09-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: California,979,0.040999999999999995,0.026099999999999998,0.0564,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionAK,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alaska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-22,2020-10-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alaska,994,0.009000000000000001,0.004,0.0154,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionGA,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-23,2020-10-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Georgia,979,0.10400000000000001,0.0768,0.131,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionWY,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wyoming,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-23,2020-10-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wyoming,118,0.042,0.0068000000000000005,0.0925,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionPR,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-21,2020-09-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Puerto Rico,980,0.032,0.0188,0.0471,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionRI,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Rhode Island,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-25,2020-10-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Rhode Island,864,0.042,0.0257,0.06269999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_AgeOver65,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-20,2020-10-08,Residual sera,All,Seniors (65+ years),65.0,,Age,Age: ≥65,12391,0.036000000000000004,0.030600000000000002,0.0406,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionNC,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-23,2020-10-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: North Carolina,932,0.067,0.047400000000000005,0.0889,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionNV,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nevada,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-23,2020-09-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nevada,980,0.078,0.058499999999999996,0.0994,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionSC,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-23,2020-10-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Carolina,816,0.091,0.0639,0.1178,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionCO,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-24,2020-10-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Colorado,951,0.03,0.017,0.0454,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionIA,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Iowa,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-23,2020-10-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Iowa,941,0.083,0.0633,0.1036,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionTX,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Texas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-23,2020-10-05,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Texas,981,0.07200000000000001,0.0519,0.0956,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionMO,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-21,2020-10-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Missouri,965,0.059000000000000004,0.04190000000000001,0.0812,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionUT,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Utah,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-23,2020-10-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Utah,937,0.053,0.0361,0.0731,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionKY,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-23,2020-10-06,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kentucky,978,0.023,0.0129,0.0346,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionNJ,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Jersey,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-21,2020-10-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Jersey,958,0.16,0.13570000000000002,0.18739999999999998,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionFL,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-25,2020-09-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Florida,981,0.079,0.0609,0.09910000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_Age0to17,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-20,2020-10-08,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Age,Age: 0-17,6371,0.08800000000000001,0.0782,0.09630000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionAR,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-23,2020-10-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arkansas,929,0.043,0.0278,0.05740000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionAL,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-21,2020-10-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alabama,942,0.08900000000000001,0.0658,0.11380000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionNE,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nebraska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-23,2020-10-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nebraska,927,0.1,0.0716,0.1288,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionDE,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-23,2020-10-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Delaware,976,0.06,0.04070000000000001,0.0812,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionOH,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-23,2020-10-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Ohio,976,0.024,0.0126,0.0364,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionPA,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-20,2020-10-05,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Pennsylvania,1255,0.107,0.0817,0.1378,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionDC,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-23,2020-10-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: District of Columbia,676,0.05,0.0326,0.07150000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionMS,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-23,2020-10-06,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Mississippi,984,0.055,0.0382,0.0731,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionNM,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-23,2020-10-06,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Mexico,979,0.036000000000000004,0.0229,0.0507,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_Female,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-20,2020-10-08,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,26377,0.066,0.0611,0.0702,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionOR,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-20,2020-10-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oregon,972,0.025,0.005699999999999999,0.056799999999999996,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionNH,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Hampshire,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-25,2020-10-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Hampshire,957,0.01,0.0028000000000000004,0.0223,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionNY,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-20,2020-10-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New York,822,0.228,0.192,0.26539999999999997,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionKS,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-22,2020-10-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kansas,936,0.05,0.0353,0.0672,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionMI,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-22,2020-10-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Michigan,979,0.034,0.0233,0.044800000000000006,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionLA,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-23,2020-10-06,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Louisiana,977,0.12,0.09630000000000001,0.1445,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionMN,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-23,2020-10-06,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Minnesota,980,0.044000000000000004,0.0292,0.059500000000000004,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionTN,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-23,2020-10-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Tennessee,976,0.091,0.0683,0.114,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionOK,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-23,2020-09-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oklahoma,979,0.055999999999999994,0.0378,0.0736,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionAZ,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arizona,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-22,2020-10-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arizona,764,0.079,0.0296,0.1443,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionME,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maine,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-25,2020-10-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maine,911,0.005,0.0008,0.0116,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionMT,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Montana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-23,2020-10-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Montana,706,0.027000000000000003,0.006,0.0652,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionHI,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Hawaii,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-22,2020-10-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Hawaii,575,0.017,0.001,0.105,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_200920to201008_RegionMA,220426_UnitedStates_CDC_200920to201008,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-09-25,2020-10-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Massachusetts,988,0.027999999999999997,0.0176,0.0404,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_Overall,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-10,2020-10-22,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,46279,0.07200000000000001,0.0683,0.0758,True,,True,,True,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-08-31,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionNV,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nevada,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-06,2020-10-16,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nevada,981,0.08199999999999999,0.064,0.10060000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionVA,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-09,2020-10-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Virginia,864,0.040999999999999995,0.024100000000000003,0.062000000000000006,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionWY,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wyoming,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-08,2020-10-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wyoming,123,0.026000000000000002,0.0046,0.057800000000000004,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_Age18to49,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-10,2020-10-22,Residual sera,All,Adults (18-64 years),18.0,49.0,Age,Age: 18-49,14577,0.087,0.0809,0.0934,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_Age50to64,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-10,2020-10-22,Residual sera,All,Adults (18-64 years),50.0,64.0,Age,Age: 50-64,12529,0.063,0.0562,0.07,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionUT,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Utah,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-05,2020-10-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Utah,978,0.091,0.063,0.1199,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionLA,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-06,2020-10-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Louisiana,980,0.098,0.0736,0.12460000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionOK,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-07,2020-10-14,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oklahoma,980,0.07400000000000001,0.050800000000000005,0.0971,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionOR,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-07,2020-10-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oregon,972,0.021,0.0087,0.0359,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionMI,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-06,2020-10-16,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Michigan,979,0.032,0.0196,0.0455,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionAK,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alaska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-06,2020-10-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alaska,971,0.015,0.0079,0.0246,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionID,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Idaho,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-05,2020-10-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Idaho,985,0.042,0.026400000000000003,0.0602,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionKY,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-07,2020-10-16,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kentucky,980,0.033,0.0195,0.0472,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_AgeOver65,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-10,2020-10-22,Residual sera,All,Seniors (65+ years),65.0,,Age,Age: ≥65,12686,0.039,0.0339,0.044500000000000005,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionSC,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-07,2020-10-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Carolina,1031,0.08,0.057800000000000004,0.10490000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_Female,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-10,2020-10-22,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,26698,0.07200000000000001,0.06730000000000001,0.0772,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionAZ,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arizona,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-07,2020-10-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arizona,940,0.048,0.0255,0.0789,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionNC,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-06,2020-10-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: North Carolina,995,0.035,0.020499999999999997,0.0504,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionNY,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-09,2020-10-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New York,820,0.219,0.1872,0.2525,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionAR,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-07,2020-10-22,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arkansas,971,0.09,0.0714,0.11380000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionNJ,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Jersey,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-07,2020-10-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Jersey,889,0.12400000000000001,0.1002,0.1517,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionNE,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nebraska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-07,2020-10-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nebraska,966,0.113,0.086,0.1413,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_Age0to17,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-10,2020-10-22,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Age,Age: 0-17,6487,0.08199999999999999,0.0732,0.0907,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionMO,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-07,2020-10-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Missouri,976,0.065,0.0437,0.0864,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionCO,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-08,2020-10-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Colorado,978,0.044000000000000004,0.0282,0.0651,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_Male,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-10,2020-10-22,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,19580,0.07200000000000001,0.0668,0.077,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionPR,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-05,2020-10-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Puerto Rico,980,0.027999999999999997,0.016399999999999998,0.0438,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionRI,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Rhode Island,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-09,2020-10-22,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Rhode Island,760,0.024,0.0143,0.0354,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionVT,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Vermont,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-09,2020-10-22,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Vermont,472,0.004,0.0,0.0122,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionME,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maine,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-09,2020-10-22,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maine,983,0.006,0.0016,0.0125,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionDC,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-07,2020-10-22,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: District of Columbia,1027,0.068,0.0499,0.0889,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionAL,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-07,2020-10-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alabama,996,0.12300000000000001,0.1,0.1499,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionPA,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-08,2020-10-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Pennsylvania,946,0.105,0.0839,0.1316,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionNH,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Hampshire,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-09,2020-10-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Hampshire,980,0.008,0.0031,0.014199999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionWI,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-07,2020-10-22,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wisconsin,973,0.05,0.034100000000000005,0.0698,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionIA,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Iowa,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-07,2020-10-22,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Iowa,976,0.13,0.0928,0.1819,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionWA,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-07,2020-10-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Washington,974,0.02,0.0091,0.032100000000000004,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionCT,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-08,2020-10-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Connecticut,988,0.023,0.013200000000000002,0.0352,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionTN,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-07,2020-10-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Tennessee,995,0.099,0.07490000000000001,0.1226,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionMD,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maryland,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-10,2020-10-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maryland,627,0.114,0.0827,0.1484,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionMS,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-05,2020-10-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Mississippi,972,0.131,0.094,0.1724,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionMN,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-06,2020-10-22,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Minnesota,984,0.075,0.0536,0.1001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionOH,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-06,2020-10-22,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Ohio,980,0.018000000000000002,0.0094,0.0275,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionWV,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-07,2020-10-22,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: West Virginia,1124,0.022000000000000002,0.0129,0.033,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionGA,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-06,2020-10-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Georgia,1008,0.085,0.0617,0.1118,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionIL,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-07,2020-10-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Illinois,979,0.057999999999999996,0.0414,0.07540000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionNM,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-06,2020-10-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Mexico,976,0.048,0.0326,0.06620000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionHI,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Hawaii,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-06,2020-10-22,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Hawaii,439,0.02,0.0055000000000000005,0.04190000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionIN,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Indiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-07,2020-10-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Indiana,1223,0.046,0.0227,0.07830000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionKS,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-06,2020-10-22,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kansas,967,0.071,0.0516,0.09179999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionTX,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Texas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-05,2020-10-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Texas,992,0.10400000000000001,0.0815,0.1298,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionMT,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Montana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-07,2020-10-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Montana,588,0.032,0.015700000000000002,0.0501,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionCA,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-08,2020-10-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: California,980,0.045,0.028999999999999998,0.06420000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionFL,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-09,2020-10-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Florida,983,0.08,0.0601,0.10220000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionDE,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-07,2020-10-22,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Delaware,980,0.07400000000000001,0.0495,0.09880000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201005to201022_RegionMA,220426_UnitedStates_CDC_201005to201022,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-09,2020-10-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Massachusetts,979,0.026000000000000002,0.015,0.0388,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_Overall,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-25,2020-11-15,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,64717,0.08,0.0772,0.08320000000000001,True,,True,,True,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-08-31,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionKY,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-26,2020-11-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kentucky,1588,0.075,0.0588,0.0943,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionAR,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-26,2020-11-06,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arkansas,1500,0.065,0.051500000000000004,0.07980000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionMI,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-26,2020-11-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Michigan,1616,0.086,0.0643,0.11050000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_Male,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-25,2020-11-15,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,26231,0.081,0.076,0.0857,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionGA,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-27,2020-11-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Georgia,1330,0.12400000000000001,0.1001,0.14880000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionPR,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-02,2020-11-14,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Puerto Rico,1300,0.038,0.0259,0.0517,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionNY,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-30,2020-11-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New York,1355,0.13,0.107,0.1536,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionMD,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maryland,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-29,2020-11-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maryland,1312,0.07200000000000001,0.053,0.0936,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionFL,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-27,2020-11-04,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Florida,1360,0.076,0.0602,0.0911,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionMA,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-02,2020-11-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Massachusetts,1115,0.038,0.0248,0.052000000000000005,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionDE,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-26,2020-11-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Delaware,949,0.10400000000000001,0.0772,0.1362,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionIN,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Indiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-29,2020-11-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Indiana,1222,0.063,0.0425,0.0859,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_Female,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-25,2020-11-15,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,38472,0.08,0.0756,0.0833,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionAL,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-26,2020-11-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alabama,1538,0.092,0.0757,0.1099,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionMO,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-02,2020-11-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Missouri,1507,0.061,0.0432,0.0797,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionSC,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-27,2020-11-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Carolina,1556,0.084,0.0694,0.0999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionMS,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-25,2020-11-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Mississippi,1530,0.11,0.0931,0.1311,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionVT,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Vermont,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-02,2020-11-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Vermont,605,0.004,0.0004,0.0098,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionOR,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-30,2020-11-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oregon,1757,0.023,0.0118,0.0358,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionRI,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Rhode Island,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-02,2020-11-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Rhode Island,1113,0.034,0.020800000000000003,0.0492,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionCA,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-26,2020-11-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: California,1315,0.066,0.0509,0.0812,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_Age0to17,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-25,2020-11-15,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Age,Age: 0-17,8721,0.102,0.09390000000000001,0.1097,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_Age50to64,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-25,2020-11-15,Residual sera,All,Adults (18-64 years),50.0,64.0,Age,Age: 50-64,18484,0.069,0.06420000000000001,0.07440000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionSD,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Dakota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-27,2020-11-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Dakota,152,0.08800000000000001,0.0394,0.1536,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionIL,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-26,2020-11-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Illinois,1557,0.129,0.10869999999999999,0.1494,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionTX,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Texas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-29,2020-11-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Texas,775,0.159,0.1155,0.2368,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionMN,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-29,2020-11-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Minnesota,1303,0.084,0.0679,0.1014,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionCO,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-30,2020-11-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Colorado,1293,0.05,0.0335,0.068,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionAK,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alaska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-30,2020-11-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alaska,1413,0.063,0.0368,0.1057,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionNJ,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Jersey,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-29,2020-11-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Jersey,1236,0.11900000000000001,0.10039999999999999,0.1387,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionWA,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-01,2020-11-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Washington,2169,0.034,0.0245,0.0444,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionPA,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-26,2020-11-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Pennsylvania,1553,0.063,0.0495,0.07690000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_Age18to49,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-25,2020-11-15,Residual sera,All,Adults (18-64 years),18.0,49.0,Age,Age: 18-49,20122,0.095,0.0897,0.1008,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionIA,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Iowa,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-28,2020-11-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Iowa,1193,0.11900000000000001,0.09369999999999999,0.1458,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionWI,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-26,2020-11-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wisconsin,1096,0.153,0.12240000000000001,0.189,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionWY,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wyoming,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-26,2020-11-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wyoming,402,0.048,0.0236,0.0762,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionCT,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-02,2020-11-14,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Connecticut,1009,0.035,0.0209,0.0499,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionKS,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-01,2020-11-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kansas,1317,0.055,0.0417,0.0706,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionID,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Idaho,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-30,2020-11-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Idaho,1302,0.063,0.04190000000000001,0.08960000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionUT,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Utah,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-25,2020-11-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Utah,1119,0.069,0.0422,0.1079,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionVA,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-29,2020-11-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Virginia,1227,0.036000000000000004,0.0207,0.055999999999999994,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionOH,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-25,2020-11-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Ohio,1661,0.073,0.0584,0.08789999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionMT,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Montana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-30,2020-11-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Montana,516,0.077,0.049800000000000004,0.11,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionHI,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Hawaii,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-29,2020-11-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Hawaii,1064,0.028999999999999998,0.0166,0.0468,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionLA,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-28,2020-11-14,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Louisiana,1316,0.09699999999999999,0.07490000000000001,0.1178,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionNH,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Hampshire,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-02,2020-11-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Hampshire,1299,0.011000000000000001,0.0038,0.0197,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionOK,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-31,2020-11-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oklahoma,1299,0.06,0.0455,0.077,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionME,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maine,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-02,2020-11-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maine,995,0.01,0.0033000000000000004,0.0179,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionNM,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-30,2020-11-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Mexico,1337,0.075,0.056799999999999996,0.09390000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_AgeOver65,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-25,2020-11-15,Residual sera,All,Seniors (65+ years),65.0,,Age,Age: ≥65,17390,0.039,0.0345,0.0431,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionWV,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-29,2020-11-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: West Virginia,1095,0.055,0.030299999999999997,0.0935,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionNC,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-27,2020-11-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: North Carolina,1520,0.075,0.0589,0.0892,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionTN,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-26,2020-11-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Tennessee,1283,0.107,0.08750000000000001,0.1257,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionAZ,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arizona,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-26,2020-11-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arizona,1800,0.096,0.0808,0.1112,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionNV,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nevada,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-25,2020-11-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nevada,1346,0.085,0.06559999999999999,0.1051,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionDC,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-27,2020-11-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: District of Columbia,1175,0.08800000000000001,0.0697,0.1067,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201025to201115_RegionNE,220426_UnitedStates_CDC_201025to201115,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nebraska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-10-30,2020-11-14,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nebraska,1288,0.11900000000000001,0.0958,0.142,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_Overall,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-09,2020-11-29,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,63721,0.094,0.091,0.0978,True,,True,,True,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-08-31,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionTN,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-09,2020-11-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Tennessee,1528,0.12,0.10289999999999999,0.1381,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionKY,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-09,2020-11-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kentucky,1719,0.077,0.058600000000000006,0.09789999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionWY,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wyoming,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-09,2020-11-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wyoming,518,0.091,0.0429,0.1494,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionUT,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Utah,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-12,2020-11-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Utah,661,0.122,0.0866,0.15380000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionMI,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-09,2020-11-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Michigan,1907,0.08800000000000001,0.0647,0.121,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionOH,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-13,2020-11-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Ohio,1341,0.128,0.1054,0.1516,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionMN,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-12,2020-11-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Minnesota,1301,0.114,0.09230000000000001,0.1383,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionPA,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-09,2020-11-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Pennsylvania,2553,0.076,0.0636,0.0883,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionWA,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-19,2020-11-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Washington,297,0.03,0.0101,0.0538,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionMT,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Montana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-11,2020-11-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Montana,486,0.091,0.06,0.125,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionGA,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-15,2020-11-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Georgia,1265,0.10300000000000001,0.0809,0.1258,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionAK,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alaska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-14,2020-11-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alaska,621,0.065,0.042800000000000005,0.09140000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionME,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maine,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-16,2020-11-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maine,565,0.006,0.001,0.0129,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionRI,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Rhode Island,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-16,2020-11-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Rhode Island,1196,0.053,0.0382,0.06849999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionOK,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-14,2020-11-17,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oklahoma,1284,0.065,0.046200000000000005,0.0852,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionHI,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Hawaii,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-13,2020-11-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Hawaii,666,0.027999999999999997,0.0134,0.0431,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionIN,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Indiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-12,2020-11-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Indiana,1166,0.062000000000000006,0.0379,0.08630000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionMA,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-16,2020-11-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Massachusetts,1286,0.045,0.0329,0.0587,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionFL,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-09,2020-11-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Florida,1692,0.102,0.0866,0.1182,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_AgeOver65,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-09,2020-11-29,Residual sera,All,Seniors (65+ years),65.0,,Age,Age: ≥65,16767,0.054000000000000006,0.0489,0.0593,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionIL,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-14,2020-11-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Illinois,2023,0.162,0.1464,0.1783,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionSD,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Dakota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-10,2020-11-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Dakota,211,0.12,0.0477,0.2021,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_Female,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-09,2020-11-29,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,37657,0.096,0.09150000000000001,0.1005,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionPR,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-16,2020-11-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Puerto Rico,1300,0.035,0.0233,0.048,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionNC,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-09,2020-11-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: North Carolina,1619,0.084,0.0649,0.1045,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionMD,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maryland,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-12,2020-11-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maryland,1237,0.095,0.0751,0.1143,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionMS,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-09,2020-11-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Mississippi,1450,0.136,0.1165,0.1561,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionAL,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-14,2020-11-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alabama,1320,0.09,0.07150000000000001,0.10980000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionOR,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-16,2020-11-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oregon,299,0.040999999999999995,0.0167,0.0709,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionDC,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-10,2020-11-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: District of Columbia,1512,0.114,0.09330000000000001,0.1342,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionKS,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-09,2020-11-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kansas,1276,0.08199999999999999,0.0639,0.1035,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionTX,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Texas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-12,2020-11-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Texas,933,0.14300000000000002,0.10619999999999999,0.1852,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_Age0to17,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-09,2020-11-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Age,Age: 0-17,7619,0.12300000000000001,0.11410000000000001,0.13140000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionNY,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-11,2020-11-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New York,1199,0.09300000000000001,0.0721,0.1124,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionCO,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-13,2020-11-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Colorado,1316,0.071,0.0472,0.09970000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_Age50to64,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-09,2020-11-29,Residual sera,All,Adults (18-64 years),50.0,64.0,Age,Age: 50-64,18272,0.08199999999999999,0.0767,0.0885,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_Male,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-09,2020-11-29,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,26064,0.092,0.0874,0.0971,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionNE,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nebraska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-13,2020-11-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nebraska,1262,0.163,0.1306,0.1961,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionDE,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-10,2020-11-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Delaware,1017,0.081,0.059699999999999996,0.10300000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionCT,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-16,2020-11-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Connecticut,1305,0.046,0.032799999999999996,0.059800000000000006,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionMO,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-09,2020-11-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Missouri,2000,0.10300000000000001,0.08140000000000001,0.1286,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionIA,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Iowa,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-13,2020-11-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Iowa,980,0.147,0.11019999999999999,0.1856,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionCA,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-09,2020-11-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: California,1285,0.079,0.0609,0.09630000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionNV,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nevada,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-09,2020-11-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nevada,1835,0.12,0.09179999999999999,0.14980000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionID,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Idaho,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-17,2020-11-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Idaho,471,0.134,0.09609999999999999,0.1773,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionNH,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Hampshire,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-16,2020-11-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Hampshire,1302,0.016,0.0072,0.025400000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_Age18to49,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-09,2020-11-29,Residual sera,All,Adults (18-64 years),18.0,49.0,Age,Age: 18-49,21063,0.107,0.10130000000000002,0.11220000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionNM,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-12,2020-11-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Mexico,1255,0.08800000000000001,0.0672,0.11109999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionAR,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-09,2020-11-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arkansas,2115,0.075,0.0625,0.0889,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionWV,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-16,2020-11-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: West Virginia,904,0.036000000000000004,0.0182,0.057800000000000004,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionLA,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-12,2020-11-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Louisiana,1286,0.09300000000000001,0.0692,0.11789999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionVA,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-12,2020-11-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Virginia,1344,0.046,0.0298,0.06559999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionVT,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Vermont,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-16,2020-11-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Vermont,464,0.006,0.0,0.0168,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionSC,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-10,2020-11-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Carolina,1710,0.106,0.0889,0.12369999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionWI,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-09,2020-11-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wisconsin,1614,0.156,0.13390000000000002,0.1813,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionAZ,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arizona,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-09,2020-11-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arizona,2301,0.114,0.0947,0.1363,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201109to201129_RegionNJ,220426_UnitedStates_CDC_201109to201129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Jersey,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-12,2020-11-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Jersey,1483,0.151,0.1292,0.17350000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_Overall,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-23,2020-12-12,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,59563,0.115,0.1109,0.1182,True,,True,,True,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-08-31,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionPR,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-30,2020-12-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Puerto Rico,1306,0.045,0.030299999999999997,0.0599,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionSC,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-23,2020-12-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Carolina,1174,0.094,0.0763,0.11560000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionID,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Idaho,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-27,2020-12-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Idaho,567,0.107,0.0731,0.1451,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionAL,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-23,2020-12-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alabama,1339,0.11699999999999999,0.0974,0.1402,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_Male,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-23,2020-12-12,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,24967,0.11800000000000001,0.11230000000000001,0.12369999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionWY,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wyoming,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-24,2020-12-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wyoming,306,0.131,0.081,0.1882,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionOH,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-25,2020-12-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Ohio,1778,0.165,0.14400000000000002,0.18730000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionTN,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-25,2020-12-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Tennessee,1333,0.149,0.1252,0.17190000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionDE,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-24,2020-12-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Delaware,1500,0.078,0.0591,0.0981,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionIN,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Indiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-26,2020-12-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Indiana,727,0.086,0.061399999999999996,0.1187,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionMT,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Montana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-29,2020-12-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Montana,540,0.09699999999999999,0.0661,0.1266,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_AgeOver65,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-23,2020-12-12,Residual sera,All,Seniors (65+ years),65.0,,Age,Age: ≥65,16430,0.063,0.0582,0.06849999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionDC,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-23,2020-12-05,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: District of Columbia,2002,0.132,0.10779999999999999,0.1531,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionFL,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-30,2020-12-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Florida,778,0.113,0.09,0.135,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionPA,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-27,2020-12-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Pennsylvania,1125,0.106,0.0858,0.1268,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionNE,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nebraska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-27,2020-12-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nebraska,1261,0.155,0.1243,0.18789999999999998,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionNV,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nevada,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-27,2020-12-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nevada,1160,0.132,0.10310000000000001,0.1623,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionNC,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-23,2020-12-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: North Carolina,973,0.073,0.055999999999999994,0.09230000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_Female,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-23,2020-12-12,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,34595,0.11199999999999999,0.10710000000000001,0.1164,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionCT,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-30,2020-12-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Connecticut,1282,0.049,0.0349,0.0645,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionWV,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-28,2020-12-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: West Virginia,1178,0.051,0.0326,0.0747,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionIA,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Iowa,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-25,2020-12-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Iowa,1278,0.197,0.1618,0.2339,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionLA,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-27,2020-12-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Louisiana,1291,0.102,0.0815,0.1213,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionWA,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-23,2020-12-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Washington,1402,0.055,0.0391,0.0732,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionKY,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-25,2020-12-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kentucky,1262,0.109,0.0895,0.1304,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionHI,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Hawaii,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-27,2020-12-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Hawaii,1259,0.045,0.0204,0.0724,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionMS,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-23,2020-12-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Mississippi,1279,0.18300000000000002,0.1553,0.2134,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_Age0to17,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-23,2020-12-12,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Age,Age: 0-17,7814,0.145,0.1343,0.15480000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionNM,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-28,2020-12-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Mexico,1298,0.129,0.1057,0.151,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionAR,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-25,2020-12-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arkansas,1441,0.092,0.0721,0.11109999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionSD,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Dakota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-25,2020-12-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Dakota,123,0.233,0.13470000000000001,0.34750000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_Age50to64,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-23,2020-12-12,Residual sera,All,Adults (18-64 years),50.0,64.0,Age,Age: 50-64,16725,0.10099999999999999,0.0944,0.10800000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionMN,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-25,2020-12-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Minnesota,1278,0.14,0.11710000000000001,0.16519999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionMA,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-30,2020-12-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Massachusetts,1291,0.062000000000000006,0.047599999999999996,0.0782,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionOR,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-30,2020-12-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oregon,1476,0.036000000000000004,0.0232,0.050499999999999996,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionMO,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-27,2020-12-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Missouri,1808,0.14800000000000002,0.12150000000000001,0.174,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionUT,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Utah,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-23,2020-12-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Utah,1141,0.21600000000000003,0.14830000000000002,0.2787,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionRI,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Rhode Island,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-30,2020-12-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Rhode Island,1240,0.087,0.0695,0.1066,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionMD,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maryland,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-26,2020-12-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maryland,1176,0.109,0.08320000000000001,0.1381,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionCO,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-26,2020-12-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Colorado,1316,0.098,0.08,0.114,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionKS,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-24,2020-12-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kansas,1282,0.09699999999999999,0.0768,0.11789999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionAZ,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arizona,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-30,2020-12-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arizona,1249,0.122,0.0985,0.1469,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionMI,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-24,2020-12-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Michigan,1109,0.10300000000000001,0.0788,0.1268,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionNH,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Hampshire,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-30,2020-12-05,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Hampshire,1307,0.019,0.0105,0.029300000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionGA,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-25,2020-12-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Georgia,1296,0.15,0.1259,0.177,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionME,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maine,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-30,2020-12-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maine,573,0.013000000000000001,0.0034000000000000002,0.0253,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionNJ,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Jersey,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-27,2020-12-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Jersey,1066,0.155,0.1308,0.1829,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionOK,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-30,2020-12-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oklahoma,1298,0.067,0.0513,0.0824,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionVT,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Vermont,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-30,2020-12-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Vermont,422,0.008,0.0004,0.018000000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionNY,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-23,2020-12-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New York,1289,0.122,0.10130000000000002,0.1458,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionVA,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-26,2020-12-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Virginia,1112,0.057,0.0345,0.0802,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionAK,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alaska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-23,2020-12-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alaska,901,0.08800000000000001,0.0617,0.1153,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionIL,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-27,2020-12-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Illinois,2209,0.23399999999999999,0.2132,0.25620000000000004,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionTX,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Texas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-26,2020-12-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Texas,655,0.18100000000000002,0.13949999999999999,0.233,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionCA,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-23,2020-12-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: California,1285,0.08900000000000001,0.0707,0.10869999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_Age18to49,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-23,2020-12-12,Residual sera,All,Adults (18-64 years),18.0,49.0,Age,Age: 18-49,18594,0.132,0.1255,0.1383,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_201123to201212_RegionWI,220426_UnitedStates_CDC_201123to201212,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2020-11-25,2020-12-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wisconsin,797,0.203,0.1645,0.24309999999999998,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_Overall,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-01,2021-02-21,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,59467,0.2,0.1952,0.2054,True,,True,,True,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-08-31,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionAZ,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arizona,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-08,2021-02-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arizona,1443,0.257,0.2316,0.28350000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionPR,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-08,2021-02-16,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Puerto Rico,1302,0.171,0.14529999999999998,0.2028,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionNV,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nevada,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-08,2021-02-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nevada,1677,0.251,0.2245,0.2763,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionOK,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-04,2021-02-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oklahoma,1296,0.19399999999999998,0.1681,0.21960000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionNC,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-08,2021-02-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: North Carolina,1309,0.20600000000000002,0.1827,0.2295,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionTX,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Texas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-07,2021-02-17,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Texas,701,0.277,0.2236,0.33039999999999997,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionLA,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-06,2021-02-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Louisiana,1298,0.151,0.1229,0.1801,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_AgeOver65,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-01,2021-02-21,Residual sera,All,Seniors (65+ years),65.0,,Age,Age: ≥65,16353,0.12400000000000001,0.11660000000000001,0.13140000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionCA,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-08,2021-02-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: California,1292,0.21600000000000003,0.1915,0.2411,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionWV,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-05,2021-02-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: West Virginia,954,0.115,0.08310000000000001,0.1506,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionAK,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alaska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-05,2021-02-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alaska,1311,0.125,0.0922,0.1641,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_Female,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-01,2021-02-21,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,34651,0.195,0.18910000000000002,0.20149999999999998,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionRI,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Rhode Island,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-08,2021-02-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Rhode Island,1270,0.138,0.1168,0.1584,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionNH,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Hampshire,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-08,2021-02-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Hampshire,1300,0.075,0.0529,0.10250000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionIL,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-08,2021-02-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Illinois,1408,0.33299999999999996,0.3029,0.365,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionOR,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-03,2021-02-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oregon,1309,0.067,0.049800000000000004,0.083,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionVT,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Vermont,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-08,2021-02-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Vermont,583,0.011000000000000001,0.0022,0.0212,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionAR,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-08,2021-02-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arkansas,1071,0.217,0.1882,0.24760000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionMO,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-08,2021-02-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Missouri,1265,0.23600000000000002,0.20350000000000001,0.2699,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionKS,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-01,2021-02-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kansas,1310,0.14800000000000002,0.1202,0.17739999999999997,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionFL,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-08,2021-02-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Florida,1330,0.19399999999999998,0.1706,0.21600000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionCO,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-04,2021-02-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Colorado,1323,0.151,0.12400000000000001,0.18059999999999998,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionTN,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-08,2021-02-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Tennessee,1350,0.273,0.2404,0.306,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionVA,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-04,2021-02-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Virginia,1025,0.105,0.0742,0.1335,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionIN,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Indiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-04,2021-02-17,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Indiana,862,0.20800000000000002,0.172,0.24370000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionMN,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-01,2021-02-16,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Minnesota,1297,0.167,0.1399,0.192,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionWA,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-04,2021-02-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Washington,1307,0.077,0.0604,0.0965,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_Male,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-01,2021-02-21,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,24816,0.20600000000000002,0.19890000000000002,0.2134,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionDC,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-08,2021-02-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: District of Columbia,1341,0.18600000000000003,0.1587,0.21309999999999998,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionMD,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maryland,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-04,2021-02-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maryland,1256,0.247,0.2113,0.2831,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionDE,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-08,2021-02-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Delaware,1337,0.158,0.135,0.1804,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionNY,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-06,2021-02-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New York,1308,0.13699999999999998,0.1153,0.1585,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionMI,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-08,2021-02-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Michigan,1336,0.189,0.1624,0.2183,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionSC,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-08,2021-02-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Carolina,1317,0.266,0.23920000000000002,0.2934,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionNJ,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Jersey,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-04,2021-02-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Jersey,1190,0.24,0.215,0.26730000000000004,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionWI,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-08,2021-02-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wisconsin,1208,0.284,0.24850000000000003,0.3251,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionOH,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-08,2021-02-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Ohio,1557,0.316,0.2921,0.34299999999999997,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_Age18to49,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-01,2021-02-21,Residual sera,All,Adults (18-64 years),18.0,49.0,Age,Age: 18-49,18756,0.218,0.20980000000000001,0.2259,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionUT,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Utah,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-08,2021-02-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Utah,1228,0.287,0.2488,0.3275,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionAL,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-08,2021-02-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alabama,1377,0.23800000000000002,0.2116,0.2651,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionKY,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-08,2021-02-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kentucky,1367,0.21300000000000002,0.1869,0.2426,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionME,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maine,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-08,2021-02-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maine,571,0.034,0.0182,0.0536,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionIA,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Iowa,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-04,2021-02-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Iowa,1294,0.22399999999999998,0.19039999999999999,0.2586,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionCT,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-08,2021-02-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Connecticut,1293,0.11199999999999999,0.09230000000000001,0.1323,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionHI,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Hawaii,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-04,2021-02-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Hawaii,1305,0.026000000000000002,0.0141,0.0425,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_Age50to64,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-01,2021-02-21,Residual sera,All,Adults (18-64 years),50.0,64.0,Age,Age: 50-64,16665,0.18100000000000002,0.17250000000000001,0.1894,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionMA,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-08,2021-02-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Massachusetts,1286,0.11599999999999999,0.09570000000000001,0.1375,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionPA,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-08,2021-02-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Pennsylvania,1485,0.20800000000000002,0.1815,0.23370000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionNM,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-03,2021-02-17,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Mexico,1298,0.172,0.147,0.2024,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionNE,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nebraska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-05,2021-02-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nebraska,1303,0.188,0.1586,0.2186,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_Age0to17,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-01,2021-02-21,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Age,Age: 0-17,7693,0.253,0.2396,0.26489999999999997,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionMS,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-08,2021-02-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Mississippi,1248,0.254,0.2227,0.2895,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionWY,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wyoming,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-08,2021-02-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wyoming,123,0.226,0.1247,0.3457,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionGA,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-08,2021-02-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Georgia,1314,0.171,0.1492,0.1962,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionID,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Idaho,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-05,2021-02-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Idaho,1318,0.18,0.1378,0.2212,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210201to210221_RegionMT,220426_UnitedStates_CDC_210201to210221,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Montana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-02,2021-02-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Montana,452,0.163,0.11789999999999999,0.20980000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_Overall,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-15,2021-03-07,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,59387,0.20800000000000002,0.2024,0.2121,True,,True,,True,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-08-31,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionMD,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maryland,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-18,2021-03-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maryland,1015,0.30100000000000005,0.2572,0.34049999999999997,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionHI,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Hawaii,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-17,2021-03-06,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Hawaii,1321,0.016,0.0078000000000000005,0.0258,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionID,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Idaho,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-19,2021-03-05,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Idaho,1309,0.17,0.12810000000000002,0.2137,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionMA,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-22,2021-03-06,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Massachusetts,1284,0.11699999999999999,0.0953,0.1381,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionAL,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-22,2021-03-05,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alabama,1291,0.28,0.2525,0.3075,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionMI,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-22,2021-03-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Michigan,1121,0.20199999999999999,0.167,0.2382,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_Age50to64,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-15,2021-03-07,Residual sera,All,Adults (18-64 years),50.0,64.0,Age,Age: 50-64,16778,0.18100000000000002,0.171,0.18910000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionPA,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-22,2021-03-04,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Pennsylvania,1520,0.18,0.1577,0.2036,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionNJ,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Jersey,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-18,2021-03-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Jersey,1270,0.284,0.2586,0.3121,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionVT,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Vermont,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-22,2021-03-05,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Vermont,521,0.028999999999999998,0.0131,0.048600000000000004,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_Male,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-15,2021-03-07,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,24418,0.214,0.207,0.22160000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionLA,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-20,2021-03-05,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Louisiana,1296,0.152,0.129,0.1768,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionAR,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-22,2021-03-05,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arkansas,1420,0.231,0.20980000000000001,0.2566,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionGA,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-18,2021-02-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Georgia,1302,0.17300000000000001,0.14880000000000002,0.19920000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionIA,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Iowa,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-19,2021-03-05,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Iowa,1263,0.20500000000000002,0.1743,0.2396,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionRI,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Rhode Island,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-22,2021-03-06,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Rhode Island,1188,0.139,0.1161,0.1637,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionOK,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-19,2021-02-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oklahoma,1299,0.2,0.17600000000000002,0.2242,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionNV,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nevada,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-22,2021-03-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nevada,1309,0.256,0.2279,0.2836,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionVA,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-18,2021-03-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Virginia,948,0.142,0.1101,0.17870000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionOH,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-22,2021-03-06,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Ohio,1398,0.316,0.28809999999999997,0.34259999999999996,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionIL,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-22,2021-03-06,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Illinois,1341,0.29100000000000004,0.2614,0.3236,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionFL,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-22,2021-03-05,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Florida,1087,0.204,0.1759,0.23070000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionNH,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Hampshire,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-22,2021-03-04,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Hampshire,1295,0.087,0.056799999999999996,0.11810000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_Female,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-15,2021-03-07,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,34969,0.201,0.19530000000000003,0.2078,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionWV,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-17,2021-03-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: West Virginia,1245,0.091,0.0698,0.1167,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionKY,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-22,2021-03-05,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kentucky,1358,0.19899999999999998,0.17350000000000002,0.22530000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionMN,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-15,2021-03-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Minnesota,1297,0.17800000000000002,0.1534,0.2079,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionSC,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-22,2021-03-04,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Carolina,1045,0.258,0.2273,0.2864,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_Age0to17,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-15,2021-03-07,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Age,Age: 0-17,8679,0.255,0.24420000000000003,0.2669,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionDC,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-22,2021-03-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: District of Columbia,1361,0.192,0.16640000000000002,0.21670000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionAK,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alaska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-16,2021-03-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alaska,1315,0.1,0.0728,0.1293,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionND,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Dakota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-22,2021-03-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: North Dakota,3,0.777,,,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_AgeOver65,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-15,2021-03-07,Residual sera,All,Seniors (65+ years),65.0,,Age,Age: ≥65,15831,0.132,0.1243,0.1392,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionCA,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-22,2021-02-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: California,1294,0.22399999999999998,0.19820000000000002,0.2495,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionNE,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nebraska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-16,2021-03-06,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nebraska,1282,0.18600000000000003,0.1539,0.2163,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionMS,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-22,2021-03-04,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Mississippi,1492,0.28300000000000003,0.2564,0.3094,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionNC,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-22,2021-03-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: North Carolina,1172,0.225,0.1975,0.2504,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionMO,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-22,2021-03-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Missouri,1277,0.23600000000000002,0.20629999999999998,0.2632,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionPR,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-22,2021-03-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Puerto Rico,1300,0.253,0.22390000000000002,0.284,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionME,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maine,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-22,2021-03-05,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maine,559,0.044000000000000004,0.0271,0.0651,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionDE,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-22,2021-03-06,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Delaware,1741,0.153,0.1317,0.17379999999999998,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionIN,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Indiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-18,2021-03-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Indiana,764,0.227,0.18359999999999999,0.2923,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionSD,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Dakota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-22,2021-03-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Dakota,88,0.297,0.1777,0.4108,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionWA,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-19,2021-03-04,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Washington,1307,0.057999999999999996,0.0441,0.0733,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionOR,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-19,2021-02-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oregon,1313,0.069,0.0517,0.0866,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionNM,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-19,2021-03-04,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Mexico,1299,0.16899999999999998,0.14400000000000002,0.1929,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionMT,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Montana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-20,2021-03-05,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Montana,556,0.152,0.1143,0.192,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionUT,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Utah,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-22,2021-03-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Utah,1308,0.27,0.23120000000000002,0.3102,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionAZ,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arizona,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-22,2021-03-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arizona,1309,0.261,0.233,0.29050000000000004,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionTX,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Texas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-18,2021-03-04,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Texas,1296,0.32799999999999996,0.2874,0.3735,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionWY,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wyoming,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-22,2021-03-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wyoming,157,0.184,0.09609999999999999,0.2748,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionNY,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-17,2021-03-06,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New York,1329,0.12400000000000001,0.1037,0.1437,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionWI,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-22,2021-03-06,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wisconsin,1249,0.305,0.2725,0.3418,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionTN,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-22,2021-03-06,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Tennessee,1272,0.28600000000000003,0.25620000000000004,0.31420000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionCO,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-15,2021-03-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Colorado,1320,0.129,0.10619999999999999,0.1524,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_Age18to49,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-15,2021-03-07,Residual sera,All,Adults (18-64 years),18.0,49.0,Age,Age: 18-49,18099,0.23,0.222,0.2386,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionKS,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-17,2021-02-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kansas,1300,0.152,0.1275,0.1779,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210215to210307_RegionCT,220426_UnitedStates_CDC_210215to210307,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-02-21,2021-03-05,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Connecticut,1281,0.128,0.1082,0.149,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_Overall,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-01,2021-03-21,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,62296,0.204,0.1997,0.2089,True,,True,,True,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-08-31,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionKS,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-05,2021-03-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kansas,1309,0.135,0.114,0.15810000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_Age0to17,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-01,2021-03-21,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Age,Age: 0-17,8702,0.251,0.24,0.2619,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionHI,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Hawaii,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-03,2021-03-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Hawaii,1318,0.024,0.014499999999999999,0.035,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionWV,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-07,2021-03-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: West Virginia,1259,0.114,0.0853,0.1418,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionNM,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-04,2021-03-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Mexico,1299,0.157,0.1334,0.1804,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionNC,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-09,2021-03-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: North Carolina,1140,0.23800000000000002,0.2114,0.2663,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionCO,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-07,2021-03-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Colorado,1325,0.11199999999999999,0.0894,0.1322,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_Age50to64,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-01,2021-03-21,Residual sera,All,Adults (18-64 years),50.0,64.0,Age,Age: 50-64,17266,0.188,0.1789,0.197,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionFL,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-08,2021-03-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Florida,1320,0.21300000000000002,0.189,0.2407,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionMD,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maryland,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-04,2021-03-17,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maryland,1390,0.2,0.1702,0.2305,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionNV,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nevada,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-08,2021-03-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nevada,1319,0.24800000000000003,0.22,0.2803,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionAR,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-08,2021-03-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arkansas,1364,0.252,0.2256,0.2761,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionUT,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Utah,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-08,2021-03-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Utah,1308,0.314,0.2749,0.3536,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionAL,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-08,2021-03-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alabama,1626,0.294,0.26739999999999997,0.3184,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionMI,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-08,2021-03-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Michigan,1317,0.197,0.16570000000000001,0.2281,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionDE,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-08,2021-03-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Delaware,1343,0.184,0.1574,0.21120000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionAK,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alaska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-02,2021-03-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alaska,1312,0.083,0.066,0.1045,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionMT,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Montana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-05,2021-03-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Montana,549,0.11800000000000001,0.0805,0.156,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionVA,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-04,2021-03-17,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Virginia,1855,0.145,0.1217,0.1796,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionID,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Idaho,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-05,2021-03-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Idaho,1297,0.154,0.1159,0.19940000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionOR,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-05,2021-03-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oregon,1312,0.063,0.0492,0.0781,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionPR,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-08,2021-03-16,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Puerto Rico,1300,0.30100000000000005,0.2743,0.33270000000000005,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionVT,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Vermont,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-08,2021-03-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Vermont,572,0.028999999999999998,0.0122,0.0556,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionWI,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-08,2021-03-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wisconsin,1279,0.315,0.2802,0.3503,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionKY,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-08,2021-03-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kentucky,1350,0.227,0.201,0.2521,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionDC,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-08,2021-03-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: District of Columbia,1365,0.21100000000000002,0.1815,0.2434,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_Male,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-01,2021-03-21,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,25422,0.204,0.1972,0.2108,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionOH,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-08,2021-03-17,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Ohio,1566,0.302,0.2796,0.3273,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionSD,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Dakota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-08,2021-03-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Dakota,167,0.268,0.155,0.4535,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionIN,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Indiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-04,2021-03-17,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Indiana,911,0.256,0.2115,0.3048,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionTX,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Texas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-04,2021-03-17,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Texas,1397,0.24,0.20170000000000002,0.2804,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_AgeOver65,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-01,2021-03-21,Residual sera,All,Seniors (65+ years),65.0,,Age,Age: ≥65,17133,0.134,0.1267,0.1414,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionPA,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-08,2021-03-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Pennsylvania,1528,0.19899999999999998,0.1721,0.2275,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionGA,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-08,2021-03-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Georgia,1299,0.17800000000000002,0.1535,0.2043,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionMA,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-08,2021-03-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Massachusetts,1276,0.11900000000000001,0.0966,0.1418,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionNH,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Hampshire,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-08,2021-03-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Hampshire,1300,0.081,0.0635,0.098,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionWY,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wyoming,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-08,2021-03-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wyoming,377,0.297,0.2432,0.3519,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionMO,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-08,2021-03-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Missouri,1436,0.227,0.19399999999999998,0.2584,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionWA,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-03,2021-03-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Washington,1312,0.067,0.0512,0.0839,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_Female,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-01,2021-03-21,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,36874,0.20500000000000002,0.19820000000000002,0.2107,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionSC,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-08,2021-03-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Carolina,1506,0.24100000000000002,0.215,0.26780000000000004,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionNE,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nebraska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-05,2021-03-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nebraska,1276,0.19100000000000003,0.16510000000000002,0.2206,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionLA,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-04,2021-03-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Louisiana,1298,0.14400000000000002,0.1216,0.16640000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionTN,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-08,2021-03-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Tennessee,1589,0.251,0.22710000000000002,0.2786,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionMS,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-08,2021-03-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Mississippi,1318,0.299,0.2675,0.3315,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionAZ,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arizona,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-08,2021-03-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arizona,1336,0.269,0.2393,0.2926,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionCT,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-08,2021-03-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Connecticut,1284,0.11199999999999999,0.09550000000000002,0.12990000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionME,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maine,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-08,2021-03-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maine,490,0.046,0.0239,0.0742,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionNY,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-01,2021-03-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New York,1308,0.139,0.1183,0.1608,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_Age18to49,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-01,2021-03-21,Residual sera,All,Adults (18-64 years),18.0,49.0,Age,Age: 18-49,19195,0.22,0.21230000000000002,0.22820000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionRI,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Rhode Island,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-08,2021-03-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Rhode Island,938,0.11800000000000001,0.09029999999999999,0.1509,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionCA,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-08,2021-03-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: California,1304,0.204,0.1794,0.22899999999999998,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionIL,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-08,2021-03-17,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Illinois,1496,0.32,0.29,0.3557,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionNJ,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Jersey,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-04,2021-03-17,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Jersey,1135,0.289,0.25989999999999996,0.3182,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionIA,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Iowa,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-04,2021-03-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Iowa,1279,0.21,0.17500000000000002,0.2487,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionOK,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-05,2021-03-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oklahoma,1300,0.182,0.1582,0.20809999999999998,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210301to210321_RegionMN,220426_UnitedStates_CDC_210301to210321,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-05,2021-03-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Minnesota,1307,0.145,0.1208,0.17170000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_Overall,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-13,2021-04-04,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,60909,0.207,0.2024,0.2115,True,,True,,True,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-08-31,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionCO,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-21,2021-03-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Colorado,1215,0.129,0.09240000000000001,0.16760000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionOK,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-18,2021-03-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oklahoma,1299,0.156,0.1343,0.1807,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionOH,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-22,2021-03-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Ohio,1338,0.34500000000000003,0.3168,0.37090000000000006,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionAZ,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arizona,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-22,2021-03-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arizona,1337,0.266,0.2404,0.29460000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionMN,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-16,2021-03-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Minnesota,1296,0.135,0.11380000000000001,0.158,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_Age0to17,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-13,2021-04-04,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Age,Age: 0-17,8396,0.259,0.24739999999999998,0.2704,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionRI,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Rhode Island,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-22,2021-04-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Rhode Island,937,0.122,0.094,0.1484,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionMI,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-22,2021-04-04,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Michigan,1319,0.231,0.19890000000000002,0.2651,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionLA,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-19,2021-04-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Louisiana,1293,0.138,0.11560000000000001,0.16469999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionWY,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wyoming,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-22,2021-04-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wyoming,697,0.242,0.18510000000000001,0.31010000000000004,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionPA,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-22,2021-04-04,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Pennsylvania,1736,0.19399999999999998,0.1697,0.21660000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionVA,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-18,2021-03-31,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Virginia,930,0.14800000000000002,0.1149,0.1847,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionDE,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-22,2021-04-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Delaware,1682,0.168,0.14830000000000002,0.19010000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionWA,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-15,2021-03-31,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Washington,1314,0.05,0.0367,0.06559999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionNJ,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Jersey,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-18,2021-03-31,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Jersey,934,0.27899999999999997,0.245,0.3155,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionTN,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-22,2021-04-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Tennessee,1578,0.27,0.23760000000000003,0.3002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionKY,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-22,2021-04-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kentucky,1382,0.23399999999999999,0.20920000000000002,0.2606,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionPR,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-22,2021-03-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Puerto Rico,1301,0.329,0.3003,0.3602,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionUT,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Utah,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-22,2021-03-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Utah,1310,0.299,0.2452,0.3505,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionCT,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-22,2021-04-04,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Connecticut,1301,0.111,0.0919,0.1308,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionMD,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maryland,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-18,2021-03-31,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maryland,915,0.259,0.2212,0.2939,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionNC,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-24,2021-03-31,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: North Carolina,1362,0.22899999999999998,0.2054,0.2563,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionDC,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-22,2021-04-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: District of Columbia,1207,0.23199999999999998,0.2025,0.2625,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_Female,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-13,2021-04-04,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,36127,0.20500000000000002,0.1986,0.2104,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionMS,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-22,2021-04-04,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Mississippi,1442,0.299,0.26,0.33740000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_Age18to49,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-13,2021-04-04,Residual sera,All,Adults (18-64 years),18.0,49.0,Age,Age: 18-49,19332,0.225,0.2172,0.2331,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_AgeOver65,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-13,2021-04-04,Residual sera,All,Seniors (65+ years),65.0,,Age,Age: ≥65,16452,0.131,0.12390000000000001,0.1384,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionNV,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nevada,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-22,2021-03-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nevada,1306,0.29600000000000004,0.2659,0.3259,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionGA,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-18,2021-04-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Georgia,1301,0.17500000000000002,0.15080000000000002,0.1998,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionME,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maine,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-22,2021-04-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maine,605,0.024,0.013200000000000002,0.0393,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionIA,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Iowa,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-19,2021-04-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Iowa,1288,0.177,0.1515,0.2036,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionFL,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-22,2021-03-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Florida,1329,0.20500000000000002,0.1826,0.2295,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionNE,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nebraska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-19,2021-04-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nebraska,1296,0.171,0.14250000000000002,0.2028,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionMT,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Montana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-22,2021-04-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Montana,540,0.153,0.1167,0.19469999999999998,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionAK,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alaska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-18,2021-04-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alaska,1313,0.13699999999999998,0.09150000000000001,0.17690000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionNY,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-16,2021-04-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New York,1297,0.122,0.1033,0.1461,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionNH,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Hampshire,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-22,2021-03-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Hampshire,1297,0.08800000000000001,0.06860000000000001,0.10779999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionMA,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-22,2021-04-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Massachusetts,1302,0.08800000000000001,0.0718,0.1043,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionKS,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-17,2021-03-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kansas,1231,0.146,0.1242,0.1698,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionIN,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Indiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-18,2021-03-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Indiana,455,0.215,0.16829999999999998,0.2711,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionMO,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-22,2021-03-31,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Missouri,1295,0.266,0.2346,0.2999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionAL,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-22,2021-04-04,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alabama,1409,0.29,0.2631,0.3153,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionVT,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Vermont,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-22,2021-04-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Vermont,556,0.017,0.005200000000000001,0.0338,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionHI,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Hawaii,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-16,2021-04-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Hawaii,1319,0.013999999999999999,0.006600000000000001,0.0252,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionAR,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-22,2021-04-04,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arkansas,1734,0.237,0.2162,0.25870000000000004,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionNM,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-19,2021-04-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Mexico,1298,0.171,0.145,0.1972,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_Male,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-18,2021-04-01,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,24781,0.21,0.2021,0.217,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionID,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Idaho,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-19,2021-04-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Idaho,1303,0.158,0.12150000000000001,0.2039,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionSC,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-22,2021-04-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Carolina,1547,0.258,0.2328,0.28500000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionTX,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Texas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-18,2021-04-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Texas,1187,0.312,0.2662,0.3521,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionSD,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Dakota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-22,2021-04-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Dakota,339,0.27899999999999997,0.1843,0.3386,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionCA,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-22,2021-03-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: California,1303,0.24,0.2146,0.2676,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionWI,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-22,2021-04-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wisconsin,1342,0.308,0.2712,0.35100000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_Age50to64,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-13,2021-04-04,Residual sera,All,Adults (18-64 years),50.0,64.0,Age,Age: 50-64,16729,0.18600000000000003,0.1776,0.19530000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionIL,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-22,2021-04-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Illinois,1457,0.28600000000000003,0.2614,0.3131,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionWV,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-21,2021-04-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: West Virginia,1086,0.11699999999999999,0.09240000000000001,0.1445,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210315to210404_RegionOR,220426_UnitedStates_CDC_210315to210404,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-17,2021-03-31,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oregon,1314,0.063,0.046900000000000004,0.0795,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_Overall,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-29,2021-04-18,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,61095,0.218,0.21239999999999998,0.2223,True,,True,,True,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-08-31,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionIA,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Iowa,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-01,2021-04-16,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Iowa,1293,0.20500000000000002,0.16920000000000002,0.24120000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionOR,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-02,2021-04-14,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oregon,1308,0.068,0.0504,0.0864,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionNV,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nevada,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-05,2021-04-16,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nevada,1307,0.27399999999999997,0.24190000000000003,0.30670000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionMT,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Montana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-05,2021-04-16,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Montana,311,0.132,0.0853,0.18170000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionVA,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-01,2021-04-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Virginia,1119,0.158,0.1264,0.19820000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionIL,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-05,2021-04-17,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Illinois,1303,0.336,0.3053,0.3682,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionOH,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-05,2021-04-17,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Ohio,1372,0.332,0.3065,0.3591,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionKS,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-02,2021-04-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kansas,1293,0.15,0.1266,0.1753,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionAL,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-05,2021-04-17,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alabama,1485,0.303,0.2736,0.33380000000000004,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionMO,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-05,2021-04-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Missouri,1347,0.26,0.22940000000000002,0.2945,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionMA,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-05,2021-04-17,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Massachusetts,1293,0.107,0.0884,0.127,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionNM,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-30,2021-04-17,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Mexico,1297,0.16399999999999998,0.14,0.18910000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_Female,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-29,2021-04-18,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,36205,0.21300000000000002,0.2061,0.21920000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_Age0to17,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-29,2021-04-18,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Age,Age: 0-17,7820,0.272,0.25980000000000003,0.28550000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionIN,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Indiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-01,2021-04-14,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Indiana,822,0.258,0.2003,0.31980000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionNE,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nebraska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-05,2021-04-16,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nebraska,1292,0.179,0.1409,0.2136,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionKY,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-05,2021-04-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kentucky,1350,0.239,0.2134,0.26530000000000004,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionTX,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Texas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-01,2021-04-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Texas,1198,0.33899999999999997,0.2992,0.38549999999999995,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionMS,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-05,2021-04-14,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Mississippi,1528,0.277,0.23809999999999998,0.3233,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionPR,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-05,2021-04-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Puerto Rico,1300,0.439,0.4067,0.4731,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionWI,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-05,2021-04-17,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wisconsin,1321,0.30100000000000005,0.2659,0.3336,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionLA,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-01,2021-04-17,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Louisiana,1294,0.145,0.1227,0.1704,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionNJ,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Jersey,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-01,2021-04-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Jersey,1143,0.313,0.2813,0.3431,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionCA,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-05,2021-04-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: California,1278,0.24100000000000002,0.2147,0.2677,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionMD,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maryland,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-01,2021-04-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maryland,1175,0.257,0.219,0.2937,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionGA,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-05,2021-04-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Georgia,1299,0.177,0.15410000000000001,0.2036,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionCT,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-05,2021-04-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Connecticut,1286,0.10400000000000001,0.0858,0.1229,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_Male,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-29,2021-04-18,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,24890,0.223,0.21530000000000002,0.2297,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionSC,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-05,2021-04-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Carolina,1384,0.242,0.21550000000000002,0.2647,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionCO,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-29,2021-04-16,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Colorado,1280,0.136,0.1082,0.1696,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionSD,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Dakota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-05,2021-04-16,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Dakota,215,0.263,0.16899999999999998,0.3882,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionUT,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Utah,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-05,2021-04-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Utah,1314,0.27399999999999997,0.2215,0.3221,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionFL,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-05,2021-04-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Florida,1314,0.223,0.1978,0.24800000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionAK,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alaska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-31,2021-04-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alaska,1309,0.099,0.061900000000000004,0.1421,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionME,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maine,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-05,2021-04-17,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maine,597,0.047,0.0281,0.0698,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionWY,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wyoming,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-05,2021-04-17,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wyoming,1012,0.29,0.23750000000000002,0.3381,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionRI,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Rhode Island,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-05,2021-04-17,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Rhode Island,944,0.12400000000000001,0.0999,0.1487,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionMI,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-05,2021-04-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Michigan,1345,0.24300000000000002,0.2132,0.2762,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionWA,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-02,2021-04-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Washington,1301,0.066,0.0492,0.0819,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionAZ,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arizona,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-05,2021-04-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arizona,1392,0.27899999999999997,0.251,0.3074,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionDC,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-05,2021-04-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: District of Columbia,1316,0.226,0.19690000000000002,0.256,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionAR,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-05,2021-04-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arkansas,1360,0.264,0.23620000000000002,0.2892,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionTN,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-05,2021-04-17,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Tennessee,1450,0.295,0.2687,0.3235,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionID,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Idaho,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-02,2021-04-16,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Idaho,1293,0.185,0.1421,0.22719999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionPA,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-05,2021-04-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Pennsylvania,1592,0.225,0.1995,0.2553,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_Age18to49,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-29,2021-04-18,Residual sera,All,Adults (18-64 years),18.0,49.0,Age,Age: 18-49,19347,0.23600000000000002,0.2277,0.2446,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionWV,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-05,2021-04-17,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: West Virginia,1035,0.105,0.0789,0.1322,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionOK,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-02,2021-04-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oklahoma,1300,0.187,0.1629,0.209,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionDE,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-05,2021-04-17,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Delaware,1480,0.167,0.1445,0.19090000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionVT,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Vermont,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-05,2021-04-17,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Vermont,600,0.024,0.0098,0.0425,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionHI,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Hawaii,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-01,2021-04-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Hawaii,1324,0.025,0.011899999999999999,0.046,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_Age50to64,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-29,2021-04-18,Residual sera,All,Adults (18-64 years),50.0,64.0,Age,Age: 50-64,17420,0.203,0.1943,0.2121,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionNY,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-30,2021-04-17,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New York,1297,0.12300000000000001,0.1032,0.1448,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionNH,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Hampshire,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-05,2021-04-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Hampshire,1304,0.079,0.0564,0.1189,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionNC,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-05,2021-04-14,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: North Carolina,1304,0.23,0.2021,0.2564,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_RegionMN,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-30,2021-04-16,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Minnesota,1297,0.111,0.09230000000000001,0.1325,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210329to210418_AgeOver65,220426_UnitedStates_CDC_210329to210418,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-03-29,2021-04-18,Residual sera,All,Seniors (65+ years),65.0,,Age,Age: ≥65,16508,0.13,0.12240000000000001,0.138,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_Overall,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-12,2021-05-02,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,59368,0.214,0.2089,0.2193,True,,True,,True,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-08-31,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionMT,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Montana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-17,2021-05-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Montana,615,0.099,0.0724,0.132,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionLA,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-16,2021-05-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Louisiana,1281,0.135,0.1103,0.1595,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionKS,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-12,2021-04-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kansas,1308,0.12300000000000001,0.0985,0.14830000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionGA,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-19,2021-04-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Georgia,1297,0.17,0.1456,0.19640000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionVT,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Vermont,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-19,2021-05-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Vermont,621,0.043,0.025099999999999997,0.0633,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionID,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Idaho,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-16,2021-05-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Idaho,1306,0.11599999999999999,0.0922,0.14400000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionIN,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Indiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-15,2021-04-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Indiana,828,0.245,0.19649999999999998,0.2916,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionOR,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-14,2021-04-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oregon,1277,0.067,0.0512,0.0855,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionME,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maine,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-18,2021-05-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maine,677,0.039,0.022799999999999997,0.0567,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionDE,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-19,2021-05-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Delaware,1192,0.189,0.162,0.2159,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionUT,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Utah,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-19,2021-04-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Utah,1300,0.278,0.2293,0.32770000000000005,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_Male,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-12,2021-05-02,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,24060,0.21600000000000003,0.2091,0.2233,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionCT,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-19,2021-05-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Connecticut,1293,0.11900000000000001,0.0999,0.1394,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionAZ,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arizona,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-19,2021-04-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arizona,1297,0.263,0.2372,0.2933,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionMD,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maryland,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-15,2021-04-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maryland,906,0.281,0.2438,0.3139,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionNV,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nevada,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-19,2021-04-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nevada,1301,0.255,0.2217,0.2919,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionOK,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-17,2021-04-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oklahoma,1299,0.177,0.1535,0.2004,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionSD,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Dakota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-19,2021-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Dakota,223,0.309,0.2154,0.4111,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionDC,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-19,2021-05-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: District of Columbia,1303,0.231,0.1973,0.2605,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionVA,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-15,2021-04-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Virginia,940,0.166,0.1286,0.2084,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionWV,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-19,2021-05-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: West Virginia,952,0.115,0.087,0.1418,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_Female,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-12,2021-05-02,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,35308,0.212,0.2059,0.21920000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionCA,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-19,2021-04-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: California,1306,0.252,0.22640000000000002,0.2799,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionAL,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-19,2021-05-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alabama,1661,0.272,0.24920000000000003,0.2995,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionRI,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Rhode Island,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-19,2021-05-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Rhode Island,980,0.12300000000000001,0.0956,0.1502,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_Age18to49,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-12,2021-05-02,Residual sera,All,Adults (18-64 years),18.0,49.0,Age,Age: 18-49,18606,0.23500000000000001,0.226,0.24239999999999998,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionMA,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-19,2021-05-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Massachusetts,1281,0.102,0.08310000000000001,0.1198,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionTX,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Texas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-16,2021-04-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Texas,944,0.29600000000000004,0.2571,0.3381,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionHI,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Hawaii,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-14,2021-05-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Hawaii,1017,0.028999999999999998,0.011899999999999999,0.053899999999999997,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionAK,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alaska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-14,2021-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alaska,1308,0.111,0.0844,0.141,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionWI,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-19,2021-04-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wisconsin,1340,0.29300000000000004,0.2468,0.33799999999999997,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionCO,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-12,2021-04-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Colorado,1323,0.11699999999999999,0.0895,0.1526,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionSC,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-19,2021-04-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Carolina,1305,0.24800000000000003,0.22390000000000002,0.2756,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionNC,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-19,2021-04-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: North Carolina,1303,0.219,0.19190000000000002,0.2462,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionIA,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Iowa,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-16,2021-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Iowa,1274,0.155,0.1233,0.1858,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionOH,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-19,2021-05-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Ohio,1470,0.375,0.34630000000000005,0.4035,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionMS,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-19,2021-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Mississippi,1462,0.27,0.24059999999999998,0.2984,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionMN,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-13,2021-04-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Minnesota,1295,0.11800000000000001,0.09550000000000002,0.1408,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_AgeOver65,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-12,2021-05-02,Residual sera,All,Seniors (65+ years),65.0,,Age,Age: ≥65,16198,0.136,0.12840000000000001,0.1435,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionPA,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-19,2021-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Pennsylvania,1229,0.212,0.184,0.2452,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionNJ,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Jersey,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-15,2021-04-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Jersey,852,0.284,0.24780000000000002,0.31980000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionWA,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-16,2021-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Washington,1310,0.055,0.041299999999999996,0.06849999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionNY,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-12,2021-04-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New York,1278,0.152,0.12630000000000002,0.1778,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionFL,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-20,2021-04-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Florida,1338,0.21100000000000002,0.19,0.2356,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionNE,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nebraska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-16,2021-05-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nebraska,1306,0.18300000000000002,0.15,0.2168,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_Age50to64,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-12,2021-05-02,Residual sera,All,Adults (18-64 years),50.0,64.0,Age,Age: 50-64,16616,0.19100000000000003,0.1816,0.1995,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionIL,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-19,2021-05-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Illinois,1359,0.315,0.2846,0.3479,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionKY,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-19,2021-05-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kentucky,1308,0.218,0.19280000000000003,0.24480000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionTN,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-19,2021-05-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Tennessee,1331,0.27,0.23750000000000002,0.3045,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_Age0to17,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-12,2021-05-02,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Age,Age: 0-17,7948,0.267,0.25379999999999997,0.2796,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionWY,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wyoming,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-19,2021-05-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wyoming,1079,0.264,0.2147,0.3152,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionAR,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-19,2021-05-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arkansas,1346,0.24300000000000002,0.21760000000000002,0.2717,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionNM,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-16,2021-05-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Mexico,1298,0.145,0.1232,0.1702,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionNH,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Hampshire,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-19,2021-04-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Hampshire,1307,0.096,0.071,0.1236,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionMO,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-19,2021-04-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Missouri,1311,0.277,0.24530000000000002,0.30829999999999996,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionMI,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-19,2021-05-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Michigan,1207,0.267,0.23329999999999998,0.3025,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210412to210502_RegionPR,220426_UnitedStates_CDC_210412to210502,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-19,2021-04-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Puerto Rico,1300,0.532,0.4985,0.5652,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_Overall,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-26,2021-05-16,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,61208,0.22100000000000003,0.21670000000000003,0.22640000000000002,True,,True,,True,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-08-31,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionMD,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maryland,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-29,2021-05-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maryland,1368,0.263,0.2343,0.2948,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionNE,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nebraska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-30,2021-05-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nebraska,1315,0.149,0.1213,0.1793,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionDC,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-03,2021-05-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: District of Columbia,1300,0.239,0.2041,0.27399999999999997,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionTX,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Texas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-30,2021-05-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Texas,967,0.307,0.2626,0.34700000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionMI,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-03,2021-05-16,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Michigan,1349,0.244,0.2089,0.2773,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionUT,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Utah,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-03,2021-05-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Utah,1305,0.267,0.2291,0.3029,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionTN,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-03,2021-05-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Tennessee,1579,0.27,0.24120000000000003,0.2968,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionID,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Idaho,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-26,2021-05-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Idaho,1302,0.158,0.1162,0.2046,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionNJ,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Jersey,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-29,2021-05-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Jersey,1512,0.324,0.2934,0.3506,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionSC,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-03,2021-05-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Carolina,1307,0.267,0.2384,0.2947,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionME,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maine,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-03,2021-05-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maine,546,0.049,0.0286,0.069,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionHI,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Hawaii,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-28,2021-05-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Hawaii,1175,0.027000000000000003,0.0165,0.0388,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_AgeOver65,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-26,2021-05-16,Residual sera,All,Seniors (65+ years),65.0,,Age,Age: ≥65,16691,0.1162,0.1162,0.12400000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionVT,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Vermont,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-03,2021-05-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Vermont,523,0.043,0.0223,0.0677,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionPA,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-03,2021-05-16,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Pennsylvania,1528,0.244,0.21489999999999998,0.2715,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionWV,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-03,2021-05-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: West Virginia,1387,0.106,0.0857,0.12869999999999998,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionPR,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-03,2021-05-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Puerto Rico,1300,0.631,0.5966,0.6617000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionMN,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-30,2021-05-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Minnesota,1289,0.141,0.1193,0.1654,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionCO,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-26,2021-05-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Colorado,1269,0.11199999999999999,0.0864,0.13970000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionOK,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-02,2021-05-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oklahoma,1300,0.141,0.1182,0.1635,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionNM,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-30,2021-05-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Mexico,1294,0.131,0.1072,0.1572,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionAR,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-03,2021-05-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arkansas,1300,0.256,0.22890000000000002,0.2853,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionMT,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Montana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-02,2021-05-14,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Montana,622,0.146,0.1024,0.196,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionWI,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-03,2021-05-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wisconsin,1323,0.276,0.2432,0.30920000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionCA,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-03,2021-05-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: California,1316,0.27399999999999997,0.2463,0.2986,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionOR,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-28,2021-05-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oregon,1299,0.05,0.0349,0.0669,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionKY,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-03,2021-05-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kentucky,1364,0.22899999999999998,0.2027,0.2551,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_Female,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-26,2021-05-16,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,36148,0.22,0.214,0.22719999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionIA,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Iowa,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-27,2021-05-14,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Iowa,1003,0.149,0.1173,0.18530000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionAZ,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arizona,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-03,2021-05-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arizona,1304,0.271,0.24239999999999998,0.29910000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionIN,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Indiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-29,2021-05-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Indiana,591,0.185,0.1444,0.2252,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionVA,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-29,2021-05-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Virginia,1481,0.158,0.12460000000000002,0.1907,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionCT,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-03,2021-05-16,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Connecticut,1282,0.10099999999999999,0.0816,0.12140000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_Age0to17,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-26,2021-05-16,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Age,Age: 0-17,8094,0.28300000000000003,0.27090000000000003,0.2956,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionDE,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-03,2021-05-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Delaware,1446,0.20800000000000002,0.1864,0.2313,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionNV,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nevada,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-03,2021-05-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nevada,1319,0.278,0.2445,0.31170000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionKS,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-29,2021-05-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kansas,1285,0.131,0.1063,0.157,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionMS,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-03,2021-05-16,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Mississippi,1462,0.277,0.2489,0.3061,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_Age50to64,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-26,2021-05-16,Residual sera,All,Adults (18-64 years),50.0,64.0,Age,Age: 50-64,17070,0.20199999999999999,0.1938,0.2111,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionRI,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Rhode Island,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-03,2021-05-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Rhode Island,897,0.11699999999999999,0.08869999999999999,0.1428,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionMO,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-03,2021-05-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Missouri,1378,0.261,0.22890000000000002,0.29309999999999997,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionNH,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Hampshire,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-03,2021-05-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Hampshire,1361,0.071,0.0538,0.1032,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_Age18to49,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-26,2021-05-16,Residual sera,All,Adults (18-64 years),18.0,49.0,Age,Age: 18-49,19353,0.245,0.23750000000000002,0.2534,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionNY,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-28,2021-05-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New York,1312,0.131,0.10779999999999999,0.1528,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionNC,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-03,2021-05-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: North Carolina,1307,0.244,0.22100000000000003,0.2697,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionSD,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Dakota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-03,2021-05-14,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Dakota,214,0.342,0.26489999999999997,0.4171,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionGA,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-30,2021-05-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Georgia,1299,0.161,0.13640000000000002,0.1872,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionAK,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alaska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-29,2021-05-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alaska,1300,0.10400000000000001,0.08070000000000001,0.13210000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionWY,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wyoming,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-03,2021-05-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wyoming,653,0.28600000000000003,0.2413,0.3315,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionWA,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-26,2021-05-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Washington,1307,0.068,0.0518,0.0852,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionMA,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-03,2021-05-16,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Massachusetts,1286,0.114,0.0934,0.1352,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionAL,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-03,2021-05-16,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alabama,1572,0.284,0.261,0.30710000000000004,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionOH,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-03,2021-05-16,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Ohio,1387,0.36700000000000005,0.34,0.3944,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_Male,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-26,2021-05-16,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,25060,0.223,0.2154,0.2304,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionFL,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-03,2021-05-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Florida,1183,0.27899999999999997,0.24980000000000002,0.3104,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionIL,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-03,2021-05-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Illinois,1443,0.354,0.32189999999999996,0.38939999999999997,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210426to210516_RegionLA,220426_UnitedStates_CDC_210426to210516,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-04-30,2021-05-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Louisiana,1285,0.133,0.1106,0.15630000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_Overall,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-10,2021-05-30,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,58978,0.215,0.2101,0.2193,True,,True,,True,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-08-31,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionOH,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-17,2021-05-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Ohio,1464,0.376,0.3478,0.40390000000000004,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionVT,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Vermont,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-17,2021-05-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Vermont,632,0.018000000000000002,0.008199999999999999,0.0305,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-06,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionRI,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Rhode Island,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-17,2021-05-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Rhode Island,917,0.126,0.1015,0.1549,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionIL,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-17,2021-05-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Illinois,1306,0.32,0.28850000000000003,0.3505,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionNC,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-17,2021-05-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: North Carolina,1272,0.227,0.20070000000000002,0.2557,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionPA,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-17,2021-05-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Pennsylvania,1078,0.227,0.19829999999999998,0.2569,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionTN,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-17,2021-05-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Tennessee,1400,0.281,0.2397,0.3236,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionKY,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-17,2021-05-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kentucky,1429,0.237,0.2116,0.2684,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionTX,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Texas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-13,2021-05-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Texas,1008,0.348,0.29600000000000004,0.4026,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionFL,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-17,2021-05-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Florida,1381,0.254,0.2295,0.2824,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionAK,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alaska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-10,2021-05-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alaska,1296,0.11900000000000001,0.0753,0.1636,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionME,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maine,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-17,2021-05-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maine,635,0.051,0.0304,0.0734,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionIN,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Indiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-13,2021-05-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Indiana,832,0.20199999999999999,0.1535,0.25010000000000004,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionHI,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Hawaii,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-11,2021-05-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Hawaii,1288,0.018000000000000002,0.0067,0.032100000000000004,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_Female,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-10,2021-05-30,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,34977,0.217,0.21030000000000001,0.2227,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionPR,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-14,2021-05-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Puerto Rico,1300,0.693,0.6607999999999999,0.7236,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionWV,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-16,2021-05-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: West Virginia,1234,0.107,0.0873,0.1266,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-06,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionNH,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Hampshire,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-17,2021-05-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Hampshire,1278,0.08900000000000001,0.0661,0.1174,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionWI,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-17,2021-05-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wisconsin,1303,0.358,0.32689999999999997,0.3957,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-06,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionMD,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maryland,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-13,2021-05-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maryland,1096,0.23600000000000002,0.2047,0.2682,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionWY,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wyoming,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-17,2021-05-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wyoming,614,0.23600000000000002,0.1912,0.2886,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-06,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionCT,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-17,2021-05-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Connecticut,1259,0.085,0.0667,0.1041,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionID,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Idaho,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-13,2021-05-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Idaho,1305,0.14,0.10710000000000001,0.17690000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionMT,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Montana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-12,2021-05-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Montana,487,0.125,0.0901,0.1569,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionOK,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-13,2021-05-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oklahoma,1300,0.113,0.0913,0.1329,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionCA,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-17,2021-05-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: California,1307,0.22899999999999998,0.2045,0.2543,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionMS,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-17,2021-05-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Mississippi,1337,0.263,0.2279,0.29960000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionGA,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-17,2021-05-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Georgia,1305,0.14300000000000002,0.12210000000000001,0.1674,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionLA,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-14,2021-05-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Louisiana,1206,0.125,0.0987,0.1524,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionNJ,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Jersey,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-13,2021-05-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Jersey,1266,0.304,0.2759,0.33140000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_Age50to64,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-10,2021-05-30,Residual sera,All,Adults (18-64 years),50.0,64.0,Age,Age: 50-64,16766,0.188,0.1802,0.1963,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_AgeOver65,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-10,2021-05-30,Residual sera,All,Seniors (65+ years),65.0,,Age,Age: ≥65,16142,0.127,0.11960000000000001,0.1348,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionIA,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Iowa,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-14,2021-05-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Iowa,906,0.11900000000000001,0.0943,0.14830000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionMN,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-12,2021-05-22,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Minnesota,1297,0.133,0.10310000000000001,0.16030000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionAL,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-17,2021-05-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alabama,1477,0.277,0.24989999999999998,0.3027,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_Age18to49,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-10,2021-05-30,Residual sera,All,Adults (18-64 years),18.0,49.0,Age,Age: 18-49,18423,0.23600000000000002,0.22829999999999998,0.2444,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_Age0to17,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-10,2021-05-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Age,Age: 0-17,7647,0.27899999999999997,0.2661,0.2922,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionNM,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-11,2021-05-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Mexico,1308,0.115,0.0947,0.1373,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionUT,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Utah,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-17,2021-05-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Utah,1309,0.271,0.2274,0.3194,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-06,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionMA,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-17,2021-05-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Massachusetts,1258,0.09699999999999999,0.076,0.1177,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionMO,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-17,2021-05-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Missouri,1383,0.253,0.2189,0.2878,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionAZ,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arizona,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-17,2021-05-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arizona,1303,0.313,0.2834,0.34259999999999996,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionDC,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-17,2021-05-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: District of Columbia,1258,0.245,0.21230000000000002,0.2756,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionMI,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-17,2021-05-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Michigan,1342,0.28500000000000003,0.25379999999999997,0.3185,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionCO,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-15,2021-05-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Colorado,1314,0.14400000000000002,0.11359999999999999,0.17260000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_Male,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-10,2021-05-30,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,23999,0.21300000000000002,0.20510000000000003,0.2205,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionOR,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-15,2021-05-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oregon,1303,0.071,0.0553,0.09050000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionDE,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-17,2021-05-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Delaware,792,0.193,0.1612,0.2263,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionVA,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-13,2021-05-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Virginia,1126,0.172,0.13240000000000002,0.21420000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-06,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionNE,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nebraska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-17,2021-05-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nebraska,1275,0.168,0.1341,0.198,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionSD,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Dakota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-17,2021-05-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Dakota,286,0.263,0.16640000000000002,0.3615,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionNY,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-11,2021-05-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New York,1257,0.129,0.10800000000000001,0.1512,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionSC,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-17,2021-05-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Carolina,1259,0.257,0.22760000000000002,0.2847,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionKS,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-14,2021-05-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kansas,1322,0.113,0.0925,0.1341,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionAR,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-17,2021-05-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arkansas,1341,0.256,0.23120000000000002,0.2808,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionNV,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nevada,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-17,2021-05-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nevada,1304,0.253,0.2257,0.28250000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210510to210530_RegionWA,220426_UnitedStates_CDC_210510to210530,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-14,2021-05-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Washington,1299,0.06,0.0446,0.0745,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-06,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_Overall,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-24,2021-06-13,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,60265,0.21600000000000003,0.21170000000000003,0.2215,True,,True,,True,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-08-31,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionCT,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-31,2021-06-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Connecticut,1285,0.094,0.0766,0.1135,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionNM,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-28,2021-06-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Mexico,1296,0.10400000000000001,0.0849,0.1242,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionNJ,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Jersey,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-27,2021-06-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Jersey,1201,0.302,0.2729,0.3348,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionGA,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-28,2021-06-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Georgia,1298,0.14400000000000002,0.1253,0.1648,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionCO,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-25,2021-06-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Colorado,1305,0.12400000000000001,0.0911,0.1617,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionOR,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-26,2021-06-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oregon,1312,0.043,0.0285,0.059000000000000004,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionNC,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-31,2021-06-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: North Carolina,1268,0.23800000000000002,0.21120000000000003,0.2636,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionAK,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alaska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-24,2021-06-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alaska,1291,0.08800000000000001,0.059000000000000004,0.1301,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionDC,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-01,2021-06-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: District of Columbia,1272,0.21,0.17870000000000003,0.2427,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionDE,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-01,2021-06-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Delaware,1369,0.195,0.1612,0.22530000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionVT,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Vermont,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-31,2021-06-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Vermont,479,0.018000000000000002,0.0049,0.0329,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionOH,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-31,2021-06-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Ohio,1357,0.373,0.3431,0.40390000000000004,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionLA,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-30,2021-06-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Louisiana,1298,0.127,0.10400000000000001,0.15109999999999998,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionNV,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nevada,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-31,2021-06-04,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nevada,1309,0.287,0.2579,0.3189,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionUT,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Utah,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-31,2021-06-05,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Utah,1306,0.277,0.23320000000000002,0.3233,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionWY,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wyoming,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-01,2021-06-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wyoming,643,0.262,0.21600000000000003,0.3149,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionMI,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-31,2021-06-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Michigan,1494,0.278,0.2502,0.3118,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionAR,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-31,2021-06-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arkansas,1331,0.22899999999999998,0.203,0.25739999999999996,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionWV,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-28,2021-06-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: West Virginia,1281,0.12400000000000001,0.1023,0.14800000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionID,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Idaho,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-28,2021-06-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Idaho,1295,0.09699999999999999,0.07540000000000001,0.12240000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionMO,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-01,2021-06-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Missouri,1403,0.265,0.2254,0.3029,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionRI,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Rhode Island,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-31,2021-06-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Rhode Island,801,0.111,0.0853,0.1392,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_Age0to17,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-24,2021-06-13,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Age,Age: 0-17,7000,0.278,0.2651,0.2907,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionMD,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maryland,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-27,2021-06-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maryland,1022,0.272,0.2404,0.306,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionCA,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-31,2021-06-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: California,1312,0.231,0.2036,0.2551,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionME,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maine,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-31,2021-06-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maine,500,0.049,0.0282,0.0713,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionWA,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-28,2021-06-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Washington,1301,0.06,0.0454,0.0761,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_Age50to64,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-24,2021-06-13,Residual sera,All,Adults (18-64 years),50.0,64.0,Age,Age: 50-64,17336,0.2,0.1917,0.20879999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionTX,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Texas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-27,2021-06-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Texas,1037,0.322,0.2807,0.35990000000000005,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionSC,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-31,2021-06-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Carolina,1281,0.277,0.2463,0.3033,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionIN,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Indiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-27,2021-06-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Indiana,759,0.256,0.21059999999999998,0.3361,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionAL,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-31,2021-06-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alabama,1460,0.292,0.2664,0.32060000000000005,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionOK,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-28,2021-06-05,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oklahoma,1301,0.128,0.10880000000000001,0.1493,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionVA,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-27,2021-06-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Virginia,1033,0.171,0.1311,0.2139,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionNY,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-30,2021-06-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New York,1317,0.132,0.1107,0.159,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionMN,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-28,2021-06-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Minnesota,1297,0.12300000000000001,0.1012,0.15,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionIL,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-31,2021-06-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Illinois,1422,0.354,0.31760000000000005,0.391,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_Female,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-24,2021-06-13,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,35811,0.214,0.2073,0.2212,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionTN,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-31,2021-06-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Tennessee,1567,0.292,0.2671,0.3186,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionFL,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-01,2021-06-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Florida,1178,0.24100000000000002,0.2161,0.26780000000000004,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_Age18to49,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-24,2021-06-13,Residual sera,All,Adults (18-64 years),18.0,49.0,Age,Age: 18-49,19348,0.23500000000000001,0.2262,0.2432,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionNH,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Hampshire,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-31,2021-06-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Hampshire,1295,0.099,0.0692,0.1328,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionMT,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Montana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-01,2021-06-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Montana,461,0.092,0.0616,0.1282,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionAZ,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arizona,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-31,2021-06-04,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arizona,1309,0.264,0.23920000000000002,0.2913,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionIA,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Iowa,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-28,2021-06-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Iowa,1175,0.157,0.1267,0.1916,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionMA,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-31,2021-06-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Massachusetts,1289,0.105,0.0853,0.12460000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionWI,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-31,2021-06-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wisconsin,1310,0.329,0.294,0.3683,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionNE,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nebraska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-28,2021-06-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nebraska,1207,0.171,0.1392,0.2064,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionPR,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-31,2021-06-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Puerto Rico,1300,0.748,0.7172,0.7791,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionSD,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Dakota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-31,2021-06-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Dakota,267,0.317,0.2207,0.4404,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionPA,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-31,2021-06-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Pennsylvania,1675,0.233,0.2093,0.2572,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionKY,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-31,2021-06-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kentucky,1416,0.268,0.2402,0.2929,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionMS,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-31,2021-06-13,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Mississippi,1504,0.315,0.281,0.35159999999999997,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_Male,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-24,2021-06-13,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,24453,0.219,0.21230000000000002,0.2262,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionKS,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-24,2021-06-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kansas,1301,0.099,0.0756,0.1247,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_AgeOver65,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-24,2021-06-13,Residual sera,All,Seniors (65+ years),65.0,,Age,Age: ≥65,16581,0.12400000000000001,0.1168,0.13210000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210524to210613_RegionHI,220426_UnitedStates_CDC_210524to210613,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Hawaii,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-05-26,2021-06-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Hawaii,1350,0.019,0.0102,0.0281,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_Overall,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-07,2021-06-27,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,63083,0.21100000000000002,0.207,0.2158,True,,True,,True,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-08-31,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionLA,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-11,2021-06-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Louisiana,1293,0.11800000000000001,0.098,0.1387,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionIN,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Indiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-10,2021-06-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Indiana,744,0.187,0.1391,0.2464,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionMT,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Montana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-13,2021-06-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Montana,507,0.067,0.0443,0.0947,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionWY,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wyoming,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-14,2021-06-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wyoming,630,0.245,0.1954,0.2923,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionAL,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-14,2021-06-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alabama,1697,0.295,0.2701,0.3207,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionHI,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Hawaii,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-08,2021-06-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Hawaii,1323,0.019,0.010900000000000002,0.027200000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_Age18to49,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-07,2021-06-27,Residual sera,All,Adults (18-64 years),18.0,49.0,Age,Age: 18-49,20495,0.23399999999999999,0.226,0.2413,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionMS,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-14,2021-06-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Mississippi,1551,0.33299999999999996,0.2995,0.365,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionAZ,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arizona,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-14,2021-06-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arizona,1413,0.28500000000000003,0.25730000000000003,0.31329999999999997,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionPR,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-14,2021-06-22,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Puerto Rico,1300,0.778,0.7490000000000001,0.8117000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_AgeOver65,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-07,2021-06-27,Residual sera,All,Seniors (65+ years),65.0,,Age,Age: ≥65,17514,0.126,0.1187,0.1328,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_Age50to64,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-07,2021-06-27,Residual sera,All,Adults (18-64 years),50.0,64.0,Age,Age: 50-64,17446,0.19100000000000003,0.1818,0.1993,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionVA,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-10,2021-06-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Virginia,821,0.16399999999999998,0.11660000000000001,0.20579999999999998,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionDC,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-14,2021-06-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: District of Columbia,1329,0.24100000000000002,0.2095,0.2749,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionMA,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-14,2021-06-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Massachusetts,1293,0.083,0.0663,0.1023,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionCA,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-14,2021-06-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: California,1308,0.253,0.22870000000000001,0.2804,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionSD,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Dakota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-14,2021-06-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Dakota,328,0.368,0.2509,0.47259999999999996,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionRI,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Rhode Island,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-14,2021-06-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Rhode Island,899,0.09300000000000001,0.0709,0.1218,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionPA,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-14,2021-06-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Pennsylvania,2637,0.24300000000000002,0.2262,0.26239999999999997,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_Female,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-07,2021-06-27,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,37481,0.20800000000000002,0.2018,0.21420000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionKY,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-14,2021-06-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kentucky,1483,0.249,0.2188,0.2743,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionME,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maine,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-14,2021-06-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maine,616,0.052000000000000005,0.027999999999999997,0.081,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionTN,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-14,2021-06-22,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Tennessee,1758,0.27899999999999997,0.2556,0.3072,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionAR,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-14,2021-06-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arkansas,1341,0.231,0.2043,0.2547,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionNY,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-11,2021-06-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New York,1312,0.126,0.1058,0.1477,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionNH,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Hampshire,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-14,2021-06-17,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Hampshire,1308,0.052000000000000005,0.0364,0.0683,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_Age0to17,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-07,2021-06-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Age,Age: 0-17,7628,0.271,0.25920000000000004,0.2823,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionCO,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-12,2021-06-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Colorado,1315,0.107,0.0764,0.1381,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionNM,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-11,2021-06-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Mexico,1306,0.11199999999999999,0.08960000000000001,0.1326,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionWI,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-14,2021-06-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wisconsin,1382,0.306,0.27649999999999997,0.3425,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionWV,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-11,2021-06-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: West Virginia,1278,0.086,0.0671,0.1035,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionKS,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-07,2021-06-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kansas,1308,0.109,0.0709,0.1462,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionMI,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-14,2021-06-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Michigan,1548,0.267,0.237,0.29460000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionTX,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Texas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-11,2021-06-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Texas,755,0.35700000000000004,0.2947,0.4153,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_Male,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-07,2021-06-27,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,25602,0.215,0.2084,0.222,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionMN,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-07,2021-06-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Minnesota,1295,0.115,0.094,0.1385,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionWA,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-10,2021-06-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Washington,1296,0.055,0.0402,0.0717,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionID,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Idaho,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-11,2021-06-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Idaho,1310,0.091,0.06730000000000001,0.11970000000000001,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionNJ,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Jersey,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-10,2021-06-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Jersey,937,0.312,0.2777,0.3453,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionUT,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Utah,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-14,2021-06-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Utah,1307,0.308,0.2618,0.3536,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionCT,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-14,2021-06-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Connecticut,1293,0.077,0.0617,0.095,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionGA,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-10,2021-06-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Georgia,1302,0.15,0.1276,0.1721,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionSC,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-14,2021-06-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Carolina,1325,0.256,0.23010000000000003,0.2857,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionIA,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Iowa,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-07,2021-06-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Iowa,1177,0.145,0.1099,0.1834,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionNV,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nevada,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-14,2021-06-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nevada,1318,0.304,0.2735,0.3332,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionAK,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alaska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-11,2021-06-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alaska,1346,0.083,0.042300000000000004,0.1331,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionVT,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Vermont,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-14,2021-06-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Vermont,541,0.03,0.0169,0.050199999999999995,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionMD,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maryland,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-11,2021-06-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maryland,776,0.231,0.1991,0.2663,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionFL,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-14,2021-06-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Florida,1363,0.275,0.2488,0.30210000000000004,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionOH,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-14,2021-06-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Ohio,1634,0.363,0.33780000000000004,0.38920000000000005,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionMO,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-14,2021-06-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Missouri,1481,0.218,0.1859,0.2516,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionNE,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nebraska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-11,2021-06-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nebraska,1300,0.12400000000000001,0.1001,0.1499,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionOR,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-10,2021-06-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oregon,1286,0.061,0.0446,0.0801,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionDE,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-14,2021-06-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Delaware,1985,0.23199999999999998,0.1907,0.2702,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionOK,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-10,2021-06-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oklahoma,1299,0.12400000000000001,0.1036,0.14470000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionNC,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-14,2021-06-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: North Carolina,1315,0.228,0.2023,0.2534,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210607to210627_RegionIL,220426_UnitedStates_CDC_210607to210627,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-14,2021-06-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Illinois,1680,0.332,0.30460000000000004,0.36229999999999996,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_Overall,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-21,2021-07-11,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,59072,0.20600000000000002,0.20170000000000002,0.21050000000000002,True,,True,,True,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-08-31,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionPA,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-28,2021-07-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Pennsylvania,1676,0.226,0.2024,0.2539,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionDE,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-28,2021-07-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Delaware,1337,0.215,0.18530000000000002,0.247,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionAL,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-28,2021-07-06,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alabama,1328,0.292,0.2629,0.3254,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionDC,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-28,2021-07-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: District of Columbia,1304,0.223,0.19579999999999997,0.25079999999999997,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionSC,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-28,2021-07-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Carolina,1299,0.262,0.2346,0.2923,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionVT,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Vermont,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-28,2021-07-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Vermont,371,0.018000000000000002,0.0048,0.033,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionCT,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-28,2021-07-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Connecticut,1299,0.065,0.050300000000000004,0.084,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_AgeOver65,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-21,2021-07-11,Residual sera,All,Seniors (65+ years),65.0,,Age,Age: ≥65,16129,0.128,0.12090000000000001,0.1359,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionOR,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-23,2021-07-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oregon,1291,0.071,0.0533,0.0916,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionTX,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Texas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-24,2021-07-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Texas,744,0.319,0.26920000000000005,0.3699,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionSD,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Dakota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-28,2021-07-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Dakota,224,0.341,0.2346,0.4915,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionIA,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Iowa,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-25,2021-07-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Iowa,1054,0.127,0.09480000000000001,0.1681,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionOK,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-26,2021-07-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oklahoma,1299,0.111,0.0909,0.1329,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionCA,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-28,2021-07-06,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: California,1314,0.21100000000000002,0.18789999999999998,0.2365,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_Female,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-21,2021-07-11,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,34903,0.204,0.1977,0.2108,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionMA,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-28,2021-07-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Massachusetts,1365,0.086,0.0684,0.1036,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionNH,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Hampshire,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-28,2021-07-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Hampshire,1274,0.065,0.047,0.0873,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionGA,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-24,2021-06-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Georgia,1298,0.12400000000000001,0.1012,0.1475,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionFL,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-29,2021-07-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Florida,1396,0.254,0.23010000000000003,0.2796,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_Male,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-21,2021-07-11,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,24169,0.20800000000000002,0.20120000000000002,0.21489999999999998,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_Age18to49,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-21,2021-07-11,Residual sera,All,Adults (18-64 years),18.0,49.0,Age,Age: 18-49,19213,0.226,0.2172,0.2331,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionIL,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-28,2021-07-06,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Illinois,1417,0.319,0.2864,0.3608,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_Age50to64,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-21,2021-07-11,Residual sera,All,Adults (18-64 years),50.0,64.0,Age,Age: 50-64,16293,0.18600000000000003,0.1773,0.1936,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionNE,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nebraska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-21,2021-07-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nebraska,1292,0.109,0.08539999999999999,0.1354,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionCO,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-25,2021-07-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Colorado,1216,0.096,0.0728,0.1252,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionWY,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wyoming,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-28,2021-07-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wyoming,396,0.308,0.2462,0.37820000000000004,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionTN,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-28,2021-07-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Tennessee,1313,0.266,0.23570000000000002,0.2953,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionIN,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Indiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-24,2021-07-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Indiana,699,0.195,0.1417,0.2551,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionAR,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-28,2021-07-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arkansas,1307,0.252,0.22399999999999998,0.2762,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionNJ,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Jersey,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-24,2021-07-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Jersey,1210,0.303,0.2742,0.33,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionWV,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-27,2021-07-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: West Virginia,1272,0.09,0.0722,0.1075,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionHI,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Hawaii,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-21,2021-07-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Hawaii,1310,0.016,0.0085,0.0256,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionMI,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-28,2021-07-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Michigan,1354,0.281,0.2488,0.30960000000000004,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionRI,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Rhode Island,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-28,2021-07-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Rhode Island,749,0.10300000000000001,0.07730000000000001,0.1322,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionMD,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maryland,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-24,2021-07-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maryland,1108,0.29300000000000004,0.2637,0.325,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionNY,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-21,2021-07-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New York,1312,0.12300000000000001,0.1033,0.1433,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionKS,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-24,2021-07-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kansas,1186,0.085,0.0602,0.1143,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionNV,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nevada,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-28,2021-07-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nevada,1300,0.267,0.23690000000000003,0.29660000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionAZ,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arizona,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-28,2021-07-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arizona,1300,0.297,0.2696,0.3257,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionWI,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-28,2021-07-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wisconsin,1507,0.28500000000000003,0.2416,0.32530000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionOH,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-28,2021-07-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Ohio,1306,0.33299999999999996,0.3063,0.3616,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionMO,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-28,2021-07-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Missouri,1609,0.237,0.2072,0.26890000000000003,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionKY,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-28,2021-07-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kentucky,1338,0.255,0.2285,0.2811,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionNM,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-23,2021-07-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Mexico,1295,0.12,0.095,0.1467,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionVA,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-24,2021-07-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Virginia,1060,0.17300000000000001,0.1313,0.22010000000000002,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionMT,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Montana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-27,2021-07-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Montana,554,0.085,0.0592,0.1101,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionID,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Idaho,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-25,2021-07-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Idaho,1310,0.109,0.07780000000000001,0.1487,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_Age0to17,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-21,2021-07-11,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Age,Age: 0-17,7437,0.26,0.2475,0.2708,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionPR,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-28,2021-07-06,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Puerto Rico,1300,0.753,0.72,0.784,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionNC,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-28,2021-07-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: North Carolina,1302,0.226,0.1998,0.2523,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionAK,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alaska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-22,2021-07-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alaska,1229,0.09300000000000001,0.060700000000000004,0.1475,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionWA,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-25,2021-07-06,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Washington,1279,0.07,0.053099999999999994,0.0908,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionME,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maine,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-28,2021-07-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maine,470,0.05,0.024100000000000003,0.0795,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionUT,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Utah,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-28,2021-07-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Utah,1298,0.29300000000000004,0.2633,0.3298,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionMS,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-28,2021-07-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Mississippi,1288,0.33799999999999997,0.2989,0.37200000000000005,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionMN,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-24,2021-07-07,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Minnesota,1297,0.11199999999999999,0.0857,0.1408,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210621to210711_RegionLA,220426_UnitedStates_CDC_210621to210711,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-06-25,2021-07-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Louisiana,1295,0.10300000000000001,0.083,0.12369999999999999,,,True,,,Stratified non-probability,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_Overall,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except IN, MD, NJ, & VA), the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-06,2021-10-03,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,64969,0.292,0.2874,0.29710000000000003,True,,True,,True,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-08-31,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionNH,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Hampshire,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-07,2021-10-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Hampshire,1759,0.151,0.1258,0.17809999999999998,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionOK,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-06,2021-09-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oklahoma,1769,0.364,0.3368,0.39170000000000005,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionMI,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-06,2021-10-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Michigan,1116,0.29,0.25620000000000004,0.3239,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionGA,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-06,2021-10-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Georgia,1743,0.37700000000000006,0.3473,0.40549999999999997,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionVT,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Vermont,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-07,2021-10-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Vermont,932,0.077,0.05,0.1099,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionIA,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Iowa,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-06,2021-10-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Iowa,1708,0.344,0.3069,0.3861,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionCA,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-06,2021-10-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: California,1387,0.281,0.25070000000000003,0.31120000000000003,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionFL,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-07,2021-10-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Florida,1594,0.34600000000000003,0.3184,0.3743,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionMO,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-08,2021-10-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Missouri,1322,0.28,0.24920000000000003,0.312,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionKY,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-06,2021-10-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kentucky,1427,0.307,0.2796,0.3393,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionME,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maine,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-06,2021-10-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maine,1181,0.081,0.061500000000000006,0.10189999999999999,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_AgeOver65,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except IN, MD, NJ, & VA), the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-06,2021-10-03,Residual sera,All,Seniors (65+ years),65.0,,Age,Age: ≥65,17784,0.163,0.15480000000000002,0.171,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionAZ,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arizona,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-07,2021-09-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arizona,935,0.342,0.3049,0.37939999999999996,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionID,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Idaho,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-06,2021-10-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Idaho,1588,0.33799999999999997,0.2876,0.3837,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionSC,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-06,2021-10-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Carolina,1600,0.335,0.30960000000000004,0.3625,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionNY,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-06,2021-10-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New York,1727,0.294,0.2665,0.32060000000000005,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionWV,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-06,2021-10-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: West Virginia,1716,0.218,0.1972,0.2399,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionWY,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wyoming,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-07,2021-09-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wyoming,461,0.344,0.2756,0.4079,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionKS,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-07,2021-09-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kansas,1748,0.28500000000000003,0.2609,0.3065,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionTX,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Texas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-09,2021-09-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Texas,379,0.43100000000000005,0.3379,0.5185000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionPR,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-06,2021-10-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Puerto Rico,1755,0.111,0.0925,0.12990000000000002,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionCT,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-06,2021-10-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Connecticut,1695,0.21100000000000002,0.1912,0.2325,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionDC,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-07,2021-10-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: District of Columbia,1306,0.271,0.2433,0.29850000000000004,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionLA,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-06,2021-10-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Louisiana,1734,0.389,0.3624,0.4157,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionAK,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alaska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-06,2021-10-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alaska,1561,0.214,0.1829,0.2511,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionDE,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-08,2021-10-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Delaware,1155,0.219,0.1932,0.2463,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_Age50to64,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except IN, MD, NJ, & VA), the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-06,2021-10-03,Residual sera,All,Adults (18-64 years),50.0,64.0,Age,Age: 50-64,14269,0.25,0.2398,0.2597,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionOH,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-06,2021-10-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Ohio,1402,0.341,0.3104,0.3691,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionMN,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-06,2021-09-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Minnesota,1695,0.28800000000000003,0.2593,0.3136,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionWI,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-07,2021-10-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wisconsin,1131,0.353,0.3172,0.3882,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionMT,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Montana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-06,2021-10-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Montana,1190,0.319,0.27340000000000003,0.36369999999999997,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionNE,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nebraska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-07,2021-10-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nebraska,1701,0.36600000000000005,0.3308,0.4044,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionUT,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Utah,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-09,2021-09-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Utah,523,0.363,0.3064,0.41600000000000004,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionNV,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nevada,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-09,2021-09-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nevada,748,0.35200000000000004,0.3115,0.3896,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionNM,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-06,2021-10-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Mexico,1742,0.226,0.20079999999999998,0.2493,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionPA,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-08,2021-10-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Pennsylvania,1282,0.258,0.22960000000000003,0.2857,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionAR,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-28,2021-10-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arkansas,372,0.324,0.2469,0.40659999999999996,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionTN,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-08,2021-10-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Tennessee,1346,0.383,0.3518,0.41450000000000004,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionOR,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-06,2021-10-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oregon,1513,0.16,0.1374,0.18300000000000002,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionCO,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-07,2021-10-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Colorado,1756,0.30100000000000005,0.27530000000000004,0.3275,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionSD,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Dakota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-07,2021-10-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Dakota,419,0.287,0.19870000000000002,0.3762,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionNC,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-06,2021-10-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: North Carolina,1767,0.266,0.24170000000000003,0.2909,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionIL,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-06,2021-10-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Illinois,1681,0.358,0.3309,0.3874,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionMS,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-10,2021-10-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Mississippi,1276,0.41700000000000004,0.38549999999999995,0.4482,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionMA,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-06,2021-10-01,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Massachusetts,1703,0.21600000000000003,0.193,0.23920000000000002,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_Age18to49,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except IN, MD, NJ, & VA), the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-06,2021-10-03,Residual sera,All,Adults (18-64 years),18.0,49.0,Age,Age: 18-49,19532,0.326,0.3171,0.335,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionRI,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Rhode Island,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-06,2021-10-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Rhode Island,1479,0.23199999999999998,0.2039,0.2614,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionWA,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-06,2021-09-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Washington,1701,0.174,0.1533,0.1942,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionAL,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-09,2021-10-03,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alabama,1494,0.396,0.3664,0.4257,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_Male,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except IN, MD, NJ, & VA), the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-06,2021-10-03,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,27264,0.295,0.2876,0.3025,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_RegionHI,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Hawaii,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-06,2021-10-02,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Hawaii,1704,0.084,0.0651,0.10460000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_210906to211003_Female,220426_UnitedStates_CDC_210906to211003,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except IN, MD, NJ, & VA), the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-09-06,2021-10-03,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,37704,0.29,0.2837,0.297,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_Overall,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-31,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,73869,0.307,0.303,0.3109,True,,True,,True,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-08-31,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionUT,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Utah,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-31,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Utah,1076,0.344,0.3097,0.3804,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionOH,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Ohio,1624,0.363,0.3346,0.3921,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionMO,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Missouri,1509,0.329,0.2997,0.3567,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionIL,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Illinois,1778,0.37,0.33659999999999995,0.4029,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_Male,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-31,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,30758,0.308,0.302,0.3148,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionMI,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Michigan,1384,0.306,0.2736,0.335,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionOR,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oregon,1797,0.17500000000000002,0.154,0.19870000000000002,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionWA,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Washington,1467,0.20500000000000002,0.1778,0.2364,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionIN,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Indiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-20,2021-10-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Indiana,133,0.35200000000000004,0.2325,0.4498,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionTN,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Tennessee,1700,0.386,0.3575,0.4147,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionAL,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-31,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alabama,1657,0.41500000000000004,0.3885,0.4426,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionRI,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Rhode Island,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Rhode Island,1729,0.24100000000000002,0.21600000000000003,0.2668,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_Age50to64,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-31,Residual sera,All,Adults (18-64 years),50.0,64.0,Age,Age: 50-64,15574,0.256,0.24739999999999998,0.26530000000000004,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionWV,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: West Virginia,1741,0.272,0.249,0.2958,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionWY,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wyoming,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wyoming,118,0.406,0.2945,0.5126,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionPR,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Puerto Rico,1756,0.111,0.0931,0.1293,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionNH,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Hampshire,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Hampshire,1713,0.17300000000000001,0.1525,0.19829999999999998,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionDE,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Delaware,1515,0.239,0.21230000000000002,0.26539999999999997,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionVA,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-20,2021-10-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Virginia,157,0.157,0.077,0.2372,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_Age18to49,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-31,Residual sera,All,Adults (18-64 years),18.0,49.0,Age,Age: 18-49,20645,0.337,0.3286,0.34490000000000004,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionFL,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Florida,1801,0.36200000000000004,0.33659999999999995,0.3885,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionCO,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Colorado,1779,0.277,0.2505,0.3063,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionVT,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Vermont,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Vermont,1721,0.076,0.056100000000000004,0.0968,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionMD,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maryland,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-20,2021-10-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maryland,123,0.233,0.1394,0.33899999999999997,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionMS,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Mississippi,1645,0.419,0.3924,0.44700000000000006,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionCA,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: California,1714,0.255,0.2279,0.2837,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionNE,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nebraska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nebraska,1731,0.405,0.3775,0.4314,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionMT,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Montana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Montana,1003,0.33299999999999996,0.2863,0.3751,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_Female,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-31,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,43111,0.305,0.29960000000000003,0.3109,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_AgeOver65,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-31,Residual sera,All,Seniors (65+ years),65.0,,Age,Age: ≥65,20582,0.171,0.1648,0.17870000000000003,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionLA,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Louisiana,1749,0.387,0.35740000000000005,0.41619999999999996,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionIA,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Iowa,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Iowa,1711,0.41100000000000003,0.37840000000000007,0.4418,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionAR,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arkansas,1317,0.35000000000000003,0.32280000000000003,0.3812,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionNC,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: North Carolina,1775,0.336,0.3074,0.3654,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionME,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maine,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-31,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maine,1739,0.115,0.09640000000000001,0.1368,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionNM,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Mexico,1738,0.277,0.2536,0.3,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionTX,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Texas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-05,2021-10-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Texas,257,0.493,0.40380000000000005,0.5755,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionNY,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New York,1771,0.306,0.2781,0.3357,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionDC,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: District of Columbia,1705,0.28,0.25079999999999997,0.3114,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionMN,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Minnesota,1719,0.314,0.28440000000000004,0.3469,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionNJ,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Jersey,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-20,2021-10-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Jersey,107,0.341,0.2321,0.4361,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionSD,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Dakota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Dakota,134,0.48200000000000004,0.36600000000000005,0.5813,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionAK,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alaska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alaska,1671,0.35200000000000004,0.3054,0.39280000000000004,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionMA,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Massachusetts,1719,0.23199999999999998,0.20809999999999998,0.2548,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionCT,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Connecticut,1745,0.222,0.1991,0.2444,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionID,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Idaho,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Idaho,1613,0.418,0.37520000000000003,0.45640000000000003,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionOK,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oklahoma,1780,0.383,0.35729999999999995,0.40840000000000004,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionNV,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nevada,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-31,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nevada,1493,0.324,0.29350000000000004,0.35380000000000006,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionKY,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kentucky,1772,0.342,0.314,0.3674,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionHI,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Hawaii,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Hawaii,1716,0.111,0.0907,0.13390000000000002,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionAZ,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arizona,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-30,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arizona,1749,0.326,0.29600000000000004,0.35369999999999996,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionSC,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Carolina,1821,0.37,0.3448,0.3985,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionGA,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Georgia,1752,0.384,0.35619999999999996,0.413,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionPA,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Pennsylvania,1748,0.264,0.2368,0.2908,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionWI,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wisconsin,1406,0.37700000000000006,0.3444,0.409,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211004to211031_RegionKS,220426_UnitedStates_CDC_211004to211031,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-10-04,2021-10-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kansas,1776,0.311,0.2859,0.3362,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_Overall,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except ND), the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-28,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,81468,0.316,0.3115,0.3209,True,,True,,True,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-08-31,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionOR,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oregon,1584,0.19399999999999998,0.1638,0.22390000000000002,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_Age50to64,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except ND), the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-28,Residual sera,All,Adults (18-64 years),50.0,64.0,Age,Age: 50-64,18528,0.266,0.2566,0.2745,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionMD,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maryland,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maryland,1910,0.264,0.24100000000000002,0.2858,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionUT,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Utah,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Utah,1456,0.419,0.386,0.45,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionPA,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Pennsylvania,1651,0.259,0.22940000000000002,0.2873,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionCO,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Colorado,1783,0.312,0.284,0.34299999999999997,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionMA,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Massachusetts,1638,0.249,0.2259,0.2721,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionWA,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Washington,1766,0.237,0.21300000000000002,0.26,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionAZ,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arizona,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arizona,1738,0.334,0.3062,0.36119999999999997,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionID,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Idaho,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Idaho,1632,0.454,0.40850000000000003,0.4944,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionVT,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Vermont,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Vermont,1542,0.07400000000000001,0.0565,0.0936,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionKY,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kentucky,1879,0.349,0.3223,0.3755,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionRI,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Rhode Island,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Rhode Island,1680,0.254,0.2262,0.2865,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionKS,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kansas,1791,0.35000000000000003,0.3211,0.3785,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionMS,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Mississippi,1601,0.44200000000000006,0.4119,0.4693,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionVA,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Virginia,1865,0.207,0.17850000000000002,0.2356,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionDC,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: District of Columbia,1783,0.295,0.2663,0.3237,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionFL,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Florida,1862,0.37200000000000005,0.34600000000000003,0.4004,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionNE,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nebraska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nebraska,1775,0.41500000000000004,0.37590000000000007,0.4504,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionTN,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Tennessee,1799,0.384,0.35710000000000003,0.4103,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionOK,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oklahoma,1742,0.364,0.34149999999999997,0.3865,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionHI,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Hawaii,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Hawaii,1707,0.102,0.08,0.1247,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionAR,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arkansas,999,0.358,0.3246,0.3904,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionGA,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-22,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Georgia,1789,0.375,0.3456,0.4031,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionCT,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Connecticut,1604,0.23399999999999999,0.20980000000000001,0.25730000000000003,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionNM,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-16,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Mexico,1769,0.294,0.27090000000000003,0.32020000000000004,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionMT,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Montana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Montana,914,0.409,0.3641,0.4534,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionAK,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alaska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-17,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alaska,1586,0.375,0.33130000000000004,0.4152,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionNH,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Hampshire,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Hampshire,1762,0.192,0.1677,0.21489999999999998,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionNJ,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Jersey,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Jersey,1865,0.327,0.3036,0.3504,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionIL,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Illinois,1929,0.385,0.35700000000000004,0.41259999999999997,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionLA,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Louisiana,1825,0.39299999999999996,0.3693,0.41759999999999997,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionSC,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Carolina,2055,0.38,0.354,0.4071,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionNY,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New York,1772,0.314,0.2859,0.34270000000000006,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionNV,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nevada,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nevada,1703,0.39,0.3586,0.4194,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionMO,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Missouri,1717,0.33899999999999997,0.3116,0.36340000000000006,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionOH,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Ohio,1790,0.397,0.3724,0.41990000000000005,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionTX,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Texas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Texas,360,0.405,0.3179,0.48840000000000006,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionDE,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-02,2021-11-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Delaware,1404,0.281,0.2518,0.3086,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionCA,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: California,1618,0.253,0.227,0.282,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionWV,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: West Virginia,1721,0.324,0.3007,0.34880000000000005,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionME,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maine,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maine,1672,0.10800000000000001,0.08869999999999999,0.1302,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionPR,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Puerto Rico,1810,0.10300000000000001,0.08449999999999999,0.12119999999999999,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionAL,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alabama,2144,0.428,0.4,0.45310000000000006,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_Female,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except ND), the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-28,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,47807,0.318,0.3119,0.3239,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionWI,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wisconsin,1393,0.364,0.3306,0.3957,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_Male,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except ND), the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-28,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,33661,0.314,0.3075,0.3208,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionMN,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Minnesota,1782,0.353,0.32420000000000004,0.38180000000000003,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_AgeOver65,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except ND), the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-28,Residual sera,All,Seniors (65+ years),65.0,,Age,Age: ≥65,23338,0.17500000000000002,0.16829999999999998,0.1818,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_Age18to49,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except ND), the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-28,Residual sera,All,Adults (18-64 years),18.0,49.0,Age,Age: 18-49,22868,0.34700000000000003,0.3385,0.3553,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionMI,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Michigan,1518,0.34600000000000003,0.3148,0.37460000000000004,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionIN,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Indiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Indiana,1146,0.35100000000000003,0.2974,0.4167,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionNC,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: North Carolina,1846,0.303,0.2768,0.33039999999999997,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211101to211128_RegionIA,220426_UnitedStates_CDC_211101to211128,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Iowa,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-01,2021-11-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Iowa,1741,0.42200000000000004,0.3898,0.455,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_Overall,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except ND & SD), the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-26,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,77680,0.335,0.3306,0.3401,True,,True,,True,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-08-31,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionNM,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-14,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Mexico,1818,0.344,0.3164,0.37270000000000003,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionMT,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Montana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Montana,944,0.47700000000000004,0.4269,0.5223,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionWI,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wisconsin,1293,0.424,0.3915,0.4545,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionTX,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Texas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Texas,855,0.43,0.38,0.48710000000000003,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionWV,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: West Virginia,1831,0.321,0.2975,0.344,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionCT,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Connecticut,1899,0.23800000000000002,0.2159,0.25670000000000004,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionDC,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: District of Columbia,1768,0.266,0.2398,0.29510000000000003,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionME,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maine,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maine,1780,0.19399999999999998,0.1686,0.2209,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionCO,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-08,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Colorado,1774,0.33,0.2937,0.36460000000000004,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionPA,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-12-01,2021-12-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Pennsylvania,852,0.35000000000000003,0.30770000000000003,0.3958,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionWA,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Washington,1774,0.23600000000000002,0.21350000000000002,0.2564,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionNC,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-22,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: North Carolina,1833,0.34500000000000003,0.3211,0.3716,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionNY,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New York,1780,0.312,0.284,0.3418,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionPR,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Puerto Rico,1799,0.09699999999999999,0.079,0.1177,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionFL,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-22,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Florida,1747,0.348,0.3229,0.37270000000000003,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionTN,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Tennessee,1753,0.408,0.3786,0.4372,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionVT,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Vermont,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Vermont,1547,0.121,0.09570000000000001,0.1478,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionOR,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oregon,1752,0.207,0.1832,0.22960000000000003,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionLA,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-14,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Louisiana,1926,0.397,0.3737,0.41990000000000005,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_Female,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except ND & SD), the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-26,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,46015,0.33799999999999997,0.33170000000000005,0.344,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionRI,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Rhode Island,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Rhode Island,1650,0.294,0.266,0.3237,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_Age50to64,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except ND & SD), the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-26,Residual sera,All,Adults (18-64 years),50.0,64.0,Age,Age: 50-64,17773,0.28800000000000003,0.2792,0.2979,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionMS,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Mississippi,1360,0.42100000000000004,0.3912,0.4536,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionMN,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Minnesota,1737,0.39,0.3588,0.4194,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionOK,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oklahoma,1779,0.385,0.3572,0.4144,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionNV,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nevada,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nevada,1240,0.399,0.3641,0.4325,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionVA,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Virginia,1759,0.23199999999999998,0.2027,0.26530000000000004,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionAL,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alabama,1576,0.402,0.3737,0.4308,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionNJ,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Jersey,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Jersey,1900,0.34700000000000003,0.32130000000000003,0.37020000000000003,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionMI,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Michigan,1298,0.386,0.3554,0.41659999999999997,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionIN,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Indiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-30,2021-12-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Indiana,1096,0.41200000000000003,0.3444,0.4851,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_AgeOver65,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except ND & SD), the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-26,Residual sera,All,Seniors (65+ years),65.0,,Age,Age: ≥65,21588,0.19100000000000003,0.18359999999999999,0.1979,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionAK,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alaska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-15,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alaska,1754,0.406,0.3699,0.43829999999999997,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionUT,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Utah,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Utah,1071,0.42600000000000005,0.3907,0.4617,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionKS,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-09,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kansas,1748,0.363,0.3358,0.3909,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionMD,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maryland,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maryland,1919,0.26,0.23620000000000002,0.2848,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionMO,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Missouri,1477,0.35200000000000004,0.322,0.3805,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_Age18to49,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except ND & SD), the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-26,Residual sera,All,Adults (18-64 years),18.0,49.0,Age,Age: 18-49,23566,0.365,0.3568,0.3738,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionHI,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Hawaii,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Hawaii,1756,0.111,0.0862,0.13670000000000002,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_Male,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except ND & SD), the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-26,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,31664,0.332,0.3249,0.3393,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionNH,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Hampshire,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-12,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Hampshire,1880,0.2,0.174,0.228,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionDE,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Delaware,721,0.289,0.2545,0.3297,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionIA,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Iowa,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Iowa,1732,0.47700000000000004,0.4455,0.5098,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionSC,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Carolina,1986,0.40299999999999997,0.3761,0.4294,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionID,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Idaho,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Idaho,1752,0.449,0.41200000000000003,0.4826,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionCA,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: California,1830,0.259,0.2353,0.2832,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionNE,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nebraska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nebraska,1828,0.42700000000000005,0.38939999999999997,0.4668,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionGA,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Georgia,1782,0.383,0.3532,0.41590000000000005,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionMA,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Massachusetts,1696,0.257,0.2331,0.2798,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionKY,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kentucky,1666,0.35200000000000004,0.32549999999999996,0.3814,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionAZ,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arizona,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arizona,1190,0.395,0.35740000000000005,0.4336,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionOH,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Ohio,1649,0.44,0.4117,0.4687,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionIL,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-11-29,2021-12-23,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Illinois,1793,0.38,0.3517,0.40880000000000005,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211129to211226_RegionAR,220426_UnitedStates_CDC_211129to211226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-12-02,2021-12-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arkansas,329,0.402,0.3418,0.4576,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_Overall,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except NV), the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-12-27,2022-01-29,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,71902,0.433,0.42840000000000006,0.4378,True,,True,,True,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-08-31,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionWA,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-12-27,2022-01-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Washington,1741,0.309,0.28500000000000003,0.33490000000000003,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionSD,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Dakota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-12,2022-01-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Dakota,101,0.489,0.39130000000000004,0.5933,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionMS,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-03,2022-01-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Mississippi,1219,0.518,0.4854,0.5547,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionAR,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-03,2022-01-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arkansas,1650,0.445,0.41960000000000003,0.4729,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionNY,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-12-27,2022-01-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New York,1777,0.49,0.4583,0.5225,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionIL,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-03,2022-01-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Illinois,1592,0.544,0.5115,0.5738000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionDC,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-03,2022-01-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: District of Columbia,1282,0.418,0.3826,0.4545,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionFL,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-03,2022-01-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Florida,1309,0.40399999999999997,0.3736,0.4363,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_Age18to49,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except NV), the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-12-27,2022-01-29,Residual sera,All,Adults (18-64 years),18.0,49.0,Age,Age: 18-49,21910,0.48,0.47100000000000003,0.49,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionID,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Idaho,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-12-27,2022-01-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Idaho,1762,0.469,0.4294,0.504,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionCO,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-03,2022-01-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Colorado,1732,0.378,0.3464,0.4092,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionVA,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-12-30,2022-01-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Virginia,1832,0.348,0.3136,0.3854,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionLA,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-12-30,2022-01-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Louisiana,1799,0.507,0.4832,0.5338,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_Age50to64,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except NV), the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-12-27,2022-01-29,Residual sera,All,Adults (18-64 years),50.0,64.0,Age,Age: 50-64,15915,0.371,0.3605,0.3809,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionAL,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-03,2022-01-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alabama,1144,0.438,0.40890000000000004,0.4698,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionWI,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-03,2022-01-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wisconsin,1257,0.561,0.528,0.5968,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionGA,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-02,2022-01-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Georgia,1787,0.495,0.4694,0.5272,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionMO,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-03,2022-01-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Missouri,1304,0.43,0.3961,0.4587,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_Female,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except NV), the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-12-27,2022-01-29,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,42222,0.444,0.43700000000000006,0.4516,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionPA,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-03,2022-01-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Pennsylvania,1802,0.45799999999999996,0.4303,0.48619999999999997,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionOR,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-12-27,2022-01-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oregon,1736,0.282,0.25739999999999996,0.3054,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionHI,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Hawaii,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-12-28,2022-01-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Hawaii,1866,0.21600000000000003,0.189,0.24730000000000002,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionKS,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-12-29,2022-01-22,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kansas,1767,0.42,0.38810000000000006,0.44689999999999996,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionMI,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-03,2022-01-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Michigan,1202,0.51,0.4814,0.5396,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionTX,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Texas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-12-30,2022-01-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Texas,581,0.528,0.46530000000000005,0.5877,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionIA,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Iowa,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-12-29,2022-01-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Iowa,1707,0.544,0.5144,0.5785,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionMD,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maryland,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-12-30,2022-01-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maryland,1992,0.383,0.3575,0.4093,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionCA,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-03,2022-01-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: California,1568,0.413,0.3835,0.4428,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_Male,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except NV), the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-12-27,2022-01-29,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,29679,0.419,0.4118,0.4275,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionOK,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-01,2022-01-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oklahoma,1801,0.457,0.4293,0.4867,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionVT,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Vermont,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-12-30,2022-01-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Vermont,1296,0.17800000000000002,0.1501,0.2136,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionNE,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nebraska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-12-28,2022-01-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nebraska,1489,0.515,0.4815,0.5491,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionME,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maine,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-12-28,2022-01-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maine,1788,0.23199999999999998,0.2059,0.26030000000000003,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionRI,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Rhode Island,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-12-30,2022-01-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Rhode Island,1473,0.446,0.4132,0.48090000000000005,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionNM,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-12-31,2022-01-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Mexico,1792,0.409,0.3834,0.4333,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionKY,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-03,2022-01-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kentucky,1509,0.438,0.4071,0.4697,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionCT,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-12-29,2022-01-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Connecticut,1791,0.389,0.3667,0.413,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionIN,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Indiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-12-30,2022-01-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Indiana,1009,0.524,0.43979999999999997,0.5841,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionTN,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-03,2022-01-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Tennessee,1253,0.507,0.47520000000000007,0.5401,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionAK,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alaska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-12-27,2022-01-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alaska,1790,0.41100000000000003,0.3728,0.4525,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionNJ,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Jersey,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-12-30,2022-01-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Jersey,1950,0.51,0.48310000000000003,0.5353,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionMT,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Montana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-12-30,2022-01-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Montana,800,0.47500000000000003,0.4292,0.5168,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionWY,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wyoming,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-10,2022-01-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wyoming,158,0.532,0.4244,0.6406999999999999,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionNC,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-03,2022-01-20,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: North Carolina,1329,0.4,0.3669,0.4343,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionWV,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-12-28,2022-01-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: West Virginia,1781,0.424,0.3973,0.4484,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_AgeOver65,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except NV), the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-12-27,2022-01-29,Residual sera,All,Seniors (65+ years),65.0,,Age,Age: ≥65,20005,0.233,0.2252,0.2414,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionSC,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-03,2022-01-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Carolina,1259,0.451,0.41840000000000005,0.48610000000000003,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionMA,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-12-29,2022-01-28,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Massachusetts,1788,0.365,0.3432,0.39060000000000006,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionNH,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Hampshire,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-03,2022-01-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Hampshire,1782,0.331,0.304,0.35840000000000005,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionPR,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-03,2022-01-27,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Puerto Rico,1802,0.187,0.1654,0.21239999999999998,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionOH,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-03,2022-01-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Ohio,1403,0.533,0.5025000000000001,0.5604,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionDE,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-04,2022-01-29,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Delaware,1549,0.38799999999999996,0.3619,0.4169,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_211227to220129_RegionMN,220426_UnitedStates_CDC_211227to220129,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2021-12-30,2022-01-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Minnesota,1755,0.483,0.4515,0.5141,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_Overall,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except MT & NH), the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-27,2022-02-26,Residual sera,All,Multiple groups,0.0,,Primary Estimate,,45810,0.5770000000000001,0.5708,0.5827,True,,True,,True,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-08-31,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionIA,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Iowa,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-02-13,2022-02-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Iowa,300,0.7070000000000001,0.6509999999999999,0.7659,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionDE,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-02-01,2022-02-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Delaware,1395,0.54,0.5112,0.5671,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionCA,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-31,2022-02-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: California,1735,0.555,0.5279,0.5852,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionNC,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-02-01,2022-02-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: North Carolina,1317,0.52,0.48869999999999997,0.5516,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionME,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maine,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-02-11,2022-02-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maine,304,0.353,0.2852,0.42369999999999997,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionDC,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-02-01,2022-02-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: District of Columbia,1125,0.636,0.5987,0.6731,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionWA,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-02-11,2022-02-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Washington,305,0.543,0.47350000000000003,0.6041,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionAL,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-02-01,2022-02-22,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alabama,1902,0.66,0.6341,0.6838,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionVT,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Vermont,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-02-11,2022-02-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Vermont,251,0.289,0.2236,0.3597,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionSD,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Dakota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-02-02,2022-02-11,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Dakota,78,0.613,0.4818,0.7212999999999999,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionAK,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alaska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-02-07,2022-02-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Alaska,301,0.61,0.5398,0.6818000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionMA,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-28,2022-02-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Massachusetts,303,0.526,0.46280000000000004,0.5906,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_Female,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except MT & NH), the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-27,2022-02-26,Residual sera,Female,Multiple groups,0.0,,Sex/Gender,,27395,0.588,0.5789,0.5954,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionUT,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Utah,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-02-01,2022-02-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Utah,1345,0.6920000000000001,0.6587999999999999,0.7223999999999999,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionPR,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-02-14,2022-02-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Puerto Rico,300,0.34299999999999997,0.2839,0.4157,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionRI,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Rhode Island,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-28,2022-02-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Rhode Island,322,0.534,0.47950000000000004,0.5891,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionCT,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-27,2022-02-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Connecticut,307,0.444,0.3809,0.5072,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_Age50to64,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except MT & NH), the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-27,2022-02-26,Residual sera,All,Adults (18-64 years),50.0,64.0,Age,Age: 50-64,10121,0.498,0.4853,0.5126,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionTN,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-02-01,2022-02-22,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Tennessee,1945,0.674,0.6492,0.6973999999999999,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_AgeOver65,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except MT & NH), the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-27,2022-02-26,Residual sera,All,Seniors (65+ years),65.0,,Age,Age: ≥65,13196,0.332,0.3215,0.3433,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionPA,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-02-01,2022-02-24,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Pennsylvania,1701,0.546,0.5184000000000001,0.5764,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_Age18to49,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except MT & NH), the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-27,2022-02-26,Residual sera,All,Adults (18-64 years),18.0,49.0,Age,Age: 18-49,11195,0.637,0.6246,0.6478,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionTX,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Texas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-27,2022-02-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Texas,1510,0.6970000000000001,0.6605,0.7291,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionNE,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nebraska,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-02-11,2022-02-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nebraska,299,0.654,0.5997,0.7099,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionNV,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nevada,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-31,2022-02-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Nevada,1572,0.601,0.5713,0.6299,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionKS,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-02-11,2022-02-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kansas,292,0.622,0.5519,0.6881999999999999,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionMI,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-31,2022-02-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Michigan,1273,0.569,0.5383,0.6002000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionWY,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wyoming,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-31,2022-02-10,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wyoming,109,0.625,0.4778,0.7454000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionMS,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-02-01,2022-02-22,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Mississippi,1830,0.6940000000000001,0.6697,0.7173,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionID,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Idaho,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-02-11,2022-02-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Idaho,299,0.6779999999999999,0.6099,0.7323000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionSC,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-02-01,2022-02-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: South Carolina,1250,0.645,0.6093999999999999,0.6765000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionLA,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-02-11,2022-02-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Louisiana,299,0.6890000000000001,0.6247,0.7495,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionGA,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-31,2022-02-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Georgia,311,0.638,0.5719,0.7066,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionIN,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Indiana,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-27,2022-02-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Indiana,1062,0.612,0.5562,0.663,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_Male,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except MT & NH), the District of Columbia, and Puerto Rico",,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-27,2022-02-26,Residual sera,Male,Multiple groups,0.0,,Sex/Gender,,18415,0.5660000000000001,0.5563,0.5749000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionIL,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-31,2022-02-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Illinois,1746,0.608,0.5795,0.6376,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionAR,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-31,2022-02-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arkansas,1349,0.64,0.6106,0.6663,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionWV,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-29,2022-02-18,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: West Virginia,317,0.546,0.4842,0.6001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionWI,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-31,2022-02-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Wisconsin,1407,0.667,0.6395000000000001,0.6954000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionAZ,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arizona,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-02-01,2022-02-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Arizona,1692,0.63,0.6014,0.6609999999999999,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionMN,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-02-11,2022-02-17,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Minnesota,299,0.608,0.5428000000000001,0.6739,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionKY,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-31,2022-02-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Kentucky,1661,0.5660000000000001,0.5354,0.5955,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionVA,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Virginia,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-27,2022-02-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Virginia,1837,0.451,0.4186,0.48100000000000004,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionNY,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-02-14,2022-02-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New York,299,0.615,0.5497,0.6844,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionHI,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Hawaii,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-29,2022-02-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Hawaii,305,0.342,0.2787,0.40280000000000005,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionOH,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-31,2022-02-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Ohio,1609,0.632,0.605,0.6614,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionOK,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-02-14,2022-02-17,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oklahoma,301,0.691,0.6251,0.7488,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionOR,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-02-11,2022-02-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Oregon,299,0.469,0.40090000000000003,0.5357999999999999,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionMD,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maryland,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-28,2022-02-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Maryland,1833,0.499,0.47130000000000005,0.5217,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionFL,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-02-01,2022-02-21,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Florida,1685,0.584,0.5577000000000001,0.61,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionNM,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-02-12,2022-02-19,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Mexico,241,0.49100000000000005,0.4071,0.5789,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionCO,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-02-14,2022-02-16,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Colorado,249,0.479,0.389,0.5745,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionMO,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-31,2022-02-26,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: Missouri,1508,0.557,0.5256000000000001,0.5872999999999999,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220426_UnitedStates_CDC_220127to220226_RegionNJ,220426_UnitedStates_CDC_220127to220226,Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories),2022-04-26,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Jersey,,"""Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories""

""Approximately every 2 weeks, we selected a convenience sample of residual sera from the pool of all available, deduplicated specimens to target equal sample numbers in 4 age groups (0-17 years, 18-49 years, 50-64 years, and ≥65 years) in each jurisdiction.""","""Specimens were excluded if they were from patients who had blood drawn for COVID-19 related conditions.""

""Reinfections are not captured.""
",2022-01-27,2022-02-25,Residual sera,All,Multiple groups,0.0,,Geographical area,Region: New Jersey,1823,0.609,0.583,0.6335000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,US CDC,US CDC,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#national-lab,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2020,USA
220427_SanDiegoCounty&Tijuana_UCSD,220427_SanDiegoCounty&Tijuana_UCSD,A cross-sectional study of factors associated with COVID-19 testing among people who inject drugs: missed opportunities for reaching those most at risk.,2022-04-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,California,,People aged ≥18 or older who injected drugs within the last month and lived in San Diego County or Tijuana,,,2021-09-10,Multiple populations,All,Multiple groups,18.0,,Primary Estimate,,571,0.30100000000000005,,,True,,,,True,Convenience,Maverick Multi-Antigen Serology,"Genalyte (San Diego, CA)",Other,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Yes,Yes,Yes,,Samantha Yeager,University of California San Diego,Not Unity-Aligned,https://dx.doi.org/10.1186/s12889-022-13273-y,2022-05-05,2024-03-01,Unverified,yeager_cross-sectional_2022,USA
220427_Arkansas_UniversityOfArkansasForMedicalSciences_OverallTestAdj,220427_Arkansas_UniversityOfArkansasForMedicalSciences,"State-wide random seroprevalence survey of SARS-CoV-2 past infection in a southern US State, 2020.",2022-04-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Arkansas,,"The target population was the
non-institutionalized adult population of the state.",,2020-05-01,2020-12-31,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,1565,0.071,0.057999999999999996,0.087,True,True,,,,Simplified probability,Access SARS-CoV-2 IgG Reagent Antibody Test,Beckman Coulter,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.938,1.0,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Victor M. Cardenas,University of Arkansas for Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0267322,2022-05-02,2023-08-15,Verified,cardenasStatewideRandomSeroprevalence2022,USA
220427_Arkansas_UniversityOfArkansasForMedicalSciences_OverallCrude,220427_Arkansas_UniversityOfArkansasForMedicalSciences,"State-wide random seroprevalence survey of SARS-CoV-2 past infection in a southern US State, 2020.",2022-04-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Arkansas,,"The target population was the
non-institutionalized adult population of the state.",,2020-05-01,2020-12-31,Household and community samples,All,Multiple groups,18.0,,Analysis,,1565,0.0684,,,,,,,True,Simplified probability,Access SARS-CoV-2 IgG Reagent Antibody Test,Beckman Coulter,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.938,1.0,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Victor M. Cardenas,University of Arkansas for Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0267322,2022-05-02,2024-03-01,Verified,cardenasStatewideRandomSeroprevalence2022,USA
220427_Arkansas_UniversityOfArkansasForMedicalSciences_Age50+,220427_Arkansas_UniversityOfArkansasForMedicalSciences,"State-wide random seroprevalence survey of SARS-CoV-2 past infection in a southern US State, 2020.",2022-04-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Arkansas,,"The target population was the
non-institutionalized adult population of the state.",,2020-05-01,2020-12-31,Household and community samples,All,Multiple groups,50.0,,Age,,748,0.050800000000000005,,,,,,,,Simplified probability,Access SARS-CoV-2 IgG Reagent Antibody Test,Beckman Coulter,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.938,1.0,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Victor M. Cardenas,University of Arkansas for Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0267322,2022-05-02,2024-03-01,Verified,cardenasStatewideRandomSeroprevalence2022,USA
220427_Arkansas_UniversityOfArkansasForMedicalSciences_Age18-49,220427_Arkansas_UniversityOfArkansasForMedicalSciences,"State-wide random seroprevalence survey of SARS-CoV-2 past infection in a southern US State, 2020.",2022-04-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Arkansas,,"The target population was the
non-institutionalized adult population of the state.",,2020-05-01,2020-12-31,Household and community samples,All,Adults (18-64 years),18.0,49.0,Age,,817,0.08449999999999999,,,,,,,,Simplified probability,Access SARS-CoV-2 IgG Reagent Antibody Test,Beckman Coulter,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.938,1.0,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Victor M. Cardenas,University of Arkansas for Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0267322,2022-05-02,2024-03-01,Verified,cardenasStatewideRandomSeroprevalence2022,USA
220427_Arkansas_UniversityOfArkansasForMedicalSciences_Time1May-Aug,220427_Arkansas_UniversityOfArkansasForMedicalSciences,"State-wide random seroprevalence survey of SARS-CoV-2 past infection in a southern US State, 2020.",2022-04-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Arkansas,,"The target population was the
non-institutionalized adult population of the state.",,2020-05-01,2020-08-31,Household and community samples,All,Multiple groups,18.0,,Time frame,May-Aug 2020,422,0.0308,,,,,,,,Simplified probability,Access SARS-CoV-2 IgG Reagent Antibody Test,Beckman Coulter,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.938,1.0,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Victor M. Cardenas,University of Arkansas for Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0267322,2022-05-12,2024-03-01,Verified,cardenasStatewideRandomSeroprevalence2022,USA
220427_Arkansas_UniversityOfArkansasForMedicalSciences_Time2Sep-Oct,220427_Arkansas_UniversityOfArkansasForMedicalSciences,"State-wide random seroprevalence survey of SARS-CoV-2 past infection in a southern US State, 2020.",2022-04-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Arkansas,,"The target population was the
non-institutionalized adult population of the state.",,2020-09-01,2020-10-31,Household and community samples,All,Multiple groups,18.0,,Time frame,Sep-Oct 2020,801,0.062400000000000004,,,,,,,,Simplified probability,Access SARS-CoV-2 IgG Reagent Antibody Test,Beckman Coulter,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.938,1.0,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Victor M. Cardenas,University of Arkansas for Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0267322,2022-05-12,2024-03-01,Verified,cardenasStatewideRandomSeroprevalence2022,USA
220427_Arkansas_UniversityOfArkansasForMedicalSciences_Time3Nov-Dec,220427_Arkansas_UniversityOfArkansasForMedicalSciences,"State-wide random seroprevalence survey of SARS-CoV-2 past infection in a southern US State, 2020.",2022-04-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Arkansas,,"The target population was the
non-institutionalized adult population of the state.",,2020-11-01,2020-12-15,Household and community samples,All,Multiple groups,18.0,,Time frame,Nov-Dec 2020,342,0.12869999999999998,,,,,,,,Simplified probability,Access SARS-CoV-2 IgG Reagent Antibody Test,Beckman Coulter,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.938,1.0,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Victor M. Cardenas,University of Arkansas for Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0267322,2022-05-12,2024-03-01,Verified,cardenasStatewideRandomSeroprevalence2022,USA
220427_Arkansas_UniversityOfArkansasForMedicalSciences_SexFemale,220427_Arkansas_UniversityOfArkansasForMedicalSciences,"State-wide random seroprevalence survey of SARS-CoV-2 past infection in a southern US State, 2020.",2022-04-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Arkansas,,"The target population was the
non-institutionalized adult population of the state.",,2020-05-01,2020-12-31,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,989,0.0748,,,,,,,,Simplified probability,Access SARS-CoV-2 IgG Reagent Antibody Test,Beckman Coulter,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.938,1.0,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Victor M. Cardenas,University of Arkansas for Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0267322,2022-05-02,2024-03-01,Verified,cardenasStatewideRandomSeroprevalence2022,USA
220427_Arkansas_UniversityOfArkansasForMedicalSciences_SexMale,220427_Arkansas_UniversityOfArkansasForMedicalSciences,"State-wide random seroprevalence survey of SARS-CoV-2 past infection in a southern US State, 2020.",2022-04-27,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Arkansas,,"The target population was the
non-institutionalized adult population of the state.",,2020-05-01,2020-12-31,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,576,0.057300000000000004,,,,,,,,Simplified probability,Access SARS-CoV-2 IgG Reagent Antibody Test,Beckman Coulter,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.938,1.0,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Unclear,Victor M. Cardenas,University of Arkansas for Medical Sciences,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0267322,2022-05-02,2024-03-01,Verified,cardenasStatewideRandomSeroprevalence2022,USA
220504_SanFrancisco_UniversityofCaliforniaSanFrancisco_Vitros,220504_SanFrancisco_UniversityofCaliforniaSanFrancisco,Using sero-epidemiology to monitor disparities in vaccination and infection with SARS-CoV-2,2022-05-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,San Francisco,"Residual blood samples taken from two hospital networks in San Francisco.

""we included patients undergoing routine blood testing [between February 4 and February 17, 2021], defined as blood chemistries and tests for sexually transmitted infections and rubella. We included patients residing in San Francisco, including those experiencing homelessness.""

""We restricted our sample to outpatient and emergency department visits for adults; for under 18 s, we included both inpatient and outpatient visits due to small numbers of available samples.""","""A total of 1,091 samples were collected, of which 77 were excluded due to participation in a separate COVID research study, and a further 15 were later excluded from further analyses as they could not be linked to antibody test results.""

""We excluded individuals who were tested for SARS-CoV-2 during the visit when they received their blood draw (except if the test was for routine purposes, such as testing prior to an elective procedure or admittance to the hospital).""

""Finally, we excluded samples if a sample from the same patient had been selected within the previous 14 days.""

""we removed the 3 samples that tested negative on Vitros and positive on Roche, which likely reflects a false negative result on the Vitros assay and/or a false positive result on the Roche assay"".

""For geographic analyses, zipcodes with fewer than 10 individuals were excluded.""",2021-02-04,2021-02-17,Residual sera,All,Multiple groups,,,Primary Estimate,Vitros Positives,915,0.2842,,,True,,,,True,Stratified non-probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.838,1.0,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Isobel Routledge,University of California San Francisco,Unity-Aligned,https://doi.org/10.1038/s41467-022-30051-x,2022-05-11,2024-03-01,Verified,routledge_using_2022,USA
220504_SanFrancisco_UniversityofCaliforniaSanFrancisco_Age_35-64,220504_SanFrancisco_UniversityofCaliforniaSanFrancisco,Using sero-epidemiology to monitor disparities in vaccination and infection with SARS-CoV-2,2022-05-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,San Francisco,"Residual blood samples taken from two hospital networks in San Francisco.

""we included patients undergoing routine blood testing [between February 4 and February 17, 2021], defined as blood chemistries and tests for sexually transmitted infections and rubella. We included patients residing in San Francisco, including those experiencing homelessness.""

""We restricted our sample to outpatient and emergency department visits for adults; for under 18 s, we included both inpatient and outpatient visits due to small numbers of available samples.""","""A total of 1,091 samples were collected, of which 77 were excluded due to participation in a separate COVID research study, and a further 15 were later excluded from further analyses as they could not be linked to antibody test results.""

""We excluded individuals who were tested for SARS-CoV-2 during the visit when they received their blood draw (except if the test was for routine purposes, such as testing prior to an elective procedure or admittance to the hospital).""

""Finally, we excluded samples if a sample from the same patient had been selected within the previous 14 days.""

""we removed the 3 samples that tested negative on Vitros and positive on Roche, which likely reflects a false negative result on the Vitros assay and/or a false positive result on the Roche assay"".

""For geographic analyses, zipcodes with fewer than 10 individuals were excluded.""",2021-02-04,2021-02-17,Residual sera,All,Adults (18-64 years),,,Age,Age: 35-64,426,0.18539999999999998,,,,,,,,Stratified non-probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.838,1.0,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Isobel Routledge,University of California San Francisco,Unity-Aligned,https://doi.org/10.1038/s41467-022-30051-x,2022-05-27,2024-03-01,Verified,routledge_using_2022,USA
220504_SanFrancisco_UniversityofCaliforniaSanFrancisco_Age_18-34,220504_SanFrancisco_UniversityofCaliforniaSanFrancisco,Using sero-epidemiology to monitor disparities in vaccination and infection with SARS-CoV-2,2022-05-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,San Francisco,"Residual blood samples taken from two hospital networks in San Francisco.

""we included patients undergoing routine blood testing [between February 4 and February 17, 2021], defined as blood chemistries and tests for sexually transmitted infections and rubella. We included patients residing in San Francisco, including those experiencing homelessness.""

""We restricted our sample to outpatient and emergency department visits for adults; for under 18 s, we included both inpatient and outpatient visits due to small numbers of available samples.""","""A total of 1,091 samples were collected, of which 77 were excluded due to participation in a separate COVID research study, and a further 15 were later excluded from further analyses as they could not be linked to antibody test results.""

""We excluded individuals who were tested for SARS-CoV-2 during the visit when they received their blood draw (except if the test was for routine purposes, such as testing prior to an elective procedure or admittance to the hospital).""

""Finally, we excluded samples if a sample from the same patient had been selected within the previous 14 days.""

""we removed the 3 samples that tested negative on Vitros and positive on Roche, which likely reflects a false negative result on the Vitros assay and/or a false positive result on the Roche assay"".

""For geographic analyses, zipcodes with fewer than 10 individuals were excluded.""",2021-02-04,2021-02-17,Residual sera,All,Adults (18-64 years),,,Age,Age: 18-34,151,0.2318,,,,,,,,Stratified non-probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.838,1.0,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Isobel Routledge,University of California San Francisco,Unity-Aligned,https://doi.org/10.1038/s41467-022-30051-x,2022-05-27,2024-03-01,Verified,routledge_using_2022,USA
220504_SanFrancisco_UniversityofCaliforniaSanFrancisco_Vitros&Roche,220504_SanFrancisco_UniversityofCaliforniaSanFrancisco,Using sero-epidemiology to monitor disparities in vaccination and infection with SARS-CoV-2,2022-05-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,San Francisco,"Residual blood samples taken from two hospital networks in San Francisco.

""we included patients undergoing routine blood testing [between February 4 and February 17, 2021], defined as blood chemistries and tests for sexually transmitted infections and rubella. We included patients residing in San Francisco, including those experiencing homelessness.""

""We restricted our sample to outpatient and emergency department visits for adults; for under 18 s, we included both inpatient and outpatient visits due to small numbers of available samples.""","""A total of 1,091 samples were collected, of which 77 were excluded due to participation in a separate COVID research study, and a further 15 were later excluded from further analyses as they could not be linked to antibody test results.""

""We excluded individuals who were tested for SARS-CoV-2 during the visit when they received their blood draw (except if the test was for routine purposes, such as testing prior to an elective procedure or admittance to the hospital).""

""Finally, we excluded samples if a sample from the same patient had been selected within the previous 14 days.""

""we removed the 3 samples that tested negative on Vitros and positive on Roche, which likely reflects a false negative result on the Vitros assay and/or a false positive result on the Roche assay"".

""For geographic analyses, zipcodes with fewer than 10 individuals were excluded.""",2021-02-04,2021-02-17,Residual sera,All,Multiple groups,,,Test used,Vitros AND Roche Positive,915,0.08630000000000002,,,,,,,,Stratified non-probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Isobel Routledge,University of California San Francisco,Unity-Aligned,https://doi.org/10.1038/s41467-022-30051-x,2022-05-11,2024-03-01,Verified,routledge_using_2022,USA
220504_SanFrancisco_UniversityofCaliforniaSanFrancisco_Age_0-17,220504_SanFrancisco_UniversityofCaliforniaSanFrancisco,Using sero-epidemiology to monitor disparities in vaccination and infection with SARS-CoV-2,2022-05-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,San Francisco,"Residual blood samples taken from two hospital networks in San Francisco.

""we included patients undergoing routine blood testing [between February 4 and February 17, 2021], defined as blood chemistries and tests for sexually transmitted infections and rubella. We included patients residing in San Francisco, including those experiencing homelessness.""

""We restricted our sample to outpatient and emergency department visits for adults; for under 18 s, we included both inpatient and outpatient visits due to small numbers of available samples.""","""A total of 1,091 samples were collected, of which 77 were excluded due to participation in a separate COVID research study, and a further 15 were later excluded from further analyses as they could not be linked to antibody test results.""

""We excluded individuals who were tested for SARS-CoV-2 during the visit when they received their blood draw (except if the test was for routine purposes, such as testing prior to an elective procedure or admittance to the hospital).""

""Finally, we excluded samples if a sample from the same patient had been selected within the previous 14 days.""

""we removed the 3 samples that tested negative on Vitros and positive on Roche, which likely reflects a false negative result on the Vitros assay and/or a false positive result on the Roche assay"".

""For geographic analyses, zipcodes with fewer than 10 individuals were excluded.""",2021-02-04,2021-02-17,Residual sera,All,Children and Youth (0-17 years),,,Age,Age: 0-17,21,0.4286,,,,,,,,Stratified non-probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.838,1.0,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Isobel Routledge,University of California San Francisco,Unity-Aligned,https://doi.org/10.1038/s41467-022-30051-x,2022-05-27,2024-03-01,Verified,routledge_using_2022,USA
220504_SanFrancisco_UniversityofCaliforniaSanFrancisco_Age_65+,220504_SanFrancisco_UniversityofCaliforniaSanFrancisco,Using sero-epidemiology to monitor disparities in vaccination and infection with SARS-CoV-2,2022-05-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,San Francisco,"Residual blood samples taken from two hospital networks in San Francisco.

""we included patients undergoing routine blood testing [between February 4 and February 17, 2021], defined as blood chemistries and tests for sexually transmitted infections and rubella. We included patients residing in San Francisco, including those experiencing homelessness.""

""We restricted our sample to outpatient and emergency department visits for adults; for under 18 s, we included both inpatient and outpatient visits due to small numbers of available samples.""","""A total of 1,091 samples were collected, of which 77 were excluded due to participation in a separate COVID research study, and a further 15 were later excluded from further analyses as they could not be linked to antibody test results.""

""We excluded individuals who were tested for SARS-CoV-2 during the visit when they received their blood draw (except if the test was for routine purposes, such as testing prior to an elective procedure or admittance to the hospital).""

""Finally, we excluded samples if a sample from the same patient had been selected within the previous 14 days.""

""we removed the 3 samples that tested negative on Vitros and positive on Roche, which likely reflects a false negative result on the Vitros assay and/or a false positive result on the Roche assay"".

""For geographic analyses, zipcodes with fewer than 10 individuals were excluded.""",2021-02-04,2021-02-17,Residual sera,All,Seniors (65+ years),,,Age,Age: 65+,377,0.40049999999999997,,,,,,,,Stratified non-probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,0.838,1.0,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,,Isobel Routledge,University of California San Francisco,Unity-Aligned,https://doi.org/10.1038/s41467-022-30051-x,2022-05-27,2024-03-01,Verified,routledge_using_2022,USA
220506_NewYorkState_NathanSKlineInstituteforPsychiatricResearch,220506_NewYorkState_NathanSKlineInstituteforPsychiatricResearch,Association Between the Use of Psychotropic Medications and the Risk of COVID-19 Infection Among Long-term Inpatients With Serious Mental Illness in a New York State-wide Psychiatric Hospital System,2022-05-06,Journal Article (Peer-Reviewed),Regional,Retrospective cohort,United States of America,New York,,"Included in this study were adult inpatients (≥18 years of age) with serious mental illness (schizophrenia, schizoaffective disorder, bipolar I disorder, or depression with psychotic features) who received testing for SARS-CoV-2 by RT-PCR or by serum IgG assay and were continuously hospitalized from March 8, 2020, until medical discharge for COVID-19 or July 1, 2020.","Patients who were admitted within 30 days prior to testing were excluded because we assessed medication exposure during the 30 days prior to testing, and information about medications could not be confirmed for patients admitted during this assessment window (eFigure in the Supplement).",2020-03-08,2020-07-01,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,18.0,,Primary Estimate,,1958,0.2921,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.1,0.996,['High'],,No,Yes,Yes,,Yes,Yes,No,,Katlyn Nemani,Nathan S. Kline Institute for Psychiatric Research,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.10743,2022-05-20,2024-03-01,Unverified,nemani_association_2022,USA
220513_California_CaliforniaDepartmentofPublicHealth_Adults_Overall,220513_California_CaliforniaDepartmentofPublicHealth_Adults,CalScope: Monitoring Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence From Vaccination and Prior Infection in Adults and Children in California May 2021-July 2021.,2022-05-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,California,,"We sampled households in 7 counties: Alameda, El Dorado, Kern, Los Angeles,
Monterey, San Diego, and Shasta. Sampled households could enroll 1 adult and 1 child (6 months to 17 years old). To randomize which eligible house-hold members participated, we instructed households to enroll the adult and child with the next upcoming birthday.",,2021-04-20,2021-06-15,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,7483,0.67,0.63,0.71,True,,True,,True,Stratified probability,ADAP SARS-CoV-2 total antibody assay,Enable Biosciences,Other,Dried Blood,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Megha Mehrotra,California Department of Public Health,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac246,2022-07-24,2024-03-21,Verified,mehrotra_calscope_2022,USA
220513_California_CaliforniaDepartmentofPublicHealth_Adults_AntiN,220513_California_CaliforniaDepartmentofPublicHealth_Adults,CalScope: Monitoring Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence From Vaccination and Prior Infection in Adults and Children in California May 2021-July 2021.,2022-05-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,California,,"We sampled households in 7 counties: Alameda, El Dorado, Kern, Los Angeles,
Monterey, San Diego, and Shasta. Sampled households could enroll 1 adult and 1 child (6 months to 17 years old). To randomize which eligible house-hold members participated, we instructed households to enroll the adult and child with the next upcoming birthday.",,2021-04-20,2021-06-15,Household and community samples,All,Multiple groups,18.0,,Test used,AntiN ,7483,0.22,0.18,0.26,,,True,,,Stratified probability,ADAP SARS-CoV-2 total antibody assay,Enable Biosciences,Other,Dried Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,1.0,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Megha Mehrotra,California Department of Public Health,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac246,2022-07-24,2024-03-21,Verified,mehrotra_calscope_2022,USA
220513_California_CaliforniaDepartmentofPublicHealth_Adults_41-65,220513_California_CaliforniaDepartmentofPublicHealth_Adults,CalScope: Monitoring Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence From Vaccination and Prior Infection in Adults and Children in California May 2021-July 2021.,2022-05-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,California,,"We sampled households in 7 counties: Alameda, El Dorado, Kern, Los Angeles,
Monterey, San Diego, and Shasta. Sampled households could enroll 1 adult and 1 child (6 months to 17 years old). To randomize which eligible house-hold members participated, we instructed households to enroll the adult and child with the next upcoming birthday.",,2021-04-20,2021-06-15,Household and community samples,All,Adults (18-64 years),41.0,65.0,Age,41-65,3458,0.26,0.2,0.33,,,True,,,Stratified probability,ADAP SARS-CoV-2 total antibody assay,Enable Biosciences,Other,Dried Blood,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,1.0,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Megha Mehrotra,California Department of Public Health,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac246,2022-07-24,2024-03-21,Verified,mehrotra_calscope_2022,USA
220513_California_CaliforniaDepartmentofPublicHealth_Adults_18-25,220513_California_CaliforniaDepartmentofPublicHealth_Adults,CalScope: Monitoring Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence From Vaccination and Prior Infection in Adults and Children in California May 2021-July 2021.,2022-05-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,California,,"We sampled households in 7 counties: Alameda, El Dorado, Kern, Los Angeles,
Monterey, San Diego, and Shasta. Sampled households could enroll 1 adult and 1 child (6 months to 17 years old). To randomize which eligible house-hold members participated, we instructed households to enroll the adult and child with the next upcoming birthday.",,2021-04-20,2021-06-15,Household and community samples,All,Adults (18-64 years),18.0,25.0,Age,18-25,285,0.4,0.18,0.62,,,True,,,Stratified probability,ADAP SARS-CoV-2 total antibody assay,Enable Biosciences,Other,Dried Blood,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,1.0,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Megha Mehrotra,California Department of Public Health,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac246,2022-07-24,2024-03-21,Verified,mehrotra_calscope_2022,USA
220513_California_CaliforniaDepartmentofPublicHealth_Adults_26-40,220513_California_CaliforniaDepartmentofPublicHealth_Adults,CalScope: Monitoring Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence From Vaccination and Prior Infection in Adults and Children in California May 2021-July 2021.,2022-05-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,California,,"We sampled households in 7 counties: Alameda, El Dorado, Kern, Los Angeles,
Monterey, San Diego, and Shasta. Sampled households could enroll 1 adult and 1 child (6 months to 17 years old). To randomize which eligible house-hold members participated, we instructed households to enroll the adult and child with the next upcoming birthday.",,2021-04-20,2021-06-15,Household and community samples,All,Adults (18-64 years),26.0,40.0,Age,26-40,1683,0.31,0.21,0.41000000000000003,,,True,,,Stratified probability,ADAP SARS-CoV-2 total antibody assay,Enable Biosciences,Other,Dried Blood,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,1.0,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Megha Mehrotra,California Department of Public Health,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac246,2022-07-24,2024-03-21,Verified,mehrotra_calscope_2022,USA
220513_California_CaliforniaDepartmentofPublicHealth_Adults_>65,220513_California_CaliforniaDepartmentofPublicHealth_Adults,CalScope: Monitoring Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence From Vaccination and Prior Infection in Adults and Children in California May 2021-July 2021.,2022-05-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,California,,"We sampled households in 7 counties: Alameda, El Dorado, Kern, Los Angeles,
Monterey, San Diego, and Shasta. Sampled households could enroll 1 adult and 1 child (6 months to 17 years old). To randomize which eligible house-hold members participated, we instructed households to enroll the adult and child with the next upcoming birthday.",,2021-04-20,2021-06-15,Household and community samples,All,Seniors (65+ years),66.0,,Age,>65,2057,0.13,0.07,0.19,,,True,,,Stratified probability,ADAP SARS-CoV-2 total antibody assay,Enable Biosciences,Other,Dried Blood,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,1.0,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Megha Mehrotra,California Department of Public Health,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac246,2022-07-24,2024-03-21,Verified,mehrotra_calscope_2022,USA
220513_California_CaliforniaDepartmentofPublicHealth_Children_Overall,220513_California_CaliforniaDepartmentofPublicHealth_Children,CalScope: Monitoring Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence From Vaccination and Prior Infection in Adults and Children in California May 2021-July 2021.,2022-05-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,California,,"We sampled households in7 counties: Alameda, El Dorado, Kern, Los Angeles,
Monterey, San Diego, and Shasta. Sampled households could enroll 1 adult and 1 child (6 months to 17 years old). To randomize which eligible house-hold members participated, we instructed households to enroll the adult and child with the next upcoming birthday",,2021-04-20,2021-06-15,Household and community samples,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,,1375,0.41000000000000003,0.35000000000000003,0.47000000000000003,True,,True,,True,Stratified probability,ADAP SARS-CoV-2 total antibody assay,Enable Biosciences,Other,Dried Blood,TotalAntibody,Spike,Validated by independent authors/third party/non-developers,1.0,1.0,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Megha Mehrotra,California Department of Public Health,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac246,2022-07-24,2024-03-21,Verified,mehrotra_calscope_2022,USA
220513_California_CaliforniaDepartmentofPublicHealth_Children_0.5-4,220513_California_CaliforniaDepartmentofPublicHealth_Children,CalScope: Monitoring Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence From Vaccination and Prior Infection in Adults and Children in California May 2021-July 2021.,2022-05-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,California,,"We sampled households in7 counties: Alameda, El Dorado, Kern, Los Angeles,
Monterey, San Diego, and Shasta. Sampled households could enroll 1 adult and 1 child (6 months to 17 years old). To randomize which eligible house-hold members participated, we instructed households to enroll the adult and child with the next upcoming birthday",,2021-04-20,2021-06-15,Household and community samples,All,Children and Youth (0-17 years),0.0,4.0,Age,0.5-4,207,0.29,0.07,0.51,,,True,,,Stratified probability,ADAP SARS-CoV-2 total antibody assay,Enable Biosciences,Other,Dried Blood,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,1.0,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Megha Mehrotra,California Department of Public Health,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac246,2022-07-24,2024-03-21,Verified,mehrotra_calscope_2022,USA
220513_California_CaliforniaDepartmentofPublicHealth_Children_5-11,220513_California_CaliforniaDepartmentofPublicHealth_Children,CalScope: Monitoring Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence From Vaccination and Prior Infection in Adults and Children in California May 2021-July 2021.,2022-05-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,California,,"We sampled households in7 counties: Alameda, El Dorado, Kern, Los Angeles,
Monterey, San Diego, and Shasta. Sampled households could enroll 1 adult and 1 child (6 months to 17 years old). To randomize which eligible house-hold members participated, we instructed households to enroll the adult and child with the next upcoming birthday",,2021-04-20,2021-06-15,Household and community samples,All,Children and Youth (0-17 years),5.0,11.0,Age,5-11,444,0.36,0.21,0.52,,,True,,,Stratified probability,ADAP SARS-CoV-2 total antibody assay,Enable Biosciences,Other,Dried Blood,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,1.0,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Megha Mehrotra,California Department of Public Health,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac246,2022-07-24,2024-03-21,Verified,mehrotra_calscope_2022,USA
220513_California_CaliforniaDepartmentofPublicHealth_Children_12-17,220513_California_CaliforniaDepartmentofPublicHealth_Children,CalScope: Monitoring Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence From Vaccination and Prior Infection in Adults and Children in California May 2021-July 2021.,2022-05-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,California,,"We sampled households in7 counties: Alameda, El Dorado, Kern, Los Angeles,
Monterey, San Diego, and Shasta. Sampled households could enroll 1 adult and 1 child (6 months to 17 years old). To randomize which eligible house-hold members participated, we instructed households to enroll the adult and child with the next upcoming birthday",,2021-04-20,2021-06-15,Household and community samples,All,Children and Youth (0-17 years),12.0,17.0,Age,12-17,724,0.27,0.17,0.37,,,True,,,Stratified probability,ADAP SARS-CoV-2 total antibody assay,Enable Biosciences,Other,Dried Blood,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,1.0,1.0,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Megha Mehrotra,California Department of Public Health,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac246,2022-07-24,2024-03-21,Verified,mehrotra_calscope_2022,USA
220513_California_CaliforniaDepartmentofPublicHealth_Children_AntiN,220513_California_CaliforniaDepartmentofPublicHealth_Children,CalScope: Monitoring Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence From Vaccination and Prior Infection in Adults and Children in California May 2021-July 2021.,2022-05-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,California,,"We sampled households in7 counties: Alameda, El Dorado, Kern, Los Angeles,
Monterey, San Diego, and Shasta. Sampled households could enroll 1 adult and 1 child (6 months to 17 years old). To randomize which eligible house-hold members participated, we instructed households to enroll the adult and child with the next upcoming birthday",,2021-04-20,2021-06-15,Household and community samples,All,Children and Youth (0-17 years),0.0,17.0,Test used,AntiN,1375,0.25,0.19,0.31,,,True,,,Stratified probability,ADAP SARS-CoV-2 total antibody assay,Enable Biosciences,Other,Dried Blood,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,1.0,['Low'],,Yes,Yes,No,,Yes,Yes,Yes,,Megha Mehrotra,California Department of Public Health,Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac246,2022-07-24,2024-03-21,Verified,mehrotra_calscope_2022,USA
220516_LittleRock_UniversityOfArkansasForMedicalSciences,220516_LittleRock_UniversityOfArkansasForMedicalSciences,Seroprevalence of SARS-CoV-2 antibodies in front-line pediatric health care workers.,2022-05-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Arkansas,Little Rock,"Volunteers were recruited between October 2020 and April 2021 from HCWs in the pediatric ED of Arkansas Children’s Hospital (LittleRock,AR), with inclusion criteria extending to any HCW working any shift in the ED at time of enrollment.",The only exclusion criterion was inability to ensure follow-up.,2020-10-25,2021-04-15,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,54,0.26,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by developers,1.0,0.946,['High'],,No,No,Yes,,Unclear,Yes,No,,Hannah Wilkins,University of Arkansas for Medical Sciences,Not Unity-Aligned,https://dx.doi.org/10.1002/emp2.12743,2022-06-03,2022-07-16,Unverified,wilkins_seroprevalence_2022,USA
220518_NewYorkCityDepartmentOfHealthAndMentalHygiene_PrimaryAdj,220518_NewYorkCityDepartmentOfHealthAndMentalHygiene,"Prevalence of SARS-CoV-2 antibodies during phased access to vaccination: results from a population-based survey in New York City, September 2020-March 2021.",2022-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York State,New York City,"Participants were recruited from Healthy NYC, a population-representative, probability-based 
panel of ~13000 NYC adults ≥18 years old, managed by the NYC DOHMH Division of 
Epidemiology.",,2020-09-15,2021-03-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,2096,0.23500000000000001,0.201,0.27399999999999997,True,,True,,True,Stratified probability,"Liaison SARS-CoV-2 S1/S2 IgG,Not reported/ Unable to specify","DiaSorin,NA",Multiple Types,Multiple Types,IgG,Spike,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Jannae Parrott,New York City Department of Health and Mental Hygiene,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000875,2022-05-30,2024-03-01,Unverified,parrott_prevalence_2022,USA
220518_NewYorkCityDepartmentOfHealthAndMentalHygiene_GeographyAdj_StatenIsland,220518_NewYorkCityDepartmentOfHealthAndMentalHygiene,"Prevalence of SARS-CoV-2 antibodies during phased access to vaccination: results from a population-based survey in New York City, September 2020-March 2021.",2022-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York State,New York City,"Participants were recruited from Healthy NYC, a population-representative, probability-based 
panel of ~13000 NYC adults ≥18 years old, managed by the NYC DOHMH Division of 
Epidemiology.",,2020-09-15,2021-03-15,Household and community samples,All,Multiple groups,,,Geographical area,NYC Boroughs,90,0.227,0.085,0.08,,,True,,,Stratified probability,"Liaison SARS-CoV-2 S1/S2 IgG,Not reported/ Unable to specify","DiaSorin,NA",Multiple Types,Multiple Types,IgG,Spike,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Jannae Parrott,New York City Department of Health and Mental Hygiene,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000875,2022-05-30,2024-03-01,Unverified,parrott_prevalence_2022,USA
220518_NewYorkCityDepartmentOfHealthAndMentalHygiene_GeographyAdj_Queens,220518_NewYorkCityDepartmentOfHealthAndMentalHygiene,"Prevalence of SARS-CoV-2 antibodies during phased access to vaccination: results from a population-based survey in New York City, September 2020-March 2021.",2022-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York State,New York City,"Participants were recruited from Healthy NYC, a population-representative, probability-based 
panel of ~13000 NYC adults ≥18 years old, managed by the NYC DOHMH Division of 
Epidemiology.",,2020-09-15,2021-03-15,Household and community samples,All,Multiple groups,,,Geographical area,NYC Boroughs,472,0.20800000000000002,0.147,0.28600000000000003,,,True,,,Stratified probability,"Liaison SARS-CoV-2 S1/S2 IgG,Not reported/ Unable to specify","DiaSorin,NA",Multiple Types,Multiple Types,IgG,Spike,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Jannae Parrott,New York City Department of Health and Mental Hygiene,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000875,2022-05-30,2024-03-01,Unverified,parrott_prevalence_2022,USA
220518_NewYorkCityDepartmentOfHealthAndMentalHygiene_SexAdj_Female,220518_NewYorkCityDepartmentOfHealthAndMentalHygiene,"Prevalence of SARS-CoV-2 antibodies during phased access to vaccination: results from a population-based survey in New York City, September 2020-March 2021.",2022-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York State,New York City,"Participants were recruited from Healthy NYC, a population-representative, probability-based 
panel of ~13000 NYC adults ≥18 years old, managed by the NYC DOHMH Division of 
Epidemiology.",,2020-09-15,2021-03-15,Household and community samples,Female,Multiple groups,,,Sex/Gender,,1336,0.23399999999999999,0.19,0.284,,,True,,,Stratified probability,"Liaison SARS-CoV-2 S1/S2 IgG,Not reported/ Unable to specify","DiaSorin,NA",Multiple Types,Multiple Types,IgG,Spike,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Jannae Parrott,New York City Department of Health and Mental Hygiene,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000875,2022-05-30,2024-03-01,Unverified,parrott_prevalence_2022,USA
220518_NewYorkCityDepartmentOfHealthAndMentalHygiene_SexAdj_Male,220518_NewYorkCityDepartmentOfHealthAndMentalHygiene,"Prevalence of SARS-CoV-2 antibodies during phased access to vaccination: results from a population-based survey in New York City, September 2020-March 2021.",2022-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York State,New York City,"Participants were recruited from Healthy NYC, a population-representative, probability-based 
panel of ~13000 NYC adults ≥18 years old, managed by the NYC DOHMH Division of 
Epidemiology.",,2020-09-15,2021-03-15,Household and community samples,Male,Multiple groups,,,Sex/Gender,,751,0.239,0.18600000000000003,0.302,,,True,,,Stratified probability,"Liaison SARS-CoV-2 S1/S2 IgG,Not reported/ Unable to specify","DiaSorin,NA",Multiple Types,Multiple Types,IgG,Spike,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Jannae Parrott,New York City Department of Health and Mental Hygiene,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000875,2022-05-30,2024-03-01,Unverified,parrott_prevalence_2022,USA
220518_NewYorkCityDepartmentOfHealthAndMentalHygiene_GeographyAdj_Manhattan,220518_NewYorkCityDepartmentOfHealthAndMentalHygiene,"Prevalence of SARS-CoV-2 antibodies during phased access to vaccination: results from a population-based survey in New York City, September 2020-March 2021.",2022-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York State,New York City,"Participants were recruited from Healthy NYC, a population-representative, probability-based 
panel of ~13000 NYC adults ≥18 years old, managed by the NYC DOHMH Division of 
Epidemiology.",,2020-09-15,2021-03-15,Household and community samples,All,Multiple groups,,,Geographical area,NYC Boroughs,617,0.20500000000000002,0.159,0.26,,,True,,,Stratified probability,"Liaison SARS-CoV-2 S1/S2 IgG,Not reported/ Unable to specify","DiaSorin,NA",Multiple Types,Multiple Types,IgG,Spike,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Jannae Parrott,New York City Department of Health and Mental Hygiene,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000875,2022-05-30,2024-03-01,Unverified,parrott_prevalence_2022,USA
220518_NewYorkCityDepartmentOfHealthAndMentalHygiene_AgeAdj_18-44,220518_NewYorkCityDepartmentOfHealthAndMentalHygiene,"Prevalence of SARS-CoV-2 antibodies during phased access to vaccination: results from a population-based survey in New York City, September 2020-March 2021.",2022-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York State,New York City,"Participants were recruited from Healthy NYC, a population-representative, probability-based 
panel of ~13000 NYC adults ≥18 years old, managed by the NYC DOHMH Division of 
Epidemiology.",,2020-09-15,2021-03-15,Household and community samples,All,Multiple groups,,,Age,,995,0.24600000000000002,0.196,0.308,,,True,,,Stratified probability,"Liaison SARS-CoV-2 S1/S2 IgG,Not reported/ Unable to specify","DiaSorin,NA",Multiple Types,Multiple Types,IgG,Spike,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Jannae Parrott,New York City Department of Health and Mental Hygiene,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000875,2022-05-30,2024-03-01,Unverified,parrott_prevalence_2022,USA
220518_NewYorkCityDepartmentOfHealthAndMentalHygiene_AgeAdj_65+,220518_NewYorkCityDepartmentOfHealthAndMentalHygiene,"Prevalence of SARS-CoV-2 antibodies during phased access to vaccination: results from a population-based survey in New York City, September 2020-March 2021.",2022-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York State,New York City,"Participants were recruited from Healthy NYC, a population-representative, probability-based 
panel of ~13000 NYC adults ≥18 years old, managed by the NYC DOHMH Division of 
Epidemiology.",,2020-09-15,2021-03-15,Household and community samples,All,Multiple groups,,,Age,,388,0.225,0.154,0.317,,,True,,,Stratified probability,"Liaison SARS-CoV-2 S1/S2 IgG,Not reported/ Unable to specify","DiaSorin,NA",Multiple Types,Multiple Types,IgG,Spike,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Jannae Parrott,New York City Department of Health and Mental Hygiene,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000875,2022-05-30,2024-03-01,Unverified,parrott_prevalence_2022,USA
220518_NewYorkCityDepartmentOfHealthAndMentalHygiene_GeographyAdj_Brooklyn,220518_NewYorkCityDepartmentOfHealthAndMentalHygiene,"Prevalence of SARS-CoV-2 antibodies during phased access to vaccination: results from a population-based survey in New York City, September 2020-March 2021.",2022-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York State,New York City,"Participants were recruited from Healthy NYC, a population-representative, probability-based 
panel of ~13000 NYC adults ≥18 years old, managed by the NYC DOHMH Division of 
Epidemiology.",,2020-09-15,2021-03-15,Household and community samples,All,Multiple groups,,,Geographical area,NYC Boroughs,654,0.268,0.201,0.349,,,True,,,Stratified probability,"Liaison SARS-CoV-2 S1/S2 IgG,Not reported/ Unable to specify","DiaSorin,NA",Multiple Types,Multiple Types,IgG,Spike,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Jannae Parrott,New York City Department of Health and Mental Hygiene,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000875,2022-05-30,2024-03-01,Unverified,parrott_prevalence_2022,USA
220518_NewYorkCityDepartmentOfHealthAndMentalHygiene_GeographyAdj_Bronx,220518_NewYorkCityDepartmentOfHealthAndMentalHygiene,"Prevalence of SARS-CoV-2 antibodies during phased access to vaccination: results from a population-based survey in New York City, September 2020-March 2021.",2022-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York State,New York City,"Participants were recruited from Healthy NYC, a population-representative, probability-based 
panel of ~13000 NYC adults ≥18 years old, managed by the NYC DOHMH Division of 
Epidemiology.",,2020-09-15,2021-03-15,Household and community samples,All,Multiple groups,,,Geographical area,NYC Boroughs,258,0.263,0.17800000000000002,0.371,,,True,,,Stratified probability,"Liaison SARS-CoV-2 S1/S2 IgG,Not reported/ Unable to specify","DiaSorin,NA",Multiple Types,Multiple Types,IgG,Spike,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Jannae Parrott,New York City Department of Health and Mental Hygiene,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000875,2022-05-30,2024-03-01,Unverified,parrott_prevalence_2022,USA
220518_NewYorkCityDepartmentOfHealthAndMentalHygiene_AgeAdj_45-64,220518_NewYorkCityDepartmentOfHealthAndMentalHygiene,"Prevalence of SARS-CoV-2 antibodies during phased access to vaccination: results from a population-based survey in New York City, September 2020-March 2021.",2022-05-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York State,New York City,"Participants were recruited from Healthy NYC, a population-representative, probability-based 
panel of ~13000 NYC adults ≥18 years old, managed by the NYC DOHMH Division of 
Epidemiology.",,2020-09-15,2021-03-15,Household and community samples,All,Multiple groups,,,Age,,700,0.23199999999999998,0.17800000000000002,0.29600000000000004,,,True,,,Stratified probability,"Liaison SARS-CoV-2 S1/S2 IgG,Not reported/ Unable to specify","DiaSorin,NA",Multiple Types,Multiple Types,IgG,Spike,,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Jannae Parrott,New York City Department of Health and Mental Hygiene,Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268822000875,2022-05-30,2024-03-01,Unverified,parrott_prevalence_2022,USA
220519_NorthCarolina_UniversityOfNorthCarolina_1AprJun_TestPopAdj,220519_NorthCarolina_UniversityOfNorthCarolina_1AprJun,Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020,2022-05-19,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Remnant plasma and serum samples were collected from four hospital-based clinical laboratories affiliated with the University of North Carolina (UNC) Health system (Table S1). These laboratories receive and process clinical samples from inpatient units as well as outpatient clinics in central NC. Each week, laboratory staff at each location, who were unaware of the patient’s clinical status or hospitalization/visit details, selected up to 300 remnant samples belonging to individuals 5 to 99 years of age.""","""study duplicates were discarded.""",2020-04-19,2020-06-20,Residual sera,All,Multiple groups,5.0,99.0,Primary Estimate,,3963,0.028999999999999998,0.018000000000000002,0.045,True,True,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,TotalAntibody,Spike,Validated by developers,0.897,0.993,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cesar Lopez,University of North Carolina,Not Unity-Aligned,https://dx.doi.org/10.1128/msphere.00841-21,2022-06-07,2022-07-16,Unverified,lopez_ethnoracial_2022,USA
220519_NorthCarolina_UniversityOfNorthCarolina_1AprJun_Age_18-49,220519_NorthCarolina_UniversityOfNorthCarolina_1AprJun,Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020,2022-05-19,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Remnant plasma and serum samples were collected from four hospital-based clinical laboratories affiliated with the University of North Carolina (UNC) Health system (Table S1). These laboratories receive and process clinical samples from inpatient units as well as outpatient clinics in central NC. Each week, laboratory staff at each location, who were unaware of the patient’s clinical status or hospitalization/visit details, selected up to 300 remnant samples belonging to individuals 5 to 99 years of age.""","""study duplicates were discarded.""",2020-04-19,2020-06-20,Residual sera,All,Adults (18-64 years),18.0,49.0,Age,Age: 18-49,1419,0.059000000000000004,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,TotalAntibody,Spike,Validated by developers,0.897,0.993,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cesar Lopez,University of North Carolina,Not Unity-Aligned,https://dx.doi.org/10.1128/msphere.00841-21,2022-06-08,2022-07-16,Unverified,lopez_ethnoracial_2022,USA
220519_NorthCarolina_UniversityOfNorthCarolina_1AprJun_Age_5-17,220519_NorthCarolina_UniversityOfNorthCarolina_1AprJun,Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020,2022-05-19,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Remnant plasma and serum samples were collected from four hospital-based clinical laboratories affiliated with the University of North Carolina (UNC) Health system (Table S1). These laboratories receive and process clinical samples from inpatient units as well as outpatient clinics in central NC. Each week, laboratory staff at each location, who were unaware of the patient’s clinical status or hospitalization/visit details, selected up to 300 remnant samples belonging to individuals 5 to 99 years of age.""","""study duplicates were discarded.""",2020-04-19,2020-06-20,Residual sera,All,Children and Youth (0-17 years),5.0,17.0,Age,Age: 5-17,289,0.042,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,TotalAntibody,Spike,Validated by developers,0.897,0.993,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cesar Lopez,University of North Carolina,Not Unity-Aligned,https://dx.doi.org/10.1128/msphere.00841-21,2022-06-08,2022-07-16,Unverified,lopez_ethnoracial_2022,USA
220519_NorthCarolina_UniversityOfNorthCarolina_1AprJun_UnAdj,220519_NorthCarolina_UniversityOfNorthCarolina_1AprJun,Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020,2022-05-19,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Remnant plasma and serum samples were collected from four hospital-based clinical laboratories affiliated with the University of North Carolina (UNC) Health system (Table S1). These laboratories receive and process clinical samples from inpatient units as well as outpatient clinics in central NC. Each week, laboratory staff at each location, who were unaware of the patient’s clinical status or hospitalization/visit details, selected up to 300 remnant samples belonging to individuals 5 to 99 years of age.""","""study duplicates were discarded.""",2020-04-19,2020-06-20,Residual sera,All,Multiple groups,5.0,99.0,Analysis,,3963,0.054000000000000006,,,,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,TotalAntibody,Spike,Validated by developers,0.897,0.993,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cesar Lopez,University of North Carolina,Not Unity-Aligned,https://dx.doi.org/10.1128/msphere.00841-21,2022-06-08,2022-07-16,Unverified,lopez_ethnoracial_2022,USA
220519_NorthCarolina_UniversityOfNorthCarolina_1AprJun_Sex_Female,220519_NorthCarolina_UniversityOfNorthCarolina_1AprJun,Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020,2022-05-19,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Remnant plasma and serum samples were collected from four hospital-based clinical laboratories affiliated with the University of North Carolina (UNC) Health system (Table S1). These laboratories receive and process clinical samples from inpatient units as well as outpatient clinics in central NC. Each week, laboratory staff at each location, who were unaware of the patient’s clinical status or hospitalization/visit details, selected up to 300 remnant samples belonging to individuals 5 to 99 years of age.""","""study duplicates were discarded.""",2020-04-19,2020-06-20,Residual sera,Female,Multiple groups,5.0,99.0,Sex/Gender,,2227,0.046,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,TotalAntibody,Spike,Validated by developers,0.897,0.993,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cesar Lopez,University of North Carolina,Not Unity-Aligned,https://dx.doi.org/10.1128/msphere.00841-21,2022-06-08,2022-07-16,Unverified,lopez_ethnoracial_2022,USA
220519_NorthCarolina_UniversityOfNorthCarolina_1AprJun_Sex_Male,220519_NorthCarolina_UniversityOfNorthCarolina_1AprJun,Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020,2022-05-19,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Remnant plasma and serum samples were collected from four hospital-based clinical laboratories affiliated with the University of North Carolina (UNC) Health system (Table S1). These laboratories receive and process clinical samples from inpatient units as well as outpatient clinics in central NC. Each week, laboratory staff at each location, who were unaware of the patient’s clinical status or hospitalization/visit details, selected up to 300 remnant samples belonging to individuals 5 to 99 years of age.""","""study duplicates were discarded.""",2020-04-19,2020-06-20,Residual sera,Male,Multiple groups,5.0,99.0,Sex/Gender,,1735,0.064,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,TotalAntibody,Spike,Validated by developers,0.897,0.993,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cesar Lopez,University of North Carolina,Not Unity-Aligned,https://dx.doi.org/10.1128/msphere.00841-21,2022-06-08,2022-07-16,Unverified,lopez_ethnoracial_2022,USA
220519_NorthCarolina_UniversityOfNorthCarolina_1AprJun_Age_50-64,220519_NorthCarolina_UniversityOfNorthCarolina_1AprJun,Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020,2022-05-19,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Remnant plasma and serum samples were collected from four hospital-based clinical laboratories affiliated with the University of North Carolina (UNC) Health system (Table S1). These laboratories receive and process clinical samples from inpatient units as well as outpatient clinics in central NC. Each week, laboratory staff at each location, who were unaware of the patient’s clinical status or hospitalization/visit details, selected up to 300 remnant samples belonging to individuals 5 to 99 years of age.""","""study duplicates were discarded.""",2020-04-19,2020-06-20,Residual sera,All,Adults (18-64 years),50.0,64.0,Age,Age: 50-64,1080,0.059000000000000004,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,TotalAntibody,Spike,Validated by developers,0.897,0.993,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cesar Lopez,University of North Carolina,Not Unity-Aligned,https://dx.doi.org/10.1128/msphere.00841-21,2022-06-08,2022-07-16,Unverified,lopez_ethnoracial_2022,USA
220519_NorthCarolina_UniversityOfNorthCarolina_1AprJun_Age_65-99,220519_NorthCarolina_UniversityOfNorthCarolina_1AprJun,Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020,2022-05-19,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Remnant plasma and serum samples were collected from four hospital-based clinical laboratories affiliated with the University of North Carolina (UNC) Health system (Table S1). These laboratories receive and process clinical samples from inpatient units as well as outpatient clinics in central NC. Each week, laboratory staff at each location, who were unaware of the patient’s clinical status or hospitalization/visit details, selected up to 300 remnant samples belonging to individuals 5 to 99 years of age.""","""study duplicates were discarded.""",2020-04-19,2020-06-20,Residual sera,All,Seniors (65+ years),65.0,99.0,Age,Age: 65-99,1175,0.046,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,TotalAntibody,Spike,Validated by developers,0.897,0.993,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cesar Lopez,University of North Carolina,Not Unity-Aligned,https://dx.doi.org/10.1128/msphere.00841-21,2022-06-08,2022-07-16,Unverified,lopez_ethnoracial_2022,USA
220519_NorthCarolina_UniversityOfNorthCarolina_2JunAug_TestPopAdj,220519_NorthCarolina_UniversityOfNorthCarolina_2JunAug,Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020,2022-05-19,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Remnant plasma and serum samples were collected from four hospital-based clinical laboratories affiliated with the University of North Carolina (UNC) Health system (Table S1). These laboratories receive and process clinical samples from inpatient units as well as outpatient clinics in central NC. Each week, laboratory staff at each location, who were unaware of the patient’s clinical status or hospitalization/visit details, selected up to 300 remnant samples belonging to individuals 5 to 99 years of age.""","""study duplicates were discarded.""",2020-06-21,2020-08-22,Residual sera,All,Multiple groups,5.0,99.0,Primary Estimate,,3851,0.102,0.085,0.122,True,True,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,TotalAntibody,Spike,Validated by developers,0.897,0.993,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cesar Lopez,University of North Carolina,Not Unity-Aligned,https://dx.doi.org/10.1128/msphere.00841-21,2022-06-07,2022-07-16,Unverified,lopez_ethnoracial_2022,USA
220519_NorthCarolina_UniversityOfNorthCarolina_2JunAug_Sex_Male,220519_NorthCarolina_UniversityOfNorthCarolina_2JunAug,Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020,2022-05-19,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Remnant plasma and serum samples were collected from four hospital-based clinical laboratories affiliated with the University of North Carolina (UNC) Health system (Table S1). These laboratories receive and process clinical samples from inpatient units as well as outpatient clinics in central NC. Each week, laboratory staff at each location, who were unaware of the patient’s clinical status or hospitalization/visit details, selected up to 300 remnant samples belonging to individuals 5 to 99 years of age.""","""study duplicates were discarded.""",2020-06-21,2020-08-22,Residual sera,Male,Multiple groups,5.0,99.0,Sex/Gender,,1676,0.115,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,TotalAntibody,Spike,Validated by developers,0.897,0.993,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cesar Lopez,University of North Carolina,Not Unity-Aligned,https://dx.doi.org/10.1128/msphere.00841-21,2022-06-08,2022-07-16,Unverified,lopez_ethnoracial_2022,USA
220519_NorthCarolina_UniversityOfNorthCarolina_2JunAug_Age_50-64,220519_NorthCarolina_UniversityOfNorthCarolina_2JunAug,Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020,2022-05-19,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Remnant plasma and serum samples were collected from four hospital-based clinical laboratories affiliated with the University of North Carolina (UNC) Health system (Table S1). These laboratories receive and process clinical samples from inpatient units as well as outpatient clinics in central NC. Each week, laboratory staff at each location, who were unaware of the patient’s clinical status or hospitalization/visit details, selected up to 300 remnant samples belonging to individuals 5 to 99 years of age.""","""study duplicates were discarded.""",2020-06-21,2020-08-22,Residual sera,All,Adults (18-64 years),50.0,64.0,Age,Age: 50-64,1082,0.12400000000000001,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,TotalAntibody,Spike,Validated by developers,0.897,0.993,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cesar Lopez,University of North Carolina,Not Unity-Aligned,https://dx.doi.org/10.1128/msphere.00841-21,2022-06-08,2022-07-16,Unverified,lopez_ethnoracial_2022,USA
220519_NorthCarolina_UniversityOfNorthCarolina_2JunAug_Age_18-49,220519_NorthCarolina_UniversityOfNorthCarolina_2JunAug,Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020,2022-05-19,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Remnant plasma and serum samples were collected from four hospital-based clinical laboratories affiliated with the University of North Carolina (UNC) Health system (Table S1). These laboratories receive and process clinical samples from inpatient units as well as outpatient clinics in central NC. Each week, laboratory staff at each location, who were unaware of the patient’s clinical status or hospitalization/visit details, selected up to 300 remnant samples belonging to individuals 5 to 99 years of age.""","""study duplicates were discarded.""",2020-06-21,2020-08-22,Residual sera,All,Adults (18-64 years),18.0,49.0,Age,Age: 18-49,1190,0.134,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,TotalAntibody,Spike,Validated by developers,0.897,0.993,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cesar Lopez,University of North Carolina,Not Unity-Aligned,https://dx.doi.org/10.1128/msphere.00841-21,2022-06-08,2022-07-16,Unverified,lopez_ethnoracial_2022,USA
220519_NorthCarolina_UniversityOfNorthCarolina_2JunAug_Age_5-17,220519_NorthCarolina_UniversityOfNorthCarolina_2JunAug,Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020,2022-05-19,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Remnant plasma and serum samples were collected from four hospital-based clinical laboratories affiliated with the University of North Carolina (UNC) Health system (Table S1). These laboratories receive and process clinical samples from inpatient units as well as outpatient clinics in central NC. Each week, laboratory staff at each location, who were unaware of the patient’s clinical status or hospitalization/visit details, selected up to 300 remnant samples belonging to individuals 5 to 99 years of age.""","""study duplicates were discarded.""",2020-06-21,2020-08-22,Residual sera,All,Children and Youth (0-17 years),5.0,17.0,Age,Age: 5-17,176,0.09699999999999999,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,TotalAntibody,Spike,Validated by developers,0.897,0.993,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cesar Lopez,University of North Carolina,Not Unity-Aligned,https://dx.doi.org/10.1128/msphere.00841-21,2022-06-08,2022-07-16,Unverified,lopez_ethnoracial_2022,USA
220519_NorthCarolina_UniversityOfNorthCarolina_2JunAug_Age_65-99,220519_NorthCarolina_UniversityOfNorthCarolina_2JunAug,Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020,2022-05-19,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Remnant plasma and serum samples were collected from four hospital-based clinical laboratories affiliated with the University of North Carolina (UNC) Health system (Table S1). These laboratories receive and process clinical samples from inpatient units as well as outpatient clinics in central NC. Each week, laboratory staff at each location, who were unaware of the patient’s clinical status or hospitalization/visit details, selected up to 300 remnant samples belonging to individuals 5 to 99 years of age.""","""study duplicates were discarded.""",2020-06-21,2020-08-22,Residual sera,All,Seniors (65+ years),65.0,99.0,Age,Age: 65-99,1403,0.102,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,TotalAntibody,Spike,Validated by developers,0.897,0.993,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cesar Lopez,University of North Carolina,Not Unity-Aligned,https://dx.doi.org/10.1128/msphere.00841-21,2022-06-08,2022-07-16,Unverified,lopez_ethnoracial_2022,USA
220519_NorthCarolina_UniversityOfNorthCarolina_2JunAug_UnAdj,220519_NorthCarolina_UniversityOfNorthCarolina_2JunAug,Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020,2022-05-19,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Remnant plasma and serum samples were collected from four hospital-based clinical laboratories affiliated with the University of North Carolina (UNC) Health system (Table S1). These laboratories receive and process clinical samples from inpatient units as well as outpatient clinics in central NC. Each week, laboratory staff at each location, who were unaware of the patient’s clinical status or hospitalization/visit details, selected up to 300 remnant samples belonging to individuals 5 to 99 years of age.""","""study duplicates were discarded.""",2020-06-21,2020-08-22,Residual sera,All,Multiple groups,5.0,99.0,Analysis,,3851,0.11800000000000001,,,,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,TotalAntibody,Spike,Validated by developers,0.897,0.993,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cesar Lopez,University of North Carolina,Not Unity-Aligned,https://dx.doi.org/10.1128/msphere.00841-21,2022-06-08,2022-07-16,Unverified,lopez_ethnoracial_2022,USA
220519_NorthCarolina_UniversityOfNorthCarolina_2JunAug_Sex_Female,220519_NorthCarolina_UniversityOfNorthCarolina_2JunAug,Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020,2022-05-19,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Remnant plasma and serum samples were collected from four hospital-based clinical laboratories affiliated with the University of North Carolina (UNC) Health system (Table S1). These laboratories receive and process clinical samples from inpatient units as well as outpatient clinics in central NC. Each week, laboratory staff at each location, who were unaware of the patient’s clinical status or hospitalization/visit details, selected up to 300 remnant samples belonging to individuals 5 to 99 years of age.""","""study duplicates were discarded.""",2020-06-21,2020-08-22,Residual sera,Female,Multiple groups,5.0,99.0,Sex/Gender,,2175,0.11900000000000001,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,TotalAntibody,Spike,Validated by developers,0.897,0.993,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cesar Lopez,University of North Carolina,Not Unity-Aligned,https://dx.doi.org/10.1128/msphere.00841-21,2022-06-08,2022-07-16,Unverified,lopez_ethnoracial_2022,USA
220519_NorthCarolina_UniversityOfNorthCarolina_3AugOct_TestPopAdj,220519_NorthCarolina_UniversityOfNorthCarolina_3AugOct,Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020,2022-05-19,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Remnant plasma and serum samples were collected from four hospital-based clinical laboratories affiliated with the University of North Carolina (UNC) Health system (Table S1). These laboratories receive and process clinical samples from inpatient units as well as outpatient clinics in central NC. Each week, laboratory staff at each location, who were unaware of the patient’s clinical status or hospitalization/visit details, selected up to 300 remnant samples belonging to individuals 5 to 99 years of age.""","""study duplicates were discarded.""",2020-08-23,2020-10-24,Residual sera,All,Multiple groups,5.0,99.0,Primary Estimate,,2510,0.091,0.07200000000000001,0.11199999999999999,True,True,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,TotalAntibody,Spike,Validated by developers,0.897,0.993,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cesar Lopez,University of North Carolina,Not Unity-Aligned,https://dx.doi.org/10.1128/msphere.00841-21,2022-06-07,2022-07-16,Unverified,lopez_ethnoracial_2022,USA
220519_NorthCarolina_UniversityOfNorthCarolina_3AugOct_Age_50-64,220519_NorthCarolina_UniversityOfNorthCarolina_3AugOct,Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020,2022-05-19,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Remnant plasma and serum samples were collected from four hospital-based clinical laboratories affiliated with the University of North Carolina (UNC) Health system (Table S1). These laboratories receive and process clinical samples from inpatient units as well as outpatient clinics in central NC. Each week, laboratory staff at each location, who were unaware of the patient’s clinical status or hospitalization/visit details, selected up to 300 remnant samples belonging to individuals 5 to 99 years of age.""","""study duplicates were discarded.""",2020-08-23,2020-10-24,Residual sera,All,Adults (18-64 years),50.0,64.0,Age,Age: 50-64,682,0.125,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,TotalAntibody,Spike,Validated by developers,0.897,0.993,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cesar Lopez,University of North Carolina,Not Unity-Aligned,https://dx.doi.org/10.1128/msphere.00841-21,2022-06-08,2022-07-16,Unverified,lopez_ethnoracial_2022,USA
220519_NorthCarolina_UniversityOfNorthCarolina_3AugOct_Age_5-17,220519_NorthCarolina_UniversityOfNorthCarolina_3AugOct,Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020,2022-05-19,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Remnant plasma and serum samples were collected from four hospital-based clinical laboratories affiliated with the University of North Carolina (UNC) Health system (Table S1). These laboratories receive and process clinical samples from inpatient units as well as outpatient clinics in central NC. Each week, laboratory staff at each location, who were unaware of the patient’s clinical status or hospitalization/visit details, selected up to 300 remnant samples belonging to individuals 5 to 99 years of age.""","""study duplicates were discarded.""",2020-08-23,2020-10-24,Residual sera,All,Children and Youth (0-17 years),5.0,17.0,Age,Age: 5-17,155,0.084,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,TotalAntibody,Spike,Validated by developers,0.897,0.993,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cesar Lopez,University of North Carolina,Not Unity-Aligned,https://dx.doi.org/10.1128/msphere.00841-21,2022-06-08,2022-07-16,Unverified,lopez_ethnoracial_2022,USA
220519_NorthCarolina_UniversityOfNorthCarolina_3AugOct_UnAdj,220519_NorthCarolina_UniversityOfNorthCarolina_3AugOct,Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020,2022-05-19,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Remnant plasma and serum samples were collected from four hospital-based clinical laboratories affiliated with the University of North Carolina (UNC) Health system (Table S1). These laboratories receive and process clinical samples from inpatient units as well as outpatient clinics in central NC. Each week, laboratory staff at each location, who were unaware of the patient’s clinical status or hospitalization/visit details, selected up to 300 remnant samples belonging to individuals 5 to 99 years of age.""","""study duplicates were discarded.""",2020-08-23,2020-10-24,Residual sera,All,Multiple groups,5.0,99.0,Analysis,,2510,0.109,,,,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,TotalAntibody,Spike,Validated by developers,0.897,0.993,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cesar Lopez,University of North Carolina,Not Unity-Aligned,https://dx.doi.org/10.1128/msphere.00841-21,2022-06-08,2022-07-16,Unverified,lopez_ethnoracial_2022,USA
220519_NorthCarolina_UniversityOfNorthCarolina_3AugOct_Sex_Male,220519_NorthCarolina_UniversityOfNorthCarolina_3AugOct,Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020,2022-05-19,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Remnant plasma and serum samples were collected from four hospital-based clinical laboratories affiliated with the University of North Carolina (UNC) Health system (Table S1). These laboratories receive and process clinical samples from inpatient units as well as outpatient clinics in central NC. Each week, laboratory staff at each location, who were unaware of the patient’s clinical status or hospitalization/visit details, selected up to 300 remnant samples belonging to individuals 5 to 99 years of age.""","""study duplicates were discarded.""",2020-08-23,2020-10-24,Residual sera,Male,Multiple groups,5.0,99.0,Sex/Gender,,1118,0.11900000000000001,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,TotalAntibody,Spike,Validated by developers,0.897,0.993,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cesar Lopez,University of North Carolina,Not Unity-Aligned,https://dx.doi.org/10.1128/msphere.00841-21,2022-06-08,2022-07-16,Unverified,lopez_ethnoracial_2022,USA
220519_NorthCarolina_UniversityOfNorthCarolina_3AugOct_Age_18-49,220519_NorthCarolina_UniversityOfNorthCarolina_3AugOct,Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020,2022-05-19,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Remnant plasma and serum samples were collected from four hospital-based clinical laboratories affiliated with the University of North Carolina (UNC) Health system (Table S1). These laboratories receive and process clinical samples from inpatient units as well as outpatient clinics in central NC. Each week, laboratory staff at each location, who were unaware of the patient’s clinical status or hospitalization/visit details, selected up to 300 remnant samples belonging to individuals 5 to 99 years of age.""","""study duplicates were discarded.""",2020-08-23,2020-10-24,Residual sera,All,Adults (18-64 years),18.0,49.0,Age,Age: 18-49,817,0.109,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,TotalAntibody,Spike,Validated by developers,0.897,0.993,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cesar Lopez,University of North Carolina,Not Unity-Aligned,https://dx.doi.org/10.1128/msphere.00841-21,2022-06-08,2022-07-16,Unverified,lopez_ethnoracial_2022,USA
220519_NorthCarolina_UniversityOfNorthCarolina_3AugOct_Age_65-99,220519_NorthCarolina_UniversityOfNorthCarolina_3AugOct,Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020,2022-05-19,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Remnant plasma and serum samples were collected from four hospital-based clinical laboratories affiliated with the University of North Carolina (UNC) Health system (Table S1). These laboratories receive and process clinical samples from inpatient units as well as outpatient clinics in central NC. Each week, laboratory staff at each location, who were unaware of the patient’s clinical status or hospitalization/visit details, selected up to 300 remnant samples belonging to individuals 5 to 99 years of age.""","""study duplicates were discarded.""",2020-08-23,2020-10-24,Residual sera,All,Seniors (65+ years),65.0,99.0,Age,Age: 65-99,856,0.10099999999999999,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,TotalAntibody,Spike,Validated by developers,0.897,0.993,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cesar Lopez,University of North Carolina,Not Unity-Aligned,https://dx.doi.org/10.1128/msphere.00841-21,2022-06-08,2022-07-16,Unverified,lopez_ethnoracial_2022,USA
220519_NorthCarolina_UniversityOfNorthCarolina_3AugOct_Sex_Female,220519_NorthCarolina_UniversityOfNorthCarolina_3AugOct,Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020,2022-05-19,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Remnant plasma and serum samples were collected from four hospital-based clinical laboratories affiliated with the University of North Carolina (UNC) Health system (Table S1). These laboratories receive and process clinical samples from inpatient units as well as outpatient clinics in central NC. Each week, laboratory staff at each location, who were unaware of the patient’s clinical status or hospitalization/visit details, selected up to 300 remnant samples belonging to individuals 5 to 99 years of age.""","""study duplicates were discarded.""",2020-08-23,2020-10-24,Residual sera,Female,Multiple groups,5.0,99.0,Sex/Gender,,1392,0.10099999999999999,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,TotalAntibody,Spike,Validated by developers,0.897,0.993,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cesar Lopez,University of North Carolina,Not Unity-Aligned,https://dx.doi.org/10.1128/msphere.00841-21,2022-06-08,2022-07-16,Unverified,lopez_ethnoracial_2022,USA
220519_NorthCarolina_UniversityOfNorthCarolina_4OctDec_TestPopAdj,220519_NorthCarolina_UniversityOfNorthCarolina_4OctDec,Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020,2022-05-19,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Remnant plasma and serum samples were collected from four hospital-based clinical laboratories affiliated with the University of North Carolina (UNC) Health system (Table S1). These laboratories receive and process clinical samples from inpatient units as well as outpatient clinics in central NC. Each week, laboratory staff at each location, who were unaware of the patient’s clinical status or hospitalization/visit details, selected up to 300 remnant samples belonging to individuals 5 to 99 years of age.""","""study duplicates were discarded.""",2020-10-25,2020-12-26,Residual sera,All,Multiple groups,5.0,99.0,Primary Estimate,,2147,0.128,0.106,0.152,True,True,True,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,TotalAntibody,Spike,Validated by developers,0.897,0.993,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cesar Lopez,University of North Carolina,Not Unity-Aligned,https://dx.doi.org/10.1128/msphere.00841-21,2022-06-07,2022-07-16,Unverified,lopez_ethnoracial_2022,USA
220519_NorthCarolina_UniversityOfNorthCarolina_4OctDec_Sex_Male,220519_NorthCarolina_UniversityOfNorthCarolina_4OctDec,Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020,2022-05-19,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Remnant plasma and serum samples were collected from four hospital-based clinical laboratories affiliated with the University of North Carolina (UNC) Health system (Table S1). These laboratories receive and process clinical samples from inpatient units as well as outpatient clinics in central NC. Each week, laboratory staff at each location, who were unaware of the patient’s clinical status or hospitalization/visit details, selected up to 300 remnant samples belonging to individuals 5 to 99 years of age.""","""study duplicates were discarded.""",2020-10-25,2020-12-26,Residual sera,Male,Multiple groups,5.0,99.0,Sex/Gender,,871,0.125,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,TotalAntibody,Spike,Validated by developers,0.897,0.993,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cesar Lopez,University of North Carolina,Not Unity-Aligned,https://dx.doi.org/10.1128/msphere.00841-21,2022-06-08,2022-07-16,Unverified,lopez_ethnoracial_2022,USA
220519_NorthCarolina_UniversityOfNorthCarolina_4OctDec_UnAdj,220519_NorthCarolina_UniversityOfNorthCarolina_4OctDec,Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020,2022-05-19,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Remnant plasma and serum samples were collected from four hospital-based clinical laboratories affiliated with the University of North Carolina (UNC) Health system (Table S1). These laboratories receive and process clinical samples from inpatient units as well as outpatient clinics in central NC. Each week, laboratory staff at each location, who were unaware of the patient’s clinical status or hospitalization/visit details, selected up to 300 remnant samples belonging to individuals 5 to 99 years of age.""","""study duplicates were discarded.""",2020-10-25,2020-12-26,Residual sera,All,Multiple groups,5.0,99.0,Analysis,,2147,0.139,,,,,,,True,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,TotalAntibody,Spike,Validated by developers,0.897,0.993,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cesar Lopez,University of North Carolina,Not Unity-Aligned,https://dx.doi.org/10.1128/msphere.00841-21,2022-06-08,2022-07-16,Unverified,lopez_ethnoracial_2022,USA
220519_NorthCarolina_UniversityOfNorthCarolina_4OctDec_Sex_Female,220519_NorthCarolina_UniversityOfNorthCarolina_4OctDec,Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020,2022-05-19,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Remnant plasma and serum samples were collected from four hospital-based clinical laboratories affiliated with the University of North Carolina (UNC) Health system (Table S1). These laboratories receive and process clinical samples from inpatient units as well as outpatient clinics in central NC. Each week, laboratory staff at each location, who were unaware of the patient’s clinical status or hospitalization/visit details, selected up to 300 remnant samples belonging to individuals 5 to 99 years of age.""","""study duplicates were discarded.""",2020-10-25,2020-12-26,Residual sera,Female,Multiple groups,5.0,99.0,Sex/Gender,,1276,0.149,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,TotalAntibody,Spike,Validated by developers,0.897,0.993,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cesar Lopez,University of North Carolina,Not Unity-Aligned,https://dx.doi.org/10.1128/msphere.00841-21,2022-06-08,2022-07-16,Unverified,lopez_ethnoracial_2022,USA
220519_NorthCarolina_UniversityOfNorthCarolina_4OctDec_Age_65-99,220519_NorthCarolina_UniversityOfNorthCarolina_4OctDec,Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020,2022-05-19,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Remnant plasma and serum samples were collected from four hospital-based clinical laboratories affiliated with the University of North Carolina (UNC) Health system (Table S1). These laboratories receive and process clinical samples from inpatient units as well as outpatient clinics in central NC. Each week, laboratory staff at each location, who were unaware of the patient’s clinical status or hospitalization/visit details, selected up to 300 remnant samples belonging to individuals 5 to 99 years of age.""","""study duplicates were discarded.""",2020-10-25,2020-12-26,Residual sera,All,Seniors (65+ years),65.0,99.0,Age,Age: 65-99,657,0.13699999999999998,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,TotalAntibody,Spike,Validated by developers,0.897,0.993,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cesar Lopez,University of North Carolina,Not Unity-Aligned,https://dx.doi.org/10.1128/msphere.00841-21,2022-06-08,2022-07-16,Unverified,lopez_ethnoracial_2022,USA
220519_NorthCarolina_UniversityOfNorthCarolina_4OctDec_Age_50-64,220519_NorthCarolina_UniversityOfNorthCarolina_4OctDec,Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020,2022-05-19,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Remnant plasma and serum samples were collected from four hospital-based clinical laboratories affiliated with the University of North Carolina (UNC) Health system (Table S1). These laboratories receive and process clinical samples from inpatient units as well as outpatient clinics in central NC. Each week, laboratory staff at each location, who were unaware of the patient’s clinical status or hospitalization/visit details, selected up to 300 remnant samples belonging to individuals 5 to 99 years of age.""","""study duplicates were discarded.""",2020-10-25,2020-12-26,Residual sera,All,Adults (18-64 years),50.0,64.0,Age,Age: 50-64,568,0.127,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,TotalAntibody,Spike,Validated by developers,0.897,0.993,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cesar Lopez,University of North Carolina,Not Unity-Aligned,https://dx.doi.org/10.1128/msphere.00841-21,2022-06-08,2022-07-16,Unverified,lopez_ethnoracial_2022,USA
220519_NorthCarolina_UniversityOfNorthCarolina_4OctDec_Age_5-17,220519_NorthCarolina_UniversityOfNorthCarolina_4OctDec,Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020,2022-05-19,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Remnant plasma and serum samples were collected from four hospital-based clinical laboratories affiliated with the University of North Carolina (UNC) Health system (Table S1). These laboratories receive and process clinical samples from inpatient units as well as outpatient clinics in central NC. Each week, laboratory staff at each location, who were unaware of the patient’s clinical status or hospitalization/visit details, selected up to 300 remnant samples belonging to individuals 5 to 99 years of age.""","""study duplicates were discarded.""",2020-10-25,2020-12-26,Residual sera,All,Children and Youth (0-17 years),5.0,17.0,Age,Age: 5-17,166,0.121,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,TotalAntibody,Spike,Validated by developers,0.897,0.993,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cesar Lopez,University of North Carolina,Not Unity-Aligned,https://dx.doi.org/10.1128/msphere.00841-21,2022-06-08,2022-07-16,Unverified,lopez_ethnoracial_2022,USA
220519_NorthCarolina_UniversityOfNorthCarolina_4OctDec_Age_18-49,220519_NorthCarolina_UniversityOfNorthCarolina_4OctDec,Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020,2022-05-19,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Carolina,,"""Remnant plasma and serum samples were collected from four hospital-based clinical laboratories affiliated with the University of North Carolina (UNC) Health system (Table S1). These laboratories receive and process clinical samples from inpatient units as well as outpatient clinics in central NC. Each week, laboratory staff at each location, who were unaware of the patient’s clinical status or hospitalization/visit details, selected up to 300 remnant samples belonging to individuals 5 to 99 years of age.""","""study duplicates were discarded.""",2020-10-25,2020-12-26,Residual sera,All,Adults (18-64 years),18.0,49.0,Age,Age: 18-49,756,0.155,,,,,,,,Sequential,Author designed (ELISA) -Spike,,ELISA,Multiple Types,TotalAntibody,Spike,Validated by developers,0.897,0.993,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Cesar Lopez,University of North Carolina,Not Unity-Aligned,https://dx.doi.org/10.1128/msphere.00841-21,2022-06-08,2022-07-16,Unverified,lopez_ethnoracial_2022,USA
220521_PennsylvaniaStateUniversity_UniversityPark,220521_PennsylvaniaStateUniversity_UniversityPark,A longitudinal study of the impact of university student return to campus on the SARS-CoV-2 seroprevalence among the community members.,2022-05-21,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Pennsylvania,University Park,"Individuals were eligible for participation in the community resident cohort if they were: ≥ 18 years old, residing in Centre County at the time of recruitment (June through September 2020); expecting to reside in Centre County until June 2021; fuent in English; and capable of providing their own consent. PSU students who remained in Centre County through spring and summer university closure were eligible for inclusion in the community resident cohort as they experienced similar geographic COVID-19 risks as community residents",,2020-08-07,2020-10-02,Students and Daycares,All,Multiple groups,19.0,99.0,Primary Estimate,,1313,0.032,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Callum Arnold,Pennsylvania State University,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-12499-5,2022-05-31,2022-07-16,Unverified,arnold_longitudinal_2022,USA
220527_US_CityUniversityOfNewYork_Period1_Overall_TestAdj,220527_US_CityUniversityOfNewYork_Period1,"SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults.",2022-05-27,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,All 50 US states; the District of Columbia; Puerto Rico; Guam.,,"""To be eligible for inclusion in the cohort, individuals had to: 1) reside in the U.S. or a U.S. territory; 2) be >18 years old; 3) provide a valid email address; and 4) demonstrate early engagement in study activities (provide baseline specimen or complete of >1 recruitment/enrollment visit).""",,2020-05-15,2020-09-15,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,Test-adjusted,4232,0.022000000000000002,0.017,0.027999999999999997,True,True,,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.917,0.988,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Denis Nash,City University of New York,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac423,2022-06-08,2023-08-15,Unverified,nash_sars-cov-2_2022,USA
220527_US_CityUniversityOfNewYork_Period1_Region_USTerritories,220527_US_CityUniversityOfNewYork_Period1,"SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults.",2022-05-27,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,All 50 US states; the District of Columbia; Puerto Rico; Guam.,,"""To be eligible for inclusion in the cohort, individuals had to: 1) reside in the U.S. or a U.S. territory; 2) be >18 years old; 3) provide a valid email address; and 4) demonstrate early engagement in study activities (provide baseline specimen or complete of >1 recruitment/enrollment visit).""",,2020-05-15,2020-09-15,Household and community samples,All,Multiple groups,18.0,,Geographical area,Geographic region: US Territories,5,0.0,0.0,0.537,,,,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.917,0.988,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Denis Nash,City University of New York,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac423,2022-06-09,2024-03-01,Unverified,nash_sars-cov-2_2022,USA
220527_US_CityUniversityOfNewYork_Period1_Sex_Female,220527_US_CityUniversityOfNewYork_Period1,"SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults.",2022-05-27,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,All 50 US states; the District of Columbia; Puerto Rico; Guam.,,"""To be eligible for inclusion in the cohort, individuals had to: 1) reside in the U.S. or a U.S. territory; 2) be >18 years old; 3) provide a valid email address; and 4) demonstrate early engagement in study activities (provide baseline specimen or complete of >1 recruitment/enrollment visit).""",,2020-05-15,2020-09-15,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,Sex: Female,2211,0.025,0.018000000000000002,0.031000000000000003,,,,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.917,0.988,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Denis Nash,City University of New York,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac423,2022-06-09,2024-03-01,Unverified,nash_sars-cov-2_2022,USA
220527_US_CityUniversityOfNewYork_Period1_Sex_Male,220527_US_CityUniversityOfNewYork_Period1,"SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults.",2022-05-27,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,All 50 US states; the District of Columbia; Puerto Rico; Guam.,,"""To be eligible for inclusion in the cohort, individuals had to: 1) reside in the U.S. or a U.S. territory; 2) be >18 years old; 3) provide a valid email address; and 4) demonstrate early engagement in study activities (provide baseline specimen or complete of >1 recruitment/enrollment visit).""",,2020-05-15,2020-09-15,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,Sex: Male,1898,0.042,0.033,0.051,,,,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.917,0.988,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Denis Nash,City University of New York,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac423,2022-06-09,2024-03-01,Unverified,nash_sars-cov-2_2022,USA
220527_US_CityUniversityOfNewYork_Period1_Region_Midwest,220527_US_CityUniversityOfNewYork_Period1,"SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults.",2022-05-27,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,All 50 US states; the District of Columbia; Puerto Rico; Guam.,,"""To be eligible for inclusion in the cohort, individuals had to: 1) reside in the U.S. or a U.S. territory; 2) be >18 years old; 3) provide a valid email address; and 4) demonstrate early engagement in study activities (provide baseline specimen or complete of >1 recruitment/enrollment visit).""",,2020-05-15,2020-09-15,Household and community samples,All,Multiple groups,18.0,,Geographical area,Geographic region: Midwest,763,0.021,0.011000000000000001,0.031000000000000003,,,,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.917,0.988,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Denis Nash,City University of New York,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac423,2022-06-09,2024-03-01,Unverified,nash_sars-cov-2_2022,USA
220527_US_CityUniversityOfNewYork_Period1_Region_Northeast,220527_US_CityUniversityOfNewYork_Period1,"SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults.",2022-05-27,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,All 50 US states; the District of Columbia; Puerto Rico; Guam.,,"""To be eligible for inclusion in the cohort, individuals had to: 1) reside in the U.S. or a U.S. territory; 2) be >18 years old; 3) provide a valid email address; and 4) demonstrate early engagement in study activities (provide baseline specimen or complete of >1 recruitment/enrollment visit).""",,2020-05-15,2020-09-15,Household and community samples,All,Multiple groups,18.0,,Geographical area,Geographic region: Northeast,1253,0.057999999999999996,0.045,0.071,,,,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.917,0.988,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Denis Nash,City University of New York,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac423,2022-06-09,2024-03-01,Unverified,nash_sars-cov-2_2022,USA
220527_US_CityUniversityOfNewYork_Period1_Age_40-49,220527_US_CityUniversityOfNewYork_Period1,"SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults.",2022-05-27,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,All 50 US states; the District of Columbia; Puerto Rico; Guam.,,"""To be eligible for inclusion in the cohort, individuals had to: 1) reside in the U.S. or a U.S. territory; 2) be >18 years old; 3) provide a valid email address; and 4) demonstrate early engagement in study activities (provide baseline specimen or complete of >1 recruitment/enrollment visit).""",,2020-05-15,2020-09-15,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,Age: 40-49,812,0.033,0.023,0.046,,,,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.917,0.988,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Denis Nash,City University of New York,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac423,2022-06-09,2024-03-01,Unverified,nash_sars-cov-2_2022,USA
220527_US_CityUniversityOfNewYork_Period1_Region_West,220527_US_CityUniversityOfNewYork_Period1,"SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults.",2022-05-27,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,All 50 US states; the District of Columbia; Puerto Rico; Guam.,,"""To be eligible for inclusion in the cohort, individuals had to: 1) reside in the U.S. or a U.S. territory; 2) be >18 years old; 3) provide a valid email address; and 4) demonstrate early engagement in study activities (provide baseline specimen or complete of >1 recruitment/enrollment visit).""",,2020-05-15,2020-09-15,Household and community samples,All,Multiple groups,18.0,,Geographical area,Geographic region: West,1043,0.013999999999999999,0.006999999999999999,0.022000000000000002,,,,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.917,0.988,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Denis Nash,City University of New York,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac423,2022-06-09,2024-03-01,Unverified,nash_sars-cov-2_2022,USA
220527_US_CityUniversityOfNewYork_Period1_Age_30-39,220527_US_CityUniversityOfNewYork_Period1,"SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults.",2022-05-27,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,All 50 US states; the District of Columbia; Puerto Rico; Guam.,,"""To be eligible for inclusion in the cohort, individuals had to: 1) reside in the U.S. or a U.S. territory; 2) be >18 years old; 3) provide a valid email address; and 4) demonstrate early engagement in study activities (provide baseline specimen or complete of >1 recruitment/enrollment visit).""",,2020-05-15,2020-09-15,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,Age: 30-39,1171,0.039,0.027999999999999997,0.05,,,,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.917,0.988,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Denis Nash,City University of New York,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac423,2022-06-09,2024-03-01,Unverified,nash_sars-cov-2_2022,USA
220527_US_CityUniversityOfNewYork_Period1_Age_18-29,220527_US_CityUniversityOfNewYork_Period1,"SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults.",2022-05-27,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,All 50 US states; the District of Columbia; Puerto Rico; Guam.,,"""To be eligible for inclusion in the cohort, individuals had to: 1) reside in the U.S. or a U.S. territory; 2) be >18 years old; 3) provide a valid email address; and 4) demonstrate early engagement in study activities (provide baseline specimen or complete of >1 recruitment/enrollment visit).""",,2020-05-15,2020-09-15,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,Age: 18-29,800,0.035,0.022000000000000002,0.048,,,,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.917,0.988,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Denis Nash,City University of New York,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac423,2022-06-09,2024-03-01,Unverified,nash_sars-cov-2_2022,USA
220527_US_CityUniversityOfNewYork_Period1_Age_50-59,220527_US_CityUniversityOfNewYork_Period1,"SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults.",2022-05-27,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,All 50 US states; the District of Columbia; Puerto Rico; Guam.,,"""To be eligible for inclusion in the cohort, individuals had to: 1) reside in the U.S. or a U.S. territory; 2) be >18 years old; 3) provide a valid email address; and 4) demonstrate early engagement in study activities (provide baseline specimen or complete of >1 recruitment/enrollment visit).""",,2020-05-15,2020-09-15,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,Age: 50-59,620,0.034,0.02,0.048,,,,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.917,0.988,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Denis Nash,City University of New York,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac423,2022-06-09,2024-03-01,Unverified,nash_sars-cov-2_2022,USA
220527_US_CityUniversityOfNewYork_Period1_Sex_NonBinaryTransgender,220527_US_CityUniversityOfNewYork_Period1,"SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults.",2022-05-27,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,All 50 US states; the District of Columbia; Puerto Rico; Guam.,,"""To be eligible for inclusion in the cohort, individuals had to: 1) reside in the U.S. or a U.S. territory; 2) be >18 years old; 3) provide a valid email address; and 4) demonstrate early engagement in study activities (provide baseline specimen or complete of >1 recruitment/enrollment visit).""",,2020-05-15,2020-09-15,Household and community samples,Other,Multiple groups,18.0,,Sex/Gender,Sex: Non-Binary/Transgender,123,0.008,0.0,0.024,,,,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.917,0.988,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Denis Nash,City University of New York,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac423,2022-06-09,2024-03-01,Unverified,nash_sars-cov-2_2022,USA
220527_US_CityUniversityOfNewYork_Period1_Region_South,220527_US_CityUniversityOfNewYork_Period1,"SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults.",2022-05-27,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,All 50 US states; the District of Columbia; Puerto Rico; Guam.,,"""To be eligible for inclusion in the cohort, individuals had to: 1) reside in the U.S. or a U.S. territory; 2) be >18 years old; 3) provide a valid email address; and 4) demonstrate early engagement in study activities (provide baseline specimen or complete of >1 recruitment/enrollment visit).""",,2020-05-15,2020-09-15,Household and community samples,All,Multiple groups,18.0,,Geographical area,Geographic region: South,1168,0.027000000000000003,0.017,0.036000000000000004,,,,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.917,0.988,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Denis Nash,City University of New York,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac423,2022-06-09,2024-03-01,Unverified,nash_sars-cov-2_2022,USA
220527_US_CityUniversityOfNewYork_Period1_Overall_UnAdj,220527_US_CityUniversityOfNewYork_Period1,"SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults.",2022-05-27,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,All 50 US states; the District of Columbia; Puerto Rico; Guam.,,"""To be eligible for inclusion in the cohort, individuals had to: 1) reside in the U.S. or a U.S. territory; 2) be >18 years old; 3) provide a valid email address; and 4) demonstrate early engagement in study activities (provide baseline specimen or complete of >1 recruitment/enrollment visit).""",,2020-05-15,2020-09-15,Household and community samples,All,Multiple groups,18.0,,Analysis,Unadjusted,4232,0.032,0.027000000000000003,0.037000000000000005,,,,,True,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.917,0.988,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Denis Nash,City University of New York,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac423,2022-06-09,2024-03-01,Unverified,nash_sars-cov-2_2022,USA
220527_US_CityUniversityOfNewYork_Period1_Age_>=60,220527_US_CityUniversityOfNewYork_Period1,"SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults.",2022-05-27,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,All 50 US states; the District of Columbia; Puerto Rico; Guam.,,"""To be eligible for inclusion in the cohort, individuals had to: 1) reside in the U.S. or a U.S. territory; 2) be >18 years old; 3) provide a valid email address; and 4) demonstrate early engagement in study activities (provide baseline specimen or complete of >1 recruitment/enrollment visit).""",,2020-05-15,2020-09-15,Household and community samples,All,Seniors (65+ years),60.0,,Age,Age: ≥ 60,829,0.016,0.006999999999999999,0.024,,,,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.917,0.988,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Denis Nash,City University of New York,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac423,2022-06-09,2024-03-01,Unverified,nash_sars-cov-2_2022,USA
220527_US_CityUniversityOfNewYork_Period2_Overall_UnAdj,220527_US_CityUniversityOfNewYork_Period2,"SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults.",2022-05-27,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,All 50 US states; the District of Columbia; Puerto Rico; Guam.,,"""To be eligible for inclusion in the cohort, individuals had to: 1) reside in the U.S. or a U.S. territory; 2) be >18 years old; 3) provide a valid email address; and 4) demonstrate early engagement in study activities (provide baseline specimen or complete of >1 recruitment/enrollment visit).""",,2020-11-15,2021-01-15,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,Unadjusted,3883,0.0737,,,True,,,,True,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.917,0.988,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Denis Nash,City University of New York,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac423,2022-06-09,2024-03-01,Unverified,nash_sars-cov-2_2022,USA
220527_US_CityUniversityOfNewYork_Period2_Sex_Female,220527_US_CityUniversityOfNewYork_Period2,"SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults.",2022-05-27,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,All 50 US states; the District of Columbia; Puerto Rico; Guam.,,"""To be eligible for inclusion in the cohort, individuals had to: 1) reside in the U.S. or a U.S. territory; 2) be >18 years old; 3) provide a valid email address; and 4) demonstrate early engagement in study activities (provide baseline specimen or complete of >1 recruitment/enrollment visit).""",,2020-11-15,2021-01-15,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,Sex: Female,2038,0.0638,,,,,,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.917,0.988,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Denis Nash,City University of New York,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac423,2022-06-09,2024-03-01,Unverified,nash_sars-cov-2_2022,USA
220527_US_CityUniversityOfNewYork_Period2_Region_South,220527_US_CityUniversityOfNewYork_Period2,"SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults.",2022-05-27,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,All 50 US states; the District of Columbia; Puerto Rico; Guam.,,"""To be eligible for inclusion in the cohort, individuals had to: 1) reside in the U.S. or a U.S. territory; 2) be >18 years old; 3) provide a valid email address; and 4) demonstrate early engagement in study activities (provide baseline specimen or complete of >1 recruitment/enrollment visit).""",,2020-11-15,2021-01-15,Household and community samples,All,Multiple groups,18.0,,Geographical area,Geographic region: South,1102,0.07440000000000001,,,,,,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.917,0.988,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Denis Nash,City University of New York,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac423,2022-06-09,2024-03-01,Unverified,nash_sars-cov-2_2022,USA
220527_US_CityUniversityOfNewYork_Period2_Region_USTerritories,220527_US_CityUniversityOfNewYork_Period2,"SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults.",2022-05-27,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,All 50 US states; the District of Columbia; Puerto Rico; Guam.,,"""To be eligible for inclusion in the cohort, individuals had to: 1) reside in the U.S. or a U.S. territory; 2) be >18 years old; 3) provide a valid email address; and 4) demonstrate early engagement in study activities (provide baseline specimen or complete of >1 recruitment/enrollment visit).""",,2020-11-15,2021-01-15,Household and community samples,All,Multiple groups,18.0,,Geographical area,Geographic region: US Territories,4,0.0,,,,,,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.917,0.988,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Denis Nash,City University of New York,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac423,2022-06-09,2024-03-01,Unverified,nash_sars-cov-2_2022,USA
220527_US_CityUniversityOfNewYork_Period2_Age_18-29,220527_US_CityUniversityOfNewYork_Period2,"SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults.",2022-05-27,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,All 50 US states; the District of Columbia; Puerto Rico; Guam.,,"""To be eligible for inclusion in the cohort, individuals had to: 1) reside in the U.S. or a U.S. territory; 2) be >18 years old; 3) provide a valid email address; and 4) demonstrate early engagement in study activities (provide baseline specimen or complete of >1 recruitment/enrollment visit).""",,2020-11-15,2021-01-15,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,Age: 18-29,722,0.0859,,,,,,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.917,0.988,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Denis Nash,City University of New York,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac423,2022-06-09,2024-03-01,Unverified,nash_sars-cov-2_2022,USA
220527_US_CityUniversityOfNewYork_Period2_Age_50-59,220527_US_CityUniversityOfNewYork_Period2,"SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults.",2022-05-27,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,All 50 US states; the District of Columbia; Puerto Rico; Guam.,,"""To be eligible for inclusion in the cohort, individuals had to: 1) reside in the U.S. or a U.S. territory; 2) be >18 years old; 3) provide a valid email address; and 4) demonstrate early engagement in study activities (provide baseline specimen or complete of >1 recruitment/enrollment visit).""",,2020-11-15,2021-01-15,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,Age: 50-59,582,0.0825,,,,,,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.917,0.988,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Denis Nash,City University of New York,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac423,2022-06-09,2024-03-01,Unverified,nash_sars-cov-2_2022,USA
220527_US_CityUniversityOfNewYork_Period2_Region_West,220527_US_CityUniversityOfNewYork_Period2,"SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults.",2022-05-27,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,All 50 US states; the District of Columbia; Puerto Rico; Guam.,,"""To be eligible for inclusion in the cohort, individuals had to: 1) reside in the U.S. or a U.S. territory; 2) be >18 years old; 3) provide a valid email address; and 4) demonstrate early engagement in study activities (provide baseline specimen or complete of >1 recruitment/enrollment visit).""",,2020-11-15,2021-01-15,Household and community samples,All,Multiple groups,18.0,,Geographical area,Geographic region: West,954,0.0608,,,,,,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.917,0.988,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Denis Nash,City University of New York,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac423,2022-06-09,2024-03-01,Unverified,nash_sars-cov-2_2022,USA
220527_US_CityUniversityOfNewYork_Period2_Sex_Male,220527_US_CityUniversityOfNewYork_Period2,"SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults.",2022-05-27,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,All 50 US states; the District of Columbia; Puerto Rico; Guam.,,"""To be eligible for inclusion in the cohort, individuals had to: 1) reside in the U.S. or a U.S. territory; 2) be >18 years old; 3) provide a valid email address; and 4) demonstrate early engagement in study activities (provide baseline specimen or complete of >1 recruitment/enrollment visit).""",,2020-11-15,2021-01-15,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,Sex: Male,1738,0.08689999999999999,,,,,,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.917,0.988,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Denis Nash,City University of New York,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac423,2022-06-09,2024-03-01,Unverified,nash_sars-cov-2_2022,USA
220527_US_CityUniversityOfNewYork_Period2_Age_>=60,220527_US_CityUniversityOfNewYork_Period2,"SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults.",2022-05-27,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,All 50 US states; the District of Columbia; Puerto Rico; Guam.,,"""To be eligible for inclusion in the cohort, individuals had to: 1) reside in the U.S. or a U.S. territory; 2) be >18 years old; 3) provide a valid email address; and 4) demonstrate early engagement in study activities (provide baseline specimen or complete of >1 recruitment/enrollment visit).""",,2020-11-15,2021-01-15,Household and community samples,All,Seniors (65+ years),60.0,,Age,Age: ≥ 60,767,0.0495,,,,,,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.917,0.988,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Denis Nash,City University of New York,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac423,2022-06-09,2024-03-01,Unverified,nash_sars-cov-2_2022,USA
220527_US_CityUniversityOfNewYork_Period2_Sex_NonBinaryTransgender,220527_US_CityUniversityOfNewYork_Period2,"SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults.",2022-05-27,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,All 50 US states; the District of Columbia; Puerto Rico; Guam.,,"""To be eligible for inclusion in the cohort, individuals had to: 1) reside in the U.S. or a U.S. territory; 2) be >18 years old; 3) provide a valid email address; and 4) demonstrate early engagement in study activities (provide baseline specimen or complete of >1 recruitment/enrollment visit).""",,2020-11-15,2021-01-15,Household and community samples,Other,Multiple groups,18.0,,Sex/Gender,Sex: Non-Binary/Transgender,107,0.0467,,,,,,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.917,0.988,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Denis Nash,City University of New York,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac423,2022-06-09,2024-03-01,Unverified,nash_sars-cov-2_2022,USA
220527_US_CityUniversityOfNewYork_Period2_Region_Midwest,220527_US_CityUniversityOfNewYork_Period2,"SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults.",2022-05-27,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,All 50 US states; the District of Columbia; Puerto Rico; Guam.,,"""To be eligible for inclusion in the cohort, individuals had to: 1) reside in the U.S. or a U.S. territory; 2) be >18 years old; 3) provide a valid email address; and 4) demonstrate early engagement in study activities (provide baseline specimen or complete of >1 recruitment/enrollment visit).""",,2020-11-15,2021-01-15,Household and community samples,All,Multiple groups,18.0,,Geographical area,Geographic region: Midwest,699,0.0758,,,,,,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.917,0.988,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Denis Nash,City University of New York,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac423,2022-06-09,2024-03-01,Unverified,nash_sars-cov-2_2022,USA
220527_US_CityUniversityOfNewYork_Period2_Region_Northeast,220527_US_CityUniversityOfNewYork_Period2,"SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults.",2022-05-27,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,All 50 US states; the District of Columbia; Puerto Rico; Guam.,,"""To be eligible for inclusion in the cohort, individuals had to: 1) reside in the U.S. or a U.S. territory; 2) be >18 years old; 3) provide a valid email address; and 4) demonstrate early engagement in study activities (provide baseline specimen or complete of >1 recruitment/enrollment visit).""",,2020-11-15,2021-01-15,Household and community samples,All,Multiple groups,18.0,,Geographical area,Geographic region: Northeast,1124,0.0827,,,,,,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.917,0.988,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Denis Nash,City University of New York,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac423,2022-06-09,2024-03-01,Unverified,nash_sars-cov-2_2022,USA
220527_US_CityUniversityOfNewYork_Period2_Age_40-49,220527_US_CityUniversityOfNewYork_Period2,"SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults.",2022-05-27,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,All 50 US states; the District of Columbia; Puerto Rico; Guam.,,"""To be eligible for inclusion in the cohort, individuals had to: 1) reside in the U.S. or a U.S. territory; 2) be >18 years old; 3) provide a valid email address; and 4) demonstrate early engagement in study activities (provide baseline specimen or complete of >1 recruitment/enrollment visit).""",,2020-11-15,2021-01-15,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,Age: 40-49,738,0.06910000000000001,,,,,,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.917,0.988,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Denis Nash,City University of New York,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac423,2022-06-09,2024-03-01,Unverified,nash_sars-cov-2_2022,USA
220527_US_CityUniversityOfNewYork_Period2_Age_30-39,220527_US_CityUniversityOfNewYork_Period2,"SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults.",2022-05-27,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,All 50 US states; the District of Columbia; Puerto Rico; Guam.,,"""To be eligible for inclusion in the cohort, individuals had to: 1) reside in the U.S. or a U.S. territory; 2) be >18 years old; 3) provide a valid email address; and 4) demonstrate early engagement in study activities (provide baseline specimen or complete of >1 recruitment/enrollment visit).""",,2020-11-15,2021-01-15,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,Age: 30-39,1074,0.081,,,,,,,,Convenience,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Dried Blood,"['IgA', 'IgG', 'IgM']",Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.917,0.988,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Denis Nash,City University of New York,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac423,2022-06-09,2024-03-01,Unverified,nash_sars-cov-2_2022,USA
220530_UnitedStates_NYUGrossmanSchoolofMedicine_Overall,220530_UnitedStates_NYUGrossmanSchoolofMedicine,Research Letter: Incidence of SARS-CoV-2 infection among unvaccinated US adults during the Omicron wave,2022-05-30,Preprint,National,Prospective cohort,United States of America,,,Self-described healthy adults who reported never receiving a SARS-CoV-2 vaccine,COVID 19 vaccination,2021-09-23,2021-11-05,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,,546,0.601,,,True,,,,True,Unclear,Author designed (type unknown),,,,,Spike,,,,['High'],,Unclear,No,Yes,,Unclear,Yes,No,,Jennifer Alejo,NYU Grossman School of Medicine,Not Unity-Aligned,10.1101/2022.05.27.22275630,2022-06-10,2023-01-03,Unverified,alejo_research_2022,USA
220601_Philadelphia_ChildrensHospitalofPhiladelphia_OverallCrude,220601_Philadelphia_ChildrensHospitalofPhiladelphia,Neighborhood Characteristics and Racial Disparities in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Seropositivity in Pregnancy.,2022-06-01,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,,Philadelphia,"Patients who gave birth from April 13, 2020, to December 31, 2020, in two hospitals in Philadelphia, Pennsylvania, that combined account for approximately 9,000 births annually, were eligible for this study.",,2020-04-13,2020-12-31,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,5991,0.09380000000000001,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,No,Yes,Unclear,Yes,Yes,Yes,Heather Burris,Children's Hospital of Philadelphia,Unity-Aligned,https://dx.doi.org/10.1097/AOG.0000000000004791,2022-06-19,2022-07-16,Unverified,burris_neighborhood_2022,USA
220601_Philadelphia_ChildrensHospitalofPhiladelphia_Age25-34,220601_Philadelphia_ChildrensHospitalofPhiladelphia,Neighborhood Characteristics and Racial Disparities in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Seropositivity in Pregnancy.,2022-06-01,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,,Philadelphia,"Patients who gave birth from April 13, 2020, to December 31, 2020, in two hospitals in Philadelphia, Pennsylvania, that combined account for approximately 9,000 births annually, were eligible for this study.",,2020-04-13,2020-12-31,Pregnant or parturient women,Female,Adults (18-64 years),25.0,34.0,Age,25-34,3459,0.09140000000000001,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,No,Yes,Unclear,Yes,Yes,Yes,Heather Burris,Children's Hospital of Philadelphia,Unity-Aligned,https://dx.doi.org/10.1097/AOG.0000000000004791,2022-06-19,2022-07-16,Unverified,burris_neighborhood_2022,USA
220601_Philadelphia_ChildrensHospitalofPhiladelphia_Age35+,220601_Philadelphia_ChildrensHospitalofPhiladelphia,Neighborhood Characteristics and Racial Disparities in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Seropositivity in Pregnancy.,2022-06-01,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,,Philadelphia,"Patients who gave birth from April 13, 2020, to December 31, 2020, in two hospitals in Philadelphia, Pennsylvania, that combined account for approximately 9,000 births annually, were eligible for this study.",,2020-04-13,2020-12-31,Pregnant or parturient women,Female,Adults (18-64 years),35.0,,Age,35+,1472,0.057699999999999994,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,No,Yes,Unclear,Yes,Yes,Yes,Heather Burris,Children's Hospital of Philadelphia,Unity-Aligned,https://dx.doi.org/10.1097/AOG.0000000000004791,2022-06-19,2022-07-16,Unverified,burris_neighborhood_2022,USA
220601_Philadelphia_ChildrensHospitalofPhiladelphia_Age<=24,220601_Philadelphia_ChildrensHospitalofPhiladelphia,Neighborhood Characteristics and Racial Disparities in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Seropositivity in Pregnancy.,2022-06-01,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,,Philadelphia,"Patients who gave birth from April 13, 2020, to December 31, 2020, in two hospitals in Philadelphia, Pennsylvania, that combined account for approximately 9,000 births annually, were eligible for this study.",,2020-04-13,2020-12-31,Pregnant or parturient women,Female,Adults (18-64 years),,24.0,Age,<=24,1060,0.1519,,,,,,,,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by independent authors/third party/non-developers,1.0,0.9890000000000001,['Moderate'],Yes,No,Yes,No,Yes,Unclear,Yes,Yes,Yes,Heather Burris,Children's Hospital of Philadelphia,Unity-Aligned,https://dx.doi.org/10.1097/AOG.0000000000004791,2022-06-19,2022-07-16,Unverified,burris_neighborhood_2022,USA
220601_Colorado_UniversityOfColoradoDenver_Primary,220601_Colorado_UniversityOfColoradoDenver,SARS-CoV-2 Infection Is Not Associated with Presence of Islet Autoantibodies in Children: Autoimmunity Screening for Kids (ASK),2022-06-01,Presentation or Conference,Regional,Cross-sectional survey ,United States of America,Colorado,,general population Colorado children aged 1-17 years,vaccinated children were excluded from analysis,2020-08-15,2021-12-15,Blood donors,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,,4172,0.311,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,,Spike,,,,['High'],,Unclear,Yes,No,,Unclear,Yes,No,,CRISTY GENO RASMUSSEN,University of Colorado Denver,Not Unity-Aligned,https://dx.doi.org/10.2337/db22-34-OR,2022-08-16,2022-08-26,Unverified,rasmussen_sars-cov-2_2022,USA
220602_NewYork_UniversityofNewYork_Phase1_Overall,220602_NewYork_UniversityofNewYork_Phase1,SARS-CoV-2 pandemic in New York metropolitan area: The view from a major urgent care provider,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"study includes patients who received a COVID-19  serologic test at CityMD sites in the New York metropolitan area (NYC, Long Island and Westchester).",,2020-03-01,2021-03-04,Residual sera,All,Multiple groups,,,Primary Estimate,,699792,0.2188,,,True,,,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9990000000000001,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Madhura S. Rane,University of New York,Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2022.05.006,2022-06-23,2024-03-01,Unverified,rane_sars-cov-2_2022,USA
220602_NewYork_UniversityofNewYork_Phase1_Age_60-69,220602_NewYork_UniversityofNewYork_Phase1,SARS-CoV-2 pandemic in New York metropolitan area: The view from a major urgent care provider,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"study includes patients who received a COVID-19  serologic test at CityMD sites in the New York metropolitan area (NYC, Long Island and Westchester).",,2020-03-01,2021-03-04,Residual sera,All,Multiple groups,60.0,69.0,Age,60-69,78170,0.24559999999999998,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9990000000000001,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Madhura S. Rane,University of New York,Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2022.05.006,2022-06-24,2024-03-01,Unverified,rane_sars-cov-2_2022,USA
220602_NewYork_UniversityofNewYork_Phase1_Age_10-14,220602_NewYork_UniversityofNewYork_Phase1,SARS-CoV-2 pandemic in New York metropolitan area: The view from a major urgent care provider,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"study includes patients who received a COVID-19  serologic test at CityMD sites in the New York metropolitan area (NYC, Long Island and Westchester).",,2020-03-01,2021-03-04,Residual sera,All,Children and Youth (0-17 years),10.0,14.0,Age,10-14,10743,0.277,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9990000000000001,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Madhura S. Rane,University of New York,Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2022.05.006,2022-06-24,2024-03-01,Unverified,rane_sars-cov-2_2022,USA
220602_NewYork_UniversityofNewYork_Phase1_Female,220602_NewYork_UniversityofNewYork_Phase1,SARS-CoV-2 pandemic in New York metropolitan area: The view from a major urgent care provider,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"study includes patients who received a COVID-19  serologic test at CityMD sites in the New York metropolitan area (NYC, Long Island and Westchester).",,2020-03-01,2021-03-04,Residual sera,Female,Multiple groups,,,Sex/Gender,,392488,0.2136,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9990000000000001,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Madhura S. Rane,University of New York,Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2022.05.006,2022-06-23,2024-03-01,Unverified,rane_sars-cov-2_2022,USA
220602_NewYork_UniversityofNewYork_Phase1_Age_40-49,220602_NewYork_UniversityofNewYork_Phase1,SARS-CoV-2 pandemic in New York metropolitan area: The view from a major urgent care provider,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"study includes patients who received a COVID-19  serologic test at CityMD sites in the New York metropolitan area (NYC, Long Island and Westchester).",,2020-03-01,2021-03-04,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,118004,0.2377,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9990000000000001,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Madhura S. Rane,University of New York,Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2022.05.006,2022-06-24,2024-03-01,Unverified,rane_sars-cov-2_2022,USA
220602_NewYork_UniversityofNewYork_Phase1_Age_5-9,220602_NewYork_UniversityofNewYork_Phase1,SARS-CoV-2 pandemic in New York metropolitan area: The view from a major urgent care provider,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"study includes patients who received a COVID-19  serologic test at CityMD sites in the New York metropolitan area (NYC, Long Island and Westchester).",,2020-03-01,2021-03-04,Residual sera,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,2596,0.2704,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9990000000000001,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Madhura S. Rane,University of New York,Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2022.05.006,2022-06-23,2024-03-01,Unverified,rane_sars-cov-2_2022,USA
220602_NewYork_UniversityofNewYork_Phase1_Age_90-99,220602_NewYork_UniversityofNewYork_Phase1,SARS-CoV-2 pandemic in New York metropolitan area: The view from a major urgent care provider,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"study includes patients who received a COVID-19  serologic test at CityMD sites in the New York metropolitan area (NYC, Long Island and Westchester).",,2020-03-01,2021-03-04,Residual sera,All,Seniors (65+ years),90.0,99.0,Age,90-99,664,0.2154,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9990000000000001,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Madhura S. Rane,University of New York,Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2022.05.006,2022-06-24,2024-03-01,Unverified,rane_sars-cov-2_2022,USA
220602_NewYork_UniversityofNewYork_Phase1_Age_>100,220602_NewYork_UniversityofNewYork_Phase1,SARS-CoV-2 pandemic in New York metropolitan area: The view from a major urgent care provider,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"study includes patients who received a COVID-19  serologic test at CityMD sites in the New York metropolitan area (NYC, Long Island and Westchester).",,2020-03-01,2021-03-04,Residual sera,All,Seniors (65+ years),100.0,,Age,>100,1,1.0,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9990000000000001,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Madhura S. Rane,University of New York,Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2022.05.006,2022-06-24,2024-03-01,Unverified,rane_sars-cov-2_2022,USA
220602_NewYork_UniversityofNewYork_Phase1_Age_30-39,220602_NewYork_UniversityofNewYork_Phase1,SARS-CoV-2 pandemic in New York metropolitan area: The view from a major urgent care provider,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"study includes patients who received a COVID-19  serologic test at CityMD sites in the New York metropolitan area (NYC, Long Island and Westchester).",,2020-03-01,2021-03-04,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,161087,0.1936,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9990000000000001,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Madhura S. Rane,University of New York,Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2022.05.006,2022-06-24,2024-03-01,Unverified,rane_sars-cov-2_2022,USA
220602_NewYork_UniversityofNewYork_Phase1_Age_20-29,220602_NewYork_UniversityofNewYork_Phase1,SARS-CoV-2 pandemic in New York metropolitan area: The view from a major urgent care provider,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"study includes patients who received a COVID-19  serologic test at CityMD sites in the New York metropolitan area (NYC, Long Island and Westchester).",,2020-03-01,2021-03-04,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29,147242,0.1841,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9990000000000001,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Madhura S. Rane,University of New York,Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2022.05.006,2022-06-24,2024-03-01,Unverified,rane_sars-cov-2_2022,USA
220602_NewYork_UniversityofNewYork_Phase1_Male,220602_NewYork_UniversityofNewYork_Phase1,SARS-CoV-2 pandemic in New York metropolitan area: The view from a major urgent care provider,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"study includes patients who received a COVID-19  serologic test at CityMD sites in the New York metropolitan area (NYC, Long Island and Westchester).",,2020-03-01,2021-03-04,Residual sera,Male,Multiple groups,,,Sex/Gender,,307297,0.2256,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9990000000000001,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Madhura S. Rane,University of New York,Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2022.05.006,2022-06-23,2024-03-01,Unverified,rane_sars-cov-2_2022,USA
220602_NewYork_UniversityofNewYork_Phase1_Age_80-89,220602_NewYork_UniversityofNewYork_Phase1,SARS-CoV-2 pandemic in New York metropolitan area: The view from a major urgent care provider,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"study includes patients who received a COVID-19  serologic test at CityMD sites in the New York metropolitan area (NYC, Long Island and Westchester).",,2020-03-01,2021-03-04,Residual sera,All,Seniors (65+ years),80.0,89.0,Age,80-89,7271,0.2066,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9990000000000001,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Madhura S. Rane,University of New York,Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2022.05.006,2022-06-24,2024-03-01,Unverified,rane_sars-cov-2_2022,USA
220602_NewYork_UniversityofNewYork_Phase1_Age_15-19,220602_NewYork_UniversityofNewYork_Phase1,SARS-CoV-2 pandemic in New York metropolitan area: The view from a major urgent care provider,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"study includes patients who received a COVID-19  serologic test at CityMD sites in the New York metropolitan area (NYC, Long Island and Westchester).",,2020-03-01,2021-03-04,Residual sera,All,Children and Youth (0-17 years),15.0,19.0,Age,15-19,23757,0.24,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9990000000000001,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Madhura S. Rane,University of New York,Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2022.05.006,2022-06-24,2024-03-01,Unverified,rane_sars-cov-2_2022,USA
220602_NewYork_UniversityofNewYork_Phase1_Age_50-59,220602_NewYork_UniversityofNewYork_Phase1,SARS-CoV-2 pandemic in New York metropolitan area: The view from a major urgent care provider,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"study includes patients who received a COVID-19  serologic test at CityMD sites in the New York metropolitan area (NYC, Long Island and Westchester).",,2020-03-01,2021-03-04,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,118224,0.2521,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9990000000000001,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Madhura S. Rane,University of New York,Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2022.05.006,2022-06-24,2024-03-01,Unverified,rane_sars-cov-2_2022,USA
220602_NewYork_UniversityofNewYork_Phase1_Age_<5,220602_NewYork_UniversityofNewYork_Phase1,SARS-CoV-2 pandemic in New York metropolitan area: The view from a major urgent care provider,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"study includes patients who received a COVID-19  serologic test at CityMD sites in the New York metropolitan area (NYC, Long Island and Westchester).",,2020-03-01,2021-03-04,Residual sera,All,Children and Youth (0-17 years),,5.0,Age,<5,87,0.1839,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9990000000000001,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Madhura S. Rane,University of New York,Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2022.05.006,2022-06-23,2024-03-01,Unverified,rane_sars-cov-2_2022,USA
220602_NewYork_UniversityofNewYork_Phase1_Age_70-79,220602_NewYork_UniversityofNewYork_Phase1,SARS-CoV-2 pandemic in New York metropolitan area: The view from a major urgent care provider,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"study includes patients who received a COVID-19  serologic test at CityMD sites in the New York metropolitan area (NYC, Long Island and Westchester).",,2020-03-01,2021-03-04,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,31946,0.2115,,,,,,,,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,,Serum,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.9990000000000001,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Madhura S. Rane,University of New York,Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2022.05.006,2022-06-24,2024-03-01,Unverified,rane_sars-cov-2_2022,USA
220602_NewYork_UniversityofNewYork_Phase2_Overall,220602_NewYork_UniversityofNewYork_Phase2,SARS-CoV-2 pandemic in New York metropolitan area: The view from a major urgent care provider,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"study includes patients who received a COVID-19  serologic test at CityMD sites in the New York metropolitan area (NYC, Long Island and Westchester).",,2021-03-05,2021-07-20,Residual sera,All,Multiple groups,,,Primary Estimate,,9367,0.3467,,,True,,,,True,Sequential,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (S)","Abbott Laboratories,Roche Diagnostics",,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,Madhura S. Rane,University of New York,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2022.05.006,2022-06-23,2024-03-01,Unverified,rane_sars-cov-2_2022,USA
220602_NewYork_UniversityofNewYork_Phase2_Age_15-19,220602_NewYork_UniversityofNewYork_Phase2,SARS-CoV-2 pandemic in New York metropolitan area: The view from a major urgent care provider,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"study includes patients who received a COVID-19  serologic test at CityMD sites in the New York metropolitan area (NYC, Long Island and Westchester).",,2021-03-05,2021-07-20,Residual sera,All,Children and Youth (0-17 years),15.0,19.0,Age,15-19,431,0.3295,,,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (S)","Abbott Laboratories,Roche Diagnostics",,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,Madhura S. Rane,University of New York,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2022.05.006,2022-06-24,2024-03-01,Unverified,rane_sars-cov-2_2022,USA
220602_NewYork_UniversityofNewYork_Phase2_Age_50-59,220602_NewYork_UniversityofNewYork_Phase2,SARS-CoV-2 pandemic in New York metropolitan area: The view from a major urgent care provider,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"study includes patients who received a COVID-19  serologic test at CityMD sites in the New York metropolitan area (NYC, Long Island and Westchester).",,2021-03-05,2021-07-20,Residual sera,All,Adults (18-64 years),50.0,59.0,Age,50-59,1690,0.384,,,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (S)","Abbott Laboratories,Roche Diagnostics",,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,Madhura S. Rane,University of New York,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2022.05.006,2022-06-24,2024-03-01,Unverified,rane_sars-cov-2_2022,USA
220602_NewYork_UniversityofNewYork_Phase2_Age_40-49,220602_NewYork_UniversityofNewYork_Phase2,SARS-CoV-2 pandemic in New York metropolitan area: The view from a major urgent care provider,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"study includes patients who received a COVID-19  serologic test at CityMD sites in the New York metropolitan area (NYC, Long Island and Westchester).",,2021-03-05,2021-07-20,Residual sera,All,Adults (18-64 years),40.0,49.0,Age,40-49,1669,0.34450000000000003,,,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (S)","Abbott Laboratories,Roche Diagnostics",,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,Madhura S. Rane,University of New York,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2022.05.006,2022-06-24,2024-03-01,Unverified,rane_sars-cov-2_2022,USA
220602_NewYork_UniversityofNewYork_Phase2_Age_20-29,220602_NewYork_UniversityofNewYork_Phase2,SARS-CoV-2 pandemic in New York metropolitan area: The view from a major urgent care provider,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"study includes patients who received a COVID-19  serologic test at CityMD sites in the New York metropolitan area (NYC, Long Island and Westchester).",,2021-03-05,2021-07-20,Residual sera,All,Adults (18-64 years),20.0,29.0,Age,20-29,1901,0.2925,,,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (S)","Abbott Laboratories,Roche Diagnostics",,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,Madhura S. Rane,University of New York,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2022.05.006,2022-06-24,2024-03-01,Unverified,rane_sars-cov-2_2022,USA
220602_NewYork_UniversityofNewYork_Phase2_Age_90-99,220602_NewYork_UniversityofNewYork_Phase2,SARS-CoV-2 pandemic in New York metropolitan area: The view from a major urgent care provider,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"study includes patients who received a COVID-19  serologic test at CityMD sites in the New York metropolitan area (NYC, Long Island and Westchester).",,2021-03-05,2021-07-20,Residual sera,All,Seniors (65+ years),90.0,99.0,Age,90-99,8,0.5,,,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (S)","Abbott Laboratories,Roche Diagnostics",,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,Madhura S. Rane,University of New York,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2022.05.006,2022-06-24,2024-03-01,Unverified,rane_sars-cov-2_2022,USA
220602_NewYork_UniversityofNewYork_Phase2_Female,220602_NewYork_UniversityofNewYork_Phase2,SARS-CoV-2 pandemic in New York metropolitan area: The view from a major urgent care provider,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"study includes patients who received a COVID-19  serologic test at CityMD sites in the New York metropolitan area (NYC, Long Island and Westchester).",,2021-03-05,2021-07-20,Residual sera,Female,Multiple groups,,,Sex/Gender,,5756,0.3442,,,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (S)","Abbott Laboratories,Roche Diagnostics",,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,Madhura S. Rane,University of New York,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2022.05.006,2022-06-23,2024-03-01,Unverified,rane_sars-cov-2_2022,USA
220602_NewYork_UniversityofNewYork_Phase2_Age_60-69,220602_NewYork_UniversityofNewYork_Phase2,SARS-CoV-2 pandemic in New York metropolitan area: The view from a major urgent care provider,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"study includes patients who received a COVID-19  serologic test at CityMD sites in the New York metropolitan area (NYC, Long Island and Westchester).",,2021-03-05,2021-07-20,Residual sera,All,Multiple groups,60.0,69.0,Age,60-69,884,0.4536,,,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (S)","Abbott Laboratories,Roche Diagnostics",,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,Madhura S. Rane,University of New York,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2022.05.006,2022-06-24,2024-03-01,Unverified,rane_sars-cov-2_2022,USA
220602_NewYork_UniversityofNewYork_Phase2_Age_70-79,220602_NewYork_UniversityofNewYork_Phase2,SARS-CoV-2 pandemic in New York metropolitan area: The view from a major urgent care provider,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"study includes patients who received a COVID-19  serologic test at CityMD sites in the New York metropolitan area (NYC, Long Island and Westchester).",,2021-03-05,2021-07-20,Residual sera,All,Seniors (65+ years),70.0,79.0,Age,70-79,361,0.4903,,,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (S)","Abbott Laboratories,Roche Diagnostics",,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,Madhura S. Rane,University of New York,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2022.05.006,2022-06-24,2024-03-01,Unverified,rane_sars-cov-2_2022,USA
220602_NewYork_UniversityofNewYork_Phase2_Age_5-9,220602_NewYork_UniversityofNewYork_Phase2,SARS-CoV-2 pandemic in New York metropolitan area: The view from a major urgent care provider,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"study includes patients who received a COVID-19  serologic test at CityMD sites in the New York metropolitan area (NYC, Long Island and Westchester).",,2021-03-05,2021-07-20,Residual sera,All,Children and Youth (0-17 years),5.0,9.0,Age,5-9,35,0.4,,,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (S)","Abbott Laboratories,Roche Diagnostics",,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,Madhura S. Rane,University of New York,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2022.05.006,2022-06-24,2024-03-01,Unverified,rane_sars-cov-2_2022,USA
220602_NewYork_UniversityofNewYork_Phase2_Age_<5,220602_NewYork_UniversityofNewYork_Phase2,SARS-CoV-2 pandemic in New York metropolitan area: The view from a major urgent care provider,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"study includes patients who received a COVID-19  serologic test at CityMD sites in the New York metropolitan area (NYC, Long Island and Westchester).",,2021-03-05,2021-07-20,Residual sera,All,Children and Youth (0-17 years),,5.0,Age,<5,4,0.0,,,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (S)","Abbott Laboratories,Roche Diagnostics",,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,Madhura S. Rane,University of New York,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2022.05.006,2022-06-24,2024-03-01,Unverified,rane_sars-cov-2_2022,USA
220602_NewYork_UniversityofNewYork_Phase2_Male,220602_NewYork_UniversityofNewYork_Phase2,SARS-CoV-2 pandemic in New York metropolitan area: The view from a major urgent care provider,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"study includes patients who received a COVID-19  serologic test at CityMD sites in the New York metropolitan area (NYC, Long Island and Westchester).",,2021-03-05,2021-07-20,Residual sera,Male,Multiple groups,,,Sex/Gender,,3611,0.35090000000000005,,,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (S)","Abbott Laboratories,Roche Diagnostics",,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,Madhura S. Rane,University of New York,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2022.05.006,2022-06-23,2024-03-01,Unverified,rane_sars-cov-2_2022,USA
220602_NewYork_UniversityofNewYork_Phase2_Age_80-89,220602_NewYork_UniversityofNewYork_Phase2,SARS-CoV-2 pandemic in New York metropolitan area: The view from a major urgent care provider,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"study includes patients who received a COVID-19  serologic test at CityMD sites in the New York metropolitan area (NYC, Long Island and Westchester).",,2021-03-05,2021-07-20,Residual sera,All,Seniors (65+ years),80.0,89.0,Age,80-89,81,0.3704,,,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (S)","Abbott Laboratories,Roche Diagnostics",,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,Madhura S. Rane,University of New York,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2022.05.006,2022-06-24,2024-03-01,Unverified,rane_sars-cov-2_2022,USA
220602_NewYork_UniversityofNewYork_Phase2_Age_10-14,220602_NewYork_UniversityofNewYork_Phase2,SARS-CoV-2 pandemic in New York metropolitan area: The view from a major urgent care provider,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"study includes patients who received a COVID-19  serologic test at CityMD sites in the New York metropolitan area (NYC, Long Island and Westchester).",,2021-03-05,2021-07-20,Residual sera,All,Children and Youth (0-17 years),10.0,14.0,Age,10-14,179,0.38549999999999995,,,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (S)","Abbott Laboratories,Roche Diagnostics",,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,Madhura S. Rane,University of New York,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2022.05.006,2022-06-24,2024-03-01,Unverified,rane_sars-cov-2_2022,USA
220602_NewYork_UniversityofNewYork_Phase2_Age_30-39,220602_NewYork_UniversityofNewYork_Phase2,SARS-CoV-2 pandemic in New York metropolitan area: The view from a major urgent care provider,2022-06-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,New York ,New York ,"study includes patients who received a COVID-19  serologic test at CityMD sites in the New York metropolitan area (NYC, Long Island and Westchester).",,2021-03-05,2021-07-20,Residual sera,All,Adults (18-64 years),30.0,39.0,Age,30-39,2124,0.29710000000000003,,,,,,,,Sequential,"Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (S)","Abbott Laboratories,Roche Diagnostics",,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Unclear,No,No,,Madhura S. Rane,University of New York,Not Unity-Aligned,https://dx.doi.org/10.1016/j.annepidem.2022.05.006,2022-06-24,2024-03-01,Unverified,rane_sars-cov-2_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Overall,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Primary Estimate,,116513,0.037000000000000005,0.034,0.04,True,,True,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_NV-2,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern New Jersey and Southeastern Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1781,0.035,0.025,0.048,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_NV-1,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New Mexico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1718,0.011000000000000001,0.006,0.021,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_EthnicityWhite,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,White,100492,0.024,0.022000000000000002,0.026000000000000002,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_ID,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Iowa Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2001,0.018000000000000002,0.011000000000000001,0.027999999999999997,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_EthnicityHispanic,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Hispanic,7403,0.07,0.059000000000000004,0.083,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_WV,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,801,0.009000000000000001,0.004,0.02,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_KS-1,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Maine Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1887,0.017,0.01,0.027000000000000003,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_CA-1,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Sacramento Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1717,0.008,0.005,0.015,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_WY,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Alabama Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1655,0.013999999999999999,0.006,0.031000000000000003,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_NM-1,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1773,0.008,0.004,0.02,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_CT,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Detroit Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1903,0.045,0.032,0.064,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_NH,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2010,0.01,0.006999999999999999,0.015,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_NE,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,New Hampshire Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1723,0.013000000000000001,0.008,0.022000000000000002,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_AR,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Nevada and Northwestern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1827,0.013999999999999999,0.006999999999999999,0.025,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_NY-2,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,982,0.013999999999999999,0.006,0.034,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_MN,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Montana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2131,0.017,0.009000000000000001,0.034,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_UT,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Vermont Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2928,0.011000000000000001,0.006999999999999999,0.017,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_FL-1,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Minnesota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,4000,0.083,0.07200000000000001,0.095,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_TN-2,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Miami Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1738,0.015,0.008,0.027999999999999997,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_EthnicityAsian,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Asian,2887,0.034,0.024,0.048,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_CR3,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 4 (West),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,36423,0.034,0.03,0.038,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_SC,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Eastern South Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1931,0.027999999999999997,0.018000000000000002,0.043,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-03-17,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_VA,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1484,0.016,0.008,0.03,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_OK,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Texas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,649,0.02,0.009000000000000001,0.043,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_CA-2,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern Nevada Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1975,0.011000000000000001,0.006999999999999999,0.019,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_TN-1,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Tennessee Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1439,0.027000000000000003,0.018000000000000002,0.040999999999999995,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-03-08,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_SexFemale,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,Female,Multiple groups,16.0,,Sex/Gender,,54852,0.036000000000000004,0.032,0.04,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_SD,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Louisiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1459,0.017,0.009000000000000001,0.033,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_SexMale,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,Male,Multiple groups,16.0,,Sex/Gender,,61661,0.038,0.033,0.044000000000000004,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_VT,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"West Virginia, Western Maryland, and Northern Virginia Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1306,0.011000000000000001,0.005,0.021,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_TX-1,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2797,0.046,0.034,0.063,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_MT,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Nebraska Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2540,0.012,0.006999999999999999,0.021,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_EthnicityOther,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Other,2083,0.032,0.024,0.043,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_MI,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Mississippi Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3854,0.045,0.034,0.057999999999999996,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_OH-2,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2003,0.015,0.008,0.027999999999999997,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-04-07,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_GA,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Hawaii Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3703,0.039,0.028999999999999998,0.052000000000000005,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_IN,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Indiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,793,0.005,0.002,0.013000000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-03-17,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_EthnicityBlack,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Black,2642,0.07,0.051,0.096,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_CR4,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 1 (Northeast),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,34641,0.021,0.018000000000000002,0.024,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_LA,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern New York and Northern New Jersey Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1721,0.08800000000000001,0.069,0.113,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_AL,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Alabama Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1422,0.025,0.015,0.042,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-02-07,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_CO,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Connecticut Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1778,0.036000000000000004,0.024,0.052000000000000005,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_NM-2,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Tampa Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2020,0.037000000000000005,0.028999999999999998,0.047,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_NY-1,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Wisconsin Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2461,0.129,0.098,0.167,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_WI,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1967,0.027000000000000003,0.016,0.047,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_AZ-1,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Northern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2489,0.037000000000000005,0.027000000000000003,0.053,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-03-17,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Age50-64,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Adults (18-64 years),50.0,64.0,Age,50-64,41923,0.032,0.026000000000000002,0.038,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_NY-3,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northwestern Oregon and Southwestern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,803,0.012,0.004,0.033,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Age30-49,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Adults (18-64 years),30.0,49.0,Age,30-49,39049,0.038,0.034,0.043,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Age65+,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Seniors (65+ years),65.0,,Age,65+,21953,0.015,0.012,0.019,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_HI,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Idaho Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,790,0.005,0.001,0.017,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_ME,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Massachusetts Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2184,0.017,0.01,0.027999999999999997,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_CR2,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 3 (South),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,24952,0.026000000000000002,0.021,0.031000000000000003,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_NJ,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern New Mexico, El Paso, and Southern Texas Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3241,0.048,0.033,0.068,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_AZ-2,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern California Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1172,0.02,0.012,0.034,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_NC,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western North Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,4151,0.013999999999999999,0.009000000000000001,0.021,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-04-22,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_CR1,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 2 (Midwest),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,19491,0.07,0.057999999999999996,0.086,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_PA,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2765,0.013999999999999999,0.009000000000000001,0.022000000000000002,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-05-12,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_FL-2,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Utah Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1998,0.061,0.045,0.08199999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_MA,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Memphis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1836,0.042,0.031000000000000003,0.057999999999999996,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_MO,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Missouri and St. Louis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1230,0.009000000000000001,0.004,0.019,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-02-24,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_ND,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Kansas and Northwestern Missouri Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1312,0.009000000000000001,0.004,0.019,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_KS-2,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,165,0.013000000000000001,0.004,0.044000000000000004,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_IL-2,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Missouri and Northern Arkansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,701,0.006,0.003,0.016,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Age16-29,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Adults (18-64 years),16.0,29.0,Age,16-29,13588,0.059000000000000004,0.05,0.07,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_OR-2,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Oregon Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,658,0.004,0.001,0.012,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-05-01,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_MD,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Maryland and National Capital Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3599,0.025,0.017,0.038,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-02-22,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_MS,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Virginia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2093,0.021,0.013999999999999999,0.031000000000000003,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_IA,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Kansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,178,0.0,0.0,0.021,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_IL-1,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Chicago Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3672,0.048,0.034,0.066,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_CA-3,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern Illinois, Southeastern Missouri, and Western Kentucky Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3441,0.025,0.019,0.032,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_KY,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Kentucky Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1070,0.017,0.01,0.028999999999999998,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-02-22,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_WA-2,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Georgia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1433,0.011000000000000001,0.005,0.022000000000000002,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_OH-1,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Oklahoma Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1877,0.027000000000000003,0.013999999999999999,0.052000000000000005,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_WA-1,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Wyoming Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1869,0.018000000000000002,0.012,0.027000000000000003,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_PR,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,South Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1006,0.009000000000000001,0.004,0.02,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202007_Region_OR-1,220613_USA_CentersforDiseaseControlandPrevention_202007,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Puerto Rico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-07-01,2020-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,903,0.013999999999999999,0.004,0.045,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Overall,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Primary Estimate,,123200,0.048,0.046,0.051,True,,True,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_HI,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Idaho Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1653,0.009000000000000001,0.005,0.018000000000000002,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_ME,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Massachusetts Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2065,0.011000000000000001,0.008,0.017,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_OH-1,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Oklahoma Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1892,0.028999999999999998,0.019,0.045,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_MO,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Tennessee Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1076,0.006,0.003,0.013000000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_MA,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Memphis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1908,0.046,0.034,0.062000000000000006,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_NC,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Oregon Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,4126,0.031000000000000003,0.022000000000000002,0.044000000000000004,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_NV-2,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern New Jersey and Southeastern Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1904,0.059000000000000004,0.046,0.075,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_CT,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Detroit Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1891,0.040999999999999995,0.026000000000000002,0.062000000000000006,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_AR,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Nevada and Northwestern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1737,0.018000000000000002,0.013000000000000001,0.025,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_IL-2,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Missouri and Northern Arkansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,755,0.03,0.018000000000000002,0.049,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_GA,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Hawaii Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3700,0.063,0.051,0.078,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_ID,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Iowa Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1935,0.038,0.026000000000000002,0.055999999999999994,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_NE,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,New Hampshire Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1753,0.028999999999999998,0.019,0.044000000000000004,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_VA,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1471,0.032,0.018000000000000002,0.054000000000000006,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_RI,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,South Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1086,0.022000000000000002,0.012,0.039,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_WI,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1918,0.027000000000000003,0.017,0.040999999999999995,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_TN-1,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Eastern South Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1387,0.028999999999999998,0.02,0.040999999999999995,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_AZ-1,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Indiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2491,0.064,0.048,0.084,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_WY,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Alabama Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1343,0.015,0.008,0.025,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_NY-2,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,932,0.021,0.01,0.040999999999999995,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_LA,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern New York and Northern New Jersey Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1746,0.098,0.078,0.12400000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_EthnicityWhite,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,White,104270,0.03,0.027999999999999997,0.032,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_CO,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Connecticut Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1807,0.034,0.024,0.048,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Age16-29,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Adults (18-64 years),16.0,29.0,Age,16-29,14618,0.07,0.064,0.077,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_TN-2,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Miami Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1723,0.044000000000000004,0.027999999999999997,0.069,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_IN,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2372,0.027999999999999997,0.019,0.040999999999999995,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_MI,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Mississippi Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3844,0.044000000000000004,0.033,0.057999999999999996,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_SC,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Northern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1950,0.065,0.05,0.084,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_MN,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Montana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2097,0.018000000000000002,0.012,0.027000000000000003,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_SD,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Louisiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1397,0.045,0.025,0.079,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_SexMale,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,Male,Multiple groups,16.0,,Sex/Gender,,62469,0.05,0.047,0.054000000000000006,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_CR3,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 4 (West),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,36228,0.059000000000000004,0.054000000000000006,0.063,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Age30-49,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Adults (18-64 years),30.0,49.0,Age,30-49,39270,0.053,0.049,0.057,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_CA-3,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern Illinois, Southeastern Missouri, and Western Kentucky Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3490,0.045,0.036000000000000004,0.055,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_OR-2,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,710,0.003,0.001,0.012,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_AZ-2,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern California Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1216,0.03,0.018000000000000002,0.051,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_NV-1,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New Mexico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1825,0.042,0.03,0.057,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_EthnicityOther,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Other,2449,0.039,0.028999999999999998,0.051,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_FL-2,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Utah Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1999,0.095,0.08199999999999999,0.11,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_WA-1,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Wyoming Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1876,0.018000000000000002,0.013000000000000001,0.025,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_OH-2,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western North Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2008,0.022000000000000002,0.015,0.031000000000000003,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_EthnicityBlack,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Black,3041,0.076,0.065,0.08900000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_VT,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"West Virginia, Western Maryland, and Northern Virginia Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1324,0.013000000000000001,0.008,0.023,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_MD,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Missouri and St. Louis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3577,0.034,0.025,0.047,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Age50-64,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Adults (18-64 years),50.0,64.0,Age,50-64,44594,0.039,0.035,0.043,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_EthnicityHispanic,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Hispanic,7736,0.106,0.094,0.11800000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_OK,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Texas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,616,0.049,0.03,0.077,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_EthnicityAsian,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Asian,3710,0.046,0.037000000000000005,0.055999999999999994,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_IA,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Kansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,156,0.019,0.006,0.062000000000000006,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_PA,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Chicago Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2721,0.013000000000000001,0.008,0.02,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_KY,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Maryland and National Capital Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1002,0.027999999999999997,0.015,0.052000000000000005,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_AL,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Kentucky Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1552,0.046,0.032,0.066,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_CR4,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 1 (Northeast),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,35656,0.035,0.031000000000000003,0.038,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_KS-1,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Maine Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1870,0.018000000000000002,0.011000000000000001,0.027999999999999997,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_IL-1,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Colorado Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3558,0.052000000000000005,0.039,0.069,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_KS-2,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,203,0.0,0.0,0.019,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_NY-3,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northwestern Oregon and Southwestern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,802,0.005,0.002,0.013000000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_OR-1,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Puerto Rico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,927,0.008,0.004,0.018000000000000002,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_NM-2,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Tampa Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2023,0.075,0.061,0.09300000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_MS,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Virginia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1964,0.057,0.044000000000000004,0.07200000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Age65+,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Seniors (65+ years),65.0,,Age,65+,24718,0.027000000000000003,0.022000000000000002,0.032,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_CR2,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 3 (South),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,26264,0.03,0.026000000000000002,0.034,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_WA-2,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Georgia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1444,0.034,0.018000000000000002,0.062000000000000006,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_FL-1,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Minnesota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3999,0.16,0.145,0.17600000000000002,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_CA-1,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Sacramento Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1732,0.018000000000000002,0.009000000000000001,0.035,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_SexFemale,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,Female,Multiple groups,16.0,,Sex/Gender,,60731,0.046,0.044000000000000004,0.049,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_CA-2,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern Nevada Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1990,0.017,0.01,0.027999999999999997,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_PR,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Rhode Island Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1994,0.01,0.005,0.018000000000000002,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_NY-1,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Wisconsin Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,4936,0.134,0.12,0.149,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_TX-1,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2894,0.07200000000000001,0.057,0.091,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_MT,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Nebraska Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2754,0.017,0.011000000000000001,0.024,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_UT,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Vermont Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2868,0.03,0.021,0.043,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_NH,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2090,0.016,0.01,0.024,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_WV,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,785,0.015,0.006999999999999999,0.033,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_CR1,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 2 (Midwest),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,23058,0.068,0.062000000000000006,0.075,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_NM-1,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1668,0.015,0.009000000000000001,0.025,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_NJ,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern New Mexico, El Paso, and Southern Texas Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3303,0.026000000000000002,0.018000000000000002,0.038,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202008_Region_ND,220613_USA_CentersforDiseaseControlandPrevention_202008,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Kansas and Northwestern Missouri Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-08-01,2020-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1365,0.022000000000000002,0.012,0.04,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Overall,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Primary Estimate,,131052,0.05,0.048,0.053,True,,True,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_EthnicityAsian,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Ethnicity,Asian,3934,0.045,0.036000000000000004,0.055999999999999994,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_KY,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Maryland and National Capital Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,928,0.026000000000000002,0.015,0.044000000000000004,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_NC,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Oregon Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,4074,0.035,0.026000000000000002,0.047,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_WV,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,774,0.021,0.011000000000000001,0.038,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_PR,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Rhode Island Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1997,0.011000000000000001,0.006,0.018000000000000002,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_NV-1,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New Mexico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1653,0.037000000000000005,0.025,0.052000000000000005,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_DE,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Detroit Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1698,0.034,0.019,0.057999999999999996,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_TN-2,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Miami Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1401,0.044000000000000004,0.026000000000000002,0.073,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_CA-1,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Sacramento Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1737,0.013999999999999999,0.006999999999999999,0.027000000000000003,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_NH,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2138,0.013999999999999999,0.008,0.025,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_WA-1,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Wyoming Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1915,0.018000000000000002,0.012,0.026000000000000002,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_IL-1,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Colorado Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3621,0.054000000000000006,0.043,0.068,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_OH-1,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Oklahoma Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1849,0.033,0.02,0.054000000000000006,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_ME,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Massachusetts Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2166,0.013000000000000001,0.008,0.022000000000000002,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_EthnicityBlack,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Ethnicity,Black,3497,0.081,0.069,0.095,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_MN,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Montana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2113,0.025,0.016,0.037000000000000005,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_TX-2,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Wisconsin Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3789,0.092,0.079,0.107,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_MD,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Missouri and St. Louis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3629,0.04,0.027999999999999997,0.055999999999999994,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Age50-64,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Adults (18-64 years),50.0,64.0,Age,50-64,47870,0.040999999999999995,0.038,0.045,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_CR1,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 2 (Midwest),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,23561,0.062000000000000006,0.055999999999999994,0.069,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_IA,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Kansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1787,0.069,0.055,0.086,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_FL-1,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Minnesota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3997,0.13699999999999998,0.12400000000000001,0.152,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_AZ-2,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern California Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1132,0.039,0.022000000000000002,0.066,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_TN-1,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Eastern South Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1341,0.032,0.024,0.043,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_HI,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Idaho Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1493,0.006999999999999999,0.004,0.013000000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_WA-2,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Georgia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1577,0.053,0.031000000000000003,0.09,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_SD,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Louisiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1362,0.049,0.03,0.079,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_ID,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Iowa Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1997,0.031000000000000003,0.022000000000000002,0.043,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_CA-2,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern Nevada Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1991,0.025,0.017,0.037000000000000005,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_CO,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Connecticut Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1862,0.035,0.024,0.049,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_IN,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2413,0.042,0.032,0.057,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_CR2,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 3 (South),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,28432,0.039,0.035,0.043,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_NM-2,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Tampa Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2112,0.08199999999999999,0.067,0.1,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Age65+,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Seniors (65+ years),65.0,,Age,65+,26927,0.025,0.021,0.028999999999999998,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_ND,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Kansas and Northwestern Missouri Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1287,0.051,0.036000000000000004,0.073,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_LA,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern New York and Northern New Jersey Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1713,0.102,0.077,0.135,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_IL-2,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Missouri and Northern Arkansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,707,0.045,0.025,0.08,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_FL-2,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Utah Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1999,0.084,0.069,0.102,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_MI,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Mississippi Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3865,0.032,0.025,0.043,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_MA,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Memphis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1927,0.036000000000000004,0.025,0.05,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_AR,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Nevada and Northwestern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1764,0.032,0.023,0.044000000000000004,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_GA,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Hawaii Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3659,0.077,0.062000000000000006,0.094,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_MS,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Virginia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1872,0.084,0.068,0.10300000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_EthnicityOther,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Ethnicity,Other,2617,0.046,0.037000000000000005,0.057999999999999996,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_PA,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Chicago Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2763,0.026000000000000002,0.018000000000000002,0.038,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_NY-3,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northwestern Oregon and Southwestern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,842,0.009000000000000001,0.005,0.019,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_OK,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Texas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,701,0.040999999999999995,0.023,0.07400000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_NY-2,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,896,0.021,0.011000000000000001,0.039,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_SC,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Northern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1918,0.054000000000000006,0.04,0.07200000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_SexMale,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,Male,Multiple groups,16.0,,Sex/Gender,,65310,0.052000000000000005,0.049,0.055,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_WI,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1915,0.051,0.036000000000000004,0.073,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Age16-29,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Adults (18-64 years),16.0,29.0,Age,16-29,15921,0.076,0.071,0.081,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_VT,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"West Virginia, Western Maryland, and Northern Virginia Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1271,0.017,0.008,0.035,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_CR3,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 4 (West),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,41527,0.062000000000000006,0.057999999999999996,0.067,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_RI,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,South Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1233,0.040999999999999995,0.025,0.066,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_UT,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Vermont Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2798,0.028999999999999998,0.021,0.040999999999999995,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Age30-49,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Adults (18-64 years),30.0,49.0,Age,30-49,40334,0.054000000000000006,0.051,0.057999999999999996,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_OR-2,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,565,0.002,0.0,0.01,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_SexFemale,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,Female,Multiple groups,16.0,,Sex/Gender,,65742,0.049,0.045,0.052000000000000005,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_EthnicityWhite,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Ethnicity,White,110497,0.035,0.033,0.036000000000000004,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_OH-2,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western North Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1939,0.017,0.011000000000000001,0.025,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_NM-1,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1702,0.013000000000000001,0.008,0.02,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_KS-1,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Maine Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1873,0.046,0.035,0.062000000000000006,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_NE,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,New Hampshire Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1651,0.038,0.026000000000000002,0.055,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_CR4,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 1 (Northeast),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,35535,0.035,0.032,0.039,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_WY,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Alabama Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1548,0.016,0.009000000000000001,0.028999999999999998,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_CT,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Delaware and Maryland Eastern Shore Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1900,0.037000000000000005,0.024,0.057,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_CA-3,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern Illinois, Southeastern Missouri, and Western Kentucky Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3469,0.04,0.03,0.053,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_VA,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1393,0.031000000000000003,0.018000000000000002,0.051,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_AL,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Kentucky Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2125,0.069,0.059000000000000004,0.08,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_AZ-1,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Indiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2632,0.066,0.054000000000000006,0.081,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_TX-1,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2752,0.064,0.05,0.08199999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_MT,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Nebraska Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2360,0.03,0.021,0.040999999999999995,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_NY-1,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Texas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,5187,0.11599999999999999,0.10400000000000001,0.129,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_OR-1,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Puerto Rico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1043,0.012,0.005,0.028999999999999998,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_EthnicityHispanic,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Ethnicity,Hispanic,8510,0.095,0.08800000000000001,0.10300000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_NJ,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern New Mexico, El Paso, and Southern Texas Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3238,0.027999999999999997,0.017,0.045,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_KS-2,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,886,0.031000000000000003,0.021,0.047,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_MO,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Tennessee Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1164,0.037000000000000005,0.025,0.055999999999999994,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202009_Region_NV-2,220613_USA_CentersforDiseaseControlandPrevention_202009,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern New Jersey and Southeastern Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-09-01,2020-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1949,0.079,0.063,0.099,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Overall,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Primary Estimate,,131731,0.059000000000000004,0.057,0.062000000000000006,True,,True,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_SexFemale,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,Female,Multiple groups,16.0,,Sex/Gender,,65497,0.057,0.054000000000000006,0.06,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_TX-2,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Wisconsin Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3807,0.08900000000000001,0.077,0.10099999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_CR4,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 1 (Northeast),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,36049,0.042,0.039,0.045,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_EthnicityOther,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Other,2656,0.048,0.039,0.057999999999999996,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_CR3,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 4 (West),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,42235,0.07,0.067,0.07400000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_KS-1,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Maine Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1817,0.066,0.052000000000000005,0.085,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_ME,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Massachusetts Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2127,0.006999999999999999,0.004,0.011000000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_RI,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,South Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1261,0.027000000000000003,0.016,0.045,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_CA-3,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern Illinois, Southeastern Missouri, and Western Kentucky Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3422,0.043,0.034,0.053,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_MA,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Memphis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1904,0.038,0.026000000000000002,0.055,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_SD,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Louisiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1335,0.099,0.078,0.125,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_WV,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,800,0.03,0.018000000000000002,0.05,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_WA-1,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Wyoming Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1936,0.018000000000000002,0.013000000000000001,0.025,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_NY-2,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,917,0.013999999999999999,0.006999999999999999,0.027999999999999997,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_WI,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1948,0.055999999999999994,0.040999999999999995,0.077,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_CA-1,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Sacramento Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1712,0.018000000000000002,0.009000000000000001,0.036000000000000004,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_MT,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Nebraska Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2247,0.053,0.042,0.067,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_EthnicityAsian,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Asian,3962,0.038,0.031000000000000003,0.047,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_IL-2,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Missouri and Northern Arkansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,655,0.099,0.069,0.141,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_NV-2,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern New Jersey and Southeastern Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1896,0.083,0.067,0.10300000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_OR-2,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,641,0.019,0.006,0.059000000000000004,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_TN-2,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Miami Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1551,0.06,0.044000000000000004,0.08199999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Age30-49,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Adults (18-64 years),30.0,49.0,Age,30-49,40875,0.061,0.057999999999999996,0.065,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_CT,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Delaware and Maryland Eastern Shore Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1903,0.04,0.026000000000000002,0.06,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_MO,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Tennessee Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1178,0.055999999999999994,0.040999999999999995,0.075,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_UT,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Vermont Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2911,0.048,0.04,0.059000000000000004,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_NE,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,New Hampshire Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1719,0.084,0.067,0.105,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_PR,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Rhode Island Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1997,0.027999999999999997,0.02,0.040999999999999995,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_NM-1,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1602,0.019,0.011000000000000001,0.033,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_MN,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Montana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2048,0.03,0.02,0.044000000000000004,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_AZ-1,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Indiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2538,0.069,0.059000000000000004,0.08199999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_CR1,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 2 (Midwest),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,23277,0.067,0.061,0.07400000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_CO,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Connecticut Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1823,0.039,0.026000000000000002,0.059000000000000004,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_IA,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Kansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1906,0.081,0.066,0.1,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_IN,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2349,0.055,0.043,0.07,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_EthnicityWhite,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,White,111094,0.044000000000000004,0.042,0.045,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_FL-2,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Utah Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1997,0.078,0.065,0.092,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_PA,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Chicago Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2773,0.027000000000000003,0.02,0.036000000000000004,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_MS,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Virginia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1608,0.105,0.087,0.128,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_NJ,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern New Mexico, El Paso, and Southern Texas Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3260,0.046,0.03,0.069,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_WA-2,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Georgia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1444,0.035,0.021,0.057999999999999996,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_AL,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Alaska Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2888,0.083,0.07200000000000001,0.096,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_OH-1,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Oklahoma Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1887,0.035,0.026000000000000002,0.048,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_KS-2,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,715,0.076,0.053,0.109,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_NY-3,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northwestern Oregon and Southwestern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,787,0.013999999999999999,0.006999999999999999,0.031000000000000003,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_NV-1,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New Mexico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1561,0.045,0.031000000000000003,0.066,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Age16-29,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Adults (18-64 years),16.0,29.0,Age,16-29,16605,0.091,0.083,0.099,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_AZ-2,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern California Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1170,0.052000000000000005,0.033,0.081,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_IL-1,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Colorado Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3608,0.073,0.06,0.08900000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_MI,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Mississippi Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3840,0.053,0.039,0.07,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_ND,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Kansas and Northwestern Missouri Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1235,0.046,0.035,0.061,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_SC,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Northern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1861,0.068,0.054000000000000006,0.086,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_GA,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Hawaii Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3644,0.099,0.083,0.11800000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_OR-1,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Puerto Rico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1026,0.024,0.013999999999999999,0.043,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_VT,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"West Virginia, Western Maryland, and Northern Virginia Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1192,0.021,0.013000000000000001,0.036000000000000004,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Age50-64,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Adults (18-64 years),50.0,64.0,Age,50-64,47458,0.049,0.046,0.053,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_FL-1,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Minnesota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,4000,0.139,0.126,0.153,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_OH-2,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western North Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1933,0.024,0.017,0.035,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_DE,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Detroit Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1595,0.037000000000000005,0.02,0.067,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_NH,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2224,0.013999999999999999,0.009000000000000001,0.021,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_NM-2,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Tampa Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2046,0.09699999999999999,0.079,0.11800000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_CR2,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 3 (South),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,28173,0.055999999999999994,0.052000000000000005,0.061,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_EthnicityHispanic,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Hispanic,8404,0.11,0.10099999999999999,0.11900000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_WY,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Alabama Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1296,0.023,0.015,0.035,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Age65+,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Seniors (65+ years),65.0,,Age,65+,26793,0.03,0.026000000000000002,0.035,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_EthnicityBlack,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Black,3618,0.092,0.079,0.106,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_SexMale,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,Male,Multiple groups,16.0,,Sex/Gender,,66234,0.062000000000000006,0.057999999999999996,0.065,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_ID,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Iowa Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2014,0.071,0.057,0.08800000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_NC,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Oregon Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,4204,0.04,0.032,0.05,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_KY,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Maryland and National Capital Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,988,0.053,0.037000000000000005,0.076,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_TN-1,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Eastern South Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1417,0.061,0.048,0.076,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_VA,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1405,0.031000000000000003,0.017,0.055,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_TX-1,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2735,0.064,0.051,0.08,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_LA,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern New York and Northern New Jersey Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1715,0.12,0.099,0.14400000000000002,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_CA-2,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern Nevada Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2108,0.035,0.025,0.048,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_MD,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Missouri and St. Louis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3620,0.045,0.035,0.057,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_HI,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Idaho Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1652,0.016,0.009000000000000001,0.03,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_NY-1,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Texas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,4929,0.12300000000000001,0.11,0.13699999999999998,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_AK,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Kentucky Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1004,0.027999999999999997,0.018000000000000002,0.042,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_OK,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Texas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,613,0.052000000000000005,0.033,0.08,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202010_Region_AR,220613_USA_CentersforDiseaseControlandPrevention_202010,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Nevada and Northwestern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-10-01,2020-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1787,0.05,0.037000000000000005,0.066,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Overall,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Primary Estimate,,134061,0.08199999999999999,0.079,0.085,True,,True,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_SexMale,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,Male,Multiple groups,16.0,,Sex/Gender,,68189,0.083,0.079,0.087,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_IL-1,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Colorado Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3611,0.11800000000000001,0.10099999999999999,0.138,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_RI,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,South Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1284,0.043,0.027999999999999997,0.066,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_AR,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Nevada and Northwestern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1788,0.121,0.10300000000000001,0.142,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_AL,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Alaska Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3452,0.107,0.09300000000000001,0.122,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_EthnicityHispanic,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Ethnicity,Hispanic,8118,0.133,0.12300000000000001,0.14300000000000002,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_WI,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1938,0.12400000000000001,0.095,0.16,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_AZ-1,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Indiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2534,0.078,0.064,0.096,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_IA,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Kansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1992,0.142,0.12400000000000001,0.162,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_CR1,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 2 (Midwest),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,23493,0.076,0.069,0.084,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_VT,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"West Virginia, Western Maryland, and Northern Virginia Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1124,0.01,0.006,0.019,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_NM-2,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Tampa Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2013,0.152,0.133,0.17300000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_FL-2,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Utah Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1998,0.08900000000000001,0.078,0.10300000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_NC,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Oregon Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,4093,0.067,0.055,0.08199999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_CA-2,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern Nevada Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1886,0.026000000000000002,0.018000000000000002,0.038,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_NE,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,New Hampshire Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1718,0.172,0.152,0.19399999999999998,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_MD,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Missouri and St. Louis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3554,0.045,0.035,0.057,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_AZ-2,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern California Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1164,0.039,0.025,0.061,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_DE,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Detroit Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1698,0.048,0.034,0.068,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_OR-1,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Puerto Rico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,994,0.016,0.01,0.025,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Age16-29,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Adults (18-64 years),16.0,29.0,Age,16-29,17895,0.126,0.11699999999999999,0.135,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_FL-1,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Minnesota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3999,0.168,0.153,0.184,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Age65+,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Seniors (65+ years),65.0,,Age,65+,26379,0.04,0.036000000000000004,0.045,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_NV-1,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New Mexico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1731,0.051,0.037000000000000005,0.07,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_CO,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Connecticut Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1821,0.07400000000000001,0.06,0.09,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_IL-2,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Missouri and Northern Arkansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,719,0.163,0.132,0.198,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_WV,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,790,0.033,0.022000000000000002,0.048,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_ME,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Massachusetts Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2103,0.015,0.01,0.021,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_WY,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Alabama Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1418,0.078,0.061,0.1,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_EthnicityOther,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Ethnicity,Other,2649,0.086,0.07400000000000001,0.1,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_CR4,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 1 (Northeast),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,35778,0.057999999999999996,0.054000000000000006,0.063,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_ID,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Iowa Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2012,0.136,0.11599999999999999,0.159,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_PA,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Chicago Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2746,0.057999999999999996,0.046,0.07200000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_AK,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Kentucky Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,786,0.043,0.03,0.062000000000000006,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_MS,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Virginia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1972,0.161,0.13699999999999998,0.189,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_MO,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Tennessee Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1190,0.10099999999999999,0.086,0.12,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_PR,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Rhode Island Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1982,0.031000000000000003,0.024,0.04,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_EthnicityWhite,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Ethnicity,White,114049,0.069,0.067,0.071,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_VA,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1440,0.057999999999999996,0.04,0.084,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_KS-2,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2042,0.07400000000000001,0.057,0.096,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_TX-1,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2845,0.11,0.08900000000000001,0.134,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Age50-64,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Adults (18-64 years),50.0,64.0,Age,50-64,48241,0.068,0.064,0.07200000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_NM-1,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1625,0.017,0.011000000000000001,0.026000000000000002,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_NY-3,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northwestern Oregon and Southwestern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,803,0.018000000000000002,0.01,0.032,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_GA,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Hawaii Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3679,0.11900000000000001,0.10099999999999999,0.141,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_IN,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2462,0.08199999999999999,0.065,0.102,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_OK,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Texas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,667,0.095,0.071,0.126,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_TN-2,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Miami Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1216,0.08199999999999999,0.057,0.11800000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_TN-1,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Eastern South Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1397,0.10400000000000001,0.08199999999999999,0.131,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_NJ,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern New Mexico, El Paso, and Southern Texas Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3296,0.053,0.038,0.073,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_HI,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Idaho Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1580,0.022000000000000002,0.013999999999999999,0.033,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_NY-2,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,936,0.037000000000000005,0.021,0.063,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_ND,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Kansas and Northwestern Missouri Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1224,0.161,0.135,0.19100000000000003,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_NY-1,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Texas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,5109,0.125,0.109,0.142,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_MT,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Nebraska Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2402,0.13699999999999998,0.11800000000000001,0.158,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_SC,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Northern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1834,0.091,0.073,0.114,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_MN,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Montana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2112,0.08800000000000001,0.071,0.107,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_EthnicityAsian,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Ethnicity,Asian,3825,0.044000000000000004,0.035,0.054000000000000006,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_SD,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Louisiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1630,0.165,0.142,0.19100000000000003,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_LA,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern New York and Northern New Jersey Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1669,0.115,0.08900000000000001,0.147,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_TX-2,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Wisconsin Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3789,0.09,0.077,0.10400000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_MI,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Mississippi Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3718,0.073,0.06,0.08800000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_NH,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2261,0.022000000000000002,0.015,0.03,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_KS-1,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Maine Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1881,0.12400000000000001,0.105,0.146,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_EthnicityBlack,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Ethnicity,Black,3438,0.10300000000000001,0.092,0.115,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_OR-2,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,639,0.024,0.013000000000000001,0.043,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Age30-49,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Adults (18-64 years),30.0,49.0,Age,30-49,41546,0.084,0.079,0.09,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_WA-1,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Wyoming Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1888,0.02,0.013999999999999999,0.027999999999999997,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_CR2,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 3 (South),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,30009,0.10099999999999999,0.095,0.10800000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_OH-2,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western North Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1930,0.057,0.045,0.073,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_CR3,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 4 (West),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,42799,0.094,0.08900000000000001,0.098,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_SexFemale,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,Female,Multiple groups,16.0,,Sex/Gender,,65872,0.08,0.077,0.084,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_CA-3,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern Illinois, Southeastern Missouri, and Western Kentucky Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3422,0.061,0.05,0.076,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_CA-1,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Sacramento Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1714,0.031000000000000003,0.02,0.049,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_WA-2,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Georgia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1509,0.054000000000000006,0.038,0.076,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_NV-2,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern New Jersey and Southeastern Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1763,0.084,0.068,0.10400000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_UT,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Vermont Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2877,0.07200000000000001,0.061,0.085,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_CT,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Delaware and Maryland Eastern Shore Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1897,0.066,0.051,0.085,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_OH-1,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Oklahoma Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1842,0.083,0.067,0.102,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_KY,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Maryland and National Capital Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,919,0.085,0.063,0.113,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202011_Region_MA,220613_USA_CentersforDiseaseControlandPrevention_202011,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Memphis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-11-01,2020-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1934,0.048,0.037000000000000005,0.063,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Overall,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Primary Estimate,,135026,0.11900000000000001,0.115,0.122,True,,True,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_NM-2,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Tampa Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1994,0.17,0.15,0.192,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_DE,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Detroit Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1715,0.09,0.065,0.122,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_NY-1,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Texas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,4978,0.165,0.147,0.185,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_ME,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Massachusetts Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2005,0.028999999999999998,0.021,0.039,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_NV-1,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New Mexico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1668,0.11800000000000001,0.095,0.14400000000000002,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_MO,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Tennessee Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1140,0.147,0.122,0.17600000000000002,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_NH,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2294,0.048,0.038,0.06,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_CR2,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 3 (South),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,30174,0.16399999999999998,0.156,0.171,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_MA,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Memphis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1911,0.084,0.065,0.107,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_NC,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Oregon Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,4157,0.083,0.07,0.09699999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_OH-2,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western North Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1982,0.138,0.11699999999999999,0.162,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_EthnicityHispanic,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Hispanic,7896,0.18100000000000002,0.167,0.195,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_NJ,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern New Mexico, El Paso, and Southern Texas Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3283,0.09699999999999999,0.075,0.125,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_CR4,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 1 (Northeast),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,36300,0.087,0.083,0.092,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_SD,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Louisiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1837,0.22399999999999998,0.201,0.249,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_AZ-1,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Indiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2451,0.10400000000000001,0.087,0.12300000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_IL-1,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Colorado Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3551,0.16,0.139,0.184,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_MD,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Missouri and St. Louis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3620,0.07200000000000001,0.059000000000000004,0.087,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_CA-3,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern Illinois, Southeastern Missouri, and Western Kentucky Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3433,0.077,0.066,0.09,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_NV-2,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern New Jersey and Southeastern Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1886,0.145,0.12300000000000001,0.171,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_EthnicityWhite,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,White,115359,0.106,0.10400000000000001,0.10800000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_ID,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Iowa Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2136,0.226,0.204,0.249,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_FL-2,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Utah Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1996,0.128,0.113,0.14400000000000002,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_CR1,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 2 (Midwest),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,23544,0.114,0.105,0.12300000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_MI,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Mississippi Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3882,0.113,0.09300000000000001,0.138,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_UT,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Vermont Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2879,0.128,0.11199999999999999,0.146,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_TX-1,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2629,0.146,0.121,0.174,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_CA-1,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Sacramento Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1657,0.028999999999999998,0.019,0.045,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_EthnicityBlack,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Black,3365,0.142,0.12400000000000001,0.162,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_MS,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Virginia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1949,0.16899999999999998,0.149,0.19100000000000003,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_LA,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern New York and Northern New Jersey Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1635,0.14800000000000002,0.12,0.18100000000000002,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_OR-2,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,667,0.034,0.019,0.057999999999999996,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Age50-64,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Adults (18-64 years),50.0,64.0,Age,50-64,50034,0.09699999999999999,0.09300000000000001,0.102,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_KY,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Maryland and National Capital Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1081,0.15,0.121,0.184,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_NY-3,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northwestern Oregon and Southwestern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,837,0.035,0.02,0.057999999999999996,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Age30-49,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Adults (18-64 years),30.0,49.0,Age,30-49,42724,0.128,0.12300000000000001,0.133,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_RI,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,South Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1359,0.057,0.04,0.08,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_VT,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"West Virginia, Western Maryland, and Northern Virginia Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1345,0.032,0.02,0.051,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_MT,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Nebraska Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2625,0.19899999999999998,0.179,0.22100000000000003,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_SC,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Northern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1936,0.092,0.07200000000000001,0.11800000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_HI,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Idaho Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1665,0.02,0.012,0.034,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_KS-2,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2089,0.151,0.128,0.177,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_IA,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Kansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1884,0.24800000000000003,0.22399999999999998,0.272,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_NM-1,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1654,0.064,0.051,0.08,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_GA,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Hawaii Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3651,0.13,0.11,0.151,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_IL-2,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Missouri and Northern Arkansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,715,0.23199999999999998,0.198,0.27,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_AL,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Alaska Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3388,0.141,0.122,0.162,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_WI,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1913,0.20800000000000002,0.17500000000000002,0.245,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_IN,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2297,0.149,0.129,0.171,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_TN-2,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Miami Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1301,0.11199999999999999,0.08,0.154,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_CR3,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 4 (West),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,43022,0.12300000000000001,0.11800000000000001,0.129,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_CT,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Delaware and Maryland Eastern Shore Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1914,0.1,0.077,0.128,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_WV,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,816,0.102,0.083,0.125,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_SexMale,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,Male,Multiple groups,16.0,,Sex/Gender,,69438,0.11900000000000001,0.114,0.12300000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Age65+,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Seniors (65+ years),65.0,,Age,65+,26178,0.063,0.057999999999999996,0.068,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_OH-1,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Oklahoma Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1879,0.162,0.141,0.18600000000000003,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_OK,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Texas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,760,0.122,0.096,0.154,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_WY,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Alabama Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1338,0.154,0.133,0.17800000000000002,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_MN,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Montana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2110,0.14800000000000002,0.129,0.17,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_VA,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1453,0.07200000000000001,0.05,0.10300000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_WA-2,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Georgia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1396,0.10400000000000001,0.07,0.153,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_CO,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Connecticut Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1794,0.122,0.102,0.145,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_WA-1,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Wyoming Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1780,0.045,0.034,0.059000000000000004,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_PR,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Rhode Island Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1986,0.039,0.03,0.05,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_TX-2,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Wisconsin Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3800,0.135,0.121,0.15,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_TN-1,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Eastern South Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1397,0.157,0.13699999999999998,0.18,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_AZ-2,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern California Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1154,0.10800000000000001,0.075,0.154,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_NY-2,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,920,0.057,0.042,0.076,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_EthnicityAsian,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Asian,3805,0.071,0.06,0.084,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_CA-2,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern Nevada Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1951,0.052000000000000005,0.039,0.069,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_FL-1,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Minnesota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3999,0.201,0.18,0.22399999999999998,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Age16-29,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Adults (18-64 years),16.0,29.0,Age,16-29,16090,0.17300000000000001,0.16399999999999998,0.18300000000000002,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_PA,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Chicago Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2698,0.114,0.1,0.129,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_AK,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Kentucky Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1203,0.127,0.105,0.153,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_EthnicityOther,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Other,2615,0.09,0.076,0.107,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_ND,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Kansas and Northwestern Missouri Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1186,0.195,0.17300000000000001,0.219,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_AR,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Nevada and Northwestern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1739,0.18300000000000002,0.16,0.209,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_OR-1,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Puerto Rico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,969,0.038,0.027000000000000003,0.053,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_NE,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,New Hampshire Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1817,0.23800000000000002,0.209,0.27,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_Region_KS-1,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Maine Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1892,0.196,0.177,0.217,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202012_SexFemale,220613_USA_CentersforDiseaseControlandPrevention_202012,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2020-12-01,2020-12-31,Blood donors,Female,Multiple groups,16.0,,Sex/Gender,,65588,0.11800000000000001,0.114,0.12300000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Overall,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Primary Estimate,,134632,0.20500000000000002,0.20199999999999999,0.209,True,,True,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_KS-2,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2019,0.264,0.24300000000000002,0.28600000000000003,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_TX-1,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2828,0.262,0.23800000000000002,0.28500000000000003,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_MD,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Missouri and St. Louis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3613,0.147,0.125,0.171,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_SexFemale,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,Female,Multiple groups,16.0,,Sex/Gender,,66193,0.189,0.184,0.193,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_WA-2,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Georgia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1515,0.17300000000000001,0.146,0.203,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_NJ,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern New Mexico, El Paso, and Southern Texas Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3287,0.167,0.14300000000000002,0.19399999999999998,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_EthnicityAsian,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Asian,3609,0.185,0.171,0.201,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_ND,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Kansas and Northwestern Missouri Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,944,0.25,0.218,0.282,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_NC,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Oregon Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,4147,0.165,0.146,0.18600000000000003,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_UT,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Vermont Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2869,0.242,0.215,0.271,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_NY-3,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northwestern Oregon and Southwestern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,802,0.165,0.139,0.195,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_AZ-2,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern California Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1138,0.182,0.147,0.223,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_HI,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Idaho Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1517,0.09300000000000001,0.076,0.113,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_ID,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Iowa Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2012,0.29600000000000004,0.272,0.32,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_MN,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Montana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2208,0.22899999999999998,0.2,0.261,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_WV,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,843,0.251,0.21100000000000002,0.29100000000000004,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_VT,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"West Virginia, Western Maryland, and Northern Virginia Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1301,0.08900000000000001,0.073,0.10800000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_WY,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Alabama Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1368,0.227,0.198,0.259,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_NV-2,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern New Jersey and Southeastern Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1868,0.23600000000000002,0.209,0.266,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_MA,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Memphis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1925,0.147,0.12400000000000001,0.17300000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_TestAntiN,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Test used,Anti-N,135592,0.159,0.156,0.162,,,True,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_KS-1,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Maine Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1871,0.31,0.28500000000000003,0.334,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_CR2,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 3 (South),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,30017,0.244,0.23600000000000002,0.252,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_IL-1,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Colorado Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3577,0.21600000000000003,0.19,0.244,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_FL-2,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Utah Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1995,0.18600000000000003,0.16899999999999998,0.204,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_MI,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Mississippi Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3840,0.192,0.174,0.212,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_TN-1,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Eastern South Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1390,0.28,0.24600000000000002,0.315,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_CA-3,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern Illinois, Southeastern Missouri, and Western Kentucky Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3461,0.189,0.17300000000000001,0.20600000000000002,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Age16-29,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Adults (18-64 years),16.0,29.0,Age,16-29,15097,0.27,0.259,0.281,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_NM-2,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Tampa Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1983,0.29100000000000004,0.264,0.318,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_EthnicityWhite,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,White,115305,0.189,0.18600000000000003,0.192,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Age30-49,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Adults (18-64 years),30.0,49.0,Age,30-49,42528,0.226,0.22,0.233,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_NH,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2160,0.12400000000000001,0.109,0.142,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_AL,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Alaska Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3430,0.277,0.251,0.304,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_SexMale,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,Male,Multiple groups,16.0,,Sex/Gender,,68439,0.22100000000000003,0.215,0.226,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_CO,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Connecticut Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1810,0.17800000000000002,0.152,0.20600000000000002,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_TN-2,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Miami Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1165,0.233,0.19399999999999998,0.27899999999999997,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_OH-1,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Oklahoma Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1872,0.262,0.231,0.29300000000000004,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_CA-1,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Sacramento Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1728,0.07400000000000001,0.055,0.098,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_VA,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1446,0.172,0.14300000000000002,0.20500000000000002,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_TX-2,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Wisconsin Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3913,0.24300000000000002,0.22399999999999998,0.264,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_LA,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern New York and Northern New Jersey Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1698,0.24300000000000002,0.214,0.275,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_PR,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Rhode Island Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1990,0.11,0.096,0.125,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_CR3,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 4 (West),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,42728,0.22,0.21300000000000002,0.227,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_NY-2,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,938,0.171,0.142,0.20500000000000002,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_GA,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Hawaii Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3660,0.22399999999999998,0.204,0.244,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_OK,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Texas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,638,0.307,0.263,0.35100000000000003,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_FL-1,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Minnesota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3998,0.24600000000000002,0.23,0.262,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_CR1,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 2 (Midwest),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,23484,0.195,0.185,0.20500000000000002,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_AZ-1,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Indiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2524,0.193,0.17,0.219,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_RI,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,South Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1391,0.171,0.14,0.20800000000000002,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_DE,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Detroit Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1585,0.17600000000000002,0.14800000000000002,0.207,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_WA-1,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Wyoming Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1872,0.083,0.066,0.10300000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_CA-2,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern Nevada Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2078,0.126,0.106,0.14800000000000002,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_AR,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Nevada and Northwestern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1832,0.26,0.233,0.287,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_OR-1,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Puerto Rico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,966,0.114,0.092,0.139,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_KY,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Maryland and National Capital Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,982,0.222,0.192,0.256,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_NV-1,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New Mexico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1722,0.21,0.184,0.23800000000000002,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_MS,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Virginia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1624,0.265,0.23600000000000002,0.29300000000000004,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_OR-2,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,640,0.106,0.077,0.145,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_NY-1,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Texas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,4803,0.24100000000000002,0.22,0.263,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_SD,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Louisiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1690,0.36,0.317,0.40299999999999997,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_EthnicityHispanic,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Hispanic,8059,0.278,0.267,0.29,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_MT,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Nebraska Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2376,0.284,0.264,0.305,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_IN,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2479,0.264,0.24,0.28800000000000003,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_WI,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1889,0.233,0.201,0.268,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_EthnicityBlack,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Black,3119,0.20500000000000002,0.188,0.223,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_EthnicityOther,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Other,2550,0.21100000000000002,0.187,0.23800000000000002,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_ME,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Massachusetts Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2179,0.12,0.10400000000000001,0.138,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_IA,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Kansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2001,0.315,0.284,0.34500000000000003,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_PA,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Chicago Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2793,0.207,0.189,0.225,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Age65+,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Seniors (65+ years),65.0,,Age,65+,26961,0.11900000000000001,0.113,0.126,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_AK,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Kentucky Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1298,0.23600000000000002,0.21300000000000002,0.26,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_NE,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,New Hampshire Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1695,0.31,0.278,0.342,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_CT,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Delaware and Maryland Eastern Shore Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1905,0.168,0.145,0.19399999999999998,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_SC,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Northern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1941,0.231,0.204,0.26,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_IL-2,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Missouri and Northern Arkansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,742,0.297,0.255,0.33899999999999997,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_OH-2,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western North Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1975,0.223,0.196,0.252,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Age50-64,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Adults (18-64 years),50.0,64.0,Age,50-64,50046,0.18100000000000002,0.17500000000000002,0.187,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_CR4,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 1 (Northeast),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,36413,0.171,0.165,0.177,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_MO,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Tennessee Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1215,0.23800000000000002,0.198,0.28300000000000003,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202101_Region_NM-1,220613_USA_CentersforDiseaseControlandPrevention_202101,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-01-01,2021-01-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1668,0.16399999999999998,0.142,0.188,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Overall,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Primary Estimate,,133288,0.335,0.331,0.33899999999999997,True,,True,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_TX-2,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Wisconsin Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,3923,0.383,0.36,0.406,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_CR3,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 4 (West),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,41840,0.36700000000000005,0.36,0.374,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_EthnicityBlack,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Ethnicity,Black,3146,0.331,0.312,0.349,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_HI,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Idaho Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1768,0.262,0.24,0.284,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_OH-1,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Oklahoma Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1849,0.341,0.31,0.37200000000000005,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_CO,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Connecticut Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1771,0.254,0.227,0.281,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_MD,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Missouri and St. Louis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,3629,0.267,0.24600000000000002,0.289,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_UT,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Vermont Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,2939,0.33799999999999997,0.317,0.358,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_IL-1,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Colorado Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,3553,0.365,0.33799999999999997,0.392,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_CA-3,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern Illinois, Southeastern Missouri, and Western Kentucky Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,3479,0.34500000000000003,0.322,0.36700000000000005,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_DE,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Detroit Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1189,0.311,0.275,0.34700000000000003,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_MT,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Nebraska Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,2369,0.401,0.374,0.429,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_AR,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Nevada and Northwestern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1529,0.41000000000000003,0.376,0.444,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_NM-1,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1567,0.336,0.308,0.363,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_WA-2,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Georgia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1418,0.321,0.277,0.365,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_CR4,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 1 (Northeast),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,36766,0.318,0.311,0.325,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_ND,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Kansas and Northwestern Missouri Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1206,0.42700000000000005,0.38799999999999996,0.467,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_RI,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,South Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1285,0.215,0.185,0.249,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_MI,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Mississippi Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,3833,0.324,0.30100000000000005,0.34600000000000003,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_OR-2,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,702,0.258,0.214,0.303,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_GA,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Hawaii Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,3696,0.369,0.33799999999999997,0.4,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_KS-2,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,2063,0.331,0.305,0.358,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_NV-2,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern New Jersey and Southeastern Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1848,0.40299999999999997,0.374,0.43200000000000005,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_IA,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Kansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1895,0.381,0.35100000000000003,0.41000000000000003,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_OH-2,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western North Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1928,0.355,0.319,0.391,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_NJ,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern New Mexico, El Paso, and Southern Texas Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,3247,0.295,0.268,0.32299999999999995,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Age16-29,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Adults (18-64 years),16.0,29.0,Age,16-29,16016,0.34,0.329,0.35100000000000003,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_LA,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern New York and Northern New Jersey Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1654,0.387,0.34500000000000003,0.428,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_OR-1,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Puerto Rico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,914,0.226,0.198,0.258,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_FL-1,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Minnesota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,3999,0.394,0.373,0.41500000000000004,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_ME,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Massachusetts Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,2072,0.239,0.21300000000000002,0.268,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_CA-1,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Sacramento Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1725,0.222,0.19100000000000003,0.257,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_NV-1,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New Mexico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1810,0.337,0.314,0.36,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_NM-2,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Tampa Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1991,0.44799999999999995,0.423,0.47200000000000003,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_TestAntiN,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Test used,Anti-N,134995,0.184,0.18100000000000002,0.18600000000000003,,,True,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_CR1,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 2 (Midwest),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,22889,0.287,0.277,0.298,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_SC,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Northern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1868,0.369,0.33899999999999997,0.4,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_TN-2,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Miami Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,855,0.35000000000000003,0.295,0.405,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_KS-1,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Maine Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1881,0.45,0.42,0.48,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_WI,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1860,0.396,0.364,0.429,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_IL-2,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Missouri and Northern Arkansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,660,0.455,0.40399999999999997,0.506,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_NE,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,New Hampshire Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1806,0.42700000000000005,0.392,0.461,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_WA-1,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Wyoming Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1923,0.22899999999999998,0.20800000000000002,0.25,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_VT,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"West Virginia, Western Maryland, and Northern Virginia Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1264,0.22899999999999998,0.204,0.257,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_EthnicityAsian,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Ethnicity,Asian,3922,0.317,0.297,0.336,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_AZ-2,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern California Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1058,0.359,0.311,0.408,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_PA,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Chicago Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,2719,0.32299999999999995,0.298,0.34700000000000003,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_EthnicityOther,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Ethnicity,Other,2681,0.299,0.275,0.324,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_KY,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Maryland and National Capital Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1044,0.363,0.32299999999999995,0.40399999999999997,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_PR,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Rhode Island Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1992,0.265,0.237,0.294,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_AZ-1,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Indiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,2505,0.39299999999999996,0.37,0.41600000000000004,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_AK,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Kentucky Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1288,0.424,0.38799999999999996,0.459,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_CR2,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 3 (South),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,29801,0.36100000000000004,0.353,0.369,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_SexFemale,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,Female,Multiple groups,16.0,,Sex/Gender,,65579,0.314,0.307,0.321,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_WY,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Alabama Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1707,0.405,0.37700000000000006,0.433,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_OK,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Texas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,648,0.54,0.48600000000000004,0.594,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_NY-2,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,898,0.272,0.237,0.307,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_IN,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,2406,0.391,0.36200000000000004,0.419,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_EthnicityWhite,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Ethnicity,White,113510,0.327,0.324,0.331,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_NY-3,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northwestern Oregon and Southwestern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,836,0.29300000000000004,0.259,0.327,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_NY-1,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Texas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,4545,0.314,0.292,0.336,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_MS,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Virginia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1745,0.44,0.408,0.473,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_TN-1,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Eastern South Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1372,0.37,0.34,0.4,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_SD,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Louisiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1625,0.41500000000000004,0.385,0.446,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Age65+,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Seniors (65+ years),65.0,,Age,65+,25807,0.38,0.37200000000000005,0.389,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_MA,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Memphis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1914,0.20500000000000002,0.182,0.22899999999999998,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_MO,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Tennessee Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1138,0.35600000000000004,0.315,0.39799999999999996,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_WV,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,779,0.36700000000000005,0.325,0.409,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_TX-1,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,2839,0.42200000000000004,0.38799999999999996,0.456,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_MN,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Montana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,2098,0.3,0.269,0.331,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_FL-2,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Utah Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,2000,0.33299999999999996,0.312,0.354,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Age30-49,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Adults (18-64 years),30.0,49.0,Age,30-49,42059,0.34299999999999997,0.336,0.35100000000000003,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_EthnicityHispanic,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Ethnicity,Hispanic,8037,0.385,0.37,0.399,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_SexMale,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,Male,Multiple groups,16.0,,Sex/Gender,,67709,0.354,0.349,0.36,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_ID,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Iowa Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,2038,0.419,0.394,0.444,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Age50-64,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Adults (18-64 years),50.0,64.0,Age,50-64,49406,0.284,0.277,0.29100000000000004,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_CT,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Delaware and Maryland Eastern Shore Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1889,0.298,0.265,0.332,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_AL,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Alaska Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,3472,0.42,0.4,0.439,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_VA,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1391,0.321,0.278,0.364,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_NC,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Oregon Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,4208,0.341,0.32,0.36200000000000004,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_CA-2,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern Nevada Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,1946,0.27,0.245,0.29600000000000004,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202102_Region_NH,220613_USA_CentersforDiseaseControlandPrevention_202102,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-02-01,2021-02-28,Blood donors,All,Multiple groups,16.0,,Geographical area,,2220,0.245,0.222,0.269,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Overall,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Primary Estimate,,134557,0.49200000000000005,0.48700000000000004,0.49600000000000005,True,,True,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_CR1,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 2 (Midwest),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,23596,0.49600000000000005,0.483,0.509,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_CO,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Connecticut Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1778,0.402,0.371,0.433,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_ND,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Kansas and Northwestern Missouri Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1168,0.56,0.53,0.589,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_GA,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Hawaii Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3649,0.485,0.461,0.509,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_LA,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern New York and Northern New Jersey Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1695,0.508,0.47600000000000003,0.539,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_MA,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Memphis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1969,0.406,0.38200000000000006,0.43100000000000005,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_SD,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Louisiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1655,0.5700000000000001,0.54,0.599,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_AZ-2,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern California Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1046,0.538,0.49,0.5860000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_IA,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Kansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2010,0.545,0.517,0.573,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_NY-1,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Texas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,4976,0.55,0.526,0.573,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_MI,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Mississippi Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3853,0.483,0.455,0.512,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_AK,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Kentucky Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1411,0.562,0.536,0.589,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_IN,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2675,0.49200000000000005,0.46799999999999997,0.517,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_CT,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Delaware and Maryland Eastern Shore Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1926,0.465,0.435,0.494,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_PR,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Rhode Island Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1993,0.36700000000000005,0.342,0.392,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Age65+,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Seniors (65+ years),65.0,,Age,65+,27757,0.728,0.72,0.736,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_TX-1,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2762,0.524,0.499,0.549,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_SC,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Northern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1864,0.503,0.47100000000000003,0.534,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_CA-1,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Sacramento Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1647,0.40399999999999997,0.374,0.434,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_HI,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Idaho Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1778,0.41700000000000004,0.389,0.445,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_FL-1,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Minnesota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,4000,0.473,0.45299999999999996,0.494,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_AR,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Nevada and Northwestern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1815,0.532,0.51,0.554,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_TX-2,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Wisconsin Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3920,0.5529999999999999,0.536,0.5700000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_WV,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,782,0.551,0.509,0.593,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Age50-64,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Adults (18-64 years),50.0,64.0,Age,50-64,49122,0.43,0.423,0.43700000000000006,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_AL,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Alaska Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3412,0.547,0.521,0.5720000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_MO,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Tennessee Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1152,0.556,0.519,0.593,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_IL-1,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Colorado Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3559,0.451,0.43,0.47200000000000003,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_KY,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Maryland and National Capital Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,922,0.573,0.529,0.618,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_OH-1,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Oklahoma Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1850,0.52,0.49100000000000005,0.549,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_CR4,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 1 (Northeast),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,36159,0.473,0.465,0.48100000000000004,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_UT,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Vermont Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2810,0.48,0.46,0.5,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_CA-3,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern Illinois, Southeastern Missouri, and Western Kentucky Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3463,0.517,0.493,0.541,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_NV-1,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New Mexico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1585,0.47200000000000003,0.44,0.504,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_RI,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,South Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1390,0.467,0.424,0.51,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_ME,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Massachusetts Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2112,0.39,0.36700000000000005,0.414,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_CR2,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 3 (South),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,30235,0.504,0.49600000000000005,0.513,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_NJ,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern New Mexico, El Paso, and Southern Texas Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3317,0.5,0.47000000000000003,0.53,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_EthnicityOther,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Other,2675,0.45,0.42600000000000005,0.474,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_NM-1,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1657,0.49,0.466,0.515,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_IL-2,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Missouri and Northern Arkansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,751,0.615,0.5710000000000001,0.659,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_KS-1,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Maine Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1860,0.599,0.5720000000000001,0.627,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Age30-49,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Adults (18-64 years),30.0,49.0,Age,30-49,40586,0.446,0.438,0.454,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_OR-2,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,623,0.42200000000000004,0.37,0.474,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_WA-2,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Georgia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1432,0.455,0.41000000000000003,0.499,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_SexFemale,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,Female,Multiple groups,16.0,,Sex/Gender,,66390,0.47100000000000003,0.465,0.478,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_NM-2,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Tampa Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1985,0.557,0.534,0.58,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_AZ-1,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Indiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2515,0.529,0.503,0.556,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_EthnicityAsian,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Asian,3968,0.443,0.418,0.469,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_MS,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Virginia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1946,0.545,0.511,0.578,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_MN,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Montana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2174,0.47200000000000003,0.446,0.499,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_NH,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2291,0.406,0.379,0.433,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_FL-2,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Utah Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1998,0.444,0.41600000000000004,0.47100000000000003,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_CA-2,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern Nevada Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1976,0.44799999999999995,0.42,0.47500000000000003,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_NY-3,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northwestern Oregon and Southwestern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,801,0.528,0.48100000000000004,0.5760000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_SexMale,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,Male,Multiple groups,16.0,,Sex/Gender,,68167,0.512,0.505,0.518,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_VA,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1476,0.509,0.46,0.5579999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_NE,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,New Hampshire Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1663,0.573,0.535,0.612,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_EthnicityBlack,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Black,3467,0.47200000000000003,0.44799999999999995,0.49600000000000005,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_WA-1,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Wyoming Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1836,0.38,0.35200000000000004,0.408,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_NY-2,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,909,0.48200000000000004,0.433,0.53,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_WY,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Alabama Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1304,0.537,0.502,0.5710000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_TN-1,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Eastern South Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1368,0.49100000000000005,0.465,0.518,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_KS-2,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2024,0.503,0.48200000000000004,0.525,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Age16-29,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Adults (18-64 years),16.0,29.0,Age,16-29,17092,0.434,0.42200000000000004,0.446,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_PA,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Chicago Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2627,0.474,0.45,0.499,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_MD,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Missouri and St. Louis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3684,0.43100000000000005,0.40399999999999997,0.459,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_OH-2,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western North Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1971,0.49600000000000005,0.469,0.523,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_EthnicityWhite,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,White,114270,0.501,0.49700000000000005,0.504,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_OR-1,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Puerto Rico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1006,0.36100000000000004,0.321,0.401,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_CR3,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 4 (West),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,42574,0.502,0.49600000000000005,0.509,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_TestAntiN,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Test used,Anti-N,135161,0.198,0.19399999999999998,0.201,,,True,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_NC,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Oregon Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,4072,0.5,0.47600000000000003,0.524,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_OK,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Texas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,635,0.643,0.603,0.684,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_ID,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Iowa Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2097,0.556,0.532,0.579,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_EthnicityHispanic,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Hispanic,8184,0.512,0.498,0.526,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_MT,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Nebraska Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2460,0.517,0.49,0.545,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_WI,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1870,0.5,0.46799999999999997,0.531,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_VT,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"West Virginia, Western Maryland, and Northern Virginia Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1278,0.365,0.33,0.4,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_NV-2,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern New Jersey and Southeastern Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1750,0.514,0.483,0.546,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_DE,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Detroit Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1323,0.434,0.392,0.47600000000000003,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202103_Region_TN-2,220613_USA_CentersforDiseaseControlandPrevention_202103,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Miami Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-03-01,2021-03-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1251,0.452,0.41000000000000003,0.494,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Overall,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Primary Estimate,,134510,0.7140000000000001,0.711,0.718,True,,True,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_IN,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2745,0.725,0.701,0.75,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_WY,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Alabama Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1279,0.665,0.638,0.693,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_MA,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Memphis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1952,0.6729999999999999,0.643,0.703,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_PA,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Chicago Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2588,0.698,0.68,0.716,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_NC,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Oregon Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,4195,0.763,0.746,0.779,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_NV-1,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New Mexico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1737,0.674,0.647,0.701,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_EthnicityBlack,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Ethnicity,Black,3771,0.6890000000000001,0.67,0.708,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_TN-2,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Miami Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1059,0.67,0.638,0.701,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_IL-2,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Missouri and Northern Arkansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,661,0.6809999999999999,0.634,0.728,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_AR,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Nevada and Northwestern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1669,0.688,0.665,0.7120000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_OR-1,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Puerto Rico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,985,0.613,0.5760000000000001,0.65,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_AZ-2,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern California Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1068,0.725,0.677,0.773,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_NY-1,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Texas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,5060,0.747,0.7290000000000001,0.7640000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_NE,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,New Hampshire Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1798,0.7909999999999999,0.763,0.816,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_EthnicityOther,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Ethnicity,Other,2887,0.65,0.626,0.6729999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_LA,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern New York and Northern New Jersey Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1553,0.7220000000000001,0.6900000000000001,0.753,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_MO,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Tennessee Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1153,0.773,0.728,0.813,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_MI,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Mississippi Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3861,0.715,0.691,0.74,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_NM-1,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1607,0.7070000000000001,0.682,0.7320000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_ME,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Massachusetts Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2019,0.6779999999999999,0.653,0.7020000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Age65+,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Seniors (65+ years),65.0,,Age,65+,29380,0.891,0.8840000000000001,0.897,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_TX-2,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Wisconsin Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3857,0.72,0.705,0.7340000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_WI,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1935,0.731,0.701,0.761,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_VA,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1409,0.736,0.7040000000000001,0.7690000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_SD,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Louisiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1541,0.696,0.66,0.731,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_KY,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Maryland and National Capital Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,963,0.747,0.7090000000000001,0.784,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_ID,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Iowa Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1963,0.6990000000000001,0.67,0.728,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_VT,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"West Virginia, Western Maryland, and Northern Virginia Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1281,0.655,0.624,0.6859999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_AK,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Kentucky Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1633,0.7690000000000001,0.746,0.79,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_NV-2,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern New Jersey and Southeastern Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1869,0.7120000000000001,0.6859999999999999,0.738,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_CO,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Connecticut Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1759,0.642,0.6070000000000001,0.6779999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_FL-2,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Utah Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2000,0.611,0.5870000000000001,0.635,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_OK,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Texas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,654,0.748,0.705,0.7909999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_PR,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Rhode Island Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1990,0.654,0.622,0.6859999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Age30-49,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Adults (18-64 years),30.0,49.0,Age,30-49,39806,0.669,0.6609999999999999,0.6759999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_CA-2,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern Nevada Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2037,0.654,0.624,0.685,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_OR-2,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,639,0.605,0.563,0.647,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_EthnicityHispanic,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Ethnicity,Hispanic,8221,0.6970000000000001,0.684,0.71,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_TN-1,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Eastern South Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1301,0.731,0.698,0.763,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_GA,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Hawaii Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3631,0.721,0.693,0.7490000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_MD,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Missouri and St. Louis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3658,0.715,0.6920000000000001,0.738,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_CA-3,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern Illinois, Southeastern Missouri, and Western Kentucky Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3430,0.74,0.721,0.76,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_WA-2,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Georgia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1403,0.7000000000000001,0.654,0.746,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_SexFemale,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,Female,Multiple groups,16.0,,Sex/Gender,,65959,0.698,0.6920000000000001,0.7040000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Age50-64,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Adults (18-64 years),50.0,64.0,Age,50-64,47945,0.735,0.73,0.741,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_MS,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Virginia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1907,0.7000000000000001,0.6759999999999999,0.723,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_CR2,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 3 (South),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,30126,0.728,0.7190000000000001,0.736,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Age16-29,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Adults (18-64 years),16.0,29.0,Age,16-29,17379,0.614,0.6020000000000001,0.625,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_KS-2,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2042,0.757,0.73,0.782,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_MN,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Montana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2046,0.7070000000000001,0.677,0.737,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_DE,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Detroit Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1646,0.711,0.6659999999999999,0.757,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_OH-1,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Oklahoma Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1893,0.773,0.742,0.8,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_CR3,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 4 (West),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,42201,0.7140000000000001,0.7070000000000001,0.721,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_WA-1,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Wyoming Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1913,0.637,0.614,0.6609999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_ND,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Kansas and Northwestern Missouri Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1189,0.7440000000000001,0.7190000000000001,0.7690000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_NH,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2301,0.644,0.616,0.6729999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_HI,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Idaho Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1794,0.667,0.643,0.691,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_TestAntiN,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Test used,Anti-N,134763,0.207,0.204,0.21,,,True,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_IA,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Kansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1894,0.745,0.721,0.77,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_CR4,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 1 (Northeast),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,36793,0.7000000000000001,0.6920000000000001,0.708,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_CA-1,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Sacramento Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1671,0.738,0.7000000000000001,0.777,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_NM-2,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Tampa Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2031,0.766,0.745,0.7859999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_OH-2,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western North Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1966,0.726,0.698,0.755,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_KS-1,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Maine Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1825,0.768,0.736,0.797,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_NJ,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern New Mexico, El Paso, and Southern Texas Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3169,0.7270000000000001,0.696,0.7590000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_IL-1,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Colorado Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3577,0.682,0.66,0.7040000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_FL-1,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Minnesota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,4000,0.662,0.644,0.68,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_NY-3,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northwestern Oregon and Southwestern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,800,0.7690000000000001,0.723,0.809,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_RI,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,South Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1458,0.634,0.601,0.6659999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_AL,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Alaska Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3407,0.6779999999999999,0.657,0.6990000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_SC,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Northern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1884,0.7170000000000001,0.685,0.7490000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_AZ-1,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Indiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2617,0.6920000000000001,0.669,0.7140000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_CR1,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 2 (Midwest),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,23400,0.7240000000000001,0.716,0.733,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_WV,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,750,0.731,0.6990000000000001,0.763,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_NY-2,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,876,0.74,0.698,0.783,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_SexMale,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,Male,Multiple groups,16.0,,Sex/Gender,,68551,0.73,0.725,0.735,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_EthnicityAsian,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Ethnicity,Asian,3992,0.7190000000000001,0.6970000000000001,0.741,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_MT,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Nebraska Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2473,0.6970000000000001,0.675,0.7190000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_CT,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Delaware and Maryland Eastern Shore Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1896,0.758,0.7320000000000001,0.782,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_UT,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Vermont Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2885,0.7190000000000001,0.6990000000000001,0.74,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_Region_TX-1,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2658,0.7170000000000001,0.6940000000000001,0.741,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202104_EthnicityWhite,220613_USA_CentersforDiseaseControlandPrevention_202104,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-04-01,2021-04-30,Blood donors,All,Multiple groups,16.0,,Ethnicity,White,113649,0.728,0.725,0.7320000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Overall,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Primary Estimate,,134949,0.833,0.8290000000000001,0.8370000000000001,True,,True,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Age16-29,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Adults (18-64 years),16.0,29.0,Age,16-29,14541,0.761,0.75,0.772,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_EthnicityOther,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Other,2749,0.8079999999999999,0.787,0.8290000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_SD,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Louisiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1466,0.797,0.774,0.818,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_MD,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Missouri and St. Louis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3702,0.891,0.875,0.905,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_NY-1,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Texas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,5061,0.8740000000000001,0.855,0.891,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_IL-1,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Colorado Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3553,0.861,0.8390000000000001,0.88,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_CA-2,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern Nevada Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1936,0.8,0.775,0.8220000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_FL-1,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Minnesota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,4000,0.762,0.745,0.779,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_WI,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1912,0.86,0.835,0.882,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_ME,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Massachusetts Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2054,0.8690000000000001,0.8470000000000001,0.887,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_CA-1,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Sacramento Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1712,0.913,0.8890000000000001,0.9309999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_AL,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Alaska Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3478,0.7640000000000001,0.746,0.78,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_UT,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Vermont Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2965,0.821,0.8,0.8390000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_TX-2,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Wisconsin Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3915,0.807,0.787,0.8250000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_NY-2,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,938,0.8520000000000001,0.812,0.885,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Age30-49,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Adults (18-64 years),30.0,49.0,Age,30-49,41081,0.812,0.805,0.8190000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_GA,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Hawaii Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3679,0.809,0.787,0.8290000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_EthnicityWhite,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,White,114250,0.838,0.835,0.84,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_NJ,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern New Mexico, El Paso, and Southern Texas Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3289,0.887,0.863,0.907,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_NY-3,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northwestern Oregon and Southwestern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,814,0.8640000000000001,0.831,0.891,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_TN-2,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Miami Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1165,0.799,0.7640000000000001,0.8300000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_PA,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Chicago Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2685,0.8150000000000001,0.797,0.8320000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_CT,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Delaware and Maryland Eastern Shore Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1915,0.8959999999999999,0.871,0.917,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_VT,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"West Virginia, Western Maryland, and Northern Virginia Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1281,0.8890000000000001,0.8620000000000001,0.9109999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_CR1,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 2 (Midwest),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,23741,0.872,0.8620000000000001,0.882,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_AZ-2,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern California Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1109,0.843,0.788,0.887,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_IN,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2778,0.8220000000000001,0.804,0.84,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_RI,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,South Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1483,0.833,0.793,0.867,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_CR2,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 3 (South),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,30258,0.833,0.8250000000000001,0.84,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_TX-1,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2707,0.774,0.743,0.802,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_FL-2,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Utah Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2000,0.742,0.7190000000000001,0.7640000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_IA,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Kansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1990,0.8300000000000001,0.8079999999999999,0.85,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_MA,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Memphis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1935,0.8959999999999999,0.875,0.913,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_TN-1,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Eastern South Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1425,0.804,0.777,0.8290000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_NV-1,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New Mexico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1713,0.767,0.741,0.7909999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_SexMale,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,Male,Multiple groups,16.0,,Sex/Gender,,66885,0.8420000000000001,0.8370000000000001,0.846,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_NV-2,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern New Jersey and Southeastern Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1868,0.7690000000000001,0.743,0.793,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_EthnicityAsian,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Asian,4210,0.91,0.8959999999999999,0.922,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_CR4,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 1 (Northeast),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,36338,0.838,0.8320000000000001,0.8440000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_SexFemale,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,Female,Multiple groups,16.0,,Sex/Gender,,68064,0.823,0.818,0.8290000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_MO,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Tennessee Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1176,0.8420000000000001,0.8059999999999999,0.873,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_PR,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Rhode Island Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1985,0.855,0.8320000000000001,0.876,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_MI,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Mississippi Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3873,0.876,0.856,0.893,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_IL-2,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Missouri and Northern Arkansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,707,0.72,0.652,0.788,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_KS-1,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Maine Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1849,0.779,0.7540000000000001,0.8029999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_AR,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Nevada and Northwestern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1734,0.7490000000000001,0.726,0.772,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_OK,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Texas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,684,0.8150000000000001,0.782,0.843,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_AZ-1,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Indiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2624,0.767,0.745,0.787,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_OH-2,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western North Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2011,0.7809999999999999,0.753,0.807,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_CR3,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 4 (West),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,42627,0.802,0.7959999999999999,0.8079999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_KS-2,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2121,0.865,0.84,0.886,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_CO,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Connecticut Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1787,0.8470000000000001,0.8240000000000001,0.868,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_AK,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Kentucky Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1275,0.783,0.753,0.8109999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_HI,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Idaho Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1670,0.8079999999999999,0.787,0.828,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_LA,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern New York and Northern New Jersey Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1623,0.788,0.761,0.813,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_MS,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Virginia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1653,0.6659999999999999,0.637,0.6950000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_EthnicityHispanic,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Hispanic,8205,0.8150000000000001,0.802,0.8270000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_VA,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1455,0.8340000000000001,0.8,0.8640000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_ID,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Iowa Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1950,0.793,0.7709999999999999,0.8140000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_NM-2,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Tampa Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2062,0.841,0.821,0.8590000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Age65+,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Seniors (65+ years),65.0,,Age,65+,29405,0.922,0.918,0.927,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_MT,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Nebraska Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2188,0.798,0.767,0.826,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_OR-1,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Puerto Rico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,953,0.841,0.8079999999999999,0.8690000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_WV,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,773,0.8029999999999999,0.762,0.838,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_TestAntiN,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Test used,Anti-N,135174,0.20199999999999999,0.19899999999999998,0.20600000000000002,,,True,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_OH-1,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Oklahoma Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1845,0.821,0.792,0.846,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_NC,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Oregon Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,4159,0.812,0.793,0.8290000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_NH,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2286,0.8740000000000001,0.855,0.891,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Age50-64,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Adults (18-64 years),50.0,64.0,Age,50-64,49922,0.86,0.856,0.863,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_SC,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Northern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1939,0.802,0.775,0.8270000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_WA-1,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Wyoming Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1924,0.863,0.838,0.8840000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_KY,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Maryland and National Capital Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,917,0.8290000000000001,0.795,0.858,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_EthnicityBlack,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Black,3550,0.792,0.7709999999999999,0.812,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_CA-3,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern Illinois, Southeastern Missouri, and Western Kentucky Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3474,0.876,0.86,0.89,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_DE,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Detroit Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1619,0.846,0.807,0.8790000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_WA-2,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Georgia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1529,0.785,0.745,0.821,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_WY,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Alabama Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1350,0.6900000000000001,0.6609999999999999,0.718,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_OR-2,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,679,0.762,0.723,0.798,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_NM-1,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1570,0.831,0.809,0.851,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_MN,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Montana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2281,0.823,0.799,0.845,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_NE,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,New Hampshire Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1698,0.833,0.8079999999999999,0.8540000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202105_Region_ND,220613_USA_CentersforDiseaseControlandPrevention_202105,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Kansas and Northwestern Missouri Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-05-01,2021-05-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,998,0.8029999999999999,0.775,0.8290000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Overall,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Primary Estimate,,134788,0.8740000000000001,0.871,0.877,True,,True,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_LA,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern New York and Northern New Jersey Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1632,0.795,0.756,0.8300000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_SexMale,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,Male,Multiple groups,16.0,,Sex/Gender,,67157,0.88,0.875,0.8840000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_DE,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Detroit Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1602,0.8890000000000001,0.8540000000000001,0.9159999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_VT,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"West Virginia, Western Maryland, and Northern Virginia Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1274,0.932,0.91,0.9490000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_AK,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Kentucky Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1362,0.8150000000000001,0.7859999999999999,0.8420000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_OH-2,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western North Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1996,0.8640000000000001,0.838,0.886,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_NM-1,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1607,0.872,0.846,0.8940000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_NH,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2415,0.902,0.8890000000000001,0.913,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_EthnicityAsian,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Ethnicity,Asian,4352,0.953,0.9440000000000001,0.96,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Age30-49,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Adults (18-64 years),30.0,49.0,Age,30-49,40646,0.8490000000000001,0.8440000000000001,0.8540000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_IA,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Kansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1951,0.846,0.813,0.8740000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_AZ-1,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Indiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2546,0.813,0.792,0.8320000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_CA-1,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Sacramento Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1742,0.932,0.908,0.9500000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_GA,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Hawaii Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3642,0.8420000000000001,0.8220000000000001,0.86,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_MD,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Missouri and St. Louis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3633,0.935,0.919,0.9470000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_TX-2,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Wisconsin Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3902,0.8290000000000001,0.8109999999999999,0.845,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_HI,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Idaho Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1980,0.9,0.881,0.917,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_CA-3,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern Illinois, Southeastern Missouri, and Western Kentucky Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3504,0.8959999999999999,0.882,0.909,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_IL-2,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Missouri and Northern Arkansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,656,0.775,0.7270000000000001,0.8170000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_TN-1,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Eastern South Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1426,0.831,0.8029999999999999,0.856,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_OH-1,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Oklahoma Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1876,0.866,0.8420000000000001,0.887,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_CO,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Connecticut Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1799,0.897,0.872,0.917,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Age16-29,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Adults (18-64 years),16.0,29.0,Age,16-29,13759,0.8490000000000001,0.84,0.8570000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_NM-2,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Tampa Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2032,0.866,0.84,0.888,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_NE,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,New Hampshire Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1756,0.8690000000000001,0.8470000000000001,0.888,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Age65+,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Seniors (65+ years),65.0,,Age,65+,30558,0.93,0.925,0.935,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_PR,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Rhode Island Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1991,0.8940000000000001,0.8690000000000001,0.914,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_OR-1,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Puerto Rico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,947,0.8790000000000001,0.85,0.904,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_NY-1,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Texas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,5116,0.919,0.9059999999999999,0.93,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_RI,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,South Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1419,0.909,0.8790000000000001,0.9329999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_PA,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Chicago Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2672,0.851,0.835,0.866,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_NV-1,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New Mexico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1647,0.795,0.7640000000000001,0.8220000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_WY,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Alabama Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1217,0.755,0.7270000000000001,0.7809999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_MI,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Mississippi Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3854,0.923,0.9059999999999999,0.9359999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_NJ,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern New Mexico, El Paso, and Southern Texas Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3295,0.903,0.875,0.925,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_SC,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Northern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1870,0.8570000000000001,0.835,0.877,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Age50-64,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Adults (18-64 years),50.0,64.0,Age,50-64,49825,0.887,0.883,0.891,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_KS-2,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2044,0.881,0.8590000000000001,0.9,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_WA-2,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Georgia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1500,0.8150000000000001,0.78,0.846,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_NV-2,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern New Jersey and Southeastern Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1892,0.826,0.798,0.851,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_EthnicityWhite,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Ethnicity,White,113736,0.872,0.8690000000000001,0.875,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_CR1,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 2 (Midwest),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,23640,0.914,0.908,0.92,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_MN,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Montana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2172,0.872,0.8470000000000001,0.8940000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_CR4,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 1 (Northeast),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,36596,0.875,0.8690000000000001,0.881,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_TestAntiN,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Test used,Anti-N,135003,0.20600000000000002,0.20199999999999999,0.209,,,True,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_CR3,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 4 (West),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,42138,0.841,0.835,0.8470000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_AL,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Alaska Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3418,0.809,0.7909999999999999,0.8250000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_TN-2,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Miami Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1122,0.846,0.807,0.8790000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_OR-2,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,624,0.8370000000000001,0.8,0.868,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_FL-2,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Utah Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2000,0.784,0.765,0.8009999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_KS-1,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Maine Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1860,0.828,0.802,0.851,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_KY,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Maryland and National Capital Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,969,0.8740000000000001,0.843,0.899,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_SexFemale,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,Female,Multiple groups,16.0,,Sex/Gender,,67631,0.867,0.863,0.871,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_FL-1,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Minnesota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3999,0.805,0.787,0.821,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_WV,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,805,0.833,0.7959999999999999,0.865,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_EthnicityOther,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Ethnicity,Other,2948,0.853,0.8320000000000001,0.872,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_NY-2,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,874,0.913,0.887,0.934,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_NC,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Oregon Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,4157,0.8520000000000001,0.835,0.868,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_EthnicityHispanic,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Ethnicity,Hispanic,8141,0.8590000000000001,0.8490000000000001,0.8690000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_SD,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Louisiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1872,0.816,0.787,0.8420000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_OK,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Texas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,671,0.865,0.835,0.89,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_MS,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Virginia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1661,0.718,0.691,0.746,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_VA,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1390,0.882,0.8490000000000001,0.909,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_WA-1,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Wyoming Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1928,0.9309999999999999,0.913,0.946,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_MT,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Nebraska Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2376,0.8190000000000001,0.797,0.838,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_ME,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Massachusetts Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1870,0.912,0.8940000000000001,0.927,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_MO,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Tennessee Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1184,0.9259999999999999,0.9009999999999999,0.9450000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_CT,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Delaware and Maryland Eastern Shore Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1895,0.938,0.924,0.9500000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_EthnicityBlack,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Ethnicity,Black,3620,0.861,0.846,0.875,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_ND,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Kansas and Northwestern Missouri Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1136,0.81,0.78,0.8370000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_IN,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2631,0.871,0.853,0.887,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_CR2,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 3 (South),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,30423,0.881,0.8740000000000001,0.887,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_AR,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Nevada and Northwestern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1496,0.784,0.761,0.805,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_MA,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Memphis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1949,0.951,0.9359999999999999,0.9620000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_IL-1,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Colorado Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3519,0.909,0.89,0.925,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_CA-2,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern Nevada Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2020,0.853,0.826,0.875,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_ID,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Iowa Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1928,0.7690000000000001,0.7390000000000001,0.797,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_AZ-2,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern California Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1148,0.885,0.853,0.9109999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_WI,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1916,0.891,0.861,0.914,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_TX-1,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2743,0.816,0.794,0.836,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_UT,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Vermont Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2797,0.8620000000000001,0.8420000000000001,0.8790000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202106_Region_NY-3,220613_USA_CentersforDiseaseControlandPrevention_202106,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northwestern Oregon and Southwestern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-06-01,2021-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,861,0.9059999999999999,0.8790000000000001,0.927,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Overall,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Primary Estimate,,140224,0.888,0.885,0.891,True,,True,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_KS-1,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Maine Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1909,0.855,0.828,0.8790000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_MT,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Nebraska Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2205,0.8590000000000001,0.831,0.883,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_AK,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Kentucky Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1288,0.8340000000000001,0.8079999999999999,0.8570000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_EthnicityAsian,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Asian,4394,0.961,0.953,0.968,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_NM-2,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Tampa Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2472,0.8940000000000001,0.877,0.908,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_NY-3,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northwestern Oregon and Southwestern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,827,0.9279999999999999,0.904,0.946,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_NY-2,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,934,0.913,0.885,0.934,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_WA-2,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Georgia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1520,0.8220000000000001,0.778,0.858,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Age30-49,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Adults (18-64 years),30.0,49.0,Age,30-49,41551,0.8640000000000001,0.8590000000000001,0.8690000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_ID,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Iowa Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1874,0.8420000000000001,0.809,0.871,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_VA,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1481,0.893,0.863,0.917,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_CR1,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 2 (Midwest),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,24262,0.925,0.919,0.9309999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Age50-64,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Adults (18-64 years),50.0,64.0,Age,50-64,52135,0.899,0.895,0.903,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_FL-2,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Utah Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2679,0.7959999999999999,0.778,0.8140000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_MA,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Memphis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1987,0.938,0.92,0.953,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_CA-3,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern Illinois, Southeastern Missouri, and Western Kentucky Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3496,0.918,0.907,0.9279999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Age65+,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Seniors (65+ years),65.0,,Age,65+,32755,0.9440000000000001,0.9400000000000001,0.9470000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_CR4,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 1 (Northeast),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,38653,0.891,0.885,0.8959999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_IA,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Kansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1976,0.8690000000000001,0.848,0.887,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_WA-1,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Wyoming Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1984,0.941,0.925,0.953,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_FL-1,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Minnesota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,4631,0.835,0.818,0.85,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_CO,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Connecticut Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2072,0.897,0.8740000000000001,0.9159999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_VT,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"West Virginia, Western Maryland, and Northern Virginia Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1184,0.941,0.9159999999999999,0.9590000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_SexFemale,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,Female,Multiple groups,16.0,,Sex/Gender,,69989,0.8790000000000001,0.8740000000000001,0.8840000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_TestAntiN,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Test used,Anti-N,140298,0.20199999999999999,0.198,0.20600000000000002,,,True,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,VITROS Anti-SARS-CoV-2 Total N Antibody Test",Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_CR3,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 4 (West),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,44664,0.8620000000000001,0.856,0.868,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_OK,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Texas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,650,0.858,0.8250000000000001,0.886,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_UT,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Vermont Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3500,0.878,0.86,0.895,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_DE,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Detroit Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1488,0.902,0.865,0.9309999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_SD,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Louisiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1537,0.798,0.77,0.8240000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_IL-1,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Colorado Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3705,0.92,0.903,0.9329999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_NE,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,New Hampshire Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1701,0.8540000000000001,0.8240000000000001,0.88,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_CR2,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 3 (South),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,30668,0.885,0.88,0.8890000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_ME,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Massachusetts Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1910,0.903,0.88,0.923,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_CA-1,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Sacramento Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1790,0.9550000000000001,0.9309999999999999,0.971,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_TX-2,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Wisconsin Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3919,0.867,0.848,0.8840000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_OH-1,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Oklahoma Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1883,0.8790000000000001,0.8520000000000001,0.9009999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_AZ-1,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Indiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2649,0.8190000000000001,0.8,0.8370000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_WY,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Alabama Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1459,0.7640000000000001,0.728,0.797,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_ND,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Kansas and Northwestern Missouri Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1304,0.8009999999999999,0.7640000000000001,0.8340000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_MN,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Montana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2086,0.9059999999999999,0.89,0.919,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_RI,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,South Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1494,0.9390000000000001,0.914,0.9570000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_GA,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Hawaii Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3734,0.8520000000000001,0.8300000000000001,0.872,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_EthnicityHispanic,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Hispanic,8768,0.8790000000000001,0.87,0.888,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_EthnicityOther,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Other,2751,0.855,0.8340000000000001,0.873,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_AZ-2,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern California Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1153,0.878,0.8490000000000001,0.902,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_EthnicityBlack,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Black,3920,0.8740000000000001,0.8620000000000001,0.886,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_TN-2,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Miami Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1325,0.835,0.8009999999999999,0.8640000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_WV,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,806,0.8640000000000001,0.826,0.8940000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_NJ,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern New Mexico, El Paso, and Southern Texas Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3325,0.93,0.91,0.9450000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_IN,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2717,0.8520000000000001,0.8340000000000001,0.8690000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_NY-1,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Texas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,5435,0.9329999999999999,0.919,0.9450000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_PR,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Rhode Island Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1977,0.915,0.899,0.929,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_TX-1,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2829,0.8420000000000001,0.818,0.863,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_OR-1,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Puerto Rico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,993,0.909,0.875,0.935,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_AR,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Nevada and Northwestern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1757,0.8270000000000001,0.7959999999999999,0.8540000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_CT,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Delaware and Maryland Eastern Shore Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1903,0.935,0.914,0.9520000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_MI,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Mississippi Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3857,0.9109999999999999,0.891,0.927,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_NV-2,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern New Jersey and Southeastern Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2051,0.831,0.81,0.85,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_EthnicityWhite,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,White,118414,0.886,0.8840000000000001,0.888,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_NV-1,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New Mexico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1950,0.818,0.795,0.8390000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_KS-2,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2072,0.905,0.888,0.919,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_WI,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1914,0.8890000000000001,0.867,0.908,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Age16-29,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Adults (18-64 years),16.0,29.0,Age,16-29,13783,0.865,0.855,0.8740000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_OH-2,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western North Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2020,0.856,0.8270000000000001,0.881,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_IL-2,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Missouri and Northern Arkansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,707,0.782,0.735,0.823,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_NM-1,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1657,0.876,0.856,0.893,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_CA-2,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern Nevada Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2326,0.853,0.826,0.877,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_PA,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Chicago Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2834,0.87,0.8520000000000001,0.886,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_KY,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Maryland and National Capital Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1000,0.883,0.856,0.905,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_SC,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Northern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1890,0.868,0.8420000000000001,0.89,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_AL,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Alaska Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3426,0.8220000000000001,0.8009999999999999,0.841,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_MD,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Missouri and St. Louis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3709,0.9440000000000001,0.93,0.956,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_MS,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Virginia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2095,0.7709999999999999,0.7440000000000001,0.7959999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_LA,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern New York and Northern New Jersey Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1697,0.855,0.828,0.878,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_OR-2,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,589,0.843,0.802,0.877,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_NC,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Oregon Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,4168,0.876,0.861,0.89,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_NH,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2429,0.903,0.885,0.919,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_TN-1,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Eastern South Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1380,0.8540000000000001,0.8320000000000001,0.8740000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_MO,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Tennessee Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1280,0.887,0.853,0.914,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_SexMale,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,Male,Multiple groups,16.0,,Sex/Gender,,70235,0.8959999999999999,0.892,0.9,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202107_Region_HI,220613_USA_CentersforDiseaseControlandPrevention_202107,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Idaho Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-07-01,2021-07-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1625,0.897,0.8740000000000001,0.9159999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Overall,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Primary Estimate,,137583,0.8959999999999999,0.893,0.899,True,,True,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_OR-2,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,624,0.8640000000000001,0.8220000000000001,0.898,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_NV-1,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New Mexico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1909,0.8370000000000001,0.812,0.8590000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_EthnicityAsian,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Asian,4309,0.968,0.96,0.975,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_WI,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1914,0.898,0.877,0.9159999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_LA,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern New York and Northern New Jersey Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1581,0.871,0.846,0.892,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_CA-1,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Sacramento Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1831,0.9620000000000001,0.9450000000000001,0.9740000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_MT,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Nebraska Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2352,0.835,0.805,0.861,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_KY,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Maryland and National Capital Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1058,0.8570000000000001,0.8220000000000001,0.886,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_IA,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Kansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1945,0.873,0.848,0.8940000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_KS-2,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2027,0.909,0.8890000000000001,0.9259999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_CT,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Delaware and Maryland Eastern Shore Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1888,0.943,0.922,0.9590000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_AL,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Alaska Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3468,0.8440000000000001,0.821,0.865,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_IL-1,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Colorado Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3576,0.919,0.904,0.9329999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_OR-1,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Puerto Rico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,982,0.922,0.8959999999999999,0.9420000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_NC,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Oregon Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,4226,0.883,0.866,0.898,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_EthnicityHispanic,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Hispanic,8564,0.892,0.882,0.902,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_FL-1,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Minnesota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,4099,0.86,0.845,0.875,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_AK,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Kentucky Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1348,0.8440000000000001,0.823,0.8620000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Age65+,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Seniors (65+ years),65.0,,Age,65+,31949,0.943,0.9400000000000001,0.946,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_NV-2,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern New Jersey and Southeastern Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1918,0.8520000000000001,0.833,0.8690000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_MA,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Memphis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1944,0.9500000000000001,0.9359999999999999,0.961,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_TN-1,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Eastern South Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1365,0.8470000000000001,0.8170000000000001,0.873,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_MI,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Mississippi Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3843,0.919,0.903,0.932,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_OK,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Texas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,694,0.8890000000000001,0.858,0.914,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_NJ,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern New Mexico, El Paso, and Southern Texas Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3171,0.919,0.903,0.934,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_SD,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Louisiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1309,0.841,0.807,0.871,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_NY-1,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Texas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,5447,0.9279999999999999,0.9159999999999999,0.9390000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_EthnicityBlack,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Black,3683,0.8940000000000001,0.881,0.905,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_ND,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Kansas and Northwestern Missouri Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1414,0.836,0.809,0.86,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_CR1,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 2 (Midwest),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,23860,0.922,0.9159999999999999,0.9279999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_NE,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,New Hampshire Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1741,0.895,0.87,0.9159999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_WA-1,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Wyoming Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1967,0.937,0.918,0.951,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_AZ-2,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern California Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1105,0.8740000000000001,0.828,0.909,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_TestAntiN,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Test used,Anti-N,137594,0.219,0.215,0.223,,,True,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,VITROS Anti-SARS-CoV-2 Total N Antibody Test",Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_AZ-1,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Indiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2608,0.8300000000000001,0.8109999999999999,0.8470000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_TX-2,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Wisconsin Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3877,0.909,0.897,0.92,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_MO,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Tennessee Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1239,0.912,0.89,0.93,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_UT,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Vermont Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3391,0.8790000000000001,0.8590000000000001,0.897,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Age50-64,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Adults (18-64 years),50.0,64.0,Age,50-64,50813,0.903,0.899,0.9059999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_NH,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2589,0.914,0.897,0.929,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_OH-1,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Oklahoma Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1913,0.892,0.866,0.913,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_IN,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2687,0.885,0.868,0.9,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_KS-1,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Maine Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1886,0.8490000000000001,0.823,0.873,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_CR4,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 1 (Northeast),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,38229,0.898,0.893,0.903,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_HI,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Idaho Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2026,0.917,0.902,0.9309999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_NM-2,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Tampa Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2079,0.886,0.867,0.904,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_WV,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,849,0.8490000000000001,0.8170000000000001,0.877,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_WA-2,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Georgia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1633,0.875,0.851,0.8959999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_PA,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Chicago Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2680,0.8590000000000001,0.84,0.876,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_IL-2,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Missouri and Northern Arkansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,668,0.768,0.706,0.821,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_EthnicityWhite,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,White,116023,0.89,0.887,0.893,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_TN-2,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Miami Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1463,0.8640000000000001,0.833,0.8890000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_SC,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Northern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1898,0.871,0.8440000000000001,0.8940000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_CR2,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 3 (South),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,30254,0.893,0.887,0.899,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_SexFemale,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,Female,Multiple groups,16.0,,Sex/Gender,,70531,0.8890000000000001,0.885,0.893,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_CA-3,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern Illinois, Southeastern Missouri, and Western Kentucky Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3482,0.924,0.912,0.935,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_NY-3,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northwestern Oregon and Southwestern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,858,0.915,0.888,0.935,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_MS,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Virginia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1948,0.8300000000000001,0.8,0.856,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_CO,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Connecticut Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1869,0.892,0.868,0.912,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Age30-49,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Adults (18-64 years),30.0,49.0,Age,30-49,40874,0.8740000000000001,0.8690000000000001,0.8790000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_WY,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Alabama Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1501,0.767,0.737,0.794,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_ID,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Iowa Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1854,0.8320000000000001,0.805,0.856,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_FL-2,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Utah Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2097,0.8240000000000001,0.8009999999999999,0.8440000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_NM-1,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1640,0.887,0.866,0.905,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_MN,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Montana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2098,0.895,0.87,0.9159999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_EthnicityOther,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Other,3023,0.878,0.8590000000000001,0.8959999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_VT,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"West Virginia, Western Maryland, and Northern Virginia Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1143,0.9470000000000001,0.932,0.9590000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_CA-2,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern Nevada Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2110,0.888,0.872,0.902,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_SexMale,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,Male,Multiple groups,16.0,,Sex/Gender,,67052,0.902,0.899,0.9059999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_VA,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1410,0.8890000000000001,0.8570000000000001,0.915,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_MD,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Missouri and St. Louis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3660,0.9470000000000001,0.934,0.9570000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_PR,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Rhode Island Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1981,0.917,0.895,0.935,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_DE,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Detroit Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1416,0.904,0.867,0.9309999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_TX-1,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2688,0.8440000000000001,0.823,0.863,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_OH-2,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western North Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1994,0.8690000000000001,0.845,0.89,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_AR,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Nevada and Northwestern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1711,0.853,0.835,0.8690000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_NY-2,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,917,0.902,0.876,0.923,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_GA,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Hawaii Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3751,0.882,0.861,0.9,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_CR3,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 4 (West),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,43259,0.877,0.871,0.883,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_RI,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,South Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1422,0.9470000000000001,0.9279999999999999,0.96,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Age16-29,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Adults (18-64 years),16.0,29.0,Age,16-29,13947,0.881,0.8740000000000001,0.8890000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202108_Region_ME,220613_USA_CentersforDiseaseControlandPrevention_202108,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Massachusetts Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-08-01,2021-08-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1801,0.923,0.904,0.9390000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Overall,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Primary Estimate,,140567,0.918,0.915,0.92,True,,True,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_NM-1,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1722,0.904,0.886,0.92,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_WA-2,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Georgia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1526,0.905,0.88,0.925,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_MD,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Missouri and St. Louis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3965,0.958,0.9470000000000001,0.966,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_IN,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2751,0.924,0.91,0.9359999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_RI,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,South Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1335,0.9520000000000001,0.932,0.9670000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_IL-1,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Colorado Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3965,0.9359999999999999,0.923,0.9470000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Age50-64,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Adults (18-64 years),50.0,64.0,Age,50-64,50545,0.925,0.922,0.9279999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_WA-1,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Wyoming Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1935,0.9450000000000001,0.929,0.958,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_NM-2,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Tampa Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1326,0.92,0.903,0.935,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_LA,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern New York and Northern New Jersey Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1411,0.935,0.903,0.956,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_EthnicityBlack,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Ethnicity,Black,4102,0.914,0.904,0.924,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_ID,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Iowa Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2288,0.8740000000000001,0.855,0.891,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Age30-49,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Adults (18-64 years),30.0,49.0,Age,30-49,41290,0.898,0.893,0.902,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_SexMale,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,Male,Multiple groups,16.0,,Sex/Gender,,69855,0.924,0.9209999999999999,0.9279999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_SD,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Louisiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1475,0.873,0.8470000000000001,0.895,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_AL,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Alaska Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3284,0.8840000000000001,0.866,0.9,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_EthnicityHispanic,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Ethnicity,Hispanic,8935,0.913,0.905,0.92,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_FL-1,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Minnesota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,4407,0.892,0.881,0.903,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_GA,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Hawaii Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,4016,0.914,0.899,0.927,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_MN,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Montana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2572,0.9109999999999999,0.892,0.9259999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_OK,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Texas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,800,0.898,0.87,0.92,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_NC,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Oregon Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,4312,0.914,0.9009999999999999,0.9259999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_TestAntiN,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Test used,Anti-N,140630,0.245,0.24100000000000002,0.25,,,True,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,VITROS Anti-SARS-CoV-2 Total N Antibody Test",Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_NY-3,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northwestern Oregon and Southwestern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,894,0.9309999999999999,0.905,0.951,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_PR,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Rhode Island Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2045,0.971,0.9570000000000001,0.98,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_AR,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Nevada and Northwestern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1563,0.877,0.8570000000000001,0.895,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_IL-2,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Missouri and Northern Arkansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,761,0.8490000000000001,0.813,0.88,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_CO,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Connecticut Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1791,0.925,0.907,0.9400000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_AZ-1,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Indiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2810,0.863,0.8420000000000001,0.882,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_OR-1,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Puerto Rico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1176,0.941,0.924,0.953,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_CR1,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 2 (Midwest),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,24884,0.934,0.929,0.9400000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_OH-1,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Oklahoma Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1863,0.903,0.883,0.92,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_KS-2,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2008,0.9209999999999999,0.9009999999999999,0.938,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_TN-1,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Eastern South Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1494,0.907,0.886,0.924,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_WY,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Alabama Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1544,0.816,0.782,0.846,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_HI,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Idaho Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2032,0.9490000000000001,0.937,0.96,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_EthnicityAsian,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Ethnicity,Asian,4964,0.9640000000000001,0.9570000000000001,0.9690000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Age16-29,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Adults (18-64 years),16.0,29.0,Age,16-29,17538,0.912,0.905,0.918,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_TX-1,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2986,0.8940000000000001,0.876,0.91,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_EthnicityWhite,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Ethnicity,White,117436,0.913,0.9109999999999999,0.9159999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_IA,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Kansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2229,0.885,0.863,0.904,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_NY-1,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Texas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,5117,0.9390000000000001,0.9259999999999999,0.9500000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_CA-1,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Sacramento Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1694,0.9550000000000001,0.937,0.968,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_CR4,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 1 (Northeast),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,37485,0.913,0.909,0.918,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_NJ,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern New Mexico, El Paso, and Southern Texas Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3453,0.941,0.925,0.9540000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_NV-1,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New Mexico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1760,0.8640000000000001,0.843,0.883,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_MI,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Mississippi Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3913,0.9279999999999999,0.912,0.9420000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_ME,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Massachusetts Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2044,0.922,0.908,0.934,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_KY,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Maryland and National Capital Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1095,0.8940000000000001,0.866,0.917,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_UT,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Vermont Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3423,0.909,0.897,0.9209999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_NH,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2749,0.918,0.905,0.93,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Age65+,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Seniors (65+ years),65.0,,Age,65+,31194,0.9520000000000001,0.9470000000000001,0.956,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_AK,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Kentucky Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1054,0.9,0.88,0.917,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_TX-2,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Wisconsin Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3072,0.9440000000000001,0.934,0.9520000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_EthnicityOther,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Ethnicity,Other,3085,0.917,0.904,0.9279999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_WV,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,791,0.8840000000000001,0.8590000000000001,0.904,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_OR-2,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,673,0.86,0.8220000000000001,0.891,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_SC,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Northern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2028,0.907,0.885,0.925,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_CA-3,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern Illinois, Southeastern Missouri, and Western Kentucky Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3447,0.924,0.9109999999999999,0.935,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_OH-2,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western North Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2113,0.876,0.8540000000000001,0.8940000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_DE,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Detroit Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1563,0.9209999999999999,0.892,0.9420000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_AZ-2,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern California Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1335,0.881,0.8540000000000001,0.903,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_PA,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Chicago Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2722,0.892,0.875,0.907,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_VT,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"West Virginia, Western Maryland, and Northern Virginia Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1314,0.9470000000000001,0.93,0.96,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_NE,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,New Hampshire Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1806,0.919,0.902,0.934,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_CA-2,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern Nevada Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1968,0.899,0.885,0.912,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_CR2,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 3 (South),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,31800,0.912,0.907,0.9159999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_KS-1,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Maine Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2139,0.867,0.8470000000000001,0.885,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_NV-2,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern New Jersey and Southeastern Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1865,0.8840000000000001,0.865,0.9009999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_MS,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Virginia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2122,0.867,0.845,0.885,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_TN-2,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Miami Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1264,0.881,0.845,0.909,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_CT,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Delaware and Maryland Eastern Shore Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2020,0.941,0.927,0.953,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_MT,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Nebraska Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2116,0.871,0.8520000000000001,0.888,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_MA,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Memphis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2176,0.9570000000000001,0.9470000000000001,0.966,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_MO,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Tennessee Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1298,0.934,0.918,0.948,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_NY-2,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1060,0.9059999999999999,0.8790000000000001,0.9279999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_WI,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1923,0.9109999999999999,0.891,0.9279999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_CR3,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 4 (West),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,44353,0.9109999999999999,0.907,0.9159999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_SexFemale,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,Female,Multiple groups,16.0,,Sex/Gender,,70712,0.9109999999999999,0.907,0.914,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_ND,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Kansas and Northwestern Missouri Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,984,0.867,0.836,0.893,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_VA,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1486,0.9279999999999999,0.904,0.9470000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202109_Region_FL-2,220613_USA_CentersforDiseaseControlandPrevention_202109,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Utah Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-09-01,2021-09-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2694,0.885,0.8690000000000001,0.9,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Overall,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Primary Estimate,,140121,0.929,0.927,0.9309999999999999,True,,True,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_WI,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1870,0.913,0.897,0.9279999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Age65+,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Seniors (65+ years),65.0,,Age,65+,32184,0.9550000000000001,0.9520000000000001,0.9570000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_LA,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern New York and Northern New Jersey Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1631,0.909,0.8840000000000001,0.9279999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_EthnicityHispanic,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Hispanic,9473,0.9259999999999999,0.918,0.934,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_TestAntiN,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Test used,Anti-N,140159,0.262,0.258,0.265,,,True,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,VITROS Anti-SARS-CoV-2 Total N Antibody Test",Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_CA-1,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Sacramento Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1677,0.9490000000000001,0.925,0.966,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_CR4,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 1 (Northeast),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,38078,0.929,0.925,0.9329999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_EthnicityWhite,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,White,116380,0.9259999999999999,0.924,0.9279999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_ID,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Iowa Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2106,0.903,0.883,0.92,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_AZ-1,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Indiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2598,0.883,0.868,0.897,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_WY,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Alabama Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1591,0.8790000000000001,0.8620000000000001,0.8940000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_OK,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Texas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,651,0.912,0.883,0.935,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_MT,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Nebraska Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2706,0.9009999999999999,0.8840000000000001,0.915,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_TX-2,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Wisconsin Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3879,0.96,0.951,0.968,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_VT,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"West Virginia, Western Maryland, and Northern Virginia Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1399,0.968,0.9540000000000001,0.978,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_EthnicityAsian,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Asian,4700,0.9670000000000001,0.958,0.9740000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_GA,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Hawaii Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3830,0.922,0.908,0.934,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_IA,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Kansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1961,0.902,0.882,0.918,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_NY-2,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,978,0.927,0.904,0.9440000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_FL-2,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Utah Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2049,0.902,0.888,0.915,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_SexFemale,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,Female,Multiple groups,16.0,,Sex/Gender,,70605,0.925,0.922,0.9279999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_NM-2,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Tampa Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2094,0.934,0.922,0.9440000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_KS-1,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Maine Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2071,0.91,0.8959999999999999,0.922,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_KY,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Maryland and National Capital Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1138,0.925,0.9,0.9440000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_NE,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,New Hampshire Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1747,0.927,0.912,0.9390000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_CA-3,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern Illinois, Southeastern Missouri, and Western Kentucky Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3448,0.9400000000000001,0.93,0.948,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_MS,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Virginia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2056,0.9059999999999999,0.888,0.922,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_NY-1,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Texas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,5412,0.9490000000000001,0.938,0.958,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_NV-2,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern New Jersey and Southeastern Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1907,0.899,0.881,0.914,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_CA-2,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern Nevada Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2088,0.9259999999999999,0.913,0.938,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_MI,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Mississippi Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3904,0.9279999999999999,0.912,0.941,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_NH,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2594,0.932,0.918,0.9440000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_VA,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1496,0.934,0.913,0.9500000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_MO,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Tennessee Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1244,0.9520000000000001,0.934,0.965,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_CR3,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 4 (West),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,44300,0.923,0.919,0.9259999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_CT,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Delaware and Maryland Eastern Shore Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2001,0.9520000000000001,0.9390000000000001,0.9620000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_TN-1,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Eastern South Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1393,0.9059999999999999,0.881,0.927,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_SexMale,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,Male,Multiple groups,16.0,,Sex/Gender,,69516,0.934,0.9309999999999999,0.9359999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_EthnicityOther,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Other,3100,0.919,0.904,0.932,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_DE,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Detroit Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1628,0.927,0.907,0.943,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_AK,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Kentucky Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1241,0.9159999999999999,0.897,0.9309999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_IN,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2643,0.935,0.9209999999999999,0.9470000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_SD,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Louisiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1559,0.8740000000000001,0.848,0.897,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_AL,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Alaska Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3465,0.915,0.904,0.925,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_AR,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Nevada and Northwestern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1761,0.899,0.882,0.915,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_OH-2,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western North Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2050,0.8940000000000001,0.8690000000000001,0.915,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_MA,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Memphis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2195,0.961,0.9470000000000001,0.9720000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_NJ,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern New Mexico, El Paso, and Southern Texas Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3224,0.943,0.925,0.956,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_SC,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Northern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1930,0.915,0.8959999999999999,0.9309999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_WV,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,842,0.893,0.866,0.915,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_TX-1,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2994,0.904,0.8890000000000001,0.918,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_ND,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Kansas and Northwestern Missouri Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1308,0.891,0.8690000000000001,0.909,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_NV-1,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New Mexico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1688,0.903,0.883,0.92,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_NY-3,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northwestern Oregon and Southwestern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,804,0.951,0.93,0.966,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_PA,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Chicago Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2730,0.897,0.881,0.9109999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_MN,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Montana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2224,0.925,0.908,0.9390000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_FL-1,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Minnesota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,4043,0.912,0.902,0.9209999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_WA-2,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Georgia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1502,0.9259999999999999,0.9009999999999999,0.9450000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_CR2,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 3 (South),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,30825,0.923,0.918,0.927,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_WA-1,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Wyoming Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1963,0.965,0.953,0.9740000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_EthnicityBlack,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Black,4386,0.93,0.92,0.938,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_KS-2,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1979,0.922,0.905,0.9359999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_NM-1,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1628,0.918,0.903,0.932,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_OR-1,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Puerto Rico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1109,0.934,0.915,0.9490000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_OR-2,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,722,0.912,0.883,0.935,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Age50-64,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Adults (18-64 years),50.0,64.0,Age,50-64,49323,0.935,0.932,0.938,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_UT,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Vermont Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2803,0.929,0.915,0.9400000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_TN-2,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Miami Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1482,0.925,0.898,0.9450000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_CR1,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 2 (Midwest),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,24836,0.943,0.938,0.948,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_NC,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Oregon Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,4330,0.914,0.902,0.925,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_IL-2,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Missouri and Northern Arkansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,711,0.883,0.856,0.9059999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_PR,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Rhode Island Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2082,0.976,0.968,0.983,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_RI,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,South Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1526,0.9490000000000001,0.9279999999999999,0.9640000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_AZ-2,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern California Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1146,0.915,0.8840000000000001,0.938,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Age30-49,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Adults (18-64 years),30.0,49.0,Age,30-49,39453,0.919,0.914,0.922,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_ME,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Massachusetts Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1973,0.938,0.9209999999999999,0.9520000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_HI,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Idaho Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2077,0.961,0.951,0.9690000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Age16-29,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Adults (18-64 years),16.0,29.0,Age,16-29,19161,0.919,0.913,0.925,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_CO,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Connecticut Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1984,0.923,0.905,0.938,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_IL-1,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Colorado Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3586,0.938,0.923,0.9500000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_MD,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Missouri and St. Louis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3702,0.96,0.9470000000000001,0.97,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202110_Region_OH-1,220613_USA_CentersforDiseaseControlandPrevention_202110,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Oklahoma Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-10-01,2021-10-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1968,0.92,0.903,0.9329999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Overall,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Primary Estimate,,135135,0.9390000000000001,0.938,0.941,True,,True,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_EthnicityAsian,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Ethnicity,Asian,4746,0.98,0.9740000000000001,0.985,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_AL,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Alaska Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3471,0.917,0.903,0.929,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_NY-1,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Texas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,5517,0.958,0.9490000000000001,0.966,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_WA-1,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Wyoming Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1927,0.973,0.96,0.9820000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_NY-3,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northwestern Oregon and Southwestern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,856,0.948,0.9309999999999999,0.9620000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_PA,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Chicago Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2534,0.93,0.917,0.9420000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_AR,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Nevada and Northwestern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1578,0.903,0.886,0.918,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_NH,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2368,0.9390000000000001,0.922,0.9520000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_MN,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Montana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2144,0.9450000000000001,0.929,0.9570000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_CR1,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 2 (Midwest),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,24111,0.953,0.948,0.9570000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Age50-64,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Adults (18-64 years),50.0,64.0,Age,50-64,45452,0.943,0.9390000000000001,0.946,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_NC,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Oregon Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,4311,0.9159999999999999,0.905,0.9259999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_OR-2,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,639,0.9279999999999999,0.9,0.948,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_SexFemale,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,Female,Multiple groups,16.0,,Sex/Gender,,67874,0.935,0.932,0.937,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_ND,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Kansas and Northwestern Missouri Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1263,0.902,0.877,0.923,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_AZ-1,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Indiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2510,0.902,0.888,0.914,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_HI,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Idaho Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1991,0.9670000000000001,0.9570000000000001,0.975,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_AZ-2,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern California Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1270,0.9259999999999999,0.899,0.9450000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_WY,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Alabama Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1469,0.9009999999999999,0.876,0.9209999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_VA,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1430,0.9500000000000001,0.932,0.9640000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_KS-1,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Maine Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1922,0.8940000000000001,0.871,0.914,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_OH-1,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Oklahoma Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1879,0.938,0.9259999999999999,0.9490000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_NJ,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern New Mexico, El Paso, and Southern Texas Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3138,0.951,0.9359999999999999,0.963,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_CR4,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 1 (Northeast),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,37072,0.9420000000000001,0.9390000000000001,0.9450000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_GA,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Hawaii Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3712,0.917,0.904,0.9279999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_TX-2,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Wisconsin Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3828,0.97,0.9640000000000001,0.975,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_CR3,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 4 (West),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,42323,0.93,0.927,0.934,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_IL-1,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Colorado Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3211,0.9470000000000001,0.9309999999999999,0.96,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_TX-1,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2770,0.9209999999999999,0.903,0.9359999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_KY,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Maryland and National Capital Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,961,0.937,0.919,0.9520000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_TestAntiN,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Test used,Anti-N,135171,0.278,0.27399999999999997,0.282,,,True,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,VITROS Anti-SARS-CoV-2 Total N Antibody Test",Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_MD,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Missouri and St. Louis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3670,0.965,0.951,0.975,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_DE,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Detroit Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1594,0.912,0.888,0.932,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_OR-1,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Puerto Rico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,986,0.948,0.9329999999999999,0.961,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_CO,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Connecticut Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1852,0.956,0.9440000000000001,0.966,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_KS-2,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2000,0.927,0.907,0.943,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_SexMale,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,Male,Multiple groups,16.0,,Sex/Gender,,67261,0.9440000000000001,0.941,0.946,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_EthnicityOther,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Ethnicity,Other,3109,0.9279999999999999,0.914,0.9400000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_NV-1,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New Mexico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1688,0.91,0.891,0.925,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_SD,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Louisiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1408,0.886,0.865,0.905,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_TN-2,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Miami Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1351,0.9209999999999999,0.8959999999999999,0.9400000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_ID,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Iowa Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1965,0.932,0.913,0.948,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_EthnicityBlack,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Ethnicity,Black,4189,0.932,0.922,0.9400000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_NV-2,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern New Jersey and Southeastern Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1826,0.91,0.8959999999999999,0.923,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_TN-1,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Eastern South Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1466,0.919,0.902,0.9329999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_IL-2,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Missouri and Northern Arkansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,732,0.88,0.845,0.908,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_NM-1,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1574,0.919,0.902,0.9329999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Age16-29,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Adults (18-64 years),16.0,29.0,Age,16-29,22681,0.9309999999999999,0.9259999999999999,0.9359999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_PR,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Rhode Island Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1994,0.975,0.963,0.983,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_CA-3,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern Illinois, Southeastern Missouri, and Western Kentucky Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3504,0.951,0.9420000000000001,0.96,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_UT,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Vermont Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2918,0.941,0.929,0.9500000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_IA,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Kansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1859,0.924,0.904,0.9400000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_WI,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1809,0.9329999999999999,0.914,0.948,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_WA-2,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Georgia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1531,0.917,0.895,0.934,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_AK,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Kentucky Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1196,0.9400000000000001,0.924,0.953,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_NE,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,New Hampshire Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1603,0.918,0.9009999999999999,0.932,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_OK,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Texas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,659,0.9209999999999999,0.893,0.943,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_CR2,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 3 (South),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,29635,0.934,0.929,0.938,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_MT,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Nebraska Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2437,0.9329999999999999,0.918,0.946,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_FL-1,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Minnesota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,4017,0.9159999999999999,0.904,0.9259999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_MS,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Virginia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2070,0.893,0.877,0.907,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_LA,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern New York and Northern New Jersey Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,881,0.918,0.892,0.938,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_IN,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2853,0.938,0.923,0.9500000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_RI,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,South Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1599,0.9670000000000001,0.9470000000000001,0.98,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_CT,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Delaware and Maryland Eastern Shore Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1993,0.96,0.9490000000000001,0.9690000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_SC,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Northern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1706,0.946,0.93,0.958,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_OH-2,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western North Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2054,0.919,0.905,0.9309999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_CA-1,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Sacramento Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1679,0.968,0.9500000000000001,0.9790000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_NY-2,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,923,0.9159999999999999,0.885,0.9390000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Age30-49,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Adults (18-64 years),30.0,49.0,Age,30-49,37259,0.9329999999999999,0.929,0.9359999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_EthnicityHispanic,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Ethnicity,Hispanic,9457,0.937,0.93,0.9440000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Age65+,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Seniors (65+ years),65.0,,Age,65+,29743,0.958,0.9540000000000001,0.961,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_CA-2,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern Nevada Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2009,0.935,0.923,0.946,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_MO,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Tennessee Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1301,0.9390000000000001,0.9109999999999999,0.958,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_MI,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Mississippi Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,3597,0.948,0.934,0.96,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_ME,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Massachusetts Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1946,0.9400000000000001,0.924,0.953,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_MA,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Memphis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2032,0.971,0.96,0.98,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_EthnicityWhite,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Ethnicity,White,111640,0.937,0.935,0.938,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_WV,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,818,0.9309999999999999,0.912,0.9470000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_FL-2,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Utah Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2030,0.924,0.9109999999999999,0.935,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_NM-2,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Tampa Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,2101,0.92,0.9059999999999999,0.932,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202111_Region_VT,220613_USA_CentersforDiseaseControlandPrevention_202111,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"West Virginia, Western Maryland, and Northern Virginia Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-11-01,2021-11-30,Blood donors,All,Multiple groups,16.0,,Geographical area,,1205,0.978,0.966,0.986,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Overall,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Primary Estimate,,136156,0.9470000000000001,0.9450000000000001,0.9490000000000001,True,,True,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_FL-1,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Minnesota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,4028,0.915,0.903,0.9259999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_DE,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Detroit Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1661,0.9440000000000001,0.92,0.961,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_IL-2,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Missouri and Northern Arkansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,729,0.914,0.887,0.935,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_CT,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Delaware and Maryland Eastern Shore Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1936,0.9550000000000001,0.935,0.9690000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_TX-2,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Wisconsin Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3497,0.9890000000000001,0.985,0.9920000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_GA,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Hawaii Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3526,0.9359999999999999,0.9209999999999999,0.948,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Age30-49,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Adults (18-64 years),30.0,49.0,Age,30-49,37913,0.941,0.938,0.9450000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_CR4,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,37345,0.9470000000000001,0.943,0.9520000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_EthnicityOther,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Other,2938,0.929,0.913,0.941,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_NE,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,New Hampshire Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1778,0.935,0.914,0.951,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_FL-2,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Utah Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2052,0.913,0.899,0.9259999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_ND,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Kansas and Northwestern Missouri Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1301,0.9309999999999999,0.91,0.9470000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_MD,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Missouri and St. Louis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3588,0.97,0.96,0.9770000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_TX-1,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2814,0.9109999999999999,0.8959999999999999,0.925,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_EthnicityAsian,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Asian,4411,0.9790000000000001,0.971,0.985,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Age50-64,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Adults (18-64 years),50.0,64.0,Age,50-64,48761,0.951,0.9490000000000001,0.953,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_TN-2,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Miami Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1369,0.937,0.918,0.9520000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_OH-2,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western North Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2117,0.934,0.919,0.9470000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_WA-1,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Wyoming Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1989,0.966,0.9520000000000001,0.976,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_SC,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Northern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1937,0.9309999999999999,0.915,0.9450000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_HI,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Idaho Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1978,0.9570000000000001,0.946,0.966,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_OK,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Texas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,698,0.9329999999999999,0.9109999999999999,0.9500000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_NY-2,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,940,0.946,0.924,0.9620000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_UT,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Vermont Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2790,0.9570000000000001,0.948,0.965,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_SD,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Louisiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1220,0.897,0.868,0.92,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_OH-1,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Oklahoma Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1900,0.943,0.924,0.9570000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_CR2,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 3 (South),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,29953,0.9470000000000001,0.943,0.951,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_EthnicityBlack,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Black,4282,0.943,0.935,0.951,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_PA,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Chicago Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2706,0.9359999999999999,0.923,0.9470000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_CA-1,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern California - Sacramento Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1741,0.956,0.929,0.973,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_NH,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,North Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2388,0.958,0.9440000000000001,0.968,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_MN,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Montana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2260,0.9590000000000001,0.9440000000000001,0.97,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_MO,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Tennessee Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1277,0.9570000000000001,0.941,0.968,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_CA-2,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern Nevada Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1918,0.941,0.927,0.9520000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Age65+,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Seniors (65+ years),65.0,,Age,65+,31959,0.963,0.96,0.966,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_LA,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern New York and Northern New Jersey Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1657,0.9450000000000001,0.9279999999999999,0.958,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_KS-1,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Maine Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1922,0.923,0.907,0.937,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_IA,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Kansas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1939,0.956,0.943,0.966,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_IN,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2562,0.9329999999999999,0.917,0.946,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_NM-1,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1644,0.9390000000000001,0.924,0.9520000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_VT,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"West Virginia, Western Maryland, and Northern Virginia Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1420,0.9670000000000001,0.956,0.976,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_OR-2,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,611,0.914,0.875,0.9420000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_NJ,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern New Mexico, El Paso, and Southern Texas Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3026,0.9520000000000001,0.934,0.965,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_ME,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Massachusetts Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1824,0.9470000000000001,0.9309999999999999,0.9590000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_TestAntiN,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Test used,Anti-N,136183,0.28800000000000003,0.284,0.292,,,True,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,VITROS Anti-SARS-CoV-2 Total N Antibody Test",Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_AK,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Kentucky Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1275,0.9420000000000001,0.927,0.9550000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_VA,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1496,0.9590000000000001,0.9470000000000001,0.9690000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_CR1,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 2 (Midwest),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,23859,0.9570000000000001,0.9520000000000001,0.9620000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_TN-1,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Eastern South Carolina Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1386,0.941,0.922,0.956,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Age16-29,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Adults (18-64 years),16.0,29.0,Age,16-29,17523,0.9390000000000001,0.9329999999999999,0.9440000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_AZ-2,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern California Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1140,0.9440000000000001,0.918,0.9620000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_NY-1,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southeastern Texas Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,5280,0.963,0.9540000000000001,0.97,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_CR3,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 4 (West),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,43031,0.9390000000000001,0.9359999999999999,0.943,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_AR,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Nevada and Northwestern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1846,0.902,0.886,0.9159999999999999,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_CO,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Connecticut Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1837,0.956,0.941,0.9670000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_RI,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,South Dakota Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1506,0.975,0.96,0.9840000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_IL-1,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Colorado Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3156,0.958,0.948,0.9670000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_NM-2,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Tampa Bay Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2005,0.9570000000000001,0.946,0.966,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_AZ-1,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Southern Indiana Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2505,0.923,0.91,0.935,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_NY-3,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northwestern Oregon and Southwestern Washington Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,811,0.9420000000000001,0.917,0.96,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_ID,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Iowa Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2218,0.938,0.922,0.951,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_SexFemale,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,Female,Multiple groups,16.0,,Sex/Gender,,70014,0.9420000000000001,0.938,0.9450000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_CA-3,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,"Southern Illinois, Southeastern Missouri, and Western Kentucky Region",,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3437,0.953,0.9440000000000001,0.961,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_MA,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Memphis Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2022,0.971,0.96,0.98,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_KY,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central Maryland and National Capital Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1156,0.948,0.9309999999999999,0.96,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_WI,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern Arizona Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1832,0.948,0.9279999999999999,0.963,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_EthnicityHispanic,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,Hispanic,8896,0.9420000000000001,0.935,0.9490000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_WV,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Western New York Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,780,0.919,0.8840000000000001,0.9440000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_NC,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Central and Western Oregon Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,4071,0.943,0.934,0.951,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_AL,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Alaska Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3405,0.924,0.9059999999999999,0.9390000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_OR-1,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Puerto Rico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1036,0.9590000000000001,0.943,0.971,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_WA-2,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Georgia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1458,0.9329999999999999,0.909,0.951,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_MI,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Mississippi Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,3888,0.9500000000000001,0.935,0.961,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_MT,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Nebraska Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2520,0.941,0.929,0.951,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_MS,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Eastern Virginia Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2064,0.9159999999999999,0.9009999999999999,0.929,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_NV-2,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Southern New Jersey and Southeastern Pennsylvania Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1880,0.927,0.913,0.9390000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_NV-1,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northern New Mexico Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1763,0.92,0.903,0.935,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_WY,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Region 1 (Northeast),,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1600,0.9059999999999999,0.891,0.92,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_EthnicityWhite,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Ethnicity,White,113661,0.946,0.9450000000000001,0.948,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_SexMale,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,Male,Multiple groups,16.0,,Sex/Gender,,66142,0.9520000000000001,0.9500000000000001,0.9540000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-26,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_PR,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Rhode Island Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,1968,0.9770000000000001,0.968,0.9840000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220613_USA_CentersforDiseaseControlandPrevention_202112_Region_KS-2,220613_USA_CentersforDiseaseControlandPrevention_202112,"Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021",2022-06-13,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Northeastern Ohio Region,,"blood donations from individuals aged 16 years and older from 66 study regions that included all 50 states; Washington, DC; and Puerto Rico.",excluding COVID-19 convalescent plasma donations,2021-12-01,2021-12-31,Blood donors,All,Multiple groups,16.0,,Geographical area,,2072,0.9550000000000001,0.9440000000000001,0.9640000000000001,,,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,Validated by manufacturers,1.0,1.0,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Jefferson Jones,Vitalant Research Institute,Unity-Aligned,https://jamanetwork.com/journals/jama/fullarticle/2793517,2022-06-25,2024-03-01,Unverified,jones_updated_2022,USA
220614_NorthernCalifornia_StanfordUniversity_Incarcerated,220614_NorthernCalifornia_StanfordUniversity_Incarcerated,"COVID-19 Preventive Measures in Northern California Jails: Perceived Deficiencies, Barriers, and Unintended Harms",2022-06-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,"""we enrolled individuals living ... in four jails in San Mateo County and Santa Clara County, California"".","""... with the exception of isolation units for COVID-19 positive individuals, units deemed by custody staff to be of high security risk, and units housing people with severe mental illnesses.""

""For all seroprevalence analyses, we excluded 82 incarcerated participants ... who were vaccinated prior to enrollment"".",2020-07-08,2021-04-30,Persons who are incarcerated,All,Multiple groups,18.0,,Primary Estimate,,690,0.1275,0.1,0.15,True,,,,True,Stratified non-probability,RightSign COVID-19 IgG/IgM Rapid Test Cassette,Hangzhou Biotest Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9209999999999999,1.0,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Yiran Liu,Stanford University,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.854343,2022-07-14,2024-03-01,Unverified,liu_covid-19_2022-1,USA
220614_NorthernCalifornia_StanfordUniversity_Staff,220614_NorthernCalifornia_StanfordUniversity_Staff,"COVID-19 Preventive Measures in Northern California Jails: Perceived Deficiencies, Barriers, and Unintended Harms",2022-06-14,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,,"""we enrolled individuals ... working in four jails in San Mateo County and Santa Clara County, California"".","""For all seroprevalence analyses, we excluded ... 77 staff participants who were vaccinated prior to enrollment"".",2020-07-08,2021-04-30,Essential non-healthcare workers,All,Adults (18-64 years),18.0,,Primary Estimate,,292,0.08220000000000001,0.06,0.12,True,,,,True,Convenience,RightSign COVID-19 IgG/IgM Rapid Test Cassette,Hangzhou Biotest Biotech Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.9209999999999999,1.0,['High'],,No,No,Yes,,Yes,Yes,Yes,,Yiran Liu,Stanford University,Not Unity-Aligned,https://dx.doi.org/10.3389/fpubh.2022.854343,2022-07-15,2024-03-01,Unverified,liu_covid-19_2022-1,USA
220615_NewJersey_RutgersNewJerseyMedicalSchool_Residents,220615_NewJersey_RutgersNewJerseyMedicalSchool_Residents,"Antibody Seroprevalence, Infection and Surveillance for SARS-CoV-2 in Residents and Staff of New Jersey Long-Term Care Facilities.",2022-06-15,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,New Jersey,,"Once the facility manager indicated participation in writing, we disseminated an educational flyer for the residents and staff. Only residents who were able to
consent for themselves were offered enrolment in the study. ",,2020-10-20,2021-03-04,Assisted living and long-term care facilities,All,Seniors (65+ years),,,Primary Estimate,,337,0.617,,,True,,,,True,Stratified non-probability,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.98,0.993,['High'],,No,No,Yes,,Yes,Yes,Yes,,Stephen Friedman,Rutgers New Jersey Medical School,Not Unity-Aligned,https://dx.doi.org/10.1007/s10900-022-01104-5,2022-06-23,2024-03-01,Unverified,friedman_antibody_2022,USA
220615_NewJersey_RutgersNewJerseyMedicalSchool_Staff,220615_NewJersey_RutgersNewJerseyMedicalSchool_Staff,"Antibody Seroprevalence, Infection and Surveillance for SARS-CoV-2 in Residents and Staff of New Jersey Long-Term Care Facilities.",2022-06-15,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,New Jersey,,"Once the facility manager indicated participation in writing, we disseminated an educational flyer for the residents and staff.",,2020-10-20,2021-03-04,Assisted living and long-term care facilities,All,Multiple groups,,,Primary Estimate,,667,0.46299999999999997,,,True,,,,True,Stratified non-probability,Platelia SARS-CoV-2 Total Ab assay,Bio-rad,ELISA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.98,0.993,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Stephen Friedman,Rutgers New Jersey Medical School,Not Unity-Aligned,https://dx.doi.org/10.1007/s10900-022-01104-5,2022-06-23,2024-03-01,Unverified,friedman_antibody_2022,USA
220627_WashingtonDC_MedStarGeorgetownUniversityHospital,220627_WashingtonDC_MedStarGeorgetownUniversityHospital,SARS-CoV-2 infection in pediatric solid organ transplant recipients - a single center observation.,2022-06-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,,Washington D.C.,"""For this descriptive study, the Organ Transplant Tracking Record database, OTTR, was queried for all pediatric SOT recipients followed at our center. Medical records were reviewed to identify patients who had at least one test for SARS-CoV-2 between March 15, 2020, (when the above transplant center policy was instituted), through June 30, 2021"" ",,2020-03-15,2021-06-30,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),,,Primary Estimate,,157,0.121,,,True,,,,True,Sequential,Liaison SARS-CoV-2 S1/S2 IgG,DiaSorin,CLIA,Serum,IgG,Spike,,,,['High'],,No,No,No,,Yes,Yes,Yes,,Saikat Paul,Medstar Georgetown University Hospital,Not Unity-Aligned,https://dx.doi.org/10.1097/MPG.0000000000003548,2022-07-07,2024-03-01,Unverified,paul_sars-cov-2_2022,USA
220704_NorthCarolina_UniversityofNorthCarolina,220704_NorthCarolina_UniversityofNorthCarolina,SARS-CoV-2 Seroprevalence: Demographic and Behavioral Factors Associated With Seropositivity Among College Students in a University Setting,2022-07-04,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,North Carolina,Chapel Hill,All UNC-CH undergraduate students enrolled in the Fall 2020 semester. ,,2020-11-18,2021-01-19,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,,680,0.09,0.054000000000000006,0.092,True,,,,True,Convenience,Author designed (ELISA) - Unknown,,,Whole Blood,TotalAntibody,Spike,Validated by developers,0.9500000000000001,0.96,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Karen Diepstra,University of North Carolina,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jadohealth.2022.06.015,2022-09-12,2022-09-12,Unverified,diepstra_sars-cov-2_2022,USA
220706_Boston_BostonUniversity,220706_Boston_BostonUniversity ,"Fifteen-Month Follow-Up of Anti-Spike Receptor-Binding Domain SARS-CoV-2 Antibodies among Healthcare Workers in Boston, MA.",2022-07-06,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Massachusetts,Boston,"""eligible participants were BMC HCWs who worked onsite during the initial wave of the COVID-19 pandemic (March 13 to May 31, 2020).""",,2020-07-01,2021-09-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,527,0.165,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Maura Dodge,Boston University School of Medicine,Not Unity-Aligned,https://dx.doi.org/10.1093/jalm/jfac056,2022-07-15,2024-03-01,Unverified,dodge_fifteen-month_2022,USA
220713_NorthCarolina_UNC_Overall,220713_NorthCarolina_UNC,"SARS-CoV-2 seroprevalence and risk factors among meat packing, produce processing, and farm workers.",2022-07-13,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,North Carolina,,"Adults (age > 18 years) who had resided and worked for at least two weeks in a meat packing plant, produce processing facility, or commercial farm in North Carolina since February of 2020 (when the first nontravel-related COVID-19 cases were identified in the US) were eligible to participate in the study.","Exclusion criteria included age less than 18; inability to provide
informed consent in English, Spanish, or a language for which an interpreter was available; and unwillingness to provide at least one blood sample.",2020-09-15,2020-12-15,Non-essential workers and unemployed persons,All,Multiple groups,18.0,,Primary Estimate,,118,0.5,,,True,,,,True,Convenience,"UNSCIENCE COVID-19 IgG/IgM antibody Rapid Test Kit,Author designed (ELISA) - Unknown","Wuhan UNscience Biotechnology Co. Ltd,NA",Multiple Types,Serum,"['IgA', 'IgG', 'IgM']",Spike,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Melissa D. Klein,University of North Carolina at Chapel Hill School of Medicine,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0000619,2023-04-25,2024-03-01,Unverified, klein_sars-cov-2_2022,USA
220716_UnitedStates_MassachusettsVeteransEpidemiologyResearchandInformationCenter_Neoteryx,220716_UnitedStates_MassachusettsVeteransEpidemiologyResearchandInformationCenter_Neoteryx,Evaluation of independent self-collected blood specimens for COVID-19 antibody detection among the US veteran population,2022-07-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"currently enrolled in MVP, open to contact from MVP, not deceased, valid email address",,2020-12-15,2021-03-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,126,0.3413,,,True,,,,True,Convenience,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,,0.6,0.88,['High'],Yes,No,No,Yes,No,Yes,Yes,No,No,Tseli Mohammed,Massachusetts Veterans Epidemiology Research and Information Center ,Unity-Aligned,https://dx.doi.org/10.1016/j.diagmicrobio.2022.115770,2022-09-12,2024-03-15,Verified,mohammed_evaluation_2022,USA
220716_UnitedStates_MassachusettsVeteransEpidemiologyResearchandInformationCenter_Tasso-SST,220716_UnitedStates_MassachusettsVeteransEpidemiologyResearchandInformationCenter_Tasso-SST,Evaluation of independent self-collected blood specimens for COVID-19 antibody detection among the US veteran population,2022-07-16,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"currently enrolled in MVP, open to contact from MVP, not deceased, valid email address",,2020-12-15,2021-03-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,113,0.6018,,,True,,,,True,Convenience,anti-SARS-CoV-2 IgG,"InBios International, Inc.",ELISA,Serum,IgG,Spike,,0.97,0.8,['High'],Yes,No,No,Yes,No,Yes,Yes,No,No,Tseli Mohammed,Massachusetts Veterans Epidemiology Research and Information Center ,Unity-Aligned,https://dx.doi.org/10.1016/j.diagmicrobio.2022.115770,2022-09-12,2024-03-15,Verified,mohammed_evaluation_2022,USA
220718_Chicago_NorthwesternUniversity_AntiRBDandNAbs,220718_Chicago_NorthwesternUniversity,COVID-19 symptom severity predicts neutralizing antibody activity in a community-based serological study.,2022-07-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Illinois,Chicago,"""A large community-based sample of adults living within the Chicago, IL metropolitan area was recruited to participate in a study called Screening for Coronavirus Antibodies in Neighborhoods (SCAN).""",,2020-06-24,2020-11-11,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,Anti-RBD IgG AND anti-spike neutralizing antibodies,4463,0.0641,,,True,,,,True,Stratified probability,"COVID-SeroKlir, Kantaro Semi-Quantitative SARS-CoV-2 IgG Antibody Kit,V-PLEX SARS-CoV-2 Panel 2 (ACE2) Kit","Kantaro Biosciences LLC,Meso Scale Diagnostics",Multiple Types,Dried Blood,"['IgG', 'Neutralizing']",Spike,,,,['Moderate'],,Yes,Yes,No,,Yes,Yes,No,,Amelia Sancilio,Northwestern University,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-15791-6,2022-07-26,2024-03-01,Unverified,sancilio_covid-19_2022,USA
220718_Chicago_NorthwesternUniversity_AntiRBD,220718_Chicago_NorthwesternUniversity,COVID-19 symptom severity predicts neutralizing antibody activity in a community-based serological study.,2022-07-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Illinois,Chicago,"""A large community-based sample of adults living within the Chicago, IL metropolitan area was recruited to participate in a study called Screening for Coronavirus Antibodies in Neighborhoods (SCAN).""",,2020-06-24,2020-11-11,Household and community samples,All,Multiple groups,18.0,,Test used,Anti-RBD IgG,4463,0.177,,,,,,,,Stratified probability,"COVID-SeroKlir, Kantaro Semi-Quantitative SARS-CoV-2 IgG Antibody Kit",Kantaro Biosciences LLC,ELISA,Dried Blood,IgG,Spike,,,,['Moderate'],,Yes,Yes,No,,Yes,Yes,No,,Amelia Sancilio,Northwestern University,Not Unity-Aligned,https://dx.doi.org/10.1038/s41598-022-15791-6,2022-07-24,2024-03-01,Unverified,sancilio_covid-19_2022,USA
220718_NorthCarolina_EastCarolinaUniversity_overall,220718_NorthCarolina_EastCarolinaUniversity,Loss of SARS-CoV-2 Seropositivity among Healthy Young Adults over Seven Months,2022-07-18,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,"North Carolina
",,"""An undergraduate or graduate student was eligible if enrolled full or parttime in fall semester 2020, listed a Pitt County residential address, was 18 years of age or older, and spoke English.""","""Students affiliated with the ECU athletics program were tested under a separate protocol and excluded.""",2020-08-26,2021-03-31,Students and Daycares,All,Adults (18-64 years),18.0,,Primary Estimate,,695,0.0978,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,0.99,1.0,['Missing'],,No,Yes,No,,Yes,Yes,Yes,,C. Suzanne Lea,East Carolina Univeristy,Not Unity-Aligned,10.1101/2022.07.15.22277688,2022-07-27,2024-03-01,Unverified,leaLossSARSCoV2Seropositivity2022,USA
220803_OrangeCounty_ChildrensHospitalofOrangeCounty,220803_OrangeCounty_ChildrensHospitalofOrangeCounty,Recurrent SARS-CoV-2 Serology Testing and Pandemic Anxiety: A Study of Pediatric Healthcare Workers,2022-08-03,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,California,Orange,HCWs at the Children’s Hospital of Orange County,,2020-04-04,2020-07-13,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,362,0.152,,,True,,,,True,Convenience,COVID-19 Rapid Test Kit IgG + IgM,Superbio Biomedical Company ,Other,,"['IgG', 'IgM']",Spike,,,,['High'],,No,No,Yes,,No,Yes,No,,Natasha Li,Children’s Hospital of Orange County,Not Unity-Aligned,https://www.mdpi.com/1660-4601/19/15/9562,2022-03-09,2024-03-01,Unverified,li_recurrent_2022-1,USA
220804_UnitedStatesofAmerica_GeorgeWashingtonUniversity,220804_UnitedStatesofAmerica_GeorgeWashingtonUniversity,Predictors of chronic COVID-19 symptoms in a community-based cohort of adults.,2022-08-04,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"""Study inclusion criteria included age>18 years, male or female, ability to sign informed consent and for those participating in the synchronous antibody testing drive the release of antibody data to the study investigator.""","""Exclusion criteria were those who were not able to complete the survey or did not agree to release their antibody data to the investigators.""",2020-05-13,2020-07-06,Household and community samples,All,Multiple groups,18.0,94.0,Primary Estimate,,6665,0.34700000000000003,,,True,,,,True,Convenience,EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit,"Epitope Diagnostics, Inc.",ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],No,No,Yes,Yes,No,Yes,Yes,Yes,Yes,Jonathan Silverberg,George Washington University,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0271310,2022-08-09,2024-03-12,Verified,silverberg_predictors_2022,USA
220815_NorthernCalifornia_UniversityofCalifornia_Round1_poptestadj,220815_NorthernCalifornia_UniversityofCalifornia_Round1,"Health inequities in SARS-CoV-2 infection, seroprevalence, and COVID-19 vaccination: Results from the East Bay COVID-19 study.",2022-08-15,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,"California
","Albany, Berkeley, El Cerrito, El Sobrante, Emeryville, Hercules, Kensington, Oakland, Piedmont, Pinole, Rich- mond, and San Pablo ","""In the screening phase, all residential addresses within the East Bay cities and communities of Albany, Berkeley, El Cerrito, El Sobrante, Emeryville, Hercules, Kensington, Oakland, Piedmont, Pinole, Richmond, and San Pablo (~307,000 residential households) were mailed an invitation to complete a consent form and screening questionnaire. Within a household, the individual aged 18 years or older with the next upcoming birthday from the date of postcard receipt, was eligible to participate. Additional eligibility criteria included living within the study region, willingness to provide biospecimens and questionnaire responses, ability to read and speak English or Spanish, and having internet access and an email address.""",,2020-07-04,2020-09-01,Household and community samples,All,Multiple groups,18.0,,Test used,Population and test adjusted,4670,0.0063,0.0004,0.02,True,True,True,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.806,1.0,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,No,Yes,Cameron Adams,University of California,Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0000647,2023-05-03,2024-04-07,Verified,adamsHealthInequitiesSARSCoV22022,USA
220815_NorthernCalifornia_UniversityofCalifornia_Round1_unadj,220815_NorthernCalifornia_UniversityofCalifornia_Round1,"Health inequities in SARS-CoV-2 infection, seroprevalence, and COVID-19 vaccination: Results from the East Bay COVID-19 study.",2022-08-15,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,"California
","Albany, Berkeley, El Cerrito, El Sobrante, Emeryville, Hercules, Kensington, Oakland, Piedmont, Pinole, Rich- mond, and San Pablo ","""In the screening phase, all residential addresses within the East Bay cities and communities of Albany, Berkeley, El Cerrito, El Sobrante, Emeryville, Hercules, Kensington, Oakland, Piedmont, Pinole, Richmond, and San Pablo (~307,000 residential households) were mailed an invitation to complete a consent form and screening questionnaire. Within a household, the individual aged 18 years or older with the next upcoming birthday from the date of postcard receipt, was eligible to participate. Additional eligibility criteria included living within the study region, willingness to provide biospecimens and questionnaire responses, ability to read and speak English or Spanish, and having internet access and an email address.""",,2020-07-04,2020-09-01,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,Unadjusted,4670,0.0062,,,,,,,,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.806,1.0,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,No,Yes,Cameron Adams,University of California,Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0000647,2023-05-03,2024-04-07,Verified,adamsHealthInequitiesSARSCoV22022,USA
220815_NorthernCalifornia_UniversityofCalifornia_Round2_poptestadj,220815_NorthernCalifornia_UniversityofCalifornia_Round2_unadj,"Health inequities in SARS-CoV-2 infection, seroprevalence, and COVID-19 vaccination: Results from the East Bay COVID-19 study.",2022-08-15,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,"California
","Albany, Berkeley, El Cerrito, El Sobrante, Emeryville, Hercules, Kensington, Oakland, Piedmont, Pinole, Rich- mond, and San Pablo ","""In the screening phase, all residential addresses within the East Bay cities and communities of Albany, Berkeley, El Cerrito, El Sobrante, Emeryville, Hercules, Kensington, Oakland, Piedmont, Pinole, Rich- mond, and San Pablo (~307,000 residential households) were mailed an invitation to complete a consent form and screening questionnaire. Within a household, the individual aged 18 years or older with the next upcoming birthday from the date of postcard receipt, was eligible to par- ticipate. Additional eligibility criteria included living within the study region, willingness to provide biospecimens and questionnaire responses, ability to read and speak English or Span- ish, and having internet access and an email address.""",,2020-10-10,2020-12-16,Household and community samples,All,Multiple groups,18.0,,Test used,Population and test adjusted,5949,0.0102,0.0017,0.024,True,True,True,,,Convenience,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG",Ortho Clinical Diagnostics Inc.,Multiple Types,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.972,1.0,['Moderate'],Yes,No,Yes,Yes,No,Unclear,Yes,Yes,Yes,Cameron Adams,University of California,Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0000647,2023-05-03,2024-04-07,Verified,adamsHealthInequitiesSARSCoV22022,USA
220815_NorthernCalifornia_UniversityofCalifornia_Round2,220815_NorthernCalifornia_UniversityofCalifornia_Round2_unadj,"Health inequities in SARS-CoV-2 infection, seroprevalence, and COVID-19 vaccination: Results from the East Bay COVID-19 study.",2022-08-15,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,"California
","Albany, Berkeley, El Cerrito, El Sobrante, Emeryville, Hercules, Kensington, Oakland, Piedmont, Pinole, Rich- mond, and San Pablo ","""In the screening phase, all residential addresses within the East Bay cities and communities of Albany, Berkeley, El Cerrito, El Sobrante, Emeryville, Hercules, Kensington, Oakland, Piedmont, Pinole, Rich- mond, and San Pablo (~307,000 residential households) were mailed an invitation to complete a consent form and screening questionnaire. Within a household, the individual aged 18 years or older with the next upcoming birthday from the date of postcard receipt, was eligible to par- ticipate. Additional eligibility criteria included living within the study region, willingness to provide biospecimens and questionnaire responses, ability to read and speak English or Span- ish, and having internet access and an email address.""",,2020-10-10,2020-12-16,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,Unadjusted,5949,0.0081,,,,,,,,Convenience,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG",Ortho Clinical Diagnostics Inc.,Multiple Types,Dried Blood,IgG,Spike,Validated by independent authors/third party/non-developers,0.972,1.0,['Moderate'],Yes,No,Yes,Yes,No,Unclear,Yes,Yes,Yes,Cameron Adams,University of California,Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0000647,2023-05-03,2024-04-07,Verified,adamsHealthInequitiesSARSCoV22022,USA
220815_NorthernCalifornia_UniversityofCalifornia_Round3_poptestadj,220815_NorthernCalifornia_UniversityofCalifornia_Round3_unadj,"Health inequities in SARS-CoV-2 infection, seroprevalence, and COVID-19 vaccination: Results from the East Bay COVID-19 study.",2022-08-15,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,"California
","Albany, Berkeley, El Cerrito, El Sobrante, Emeryville, Hercules, Kensington, Oakland, Piedmont, Pinole, Rich- mond, and San Pablo ","""In the screening phase, all residential addresses within the East Bay cities and communities of Albany, Berkeley, El Cerrito, El Sobrante, Emeryville, Hercules, Kensington, Oakland, Piedmont, Pinole, Rich- mond, and San Pablo (~307,000 residential households) were mailed an invitation to complete a consent form and screening questionnaire. Within a household, the individual aged 18 years or older with the next upcoming birthday from the date of postcard receipt, was eligible to par- ticipate. Additional eligibility criteria included living within the study region, willingness to provide biospecimens and questionnaire responses, ability to read and speak English or Span- ish, and having internet access and an email address.""",,2021-02-11,2021-03-20,Household and community samples,All,Multiple groups,18.0,,Test used,Population and test adjusted,5991,0.0219,0.0149,0.0318,True,True,True,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",Multiple Types,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.889,1.0,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,No,Yes,Cameron Adams,University of California,Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0000647,2023-05-03,2024-04-07,Verified,adamsHealthInequitiesSARSCoV22022,USA
220815_NorthernCalifornia_UniversityofCalifornia_Round3,220815_NorthernCalifornia_UniversityofCalifornia_Round3_unadj,"Health inequities in SARS-CoV-2 infection, seroprevalence, and COVID-19 vaccination: Results from the East Bay COVID-19 study.",2022-08-15,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,"California
","Albany, Berkeley, El Cerrito, El Sobrante, Emeryville, Hercules, Kensington, Oakland, Piedmont, Pinole, Rich- mond, and San Pablo ","""In the screening phase, all residential addresses within the East Bay cities and communities of Albany, Berkeley, El Cerrito, El Sobrante, Emeryville, Hercules, Kensington, Oakland, Piedmont, Pinole, Rich- mond, and San Pablo (~307,000 residential households) were mailed an invitation to complete a consent form and screening questionnaire. Within a household, the individual aged 18 years or older with the next upcoming birthday from the date of postcard receipt, was eligible to par- ticipate. Additional eligibility criteria included living within the study region, willingness to provide biospecimens and questionnaire responses, ability to read and speak English or Span- ish, and having internet access and an email address.""",,2021-02-11,2021-03-20,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,Unadjusted,5991,0.0183,,,,,,,,Convenience,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",Multiple Types,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.889,1.0,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,No,Yes,Cameron Adams,University of California,Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0000647,2023-05-03,2024-04-07,Verified,adamsHealthInequitiesSARSCoV22022,USA
220817_LosAngelesCounty_CedarsSinaiMedicalCenter_Overall,220817_LosAngelesCounty_CedarsSinaiMedicalCenter,Awareness of SARS-CoV-2 Omicron Variant Infection Among Adults With Recent COVID-19 Seropositivity,2022-08-17,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,California,,"""Individuals who were registered as adult employees or patients at Cedars-Sinai Medical Center, an academic medical center in Southern California, were enrolled in the longitudinal serological study of COVID-19 risks and outcomes.""

Providing at least two blood draws ""collected from at least 2 serial time points, including at least 1 time point after the end of the Delta variant surge (September 15, 2021) and at least 1 subsequent time point after the start of the Omicron variant surge (December 15, 2021) in the region.""",NR. Some exclusion criteria are mentioned but for another outcome other than seroprevalence.,2021-12-15,2022-05-04,Multiple populations,All,Multiple groups,10.0,96.0,Primary Estimate,Overall,2479,0.10650000000000001,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.8420000000000001,1.0,['High'],,No,Yes,Yes,,Yes,Yes,No,,Sandy Joung,Cedars-Sinai Medical Center,Not Unity-Aligned,http://doi.org/10.1001/jamanetworkopen.2022.27241,2022-09-22,2024-03-01,Unverified,joung_awareness_2022,USA
220822_NewYork_NewYorkStateDepartmentofHealth,220822_NewYork_NewYorkStateDepartmentofHealth,"Utility of Newborn Dried Blood Spots to Ascertain Seroprevalence of SARS-CoV-2 Antibodies Among Individuals Giving Birth in New York State, November 2019 to November 2021.",2022-08-22,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,New York State,,"""DBS samples from infants born in New York State from November 1,2019, through November 30, 2021.""",,2019-11-01,2021-11-30,Perinatal,All,Children and Youth (0-17 years),,,Primary Estimate,,415293,0.2,,,True,,,,True,Sequential,Author designed (Luminex),,Luminex,Dried Blood,IgG,Spike,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Amanda Damjanovic,New York State Department of Health,Not Unity-Aligned,https://dx.doi.org/10.1001/jamanetworkopen.2022.27995,2022-09-01,2022-09-02,Unverified,damjanovic_utility_2022,USA
220909_Texas_UniversityOfTexas_2020Oct-2021Oct_PopAdj_Overall,220909_Texas_UniversityOfTexas,Methodology to estimate natural- and vaccine-induced antibodies to SARS-CoV-2 in a large geographic region,2022-09-09,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Texas,,"""Texas CARES is a prospective convenience sample of adult retail/business employees, K-12 and university educators and university students, those attending Health Resources and Services Administration (HRSA)- designated federally qualified health centers (FQHCs), and children 5–17 years, all of whom agreed to longitudinal monitoring of SARS-CoV-2 antibody status every three months (three time points) from 10/1/ 2020–10/31/2021.""

""Recruitment efforts were taken to enroll rural and urban participants spanning the state.""",,2020-10-01,2021-10-31,Multiple populations,All,Multiple groups,5.0,,Primary Estimate,"Overall; Oct 1, 2020 to Oct 31, 2021.",88605,0.35000000000000003,0.331,0.369,True,,True,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9982,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Stacia DeSantis,University of Texas,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273694,2022-09-19,2024-03-01,Unverified,desantis_methodology_2022,USA
220909_Texas_UniversityOfTexas_2021Oct_UnAdj_Age30-39,220909_Texas_UniversityOfTexas,Methodology to estimate natural- and vaccine-induced antibodies to SARS-CoV-2 in a large geographic region,2022-09-09,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Texas,,"""Texas CARES is a prospective convenience sample of adult retail/business employees, K-12 and university educators and university students, those attending Health Resources and Services Administration (HRSA)- designated federally qualified health centers (FQHCs), and children 5–17 years, all of whom agreed to longitudinal monitoring of SARS-CoV-2 antibody status every three months (three time points) from 10/1/ 2020–10/31/2021.""

""Recruitment efforts were taken to enroll rural and urban participants spanning the state.""",,2021-10-01,2021-10-31,Multiple populations,All,Adults (18-64 years),30.0,39.0,Age,Age group: 30-39,556,0.25,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9982,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Stacia DeSantis,University of Texas,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273694,2022-09-21,2024-03-01,Unverified,desantis_methodology_2022,USA
220909_Texas_UniversityOfTexas_2021Oct_UnAdj_Age16-17,220909_Texas_UniversityOfTexas,Methodology to estimate natural- and vaccine-induced antibodies to SARS-CoV-2 in a large geographic region,2022-09-09,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Texas,,"""Texas CARES is a prospective convenience sample of adult retail/business employees, K-12 and university educators and university students, those attending Health Resources and Services Administration (HRSA)- designated federally qualified health centers (FQHCs), and children 5–17 years, all of whom agreed to longitudinal monitoring of SARS-CoV-2 antibody status every three months (three time points) from 10/1/ 2020–10/31/2021.""

""Recruitment efforts were taken to enroll rural and urban participants spanning the state.""",,2021-10-01,2021-10-31,Multiple populations,All,Children and Youth (0-17 years),16.0,17.0,Age,Age group: 16-17,25,0.48,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9982,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Stacia DeSantis,University of Texas,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273694,2022-09-21,2024-03-01,Unverified,desantis_methodology_2022,USA
220909_Texas_UniversityOfTexas_2021Oct_UnAdj_Age65-74,220909_Texas_UniversityOfTexas,Methodology to estimate natural- and vaccine-induced antibodies to SARS-CoV-2 in a large geographic region,2022-09-09,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Texas,,"""Texas CARES is a prospective convenience sample of adult retail/business employees, K-12 and university educators and university students, those attending Health Resources and Services Administration (HRSA)- designated federally qualified health centers (FQHCs), and children 5–17 years, all of whom agreed to longitudinal monitoring of SARS-CoV-2 antibody status every three months (three time points) from 10/1/ 2020–10/31/2021.""

""Recruitment efforts were taken to enroll rural and urban participants spanning the state.""",,2021-10-01,2021-10-31,Multiple populations,All,Seniors (65+ years),65.0,74.0,Age,Age group: 65-74,534,0.19100000000000003,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9982,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Stacia DeSantis,University of Texas,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273694,2022-09-21,2024-03-01,Unverified,desantis_methodology_2022,USA
220909_Texas_UniversityOfTexas_2021Oct_UnAdj_Age50-64,220909_Texas_UniversityOfTexas,Methodology to estimate natural- and vaccine-induced antibodies to SARS-CoV-2 in a large geographic region,2022-09-09,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Texas,,"""Texas CARES is a prospective convenience sample of adult retail/business employees, K-12 and university educators and university students, those attending Health Resources and Services Administration (HRSA)- designated federally qualified health centers (FQHCs), and children 5–17 years, all of whom agreed to longitudinal monitoring of SARS-CoV-2 antibody status every three months (three time points) from 10/1/ 2020–10/31/2021.""

""Recruitment efforts were taken to enroll rural and urban participants spanning the state.""",,2021-10-01,2021-10-31,Multiple populations,All,Adults (18-64 years),50.0,64.0,Age,Age group: 50-64,988,0.2783,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9982,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Stacia DeSantis,University of Texas,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273694,2022-09-21,2024-03-01,Unverified,desantis_methodology_2022,USA
220909_Texas_UniversityOfTexas_2021Oct_UnAdj_Age75-79,220909_Texas_UniversityOfTexas,Methodology to estimate natural- and vaccine-induced antibodies to SARS-CoV-2 in a large geographic region,2022-09-09,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Texas,,"""Texas CARES is a prospective convenience sample of adult retail/business employees, K-12 and university educators and university students, those attending Health Resources and Services Administration (HRSA)- designated federally qualified health centers (FQHCs), and children 5–17 years, all of whom agreed to longitudinal monitoring of SARS-CoV-2 antibody status every three months (three time points) from 10/1/ 2020–10/31/2021.""

""Recruitment efforts were taken to enroll rural and urban participants spanning the state.""",,2021-10-01,2021-10-31,Multiple populations,All,Seniors (65+ years),75.0,79.0,Age,Age group: 75-79,76,0.10529999999999999,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9982,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Stacia DeSantis,University of Texas,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273694,2022-09-21,2024-03-01,Unverified,desantis_methodology_2022,USA
220909_Texas_UniversityOfTexas_2021Oct_UnAdj_Age18-29,220909_Texas_UniversityOfTexas,Methodology to estimate natural- and vaccine-induced antibodies to SARS-CoV-2 in a large geographic region,2022-09-09,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Texas,,"""Texas CARES is a prospective convenience sample of adult retail/business employees, K-12 and university educators and university students, those attending Health Resources and Services Administration (HRSA)- designated federally qualified health centers (FQHCs), and children 5–17 years, all of whom agreed to longitudinal monitoring of SARS-CoV-2 antibody status every three months (three time points) from 10/1/ 2020–10/31/2021.""

""Recruitment efforts were taken to enroll rural and urban participants spanning the state.""",,2021-10-01,2021-10-31,Multiple populations,All,Adults (18-64 years),18.0,29.0,Age,Age group: 18-29,151,0.298,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9982,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Stacia DeSantis,University of Texas,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273694,2022-09-21,2024-03-01,Unverified,desantis_methodology_2022,USA
220909_Texas_UniversityOfTexas_2021Oct_UnAdj_AgeAbove85,220909_Texas_UniversityOfTexas,Methodology to estimate natural- and vaccine-induced antibodies to SARS-CoV-2 in a large geographic region,2022-09-09,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Texas,,"""Texas CARES is a prospective convenience sample of adult retail/business employees, K-12 and university educators and university students, those attending Health Resources and Services Administration (HRSA)- designated federally qualified health centers (FQHCs), and children 5–17 years, all of whom agreed to longitudinal monitoring of SARS-CoV-2 antibody status every three months (three time points) from 10/1/ 2020–10/31/2021.""

""Recruitment efforts were taken to enroll rural and urban participants spanning the state.""",,2021-10-01,2021-10-31,Multiple populations,All,Seniors (65+ years),85.0,,Age,Age group: 85+,7,0.2857,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9982,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Stacia DeSantis,University of Texas,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273694,2022-09-21,2024-03-01,Unverified,desantis_methodology_2022,USA
220909_Texas_UniversityOfTexas_2021Oct_UnAdj_Age40-49,220909_Texas_UniversityOfTexas,Methodology to estimate natural- and vaccine-induced antibodies to SARS-CoV-2 in a large geographic region,2022-09-09,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Texas,,"""Texas CARES is a prospective convenience sample of adult retail/business employees, K-12 and university educators and university students, those attending Health Resources and Services Administration (HRSA)- designated federally qualified health centers (FQHCs), and children 5–17 years, all of whom agreed to longitudinal monitoring of SARS-CoV-2 antibody status every three months (three time points) from 10/1/ 2020–10/31/2021.""

""Recruitment efforts were taken to enroll rural and urban participants spanning the state.""",,2021-10-01,2021-10-31,Multiple populations,All,Adults (18-64 years),40.0,49.0,Age,Age group: 40-49,692,0.2977,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9982,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Stacia DeSantis,University of Texas,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273694,2022-09-21,2024-03-01,Unverified,desantis_methodology_2022,USA
220909_Texas_UniversityOfTexas_2021Oct_UnAdj_Age5-15,220909_Texas_UniversityOfTexas,Methodology to estimate natural- and vaccine-induced antibodies to SARS-CoV-2 in a large geographic region,2022-09-09,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Texas,,"""Texas CARES is a prospective convenience sample of adult retail/business employees, K-12 and university educators and university students, those attending Health Resources and Services Administration (HRSA)- designated federally qualified health centers (FQHCs), and children 5–17 years, all of whom agreed to longitudinal monitoring of SARS-CoV-2 antibody status every three months (three time points) from 10/1/ 2020–10/31/2021.""

""Recruitment efforts were taken to enroll rural and urban participants spanning the state.""",,2021-10-01,2021-10-31,Multiple populations,All,Children and Youth (0-17 years),5.0,15.0,Age,Age group: 5-15,132,0.48479999999999995,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9982,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Stacia DeSantis,University of Texas,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273694,2022-09-21,2024-03-01,Unverified,desantis_methodology_2022,USA
220909_Texas_UniversityOfTexas_2021Oct_UnAdj_Age80-84,220909_Texas_UniversityOfTexas,Methodology to estimate natural- and vaccine-induced antibodies to SARS-CoV-2 in a large geographic region,2022-09-09,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Texas,,"""Texas CARES is a prospective convenience sample of adult retail/business employees, K-12 and university educators and university students, those attending Health Resources and Services Administration (HRSA)- designated federally qualified health centers (FQHCs), and children 5–17 years, all of whom agreed to longitudinal monitoring of SARS-CoV-2 antibody status every three months (three time points) from 10/1/ 2020–10/31/2021.""

""Recruitment efforts were taken to enroll rural and urban participants spanning the state.""",,2021-10-01,2021-10-31,Multiple populations,All,Seniors (65+ years),80.0,84.0,Age,Age group: 80-84,13,0.23079999999999998,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.9982,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Stacia DeSantis,University of Texas,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0273694,2022-09-21,2024-03-01,Unverified,desantis_methodology_2022,USA
220912_WashingtonDC_ChildrensNationalHospital_Overall,220912_WashingtonDC_ChildrensNationalHospital,Examining multi-level immune response to determine prevalence of COVID-19 in pediatric tonsillectomy.,2022-09-14,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Washington DC,Washington DC,"Patients scheduled to undergo tonsillectomy at CNH were invited to partici- pate in the study between September 25, 2020 and January 15, 2021. We recruited 100 patients randomly over the study period with recruitment limited by resources available to process tissues on the same day as surgery.","There were no exclusions to involvement in the study, and study involvement was voluntary. ",2020-09-25,2021-01-15,Representative patient population,All,Children and Youth (0-17 years),2.0,18.0,Primary Estimate,,100,0.19,,,True,,,,True,Self-referral,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",Spike,Validated by developers,1.0,1.0,['High'],,No,No,Yes,,Unclear,Yes,Yes,,Pamela Mudd,Children's National Hospital,Not Unity-Aligned,https://dx.doi.org/10.1002/lary.30382,2022-09-19,2022-09-19,Unverified,mudd_examining_2022,USA
220915_PittCounty_EastCarolinaUniversity_Overall,220915_PittCounty_EastCarolinaUniversity,Waning of SARS-CoV-2 Seropositivity among Healthy Young Adults over Seven Months.,2022-09-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,North Carolina,Greenville,"An undergraduate or graduate student was eligible if enrolled full or part-time in fall semester 2020, listed a Pitt County residential address, was 18 years of age or older, and spoke English. ",Students affiliated with the ECU athletics program were excluded due to testing under a separate protocol.,2020-08-26,2021-03-31,Students and Daycares,All,Adults (18-64 years),,,Primary Estimate,,136,0.2058823529,,,True,,,,True,Simplified probability,Author designed (CLIA) -Nucleocapsid,,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,Yes,No,No,,Unclear,Yes,No,,Suzanne Lea,East Carolina University,Not Unity-Aligned,https://dx.doi.org/10.3390/vaccines10091532,2022-10-20,2022-10-20,Unverified,lea_waning_2022,USA
210916_Ohio_UniversityHospitalsClevelandMedicalCenter_Overall,220916_Ohio_UniversityHospitalsClevelandMedicalCenter,"SARS-CoV-2 Seroprevalence Among First Responders in Northeastern Ohio, 2020.",2022-09-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Ohio,,"All first responders who work in the region, were older than 18 years of age and able to provide consent were invited to participate. ",There were no additional exclusion criteria.,2020-05-22,2020-09-15,Essential non-healthcare workers,All,Multiple groups,18.0,,Primary Estimate,Overall,3080,0.024,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Xiaochun Zhang,University Hospitals Cleveland Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1177/00333549221119143,2022-10-19,2024-03-01,Unverified,zhangSARSCoV2SeroprevalenceFirst2021-1,USA
210916_Ohio_UniversityHospitalsClevelandMedicalCenter_60+,220916_Ohio_UniversityHospitalsClevelandMedicalCenter,"SARS-CoV-2 Seroprevalence Among First Responders in Northeastern Ohio, 2020.",2022-09-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Ohio,,"All first responders who work in the region, were older than 18 years of age and able to provide consent were invited to participate. ",There were no additional exclusion criteria.,2020-05-22,2020-09-15,Essential non-healthcare workers,All,Seniors (65+ years),60.0,,Age,60+,248,0.0202,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Xiaochun Zhang,University Hospitals Cleveland Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1177/00333549221119143,2022-10-19,2024-03-01,Unverified,zhangSARSCoV2SeroprevalenceFirst2021-1,USA
210916_Ohio_UniversityHospitalsClevelandMedicalCenter_50-59,220916_Ohio_UniversityHospitalsClevelandMedicalCenter,"SARS-CoV-2 Seroprevalence Among First Responders in Northeastern Ohio, 2020.",2022-09-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Ohio,,"All first responders who work in the region, were older than 18 years of age and able to provide consent were invited to participate. ",There were no additional exclusion criteria.,2020-05-22,2020-09-15,Essential non-healthcare workers,All,Adults (18-64 years),50.0,60.0,Age,50-60,695,0.0187,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Xiaochun Zhang,University Hospitals Cleveland Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1177/00333549221119143,2022-10-19,2024-03-01,Unverified,zhangSARSCoV2SeroprevalenceFirst2021-1,USA
210916_Ohio_UniversityHospitalsClevelandMedicalCenter_30-39,220916_Ohio_UniversityHospitalsClevelandMedicalCenter,"SARS-CoV-2 Seroprevalence Among First Responders in Northeastern Ohio, 2020.",2022-09-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Ohio,,"All first responders who work in the region, were older than 18 years of age and able to provide consent were invited to participate. ",There were no additional exclusion criteria.,2020-05-22,2020-09-15,Essential non-healthcare workers,All,Adults (18-64 years),30.0,39.0,Age,30-39,773,0.0233,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Xiaochun Zhang,University Hospitals Cleveland Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1177/00333549221119143,2022-10-19,2024-03-01,Unverified,zhangSARSCoV2SeroprevalenceFirst2021-1,USA
210916_Ohio_UniversityHospitalsClevelandMedicalCenter_40-49,220916_Ohio_UniversityHospitalsClevelandMedicalCenter,"SARS-CoV-2 Seroprevalence Among First Responders in Northeastern Ohio, 2020.",2022-09-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Ohio,,"All first responders who work in the region, were older than 18 years of age and able to provide consent were invited to participate. ",There were no additional exclusion criteria.,2020-05-22,2020-09-15,Essential non-healthcare workers,All,Adults (18-64 years),40.0,49.0,Age,40-49,858,0.0245,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Xiaochun Zhang,University Hospitals Cleveland Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1177/00333549221119143,2022-10-19,2024-03-01,Unverified,zhangSARSCoV2SeroprevalenceFirst2021-1,USA
210916_Ohio_UniversityHospitalsClevelandMedicalCenter_18-29,220916_Ohio_UniversityHospitalsClevelandMedicalCenter,"SARS-CoV-2 Seroprevalence Among First Responders in Northeastern Ohio, 2020.",2022-09-16,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Ohio,,"All first responders who work in the region, were older than 18 years of age and able to provide consent were invited to participate. ",There were no additional exclusion criteria.,2020-05-22,2020-09-15,Essential non-healthcare workers,All,Adults (18-64 years),18.0,29.0,Age,18-29,505,0.0317,,,,,,,,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.996,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Xiaochun Zhang,University Hospitals Cleveland Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1177/00333549221119143,2022-10-19,2024-03-01,Unverified,zhangSARSCoV2SeroprevalenceFirst2021-1,USA
220922_Atlanta_EmoryUniversitySchoolofMedicine,220922_Atlanta_EmoryUniversitySchoolofMedicine,"Estimating severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence from residual clinical blood samples, January-March 2021.",2022-09-22,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Georgia,Atlanta,,,2021-01-22,2021-03-12,Residual sera,All,Multiple groups,,,Primary Estimate,,2406,0.1699916874,,,True,,,,True,Convenience,Simoa Serological Test,Quanterix,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Daniel Graciaa,Emory University School of Medicine,Not Unity-Aligned,https://dx.doi.org/10.1017/ash.2022.298,2022-12-29,2023-03-19,Unverified,graciaa_estimating_2022,USA
220922_Atlanta_EmoryUniversitySchoolofMedicine_Timepoint_210212,220922_Atlanta_EmoryUniversitySchoolofMedicine,"Estimating severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence from residual clinical blood samples, January-March 2021.",2022-09-22,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Georgia,Atlanta,,,2021-02-12,2021-02-12,Residual sera,All,Multiple groups,,,Time frame,"Feb 12, 2021",336,0.18154761900000002,,,,,,,,Convenience,Simoa Serological Test,Quanterix,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Daniel Graciaa,Emory University School of Medicine,Not Unity-Aligned,https://dx.doi.org/10.1017/ash.2022.298,2023-01-04,2023-03-19,Unverified,graciaa_estimating_2022,USA
220922_Atlanta_EmoryUniversitySchoolofMedicine_Timepoint_210205,220922_Atlanta_EmoryUniversitySchoolofMedicine,"Estimating severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence from residual clinical blood samples, January-March 2021.",2022-09-22,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Georgia,Atlanta,,,2021-02-05,2021-02-05,Residual sera,All,Multiple groups,,,Time frame,"Feb 5, 2021",243,0.13991769550000002,,,,,,,,Convenience,Simoa Serological Test,Quanterix,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Daniel Graciaa,Emory University School of Medicine,Not Unity-Aligned,https://dx.doi.org/10.1017/ash.2022.298,2023-01-04,2023-03-19,Unverified,graciaa_estimating_2022,USA
220922_Atlanta_EmoryUniversitySchoolofMedicine_Timepoint_210305,220922_Atlanta_EmoryUniversitySchoolofMedicine,"Estimating severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence from residual clinical blood samples, January-March 2021.",2022-09-22,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Georgia,Atlanta,,,2021-03-05,2021-03-05,Residual sera,All,Multiple groups,,,Time frame,"Mar 5, 2021",426,0.19718309860000002,,,,,,,,Convenience,Simoa Serological Test,Quanterix,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Daniel Graciaa,Emory University School of Medicine,Not Unity-Aligned,https://dx.doi.org/10.1017/ash.2022.298,2023-01-04,2023-03-19,Unverified,graciaa_estimating_2022,USA
220922_Atlanta_EmoryUniversitySchoolofMedicine_Timepoint_210122,220922_Atlanta_EmoryUniversitySchoolofMedicine,"Estimating severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence from residual clinical blood samples, January-March 2021.",2022-09-22,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Georgia,Atlanta,,,2021-01-22,2021-01-22,Residual sera,All,Multiple groups,,,Time frame,"Jan 22, 2021",301,0.1893687708,,,,,,,,Convenience,Simoa Serological Test,Quanterix,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Daniel Graciaa,Emory University School of Medicine,Not Unity-Aligned,https://dx.doi.org/10.1017/ash.2022.298,2023-01-04,2023-03-19,Unverified,graciaa_estimating_2022,USA
220922_Atlanta_EmoryUniversitySchoolofMedicine_Timepoint_210219,220922_Atlanta_EmoryUniversitySchoolofMedicine,"Estimating severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence from residual clinical blood samples, January-March 2021.",2022-09-22,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Georgia,Atlanta,,,2021-02-19,2021-02-19,Residual sera,All,Multiple groups,,,Time frame,"Feb 19, 2021",371,0.09703504043000001,,,,,,,,Convenience,Simoa Serological Test,Quanterix,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Daniel Graciaa,Emory University School of Medicine,Not Unity-Aligned,https://dx.doi.org/10.1017/ash.2022.298,2023-01-04,2023-03-19,Unverified,graciaa_estimating_2022,USA
220922_Atlanta_EmoryUniversitySchoolofMedicine_Timepoint_210312,220922_Atlanta_EmoryUniversitySchoolofMedicine,"Estimating severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence from residual clinical blood samples, January-March 2021.",2022-09-22,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Georgia,Atlanta,,,2021-03-12,2021-03-12,Residual sera,All,Multiple groups,,,Time frame,"Mar 12, 2021",100,0.17,,,,,,,,Convenience,Simoa Serological Test,Quanterix,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Daniel Graciaa,Emory University School of Medicine,Not Unity-Aligned,https://dx.doi.org/10.1017/ash.2022.298,2023-01-04,2023-03-19,Unverified,graciaa_estimating_2022,USA
220922_Atlanta_EmoryUniversitySchoolofMedicine_Timepoint_210226,220922_Atlanta_EmoryUniversitySchoolofMedicine,"Estimating severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence from residual clinical blood samples, January-March 2021.",2022-09-22,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Georgia,Atlanta,,,2021-02-26,2021-02-26,Residual sera,All,Multiple groups,,,Time frame,"Feb 26, 2021",291,0.1340206186,,,,,,,,Convenience,Simoa Serological Test,Quanterix,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Daniel Graciaa,Emory University School of Medicine,Not Unity-Aligned,https://dx.doi.org/10.1017/ash.2022.298,2023-01-04,2023-03-19,Unverified,graciaa_estimating_2022,USA
220922_Atlanta_EmoryUniversitySchoolofMedicine_Timepoint_210129,220922_Atlanta_EmoryUniversitySchoolofMedicine,"Estimating severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence from residual clinical blood samples, January-March 2021.",2022-09-22,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,United States of America,Georgia,Atlanta,,,2021-01-29,2021-01-29,Residual sera,All,Multiple groups,,,Time frame,"Jan 29, 2021",338,0.23964497040000002,,,,,,,,Convenience,Simoa Serological Test,Quanterix,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Daniel Graciaa,Emory University School of Medicine,Not Unity-Aligned,https://dx.doi.org/10.1017/ash.2022.298,2023-01-04,2023-03-19,Unverified,graciaa_estimating_2022,USA
220930_Maryland_JohnsHopkinsUniversity,220930_Maryland_JohnsHopkinsUniversity,Predictors of Severe Acute Respiratory Syndrome Coronavirus 2 Seropositivity Before Coronavirus Disease 2019 Vaccination Among Children 0-4 Years and Their Household Members in the SEARCh Study.,2022-09-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Maryland,,""" 175 Maryland households (690 participants) with ≥1 child aged 0–4 years during November 2020–March 2021""","""individuals vaccinated against COVID-19
were ineligible""",2020-11-15,2021-03-15,Household and community samples,All,Multiple groups,,,Primary Estimate,,681,0.081,,,True,,,,True,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Maria Garcia Quesada,Johns Hopkins University,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac507,2022-11-10,2024-03-01,Unverified,garcia_quesada_predictors_2022,USA
220930_Maryland_JohnsHopkinsUniversity_Age_5-17,220930_Maryland_JohnsHopkinsUniversity,Predictors of Severe Acute Respiratory Syndrome Coronavirus 2 Seropositivity Before Coronavirus Disease 2019 Vaccination Among Children 0-4 Years and Their Household Members in the SEARCh Study.,2022-09-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Maryland,,""" 175 Maryland households (690 participants) with ≥1 child aged 0–4 years during November 2020–March 2021""","""individuals vaccinated against COVID-19
were ineligible""",2020-11-15,2021-03-15,Household and community samples,All,Children and Youth (0-17 years),,,Age,5-17,96,0.135,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Maria Garcia Quesada,Johns Hopkins University,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac507,2022-11-10,2024-03-01,Unverified,garcia_quesada_predictors_2022,USA
220930_Maryland_JohnsHopkinsUniversity_Age_0-4,220930_Maryland_JohnsHopkinsUniversity,Predictors of Severe Acute Respiratory Syndrome Coronavirus 2 Seropositivity Before Coronavirus Disease 2019 Vaccination Among Children 0-4 Years and Their Household Members in the SEARCh Study.,2022-09-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Maryland,,""" 175 Maryland households (690 participants) with ≥1 child aged 0–4 years during November 2020–March 2021""","""individuals vaccinated against COVID-19
were ineligible""",2020-11-15,2021-03-15,Household and community samples,All,Children and Youth (0-17 years),,,Age,0-4,254,0.059000000000000004,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Maria Garcia Quesada,Johns Hopkins University,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac507,2022-11-10,2024-03-01,Unverified,garcia_quesada_predictors_2022,USA
220930_Maryland_JohnsHopkinsUniversity_Age_>=18,220930_Maryland_JohnsHopkinsUniversity,Predictors of Severe Acute Respiratory Syndrome Coronavirus 2 Seropositivity Before Coronavirus Disease 2019 Vaccination Among Children 0-4 Years and Their Household Members in the SEARCh Study.,2022-09-30,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Maryland,,""" 175 Maryland households (690 participants) with ≥1 child aged 0–4 years during November 2020–March 2021""","""individuals vaccinated against COVID-19
were ineligible""",2020-11-15,2021-03-15,Household and community samples,All,Adults (18-64 years),,,Age,>=18,331,0.08199999999999999,,,,,,,,Convenience,"Elecsys® Anti‐SARS‐CoV‐2 (S),Elecsys® Anti‐SARS‐CoV‐2 (N)",Roche Diagnostics,CLIA,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,No,,Maria Garcia Quesada,Johns Hopkins University,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac507,2022-11-10,2024-03-01,Unverified,garcia_quesada_predictors_2022,USA
221009_OlmstedCounty_MayoClinic_overall,221009_OlmstedCounty_MayoClinic,"Rates of Asymptomatic COVID-19 Infection and Associated Factors in Olmsted County, MN in the Pre-Vaccination Era.",2022-10-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Minnesota,,"""n collaboration with Olmsted County Public Health Services, we invited county
employees and first responders (police, fire, sheriff) to participate in a seroprevalence study in
November, 2020. ""

""A small group of employees from Zumbro Valley Health
Center were also invited and contributed to the county group""",,2020-11-15,2021-02-15,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,755,0.077,,,True,,,,True,Convenience,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,Luminex,Dried Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.961,0.9720000000000001,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Celine Vachon,Mayo Clinic,Not Unity-Aligned,https://dx.doi.org/10.1016/j.mayocpiqo.2022.10.001,2022-11-02,2024-03-01,Unverified,vachon_rates_2022,USA
221012_Rochester_OaklandUniversity_overall,221012_Rochester_OaklandUniversity,Incidence of New or Worsening Overactive Bladder Among Patients with a Prior SARS-CoV-2 Infection: A Cohort Study.,2022-10-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Michigan,Rochester,"""Inclusion criteria for the present study were participation in the BLAST COVID study, age !18 yr, and agreement to participate in future studies. ""","""Exclusion criteria included decisional impairment and those unable to complete the electronic survey.""",2020-04-13,2020-05-28,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,1895,0.31930000000000003,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Plasma,IgG,,Validated by independent authors/third party/non-developers,0.9934999999999999,0.9814,['High'],,No,Yes,No,,Yes,Yes,Yes,,Ly Hoang Roberts,Oakland University ,Not Unity-Aligned,https://dx.doi.org/10.1016/j.euros.2022.10.001,2022-10-28,2024-03-01,Unverified,hoangrobertsIncidenceNewWorsening2022,USA
221012_UnitedStates_UniversityofWashington_infants,221012_UnitedStates_UniversityofWashington_infants,SARS-CoV-2 specific antibody trajectories in mothers and infants over two months following maternal infection,2022-10-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,,Washington,"""Participating mothers had to be ≥18 years of age and the caregiver of a child ≤36 months of age. The present study used only data from dyads enrolled after 28 days postpartum (antibody results of dyads enrolled < 28 days postpartum are described in the Supplementary Information). Additional eligibility requirements related to maternal COVID-19 status and child feeding status varied by recruitment group; no other demographic or health information were used as inclusion or exclusion criteria""",,2020-06-15,2021-03-15,Residual sera,All,Children and Youth (0-17 years),,,Primary Estimate,,24,0.375,,,True,,,,True,Sequential,Not reported/ Unable to specify,,ELISA,Dried Blood,"['IgA', 'IgG']",Spike,,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Melanie Ann Martin,University of Washington,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2022.1015002,2022-11-14,2022-11-18,Unverified,martinSARSCoV2SpecificAntibody2022,USA
221012_UnitedStates_UniversityofWashington_mothers,221012_UnitedStates_UniversityofWashington_mothers,SARS-CoV-2 specific antibody trajectories in mothers and infants over two months following maternal infection,2022-10-12,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,,Washington,"""Participating mothers had to be ≥18 years of age and the caregiver of a child ≤36 months of age. The present study used only data from dyads enrolled after 28 days postpartum (antibody results of dyads enrolled < 28 days postpartum are described in the Supplementary Information). Additional eligibility requirements related to maternal COVID-19 status and child feeding status varied by recruitment group; no other demographic or health information were used as inclusion or exclusion criteria""",,2020-06-15,2021-03-15,Residual sera,Female,Adults (18-64 years),24.0,45.0,Primary Estimate,,57,0.807,,,True,,,,True,Sequential,Not reported/ Unable to specify,,ELISA,Dried Blood,"['IgA', 'IgG']",Spike,,,,['High'],,No,No,No,,Unclear,Yes,No,,Melanie Ann Martin,University of Washington,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2022.1015002,2022-11-14,2022-11-18,Unverified,martinSARSCoV2SpecificAntibody2022,USA
221026_MiamiDade_UniversityOfMiami_Overall,221026_MiamiDade_UniversityOfMiami,Infection with SARS-CoV-2 is associated with menstrual irregularities among women of reproductive age,2022-10-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Florida,,"""Inclusion criteria included being a cisgender woman between 18–45 years old, reporting sexual activity in the past three months, being confirmed HIV-negative, no intrauterine device, no history of surgical treatment of the cervix or cervical intra-epithelial neoplasia grade 2 or 3, no chlamydia or gonorrhea in the past two months, no antibiotic use in the past two months, and no allergy to metronidazole.""","""In the current analysis, women were excluded for factors that could impact menstruation, including taking hormonal contraceptives, female hormones, or pregnancy within the last year.""",2020-10-15,2021-09-15,Household and community samples,Female,Adults (18-64 years),18.0,45.0,Primary Estimate,,73,0.4932,,,True,,,,True,Convenience,CoronaCHEK COVID-19 IgG/IgM Rapid Test Cassette,Hangzhou Biotest Biotech Co Ltd,LFIA,Whole Blood,IgG,Spike,,,,['High'],,No,No,No,,Unclear,Yes,No,,Emily Cherenack,University of Miami,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0276131,2022-11-01,2022-11-02,Unverified,cherenack_infection_2022,USA
221030_Boston_BostonUniversity,221030_Boston_BostonUniversity,"Comparison of SARS-CoV-2 anti-spike IgG and anti-nucleoprotein IgG seroprevalence amongst a pre-vaccine cohort of healthcare workers at an academic medical center in Boston, Massachusetts",2022-10-30,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Massachusetts,Boston,"A total of 1,743 HCWs at Boston Medical Center (BMC) provided serum samples that were analyzed for SARS-CoV-2 anti-S IgG and IgM",,2020-07-13,2020-07-26,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1743,0.072,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Manisha Cole,Boston University,Not Unity-Aligned,https://dx.doi.org/10.21037/jlpm-22-19,2023-04-12,2024-03-01,Unverified,cole_comparison_2022,USA
221114_UnitedStates_CentersforDiseaseControlandPrevention_overall,221114_UnitedStates_CentersforDiseaseControlandPrevention,"Occupations Associated with SARS-CoV-2 Infection and Vaccination, U.S. Blood Donors, July 2021-December 2021.",2022-11-14,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"""From May 4, 2021 to December 31, 2021, 347,447 first-time anti-spike (S) reactive American Red Cross (ARC) donors as well as all anti-S non-reactive donors were eligible for an electronic survey approximately 2 weeks after donation if they were age 18 or older, were accessible by email, and spoke English. ""","""145 responses from individuals who were anti-spike reactive, anti-nucleocapsid non-reactive, and with no history of vaccination were excluded from this analysis""",2021-05-04,2021-12-31,Blood donors,All,Multiple groups,18.0,,Primary Estimate,,85986,0.11050000000000001,,,True,,,,True,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],No,Unclear,Yes,Yes,No,Yes,Yes,Yes,No,Melisa Shah,Centers for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac883,2022-11-22,2024-04-18,Verified,shahOccupationsAssociatedSARSCoV22022,USA
221114_UnitedStates_CentersforDiseaseControlandPrevention_south,221114_UnitedStates_CentersforDiseaseControlandPrevention,"Occupations Associated with SARS-CoV-2 Infection and Vaccination, U.S. Blood Donors, July 2021-December 2021.",2022-11-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,South,,"""From May 4, 2021 to December 31, 2021, 347,447 first-time anti-spike (S) reactive American Red Cross (ARC) donors as well as all anti-S non-reactive donors were eligible for an electronic survey approximately 2 weeks after donation if they were age 18 or older, were accessible by email, and spoke English. ""","""145 responses from individuals who were anti-spike reactive, anti-nucleocapsid non-reactive, and with no history of vaccination were excluded from this analysis""",2021-05-04,2021-12-31,Blood donors,All,Multiple groups,18.0,,Geographical area,South,21400,0.1201,,,,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],No,Unclear,Yes,Yes,No,Yes,Yes,Yes,No,Melisa Shah,Centers for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac883,2022-11-22,2024-04-18,Verified,shahOccupationsAssociatedSARSCoV22022,USA
221114_UnitedStates_CentersforDiseaseControlandPrevention_female,221114_UnitedStates_CentersforDiseaseControlandPrevention,"Occupations Associated with SARS-CoV-2 Infection and Vaccination, U.S. Blood Donors, July 2021-December 2021.",2022-11-14,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"""From May 4, 2021 to December 31, 2021, 347,447 first-time anti-spike (S) reactive American Red Cross (ARC) donors as well as all anti-S non-reactive donors were eligible for an electronic survey approximately 2 weeks after donation if they were age 18 or older, were accessible by email, and spoke English. ""","""145 responses from individuals who were anti-spike reactive, anti-nucleocapsid non-reactive, and with no history of vaccination were excluded from this analysis""",2021-05-04,2021-12-31,Blood donors,Female,Multiple groups,18.0,,Sex/Gender,,51254,0.1151,,,,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],No,Unclear,Yes,Yes,No,Yes,Yes,Yes,No,Melisa Shah,Centers for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac883,2022-11-22,2024-04-18,Verified,shahOccupationsAssociatedSARSCoV22022,USA
221114_UnitedStates_CentersforDiseaseControlandPrevention_55to74,221114_UnitedStates_CentersforDiseaseControlandPrevention,"Occupations Associated with SARS-CoV-2 Infection and Vaccination, U.S. Blood Donors, July 2021-December 2021.",2022-11-14,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"""From May 4, 2021 to December 31, 2021, 347,447 first-time anti-spike (S) reactive American Red Cross (ARC) donors as well as all anti-S non-reactive donors were eligible for an electronic survey approximately 2 weeks after donation if they were age 18 or older, were accessible by email, and spoke English. ""","""145 responses from individuals who were anti-spike reactive, anti-nucleocapsid non-reactive, and with no history of vaccination were excluded from this analysis""",2021-05-04,2021-12-31,Blood donors,All,Multiple groups,55.0,74.0,Age,55-74,42009,0.0861,,,,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],No,Unclear,Yes,Yes,No,Yes,Yes,Yes,No,Melisa Shah,Centers for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac883,2022-11-22,2024-04-18,Verified,shahOccupationsAssociatedSARSCoV22022,USA
221114_UnitedStates_CentersforDiseaseControlandPrevention_northeast,221114_UnitedStates_CentersforDiseaseControlandPrevention,"Occupations Associated with SARS-CoV-2 Infection and Vaccination, U.S. Blood Donors, July 2021-December 2021.",2022-11-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Northeast,,"""From May 4, 2021 to December 31, 2021, 347,447 first-time anti-spike (S) reactive American Red Cross (ARC) donors as well as all anti-S non-reactive donors were eligible for an electronic survey approximately 2 weeks after donation if they were age 18 or older, were accessible by email, and spoke English. ""","""145 responses from individuals who were anti-spike reactive, anti-nucleocapsid non-reactive, and with no history of vaccination were excluded from this analysis""",2021-05-04,2021-12-31,Blood donors,All,Multiple groups,18.0,,Geographical area,Northeast,18871,0.08230000000000001,,,,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],No,Unclear,Yes,Yes,No,Yes,Yes,Yes,No,Melisa Shah,Centers for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac883,2022-11-22,2024-04-18,Verified,shahOccupationsAssociatedSARSCoV22022,USA
221114_UnitedStates_CentersforDiseaseControlandPrevention_west,221114_UnitedStates_CentersforDiseaseControlandPrevention,"Occupations Associated with SARS-CoV-2 Infection and Vaccination, U.S. Blood Donors, July 2021-December 2021.",2022-11-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,West,,"""From May 4, 2021 to December 31, 2021, 347,447 first-time anti-spike (S) reactive American Red Cross (ARC) donors as well as all anti-S non-reactive donors were eligible for an electronic survey approximately 2 weeks after donation if they were age 18 or older, were accessible by email, and spoke English. ""","""145 responses from individuals who were anti-spike reactive, anti-nucleocapsid non-reactive, and with no history of vaccination were excluded from this analysis""",2021-05-04,2021-12-31,Blood donors,All,Multiple groups,18.0,,Geographical area,West,22631,0.10779999999999999,,,,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],No,Unclear,Yes,Yes,No,Yes,Yes,Yes,No,Melisa Shah,Centers for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac883,2022-11-22,2024-04-18,Verified,shahOccupationsAssociatedSARSCoV22022,USA
221114_UnitedStates_CentersforDiseaseControlandPrevention_75plus,221114_UnitedStates_CentersforDiseaseControlandPrevention,"Occupations Associated with SARS-CoV-2 Infection and Vaccination, U.S. Blood Donors, July 2021-December 2021.",2022-11-14,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"""From May 4, 2021 to December 31, 2021, 347,447 first-time anti-spike (S) reactive American Red Cross (ARC) donors as well as all anti-S non-reactive donors were eligible for an electronic survey approximately 2 weeks after donation if they were age 18 or older, were accessible by email, and spoke English. ""","""145 responses from individuals who were anti-spike reactive, anti-nucleocapsid non-reactive, and with no history of vaccination were excluded from this analysis""",2021-05-04,2021-12-31,Blood donors,All,Seniors (65+ years),75.0,,Age,75+,2535,0.0635,,,,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],No,Unclear,Yes,Yes,No,Yes,Yes,Yes,No,Melisa Shah,Centers for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac883,2022-11-22,2024-04-18,Verified,shahOccupationsAssociatedSARSCoV22022,USA
221114_UnitedStates_CentersforDiseaseControlandPrevention_male,221114_UnitedStates_CentersforDiseaseControlandPrevention,"Occupations Associated with SARS-CoV-2 Infection and Vaccination, U.S. Blood Donors, July 2021-December 2021.",2022-11-14,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"""From May 4, 2021 to December 31, 2021, 347,447 first-time anti-spike (S) reactive American Red Cross (ARC) donors as well as all anti-S non-reactive donors were eligible for an electronic survey approximately 2 weeks after donation if they were age 18 or older, were accessible by email, and spoke English. ""","""145 responses from individuals who were anti-spike reactive, anti-nucleocapsid non-reactive, and with no history of vaccination were excluded from this analysis""",2021-05-04,2021-12-31,Blood donors,Male,Multiple groups,18.0,,Sex/Gender,,34732,0.1039,,,,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],No,Unclear,Yes,Yes,No,Yes,Yes,Yes,No,Melisa Shah,Centers for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac883,2022-11-22,2024-04-18,Verified,shahOccupationsAssociatedSARSCoV22022,USA
221114_UnitedStates_CentersforDiseaseControlandPrevention_35to54,221114_UnitedStates_CentersforDiseaseControlandPrevention,"Occupations Associated with SARS-CoV-2 Infection and Vaccination, U.S. Blood Donors, July 2021-December 2021.",2022-11-14,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"""From May 4, 2021 to December 31, 2021, 347,447 first-time anti-spike (S) reactive American Red Cross (ARC) donors as well as all anti-S non-reactive donors were eligible for an electronic survey approximately 2 weeks after donation if they were age 18 or older, were accessible by email, and spoke English. ""","""145 responses from individuals who were anti-spike reactive, anti-nucleocapsid non-reactive, and with no history of vaccination were excluded from this analysis""",2021-05-04,2021-12-31,Blood donors,All,Adults (18-64 years),35.0,54.0,Age,35-54,31218,0.13369999999999999,,,,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],No,Unclear,Yes,Yes,No,Yes,Yes,Yes,No,Melisa Shah,Centers for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac883,2022-11-22,2024-04-18,Verified,shahOccupationsAssociatedSARSCoV22022,USA
221114_UnitedStates_CentersforDiseaseControlandPrevention_midwest,221114_UnitedStates_CentersforDiseaseControlandPrevention,"Occupations Associated with SARS-CoV-2 Infection and Vaccination, U.S. Blood Donors, July 2021-December 2021.",2022-11-14,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Midwest,,"""From May 4, 2021 to December 31, 2021, 347,447 first-time anti-spike (S) reactive American Red Cross (ARC) donors as well as all anti-S non-reactive donors were eligible for an electronic survey approximately 2 weeks after donation if they were age 18 or older, were accessible by email, and spoke English. ""","""145 responses from individuals who were anti-spike reactive, anti-nucleocapsid non-reactive, and with no history of vaccination were excluded from this analysis""",2021-05-04,2021-12-31,Blood donors,All,Multiple groups,18.0,,Geographical area,Midwest,23035,0.1273,,,,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],No,Unclear,Yes,Yes,No,Yes,Yes,Yes,No,Melisa Shah,Centers for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac883,2022-11-22,2024-04-18,Verified,shahOccupationsAssociatedSARSCoV22022,USA
221114_UnitedStates_CentersforDiseaseControlandPrevention_18to34,221114_UnitedStates_CentersforDiseaseControlandPrevention,"Occupations Associated with SARS-CoV-2 Infection and Vaccination, U.S. Blood Donors, July 2021-December 2021.",2022-11-14,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"""From May 4, 2021 to December 31, 2021, 347,447 first-time anti-spike (S) reactive American Red Cross (ARC) donors as well as all anti-S non-reactive donors were eligible for an electronic survey approximately 2 weeks after donation if they were age 18 or older, were accessible by email, and spoke English. ""","""145 responses from individuals who were anti-spike reactive, anti-nucleocapsid non-reactive, and with no history of vaccination were excluded from this analysis""",2021-05-04,2021-12-31,Blood donors,All,Adults (18-64 years),18.0,34.0,Age,18-34,10224,0.1515,,,,,,,,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['High'],No,Unclear,Yes,Yes,No,Yes,Yes,Yes,No,Melisa Shah,Centers for Disease Control and Prevention,Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac883,2022-11-22,2024-04-18,Verified,shahOccupationsAssociatedSARSCoV22022,USA
221123_ChapelHill_UniversityOfNorthCarolina_Overall,221123_ChapelHill_UniversityOfNorthCarolina,Single-center serological surveillance of SARS-CoV-2 in pregnant patients presenting to labor and delivery,2022-11-23,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,North Carolina,Chapel Hill,"""a prospective surveillance study was conducted among pregnant women"".

""Patients were approached for potential participation when study staff were available and gave consent and enrolled at the time of admission to labor and delivery.""","""Patients aged under 18 years and those unable to understand either English or Spanish were excluded.""",2020-04-25,2020-09-22,Pregnant or parturient women,Female,Adults (18-64 years),18.0,,Primary Estimate,,388,0.049,0.029700000000000004,0.07540000000000001,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,0.98,1.0,['High'],Yes,No,No,No,No,Unclear,Yes,Yes,Unclear,Kim Boggess,University of North Carolina,Unity-Aligned,https://dx.doi.org/10.1002/ijgo.14587,2022-12-09,2023-03-19,Unverified,boggess_single-center_2022,USA
221202_USA_CDC_Overall_AntiS,221202_USA_CDC,"SARS-CoV-2 Serology and Self-Reported Infection Among Adults — National Health and Nutrition Examination Survey, United States, August 2021–May 2022",2022-12-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"""Preliminary data for adults aged ≥18 years from the first 10 primary sampling units (visited during periods of SARS-CoV-2 Delta [August–November 2021] and Omicron [December 2021–May 2022] variant predominance) (6) were analyzed as a convenience sample""","""Among 1,581 participants with serology results, seven were excluded (including three with “don’t know” or “refused” responses for self-reported COVID-19 history and four with a combined serology result of anti-S–negative and anti-N positive**) leaving an analytic sample of 1,574.""",2021-08-15,2022-05-15,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,1574,0.915,,,True,,,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,,"IgG, IgM, IgA",Spike,,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Lara Akinbami,US CDC,Not Unity-Aligned,http://dx.doi.org/10.15585/mmwr.mm7148a4,2022-12-16,2024-03-01,Unverified,akinbami_sars-cov-2_2022,USA
221202_USA_CDC_Overall_AntiN,221202_USA_CDC,"SARS-CoV-2 Serology and Self-Reported Infection Among Adults — National Health and Nutrition Examination Survey, United States, August 2021–May 2022",2022-12-02,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"""Preliminary data for adults aged ≥18 years from the first 10 primary sampling units (visited during periods of SARS-CoV-2 Delta [August–November 2021] and Omicron [December 2021–May 2022] variant predominance) (6) were analyzed as a convenience sample""","""Among 1,581 participants with serology results, seven were excluded (including three with “don’t know” or “refused” responses for self-reported COVID-19 history and four with a combined serology result of anti-S–negative and anti-N positive**) leaving an analytic sample of 1,574.""",2021-08-15,2022-05-15,Household and community samples,All,Multiple groups,18.0,,Test used,,1574,0.41600000000000004,,,,,,,,Convenience,VITROS Anti-SARS-CoV-2 Total N Antibody Test,Ortho Clinical Diagnostics Inc.,CLIA,,"IgG, IgM, IgA",Nucleocapsid (N-protein),,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Lara Akinbami,US CDC,Not Unity-Aligned,http://dx.doi.org/10.15585/mmwr.mm7148a4,2022-12-16,2023-03-22,Unverified,akinbami_sars-cov-2_2022,USA
221203_UnitedStatesofAmerica_CentersforDiseaseControlandPrevention_DecJan2022,221203_UnitedStatesofAmerica_CentersforDiseaseControlandPrevention,"Estimated SARS-CoV-2 antibody seroprevalence trends and relationship to reported case prevalence from a repeated, cross-sectional study in the 50 states and the District of Columbia, United States-October 25, 2020-February 26, 2022",2022-12-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"""Remnants of serum specimens submitted to clinicallaboratories for routine, clinical screening, or diagnostic testing from 51 U.S. jurisdictions (50 U.S. states andD.C.) between October 25, 2020, and February 26, 2022,were examined. """,,2021-12-27,2022-01-29,Residual sera,All,Multiple groups,,,Time frame,"Dec 27, 2021 - Jan 29 2022",70091,0.437,0.433,0.442,True,,,,True,Sequential,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",Multiple Types,Serum,IgG,"['Nucleocapsid (N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Ryan Wiegand,Centers for Disease Control and Prevention,Not Unity-Aligned,10.1016/j.lana.2022.100403,2023-03-09,2024-03-01,Unverified,wiegand_estimated_2023,USA
221203_UnitedStatesofAmerica_CentersforDiseaseControlandPrevention_JanFeb2022,221203_UnitedStatesofAmerica_CentersforDiseaseControlandPrevention,"Estimated SARS-CoV-2 antibody seroprevalence trends and relationship to reported case prevalence from a repeated, cross-sectional study in the 50 states and the District of Columbia, United States-October 25, 2020-February 26, 2022",2022-12-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"""Remnants of serum specimens submitted to clinicallaboratories for routine, clinical screening, or diagnostic testing from 51 U.S. jurisdictions (50 U.S. states andD.C.) between October 25, 2020, and February 26, 2022,were examined. """,,2022-01-27,2022-02-26,Residual sera,All,Multiple groups,,,Time frame,Jan 27 2022 - Feb 26 2022,45509,0.582,0.574,0.589,True,,,,True,Sequential,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",Multiple Types,Serum,IgG,"['Nucleocapsid (N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Ryan Wiegand,Centers for Disease Control and Prevention,Not Unity-Aligned,10.1016/j.lana.2022.100403,2023-03-09,2024-03-01,Unverified,wiegand_estimated_2023,USA
221203_UnitedStatesofAmerica_CentersforDiseaseControlandPrevention_OctNov2020,221203_UnitedStatesofAmerica_CentersforDiseaseControlandPrevention,"Estimated SARS-CoV-2 antibody seroprevalence trends and relationship to reported case prevalence from a repeated, cross-sectional study in the 50 states and the District of Columbia, United States-October 25, 2020-February 26, 2022",2022-12-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"""Remnants of serum specimens submitted to clinicallaboratories for routine, clinical screening, or diagnostic testing from 51 U.S. jurisdictions (50 U.S. states andD.C.) between October 25, 2020, and February 26, 2022,were examined. """,,2020-10-25,2020-11-15,Residual sera,All,Multiple groups,,,Primary Estimate,,63111,0.08,0.079,0.081,True,,,,True,Sequential,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",Multiple Types,Serum,IgG,"['Nucleocapsid (N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Ryan Wiegand,Centers for Disease Control and Prevention,Not Unity-Aligned,10.1016/j.lana.2022.100403,2023-03-09,2024-03-01,Unverified,wiegand_estimated_2023,USA
221203_UnitedStatesofAmerica_CentersforDiseaseControlandPrevention_JanFeb2021,221203_UnitedStatesofAmerica_CentersforDiseaseControlandPrevention,"Estimated SARS-CoV-2 antibody seroprevalence trends and relationship to reported case prevalence from a repeated, cross-sectional study in the 50 states and the District of Columbia, United States-October 25, 2020-February 26, 2022",2022-12-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"""Remnants of serum specimens submitted to clinicallaboratories for routine, clinical screening, or diagnostic testing from 51 U.S. jurisdictions (50 U.S. states andD.C.) between October 25, 2020, and February 26, 2022,were examined. """,,2021-01-17,2021-02-07,Residual sera,All,Multiple groups,,,Time frame,"Jan 17, 2021 - Feb 7, 2021",57819,0.206,0.204,0.209,True,,,,True,Sequential,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",Multiple Types,Serum,IgG,"['Nucleocapsid (N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Ryan Wiegand,Centers for Disease Control and Prevention,Not Unity-Aligned,10.1016/j.lana.2022.100403,2023-03-09,2024-03-01,Unverified,wiegand_estimated_2023,USA
221203_UnitedStatesofAmerica_CentersforDiseaseControlandPrevention_SeptOct2021,221203_UnitedStatesofAmerica_CentersforDiseaseControlandPrevention,"Estimated SARS-CoV-2 antibody seroprevalence trends and relationship to reported case prevalence from a repeated, cross-sectional study in the 50 states and the District of Columbia, United States-October 25, 2020-February 26, 2022",2022-12-03,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,United States of America,,,"""Remnants of serum specimens submitted to clinicallaboratories for routine, clinical screening, or diagnostic testing from 51 U.S. jurisdictions (50 U.S. states andD.C.) between October 25, 2020, and February 26, 2022,were examined. """,,2021-09-06,2021-10-03,Residual sera,All,Multiple groups,,,Time frame,"Sept 6, 2021 - Oct 3, 2021",63199,0.293,0.29,0.297,True,,,,True,Sequential,"Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Abbott Laboratories,Ortho Clinical Diagnostics Inc.,Roche Diagnostics",Multiple Types,Serum,IgG,"['Nucleocapsid (N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Ryan Wiegand,Centers for Disease Control and Prevention,Not Unity-Aligned,10.1016/j.lana.2022.100403,2023-03-09,2024-03-01,Unverified,wiegand_estimated_2023,USA
221207_NewMexico_UniversityOfNewMexico,221207_NewMexico_UniversityOfNewMexico,Prevalence of Asymptomatic COVID-19 Infection Among Air Medical Crew,2022-12-07,Presentation or Conference,Local,Cross-sectional survey ,United States of America,,New Mexico,Air medical crew tested at the University of New Mexico Center for Global Health Laboratory.,,2021-06-15,2021-10-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,42,0.0952,,,True,,,,True,Convenience,Not reported/ Unable to specify,,ELISA,Serum,,,,,,['High'],,No,No,No,,Unclear,Yes,No,,Amy Armbruster,University of New Mexico,Not Unity-Aligned,https://dx.doi.org/10.1016/j.amj.2022.10.004,2023-05-03,2023-05-04,Unverified,armbruster_prevalence_2022,USA
221214_Omaha_UniversityOfNebraskaMedicalCenter,221214_Omaha_UniversityOfNebraskaMedicalCenter,Incidence of unknown COVID-19 infection in a cohort of emergency physicians and advance practice providers,2022-12-14,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Nebraska,Omaha,"This study was conducted at a level I trauma center with an emergency medicine residency and approximately 64,000 annual ED patient visits.

Subjects were considered attending emergency physicians, emergency medicine residents/fellows, and APPs [Advanced Practitioner Providers]. All study participants provided care to COVID-19 patients on a regular basis over the 12 months prior to study enrollment.",,2022-05-01,2022-06-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,69,1.0,,,True,,,,True,Convenience,xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay,Luminex Corporation,,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Aaron Barksdale,University of Nebraska Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ajem.2022.12.012,2023-01-12,2024-03-01,Unverified,barksdale_incidence_2023,USA
221215_US_UniformedServicesUniversityoftheHealthSciences_blood_AntiS,221215_US_UniformedServicesUniversityoftheHealthSciences,Evaluating SARS-CoV-2 Surveillance Strategies at the United States Naval Academy: A Comparison of Saliva and Dried Blood Spot Serosurveillance Against Molecular-Confirmed Case Detection,2022-12-15,Presentation or Conference,Regional,Repeated cross-sectional study,United States of America,Maryland,,"Dried blood spots (DBS) and saliva were collected in August 2020, December 2020, February 2021 (saliva only) and April/May 2021 to measure anti-SARS-CoV-2 spike (S) and nucleoprotein (NP) IgG by United States Naval Academy",,2020-08-15,2021-02-15,Blood donors,All,Adults (18-64 years),,,Primary Estimate,overall estimate against Anti-S IgG on DBS ,97,0.08199999999999999,,,True,,,,,Unclear,Not reported/ Unable to specify,,,Dried Blood,IgG,Spike,,,,['High'],,Unclear,No,No,,Unclear,Yes,No,,Liana Andronescu,Uniformed Services University of the Health Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac492.1511,2023-02-06,2023-03-19,Unverified,andronescu_1884_2022,USA
221215_US_UniformedServicesUniversityoftheHealthSciences_blood_AntiNP,221215_US_UniformedServicesUniversityoftheHealthSciences,Evaluating SARS-CoV-2 Surveillance Strategies at the United States Naval Academy: A Comparison of Saliva and Dried Blood Spot Serosurveillance Against Molecular-Confirmed Case Detection,2022-12-15,Presentation or Conference,Regional,Repeated cross-sectional study,United States of America,Maryland,,"Dried blood spots (DBS) and saliva were collected in August 2020, December 2020, February 2021 (saliva only) and April/May 2021 to measure anti-SARS-CoV-2 spike (S) and nucleoprotein (NP) IgG by United States Naval Academy",,2020-08-15,2021-02-15,Blood donors,All,Adults (18-64 years),,,Test used,overall estimate against Anti-NP IgG on DBS ,97,0.052000000000000005,,,,,,,True,Unclear,Not reported/ Unable to specify,,,Dried Blood,IgG,Nucleocapsid(N-protein),,,,['High'],,Unclear,No,No,,Unclear,Yes,No,,Liana Andronescu,Uniformed Services University of the Health Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac492.1511,2023-02-06,2023-03-19,Unverified,andronescu_1884_2022,USA
221215_US_UniformedServicesUniversityoftheHealthSciences_saliva_AntiS,221215_US_UniformedServicesUniversityoftheHealthSciences,Evaluating SARS-CoV-2 Surveillance Strategies at the United States Naval Academy: A Comparison of Saliva and Dried Blood Spot Serosurveillance Against Molecular-Confirmed Case Detection,2022-12-15,Presentation or Conference,Regional,Repeated cross-sectional study,United States of America,Maryland,,"Dried blood spots (DBS) and saliva were collected in August 2020, December 2020, February 2021 (saliva only) and April/May 2021 to measure anti-SARS-CoV-2 spike (S) and nucleoprotein (NP) IgG by United States Naval Academy",,2020-08-15,2021-02-15,Blood donors,All,Adults (18-64 years),,,Test used,overall estimate against Anti-S IgG on saliva ,48,0.146,,,,,,,,Unclear,Not reported/ Unable to specify,,,Serum,IgG,Spike,,,,['High'],,Unclear,No,No,,Unclear,Yes,No,,Liana Andronescu,Uniformed Services University of the Health Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac492.1511,2023-02-06,2023-03-19,Unverified,andronescu_1884_2022,USA
221215_US_UniformedServicesUniversityoftheHealthSciences_saliva_AntiNP,221215_US_UniformedServicesUniversityoftheHealthSciences,Evaluating SARS-CoV-2 Surveillance Strategies at the United States Naval Academy: A Comparison of Saliva and Dried Blood Spot Serosurveillance Against Molecular-Confirmed Case Detection,2022-12-15,Presentation or Conference,Regional,Repeated cross-sectional study,United States of America,Maryland,,"Dried blood spots (DBS) and saliva were collected in August 2020, December 2020, February 2021 (saliva only) and April/May 2021 to measure anti-SARS-CoV-2 spike (S) and nucleoprotein (NP) IgG by United States Naval Academy",,2020-08-15,2021-02-15,Blood donors,All,Adults (18-64 years),,,Test used,overall estimate against Anti-NP IgG on saliva ,48,0.146,,,,,,,,Unclear,Not reported/ Unable to specify,,,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,Unclear,No,No,,Unclear,Yes,No,,Liana Andronescu,Uniformed Services University of the Health Sciences,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac492.1511,2023-02-06,2023-03-19,Unverified,andronescu_1884_2022,USA
221215_Flint_HurleyMedicalCenter,221215_Flint_HurleyMedicalCenter,Repeated Assessment of SARS-CoV-2 Seroprevalence among Health Care Workers Early in the Pandemic: Relationship to Workplace Exposures,2022-12-15,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Michigan,,"HCWs from patient care (PC) and non-patient care (NPC) areas conducted from April 2020 through Dec 2020 at Hurley Medical Center in Flint, Michigan",,2020-04-15,2020-12-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,192,0.198,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,Spike,,,,['High'],,No,No,No,,Unclear,Yes,No,,Sherry Demian,Hurley Medical Center,Not Unity-Aligned,https://dx.doi.org/10.1093/ofid/ofac492.1518,2023-02-10,2023-03-19,Unverified,demian_1891_2022,USA
20221220_Indiana_IndianaUniversitySchoolOfPublicHealthBloomington_Baseline,20221220_Indiana_IndianaUniversitySchoolOfPublicHealthBloomington,Does receiving a SARS-CoV-2 antibody test result change COVID-19 protective behaviors? Testing risk compensation in undergraduate students with a randomized controlled trial,2022-12-20,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Indiana,Bloomington,"Students in the sample were eligible to participate if they were (1) aged 18 years or older, (2) a current IU Bloomington undergraduate student, and (3) currently residing in Monroe County, Indiana.","Tacit refusal, Explicit refusal or withdrawal, missed baseline visit",2020-09-14,2020-09-30,Students and Daycares,All,Adults (18-64 years),18.0,,Primary Estimate,Sept 2020,1076,0.046900000000000004,,,True,,,,True,Convenience,Colloidal Gold IgM/IgG rapid assay kit,BGI Genomics,LFIA,Whole Blood,"IgG, IgM",[],,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Christina Ludema,Indiana University School of Public Health-Bloomington,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0279347,2023-01-13,2023-03-19,Unverified,ludema_does_2022,USA
221222_USA_JohnsHopkinsBloombergSchoolofPublicHealth_Primary,221222_USA_JohnsHopkinsBloombergSchoolofPublicHealth,"SARS-CoV-2 Infection and Testing Experiences in a Nationwide Sample of Transgender and Gender-Diverse Adults, June-December 2021",2022-12-22,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Participants were eligible if they were aged ≥18 years; identified
as trans masculine, trans feminine, or nonbinary; resided
in any US state or territory; and spoke English or Spanish.","To validate participation and mitigate the risk of fraudulent participation, we used a 2-step verification procedure, we excluded voice-over-internet protocol telephone numbers in registration, we used internal algorithms to run real-time checks on duplicate information, and staff contacted
participants when registration information was flagged.",2021-06-14,2021-12-16,Representative patient population,Other,Multiple groups,18.0,78.0,Primary Estimate,,475,0.0989,,,True,,,,True,Self-referral,"Platelia SARS-CoV-2 Total Ab assay,Anti-SARS-CoV-2 NCP ELISA (IgG)","Bio-rad,EUROIMMUN",Multiple Types,Dried Blood,"['IgA', 'IgG', 'IgM']",,,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Andrea L. Wirtz,Johns Hopkins Bloomberg School of Public Health,Not Unity-Aligned,https://dx.doi.org/10.1177/00333549221138853,2023-01-13,2024-03-01,Unverified,wirtz_sars-cov-2_2022,USA
221230_Seattle_UniversityofWashington,221230_Seattle_UniversityofWashington,SARS-CoV-2 seroprevalence and longitudinal antibody response following natural infection in pregnancy: a prospective cohort study,2022-12-30,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Washington,Seattle,"Pregnant people aged ≥18 years seeking antenatal care at 14 affiliated clinics, or admitted to three labor and delivery units, at University of Washington (UW)-affiliated medical centers were eligible for participation in the seroprevalence study ","Individuals who did not have a blood sample available for antibody testing but provided consent for screening (929/2218, 42%) were not screened in the seroprevalence study",2020-12-09,2021-06-30,Pregnant or parturient women,Female,Adults (18-64 years),18.0,,Primary Estimate,,1289,0.0504,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9990000000000001,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Alison L. Drake,University of Washington,Unity-Aligned,10.1101/2022.12.28.22284017,2023-02-01,2024-03-01,Unverified,drake_sars-cov-2_2022,USA
230118_Holyoke_MassachusettsGeneralHospital_Primary,230118_Holyoke_MassachusettsGeneralHospital,"Disparities in SARS-CoV-2 Infection by Race, Ethnicity, Language, and Social Vulnerability: Evidence from a Citywide Seroprevalence Study in Massachusetts, USA",2023-01-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Massachusetts,Holyoke,"""Among selected addresses, all individual household members aged ≥ 6 months and residing at the address were eligible""",,2020-11-15,2021-01-15,Household and community samples,All,Multiple groups,6.0,,Primary Estimate,,328,0.08199999999999999,,,True,,,,True,Stratified probability,Author designed (ELISA) -Spike,,ELISA,Dried Blood,"['IgG', 'IgM']",Spike,Validated by developers,0.706,0.995,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Wilfredo R Matias,Massachusetts General Hospital,Not Unity-Aligned,https://dx.doi.org/10.1007/s40615-022-01502-4,2023-02-10,2023-03-19,Unverified,matias_disparities_2023,USA
230119_NorthCarolina_JohnsHopkinsUniversity_Overall,230119_NorthCarolina_JohnsHopkinsUniversity,"SARS-CoV-2 Antibody Prevalence among Industrial Livestock Operation Workers and Nearby Community Residents, North Carolina, 2021 to 2022",2023-01-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,"""participants living in households with at least one adult working at an industrial hog or poultry operation, meatpacking plant, or animal rendering plant (industrial livestock operation household group [ILO]), participants living near these facilities without any known occupational exposure to livestock (ILO neighbors [ILON]), and participants living in metropolitan areas of North Carolina (metro)"".

""All households had at least one adult (18+ years old) enrolled into the study. In addition to the one adult, all household members of any age were eligible to be enrolled. Eligibility criteria for all groups also included the ability to understand spoken English or Spanish and access to a household phone or mobile device and refrigerator.""",,2021-02-23,2022-07-18,Household and community samples,All,Multiple groups,5.0,83.0,Primary Estimate,Positive for RBD,233,0.7253000000000001,,,True,,,,True,Convenience,Author designed (Luminex),,Luminex,Saliva,IgG,Spike,Validated by developers,0.9940000000000001,0.993,['High'],Yes,No,No,Yes,No,Unclear,Yes,Yes,Unclear,Carolyn Gigot,Johns Hopkins Bloomberg School of Public Health,Unity-Aligned,https://dx.doi.org/10.1128/msphere.00522-22,2023-02-10,2024-04-12,Verified,gigot_sars-cov-2_2023,USA
230119_NorthCarolina_JohnsHopkinsUniversity_220311-220718,230119_NorthCarolina_JohnsHopkinsUniversity,"SARS-CoV-2 Antibody Prevalence among Industrial Livestock Operation Workers and Nearby Community Residents, North Carolina, 2021 to 2022",2023-01-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,"""participants living in households with at least one adult working at an industrial hog or poultry operation, meatpacking plant, or animal rendering plant (industrial livestock operation household group [ILO]), participants living near these facilities without any known occupational exposure to livestock (ILO neighbors [ILON]), and participants living in metropolitan areas of North Carolina (metro)"".

""All households had at least one adult (18+ years old) enrolled into the study. In addition to the one adult, all household members of any age were eligible to be enrolled. Eligibility criteria for all groups also included the ability to understand spoken English or Spanish and access to a household phone or mobile device and refrigerator.""",,2022-03-11,2022-07-18,Household and community samples,All,Multiple groups,5.0,83.0,Time frame,Time frame: 3/11/22-7/18/22,58,0.776,,,,,,,,Convenience,Author designed (Luminex),,Luminex,Saliva,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.976,0.9940000000000001,['High'],Yes,No,No,Yes,No,Unclear,Yes,Yes,Unclear,Carolyn Gigot,Johns Hopkins Bloomberg School of Public Health,Unity-Aligned,https://dx.doi.org/10.1128/msphere.00522-22,2023-02-10,2024-04-12,Verified,gigot_sars-cov-2_2023,USA
230119_NorthCarolina_JohnsHopkinsUniversity_210430-210906,230119_NorthCarolina_JohnsHopkinsUniversity,"SARS-CoV-2 Antibody Prevalence among Industrial Livestock Operation Workers and Nearby Community Residents, North Carolina, 2021 to 2022",2023-01-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,"""participants living in households with at least one adult working at an industrial hog or poultry operation, meatpacking plant, or animal rendering plant (industrial livestock operation household group [ILO]), participants living near these facilities without any known occupational exposure to livestock (ILO neighbors [ILON]), and participants living in metropolitan areas of North Carolina (metro)"".

""All households had at least one adult (18+ years old) enrolled into the study. In addition to the one adult, all household members of any age were eligible to be enrolled. Eligibility criteria for all groups also included the ability to understand spoken English or Spanish and access to a household phone or mobile device and refrigerator.""",,2021-04-30,2021-09-06,Household and community samples,All,Multiple groups,5.0,83.0,Time frame,Time frame: 4/30/21-9/6/21,58,0.39659999999999995,,,,,,,,Convenience,Author designed (Luminex),,Luminex,Saliva,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.976,0.9940000000000001,['High'],Yes,No,No,Yes,No,Unclear,Yes,Yes,Unclear,Carolyn Gigot,Johns Hopkins Bloomberg School of Public Health,Unity-Aligned,https://dx.doi.org/10.1128/msphere.00522-22,2023-02-10,2024-04-12,Verified,gigot_sars-cov-2_2023,USA
230119_NorthCarolina_JohnsHopkinsUniversity_55-83,230119_NorthCarolina_JohnsHopkinsUniversity,"SARS-CoV-2 Antibody Prevalence among Industrial Livestock Operation Workers and Nearby Community Residents, North Carolina, 2021 to 2022",2023-01-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,"""participants living in households with at least one adult working at an industrial hog or poultry operation, meatpacking plant, or animal rendering plant (industrial livestock operation household group [ILO]), participants living near these facilities without any known occupational exposure to livestock (ILO neighbors [ILON]), and participants living in metropolitan areas of North Carolina (metro)"".

""All households had at least one adult (18+ years old) enrolled into the study. In addition to the one adult, all household members of any age were eligible to be enrolled. Eligibility criteria for all groups also included the ability to understand spoken English or Spanish and access to a household phone or mobile device and refrigerator.""",,2021-02-23,2022-07-18,Household and community samples,All,Multiple groups,5.0,83.0,Age,55-83,57,0.474,,,,,,,,Convenience,Author designed (Luminex),,Luminex,Saliva,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.976,0.9940000000000001,['High'],Yes,No,No,Yes,No,Unclear,Yes,Yes,Unclear,Carolyn Gigot,Johns Hopkins Bloomberg School of Public Health,Unity-Aligned,https://dx.doi.org/10.1128/msphere.00522-22,2024-04-12,2024-04-12,Unverified,gigot_sars-cov-2_2023,USA
230119_NorthCarolina_JohnsHopkinsUniversity_AntiNandRBD,230119_NorthCarolina_JohnsHopkinsUniversity,"SARS-CoV-2 Antibody Prevalence among Industrial Livestock Operation Workers and Nearby Community Residents, North Carolina, 2021 to 2022",2023-01-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,"""participants living in households with at least one adult working at an industrial hog or poultry operation, meatpacking plant, or animal rendering plant (industrial livestock operation household group [ILO]), participants living near these facilities without any known occupational exposure to livestock (ILO neighbors [ILON]), and participants living in metropolitan areas of North Carolina (metro)"".

""All households had at least one adult (18+ years old) enrolled into the study. In addition to the one adult, all household members of any age were eligible to be enrolled. Eligibility criteria for all groups also included the ability to understand spoken English or Spanish and access to a household phone or mobile device and refrigerator.""",,2021-02-23,2022-07-18,Household and community samples,All,Multiple groups,5.0,83.0,Test used,Positive for both N and RBD,233,0.5107,,,,,,,,Convenience,Author designed (Luminex),,Luminex,Saliva,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.976,0.9940000000000001,['High'],Yes,No,No,Yes,No,Unclear,Yes,Yes,Unclear,Carolyn Gigot,Johns Hopkins Bloomberg School of Public Health,Unity-Aligned,https://dx.doi.org/10.1128/msphere.00522-22,2023-02-10,2024-04-12,Verified,gigot_sars-cov-2_2023,USA
230119_NorthCarolina_JohnsHopkinsUniversity_42-55,230119_NorthCarolina_JohnsHopkinsUniversity,"SARS-CoV-2 Antibody Prevalence among Industrial Livestock Operation Workers and Nearby Community Residents, North Carolina, 2021 to 2022",2023-01-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,"""participants living in households with at least one adult working at an industrial hog or poultry operation, meatpacking plant, or animal rendering plant (industrial livestock operation household group [ILO]), participants living near these facilities without any known occupational exposure to livestock (ILO neighbors [ILON]), and participants living in metropolitan areas of North Carolina (metro)"".

""All households had at least one adult (18+ years old) enrolled into the study. In addition to the one adult, all household members of any age were eligible to be enrolled. Eligibility criteria for all groups also included the ability to understand spoken English or Spanish and access to a household phone or mobile device and refrigerator.""",,2021-02-23,2022-07-18,Household and community samples,All,Multiple groups,5.0,83.0,Age,42-55,57,0.614,,,,,,,,Convenience,Author designed (Luminex),,Luminex,Saliva,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.976,0.9940000000000001,['High'],Yes,No,No,Yes,No,Unclear,Yes,Yes,Unclear,Carolyn Gigot,Johns Hopkins Bloomberg School of Public Health,Unity-Aligned,https://dx.doi.org/10.1128/msphere.00522-22,2024-04-12,2024-04-12,Unverified,gigot_sars-cov-2_2023,USA
230119_NorthCarolina_JohnsHopkinsUniversity_210223-210430,230119_NorthCarolina_JohnsHopkinsUniversity,"SARS-CoV-2 Antibody Prevalence among Industrial Livestock Operation Workers and Nearby Community Residents, North Carolina, 2021 to 2022",2023-01-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,"""participants living in households with at least one adult working at an industrial hog or poultry operation, meatpacking plant, or animal rendering plant (industrial livestock operation household group [ILO]), participants living near these facilities without any known occupational exposure to livestock (ILO neighbors [ILON]), and participants living in metropolitan areas of North Carolina (metro)"".

""All households had at least one adult (18+ years old) enrolled into the study. In addition to the one adult, all household members of any age were eligible to be enrolled. Eligibility criteria for all groups also included the ability to understand spoken English or Spanish and access to a household phone or mobile device and refrigerator.""",,2021-02-23,2021-04-30,Household and community samples,All,Multiple groups,5.0,83.0,Time frame,Time frame: 2/23/21-4/30/21,59,0.2373,,,,,,,,Convenience,Author designed (Luminex),,Luminex,Saliva,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.976,0.9940000000000001,['High'],Yes,No,No,Yes,No,Unclear,Yes,Yes,Unclear,Carolyn Gigot,Johns Hopkins Bloomberg School of Public Health,Unity-Aligned,https://dx.doi.org/10.1128/msphere.00522-22,2023-02-10,2024-04-12,Verified,gigot_sars-cov-2_2023,USA
230119_NorthCarolina_JohnsHopkinsUniversity_5-27,230119_NorthCarolina_JohnsHopkinsUniversity,"SARS-CoV-2 Antibody Prevalence among Industrial Livestock Operation Workers and Nearby Community Residents, North Carolina, 2021 to 2022",2023-01-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,"""participants living in households with at least one adult working at an industrial hog or poultry operation, meatpacking plant, or animal rendering plant (industrial livestock operation household group [ILO]), participants living near these facilities without any known occupational exposure to livestock (ILO neighbors [ILON]), and participants living in metropolitan areas of North Carolina (metro)"".

""All households had at least one adult (18+ years old) enrolled into the study. In addition to the one adult, all household members of any age were eligible to be enrolled. Eligibility criteria for all groups also included the ability to understand spoken English or Spanish and access to a household phone or mobile device and refrigerator.""",,2021-02-23,2022-07-18,Household and community samples,All,Multiple groups,5.0,83.0,Age,5-27,58,0.466,,,,,,,,Convenience,Author designed (Luminex),,Luminex,Saliva,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.976,0.9940000000000001,['High'],Yes,No,No,Yes,No,Unclear,Yes,Yes,Unclear,Carolyn Gigot,Johns Hopkins Bloomberg School of Public Health,Unity-Aligned,https://dx.doi.org/10.1128/msphere.00522-22,2024-04-12,2024-04-12,Unverified,gigot_sars-cov-2_2023,USA
230119_NorthCarolina_JohnsHopkinsUniversity_210906-220311,230119_NorthCarolina_JohnsHopkinsUniversity,"SARS-CoV-2 Antibody Prevalence among Industrial Livestock Operation Workers and Nearby Community Residents, North Carolina, 2021 to 2022",2023-01-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,"""participants living in households with at least one adult working at an industrial hog or poultry operation, meatpacking plant, or animal rendering plant (industrial livestock operation household group [ILO]), participants living near these facilities without any known occupational exposure to livestock (ILO neighbors [ILON]), and participants living in metropolitan areas of North Carolina (metro)"".

""All households had at least one adult (18+ years old) enrolled into the study. In addition to the one adult, all household members of any age were eligible to be enrolled. Eligibility criteria for all groups also included the ability to understand spoken English or Spanish and access to a household phone or mobile device and refrigerator.""",,2021-09-06,2022-03-11,Household and community samples,All,Multiple groups,5.0,83.0,Time frame,Time frame: 9/6/21-3/11/22,58,0.6379,,,,,,,,Convenience,Author designed (Luminex),,Luminex,Saliva,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.976,0.9940000000000001,['High'],Yes,No,No,Yes,No,Unclear,Yes,Yes,Unclear,Carolyn Gigot,Johns Hopkins Bloomberg School of Public Health,Unity-Aligned,https://dx.doi.org/10.1128/msphere.00522-22,2023-02-10,2024-04-12,Verified,gigot_sars-cov-2_2023,USA
230119_NorthCarolina_JohnsHopkinsUniversity_27-41,230119_NorthCarolina_JohnsHopkinsUniversity,"SARS-CoV-2 Antibody Prevalence among Industrial Livestock Operation Workers and Nearby Community Residents, North Carolina, 2021 to 2022",2023-01-19,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,North Carolina,,"""participants living in households with at least one adult working at an industrial hog or poultry operation, meatpacking plant, or animal rendering plant (industrial livestock operation household group [ILO]), participants living near these facilities without any known occupational exposure to livestock (ILO neighbors [ILON]), and participants living in metropolitan areas of North Carolina (metro)"".

""All households had at least one adult (18+ years old) enrolled into the study. In addition to the one adult, all household members of any age were eligible to be enrolled. Eligibility criteria for all groups also included the ability to understand spoken English or Spanish and access to a household phone or mobile device and refrigerator.""",,2021-02-23,2022-07-18,Household and community samples,All,Multiple groups,5.0,83.0,Age,27-41,58,0.483,,,,,,,,Convenience,Author designed (Luminex),,Luminex,Saliva,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by developers,0.976,0.9940000000000001,['High'],Yes,No,No,Yes,No,Unclear,Yes,Yes,Unclear,Carolyn Gigot,Johns Hopkins Bloomberg School of Public Health,Unity-Aligned,https://dx.doi.org/10.1128/msphere.00522-22,2024-04-12,2024-04-12,Unverified,gigot_sars-cov-2_2023,USA
220815_US_CDC_Round25_2021Sep_Overall,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except IN, MD, NJ, & VA), the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-06,2021-10-03,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,,13384,0.384,0.374,0.3944,True,,True,,True,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-01,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionMA,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-06,2021-10-01,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Massachusetts,450,0.27899999999999997,0.2359,0.322,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionWV,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-06,2021-10-02,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: West Virginia,234,0.277,0.2186,0.33740000000000003,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionOK,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-06,2021-09-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Oklahoma,326,0.48200000000000004,0.4291,0.5382,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionAR,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-28,2021-10-03,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Arkansas,114,0.452,0.3397,0.5629,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionKY,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-06,2021-10-03,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Kentucky,445,0.395,0.34659999999999996,0.44320000000000004,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionCA,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-06,2021-10-03,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: California,504,0.334,0.2872,0.378,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionNM,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-06,2021-10-02,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New Mexico,378,0.251,0.2016,0.3061,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_Age12-17,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except IN, MD, NJ, & VA), the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-06,2021-10-03,Residual sera,All,Children and Youth (0-17 years),12.0,17.0,Age,Age: 12-17,8146,0.39799999999999996,0.38560000000000005,0.4105,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionNV,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nevada,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-09,2021-09-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Nevada,187,0.41000000000000003,0.3286,0.4852,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionLA,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-06,2021-10-02,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Louisiana,493,0.534,0.48610000000000003,0.5824,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionNY,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-06,2021-10-03,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New York,633,0.306,0.26789999999999997,0.3436,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionOR,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-06,2021-10-01,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Oregon,185,0.28300000000000003,0.2056,0.35590000000000005,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionCO,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-07,2021-10-01,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Colorado,320,0.401,0.3368,0.46590000000000004,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionNC,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-06,2021-10-02,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: North Carolina,583,0.36200000000000004,0.3271,0.399,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionIL,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-06,2021-10-02,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Illinois,677,0.451,0.408,0.48869999999999997,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionAL,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-09,2021-10-03,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Alabama,484,0.5700000000000001,0.5239,0.6165,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionMS,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-10,2021-10-02,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Mississippi,347,0.584,0.5336,0.6349,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionKS,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-07,2021-09-25,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Kansas,325,0.34,0.2846,0.3957,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionAZ,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arizona,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-07,2021-09-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Arizona,310,0.423,0.3627,0.4804,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionMO,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-08,2021-10-02,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Missouri,237,0.307,0.23370000000000002,0.3712,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionPR,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-06,2021-10-01,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Puerto Rico,656,0.095,0.0729,0.12090000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionDE,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-08,2021-10-03,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Delaware,267,0.302,0.2443,0.3597,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionPA,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-08,2021-10-02,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Pennsylvania,514,0.3,0.2638,0.34159999999999996,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionWA,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-06,2021-09-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Washington,259,0.226,0.16940000000000002,0.27940000000000004,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionFL,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-07,2021-10-02,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Florida,573,0.512,0.4698,0.5543,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionGA,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-06,2021-10-02,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Georgia,645,0.461,0.4232,0.5042,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionOH,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-06,2021-10-03,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Ohio,440,0.425,0.37340000000000007,0.47340000000000004,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionWI,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-07,2021-10-02,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Wisconsin,138,0.449,0.3586,0.5437,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionUT,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Utah,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-09,2021-09-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Utah,87,0.49100000000000005,0.37950000000000006,0.6107,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_Age0-11,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except IN, MD, NJ, & VA), the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-06,2021-10-03,Residual sera,All,Children and Youth (0-17 years),0.0,11.0,Age,Age: 0-11,5238,0.364,0.3493,0.3788,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionCT,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-06,2021-10-01,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Connecticut,364,0.24100000000000002,0.1963,0.2859,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionDC,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-07,2021-10-02,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: District of Columbia,312,0.461,0.402,0.5188,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionHI,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Hawaii,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-06,2021-10-02,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Hawaii,84,0.092,0.0317,0.1641,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionSC,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-06,2021-10-01,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: South Carolina,478,0.46299999999999997,0.41259999999999997,0.5136000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionMN,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-06,2021-09-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Minnesota,205,0.28,0.20870000000000002,0.35240000000000005,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionTN,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-08,2021-10-03,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Tennessee,440,0.579,0.5282,0.6255,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionMI,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-06,2021-10-02,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Michigan,128,0.384,0.2983,0.4712,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round25_2021Sep_RegionNH,220815_US_CDC_Round25_2021Sep,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Hampshire,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-09-07,2021-10-02,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New Hampshire,84,0.23500000000000001,0.1354,0.3511,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_Overall,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-31,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,,17068,0.42,0.4111,0.4292,True,,True,,True,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionMO,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Missouri,381,0.449,0.3915,0.5023,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionME,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maine,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-31,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Maine,104,0.167,0.0928,0.2458,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionAR,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Arkansas,361,0.457,0.4021,0.515,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionNC,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: North Carolina,651,0.449,0.40950000000000003,0.4903,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionMS,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Mississippi,484,0.549,0.5008,0.5942000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionDC,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: District of Columbia,562,0.425,0.38,0.47140000000000004,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionNY,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-28,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New York,617,0.387,0.3473,0.4257,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionMA,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Massachusetts,407,0.277,0.2322,0.3257,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_Age0-11,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-31,Residual sera,All,Children and Youth (0-17 years),0.0,11.0,Age,Age: 0-11,7159,0.42200000000000004,0.4087,0.43560000000000004,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionRI,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Rhode Island,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Rhode Island,78,0.26,0.1593,0.36729999999999996,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionAL,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-31,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Alabama,576,0.554,0.5136000000000001,0.5972,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionKY,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Kentucky,615,0.441,0.401,0.4826,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionPA,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Pennsylvania,614,0.294,0.25579999999999997,0.33530000000000004,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionCA,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: California,653,0.38,0.34259999999999996,0.4175,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionWV,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: West Virginia,264,0.363,0.3031,0.42460000000000003,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9979999999999999,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionLA,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Louisiana,628,0.515,0.47090000000000004,0.5567000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_Age12-17,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-31,Residual sera,All,Children and Youth (0-17 years),12.0,17.0,Age,Age: 12-17,9909,0.419,0.4068,0.43119999999999997,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionCT,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Connecticut,390,0.264,0.2163,0.3159,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionGA,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Georgia,645,0.484,0.443,0.5271,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionNV,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nevada,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-31,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Nevada,438,0.406,0.359,0.4562,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionKS,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-28,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Kansas,588,0.438,0.39799999999999996,0.48369999999999996,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionDE,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Delaware,414,0.33299999999999996,0.2831,0.3822,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionFL,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Florida,667,0.48100000000000004,0.443,0.5207,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionNM,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New Mexico,377,0.315,0.264,0.3653,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionOH,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Ohio,521,0.49100000000000005,0.4462,0.5384000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionAZ,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arizona,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Arizona,602,0.45299999999999996,0.4161,0.5001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionMN,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Minnesota,317,0.359,0.2994,0.4238,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionCO,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Colorado,535,0.409,0.3577,0.46409999999999996,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionNH,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Hampshire,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New Hampshire,97,0.18600000000000003,0.1077,0.2735,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionUT,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Utah,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-31,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Utah,199,0.457,0.3797,0.5303,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionHI,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Hawaii,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Hawaii,78,0.131,0.053200000000000004,0.21960000000000002,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionOR,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Oregon,103,0.282,0.20149999999999998,0.37939999999999996,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionTN,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Tennessee,608,0.54,0.5006,0.585,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionSC,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: South Carolina,668,0.523,0.48619999999999997,0.561,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionOK,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-26,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Oklahoma,576,0.525,0.47880000000000006,0.5647,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionNE,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nebraska,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Nebraska,119,0.538,0.4515,0.6281,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionIL,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Illinois,645,0.42200000000000004,0.381,0.4626,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionIA,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Iowa,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Iowa,80,0.533,0.4167,0.6558,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionWI,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Wisconsin,182,0.48600000000000004,0.4021,0.5604,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9979999999999999,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionPR,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Puerto Rico,652,0.10300000000000001,0.0806,0.12840000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round26_2021Oct_RegionMI,220815_US_CDC_Round26_2021Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-10-04,2021-10-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Michigan,248,0.443,0.38,0.506,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_Overall,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except ND), the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-28,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,,16734,0.429,0.41990000000000005,0.43700000000000006,True,,True,,True,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionWA,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Washington,282,0.275,0.2252,0.3276,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionCA,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: California,692,0.341,0.3036,0.3779,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionPR,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-28,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Puerto Rico,705,0.111,0.0874,0.1368,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionOH,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-26,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Ohio,578,0.5720000000000001,0.5314,0.6081000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionNJ,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Jersey,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-28,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New Jersey,341,0.46,0.4007,0.5142,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionTN,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Tennessee,654,0.573,0.5341,0.6118,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_Age12-17,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except ND), the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-28,Residual sera,All,Children and Youth (0-17 years),12.0,17.0,Age,Age: 12-17,9898,0.42600000000000005,0.41509999999999997,0.43710000000000004,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionWV,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: West Virginia,242,0.41000000000000003,0.3482,0.47250000000000003,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9979999999999999,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionLA,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-18,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Louisiana,424,0.546,0.4983,0.5937,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionNM,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-16,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New Mexico,219,0.42200000000000004,0.3557,0.4953,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionDC,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: District of Columbia,610,0.43100000000000005,0.3925,0.4729,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionPA,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Pennsylvania,565,0.325,0.2805,0.3658,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionNH,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Hampshire,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New Hampshire,138,0.302,0.2122,0.39549999999999996,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionMN,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-23,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Minnesota,221,0.446,0.3682,0.5205,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionOR,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Oregon,109,0.264,0.17579999999999998,0.34770000000000006,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionCO,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-12,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Colorado,188,0.44799999999999995,0.3683,0.5233,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionMS,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Mississippi,425,0.59,0.5384000000000001,0.6399,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionNC,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: North Carolina,634,0.43200000000000005,0.3875,0.4707,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionMA,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-26,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Massachusetts,428,0.33899999999999997,0.2918,0.3849,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionFL,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Florida,708,0.504,0.4682,0.5423,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionNY,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-23,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New York,633,0.34500000000000003,0.3093,0.3848,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionWI,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Wisconsin,201,0.518,0.44070000000000004,0.5931000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9979999999999999,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionAZ,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arizona,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Arizona,605,0.48700000000000004,0.4465,0.5286,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionVA,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Virginia,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-28,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Virginia,91,0.282,0.1825,0.38270000000000004,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionAR,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Arkansas,280,0.505,0.44200000000000006,0.5622,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionDE,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-02,2021-11-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Delaware,344,0.369,0.3199,0.41869999999999996,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionME,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maine,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Maine,88,0.12,0.0534,0.20510000000000003,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionOK,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-09,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Oklahoma,263,0.51,0.449,0.5695,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionIL,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Illinois,702,0.424,0.3885,0.4626,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_Age0-11,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except ND), the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-28,Residual sera,All,Children and Youth (0-17 years),0.0,11.0,Age,Age: 0-11,6836,0.43200000000000005,0.418,0.44560000000000005,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionGA,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-22,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Georgia,658,0.549,0.5074000000000001,0.5891,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionKY,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Kentucky,634,0.465,0.42600000000000005,0.5079,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionMO,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Missouri,419,0.438,0.383,0.4854,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionCT,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Connecticut,395,0.267,0.2233,0.31329999999999997,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionMD,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maryland,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-28,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Maryland,195,0.36200000000000004,0.28800000000000003,0.4403,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionMI,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Michigan,217,0.45,0.3862,0.5165,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionAL,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-26,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Alabama,633,0.5870000000000001,0.5482,0.6271,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionNV,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nevada,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-26,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Nevada,515,0.43200000000000005,0.38680000000000003,0.47409999999999997,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionUT,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Utah,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Utah,310,0.552,0.4914,0.612,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionSC,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: South Carolina,641,0.544,0.502,0.5860000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round27_2021Nov_RegionKS,220815_US_CDC_Round27_2021Nov,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-01,2021-11-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Kansas,238,0.47700000000000004,0.4079,0.543,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_Overall,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except ND & SD), the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-26,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,,14753,0.451,0.4404,0.4595,True,,True,,True,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionUT,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Utah,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-21,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Utah,259,0.515,0.4521,0.5754,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionWV,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: West Virginia,237,0.425,0.3572,0.49450000000000005,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9979999999999999,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionID,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Idaho,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-23,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Idaho,120,0.627,0.5224,0.7201000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionNY,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-18,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New York,662,0.408,0.3697,0.446,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionFL,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-22,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Florida,648,0.5,0.4582,0.5401,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionAR,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-12-02,2021-12-18,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Arkansas,115,0.514,0.4037,0.612,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionSC,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-23,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: South Carolina,710,0.535,0.4928,0.5776,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionOK,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-21,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Oklahoma,146,0.484,0.3998,0.5795,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionMA,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-23,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Massachusetts,352,0.29300000000000004,0.2408,0.344,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionIA,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Iowa,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Iowa,76,0.66,0.5522,0.7615000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionMI,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-23,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Michigan,157,0.585,0.4975,0.6697,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionCA,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: California,670,0.36600000000000005,0.3284,0.40520000000000006,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionMD,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maryland,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-26,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Maryland,156,0.33799999999999997,0.25980000000000003,0.4193,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionPR,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-20,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Puerto Rico,683,0.102,0.0785,0.1264,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionME,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maine,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-26,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Maine,84,0.359,0.2479,0.47259999999999996,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionCO,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-08,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Colorado,114,0.444,0.3229,0.5540999999999999,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionTX,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Texas,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Texas,82,0.59,0.44670000000000004,0.7256,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionKY,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-26,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Kentucky,506,0.507,0.4612,0.5555,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionMN,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Minnesota,277,0.438,0.37520000000000003,0.4983,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionAZ,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arizona,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-20,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Arizona,442,0.47100000000000003,0.4225,0.5139,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionMO,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-23,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Missouri,327,0.418,0.3622,0.4786,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionDC,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-23,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: District of Columbia,581,0.42,0.38170000000000004,0.4645,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionNC,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-22,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: North Carolina,672,0.483,0.4425,0.5251,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_Age12-17,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except ND & SD), the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-26,Residual sera,All,Children and Youth (0-17 years),12.0,17.0,Age,Age: 12-17,8723,0.456,0.4437,0.469,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_Age0-11,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except ND & SD), the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-26,Residual sera,All,Children and Youth (0-17 years),0.0,11.0,Age,Age: 0-11,6030,0.44200000000000006,0.42810000000000004,0.4576,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionOH,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-26,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Ohio,476,0.638,0.593,0.6827,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionNV,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nevada,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-21,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Nevada,371,0.465,0.4143,0.5183,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionMS,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-23,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Mississippi,331,0.579,0.5245000000000001,0.6364,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionWA,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-21,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Washington,460,0.32299999999999995,0.2824,0.36229999999999996,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9979999999999999,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionNM,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-14,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New Mexico,186,0.435,0.35369999999999996,0.5073,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionPA,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-12-01,2021-12-26,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Pennsylvania,263,0.374,0.3177,0.4308,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionNJ,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Jersey,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-26,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New Jersey,266,0.461,0.3994,0.5251,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionTN,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-23,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Tennessee,552,0.58,0.5385,0.627,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionLA,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-14,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Louisiana,328,0.546,0.4858,0.6052000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionCT,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-23,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Connecticut,368,0.298,0.2486,0.3478,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionDE,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-23,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Delaware,154,0.459,0.3711,0.5414,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionKS,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-09,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Kansas,165,0.485,0.4001,0.5606,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionAL,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Alabama,517,0.578,0.5315,0.6227,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionWI,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-23,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Wisconsin,188,0.574,0.502,0.6501,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9979999999999999,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionOR,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-18,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Oregon,261,0.284,0.2258,0.3469,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionIL,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-23,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Illinois,634,0.452,0.4114,0.4908,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round28_2021Dec_RegionGA,220815_US_CDC_Round28_2021Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-11-29,2021-12-20,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Georgia,654,0.49600000000000005,0.46030000000000004,0.5369,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_Overall,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except NV), the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-12-27,2022-01-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,,14072,0.578,0.5679,0.5885,True,,True,,True,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionCT,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-12-29,2022-01-28,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Connecticut,353,0.46799999999999997,0.4136,0.5217,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionNC,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-03,2022-01-20,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: North Carolina,495,0.525,0.47909999999999997,0.5670000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionNJ,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Jersey,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-12-30,2022-01-28,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New Jersey,240,0.701,0.6435,0.7645000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionMS,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-03,2022-01-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Mississippi,335,0.7040000000000001,0.6481,0.7562000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionNM,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-12-31,2022-01-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New Mexico,259,0.551,0.48610000000000003,0.6148,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionMI,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-03,2022-01-28,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Michigan,162,0.669,0.5915,0.7415,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionCA,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-03,2022-01-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: California,634,0.46799999999999997,0.42590000000000006,0.51,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionWA,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-12-27,2022-01-25,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Washington,472,0.425,0.3797,0.4698,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionPR,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-03,2022-01-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Puerto Rico,696,0.20199999999999999,0.1705,0.23190000000000002,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionAL,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-03,2022-01-25,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Alabama,358,0.634,0.5827,0.6888,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionMA,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-12-29,2022-01-28,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Massachusetts,373,0.49600000000000005,0.4449,0.5468000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionWI,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-03,2022-01-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Wisconsin,251,0.7690000000000001,0.7073999999999999,0.8290000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionTN,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-03,2022-01-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Tennessee,429,0.7270000000000001,0.6781999999999999,0.7713,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionFL,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-03,2022-01-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Florida,517,0.623,0.5747,0.6661,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionLA,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-12-30,2022-01-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Louisiana,485,0.6559999999999999,0.6052000000000001,0.7029000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionOH,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-03,2022-01-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Ohio,438,0.71,0.6648000000000001,0.7522,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionDE,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-04,2022-01-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Delaware,301,0.569,0.5114,0.6245,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionOR,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-12-27,2022-01-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Oregon,346,0.444,0.39170000000000005,0.5018,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_Age0-11,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except NV), the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-12-27,2022-01-29,Residual sera,All,Children and Youth (0-17 years),0.0,11.0,Age,Age: 0-11,5616,0.58,0.5638000000000001,0.5965,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionOK,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-01,2022-01-21,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Oklahoma,200,0.618,0.5418999999999999,0.6847,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionIA,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Iowa,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-12-29,2022-01-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Iowa,84,0.703,0.6038,0.8034,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionPA,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-03,2022-01-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Pennsylvania,636,0.5579999999999999,0.5178,0.5969,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionME,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maine,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-12-28,2022-01-28,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Maine,95,0.295,0.19920000000000002,0.39799999999999996,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionDC,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-03,2022-01-25,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: District of Columbia,413,0.691,0.6453,0.7371,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionSC,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-03,2022-01-21,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: South Carolina,432,0.603,0.5524,0.6562,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionCO,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-03,2022-01-21,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Colorado,344,0.5,0.4341,0.5709000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionMD,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maryland,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-12-30,2022-01-28,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Maryland,154,0.49100000000000005,0.40840000000000004,0.5752,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionID,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Idaho,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-12-27,2022-01-25,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Idaho,107,0.642,0.5121,0.7599,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionWV,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-12-28,2022-01-28,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: West Virginia,226,0.515,0.43979999999999997,0.5846,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.9979999999999999,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionNH,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Hampshire,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-03,2022-01-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New Hampshire,113,0.40700000000000003,0.3141,0.5021,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_Age12-17,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except NV), the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-12-27,2022-01-29,Residual sera,All,Children and Youth (0-17 years),12.0,17.0,Age,Age: 12-17,8456,0.5770000000000001,0.5636,0.5903,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionAR,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-03,2022-01-28,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Arkansas,358,0.613,0.554,0.6645000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionKY,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-03,2022-01-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Kentucky,515,0.559,0.5082,0.6068,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionNY,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-12-27,2022-01-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New York,607,0.5860000000000001,0.5418000000000001,0.6307,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionNE,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nebraska,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-12-28,2022-01-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Nebraska,76,0.574,0.462,0.6811,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionGA,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-02,2022-01-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Georgia,659,0.6729999999999999,0.6388,0.7112,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionIL,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-03,2022-01-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Illinois,615,0.677,0.6347,0.7167,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionMO,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-03,2022-01-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Missouri,282,0.633,0.5736,0.6924,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionMN,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-12-30,2022-01-25,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Minnesota,191,0.532,0.4479,0.6152000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round29_2022Jan_RegionKS,220815_US_CDC_Round29_2022Jan,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2021-12-29,2022-01-22,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Kansas,389,0.5579999999999999,0.4983,0.6054,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_Overall,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except MT & NH), the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-27,2022-02-26,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,,11298,0.746,0.7353000000000001,0.7556999999999999,True,,True,,True,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionKS,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-02-11,2022-02-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Kansas,104,0.74,0.6491,0.8275,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionAR,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-31,2022-02-25,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Arkansas,221,0.813,0.751,0.872,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionNV,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nevada,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-31,2022-02-25,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Nevada,453,0.765,0.7216,0.8029999999999999,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionAZ,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arizona,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-02-01,2022-02-25,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Arizona,647,0.792,0.7548,0.8273,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionDE,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-02-01,2022-02-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Delaware,292,0.752,0.7017,0.7998000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionMA,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-28,2022-02-18,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Massachusetts,94,0.653,0.5579999999999999,0.7387,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionOR,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-02-11,2022-02-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Oregon,86,0.594,0.47380000000000005,0.7062999999999999,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionCA,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-31,2022-02-21,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: California,622,0.6609999999999999,0.6217,0.7000000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionCT,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-27,2022-02-18,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Connecticut,104,0.5710000000000001,0.4706,0.6652,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionKY,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-31,2022-02-25,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Kentucky,571,0.7270000000000001,0.6854000000000001,0.7648999999999999,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionFL,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-02-01,2022-02-21,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Florida,599,0.805,0.7712000000000001,0.8414,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionNY,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-02-14,2022-02-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New York,108,0.758,0.6687000000000001,0.8425,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionMD,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maryland,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-28,2022-02-25,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Maryland,208,0.6070000000000001,0.5338,0.6861,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionUT,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Utah,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-02-01,2022-02-25,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Utah,210,0.8390000000000001,0.7866,0.8925000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionVA,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Virginia,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-27,2022-02-25,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Virginia,95,0.5670000000000001,0.4593,0.6802,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionLA,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-02-11,2022-02-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Louisiana,107,0.851,0.7802,0.9169,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionDC,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-02-01,2022-02-18,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: District of Columbia,207,0.828,0.7711,0.8814000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionNC,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-02-01,2022-02-18,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: North Carolina,502,0.6900000000000001,0.6467,0.7321,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_Age12-17,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except MT & NH), the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-27,2022-02-26,Residual sera,All,Children and Youth (0-17 years),12.0,17.0,Age,Age: 12-17,7005,0.742,0.7276,0.7545999999999999,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionAL,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-02-01,2022-02-22,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Alabama,646,0.816,0.7796,0.8486,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionPA,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-02-01,2022-02-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Pennsylvania,609,0.6609999999999999,0.6189,0.6995,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionMO,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-31,2022-02-26,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Missouri,376,0.6940000000000001,0.6456000000000001,0.7428,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionTN,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-02-01,2022-02-22,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Tennessee,578,0.861,0.8331000000000001,0.8917,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionOH,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-31,2022-02-26,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Ohio,507,0.841,0.8104000000000001,0.8743000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionPR,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-02-14,2022-02-18,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Puerto Rico,110,0.438,0.33170000000000005,0.5362,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionWI,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-31,2022-02-26,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Wisconsin,301,0.8520000000000001,0.8109999999999999,0.8934000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionSC,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-02-01,2022-02-18,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: South Carolina,437,0.833,0.7942,0.8741,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionNJ,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Jersey,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-27,2022-02-25,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New Jersey,299,0.809,0.7624,0.8556999999999999,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionWA,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-02-11,2022-02-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Washington,101,0.5870000000000001,0.48950000000000005,0.6825,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_Age0-11,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states (except MT & NH), the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-27,2022-02-26,Residual sera,All,Children and Youth (0-17 years),0.0,11.0,Age,Age: 0-11,4293,0.752,0.736,0.768,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionIL,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-31,2022-02-26,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Illinois,649,0.766,0.7333,0.8007,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionCO,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-02-14,2022-02-16,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Colorado,92,0.785,0.6829000000000001,0.8756999999999999,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionNM,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-02-12,2022-02-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New Mexico,75,0.631,0.49350000000000005,0.7598,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionMI,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-31,2022-02-25,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Michigan,191,0.782,0.7183,0.8415,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionTX,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Texas,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-27,2022-02-25,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Texas,207,0.8940000000000001,0.8388,0.9398000000000001,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionMS,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-02-01,2022-02-22,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Mississippi,474,0.85,0.8095,0.8836,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round30_2022Feb_RegionGA,220815_US_CDC_Round30_2022Feb,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-01-31,2022-02-18,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Georgia,115,0.833,0.7619,0.8983,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_Overall_antiNorS,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,Overall anti-S or anti-N,28089,0.892,0.8865000000000001,0.897,True,,True,,True,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionAL,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Alabama,681,0.903,0.8687,0.9303,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionIN,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Indiana,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Indiana,682,0.912,0.88,0.9381999999999999,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionNH,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Hampshire,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New Hampshire,594,0.861,0.8122,0.9004000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionRI,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Rhode Island,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Rhode Island,152,0.8640000000000001,0.7818,0.9246,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionME,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maine,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Maine,304,0.752,0.67,0.8218000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionAZ,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arizona,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-03-28,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Arizona,561,0.9400000000000001,0.908,0.9629000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionUT,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Utah,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Utah,238,0.917,0.8481000000000001,0.9619,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionWV,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: West Virginia,636,0.868,0.8343,0.8966,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionAK,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alaska,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Alaska,269,0.915,0.8473999999999999,0.9591,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionSC,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: South Carolina,586,0.865,0.8127,0.9065000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionCA,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-14,2022-04-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: California,675,0.8620000000000001,0.8306,0.8894,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionMI,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-28,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Michigan,676,0.905,0.8726,0.9312,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionMT,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Montana,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Montana,111,0.9109999999999999,0.8165000000000001,0.9666,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionKY,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Kentucky,641,0.8640000000000001,0.8173,0.9019,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionDE,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Delaware,958,0.891,0.865,0.9133,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionMO,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Missouri,672,0.923,0.8961,0.9454000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionDC,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: District of Columbia,531,0.888,0.8319,0.9298000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionCT,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Connecticut,741,0.882,0.8494,0.9103,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionMD,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maryland,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-26,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Maryland,713,0.876,0.8390000000000001,0.9072,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionVT,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Vermont,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Vermont,133,0.8270000000000001,0.7117,0.9096,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_SexFemale,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-30,Residual sera,Female,Children and Youth (0-17 years),0.0,17.0,Sex/Gender,,15739,0.899,0.8919,0.9059999999999999,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionFL,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Florida,678,0.912,0.8768000000000001,0.9398000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_Age12-17,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-30,Residual sera,All,Children and Youth (0-17 years),12.0,17.0,Age,Age: 12-17,15064,0.9620000000000001,0.9572,0.9659000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionOK,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Oklahoma,668,0.873,0.8354,0.905,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionNJ,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Jersey,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New Jersey,658,0.8440000000000001,0.8053,0.8784000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionWI,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Wisconsin,445,0.902,0.8367,0.9476000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionIL,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Illinois,673,0.8540000000000001,0.8188,0.8845999999999999,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionNE,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nebraska,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Nebraska,232,0.875,0.8077,0.9257,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionKS,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Kansas,667,0.876,0.8411,0.9054000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionID,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Idaho,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Idaho,366,0.899,0.8270000000000001,0.9483,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionOR,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-28,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Oregon,645,0.866,0.821,0.9032,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionMN,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Minnesota,683,0.846,0.7924,0.8896,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionPA,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Pennsylvania,657,0.883,0.8440000000000001,0.9148999999999999,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionIA,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Iowa,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-28,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Iowa,278,0.887,0.8279000000000001,0.9313,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionTX,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Texas,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Texas,668,0.895,0.858,0.9246,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_Overall_antiS,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Test used,Overall anti-S,28089,0.8240000000000001,0.8181,0.8304,,,True,,,Stratified non-probability,VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2023-02-07,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionCO,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-28,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Colorado,688,0.895,0.8509000000000001,0.9299,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_Age5-11,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-30,Residual sera,All,Children and Youth (0-17 years),5.0,11.0,Age,Age: 5-11,9810,0.91,0.9028,0.9169,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionHI,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Hawaii,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Hawaii,219,0.735,0.6635,0.7985,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionNM,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New Mexico,615,0.858,0.8046,0.9018,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionNV,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nevada,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-10,2022-04-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Nevada,687,0.878,0.8440000000000001,0.9061,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_SexMale,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-30,Residual sera,Male,Children and Youth (0-17 years),0.0,17.0,Sex/Gender,,12350,0.8840000000000001,0.8763,0.8919,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionLA,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Louisiana,648,0.913,0.8797,0.9392,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_Overall_antiN,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Test used,Overall anti-N,28311,0.77,0.7634000000000001,0.7766,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2023-02-07,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionGA,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-28,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Georgia,685,0.9009999999999999,0.8634000000000001,0.9304000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionMS,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Mississippi,668,0.917,0.8891,0.9401999999999999,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_Age0-4,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-30,Residual sera,All,Children and Youth (0-17 years),0.0,4.0,Age,Age: 0-4,3215,0.723,0.7044,0.7412000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionOH,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Ohio,673,0.909,0.8776999999999999,0.9338,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionPR,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Puerto Rico,670,0.8300000000000001,0.7981999999999999,0.8590000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionAR,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-28,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Arkansas,666,0.892,0.8578,0.9206000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionWA,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Washington,627,0.8109999999999999,0.7737,0.8453,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionNC,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-26,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: North Carolina,677,0.8790000000000001,0.8412000000000001,0.9113,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionNY,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New York,661,0.892,0.8591,0.92,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionTN,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-29,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Tennessee,677,0.93,0.9013,0.9526000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionMA,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-30,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Massachusetts,618,0.866,0.8306,0.897,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round31_2022Mar-Apr_RegionVA,220815_US_CDC_Round31_2022Mar-Apr,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Virginia,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-03-07,2022-04-27,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Virginia,702,0.883,0.8462999999999999,0.9136,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_Overall_antiNorS,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-26,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,Overall anti-S or anti-N,26624,0.9009999999999999,0.8956999999999999,0.9063,True,,True,,True,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionDC,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-22,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: District of Columbia,384,0.886,0.8166,0.9365000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionVA,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Virginia,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-23,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Virginia,462,0.887,0.8443,0.9213,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionNM,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-25,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New Mexico,645,0.925,0.8829000000000001,0.9561000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionWI,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-25,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Wisconsin,419,0.923,0.8623999999999999,0.9625,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionMD,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maryland,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-23,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Maryland,447,0.893,0.8515,0.9259000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_Age0-4,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-26,Residual sera,All,Children and Youth (0-17 years),0.0,4.0,Age,Age: 0-4,3346,0.745,0.7262000000000001,0.7628,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionTX,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Texas,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-25,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Texas,651,0.8959999999999999,0.8618000000000001,0.9248000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionKY,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Kentucky,647,0.8740000000000001,0.8349,0.907,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_Age5-11,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-26,Residual sera,All,Children and Youth (0-17 years),5.0,11.0,Age,Age: 5-11,8999,0.918,0.9106000000000001,0.9255,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionOR,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Oregon,656,0.861,0.8129000000000001,0.9014,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionME,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maine,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-25,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Maine,299,0.866,0.8079000000000001,0.912,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionTN,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Tennessee,681,0.9,0.8640000000000001,0.9298000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionMN,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Minnesota,673,0.902,0.8666,0.9308,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionPA,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-25,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Pennsylvania,656,0.872,0.8379000000000001,0.9014,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionCA,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-25,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: California,655,0.856,0.823,0.8845000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionOH,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-25,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Ohio,655,0.9009999999999999,0.8691,0.9276000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionNC,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-23,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: North Carolina,463,0.865,0.813,0.9066,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionAK,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alaska,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Alaska,210,0.909,0.8423999999999999,0.9544,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionCO,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Colorado,645,0.9109999999999999,0.8728,0.9415000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionUT,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Utah,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-23,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Utah,268,0.941,0.8773000000000001,0.978,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionKS,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Kansas,635,0.912,0.8806,0.9375,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionNV,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nevada,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-18,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Nevada,588,0.891,0.8545999999999999,0.9201,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionWA,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Washington,654,0.8570000000000001,0.8228,0.8864000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionRI,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Rhode Island,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-03,2022-06-25,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Rhode Island,129,0.851,0.7621,0.9166,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionMI,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Michigan,691,0.908,0.8761,0.9335,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionIL,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Illinois,680,0.891,0.8575,0.9192,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionMS,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Mississippi,660,0.91,0.8822,0.9326000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionNY,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-25,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New York,653,0.919,0.8872,0.9436,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionGA,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Georgia,684,0.9109999999999999,0.8795999999999999,0.9368000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionNE,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nebraska,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Nebraska,178,0.89,0.8138,0.9431,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionWV,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-25,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: West Virginia,630,0.878,0.8484,0.9039,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_SexMale,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-26,Residual sera,Male,Children and Youth (0-17 years),0.0,17.0,Sex/Gender,,11924,0.8840000000000001,0.8756999999999999,0.8922,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionVT,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Vermont,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Vermont,128,0.799,0.6973999999999999,0.8785,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionFL,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Florida,681,0.9279999999999999,0.8937,0.9542,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionIN,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Indiana,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Indiana,686,0.892,0.8553000000000001,0.9217000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionAL,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Alabama,648,0.91,0.872,0.9395,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_SexFemale,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-26,Residual sera,Female,Children and Youth (0-17 years),0.0,17.0,Sex/Gender,,14700,0.918,0.9112,0.9244,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionID,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Idaho,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-25,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Idaho,241,0.918,0.8434999999999999,0.9641,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_Overall_antiN,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-26,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Test used,Overall anti-N,26702,0.797,0.7902,0.8038,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2023-02-07,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionHI,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Hawaii,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-25,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Hawaii,183,0.816,0.7312000000000001,0.8833,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionSC,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-23,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: South Carolina,453,0.898,0.8508,0.9337000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionDE,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-25,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Delaware,1187,0.8690000000000001,0.8451000000000001,0.8896,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionNJ,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Jersey,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-25,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New Jersey,660,0.871,0.8347,0.9018,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_Age12-17,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-26,Residual sera,All,Children and Youth (0-17 years),12.0,17.0,Age,Age: 12-17,14279,0.968,0.9634,0.9715,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionPR,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-05,2022-06-25,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Puerto Rico,628,0.888,0.8593000000000001,0.913,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionIA,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Iowa,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Iowa,257,0.902,0.8455,0.943,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionNH,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Hampshire,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-25,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New Hampshire,501,0.885,0.8421,0.9198999999999999,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionMA,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-25,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Massachusetts,625,0.897,0.8656,0.923,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionMT,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Montana,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-26,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Montana,209,0.932,0.8563,0.9756,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionCT,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-25,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Connecticut,666,0.903,0.8725,0.9279000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_Overall_antiS,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-26,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Test used,Overall anti-S,26647,0.8220000000000001,0.8149,0.828,,,True,,,Stratified non-probability,VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2023-02-07,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionAR,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-22,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Arkansas,633,0.892,0.8569,0.9207,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionAZ,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arizona,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-09,2022-06-17,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Arizona,519,0.918,0.8786,0.9470999999999999,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionOK,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-03,2022-06-23,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Oklahoma,670,0.898,0.8692000000000001,0.9226000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionMO,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Missouri,649,0.904,0.8722,0.9297,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220815_US_CDC_Round32_2022May-Jun_RegionLA,220815_US_CDC_Round32_2022May-Jun,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-05-02,2022-06-24,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Louisiana,658,0.9109999999999999,0.8794,0.9358,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-09-02,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_Overall_antiNorS,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-20,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,Overall anti-S or anti-N,27360,0.938,0.9331999999999999,0.9417,True,,True,,True,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionAZ,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arizona,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-07-06,2022-08-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Arizona,688,0.9450000000000001,0.9166,0.9656,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_Age0-4,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-20,Residual sera,All,Children and Youth (0-17 years),0.0,4.0,Age,Age: 0-4,2942,0.8240000000000001,0.8069,0.8402,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionNV,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nevada,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-20,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Nevada,672,0.953,0.9301,0.9708,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionWV,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: West Virginia,599,0.897,0.8672,0.9223,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_Age12-17,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-20,Residual sera,All,Children and Youth (0-17 years),12.0,17.0,Age,Age: 12-17,14785,0.9790000000000001,0.9748000000000001,0.9818000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionOK,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-18,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Oklahoma,668,0.9470000000000001,0.9224,0.9657,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionMN,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-20,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Minnesota,656,0.9450000000000001,0.9188,0.9642000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionVA,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Virginia,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-07-01,2022-08-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Virginia,606,0.9400000000000001,0.909,0.9623,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionWA,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-15,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Washington,654,0.8840000000000001,0.8504,0.9118,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionUT,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Utah,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Utah,208,0.9870000000000001,0.9699,0.9961,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionMI,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Michigan,669,0.929,0.9004000000000001,0.9518000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionMA,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Massachusetts,564,0.9450000000000001,0.9174,0.9659000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionME,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maine,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Maine,281,0.8940000000000001,0.8224,0.9437000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_Overall_antiS,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-20,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Test used,Overall anti-S,27378,0.858,0.8519,0.8637,,,True,,,Stratified non-probability,VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2023-02-07,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionRI,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Rhode Island,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-20,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Rhode Island,203,0.943,0.8893000000000001,0.9758,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionIN,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Indiana,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Indiana,672,0.923,0.8885,0.9501999999999999,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionTX,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Texas,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Texas,668,0.956,0.9257,0.9761,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionNE,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nebraska,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-17,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Nebraska,154,0.924,0.8495,0.9687000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionIA,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Iowa,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Iowa,249,0.958,0.9036,0.9863,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_SexFemale,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-20,Residual sera,Female,Children and Youth (0-17 years),0.0,17.0,Sex/Gender,,14857,0.9470000000000001,0.9416,0.9523999999999999,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionIL,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Illinois,672,0.9309999999999999,0.8992,0.9559000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionPA,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-20,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Pennsylvania,658,0.9420000000000001,0.9124,0.9644,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionDE,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-20,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Delaware,1149,0.92,0.8997,0.9377,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionMT,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Montana,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Montana,173,0.9550000000000001,0.8568000000000001,0.9932,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_Overall_antiN,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-20,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Test used,Overall anti-N,27553,0.863,0.8572,0.8684999999999999,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2023-02-07,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionAR,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-17,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Arkansas,695,0.919,0.8874,0.9440999999999999,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionTN,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Tennessee,654,0.9309999999999999,0.8926999999999999,0.9592,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_Age5-11,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-20,Residual sera,All,Children and Youth (0-17 years),5.0,11.0,Age,Age: 5-11,9633,0.953,0.9478,0.9583,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionOR,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-16,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Oregon,661,0.919,0.8898999999999999,0.9427,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionMO,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-18,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Missouri,696,0.912,0.8754000000000001,0.9401999999999999,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionGA,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Georgia,653,0.918,0.8784000000000001,0.9474,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionKS,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-18,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Kansas,688,0.9540000000000001,0.93,0.9712000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionID,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Idaho,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Idaho,247,0.9329999999999999,0.8609,0.9749,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionMS,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Mississippi,620,0.934,0.9067000000000001,0.9551999999999999,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionWI,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-20,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Wisconsin,373,0.8840000000000001,0.8131,0.9353,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionNC,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-30,2022-08-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: North Carolina,585,0.922,0.8823000000000001,0.9521,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionFL,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-17,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Florida,677,0.934,0.8976999999999999,0.9609000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionNY,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New York,653,0.927,0.8953,0.9519,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionHI,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Hawaii,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Hawaii,188,0.868,0.7897,0.9248000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionAK,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alaska,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-20,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Alaska,220,0.9359999999999999,0.8645,0.9770000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionSC,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: South Carolina,450,0.9390000000000001,0.9018,0.9655,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionNJ,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Jersey,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New Jersey,655,0.924,0.8939,0.9481,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionMD,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maryland,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-07-01,2022-08-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Maryland,637,0.934,0.9009999999999999,0.9584999999999999,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionCO,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-17,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Colorado,722,0.971,0.9469,0.9865,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionVT,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Vermont,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Vermont,122,0.9420000000000001,0.8689,0.9813,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionKY,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Kentucky,630,0.927,0.895,0.9512,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionCT,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-20,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Connecticut,650,0.9390000000000001,0.9113,0.9603,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionNM,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-20,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New Mexico,667,0.923,0.8745999999999999,0.9577,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionAL,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Alabama,645,0.922,0.8848,0.9501999999999999,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionPR,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-20,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Puerto Rico,672,0.897,0.8698,0.92,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionNH,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Hampshire,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-20,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New Hampshire,543,0.912,0.8637,0.9469,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionLA,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-20,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Louisiana,665,0.9490000000000001,0.9237000000000001,0.9673999999999999,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_SexMale,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-20,Residual sera,Male,Children and Youth (0-17 years),0.0,17.0,Sex/Gender,,12503,0.9279999999999999,0.9209999999999999,0.9344,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionCA,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-20,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: California,698,0.92,0.8926999999999999,0.9416,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionOH,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-19,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Ohio,641,0.9450000000000001,0.9167000000000001,0.9665,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
220930_US_CDC_Round33_2022Jul-Aug_RegionDC,220930_US_CDC_Round33_2022Jul-Aug,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-06-27,2022-08-18,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: District of Columbia,437,0.9420000000000001,0.886,0.976,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-10-05,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_Overall_antiNorS,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-16,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,Overall anti-S or anti-N,26174,0.9590000000000001,0.9554,0.9626000000000001,True,,True,,True,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_Age12-17,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-16,Residual sera,All,Children and Youth (0-17 years),12.0,17.0,Age,Age: 12-17,14167,0.986,0.9832,0.9881000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionVT,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Vermont,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-14,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Vermont,116,0.953,0.8788,0.9879000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionNV,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nevada,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-16,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Nevada,669,0.965,0.9343000000000001,0.9840000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionOR,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oregon,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-14,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Oregon,648,0.9500000000000001,0.9218000000000001,0.9703,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionNC,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,North Carolina,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-15,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: North Carolina,512,0.9470000000000001,0.9105,0.9712999999999999,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionNM,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Mexico,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-15,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New Mexico,656,0.958,0.9256000000000001,0.9793000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionMS,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Mississippi,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-14,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Mississippi,622,0.9550000000000001,0.9319,0.9723999999999999,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_Age0-4,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-16,Residual sera,All,Children and Youth (0-17 years),0.0,4.0,Age,Age: 0-4,2891,0.887,0.8729000000000001,0.9009,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionPA,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Pennsylvania,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-15,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Pennsylvania,646,0.9740000000000001,0.9523,0.9872,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionDC,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Local,Repeated cross-sectional study,United States of America,,District of Columbia,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-23,2022-10-15,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: District of Columbia,137,0.997,0.9845,0.9999,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionFL,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Florida,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-14,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Florida,693,0.96,0.9288,0.98,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionNY,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New York,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-15,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New York,677,0.946,0.9192,0.9662999999999999,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionCO,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Colorado,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-14,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Colorado,655,0.9740000000000001,0.9498000000000001,0.9888,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionMT,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Montana,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-13,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Montana,138,0.9500000000000001,0.8749,0.9866,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionLA,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Louisiana,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-15,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Louisiana,668,0.9550000000000001,0.9278000000000001,0.9743,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionTX,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Texas,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-14,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Texas,673,0.9690000000000001,0.9451999999999999,0.9844,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionNH,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Hampshire,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-15,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New Hampshire,483,0.953,0.9108,0.9787,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_Age5-11,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-16,Residual sera,All,Children and Youth (0-17 years),5.0,11.0,Age,Age: 5-11,9116,0.97,0.9648000000000001,0.9740000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionMD,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maryland,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-23,2022-10-15,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Maryland,615,0.9570000000000001,0.9244,0.9784999999999999,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_Overall_antiN,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-16,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Test used,Overall anti-N,26286,0.903,0.8975,0.9078,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2023-02-07,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionPR,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Puerto Rico,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-15,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Puerto Rico,670,0.9309999999999999,0.9063,0.9501999999999999,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionVA,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Virginia,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-23,2022-10-15,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Virginia,536,0.9550000000000001,0.9301,0.9737000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionMI,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Michigan,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-14,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Michigan,669,0.9520000000000001,0.9261,0.9715,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_SexMale,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-16,Residual sera,Male,Children and Youth (0-17 years),0.0,17.0,Sex/Gender,Sex: male,11646,0.953,0.9468000000000001,0.9581000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionMO,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Missouri,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-14,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Missouri,640,0.9540000000000001,0.9296,0.9717,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionUT,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Utah,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-14,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Utah,305,0.996,0.9872,0.9991,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionWI,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Wisconsin,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-15,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Wisconsin,390,0.971,0.937,0.9898,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionSC,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,South Carolina,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-15,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: South Carolina,362,0.93,0.8805,0.9634,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionID,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Idaho,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-14,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Idaho,221,0.976,0.9440999999999999,0.9927,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionTN,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Tennessee,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-12,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Tennessee,557,0.948,0.9114,0.9731000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionRI,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Rhode Island,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-14,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Rhode Island,128,0.9450000000000001,0.8731,0.9828,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionWA,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Washington,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-10,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Washington,644,0.924,0.8946,0.9479000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionHI,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Hawaii,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-13,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Hawaii,203,0.9420000000000001,0.8959,0.9716,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionAK,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alaska,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-15,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Alaska,232,0.9440000000000001,0.8826,0.9792000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionAL,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Alabama,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-12,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Alabama,518,0.968,0.9425,0.9839,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionGA,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Georgia,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-12,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Georgia,558,0.9670000000000001,0.9261,0.9888,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_Overall_antiS,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-16,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Test used,Overall anti-S,26190,0.891,0.8855,0.8963,,,True,,,Stratified non-probability,VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2023-02-07,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionNJ,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,New Jersey,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-15,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: New Jersey,655,0.951,0.9246,0.9701000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_SexFemale,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-16,Residual sera,Female,Children and Youth (0-17 years),0.0,17.0,Sex/Gender,Sex: female,14528,0.965,0.9608,0.9697,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionOK,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Oklahoma,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-27,2022-10-14,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Oklahoma,665,0.948,0.9188,0.9694,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionAR,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arkansas,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-14,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Arkansas,635,0.9490000000000001,0.9247,0.9676000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionNE,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Nebraska,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-14,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Nebraska,178,0.958,0.8906999999999999,0.9895999999999999,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionIN,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Indiana,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-14,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Indiana,683,0.961,0.9417,0.976,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionOH,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Ohio,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-15,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Ohio,644,0.9520000000000001,0.9259999999999999,0.9715,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionCA,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,California,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-14,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: California,667,0.9470000000000001,0.9229,0.9646,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionMA,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Massachusetts,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-14,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Massachusetts,546,0.97,0.9461,0.9856999999999999,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionCT,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Connecticut,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-15,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Connecticut,654,0.9620000000000001,0.9390999999999999,0.9782,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionMN,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Minnesota,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-14,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Minnesota,654,0.915,0.8458,0.9597,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionAZ,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Arizona,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-12,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Arizona,648,0.9450000000000001,0.917,0.9658,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionIA,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Iowa,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-14,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Iowa,231,0.956,0.9054000000000001,0.9837,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionWV,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,West Virginia,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-15,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: West Virginia,631,0.932,0.9062000000000001,0.9523,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionKS,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kansas,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-14,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Kansas,663,0.9550000000000001,0.9294,0.9727,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionIL,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Illinois,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-14,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Illinois,688,0.9690000000000001,0.9428000000000001,0.9849,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionKY,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Kentucky,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-14,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Kentucky,643,0.966,0.9395,0.9837,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionME,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Maine,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-14,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Maine,284,0.943,0.8962000000000001,0.9731000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
221215_US_CDC_Round34_2022Sep-Oct_RegionDE,221215_US_CDC_Round34_2022Sep-Oct,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,Regional,Repeated cross-sectional study,United States of America,Delaware,,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-08-22,2022-10-15,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Geographical area,Region: Delaware,1128,0.953,0.9374,0.9659000000000001,,,True,,,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2022-12-21,2024-03-01,Unverified,cdc_nationwide_2022,USA
230127_US_CDC_Round35_2022Nov-Dec_Overall_antiNorS,230127_US_CDC_Round35_2022Nov-Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-10-17,2022-12-11,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Primary Estimate,Overall anti-S or anti-N,26663,0.963,0.9591,0.9662000000000001,True,,True,,True,Stratified non-probability,"VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics",CLIA,Serum,"['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2023-02-03,2024-03-01,Unverified,cdc_nationwide_2022,USA
230127_US_CDC_Round35_2022Nov-Dec_Overall_antiS,230127_US_CDC_Round35_2022Nov-Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-10-17,2022-12-11,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Test used,Overall anti-S,26691,0.899,0.8937,0.9044,,,True,,,Stratified non-probability,VITROS® Anti-SARS-CoV-2 IgG Quantitative Test,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,Validated by manufacturers,,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2023-02-07,2024-03-01,Unverified,cdc_nationwide_2022,USA
230127_US_CDC_Round35_2022Nov-Dec_Overall_antiN,230127_US_CDC_Round35_2022Nov-Dec,Nationwide Commercial Lab Pediatric Antibody Seroprevalence,2023-01-27,Institutional Report,National,Repeated cross-sectional study,United States of America,"All 50 states, the District of Columbia, and Puerto Rico",,U.S. pediatric population (aged 6 months to 17 years),"""Reinfections are not included.""

""Specimens were excluded if they were from patients who had blood drawn for assessment of COVID-19 infection status.""

""Seroprevalence estimates for demographic strata with < 50 samples are not displayed.""",2022-10-17,2022-12-11,Residual sera,All,Children and Youth (0-17 years),0.0,17.0,Test used,Overall anti-N,26842,0.919,0.914,0.9235,,,True,,,Stratified non-probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.998,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence,2023-02-07,2024-03-01,Unverified,cdc_nationwide_2022,USA
230301_Michigan_UniversityofMichigan_Overall,230301_Michigan_UniversityofMichigan,Respiratory virus circulation during the first year of the COVID-19 pandemic in the Household Influenza Vaccine Evaluation (HIVE) cohort,2023-03-01,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Michigan,,"""Eligible households must have ≥3 persons living at the same address with at least one child aged <10 years at the time of initial enrollment. In mid-2020, eligibility was expanded to those with at least one child aged <21 years.""

""We retained households throughout the study period even if children aged out of the original eligibility criteria.""","""Participants were removed from the study follow-up only if they chose to withdraw.""",2020-07-17,2021-04-30,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,Over the entire study period,409,0.071,,,True,,,,True,Convenience,Meso Scale Discovery multiplex assay,Meso Scale Discovery,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,No,,Unclear,Yes,No,,Sydney Fine,University of Michigan,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.13106,2023-03-30,2023-06-22,Unverified,fine_respiratory_2023,USA
230301_Michigan_UniversityofMichigan_2020summer,230301_Michigan_UniversityofMichigan,Respiratory virus circulation during the first year of the COVID-19 pandemic in the Household Influenza Vaccine Evaluation (HIVE) cohort,2023-03-01,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Michigan,,"""Eligible households must have ≥3 persons living at the same address with at least one child aged <10 years at the time of initial enrollment. In mid-2020, eligibility was expanded to those with at least one child aged <21 years.""

""We retained households throughout the study period even if children aged out of the original eligibility criteria.""","""Participants were removed from the study follow-up only if they chose to withdraw.""",2020-07-17,2020-08-31,Household and community samples,All,Multiple groups,0.0,,Time frame,Summer 2020,265,0.053,,,,,,,,Convenience,Meso Scale Discovery multiplex assay,Meso Scale Discovery,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,No,,Unclear,Yes,No,,Sydney Fine,University of Michigan,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.13106,2023-03-30,2023-06-22,Unverified,fine_respiratory_2023,USA
230301_Michigan_UniversityofMichigan_2020fallWinter,230301_Michigan_UniversityofMichigan,Respiratory virus circulation during the first year of the COVID-19 pandemic in the Household Influenza Vaccine Evaluation (HIVE) cohort,2023-03-01,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Michigan,,"""Eligible households must have ≥3 persons living at the same address with at least one child aged <10 years at the time of initial enrollment. In mid-2020, eligibility was expanded to those with at least one child aged <21 years.""

""We retained households throughout the study period even if children aged out of the original eligibility criteria.""","""Participants were removed from the study follow-up only if they chose to withdraw.""",2020-09-01,2021-02-03,Household and community samples,All,Multiple groups,0.0,,Time frame,Fall-winter 2020,269,0.03,,,,,,,,Convenience,Meso Scale Discovery multiplex assay,Meso Scale Discovery,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,No,,Unclear,Yes,No,,Sydney Fine,University of Michigan,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.13106,2023-03-30,2023-06-22,Unverified,fine_respiratory_2023,USA
230301_Michigan_UniversityofMichigan_2021spring,230301_Michigan_UniversityofMichigan,Respiratory virus circulation during the first year of the COVID-19 pandemic in the Household Influenza Vaccine Evaluation (HIVE) cohort,2023-03-01,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Michigan,,"""Eligible households must have ≥3 persons living at the same address with at least one child aged <10 years at the time of initial enrollment. In mid-2020, eligibility was expanded to those with at least one child aged <21 years.""

""We retained households throughout the study period even if children aged out of the original eligibility criteria.""","""Participants were removed from the study follow-up only if they chose to withdraw.""",2021-03-09,2021-04-30,Household and community samples,All,Multiple groups,0.0,,Time frame,Spring 2021,62,0.113,,,,,,,,Convenience,Meso Scale Discovery multiplex assay,Meso Scale Discovery,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,No,,Unclear,Yes,No,,Sydney Fine,University of Michigan,Not Unity-Aligned,https://dx.doi.org/10.1111/irv.13106,2023-03-30,2023-06-22,Unverified,fine_respiratory_2023,USA
230309_USA_YaleSchoolofMedicine_Primary,230309_USA_YaleSchoolofMedicine,Occupational Risk Factors for SARS-CoV-2 Seropositivity in Healthcare Workers: Results of a Longitudinal Cohort.,2023-03-09,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Connecticut,,"Human subjects greater than 18 years of age who worked at a single, metropolitan academic hospital in Northeastern, USA were recruited through announcements at regularly scheduled staff meetings and via email beginning in March, 2020 with baseline survey and serum collection.",,2020-03-08,2020-05-08,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,HCW overall seroprevalence,1233,0.058,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,,IgG,Spike,,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Louis E Fazen,Yale School of Medicine,Not Unity-Aligned,https://dx.doi.org/10.1097/JOM.0000000000002831,2023-03-20,2023-03-21,Unverified,occupational_fazen_2023,USA
230315_NorthCarolina_UniversityOfNorthCarolina_Overall,230315_NorthCarolina_UniversityOfNorthCarolina,Seroepidemiology and Risk Factors for SARS-CoV-2 Infection Among Household Members of Food Processing and Farm Workers in North Carolina,2023-03-15,Preprint,Regional,Cross-sectional survey ,United States of America,North Carolina,,"""Adults aged 18 years and older who had worked for at least two weeks in a meat packing plant, food processing facility, or commercial farm beginning February 1, 2020 and resided in NC were recruited and were classified as the index worker. Household members of index workers at least 12 months of age were invited to participate.""","""Children under 12 months of age were excluded because maternal antibodies transferred transplacentally could confound serological results.""",2020-09-15,2020-12-15,Multiple populations,All,Multiple groups,1.0,,Primary Estimate,,218,0.5,,,True,,,,True,Convenience,"Author designed (ELISA) - Unknown,UNSCIENCE COVID-19 IgG/IgM antibody Rapid Test Kit","NA,Wuhan UNscience Biotechnology Co. Ltd",Multiple Types,Plasma,"['IgG', 'IgM', 'TotalAntibody']",Spike,Validated by developers,,,['High'],,No,No,Yes,,Unclear,No,No,,Michael Sciaudone,University of North Carolina,Not Unity-Aligned,http://doi.org/10.2139/ssrn.4362126,2023-04-05,2024-03-01,Unverified,sciaudone_seroepidemiology_2023,USA
230321_Seattle_SeattleChildrensHospital_PrimaryEstimate,230321_Seattle_SeattleChildrensHospital,Seroprevalence and Clinical Characteristics of SARS-CoV-2 Infection in Children with Cystic Fibrosis,2023-03-21,Preprint,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Washington,Seattle,"""All children and adolescents with CF followed at Seattle Children’s Hospital were eligible to enroll between July 20, 2020, and February 28, 2021""",,2020-07-15,2022-03-15,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),7.0,17.0,Primary Estimate,,125,0.11,,,True,,,,True,Convenience,"Abbott Architect SARS-CoV-2 IgG,AdviseDX SARS-CoV-2 anti-IgG II assay",Abbott Laboratories,,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,,,['High'],,No,No,Yes,,Unclear,No,No,,Rafael Hernandez,Seattle Children's Hospitals,Not Unity-Aligned,10.22541/au.167937305.53541604/v1,2023-04-04,2024-03-01,Unverified,hernandez_seroprevalence_2023,USA
230323_JeffersonCounty_UniversityOfLouisville_Probability1,230323_JeffersonCounty_UniversityOfLouisville_Probability1,Stratified Simple Random Sampling Versus Volunteer Community-Wide Sampling for Estimates of COVID-19 Prevalence,2023-03-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Kentucky,,we conducted stratified simple random sampling (Table 1). Participants were residents aged 18 years or older,,2020-06-15,2021-08-15,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,7296,0.132,,,True,,,,True,Simplified probability,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Rachel J Keith,University Of Louisville,Not Unity-Aligned,https://dx.doi.org/10.2105/AJPH.2023.307303,2023-06-30,2023-07-04,Unverified,keithStratifiedSimpleRandom2023,USA
230323_JeffersonCounty_UniversityOfLouisville_Volunteer2,230323_JeffersonCounty_UniversityOfLouisville_Volunteer2,Stratified Simple Random Sampling Versus Volunteer Community-Wide Sampling for Estimates of COVID-19 Prevalence,2023-03-23,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Kentucky,,we conducted stratified simple random sampling (Table 1). Participants were residents aged 18 years or older,,2020-06-15,2021-08-15,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,7919,0.141,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,Yes,Yes,,Unclear,Yes,No,,Rachel J Keith,University Of Louisville,Not Unity-Aligned,https://dx.doi.org/10.2105/AJPH.2023.307303,2023-06-30,2023-07-04,Unverified,keithStratifiedSimpleRandom2023,USA
220327_Colorado_Colorado DepartmentofPublicHealthandEnvironment_Overall,220327_Colorado_Colorado DepartmentofPublicHealthandEnvironment,"SARS-CoV-2 Seroprevalence Compared with Confirmed COVID-19 Cases among Children, Colorado, USA, May-July 2021.",2023-03-27,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"Residual serum specimens from children 1–17 years of age at the time of blood collection were eligible for inclusion.  We selected eligible children sequentially. After selecting approximately half of the 1,000 planned specimens, we oversampled from the 1–4-year age group and non-Hispanic Black children to improve representativeness for subgroup analysis. To improve the sensitivity of positive serology results as a proxy for previous SARS-CoV-2 infection and to avoid misclassification error among previously vaccinated children not previously infected (Appendix Table 1), we excluded from final analysis children who had received >1 SARS-CoV-2 vaccine dose on any date before the serum specimen collection date. ","To improve generalizability, we excluded specimens from subspecialty outpatient clinics (e.g., oncology, cardiology). We also excluded non-Colorado residents from the final analysis. We excluded children who had received >1 SARS-CoV-2 vaccine doses",2021-05-12,2021-07-13,Residual sera,All,Children and Youth (0-17 years),1.0,17.0,Primary Estimate,,829,0.367,0.334,0.401,True,,,,True,Sequential,"Alinity i SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG","Abbott Laboratories,EUROIMMUN",Multiple Types,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,Yes,Yes,,Yes,Yes,No,,Shannon C. O’Brien,Colorado Department of Public Health and Environment,Not Unity-Aligned,https://dx.doi.org/10.3201/eid2905.221541,2023-05-08,2024-03-01,Unverified,obrien_sars-cov-2_2023,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Overall,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Primary Estimate,Overall Anti-S,70584,0.9431,0.919,0.9603,True,,True,,True,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Age30-49,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Adults (18-64 years),30.0,49.0,Age,Age: 30-49 years,16588,0.9490999999999999,0.9384,0.958,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Maryland,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Maryland,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Maryland,863,0.9376000000000001,0.8764000000000001,0.9695999999999999,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_WestVirginia,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,West Virginia,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: West Virginia,234,0.9461,0.9102,0.9681000000000001,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_SouthDakota,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,South Dakota,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: South Dakota,832,0.9639,0.9490000000000001,0.9745,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Minnesota,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Minnesota,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Minnesota,2640,0.9666,0.9512999999999999,0.9772,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Nevada,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Nevada,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Nevada,2255,0.9607,0.9521,0.9677,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_NewYork,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,New York,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: New York,2370,0.9425,0.8851000000000001,0.9721,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Age65+,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Seniors (65+ years),65.0,,Age,Age: 65 years and over,22695,0.9046,0.7698,0.9642000000000001,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Texas,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Texas,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Texas,1773,0.9608,0.9422,0.9734999999999999,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Wisconsin,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Wisconsin,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Wisconsin,2048,0.9311,0.8901000000000001,0.9575,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Florida,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Florida,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Florida,13,0.8584999999999999,0.4451,0.9787,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Age50-64,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Adults (18-64 years),50.0,64.0,Age,Age: 50-64 years,27732,0.9496,0.9424,0.956,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Arkansas,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Arkansas,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Arkansas,110,0.9548000000000001,0.8468000000000001,0.9878,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Oklahoma,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Oklahoma,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Oklahoma,270,0.9584,0.8918,0.9847,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Georgia,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Georgia,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Georgia,1624,0.9484,0.9124,0.9701000000000001,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Montana,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Montana,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Montana,1135,0.9538,0.9334,0.9682,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_NewJersey,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,New Jersey,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: New Jersey,622,0.9738,0.9361,0.9895,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Massachusetts,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Massachusetts,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Massachusetts,1194,0.9684,0.9408,0.9833,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_NorthDakota,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,North Dakota,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: North Dakota,1246,0.9538,0.9420000000000001,0.9633,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Kentucky,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Kentucky,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Kentucky,632,0.9603,0.9431999999999999,0.9723,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Oregon,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Oregon,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Oregon,1310,0.9236,0.8972,0.9436,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Alabama,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Alabama,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Alabama,282,0.9106000000000001,0.8192,0.9581000000000001,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_SouthCarolina,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,South Carolina,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: South Carolina,752,0.9605,0.9244,0.9797,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Arizona,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Arizona,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Arizona,4837,0.9393000000000001,0.9283,0.9487000000000001,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_SexMale,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,Male,Multiple groups,16.0,,Sex/Gender,Sex: male,35833,0.9507,0.9440000000000001,0.9567,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_NorthCarolina,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,North Carolina,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: North Carolina,2254,0.9499,0.9262,0.9662999999999999,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Iowa,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Iowa,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Iowa,345,0.9844,0.9644,0.9933,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Age16-29,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Adults (18-64 years),16.0,29.0,Age,Age: 16-29 years,3569,0.9672000000000001,0.9562,0.9756,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_NewHampshire,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,New Hampshire,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: New Hampshire,599,0.9656,0.9440000000000001,0.9790000000000001,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Vermont,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Vermont,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Vermont,229,0.9385,0.8718000000000001,0.9717,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Connecticut,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Connecticut,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Connecticut,1241,0.9677,0.9477,0.9802,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Kansas,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Kansas,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Kansas,1315,0.9631000000000001,0.9479000000000001,0.9740000000000001,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_NewMexico,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,New Mexico,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: New Mexico,1824,0.9476000000000001,0.9363,0.9570000000000001,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Louisiana,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Louisiana,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Louisiana,513,0.9656,0.9453,0.9784999999999999,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_AntiN,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Test used,Anti-N,40800,0.5871000000000001,0.5617,0.6119,,,True,,,Simplified probability,VITROS Anti-SARS-CoV-2 Total N Antibody Test,Ortho Clinical Diagnostics Inc.,CLIA,Serum,"IgG, IgM, IgA",Nucleocapsid (N-protein),,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2023-03-22,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Mississippi,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Mississippi,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Mississippi,544,0.9231999999999999,0.843,0.9641,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Maine,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Maine,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Maine,476,0.9638,0.9437000000000001,0.9768000000000001,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Washington,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Washington,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Washington,1422,0.9381999999999999,0.9048999999999999,0.9604,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Colorado,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Colorado,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Colorado,4623,0.9588,0.9520000000000001,0.9647,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Michigan,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Michigan,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Michigan,2269,0.9442,0.9141,0.9642000000000001,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_DistrictOfColumbia,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,,District of Columbia,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: District of Columbia,64,1.0,0.9434,1.0,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Wyoming,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Wyoming,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Wyoming,538,0.9323,0.9092,0.9499,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Tennessee,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Tennessee,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Tennessee,1075,0.948,0.9246,0.9643,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Utah,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Utah,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Utah,1169,0.9504000000000001,0.9101,0.9732,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Illinois,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Illinois,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Illinois,1227,0.9604,0.9340999999999999,0.9765,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_California,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,California,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: California,9708,0.9475,0.9386,0.9553,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Delaware,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Delaware,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Delaware,11,1.0,0.7412000000000001,1.0,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Idaho,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Idaho,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Idaho,1150,0.9444,0.9244,0.9594,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Virginia,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Virginia,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Virginia,1709,0.9288,0.8952,0.9522,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Nebraska,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Nebraska,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Nebraska,1455,0.9659000000000001,0.9503,0.9767,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Pennsylvania,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Pennsylvania,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Pennsylvania,1757,0.9302,0.8844,0.9587000000000001,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Ohio,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Ohio,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Ohio,3492,0.9333,0.9068,0.9527,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Missouri,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Missouri,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Missouri,1240,0.9470999999999999,0.9203,0.9652,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_SexFemale,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,Female,Multiple groups,16.0,,Sex/Gender,Sex: female,34751,0.9352,0.8849,0.9644,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
221219_US_CDC_BloodDonors_2022Apr-Jun_Indiana,221219_US_CDC_BloodDonors_2022Apr-Jun,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,Regional,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Indiana,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-04-01,2022-06-30,Blood donors,All,Multiple groups,16.0,,Geographical area,State: Indiana,1293,0.9451999999999999,0.9031,0.9697,,,True,,,Simplified probability,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['Low'],,Yes,Yes,Yes,,Yes,Yes,Yes,,US CDC,US Centers for Disease Control and Prevention,Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-01-09,2024-03-01,Unverified,cdc_2022_2022,USA
230403_US_CDC_BloodDonors_2022Jul-Sep_Overall,230403_US_CDC_BloodDonors_2022Jul-Sep,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-07-01,2022-09-30,Blood donors,All,Multiple groups,16.0,,Primary Estimate,Overall Anti-S or Anti-N,68881,0.9599,0.9415,0.9726,True,,True,,True,Simplified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,VITROS Anti-SARS-CoV-2 Total N Antibody Test",Ortho Clinical Diagnostics Inc.,"CLIA,CLIA",Serum,"['IgG', 'IgG, IgM, IgA']","['Nucleocapsid (N-protein)', 'Spike']",,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-04-25,2024-03-01,Unverified,cdc_2022_2022,USA
230403_US_CDC_BloodDonors_2022Jul-Sep_AntiN,230403_US_CDC_BloodDonors_2022Jul-Sep,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-07-01,2022-09-30,Blood donors,All,Multiple groups,16.0,,Test used,Anti-N,47307,0.7019,0.6813,0.7218,,,True,,,Simplified probability,VITROS Anti-SARS-CoV-2 Total N Antibody Test,Ortho Clinical Diagnostics Inc.,CLIA,Serum,"IgG, IgM, IgA",Nucleocapsid (N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-04-25,2023-04-26,Unverified,cdc_2022_2022,USA
230628_US_CDC_BloodDonors_2022Jan-Mar_Overall,230628_US_CDC_BloodDonors_2022Jan-Mar,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-01-01,2022-03-31,Blood donors,All,Multiple groups,16.0,,Primary Estimate,Overall Anti-S or Anti-N,70938,0.922,0.8957,0.9421,True,,True,,True,Simplified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,VITROS Anti-SARS-CoV-2 Total N Antibody Test",Ortho Clinical Diagnostics Inc.,"CLIA,CLIA",Serum,"['IgG', 'IgG, IgM, IgA']","['Nucleocapsid (N-protein)', 'Spike']",,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-07-27,2024-03-01,Unverified,cdc_2022_2022,USA
230628_US_CDC_BloodDonors_2022Jan-Mar_AntiN,230628_US_CDC_BloodDonors_2022Jan-Mar,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,National,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-01-01,2022-03-31,Blood donors,All,Multiple groups,16.0,,Test used,Anti-N,34616,0.4876,0.4631,0.5121,,,True,,,Simplified probability,VITROS Anti-SARS-CoV-2 Total N Antibody Test,Ortho Clinical Diagnostics Inc.,CLIA,Serum,"IgG, IgM, IgA",Nucleocapsid (N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-07-27,2023-08-15,Unverified,cdc_2022_2022,USA
230726_US_CDC_BloodDonors_2022Oct-Dec_Overall,230628_US_CDC_BloodDonors_2022Oct-Dec,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,National,Prospective cohort,United States of America,,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-10-01,2022-12-31,Blood donors,All,Multiple groups,16.0,,Primary Estimate,Overall Anti-S or Anti-N,66489,0.9671,0.9385,0.9827,True,,True,,True,Simplified probability,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,VITROS Anti-SARS-CoV-2 Total N Antibody Test",Ortho Clinical Diagnostics Inc.,"CLIA,CLIA",Serum,"['IgG', 'IgG, IgM, IgA']","['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-07-26,2024-03-09,Unverified,cdc_2022_2022,USA
230726_US_CDC_BloodDonors_2022Oct-Dec_AntiN,230628_US_CDC_BloodDonors_2022Oct-Dec,2022 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations),2023-04-03,Institutional Report,National,Prospective cohort,United States of America,,,"""Persons ≥ 16 years"".

From http://doi.org/10.1111/trf.16943:
""All routine blood donations were eligible for inclusion with the exception of COVID-19 convalescent plasma (CCP) donations to avoid upward bias in seroprevalence estimates due to specific recruitment of previously infected individuals into CCP programs"".","""Specimens were exclude  if they had missing demographic data.""",2022-10-01,2022-12-31,Blood donors,All,Multiple groups,16.0,,Test used,Anti-N,49970,0.7754,0.7507,0.7984,,,True,,,Simplified probability,VITROS Anti-SARS-CoV-2 Total N Antibody Test,Ortho Clinical Diagnostics Inc.,CLIA,Serum,"IgG, IgM, IgA",Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,US CDC,US Centers for Disease Control and Prevention,Not Unity-Aligned,https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022,2023-07-26,2024-03-09,Unverified,cdc_2022_2022,USA
230403_NorthCarolina_LevineChildren’sHospital_August21,230403_NorthCarolina_LevineChildren’sHospital_August21,Characterization of Infection-Induced SARS-CoV-2 Seroprevalence Amongst Children and Adolescents in North Carolina.,2023-04-03,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,North Carolina,"Charlotte, Winston-Salem, and Raleigh",""" From
2 April 2021 to 24 June 2021, we enrolled children between the
ages of 2 and 17 years at three North Carolina healthcare systems
based in the cities of Charlotte, Winston-Salem, and Raleigh.
Caregivers consented and participants aged ≥13 years assented
electronically.""",,2021-08-01,2021-08-31,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),2.0,17.0,Primary Estimate,,1058,0.405,0.345,0.464,True,True,,,True,Convenience,2019-nCoV IgG Rapid Test,Innovita Biological Technology Co. Ltd,LFIA,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.845,0.99,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Amina Ahmed,"Levine Children’s Hospital, Atrium",Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268823000481,2023-05-03,2023-05-04,Unverified,ahmedCharacterisationInfectioninducedSARSCoV22023,USA
230403_NorthCarolina_LevineChildren’sHospital_July21,230403_NorthCarolina_LevineChildren’sHospital_July21,Characterization of Infection-Induced SARS-CoV-2 Seroprevalence Amongst Children and Adolescents in North Carolina.,2023-04-03,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,North Carolina,"Charlotte, Winston-Salem, and Raleigh",""" From
2 April 2021 to 24 June 2021, we enrolled children between the
ages of 2 and 17 years at three North Carolina healthcare systems
based in the cities of Charlotte, Winston-Salem, and Raleigh.
Caregivers consented and participants aged ≥13 years assented
electronically.""",,2021-07-01,2021-07-31,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),2.0,17.0,Primary Estimate,,1058,0.342,0.281,0.401,True,True,,,True,Convenience,2019-nCoV IgG Rapid Test,Innovita Biological Technology Co. Ltd,LFIA,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.845,0.99,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Amina Ahmed,"Levine Children’s Hospital, Atrium",Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268823000481,2023-05-03,2023-05-04,Unverified,ahmedCharacterisationInfectioninducedSARSCoV22023,USA
230403_NorthCarolina_LevineChildren’sHospital_June21,230403_NorthCarolina_LevineChildren’sHospital_June21,Characterization of Infection-Induced SARS-CoV-2 Seroprevalence Amongst Children and Adolescents in North Carolina.,2023-04-03,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,North Carolina,"Charlotte, Winston-Salem, and Raleigh",""" From
2 April 2021 to 24 June 2021, we enrolled children between the
ages of 2 and 17 years at three North Carolina healthcare systems
based in the cities of Charlotte, Winston-Salem, and Raleigh.
Caregivers consented and participants aged ≥13 years assented
electronically.""",,2021-06-01,2021-06-30,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),2.0,17.0,Primary Estimate,,1058,0.344,0.272,0.419,True,True,,,True,Convenience,2019-nCoV IgG Rapid Test,Innovita Biological Technology Co. Ltd,LFIA,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.845,0.99,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Amina Ahmed,"Levine Children’s Hospital, Atrium",Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268823000481,2023-05-03,2023-05-04,Unverified,ahmedCharacterisationInfectioninducedSARSCoV22023,USA
230403_NorthCarolina_LevineChildren’sHospital_May21,230403_NorthCarolina_LevineChildren’sHospital_May21,Characterization of Infection-Induced SARS-CoV-2 Seroprevalence Amongst Children and Adolescents in North Carolina.,2023-04-03,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,North Carolina,"Charlotte, Winston-Salem, and Raleigh",""" From
2 April 2021 to 24 June 2021, we enrolled children between the
ages of 2 and 17 years at three North Carolina healthcare systems
based in the cities of Charlotte, Winston-Salem, and Raleigh.
Caregivers consented and participants aged ≥13 years assented
electronically.""",,2021-05-01,2021-05-31,Residual sera,All,Children and Youth (0-17 years),2.0,17.0,Primary Estimate,,1058,0.152,0.09,0.22,True,True,,,True,Convenience,2019-nCoV IgG Rapid Test,Innovita Biological Technology Co. Ltd,LFIA,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.845,0.99,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Amina Ahmed,"Levine Children’s Hospital, Atrium",Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268823000481,2023-05-03,2023-05-09,Unverified,ahmedCharacterisationInfectioninducedSARSCoV22023,USA
230403_NorthCarolina_LevineChildren’sHospital_Oct21,230403_NorthCarolina_LevineChildren’sHospital_Oct21,Characterization of Infection-Induced SARS-CoV-2 Seroprevalence Amongst Children and Adolescents in North Carolina.,2023-04-03,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,North Carolina,"Charlotte, Winston-Salem, and Raleigh",""" From
2 April 2021 to 24 June 2021, we enrolled children between the
ages of 2 and 17 years at three North Carolina healthcare systems
based in the cities of Charlotte, Winston-Salem, and Raleigh.
Caregivers consented and participants aged ≥13 years assented
electronically.""",,2021-10-01,2021-10-31,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),2.0,17.0,Primary Estimate,,1058,0.541,0.467,0.611,True,True,,,True,Convenience,2019-nCoV IgG Rapid Test,Innovita Biological Technology Co. Ltd,LFIA,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.845,0.99,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Amina Ahmed,"Levine Children’s Hospital, Atrium",Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268823000481,2023-05-03,2023-05-04,Unverified,ahmedCharacterisationInfectioninducedSARSCoV22023,USA
230403_NorthCarolina_LevineChildren’sHospital_Sept21,230403_NorthCarolina_LevineChildren’sHospital_Sept21,Characterization of Infection-Induced SARS-CoV-2 Seroprevalence Amongst Children and Adolescents in North Carolina.,2023-04-03,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,North Carolina,"Charlotte, Winston-Salem, and Raleigh",""" From
2 April 2021 to 24 June 2021, we enrolled children between the
ages of 2 and 17 years at three North Carolina healthcare systems
based in the cities of Charlotte, Winston-Salem, and Raleigh.
Caregivers consented and participants aged ≥13 years assented
electronically.""",,2021-09-01,2021-09-30,Patients seeking care for non-COVID-19 reasons,All,Children and Youth (0-17 years),2.0,17.0,Primary Estimate,,1058,0.392,0.323,0.456,True,True,,,True,Convenience,2019-nCoV IgG Rapid Test,Innovita Biological Technology Co. Ltd,LFIA,Whole Blood,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.845,0.99,['High'],,No,Yes,Yes,,Unclear,Yes,Yes,,Amina Ahmed,"Levine Children’s Hospital, Atrium",Not Unity-Aligned,https://dx.doi.org/10.1017/S0950268823000481,2023-05-03,2023-05-04,Unverified,ahmedCharacterisationInfectioninducedSARSCoV22023,USA
230419_Torrance_UniversityofCaliforniaLosAngeles_Baseline,230419_Torrance_UniversityofCaliforniaLosAngeles_Baseline,Longitudinal analysis of SARS-CoV-2 infection and vaccination in the LA-SPARTA cohort reveals increased risk of infection in vaccinated Hispanic participants,2023-04-19,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,,Torrance,"We prospectively enrolled 200 participants with a high risk of SARS-CoV-2 occupational exposure, irrespective of history of SARS-CoV-2 vaccination or natural infection. Participants were enrolled on the campuses of Harbor-UCLA Medical Center and The Lundquist Institute for Biomedical Innovation at Harbor- UCLA in Torrance, CA, between December 2021 and April 2021.",,2021-12-01,2021-12-01,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,200,0.235,,,True,,,,True,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Meagan Jenkins,University of California Los Angeles,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2023.1139915,2023-06-02,2023-06-03,Unverified,jenkins_longitudinal_2023,USA
230419_Torrance_UniversityofCaliforniaLosAngeles_Prospective,230419_Torrance_UniversityofCaliforniaLosAngeles_Prospective,Longitudinal analysis of SARS-CoV-2 infection and vaccination in the LA-SPARTA cohort reveals increased risk of infection in vaccinated Hispanic participants,2023-04-19,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,,Torrance,"We prospectively enrolled 200 participants with a high risk of SARS-CoV-2 occupational exposure, irrespective of history of SARS-CoV-2 vaccination or natural infection. Participants were enrolled on the campuses of Harbor-UCLA Medical Center and The Lundquist Institute for Biomedical Innovation at Harbor- UCLA in Torrance, CA, between December 2021 and April 2021.",,2021-12-01,2022-04-15,Health care workers and caregivers,All,Multiple groups,,,Primary Estimate,,200,0.33,,,True,,,,True,Convenience,Author designed (ELISA) - Nucleocapsid,,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Meagan Jenkins,University of California Los Angeles,Not Unity-Aligned,https://dx.doi.org/10.3389/fimmu.2023.1139915,2023-06-02,2023-06-03,Unverified,jenkins_longitudinal_2023,USA
230430_Texas_UniversityofTexasHealthScienceCenter_Overall,230430_Texas_UniversityofTexasHealthScienceCenter,SARS-CoV-2 Serostatus and COVID-19 Illness Characteristics by Variant Time Period in Non-Hospitalized Children and Adolescents,2023-04-30,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Texas,,volunteer sample from the general population that includes participants ages 5 to 90 years.,,2020-10-15,2022-11-15,Household and community samples,All,Children and Youth (0-17 years),5.0,19.0,Primary Estimate,,3911,0.572,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Sarah Messiah ,University of Texas Health Science Center,Unity-Aligned,https://dx.doi.org/10.3390/children10050818,2023-06-30,2024-03-01,Unverified,messiah_sars-cov-2_2023,USA
230430_Texas_UniversityofTexasHealthScienceCenter_Time1,230430_Texas_UniversityofTexasHealthScienceCenter,SARS-CoV-2 Serostatus and COVID-19 Illness Characteristics by Variant Time Period in Non-Hospitalized Children and Adolescents,2023-04-30,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Texas,,volunteer sample from the general population that includes participants ages 5 to 90 years.,,2020-10-15,2021-01-05,Household and community samples,All,Children and Youth (0-17 years),5.0,19.0,Time frame,Oct 2020 - 5 Jan 2021,1196,0.264,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Sarah Messiah ,University of Texas Health Science Center,Unity-Aligned,https://dx.doi.org/10.3390/children10050818,2023-06-30,2024-03-01,Unverified,messiah_sars-cov-2_2023,USA
230430_Texas_UniversityofTexasHealthScienceCenter_Time4,230430_Texas_UniversityofTexasHealthScienceCenter,SARS-CoV-2 Serostatus and COVID-19 Illness Characteristics by Variant Time Period in Non-Hospitalized Children and Adolescents,2023-04-30,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Texas,,volunteer sample from the general population that includes participants ages 5 to 90 years.,,2022-03-26,2022-11-15,Household and community samples,All,Children and Youth (0-17 years),5.0,19.0,Time frame,26 March 2022 - November 2022,1195,0.0772,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Sarah Messiah ,University of Texas Health Science Center,Unity-Aligned,https://dx.doi.org/10.3390/children10050818,2023-06-30,2024-03-01,Unverified,messiah_sars-cov-2_2023,USA
230430_Texas_UniversityofTexasHealthScienceCenter_Time2,230430_Texas_UniversityofTexasHealthScienceCenter,SARS-CoV-2 Serostatus and COVID-19 Illness Characteristics by Variant Time Period in Non-Hospitalized Children and Adolescents,2023-04-30,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Texas,,volunteer sample from the general population that includes participants ages 5 to 90 years.,,2021-07-01,2021-11-30,Household and community samples,All,Children and Youth (0-17 years),5.0,19.0,Time frame,1 July 2021 to 30 November 2021,2916,0.0994,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Sarah Messiah ,University of Texas Health Science Center,Unity-Aligned,https://dx.doi.org/10.3390/children10050818,2023-06-30,2024-03-01,Unverified,messiah_sars-cov-2_2023,USA
230430_Texas_UniversityofTexasHealthScienceCenter_Time3,230430_Texas_UniversityofTexasHealthScienceCenter,SARS-CoV-2 Serostatus and COVID-19 Illness Characteristics by Variant Time Period in Non-Hospitalized Children and Adolescents,2023-04-30,Journal Article (Peer-Reviewed),Regional,Prospective cohort,United States of America,Texas,,volunteer sample from the general population that includes participants ages 5 to 90 years.,,2021-12-25,2021-03-19,Household and community samples,All,Children and Youth (0-17 years),5.0,19.0,Time frame,25 December 2021 to 19 March 2022,1270,0.1895,,,,,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,,Nucleocapsid(N-protein),Validated by manufacturers,0.995,0.998,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Sarah Messiah ,University of Texas Health Science Center,Unity-Aligned,https://dx.doi.org/10.3390/children10050818,2023-06-30,2024-03-01,Unverified,messiah_sars-cov-2_2023,USA
230510_USA_AmericanRedCross_AntiS_Overall,230510_USA_AmericanRedCross,"Trajectory and Demographic Correlates of Antibodies to SARS-CoV-2 Nucleocapsid in Recently Infected Blood Donors, United States",2023-05-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"During June 2020‒June 2021, the American Red Cross tested >5.2 million blood donations from 2.4 million blood donors [across the United States]. ",,2020-06-15,2021-06-15,Blood donors,All,Multiple groups,,,Primary Estimate,,2448127,0.4464,,,True,,,,True,Sequential,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Ortho Clinical Diagnostics Inc.,CLIA,Serum,TotalAntibody,Spike,,,,['Moderate'],Yes,No,Yes,No,No,Yes,Yes,Yes,,James Haynes,American Red Cross,Unity-Aligned,https://dx.doi.org/10.3201/eid2907.230173,2023-05-31,2024-03-01,Unverified,haynes_trajectory_2023,USA
230510_USA_AmericanRedCross_AntiSandAntiN,230510_USA_AmericanRedCross,"Trajectory and Demographic Correlates of Antibodies to SARS-CoV-2 Nucleocapsid in Recently Infected Blood Donors, United States",2023-05-10,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"During June 2020‒June 2021, the American Red Cross tested >5.2 million blood donations from 2.4 million blood donors [across the United States]. ",,2020-06-15,2021-06-15,Blood donors,All,Multiple groups,,,Test used,,2448127,0.1313,,,,,,,,Sequential,"VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Elecsys® Anti‐SARS‐CoV‐2 (N)","Ortho Clinical Diagnostics Inc.,Roche Diagnostics","CLIA,CLIA, CMIA",Serum,TotalAntibody,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],Yes,No,Yes,No,No,Yes,Yes,Yes,,James Haynes,American Red Cross,Unity-Aligned,https://dx.doi.org/10.3201/eid2907.230173,2023-05-31,2024-03-01,Unverified,haynes_trajectory_2023,USA
230512_Seattle_SeattleChildrensResearchInstitute_3rdRound_6m,230512_Seattle_SeattleChildrensResearchInstitute_3rdRound_6m,Paediatric healthcare and hospital worker SARS-CoV-2 IgG antibody: A longitudinal cohort study.,2023-05-12,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Washington,Seattle,Staff members were eligible to participate if they were aged ≥ 18 years and worked in a clinical setting. Only staff members with direct patient contact were eligible to participate. Eligibility details have been described previously [11].,,2020-10-31,2020-12-11,Health care workers and caregivers,All,Adults (18-64 years),19.0,67.0,Primary Estimate,,429,0.014,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Kaitlin Cappetto,Seattle Children’s Research Institute,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijregi.2023.05.001,2023-06-27,2024-03-01,Unverified,cappetto_paediatric_2023,USA
230512_Seattle_SeattleChildrensResearchInstitute_4thRound_12m_AntiS_Primary,230512_Seattle_SeattleChildrensResearchInstitute_4thRound_12m,Paediatric healthcare and hospital worker SARS-CoV-2 IgG antibody: A longitudinal cohort study.,2023-05-12,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Washington,Seattle,Staff members were eligible to participate if they were aged ≥ 18 years and worked in a clinical setting. Only staff members with direct patient contact were eligible to participate. Eligibility details have been described previously [11].,,2021-05-03,2021-06-15,Health care workers and caregivers,All,Adults (18-64 years),19.0,67.0,Primary Estimate,,383,0.9791,,,True,,,,True,Convenience,AdviseDX SARS-CoV-2 anti-IgG II assay,Abbott Laboratories,CLIA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.956,1.0,['High'],,No,No,Yes,,Yes,Yes,Yes,,Kaitlin Cappetto,Seattle Children’s Research Institute,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijregi.2023.05.001,2023-06-27,2024-03-01,Unverified,cappetto_paediatric_2023,USA
230516_OrangeCounty_UniversityOfSouthernCalifornia,230516_OrangeCounty_UniversityOfSouthernCalifornia,Risk factors for SARS-CoV-2 seropositivity in a health care worker population during the early pandemic.,2023-05-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,Orange County,"From an eligible population of 5,349 HCWs",,2020-05-15,2020-06-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,1557,0.108,,,True,,,,True,Stratified non-probability,Author designed (ELISA) -Spike,,ELISA,Serum,"['IgG', 'IgM']",,,0.93,0.98,['Moderate'],,No,Yes,No,,Unclear,Yes,Yes,,Sebastian D. Schubl,University of Southern California,Not Unity-Aligned,https://dx.doi.org/10.1186/s12879-023-08284-y,2023-06-02,2023-06-03,Unverified,schubl_risk_2023,USA
230524_UnitedStatesofAmerica_RigattiRiskAnalytics,230524_UnitedStatesofAmerica_RigattiRiskAnalytics,Prevalence of Antibodies to COVID-19 Due to Infection or Vaccination in US Adults.,2023-05-24,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,United States of America,,,"""insurance applicants for routine risk assessment were collected.""",,2022-04-25,2022-04-26,Household and community samples,All,Adults (18-64 years),,,Primary Estimate,,2584,0.973,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,[],"['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,Unclear,Yes,No,,Unclear,Yes,No,,Robert Stout,Rigatti Risk Analytics,Not Unity-Aligned,https://dx.doi.org/10.17849/insm-50-01-02.1,2023-06-29,2023-07-04,Unverified,stout_prevalence_2023,USA
230531_LosAngeles_UniversityOfSouthernCalifornia_Adults_PopAdj,230531_LosAngeles_UniversityOfSouthernCalifornia_Adults,Cross-sectional study examining household factors associated with SARS-CoV-2 seropositivity in low-income children in Los Angeles,2023-05-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,Los Angeles,"A random sample of households who had received healthcare at AltaMed Medical Group was invited to participate. Households with at least one adult and one paediatric participant between 5 and 17 years of age were eligible to participate.

Participants were selected from a simple random sampling of households with individuals who received healthcare at 1 of the 12 clinics operated by AltaMed Medical Group (one of the largest safety net providers in Los Angeles).

The majority of the sample was ... Hispanic (98.62%) and had a high school education or less (83.77%).",,2021-02-01,2021-05-23,Residual sera,All,Multiple groups,18.0,89.0,Primary Estimate,Pop-adjusted using the fixed and random effect.,390,0.6358,0.6039,0.6524,True,,True,,True,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,Architect Anti-SARS-CoV-2 IgM",Abbott Laboratories,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),,,,['High'],,Yes,No,Yes,,No,Yes,No,,Jason Doctor,University of Southern California,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2022-070291 ,2023-06-28,2024-03-01,Unverified,doctor_cross-sectional_2023,USA
230531_LosAngeles_UniversityOfSouthernCalifornia_Children_PopAdj,230531_LosAngeles_UniversityOfSouthernCalifornia_Children,Cross-sectional study examining household factors associated with SARS-CoV-2 seropositivity in low-income children in Los Angeles,2023-05-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,California,Los Angeles,"A random sample of households who had received healthcare at AltaMed Medical Group was invited to participate. Households with at least one adult and one paediatric participant between 5 and 17 years of age were eligible to participate.

Participants were selected from a simple random sampling of households with individuals who received healthcare at 1 of the 12 clinics operated by AltaMed Medical Group (one of the largest safety net providers in Los Angeles).

The majority of the sample was ... Hispanic (98.62%) and had a high school education or less (83.77%).",,2021-02-01,2021-05-23,Residual sera,All,Children and Youth (0-17 years),5.0,17.0,Primary Estimate,Pop-adjusted using the fixed and random effect.,332,0.5211,0.4961,0.5519,True,,True,,True,Simplified probability,"Abbott Architect SARS-CoV-2 IgG,Architect Anti-SARS-CoV-2 IgM",Abbott Laboratories,CLIA,Serum,"['IgG', 'IgM']",Nucleocapsid(N-protein),,,,['High'],,Yes,No,Yes,,No,Yes,No,,Jason Doctor,University of Southern California,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2022-070291 ,2023-06-28,2024-03-01,Unverified,doctor_cross-sectional_2023,USA
230608_HowardCounty_JohnsHopkinsUniversity,230608_HowardCounty_JohnsHopkinsUniversity,"A Saliva-Based Serological and Behavioral Analysis of SARS-CoV-2 Antibody Prevalence in Howard County, Maryland",2023-06-08,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Maryland,,"A cross-sectional, salivabased serological study of 2,880 residents of Howard County, Maryland, was carried out from July through September 2021.

There was no age limitation for study participation.","Fig 4:
- Exclude samples with incomplete data
- Exclude samples without a verifiable Howard County address
- Exclude samples with insufficient titer
- Exclude samples without household survey data from behavioral analysis

Samples with IgG signals below the threshold with insufficient total IgG were considered indeterminate and excluded from analyses (to improve sensitivity).",2021-07-04,2021-09-19,Household and community samples,All,Multiple groups,0.0,,Primary Estimate,Weighted by sample proportions of various demographics,2293,0.119,0.092,0.151,True,,True,,True,Stratified non-probability,Author designed (Multiplex),,Other,Saliva,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Validated by independent authors/third party/non-developers,0.988,1.0,['Moderate'],Yes,No,Yes,Yes,No,Unclear,Yes,Yes,,Alan Brown,Johns Hopkins University,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.02765-22,2023-06-28,2024-04-30,Verified,brown_saliva-based_2023,USA
230608_Fayetteville_UniversityofArkansas_Dec20_Overall,230608_Fayetteville_UniversityofArkansas_Dec20,A longitudinal study of SARS-CoV-2 antibody seroprevalence and mitigation behaviors among college students at an Arkansas University,2023-06-08,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Arkansas,Fayettville, Inclusion criteria were 18 to 24 years of age and registered as an undergraduate for on-campus classes.,"Exclusion criteria were self-report of an immune compromising condition, cancer chemotherapy in the past two months, intravenous immunoglobulin treatment, or steroid treatment in the past 30 days.",2020-12-01,2020-12-31,Students and Daycares,All,Adults (18-64 years),18.0,24.0,Primary Estimate,,275,0.13,0.09,0.18,True,,,,True,Convenience,"Access SARS-CoV-2 IgG Reagent Antibody Test,Author designed (ELISA) -Spike","Beckman Coulter,NA",ELISA,Serum,IgG,Spike,Validated by manufacturers,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Jaimi Allen,University of Arkansas,Not Unity-Aligned,https://dx.doi.org/10.1080/07448481.2023.2217456,2023-06-30,2024-03-01,Unverified,allen_longitudinal_2023,USA
230608_Fayetteville_UniversityofArkansas_Mar21_Overall,230608_Fayetteville_UniversityofArkansas_Mar21,A longitudinal study of SARS-CoV-2 antibody seroprevalence and mitigation behaviors among college students at an Arkansas University,2023-06-08,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Arkansas,Fayettville, Inclusion criteria were 18 to 24 years of age and registered as an undergraduate for on-campus classes.,"Exclusion criteria were self-report of an immune compromising condition, cancer chemotherapy in the past two months, intravenous immunoglobulin treatment, or steroid treatment in the past 30 days.",2021-03-01,2021-03-31,Students and Daycares,All,Adults (18-64 years),18.0,24.0,Primary Estimate,,241,0.45,0.39,0.52,True,,,,True,Convenience,"Access SARS-CoV-2 IgG Reagent Antibody Test,Author designed (ELISA) -Spike","Beckman Coulter,NA",ELISA,Serum,IgG,Spike,Validated by manufacturers,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Jaimi Allen,University of Arkansas,Not Unity-Aligned,https://dx.doi.org/10.1080/07448481.2023.2217456,2023-06-30,2024-03-01,Unverified,allen_longitudinal_2023,USA
230608_Fayetteville_UniversityofArkansas_Sept20_Overall,230608_Fayetteville_UniversityofArkansas_Sept20,A longitudinal study of SARS-CoV-2 antibody seroprevalence and mitigation behaviors among college students at an Arkansas University,2023-06-08,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,Arkansas,Fayettville, Inclusion criteria were 18 to 24 years of age and registered as an undergraduate for on-campus classes.,"Exclusion criteria were self-report of an immune compromising condition, cancer chemotherapy in the past two months, intravenous immunoglobulin treatment, or steroid treatment in the past 30 days.",2020-09-01,2020-09-30,Students and Daycares,All,Adults (18-64 years),18.0,24.0,Primary Estimate,,344,0.18,0.14,0.23,True,,,,True,Convenience,"Access SARS-CoV-2 IgG Reagent Antibody Test,Author designed (ELISA) -Spike","Beckman Coulter,NA",ELISA,Serum,IgG,Spike,Validated by manufacturers,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Jaimi Allen,University of Arkansas,Not Unity-Aligned,https://dx.doi.org/10.1080/07448481.2023.2217456,2023-06-30,2024-03-01,Unverified,allen_longitudinal_2023,USA
230615_Minnesota_UniversityofMinnesota_Overall,230615_Minnesota_UniversityofMinnesota,"Demographic, social, and behavioral correlates of SARS-CoV-2 seropositivity in a representative, population-based study of Minnesota residents.",2023-06-15,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Minnesota,,Minnesota residents who participated in COVID-19 household impact survey.,,2020-12-29,2021-02-26,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,537,0.095,,,True,,,,True,Convenience,Q-Plex SARS-CoV-2 Human IgG (4-Plex),Quansys Biosciences,CLIA,Whole Blood,IgG,,,,,['High'],Yes,No,No,Yes,Yes,Yes,Yes,Yes,Yes,Jordan Abhold,University of Minnesota,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0279660,2023-06-28,2024-04-25,Verified,abhold_demographic_2023,USA
230615_Minnesota_UniversityofMinnesota_Age_23-64,230615_Minnesota_UniversityofMinnesota,"Demographic, social, and behavioral correlates of SARS-CoV-2 seropositivity in a representative, population-based study of Minnesota residents.",2023-06-15,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Minnesota,,Minnesota residents who participated in COVID-19 household impact survey.,,2020-12-29,2021-02-26,Household and community samples,All,Adults (18-64 years),23.0,64.0,Age,23-64 years,97,0.0928,,,,,,,,Convenience,Q-Plex SARS-CoV-2 Human IgG (4-Plex),Quansys Biosciences,CLIA,Whole Blood,IgG,,,,,['High'],Yes,No,No,Yes,Yes,Yes,Yes,Yes,Yes,Jordan Abhold,University of Minnesota,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0279660,2024-04-25,2024-04-25,Verified,abhold_demographic_2023,USA
230615_Minnesota_UniversityofMinnesota_Age_65+,230615_Minnesota_UniversityofMinnesota,"Demographic, social, and behavioral correlates of SARS-CoV-2 seropositivity in a representative, population-based study of Minnesota residents.",2023-06-15,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Minnesota,,Minnesota residents who participated in COVID-19 household impact survey.,,2020-12-29,2021-02-26,Household and community samples,All,Seniors (65+ years),65.0,,Age,65+ years,54,0.1481,,,,,,,,Convenience,Q-Plex SARS-CoV-2 Human IgG (4-Plex),Quansys Biosciences,CLIA,Whole Blood,IgG,,,,,['High'],Yes,No,No,Yes,Yes,Yes,Yes,Yes,Yes,Jordan Abhold,University of Minnesota,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0279660,2024-04-25,2024-04-25,Verified,abhold_demographic_2023,USA
230615_Minnesota_UniversityofMinnesota_Age_18-22,230615_Minnesota_UniversityofMinnesota,"Demographic, social, and behavioral correlates of SARS-CoV-2 seropositivity in a representative, population-based study of Minnesota residents.",2023-06-15,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Minnesota,,Minnesota residents who participated in COVID-19 household impact survey.,,2020-12-29,2021-02-26,Household and community samples,All,Adults (18-64 years),18.0,22.0,Age,18-22 years,386,0.0881,,,,,,,,Convenience,Q-Plex SARS-CoV-2 Human IgG (4-Plex),Quansys Biosciences,CLIA,Whole Blood,IgG,,,,,['High'],Yes,No,No,Yes,Yes,Yes,Yes,Yes,Yes,Jordan Abhold,University of Minnesota,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0279660,2024-04-25,2024-04-25,Verified,abhold_demographic_2023,USA
230624_UnitedStates_MountSinai,230624_UnitedStates_MountSinai,Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium,2023-06-24,Journal Article (Peer-Reviewed),National,Prospective cohort,United States of America,,,"Our initial core objective was to include all adult patients with IBD who entered the infusion center for vedolizumab or infliximab (originator or biosimilars), as well as intravenous ustekinumab induction, regardless of history of known COVID-19 infection, and without any exclusion criteria.",None,2020-05-15,2021-12-15,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,235,0.0894,,,True,,,,True,Convenience,Atellica® IM SARS-CoV-2 Total (COV2T),Siemens,CLIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,No,No,No,,Yes,Yes,Yes,,Serre-Yu Wong,Mount Sinai,Not Unity-Aligned,https://dx.doi.org/10.1093/ibd/izad097,2023-08-02,2024-03-01,Unverified,wong_geography_2023,USA
230626_Arizona_ArizonaStateUniversity,230626_Arizona_ArizonaStateUniversity,Serological survey to estimate SARS-CoV-2 infection and antibody seroprevalence at a large public university: A cross-sectional study.,2023-06-26,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Arizona,,18+,,2021-09-13,2021-09-17,Students and Daycares,All,Multiple groups,18.0,65.0,Primary Estimate,anti-RBD by LFIA,1063,0.897,,,True,,,,True,Stratified probability,Sienna-Clarity COVIBLOCK COVID-19 IgG/IgM Rapid Test Cassette,Salofa Oy,LFIA,Serum,IgG,Spike,,,,['High'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Ching-Wen Hou,Arizona State University,Not Unity-Aligned,https://dx.doi.org/10.1136/bmjopen-2023-072627,2023-03-09,2024-03-01,Unverified,hou_serological_2023,USA
230712_Oregon_OregonHealthAuthority_Point1,230712_Oregon_OregonHealthAuthority,"Pediatric SARS-CoV-2 Seroprevalence, Oregon, USA, November 1, 2020-June 30, 2022",2023-07-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Oregon,,"""We recruited Oregon healthcare facilities with >6 inpatient pediatric hospital beds to participate in this study and asked them to provide
<100 specimens per phase; 5 facilities agreed to participate. We asked facilities to submit random samples of deidentified residual serum samples from patients <17 years of age visiting any ambulatory, emergency, or inpatient healthcare setting and to include specimen collection date and patient’s date of birth."" ",,2020-11-01,2020-12-31,Residual sera,All,Children and Youth (0-17 years),,17.0,Time frame,"Nov 1, 2020 - Dec 31, 2020",438,0.033,0.002,0.052,True,,True,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,"CLIA, CMIA",Serum,IgG,Nucleocapsid (N-protein),,1.0,0.996,['Moderate'],Yes,No,No,No,Yes,Yes,Yes,Yes,,Rebecca A. Falender,Oregon Health Authority,Unity-Aligned,https://dx.doi.org/10.3201/eid2908.230471,2023-08-24,2024-03-01,Unverified,falender_pediatric_2023,USA
230712_Oregon_OregonHealthAuthority_Point3,230712_Oregon_OregonHealthAuthority,"Pediatric SARS-CoV-2 Seroprevalence, Oregon, USA, November 1, 2020-June 30, 2022",2023-07-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Oregon,,"""We recruited Oregon healthcare facilities with >6 inpatient pediatric hospital beds to participate in this study and asked them to provide
<100 specimens per phase; 5 facilities agreed to participate. We asked facilities to submit random samples of deidentified residual serum samples from patients <17 years of age visiting any ambulatory, emergency, or inpatient healthcare setting and to include specimen collection date and patient’s date of birth."" ",,2021-12-01,2021-12-31,Residual sera,All,Children and Youth (0-17 years),,17.0,Time frame,"Dec 1, 2021 - Dec 31, 2022",278,0.134,0.098,0.184,True,,True,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,"CLIA, CMIA",Serum,IgG,Nucleocapsid (N-protein),,1.0,0.996,['Moderate'],Yes,No,No,No,Yes,Yes,Yes,Yes,,Rebecca A. Falender,Oregon Health Authority,Unity-Aligned,https://dx.doi.org/10.3201/eid2908.230471,2023-08-24,2024-03-01,Unverified,falender_pediatric_2023,USA
230712_Oregon_OregonHealthAuthority_Point2,230712_Oregon_OregonHealthAuthority,"Pediatric SARS-CoV-2 Seroprevalence, Oregon, USA, November 1, 2020-June 30, 2022",2023-07-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Oregon,,"""We recruited Oregon healthcare facilities with >6 inpatient pediatric hospital beds to participate in this study and asked them to provide
<100 specimens per phase; 5 facilities agreed to participate. We asked facilities to submit random samples of deidentified residual serum samples from patients <17 years of age visiting any ambulatory, emergency, or inpatient healthcare setting and to include specimen collection date and patient’s date of birth."" ",,2021-10-01,2021-10-31,Residual sera,All,Children and Youth (0-17 years),,17.0,Time frame,"Oct 1, 2021 - Oct 31, 2021",370,0.118,0.09,0.161,True,,True,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,"CLIA, CMIA",Serum,IgG,Nucleocapsid (N-protein),,1.0,0.996,['Moderate'],Yes,No,No,No,Yes,Yes,Yes,Yes,,Rebecca A. Falender,Oregon Health Authority,Unity-Aligned,https://dx.doi.org/10.3201/eid2908.230471,2023-08-24,2024-03-01,Unverified,falender_pediatric_2023,USA
230712_Oregon_OregonHealthAuthority_Point5,230712_Oregon_OregonHealthAuthority,"Pediatric SARS-CoV-2 Seroprevalence, Oregon, USA, November 1, 2020-June 30, 2022",2023-07-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Oregon,,"""We recruited Oregon healthcare facilities with >6 inpatient pediatric hospital beds to participate in this study and asked them to provide
<100 specimens per phase; 5 facilities agreed to participate. We asked facilities to submit random samples of deidentified residual serum samples from patients <17 years of age visiting any ambulatory, emergency, or inpatient healthcare setting and to include specimen collection date and patient’s date of birth."" ",,2022-04-01,2022-04-30,Residual sera,All,Children and Youth (0-17 years),,17.0,Time frame,"April 1, 2022 - April 30, 2022",279,0.269,0.222,0.333,True,,True,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,"CLIA, CMIA",Serum,IgG,Nucleocapsid (N-protein),,1.0,0.996,['Moderate'],Yes,No,No,No,Yes,Yes,Yes,Yes,,Rebecca A. Falender,Oregon Health Authority,Unity-Aligned,https://dx.doi.org/10.3201/eid2908.230471,2023-08-24,2024-03-01,Unverified,falender_pediatric_2023,USA
230712_Oregon_OregonHealthAuthority_Point4,230712_Oregon_OregonHealthAuthority,"Pediatric SARS-CoV-2 Seroprevalence, Oregon, USA, November 1, 2020-June 30, 2022",2023-07-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Oregon,,"""We recruited Oregon healthcare facilities with >6 inpatient pediatric hospital beds to participate in this study and asked them to provide
<100 specimens per phase; 5 facilities agreed to participate. We asked facilities to submit random samples of deidentified residual serum samples from patients <17 years of age visiting any ambulatory, emergency, or inpatient healthcare setting and to include specimen collection date and patient’s date of birth."" ",,2022-02-01,2022-02-28,Residual sera,All,Children and Youth (0-17 years),,17.0,Time frame,"Feb 1, 2022 - Feb 28, 2022",215,0.388,0.328,0.465,True,,True,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,"CLIA, CMIA",Serum,IgG,Nucleocapsid (N-protein),,1.0,0.996,['Moderate'],Yes,No,No,No,Yes,Yes,Yes,Yes,,Rebecca A. Falender,Oregon Health Authority,Unity-Aligned,https://dx.doi.org/10.3201/eid2908.230471,2023-08-24,2024-03-01,Unverified,falender_pediatric_2023,USA
230712_Oregon_OregonHealthAuthority_Point6,230712_Oregon_OregonHealthAuthority,"Pediatric SARS-CoV-2 Seroprevalence, Oregon, USA, November 1, 2020-June 30, 2022",2023-07-12,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,Oregon,,"""We recruited Oregon healthcare facilities with >6 inpatient pediatric hospital beds to participate in this study and asked them to provide
<100 specimens per phase; 5 facilities agreed to participate. We asked facilities to submit random samples of deidentified residual serum samples from patients <17 years of age visiting any ambulatory, emergency, or inpatient healthcare setting and to include specimen collection date and patient’s date of birth."" ",,2022-06-01,2022-06-30,Residual sera,All,Children and Youth (0-17 years),,17.0,Primary Estimate,,289,0.298,0.25,0.362,True,,True,,True,Sequential,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,"CLIA, CMIA",Serum,IgG,Nucleocapsid (N-protein),,1.0,0.996,['Moderate'],Yes,No,No,No,Yes,Yes,Yes,Yes,,Rebecca A. Falender,Oregon Health Authority,Unity-Aligned,https://dx.doi.org/10.3201/eid2908.230471,2023-08-24,2024-03-01,Unverified,falender_pediatric_2023,USA
230717_Utah_UniversityOfUtah_AntiS_Primary,230717_Utah_UniversityOfUtah,Sex difference in the discordance between Abbott Architect and EuroImmun serological assays,2023-07-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Utah,,"As a part of HERO, a sample of Utah residents took part.

From https://eccles-wpmedia.s3.us-west-2.amazonaws.com/utah-hero/wp-content/uploads/2021/03/HERO-Report-11_24-edition.pdf:

Residents age 12 or older were then referred for blood and/or nasal swab testing.",,2020-06-10,2020-08-15,Household and community samples,All,Multiple groups,12.0,,Primary Estimate,Anti-S via the EUROIMMUN test,8166,0.0302,,,True,,,,True,Stratified non-probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['Moderate'],Unclear,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Joel Hartsell,University of Utah,Unity-Aligned,https://dx.doi.org/10.7717/peerj.15247,2023-08-21,2024-04-25,Verified,hartsell_sex_2023,USA
230717_Utah_UniversityOfUtah_AntiN,230717_Utah_UniversityOfUtah,Sex difference in the discordance between Abbott Architect and EuroImmun serological assays,2023-07-17,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,United States of America,Utah,,"As a part of HERO, a sample of Utah residents took part.

From https://eccles-wpmedia.s3.us-west-2.amazonaws.com/utah-hero/wp-content/uploads/2021/03/HERO-Report-11_24-edition.pdf:

Residents age 12 or older were then referred for blood and/or nasal swab testing.",,2020-06-10,2020-08-15,Household and community samples,All,Multiple groups,12.0,,Test used,Anti-N via the Abbott test,8166,0.0138,,,,,,,,Stratified non-probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),,,,['Moderate'],Unclear,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Joel Hartsell,University of Utah,Unity-Aligned,https://dx.doi.org/10.7717/peerj.15247,2023-08-21,2024-04-25,Verified,hartsell_sex_2023,USA
230723_Colorado_DenverHealthandHospitalAuthority_Overall,230723_Colorado_DenverHealthandHospitalAuthority,Prevalence of SARS-CoV-2 Antibodies Among Healthy Children From Colorado From 2020 to 2021: A Brief Report.,2023-07-23,Journal Article (Peer-Reviewed),Regional,Retrospective cohort,United States of America,Colorado,,4717 general population Colorado children aged 1 to 17-years-old participating in the Autoimmunity Screening for Kids (ASK) type 1 diabetes screening study,"children were not recruited based on history of COVID-19 disease or vaccination status. Ill children, including those with SARS-CoV-2 infection in the prior 2 weeks, were not enrolled to protect study personnel",2020-07-15,2021-12-15,Blood donors,All,Children and Youth (0-17 years),1.0,17.0,Primary Estimate,,4717,0.322,,,True,,,,True,Entire sample,Not reported/ Unable to specify,,CLIA,,,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,No,,Holly Frost,Denver Health and Hospital Authority,Not Unity-Aligned,https://dx.doi.org/10.1177/21501319231189147,2023-08-22,2023-08-23,Unverified,frost_prevalence_2023,USA
230802_California_CaliforniaDepartmentofPublicHealth_Overall,230802_California_CaliforniaDepartmentofPublicHealth,Shadow of a Pandemic: Persistence of Prenatal SARS-CoV-2 Antibodies in Newborn Blood Spots.,2023-08-02,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,California,,"From 12 through 72 h after birth, a neonate’s blood is collected on DBS filter paper, dried, and shipped for laboratory testing.",parents or guardians decline screening or opt out of specimen storage,2020-10-01,2021-03-31,Residual sera,All,Children and Youth (0-17 years),0.0,0.0,Primary Estimate,,2890,0.157,0.143,0.17,True,,,,True,Stratified probability,Author designed (type unknown),,,Multiple Types,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,,,['Moderate'],Yes,Yes,Yes,No,Yes,Unclear,Yes,No,Yes,,California Department of Public Health,Not Unity-Aligned,https://dx.doi.org/10.3390/ijns9030043,2023-09-20,2023-09-21,Unverified,sciortino_shadow_2023,USA
230802_California_CaliforniaDepartmentofPublicHealth_Oct2020,230802_California_CaliforniaDepartmentofPublicHealth,Shadow of a Pandemic: Persistence of Prenatal SARS-CoV-2 Antibodies in Newborn Blood Spots.,2023-08-02,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,California,,"From 12 through 72 h after birth, a neonate’s blood is collected on DBS filter paper, dried, and shipped for laboratory testing.",parents or guardians decline screening or opt out of specimen storage,2020-10-15,2020-10-15,Residual sera,All,Children and Youth (0-17 years),0.0,0.0,Time frame,Oct 2020 one-day snapshot,1238,0.119,0.101,0.137,,,,,True,Simplified probability,Author designed (type unknown),,,Multiple Types,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,,,['Moderate'],Yes,Yes,Yes,No,Yes,Unclear,Yes,No,Yes,,California Department of Public Health,Not Unity-Aligned,https://dx.doi.org/10.3390/ijns9030043,2023-09-20,2023-09-21,Unverified,sciortino_shadow_2023,USA
230802_California_CaliforniaDepartmentofPublicHealth_Mar2021,230802_California_CaliforniaDepartmentofPublicHealth,Shadow of a Pandemic: Persistence of Prenatal SARS-CoV-2 Antibodies in Newborn Blood Spots.,2023-08-02,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,California,,"From 12 through 72 h after birth, a neonate’s blood is collected on DBS filter paper, dried, and shipped for laboratory testing.",parents or guardians decline screening or opt out of specimen storage,2021-03-15,2021-03-15,Residual sera,All,Children and Youth (0-17 years),0.0,0.0,Time frame,Mar 2021 one-day snapshot,496,0.333,0.291,0.374,,,,,True,Simplified probability,Author designed (type unknown),,,Multiple Types,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,,,['Moderate'],Yes,Yes,Yes,No,Yes,Unclear,Yes,No,Yes,,California Department of Public Health,Not Unity-Aligned,https://dx.doi.org/10.3390/ijns9030043,2023-09-20,2023-09-21,Unverified,sciortino_shadow_2023,USA
230802_California_CaliforniaDepartmentofPublicHealth_Dec2020,230802_California_CaliforniaDepartmentofPublicHealth,Shadow of a Pandemic: Persistence of Prenatal SARS-CoV-2 Antibodies in Newborn Blood Spots.,2023-08-02,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,United States of America,California,,"From 12 through 72 h after birth, a neonate’s blood is collected on DBS filter paper, dried, and shipped for laboratory testing.",parents or guardians decline screening or opt out of specimen storage,2020-12-15,2020-12-15,Residual sera,All,Children and Youth (0-17 years),0.0,0.0,Time frame,Dec 2020 one-day snapshot,1156,0.122,0.103,0.141,,,,,True,Simplified probability,Author designed (type unknown),,,Multiple Types,"['IgA', 'IgG', 'IgM']",Spike,Validated by developers,,,['Moderate'],Yes,Yes,Yes,No,Yes,Unclear,Yes,No,Yes,,California Department of Public Health,Not Unity-Aligned,https://dx.doi.org/10.3390/ijns9030043,2023-09-20,2023-09-21,Unverified,sciortino_shadow_2023,USA
230804_Missouri_WashingtonUniversitySchoolofMedicine_baseline,230804_Missouri_WashingtonUniversitySchoolofMedicine_baseline,"Seroprevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) antibodies among healthcare personnel in the Midwestern United States, September 2020-April 2021.",2023-08-04,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Missouri,St. Louis,"""Participants were HCP aged ≥18 years, who were employed at Barnes-Jewish Hospital, St. Louis Children’s Hospital, or Washington University School of Medicine in St. Louis. HCP were eligible to participate in the study if they provided cared for COVID-19 patients. HCP with nondirect patient-care roles who handled specimens with potential SARS- CoV-2 (eg, laboratory personnel) or who worked in a COVID-19 ward or ICU (eg, dining services, pharmacist, dietitian) were also eligible to participate.""","""HCP who were participating in a COVID-19 vaccine trial and those with a history of COVID-19, diagnosed via a positive SARS-CoV-2 PCR, antigen, or serologic antibody test, were excluded.""",2020-09-15,2020-12-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,400,0.045,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.99,1.0,['High'],,No,No,Yes,,Yes,Yes,Yes,,Rachel E. Bosserman,Washington University School of Medicine,Not Unity-Aligned,https://dx.doi.org/10.1017/ash.2022.375,2023-09-22,2024-03-01,Unverified,bossermanSeroprevalenceSevereAcute2023,USA
230804_Missouri_WashingtonUniversitySchoolofMedicine_followup,230804_Missouri_WashingtonUniversitySchoolofMedicine_followup,"Seroprevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) antibodies among healthcare personnel in the Midwestern United States, September 2020-April 2021.",2023-08-04,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,United States of America,Missouri,St. Louis,"""Participants were HCP aged ≥18 years, who were employed at Barnes-Jewish Hospital, St. Louis Children’s Hospital, or Washington University School of Medicine in St. Louis. HCP were eligible to participate in the study if they provided cared for COVID-19 patients. HCP with nondirect patient-care roles who handled specimens with potential SARS- CoV-2 (eg, laboratory personnel) or who worked in a COVID-19 ward or ICU (eg, dining services, pharmacist, dietitian) were also eligible to participate.""","""HCP who were participating in a COVID-19 vaccine trial and those with a history of COVID-19, diagnosed via a positive SARS-CoV-2 PCR, antigen, or serologic antibody test, were excluded.""",2020-12-15,2021-04-15,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,400,0.773,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.99,1.0,['High'],,No,No,No,,Yes,Yes,Yes,,Rachel E. Bosserman,Washington University School of Medicine,Not Unity-Aligned,https://dx.doi.org/10.1017/ash.2022.375,2023-09-22,2024-03-01,Unverified,bossermanSeroprevalenceSevereAcute2023,USA
230819_Aurora_UniversityOfColoradoAnschutzMedicalCampus,230819_Aurora_UniversityOfColoradoAnschutzMedicalCampus,Longitudinal Qualitative and Quantitative Evaluation of SARS-CoV-2 Antibodies in Immunized Health Care Workers,2023-08-19,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Colorado,Aurora,"Health care professionals (n ¼ 72) volunteered serum samples (n ¼ 339) before, during, and after vaccination with either BNT162b2 or mRNA-1273.

Samples were collected –185 6 72.7 days (average 6 SD; range, –272 to –2; n ¼ 43) before vaccination (T0) to determine baseline antibody reactivity.",,2020-12-15,2021-03-15,Health care workers and caregivers,All,Multiple groups,22.0,74.0,Primary Estimate,,43,0.0465,,,True,,,,True,Convenience,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,Ortho Clinical Diagnostics Inc.,CLIA,Serum,IgG,Spike,,,,['High'],,No,No,Yes,,Yes,Yes,Yes,,Ellie Hong,University of Colorado Anschutz Medical Campus,Not Unity-Aligned,https://dx.doi.org/10.5858/arpa.2023-0014-OA,2023-09-25,2024-03-01,Unverified,hong_longitudinal_2023,USA
230824_Seattle_UniversityOfWashington,230824_Seattle_UniversityOfWashington,Severe acute respiratory syndrome coronavirus 2 seroprevalence and longitudinal antibody response following natural infection in pregnancy: A prospective cohort study.,2023-08-24,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Washington,Seattle,"Pregnant people aged ⩾ 18 years seeking antenatal care at 14 affiliated clinics, or admitted to three labor and delivery units, at University of Washington (UW)-affiliated medical centers were eligible for participation in the seroprevalence study (see Supplemental Table 1).","Participants were excluded if they were < 18 years old, not receiving antenatal care at a UW study site, a non-pregnant adult, did not have a blood sample collected during routine antenatal care, or a sample that lacked the blood volume needed to conduct SARS-CoV-2 anti-N IgG testing.",2020-12-09,2021-06-30,Pregnant or parturient women,Female,Adults (18-64 years),18.0,,Primary Estimate,,1284,0.0506,,,True,,,,True,Convenience,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Serum,IgG,Nucleocapsid(N-protein),Validated by manufacturers,1.0,0.999,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Alison Drake,University of Washington,Unity-Aligned,https://dx.doi.org/10.1177/17455057231190955,2023-09-25,2024-04-24,Verified,drake_severe_2023,USA
230829_Arizona_ArizonaStateUniversity,230829_Arizona_ArizonaStateUniversity,Estimating seroprevalence of SARS-CoV-2 infection after a highly contagious Omicron outbreak: A cross sectional study in a university setting,2023-08-29,Preprint,Regional,Prospective cohort,United States of America,Arizona,,"Objective: This study aimed to investigate the seroprevalence of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) antibodies among individuals aged 18 years and older.

Settings: Population-based study was conducted within the Arizona State University (ASU) community.

Participants: The study recruited 1,397 adult participants that volunteered over a period of three days (March 1-March 3 of 2022).",,2022-03-01,2022-03-03,Multiple populations,All,Adults (18-64 years),18.0,,Primary Estimate,Anti-S IgG based on Beckman Coulter test,1397,0.963,,,True,,,,True,Convenience,Access SARS-CoV-2 IgG Reagent Antibody Test,Beckman Coulter,CLIA,Serum,IgG,Spike,,,,['High'],,No,Yes,Yes,,Yes,Yes,Yes,,Ching-Wen Hou,Arizona State University,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2023.08.29.23293775v1,2023-09-22,2024-03-01,Unverified,hou_estimating_2023,USA
230901_Baltimore_JohnsHopkinsUniversity,230901_Baltimore_JohnsHopkinsUniversity,"Prevalence and correlates of SARS-CoV-2 seropositivity among people who inject drugs in Baltimore, Maryland.",2023-09-01,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,United States of America,Maryland,Baltimore,"""Eligible participants were ≥18 years of age and reported a history of injection drug use. """,,2020-12-15,2022-07-15,Residual sera,All,Adults (18-64 years),28.0,77.0,Primary Estimate,,561,0.627,0.586,0.668,True,,,,True,Convenience,V-PLEX SARS-CoV-2 Panel 2 (ACE2) Kit,Meso Scale Diagnostics,Neutralization,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.938,0.995,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Eshan U. Patel,"Johns Hopkins University
",Unity-Aligned,https://dx.doi.org/10.1016/j.dadr.2023.100184,2023-09-22,2024-04-29,Verified,patelPrevalenceCorrelatesSARSCoV22023,USA
231113_NewYork_IcahnSchoolofMedicine_Jan2023,231113_NewYork_IcahnSchoolofMedicine,Longitudinal nucleocapsid antibody testing reveals undocumented SARS-CoV-2 infections in patients with lung cancer,2023-11-13,Journal Article (Peer-Reviewed),Local,Prospective cohort,United States of America,New York,New York City,Lung Cancer patients in New York City,,2023-01-01,2023-01-31,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),32.0,100.0,Primary Estimate,,175,0.68,,,True,,,,True,Convenience,V-PLEX SARS-CoV-2 Panel 2 (ACE2) Kit,Meso Scale Diagnostics,Neutralization,Plasma,IgG,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,No,Yes,No,,Yes,Yes,Yes,,Ananda Rodilla,Icahn School of Medicine at Mount Sinai,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ccell.2023.09.017,2024-03-09,2024-03-09,Unverified,rodilla_longitudinal_2023,USA
231009_Maryland_JohnsHopkinsUniversity_Time2,"231009_Maryland_JohnsHopkinsUniversity_TimePeriod1, 231009_Maryland_JohnsHopkinsUniversity_TimePeriod2, 231009_Maryland_JohnsHopkinsUniversity_TimePeriod3, 231009_Maryland_JohnsHopkinsUniversity_TimePeriod4, 231009_Maryland_JohnsHopkinsUniversity_TimePeriod5",Hundred-fold increase in SARS-CoV-2 spike antibody levels over three years in a hospital clinical laboratory,2023-10-09,Journal Article (Peer-Reviewed),Regional,Retrospective cohort,"United States of America,United States of America,United States of America,United States of America,United States of America",Maryland,,"Over a 3-year period (April 2020–February 2023), we performed a retrospective analysis of spike IgG antibodies measured by a tertiary hospital clinical immunology laboratory using the Euroimmun SARS-CoV-2 IgG ELISA. The 3-year interval was classified into five periods based on the SARS-CoV-2 strain variant epidemiology. A total of 15,820 sera, derived from 11,022 individuals (6,362 females and 4,660 males) ranging from severe immunocompromised state to routine health visits, were tested",,2021-01-15,2021-06-15,Residual sera,All,Multiple groups,,,Primary Estimate,,3039,0.5331,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,"[{'error': '#ERROR!'}, {'error': '#ERROR!'}, {'error': '#ERROR!'}, {'error': '#ERROR!'}, {'error': '#ERROR!'}]",No,No,{'error': '#ERROR!'},Yes,No,{'error': '#ERROR!'},Yes,{'error': '#ERROR!'},Unclear,Patrizio Caturegli,Johns Hopkins University,{'error': '#ERROR!'},https://dx.doi.org/10.1128/spectrum.02183-23,2024-03-08,2024-05-01,Unverified,caturegli_hundred-fold_2023,USA
231009_Maryland_JohnsHopkinsUniversity_Time4,"231009_Maryland_JohnsHopkinsUniversity_TimePeriod1, 231009_Maryland_JohnsHopkinsUniversity_TimePeriod2, 231009_Maryland_JohnsHopkinsUniversity_TimePeriod3, 231009_Maryland_JohnsHopkinsUniversity_TimePeriod4, 231009_Maryland_JohnsHopkinsUniversity_TimePeriod5",Hundred-fold increase in SARS-CoV-2 spike antibody levels over three years in a hospital clinical laboratory,2023-10-09,Journal Article (Peer-Reviewed),Regional,Retrospective cohort,"United States of America,United States of America,United States of America,United States of America,United States of America",Maryland,,"Over a 3-year period (April 2020–February 2023), we performed a retrospective analysis of spike IgG antibodies measured by a tertiary hospital clinical immunology laboratory using the Euroimmun SARS-CoV-2 IgG ELISA. The 3-year interval was classified into five periods based on the SARS-CoV-2 strain variant epidemiology. A total of 15,820 sera, derived from 11,022 individuals (6,362 females and 4,660 males) ranging from severe immunocompromised state to routine health visits, were tested",,2021-12-15,2022-06-15,Residual sera,All,Multiple groups,,,Primary Estimate,,3526,0.8729,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,"[{'error': '#ERROR!'}, {'error': '#ERROR!'}, {'error': '#ERROR!'}, {'error': '#ERROR!'}, {'error': '#ERROR!'}]",No,No,{'error': '#ERROR!'},Yes,No,{'error': '#ERROR!'},Yes,{'error': '#ERROR!'},Unclear,Patrizio Caturegli,Johns Hopkins University,{'error': '#ERROR!'},https://dx.doi.org/10.1128/spectrum.02183-23,2024-03-08,2024-05-01,Unverified,caturegli_hundred-fold_2023,USA
231009_Maryland_JohnsHopkinsUniversity_Time1,"231009_Maryland_JohnsHopkinsUniversity_TimePeriod1, 231009_Maryland_JohnsHopkinsUniversity_TimePeriod2, 231009_Maryland_JohnsHopkinsUniversity_TimePeriod3, 231009_Maryland_JohnsHopkinsUniversity_TimePeriod4, 231009_Maryland_JohnsHopkinsUniversity_TimePeriod5",Hundred-fold increase in SARS-CoV-2 spike antibody levels over three years in a hospital clinical laboratory,2023-10-09,Journal Article (Peer-Reviewed),Regional,Retrospective cohort,"United States of America,United States of America,United States of America,United States of America,United States of America",Maryland,,"Over a 3-year period (April 2020–February 2023), we performed a retrospective analysis of spike IgG antibodies measured by a tertiary hospital clinical immunology laboratory using the Euroimmun SARS-CoV-2 IgG ELISA. The 3-year interval was classified into five periods based on the SARS-CoV-2 strain variant epidemiology. A total of 15,820 sera, derived from 11,022 individuals (6,362 females and 4,660 males) ranging from severe immunocompromised state to routine health visits, were tested",,2020-04-15,2020-12-15,Residual sera,All,Multiple groups,,,Primary Estimate,,3109,0.148,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,"[{'error': '#ERROR!'}, {'error': '#ERROR!'}, {'error': '#ERROR!'}, {'error': '#ERROR!'}, {'error': '#ERROR!'}]",No,No,{'error': '#ERROR!'},Yes,No,{'error': '#ERROR!'},Yes,{'error': '#ERROR!'},Unclear,Patrizio Caturegli,Johns Hopkins University,{'error': '#ERROR!'},https://dx.doi.org/10.1128/spectrum.02183-23,2024-03-08,2024-05-01,Unverified,caturegli_hundred-fold_2023,USA
231009_Maryland_JohnsHopkinsUniversity_Time5,"231009_Maryland_JohnsHopkinsUniversity_TimePeriod1, 231009_Maryland_JohnsHopkinsUniversity_TimePeriod2, 231009_Maryland_JohnsHopkinsUniversity_TimePeriod3, 231009_Maryland_JohnsHopkinsUniversity_TimePeriod4, 231009_Maryland_JohnsHopkinsUniversity_TimePeriod5",Hundred-fold increase in SARS-CoV-2 spike antibody levels over three years in a hospital clinical laboratory,2023-10-09,Journal Article (Peer-Reviewed),Regional,Retrospective cohort,"United States of America,United States of America,United States of America,United States of America,United States of America",Maryland,,"Over a 3-year period (April 2020–February 2023), we performed a retrospective analysis of spike IgG antibodies measured by a tertiary hospital clinical immunology laboratory using the Euroimmun SARS-CoV-2 IgG ELISA. The 3-year interval was classified into five periods based on the SARS-CoV-2 strain variant epidemiology. A total of 15,820 sera, derived from 11,022 individuals (6,362 females and 4,660 males) ranging from severe immunocompromised state to routine health visits, were tested",,2022-07-15,2023-02-15,Residual sera,All,Multiple groups,,,Primary Estimate,,2422,0.9521,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,"[{'error': '#ERROR!'}, {'error': '#ERROR!'}, {'error': '#ERROR!'}, {'error': '#ERROR!'}, {'error': '#ERROR!'}]",No,No,{'error': '#ERROR!'},Yes,No,{'error': '#ERROR!'},Yes,{'error': '#ERROR!'},Unclear,Patrizio Caturegli,Johns Hopkins University,{'error': '#ERROR!'},https://dx.doi.org/10.1128/spectrum.02183-23,2024-03-08,2024-05-01,Unverified,caturegli_hundred-fold_2023,USA
231009_Maryland_JohnsHopkinsUniversity_Time3,"231009_Maryland_JohnsHopkinsUniversity_TimePeriod1, 231009_Maryland_JohnsHopkinsUniversity_TimePeriod2, 231009_Maryland_JohnsHopkinsUniversity_TimePeriod3, 231009_Maryland_JohnsHopkinsUniversity_TimePeriod4, 231009_Maryland_JohnsHopkinsUniversity_TimePeriod5",Hundred-fold increase in SARS-CoV-2 spike antibody levels over three years in a hospital clinical laboratory,2023-10-09,Journal Article (Peer-Reviewed),Regional,Retrospective cohort,"United States of America,United States of America,United States of America,United States of America,United States of America",Maryland,,"Over a 3-year period (April 2020–February 2023), we performed a retrospective analysis of spike IgG antibodies measured by a tertiary hospital clinical immunology laboratory using the Euroimmun SARS-CoV-2 IgG ELISA. The 3-year interval was classified into five periods based on the SARS-CoV-2 strain variant epidemiology. A total of 15,820 sera, derived from 11,022 individuals (6,362 females and 4,660 males) ranging from severe immunocompromised state to routine health visits, were tested",,2021-07-15,2021-11-15,Residual sera,All,Multiple groups,,,Primary Estimate,,3724,0.7538,,,True,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,"[{'error': '#ERROR!'}, {'error': '#ERROR!'}, {'error': '#ERROR!'}, {'error': '#ERROR!'}, {'error': '#ERROR!'}]",No,No,{'error': '#ERROR!'},Yes,No,{'error': '#ERROR!'},Yes,{'error': '#ERROR!'},Unclear,Patrizio Caturegli,Johns Hopkins University,{'error': '#ERROR!'},https://dx.doi.org/10.1128/spectrum.02183-23,2024-03-08,2024-05-01,Unverified,caturegli_hundred-fold_2023,USA
210301_Uzbekistan_ResearchInstituteofVirology,210301_Uzbekistan_ResearchInstituteofVirology,FORMATION of HERD IMMUNITY to SARS-CoV-2 in the REGIONS of UZBEKISTAN,2021-03-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Uzbekistan,,,people who sought medical help at an outpatient clinic at their place of residence ,,2020-08-27,2020-09-11,Residual sera,All,Multiple groups,,,Primary Estimate,gen pop Uzbekistan,86879,0.231,0.23,0.23199999999999998,True,,,,True,Convenience,Wantai Rapid Test for Total Antibody to SARS-CoV-2,Beijing Wantai Biological,LFIA,Whole Blood,"['IgG', 'IgM']",,,,,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,Unclear,R A Rakhimov ,Research Institute of Virology,Unity-Aligned,https://ejmcm.com/article_9453.html,2021-05-17,2024-03-01,Unverified,r_a_formation_2021,UZB
210731_Caracas_UniversidadCentraldeVenezuela,210731_Caracas_UniversidadCentraldeVenezuela,IgG Antibody response to the Sputnik V vaccine: previous SARS-CoV-2 seropositive individuals might need just one vaccine dose.,2021-07-31,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Venezuela (Bolivarian Republic of),,Caracas,"healthcare workers who presented for vaccination (n=149) at a public hospital in Caracas, Venezuela.

Only vaccine recipients who provided a baseline (pre-vaccine) sample, a sample at application of dose 2 and a sample 6 weeks after dose 2 were included in this study (n= 86).",,2021-02-01,2021-02-06,Health care workers and caregivers,All,Multiple groups,21.0,76.0,Primary Estimate,,86,0.314,,,True,,,,True,Simplified probability,Author designed (Multiplex),,ELISA,Serum,IgG,"['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],Yes,Yes,No,Yes,No,Unclear,Yes,No,No,Franklin Claro,Universidad Central de Venezuela,Not Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.07.070,2021-08-10,2022-07-16,Verified,claro_igg_2021,VEN
201118_HoChiMinhCity_OxfordUniversityClinicalResearchUnit_overall,201118_HoChiMinhCity_OxfordUniversityClinicalResearchUnit,Absence of SARS-CoV-2 antibodies in health care workers of a tertiary referral hospital for COVID-19 in southern Vietnam.,2020-11-18,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Viet Nam,Đông Nam Bộ,Ho Chi Minh City,"We invited any hospital staff regardless of
their occupations and the nature of their work to participate in
the study.",,2020-08-23,2020-08-30,Health care workers and caregivers,All,Adults (18-64 years),20.0,60.0,Primary Estimate,Overall HCW,408,0.0,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.9720000000000001,0.998,['High'],Yes,No,No,Yes,Unclear,Yes,Yes,Yes,No,Nguyen Van Vinh Chau,Oxford University Clinical Research Unit,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jinf.2020.11.018,2021-01-23,2024-03-01,Verified,chau_absence_2020,VNM
210302_Vietnam_UniversitatsklinikumTubingen_HCW_ELISA_TotalAb,210302_Vietnam_UniversitatsklinikumTubingen_HCW,Viral and serological testing of SARS-CoV-2 among health care workers and patients in Vietnam,2021-03-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Viet Nam,Red River Delta,Hanoi,HCWs (n = 1065) who had previously tested negative for SARS-CoV-2 by RT-PCR ,,2020-03-01,2021-01-08,Health care workers and caregivers,All,Adults (18-64 years),20.0,60.0,Primary Estimate,Healthcare workers,1065,0.005600000000000001,,,True,,,,True,Unclear,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,,TotalAntibody,Spike,,,,['High'],No,Unclear,Yes,Yes,No,Yes,Yes,Yes,Unclear,Le Huu Song,Universitätsklinikum Tübingen,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2021.100113,2021-04-10,2024-03-01,Verified,song_viral_2021,VNM
210302_Vietnam_UniversitatsklinikumTubingen_patients_ELISA_TotalAb,210302_Vietnam_UniversitatsklinikumTubingen_outpatients,Viral and serological testing of SARS-CoV-2 among health care workers and patients in Vietnam,2021-03-02,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Viet Nam,Red River Delta,Hanoi,Hospitalised patients (n = 288) who had previously tested negative for SARS-CoV-2 by RT-PCR ,,2020-03-01,2021-01-08,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,Respiratory hospital patients,288,0.0,,,True,,,,True,Unclear,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,,TotalAntibody,Spike,,,,['High'],No,Unclear,No,No,Unclear,Yes,Yes,Yes,Unclear,Le Huu Song,Universitätsklinikum Tübingen,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanwpc.2021.100113,2021-04-10,2024-03-01,Verified,song_viral_2021,VNM
210610_Vietnam_TheUniversityOfSydney_GenPop1_Female,210610_Vietnam_TheUniversityOfSydney_GenPop1,Sero-prevalence of sars-cov-2 antibodies in high-risk populations in vietnam,2021-06-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Viet Nam,"Hanoi Capital, Quang Nam Province, Da Nang Province","Hoi sub-commune in Ha Loi commune, Me Linh district, Hanoi Capital,  Giao Ai sub-commune in Dien Hong commune, Dien Ban, Quang Nam Province, Luu Minh sub-commune in Ha Lam Town, Quang Nam, Le Son Nam sub-commune in Hoa Tien commune, Da Nang ","All people residing in each sub-commune during the outbreaks who were aged 5 years and
older and who were capable of giving consent, or having consent given by a guardian (for
children <16 years), were eligible to participate.
Enrolled participants
were classified as close contacts, household contacts, or general community members.
Close contacts of COVID-19 cases were those who been within a two-meter distance of the
COVID-19 case for at least 15 min, or had been present in the same room for at least two
hours during the infectious period (that is, from 48 h prior to symptom onset or diagnosis
until the person with confirmed COVID-19 was placed in isolation). Household contacts of
a COVID-19 case were those who were not close contacts, but who were living in the same
dwelling and sharing meals or the kitchen with a COVID-19 case during the infectious
period. General community members were those who were not close or household contacts
of the COVID-19 case, but were living in the same sub-commune as the COVID-19 case.
","Individuals were excluded if they were unable or refused to provide consent, were less than
five years of age or if they were a household/community member who had not stayed in the
same house/sub-commune during the infectious period. Individuals who were documented as
PCR-positive for COVID-19 during the outbreaks were excluded from testing",2020-09-04,2020-11-23,Household and community samples,Female,Multiple groups,,,Sex/Gender,,1410,0.005,,,True,,,,True,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.968,0.998,['High'],No,Unclear,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Tasnim Hasan,The University of Sydney,Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph18126353,2021-09-29,2024-03-01,Verified,hasan_sero-prevalence_2021-1,VNM
210610_Vietnam_TheUniversityOfSydney_GenPop1_overall,210610_Vietnam_TheUniversityOfSydney_GenPop1,Sero-prevalence of sars-cov-2 antibodies in high-risk populations in vietnam,2021-06-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Viet Nam,"Hanoi Capital, Quang Nam Province, Da Nang Province","Hoi sub-commune in Ha Loi commune, Me Linh district, Hanoi Capital,  Giao Ai sub-commune in Dien Hong commune, Dien Ban, Quang Nam Province, Luu Minh sub-commune in Ha Lam Town, Quang Nam, Le Son Nam sub-commune in Hoa Tien commune, Da Nang ","All people residing in each sub-commune during the outbreaks who were aged 5 years and
older and who were capable of giving consent, or having consent given by a guardian (for
children <16 years), were eligible to participate.
Enrolled participants
were classified as close contacts, household contacts, or general community members.
Close contacts of COVID-19 cases were those who been within a two-meter distance of the
COVID-19 case for at least 15 min, or had been present in the same room for at least two
hours during the infectious period (that is, from 48 h prior to symptom onset or diagnosis
until the person with confirmed COVID-19 was placed in isolation). Household contacts of
a COVID-19 case were those who were not close contacts, but who were living in the same
dwelling and sharing meals or the kitchen with a COVID-19 case during the infectious
period. General community members were those who were not close or household contacts
of the COVID-19 case, but were living in the same sub-commune as the COVID-19 case.
","Individuals were excluded if they were unable or refused to provide consent, were less than
five years of age or if they were a household/community member who had not stayed in the
same house/sub-commune during the infectious period. Individuals who were documented as
PCR-positive for COVID-19 during the outbreaks were excluded from testing",2020-09-04,2020-11-23,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,"Overall, unadjusted",3034,0.004,,,True,,,,True,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.968,0.998,['High'],No,Unclear,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Tasnim Hasan,The University of Sydney,Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph18126353,2021-06-21,2024-03-01,Verified,hasan_sero-prevalence_2021-1,VNM
210610_Vietnam_TheUniversityOfSydney_GenPop1_Male,210610_Vietnam_TheUniversityOfSydney_GenPop1,Sero-prevalence of sars-cov-2 antibodies in high-risk populations in vietnam,2021-06-11,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Viet Nam,"Hanoi Capital, Quang Nam Province, Da Nang Province","Hoi sub-commune in Ha Loi commune, Me Linh district, Hanoi Capital,  Giao Ai sub-commune in Dien Hong commune, Dien Ban, Quang Nam Province, Luu Minh sub-commune in Ha Lam Town, Quang Nam, Le Son Nam sub-commune in Hoa Tien commune, Da Nang ","All people residing in each sub-commune during the outbreaks who were aged 5 years and
older and who were capable of giving consent, or having consent given by a guardian (for
children <16 years), were eligible to participate.
Enrolled participants
were classified as close contacts, household contacts, or general community members.
Close contacts of COVID-19 cases were those who been within a two-meter distance of the
COVID-19 case for at least 15 min, or had been present in the same room for at least two
hours during the infectious period (that is, from 48 h prior to symptom onset or diagnosis
until the person with confirmed COVID-19 was placed in isolation). Household contacts of
a COVID-19 case were those who were not close contacts, but who were living in the same
dwelling and sharing meals or the kitchen with a COVID-19 case during the infectious
period. General community members were those who were not close or household contacts
of the COVID-19 case, but were living in the same sub-commune as the COVID-19 case.
","Individuals were excluded if they were unable or refused to provide consent, were less than
five years of age or if they were a household/community member who had not stayed in the
same house/sub-commune during the infectious period. Individuals who were documented as
PCR-positive for COVID-19 during the outbreaks were excluded from testing",2020-09-04,2020-11-23,Household and community samples,Male,Multiple groups,,,Sex/Gender,,1624,0.0037,,,True,,,,True,Unclear,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.968,0.998,['High'],No,Unclear,Yes,Yes,Unclear,Yes,Yes,Yes,Yes,Tasnim Hasan,The University of Sydney,Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph18126353,2021-09-29,2024-03-01,Verified,hasan_sero-prevalence_2021-1,VNM
210610_Vietnam_TheUniversityOfSydney_HCW2_overall,210610_Vietnam_TheUniversityOfSydney_HCW2,Sero-prevalence of sars-cov-2 antibodies in high-risk populations in vietnam,2021-06-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Viet Nam,Da Nang,,"HCWs were enrolled at two health care facilities: Da Nang Lung Hospital, a provincial hospital in Da Nang, and Hoa Vang District Hospital, a district hospital in Da Nang. All HCWs enrolled were directly involved in the care of COVID-19 cases.",,2020-11-24,2020-11-30,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,"Overall, unadjusted",148,0.0,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,IgG,,Validated by independent authors/third party/non-developers,0.968,0.998,['High'],No,No,No,Yes,Unclear,Yes,Yes,Yes,Unclear,Tasnim Hasan,The University of Sydney,Not Unity-Aligned,http://dx.doi.org/10.3390/ijerph18126353,2021-06-21,2024-03-01,Verified,hasan_sero-prevalence_2021-1,VNM
210927_Hanoi_NationalCenterforGlobalHealthandMedicine_primary,210927_Hanoi_NationalCenterforGlobalHealthandMedicine,"Evaluation of SARS-CoV-2 Antibodies and the Impact of COVID-19 on the HIV Care Continuum, Economic Security, Risky Health Behaviors, and Mental Health Among HIV-Infected Individuals in Vietnam.",2021-09-27,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Viet Nam,,Hanoi,hospital-based cohort of PLHIV receiving ART (aged ≥ 18 years),,2020-06-01,2020-07-31,Patients seeking care for non-COVID-19 reasons,All,Multiple groups,,,Primary Estimate,,1243,0.002,,,True,,,,True,Unclear,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,,,,,['Moderate'],,Unclear,Yes,Yes,,Yes,Yes,Yes,,Shoko Matsumoto,National Center for Global Health and Medicine,Not Unity-Aligned,https://dx.doi.org/10.1007/s10461-021-03464-w,2021-10-12,2024-03-01,Unverified,matsumoto_evaluation_2021,VNM
211211_Vietnam_UniversityofSydney_BacMaSubCommune,211211_Vietnam_UniversityofSydney_BacMaSubCommune,The prevalence of SARS-CoV-2 antibodies in quarantine workers and high-risk communities in Vietnam,2021-12-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Viet Nam,Quang Ninh,,"""All household and close contacts of COVID-19 cases and all community members residing in the two selected sub-communes were invited to participate in the study. A list of community members for each
sub-commune was obtained from local authorities. An invitation letter
and information sheet were sent to each household with details of the
study. Community members were invited to a study location. For those
who did not attend, the study team visited the house to further extend
an invitation to participate voluntarily in the study.""",,2021-01-01,2021-02-28,Household and community samples,All,Multiple groups,,,Primary Estimate,,897,0.001,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,,Whole Blood,,,,0.968,0.998,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Tasnim Hasan,University of Sydney,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665841/,2022-06-29,2022-07-16,Unverified,hasan_prevalence_2022,VNM
211211_Vietnam_UniversityofSydney_HCWs,211211_Vietnam_UniversityofSydney_HCWs,The prevalence of SARS-CoV-2 antibodies in quarantine workers and high-risk communities in Vietnam,2021-12-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Viet Nam,Quang Ninh,,"""Additionally, testing was carried out on clinical and non-clinical quarantine workers at two isolation facilities in Quang Ninh province, which housed contacts of COVID-19 cases and had the highest number of reported COVID-19 diagnoses. Only two facilities were included due to time and funding limitations.""","NR
",2021-01-01,2021-02-28,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,15,0.067,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,,Whole Blood,,,,0.968,0.998,['High'],,No,No,Yes,,Unclear,Yes,Yes,,Tasnim Hasan,University of Sydney,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665841/,2022-06-29,2022-07-16,Unverified,hasan_prevalence_2022,VNM
211211_Vietnam_UniversityofSydney_LogisticandSecurity,211211_Vietnam_UniversityofSydney_LogisticandSecurity,The prevalence of SARS-CoV-2 antibodies in quarantine workers and high-risk communities in Vietnam,2021-12-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Viet Nam,Quang Ninh,,"""Additionally, testing was carried out on clinical and non-clinical quarantine workers at two isolation facilities in Quang Ninh province, which housed contacts of COVID-19 cases and had the highest number of reported COVID-19 diagnoses. Only two facilities were included due to time and funding limitations.""","NR
",2021-01-01,2021-02-28,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,11,0.0,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,,Whole Blood,,,,0.968,0.998,['High'],,No,No,Yes,,Unclear,Yes,Yes,,Tasnim Hasan,University of Sydney,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665841/,2022-06-29,2022-07-16,Unverified,hasan_prevalence_2022,VNM
211211_Vietnam_UniversityofSydney_SpecimenCollectors,211211_Vietnam_UniversityofSydney_SpecimenCollectors,The prevalence of SARS-CoV-2 antibodies in quarantine workers and high-risk communities in Vietnam,2021-12-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Viet Nam,Quang Ninh,,"""Additionally, testing was carried out on clinical and non-clinical quarantine workers at two isolation facilities in Quang Ninh province, which housed contacts of COVID-19 cases and had the highest number of reported COVID-19 diagnoses. Only two facilities were included due to time and funding limitations.""","NR
",2021-01-01,2021-02-28,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,,24,0.0,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,,Whole Blood,,,,0.968,0.998,['High'],,No,No,Yes,,Unclear,Yes,Yes,,Tasnim Hasan,University of Sydney,Not Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665841/,2022-06-29,2022-07-16,Unverified,hasan_prevalence_2022,VNM
211211_Vietnam_UniversityofSydney_TienSubCommune,211211_Vietnam_UniversityofSydney_TienSubCommune,The prevalence of SARS-CoV-2 antibodies in quarantine workers and high-risk communities in Vietnam,2021-12-11,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Viet Nam,Hai Duong,,"""All household and close contacts of COVID-19 cases and all community members residing in the two selected sub-communes were invited to participate in the study. A list of community members for each
sub-commune was obtained from local authorities. An invitation letter
and information sheet were sent to each household with details of the
study. Community members were invited to a study location. For those
who did not attend, the study team visited the house to further extend
an invitation to participate voluntarily in the study.""",,2021-01-01,2021-02-28,Household and community samples,All,Multiple groups,,,Primary Estimate,,1172,0.004,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,,Whole Blood,,,,0.968,0.998,['Moderate'],,No,Yes,Yes,,Unclear,Yes,Yes,,Tasnim Hasan,University of Sydney,Unity-Aligned,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665841/,2022-06-29,2022-07-16,Unverified,hasan_prevalence_2022,VNM
220126_HoChiMinhCity_PasteurInstituteOfHoChiMinhCity_PopAdj_Overall,220126_HoChiMinhCity_PasteurInstituteOfHoChiMinhCity,"Seroprevalence of SARS-CoV-2 Neutralizing Antibodies among Blood Donors in Ho Chi Minh City, Vietnam, August-November 2020.",2022-01-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Viet Nam,,Ho Chi Minh City,"""Eligibility criteria for this study were voluntarily donating blood at blood donation sessions in the community, age 18 to 59 years, living in Ho Chi Minh City for 3 months or more, and willingness to provide informed consent.""","""We excluded from the analysis individuals who refused to be interviewed for collecting study information.""",2020-08-27,2020-11-07,Blood donors,All,Adults (18-64 years),18.0,59.0,Primary Estimate,,885,0.002,0.0005,0.008100000000000001,True,,True,,True,Sequential,Author designed (Neutralization Assay),,Neutralization,Serum,IgG,,Validated by independent authors/third party/non-developers,,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Hanh Hong Ho Nguyen,Pasteur Institute of Ho Chi Minh City,Not Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.21-0259,2022-02-01,2022-07-16,Unverified,nguyen_seroprevalence_2022,VNM
220126_HoChiMinhCity_PasteurInstituteOfHoChiMinhCity_UnAdj_Overall,220126_HoChiMinhCity_PasteurInstituteOfHoChiMinhCity,"Seroprevalence of SARS-CoV-2 Neutralizing Antibodies among Blood Donors in Ho Chi Minh City, Vietnam, August-November 2020.",2022-01-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Viet Nam,,Ho Chi Minh City,"""Eligibility criteria for this study were voluntarily donating blood at blood donation sessions in the community, age 18 to 59 years, living in Ho Chi Minh City for 3 months or more, and willingness to provide informed consent.""","""We excluded from the analysis individuals who refused to be interviewed for collecting study information.""",2020-08-27,2020-11-07,Blood donors,All,Adults (18-64 years),18.0,59.0,Analysis,,885,0.0023,0.0006,0.008199999999999999,,,,,,Sequential,Author designed (Neutralization Assay),,Neutralization,Serum,IgG,,Validated by independent authors/third party/non-developers,,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Hanh Hong Ho Nguyen,Pasteur Institute of Ho Chi Minh City,Not Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.21-0259,2022-02-01,2022-12-11,Unverified,nguyen_seroprevalence_2022,VNM
220126_HoChiMinhCity_PasteurInstituteOfHoChiMinhCity_PopAdj_Age_30–39,220126_HoChiMinhCity_PasteurInstituteOfHoChiMinhCity,"Seroprevalence of SARS-CoV-2 Neutralizing Antibodies among Blood Donors in Ho Chi Minh City, Vietnam, August-November 2020.",2022-01-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Viet Nam,,Ho Chi Minh City,"""Eligibility criteria for this study were voluntarily donating blood at blood donation sessions in the community, age 18 to 59 years, living in Ho Chi Minh City for 3 months or more, and willingness to provide informed consent.""","""We excluded from the analysis individuals who refused to be interviewed for collecting study information.""",2020-08-27,2020-11-07,Blood donors,All,Adults (18-64 years),30.0,39.0,Age,Age: 30–39,227,0.0044,0.0006,0.031000000000000003,,,True,,,Sequential,Author designed (Neutralization Assay),,Neutralization,Serum,IgG,,Validated by independent authors/third party/non-developers,,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Hanh Hong Ho Nguyen,Pasteur Institute of Ho Chi Minh City,Not Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.21-0259,2022-02-02,2022-07-16,Unverified,nguyen_seroprevalence_2022,VNM
220126_HoChiMinhCity_PasteurInstituteOfHoChiMinhCity_PopAdj_Age_20–29,220126_HoChiMinhCity_PasteurInstituteOfHoChiMinhCity,"Seroprevalence of SARS-CoV-2 Neutralizing Antibodies among Blood Donors in Ho Chi Minh City, Vietnam, August-November 2020.",2022-01-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Viet Nam,,Ho Chi Minh City,"""Eligibility criteria for this study were voluntarily donating blood at blood donation sessions in the community, age 18 to 59 years, living in Ho Chi Minh City for 3 months or more, and willingness to provide informed consent.""","""We excluded from the analysis individuals who refused to be interviewed for collecting study information.""",2020-08-27,2020-11-07,Blood donors,All,Adults (18-64 years),20.0,29.0,Age,Age: 20–29,245,0.0040999999999999995,0.0006,0.028999999999999998,,,True,,,Sequential,Author designed (Neutralization Assay),,Neutralization,Serum,IgG,,Validated by independent authors/third party/non-developers,,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Hanh Hong Ho Nguyen,Pasteur Institute of Ho Chi Minh City,Not Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.21-0259,2022-02-02,2022-07-16,Unverified,nguyen_seroprevalence_2022,VNM
220126_HoChiMinhCity_PasteurInstituteOfHoChiMinhCity_PopAdj_Age_40–49,220126_HoChiMinhCity_PasteurInstituteOfHoChiMinhCity,"Seroprevalence of SARS-CoV-2 Neutralizing Antibodies among Blood Donors in Ho Chi Minh City, Vietnam, August-November 2020.",2022-01-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Viet Nam,,Ho Chi Minh City,"""Eligibility criteria for this study were voluntarily donating blood at blood donation sessions in the community, age 18 to 59 years, living in Ho Chi Minh City for 3 months or more, and willingness to provide informed consent.""","""We excluded from the analysis individuals who refused to be interviewed for collecting study information.""",2020-08-27,2020-11-07,Blood donors,All,Adults (18-64 years),40.0,49.0,Age,Age: 40–49,191,0.0,,,,,True,,,Sequential,Author designed (Neutralization Assay),,Neutralization,Serum,IgG,,Validated by independent authors/third party/non-developers,,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Hanh Hong Ho Nguyen,Pasteur Institute of Ho Chi Minh City,Not Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.21-0259,2022-02-02,2022-07-16,Unverified,nguyen_seroprevalence_2022,VNM
220126_HoChiMinhCity_PasteurInstituteOfHoChiMinhCity_PopAdj_Age_50–59,220126_HoChiMinhCity_PasteurInstituteOfHoChiMinhCity,"Seroprevalence of SARS-CoV-2 Neutralizing Antibodies among Blood Donors in Ho Chi Minh City, Vietnam, August-November 2020.",2022-01-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Viet Nam,,Ho Chi Minh City,"""Eligibility criteria for this study were voluntarily donating blood at blood donation sessions in the community, age 18 to 59 years, living in Ho Chi Minh City for 3 months or more, and willingness to provide informed consent.""","""We excluded from the analysis individuals who refused to be interviewed for collecting study information.""",2020-08-27,2020-11-07,Blood donors,All,Adults (18-64 years),50.0,59.0,Age,Age: 50–59,143,0.0,,,,,True,,,Sequential,Author designed (Neutralization Assay),,Neutralization,Serum,IgG,,Validated by independent authors/third party/non-developers,,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Hanh Hong Ho Nguyen,Pasteur Institute of Ho Chi Minh City,Not Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.21-0259,2022-02-02,2022-07-16,Unverified,nguyen_seroprevalence_2022,VNM
220126_HoChiMinhCity_PasteurInstituteOfHoChiMinhCity_PopAdj_Age_18–19,220126_HoChiMinhCity_PasteurInstituteOfHoChiMinhCity,"Seroprevalence of SARS-CoV-2 Neutralizing Antibodies among Blood Donors in Ho Chi Minh City, Vietnam, August-November 2020.",2022-01-26,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Viet Nam,,Ho Chi Minh City,"""Eligibility criteria for this study were voluntarily donating blood at blood donation sessions in the community, age 18 to 59 years, living in Ho Chi Minh City for 3 months or more, and willingness to provide informed consent.""","""We excluded from the analysis individuals who refused to be interviewed for collecting study information.""",2020-08-27,2020-11-07,Blood donors,All,Adults (18-64 years),18.0,19.0,Age,Age: 18–19,79,0.0,,,,,True,,,Sequential,Author designed (Neutralization Assay),,Neutralization,Serum,IgG,,Validated by independent authors/third party/non-developers,,1.0,['Moderate'],,No,Yes,Yes,,Unclear,Yes,No,,Hanh Hong Ho Nguyen,Pasteur Institute of Ho Chi Minh City,Not Unity-Aligned,https://dx.doi.org/10.4269/ajtmh.21-0259,2022-02-02,2022-07-16,Unverified,nguyen_seroprevalence_2022,VNM
220620_Vietnam_UnitedStatesCDC,220620_Vietnam_UnitedStatesCDC,Presence of SARS-CoV-2 Antibodies among Vietnamese Healthcare Workers by Dosing Interval for ChAdOx1 nCoV-19 Vaccine.,2022-06-20,Journal Article (Peer-Reviewed),National,Prospective cohort,Viet Nam,Red River Delta,Hanoi,"All consenting hospital 
4 workers participated in a baseline COVID-19 seroprevalence survey in February 2021.","Participants were excluded from the analysis if they 
9 only had data prior to vaccination or at 3 months post-dose 2",2021-02-01,2021-02-28,Health care workers and caregivers,All,Multiple groups,16.0,,Primary Estimate,,617,0.0016,,,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,ELISA,Serum,IgG,Nucleocapsid(N-protein),,,,['High'],,No,Yes,No,,Yes,Yes,Yes,,Dien Vu,U.S. Centers for Disease Control and Prevention,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciac493,2022-06-29,2024-03-01,Unverified,vu_presence_2022,VNM
221031_Hanoi_VietnamNationalChildrensHospital_Overall,221031_Hanoi_VietnamNationalChildrensHospital,"High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Children in Vietnam: An Observational, Hospital-based Study",2022-10-31,Preprint,Local,Cross-sectional survey ,Viet Nam,,Hanoi,"""In-patient or out-patient children aged from 0 to 18 years old seeking medical care at Vietnam National Children's Hospital for any condition unrelated to acute COVID-19 were eligible to participate. For both groups, additional eligibility criteria were having residual blood specimens collected from routine biochemistry tests.""","""Patients with positive antigen tests for SARS-CoV-2 at enrollment, those who received COVID-19 inoculation within six months, those with blood samples stored over 24 hours or not enough residual blood (at least 2 ml), or those with refused from their guardians to participate in this study were excluded.""",2022-03-13,2022-04-03,Residual sera,All,Children and Youth (0-17 years),0.0,18.0,Primary Estimate,,4032,0.5915,,,True,,,,True,Simplified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9641,0.9999,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Dien Minh Tran,Vietnam National Children’s Hospital,Not Unity-Aligned,http://doi.org/10.20944/preprints202210.0471.v1,2022-11-09,2024-03-01,Unverified,tran_high_2022,VNM
221031_Hanoi_VietnamNationalChildrensHospital_SexMale,221031_Hanoi_VietnamNationalChildrensHospital,"High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Children in Vietnam: An Observational, Hospital-based Study",2022-10-31,Preprint,Local,Cross-sectional survey ,Viet Nam,,Hanoi,"""In-patient or out-patient children aged from 0 to 18 years old seeking medical care at Vietnam National Children's Hospital for any condition unrelated to acute COVID-19 were eligible to participate. For both groups, additional eligibility criteria were having residual blood specimens collected from routine biochemistry tests.""","""Patients with positive antigen tests for SARS-CoV-2 at enrollment, those who received COVID-19 inoculation within six months, those with blood samples stored over 24 hours or not enough residual blood (at least 2 ml), or those with refused from their guardians to participate in this study were excluded.""",2022-03-13,2022-04-03,Residual sera,Male,Children and Youth (0-17 years),0.0,18.0,Sex/Gender,,2447,0.5860000000000001,,,,,,,,Simplified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9641,0.9999,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Dien Minh Tran,Vietnam National Children’s Hospital,Not Unity-Aligned,http://doi.org/10.20944/preprints202210.0471.v1,2022-11-09,2024-03-01,Unverified,tran_high_2022,VNM
221031_Hanoi_VietnamNationalChildrensHospital_SexFemale,221031_Hanoi_VietnamNationalChildrensHospital,"High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Children in Vietnam: An Observational, Hospital-based Study",2022-10-31,Preprint,Local,Cross-sectional survey ,Viet Nam,,Hanoi,"""In-patient or out-patient children aged from 0 to 18 years old seeking medical care at Vietnam National Children's Hospital for any condition unrelated to acute COVID-19 were eligible to participate. For both groups, additional eligibility criteria were having residual blood specimens collected from routine biochemistry tests.""","""Patients with positive antigen tests for SARS-CoV-2 at enrollment, those who received COVID-19 inoculation within six months, those with blood samples stored over 24 hours or not enough residual blood (at least 2 ml), or those with refused from their guardians to participate in this study were excluded.""",2022-03-13,2022-04-03,Residual sera,Female,Children and Youth (0-17 years),0.0,18.0,Sex/Gender,,1585,0.6,,,,,,,,Simplified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9641,0.9999,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Dien Minh Tran,Vietnam National Children’s Hospital,Not Unity-Aligned,http://doi.org/10.20944/preprints202210.0471.v1,2022-11-09,2024-03-01,Unverified,tran_high_2022,VNM
221031_Hanoi_VietnamNationalChildrensHospital_AgeBelow12Months,221031_Hanoi_VietnamNationalChildrensHospital,"High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Children in Vietnam: An Observational, Hospital-based Study",2022-10-31,Preprint,Local,Cross-sectional survey ,Viet Nam,,Hanoi,"""In-patient or out-patient children aged from 0 to 18 years old seeking medical care at Vietnam National Children's Hospital for any condition unrelated to acute COVID-19 were eligible to participate. For both groups, additional eligibility criteria were having residual blood specimens collected from routine biochemistry tests.""","""Patients with positive antigen tests for SARS-CoV-2 at enrollment, those who received COVID-19 inoculation within six months, those with blood samples stored over 24 hours or not enough residual blood (at least 2 ml), or those with refused from their guardians to participate in this study were excluded.""",2022-03-13,2022-04-03,Residual sera,All,Children and Youth (0-17 years),0.0,1.0,Age,Age: ≤ 12 months,939,0.5921000000000001,,,,,,,,Simplified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9641,0.9999,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Dien Minh Tran,Vietnam National Children’s Hospital,Not Unity-Aligned,http://doi.org/10.20944/preprints202210.0471.v1,2022-11-09,2024-03-01,Unverified,tran_high_2022,VNM
221031_Hanoi_VietnamNationalChildrensHospital_Age36-59Months,221031_Hanoi_VietnamNationalChildrensHospital,"High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Children in Vietnam: An Observational, Hospital-based Study",2022-10-31,Preprint,Local,Cross-sectional survey ,Viet Nam,,Hanoi,"""In-patient or out-patient children aged from 0 to 18 years old seeking medical care at Vietnam National Children's Hospital for any condition unrelated to acute COVID-19 were eligible to participate. For both groups, additional eligibility criteria were having residual blood specimens collected from routine biochemistry tests.""","""Patients with positive antigen tests for SARS-CoV-2 at enrollment, those who received COVID-19 inoculation within six months, those with blood samples stored over 24 hours or not enough residual blood (at least 2 ml), or those with refused from their guardians to participate in this study were excluded.""",2022-03-13,2022-04-03,Residual sera,All,Children and Youth (0-17 years),3.0,5.0,Age,Age: 36 to <60 months,628,0.5748,,,,,,,,Simplified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9641,0.9999,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Dien Minh Tran,Vietnam National Children’s Hospital,Not Unity-Aligned,http://doi.org/10.20944/preprints202210.0471.v1,2022-11-09,2024-03-01,Unverified,tran_high_2022,VNM
221031_Hanoi_VietnamNationalChildrensHospital_AgeAbove144Months,221031_Hanoi_VietnamNationalChildrensHospital,"High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Children in Vietnam: An Observational, Hospital-based Study",2022-10-31,Preprint,Local,Cross-sectional survey ,Viet Nam,,Hanoi,"""In-patient or out-patient children aged from 0 to 18 years old seeking medical care at Vietnam National Children's Hospital for any condition unrelated to acute COVID-19 were eligible to participate. For both groups, additional eligibility criteria were having residual blood specimens collected from routine biochemistry tests.""","""Patients with positive antigen tests for SARS-CoV-2 at enrollment, those who received COVID-19 inoculation within six months, those with blood samples stored over 24 hours or not enough residual blood (at least 2 ml), or those with refused from their guardians to participate in this study were excluded.""",2022-03-13,2022-04-03,Residual sera,All,Children and Youth (0-17 years),12.0,18.0,Age,Age: ≥ 144 months,116,0.6552,,,,,,,,Simplified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9641,0.9999,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Dien Minh Tran,Vietnam National Children’s Hospital,Not Unity-Aligned,http://doi.org/10.20944/preprints202210.0471.v1,2022-11-09,2024-03-01,Unverified,tran_high_2022,VNM
221031_Hanoi_VietnamNationalChildrensHospital_Age60-143Months,221031_Hanoi_VietnamNationalChildrensHospital,"High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Children in Vietnam: An Observational, Hospital-based Study",2022-10-31,Preprint,Local,Cross-sectional survey ,Viet Nam,,Hanoi,"""In-patient or out-patient children aged from 0 to 18 years old seeking medical care at Vietnam National Children's Hospital for any condition unrelated to acute COVID-19 were eligible to participate. For both groups, additional eligibility criteria were having residual blood specimens collected from routine biochemistry tests.""","""Patients with positive antigen tests for SARS-CoV-2 at enrollment, those who received COVID-19 inoculation within six months, those with blood samples stored over 24 hours or not enough residual blood (at least 2 ml), or those with refused from their guardians to participate in this study were excluded.""",2022-03-13,2022-04-03,Residual sera,All,Children and Youth (0-17 years),5.0,12.0,Age,Age: 60 to <144 months,1382,0.5427000000000001,,,,,,,,Simplified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9641,0.9999,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Dien Minh Tran,Vietnam National Children’s Hospital,Not Unity-Aligned,http://doi.org/10.20944/preprints202210.0471.v1,2022-11-09,2024-03-01,Unverified,tran_high_2022,VNM
221031_Hanoi_VietnamNationalChildrensHospital_Age13-35Months,221031_Hanoi_VietnamNationalChildrensHospital,"High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Children in Vietnam: An Observational, Hospital-based Study",2022-10-31,Preprint,Local,Cross-sectional survey ,Viet Nam,,Hanoi,"""In-patient or out-patient children aged from 0 to 18 years old seeking medical care at Vietnam National Children's Hospital for any condition unrelated to acute COVID-19 were eligible to participate. For both groups, additional eligibility criteria were having residual blood specimens collected from routine biochemistry tests.""","""Patients with positive antigen tests for SARS-CoV-2 at enrollment, those who received COVID-19 inoculation within six months, those with blood samples stored over 24 hours or not enough residual blood (at least 2 ml), or those with refused from their guardians to participate in this study were excluded.""",2022-03-13,2022-04-03,Residual sera,All,Children and Youth (0-17 years),1.0,3.0,Age,Age: 13 to <36 months,967,0.6639,,,,,,,,Simplified probability,ADVIA Centaur Immunoassay System,Siemens,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.9641,0.9999,['Moderate'],,Yes,Yes,Yes,,Unclear,Yes,Yes,,Dien Minh Tran,Vietnam National Children’s Hospital,Not Unity-Aligned,http://doi.org/10.20944/preprints202210.0471.v1,2022-11-09,2024-03-01,Unverified,tran_high_2022,VNM
211216_Aden_HadhramoutUniversity_Primary,211216_Aden_HadhramoutUniversity,"SARS-CoV-2 seroprevalence in Aden, Yemen: a population-based study",2021-12-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Yemen,Adan Governorate,Aden,Residents of Aden,,2020-11-15,2020-12-15,Household and community samples,All,Multiple groups,0.0,90.0,Primary Estimate,,2001,0.27399999999999997,0.256,0.29300000000000004,True,,,,True,Stratified probability,"COVID-19 IgG/IgM Rapid Test Cassette,Wantai SARS-CoV-2 Total Ab ELISA","Healgen,Beijing Wantai Biological",Multiple Types,Serum,"['IgG', 'IgM']",Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Abdulla Bin-Ghouth,"World Health Organization Country Office, Yemen",Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.12.330,2022-01-18,2024-03-01,Verified,bin-ghouth_sars-cov-2_2022,YEM
211216_Aden_HadhramoutUniversity_Sex_Male,211216_Aden_HadhramoutUniversity,"SARS-CoV-2 seroprevalence in Aden, Yemen: a population-based study",2021-12-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Yemen,Adan Governorate,Aden,Residents of Aden,,2020-11-15,2020-12-15,Household and community samples,Male,Multiple groups,0.0,90.0,Sex/Gender,,1037,0.23,,,,,,,,Stratified probability,"COVID-19 IgG/IgM Rapid Test Cassette,Wantai SARS-CoV-2 Total Ab ELISA","Healgen,Beijing Wantai Biological",Multiple Types,Serum,"['IgG', 'IgM']",Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Abdulla Bin-Ghouth,"World Health Organization Country Office, Yemen",Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.12.330,2022-01-18,2024-03-01,Verified,bin-ghouth_sars-cov-2_2022,YEM
211216_Aden_HadhramoutUniversity_Age_5-14,211216_Aden_HadhramoutUniversity,"SARS-CoV-2 seroprevalence in Aden, Yemen: a population-based study",2021-12-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Yemen,Adan Governorate,Aden,Residents of Aden,,2020-11-15,2020-12-15,Household and community samples,All,Children and Youth (0-17 years),5.0,14.0,Age,5-14,252,0.242,,,,,,,,Stratified probability,"COVID-19 IgG/IgM Rapid Test Cassette,Wantai SARS-CoV-2 Total Ab ELISA","Healgen,Beijing Wantai Biological",Multiple Types,Serum,"['IgG', 'IgM']",Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Abdulla Bin-Ghouth,"World Health Organization Country Office, Yemen",Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.12.330,2022-01-18,2024-03-01,Verified,bin-ghouth_sars-cov-2_2022,YEM
211216_Aden_HadhramoutUniversity_Age_30-44,211216_Aden_HadhramoutUniversity,"SARS-CoV-2 seroprevalence in Aden, Yemen: a population-based study",2021-12-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Yemen,Adan Governorate,Aden,Residents of Aden,,2020-11-15,2020-12-15,Household and community samples,All,Adults (18-64 years),30.0,44.0,Age,30-44,553,0.28,,,,,,,,Stratified probability,"COVID-19 IgG/IgM Rapid Test Cassette,Wantai SARS-CoV-2 Total Ab ELISA","Healgen,Beijing Wantai Biological",Multiple Types,Serum,"['IgG', 'IgM']",Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Abdulla Bin-Ghouth,"World Health Organization Country Office, Yemen",Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.12.330,2022-01-18,2024-03-01,Verified,bin-ghouth_sars-cov-2_2022,YEM
211216_Aden_HadhramoutUniversity_Sex_Female,211216_Aden_HadhramoutUniversity,"SARS-CoV-2 seroprevalence in Aden, Yemen: a population-based study",2021-12-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Yemen,Adan Governorate,Aden,Residents of Aden,,2020-11-15,2020-12-15,Household and community samples,Female,Multiple groups,0.0,90.0,Sex/Gender,,964,0.32,,,,,,,,Stratified probability,"COVID-19 IgG/IgM Rapid Test Cassette,Wantai SARS-CoV-2 Total Ab ELISA","Healgen,Beijing Wantai Biological",Multiple Types,Serum,"['IgG', 'IgM']",Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Abdulla Bin-Ghouth,"World Health Organization Country Office, Yemen",Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.12.330,2022-01-18,2024-03-01,Verified,bin-ghouth_sars-cov-2_2022,YEM
211216_Aden_HadhramoutUniversity_Age_<5,211216_Aden_HadhramoutUniversity,"SARS-CoV-2 seroprevalence in Aden, Yemen: a population-based study",2021-12-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Yemen,Adan Governorate,Aden,Residents of Aden,,2020-11-15,2020-12-15,Household and community samples,All,Children and Youth (0-17 years),0.0,4.0,Age,<5,13,0.23,,,,,,,,Stratified probability,"COVID-19 IgG/IgM Rapid Test Cassette,Wantai SARS-CoV-2 Total Ab ELISA","Healgen,Beijing Wantai Biological",Multiple Types,Serum,"['IgG', 'IgM']",Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Abdulla Bin-Ghouth,"World Health Organization Country Office, Yemen",Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.12.330,2022-01-18,2024-03-01,Verified,bin-ghouth_sars-cov-2_2022,YEM
211216_Aden_HadhramoutUniversity_Age_>=65,211216_Aden_HadhramoutUniversity,"SARS-CoV-2 seroprevalence in Aden, Yemen: a population-based study",2021-12-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Yemen,Adan Governorate,Aden,Residents of Aden,,2020-11-15,2020-12-15,Household and community samples,All,Seniors (65+ years),65.0,90.0,Age,>=65,111,0.252,,,,,,,,Stratified probability,"COVID-19 IgG/IgM Rapid Test Cassette,Wantai SARS-CoV-2 Total Ab ELISA","Healgen,Beijing Wantai Biological",Multiple Types,Serum,"['IgG', 'IgM']",Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Abdulla Bin-Ghouth,"World Health Organization Country Office, Yemen",Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.12.330,2022-01-18,2024-03-01,Verified,bin-ghouth_sars-cov-2_2022,YEM
211216_Aden_HadhramoutUniversity_Age_15-29,211216_Aden_HadhramoutUniversity,"SARS-CoV-2 seroprevalence in Aden, Yemen: a population-based study",2021-12-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Yemen,Adan Governorate,Aden,Residents of Aden,,2020-11-15,2020-12-15,Household and community samples,All,Multiple groups,15.0,29.0,Age,15-29,624,0.282,,,,,,,,Stratified probability,"COVID-19 IgG/IgM Rapid Test Cassette,Wantai SARS-CoV-2 Total Ab ELISA","Healgen,Beijing Wantai Biological",Multiple Types,Serum,"['IgG', 'IgM']",Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Abdulla Bin-Ghouth,"World Health Organization Country Office, Yemen",Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.12.330,2022-01-18,2024-03-01,Verified,bin-ghouth_sars-cov-2_2022,YEM
211216_Aden_HadhramoutUniversity_Age_45-64,211216_Aden_HadhramoutUniversity,"SARS-CoV-2 seroprevalence in Aden, Yemen: a population-based study",2021-12-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Yemen,Adan Governorate,Aden,Residents of Aden,,2020-11-15,2020-12-15,Household and community samples,All,Adults (18-64 years),45.0,64.0,Age,45-64,448,0.281,,,,,,,,Stratified probability,"COVID-19 IgG/IgM Rapid Test Cassette,Wantai SARS-CoV-2 Total Ab ELISA","Healgen,Beijing Wantai Biological",Multiple Types,Serum,"['IgG', 'IgM']",Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,No,Unclear,Abdulla Bin-Ghouth,"World Health Organization Country Office, Yemen",Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2021.12.330,2022-01-18,2024-03-01,Verified,bin-ghouth_sars-cov-2_2022,YEM
221109_Aden_Epicentre_round1,221109_Aden_Epicentre_round1,"High seroprevalence of antibodies against SARS-CoV-2 among healthcare workers 8 months after the first wave in Aden, Yemen.",2022-11-09,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Yemen,,Aden,"""All staff members (n = 404) were invited to take part in the study on a voluntary basis""
",,2020-09-27,2020-11-08,Health care workers and caregivers,All,Adults (18-64 years),20.0,,Primary Estimate,,356,0.194,0.18,0.207,True,,True,,True,Convenience,NG-Test® finger-prick test,NG Biotech Laboratoires,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,1.0,1.0,['High'],,No,No,Yes,,No,Yes,Yes,,Rami Malaeb,Epicentre,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0000767,2023-05-07,2024-03-01,Unverified,malaebHighSeroprevalenceAntibodies2022,YEM
221109_Aden_Epicentre_round2,221109_Aden_Epicentre_round2,"High seroprevalence of antibodies against SARS-CoV-2 among healthcare workers 8 months after the first wave in Aden, Yemen.",2022-11-09,Journal Article (Peer-Reviewed),Local,Cross-sectional study with prospective cohort follow up of a subset of the sample,Yemen,,Aden,"""A final screening was scheduled on the 10th of January 2021 after access to ECLIA testing became possible. As it was not feasible to invite all the staff members to participate in the final round, a sub-sample was invited including 61 of those who had tested positive in previous rounds, and 100 among those who had tested nega- tive. """,,2021-01-10,2021-01-24,Health care workers and caregivers,All,Adults (18-64 years),20.0,,Primary Estimate,,161,0.08,0.066,0.094,True,,True,,True,Convenience,NG-Test® finger-prick test,NG Biotech Laboratoires,LFIA,Whole Blood,"['IgG', 'IgM']",Nucleocapsid(N-protein),Validated by manufacturers,1.0,1.0,['High'],,No,No,Yes,,No,Yes,Yes,,Rami Malaeb,Epicentre,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pgph.0000767,2023-05-07,2024-03-01,Unverified,malaebHighSeroprevalenceAntibodies2022,YEM
230330_Yemen_UniversityofAden,230330_Yemen_UniversityofAden,"Seroprevalence of SARS-CoV-2 Among Healthcare Workers in Two Governorates Hospitals, Yemen",2023-03-30,Preprint,Local,Cross-sectional survey ,Yemen,,,"""the study population included a range of HCWs, such as doctors, nurses, x-ray physicians, dentists, laboratory personnel, pharmacists, respiratory therapists, and nutritionists, in addition to auxiliary HCWs such as clerks, housekeeping staff, laundry personnel, and social workers.""","""Those who didn't agree to participate in the study and did not fill in the questionnaire were excluded.""",2022-06-15,2022-09-15,Health care workers and caregivers,All,Adults (18-64 years),25.0,45.0,Primary Estimate,,404,0.943,0.921,0.965,True,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown),Roche Diagnostics,"CLIA, CMIA",,"IgG, IgM, IgA",[],,,,['High'],,No,No,No,,Unclear,Yes,No,,Watheq Thabet Taher,University of Aden,Not Unity-Aligned,10.21203/rs.3.rs-2669249/v1,2023-05-04,2023-05-05,Unverified,taher_seroprevalence_2023,YEM
210309_Zambia_ZambiaMinistryofHealth_overall,210309_Zambia_ZambiaMinistryofHealth,"Prevalence of SARS-CoV-2 in six districts in Zambia in July, 2020: a cross-sectional cluster sample survey",2021-03-09,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Zambia,"Kabwe, Livingstone, Lusaka, Nakonde, Ndola, Solwezi",,"Residents of households in six districts of Zambia (Kabwe, Livingstone, Lusaka, Nakonde, Ndola, and Solwezi) between July 4 and July 27, 2020. All individuals (of any age) who had slept in the selected house the night before the survey was done were eligible for participation in the survey.",excluding 333 participants for whom epidemiological data were disassociated from laboratory results,2020-07-04,2020-07-27,Household and community samples,All,Multiple groups,,,Primary Estimate,,2704,0.021,0.011000000000000001,0.031000000000000003,True,,True,True,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Plasma,IgG,Spike,,,,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Lloyd B Mulenga,Zambia Ministry of Health,Unity-Aligned,https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(21)00053-X/fulltext,2021-03-13,2024-03-01,Verified,mulenga_prevalence_2021,ZMB
210330_Zambia_ZambiaMinistryofHealth_HCW,210330_Zambia_ZambiaMinistryofHealth,"Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) among Health Care Workers-Zambia, July 2020",2021-03-30,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Zambia,"Kabwe, Livingstone, Lusaka, Nakonde, Ndola, Solwezi, Pooled",,"A cross-sectional survey of SARS-CoV-2 prevalence among HCWs was conducted during July 2–31, 2020, at 20 health facilities in six districts across Zambia. The districts were purposefully selected based on high rates of confirmed COVID-19 cases, mixture of urban and rural setting, and being travel corridors to and from the neighboring countries. A convenience sample of HCWs at the selected HFs who were present during the survey dates were recruited with the goal of reaching 600 participants. For smaller HFs (e.g., health centers), all HCWs were included; for larger HFs (e.g., hospitals), 50 HCWs were invited to participate.",,2020-07-02,2020-07-31,Health care workers and caregivers,All,Multiple groups,10.0,,Primary Estimate,,575,0.022000000000000002,0.005,0.039,True,,,,True,Stratified non-probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Plasma,IgG,Spike,Validated by manufacturers,0.9,1.0,['High'],,No,No,No,,Yes,Yes,Yes,,Sombo Fwoloshi,Zambia Ministry of Health,Not Unity-Aligned,https://dx.doi.org/10.1093/cid/ciab273,2021-05-02,2024-03-01,Unverified,fwoloshi_prevalence_2021,ZMB
210506_Zambia_CentreForInfectiousDiseaseResearchInZambia_Kalulushi1_HCW,210506_Zambia_CentreForInfectiousDiseaseResearchInZambia_Kalulushi1,"Comparable
  exposure to SARS-CoV-2 in young children and healthcare workers in Zambia",2021-05-06,Preprint,Local,Cross-sectional survey ,Zambia,Copperbelt Province ,Kalulushi,"Inclusion criteria for the healthcare workers were individuals formally employed within a public health facility or students enrolled at an allied healthcare training institution in the district, aged ≥18 years and willing to consent and meet study training and follow up requirements. ","Refusal to consent, pregnancy, yeast allergy, hypersensitivity, acute febrile illness and receipt of steroids, immune modulators or blood products were exclusionary criteria.",2020-08-01,2020-08-30,Health care workers and caregivers,All,Adults (18-64 years),18.0,,Primary Estimate,,237,0.08,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,,,,['High'],Yes,No,No,Yes,Unclear,Unclear,Yes,No,Unclear,Natasha Makabilo Laban,Centre for Infectious Disease Research in Zambia,Not Unity-Aligned,https://wellcomeopenresearch.org/articles/6-97/v1,2021-05-19,2022-07-16,Verified,laban_comparable_2021,ZMB
210506_Zambia_CentreForInfectiousDiseaseResearchInZambia_Lusaka2_Infants,210506_Zambia_CentreForInfectiousDiseaseResearchInZambia_Lusaka2,"Comparable
  exposure to SARS-CoV-2 in young children and healthcare workers in Zambia",2021-05-06,Preprint,Local,Cross-sectional survey ,Zambia,Lusaka Province,Lusaka,"Criteria for enrolment included the mothers’ willingness to participate voluntarily and provide consent, child’s’ eligibility for Rotarix vaccination as per national policy and mothers’ willingness for child to undergo defined study procedures and residence in the study area for the duration of the study.
Eligible, consenting mothers were enrolled and followed up until the child attained 2 years of age.","Contraindication to rotavirus vaccination, previous receipt of rotavirus vaccine, recent immunosuppressive therapy including high-dose systemic corticosteroids, history of receiving blood transfusion or blood products, including immunoglobulins within the previous 6 months, any condition deemed by the study investigator to pose potential harm to the child or jeopardize the validity of study result and any existing congenital anomalies constituted exclusionary criteria. ",2020-08-15,2020-12-15,Household and community samples,All,Children and Youth (0-17 years),0.0,2.0,Primary Estimate,,150,0.06,,,True,,,,True,Convenience,Author designed (ELISA) -Spike,,ELISA,Plasma,IgG,Spike,,,,['High'],No,No,No,Yes,Unclear,Unclear,Yes,No,Unclear,Natasha Makabilo Laban,Centre for Infectious Disease Research in Zambia,Not Unity-Aligned,https://wellcomeopenresearch.org/articles/6-97/v1,2021-05-19,2022-07-16,Verified,laban_comparable_2021,ZMB
210801_Zambia_USCDC_Outpatient_Primary_Adj,210801_Zambia_USCDC_Outpatient,"SARS-CoV-2 Prevalence among Outpatients during Community Transmission, Zambia, July 2020.",2021-08-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Zambia,"Kabwe, Livingstone, Lusaka, Nakonde, Ndola, Solwezi",,"patients attending 20 outpatient clinics, including hospitals and health centers, in 6 districts in Zambia. We recruited participants from outpatient departments regardless of their reason for visiting
the facilities.",,2020-07-02,2020-07-31,Residual sera,All,Multiple groups,,,Primary Estimate,,1657,0.08199999999999999,0.051,0.114,True,True,,True,,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.657,1.0,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,No,Jonas Z Hines,US Centers for Disease Control and Prevention,Unity-Aligned,https://wwwnc.cdc.gov/eid/article/27/8/21-0502_article,2021-07-27,2023-08-15,Verified,hines_sars-cov-2_2021,ZMB
210801_Zambia_USCDC_Outpatient_Unadj,210801_Zambia_USCDC_Outpatient,"SARS-CoV-2 Prevalence among Outpatients during Community Transmission, Zambia, July 2020.",2021-08-01,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Zambia,"Kabwe, Livingstone, Lusaka, Nakonde, Ndola, Solwezi",,"patients attending 20 outpatient clinics, including hospitals and health centers, in 6 districts in Zambia. We recruited participants from outpatient departments regardless of their reason for visiting
the facilities.",,2020-07-02,2020-07-31,Residual sera,All,Multiple groups,,,Analysis,,1657,0.053,0.033,0.073,,,,,True,Convenience,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.657,1.0,['Moderate'],Yes,No,Yes,No,Unclear,Yes,Yes,Yes,No,Jonas Z Hines,US Centers for Disease Control and Prevention,Unity-Aligned,https://wwwnc.cdc.gov/eid/article/27/8/21-0502_article,2021-08-05,2024-03-01,Verified,hines_sars-cov-2_2021,ZMB
220316_Zambia_Zambart_Primary,220316_Zambia_Zambart,SARS-CoV-2 seroprevalence and associated risk factors in peri-urban Zambia: a population-based study.,2022-03-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Zambia,Zambian Central Province,,Individuals aged ≥15 years enrolled in the TREATS TB-prevalence survey were selected for antibody testing (sub-study),,2020-10-15,2021-03-15,Household and community samples,All,Multiple groups,15.0,,Primary Estimate,,2977,0.135,,,True,,,,True,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.99,1.0,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Kwame Shanaube,Zambart,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2022.03.021,2022-04-03,2024-03-01,Verified,shanaube_sars-cov-2_2022,ZMB
220316_Zambia_Zambart_Age_20-29,220316_Zambia_Zambart,SARS-CoV-2 seroprevalence and associated risk factors in peri-urban Zambia: a population-based study.,2022-03-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Zambia,Zambian Central Province,,Individuals aged ≥15 years enrolled in the TREATS TB-prevalence survey were selected for antibody testing (sub-study),,2020-10-15,2021-03-15,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,960,0.14300000000000002,,,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.99,1.0,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Kwame Shanaube,Zambart,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2022.03.021,2022-04-03,2024-03-01,Verified,shanaube_sars-cov-2_2022,ZMB
220316_Zambia_Zambart_Age_50+,220316_Zambia_Zambart,SARS-CoV-2 seroprevalence and associated risk factors in peri-urban Zambia: a population-based study.,2022-03-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Zambia,Zambian Central Province,,Individuals aged ≥15 years enrolled in the TREATS TB-prevalence survey were selected for antibody testing (sub-study),,2020-10-15,2021-03-15,Household and community samples,All,Multiple groups,50.0,,Age,50+,435,0.154,,,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.99,1.0,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Kwame Shanaube,Zambart,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2022.03.021,2022-04-03,2024-03-01,Verified,shanaube_sars-cov-2_2022,ZMB
220316_Zambia_Zambart_Age_15-19,220316_Zambia_Zambart,SARS-CoV-2 seroprevalence and associated risk factors in peri-urban Zambia: a population-based study.,2022-03-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Zambia,Zambian Central Province,,Individuals aged ≥15 years enrolled in the TREATS TB-prevalence survey were selected for antibody testing (sub-study),,2020-10-15,2021-03-15,Household and community samples,All,Multiple groups,15.0,19.0,Age,15-19,761,0.09699999999999999,,,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.99,1.0,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Kwame Shanaube,Zambart,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2022.03.021,2022-04-03,2024-03-01,Verified,shanaube_sars-cov-2_2022,ZMB
220316_Zambia_Zambart_Age_30-39,220316_Zambia_Zambart,SARS-CoV-2 seroprevalence and associated risk factors in peri-urban Zambia: a population-based study.,2022-03-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Zambia,Zambian Central Province,,Individuals aged ≥15 years enrolled in the TREATS TB-prevalence survey were selected for antibody testing (sub-study),,2020-10-15,2021-03-15,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,510,0.14300000000000002,,,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.99,1.0,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Kwame Shanaube,Zambart,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2022.03.021,2022-04-03,2024-03-01,Verified,shanaube_sars-cov-2_2022,ZMB
220316_Zambia_Zambart_Sex_Male,220316_Zambia_Zambart,SARS-CoV-2 seroprevalence and associated risk factors in peri-urban Zambia: a population-based study.,2022-03-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Zambia,Zambian Central Province,,Individuals aged ≥15 years enrolled in the TREATS TB-prevalence survey were selected for antibody testing (sub-study),,2020-10-15,2021-03-15,Household and community samples,Male,Multiple groups,15.0,,Sex/Gender,,1246,0.127,,,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.99,1.0,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Kwame Shanaube,Zambart,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2022.03.021,2022-04-03,2024-03-01,Verified,shanaube_sars-cov-2_2022,ZMB
220316_Zambia_Zambart_Sex_Female,220316_Zambia_Zambart,SARS-CoV-2 seroprevalence and associated risk factors in peri-urban Zambia: a population-based study.,2022-03-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Zambia,Zambian Central Province,,Individuals aged ≥15 years enrolled in the TREATS TB-prevalence survey were selected for antibody testing (sub-study),,2020-10-15,2021-03-15,Household and community samples,Female,Multiple groups,15.0,,Sex/Gender,,1731,0.14,,,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.99,1.0,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Kwame Shanaube,Zambart,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2022.03.021,2022-04-03,2024-03-01,Verified,shanaube_sars-cov-2_2022,ZMB
220316_Zambia_Zambart_Age_40-49,220316_Zambia_Zambart,SARS-CoV-2 seroprevalence and associated risk factors in peri-urban Zambia: a population-based study.,2022-03-16,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Zambia,Zambian Central Province,,Individuals aged ≥15 years enrolled in the TREATS TB-prevalence survey were selected for antibody testing (sub-study),,2020-10-15,2021-03-15,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,311,0.161,,,,,,,,Simplified probability,Abbott Architect SARS-CoV-2 IgG,Abbott Laboratories,CLIA,Plasma,IgG,Nucleocapsid(N-protein),Validated by manufacturers,0.99,1.0,['Moderate'],Yes,Yes,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Kwame Shanaube,Zambart,Unity-Aligned,https://dx.doi.org/10.1016/j.ijid.2022.03.021,2022-04-03,2024-03-01,Verified,shanaube_sars-cov-2_2022,ZMB
221212_USA_RTIInternational_Zambia,221212_USA_RTIInternational_Zambia,"COVID-19 Antibody Positivity Over Time and Pregnancy Outcomes in Seven Low-and-Middle-Income Countries: A Prospective, Observational Study of the Global Network for Women's and Children's Health Research.",2022-12-12,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Zambia,,,"""The COVID-19 antibody study, embedded within the MNHR, included a sub-set of women who were approached at delivery and enrolled. We collected a serum sample at or near delivery for each mother who was approached and consented.""", Women who did not consent to give blood for testing. Indeterminate results are excluded. ,2020-02-01,2020-02-29,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,1793,0.278,,,True,,,,True,Convenience,ELISA SARS-CoV-2 IgG Test System,Zeus,ELISA,Serum,IgG,"Nucleocapsid (N-protein), Spike",,,,['Moderate'],Yes,No,Yes,Yes,No,Yes,Yes,Yes,Unclear,Robert L. Goldenberg,RTI International,Unity-Aligned,https://dx.doi.org/10.1111/1471-0528.17366,2022-12-24,2024-03-01,Unverified,goldenberg_covid-19_2022,ZMB
230720_Zambia_JawaharlalNehruMedicalCollege_Overall,230720_Zambia_JawaharlalNehruMedicalCollege,COVID-19 symptoms and antibody positivity among unvaccinated pregnant women: An observational study in seven countries from the Global Network,2023-07-20,Journal Article (Peer-Reviewed),National,Prospective cohort,Zambia,,,staff (registry administrators [RAs]) identified pregnant women in their respective clusters,vaccinated pregnant women,2020-10-01,2022-06-30,Pregnant or parturient women,Female,Adults (18-64 years),,,Primary Estimate,,2667,0.337,,,True,,,,True,Stratified non-probability,Not reported/ Unable to specify,,,Serum,,,,,,['High'],,No,Yes,No,,Unclear,Yes,No,,Avinash Kavi,Jawaharlal Nehru Medical College,Not Unity-Aligned,https://dx.doi.org/10.1111/1471-0528.17604,2023-08-22,2023-08-23,Unverified,kavi_covid-19_2023,ZMB
210331_Bulawayo_UniversityofEdinburgh_Primary,210331_Bulawayo_UniversityofEdinburgh,SARS-CoV-2 Serological testing in frontline health workers in Zimbabwe,2021-03-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Zimbabwe,Bulawayo,,"every worker who comes into contact with patients on a daily basis, i.e. patient-facing worker who consented at each of the selected 24 health facilities. Thus, all patient-facing workers ranging from security, cleaners, laundry, student nurses, nurses, administrators and doctors were included in the study population.",HCW refused to participate in the study,2020-06-09,2020-06-22,Health care workers and caregivers,All,Multiple groups,18.0,73.0,Primary Estimate,,635,0.08900000000000001,0.069,0.115,True,,,,True,Self-referral,UNSCIENCE COVID-19 IgG/IgM antibody Rapid Test Kit,Wuhan UNscience Biotechnology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9851099999999999,0.88208,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Simbarashe Rusakaniko,University of Edinburgh,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0009254,2021-04-16,2024-03-01,Verified,rusakaniko_sars-cov-2_2021,ZWE
210331_Bulawayo_UniversityofEdinburgh_Age5357,210331_Bulawayo_UniversityofEdinburgh,SARS-CoV-2 Serological testing in frontline health workers in Zimbabwe,2021-03-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Zimbabwe,Bulawayo,,"every worker who comes into contact with patients on a daily basis, i.e. patient-facing worker who consented at each of the selected 24 health facilities. Thus, all patient-facing workers ranging from security, cleaners, laundry, student nurses, nurses, administrators and doctors were included in the study population.",HCW refused to participate in the study,2020-06-09,2020-06-22,Health care workers and caregivers,All,Adults (18-64 years),53.0,57.0,Age,53-57,73,0.096,,,,,,,,Self-referral,UNSCIENCE COVID-19 IgG/IgM antibody Rapid Test Kit,Wuhan UNscience Biotechnology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9851099999999999,0.88208,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Simbarashe Rusakaniko,University of Edinburgh,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0009254,2021-07-30,2024-03-01,Verified,rusakaniko_sars-cov-2_2021,ZWE
210331_Bulawayo_UniversityofEdinburgh_Age3337,210331_Bulawayo_UniversityofEdinburgh,SARS-CoV-2 Serological testing in frontline health workers in Zimbabwe,2021-03-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Zimbabwe,Bulawayo,,"every worker who comes into contact with patients on a daily basis, i.e. patient-facing worker who consented at each of the selected 24 health facilities. Thus, all patient-facing workers ranging from security, cleaners, laundry, student nurses, nurses, administrators and doctors were included in the study population.",HCW refused to participate in the study,2020-06-09,2020-06-22,Health care workers and caregivers,All,Adults (18-64 years),33.0,37.0,Age,33-37,86,0.057999999999999996,,,,,,,,Self-referral,UNSCIENCE COVID-19 IgG/IgM antibody Rapid Test Kit,Wuhan UNscience Biotechnology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9851099999999999,0.88208,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Simbarashe Rusakaniko,University of Edinburgh,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0009254,2021-07-30,2024-03-01,Verified,rusakaniko_sars-cov-2_2021,ZWE
210331_Bulawayo_UniversityofEdinburgh_Age6367,210331_Bulawayo_UniversityofEdinburgh,SARS-CoV-2 Serological testing in frontline health workers in Zimbabwe,2021-03-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Zimbabwe,Bulawayo,,"every worker who comes into contact with patients on a daily basis, i.e. patient-facing worker who consented at each of the selected 24 health facilities. Thus, all patient-facing workers ranging from security, cleaners, laundry, student nurses, nurses, administrators and doctors were included in the study population.",HCW refused to participate in the study,2020-06-09,2020-06-22,Health care workers and caregivers,All,Seniors (65+ years),63.0,67.0,Age,63-66,16,0.313,,,,,,,,Self-referral,UNSCIENCE COVID-19 IgG/IgM antibody Rapid Test Kit,Wuhan UNscience Biotechnology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9851099999999999,0.88208,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Simbarashe Rusakaniko,University of Edinburgh,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0009254,2021-07-30,2024-03-01,Verified,rusakaniko_sars-cov-2_2021,ZWE
210331_Bulawayo_UniversityofEdinburgh_Age2832,210331_Bulawayo_UniversityofEdinburgh,SARS-CoV-2 Serological testing in frontline health workers in Zimbabwe,2021-03-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Zimbabwe,Bulawayo,,"every worker who comes into contact with patients on a daily basis, i.e. patient-facing worker who consented at each of the selected 24 health facilities. Thus, all patient-facing workers ranging from security, cleaners, laundry, student nurses, nurses, administrators and doctors were included in the study population.",HCW refused to participate in the study,2020-06-09,2020-06-22,Health care workers and caregivers,All,Adults (18-64 years),28.0,32.0,Age,28-32,82,0.061,,,,,,,,Self-referral,UNSCIENCE COVID-19 IgG/IgM antibody Rapid Test Kit,Wuhan UNscience Biotechnology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9851099999999999,0.88208,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Simbarashe Rusakaniko,University of Edinburgh,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0009254,2021-07-30,2024-03-01,Verified,rusakaniko_sars-cov-2_2021,ZWE
210331_Bulawayo_UniversityofEdinburgh_Age1822,210331_Bulawayo_UniversityofEdinburgh,SARS-CoV-2 Serological testing in frontline health workers in Zimbabwe,2021-03-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Zimbabwe,Bulawayo,,"every worker who comes into contact with patients on a daily basis, i.e. patient-facing worker who consented at each of the selected 24 health facilities. Thus, all patient-facing workers ranging from security, cleaners, laundry, student nurses, nurses, administrators and doctors were included in the study population.",HCW refused to participate in the study,2020-06-09,2020-06-22,Health care workers and caregivers,All,Adults (18-64 years),18.0,22.0,Age,18-22,33,0.152,,,,,,,,Self-referral,UNSCIENCE COVID-19 IgG/IgM antibody Rapid Test Kit,Wuhan UNscience Biotechnology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9851099999999999,0.88208,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Simbarashe Rusakaniko,University of Edinburgh,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0009254,2021-07-30,2024-03-01,Verified,rusakaniko_sars-cov-2_2021,ZWE
210331_Bulawayo_UniversityofEdinburgh_Age6873,210331_Bulawayo_UniversityofEdinburgh,SARS-CoV-2 Serological testing in frontline health workers in Zimbabwe,2021-03-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Zimbabwe,Bulawayo,,"every worker who comes into contact with patients on a daily basis, i.e. patient-facing worker who consented at each of the selected 24 health facilities. Thus, all patient-facing workers ranging from security, cleaners, laundry, student nurses, nurses, administrators and doctors were included in the study population.",HCW refused to participate in the study,2020-06-09,2020-06-22,Health care workers and caregivers,All,Seniors (65+ years),68.0,73.0,Age,68-73,6,0.0,,,,,,,,Self-referral,UNSCIENCE COVID-19 IgG/IgM antibody Rapid Test Kit,Wuhan UNscience Biotechnology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9851099999999999,0.88208,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Simbarashe Rusakaniko,University of Edinburgh,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0009254,2021-07-30,2024-03-01,Verified,rusakaniko_sars-cov-2_2021,ZWE
210331_Bulawayo_UniversityofEdinburgh_Age2327,210331_Bulawayo_UniversityofEdinburgh,SARS-CoV-2 Serological testing in frontline health workers in Zimbabwe,2021-03-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Zimbabwe,Bulawayo,,"every worker who comes into contact with patients on a daily basis, i.e. patient-facing worker who consented at each of the selected 24 health facilities. Thus, all patient-facing workers ranging from security, cleaners, laundry, student nurses, nurses, administrators and doctors were included in the study population.",HCW refused to participate in the study,2020-06-09,2020-06-22,Health care workers and caregivers,All,Adults (18-64 years),23.0,27.0,Age,23-27,57,0.105,,,,,,,,Self-referral,UNSCIENCE COVID-19 IgG/IgM antibody Rapid Test Kit,Wuhan UNscience Biotechnology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9851099999999999,0.88208,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Simbarashe Rusakaniko,University of Edinburgh,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0009254,2021-07-30,2024-03-01,Verified,rusakaniko_sars-cov-2_2021,ZWE
210331_Bulawayo_UniversityofEdinburgh_Age4852,210331_Bulawayo_UniversityofEdinburgh,SARS-CoV-2 Serological testing in frontline health workers in Zimbabwe,2021-03-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Zimbabwe,Bulawayo,,"every worker who comes into contact with patients on a daily basis, i.e. patient-facing worker who consented at each of the selected 24 health facilities. Thus, all patient-facing workers ranging from security, cleaners, laundry, student nurses, nurses, administrators and doctors were included in the study population.",HCW refused to participate in the study,2020-06-09,2020-06-22,Health care workers and caregivers,All,Adults (18-64 years),48.0,52.0,Age,48-52,66,0.076,,,,,,,,Self-referral,UNSCIENCE COVID-19 IgG/IgM antibody Rapid Test Kit,Wuhan UNscience Biotechnology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9851099999999999,0.88208,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Simbarashe Rusakaniko,University of Edinburgh,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0009254,2021-07-30,2024-03-01,Verified,rusakaniko_sars-cov-2_2021,ZWE
210331_Bulawayo_UniversityofEdinburgh_Age4347,210331_Bulawayo_UniversityofEdinburgh,SARS-CoV-2 Serological testing in frontline health workers in Zimbabwe,2021-03-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Zimbabwe,Bulawayo,,"every worker who comes into contact with patients on a daily basis, i.e. patient-facing worker who consented at each of the selected 24 health facilities. Thus, all patient-facing workers ranging from security, cleaners, laundry, student nurses, nurses, administrators and doctors were included in the study population.",HCW refused to participate in the study,2020-06-09,2020-06-22,Health care workers and caregivers,All,Adults (18-64 years),43.0,47.0,Age,43-47,70,0.129,,,,,,,,Self-referral,UNSCIENCE COVID-19 IgG/IgM antibody Rapid Test Kit,Wuhan UNscience Biotechnology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9851099999999999,0.88208,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Simbarashe Rusakaniko,University of Edinburgh,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0009254,2021-07-30,2024-03-01,Verified,rusakaniko_sars-cov-2_2021,ZWE
210331_Bulawayo_UniversityofEdinburgh_Age3842,210331_Bulawayo_UniversityofEdinburgh,SARS-CoV-2 Serological testing in frontline health workers in Zimbabwe,2021-03-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Zimbabwe,Bulawayo,,"every worker who comes into contact with patients on a daily basis, i.e. patient-facing worker who consented at each of the selected 24 health facilities. Thus, all patient-facing workers ranging from security, cleaners, laundry, student nurses, nurses, administrators and doctors were included in the study population.",HCW refused to participate in the study,2020-06-09,2020-06-22,Health care workers and caregivers,All,Adults (18-64 years),38.0,42.0,Age,38-42,88,0.068,,,,,,,,Self-referral,UNSCIENCE COVID-19 IgG/IgM antibody Rapid Test Kit,Wuhan UNscience Biotechnology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9851099999999999,0.88208,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Simbarashe Rusakaniko,University of Edinburgh,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0009254,2021-07-30,2024-03-01,Verified,rusakaniko_sars-cov-2_2021,ZWE
210331_Bulawayo_UniversityofEdinburgh_Age5862,210331_Bulawayo_UniversityofEdinburgh,SARS-CoV-2 Serological testing in frontline health workers in Zimbabwe,2021-03-31,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Zimbabwe,Bulawayo,,"every worker who comes into contact with patients on a daily basis, i.e. patient-facing worker who consented at each of the selected 24 health facilities. Thus, all patient-facing workers ranging from security, cleaners, laundry, student nurses, nurses, administrators and doctors were included in the study population.",HCW refused to participate in the study,2020-06-09,2020-06-22,Health care workers and caregivers,All,Adults (18-64 years),58.0,62.0,Age,58-62,58,0.069,,,,,,,,Self-referral,UNSCIENCE COVID-19 IgG/IgM antibody Rapid Test Kit,Wuhan UNscience Biotechnology Co. Ltd,LFIA,Whole Blood,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Validated by manufacturers,0.9851099999999999,0.88208,['High'],No,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Simbarashe Rusakaniko,University of Edinburgh,Not Unity-Aligned,https://dx.doi.org/10.1371/journal.pntd.0009254,2021-07-30,2024-03-01,Verified,rusakaniko_sars-cov-2_2021,ZWE
211023_Harare_BiomedicalResearchandTrainingInstituteHarare_February2021_Overall,211023_Harare_BiomedicalResearchandTrainingInstituteHarare_February2021,"Community SARS-CoV-2 seroprevalence before and after the second wave of SARS-CoV-2 infection in Harare, Zimbabwe.",2021-10-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Zimbabwe,Harare,Harare,"randomly selected households aiming for a total of 2000 participants in three communi- ties in Harare namely Budiriro, Highfield and Mbare

Individuals of any age who had slept three out of the last seven nights in the household before the survey team visited were eligible for participation in the survey.",,2021-02-10,2021-04-17,Household and community samples,All,Multiple groups,0.0,100.0,Primary Estimate,,1530,0.53,0.49600000000000005,0.564,True,,,,True,Simplified probability,Author designed (type unknown),,Other,Dried Blood,,Nucleocapsid(N-protein),Validated by developers,0.9920000000000001,0.9865,['Moderate'],No,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Yes,Arun Fryatt,Biomedical Research and Training Institute,Unity-Aligned,https://dx.doi.org/10.1016/j.eclinm.2021.101172,2021-11-09,2022-07-16,Verified,fryatt_community_2021,ZWE
211023_Harare_BiomedicalResearchandTrainingInstituteHarare_November2020_Overall,211023_Harare_BiomedicalResearchandTrainingInstituteHarare_November2020,"Community SARS-CoV-2 seroprevalence before and after the second wave of SARS-CoV-2 infection in Harare, Zimbabwe.",2021-10-23,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Zimbabwe,Harare,Harare,"randomly selected households aiming for a total of 2000 participants in three communi- ties in Harare namely Budiriro, Highfield and Mbare

Individuals of any age who had slept three out of the last seven nights in the household before the survey team visited were eligible for participation in the survey.",,2020-11-20,2020-12-20,Household and community samples,All,Multiple groups,0.0,100.0,Primary Estimate,,620,0.19,0.151,0.23500000000000001,True,,,,True,Simplified probability,Author designed (type unknown),,Other,Dried Blood,,Nucleocapsid(N-protein),Validated by developers,0.9920000000000001,0.9865,['Moderate'],No,Yes,Yes,Yes,Unclear,Unclear,Yes,Yes,Yes,Arun Fryatt,Biomedical Research and Training Institute,Unity-Aligned,https://dx.doi.org/10.1016/j.eclinm.2021.101172,2021-11-09,2022-07-16,Verified,fryatt_community_2021,ZWE
221129_Bulawayo_MidlandsStateUniversity_Primary,221129_Bulawayo_MidlandsStateUniversity,"Peptide microarray analysis of in-silico predicted B-cell epitopes in SARS-CoV-2 sero-positive healthcare workers in Bulawayo, Zimbabwe",2022-11-29,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Zimbabwe,Matabeleland,Bulawayo,"""healthcare workers (cleaners, security officers, nurses, administrators, and doctors) were recruited into the study from health facilities in Bulawayo, Zimbabwe""",Those who refused consent,2020-06-01,2020-06-30,Health care workers and caregivers,All,Multiple groups,20.0,64.0,Primary Estimate,,53,0.1887,,,True,,,,True,Unclear,"UNSCIENCE COVID-19 IgG/IgM antibody Rapid Test Kit,Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit ","Wuhan UNscience Biotechnology Co. Ltd,SD Biosensor",LFIA,Serum,"['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",,,,['High'],,Unclear,No,Yes,,Yes,Yes,No,,Arthur Vengesai,University of Zimbabwe,Not Unity-Aligned,https://dx.doi.org/10.1016/j.actatropica.2022.106781,2023-01-13,2024-03-01,Unverified,vengesai_peptide_2023,ZWE
210107_WestBank_ArabAmericanUniversity_Households_overall_adj,210107_WestBank_ArabAmericanUniversity_Households,Seroprevalence of SARS-CoV-2 in the West Bank region of Palestine: a cross-sectional seroepidemiological study,2021-01-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,occupied Palestinian territory - including east Jerusalem,,West Bank,non-institutionalised Palestinian population residing in the West Bank,The random sample did not include children under the age of 15,2020-06-15,2020-06-30,Household and community samples,All,Multiple groups,15.0,,Primary Estimate,,1355,0.0,0.0,0.0043,True,True,True,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.8387000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Nouar Qutob,Arab American University ,Unity-Aligned,https://bmjopen.bmj.com/content/11/2/e044552,2021-02-18,2023-07-04,Verified,qutob_seroprevalence_2021,PSE
210107_WestBank_ArabAmericanUniversity_Households_overall_popadj_testunadj,210107_WestBank_ArabAmericanUniversity_Households,Seroprevalence of SARS-CoV-2 in the West Bank region of Palestine: a cross-sectional seroepidemiological study,2021-01-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,occupied Palestinian territory - including east Jerusalem,,West Bank,non-institutionalised Palestinian population residing in the West Bank,The random sample did not include children under the age of 15,2020-06-15,2020-06-30,Household and community samples,All,Multiple groups,15.0,,Analysis,,1355,0.0,0.0,0.0036,,,True,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,0.8387000000000001,1.0,['Low'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Nouar Qutob,Arab American University ,Unity-Aligned,https://bmjopen.bmj.com/content/11/2/e044552,2021-03-29,2024-03-01,Verified,qutob_seroprevalence_2021,PSE
210107_WestBank_ArabAmericanUniversity_LabReferrals_overall_adj,210107_WestBank_ArabAmericanUniversity_LabReferrals ,Seroprevalence of SARS-CoV-2 in the West Bank region of Palestine: a cross-sectional seroepidemiological study,2021-01-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,occupied Palestinian territory - including east Jerusalem,,West Bank,participants from Medi- care medical laboratories network referrals between 1st May 2020 and 9th July 2020 in 16 branches in the West Bank ,,2020-05-01,2020-07-09,Residual sera,All,Multiple groups,,,Primary Estimate,,1136,0.0034999999999999996,0.0013000000000000002,0.0116,True,True,,,,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.8387000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Nouar Qutob,Arab American University ,Unity-Aligned,https://bmjopen.bmj.com/content/11/2/e044552,2021-02-18,2023-07-04,Verified,qutob_seroprevalence_2021,PSE
210107_WestBank_ArabAmericanUniversity_LabReferrals_overall_unadj,210107_WestBank_ArabAmericanUniversity_LabReferrals ,Seroprevalence of SARS-CoV-2 in the West Bank region of Palestine: a cross-sectional seroepidemiological study,2021-01-07,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,occupied Palestinian territory - including east Jerusalem,,West Bank,participants from Medi- care medical laboratories network referrals between 1st May 2020 and 9th July 2020 in 16 branches in the West Bank ,,2020-05-01,2020-07-09,Residual sera,All,Multiple groups,,,Analysis,,1136,0.0034999999999999996,0.0013000000000000002,0.0096,,,,,True,Convenience,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,Nucleocapsid(N-protein),Validated by independent authors/third party/non-developers,1.0,0.8387000000000001,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,,Nouar Qutob,Arab American University ,Unity-Aligned,https://bmjopen.bmj.com/content/11/2/e044552,2021-03-29,2024-03-01,Verified,qutob_seroprevalence_2021,PSE
211007_Palestine_PalestinianNationalInstituteofPublicHealth_Gaza_Overall,211007_Palestine_PalestinianNationalInstituteofPublicHealth_Gaza,Sero Prevalence of COVID-19 in Palestine in 2020,2021-10-07,Preprint,Regional,Cross-sectional survey ,occupied Palestinian territory - including east Jerusalem,Gaza,,"All individuals over the age of 10 years irrespective of known prior COVID-19 infection who resided in the area under study during the period of SARS-CoV-2 transmission and who can give consent, or in the case of minor children, whose legal guardian can give consent for them.","All individuals who refuse or are unable to give informed consent, or who present contraindication to venipuncture. Prisoners were excluded due to logistical difficulties. Individuals with conditions that make sampling them potentially harmful and persons currently infected with COVID-19.",2020-12-01,2020-12-31,Household and community samples,All,Multiple groups,10.0,,Primary Estimate,,2904,0.4,,,True,,,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.988,0.9998,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,I Rayan,Palestinian National Institute of Public Health,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.10.04.21263131v1,2021-10-13,2024-03-01,Verified,rayan_seroprevalence_2021,PSE
211007_Palestine_PalestinianNationalInstituteofPublicHealth_Gaza_Male,211007_Palestine_PalestinianNationalInstituteofPublicHealth_Gaza,Sero Prevalence of COVID-19 in Palestine in 2020,2021-10-07,Preprint,Regional,Cross-sectional survey ,occupied Palestinian territory - including east Jerusalem,Gaza,,"All individuals over the age of 10 years irrespective of known prior COVID-19 infection who resided in the area under study during the period of SARS-CoV-2 transmission and who can give consent, or in the case of minor children, whose legal guardian can give consent for them.","All individuals who refuse or are unable to give informed consent, or who present contraindication to venipuncture. Prisoners were excluded due to logistical difficulties. Individuals with conditions that make sampling them potentially harmful and persons currently infected with COVID-19.",2020-12-01,2020-12-31,Household and community samples,Male,Multiple groups,10.0,,Sex/Gender,,1452,0.39,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.988,0.9998,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,I Rayan,Palestinian National Institute of Public Health,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.10.04.21263131v1,2021-10-13,2024-03-01,Verified,rayan_seroprevalence_2021,PSE
211007_Palestine_PalestinianNationalInstituteofPublicHealth_Gaza_Female,211007_Palestine_PalestinianNationalInstituteofPublicHealth_Gaza,Sero Prevalence of COVID-19 in Palestine in 2020,2021-10-07,Preprint,Regional,Cross-sectional survey ,occupied Palestinian territory - including east Jerusalem,Gaza,,"All individuals over the age of 10 years irrespective of known prior COVID-19 infection who resided in the area under study during the period of SARS-CoV-2 transmission and who can give consent, or in the case of minor children, whose legal guardian can give consent for them.","All individuals who refuse or are unable to give informed consent, or who present contraindication to venipuncture. Prisoners were excluded due to logistical difficulties. Individuals with conditions that make sampling them potentially harmful and persons currently infected with COVID-19.",2020-12-01,2020-12-31,Household and community samples,Female,Multiple groups,10.0,,Sex/Gender,,1452,0.43,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.988,0.9998,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,I Rayan,Palestinian National Institute of Public Health,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.10.04.21263131v1,2021-10-13,2024-03-01,Verified,rayan_seroprevalence_2021,PSE
211007_Palestine_PalestinianNationalInstituteofPublicHealth_WestBank_Overall,211007_Palestine_PalestinianNationalInstituteofPublicHealth_WestBank,Sero Prevalence of COVID-19 in Palestine in 2020,2021-10-07,Preprint,Regional,Cross-sectional survey ,occupied Palestinian territory - including east Jerusalem,West Bank,,"All individuals over the age of 10 years irrespective of known prior COVID-19 infection who resided in the area under study during the period of SARS-CoV-2 transmission and who can give consent, or in the case of minor children, whose legal guardian can give consent for them.","All individuals who refuse or are unable to give informed consent, or who present contraindication to venipuncture. Prisoners were excluded due to logistical difficulties. Individuals with conditions that make sampling them potentially harmful and persons currently infected with COVID-19.",2020-12-01,2020-12-31,Household and community samples,All,Multiple groups,10.0,,Primary Estimate,,4356,0.38,,,True,,,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.988,0.9998,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,I Rayan,Palestinian National Institute of Public Health,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.10.04.21263131v1,2021-10-13,2024-03-01,Verified,rayan_seroprevalence_2021,PSE
211007_Palestine_PalestinianNationalInstituteofPublicHealth_WestBank_Female,211007_Palestine_PalestinianNationalInstituteofPublicHealth_WestBank,Sero Prevalence of COVID-19 in Palestine in 2020,2021-10-07,Preprint,Regional,Cross-sectional survey ,occupied Palestinian territory - including east Jerusalem,West Bank,,"All individuals over the age of 10 years irrespective of known prior COVID-19 infection who resided in the area under study during the period of SARS-CoV-2 transmission and who can give consent, or in the case of minor children, whose legal guardian can give consent for them.","All individuals who refuse or are unable to give informed consent, or who present contraindication to venipuncture. Prisoners were excluded due to logistical difficulties. Individuals with conditions that make sampling them potentially harmful and persons currently infected with COVID-19.",2020-12-01,2020-12-31,Household and community samples,Female,Multiple groups,10.0,,Sex/Gender,,2178,0.46,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.988,0.9998,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,I Rayan,Palestinian National Institute of Public Health,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.10.04.21263131v1,2021-10-13,2024-03-01,Verified,rayan_seroprevalence_2021,PSE
211007_Palestine_PalestinianNationalInstituteofPublicHealth_WestBank_Male,211007_Palestine_PalestinianNationalInstituteofPublicHealth_WestBank,Sero Prevalence of COVID-19 in Palestine in 2020,2021-10-07,Preprint,Regional,Cross-sectional survey ,occupied Palestinian territory - including east Jerusalem,West Bank,,"All individuals over the age of 10 years irrespective of known prior COVID-19 infection who resided in the area under study during the period of SARS-CoV-2 transmission and who can give consent, or in the case of minor children, whose legal guardian can give consent for them.","All individuals who refuse or are unable to give informed consent, or who present contraindication to venipuncture. Prisoners were excluded due to logistical difficulties. Individuals with conditions that make sampling them potentially harmful and persons currently infected with COVID-19.",2020-12-01,2020-12-31,Household and community samples,Male,Multiple groups,10.0,,Sex/Gender,,2178,0.32,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,IgG,Spike,Validated by manufacturers,0.988,0.9998,['Moderate'],Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Unclear,I Rayan,Palestinian National Institute of Public Health,Unity-Aligned,https://www.medrxiv.org/content/10.1101/2021.10.04.21263131v1,2021-10-13,2024-03-01,Verified,rayan_seroprevalence_2021,PSE
211008_Palestine_An-NajahNationalUniversity_Overall,211008_Palestine_An-NajahNationalUniversity,Prevalence of SARS-CoV-2 antibodies in the Palestinian population: A primary health center-based cross-sectional study.,2021-10-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,occupied Palestinian territory - including east Jerusalem,West Bank,,"People who visited the PHC centers in all West Bank governorates (Jenin, Tubas, Tulkarm, Qalqilia, Nablus, Salfit, Ramallah, Jericho, Jeruzalem, Bethlehem, and Hebron) for different reasons, excluding children and adolescents (age <18 years) comprised the study population.",children and adolescents (age <18 years),2020-11-01,2020-12-31,Residual sera,All,Multiple groups,18.0,,Primary Estimate,,1269,0.2403,0.217,0.265,True,,,,True,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,,,,,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Beesan Maraqa,An-Najah National University,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0258255,2021-10-19,2024-03-01,Verified,maraqa_prevalence_2021,PSE
211008_Palestine_An-NajahNationalUniversity_Age31-59,211008_Palestine_An-NajahNationalUniversity,Prevalence of SARS-CoV-2 antibodies in the Palestinian population: A primary health center-based cross-sectional study.,2021-10-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,occupied Palestinian territory - including east Jerusalem,West Bank,,"People who visited the PHC centers in all West Bank governorates (Jenin, Tubas, Tulkarm, Qalqilia, Nablus, Salfit, Ramallah, Jericho, Jeruzalem, Bethlehem, and Hebron) for different reasons, excluding children and adolescents (age <18 years) comprised the study population.",children and adolescents (age <18 years),2020-11-01,2020-12-31,Residual sera,All,Adults (18-64 years),31.0,59.0,Age,31-59,684,0.2778,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,,,,,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Beesan Maraqa,An-Najah National University,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0258255,2021-10-19,2024-03-01,Verified,maraqa_prevalence_2021,PSE
211008_Palestine_An-NajahNationalUniversity_South,211008_Palestine_An-NajahNationalUniversity,Prevalence of SARS-CoV-2 antibodies in the Palestinian population: A primary health center-based cross-sectional study.,2021-10-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,occupied Palestinian territory - including east Jerusalem,West Bank,,"People who visited the PHC centers in all West Bank governorates (Jenin, Tubas, Tulkarm, Qalqilia, Nablus, Salfit, Ramallah, Jericho, Jeruzalem, Bethlehem, and Hebron) for different reasons, excluding children and adolescents (age <18 years) comprised the study population.",children and adolescents (age <18 years),2020-11-01,2020-12-31,Residual sera,All,Multiple groups,18.0,,Geographical area,South,431,0.341,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,,,,,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Beesan Maraqa,An-Najah National University,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0258255,2021-12-16,2024-03-01,Verified,maraqa_prevalence_2021,PSE
211008_Palestine_An-NajahNationalUniversity_North,211008_Palestine_An-NajahNationalUniversity,Prevalence of SARS-CoV-2 antibodies in the Palestinian population: A primary health center-based cross-sectional study.,2021-10-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,occupied Palestinian territory - including east Jerusalem,West Bank,,"People who visited the PHC centers in all West Bank governorates (Jenin, Tubas, Tulkarm, Qalqilia, Nablus, Salfit, Ramallah, Jericho, Jeruzalem, Bethlehem, and Hebron) for different reasons, excluding children and adolescents (age <18 years) comprised the study population.",children and adolescents (age <18 years),2020-11-01,2020-12-31,Residual sera,All,Multiple groups,18.0,,Geographical area,North,549,0.16899999999999998,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,,,,,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Beesan Maraqa,An-Najah National University,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0258255,2021-12-16,2024-03-01,Verified,maraqa_prevalence_2021,PSE
211008_Palestine_An-NajahNationalUniversity_Middle,211008_Palestine_An-NajahNationalUniversity,Prevalence of SARS-CoV-2 antibodies in the Palestinian population: A primary health center-based cross-sectional study.,2021-10-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,occupied Palestinian territory - including east Jerusalem,West Bank,,"People who visited the PHC centers in all West Bank governorates (Jenin, Tubas, Tulkarm, Qalqilia, Nablus, Salfit, Ramallah, Jericho, Jeruzalem, Bethlehem, and Hebron) for different reasons, excluding children and adolescents (age <18 years) comprised the study population.",children and adolescents (age <18 years),2020-11-01,2020-12-31,Residual sera,All,Multiple groups,18.0,,Geographical area,Middle,289,0.225,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,,,,,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Beesan Maraqa,An-Najah National University,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0258255,2021-12-16,2024-03-01,Verified,maraqa_prevalence_2021,PSE
211008_Palestine_An-NajahNationalUniversity_Male,211008_Palestine_An-NajahNationalUniversity,Prevalence of SARS-CoV-2 antibodies in the Palestinian population: A primary health center-based cross-sectional study.,2021-10-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,occupied Palestinian territory - including east Jerusalem,West Bank,,"People who visited the PHC centers in all West Bank governorates (Jenin, Tubas, Tulkarm, Qalqilia, Nablus, Salfit, Ramallah, Jericho, Jeruzalem, Bethlehem, and Hebron) for different reasons, excluding children and adolescents (age <18 years) comprised the study population.",children and adolescents (age <18 years),2020-11-01,2020-12-31,Residual sera,Male,Multiple groups,18.0,,Sex/Gender,,507,0.1696,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,,,,,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Beesan Maraqa,An-Najah National University,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0258255,2021-10-19,2024-03-01,Verified,maraqa_prevalence_2021,PSE
211008_Palestine_An-NajahNationalUniversity_Age<=30,211008_Palestine_An-NajahNationalUniversity,Prevalence of SARS-CoV-2 antibodies in the Palestinian population: A primary health center-based cross-sectional study.,2021-10-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,occupied Palestinian territory - including east Jerusalem,West Bank,,"People who visited the PHC centers in all West Bank governorates (Jenin, Tubas, Tulkarm, Qalqilia, Nablus, Salfit, Ramallah, Jericho, Jeruzalem, Bethlehem, and Hebron) for different reasons, excluding children and adolescents (age <18 years) comprised the study population.",children and adolescents (age <18 years),2020-11-01,2020-12-31,Residual sera,All,Adults (18-64 years),18.0,30.0,Age,<=30,386,0.17620000000000002,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,,,,,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Beesan Maraqa,An-Najah National University,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0258255,2021-10-19,2024-03-01,Verified,maraqa_prevalence_2021,PSE
211008_Palestine_An-NajahNationalUniversity_Age>=60,211008_Palestine_An-NajahNationalUniversity,Prevalence of SARS-CoV-2 antibodies in the Palestinian population: A primary health center-based cross-sectional study.,2021-10-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,occupied Palestinian territory - including east Jerusalem,West Bank,,"People who visited the PHC centers in all West Bank governorates (Jenin, Tubas, Tulkarm, Qalqilia, Nablus, Salfit, Ramallah, Jericho, Jeruzalem, Bethlehem, and Hebron) for different reasons, excluding children and adolescents (age <18 years) comprised the study population.",children and adolescents (age <18 years),2020-11-01,2020-12-31,Residual sera,All,Seniors (65+ years),60.0,,Age,>=60,199,0.23620000000000002,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,,,,,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Beesan Maraqa,An-Najah National University,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0258255,2021-10-19,2024-03-01,Verified,maraqa_prevalence_2021,PSE
211008_Palestine_An-NajahNationalUniversity_Female,211008_Palestine_An-NajahNationalUniversity,Prevalence of SARS-CoV-2 antibodies in the Palestinian population: A primary health center-based cross-sectional study.,2021-10-08,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,occupied Palestinian territory - including east Jerusalem,West Bank,,"People who visited the PHC centers in all West Bank governorates (Jenin, Tubas, Tulkarm, Qalqilia, Nablus, Salfit, Ramallah, Jericho, Jeruzalem, Bethlehem, and Hebron) for different reasons, excluding children and adolescents (age <18 years) comprised the study population.",children and adolescents (age <18 years),2020-11-01,2020-12-31,Residual sera,Female,Multiple groups,18.0,,Sex/Gender,,762,0.2874,,,,,,,,Simplified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,TotalAntibody,,,,,['Moderate'],No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Unclear,Beesan Maraqa,An-Najah National University,Unity-Aligned,https://dx.doi.org/10.1371/journal.pone.0258255,2021-10-19,2024-03-01,Verified,maraqa_prevalence_2021,PSE
220817_WestBank_ArabAmericanUniversityofPalestine_Overall_TotalAntibodies_Primary,220817_WestBank_ArabAmericanUniversityofPalestine,Seroprevalence of SARS-CoV-2 Antibodies among Vaccinated and Non-Vaccinated Adults in the West Bank: Results of a Repeated Cross-Sectional Study.,2022-08-17,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,occupied Palestinian territory - including east Jerusalem,"""11 governorates in West Bank, Palestine""",,Adults aged 18+,,2021-09-14,2021-10-21,Household and community samples,All,Multiple groups,18.0,,Primary Estimate,,910,0.7590000000000001,,,True,,,,True,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Faisal Awartani,Arab American University of Palestine,Unity-Aligned,https://dx.doi.org/10.3390/vaccines10081332,2022-09-11,2024-04-29,Verified,awartani_seroprevalence_2022,PSE
220817_WestBank_ArabAmericanUniversityofPalestine_Males_TotalAntibodies,220817_WestBank_ArabAmericanUniversityofPalestine,Seroprevalence of SARS-CoV-2 Antibodies among Vaccinated and Non-Vaccinated Adults in the West Bank: Results of a Repeated Cross-Sectional Study.,2022-08-17,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,occupied Palestinian territory - including east Jerusalem,"""11 governorates in West Bank, Palestine""",,Adults aged 18+,,2021-09-14,2021-10-21,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,442,0.742,,,,,,,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Faisal Awartani,Arab American University of Palestine,Unity-Aligned,https://dx.doi.org/10.3390/vaccines10081332,2022-09-16,2024-04-29,Verified,awartani_seroprevalence_2022,PSE
220817_WestBank_ArabAmericanUniversityofPalestine_Ages50+_TotalAntibodies,220817_WestBank_ArabAmericanUniversityofPalestine,Seroprevalence of SARS-CoV-2 Antibodies among Vaccinated and Non-Vaccinated Adults in the West Bank: Results of a Repeated Cross-Sectional Study.,2022-08-17,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,occupied Palestinian territory - including east Jerusalem,"""11 governorates in West Bank, Palestine""",,Adults aged 18+,,2021-09-14,2021-10-21,Household and community samples,All,Multiple groups,50.0,,Age,ages 50+,221,0.8420000000000001,,,,,,,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Faisal Awartani,Arab American University of Palestine,Unity-Aligned,https://dx.doi.org/10.3390/vaccines10081332,2022-09-16,2024-04-29,Verified,awartani_seroprevalence_2022,PSE
220817_WestBank_ArabAmericanUniversityofPalestine_Females_TotalAntibodies,220817_WestBank_ArabAmericanUniversityofPalestine,Seroprevalence of SARS-CoV-2 Antibodies among Vaccinated and Non-Vaccinated Adults in the West Bank: Results of a Repeated Cross-Sectional Study.,2022-08-17,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,occupied Palestinian territory - including east Jerusalem,"""11 governorates in West Bank, Palestine""",,Adults aged 18+,,2021-09-14,2021-10-21,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,468,0.7759999999999999,,,,,,,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Faisal Awartani,Arab American University of Palestine,Unity-Aligned,https://dx.doi.org/10.3390/vaccines10081332,2022-09-16,2024-04-29,Verified,awartani_seroprevalence_2022,PSE
220817_WestBank_ArabAmericanUniversityofPalestine_Males_AntiNProtein,220817_WestBank_ArabAmericanUniversityofPalestine,Seroprevalence of SARS-CoV-2 Antibodies among Vaccinated and Non-Vaccinated Adults in the West Bank: Results of a Repeated Cross-Sectional Study.,2022-08-17,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,occupied Palestinian territory - including east Jerusalem,"""11 governorates in West Bank, Palestine""",,Adults aged 18+,,2021-09-14,2021-10-21,Household and community samples,Male,Multiple groups,18.0,,Sex/Gender,,442,0.42,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Faisal Awartani,Arab American University of Palestine,Unity-Aligned,https://dx.doi.org/10.3390/vaccines10081332,2022-09-16,2024-04-29,Verified,awartani_seroprevalence_2022,PSE
220817_WestBank_ArabAmericanUniversityofPalestine_Ages18-29_TotalAntibodies,220817_WestBank_ArabAmericanUniversityofPalestine,Seroprevalence of SARS-CoV-2 Antibodies among Vaccinated and Non-Vaccinated Adults in the West Bank: Results of a Repeated Cross-Sectional Study.,2022-08-17,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,occupied Palestinian territory - including east Jerusalem,"""11 governorates in West Bank, Palestine""",,Adults aged 18+,,2021-09-14,2021-10-21,Household and community samples,All,Adults (18-64 years),18.0,29.0,Age,ages 18-29,367,0.6920000000000001,,,,,,,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Faisal Awartani,Arab American University of Palestine,Unity-Aligned,https://dx.doi.org/10.3390/vaccines10081332,2022-09-16,2024-04-29,Verified,awartani_seroprevalence_2022,PSE
220817_WestBank_ArabAmericanUniversityofPalestine_Ages30-49_TotalAntibodies,220817_WestBank_ArabAmericanUniversityofPalestine,Seroprevalence of SARS-CoV-2 Antibodies among Vaccinated and Non-Vaccinated Adults in the West Bank: Results of a Repeated Cross-Sectional Study.,2022-08-17,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,occupied Palestinian territory - including east Jerusalem,"""11 governorates in West Bank, Palestine""",,Adults aged 18+,,2021-09-14,2021-10-21,Household and community samples,All,Adults (18-64 years),30.0,49.0,Age,ages 30-49,322,0.78,,,,,,,,Stratified probability,"Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)",Roche Diagnostics,,Serum,,"['Nucleocapsid(N-protein)', 'Spike']",,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Faisal Awartani,Arab American University of Palestine,Unity-Aligned,https://dx.doi.org/10.3390/vaccines10081332,2022-09-16,2024-04-29,Verified,awartani_seroprevalence_2022,PSE
220817_WestBank_ArabAmericanUniversityofPalestine_Females_AntiNProtein,220817_WestBank_ArabAmericanUniversityofPalestine,Seroprevalence of SARS-CoV-2 Antibodies among Vaccinated and Non-Vaccinated Adults in the West Bank: Results of a Repeated Cross-Sectional Study.,2022-08-17,Journal Article (Peer-Reviewed),Regional,Repeated cross-sectional study,occupied Palestinian territory - including east Jerusalem,"""11 governorates in West Bank, Palestine""",,Adults aged 18+,,2021-09-14,2021-10-21,Household and community samples,Female,Multiple groups,18.0,,Sex/Gender,,468,0.618,,,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,,Serum,,Nucleocapsid(N-protein),,,,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,No,,Faisal Awartani,Arab American University of Palestine,Unity-Aligned,https://dx.doi.org/10.3390/vaccines10081332,2022-09-16,2024-04-29,Verified,awartani_seroprevalence_2022,PSE
230201_Japan_NationalInstituteofInfectiousDiseases_December2021_AntiN_PopAdj,230201_Japan_NationalInstituteofInfectiousDiseases_December2021,National seroepidemiological study of COVID-19 after the initial rollout of vaccines: Before and at the peak of the Omicron-dominant period in Japan.,2023-02-01,Journal Article (Peer-Reviewed),Regional,,,"Miyagi, Tokyo, Aichi, Osaka, and Fukuoka prefectures",,,,2021-12-01,2021-12-31,Household and community samples,All,Multiple groups,20.0,,Primary Estimate,,8147,0.022,0.019,0.025,True,,True,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"IgG, IgM, IgA",Nucleocapsid(N-protein),,0.994,0.981,[{'error': '#ERROR!'}],,No,{'error': '#ERROR!'},No,,{'error': '#ERROR!'},Yes,{'error': '#ERROR!'},,Takeshi Arashiro,,{'error': '#ERROR!'},https://dx.doi.org/10.1111/irv.13094,2024-04-02,2024-04-02,Verified,arashiro_national_2023,
230201_Japan_NationalInstituteofInfectiousDiseases_December2021_AntiS_PopAdj,230201_Japan_NationalInstituteofInfectiousDiseases_December2021,National seroepidemiological study of COVID-19 after the initial rollout of vaccines: Before and at the peak of the Omicron-dominant period in Japan.,2023-02-01,Journal Article (Peer-Reviewed),Regional,,,"Miyagi, Tokyo, Aichi, Osaka, and Fukuoka prefectures",,,,2021-12-01,2021-12-31,Household and community samples,All,Multiple groups,20.0,,Primary Estimate,,8147,0.963,0.958,0.966,True,,True,,True,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,"IgG, IgM, IgA",Spike,,0.977,1.0,[{'error': '#ERROR!'}],,No,{'error': '#ERROR!'},No,,{'error': '#ERROR!'},Yes,{'error': '#ERROR!'},,Takeshi Arashiro,,{'error': '#ERROR!'},https://dx.doi.org/10.1111/irv.13094,2024-04-02,2024-04-02,Verified,arashiro_national_2023,
230201_Japan_NationalInstituteofInfectiousDiseases_December2021_AntiN_Unadj,230201_Japan_NationalInstituteofInfectiousDiseases_December2021,National seroepidemiological study of COVID-19 after the initial rollout of vaccines: Before and at the peak of the Omicron-dominant period in Japan.,2023-02-01,Journal Article (Peer-Reviewed),Regional,,,"Miyagi, Tokyo, Aichi, Osaka, and Fukuoka prefectures",,,,2021-12-01,2021-12-31,Household and community samples,All,Multiple groups,20.0,,Analysis,,8147,0.022,0.019,0.025,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (N),Roche Diagnostics,CLIA,Serum,"IgG, IgM, IgA",Nucleocapsid(N-protein),,0.994,0.981,[{'error': '#ERROR!'}],,No,{'error': '#ERROR!'},No,,{'error': '#ERROR!'},Yes,{'error': '#ERROR!'},,Takeshi Arashiro,,{'error': '#ERROR!'},https://dx.doi.org/10.1111/irv.13094,2024-04-02,2024-04-02,Verified,arashiro_national_2023,
230201_Japan_NationalInstituteofInfectiousDiseases_December2021_AntiS_Unadj,230201_Japan_NationalInstituteofInfectiousDiseases_December2021,National seroepidemiological study of COVID-19 after the initial rollout of vaccines: Before and at the peak of the Omicron-dominant period in Japan.,2023-02-01,Journal Article (Peer-Reviewed),Regional,,,"Miyagi, Tokyo, Aichi, Osaka, and Fukuoka prefectures",,,,2021-12-01,2021-12-31,Household and community samples,All,Multiple groups,20.0,,Analysis,,8147,0.963,0.959,0.967,,,,,,Stratified probability,Elecsys® Anti‐SARS‐CoV‐2 (S),Roche Diagnostics,CLIA,Serum,"IgG, IgM, IgA",Spike,,0.977,1.0,[{'error': '#ERROR!'}],,No,{'error': '#ERROR!'},No,,{'error': '#ERROR!'},Yes,{'error': '#ERROR!'},,Takeshi Arashiro,,{'error': '#ERROR!'},https://dx.doi.org/10.1111/irv.13094,2024-04-02,2024-04-02,Verified,arashiro_national_2023,